id category subject predicate object publications sources primary_knowledge_source knowledge_level agent_type supporting_text original_object original_subject uuid:4f271369-9e64-4961-90bd-f8e7489cc35e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8327 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:bd8d3761-cee0-49ba-a939-5c1e77f3c173"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bb11f651-1845-4e66-b326-92e4961f0b36"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Renese is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Renese has also been found useful in edema due to various forms of renal dysfunction as: Nephrotic syndrome; Acute glomerulonephritis; and Chronic renal failure. Renese is indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension. uuid:b82dc84e-eb6c-4337-b64b-78bbc3b6b7c8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8327 biolink:treats MONDO:0005155 PMID:41385096 "[{""id"":""uuid:d5f293dd-d526-44a3-8e1a-b184d0a171f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5716285f-ba02-4423-aa23-80f975df5aa7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Renese is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Renese has also been found useful in edema due to various forms of renal dysfunction as: Nephrotic syndrome; Acute glomerulonephritis; and Chronic renal failure. Renese is indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension. uuid:1bd403bb-930c-4a47-8477-c91fd6af4d20 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8327 biolink:treats MONDO:0005377 PMID:41385096 "[{""id"":""uuid:557ada5d-9702-48c4-8c5b-ba34ef6072b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:06fb7021-6619-4940-ae30-5fda205e2623"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Renese is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Renese has also been found useful in edema due to various forms of renal dysfunction as: Nephrotic syndrome; Acute glomerulonephritis; and Chronic renal failure. Renese is indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension. uuid:c58e0341-9f2e-4bf9-a330-9701933b3482 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8327 biolink:treats UMLS:C0156221 PMID:41385096 "[{""id"":""uuid:2726b6bf-1b2c-41ee-a90d-d4880573cfc7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d24c1e62-cdfc-4cb4-864c-e52249cf9c6d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Renese is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Renese has also been found useful in edema due to various forms of renal dysfunction as: Nephrotic syndrome; Acute glomerulonephritis; and Chronic renal failure. Renese is indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension. uuid:54cb5b36-e5f9-40cf-9210-aafa7386673e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8327 biolink:treats MONDO:0005300 PMID:41385096 "[{""id"":""uuid:bedf5564-1e35-46b7-90a9-2eca5171fe61"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4291c384-a72f-4d53-bd96-4ef9ce3e1b06"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Renese is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Renese has also been found useful in edema due to various forms of renal dysfunction as: Nephrotic syndrome; Acute glomerulonephritis; and Chronic renal failure. Renese is indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension. uuid:3e9adc81-5ac8-4e57-8aa9-a1c452e38aaa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8327 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:9ede31d9-f500-4a67-a0c7-7223fb798491"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:23e3dbbb-f335-4927-b5c2-763ec3ccaf76"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Renese is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Renese has also been found useful in edema due to various forms of renal dysfunction as: Nephrotic syndrome; Acute glomerulonephritis; and Chronic renal failure. Renese is indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension. uuid:c30e22c4-bbd7-432e-93ab-4ceea27092b7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64354 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:6cd679b1-8174-488c-9198-cf2d84f19fce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:adeb82fe-4441-4727-80bd-4b2c77421d09"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MYKROX Tablets are indicated for the treatment of hypertension, alone or in combination with other antihypertensive drugs of a different class. MYKROX TABLETS HAVE NOT BEEN EVALUATED FOR THE TREATMENT OF CONGESTIVE HEART FAILURE OR FLUID RETENTION DUE TO RENAL OR HEPATIC DISEASE AND THE CORRECT DOSAGE FOR THESE CONDITIONS AND OTHER EDEMA STATES HAS NOT BEEN ESTABLISHED. SINCE A SAFE AND EFFECTIVE DIURETIC DOSE HAS NOT BEEN ESTABLISHED, MYKROX TABLETS SHOULD NOT BE USED WHEN DIURESIS IS DESIRED. uuid:649f3ed9-eaa6-4951-b7fb-8cb5b63f8d07 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9613 biolink:treats MONDO:0011072 PMID:41385096 "[{""id"":""uuid:b7e2ea3b-cfbd-4d93-8fa8-f81033a9a2ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a2e849fc-a856-46ec-bd24-8ce882029752"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TOLINASE Tablets are indicated as an adjunct to diet to lower the blood glucose in patients with noninsulin dependent diabetes mellitus (Type II) whose hyperglycemia cannot be satisfactorily controlled by diet alone. In initiating treatment for noninsulin-dependent diabetes, diet should be emphasized as the primary form of treatment. Caloric restriction and weight loss are essential in the obese diabetic patient. Proper dietary management alone may be effective in controlling the blood glucose and symptoms of hyperglycemia. The importance of regular physical activity should also be stressed and cardiovascular risk factors should be identified and corrective measures taken where possible. If this treatment program fails to reduce symptoms and/or blood glucose, the use of an oral sulfonylurea or insulin should be considered. Use of TOLINASE must be viewed by both the physician and patient as a treatment in addition to diet and not as a substitute for diet or as a convenient mechanism for avoiding dietary restraint. Furthermore, loss of blood glucose control on diet alone may be transient thus requiring only short-term administration of TOLINASE. During maintenance programs, TOLINASE should be discontinued if satisfactory lowering of blood glucose is no longer achieved. Judgments should be based on regular clinical and laboratory evaluations. In considering the use of TOLINASE in asymptomatic patients, it should be recognized that controlling the blood glucose in noninsulin-dependent diabetes has not been definitely established to be effective in preventing the long-term cardiovascular or neural complications of diabetes. uuid:8e16d623-9a47-4de0-bf38-f30d47361d6c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9613 biolink:treats MONDO:0002909 PMID:41385096 "[{""id"":""uuid:919048e6-f887-42b5-88e4-11e8309f3414"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3feb94e5-9876-4a60-a04b-6d00f37a3dfb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TOLINASE Tablets are indicated as an adjunct to diet to lower the blood glucose in patients with noninsulin dependent diabetes mellitus (Type II) whose hyperglycemia cannot be satisfactorily controlled by diet alone. In initiating treatment for noninsulin-dependent diabetes, diet should be emphasized as the primary form of treatment. Caloric restriction and weight loss are essential in the obese diabetic patient. Proper dietary management alone may be effective in controlling the blood glucose and symptoms of hyperglycemia. The importance of regular physical activity should also be stressed and cardiovascular risk factors should be identified and corrective measures taken where possible. If this treatment program fails to reduce symptoms and/or blood glucose, the use of an oral sulfonylurea or insulin should be considered. Use of TOLINASE must be viewed by both the physician and patient as a treatment in addition to diet and not as a substitute for diet or as a convenient mechanism for avoiding dietary restraint. Furthermore, loss of blood glucose control on diet alone may be transient thus requiring only short-term administration of TOLINASE. During maintenance programs, TOLINASE should be discontinued if satisfactory lowering of blood glucose is no longer achieved. Judgments should be based on regular clinical and laboratory evaluations. In considering the use of TOLINASE in asymptomatic patients, it should be recognized that controlling the blood glucose in noninsulin-dependent diabetes has not been definitely established to be effective in preventing the long-term cardiovascular or neural complications of diabetes. uuid:66f8b73d-4cf3-4ba7-bd62-cd18c7d69b96 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6754 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:bc06b27c-2863-4c1f-b79d-8113480e8172"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:be7a1d61-facd-4b69-8d9b-0332e6bce0a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Meperidine is indicated for the relief of moderate to severe pain. uuid:19d25267-157b-4b46-a316-4967f23f02a1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5120 biolink:treats MONDO:0009420 PMID:41385096 "[{""id"":""uuid:fdc0cdfa-6d21-4a25-ae9c-cc434a279124"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:719ea518-53d0-4831-85fc-30dc6751a03a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In the male —HALOTESTIN Tablets are indicated for Replacement therapy in conditions associated with symptoms of deficiency or absence of endogenous testosterone. Primary hypogonadism (congenital or acquired) testicular failure due to cryptorchidism, bilateral torsion, orchitis , vanishing testis syndrome; or orchidectomy. Hypogonadotropic hypogonadism (congenital or acquired)—idiopathic gonadotropin or LHRH deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation. Delayed puberty, provided it has been definitely established as such, and is not just a familial trait. In the female —HALOTESTIN Tablets are indicated for palliation of androgen-responsive recurrent mammary cancer in women who are more than one year but less than five years postmenopausal, or who have been proven to have a hormone- dependent tumor as shown by previous beneficial response to castration. uuid:dbbeed74-3b9f-44dd-be57-dd0a681d1ae9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5120 biolink:treats MONDO:0023554 PMID:41385096 "[{""id"":""uuid:553033e5-a9a4-4ac1-89ad-615d70eccc03"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6687f8b7-0dbd-416d-b42d-07b478cdf98c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In the male —HALOTESTIN Tablets are indicated for Replacement therapy in conditions associated with symptoms of deficiency or absence of endogenous testosterone. Primary hypogonadism (congenital or acquired) testicular failure due to cryptorchidism, bilateral torsion, orchitis , vanishing testis syndrome; or orchidectomy. Hypogonadotropic hypogonadism (congenital or acquired)—idiopathic gonadotropin or LHRH deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation. Delayed puberty, provided it has been definitely established as such, and is not just a familial trait. In the female —HALOTESTIN Tablets are indicated for palliation of androgen-responsive recurrent mammary cancer in women who are more than one year but less than five years postmenopausal, or who have been proven to have a hormone- dependent tumor as shown by previous beneficial response to castration. uuid:df771f76-10ca-4dbf-87b4-5d05e603b8d8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5120 biolink:treats MONDO:0009047 PMID:41385096 "[{""id"":""uuid:88103826-8826-460e-b99d-8f54033acd47"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:45c8bd0c-a24f-45eb-aa41-ec67fea6a055"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In the male —HALOTESTIN Tablets are indicated for Replacement therapy in conditions associated with symptoms of deficiency or absence of endogenous testosterone. Primary hypogonadism (congenital or acquired) testicular failure due to cryptorchidism, bilateral torsion, orchitis , vanishing testis syndrome; or orchidectomy. Hypogonadotropic hypogonadism (congenital or acquired)—idiopathic gonadotropin or LHRH deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation. Delayed puberty, provided it has been definitely established as such, and is not just a familial trait. In the female —HALOTESTIN Tablets are indicated for palliation of androgen-responsive recurrent mammary cancer in women who are more than one year but less than five years postmenopausal, or who have been proven to have a hormone- dependent tumor as shown by previous beneficial response to castration. uuid:5e0f9ba0-a850-4dbd-9238-4d48ce134408 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5120 biolink:treats MONDO:0008573 PMID:41385096 "[{""id"":""uuid:ee59ea9b-f30e-47bc-90be-d377d5927f09"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:05f24245-487c-4c12-a83d-bf8669acd91f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In the male —HALOTESTIN Tablets are indicated for Replacement therapy in conditions associated with symptoms of deficiency or absence of endogenous testosterone. Primary hypogonadism (congenital or acquired) testicular failure due to cryptorchidism, bilateral torsion, orchitis , vanishing testis syndrome; or orchidectomy. Hypogonadotropic hypogonadism (congenital or acquired)—idiopathic gonadotropin or LHRH deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation. Delayed puberty, provided it has been definitely established as such, and is not just a familial trait. In the female —HALOTESTIN Tablets are indicated for palliation of androgen-responsive recurrent mammary cancer in women who are more than one year but less than five years postmenopausal, or who have been proven to have a hormone- dependent tumor as shown by previous beneficial response to castration. uuid:25a73a36-5cc8-4fea-9de4-c3b1c85a4ece biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5120 biolink:treats MONDO:0006882 PMID:41385096 "[{""id"":""uuid:a173dd36-02d1-42ad-ba02-d2208cb6c8d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9a95f3ad-3618-4bd9-9bde-b43dc891c08f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In the male —HALOTESTIN Tablets are indicated for Replacement therapy in conditions associated with symptoms of deficiency or absence of endogenous testosterone. Primary hypogonadism (congenital or acquired) testicular failure due to cryptorchidism, bilateral torsion, orchitis , vanishing testis syndrome; or orchidectomy. Hypogonadotropic hypogonadism (congenital or acquired)—idiopathic gonadotropin or LHRH deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation. Delayed puberty, provided it has been definitely established as such, and is not just a familial trait. In the female —HALOTESTIN Tablets are indicated for palliation of androgen-responsive recurrent mammary cancer in women who are more than one year but less than five years postmenopausal, or who have been proven to have a hormone- dependent tumor as shown by previous beneficial response to castration. uuid:c7e2fb7e-7a5c-4cf3-b7d2-64c53ba0682a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5120 biolink:treats MONDO:8000015 PMID:41385096 "[{""id"":""uuid:485e2ac6-89f9-482c-b2c1-5bce7edd275d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:77be3e17-3838-4b65-825b-49410c3408bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In the male —HALOTESTIN Tablets are indicated for Replacement therapy in conditions associated with symptoms of deficiency or absence of endogenous testosterone. Primary hypogonadism (congenital or acquired) testicular failure due to cryptorchidism, bilateral torsion, orchitis , vanishing testis syndrome; or orchidectomy. Hypogonadotropic hypogonadism (congenital or acquired)—idiopathic gonadotropin or LHRH deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation. Delayed puberty, provided it has been definitely established as such, and is not just a familial trait. In the female —HALOTESTIN Tablets are indicated for palliation of androgen-responsive recurrent mammary cancer in women who are more than one year but less than five years postmenopausal, or who have been proven to have a hormone- dependent tumor as shown by previous beneficial response to castration. uuid:b9fd867b-ebc1-43d6-a9ed-c464e5d07b25 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5120 biolink:treats MONDO:0018555 PMID:41385096 "[{""id"":""uuid:a15e2934-ca11-4626-a526-0b1e163f4391"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bad95e4a-1dca-49d6-9016-020ba01ea3e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In the male —HALOTESTIN Tablets are indicated for Replacement therapy in conditions associated with symptoms of deficiency or absence of endogenous testosterone. Primary hypogonadism (congenital or acquired) testicular failure due to cryptorchidism, bilateral torsion, orchitis , vanishing testis syndrome; or orchidectomy. Hypogonadotropic hypogonadism (congenital or acquired)—idiopathic gonadotropin or LHRH deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation. Delayed puberty, provided it has been definitely established as such, and is not just a familial trait. In the female —HALOTESTIN Tablets are indicated for palliation of androgen-responsive recurrent mammary cancer in women who are more than one year but less than five years postmenopausal, or who have been proven to have a hormone- dependent tumor as shown by previous beneficial response to castration. uuid:d82e0e69-b1ea-46b1-a8aa-77c7b667c8d6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5120 biolink:treats MONDO:0013914 PMID:41385096 "[{""id"":""uuid:2a16c4e2-104f-4a09-81e3-8f6acf40c7bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3e535517-443b-4aef-a1f1-9e26edd2a3d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In the male —HALOTESTIN Tablets are indicated for Replacement therapy in conditions associated with symptoms of deficiency or absence of endogenous testosterone. Primary hypogonadism (congenital or acquired) testicular failure due to cryptorchidism, bilateral torsion, orchitis , vanishing testis syndrome; or orchidectomy. Hypogonadotropic hypogonadism (congenital or acquired)—idiopathic gonadotropin or LHRH deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation. Delayed puberty, provided it has been definitely established as such, and is not just a familial trait. In the female —HALOTESTIN Tablets are indicated for palliation of androgen-responsive recurrent mammary cancer in women who are more than one year but less than five years postmenopausal, or who have been proven to have a hormone- dependent tumor as shown by previous beneficial response to castration. uuid:023e6289-3b96-4c6d-9f46-d3f935b1fe13 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5120 biolink:treats HP:0000823 PMID:41385096 "[{""id"":""uuid:5c0b9259-99a6-4cfc-b2cb-26a8c6c43eee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b0ebbc3e-22ac-4c4d-b61e-00afa1b11880"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In the male —HALOTESTIN Tablets are indicated for Replacement therapy in conditions associated with symptoms of deficiency or absence of endogenous testosterone. Primary hypogonadism (congenital or acquired) testicular failure due to cryptorchidism, bilateral torsion, orchitis , vanishing testis syndrome; or orchidectomy. Hypogonadotropic hypogonadism (congenital or acquired)—idiopathic gonadotropin or LHRH deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation. Delayed puberty, provided it has been definitely established as such, and is not just a familial trait. In the female —HALOTESTIN Tablets are indicated for palliation of androgen-responsive recurrent mammary cancer in women who are more than one year but less than five years postmenopausal, or who have been proven to have a hormone- dependent tumor as shown by previous beneficial response to castration. uuid:c466136e-e1d8-4057-ad97-993691081107 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5120 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:e0de23c7-a534-4ddf-ae6c-bf54aa8997a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f7125ed0-8aea-4cf2-8f14-0c02f6ce4e37"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In the male —HALOTESTIN Tablets are indicated for Replacement therapy in conditions associated with symptoms of deficiency or absence of endogenous testosterone. Primary hypogonadism (congenital or acquired) testicular failure due to cryptorchidism, bilateral torsion, orchitis , vanishing testis syndrome; or orchidectomy. Hypogonadotropic hypogonadism (congenital or acquired)—idiopathic gonadotropin or LHRH deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation. Delayed puberty, provided it has been definitely established as such, and is not just a familial trait. In the female —HALOTESTIN Tablets are indicated for palliation of androgen-responsive recurrent mammary cancer in women who are more than one year but less than five years postmenopausal, or who have been proven to have a hormone- dependent tumor as shown by previous beneficial response to castration. uuid:938ef2c1-091c-42a8-beb3-1b0171b87827 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4317 biolink:treats MONDO:0043797 PMID:41385096 "[{""id"":""uuid:4e6fb07c-f40d-4831-bbcd-f3ed448778d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ad923cea-bd48-46a9-b941-eba93afca02a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In Chronic Spasticity: Dantrium is indicated in controlling the manifestations of clinical spasticity resulting from upper motor neuron disorders (e.g., spinal cord injury, stroke, cerebral palsy, or multiple sclerosis). It is of particular benefit to the patient whose functional rehabilitation has been retarded by the sequelae of spasticity. Such patients must have presumably reversible spasticity where relief of spasticity will aid in restoring residual function. Dantrium is not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders. If improvement occurs, it will ordinarily occur within the dosage titration (see DOSAGE AND ADMINISTRATION ), and will be manifested by a decrease in the severity of spasticity and the ability to resume a daily function not quite attainable without Dantrium. Occasionally, subtle but meaningful improvement in spasticity may occur with Dantrium therapy. In such instances, information regarding improvement should be solicited from the patient and those who are in constant daily contact and attendance with him. Brief withdrawal of Dantrium for a period of 2 to 4 days will frequently demonstrate exacerbation of the manifestations of spasticity and may serve to confirm a clinical impression. A decision to continue the administration of Dantrium on a long-term basis is justified if introduction of the drug into the patient's regimen: produces a significant reduction in painful and/or disabling spasticity such as clonus, or permits a significant reduction in the intensity and/or degree of nursing care required, or rids the patient of any annoying manifestation of spasticity considered important by the patient himself. uuid:8652d5a8-7143-43d9-bcdd-7b550a4b2e7f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4317 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:98ff7b71-1e2a-471b-88e8-332be05e74df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4b740055-c7ae-4df4-9dac-a9a50ffafce3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In Chronic Spasticity: Dantrium is indicated in controlling the manifestations of clinical spasticity resulting from upper motor neuron disorders (e.g., spinal cord injury, stroke, cerebral palsy, or multiple sclerosis). It is of particular benefit to the patient whose functional rehabilitation has been retarded by the sequelae of spasticity. Such patients must have presumably reversible spasticity where relief of spasticity will aid in restoring residual function. Dantrium is not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders. If improvement occurs, it will ordinarily occur within the dosage titration (see DOSAGE AND ADMINISTRATION ), and will be manifested by a decrease in the severity of spasticity and the ability to resume a daily function not quite attainable without Dantrium. Occasionally, subtle but meaningful improvement in spasticity may occur with Dantrium therapy. In such instances, information regarding improvement should be solicited from the patient and those who are in constant daily contact and attendance with him. Brief withdrawal of Dantrium for a period of 2 to 4 days will frequently demonstrate exacerbation of the manifestations of spasticity and may serve to confirm a clinical impression. A decision to continue the administration of Dantrium on a long-term basis is justified if introduction of the drug into the patient's regimen: produces a significant reduction in painful and/or disabling spasticity such as clonus, or permits a significant reduction in the intensity and/or degree of nursing care required, or rids the patient of any annoying manifestation of spasticity considered important by the patient himself. uuid:80061d29-460d-4dee-b30e-88038ba78b0d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4317 biolink:treats MONDO:0006497 PMID:41385096 "[{""id"":""uuid:7346fce4-aa4b-412d-8c3a-76f58634be28"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d81f25b0-6e0c-40b5-b0b8-e429847d4e6b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In Chronic Spasticity: Dantrium is indicated in controlling the manifestations of clinical spasticity resulting from upper motor neuron disorders (e.g., spinal cord injury, stroke, cerebral palsy, or multiple sclerosis). It is of particular benefit to the patient whose functional rehabilitation has been retarded by the sequelae of spasticity. Such patients must have presumably reversible spasticity where relief of spasticity will aid in restoring residual function. Dantrium is not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders. If improvement occurs, it will ordinarily occur within the dosage titration (see DOSAGE AND ADMINISTRATION ), and will be manifested by a decrease in the severity of spasticity and the ability to resume a daily function not quite attainable without Dantrium. Occasionally, subtle but meaningful improvement in spasticity may occur with Dantrium therapy. In such instances, information regarding improvement should be solicited from the patient and those who are in constant daily contact and attendance with him. Brief withdrawal of Dantrium for a period of 2 to 4 days will frequently demonstrate exacerbation of the manifestations of spasticity and may serve to confirm a clinical impression. A decision to continue the administration of Dantrium on a long-term basis is justified if introduction of the drug into the patient's regimen: produces a significant reduction in painful and/or disabling spasticity such as clonus, or permits a significant reduction in the intensity and/or degree of nursing care required, or rids the patient of any annoying manifestation of spasticity considered important by the patient himself. uuid:3f9af204-940f-4f40-aa29-a0621fbc5f54 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4317 biolink:treats MONDO:0005301 PMID:41385096 "[{""id"":""uuid:59db8fa4-956a-4777-8b2d-7c22951ad7c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:14cac716-584d-4be9-a3f3-060a14a680c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In Chronic Spasticity: Dantrium is indicated in controlling the manifestations of clinical spasticity resulting from upper motor neuron disorders (e.g., spinal cord injury, stroke, cerebral palsy, or multiple sclerosis). It is of particular benefit to the patient whose functional rehabilitation has been retarded by the sequelae of spasticity. Such patients must have presumably reversible spasticity where relief of spasticity will aid in restoring residual function. Dantrium is not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders. If improvement occurs, it will ordinarily occur within the dosage titration (see DOSAGE AND ADMINISTRATION ), and will be manifested by a decrease in the severity of spasticity and the ability to resume a daily function not quite attainable without Dantrium. Occasionally, subtle but meaningful improvement in spasticity may occur with Dantrium therapy. In such instances, information regarding improvement should be solicited from the patient and those who are in constant daily contact and attendance with him. Brief withdrawal of Dantrium for a period of 2 to 4 days will frequently demonstrate exacerbation of the manifestations of spasticity and may serve to confirm a clinical impression. A decision to continue the administration of Dantrium on a long-term basis is justified if introduction of the drug into the patient's regimen: produces a significant reduction in painful and/or disabling spasticity such as clonus, or permits a significant reduction in the intensity and/or degree of nursing care required, or rids the patient of any annoying manifestation of spasticity considered important by the patient himself. uuid:f4d5d7ca-bf74-4541-93d6-c6cbd8174087 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6504 biolink:treats MONDO:0004985 PMID:41385096 "[{""id"":""uuid:f49de98c-8d65-441b-a7fa-97974fb41e21"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b9673f99-9dd1-4758-a7d6-55f14f3d6729"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lithium carbonate is indicated in the treatment of manic episodes of manic-depressive illness. Maintenance therapy prevents or diminishes the intensity of subsequent episodes in those manic-depressive patients with a history of mania. Typical symptoms of mania include pressure of speech, motor hyperactivity, reduced need for sleep, flight of ideas, grandiosity, elation, poor judgment, aggressiveness, and possibly hostility. When given to a patient experiencing a manic episode, lithium may produce a normalization of symptomatology within 1 to 3 weeks. uuid:b8c80a7c-ed05-494d-b02a-906d1f1ae811 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6504 biolink:treats HP:0100754 PMID:41385096 "[{""id"":""uuid:276020c1-7ba0-4652-bf5e-44db9e37c59d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:41b437c8-0513-4b07-aac8-fbd59b0edf0b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lithium carbonate is indicated in the treatment of manic episodes of manic-depressive illness. Maintenance therapy prevents or diminishes the intensity of subsequent episodes in those manic-depressive patients with a history of mania. Typical symptoms of mania include pressure of speech, motor hyperactivity, reduced need for sleep, flight of ideas, grandiosity, elation, poor judgment, aggressiveness, and possibly hostility. When given to a patient experiencing a manic episode, lithium may produce a normalization of symptomatology within 1 to 3 weeks. uuid:db20f244-8555-437d-8c9b-d4b940b1640e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9763 biolink:treats UMLS:C0949083 PMID:41385096 "[{""id"":""uuid:93d7c3f7-6d16-454e-b7d2-16a446aa57e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fb0b56b2-e521-48c6-8def-b275d531b86f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TROVAN is indicated for the treatment of patients initiating therapy in in-patient health care facilities (i.e., hospitals and long term nursing care facilities) with serious, life- or limb-threatening infections caused by susceptible strains of the designated microorganisms in the conditions listed below. (See DOSAGE AND ADMINISTRATION .) Nosocomial pneumonia caused by Escherichia coli, Pseudomonas aeruginosa, Haemophilus influenzae , or Staphylococcus aureus . As with other antimicrobials, where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with either an aminoglycoside or aztreonam may be clinically indicated. Community acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae, Staphylococcus aureus, Mycoplasma pneumoniae, Moraxella catarrhalis, Legionella pneumophila, or Chlamydia pneumoniae . Complicated intra-abdominal infections, including post-surgical infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Peptostreptococcus species, or Prevotella species. Gynecologic and pelvic infections including endomyometritis, parametritis, septic abortion and post-partum infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Enterococcus faecalis, Streptococcus agalactiae, Peptostreptococcus species, Prevotella species, or Gardnerella vaginalis. Complicated skin and skin structure infections, including diabetic foot infections, caused by Staphylococcus aureus, Streptococcus agalactiae, Pseudomonas aeruginosa, Enterococcus faecalis, Escherichia coli, or Proteus mirabilis. NOTE : TROVAN has not been studied in the treatment of osteomyelitis. (See WARNINGS .) uuid:89eb9c81-69b5-4e4c-a743-ed58bb9d7f6b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9763 biolink:treats UMLS:C0694549 PMID:41385096 "[{""id"":""uuid:8ce2dea4-ce98-48e8-8450-ae8b580d8e72"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:235d9998-06bb-49b5-9dde-221728960c72"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TROVAN is indicated for the treatment of patients initiating therapy in in-patient health care facilities (i.e., hospitals and long term nursing care facilities) with serious, life- or limb-threatening infections caused by susceptible strains of the designated microorganisms in the conditions listed below. (See DOSAGE AND ADMINISTRATION .) Nosocomial pneumonia caused by Escherichia coli, Pseudomonas aeruginosa, Haemophilus influenzae , or Staphylococcus aureus . As with other antimicrobials, where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with either an aminoglycoside or aztreonam may be clinically indicated. Community acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae, Staphylococcus aureus, Mycoplasma pneumoniae, Moraxella catarrhalis, Legionella pneumophila, or Chlamydia pneumoniae . Complicated intra-abdominal infections, including post-surgical infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Peptostreptococcus species, or Prevotella species. Gynecologic and pelvic infections including endomyometritis, parametritis, septic abortion and post-partum infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Enterococcus faecalis, Streptococcus agalactiae, Peptostreptococcus species, Prevotella species, or Gardnerella vaginalis. Complicated skin and skin structure infections, including diabetic foot infections, caused by Staphylococcus aureus, Streptococcus agalactiae, Pseudomonas aeruginosa, Enterococcus faecalis, Escherichia coli, or Proteus mirabilis. NOTE : TROVAN has not been studied in the treatment of osteomyelitis. (See WARNINGS .) uuid:c8c729d0-6db0-4ed0-a778-056ab4a5e0d4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9763 biolink:treats MONDO:0000922 PMID:41385096 "[{""id"":""uuid:d41bb0c7-5ae3-4c0c-866d-3d601201fa63"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aa191a6f-02ad-4c21-83a0-22563703f4be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TROVAN is indicated for the treatment of patients initiating therapy in in-patient health care facilities (i.e., hospitals and long term nursing care facilities) with serious, life- or limb-threatening infections caused by susceptible strains of the designated microorganisms in the conditions listed below. (See DOSAGE AND ADMINISTRATION .) Nosocomial pneumonia caused by Escherichia coli, Pseudomonas aeruginosa, Haemophilus influenzae , or Staphylococcus aureus . As with other antimicrobials, where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with either an aminoglycoside or aztreonam may be clinically indicated. Community acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae, Staphylococcus aureus, Mycoplasma pneumoniae, Moraxella catarrhalis, Legionella pneumophila, or Chlamydia pneumoniae . Complicated intra-abdominal infections, including post-surgical infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Peptostreptococcus species, or Prevotella species. Gynecologic and pelvic infections including endomyometritis, parametritis, septic abortion and post-partum infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Enterococcus faecalis, Streptococcus agalactiae, Peptostreptococcus species, Prevotella species, or Gardnerella vaginalis. Complicated skin and skin structure infections, including diabetic foot infections, caused by Staphylococcus aureus, Streptococcus agalactiae, Pseudomonas aeruginosa, Enterococcus faecalis, Escherichia coli, or Proteus mirabilis. NOTE : TROVAN has not been studied in the treatment of osteomyelitis. (See WARNINGS .) uuid:b94c69ad-29d4-44fb-82d7-c784c6dfa32f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9763 biolink:treats MONDO:0042451 PMID:41385096 "[{""id"":""uuid:bdf8616f-180e-4b30-8c9d-36a46bbf1c64"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b85e55f8-40e1-474f-8a50-36f9f2617b2a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TROVAN is indicated for the treatment of patients initiating therapy in in-patient health care facilities (i.e., hospitals and long term nursing care facilities) with serious, life- or limb-threatening infections caused by susceptible strains of the designated microorganisms in the conditions listed below. (See DOSAGE AND ADMINISTRATION .) Nosocomial pneumonia caused by Escherichia coli, Pseudomonas aeruginosa, Haemophilus influenzae , or Staphylococcus aureus . As with other antimicrobials, where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with either an aminoglycoside or aztreonam may be clinically indicated. Community acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae, Staphylococcus aureus, Mycoplasma pneumoniae, Moraxella catarrhalis, Legionella pneumophila, or Chlamydia pneumoniae . Complicated intra-abdominal infections, including post-surgical infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Peptostreptococcus species, or Prevotella species. Gynecologic and pelvic infections including endomyometritis, parametritis, septic abortion and post-partum infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Enterococcus faecalis, Streptococcus agalactiae, Peptostreptococcus species, Prevotella species, or Gardnerella vaginalis. Complicated skin and skin structure infections, including diabetic foot infections, caused by Staphylococcus aureus, Streptococcus agalactiae, Pseudomonas aeruginosa, Enterococcus faecalis, Escherichia coli, or Proteus mirabilis. NOTE : TROVAN has not been studied in the treatment of osteomyelitis. (See WARNINGS .) uuid:1dff61f1-01bb-4687-8b76-816a2ad24ff2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9763 biolink:treats MONDO:0006887 PMID:41385096 "[{""id"":""uuid:85473a4c-ec75-4b0d-811b-fa07325a7c7e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:20373ea1-74e4-4661-958b-e9cc7bf8ac89"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TROVAN is indicated for the treatment of patients initiating therapy in in-patient health care facilities (i.e., hospitals and long term nursing care facilities) with serious, life- or limb-threatening infections caused by susceptible strains of the designated microorganisms in the conditions listed below. (See DOSAGE AND ADMINISTRATION .) Nosocomial pneumonia caused by Escherichia coli, Pseudomonas aeruginosa, Haemophilus influenzae , or Staphylococcus aureus . As with other antimicrobials, where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with either an aminoglycoside or aztreonam may be clinically indicated. Community acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae, Staphylococcus aureus, Mycoplasma pneumoniae, Moraxella catarrhalis, Legionella pneumophila, or Chlamydia pneumoniae . Complicated intra-abdominal infections, including post-surgical infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Peptostreptococcus species, or Prevotella species. Gynecologic and pelvic infections including endomyometritis, parametritis, septic abortion and post-partum infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Enterococcus faecalis, Streptococcus agalactiae, Peptostreptococcus species, Prevotella species, or Gardnerella vaginalis. Complicated skin and skin structure infections, including diabetic foot infections, caused by Staphylococcus aureus, Streptococcus agalactiae, Pseudomonas aeruginosa, Enterococcus faecalis, Escherichia coli, or Proteus mirabilis. NOTE : TROVAN has not been studied in the treatment of osteomyelitis. (See WARNINGS .) uuid:9212516e-3a73-4c6e-ba95-005a22d1e8f7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9763 biolink:treats DOID:2910 PMID:41385096 "[{""id"":""uuid:c358645b-6c12-4713-bcc8-ca8620bc5f3d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a0fd26cb-4095-4cf3-9ee3-3108b4f1083c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TROVAN is indicated for the treatment of patients initiating therapy in in-patient health care facilities (i.e., hospitals and long term nursing care facilities) with serious, life- or limb-threatening infections caused by susceptible strains of the designated microorganisms in the conditions listed below. (See DOSAGE AND ADMINISTRATION .) Nosocomial pneumonia caused by Escherichia coli, Pseudomonas aeruginosa, Haemophilus influenzae , or Staphylococcus aureus . As with other antimicrobials, where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with either an aminoglycoside or aztreonam may be clinically indicated. Community acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae, Staphylococcus aureus, Mycoplasma pneumoniae, Moraxella catarrhalis, Legionella pneumophila, or Chlamydia pneumoniae . Complicated intra-abdominal infections, including post-surgical infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Peptostreptococcus species, or Prevotella species. Gynecologic and pelvic infections including endomyometritis, parametritis, septic abortion and post-partum infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Enterococcus faecalis, Streptococcus agalactiae, Peptostreptococcus species, Prevotella species, or Gardnerella vaginalis. Complicated skin and skin structure infections, including diabetic foot infections, caused by Staphylococcus aureus, Streptococcus agalactiae, Pseudomonas aeruginosa, Enterococcus faecalis, Escherichia coli, or Proteus mirabilis. NOTE : TROVAN has not been studied in the treatment of osteomyelitis. (See WARNINGS .) uuid:6b389904-4310-45b7-8cfc-9be16cc9ff14 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9763 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:8164315f-afcd-4f56-9cba-717119b74be8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2192e1dd-4670-4dee-a184-adfcf181212a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TROVAN is indicated for the treatment of patients initiating therapy in in-patient health care facilities (i.e., hospitals and long term nursing care facilities) with serious, life- or limb-threatening infections caused by susceptible strains of the designated microorganisms in the conditions listed below. (See DOSAGE AND ADMINISTRATION .) Nosocomial pneumonia caused by Escherichia coli, Pseudomonas aeruginosa, Haemophilus influenzae , or Staphylococcus aureus . As with other antimicrobials, where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with either an aminoglycoside or aztreonam may be clinically indicated. Community acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae, Staphylococcus aureus, Mycoplasma pneumoniae, Moraxella catarrhalis, Legionella pneumophila, or Chlamydia pneumoniae . Complicated intra-abdominal infections, including post-surgical infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Peptostreptococcus species, or Prevotella species. Gynecologic and pelvic infections including endomyometritis, parametritis, septic abortion and post-partum infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Enterococcus faecalis, Streptococcus agalactiae, Peptostreptococcus species, Prevotella species, or Gardnerella vaginalis. Complicated skin and skin structure infections, including diabetic foot infections, caused by Staphylococcus aureus, Streptococcus agalactiae, Pseudomonas aeruginosa, Enterococcus faecalis, Escherichia coli, or Proteus mirabilis. NOTE : TROVAN has not been studied in the treatment of osteomyelitis. (See WARNINGS .) uuid:633f6c5e-9841-498e-9679-9eda05932e90 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9763 biolink:treats UMLS:C0744130 PMID:41385096 "[{""id"":""uuid:910027cf-d683-4236-9e7c-7532b8893e29"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c75a5d26-814d-4815-bbca-812f4e59d05b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TROVAN is indicated for the treatment of patients initiating therapy in in-patient health care facilities (i.e., hospitals and long term nursing care facilities) with serious, life- or limb-threatening infections caused by susceptible strains of the designated microorganisms in the conditions listed below. (See DOSAGE AND ADMINISTRATION .) Nosocomial pneumonia caused by Escherichia coli, Pseudomonas aeruginosa, Haemophilus influenzae , or Staphylococcus aureus . As with other antimicrobials, where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with either an aminoglycoside or aztreonam may be clinically indicated. Community acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae, Staphylococcus aureus, Mycoplasma pneumoniae, Moraxella catarrhalis, Legionella pneumophila, or Chlamydia pneumoniae . Complicated intra-abdominal infections, including post-surgical infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Peptostreptococcus species, or Prevotella species. Gynecologic and pelvic infections including endomyometritis, parametritis, septic abortion and post-partum infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Enterococcus faecalis, Streptococcus agalactiae, Peptostreptococcus species, Prevotella species, or Gardnerella vaginalis. Complicated skin and skin structure infections, including diabetic foot infections, caused by Staphylococcus aureus, Streptococcus agalactiae, Pseudomonas aeruginosa, Enterococcus faecalis, Escherichia coli, or Proteus mirabilis. NOTE : TROVAN has not been studied in the treatment of osteomyelitis. (See WARNINGS .) uuid:83dbb54a-2349-455e-a077-172b6326814d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4317 biolink:treats MONDO:0018493 PMID:41385096 "[{""id"":""uuid:680a1e30-6f46-4fbd-8412-19a62e7e7f67"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dec31adc-cc53-4e67-afa5-3faa217e5920"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dantrium Intravenous is indicated, along with appropriate supportive measures, for the management of the fulminant hypermetabolism of skeletal muscle characteristic of malignant hyperthermia crises in patients of all ages. Dantrium Intravenous should be administered by continuous rapid intravenous push as soon as the malignant hyperthermia reaction is recognized (i.e., tachycardia, tachypnea, central venous desaturation, hypercarbia, metabolic acidosis, skeletal muscle rigidity, increased utilization of anesthesia circuit carbon dioxide absorber, cyanosis and mottling of the skin, and, in many cases, fever). Dantrium Intravenous is also indicated preoperatively, and sometimes postoperatively, to prevent or attenuate the development of clinical and laboratory signs of malignant hyperthermia in individuals judged to be malignant hyperthermia susceptible. uuid:774e7fed-9695-4101-9652-17412284a2b4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133011 biolink:treats MONDO:0019359 PMID:41385096 "[{""id"":""uuid:49c198c6-a344-42de-b93a-f02a12638908"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b3315b8f-29ee-4c1c-96f0-e1f50d9dc046"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxytetracycline is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers), Mycoplasma pneumoniae (PPLO, Eaton Agent), Agents of psittacosis and ornithosis, Agents of lymphogranuloma venereum and granuloma inguinale, The spirochetal agent of relapsing fever ( Borrelia recurrentis ). The following gram negative microorganisms: Haemophilus ducreyi (chancroid), Pasteurella pestis , and Pasteurella tularensis , Bartonella bacilliformis , Bacteroides species, Vibrio comma and Vibrio fetus , Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Oxytetracycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli , Enterobacter aerogenes (formerly Aerobacter aerogenes ), Shigella species, Mima species and Herellea species, Haemophilus influenzae (respiratory infections), Klebsiella species (respiratory and urinary infections). Oxytetracycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to Group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Diplococcus pneumoniae , Staphylococcus aureus , skin and soft-tissue infections. Oxytetracycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of infections due to: Neisseria gonorrhoeae , Treponema pallidum and Treponema pertenue (syphilis and yaws), Listeria monocytogenes , Clostridium species, Bacillus anthracis , Fusobacterium fusiforme (Vincent's infection), Actinomyces species. In acute intestinal amebiasis, the tetracyclines may be a useful adjunct to amebicides. In severe acne, the tetracyclines may be useful adjunctive therapy. Tetracyclines are indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis may be treated with oral tetracyclines or with a combination of oral and topical agents. uuid:2a88c1ed-16dd-4678-8016-a6e302e1efeb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133011 biolink:treats MONDO:0001246 PMID:41385096 "[{""id"":""uuid:ddf9be69-7592-4b2b-8ea2-1e3323fb62bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ed0be4d6-6f97-4c03-9e31-6dd4dfe580dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxytetracycline is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers), Mycoplasma pneumoniae (PPLO, Eaton Agent), Agents of psittacosis and ornithosis, Agents of lymphogranuloma venereum and granuloma inguinale, The spirochetal agent of relapsing fever ( Borrelia recurrentis ). The following gram negative microorganisms: Haemophilus ducreyi (chancroid), Pasteurella pestis , and Pasteurella tularensis , Bartonella bacilliformis , Bacteroides species, Vibrio comma and Vibrio fetus , Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Oxytetracycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli , Enterobacter aerogenes (formerly Aerobacter aerogenes ), Shigella species, Mima species and Herellea species, Haemophilus influenzae (respiratory infections), Klebsiella species (respiratory and urinary infections). Oxytetracycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to Group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Diplococcus pneumoniae , Staphylococcus aureus , skin and soft-tissue infections. Oxytetracycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of infections due to: Neisseria gonorrhoeae , Treponema pallidum and Treponema pertenue (syphilis and yaws), Listeria monocytogenes , Clostridium species, Bacillus anthracis , Fusobacterium fusiforme (Vincent's infection), Actinomyces species. In acute intestinal amebiasis, the tetracyclines may be a useful adjunct to amebicides. In severe acne, the tetracyclines may be useful adjunctive therapy. Tetracyclines are indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis may be treated with oral tetracyclines or with a combination of oral and topical agents. uuid:d367591b-35f7-45ee-89ec-48f07c1886dc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133011 biolink:treats MONDO:0019186 PMID:41385096 "[{""id"":""uuid:c9e84e04-f62d-48bf-bcf9-116d09c4fa01"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3afc4302-9683-4556-a916-ff6f9b961a5b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxytetracycline is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers), Mycoplasma pneumoniae (PPLO, Eaton Agent), Agents of psittacosis and ornithosis, Agents of lymphogranuloma venereum and granuloma inguinale, The spirochetal agent of relapsing fever ( Borrelia recurrentis ). The following gram negative microorganisms: Haemophilus ducreyi (chancroid), Pasteurella pestis , and Pasteurella tularensis , Bartonella bacilliformis , Bacteroides species, Vibrio comma and Vibrio fetus , Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Oxytetracycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli , Enterobacter aerogenes (formerly Aerobacter aerogenes ), Shigella species, Mima species and Herellea species, Haemophilus influenzae (respiratory infections), Klebsiella species (respiratory and urinary infections). Oxytetracycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to Group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Diplococcus pneumoniae , Staphylococcus aureus , skin and soft-tissue infections. Oxytetracycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of infections due to: Neisseria gonorrhoeae , Treponema pallidum and Treponema pertenue (syphilis and yaws), Listeria monocytogenes , Clostridium species, Bacillus anthracis , Fusobacterium fusiforme (Vincent's infection), Actinomyces species. In acute intestinal amebiasis, the tetracyclines may be a useful adjunct to amebicides. In severe acne, the tetracyclines may be useful adjunctive therapy. Tetracyclines are indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis may be treated with oral tetracyclines or with a combination of oral and topical agents. uuid:28675d6b-e379-456d-a82e-8cc5eaa185b5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133011 biolink:treats MONDO:0019360 PMID:41385096 "[{""id"":""uuid:0d9dda6b-d21e-4362-94e5-500e67e7e591"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:81804b29-76cf-4435-a2c2-2c8858edc7da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxytetracycline is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers), Mycoplasma pneumoniae (PPLO, Eaton Agent), Agents of psittacosis and ornithosis, Agents of lymphogranuloma venereum and granuloma inguinale, The spirochetal agent of relapsing fever ( Borrelia recurrentis ). The following gram negative microorganisms: Haemophilus ducreyi (chancroid), Pasteurella pestis , and Pasteurella tularensis , Bartonella bacilliformis , Bacteroides species, Vibrio comma and Vibrio fetus , Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Oxytetracycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli , Enterobacter aerogenes (formerly Aerobacter aerogenes ), Shigella species, Mima species and Herellea species, Haemophilus influenzae (respiratory infections), Klebsiella species (respiratory and urinary infections). Oxytetracycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to Group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Diplococcus pneumoniae , Staphylococcus aureus , skin and soft-tissue infections. Oxytetracycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of infections due to: Neisseria gonorrhoeae , Treponema pallidum and Treponema pertenue (syphilis and yaws), Listeria monocytogenes , Clostridium species, Bacillus anthracis , Fusobacterium fusiforme (Vincent's infection), Actinomyces species. In acute intestinal amebiasis, the tetracyclines may be a useful adjunct to amebicides. In severe acne, the tetracyclines may be useful adjunctive therapy. Tetracyclines are indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis may be treated with oral tetracyclines or with a combination of oral and topical agents. uuid:f17db2fc-8f5f-44a4-8700-12808a933836 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133011 biolink:treats MONDO:0025294 PMID:41385096 "[{""id"":""uuid:4d918a11-1c37-43ff-9b05-cce24d0f828f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f0c272c1-9533-43c6-ab17-12a0ba5754aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxytetracycline is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers), Mycoplasma pneumoniae (PPLO, Eaton Agent), Agents of psittacosis and ornithosis, Agents of lymphogranuloma venereum and granuloma inguinale, The spirochetal agent of relapsing fever ( Borrelia recurrentis ). The following gram negative microorganisms: Haemophilus ducreyi (chancroid), Pasteurella pestis , and Pasteurella tularensis , Bartonella bacilliformis , Bacteroides species, Vibrio comma and Vibrio fetus , Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Oxytetracycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli , Enterobacter aerogenes (formerly Aerobacter aerogenes ), Shigella species, Mima species and Herellea species, Haemophilus influenzae (respiratory infections), Klebsiella species (respiratory and urinary infections). Oxytetracycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to Group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Diplococcus pneumoniae , Staphylococcus aureus , skin and soft-tissue infections. Oxytetracycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of infections due to: Neisseria gonorrhoeae , Treponema pallidum and Treponema pertenue (syphilis and yaws), Listeria monocytogenes , Clostridium species, Bacillus anthracis , Fusobacterium fusiforme (Vincent's infection), Actinomyces species. In acute intestinal amebiasis, the tetracyclines may be a useful adjunct to amebicides. In severe acne, the tetracyclines may be useful adjunctive therapy. Tetracyclines are indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis may be treated with oral tetracyclines or with a combination of oral and topical agents. uuid:1edeefbf-6333-4384-8121-6044cc56706d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133011 biolink:treats MONDO:0005867 PMID:41385096 "[{""id"":""uuid:341cf58a-c97a-4b1b-b66e-d8a892db72a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:50b059a3-a767-4c4f-9ec0-0b3f024feeec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxytetracycline is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers), Mycoplasma pneumoniae (PPLO, Eaton Agent), Agents of psittacosis and ornithosis, Agents of lymphogranuloma venereum and granuloma inguinale, The spirochetal agent of relapsing fever ( Borrelia recurrentis ). The following gram negative microorganisms: Haemophilus ducreyi (chancroid), Pasteurella pestis , and Pasteurella tularensis , Bartonella bacilliformis , Bacteroides species, Vibrio comma and Vibrio fetus , Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Oxytetracycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli , Enterobacter aerogenes (formerly Aerobacter aerogenes ), Shigella species, Mima species and Herellea species, Haemophilus influenzae (respiratory infections), Klebsiella species (respiratory and urinary infections). Oxytetracycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to Group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Diplococcus pneumoniae , Staphylococcus aureus , skin and soft-tissue infections. Oxytetracycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of infections due to: Neisseria gonorrhoeae , Treponema pallidum and Treponema pertenue (syphilis and yaws), Listeria monocytogenes , Clostridium species, Bacillus anthracis , Fusobacterium fusiforme (Vincent's infection), Actinomyces species. In acute intestinal amebiasis, the tetracyclines may be a useful adjunct to amebicides. In severe acne, the tetracyclines may be useful adjunctive therapy. Tetracyclines are indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis may be treated with oral tetracyclines or with a combination of oral and topical agents. uuid:def146c6-08f6-46cb-b037-015a954f8cce biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133011 biolink:treats MONDO:0005888 PMID:41385096 "[{""id"":""uuid:e67e59a6-0336-47c4-86b6-f7a0e2c0800d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:51c7a67f-db5f-4cba-9185-a0207b41c0b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxytetracycline is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers), Mycoplasma pneumoniae (PPLO, Eaton Agent), Agents of psittacosis and ornithosis, Agents of lymphogranuloma venereum and granuloma inguinale, The spirochetal agent of relapsing fever ( Borrelia recurrentis ). The following gram negative microorganisms: Haemophilus ducreyi (chancroid), Pasteurella pestis , and Pasteurella tularensis , Bartonella bacilliformis , Bacteroides species, Vibrio comma and Vibrio fetus , Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Oxytetracycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli , Enterobacter aerogenes (formerly Aerobacter aerogenes ), Shigella species, Mima species and Herellea species, Haemophilus influenzae (respiratory infections), Klebsiella species (respiratory and urinary infections). Oxytetracycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to Group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Diplococcus pneumoniae , Staphylococcus aureus , skin and soft-tissue infections. Oxytetracycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of infections due to: Neisseria gonorrhoeae , Treponema pallidum and Treponema pertenue (syphilis and yaws), Listeria monocytogenes , Clostridium species, Bacillus anthracis , Fusobacterium fusiforme (Vincent's infection), Actinomyces species. In acute intestinal amebiasis, the tetracyclines may be a useful adjunct to amebicides. In severe acne, the tetracyclines may be useful adjunctive therapy. Tetracyclines are indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis may be treated with oral tetracyclines or with a combination of oral and topical agents. uuid:75915ede-f248-44eb-b1fb-bbbf6a3467a6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133011 biolink:treats MONDO:0005834 PMID:41385096 "[{""id"":""uuid:4c9e0c79-d669-46f4-a1ff-cdba3766f9b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fa0ab4cc-14a1-4fe3-86ee-5c090e4f5d5d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxytetracycline is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers), Mycoplasma pneumoniae (PPLO, Eaton Agent), Agents of psittacosis and ornithosis, Agents of lymphogranuloma venereum and granuloma inguinale, The spirochetal agent of relapsing fever ( Borrelia recurrentis ). The following gram negative microorganisms: Haemophilus ducreyi (chancroid), Pasteurella pestis , and Pasteurella tularensis , Bartonella bacilliformis , Bacteroides species, Vibrio comma and Vibrio fetus , Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Oxytetracycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli , Enterobacter aerogenes (formerly Aerobacter aerogenes ), Shigella species, Mima species and Herellea species, Haemophilus influenzae (respiratory infections), Klebsiella species (respiratory and urinary infections). Oxytetracycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to Group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Diplococcus pneumoniae , Staphylococcus aureus , skin and soft-tissue infections. Oxytetracycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of infections due to: Neisseria gonorrhoeae , Treponema pallidum and Treponema pertenue (syphilis and yaws), Listeria monocytogenes , Clostridium species, Bacillus anthracis , Fusobacterium fusiforme (Vincent's infection), Actinomyces species. In acute intestinal amebiasis, the tetracyclines may be a useful adjunct to amebicides. In severe acne, the tetracyclines may be useful adjunctive therapy. Tetracyclines are indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis may be treated with oral tetracyclines or with a combination of oral and topical agents. uuid:15a269d4-733d-479d-a63e-dc41648556cb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133011 biolink:treats MONDO:0005777 PMID:41385096 "[{""id"":""uuid:f5d5e75e-6729-454d-b47b-d497301733e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cbda0d34-bb0f-4389-8959-c40eea511a2c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxytetracycline is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers), Mycoplasma pneumoniae (PPLO, Eaton Agent), Agents of psittacosis and ornithosis, Agents of lymphogranuloma venereum and granuloma inguinale, The spirochetal agent of relapsing fever ( Borrelia recurrentis ). The following gram negative microorganisms: Haemophilus ducreyi (chancroid), Pasteurella pestis , and Pasteurella tularensis , Bartonella bacilliformis , Bacteroides species, Vibrio comma and Vibrio fetus , Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Oxytetracycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli , Enterobacter aerogenes (formerly Aerobacter aerogenes ), Shigella species, Mima species and Herellea species, Haemophilus influenzae (respiratory infections), Klebsiella species (respiratory and urinary infections). Oxytetracycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to Group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Diplococcus pneumoniae , Staphylococcus aureus , skin and soft-tissue infections. Oxytetracycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of infections due to: Neisseria gonorrhoeae , Treponema pallidum and Treponema pertenue (syphilis and yaws), Listeria monocytogenes , Clostridium species, Bacillus anthracis , Fusobacterium fusiforme (Vincent's infection), Actinomyces species. In acute intestinal amebiasis, the tetracyclines may be a useful adjunct to amebicides. In severe acne, the tetracyclines may be useful adjunctive therapy. Tetracyclines are indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis may be treated with oral tetracyclines or with a combination of oral and topical agents. uuid:e6abc58f-35c3-4976-bc73-158382e91d1d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133011 biolink:treats MONDO:0019633 PMID:41385096 "[{""id"":""uuid:71459754-29d0-462a-861b-6c9dd05a49e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:49d44ff3-651e-46ea-a628-375ef47ae79c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxytetracycline is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers), Mycoplasma pneumoniae (PPLO, Eaton Agent), Agents of psittacosis and ornithosis, Agents of lymphogranuloma venereum and granuloma inguinale, The spirochetal agent of relapsing fever ( Borrelia recurrentis ). The following gram negative microorganisms: Haemophilus ducreyi (chancroid), Pasteurella pestis , and Pasteurella tularensis , Bartonella bacilliformis , Bacteroides species, Vibrio comma and Vibrio fetus , Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Oxytetracycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli , Enterobacter aerogenes (formerly Aerobacter aerogenes ), Shigella species, Mima species and Herellea species, Haemophilus influenzae (respiratory infections), Klebsiella species (respiratory and urinary infections). Oxytetracycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to Group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Diplococcus pneumoniae , Staphylococcus aureus , skin and soft-tissue infections. Oxytetracycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of infections due to: Neisseria gonorrhoeae , Treponema pallidum and Treponema pertenue (syphilis and yaws), Listeria monocytogenes , Clostridium species, Bacillus anthracis , Fusobacterium fusiforme (Vincent's infection), Actinomyces species. In acute intestinal amebiasis, the tetracyclines may be a useful adjunct to amebicides. In severe acne, the tetracyclines may be useful adjunctive therapy. Tetracyclines are indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis may be treated with oral tetracyclines or with a combination of oral and topical agents. uuid:966270cb-688d-458b-81b3-8473f9e0c281 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133011 biolink:treats MONDO:0001797 PMID:41385096 "[{""id"":""uuid:b3d001ba-efcb-489a-95dc-5ac81acccc70"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9398ab95-d169-4002-a027-97b2c8be720a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxytetracycline is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers), Mycoplasma pneumoniae (PPLO, Eaton Agent), Agents of psittacosis and ornithosis, Agents of lymphogranuloma venereum and granuloma inguinale, The spirochetal agent of relapsing fever ( Borrelia recurrentis ). The following gram negative microorganisms: Haemophilus ducreyi (chancroid), Pasteurella pestis , and Pasteurella tularensis , Bartonella bacilliformis , Bacteroides species, Vibrio comma and Vibrio fetus , Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Oxytetracycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli , Enterobacter aerogenes (formerly Aerobacter aerogenes ), Shigella species, Mima species and Herellea species, Haemophilus influenzae (respiratory infections), Klebsiella species (respiratory and urinary infections). Oxytetracycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to Group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Diplococcus pneumoniae , Staphylococcus aureus , skin and soft-tissue infections. Oxytetracycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of infections due to: Neisseria gonorrhoeae , Treponema pallidum and Treponema pertenue (syphilis and yaws), Listeria monocytogenes , Clostridium species, Bacillus anthracis , Fusobacterium fusiforme (Vincent's infection), Actinomyces species. In acute intestinal amebiasis, the tetracyclines may be a useful adjunct to amebicides. In severe acne, the tetracyclines may be useful adjunctive therapy. Tetracyclines are indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis may be treated with oral tetracyclines or with a combination of oral and topical agents. uuid:d63a8971-c2a8-459a-a1c3-62f7f0b9991f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133011 biolink:treats MONDO:0019095 PMID:41385096 "[{""id"":""uuid:be6fe465-7b79-4066-a911-832dae0035f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:164c2790-5b60-4bff-8189-52eff1015ca9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxytetracycline is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers), Mycoplasma pneumoniae (PPLO, Eaton Agent), Agents of psittacosis and ornithosis, Agents of lymphogranuloma venereum and granuloma inguinale, The spirochetal agent of relapsing fever ( Borrelia recurrentis ). The following gram negative microorganisms: Haemophilus ducreyi (chancroid), Pasteurella pestis , and Pasteurella tularensis , Bartonella bacilliformis , Bacteroides species, Vibrio comma and Vibrio fetus , Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Oxytetracycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli , Enterobacter aerogenes (formerly Aerobacter aerogenes ), Shigella species, Mima species and Herellea species, Haemophilus influenzae (respiratory infections), Klebsiella species (respiratory and urinary infections). Oxytetracycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to Group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Diplococcus pneumoniae , Staphylococcus aureus , skin and soft-tissue infections. Oxytetracycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of infections due to: Neisseria gonorrhoeae , Treponema pallidum and Treponema pertenue (syphilis and yaws), Listeria monocytogenes , Clostridium species, Bacillus anthracis , Fusobacterium fusiforme (Vincent's infection), Actinomyces species. In acute intestinal amebiasis, the tetracyclines may be a useful adjunct to amebicides. In severe acne, the tetracyclines may be useful adjunctive therapy. Tetracyclines are indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis may be treated with oral tetracyclines or with a combination of oral and topical agents. uuid:c7be4282-2f04-46be-87c5-5ab39b0194be biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133011 biolink:treats MONDO:0018077 PMID:41385096 "[{""id"":""uuid:76e2ef1d-38f6-428d-a334-0216a902f9d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c6e8e72b-1d9d-444a-9cfc-f0728ba3f670"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxytetracycline is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers), Mycoplasma pneumoniae (PPLO, Eaton Agent), Agents of psittacosis and ornithosis, Agents of lymphogranuloma venereum and granuloma inguinale, The spirochetal agent of relapsing fever ( Borrelia recurrentis ). The following gram negative microorganisms: Haemophilus ducreyi (chancroid), Pasteurella pestis , and Pasteurella tularensis , Bartonella bacilliformis , Bacteroides species, Vibrio comma and Vibrio fetus , Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Oxytetracycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli , Enterobacter aerogenes (formerly Aerobacter aerogenes ), Shigella species, Mima species and Herellea species, Haemophilus influenzae (respiratory infections), Klebsiella species (respiratory and urinary infections). Oxytetracycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to Group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Diplococcus pneumoniae , Staphylococcus aureus , skin and soft-tissue infections. Oxytetracycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of infections due to: Neisseria gonorrhoeae , Treponema pallidum and Treponema pertenue (syphilis and yaws), Listeria monocytogenes , Clostridium species, Bacillus anthracis , Fusobacterium fusiforme (Vincent's infection), Actinomyces species. In acute intestinal amebiasis, the tetracyclines may be a useful adjunct to amebicides. In severe acne, the tetracyclines may be useful adjunctive therapy. Tetracyclines are indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis may be treated with oral tetracyclines or with a combination of oral and topical agents. uuid:8f0b6ccb-84bf-40f2-8c3a-896e5111edc0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133011 biolink:treats MONDO:0020920 PMID:41385096 "[{""id"":""uuid:a0d56261-366c-43c9-87f4-1639ad1376ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a7ee3cd1-9b8e-485d-b6d8-d9ea684da68c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxytetracycline is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers), Mycoplasma pneumoniae (PPLO, Eaton Agent), Agents of psittacosis and ornithosis, Agents of lymphogranuloma venereum and granuloma inguinale, The spirochetal agent of relapsing fever ( Borrelia recurrentis ). The following gram negative microorganisms: Haemophilus ducreyi (chancroid), Pasteurella pestis , and Pasteurella tularensis , Bartonella bacilliformis , Bacteroides species, Vibrio comma and Vibrio fetus , Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Oxytetracycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli , Enterobacter aerogenes (formerly Aerobacter aerogenes ), Shigella species, Mima species and Herellea species, Haemophilus influenzae (respiratory infections), Klebsiella species (respiratory and urinary infections). Oxytetracycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to Group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Diplococcus pneumoniae , Staphylococcus aureus , skin and soft-tissue infections. Oxytetracycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of infections due to: Neisseria gonorrhoeae , Treponema pallidum and Treponema pertenue (syphilis and yaws), Listeria monocytogenes , Clostridium species, Bacillus anthracis , Fusobacterium fusiforme (Vincent's infection), Actinomyces species. In acute intestinal amebiasis, the tetracyclines may be a useful adjunct to amebicides. In severe acne, the tetracyclines may be useful adjunctive therapy. Tetracyclines are indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis may be treated with oral tetracyclines or with a combination of oral and topical agents. uuid:97d4cebf-03a2-404b-9a84-c68d09216b7d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133011 biolink:treats MONDO:0019345 PMID:41385096 "[{""id"":""uuid:a0e32866-8f0b-417b-b8ac-31cf55bb7c3e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:08674c6e-0f5d-4369-a5a8-1011db9da20f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxytetracycline is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers), Mycoplasma pneumoniae (PPLO, Eaton Agent), Agents of psittacosis and ornithosis, Agents of lymphogranuloma venereum and granuloma inguinale, The spirochetal agent of relapsing fever ( Borrelia recurrentis ). The following gram negative microorganisms: Haemophilus ducreyi (chancroid), Pasteurella pestis , and Pasteurella tularensis , Bartonella bacilliformis , Bacteroides species, Vibrio comma and Vibrio fetus , Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Oxytetracycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli , Enterobacter aerogenes (formerly Aerobacter aerogenes ), Shigella species, Mima species and Herellea species, Haemophilus influenzae (respiratory infections), Klebsiella species (respiratory and urinary infections). Oxytetracycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to Group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Diplococcus pneumoniae , Staphylococcus aureus , skin and soft-tissue infections. Oxytetracycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of infections due to: Neisseria gonorrhoeae , Treponema pallidum and Treponema pertenue (syphilis and yaws), Listeria monocytogenes , Clostridium species, Bacillus anthracis , Fusobacterium fusiforme (Vincent's infection), Actinomyces species. In acute intestinal amebiasis, the tetracyclines may be a useful adjunct to amebicides. In severe acne, the tetracyclines may be useful adjunctive therapy. Tetracyclines are indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis may be treated with oral tetracyclines or with a combination of oral and topical agents. uuid:c3ad1d6b-8da8-4dfa-8715-eb779ad2ce1f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133011 biolink:treats MONDO:0006635 PMID:41385096 "[{""id"":""uuid:e5c144f1-86e9-4745-aec7-8beefe97d990"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d2fb4f3a-866c-45b4-b4f9-0bcf7cf35201"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxytetracycline is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers), Mycoplasma pneumoniae (PPLO, Eaton Agent), Agents of psittacosis and ornithosis, Agents of lymphogranuloma venereum and granuloma inguinale, The spirochetal agent of relapsing fever ( Borrelia recurrentis ). The following gram negative microorganisms: Haemophilus ducreyi (chancroid), Pasteurella pestis , and Pasteurella tularensis , Bartonella bacilliformis , Bacteroides species, Vibrio comma and Vibrio fetus , Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Oxytetracycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli , Enterobacter aerogenes (formerly Aerobacter aerogenes ), Shigella species, Mima species and Herellea species, Haemophilus influenzae (respiratory infections), Klebsiella species (respiratory and urinary infections). Oxytetracycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to Group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Diplococcus pneumoniae , Staphylococcus aureus , skin and soft-tissue infections. Oxytetracycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of infections due to: Neisseria gonorrhoeae , Treponema pallidum and Treponema pertenue (syphilis and yaws), Listeria monocytogenes , Clostridium species, Bacillus anthracis , Fusobacterium fusiforme (Vincent's infection), Actinomyces species. In acute intestinal amebiasis, the tetracyclines may be a useful adjunct to amebicides. In severe acne, the tetracyclines may be useful adjunctive therapy. Tetracyclines are indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis may be treated with oral tetracyclines or with a combination of oral and topical agents. uuid:d84e85b7-827e-4288-84be-b76b9361f4d6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133011 biolink:treats MONDO:0006926 PMID:41385096 "[{""id"":""uuid:da978082-1015-4fb6-93d4-548151b41055"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:807c6fb2-27d1-4bac-adb2-ff4b73bea5d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxytetracycline is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers), Mycoplasma pneumoniae (PPLO, Eaton Agent), Agents of psittacosis and ornithosis, Agents of lymphogranuloma venereum and granuloma inguinale, The spirochetal agent of relapsing fever ( Borrelia recurrentis ). The following gram negative microorganisms: Haemophilus ducreyi (chancroid), Pasteurella pestis , and Pasteurella tularensis , Bartonella bacilliformis , Bacteroides species, Vibrio comma and Vibrio fetus , Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Oxytetracycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli , Enterobacter aerogenes (formerly Aerobacter aerogenes ), Shigella species, Mima species and Herellea species, Haemophilus influenzae (respiratory infections), Klebsiella species (respiratory and urinary infections). Oxytetracycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to Group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Diplococcus pneumoniae , Staphylococcus aureus , skin and soft-tissue infections. Oxytetracycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of infections due to: Neisseria gonorrhoeae , Treponema pallidum and Treponema pertenue (syphilis and yaws), Listeria monocytogenes , Clostridium species, Bacillus anthracis , Fusobacterium fusiforme (Vincent's infection), Actinomyces species. In acute intestinal amebiasis, the tetracyclines may be a useful adjunct to amebicides. In severe acne, the tetracyclines may be useful adjunctive therapy. Tetracyclines are indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis may be treated with oral tetracyclines or with a combination of oral and topical agents. uuid:b719ac26-2239-43c2-a626-3fb118789b26 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133011 biolink:treats MONDO:0030602 PMID:41385096 "[{""id"":""uuid:a275e5ca-e7b1-4ef9-b216-def9f2176c25"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:769cc00a-0bd3-4c63-88f0-9672c1573ec6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxytetracycline is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers), Mycoplasma pneumoniae (PPLO, Eaton Agent), Agents of psittacosis and ornithosis, Agents of lymphogranuloma venereum and granuloma inguinale, The spirochetal agent of relapsing fever ( Borrelia recurrentis ). The following gram negative microorganisms: Haemophilus ducreyi (chancroid), Pasteurella pestis , and Pasteurella tularensis , Bartonella bacilliformis , Bacteroides species, Vibrio comma and Vibrio fetus , Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Oxytetracycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli , Enterobacter aerogenes (formerly Aerobacter aerogenes ), Shigella species, Mima species and Herellea species, Haemophilus influenzae (respiratory infections), Klebsiella species (respiratory and urinary infections). Oxytetracycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to Group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Diplococcus pneumoniae , Staphylococcus aureus , skin and soft-tissue infections. Oxytetracycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of infections due to: Neisseria gonorrhoeae , Treponema pallidum and Treponema pertenue (syphilis and yaws), Listeria monocytogenes , Clostridium species, Bacillus anthracis , Fusobacterium fusiforme (Vincent's infection), Actinomyces species. In acute intestinal amebiasis, the tetracyclines may be a useful adjunct to amebicides. In severe acne, the tetracyclines may be useful adjunctive therapy. Tetracyclines are indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis may be treated with oral tetracyclines or with a combination of oral and topical agents. uuid:b6ab922a-2883-4ff8-99b7-fbadf4c9c0d7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133011 biolink:treats MONDO:0030603 PMID:41385096 "[{""id"":""uuid:e457d4a8-ae83-4f2d-85a3-e6cb46672a6f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1b3167d1-f55a-4882-82cb-74f3abebe599"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxytetracycline is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers), Mycoplasma pneumoniae (PPLO, Eaton Agent), Agents of psittacosis and ornithosis, Agents of lymphogranuloma venereum and granuloma inguinale, The spirochetal agent of relapsing fever ( Borrelia recurrentis ). The following gram negative microorganisms: Haemophilus ducreyi (chancroid), Pasteurella pestis , and Pasteurella tularensis , Bartonella bacilliformis , Bacteroides species, Vibrio comma and Vibrio fetus , Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Oxytetracycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli , Enterobacter aerogenes (formerly Aerobacter aerogenes ), Shigella species, Mima species and Herellea species, Haemophilus influenzae (respiratory infections), Klebsiella species (respiratory and urinary infections). Oxytetracycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to Group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Diplococcus pneumoniae , Staphylococcus aureus , skin and soft-tissue infections. Oxytetracycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of infections due to: Neisseria gonorrhoeae , Treponema pallidum and Treponema pertenue (syphilis and yaws), Listeria monocytogenes , Clostridium species, Bacillus anthracis , Fusobacterium fusiforme (Vincent's infection), Actinomyces species. In acute intestinal amebiasis, the tetracyclines may be a useful adjunct to amebicides. In severe acne, the tetracyclines may be useful adjunctive therapy. Tetracyclines are indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis may be treated with oral tetracyclines or with a combination of oral and topical agents. uuid:2e29bd37-9730-4300-ad90-e7b4c01fcf7d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133011 biolink:treats MONDO:0021680 PMID:41385096 "[{""id"":""uuid:13f8787e-fdd3-49ba-8d5a-05573b1dd5a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0cf6bdb0-c024-4b72-97f3-36faf4e7a1d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxytetracycline is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers), Mycoplasma pneumoniae (PPLO, Eaton Agent), Agents of psittacosis and ornithosis, Agents of lymphogranuloma venereum and granuloma inguinale, The spirochetal agent of relapsing fever ( Borrelia recurrentis ). The following gram negative microorganisms: Haemophilus ducreyi (chancroid), Pasteurella pestis , and Pasteurella tularensis , Bartonella bacilliformis , Bacteroides species, Vibrio comma and Vibrio fetus , Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Oxytetracycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli , Enterobacter aerogenes (formerly Aerobacter aerogenes ), Shigella species, Mima species and Herellea species, Haemophilus influenzae (respiratory infections), Klebsiella species (respiratory and urinary infections). Oxytetracycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to Group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Diplococcus pneumoniae , Staphylococcus aureus , skin and soft-tissue infections. Oxytetracycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of infections due to: Neisseria gonorrhoeae , Treponema pallidum and Treponema pertenue (syphilis and yaws), Listeria monocytogenes , Clostridium species, Bacillus anthracis , Fusobacterium fusiforme (Vincent's infection), Actinomyces species. In acute intestinal amebiasis, the tetracyclines may be a useful adjunct to amebicides. In severe acne, the tetracyclines may be useful adjunctive therapy. Tetracyclines are indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis may be treated with oral tetracyclines or with a combination of oral and topical agents. uuid:96010e41-bb09-4536-b20a-05925fa8e785 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133011 biolink:treats MONDO:0005114 PMID:41385096 "[{""id"":""uuid:1d66f852-a51c-4303-8d5a-dbf7d04bf91b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2e56d023-a728-4957-bad2-df529a2253e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxytetracycline is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers), Mycoplasma pneumoniae (PPLO, Eaton Agent), Agents of psittacosis and ornithosis, Agents of lymphogranuloma venereum and granuloma inguinale, The spirochetal agent of relapsing fever ( Borrelia recurrentis ). The following gram negative microorganisms: Haemophilus ducreyi (chancroid), Pasteurella pestis , and Pasteurella tularensis , Bartonella bacilliformis , Bacteroides species, Vibrio comma and Vibrio fetus , Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Oxytetracycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli , Enterobacter aerogenes (formerly Aerobacter aerogenes ), Shigella species, Mima species and Herellea species, Haemophilus influenzae (respiratory infections), Klebsiella species (respiratory and urinary infections). Oxytetracycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to Group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Diplococcus pneumoniae , Staphylococcus aureus , skin and soft-tissue infections. Oxytetracycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of infections due to: Neisseria gonorrhoeae , Treponema pallidum and Treponema pertenue (syphilis and yaws), Listeria monocytogenes , Clostridium species, Bacillus anthracis , Fusobacterium fusiforme (Vincent's infection), Actinomyces species. In acute intestinal amebiasis, the tetracyclines may be a useful adjunct to amebicides. In severe acne, the tetracyclines may be useful adjunctive therapy. Tetracyclines are indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis may be treated with oral tetracyclines or with a combination of oral and topical agents. uuid:2e001603-522e-42b0-86a3-aee1f9dbba0f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133011 biolink:treats MONDO:0005545 PMID:41385096 "[{""id"":""uuid:91294e4a-cfc1-4578-85ed-b75b1f9932c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:817d104a-eedc-41fb-ac3a-2450d7801ee6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxytetracycline is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers), Mycoplasma pneumoniae (PPLO, Eaton Agent), Agents of psittacosis and ornithosis, Agents of lymphogranuloma venereum and granuloma inguinale, The spirochetal agent of relapsing fever ( Borrelia recurrentis ). The following gram negative microorganisms: Haemophilus ducreyi (chancroid), Pasteurella pestis , and Pasteurella tularensis , Bartonella bacilliformis , Bacteroides species, Vibrio comma and Vibrio fetus , Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Oxytetracycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli , Enterobacter aerogenes (formerly Aerobacter aerogenes ), Shigella species, Mima species and Herellea species, Haemophilus influenzae (respiratory infections), Klebsiella species (respiratory and urinary infections). Oxytetracycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to Group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Diplococcus pneumoniae , Staphylococcus aureus , skin and soft-tissue infections. Oxytetracycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of infections due to: Neisseria gonorrhoeae , Treponema pallidum and Treponema pertenue (syphilis and yaws), Listeria monocytogenes , Clostridium species, Bacillus anthracis , Fusobacterium fusiforme (Vincent's infection), Actinomyces species. In acute intestinal amebiasis, the tetracyclines may be a useful adjunct to amebicides. In severe acne, the tetracyclines may be useful adjunctive therapy. Tetracyclines are indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis may be treated with oral tetracyclines or with a combination of oral and topical agents. uuid:c215897a-3487-4e55-bc81-a824216b2e3b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133011 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:0bb23cd4-2459-44fe-b377-8f8ef779fd66"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2c4f79af-24f3-4dc4-8478-aa80e95cacd1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxytetracycline is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers), Mycoplasma pneumoniae (PPLO, Eaton Agent), Agents of psittacosis and ornithosis, Agents of lymphogranuloma venereum and granuloma inguinale, The spirochetal agent of relapsing fever ( Borrelia recurrentis ). The following gram negative microorganisms: Haemophilus ducreyi (chancroid), Pasteurella pestis , and Pasteurella tularensis , Bartonella bacilliformis , Bacteroides species, Vibrio comma and Vibrio fetus , Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Oxytetracycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli , Enterobacter aerogenes (formerly Aerobacter aerogenes ), Shigella species, Mima species and Herellea species, Haemophilus influenzae (respiratory infections), Klebsiella species (respiratory and urinary infections). Oxytetracycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to Group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Diplococcus pneumoniae , Staphylococcus aureus , skin and soft-tissue infections. Oxytetracycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of infections due to: Neisseria gonorrhoeae , Treponema pallidum and Treponema pertenue (syphilis and yaws), Listeria monocytogenes , Clostridium species, Bacillus anthracis , Fusobacterium fusiforme (Vincent's infection), Actinomyces species. In acute intestinal amebiasis, the tetracyclines may be a useful adjunct to amebicides. In severe acne, the tetracyclines may be useful adjunctive therapy. Tetracyclines are indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis may be treated with oral tetracyclines or with a combination of oral and topical agents. uuid:f26bd4b8-813e-470a-b8a2-c341abc38870 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133011 biolink:treats MONDO:0004277 PMID:41385096 "[{""id"":""uuid:ff4cb15a-440c-49fa-b6ee-bb2a5fc7ad8b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:345e09da-1a42-4c87-9085-628c4609333b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxytetracycline is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers), Mycoplasma pneumoniae (PPLO, Eaton Agent), Agents of psittacosis and ornithosis, Agents of lymphogranuloma venereum and granuloma inguinale, The spirochetal agent of relapsing fever ( Borrelia recurrentis ). The following gram negative microorganisms: Haemophilus ducreyi (chancroid), Pasteurella pestis , and Pasteurella tularensis , Bartonella bacilliformis , Bacteroides species, Vibrio comma and Vibrio fetus , Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Oxytetracycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli , Enterobacter aerogenes (formerly Aerobacter aerogenes ), Shigella species, Mima species and Herellea species, Haemophilus influenzae (respiratory infections), Klebsiella species (respiratory and urinary infections). Oxytetracycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to Group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Diplococcus pneumoniae , Staphylococcus aureus , skin and soft-tissue infections. Oxytetracycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of infections due to: Neisseria gonorrhoeae , Treponema pallidum and Treponema pertenue (syphilis and yaws), Listeria monocytogenes , Clostridium species, Bacillus anthracis , Fusobacterium fusiforme (Vincent's infection), Actinomyces species. In acute intestinal amebiasis, the tetracyclines may be a useful adjunct to amebicides. In severe acne, the tetracyclines may be useful adjunctive therapy. Tetracyclines are indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis may be treated with oral tetracyclines or with a combination of oral and topical agents. uuid:c6674bb9-b20c-4ff1-a0a8-7fb1aa12cf04 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133011 biolink:treats MONDO:0005976 PMID:41385096 "[{""id"":""uuid:996519ad-f0a6-4a73-90c5-5493eb8f956e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a26d4b1e-af5a-474c-a650-24602021b2e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxytetracycline is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers), Mycoplasma pneumoniae (PPLO, Eaton Agent), Agents of psittacosis and ornithosis, Agents of lymphogranuloma venereum and granuloma inguinale, The spirochetal agent of relapsing fever ( Borrelia recurrentis ). The following gram negative microorganisms: Haemophilus ducreyi (chancroid), Pasteurella pestis , and Pasteurella tularensis , Bartonella bacilliformis , Bacteroides species, Vibrio comma and Vibrio fetus , Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Oxytetracycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli , Enterobacter aerogenes (formerly Aerobacter aerogenes ), Shigella species, Mima species and Herellea species, Haemophilus influenzae (respiratory infections), Klebsiella species (respiratory and urinary infections). Oxytetracycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to Group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Diplococcus pneumoniae , Staphylococcus aureus , skin and soft-tissue infections. Oxytetracycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of infections due to: Neisseria gonorrhoeae , Treponema pallidum and Treponema pertenue (syphilis and yaws), Listeria monocytogenes , Clostridium species, Bacillus anthracis , Fusobacterium fusiforme (Vincent's infection), Actinomyces species. In acute intestinal amebiasis, the tetracyclines may be a useful adjunct to amebicides. In severe acne, the tetracyclines may be useful adjunctive therapy. Tetracyclines are indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis may be treated with oral tetracyclines or with a combination of oral and topical agents. uuid:06fc33bf-7474-4edd-b117-b5b47c80b05d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133011 biolink:treats MONDO:0006019 PMID:41385096 "[{""id"":""uuid:03b87af5-4601-4a85-a972-4dcdc3678c25"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2b3e2384-79c6-46cf-8615-91673677972e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxytetracycline is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers), Mycoplasma pneumoniae (PPLO, Eaton Agent), Agents of psittacosis and ornithosis, Agents of lymphogranuloma venereum and granuloma inguinale, The spirochetal agent of relapsing fever ( Borrelia recurrentis ). The following gram negative microorganisms: Haemophilus ducreyi (chancroid), Pasteurella pestis , and Pasteurella tularensis , Bartonella bacilliformis , Bacteroides species, Vibrio comma and Vibrio fetus , Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Oxytetracycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli , Enterobacter aerogenes (formerly Aerobacter aerogenes ), Shigella species, Mima species and Herellea species, Haemophilus influenzae (respiratory infections), Klebsiella species (respiratory and urinary infections). Oxytetracycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to Group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Diplococcus pneumoniae , Staphylococcus aureus , skin and soft-tissue infections. Oxytetracycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of infections due to: Neisseria gonorrhoeae , Treponema pallidum and Treponema pertenue (syphilis and yaws), Listeria monocytogenes , Clostridium species, Bacillus anthracis , Fusobacterium fusiforme (Vincent's infection), Actinomyces species. In acute intestinal amebiasis, the tetracyclines may be a useful adjunct to amebicides. In severe acne, the tetracyclines may be useful adjunctive therapy. Tetracyclines are indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis may be treated with oral tetracyclines or with a combination of oral and topical agents. uuid:2f4c6922-15b6-4b6d-9f80-aaac5b377dc1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133011 biolink:treats MONDO:0005828 PMID:41385096 "[{""id"":""uuid:b33b49d8-9771-48f9-942e-4ea9d5ad8ff5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:12ddd67c-af8d-496a-812d-fdef120d7721"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxytetracycline is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers), Mycoplasma pneumoniae (PPLO, Eaton Agent), Agents of psittacosis and ornithosis, Agents of lymphogranuloma venereum and granuloma inguinale, The spirochetal agent of relapsing fever ( Borrelia recurrentis ). The following gram negative microorganisms: Haemophilus ducreyi (chancroid), Pasteurella pestis , and Pasteurella tularensis , Bartonella bacilliformis , Bacteroides species, Vibrio comma and Vibrio fetus , Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Oxytetracycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli , Enterobacter aerogenes (formerly Aerobacter aerogenes ), Shigella species, Mima species and Herellea species, Haemophilus influenzae (respiratory infections), Klebsiella species (respiratory and urinary infections). Oxytetracycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to Group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Diplococcus pneumoniae , Staphylococcus aureus , skin and soft-tissue infections. Oxytetracycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of infections due to: Neisseria gonorrhoeae , Treponema pallidum and Treponema pertenue (syphilis and yaws), Listeria monocytogenes , Clostridium species, Bacillus anthracis , Fusobacterium fusiforme (Vincent's infection), Actinomyces species. In acute intestinal amebiasis, the tetracyclines may be a useful adjunct to amebicides. In severe acne, the tetracyclines may be useful adjunctive therapy. Tetracyclines are indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis may be treated with oral tetracyclines or with a combination of oral and topical agents. uuid:183c5c60-412f-41ad-a519-1109cea33d7f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133011 biolink:treats MONDO:0024388 PMID:41385096 "[{""id"":""uuid:e00c2e07-1f0c-407e-a757-9f765c3c4515"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a3aae647-4c51-4044-b5a6-611512acbb5a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxytetracycline is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers), Mycoplasma pneumoniae (PPLO, Eaton Agent), Agents of psittacosis and ornithosis, Agents of lymphogranuloma venereum and granuloma inguinale, The spirochetal agent of relapsing fever ( Borrelia recurrentis ). The following gram negative microorganisms: Haemophilus ducreyi (chancroid), Pasteurella pestis , and Pasteurella tularensis , Bartonella bacilliformis , Bacteroides species, Vibrio comma and Vibrio fetus , Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Oxytetracycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli , Enterobacter aerogenes (formerly Aerobacter aerogenes ), Shigella species, Mima species and Herellea species, Haemophilus influenzae (respiratory infections), Klebsiella species (respiratory and urinary infections). Oxytetracycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to Group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Diplococcus pneumoniae , Staphylococcus aureus , skin and soft-tissue infections. Oxytetracycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of infections due to: Neisseria gonorrhoeae , Treponema pallidum and Treponema pertenue (syphilis and yaws), Listeria monocytogenes , Clostridium species, Bacillus anthracis , Fusobacterium fusiforme (Vincent's infection), Actinomyces species. In acute intestinal amebiasis, the tetracyclines may be a useful adjunct to amebicides. In severe acne, the tetracyclines may be useful adjunctive therapy. Tetracyclines are indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis may be treated with oral tetracyclines or with a combination of oral and topical agents. uuid:b8164517-7777-4196-bae1-d94f40ba68e9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133011 biolink:treats MONDO:0005119 PMID:41385096 "[{""id"":""uuid:ddfe6182-0cbf-4f1d-8f05-bb658252e3d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:19cf2689-8e25-425e-a74e-3e34f93b491f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxytetracycline is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers), Mycoplasma pneumoniae (PPLO, Eaton Agent), Agents of psittacosis and ornithosis, Agents of lymphogranuloma venereum and granuloma inguinale, The spirochetal agent of relapsing fever ( Borrelia recurrentis ). The following gram negative microorganisms: Haemophilus ducreyi (chancroid), Pasteurella pestis , and Pasteurella tularensis , Bartonella bacilliformis , Bacteroides species, Vibrio comma and Vibrio fetus , Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Oxytetracycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli , Enterobacter aerogenes (formerly Aerobacter aerogenes ), Shigella species, Mima species and Herellea species, Haemophilus influenzae (respiratory infections), Klebsiella species (respiratory and urinary infections). Oxytetracycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to Group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Diplococcus pneumoniae , Staphylococcus aureus , skin and soft-tissue infections. Oxytetracycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of infections due to: Neisseria gonorrhoeae , Treponema pallidum and Treponema pertenue (syphilis and yaws), Listeria monocytogenes , Clostridium species, Bacillus anthracis , Fusobacterium fusiforme (Vincent's infection), Actinomyces species. In acute intestinal amebiasis, the tetracyclines may be a useful adjunct to amebicides. In severe acne, the tetracyclines may be useful adjunctive therapy. Tetracyclines are indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis may be treated with oral tetracyclines or with a combination of oral and topical agents. uuid:e1bd78ea-9535-41d0-bc7f-5b968c856364 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133011 biolink:treats MONDO:0005631 PMID:41385096 "[{""id"":""uuid:ad37fbcf-2235-42e7-a635-546de1d14e31"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:44039cc2-9539-4e44-9b6f-bea7ca537701"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxytetracycline is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers), Mycoplasma pneumoniae (PPLO, Eaton Agent), Agents of psittacosis and ornithosis, Agents of lymphogranuloma venereum and granuloma inguinale, The spirochetal agent of relapsing fever ( Borrelia recurrentis ). The following gram negative microorganisms: Haemophilus ducreyi (chancroid), Pasteurella pestis , and Pasteurella tularensis , Bartonella bacilliformis , Bacteroides species, Vibrio comma and Vibrio fetus , Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Oxytetracycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli , Enterobacter aerogenes (formerly Aerobacter aerogenes ), Shigella species, Mima species and Herellea species, Haemophilus influenzae (respiratory infections), Klebsiella species (respiratory and urinary infections). Oxytetracycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to Group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Diplococcus pneumoniae , Staphylococcus aureus , skin and soft-tissue infections. Oxytetracycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of infections due to: Neisseria gonorrhoeae , Treponema pallidum and Treponema pertenue (syphilis and yaws), Listeria monocytogenes , Clostridium species, Bacillus anthracis , Fusobacterium fusiforme (Vincent's infection), Actinomyces species. In acute intestinal amebiasis, the tetracyclines may be a useful adjunct to amebicides. In severe acne, the tetracyclines may be useful adjunctive therapy. Tetracyclines are indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis may be treated with oral tetracyclines or with a combination of oral and topical agents. uuid:914b7e62-88f9-46b0-a998-2a78c514d01b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133011 biolink:treats MONDO:0005644 PMID:41385096 "[{""id"":""uuid:1ca26572-0332-439a-8367-033980c16816"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:20828383-82a5-4ccf-b78d-bddd31a1a49b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxytetracycline is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers), Mycoplasma pneumoniae (PPLO, Eaton Agent), Agents of psittacosis and ornithosis, Agents of lymphogranuloma venereum and granuloma inguinale, The spirochetal agent of relapsing fever ( Borrelia recurrentis ). The following gram negative microorganisms: Haemophilus ducreyi (chancroid), Pasteurella pestis , and Pasteurella tularensis , Bartonella bacilliformis , Bacteroides species, Vibrio comma and Vibrio fetus , Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Oxytetracycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli , Enterobacter aerogenes (formerly Aerobacter aerogenes ), Shigella species, Mima species and Herellea species, Haemophilus influenzae (respiratory infections), Klebsiella species (respiratory and urinary infections). Oxytetracycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to Group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Diplococcus pneumoniae , Staphylococcus aureus , skin and soft-tissue infections. Oxytetracycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of infections due to: Neisseria gonorrhoeae , Treponema pallidum and Treponema pertenue (syphilis and yaws), Listeria monocytogenes , Clostridium species, Bacillus anthracis , Fusobacterium fusiforme (Vincent's infection), Actinomyces species. In acute intestinal amebiasis, the tetracyclines may be a useful adjunct to amebicides. In severe acne, the tetracyclines may be useful adjunctive therapy. Tetracyclines are indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis may be treated with oral tetracyclines or with a combination of oral and topical agents. uuid:f4647ab3-7471-4cb9-8022-9d504a92d427 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133011 biolink:treats MONDO:0011438 PMID:41385096 "[{""id"":""uuid:cc64b9c7-5b4d-447d-b6c6-da776821984d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ddc68e80-1a90-439f-a8e4-1c5975940939"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxytetracycline is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers), Mycoplasma pneumoniae (PPLO, Eaton Agent), Agents of psittacosis and ornithosis, Agents of lymphogranuloma venereum and granuloma inguinale, The spirochetal agent of relapsing fever ( Borrelia recurrentis ). The following gram negative microorganisms: Haemophilus ducreyi (chancroid), Pasteurella pestis , and Pasteurella tularensis , Bartonella bacilliformis , Bacteroides species, Vibrio comma and Vibrio fetus , Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Oxytetracycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli , Enterobacter aerogenes (formerly Aerobacter aerogenes ), Shigella species, Mima species and Herellea species, Haemophilus influenzae (respiratory infections), Klebsiella species (respiratory and urinary infections). Oxytetracycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to Group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Diplococcus pneumoniae , Staphylococcus aureus , skin and soft-tissue infections. Oxytetracycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of infections due to: Neisseria gonorrhoeae , Treponema pallidum and Treponema pertenue (syphilis and yaws), Listeria monocytogenes , Clostridium species, Bacillus anthracis , Fusobacterium fusiforme (Vincent's infection), Actinomyces species. In acute intestinal amebiasis, the tetracyclines may be a useful adjunct to amebicides. In severe acne, the tetracyclines may be useful adjunctive therapy. Tetracyclines are indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis may be treated with oral tetracyclines or with a combination of oral and topical agents. uuid:2c271d39-3e80-4bb0-b01c-be5c152f9604 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133011 biolink:treats MONDO:0001249 PMID:41385096 "[{""id"":""uuid:8c39f7c4-962e-47f6-a579-e013cd89008f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:16de581d-0e65-4463-9432-c6b0158fa4b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxytetracycline is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers), Mycoplasma pneumoniae (PPLO, Eaton Agent), Agents of psittacosis and ornithosis, Agents of lymphogranuloma venereum and granuloma inguinale, The spirochetal agent of relapsing fever ( Borrelia recurrentis ). The following gram negative microorganisms: Haemophilus ducreyi (chancroid), Pasteurella pestis , and Pasteurella tularensis , Bartonella bacilliformis , Bacteroides species, Vibrio comma and Vibrio fetus , Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Oxytetracycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli , Enterobacter aerogenes (formerly Aerobacter aerogenes ), Shigella species, Mima species and Herellea species, Haemophilus influenzae (respiratory infections), Klebsiella species (respiratory and urinary infections). Oxytetracycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to Group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Diplococcus pneumoniae , Staphylococcus aureus , skin and soft-tissue infections. Oxytetracycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of infections due to: Neisseria gonorrhoeae , Treponema pallidum and Treponema pertenue (syphilis and yaws), Listeria monocytogenes , Clostridium species, Bacillus anthracis , Fusobacterium fusiforme (Vincent's infection), Actinomyces species. In acute intestinal amebiasis, the tetracyclines may be a useful adjunct to amebicides. In severe acne, the tetracyclines may be useful adjunctive therapy. Tetracyclines are indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis may be treated with oral tetracyclines or with a combination of oral and topical agents. uuid:e6ea5366-9f85-4204-b6e3-55f76f463b6a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133011 biolink:treats MONDO:0005808 PMID:41385096 "[{""id"":""uuid:40d3e1fb-e878-43a2-bf52-094651637fd0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:896b93ce-4a84-4df7-ae57-6d4702120ec7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxytetracycline is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers), Mycoplasma pneumoniae (PPLO, Eaton Agent), Agents of psittacosis and ornithosis, Agents of lymphogranuloma venereum and granuloma inguinale, The spirochetal agent of relapsing fever ( Borrelia recurrentis ). The following gram negative microorganisms: Haemophilus ducreyi (chancroid), Pasteurella pestis , and Pasteurella tularensis , Bartonella bacilliformis , Bacteroides species, Vibrio comma and Vibrio fetus , Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Oxytetracycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli , Enterobacter aerogenes (formerly Aerobacter aerogenes ), Shigella species, Mima species and Herellea species, Haemophilus influenzae (respiratory infections), Klebsiella species (respiratory and urinary infections). Oxytetracycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to Group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Diplococcus pneumoniae , Staphylococcus aureus , skin and soft-tissue infections. Oxytetracycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of infections due to: Neisseria gonorrhoeae , Treponema pallidum and Treponema pertenue (syphilis and yaws), Listeria monocytogenes , Clostridium species, Bacillus anthracis , Fusobacterium fusiforme (Vincent's infection), Actinomyces species. In acute intestinal amebiasis, the tetracyclines may be a useful adjunct to amebicides. In severe acne, the tetracyclines may be useful adjunctive therapy. Tetracyclines are indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis may be treated with oral tetracyclines or with a combination of oral and topical agents. uuid:c473588d-dd9b-4c7e-a632-e87ed04b89d5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2904 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:50da6889-3045-44dd-8a90-1335fce9e926"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f36dbe96-d695-424d-81be-c6f023e83d95"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension Atenolol tablets are indicated in the management of hypertension. They may be used alone or concomitantly with other antihypertensive agents, particularly with a thiazide-type diuretic. Angina Pectoris Due to Coronary Atherosclerosis Atenolol tablets are indicated for the long-term management of patients with angina pectoris. Acute Myocardial Infarction Atenolol tablets are indicated in the management of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce cardiovascular mortality. Treatment can be initiated as soon as the patient’s clinical condition allows. (See DOSAGE AND ADMINISTRATION , CONTRAINDICATIONS , and WARNINGS .) In general, there is no basis for treating patients like those who were excluded from the ISIS-1 trial (blood pressure less than 100 mm Hg systolic, heart rate less than 50 bpm) or have other reasons to avoid beta blockade. As noted above, some subgroups (e.g., elderly patients with systolic blood pressure below 120 mm Hg) seemed less likely to benefit. uuid:5a853881-c604-4e79-a451-5e320a1f902c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2904 biolink:treats HP:0001681 PMID:41385096 "[{""id"":""uuid:8440e063-52f1-45a1-8707-954563cd0f6b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2c9d4702-0162-41b0-b581-3a20ffa87562"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension Atenolol tablets are indicated in the management of hypertension. They may be used alone or concomitantly with other antihypertensive agents, particularly with a thiazide-type diuretic. Angina Pectoris Due to Coronary Atherosclerosis Atenolol tablets are indicated for the long-term management of patients with angina pectoris. Acute Myocardial Infarction Atenolol tablets are indicated in the management of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce cardiovascular mortality. Treatment can be initiated as soon as the patient’s clinical condition allows. (See DOSAGE AND ADMINISTRATION , CONTRAINDICATIONS , and WARNINGS .) In general, there is no basis for treating patients like those who were excluded from the ISIS-1 trial (blood pressure less than 100 mm Hg systolic, heart rate less than 50 bpm) or have other reasons to avoid beta blockade. As noted above, some subgroups (e.g., elderly patients with systolic blood pressure below 120 mm Hg) seemed less likely to benefit. uuid:7a76659d-950b-44c3-92d4-a778f4a93596 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2904 biolink:treats MONDO:0004781 PMID:41385096 "[{""id"":""uuid:82c5fc54-fe1c-45a9-94a5-ab8fa0f251a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4ade7ab7-c723-47bc-86e8-58a4a9c552fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension Atenolol tablets are indicated in the management of hypertension. They may be used alone or concomitantly with other antihypertensive agents, particularly with a thiazide-type diuretic. Angina Pectoris Due to Coronary Atherosclerosis Atenolol tablets are indicated for the long-term management of patients with angina pectoris. Acute Myocardial Infarction Atenolol tablets are indicated in the management of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce cardiovascular mortality. Treatment can be initiated as soon as the patient’s clinical condition allows. (See DOSAGE AND ADMINISTRATION , CONTRAINDICATIONS , and WARNINGS .) In general, there is no basis for treating patients like those who were excluded from the ISIS-1 trial (blood pressure less than 100 mm Hg systolic, heart rate less than 50 bpm) or have other reasons to avoid beta blockade. As noted above, some subgroups (e.g., elderly patients with systolic blood pressure below 120 mm Hg) seemed less likely to benefit. uuid:a0c17d28-e306-40c3-b677-559a1fd18c46 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:374687 biolink:treats MONDO:0006939 PMID:41385096 "[{""id"":""uuid:c5198382-ed03-4fbc-bb8b-2a96929929d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bb54c8e4-8c63-4c8e-aed8-6680bc4dd8e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of this drug by the National Academy of Sciences-National Research Council and/or other information, FDA has classified the indications as follows: ""Lacking substantial evidence of effectiveness as a fixed combination"": Urobiotic-250 is indicated in the therapy of a number of genitourinary infections caused by susceptible organisms. These infections include the following: pyelonephritis, pyelitis, ureteritis, cystitis, prostatitis, and urethritis. Since both Terramycin and sulfamethizole provide effective levels in blood, tissue, and urine, Urobiotic-250 provides a multiple antimicrobial approach at the site of infection. Both antibacterial components are active against the most common urinary pathogens, including Escherichia coli, Pseudomonas aeruginosa, Aerobacter aerogenes, Streptococcus faecalis, Streptococcus hemolyticus , and Micrococcus pyogenes . Urobiotic-250 is particularly useful in the treatment of infections caused by bacteria more sensitive to the combination than to either component alone. The combination is also of value in those cases with mixed infections, and in those instances where the causative organism is unknown pending laboratory isolation. Final classification of the less than effective indications requires further investigation. Clinical studies to substantiate the efficacy of Urobiotic 250 are ongoing. Completion of these ongoing studies will provide data for final classification of these indications ." uuid:c0f97530-e4ca-4e30-8e34-b99d96fe18dd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:374687 biolink:treats MONDO:0006938 PMID:41385096 "[{""id"":""uuid:2640e1d8-7cbc-4ff2-8fd6-fdb1da93d975"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ca2db818-c71e-4553-8d2d-8d0759a821bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of this drug by the National Academy of Sciences-National Research Council and/or other information, FDA has classified the indications as follows: ""Lacking substantial evidence of effectiveness as a fixed combination"": Urobiotic-250 is indicated in the therapy of a number of genitourinary infections caused by susceptible organisms. These infections include the following: pyelonephritis, pyelitis, ureteritis, cystitis, prostatitis, and urethritis. Since both Terramycin and sulfamethizole provide effective levels in blood, tissue, and urine, Urobiotic-250 provides a multiple antimicrobial approach at the site of infection. Both antibacterial components are active against the most common urinary pathogens, including Escherichia coli, Pseudomonas aeruginosa, Aerobacter aerogenes, Streptococcus faecalis, Streptococcus hemolyticus , and Micrococcus pyogenes . Urobiotic-250 is particularly useful in the treatment of infections caused by bacteria more sensitive to the combination than to either component alone. The combination is also of value in those cases with mixed infections, and in those instances where the causative organism is unknown pending laboratory isolation. Final classification of the less than effective indications requires further investigation. Clinical studies to substantiate the efficacy of Urobiotic 250 are ongoing. Completion of these ongoing studies will provide data for final classification of these indications ." uuid:5a4d33cd-3d4f-4c42-a173-569e424b57b3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:374687 biolink:treats MONDO:0021960 PMID:41385096 "[{""id"":""uuid:e45d4eb0-2114-4a74-9a07-e1db9023315e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e05a2ac9-b5c5-416c-b700-e1bc948a44a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of this drug by the National Academy of Sciences-National Research Council and/or other information, FDA has classified the indications as follows: ""Lacking substantial evidence of effectiveness as a fixed combination"": Urobiotic-250 is indicated in the therapy of a number of genitourinary infections caused by susceptible organisms. These infections include the following: pyelonephritis, pyelitis, ureteritis, cystitis, prostatitis, and urethritis. Since both Terramycin and sulfamethizole provide effective levels in blood, tissue, and urine, Urobiotic-250 provides a multiple antimicrobial approach at the site of infection. Both antibacterial components are active against the most common urinary pathogens, including Escherichia coli, Pseudomonas aeruginosa, Aerobacter aerogenes, Streptococcus faecalis, Streptococcus hemolyticus , and Micrococcus pyogenes . Urobiotic-250 is particularly useful in the treatment of infections caused by bacteria more sensitive to the combination than to either component alone. The combination is also of value in those cases with mixed infections, and in those instances where the causative organism is unknown pending laboratory isolation. Final classification of the less than effective indications requires further investigation. Clinical studies to substantiate the efficacy of Urobiotic 250 are ongoing. Completion of these ongoing studies will provide data for final classification of these indications ." uuid:d762b25e-3608-4402-a4fe-158ada8d2660 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:374687 biolink:treats MONDO:0006032 PMID:41385096 "[{""id"":""uuid:e0da08f9-cd7e-4273-b936-5a88e28c9033"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cc7b0635-5ca6-4a67-b666-788e5e3f9893"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of this drug by the National Academy of Sciences-National Research Council and/or other information, FDA has classified the indications as follows: ""Lacking substantial evidence of effectiveness as a fixed combination"": Urobiotic-250 is indicated in the therapy of a number of genitourinary infections caused by susceptible organisms. These infections include the following: pyelonephritis, pyelitis, ureteritis, cystitis, prostatitis, and urethritis. Since both Terramycin and sulfamethizole provide effective levels in blood, tissue, and urine, Urobiotic-250 provides a multiple antimicrobial approach at the site of infection. Both antibacterial components are active against the most common urinary pathogens, including Escherichia coli, Pseudomonas aeruginosa, Aerobacter aerogenes, Streptococcus faecalis, Streptococcus hemolyticus , and Micrococcus pyogenes . Urobiotic-250 is particularly useful in the treatment of infections caused by bacteria more sensitive to the combination than to either component alone. The combination is also of value in those cases with mixed infections, and in those instances where the causative organism is unknown pending laboratory isolation. Final classification of the less than effective indications requires further investigation. Clinical studies to substantiate the efficacy of Urobiotic 250 are ongoing. Completion of these ongoing studies will provide data for final classification of these indications ." uuid:09a8d756-8e67-4287-b5ca-60a828587c7f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:374687 biolink:treats MONDO:0005280 PMID:41385096 "[{""id"":""uuid:27480b9a-62a1-40c2-8a79-a73ef9156ffb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:233ea157-bb68-4061-927b-4bc7c84e1023"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of this drug by the National Academy of Sciences-National Research Council and/or other information, FDA has classified the indications as follows: ""Lacking substantial evidence of effectiveness as a fixed combination"": Urobiotic-250 is indicated in the therapy of a number of genitourinary infections caused by susceptible organisms. These infections include the following: pyelonephritis, pyelitis, ureteritis, cystitis, prostatitis, and urethritis. Since both Terramycin and sulfamethizole provide effective levels in blood, tissue, and urine, Urobiotic-250 provides a multiple antimicrobial approach at the site of infection. Both antibacterial components are active against the most common urinary pathogens, including Escherichia coli, Pseudomonas aeruginosa, Aerobacter aerogenes, Streptococcus faecalis, Streptococcus hemolyticus , and Micrococcus pyogenes . Urobiotic-250 is particularly useful in the treatment of infections caused by bacteria more sensitive to the combination than to either component alone. The combination is also of value in those cases with mixed infections, and in those instances where the causative organism is unknown pending laboratory isolation. Final classification of the less than effective indications requires further investigation. Clinical studies to substantiate the efficacy of Urobiotic 250 are ongoing. Completion of these ongoing studies will provide data for final classification of these indications ." uuid:06583f7f-cb48-46dc-9064-b7e1402a4a89 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:374687 biolink:treats MONDO:0005297 PMID:41385096 "[{""id"":""uuid:5b7200ff-c33c-4a3d-bea5-44712de93477"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5ad5843c-e56a-4cf9-925b-1366f0e2094e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of this drug by the National Academy of Sciences-National Research Council and/or other information, FDA has classified the indications as follows: ""Lacking substantial evidence of effectiveness as a fixed combination"": Urobiotic-250 is indicated in the therapy of a number of genitourinary infections caused by susceptible organisms. These infections include the following: pyelonephritis, pyelitis, ureteritis, cystitis, prostatitis, and urethritis. Since both Terramycin and sulfamethizole provide effective levels in blood, tissue, and urine, Urobiotic-250 provides a multiple antimicrobial approach at the site of infection. Both antibacterial components are active against the most common urinary pathogens, including Escherichia coli, Pseudomonas aeruginosa, Aerobacter aerogenes, Streptococcus faecalis, Streptococcus hemolyticus , and Micrococcus pyogenes . Urobiotic-250 is particularly useful in the treatment of infections caused by bacteria more sensitive to the combination than to either component alone. The combination is also of value in those cases with mixed infections, and in those instances where the causative organism is unknown pending laboratory isolation. Final classification of the less than effective indications requires further investigation. Clinical studies to substantiate the efficacy of Urobiotic 250 are ongoing. Completion of these ongoing studies will provide data for final classification of these indications ." uuid:5a4b8ff8-d72b-4d5c-b8d9-7587b36db1b2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:370642 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:e88144fe-c1d9-4a47-91e8-58fd6b97e31c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6573ff48-c3c6-4f04-a3c3-4b5209aacc4a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydrocodone bitartrate and acetaminophen tablets are indicated for the relief of moderate to moderately severe pain. uuid:5b131b9f-f614-4bd5-8578-63723059fd8f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:216913 biolink:treats MONDO:0009688 PMID:41385096 "[{""id"":""uuid:485f6cac-b10f-4c53-839d-785eefd40fc0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3c392b30-4f3b-430f-bf71-af69c8643fd9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ENLON-PLUS (edrophonium chloride, USP and atropine sulfate, USP) Injection is recommended as a reversal agent or antagonist of nondepolarizing neuromuscular blocking agents. It is not effective against depolarizing neuromuscular blocking agents. It is also useful if used adjunctively in the treatment of respiratory depression caused by curare overdosage. The appropriateness of the specific fixed ratio of edrophonium and atropine contained in ENLON-PLUS has not been evaluated in myasthenia gravis. Therefore, ENLON-PLUS is not recommended for use in the differential diagnosis of this condition. uuid:9cb84469-4e7f-48ce-bf55-5865061b5dc9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:216913 biolink:treats MONDO:0043775 PMID:41385096 "[{""id"":""uuid:6e1127aa-6f4a-4a77-99c5-d90088a275cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:19e60726-3f64-4f1d-bfdd-fe4aa96ed788"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ENLON-PLUS (edrophonium chloride, USP and atropine sulfate, USP) Injection is recommended as a reversal agent or antagonist of nondepolarizing neuromuscular blocking agents. It is not effective against depolarizing neuromuscular blocking agents. It is also useful if used adjunctively in the treatment of respiratory depression caused by curare overdosage. The appropriateness of the specific fixed ratio of edrophonium and atropine contained in ENLON-PLUS has not been evaluated in myasthenia gravis. Therefore, ENLON-PLUS is not recommended for use in the differential diagnosis of this condition. uuid:5054e7ec-c027-458e-9680-2ca9e016b565 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3699 biolink:treats MONDO:0005412 PMID:41385096 "[{""id"":""uuid:3638fa43-c22f-4aa9-824c-3fa0b85c5648"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8ef61f1d-5f33-483f-9ff3-6e6eae6d7ad7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cimetidine hydrochloride injection is indicated in: (1) Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks and there is rarely reason to use cimetidine at full dosage for longer than 6 to 8 weeks (see DOSAGE AND ADMINISTRATION − Duodenal Ulcer). Concomitant antacids should be given as needed for relief of pain. However, simultaneous administration of oral cimetidine and antacids is not recommended, since antacids have been reported to interfere with the absorption of oral cimetidine. (2) Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of active ulcer. Patients have been maintained on continued treatment with cimetidine 400 mg h.s. for periods of up to five years. (3) Short-term treatment of active benign gastric ulcer. There is no information concerning usefulness of treatment periods of longer than 8 weeks. (4) Prevention of upper gastrointestinal bleeding in critically ill patients. (5) The treatment of pathological hypersecretory conditions (i.e., Zollinger-Ellison Syndrome, systemic mastocytosis, multiple endocrine adenomas). uuid:a8b74a2c-383d-4ed7-a668-cf143858cd61 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3699 biolink:treats MONDO:0001126 PMID:41385096 "[{""id"":""uuid:1c9dfb8e-5471-4d29-93ba-05c3ab8c72d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e31172e2-4973-4549-bc4a-2b1a28dbcf9b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cimetidine hydrochloride injection is indicated in: (1) Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks and there is rarely reason to use cimetidine at full dosage for longer than 6 to 8 weeks (see DOSAGE AND ADMINISTRATION − Duodenal Ulcer). Concomitant antacids should be given as needed for relief of pain. However, simultaneous administration of oral cimetidine and antacids is not recommended, since antacids have been reported to interfere with the absorption of oral cimetidine. (2) Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of active ulcer. Patients have been maintained on continued treatment with cimetidine 400 mg h.s. for periods of up to five years. (3) Short-term treatment of active benign gastric ulcer. There is no information concerning usefulness of treatment periods of longer than 8 weeks. (4) Prevention of upper gastrointestinal bleeding in critically ill patients. (5) The treatment of pathological hypersecretory conditions (i.e., Zollinger-Ellison Syndrome, systemic mastocytosis, multiple endocrine adenomas). uuid:10545b7d-24d1-4524-9f13-2942105b31ab biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3699 biolink:treats MONDO:0016586 PMID:41385096 "[{""id"":""uuid:b90129e4-13f8-4aad-aab6-52e352313207"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ef7a2b29-2454-40fd-b8ae-88cbf7d255f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cimetidine hydrochloride injection is indicated in: (1) Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks and there is rarely reason to use cimetidine at full dosage for longer than 6 to 8 weeks (see DOSAGE AND ADMINISTRATION − Duodenal Ulcer). Concomitant antacids should be given as needed for relief of pain. However, simultaneous administration of oral cimetidine and antacids is not recommended, since antacids have been reported to interfere with the absorption of oral cimetidine. (2) Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of active ulcer. Patients have been maintained on continued treatment with cimetidine 400 mg h.s. for periods of up to five years. (3) Short-term treatment of active benign gastric ulcer. There is no information concerning usefulness of treatment periods of longer than 8 weeks. (4) Prevention of upper gastrointestinal bleeding in critically ill patients. (5) The treatment of pathological hypersecretory conditions (i.e., Zollinger-Ellison Syndrome, systemic mastocytosis, multiple endocrine adenomas). uuid:95ccba81-2da7-4d97-86ee-1cecea8e2ef4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3699 biolink:treats MONDO:0017169 PMID:41385096 "[{""id"":""uuid:874f75e2-b9cc-4802-aa7f-78b8362ce552"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:726b00ec-a6bd-4bd9-bbb6-1037ba53a357"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cimetidine hydrochloride injection is indicated in: (1) Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks and there is rarely reason to use cimetidine at full dosage for longer than 6 to 8 weeks (see DOSAGE AND ADMINISTRATION − Duodenal Ulcer). Concomitant antacids should be given as needed for relief of pain. However, simultaneous administration of oral cimetidine and antacids is not recommended, since antacids have been reported to interfere with the absorption of oral cimetidine. (2) Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of active ulcer. Patients have been maintained on continued treatment with cimetidine 400 mg h.s. for periods of up to five years. (3) Short-term treatment of active benign gastric ulcer. There is no information concerning usefulness of treatment periods of longer than 8 weeks. (4) Prevention of upper gastrointestinal bleeding in critically ill patients. (5) The treatment of pathological hypersecretory conditions (i.e., Zollinger-Ellison Syndrome, systemic mastocytosis, multiple endocrine adenomas). uuid:315fba01-96eb-4269-857c-86d56fd72983 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59773 biolink:treats MONDO:0007950 PMID:41385096 "[{""id"":""uuid:849f58b3-a43e-4761-a99a-4ed04ecbda0c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bd8cc394-0987-45b3-a1a2-ad7e102d4e2a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] GASTROCROM is indicated in the management of patients with mastocytosis. Use of this product has been associated with improvement in diarrhea, flushing, headaches, vomiting, urticaria, abdominal pain, nausea, and itching in some patients. uuid:91c6ea51-c132-4256-9722-53de14798748 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:54692993 biolink:treats MONDO:0006668 PMID:41385096 "[{""id"":""uuid:8448e709-b9df-4f4d-ac1a-9b0234d7cb42"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c02994fc-bcfb-4b14-87be-eced26ac6630"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical radiation, thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus Streptococci , including Streptococcus pneumoniae Escherichia coli Neisseria species The product does not provide adequate coverage against: Haemophilus influenzae Klebsiella/Enterobacter species Pseudomonas aeruginosa Serratia marcescens uuid:4e28019a-0e93-4c38-a277-b2b3adb8ef2c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:54692993 biolink:treats UMLS:C0008690 PMID:41385096 "[{""id"":""uuid:4dab6dcd-9453-4b19-8626-310a095e9347"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9b272b9d-1597-44d7-8484-6ebcd7c254ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical radiation, thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus Streptococci , including Streptococcus pneumoniae Escherichia coli Neisseria species The product does not provide adequate coverage against: Haemophilus influenzae Klebsiella/Enterobacter species Pseudomonas aeruginosa Serratia marcescens uuid:94b541ba-7847-408c-9bd0-3cb072bf97c8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:54692993 biolink:treats UMLS:C0339289 PMID:41385096 "[{""id"":""uuid:b4935992-7c09-4086-b42c-bbf5f8829cf8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e88824d6-1388-4c30-9694-b5b20d9cc38a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical radiation, thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus Streptococci , including Streptococcus pneumoniae Escherichia coli Neisseria species The product does not provide adequate coverage against: Haemophilus influenzae Klebsiella/Enterobacter species Pseudomonas aeruginosa Serratia marcescens uuid:6fbecfce-5526-49ff-a86d-f08eacaf6ec7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77733 biolink:treats HP:0004763 PMID:41385096 "[{""id"":""uuid:ba191dbb-5667-448d-90b7-65651add8f88"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f90c444e-58c7-4ade-bbff-7321fe825ef8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:b03b444a-92a2-4cb1-b1ef-d56b81d76126"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous Verapamil HCI is indicated for the following: Rapid conversion to sinus rhythm of paroxysmal supraventricular tachycardias, including those associated with accessory bypass tracts (Wolff-Parkinson-White [W-P-W] and Lown-Ganong-Levine [L-G-L] syndromes). When clinically advisable, appropriate vagal maneuvers (e.g., Valsalva maneuver) should be attempted prior to verapamil hydrochloride administration. Temporary control of rapid ventricular rate in atrial flutter or atrial fibrillation except when the atrial flutter and/or atrial fibrillation are associated with accessory bypass tracts (Wolff-Parkinson-White [W-P-W] and Lown-Ganong-Levine [L-G-L] syndromes). In controlled studies in the United States, about 60% of patients with supraventricular tachycardia converted to normal sinus rhythm within 10 minutes after intravenous verapamil. Uncontrolled studies reported in the world literature describe a conversion rate of about 80%. About 70% of patients with atrial flutter and/or fibrillation with a fast ventricular rate respond with a decrease in ventricular rate of at least 20%. Conversion of atrial flutter or fibrillation to sinus rhythm is uncommon (about 10%) after verapamil and may reflect the spontaneous conversion rate, since the conversion rate after placebo was similar. Slowing of the ventricular rate in patients with atrial fibrillation/flutter lasts 30 to 60 minutes after a single injection. Because a small fraction (<1%) of patients treated with verapamil respond with life-threatening adverse responses (rapid ventricular rate In atrial flutter/fibrillation and an accessory bypass tract, marked hypotension, or extreme bradycardia/asystole - see Contraindications and Warnings ), the initial use of intravenous verapamil should, if possible, be in a treatment setting with monitoring and resuscitation facilities, including DC-cardioversion capability (see Suggested Treatment of Acute Cardiovascular Adverse Reactions ). As familiarity with the patient's response is gained, use in an office setting may be acceptable. Cardioversion has been used safely and effectively after intravenous verapamil.|[PMDA] A drug with a new additional dosage indicated for the treatment of tachyarrhythmia in pediatric patients (paroxysmal supraventricular tachycardia, paroxysmal atrial fibrillation, paroxysmal atrial flutter). [Public knowledge-based application after PAFSC's preliminary assessment] uuid:0e30b876-e100-451d-a0ac-4a274fc3beb5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77733 biolink:treats MONDO:0008685 PMID:41385096 "[{""id"":""uuid:cbeb3e4b-f58e-49c4-b3f3-110f9979cfc8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d5678f1c-1876-4c4b-b5ef-dc2f2b804e85"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous Verapamil HCI is indicated for the following: Rapid conversion to sinus rhythm of paroxysmal supraventricular tachycardias, including those associated with accessory bypass tracts (Wolff-Parkinson-White [W-P-W] and Lown-Ganong-Levine [L-G-L] syndromes). When clinically advisable, appropriate vagal maneuvers (e.g., Valsalva maneuver) should be attempted prior to verapamil hydrochloride administration. Temporary control of rapid ventricular rate in atrial flutter or atrial fibrillation except when the atrial flutter and/or atrial fibrillation are associated with accessory bypass tracts (Wolff-Parkinson-White [W-P-W] and Lown-Ganong-Levine [L-G-L] syndromes). In controlled studies in the United States, about 60% of patients with supraventricular tachycardia converted to normal sinus rhythm within 10 minutes after intravenous verapamil. Uncontrolled studies reported in the world literature describe a conversion rate of about 80%. About 70% of patients with atrial flutter and/or fibrillation with a fast ventricular rate respond with a decrease in ventricular rate of at least 20%. Conversion of atrial flutter or fibrillation to sinus rhythm is uncommon (about 10%) after verapamil and may reflect the spontaneous conversion rate, since the conversion rate after placebo was similar. Slowing of the ventricular rate in patients with atrial fibrillation/flutter lasts 30 to 60 minutes after a single injection. Because a small fraction (<1%) of patients treated with verapamil respond with life-threatening adverse responses (rapid ventricular rate In atrial flutter/fibrillation and an accessory bypass tract, marked hypotension, or extreme bradycardia/asystole - see Contraindications and Warnings ), the initial use of intravenous verapamil should, if possible, be in a treatment setting with monitoring and resuscitation facilities, including DC-cardioversion capability (see Suggested Treatment of Acute Cardiovascular Adverse Reactions ). As familiarity with the patient's response is gained, use in an office setting may be acceptable. Cardioversion has been used safely and effectively after intravenous verapamil. uuid:da9634ad-f9ad-4873-a98a-bd0bad50fd89 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77733 biolink:treats MONDO:0005310 PMID:41385096 "[{""id"":""uuid:b8fedb89-9e93-4457-8307-917e314b3bca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:bc593280-2c1f-4560-9bbd-494ba9f8c4f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:46fe46cf-6108-4880-87a6-4894aaf81fe5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous Verapamil HCI is indicated for the following: Rapid conversion to sinus rhythm of paroxysmal supraventricular tachycardias, including those associated with accessory bypass tracts (Wolff-Parkinson-White [W-P-W] and Lown-Ganong-Levine [L-G-L] syndromes). When clinically advisable, appropriate vagal maneuvers (e.g., Valsalva maneuver) should be attempted prior to verapamil hydrochloride administration. Temporary control of rapid ventricular rate in atrial flutter or atrial fibrillation except when the atrial flutter and/or atrial fibrillation are associated with accessory bypass tracts (Wolff-Parkinson-White [W-P-W] and Lown-Ganong-Levine [L-G-L] syndromes). In controlled studies in the United States, about 60% of patients with supraventricular tachycardia converted to normal sinus rhythm within 10 minutes after intravenous verapamil. Uncontrolled studies reported in the world literature describe a conversion rate of about 80%. About 70% of patients with atrial flutter and/or fibrillation with a fast ventricular rate respond with a decrease in ventricular rate of at least 20%. Conversion of atrial flutter or fibrillation to sinus rhythm is uncommon (about 10%) after verapamil and may reflect the spontaneous conversion rate, since the conversion rate after placebo was similar. Slowing of the ventricular rate in patients with atrial fibrillation/flutter lasts 30 to 60 minutes after a single injection. Because a small fraction (<1%) of patients treated with verapamil respond with life-threatening adverse responses (rapid ventricular rate In atrial flutter/fibrillation and an accessory bypass tract, marked hypotension, or extreme bradycardia/asystole - see Contraindications and Warnings ), the initial use of intravenous verapamil should, if possible, be in a treatment setting with monitoring and resuscitation facilities, including DC-cardioversion capability (see Suggested Treatment of Acute Cardiovascular Adverse Reactions ). As familiarity with the patient's response is gained, use in an office setting may be acceptable. Cardioversion has been used safely and effectively after intravenous verapamil.|[PMDA] A drug with a new additional indication and a new dosage for the treatment of tachyarrhythmia in pediatric patients (atrial fibrillation, atrial flutter, paroxysmal supraventricular tachycardia). [Public knowledge-based application after PAFSC's preliminary assessment] uuid:0e6603c3-2507-4c81-8ea0-0c7b94d587d3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77733 biolink:treats MONDO:0004981 PMID:41385096 "[{""id"":""uuid:741f6dd9-8f8f-4333-8ee5-a9832c905d67"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6b3f529f-294a-41b4-9610-856772472b5e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c9ae6825-f31b-4a57-9a3a-878852d9c3c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous Verapamil HCI is indicated for the following: Rapid conversion to sinus rhythm of paroxysmal supraventricular tachycardias, including those associated with accessory bypass tracts (Wolff-Parkinson-White [W-P-W] and Lown-Ganong-Levine [L-G-L] syndromes). When clinically advisable, appropriate vagal maneuvers (e.g., Valsalva maneuver) should be attempted prior to verapamil hydrochloride administration. Temporary control of rapid ventricular rate in atrial flutter or atrial fibrillation except when the atrial flutter and/or atrial fibrillation are associated with accessory bypass tracts (Wolff-Parkinson-White [W-P-W] and Lown-Ganong-Levine [L-G-L] syndromes). In controlled studies in the United States, about 60% of patients with supraventricular tachycardia converted to normal sinus rhythm within 10 minutes after intravenous verapamil. Uncontrolled studies reported in the world literature describe a conversion rate of about 80%. About 70% of patients with atrial flutter and/or fibrillation with a fast ventricular rate respond with a decrease in ventricular rate of at least 20%. Conversion of atrial flutter or fibrillation to sinus rhythm is uncommon (about 10%) after verapamil and may reflect the spontaneous conversion rate, since the conversion rate after placebo was similar. Slowing of the ventricular rate in patients with atrial fibrillation/flutter lasts 30 to 60 minutes after a single injection. Because a small fraction (<1%) of patients treated with verapamil respond with life-threatening adverse responses (rapid ventricular rate In atrial flutter/fibrillation and an accessory bypass tract, marked hypotension, or extreme bradycardia/asystole - see Contraindications and Warnings ), the initial use of intravenous verapamil should, if possible, be in a treatment setting with monitoring and resuscitation facilities, including DC-cardioversion capability (see Suggested Treatment of Acute Cardiovascular Adverse Reactions ). As familiarity with the patient's response is gained, use in an office setting may be acceptable. Cardioversion has been used safely and effectively after intravenous verapamil.|[PMDA] A drug with a new additional indication and a new dosage for the treatment of tachyarrhythmia in pediatric patients (atrial fibrillation, atrial flutter, paroxysmal supraventricular tachycardia). [Public knowledge-based application after PAFSC's preliminary assessment] uuid:c09c5936-98ee-4051-ba5b-f20914251991 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6709 biolink:treats HP:0002018 PMID:41385096 "[{""id"":""uuid:88a406c5-dd74-48a4-8a9e-97f5291a8b99"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:39b5a742-b20e-46c7-a336-549601771c64"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prophylactic treatment and management of nausea and vomiting, and dizziness associated with motion sickness. uuid:493d3aaf-6f5d-428d-a025-2a2717900ec7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6709 biolink:treats HP:0002013 PMID:41385096 "[{""id"":""uuid:c8840570-3a51-409b-9cf9-731b0908467e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:edf873cb-a7b4-42d2-9fc5-499cb16bcc5b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prophylactic treatment and management of nausea and vomiting, and dizziness associated with motion sickness. uuid:15c1555d-d287-4a83-8897-67272c1ec736 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6709 biolink:treats MONDO:0002317 PMID:41385096 "[{""id"":""uuid:cdbbaac1-0dfe-4c6e-b695-ea06e8973d4f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4cfa67dd-d4d1-4f90-b7c4-315822465f8c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prophylactic treatment and management of nausea and vomiting, and dizziness associated with motion sickness. uuid:00ee2d74-2c93-430b-9c4a-8f7c373a2e34 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6904 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:f2e9f663-16b2-4453-be74-9d2b975c845c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d7afb2d2-d9d3-4dc0-ba2a-5ef4e1d38d14"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Myocardial Infarction Metoprolol tartrate injection and tablets are indicated in the treatment of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce cardiovascular mortality. Treatment with intravenous metoprolol tartrate can be initiated as soon as the patient’s clinical condition allows (see DOSAGE AND ADMINISTRATION , CONTRAINDICATIONS , and WARNINGS ). Alternatively, treatment can begin within 3 to 10 days of the acute event (see DOSAGE AND ADMINISTRATION ). uuid:dc69406c-2e73-4d83-ac31-ce552ca6ea20 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6904 biolink:treats MONDO:0004781 PMID:41385096 "[{""id"":""uuid:c7b405d3-2bde-41c8-a9e9-c57db95228e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5a74f825-a2d0-42df-be0b-9a613af855db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Myocardial Infarction Metoprolol tartrate injection and tablets are indicated in the treatment of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce cardiovascular mortality. Treatment with intravenous metoprolol tartrate can be initiated as soon as the patient’s clinical condition allows (see DOSAGE AND ADMINISTRATION , CONTRAINDICATIONS , and WARNINGS ). Alternatively, treatment can begin within 3 to 10 days of the acute event (see DOSAGE AND ADMINISTRATION ). uuid:84663d3b-afe9-4906-819f-24fd6466c115 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6539 biolink:treats MONDO:0002125 PMID:41385096 "[{""id"":""uuid:8bc4a3d7-d222-49bf-8253-c35cbbf7ef64"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0958be6a-b477-4f92-bf86-fb285d099690"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:d9a2753a-fd9d-4a79-b5f6-dc1fa354ae0a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Status Epilepticus Lorazepam injection is indicated for the treatment of status epilepticus. Preanesthetic Lorazepam injection is indicated in adult patients for preanesthetic medication, producing sedation (sleepiness or drowsiness), relief of anxiety, and a decreased ability to recall events related to the day of surgery. It is most useful in those patients who are anxious about their surgical procedure and who would prefer to have diminished recall of the events of the day of surgery (see PRECAUTIONS, Information for Patients ).|[PMDA] A drug with a new route of administration indicated for the treatment of status epilepticus. uuid:6a3d7e44-2da3-483e-841c-31d5136efc43 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6539 biolink:treats MONDO:0011918 PMID:41385096 "[{""id"":""uuid:d45a19a4-ad83-4bf0-8311-e4df1998c429"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:26e60131-372e-4402-aa4d-2f2e33c9c849"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Status Epilepticus Lorazepam injection is indicated for the treatment of status epilepticus. Preanesthetic Lorazepam injection is indicated in adult patients for preanesthetic medication, producing sedation (sleepiness or drowsiness), relief of anxiety, and a decreased ability to recall events related to the day of surgery. It is most useful in those patients who are anxious about their surgical procedure and who would prefer to have diminished recall of the events of the day of surgery (see PRECAUTIONS, Information for Patients ). uuid:d5d0e3e3-8f26-40c0-b173-d4a3db505e6d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31625 biolink:treats MONDO:0003799 PMID:41385096 "[{""id"":""uuid:393fdc57-878b-42b4-96dc-deb65562274e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9a7ac22c-276c-4511-9efd-c4caeb6039a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FLUOR-OP is indicated for the treatment of corticosteroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe. uuid:8e8142db-7879-4dbd-a251-2ce610312959 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31625 biolink:treats MONDO:0003085 PMID:41385096 "[{""id"":""uuid:7db7e020-f229-4f0d-9e6d-4e2dd766e4c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:41d0a4f0-f1a9-490b-9918-847cbf5c26f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FLUOR-OP is indicated for the treatment of corticosteroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe. uuid:cda9a0a2-fa3a-4d3f-84d9-326705cb0d16 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3611 biolink:treats MONDO:0005618 PMID:41385096 "[{""id"":""uuid:2d7be461-3ae3-4ec1-84a0-82c8c15b65fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0458360d-2b48-4384-b421-6fa4d0b96dc0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Chlordiazepoxide HCI Capsules are indicated for the management of anxiety disorders or for the short-term relief of symptoms of anxiety, withdrawal symptoms of acute alcoholism, and preoperative apprehension and anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The effectiveness of chlordiazepoxide in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient. uuid:6109e09b-ed8d-46a4-900e-bc02c3421845 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3611 biolink:treats MONDO:0011918 PMID:41385096 "[{""id"":""uuid:6ae43c83-d0f9-4e77-8132-cee6ea9e3c86"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cf7ff0af-4154-4f0b-9f1a-d5d637ca104e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Chlordiazepoxide HCI Capsules are indicated for the management of anxiety disorders or for the short-term relief of symptoms of anxiety, withdrawal symptoms of acute alcoholism, and preoperative apprehension and anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The effectiveness of chlordiazepoxide in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient. uuid:36df1e48-fa76-4a20-9b4a-d85385333cba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3611 biolink:treats MONDO:0005433 PMID:41385096 "[{""id"":""uuid:2624fffe-5195-4ef3-bdf6-75675e6687be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5120cbcf-45ae-4625-a4b2-a6ac9c7b1ddd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Chlordiazepoxide HCI Capsules are indicated for the management of anxiety disorders or for the short-term relief of symptoms of anxiety, withdrawal symptoms of acute alcoholism, and preoperative apprehension and anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The effectiveness of chlordiazepoxide in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient. uuid:5f12d5cc-2ae1-4a40-abb9-415e8f805590 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135679 biolink:treats UMLS:C0339164 PMID:41385096 "[{""id"":""uuid:9edb87af-a54c-4e71-b9c8-6e5cb24e57d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d820e5b9-c515-419a-a6a2-c34f7b5e323a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LIVOSTIN™ 0.05% (levocabastine hydrochloride ophthalmic suspension) is indicated for the temporary relief of the signs and symptoms of seasonal allergic conjunctivitis. uuid:d4f61caf-be89-4d68-9dbf-39d8e06fa7b2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:34829 biolink:treats MONDO:0002313 PMID:41385096 "[{""id"":""uuid:7d40112b-603f-4448-a7e2-989545c2b08a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9fa25f30-8e69-495f-8557-e0715ae07ba3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] HMS ® (medrysone ophthalmic suspension) is indicated for the treatment of allergic conjunctivitis, vernal conjunctivitis, episcleritis, and epinephrine sensitivity. uuid:41b2a1b0-83de-4949-aaaa-a8be55b8a14c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:34829 biolink:treats MONDO:0001439 PMID:41385096 "[{""id"":""uuid:23032bad-e182-4f3a-a751-561eac65b095"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4750e6a9-fbc6-4194-a8ed-15f7cf1997c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] HMS ® (medrysone ophthalmic suspension) is indicated for the treatment of allergic conjunctivitis, vernal conjunctivitis, episcleritis, and epinephrine sensitivity. uuid:39b61e7e-8caf-4e0c-9210-c295d513c37f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6909 biolink:treats MONDO:0002154 PMID:41385096 "[{""id"":""uuid:d59cbf3e-a550-4a48-9e44-fe5b74e30721"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a6b8a2e1-03b7-4488-97fa-908f7537aeaa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Metronidazole is indicated for the treatment of symptomatic trichomoniasis in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures). uuid:db02c266-d407-4565-9d06-54262ceaee25 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8461 biolink:treats MONDO:0100053 PMID:41385096 "[{""id"":""uuid:3db489c0-007c-48a2-ac0d-15d2bd6d850f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:df201ac1-f3a0-40fd-b0c6-269d26bc1bd8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Promethazine HCl Injection is indicated for the following conditions: Amelioration of allergic reactions to blood or plasma. In anaphylaxis as an adjunct to epinephrine and other standard measures after the acute symptoms have been controlled. For other uncomplicated allergic conditions of the immediate type when oral therapy is impossible or contraindicated. For sedation and relief of apprehension and to produce light sleep from which the patient can be easily aroused. Active treatment of motion sickness. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. As an adjunct to analgesics for the control of postoperative pain. Preoperative, postoperative, and obstetric (during labor) sedation. Intravenously in special surgical situations, such as repeated bronchoscopy, ophthalmic surgery, and poor-risk patients, with reduced amounts of meperidine or other narcotic analgesic as an adjunct to anesthesia and analgesia. uuid:a6b80296-1107-42a7-a47f-a17d180810a5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8461 biolink:treats MONDO:0008015 PMID:41385096 "[{""id"":""uuid:34bf135e-97d5-48c2-a177-42099b37cff1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:01f3316b-b094-4c74-b72a-6ca55af6702d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Promethazine HCl Injection is indicated for the following conditions: Amelioration of allergic reactions to blood or plasma. In anaphylaxis as an adjunct to epinephrine and other standard measures after the acute symptoms have been controlled. For other uncomplicated allergic conditions of the immediate type when oral therapy is impossible or contraindicated. For sedation and relief of apprehension and to produce light sleep from which the patient can be easily aroused. Active treatment of motion sickness. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. As an adjunct to analgesics for the control of postoperative pain. Preoperative, postoperative, and obstetric (during labor) sedation. Intravenously in special surgical situations, such as repeated bronchoscopy, ophthalmic surgery, and poor-risk patients, with reduced amounts of meperidine or other narcotic analgesic as an adjunct to anesthesia and analgesia. uuid:56af8699-6ef8-482b-bb44-c03268ce438b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8461 biolink:treats HP:0002018 PMID:41385096 "[{""id"":""uuid:0645c305-7b03-4d50-b5f5-d0b3afc0f942"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6792c332-bc81-45d3-af2a-129253e693e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Promethazine HCl Injection is indicated for the following conditions: Amelioration of allergic reactions to blood or plasma. In anaphylaxis as an adjunct to epinephrine and other standard measures after the acute symptoms have been controlled. For other uncomplicated allergic conditions of the immediate type when oral therapy is impossible or contraindicated. For sedation and relief of apprehension and to produce light sleep from which the patient can be easily aroused. Active treatment of motion sickness. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. As an adjunct to analgesics for the control of postoperative pain. Preoperative, postoperative, and obstetric (during labor) sedation. Intravenously in special surgical situations, such as repeated bronchoscopy, ophthalmic surgery, and poor-risk patients, with reduced amounts of meperidine or other narcotic analgesic as an adjunct to anesthesia and analgesia. uuid:8033df14-7990-40f6-a22d-7773f711d629 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8461 biolink:treats HP:0002013 PMID:41385096 "[{""id"":""uuid:c1ef2145-58f2-40d3-9935-10d2ea7d4c53"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:36e3f694-5ef0-43ee-9749-c0d5591a4f56"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Promethazine HCl Injection is indicated for the following conditions: Amelioration of allergic reactions to blood or plasma. In anaphylaxis as an adjunct to epinephrine and other standard measures after the acute symptoms have been controlled. For other uncomplicated allergic conditions of the immediate type when oral therapy is impossible or contraindicated. For sedation and relief of apprehension and to produce light sleep from which the patient can be easily aroused. Active treatment of motion sickness. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. As an adjunct to analgesics for the control of postoperative pain. Preoperative, postoperative, and obstetric (during labor) sedation. Intravenously in special surgical situations, such as repeated bronchoscopy, ophthalmic surgery, and poor-risk patients, with reduced amounts of meperidine or other narcotic analgesic as an adjunct to anesthesia and analgesia. uuid:9da07ac0-22f5-43f4-bde0-c3ce6dbb6135 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8461 biolink:treats NCIT:C34887 PMID:41385096 "[{""id"":""uuid:0e7a7a3e-5e22-4886-8111-d4a77496a386"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0748aa34-8cd7-4b62-ad2e-932d300358ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Promethazine HCl Injection is indicated for the following conditions: Amelioration of allergic reactions to blood or plasma. In anaphylaxis as an adjunct to epinephrine and other standard measures after the acute symptoms have been controlled. For other uncomplicated allergic conditions of the immediate type when oral therapy is impossible or contraindicated. For sedation and relief of apprehension and to produce light sleep from which the patient can be easily aroused. Active treatment of motion sickness. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. As an adjunct to analgesics for the control of postoperative pain. Preoperative, postoperative, and obstetric (during labor) sedation. Intravenously in special surgical situations, such as repeated bronchoscopy, ophthalmic surgery, and poor-risk patients, with reduced amounts of meperidine or other narcotic analgesic as an adjunct to anesthesia and analgesia. uuid:54261f49-3fd7-44d7-b081-8f81504445f3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:553473 biolink:treats MONDO:0024355 PMID:41385096 "[{""id"":""uuid:9040b7cc-f6e6-4fe1-916c-026e400437c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:02c68676-2b2d-4063-9a7e-47478b9c9ad9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefizox (ceftizoxime for injection, USP) is indicated in the treatment of infections due to susceptible strains of the microorganisms listed below. Lower Respiratory Tract Infections caused by Klebsiella spp.; Proteus mirabilis ; Escherichia coli; Haemophilus influenzae including ampicillin‐resistant strains; Staphylococcus aureus (penicillinase­ and nonpenicillinase‐producing); Serratia spp.; Enterobacter spp.; Bacteroides spp.; and Streptococcus spp. including S. pneumoniae , but excluding enterococci. Urinary Tract Infections caused by Staphylococcus aureus (penicillinase‐ and nonpenicillinase‐producing); Escherichia coli ; Pseudomonas spp. including P. aeruginosa ; Proteus mirabilis ; P. vulgaris ; Providencia rettgeri (formerly Proteus rettgeri ) and Morganella morganii (formerly Proteus morganii ); Klebsiella spp.; Serratia spp. including S. marcescens ; and Enterobacter spp. Gonorrhea including uncomplicated cervical and urethral gonorrhea caused by Neisseria gonorrhoeae . Pelvic Inflammatory Disease caused by Neisseria gonorrhoeae, Escherichia coli or Streptococcus agalactiae . NOTE: Ceftizoxime, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti­chlamydial coverage should be added. Intra‐Abdominal Infections caused by Escherichia coli; Staphylococcus epidermidis; Streptococcus spp. (excluding enterococci); Enterobacter spp.; Klebsiella spp.; Bacteroides spp. including B. fragilis ; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Septicemia caused by Streptococcus spp. including S. pneumoniae (but excluding enterococci); Staphylococcus aureus (penicillinase‐ and nonpenicillinase‐producing); Escherichia coli; Bacteroides spp. including B. fragilis ; Klebsiella spp.; and Serratia spp. Skin and Skin Structure Infections caused by Staphylococcus aureus (penicillinase‐ and nonpenicillinase‐producing); Staphylococcus epidermidis ; Escherichia coli; Klebsiella spp.; Streptococcus spp. including Streptococcus pyogenes (but excluding enterococci); Proteus mirabilis ; Serratia spp.; Enterobacter spp.; Bacteroides spp. including B. fragilis ; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Bone and Joint Infections caused by Staphylococcus aureus (penicillinase‐ and nonpenicillinase‐producing); Streptococcus spp. (excluding enterococci); Proteus mirabilis ; Bacteroides spp.; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Meningitis caused by Haemophilus influenzae . Cefizox has also been used successfully in the treatment of a limited number of pediatric and adult cases of meningitis caused by Streptococcus pneumoniae . Cefizox has been effective in the treatment of seriously ill, compromised patients, including those who were debilitated, immunosuppressed, or neutropenic. Infections caused by aerobic gram‐negative and by mixtures of organisms resistant to other cephalosporins, aminoglycosides, or penicillins have responded to treatment with Cefizox. Because of the serious nature of some urinary tract infections due to P. aeruginosa and because many strains of Pseudomonas species are only moderately susceptible to Cefizox, higher dosage is recommended. Other therapy should be instituted if the response is not prompt. Susceptibility studies on specimens obtained prior to therapy should be used to determine the response of causative organisms to Cefizox. Therapy with Cefizox may be initiated pending results of the studies; however, treatment should be adjusted according to study findings. In serious infections, Cefizox has been used concomitantly with aminoglycosides (see PRECAUTIONS ). Before using Cefizox concomitantly with other antibiotics, the prescribing information for those agents should be reviewed for contraindications, warnings, precautions, and adverse reactions. Renal function should be carefully monitored. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefizox and other antibacterial drugs, Cefizox should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:2f7f2932-ed66-4fc7-be55-8ea855d2c157 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:553473 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:aa018de6-295f-483c-9a04-d8e3b557a026"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5048fa6d-33a7-4275-9979-60d7f702de81"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefizox (ceftizoxime for injection, USP) is indicated in the treatment of infections due to susceptible strains of the microorganisms listed below. Lower Respiratory Tract Infections caused by Klebsiella spp.; Proteus mirabilis ; Escherichia coli; Haemophilus influenzae including ampicillin‐resistant strains; Staphylococcus aureus (penicillinase­ and nonpenicillinase‐producing); Serratia spp.; Enterobacter spp.; Bacteroides spp.; and Streptococcus spp. including S. pneumoniae , but excluding enterococci. Urinary Tract Infections caused by Staphylococcus aureus (penicillinase‐ and nonpenicillinase‐producing); Escherichia coli ; Pseudomonas spp. including P. aeruginosa ; Proteus mirabilis ; P. vulgaris ; Providencia rettgeri (formerly Proteus rettgeri ) and Morganella morganii (formerly Proteus morganii ); Klebsiella spp.; Serratia spp. including S. marcescens ; and Enterobacter spp. Gonorrhea including uncomplicated cervical and urethral gonorrhea caused by Neisseria gonorrhoeae . Pelvic Inflammatory Disease caused by Neisseria gonorrhoeae, Escherichia coli or Streptococcus agalactiae . NOTE: Ceftizoxime, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti­chlamydial coverage should be added. Intra‐Abdominal Infections caused by Escherichia coli; Staphylococcus epidermidis; Streptococcus spp. (excluding enterococci); Enterobacter spp.; Klebsiella spp.; Bacteroides spp. including B. fragilis ; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Septicemia caused by Streptococcus spp. including S. pneumoniae (but excluding enterococci); Staphylococcus aureus (penicillinase‐ and nonpenicillinase‐producing); Escherichia coli; Bacteroides spp. including B. fragilis ; Klebsiella spp.; and Serratia spp. Skin and Skin Structure Infections caused by Staphylococcus aureus (penicillinase‐ and nonpenicillinase‐producing); Staphylococcus epidermidis ; Escherichia coli; Klebsiella spp.; Streptococcus spp. including Streptococcus pyogenes (but excluding enterococci); Proteus mirabilis ; Serratia spp.; Enterobacter spp.; Bacteroides spp. including B. fragilis ; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Bone and Joint Infections caused by Staphylococcus aureus (penicillinase‐ and nonpenicillinase‐producing); Streptococcus spp. (excluding enterococci); Proteus mirabilis ; Bacteroides spp.; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Meningitis caused by Haemophilus influenzae . Cefizox has also been used successfully in the treatment of a limited number of pediatric and adult cases of meningitis caused by Streptococcus pneumoniae . Cefizox has been effective in the treatment of seriously ill, compromised patients, including those who were debilitated, immunosuppressed, or neutropenic. Infections caused by aerobic gram‐negative and by mixtures of organisms resistant to other cephalosporins, aminoglycosides, or penicillins have responded to treatment with Cefizox. Because of the serious nature of some urinary tract infections due to P. aeruginosa and because many strains of Pseudomonas species are only moderately susceptible to Cefizox, higher dosage is recommended. Other therapy should be instituted if the response is not prompt. Susceptibility studies on specimens obtained prior to therapy should be used to determine the response of causative organisms to Cefizox. Therapy with Cefizox may be initiated pending results of the studies; however, treatment should be adjusted according to study findings. In serious infections, Cefizox has been used concomitantly with aminoglycosides (see PRECAUTIONS ). Before using Cefizox concomitantly with other antibiotics, the prescribing information for those agents should be reviewed for contraindications, warnings, precautions, and adverse reactions. Renal function should be carefully monitored. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefizox and other antibacterial drugs, Cefizox should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:4bed8f09-ee10-4f63-a4c6-74e686d83947 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:553473 biolink:treats MONDO:0004277 PMID:41385096 "[{""id"":""uuid:8e6b110b-752a-45c8-a812-4d1a1a011777"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f5f44e03-85b9-4b2e-8d5e-c14c96936f67"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefizox (ceftizoxime for injection, USP) is indicated in the treatment of infections due to susceptible strains of the microorganisms listed below. Lower Respiratory Tract Infections caused by Klebsiella spp.; Proteus mirabilis ; Escherichia coli; Haemophilus influenzae including ampicillin‐resistant strains; Staphylococcus aureus (penicillinase­ and nonpenicillinase‐producing); Serratia spp.; Enterobacter spp.; Bacteroides spp.; and Streptococcus spp. including S. pneumoniae , but excluding enterococci. Urinary Tract Infections caused by Staphylococcus aureus (penicillinase‐ and nonpenicillinase‐producing); Escherichia coli ; Pseudomonas spp. including P. aeruginosa ; Proteus mirabilis ; P. vulgaris ; Providencia rettgeri (formerly Proteus rettgeri ) and Morganella morganii (formerly Proteus morganii ); Klebsiella spp.; Serratia spp. including S. marcescens ; and Enterobacter spp. Gonorrhea including uncomplicated cervical and urethral gonorrhea caused by Neisseria gonorrhoeae . Pelvic Inflammatory Disease caused by Neisseria gonorrhoeae, Escherichia coli or Streptococcus agalactiae . NOTE: Ceftizoxime, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti­chlamydial coverage should be added. Intra‐Abdominal Infections caused by Escherichia coli; Staphylococcus epidermidis; Streptococcus spp. (excluding enterococci); Enterobacter spp.; Klebsiella spp.; Bacteroides spp. including B. fragilis ; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Septicemia caused by Streptococcus spp. including S. pneumoniae (but excluding enterococci); Staphylococcus aureus (penicillinase‐ and nonpenicillinase‐producing); Escherichia coli; Bacteroides spp. including B. fragilis ; Klebsiella spp.; and Serratia spp. Skin and Skin Structure Infections caused by Staphylococcus aureus (penicillinase‐ and nonpenicillinase‐producing); Staphylococcus epidermidis ; Escherichia coli; Klebsiella spp.; Streptococcus spp. including Streptococcus pyogenes (but excluding enterococci); Proteus mirabilis ; Serratia spp.; Enterobacter spp.; Bacteroides spp. including B. fragilis ; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Bone and Joint Infections caused by Staphylococcus aureus (penicillinase‐ and nonpenicillinase‐producing); Streptococcus spp. (excluding enterococci); Proteus mirabilis ; Bacteroides spp.; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Meningitis caused by Haemophilus influenzae . Cefizox has also been used successfully in the treatment of a limited number of pediatric and adult cases of meningitis caused by Streptococcus pneumoniae . Cefizox has been effective in the treatment of seriously ill, compromised patients, including those who were debilitated, immunosuppressed, or neutropenic. Infections caused by aerobic gram‐negative and by mixtures of organisms resistant to other cephalosporins, aminoglycosides, or penicillins have responded to treatment with Cefizox. Because of the serious nature of some urinary tract infections due to P. aeruginosa and because many strains of Pseudomonas species are only moderately susceptible to Cefizox, higher dosage is recommended. Other therapy should be instituted if the response is not prompt. Susceptibility studies on specimens obtained prior to therapy should be used to determine the response of causative organisms to Cefizox. Therapy with Cefizox may be initiated pending results of the studies; however, treatment should be adjusted according to study findings. In serious infections, Cefizox has been used concomitantly with aminoglycosides (see PRECAUTIONS ). Before using Cefizox concomitantly with other antibiotics, the prescribing information for those agents should be reviewed for contraindications, warnings, precautions, and adverse reactions. Renal function should be carefully monitored. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefizox and other antibacterial drugs, Cefizox should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:6fd74286-a0fb-4a91-bfdf-f980aeab94e6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:553473 biolink:treats MONDO:0000922 PMID:41385096 "[{""id"":""uuid:26bd8a21-2945-4276-a9d9-e1ad3290402c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7b21ffff-016e-4c1c-aa9c-02746a2b7d80"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefizox (ceftizoxime for injection, USP) is indicated in the treatment of infections due to susceptible strains of the microorganisms listed below. Lower Respiratory Tract Infections caused by Klebsiella spp.; Proteus mirabilis ; Escherichia coli; Haemophilus influenzae including ampicillin‐resistant strains; Staphylococcus aureus (penicillinase­ and nonpenicillinase‐producing); Serratia spp.; Enterobacter spp.; Bacteroides spp.; and Streptococcus spp. including S. pneumoniae , but excluding enterococci. Urinary Tract Infections caused by Staphylococcus aureus (penicillinase‐ and nonpenicillinase‐producing); Escherichia coli ; Pseudomonas spp. including P. aeruginosa ; Proteus mirabilis ; P. vulgaris ; Providencia rettgeri (formerly Proteus rettgeri ) and Morganella morganii (formerly Proteus morganii ); Klebsiella spp.; Serratia spp. including S. marcescens ; and Enterobacter spp. Gonorrhea including uncomplicated cervical and urethral gonorrhea caused by Neisseria gonorrhoeae . Pelvic Inflammatory Disease caused by Neisseria gonorrhoeae, Escherichia coli or Streptococcus agalactiae . NOTE: Ceftizoxime, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti­chlamydial coverage should be added. Intra‐Abdominal Infections caused by Escherichia coli; Staphylococcus epidermidis; Streptococcus spp. (excluding enterococci); Enterobacter spp.; Klebsiella spp.; Bacteroides spp. including B. fragilis ; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Septicemia caused by Streptococcus spp. including S. pneumoniae (but excluding enterococci); Staphylococcus aureus (penicillinase‐ and nonpenicillinase‐producing); Escherichia coli; Bacteroides spp. including B. fragilis ; Klebsiella spp.; and Serratia spp. Skin and Skin Structure Infections caused by Staphylococcus aureus (penicillinase‐ and nonpenicillinase‐producing); Staphylococcus epidermidis ; Escherichia coli; Klebsiella spp.; Streptococcus spp. including Streptococcus pyogenes (but excluding enterococci); Proteus mirabilis ; Serratia spp.; Enterobacter spp.; Bacteroides spp. including B. fragilis ; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Bone and Joint Infections caused by Staphylococcus aureus (penicillinase‐ and nonpenicillinase‐producing); Streptococcus spp. (excluding enterococci); Proteus mirabilis ; Bacteroides spp.; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Meningitis caused by Haemophilus influenzae . Cefizox has also been used successfully in the treatment of a limited number of pediatric and adult cases of meningitis caused by Streptococcus pneumoniae . Cefizox has been effective in the treatment of seriously ill, compromised patients, including those who were debilitated, immunosuppressed, or neutropenic. Infections caused by aerobic gram‐negative and by mixtures of organisms resistant to other cephalosporins, aminoglycosides, or penicillins have responded to treatment with Cefizox. Because of the serious nature of some urinary tract infections due to P. aeruginosa and because many strains of Pseudomonas species are only moderately susceptible to Cefizox, higher dosage is recommended. Other therapy should be instituted if the response is not prompt. Susceptibility studies on specimens obtained prior to therapy should be used to determine the response of causative organisms to Cefizox. Therapy with Cefizox may be initiated pending results of the studies; however, treatment should be adjusted according to study findings. In serious infections, Cefizox has been used concomitantly with aminoglycosides (see PRECAUTIONS ). Before using Cefizox concomitantly with other antibiotics, the prescribing information for those agents should be reviewed for contraindications, warnings, precautions, and adverse reactions. Renal function should be carefully monitored. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefizox and other antibacterial drugs, Cefizox should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:da10ffd3-a878-4f78-ae9b-d2e5921f397c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:553473 biolink:treats UMLS:C1112209 PMID:41385096 "[{""id"":""uuid:404fa969-a3a8-4a4d-b265-eff9a76c6d8e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:392edde2-ed80-478e-b6d2-20cd1c3f8102"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefizox (ceftizoxime for injection, USP) is indicated in the treatment of infections due to susceptible strains of the microorganisms listed below. Lower Respiratory Tract Infections caused by Klebsiella spp.; Proteus mirabilis ; Escherichia coli; Haemophilus influenzae including ampicillin‐resistant strains; Staphylococcus aureus (penicillinase­ and nonpenicillinase‐producing); Serratia spp.; Enterobacter spp.; Bacteroides spp.; and Streptococcus spp. including S. pneumoniae , but excluding enterococci. Urinary Tract Infections caused by Staphylococcus aureus (penicillinase‐ and nonpenicillinase‐producing); Escherichia coli ; Pseudomonas spp. including P. aeruginosa ; Proteus mirabilis ; P. vulgaris ; Providencia rettgeri (formerly Proteus rettgeri ) and Morganella morganii (formerly Proteus morganii ); Klebsiella spp.; Serratia spp. including S. marcescens ; and Enterobacter spp. Gonorrhea including uncomplicated cervical and urethral gonorrhea caused by Neisseria gonorrhoeae . Pelvic Inflammatory Disease caused by Neisseria gonorrhoeae, Escherichia coli or Streptococcus agalactiae . NOTE: Ceftizoxime, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti­chlamydial coverage should be added. Intra‐Abdominal Infections caused by Escherichia coli; Staphylococcus epidermidis; Streptococcus spp. (excluding enterococci); Enterobacter spp.; Klebsiella spp.; Bacteroides spp. including B. fragilis ; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Septicemia caused by Streptococcus spp. including S. pneumoniae (but excluding enterococci); Staphylococcus aureus (penicillinase‐ and nonpenicillinase‐producing); Escherichia coli; Bacteroides spp. including B. fragilis ; Klebsiella spp.; and Serratia spp. Skin and Skin Structure Infections caused by Staphylococcus aureus (penicillinase‐ and nonpenicillinase‐producing); Staphylococcus epidermidis ; Escherichia coli; Klebsiella spp.; Streptococcus spp. including Streptococcus pyogenes (but excluding enterococci); Proteus mirabilis ; Serratia spp.; Enterobacter spp.; Bacteroides spp. including B. fragilis ; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Bone and Joint Infections caused by Staphylococcus aureus (penicillinase‐ and nonpenicillinase‐producing); Streptococcus spp. (excluding enterococci); Proteus mirabilis ; Bacteroides spp.; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Meningitis caused by Haemophilus influenzae . Cefizox has also been used successfully in the treatment of a limited number of pediatric and adult cases of meningitis caused by Streptococcus pneumoniae . Cefizox has been effective in the treatment of seriously ill, compromised patients, including those who were debilitated, immunosuppressed, or neutropenic. Infections caused by aerobic gram‐negative and by mixtures of organisms resistant to other cephalosporins, aminoglycosides, or penicillins have responded to treatment with Cefizox. Because of the serious nature of some urinary tract infections due to P. aeruginosa and because many strains of Pseudomonas species are only moderately susceptible to Cefizox, higher dosage is recommended. Other therapy should be instituted if the response is not prompt. Susceptibility studies on specimens obtained prior to therapy should be used to determine the response of causative organisms to Cefizox. Therapy with Cefizox may be initiated pending results of the studies; however, treatment should be adjusted according to study findings. In serious infections, Cefizox has been used concomitantly with aminoglycosides (see PRECAUTIONS ). Before using Cefizox concomitantly with other antibiotics, the prescribing information for those agents should be reviewed for contraindications, warnings, precautions, and adverse reactions. Renal function should be carefully monitored. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefizox and other antibacterial drugs, Cefizox should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:6cdc12a9-c418-41a0-912f-6551ec0f5031 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:553473 biolink:treats MONDO:0700217 PMID:41385096 "[{""id"":""uuid:61361244-f695-4612-8a38-5e344e681cce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aa964579-d0e5-41bb-b0a9-fd06980064b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefizox (ceftizoxime for injection, USP) is indicated in the treatment of infections due to susceptible strains of the microorganisms listed below. Lower Respiratory Tract Infections caused by Klebsiella spp.; Proteus mirabilis ; Escherichia coli; Haemophilus influenzae including ampicillin‐resistant strains; Staphylococcus aureus (penicillinase­ and nonpenicillinase‐producing); Serratia spp.; Enterobacter spp.; Bacteroides spp.; and Streptococcus spp. including S. pneumoniae , but excluding enterococci. Urinary Tract Infections caused by Staphylococcus aureus (penicillinase‐ and nonpenicillinase‐producing); Escherichia coli ; Pseudomonas spp. including P. aeruginosa ; Proteus mirabilis ; P. vulgaris ; Providencia rettgeri (formerly Proteus rettgeri ) and Morganella morganii (formerly Proteus morganii ); Klebsiella spp.; Serratia spp. including S. marcescens ; and Enterobacter spp. Gonorrhea including uncomplicated cervical and urethral gonorrhea caused by Neisseria gonorrhoeae . Pelvic Inflammatory Disease caused by Neisseria gonorrhoeae, Escherichia coli or Streptococcus agalactiae . NOTE: Ceftizoxime, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti­chlamydial coverage should be added. Intra‐Abdominal Infections caused by Escherichia coli; Staphylococcus epidermidis; Streptococcus spp. (excluding enterococci); Enterobacter spp.; Klebsiella spp.; Bacteroides spp. including B. fragilis ; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Septicemia caused by Streptococcus spp. including S. pneumoniae (but excluding enterococci); Staphylococcus aureus (penicillinase‐ and nonpenicillinase‐producing); Escherichia coli; Bacteroides spp. including B. fragilis ; Klebsiella spp.; and Serratia spp. Skin and Skin Structure Infections caused by Staphylococcus aureus (penicillinase‐ and nonpenicillinase‐producing); Staphylococcus epidermidis ; Escherichia coli; Klebsiella spp.; Streptococcus spp. including Streptococcus pyogenes (but excluding enterococci); Proteus mirabilis ; Serratia spp.; Enterobacter spp.; Bacteroides spp. including B. fragilis ; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Bone and Joint Infections caused by Staphylococcus aureus (penicillinase‐ and nonpenicillinase‐producing); Streptococcus spp. (excluding enterococci); Proteus mirabilis ; Bacteroides spp.; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Meningitis caused by Haemophilus influenzae . Cefizox has also been used successfully in the treatment of a limited number of pediatric and adult cases of meningitis caused by Streptococcus pneumoniae . Cefizox has been effective in the treatment of seriously ill, compromised patients, including those who were debilitated, immunosuppressed, or neutropenic. Infections caused by aerobic gram‐negative and by mixtures of organisms resistant to other cephalosporins, aminoglycosides, or penicillins have responded to treatment with Cefizox. Because of the serious nature of some urinary tract infections due to P. aeruginosa and because many strains of Pseudomonas species are only moderately susceptible to Cefizox, higher dosage is recommended. Other therapy should be instituted if the response is not prompt. Susceptibility studies on specimens obtained prior to therapy should be used to determine the response of causative organisms to Cefizox. Therapy with Cefizox may be initiated pending results of the studies; however, treatment should be adjusted according to study findings. In serious infections, Cefizox has been used concomitantly with aminoglycosides (see PRECAUTIONS ). Before using Cefizox concomitantly with other antibiotics, the prescribing information for those agents should be reviewed for contraindications, warnings, precautions, and adverse reactions. Renal function should be carefully monitored. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefizox and other antibacterial drugs, Cefizox should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:ff5da1a4-0c76-4b20-aff7-ead0329c55c8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:553473 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:6027d03f-f159-403c-9cd4-f08304783cb8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:427a662a-a979-4cb4-8356-81250b24e99e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefizox (ceftizoxime for injection, USP) is indicated in the treatment of infections due to susceptible strains of the microorganisms listed below. Lower Respiratory Tract Infections caused by Klebsiella spp.; Proteus mirabilis ; Escherichia coli; Haemophilus influenzae including ampicillin‐resistant strains; Staphylococcus aureus (penicillinase­ and nonpenicillinase‐producing); Serratia spp.; Enterobacter spp.; Bacteroides spp.; and Streptococcus spp. including S. pneumoniae , but excluding enterococci. Urinary Tract Infections caused by Staphylococcus aureus (penicillinase‐ and nonpenicillinase‐producing); Escherichia coli ; Pseudomonas spp. including P. aeruginosa ; Proteus mirabilis ; P. vulgaris ; Providencia rettgeri (formerly Proteus rettgeri ) and Morganella morganii (formerly Proteus morganii ); Klebsiella spp.; Serratia spp. including S. marcescens ; and Enterobacter spp. Gonorrhea including uncomplicated cervical and urethral gonorrhea caused by Neisseria gonorrhoeae . Pelvic Inflammatory Disease caused by Neisseria gonorrhoeae, Escherichia coli or Streptococcus agalactiae . NOTE: Ceftizoxime, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti­chlamydial coverage should be added. Intra‐Abdominal Infections caused by Escherichia coli; Staphylococcus epidermidis; Streptococcus spp. (excluding enterococci); Enterobacter spp.; Klebsiella spp.; Bacteroides spp. including B. fragilis ; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Septicemia caused by Streptococcus spp. including S. pneumoniae (but excluding enterococci); Staphylococcus aureus (penicillinase‐ and nonpenicillinase‐producing); Escherichia coli; Bacteroides spp. including B. fragilis ; Klebsiella spp.; and Serratia spp. Skin and Skin Structure Infections caused by Staphylococcus aureus (penicillinase‐ and nonpenicillinase‐producing); Staphylococcus epidermidis ; Escherichia coli; Klebsiella spp.; Streptococcus spp. including Streptococcus pyogenes (but excluding enterococci); Proteus mirabilis ; Serratia spp.; Enterobacter spp.; Bacteroides spp. including B. fragilis ; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Bone and Joint Infections caused by Staphylococcus aureus (penicillinase‐ and nonpenicillinase‐producing); Streptococcus spp. (excluding enterococci); Proteus mirabilis ; Bacteroides spp.; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Meningitis caused by Haemophilus influenzae . Cefizox has also been used successfully in the treatment of a limited number of pediatric and adult cases of meningitis caused by Streptococcus pneumoniae . Cefizox has been effective in the treatment of seriously ill, compromised patients, including those who were debilitated, immunosuppressed, or neutropenic. Infections caused by aerobic gram‐negative and by mixtures of organisms resistant to other cephalosporins, aminoglycosides, or penicillins have responded to treatment with Cefizox. Because of the serious nature of some urinary tract infections due to P. aeruginosa and because many strains of Pseudomonas species are only moderately susceptible to Cefizox, higher dosage is recommended. Other therapy should be instituted if the response is not prompt. Susceptibility studies on specimens obtained prior to therapy should be used to determine the response of causative organisms to Cefizox. Therapy with Cefizox may be initiated pending results of the studies; however, treatment should be adjusted according to study findings. In serious infections, Cefizox has been used concomitantly with aminoglycosides (see PRECAUTIONS ). Before using Cefizox concomitantly with other antibiotics, the prescribing information for those agents should be reviewed for contraindications, warnings, precautions, and adverse reactions. Renal function should be carefully monitored. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefizox and other antibacterial drugs, Cefizox should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:fc0cf2df-0d6b-40ae-9ba6-541df67630a6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:553473 biolink:treats UMLS:C0851989 PMID:41385096 "[{""id"":""uuid:280bf76d-6980-4594-aa5b-4a0ab571ffc6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:74a4b19b-dc4b-4607-a6a8-b887ddda5192"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefizox (ceftizoxime for injection, USP) is indicated in the treatment of infections due to susceptible strains of the microorganisms listed below. Lower Respiratory Tract Infections caused by Klebsiella spp.; Proteus mirabilis ; Escherichia coli; Haemophilus influenzae including ampicillin‐resistant strains; Staphylococcus aureus (penicillinase­ and nonpenicillinase‐producing); Serratia spp.; Enterobacter spp.; Bacteroides spp.; and Streptococcus spp. including S. pneumoniae , but excluding enterococci. Urinary Tract Infections caused by Staphylococcus aureus (penicillinase‐ and nonpenicillinase‐producing); Escherichia coli ; Pseudomonas spp. including P. aeruginosa ; Proteus mirabilis ; P. vulgaris ; Providencia rettgeri (formerly Proteus rettgeri ) and Morganella morganii (formerly Proteus morganii ); Klebsiella spp.; Serratia spp. including S. marcescens ; and Enterobacter spp. Gonorrhea including uncomplicated cervical and urethral gonorrhea caused by Neisseria gonorrhoeae . Pelvic Inflammatory Disease caused by Neisseria gonorrhoeae, Escherichia coli or Streptococcus agalactiae . NOTE: Ceftizoxime, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti­chlamydial coverage should be added. Intra‐Abdominal Infections caused by Escherichia coli; Staphylococcus epidermidis; Streptococcus spp. (excluding enterococci); Enterobacter spp.; Klebsiella spp.; Bacteroides spp. including B. fragilis ; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Septicemia caused by Streptococcus spp. including S. pneumoniae (but excluding enterococci); Staphylococcus aureus (penicillinase‐ and nonpenicillinase‐producing); Escherichia coli; Bacteroides spp. including B. fragilis ; Klebsiella spp.; and Serratia spp. Skin and Skin Structure Infections caused by Staphylococcus aureus (penicillinase‐ and nonpenicillinase‐producing); Staphylococcus epidermidis ; Escherichia coli; Klebsiella spp.; Streptococcus spp. including Streptococcus pyogenes (but excluding enterococci); Proteus mirabilis ; Serratia spp.; Enterobacter spp.; Bacteroides spp. including B. fragilis ; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Bone and Joint Infections caused by Staphylococcus aureus (penicillinase‐ and nonpenicillinase‐producing); Streptococcus spp. (excluding enterococci); Proteus mirabilis ; Bacteroides spp.; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Meningitis caused by Haemophilus influenzae . Cefizox has also been used successfully in the treatment of a limited number of pediatric and adult cases of meningitis caused by Streptococcus pneumoniae . Cefizox has been effective in the treatment of seriously ill, compromised patients, including those who were debilitated, immunosuppressed, or neutropenic. Infections caused by aerobic gram‐negative and by mixtures of organisms resistant to other cephalosporins, aminoglycosides, or penicillins have responded to treatment with Cefizox. Because of the serious nature of some urinary tract infections due to P. aeruginosa and because many strains of Pseudomonas species are only moderately susceptible to Cefizox, higher dosage is recommended. Other therapy should be instituted if the response is not prompt. Susceptibility studies on specimens obtained prior to therapy should be used to determine the response of causative organisms to Cefizox. Therapy with Cefizox may be initiated pending results of the studies; however, treatment should be adjusted according to study findings. In serious infections, Cefizox has been used concomitantly with aminoglycosides (see PRECAUTIONS ). Before using Cefizox concomitantly with other antibiotics, the prescribing information for those agents should be reviewed for contraindications, warnings, precautions, and adverse reactions. Renal function should be carefully monitored. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefizox and other antibacterial drugs, Cefizox should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:c45c2667-3cbc-4be3-819b-f889efba225f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:553473 biolink:treats MONDO:0021108 PMID:41385096 "[{""id"":""uuid:42e76d37-15bc-465e-866f-4e5b262c9e00"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:71297377-c0df-4c39-95a3-ba36da49c2b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefizox (ceftizoxime for injection, USP) is indicated in the treatment of infections due to susceptible strains of the microorganisms listed below. Lower Respiratory Tract Infections caused by Klebsiella spp.; Proteus mirabilis ; Escherichia coli; Haemophilus influenzae including ampicillin‐resistant strains; Staphylococcus aureus (penicillinase­ and nonpenicillinase‐producing); Serratia spp.; Enterobacter spp.; Bacteroides spp.; and Streptococcus spp. including S. pneumoniae , but excluding enterococci. Urinary Tract Infections caused by Staphylococcus aureus (penicillinase‐ and nonpenicillinase‐producing); Escherichia coli ; Pseudomonas spp. including P. aeruginosa ; Proteus mirabilis ; P. vulgaris ; Providencia rettgeri (formerly Proteus rettgeri ) and Morganella morganii (formerly Proteus morganii ); Klebsiella spp.; Serratia spp. including S. marcescens ; and Enterobacter spp. Gonorrhea including uncomplicated cervical and urethral gonorrhea caused by Neisseria gonorrhoeae . Pelvic Inflammatory Disease caused by Neisseria gonorrhoeae, Escherichia coli or Streptococcus agalactiae . NOTE: Ceftizoxime, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti­chlamydial coverage should be added. Intra‐Abdominal Infections caused by Escherichia coli; Staphylococcus epidermidis; Streptococcus spp. (excluding enterococci); Enterobacter spp.; Klebsiella spp.; Bacteroides spp. including B. fragilis ; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Septicemia caused by Streptococcus spp. including S. pneumoniae (but excluding enterococci); Staphylococcus aureus (penicillinase‐ and nonpenicillinase‐producing); Escherichia coli; Bacteroides spp. including B. fragilis ; Klebsiella spp.; and Serratia spp. Skin and Skin Structure Infections caused by Staphylococcus aureus (penicillinase‐ and nonpenicillinase‐producing); Staphylococcus epidermidis ; Escherichia coli; Klebsiella spp.; Streptococcus spp. including Streptococcus pyogenes (but excluding enterococci); Proteus mirabilis ; Serratia spp.; Enterobacter spp.; Bacteroides spp. including B. fragilis ; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Bone and Joint Infections caused by Staphylococcus aureus (penicillinase‐ and nonpenicillinase‐producing); Streptococcus spp. (excluding enterococci); Proteus mirabilis ; Bacteroides spp.; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Meningitis caused by Haemophilus influenzae . Cefizox has also been used successfully in the treatment of a limited number of pediatric and adult cases of meningitis caused by Streptococcus pneumoniae . Cefizox has been effective in the treatment of seriously ill, compromised patients, including those who were debilitated, immunosuppressed, or neutropenic. Infections caused by aerobic gram‐negative and by mixtures of organisms resistant to other cephalosporins, aminoglycosides, or penicillins have responded to treatment with Cefizox. Because of the serious nature of some urinary tract infections due to P. aeruginosa and because many strains of Pseudomonas species are only moderately susceptible to Cefizox, higher dosage is recommended. Other therapy should be instituted if the response is not prompt. Susceptibility studies on specimens obtained prior to therapy should be used to determine the response of causative organisms to Cefizox. Therapy with Cefizox may be initiated pending results of the studies; however, treatment should be adjusted according to study findings. In serious infections, Cefizox has been used concomitantly with aminoglycosides (see PRECAUTIONS ). Before using Cefizox concomitantly with other antibiotics, the prescribing information for those agents should be reviewed for contraindications, warnings, precautions, and adverse reactions. Renal function should be carefully monitored. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefizox and other antibacterial drugs, Cefizox should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:ea3c44ca-39a6-422e-895f-b5cff8032aae biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:553473 biolink:treats MONDO:0100128 PMID:41385096 "[{""id"":""uuid:ce655c72-bd43-4268-b785-e85222387fc0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:05877e85-24ad-4e6b-b7ea-6ec938f598ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefizox (ceftizoxime injection) is indicated in the treatment of infections due to susceptible strains of the microorganisms listed below. Lower Respiratory Tract Infections caused by Klebsiella spp.; Proteus mirabilis ; Escherichia coli; Haemophilus influenzae including ampicillin­resistant strains; Staphylococcus aureus (penicillinase­ and nonpenicillinase­producing); Serratia spp.; Enterobacter spp.; Bacteroides spp.; and Streptococcus spp. including S. pneumoniae , but excluding enterococci. Urinary Tract Infections caused by Staphylococcus aureus (penicillinase­ and nonpenicillinase­producing); Escherichia coli ; Pseudomonas spp. including P. aeruginosa ; Proteus mirabilis ; P. vulgaris ; Providencia rettgeri (formerly Proteus rettgeri ) and Morganella morganii (formerly Proteus morganii ); Klebsiella spp.; Serratia spp. including S. marcescens ; and Enterobacter spp. Gonorrhea including uncomplicated cervical and urethral gonorrhea caused by Neisseria gonorrhoeae . Pelvic Inflammatory Disease caused by Neisseria gonorrhoeae, Escherichia coli or Streptococcus agalactiae . NOTE: Ceftizoxime, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti­chlamydial coverage should be added. Intra­Abdominal Infections caused by Escherichia coli; Staphylococcus epidermidis; Streptococcus spp. (excluding enterococci); Enterobacter spp.; Klebsiella spp.; Bacteroides spp. including B. fragilis ; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Septicemia caused by Streptococcus spp. including S. pneumoniae (but excluding enterococci); Staphylococcus aureus (penicillinase­ and nonpenicillinase­producing); Escherichia coli; Bacteroides spp. including B. fragilis ; Klebsiella spp.; and Serratia spp. Skin and Skin Structure Infections caused by Staphylococcus aureus (penicillinase­ and nonpenicillinase­producing); Staphylococcus epidermidis ; Escherichia coli; Klebsiella spp.; Streptococcus spp. including Streptococcus pyogenes (but excluding enterococci); Proteus mirabilis ; Serratia spp.; Enterobacter spp.; Bacteroides spp. including B. fragilis ; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Bone and Joint Infections caused by Staphylococcus aureus (penicillinase­ and nonpenicillinase­producing); Streptococcus spp. (excluding enterococci); Proteus mirabilis ; Bacteroides spp.; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Meningitis caused by Haemophilus influenzae . Cefizox has also been used successfully in the treatment of a limited number of pediatric and adult cases of meningitis caused by Streptococcus pneumoniae . Cefizox has been effective in the treatment of seriously ill, compromised patients, including those who were debilitated, immunosuppressed, or neutropenic. Infections caused by aerobic gram­negative and by mixtures of organisms resistant to other cephalosporins, aminoglycosides, or penicillins have responded to treatment with Cefizox. Because of the serious nature of some urinary tract infections due to P. aeruginosa and because many strains of Pseudomonas species are only moderately susceptible to Cefizox, higher dosage is recommended. Other therapy should be instituted if the response is not prompt. Susceptibility studies on specimens obtained prior to therapy should be used to determine the response of causative organisms to Cefizox. Therapy with Cefizox may be initiated pending results of the studies; however, treatment should be adjusted according to study findings. In serious infections, Cefizox has been used concomitantly with aminoglycosides (see PRECAUTIONS ). Before using Cefizox concomitantly with other antibiotics, the prescribing information for those agents should be reviewed for contraindications, warnings, precautions, and adverse reactions. Renal function should be carefully monitored. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefizox and other antibacterial drugs, Cefizox should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:e96484b4-d157-43a9-801d-2aeb4029a8f2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:553473 biolink:treats MONDO:0005113 PMID:41385096 "[{""id"":""uuid:ea0179b5-9e18-4e49-938c-603b0dbd2a46"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d543a476-6594-4b4c-acba-3a072d4e02bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefizox (ceftizoxime injection) is indicated in the treatment of infections due to susceptible strains of the microorganisms listed below. Lower Respiratory Tract Infections caused by Klebsiella spp.; Proteus mirabilis ; Escherichia coli; Haemophilus influenzae including ampicillin­resistant strains; Staphylococcus aureus (penicillinase­ and nonpenicillinase­producing); Serratia spp.; Enterobacter spp.; Bacteroides spp.; and Streptococcus spp. including S. pneumoniae , but excluding enterococci. Urinary Tract Infections caused by Staphylococcus aureus (penicillinase­ and nonpenicillinase­producing); Escherichia coli ; Pseudomonas spp. including P. aeruginosa ; Proteus mirabilis ; P. vulgaris ; Providencia rettgeri (formerly Proteus rettgeri ) and Morganella morganii (formerly Proteus morganii ); Klebsiella spp.; Serratia spp. including S. marcescens ; and Enterobacter spp. Gonorrhea including uncomplicated cervical and urethral gonorrhea caused by Neisseria gonorrhoeae . Pelvic Inflammatory Disease caused by Neisseria gonorrhoeae, Escherichia coli or Streptococcus agalactiae . NOTE: Ceftizoxime, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti­chlamydial coverage should be added. Intra­Abdominal Infections caused by Escherichia coli; Staphylococcus epidermidis; Streptococcus spp. (excluding enterococci); Enterobacter spp.; Klebsiella spp.; Bacteroides spp. including B. fragilis ; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Septicemia caused by Streptococcus spp. including S. pneumoniae (but excluding enterococci); Staphylococcus aureus (penicillinase­ and nonpenicillinase­producing); Escherichia coli; Bacteroides spp. including B. fragilis ; Klebsiella spp.; and Serratia spp. Skin and Skin Structure Infections caused by Staphylococcus aureus (penicillinase­ and nonpenicillinase­producing); Staphylococcus epidermidis ; Escherichia coli; Klebsiella spp.; Streptococcus spp. including Streptococcus pyogenes (but excluding enterococci); Proteus mirabilis ; Serratia spp.; Enterobacter spp.; Bacteroides spp. including B. fragilis ; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Bone and Joint Infections caused by Staphylococcus aureus (penicillinase­ and nonpenicillinase­producing); Streptococcus spp. (excluding enterococci); Proteus mirabilis ; Bacteroides spp.; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Meningitis caused by Haemophilus influenzae . Cefizox has also been used successfully in the treatment of a limited number of pediatric and adult cases of meningitis caused by Streptococcus pneumoniae . Cefizox has been effective in the treatment of seriously ill, compromised patients, including those who were debilitated, immunosuppressed, or neutropenic. Infections caused by aerobic gram­negative and by mixtures of organisms resistant to other cephalosporins, aminoglycosides, or penicillins have responded to treatment with Cefizox. Because of the serious nature of some urinary tract infections due to P. aeruginosa and because many strains of Pseudomonas species are only moderately susceptible to Cefizox, higher dosage is recommended. Other therapy should be instituted if the response is not prompt. Susceptibility studies on specimens obtained prior to therapy should be used to determine the response of causative organisms to Cefizox. Therapy with Cefizox may be initiated pending results of the studies; however, treatment should be adjusted according to study findings. In serious infections, Cefizox has been used concomitantly with aminoglycosides (see PRECAUTIONS ). Before using Cefizox concomitantly with other antibiotics, the prescribing information for those agents should be reviewed for contraindications, warnings, precautions, and adverse reactions. Renal function should be carefully monitored. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefizox and other antibacterial drugs, Cefizox should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:1ebafdcf-2739-48ba-a10a-7beea1007ecd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17303 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:534a836b-ccfd-4bd9-9a0a-139d4eaa4332"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0a68a5c6-3cb4-4c22-8bb0-37e0d0a09a6f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:afaa7cb8-fec7-4fbd-95db-c774428bcfa2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Morphine sulfate extended-release tablets are a controlled release oral morphine formulation indicated for the relief of moderate to severe pain. They are intended for use in patients who require repeated dosing with potent opioid analgesics over periods of more than a few days.|[PMDA] Drugs with a new formulation, a sustained-release preparation containing morphine hydrochloride given once a day uuid:fac55f06-5379-4ccc-83ed-ed7ea2b1d4c9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6801 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:6c23c536-149e-44f1-a88e-72fbbc0a386e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:04f807e7-5343-42dc-ba52-409de7107ebf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:6eed33df-e4bf-4691-ba89-2a149ed3efff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Metformin hydrochloride tablets, as monotherapy, are indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes. Metformin is indicated in patients 10 years of age and older. Metformin may be used concomitantly with a sulfonylurea or insulin to improve glycemic control in adults (17 years of age and older).|[PMDA] A drug with a new dosage exceeding the maximum dosage (750 mg/day) of the conventional formulation indicated for the treatment of type 2 diabetes mellitus (for use only in patients who have not responded sufficiently to either [1] diet and exercise therapies alone or [2] sulfonylurea along with diet and exercise therapies). uuid:ef393df3-c642-4320-90db-dc222816eb33 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6129 biolink:treats NCIT:C27003 PMID:41385096 "[{""id"":""uuid:11316cb9-6c5a-4e91-934f-18f6b3040fba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:771932bb-a66a-45ff-a722-64c503e5afbd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ketorolac tromethamine is indicated for the short-term (≤5 days) management of moderately severe acute pain that requires analgesia at the opioid level, usually in a postoperative setting. Therapy should always be initiated with Ketorolac Tromethamine Injection and ketorolac tromethamine tablets are to be used only as continuation treatment, if necessary. Combined use of Ketorolac Tromethamine Injection and ketorolac tromethamine tablets is not to exceed 5 days of use because of the potential of increasing the frequency and severity of adverse reactions associated with the recommended doses (see WARNINGS , PRECAUTIONS , DOSAGE AND ADMINISTRATION and ADVERSE REACTIONS ). Patients should be switched to alternative analgesics as soon as possible, but ketorolac tromethamine therapy is not to exceed 5 days. Ketorolac Tromethamine Injection has been used concomitantly with morphine and meperidine and has shown an opioid-sparing effect. For breakthrough pain, it is recommended to supplement the lower end of the Ketorolac Tromethamine Injection dosage range with low doses of narcotics prn, unless otherwise contraindicated. Ketorolac Tromethamine Injection and narcotics should not be administered in the same syringe (see DOSAGE AND ADMINISTRATION - Pharmaceutical Information for Ketorolac Tromethamine Injection ). uuid:8549d062-6bff-4557-a750-a25fa4891dd7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5784 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:06be41eb-868e-4508-997d-41c81bf66a6e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:25227273-01e7-4177-8d22-3a5589dcae1c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Saluron® is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis and corticosteroid and estrogen therapy. Saluron® has also been found useful in edema due to various forms of renal dysfunction, such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. Saluron® is indicated in the management of hypertension, either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension. uuid:239f919a-aacb-4f47-8934-b4d0e5d581c8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5784 biolink:treats MONDO:0005155 PMID:41385096 "[{""id"":""uuid:2afb1f2f-e181-4054-800a-e9c473e82ff5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e7535b95-f9e0-4d5f-ba8d-91aee5ccc986"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Saluron® is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis and corticosteroid and estrogen therapy. Saluron® has also been found useful in edema due to various forms of renal dysfunction, such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. Saluron® is indicated in the management of hypertension, either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension. uuid:a24d33c5-29b3-4bad-92d4-8363b7a0a721 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5784 biolink:treats MONDO:0005377 PMID:41385096 "[{""id"":""uuid:9f339fb6-9b83-4e7e-a3e7-dfec3b13f970"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:462cedc1-0c06-408e-8c74-d7b761d43967"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Saluron® is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis and corticosteroid and estrogen therapy. Saluron® has also been found useful in edema due to various forms of renal dysfunction, such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. Saluron® is indicated in the management of hypertension, either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension. uuid:56ae403b-2524-4551-b046-8bc048748496 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5784 biolink:treats UMLS:C0156221 PMID:41385096 "[{""id"":""uuid:3b519b50-23d9-4e66-b07c-99d040ae0d04"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6c348cef-c0e1-42e6-b1a0-f1d2cfcebd03"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Saluron® is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis and corticosteroid and estrogen therapy. Saluron® has also been found useful in edema due to various forms of renal dysfunction, such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. Saluron® is indicated in the management of hypertension, either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension. uuid:20dce4f1-6808-4f80-96cc-4c748ccf6ab5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5784 biolink:treats MONDO:0005300 PMID:41385096 "[{""id"":""uuid:d44bf1f5-af72-457a-9478-3afd829811f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b8d2be0c-084a-4a57-b83b-5804e54369bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Saluron® is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis and corticosteroid and estrogen therapy. Saluron® has also been found useful in edema due to various forms of renal dysfunction, such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. Saluron® is indicated in the management of hypertension, either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension. uuid:b0d82f81-f035-48e1-8b49-6ae02cbf7b79 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5784 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:3bdb1952-e4a4-4a96-bb24-5bb724ba3f40"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:edf5c1e4-3dbc-4d95-98d2-a5de74726535"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Saluron® is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis and corticosteroid and estrogen therapy. Saluron® has also been found useful in edema due to various forms of renal dysfunction, such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. Saluron® is indicated in the management of hypertension, either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension. uuid:a7c25b4f-8a08-4bf9-a541-7c2e7cbe3b8b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7470 biolink:treats MONDO:0005552 PMID:41385096 "[{""id"":""uuid:a8484222-fdb2-44c5-8e8c-02027d14a9c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9d7d45d3-e71f-4f9a-91f6-91c470f64902"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VA SO CON REGULAR is indicated for use as a topical ocular vasoconstrictor. uuid:3a6448e6-0a7c-4378-8635-2ede12d3731c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9327 biolink:treats MONDO:0003799 PMID:41385096 "[{""id"":""uuid:de1bf606-9501-4bbc-b960-dbdb66979f24"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b2f4e78a-ec66-445d-8fce-2c3ecf793eed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the treatment of conjunctivitis and other superficial ocular infections due to susceptible microorganisms and as an adjunctive in systemic sulfonamide therapy of trachoma: Escherichia coli, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus (viridans group), Haemophilus influenzae, Klebsiella species , and Enterobacter species. Topically applied sulfonamides do not provide adequate coverage against Neisseria species, Serratia marcescens and Pseudomonas aeruginosa. A significant percentage of staphylococcal isolates are completely resistant to sulfa drugs. uuid:cd837351-5428-4f9a-9f52-e5006f13329a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9327 biolink:treats MONDO:0001249 PMID:41385096 "[{""id"":""uuid:9c2f9873-4a94-45f1-b03d-c241667167fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e81c73e8-1479-4140-9ffe-d1f6d613e05a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the treatment of conjunctivitis and other superficial ocular infections due to susceptible microorganisms and as an adjunctive in systemic sulfonamide therapy of trachoma: Escherichia coli, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus (viridans group), Haemophilus influenzae, Klebsiella species , and Enterobacter species. Topically applied sulfonamides do not provide adequate coverage against Neisseria species, Serratia marcescens and Pseudomonas aeruginosa. A significant percentage of staphylococcal isolates are completely resistant to sulfa drugs. uuid:efacb1d0-ed51-4eca-b307-624edfa23522 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4653 biolink:treats MONDO:0005010 PMID:41385096 "[{""id"":""uuid:3d8a460a-abe6-4adc-ab90-529fbd255e20"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a9a3ab4e-9ae9-4e00-98f1-8239efa2ef30"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dipyridamole injection is indicated as an alternative to exercise in thallium myocardial perfusion imaging for the evaluation of coronary artery disease in patients who cannot exercise adequately. In a study of about 1100 patients who underwent coronary arteriography and dipyridamole injection assisted thallium imaging, the results of both tests were interpreted blindly and the sensitivity and specificity of the dipyridamole thallium study in predicting the angiographic outcome were calculated. The sensitivity of the dipyridamole test (true positive dipyridamole divided by the total number of patients with positive angiography) was about 85%. The specificity (true negative divided by the number of patients with negative angiograms) was about 50%. In a subset of patients who had exercise thallium imaging as well as dipyridamole thallium imaging, sensitivity and specificity of the two tests was almost identical. uuid:c7e6067f-7c63-44ca-a6d9-a53c4eaceb87 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9737 biolink:treats MONDO:0019121 PMID:41385096 "[{""id"":""uuid:05ce7c49-8a24-408d-83b4-92535ead4389"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7c6dd365-d4e2-421e-863b-0fca431f0ee6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Neutrexin (trimetrexate glucuronate for injection) with concurrent leucovorin administration (leucovorin protection) is indicated as an alternative therapy for the treatment of moderate-to-severe Pneumocystis carinii pneumonia (PCP) in immunocompromised patients, including patients with the acquired immunodeficiency syndrome (AIDS), who are intolerant of, or are refractory to, trimethoprim-sulfamethoxazole therapy or for whom trimethoprim-sulfamethoxazole is contraindicated. uuid:c7473ba6-4b56-45fb-8190-a042916b73aa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9737 biolink:treats MONDO:0012268 PMID:41385096 "[{""id"":""uuid:a6b51c3a-6ae9-41bf-89ac-622736f7ae2d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5fa9fae1-d375-4bfb-ab90-36976c009bf4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Neutrexin (trimetrexate glucuronate for injection) with concurrent leucovorin administration (leucovorin protection) is indicated as an alternative therapy for the treatment of moderate-to-severe Pneumocystis carinii pneumonia (PCP) in immunocompromised patients, including patients with the acquired immunodeficiency syndrome (AIDS), who are intolerant of, or are refractory to, trimethoprim-sulfamethoxazole therapy or for whom trimethoprim-sulfamethoxazole is contraindicated. uuid:23d65b81-b92b-4a0e-a264-8e2e7a6848e0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5818 biolink:treats MONDO:0011918 PMID:41385096 "[{""id"":""uuid:23be9623-2a2c-455d-9bca-80eb0e84ed9f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:41795f3d-c249-4bf0-a8e5-676367bfd32a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested. Useful in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses, and in histamine-mediated pruritus. As a sedative when used as premedication and following general anesthesia, Hydroxyzine may potentiate meperidine (Demerol®) and barbiturates , so their use in pre-anesthetic adjunctive therapy should be modified on an individual basis. Atropine and other belladonna alkaloids are not affected by the drug. Hydroxyzine is not known to interfere with the action of digitalis in any way and it may be used concurrently with this agent. The effectiveness of hydroxyzine as an antianxiety agent for long term use, that is more than 4 months, has not been assessed by systematic clinical studies. The physician should reassess periodically the usefulness of the drug for the individual patient. uuid:56457a2b-cf45-4b7e-8058-865e86170a85 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5818 biolink:treats UMLS:C0233494 PMID:41385096 "[{""id"":""uuid:e37b6754-77ed-43b0-8c1e-bd314db4d699"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:901fb5cb-b9c1-4fc5-9cbf-334f237c6dbb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested. Useful in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses, and in histamine-mediated pruritus. As a sedative when used as premedication and following general anesthesia, Hydroxyzine may potentiate meperidine (Demerol®) and barbiturates , so their use in pre-anesthetic adjunctive therapy should be modified on an individual basis. Atropine and other belladonna alkaloids are not affected by the drug. Hydroxyzine is not known to interfere with the action of digitalis in any way and it may be used concurrently with this agent. The effectiveness of hydroxyzine as an antianxiety agent for long term use, that is more than 4 months, has not been assessed by systematic clinical studies. The physician should reassess periodically the usefulness of the drug for the individual patient. uuid:5aad2e87-ee3d-4fb1-b017-015f8baf1dfb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5818 biolink:treats HP:0000989 PMID:41385096 "[{""id"":""uuid:08af710e-9c4a-4ebe-afdb-1bb115040a23"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:04bb3d2f-9cf5-41e6-9204-f1af8cc9680c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested. Useful in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses, and in histamine-mediated pruritus. As a sedative when used as premedication and following general anesthesia, Hydroxyzine may potentiate meperidine (Demerol®) and barbiturates , so their use in pre-anesthetic adjunctive therapy should be modified on an individual basis. Atropine and other belladonna alkaloids are not affected by the drug. Hydroxyzine is not known to interfere with the action of digitalis in any way and it may be used concurrently with this agent. The effectiveness of hydroxyzine as an antianxiety agent for long term use, that is more than 4 months, has not been assessed by systematic clinical studies. The physician should reassess periodically the usefulness of the drug for the individual patient. uuid:df34e850-5ba8-42f0-b9b6-75574e00de1c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5818 biolink:treats MONDO:0850230 PMID:41385096 "[{""id"":""uuid:1a325bbf-be32-4533-a872-3cc73c02ceec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3e33e937-59f5-4d17-ba05-04c70f3f6f19"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested. Useful in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses, and in histamine-mediated pruritus. As a sedative when used as premedication and following general anesthesia, Hydroxyzine may potentiate meperidine (Demerol®) and barbiturates , so their use in pre-anesthetic adjunctive therapy should be modified on an individual basis. Atropine and other belladonna alkaloids are not affected by the drug. Hydroxyzine is not known to interfere with the action of digitalis in any way and it may be used concurrently with this agent. The effectiveness of hydroxyzine as an antianxiety agent for long term use, that is more than 4 months, has not been assessed by systematic clinical studies. The physician should reassess periodically the usefulness of the drug for the individual patient. uuid:3fc9ccf9-4ad5-4776-b17d-d8aff9a2019d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5818 biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:3fb849c9-d10b-42d2-85f8-272e280a5e7b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8e8425de-fd91-4692-a726-7cbc6cc94a7e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested. Useful in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses, and in histamine-mediated pruritus. As a sedative when used as premedication and following general anesthesia, Hydroxyzine may potentiate meperidine (Demerol®) and barbiturates , so their use in pre-anesthetic adjunctive therapy should be modified on an individual basis. Atropine and other belladonna alkaloids are not affected by the drug. Hydroxyzine is not known to interfere with the action of digitalis in any way and it may be used concurrently with this agent. The effectiveness of hydroxyzine as an antianxiety agent for long term use, that is more than 4 months, has not been assessed by systematic clinical studies. The physician should reassess periodically the usefulness of the drug for the individual patient. uuid:f7b2ce49-cac4-4b0c-992b-75755341bb28 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5818 biolink:treats MONDO:0005480 PMID:41385096 "[{""id"":""uuid:257c1e72-81bc-4c30-9eda-dc8f8775c854"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fe79c1db-4163-44a7-ad86-54d16a64153d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested. Useful in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses, and in histamine-mediated pruritus. As a sedative when used as premedication and following general anesthesia, Hydroxyzine may potentiate meperidine (Demerol®) and barbiturates , so their use in pre-anesthetic adjunctive therapy should be modified on an individual basis. Atropine and other belladonna alkaloids are not affected by the drug. Hydroxyzine is not known to interfere with the action of digitalis in any way and it may be used concurrently with this agent. The effectiveness of hydroxyzine as an antianxiety agent for long term use, that is more than 4 months, has not been assessed by systematic clinical studies. The physician should reassess periodically the usefulness of the drug for the individual patient. uuid:f2c18b86-f2a0-4585-8c49-98d29eeebc43 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:187893 biolink:treats MONDO:0005301 PMID:41385096 "[{""id"":""uuid:cec2dc44-a44b-44f0-982c-8fc42254ecf4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7626b514-1cd2-404b-9154-22c0bede3c7d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KEMSTRO™ is useful for the alleviation of signs and symptoms of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity. Patients should have reversible spasticity so that treatment with KEMSTRO™ will aid in restoring residual function. KEMSTRO™ may also be of some value in patients with spinal cord injuries and other spinal cord diseases. KEMSTRO™ is not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders. The efficacy of KEMSTRO™ in stroke, cerebral palsy, and Parkinson's disease has not been established and, therefore, it is not recommended for these conditions. uuid:913b2016-7b29-4d75-95d5-9b9718324fdb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:187893 biolink:treats MONDO:0043797 PMID:41385096 "[{""id"":""uuid:37594c91-9dd1-4620-9b7b-bee0418176dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:557f10ae-1557-42c1-8be1-3c453197a3e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KEMSTRO™ is useful for the alleviation of signs and symptoms of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity. Patients should have reversible spasticity so that treatment with KEMSTRO™ will aid in restoring residual function. KEMSTRO™ may also be of some value in patients with spinal cord injuries and other spinal cord diseases. KEMSTRO™ is not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders. The efficacy of KEMSTRO™ in stroke, cerebral palsy, and Parkinson's disease has not been established and, therefore, it is not recommended for these conditions. uuid:4b75403a-7762-4087-b154-4815615943dd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:187893 biolink:treats MONDO:0002545 PMID:41385096 "[{""id"":""uuid:c0fca9fd-30eb-4386-b56f-e97e3a36e0be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6bf9cc88-b2a4-4346-b406-290fba39087f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KEMSTRO™ is useful for the alleviation of signs and symptoms of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity. Patients should have reversible spasticity so that treatment with KEMSTRO™ will aid in restoring residual function. KEMSTRO™ may also be of some value in patients with spinal cord injuries and other spinal cord diseases. KEMSTRO™ is not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders. The efficacy of KEMSTRO™ in stroke, cerebral palsy, and Parkinson's disease has not been established and, therefore, it is not recommended for these conditions. uuid:93ec6705-0436-4875-9860-7650743909f2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4530 biolink:treats NCIT:C120380 PMID:41385096 "[{""id"":""uuid:dbbb7747-2151-422d-bd32-7e6fcf8317c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4032aaf1-68b6-4bec-b109-d764ac5dd257"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diethylpropion hydrochloride tablets are indicated in the management of exogenous obesity as a short-term adjunct (a few weeks) in a regiment of weight reduction based on caloric restriction. The usefulness of agents of this class should be measured against possible risk factors inherent in their use such as those described (see CLINICAL PHARMACOLOGY ). uuid:f89ab505-2cb1-4f48-8903-98a783178d5e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3437 biolink:treats MONDO:0005338 PMID:41385096 "[{""id"":""uuid:fe77b7e5-aaee-4ef5-9de2-1623a2a7d34c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7b6041de-2f27-4105-82d5-86fb4955522b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ocupress Ophthalmic Solution, 1%, has been shown to be effective in lowering intraocular pressure and may be used in patients with chronic open-angle glaucoma and intraocular hypertension. It may be used alone or in combination with other intraocular pressure lowering medications. uuid:64b9517d-fdf6-4357-8a59-14845e404696 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3437 biolink:treats MONDO:0006875 PMID:41385096 "[{""id"":""uuid:8ff5ea55-86f7-4049-9223-42239b0d8037"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2f7079ec-b6f7-4c69-a8c5-b15c720418d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ocupress Ophthalmic Solution, 1%, has been shown to be effective in lowering intraocular pressure and may be used in patients with chronic open-angle glaucoma and intraocular hypertension. It may be used alone or in combination with other intraocular pressure lowering medications. uuid:59b10573-5fb4-4bcd-96a2-5f669ab753ff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6887 biolink:treats MONDO:0007743 PMID:41385096 "[{""id"":""uuid:abead3cd-30c2-4d71-98bd-e64ee2686aa8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:960c68e5-d03f-4142-a779-4f88b36a7fc3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Attention Deficit Disorders (previously known as Minimal Brain Dysfunction in Children). Other terms being used to describe the behavioral syndrome below include: Hyperkinetic Child Syndrome, Minimal Brain Damage, Minimal Cerebral Dysfunction, Minor Cerebral Dysfunction. Methylphenidate hydrochloride is indicated as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate-to-severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. The diagnosis of this syndrome should not be made with finality when these symptoms are only of comparatively recent origin. Nonlocalizing (soft) neurological signs, learning disability, and abnormal EEG may or may not be present, and a diagnosis of central nervous system dysfunction may or may not be warranted. uuid:970054cb-f23a-4d54-8c96-66cddad83abf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6887 biolink:treats MONDO:0043510 PMID:41385096 "[{""id"":""uuid:54bce4e4-b009-4288-a67e-8f54915e700e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:350ec2d5-94dc-4588-8bf1-3ec86b398aa5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Attention Deficit Disorders (previously known as Minimal Brain Dysfunction in Children). Other terms being used to describe the behavioral syndrome below include: Hyperkinetic Child Syndrome, Minimal Brain Damage, Minimal Cerebral Dysfunction, Minor Cerebral Dysfunction. Methylphenidate hydrochloride is indicated as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate-to-severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. The diagnosis of this syndrome should not be made with finality when these symptoms are only of comparatively recent origin. Nonlocalizing (soft) neurological signs, learning disability, and abnormal EEG may or may not be present, and a diagnosis of central nervous system dysfunction may or may not be warranted. uuid:4281a9a9-a6e0-49be-a27f-47aa67aa0f97 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6887 biolink:treats MONDO:0004681 PMID:41385096 "[{""id"":""uuid:3a698d7a-a598-4379-8aee-5246c73a0acf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fddcd571-956b-44a1-8337-49bb2592a182"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Attention Deficit Disorders (previously known as Minimal Brain Dysfunction in Children). Other terms being used to describe the behavioral syndrome below include: Hyperkinetic Child Syndrome, Minimal Brain Damage, Minimal Cerebral Dysfunction, Minor Cerebral Dysfunction. Methylphenidate hydrochloride is indicated as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate-to-severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. The diagnosis of this syndrome should not be made with finality when these symptoms are only of comparatively recent origin. Nonlocalizing (soft) neurological signs, learning disability, and abnormal EEG may or may not be present, and a diagnosis of central nervous system dysfunction may or may not be warranted. uuid:d0624434-4909-47c4-8be5-1df9e8737e6d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75722 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:b472f9c7-eba7-4e2d-80d5-1c8072dd52d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:33377aca-923b-4d13-8c72-1273cf21798c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tramadol hydrochloride tablets are indicated for the management of moderate to moderately severe pain in adults. uuid:7d219ae0-f050-4f02-ae18-1f2a198991b3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:21659 biolink:treats MONDO:0006668 PMID:41385096 "[{""id"":""uuid:e1834be4-e8af-4a6d-aea7-791b1860f98c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e9b4b233-66d2-4dcc-a0cd-019387a3127c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Neomycin and polymyxin B sulfates and bacitracin zinc with hydrocortisone acetate ophthalmic ointment is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial infection exists. Ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of corticosteroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye (see CLINICAL PHARMACOLOGY: Microbiology ). The particular anti-infective drugs in this product are active against the following common bacterial eye pathogens: Staphylococcus aureus, streptococci, including Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae, Klebsiella/Enterobacter species, Neisseria species, and Pseudomonas aeruginosa. The product does not provide adequate coverage against Serratia marcescens. uuid:ac7a9a10-2486-4d0c-96f5-b41fbe68f4ce biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:21659 biolink:treats UMLS:C0008690 PMID:41385096 "[{""id"":""uuid:b4192a6d-20b1-4df8-8e67-ff748bca586f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f6f92c60-b985-4126-9d8f-1cfc0e3f9057"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Neomycin and polymyxin B sulfates and bacitracin zinc with hydrocortisone acetate ophthalmic ointment is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial infection exists. Ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of corticosteroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye (see CLINICAL PHARMACOLOGY: Microbiology ). The particular anti-infective drugs in this product are active against the following common bacterial eye pathogens: Staphylococcus aureus, streptococci, including Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae, Klebsiella/Enterobacter species, Neisseria species, and Pseudomonas aeruginosa. The product does not provide adequate coverage against Serratia marcescens. uuid:0caaae4e-ee79-48f7-94e1-a2e467b862b2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:21659 biolink:treats UMLS:C0339289 PMID:41385096 "[{""id"":""uuid:831ffcf8-aaab-4fc9-ab79-31aaccbf626c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:90dd8bcb-a853-46cd-be4f-e51bb3c6f957"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Neomycin and polymyxin B sulfates and bacitracin zinc with hydrocortisone acetate ophthalmic ointment is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial infection exists. Ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of corticosteroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye (see CLINICAL PHARMACOLOGY: Microbiology ). The particular anti-infective drugs in this product are active against the following common bacterial eye pathogens: Staphylococcus aureus, streptococci, including Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae, Klebsiella/Enterobacter species, Neisseria species, and Pseudomonas aeruginosa. The product does not provide adequate coverage against Serratia marcescens. uuid:b2efab68-ad1c-4446-bac9-b411a1837701 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50648 biolink:treats MONDO:0005055 PMID:41385096 "[{""id"":""uuid:69b27189-81a5-4d8b-a380-d3887f7bf3f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f265e107-2fa2-4d87-b7de-2318dffd35f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Panretin® gel is indicated for topical treatment of cutaneous lesions in patients with AIDS-related Kaposi’s sarcoma. Panretin® gel is not indicated when systemic anti-KS therapy is required (e.g., more than 10 new KS lesions in the prior month, symptomatic lymphedema, symptomatic pulmonary KS, or symptomatic visceral involvement). There is no experience to date using Panretin® gel with systemic anti-KS treatment. uuid:38e049c4-c817-463d-8a0f-dc92e54448e5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50648 biolink:treats MONDO:0019297 PMID:41385096 "[{""id"":""uuid:47834d76-e2d8-4bcc-8107-162a9b9422a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4eba3d36-8894-4db0-b618-df43f5e15eff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Panretin® gel is indicated for topical treatment of cutaneous lesions in patients with AIDS-related Kaposi’s sarcoma. Panretin® gel is not indicated when systemic anti-KS therapy is required (e.g., more than 10 new KS lesions in the prior month, symptomatic lymphedema, symptomatic pulmonary KS, or symptomatic visceral involvement). There is no experience to date using Panretin® gel with systemic anti-KS treatment. uuid:117058df-eb04-4f41-974b-04f5c84c26f5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17698 biolink:treats MONDO:0043885 PMID:41385096 "[{""id"":""uuid:8c0f3558-b3cf-42e3-a1fc-a12a04244fdf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2041e6b4-c78e-406d-9450-334c87e9a828"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Chloramphenicol should be used only in those serious infections for which less potentially dangerous drugs are ineffective or contraindicated. Bacteriological studies should be performed to determine the causative organisms and their sensitivity to chloramphenicol (see Boxed Warning ). Chloromycetin Ophthalmic Ointment, 1% (Chloramphenicol Ophthalmic Ointment, USP) is indicated for the treatment of surface ocular infections involving the conjunctiva and/or cornea caused by chloramphenicol-susceptible organisms. The particular antiinfective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus Streptococcus , including Streptococcus pneumoniae Escherichia coli Haemophilus influenzae Klebsiella/Enterobacter species Moraxella lucunata (Morax-Axenfeld bacillus) Neisseria species This product does not provide adequate coverage against: Pseudomonas aeruginosa Serratia marcescens uuid:781a3f7a-1de9-4efd-aa9d-552c6eb731c8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17698 biolink:treats MONDO:0003799 PMID:41385096 "[{""id"":""uuid:6a4aa5a9-4a7b-483d-b94f-28809669a96e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f7195508-be7a-4978-993d-f7c134ac5b8f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Chloramphenicol should be used only in those serious infections for which less potentially dangerous drugs are ineffective or contraindicated. Bacteriological studies should be performed to determine the causative organisms and their sensitivity to chloramphenicol (see Boxed Warning ). Chloromycetin Ophthalmic Ointment, 1% (Chloramphenicol Ophthalmic Ointment, USP) is indicated for the treatment of surface ocular infections involving the conjunctiva and/or cornea caused by chloramphenicol-susceptible organisms. The particular antiinfective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus Streptococcus , including Streptococcus pneumoniae Escherichia coli Haemophilus influenzae Klebsiella/Enterobacter species Moraxella lucunata (Morax-Axenfeld bacillus) Neisseria species This product does not provide adequate coverage against: Pseudomonas aeruginosa Serratia marcescens uuid:37ce79b0-adfb-4c94-a461-7079f1e0f21e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17698 biolink:treats MONDO:0023865 PMID:41385096 "[{""id"":""uuid:8a7e4ac6-7ec8-4ab8-85d1-ffd8dd453ef6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:36e33f8e-b4cf-4297-bb4f-2aafffe7de76"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Chloramphenicol should be used only in those serious infections for which less potentially dangerous drugs are ineffective or contraindicated. Bacteriological studies should be performed to determine the causative organisms and their sensitivity to chloramphenicol (see Boxed Warning ). Chloromycetin Ophthalmic Ointment, 1% (Chloramphenicol Ophthalmic Ointment, USP) is indicated for the treatment of surface ocular infections involving the conjunctiva and/or cornea caused by chloramphenicol-susceptible organisms. The particular antiinfective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus Streptococcus , including Streptococcus pneumoniae Escherichia coli Haemophilus influenzae Klebsiella/Enterobacter species Moraxella lucunata (Morax-Axenfeld bacillus) Neisseria species This product does not provide adequate coverage against: Pseudomonas aeruginosa Serratia marcescens uuid:c8cf0cc4-66d8-473c-8555-b8935dfa3fc0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:376030 biolink:treats MONDO:0003799 PMID:41385096 "[{""id"":""uuid:b888ffde-2c5f-4a47-8504-647289180f59"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1b45a7d5-d874-4629-8a99-98165a638e2f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NEOSPORIN Ophthalmic Ointment is indicated for the topical treatment of superficial infections of the external eye and its adnexa caused by susceptible bacteria. Such infections encompass conjunctivitis, keratitis and keratoconjunctivitis, blepharitis and blepharoconjunctivitis. uuid:e517d12b-cdde-4a48-a63b-a15a07e7bfe8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:376030 biolink:treats MONDO:0003085 PMID:41385096 "[{""id"":""uuid:2dc262d3-7d14-4bc1-a017-704238fb94b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:98c516d4-7f94-47af-a88a-f1f9e0d079b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NEOSPORIN Ophthalmic Ointment is indicated for the topical treatment of superficial infections of the external eye and its adnexa caused by susceptible bacteria. Such infections encompass conjunctivitis, keratitis and keratoconjunctivitis, blepharitis and blepharoconjunctivitis. uuid:ec89b9fb-5a25-46d7-b3e8-5cb6ccc69692 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:376030 biolink:treats MONDO:0004768 PMID:41385096 "[{""id"":""uuid:c57d7728-28a7-498f-b73e-3b664897afb4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:72f08af8-ac03-4b0a-94a9-ac562e26d6bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NEOSPORIN Ophthalmic Ointment is indicated for the topical treatment of superficial infections of the external eye and its adnexa caused by susceptible bacteria. Such infections encompass conjunctivitis, keratitis and keratoconjunctivitis, blepharitis and blepharoconjunctivitis. uuid:1145d5a9-d6cf-47f1-9420-216dc4039c27 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:376030 biolink:treats MONDO:0004785 PMID:41385096 "[{""id"":""uuid:ba7a60c2-dce4-4b7b-a18f-c24f63b6c2a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:78b5d376-8c5f-4fa1-8cc4-c2bb282cb2dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NEOSPORIN Ophthalmic Ointment is indicated for the topical treatment of superficial infections of the external eye and its adnexa caused by susceptible bacteria. Such infections encompass conjunctivitis, keratitis and keratoconjunctivitis, blepharitis and blepharoconjunctivitis. uuid:b16e0ecc-916b-4422-b335-6693ee552e7b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:376030 biolink:treats MONDO:0002307 PMID:41385096 "[{""id"":""uuid:203b8bd7-9617-49ee-9792-dafb57b22bbe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c20b2119-bbca-46f3-951a-7f8f2d08d4f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NEOSPORIN Ophthalmic Ointment is indicated for the topical treatment of superficial infections of the external eye and its adnexa caused by susceptible bacteria. Such infections encompass conjunctivitis, keratitis and keratoconjunctivitis, blepharitis and blepharoconjunctivitis. uuid:0d046857-f82b-46cc-826a-c2434ffc92b2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8776 biolink:treats MONDO:0005412 PMID:41385096 "[{""id"":""uuid:7086e21f-fee7-48c0-940f-e982e5c0a5bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:20e18553-00c7-4ae2-84d2-19bab65b9273"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ranitidine tablets are indicated in: 1.Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks. Studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than eight weeks. 2. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. No placebo-controlled comparative studies have been carried out for periods of longer than 1 year. 3. The treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome and systemic mastocytosis). 4. Short-term treatment of active, benign gastric ulcer. Most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated. Studies available to date have not assessed the safety of ranitidine in uncomplicated, benign gastric ulcer for periods of more than 6 weeks. 5. Maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers. Placebo-controlled studies have been carried out for 1 year. 6. Treatment of GERD: Symptomatic relief commonly occurs within 24 hours after starting therapy with ranitidine 150 mg b.i.d. 7. Treatment of endoscopically diagnosed erosive esophagitis. Symptomatic relief of heartburn commonly occurs within 24 hours of therapy initiation with ranitidine 150 mg q.i.d. 8.Maintenance of healing of erosive esophagitis. Placebo-controlled trials have been carried out for 48 weeks. Concomitant antacids should be given as needed for pain relief to patients with active duodenal ulcer; active, benign gastric ulcer; hypersecretory states; GERD; and erosive esophagitis. uuid:cfd983a4-6679-4898-b83e-63d6cb6147ca biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8776 biolink:treats MONDO:0016586 PMID:41385096 "[{""id"":""uuid:d0a0a6c0-ed80-44ce-bd78-e4a62398aa28"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5474e4bb-4e8b-48b5-8cda-6b3116ad76a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ranitidine tablets are indicated in: 1.Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks. Studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than eight weeks. 2. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. No placebo-controlled comparative studies have been carried out for periods of longer than 1 year. 3. The treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome and systemic mastocytosis). 4. Short-term treatment of active, benign gastric ulcer. Most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated. Studies available to date have not assessed the safety of ranitidine in uncomplicated, benign gastric ulcer for periods of more than 6 weeks. 5. Maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers. Placebo-controlled studies have been carried out for 1 year. 6. Treatment of GERD: Symptomatic relief commonly occurs within 24 hours after starting therapy with ranitidine 150 mg b.i.d. 7. Treatment of endoscopically diagnosed erosive esophagitis. Symptomatic relief of heartburn commonly occurs within 24 hours of therapy initiation with ranitidine 150 mg q.i.d. 8.Maintenance of healing of erosive esophagitis. Placebo-controlled trials have been carried out for 48 weeks. Concomitant antacids should be given as needed for pain relief to patients with active duodenal ulcer; active, benign gastric ulcer; hypersecretory states; GERD; and erosive esophagitis. uuid:59848560-ae56-467c-9f5f-db65ac853eea biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8776 biolink:treats MONDO:0001126 PMID:41385096 "[{""id"":""uuid:6802e05c-0b8c-47ae-8a2a-96e1063a25eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:348f8c45-4aea-4237-8a55-c5eec17951a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ranitidine tablets are indicated in: 1.Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks. Studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than eight weeks. 2. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. No placebo-controlled comparative studies have been carried out for periods of longer than 1 year. 3. The treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome and systemic mastocytosis). 4. Short-term treatment of active, benign gastric ulcer. Most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated. Studies available to date have not assessed the safety of ranitidine in uncomplicated, benign gastric ulcer for periods of more than 6 weeks. 5. Maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers. Placebo-controlled studies have been carried out for 1 year. 6. Treatment of GERD: Symptomatic relief commonly occurs within 24 hours after starting therapy with ranitidine 150 mg b.i.d. 7. Treatment of endoscopically diagnosed erosive esophagitis. Symptomatic relief of heartburn commonly occurs within 24 hours of therapy initiation with ranitidine 150 mg q.i.d. 8.Maintenance of healing of erosive esophagitis. Placebo-controlled trials have been carried out for 48 weeks. Concomitant antacids should be given as needed for pain relief to patients with active duodenal ulcer; active, benign gastric ulcer; hypersecretory states; GERD; and erosive esophagitis. uuid:da4b1837-0db7-4d52-9cdc-694c57c2a774 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8776 biolink:treats UMLS:C0267055 PMID:41385096 "[{""id"":""uuid:9996c07f-f432-4603-91fa-8bb09cec3e0a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8fb7debd-401b-4532-be87-ef60ab08ab95"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ranitidine tablets are indicated in: 1.Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks. Studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than eight weeks. 2. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. No placebo-controlled comparative studies have been carried out for periods of longer than 1 year. 3. The treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome and systemic mastocytosis). 4. Short-term treatment of active, benign gastric ulcer. Most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated. Studies available to date have not assessed the safety of ranitidine in uncomplicated, benign gastric ulcer for periods of more than 6 weeks. 5. Maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers. Placebo-controlled studies have been carried out for 1 year. 6. Treatment of GERD: Symptomatic relief commonly occurs within 24 hours after starting therapy with ranitidine 150 mg b.i.d. 7. Treatment of endoscopically diagnosed erosive esophagitis. Symptomatic relief of heartburn commonly occurs within 24 hours of therapy initiation with ranitidine 150 mg q.i.d. 8.Maintenance of healing of erosive esophagitis. Placebo-controlled trials have been carried out for 48 weeks. Concomitant antacids should be given as needed for pain relief to patients with active duodenal ulcer; active, benign gastric ulcer; hypersecretory states; GERD; and erosive esophagitis. uuid:a0ddbab1-4275-4bea-885f-eca478989020 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4975 biolink:treats MONDO:0005412 PMID:41385096 "[{""id"":""uuid:c93167a3-c645-4a73-b1e5-f21a334b52ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ed64bda8-7de9-4ba3-a3ec-5c064c25e431"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FLUXID™ is indicated in: 1. Short term treatment of active duodenal ulcer. Most adult patients heal within 4 weeks; there is rarely reason to use famotidine at full dosage for longer than 6 to 8 weeks. Studies have not assessed the safety of famotidine in uncomplicated active duodenal ulcer for periods of more than eight weeks. 2. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of an active ulcer. Controlled studies in adults have not extended beyond one year. 3. Short term treatment of active benign gastric ulcer. Most adult patients heal within 6 weeks. Studies have not assessed the safety or efficacy of famotidine in uncomplicated active benign gastric ulcer for periods of more than 8 weeks. 4. Short term treatment of gastroesophageal reflux disease (GERD) . FLUXID™ is indicated for short term treatment of patients with symptoms of GERD (see CLINICAL PHARMACOLOGY IN ADULTS, Clinical Studies ). FLUXID™ is also indicated for the short term treatment of esophagitis due to GERD including erosive or ulcerative disease diagnosed by endoscopy (see CLINICAL PHARMACOLOGY IN ADULTS, Clinical Studies ). 5. Treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison Syndrome, multiple endocrine adenomas) (see CLINICAL PHARMACOLOGY IN ADULTS, Clinical Studies ). uuid:f909fd70-5943-4c0a-98a1-f918e5eda2ac biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4975 biolink:treats MONDO:0001126 PMID:41385096 "[{""id"":""uuid:3cbadd55-4c35-4d95-a58b-a18e54821847"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a835e9df-58e9-40bf-a65c-ad6edccb91ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FLUXID™ is indicated in: 1. Short term treatment of active duodenal ulcer. Most adult patients heal within 4 weeks; there is rarely reason to use famotidine at full dosage for longer than 6 to 8 weeks. Studies have not assessed the safety of famotidine in uncomplicated active duodenal ulcer for periods of more than eight weeks. 2. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of an active ulcer. Controlled studies in adults have not extended beyond one year. 3. Short term treatment of active benign gastric ulcer. Most adult patients heal within 6 weeks. Studies have not assessed the safety or efficacy of famotidine in uncomplicated active benign gastric ulcer for periods of more than 8 weeks. 4. Short term treatment of gastroesophageal reflux disease (GERD) . FLUXID™ is indicated for short term treatment of patients with symptoms of GERD (see CLINICAL PHARMACOLOGY IN ADULTS, Clinical Studies ). FLUXID™ is also indicated for the short term treatment of esophagitis due to GERD including erosive or ulcerative disease diagnosed by endoscopy (see CLINICAL PHARMACOLOGY IN ADULTS, Clinical Studies ). 5. Treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison Syndrome, multiple endocrine adenomas) (see CLINICAL PHARMACOLOGY IN ADULTS, Clinical Studies ). uuid:059979c5-5307-4479-b0be-eb217650d37a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4975 biolink:treats MONDO:0006896 PMID:41385096 "[{""id"":""uuid:0de4c3d7-0d39-4a12-b471-8a84da2df939"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bfb8bb5f-62d8-4e04-b39e-7386ab12d8d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FLUXID™ is indicated in: 1. Short term treatment of active duodenal ulcer. Most adult patients heal within 4 weeks; there is rarely reason to use famotidine at full dosage for longer than 6 to 8 weeks. Studies have not assessed the safety of famotidine in uncomplicated active duodenal ulcer for periods of more than eight weeks. 2. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of an active ulcer. Controlled studies in adults have not extended beyond one year. 3. Short term treatment of active benign gastric ulcer. Most adult patients heal within 6 weeks. Studies have not assessed the safety or efficacy of famotidine in uncomplicated active benign gastric ulcer for periods of more than 8 weeks. 4. Short term treatment of gastroesophageal reflux disease (GERD) . FLUXID™ is indicated for short term treatment of patients with symptoms of GERD (see CLINICAL PHARMACOLOGY IN ADULTS, Clinical Studies ). FLUXID™ is also indicated for the short term treatment of esophagitis due to GERD including erosive or ulcerative disease diagnosed by endoscopy (see CLINICAL PHARMACOLOGY IN ADULTS, Clinical Studies ). 5. Treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison Syndrome, multiple endocrine adenomas) (see CLINICAL PHARMACOLOGY IN ADULTS, Clinical Studies ). uuid:d6175620-5b18-4b1c-88c5-cc86a51ede45 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4975 biolink:treats MONDO:0017169 PMID:41385096 "[{""id"":""uuid:d901fdfd-61b0-4965-bb1e-47421a1ec363"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:24f92391-9bd8-4240-8990-6d961a43faf8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FLUXID™ is indicated in: 1. Short term treatment of active duodenal ulcer. Most adult patients heal within 4 weeks; there is rarely reason to use famotidine at full dosage for longer than 6 to 8 weeks. Studies have not assessed the safety of famotidine in uncomplicated active duodenal ulcer for periods of more than eight weeks. 2. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of an active ulcer. Controlled studies in adults have not extended beyond one year. 3. Short term treatment of active benign gastric ulcer. Most adult patients heal within 6 weeks. Studies have not assessed the safety or efficacy of famotidine in uncomplicated active benign gastric ulcer for periods of more than 8 weeks. 4. Short term treatment of gastroesophageal reflux disease (GERD) . FLUXID™ is indicated for short term treatment of patients with symptoms of GERD (see CLINICAL PHARMACOLOGY IN ADULTS, Clinical Studies ). FLUXID™ is also indicated for the short term treatment of esophagitis due to GERD including erosive or ulcerative disease diagnosed by endoscopy (see CLINICAL PHARMACOLOGY IN ADULTS, Clinical Studies ). 5. Treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison Syndrome, multiple endocrine adenomas) (see CLINICAL PHARMACOLOGY IN ADULTS, Clinical Studies ). uuid:13f5801c-a80f-4cf1-befa-57ea0897511e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6067 biolink:treats MONDO:0011438 PMID:41385096 "[{""id"":""uuid:22259e05-d64e-4fb1-a25e-4b9ac7853024"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:33e18373-e368-4ccb-a399-7a1fe295a479"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sotret is indicated for the treatment of severe recalcitrant nodular acne. Nodules are inflammatory lesions with a diameter of 5 mm or greater. The nodules may become suppurative or hemorrhagic. “Severe,” by definition, 2 means “many” as opposed to “few or several” nodules. Because of significant adverse effects associated with its use, Sotret should be reserved for patients with severe nodular acne who are unresponsive to conventional therapy, including systemic antibiotics. In addition, Sotret is indicated only for those female patients who are not pregnant, because Sotret can cause severe birth defects (see Boxed CONTRAINDICATIONS AND WARNINGS ). A single course of therapy for 15 to 20 weeks has been shown to result in complete and prolonged remission of disease in many patients. 1,3,4 If a second course of therapy is needed, it should not be initiated until at least 8 weeks after completion of the first course, because experience has shown that patients may continue to improve while off isotretinoin capsules. The optimal interval before retreatment has not been defined for patients who have not completed skeletal growth (see WARNINGS: Skeletal: Bone Mineral Density, Hyperostosis , and Premature Epiphyseal Closure ). uuid:c827eaca-a2fe-4a35-9ef7-93492fa1b4bb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:370748 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:0a1294a0-6e97-434f-aec1-018774f95084"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2cd022ed-1352-448f-b391-c23b6eaf8899"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Acetaminophen and codeine phosphate tablets are indicated for the relief of mild to moderately severe pain. uuid:e087f7e1-111f-4099-9191-422e844544b8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63622 biolink:treats HP:0004308 PMID:41385096 "[{""id"":""uuid:44ce15ff-08d1-4f9b-bc87-34b96dd7545e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:42d6caca-774c-43e7-a85c-69d4c66fa97b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sotalol is indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that in the judgment of the physician are life-threatening. Because of the proarrhythmic effects of sotalol (See WARNINGS ), including a 1.5 to 2% rate of torsade de pointes or new VT/VF in patients with either NSVT or supraventricular arrhythmias, its use in patients with less severe arrhythmias, even if the patients are symptomatic, is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of sotalol treatment or increasing doses, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. The response to treatment should then be evaluated by a suitable method (e.g., PES or Holter monitoring) prior to continuing the patient on chronic therapy. Various approaches have been used to determine the response to antiarrhythmic therapy, including sotalol. In the ESVEM Trial, response by Holter monitoring was tentatively defined as 100% suppression of ventricular tachycardia, 90% suppression of non-sustained VT, 80% suppression of paired VPCs, and 75% suppression of total VPCs in patients who had at least 10 VPCs/hour at baseline; this tentative response was confirmed if VT lasting 5 or more beats was not observed during treadmill exercise testing using a standard Bruce protocol. The PES protocol utilized a maximum of three extrastimuli at three pacing cycle lengths and two right ventricular pacing sites. Response to PES was defined as prevention of induction of the following: 1) monomorphic VT lasting over 15 seconds; 2) non-sustained polymorphic VT containing more than 15 beats of monomorphic VT in patients with a history of monomorphic VT; 3) polymorphic VT or VF greater than 15 beats in patients with VF or a history of aborted sudden death without monomorphic VT; and 4) two episodes of polymorphic VT or VF of greater than 15 beats in a patient presenting with monomorphic VT. Sustained VT or NSVT producing hypotension during the final treadmill test was considered a drug failure. In a multicenter open-label long-term study of sotalol in patients with life-threatening ventricular arrhythmias which had proved refractory to other antiarrhythmic medications, response by Holter monitoring was defined as in ESVEM. Response by PES was defined as non-inducibility of sustained VT by at least double extrastimuli delivered at a pacing cycle length of 400 msec. Overall survival and arrhythmia recurrence rates in this study were similar to those seen in ESVEM, although there was no comparative group to allow a definitive assessment of outcome. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias. Sotalol is also indicated for the maintenance of normal sinus rhythm [delay in time to recurrence of atrial fibrillation/atrial flutter (AFIB/AFL)] in patients with symptomatic AFIB/AFL who are currently in sinus rhythm and is marketed under the brand name BETAPACE AF™. Sotalol is not approved for the AFIB/AFL indication and should not be substituted for BETAPACE AF™ because only BETAPACE AF is distributed with a patient package insert that is appropriate for patients with AFIB/AFL. uuid:83f30c35-c208-4b68-9d57-0b4bd615786b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63622 biolink:treats UMLS:C0750197 PMID:41385096 "[{""id"":""uuid:94f2cf00-3810-4126-a209-443b0bbf2a06"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:16fc08ba-a49c-499c-8608-a895bc772787"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sotalol is indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that in the judgment of the physician are life-threatening. Because of the proarrhythmic effects of sotalol (See WARNINGS ), including a 1.5 to 2% rate of torsade de pointes or new VT/VF in patients with either NSVT or supraventricular arrhythmias, its use in patients with less severe arrhythmias, even if the patients are symptomatic, is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of sotalol treatment or increasing doses, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. The response to treatment should then be evaluated by a suitable method (e.g., PES or Holter monitoring) prior to continuing the patient on chronic therapy. Various approaches have been used to determine the response to antiarrhythmic therapy, including sotalol. In the ESVEM Trial, response by Holter monitoring was tentatively defined as 100% suppression of ventricular tachycardia, 90% suppression of non-sustained VT, 80% suppression of paired VPCs, and 75% suppression of total VPCs in patients who had at least 10 VPCs/hour at baseline; this tentative response was confirmed if VT lasting 5 or more beats was not observed during treadmill exercise testing using a standard Bruce protocol. The PES protocol utilized a maximum of three extrastimuli at three pacing cycle lengths and two right ventricular pacing sites. Response to PES was defined as prevention of induction of the following: 1) monomorphic VT lasting over 15 seconds; 2) non-sustained polymorphic VT containing more than 15 beats of monomorphic VT in patients with a history of monomorphic VT; 3) polymorphic VT or VF greater than 15 beats in patients with VF or a history of aborted sudden death without monomorphic VT; and 4) two episodes of polymorphic VT or VF of greater than 15 beats in a patient presenting with monomorphic VT. Sustained VT or NSVT producing hypotension during the final treadmill test was considered a drug failure. In a multicenter open-label long-term study of sotalol in patients with life-threatening ventricular arrhythmias which had proved refractory to other antiarrhythmic medications, response by Holter monitoring was defined as in ESVEM. Response by PES was defined as non-inducibility of sustained VT by at least double extrastimuli delivered at a pacing cycle length of 400 msec. Overall survival and arrhythmia recurrence rates in this study were similar to those seen in ESVEM, although there was no comparative group to allow a definitive assessment of outcome. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias. Sotalol is also indicated for the maintenance of normal sinus rhythm [delay in time to recurrence of atrial fibrillation/atrial flutter (AFIB/AFL)] in patients with symptomatic AFIB/AFL who are currently in sinus rhythm and is marketed under the brand name BETAPACE AF™. Sotalol is not approved for the AFIB/AFL indication and should not be substituted for BETAPACE AF™ because only BETAPACE AF is distributed with a patient package insert that is appropriate for patients with AFIB/AFL. uuid:ae2aa533-adcb-4583-a117-99ab8c9f83e6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63622 biolink:treats MONDO:0013317 PMID:41385096 "[{""id"":""uuid:b6de5978-a931-4950-ba2f-d98423040a5d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:592ef8f7-72e4-4518-a824-c7215d559449"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sotalol is indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that in the judgment of the physician are life-threatening. Because of the proarrhythmic effects of sotalol (See WARNINGS ), including a 1.5 to 2% rate of torsade de pointes or new VT/VF in patients with either NSVT or supraventricular arrhythmias, its use in patients with less severe arrhythmias, even if the patients are symptomatic, is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of sotalol treatment or increasing doses, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. The response to treatment should then be evaluated by a suitable method (e.g., PES or Holter monitoring) prior to continuing the patient on chronic therapy. Various approaches have been used to determine the response to antiarrhythmic therapy, including sotalol. In the ESVEM Trial, response by Holter monitoring was tentatively defined as 100% suppression of ventricular tachycardia, 90% suppression of non-sustained VT, 80% suppression of paired VPCs, and 75% suppression of total VPCs in patients who had at least 10 VPCs/hour at baseline; this tentative response was confirmed if VT lasting 5 or more beats was not observed during treadmill exercise testing using a standard Bruce protocol. The PES protocol utilized a maximum of three extrastimuli at three pacing cycle lengths and two right ventricular pacing sites. Response to PES was defined as prevention of induction of the following: 1) monomorphic VT lasting over 15 seconds; 2) non-sustained polymorphic VT containing more than 15 beats of monomorphic VT in patients with a history of monomorphic VT; 3) polymorphic VT or VF greater than 15 beats in patients with VF or a history of aborted sudden death without monomorphic VT; and 4) two episodes of polymorphic VT or VF of greater than 15 beats in a patient presenting with monomorphic VT. Sustained VT or NSVT producing hypotension during the final treadmill test was considered a drug failure. In a multicenter open-label long-term study of sotalol in patients with life-threatening ventricular arrhythmias which had proved refractory to other antiarrhythmic medications, response by Holter monitoring was defined as in ESVEM. Response by PES was defined as non-inducibility of sustained VT by at least double extrastimuli delivered at a pacing cycle length of 400 msec. Overall survival and arrhythmia recurrence rates in this study were similar to those seen in ESVEM, although there was no comparative group to allow a definitive assessment of outcome. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias. Sotalol is also indicated for the maintenance of normal sinus rhythm [delay in time to recurrence of atrial fibrillation/atrial flutter (AFIB/AFL)] in patients with symptomatic AFIB/AFL who are currently in sinus rhythm and is marketed under the brand name BETAPACE AF™. Sotalol is not approved for the AFIB/AFL indication and should not be substituted for BETAPACE AF™ because only BETAPACE AF is distributed with a patient package insert that is appropriate for patients with AFIB/AFL. uuid:d8bd50d3-d8bd-4d45-a292-c1104f509812 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63622 biolink:treats MONDO:0004981 PMID:41385096 "[{""id"":""uuid:a6c02450-7fab-4893-8c0e-cf607d24d8f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fa0e3aa9-1239-49cb-9781-e75013c01bd3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sotalol is indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that in the judgment of the physician are life-threatening. Because of the proarrhythmic effects of sotalol (See WARNINGS ), including a 1.5 to 2% rate of torsade de pointes or new VT/VF in patients with either NSVT or supraventricular arrhythmias, its use in patients with less severe arrhythmias, even if the patients are symptomatic, is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of sotalol treatment or increasing doses, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. The response to treatment should then be evaluated by a suitable method (e.g., PES or Holter monitoring) prior to continuing the patient on chronic therapy. Various approaches have been used to determine the response to antiarrhythmic therapy, including sotalol. In the ESVEM Trial, response by Holter monitoring was tentatively defined as 100% suppression of ventricular tachycardia, 90% suppression of non-sustained VT, 80% suppression of paired VPCs, and 75% suppression of total VPCs in patients who had at least 10 VPCs/hour at baseline; this tentative response was confirmed if VT lasting 5 or more beats was not observed during treadmill exercise testing using a standard Bruce protocol. The PES protocol utilized a maximum of three extrastimuli at three pacing cycle lengths and two right ventricular pacing sites. Response to PES was defined as prevention of induction of the following: 1) monomorphic VT lasting over 15 seconds; 2) non-sustained polymorphic VT containing more than 15 beats of monomorphic VT in patients with a history of monomorphic VT; 3) polymorphic VT or VF greater than 15 beats in patients with VF or a history of aborted sudden death without monomorphic VT; and 4) two episodes of polymorphic VT or VF of greater than 15 beats in a patient presenting with monomorphic VT. Sustained VT or NSVT producing hypotension during the final treadmill test was considered a drug failure. In a multicenter open-label long-term study of sotalol in patients with life-threatening ventricular arrhythmias which had proved refractory to other antiarrhythmic medications, response by Holter monitoring was defined as in ESVEM. Response by PES was defined as non-inducibility of sustained VT by at least double extrastimuli delivered at a pacing cycle length of 400 msec. Overall survival and arrhythmia recurrence rates in this study were similar to those seen in ESVEM, although there was no comparative group to allow a definitive assessment of outcome. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias. Sotalol is also indicated for the maintenance of normal sinus rhythm [delay in time to recurrence of atrial fibrillation/atrial flutter (AFIB/AFL)] in patients with symptomatic AFIB/AFL who are currently in sinus rhythm and is marketed under the brand name BETAPACE AF™. Sotalol is not approved for the AFIB/AFL indication and should not be substituted for BETAPACE AF™ because only BETAPACE AF is distributed with a patient package insert that is appropriate for patients with AFIB/AFL. uuid:6360172d-ba74-4e8b-b6d7-f33bf65d2f89 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63622 biolink:treats MONDO:0005310 PMID:41385096 "[{""id"":""uuid:03007cfc-2020-4ac9-ae28-3956df81cc2a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f397685a-1bd8-4216-bc1a-2093c947e171"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sotalol is indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that in the judgment of the physician are life-threatening. Because of the proarrhythmic effects of sotalol (See WARNINGS ), including a 1.5 to 2% rate of torsade de pointes or new VT/VF in patients with either NSVT or supraventricular arrhythmias, its use in patients with less severe arrhythmias, even if the patients are symptomatic, is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of sotalol treatment or increasing doses, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. The response to treatment should then be evaluated by a suitable method (e.g., PES or Holter monitoring) prior to continuing the patient on chronic therapy. Various approaches have been used to determine the response to antiarrhythmic therapy, including sotalol. In the ESVEM Trial, response by Holter monitoring was tentatively defined as 100% suppression of ventricular tachycardia, 90% suppression of non-sustained VT, 80% suppression of paired VPCs, and 75% suppression of total VPCs in patients who had at least 10 VPCs/hour at baseline; this tentative response was confirmed if VT lasting 5 or more beats was not observed during treadmill exercise testing using a standard Bruce protocol. The PES protocol utilized a maximum of three extrastimuli at three pacing cycle lengths and two right ventricular pacing sites. Response to PES was defined as prevention of induction of the following: 1) monomorphic VT lasting over 15 seconds; 2) non-sustained polymorphic VT containing more than 15 beats of monomorphic VT in patients with a history of monomorphic VT; 3) polymorphic VT or VF greater than 15 beats in patients with VF or a history of aborted sudden death without monomorphic VT; and 4) two episodes of polymorphic VT or VF of greater than 15 beats in a patient presenting with monomorphic VT. Sustained VT or NSVT producing hypotension during the final treadmill test was considered a drug failure. In a multicenter open-label long-term study of sotalol in patients with life-threatening ventricular arrhythmias which had proved refractory to other antiarrhythmic medications, response by Holter monitoring was defined as in ESVEM. Response by PES was defined as non-inducibility of sustained VT by at least double extrastimuli delivered at a pacing cycle length of 400 msec. Overall survival and arrhythmia recurrence rates in this study were similar to those seen in ESVEM, although there was no comparative group to allow a definitive assessment of outcome. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias. Sotalol is also indicated for the maintenance of normal sinus rhythm [delay in time to recurrence of atrial fibrillation/atrial flutter (AFIB/AFL)] in patients with symptomatic AFIB/AFL who are currently in sinus rhythm and is marketed under the brand name BETAPACE AF™. Sotalol is not approved for the AFIB/AFL indication and should not be substituted for BETAPACE AF™ because only BETAPACE AF is distributed with a patient package insert that is appropriate for patients with AFIB/AFL. uuid:9f182be1-984e-4e4d-93c5-c727b1d4185e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:251408 biolink:treats MONDO:0009688 PMID:41385096 "[{""id"":""uuid:0d33de6b-d9a6-4c17-91d8-efa8d78c2138"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4a2627d8-aff2-41b7-96e4-b5b5661888a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ENLON is recommended for the differential diagnosis of myasthenia gravis and as an adjunct in the evaluation of treatment requirements in this disease. It may also be used for evaluating emergency treatment in myasthenic crises. Because of its brief duration of action, it is not recommended for maintenance therapy in myasthenia gravis. ENLON is also useful whenever a curare antagonist is needed to reverse the neuromuscular block produced by curare, tubocurarine, gallamine triethiodide or dimethyl-tubocurarine. It is not effective against decamethonium bromide and succinylcholine chloride. It may be used adjunctively in the treatment of respiratory depression caused by curare overdosage. uuid:80f07d8d-c66d-4360-a677-92b17eaaf660 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:251408 biolink:treats MONDO:0021113 PMID:41385096 "[{""id"":""uuid:7d622699-417f-4a40-be38-04f9c18f9360"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9d4d8c5f-9742-4013-ab0e-e1fa72d71d14"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ENLON is recommended for the differential diagnosis of myasthenia gravis and as an adjunct in the evaluation of treatment requirements in this disease. It may also be used for evaluating emergency treatment in myasthenic crises. Because of its brief duration of action, it is not recommended for maintenance therapy in myasthenia gravis. ENLON is also useful whenever a curare antagonist is needed to reverse the neuromuscular block produced by curare, tubocurarine, gallamine triethiodide or dimethyl-tubocurarine. It is not effective against decamethonium bromide and succinylcholine chloride. It may be used adjunctively in the treatment of respiratory depression caused by curare overdosage. uuid:df6972a2-0a8f-4009-ba4a-128166a5387a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28177 biolink:treats MONDO:0850282 PMID:41385096 "[{""id"":""uuid:5dbac299-a445-44d1-8c0f-e49ed95b8d01"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1e7c82f4-ebe2-44ff-8d65-cf3cd90e1cdf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Theophylline is indicated for the treatment of the symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, e.g., emphysema and chronic bronchitis. uuid:0c78b995-c8f5-4af7-b940-6657905c184f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28177 biolink:treats MONDO:0004849 PMID:41385096 "[{""id"":""uuid:c9f4691d-54f3-4288-971d-f90be028fc97"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2eddef79-9a35-46fa-8f3e-42d0d8b109d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Theophylline is indicated for the treatment of the symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, e.g., emphysema and chronic bronchitis. uuid:75e82c60-c0aa-434c-8c4d-8e7c78832e6d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28177 biolink:treats MONDO:0005607 PMID:41385096 "[{""id"":""uuid:162070ec-827d-4add-b642-86b89a1170c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:43ed2767-ac4e-4db7-aad3-f0ac56c6375a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Theophylline is indicated for the treatment of the symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, e.g., emphysema and chronic bronchitis. uuid:25d0e7f9-8341-47a9-a004-bfdac6d30316 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6741 biolink:treats MONDO:0005178 PMID:41385096 "[{""id"":""uuid:8ad0845c-6d2d-4a9c-b939-3bd6e49e175c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d4f563d7-6890-442b-b24c-0c11ede7f41c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of meloxicam tablets and other treatment options before deciding to use meloxicam tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Meloxicam tablets are indicated for relief of the signs and symptoms of osteoarthritis. uuid:a8b5e789-9f29-4034-8fb0-7f222bffdb8c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1154705 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:d4413ea2-7a06-4169-9fee-6fa3ed616bca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7752206c-e4eb-4c02-9f2d-acfbb0fa4c90"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bisoprolol and hydrochlorothiazide is indicated in the management of hypertension. uuid:5232c98c-3047-43f5-a350-c57fa41f104c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6923 biolink:treats MONDO:0006014 PMID:41385096 "[{""id"":""uuid:cc6285b8-c487-4c77-9ff1-73f258b21e46"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:66a2c5a5-6b5f-415c-bfe0-54fa1284270c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MONISTAT 3 Vaginal Suppositories are indicated for the local treatment of vulvovaginal candidiasis (moniliasis). Effectiveness in pregnancy and in diabetic patients has not been established. As MONISTAT is effective only for candidal vulvovaginitis, the diagnosis should be confirmed by KOH smear and/or cultures. Other pathogens commonly associated with vulvovaginitis ( Trichomonas and Haemophilus vaginalis [Gardnerella] ) should be ruled out by appropriate laboratory methods. uuid:39fbd958-024a-4225-8b30-9faf406ecb59 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6923 biolink:treats UMLS:C0343886 PMID:41385096 "[{""id"":""uuid:318207b5-93ff-4100-a988-1e4cf555ee9d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fc7962b5-1476-47b5-91fd-61ce4c0a6ccf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MONISTAT 3 Vaginal Suppositories are indicated for the local treatment of vulvovaginal candidiasis (moniliasis). Effectiveness in pregnancy and in diabetic patients has not been established. As MONISTAT is effective only for candidal vulvovaginitis, the diagnosis should be confirmed by KOH smear and/or cultures. Other pathogens commonly associated with vulvovaginitis ( Trichomonas and Haemophilus vaginalis [Gardnerella] ) should be ruled out by appropriate laboratory methods. uuid:56b2f3e2-b150-4e5e-8d84-4131f38deab3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5296 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:b474e48b-2000-46d0-80fb-24509897f593"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:173669c0-c468-496f-8966-14206472e445"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gemfibrozil tablets are indicated as adjunctive therapy to diet for: Treatment of adult patients with very high elevations of serum triglyceride levels (Types IV and V hyperlipidemia) who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Patients who present such risk typically have serum triglycerides over 2000 mg/dL and have elevations of VLDL-cholesterol as well as fasting chylomicrons (Type V hyperlipidemia). Subjects who consistently have total serum or plasma triglycerides below 1000 mg/dL are unlikely to present a risk of pancreatitis. Gemfibrozil therapy may be considered for those subjects with triglyceride elevations between 1000 and 2000 mg/dL who have a history of pancreatitis or of recurrent abdominal pain typical of pancreatitis. It is recognized that some Type IV patients with triglycerides under 1000 mg/dL may, through dietary or alcoholic indiscretion, convert to a Type V pattern with massive triglyceride elevations accompanying fasting chylomicronemia, but the influence of gemfibrozil therapy on the risk of pancreatitis in such situations has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of very low density lipoprotein (VLDL). Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV, and V hyperlipoproteinemia (ref. 5). Reducing the risk of developing coronary heart disease only in Type IIb patients without history of or symptoms of existing coronary heart disease who have had an inadequate response to weight loss, dietary therapy, exercise, and other pharmacologic agents (such as bile acid sequestrants and nicotinic acid, known to reduce LDL- and raise HDL-cholesterol) and who have the following triad of lipid abnormalities: low HDL-cholesterol levels in addition to elevated LDL-cholesterol and elevated triglycerides (see WARNINGS , PRECAUTIONS , and CLINICAL PHARMACOLOGY ). The National Cholesterol Education Program has defined a serum HDL-cholesterol value that is consistently below 35 mg/dL as constituting an independent risk factor for coronary heart disease (ref. 6). Patients with significantly elevated triglycerides should be closely observed when treated with gemfibrozil. In some patients with high triglyceride levels, treatment with gemfibrozil is associated with a significant increase in LDL-cholesterol. BECAUSE OF POTENTIAL TOXICITY SUCH AS MALIGNANCY, GALLBLADDER DISEASE, ABDOMINAL PAIN LEADING TO APPENDECTOMY AND OTHER ABDOMINAL SURGERIES, AN INCREASED INCIDENCE IN NONCORONARY MORTALITY, AND THE 44% RELATIVE INCREASE DURING THE TRIAL PERIOD IN AGE-ADJUSTED ALL-CAUSE MORTALITY SEEN WITH THE CHEMICALLY AND PHARMACOLOGICALLY RELATED DRUG, CLOFIBRATE, THE POTENTIAL BENEFIT OF GEMFIBROZIL IN TREATING TYPE IIA PATIENTS WITH ELEVATIONS OF LDL-CHOLESTEROL ONLY IS NOT LIKELY TO OUTWEIGH THE RISKS. GEMFIBROZIL IS ALSO NOT INDICATED FOR THE TREATMENT OF PATIENTS WITH LOW HDL- CHOLESTEROL AS THEIR ONLY LIPID ABNORMALITY. In a subgroup analysis of patients in the Helsinki Heart Study with above-median HDL-cholesterol values at baseline (greater than 46.4 mg/dL), the incidence of serious coronary events was similar for gemfibrozil and placebo subgroups (see Table I ). The initial treatment for dyslipidemia is dietary therapy specific for the type of lipoprotein abnormality. Excess body weight and excess alcohol intake may be important factors in hypertriglyceridemia and should be managed prior to any drug therapy. Physical exercise can be an important ancillary measure, and has been associated with rises in HDL-cholesterol. Diseases contributory to hyperlipidemia such as hypothyroidism or diabetes mellitus should be looked for and adequately treated. Estrogen therapy is sometimes associated with massive rises in plasma triglycerides, especially in subjects with familial hypertriglyceridemia. In such cases, discontinuation of estrogen therapy may obviate the need for specific drug therapy of hypertriglyceridemia. The use of drugs should be considered only when reasonable attempts have been made to obtain satisfactory results with nondrug methods. If the decision is made to use drugs, the patient should be instructed that this does not reduce the importance of adhering to diet. uuid:e719aec4-6b7a-459b-8846-dbef024ddf70 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5296 biolink:treats MONDO:0007788 PMID:41385096 "[{""id"":""uuid:40a5576a-ef14-4993-a156-deac8b05bdf4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:84a491b3-a48e-4a56-8afb-6da8b04d254d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gemfibrozil tablets are indicated as adjunctive therapy to diet for: Treatment of adult patients with very high elevations of serum triglyceride levels (Types IV and V hyperlipidemia) who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Patients who present such risk typically have serum triglycerides over 2000 mg/dL and have elevations of VLDL-cholesterol as well as fasting chylomicrons (Type V hyperlipidemia). Subjects who consistently have total serum or plasma triglycerides below 1000 mg/dL are unlikely to present a risk of pancreatitis. Gemfibrozil therapy may be considered for those subjects with triglyceride elevations between 1000 and 2000 mg/dL who have a history of pancreatitis or of recurrent abdominal pain typical of pancreatitis. It is recognized that some Type IV patients with triglycerides under 1000 mg/dL may, through dietary or alcoholic indiscretion, convert to a Type V pattern with massive triglyceride elevations accompanying fasting chylomicronemia, but the influence of gemfibrozil therapy on the risk of pancreatitis in such situations has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of very low density lipoprotein (VLDL). Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV, and V hyperlipoproteinemia (ref. 5). Reducing the risk of developing coronary heart disease only in Type IIb patients without history of or symptoms of existing coronary heart disease who have had an inadequate response to weight loss, dietary therapy, exercise, and other pharmacologic agents (such as bile acid sequestrants and nicotinic acid, known to reduce LDL- and raise HDL-cholesterol) and who have the following triad of lipid abnormalities: low HDL-cholesterol levels in addition to elevated LDL-cholesterol and elevated triglycerides (see WARNINGS , PRECAUTIONS , and CLINICAL PHARMACOLOGY ). The National Cholesterol Education Program has defined a serum HDL-cholesterol value that is consistently below 35 mg/dL as constituting an independent risk factor for coronary heart disease (ref. 6). Patients with significantly elevated triglycerides should be closely observed when treated with gemfibrozil. In some patients with high triglyceride levels, treatment with gemfibrozil is associated with a significant increase in LDL-cholesterol. BECAUSE OF POTENTIAL TOXICITY SUCH AS MALIGNANCY, GALLBLADDER DISEASE, ABDOMINAL PAIN LEADING TO APPENDECTOMY AND OTHER ABDOMINAL SURGERIES, AN INCREASED INCIDENCE IN NONCORONARY MORTALITY, AND THE 44% RELATIVE INCREASE DURING THE TRIAL PERIOD IN AGE-ADJUSTED ALL-CAUSE MORTALITY SEEN WITH THE CHEMICALLY AND PHARMACOLOGICALLY RELATED DRUG, CLOFIBRATE, THE POTENTIAL BENEFIT OF GEMFIBROZIL IN TREATING TYPE IIA PATIENTS WITH ELEVATIONS OF LDL-CHOLESTEROL ONLY IS NOT LIKELY TO OUTWEIGH THE RISKS. GEMFIBROZIL IS ALSO NOT INDICATED FOR THE TREATMENT OF PATIENTS WITH LOW HDL- CHOLESTEROL AS THEIR ONLY LIPID ABNORMALITY. In a subgroup analysis of patients in the Helsinki Heart Study with above-median HDL-cholesterol values at baseline (greater than 46.4 mg/dL), the incidence of serious coronary events was similar for gemfibrozil and placebo subgroups (see Table I ). The initial treatment for dyslipidemia is dietary therapy specific for the type of lipoprotein abnormality. Excess body weight and excess alcohol intake may be important factors in hypertriglyceridemia and should be managed prior to any drug therapy. Physical exercise can be an important ancillary measure, and has been associated with rises in HDL-cholesterol. Diseases contributory to hyperlipidemia such as hypothyroidism or diabetes mellitus should be looked for and adequately treated. Estrogen therapy is sometimes associated with massive rises in plasma triglycerides, especially in subjects with familial hypertriglyceridemia. In such cases, discontinuation of estrogen therapy may obviate the need for specific drug therapy of hypertriglyceridemia. The use of drugs should be considered only when reasonable attempts have been made to obtain satisfactory results with nondrug methods. If the decision is made to use drugs, the patient should be instructed that this does not reduce the importance of adhering to diet. uuid:7b53dda1-719a-4953-9ef8-346b22e94d84 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5296 biolink:treats MONDO:0007762 PMID:41385096 "[{""id"":""uuid:308067d0-9011-4cba-baee-b6c64662d924"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4c400e91-59c3-48bf-8b75-d61a158584a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gemfibrozil tablets are indicated as adjunctive therapy to diet for: Treatment of adult patients with very high elevations of serum triglyceride levels (Types IV and V hyperlipidemia) who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Patients who present such risk typically have serum triglycerides over 2000 mg/dL and have elevations of VLDL-cholesterol as well as fasting chylomicrons (Type V hyperlipidemia). Subjects who consistently have total serum or plasma triglycerides below 1000 mg/dL are unlikely to present a risk of pancreatitis. Gemfibrozil therapy may be considered for those subjects with triglyceride elevations between 1000 and 2000 mg/dL who have a history of pancreatitis or of recurrent abdominal pain typical of pancreatitis. It is recognized that some Type IV patients with triglycerides under 1000 mg/dL may, through dietary or alcoholic indiscretion, convert to a Type V pattern with massive triglyceride elevations accompanying fasting chylomicronemia, but the influence of gemfibrozil therapy on the risk of pancreatitis in such situations has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of very low density lipoprotein (VLDL). Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV, and V hyperlipoproteinemia (ref. 5). Reducing the risk of developing coronary heart disease only in Type IIb patients without history of or symptoms of existing coronary heart disease who have had an inadequate response to weight loss, dietary therapy, exercise, and other pharmacologic agents (such as bile acid sequestrants and nicotinic acid, known to reduce LDL- and raise HDL-cholesterol) and who have the following triad of lipid abnormalities: low HDL-cholesterol levels in addition to elevated LDL-cholesterol and elevated triglycerides (see WARNINGS , PRECAUTIONS , and CLINICAL PHARMACOLOGY ). The National Cholesterol Education Program has defined a serum HDL-cholesterol value that is consistently below 35 mg/dL as constituting an independent risk factor for coronary heart disease (ref. 6). Patients with significantly elevated triglycerides should be closely observed when treated with gemfibrozil. In some patients with high triglyceride levels, treatment with gemfibrozil is associated with a significant increase in LDL-cholesterol. BECAUSE OF POTENTIAL TOXICITY SUCH AS MALIGNANCY, GALLBLADDER DISEASE, ABDOMINAL PAIN LEADING TO APPENDECTOMY AND OTHER ABDOMINAL SURGERIES, AN INCREASED INCIDENCE IN NONCORONARY MORTALITY, AND THE 44% RELATIVE INCREASE DURING THE TRIAL PERIOD IN AGE-ADJUSTED ALL-CAUSE MORTALITY SEEN WITH THE CHEMICALLY AND PHARMACOLOGICALLY RELATED DRUG, CLOFIBRATE, THE POTENTIAL BENEFIT OF GEMFIBROZIL IN TREATING TYPE IIA PATIENTS WITH ELEVATIONS OF LDL-CHOLESTEROL ONLY IS NOT LIKELY TO OUTWEIGH THE RISKS. GEMFIBROZIL IS ALSO NOT INDICATED FOR THE TREATMENT OF PATIENTS WITH LOW HDL- CHOLESTEROL AS THEIR ONLY LIPID ABNORMALITY. In a subgroup analysis of patients in the Helsinki Heart Study with above-median HDL-cholesterol values at baseline (greater than 46.4 mg/dL), the incidence of serious coronary events was similar for gemfibrozil and placebo subgroups (see Table I ). The initial treatment for dyslipidemia is dietary therapy specific for the type of lipoprotein abnormality. Excess body weight and excess alcohol intake may be important factors in hypertriglyceridemia and should be managed prior to any drug therapy. Physical exercise can be an important ancillary measure, and has been associated with rises in HDL-cholesterol. Diseases contributory to hyperlipidemia such as hypothyroidism or diabetes mellitus should be looked for and adequately treated. Estrogen therapy is sometimes associated with massive rises in plasma triglycerides, especially in subjects with familial hypertriglyceridemia. In such cases, discontinuation of estrogen therapy may obviate the need for specific drug therapy of hypertriglyceridemia. The use of drugs should be considered only when reasonable attempts have been made to obtain satisfactory results with nondrug methods. If the decision is made to use drugs, the patient should be instructed that this does not reduce the importance of adhering to diet. uuid:31d28db3-1655-431d-af4d-1555295a637c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5296 biolink:treats MONDO:0004982 PMID:41385096 "[{""id"":""uuid:8a14dcb1-62c6-4881-95ad-e0c3beaeb107"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b37be628-5194-4470-a26d-229f7a7f31ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gemfibrozil tablets are indicated as adjunctive therapy to diet for: Treatment of adult patients with very high elevations of serum triglyceride levels (Types IV and V hyperlipidemia) who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Patients who present such risk typically have serum triglycerides over 2000 mg/dL and have elevations of VLDL-cholesterol as well as fasting chylomicrons (Type V hyperlipidemia). Subjects who consistently have total serum or plasma triglycerides below 1000 mg/dL are unlikely to present a risk of pancreatitis. Gemfibrozil therapy may be considered for those subjects with triglyceride elevations between 1000 and 2000 mg/dL who have a history of pancreatitis or of recurrent abdominal pain typical of pancreatitis. It is recognized that some Type IV patients with triglycerides under 1000 mg/dL may, through dietary or alcoholic indiscretion, convert to a Type V pattern with massive triglyceride elevations accompanying fasting chylomicronemia, but the influence of gemfibrozil therapy on the risk of pancreatitis in such situations has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of very low density lipoprotein (VLDL). Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV, and V hyperlipoproteinemia (ref. 5). Reducing the risk of developing coronary heart disease only in Type IIb patients without history of or symptoms of existing coronary heart disease who have had an inadequate response to weight loss, dietary therapy, exercise, and other pharmacologic agents (such as bile acid sequestrants and nicotinic acid, known to reduce LDL- and raise HDL-cholesterol) and who have the following triad of lipid abnormalities: low HDL-cholesterol levels in addition to elevated LDL-cholesterol and elevated triglycerides (see WARNINGS , PRECAUTIONS , and CLINICAL PHARMACOLOGY ). The National Cholesterol Education Program has defined a serum HDL-cholesterol value that is consistently below 35 mg/dL as constituting an independent risk factor for coronary heart disease (ref. 6). Patients with significantly elevated triglycerides should be closely observed when treated with gemfibrozil. In some patients with high triglyceride levels, treatment with gemfibrozil is associated with a significant increase in LDL-cholesterol. BECAUSE OF POTENTIAL TOXICITY SUCH AS MALIGNANCY, GALLBLADDER DISEASE, ABDOMINAL PAIN LEADING TO APPENDECTOMY AND OTHER ABDOMINAL SURGERIES, AN INCREASED INCIDENCE IN NONCORONARY MORTALITY, AND THE 44% RELATIVE INCREASE DURING THE TRIAL PERIOD IN AGE-ADJUSTED ALL-CAUSE MORTALITY SEEN WITH THE CHEMICALLY AND PHARMACOLOGICALLY RELATED DRUG, CLOFIBRATE, THE POTENTIAL BENEFIT OF GEMFIBROZIL IN TREATING TYPE IIA PATIENTS WITH ELEVATIONS OF LDL-CHOLESTEROL ONLY IS NOT LIKELY TO OUTWEIGH THE RISKS. GEMFIBROZIL IS ALSO NOT INDICATED FOR THE TREATMENT OF PATIENTS WITH LOW HDL- CHOLESTEROL AS THEIR ONLY LIPID ABNORMALITY. In a subgroup analysis of patients in the Helsinki Heart Study with above-median HDL-cholesterol values at baseline (greater than 46.4 mg/dL), the incidence of serious coronary events was similar for gemfibrozil and placebo subgroups (see Table I ). The initial treatment for dyslipidemia is dietary therapy specific for the type of lipoprotein abnormality. Excess body weight and excess alcohol intake may be important factors in hypertriglyceridemia and should be managed prior to any drug therapy. Physical exercise can be an important ancillary measure, and has been associated with rises in HDL-cholesterol. Diseases contributory to hyperlipidemia such as hypothyroidism or diabetes mellitus should be looked for and adequately treated. Estrogen therapy is sometimes associated with massive rises in plasma triglycerides, especially in subjects with familial hypertriglyceridemia. In such cases, discontinuation of estrogen therapy may obviate the need for specific drug therapy of hypertriglyceridemia. The use of drugs should be considered only when reasonable attempts have been made to obtain satisfactory results with nondrug methods. If the decision is made to use drugs, the patient should be instructed that this does not reduce the importance of adhering to diet. uuid:956f74ef-411c-43ae-a712-5c34f3e149d5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5296 biolink:treats MONDO:0005010 PMID:41385096 "[{""id"":""uuid:b3173dfa-e4e8-4c7a-88a1-0b8235d1070a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ba24c6e4-4b35-403a-99d7-b47c01ea44d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gemfibrozil tablets are indicated as adjunctive therapy to diet for: Treatment of adult patients with very high elevations of serum triglyceride levels (Types IV and V hyperlipidemia) who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Patients who present such risk typically have serum triglycerides over 2000 mg/dL and have elevations of VLDL-cholesterol as well as fasting chylomicrons (Type V hyperlipidemia). Subjects who consistently have total serum or plasma triglycerides below 1000 mg/dL are unlikely to present a risk of pancreatitis. Gemfibrozil therapy may be considered for those subjects with triglyceride elevations between 1000 and 2000 mg/dL who have a history of pancreatitis or of recurrent abdominal pain typical of pancreatitis. It is recognized that some Type IV patients with triglycerides under 1000 mg/dL may, through dietary or alcoholic indiscretion, convert to a Type V pattern with massive triglyceride elevations accompanying fasting chylomicronemia, but the influence of gemfibrozil therapy on the risk of pancreatitis in such situations has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of very low density lipoprotein (VLDL). Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV, and V hyperlipoproteinemia (ref. 5). Reducing the risk of developing coronary heart disease only in Type IIb patients without history of or symptoms of existing coronary heart disease who have had an inadequate response to weight loss, dietary therapy, exercise, and other pharmacologic agents (such as bile acid sequestrants and nicotinic acid, known to reduce LDL- and raise HDL-cholesterol) and who have the following triad of lipid abnormalities: low HDL-cholesterol levels in addition to elevated LDL-cholesterol and elevated triglycerides (see WARNINGS , PRECAUTIONS , and CLINICAL PHARMACOLOGY ). The National Cholesterol Education Program has defined a serum HDL-cholesterol value that is consistently below 35 mg/dL as constituting an independent risk factor for coronary heart disease (ref. 6). Patients with significantly elevated triglycerides should be closely observed when treated with gemfibrozil. In some patients with high triglyceride levels, treatment with gemfibrozil is associated with a significant increase in LDL-cholesterol. BECAUSE OF POTENTIAL TOXICITY SUCH AS MALIGNANCY, GALLBLADDER DISEASE, ABDOMINAL PAIN LEADING TO APPENDECTOMY AND OTHER ABDOMINAL SURGERIES, AN INCREASED INCIDENCE IN NONCORONARY MORTALITY, AND THE 44% RELATIVE INCREASE DURING THE TRIAL PERIOD IN AGE-ADJUSTED ALL-CAUSE MORTALITY SEEN WITH THE CHEMICALLY AND PHARMACOLOGICALLY RELATED DRUG, CLOFIBRATE, THE POTENTIAL BENEFIT OF GEMFIBROZIL IN TREATING TYPE IIA PATIENTS WITH ELEVATIONS OF LDL-CHOLESTEROL ONLY IS NOT LIKELY TO OUTWEIGH THE RISKS. GEMFIBROZIL IS ALSO NOT INDICATED FOR THE TREATMENT OF PATIENTS WITH LOW HDL- CHOLESTEROL AS THEIR ONLY LIPID ABNORMALITY. In a subgroup analysis of patients in the Helsinki Heart Study with above-median HDL-cholesterol values at baseline (greater than 46.4 mg/dL), the incidence of serious coronary events was similar for gemfibrozil and placebo subgroups (see Table I ). The initial treatment for dyslipidemia is dietary therapy specific for the type of lipoprotein abnormality. Excess body weight and excess alcohol intake may be important factors in hypertriglyceridemia and should be managed prior to any drug therapy. Physical exercise can be an important ancillary measure, and has been associated with rises in HDL-cholesterol. Diseases contributory to hyperlipidemia such as hypothyroidism or diabetes mellitus should be looked for and adequately treated. Estrogen therapy is sometimes associated with massive rises in plasma triglycerides, especially in subjects with familial hypertriglyceridemia. In such cases, discontinuation of estrogen therapy may obviate the need for specific drug therapy of hypertriglyceridemia. The use of drugs should be considered only when reasonable attempts have been made to obtain satisfactory results with nondrug methods. If the decision is made to use drugs, the patient should be instructed that this does not reduce the importance of adhering to diet. uuid:33252bf2-2e95-4435-a48c-f90702474091 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5296 biolink:treats MONDO:0007759 PMID:41385096 "[{""id"":""uuid:e637f5d5-5040-47ac-9592-62ff03b54b9e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aca2eff4-dee5-4e9e-bd76-f388a7521528"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gemfibrozil tablets are indicated as adjunctive therapy to diet for: Treatment of adult patients with very high elevations of serum triglyceride levels (Types IV and V hyperlipidemia) who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Patients who present such risk typically have serum triglycerides over 2000 mg/dL and have elevations of VLDL-cholesterol as well as fasting chylomicrons (Type V hyperlipidemia). Subjects who consistently have total serum or plasma triglycerides below 1000 mg/dL are unlikely to present a risk of pancreatitis. Gemfibrozil therapy may be considered for those subjects with triglyceride elevations between 1000 and 2000 mg/dL who have a history of pancreatitis or of recurrent abdominal pain typical of pancreatitis. It is recognized that some Type IV patients with triglycerides under 1000 mg/dL may, through dietary or alcoholic indiscretion, convert to a Type V pattern with massive triglyceride elevations accompanying fasting chylomicronemia, but the influence of gemfibrozil therapy on the risk of pancreatitis in such situations has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of very low density lipoprotein (VLDL). Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV, and V hyperlipoproteinemia (ref. 5). Reducing the risk of developing coronary heart disease only in Type IIb patients without history of or symptoms of existing coronary heart disease who have had an inadequate response to weight loss, dietary therapy, exercise, and other pharmacologic agents (such as bile acid sequestrants and nicotinic acid, known to reduce LDL- and raise HDL-cholesterol) and who have the following triad of lipid abnormalities: low HDL-cholesterol levels in addition to elevated LDL-cholesterol and elevated triglycerides (see WARNINGS , PRECAUTIONS , and CLINICAL PHARMACOLOGY ). The National Cholesterol Education Program has defined a serum HDL-cholesterol value that is consistently below 35 mg/dL as constituting an independent risk factor for coronary heart disease (ref. 6). Patients with significantly elevated triglycerides should be closely observed when treated with gemfibrozil. In some patients with high triglyceride levels, treatment with gemfibrozil is associated with a significant increase in LDL-cholesterol. BECAUSE OF POTENTIAL TOXICITY SUCH AS MALIGNANCY, GALLBLADDER DISEASE, ABDOMINAL PAIN LEADING TO APPENDECTOMY AND OTHER ABDOMINAL SURGERIES, AN INCREASED INCIDENCE IN NONCORONARY MORTALITY, AND THE 44% RELATIVE INCREASE DURING THE TRIAL PERIOD IN AGE-ADJUSTED ALL-CAUSE MORTALITY SEEN WITH THE CHEMICALLY AND PHARMACOLOGICALLY RELATED DRUG, CLOFIBRATE, THE POTENTIAL BENEFIT OF GEMFIBROZIL IN TREATING TYPE IIA PATIENTS WITH ELEVATIONS OF LDL-CHOLESTEROL ONLY IS NOT LIKELY TO OUTWEIGH THE RISKS. GEMFIBROZIL IS ALSO NOT INDICATED FOR THE TREATMENT OF PATIENTS WITH LOW HDL- CHOLESTEROL AS THEIR ONLY LIPID ABNORMALITY. In a subgroup analysis of patients in the Helsinki Heart Study with above-median HDL-cholesterol values at baseline (greater than 46.4 mg/dL), the incidence of serious coronary events was similar for gemfibrozil and placebo subgroups (see Table I ). The initial treatment for dyslipidemia is dietary therapy specific for the type of lipoprotein abnormality. Excess body weight and excess alcohol intake may be important factors in hypertriglyceridemia and should be managed prior to any drug therapy. Physical exercise can be an important ancillary measure, and has been associated with rises in HDL-cholesterol. Diseases contributory to hyperlipidemia such as hypothyroidism or diabetes mellitus should be looked for and adequately treated. Estrogen therapy is sometimes associated with massive rises in plasma triglycerides, especially in subjects with familial hypertriglyceridemia. In such cases, discontinuation of estrogen therapy may obviate the need for specific drug therapy of hypertriglyceridemia. The use of drugs should be considered only when reasonable attempts have been made to obtain satisfactory results with nondrug methods. If the decision is made to use drugs, the patient should be instructed that this does not reduce the importance of adhering to diet. uuid:38d561f5-b5cb-44be-af0a-b5d38730a22f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5296 biolink:treats MONDO:0009387 PMID:41385096 "[{""id"":""uuid:099f7ed2-d1b0-41a7-aa5f-e4a18a6e26b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b27f0366-945a-4c28-8306-02b7253e1cae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gemfibrozil tablets are indicated as adjunctive therapy to diet for: Treatment of adult patients with very high elevations of serum triglyceride levels (Types IV and V hyperlipidemia) who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Patients who present such risk typically have serum triglycerides over 2000 mg/dL and have elevations of VLDL-cholesterol as well as fasting chylomicrons (Type V hyperlipidemia). Subjects who consistently have total serum or plasma triglycerides below 1000 mg/dL are unlikely to present a risk of pancreatitis. Gemfibrozil therapy may be considered for those subjects with triglyceride elevations between 1000 and 2000 mg/dL who have a history of pancreatitis or of recurrent abdominal pain typical of pancreatitis. It is recognized that some Type IV patients with triglycerides under 1000 mg/dL may, through dietary or alcoholic indiscretion, convert to a Type V pattern with massive triglyceride elevations accompanying fasting chylomicronemia, but the influence of gemfibrozil therapy on the risk of pancreatitis in such situations has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of very low density lipoprotein (VLDL). Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV, and V hyperlipoproteinemia (ref. 5). Reducing the risk of developing coronary heart disease only in Type IIb patients without history of or symptoms of existing coronary heart disease who have had an inadequate response to weight loss, dietary therapy, exercise, and other pharmacologic agents (such as bile acid sequestrants and nicotinic acid, known to reduce LDL- and raise HDL-cholesterol) and who have the following triad of lipid abnormalities: low HDL-cholesterol levels in addition to elevated LDL-cholesterol and elevated triglycerides (see WARNINGS , PRECAUTIONS , and CLINICAL PHARMACOLOGY ). The National Cholesterol Education Program has defined a serum HDL-cholesterol value that is consistently below 35 mg/dL as constituting an independent risk factor for coronary heart disease (ref. 6). Patients with significantly elevated triglycerides should be closely observed when treated with gemfibrozil. In some patients with high triglyceride levels, treatment with gemfibrozil is associated with a significant increase in LDL-cholesterol. BECAUSE OF POTENTIAL TOXICITY SUCH AS MALIGNANCY, GALLBLADDER DISEASE, ABDOMINAL PAIN LEADING TO APPENDECTOMY AND OTHER ABDOMINAL SURGERIES, AN INCREASED INCIDENCE IN NONCORONARY MORTALITY, AND THE 44% RELATIVE INCREASE DURING THE TRIAL PERIOD IN AGE-ADJUSTED ALL-CAUSE MORTALITY SEEN WITH THE CHEMICALLY AND PHARMACOLOGICALLY RELATED DRUG, CLOFIBRATE, THE POTENTIAL BENEFIT OF GEMFIBROZIL IN TREATING TYPE IIA PATIENTS WITH ELEVATIONS OF LDL-CHOLESTEROL ONLY IS NOT LIKELY TO OUTWEIGH THE RISKS. GEMFIBROZIL IS ALSO NOT INDICATED FOR THE TREATMENT OF PATIENTS WITH LOW HDL- CHOLESTEROL AS THEIR ONLY LIPID ABNORMALITY. In a subgroup analysis of patients in the Helsinki Heart Study with above-median HDL-cholesterol values at baseline (greater than 46.4 mg/dL), the incidence of serious coronary events was similar for gemfibrozil and placebo subgroups (see Table I ). The initial treatment for dyslipidemia is dietary therapy specific for the type of lipoprotein abnormality. Excess body weight and excess alcohol intake may be important factors in hypertriglyceridemia and should be managed prior to any drug therapy. Physical exercise can be an important ancillary measure, and has been associated with rises in HDL-cholesterol. Diseases contributory to hyperlipidemia such as hypothyroidism or diabetes mellitus should be looked for and adequately treated. Estrogen therapy is sometimes associated with massive rises in plasma triglycerides, especially in subjects with familial hypertriglyceridemia. In such cases, discontinuation of estrogen therapy may obviate the need for specific drug therapy of hypertriglyceridemia. The use of drugs should be considered only when reasonable attempts have been made to obtain satisfactory results with nondrug methods. If the decision is made to use drugs, the patient should be instructed that this does not reduce the importance of adhering to diet. uuid:062f5ec1-137d-49cc-aaf8-e8503102f912 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5296 biolink:treats MONDO:0005420 PMID:41385096 "[{""id"":""uuid:68075bf8-bb45-492a-ad5f-f478bf8b36aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0eddf4b3-1239-4c69-b8c7-ac9131ba08d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gemfibrozil tablets are indicated as adjunctive therapy to diet for: Treatment of adult patients with very high elevations of serum triglyceride levels (Types IV and V hyperlipidemia) who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Patients who present such risk typically have serum triglycerides over 2000 mg/dL and have elevations of VLDL-cholesterol as well as fasting chylomicrons (Type V hyperlipidemia). Subjects who consistently have total serum or plasma triglycerides below 1000 mg/dL are unlikely to present a risk of pancreatitis. Gemfibrozil therapy may be considered for those subjects with triglyceride elevations between 1000 and 2000 mg/dL who have a history of pancreatitis or of recurrent abdominal pain typical of pancreatitis. It is recognized that some Type IV patients with triglycerides under 1000 mg/dL may, through dietary or alcoholic indiscretion, convert to a Type V pattern with massive triglyceride elevations accompanying fasting chylomicronemia, but the influence of gemfibrozil therapy on the risk of pancreatitis in such situations has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of very low density lipoprotein (VLDL). Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV, and V hyperlipoproteinemia (ref. 5). Reducing the risk of developing coronary heart disease only in Type IIb patients without history of or symptoms of existing coronary heart disease who have had an inadequate response to weight loss, dietary therapy, exercise, and other pharmacologic agents (such as bile acid sequestrants and nicotinic acid, known to reduce LDL- and raise HDL-cholesterol) and who have the following triad of lipid abnormalities: low HDL-cholesterol levels in addition to elevated LDL-cholesterol and elevated triglycerides (see WARNINGS , PRECAUTIONS , and CLINICAL PHARMACOLOGY ). The National Cholesterol Education Program has defined a serum HDL-cholesterol value that is consistently below 35 mg/dL as constituting an independent risk factor for coronary heart disease (ref. 6). Patients with significantly elevated triglycerides should be closely observed when treated with gemfibrozil. In some patients with high triglyceride levels, treatment with gemfibrozil is associated with a significant increase in LDL-cholesterol. BECAUSE OF POTENTIAL TOXICITY SUCH AS MALIGNANCY, GALLBLADDER DISEASE, ABDOMINAL PAIN LEADING TO APPENDECTOMY AND OTHER ABDOMINAL SURGERIES, AN INCREASED INCIDENCE IN NONCORONARY MORTALITY, AND THE 44% RELATIVE INCREASE DURING THE TRIAL PERIOD IN AGE-ADJUSTED ALL-CAUSE MORTALITY SEEN WITH THE CHEMICALLY AND PHARMACOLOGICALLY RELATED DRUG, CLOFIBRATE, THE POTENTIAL BENEFIT OF GEMFIBROZIL IN TREATING TYPE IIA PATIENTS WITH ELEVATIONS OF LDL-CHOLESTEROL ONLY IS NOT LIKELY TO OUTWEIGH THE RISKS. GEMFIBROZIL IS ALSO NOT INDICATED FOR THE TREATMENT OF PATIENTS WITH LOW HDL- CHOLESTEROL AS THEIR ONLY LIPID ABNORMALITY. In a subgroup analysis of patients in the Helsinki Heart Study with above-median HDL-cholesterol values at baseline (greater than 46.4 mg/dL), the incidence of serious coronary events was similar for gemfibrozil and placebo subgroups (see Table I ). The initial treatment for dyslipidemia is dietary therapy specific for the type of lipoprotein abnormality. Excess body weight and excess alcohol intake may be important factors in hypertriglyceridemia and should be managed prior to any drug therapy. Physical exercise can be an important ancillary measure, and has been associated with rises in HDL-cholesterol. Diseases contributory to hyperlipidemia such as hypothyroidism or diabetes mellitus should be looked for and adequately treated. Estrogen therapy is sometimes associated with massive rises in plasma triglycerides, especially in subjects with familial hypertriglyceridemia. In such cases, discontinuation of estrogen therapy may obviate the need for specific drug therapy of hypertriglyceridemia. The use of drugs should be considered only when reasonable attempts have been made to obtain satisfactory results with nondrug methods. If the decision is made to use drugs, the patient should be instructed that this does not reduce the importance of adhering to diet. uuid:39e840f2-4bda-4c0b-8abf-4c8c4231ba4c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5296 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:7a87e72e-e89d-412b-ac65-901a6ee65a1d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bd38f916-cca9-4569-97b9-b74db72d5c3e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gemfibrozil tablets are indicated as adjunctive therapy to diet for: Treatment of adult patients with very high elevations of serum triglyceride levels (Types IV and V hyperlipidemia) who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Patients who present such risk typically have serum triglycerides over 2000 mg/dL and have elevations of VLDL-cholesterol as well as fasting chylomicrons (Type V hyperlipidemia). Subjects who consistently have total serum or plasma triglycerides below 1000 mg/dL are unlikely to present a risk of pancreatitis. Gemfibrozil therapy may be considered for those subjects with triglyceride elevations between 1000 and 2000 mg/dL who have a history of pancreatitis or of recurrent abdominal pain typical of pancreatitis. It is recognized that some Type IV patients with triglycerides under 1000 mg/dL may, through dietary or alcoholic indiscretion, convert to a Type V pattern with massive triglyceride elevations accompanying fasting chylomicronemia, but the influence of gemfibrozil therapy on the risk of pancreatitis in such situations has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of very low density lipoprotein (VLDL). Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV, and V hyperlipoproteinemia (ref. 5). Reducing the risk of developing coronary heart disease only in Type IIb patients without history of or symptoms of existing coronary heart disease who have had an inadequate response to weight loss, dietary therapy, exercise, and other pharmacologic agents (such as bile acid sequestrants and nicotinic acid, known to reduce LDL- and raise HDL-cholesterol) and who have the following triad of lipid abnormalities: low HDL-cholesterol levels in addition to elevated LDL-cholesterol and elevated triglycerides (see WARNINGS , PRECAUTIONS , and CLINICAL PHARMACOLOGY ). The National Cholesterol Education Program has defined a serum HDL-cholesterol value that is consistently below 35 mg/dL as constituting an independent risk factor for coronary heart disease (ref. 6). Patients with significantly elevated triglycerides should be closely observed when treated with gemfibrozil. In some patients with high triglyceride levels, treatment with gemfibrozil is associated with a significant increase in LDL-cholesterol. BECAUSE OF POTENTIAL TOXICITY SUCH AS MALIGNANCY, GALLBLADDER DISEASE, ABDOMINAL PAIN LEADING TO APPENDECTOMY AND OTHER ABDOMINAL SURGERIES, AN INCREASED INCIDENCE IN NONCORONARY MORTALITY, AND THE 44% RELATIVE INCREASE DURING THE TRIAL PERIOD IN AGE-ADJUSTED ALL-CAUSE MORTALITY SEEN WITH THE CHEMICALLY AND PHARMACOLOGICALLY RELATED DRUG, CLOFIBRATE, THE POTENTIAL BENEFIT OF GEMFIBROZIL IN TREATING TYPE IIA PATIENTS WITH ELEVATIONS OF LDL-CHOLESTEROL ONLY IS NOT LIKELY TO OUTWEIGH THE RISKS. GEMFIBROZIL IS ALSO NOT INDICATED FOR THE TREATMENT OF PATIENTS WITH LOW HDL- CHOLESTEROL AS THEIR ONLY LIPID ABNORMALITY. In a subgroup analysis of patients in the Helsinki Heart Study with above-median HDL-cholesterol values at baseline (greater than 46.4 mg/dL), the incidence of serious coronary events was similar for gemfibrozil and placebo subgroups (see Table I ). The initial treatment for dyslipidemia is dietary therapy specific for the type of lipoprotein abnormality. Excess body weight and excess alcohol intake may be important factors in hypertriglyceridemia and should be managed prior to any drug therapy. Physical exercise can be an important ancillary measure, and has been associated with rises in HDL-cholesterol. Diseases contributory to hyperlipidemia such as hypothyroidism or diabetes mellitus should be looked for and adequately treated. Estrogen therapy is sometimes associated with massive rises in plasma triglycerides, especially in subjects with familial hypertriglyceridemia. In such cases, discontinuation of estrogen therapy may obviate the need for specific drug therapy of hypertriglyceridemia. The use of drugs should be considered only when reasonable attempts have been made to obtain satisfactory results with nondrug methods. If the decision is made to use drugs, the patient should be instructed that this does not reduce the importance of adhering to diet. uuid:885beed4-5346-4c95-ad33-63edffbe83b5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5296 biolink:treats MONDO:0005347 PMID:41385096 "[{""id"":""uuid:40606da0-688a-4a39-b09b-ad5771f03650"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eb072f4b-0d80-40ec-92b6-3289f57cd732"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gemfibrozil tablets are indicated as adjunctive therapy to diet for: Treatment of adult patients with very high elevations of serum triglyceride levels (Types IV and V hyperlipidemia) who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Patients who present such risk typically have serum triglycerides over 2000 mg/dL and have elevations of VLDL-cholesterol as well as fasting chylomicrons (Type V hyperlipidemia). Subjects who consistently have total serum or plasma triglycerides below 1000 mg/dL are unlikely to present a risk of pancreatitis. Gemfibrozil therapy may be considered for those subjects with triglyceride elevations between 1000 and 2000 mg/dL who have a history of pancreatitis or of recurrent abdominal pain typical of pancreatitis. It is recognized that some Type IV patients with triglycerides under 1000 mg/dL may, through dietary or alcoholic indiscretion, convert to a Type V pattern with massive triglyceride elevations accompanying fasting chylomicronemia, but the influence of gemfibrozil therapy on the risk of pancreatitis in such situations has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of very low density lipoprotein (VLDL). Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV, and V hyperlipoproteinemia (ref. 5). Reducing the risk of developing coronary heart disease only in Type IIb patients without history of or symptoms of existing coronary heart disease who have had an inadequate response to weight loss, dietary therapy, exercise, and other pharmacologic agents (such as bile acid sequestrants and nicotinic acid, known to reduce LDL- and raise HDL-cholesterol) and who have the following triad of lipid abnormalities: low HDL-cholesterol levels in addition to elevated LDL-cholesterol and elevated triglycerides (see WARNINGS , PRECAUTIONS , and CLINICAL PHARMACOLOGY ). The National Cholesterol Education Program has defined a serum HDL-cholesterol value that is consistently below 35 mg/dL as constituting an independent risk factor for coronary heart disease (ref. 6). Patients with significantly elevated triglycerides should be closely observed when treated with gemfibrozil. In some patients with high triglyceride levels, treatment with gemfibrozil is associated with a significant increase in LDL-cholesterol. BECAUSE OF POTENTIAL TOXICITY SUCH AS MALIGNANCY, GALLBLADDER DISEASE, ABDOMINAL PAIN LEADING TO APPENDECTOMY AND OTHER ABDOMINAL SURGERIES, AN INCREASED INCIDENCE IN NONCORONARY MORTALITY, AND THE 44% RELATIVE INCREASE DURING THE TRIAL PERIOD IN AGE-ADJUSTED ALL-CAUSE MORTALITY SEEN WITH THE CHEMICALLY AND PHARMACOLOGICALLY RELATED DRUG, CLOFIBRATE, THE POTENTIAL BENEFIT OF GEMFIBROZIL IN TREATING TYPE IIA PATIENTS WITH ELEVATIONS OF LDL-CHOLESTEROL ONLY IS NOT LIKELY TO OUTWEIGH THE RISKS. GEMFIBROZIL IS ALSO NOT INDICATED FOR THE TREATMENT OF PATIENTS WITH LOW HDL- CHOLESTEROL AS THEIR ONLY LIPID ABNORMALITY. In a subgroup analysis of patients in the Helsinki Heart Study with above-median HDL-cholesterol values at baseline (greater than 46.4 mg/dL), the incidence of serious coronary events was similar for gemfibrozil and placebo subgroups (see Table I ). The initial treatment for dyslipidemia is dietary therapy specific for the type of lipoprotein abnormality. Excess body weight and excess alcohol intake may be important factors in hypertriglyceridemia and should be managed prior to any drug therapy. Physical exercise can be an important ancillary measure, and has been associated with rises in HDL-cholesterol. Diseases contributory to hyperlipidemia such as hypothyroidism or diabetes mellitus should be looked for and adequately treated. Estrogen therapy is sometimes associated with massive rises in plasma triglycerides, especially in subjects with familial hypertriglyceridemia. In such cases, discontinuation of estrogen therapy may obviate the need for specific drug therapy of hypertriglyceridemia. The use of drugs should be considered only when reasonable attempts have been made to obtain satisfactory results with nondrug methods. If the decision is made to use drugs, the patient should be instructed that this does not reduce the importance of adhering to diet. uuid:a2d1c3fe-887c-437f-81d3-3261081dde38 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5296 biolink:treats HP:0003119 PMID:41385096 "[{""id"":""uuid:7bb2822a-2e1e-45d1-a3d4-a9d2b9f74b98"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d26e0f1a-b968-4493-91ca-d4eb7a0bebd0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gemfibrozil tablets are indicated as adjunctive therapy to diet for: Treatment of adult patients with very high elevations of serum triglyceride levels (Types IV and V hyperlipidemia) who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Patients who present such risk typically have serum triglycerides over 2000 mg/dL and have elevations of VLDL-cholesterol as well as fasting chylomicrons (Type V hyperlipidemia). Subjects who consistently have total serum or plasma triglycerides below 1000 mg/dL are unlikely to present a risk of pancreatitis. Gemfibrozil therapy may be considered for those subjects with triglyceride elevations between 1000 and 2000 mg/dL who have a history of pancreatitis or of recurrent abdominal pain typical of pancreatitis. It is recognized that some Type IV patients with triglycerides under 1000 mg/dL may, through dietary or alcoholic indiscretion, convert to a Type V pattern with massive triglyceride elevations accompanying fasting chylomicronemia, but the influence of gemfibrozil therapy on the risk of pancreatitis in such situations has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of very low density lipoprotein (VLDL). Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV, and V hyperlipoproteinemia (ref. 5). Reducing the risk of developing coronary heart disease only in Type IIb patients without history of or symptoms of existing coronary heart disease who have had an inadequate response to weight loss, dietary therapy, exercise, and other pharmacologic agents (such as bile acid sequestrants and nicotinic acid, known to reduce LDL- and raise HDL-cholesterol) and who have the following triad of lipid abnormalities: low HDL-cholesterol levels in addition to elevated LDL-cholesterol and elevated triglycerides (see WARNINGS , PRECAUTIONS , and CLINICAL PHARMACOLOGY ). The National Cholesterol Education Program has defined a serum HDL-cholesterol value that is consistently below 35 mg/dL as constituting an independent risk factor for coronary heart disease (ref. 6). Patients with significantly elevated triglycerides should be closely observed when treated with gemfibrozil. In some patients with high triglyceride levels, treatment with gemfibrozil is associated with a significant increase in LDL-cholesterol. BECAUSE OF POTENTIAL TOXICITY SUCH AS MALIGNANCY, GALLBLADDER DISEASE, ABDOMINAL PAIN LEADING TO APPENDECTOMY AND OTHER ABDOMINAL SURGERIES, AN INCREASED INCIDENCE IN NONCORONARY MORTALITY, AND THE 44% RELATIVE INCREASE DURING THE TRIAL PERIOD IN AGE-ADJUSTED ALL-CAUSE MORTALITY SEEN WITH THE CHEMICALLY AND PHARMACOLOGICALLY RELATED DRUG, CLOFIBRATE, THE POTENTIAL BENEFIT OF GEMFIBROZIL IN TREATING TYPE IIA PATIENTS WITH ELEVATIONS OF LDL-CHOLESTEROL ONLY IS NOT LIKELY TO OUTWEIGH THE RISKS. GEMFIBROZIL IS ALSO NOT INDICATED FOR THE TREATMENT OF PATIENTS WITH LOW HDL- CHOLESTEROL AS THEIR ONLY LIPID ABNORMALITY. In a subgroup analysis of patients in the Helsinki Heart Study with above-median HDL-cholesterol values at baseline (greater than 46.4 mg/dL), the incidence of serious coronary events was similar for gemfibrozil and placebo subgroups (see Table I ). The initial treatment for dyslipidemia is dietary therapy specific for the type of lipoprotein abnormality. Excess body weight and excess alcohol intake may be important factors in hypertriglyceridemia and should be managed prior to any drug therapy. Physical exercise can be an important ancillary measure, and has been associated with rises in HDL-cholesterol. Diseases contributory to hyperlipidemia such as hypothyroidism or diabetes mellitus should be looked for and adequately treated. Estrogen therapy is sometimes associated with massive rises in plasma triglycerides, especially in subjects with familial hypertriglyceridemia. In such cases, discontinuation of estrogen therapy may obviate the need for specific drug therapy of hypertriglyceridemia. The use of drugs should be considered only when reasonable attempts have been made to obtain satisfactory results with nondrug methods. If the decision is made to use drugs, the patient should be instructed that this does not reduce the importance of adhering to diet. uuid:9d088a46-422a-48e6-9626-69e21f438d21 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6344 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:d5f45446-de2d-4428-8bb0-ef181c054299"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cd26aec2-eb94-4886-8e19-6ab68de154c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Labetalol hydrochloride tablets are indicated in the management of hypertension. Labetalol tablets may be used alone or in combination with other antihypertensive agents, especially thiazide and loop diuretics. uuid:1bc1786b-e9b0-457e-811b-b34910249e99 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3310 biolink:treats MONDO:0000328 PMID:41385096 "[{""id"":""uuid:f68e9167-85dc-4ade-83d7-d6ddd81f875d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:862e9b68-9693-4146-bd3e-bbd6e93efc21"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PhosLo is indicated for the control of hyperphosphatemia in end stage renal failure and does not promote aluminum absorption. uuid:8fedb63d-3b7f-4a74-9fbf-f6b7ae99c4c3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3310 biolink:treats MONDO:0004375 PMID:41385096 "[{""id"":""uuid:9f339fe6-f590-4640-bf84-1c391f1fcfda"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:17a8172f-7c30-450f-be29-b34ffd13abe0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PhosLo is indicated for the control of hyperphosphatemia in end stage renal failure and does not promote aluminum absorption. uuid:2752a613-a63c-4e5c-930c-4ebd601424f5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6060 biolink:treats HP:0001681 PMID:41385096 "[{""id"":""uuid:5a4af21a-ce99-451e-b85a-2289db3e6df7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3eaad210-39bc-4940-bb0e-5c3fc68ecae6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] dilatrate®-SR sustained release capsules are indicated for the prevention of angina pectoris due to coronary artery disease. The onset of action of controlled-release oral isosorbide dinitrate is not sufficiently rapid for this product to be useful in aborting an acute anginal episode. uuid:f5cf03b8-082a-4b9e-b228-8d0c0f92dc0e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6060 biolink:treats MONDO:0005010 PMID:41385096 "[{""id"":""uuid:b70b110c-bfa4-4cb6-b7f6-8bde2074b1de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7798606c-c976-45c0-9d3d-579b34aca360"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] dilatrate®-SR sustained release capsules are indicated for the prevention of angina pectoris due to coronary artery disease. The onset of action of controlled-release oral isosorbide dinitrate is not sufficiently rapid for this product to be useful in aborting an acute anginal episode. uuid:f175ca16-2284-48d4-bcc9-e9d565ae1f50 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27470 biolink:treats MONDO:0001700 PMID:41385096 "[{""id"":""uuid:6b3e123d-0539-4880-b5f1-d4df30ec1464"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0e56ccb6-025d-49d9-8145-a201a5a9823c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Folic acid is effective in the treatment of megaloblastic anemias due to a deficiency of folic acid (as may be seen in tropical or nontropical sprue) and in anemias of nutritional origin, pregnancy, infancy, or childhood. uuid:9bb4844d-ddc3-4c64-90c6-8f6f178e1011 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27470 biolink:treats MONDO:0001078 PMID:41385096 "[{""id"":""uuid:235a0c99-b707-46bf-81f2-4191e3d64116"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f567f92d-4611-4210-b4e8-6ad2cdd8db9e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Folic acid is effective in the treatment of megaloblastic anemias due to a deficiency of folic acid (as may be seen in tropical or nontropical sprue) and in anemias of nutritional origin, pregnancy, infancy, or childhood. uuid:a303b0f0-dde0-47a2-b63e-ab75b565bcd7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27470 biolink:treats MONDO:0005130 PMID:41385096 "[{""id"":""uuid:8e065268-e49f-4c74-be43-21b726c2cdb6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ef65ae9c-2a86-45f1-a2b1-4a802b8a543a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Folic acid is effective in the treatment of megaloblastic anemias due to a deficiency of folic acid (as may be seen in tropical or nontropical sprue) and in anemias of nutritional origin, pregnancy, infancy, or childhood. uuid:1a12c280-1742-4b7f-80ed-a92de6aafaed biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27470 biolink:treats UMLS:C0271903 PMID:41385096 "[{""id"":""uuid:b7731719-d702-4a48-bd4b-b77de849ae21"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:45fa4eb9-768e-427c-bf02-f3497cdbb7e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Folic acid is effective in the treatment of megaloblastic anemias due to a deficiency of folic acid (as may be seen in tropical or nontropical sprue) and in anemias of nutritional origin, pregnancy, infancy, or childhood. uuid:6cf8dac5-cf15-4853-a179-01c746d7be6d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0005093 PMID:41385096 "[{""id"":""uuid:82946653-33ef-4244-8d75-87ab3b424f0f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f2b54a18-aaae-412a-9a09-e1d10847010b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Augmented Betamethasone Dipropionate Ointment is indicated for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. uuid:b78df92e-0295-4b33-bf03-503abca3eef9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2549 biolink:treats MONDO:0001358 PMID:41385096 "[{""id"":""uuid:271467ee-c49e-4164-8ced-c30d8e23d3b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:415a1471-0ce8-4c06-9236-a3010abdc0f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Albuterol Inhalation Aerosol is indicated in patients 12 years of age and older, for the prevention and relief of bronchospasm in patients with reversible obstructive airway disease, and for the prevention of exercise-induced bronchospasm. uuid:2edd5b7a-b43e-46d0-9062-7f966819c637 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2549 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:21b87c6e-6541-4adf-a313-723ebc72b105"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d3f1f455-71d6-427b-adaa-47fdf6632764"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Albuterol Inhalation Aerosol is indicated in patients 12 years of age and older, for the prevention and relief of bronchospasm in patients with reversible obstructive airway disease, and for the prevention of exercise-induced bronchospasm. uuid:8a4eb246-1195-4844-9b49-cb0fab47a34a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2549 biolink:treats MONDO:0850286 PMID:41385096 "[{""id"":""uuid:f0b4d25b-e6ff-4872-9bfc-9df7b10c7507"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a9ccde2c-242a-49bc-ba2f-fcf9f552b3bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Albuterol Inhalation Aerosol is indicated in patients 12 years of age and older, for the prevention and relief of bronchospasm in patients with reversible obstructive airway disease, and for the prevention of exercise-induced bronchospasm. UMLS:C0015263 uuid:09412e37-320e-44d3-86be-e426ffff2370 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:187893 biolink:treats HP:0002169 PMID:41385096 "[{""id"":""uuid:56b4a851-92be-4292-b763-fd625b2d9bf7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:74252dfa-adb2-4aaa-ac31-e1892c66cc8f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Baclofen is useful for the alleviation of signs and symptoms of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity. Patients should have reversible spasticity so that baclofen treatment will aid in restoring residual function. Baclofen may also be of some value in patients with spinal cord injuries and other spinal cord diseases. Baclofen is not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders. The efficacy of baclofen in stroke, cerebral palsy, and Parkinson’s disease has not been established and, therefore, it is not recommended for these conditions. uuid:acd0178e-7fc0-4d02-bfb1-c2417cb04a07 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:187893 biolink:treats HP:0002063 PMID:41385096 "[{""id"":""uuid:a8f7f250-4017-44d8-8403-112c9c223729"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:89eecd94-104f-42f7-8ad3-caa5663944ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Baclofen is useful for the alleviation of signs and symptoms of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity. Patients should have reversible spasticity so that baclofen treatment will aid in restoring residual function. Baclofen may also be of some value in patients with spinal cord injuries and other spinal cord diseases. Baclofen is not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders. The efficacy of baclofen in stroke, cerebral palsy, and Parkinson’s disease has not been established and, therefore, it is not recommended for these conditions. uuid:abba5717-e9c8-4cd9-8ef8-7421d21c894a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:187893 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:5d56c0b8-68f3-456c-9240-58be2419ea9e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7f2c55d4-9e4d-4998-bbd3-8a9aef44edf5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Baclofen is useful for the alleviation of signs and symptoms of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity. Patients should have reversible spasticity so that baclofen treatment will aid in restoring residual function. Baclofen may also be of some value in patients with spinal cord injuries and other spinal cord diseases. Baclofen is not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders. The efficacy of baclofen in stroke, cerebral palsy, and Parkinson’s disease has not been established and, therefore, it is not recommended for these conditions. uuid:7116ea22-e8e3-4b34-adf8-711520673f44 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:187893 biolink:treats MONDO:0006497 PMID:41385096 "[{""id"":""uuid:729a7b06-b171-4143-804e-9804073308a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7800bf8a-90eb-412f-8ba4-285de15ec052"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Baclofen is useful for the alleviation of signs and symptoms of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity. Patients should have reversible spasticity so that baclofen treatment will aid in restoring residual function. Baclofen may also be of some value in patients with spinal cord injuries and other spinal cord diseases. Baclofen is not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders. The efficacy of baclofen in stroke, cerebral palsy, and Parkinson’s disease has not been established and, therefore, it is not recommended for these conditions. uuid:c4650eb1-ca05-4e96-8af4-bd8e24067340 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:187893 biolink:treats MONDO:0005180 PMID:41385096 "[{""id"":""uuid:1c9d72f7-abe0-43d8-8246-e791e41ca49e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:53613b4f-5b57-4a13-9476-7b96efecf68d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Baclofen is useful for the alleviation of signs and symptoms of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity. Patients should have reversible spasticity so that baclofen treatment will aid in restoring residual function. Baclofen may also be of some value in patients with spinal cord injuries and other spinal cord diseases. Baclofen is not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders. The efficacy of baclofen in stroke, cerebral palsy, and Parkinson’s disease has not been established and, therefore, it is not recommended for these conditions. uuid:0c93f422-fef6-4a95-8b8b-82988374a446 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:42797 biolink:treats MONDO:0041052 PMID:41385096 "[{""id"":""uuid:68246483-93a3-4038-b456-3af68998bf4e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d74a043d-7410-4f5e-9a3c-4ad85edb2a4f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gabapentin is indicated for the management of postherpetic neuralgia in adults. uuid:c463f4f0-b99b-48ea-881d-3143cd9bde3f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5141 biolink:treats MONDO:0017861 PMID:41385096 "[{""id"":""uuid:35330371-b344-4733-9120-7d9774e5cb1e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d48568ad-876f-41b3-bcaf-05438417c63a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:245b8bf6-5284-460f-abfe-50c05ea87a08"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Antizol is indicated as an antidote for ethylene glycol (such as antifreeze) or methanol poisoning, or for use in suspected ethylene glycol or methanol ingestion, either alone or in combination with hemodialysis (see DOSAGE AND ADMINISTRATION ).|[PMDA] A drug with a new active ingredient indicated for the treatment of ethylene glycol and methanol poisonings. uuid:fde686ac-9d80-486b-8efc-676b4accfdc6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5141 biolink:treats MONDO:0017860 PMID:41385096 "[{""id"":""uuid:c9b80e9c-8b97-4688-8d43-1fe1c92774a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f3015147-48fe-44a0-b926-89437e73ec7e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:29ed73df-8f5e-4a40-8324-5cd90eb6cfac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Antizol is indicated as an antidote for ethylene glycol (such as antifreeze) or methanol poisoning, or for use in suspected ethylene glycol or methanol ingestion, either alone or in combination with hemodialysis (see DOSAGE AND ADMINISTRATION ).|[PMDA] A drug with a new active ingredient indicated for the treatment of ethylene glycol and methanol poisonings. uuid:4ddca16a-2031-4746-b75c-6b241d5eb10f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7466 biolink:treats MONDO:0002280 PMID:41385096 "[{""id"":""uuid:439d21ce-3af4-495d-ac3d-fa06600c1d09"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:33373ffb-ed8b-49b9-a653-003142f25391"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nandrolone decanoate is indicated for the management of the anemia of renal insufficiency and has been shown to increase hemoglobin and red cell mass. Surgically induced anephric patients have been reported to be less responsive. uuid:137923be-fe6f-423b-8fa6-24781261d5dc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9637 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:d4fff33e-1f18-4e30-a174-b01929c99154"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eea9ce74-faf8-4853-8323-a29433dc403d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DEMADEX is indicated for the treatment of edema associated with congestive heart failure, renal disease, or hepatic disease. Use of torsemide has been found to be effective for the treatment of edema associated with chronic renal failure. Chronic use of any diuretic in hepatic disease has not been studied in adequate and well-controlled trials. DEMADEX intravenous injection is indicated when a rapid onset of diuresis is desired or when oral administration is impractical. DEMADEX is indicated for the treatment of hypertension alone or in combination with other antihypertensive agents. uuid:78a5258e-1f9d-4709-b068-e4c997d7a872 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9637 biolink:treats MONDO:0005240 PMID:41385096 "[{""id"":""uuid:6a0cd9b9-b4b3-4a4b-b7f4-12835d76f2d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ef031310-4f30-4672-b863-a7b0ad74d0f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DEMADEX is indicated for the treatment of edema associated with congestive heart failure, renal disease, or hepatic disease. Use of torsemide has been found to be effective for the treatment of edema associated with chronic renal failure. Chronic use of any diuretic in hepatic disease has not been studied in adequate and well-controlled trials. DEMADEX intravenous injection is indicated when a rapid onset of diuresis is desired or when oral administration is impractical. DEMADEX is indicated for the treatment of hypertension alone or in combination with other antihypertensive agents. uuid:b00289ec-1bea-4d46-844c-593f95b75684 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9637 biolink:treats MONDO:0005154 PMID:41385096 "[{""id"":""uuid:9e0f9df3-483e-48d6-a981-fd92927fc2b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:db27f0c4-3483-4812-b627-89f8199c2421"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DEMADEX is indicated for the treatment of edema associated with congestive heart failure, renal disease, or hepatic disease. Use of torsemide has been found to be effective for the treatment of edema associated with chronic renal failure. Chronic use of any diuretic in hepatic disease has not been studied in adequate and well-controlled trials. DEMADEX intravenous injection is indicated when a rapid onset of diuresis is desired or when oral administration is impractical. DEMADEX is indicated for the treatment of hypertension alone or in combination with other antihypertensive agents. uuid:8277caf5-fe36-4ee2-8fa5-71b0912b50cc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9637 biolink:treats MONDO:0005300 PMID:41385096 "[{""id"":""uuid:4a190168-ae07-4e04-9829-8321ae1a2b5a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fd48f388-7b2d-444b-8aaa-1ccc72a66e68"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DEMADEX is indicated for the treatment of edema associated with congestive heart failure, renal disease, or hepatic disease. Use of torsemide has been found to be effective for the treatment of edema associated with chronic renal failure. Chronic use of any diuretic in hepatic disease has not been studied in adequate and well-controlled trials. DEMADEX intravenous injection is indicated when a rapid onset of diuresis is desired or when oral administration is impractical. DEMADEX is indicated for the treatment of hypertension alone or in combination with other antihypertensive agents. uuid:522a3301-1ab6-4ee7-a051-1c24284a5b5f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9637 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:67f7eb7d-5cc4-41ae-956f-c10951d36c86"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:60b7755b-157b-4ff3-8bb0-95f0f5d9354f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DEMADEX is indicated for the treatment of edema associated with congestive heart failure, renal disease, or hepatic disease. Use of torsemide has been found to be effective for the treatment of edema associated with chronic renal failure. Chronic use of any diuretic in hepatic disease has not been studied in adequate and well-controlled trials. DEMADEX intravenous injection is indicated when a rapid onset of diuresis is desired or when oral administration is impractical. DEMADEX is indicated for the treatment of hypertension alone or in combination with other antihypertensive agents. uuid:3be4c07a-ce96-4a76-80e1-cf17201cd40b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7025 biolink:treats MONDO:0004592 PMID:41385096 "[{""id"":""uuid:b223e732-3997-46e0-b0c7-35d7c77b3700"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:319eb2f2-4b1d-4b96-b019-0e3f047a7827"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Centany (mupirocin ointment),2% is indicated for the topical treatment of impetigo due to: Staphylococcus aureus and Streptococcus pyogenes . uuid:33ea8d59-2fdb-4eaa-8375-5b6cd8c7aad8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7025 biolink:treats MONDO:0005545 PMID:41385096 "[{""id"":""uuid:363fe716-9be7-48be-b994-d97c882ba7b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:03132990-b408-425b-bf88-88d8f7bc60a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Centany (mupirocin ointment),2% is indicated for the topical treatment of impetigo due to: Staphylococcus aureus and Streptococcus pyogenes . uuid:78396f17-5ef7-498e-afb7-3b59f9e7cd50 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7025 biolink:treats UMLS:C0554628 PMID:41385096 "[{""id"":""uuid:1d00c1fd-4c92-4468-8e52-9b486ae05702"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ba6e476a-da1f-4ff0-9037-d015f5450fb4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Centany (mupirocin ointment),2% is indicated for the topical treatment of impetigo due to: Staphylococcus aureus and Streptococcus pyogenes . uuid:2d5b809e-1f8f-48b6-813a-2b7ccbc47020 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:56841838 biolink:treats MONDO:0006668 PMID:41385096 "[{""id"":""uuid:4ceb7798-dfa4-4bcd-9717-844292bb1631"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:24ac9e04-e64c-440b-abb4-61da2ae42f08"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FML-S® ophthalmic suspension is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe, where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The anti-infective drug in this product, sulfacetamide, is active against the following common bacterial eye pathogens: Escherichia coli, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus (viridans group), Haemophilus influenzae, Klebsiella species, and Enterobacter species. This product does not provide adequate coverage against Neisseria species and Serratia marcescens. A significant percentage of staphylococcal isolates are completely resistant to sulfa drugs. uuid:388f664d-5275-48fd-81b7-a4e1a1ef6f02 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:56841838 biolink:treats UMLS:C0008690 PMID:41385096 "[{""id"":""uuid:87276fde-c4b9-4050-82cf-15da0735b855"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:07f4e9d6-2d92-4c81-9d5a-3ce79f261829"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FML-S® ophthalmic suspension is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe, where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The anti-infective drug in this product, sulfacetamide, is active against the following common bacterial eye pathogens: Escherichia coli, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus (viridans group), Haemophilus influenzae, Klebsiella species, and Enterobacter species. This product does not provide adequate coverage against Neisseria species and Serratia marcescens. A significant percentage of staphylococcal isolates are completely resistant to sulfa drugs. uuid:7abc811f-39d6-48eb-86a1-055f8c3b03de biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:56841838 biolink:treats UMLS:C0339289 PMID:41385096 "[{""id"":""uuid:212554dd-cf5d-415f-b27f-5dea02ff32c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a2eeb3c1-e150-4fff-be6f-4c5f4c7a490a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FML-S® ophthalmic suspension is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe, where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The anti-infective drug in this product, sulfacetamide, is active against the following common bacterial eye pathogens: Escherichia coli, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus (viridans group), Haemophilus influenzae, Klebsiella species, and Enterobacter species. This product does not provide adequate coverage against Neisseria species and Serratia marcescens. A significant percentage of staphylococcal isolates are completely resistant to sulfa drugs. uuid:ed0931e9-7d4c-49ab-88b6-3aabfccea056 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:56841838 biolink:treats MONDO:0020920 PMID:41385096 "[{""id"":""uuid:bec10718-d054-4ff0-9261-ae2cd7ee64aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:30b04cfb-7009-4dd0-baaa-88071e681a69"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FML-S® ophthalmic suspension is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe, where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The anti-infective drug in this product, sulfacetamide, is active against the following common bacterial eye pathogens: Escherichia coli, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus (viridans group), Haemophilus influenzae, Klebsiella species, and Enterobacter species. This product does not provide adequate coverage against Neisseria species and Serratia marcescens. A significant percentage of staphylococcal isolates are completely resistant to sulfa drugs. uuid:eaeaa5fb-b54a-4ffd-96d7-91c7e9b495fe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:56841838 biolink:treats MONDO:0005545 PMID:41385096 "[{""id"":""uuid:34df6db3-e9f5-4573-a1a2-011b41f9496e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4f457979-307e-4f09-aeec-98afbe2ac776"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FML-S® ophthalmic suspension is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe, where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The anti-infective drug in this product, sulfacetamide, is active against the following common bacterial eye pathogens: Escherichia coli, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus (viridans group), Haemophilus influenzae, Klebsiella species, and Enterobacter species. This product does not provide adequate coverage against Neisseria species and Serratia marcescens. A significant percentage of staphylococcal isolates are completely resistant to sulfa drugs. uuid:3a35ae38-bd0a-4b4a-9c9d-66a55e806503 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:56841838 biolink:treats MONDO:0005114 PMID:41385096 "[{""id"":""uuid:2ad4bccc-35eb-4f92-953b-77cf62e81313"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:006fa4f1-5829-4ffd-af1a-ea64bd14ece0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FML-S® ophthalmic suspension is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe, where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The anti-infective drug in this product, sulfacetamide, is active against the following common bacterial eye pathogens: Escherichia coli, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus (viridans group), Haemophilus influenzae, Klebsiella species, and Enterobacter species. This product does not provide adequate coverage against Neisseria species and Serratia marcescens. A significant percentage of staphylococcal isolates are completely resistant to sulfa drugs. uuid:3d9a37d9-3f7d-4d31-805b-27e85fdbf401 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:56841838 biolink:treats UMLS:C1096266 PMID:41385096 "[{""id"":""uuid:6e0ff84f-528f-424b-8aec-9359b9a10ff9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:445ac42d-4c6f-4371-a642-c1777d42a0de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FML-S® ophthalmic suspension is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe, where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The anti-infective drug in this product, sulfacetamide, is active against the following common bacterial eye pathogens: Escherichia coli, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus (viridans group), Haemophilus influenzae, Klebsiella species, and Enterobacter species. This product does not provide adequate coverage against Neisseria species and Serratia marcescens. A significant percentage of staphylococcal isolates are completely resistant to sulfa drugs. uuid:9b0cde3a-34b6-4e1b-90b0-9d66927ea1f9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:56841838 biolink:treats UMLS:C0348321 PMID:41385096 "[{""id"":""uuid:4b4f37d1-c6d0-4417-9ac0-10919ad44a56"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:65be56e6-46aa-4cdd-a3de-7322512bff62"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FML-S® ophthalmic suspension is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe, where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The anti-infective drug in this product, sulfacetamide, is active against the following common bacterial eye pathogens: Escherichia coli, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus (viridans group), Haemophilus influenzae, Klebsiella species, and Enterobacter species. This product does not provide adequate coverage against Neisseria species and Serratia marcescens. A significant percentage of staphylococcal isolates are completely resistant to sulfa drugs. uuid:04c5b64a-ca37-4c03-b116-bb67059b902e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:56841838 biolink:treats MONDO:0030603 PMID:41385096 "[{""id"":""uuid:1880175d-62ba-4afb-9a2c-b0317f4d332f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4c99ec50-2bd2-4ebd-8123-43e88d1a1fb4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FML-S® ophthalmic suspension is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe, where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The anti-infective drug in this product, sulfacetamide, is active against the following common bacterial eye pathogens: Escherichia coli, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus (viridans group), Haemophilus influenzae, Klebsiella species, and Enterobacter species. This product does not provide adequate coverage against Neisseria species and Serratia marcescens. A significant percentage of staphylococcal isolates are completely resistant to sulfa drugs. uuid:7a178b60-ccff-4bc3-9b84-09cf7752a11b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:373644 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:d1202094-a21c-4c59-8665-c09eabb3bdad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:49b008e7-c969-48df-afbd-a0e79449e827"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Propoxyphene hydrochloride and acetaminophen tablets are indicated for the relief of mild-to-moderate pain, either when pain is present alone or when it is accompanied by fever. uuid:a8141966-d1fb-478a-8efa-f5fa4ea653e8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:373644 biolink:treats HP:0001945 PMID:41385096 "[{""id"":""uuid:8d214651-e803-4785-bb13-80922f9f9ff7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2850f32f-71fa-4bdd-bcec-48ad337f5448"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Propoxyphene hydrochloride and acetaminophen tablets are indicated for the relief of mild-to-moderate pain, either when pain is present alone or when it is accompanied by fever. uuid:0123d04b-7976-42fc-a3eb-a7c9eef4c9ab biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4735 biolink:treats MONDO:0001566 PMID:41385096 "[{""id"":""uuid:42f692f2-ada2-456e-a279-05dec28994ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:16e4b33b-96fb-49cc-9753-df6733409f03"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endrate (Edetate Disodium Injection, USP) is indicated in selected patients for the emergency treatment of hypercalcemia and for the control of ventricular arrhythmias associated with digitalis toxicity. uuid:9b89d1f6-911a-45c8-9158-14c413d4cf1d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0019359 PMID:41385096 "[{""id"":""uuid:39689c4f-8856-4e0c-bcb9-f3003e011df0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3a7bf06e-dde2-4a6f-b8f2-c84f973b8409"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (omithosis) caused by Chlamydia psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis (formerly Pasteurella pestis ). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis ). Cholera caused by Vibrio cholerae (formerly Vibrio comma ). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus ). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes (formerly Aerobacter aerogenes ) Shigella species Acinetobacter species (formerly Mima species and Herellea species) Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following grampositive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus p neumoniae ). Skin and skin structure infections caused by Staphylococcus aureus . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure); to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . Doxycycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent’s infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:0d6af825-cb6c-4ec5-96ce-580f720b717b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0001246 PMID:41385096 "[{""id"":""uuid:bfc497d2-d113-4da3-99d6-e8cf112566d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5039f694-e881-48fa-8b90-73db66d4637d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (omithosis) caused by Chlamydia psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis (formerly Pasteurella pestis ). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis ). Cholera caused by Vibrio cholerae (formerly Vibrio comma ). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus ). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes (formerly Aerobacter aerogenes ) Shigella species Acinetobacter species (formerly Mima species and Herellea species) Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following grampositive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus p neumoniae ). Skin and skin structure infections caused by Staphylococcus aureus . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure); to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . Doxycycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent’s infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:ddc7c98a-3ce9-4c57-b981-59efc757ee05 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0019186 PMID:41385096 "[{""id"":""uuid:e6e41cba-1992-4746-8477-3ac93b470cbe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5537324d-3ad7-41fc-9ef0-8d9efb42d6e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (omithosis) caused by Chlamydia psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis (formerly Pasteurella pestis ). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis ). Cholera caused by Vibrio cholerae (formerly Vibrio comma ). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus ). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes (formerly Aerobacter aerogenes ) Shigella species Acinetobacter species (formerly Mima species and Herellea species) Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following grampositive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus p neumoniae ). Skin and skin structure infections caused by Staphylococcus aureus . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure); to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . Doxycycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent’s infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:340a9fb8-c042-4266-8d50-f62ccbda7cd9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0019360 PMID:41385096 "[{""id"":""uuid:1543b1c5-8bb3-46ee-bf9e-e9c334afdae9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d1811bff-c094-43fc-aee6-f31813405516"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (omithosis) caused by Chlamydia psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis (formerly Pasteurella pestis ). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis ). Cholera caused by Vibrio cholerae (formerly Vibrio comma ). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus ). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes (formerly Aerobacter aerogenes ) Shigella species Acinetobacter species (formerly Mima species and Herellea species) Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following grampositive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus p neumoniae ). Skin and skin structure infections caused by Staphylococcus aureus . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure); to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . Doxycycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent’s infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:91e7b6a4-5db9-48a0-bd6e-7cc2db2b01f8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0025294 PMID:41385096 "[{""id"":""uuid:5e1954ff-3f80-478c-8fde-6f69c7208364"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f57f647a-8c57-4781-80ea-00bdcece6ff2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (omithosis) caused by Chlamydia psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis (formerly Pasteurella pestis ). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis ). Cholera caused by Vibrio cholerae (formerly Vibrio comma ). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus ). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes (formerly Aerobacter aerogenes ) Shigella species Acinetobacter species (formerly Mima species and Herellea species) Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following grampositive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus p neumoniae ). Skin and skin structure infections caused by Staphylococcus aureus . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure); to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . Doxycycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent’s infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:1e268d08-a02b-4e8e-b5dc-e85f7e096977 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0024355 PMID:41385096 "[{""id"":""uuid:898891a2-7497-4593-b4fa-9cf3e289a58b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8aa18c5b-c42d-48b2-b013-05c9c43f1e9b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (omithosis) caused by Chlamydia psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis (formerly Pasteurella pestis ). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis ). Cholera caused by Vibrio cholerae (formerly Vibrio comma ). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus ). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes (formerly Aerobacter aerogenes ) Shigella species Acinetobacter species (formerly Mima species and Herellea species) Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following grampositive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus p neumoniae ). Skin and skin structure infections caused by Staphylococcus aureus . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure); to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . Doxycycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent’s infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:2367b57a-eac7-4a0f-9872-70f7c3d5950f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0005834 PMID:41385096 "[{""id"":""uuid:062665f4-bed9-4c8c-9713-3a8d8dc438c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1207c847-488b-4eb1-a022-3a50edbf426a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (omithosis) caused by Chlamydia psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis (formerly Pasteurella pestis ). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis ). Cholera caused by Vibrio cholerae (formerly Vibrio comma ). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus ). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes (formerly Aerobacter aerogenes ) Shigella species Acinetobacter species (formerly Mima species and Herellea species) Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following grampositive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus p neumoniae ). Skin and skin structure infections caused by Staphylococcus aureus . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure); to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . Doxycycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent’s infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:286b47f4-41cb-4ec8-97a2-ab4ffdf32e98 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0005888 PMID:41385096 "[{""id"":""uuid:5f0ab9f1-5bf4-4218-992f-d9fb4b19befb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:39fe48ec-6be2-4920-842d-b5869e65a965"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (omithosis) caused by Chlamydia psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis (formerly Pasteurella pestis ). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis ). Cholera caused by Vibrio cholerae (formerly Vibrio comma ). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus ). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes (formerly Aerobacter aerogenes ) Shigella species Acinetobacter species (formerly Mima species and Herellea species) Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following grampositive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus p neumoniae ). Skin and skin structure infections caused by Staphylococcus aureus . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure); to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . Doxycycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent’s infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:8f4fafee-e440-47f6-8b19-a64921d91200 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0001249 PMID:41385096 "[{""id"":""uuid:202e72a2-8e3b-4825-8c47-ccd59a0a1e0f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e884f1cf-eb8d-4e3e-98b2-ad5870788d73"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (omithosis) caused by Chlamydia psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis (formerly Pasteurella pestis ). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis ). Cholera caused by Vibrio cholerae (formerly Vibrio comma ). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus ). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes (formerly Aerobacter aerogenes ) Shigella species Acinetobacter species (formerly Mima species and Herellea species) Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following grampositive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus p neumoniae ). Skin and skin structure infections caused by Staphylococcus aureus . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure); to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . Doxycycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent’s infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:0d3bc9a4-df80-40bb-9439-513e260148c6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0005808 PMID:41385096 "[{""id"":""uuid:76355b38-24d4-4846-9607-13d3ecc56c4f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6c0b64ea-a3d1-46f8-b4ea-a2efef8a6a75"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (omithosis) caused by Chlamydia psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis (formerly Pasteurella pestis ). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis ). Cholera caused by Vibrio cholerae (formerly Vibrio comma ). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus ). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes (formerly Aerobacter aerogenes ) Shigella species Acinetobacter species (formerly Mima species and Herellea species) Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following grampositive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus p neumoniae ). Skin and skin structure infections caused by Staphylococcus aureus . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure); to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . Doxycycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent’s infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:877137a3-3c68-4dd6-91b8-4daf52d8a5cb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0021697 PMID:41385096 "[{""id"":""uuid:ab496362-74d4-4cf1-97c4-601b31f45198"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9bea71e3-b657-4f3a-a340-40fb3682ecab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (omithosis) caused by Chlamydia psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis (formerly Pasteurella pestis ). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis ). Cholera caused by Vibrio cholerae (formerly Vibrio comma ). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus ). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes (formerly Aerobacter aerogenes ) Shigella species Acinetobacter species (formerly Mima species and Herellea species) Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following grampositive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus p neumoniae ). Skin and skin structure infections caused by Staphylococcus aureus . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure); to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . Doxycycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent’s infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:5b558423-2ee7-4fde-ad6f-fe7dc3afe04d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0005297 PMID:41385096 "[{""id"":""uuid:53c0fa99-b0f6-47eb-be36-b0fa1ce3c5f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:16410104-e3d0-4c23-961e-d27eab974723"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (omithosis) caused by Chlamydia psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis (formerly Pasteurella pestis ). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis ). Cholera caused by Vibrio cholerae (formerly Vibrio comma ). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus ). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes (formerly Aerobacter aerogenes ) Shigella species Acinetobacter species (formerly Mima species and Herellea species) Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following grampositive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus p neumoniae ). Skin and skin structure infections caused by Staphylococcus aureus . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure); to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . Doxycycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent’s infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:7b9f0f37-b182-433f-a6fc-ccae79cd6ea3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0019633 PMID:41385096 "[{""id"":""uuid:e2c94d7b-faae-4a84-ad01-1abc93dfd5c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a8e101e1-de87-4e49-9ab3-4d355e1e0538"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (omithosis) caused by Chlamydia psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis (formerly Pasteurella pestis ). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis ). Cholera caused by Vibrio cholerae (formerly Vibrio comma ). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus ). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes (formerly Aerobacter aerogenes ) Shigella species Acinetobacter species (formerly Mima species and Herellea species) Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following grampositive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus p neumoniae ). Skin and skin structure infections caused by Staphylococcus aureus . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure); to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . Doxycycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent’s infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:64322e0c-480c-4005-8b6b-23347c735b89 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0001797 PMID:41385096 "[{""id"":""uuid:f1f7f193-398d-4e86-b0a0-4e017323d265"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:785cfef0-1498-4c5a-8f5d-fefa16ce1298"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (omithosis) caused by Chlamydia psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis (formerly Pasteurella pestis ). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis ). Cholera caused by Vibrio cholerae (formerly Vibrio comma ). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus ). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes (formerly Aerobacter aerogenes ) Shigella species Acinetobacter species (formerly Mima species and Herellea species) Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following grampositive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus p neumoniae ). Skin and skin structure infections caused by Staphylococcus aureus . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure); to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . Doxycycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent’s infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:4223f563-89fd-4b0a-ad9f-f72b9494b788 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0019095 PMID:41385096 "[{""id"":""uuid:8836d790-3f80-4e4c-b20c-f29048ab3616"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c1754275-4044-4f45-a302-49fa38238be2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (omithosis) caused by Chlamydia psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis (formerly Pasteurella pestis ). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis ). Cholera caused by Vibrio cholerae (formerly Vibrio comma ). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus ). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes (formerly Aerobacter aerogenes ) Shigella species Acinetobacter species (formerly Mima species and Herellea species) Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following grampositive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus p neumoniae ). Skin and skin structure infections caused by Staphylococcus aureus . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure); to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . Doxycycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent’s infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:404e8cab-4704-42b9-9fcc-77ffb09fb2c3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0018077 PMID:41385096 "[{""id"":""uuid:caab4976-8f34-4501-a965-ceb8eaf8670e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:88b43b53-23d3-4742-8f8b-3d73eb318038"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (omithosis) caused by Chlamydia psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis (formerly Pasteurella pestis ). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis ). Cholera caused by Vibrio cholerae (formerly Vibrio comma ). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus ). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes (formerly Aerobacter aerogenes ) Shigella species Acinetobacter species (formerly Mima species and Herellea species) Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following grampositive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus p neumoniae ). Skin and skin structure infections caused by Staphylococcus aureus . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure); to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . Doxycycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent’s infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:2fd0d3ea-6913-460b-a6e9-1d90cbcf5b8b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0015766 PMID:41385096 "[{""id"":""uuid:79735bf6-4e3c-430c-8bba-ab4b2212d90d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aae1b545-5d5d-4c41-88b6-c81f8170264d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (omithosis) caused by Chlamydia psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis (formerly Pasteurella pestis ). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis ). Cholera caused by Vibrio cholerae (formerly Vibrio comma ). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus ). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes (formerly Aerobacter aerogenes ) Shigella species Acinetobacter species (formerly Mima species and Herellea species) Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following grampositive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus p neumoniae ). Skin and skin structure infections caused by Staphylococcus aureus . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure); to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . Doxycycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent’s infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:03d68296-cd58-4cb4-89d0-40843a719b97 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0040728 PMID:41385096 "[{""id"":""uuid:367640dd-f29c-4fdf-a41e-2d00eb8f3506"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1d83f975-1c96-42b3-b7b5-17ee171104bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (omithosis) caused by Chlamydia psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis (formerly Pasteurella pestis ). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis ). Cholera caused by Vibrio cholerae (formerly Vibrio comma ). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus ). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes (formerly Aerobacter aerogenes ) Shigella species Acinetobacter species (formerly Mima species and Herellea species) Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following grampositive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus p neumoniae ). Skin and skin structure infections caused by Staphylococcus aureus . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure); to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . Doxycycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent’s infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:b50c4621-f41d-439d-8820-e1adc1f26104 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0005683 PMID:41385096 "[{""id"":""uuid:e4180e44-2daa-4a10-8c39-e3c97d628359"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:332c5111-b66b-4b21-a144-87cccdbed169"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (omithosis) caused by Chlamydia psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis (formerly Pasteurella pestis ). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis ). Cholera caused by Vibrio cholerae (formerly Vibrio comma ). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus ). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes (formerly Aerobacter aerogenes ) Shigella species Acinetobacter species (formerly Mima species and Herellea species) Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following grampositive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus p neumoniae ). Skin and skin structure infections caused by Staphylococcus aureus . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure); to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . Doxycycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent’s infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:5389dd17-6d88-4501-ace2-94683a6d0e93 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0005664 PMID:41385096 "[{""id"":""uuid:af42ae16-c822-49ad-a24d-dc98888f0f75"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c8c078a2-6440-496c-b771-56d263af98c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (omithosis) caused by Chlamydia psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis (formerly Pasteurella pestis ). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis ). Cholera caused by Vibrio cholerae (formerly Vibrio comma ). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus ). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes (formerly Aerobacter aerogenes ) Shigella species Acinetobacter species (formerly Mima species and Herellea species) Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following grampositive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus p neumoniae ). Skin and skin structure infections caused by Staphylococcus aureus . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure); to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . Doxycycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent’s infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:c8ad0250-6a3c-479f-92c0-1521adff7c7d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0005777 PMID:41385096 "[{""id"":""uuid:709944f9-b5b9-4612-98ef-f798b0fe544c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:44aed825-930f-4519-8b06-e62bdd11b3bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (omithosis) caused by Chlamydia psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis (formerly Pasteurella pestis ). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis ). Cholera caused by Vibrio cholerae (formerly Vibrio comma ). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus ). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes (formerly Aerobacter aerogenes ) Shigella species Acinetobacter species (formerly Mima species and Herellea species) Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following grampositive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus p neumoniae ). Skin and skin structure infections caused by Staphylococcus aureus . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure); to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . Doxycycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent’s infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:69421bba-37bd-4bb4-bf36-592c807765b0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0020920 PMID:41385096 "[{""id"":""uuid:4a923632-5df1-426a-aa2b-50b02c59d499"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d0da7d6b-70ce-41ac-93c7-df543ab952d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (omithosis) caused by Chlamydia psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis (formerly Pasteurella pestis ). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis ). Cholera caused by Vibrio cholerae (formerly Vibrio comma ). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus ). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes (formerly Aerobacter aerogenes ) Shigella species Acinetobacter species (formerly Mima species and Herellea species) Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following grampositive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus p neumoniae ). Skin and skin structure infections caused by Staphylococcus aureus . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure); to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . Doxycycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent’s infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:e042c67e-6f3d-4f5b-a42e-057951894458 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0019345 PMID:41385096 "[{""id"":""uuid:ff972583-1cb4-4028-8f89-a0b68144717a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:70fa0fee-4660-480d-8621-20f41b0d82aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (omithosis) caused by Chlamydia psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis (formerly Pasteurella pestis ). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis ). Cholera caused by Vibrio cholerae (formerly Vibrio comma ). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus ). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes (formerly Aerobacter aerogenes ) Shigella species Acinetobacter species (formerly Mima species and Herellea species) Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following grampositive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus p neumoniae ). Skin and skin structure infections caused by Staphylococcus aureus . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure); to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . Doxycycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent’s infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:b72f8466-06ef-429b-a3b7-6535776eb5d6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0006635 PMID:41385096 "[{""id"":""uuid:26fb75b8-18d9-4a54-911e-d1abc1c8e7c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e47e6ddf-939a-4621-b2f2-947dcb14db86"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (omithosis) caused by Chlamydia psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis (formerly Pasteurella pestis ). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis ). Cholera caused by Vibrio cholerae (formerly Vibrio comma ). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus ). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes (formerly Aerobacter aerogenes ) Shigella species Acinetobacter species (formerly Mima species and Herellea species) Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following grampositive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus p neumoniae ). Skin and skin structure infections caused by Staphylococcus aureus . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure); to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . Doxycycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent’s infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:71d78653-7396-4b91-9f49-60ea37430903 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats HP:0005376 PMID:41385096 "[{""id"":""uuid:37c97a7f-ffa5-4316-ac89-dd6dbc8af510"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b4178a8d-4a8e-4ad0-8fb3-229efb498346"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (omithosis) caused by Chlamydia psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis (formerly Pasteurella pestis ). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis ). Cholera caused by Vibrio cholerae (formerly Vibrio comma ). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus ). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes (formerly Aerobacter aerogenes ) Shigella species Acinetobacter species (formerly Mima species and Herellea species) Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following grampositive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus p neumoniae ). Skin and skin structure infections caused by Staphylococcus aureus . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure); to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . Doxycycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent’s infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:c9fad36e-7584-410d-a331-ee0991a933e5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0030603 PMID:41385096 "[{""id"":""uuid:e30f14fe-2249-42f8-8af3-f50bbd4c5b4e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0ea88da1-4771-413b-a338-8843b3d6d886"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (omithosis) caused by Chlamydia psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis (formerly Pasteurella pestis ). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis ). Cholera caused by Vibrio cholerae (formerly Vibrio comma ). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus ). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes (formerly Aerobacter aerogenes ) Shigella species Acinetobacter species (formerly Mima species and Herellea species) Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following grampositive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus p neumoniae ). Skin and skin structure infections caused by Staphylococcus aureus . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure); to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . Doxycycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent’s infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:7ec415de-f2ca-4836-a4ba-46d4a7906392 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats UMLS:C0041912 PMID:41385096 "[{""id"":""uuid:f3e91835-f9c6-4493-b12e-3c4aae229d33"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:acf41712-bae6-4fcd-b5cb-65279970bc01"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (omithosis) caused by Chlamydia psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis (formerly Pasteurella pestis ). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis ). Cholera caused by Vibrio cholerae (formerly Vibrio comma ). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus ). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes (formerly Aerobacter aerogenes ) Shigella species Acinetobacter species (formerly Mima species and Herellea species) Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following grampositive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus p neumoniae ). Skin and skin structure infections caused by Staphylococcus aureus . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure); to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . Doxycycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent’s infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:a6aafc50-2e12-4ced-b49e-a160e52d0aaa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:0e3af307-fe6f-4efa-83f6-b015724ee684"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:02646a0a-4a54-4652-864e-e00be540b143"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (omithosis) caused by Chlamydia psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis (formerly Pasteurella pestis ). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis ). Cholera caused by Vibrio cholerae (formerly Vibrio comma ). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus ). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes (formerly Aerobacter aerogenes ) Shigella species Acinetobacter species (formerly Mima species and Herellea species) Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following grampositive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus p neumoniae ). Skin and skin structure infections caused by Staphylococcus aureus . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure); to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . Doxycycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent’s infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:2855df56-5b6c-4e46-8a0f-d247a3c40001 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0005119 PMID:41385096 "[{""id"":""uuid:da731029-244b-42dd-aabb-5a015bc6af74"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d896f962-b74d-4522-8fd2-2e72e8033c08"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (omithosis) caused by Chlamydia psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis (formerly Pasteurella pestis ). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis ). Cholera caused by Vibrio cholerae (formerly Vibrio comma ). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus ). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes (formerly Aerobacter aerogenes ) Shigella species Acinetobacter species (formerly Mima species and Herellea species) Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following grampositive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus p neumoniae ). Skin and skin structure infections caused by Staphylococcus aureus . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure); to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . Doxycycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent’s infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:aed744d2-c063-410a-a496-836f7981c0aa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0004277 PMID:41385096 "[{""id"":""uuid:9e0cc043-5d0b-4527-b9de-ac1054a5f4aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:26c5cb5a-92dd-4767-9672-a3349e69fd7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (omithosis) caused by Chlamydia psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis (formerly Pasteurella pestis ). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis ). Cholera caused by Vibrio cholerae (formerly Vibrio comma ). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus ). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes (formerly Aerobacter aerogenes ) Shigella species Acinetobacter species (formerly Mima species and Herellea species) Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following grampositive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus p neumoniae ). Skin and skin structure infections caused by Staphylococcus aureus . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure); to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . Doxycycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent’s infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:1c493b28-4920-4338-b85d-eacc1e2ef2a4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0005976 PMID:41385096 "[{""id"":""uuid:2eedf00b-381d-4267-92d6-63a39ebf9114"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1da6bbf8-ffd4-4ce2-aca5-988e10f32c96"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (omithosis) caused by Chlamydia psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis (formerly Pasteurella pestis ). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis ). Cholera caused by Vibrio cholerae (formerly Vibrio comma ). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus ). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes (formerly Aerobacter aerogenes ) Shigella species Acinetobacter species (formerly Mima species and Herellea species) Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following grampositive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus p neumoniae ). Skin and skin structure infections caused by Staphylococcus aureus . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure); to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . Doxycycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent’s infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:c27da083-6304-4c61-9b4a-46c98af38766 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0006019 PMID:41385096 "[{""id"":""uuid:4866f9fb-55cb-4850-acff-a44ae9967a93"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:14aea869-fdf9-492c-9502-794a2009733d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (omithosis) caused by Chlamydia psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis (formerly Pasteurella pestis ). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis ). Cholera caused by Vibrio cholerae (formerly Vibrio comma ). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus ). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes (formerly Aerobacter aerogenes ) Shigella species Acinetobacter species (formerly Mima species and Herellea species) Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following grampositive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus p neumoniae ). Skin and skin structure infections caused by Staphylococcus aureus . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure); to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . Doxycycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent’s infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:43ea7c4d-5c5a-4be8-8b36-334cd8384916 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0005828 PMID:41385096 "[{""id"":""uuid:b79c9839-a448-4fff-8197-1a8f5a6b9eca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:08dc2906-b977-4b98-8a0f-33cc574112c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (omithosis) caused by Chlamydia psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis (formerly Pasteurella pestis ). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis ). Cholera caused by Vibrio cholerae (formerly Vibrio comma ). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus ). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes (formerly Aerobacter aerogenes ) Shigella species Acinetobacter species (formerly Mima species and Herellea species) Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following grampositive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus p neumoniae ). Skin and skin structure infections caused by Staphylococcus aureus . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure); to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . Doxycycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent’s infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:0bbfab35-745c-41ec-aeb1-45897d26533b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0005631 PMID:41385096 "[{""id"":""uuid:3b3cb20e-13a5-4bec-8c87-d76282e07d9b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8dfb20b6-6ac9-4b10-bd4f-0b5ce1802ecf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (omithosis) caused by Chlamydia psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis (formerly Pasteurella pestis ). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis ). Cholera caused by Vibrio cholerae (formerly Vibrio comma ). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus ). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes (formerly Aerobacter aerogenes ) Shigella species Acinetobacter species (formerly Mima species and Herellea species) Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following grampositive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus p neumoniae ). Skin and skin structure infections caused by Staphylococcus aureus . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure); to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . Doxycycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent’s infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:1f3ea771-b9fe-489d-b824-b4d3c9754d6a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0024388 PMID:41385096 "[{""id"":""uuid:dc9388a1-9374-4174-871f-83acdd489314"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8dc00cc0-2df8-488f-9ede-243c99010880"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (omithosis) caused by Chlamydia psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis (formerly Pasteurella pestis ). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis ). Cholera caused by Vibrio cholerae (formerly Vibrio comma ). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus ). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes (formerly Aerobacter aerogenes ) Shigella species Acinetobacter species (formerly Mima species and Herellea species) Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following grampositive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus p neumoniae ). Skin and skin structure infections caused by Staphylococcus aureus . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure); to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . Doxycycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent’s infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:6e07433f-63d7-47ec-918a-64d97fa9f7e1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0005644 PMID:41385096 "[{""id"":""uuid:4fad2428-7754-40f9-9456-03f032e9a6e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9d2e08dc-c187-4252-88d7-a0f8ae0137d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (omithosis) caused by Chlamydia psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis (formerly Pasteurella pestis ). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis ). Cholera caused by Vibrio cholerae (formerly Vibrio comma ). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus ). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes (formerly Aerobacter aerogenes ) Shigella species Acinetobacter species (formerly Mima species and Herellea species) Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following grampositive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus p neumoniae ). Skin and skin structure infections caused by Staphylococcus aureus . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure); to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . Doxycycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent’s infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:b4280e39-157a-48ad-bceb-ebd1f539efee biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0011438 PMID:41385096 "[{""id"":""uuid:bc2f36ed-210a-4d74-8eea-abfdf4341de6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:44a5d898-f0bd-4f40-a3fa-beab6ca4a6b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (omithosis) caused by Chlamydia psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis (formerly Pasteurella pestis ). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis ). Cholera caused by Vibrio cholerae (formerly Vibrio comma ). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus ). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes (formerly Aerobacter aerogenes ) Shigella species Acinetobacter species (formerly Mima species and Herellea species) Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following grampositive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus p neumoniae ). Skin and skin structure infections caused by Staphylococcus aureus . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure); to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . Doxycycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent’s infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:fe0c3072-44b0-45b6-b651-854d9a0c7190 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats UMLS:C5779507 PMID:41385096 "[{""id"":""uuid:0c6a7bae-bb80-4852-a0ba-bf41639dff9c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:006d6a75-088f-413d-93a1-907afdaf42f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cortifoam® is indicated as adjunctive therapy in the topical treatment of ulcerative proctitis of the distal portion of the rectum in patients who cannot retain hydrocortisone or other corticosteroid enemas. uuid:c9614905-802e-4968-ba03-dee0b53ecb88 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5855 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:f219f3a2-89c7-47bf-bfda-efab738c897a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:da62cc3b-7ef0-4eab-bdbb-20282d42745e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of ibuprofen tablets and other treatment options before deciding to use ibuprofen. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Ibuprofen tablets are indicated for relief of the signs and symptoms of rheumatoid arthritis and osteoarthritis. Ibuprofen tablets are indicated for relief of mild to moderate pain. Ibuprofen tablets are also indicated for the treatment of primary dysmenorrhea. Controlled clinical trials to establish the safety and effectiveness of ibuprofen tablets in children have not been conducted. uuid:5c67147b-2db4-4845-8a59-08d8a4282ddc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5855 biolink:treats MONDO:0005178 PMID:41385096 "[{""id"":""uuid:1233bcb5-c610-43de-83c7-8023d5e56716"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:02c82586-628a-499b-a877-9d7af2d57c32"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of ibuprofen tablets and other treatment options before deciding to use ibuprofen. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Ibuprofen tablets are indicated for relief of the signs and symptoms of rheumatoid arthritis and osteoarthritis. Ibuprofen tablets are indicated for relief of mild to moderate pain. Ibuprofen tablets are also indicated for the treatment of primary dysmenorrhea. Controlled clinical trials to establish the safety and effectiveness of ibuprofen tablets in children have not been conducted. uuid:2b8c3379-7989-4162-987e-d90753680de3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5855 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:629d48b8-7913-44ef-875c-5b396cfe9117"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0d7f1636-c638-445b-8fee-4c8b395b273b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of ibuprofen tablets and other treatment options before deciding to use ibuprofen. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Ibuprofen tablets are indicated for relief of the signs and symptoms of rheumatoid arthritis and osteoarthritis. Ibuprofen tablets are indicated for relief of mild to moderate pain. Ibuprofen tablets are also indicated for the treatment of primary dysmenorrhea. Controlled clinical trials to establish the safety and effectiveness of ibuprofen tablets in children have not been conducted. uuid:0a281179-4714-4e5c-a753-16d92c132b93 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5855 biolink:treats MONDO:1060206 PMID:41385096 "[{""id"":""uuid:2b1cff0b-1996-4d4b-a6a3-01d79ec98d12"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8c963316-9324-4f44-b97c-27856d0b027b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of ibuprofen tablets and other treatment options before deciding to use ibuprofen. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Ibuprofen tablets are indicated for relief of the signs and symptoms of rheumatoid arthritis and osteoarthritis. Ibuprofen tablets are indicated for relief of mild to moderate pain. Ibuprofen tablets are also indicated for the treatment of primary dysmenorrhea. Controlled clinical trials to establish the safety and effectiveness of ibuprofen tablets in children have not been conducted. UMLS:C0149875 uuid:07f0cd13-5a2e-44e7-b49a-af8a5c533c6b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1157483 biolink:treats MONDO:0005412 PMID:41385096 "[{""id"":""uuid:ac70a043-9386-4a25-be8c-b3c278aa944c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:50c9ae1f-ba59-4391-9743-15433dab6061"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZEGERID with Magnesium Hydroxide is indicated for short-term treatment of active duodenal ulcer. Most patients heal within four weeks. Some patients may require an additional four weeks of therapy. uuid:03e1250b-0ad3-4634-95f5-6c3d0700abef biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28787 biolink:treats HP:0001681 PMID:41385096 "[{""id"":""uuid:bbfec5b3-0209-43ca-a133-8b0285fd8941"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:08898eb6-32e4-4f8f-9441-b56fd6a82122"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nitrolingual ® Pumpspray is indicated for acute relief of an attack or prophylaxis of angina pectoris due to coronary artery disease. uuid:0454abcb-8ea4-4f43-add0-0fe4b70ea13d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28787 biolink:treats MONDO:0005010 PMID:41385096 "[{""id"":""uuid:a9a18d41-42ce-443e-b090-378e9f3a845c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:361f141d-676e-4e63-9a44-c5eff65fa456"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nitrolingual ® Pumpspray is indicated for acute relief of an attack or prophylaxis of angina pectoris due to coronary artery disease. uuid:c85986be-2bb0-4e8c-b2bf-f0510aeb9354 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0000004 PMID:41385096 "[{""id"":""uuid:4ad559eb-3f18-45fb-8717-817f69b0741c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fed60184-2a66-448f-b0b3-84a549525202"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:6972ccee-64f1-4d64-ba0c-a9f44281787d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0018479 PMID:41385096 "[{""id"":""uuid:c54cc2fe-b25b-46c3-9938-3d3e5abc53bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b9910744-bb67-4f03-a353-3bb5d555bb79"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:7fef96cf-91d8-4963-b33e-ffcd07cd7167 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0006982 PMID:41385096 "[{""id"":""uuid:a0a57c01-d68a-4074-b34b-8795133a81e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e7d07a0b-e3ae-4ffe-a04f-45d1fc31f5a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:2e3ee7ce-1e81-4754-ba80-f4eeb7dbd663 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0043455 PMID:41385096 "[{""id"":""uuid:0dddefe8-1029-44df-bdd2-72a5b93db7b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c3f39959-76d3-47b5-8233-341147a6567e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:9ba66622-0afb-44f9-8470-5258da327577 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0011849 PMID:41385096 "[{""id"":""uuid:cd957471-2bb4-476f-a22d-0d99e2e19684"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cec86406-a3d0-41bd-84c5-19feec5ec7c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:09cb203b-75c2-4ac7-a354-58fe07a70a81 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:8c8b6cd8-caf8-4ade-b6fb-e8995f10cae8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:27d55c9f-0719-47c4-986e-1b523591c00e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:b1e4adb3-9fb3-4ca6-8ef6-c12f6045c207 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0011429 PMID:41385096 "[{""id"":""uuid:31fcb750-66b1-4765-93c6-136886d747ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:917c0fbf-f6bc-4427-90aa-b2df066ab57e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:c6a90b15-99fb-408a-b760-e81c539d8084 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0005306 PMID:41385096 "[{""id"":""uuid:18ff57c4-4233-4637-8738-ebac75c373a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:afcba2be-7d55-45f8-bac3-7a4eddcbb9e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:82fffb9e-5a31-4b96-8da6-3a3df735fc28 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats UMLS:C1290158 PMID:41385096 "[{""id"":""uuid:1eacd8a4-58bd-46da-a673-19d3ae4ae69e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:212e9f98-8144-41b7-b88b-e5c345e38496"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:15709b2e-23f8-44df-a78c-6d83c28a9b27 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0040698 PMID:41385096 "[{""id"":""uuid:dae7adb3-165c-4968-a776-1947d6948130"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e1cb031f-1b5b-4e55-ba97-6e2d077e83e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:6a5e615a-a706-4b30-8bd7-bdbc58c3e3bf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0004855 PMID:41385096 "[{""id"":""uuid:75dbaa26-875f-4b74-a6dc-8550d84fd4f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:997750b0-8277-4920-870f-84fe00f5192a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:b9fafb5e-6e66-4b5b-8bd0-5ac431cf48b1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats UMLS:C0149896 PMID:41385096 "[{""id"":""uuid:36bf51b6-1944-4591-a961-f1214c199cd2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a79a58d2-c9fe-4c29-9ad3-73fc1bb8a2fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:0082245d-4eb0-4883-b987-9befb7d28760 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0005178 PMID:41385096 "[{""id"":""uuid:cd5f925d-96b1-468a-91b7-b838af12b645"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cb997874-3590-48c4-a42d-471c9910ca9c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:62fb5e8c-a59d-4259-9287-3e2f2e8a2d3d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0001875 PMID:41385096 "[{""id"":""uuid:fc29ea95-df3b-4223-acbc-aacd9998f5ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f6724810-b4c2-48a6-b132-c9c1b08ce8de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:ebfa5294-49b1-4c50-ae40-36c73fb5ffaa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats UMLS:C5441648 PMID:41385096 "[{""id"":""uuid:c64e0c48-e650-47e1-87b7-eefc4eaeeab4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:74b7de7e-60bc-4c02-b8d5-2e6cd7c3e7e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:b3ae0071-f8e7-4e4d-ae2b-3e71e1f37f4f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0016367 PMID:41385096 "[{""id"":""uuid:6fcfb617-2df8-4475-b0cc-ae948fb4ebe2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c391829e-5a77-4a26-87f8-b8b1173620e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:152f098b-15bf-4ed8-897b-e721108c38a4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0019127 PMID:41385096 "[{""id"":""uuid:715fe80c-09a7-4b38-b32e-0a678b4cf876"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fb3b50f8-d7aa-4b2b-9fa3-c384ff249d64"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:bbb5cc4e-2c4a-4aaf-b48b-941750f5022c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0006594 PMID:41385096 "[{""id"":""uuid:9bd737ba-b331-4cfe-b6d5-836b47730038"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5b4710ad-cbca-4e42-9321-ab8e07f6d5e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:c3c50856-9ef5-4a9c-ad39-7c9143f871d7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0015614 PMID:41385096 "[{""id"":""uuid:c7be704c-cb2c-4e57-878a-129a3c32a0ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f1b3776a-0e43-4968-858a-45e80e090e66"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:550ee216-ad8b-4112-8d7d-db9e86117adf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0006545 PMID:41385096 "[{""id"":""uuid:536e1754-0c40-41b0-a627-13e6ac2b3053"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:17151339-3b0c-48b5-8963-31ff5285eb70"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:a1f9909b-b64c-4497-a1dd-d899292c1606 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0018229 PMID:41385096 "[{""id"":""uuid:67dddf76-5113-4726-8cbd-39302cd2c3f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:06df8ce7-e4ad-4d29-83fd-51223d899357"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:b2f25487-1fcc-477b-8ef1-446d126d7da5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0043233 PMID:41385096 "[{""id"":""uuid:c075f2a6-3565-4531-9035-3e2ec1ddbfda"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3f4a6fc9-7568-485c-9731-e13c8e91d17b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:ddf2e594-ca8e-48eb-b5d6-8a3ed48d815b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0009691 PMID:41385096 "[{""id"":""uuid:0e52889c-2dd6-40ef-9a1e-549aae32fd7c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d9901f35-5acd-4398-928e-5409ec1381a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:f15f6958-4a1a-4837-b16a-8f75f1ff8f2b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0005083 PMID:41385096 "[{""id"":""uuid:798cead8-32f1-4baf-8dbd-d2d29ff505d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:49de3bba-52ad-4204-ad54-e11ae458ee3e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:749644a8-d924-49bb-a34c-ae0820864dbe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0006608 PMID:41385096 "[{""id"":""uuid:6d150979-d545-4697-b23b-48e9945882d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d54b018b-8af0-4b08-8940-7b32476a022d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:1ea085b1-6407-45ad-ba1d-09f0bb03fea2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0005324 PMID:41385096 "[{""id"":""uuid:e5cb6b8e-886d-477d-ade9-175b43887751"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2c00effb-c3c8-4282-ab01-94d6218ec6d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:38aeb4c6-d7f9-46c5-8af4-02b35d03d173 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0024332 PMID:41385096 "[{""id"":""uuid:7c6fffc1-891f-493f-8cc0-90ca9439014b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9491f1f7-db6e-4d59-ad74-86f75359ae78"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:9768fc1d-84e6-4c41-93f8-827f6487b439 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0043789 PMID:41385096 "[{""id"":""uuid:4a527ea2-6e22-46ba-84fa-58c5517343b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:31d0a97d-641b-4330-bc78-61d1c756b0f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:ca9c428f-079e-4352-97d8-58d3908043bd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:ced0ab1c-294a-4711-8325-f5151d4fc471"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5959fcd4-343b-49e1-bb98-27504f0bd91c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:0c0de855-9ea6-4df4-98e8-925fdc430189 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0005480 PMID:41385096 "[{""id"":""uuid:0e56e5dd-a193-4a87-b43f-3b850e971dc3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:160a7113-79aa-4728-8bde-2d821a2fcdef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:51fe3241-4927-44c3-8e7d-a5b613f14606 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:3d1a3da7-d002-4afe-9b39-b5fe3b82c0b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3a663576-eacf-4090-aeee-385475c42577"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:4d093ec1-fdf4-4933-b707-38d01a78970c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0000775 PMID:41385096 "[{""id"":""uuid:3b3843dd-3489-4221-a639-8515564a529e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:17e4342a-28de-48d6-89df-d4c078f9f452"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:43503386-63ba-4b21-8588-7dbf2c07bcae biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0003085 PMID:41385096 "[{""id"":""uuid:ec758ed1-72f3-45dc-aa7e-bb425d62df79"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ca71ced9-f067-4fc6-82d4-e872e1bd5ba3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:34c57e65-ac2c-4d17-b7b1-3608211f0b7d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0001034 PMID:41385096 "[{""id"":""uuid:13bb9ecf-2901-4ea7-8166-ab48a17c4ed7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6223aee6-c748-4466-8afb-609c935d47f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:a28814c1-a964-4a52-940e-657b4cfe279a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0005883 PMID:41385096 "[{""id"":""uuid:671c1c00-0284-4c08-aa28-4801cd0a5cf8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8be9e035-c799-47ec-a4c4-f1ffa1677971"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:7cbfe7fc-9ded-4386-835d-7b3acc7d8353 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0006814 PMID:41385096 "[{""id"":""uuid:fbec8301-a82f-4467-b5f5-2b3a1a43663a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0afd476c-36f1-44e1-b703-243985077e0c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:079d1f90-216a-4857-849e-99e796268b76 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0004773 PMID:41385096 "[{""id"":""uuid:008a6271-ee61-43c6-9d24-b2e98642a54a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8a9d72e6-568a-4af1-9115-3c6a77e659d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:c55c8d43-229d-4669-b066-f4bb342cf186 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0004674 PMID:41385096 "[{""id"":""uuid:05862fd1-db8b-4e70-a5e4-aca1be518ae1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4e4bfe6b-19b2-439b-a3e2-f0425da6607c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:69b6e706-5521-4635-a1cc-cfbe71970944 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0006651 PMID:41385096 "[{""id"":""uuid:fdd4b5e0-541e-4ca8-82c5-c80908b9fd24"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9da435f4-d907-4908-8525-d5999c23e99a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:1d209cb7-5764-4105-b5c6-c46468e3631a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0006918 PMID:41385096 "[{""id"":""uuid:cbe861bc-7ea4-4756-ad10-1cbb9a6d6b48"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:65a51b3a-a6b4-41fd-9de3-3eb0803231f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:381201b0-d6a2-40ff-92e4-a2f289064c7d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0001280 PMID:41385096 "[{""id"":""uuid:3381d667-c9d1-4d9e-a907-1a7af2d521bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9a8abc22-b398-4477-854a-4790af5ef73b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:7766b4ad-c084-49c8-a62c-1f8fe219dc0e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0005885 PMID:41385096 "[{""id"":""uuid:c27615a3-58c8-4c0c-a28e-49c6ea4045a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:55c7b956-dd30-4f5c-b854-985027724006"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:b239d645-0ed1-4266-ae61-f1497d62ab63 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0019198 PMID:41385096 "[{""id"":""uuid:40888cf9-3992-4a90-880e-0a20cb408d86"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3791f239-5e51-45a1-9e3b-3350143c48a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:a723aff6-fea8-482e-a2d1-f34f15449758 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0019338 PMID:41385096 "[{""id"":""uuid:d9ab6df1-d50b-470d-9d15-44d3697dd856"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8bcc5132-5bfb-4d8c-9be2-3059b919eaff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:77670565-1afa-4c6e-aebd-9cb03ee27b9e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0015274 PMID:41385096 "[{""id"":""uuid:00463157-5ed9-4722-856e-3b90a7aa15ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e57e0b3c-73a8-44d0-87ae-75f0cbae8058"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:f8b5c831-0f32-458b-8b7c-64fce3415e10 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0006052 PMID:41385096 "[{""id"":""uuid:614dc62a-3e8b-4460-85dd-f541ea4921db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dbb41d3b-0d59-466e-adb3-8e54f17bf369"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:00476842-cf3d-4d9c-b8a8-9b9f677cf37a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0005848 PMID:41385096 "[{""id"":""uuid:55119033-640f-45b8-a1ac-c4bd6ab26a18"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:43fcac39-f39e-4e46-a142-03adde3b0333"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:1cd89504-4883-42e5-9990-638bbef3bbcb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0002572 PMID:41385096 "[{""id"":""uuid:52e3d9b9-ea83-408a-8255-dbfe4c9998a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5dfb8ddc-701e-4555-833c-99d322750b95"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:2f48d520-67b3-45da-9dbf-cf24e55cb16e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0019098 PMID:41385096 "[{""id"":""uuid:e7e0eac8-cf64-4efd-b2db-4aa944526fa8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:57b9f71f-d46d-4db5-a473-c662c7f757fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:a3c013fc-0616-4d48-a0fa-3c2799540f21 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0001198 PMID:41385096 "[{""id"":""uuid:226e639c-5466-450d-9c3f-f2e5bad54e9e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b4f13eda-bce1-435d-b123-b9fde41a7d20"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:1df758e4-568b-4be4-943c-ef828d572eec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats UMLS:C0002879 PMID:41385096 "[{""id"":""uuid:1c96ac4a-02ef-46c4-84e0-840ec17d0e81"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:21301386-fbe6-4ffa-a0da-5cc336cf8f9b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:21b6c78f-5a14-4b93-be1f-80a2484a99be biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0020108 PMID:41385096 "[{""id"":""uuid:a46bfce1-054c-4466-be60-1463e99344cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:824734ea-2c96-4398-81e9-d6ec458205e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:71be46d8-ab86-4e44-a603-4287d2ae904a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0002280 PMID:41385096 "[{""id"":""uuid:d023866e-6ded-4bb3-b0d9-62251c6c33d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4ad31cfc-15be-4093-b608-064b8c7ed1ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:fb3bd903-46ec-4f14-8465-4a182c512e40 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0015253 PMID:41385096 "[{""id"":""uuid:fd266255-9277-48ea-93c8-e5bcfc40e39c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a5f0b2a3-e2f0-4c29-826a-34bfc40762fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:d1e4018b-afde-4223-91aa-3fef64f2423a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats HP:0001908 PMID:41385096 "[{""id"":""uuid:2a657cf1-f623-4bd5-81fa-adf383cf43f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0c78a090-c6a4-444d-9868-8230a434df4a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:31d189b3-83ec-45dd-bf85-e5d8c00cbb61 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0005059 PMID:41385096 "[{""id"":""uuid:d81e0a72-6fc7-4439-84d2-68300d226f8d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8435dce7-9745-44ec-a80d-ad222bb4a5a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:a46f5978-9726-403b-9df3-79f69e92f106 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0004095 PMID:41385096 "[{""id"":""uuid:1bdb3d0d-2c2d-4783-b2a9-572604b8a4a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:edfa82de-102a-4016-ab3c-cfce00ec854a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:8a1de42a-e0fd-4231-a5dc-e48ea2095d44 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0004355 PMID:41385096 "[{""id"":""uuid:41b4ca45-8f35-4ae4-99ad-2f081d76c0f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0f99b60b-717e-4a4e-b472-ab61840cc43f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:acea20ed-2840-42e7-9561-919ee9d5ad11 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats UMLS:C0268732 PMID:41385096 "[{""id"":""uuid:38e5fc9e-9d07-4bd8-ba75-d41ae7488334"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c0b879be-46a1-4aac-8b83-7cb4dc8761be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:dbfbf9be-5a5d-4aa1-931c-fb8b761eeff6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0005101 PMID:41385096 "[{""id"":""uuid:e5f373bd-8423-4bcd-9f96-fb9d23156e80"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:648711bd-3656-428a-8be4-30bd7fbf908b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:8848d69d-773c-445c-a3da-da8fc5101d8d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats UMLS:C0678202 PMID:41385096 "[{""id"":""uuid:3668a6a3-8ee0-4e6a-a147-3b7d36c9126f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5527ace5-5aa1-4865-ad12-fd3792ec1ea2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:950e957f-733f-4171-9d38-fa8d62db3534 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0005301 PMID:41385096 "[{""id"":""uuid:9364e0ee-0b27-40c9-93ec-77c209a8b626"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4f183698-5176-4b04-b8d5-d58dd1edee48"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:de39a903-d569-473d-80c4-66e376b7394a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0006042 PMID:41385096 "[{""id"":""uuid:d85d1361-1de9-4971-ab1e-18e102c74d63"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d6f314e2-fab1-45e1-833a-38fdff64a5b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:336cac7b-7c9a-4090-aa77-411ea20df80e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0019444 PMID:41385096 "[{""id"":""uuid:fa1ded7c-fbed-43ad-b72f-12728a6af6e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f495dd01-7fdc-42ec-85de-60772167b9a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:579d6c8a-a9eb-421f-99c4-e588afbe62f5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17549 biolink:treats MONDO:0005173 PMID:41385096 "[{""id"":""uuid:536bcbd8-e333-47c6-9071-37ecf833e532"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:49019f8f-4365-49fb-bb31-b23945af9d0f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:0c225c80-d4fe-4c28-89d5-17bc5afc6fc8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/gliolan""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] The LEVULAN KERASTICK for Topical Solution plus blue light illumination using the BLU-U Blue Light Photodynamic Therapy Illuminator is indicated for the treatment of minimally to moderately thick actinic keratoses (Grade 1 or 2, see table 2 for definition) of the face or scalp.|[EMA] Treatment of actinic keratosis of mild to moderate severity on the face and scalp (Olsen grade 1 to 2; see section 5.1) and of field cancerization in adults.Treatment of superficial and/or nodular basal cell carcinoma unsuitable for surgical treatment due to possible treatment-related morbidity and/or poor cosmetic outcome in adults. uuid:ba7ce57d-a4d3-43ea-8b11-e7cda337533b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0000004 PMID:41385096 "[{""id"":""uuid:c1ac4b22-8c4d-4ddd-ac22-134afc8167b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5984abe3-9422-4d3f-be56-59cc97d4f39f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:b6ac85e0-6856-4176-b487-a228a8f906a4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0018479 PMID:41385096 "[{""id"":""uuid:5396e551-f0ce-43a0-bbb6-f095ccedcbd8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:65b6c7b4-8ab2-4a30-8e63-1d8af928994c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:8815d12b-eeb2-45d7-9678-0d3f79305cc2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0043455 PMID:41385096 "[{""id"":""uuid:02780768-001a-48b5-8e17-4a1047dc8294"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:646b9f52-485a-4403-bbae-28ace41c1313"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:6cd3d503-b5e9-4d6e-8d95-90a7923c9460 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0006982 PMID:41385096 "[{""id"":""uuid:956f5128-4530-42a5-9489-a5295952ed17"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a2b07d98-49f6-48e7-a840-55ba5ea3deec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:2ee2f6a3-fdd2-496c-86d3-5246496e4bdd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0011849 PMID:41385096 "[{""id"":""uuid:069894bf-e16a-4972-b900-9c28a19e8a7d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:04e69bb7-6c8b-4fa6-b0ef-45a3e1fab44a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:a17d9565-8936-40fd-8245-bc1476fa2eda biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:6ec2c359-4035-46d9-908f-33494586eb22"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dd73228d-e22f-4a6a-ab20-235923dd8258"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:c0cec414-f1f7-449d-9291-691c1d2ac4bb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0011429 PMID:41385096 "[{""id"":""uuid:04d368d7-c23c-4c4d-951a-0bf83daf0ee4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cf776c1a-63ad-4b9b-9dbb-29e0719707fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:da1d2c9f-6eb0-4b8d-b88f-9928ff22615b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0005306 PMID:41385096 "[{""id"":""uuid:b1cbbeee-6861-416e-b826-27bf0280e968"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6cb97cc9-962f-447d-be78-64b8740b9068"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:b350aa56-33e6-4d31-b168-cac15ef3a085 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats UMLS:C1290158 PMID:41385096 "[{""id"":""uuid:a6f71381-6e0f-4af4-94bc-0e972a8c0944"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5041a3e4-7d73-4038-9c6d-9456126ffefc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:d4e167ae-81fc-418a-851b-3c168481b27d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0040698 PMID:41385096 "[{""id"":""uuid:ad55cc3c-20b2-40e3-af0d-5aef33f8fc37"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:baf6a8ff-748d-4c30-a3f7-4fc331793b6a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:fff1b847-bf38-4dc6-a753-6266266855bc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0004855 PMID:41385096 "[{""id"":""uuid:b973ddcc-393a-4ec1-b004-e527ce5df83b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:449b58da-6068-4646-b708-704c38e1d24e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:be039142-6070-4555-916c-e214ffe3137c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats UMLS:C0149896 PMID:41385096 "[{""id"":""uuid:01a375f8-585e-4d5d-b90d-b9e4d4fae16f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8336865c-e8b9-4207-9a96-f7c6ecc89b75"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:bbd38989-221a-431a-99ca-7dcc8d4e1ab9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0005178 PMID:41385096 "[{""id"":""uuid:6a581413-1558-4158-b0b5-c69ef0a89110"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:730e3c62-cbc5-426c-bde2-58ba429b0c4f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:5922af23-c118-4a83-9926-ce1bef658e13 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0001875 PMID:41385096 "[{""id"":""uuid:b843421b-cdc8-44a6-8d33-d79d2604a76d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e72154ec-2612-4043-a583-d501f1fcb724"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:31c2be8d-7989-43c2-bbd9-059c6cf3f7ed biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0016367 PMID:41385096 "[{""id"":""uuid:5f89c331-ca40-4a1b-b2e5-4d502debf0fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d029fa76-9592-4716-87ce-893196440e7f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:1ef1b470-28f6-4ed2-88e4-5812a3c89523 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0019127 PMID:41385096 "[{""id"":""uuid:f358793f-10a4-4e28-a4a8-a4e67ebfa76c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:35e0b2e1-5370-4f97-8276-f8f8e4982963"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:66d680e6-f8a3-4fa0-812e-26381f91ca13 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats UMLS:C5441648 PMID:41385096 "[{""id"":""uuid:3cf73c17-87d3-4d14-8b30-1cf16b5f78a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3dc6f9e5-55b1-44b5-be94-256a0f070b95"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:37388b1c-4d26-4df4-bb13-e3e775dcdc95 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0006594 PMID:41385096 "[{""id"":""uuid:a2bf6834-0b27-4f1c-9c07-b2ede4b21189"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:63e38785-4700-4983-a86a-2a793042de68"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:95a5b0b7-e2df-4d46-96eb-1f836bd2fc0c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0015614 PMID:41385096 "[{""id"":""uuid:c0071db5-8ae0-4ba8-88da-ef61e5bb1758"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9ef858b5-1d65-416e-9b93-820950533bf4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:e3b7755e-a18f-4bb0-950b-daf6df4fb4bf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0006545 PMID:41385096 "[{""id"":""uuid:b89693f3-a6f7-4f83-8fe0-784f9b51028b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:85cb3db6-e548-415c-973f-fcb16b31b7fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:54408bdb-ac24-4610-be37-340c436b0b3d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0018229 PMID:41385096 "[{""id"":""uuid:ef8c6749-6e2b-484f-a01c-1dcacf51891f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:34e82f3b-1cbe-4f49-b518-a1276df928eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:9207a8f0-ce39-4c68-b210-6f4add30ff22 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0043233 PMID:41385096 "[{""id"":""uuid:6190713a-8332-4272-912e-b8496ae51608"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c6377502-8222-4e5a-b0bc-cb0b7720af3c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:75b99630-a19d-4d44-ada8-3b32d2c8cf78 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0009691 PMID:41385096 "[{""id"":""uuid:cada7d32-91b3-4aef-add4-546e4951719b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4b5ce6f6-e15a-4844-83a4-1da3d4ce06ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:4b6e4da5-f353-4d59-8506-dadaca29ce37 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0005083 PMID:41385096 "[{""id"":""uuid:b438e4b3-63a3-4521-b4a3-574ce3615853"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:02c7fc6a-6884-4703-9ff5-1264a3d338fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:b4020a1d-4bdc-4e1d-bbd8-704c659436d0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0006608 PMID:41385096 "[{""id"":""uuid:bc51a784-3b5d-4208-85d3-c57254263088"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5ffefccd-3f88-486b-af46-cac935f31a39"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:f041c92a-666a-4857-8adc-13d592e6a75a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0005324 PMID:41385096 "[{""id"":""uuid:260cada5-159d-4e26-af5d-4b75830cf072"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:45a6d8ec-89e1-4dfc-96e2-cef51c6b99b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:af65c41a-4dfa-4cb3-b4d4-8c8e37055e28 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0024332 PMID:41385096 "[{""id"":""uuid:b11395fb-cf9e-47f5-8f8b-2de645fde5b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8408eab8-6086-4a68-a173-a7a728488a67"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:1ebfc790-a7c5-4b1f-b655-1d595d8986d6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:98319117-50f3-4072-b440-da573e4d22f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8bec9ca0-45db-4bfb-9421-e4a14619da13"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:bcaaf038-0fe2-4d8e-9853-72671805ed27 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0005480 PMID:41385096 "[{""id"":""uuid:cda68946-623b-4058-a41d-18a84960af76"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:613d640b-7ea9-4f17-a1b1-b60cc7849410"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:d7598bfd-38c8-43d9-8f19-2a2b5af06c3d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:96dee122-5915-421c-8a58-3ed361d812e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0d96a925-9b5d-49e7-8896-26c174040839"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:afd5b153-5d63-482d-9187-8a56f5bc9acf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0043789 PMID:41385096 "[{""id"":""uuid:dfa0cac3-8c98-458c-bc89-3be0a9fac867"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7cf514de-16fb-4789-865e-135631c51af5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:f5663646-baac-4a98-8901-200b6374eba4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0000775 PMID:41385096 "[{""id"":""uuid:632dd7d3-9a34-4258-8357-4e2f887fc78a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:58188532-ee2c-4f2b-97e1-269ec52df3a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:5cf4307e-fce3-4ceb-8b96-1b77aaecd995 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0001034 PMID:41385096 "[{""id"":""uuid:a774bc53-d64c-44a5-b7a1-12e5f1041791"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7d1e4c57-142c-46b1-94cc-714f3ec56f02"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:ac045086-a148-4a7e-8152-95ea84635538 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0005883 PMID:41385096 "[{""id"":""uuid:9e655baa-edab-46a2-9b50-d1cdb9fcef32"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7c652ebe-8a42-44e8-a991-c1ae38fe3ede"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:bfe92e7b-54b5-4f52-8e2c-15806e1403a9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0006651 PMID:41385096 "[{""id"":""uuid:d2be6833-b6c9-408b-befa-ed013cb54a66"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bfb0f9f2-e437-443f-b84b-bf9fbd678709"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:ab72d36f-8d2f-4804-8d05-c07f88ddcab5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0006918 PMID:41385096 "[{""id"":""uuid:b5e657eb-c163-4c37-880d-f086e1f29d6e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8dd54966-9d96-48ad-8969-153f3884e7db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:e97f9376-bb4a-4fd0-8048-4ff813115b4c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0001280 PMID:41385096 "[{""id"":""uuid:2322ba63-77b7-4f0d-a538-0bcedc4e5658"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b3ad3f69-ab8f-497e-87e8-e3364b214577"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:32819238-854e-4661-8ccb-9c183c841b17 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0019198 PMID:41385096 "[{""id"":""uuid:67c86dff-c982-4524-8c45-24d8d3ec309a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a0c4d0b3-e992-48d8-ad8b-0d42ac0aac4c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:97902ad8-4233-4cca-bb06-cb28e9a6a4cd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0003085 PMID:41385096 "[{""id"":""uuid:2f094755-fa44-4434-8b21-dceee4df6cfe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:50a67985-f631-4844-b7e4-84c7bcd038f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:c64c70d7-c519-4c0a-8eb7-3c9f3a85fab2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0004674 PMID:41385096 "[{""id"":""uuid:4928259f-cb27-4e1d-b17a-f4e1e8870363"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:27a6cb0a-1533-4f78-a223-c5f3092fd691"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:aaf94b0a-3b19-4a9f-ab60-e59be90e3bd8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0005885 PMID:41385096 "[{""id"":""uuid:28a26e6a-7d7a-4f71-b23c-b363eee25389"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:78858d66-6517-4c9f-9bb3-ee0bba35b84d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:0c71a038-6f95-44b9-ba4f-9fa7298c6932 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0006814 PMID:41385096 "[{""id"":""uuid:ec8cd236-15d3-4704-a8b6-af351d911441"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cf9e2901-59a3-4019-b304-8febf2da2f92"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:e038c066-f066-46a6-8b45-7bfff58bee23 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0004773 PMID:41385096 "[{""id"":""uuid:36bda08d-cc82-44d0-b393-7015443acfcf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:863fe1f7-7d5a-494c-86e9-15bf77316963"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:74161069-6393-450f-83d5-72348a6a9d3c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0019338 PMID:41385096 "[{""id"":""uuid:165526ba-0744-451f-a751-5756f789f97e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:72894338-47ea-4693-be5f-2a90b4719c52"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:22587422-6bd7-4075-9486-1a88b622be3e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0015274 PMID:41385096 "[{""id"":""uuid:fae8504b-233e-4d85-9fc0-f458299ffd23"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7c7bda49-152f-4be0-ba0c-2a3ef2a4d6bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:5ae72ebf-8939-4cd1-987b-d645806f9a02 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0006052 PMID:41385096 "[{""id"":""uuid:98781952-282f-4fb3-9b12-afa55f007421"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b52d6a4d-0569-45d4-be58-75c0b95368bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:f3ccd56d-f176-4af1-b34d-8edad408dae6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0005848 PMID:41385096 "[{""id"":""uuid:72ec61d7-45a1-42e8-a8ee-5df221392676"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f16bdf94-eeca-4afe-af82-6af632a8fd4f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:430714d6-53ba-4e09-8bc4-6822da8aa47b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0002572 PMID:41385096 "[{""id"":""uuid:23d4ec85-bea0-4213-a02b-31fa613bc1f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7f0c44d4-65c9-4e7b-8464-bff0f75460cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:050f9fe6-aa39-4295-a912-08fd5c3e5681 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0019098 PMID:41385096 "[{""id"":""uuid:6b97b2a6-9d95-4739-af26-84eeca4bf67a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6acf8aee-6000-4464-b020-489ddd363567"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:35e321cc-b92b-4307-9ec3-5f4013df06f9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0001198 PMID:41385096 "[{""id"":""uuid:a499e7dc-4687-4994-88cb-e0ed7cf07f1f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:81b01018-b53c-400d-b518-d3624a8d7162"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:5025bab8-b5d9-4c40-b5b9-6ff2bc7ece95 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats UMLS:C0002879 PMID:41385096 "[{""id"":""uuid:fa6d4ff5-4823-496b-889b-b068ac3502c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9be67d41-dc2a-40c5-8990-d1f1ded4d869"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:d71d4697-485d-4ed1-bf39-28b580c8101e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0020108 PMID:41385096 "[{""id"":""uuid:483d067d-29f0-441f-9fb3-f2f0201df4c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5c666f10-7013-4912-b72b-9c8e8b5adb24"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:a6454cd5-1b79-4b24-a69c-ab70d9dafa31 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0002280 PMID:41385096 "[{""id"":""uuid:083c6b99-52f6-4f36-9173-5946380d82c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2f356a6b-d07c-4466-ac97-d58584597d06"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:66bcadef-f567-4e45-b689-284024fe6c44 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0015253 PMID:41385096 "[{""id"":""uuid:ab6fbdef-d73c-489c-b1ab-93b87815d107"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:93ed61be-022b-4900-a5e5-a62565085a1b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:92862249-5c34-41c5-bdd2-1558dfc80e6f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats HP:0001908 PMID:41385096 "[{""id"":""uuid:1de5342a-e0e0-4964-9474-e44ce32dcf86"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4a68976d-d847-49d2-a154-40d18a42adfb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:b0f358fc-1231-4436-b914-dafbf9137276 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0005059 PMID:41385096 "[{""id"":""uuid:2e06ed06-2031-40bd-a246-2485dfe1691a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3b6aa797-848c-4a2d-9ac0-b289437d51de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:dd6b49a2-1281-4cc4-8ba0-0fd748cac9ca biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0004095 PMID:41385096 "[{""id"":""uuid:7ac05981-6f7e-491a-8b2e-86df6e3b299e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:29381401-4770-494b-84cc-1d53b82c6104"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:4b0d37b1-88e0-4432-adf6-6f17ae80e9d9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0004355 PMID:41385096 "[{""id"":""uuid:294cd9c6-5dfa-4b72-a9d9-afd1ddb8085b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:43132c4e-b98d-48e9-888e-bb97cff89a87"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:f4fa9e74-40d5-4af7-a734-082ba01e0b53 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0005377 PMID:41385096 "[{""id"":""uuid:d4b3a1fd-f0d5-4538-ae7e-cd18829b30c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0f3721b3-2a56-4dfe-9ac4-ac00a481be02"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:c7941ae3-49ef-405d-a7c8-d01dad2ce094 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0005101 PMID:41385096 "[{""id"":""uuid:b28098f6-1113-4275-9d8d-b60b4c57d46f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6e0a7a31-c9ac-4a42-870f-37b61f4e85c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:c24dbdfd-2713-43c0-ba63-fd761bf22bdc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats UMLS:C0678202 PMID:41385096 "[{""id"":""uuid:dab422db-a308-4240-b2e7-a2fb46cd253d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:68d0b70c-cadf-4a0c-9cc9-8760159415f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:cc7fd516-7dc3-49d3-8b29-2b01b19f8b55 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0005301 PMID:41385096 "[{""id"":""uuid:8bb21f9d-056a-43fe-951e-41193efa81e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:330fd32e-2b06-4322-8723-aedb92aa6f59"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:1f6f7b42-d890-4c42-8d0a-9321f5252855 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0006042 PMID:41385096 "[{""id"":""uuid:49b3408d-8991-4802-a16e-85ace791efeb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6db1d76f-58b0-4960-bfe7-522ffc0b597b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:4edda3e3-4d32-49e8-9f1b-91ddd3c0af7d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0019444 PMID:41385096 "[{""id"":""uuid:f7d6ee43-8a5a-4c7c-a778-f69836c6ec18"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2001e82c-9477-40ad-8abc-e7b1f23ac97d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:d4226c2c-9f21-4cf7-897e-1d5c77ef75cc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41774 biolink:treats UMLS:C0278488 PMID:41385096 "[{""id"":""uuid:1c83e739-9c68-4a5f-810d-c9446bcc4e3d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5f7af6ac-5701-4d1e-aa0c-a9e59e667b77"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Metastatic Breast Cancer: Tamoxifen citrate tablets are effective in the treatment of metastatic breast cancer in women and men. In premenopausal women with metastatic breast cancer, tamoxifen is an alternative to oophorectomy or ovarian irradiation. Available evidence indicates that patients whose tumors are estrogen receptor positive are more likely to benefit from tamoxifen therapy. uuid:55f77e98-57ee-4522-8041-fa7506612ed8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47426 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:85edeecf-eab4-4288-8bd2-0ed3397713e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ba356212-bae4-48e9-ad11-6dcbbd722819"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Furosemide is indicated in adults and pediatric patients for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. Furosemide is particularly useful when an agent with greater diuretic potential is desired. uuid:c6eccf19-6846-40ff-8a97-bacf43e4e03a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47426 biolink:treats MONDO:0005155 PMID:41385096 "[{""id"":""uuid:93449a50-1eb3-49a7-9d69-353f16348a27"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e7c9834c-7d00-41e8-9d25-257b4a637841"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Furosemide is indicated in adults and pediatric patients for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. Furosemide is particularly useful when an agent with greater diuretic potential is desired. uuid:8ad93628-df9d-42cf-9621-783ada8f57d6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47426 biolink:treats MONDO:0005240 PMID:41385096 "[{""id"":""uuid:b93347f5-3297-4475-a3a0-9c21e8413283"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2cd5c5c9-9a58-4b29-90f6-abfc5fc29f5e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Furosemide is indicated in adults and pediatric patients for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. Furosemide is particularly useful when an agent with greater diuretic potential is desired. uuid:01a3b7c5-a7f5-4d21-810d-b11a9c7b85e7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47426 biolink:treats MONDO:0005377 PMID:41385096 "[{""id"":""uuid:e21f9c9c-a178-480e-82ba-20949ba78535"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:877e770b-a570-40dc-969d-ead016714298"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Furosemide is indicated in adults and pediatric patients for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. Furosemide is particularly useful when an agent with greater diuretic potential is desired. uuid:5160a7dd-aebc-4d48-9087-b694cae63d38 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17750 biolink:treats MONDO:0004737 PMID:41385096 "[{""id"":""uuid:5b3d3ee6-1a34-43a2-8322-389a4c1a59fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1b7933f4-1b3e-48f6-8da5-fa344656fc8d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:4a21f5b1-e7e1-4288-86b5-1d7df46d9207"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:6e23cafe-dc11-422c-bdb5-975656987e55"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cystadane (betaine anhydrous for oral solution) is indicated for the treatment of homocystinuria to decrease elevated homocysteine blood levels. Included within the category of homocystinuria are deficiencies or defects in: cystathionine beta-synthase (CBS), 5,10-methylenetetrahydrofolate reductase (MTHFR), cobalamin cofactor metabolism ( cbl ). Patient response to Cystadane can be monitored by homocysteine plasma levels (see DOSAGE AND ADMINISTRATION ). Response usually occurs within a week and steady state within a month. Cystadane has been administered concomitantly with vitamin B 6 (pyridoxine), vitamin B 12 (cobalamin), and folate.|[EMA] Amversio is indicated as adjunctive treatment of homocystinuria, involving deficiencies or defects in:• cystathionine beta-synthase (CBS),• 5,10 methylene tetrahydrofolate reductase (MTHFR),• cobalamin cofactor metabolism (cbl).|[PMDA] A drug with a new active ingredient indicated for the treatment of homocystinuria. [Orphan drug] uuid:b098397c-42e3-4b20-8c7c-c99900252285 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17750 biolink:treats MONDO:0009352 PMID:41385096 "[{""id"":""uuid:2bee2610-0979-4694-864f-78e9c75bf248"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a68f9b3c-98d8-46fb-8baa-1f6577589881"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cystadane (betaine anhydrous for oral solution) is indicated for the treatment of homocystinuria to decrease elevated homocysteine blood levels. Included within the category of homocystinuria are deficiencies or defects in: cystathionine beta-synthase (CBS), 5,10-methylenetetrahydrofolate reductase (MTHFR), cobalamin cofactor metabolism ( cbl ). Patient response to Cystadane can be monitored by homocysteine plasma levels (see DOSAGE AND ADMINISTRATION ). Response usually occurs within a week and steady state within a month. Cystadane has been administered concomitantly with vitamin B 6 (pyridoxine), vitamin B 12 (cobalamin), and folate. uuid:69aa658a-6916-440d-bfae-ea6ec89700aa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17750 biolink:treats MONDO:0009353 PMID:41385096 "[{""id"":""uuid:4f45b549-4682-4806-80a7-743c0adfd441"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3df58c60-c50e-434d-b057-f53bdbaa3ed7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cystadane (betaine anhydrous for oral solution) is indicated for the treatment of homocystinuria to decrease elevated homocysteine blood levels. Included within the category of homocystinuria are deficiencies or defects in: cystathionine beta-synthase (CBS), 5,10-methylenetetrahydrofolate reductase (MTHFR), cobalamin cofactor metabolism ( cbl ). Patient response to Cystadane can be monitored by homocysteine plasma levels (see DOSAGE AND ADMINISTRATION ). Response usually occurs within a week and steady state within a month. Cystadane has been administered concomitantly with vitamin B 6 (pyridoxine), vitamin B 12 (cobalamin), and folate. uuid:fb7e9de7-2951-4ef6-86a2-570bbbf9c10f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17750 biolink:treats MONDO:0019220 PMID:41385096 "[{""id"":""uuid:5396c76a-b2b2-4ba6-b9cf-5b35213ded7c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8fafa5f3-7926-4d3b-ab26-1af18a0211fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cystadane (betaine anhydrous for oral solution) is indicated for the treatment of homocystinuria to decrease elevated homocysteine blood levels. Included within the category of homocystinuria are deficiencies or defects in: cystathionine beta-synthase (CBS), 5,10-methylenetetrahydrofolate reductase (MTHFR), cobalamin cofactor metabolism ( cbl ). Patient response to Cystadane can be monitored by homocysteine plasma levels (see DOSAGE AND ADMINISTRATION ). Response usually occurs within a week and steady state within a month. Cystadane has been administered concomitantly with vitamin B 6 (pyridoxine), vitamin B 12 (cobalamin), and folate. uuid:8d917f70-ca15-4d3a-ad95-888de148ec97 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:204734 biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:404b20ee-4f53-4c05-9c3e-6693881c84d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e840e18d-39bb-4b91-a968-a1451b90fc78"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Desonate Gel is indicated for the treatment of mild to moderate atopic dermatitis in patients 3 months of age and older. Patients should be instructed to use Desonate Gel for the minimum amount of time as necessary to achieve the desired results because of the potential for Desonate Gel to suppress the hypothalamic-pituitary-adrenal (HPA) axis (see PRECAUTIONS ). Treatment should not exceed 4 consecutive weeks. uuid:5de24ae9-57b7-45cc-a544-311262e6b82a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:607 biolink:treats MONDO:0005302 PMID:41385096 "[{""id"":""uuid:9684fb73-c52e-4a86-b112-11919d4313a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f9d9aa71-1581-4e55-877e-5554e9f6dac7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, and amphetamine sulfate tablets are indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and Narcolepsy. MESH:C090411 uuid:cbf1e60a-f2d1-4729-8339-9e23488e4449 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:607 biolink:treats MONDO:0021107 PMID:41385096 "[{""id"":""uuid:1954b8e1-c6cd-4c29-b574-fcbae8088db3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ee733f64-a05b-43a1-bf0b-c7b636a20018"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, and amphetamine sulfate tablets are indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and Narcolepsy. MESH:C090411 uuid:ffa193a5-9828-4054-804c-e754d03ae3d5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7820 biolink:treats MONDO:0005298 PMID:41385096 "[{""id"":""uuid:23026778-7554-46f5-a4b9-ba461e0d3e49"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a4f8d6fd-05e0-4928-902e-ba3d5037f120"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxandrin is indicated as adjunctive therapy to promote weight gain after weight loss following extensive surgery, chronic infections, or severe trauma, and in some patients who without definite pathophysiologic reasons fail to gain or to maintain normal weight, to offset the protein catabolism associated with prolonged administration of corticosteroids, and for the relief of the bone pain frequently accompanying osteoporosis (See DOSAGE AND ADMINISTRATION ). uuid:f355e237-b6bc-4701-bab4-fff00e475053 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8232 biolink:treats UMLS:C1112209 PMID:41385096 "[{""id"":""uuid:2089931f-9a1d-45af-adbd-1bdc97952303"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cb668ea5-0a62-42ac-b494-be48ae93c01a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapeutic: PIPRACIL is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below: Intra-Abdominal Infections including hepatobiliary and surgical infections caused by E. coli , Pseudomonas aeruginosa , enterococci, Clostridium spp., anaerobic cocci, or Bacteroides spp., including B. fragilis. Urinary Tract Infections caused by E. coli , Klebsiella spp., P. aeruginosa , Proteus spp., including P. mirabilis , or enterococci. Gynecologic Infections including endometritis, pelvic inflammatory disease, pelvic cellulitis caused by Bacteroides spp., including B. fragilis , anaerobic cocci, Neisseria gonorrhoeae , or enterococci ( E. faecalis ). Septicemia including bacteremia caused by E. coli , Klebsiella spp., Enterobacter spp., Serratia spp., P. mirabilis , S. pneumoniae , enterococci, P. aeruginosa , Bacteroides spp., or anaerobic cocci. Lower RespiratoryTract Infections caused by E. coli , Klebsiella spp., Enterobacter spp., P . aeruginosa , Serratia spp., H. influenzae , Bacteroides spp., or anaerobic cocci. Although improvement has been noted in patients with cystic fibrosis, lasting bacterial eradication may not necessarily be achieved. Skin and Skin Structure Infections caused by E. coli , Klebsiella spp., Serratia spp., Acinetobacter spp., Enterobacter spp., P. aeruginosa , Morganella morganii , Providencia rettgeri , Proteus vulgaris , P. mirabilis , Bacteroides spp., including B. fragilis , anaerobic cocci, or enterococci. Bone and Joint Infections caused by P. aeruginosa , enterococci, Bacteroides spp., or anaerobic cocci. Uncomplicated Gonococcal Urethritis caused by N. gonorrhoeae. PIPRACIL has also been shown to be clinically effective for the treatment of infections at various sites caused by Streptococcus species including S. pyogenes and S. pneumoniae ; however, infections caused by these organisms are ordinarily treated with more narrow spectrum penicillins. Because of its broad spectrum of bactericidal activity against gram-positive and gram-negative aerobic and anaerobic bacteria, PIPRACIL is particularly useful for the treatment of mixed infections and presumptive therapy prior to the identification of the causative organisms. Also, PIPRACIL may be administered as single drug therapy in some situations where normally two antibiotics might be employed. Piperacillin has been successfully used with aminoglycosides, especially in patients with impaired host defenses. Both drugs should be used in full therapeutic doses. Appropriate cultures should be made for susceptibility testing before initiating therapy and therapy adjusted, if appropriate, once the results are known. Prophylaxis: PIPRACIL is indicated for prophylactic use in surgery including intra-abdominal (gastrointestinal and biliary) procedures, vaginal hysterectomy, abdominal hysterectomy, and cesarean section. Effective prophylactic use depends on the time of administration; PIPRACIL should be given one-half to one hour before the operation so that effective levels can be achieved in the site prior to the procedure. The prophylactic use of piperacillin should be stopped within 24 hours, since continuing administration of any antibiotic increases the possibility of adverse reactions, but in the majority of surgical procedures, does not reduce the incidence of subsequent infections. If there are signs of infection, specimens for culture and susceptibility testing should be obtained for identification of the causative microorganism so that appropriate therapy can be instituted. To reduce the development of drug-resistant bacteria and maintain the effectiveness of PIPRACIL and other antibacterial drugs, PIPRACILshould only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:b4c44c39-9440-46eb-8f19-24125f0ba66f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8232 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:9e445d8a-7d22-48b6-bc3c-cb3019115462"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e979d10f-dc5c-4df3-90c7-e6973e248377"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapeutic: PIPRACIL is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below: Intra-Abdominal Infections including hepatobiliary and surgical infections caused by E. coli , Pseudomonas aeruginosa , enterococci, Clostridium spp., anaerobic cocci, or Bacteroides spp., including B. fragilis. Urinary Tract Infections caused by E. coli , Klebsiella spp., P. aeruginosa , Proteus spp., including P. mirabilis , or enterococci. Gynecologic Infections including endometritis, pelvic inflammatory disease, pelvic cellulitis caused by Bacteroides spp., including B. fragilis , anaerobic cocci, Neisseria gonorrhoeae , or enterococci ( E. faecalis ). Septicemia including bacteremia caused by E. coli , Klebsiella spp., Enterobacter spp., Serratia spp., P. mirabilis , S. pneumoniae , enterococci, P. aeruginosa , Bacteroides spp., or anaerobic cocci. Lower RespiratoryTract Infections caused by E. coli , Klebsiella spp., Enterobacter spp., P . aeruginosa , Serratia spp., H. influenzae , Bacteroides spp., or anaerobic cocci. Although improvement has been noted in patients with cystic fibrosis, lasting bacterial eradication may not necessarily be achieved. Skin and Skin Structure Infections caused by E. coli , Klebsiella spp., Serratia spp., Acinetobacter spp., Enterobacter spp., P. aeruginosa , Morganella morganii , Providencia rettgeri , Proteus vulgaris , P. mirabilis , Bacteroides spp., including B. fragilis , anaerobic cocci, or enterococci. Bone and Joint Infections caused by P. aeruginosa , enterococci, Bacteroides spp., or anaerobic cocci. Uncomplicated Gonococcal Urethritis caused by N. gonorrhoeae. PIPRACIL has also been shown to be clinically effective for the treatment of infections at various sites caused by Streptococcus species including S. pyogenes and S. pneumoniae ; however, infections caused by these organisms are ordinarily treated with more narrow spectrum penicillins. Because of its broad spectrum of bactericidal activity against gram-positive and gram-negative aerobic and anaerobic bacteria, PIPRACIL is particularly useful for the treatment of mixed infections and presumptive therapy prior to the identification of the causative organisms. Also, PIPRACIL may be administered as single drug therapy in some situations where normally two antibiotics might be employed. Piperacillin has been successfully used with aminoglycosides, especially in patients with impaired host defenses. Both drugs should be used in full therapeutic doses. Appropriate cultures should be made for susceptibility testing before initiating therapy and therapy adjusted, if appropriate, once the results are known. Prophylaxis: PIPRACIL is indicated for prophylactic use in surgery including intra-abdominal (gastrointestinal and biliary) procedures, vaginal hysterectomy, abdominal hysterectomy, and cesarean section. Effective prophylactic use depends on the time of administration; PIPRACIL should be given one-half to one hour before the operation so that effective levels can be achieved in the site prior to the procedure. The prophylactic use of piperacillin should be stopped within 24 hours, since continuing administration of any antibiotic increases the possibility of adverse reactions, but in the majority of surgical procedures, does not reduce the incidence of subsequent infections. If there are signs of infection, specimens for culture and susceptibility testing should be obtained for identification of the causative microorganism so that appropriate therapy can be instituted. To reduce the development of drug-resistant bacteria and maintain the effectiveness of PIPRACIL and other antibacterial drugs, PIPRACILshould only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:9b5c825e-a482-488e-9de7-39d2c85ae8d5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8232 biolink:treats MONDO:0000918 PMID:41385096 "[{""id"":""uuid:ff60663d-ed21-4154-8d78-e35b7d9f769f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:722d9d7f-ea61-4d79-8e5a-50101ce4a9fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapeutic: PIPRACIL is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below: Intra-Abdominal Infections including hepatobiliary and surgical infections caused by E. coli , Pseudomonas aeruginosa , enterococci, Clostridium spp., anaerobic cocci, or Bacteroides spp., including B. fragilis. Urinary Tract Infections caused by E. coli , Klebsiella spp., P. aeruginosa , Proteus spp., including P. mirabilis , or enterococci. Gynecologic Infections including endometritis, pelvic inflammatory disease, pelvic cellulitis caused by Bacteroides spp., including B. fragilis , anaerobic cocci, Neisseria gonorrhoeae , or enterococci ( E. faecalis ). Septicemia including bacteremia caused by E. coli , Klebsiella spp., Enterobacter spp., Serratia spp., P. mirabilis , S. pneumoniae , enterococci, P. aeruginosa , Bacteroides spp., or anaerobic cocci. Lower RespiratoryTract Infections caused by E. coli , Klebsiella spp., Enterobacter spp., P . aeruginosa , Serratia spp., H. influenzae , Bacteroides spp., or anaerobic cocci. Although improvement has been noted in patients with cystic fibrosis, lasting bacterial eradication may not necessarily be achieved. Skin and Skin Structure Infections caused by E. coli , Klebsiella spp., Serratia spp., Acinetobacter spp., Enterobacter spp., P. aeruginosa , Morganella morganii , Providencia rettgeri , Proteus vulgaris , P. mirabilis , Bacteroides spp., including B. fragilis , anaerobic cocci, or enterococci. Bone and Joint Infections caused by P. aeruginosa , enterococci, Bacteroides spp., or anaerobic cocci. Uncomplicated Gonococcal Urethritis caused by N. gonorrhoeae. PIPRACIL has also been shown to be clinically effective for the treatment of infections at various sites caused by Streptococcus species including S. pyogenes and S. pneumoniae ; however, infections caused by these organisms are ordinarily treated with more narrow spectrum penicillins. Because of its broad spectrum of bactericidal activity against gram-positive and gram-negative aerobic and anaerobic bacteria, PIPRACIL is particularly useful for the treatment of mixed infections and presumptive therapy prior to the identification of the causative organisms. Also, PIPRACIL may be administered as single drug therapy in some situations where normally two antibiotics might be employed. Piperacillin has been successfully used with aminoglycosides, especially in patients with impaired host defenses. Both drugs should be used in full therapeutic doses. Appropriate cultures should be made for susceptibility testing before initiating therapy and therapy adjusted, if appropriate, once the results are known. Prophylaxis: PIPRACIL is indicated for prophylactic use in surgery including intra-abdominal (gastrointestinal and biliary) procedures, vaginal hysterectomy, abdominal hysterectomy, and cesarean section. Effective prophylactic use depends on the time of administration; PIPRACIL should be given one-half to one hour before the operation so that effective levels can be achieved in the site prior to the procedure. The prophylactic use of piperacillin should be stopped within 24 hours, since continuing administration of any antibiotic increases the possibility of adverse reactions, but in the majority of surgical procedures, does not reduce the incidence of subsequent infections. If there are signs of infection, specimens for culture and susceptibility testing should be obtained for identification of the causative microorganism so that appropriate therapy can be instituted. To reduce the development of drug-resistant bacteria and maintain the effectiveness of PIPRACIL and other antibacterial drugs, PIPRACILshould only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:e353222d-69ad-4140-8f33-61ca33959e18 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8232 biolink:treats MONDO:0000922 PMID:41385096 "[{""id"":""uuid:db78086c-1970-4610-bbb1-38baeea2f638"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cea6ada8-058d-4ffe-bad3-208a3c302454"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapeutic: PIPRACIL is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below: Intra-Abdominal Infections including hepatobiliary and surgical infections caused by E. coli , Pseudomonas aeruginosa , enterococci, Clostridium spp., anaerobic cocci, or Bacteroides spp., including B. fragilis. Urinary Tract Infections caused by E. coli , Klebsiella spp., P. aeruginosa , Proteus spp., including P. mirabilis , or enterococci. Gynecologic Infections including endometritis, pelvic inflammatory disease, pelvic cellulitis caused by Bacteroides spp., including B. fragilis , anaerobic cocci, Neisseria gonorrhoeae , or enterococci ( E. faecalis ). Septicemia including bacteremia caused by E. coli , Klebsiella spp., Enterobacter spp., Serratia spp., P. mirabilis , S. pneumoniae , enterococci, P. aeruginosa , Bacteroides spp., or anaerobic cocci. Lower RespiratoryTract Infections caused by E. coli , Klebsiella spp., Enterobacter spp., P . aeruginosa , Serratia spp., H. influenzae , Bacteroides spp., or anaerobic cocci. Although improvement has been noted in patients with cystic fibrosis, lasting bacterial eradication may not necessarily be achieved. Skin and Skin Structure Infections caused by E. coli , Klebsiella spp., Serratia spp., Acinetobacter spp., Enterobacter spp., P. aeruginosa , Morganella morganii , Providencia rettgeri , Proteus vulgaris , P. mirabilis , Bacteroides spp., including B. fragilis , anaerobic cocci, or enterococci. Bone and Joint Infections caused by P. aeruginosa , enterococci, Bacteroides spp., or anaerobic cocci. Uncomplicated Gonococcal Urethritis caused by N. gonorrhoeae. PIPRACIL has also been shown to be clinically effective for the treatment of infections at various sites caused by Streptococcus species including S. pyogenes and S. pneumoniae ; however, infections caused by these organisms are ordinarily treated with more narrow spectrum penicillins. Because of its broad spectrum of bactericidal activity against gram-positive and gram-negative aerobic and anaerobic bacteria, PIPRACIL is particularly useful for the treatment of mixed infections and presumptive therapy prior to the identification of the causative organisms. Also, PIPRACIL may be administered as single drug therapy in some situations where normally two antibiotics might be employed. Piperacillin has been successfully used with aminoglycosides, especially in patients with impaired host defenses. Both drugs should be used in full therapeutic doses. Appropriate cultures should be made for susceptibility testing before initiating therapy and therapy adjusted, if appropriate, once the results are known. Prophylaxis: PIPRACIL is indicated for prophylactic use in surgery including intra-abdominal (gastrointestinal and biliary) procedures, vaginal hysterectomy, abdominal hysterectomy, and cesarean section. Effective prophylactic use depends on the time of administration; PIPRACIL should be given one-half to one hour before the operation so that effective levels can be achieved in the site prior to the procedure. The prophylactic use of piperacillin should be stopped within 24 hours, since continuing administration of any antibiotic increases the possibility of adverse reactions, but in the majority of surgical procedures, does not reduce the incidence of subsequent infections. If there are signs of infection, specimens for culture and susceptibility testing should be obtained for identification of the causative microorganism so that appropriate therapy can be instituted. To reduce the development of drug-resistant bacteria and maintain the effectiveness of PIPRACIL and other antibacterial drugs, PIPRACILshould only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:cad827a0-c06e-4546-bf4d-c1fa1337f1d0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8232 biolink:treats MONDO:0006887 PMID:41385096 "[{""id"":""uuid:949b004b-02d9-43ce-b89e-51a1e7a17aa4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4173bf38-041f-4dcc-bab9-0b976c5e3afa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:5215d4d5-4564-42e4-ad0c-6af9b5e6322d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapeutic: PIPRACIL is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below: Intra-Abdominal Infections including hepatobiliary and surgical infections caused by E. coli , Pseudomonas aeruginosa , enterococci, Clostridium spp., anaerobic cocci, or Bacteroides spp., including B. fragilis. Urinary Tract Infections caused by E. coli , Klebsiella spp., P. aeruginosa , Proteus spp., including P. mirabilis , or enterococci. Gynecologic Infections including endometritis, pelvic inflammatory disease, pelvic cellulitis caused by Bacteroides spp., including B. fragilis , anaerobic cocci, Neisseria gonorrhoeae , or enterococci ( E. faecalis ). Septicemia including bacteremia caused by E. coli , Klebsiella spp., Enterobacter spp., Serratia spp., P. mirabilis , S. pneumoniae , enterococci, P. aeruginosa , Bacteroides spp., or anaerobic cocci. Lower RespiratoryTract Infections caused by E. coli , Klebsiella spp., Enterobacter spp., P . aeruginosa , Serratia spp., H. influenzae , Bacteroides spp., or anaerobic cocci. Although improvement has been noted in patients with cystic fibrosis, lasting bacterial eradication may not necessarily be achieved. Skin and Skin Structure Infections caused by E. coli , Klebsiella spp., Serratia spp., Acinetobacter spp., Enterobacter spp., P. aeruginosa , Morganella morganii , Providencia rettgeri , Proteus vulgaris , P. mirabilis , Bacteroides spp., including B. fragilis , anaerobic cocci, or enterococci. Bone and Joint Infections caused by P. aeruginosa , enterococci, Bacteroides spp., or anaerobic cocci. Uncomplicated Gonococcal Urethritis caused by N. gonorrhoeae. PIPRACIL has also been shown to be clinically effective for the treatment of infections at various sites caused by Streptococcus species including S. pyogenes and S. pneumoniae ; however, infections caused by these organisms are ordinarily treated with more narrow spectrum penicillins. Because of its broad spectrum of bactericidal activity against gram-positive and gram-negative aerobic and anaerobic bacteria, PIPRACIL is particularly useful for the treatment of mixed infections and presumptive therapy prior to the identification of the causative organisms. Also, PIPRACIL may be administered as single drug therapy in some situations where normally two antibiotics might be employed. Piperacillin has been successfully used with aminoglycosides, especially in patients with impaired host defenses. Both drugs should be used in full therapeutic doses. Appropriate cultures should be made for susceptibility testing before initiating therapy and therapy adjusted, if appropriate, once the results are known. Prophylaxis: PIPRACIL is indicated for prophylactic use in surgery including intra-abdominal (gastrointestinal and biliary) procedures, vaginal hysterectomy, abdominal hysterectomy, and cesarean section. Effective prophylactic use depends on the time of administration; PIPRACIL should be given one-half to one hour before the operation so that effective levels can be achieved in the site prior to the procedure. The prophylactic use of piperacillin should be stopped within 24 hours, since continuing administration of any antibiotic increases the possibility of adverse reactions, but in the majority of surgical procedures, does not reduce the incidence of subsequent infections. If there are signs of infection, specimens for culture and susceptibility testing should be obtained for identification of the causative microorganism so that appropriate therapy can be instituted. To reduce the development of drug-resistant bacteria and maintain the effectiveness of PIPRACIL and other antibacterial drugs, PIPRACILshould only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.|[PMDA] Drugs with a new dosage indicated for the treatment of sepsis, acute bronchitis, pneumonia, lung abscess, thoracic empyema, secondary infection of chronic respiratory disease, cystitis, pyelonephritis, cholecystitis, choledochitis, bartholinitis, intrauterine infection, uterine adnexitis, parametritis, and purulent meningitis. uuid:4009aee7-bfe3-4422-95fe-773e9c87206a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8232 biolink:treats MONDO:0700217 PMID:41385096 "[{""id"":""uuid:3aff4eea-2e7b-4922-a121-2067012c0327"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e45a5ec4-e03a-4682-b0b0-f1623bc899f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapeutic: PIPRACIL is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below: Intra-Abdominal Infections including hepatobiliary and surgical infections caused by E. coli , Pseudomonas aeruginosa , enterococci, Clostridium spp., anaerobic cocci, or Bacteroides spp., including B. fragilis. Urinary Tract Infections caused by E. coli , Klebsiella spp., P. aeruginosa , Proteus spp., including P. mirabilis , or enterococci. Gynecologic Infections including endometritis, pelvic inflammatory disease, pelvic cellulitis caused by Bacteroides spp., including B. fragilis , anaerobic cocci, Neisseria gonorrhoeae , or enterococci ( E. faecalis ). Septicemia including bacteremia caused by E. coli , Klebsiella spp., Enterobacter spp., Serratia spp., P. mirabilis , S. pneumoniae , enterococci, P. aeruginosa , Bacteroides spp., or anaerobic cocci. Lower RespiratoryTract Infections caused by E. coli , Klebsiella spp., Enterobacter spp., P . aeruginosa , Serratia spp., H. influenzae , Bacteroides spp., or anaerobic cocci. Although improvement has been noted in patients with cystic fibrosis, lasting bacterial eradication may not necessarily be achieved. Skin and Skin Structure Infections caused by E. coli , Klebsiella spp., Serratia spp., Acinetobacter spp., Enterobacter spp., P. aeruginosa , Morganella morganii , Providencia rettgeri , Proteus vulgaris , P. mirabilis , Bacteroides spp., including B. fragilis , anaerobic cocci, or enterococci. Bone and Joint Infections caused by P. aeruginosa , enterococci, Bacteroides spp., or anaerobic cocci. Uncomplicated Gonococcal Urethritis caused by N. gonorrhoeae. PIPRACIL has also been shown to be clinically effective for the treatment of infections at various sites caused by Streptococcus species including S. pyogenes and S. pneumoniae ; however, infections caused by these organisms are ordinarily treated with more narrow spectrum penicillins. Because of its broad spectrum of bactericidal activity against gram-positive and gram-negative aerobic and anaerobic bacteria, PIPRACIL is particularly useful for the treatment of mixed infections and presumptive therapy prior to the identification of the causative organisms. Also, PIPRACIL may be administered as single drug therapy in some situations where normally two antibiotics might be employed. Piperacillin has been successfully used with aminoglycosides, especially in patients with impaired host defenses. Both drugs should be used in full therapeutic doses. Appropriate cultures should be made for susceptibility testing before initiating therapy and therapy adjusted, if appropriate, once the results are known. Prophylaxis: PIPRACIL is indicated for prophylactic use in surgery including intra-abdominal (gastrointestinal and biliary) procedures, vaginal hysterectomy, abdominal hysterectomy, and cesarean section. Effective prophylactic use depends on the time of administration; PIPRACIL should be given one-half to one hour before the operation so that effective levels can be achieved in the site prior to the procedure. The prophylactic use of piperacillin should be stopped within 24 hours, since continuing administration of any antibiotic increases the possibility of adverse reactions, but in the majority of surgical procedures, does not reduce the incidence of subsequent infections. If there are signs of infection, specimens for culture and susceptibility testing should be obtained for identification of the causative microorganism so that appropriate therapy can be instituted. To reduce the development of drug-resistant bacteria and maintain the effectiveness of PIPRACIL and other antibacterial drugs, PIPRACILshould only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:38e2b8aa-0891-48ac-b09e-58bbca7747b1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8232 biolink:treats MONDO:0005229 PMID:41385096 "[{""id"":""uuid:66c94282-93c4-489c-80eb-3922a225c4cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:edbd14db-635f-4dd8-873d-2fe129554e75"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapeutic: PIPRACIL is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below: Intra-Abdominal Infections including hepatobiliary and surgical infections caused by E. coli , Pseudomonas aeruginosa , enterococci, Clostridium spp., anaerobic cocci, or Bacteroides spp., including B. fragilis. Urinary Tract Infections caused by E. coli , Klebsiella spp., P. aeruginosa , Proteus spp., including P. mirabilis , or enterococci. Gynecologic Infections including endometritis, pelvic inflammatory disease, pelvic cellulitis caused by Bacteroides spp., including B. fragilis , anaerobic cocci, Neisseria gonorrhoeae , or enterococci ( E. faecalis ). Septicemia including bacteremia caused by E. coli , Klebsiella spp., Enterobacter spp., Serratia spp., P. mirabilis , S. pneumoniae , enterococci, P. aeruginosa , Bacteroides spp., or anaerobic cocci. Lower RespiratoryTract Infections caused by E. coli , Klebsiella spp., Enterobacter spp., P . aeruginosa , Serratia spp., H. influenzae , Bacteroides spp., or anaerobic cocci. Although improvement has been noted in patients with cystic fibrosis, lasting bacterial eradication may not necessarily be achieved. Skin and Skin Structure Infections caused by E. coli , Klebsiella spp., Serratia spp., Acinetobacter spp., Enterobacter spp., P. aeruginosa , Morganella morganii , Providencia rettgeri , Proteus vulgaris , P. mirabilis , Bacteroides spp., including B. fragilis , anaerobic cocci, or enterococci. Bone and Joint Infections caused by P. aeruginosa , enterococci, Bacteroides spp., or anaerobic cocci. Uncomplicated Gonococcal Urethritis caused by N. gonorrhoeae. PIPRACIL has also been shown to be clinically effective for the treatment of infections at various sites caused by Streptococcus species including S. pyogenes and S. pneumoniae ; however, infections caused by these organisms are ordinarily treated with more narrow spectrum penicillins. Because of its broad spectrum of bactericidal activity against gram-positive and gram-negative aerobic and anaerobic bacteria, PIPRACIL is particularly useful for the treatment of mixed infections and presumptive therapy prior to the identification of the causative organisms. Also, PIPRACIL may be administered as single drug therapy in some situations where normally two antibiotics might be employed. Piperacillin has been successfully used with aminoglycosides, especially in patients with impaired host defenses. Both drugs should be used in full therapeutic doses. Appropriate cultures should be made for susceptibility testing before initiating therapy and therapy adjusted, if appropriate, once the results are known. Prophylaxis: PIPRACIL is indicated for prophylactic use in surgery including intra-abdominal (gastrointestinal and biliary) procedures, vaginal hysterectomy, abdominal hysterectomy, and cesarean section. Effective prophylactic use depends on the time of administration; PIPRACIL should be given one-half to one hour before the operation so that effective levels can be achieved in the site prior to the procedure. The prophylactic use of piperacillin should be stopped within 24 hours, since continuing administration of any antibiotic increases the possibility of adverse reactions, but in the majority of surgical procedures, does not reduce the incidence of subsequent infections. If there are signs of infection, specimens for culture and susceptibility testing should be obtained for identification of the causative microorganism so that appropriate therapy can be instituted. To reduce the development of drug-resistant bacteria and maintain the effectiveness of PIPRACIL and other antibacterial drugs, PIPRACILshould only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:f868d56e-79aa-4052-a445-b8bc768b0487 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8232 biolink:treats MONDO:0024355 PMID:41385096 "[{""id"":""uuid:2d576906-065d-4a12-8fc3-839492e28ea9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:72814bfe-8b44-410d-8bea-3f6017c93a33"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapeutic: PIPRACIL is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below: Intra-Abdominal Infections including hepatobiliary and surgical infections caused by E. coli , Pseudomonas aeruginosa , enterococci, Clostridium spp., anaerobic cocci, or Bacteroides spp., including B. fragilis. Urinary Tract Infections caused by E. coli , Klebsiella spp., P. aeruginosa , Proteus spp., including P. mirabilis , or enterococci. Gynecologic Infections including endometritis, pelvic inflammatory disease, pelvic cellulitis caused by Bacteroides spp., including B. fragilis , anaerobic cocci, Neisseria gonorrhoeae , or enterococci ( E. faecalis ). Septicemia including bacteremia caused by E. coli , Klebsiella spp., Enterobacter spp., Serratia spp., P. mirabilis , S. pneumoniae , enterococci, P. aeruginosa , Bacteroides spp., or anaerobic cocci. Lower RespiratoryTract Infections caused by E. coli , Klebsiella spp., Enterobacter spp., P . aeruginosa , Serratia spp., H. influenzae , Bacteroides spp., or anaerobic cocci. Although improvement has been noted in patients with cystic fibrosis, lasting bacterial eradication may not necessarily be achieved. Skin and Skin Structure Infections caused by E. coli , Klebsiella spp., Serratia spp., Acinetobacter spp., Enterobacter spp., P. aeruginosa , Morganella morganii , Providencia rettgeri , Proteus vulgaris , P. mirabilis , Bacteroides spp., including B. fragilis , anaerobic cocci, or enterococci. Bone and Joint Infections caused by P. aeruginosa , enterococci, Bacteroides spp., or anaerobic cocci. Uncomplicated Gonococcal Urethritis caused by N. gonorrhoeae. PIPRACIL has also been shown to be clinically effective for the treatment of infections at various sites caused by Streptococcus species including S. pyogenes and S. pneumoniae ; however, infections caused by these organisms are ordinarily treated with more narrow spectrum penicillins. Because of its broad spectrum of bactericidal activity against gram-positive and gram-negative aerobic and anaerobic bacteria, PIPRACIL is particularly useful for the treatment of mixed infections and presumptive therapy prior to the identification of the causative organisms. Also, PIPRACIL may be administered as single drug therapy in some situations where normally two antibiotics might be employed. Piperacillin has been successfully used with aminoglycosides, especially in patients with impaired host defenses. Both drugs should be used in full therapeutic doses. Appropriate cultures should be made for susceptibility testing before initiating therapy and therapy adjusted, if appropriate, once the results are known. Prophylaxis: PIPRACIL is indicated for prophylactic use in surgery including intra-abdominal (gastrointestinal and biliary) procedures, vaginal hysterectomy, abdominal hysterectomy, and cesarean section. Effective prophylactic use depends on the time of administration; PIPRACIL should be given one-half to one hour before the operation so that effective levels can be achieved in the site prior to the procedure. The prophylactic use of piperacillin should be stopped within 24 hours, since continuing administration of any antibiotic increases the possibility of adverse reactions, but in the majority of surgical procedures, does not reduce the incidence of subsequent infections. If there are signs of infection, specimens for culture and susceptibility testing should be obtained for identification of the causative microorganism so that appropriate therapy can be instituted. To reduce the development of drug-resistant bacteria and maintain the effectiveness of PIPRACIL and other antibacterial drugs, PIPRACILshould only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:5237ba77-532b-496f-8437-d2c38b3a0921 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8232 biolink:treats MONDO:0009061 PMID:41385096 "[{""id"":""uuid:f3289039-a679-4cc2-bc5c-8265b271feb0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f5e436a8-0122-4b3d-aa24-07359ce8ac2e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapeutic: PIPRACIL is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below: Intra-Abdominal Infections including hepatobiliary and surgical infections caused by E. coli , Pseudomonas aeruginosa , enterococci, Clostridium spp., anaerobic cocci, or Bacteroides spp., including B. fragilis. Urinary Tract Infections caused by E. coli , Klebsiella spp., P. aeruginosa , Proteus spp., including P. mirabilis , or enterococci. Gynecologic Infections including endometritis, pelvic inflammatory disease, pelvic cellulitis caused by Bacteroides spp., including B. fragilis , anaerobic cocci, Neisseria gonorrhoeae , or enterococci ( E. faecalis ). Septicemia including bacteremia caused by E. coli , Klebsiella spp., Enterobacter spp., Serratia spp., P. mirabilis , S. pneumoniae , enterococci, P. aeruginosa , Bacteroides spp., or anaerobic cocci. Lower RespiratoryTract Infections caused by E. coli , Klebsiella spp., Enterobacter spp., P . aeruginosa , Serratia spp., H. influenzae , Bacteroides spp., or anaerobic cocci. Although improvement has been noted in patients with cystic fibrosis, lasting bacterial eradication may not necessarily be achieved. Skin and Skin Structure Infections caused by E. coli , Klebsiella spp., Serratia spp., Acinetobacter spp., Enterobacter spp., P. aeruginosa , Morganella morganii , Providencia rettgeri , Proteus vulgaris , P. mirabilis , Bacteroides spp., including B. fragilis , anaerobic cocci, or enterococci. Bone and Joint Infections caused by P. aeruginosa , enterococci, Bacteroides spp., or anaerobic cocci. Uncomplicated Gonococcal Urethritis caused by N. gonorrhoeae. PIPRACIL has also been shown to be clinically effective for the treatment of infections at various sites caused by Streptococcus species including S. pyogenes and S. pneumoniae ; however, infections caused by these organisms are ordinarily treated with more narrow spectrum penicillins. Because of its broad spectrum of bactericidal activity against gram-positive and gram-negative aerobic and anaerobic bacteria, PIPRACIL is particularly useful for the treatment of mixed infections and presumptive therapy prior to the identification of the causative organisms. Also, PIPRACIL may be administered as single drug therapy in some situations where normally two antibiotics might be employed. Piperacillin has been successfully used with aminoglycosides, especially in patients with impaired host defenses. Both drugs should be used in full therapeutic doses. Appropriate cultures should be made for susceptibility testing before initiating therapy and therapy adjusted, if appropriate, once the results are known. Prophylaxis: PIPRACIL is indicated for prophylactic use in surgery including intra-abdominal (gastrointestinal and biliary) procedures, vaginal hysterectomy, abdominal hysterectomy, and cesarean section. Effective prophylactic use depends on the time of administration; PIPRACIL should be given one-half to one hour before the operation so that effective levels can be achieved in the site prior to the procedure. The prophylactic use of piperacillin should be stopped within 24 hours, since continuing administration of any antibiotic increases the possibility of adverse reactions, but in the majority of surgical procedures, does not reduce the incidence of subsequent infections. If there are signs of infection, specimens for culture and susceptibility testing should be obtained for identification of the causative microorganism so that appropriate therapy can be instituted. To reduce the development of drug-resistant bacteria and maintain the effectiveness of PIPRACIL and other antibacterial drugs, PIPRACILshould only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:006caeec-4030-463f-8cc4-e765bcea9861 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8232 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:1e646435-a0b6-425a-bbe4-82b2877be984"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:affa3e48-fded-4225-b1e3-04f9bc0d28e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapeutic: PIPRACIL is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below: Intra-Abdominal Infections including hepatobiliary and surgical infections caused by E. coli , Pseudomonas aeruginosa , enterococci, Clostridium spp., anaerobic cocci, or Bacteroides spp., including B. fragilis. Urinary Tract Infections caused by E. coli , Klebsiella spp., P. aeruginosa , Proteus spp., including P. mirabilis , or enterococci. Gynecologic Infections including endometritis, pelvic inflammatory disease, pelvic cellulitis caused by Bacteroides spp., including B. fragilis , anaerobic cocci, Neisseria gonorrhoeae , or enterococci ( E. faecalis ). Septicemia including bacteremia caused by E. coli , Klebsiella spp., Enterobacter spp., Serratia spp., P. mirabilis , S. pneumoniae , enterococci, P. aeruginosa , Bacteroides spp., or anaerobic cocci. Lower RespiratoryTract Infections caused by E. coli , Klebsiella spp., Enterobacter spp., P . aeruginosa , Serratia spp., H. influenzae , Bacteroides spp., or anaerobic cocci. Although improvement has been noted in patients with cystic fibrosis, lasting bacterial eradication may not necessarily be achieved. Skin and Skin Structure Infections caused by E. coli , Klebsiella spp., Serratia spp., Acinetobacter spp., Enterobacter spp., P. aeruginosa , Morganella morganii , Providencia rettgeri , Proteus vulgaris , P. mirabilis , Bacteroides spp., including B. fragilis , anaerobic cocci, or enterococci. Bone and Joint Infections caused by P. aeruginosa , enterococci, Bacteroides spp., or anaerobic cocci. Uncomplicated Gonococcal Urethritis caused by N. gonorrhoeae. PIPRACIL has also been shown to be clinically effective for the treatment of infections at various sites caused by Streptococcus species including S. pyogenes and S. pneumoniae ; however, infections caused by these organisms are ordinarily treated with more narrow spectrum penicillins. Because of its broad spectrum of bactericidal activity against gram-positive and gram-negative aerobic and anaerobic bacteria, PIPRACIL is particularly useful for the treatment of mixed infections and presumptive therapy prior to the identification of the causative organisms. Also, PIPRACIL may be administered as single drug therapy in some situations where normally two antibiotics might be employed. Piperacillin has been successfully used with aminoglycosides, especially in patients with impaired host defenses. Both drugs should be used in full therapeutic doses. Appropriate cultures should be made for susceptibility testing before initiating therapy and therapy adjusted, if appropriate, once the results are known. Prophylaxis: PIPRACIL is indicated for prophylactic use in surgery including intra-abdominal (gastrointestinal and biliary) procedures, vaginal hysterectomy, abdominal hysterectomy, and cesarean section. Effective prophylactic use depends on the time of administration; PIPRACIL should be given one-half to one hour before the operation so that effective levels can be achieved in the site prior to the procedure. The prophylactic use of piperacillin should be stopped within 24 hours, since continuing administration of any antibiotic increases the possibility of adverse reactions, but in the majority of surgical procedures, does not reduce the incidence of subsequent infections. If there are signs of infection, specimens for culture and susceptibility testing should be obtained for identification of the causative microorganism so that appropriate therapy can be instituted. To reduce the development of drug-resistant bacteria and maintain the effectiveness of PIPRACIL and other antibacterial drugs, PIPRACILshould only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:bd8870ef-a7af-4275-a111-f0ad21fb9412 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8232 biolink:treats UMLS:C0851989 PMID:41385096 "[{""id"":""uuid:b3ec9be4-071c-4ace-b630-3d9c4f139887"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:135400f7-5e6c-447f-bb82-39438e9783cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapeutic: PIPRACIL is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below: Intra-Abdominal Infections including hepatobiliary and surgical infections caused by E. coli , Pseudomonas aeruginosa , enterococci, Clostridium spp., anaerobic cocci, or Bacteroides spp., including B. fragilis. Urinary Tract Infections caused by E. coli , Klebsiella spp., P. aeruginosa , Proteus spp., including P. mirabilis , or enterococci. Gynecologic Infections including endometritis, pelvic inflammatory disease, pelvic cellulitis caused by Bacteroides spp., including B. fragilis , anaerobic cocci, Neisseria gonorrhoeae , or enterococci ( E. faecalis ). Septicemia including bacteremia caused by E. coli , Klebsiella spp., Enterobacter spp., Serratia spp., P. mirabilis , S. pneumoniae , enterococci, P. aeruginosa , Bacteroides spp., or anaerobic cocci. Lower RespiratoryTract Infections caused by E. coli , Klebsiella spp., Enterobacter spp., P . aeruginosa , Serratia spp., H. influenzae , Bacteroides spp., or anaerobic cocci. Although improvement has been noted in patients with cystic fibrosis, lasting bacterial eradication may not necessarily be achieved. Skin and Skin Structure Infections caused by E. coli , Klebsiella spp., Serratia spp., Acinetobacter spp., Enterobacter spp., P. aeruginosa , Morganella morganii , Providencia rettgeri , Proteus vulgaris , P. mirabilis , Bacteroides spp., including B. fragilis , anaerobic cocci, or enterococci. Bone and Joint Infections caused by P. aeruginosa , enterococci, Bacteroides spp., or anaerobic cocci. Uncomplicated Gonococcal Urethritis caused by N. gonorrhoeae. PIPRACIL has also been shown to be clinically effective for the treatment of infections at various sites caused by Streptococcus species including S. pyogenes and S. pneumoniae ; however, infections caused by these organisms are ordinarily treated with more narrow spectrum penicillins. Because of its broad spectrum of bactericidal activity against gram-positive and gram-negative aerobic and anaerobic bacteria, PIPRACIL is particularly useful for the treatment of mixed infections and presumptive therapy prior to the identification of the causative organisms. Also, PIPRACIL may be administered as single drug therapy in some situations where normally two antibiotics might be employed. Piperacillin has been successfully used with aminoglycosides, especially in patients with impaired host defenses. Both drugs should be used in full therapeutic doses. Appropriate cultures should be made for susceptibility testing before initiating therapy and therapy adjusted, if appropriate, once the results are known. Prophylaxis: PIPRACIL is indicated for prophylactic use in surgery including intra-abdominal (gastrointestinal and biliary) procedures, vaginal hysterectomy, abdominal hysterectomy, and cesarean section. Effective prophylactic use depends on the time of administration; PIPRACIL should be given one-half to one hour before the operation so that effective levels can be achieved in the site prior to the procedure. The prophylactic use of piperacillin should be stopped within 24 hours, since continuing administration of any antibiotic increases the possibility of adverse reactions, but in the majority of surgical procedures, does not reduce the incidence of subsequent infections. If there are signs of infection, specimens for culture and susceptibility testing should be obtained for identification of the causative microorganism so that appropriate therapy can be instituted. To reduce the development of drug-resistant bacteria and maintain the effectiveness of PIPRACIL and other antibacterial drugs, PIPRACILshould only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:e80eea40-db39-4d0a-8e45-6d61202dc262 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8232 biolink:treats MONDO:0020971 PMID:41385096 "[{""id"":""uuid:72bfa863-c5ed-4342-967a-dc0cf5a60f83"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1c0e350f-8778-4673-b2ce-165367d653df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapeutic: PIPRACIL is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below: Intra-Abdominal Infections including hepatobiliary and surgical infections caused by E. coli , Pseudomonas aeruginosa , enterococci, Clostridium spp., anaerobic cocci, or Bacteroides spp., including B. fragilis. Urinary Tract Infections caused by E. coli , Klebsiella spp., P. aeruginosa , Proteus spp., including P. mirabilis , or enterococci. Gynecologic Infections including endometritis, pelvic inflammatory disease, pelvic cellulitis caused by Bacteroides spp., including B. fragilis , anaerobic cocci, Neisseria gonorrhoeae , or enterococci ( E. faecalis ). Septicemia including bacteremia caused by E. coli , Klebsiella spp., Enterobacter spp., Serratia spp., P. mirabilis , S. pneumoniae , enterococci, P. aeruginosa , Bacteroides spp., or anaerobic cocci. Lower RespiratoryTract Infections caused by E. coli , Klebsiella spp., Enterobacter spp., P . aeruginosa , Serratia spp., H. influenzae , Bacteroides spp., or anaerobic cocci. Although improvement has been noted in patients with cystic fibrosis, lasting bacterial eradication may not necessarily be achieved. Skin and Skin Structure Infections caused by E. coli , Klebsiella spp., Serratia spp., Acinetobacter spp., Enterobacter spp., P. aeruginosa , Morganella morganii , Providencia rettgeri , Proteus vulgaris , P. mirabilis , Bacteroides spp., including B. fragilis , anaerobic cocci, or enterococci. Bone and Joint Infections caused by P. aeruginosa , enterococci, Bacteroides spp., or anaerobic cocci. Uncomplicated Gonococcal Urethritis caused by N. gonorrhoeae. PIPRACIL has also been shown to be clinically effective for the treatment of infections at various sites caused by Streptococcus species including S. pyogenes and S. pneumoniae ; however, infections caused by these organisms are ordinarily treated with more narrow spectrum penicillins. Because of its broad spectrum of bactericidal activity against gram-positive and gram-negative aerobic and anaerobic bacteria, PIPRACIL is particularly useful for the treatment of mixed infections and presumptive therapy prior to the identification of the causative organisms. Also, PIPRACIL may be administered as single drug therapy in some situations where normally two antibiotics might be employed. Piperacillin has been successfully used with aminoglycosides, especially in patients with impaired host defenses. Both drugs should be used in full therapeutic doses. Appropriate cultures should be made for susceptibility testing before initiating therapy and therapy adjusted, if appropriate, once the results are known. Prophylaxis: PIPRACIL is indicated for prophylactic use in surgery including intra-abdominal (gastrointestinal and biliary) procedures, vaginal hysterectomy, abdominal hysterectomy, and cesarean section. Effective prophylactic use depends on the time of administration; PIPRACIL should be given one-half to one hour before the operation so that effective levels can be achieved in the site prior to the procedure. The prophylactic use of piperacillin should be stopped within 24 hours, since continuing administration of any antibiotic increases the possibility of adverse reactions, but in the majority of surgical procedures, does not reduce the incidence of subsequent infections. If there are signs of infection, specimens for culture and susceptibility testing should be obtained for identification of the causative microorganism so that appropriate therapy can be instituted. To reduce the development of drug-resistant bacteria and maintain the effectiveness of PIPRACIL and other antibacterial drugs, PIPRACILshould only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:ea1e554e-dc14-45dd-ad5b-67757a6ca59f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10125 biolink:treats MONDO:0013600 PMID:41385096 "[{""id"":""uuid:d0d87f9e-d53b-412e-a399-62afef36a4b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:da61db4d-c033-420e-b029-ba529afe2cc9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Zolpidem tartrate tablets are indicated for the short-term treatment of insomnia characterized by difficulties with sleep initiation. Zolpidem tartrate tablets have been shown to decrease sleep latency for up to 35 days in controlled clinical studies [see Clinical Studies (14) ] . The clinical trials performed in support of efficacy were 4-5 weeks in duration with the final formal assessments of sleep latency performed at the end of treatment. uuid:c46bccef-7651-48bb-bfc9-f7f294d98edb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17439 biolink:treats MONDO:0008228 PMID:41385096 "[{""id"":""uuid:b0d9400e-5fb9-497c-bd31-bfc1ed827483"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:28e2f22b-56a4-4c69-9129-2e7916ccdca3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nascobal Nasal Spray is indicated for the maintenance of normal hematologic status in pernicious anemia patients who are in remission following intramuscular vitamin B 12 therapy and who have no nervous system involvement. Nascobal Nasal Spray is also indicated as a supplement for other vitamin B 12 deficiencies, including: I. Dietary deficiency of vitamin B 12 occurring in strict vegetarians (Isolated vitamin B 12 deficiency is very rare). II. Malabsorption of vitamin B 12 resulting from structural or functional damage to the stomach, where intrinsic factor is secreted, or to the ileum, where intrinsic factor facilitates vitamin B 12 absorption. These conditions include HIV infection, AIDS, Crohn's disease, tropical sprue, and nontropical sprue (idiopathic steatorrhea, gluten-induced enteropathy). Folate deficiency in these patients is usually more severe than vitamin B 12 deficiency. III. Inadequate secretion of intrinsic factor, resulting from lesions that destroy the gastric mucosa (ingestion of corrosives, extensive neoplasia), and a number of conditions associated with a variable degree of gastric atrophy (such as multiple sclerosis, HIV infection, AIDS, certain endocrine disorders, iron deficiency, and subtotal gastrectomy). Total gastrectomy always produces vitamin B 12 deficiency. Structural lesions leading to vitamin B 12 deficiency include regional ileitis, ileal resections, malignancies, etc. IV. Competition for vitamin B 12 by intestinal parasites or bacteria. The fish tapeworm (Diphyllobothrium latum) absorbs huge quantities of vitamin B 12 and infested patients often have associated gastric atrophy. The blind loop syndrome may produce deficiency of vitamin B 12 or folate. V. Inadequate utilization of vitamin B 12 . This may occur if antimetabolites for the vitamin are employed in the treatment of neoplasia. It may be possible to treat the underlying disease by surgical correction of anatomic lesions leading to small bowel bacterial overgrowth, expulsion of fish tapeworm, discontinuation of drugs leading to vitamin malabsorption (see Drug/Laboratory Test Interactions ), use of a gluten free diet in nontropical sprue, or administration of antibiotics in tropical sprue. Such measures remove the need for long-term administration of vitamin B 12 . Requirements of vitamin B 12 in excess of normal (due to pregnancy, thyrotoxicosis, hemolytic anemia, hemorrhage, malignancy, hepatic and renal disease) can usually be met with intranasal or oral supplementation. Nascobal Nasal Spray is not suitable for vitamin B 12 absorption test (Schilling Test). uuid:d466048a-61fd-49b9-a6d6-42e911dcd719 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17439 biolink:treats MONDO:0020696 PMID:41385096 "[{""id"":""uuid:c7ba4a0b-085d-4eea-8982-c483553e342d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c5e554b7-ebfd-4819-8762-25a7b8a2c45d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nascobal Nasal Spray is indicated for the maintenance of normal hematologic status in pernicious anemia patients who are in remission following intramuscular vitamin B 12 therapy and who have no nervous system involvement. Nascobal Nasal Spray is also indicated as a supplement for other vitamin B 12 deficiencies, including: I. Dietary deficiency of vitamin B 12 occurring in strict vegetarians (Isolated vitamin B 12 deficiency is very rare). II. Malabsorption of vitamin B 12 resulting from structural or functional damage to the stomach, where intrinsic factor is secreted, or to the ileum, where intrinsic factor facilitates vitamin B 12 absorption. These conditions include HIV infection, AIDS, Crohn's disease, tropical sprue, and nontropical sprue (idiopathic steatorrhea, gluten-induced enteropathy). Folate deficiency in these patients is usually more severe than vitamin B 12 deficiency. III. Inadequate secretion of intrinsic factor, resulting from lesions that destroy the gastric mucosa (ingestion of corrosives, extensive neoplasia), and a number of conditions associated with a variable degree of gastric atrophy (such as multiple sclerosis, HIV infection, AIDS, certain endocrine disorders, iron deficiency, and subtotal gastrectomy). Total gastrectomy always produces vitamin B 12 deficiency. Structural lesions leading to vitamin B 12 deficiency include regional ileitis, ileal resections, malignancies, etc. IV. Competition for vitamin B 12 by intestinal parasites or bacteria. The fish tapeworm (Diphyllobothrium latum) absorbs huge quantities of vitamin B 12 and infested patients often have associated gastric atrophy. The blind loop syndrome may produce deficiency of vitamin B 12 or folate. V. Inadequate utilization of vitamin B 12 . This may occur if antimetabolites for the vitamin are employed in the treatment of neoplasia. It may be possible to treat the underlying disease by surgical correction of anatomic lesions leading to small bowel bacterial overgrowth, expulsion of fish tapeworm, discontinuation of drugs leading to vitamin malabsorption (see Drug/Laboratory Test Interactions ), use of a gluten free diet in nontropical sprue, or administration of antibiotics in tropical sprue. Such measures remove the need for long-term administration of vitamin B 12 . Requirements of vitamin B 12 in excess of normal (due to pregnancy, thyrotoxicosis, hemolytic anemia, hemorrhage, malignancy, hepatic and renal disease) can usually be met with intranasal or oral supplementation. Nascobal Nasal Spray is not suitable for vitamin B 12 absorption test (Schilling Test). uuid:f8d198ed-508b-45ed-a6d1-a16a627fddb0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17439 biolink:treats MONDO:0005011 PMID:41385096 "[{""id"":""uuid:94873c9b-80f5-4e80-840f-f707f9375648"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:80c8689e-26a3-43bb-afff-60790d663b45"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nascobal Nasal Spray is indicated for the maintenance of normal hematologic status in pernicious anemia patients who are in remission following intramuscular vitamin B 12 therapy and who have no nervous system involvement. Nascobal Nasal Spray is also indicated as a supplement for other vitamin B 12 deficiencies, including: I. Dietary deficiency of vitamin B 12 occurring in strict vegetarians (Isolated vitamin B 12 deficiency is very rare). II. Malabsorption of vitamin B 12 resulting from structural or functional damage to the stomach, where intrinsic factor is secreted, or to the ileum, where intrinsic factor facilitates vitamin B 12 absorption. These conditions include HIV infection, AIDS, Crohn's disease, tropical sprue, and nontropical sprue (idiopathic steatorrhea, gluten-induced enteropathy). Folate deficiency in these patients is usually more severe than vitamin B 12 deficiency. III. Inadequate secretion of intrinsic factor, resulting from lesions that destroy the gastric mucosa (ingestion of corrosives, extensive neoplasia), and a number of conditions associated with a variable degree of gastric atrophy (such as multiple sclerosis, HIV infection, AIDS, certain endocrine disorders, iron deficiency, and subtotal gastrectomy). Total gastrectomy always produces vitamin B 12 deficiency. Structural lesions leading to vitamin B 12 deficiency include regional ileitis, ileal resections, malignancies, etc. IV. Competition for vitamin B 12 by intestinal parasites or bacteria. The fish tapeworm (Diphyllobothrium latum) absorbs huge quantities of vitamin B 12 and infested patients often have associated gastric atrophy. The blind loop syndrome may produce deficiency of vitamin B 12 or folate. V. Inadequate utilization of vitamin B 12 . This may occur if antimetabolites for the vitamin are employed in the treatment of neoplasia. It may be possible to treat the underlying disease by surgical correction of anatomic lesions leading to small bowel bacterial overgrowth, expulsion of fish tapeworm, discontinuation of drugs leading to vitamin malabsorption (see Drug/Laboratory Test Interactions ), use of a gluten free diet in nontropical sprue, or administration of antibiotics in tropical sprue. Such measures remove the need for long-term administration of vitamin B 12 . Requirements of vitamin B 12 in excess of normal (due to pregnancy, thyrotoxicosis, hemolytic anemia, hemorrhage, malignancy, hepatic and renal disease) can usually be met with intranasal or oral supplementation. Nascobal Nasal Spray is not suitable for vitamin B 12 absorption test (Schilling Test). uuid:4e05be33-0fa4-492c-935e-c61646e651b0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17439 biolink:treats MONDO:0001078 PMID:41385096 "[{""id"":""uuid:81530a98-ad11-4b25-b1f5-a6147270a98b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:affe86f4-0a50-407c-970b-c883fe2789e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nascobal Nasal Spray is indicated for the maintenance of normal hematologic status in pernicious anemia patients who are in remission following intramuscular vitamin B 12 therapy and who have no nervous system involvement. Nascobal Nasal Spray is also indicated as a supplement for other vitamin B 12 deficiencies, including: I. Dietary deficiency of vitamin B 12 occurring in strict vegetarians (Isolated vitamin B 12 deficiency is very rare). II. Malabsorption of vitamin B 12 resulting from structural or functional damage to the stomach, where intrinsic factor is secreted, or to the ileum, where intrinsic factor facilitates vitamin B 12 absorption. These conditions include HIV infection, AIDS, Crohn's disease, tropical sprue, and nontropical sprue (idiopathic steatorrhea, gluten-induced enteropathy). Folate deficiency in these patients is usually more severe than vitamin B 12 deficiency. III. Inadequate secretion of intrinsic factor, resulting from lesions that destroy the gastric mucosa (ingestion of corrosives, extensive neoplasia), and a number of conditions associated with a variable degree of gastric atrophy (such as multiple sclerosis, HIV infection, AIDS, certain endocrine disorders, iron deficiency, and subtotal gastrectomy). Total gastrectomy always produces vitamin B 12 deficiency. Structural lesions leading to vitamin B 12 deficiency include regional ileitis, ileal resections, malignancies, etc. IV. Competition for vitamin B 12 by intestinal parasites or bacteria. The fish tapeworm (Diphyllobothrium latum) absorbs huge quantities of vitamin B 12 and infested patients often have associated gastric atrophy. The blind loop syndrome may produce deficiency of vitamin B 12 or folate. V. Inadequate utilization of vitamin B 12 . This may occur if antimetabolites for the vitamin are employed in the treatment of neoplasia. It may be possible to treat the underlying disease by surgical correction of anatomic lesions leading to small bowel bacterial overgrowth, expulsion of fish tapeworm, discontinuation of drugs leading to vitamin malabsorption (see Drug/Laboratory Test Interactions ), use of a gluten free diet in nontropical sprue, or administration of antibiotics in tropical sprue. Such measures remove the need for long-term administration of vitamin B 12 . Requirements of vitamin B 12 in excess of normal (due to pregnancy, thyrotoxicosis, hemolytic anemia, hemorrhage, malignancy, hepatic and renal disease) can usually be met with intranasal or oral supplementation. Nascobal Nasal Spray is not suitable for vitamin B 12 absorption test (Schilling Test). uuid:53960668-d98d-40f0-8570-3828e7cfe21f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17439 biolink:treats MONDO:0005130 PMID:41385096 "[{""id"":""uuid:c7401da3-0538-4389-8380-16720bf3aa0e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:30aa094a-32d6-4540-9bab-b6426f2e8d72"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nascobal Nasal Spray is indicated for the maintenance of normal hematologic status in pernicious anemia patients who are in remission following intramuscular vitamin B 12 therapy and who have no nervous system involvement. Nascobal Nasal Spray is also indicated as a supplement for other vitamin B 12 deficiencies, including: I. Dietary deficiency of vitamin B 12 occurring in strict vegetarians (Isolated vitamin B 12 deficiency is very rare). II. Malabsorption of vitamin B 12 resulting from structural or functional damage to the stomach, where intrinsic factor is secreted, or to the ileum, where intrinsic factor facilitates vitamin B 12 absorption. These conditions include HIV infection, AIDS, Crohn's disease, tropical sprue, and nontropical sprue (idiopathic steatorrhea, gluten-induced enteropathy). Folate deficiency in these patients is usually more severe than vitamin B 12 deficiency. III. Inadequate secretion of intrinsic factor, resulting from lesions that destroy the gastric mucosa (ingestion of corrosives, extensive neoplasia), and a number of conditions associated with a variable degree of gastric atrophy (such as multiple sclerosis, HIV infection, AIDS, certain endocrine disorders, iron deficiency, and subtotal gastrectomy). Total gastrectomy always produces vitamin B 12 deficiency. Structural lesions leading to vitamin B 12 deficiency include regional ileitis, ileal resections, malignancies, etc. IV. Competition for vitamin B 12 by intestinal parasites or bacteria. The fish tapeworm (Diphyllobothrium latum) absorbs huge quantities of vitamin B 12 and infested patients often have associated gastric atrophy. The blind loop syndrome may produce deficiency of vitamin B 12 or folate. V. Inadequate utilization of vitamin B 12 . This may occur if antimetabolites for the vitamin are employed in the treatment of neoplasia. It may be possible to treat the underlying disease by surgical correction of anatomic lesions leading to small bowel bacterial overgrowth, expulsion of fish tapeworm, discontinuation of drugs leading to vitamin malabsorption (see Drug/Laboratory Test Interactions ), use of a gluten free diet in nontropical sprue, or administration of antibiotics in tropical sprue. Such measures remove the need for long-term administration of vitamin B 12 . Requirements of vitamin B 12 in excess of normal (due to pregnancy, thyrotoxicosis, hemolytic anemia, hemorrhage, malignancy, hepatic and renal disease) can usually be met with intranasal or oral supplementation. Nascobal Nasal Spray is not suitable for vitamin B 12 absorption test (Schilling Test). uuid:c74176f2-335f-4e8a-9bc1-be4be8d03342 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17439 biolink:treats MONDO:0001075 PMID:41385096 "[{""id"":""uuid:2712ef4c-dcf6-47c4-a470-639e85864797"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7b5d958a-0049-44aa-825a-8c176655e0da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nascobal Nasal Spray is indicated for the maintenance of normal hematologic status in pernicious anemia patients who are in remission following intramuscular vitamin B 12 therapy and who have no nervous system involvement. Nascobal Nasal Spray is also indicated as a supplement for other vitamin B 12 deficiencies, including: I. Dietary deficiency of vitamin B 12 occurring in strict vegetarians (Isolated vitamin B 12 deficiency is very rare). II. Malabsorption of vitamin B 12 resulting from structural or functional damage to the stomach, where intrinsic factor is secreted, or to the ileum, where intrinsic factor facilitates vitamin B 12 absorption. These conditions include HIV infection, AIDS, Crohn's disease, tropical sprue, and nontropical sprue (idiopathic steatorrhea, gluten-induced enteropathy). Folate deficiency in these patients is usually more severe than vitamin B 12 deficiency. III. Inadequate secretion of intrinsic factor, resulting from lesions that destroy the gastric mucosa (ingestion of corrosives, extensive neoplasia), and a number of conditions associated with a variable degree of gastric atrophy (such as multiple sclerosis, HIV infection, AIDS, certain endocrine disorders, iron deficiency, and subtotal gastrectomy). Total gastrectomy always produces vitamin B 12 deficiency. Structural lesions leading to vitamin B 12 deficiency include regional ileitis, ileal resections, malignancies, etc. IV. Competition for vitamin B 12 by intestinal parasites or bacteria. The fish tapeworm (Diphyllobothrium latum) absorbs huge quantities of vitamin B 12 and infested patients often have associated gastric atrophy. The blind loop syndrome may produce deficiency of vitamin B 12 or folate. V. Inadequate utilization of vitamin B 12 . This may occur if antimetabolites for the vitamin are employed in the treatment of neoplasia. It may be possible to treat the underlying disease by surgical correction of anatomic lesions leading to small bowel bacterial overgrowth, expulsion of fish tapeworm, discontinuation of drugs leading to vitamin malabsorption (see Drug/Laboratory Test Interactions ), use of a gluten free diet in nontropical sprue, or administration of antibiotics in tropical sprue. Such measures remove the need for long-term administration of vitamin B 12 . Requirements of vitamin B 12 in excess of normal (due to pregnancy, thyrotoxicosis, hemolytic anemia, hemorrhage, malignancy, hepatic and renal disease) can usually be met with intranasal or oral supplementation. Nascobal Nasal Spray is not suitable for vitamin B 12 absorption test (Schilling Test). uuid:93e68bb6-1306-435a-8e20-f5029039eb28 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17439 biolink:treats MONDO:0005301 PMID:41385096 "[{""id"":""uuid:7741db5b-95fd-43fd-a311-b11553973c13"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fb2c83e7-0615-48dd-839d-65d130fb3fb2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nascobal Nasal Spray is indicated for the maintenance of normal hematologic status in pernicious anemia patients who are in remission following intramuscular vitamin B 12 therapy and who have no nervous system involvement. Nascobal Nasal Spray is also indicated as a supplement for other vitamin B 12 deficiencies, including: I. Dietary deficiency of vitamin B 12 occurring in strict vegetarians (Isolated vitamin B 12 deficiency is very rare). II. Malabsorption of vitamin B 12 resulting from structural or functional damage to the stomach, where intrinsic factor is secreted, or to the ileum, where intrinsic factor facilitates vitamin B 12 absorption. These conditions include HIV infection, AIDS, Crohn's disease, tropical sprue, and nontropical sprue (idiopathic steatorrhea, gluten-induced enteropathy). Folate deficiency in these patients is usually more severe than vitamin B 12 deficiency. III. Inadequate secretion of intrinsic factor, resulting from lesions that destroy the gastric mucosa (ingestion of corrosives, extensive neoplasia), and a number of conditions associated with a variable degree of gastric atrophy (such as multiple sclerosis, HIV infection, AIDS, certain endocrine disorders, iron deficiency, and subtotal gastrectomy). Total gastrectomy always produces vitamin B 12 deficiency. Structural lesions leading to vitamin B 12 deficiency include regional ileitis, ileal resections, malignancies, etc. IV. Competition for vitamin B 12 by intestinal parasites or bacteria. The fish tapeworm (Diphyllobothrium latum) absorbs huge quantities of vitamin B 12 and infested patients often have associated gastric atrophy. The blind loop syndrome may produce deficiency of vitamin B 12 or folate. V. Inadequate utilization of vitamin B 12 . This may occur if antimetabolites for the vitamin are employed in the treatment of neoplasia. It may be possible to treat the underlying disease by surgical correction of anatomic lesions leading to small bowel bacterial overgrowth, expulsion of fish tapeworm, discontinuation of drugs leading to vitamin malabsorption (see Drug/Laboratory Test Interactions ), use of a gluten free diet in nontropical sprue, or administration of antibiotics in tropical sprue. Such measures remove the need for long-term administration of vitamin B 12 . Requirements of vitamin B 12 in excess of normal (due to pregnancy, thyrotoxicosis, hemolytic anemia, hemorrhage, malignancy, hepatic and renal disease) can usually be met with intranasal or oral supplementation. Nascobal Nasal Spray is not suitable for vitamin B 12 absorption test (Schilling Test). uuid:bb7f841c-6273-4009-8201-33c3ab4d9119 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17439 biolink:treats UMLS:C0240066 PMID:41385096 "[{""id"":""uuid:c3ce8269-a088-4e3a-a727-0ce6fbf0a73d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:96995752-f9fa-4e15-8c63-d7f3c59e1efb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nascobal Nasal Spray is indicated for the maintenance of normal hematologic status in pernicious anemia patients who are in remission following intramuscular vitamin B 12 therapy and who have no nervous system involvement. Nascobal Nasal Spray is also indicated as a supplement for other vitamin B 12 deficiencies, including: I. Dietary deficiency of vitamin B 12 occurring in strict vegetarians (Isolated vitamin B 12 deficiency is very rare). II. Malabsorption of vitamin B 12 resulting from structural or functional damage to the stomach, where intrinsic factor is secreted, or to the ileum, where intrinsic factor facilitates vitamin B 12 absorption. These conditions include HIV infection, AIDS, Crohn's disease, tropical sprue, and nontropical sprue (idiopathic steatorrhea, gluten-induced enteropathy). Folate deficiency in these patients is usually more severe than vitamin B 12 deficiency. III. Inadequate secretion of intrinsic factor, resulting from lesions that destroy the gastric mucosa (ingestion of corrosives, extensive neoplasia), and a number of conditions associated with a variable degree of gastric atrophy (such as multiple sclerosis, HIV infection, AIDS, certain endocrine disorders, iron deficiency, and subtotal gastrectomy). Total gastrectomy always produces vitamin B 12 deficiency. Structural lesions leading to vitamin B 12 deficiency include regional ileitis, ileal resections, malignancies, etc. IV. Competition for vitamin B 12 by intestinal parasites or bacteria. The fish tapeworm (Diphyllobothrium latum) absorbs huge quantities of vitamin B 12 and infested patients often have associated gastric atrophy. The blind loop syndrome may produce deficiency of vitamin B 12 or folate. V. Inadequate utilization of vitamin B 12 . This may occur if antimetabolites for the vitamin are employed in the treatment of neoplasia. It may be possible to treat the underlying disease by surgical correction of anatomic lesions leading to small bowel bacterial overgrowth, expulsion of fish tapeworm, discontinuation of drugs leading to vitamin malabsorption (see Drug/Laboratory Test Interactions ), use of a gluten free diet in nontropical sprue, or administration of antibiotics in tropical sprue. Such measures remove the need for long-term administration of vitamin B 12 . Requirements of vitamin B 12 in excess of normal (due to pregnancy, thyrotoxicosis, hemolytic anemia, hemorrhage, malignancy, hepatic and renal disease) can usually be met with intranasal or oral supplementation. Nascobal Nasal Spray is not suitable for vitamin B 12 absorption test (Schilling Test). uuid:86a97619-ddc4-46d7-83bf-a927cdc1c25b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17439 biolink:treats MONDO:0000709 PMID:41385096 "[{""id"":""uuid:c83b75a3-334b-4930-ac30-2a83a6b0bb20"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:76587f29-ff04-4f14-af14-b496af476014"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nascobal Nasal Spray is indicated for the maintenance of normal hematologic status in pernicious anemia patients who are in remission following intramuscular vitamin B 12 therapy and who have no nervous system involvement. Nascobal Nasal Spray is also indicated as a supplement for other vitamin B 12 deficiencies, including: I. Dietary deficiency of vitamin B 12 occurring in strict vegetarians (Isolated vitamin B 12 deficiency is very rare). II. Malabsorption of vitamin B 12 resulting from structural or functional damage to the stomach, where intrinsic factor is secreted, or to the ileum, where intrinsic factor facilitates vitamin B 12 absorption. These conditions include HIV infection, AIDS, Crohn's disease, tropical sprue, and nontropical sprue (idiopathic steatorrhea, gluten-induced enteropathy). Folate deficiency in these patients is usually more severe than vitamin B 12 deficiency. III. Inadequate secretion of intrinsic factor, resulting from lesions that destroy the gastric mucosa (ingestion of corrosives, extensive neoplasia), and a number of conditions associated with a variable degree of gastric atrophy (such as multiple sclerosis, HIV infection, AIDS, certain endocrine disorders, iron deficiency, and subtotal gastrectomy). Total gastrectomy always produces vitamin B 12 deficiency. Structural lesions leading to vitamin B 12 deficiency include regional ileitis, ileal resections, malignancies, etc. IV. Competition for vitamin B 12 by intestinal parasites or bacteria. The fish tapeworm (Diphyllobothrium latum) absorbs huge quantities of vitamin B 12 and infested patients often have associated gastric atrophy. The blind loop syndrome may produce deficiency of vitamin B 12 or folate. V. Inadequate utilization of vitamin B 12 . This may occur if antimetabolites for the vitamin are employed in the treatment of neoplasia. It may be possible to treat the underlying disease by surgical correction of anatomic lesions leading to small bowel bacterial overgrowth, expulsion of fish tapeworm, discontinuation of drugs leading to vitamin malabsorption (see Drug/Laboratory Test Interactions ), use of a gluten free diet in nontropical sprue, or administration of antibiotics in tropical sprue. Such measures remove the need for long-term administration of vitamin B 12 . Requirements of vitamin B 12 in excess of normal (due to pregnancy, thyrotoxicosis, hemolytic anemia, hemorrhage, malignancy, hepatic and renal disease) can usually be met with intranasal or oral supplementation. Nascobal Nasal Spray is not suitable for vitamin B 12 absorption test (Schilling Test). uuid:e170cb41-b8e8-4ad8-bfcc-e10c2f22a689 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17439 biolink:treats MONDO:0005673 PMID:41385096 "[{""id"":""uuid:ed224d92-cb17-41b0-96c8-eebb12505176"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d9d4ff0a-2121-49f0-bd63-7fce8d87bfcc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nascobal Nasal Spray is indicated for the maintenance of normal hematologic status in pernicious anemia patients who are in remission following intramuscular vitamin B 12 therapy and who have no nervous system involvement. Nascobal Nasal Spray is also indicated as a supplement for other vitamin B 12 deficiencies, including: I. Dietary deficiency of vitamin B 12 occurring in strict vegetarians (Isolated vitamin B 12 deficiency is very rare). II. Malabsorption of vitamin B 12 resulting from structural or functional damage to the stomach, where intrinsic factor is secreted, or to the ileum, where intrinsic factor facilitates vitamin B 12 absorption. These conditions include HIV infection, AIDS, Crohn's disease, tropical sprue, and nontropical sprue (idiopathic steatorrhea, gluten-induced enteropathy). Folate deficiency in these patients is usually more severe than vitamin B 12 deficiency. III. Inadequate secretion of intrinsic factor, resulting from lesions that destroy the gastric mucosa (ingestion of corrosives, extensive neoplasia), and a number of conditions associated with a variable degree of gastric atrophy (such as multiple sclerosis, HIV infection, AIDS, certain endocrine disorders, iron deficiency, and subtotal gastrectomy). Total gastrectomy always produces vitamin B 12 deficiency. Structural lesions leading to vitamin B 12 deficiency include regional ileitis, ileal resections, malignancies, etc. IV. Competition for vitamin B 12 by intestinal parasites or bacteria. The fish tapeworm (Diphyllobothrium latum) absorbs huge quantities of vitamin B 12 and infested patients often have associated gastric atrophy. The blind loop syndrome may produce deficiency of vitamin B 12 or folate. V. Inadequate utilization of vitamin B 12 . This may occur if antimetabolites for the vitamin are employed in the treatment of neoplasia. It may be possible to treat the underlying disease by surgical correction of anatomic lesions leading to small bowel bacterial overgrowth, expulsion of fish tapeworm, discontinuation of drugs leading to vitamin malabsorption (see Drug/Laboratory Test Interactions ), use of a gluten free diet in nontropical sprue, or administration of antibiotics in tropical sprue. Such measures remove the need for long-term administration of vitamin B 12 . Requirements of vitamin B 12 in excess of normal (due to pregnancy, thyrotoxicosis, hemolytic anemia, hemorrhage, malignancy, hepatic and renal disease) can usually be met with intranasal or oral supplementation. Nascobal Nasal Spray is not suitable for vitamin B 12 absorption test (Schilling Test). uuid:826cff83-d6f3-48ed-8ebc-c39f197d8d84 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17439 biolink:treats MONDO:0010138 PMID:41385096 "[{""id"":""uuid:5bc8ad31-d835-431f-8b55-2d51f047d562"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bfb88683-469a-4f16-ae7f-165ca494dd72"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nascobal Nasal Spray is indicated for the maintenance of normal hematologic status in pernicious anemia patients who are in remission following intramuscular vitamin B 12 therapy and who have no nervous system involvement. Nascobal Nasal Spray is also indicated as a supplement for other vitamin B 12 deficiencies, including: I. Dietary deficiency of vitamin B 12 occurring in strict vegetarians (Isolated vitamin B 12 deficiency is very rare). II. Malabsorption of vitamin B 12 resulting from structural or functional damage to the stomach, where intrinsic factor is secreted, or to the ileum, where intrinsic factor facilitates vitamin B 12 absorption. These conditions include HIV infection, AIDS, Crohn's disease, tropical sprue, and nontropical sprue (idiopathic steatorrhea, gluten-induced enteropathy). Folate deficiency in these patients is usually more severe than vitamin B 12 deficiency. III. Inadequate secretion of intrinsic factor, resulting from lesions that destroy the gastric mucosa (ingestion of corrosives, extensive neoplasia), and a number of conditions associated with a variable degree of gastric atrophy (such as multiple sclerosis, HIV infection, AIDS, certain endocrine disorders, iron deficiency, and subtotal gastrectomy). Total gastrectomy always produces vitamin B 12 deficiency. Structural lesions leading to vitamin B 12 deficiency include regional ileitis, ileal resections, malignancies, etc. IV. Competition for vitamin B 12 by intestinal parasites or bacteria. The fish tapeworm (Diphyllobothrium latum) absorbs huge quantities of vitamin B 12 and infested patients often have associated gastric atrophy. The blind loop syndrome may produce deficiency of vitamin B 12 or folate. V. Inadequate utilization of vitamin B 12 . This may occur if antimetabolites for the vitamin are employed in the treatment of neoplasia. It may be possible to treat the underlying disease by surgical correction of anatomic lesions leading to small bowel bacterial overgrowth, expulsion of fish tapeworm, discontinuation of drugs leading to vitamin malabsorption (see Drug/Laboratory Test Interactions ), use of a gluten free diet in nontropical sprue, or administration of antibiotics in tropical sprue. Such measures remove the need for long-term administration of vitamin B 12 . Requirements of vitamin B 12 in excess of normal (due to pregnancy, thyrotoxicosis, hemolytic anemia, hemorrhage, malignancy, hepatic and renal disease) can usually be met with intranasal or oral supplementation. Nascobal Nasal Spray is not suitable for vitamin B 12 absorption test (Schilling Test). uuid:159f3b58-d948-4e07-b9ba-0ae205202bfc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17439 biolink:treats MONDO:0003664 PMID:41385096 "[{""id"":""uuid:0fd9d5e7-d261-4e88-9178-8bb97d78e1e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6f312d75-cd5c-4b5e-8b23-98f24df2f5ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nascobal Nasal Spray is indicated for the maintenance of normal hematologic status in pernicious anemia patients who are in remission following intramuscular vitamin B 12 therapy and who have no nervous system involvement. Nascobal Nasal Spray is also indicated as a supplement for other vitamin B 12 deficiencies, including: I. Dietary deficiency of vitamin B 12 occurring in strict vegetarians (Isolated vitamin B 12 deficiency is very rare). II. Malabsorption of vitamin B 12 resulting from structural or functional damage to the stomach, where intrinsic factor is secreted, or to the ileum, where intrinsic factor facilitates vitamin B 12 absorption. These conditions include HIV infection, AIDS, Crohn's disease, tropical sprue, and nontropical sprue (idiopathic steatorrhea, gluten-induced enteropathy). Folate deficiency in these patients is usually more severe than vitamin B 12 deficiency. III. Inadequate secretion of intrinsic factor, resulting from lesions that destroy the gastric mucosa (ingestion of corrosives, extensive neoplasia), and a number of conditions associated with a variable degree of gastric atrophy (such as multiple sclerosis, HIV infection, AIDS, certain endocrine disorders, iron deficiency, and subtotal gastrectomy). Total gastrectomy always produces vitamin B 12 deficiency. Structural lesions leading to vitamin B 12 deficiency include regional ileitis, ileal resections, malignancies, etc. IV. Competition for vitamin B 12 by intestinal parasites or bacteria. The fish tapeworm (Diphyllobothrium latum) absorbs huge quantities of vitamin B 12 and infested patients often have associated gastric atrophy. The blind loop syndrome may produce deficiency of vitamin B 12 or folate. V. Inadequate utilization of vitamin B 12 . This may occur if antimetabolites for the vitamin are employed in the treatment of neoplasia. It may be possible to treat the underlying disease by surgical correction of anatomic lesions leading to small bowel bacterial overgrowth, expulsion of fish tapeworm, discontinuation of drugs leading to vitamin malabsorption (see Drug/Laboratory Test Interactions ), use of a gluten free diet in nontropical sprue, or administration of antibiotics in tropical sprue. Such measures remove the need for long-term administration of vitamin B 12 . Requirements of vitamin B 12 in excess of normal (due to pregnancy, thyrotoxicosis, hemolytic anemia, hemorrhage, malignancy, hepatic and renal disease) can usually be met with intranasal or oral supplementation. Nascobal Nasal Spray is not suitable for vitamin B 12 absorption test (Schilling Test). uuid:94b39fb6-a929-4be4-a3dd-e4c19434b68b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17439 biolink:treats MONDO:0005154 PMID:41385096 "[{""id"":""uuid:ee801c2e-a925-4d74-86e1-895532952718"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4595e06c-1065-419a-97d7-0fb94a52fdc4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nascobal Nasal Spray is indicated for the maintenance of normal hematologic status in pernicious anemia patients who are in remission following intramuscular vitamin B 12 therapy and who have no nervous system involvement. Nascobal Nasal Spray is also indicated as a supplement for other vitamin B 12 deficiencies, including: I. Dietary deficiency of vitamin B 12 occurring in strict vegetarians (Isolated vitamin B 12 deficiency is very rare). II. Malabsorption of vitamin B 12 resulting from structural or functional damage to the stomach, where intrinsic factor is secreted, or to the ileum, where intrinsic factor facilitates vitamin B 12 absorption. These conditions include HIV infection, AIDS, Crohn's disease, tropical sprue, and nontropical sprue (idiopathic steatorrhea, gluten-induced enteropathy). Folate deficiency in these patients is usually more severe than vitamin B 12 deficiency. III. Inadequate secretion of intrinsic factor, resulting from lesions that destroy the gastric mucosa (ingestion of corrosives, extensive neoplasia), and a number of conditions associated with a variable degree of gastric atrophy (such as multiple sclerosis, HIV infection, AIDS, certain endocrine disorders, iron deficiency, and subtotal gastrectomy). Total gastrectomy always produces vitamin B 12 deficiency. Structural lesions leading to vitamin B 12 deficiency include regional ileitis, ileal resections, malignancies, etc. IV. Competition for vitamin B 12 by intestinal parasites or bacteria. The fish tapeworm (Diphyllobothrium latum) absorbs huge quantities of vitamin B 12 and infested patients often have associated gastric atrophy. The blind loop syndrome may produce deficiency of vitamin B 12 or folate. V. Inadequate utilization of vitamin B 12 . This may occur if antimetabolites for the vitamin are employed in the treatment of neoplasia. It may be possible to treat the underlying disease by surgical correction of anatomic lesions leading to small bowel bacterial overgrowth, expulsion of fish tapeworm, discontinuation of drugs leading to vitamin malabsorption (see Drug/Laboratory Test Interactions ), use of a gluten free diet in nontropical sprue, or administration of antibiotics in tropical sprue. Such measures remove the need for long-term administration of vitamin B 12 . Requirements of vitamin B 12 in excess of normal (due to pregnancy, thyrotoxicosis, hemolytic anemia, hemorrhage, malignancy, hepatic and renal disease) can usually be met with intranasal or oral supplementation. Nascobal Nasal Spray is not suitable for vitamin B 12 absorption test (Schilling Test). uuid:51b59e49-130f-4c7a-b63d-b1952affb054 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17439 biolink:treats MONDO:0005240 PMID:41385096 "[{""id"":""uuid:89444aca-1fac-45a1-addf-0aedc7ecd075"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c5770bff-5b12-41a4-9e7a-461fb4c7cc67"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nascobal Nasal Spray is indicated for the maintenance of normal hematologic status in pernicious anemia patients who are in remission following intramuscular vitamin B 12 therapy and who have no nervous system involvement. Nascobal Nasal Spray is also indicated as a supplement for other vitamin B 12 deficiencies, including: I. Dietary deficiency of vitamin B 12 occurring in strict vegetarians (Isolated vitamin B 12 deficiency is very rare). II. Malabsorption of vitamin B 12 resulting from structural or functional damage to the stomach, where intrinsic factor is secreted, or to the ileum, where intrinsic factor facilitates vitamin B 12 absorption. These conditions include HIV infection, AIDS, Crohn's disease, tropical sprue, and nontropical sprue (idiopathic steatorrhea, gluten-induced enteropathy). Folate deficiency in these patients is usually more severe than vitamin B 12 deficiency. III. Inadequate secretion of intrinsic factor, resulting from lesions that destroy the gastric mucosa (ingestion of corrosives, extensive neoplasia), and a number of conditions associated with a variable degree of gastric atrophy (such as multiple sclerosis, HIV infection, AIDS, certain endocrine disorders, iron deficiency, and subtotal gastrectomy). Total gastrectomy always produces vitamin B 12 deficiency. Structural lesions leading to vitamin B 12 deficiency include regional ileitis, ileal resections, malignancies, etc. IV. Competition for vitamin B 12 by intestinal parasites or bacteria. The fish tapeworm (Diphyllobothrium latum) absorbs huge quantities of vitamin B 12 and infested patients often have associated gastric atrophy. The blind loop syndrome may produce deficiency of vitamin B 12 or folate. V. Inadequate utilization of vitamin B 12 . This may occur if antimetabolites for the vitamin are employed in the treatment of neoplasia. It may be possible to treat the underlying disease by surgical correction of anatomic lesions leading to small bowel bacterial overgrowth, expulsion of fish tapeworm, discontinuation of drugs leading to vitamin malabsorption (see Drug/Laboratory Test Interactions ), use of a gluten free diet in nontropical sprue, or administration of antibiotics in tropical sprue. Such measures remove the need for long-term administration of vitamin B 12 . Requirements of vitamin B 12 in excess of normal (due to pregnancy, thyrotoxicosis, hemolytic anemia, hemorrhage, malignancy, hepatic and renal disease) can usually be met with intranasal or oral supplementation. Nascobal Nasal Spray is not suitable for vitamin B 12 absorption test (Schilling Test). uuid:e466b92a-1590-442a-a781-d50092bf1a06 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:145499 biolink:treats MONDO:0004975 PMID:41385096 "[{""id"":""uuid:6860b564-3e1c-4bb8-9872-bc393c697dc0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:bc76116e-b938-4d5f-a82d-807c96e4be52"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f627a7f4-a886-4415-bec7-02efcef4f9f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ARICEPT® is indicated for the treatment of dementia of the Alzheimer's type. Efficacy has been demonstrated in patients with mild to moderate Alzheimer's Disease, as well as in patients with severe Alzheimer's Disease.|[PMDA] Drugs with a new active ingredient indicated for inhibiting progression of symptoms of dementia in patients with Alzheimer's disease. uuid:278be8b3-cfcb-439f-9f19-ba57c5052485 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47426 biolink:treats HP:0000969 PMID:41385096 "[{""id"":""uuid:7adfc44b-07a3-4e67-8f38-53fd21c0e422"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d377770b-66cc-4799-ba5b-dc98db59c0cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Edema: Furosemide is indicated in adults and pediatric patients for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephritic syndrome. Furosemide is particularly useful when an agent with greater diuretic potential is desired. Hypertension: Oral furosemide may be used in adults for the treatment of hypertension alone or in combination with other antihypertensive agents. Hypertensive patients who cannot be adequately controlled with thiazides will probably also not be adequately controlled with furosemide alone. uuid:aa064ece-20cf-4b61-8047-de38ab09e807 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47426 biolink:treats UMLS:C0268732 PMID:41385096 "[{""id"":""uuid:5ce8e74b-bba8-4b11-bbeb-15c4aeb552ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9b4a89b7-abbc-4faa-bb17-4b052ed561ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Edema: Furosemide is indicated in adults and pediatric patients for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephritic syndrome. Furosemide is particularly useful when an agent with greater diuretic potential is desired. Hypertension: Oral furosemide may be used in adults for the treatment of hypertension alone or in combination with other antihypertensive agents. Hypertensive patients who cannot be adequately controlled with thiazides will probably also not be adequately controlled with furosemide alone. uuid:8b61ca5b-9611-43df-bf61-ee8257a97a66 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47426 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:8e821383-ce94-4f11-8268-e90fd020d61a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:41bc1fcc-df82-495f-a3a7-b9f14907c905"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Edema: Furosemide is indicated in adults and pediatric patients for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephritic syndrome. Furosemide is particularly useful when an agent with greater diuretic potential is desired. Hypertension: Oral furosemide may be used in adults for the treatment of hypertension alone or in combination with other antihypertensive agents. Hypertensive patients who cannot be adequately controlled with thiazides will probably also not be adequately controlled with furosemide alone. uuid:1d70d74a-9c41-45f1-9741-1943a8a42d3c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6923 biolink:treats MONDO:0005984 PMID:41385096 "[{""id"":""uuid:c2a2c4be-ed91-4be3-8554-b1efa53fb525"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ff532638-ca13-476a-9872-e9cf0703176a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For topical application in the treatment of tinea pedis (athlete's foot), tinea cruris, and tinea corporis caused by Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum, in the treatment of cutaneous candidiasis (moniliasis), and in the treatment of tinea versicolor. uuid:910eb8be-b37e-4ba9-b266-45139baeb07f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6923 biolink:treats MONDO:0001405 PMID:41385096 "[{""id"":""uuid:24471839-d790-4b20-9bac-22c546b1c542"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:af0aaf4b-6c94-44af-bd75-66334ea1e3e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For topical application in the treatment of tinea pedis (athlete's foot), tinea cruris, and tinea corporis caused by Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum, in the treatment of cutaneous candidiasis (moniliasis), and in the treatment of tinea versicolor. uuid:7421f09e-fa96-490c-8f8d-9aed0411dce8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6923 biolink:treats MONDO:0001461 PMID:41385096 "[{""id"":""uuid:68fe108d-840e-4ac2-825f-29cc5ed728f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:36f0e20c-f097-4735-a47a-05413699a5fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For topical application in the treatment of tinea pedis (athlete's foot), tinea cruris, and tinea corporis caused by Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum, in the treatment of cutaneous candidiasis (moniliasis), and in the treatment of tinea versicolor. uuid:c0a40aaa-521c-4c3c-9306-0387abfe8f30 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6923 biolink:treats MONDO:0000879 PMID:41385096 "[{""id"":""uuid:d8ddb1ce-7d86-4214-a987-33c1474651ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:83d43d3b-dda4-4494-abf1-6f190911cd7c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For topical application in the treatment of tinea pedis (athlete's foot), tinea cruris, and tinea corporis caused by Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum, in the treatment of cutaneous candidiasis (moniliasis), and in the treatment of tinea versicolor. uuid:8fe5ab1e-93b1-418f-94f1-71253a519ebe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6923 biolink:treats MONDO:0005915 PMID:41385096 "[{""id"":""uuid:5099be51-6d93-403c-88ab-c75ee890cd6d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d4e5323a-24d1-4052-a2b2-f9584fff665f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For topical application in the treatment of tinea pedis (athlete's foot), tinea cruris, and tinea corporis caused by Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum, in the treatment of cutaneous candidiasis (moniliasis), and in the treatment of tinea versicolor. uuid:c74eadb1-ffa5-4f43-baef-2e6548b41e09 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27470 biolink:treats MONDO:0009197 PMID:41385096 "[{""id"":""uuid:9bca162c-f3ee-457c-9ae6-7113e1b7bfea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:82ac716e-6c32-48e4-b5dc-46e59a8a1845"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Folic acid is effective in the treatment of megaloblastic anemias due to deficiency of folic acid (as may be seen in tropical or nontropical sprue) and in anemias of nutritional origin, pregnancy, infancy, or childhood. uuid:8e453788-5aea-4395-926e-bad598a34142 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8776 biolink:treats MONDO:0007186 PMID:41385096 "[{""id"":""uuid:466b1c8e-14f9-4e90-b46f-1f94f7aeeb4b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6be2361d-c058-40ac-8179-e466fd0246b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ranitidine is indicated in: Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks. Studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than 8 weeks. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. No placebo-controlled comparative studies have been carried out for periods of longer than 1 year. The treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome and systemic mastocytosis). Short-term treatment of active, benign gastric ulcer. Most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated. Studies available to date have not assessed the safety of ranitidine in uncomplicated, benign gastric ulcer for periods of more than 6 weeks. Maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers. Placebo-controlled studies have been carried out for 1 year. Treatment of GERD. Symptomatic relief commonly occurs within 24 hours after starting therapy with ranitidine 150 mg b.i.d. Treatment of endoscopically diagnosed erosive esophagitis. Symptomatic relief of heartburn commonly occurs within 24 hours of therapy initiation with ranitidine 150 mg q.i.d. Maintenance of healing of erosive esophagitis. Placebo-controlled trials have been carried out for 48 weeks. Concomitant antacids should be given as needed for pain relief to patients with active duodenal ulcer; active, benign gastric ulcer; hypersecretory states; GERD; and erosive esophagitis. uuid:10df75d1-619e-4d02-94d3-05647117fc1e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:101278 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:f6f14615-2249-4323-a0b8-a51b1dbfc72b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:10f9224b-5f4a-468f-bffc-38a581a480ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diltiazem Hydrochloride Extended Release Tablets are indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive medications. Diltiazem Hydrochloride Extended Release Tablets are indicated for the management of chronic stable angina. uuid:e965cae1-a17d-4a99-b7e1-9ab20a7f2e91 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:70691422 biolink:treats MONDO:0005240 PMID:41385096 "[{""id"":""uuid:72c2b413-1310-4890-8f1a-4bbccb196830"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:37feb1f1-4799-4b11-a790-8f662d898375"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] GLOFIL ® -125 (Sodium Iothalamate I-125 Injection) is indicated for evaluation of glomerular filtration in the diagnosis or monitoring of patients with renal disease. uuid:3bffed9f-5358-4373-88ee-0516e3a96e42 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:24847961 biolink:treats HP:0012228 PMID:41385096 "[{""id"":""uuid:332a4e2e-b796-468e-9323-ff820084dfdc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:87cd2307-8a9d-4679-8e4a-375a9b226f08"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Butalbital aspirin, and caffeine capsules are indicated for the relief of the symptom complex of tension (or muscle contraction) headache. Evidence supporting the efficacy and safety of butalbital, aspirin, and caffeine capsules in the treatment of multiple recurrent headaches is unavailable. Caution in this regard is required because butalbital is habit-forming and potentially abusable. uuid:4b5cc6f3-5ec1-47d9-93d3-1e3365edba7e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:24847961 biolink:treats UMLS:C0393736 PMID:41385096 "[{""id"":""uuid:f206468e-8d53-46f1-b3bc-c6853f944119"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d61a00cf-34da-46f4-8531-2aea5e7d834c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Butalbital aspirin, and caffeine capsules are indicated for the relief of the symptom complex of tension (or muscle contraction) headache. Evidence supporting the efficacy and safety of butalbital, aspirin, and caffeine capsules in the treatment of multiple recurrent headaches is unavailable. Caution in this regard is required because butalbital is habit-forming and potentially abusable. uuid:36e3d45b-1343-488b-9abb-bf55889344a7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5778 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:f8a58264-66ee-429e-ae00-d20e5052ab01"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d128b6e2-7fae-4510-8df2-b637e30a2e68"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydrochlorothiazide Tablet, USP is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Hydrochlorothiazide Tablet, USP has also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. Hydrochlorothiazide Tablet, USP is indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension. uuid:42c33afb-dbfc-474f-bc90-3401b2e27ea7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5778 biolink:treats MONDO:0005155 PMID:41385096 "[{""id"":""uuid:a7534fdf-3913-4deb-9bb1-c28178149df8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:52ce4948-3076-47e4-9279-f3d35ab8fb2e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydrochlorothiazide Tablet, USP is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Hydrochlorothiazide Tablet, USP has also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. Hydrochlorothiazide Tablet, USP is indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension. uuid:82be721c-4648-419b-b356-eb384ace6b87 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5778 biolink:treats MONDO:0005377 PMID:41385096 "[{""id"":""uuid:ac15496f-372a-478a-9ded-1cca3e7c1c4b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4caa4426-1d43-4883-9609-86fd838501ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydrochlorothiazide Tablet, USP is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Hydrochlorothiazide Tablet, USP has also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. Hydrochlorothiazide Tablet, USP is indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension. uuid:6fe60e58-8298-4ca0-b45b-43a6d5709739 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5778 biolink:treats UMLS:C0156221 PMID:41385096 "[{""id"":""uuid:ea3160bc-9303-4477-9526-11d6d37d432c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e383bd05-206a-4fb6-bbba-2da1ebb61aae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydrochlorothiazide Tablet, USP is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Hydrochlorothiazide Tablet, USP has also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. Hydrochlorothiazide Tablet, USP is indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension. uuid:3c49edcf-52f9-4f25-b3d4-55a290535866 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5778 biolink:treats MONDO:0005300 PMID:41385096 "[{""id"":""uuid:1dce167d-0709-4da5-acfb-7410037ec73a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a31a9d5c-9a95-4ff0-9ac9-8646b6ce2665"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydrochlorothiazide Tablet, USP is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Hydrochlorothiazide Tablet, USP has also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. Hydrochlorothiazide Tablet, USP is indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension. uuid:74a81c28-33d4-4685-877e-3983d0d6141b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5778 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:68b18e8b-8422-457b-b140-8f69f6adb028"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7296b59c-ec82-4b27-b21a-ee33fbf55b2e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydrochlorothiazide Tablet, USP is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Hydrochlorothiazide Tablet, USP has also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. Hydrochlorothiazide Tablet, USP is indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension. uuid:acf6ccbb-d14d-410c-9949-b95b191c5129 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation MESH:C106429 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:e45b2c5c-ccd4-4a1f-a98e-6c05f559d5c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6caa1d87-41a5-4c63-bee2-610e4de5ce51"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Acetaminophen, Caffeine and Dihydrocodeine Bitartrate Tablets are indicated for the relief of moderate to moderately severe pain. uuid:a069e2ee-7cf8-4f9e-a512-ca37f8e57a1e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7476 biolink:treats MONDO:0011429 PMID:41385096 "[{""id"":""uuid:d7b850b6-7c4a-4251-bc3b-ade179720673"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:500b529c-5347-43fb-a052-df4dd7fd77dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of naproxen and other treatment options before deciding to use naproxen. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Naproxen tablets are indicated: For relief of mild to moderate pain For relief of signs and symptoms of juvenile arthritis For relief of the signs and symptoms of rheumatoid arthritis For relief of the signs and symptoms of osteoarthritis For treatment of primary dysmenorrhea For acute or long-term use in the relief of signs and symptoms of the following: Ankylosing spondylitis Acute painful shoulder (Acute subacromial bursitis/supraspinatus tendinitis) Acute gouty arthritis uuid:42864b6b-02b4-4b44-bce1-3a5ad8b37179 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7476 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:7ec8f164-2c51-4696-ae78-57c7ad1e209f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:55109202-7754-4aaf-bf35-9f3eb897b9b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of naproxen and other treatment options before deciding to use naproxen. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Naproxen tablets are indicated: For relief of mild to moderate pain For relief of signs and symptoms of juvenile arthritis For relief of the signs and symptoms of rheumatoid arthritis For relief of the signs and symptoms of osteoarthritis For treatment of primary dysmenorrhea For acute or long-term use in the relief of signs and symptoms of the following: Ankylosing spondylitis Acute painful shoulder (Acute subacromial bursitis/supraspinatus tendinitis) Acute gouty arthritis uuid:6cd891e7-c9bf-4282-ac64-932d55d794b1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7476 biolink:treats MONDO:0005178 PMID:41385096 "[{""id"":""uuid:9aa5f6f8-0aa9-471e-bc36-df33672e6012"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8f8f7534-43f3-40e5-bea3-7f82f875c565"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of naproxen and other treatment options before deciding to use naproxen. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Naproxen tablets are indicated: For relief of mild to moderate pain For relief of signs and symptoms of juvenile arthritis For relief of the signs and symptoms of rheumatoid arthritis For relief of the signs and symptoms of osteoarthritis For treatment of primary dysmenorrhea For acute or long-term use in the relief of signs and symptoms of the following: Ankylosing spondylitis Acute painful shoulder (Acute subacromial bursitis/supraspinatus tendinitis) Acute gouty arthritis uuid:a00f681c-c2a8-472a-8bee-7e2c4bb2b41e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7476 biolink:treats MONDO:1060206 PMID:41385096 "[{""id"":""uuid:4e611c26-b72e-4cc2-96a6-3cd23c336711"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4395adbb-19bf-48b6-abeb-27ee2a926fe1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of naproxen and other treatment options before deciding to use naproxen. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Naproxen tablets are indicated: For relief of mild to moderate pain For relief of signs and symptoms of juvenile arthritis For relief of the signs and symptoms of rheumatoid arthritis For relief of the signs and symptoms of osteoarthritis For treatment of primary dysmenorrhea For acute or long-term use in the relief of signs and symptoms of the following: Ankylosing spondylitis Acute painful shoulder (Acute subacromial bursitis/supraspinatus tendinitis) Acute gouty arthritis UMLS:C0149875 uuid:6567d32f-482a-413d-88cf-ee9164202ee6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7476 biolink:treats MONDO:0005306 PMID:41385096 "[{""id"":""uuid:88b54486-ff8b-4e23-ba93-04c7a5601251"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9336d53a-f157-47a7-95b0-5ae596b7a4e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of naproxen and other treatment options before deciding to use naproxen. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Naproxen tablets are indicated: For relief of mild to moderate pain For relief of signs and symptoms of juvenile arthritis For relief of the signs and symptoms of rheumatoid arthritis For relief of the signs and symptoms of osteoarthritis For treatment of primary dysmenorrhea For acute or long-term use in the relief of signs and symptoms of the following: Ankylosing spondylitis Acute painful shoulder (Acute subacromial bursitis/supraspinatus tendinitis) Acute gouty arthritis uuid:4fd1732c-08d6-4364-8c33-9e6ffa0c18ec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7476 biolink:treats UMLS:C0149896 PMID:41385096 "[{""id"":""uuid:aad0f900-5659-4650-83dd-0605acb30b71"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c115ce13-db91-479d-bb73-4cb3328e67d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of naproxen and other treatment options before deciding to use naproxen. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Naproxen tablets are indicated: For relief of mild to moderate pain For relief of signs and symptoms of juvenile arthritis For relief of the signs and symptoms of rheumatoid arthritis For relief of the signs and symptoms of osteoarthritis For treatment of primary dysmenorrhea For acute or long-term use in the relief of signs and symptoms of the following: Ankylosing spondylitis Acute painful shoulder (Acute subacromial bursitis/supraspinatus tendinitis) Acute gouty arthritis uuid:14c41b9b-43fc-498c-b27a-c61d2c3d280c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6061 biolink:treats HP:0001681 PMID:41385096 "[{""id"":""uuid:6863baa0-77db-47c8-9209-d003d7bfc313"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b04c6873-d6c3-4e8d-abaf-f9e1f3b5f802"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Isosorbide Dinitrate Extended-release Tablets are indicated for the prevention of angina pectoris due to coronary artery disease. The onset of action of controlled-release oral isosorbide dinitrate is not sufficiently rapid for this product to be useful in aborting an acute anginal episode. uuid:5bb2d501-f313-416d-957d-0b64d370f00e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6061 biolink:treats MONDO:0005010 PMID:41385096 "[{""id"":""uuid:678eb447-2c08-4fec-ad6f-0d0d9c6ac969"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4d75de67-1f6c-45e0-a157-b13e5ebd834c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Isosorbide Dinitrate Extended-release Tablets are indicated for the prevention of angina pectoris due to coronary artery disease. The onset of action of controlled-release oral isosorbide dinitrate is not sufficiently rapid for this product to be useful in aborting an acute anginal episode. uuid:0cc77366-d898-4f26-866c-f110bea4cc59 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0019359 PMID:41385096 "[{""id"":""uuid:704c0085-340d-4718-bf58-923b24234250"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:46d8bc38-e2fa-4aad-8bb8-00a9e9f6b21a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Minocycline Hydrochloride Capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by Rickettsiae Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections caused by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin) Brucellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Minocycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Straphylococcus aureus . (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal infections when penicillin is contraindicated. Infections in women caused by Neisseria gonorrhoeae Syphilis caused by Treponema pallidum subspecies pallidum Yaws caused by Treponema pallidum subspecies pertenue Listeriosis due to Listeria monocytogenes Anthrax due to Bacillus anthracis Vincent's infection caused by Fusobacteruim fusiforme Actinomycosis caused by Actinomyces israelii Infections caused by Clostridium species In acute intestinal amebiasis , minocycline may be a useful adjunct to amebicides. In severe acne , minocycline may be useful adjunctive therapy. Oral minocycline is indicated in the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:2bc729e8-b4af-4c13-ae88-a9e99c481018 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0001246 PMID:41385096 "[{""id"":""uuid:ba850a82-9855-40c2-8d96-9654771bda84"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e5d5a2dd-7123-42b2-b2b8-f6fde94d7b94"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Minocycline Hydrochloride Capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by Rickettsiae Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections caused by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin) Brucellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Minocycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Straphylococcus aureus . (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal infections when penicillin is contraindicated. Infections in women caused by Neisseria gonorrhoeae Syphilis caused by Treponema pallidum subspecies pallidum Yaws caused by Treponema pallidum subspecies pertenue Listeriosis due to Listeria monocytogenes Anthrax due to Bacillus anthracis Vincent's infection caused by Fusobacteruim fusiforme Actinomycosis caused by Actinomyces israelii Infections caused by Clostridium species In acute intestinal amebiasis , minocycline may be a useful adjunct to amebicides. In severe acne , minocycline may be useful adjunctive therapy. Oral minocycline is indicated in the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:f2246ac0-ee68-4d94-8690-409968e269f9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0019186 PMID:41385096 "[{""id"":""uuid:81fb9a7d-3f3d-4a54-bfbb-2e8137af24f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:55b95587-2479-48a2-86fc-af0d8deeb184"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Minocycline Hydrochloride Capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by Rickettsiae Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections caused by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin) Brucellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Minocycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Straphylococcus aureus . (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal infections when penicillin is contraindicated. Infections in women caused by Neisseria gonorrhoeae Syphilis caused by Treponema pallidum subspecies pallidum Yaws caused by Treponema pallidum subspecies pertenue Listeriosis due to Listeria monocytogenes Anthrax due to Bacillus anthracis Vincent's infection caused by Fusobacteruim fusiforme Actinomycosis caused by Actinomyces israelii Infections caused by Clostridium species In acute intestinal amebiasis , minocycline may be a useful adjunct to amebicides. In severe acne , minocycline may be useful adjunctive therapy. Oral minocycline is indicated in the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:c533a5c7-1fee-40ff-86e7-1b2d8f551314 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0019360 PMID:41385096 "[{""id"":""uuid:744fa803-1506-4e2e-ad3b-4091b34d7d8f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4b3e7a57-49f0-4923-b464-1bf4312f743e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Minocycline Hydrochloride Capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by Rickettsiae Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections caused by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin) Brucellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Minocycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Straphylococcus aureus . (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal infections when penicillin is contraindicated. Infections in women caused by Neisseria gonorrhoeae Syphilis caused by Treponema pallidum subspecies pallidum Yaws caused by Treponema pallidum subspecies pertenue Listeriosis due to Listeria monocytogenes Anthrax due to Bacillus anthracis Vincent's infection caused by Fusobacteruim fusiforme Actinomycosis caused by Actinomyces israelii Infections caused by Clostridium species In acute intestinal amebiasis , minocycline may be a useful adjunct to amebicides. In severe acne , minocycline may be useful adjunctive therapy. Oral minocycline is indicated in the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:c38a4131-6eed-47cf-b8b3-bf392dd761cd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0025294 PMID:41385096 "[{""id"":""uuid:5e1440e5-f463-4938-92bb-84d159416f7b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d7294be4-f1f6-44a5-af62-be88edd70dfc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Minocycline Hydrochloride Capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by Rickettsiae Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections caused by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin) Brucellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Minocycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Straphylococcus aureus . (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal infections when penicillin is contraindicated. Infections in women caused by Neisseria gonorrhoeae Syphilis caused by Treponema pallidum subspecies pallidum Yaws caused by Treponema pallidum subspecies pertenue Listeriosis due to Listeria monocytogenes Anthrax due to Bacillus anthracis Vincent's infection caused by Fusobacteruim fusiforme Actinomycosis caused by Actinomyces israelii Infections caused by Clostridium species In acute intestinal amebiasis , minocycline may be a useful adjunct to amebicides. In severe acne , minocycline may be useful adjunctive therapy. Oral minocycline is indicated in the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:7d84f615-51cd-4393-876a-bd2442c40d3f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0024355 PMID:41385096 "[{""id"":""uuid:0be4a94d-db70-48ed-8dd2-36bd199b2a2c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b1c424f3-9c19-4f99-82fc-31e2ddc5e93f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Minocycline Hydrochloride Capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by Rickettsiae Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections caused by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin) Brucellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Minocycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Straphylococcus aureus . (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal infections when penicillin is contraindicated. Infections in women caused by Neisseria gonorrhoeae Syphilis caused by Treponema pallidum subspecies pallidum Yaws caused by Treponema pallidum subspecies pertenue Listeriosis due to Listeria monocytogenes Anthrax due to Bacillus anthracis Vincent's infection caused by Fusobacteruim fusiforme Actinomycosis caused by Actinomyces israelii Infections caused by Clostridium species In acute intestinal amebiasis , minocycline may be a useful adjunct to amebicides. In severe acne , minocycline may be useful adjunctive therapy. Oral minocycline is indicated in the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:c7d43263-8d1f-46a3-a177-1c0baf60b4dc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0005834 PMID:41385096 "[{""id"":""uuid:d2a0b50f-d5a4-4314-b47f-b57fdfd88032"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:be7cb705-53ff-464c-b84a-005bef854947"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Minocycline Hydrochloride Capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by Rickettsiae Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections caused by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin) Brucellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Minocycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Straphylococcus aureus . (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal infections when penicillin is contraindicated. Infections in women caused by Neisseria gonorrhoeae Syphilis caused by Treponema pallidum subspecies pallidum Yaws caused by Treponema pallidum subspecies pertenue Listeriosis due to Listeria monocytogenes Anthrax due to Bacillus anthracis Vincent's infection caused by Fusobacteruim fusiforme Actinomycosis caused by Actinomyces israelii Infections caused by Clostridium species In acute intestinal amebiasis , minocycline may be a useful adjunct to amebicides. In severe acne , minocycline may be useful adjunctive therapy. Oral minocycline is indicated in the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:a800d19d-7ed5-460f-9b05-e949cf6f52e3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0005888 PMID:41385096 "[{""id"":""uuid:ae67150d-4243-4474-b3b1-53cbf4ae2842"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dc2eda22-80c7-46fc-ac7e-e453ef926d42"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Minocycline Hydrochloride Capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by Rickettsiae Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections caused by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin) Brucellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Minocycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Straphylococcus aureus . (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal infections when penicillin is contraindicated. Infections in women caused by Neisseria gonorrhoeae Syphilis caused by Treponema pallidum subspecies pallidum Yaws caused by Treponema pallidum subspecies pertenue Listeriosis due to Listeria monocytogenes Anthrax due to Bacillus anthracis Vincent's infection caused by Fusobacteruim fusiforme Actinomycosis caused by Actinomyces israelii Infections caused by Clostridium species In acute intestinal amebiasis , minocycline may be a useful adjunct to amebicides. In severe acne , minocycline may be useful adjunctive therapy. Oral minocycline is indicated in the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:138d947e-06a4-48ca-8d3e-4c99adfae90e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0001249 PMID:41385096 "[{""id"":""uuid:d21900f6-049c-427b-bb78-7c1cafdacfe8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:81c5dd4e-6c9c-4a89-81b7-f63bcb57f9f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Minocycline Hydrochloride Capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by Rickettsiae Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections caused by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin) Brucellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Minocycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Straphylococcus aureus . (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal infections when penicillin is contraindicated. Infections in women caused by Neisseria gonorrhoeae Syphilis caused by Treponema pallidum subspecies pallidum Yaws caused by Treponema pallidum subspecies pertenue Listeriosis due to Listeria monocytogenes Anthrax due to Bacillus anthracis Vincent's infection caused by Fusobacteruim fusiforme Actinomycosis caused by Actinomyces israelii Infections caused by Clostridium species In acute intestinal amebiasis , minocycline may be a useful adjunct to amebicides. In severe acne , minocycline may be useful adjunctive therapy. Oral minocycline is indicated in the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:df6d5ac3-1d44-4e5b-8854-49ccb7b87dc5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0005808 PMID:41385096 "[{""id"":""uuid:1b4a3fe6-0872-4e50-ba3d-0100a34095dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9631dc08-6885-4625-92ca-de203035fa40"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Minocycline Hydrochloride Capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by Rickettsiae Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections caused by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin) Brucellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Minocycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Straphylococcus aureus . (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal infections when penicillin is contraindicated. Infections in women caused by Neisseria gonorrhoeae Syphilis caused by Treponema pallidum subspecies pallidum Yaws caused by Treponema pallidum subspecies pertenue Listeriosis due to Listeria monocytogenes Anthrax due to Bacillus anthracis Vincent's infection caused by Fusobacteruim fusiforme Actinomycosis caused by Actinomyces israelii Infections caused by Clostridium species In acute intestinal amebiasis , minocycline may be a useful adjunct to amebicides. In severe acne , minocycline may be useful adjunctive therapy. Oral minocycline is indicated in the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:c01cdb7b-d7f2-4b3e-b548-c135a0de95df biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0005297 PMID:41385096 "[{""id"":""uuid:904b0830-c0c2-497d-bc60-4244b08e0f63"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bc7ada8a-09e8-4d41-8d59-4c5d3b5d98f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Minocycline Hydrochloride Capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by Rickettsiae Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections caused by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin) Brucellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Minocycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Straphylococcus aureus . (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal infections when penicillin is contraindicated. Infections in women caused by Neisseria gonorrhoeae Syphilis caused by Treponema pallidum subspecies pallidum Yaws caused by Treponema pallidum subspecies pertenue Listeriosis due to Listeria monocytogenes Anthrax due to Bacillus anthracis Vincent's infection caused by Fusobacteruim fusiforme Actinomycosis caused by Actinomyces israelii Infections caused by Clostridium species In acute intestinal amebiasis , minocycline may be a useful adjunct to amebicides. In severe acne , minocycline may be useful adjunctive therapy. Oral minocycline is indicated in the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:dad09afd-dd50-49cb-ac28-eee1ca12c0e5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0019633 PMID:41385096 "[{""id"":""uuid:285cc330-9d42-4b21-87be-5fc91c80c784"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:10d51b26-ee36-49f9-bc89-263027c12f4a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Minocycline Hydrochloride Capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by Rickettsiae Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections caused by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin) Brucellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Minocycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Straphylococcus aureus . (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal infections when penicillin is contraindicated. Infections in women caused by Neisseria gonorrhoeae Syphilis caused by Treponema pallidum subspecies pallidum Yaws caused by Treponema pallidum subspecies pertenue Listeriosis due to Listeria monocytogenes Anthrax due to Bacillus anthracis Vincent's infection caused by Fusobacteruim fusiforme Actinomycosis caused by Actinomyces israelii Infections caused by Clostridium species In acute intestinal amebiasis , minocycline may be a useful adjunct to amebicides. In severe acne , minocycline may be useful adjunctive therapy. Oral minocycline is indicated in the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:35d686c8-66f8-4a0d-8846-df237752f783 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0001797 PMID:41385096 "[{""id"":""uuid:9d1e5c3a-10c8-4af3-a22d-46ea437fbe2d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c5b0a14b-f610-4be6-a4c8-371413ad1b69"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Minocycline Hydrochloride Capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by Rickettsiae Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections caused by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin) Brucellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Minocycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Straphylococcus aureus . (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal infections when penicillin is contraindicated. Infections in women caused by Neisseria gonorrhoeae Syphilis caused by Treponema pallidum subspecies pallidum Yaws caused by Treponema pallidum subspecies pertenue Listeriosis due to Listeria monocytogenes Anthrax due to Bacillus anthracis Vincent's infection caused by Fusobacteruim fusiforme Actinomycosis caused by Actinomyces israelii Infections caused by Clostridium species In acute intestinal amebiasis , minocycline may be a useful adjunct to amebicides. In severe acne , minocycline may be useful adjunctive therapy. Oral minocycline is indicated in the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:70f9e410-8ced-410d-aa9d-3ac6de0a125d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0019095 PMID:41385096 "[{""id"":""uuid:fb1992c7-001d-4daa-bf86-5ff8b22829a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2221ba4c-8067-4e60-a6a0-eaa8a3a49f52"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Minocycline Hydrochloride Capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by Rickettsiae Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections caused by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin) Brucellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Minocycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Straphylococcus aureus . (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal infections when penicillin is contraindicated. Infections in women caused by Neisseria gonorrhoeae Syphilis caused by Treponema pallidum subspecies pallidum Yaws caused by Treponema pallidum subspecies pertenue Listeriosis due to Listeria monocytogenes Anthrax due to Bacillus anthracis Vincent's infection caused by Fusobacteruim fusiforme Actinomycosis caused by Actinomyces israelii Infections caused by Clostridium species In acute intestinal amebiasis , minocycline may be a useful adjunct to amebicides. In severe acne , minocycline may be useful adjunctive therapy. Oral minocycline is indicated in the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:314c8b65-a26e-4c5b-82d2-fff6c8e1a9e7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0018077 PMID:41385096 "[{""id"":""uuid:d172d6e9-6960-460d-8e8e-fa81d9a0be00"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:60818be4-b66c-46d6-8bb6-915390eef2cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Minocycline Hydrochloride Capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by Rickettsiae Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections caused by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin) Brucellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Minocycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Straphylococcus aureus . (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal infections when penicillin is contraindicated. Infections in women caused by Neisseria gonorrhoeae Syphilis caused by Treponema pallidum subspecies pallidum Yaws caused by Treponema pallidum subspecies pertenue Listeriosis due to Listeria monocytogenes Anthrax due to Bacillus anthracis Vincent's infection caused by Fusobacteruim fusiforme Actinomycosis caused by Actinomyces israelii Infections caused by Clostridium species In acute intestinal amebiasis , minocycline may be a useful adjunct to amebicides. In severe acne , minocycline may be useful adjunctive therapy. Oral minocycline is indicated in the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:39805955-012b-4d6d-94f0-dfbb8ab048e5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0015766 PMID:41385096 "[{""id"":""uuid:3db91353-b59b-4815-b783-44e6962dfecf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:05c8db66-7dc5-46f5-993f-5f34987905df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Minocycline Hydrochloride Capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by Rickettsiae Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections caused by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin) Brucellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Minocycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Straphylococcus aureus . (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal infections when penicillin is contraindicated. Infections in women caused by Neisseria gonorrhoeae Syphilis caused by Treponema pallidum subspecies pallidum Yaws caused by Treponema pallidum subspecies pertenue Listeriosis due to Listeria monocytogenes Anthrax due to Bacillus anthracis Vincent's infection caused by Fusobacteruim fusiforme Actinomycosis caused by Actinomyces israelii Infections caused by Clostridium species In acute intestinal amebiasis , minocycline may be a useful adjunct to amebicides. In severe acne , minocycline may be useful adjunctive therapy. Oral minocycline is indicated in the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:4fd86dc0-445c-4d25-9850-2d2d1b1fe253 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0040728 PMID:41385096 "[{""id"":""uuid:4ceefae6-6f2e-41c1-bb49-5ba870767407"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d60ac467-a92f-46f1-8d5d-d19ec017d7d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Minocycline Hydrochloride Capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by Rickettsiae Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections caused by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin) Brucellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Minocycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Straphylococcus aureus . (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal infections when penicillin is contraindicated. Infections in women caused by Neisseria gonorrhoeae Syphilis caused by Treponema pallidum subspecies pallidum Yaws caused by Treponema pallidum subspecies pertenue Listeriosis due to Listeria monocytogenes Anthrax due to Bacillus anthracis Vincent's infection caused by Fusobacteruim fusiforme Actinomycosis caused by Actinomyces israelii Infections caused by Clostridium species In acute intestinal amebiasis , minocycline may be a useful adjunct to amebicides. In severe acne , minocycline may be useful adjunctive therapy. Oral minocycline is indicated in the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:ff6bb3d9-183c-4bee-9141-f69613d1a89d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0005683 PMID:41385096 "[{""id"":""uuid:8ba2041e-7497-4a7a-9b92-f0cc89a45bee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:477285b8-5745-4b87-b66a-2044ec27c894"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Minocycline Hydrochloride Capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by Rickettsiae Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections caused by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin) Brucellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Minocycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Straphylococcus aureus . (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal infections when penicillin is contraindicated. Infections in women caused by Neisseria gonorrhoeae Syphilis caused by Treponema pallidum subspecies pallidum Yaws caused by Treponema pallidum subspecies pertenue Listeriosis due to Listeria monocytogenes Anthrax due to Bacillus anthracis Vincent's infection caused by Fusobacteruim fusiforme Actinomycosis caused by Actinomyces israelii Infections caused by Clostridium species In acute intestinal amebiasis , minocycline may be a useful adjunct to amebicides. In severe acne , minocycline may be useful adjunctive therapy. Oral minocycline is indicated in the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:11a4d474-6405-430a-b8c1-8605eb56b5f2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0005777 PMID:41385096 "[{""id"":""uuid:5c1aaa4f-4445-40ea-8757-8c8fcde98d0d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d0ef33f5-8ccc-410b-a514-e201ce6a3a79"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Minocycline Hydrochloride Capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by Rickettsiae Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections caused by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin) Brucellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Minocycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Straphylococcus aureus . (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal infections when penicillin is contraindicated. Infections in women caused by Neisseria gonorrhoeae Syphilis caused by Treponema pallidum subspecies pallidum Yaws caused by Treponema pallidum subspecies pertenue Listeriosis due to Listeria monocytogenes Anthrax due to Bacillus anthracis Vincent's infection caused by Fusobacteruim fusiforme Actinomycosis caused by Actinomyces israelii Infections caused by Clostridium species In acute intestinal amebiasis , minocycline may be a useful adjunct to amebicides. In severe acne , minocycline may be useful adjunctive therapy. Oral minocycline is indicated in the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:dd8784a2-43ef-41cb-a11b-582b1bb5dd9b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0020920 PMID:41385096 "[{""id"":""uuid:32b42971-1dc4-47bd-9a96-a71cd4113191"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0f459f9d-cc8e-44d9-8292-6e7750156b00"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Minocycline Hydrochloride Capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by Rickettsiae Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections caused by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin) Brucellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Minocycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Straphylococcus aureus . (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal infections when penicillin is contraindicated. Infections in women caused by Neisseria gonorrhoeae Syphilis caused by Treponema pallidum subspecies pallidum Yaws caused by Treponema pallidum subspecies pertenue Listeriosis due to Listeria monocytogenes Anthrax due to Bacillus anthracis Vincent's infection caused by Fusobacteruim fusiforme Actinomycosis caused by Actinomyces israelii Infections caused by Clostridium species In acute intestinal amebiasis , minocycline may be a useful adjunct to amebicides. In severe acne , minocycline may be useful adjunctive therapy. Oral minocycline is indicated in the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:352bf468-b7fa-42c2-bddb-4a5110039d08 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0019345 PMID:41385096 "[{""id"":""uuid:b7fb0943-f9e1-4004-a2f7-25baf3aea699"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ff15bb2f-266f-4f21-9986-e64d9bb6869d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Minocycline Hydrochloride Capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by Rickettsiae Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections caused by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin) Brucellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Minocycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Straphylococcus aureus . (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal infections when penicillin is contraindicated. Infections in women caused by Neisseria gonorrhoeae Syphilis caused by Treponema pallidum subspecies pallidum Yaws caused by Treponema pallidum subspecies pertenue Listeriosis due to Listeria monocytogenes Anthrax due to Bacillus anthracis Vincent's infection caused by Fusobacteruim fusiforme Actinomycosis caused by Actinomyces israelii Infections caused by Clostridium species In acute intestinal amebiasis , minocycline may be a useful adjunct to amebicides. In severe acne , minocycline may be useful adjunctive therapy. Oral minocycline is indicated in the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:755d62bd-378f-437e-8ab8-ed7e02a7b48a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0006635 PMID:41385096 "[{""id"":""uuid:5d3eea03-0785-48a1-a9c7-35d082875cbb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:22b7858a-dd21-493e-ba13-a5fd443c9a25"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Minocycline Hydrochloride Capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by Rickettsiae Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections caused by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin) Brucellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Minocycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Straphylococcus aureus . (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal infections when penicillin is contraindicated. Infections in women caused by Neisseria gonorrhoeae Syphilis caused by Treponema pallidum subspecies pallidum Yaws caused by Treponema pallidum subspecies pertenue Listeriosis due to Listeria monocytogenes Anthrax due to Bacillus anthracis Vincent's infection caused by Fusobacteruim fusiforme Actinomycosis caused by Actinomyces israelii Infections caused by Clostridium species In acute intestinal amebiasis , minocycline may be a useful adjunct to amebicides. In severe acne , minocycline may be useful adjunctive therapy. Oral minocycline is indicated in the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:5f535032-cff2-4136-960c-ebf70aa1c266 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats HP:0005376 PMID:41385096 "[{""id"":""uuid:217d0eda-1e81-444a-8f35-d29f446c175b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0da2d5a9-9615-402d-aebe-44560aaa6eaa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Minocycline Hydrochloride Capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by Rickettsiae Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections caused by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin) Brucellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Minocycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Straphylococcus aureus . (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal infections when penicillin is contraindicated. Infections in women caused by Neisseria gonorrhoeae Syphilis caused by Treponema pallidum subspecies pallidum Yaws caused by Treponema pallidum subspecies pertenue Listeriosis due to Listeria monocytogenes Anthrax due to Bacillus anthracis Vincent's infection caused by Fusobacteruim fusiforme Actinomycosis caused by Actinomyces israelii Infections caused by Clostridium species In acute intestinal amebiasis , minocycline may be a useful adjunct to amebicides. In severe acne , minocycline may be useful adjunctive therapy. Oral minocycline is indicated in the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:cbe1695e-2279-4085-ba91-aead5f61da3c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0030603 PMID:41385096 "[{""id"":""uuid:ca2fe8c2-f26f-4e5d-9e49-8344d09d32d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1858155d-e9f5-4c00-ab18-59768451575f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Minocycline Hydrochloride Capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by Rickettsiae Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections caused by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin) Brucellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Minocycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Straphylococcus aureus . (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal infections when penicillin is contraindicated. Infections in women caused by Neisseria gonorrhoeae Syphilis caused by Treponema pallidum subspecies pallidum Yaws caused by Treponema pallidum subspecies pertenue Listeriosis due to Listeria monocytogenes Anthrax due to Bacillus anthracis Vincent's infection caused by Fusobacteruim fusiforme Actinomycosis caused by Actinomyces israelii Infections caused by Clostridium species In acute intestinal amebiasis , minocycline may be a useful adjunct to amebicides. In severe acne , minocycline may be useful adjunctive therapy. Oral minocycline is indicated in the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:5a2d29fb-0cc4-45e7-9aaf-a847da32caf6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:5f13dbf9-2026-42e6-a587-fd639e30ef36"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:73ef95e9-c085-402c-a1a1-d4eb5b80ea84"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Minocycline Hydrochloride Capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by Rickettsiae Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections caused by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin) Brucellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Minocycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Straphylococcus aureus . (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal infections when penicillin is contraindicated. Infections in women caused by Neisseria gonorrhoeae Syphilis caused by Treponema pallidum subspecies pallidum Yaws caused by Treponema pallidum subspecies pertenue Listeriosis due to Listeria monocytogenes Anthrax due to Bacillus anthracis Vincent's infection caused by Fusobacteruim fusiforme Actinomycosis caused by Actinomyces israelii Infections caused by Clostridium species In acute intestinal amebiasis , minocycline may be a useful adjunct to amebicides. In severe acne , minocycline may be useful adjunctive therapy. Oral minocycline is indicated in the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:9115171d-f125-470e-a2e6-893fd15fe5f1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0004277 PMID:41385096 "[{""id"":""uuid:9529eece-7743-4919-8aa8-fbd1b0b142bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6d8dbdcc-79ad-49a4-a9e8-32e44142e405"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Minocycline Hydrochloride Capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by Rickettsiae Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections caused by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin) Brucellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Minocycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Straphylococcus aureus . (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal infections when penicillin is contraindicated. Infections in women caused by Neisseria gonorrhoeae Syphilis caused by Treponema pallidum subspecies pallidum Yaws caused by Treponema pallidum subspecies pertenue Listeriosis due to Listeria monocytogenes Anthrax due to Bacillus anthracis Vincent's infection caused by Fusobacteruim fusiforme Actinomycosis caused by Actinomyces israelii Infections caused by Clostridium species In acute intestinal amebiasis , minocycline may be a useful adjunct to amebicides. In severe acne , minocycline may be useful adjunctive therapy. Oral minocycline is indicated in the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:72acf668-0f06-4904-8cc4-260f90865e90 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0005976 PMID:41385096 "[{""id"":""uuid:ce8707a4-54d4-4860-9c7c-fe3f5ed2b6ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0abf128a-482a-4991-af88-26dadd641dd4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Minocycline Hydrochloride Capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by Rickettsiae Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections caused by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin) Brucellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Minocycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Straphylococcus aureus . (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal infections when penicillin is contraindicated. Infections in women caused by Neisseria gonorrhoeae Syphilis caused by Treponema pallidum subspecies pallidum Yaws caused by Treponema pallidum subspecies pertenue Listeriosis due to Listeria monocytogenes Anthrax due to Bacillus anthracis Vincent's infection caused by Fusobacteruim fusiforme Actinomycosis caused by Actinomyces israelii Infections caused by Clostridium species In acute intestinal amebiasis , minocycline may be a useful adjunct to amebicides. In severe acne , minocycline may be useful adjunctive therapy. Oral minocycline is indicated in the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:4b0d13b8-8412-4f0e-ab2b-b715cbdc1e31 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0006019 PMID:41385096 "[{""id"":""uuid:2c29a6c8-ce40-4a76-b227-160c61e05784"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ea19b0d0-188f-4b4d-8560-321d5e7a4dcf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Minocycline Hydrochloride Capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by Rickettsiae Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections caused by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin) Brucellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Minocycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Straphylococcus aureus . (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal infections when penicillin is contraindicated. Infections in women caused by Neisseria gonorrhoeae Syphilis caused by Treponema pallidum subspecies pallidum Yaws caused by Treponema pallidum subspecies pertenue Listeriosis due to Listeria monocytogenes Anthrax due to Bacillus anthracis Vincent's infection caused by Fusobacteruim fusiforme Actinomycosis caused by Actinomyces israelii Infections caused by Clostridium species In acute intestinal amebiasis , minocycline may be a useful adjunct to amebicides. In severe acne , minocycline may be useful adjunctive therapy. Oral minocycline is indicated in the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:942521e6-9daf-4d5a-b01b-9e02f7780aff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0005828 PMID:41385096 "[{""id"":""uuid:9cbc55bd-0f50-4b8d-8e35-6e52b1f59cef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4185dd7a-1677-4635-9b3c-cc4e68a8ca13"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Minocycline Hydrochloride Capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by Rickettsiae Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections caused by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin) Brucellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Minocycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Straphylococcus aureus . (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal infections when penicillin is contraindicated. Infections in women caused by Neisseria gonorrhoeae Syphilis caused by Treponema pallidum subspecies pallidum Yaws caused by Treponema pallidum subspecies pertenue Listeriosis due to Listeria monocytogenes Anthrax due to Bacillus anthracis Vincent's infection caused by Fusobacteruim fusiforme Actinomycosis caused by Actinomyces israelii Infections caused by Clostridium species In acute intestinal amebiasis , minocycline may be a useful adjunct to amebicides. In severe acne , minocycline may be useful adjunctive therapy. Oral minocycline is indicated in the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:60ae6eb6-e5e4-4f88-ad7e-33796353987f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0005119 PMID:41385096 "[{""id"":""uuid:ee31a4db-13dc-4abb-a1ca-1f451993537b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bf9315ff-f6a6-4ed9-ba72-22ce0467d35c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Minocycline Hydrochloride Capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by Rickettsiae Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections caused by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin) Brucellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Minocycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Straphylococcus aureus . (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal infections when penicillin is contraindicated. Infections in women caused by Neisseria gonorrhoeae Syphilis caused by Treponema pallidum subspecies pallidum Yaws caused by Treponema pallidum subspecies pertenue Listeriosis due to Listeria monocytogenes Anthrax due to Bacillus anthracis Vincent's infection caused by Fusobacteruim fusiforme Actinomycosis caused by Actinomyces israelii Infections caused by Clostridium species In acute intestinal amebiasis , minocycline may be a useful adjunct to amebicides. In severe acne , minocycline may be useful adjunctive therapy. Oral minocycline is indicated in the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:ac343504-d4a3-4f38-94c5-c3a3c0a95637 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0005631 PMID:41385096 "[{""id"":""uuid:7f2d2600-4ffc-4055-82dd-8482daa7b6b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5aa4b467-ae9f-49ed-a89f-de9ed8f2ddb7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Minocycline Hydrochloride Capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by Rickettsiae Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections caused by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin) Brucellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Minocycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Straphylococcus aureus . (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal infections when penicillin is contraindicated. Infections in women caused by Neisseria gonorrhoeae Syphilis caused by Treponema pallidum subspecies pallidum Yaws caused by Treponema pallidum subspecies pertenue Listeriosis due to Listeria monocytogenes Anthrax due to Bacillus anthracis Vincent's infection caused by Fusobacteruim fusiforme Actinomycosis caused by Actinomyces israelii Infections caused by Clostridium species In acute intestinal amebiasis , minocycline may be a useful adjunct to amebicides. In severe acne , minocycline may be useful adjunctive therapy. Oral minocycline is indicated in the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:bf934343-f77e-4db1-90f8-2db315a93958 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0024388 PMID:41385096 "[{""id"":""uuid:c0fa6e48-c180-4ac1-9104-051fb1233001"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:404a1dd1-8f12-4cdb-a824-2ac3c474f72a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Minocycline Hydrochloride Capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by Rickettsiae Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections caused by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin) Brucellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Minocycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Straphylococcus aureus . (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal infections when penicillin is contraindicated. Infections in women caused by Neisseria gonorrhoeae Syphilis caused by Treponema pallidum subspecies pallidum Yaws caused by Treponema pallidum subspecies pertenue Listeriosis due to Listeria monocytogenes Anthrax due to Bacillus anthracis Vincent's infection caused by Fusobacteruim fusiforme Actinomycosis caused by Actinomyces israelii Infections caused by Clostridium species In acute intestinal amebiasis , minocycline may be a useful adjunct to amebicides. In severe acne , minocycline may be useful adjunctive therapy. Oral minocycline is indicated in the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:4b8a89f6-ae89-4ebb-8b32-3badef3193bd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0005644 PMID:41385096 "[{""id"":""uuid:06203501-e304-46d3-8dc1-9ca0b6b62abb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:303bd278-42f1-4fa7-a513-be6401d017f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Minocycline Hydrochloride Capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by Rickettsiae Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections caused by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin) Brucellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Minocycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Straphylococcus aureus . (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal infections when penicillin is contraindicated. Infections in women caused by Neisseria gonorrhoeae Syphilis caused by Treponema pallidum subspecies pallidum Yaws caused by Treponema pallidum subspecies pertenue Listeriosis due to Listeria monocytogenes Anthrax due to Bacillus anthracis Vincent's infection caused by Fusobacteruim fusiforme Actinomycosis caused by Actinomyces israelii Infections caused by Clostridium species In acute intestinal amebiasis , minocycline may be a useful adjunct to amebicides. In severe acne , minocycline may be useful adjunctive therapy. Oral minocycline is indicated in the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:920a3057-8c74-4f03-963a-7ce2835f3b42 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0011438 PMID:41385096 "[{""id"":""uuid:d2923c57-922d-46a2-86c7-6e259c60d7a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aae2b8ce-e3f3-43b7-8f39-51ae43c29cf4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Minocycline Hydrochloride Capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by Rickettsiae Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections caused by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin) Brucellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Minocycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Straphylococcus aureus . (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal infections when penicillin is contraindicated. Infections in women caused by Neisseria gonorrhoeae Syphilis caused by Treponema pallidum subspecies pallidum Yaws caused by Treponema pallidum subspecies pertenue Listeriosis due to Listeria monocytogenes Anthrax due to Bacillus anthracis Vincent's infection caused by Fusobacteruim fusiforme Actinomycosis caused by Actinomyces israelii Infections caused by Clostridium species In acute intestinal amebiasis , minocycline may be a useful adjunct to amebicides. In severe acne , minocycline may be useful adjunctive therapy. Oral minocycline is indicated in the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:bd722931-0e54-4683-ad37-c9663631f279 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0043314 PMID:41385096 "[{""id"":""uuid:ff068130-0e88-451c-9d7f-48fbe322f36f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a7c24f74-da37-4402-a063-e3e18f05b4f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Minocycline Hydrochloride Capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by Rickettsiae Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections caused by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin) Brucellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Minocycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Straphylococcus aureus . (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal infections when penicillin is contraindicated. Infections in women caused by Neisseria gonorrhoeae Syphilis caused by Treponema pallidum subspecies pallidum Yaws caused by Treponema pallidum subspecies pertenue Listeriosis due to Listeria monocytogenes Anthrax due to Bacillus anthracis Vincent's infection caused by Fusobacteruim fusiforme Actinomycosis caused by Actinomyces israelii Infections caused by Clostridium species In acute intestinal amebiasis , minocycline may be a useful adjunct to amebicides. In severe acne , minocycline may be useful adjunctive therapy. Oral minocycline is indicated in the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:a75a5da9-42a2-441d-951b-8ea1b01d8edd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7457 biolink:treats UMLS:C0572061 PMID:41385096 "[{""id"":""uuid:2088ae07-42d5-47c1-aced-2a6bbe4eb784"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cc6193ed-f111-47c8-8527-2aa83e71d35d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] REVEX is indicated for the complete or partial reversal of opioid drug effects, including respiratory depression, induced by either natural or synthetic opioids. REVEX is indicated in the management of known or suspected opioid overdose. uuid:66cfed66-b58a-4da9-93de-7f7701d1c6ba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7457 biolink:treats MONDO:0043775 PMID:41385096 "[{""id"":""uuid:9f4ef04a-11d6-4bf0-a24a-4e2abef503f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:573ce449-6fd3-4c58-a621-72106fb0fa70"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] REVEX is indicated for the complete or partial reversal of opioid drug effects, including respiratory depression, induced by either natural or synthetic opioids. REVEX is indicated in the management of known or suspected opioid overdose. uuid:802d3e69-661b-4247-84fc-ce89e4743933 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50673 biolink:treats MONDO:0004425 PMID:41385096 "[{""id"":""uuid:7d83c25a-9355-4779-ac4f-49a9887e4d1f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1e0bd888-8478-4e90-99d3-b038d7743702"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methimazole is indicated in the medical treatment of hyperthyroidism. Long-term therapy may lead to remission of the disease. Methimazole may be used to ameliorate hyperthyroidism in preparation for subtotal thyroidectomy or radioactive iodine therapy. Methimazole is also used when thyroidectomy is contraindicated or not advisable. uuid:00bda256-714f-476a-aa19-b6fb118d855f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64198 biolink:treats UMLS:C0311375 PMID:41385096 "[{""id"":""uuid:f01970a1-0c6d-4bf6-8423-69a03e42ddc8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3cc2fb46-4997-4515-8ff1-5da883e637c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BAL in Oil (Dimercaprol Injection USP) is indicated in the treatment of arsenic, gold and mercury poisoning. It is indicated in acute lead poisoning when used concomitantly with Edetate Calcium Disodium Injection USP. Dimercaprol Injection USP is effective for use in acute poisoning by mercury salts if therapy is begun within one or two hours following ingestion. It is not very effective for chronic mercury poisoning. Dimercaprol Injection USP is of questionable value in poisoning caused by other heavy metals such as antimony and bismuth. It should not be used in iron, cadmium, or selenium poisoning because the resulting dimercaprol-metal complexes are more toxic than the metal alone, especially to the kidneys. uuid:f5c77b90-9d7c-4b0e-ac3a-f82fd23e0db6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64198 biolink:treats UMLS:C0274944 PMID:41385096 "[{""id"":""uuid:2ca49dd4-015a-4702-8735-94dee0a4c792"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7f7bf1a3-2fb3-4740-b3b3-c02d49a1d869"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BAL in Oil (Dimercaprol Injection USP) is indicated in the treatment of arsenic, gold and mercury poisoning. It is indicated in acute lead poisoning when used concomitantly with Edetate Calcium Disodium Injection USP. Dimercaprol Injection USP is effective for use in acute poisoning by mercury salts if therapy is begun within one or two hours following ingestion. It is not very effective for chronic mercury poisoning. Dimercaprol Injection USP is of questionable value in poisoning caused by other heavy metals such as antimony and bismuth. It should not be used in iron, cadmium, or selenium poisoning because the resulting dimercaprol-metal complexes are more toxic than the metal alone, especially to the kidneys. uuid:14e30e6e-d90c-43bb-8595-b7eb624c0df7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64198 biolink:treats MONDO:0018020 PMID:41385096 "[{""id"":""uuid:647ee896-43e9-4dc9-b23d-dc377ddc1616"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d730209e-97ae-4d16-a1f0-5cd6eb6fe5fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BAL in Oil (Dimercaprol Injection USP) is indicated in the treatment of arsenic, gold and mercury poisoning. It is indicated in acute lead poisoning when used concomitantly with Edetate Calcium Disodium Injection USP. Dimercaprol Injection USP is effective for use in acute poisoning by mercury salts if therapy is begun within one or two hours following ingestion. It is not very effective for chronic mercury poisoning. Dimercaprol Injection USP is of questionable value in poisoning caused by other heavy metals such as antimony and bismuth. It should not be used in iron, cadmium, or selenium poisoning because the resulting dimercaprol-metal complexes are more toxic than the metal alone, especially to the kidneys. uuid:837eee28-4e70-48dc-a019-6aa3153e584e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64198 biolink:treats MONDO:0018019 PMID:41385096 "[{""id"":""uuid:e3050417-efb0-4f2e-a305-544cc43e75e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:47d2d8b6-b61e-4748-a61c-33392299f671"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BAL in Oil (Dimercaprol Injection USP) is indicated in the treatment of arsenic, gold and mercury poisoning. It is indicated in acute lead poisoning when used concomitantly with Edetate Calcium Disodium Injection USP. Dimercaprol Injection USP is effective for use in acute poisoning by mercury salts if therapy is begun within one or two hours following ingestion. It is not very effective for chronic mercury poisoning. Dimercaprol Injection USP is of questionable value in poisoning caused by other heavy metals such as antimony and bismuth. It should not be used in iron, cadmium, or selenium poisoning because the resulting dimercaprol-metal complexes are more toxic than the metal alone, especially to the kidneys. uuid:fdd8294f-e007-47d0-8e93-f846532db733 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64198 biolink:treats UMLS:C0553526 PMID:41385096 "[{""id"":""uuid:ef4e1421-67c0-45eb-8cf0-36bb254a7985"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:430ca356-b2ed-453d-8d9a-5e77ae68c043"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BAL in Oil (Dimercaprol Injection USP) is indicated in the treatment of arsenic, gold and mercury poisoning. It is indicated in acute lead poisoning when used concomitantly with Edetate Calcium Disodium Injection USP. Dimercaprol Injection USP is effective for use in acute poisoning by mercury salts if therapy is begun within one or two hours following ingestion. It is not very effective for chronic mercury poisoning. Dimercaprol Injection USP is of questionable value in poisoning caused by other heavy metals such as antimony and bismuth. It should not be used in iron, cadmium, or selenium poisoning because the resulting dimercaprol-metal complexes are more toxic than the metal alone, especially to the kidneys. uuid:ee6be39f-50ed-4b06-a6bd-a8a8a8752693 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64198 biolink:treats UMLS:C0274920 PMID:41385096 "[{""id"":""uuid:aafdbb37-64e5-431f-b191-6568f48bcedc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cd55556c-00df-4f12-99e6-27041d86654b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BAL in Oil (Dimercaprol Injection USP) is indicated in the treatment of arsenic, gold and mercury poisoning. It is indicated in acute lead poisoning when used concomitantly with Edetate Calcium Disodium Injection USP. Dimercaprol Injection USP is effective for use in acute poisoning by mercury salts if therapy is begun within one or two hours following ingestion. It is not very effective for chronic mercury poisoning. Dimercaprol Injection USP is of questionable value in poisoning caused by other heavy metals such as antimony and bismuth. It should not be used in iron, cadmium, or selenium poisoning because the resulting dimercaprol-metal complexes are more toxic than the metal alone, especially to the kidneys. uuid:8f5cd691-d473-4613-83bd-ccdd35611d00 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64198 biolink:treats MONDO:0043523 PMID:41385096 "[{""id"":""uuid:ea27d8cd-7df7-4102-914a-3618586d5af7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2449362e-8462-468a-9cc4-051a0dbe6915"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BAL in Oil (Dimercaprol Injection USP) is indicated in the treatment of arsenic, gold and mercury poisoning. It is indicated in acute lead poisoning when used concomitantly with Edetate Calcium Disodium Injection USP. Dimercaprol Injection USP is effective for use in acute poisoning by mercury salts if therapy is begun within one or two hours following ingestion. It is not very effective for chronic mercury poisoning. Dimercaprol Injection USP is of questionable value in poisoning caused by other heavy metals such as antimony and bismuth. It should not be used in iron, cadmium, or selenium poisoning because the resulting dimercaprol-metal complexes are more toxic than the metal alone, especially to the kidneys. uuid:38506963-714c-4498-ba65-1027869ec976 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64198 biolink:treats UMLS:C0274973 PMID:41385096 "[{""id"":""uuid:8acad60f-0d3a-4692-83ac-75060b4e70a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ab26a253-2a77-4213-8850-4874782af88b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BAL in Oil (Dimercaprol Injection USP) is indicated in the treatment of arsenic, gold and mercury poisoning. It is indicated in acute lead poisoning when used concomitantly with Edetate Calcium Disodium Injection USP. Dimercaprol Injection USP is effective for use in acute poisoning by mercury salts if therapy is begun within one or two hours following ingestion. It is not very effective for chronic mercury poisoning. Dimercaprol Injection USP is of questionable value in poisoning caused by other heavy metals such as antimony and bismuth. It should not be used in iron, cadmium, or selenium poisoning because the resulting dimercaprol-metal complexes are more toxic than the metal alone, especially to the kidneys. uuid:6825d4be-fcfd-42ac-aa89-1c56da3966bf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5130 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:5cb1b603-5081-4739-961a-8a3601537cfe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6a6f4c71-1c11-4ccb-92c3-ac545d021102"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of Flurbiprofen tablet, USP and other treatment options before deciding to use Flurbiprofen tablet, USP. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Flurbiprofen tablet, USP is indicated: For relief of the signs and symptoms of rheumatoid arthritis. For relief of the signs and symptoms of osteoarthritis. uuid:27207b52-e4d3-416d-ae44-132f11d06ade biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5130 biolink:treats MONDO:0005178 PMID:41385096 "[{""id"":""uuid:65b2e4c0-f771-498c-ae2e-a13153452b44"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c9cc2b71-180c-4f21-a55b-e65abbcd4e8c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of Flurbiprofen tablet, USP and other treatment options before deciding to use Flurbiprofen tablet, USP. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Flurbiprofen tablet, USP is indicated: For relief of the signs and symptoms of rheumatoid arthritis. For relief of the signs and symptoms of osteoarthritis. uuid:7528a891-a6b3-42d8-8d6e-b0113481f74d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9123 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:09446f7d-0c94-458e-b3b4-6a69a2ba36a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3db3c450-b4e1-4c56-b7a4-c8c24e7e6738"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sertraline hydrochloride tablets are indicated for the treatment of major depressive disorder in adults. The efficacy of sertraline in the treatment of a major depressive episode was established in six to eight week controlled trials of adult outpatients whose diagnoses corresponded most closely to the DSM-III category of major depressive disorder (see Clinical Trials under CLINICAL PHARMACOLOGY ). A major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks); it should include at least 4 of the following 8 symptoms: change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suicide attempt or suicidal ideation. The antidepressant action of sertraline in hospitalized depressed patients has not been adequately studied. The efficacy of sertraline in maintaining an antidepressant response for up to 44 weeks following 8 weeks of open-label acute treatment (52 weeks total) was demonstrated in a placebo-controlled trial. The usefulness of the drug in patients receiving sertraline for extended periods should be reevaluated periodically (see Clinical Trials under CLINICAL PHARMACOLOGY ). uuid:3a8ab828-9bc2-49b0-a25f-6d8d7a1c36aa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63617 biolink:treats MONDO:0005180 PMID:41385096 "[{""id"":""uuid:40512c4c-33bd-4bd1-b9b9-ac1f511b4f0f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:41fa05f2-19bb-4cd7-85ee-2d5be3228c82"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Permax is indicated as adjunctive treatment to levodopa/carbidopa in the management of the signs and symptoms of Parkinson's disease. Evidence to support the efficacy of pergolide as an antiparkinsonian adjunct was obtained in a multicenter study enrolling 376 patients with mild to moderate Parkinson's disease who were intolerant to l -dopa/carbidopa as manifested by moderate to severe dyskinesia and/or on-off phenomena. On average, the patients evaluated had been on l -dopa/carbidopa for 3.9 years (range, 2 days to 16.8 years). The administration of pergolide permitted a 5% to 30% reduction in the daily dose of l -dopa. On average, these patients treated with pergolide maintained an equivalent or better clinical status than they exhibited at baseline. uuid:ff17fb45-4bcb-4dbe-9d94-35e8ff44e4a4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63617 biolink:treats HP:0100660 PMID:41385096 "[{""id"":""uuid:6a26c83b-225d-48c8-9e83-b3bf1508f8e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2d3dc24c-39f4-4981-9cb0-c76a70262ae6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Permax is indicated as adjunctive treatment to levodopa/carbidopa in the management of the signs and symptoms of Parkinson's disease. Evidence to support the efficacy of pergolide as an antiparkinsonian adjunct was obtained in a multicenter study enrolling 376 patients with mild to moderate Parkinson's disease who were intolerant to l -dopa/carbidopa as manifested by moderate to severe dyskinesia and/or on-off phenomena. On average, the patients evaluated had been on l -dopa/carbidopa for 3.9 years (range, 2 days to 16.8 years). The administration of pergolide permitted a 5% to 30% reduction in the daily dose of l -dopa. On average, these patients treated with pergolide maintained an equivalent or better clinical status than they exhibited at baseline. uuid:c570f495-4931-4ba4-8b73-b538bc5ef630 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9073 biolink:treats MONDO:0013600 PMID:41385096 "[{""id"":""uuid:170fb2cb-90f1-4ee2-9cc5-959581d62c6a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a31b3111-5544-436a-b9cc-18e9108de582"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] A. Hypnotic, for the short-term treatment of insomnia, since it appears to lose its effectiveness for sleep induction and sleep maintenance after 2 weeks (see Clinical Pharmacology). B. Preanesthetic uuid:6fa405e9-f4c2-41b1-883d-e2ba9a725ee9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2668 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:7de151d9-ee93-4021-9f49-656bb11db866"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1a96d2b4-e60c-4f09-aeba-7bbfb0d62649"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:15d883e2-8c8c-4430-9492-5e070d8bc03c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Hypertension Amlodipine besylate is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents. 2. Chronic Stable Angina Amlodipine besylate is indicated for the treatment of chronic stable angina. Amlodipine besylate may be used alone or in combination with other antianginal agents. 3. Vasospastic Angina (Prinzmetal's or Variant Angina) Amlodipine besylate is indicated for the treatment of confirmed or suspected vasospastic angina. Amlodipine besylate may be used as monotherapy or in combination with other antianginal drugs.|[PMDA] Drugs with a new additional pediatric dosages. These drugs are indicated for the treatment of hypertension. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:3717b612-a24d-468c-8215-1f0aa16375ae biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2668 biolink:treats MONDO:0006021 PMID:41385096 "[{""id"":""uuid:a2749539-3b64-45c7-8643-5f086fd1a377"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2e6aa544-3dc9-4645-ae53-4cc05f8119b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Hypertension Amlodipine besylate is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents. 2. Chronic Stable Angina Amlodipine besylate is indicated for the treatment of chronic stable angina. Amlodipine besylate may be used alone or in combination with other antianginal agents. 3. Vasospastic Angina (Prinzmetal's or Variant Angina) Amlodipine besylate is indicated for the treatment of confirmed or suspected vasospastic angina. Amlodipine besylate may be used as monotherapy or in combination with other antianginal drugs. uuid:34cc8b38-1080-4260-8c28-465fe074a951 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7660 biolink:treats MONDO:0002040 PMID:41385096 "[{""id"":""uuid:c80a64a8-11da-4c48-8020-be5bac00e0f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cbd4a2f6-5d3d-44b8-a494-371c012a1981"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nystatin topical powder is indicated in the treatment of cutaneous or mucocutaneous mycotic infections caused by Candida albicans and other susceptible Candida species. This topical powder is not indicated for systemic, oral, intravaginal or ophthalmic use. uuid:2b780c52-72b8-4773-b863-fa70b66a1f08 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7660 biolink:treats MONDO:0002041 PMID:41385096 "[{""id"":""uuid:3ff1384d-83be-446d-b250-00f4424762ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:27ef3691-96e0-42a0-a4a0-0ed001723098"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nystatin topical powder is indicated in the treatment of cutaneous or mucocutaneous mycotic infections caused by Candida albicans and other susceptible Candida species. This topical powder is not indicated for systemic, oral, intravaginal or ophthalmic use. uuid:d8db6bb0-9b45-4d35-9ca9-c73df535dced biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:85783 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:6f8eb6ad-60e3-4e84-b1d2-a7353385a25a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a5f3452b-473f-47b1-87af-8c8b2fb069a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lisinopril and hydrochlorothiazide tablets are indicated for the treatment of hypertension. These fixed-dose combinations are not indicated for initial therapy (see DOSAGE AND ADMINISTRATION ). In using lisinopril and hydrochlorothiazide, consideration should be given to the fact that an angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that lisinopril does not have a similar risk. (See WARNINGS .) In considering use of lisinopril and hydrochlorothiazide, it should be noted that black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks. (See WARNINGS, Angioedema .) uuid:c9703fe4-dc8c-4a4f-a7da-3d46abf7e51a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:85783 biolink:treats MONDO:0001609 PMID:41385096 "[{""id"":""uuid:4be6da1c-dad6-4f7e-9c59-98919bd346da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a63babfc-5ba7-4d7d-a3ff-b4e564b39c25"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lisinopril and hydrochlorothiazide tablets are indicated for the treatment of hypertension. These fixed-dose combinations are not indicated for initial therapy (see DOSAGE AND ADMINISTRATION ). In using lisinopril and hydrochlorothiazide, consideration should be given to the fact that an angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that lisinopril does not have a similar risk. (See WARNINGS .) In considering use of lisinopril and hydrochlorothiazide, it should be noted that black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks. (See WARNINGS, Angioedema .) uuid:dfd4cc31-4168-434b-8458-668f66af4a28 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:85783 biolink:treats MONDO:0001343 PMID:41385096 "[{""id"":""uuid:180fde70-6d36-435b-bb15-7841b4c4ebdd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b1db7da4-29e9-42e7-bdc7-ad02018e3d0c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lisinopril and hydrochlorothiazide tablets are indicated for the treatment of hypertension. These fixed-dose combinations are not indicated for initial therapy (see DOSAGE AND ADMINISTRATION ). In using lisinopril and hydrochlorothiazide, consideration should be given to the fact that an angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that lisinopril does not have a similar risk. (See WARNINGS .) In considering use of lisinopril and hydrochlorothiazide, it should be noted that black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks. (See WARNINGS, Angioedema .) uuid:7c485e97-1424-429c-ba70-56fd693d72c3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:85783 biolink:treats MONDO:0010481 PMID:41385096 "[{""id"":""uuid:c7c7e894-8928-44fd-bc47-668fc1eb9cb3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d97318a3-e198-421c-a773-4c086fa29584"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lisinopril and hydrochlorothiazide tablets are indicated for the treatment of hypertension. These fixed-dose combinations are not indicated for initial therapy (see DOSAGE AND ADMINISTRATION ). In using lisinopril and hydrochlorothiazide, consideration should be given to the fact that an angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that lisinopril does not have a similar risk. (See WARNINGS .) In considering use of lisinopril and hydrochlorothiazide, it should be noted that black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks. (See WARNINGS, Angioedema .) uuid:6443b969-5a6f-4bbf-bdc2-b60b3664e5b3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:167309 biolink:treats MONDO:0005530 PMID:41385096 "[{""id"":""uuid:cbcbaa01-982a-4d34-bcfa-3697a03902af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:263863ab-f279-4f94-9aa8-51a0514a5674"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Detoxification treatment of opioid addiction (heroin or other morphine-like drugs). Maintenance treatment of opioid addiction (heroin or other morphine-like drugs), in conjunction with appropriate social and medical services. uuid:d74dbe6f-0457-4f95-970d-ebb8ed18086b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:167309 biolink:treats MONDO:0005367 PMID:41385096 "[{""id"":""uuid:0f9d96bf-4ad9-40bc-8151-c2e7708d5d87"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:885ade0e-498b-4879-947d-4a20dcb43945"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Detoxification treatment of opioid addiction (heroin or other morphine-like drugs). Maintenance treatment of opioid addiction (heroin or other morphine-like drugs), in conjunction with appropriate social and medical services. uuid:f47bb1b7-3b60-4406-8095-9aa7b66a54d7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:167309 biolink:treats MONDO:0005303 PMID:41385096 "[{""id"":""uuid:0cb29b88-2d48-42ee-b9ff-92380417a424"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6467f714-2def-4ed6-a5c1-a37250b3aa28"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Detoxification treatment of opioid addiction (heroin or other morphine-like drugs). Maintenance treatment of opioid addiction (heroin or other morphine-like drugs), in conjunction with appropriate social and medical services. uuid:becacb01-80d5-4e7c-91b7-461b8de70f6a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5138 biolink:treats UMLS:C0233697 PMID:41385096 "[{""id"":""uuid:9a26a2de-de97-401a-ad99-1accf47d4557"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:db99c28f-644b-43cd-8ba0-0620a033030e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fluvoxamine Maleate Tablets are indicated for the treatment of obsessions and compulsions in patients with Obsessive Compulsive Disorder (OCD), as defined in the DSM-III-R. The obsessions or compulsions cause marked distress, are time-consuming, or significantly interfere with social or occupational functioning. The efficacy of Fluvoxamine Maleate Tablets was established in three 10-week trials with obsessive compulsive outpatients with the diagnosis of Obsessive Compulsive Disorder as defined in DSM-III-R. (See Clinical Trials under CLINICAL PHARMACOLOGY .) Obsessive Compulsive Disorder is characterized by recurrent and persistent ideas, thoughts, impulses or images (obsessions) that are ego- dystonic and/or repetitive, purposeful, and intentional behaviors (compulsions) that are recognized by the person as excessive or unreasonable. The effectiveness of Fluvoxamine Maleate Tablets for long-term use, i.e., for more than 10 weeks, has not been systematically evaluated in placebo-controlled trials. Therefore, the physician who elects to use Fluvoxamine Maleate Tablets for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient. (See DOSAGE AND ADMINISTRATION .) uuid:326b2901-439b-431b-94e4-4c7674e8006d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5138 biolink:treats MONDO:0008114 PMID:41385096 "[{""id"":""uuid:2b895d44-c328-4c02-bef6-83b36505ec3c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2e9aaab6-e761-4e3e-b48f-0711c500ffdc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fluvoxamine Maleate Tablets are indicated for the treatment of obsessions and compulsions in patients with Obsessive Compulsive Disorder (OCD), as defined in the DSM-III-R. The obsessions or compulsions cause marked distress, are time-consuming, or significantly interfere with social or occupational functioning. The efficacy of Fluvoxamine Maleate Tablets was established in three 10-week trials with obsessive compulsive outpatients with the diagnosis of Obsessive Compulsive Disorder as defined in DSM-III-R. (See Clinical Trials under CLINICAL PHARMACOLOGY .) Obsessive Compulsive Disorder is characterized by recurrent and persistent ideas, thoughts, impulses or images (obsessions) that are ego- dystonic and/or repetitive, purposeful, and intentional behaviors (compulsions) that are recognized by the person as excessive or unreasonable. The effectiveness of Fluvoxamine Maleate Tablets for long-term use, i.e., for more than 10 weeks, has not been systematically evaluated in placebo-controlled trials. Therefore, the physician who elects to use Fluvoxamine Maleate Tablets for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient. (See DOSAGE AND ADMINISTRATION .) uuid:fe5d71e7-c70f-462c-8f91-0b4a7567d965 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29103 biolink:treats MONDO:0003019 PMID:41385096 "[{""id"":""uuid:2650042e-ecfa-47d5-96f5-a6e64e6a1938"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:12aa9f6f-f31f-4aa4-b59f-deba1572cb44"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BECAUSE OF REPORTS OF INTESTINAL AND GASTRIC ULCERATION AND BLEEDING WITH CONTROLLED-RELEASE POTASSIUM CHLORIDE PREPARATIONS, THESE DRUGS SHOULD BE RESERVED FOR THOSE PATIENTS WHO CANNOT TOLERATE OR REFUSE TO TAKE LIQUID OR EFFERVESCENT POTASSIUM PREPARATIONS OR FOR PATIENTS IN WHOM THERE IS A PROBLEM OF COMPLIANCE WITH THESE PREPARATIONS. For the treatment of patients with hypokalemia, with or without metabolic alkalosis, in digitalis intoxications, and in patients with hypokalemic familial periodic paralysis. If hypokalemia is the result of diuretic therapy, consideration should be given to the use of a lower dose of diuretic, which may be sufficient without leading to hypokalemia. For the prevention of hypokalemia in patients who would be at particular risk if hypokalemia were to develop, e.g., digitalized patients or patients with significant cardiac arrhythmias, hepatic cirrhosis with ascites, states of aldosterone excess with normal renal function, potassium-losing nephropathy, and certain diarrheal states. The use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension is often unnecessary when such patients have a normal dietary pattern and when low doses of the diuretic are used. Serum potassium should be checked periodically, however, and if hypokalemia occurs, dietary supplementation with potassium-containing foods may be adequate to control milder cases. In more severe cases, and if dose adjustment of the diuretic is ineffective or unwarranted, supplementation with potassium salts may be indicated. uuid:823f32f6-f808-4ce2-9b8d-e044975635ec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29103 biolink:treats HP:0200114 PMID:41385096 "[{""id"":""uuid:31923319-276f-42b1-9e19-6d2acd3612f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:77ce52c5-ef45-46a2-a5db-3fbe1b5ca07a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BECAUSE OF REPORTS OF INTESTINAL AND GASTRIC ULCERATION AND BLEEDING WITH CONTROLLED-RELEASE POTASSIUM CHLORIDE PREPARATIONS, THESE DRUGS SHOULD BE RESERVED FOR THOSE PATIENTS WHO CANNOT TOLERATE OR REFUSE TO TAKE LIQUID OR EFFERVESCENT POTASSIUM PREPARATIONS OR FOR PATIENTS IN WHOM THERE IS A PROBLEM OF COMPLIANCE WITH THESE PREPARATIONS. For the treatment of patients with hypokalemia, with or without metabolic alkalosis, in digitalis intoxications, and in patients with hypokalemic familial periodic paralysis. If hypokalemia is the result of diuretic therapy, consideration should be given to the use of a lower dose of diuretic, which may be sufficient without leading to hypokalemia. For the prevention of hypokalemia in patients who would be at particular risk if hypokalemia were to develop, e.g., digitalized patients or patients with significant cardiac arrhythmias, hepatic cirrhosis with ascites, states of aldosterone excess with normal renal function, potassium-losing nephropathy, and certain diarrheal states. The use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension is often unnecessary when such patients have a normal dietary pattern and when low doses of the diuretic are used. Serum potassium should be checked periodically, however, and if hypokalemia occurs, dietary supplementation with potassium-containing foods may be adequate to control milder cases. In more severe cases, and if dose adjustment of the diuretic is ineffective or unwarranted, supplementation with potassium salts may be indicated. uuid:58f0f4cd-b08f-4abd-91a9-5783aae1feb0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29103 biolink:treats MONDO:0017863 PMID:41385096 "[{""id"":""uuid:c031f102-db1a-45eb-8cb9-ec01ba46bfe6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9575adb9-a27a-4ba8-98ce-a17e42c69e7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BECAUSE OF REPORTS OF INTESTINAL AND GASTRIC ULCERATION AND BLEEDING WITH CONTROLLED-RELEASE POTASSIUM CHLORIDE PREPARATIONS, THESE DRUGS SHOULD BE RESERVED FOR THOSE PATIENTS WHO CANNOT TOLERATE OR REFUSE TO TAKE LIQUID OR EFFERVESCENT POTASSIUM PREPARATIONS OR FOR PATIENTS IN WHOM THERE IS A PROBLEM OF COMPLIANCE WITH THESE PREPARATIONS. For the treatment of patients with hypokalemia, with or without metabolic alkalosis, in digitalis intoxications, and in patients with hypokalemic familial periodic paralysis. If hypokalemia is the result of diuretic therapy, consideration should be given to the use of a lower dose of diuretic, which may be sufficient without leading to hypokalemia. For the prevention of hypokalemia in patients who would be at particular risk if hypokalemia were to develop, e.g., digitalized patients or patients with significant cardiac arrhythmias, hepatic cirrhosis with ascites, states of aldosterone excess with normal renal function, potassium-losing nephropathy, and certain diarrheal states. The use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension is often unnecessary when such patients have a normal dietary pattern and when low doses of the diuretic are used. Serum potassium should be checked periodically, however, and if hypokalemia occurs, dietary supplementation with potassium-containing foods may be adequate to control milder cases. In more severe cases, and if dose adjustment of the diuretic is ineffective or unwarranted, supplementation with potassium salts may be indicated. uuid:57001c50-b344-42e8-8d6c-8b53173d9706 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29103 biolink:treats MONDO:0008223 PMID:41385096 "[{""id"":""uuid:8a1ea453-7238-4bcc-84ad-ec358779b0fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bbc5c823-c30f-4762-840f-89c413859ae1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BECAUSE OF REPORTS OF INTESTINAL AND GASTRIC ULCERATION AND BLEEDING WITH CONTROLLED-RELEASE POTASSIUM CHLORIDE PREPARATIONS, THESE DRUGS SHOULD BE RESERVED FOR THOSE PATIENTS WHO CANNOT TOLERATE OR REFUSE TO TAKE LIQUID OR EFFERVESCENT POTASSIUM PREPARATIONS OR FOR PATIENTS IN WHOM THERE IS A PROBLEM OF COMPLIANCE WITH THESE PREPARATIONS. For the treatment of patients with hypokalemia, with or without metabolic alkalosis, in digitalis intoxications, and in patients with hypokalemic familial periodic paralysis. If hypokalemia is the result of diuretic therapy, consideration should be given to the use of a lower dose of diuretic, which may be sufficient without leading to hypokalemia. For the prevention of hypokalemia in patients who would be at particular risk if hypokalemia were to develop, e.g., digitalized patients or patients with significant cardiac arrhythmias, hepatic cirrhosis with ascites, states of aldosterone excess with normal renal function, potassium-losing nephropathy, and certain diarrheal states. The use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension is often unnecessary when such patients have a normal dietary pattern and when low doses of the diuretic are used. Serum potassium should be checked periodically, however, and if hypokalemia occurs, dietary supplementation with potassium-containing foods may be adequate to control milder cases. In more severe cases, and if dose adjustment of the diuretic is ineffective or unwarranted, supplementation with potassium salts may be indicated. uuid:5906bc33-3c3c-4ecd-8e4d-18ed5fe5afec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29103 biolink:treats MONDO:0007263 PMID:41385096 "[{""id"":""uuid:fb758142-f2b8-4ffd-8762-97e0670262dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ba486579-3d04-4c4a-9abf-5bd76c6fb7b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BECAUSE OF REPORTS OF INTESTINAL AND GASTRIC ULCERATION AND BLEEDING WITH CONTROLLED-RELEASE POTASSIUM CHLORIDE PREPARATIONS, THESE DRUGS SHOULD BE RESERVED FOR THOSE PATIENTS WHO CANNOT TOLERATE OR REFUSE TO TAKE LIQUID OR EFFERVESCENT POTASSIUM PREPARATIONS OR FOR PATIENTS IN WHOM THERE IS A PROBLEM OF COMPLIANCE WITH THESE PREPARATIONS. For the treatment of patients with hypokalemia, with or without metabolic alkalosis, in digitalis intoxications, and in patients with hypokalemic familial periodic paralysis. If hypokalemia is the result of diuretic therapy, consideration should be given to the use of a lower dose of diuretic, which may be sufficient without leading to hypokalemia. For the prevention of hypokalemia in patients who would be at particular risk if hypokalemia were to develop, e.g., digitalized patients or patients with significant cardiac arrhythmias, hepatic cirrhosis with ascites, states of aldosterone excess with normal renal function, potassium-losing nephropathy, and certain diarrheal states. The use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension is often unnecessary when such patients have a normal dietary pattern and when low doses of the diuretic are used. Serum potassium should be checked periodically, however, and if hypokalemia occurs, dietary supplementation with potassium-containing foods may be adequate to control milder cases. In more severe cases, and if dose adjustment of the diuretic is ineffective or unwarranted, supplementation with potassium salts may be indicated. uuid:86386699-ba94-4c42-9da6-7f7fb5e78fce biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29103 biolink:treats MONDO:0005155 PMID:41385096 "[{""id"":""uuid:df1e0108-a77b-48a9-848a-b08f8b458b5f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:225a224d-b51d-453c-a45c-3a94ef0bb2c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BECAUSE OF REPORTS OF INTESTINAL AND GASTRIC ULCERATION AND BLEEDING WITH CONTROLLED-RELEASE POTASSIUM CHLORIDE PREPARATIONS, THESE DRUGS SHOULD BE RESERVED FOR THOSE PATIENTS WHO CANNOT TOLERATE OR REFUSE TO TAKE LIQUID OR EFFERVESCENT POTASSIUM PREPARATIONS OR FOR PATIENTS IN WHOM THERE IS A PROBLEM OF COMPLIANCE WITH THESE PREPARATIONS. For the treatment of patients with hypokalemia, with or without metabolic alkalosis, in digitalis intoxications, and in patients with hypokalemic familial periodic paralysis. If hypokalemia is the result of diuretic therapy, consideration should be given to the use of a lower dose of diuretic, which may be sufficient without leading to hypokalemia. For the prevention of hypokalemia in patients who would be at particular risk if hypokalemia were to develop, e.g., digitalized patients or patients with significant cardiac arrhythmias, hepatic cirrhosis with ascites, states of aldosterone excess with normal renal function, potassium-losing nephropathy, and certain diarrheal states. The use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension is often unnecessary when such patients have a normal dietary pattern and when low doses of the diuretic are used. Serum potassium should be checked periodically, however, and if hypokalemia occurs, dietary supplementation with potassium-containing foods may be adequate to control milder cases. In more severe cases, and if dose adjustment of the diuretic is ineffective or unwarranted, supplementation with potassium salts may be indicated. uuid:3c82b8e6-cadb-4796-836b-fca5bc7e1ef9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29103 biolink:treats MONDO:0001673 PMID:41385096 "[{""id"":""uuid:399847f9-6c6a-45e1-b6a5-d5d0aaf8c150"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f25a8dee-a482-4583-8067-99bb063f19e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BECAUSE OF REPORTS OF INTESTINAL AND GASTRIC ULCERATION AND BLEEDING WITH CONTROLLED-RELEASE POTASSIUM CHLORIDE PREPARATIONS, THESE DRUGS SHOULD BE RESERVED FOR THOSE PATIENTS WHO CANNOT TOLERATE OR REFUSE TO TAKE LIQUID OR EFFERVESCENT POTASSIUM PREPARATIONS OR FOR PATIENTS IN WHOM THERE IS A PROBLEM OF COMPLIANCE WITH THESE PREPARATIONS. For the treatment of patients with hypokalemia, with or without metabolic alkalosis, in digitalis intoxications, and in patients with hypokalemic familial periodic paralysis. If hypokalemia is the result of diuretic therapy, consideration should be given to the use of a lower dose of diuretic, which may be sufficient without leading to hypokalemia. For the prevention of hypokalemia in patients who would be at particular risk if hypokalemia were to develop, e.g., digitalized patients or patients with significant cardiac arrhythmias, hepatic cirrhosis with ascites, states of aldosterone excess with normal renal function, potassium-losing nephropathy, and certain diarrheal states. The use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension is often unnecessary when such patients have a normal dietary pattern and when low doses of the diuretic are used. Serum potassium should be checked periodically, however, and if hypokalemia occurs, dietary supplementation with potassium-containing foods may be adequate to control milder cases. In more severe cases, and if dose adjustment of the diuretic is ineffective or unwarranted, supplementation with potassium salts may be indicated. uuid:cccd6fef-f777-4435-b993-4b6b139e0500 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29103 biolink:treats MONDO:0001134 PMID:41385096 "[{""id"":""uuid:c5b241a4-a0ab-45ad-9892-361fc47d007e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cfdeb604-be36-4ad0-9ad5-b7eca5ea26cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BECAUSE OF REPORTS OF INTESTINAL AND GASTRIC ULCERATION AND BLEEDING WITH CONTROLLED-RELEASE POTASSIUM CHLORIDE PREPARATIONS, THESE DRUGS SHOULD BE RESERVED FOR THOSE PATIENTS WHO CANNOT TOLERATE OR REFUSE TO TAKE LIQUID OR EFFERVESCENT POTASSIUM PREPARATIONS OR FOR PATIENTS IN WHOM THERE IS A PROBLEM OF COMPLIANCE WITH THESE PREPARATIONS. For the treatment of patients with hypokalemia, with or without metabolic alkalosis, in digitalis intoxications, and in patients with hypokalemic familial periodic paralysis. If hypokalemia is the result of diuretic therapy, consideration should be given to the use of a lower dose of diuretic, which may be sufficient without leading to hypokalemia. For the prevention of hypokalemia in patients who would be at particular risk if hypokalemia were to develop, e.g., digitalized patients or patients with significant cardiac arrhythmias, hepatic cirrhosis with ascites, states of aldosterone excess with normal renal function, potassium-losing nephropathy, and certain diarrheal states. The use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension is often unnecessary when such patients have a normal dietary pattern and when low doses of the diuretic are used. Serum potassium should be checked periodically, however, and if hypokalemia occurs, dietary supplementation with potassium-containing foods may be adequate to control milder cases. In more severe cases, and if dose adjustment of the diuretic is ineffective or unwarranted, supplementation with potassium salts may be indicated. uuid:9972e9da-4ca4-415a-b8ff-6250502997ed biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:91495 biolink:treats MONDO:0005002 PMID:41385096 "[{""id"":""uuid:e9ab85c4-2709-454a-b639-c5e68c42a968"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:652ce62d-eb7a-419f-808d-c850bbfc5741"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ipratropium Bromide Inhalation Solution administered either alone or with other bronchodilators, especially beta adrenergics, is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema. uuid:895a9f46-ad20-4924-9e02-0f3314c99509 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:91495 biolink:treats MONDO:0005607 PMID:41385096 "[{""id"":""uuid:f6477463-5991-49c9-875b-6198462ea851"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:83470c59-7854-4ef9-afae-569257b2da81"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ipratropium Bromide Inhalation Solution administered either alone or with other bronchodilators, especially beta adrenergics, is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema. uuid:125d1019-0629-4c1d-831b-a07b8e37facd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:91495 biolink:treats MONDO:0004849 PMID:41385096 "[{""id"":""uuid:10b5d11d-f25b-4ecc-88f9-9158f1caee90"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d128b876-2729-4a00-a556-ec8ef3b8a87c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ipratropium Bromide Inhalation Solution administered either alone or with other bronchodilators, especially beta adrenergics, is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema. uuid:b9fb9bfd-efae-4b0d-9840-2276f38705fd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:42355 biolink:treats MONDO:0011438 PMID:41385096 "[{""id"":""uuid:6ca4ac51-3f5a-431c-b4c2-2edfa2c302b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bb2ee683-0e29-4bfe-8918-33337f080541"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Erythromycin pledgets, USP are indicated for the topical treatment of acne vulgaris. uuid:aa5467d3-4a1b-4365-91ce-e3365b97ffff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0008315 PMID:41385096 "[{""id"":""uuid:c58d00c3-b156-42cc-bc28-c86cec8447a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:23a8f118-4ca5-45b6-a07f-54ee3d372507"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Viadur ® is indicated in the palliative treatment of advanced prostate cancer. uuid:02cf6d7d-6d7e-43a2-a2a8-edda5fb6b6a9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3441 biolink:treats HP:0025169 PMID:41385096 "[{""id"":""uuid:b3e72676-8568-4d50-a594-2f8b814f9360"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:70e4ca9a-746b-418f-a44a-644d32f11d1b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carvedilol is an alpha/beta-adrenergic blocking agent indicated for the treatment of: Left ventricular dysfunction following myocardial infarction in clinically stable patients (1.1) Hypertension (1.2) uuid:3b0529f7-8c32-4097-afb2-c4c726c9fb9b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3441 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:c1984381-1f28-4015-86ab-97e6f16cb110"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b00fee72-0e80-4747-ad65-90fa9de4633f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carvedilol is an alpha/beta-adrenergic blocking agent indicated for the treatment of: Left ventricular dysfunction following myocardial infarction in clinically stable patients (1.1) Hypertension (1.2) uuid:a41e3902-106a-4d2f-acce-4595e051c706 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:167309 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:77022fc6-6082-4151-9300-4f7e0ee27afc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b2d94d7b-4221-4b90-b709-bc390e7ea25b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the treatment of moderate to severe pain not responsive to non-narcotic analgesics. For use in temporary treatment of opioid dependence in patients unable to take oral medication. Outpatient maintenance and outpatient detoxification treatment may be provided only by opioid treatment programs (OTPs) certified by the Federal Substance Abuse and Mental Health Services Administration (SAMHSA) and registered by the Drug Enforcement Administration (DEA). This does not preclude the maintenance treatment of a patient with concurrent opioid addiction who is hospitalized for conditions other than opioid addiction and who requires temporary maintenance during the critical period of hospitalization, or of a patient whose enrollment has been verified in a program which has been certified for maintenance treatment with methadone. uuid:ccdfa5df-f11b-4fcb-af68-bc466689afbf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:8358fae9-329f-472d-b4d5-bde3094ea2e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:74f4a982-5bcf-48ce-adc9-0d1659c21426"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. uuid:855f128e-a9ba-4de3-90b6-b16c12e4a986 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:6ad58ae2-8db7-4c76-b86c-0080806690c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:02940562-f60c-46e0-830f-2892a616f2c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. uuid:71ce8b1d-cdaf-47ee-833a-d3ca3e0258d1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0005480 PMID:41385096 "[{""id"":""uuid:01b00403-dfbb-453e-89bc-5a0db7cec933"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:42b75434-9861-419a-8f3d-ade15e480d4a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. uuid:cc0fc548-0343-42ca-8e72-871a7008e5ee biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0000775 PMID:41385096 "[{""id"":""uuid:fdb8cdbc-b105-4acf-bd88-53c5b31ba90b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0fe0ae67-11c7-48b6-a285-ed3a7e6f354f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. uuid:fd0f6e95-df5f-4f06-8de2-91c32b99979e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0024332 PMID:41385096 "[{""id"":""uuid:071a4b06-8b08-4fb4-bcc0-d27ff0f98da7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6a24511a-940d-4347-9bb8-4350a7d417f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. uuid:8c500f64-d1ba-435b-bdf5-e1306583c2f3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0005324 PMID:41385096 "[{""id"":""uuid:611a26ae-9214-42bb-adae-deb9bdc2f8d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:46eb0ce2-a324-4ef4-a6a1-772cb142658e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. uuid:5cbaa9cd-225b-47cb-afe3-5f26dff6a693 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0043789 PMID:41385096 "[{""id"":""uuid:f98ee20e-bd2b-448a-be3f-d57ce7609e36"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:509a3cda-f6d0-4634-a7f3-42b4fa586165"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. uuid:448f60ce-c244-4c3f-8d76-f1567ea423a6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:474053 biolink:treats MONDO:0024355 PMID:41385096 "[{""id"":""uuid:0c38fd8c-9c31-4965-acd1-7b5472e3cf92"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:afb7dd64-df1b-4183-9d84-7c6e04cade7d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefazolin for injection is indicated in the treatment of the following serious infections due to susceptible organisms: Respiratory Tract Infections due to S. pneumoniae, Klebsiella species, H. influenzae, S. aureus (penicillin-sensitive and penicillin-resistant), and group A beta-hemolytic streptococci. Injectable benzathine penicillin is considered to be the drug of choice in treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cefazolin for injection is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of Cefazolin for injection in the subsequent prevention of rheumatic fever are not available at present. Urinary Tract Infections due to E. coli, P. mirabilis, Klebsiella species, and some strains of enterobacter and enterococci. Skin and Skin Structure Infections due to S. aureus (penicillin-sensitive and penicillin-resistant), group A beta-hemolytic streptococci, and other strains of streptococci. Biliary Tract Infections due to E. coli, various strains of streptococci, P. mirabilis, Klebsiella species, and S. aureus. Bone and Joint Infections due to S. aureus. Genital Infections (i.e., prostatitis, epididymitis) due to E. coli, P. mirabilis, Klebsiella species, and some strains of enterococci. Septicemia due to S. pneumoniae, S. aureus (penicillin-sensitive and penicillin-resistant), P. mirabilis, E. coli , and Klebsiella species. Endocarditis due to S. aureus (penicillin-sensitive and penicillin-resistant) and group A beta-hemolytic streptococci. Perioperative Prophylaxis the prophylactic administration of Cefazolin for injection preoperatively, intraoperatively, and postoperatively may reduce the incidence of certain postoperative infections in patients undergoing surgical procedures which are classified as contaminated or potentially contaminated (e.g., vaginal hysterectomy, and cholecystectomy in high-risk patients such as those older than 70 years, with acute cholecystitis, obstructive jaundice, or common duct bile stones). The perioperative use of Cefazolin for injection may also be effective in surgical patients in whom infection at the operative site would present a serious risk (e.g., during open-heart surgery and prosthetic arthroplasty). The prophylactic administration of Cefazolin for injection should usually be discontinued within a 24 hour period after the surgical procedure. In surgery where the occurrence of infection may be particularly devastating (e.g., open-heart surgery and prosthetic arthroplasty), the prophylactic administration of Cefazolin for injection may be continued for 3 to 5 days following the completion of surgery. If there are signs of infection, specimens for cultures should be obtained for the identification of the causative organism so that appropriate therapy may be instituted.(See DOSAGE AND ADMINISTRATION .) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefazolin for injection and other antibacterial drugs, Cefazolin for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:2cccec2f-9e77-463f-97f9-931faa369035 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:474053 biolink:treats MONDO:0021680 PMID:41385096 "[{""id"":""uuid:6a9c570e-b4ab-49d6-8b30-6702bb604b8b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:13edf8a3-1267-4e1d-8386-7356f800687c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefazolin for injection is indicated in the treatment of the following serious infections due to susceptible organisms: Respiratory Tract Infections due to S. pneumoniae, Klebsiella species, H. influenzae, S. aureus (penicillin-sensitive and penicillin-resistant), and group A beta-hemolytic streptococci. Injectable benzathine penicillin is considered to be the drug of choice in treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cefazolin for injection is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of Cefazolin for injection in the subsequent prevention of rheumatic fever are not available at present. Urinary Tract Infections due to E. coli, P. mirabilis, Klebsiella species, and some strains of enterobacter and enterococci. Skin and Skin Structure Infections due to S. aureus (penicillin-sensitive and penicillin-resistant), group A beta-hemolytic streptococci, and other strains of streptococci. Biliary Tract Infections due to E. coli, various strains of streptococci, P. mirabilis, Klebsiella species, and S. aureus. Bone and Joint Infections due to S. aureus. Genital Infections (i.e., prostatitis, epididymitis) due to E. coli, P. mirabilis, Klebsiella species, and some strains of enterococci. Septicemia due to S. pneumoniae, S. aureus (penicillin-sensitive and penicillin-resistant), P. mirabilis, E. coli , and Klebsiella species. Endocarditis due to S. aureus (penicillin-sensitive and penicillin-resistant) and group A beta-hemolytic streptococci. Perioperative Prophylaxis the prophylactic administration of Cefazolin for injection preoperatively, intraoperatively, and postoperatively may reduce the incidence of certain postoperative infections in patients undergoing surgical procedures which are classified as contaminated or potentially contaminated (e.g., vaginal hysterectomy, and cholecystectomy in high-risk patients such as those older than 70 years, with acute cholecystitis, obstructive jaundice, or common duct bile stones). The perioperative use of Cefazolin for injection may also be effective in surgical patients in whom infection at the operative site would present a serious risk (e.g., during open-heart surgery and prosthetic arthroplasty). The prophylactic administration of Cefazolin for injection should usually be discontinued within a 24 hour period after the surgical procedure. In surgery where the occurrence of infection may be particularly devastating (e.g., open-heart surgery and prosthetic arthroplasty), the prophylactic administration of Cefazolin for injection may be continued for 3 to 5 days following the completion of surgery. If there are signs of infection, specimens for cultures should be obtained for the identification of the causative organism so that appropriate therapy may be instituted.(See DOSAGE AND ADMINISTRATION .) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefazolin for injection and other antibacterial drugs, Cefazolin for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:5764df02-1a49-4aa3-b861-8997f0f446f6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:474053 biolink:treats MONDO:0017767 PMID:41385096 "[{""id"":""uuid:2274ff72-706f-474b-b956-41c293248d8e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6fb82a52-3caf-4821-9735-476361d48f8d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefazolin for injection is indicated in the treatment of the following serious infections due to susceptible organisms: Respiratory Tract Infections due to S. pneumoniae, Klebsiella species, H. influenzae, S. aureus (penicillin-sensitive and penicillin-resistant), and group A beta-hemolytic streptococci. Injectable benzathine penicillin is considered to be the drug of choice in treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cefazolin for injection is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of Cefazolin for injection in the subsequent prevention of rheumatic fever are not available at present. Urinary Tract Infections due to E. coli, P. mirabilis, Klebsiella species, and some strains of enterobacter and enterococci. Skin and Skin Structure Infections due to S. aureus (penicillin-sensitive and penicillin-resistant), group A beta-hemolytic streptococci, and other strains of streptococci. Biliary Tract Infections due to E. coli, various strains of streptococci, P. mirabilis, Klebsiella species, and S. aureus. Bone and Joint Infections due to S. aureus. Genital Infections (i.e., prostatitis, epididymitis) due to E. coli, P. mirabilis, Klebsiella species, and some strains of enterococci. Septicemia due to S. pneumoniae, S. aureus (penicillin-sensitive and penicillin-resistant), P. mirabilis, E. coli , and Klebsiella species. Endocarditis due to S. aureus (penicillin-sensitive and penicillin-resistant) and group A beta-hemolytic streptococci. Perioperative Prophylaxis the prophylactic administration of Cefazolin for injection preoperatively, intraoperatively, and postoperatively may reduce the incidence of certain postoperative infections in patients undergoing surgical procedures which are classified as contaminated or potentially contaminated (e.g., vaginal hysterectomy, and cholecystectomy in high-risk patients such as those older than 70 years, with acute cholecystitis, obstructive jaundice, or common duct bile stones). The perioperative use of Cefazolin for injection may also be effective in surgical patients in whom infection at the operative site would present a serious risk (e.g., during open-heart surgery and prosthetic arthroplasty). The prophylactic administration of Cefazolin for injection should usually be discontinued within a 24 hour period after the surgical procedure. In surgery where the occurrence of infection may be particularly devastating (e.g., open-heart surgery and prosthetic arthroplasty), the prophylactic administration of Cefazolin for injection may be continued for 3 to 5 days following the completion of surgery. If there are signs of infection, specimens for cultures should be obtained for the identification of the causative organism so that appropriate therapy may be instituted.(See DOSAGE AND ADMINISTRATION .) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefazolin for injection and other antibacterial drugs, Cefazolin for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:7cf7b9b9-5e20-434c-91f7-cccf36338888 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:474053 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:62d640e1-b6b3-40d7-a336-1f9aeff58728"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:92914b7d-4382-405c-bb40-b99a48314631"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefazolin for injection is indicated in the treatment of the following serious infections due to susceptible organisms: Respiratory Tract Infections due to S. pneumoniae, Klebsiella species, H. influenzae, S. aureus (penicillin-sensitive and penicillin-resistant), and group A beta-hemolytic streptococci. Injectable benzathine penicillin is considered to be the drug of choice in treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cefazolin for injection is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of Cefazolin for injection in the subsequent prevention of rheumatic fever are not available at present. Urinary Tract Infections due to E. coli, P. mirabilis, Klebsiella species, and some strains of enterobacter and enterococci. Skin and Skin Structure Infections due to S. aureus (penicillin-sensitive and penicillin-resistant), group A beta-hemolytic streptococci, and other strains of streptococci. Biliary Tract Infections due to E. coli, various strains of streptococci, P. mirabilis, Klebsiella species, and S. aureus. Bone and Joint Infections due to S. aureus. Genital Infections (i.e., prostatitis, epididymitis) due to E. coli, P. mirabilis, Klebsiella species, and some strains of enterococci. Septicemia due to S. pneumoniae, S. aureus (penicillin-sensitive and penicillin-resistant), P. mirabilis, E. coli , and Klebsiella species. Endocarditis due to S. aureus (penicillin-sensitive and penicillin-resistant) and group A beta-hemolytic streptococci. Perioperative Prophylaxis the prophylactic administration of Cefazolin for injection preoperatively, intraoperatively, and postoperatively may reduce the incidence of certain postoperative infections in patients undergoing surgical procedures which are classified as contaminated or potentially contaminated (e.g., vaginal hysterectomy, and cholecystectomy in high-risk patients such as those older than 70 years, with acute cholecystitis, obstructive jaundice, or common duct bile stones). The perioperative use of Cefazolin for injection may also be effective in surgical patients in whom infection at the operative site would present a serious risk (e.g., during open-heart surgery and prosthetic arthroplasty). The prophylactic administration of Cefazolin for injection should usually be discontinued within a 24 hour period after the surgical procedure. In surgery where the occurrence of infection may be particularly devastating (e.g., open-heart surgery and prosthetic arthroplasty), the prophylactic administration of Cefazolin for injection may be continued for 3 to 5 days following the completion of surgery. If there are signs of infection, specimens for cultures should be obtained for the identification of the causative organism so that appropriate therapy may be instituted.(See DOSAGE AND ADMINISTRATION .) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefazolin for injection and other antibacterial drugs, Cefazolin for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:0cfb0bcb-7791-41ef-9765-1f30e57b888f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:474053 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:561c6909-2767-4ca2-b227-4b48e9946701"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9f3dd918-9424-418c-81e3-ef58012092c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefazolin for injection is indicated in the treatment of the following serious infections due to susceptible organisms: Respiratory Tract Infections due to S. pneumoniae, Klebsiella species, H. influenzae, S. aureus (penicillin-sensitive and penicillin-resistant), and group A beta-hemolytic streptococci. Injectable benzathine penicillin is considered to be the drug of choice in treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cefazolin for injection is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of Cefazolin for injection in the subsequent prevention of rheumatic fever are not available at present. Urinary Tract Infections due to E. coli, P. mirabilis, Klebsiella species, and some strains of enterobacter and enterococci. Skin and Skin Structure Infections due to S. aureus (penicillin-sensitive and penicillin-resistant), group A beta-hemolytic streptococci, and other strains of streptococci. Biliary Tract Infections due to E. coli, various strains of streptococci, P. mirabilis, Klebsiella species, and S. aureus. Bone and Joint Infections due to S. aureus. Genital Infections (i.e., prostatitis, epididymitis) due to E. coli, P. mirabilis, Klebsiella species, and some strains of enterococci. Septicemia due to S. pneumoniae, S. aureus (penicillin-sensitive and penicillin-resistant), P. mirabilis, E. coli , and Klebsiella species. Endocarditis due to S. aureus (penicillin-sensitive and penicillin-resistant) and group A beta-hemolytic streptococci. Perioperative Prophylaxis the prophylactic administration of Cefazolin for injection preoperatively, intraoperatively, and postoperatively may reduce the incidence of certain postoperative infections in patients undergoing surgical procedures which are classified as contaminated or potentially contaminated (e.g., vaginal hysterectomy, and cholecystectomy in high-risk patients such as those older than 70 years, with acute cholecystitis, obstructive jaundice, or common duct bile stones). The perioperative use of Cefazolin for injection may also be effective in surgical patients in whom infection at the operative site would present a serious risk (e.g., during open-heart surgery and prosthetic arthroplasty). The prophylactic administration of Cefazolin for injection should usually be discontinued within a 24 hour period after the surgical procedure. In surgery where the occurrence of infection may be particularly devastating (e.g., open-heart surgery and prosthetic arthroplasty), the prophylactic administration of Cefazolin for injection may be continued for 3 to 5 days following the completion of surgery. If there are signs of infection, specimens for cultures should be obtained for the identification of the causative organism so that appropriate therapy may be instituted.(See DOSAGE AND ADMINISTRATION .) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefazolin for injection and other antibacterial drugs, Cefazolin for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:72522b15-d067-4e11-b2bc-396c5ab59276 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:474053 biolink:treats UMLS:C0851989 PMID:41385096 "[{""id"":""uuid:089c8e8d-6da6-4c38-aa8d-1dc3aec25e1f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9e8f66b7-04ab-42ec-a317-47aaade02175"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefazolin for injection is indicated in the treatment of the following serious infections due to susceptible organisms: Respiratory Tract Infections due to S. pneumoniae, Klebsiella species, H. influenzae, S. aureus (penicillin-sensitive and penicillin-resistant), and group A beta-hemolytic streptococci. Injectable benzathine penicillin is considered to be the drug of choice in treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cefazolin for injection is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of Cefazolin for injection in the subsequent prevention of rheumatic fever are not available at present. Urinary Tract Infections due to E. coli, P. mirabilis, Klebsiella species, and some strains of enterobacter and enterococci. Skin and Skin Structure Infections due to S. aureus (penicillin-sensitive and penicillin-resistant), group A beta-hemolytic streptococci, and other strains of streptococci. Biliary Tract Infections due to E. coli, various strains of streptococci, P. mirabilis, Klebsiella species, and S. aureus. Bone and Joint Infections due to S. aureus. Genital Infections (i.e., prostatitis, epididymitis) due to E. coli, P. mirabilis, Klebsiella species, and some strains of enterococci. Septicemia due to S. pneumoniae, S. aureus (penicillin-sensitive and penicillin-resistant), P. mirabilis, E. coli , and Klebsiella species. Endocarditis due to S. aureus (penicillin-sensitive and penicillin-resistant) and group A beta-hemolytic streptococci. Perioperative Prophylaxis the prophylactic administration of Cefazolin for injection preoperatively, intraoperatively, and postoperatively may reduce the incidence of certain postoperative infections in patients undergoing surgical procedures which are classified as contaminated or potentially contaminated (e.g., vaginal hysterectomy, and cholecystectomy in high-risk patients such as those older than 70 years, with acute cholecystitis, obstructive jaundice, or common duct bile stones). The perioperative use of Cefazolin for injection may also be effective in surgical patients in whom infection at the operative site would present a serious risk (e.g., during open-heart surgery and prosthetic arthroplasty). The prophylactic administration of Cefazolin for injection should usually be discontinued within a 24 hour period after the surgical procedure. In surgery where the occurrence of infection may be particularly devastating (e.g., open-heart surgery and prosthetic arthroplasty), the prophylactic administration of Cefazolin for injection may be continued for 3 to 5 days following the completion of surgery. If there are signs of infection, specimens for cultures should be obtained for the identification of the causative organism so that appropriate therapy may be instituted.(See DOSAGE AND ADMINISTRATION .) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefazolin for injection and other antibacterial drugs, Cefazolin for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:035c36bd-01fc-425e-a363-5d45868f9e26 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:474053 biolink:treats MONDO:0005280 PMID:41385096 "[{""id"":""uuid:4c60dddd-fbac-41e9-9d8e-cda3dbbdc266"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9d00913e-00fb-42b2-8661-46c9aba614ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefazolin for injection is indicated in the treatment of the following serious infections due to susceptible organisms: Respiratory Tract Infections due to S. pneumoniae, Klebsiella species, H. influenzae, S. aureus (penicillin-sensitive and penicillin-resistant), and group A beta-hemolytic streptococci. Injectable benzathine penicillin is considered to be the drug of choice in treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cefazolin for injection is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of Cefazolin for injection in the subsequent prevention of rheumatic fever are not available at present. Urinary Tract Infections due to E. coli, P. mirabilis, Klebsiella species, and some strains of enterobacter and enterococci. Skin and Skin Structure Infections due to S. aureus (penicillin-sensitive and penicillin-resistant), group A beta-hemolytic streptococci, and other strains of streptococci. Biliary Tract Infections due to E. coli, various strains of streptococci, P. mirabilis, Klebsiella species, and S. aureus. Bone and Joint Infections due to S. aureus. Genital Infections (i.e., prostatitis, epididymitis) due to E. coli, P. mirabilis, Klebsiella species, and some strains of enterococci. Septicemia due to S. pneumoniae, S. aureus (penicillin-sensitive and penicillin-resistant), P. mirabilis, E. coli , and Klebsiella species. Endocarditis due to S. aureus (penicillin-sensitive and penicillin-resistant) and group A beta-hemolytic streptococci. Perioperative Prophylaxis the prophylactic administration of Cefazolin for injection preoperatively, intraoperatively, and postoperatively may reduce the incidence of certain postoperative infections in patients undergoing surgical procedures which are classified as contaminated or potentially contaminated (e.g., vaginal hysterectomy, and cholecystectomy in high-risk patients such as those older than 70 years, with acute cholecystitis, obstructive jaundice, or common duct bile stones). The perioperative use of Cefazolin for injection may also be effective in surgical patients in whom infection at the operative site would present a serious risk (e.g., during open-heart surgery and prosthetic arthroplasty). The prophylactic administration of Cefazolin for injection should usually be discontinued within a 24 hour period after the surgical procedure. In surgery where the occurrence of infection may be particularly devastating (e.g., open-heart surgery and prosthetic arthroplasty), the prophylactic administration of Cefazolin for injection may be continued for 3 to 5 days following the completion of surgery. If there are signs of infection, specimens for cultures should be obtained for the identification of the causative organism so that appropriate therapy may be instituted.(See DOSAGE AND ADMINISTRATION .) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefazolin for injection and other antibacterial drugs, Cefazolin for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:ad4aaa21-f0ff-49a0-a17c-8849e6645b31 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:474053 biolink:treats MONDO:0004779 PMID:41385096 "[{""id"":""uuid:37e0f850-ed8c-42be-901d-afe6725fd5d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:166fc1f8-6394-4607-9a49-16dfe94d974f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefazolin for injection is indicated in the treatment of the following serious infections due to susceptible organisms: Respiratory Tract Infections due to S. pneumoniae, Klebsiella species, H. influenzae, S. aureus (penicillin-sensitive and penicillin-resistant), and group A beta-hemolytic streptococci. Injectable benzathine penicillin is considered to be the drug of choice in treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cefazolin for injection is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of Cefazolin for injection in the subsequent prevention of rheumatic fever are not available at present. Urinary Tract Infections due to E. coli, P. mirabilis, Klebsiella species, and some strains of enterobacter and enterococci. Skin and Skin Structure Infections due to S. aureus (penicillin-sensitive and penicillin-resistant), group A beta-hemolytic streptococci, and other strains of streptococci. Biliary Tract Infections due to E. coli, various strains of streptococci, P. mirabilis, Klebsiella species, and S. aureus. Bone and Joint Infections due to S. aureus. Genital Infections (i.e., prostatitis, epididymitis) due to E. coli, P. mirabilis, Klebsiella species, and some strains of enterococci. Septicemia due to S. pneumoniae, S. aureus (penicillin-sensitive and penicillin-resistant), P. mirabilis, E. coli , and Klebsiella species. Endocarditis due to S. aureus (penicillin-sensitive and penicillin-resistant) and group A beta-hemolytic streptococci. Perioperative Prophylaxis the prophylactic administration of Cefazolin for injection preoperatively, intraoperatively, and postoperatively may reduce the incidence of certain postoperative infections in patients undergoing surgical procedures which are classified as contaminated or potentially contaminated (e.g., vaginal hysterectomy, and cholecystectomy in high-risk patients such as those older than 70 years, with acute cholecystitis, obstructive jaundice, or common duct bile stones). The perioperative use of Cefazolin for injection may also be effective in surgical patients in whom infection at the operative site would present a serious risk (e.g., during open-heart surgery and prosthetic arthroplasty). The prophylactic administration of Cefazolin for injection should usually be discontinued within a 24 hour period after the surgical procedure. In surgery where the occurrence of infection may be particularly devastating (e.g., open-heart surgery and prosthetic arthroplasty), the prophylactic administration of Cefazolin for injection may be continued for 3 to 5 days following the completion of surgery. If there are signs of infection, specimens for cultures should be obtained for the identification of the causative organism so that appropriate therapy may be instituted.(See DOSAGE AND ADMINISTRATION .) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefazolin for injection and other antibacterial drugs, Cefazolin for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:7fad703f-95d5-4029-aaf4-9e6b4b7d6485 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:474053 biolink:treats MONDO:0700217 PMID:41385096 "[{""id"":""uuid:3dbdfacd-45e5-42d2-8e88-49700462d1a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dfba9681-85ab-47df-8bb2-356094d9280f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefazolin for injection is indicated in the treatment of the following serious infections due to susceptible organisms: Respiratory Tract Infections due to S. pneumoniae, Klebsiella species, H. influenzae, S. aureus (penicillin-sensitive and penicillin-resistant), and group A beta-hemolytic streptococci. Injectable benzathine penicillin is considered to be the drug of choice in treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cefazolin for injection is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of Cefazolin for injection in the subsequent prevention of rheumatic fever are not available at present. Urinary Tract Infections due to E. coli, P. mirabilis, Klebsiella species, and some strains of enterobacter and enterococci. Skin and Skin Structure Infections due to S. aureus (penicillin-sensitive and penicillin-resistant), group A beta-hemolytic streptococci, and other strains of streptococci. Biliary Tract Infections due to E. coli, various strains of streptococci, P. mirabilis, Klebsiella species, and S. aureus. Bone and Joint Infections due to S. aureus. Genital Infections (i.e., prostatitis, epididymitis) due to E. coli, P. mirabilis, Klebsiella species, and some strains of enterococci. Septicemia due to S. pneumoniae, S. aureus (penicillin-sensitive and penicillin-resistant), P. mirabilis, E. coli , and Klebsiella species. Endocarditis due to S. aureus (penicillin-sensitive and penicillin-resistant) and group A beta-hemolytic streptococci. Perioperative Prophylaxis the prophylactic administration of Cefazolin for injection preoperatively, intraoperatively, and postoperatively may reduce the incidence of certain postoperative infections in patients undergoing surgical procedures which are classified as contaminated or potentially contaminated (e.g., vaginal hysterectomy, and cholecystectomy in high-risk patients such as those older than 70 years, with acute cholecystitis, obstructive jaundice, or common duct bile stones). The perioperative use of Cefazolin for injection may also be effective in surgical patients in whom infection at the operative site would present a serious risk (e.g., during open-heart surgery and prosthetic arthroplasty). The prophylactic administration of Cefazolin for injection should usually be discontinued within a 24 hour period after the surgical procedure. In surgery where the occurrence of infection may be particularly devastating (e.g., open-heart surgery and prosthetic arthroplasty), the prophylactic administration of Cefazolin for injection may be continued for 3 to 5 days following the completion of surgery. If there are signs of infection, specimens for cultures should be obtained for the identification of the causative organism so that appropriate therapy may be instituted.(See DOSAGE AND ADMINISTRATION .) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefazolin for injection and other antibacterial drugs, Cefazolin for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:883661f5-6688-45ef-9503-c169126d3a80 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:474053 biolink:treats MONDO:0005025 PMID:41385096 "[{""id"":""uuid:9d53490f-db1b-4fca-93b3-189ec8c0becc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0014b611-7bbd-425a-b284-77d2aa0d020f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefazolin for injection is indicated in the treatment of the following serious infections due to susceptible organisms: Respiratory Tract Infections due to S. pneumoniae, Klebsiella species, H. influenzae, S. aureus (penicillin-sensitive and penicillin-resistant), and group A beta-hemolytic streptococci. Injectable benzathine penicillin is considered to be the drug of choice in treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cefazolin for injection is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of Cefazolin for injection in the subsequent prevention of rheumatic fever are not available at present. Urinary Tract Infections due to E. coli, P. mirabilis, Klebsiella species, and some strains of enterobacter and enterococci. Skin and Skin Structure Infections due to S. aureus (penicillin-sensitive and penicillin-resistant), group A beta-hemolytic streptococci, and other strains of streptococci. Biliary Tract Infections due to E. coli, various strains of streptococci, P. mirabilis, Klebsiella species, and S. aureus. Bone and Joint Infections due to S. aureus. Genital Infections (i.e., prostatitis, epididymitis) due to E. coli, P. mirabilis, Klebsiella species, and some strains of enterococci. Septicemia due to S. pneumoniae, S. aureus (penicillin-sensitive and penicillin-resistant), P. mirabilis, E. coli , and Klebsiella species. Endocarditis due to S. aureus (penicillin-sensitive and penicillin-resistant) and group A beta-hemolytic streptococci. Perioperative Prophylaxis the prophylactic administration of Cefazolin for injection preoperatively, intraoperatively, and postoperatively may reduce the incidence of certain postoperative infections in patients undergoing surgical procedures which are classified as contaminated or potentially contaminated (e.g., vaginal hysterectomy, and cholecystectomy in high-risk patients such as those older than 70 years, with acute cholecystitis, obstructive jaundice, or common duct bile stones). The perioperative use of Cefazolin for injection may also be effective in surgical patients in whom infection at the operative site would present a serious risk (e.g., during open-heart surgery and prosthetic arthroplasty). The prophylactic administration of Cefazolin for injection should usually be discontinued within a 24 hour period after the surgical procedure. In surgery where the occurrence of infection may be particularly devastating (e.g., open-heart surgery and prosthetic arthroplasty), the prophylactic administration of Cefazolin for injection may be continued for 3 to 5 days following the completion of surgery. If there are signs of infection, specimens for cultures should be obtained for the identification of the causative organism so that appropriate therapy may be instituted.(See DOSAGE AND ADMINISTRATION .) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefazolin for injection and other antibacterial drugs, Cefazolin for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:53a92f56-bdf0-4a01-9d9d-2b94d46b9c33 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:474053 biolink:treats MONDO:0043994 PMID:41385096 "[{""id"":""uuid:f537fba0-85e2-4b00-90ae-83cb324f863a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f32b165f-6e55-4290-b93b-b25acdd72383"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefazolin for injection is indicated in the treatment of the following serious infections due to susceptible organisms: Respiratory Tract Infections due to S. pneumoniae, Klebsiella species, H. influenzae, S. aureus (penicillin-sensitive and penicillin-resistant), and group A beta-hemolytic streptococci. Injectable benzathine penicillin is considered to be the drug of choice in treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cefazolin for injection is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of Cefazolin for injection in the subsequent prevention of rheumatic fever are not available at present. Urinary Tract Infections due to E. coli, P. mirabilis, Klebsiella species, and some strains of enterobacter and enterococci. Skin and Skin Structure Infections due to S. aureus (penicillin-sensitive and penicillin-resistant), group A beta-hemolytic streptococci, and other strains of streptococci. Biliary Tract Infections due to E. coli, various strains of streptococci, P. mirabilis, Klebsiella species, and S. aureus. Bone and Joint Infections due to S. aureus. Genital Infections (i.e., prostatitis, epididymitis) due to E. coli, P. mirabilis, Klebsiella species, and some strains of enterococci. Septicemia due to S. pneumoniae, S. aureus (penicillin-sensitive and penicillin-resistant), P. mirabilis, E. coli , and Klebsiella species. Endocarditis due to S. aureus (penicillin-sensitive and penicillin-resistant) and group A beta-hemolytic streptococci. Perioperative Prophylaxis the prophylactic administration of Cefazolin for injection preoperatively, intraoperatively, and postoperatively may reduce the incidence of certain postoperative infections in patients undergoing surgical procedures which are classified as contaminated or potentially contaminated (e.g., vaginal hysterectomy, and cholecystectomy in high-risk patients such as those older than 70 years, with acute cholecystitis, obstructive jaundice, or common duct bile stones). The perioperative use of Cefazolin for injection may also be effective in surgical patients in whom infection at the operative site would present a serious risk (e.g., during open-heart surgery and prosthetic arthroplasty). The prophylactic administration of Cefazolin for injection should usually be discontinued within a 24 hour period after the surgical procedure. In surgery where the occurrence of infection may be particularly devastating (e.g., open-heart surgery and prosthetic arthroplasty), the prophylactic administration of Cefazolin for injection may be continued for 3 to 5 days following the completion of surgery. If there are signs of infection, specimens for cultures should be obtained for the identification of the causative organism so that appropriate therapy may be instituted.(See DOSAGE AND ADMINISTRATION .) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefazolin for injection and other antibacterial drugs, Cefazolin for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:d14cd80f-9f5f-48fb-98f7-7a528de5072c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:474053 biolink:treats MONDO:0006874 PMID:41385096 "[{""id"":""uuid:7f6abbc5-4bd6-4524-902c-c009d51401ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:16eb145e-9766-4ea7-a764-3be26a73bcdc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefazolin for injection is indicated in the treatment of the following serious infections due to susceptible organisms: Respiratory Tract Infections due to S. pneumoniae, Klebsiella species, H. influenzae, S. aureus (penicillin-sensitive and penicillin-resistant), and group A beta-hemolytic streptococci. Injectable benzathine penicillin is considered to be the drug of choice in treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cefazolin for injection is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of Cefazolin for injection in the subsequent prevention of rheumatic fever are not available at present. Urinary Tract Infections due to E. coli, P. mirabilis, Klebsiella species, and some strains of enterobacter and enterococci. Skin and Skin Structure Infections due to S. aureus (penicillin-sensitive and penicillin-resistant), group A beta-hemolytic streptococci, and other strains of streptococci. Biliary Tract Infections due to E. coli, various strains of streptococci, P. mirabilis, Klebsiella species, and S. aureus. Bone and Joint Infections due to S. aureus. Genital Infections (i.e., prostatitis, epididymitis) due to E. coli, P. mirabilis, Klebsiella species, and some strains of enterococci. Septicemia due to S. pneumoniae, S. aureus (penicillin-sensitive and penicillin-resistant), P. mirabilis, E. coli , and Klebsiella species. Endocarditis due to S. aureus (penicillin-sensitive and penicillin-resistant) and group A beta-hemolytic streptococci. Perioperative Prophylaxis the prophylactic administration of Cefazolin for injection preoperatively, intraoperatively, and postoperatively may reduce the incidence of certain postoperative infections in patients undergoing surgical procedures which are classified as contaminated or potentially contaminated (e.g., vaginal hysterectomy, and cholecystectomy in high-risk patients such as those older than 70 years, with acute cholecystitis, obstructive jaundice, or common duct bile stones). The perioperative use of Cefazolin for injection may also be effective in surgical patients in whom infection at the operative site would present a serious risk (e.g., during open-heart surgery and prosthetic arthroplasty). The prophylactic administration of Cefazolin for injection should usually be discontinued within a 24 hour period after the surgical procedure. In surgery where the occurrence of infection may be particularly devastating (e.g., open-heart surgery and prosthetic arthroplasty), the prophylactic administration of Cefazolin for injection may be continued for 3 to 5 days following the completion of surgery. If there are signs of infection, specimens for cultures should be obtained for the identification of the causative organism so that appropriate therapy may be instituted.(See DOSAGE AND ADMINISTRATION .) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefazolin for injection and other antibacterial drugs, Cefazolin for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:fc5bfa1d-8a92-4ac8-9efd-7c862a01a291 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9654 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:69c079dd-48fb-4b0d-8a95-04c275aa4911"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:48838b99-40b0-4dba-85fa-5f415a4386ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Trazodone hydrochloride is indicated for the treatment of depression. The efficacy of trazodone has been demonstrated in both inpatient and out-patient settings and for depressed patients with and without prominent anxiety. The depressive illness of patients studied corresponds to the Major Depressive Episode criteria of the American Psychiatric Association’s Diagnostic and Statistical Manual, III. a Major Depressive Episode implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least four of the following eight symptoms: change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigability, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and suicidal ideation or attempts. uuid:63fcf74d-e31b-41d6-96c0-04a28fc3f531 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1154057 biolink:treats HP:0012228 PMID:41385096 "[{""id"":""uuid:61bfa1b8-3337-48f1-a017-83a4ea49bd57"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7afe99cd-35fa-469e-99c4-e2454ba9ad43"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Butalbital, Aspirin, Caffeine and Codeine Phosphate Capsules are indicated for the relief of the symptom complex of tension (or muscle contraction) headache. Evidence supporting the efficacy of butalbital, aspirin, caffeine and codeine phosphate capsules is derived from 2 multi-clinic trials that compared patients with tension headache randomly assigned to 4 parallel treatments: 1) butalbital, aspirin, caffeine and codeine; 2) codeine; 3) butalbital, aspirin and caffeine; 4) placebo. Response was assessed over the course of the first 4 hours of each of 2 distinct headaches, separated by at least 24 hours. The combination product of butalbital, aspirin, caffeine and codeine proved statistically significantly superior to each of its components and to placebo on measures of pain relief. Evidence supporting the efficacy and safety of butalbital, aspirin, caffeine and codeine in the treatment of multiple recurrent headaches is unavailable. Caution in this regard is required because codeine and butalbital are habit-forming and potentially abusable. uuid:5b55f9f1-2406-4fdf-b619-e699cac0d0ec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4710 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:9fa5a2ac-f983-4c42-9db1-f4263dbace46"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6ee6d350-a647-400f-a9a4-ad6e3e9c3dfe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Doxepin hydrochloride capsules are recommended for the treatment of: Psychoneurotic patients with depression and/or anxiety. Depression and/or anxiety associated with alcoholism (not to be taken concomitantly with alcohol). Depression and/or anxiety associated with organic disease (the possibility of drug interaction should be considered if the patient is receiving other drugs concomitantly). Psychotic depressive disorders with associated anxiety including involutional depression and manic-depressive disorders. The target symptoms of psychoneurosis that respond particularly well to doxepin hydrochloride capsules include anxiety, tension, depression, somatic symptoms and concerns, sleep disturbances, guilt, lack of energy, fear, apprehension and worry. Clinical experience has shown that doxepin hydrochloride capsules are safe and well tolerated even in the elderly patient. Owing to lack of clinical experience in the pediatric population, doxepin hydrochloride capsules are not recommended for use in children under 12 years of age. uuid:1d318b17-d27f-43cb-94d2-aa989b94b5b3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4710 biolink:treats MONDO:0011918 PMID:41385096 "[{""id"":""uuid:3d748507-ec98-4ae5-9218-aba7c31b14c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:db8522f5-0852-4abe-9c5b-7d58cedff0a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Doxepin hydrochloride capsules are recommended for the treatment of: Psychoneurotic patients with depression and/or anxiety. Depression and/or anxiety associated with alcoholism (not to be taken concomitantly with alcohol). Depression and/or anxiety associated with organic disease (the possibility of drug interaction should be considered if the patient is receiving other drugs concomitantly). Psychotic depressive disorders with associated anxiety including involutional depression and manic-depressive disorders. The target symptoms of psychoneurosis that respond particularly well to doxepin hydrochloride capsules include anxiety, tension, depression, somatic symptoms and concerns, sleep disturbances, guilt, lack of energy, fear, apprehension and worry. Clinical experience has shown that doxepin hydrochloride capsules are safe and well tolerated even in the elderly patient. Owing to lack of clinical experience in the pediatric population, doxepin hydrochloride capsules are not recommended for use in children under 12 years of age. uuid:ed4f0986-549c-44e7-952b-fa25bace4415 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4710 biolink:treats MONDO:0007079 PMID:41385096 "[{""id"":""uuid:266f43e9-6f77-4c33-9f98-a8e817c3f2a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c2ab7f16-efc3-4df1-910d-4e3978c6b839"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Doxepin hydrochloride capsules are recommended for the treatment of: Psychoneurotic patients with depression and/or anxiety. Depression and/or anxiety associated with alcoholism (not to be taken concomitantly with alcohol). Depression and/or anxiety associated with organic disease (the possibility of drug interaction should be considered if the patient is receiving other drugs concomitantly). Psychotic depressive disorders with associated anxiety including involutional depression and manic-depressive disorders. The target symptoms of psychoneurosis that respond particularly well to doxepin hydrochloride capsules include anxiety, tension, depression, somatic symptoms and concerns, sleep disturbances, guilt, lack of energy, fear, apprehension and worry. Clinical experience has shown that doxepin hydrochloride capsules are safe and well tolerated even in the elderly patient. Owing to lack of clinical experience in the pediatric population, doxepin hydrochloride capsules are not recommended for use in children under 12 years of age. uuid:db5b154d-637a-4905-90d8-5f22335e5c9b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4710 biolink:treats UMLS:C0277542 PMID:41385096 "[{""id"":""uuid:c0f1a4bd-f402-4439-b72e-eeb20fd9e7b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:29dbc451-7ef8-4324-ade7-b91ce64cbb4f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Doxepin hydrochloride capsules are recommended for the treatment of: Psychoneurotic patients with depression and/or anxiety. Depression and/or anxiety associated with alcoholism (not to be taken concomitantly with alcohol). Depression and/or anxiety associated with organic disease (the possibility of drug interaction should be considered if the patient is receiving other drugs concomitantly). Psychotic depressive disorders with associated anxiety including involutional depression and manic-depressive disorders. The target symptoms of psychoneurosis that respond particularly well to doxepin hydrochloride capsules include anxiety, tension, depression, somatic symptoms and concerns, sleep disturbances, guilt, lack of energy, fear, apprehension and worry. Clinical experience has shown that doxepin hydrochloride capsules are safe and well tolerated even in the elderly patient. Owing to lack of clinical experience in the pediatric population, doxepin hydrochloride capsules are not recommended for use in children under 12 years of age. uuid:8e66351f-9c01-4438-a883-a6a7348cd0cd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4710 biolink:treats UMLS:C0011574 PMID:41385096 "[{""id"":""uuid:26abb79c-4db7-43be-a17f-6d69e0d7af16"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dd52768f-2303-479e-99dc-ad1f366d4b68"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Doxepin hydrochloride capsules are recommended for the treatment of: Psychoneurotic patients with depression and/or anxiety. Depression and/or anxiety associated with alcoholism (not to be taken concomitantly with alcohol). Depression and/or anxiety associated with organic disease (the possibility of drug interaction should be considered if the patient is receiving other drugs concomitantly). Psychotic depressive disorders with associated anxiety including involutional depression and manic-depressive disorders. The target symptoms of psychoneurosis that respond particularly well to doxepin hydrochloride capsules include anxiety, tension, depression, somatic symptoms and concerns, sleep disturbances, guilt, lack of energy, fear, apprehension and worry. Clinical experience has shown that doxepin hydrochloride capsules are safe and well tolerated even in the elderly patient. Owing to lack of clinical experience in the pediatric population, doxepin hydrochloride capsules are not recommended for use in children under 12 years of age. uuid:fff52d83-d200-4832-9425-76def1ea5a85 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4710 biolink:treats MONDO:0005371 PMID:41385096 "[{""id"":""uuid:efa89f57-ea1a-4d39-b659-80caf90ea045"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:56fdd791-b631-4e3a-b9da-f57a44a0d8ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Doxepin hydrochloride capsules are recommended for the treatment of: Psychoneurotic patients with depression and/or anxiety. Depression and/or anxiety associated with alcoholism (not to be taken concomitantly with alcohol). Depression and/or anxiety associated with organic disease (the possibility of drug interaction should be considered if the patient is receiving other drugs concomitantly). Psychotic depressive disorders with associated anxiety including involutional depression and manic-depressive disorders. The target symptoms of psychoneurosis that respond particularly well to doxepin hydrochloride capsules include anxiety, tension, depression, somatic symptoms and concerns, sleep disturbances, guilt, lack of energy, fear, apprehension and worry. Clinical experience has shown that doxepin hydrochloride capsules are safe and well tolerated even in the elderly patient. Owing to lack of clinical experience in the pediatric population, doxepin hydrochloride capsules are not recommended for use in children under 12 years of age. uuid:8bc629a6-4cc2-4b90-8b36-28e9ec478d8e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4710 biolink:treats MONDO:0005379 PMID:41385096 "[{""id"":""uuid:41ebb0a2-a39d-4ed1-9bce-285e69e0cd28"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:95dcbaa6-91f1-44c9-8229-b8ca8bf7961a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Doxepin hydrochloride capsules are recommended for the treatment of: Psychoneurotic patients with depression and/or anxiety. Depression and/or anxiety associated with alcoholism (not to be taken concomitantly with alcohol). Depression and/or anxiety associated with organic disease (the possibility of drug interaction should be considered if the patient is receiving other drugs concomitantly). Psychotic depressive disorders with associated anxiety including involutional depression and manic-depressive disorders. The target symptoms of psychoneurosis that respond particularly well to doxepin hydrochloride capsules include anxiety, tension, depression, somatic symptoms and concerns, sleep disturbances, guilt, lack of energy, fear, apprehension and worry. Clinical experience has shown that doxepin hydrochloride capsules are safe and well tolerated even in the elderly patient. Owing to lack of clinical experience in the pediatric population, doxepin hydrochloride capsules are not recommended for use in children under 12 years of age. uuid:8f73c8fb-9aea-4805-965e-754025f77041 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:36572 biolink:treats MONDO:0005180 PMID:41385096 "[{""id"":""uuid:3e11a357-477b-43fc-846a-fcafda8e4b11"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:6e1a18d0-74f2-4bc5-9ad4-845225df7841"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ee1d92e3-6d13-437d-b177-afac894be3a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/stalevo""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] PARCOPA ® is indicated in the treatment of the symptoms of idiopathic Parkinson’s disease (paralysis agitans), postencephalitic parkinsonism, and symptomatic parkinsonism which may follow injury to the nervous system by carbon monoxide intoxication and/or manganese intoxication. PARCOPA ® is indicated in these conditions to permit the administration of lower doses of levodopa with reduced nausea and vomiting, with more rapid dosage titration, with a somewhat smoother response, and with supplemental pyridoxine (vitamin B 6 ). In some patients, a somewhat smoother antiparkinsonian effect results from therapy with carbidopa-levodopa than with levodopa. However, patients with markedly irregular (“on-off”) responses to levodopa have not been shown to benefit from carbidopa-levodopa therapy. Although the administration of carbidopa permits control of parkinsonism and Parkinson’s disease with much lower doses of levodopa, there is no conclusive evidence at present that this is beneficial other than in reducing nausea and vomiting, permitting more rapid titration, and providing a somewhat smoother response to levodopa. Certain patients who responded poorly to levodopa have improved when carbidopa-levodopa was substituted. This is most likely due to decreased peripheral decarboxylation of levodopa which results from administration of carbidopa rather than to a primary effect of carbidopa on the nervous system. Carbidopa has not been shown to enhance the intrinsic efficacy of levodopa in parkinsonian syndromes. In considering whether to give PARCOPA ® to patients already on levodopa who have nausea and/or vomiting, the practitioner should be aware that, while many patients may be expected to improve, some do not. Since one cannot predict which patients are likely to improve, this can only be determined by a trial of therapy. It should be further noted that in controlled trials comparing carbidopa-levodopa with levodopa, about half of the patients with nausea and/or vomiting on levodopa improved spontaneously despite being retained on the same dose of levodopa during the controlled portion of the trial.|[EMA] Stalevo is indicated for the treatment of adult patients with Parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa / dopa-decarboxylase (DDC)-inhibitor treatment. uuid:67a55c5f-e09f-439e-8d3d-c463d4e254d0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:36572 biolink:treats MONDO:0008193 PMID:41385096 "[{""id"":""uuid:8c8b31d6-4f7f-451c-aceb-87c2a958ffdc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:44de6f6b-a892-4f00-bd3a-da3bc483cec1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PARCOPA ® is indicated in the treatment of the symptoms of idiopathic Parkinson’s disease (paralysis agitans), postencephalitic parkinsonism, and symptomatic parkinsonism which may follow injury to the nervous system by carbon monoxide intoxication and/or manganese intoxication. PARCOPA ® is indicated in these conditions to permit the administration of lower doses of levodopa with reduced nausea and vomiting, with more rapid dosage titration, with a somewhat smoother response, and with supplemental pyridoxine (vitamin B 6 ). In some patients, a somewhat smoother antiparkinsonian effect results from therapy with carbidopa-levodopa than with levodopa. However, patients with markedly irregular (“on-off”) responses to levodopa have not been shown to benefit from carbidopa-levodopa therapy. Although the administration of carbidopa permits control of parkinsonism and Parkinson’s disease with much lower doses of levodopa, there is no conclusive evidence at present that this is beneficial other than in reducing nausea and vomiting, permitting more rapid titration, and providing a somewhat smoother response to levodopa. Certain patients who responded poorly to levodopa have improved when carbidopa-levodopa was substituted. This is most likely due to decreased peripheral decarboxylation of levodopa which results from administration of carbidopa rather than to a primary effect of carbidopa on the nervous system. Carbidopa has not been shown to enhance the intrinsic efficacy of levodopa in parkinsonian syndromes. In considering whether to give PARCOPA ® to patients already on levodopa who have nausea and/or vomiting, the practitioner should be aware that, while many patients may be expected to improve, some do not. Since one cannot predict which patients are likely to improve, this can only be determined by a trial of therapy. It should be further noted that in controlled trials comparing carbidopa-levodopa with levodopa, about half of the patients with nausea and/or vomiting on levodopa improved spontaneously despite being retained on the same dose of levodopa during the controlled portion of the trial. uuid:92112d43-b1d2-4160-aa83-f506d92d5c5d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:36572 biolink:treats MONDO:0001945 PMID:41385096 "[{""id"":""uuid:d0e2f863-96be-497f-99f9-fd799cfcd77a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:71b81c60-db7f-4f42-a6ed-edb58c70485b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PARCOPA ® is indicated in the treatment of the symptoms of idiopathic Parkinson’s disease (paralysis agitans), postencephalitic parkinsonism, and symptomatic parkinsonism which may follow injury to the nervous system by carbon monoxide intoxication and/or manganese intoxication. PARCOPA ® is indicated in these conditions to permit the administration of lower doses of levodopa with reduced nausea and vomiting, with more rapid dosage titration, with a somewhat smoother response, and with supplemental pyridoxine (vitamin B 6 ). In some patients, a somewhat smoother antiparkinsonian effect results from therapy with carbidopa-levodopa than with levodopa. However, patients with markedly irregular (“on-off”) responses to levodopa have not been shown to benefit from carbidopa-levodopa therapy. Although the administration of carbidopa permits control of parkinsonism and Parkinson’s disease with much lower doses of levodopa, there is no conclusive evidence at present that this is beneficial other than in reducing nausea and vomiting, permitting more rapid titration, and providing a somewhat smoother response to levodopa. Certain patients who responded poorly to levodopa have improved when carbidopa-levodopa was substituted. This is most likely due to decreased peripheral decarboxylation of levodopa which results from administration of carbidopa rather than to a primary effect of carbidopa on the nervous system. Carbidopa has not been shown to enhance the intrinsic efficacy of levodopa in parkinsonian syndromes. In considering whether to give PARCOPA ® to patients already on levodopa who have nausea and/or vomiting, the practitioner should be aware that, while many patients may be expected to improve, some do not. Since one cannot predict which patients are likely to improve, this can only be determined by a trial of therapy. It should be further noted that in controlled trials comparing carbidopa-levodopa with levodopa, about half of the patients with nausea and/or vomiting on levodopa improved spontaneously despite being retained on the same dose of levodopa during the controlled portion of the trial. uuid:19ffa332-7937-4fb6-a801-8a094296f95c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:36572 biolink:treats MONDO:0021095 PMID:41385096 "[{""id"":""uuid:357fd894-3d95-4c71-a334-9ba181c62512"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4bff477a-b2aa-4c2d-a1ad-2a0acb89f9a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PARCOPA ® is indicated in the treatment of the symptoms of idiopathic Parkinson’s disease (paralysis agitans), postencephalitic parkinsonism, and symptomatic parkinsonism which may follow injury to the nervous system by carbon monoxide intoxication and/or manganese intoxication. PARCOPA ® is indicated in these conditions to permit the administration of lower doses of levodopa with reduced nausea and vomiting, with more rapid dosage titration, with a somewhat smoother response, and with supplemental pyridoxine (vitamin B 6 ). In some patients, a somewhat smoother antiparkinsonian effect results from therapy with carbidopa-levodopa than with levodopa. However, patients with markedly irregular (“on-off”) responses to levodopa have not been shown to benefit from carbidopa-levodopa therapy. Although the administration of carbidopa permits control of parkinsonism and Parkinson’s disease with much lower doses of levodopa, there is no conclusive evidence at present that this is beneficial other than in reducing nausea and vomiting, permitting more rapid titration, and providing a somewhat smoother response to levodopa. Certain patients who responded poorly to levodopa have improved when carbidopa-levodopa was substituted. This is most likely due to decreased peripheral decarboxylation of levodopa which results from administration of carbidopa rather than to a primary effect of carbidopa on the nervous system. Carbidopa has not been shown to enhance the intrinsic efficacy of levodopa in parkinsonian syndromes. In considering whether to give PARCOPA ® to patients already on levodopa who have nausea and/or vomiting, the practitioner should be aware that, while many patients may be expected to improve, some do not. Since one cannot predict which patients are likely to improve, this can only be determined by a trial of therapy. It should be further noted that in controlled trials comparing carbidopa-levodopa with levodopa, about half of the patients with nausea and/or vomiting on levodopa improved spontaneously despite being retained on the same dose of levodopa during the controlled portion of the trial. uuid:c45fb280-c16e-46c5-a60a-9c5b75bf1e21 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47898 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:88b918e6-0222-46de-aa83-63910f9f82ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7af38fcb-f318-47bd-8c64-036fae945dd7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:62dac2c3-8d20-4943-92a3-c4bda471db72"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Epirubicin Hydrochloride Injection is indicated as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer.|[PMDA] A new indication and a new dosage regimen in combination with other anti-cancer agents for the treatment of breast cancer [Combination chemotherapy with anti-cancer drgs] uuid:575e9f65-f623-4e77-8492-7a96a15a8c3e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28304 biolink:treats HP:0002625 PMID:41385096 "[{""id"":""uuid:b7b67c60-61aa-4bc4-98e3-236d1d52a4e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:98546273-711e-4915-a57c-6a61465e875e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Heparin Sodium Injection is indicated for: Anticoagulant therapy in prophylaxis and treatment of venous thrombosis and its extension; (In a low-dose regimen) for prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdomino-thoracic surgery or who for other reasons are at risk of developing thromboembolic disease (see DOSAGE AND ADMINISTRATION ); Prophylaxis and treatment of pulmonary embolism; Atrial fibrillation with embolization; Diagnosis and treatment of acute and chronic consumption coagulopathies (disseminated intravascular coagulation); Prevention of clotting in arterial and heart surgery; Prophylaxis and treatment of peripheral arterial embolism; As an anticoagulant in blood transfusions, extracorporeal circulation, and dialysis procedures and in blood samples for laboratory purposes. uuid:cf3046dc-67a9-439b-b4b9-3132ccb21f7a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28304 biolink:treats MONDO:0005279 PMID:41385096 "[{""id"":""uuid:d089b19d-83c5-4797-ba09-abb149a83504"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:56b4e504-efca-4eb9-967d-ddf40b298f36"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Heparin Sodium Injection is indicated for: Anticoagulant therapy in prophylaxis and treatment of venous thrombosis and its extension; (In a low-dose regimen) for prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdomino-thoracic surgery or who for other reasons are at risk of developing thromboembolic disease (see DOSAGE AND ADMINISTRATION ); Prophylaxis and treatment of pulmonary embolism; Atrial fibrillation with embolization; Diagnosis and treatment of acute and chronic consumption coagulopathies (disseminated intravascular coagulation); Prevention of clotting in arterial and heart surgery; Prophylaxis and treatment of peripheral arterial embolism; As an anticoagulant in blood transfusions, extracorporeal circulation, and dialysis procedures and in blood samples for laboratory purposes. uuid:0353af6d-4b7a-4b2d-a983-2d79050008c8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28304 biolink:treats HP:0001907 PMID:41385096 "[{""id"":""uuid:205989a6-4619-4c17-9af0-9fdaa2d29f25"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e5a5a4b8-c9d5-4596-b7a7-38605e989c13"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Heparin Sodium Injection is indicated for: Anticoagulant therapy in prophylaxis and treatment of venous thrombosis and its extension; (In a low-dose regimen) for prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdomino-thoracic surgery or who for other reasons are at risk of developing thromboembolic disease (see DOSAGE AND ADMINISTRATION ); Prophylaxis and treatment of pulmonary embolism; Atrial fibrillation with embolization; Diagnosis and treatment of acute and chronic consumption coagulopathies (disseminated intravascular coagulation); Prevention of clotting in arterial and heart surgery; Prophylaxis and treatment of peripheral arterial embolism; As an anticoagulant in blood transfusions, extracorporeal circulation, and dialysis procedures and in blood samples for laboratory purposes. uuid:4ef071ed-632a-4231-9077-cbc6a34e61a9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28304 biolink:treats MONDO:0001243 PMID:41385096 "[{""id"":""uuid:48b52183-d555-4909-a744-a1deed90266f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5c397f2d-19c6-4cbd-bacd-8966e9c249e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Heparin Sodium Injection is indicated for: Anticoagulant therapy in prophylaxis and treatment of venous thrombosis and its extension; (In a low-dose regimen) for prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdomino-thoracic surgery or who for other reasons are at risk of developing thromboembolic disease (see DOSAGE AND ADMINISTRATION ); Prophylaxis and treatment of pulmonary embolism; Atrial fibrillation with embolization; Diagnosis and treatment of acute and chronic consumption coagulopathies (disseminated intravascular coagulation); Prevention of clotting in arterial and heart surgery; Prophylaxis and treatment of peripheral arterial embolism; As an anticoagulant in blood transfusions, extracorporeal circulation, and dialysis procedures and in blood samples for laboratory purposes. uuid:00588673-e803-48d3-b795-3c3c42536020 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28304 biolink:treats UMLS:C0564750 PMID:41385096 "[{""id"":""uuid:11cf0019-f29a-4ccd-8d1c-3328c5499d64"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6991f5a3-571f-4e6c-a987-bbca4f8279d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Heparin Sodium Injection is indicated for: Anticoagulant therapy in prophylaxis and treatment of venous thrombosis and its extension; (In a low-dose regimen) for prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdomino-thoracic surgery or who for other reasons are at risk of developing thromboembolic disease (see DOSAGE AND ADMINISTRATION ); Prophylaxis and treatment of pulmonary embolism; Atrial fibrillation with embolization; Diagnosis and treatment of acute and chronic consumption coagulopathies (disseminated intravascular coagulation); Prevention of clotting in arterial and heart surgery; Prophylaxis and treatment of peripheral arterial embolism; As an anticoagulant in blood transfusions, extracorporeal circulation, and dialysis procedures and in blood samples for laboratory purposes. uuid:07f9b1a3-4a72-485c-84c1-f63c055235e6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7640 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:a722ae82-02f0-47bb-9b60-71660f107cfc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:089e86bd-a987-4d3c-a396-7134864166b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nortriptyline hydrochloride is indicated for the relief of symptoms of depression. Endogenous depressions are more likely to be alleviated than are other depressive states. uuid:8ded5a06-06aa-4160-b864-252156ed11fd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7640 biolink:treats MONDO:0012048 PMID:41385096 "[{""id"":""uuid:dcc3f92f-f15e-4df0-9bce-92b8598c722b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:df93d574-46c1-4ce2-a645-a2c29e5d0c2b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nortriptyline hydrochloride is indicated for the relief of symptoms of depression. Endogenous depressions are more likely to be alleviated than are other depressive states. uuid:1f4ff998-f83a-4415-b5ce-02625b8a222a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3723 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:46b04f5f-d88e-44bc-a3b3-ac4ded893241"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7b7f1afa-f6f3-440f-ba82-8ce8108581bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Citalopram HBr is indicated for the treatment of depression. The efficacy of citalopram HBr in the treatment of depression was established in 4-6 week controlled trials of outpatients whose diagnosis corresponded most closely to the DSM-III and DSM-III-R category of major depressive disorder (see CLINICAL PHARMACOLOGY ). A major depressive episode (DSM-IV) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least five of the following nine symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. The antidepressant action of citalopram in hospitalized depressed patients has not been adequately studied. The efficacy of citalopram in maintaining an antidepressant response for up to 24 weeks following 6 to 8 weeks of acute treatment was demonstrated in two placebo-controlled trials (see CLINICAL PHARMACOLOGY ). Nevertheless, the physician who elects to use citalopram for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient. uuid:bf95d9b2-db47-4da4-9313-b48b0efa7765 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9150 biolink:treats MONDO:0005010 PMID:41385096 "[{""id"":""uuid:74aa33a0-9085-4869-8972-0b07d3936908"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fd9fa3f3-9107-4e3d-bbcb-05af98e2b0ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol (see National Cholesterol Education Program [NCEP] Treatment Guidelines , below). In patients with CHD or at high risk of CHD, Simvastatin Orally Disintegrating Tablets can be started simultaneously with diet. uuid:640b2083-b05c-4f28-9f14-2273d205ff79 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:78320 biolink:treats HP:0000958 PMID:41385096 "[{""id"":""uuid:df3e58ab-cd50-4bbb-9105-3afafe1d117e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9c245894-e47d-4484-8cb0-118e38504203"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lac-Hydrin Cream is indicated for the treatment of dry, scaly skin (xerosis) and ichthyosis vulgaris and for temporary relief of itching associated with these conditions. uuid:eb731e5a-fc64-4f9c-a876-195095d7feab biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:78320 biolink:treats MONDO:0024304 PMID:41385096 "[{""id"":""uuid:43b4b01e-84fe-4ba3-a878-60753584dd4d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3b0b9591-678d-467e-a30d-6dd9c26d201b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lac-Hydrin Cream is indicated for the treatment of dry, scaly skin (xerosis) and ichthyosis vulgaris and for temporary relief of itching associated with these conditions. uuid:65402461-aa20-45bf-b2b4-7975c5207b46 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3479 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:cf35917a-4c68-402e-a910-ecfaf95b97c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:73cd91eb-1778-49de-b8a5-2eb04a1c73ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefadroxil monohydrate is indicated for the treatment of patients with infection caused by susceptible strains of the designated organisms in the following diseases: Urinary tract infections caused by E. coli , P. mirabilis , and Klebsiella species. Skin and skin structure infections caused by staphylococci and/or streptococci. Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes (Group A beta-hemolytic streptococci). Note : Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefadroxil monohydrate is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefadroxil monohydrate for the prophylaxis of subsequent rheumatic fever are not available. Note : Culture and susceptibility tests should be initiated prior to and during therapy. Renal function studies should be performed when indicated. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefadroxil monohydrate and other antibacterial drugs, cefadroxil monohydrate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:5ac7b931-7dcd-400c-97dd-6f57925c3edc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3479 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:cbecb26a-1db6-4c0a-87a9-df36cb36cd1a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5095b9f5-28d1-4879-a66e-a5a3de7c7957"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefadroxil monohydrate is indicated for the treatment of patients with infection caused by susceptible strains of the designated organisms in the following diseases: Urinary tract infections caused by E. coli , P. mirabilis , and Klebsiella species. Skin and skin structure infections caused by staphylococci and/or streptococci. Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes (Group A beta-hemolytic streptococci). Note : Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefadroxil monohydrate is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefadroxil monohydrate for the prophylaxis of subsequent rheumatic fever are not available. Note : Culture and susceptibility tests should be initiated prior to and during therapy. Renal function studies should be performed when indicated. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefadroxil monohydrate and other antibacterial drugs, cefadroxil monohydrate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:11dd8023-7c2c-473c-9f2b-b79de232ba29 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3479 biolink:treats MONDO:0002258 PMID:41385096 "[{""id"":""uuid:9a333eff-8e77-49f0-8e85-2567708c950a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1ba57732-1bc4-4b51-9d7a-d935751d71e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefadroxil monohydrate is indicated for the treatment of patients with infection caused by susceptible strains of the designated organisms in the following diseases: Urinary tract infections caused by E. coli , P. mirabilis , and Klebsiella species. Skin and skin structure infections caused by staphylococci and/or streptococci. Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes (Group A beta-hemolytic streptococci). Note : Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefadroxil monohydrate is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefadroxil monohydrate for the prophylaxis of subsequent rheumatic fever are not available. Note : Culture and susceptibility tests should be initiated prior to and during therapy. Renal function studies should be performed when indicated. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefadroxil monohydrate and other antibacterial drugs, cefadroxil monohydrate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:5efc4856-2eac-4f53-bc05-d7c0342e6ff6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3479 biolink:treats MONDO:0001039 PMID:41385096 "[{""id"":""uuid:a70a8a36-5279-467e-b5ee-08644543c689"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:085ae3d7-b4a8-4719-9bc2-f752e61d039b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefadroxil monohydrate is indicated for the treatment of patients with infection caused by susceptible strains of the designated organisms in the following diseases: Urinary tract infections caused by E. coli , P. mirabilis , and Klebsiella species. Skin and skin structure infections caused by staphylococci and/or streptococci. Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes (Group A beta-hemolytic streptococci). Note : Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefadroxil monohydrate is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefadroxil monohydrate for the prophylaxis of subsequent rheumatic fever are not available. Note : Culture and susceptibility tests should be initiated prior to and during therapy. Renal function studies should be performed when indicated. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefadroxil monohydrate and other antibacterial drugs, cefadroxil monohydrate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:7d025258-7a12-4403-b8ec-787b0185b90d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3479 biolink:treats MONDO:0017767 PMID:41385096 "[{""id"":""uuid:8de967f3-c8fa-4009-9ccc-e41eddffeabf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9e2fd75d-da29-4c56-965d-aa12cd065a59"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefadroxil monohydrate is indicated for the treatment of patients with infection caused by susceptible strains of the designated organisms in the following diseases: Urinary tract infections caused by E. coli , P. mirabilis , and Klebsiella species. Skin and skin structure infections caused by staphylococci and/or streptococci. Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes (Group A beta-hemolytic streptococci). Note : Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefadroxil monohydrate is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefadroxil monohydrate for the prophylaxis of subsequent rheumatic fever are not available. Note : Culture and susceptibility tests should be initiated prior to and during therapy. Renal function studies should be performed when indicated. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefadroxil monohydrate and other antibacterial drugs, cefadroxil monohydrate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:4ef69d36-4057-4df3-bce1-0c6d0f1005bb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8499 biolink:treats HP:0004755 PMID:41385096 "[{""id"":""uuid:b4ff7d05-e602-47d1-9f11-46f4a9f591d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8dbf1446-8e21-4353-b737-53e58fe50097"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous administration is usually reserved for life-threatening arrhythmias or those occurring under anesthesia. Supraventricular arrhythmiasIntravenous propranolol is indicated for the short-term treatment of supraventricular tachycardia, including Wolff-Parkinson-White syndrome and thyrotoxicosis, to decrease ventricular rate. Use in patients with atrial flutter or atrial fibrillation should be reserved for arrythmias unresponsive to standard therapy or when more prolonged control is required. Reversion to normal sinus rhythm has occasionally been observed, predominantly in patients with sinus or atrial tachycardia. Ventricular tachycardias With the exception of those induced by catecholamines or digitalis, propranolol is not the drug of first choice. In critical situations when cardioversion techniques or other drugs are not indicated or are not effective, propranolol may be considered. If, after consideration of the risks involved, propranolol is used, it should be given intravenously in low dosage and very slowly, as the failing heart requires some sympathetic drive for maintenance of myocardial tone. (See ). Some patients may respond with complete reversion to normal sinus rhythm, but reduction in ventricular rate is more likely. Ventricular arrhythmias do not respond to propranolol as predictably as do the supraventricular arrhythmias. Intravenous propranolol is indicated for the treatment of persistent premature ventricular extrasystoles that impair the well-being of the patient and do not respond to conventional measures. Tachyarrhythmias of digitalis intoxicationIntravenous propranolol is indicated to control ventricular rate in life-threatening digitalis-induced arrhythmias. Severe bradycardia may occur. (See ). Resistant tachyarrhythmias due to excessive catecholamine action during anesthesia Intravenous propranolol is indicated to abolish tachyarrhythmias due to excessive catecholamine action during anesthesia when other measures fail. These arrhythmias may arise because of release of endogenous catecholamines or administration of catecholamines. All general inhalation anesthetics produce some degree of myocardial depression. Therefore, when propranolol is used to treat arrhythmias during anesthesia, it should be used with extreme caution, usually with constant monitoring of the ECG and central venous pressure. (See ). uuid:5a63bcd8-366f-49a3-b4bd-17c28cebbca4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8499 biolink:treats MONDO:0008685 PMID:41385096 "[{""id"":""uuid:019fb311-7395-4c94-87be-4cfc541bcffe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cb154c88-b195-4fec-9524-f65a5e4b87df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous administration is usually reserved for life-threatening arrhythmias or those occurring under anesthesia. Supraventricular arrhythmiasIntravenous propranolol is indicated for the short-term treatment of supraventricular tachycardia, including Wolff-Parkinson-White syndrome and thyrotoxicosis, to decrease ventricular rate. Use in patients with atrial flutter or atrial fibrillation should be reserved for arrythmias unresponsive to standard therapy or when more prolonged control is required. Reversion to normal sinus rhythm has occasionally been observed, predominantly in patients with sinus or atrial tachycardia. Ventricular tachycardias With the exception of those induced by catecholamines or digitalis, propranolol is not the drug of first choice. In critical situations when cardioversion techniques or other drugs are not indicated or are not effective, propranolol may be considered. If, after consideration of the risks involved, propranolol is used, it should be given intravenously in low dosage and very slowly, as the failing heart requires some sympathetic drive for maintenance of myocardial tone. (See ). Some patients may respond with complete reversion to normal sinus rhythm, but reduction in ventricular rate is more likely. Ventricular arrhythmias do not respond to propranolol as predictably as do the supraventricular arrhythmias. Intravenous propranolol is indicated for the treatment of persistent premature ventricular extrasystoles that impair the well-being of the patient and do not respond to conventional measures. Tachyarrhythmias of digitalis intoxicationIntravenous propranolol is indicated to control ventricular rate in life-threatening digitalis-induced arrhythmias. Severe bradycardia may occur. (See ). Resistant tachyarrhythmias due to excessive catecholamine action during anesthesia Intravenous propranolol is indicated to abolish tachyarrhythmias due to excessive catecholamine action during anesthesia when other measures fail. These arrhythmias may arise because of release of endogenous catecholamines or administration of catecholamines. All general inhalation anesthetics produce some degree of myocardial depression. Therefore, when propranolol is used to treat arrhythmias during anesthesia, it should be used with extreme caution, usually with constant monitoring of the ECG and central venous pressure. (See ). uuid:35e003a1-3a59-4747-b5ff-3a37950553bd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8499 biolink:treats MONDO:0010138 PMID:41385096 "[{""id"":""uuid:ed677bfe-21ba-4dab-ab15-2879e195f82c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:37dd45dd-373b-4bc0-af26-3d54a3e0c598"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous administration is usually reserved for life-threatening arrhythmias or those occurring under anesthesia. Supraventricular arrhythmiasIntravenous propranolol is indicated for the short-term treatment of supraventricular tachycardia, including Wolff-Parkinson-White syndrome and thyrotoxicosis, to decrease ventricular rate. Use in patients with atrial flutter or atrial fibrillation should be reserved for arrythmias unresponsive to standard therapy or when more prolonged control is required. Reversion to normal sinus rhythm has occasionally been observed, predominantly in patients with sinus or atrial tachycardia. Ventricular tachycardias With the exception of those induced by catecholamines or digitalis, propranolol is not the drug of first choice. In critical situations when cardioversion techniques or other drugs are not indicated or are not effective, propranolol may be considered. If, after consideration of the risks involved, propranolol is used, it should be given intravenously in low dosage and very slowly, as the failing heart requires some sympathetic drive for maintenance of myocardial tone. (See ). Some patients may respond with complete reversion to normal sinus rhythm, but reduction in ventricular rate is more likely. Ventricular arrhythmias do not respond to propranolol as predictably as do the supraventricular arrhythmias. Intravenous propranolol is indicated for the treatment of persistent premature ventricular extrasystoles that impair the well-being of the patient and do not respond to conventional measures. Tachyarrhythmias of digitalis intoxicationIntravenous propranolol is indicated to control ventricular rate in life-threatening digitalis-induced arrhythmias. Severe bradycardia may occur. (See ). Resistant tachyarrhythmias due to excessive catecholamine action during anesthesia Intravenous propranolol is indicated to abolish tachyarrhythmias due to excessive catecholamine action during anesthesia when other measures fail. These arrhythmias may arise because of release of endogenous catecholamines or administration of catecholamines. All general inhalation anesthetics produce some degree of myocardial depression. Therefore, when propranolol is used to treat arrhythmias during anesthesia, it should be used with extreme caution, usually with constant monitoring of the ECG and central venous pressure. (See ). uuid:2ae77d98-06a2-4a57-ab12-0999caae9b19 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8499 biolink:treats MONDO:0005310 PMID:41385096 "[{""id"":""uuid:74a9e211-47c5-4d6a-bd77-24b3c3424302"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a7e74e7c-f064-49d2-952b-a70252f86b5d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous administration is usually reserved for life-threatening arrhythmias or those occurring under anesthesia. Supraventricular arrhythmiasIntravenous propranolol is indicated for the short-term treatment of supraventricular tachycardia, including Wolff-Parkinson-White syndrome and thyrotoxicosis, to decrease ventricular rate. Use in patients with atrial flutter or atrial fibrillation should be reserved for arrythmias unresponsive to standard therapy or when more prolonged control is required. Reversion to normal sinus rhythm has occasionally been observed, predominantly in patients with sinus or atrial tachycardia. Ventricular tachycardias With the exception of those induced by catecholamines or digitalis, propranolol is not the drug of first choice. In critical situations when cardioversion techniques or other drugs are not indicated or are not effective, propranolol may be considered. If, after consideration of the risks involved, propranolol is used, it should be given intravenously in low dosage and very slowly, as the failing heart requires some sympathetic drive for maintenance of myocardial tone. (See ). Some patients may respond with complete reversion to normal sinus rhythm, but reduction in ventricular rate is more likely. Ventricular arrhythmias do not respond to propranolol as predictably as do the supraventricular arrhythmias. Intravenous propranolol is indicated for the treatment of persistent premature ventricular extrasystoles that impair the well-being of the patient and do not respond to conventional measures. Tachyarrhythmias of digitalis intoxicationIntravenous propranolol is indicated to control ventricular rate in life-threatening digitalis-induced arrhythmias. Severe bradycardia may occur. (See ). Resistant tachyarrhythmias due to excessive catecholamine action during anesthesia Intravenous propranolol is indicated to abolish tachyarrhythmias due to excessive catecholamine action during anesthesia when other measures fail. These arrhythmias may arise because of release of endogenous catecholamines or administration of catecholamines. All general inhalation anesthetics produce some degree of myocardial depression. Therefore, when propranolol is used to treat arrhythmias during anesthesia, it should be used with extreme caution, usually with constant monitoring of the ECG and central venous pressure. (See ). uuid:8da081f0-fc60-4091-b5e3-b2241639811e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8499 biolink:treats MONDO:0004981 PMID:41385096 "[{""id"":""uuid:64e22e19-f6f0-4609-a592-d8802c5054fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e8a6fd3f-426b-40ab-827a-33eb3342c739"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ea35de52-9753-4c39-9fcc-b6a6a962aae2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous administration is usually reserved for life-threatening arrhythmias or those occurring under anesthesia. Supraventricular arrhythmiasIntravenous propranolol is indicated for the short-term treatment of supraventricular tachycardia, including Wolff-Parkinson-White syndrome and thyrotoxicosis, to decrease ventricular rate. Use in patients with atrial flutter or atrial fibrillation should be reserved for arrythmias unresponsive to standard therapy or when more prolonged control is required. Reversion to normal sinus rhythm has occasionally been observed, predominantly in patients with sinus or atrial tachycardia. Ventricular tachycardias With the exception of those induced by catecholamines or digitalis, propranolol is not the drug of first choice. In critical situations when cardioversion techniques or other drugs are not indicated or are not effective, propranolol may be considered. If, after consideration of the risks involved, propranolol is used, it should be given intravenously in low dosage and very slowly, as the failing heart requires some sympathetic drive for maintenance of myocardial tone. (See ). Some patients may respond with complete reversion to normal sinus rhythm, but reduction in ventricular rate is more likely. Ventricular arrhythmias do not respond to propranolol as predictably as do the supraventricular arrhythmias. Intravenous propranolol is indicated for the treatment of persistent premature ventricular extrasystoles that impair the well-being of the patient and do not respond to conventional measures. Tachyarrhythmias of digitalis intoxicationIntravenous propranolol is indicated to control ventricular rate in life-threatening digitalis-induced arrhythmias. Severe bradycardia may occur. (See ). Resistant tachyarrhythmias due to excessive catecholamine action during anesthesia Intravenous propranolol is indicated to abolish tachyarrhythmias due to excessive catecholamine action during anesthesia when other measures fail. These arrhythmias may arise because of release of endogenous catecholamines or administration of catecholamines. All general inhalation anesthetics produce some degree of myocardial depression. Therefore, when propranolol is used to treat arrhythmias during anesthesia, it should be used with extreme caution, usually with constant monitoring of the ECG and central venous pressure. (See ).|[PMDA] Drugs with new additional pediatric dosages for extrasystole (supraventricular/ventricular), the prevention of paroxysmal tachycardia, atrial fibrillation with rapid ventricular response (bradycardiac effect), sinus tachycardia, atrial fibrillation, and the prevention of paroxysmal atrial fibrillation. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:80f86006-c1ef-4060-9db5-0a1a3b671c48 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8499 biolink:treats HP:0011703 PMID:41385096 "[{""id"":""uuid:c4d3951c-b484-4b4f-b7b3-2b7031df46b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:97a96c06-9a8d-433f-9cb3-55c40dbd3624"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:194a41b2-9093-485c-9124-fc9d4a8eecfe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous administration is usually reserved for life-threatening arrhythmias or those occurring under anesthesia. Supraventricular arrhythmiasIntravenous propranolol is indicated for the short-term treatment of supraventricular tachycardia, including Wolff-Parkinson-White syndrome and thyrotoxicosis, to decrease ventricular rate. Use in patients with atrial flutter or atrial fibrillation should be reserved for arrythmias unresponsive to standard therapy or when more prolonged control is required. Reversion to normal sinus rhythm has occasionally been observed, predominantly in patients with sinus or atrial tachycardia. Ventricular tachycardias With the exception of those induced by catecholamines or digitalis, propranolol is not the drug of first choice. In critical situations when cardioversion techniques or other drugs are not indicated or are not effective, propranolol may be considered. If, after consideration of the risks involved, propranolol is used, it should be given intravenously in low dosage and very slowly, as the failing heart requires some sympathetic drive for maintenance of myocardial tone. (See ). Some patients may respond with complete reversion to normal sinus rhythm, but reduction in ventricular rate is more likely. Ventricular arrhythmias do not respond to propranolol as predictably as do the supraventricular arrhythmias. Intravenous propranolol is indicated for the treatment of persistent premature ventricular extrasystoles that impair the well-being of the patient and do not respond to conventional measures. Tachyarrhythmias of digitalis intoxicationIntravenous propranolol is indicated to control ventricular rate in life-threatening digitalis-induced arrhythmias. Severe bradycardia may occur. (See ). Resistant tachyarrhythmias due to excessive catecholamine action during anesthesia Intravenous propranolol is indicated to abolish tachyarrhythmias due to excessive catecholamine action during anesthesia when other measures fail. These arrhythmias may arise because of release of endogenous catecholamines or administration of catecholamines. All general inhalation anesthetics produce some degree of myocardial depression. Therefore, when propranolol is used to treat arrhythmias during anesthesia, it should be used with extreme caution, usually with constant monitoring of the ECG and central venous pressure. (See ).|[PMDA] Drugs with new additional pediatric dosages for extrasystole (supraventricular/ventricular), the prevention of paroxysmal tachycardia, atrial fibrillation with rapid ventricular response (bradycardiac effect), sinus tachycardia, atrial fibrillation, and the prevention of paroxysmal atrial fibrillation. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:c5bfe050-bd44-4b71-a64b-ff4e6608af6a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8499 biolink:treats MONDO:0005479 PMID:41385096 "[{""id"":""uuid:87586da7-2902-4304-bae0-83a6298ca715"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3ce06754-5901-445f-8800-3a8fa8ae6140"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous administration is usually reserved for life-threatening arrhythmias or those occurring under anesthesia. Supraventricular arrhythmiasIntravenous propranolol is indicated for the short-term treatment of supraventricular tachycardia, including Wolff-Parkinson-White syndrome and thyrotoxicosis, to decrease ventricular rate. Use in patients with atrial flutter or atrial fibrillation should be reserved for arrythmias unresponsive to standard therapy or when more prolonged control is required. Reversion to normal sinus rhythm has occasionally been observed, predominantly in patients with sinus or atrial tachycardia. Ventricular tachycardias With the exception of those induced by catecholamines or digitalis, propranolol is not the drug of first choice. In critical situations when cardioversion techniques or other drugs are not indicated or are not effective, propranolol may be considered. If, after consideration of the risks involved, propranolol is used, it should be given intravenously in low dosage and very slowly, as the failing heart requires some sympathetic drive for maintenance of myocardial tone. (See ). Some patients may respond with complete reversion to normal sinus rhythm, but reduction in ventricular rate is more likely. Ventricular arrhythmias do not respond to propranolol as predictably as do the supraventricular arrhythmias. Intravenous propranolol is indicated for the treatment of persistent premature ventricular extrasystoles that impair the well-being of the patient and do not respond to conventional measures. Tachyarrhythmias of digitalis intoxicationIntravenous propranolol is indicated to control ventricular rate in life-threatening digitalis-induced arrhythmias. Severe bradycardia may occur. (See ). Resistant tachyarrhythmias due to excessive catecholamine action during anesthesia Intravenous propranolol is indicated to abolish tachyarrhythmias due to excessive catecholamine action during anesthesia when other measures fail. These arrhythmias may arise because of release of endogenous catecholamines or administration of catecholamines. All general inhalation anesthetics produce some degree of myocardial depression. Therefore, when propranolol is used to treat arrhythmias during anesthesia, it should be used with extreme caution, usually with constant monitoring of the ECG and central venous pressure. (See ). uuid:7f5f3ef9-0116-435b-88b0-0f7c5c9a2594 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8499 biolink:treats HP:0006682 PMID:41385096 "[{""id"":""uuid:1cfc3d31-5c46-47ec-af1c-ad4d3fac59c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e3ce90d2-3867-4169-8a2b-a01009e39076"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous administration is usually reserved for life-threatening arrhythmias or those occurring under anesthesia. Supraventricular arrhythmiasIntravenous propranolol is indicated for the short-term treatment of supraventricular tachycardia, including Wolff-Parkinson-White syndrome and thyrotoxicosis, to decrease ventricular rate. Use in patients with atrial flutter or atrial fibrillation should be reserved for arrythmias unresponsive to standard therapy or when more prolonged control is required. Reversion to normal sinus rhythm has occasionally been observed, predominantly in patients with sinus or atrial tachycardia. Ventricular tachycardias With the exception of those induced by catecholamines or digitalis, propranolol is not the drug of first choice. In critical situations when cardioversion techniques or other drugs are not indicated or are not effective, propranolol may be considered. If, after consideration of the risks involved, propranolol is used, it should be given intravenously in low dosage and very slowly, as the failing heart requires some sympathetic drive for maintenance of myocardial tone. (See ). Some patients may respond with complete reversion to normal sinus rhythm, but reduction in ventricular rate is more likely. Ventricular arrhythmias do not respond to propranolol as predictably as do the supraventricular arrhythmias. Intravenous propranolol is indicated for the treatment of persistent premature ventricular extrasystoles that impair the well-being of the patient and do not respond to conventional measures. Tachyarrhythmias of digitalis intoxicationIntravenous propranolol is indicated to control ventricular rate in life-threatening digitalis-induced arrhythmias. Severe bradycardia may occur. (See ). Resistant tachyarrhythmias due to excessive catecholamine action during anesthesia Intravenous propranolol is indicated to abolish tachyarrhythmias due to excessive catecholamine action during anesthesia when other measures fail. These arrhythmias may arise because of release of endogenous catecholamines or administration of catecholamines. All general inhalation anesthetics produce some degree of myocardial depression. Therefore, when propranolol is used to treat arrhythmias during anesthesia, it should be used with extreme caution, usually with constant monitoring of the ECG and central venous pressure. (See ). uuid:d3b5c805-9d23-426e-8dad-8270edc09d27 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8499 biolink:treats MONDO:0007263 PMID:41385096 "[{""id"":""uuid:434dc4bb-db98-41d1-8d8d-7637bc004d2f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3750e4ca-c0b5-4684-a196-b926724c63f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous administration is usually reserved for life-threatening arrhythmias or those occurring under anesthesia. Supraventricular arrhythmiasIntravenous propranolol is indicated for the short-term treatment of supraventricular tachycardia, including Wolff-Parkinson-White syndrome and thyrotoxicosis, to decrease ventricular rate. Use in patients with atrial flutter or atrial fibrillation should be reserved for arrythmias unresponsive to standard therapy or when more prolonged control is required. Reversion to normal sinus rhythm has occasionally been observed, predominantly in patients with sinus or atrial tachycardia. Ventricular tachycardias With the exception of those induced by catecholamines or digitalis, propranolol is not the drug of first choice. In critical situations when cardioversion techniques or other drugs are not indicated or are not effective, propranolol may be considered. If, after consideration of the risks involved, propranolol is used, it should be given intravenously in low dosage and very slowly, as the failing heart requires some sympathetic drive for maintenance of myocardial tone. (See ). Some patients may respond with complete reversion to normal sinus rhythm, but reduction in ventricular rate is more likely. Ventricular arrhythmias do not respond to propranolol as predictably as do the supraventricular arrhythmias. Intravenous propranolol is indicated for the treatment of persistent premature ventricular extrasystoles that impair the well-being of the patient and do not respond to conventional measures. Tachyarrhythmias of digitalis intoxicationIntravenous propranolol is indicated to control ventricular rate in life-threatening digitalis-induced arrhythmias. Severe bradycardia may occur. (See ). Resistant tachyarrhythmias due to excessive catecholamine action during anesthesia Intravenous propranolol is indicated to abolish tachyarrhythmias due to excessive catecholamine action during anesthesia when other measures fail. These arrhythmias may arise because of release of endogenous catecholamines or administration of catecholamines. All general inhalation anesthetics produce some degree of myocardial depression. Therefore, when propranolol is used to treat arrhythmias during anesthesia, it should be used with extreme caution, usually with constant monitoring of the ECG and central venous pressure. (See ). uuid:3d93fef3-d3f1-4fb9-b103-5b59c6dc10bc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0005664 PMID:41385096 "[{""id"":""uuid:29f797d5-d9e2-4cc6-894d-ed6d5e0fbd90"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:de2dff93-193f-4255-8494-6b8a8db79a96"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Minocycline hydrochloride tablets are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydia psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunoflourescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Minocycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Enterobacter aerogenes. Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride tablets are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus . (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal infections. Infections in women caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum subspecies pallidum . Yaws caused by Treponema pallidum subspecies pertenue . Listeriosis due to Listeria monocytogenes . Anthrax due to Bacillus anthracis . Vincent’s infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis , minocycline may be useful adjunct to amebicides. In severe acne, minocycline may be useful adjunctive therapy. Oral minocycline is indicated in the treatment of asymptomatic carriers of Neisseria meningitides to eliminate the meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carrier, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum . To reduce the development of drug-resistant bacteria and maintain the effectiveness of, minocycline hydrochloride tablets and other antibacterial drugs, minocycline hydrochloride tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antimicrobial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:2ef2e000-ca7b-48e6-a109-05f3eb248b5c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5001 biolink:treats UMLS:C0342879 PMID:41385096 "[{""id"":""uuid:cae61b04-c991-4922-ae26-00878a247267"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:74627e02-f002-4910-b850-fc5111d34c2c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Antara is indicated as adjunctive therapy to diet to reduce elevated LDL-C, Total-C, Triglycerides, and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types II a and II b). Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and non-pharmacological interventions alone has been inadequate (see National Cholesterol Education Program [NCEP] Treatment Guidelines, below ). uuid:1a56ab92-2815-4ae2-9f3c-b440a6265d59 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5001 biolink:treats HP:0003119 PMID:41385096 "[{""id"":""uuid:2f23f245-a4f2-4dab-8ff4-e7717c1fcca4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:46bbe671-e992-457b-84aa-66ab194912cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Antara is indicated as adjunctive therapy to diet to reduce elevated LDL-C, Total-C, Triglycerides, and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types II a and II b). Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and non-pharmacological interventions alone has been inadequate (see National Cholesterol Education Program [NCEP] Treatment Guidelines, below ). uuid:7f822fbd-8218-4bde-a394-2e1b73a65cdd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3534 biolink:treats MONDO:0024355 PMID:41385096 "[{""id"":""uuid:d023678a-91cc-417b-9fa4-68d79c18ca81"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4c1f8257-9add-4dfa-abb8-616eb1cdef05"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Keflex is indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms: Respiratory tract infections caused by Streptococcus pneumoniae and Streptococcus pyogenes (Penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Keflex is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of Keflex in the subsequent prevention of rheumatic fever are not available at present.) Otitis media due to Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, Streptococcus pyogenes , and Moraxella catarrhalis Skin and skin structure infections caused by Staphylococcus aureus and/or Streptococcus pyogenes Bone infections caused by Staphylococcus aureus and/or Proteus mirabilis Genitourinary tract infections, including acute prostatitis, caused by Escherichia coli, Proteus mirabilis, and Klebsiella pneumoniae Note — Culture and susceptibility tests should be initiated prior to and during therapy. Renal function studies should be performed when indicated. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Keflex and other antibacterial drugs, Keflex should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:1522e5cb-54bf-48c2-b53b-e186112c4876 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3534 biolink:treats MONDO:0021680 PMID:41385096 "[{""id"":""uuid:1328a8aa-b3e3-4d33-957e-ec17535dcde9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e673c66d-7ae1-455e-baea-feb6e8a2db6a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Keflex is indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms: Respiratory tract infections caused by Streptococcus pneumoniae and Streptococcus pyogenes (Penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Keflex is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of Keflex in the subsequent prevention of rheumatic fever are not available at present.) Otitis media due to Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, Streptococcus pyogenes , and Moraxella catarrhalis Skin and skin structure infections caused by Staphylococcus aureus and/or Streptococcus pyogenes Bone infections caused by Staphylococcus aureus and/or Proteus mirabilis Genitourinary tract infections, including acute prostatitis, caused by Escherichia coli, Proteus mirabilis, and Klebsiella pneumoniae Note — Culture and susceptibility tests should be initiated prior to and during therapy. Renal function studies should be performed when indicated. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Keflex and other antibacterial drugs, Keflex should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:1cb05e9a-5932-4af8-ba55-45800fa18ea1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3534 biolink:treats MONDO:0017767 PMID:41385096 "[{""id"":""uuid:7de0b6db-2da1-4e0e-a4a4-b2ce24db490c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4481ee37-900c-45da-8231-27ae5cbebd93"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Keflex is indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms: Respiratory tract infections caused by Streptococcus pneumoniae and Streptococcus pyogenes (Penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Keflex is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of Keflex in the subsequent prevention of rheumatic fever are not available at present.) Otitis media due to Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, Streptococcus pyogenes , and Moraxella catarrhalis Skin and skin structure infections caused by Staphylococcus aureus and/or Streptococcus pyogenes Bone infections caused by Staphylococcus aureus and/or Proteus mirabilis Genitourinary tract infections, including acute prostatitis, caused by Escherichia coli, Proteus mirabilis, and Klebsiella pneumoniae Note — Culture and susceptibility tests should be initiated prior to and during therapy. Renal function studies should be performed when indicated. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Keflex and other antibacterial drugs, Keflex should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:e796569f-95ba-4c2f-8e55-514bfa130e71 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3534 biolink:treats MONDO:0005441 PMID:41385096 "[{""id"":""uuid:91b7b601-31db-40c8-bfcc-3b95af4b9f21"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4df8b28f-a75e-4291-b1e8-0b85e524a279"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Keflex is indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms: Respiratory tract infections caused by Streptococcus pneumoniae and Streptococcus pyogenes (Penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Keflex is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of Keflex in the subsequent prevention of rheumatic fever are not available at present.) Otitis media due to Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, Streptococcus pyogenes , and Moraxella catarrhalis Skin and skin structure infections caused by Staphylococcus aureus and/or Streptococcus pyogenes Bone infections caused by Staphylococcus aureus and/or Proteus mirabilis Genitourinary tract infections, including acute prostatitis, caused by Escherichia coli, Proteus mirabilis, and Klebsiella pneumoniae Note — Culture and susceptibility tests should be initiated prior to and during therapy. Renal function studies should be performed when indicated. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Keflex and other antibacterial drugs, Keflex should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:1280b1d6-e3af-4039-b611-7ac043d4bec5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3534 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:f5ff34f8-f881-463b-ac3f-08316cecbea3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:afdc3f07-6861-4ae0-a1bb-a57006673d3b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Keflex is indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms: Respiratory tract infections caused by Streptococcus pneumoniae and Streptococcus pyogenes (Penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Keflex is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of Keflex in the subsequent prevention of rheumatic fever are not available at present.) Otitis media due to Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, Streptococcus pyogenes , and Moraxella catarrhalis Skin and skin structure infections caused by Staphylococcus aureus and/or Streptococcus pyogenes Bone infections caused by Staphylococcus aureus and/or Proteus mirabilis Genitourinary tract infections, including acute prostatitis, caused by Escherichia coli, Proteus mirabilis, and Klebsiella pneumoniae Note — Culture and susceptibility tests should be initiated prior to and during therapy. Renal function studies should be performed when indicated. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Keflex and other antibacterial drugs, Keflex should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:0ea10945-c641-442e-8bfd-6c7b90eedaf3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3534 biolink:treats MONDO:0005246 PMID:41385096 "[{""id"":""uuid:0dceb89c-a743-4a87-8b00-11fe9688fbdf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dd77fb59-65eb-40bc-809f-3b4ac117c536"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Keflex is indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms: Respiratory tract infections caused by Streptococcus pneumoniae and Streptococcus pyogenes (Penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Keflex is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of Keflex in the subsequent prevention of rheumatic fever are not available at present.) Otitis media due to Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, Streptococcus pyogenes , and Moraxella catarrhalis Skin and skin structure infections caused by Staphylococcus aureus and/or Streptococcus pyogenes Bone infections caused by Staphylococcus aureus and/or Proteus mirabilis Genitourinary tract infections, including acute prostatitis, caused by Escherichia coli, Proteus mirabilis, and Klebsiella pneumoniae Note — Culture and susceptibility tests should be initiated prior to and during therapy. Renal function studies should be performed when indicated. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Keflex and other antibacterial drugs, Keflex should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:712f98d8-d1e1-42c3-a3aa-1215846e9860 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3534 biolink:treats UMLS:C0852158 PMID:41385096 "[{""id"":""uuid:42f9e912-07fa-4a3f-a112-ec14abeccb86"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:76aa1cb9-0cbb-467a-8959-eb49d1ba883d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Keflex is indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms: Respiratory tract infections caused by Streptococcus pneumoniae and Streptococcus pyogenes (Penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Keflex is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of Keflex in the subsequent prevention of rheumatic fever are not available at present.) Otitis media due to Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, Streptococcus pyogenes , and Moraxella catarrhalis Skin and skin structure infections caused by Staphylococcus aureus and/or Streptococcus pyogenes Bone infections caused by Staphylococcus aureus and/or Proteus mirabilis Genitourinary tract infections, including acute prostatitis, caused by Escherichia coli, Proteus mirabilis, and Klebsiella pneumoniae Note — Culture and susceptibility tests should be initiated prior to and during therapy. Renal function studies should be performed when indicated. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Keflex and other antibacterial drugs, Keflex should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:b9676458-0a81-4aee-8762-e1be8b6e2495 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3534 biolink:treats UMLS:C0149524 PMID:41385096 "[{""id"":""uuid:5e9c7108-9e06-4073-b3f1-0d6740df6eae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e5116e14-2e37-4bd1-a21b-8b697ce59343"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Keflex is indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms: Respiratory tract infections caused by Streptococcus pneumoniae and Streptococcus pyogenes (Penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Keflex is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of Keflex in the subsequent prevention of rheumatic fever are not available at present.) Otitis media due to Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, Streptococcus pyogenes , and Moraxella catarrhalis Skin and skin structure infections caused by Staphylococcus aureus and/or Streptococcus pyogenes Bone infections caused by Staphylococcus aureus and/or Proteus mirabilis Genitourinary tract infections, including acute prostatitis, caused by Escherichia coli, Proteus mirabilis, and Klebsiella pneumoniae Note — Culture and susceptibility tests should be initiated prior to and during therapy. Renal function studies should be performed when indicated. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Keflex and other antibacterial drugs, Keflex should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:659ec99e-577f-4810-becc-ba854bc0c7b1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3387 biolink:treats MONDO:0006710 PMID:41385096 "[{""id"":""uuid:5c4dc247-ae25-42c4-8d5b-a7345941f9c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1c035e92-031c-445f-90ea-8bd50572e934"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carbamazepine is indicated for use as an anticonvulsant drug. Evidence supporting efficacy of carbamazepine as an anticonvulsant was derived from active drug-controlled studies that enrolled patients with the following seizure types: Partial seizures with complex symptomatology (psychomotor, temporal lobe). Patients with these seizures appear to show greater improvement than those with other types. Generalized tonic-clonic seizures (grand mal). Mixed seizure patterns which include the above, or other partial or generalized seizures. Absence seizures (petitmal) do not appear to be controlled by carbamazepine (see PRECAUTIONS, General ). uuid:7ce304a1-4d13-4abf-a9a8-ce0206f6f4f2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3387 biolink:treats MONDO:0005754 PMID:41385096 "[{""id"":""uuid:3dfbaeee-c158-464c-8220-14905536e956"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5dde6035-25a0-49d7-aa6d-365c82c7811d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carbamazepine is indicated for use as an anticonvulsant drug. Evidence supporting efficacy of carbamazepine as an anticonvulsant was derived from active drug-controlled studies that enrolled patients with the following seizure types: Partial seizures with complex symptomatology (psychomotor, temporal lobe). Patients with these seizures appear to show greater improvement than those with other types. Generalized tonic-clonic seizures (grand mal). Mixed seizure patterns which include the above, or other partial or generalized seizures. Absence seizures (petitmal) do not appear to be controlled by carbamazepine (see PRECAUTIONS, General ). uuid:e252cd7c-2044-4982-af40-77ca00ca1a03 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3387 biolink:treats MONDO:0005027 PMID:41385096 "[{""id"":""uuid:1426c66c-977f-452f-996c-0633b2331214"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c606236d-5cae-4319-b857-3ef6baf4a47a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carbamazepine is indicated for use as an anticonvulsant drug. Evidence supporting efficacy of carbamazepine as an anticonvulsant was derived from active drug-controlled studies that enrolled patients with the following seizure types: Partial seizures with complex symptomatology (psychomotor, temporal lobe). Patients with these seizures appear to show greater improvement than those with other types. Generalized tonic-clonic seizures (grand mal). Mixed seizure patterns which include the above, or other partial or generalized seizures. Absence seizures (petitmal) do not appear to be controlled by carbamazepine (see PRECAUTIONS, General ). uuid:2fca59a0-77b1-4abd-b117-bc21d2d7a715 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:23742 biolink:treats HP:0000969 PMID:41385096 "[{""id"":""uuid:c4f27a43-ff92-4279-847f-2e125459a648"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c55d3423-231e-4abe-a149-ca5878a341a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] This fixed combination drug is not indicated for the initial therapy of edema or hypertension except in individuals in whom the development of hypokalemia cannot be risked. Triamterene and Hydrochlorothiazide Tablets are indicated for the treatment of hypertension or edema in patients who develop hypokalemia on hydrochlorothiazide alone. Triamterene and hydrochlorothiazide is also indicated for those patients who require a thiazide diuretic and in whom the development of hypokalemia cannot be risked (e.g., patients on concomitant digitalis preparations, or with a history of cardiac arrhythmias, etc.). Triamterene and hydrochlorothiazide may be used alone or in combination with other antihypertensive drugs such as beta-blockers. Since triamterene and hydrochlorothiazide may enhance the actions of these drugs, dosage adjustments may be necessary. uuid:052df421-6c21-4f1e-8540-07c876129ad7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:23742 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:c881ced5-5d9f-4528-b779-6ec79a7cd15f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2c13cc7c-7e1a-4f19-99cd-f40019a8a9e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] This fixed combination drug is not indicated for the initial therapy of edema or hypertension except in individuals in whom the development of hypokalemia cannot be risked. Triamterene and Hydrochlorothiazide Tablets are indicated for the treatment of hypertension or edema in patients who develop hypokalemia on hydrochlorothiazide alone. Triamterene and hydrochlorothiazide is also indicated for those patients who require a thiazide diuretic and in whom the development of hypokalemia cannot be risked (e.g., patients on concomitant digitalis preparations, or with a history of cardiac arrhythmias, etc.). Triamterene and hydrochlorothiazide may be used alone or in combination with other antihypertensive drugs such as beta-blockers. Since triamterene and hydrochlorothiazide may enhance the actions of these drugs, dosage adjustments may be necessary. uuid:c56b4dd2-65b8-4424-9633-564a9a3c9cd0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:23742 biolink:treats MONDO:0003019 PMID:41385096 "[{""id"":""uuid:893b7042-fe7e-491f-93cf-d1758875a0e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:01131606-322a-419f-ba68-8917c8db59ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] This fixed combination drug is not indicated for the initial therapy of edema or hypertension except in individuals in whom the development of hypokalemia cannot be risked. Triamterene and Hydrochlorothiazide Tablets are indicated for the treatment of hypertension or edema in patients who develop hypokalemia on hydrochlorothiazide alone. Triamterene and hydrochlorothiazide is also indicated for those patients who require a thiazide diuretic and in whom the development of hypokalemia cannot be risked (e.g., patients on concomitant digitalis preparations, or with a history of cardiac arrhythmias, etc.). Triamterene and hydrochlorothiazide may be used alone or in combination with other antihypertensive drugs such as beta-blockers. Since triamterene and hydrochlorothiazide may enhance the actions of these drugs, dosage adjustments may be necessary. uuid:740cfe71-cd79-4c30-b79c-d9836f5480a7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:23742 biolink:treats MONDO:0007263 PMID:41385096 "[{""id"":""uuid:0be77503-2276-4f63-81bb-3fbdb45806eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a47a83a8-05fa-4689-b945-16139c95afaa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] This fixed combination drug is not indicated for the initial therapy of edema or hypertension except in individuals in whom the development of hypokalemia cannot be risked. Triamterene and Hydrochlorothiazide Tablets are indicated for the treatment of hypertension or edema in patients who develop hypokalemia on hydrochlorothiazide alone. Triamterene and hydrochlorothiazide is also indicated for those patients who require a thiazide diuretic and in whom the development of hypokalemia cannot be risked (e.g., patients on concomitant digitalis preparations, or with a history of cardiac arrhythmias, etc.). Triamterene and hydrochlorothiazide may be used alone or in combination with other antihypertensive drugs such as beta-blockers. Since triamterene and hydrochlorothiazide may enhance the actions of these drugs, dosage adjustments may be necessary. uuid:132f6c76-3b08-410b-8db1-563e2a29a13d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6532 biolink:treats MONDO:0000257 PMID:41385096 "[{""id"":""uuid:b616ad95-eb6a-46f8-bd4c-6ef81c0abdb4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:02824d91-72be-42a6-b2ed-f32bfe54fdba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] IMODIUM® (loperamide hydrochloride) is indicated for the control and symptomatic relief of acute nonspecific diarrhea and of chronic diarrhea associated with inflammatory bowel disease. IMODIUM® is also indicated for reducing the volume of discharge from ileostomies. uuid:6184e2fd-9480-4106-8f33-4e22af310bdc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6532 biolink:treats MONDO:0005265 PMID:41385096 "[{""id"":""uuid:2a853477-3759-4564-b09d-284e1663542b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a37f6c13-5204-4825-bab6-e40df5dd8ce9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] IMODIUM® (loperamide hydrochloride) is indicated for the control and symptomatic relief of acute nonspecific diarrhea and of chronic diarrhea associated with inflammatory bowel disease. IMODIUM® is also indicated for reducing the volume of discharge from ileostomies. uuid:0aa28c79-dca6-446d-9147-87c1c5f56467 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28901 biolink:treats MONDO:0011996 PMID:41385096 "[{""id"":""uuid:453fb9e1-feac-43fe-a9cc-b94f3f3c0644"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6a4c3476-e508-4acf-92c2-0fcb4c748d82"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BUSULFEX ® (busulfan) Injection is indicated for use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia. uuid:630102f2-2a8e-4ff0-94e6-5609f91f19be biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47381 biolink:treats MONDO:0005129 PMID:41385096 "[{""id"":""uuid:d5557da7-1966-4470-bcd6-dbf9cf8b048a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4b4abea2-3796-4003-bf5c-d349eb8de36f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diclofenac Sodium Ophthalmic Solution, 0.1% is indicated for the treatment of postoperative inflammation in patients who have undergone cataract extraction. uuid:42ae26a6-2447-4e76-929f-4d99be94feb8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4708 biolink:treats MONDO:0010811 PMID:41385096 "[{""id"":""uuid:62319daf-3679-4041-8c24-150a1dafdaf1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ed280849-4ee6-443b-8b97-f424966d8878"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] A. Benign Prostatic Hyperplasia (BPH) Doxazosin mesylate tablets are indicated for the treatment of both the urinary outflow obstruction and obstructive and irritative symptoms associated with BPH: obstructive symptoms (hesitation, intermittency, dribbling, weak urinary stream, incomplete emptying of the bladder) and irritative symptoms (nocturia, daytime frequency, urgency, burning). Doxazosin mesylate tablets may be used in all BPH patients whether hypertensive or normotensive. In patients with hypertension and BPH, both conditions were effectively treated with doxazosin mesylate tablet monotherapy. Doxazosin mesylate tablets provides rapid improvement in symptoms and urinary flow rate in 66-71% of patients. Sustained improvements with doxazosin mesylate tablets were seen in patients treated for up to 14 weeks in double-blind studies and up to 2 years in open-label studies. B. Hypertension Doxazosin mesylate tablets are also indicated for the treatment of hypertension. Doxazosin mesylate tablets may be used alone or in combination with diuretics, beta-adrenergic blocking agents, calcium channel blockers or angiotensin-converting enzyme inhibitors. uuid:946244f5-06e8-428d-a421-3c4b2497d0eb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4708 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:aaebf9b5-a5be-4a34-be2a-860a52477033"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:490f215c-ae02-48c4-92d9-669f6ed8caa7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] A. Benign Prostatic Hyperplasia (BPH) Doxazosin mesylate tablets are indicated for the treatment of both the urinary outflow obstruction and obstructive and irritative symptoms associated with BPH: obstructive symptoms (hesitation, intermittency, dribbling, weak urinary stream, incomplete emptying of the bladder) and irritative symptoms (nocturia, daytime frequency, urgency, burning). Doxazosin mesylate tablets may be used in all BPH patients whether hypertensive or normotensive. In patients with hypertension and BPH, both conditions were effectively treated with doxazosin mesylate tablet monotherapy. Doxazosin mesylate tablets provides rapid improvement in symptoms and urinary flow rate in 66-71% of patients. Sustained improvements with doxazosin mesylate tablets were seen in patients treated for up to 14 weeks in double-blind studies and up to 2 years in open-label studies. B. Hypertension Doxazosin mesylate tablets are also indicated for the treatment of hypertension. Doxazosin mesylate tablets may be used alone or in combination with diuretics, beta-adrenergic blocking agents, calcium channel blockers or angiotensin-converting enzyme inhibitors. uuid:878f7d26-4092-44c2-a0a7-22e1245bacc2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3223 biolink:treats MONDO:0005618 PMID:41385096 "[{""id"":""uuid:c6753f0f-0a62-409c-80e5-dbb97e5df3ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:854fd9a3-35dc-417a-9730-4fac355bbe6c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Buspirone hydrochloride tablets are indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The efficacy of buspirone has been demonstrated in controlled clinical trials of outpatients whose diagnosis roughly corresponds to Generalized Anxiety Disorder (GAD). Many of the patients enrolled in these studies also had coexisting depressive symptoms and buspirone relieved anxiety in the presence of these coexisting depressive symptoms. The patients evaluated in these studies had experienced symptoms for periods of 1 month to over 1 year prior to the study, with an average symptom duration of 6 months. Generalized Anxiety Disorder (300.02) is described in the American Psychiatric Association’s Diagnostic and Statistical Manual, III 1 as follows: Generalized, persistent anxiety (of at least 1 month continual duration), manifested by symptoms from three of the four following categories: Motor tension: shakiness, jitteriness, jumpiness, trembling, tension, muscle aches, fatigability, inability to relax, eyelid twitch, furrowed brow, strained face, fidgeting, restlessness, easy startle. Autonomic hyperactivity: sweating, heart pounding or racing, cold, clammy hands, dry mouth, dizziness, lightheadedness, paresthesias (tingling in hands or feet), upset stomach, hot or cold spells, frequent urination, diarrhea, discomfort in the pit of the stomach, lump in the throat, flushing, pallor, high resting pulse and respiration rate. Apprehensive expectation: anxiety, worry, fear, rumination, and anticipation of misfortune to self or others. Vigilance and scanning: hyperattentiveness resulting in distractibility, difficulty in concentrating, insomnia, feeling ""on edge"", irritability, impatience. The above symptoms would not be due to another mental disorder, such as a depressive disorder or schizophrenia. However, mild depressive symptoms are common in GAD. The effectiveness of buspirone in long-term use, that is, for more than 3 to 4 weeks, has not been demonstrated in controlled trials. There is no body of evidence available that systematically addresses the appropriate duration of treatment for GAD. However, in a study of long-term use, 264 patients were treated with buspirone for 1 year without ill effect. Therefore, the physician who elects to use buspirone for extended periods should periodically reassess the usefulness of the drug for the individual patient." uuid:f8714f04-8b69-486b-a0fa-e41fb8cce1f4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3223 biolink:treats MONDO:0011918 PMID:41385096 "[{""id"":""uuid:ebb0071c-4771-47aa-8c35-fa8af36f552b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:19a8fd55-d0fa-44d2-873b-238fa44c4155"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Buspirone hydrochloride tablets are indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The efficacy of buspirone has been demonstrated in controlled clinical trials of outpatients whose diagnosis roughly corresponds to Generalized Anxiety Disorder (GAD). Many of the patients enrolled in these studies also had coexisting depressive symptoms and buspirone relieved anxiety in the presence of these coexisting depressive symptoms. The patients evaluated in these studies had experienced symptoms for periods of 1 month to over 1 year prior to the study, with an average symptom duration of 6 months. Generalized Anxiety Disorder (300.02) is described in the American Psychiatric Association’s Diagnostic and Statistical Manual, III 1 as follows: Generalized, persistent anxiety (of at least 1 month continual duration), manifested by symptoms from three of the four following categories: Motor tension: shakiness, jitteriness, jumpiness, trembling, tension, muscle aches, fatigability, inability to relax, eyelid twitch, furrowed brow, strained face, fidgeting, restlessness, easy startle. Autonomic hyperactivity: sweating, heart pounding or racing, cold, clammy hands, dry mouth, dizziness, lightheadedness, paresthesias (tingling in hands or feet), upset stomach, hot or cold spells, frequent urination, diarrhea, discomfort in the pit of the stomach, lump in the throat, flushing, pallor, high resting pulse and respiration rate. Apprehensive expectation: anxiety, worry, fear, rumination, and anticipation of misfortune to self or others. Vigilance and scanning: hyperattentiveness resulting in distractibility, difficulty in concentrating, insomnia, feeling ""on edge"", irritability, impatience. The above symptoms would not be due to another mental disorder, such as a depressive disorder or schizophrenia. However, mild depressive symptoms are common in GAD. The effectiveness of buspirone in long-term use, that is, for more than 3 to 4 weeks, has not been demonstrated in controlled trials. There is no body of evidence available that systematically addresses the appropriate duration of treatment for GAD. However, in a study of long-term use, 264 patients were treated with buspirone for 1 year without ill effect. Therefore, the physician who elects to use buspirone for extended periods should periodically reassess the usefulness of the drug for the individual patient." uuid:57ea458d-09d7-46f5-8ddf-f58f927a9125 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3223 biolink:treats MONDO:0001942 PMID:41385096 "[{""id"":""uuid:8d1d7f60-5aa6-4840-9112-c1861bfa409f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cfc91aaa-5941-4ac6-80ff-cdd4fcd25c6f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Buspirone hydrochloride tablets are indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The efficacy of buspirone has been demonstrated in controlled clinical trials of outpatients whose diagnosis roughly corresponds to Generalized Anxiety Disorder (GAD). Many of the patients enrolled in these studies also had coexisting depressive symptoms and buspirone relieved anxiety in the presence of these coexisting depressive symptoms. The patients evaluated in these studies had experienced symptoms for periods of 1 month to over 1 year prior to the study, with an average symptom duration of 6 months. Generalized Anxiety Disorder (300.02) is described in the American Psychiatric Association’s Diagnostic and Statistical Manual, III 1 as follows: Generalized, persistent anxiety (of at least 1 month continual duration), manifested by symptoms from three of the four following categories: Motor tension: shakiness, jitteriness, jumpiness, trembling, tension, muscle aches, fatigability, inability to relax, eyelid twitch, furrowed brow, strained face, fidgeting, restlessness, easy startle. Autonomic hyperactivity: sweating, heart pounding or racing, cold, clammy hands, dry mouth, dizziness, lightheadedness, paresthesias (tingling in hands or feet), upset stomach, hot or cold spells, frequent urination, diarrhea, discomfort in the pit of the stomach, lump in the throat, flushing, pallor, high resting pulse and respiration rate. Apprehensive expectation: anxiety, worry, fear, rumination, and anticipation of misfortune to self or others. Vigilance and scanning: hyperattentiveness resulting in distractibility, difficulty in concentrating, insomnia, feeling ""on edge"", irritability, impatience. The above symptoms would not be due to another mental disorder, such as a depressive disorder or schizophrenia. However, mild depressive symptoms are common in GAD. The effectiveness of buspirone in long-term use, that is, for more than 3 to 4 weeks, has not been demonstrated in controlled trials. There is no body of evidence available that systematically addresses the appropriate duration of treatment for GAD. However, in a study of long-term use, 264 patients were treated with buspirone for 1 year without ill effect. Therefore, the physician who elects to use buspirone for extended periods should periodically reassess the usefulness of the drug for the individual patient." uuid:2d8fa740-934a-40d9-a5ff-ef9d95cd7e85 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0006604 PMID:41385096 "[{""id"":""uuid:e3bcd82d-175f-47d6-a747-5eb5832641a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:72c9163a-3459-4ae6-a030-b534f6e27d76"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. uuid:397157ae-0fc1-4f91-ba02-0ac2684ad66f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0033816 PMID:41385096 "[{""id"":""uuid:ca16b8aa-0540-464b-91b5-5d9eabc8e4cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7eaf979f-f998-429a-96a5-1da6f274fa4e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. uuid:82a16d4c-94f5-43b0-a083-57749632a1e0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats UMLS:C1275687 PMID:41385096 "[{""id"":""uuid:94e71efa-7019-4ee9-bce6-1d99e3929cb5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fdb71a9c-8dbf-4dbd-bd9f-d93c1309dd79"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. uuid:c5830cbb-79ac-4929-9a77-158d6a118d07 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats UMLS:C0010543 PMID:41385096 "[{""id"":""uuid:671e37e2-e100-4ae3-b339-8c48d6edde01"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d13af2cd-ba5f-4640-a705-c5d418a99a68"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. uuid:8deb0f35-dc9b-4d32-8e04-9d279ba77dd8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0006668 PMID:41385096 "[{""id"":""uuid:5cc0a017-7260-4349-b5f7-d6e334973272"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2ec484e5-8655-4b72-a07e-d1a041f8ad3d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. uuid:7df194fd-941f-4269-ade9-9186dc3856c2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats UMLS:C0339289 PMID:41385096 "[{""id"":""uuid:1f465cd4-5052-436a-a9c4-9bde3138cb65"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9bd49b9a-4983-4fd0-acee-095984dc3118"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. uuid:2d696d05-bc08-4745-a5d9-72fc7def2f64 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3082 biolink:treats MONDO:0006875 PMID:41385096 "[{""id"":""uuid:3fb2df02-81fe-4518-b68f-1285ff5ff99b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dad2f748-92d4-4afb-b485-2190a872560d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BETOPTIC Ophthalmic Solution has been shown to be effective in lowering intraocular pressure and is indicated in the treatment of ocular hypertension and chronic open-angle glaucoma. It may be used alone or in combination with other anti-glaucoma drugs. In clinical studies BETOPTIC was safely used to lower intraocular pressure in 47 patients with both glaucoma and reactive airway disease who were followed for a mean period of 15 months. However, caution should be used in treating patients with severe reactive airway disease or a history of asthma. uuid:5ae0d1ba-070b-4ded-8c72-255aac67725c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3082 biolink:treats MONDO:0005338 PMID:41385096 "[{""id"":""uuid:3ba5e8e9-2f50-4fc4-ae2f-f180a5a7a62a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8de0f20a-646d-4e2b-b9f9-eae92b926181"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BETOPTIC Ophthalmic Solution has been shown to be effective in lowering intraocular pressure and is indicated in the treatment of ocular hypertension and chronic open-angle glaucoma. It may be used alone or in combination with other anti-glaucoma drugs. In clinical studies BETOPTIC was safely used to lower intraocular pressure in 47 patients with both glaucoma and reactive airway disease who were followed for a mean period of 15 months. However, caution should be used in treating patients with severe reactive airway disease or a history of asthma. uuid:a2fb5108-7647-4782-8130-a5d5944fdba6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3082 biolink:treats MONDO:0005041 PMID:41385096 "[{""id"":""uuid:8fb23faa-dec0-4e0a-9d1c-f349690c60fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:77347d82-1974-41cc-9bf1-7bec000c1878"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BETOPTIC Ophthalmic Solution has been shown to be effective in lowering intraocular pressure and is indicated in the treatment of ocular hypertension and chronic open-angle glaucoma. It may be used alone or in combination with other anti-glaucoma drugs. In clinical studies BETOPTIC was safely used to lower intraocular pressure in 47 patients with both glaucoma and reactive airway disease who were followed for a mean period of 15 months. However, caution should be used in treating patients with severe reactive airway disease or a history of asthma. uuid:37339834-e3b0-40d7-8711-d23f7c6ebe43 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3082 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:2b0947be-0dac-49a6-bb13-fb91019e9467"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7b559c5a-d97a-46b2-b9da-61ee5d1255c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BETOPTIC Ophthalmic Solution has been shown to be effective in lowering intraocular pressure and is indicated in the treatment of ocular hypertension and chronic open-angle glaucoma. It may be used alone or in combination with other anti-glaucoma drugs. In clinical studies BETOPTIC was safely used to lower intraocular pressure in 47 patients with both glaucoma and reactive airway disease who were followed for a mean period of 15 months. However, caution should be used in treating patients with severe reactive airway disease or a history of asthma. uuid:a524e4d8-f290-4b18-872e-5d0aa19c8f68 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63619 biolink:treats MONDO:1030011 PMID:41385096 "[{""id"":""uuid:dada8d69-6b89-4880-a7f1-3d97afd8a9bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a89ace38-ffe4-4fb0-8367-559751f751b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In patients without structural heart disease, propafenone HCl is indicated to prolong the time to recurrence of - paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms. - paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms. As with other agents, some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. Concomitant treatment with drugs that increase the functional AV refractory period is recommended. The use of propafenone in patients with chronic atrial fibrillation has not been evaluated. Propafenone should not be used to control ventricular rate during atrial fibrillation. Propafenone is also indicated for the treatment of - documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening. Because of the proarrhythmic effects of propafenone, its use with lesser ventricular arrhythmias is not recommended, even if patients are symptomatic, and any use of the drug should be reserved for patients in whom, in the opinion of the physician, the potential benefits out-weigh the risks. Initiation of propafenone treatment, as with other antiarrhythmics used to treat life-threatening ventricular arrhythmias, should be carried out in the hospital. Propafenone, like other antiarrhythmic drugs, has not been shown to enhance survival in patients with ventricular or atrial arrhythmias. uuid:3748640a-252c-4c23-b1b3-29a46d370418 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63619 biolink:treats UMLS:C0741292 PMID:41385096 "[{""id"":""uuid:2efe42aa-6d32-419a-b2ba-d6d935e12145"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7b489283-11b1-4746-a974-5fd4b5fc58a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In patients without structural heart disease, propafenone HCl is indicated to prolong the time to recurrence of - paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms. - paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms. As with other agents, some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. Concomitant treatment with drugs that increase the functional AV refractory period is recommended. The use of propafenone in patients with chronic atrial fibrillation has not been evaluated. Propafenone should not be used to control ventricular rate during atrial fibrillation. Propafenone is also indicated for the treatment of - documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening. Because of the proarrhythmic effects of propafenone, its use with lesser ventricular arrhythmias is not recommended, even if patients are symptomatic, and any use of the drug should be reserved for patients in whom, in the opinion of the physician, the potential benefits out-weigh the risks. Initiation of propafenone treatment, as with other antiarrhythmics used to treat life-threatening ventricular arrhythmias, should be carried out in the hospital. Propafenone, like other antiarrhythmic drugs, has not been shown to enhance survival in patients with ventricular or atrial arrhythmias. uuid:6200c9e7-3ded-4178-a76b-d1261ab1d48b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63619 biolink:treats HP:0004763 PMID:41385096 "[{""id"":""uuid:482c5cbd-7a27-4724-bafd-55262285348d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3ab1a21a-d6d8-45f3-904e-b39ae9b7d7e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In patients without structural heart disease, propafenone HCl is indicated to prolong the time to recurrence of - paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms. - paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms. As with other agents, some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. Concomitant treatment with drugs that increase the functional AV refractory period is recommended. The use of propafenone in patients with chronic atrial fibrillation has not been evaluated. Propafenone should not be used to control ventricular rate during atrial fibrillation. Propafenone is also indicated for the treatment of - documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening. Because of the proarrhythmic effects of propafenone, its use with lesser ventricular arrhythmias is not recommended, even if patients are symptomatic, and any use of the drug should be reserved for patients in whom, in the opinion of the physician, the potential benefits out-weigh the risks. Initiation of propafenone treatment, as with other antiarrhythmics used to treat life-threatening ventricular arrhythmias, should be carried out in the hospital. Propafenone, like other antiarrhythmic drugs, has not been shown to enhance survival in patients with ventricular or atrial arrhythmias. uuid:ace4757e-ec24-43e1-a6d6-37e0e2e6e0f8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63619 biolink:treats HP:0004308 PMID:41385096 "[{""id"":""uuid:5315cfa3-da8c-4e01-b87a-514402927ca3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6054ee3b-370f-4add-a75b-1c96d27a356b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In patients without structural heart disease, propafenone HCl is indicated to prolong the time to recurrence of - paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms. - paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms. As with other agents, some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. Concomitant treatment with drugs that increase the functional AV refractory period is recommended. The use of propafenone in patients with chronic atrial fibrillation has not been evaluated. Propafenone should not be used to control ventricular rate during atrial fibrillation. Propafenone is also indicated for the treatment of - documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening. Because of the proarrhythmic effects of propafenone, its use with lesser ventricular arrhythmias is not recommended, even if patients are symptomatic, and any use of the drug should be reserved for patients in whom, in the opinion of the physician, the potential benefits out-weigh the risks. Initiation of propafenone treatment, as with other antiarrhythmics used to treat life-threatening ventricular arrhythmias, should be carried out in the hospital. Propafenone, like other antiarrhythmic drugs, has not been shown to enhance survival in patients with ventricular or atrial arrhythmias. uuid:a8926259-5cd3-4019-9be9-a53a51baddbe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63619 biolink:treats UMLS:C0750197 PMID:41385096 "[{""id"":""uuid:80df1069-beab-4754-be85-7f19aecfde80"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:47d6e104-aa78-4a0d-849e-2ecaa53ffc29"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In patients without structural heart disease, propafenone HCl is indicated to prolong the time to recurrence of - paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms. - paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms. As with other agents, some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. Concomitant treatment with drugs that increase the functional AV refractory period is recommended. The use of propafenone in patients with chronic atrial fibrillation has not been evaluated. Propafenone should not be used to control ventricular rate during atrial fibrillation. Propafenone is also indicated for the treatment of - documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening. Because of the proarrhythmic effects of propafenone, its use with lesser ventricular arrhythmias is not recommended, even if patients are symptomatic, and any use of the drug should be reserved for patients in whom, in the opinion of the physician, the potential benefits out-weigh the risks. Initiation of propafenone treatment, as with other antiarrhythmics used to treat life-threatening ventricular arrhythmias, should be carried out in the hospital. Propafenone, like other antiarrhythmic drugs, has not been shown to enhance survival in patients with ventricular or atrial arrhythmias. uuid:c0bf4a2e-42db-43ec-ae40-942ea3da4df4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63619 biolink:treats MONDO:0004981 PMID:41385096 "[{""id"":""uuid:f1a08fa0-b81f-4fbe-8289-82a2d9dfadcc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:77f9698c-eaff-448a-811d-8af441e3c11e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In patients without structural heart disease, propafenone HCl is indicated to prolong the time to recurrence of - paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms. - paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms. As with other agents, some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. Concomitant treatment with drugs that increase the functional AV refractory period is recommended. The use of propafenone in patients with chronic atrial fibrillation has not been evaluated. Propafenone should not be used to control ventricular rate during atrial fibrillation. Propafenone is also indicated for the treatment of - documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening. Because of the proarrhythmic effects of propafenone, its use with lesser ventricular arrhythmias is not recommended, even if patients are symptomatic, and any use of the drug should be reserved for patients in whom, in the opinion of the physician, the potential benefits out-weigh the risks. Initiation of propafenone treatment, as with other antiarrhythmics used to treat life-threatening ventricular arrhythmias, should be carried out in the hospital. Propafenone, like other antiarrhythmic drugs, has not been shown to enhance survival in patients with ventricular or atrial arrhythmias. uuid:18706811-d8f8-4e35-845f-058fceacc7b1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63619 biolink:treats MONDO:0005310 PMID:41385096 "[{""id"":""uuid:8a91c0c1-8de1-45c9-af57-23b8d24c8402"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:397a6e2d-1466-4090-8ca2-9c3c51402623"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In patients without structural heart disease, propafenone HCl is indicated to prolong the time to recurrence of - paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms. - paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms. As with other agents, some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. Concomitant treatment with drugs that increase the functional AV refractory period is recommended. The use of propafenone in patients with chronic atrial fibrillation has not been evaluated. Propafenone should not be used to control ventricular rate during atrial fibrillation. Propafenone is also indicated for the treatment of - documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening. Because of the proarrhythmic effects of propafenone, its use with lesser ventricular arrhythmias is not recommended, even if patients are symptomatic, and any use of the drug should be reserved for patients in whom, in the opinion of the physician, the potential benefits out-weigh the risks. Initiation of propafenone treatment, as with other antiarrhythmics used to treat life-threatening ventricular arrhythmias, should be carried out in the hospital. Propafenone, like other antiarrhythmic drugs, has not been shown to enhance survival in patients with ventricular or atrial arrhythmias. uuid:739dbcae-386b-4708-a8e8-b2b951b390da biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4657 biolink:treats UMLS:C0750197 PMID:41385096 "[{""id"":""uuid:d0abc333-afca-42cd-801f-a0b2563e5e86"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:01dc57c4-e6b3-4724-8e41-a46d0cb891c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Disopyramide Phosphate Extended-release Capsules, USP are indicated for the treatment of documented ventricular arrhythmias such as sustained ventricular tachycardia, that in the judgement of the physician, are life-threatening. Because of the proarrhythmic effects of disopyramide, its use with lesser arrhythmias is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of disopyramide treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. The extended-release capsules should not be used initially if rapid establishment of disopyramide plasma levels is desired. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias. uuid:efd485bf-e2b8-4814-93ae-592b7cffe22a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4657 biolink:treats HP:0004308 PMID:41385096 "[{""id"":""uuid:653f940e-bb3a-42c6-b627-a73714096084"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:002d0de1-71cc-4adb-b478-2338bd25d44a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Disopyramide Phosphate Extended-release Capsules, USP are indicated for the treatment of documented ventricular arrhythmias such as sustained ventricular tachycardia, that in the judgement of the physician, are life-threatening. Because of the proarrhythmic effects of disopyramide, its use with lesser arrhythmias is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of disopyramide treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. The extended-release capsules should not be used initially if rapid establishment of disopyramide plasma levels is desired. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias. uuid:d11e577b-398a-4aa6-8354-84be8c271523 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4657 biolink:treats HP:0006682 PMID:41385096 "[{""id"":""uuid:6b4ef132-f803-4b5b-ae7f-05532e610a60"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:14938c85-2804-4f6b-9552-e508005d700a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Disopyramide Phosphate Extended-release Capsules, USP are indicated for the treatment of documented ventricular arrhythmias such as sustained ventricular tachycardia, that in the judgement of the physician, are life-threatening. Because of the proarrhythmic effects of disopyramide, its use with lesser arrhythmias is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of disopyramide treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. The extended-release capsules should not be used initially if rapid establishment of disopyramide plasma levels is desired. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias. uuid:c98737ac-0fe8-41be-92d0-ab9186d9cc3d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0005377 PMID:41385096 "[{""id"":""uuid:5529a046-cd84-4cf4-b333-21024822ea27"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ef2dfa52-d08c-49ce-bc27-c78ebd033035"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PrednisoLONE Syrup (PrednisoLONE Oral Solution USP) is indicated in the following conditions: Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice: synthetic analogs may be used in conjunction with mineralocorticoids where applicable: in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and Iridocyclitis Respiratory Disorders Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate chemotherapy Aspiration pneumonitis Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. In addition to the above indications, PrednisoLONE Syrup (PrednisoLONE Oral Solution USP) is indicated for systemic dermatomyositis (polymyositis). uuid:280f9ff7-bf31-4176-8bd1-667e21436b49 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2645731 biolink:treats MONDO:0005338 PMID:41385096 "[{""id"":""uuid:6dfcbf31-72f2-4d63-bdce-becdd227e794"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0e7851dd-ed4b-4dfc-971c-9a6dd25db6fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Betoptic ® Pilo Ophthalmic Suspension is indicated for the reduction of elevated intraocular pressure in patients with primary open-angle glaucoma and ocular hypertension who are insufficiently responsive to Betoptic ® -S (failed to achieve target IOP determined after multiple measurements over time). It is not known whether Betoptic ® Pilo is equivalent in IOP lowering efficacy to the administration of Betoptic ® -S 0.25% and pilocarpine 1.75% dosed separately. It is not known whether Betoptic ® Pilo is equivalent to other beta-blockers given in combination with pilocarpine. uuid:db2f9ed2-5fb6-4d60-a7d7-ede949e79dce biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2645731 biolink:treats MONDO:0006875 PMID:41385096 "[{""id"":""uuid:3ef56e6c-8329-4ff9-ad49-01a4eac07850"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5070d77a-a42a-4096-91c1-e53f1dea9092"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Betoptic ® Pilo Ophthalmic Suspension is indicated for the reduction of elevated intraocular pressure in patients with primary open-angle glaucoma and ocular hypertension who are insufficiently responsive to Betoptic ® -S (failed to achieve target IOP determined after multiple measurements over time). It is not known whether Betoptic ® Pilo is equivalent in IOP lowering efficacy to the administration of Betoptic ® -S 0.25% and pilocarpine 1.75% dosed separately. It is not known whether Betoptic ® Pilo is equivalent to other beta-blockers given in combination with pilocarpine. uuid:8e61d3c3-72dd-4758-96a3-d8801f2a879f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3011 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:6c15364a-9474-46c3-b294-92a60ba845ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0d9c0184-c31e-4b80-9d31-9d9f6efa542e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Benazepril hydrochloride tablets are indicated for the treatment of hypertension. Benazepril hydrochloride tablets may be used alone or in combination with thiazide diuretics. In using benazepril hydrochloride tablets, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that benazepril hydrochloride tablets do not have a similar risk (see WARNINGS ). Black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to nonblacks. It should also be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in nonblacks. uuid:7eee9d55-618c-44db-912a-44e5be91b468 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3011 biolink:treats MONDO:0001609 PMID:41385096 "[{""id"":""uuid:65faa8f6-f351-41d8-8c2b-4fefc2c1aec3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:33bb012f-5c73-44ca-826b-11734ad78030"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Benazepril hydrochloride tablets are indicated for the treatment of hypertension. Benazepril hydrochloride tablets may be used alone or in combination with thiazide diuretics. In using benazepril hydrochloride tablets, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that benazepril hydrochloride tablets do not have a similar risk (see WARNINGS ). Black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to nonblacks. It should also be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in nonblacks. uuid:7110bcbd-8902-4b1f-8676-52d44da4da1c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3011 biolink:treats MONDO:0001343 PMID:41385096 "[{""id"":""uuid:5144bd27-a7a6-494e-b785-ef1260a20b68"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e3d0b040-1b31-43dd-b01a-a1514843ceba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Benazepril hydrochloride tablets are indicated for the treatment of hypertension. Benazepril hydrochloride tablets may be used alone or in combination with thiazide diuretics. In using benazepril hydrochloride tablets, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that benazepril hydrochloride tablets do not have a similar risk (see WARNINGS ). Black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to nonblacks. It should also be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in nonblacks. uuid:687bfc26-dd84-41f6-96a3-52c6dcff90e1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3011 biolink:treats MONDO:0010481 PMID:41385096 "[{""id"":""uuid:fe754808-206b-4c3c-be3f-84208678c9c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bde40197-62ea-4f26-8dfc-8eedeba15b07"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Benazepril hydrochloride tablets are indicated for the treatment of hypertension. Benazepril hydrochloride tablets may be used alone or in combination with thiazide diuretics. In using benazepril hydrochloride tablets, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that benazepril hydrochloride tablets do not have a similar risk (see WARNINGS ). Black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to nonblacks. It should also be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in nonblacks. uuid:d1f5f8b5-d6dd-43f1-aeb8-3ac01c5222f0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5790 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:29e4253b-f5d8-4e45-9765-091768f500eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3d95daed-e297-44f2-9713-94effcf3fb3f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydromorphone hydrochloride tablets are indicated for the management of pain in patients where an opioid analgesic is appropriate. uuid:5e5f6666-dcf2-4804-b137-c7a568687769 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68638 biolink:treats MONDO:0006604 PMID:41385096 "[{""id"":""uuid:c32e0d19-746b-48ce-b218-5b3393de330f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:62c12065-a80f-40ee-9989-d0f77939fbb5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe. These include allergic conjunctivitis, acne rosacea, superficial punctate keratits, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivities when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical or thermal burns, or penetration of foreign bodies. uuid:7198995f-0fb8-4e3d-9b15-198c05f4b682 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68638 biolink:treats MONDO:0033816 PMID:41385096 "[{""id"":""uuid:88a78759-620f-459a-95e5-5ba3f90cc456"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:92ce1a8c-50d1-4e61-844a-c37d4dfff710"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe. These include allergic conjunctivitis, acne rosacea, superficial punctate keratits, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivities when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical or thermal burns, or penetration of foreign bodies. uuid:e3cb4a4e-498e-4bed-a077-8be0df659ddc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68638 biolink:treats UMLS:C1275687 PMID:41385096 "[{""id"":""uuid:f7ddf6ca-68df-4e78-a774-278cb16192d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6ec2b076-21a6-4548-a211-92a9cc6c2d18"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe. These include allergic conjunctivitis, acne rosacea, superficial punctate keratits, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivities when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical or thermal burns, or penetration of foreign bodies. uuid:786ab9d4-8099-41f7-9602-8a3f52ce9dd0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68638 biolink:treats MONDO:0006814 PMID:41385096 "[{""id"":""uuid:b7b01685-c496-4e1c-b11b-aac3b7e000db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d66a6468-83dd-48de-bdaf-1e9c33b05118"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe. These include allergic conjunctivitis, acne rosacea, superficial punctate keratits, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivities when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical or thermal burns, or penetration of foreign bodies. uuid:e7619464-496c-4431-9d35-6671de5c1609 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68638 biolink:treats UMLS:C0010543 PMID:41385096 "[{""id"":""uuid:dd10f78f-ed80-4086-a46b-e0d495b49162"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ccdf1d07-99b9-4d05-b5db-c9024996872c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe. These include allergic conjunctivitis, acne rosacea, superficial punctate keratits, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivities when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical or thermal burns, or penetration of foreign bodies. uuid:b114d7fc-fa7a-48a4-8fa7-9afa19789ac1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68638 biolink:treats UMLS:C0497209 PMID:41385096 "[{""id"":""uuid:e5bd1238-c201-4fa7-aca8-2930198c98fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b6d1cd6f-33da-4ebf-a87d-b6152057344d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe. These include allergic conjunctivitis, acne rosacea, superficial punctate keratits, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivities when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical or thermal burns, or penetration of foreign bodies. uuid:55c39cea-af72-4a64-9952-a5ce3ecc0756 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68638 biolink:treats UMLS:C0339289 PMID:41385096 "[{""id"":""uuid:ac1b4472-1abb-4806-aab8-abb4d2389f09"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:178ca58c-7036-4806-be97-d89b621fc79b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe. These include allergic conjunctivitis, acne rosacea, superficial punctate keratits, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivities when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical or thermal burns, or penetration of foreign bodies. uuid:53ce2d0a-2c79-4eed-8d8a-a518589594f5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4786 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:709dd6c8-5089-4578-8e5b-4a912ffe4cb5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1351c5d2-c1c2-42fc-927c-59635098c81e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Enalaprilat injection is indicated for the treatment of hypertension when oral therapy is not practical. Enalaprilat injection has been studied with only one other antihypertensive agent, furosemide, which showed approximately additive effects on blood pressure. Enalapril, the pro-drug of enalaprilat, has been used extensively with a variety of other antihypertensive agents, without apparent difficulty except for occasional hypotension. In using enalaprilat injection, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalaprilat injection does not have a similar risk (See WARNINGS ). In considering use of enalaprilat injection, it should be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, it should be noted that black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks (See WARNINGS , Angioedema ). uuid:871ab0f7-c6aa-4cbc-a148-580c59bc102a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4786 biolink:treats MONDO:0001609 PMID:41385096 "[{""id"":""uuid:6fb65390-8b10-4b4e-a93d-9d25d0c09c36"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c60eed1b-ef99-4391-8382-dfe25f30b143"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Enalaprilat injection is indicated for the treatment of hypertension when oral therapy is not practical. Enalaprilat injection has been studied with only one other antihypertensive agent, furosemide, which showed approximately additive effects on blood pressure. Enalapril, the pro-drug of enalaprilat, has been used extensively with a variety of other antihypertensive agents, without apparent difficulty except for occasional hypotension. In using enalaprilat injection, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalaprilat injection does not have a similar risk (See WARNINGS ). In considering use of enalaprilat injection, it should be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, it should be noted that black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks (See WARNINGS , Angioedema ). uuid:c36579d6-7c81-4f06-b225-5aa7a613020f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4786 biolink:treats MONDO:0001343 PMID:41385096 "[{""id"":""uuid:e8b38f79-090d-43d7-a24e-c0f037f0beac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:781a6fdc-dbd8-4d6f-b7d0-0c35231b0762"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Enalaprilat injection is indicated for the treatment of hypertension when oral therapy is not practical. Enalaprilat injection has been studied with only one other antihypertensive agent, furosemide, which showed approximately additive effects on blood pressure. Enalapril, the pro-drug of enalaprilat, has been used extensively with a variety of other antihypertensive agents, without apparent difficulty except for occasional hypotension. In using enalaprilat injection, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalaprilat injection does not have a similar risk (See WARNINGS ). In considering use of enalaprilat injection, it should be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, it should be noted that black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks (See WARNINGS , Angioedema ). uuid:b159235b-5a23-4426-a8a2-fb3a8bf3a998 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4786 biolink:treats MONDO:0010481 PMID:41385096 "[{""id"":""uuid:9b09312f-4040-47fb-b2b3-6473e66df606"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4043fea9-472f-447f-b647-fbbcb38a385d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Enalaprilat injection is indicated for the treatment of hypertension when oral therapy is not practical. Enalaprilat injection has been studied with only one other antihypertensive agent, furosemide, which showed approximately additive effects on blood pressure. Enalapril, the pro-drug of enalaprilat, has been used extensively with a variety of other antihypertensive agents, without apparent difficulty except for occasional hypotension. In using enalaprilat injection, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalaprilat injection does not have a similar risk (See WARNINGS ). In considering use of enalaprilat injection, it should be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, it should be noted that black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks (See WARNINGS , Angioedema ). uuid:54a4a7ef-7962-405f-b385-68367b695fe2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9362 biolink:treats HP:0000616 PMID:41385096 "[{""id"":""uuid:f59e5f5f-ced7-43d2-9eae-e8629c2e6bc5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7f985d54-8874-4855-96e8-8898fd56a33b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PROFENAL Ophthalmic Solution is indicated for inhibition of intraoperative miosis. uuid:f968e268-97f7-42de-9f30-90f585ba7697 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2682 biolink:treats MONDO:0000240 PMID:41385096 "[{""id"":""uuid:639b923a-f379-4cf4-ae00-9d605362a832"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1970b9bc-bdc5-4c60-911f-5c16642f7972"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AMPHOTEC is indicated for the treatment of invasive aspergillosis in patients where renal impairment or unacceptable toxicity precludes the use of amphotericin B deoxycholate in effective doses, and in patients with invasive aspergillosis where prior amphotericin B deoxycholate therapy has failed. uuid:d5cb228e-4c33-4848-bb76-6a560c4565ee biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0006604 PMID:41385096 "[{""id"":""uuid:7a9d6e62-589b-444c-b78e-90d89586c888"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:84578c6e-3775-488f-bc0f-443aa979da26"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctuate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. uuid:489a0137-b07e-43e2-9609-1532ac7397d4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0001465 PMID:41385096 "[{""id"":""uuid:e840d86a-49b1-4e7d-b455-b1ef903d9146"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:39ace67a-1512-4095-867b-d491ce926672"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctuate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. uuid:76db1216-e69e-4704-a2bf-eebbff9ffc34 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats UMLS:C1275687 PMID:41385096 "[{""id"":""uuid:1a999ec4-dd8f-45b2-97ae-3f368c8b57bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7549d7b8-99b8-433b-abea-5fc3ec2b2b99"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctuate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. uuid:3f9ef063-0a9b-4a6b-b1c0-c9ed8837e5d0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0006814 PMID:41385096 "[{""id"":""uuid:5e3d257d-6ab2-41f6-a121-f2ee90f8ad7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3848bab5-db5e-4208-bb26-ab9100189dd6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctuate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. uuid:125fe84b-6c1b-43ae-b42a-fb4209613d74 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats UMLS:C0010543 PMID:41385096 "[{""id"":""uuid:80a0cf3d-f806-46a2-b7f3-aeefc981dd94"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:253cd6eb-979b-4bba-b369-ea4fd2febc2e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctuate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. uuid:1d793112-63e1-4ff5-8f0b-eb9552322395 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0006668 PMID:41385096 "[{""id"":""uuid:9aa34da5-8c0f-4194-8eab-e986c9730bfd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bb0b2387-d7b6-4a10-b369-48a7c6f7980e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctuate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. uuid:926f96eb-4ef2-4f8b-93db-bcb1cb809dce biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats UMLS:C0339289 PMID:41385096 "[{""id"":""uuid:af1c01f3-583b-4f8e-b349-4adce3f306c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:924e1abe-ddf5-4868-bed8-f28fe7fe12e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctuate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. uuid:7c7970ca-2344-494a-8b9f-8641a10831f1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:724125 biolink:treats MONDO:0005173 PMID:41385096 "[{""id"":""uuid:e4f4bbee-01be-481b-826a-d29b5a01a951"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2019d4c6-7edc-4c87-8ffb-95ce9d3b035e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Metvixia Cream in combination with 570 to 670 nm wavelength red light illumination using the CureLight BroadBand Model CureLight 01 lamp is indicated for treatment of non-hyperkeratotic actinic keratoses of the face and scalp in immunocompetent patients when used in conjunction with lesion preparation (debridement using a sharp dermal curette) in the physician’s office when other therapies are unacceptable or considered medically less appropriate. uuid:874c7788-53e8-49e4-8ff1-7d8f901512e3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0011786 PMID:41385096 "[{""id"":""uuid:fc1ae308-5611-41cc-99fd-297817c00aa3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b5833602-2f58-40a0-a026-3695dc97da7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prednisolone syrup is indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice: synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia ( RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. In addition to the above indications prednisolone syrup is indicated for systemic dermatomyositis (polymyositis). uuid:5542a392-cfd2-4f1b-9359-2abc6c9ce42c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0009197 PMID:41385096 "[{""id"":""uuid:eb15dc2f-023b-4aee-8043-c826e7fae7c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:274ffdb9-ce3d-475b-bfb7-7dfe8244349a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prednisolone syrup is indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice: synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia ( RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. In addition to the above indications prednisolone syrup is indicated for systemic dermatomyositis (polymyositis). uuid:f9ea15a6-3965-4433-88f7-a9b7bdace507 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6060 biolink:treats MONDO:0005041 PMID:41385096 "[{""id"":""uuid:6ae34e30-494a-4826-a0e3-230fc2572389"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2b646580-263d-40f3-92dd-4d089539a6fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the short-term reduction of intraocular pressure. May be used prior to and after intraocular surgery. May be used to interrupt an acute attack of glaucoma. uuid:97b6b43f-51fb-4b3b-8ae6-049b4ebeabfc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9613 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:5a61b7bf-7eb6-4dc6-b5e2-602222c7e7dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:190b50fd-96fb-4413-8b6f-292092477bb0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tolazamide tablets are indicated as an adjunct to diet to lower the blood glucose in patients with noninsulin-dependent diabetes mellitus (Type II) whose hyperglycemia cannot be satisfactorily controlled by diet alone. In initiating treatment for noninsulin-dependent diabetes, diet should be emphasized as the primary form of treatment. Caloric restriction and weight loss are essential in the obese diabetic patient. Proper dietary management alone may be effective in controlling the blood glucose and symptoms of hyperglycemia. The importance of regular physical activity should also be stressed and cardiovascular risk factors should be identified and corrective measures taken where possible. If this treatment program fails to reduce symptoms and/or blood glucose, the use of an oral sulfonylurea or insulin should be considered. Use of tolazamide must be viewed by both the physician and patient as a treatment in addition to diet and not as a substitute for diet or as a convenient mechanism for avoiding dietary restraint. Furthermore, loss of blood glucose control on diet alone may be transient thus requiring only short-term administration of tolazamide. During maintenance programs, tolazamide should be discontinued if satisfactory lowering of blood glucose is no longer achieved. Judgments should be based on regular clinical and laboratory evaluations. In considering the use of tolazamide in asymptomatic patients, it should be recognized that controlling the blood glucose in noninsulin-dependent diabetes has not been definitely established to be effective in preventing the long-term cardiovascular or neural complications of diabetes. uuid:5868109c-5262-4a9e-871e-bbf03b636fc6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4717 biolink:treats HP:0002018 PMID:41385096 "[{""id"":""uuid:867f830a-0f45-4872-9703-79abd5e2bf7b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1dd1c85a-1819-4924-86ac-fffdac1fde7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INAPSINE (droperidol) is indicated to reduce the incidence of nausea and vomiting associated with surgical and diagnostic procedures. uuid:285e839a-2310-4447-95ec-16682dd01980 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4717 biolink:treats HP:0002013 PMID:41385096 "[{""id"":""uuid:36ed6d86-8e82-4d45-afd5-a59154a01bed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2e4924bb-d013-48a7-997b-36d4b6432848"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INAPSINE (droperidol) is indicated to reduce the incidence of nausea and vomiting associated with surgical and diagnostic procedures. uuid:57a3908e-19f1-4381-b94e-013094b27c86 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6427 biolink:treats MONDO:0004956 PMID:41385096 "[{""id"":""uuid:30d617d8-97d5-4eea-ae5e-b9baadb8b35b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3bce2662-68af-475a-bb0a-15d430130676"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LUPRON INJECTION (leuprolide acetate) is indicated in the palliative treatment of advanced prostatic cancer. uuid:c7f1cb68-4366-4163-9302-2962cef326b1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28864 biolink:treats MONDO:0700217 PMID:41385096 "[{""id"":""uuid:4818280f-afbf-45be-a26f-b0b3ad4f11f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eb5313ba-b50e-47e9-bca4-de1d404ad03e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Tobramycin Injection USP and other antibacterial drugs, Tobramycin Injection USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tobramycin is indicated for the treatment of serious bacterial infections caused by susceptible strains of the designated microorganisms in the diseases listed below: Septicemia in the pediatric patient and adult caused by P. aeruginosa, E. coli., and Klebsiella spp Lower respiratory tract infections caused by P. aeruginosa, Klebsiella spp, Enterobacter spp, Serratia spp, E. coli, and S. aureus (penicillinase and non-penicillinase-producing strains) Serious central nervous system infections (meningitis) caused by susceptible organisms. Intra-abdominal infections, including peritonitis, caused by E. coli, Klebsiella spp, and Enterobacter spp Skin, bone, and skin-structure infections caused by P. aeruginosa, Proteus spp, E. coli, Klebsiella spp, Enterobacter spp, and S. aureus Complicated and recurrent urinary tract infections caused by P. aeruginosa, Proteus spp (indole-positive and indole-negative), E. coli, Klebsiella spp, Enterobacter spp, Serratia spp, S. aureus, Providencia, and Citrobacter spp Aminoglycosides, including tobramycin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics having less potential toxicity. Tobramycin may be considered in serious staphylococcal infections when penicillin or other potentially less toxic drugs are contraindicated and when bacterial susceptibility testing and clinical judgment indicate its use. Bacterial cultures should be obtained prior to and during treatment to isolate and identify etiologic organisms and to test their susceptibility to tobramycin. If susceptibility tests show that the causative organisms are resistant to tobramycin, other appropriate therapy should be instituted. In patients in whom a serious life-threatening gram-negative infection is suspected, including those in whom concurrent therapy with penicillin or cephalosporin and an aminoglycoside may be indicated, treatment with tobramycin may be initiated before the results of susceptibility studies are obtained. The decision to continue therapy with tobramycin should be based on the results of susceptibility studies, the severity of the infection, and the important additional concepts discussed in the WARNINGS box above. uuid:4ecd7e48-be14-41a5-a43b-1584fcfb7533 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28864 biolink:treats MONDO:0024355 PMID:41385096 "[{""id"":""uuid:d4ddd9f0-aebe-4081-a9fa-e2b87d26cbd0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:12134302-5c25-4d76-9c66-07293f2f2088"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c725d3a4-74b0-46a2-8bd7-17a75cbab449"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Tobramycin Injection USP and other antibacterial drugs, Tobramycin Injection USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tobramycin is indicated for the treatment of serious bacterial infections caused by susceptible strains of the designated microorganisms in the diseases listed below: Septicemia in the pediatric patient and adult caused by P. aeruginosa, E. coli., and Klebsiella spp Lower respiratory tract infections caused by P. aeruginosa, Klebsiella spp, Enterobacter spp, Serratia spp, E. coli, and S. aureus (penicillinase and non-penicillinase-producing strains) Serious central nervous system infections (meningitis) caused by susceptible organisms. Intra-abdominal infections, including peritonitis, caused by E. coli, Klebsiella spp, and Enterobacter spp Skin, bone, and skin-structure infections caused by P. aeruginosa, Proteus spp, E. coli, Klebsiella spp, Enterobacter spp, and S. aureus Complicated and recurrent urinary tract infections caused by P. aeruginosa, Proteus spp (indole-positive and indole-negative), E. coli, Klebsiella spp, Enterobacter spp, Serratia spp, S. aureus, Providencia, and Citrobacter spp Aminoglycosides, including tobramycin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics having less potential toxicity. Tobramycin may be considered in serious staphylococcal infections when penicillin or other potentially less toxic drugs are contraindicated and when bacterial susceptibility testing and clinical judgment indicate its use. Bacterial cultures should be obtained prior to and during treatment to isolate and identify etiologic organisms and to test their susceptibility to tobramycin. If susceptibility tests show that the causative organisms are resistant to tobramycin, other appropriate therapy should be instituted. In patients in whom a serious life-threatening gram-negative infection is suspected, including those in whom concurrent therapy with penicillin or cephalosporin and an aminoglycoside may be indicated, treatment with tobramycin may be initiated before the results of susceptibility studies are obtained. The decision to continue therapy with tobramycin should be based on the results of susceptibility studies, the severity of the infection, and the important additional concepts discussed in the WARNINGS box above.|[PMDA] A drug with a new route of administration indicated for the improvement of symptoms associated with respiratory infection caused by Pseudomonas aeruginosa in cystic fibrosis patients. uuid:c0cd7688-27b6-4157-bbf6-b1dde9a15187 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28864 biolink:treats MONDO:0021108 PMID:41385096 "[{""id"":""uuid:389041e0-952e-4723-a044-665bd1fb146a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e48520bb-0df3-414a-9024-bfc99ec62cdd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Tobramycin Injection USP and other antibacterial drugs, Tobramycin Injection USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tobramycin is indicated for the treatment of serious bacterial infections caused by susceptible strains of the designated microorganisms in the diseases listed below: Septicemia in the pediatric patient and adult caused by P. aeruginosa, E. coli., and Klebsiella spp Lower respiratory tract infections caused by P. aeruginosa, Klebsiella spp, Enterobacter spp, Serratia spp, E. coli, and S. aureus (penicillinase and non-penicillinase-producing strains) Serious central nervous system infections (meningitis) caused by susceptible organisms. Intra-abdominal infections, including peritonitis, caused by E. coli, Klebsiella spp, and Enterobacter spp Skin, bone, and skin-structure infections caused by P. aeruginosa, Proteus spp, E. coli, Klebsiella spp, Enterobacter spp, and S. aureus Complicated and recurrent urinary tract infections caused by P. aeruginosa, Proteus spp (indole-positive and indole-negative), E. coli, Klebsiella spp, Enterobacter spp, Serratia spp, S. aureus, Providencia, and Citrobacter spp Aminoglycosides, including tobramycin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics having less potential toxicity. Tobramycin may be considered in serious staphylococcal infections when penicillin or other potentially less toxic drugs are contraindicated and when bacterial susceptibility testing and clinical judgment indicate its use. Bacterial cultures should be obtained prior to and during treatment to isolate and identify etiologic organisms and to test their susceptibility to tobramycin. If susceptibility tests show that the causative organisms are resistant to tobramycin, other appropriate therapy should be instituted. In patients in whom a serious life-threatening gram-negative infection is suspected, including those in whom concurrent therapy with penicillin or cephalosporin and an aminoglycoside may be indicated, treatment with tobramycin may be initiated before the results of susceptibility studies are obtained. The decision to continue therapy with tobramycin should be based on the results of susceptibility studies, the severity of the infection, and the important additional concepts discussed in the WARNINGS box above. uuid:5a560816-1b98-4a5e-ac67-d934a0a74d4e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28864 biolink:treats UMLS:C1112209 PMID:41385096 "[{""id"":""uuid:dc7768aa-4408-432e-92f4-dc4915a8c8fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:58f53ee8-8d48-4013-88bc-2325f471ec1d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Tobramycin Injection USP and other antibacterial drugs, Tobramycin Injection USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tobramycin is indicated for the treatment of serious bacterial infections caused by susceptible strains of the designated microorganisms in the diseases listed below: Septicemia in the pediatric patient and adult caused by P. aeruginosa, E. coli., and Klebsiella spp Lower respiratory tract infections caused by P. aeruginosa, Klebsiella spp, Enterobacter spp, Serratia spp, E. coli, and S. aureus (penicillinase and non-penicillinase-producing strains) Serious central nervous system infections (meningitis) caused by susceptible organisms. Intra-abdominal infections, including peritonitis, caused by E. coli, Klebsiella spp, and Enterobacter spp Skin, bone, and skin-structure infections caused by P. aeruginosa, Proteus spp, E. coli, Klebsiella spp, Enterobacter spp, and S. aureus Complicated and recurrent urinary tract infections caused by P. aeruginosa, Proteus spp (indole-positive and indole-negative), E. coli, Klebsiella spp, Enterobacter spp, Serratia spp, S. aureus, Providencia, and Citrobacter spp Aminoglycosides, including tobramycin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics having less potential toxicity. Tobramycin may be considered in serious staphylococcal infections when penicillin or other potentially less toxic drugs are contraindicated and when bacterial susceptibility testing and clinical judgment indicate its use. Bacterial cultures should be obtained prior to and during treatment to isolate and identify etiologic organisms and to test their susceptibility to tobramycin. If susceptibility tests show that the causative organisms are resistant to tobramycin, other appropriate therapy should be instituted. In patients in whom a serious life-threatening gram-negative infection is suspected, including those in whom concurrent therapy with penicillin or cephalosporin and an aminoglycoside may be indicated, treatment with tobramycin may be initiated before the results of susceptibility studies are obtained. The decision to continue therapy with tobramycin should be based on the results of susceptibility studies, the severity of the infection, and the important additional concepts discussed in the WARNINGS box above. uuid:ff7c47fd-82d6-4305-a5cc-f9edfe8f1cef biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28864 biolink:treats MONDO:0004522 PMID:41385096 "[{""id"":""uuid:99f02951-1cd9-4535-a900-328936a30e7c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d6bc8952-671a-439e-b25d-96f674c4adac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Tobramycin Injection USP and other antibacterial drugs, Tobramycin Injection USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tobramycin is indicated for the treatment of serious bacterial infections caused by susceptible strains of the designated microorganisms in the diseases listed below: Septicemia in the pediatric patient and adult caused by P. aeruginosa, E. coli., and Klebsiella spp Lower respiratory tract infections caused by P. aeruginosa, Klebsiella spp, Enterobacter spp, Serratia spp, E. coli, and S. aureus (penicillinase and non-penicillinase-producing strains) Serious central nervous system infections (meningitis) caused by susceptible organisms. Intra-abdominal infections, including peritonitis, caused by E. coli, Klebsiella spp, and Enterobacter spp Skin, bone, and skin-structure infections caused by P. aeruginosa, Proteus spp, E. coli, Klebsiella spp, Enterobacter spp, and S. aureus Complicated and recurrent urinary tract infections caused by P. aeruginosa, Proteus spp (indole-positive and indole-negative), E. coli, Klebsiella spp, Enterobacter spp, Serratia spp, S. aureus, Providencia, and Citrobacter spp Aminoglycosides, including tobramycin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics having less potential toxicity. Tobramycin may be considered in serious staphylococcal infections when penicillin or other potentially less toxic drugs are contraindicated and when bacterial susceptibility testing and clinical judgment indicate its use. Bacterial cultures should be obtained prior to and during treatment to isolate and identify etiologic organisms and to test their susceptibility to tobramycin. If susceptibility tests show that the causative organisms are resistant to tobramycin, other appropriate therapy should be instituted. In patients in whom a serious life-threatening gram-negative infection is suspected, including those in whom concurrent therapy with penicillin or cephalosporin and an aminoglycoside may be indicated, treatment with tobramycin may be initiated before the results of susceptibility studies are obtained. The decision to continue therapy with tobramycin should be based on the results of susceptibility studies, the severity of the infection, and the important additional concepts discussed in the WARNINGS box above. uuid:1d67ef4e-ac11-47b2-8a64-f716d2ecb3b0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28864 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:4bca4866-5e5d-4413-807b-3747c0e8d0b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:696383d4-9be7-430d-9521-28f2a425fafb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Tobramycin Injection USP and other antibacterial drugs, Tobramycin Injection USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tobramycin is indicated for the treatment of serious bacterial infections caused by susceptible strains of the designated microorganisms in the diseases listed below: Septicemia in the pediatric patient and adult caused by P. aeruginosa, E. coli., and Klebsiella spp Lower respiratory tract infections caused by P. aeruginosa, Klebsiella spp, Enterobacter spp, Serratia spp, E. coli, and S. aureus (penicillinase and non-penicillinase-producing strains) Serious central nervous system infections (meningitis) caused by susceptible organisms. Intra-abdominal infections, including peritonitis, caused by E. coli, Klebsiella spp, and Enterobacter spp Skin, bone, and skin-structure infections caused by P. aeruginosa, Proteus spp, E. coli, Klebsiella spp, Enterobacter spp, and S. aureus Complicated and recurrent urinary tract infections caused by P. aeruginosa, Proteus spp (indole-positive and indole-negative), E. coli, Klebsiella spp, Enterobacter spp, Serratia spp, S. aureus, Providencia, and Citrobacter spp Aminoglycosides, including tobramycin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics having less potential toxicity. Tobramycin may be considered in serious staphylococcal infections when penicillin or other potentially less toxic drugs are contraindicated and when bacterial susceptibility testing and clinical judgment indicate its use. Bacterial cultures should be obtained prior to and during treatment to isolate and identify etiologic organisms and to test their susceptibility to tobramycin. If susceptibility tests show that the causative organisms are resistant to tobramycin, other appropriate therapy should be instituted. In patients in whom a serious life-threatening gram-negative infection is suspected, including those in whom concurrent therapy with penicillin or cephalosporin and an aminoglycoside may be indicated, treatment with tobramycin may be initiated before the results of susceptibility studies are obtained. The decision to continue therapy with tobramycin should be based on the results of susceptibility studies, the severity of the infection, and the important additional concepts discussed in the WARNINGS box above. uuid:b5d21a7c-8abe-433d-9b92-82ce205d810e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28864 biolink:treats MONDO:0005246 PMID:41385096 "[{""id"":""uuid:627563a6-ad84-4417-8525-8b5bc9ca63e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dcb19427-c6b3-44e5-9270-3ebdbbb4b10c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Tobramycin Injection USP and other antibacterial drugs, Tobramycin Injection USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tobramycin is indicated for the treatment of serious bacterial infections caused by susceptible strains of the designated microorganisms in the diseases listed below: Septicemia in the pediatric patient and adult caused by P. aeruginosa, E. coli., and Klebsiella spp Lower respiratory tract infections caused by P. aeruginosa, Klebsiella spp, Enterobacter spp, Serratia spp, E. coli, and S. aureus (penicillinase and non-penicillinase-producing strains) Serious central nervous system infections (meningitis) caused by susceptible organisms. Intra-abdominal infections, including peritonitis, caused by E. coli, Klebsiella spp, and Enterobacter spp Skin, bone, and skin-structure infections caused by P. aeruginosa, Proteus spp, E. coli, Klebsiella spp, Enterobacter spp, and S. aureus Complicated and recurrent urinary tract infections caused by P. aeruginosa, Proteus spp (indole-positive and indole-negative), E. coli, Klebsiella spp, Enterobacter spp, Serratia spp, S. aureus, Providencia, and Citrobacter spp Aminoglycosides, including tobramycin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics having less potential toxicity. Tobramycin may be considered in serious staphylococcal infections when penicillin or other potentially less toxic drugs are contraindicated and when bacterial susceptibility testing and clinical judgment indicate its use. Bacterial cultures should be obtained prior to and during treatment to isolate and identify etiologic organisms and to test their susceptibility to tobramycin. If susceptibility tests show that the causative organisms are resistant to tobramycin, other appropriate therapy should be instituted. In patients in whom a serious life-threatening gram-negative infection is suspected, including those in whom concurrent therapy with penicillin or cephalosporin and an aminoglycoside may be indicated, treatment with tobramycin may be initiated before the results of susceptibility studies are obtained. The decision to continue therapy with tobramycin should be based on the results of susceptibility studies, the severity of the infection, and the important additional concepts discussed in the WARNINGS box above. uuid:d2533b12-fa40-40c7-955d-71423830f7d9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28864 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:92c418b3-c443-4084-b002-8511140cf6f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:25d713ad-c7fe-45c2-ba5d-c0ec94077ffc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Tobramycin Injection USP and other antibacterial drugs, Tobramycin Injection USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tobramycin is indicated for the treatment of serious bacterial infections caused by susceptible strains of the designated microorganisms in the diseases listed below: Septicemia in the pediatric patient and adult caused by P. aeruginosa, E. coli., and Klebsiella spp Lower respiratory tract infections caused by P. aeruginosa, Klebsiella spp, Enterobacter spp, Serratia spp, E. coli, and S. aureus (penicillinase and non-penicillinase-producing strains) Serious central nervous system infections (meningitis) caused by susceptible organisms. Intra-abdominal infections, including peritonitis, caused by E. coli, Klebsiella spp, and Enterobacter spp Skin, bone, and skin-structure infections caused by P. aeruginosa, Proteus spp, E. coli, Klebsiella spp, Enterobacter spp, and S. aureus Complicated and recurrent urinary tract infections caused by P. aeruginosa, Proteus spp (indole-positive and indole-negative), E. coli, Klebsiella spp, Enterobacter spp, Serratia spp, S. aureus, Providencia, and Citrobacter spp Aminoglycosides, including tobramycin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics having less potential toxicity. Tobramycin may be considered in serious staphylococcal infections when penicillin or other potentially less toxic drugs are contraindicated and when bacterial susceptibility testing and clinical judgment indicate its use. Bacterial cultures should be obtained prior to and during treatment to isolate and identify etiologic organisms and to test their susceptibility to tobramycin. If susceptibility tests show that the causative organisms are resistant to tobramycin, other appropriate therapy should be instituted. In patients in whom a serious life-threatening gram-negative infection is suspected, including those in whom concurrent therapy with penicillin or cephalosporin and an aminoglycoside may be indicated, treatment with tobramycin may be initiated before the results of susceptibility studies are obtained. The decision to continue therapy with tobramycin should be based on the results of susceptibility studies, the severity of the infection, and the important additional concepts discussed in the WARNINGS box above. uuid:e31cb1bb-998b-4a3a-8ba2-83765e5bd4ec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28864 biolink:treats HP:0000010 PMID:41385096 "[{""id"":""uuid:4853e97d-f77e-48a2-9ea3-4f0f286c0a0a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:933b75d8-19c0-44b5-bc8f-0c642caf6037"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Tobramycin Injection USP and other antibacterial drugs, Tobramycin Injection USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tobramycin is indicated for the treatment of serious bacterial infections caused by susceptible strains of the designated microorganisms in the diseases listed below: Septicemia in the pediatric patient and adult caused by P. aeruginosa, E. coli., and Klebsiella spp Lower respiratory tract infections caused by P. aeruginosa, Klebsiella spp, Enterobacter spp, Serratia spp, E. coli, and S. aureus (penicillinase and non-penicillinase-producing strains) Serious central nervous system infections (meningitis) caused by susceptible organisms. Intra-abdominal infections, including peritonitis, caused by E. coli, Klebsiella spp, and Enterobacter spp Skin, bone, and skin-structure infections caused by P. aeruginosa, Proteus spp, E. coli, Klebsiella spp, Enterobacter spp, and S. aureus Complicated and recurrent urinary tract infections caused by P. aeruginosa, Proteus spp (indole-positive and indole-negative), E. coli, Klebsiella spp, Enterobacter spp, Serratia spp, S. aureus, Providencia, and Citrobacter spp Aminoglycosides, including tobramycin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics having less potential toxicity. Tobramycin may be considered in serious staphylococcal infections when penicillin or other potentially less toxic drugs are contraindicated and when bacterial susceptibility testing and clinical judgment indicate its use. Bacterial cultures should be obtained prior to and during treatment to isolate and identify etiologic organisms and to test their susceptibility to tobramycin. If susceptibility tests show that the causative organisms are resistant to tobramycin, other appropriate therapy should be instituted. In patients in whom a serious life-threatening gram-negative infection is suspected, including those in whom concurrent therapy with penicillin or cephalosporin and an aminoglycoside may be indicated, treatment with tobramycin may be initiated before the results of susceptibility studies are obtained. The decision to continue therapy with tobramycin should be based on the results of susceptibility studies, the severity of the infection, and the important additional concepts discussed in the WARNINGS box above. uuid:f85565bd-2560-471b-8ae7-bffa3d19a020 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28864 biolink:treats MONDO:0024313 PMID:41385096 "[{""id"":""uuid:aad07be3-e864-42f1-b401-7b047972b924"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8bc042b5-29a7-42a5-8543-56ad92e59acf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Tobramycin Injection USP and other antibacterial drugs, Tobramycin Injection USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tobramycin is indicated for the treatment of serious bacterial infections caused by susceptible strains of the designated microorganisms in the diseases listed below: Septicemia in the pediatric patient and adult caused by P. aeruginosa, E. coli., and Klebsiella spp Lower respiratory tract infections caused by P. aeruginosa, Klebsiella spp, Enterobacter spp, Serratia spp, E. coli, and S. aureus (penicillinase and non-penicillinase-producing strains) Serious central nervous system infections (meningitis) caused by susceptible organisms. Intra-abdominal infections, including peritonitis, caused by E. coli, Klebsiella spp, and Enterobacter spp Skin, bone, and skin-structure infections caused by P. aeruginosa, Proteus spp, E. coli, Klebsiella spp, Enterobacter spp, and S. aureus Complicated and recurrent urinary tract infections caused by P. aeruginosa, Proteus spp (indole-positive and indole-negative), E. coli, Klebsiella spp, Enterobacter spp, Serratia spp, S. aureus, Providencia, and Citrobacter spp Aminoglycosides, including tobramycin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics having less potential toxicity. Tobramycin may be considered in serious staphylococcal infections when penicillin or other potentially less toxic drugs are contraindicated and when bacterial susceptibility testing and clinical judgment indicate its use. Bacterial cultures should be obtained prior to and during treatment to isolate and identify etiologic organisms and to test their susceptibility to tobramycin. If susceptibility tests show that the causative organisms are resistant to tobramycin, other appropriate therapy should be instituted. In patients in whom a serious life-threatening gram-negative infection is suspected, including those in whom concurrent therapy with penicillin or cephalosporin and an aminoglycoside may be indicated, treatment with tobramycin may be initiated before the results of susceptibility studies are obtained. The decision to continue therapy with tobramycin should be based on the results of susceptibility studies, the severity of the infection, and the important additional concepts discussed in the WARNINGS box above. uuid:64e69709-2f56-47bf-88f3-d985c4929a46 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4784 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:7c757d95-304c-4c37-a867-956b1e28503f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6324d387-6357-4d5f-a244-c95f92817ba7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:127d8b7d-0d1b-4da2-b163-fc8cafa1a875"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension Enalapril maleate is indicated for the treatment of hypertension. Enalapril maleate is effective alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. The blood pressure lowering effects of enalapril maleate and thiazides are approximately additive. Heart Failure Enalapril maleate is indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. In these patients enalapril maleate improves symptoms, increases survival, and decreases the frequency of hospitalization (see CLINICAL PHARMACOLOGY, Heart Failure, Mortality Trials for details and limitations of survival trials). Asymptomatic Left Ventricular Dysfunction In clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction <35 percent), enalapril maleate decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure. (See CLINICAL PHARMACOLOGY, Heart Failure, Mortality Trials for details and limitations of survival trials.) In using enalapril maleate consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalapril maleate does not have a similar risk. (See WARNINGS. ) In considering use of enalapril maleate, it should be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, it should be noted that black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks. (See WARNINGS, Angioedema. )|[PMDA] Drugs with a new additional pediatric dosage. These drugs are indicated for the treatment of hypertension. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:eba5bb81-5f1d-438f-9a5b-7b185bc29810 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4784 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:16acd670-ff71-4a57-b65e-9ccdaac7baeb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ea77334a-d406-46f0-91d1-621c9f0ae7be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension Enalapril maleate is indicated for the treatment of hypertension. Enalapril maleate is effective alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. The blood pressure lowering effects of enalapril maleate and thiazides are approximately additive. Heart Failure Enalapril maleate is indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. In these patients enalapril maleate improves symptoms, increases survival, and decreases the frequency of hospitalization (see CLINICAL PHARMACOLOGY, Heart Failure, Mortality Trials for details and limitations of survival trials). Asymptomatic Left Ventricular Dysfunction In clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction <35 percent), enalapril maleate decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure. (See CLINICAL PHARMACOLOGY, Heart Failure, Mortality Trials for details and limitations of survival trials.) In using enalapril maleate consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalapril maleate does not have a similar risk. (See WARNINGS. ) In considering use of enalapril maleate, it should be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, it should be noted that black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks. (See WARNINGS, Angioedema. ) uuid:1281eae9-68e3-43e8-9709-efdefd54ef21 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4784 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:dfa9b713-629f-450c-825e-25af147b2683"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:c6c4f874-f5d7-4404-b58a-8ef8b96dad13"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:fdf89669-94e0-49ac-b178-d48c4d2cdb50"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension Enalapril maleate is indicated for the treatment of hypertension. Enalapril maleate is effective alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. The blood pressure lowering effects of enalapril maleate and thiazides are approximately additive. Heart Failure Enalapril maleate is indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. In these patients enalapril maleate improves symptoms, increases survival, and decreases the frequency of hospitalization (see CLINICAL PHARMACOLOGY, Heart Failure, Mortality Trials for details and limitations of survival trials). Asymptomatic Left Ventricular Dysfunction In clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction <35 percent), enalapril maleate decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure. (See CLINICAL PHARMACOLOGY, Heart Failure, Mortality Trials for details and limitations of survival trials.) In using enalapril maleate consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalapril maleate does not have a similar risk. (See WARNINGS. ) In considering use of enalapril maleate, it should be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, it should be noted that black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks. (See WARNINGS, Angioedema. )|[EMA] Treatment of heart failure. uuid:126013fd-6546-4cdd-a273-7a49b05084e3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4469 biolink:treats MONDO:0021107 PMID:41385096 "[{""id"":""uuid:9fe80fc8-287d-42e8-9481-d1289c4c9820"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1912eeed-375d-4717-9200-c806432fc1cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dextroamphetamine sulfate tablets are indicated in: 1. Narcolepsy . 2. Attention Deficit Disorder with Hyperactivity : As an integral part of a total treatment program that typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in pediatric patients (ages 3 years to 16 years) with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. The diagnosis of this syndrome should not be made with finality when these symptoms are only of comparatively recent origin. Nonlocalizing (soft) neurological signs, learning disability, and abnormal EEG may or may not be present, and a diagnosis of central nervous system dysfunction may or may not be warranted. uuid:6f17d472-12bd-4dde-9f59-11b99280d60b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4469 biolink:treats MONDO:0007743 PMID:41385096 "[{""id"":""uuid:bf5a5364-aa36-42e8-854f-0006b4e3b094"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c54bb232-8559-493b-9636-4e1a82fd7093"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dextroamphetamine sulfate tablets are indicated in: 1. Narcolepsy . 2. Attention Deficit Disorder with Hyperactivity : As an integral part of a total treatment program that typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in pediatric patients (ages 3 years to 16 years) with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. The diagnosis of this syndrome should not be made with finality when these symptoms are only of comparatively recent origin. Nonlocalizing (soft) neurological signs, learning disability, and abnormal EEG may or may not be present, and a diagnosis of central nervous system dysfunction may or may not be warranted. uuid:a3a0632b-8f5f-4772-ade2-5730df659c4c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5931 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:c8f72178-7f70-431a-90af-d603c1e02cca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:cd910cc2-5029-4688-9951-8c70e2aa1ded"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:5e5e2481-8777-40d1-b0c0-7e89b17a722d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/semglee""]},{""id"":""uuid:5257d2e0-23ea-4e46-bc2b-e12ec4b8827c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EXUBERA is indicated for the treatment of adult patients with diabetes mellitus for the control of hyperglycemia. EXUBERA has an onset of action similar to rapid-acting insulin analogs and has a duration of glucose-lowering activity comparable to subcutaneously administered regular human insulin. In patients with type 1 diabetes, EXUBERA should be used in regimens that include a longer-acting insulin. In patients with type 2 diabetes, EXUBERA can be used as monotherapy or in combination with oral agents or longer-acting insulins.|[EMA] Treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above.|[PMDA] A drug in a new dosage form indicated for the treatment of diabetes mellitus in cases where insulin therapy is indicated. uuid:50448eba-a4a6-4ea6-afa3-02616caef020 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5931 biolink:treats MONDO:0002909 PMID:41385096 "[{""id"":""uuid:08a7e1d4-dd33-4f40-8d06-95b4f97661fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:13ca969d-c543-4819-96d3-f125947ca0bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EXUBERA is indicated for the treatment of adult patients with diabetes mellitus for the control of hyperglycemia. EXUBERA has an onset of action similar to rapid-acting insulin analogs and has a duration of glucose-lowering activity comparable to subcutaneously administered regular human insulin. In patients with type 1 diabetes, EXUBERA should be used in regimens that include a longer-acting insulin. In patients with type 2 diabetes, EXUBERA can be used as monotherapy or in combination with oral agents or longer-acting insulins. uuid:e8275c3b-981b-40af-9be3-669f8d75ac9d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5931 biolink:treats MONDO:0005147 PMID:41385096 "[{""id"":""uuid:2fdcc330-815d-4b11-b825-648d2da6db64"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9bb51b02-bab2-4eec-b92b-7a5dda1478be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EXUBERA is indicated for the treatment of adult patients with diabetes mellitus for the control of hyperglycemia. EXUBERA has an onset of action similar to rapid-acting insulin analogs and has a duration of glucose-lowering activity comparable to subcutaneously administered regular human insulin. In patients with type 1 diabetes, EXUBERA should be used in regimens that include a longer-acting insulin. In patients with type 2 diabetes, EXUBERA can be used as monotherapy or in combination with oral agents or longer-acting insulins. uuid:767896e5-f782-4da2-a71f-b40ff422d4fd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5931 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:5f89173c-6ddd-496b-9c42-b2c25a177459"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cc11d301-0502-4a62-a813-0c934c6b295c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EXUBERA is indicated for the treatment of adult patients with diabetes mellitus for the control of hyperglycemia. EXUBERA has an onset of action similar to rapid-acting insulin analogs and has a duration of glucose-lowering activity comparable to subcutaneously administered regular human insulin. In patients with type 1 diabetes, EXUBERA should be used in regimens that include a longer-acting insulin. In patients with type 2 diabetes, EXUBERA can be used as monotherapy or in combination with oral agents or longer-acting insulins. uuid:7f378883-5fac-4d91-b276-7297aded2888 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2676 biolink:treats MONDO:0021666 PMID:41385096 "[{""id"":""uuid:2c43bf51-1f63-4f5e-b9db-f0b10ee2f628"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8eb1bd40-3646-4e06-a354-c7de73e534ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin and other antibacterial drugs, amoxicillin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Amoxicillin is indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) strains of the designated microorganisms in the conditions listed below: Infections of the ear, nose, and throat –due to Streptococcus spp. (α- and β-hemolytic strains only), Streptococcus pneumoniae, Staphylococcus spp., or H. influenzae. Infections of the genitourinary tract – due to E. coli, P. mirabilis, or E. faecalis. Infections of the skin and skin structure – due to Streptococcus spp. (α- and β-hemolytic strains only), Staphylococcus spp., or E. coli. Infections of the lower respiratory tract due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Gonorrhea, acute uncomplicated (ano-genital and urethral infections) due to N. gonorrhoeae (males and females). H. pylori eradication to reduce the risk of duodenal ulcer recurrence Triple therapy: Amoxicillin /clarithromycin/lansoprazole Amoxicillin, in combination with clarithromycin plus lansoprazole as triple therapy, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) to eradicate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION . ) Dual therapy: Amoxicillin/lansoprazole Amoxicillin, in combination with lansoprazole delayed-release capsules as dual therapy, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected. (See the clarithromycin package insert, MICROBIOLOGY.) Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION . ) Indicated surgical procedures should be performed. uuid:c1c2df6d-6f1c-473c-a5cb-048862d79e5f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2676 biolink:treats MONDO:0002436 PMID:41385096 "[{""id"":""uuid:d20e6437-6d79-44ac-9749-079b8dadcf14"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:33a4c75f-affe-45e8-bc1c-682b382405ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin and other antibacterial drugs, amoxicillin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Amoxicillin is indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) strains of the designated microorganisms in the conditions listed below: Infections of the ear, nose, and throat –due to Streptococcus spp. (α- and β-hemolytic strains only), Streptococcus pneumoniae, Staphylococcus spp., or H. influenzae. Infections of the genitourinary tract – due to E. coli, P. mirabilis, or E. faecalis. Infections of the skin and skin structure – due to Streptococcus spp. (α- and β-hemolytic strains only), Staphylococcus spp., or E. coli. Infections of the lower respiratory tract due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Gonorrhea, acute uncomplicated (ano-genital and urethral infections) due to N. gonorrhoeae (males and females). H. pylori eradication to reduce the risk of duodenal ulcer recurrence Triple therapy: Amoxicillin /clarithromycin/lansoprazole Amoxicillin, in combination with clarithromycin plus lansoprazole as triple therapy, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) to eradicate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION . ) Dual therapy: Amoxicillin/lansoprazole Amoxicillin, in combination with lansoprazole delayed-release capsules as dual therapy, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected. (See the clarithromycin package insert, MICROBIOLOGY.) Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION . ) Indicated surgical procedures should be performed. uuid:2c7f8f76-54b3-4e32-b454-30760300b2d2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2676 biolink:treats MONDO:0002258 PMID:41385096 "[{""id"":""uuid:58f1c054-c58f-4586-89c5-d877265485bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9ed8fb89-6538-418c-bf2a-907079937938"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin and other antibacterial drugs, amoxicillin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Amoxicillin is indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) strains of the designated microorganisms in the conditions listed below: Infections of the ear, nose, and throat –due to Streptococcus spp. (α- and β-hemolytic strains only), Streptococcus pneumoniae, Staphylococcus spp., or H. influenzae. Infections of the genitourinary tract – due to E. coli, P. mirabilis, or E. faecalis. Infections of the skin and skin structure – due to Streptococcus spp. (α- and β-hemolytic strains only), Staphylococcus spp., or E. coli. Infections of the lower respiratory tract due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Gonorrhea, acute uncomplicated (ano-genital and urethral infections) due to N. gonorrhoeae (males and females). H. pylori eradication to reduce the risk of duodenal ulcer recurrence Triple therapy: Amoxicillin /clarithromycin/lansoprazole Amoxicillin, in combination with clarithromycin plus lansoprazole as triple therapy, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) to eradicate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION . ) Dual therapy: Amoxicillin/lansoprazole Amoxicillin, in combination with lansoprazole delayed-release capsules as dual therapy, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected. (See the clarithromycin package insert, MICROBIOLOGY.) Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION . ) Indicated surgical procedures should be performed. uuid:c26bc834-6b91-4875-af9a-8ab4e310ec11 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2676 biolink:treats MONDO:0006002 PMID:41385096 "[{""id"":""uuid:ea4eed9c-1f1c-4d0b-8817-2fe735af4d14"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6a8e85c6-bc53-4218-8f52-0610bcaefec3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin and other antibacterial drugs, amoxicillin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Amoxicillin is indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) strains of the designated microorganisms in the conditions listed below: Infections of the ear, nose, and throat –due to Streptococcus spp. (α- and β-hemolytic strains only), Streptococcus pneumoniae, Staphylococcus spp., or H. influenzae. Infections of the genitourinary tract – due to E. coli, P. mirabilis, or E. faecalis. Infections of the skin and skin structure – due to Streptococcus spp. (α- and β-hemolytic strains only), Staphylococcus spp., or E. coli. Infections of the lower respiratory tract due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Gonorrhea, acute uncomplicated (ano-genital and urethral infections) due to N. gonorrhoeae (males and females). H. pylori eradication to reduce the risk of duodenal ulcer recurrence Triple therapy: Amoxicillin /clarithromycin/lansoprazole Amoxicillin, in combination with clarithromycin plus lansoprazole as triple therapy, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) to eradicate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION . ) Dual therapy: Amoxicillin/lansoprazole Amoxicillin, in combination with lansoprazole delayed-release capsules as dual therapy, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected. (See the clarithromycin package insert, MICROBIOLOGY.) Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION . ) Indicated surgical procedures should be performed. uuid:f807b20b-96f3-4a7d-9be2-09d3ea016360 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2676 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:e94fed28-1d01-4d27-82b8-9a065611a533"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8a3f5580-7a3a-4e1b-8d08-705d1805115f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin and other antibacterial drugs, amoxicillin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Amoxicillin is indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) strains of the designated microorganisms in the conditions listed below: Infections of the ear, nose, and throat –due to Streptococcus spp. (α- and β-hemolytic strains only), Streptococcus pneumoniae, Staphylococcus spp., or H. influenzae. Infections of the genitourinary tract – due to E. coli, P. mirabilis, or E. faecalis. Infections of the skin and skin structure – due to Streptococcus spp. (α- and β-hemolytic strains only), Staphylococcus spp., or E. coli. Infections of the lower respiratory tract due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Gonorrhea, acute uncomplicated (ano-genital and urethral infections) due to N. gonorrhoeae (males and females). H. pylori eradication to reduce the risk of duodenal ulcer recurrence Triple therapy: Amoxicillin /clarithromycin/lansoprazole Amoxicillin, in combination with clarithromycin plus lansoprazole as triple therapy, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) to eradicate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION . ) Dual therapy: Amoxicillin/lansoprazole Amoxicillin, in combination with lansoprazole delayed-release capsules as dual therapy, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected. (See the clarithromycin package insert, MICROBIOLOGY.) Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION . ) Indicated surgical procedures should be performed. uuid:a364b45a-49ad-4fa9-8282-2cb05dce31eb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2676 biolink:treats MONDO:0024355 PMID:41385096 "[{""id"":""uuid:2c9ecffc-a5fd-47f9-b4fb-f6febc72a62b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ab7b273c-872b-4fd9-a089-de680fb5f927"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin and other antibacterial drugs, amoxicillin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Amoxicillin is indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) strains of the designated microorganisms in the conditions listed below: Infections of the ear, nose, and throat –due to Streptococcus spp. (α- and β-hemolytic strains only), Streptococcus pneumoniae, Staphylococcus spp., or H. influenzae. Infections of the genitourinary tract – due to E. coli, P. mirabilis, or E. faecalis. Infections of the skin and skin structure – due to Streptococcus spp. (α- and β-hemolytic strains only), Staphylococcus spp., or E. coli. Infections of the lower respiratory tract due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Gonorrhea, acute uncomplicated (ano-genital and urethral infections) due to N. gonorrhoeae (males and females). H. pylori eradication to reduce the risk of duodenal ulcer recurrence Triple therapy: Amoxicillin /clarithromycin/lansoprazole Amoxicillin, in combination with clarithromycin plus lansoprazole as triple therapy, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) to eradicate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION . ) Dual therapy: Amoxicillin/lansoprazole Amoxicillin, in combination with lansoprazole delayed-release capsules as dual therapy, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected. (See the clarithromycin package insert, MICROBIOLOGY.) Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION . ) Indicated surgical procedures should be performed. uuid:5a5053ed-15d7-4908-9a0a-bad4407b5019 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2676 biolink:treats MONDO:0004277 PMID:41385096 "[{""id"":""uuid:6ded6512-c018-415b-844c-e12d97a0a711"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1aff2b8b-a22b-49ee-b4f9-489d31f92eaf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin and other antibacterial drugs, amoxicillin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Amoxicillin is indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) strains of the designated microorganisms in the conditions listed below: Infections of the ear, nose, and throat –due to Streptococcus spp. (α- and β-hemolytic strains only), Streptococcus pneumoniae, Staphylococcus spp., or H. influenzae. Infections of the genitourinary tract – due to E. coli, P. mirabilis, or E. faecalis. Infections of the skin and skin structure – due to Streptococcus spp. (α- and β-hemolytic strains only), Staphylococcus spp., or E. coli. Infections of the lower respiratory tract due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Gonorrhea, acute uncomplicated (ano-genital and urethral infections) due to N. gonorrhoeae (males and females). H. pylori eradication to reduce the risk of duodenal ulcer recurrence Triple therapy: Amoxicillin /clarithromycin/lansoprazole Amoxicillin, in combination with clarithromycin plus lansoprazole as triple therapy, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) to eradicate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION . ) Dual therapy: Amoxicillin/lansoprazole Amoxicillin, in combination with lansoprazole delayed-release capsules as dual therapy, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected. (See the clarithromycin package insert, MICROBIOLOGY.) Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION . ) Indicated surgical procedures should be performed. uuid:ae246c1c-1390-4d79-980c-71264271dda2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2676 biolink:treats HP:0005202 PMID:41385096 "[{""id"":""uuid:9791904a-9f93-447f-9915-fa626149e1ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7b2655b9-87c0-42e1-b5f6-d078ecee5446"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin and other antibacterial drugs, amoxicillin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Amoxicillin is indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) strains of the designated microorganisms in the conditions listed below: Infections of the ear, nose, and throat –due to Streptococcus spp. (α- and β-hemolytic strains only), Streptococcus pneumoniae, Staphylococcus spp., or H. influenzae. Infections of the genitourinary tract – due to E. coli, P. mirabilis, or E. faecalis. Infections of the skin and skin structure – due to Streptococcus spp. (α- and β-hemolytic strains only), Staphylococcus spp., or E. coli. Infections of the lower respiratory tract due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Gonorrhea, acute uncomplicated (ano-genital and urethral infections) due to N. gonorrhoeae (males and females). H. pylori eradication to reduce the risk of duodenal ulcer recurrence Triple therapy: Amoxicillin /clarithromycin/lansoprazole Amoxicillin, in combination with clarithromycin plus lansoprazole as triple therapy, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) to eradicate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION . ) Dual therapy: Amoxicillin/lansoprazole Amoxicillin, in combination with lansoprazole delayed-release capsules as dual therapy, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected. (See the clarithromycin package insert, MICROBIOLOGY.) Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION . ) Indicated surgical procedures should be performed. uuid:13d1e8d0-4e71-4ced-a2ed-5a604b1df8ad biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2676 biolink:treats MONDO:0005412 PMID:41385096 "[{""id"":""uuid:d8d61070-0b87-4057-91fa-dbc7d4b7f94a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9990388f-7284-4b7e-8a5a-4a00bd9e511e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin and other antibacterial drugs, amoxicillin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Amoxicillin is indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) strains of the designated microorganisms in the conditions listed below: Infections of the ear, nose, and throat –due to Streptococcus spp. (α- and β-hemolytic strains only), Streptococcus pneumoniae, Staphylococcus spp., or H. influenzae. Infections of the genitourinary tract – due to E. coli, P. mirabilis, or E. faecalis. Infections of the skin and skin structure – due to Streptococcus spp. (α- and β-hemolytic strains only), Staphylococcus spp., or E. coli. Infections of the lower respiratory tract due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Gonorrhea, acute uncomplicated (ano-genital and urethral infections) due to N. gonorrhoeae (males and females). H. pylori eradication to reduce the risk of duodenal ulcer recurrence Triple therapy: Amoxicillin /clarithromycin/lansoprazole Amoxicillin, in combination with clarithromycin plus lansoprazole as triple therapy, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) to eradicate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION . ) Dual therapy: Amoxicillin/lansoprazole Amoxicillin, in combination with lansoprazole delayed-release capsules as dual therapy, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected. (See the clarithromycin package insert, MICROBIOLOGY.) Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION . ) Indicated surgical procedures should be performed. uuid:a66e6a28-aaa2-4e5a-b21e-807d11076577 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7UQ7X4Y489 biolink:treats HP:0002625 PMID:41385096 "[{""id"":""uuid:e18918fb-0b09-4b6b-9792-46cf1862af74"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:af04145b-c73c-48cf-89f0-5332871f79c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INNOHEP® is indicated for the treatment of acute symptomatic deep vein thrombosis with or without pulmonary embolism when administered in conjunction with warfarin sodium. The safety and effectiveness of INNOHEP® were established in hospitalized patients. uuid:85398e1d-59e0-47ce-aa75-878b9f407eb7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7UQ7X4Y489 biolink:treats MONDO:0005279 PMID:41385096 "[{""id"":""uuid:80df0b39-ddba-4a7a-bcee-ab99e19dc2b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0915e84c-cb22-42be-8bfd-7cb20da3d7ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INNOHEP® is indicated for the treatment of acute symptomatic deep vein thrombosis with or without pulmonary embolism when administered in conjunction with warfarin sodium. The safety and effectiveness of INNOHEP® were established in hospitalized patients. uuid:72695462-2108-4559-b55f-99125b147372 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5103 biolink:treats UMLS:C0572933 PMID:41385096 "[{""id"":""uuid:3f557321-d342-4c2a-b6b5-fcf6d2be63e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:514448d7-9c74-4f11-b96d-3f009e3d6050"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Flumazenil injection, USP is indicated for the complete or partial reversal of the sedative effects of benzodiazepines in cases where general anesthesia has been induced and/or maintained with benzodiazepines, where sedation has been produced with benzodiazepines for diagnostic and therapeutic procedures, and for the management of benzodiazepine overdose. uuid:8bfdd4e1-bb30-471e-b6de-5e3198062b09 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77733 biolink:treats MONDO:0001134 PMID:41385096 "[{""id"":""uuid:8f139467-6cd3-4eab-81b3-7349fcfc6d13"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b4296a72-6a45-489d-af4c-87d9258940af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ISOPTIN SR (verapamil HCI) is indicated for the management of essential hypertension. uuid:12c4dbf8-681d-484a-83d3-d2f7b2e6ace1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6916 biolink:treats UMLS:C0750197 PMID:41385096 "[{""id"":""uuid:a82736e5-4fd0-4e19-a05b-691686a74339"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:67f8317e-9242-4ef8-886d-8b46de02fbb0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mexiletine Hydrochloride Capsules are indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgement of the physician, are life-threatening. Because of the proarrhythmic effects of mexiletine, its use with lesser arrhythmias is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of mexiletine treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias. uuid:4ee683ef-534d-4639-95c6-a90f4e42e966 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6916 biolink:treats HP:0004308 PMID:41385096 "[{""id"":""uuid:9a1fab81-a8af-41dc-9c46-00a77874c49f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cbe0b210-8ca1-4021-8385-cb4a28e4df20"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mexiletine Hydrochloride Capsules are indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgement of the physician, are life-threatening. Because of the proarrhythmic effects of mexiletine, its use with lesser arrhythmias is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of mexiletine treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias. uuid:5b9fb846-9963-492f-86ed-890bf4ddff6b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6916 biolink:treats HP:0006682 PMID:41385096 "[{""id"":""uuid:b521447d-0cb3-46c8-90de-e751388bc058"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a3aa5935-4b16-418b-a446-eb375defe294"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mexiletine Hydrochloride Capsules are indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgement of the physician, are life-threatening. Because of the proarrhythmic effects of mexiletine, its use with lesser arrhythmias is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of mexiletine treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias. uuid:b5c08844-7617-4d63-a543-00ac7ec34fea biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3756 biolink:treats UMLS:C0347869 PMID:41385096 "[{""id"":""uuid:67e88a94-53eb-415b-9719-44bfa3c44f24"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:16da8c10-c0fa-4948-9d1e-f125e0205d42"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Seizure Disorders: Clonazepam is useful alone or as an adjunct in the treatment of the Lennox-Gastaut syndrome (petit mal variant), akinetic and myoclonic seizures. In patients with absence seizures (petit mal) who have failed to respond to succinimides, clonazepam may be useful. In some studies, up to 30% of patients have shown a loss of anticonvulsant activity, often within three months of administration. In some cases, dosage adjustment may re-establish efficacy. Panic Disorder: Clonazepam is indicated for the treatment of panic disorder, with or without agoraphobia, as defined in DSM-IV. Panic disorder is characterized by the occurrence of unexpected panic attacks and associated concern about having additional attacks, worry about the implications or consequences of the attacks, and/or a significant change in behavior related to the attacks. The efficacy of clonazepam was established in two 6- to 9-week trials in panic disorder patients whose diagnoses corresponded to the DSM-lllR category of panic disorder (see CLINICAL PHARMACOLOGY: Clinical Trials ). Panic disorder (DSM-IV) is characterized by recurrent unexpected panic attacks, i.e., a discrete period of intense fear or discomfort in which four (or more) of the following symptoms develop abruptly and reach a peak within 10 minutes: (1) palpitations, pounding heart or accelerated heart rate; (2) sweating; (3) trembling or shaking; (4) sensations of shortness of breath or smothering; (5) feeling of choking; (6) chest pain or discomfort; (7) nausea or abdominal distress; (8) feeling dizzy, unsteady, lightheaded or faint; (9) derealization (feelings of unreality) or depersonalization (being detached from oneself); (10) fear of losing control; (11) fear of dying; (12) paresthesias (numbness or tingling sensations); (13) chills or hot flushes. The effectiveness of clonazepam in long-term use, that is, for more than 9 weeks, has not been systematically studied in controlled clinical trials. The physician who elects to use clonazepam for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION ). uuid:ad89880c-2f3a-467c-9dd3-86d98ad84668 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3756 biolink:treats HP:0032794 PMID:41385096 "[{""id"":""uuid:0a9474d0-8354-4058-8973-f576bcc8c9b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:94599475-b098-4a6c-8ce9-bc5fc36d9c5f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Seizure Disorders: Clonazepam is useful alone or as an adjunct in the treatment of the Lennox-Gastaut syndrome (petit mal variant), akinetic and myoclonic seizures. In patients with absence seizures (petit mal) who have failed to respond to succinimides, clonazepam may be useful. In some studies, up to 30% of patients have shown a loss of anticonvulsant activity, often within three months of administration. In some cases, dosage adjustment may re-establish efficacy. Panic Disorder: Clonazepam is indicated for the treatment of panic disorder, with or without agoraphobia, as defined in DSM-IV. Panic disorder is characterized by the occurrence of unexpected panic attacks and associated concern about having additional attacks, worry about the implications or consequences of the attacks, and/or a significant change in behavior related to the attacks. The efficacy of clonazepam was established in two 6- to 9-week trials in panic disorder patients whose diagnoses corresponded to the DSM-lllR category of panic disorder (see CLINICAL PHARMACOLOGY: Clinical Trials ). Panic disorder (DSM-IV) is characterized by recurrent unexpected panic attacks, i.e., a discrete period of intense fear or discomfort in which four (or more) of the following symptoms develop abruptly and reach a peak within 10 minutes: (1) palpitations, pounding heart or accelerated heart rate; (2) sweating; (3) trembling or shaking; (4) sensations of shortness of breath or smothering; (5) feeling of choking; (6) chest pain or discomfort; (7) nausea or abdominal distress; (8) feeling dizzy, unsteady, lightheaded or faint; (9) derealization (feelings of unreality) or depersonalization (being detached from oneself); (10) fear of losing control; (11) fear of dying; (12) paresthesias (numbness or tingling sensations); (13) chills or hot flushes. The effectiveness of clonazepam in long-term use, that is, for more than 9 weeks, has not been systematically studied in controlled clinical trials. The physician who elects to use clonazepam for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION ). uuid:1cea9c2b-adbc-4042-ad60-e2b23e603e2d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3756 biolink:treats MONDO:0005383 PMID:41385096 "[{""id"":""uuid:7a27c064-18cd-419e-97c3-645d40b7e8ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f3b8e4eb-e09c-4f92-bc88-2425d9333903"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Seizure Disorders: Clonazepam is useful alone or as an adjunct in the treatment of the Lennox-Gastaut syndrome (petit mal variant), akinetic and myoclonic seizures. In patients with absence seizures (petit mal) who have failed to respond to succinimides, clonazepam may be useful. In some studies, up to 30% of patients have shown a loss of anticonvulsant activity, often within three months of administration. In some cases, dosage adjustment may re-establish efficacy. Panic Disorder: Clonazepam is indicated for the treatment of panic disorder, with or without agoraphobia, as defined in DSM-IV. Panic disorder is characterized by the occurrence of unexpected panic attacks and associated concern about having additional attacks, worry about the implications or consequences of the attacks, and/or a significant change in behavior related to the attacks. The efficacy of clonazepam was established in two 6- to 9-week trials in panic disorder patients whose diagnoses corresponded to the DSM-lllR category of panic disorder (see CLINICAL PHARMACOLOGY: Clinical Trials ). Panic disorder (DSM-IV) is characterized by recurrent unexpected panic attacks, i.e., a discrete period of intense fear or discomfort in which four (or more) of the following symptoms develop abruptly and reach a peak within 10 minutes: (1) palpitations, pounding heart or accelerated heart rate; (2) sweating; (3) trembling or shaking; (4) sensations of shortness of breath or smothering; (5) feeling of choking; (6) chest pain or discomfort; (7) nausea or abdominal distress; (8) feeling dizzy, unsteady, lightheaded or faint; (9) derealization (feelings of unreality) or depersonalization (being detached from oneself); (10) fear of losing control; (11) fear of dying; (12) paresthesias (numbness or tingling sensations); (13) chills or hot flushes. The effectiveness of clonazepam in long-term use, that is, for more than 9 weeks, has not been systematically studied in controlled clinical trials. The physician who elects to use clonazepam for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION ). uuid:aeac2490-8c82-4ff3-9285-0a470d82b206 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:151392 biolink:treats MONDO:0024355 PMID:41385096 "[{""id"":""uuid:47b9b3e9-33be-40fc-a9ff-4d07d6387bae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5e6937ee-8299-4ffc-bbe7-e6f8c2abe48a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amoxicillin and clavulanate potassium for oral suspension, and amoxicillin and clavulanate potassium tablets (chewable) is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower Respiratory Tract Infections - caused by β-lactamase-producing strains of H. influenzae and M. catarrhalis . Otitis Media - caused by β-lactamase-producing strains of H. influenzae and M. catarrhalis . Sinusitis - caused by β-lactamase-producing strains of H. influenzae and M. catarrhalis . Skin and Skin Structure Infections - caused by β-lactamase-producing strains of S. aureus , E. coli , and Klebsiella spp. Urinary Tract Infections - caused by β-lactamase-producing strains of E. coli , Klebsiella spp. and Enterobacter spp. While amoxicillin and clavulanate potassium is indicated only for the conditions listed above, infections caused by ampicillin-susceptible organisms are also amenable to treatment with amoxicillin and clavulanate potassium due to its amoxicillin content. Therefore, mixed infections caused by ampicillin-susceptible organisms and β-lactamase-producing organisms susceptible to amoxicillin and clavulanate potassium should not require the addition of another antibiotic. Because amoxicillin has greater in vitro activity against S. pneumoniae than does ampicillin or penicillin, the majority of S. pneumoniae strains with intermediate susceptibility to ampicillin or penicillin are fully susceptible to amoxicillin and amoxicillin and clavulanate potassium. (See Microbiology .) To reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin and clavulanate potassium for oral suspension, and amoxicillin and clavulanate potassium tablets (chewable) and other antibacterial drugs, amoxicillin and clavulanate potassium for oral suspension, and amoxicillin and clavulanate potassium tablets (chewable) should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Bacteriological studies, to determine the causative organisms and their susceptibility to amoxicillin and clavulanate potassium for oral suspension, and amoxicillin and clavulanate potassium tablets (chewable) should be performed together with any indicated surgical procedures. uuid:a3ed6c93-8365-49b0-b458-a55a3fb04664 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:151392 biolink:treats MONDO:0005441 PMID:41385096 "[{""id"":""uuid:a4fb9401-705f-480b-8186-e22e99ec18ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:38cb3166-fb79-45d6-8c36-565e32e4042d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amoxicillin and clavulanate potassium for oral suspension, and amoxicillin and clavulanate potassium tablets (chewable) is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower Respiratory Tract Infections - caused by β-lactamase-producing strains of H. influenzae and M. catarrhalis . Otitis Media - caused by β-lactamase-producing strains of H. influenzae and M. catarrhalis . Sinusitis - caused by β-lactamase-producing strains of H. influenzae and M. catarrhalis . Skin and Skin Structure Infections - caused by β-lactamase-producing strains of S. aureus , E. coli , and Klebsiella spp. Urinary Tract Infections - caused by β-lactamase-producing strains of E. coli , Klebsiella spp. and Enterobacter spp. While amoxicillin and clavulanate potassium is indicated only for the conditions listed above, infections caused by ampicillin-susceptible organisms are also amenable to treatment with amoxicillin and clavulanate potassium due to its amoxicillin content. Therefore, mixed infections caused by ampicillin-susceptible organisms and β-lactamase-producing organisms susceptible to amoxicillin and clavulanate potassium should not require the addition of another antibiotic. Because amoxicillin has greater in vitro activity against S. pneumoniae than does ampicillin or penicillin, the majority of S. pneumoniae strains with intermediate susceptibility to ampicillin or penicillin are fully susceptible to amoxicillin and amoxicillin and clavulanate potassium. (See Microbiology .) To reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin and clavulanate potassium for oral suspension, and amoxicillin and clavulanate potassium tablets (chewable) and other antibacterial drugs, amoxicillin and clavulanate potassium for oral suspension, and amoxicillin and clavulanate potassium tablets (chewable) should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Bacteriological studies, to determine the causative organisms and their susceptibility to amoxicillin and clavulanate potassium for oral suspension, and amoxicillin and clavulanate potassium tablets (chewable) should be performed together with any indicated surgical procedures. uuid:60ca9266-5998-425a-83b6-e5d300a867a4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:151392 biolink:treats MONDO:0005961 PMID:41385096 "[{""id"":""uuid:73ef009f-223b-48ed-b604-38ed199566a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0110f20b-08db-4a04-a23e-43936b639c00"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:3eaadeae-b8d7-4f36-8848-7b8279a7eb01"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amoxicillin and clavulanate potassium for oral suspension, and amoxicillin and clavulanate potassium tablets (chewable) is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower Respiratory Tract Infections - caused by β-lactamase-producing strains of H. influenzae and M. catarrhalis . Otitis Media - caused by β-lactamase-producing strains of H. influenzae and M. catarrhalis . Sinusitis - caused by β-lactamase-producing strains of H. influenzae and M. catarrhalis . Skin and Skin Structure Infections - caused by β-lactamase-producing strains of S. aureus , E. coli , and Klebsiella spp. Urinary Tract Infections - caused by β-lactamase-producing strains of E. coli , Klebsiella spp. and Enterobacter spp. While amoxicillin and clavulanate potassium is indicated only for the conditions listed above, infections caused by ampicillin-susceptible organisms are also amenable to treatment with amoxicillin and clavulanate potassium due to its amoxicillin content. Therefore, mixed infections caused by ampicillin-susceptible organisms and β-lactamase-producing organisms susceptible to amoxicillin and clavulanate potassium should not require the addition of another antibiotic. Because amoxicillin has greater in vitro activity against S. pneumoniae than does ampicillin or penicillin, the majority of S. pneumoniae strains with intermediate susceptibility to ampicillin or penicillin are fully susceptible to amoxicillin and amoxicillin and clavulanate potassium. (See Microbiology .) To reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin and clavulanate potassium for oral suspension, and amoxicillin and clavulanate potassium tablets (chewable) and other antibacterial drugs, amoxicillin and clavulanate potassium for oral suspension, and amoxicillin and clavulanate potassium tablets (chewable) should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Bacteriological studies, to determine the causative organisms and their susceptibility to amoxicillin and clavulanate potassium for oral suspension, and amoxicillin and clavulanate potassium tablets (chewable) should be performed together with any indicated surgical procedures.|[PMDA] A drug with a new additional indication for the treatment of sinusitis. uuid:91bbf155-12c2-431c-a03c-cfdbea36b6bc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:151392 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:e9212f0a-3b8e-45de-872e-f1f74eddb419"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:fb58d11c-e9e8-4f4a-a0a6-4fafe1538310"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:03f6b66b-7544-4da0-88e7-1b3cf4f033e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amoxicillin and clavulanate potassium for oral suspension, and amoxicillin and clavulanate potassium tablets (chewable) is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower Respiratory Tract Infections - caused by β-lactamase-producing strains of H. influenzae and M. catarrhalis . Otitis Media - caused by β-lactamase-producing strains of H. influenzae and M. catarrhalis . Sinusitis - caused by β-lactamase-producing strains of H. influenzae and M. catarrhalis . Skin and Skin Structure Infections - caused by β-lactamase-producing strains of S. aureus , E. coli , and Klebsiella spp. Urinary Tract Infections - caused by β-lactamase-producing strains of E. coli , Klebsiella spp. and Enterobacter spp. While amoxicillin and clavulanate potassium is indicated only for the conditions listed above, infections caused by ampicillin-susceptible organisms are also amenable to treatment with amoxicillin and clavulanate potassium due to its amoxicillin content. Therefore, mixed infections caused by ampicillin-susceptible organisms and β-lactamase-producing organisms susceptible to amoxicillin and clavulanate potassium should not require the addition of another antibiotic. Because amoxicillin has greater in vitro activity against S. pneumoniae than does ampicillin or penicillin, the majority of S. pneumoniae strains with intermediate susceptibility to ampicillin or penicillin are fully susceptible to amoxicillin and amoxicillin and clavulanate potassium. (See Microbiology .) To reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin and clavulanate potassium for oral suspension, and amoxicillin and clavulanate potassium tablets (chewable) and other antibacterial drugs, amoxicillin and clavulanate potassium for oral suspension, and amoxicillin and clavulanate potassium tablets (chewable) should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Bacteriological studies, to determine the causative organisms and their susceptibility to amoxicillin and clavulanate potassium for oral suspension, and amoxicillin and clavulanate potassium tablets (chewable) should be performed together with any indicated surgical procedures.|[PMDA] A drug with a new indication for the treatment of superficial skin infections, deep skin infections, lymphangitis and lymphadenitis, chronic pyoderma, laryngopharyngitis, tonsillitis, acute bronchitis, cystitis, and pyelonephritis. uuid:f3e2ad4c-89e1-4c14-958d-8eef4776e1d3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:151392 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:be0c4304-a50c-47cd-9d4b-3d6af5b4409a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:64f9fca7-e406-40e4-846b-944c67d942d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amoxicillin and clavulanate potassium for oral suspension, and amoxicillin and clavulanate potassium tablets (chewable) is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower Respiratory Tract Infections - caused by β-lactamase-producing strains of H. influenzae and M. catarrhalis . Otitis Media - caused by β-lactamase-producing strains of H. influenzae and M. catarrhalis . Sinusitis - caused by β-lactamase-producing strains of H. influenzae and M. catarrhalis . Skin and Skin Structure Infections - caused by β-lactamase-producing strains of S. aureus , E. coli , and Klebsiella spp. Urinary Tract Infections - caused by β-lactamase-producing strains of E. coli , Klebsiella spp. and Enterobacter spp. While amoxicillin and clavulanate potassium is indicated only for the conditions listed above, infections caused by ampicillin-susceptible organisms are also amenable to treatment with amoxicillin and clavulanate potassium due to its amoxicillin content. Therefore, mixed infections caused by ampicillin-susceptible organisms and β-lactamase-producing organisms susceptible to amoxicillin and clavulanate potassium should not require the addition of another antibiotic. Because amoxicillin has greater in vitro activity against S. pneumoniae than does ampicillin or penicillin, the majority of S. pneumoniae strains with intermediate susceptibility to ampicillin or penicillin are fully susceptible to amoxicillin and amoxicillin and clavulanate potassium. (See Microbiology .) To reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin and clavulanate potassium for oral suspension, and amoxicillin and clavulanate potassium tablets (chewable) and other antibacterial drugs, amoxicillin and clavulanate potassium for oral suspension, and amoxicillin and clavulanate potassium tablets (chewable) should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Bacteriological studies, to determine the causative organisms and their susceptibility to amoxicillin and clavulanate potassium for oral suspension, and amoxicillin and clavulanate potassium tablets (chewable) should be performed together with any indicated surgical procedures. uuid:7bbf285d-95e1-4ec8-86fa-58f21d2c2dd3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6706 biolink:treats MONDO:0001134 PMID:41385096 "[{""id"":""uuid:cba3a7a6-2987-448c-805d-635e11ab3a99"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:21ef7181-c83d-4e8a-b27e-253f9841acbb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the management of moderately severe to severe essential hypertension and in uncomplicated cases of malignant hypertension. uuid:85f8c85e-0185-497e-9341-fa5e80ecf7e4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6706 biolink:treats MONDO:0006846 PMID:41385096 "[{""id"":""uuid:1bec7f84-4b5a-4101-afe3-1e72a6202513"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a63a5faf-7e4e-4749-9d38-314662363b11"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the management of moderately severe to severe essential hypertension and in uncomplicated cases of malignant hypertension. uuid:1ba32886-bd34-4595-bfb8-d01cc828eb39 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:370778 biolink:treats MONDO:0005324 PMID:41385096 "[{""id"":""uuid:6ac417b1-e447-448e-88f8-b35993633680"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5c52a7b6-8798-40dd-8e82-406d0a257596"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SEMPREX-D Capsules are indicated for relief of symptoms associated with seasonal allergic rhinitis such as sneezing, rhinorrhea, pruritus, lacrimation, and nasal congestion. SEMPREX-D Capsules should be administered when both the antihistaminic activity of acrivastine and the nasal decongestant activity of pseudoephedrine are desired (see CLINICAL PHARMACOLOGY ). The efficacy of SEMPREX-D Capsules beyond 14 days of continuous treatment in patients with seasonal allergic rhinitis has not been adequately investigated in clinical trials. SEMPREX-D Capsules have not been adequately studied for effectiveness in relieving the symptoms of the common cold. uuid:d0bee775-554e-482e-94d0-a53ba405ca52 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:370778 biolink:treats MONDO:0005709 PMID:41385096 "[{""id"":""uuid:4c541e23-2b14-4aef-8bc1-223421df9ddf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fcf65295-a956-4fa5-96ba-c7cac5962655"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SEMPREX-D Capsules are indicated for relief of symptoms associated with seasonal allergic rhinitis such as sneezing, rhinorrhea, pruritus, lacrimation, and nasal congestion. SEMPREX-D Capsules should be administered when both the antihistaminic activity of acrivastine and the nasal decongestant activity of pseudoephedrine are desired (see CLINICAL PHARMACOLOGY ). The efficacy of SEMPREX-D Capsules beyond 14 days of continuous treatment in patients with seasonal allergic rhinitis has not been adequately investigated in clinical trials. SEMPREX-D Capsules have not been adequately studied for effectiveness in relieving the symptoms of the common cold. uuid:c7b4fc84-bac4-4ede-b252-870344eaf6d8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9943 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:0b686977-f16b-4584-a4d3-432c93c2e92f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b391ea84-db6a-4b1d-9952-25439e397ce3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Venlafaxine Extended Release Tablets are a selective serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for: Major Depressive Disorder (MDD) ( 1.1 ) Social Anxiety Disorder (SAD) ( 1.2 ) uuid:92269a7d-d46d-4c47-ad6c-83fc96748e3c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9943 biolink:treats MONDO:0001247 PMID:41385096 "[{""id"":""uuid:b12a9aef-d9c7-4514-bb6f-c7ef59fd71f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e24bd576-8d8a-4f70-81f8-ddc2e864ebeb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Venlafaxine Extended Release Tablets are a selective serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for: Major Depressive Disorder (MDD) ( 1.1 ) Social Anxiety Disorder (SAD) ( 1.2 ) uuid:2537271b-0682-422e-8386-cbee96be7357 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7D96IR0PPM biolink:treats MONDO:0004967 PMID:41385096 "[{""id"":""uuid:cba45122-7a04-4a21-8bab-9ff17851cd66"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4f1f31a8-5d10-4d07-ab27-296235695ae5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:86c657af-d5ca-422b-9f66-60ed798c9c93"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/oncaspar""]},{""id"":""uuid:3ebc724c-2053-4e03-b534-b6d70f9827ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oncaspar ® is indicated as a component of a multi-agent chemotherapeutic regimen for treatment of patients with: First line acute lymphoblastic leukemia (1.1) Acute lymphoblastic leukemia and hypersensitivity to asparaginase (1.2)|[EMA] Oncaspar is indicated as a component of antineoplastic combination therapy in acute lymphoblastic leukaemia (ALL) in paediatric patients from birth to 18 years, and adult patients.|[PMDA] A drug with a new active ingredient indicated for the treatment of acute lymphocytic leukemia and malignant lymphoma. uuid:b5199677-971b-48d9-8778-98528c3b94fe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:83G67E21XI biolink:treats MONDO:0005279 PMID:41385096 "[{""id"":""uuid:03fbdcb5-04d0-4d60-9cb3-61952977f06c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8f8352d2-d6bf-4e41-b646-7411680aeaee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Kinlytic™ is indicated in adults: For the lysis of acute massive pulmonary emboli, defined as obstruction of blood flow to a lobe or multiple segments. For the lysis of pulmonary emboli accompanied by unstable hemodynamics, i.e., failure to maintain blood pressure without supportive measures. The diagnosis should be confirmed by objective means, such as pulmonary angiography or non-invasive procedures such as lung scanning. uuid:278d9257-42c0-4ba7-b5b5-c21280e80dfa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8774 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:9599cfb9-a746-4a54-ae02-02b015ab2192"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f9fe9643-c968-4d80-afaf-ae0b42934e1b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ramipril is indicated for the treatment of hypertension. It may be used alone or in combination with thiazide diuretics. In using ramipril, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that ramipril does not have a similar risk. (See WARNINGS . ) In considering use of ramipril, it should be noted that in controlled trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients. (see WARNINGS , Angioedema . ) uuid:565a7224-fbe6-42eb-a240-3be62092f38c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8774 biolink:treats MONDO:0001609 PMID:41385096 "[{""id"":""uuid:391ea343-9bd8-4b5c-a166-b20c45d27635"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0bf5b8c2-4c68-4132-848d-9e69d78c730c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ramipril is indicated for the treatment of hypertension. It may be used alone or in combination with thiazide diuretics. In using ramipril, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that ramipril does not have a similar risk. (See WARNINGS . ) In considering use of ramipril, it should be noted that in controlled trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients. (see WARNINGS , Angioedema . ) uuid:cc9b29cc-9200-4187-8f21-b0439405ea0f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8774 biolink:treats MONDO:0001343 PMID:41385096 "[{""id"":""uuid:3626dca9-733e-4592-b92e-b9914363ed3d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b30f21fe-7630-42c9-aece-d3d0c55d36d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ramipril is indicated for the treatment of hypertension. It may be used alone or in combination with thiazide diuretics. In using ramipril, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that ramipril does not have a similar risk. (See WARNINGS . ) In considering use of ramipril, it should be noted that in controlled trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients. (see WARNINGS , Angioedema . ) uuid:0dda95e9-7b93-4385-bba7-bd6b387faa4a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8774 biolink:treats MONDO:0010481 PMID:41385096 "[{""id"":""uuid:09a5c3ee-6a55-4f16-9f9d-abd6930e513f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:012d9483-ead0-4dd4-83e5-5291f0011bd2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ramipril is indicated for the treatment of hypertension. It may be used alone or in combination with thiazide diuretics. In using ramipril, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that ramipril does not have a similar risk. (See WARNINGS . ) In considering use of ramipril, it should be noted that in controlled trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients. (see WARNINGS , Angioedema . ) uuid:cf6f8ec0-14ec-42c2-9370-6def7d7af281 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8461 biolink:treats MONDO:0024332 PMID:41385096 "[{""id"":""uuid:903f8e82-16e0-4a4c-a5b3-0e2628e75bbd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1301dcec-fc18-4a3e-a002-627e61cb5406"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Promethazine is useful for: Perennial and seasonal allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma. Dermographism. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative, or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of post-operative pain. Sedation in both children and adults, as well as relief of apprehension and production of light sleep from which the patient can be easily aroused. Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients. uuid:838a7f0d-3437-4c1a-a46f-cc2decd2f685 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8461 biolink:treats MONDO:0005324 PMID:41385096 "[{""id"":""uuid:fea89b24-393f-459f-adf5-185f25ba65f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c0f57b4b-4749-4ce2-bd19-52c2fa4c8306"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Promethazine is useful for: Perennial and seasonal allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma. Dermographism. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative, or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of post-operative pain. Sedation in both children and adults, as well as relief of apprehension and production of light sleep from which the patient can be easily aroused. Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients. uuid:a9e4b766-df8f-459d-8ede-a9224b74ae8e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8461 biolink:treats MONDO:0006004 PMID:41385096 "[{""id"":""uuid:b80a967d-ecf1-49ce-9ba4-99791e42b80d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:700a78c9-5001-4808-ba71-b98db7738d60"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Promethazine is useful for: Perennial and seasonal allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma. Dermographism. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative, or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of post-operative pain. Sedation in both children and adults, as well as relief of apprehension and production of light sleep from which the patient can be easily aroused. Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients. uuid:c1f4214e-8c77-41d3-a0b6-f45455a0d750 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8461 biolink:treats MONDO:0005492 PMID:41385096 "[{""id"":""uuid:b27cfeaa-0d26-43cc-8ccf-dc3e38ba8611"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:83a6d826-ac8a-46ab-b45e-3f58b97b9a0b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Promethazine is useful for: Perennial and seasonal allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma. Dermographism. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative, or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of post-operative pain. Sedation in both children and adults, as well as relief of apprehension and production of light sleep from which the patient can be easily aroused. Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients. uuid:9020b5c2-0885-4182-8a92-9a92bacf220e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8461 biolink:treats MONDO:0010481 PMID:41385096 "[{""id"":""uuid:4ca094ca-08cd-47a3-9c44-65de4bd7877d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7390bf51-703f-408a-b7e7-2e3816255327"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Promethazine is useful for: Perennial and seasonal allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma. Dermographism. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative, or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of post-operative pain. Sedation in both children and adults, as well as relief of apprehension and production of light sleep from which the patient can be easily aroused. Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients. uuid:ae2eb3b4-7012-4e54-8a3a-e002f01ba9eb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8461 biolink:treats MONDO:0007448 PMID:41385096 "[{""id"":""uuid:06e4ea7d-da9b-4e29-8e05-846d6d0aaae4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9f11682d-7573-4fc9-bfba-0fc011bb2fe1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Promethazine is useful for: Perennial and seasonal allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma. Dermographism. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative, or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of post-operative pain. Sedation in both children and adults, as well as relief of apprehension and production of light sleep from which the patient can be easily aroused. Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients. uuid:31444371-d4a2-46e5-b7b2-30a8fc20e2b3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3515 biolink:treats MONDO:0002258 PMID:41385096 "[{""id"":""uuid:394ef56c-59da-4665-937f-bf504a724587"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:48883a6c-6d5a-4518-a561-34e516eed643"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NOTE: CEFUROXIME AXETIL TABLETS AND CEFUROXIME AXETIL FOR ORAL SUSPENSION ARE NOT BIOEQUIVALENT AND ARE NOT SUBSTITUTABLE ON A MILLIGRAM-PER-MILLIGRAM BASIS (SEE CLINICAL PHARMACOLOGY ). Cefuroxime Axetil Tablets: Cefuroxime axetil tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below: 1. Pharyngitis/Tonsillitis caused by Streptococcus pyogenes. NOTE: The usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. Cefuroxime axetil tablets are generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefuroxime in the subsequent prevention of rheumatic fever are not available. Please also note that in all clinical trials, all isolates had to be sensitive to both penicillin and cefuroxime. There are no data from adequate and well-controlled trials to demonstrate the effectiveness of cefuroxime in the treatment of penicillin-resistant strains of Streptococcus pyogenes. 2. Acute Bacterial Otitis Media caused by Streptococcus pneumoniae , Haemophilus influenzae (including beta-lactamase–producing strains), Moraxella catarrhalis (including beta-lactamase–producing strains), or Streptococcus pyogenes. 3. Acute Bacterial Maxillary Sinusitis caused by Streptococcus pneumoniae or Haemophilus influenzae (non-beta-lactamase–producing strains only). (See CLINICAL STUDIES section.) NOTE: In view of the insufficient numbers of isolates of beta-lactamase–producing strains of Haemophilus influenzae and Moraxella catarrhalis that were obtained from clinical trials with cefuroxime axetil tablets for patients with acute bacterial maxillary sinusitis, it was not possible to adequately evaluate the effectiveness of cefuroxime axetil tablets for sinus infections known, suspected, or considered potentially to be caused by beta-lactamase–producing Haemophilus influenzae or Moraxella catarrhalis. 4. Acute Bacterial Exacerbations of Chronic Bronchitis and Secondary Bacterial Infections of Acute Bronchitis caused by Streptococcus pneumoniae , Haemophilus influenzae (beta-lactamase negative strains), or Haemophilus parainfluenzae (beta-lactamase negative strains). (See DOSAGE AND ADMINISTRATION section and CLINICAL STUDIES section.) 5. Uncomplicated Skin and Skin-Structure Infections caused by Staphylococcus aureus (including beta-lactamase–producing strains) or Streptococcus pyogenes. 6. Uncomplicated Urinary Tract Infections caused by Escherichia coli or Klebsiella pneumoniae . 7. Uncomplicated Gonorrhea, urethral and endocervical, caused by penicillinase-producing and non-penicillinase–producing strains of Neisseria gonorrhoeae and uncomplicated gonorrhea, rectal, in females, caused by non-penicillinase–producing strains of Neisseria gonorrhoeae . 8. Early Lyme Disease (erythema migrans) caused by Borrelia burgdorferi . To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefuroxime axetil tablets and other antibacterial drugs, cefuroxime axetil tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:e61dbf48-dd8e-4df0-a83a-39a1d156c9a7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3515 biolink:treats MONDO:0001039 PMID:41385096 "[{""id"":""uuid:e3b33b29-a2a0-4f65-b4c9-3a625e9b77f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7a18d0a3-1f8d-4512-be52-635c052f62f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NOTE: CEFUROXIME AXETIL TABLETS AND CEFUROXIME AXETIL FOR ORAL SUSPENSION ARE NOT BIOEQUIVALENT AND ARE NOT SUBSTITUTABLE ON A MILLIGRAM-PER-MILLIGRAM BASIS (SEE CLINICAL PHARMACOLOGY ). Cefuroxime Axetil Tablets: Cefuroxime axetil tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below: 1. Pharyngitis/Tonsillitis caused by Streptococcus pyogenes. NOTE: The usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. Cefuroxime axetil tablets are generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefuroxime in the subsequent prevention of rheumatic fever are not available. Please also note that in all clinical trials, all isolates had to be sensitive to both penicillin and cefuroxime. There are no data from adequate and well-controlled trials to demonstrate the effectiveness of cefuroxime in the treatment of penicillin-resistant strains of Streptococcus pyogenes. 2. Acute Bacterial Otitis Media caused by Streptococcus pneumoniae , Haemophilus influenzae (including beta-lactamase–producing strains), Moraxella catarrhalis (including beta-lactamase–producing strains), or Streptococcus pyogenes. 3. Acute Bacterial Maxillary Sinusitis caused by Streptococcus pneumoniae or Haemophilus influenzae (non-beta-lactamase–producing strains only). (See CLINICAL STUDIES section.) NOTE: In view of the insufficient numbers of isolates of beta-lactamase–producing strains of Haemophilus influenzae and Moraxella catarrhalis that were obtained from clinical trials with cefuroxime axetil tablets for patients with acute bacterial maxillary sinusitis, it was not possible to adequately evaluate the effectiveness of cefuroxime axetil tablets for sinus infections known, suspected, or considered potentially to be caused by beta-lactamase–producing Haemophilus influenzae or Moraxella catarrhalis. 4. Acute Bacterial Exacerbations of Chronic Bronchitis and Secondary Bacterial Infections of Acute Bronchitis caused by Streptococcus pneumoniae , Haemophilus influenzae (beta-lactamase negative strains), or Haemophilus parainfluenzae (beta-lactamase negative strains). (See DOSAGE AND ADMINISTRATION section and CLINICAL STUDIES section.) 5. Uncomplicated Skin and Skin-Structure Infections caused by Staphylococcus aureus (including beta-lactamase–producing strains) or Streptococcus pyogenes. 6. Uncomplicated Urinary Tract Infections caused by Escherichia coli or Klebsiella pneumoniae . 7. Uncomplicated Gonorrhea, urethral and endocervical, caused by penicillinase-producing and non-penicillinase–producing strains of Neisseria gonorrhoeae and uncomplicated gonorrhea, rectal, in females, caused by non-penicillinase–producing strains of Neisseria gonorrhoeae . 8. Early Lyme Disease (erythema migrans) caused by Borrelia burgdorferi . To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefuroxime axetil tablets and other antibacterial drugs, cefuroxime axetil tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:7040d6e6-5b5e-4165-8679-850afabf84bd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3515 biolink:treats MONDO:0001031 PMID:41385096 "[{""id"":""uuid:1ba19070-07eb-46f3-98d5-fac27b9eea17"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5a961bf6-4b29-4cb0-b784-3db4eed90ae8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NOTE: CEFUROXIME AXETIL TABLETS AND CEFUROXIME AXETIL FOR ORAL SUSPENSION ARE NOT BIOEQUIVALENT AND ARE NOT SUBSTITUTABLE ON A MILLIGRAM-PER-MILLIGRAM BASIS (SEE CLINICAL PHARMACOLOGY ). Cefuroxime Axetil Tablets: Cefuroxime axetil tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below: 1. Pharyngitis/Tonsillitis caused by Streptococcus pyogenes. NOTE: The usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. Cefuroxime axetil tablets are generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefuroxime in the subsequent prevention of rheumatic fever are not available. Please also note that in all clinical trials, all isolates had to be sensitive to both penicillin and cefuroxime. There are no data from adequate and well-controlled trials to demonstrate the effectiveness of cefuroxime in the treatment of penicillin-resistant strains of Streptococcus pyogenes. 2. Acute Bacterial Otitis Media caused by Streptococcus pneumoniae , Haemophilus influenzae (including beta-lactamase–producing strains), Moraxella catarrhalis (including beta-lactamase–producing strains), or Streptococcus pyogenes. 3. Acute Bacterial Maxillary Sinusitis caused by Streptococcus pneumoniae or Haemophilus influenzae (non-beta-lactamase–producing strains only). (See CLINICAL STUDIES section.) NOTE: In view of the insufficient numbers of isolates of beta-lactamase–producing strains of Haemophilus influenzae and Moraxella catarrhalis that were obtained from clinical trials with cefuroxime axetil tablets for patients with acute bacterial maxillary sinusitis, it was not possible to adequately evaluate the effectiveness of cefuroxime axetil tablets for sinus infections known, suspected, or considered potentially to be caused by beta-lactamase–producing Haemophilus influenzae or Moraxella catarrhalis. 4. Acute Bacterial Exacerbations of Chronic Bronchitis and Secondary Bacterial Infections of Acute Bronchitis caused by Streptococcus pneumoniae , Haemophilus influenzae (beta-lactamase negative strains), or Haemophilus parainfluenzae (beta-lactamase negative strains). (See DOSAGE AND ADMINISTRATION section and CLINICAL STUDIES section.) 5. Uncomplicated Skin and Skin-Structure Infections caused by Staphylococcus aureus (including beta-lactamase–producing strains) or Streptococcus pyogenes. 6. Uncomplicated Urinary Tract Infections caused by Escherichia coli or Klebsiella pneumoniae . 7. Uncomplicated Gonorrhea, urethral and endocervical, caused by penicillinase-producing and non-penicillinase–producing strains of Neisseria gonorrhoeae and uncomplicated gonorrhea, rectal, in females, caused by non-penicillinase–producing strains of Neisseria gonorrhoeae . 8. Early Lyme Disease (erythema migrans) caused by Borrelia burgdorferi . To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefuroxime axetil tablets and other antibacterial drugs, cefuroxime axetil tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:7b6cbec8-1c25-483e-8d59-0a49b6c39ea0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3515 biolink:treats MONDO:0002186 PMID:41385096 "[{""id"":""uuid:1ef339b9-e33b-47b0-9d04-101194f73205"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cf059418-ac73-4188-92a4-4ab5202a8728"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NOTE: CEFUROXIME AXETIL TABLETS AND CEFUROXIME AXETIL FOR ORAL SUSPENSION ARE NOT BIOEQUIVALENT AND ARE NOT SUBSTITUTABLE ON A MILLIGRAM-PER-MILLIGRAM BASIS (SEE CLINICAL PHARMACOLOGY ). Cefuroxime Axetil Tablets: Cefuroxime axetil tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below: 1. Pharyngitis/Tonsillitis caused by Streptococcus pyogenes. NOTE: The usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. Cefuroxime axetil tablets are generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefuroxime in the subsequent prevention of rheumatic fever are not available. Please also note that in all clinical trials, all isolates had to be sensitive to both penicillin and cefuroxime. There are no data from adequate and well-controlled trials to demonstrate the effectiveness of cefuroxime in the treatment of penicillin-resistant strains of Streptococcus pyogenes. 2. Acute Bacterial Otitis Media caused by Streptococcus pneumoniae , Haemophilus influenzae (including beta-lactamase–producing strains), Moraxella catarrhalis (including beta-lactamase–producing strains), or Streptococcus pyogenes. 3. Acute Bacterial Maxillary Sinusitis caused by Streptococcus pneumoniae or Haemophilus influenzae (non-beta-lactamase–producing strains only). (See CLINICAL STUDIES section.) NOTE: In view of the insufficient numbers of isolates of beta-lactamase–producing strains of Haemophilus influenzae and Moraxella catarrhalis that were obtained from clinical trials with cefuroxime axetil tablets for patients with acute bacterial maxillary sinusitis, it was not possible to adequately evaluate the effectiveness of cefuroxime axetil tablets for sinus infections known, suspected, or considered potentially to be caused by beta-lactamase–producing Haemophilus influenzae or Moraxella catarrhalis. 4. Acute Bacterial Exacerbations of Chronic Bronchitis and Secondary Bacterial Infections of Acute Bronchitis caused by Streptococcus pneumoniae , Haemophilus influenzae (beta-lactamase negative strains), or Haemophilus parainfluenzae (beta-lactamase negative strains). (See DOSAGE AND ADMINISTRATION section and CLINICAL STUDIES section.) 5. Uncomplicated Skin and Skin-Structure Infections caused by Staphylococcus aureus (including beta-lactamase–producing strains) or Streptococcus pyogenes. 6. Uncomplicated Urinary Tract Infections caused by Escherichia coli or Klebsiella pneumoniae . 7. Uncomplicated Gonorrhea, urethral and endocervical, caused by penicillinase-producing and non-penicillinase–producing strains of Neisseria gonorrhoeae and uncomplicated gonorrhea, rectal, in females, caused by non-penicillinase–producing strains of Neisseria gonorrhoeae . 8. Early Lyme Disease (erythema migrans) caused by Borrelia burgdorferi . To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefuroxime axetil tablets and other antibacterial drugs, cefuroxime axetil tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:acffa8c4-db3f-4c4b-b59f-f9246fcf131f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3515 biolink:treats UMLS:C0853854 PMID:41385096 "[{""id"":""uuid:363afbc8-64ab-4a96-b260-b7dec8f471c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:74c041ba-37b3-47ff-8607-bfb6f296eb33"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NOTE: CEFUROXIME AXETIL TABLETS AND CEFUROXIME AXETIL FOR ORAL SUSPENSION ARE NOT BIOEQUIVALENT AND ARE NOT SUBSTITUTABLE ON A MILLIGRAM-PER-MILLIGRAM BASIS (SEE CLINICAL PHARMACOLOGY ). Cefuroxime Axetil Tablets: Cefuroxime axetil tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below: 1. Pharyngitis/Tonsillitis caused by Streptococcus pyogenes. NOTE: The usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. Cefuroxime axetil tablets are generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefuroxime in the subsequent prevention of rheumatic fever are not available. Please also note that in all clinical trials, all isolates had to be sensitive to both penicillin and cefuroxime. There are no data from adequate and well-controlled trials to demonstrate the effectiveness of cefuroxime in the treatment of penicillin-resistant strains of Streptococcus pyogenes. 2. Acute Bacterial Otitis Media caused by Streptococcus pneumoniae , Haemophilus influenzae (including beta-lactamase–producing strains), Moraxella catarrhalis (including beta-lactamase–producing strains), or Streptococcus pyogenes. 3. Acute Bacterial Maxillary Sinusitis caused by Streptococcus pneumoniae or Haemophilus influenzae (non-beta-lactamase–producing strains only). (See CLINICAL STUDIES section.) NOTE: In view of the insufficient numbers of isolates of beta-lactamase–producing strains of Haemophilus influenzae and Moraxella catarrhalis that were obtained from clinical trials with cefuroxime axetil tablets for patients with acute bacterial maxillary sinusitis, it was not possible to adequately evaluate the effectiveness of cefuroxime axetil tablets for sinus infections known, suspected, or considered potentially to be caused by beta-lactamase–producing Haemophilus influenzae or Moraxella catarrhalis. 4. Acute Bacterial Exacerbations of Chronic Bronchitis and Secondary Bacterial Infections of Acute Bronchitis caused by Streptococcus pneumoniae , Haemophilus influenzae (beta-lactamase negative strains), or Haemophilus parainfluenzae (beta-lactamase negative strains). (See DOSAGE AND ADMINISTRATION section and CLINICAL STUDIES section.) 5. Uncomplicated Skin and Skin-Structure Infections caused by Staphylococcus aureus (including beta-lactamase–producing strains) or Streptococcus pyogenes. 6. Uncomplicated Urinary Tract Infections caused by Escherichia coli or Klebsiella pneumoniae . 7. Uncomplicated Gonorrhea, urethral and endocervical, caused by penicillinase-producing and non-penicillinase–producing strains of Neisseria gonorrhoeae and uncomplicated gonorrhea, rectal, in females, caused by non-penicillinase–producing strains of Neisseria gonorrhoeae . 8. Early Lyme Disease (erythema migrans) caused by Borrelia burgdorferi . To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefuroxime axetil tablets and other antibacterial drugs, cefuroxime axetil tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:091e0d48-9e66-4308-87ba-8d94505f9c5a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3515 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:a387b410-5e66-4bfb-a355-3439639ffa11"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8d78401f-239d-4a3c-ba2e-507d0e647375"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NOTE: CEFUROXIME AXETIL TABLETS AND CEFUROXIME AXETIL FOR ORAL SUSPENSION ARE NOT BIOEQUIVALENT AND ARE NOT SUBSTITUTABLE ON A MILLIGRAM-PER-MILLIGRAM BASIS (SEE CLINICAL PHARMACOLOGY ). Cefuroxime Axetil Tablets: Cefuroxime axetil tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below: 1. Pharyngitis/Tonsillitis caused by Streptococcus pyogenes. NOTE: The usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. Cefuroxime axetil tablets are generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefuroxime in the subsequent prevention of rheumatic fever are not available. Please also note that in all clinical trials, all isolates had to be sensitive to both penicillin and cefuroxime. There are no data from adequate and well-controlled trials to demonstrate the effectiveness of cefuroxime in the treatment of penicillin-resistant strains of Streptococcus pyogenes. 2. Acute Bacterial Otitis Media caused by Streptococcus pneumoniae , Haemophilus influenzae (including beta-lactamase–producing strains), Moraxella catarrhalis (including beta-lactamase–producing strains), or Streptococcus pyogenes. 3. Acute Bacterial Maxillary Sinusitis caused by Streptococcus pneumoniae or Haemophilus influenzae (non-beta-lactamase–producing strains only). (See CLINICAL STUDIES section.) NOTE: In view of the insufficient numbers of isolates of beta-lactamase–producing strains of Haemophilus influenzae and Moraxella catarrhalis that were obtained from clinical trials with cefuroxime axetil tablets for patients with acute bacterial maxillary sinusitis, it was not possible to adequately evaluate the effectiveness of cefuroxime axetil tablets for sinus infections known, suspected, or considered potentially to be caused by beta-lactamase–producing Haemophilus influenzae or Moraxella catarrhalis. 4. Acute Bacterial Exacerbations of Chronic Bronchitis and Secondary Bacterial Infections of Acute Bronchitis caused by Streptococcus pneumoniae , Haemophilus influenzae (beta-lactamase negative strains), or Haemophilus parainfluenzae (beta-lactamase negative strains). (See DOSAGE AND ADMINISTRATION section and CLINICAL STUDIES section.) 5. Uncomplicated Skin and Skin-Structure Infections caused by Staphylococcus aureus (including beta-lactamase–producing strains) or Streptococcus pyogenes. 6. Uncomplicated Urinary Tract Infections caused by Escherichia coli or Klebsiella pneumoniae . 7. Uncomplicated Gonorrhea, urethral and endocervical, caused by penicillinase-producing and non-penicillinase–producing strains of Neisseria gonorrhoeae and uncomplicated gonorrhea, rectal, in females, caused by non-penicillinase–producing strains of Neisseria gonorrhoeae . 8. Early Lyme Disease (erythema migrans) caused by Borrelia burgdorferi . To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefuroxime axetil tablets and other antibacterial drugs, cefuroxime axetil tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:ddaf208b-3b5b-4263-8550-247754c22d4a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3515 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:b4ea2c08-dbc7-407e-8484-a3747aaa57c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3e178076-9dbc-4c04-90ee-c08a1799b139"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NOTE: CEFUROXIME AXETIL TABLETS AND CEFUROXIME AXETIL FOR ORAL SUSPENSION ARE NOT BIOEQUIVALENT AND ARE NOT SUBSTITUTABLE ON A MILLIGRAM-PER-MILLIGRAM BASIS (SEE CLINICAL PHARMACOLOGY ). Cefuroxime Axetil Tablets: Cefuroxime axetil tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below: 1. Pharyngitis/Tonsillitis caused by Streptococcus pyogenes. NOTE: The usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. Cefuroxime axetil tablets are generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefuroxime in the subsequent prevention of rheumatic fever are not available. Please also note that in all clinical trials, all isolates had to be sensitive to both penicillin and cefuroxime. There are no data from adequate and well-controlled trials to demonstrate the effectiveness of cefuroxime in the treatment of penicillin-resistant strains of Streptococcus pyogenes. 2. Acute Bacterial Otitis Media caused by Streptococcus pneumoniae , Haemophilus influenzae (including beta-lactamase–producing strains), Moraxella catarrhalis (including beta-lactamase–producing strains), or Streptococcus pyogenes. 3. Acute Bacterial Maxillary Sinusitis caused by Streptococcus pneumoniae or Haemophilus influenzae (non-beta-lactamase–producing strains only). (See CLINICAL STUDIES section.) NOTE: In view of the insufficient numbers of isolates of beta-lactamase–producing strains of Haemophilus influenzae and Moraxella catarrhalis that were obtained from clinical trials with cefuroxime axetil tablets for patients with acute bacterial maxillary sinusitis, it was not possible to adequately evaluate the effectiveness of cefuroxime axetil tablets for sinus infections known, suspected, or considered potentially to be caused by beta-lactamase–producing Haemophilus influenzae or Moraxella catarrhalis. 4. Acute Bacterial Exacerbations of Chronic Bronchitis and Secondary Bacterial Infections of Acute Bronchitis caused by Streptococcus pneumoniae , Haemophilus influenzae (beta-lactamase negative strains), or Haemophilus parainfluenzae (beta-lactamase negative strains). (See DOSAGE AND ADMINISTRATION section and CLINICAL STUDIES section.) 5. Uncomplicated Skin and Skin-Structure Infections caused by Staphylococcus aureus (including beta-lactamase–producing strains) or Streptococcus pyogenes. 6. Uncomplicated Urinary Tract Infections caused by Escherichia coli or Klebsiella pneumoniae . 7. Uncomplicated Gonorrhea, urethral and endocervical, caused by penicillinase-producing and non-penicillinase–producing strains of Neisseria gonorrhoeae and uncomplicated gonorrhea, rectal, in females, caused by non-penicillinase–producing strains of Neisseria gonorrhoeae . 8. Early Lyme Disease (erythema migrans) caused by Borrelia burgdorferi . To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefuroxime axetil tablets and other antibacterial drugs, cefuroxime axetil tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:f26466fa-c20a-49c7-a0d7-0da531f4384a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3515 biolink:treats MONDO:0004277 PMID:41385096 "[{""id"":""uuid:9ee3945c-ad5c-4094-b8f6-0e4703fc47fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:229a0606-51c3-4cbe-bad7-6bb9c9362722"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NOTE: CEFUROXIME AXETIL TABLETS AND CEFUROXIME AXETIL FOR ORAL SUSPENSION ARE NOT BIOEQUIVALENT AND ARE NOT SUBSTITUTABLE ON A MILLIGRAM-PER-MILLIGRAM BASIS (SEE CLINICAL PHARMACOLOGY ). Cefuroxime Axetil Tablets: Cefuroxime axetil tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below: 1. Pharyngitis/Tonsillitis caused by Streptococcus pyogenes. NOTE: The usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. Cefuroxime axetil tablets are generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefuroxime in the subsequent prevention of rheumatic fever are not available. Please also note that in all clinical trials, all isolates had to be sensitive to both penicillin and cefuroxime. There are no data from adequate and well-controlled trials to demonstrate the effectiveness of cefuroxime in the treatment of penicillin-resistant strains of Streptococcus pyogenes. 2. Acute Bacterial Otitis Media caused by Streptococcus pneumoniae , Haemophilus influenzae (including beta-lactamase–producing strains), Moraxella catarrhalis (including beta-lactamase–producing strains), or Streptococcus pyogenes. 3. Acute Bacterial Maxillary Sinusitis caused by Streptococcus pneumoniae or Haemophilus influenzae (non-beta-lactamase–producing strains only). (See CLINICAL STUDIES section.) NOTE: In view of the insufficient numbers of isolates of beta-lactamase–producing strains of Haemophilus influenzae and Moraxella catarrhalis that were obtained from clinical trials with cefuroxime axetil tablets for patients with acute bacterial maxillary sinusitis, it was not possible to adequately evaluate the effectiveness of cefuroxime axetil tablets for sinus infections known, suspected, or considered potentially to be caused by beta-lactamase–producing Haemophilus influenzae or Moraxella catarrhalis. 4. Acute Bacterial Exacerbations of Chronic Bronchitis and Secondary Bacterial Infections of Acute Bronchitis caused by Streptococcus pneumoniae , Haemophilus influenzae (beta-lactamase negative strains), or Haemophilus parainfluenzae (beta-lactamase negative strains). (See DOSAGE AND ADMINISTRATION section and CLINICAL STUDIES section.) 5. Uncomplicated Skin and Skin-Structure Infections caused by Staphylococcus aureus (including beta-lactamase–producing strains) or Streptococcus pyogenes. 6. Uncomplicated Urinary Tract Infections caused by Escherichia coli or Klebsiella pneumoniae . 7. Uncomplicated Gonorrhea, urethral and endocervical, caused by penicillinase-producing and non-penicillinase–producing strains of Neisseria gonorrhoeae and uncomplicated gonorrhea, rectal, in females, caused by non-penicillinase–producing strains of Neisseria gonorrhoeae . 8. Early Lyme Disease (erythema migrans) caused by Borrelia burgdorferi . To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefuroxime axetil tablets and other antibacterial drugs, cefuroxime axetil tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:6d740190-7246-44ad-a9c3-c5d2845696fd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3515 biolink:treats MONDO:0019632 PMID:41385096 "[{""id"":""uuid:fa934bfb-ef3e-4c39-88e0-e818a8b00957"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4b86dbd5-96f9-4764-bd91-0d728e961d02"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NOTE: CEFUROXIME AXETIL TABLETS AND CEFUROXIME AXETIL FOR ORAL SUSPENSION ARE NOT BIOEQUIVALENT AND ARE NOT SUBSTITUTABLE ON A MILLIGRAM-PER-MILLIGRAM BASIS (SEE CLINICAL PHARMACOLOGY ). Cefuroxime Axetil Tablets: Cefuroxime axetil tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below: 1. Pharyngitis/Tonsillitis caused by Streptococcus pyogenes. NOTE: The usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. Cefuroxime axetil tablets are generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefuroxime in the subsequent prevention of rheumatic fever are not available. Please also note that in all clinical trials, all isolates had to be sensitive to both penicillin and cefuroxime. There are no data from adequate and well-controlled trials to demonstrate the effectiveness of cefuroxime in the treatment of penicillin-resistant strains of Streptococcus pyogenes. 2. Acute Bacterial Otitis Media caused by Streptococcus pneumoniae , Haemophilus influenzae (including beta-lactamase–producing strains), Moraxella catarrhalis (including beta-lactamase–producing strains), or Streptococcus pyogenes. 3. Acute Bacterial Maxillary Sinusitis caused by Streptococcus pneumoniae or Haemophilus influenzae (non-beta-lactamase–producing strains only). (See CLINICAL STUDIES section.) NOTE: In view of the insufficient numbers of isolates of beta-lactamase–producing strains of Haemophilus influenzae and Moraxella catarrhalis that were obtained from clinical trials with cefuroxime axetil tablets for patients with acute bacterial maxillary sinusitis, it was not possible to adequately evaluate the effectiveness of cefuroxime axetil tablets for sinus infections known, suspected, or considered potentially to be caused by beta-lactamase–producing Haemophilus influenzae or Moraxella catarrhalis. 4. Acute Bacterial Exacerbations of Chronic Bronchitis and Secondary Bacterial Infections of Acute Bronchitis caused by Streptococcus pneumoniae , Haemophilus influenzae (beta-lactamase negative strains), or Haemophilus parainfluenzae (beta-lactamase negative strains). (See DOSAGE AND ADMINISTRATION section and CLINICAL STUDIES section.) 5. Uncomplicated Skin and Skin-Structure Infections caused by Staphylococcus aureus (including beta-lactamase–producing strains) or Streptococcus pyogenes. 6. Uncomplicated Urinary Tract Infections caused by Escherichia coli or Klebsiella pneumoniae . 7. Uncomplicated Gonorrhea, urethral and endocervical, caused by penicillinase-producing and non-penicillinase–producing strains of Neisseria gonorrhoeae and uncomplicated gonorrhea, rectal, in females, caused by non-penicillinase–producing strains of Neisseria gonorrhoeae . 8. Early Lyme Disease (erythema migrans) caused by Borrelia burgdorferi . To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefuroxime axetil tablets and other antibacterial drugs, cefuroxime axetil tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:a1f33493-8f5b-4bc4-a2c4-fd346175d71e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3515 biolink:treats HP:0031180 PMID:41385096 "[{""id"":""uuid:e9e8e1ec-034c-4423-854c-311f0bcb4b4d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:11edf996-2c29-4b2d-bab2-cee4ee1e270f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NOTE: CEFUROXIME AXETIL TABLETS AND CEFUROXIME AXETIL FOR ORAL SUSPENSION ARE NOT BIOEQUIVALENT AND ARE NOT SUBSTITUTABLE ON A MILLIGRAM-PER-MILLIGRAM BASIS (SEE CLINICAL PHARMACOLOGY ). Cefuroxime Axetil Tablets: Cefuroxime axetil tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below: 1. Pharyngitis/Tonsillitis caused by Streptococcus pyogenes. NOTE: The usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. Cefuroxime axetil tablets are generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefuroxime in the subsequent prevention of rheumatic fever are not available. Please also note that in all clinical trials, all isolates had to be sensitive to both penicillin and cefuroxime. There are no data from adequate and well-controlled trials to demonstrate the effectiveness of cefuroxime in the treatment of penicillin-resistant strains of Streptococcus pyogenes. 2. Acute Bacterial Otitis Media caused by Streptococcus pneumoniae , Haemophilus influenzae (including beta-lactamase–producing strains), Moraxella catarrhalis (including beta-lactamase–producing strains), or Streptococcus pyogenes. 3. Acute Bacterial Maxillary Sinusitis caused by Streptococcus pneumoniae or Haemophilus influenzae (non-beta-lactamase–producing strains only). (See CLINICAL STUDIES section.) NOTE: In view of the insufficient numbers of isolates of beta-lactamase–producing strains of Haemophilus influenzae and Moraxella catarrhalis that were obtained from clinical trials with cefuroxime axetil tablets for patients with acute bacterial maxillary sinusitis, it was not possible to adequately evaluate the effectiveness of cefuroxime axetil tablets for sinus infections known, suspected, or considered potentially to be caused by beta-lactamase–producing Haemophilus influenzae or Moraxella catarrhalis. 4. Acute Bacterial Exacerbations of Chronic Bronchitis and Secondary Bacterial Infections of Acute Bronchitis caused by Streptococcus pneumoniae , Haemophilus influenzae (beta-lactamase negative strains), or Haemophilus parainfluenzae (beta-lactamase negative strains). (See DOSAGE AND ADMINISTRATION section and CLINICAL STUDIES section.) 5. Uncomplicated Skin and Skin-Structure Infections caused by Staphylococcus aureus (including beta-lactamase–producing strains) or Streptococcus pyogenes. 6. Uncomplicated Urinary Tract Infections caused by Escherichia coli or Klebsiella pneumoniae . 7. Uncomplicated Gonorrhea, urethral and endocervical, caused by penicillinase-producing and non-penicillinase–producing strains of Neisseria gonorrhoeae and uncomplicated gonorrhea, rectal, in females, caused by non-penicillinase–producing strains of Neisseria gonorrhoeae . 8. Early Lyme Disease (erythema migrans) caused by Borrelia burgdorferi . To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefuroxime axetil tablets and other antibacterial drugs, cefuroxime axetil tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:2fc9312c-d195-40aa-a19b-b37dd285351f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5775 biolink:treats MONDO:0001134 PMID:41385096 "[{""id"":""uuid:9d630444-cd37-4c89-9f6f-cc758f8ce70a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3ce8dcf8-c1bd-48d5-8144-69db9e90c2b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Essential hypertension, alone or as an adjunct. uuid:7c5fd98c-ecd1-4b77-8385-f41d8ef2fecf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2611 biolink:treats MONDO:0005383 PMID:41385096 "[{""id"":""uuid:a85b5a2a-223c-42f7-9835-916d47499b51"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c9b2f97a-31b6-4dde-87f7-15861713f32d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Alprazolam extended-release tablets are indicated for the treatment of panic disorder, with or without agoraphobia. This claim is supported on the basis of two positive studies with alprazolam extended-release tablets conducted in patients whose diagnoses corresponded closely to the DSM-III-R/IV criteria for panic disorder (see CLINICAL STUDIES ). Panic disorder (DSM-IV) is characterized by recurrent unexpected panic attacks, i.e., a discrete period of intense fear or discomfort in which four (or more) of the following symptoms develop abruptly and reach a peak within 10 minutes: (1) palpitations, pounding heart, or accelerated heart rate; (2) sweating; (3) trembling or shaking; (4) sensations of shortness of breath or smothering; (5) feeling of choking; (6) chest pain or discomfort; (7) nausea or abdominal distress; (8) feeling dizzy, unsteady, lightheaded, or faint; (9) derealization (feelings of unreality) or depersonalization (being detached from oneself); (10) fear of losing control; (11) fear of dying; (12) paresthesias (numbness or tingling sensations); (13) chills or hot flushes. The longer-term efficacy of alprazolam extended-release tablets has not been systematically evaluated. Thus, the physician who elects to use this drug for periods longer than 8 weeks should periodically reassess the usefulness of the drug for the individual patient. uuid:4edb5fda-e567-4ea2-912e-07d237a75249 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2611 biolink:treats MONDO:0003709 PMID:41385096 "[{""id"":""uuid:3c48b990-4c64-4d08-b89b-b923309c790f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0a76d19e-e688-42f3-aaf4-73f6e7b3604a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Alprazolam extended-release tablets are indicated for the treatment of panic disorder, with or without agoraphobia. This claim is supported on the basis of two positive studies with alprazolam extended-release tablets conducted in patients whose diagnoses corresponded closely to the DSM-III-R/IV criteria for panic disorder (see CLINICAL STUDIES ). Panic disorder (DSM-IV) is characterized by recurrent unexpected panic attacks, i.e., a discrete period of intense fear or discomfort in which four (or more) of the following symptoms develop abruptly and reach a peak within 10 minutes: (1) palpitations, pounding heart, or accelerated heart rate; (2) sweating; (3) trembling or shaking; (4) sensations of shortness of breath or smothering; (5) feeling of choking; (6) chest pain or discomfort; (7) nausea or abdominal distress; (8) feeling dizzy, unsteady, lightheaded, or faint; (9) derealization (feelings of unreality) or depersonalization (being detached from oneself); (10) fear of losing control; (11) fear of dying; (12) paresthesias (numbness or tingling sensations); (13) chills or hot flushes. The longer-term efficacy of alprazolam extended-release tablets has not been systematically evaluated. Thus, the physician who elects to use this drug for periods longer than 8 weeks should periodically reassess the usefulness of the drug for the individual patient. uuid:d35f0320-3e9e-48c4-ab7b-51f203d17c11 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8665 biolink:treats MONDO:0029000 PMID:41385096 "[{""id"":""uuid:d8265830-d8d3-4a38-86df-58871987b206"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f5a675a3-4f95-43c3-a24a-97d71a0db905"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pyridostigmine bromide is indicated for pretreatment against the lethal effects of Soman nerve agent poisoning. Pyridostigmine is intended for use in conjunction with protective garments, including a mask. At the first sign of nerve agent poisoning, pyridostigmine should be stopped, and atropine and pralidoxime therapy started immediately. The evidence for the effectiveness of pyridostigmine as pretreatment against Soman-induced toxicity was derived from animal studies alone [see Nonclinical Toxicology (13.2) ]. FOR MILITARY MEDICAL USE ONLY uuid:46a77c2b-5c72-4426-af48-565d31a03c66 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:101853 biolink:treats UMLS:C1735365 PMID:41385096 "[{""id"":""uuid:c2b9bae1-77f2-4397-9418-1b47089dbebd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:157eb5ff-b0ee-4cd1-9fe8-43e67b4b4ffd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FACTIVE is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions listed below. (See DOSAGE AND ADMINISTRATION and CLINICAL STUDIES . ) Acute bacterial exacerbation of chronic bronchitis caused by Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis . Community-acquired pneumonia (of mild to moderate severity) caused by Streptococcus pneumoniae (including multi-drug resistant strains [MDRSP])*, Haemophilus influenzae, Moraxella catarrhalis, Mycoplasma pneumoniae, Chlamydia pneumoniae, or Klebsiella pneumoniae . *MDRSP: multi-drug resistant Streptococcus pneumoniae , includes isolates previously known as PRSP (penicillin-resistant Streptococcus pneumoniae ), and are strains resistant to two or more of the following antibiotics: penicillin (MIC ≥2 μg/mL), 2nd generation cephalosporins (e.g., cefuroxime), macrolides, tetracyclines and trimethoprim/sulfamethoxazole. To reduce the development of drug-resistant bacteria and maintain the effectiveness of FACTIVE and other antibacterial drugs, FACTIVE should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:4bfaf44c-23dd-472b-962c-be0518e8247d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:101853 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:6b893a44-0760-4a3b-99f5-a5cfbff9e431"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b0e1a574-177b-4d35-8619-b359d49cd2b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FACTIVE is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions listed below. (See DOSAGE AND ADMINISTRATION and CLINICAL STUDIES . ) Acute bacterial exacerbation of chronic bronchitis caused by Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis . Community-acquired pneumonia (of mild to moderate severity) caused by Streptococcus pneumoniae (including multi-drug resistant strains [MDRSP])*, Haemophilus influenzae, Moraxella catarrhalis, Mycoplasma pneumoniae, Chlamydia pneumoniae, or Klebsiella pneumoniae . *MDRSP: multi-drug resistant Streptococcus pneumoniae , includes isolates previously known as PRSP (penicillin-resistant Streptococcus pneumoniae ), and are strains resistant to two or more of the following antibiotics: penicillin (MIC ≥2 μg/mL), 2nd generation cephalosporins (e.g., cefuroxime), macrolides, tetracyclines and trimethoprim/sulfamethoxazole. To reduce the development of drug-resistant bacteria and maintain the effectiveness of FACTIVE and other antibacterial drugs, FACTIVE should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:c004237c-3bb6-4dbf-a87d-0b75c226bf32 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63618 biolink:treats MONDO:0005010 PMID:41385096 "[{""id"":""uuid:4b9c9ec6-e869-4a46-8427-b4280047becc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c980977b-a3cb-45d0-896c-0bdb2ad0f31e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with Pravastatin Sodium Tablets should be considered in those individuals at increased risk for atherosclerosis-related clinical events as a function of cholesterol level, the presence or absence of coronary heart disease, and other risk factors. uuid:e851b298-2239-46bf-b97a-4ca632fef074 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6741 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:30d8ac7a-d657-41ba-a4d3-2d1c332918f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:040e4428-d33d-4e7c-a2f9-683aab672e5a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of meloxicam tablets and other treatment options before deciding to use meloxicam tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Meloxicam tablets are indicated for relief of the signs and symptoms of osteoarthritis and rheumatoid arthritis. uuid:0f08e192-a0e4-4eb6-b082-2aedbb08168c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3764 biolink:treats UMLS:C0919659 PMID:41385096 "[{""id"":""uuid:4be3ba7b-8abe-4c84-b30c-df1b1794eb74"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1c44f974-761b-4cf6-a3db-427a8bcc269e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clotrimazole Troches (clotrimazole lozenges) are indicated for the local treatment of oropharyngeal candidiasis. The diagnosis should be confirmed by a KOH smear and/or culture prior to treatment. Clotrimazole Troches (clotrimazole lozenges) are also indicated prophylactically to reduce the incidence of oropharyngeal candidiasis in patients immunocompromised by conditions that include chemotherapy, radiotherapy, or steroid therapy utilized in the treatment of leukemia, solid tumors, or renal transplantation. There are no data from adequate and well-controlled trials to establish the safety and efficacy of this product for prophylactic use in patients immunocompromised by etiologies other than those listed in the previous sentence. (See DOSAGE AND ADMINISTRATION .) uuid:ae0075d8-1cc0-4e4f-881d-2cbe5862205f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3764 biolink:treats MONDO:0005059 PMID:41385096 "[{""id"":""uuid:bb784f96-ac99-4652-824a-8d721b6bfb0b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4d91b7f6-5584-499c-b1ae-3621c324718d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clotrimazole Troches (clotrimazole lozenges) are indicated for the local treatment of oropharyngeal candidiasis. The diagnosis should be confirmed by a KOH smear and/or culture prior to treatment. Clotrimazole Troches (clotrimazole lozenges) are also indicated prophylactically to reduce the incidence of oropharyngeal candidiasis in patients immunocompromised by conditions that include chemotherapy, radiotherapy, or steroid therapy utilized in the treatment of leukemia, solid tumors, or renal transplantation. There are no data from adequate and well-controlled trials to establish the safety and efficacy of this product for prophylactic use in patients immunocompromised by etiologies other than those listed in the previous sentence. (See DOSAGE AND ADMINISTRATION .) uuid:5d7f0ba5-2f6f-47e0-a192-00b0acaf1084 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3764 biolink:treats UMLS:C0280100 PMID:41385096 "[{""id"":""uuid:13c8439a-67f6-4533-b7cc-af465594f249"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4d7555ea-1862-4f53-bd64-9678f12aa3ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clotrimazole Troches (clotrimazole lozenges) are indicated for the local treatment of oropharyngeal candidiasis. The diagnosis should be confirmed by a KOH smear and/or culture prior to treatment. Clotrimazole Troches (clotrimazole lozenges) are also indicated prophylactically to reduce the incidence of oropharyngeal candidiasis in patients immunocompromised by conditions that include chemotherapy, radiotherapy, or steroid therapy utilized in the treatment of leukemia, solid tumors, or renal transplantation. There are no data from adequate and well-controlled trials to establish the safety and efficacy of this product for prophylactic use in patients immunocompromised by etiologies other than those listed in the previous sentence. (See DOSAGE AND ADMINISTRATION .) uuid:14c480f1-401a-4aea-b4b5-1220956a7181 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7903 biolink:treats MONDO:0043455 PMID:41385096 "[{""id"":""uuid:033cea29-c148-4244-9068-a1e06d868b68"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:341ee560-3562-4537-a7b5-306db6d2fd24"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pamidronate disodium, in conjunction with adequate hydration, is indicated for the treatment of moderate or severe hypercalcemia associated with malignancy, with or without bone metastases. Patients who have either epidermoid or non-epidermoid tumors respond to treatment with pamidronate disodium. Vigorous saline hydration, an integral part of hypercalcemia therapy, should be initiated promptly and an attempt should be made to restore the urine output to about 2 L/day throughout treatment. Mild or asymptomatic hypercalcemia may be treated with conservative measures (i.e., saline hydration, with or without loop diuretics). Patients should be hydrated adequately throughout the treatment, but overhydration, especially in those patients who have cardiac failure, must be avoided. Diuretic therapy should not be employed prior to correction of hypovolemia. The safety and efficacy of pamidronate disodium in the treatment of hypercalcemia associated with hyperparathyroidism or with other non-tumor-related conditions has not been established. uuid:c96c8921-1384-4d22-b301-d7de2e51c8ed biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0000004 PMID:41385096 "[{""id"":""uuid:86f4f5d1-bae3-4ca9-b38e-878e2b124fa8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1b491533-0e52-4656-a48b-6de903665e89"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:1d017adf-b7f3-422f-997c-17b2cd4cef81 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0018479 PMID:41385096 "[{""id"":""uuid:640279da-e304-4245-aa9d-96ea4c9610d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:de116f93-780b-4fcf-9719-39e19f8bb003"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:96c1d40e-10a9-45db-8f53-9e3634486c38 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0006982 PMID:41385096 "[{""id"":""uuid:a12b0790-d6c1-4dfb-a6a0-eb7d9b8d8a9f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7e36e57c-3313-4969-bd75-82cdb0951cba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:43e2b34c-42ae-4da1-9a6f-6a47f820dc0d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0043455 PMID:41385096 "[{""id"":""uuid:45d19dc4-8d6d-4c4a-9d9e-ca6b5c41ad49"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2f04486f-9842-46ea-9d22-aabc737dd742"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:f5d76d6b-d4bb-441f-9535-6529fc7184b8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0011849 PMID:41385096 "[{""id"":""uuid:b28d060e-930f-4207-a162-ac1830a26f3b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1dca2c0d-b195-4b86-b364-9aacdfe00f2a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:16392f45-d132-43a4-8f23-15cc9faec1d9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:4066ec5f-a224-4621-b658-a0c4652908a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0652e25f-fd09-44f1-98bb-b00153e1f7fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:4ef90b46-2228-496d-b1c1-da5a6370eff9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0011429 PMID:41385096 "[{""id"":""uuid:eadebc0b-a005-4b4e-86f2-17791a48e69f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1b88dc94-e082-4ecc-bb5a-77a13f36d95b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:9058562b-9cc0-42fd-bf22-69b41501b8d5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0005306 PMID:41385096 "[{""id"":""uuid:14e1fbe8-6e22-4912-9438-8953392812d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8f9753d4-4833-4aca-828a-87feaa55bd35"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:8618e3dc-3bdd-4bc8-9ebc-872f77651c25 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats UMLS:C1290158 PMID:41385096 "[{""id"":""uuid:e09c65f5-0ef3-4a9e-8c8d-6e2ad4c9082e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6f91f5b7-c58d-45f4-b881-87284e8ba598"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:dc5727af-65fa-4836-8618-21e7602e5b50 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0040698 PMID:41385096 "[{""id"":""uuid:de6bdc9d-9e5d-4c5b-a076-205f6f7e9954"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fc7125f6-c232-4912-94fb-414dc4b975e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:65960cc2-3b7c-45d0-9999-6441127a4ce4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0004855 PMID:41385096 "[{""id"":""uuid:a95e7ae2-ff78-4618-9f8a-4d8c0d1fb9d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:db72195e-a156-47e2-8114-ec2ca5829c3b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:a246440c-37d5-4820-be80-d4a60a30f666 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats UMLS:C0149896 PMID:41385096 "[{""id"":""uuid:903df33a-8d82-4249-957a-a62fea70f8d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4fd78c92-fe89-4af7-9a0b-c1502e6de98d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:10435914-4a56-4a13-8c84-8dc2a94084b7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0002400 PMID:41385096 "[{""id"":""uuid:9b19f120-aa1c-4bcc-bc85-98a5ce6d16fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4f112712-6a3b-4371-b37d-0d974a0c8b22"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:d2e7eb3f-098e-4109-8a98-9eafb8b01268 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0005178 PMID:41385096 "[{""id"":""uuid:f9b32e63-b13f-4495-a698-82bea98e02be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e3892fb1-6125-436e-a5f1-ace0765e4c47"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:8af204be-b5f6-472a-b436-b31c5fa18269 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0001875 PMID:41385096 "[{""id"":""uuid:ec2ef8c9-41f8-431b-b712-ee5a5ca85056"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3ea4b4d4-6f6e-4e30-b2e5-da6833e7136e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:37cb26f7-87c6-44ab-816d-136c23116a0c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats UMLS:C5441648 PMID:41385096 "[{""id"":""uuid:ac80101b-c45f-488e-91b4-a5f18af6e591"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:09f014a1-2071-4c87-90ff-eaf88a699723"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:92ccb5e0-06e1-4aa9-990b-aee19dd86aff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0016367 PMID:41385096 "[{""id"":""uuid:31bc05a3-d4d7-4f07-8e0a-ce1ea95d2264"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b58bab42-767b-490d-a232-34d520f862f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:c449636b-d557-4293-b6ea-1452b0b8ac28 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0019127 PMID:41385096 "[{""id"":""uuid:28293622-0f39-466e-9dff-27ed797644d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cec0bba6-4a22-4b95-9db6-69503a1abfd9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:94a4727a-61a2-42af-b8fc-cfae87dde179 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0006594 PMID:41385096 "[{""id"":""uuid:f788f125-4751-4d22-a02f-88444d86624e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b85c132a-7d48-4a98-8a5a-9c427e19acad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:28a25f86-529a-4d66-8e55-52139fd49289 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0015614 PMID:41385096 "[{""id"":""uuid:c1d48325-50a8-4c8a-892f-92ea9c342baf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:70f89106-3f65-4815-9a33-393656f65cd1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:d1c72930-3f28-4ef2-a496-3c390bcd974d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0006545 PMID:41385096 "[{""id"":""uuid:dfff9ef7-3d2f-4c81-aaee-13e54343a4b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3a36fabc-2710-4b6f-8a86-b4a504c79a6e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:74c55a8c-880a-406b-a311-8fc0e10aab86 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0018229 PMID:41385096 "[{""id"":""uuid:8cc27e18-18be-4aa2-b396-69fe9542c1ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0f725259-6a8c-43cb-919c-df7ea2f33aa7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:94393544-667d-4762-b0f7-1dce3094ccd9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0043233 PMID:41385096 "[{""id"":""uuid:2dec1ce2-da4f-49c4-af8f-774c12292ee9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0065291d-5111-495b-946f-c2dded89d3fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:3865bc95-99eb-46d0-8957-0e9179a1663e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0009691 PMID:41385096 "[{""id"":""uuid:76d8b19d-9ab0-4324-90bd-6e0bcc336ebb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1d0dd69b-ad79-4a05-80ac-f57c47902dd8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:5ae8c415-d930-4ae9-97ad-7a0cfe61dfc6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0005083 PMID:41385096 "[{""id"":""uuid:20891891-3bd4-47c1-9394-971a0fd4e80c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c48d9518-afd3-4b88-8b2f-fd9c8354e4cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:046e26aa-766d-4b0f-82ea-d608883e669f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0006608 PMID:41385096 "[{""id"":""uuid:0714cdcd-5f24-4801-82b1-b2f2bb400361"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:15344886-98f4-41e4-87b3-3a54da5ecff5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:70e3f31d-a64c-45f1-9115-c6fae8bf7ea1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0005324 PMID:41385096 "[{""id"":""uuid:72a94a53-32e9-4ff1-98a0-1f1f31dfa750"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f9089ad3-a411-497a-ba7a-09bf94a182fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:909afd73-fc1c-4d09-a050-7c2303c067b3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0024332 PMID:41385096 "[{""id"":""uuid:39642fa6-596a-4f45-8609-1f4e0c0d8e02"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:91b3ef31-8af5-4759-a3ce-01aa4a1768e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:c6eb9696-d037-4a4d-a8da-608618086daf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:ad7eba78-67da-46fc-855c-efec1903c40e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d16f3821-2683-4ae3-a87b-c10e42e844aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:58263b5c-bdf6-4149-99f2-81ce7e0ba2b0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0005480 PMID:41385096 "[{""id"":""uuid:20b9cb97-4492-41d2-9d51-2ccdd5c64750"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e3faf471-18a0-4ca3-96b6-6255b5736ce2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:324cfecc-be96-4136-bdcf-b6f820399cde biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:3b01bb20-069d-4f28-8691-734dedfb78f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:01c9c460-1f38-4055-a24f-7dcb81a6ab84"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:96ba18cf-8067-4f78-9555-22cbd6857415 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0043789 PMID:41385096 "[{""id"":""uuid:35a484a1-c6ba-4115-8de0-36f03b90674e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:759285b5-c9ba-43b1-bb6f-3623698ec550"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:2d9ec344-c5cd-4790-b05f-a5de8c9e7f8e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0000775 PMID:41385096 "[{""id"":""uuid:27b500d4-69ee-411f-8075-12bba5840d2e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aa179d38-2968-4d02-bd8a-820804bcb825"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:f1aa4ae6-5eae-47c7-8271-6fba2572c5ca biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0003085 PMID:41385096 "[{""id"":""uuid:6f82ad35-4776-4ce7-9f16-6278d3410d26"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:68deec48-c1c2-4e5a-a411-faed2c661999"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:f50d0a15-0fe1-4868-bf50-99fd20595e0b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0001034 PMID:41385096 "[{""id"":""uuid:624066ad-9492-4bac-9573-02cbac2b68af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c50c20f8-9d53-4532-96af-cd213c26e227"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:f6983ca8-a2a0-4935-bd16-c52454d7b1f8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0005883 PMID:41385096 "[{""id"":""uuid:ed36d193-8b2c-4751-a58f-66f786dc2851"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0ea63cf0-5d0d-4e37-a719-f1e274f9379b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:5b04ea10-0652-4312-b636-28dedb5b10ec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0006814 PMID:41385096 "[{""id"":""uuid:5746703c-4cc3-42d0-bc10-45360e69ab3f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9f216b4f-b792-4b70-badf-a7426e79a49e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:19e12743-0b8f-4d3b-8613-f371d533e1e3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0004773 PMID:41385096 "[{""id"":""uuid:0865b105-b160-4e76-b028-5f0c4891a0a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:884ff52f-b787-48d1-88da-4cc12016387e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:a94aee1e-6b6b-4227-ab35-cdf8aac0d9d7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0004674 PMID:41385096 "[{""id"":""uuid:a17ef8ce-f220-4a26-b556-29f0933ed441"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f710c630-e58c-4844-a1ce-d2e165cc2bab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:eff81b5f-becc-40d0-a079-78ef216e17d8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0006651 PMID:41385096 "[{""id"":""uuid:dfc86470-64f0-4ff0-9e2c-94c482db9168"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b8e44434-ace2-4267-aa38-99d4e910a984"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:bffea5c7-67b0-4743-9dbe-e587bb397329 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0006918 PMID:41385096 "[{""id"":""uuid:97b5d843-3c53-44d3-bca5-96e3ae148c41"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:556e6752-b3fc-41a8-8722-9462bf3be16a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:7ea02ab0-6d29-47dc-ae9e-91ea6ca9c37b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0001280 PMID:41385096 "[{""id"":""uuid:8e57df61-10f6-4e17-b1d9-6acfc99ec9fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4cc9af13-c8ef-4ac4-b5b1-533b06979d17"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:3b08ea66-694c-4a77-90ec-2963884e0f78 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0005885 PMID:41385096 "[{""id"":""uuid:c05331f1-571b-4a8f-9f60-39a4cddaa68b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:02b89145-5984-4643-9a05-756641c4fea4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:cc9249eb-7350-4397-bd7d-f21dc4514438 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0019198 PMID:41385096 "[{""id"":""uuid:443e3dcb-a3fc-4fab-8049-8b071c377bb5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:79cf334b-fb8f-41fc-9c14-f42b3d53f884"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:12d53666-3d72-4435-b702-31c927e44e5c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0019338 PMID:41385096 "[{""id"":""uuid:917fb639-ebb7-4e22-a5de-c465ed70822d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4868f22e-89a4-4bd7-ae9c-d44278eb051e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:6078d3be-d06e-403c-95e9-d0823e756467 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0015274 PMID:41385096 "[{""id"":""uuid:dbb51234-ce90-4731-890c-bb3c8c0abcfd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a994d1f0-92f4-49c9-90f9-b8e48049c6e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:dddb9e88-beee-478d-b250-f96d399de2a6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0006052 PMID:41385096 "[{""id"":""uuid:9d4beb24-478b-45f0-b6a6-a208e502ae95"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:14577cd4-b845-48c5-a671-b929e12d2b80"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:65facd1b-ebbf-49b8-bc3b-81468fad90f1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0005848 PMID:41385096 "[{""id"":""uuid:14097d49-932f-46eb-9a74-47ecf64967ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f1e57e26-33c6-41c9-97a1-89e06c0c8d96"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:307e9c0f-ea70-44ab-9efc-316073e0a00d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0002572 PMID:41385096 "[{""id"":""uuid:0fe16261-ce74-447a-b01b-cc65961c9e53"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0dc4d8cd-dd75-4d30-a50e-ecfaf453acc5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:0d4a41ce-1e9e-4463-9020-faa186ccde2b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0019098 PMID:41385096 "[{""id"":""uuid:2caa5d25-fa33-488a-afa7-c60556c5df7b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:09f69a98-d27b-40a4-bf21-4b21c56f6754"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:506e2092-88a5-40d5-aac1-baf7e67ee886 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0001198 PMID:41385096 "[{""id"":""uuid:80c9f231-8595-49a4-b218-610a9a075194"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:793e36de-4463-4e45-ab64-5f101b0ee802"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:d04661a8-c7bd-43fa-99e5-2cb2d0b89a33 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats UMLS:C0002879 PMID:41385096 "[{""id"":""uuid:5124cec4-590e-44b2-a47f-9bd824dc4d23"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5f31b9d9-5dd6-44b8-bf6e-6309d0d2e894"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:991a63a5-fd07-49b6-bac5-060b554f1bda biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0020108 PMID:41385096 "[{""id"":""uuid:a0b537bd-9ca0-4231-a3a2-2830f155c15a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fad34839-f6f3-4fea-90cf-ffadc508356a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:38cc2cee-f6de-453d-ad76-bed619d455c6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0002280 PMID:41385096 "[{""id"":""uuid:638b3b1e-93be-4ad0-b616-00c7a5d56532"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3e04cc01-29f9-4414-aab6-ec4423aab26e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:17fd4609-e312-46cf-8c09-758103e7e5ec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0015253 PMID:41385096 "[{""id"":""uuid:1c90eedf-6355-4ec0-b086-999ac3807fac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b0db4281-c0ff-411e-a019-7790eea5d10a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:342c81a0-eec2-4e99-9436-3245f486e8e9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats HP:0001908 PMID:41385096 "[{""id"":""uuid:ec9fd2a7-325e-4651-8285-8c6447d48a70"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6079ab2f-a1aa-4506-81c7-8be01799942c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:a24dfcf8-9a6a-4143-93f2-df09e6e59db9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0005059 PMID:41385096 "[{""id"":""uuid:2f572220-5f92-4333-8b4e-a4999ff25609"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e408437e-8937-423e-9a3a-1dc89f9daea6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:12f9fb2a-0fa2-4bbd-ab31-32a977de15e4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0004095 PMID:41385096 "[{""id"":""uuid:0e416133-872b-4d50-a8db-d211a342f899"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1125b0c1-4e48-416f-b0e5-3c7d5af13ff4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:9d1cec66-835c-477b-ac2b-8fb578e6cad4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0004355 PMID:41385096 "[{""id"":""uuid:f06256d5-238d-4416-a771-7d81b0fdf227"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0c96cb3b-781a-4dcd-b8aa-c0c4a1456a5c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:7a01524b-b5a1-4d88-87c0-a8fa2d21cbb0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0005377 PMID:41385096 "[{""id"":""uuid:e2eeb39f-99cc-44cc-af3e-6111ac0d8c7f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6f0bfbd6-07bf-4cbf-8ae0-e94c130f5d63"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:793bd7b3-19ed-41bf-b938-ca70fe32cf0b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0007008 PMID:41385096 "[{""id"":""uuid:0c3539e0-1f7b-4400-bdaf-d5c073060986"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:48f86c45-283a-402d-a801-a9e40fc68495"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:59112d7b-08ae-4988-aaee-c8fab3e93779 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0005101 PMID:41385096 "[{""id"":""uuid:58578d68-4a1d-4883-9ba4-dff1a52fcf9c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d53fa2a3-2bd1-464f-bb63-e7a9646a8ead"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:27e8f568-cfec-4fdc-ae58-2e3d3436a71b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats UMLS:C0678202 PMID:41385096 "[{""id"":""uuid:9a30dcf3-3a42-42ff-a1d1-65827148c5d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dc8ed5f3-c5bf-4258-95ee-33d1cec50957"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:51db9fa5-d41e-4997-8dfd-70a9299a3d3b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0006042 PMID:41385096 "[{""id"":""uuid:0ea0ddf1-f0b8-4f18-b180-6db5fa88f3f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5acc2865-78d3-4167-a345-8c1dc8187b96"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:7d8bfbc7-fc63-42ad-9409-9b871295473a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0019444 PMID:41385096 "[{""id"":""uuid:7ca631a9-0376-4be2-8a40-ba01703be56a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b275bdba-e4b2-41d7-aacb-c6da52e9475d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:3cc8f7b0-fb0c-424f-918b-d314b55096d4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:39867 biolink:treats MONDO:0004985 PMID:41385096 "[{""id"":""uuid:47f1a238-4f1e-4f05-92b4-19572539d9f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b78daaa1-009f-4707-90d3-2ffc74a75016"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Divalproex sodium is indicated for the treatment of the manic episodes associated with bipolar disorder. A manic episode is a distinct period of abnormally and persistently elevated, expansive, or irritable mood. Typical symptoms of mania include pressure of speech, motor hyperactivity, reduced need for sleep, flight of ideas, grandiosity, poor judgement, aggressiveness, and possible hostility. The efficacy of divalproex sodium was established in 3 week trials with patients meeting DSM-III-R criteria for bipolar disorder who were hospitalized for acute mania (See Clinical Trials under CLINICAL PHARMACOLOGY ). The safety and effectiveness of divalproex sodium for long-term use in mania, i.e., more than 3 weeks, has not been systematically evaluated in controlled clinical trials. Therefore, physicians who elect to use divalproex sodium for extended periods should continually reevaluate the long-term usefulness of the drug for the individual patient. uuid:9026a60c-4513-4add-bb41-103439ed944f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:39867 biolink:treats UMLS:C0235165 PMID:41385096 "[{""id"":""uuid:97bf72ac-7448-4a06-856b-e465f6b78663"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:537a3554-f27d-4882-a1b7-80bef7586d0b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Divalproex sodium is indicated for the treatment of the manic episodes associated with bipolar disorder. A manic episode is a distinct period of abnormally and persistently elevated, expansive, or irritable mood. Typical symptoms of mania include pressure of speech, motor hyperactivity, reduced need for sleep, flight of ideas, grandiosity, poor judgement, aggressiveness, and possible hostility. The efficacy of divalproex sodium was established in 3 week trials with patients meeting DSM-III-R criteria for bipolar disorder who were hospitalized for acute mania (See Clinical Trials under CLINICAL PHARMACOLOGY ). The safety and effectiveness of divalproex sodium for long-term use in mania, i.e., more than 3 weeks, has not been systematically evaluated in controlled clinical trials. Therefore, physicians who elect to use divalproex sodium for extended periods should continually reevaluate the long-term usefulness of the drug for the individual patient. uuid:37a938fc-5644-4846-b685-f7aa9894ca11 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2676 biolink:treats MONDO:0001039 PMID:41385096 "[{""id"":""uuid:ed770597-869b-42d7-ba84-9a0e0810012a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a854a922-70db-4e9a-820f-423aa5516340"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MOXATAG is a penicillin-class antibacterial indicated for the treatment of tonsillitis and/or pharyngitis secondary to Streptococcus pyogenes in adults and pediatric patients 12 years or older. ( 1 ) uuid:b334ac8d-d6b7-4fbe-9b31-e299d85311a8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3032 biolink:treats HP:0012735 PMID:41385096 "[{""id"":""uuid:484cfdcc-b74a-453b-b78b-71effd8f1c28"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a47975bb-b8b3-4e5d-8572-cd951bfe83ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Benzonatate capsules, USP are indicated for the symptomatic relief of cough. uuid:b1830108-d29c-4cb0-8472-18a407221564 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:XM33Q67UVH biolink:treats UMLS:C1306762 PMID:41385096 "[{""id"":""uuid:f3daadf9-5ce1-43d3-a565-da5ea8f2c7bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bad6f1b0-de78-47e5-ac25-4330dab11152"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VASOVIST is indicated for use as a contrast agent in magnetic resonance angiography (MRA) to evaluate aortoiliac occlusive disease (AIOD) in adults with known or suspected peripheral vascular disease [ see Clinical Studies (14) ] . uuid:e3dc29d4-c700-4e32-81cf-189ed41e96d9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:XM33Q67UVH biolink:treats MONDO:0005294 PMID:41385096 "[{""id"":""uuid:6a5d4298-1073-4937-a474-2133ec97b538"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:140b41e9-3bc6-4987-b3ff-f4b6b6c3d378"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VASOVIST is indicated for use as a contrast agent in magnetic resonance angiography (MRA) to evaluate aortoiliac occlusive disease (AIOD) in adults with known or suspected peripheral vascular disease [ see Clinical Studies (14) ] . uuid:791b08b8-a758-470b-a14d-d48dbc4ee672 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0007008 PMID:41385096 "[{""id"":""uuid:2a7697d9-8216-4715-b117-8647d6c166ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ba5bcd59-f317-4371-b320-365312e55bbd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prednisone tablets are indicated in the following conditions: Endocrine disorders: primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. Rheumatic disorders: as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy), ankylosing spondylitis, acute and subacute bursitis, acute nonspecific tenosynovitis, acute gouty arthritis, post-traumatic osteoarthritis, synovitis of osteoarthritis, epicondylitis. Collagen diseases: during an exacerbation or as maintenance therapy in selected cases of: systemic lupus erythematosus, systemic dermatomyositis (polymyositis), acute rheumatic carditis. Dermatologic diseases: pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative dermatitis; mycosis fungoides; severe psoriasis; severe seborrheic dermatitis. Allergic states: control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: seasonal or perennial allergic rhinitis; bronchial asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. Ophthalmic diseases: severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: allergic corneal marginal ulcers, herpes zoster ophthalmicus, anterior segment inflammation, diffuse posterior uveitis and choroiditis, sympathetic ophthalmia, allergic conjunctivitis, keratitis, chorioretinitis, optic neuritis, iritis and iridocyclitis. Respiratory diseases: symptomatic sarcoidosis; Loeffler’s syndrome not manageable by other means; berylliosis; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; aspiration pneumonitis. Hematologic disorders: idiopathic thrombocytopenic purpura in adults; secondary thrombocytopenia in adults; acquired (autoimmune) hemolytic anemia; erythroblastopenia (RBC anemia); congenital (erythroid) hypoplastic anemia. Neoplastic diseases: for palliative management of: leukemias and lymphomas in adults, acute leukemia of childhood. Edematous states: to induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. Gastrointestinal diseases: to tide the patient over a critical period of the disease in: ulcerative colitis, regional enteritis. Nervous system: acute exacerbations of multiple sclerosis. Miscellaneous: tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy; trichinosis with neurologic or myocardial involvement. uuid:89e69201-a611-487d-b467-38ca34ead5ce biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1162674 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:c8e5c725-4025-4508-9fc3-4fbba19f75ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:38ab9935-4f21-44e0-990b-a96bac665118"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fosinopril sodium and hydrochlorothiazide tablets are indicated for the treatment of hypertension. These fixed dose combinations are not indicated for initial therapy. (See DOSAGE AND ADMINISTRATION .) In using fosinopril sodium-hydrochlorothiazide tablets, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that fosinopril does not have a similar risk (see WARNINGS: Neutropenia/Agranulocytosis ). ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients (see WARNINGS: Head and Neck Angioedema and Intestinal Angiodema .) uuid:53343b94-d69f-4515-bcec-35dc6d240cae biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1162674 biolink:treats MONDO:0001609 PMID:41385096 "[{""id"":""uuid:c4b67982-69d1-410f-af22-cfc479bcfda4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:76153f35-1f45-44a4-aa80-70adf6f2424c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fosinopril sodium and hydrochlorothiazide tablets are indicated for the treatment of hypertension. These fixed dose combinations are not indicated for initial therapy. (See DOSAGE AND ADMINISTRATION .) In using fosinopril sodium-hydrochlorothiazide tablets, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that fosinopril does not have a similar risk (see WARNINGS: Neutropenia/Agranulocytosis ). ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients (see WARNINGS: Head and Neck Angioedema and Intestinal Angiodema .) uuid:f9897424-4ba2-4dae-b8a0-05ba0c71b6c8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1162674 biolink:treats MONDO:0001343 PMID:41385096 "[{""id"":""uuid:8945e9bf-3358-49c1-ba30-c35961700530"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c087221a-e5b1-4fd4-88d6-a48e312268bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fosinopril sodium and hydrochlorothiazide tablets are indicated for the treatment of hypertension. These fixed dose combinations are not indicated for initial therapy. (See DOSAGE AND ADMINISTRATION .) In using fosinopril sodium-hydrochlorothiazide tablets, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that fosinopril does not have a similar risk (see WARNINGS: Neutropenia/Agranulocytosis ). ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients (see WARNINGS: Head and Neck Angioedema and Intestinal Angiodema .) uuid:53dfb751-5e7e-4060-89da-6204eea8c1d7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1162674 biolink:treats MONDO:0010481 PMID:41385096 "[{""id"":""uuid:284e91a8-477c-403e-b46c-6039cef08c63"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4e80c54c-6278-4e7a-b609-9400044967ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fosinopril sodium and hydrochlorothiazide tablets are indicated for the treatment of hypertension. These fixed dose combinations are not indicated for initial therapy. (See DOSAGE AND ADMINISTRATION .) In using fosinopril sodium-hydrochlorothiazide tablets, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that fosinopril does not have a similar risk (see WARNINGS: Neutropenia/Agranulocytosis ). ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients (see WARNINGS: Head and Neck Angioedema and Intestinal Angiodema .) uuid:63619aa4-6310-4616-8715-bd8fb63e46ed biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59750 biolink:treats MONDO:0005093 PMID:41385096 "[{""id"":""uuid:6bc150f2-52be-41ea-9341-5bd61e6489cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8431840b-77e5-4174-9117-e844beeb55e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] psorcon (diflorasone diacetate cream), 0.05% is a high potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. uuid:cbd7b851-9872-4311-b655-399bf5febb32 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17823 biolink:treats HP:0002901 PMID:41385096 "[{""id"":""uuid:479e92bb-42e3-4f67-bdc7-428398adbf3c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:09b8ff36-743f-43ec-83ec-aeed6649e3ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Calcitriol Injection is indicated in the management of hypocalcemia in patients undergoing chronic renal dialysis. It has been shown to significantly reduce elevated parathyroid hormone levels. Reduction of PTH has been shown to result in an improvement in renal osteodystrophy. uuid:9776cd53-2b6a-4cb2-861b-cd7674c5d411 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17823 biolink:treats MONDO:0006946 PMID:41385096 "[{""id"":""uuid:9e421dfb-49ef-41ab-910e-2afaffa33336"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3dd37912-d415-4b55-bf2d-6b061623b2b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Calcitriol Injection is indicated in the management of hypocalcemia in patients undergoing chronic renal dialysis. It has been shown to significantly reduce elevated parathyroid hormone levels. Reduction of PTH has been shown to result in an improvement in renal osteodystrophy. uuid:e4b0347b-0f35-41a3-803f-9462b3b2c001 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49713 biolink:treats MONDO:0004985 PMID:41385096 "[{""id"":""uuid:2872aef1-d604-4cc9-9cbd-314244277022"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5b545ac3-58ca-4cfe-9ecd-ff87d52ee5de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lithium is indicated in the treatment of manic episodes of Bipolar Disorder. Bipolar Disorder, Manic (DSM-III) is equivalent to Manic Depressive illness, Manic, in the older DSM-II terminology. Lithium is also indicated as a maintenance treatment for individuals with a diagnosis of Bipolar Disorder. Maintenance therapy reduces the frequency of manic episodes and diminishes the intensity of those episodes which may occur. Typical symptoms of mania include pressure of speech, motor hyperactivity, reduced need for sleep, flight of ideas, grandiosity, elation, poor judgment, aggressiveness, and possibly hostility. When given to a patient experiencing a manic episode, lithium may produce a normalization of symptomatology within 1 to 3 weeks. uuid:7c76cc8f-237f-474d-93d5-32d6f0e57873 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63599 biolink:treats MONDO:0004948 PMID:41385096 "[{""id"":""uuid:be4cb5f4-3e13-47f3-85df-505666071b47"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:bab5deaa-c429-4044-badb-33da4c462312"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:1d9e1d8e-8519-44fb-b10d-50eebf59fad1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fludarabine phosphate is indicated as a single agent for the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) whose disease has not responded to or has progressed during or after treatment with at least one standard alkylating-agent containing regimen. Studies demonstrating clinical benefit such as prolongation of survival or relief of symptoms have not been performed. Studies providing a direct comparison of the clinical efficacy and safety of orally administered fludarabine phosphate relative to intravenously administered fludarabine phosphate have not been performed.|[PMDA] A drug with a new additional indication for the treatment of chronic lymphocytic leukemia with anemia or thrombocytopenia. uuid:576c795d-5045-4ade-958e-b9b0540bed33 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63599 biolink:treats UMLS:C0861880 PMID:41385096 "[{""id"":""uuid:ed4c9949-8e2f-42e5-8a23-1b2ee81a11f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f4d22d8f-c605-4a1f-a076-5eb9f2aa267a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fludarabine phosphate is indicated as a single agent for the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) whose disease has not responded to or has progressed during or after treatment with at least one standard alkylating-agent containing regimen. Studies demonstrating clinical benefit such as prolongation of survival or relief of symptoms have not been performed. Studies providing a direct comparison of the clinical efficacy and safety of orally administered fludarabine phosphate relative to intravenously administered fludarabine phosphate have not been performed. uuid:280f8ff8-0a43-4282-a67a-2a5b76524c67 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7494 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:1f0d693c-1bc0-445c-9920-7e05280d6353"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5ad5b8c6-e0ea-4cc2-abea-4641fe1300f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nefazodone hydrochloride tablets, USP is indicated for the treatment of depression. When deciding among the alternative treatments available for this condition, the prescriber should consider the risk of hepatic failure associated with nefazodone hydrochloride tablets, USP treatment (see WARNINGS ). In many cases, this would lead to the conclusion that other drugs should be tried first. The efficacy of nefazodone in the treatment of depression was established in 6 to 8 week controlled trials of outpatients and in a 6-week controlled trial of depressed inpatients whose diagnoses corresponded most closely to the DSM-III or DSM-IIIR category of major depressive disorder (see CLINICAL PHARMACOLOGY ). A major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks). It must include either depressed mood or loss of interest or pleasure and at least five of the following nine symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. The efficacy of nefazodone in reducing relapse in patients with major depression who were judged to have had a satisfactory clinical response to 16 weeks of open-label nefazodone treatment for an acute depressive episode has been demonstrated in a randomized placebo-controlled trial (see CLINICAL PHARMACOLOGY ). Although remitted patients were followed for as long as 36 weeks in the study cited (i.e., 52 weeks total), the physician who elects to use nefazodone for extended periods should periodically reevaluate the long-term usefulness of the drug for the individual patient. uuid:f18f6836-64f7-4e92-82a7-179e311ed56b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2647566 biolink:treats MONDO:0005271 PMID:41385096 "[{""id"":""uuid:689890b1-0f2e-4885-9147-8ee644ce7f3e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:299cc904-1d9a-47d1-a5ea-2499a528fa89"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pseudodine™ C Cough Syrup is indicated for temporary relief of coughs and upper respiratory symptoms, including nasal congestion, associated with allergy or the common cold. uuid:37d68eb9-c27f-4399-ac54-8e0a2fa54b9c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2647566 biolink:treats MONDO:0005709 PMID:41385096 "[{""id"":""uuid:e4b177da-92b9-4d7c-89c0-71c7644bbfbb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:be36f200-1e30-4dd7-a159-bd42b68b7a34"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pseudodine™ C Cough Syrup is indicated for temporary relief of coughs and upper respiratory symptoms, including nasal congestion, associated with allergy or the common cold. uuid:ef1a360c-57bf-42ca-9573-cc5af9fae06e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7903 biolink:treats MONDO:0001741 PMID:41385096 "[{""id"":""uuid:cbfd81ae-9a6b-4bdb-a3ad-a87d00982229"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ca5bf04c-722d-4f47-8f81-af6076bab079"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pamidronate disodium in conjunction with adequate hydration, is indicated for the treatment of moderate or severe hypercalcemia associated with malignancy, with or without bone metastases. Patients who have either epidermoid or non-epidermoid tumors respond to treatment with pamidronate disodium. Vigorous saline hydration, an integral part of hypercalcemia therapy, should be initiated promptly and an attempt should be made to restore the urine output to about 2 L/day throughout treatment. Mild or asymptomatic hypercalcemia may be treated with conservative measures (i.e., saline hydration, with or without loop diuretics). Patients should be hydrated adequately throughout the treatment, but overhydration, especially in those patients who have cardiac failure, must be avoided. Diuretic therapy should not be employed prior to correction of hypovolemia. The safety and efficacy of pamidronate disodium in the treatment of hypercalcemia associated with hyperparathyroidism or with other non-tumor-related conditions has not been established. uuid:36e0b5b4-880a-46de-ba15-c23d4e8debca biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71415 biolink:treats MONDO:0005247 PMID:41385096 "[{""id"":""uuid:531f2d7e-aa00-49e4-a641-bdc0c1050e7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2b8c3431-25e8-4de8-ac01-06d90c932c4b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Macrobid is indicated only for the treatment of acute uncomplicated urinary tract infections (acute cystitis) caused by susceptible strains of Escherichia coli or Staphylococcus saprophyticus. Nitrofurantoin is not indicated for the treatment of pyelonephritis or perinephric abscesses. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Macrobid and other antibacterial drugs, Macrobid should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Nitrofurantoins lack the broader tissue distribution of other therapeutic agents approved for urinary tract infections. Consequently, many patients who are treated with Macrobid are predisposed to persistence or reappearance of bacteriuria. (See CLINICAL STUDIES .) Urine specimens for culture and susceptibility testing should be obtained before and after completion of therapy. If persistence or reappearance of bacteriuria occurs after treatment with Macrobid , other therapeutic agents with broader tissue distribution should be selected. In considering the use of Macrobid , lower eradication rates should be balanced against the increased potential for systemic toxicity and for the development of antimicrobial resistance when agents with broader tissue distribution are utilized. uuid:7fe55968-255a-48a6-b044-0785d24f9c28 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71415 biolink:treats MONDO:0001650 PMID:41385096 "[{""id"":""uuid:9dd95bad-b083-4925-9b84-855da5bb52e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:743df878-2d5e-4b50-847a-4fdacbe913f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Macrobid is indicated only for the treatment of acute uncomplicated urinary tract infections (acute cystitis) caused by susceptible strains of Escherichia coli or Staphylococcus saprophyticus. Nitrofurantoin is not indicated for the treatment of pyelonephritis or perinephric abscesses. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Macrobid and other antibacterial drugs, Macrobid should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Nitrofurantoins lack the broader tissue distribution of other therapeutic agents approved for urinary tract infections. Consequently, many patients who are treated with Macrobid are predisposed to persistence or reappearance of bacteriuria. (See CLINICAL STUDIES .) Urine specimens for culture and susceptibility testing should be obtained before and after completion of therapy. If persistence or reappearance of bacteriuria occurs after treatment with Macrobid , other therapeutic agents with broader tissue distribution should be selected. In considering the use of Macrobid , lower eradication rates should be balanced against the increased potential for systemic toxicity and for the development of antimicrobial resistance when agents with broader tissue distribution are utilized. uuid:665e58ff-414a-4c40-9e31-d70ae63b6624 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71415 biolink:treats MONDO:0006939 PMID:41385096 "[{""id"":""uuid:c9f7ed24-225a-495a-88ed-22637ca819a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:62d747e4-e0b0-4c47-bafc-096d42560240"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Macrobid is indicated only for the treatment of acute uncomplicated urinary tract infections (acute cystitis) caused by susceptible strains of Escherichia coli or Staphylococcus saprophyticus. Nitrofurantoin is not indicated for the treatment of pyelonephritis or perinephric abscesses. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Macrobid and other antibacterial drugs, Macrobid should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Nitrofurantoins lack the broader tissue distribution of other therapeutic agents approved for urinary tract infections. Consequently, many patients who are treated with Macrobid are predisposed to persistence or reappearance of bacteriuria. (See CLINICAL STUDIES .) Urine specimens for culture and susceptibility testing should be obtained before and after completion of therapy. If persistence or reappearance of bacteriuria occurs after treatment with Macrobid , other therapeutic agents with broader tissue distribution should be selected. In considering the use of Macrobid , lower eradication rates should be balanced against the increased potential for systemic toxicity and for the development of antimicrobial resistance when agents with broader tissue distribution are utilized. uuid:6b84d961-24b5-4092-a288-c8b4cfbf329f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71415 biolink:treats HP:0032619 PMID:41385096 "[{""id"":""uuid:42324fad-8515-44c9-9975-7e4949411272"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d7a546f7-66e7-458b-865e-0a121c549192"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Macrobid is indicated only for the treatment of acute uncomplicated urinary tract infections (acute cystitis) caused by susceptible strains of Escherichia coli or Staphylococcus saprophyticus. Nitrofurantoin is not indicated for the treatment of pyelonephritis or perinephric abscesses. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Macrobid and other antibacterial drugs, Macrobid should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Nitrofurantoins lack the broader tissue distribution of other therapeutic agents approved for urinary tract infections. Consequently, many patients who are treated with Macrobid are predisposed to persistence or reappearance of bacteriuria. (See CLINICAL STUDIES .) Urine specimens for culture and susceptibility testing should be obtained before and after completion of therapy. If persistence or reappearance of bacteriuria occurs after treatment with Macrobid , other therapeutic agents with broader tissue distribution should be selected. In considering the use of Macrobid , lower eradication rates should be balanced against the increased potential for systemic toxicity and for the development of antimicrobial resistance when agents with broader tissue distribution are utilized. uuid:276a87ab-6a52-4432-a45a-8178f76c9531 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71415 biolink:treats MONDO:0001882 PMID:41385096 "[{""id"":""uuid:dbf7bd78-4a69-40c4-8c4b-753591d81dde"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0e1dcb00-8a09-491f-8c91-7ed8568e785f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Macrobid is indicated only for the treatment of acute uncomplicated urinary tract infections (acute cystitis) caused by susceptible strains of Escherichia coli or Staphylococcus saprophyticus. Nitrofurantoin is not indicated for the treatment of pyelonephritis or perinephric abscesses. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Macrobid and other antibacterial drugs, Macrobid should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Nitrofurantoins lack the broader tissue distribution of other therapeutic agents approved for urinary tract infections. Consequently, many patients who are treated with Macrobid are predisposed to persistence or reappearance of bacteriuria. (See CLINICAL STUDIES .) Urine specimens for culture and susceptibility testing should be obtained before and after completion of therapy. If persistence or reappearance of bacteriuria occurs after treatment with Macrobid , other therapeutic agents with broader tissue distribution should be selected. In considering the use of Macrobid , lower eradication rates should be balanced against the increased potential for systemic toxicity and for the development of antimicrobial resistance when agents with broader tissue distribution are utilized. uuid:a80452a3-d1dc-4e4f-a067-27637e0fe845 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71415 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:317a609b-f7e2-44d7-9f6c-9327b26d4475"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:245794c2-495a-4d92-b17f-ce004616f72a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Macrodantin is specifically indicated for the treatment of urinary tract infections when due to susceptible strains of Escherichia coli, enterococci , Staphylococcus aureus , and certain susceptible strains of Klebsiella and Enterobacter species. Nitrofurantoin is not indicated for the treatment of pyelonephritis or perinephric abscesses. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Macrodantin and other antibacterial drugs, Macrodantin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Nitrofurantoins lack the broader tissue distribution of other therapeutic agents approved for urinary tract infections. Consequently, many patients who are treated with Macrodantin are predisposed to persistence or reappearance of bacteriuria. Urine specimens for culture and susceptibility testing should be obtained before and after completion of therapy. If persistence or reappearance of bacteriuria occurs after treatment with Macrodantin , other therapeutic agents with broader tissue distribution should be selected. In considering the use of Macrodantin , lower eradication rates should be balanced against the increased potential for systemic toxicity and for the development of antimicrobial resistance when agents with broader tissue distribution are utilized. uuid:dee995da-3fd4-48d2-8f88-90cdfabb1990 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32888 biolink:treats MONDO:0004525 PMID:41385096 "[{""id"":""uuid:2faf9442-6a51-4d69-9e6e-c01391edaf4b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4a6d79c4-5487-4d7a-95a6-9094c86059f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lindane Lotion is indicated for the treatment of scabies (infestations of Sarcoptes scabei ) only in patients who: cannot tolerate other approved therapies, or have failed treatment with other approved therapies. Lindane Lotion should be used in the context of an overall scabies management program that includes: Microscopic evaluation of skin scrapings to confirm the diagnosis. Evaluation and treatment of sexual contacts simultaneously. Sexual contacts should be prescribed Lindane Lotion only if they either have failed to respond to adequate doses of other approved therapies or are intolerant of other approved therapies. Washing of all recently worn clothing, underwear, pajamas, used sheets, pillowcases, and towels in very hot water or dry-cleaned. Caregivers applying this product to patients should wear gloves less permeable to Lindane, such as nitrile, latex with neoprene, or sheer vinyl, and thoroughly clean hands after application. Natural latex gloves should be avoided because they are more permeable to Lindane. Lindane Lotion does not prevent infestation or reinfestation and should not be used to ward off a possible infestation. uuid:7d821906-c045-4213-b7b0-97e97f10fb99 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32888 biolink:treats MONDO:0003471 PMID:41385096 "[{""id"":""uuid:1dfe6789-342f-4e72-83de-1b70a2455bae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:51ab59b4-09ad-424d-b7a8-3069359712e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Lindane Shampoo is indicated for the treatment of head lice (infestations of Pediculosis humanis capitis ), crab lice (infestations of Pthirus pubis ), and their ova only in patients who cannot tolerate other approved therapies, or have failed treatment with other approved therapies. Lindane Shampoo should be used in the context of an overall lice management program that includes: Visual inspection to ensure that the patient is currently infested with live lice (empty egg casings or ""nits"" can remain on hair shaft long after true infestation). Manual removal of nits using a comb designed for this purpose and/or individual removal with tweezers followed by close examination of the hair and scalp. Evaluation and treatment of sexual contacts simultaneously. Sexual contacts should be prescribed Lindane Shampoo only if they either have failed to respond to adequate doses of other approved therapies or are intolerant of other approved therapies. All recently worn clothing, underwear, pajamas, used sheets, pillowcases, and towels should be washed in very hot water or dry-cleaned. Caregivers applying this product to patients should wear gloves less permeable to Lindane such as nitrile, latex with neoprene or sheer vinyl, and thoroughly clean hands after application. Natural latex gloves should be avoided because they are more permeable to Lindane. Lindane Shampoo does not prevent infestation or reinfestation and should not be used to ward off a possible infestation." uuid:140a0800-20a2-45af-aa75-7d5e2b659874 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32888 biolink:treats MONDO:0001794 PMID:41385096 "[{""id"":""uuid:d2e04b21-090c-4786-bc3f-7a232f8d4638"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ba06b4e4-ceeb-4c2c-af4c-4059905ad432"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Lindane Shampoo is indicated for the treatment of head lice (infestations of Pediculosis humanis capitis ), crab lice (infestations of Pthirus pubis ), and their ova only in patients who cannot tolerate other approved therapies, or have failed treatment with other approved therapies. Lindane Shampoo should be used in the context of an overall lice management program that includes: Visual inspection to ensure that the patient is currently infested with live lice (empty egg casings or ""nits"" can remain on hair shaft long after true infestation). Manual removal of nits using a comb designed for this purpose and/or individual removal with tweezers followed by close examination of the hair and scalp. Evaluation and treatment of sexual contacts simultaneously. Sexual contacts should be prescribed Lindane Shampoo only if they either have failed to respond to adequate doses of other approved therapies or are intolerant of other approved therapies. All recently worn clothing, underwear, pajamas, used sheets, pillowcases, and towels should be washed in very hot water or dry-cleaned. Caregivers applying this product to patients should wear gloves less permeable to Lindane such as nitrile, latex with neoprene or sheer vinyl, and thoroughly clean hands after application. Natural latex gloves should be avoided because they are more permeable to Lindane. Lindane Shampoo does not prevent infestation or reinfestation and should not be used to ward off a possible infestation." uuid:02a6f365-9d75-48b0-bd83-035e70c1bfb8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3614 biolink:treats MONDO:0002508 PMID:41385096 "[{""id"":""uuid:b7ae51c3-9bfa-43ae-bd94-ae214254046c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0b8fbc5a-6a62-440e-a1f7-5d3525674ea0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Chlorhexidine Gluconate Oral Rinse is indicated for use between dental visits as part of a professional program for the treatment of gingivitis as characterized by redness and swelling of the gingivae, including gingival bleeding upon probing. Chlorhexidine gluconate has not been tested among patients with acute necrotizing ulcerative gingivitis (ANUG). For patients having coexisting gingivitis and periodontitis, see PRECAUTIONS . uuid:a76a6d8f-c742-463c-bec2-80d27853ab73 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3614 biolink:treats MONDO:0006865 PMID:41385096 "[{""id"":""uuid:b31cd758-885e-484b-aaf0-d8169539f69f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:67bc6ac5-6ed2-4117-8845-5d64e3d5ec66"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Chlorhexidine Gluconate Oral Rinse is indicated for use between dental visits as part of a professional program for the treatment of gingivitis as characterized by redness and swelling of the gingivae, including gingival bleeding upon probing. Chlorhexidine gluconate has not been tested among patients with acute necrotizing ulcerative gingivitis (ANUG). For patients having coexisting gingivitis and periodontitis, see PRECAUTIONS . uuid:429b598a-22d6-4cd7-8608-c2593f312608 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1156197 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:3913aa11-2c34-436e-b5b4-61c03f2c041e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:34fdf007-c70c-43c0-b424-90251878e92c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Glyburide and Metformin Hydrochloride Tablets is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. uuid:dc003ae5-f369-4508-a48a-9a885e25804f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0015129 PMID:41385096 "[{""id"":""uuid:9228f173-8dcf-451e-b492-0d0ecb3cd3f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5a2f7df6-84f1-4e63-b954-8f4204184002"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer uuid:b309df4a-c49b-4bcd-a584-945d2ea38913 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0043370 PMID:41385096 "[{""id"":""uuid:fb495bae-3f02-4a4f-a2a6-941cb902596e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0889cbf5-8ffd-46bd-a106-416f5d047670"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer uuid:31b050b4-2ca9-42d0-86c4-fcfa55efb1cb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0018479 PMID:41385096 "[{""id"":""uuid:410f7081-3441-499c-bde6-d6c6f3614735"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f9b5de7e-83be-48a3-a44f-30c949aed909"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer uuid:42d539e6-8a5e-4fc0-b6cd-5225f9e5246a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0006982 PMID:41385096 "[{""id"":""uuid:84f6c5fa-e10d-4234-8f9b-3abe846ba6a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:68ae06d9-7c87-4274-ac91-8c6e03260eda"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer uuid:ffcd9eaf-18b5-47c0-9be6-a5f0e9fef9c7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0043455 PMID:41385096 "[{""id"":""uuid:fed7b923-6716-4b5e-9f74-80fe4f416dc6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2e1a0999-5db8-458a-ab41-6df7eff7fe8e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer uuid:8eea0ca4-4015-4ac2-b30b-ce036aa150cc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:144093 biolink:treats MONDO:0004956 PMID:41385096 "[{""id"":""uuid:944b9a43-9116-4df9-b679-4408a5c7256e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1db812e2-26e2-4db5-8d92-49ce172a2838"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bicalutamide Tablets, USP 50 mg daily are indicated for use in combination therapy with a luteinizing hormone-releasing hormone (LHRH) analog for the treatment of Stage D 2 metastatic carcinoma of the prostate. Bicalutamide Tablets, USP 150 mg daily are not approved for use alone or with other treatments [see Clinical Studies (14.2) ]. uuid:080e1dcd-f0ad-411a-b7a5-5301b40b5c4d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB10385 biolink:treats MONDO:0005324 PMID:41385096 "[{""id"":""uuid:b5548bd4-d6e7-412d-97bc-b3951b10173a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:315b96eb-7677-4bba-a4a0-c31204d7d666"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Allergenic extract is indicated for diagnostic testing and treatment (immunotherapy) of patients whose histories indicate allergic symptoms upon natural exposure to short ragweed pollen. Confirmation is determined by skin testing. uuid:e82101dd-8852-40a0-9eeb-a9345511b67a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB10499 biolink:treats MONDO:0005271 PMID:41385096 "[{""id"":""uuid:a05aa184-d146-4663-bce8-90f445457f98"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3e695bd5-1011-425d-9692-97bf2ff9d462"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Allergenic extract is indicated for diagnostic testing and for the treatment (immunotherapy) of patients whose histories indicate that upon natural exposure to cat allergen, they experience allergic symptoms. Confirmation is determined by skin testing. An orderly approach to the diagnostic use of allergenic extracts usually begins with direct skin testing. uuid:fc5f7627-e8ee-4252-a405-662be0708594 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB10499 biolink:treats UMLS:C0339805 PMID:41385096 "[{""id"":""uuid:9fb001f5-d917-4653-8dbd-460ef4bc36dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b812bb1f-f4ea-4c15-bd2b-883e94e7558b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Allergenic extract is indicated for diagnostic testing and for the treatment (immunotherapy) of patients whose histories indicate that upon natural exposure to cat allergen, they experience allergic symptoms. Confirmation is determined by skin testing. An orderly approach to the diagnostic use of allergenic extracts usually begins with direct skin testing. uuid:64303da9-fcee-4ba2-973b-c77b87665693 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15367 biolink:treats MONDO:0011438 PMID:41385096 "[{""id"":""uuid:d92bf0c8-bf9b-48f0-ada4-c73817b21870"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ecb2e536-98b5-4766-bd7a-c6f38fd6cea9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tretinoin gel and cream are indicated for topical application in the treatment of acne vulgaris. The safety and efficacy of the long-term use of this product in the treatment of other disorders have not been established. uuid:bc08b7af-99e4-4b9e-b756-c54909667678 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7577 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:800fa722-2807-4164-9046-49f7654bc64b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:68a0d2e5-1830-4dd2-be81-4c4e5ad5b28c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nisoldipine is indicated for the treatment of hypertension. It maybe used alone or in combination with other antihypertensive agents. uuid:01b04d23-88c8-444d-a6a1-cf8ab5e6c7f1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6761 biolink:treats MONDO:0005618 PMID:41385096 "[{""id"":""uuid:2169d1d9-90e9-456a-980b-dc9d4e9cf3b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:43c6ee82-a63c-4832-b523-589b3c73641e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Meprobamate tablets are indicated for the management of anxietydisorders or for the short-term relief of the symptoms of anxiety.Anxiety or tension associated with the stress of everyday life usuallydo not require treatment with an anxiolytic. The effectiveness of meprobamate tablets in long-term use, that is,more than 4 months, has not been assessed by systematic clinicalstudies. The physician should periodically reassess the usefulness ofthe drug for the individual patient. uuid:7802175f-698a-4426-95de-dc7999299a3a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6761 biolink:treats MONDO:0011918 PMID:41385096 "[{""id"":""uuid:6b9ac0f9-964f-45e7-a80f-894f21821d25"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:276153f9-7113-47cc-b269-28ea9a4c26ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Meprobamate tablets are indicated for the management of anxietydisorders or for the short-term relief of the symptoms of anxiety.Anxiety or tension associated with the stress of everyday life usuallydo not require treatment with an anxiolytic. The effectiveness of meprobamate tablets in long-term use, that is,more than 4 months, has not been assessed by systematic clinicalstudies. The physician should periodically reassess the usefulness ofthe drug for the individual patient. uuid:3cb94a2f-9648-4d62-ad85-a71268daa120 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:585948 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:ca765a0c-9ccd-4d0e-94b3-7afa9c00f2c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:83469233-ad22-4621-a54d-11b7cf3e4573"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Felodipine extended-release tablets are indicated for the treatment of hypertension. Felodipine extended-release tablets may be used alone or concomitantly with other antihypertensive agents. uuid:0bef1e83-29e8-470a-be8a-9a4ce54c655b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB10394 biolink:treats UMLS:C1387134 PMID:41385096 "[{""id"":""uuid:eb637ba9-73bf-4c2c-bf2c-52781a5b7014"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9bc113ab-e826-4396-bba1-4a4d1f20ef45"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Allergenic extract is indicated for diagnostic testing and treatment (immunotherapy) of patients whose histories indicate allergic symptoms upon natural exposure to grass allergens. Confirmation is determined by skin testing. 10,000 BAU/ml extracts are intended for percutaneous testing. If negative, 100,000 BAU/ml products can be used for percutaneous test. Dilutions made from 10,000 BAU/ml products are indicated for immunotherapy of previously untreated patients. If 10,000 BAU/ml product is tolerated and symptoms persist, dilutions made from 100,000 BAU/ml can be administered. Standardized Grass Pollen extracts labeled in Bioequivalent Allergy Units (BAU/ml) are not interchangeable with grass pollen extracts labeled In Allergy Units (AU/ml) or with non-standardized grass pollen extracts. uuid:052e98f2-4ad3-455a-91dd-5a73a3a3ba56 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB10394 biolink:treats MONDO:0005271 PMID:41385096 "[{""id"":""uuid:43662b41-e642-45c1-9a4c-9d59002ef748"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aeb19d62-48ac-4d21-8d88-7d3ce0e038d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Allergenic extract is indicated for diagnostic testing and treatment (immunotherapy) of patients whose histories indicate allergic symptoms upon natural exposure to grass allergens. Confirmation is determined by skin testing. 10,000 BAU/ml extracts are intended for percutaneous testing. If negative, 100,000 BAU/ml products can be used for percutaneous test. Dilutions made from 10,000 BAU/ml products are indicated for immunotherapy of previously untreated patients. If 10,000 BAU/ml product is tolerated and symptoms persist, dilutions made from 100,000 BAU/ml can be administered. Standardized Grass Pollen extracts labeled in Bioequivalent Allergy Units (BAU/ml) are not interchangeable with grass pollen extracts labeled In Allergy Units (AU/ml) or with non-standardized grass pollen extracts. uuid:421c8dee-c7b8-4261-a085-349388481625 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:54955 biolink:treats MONDO:0003799 PMID:41385096 "[{""id"":""uuid:b67d171b-e099-471b-98b0-54735cf2b984"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5ec81c41-627e-4e16-9587-f727c0d6b441"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bacitracin Zinc and Polymyxin B Sulfate Ophthalmic Ointment is indicated for the topical treatment of superficial infections of the external eye and its adnexa caused by susceptible bacteria. Such infections encompass conjunctivitis, keratitis and keratoconjunctivitis, blepharitis and blepharoconjunctivitis. uuid:a52e76a8-a8db-4c14-bc25-036ca02de167 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:54955 biolink:treats MONDO:0003085 PMID:41385096 "[{""id"":""uuid:7be5da93-9f85-41d0-ad18-b99d2595cbdb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:144e2c38-9289-447d-86a3-e0b992f29ec1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bacitracin Zinc and Polymyxin B Sulfate Ophthalmic Ointment is indicated for the topical treatment of superficial infections of the external eye and its adnexa caused by susceptible bacteria. Such infections encompass conjunctivitis, keratitis and keratoconjunctivitis, blepharitis and blepharoconjunctivitis. uuid:43a6ac2f-ec03-4960-883d-e66d428f1380 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:54955 biolink:treats MONDO:0004768 PMID:41385096 "[{""id"":""uuid:1d196385-2994-408b-acd9-ee84705ce0c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bbfcacc6-4cec-448f-99a4-7b4095ef9efc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bacitracin Zinc and Polymyxin B Sulfate Ophthalmic Ointment is indicated for the topical treatment of superficial infections of the external eye and its adnexa caused by susceptible bacteria. Such infections encompass conjunctivitis, keratitis and keratoconjunctivitis, blepharitis and blepharoconjunctivitis. uuid:aa42c888-bbe4-49f5-ab19-0fcfbf9b994e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:54955 biolink:treats MONDO:0004785 PMID:41385096 "[{""id"":""uuid:54915545-087e-4fed-bec1-96da4bba98bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8398fd67-54a3-4050-9ff4-6935853c1c04"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bacitracin Zinc and Polymyxin B Sulfate Ophthalmic Ointment is indicated for the topical treatment of superficial infections of the external eye and its adnexa caused by susceptible bacteria. Such infections encompass conjunctivitis, keratitis and keratoconjunctivitis, blepharitis and blepharoconjunctivitis. uuid:a960ca8f-1ccc-4386-825b-5c0858087b63 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:54955 biolink:treats MONDO:0002307 PMID:41385096 "[{""id"":""uuid:c2dd2721-0036-4b4b-b880-d48572726bdd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2a9abfb2-cc88-4bab-a98d-43fe55a9018e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bacitracin Zinc and Polymyxin B Sulfate Ophthalmic Ointment is indicated for the topical treatment of superficial infections of the external eye and its adnexa caused by susceptible bacteria. Such infections encompass conjunctivitis, keratitis and keratoconjunctivitis, blepharitis and blepharoconjunctivitis. uuid:f70bd59f-b4bf-4541-b053-9603564885de biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3757 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:d4f69160-e33c-49e9-b543-05c1e67c17a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e0c47b66-c7f0-4aab-94f7-48dc4cfb1fd5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clonidine hydrochloride is indicated in the treatment of hypertension. Clonidine hydrochloride may be employed alone or concomitantly with other antihypertensive agents. uuid:3cb3f334-5340-4d0c-9e0d-21e920a7a2bc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27732 biolink:treats MONDO:0020567 PMID:41385096 "[{""id"":""uuid:822493d6-20fb-4205-8149-d95add702f1e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:eff5816d-ad8a-40fc-8fa4-56c4e41c7960"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:4729865f-6576-4cbd-a25d-82526788c5b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f3d08835-c0a2-45d8-9635-9e78a2dd880d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Caffeine citrate injection and caffeine citrate oral solution are indicated for the short term treatment of apnea of prematurity in infants between 28 and <33 weeks gestational age.|[EMA] Treatment of primary apnoea of premature newborns.|[PMDA] A drug with a new route of administration indicated for the treatment of primary apnea (apnea of prematurity) in immature or low birth weight infants. [Orphan drug] uuid:4da43567-ca01-46d7-862b-620fcead3c9d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3757 biolink:treats MONDO:0004992 PMID:41385096 "[{""id"":""uuid:ca8c50ab-0d4e-4acd-9a3e-4d88ad4f3a0d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ac916093-6aa0-4d4a-855d-296eb61df51d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clonidine hydrochloride is indicated in combination with opiates for the treatment of severe pain in cancer patients that is not adequately relieved by opioid analgesics alone. Epidural clonidine is more likely to be effective in patients with neuropathic pain than somatic or visceral pain (see CLINICAL PHARMACOLOGY, Clinical Trials ). The safety of this drug product has only been established in a highly selected group of cancer patients, and only after an adequate trial of opioid analgesia. Other use is of unproven safety and is not recommended. In a rare patient, the potential benefits may outweigh the known risks (see WARNINGS ). uuid:d292b0c3-b4ea-411c-9d4d-84f97666c976 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3757 biolink:treats UMLS:C0234245 PMID:41385096 "[{""id"":""uuid:62c70e22-1e13-4b64-985f-e917941f38c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:326f85d9-7bfb-48e7-a55c-79aa64811b52"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clonidine hydrochloride is indicated in combination with opiates for the treatment of severe pain in cancer patients that is not adequately relieved by opioid analgesics alone. Epidural clonidine is more likely to be effective in patients with neuropathic pain than somatic or visceral pain (see CLINICAL PHARMACOLOGY, Clinical Trials ). The safety of this drug product has only been established in a highly selected group of cancer patients, and only after an adequate trial of opioid analgesia. Other use is of unproven safety and is not recommended. In a rare patient, the potential benefits may outweigh the known risks (see WARNINGS ). uuid:d7b061e6-8661-42bb-be79-5b4e7f4b253a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16714 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:38907aaa-1019-4ed1-9084-35da84d87dd6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2686ce29-f019-4681-b434-88807ff44744"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Codeine sulfate is an opioid analgesic indicated for the relief of mild to moderately severe pain where the use of an opioid analgesic is appropriate. uuid:1d9b546b-1dc2-4483-b7c6-843b1f0ccfc8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:371909 biolink:treats MONDO:0001673 PMID:41385096 "[{""id"":""uuid:07f47bba-e9b0-47c6-b42c-c9a9e890819d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:54f65d66-a9f5-4824-8066-8b7439759072"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lomotil is effective as adjunctive therapy in the management of diarrhea. uuid:802b605f-d658-4eaa-a025-ecd6aaadb9f0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7551 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:1fdb351a-732e-4022-be18-7ce8749e233e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6b91a253-8890-4695-b82e-fb7b81c6742f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nicardipine hydrochloride injection is indicated for the short-term treatment of hypertension when oral therapy is not feasible or not desirable. For prolonged control of blood pressure, patients should be transferred to oral medication as soon as their clinical condition permits (see DOSAGE AND ADMINISTRATION ). uuid:87a99dd0-8f5c-444e-bb4e-dbec1aca02c5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28876 biolink:treats MONDO:0009693 PMID:41385096 "[{""id"":""uuid:7cc3c5d5-fe5b-462f-9906-2e2e7076fc95"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:2d534954-85a0-4bab-b831-5c390602d1ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:0b94a188-4ac6-4135-9fd3-a256895e826d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Melphalan Hydrochloride for Injection is indicated for the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate.|[EMA] High-dose of Phelinun used alone or in combination with other cytotoxic medicinal products and/or total body irradiation is indicated in the treatment of:multiple myeloma,malignant lymphoma (Hodgkin, non-Hodgkin lymphoma),acute lymphoblastic and myeloblastic leukemia,childhood neuroblastoma,ovarian cancer,mammary adenocarcinoma.Phelinun in combination with other cytotoxic medicinal products is indicated as reduced intensity conditioning (RIC) treatment prior to allogeneic haematopoietic stem cell transplantation (allo-HSCT) in malignant haematological diseases in adults.Phelinun in combination with other cytotoxic medicinal products is indicated as conditioning regimen prior to allogeneic haematopoietic stem cell transplantation in haematological diseases in the paediatric population as:Myeloablative conditioning (MAC) treatment in case of malignant haematological diseasesRIC treatment in case of non-malignant haematological diseases. uuid:9f24d6e4-8b9e-4134-8ee1-a609ec03a139 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1151145 biolink:treats MONDO:0005178 PMID:41385096 "[{""id"":""uuid:f416d77a-01a3-47d0-97d0-656bf1f10632"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5202cb2d-51c9-476b-b87b-a2816b81f107"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of ARTHROTEC and other treatment options before deciding to use ARTHROTEC. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). ARTHROTEC is indicated for treatment of the signs and symptoms of osteoarthritis or rheumatoid arthritis in patients at high risk of developing NSAID-induced gastric and duodenal ulcers and their complications. See WARNINGS, Gastrointestinal Effects - Risk of Ulceration, Bleeding and Perforation for a list of factors that may increase the risk of NSAID-induced gastric and duodenal ulcers and their complications. uuid:189ddae5-90db-45d3-8750-99d1a61fa754 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1151145 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:c433c51d-d254-4427-92d9-5ff9bc05b834"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:91946ad3-6b33-4255-9a36-a7bf02a35ea3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of ARTHROTEC and other treatment options before deciding to use ARTHROTEC. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). ARTHROTEC is indicated for treatment of the signs and symptoms of osteoarthritis or rheumatoid arthritis in patients at high risk of developing NSAID-induced gastric and duodenal ulcers and their complications. See WARNINGS, Gastrointestinal Effects - Risk of Ulceration, Bleeding and Perforation for a list of factors that may increase the risk of NSAID-induced gastric and duodenal ulcers and their complications. uuid:3b2e2e10-c465-4e85-8f8a-0c81fc74d8e8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1151145 biolink:treats MONDO:0001126 PMID:41385096 "[{""id"":""uuid:02447abc-fef5-4ce3-89d2-aa8283f8f0e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:394c8ea6-04e3-444d-abd9-53217b62635c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of ARTHROTEC and other treatment options before deciding to use ARTHROTEC. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). ARTHROTEC is indicated for treatment of the signs and symptoms of osteoarthritis or rheumatoid arthritis in patients at high risk of developing NSAID-induced gastric and duodenal ulcers and their complications. See WARNINGS, Gastrointestinal Effects - Risk of Ulceration, Bleeding and Perforation for a list of factors that may increase the risk of NSAID-induced gastric and duodenal ulcers and their complications. uuid:9110db0d-4ec2-4f4f-afe6-30f0960c1f9b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1151145 biolink:treats MONDO:0005412 PMID:41385096 "[{""id"":""uuid:4643c0e8-0bff-4845-b8d1-ca48f118f51f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:41415404-bdd6-450e-986b-ea4dfec20ea2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of ARTHROTEC and other treatment options before deciding to use ARTHROTEC. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). ARTHROTEC is indicated for treatment of the signs and symptoms of osteoarthritis or rheumatoid arthritis in patients at high risk of developing NSAID-induced gastric and duodenal ulcers and their complications. See WARNINGS, Gastrointestinal Effects - Risk of Ulceration, Bleeding and Perforation for a list of factors that may increase the risk of NSAID-induced gastric and duodenal ulcers and their complications. uuid:6ae64bda-6764-42bf-b4e9-a2970809c03c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6904 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:70af4cba-bfa3-4e21-a68f-ac8c785477ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e6350c7c-fb58-42d9-8afe-32d87379bdad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Metoprolol succinate extended-release tablets are indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents. uuid:a0ff4bf7-176d-4e0b-a5f1-eaa27b550d3b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3561 biolink:treats MONDO:0024332 PMID:41385096 "[{""id"":""uuid:78047a90-56ad-44c1-860f-eee3ffbcb3d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:05de5415-54ee-41ee-ae7f-f6497d9d96a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cetirizine hydrochloride syrup is indicated for the relief of symptoms associated with perennial allergic rhinitis due to allergens such as dust mites, animal dander and molds in children 6 to 23 months of age. Symptoms treated effectively include sneezing, rhinorrhea, postnasal discharge, nasal pruritus, ocular pruritus, and tearing. uuid:3cf86bbe-5c9f-483e-97f7-7c69a7f9b3e3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4551 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:bcb5d764-ba76-4d60-b192-bac024c3f44f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:74e09911-b061-466e-8cd7-62e7ead4e254"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE: Heart Failure: Digoxin is indicated for the treatment of mild to moderate heart failure. Digoxin increases left ventricular ejection fraction and improves heart failure symptoms as evidenced by exercise capacity and heart failure-related hospitalizations and emergency care, while having no effect on mortality. Where possible, digoxin should be used with a diuretic and an angiotensinconverting enzyme inhibitor, but an optimal order for starting these three drugs cannot be specified. Atrial Fibrillation: Digoxin is indicated for the control of ventricular response rate in patients with chronic atrial fibrillation uuid:a84ad6aa-629a-4f63-ae0d-0ff4b1505e50 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4551 biolink:treats MONDO:0004981 PMID:41385096 "[{""id"":""uuid:14910004-50a2-4a4e-a6a6-93fbe05fd9d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c33bcdc9-1a25-460a-be77-dc68dc18b5aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE: Heart Failure: Digoxin is indicated for the treatment of mild to moderate heart failure. Digoxin increases left ventricular ejection fraction and improves heart failure symptoms as evidenced by exercise capacity and heart failure-related hospitalizations and emergency care, while having no effect on mortality. Where possible, digoxin should be used with a diuretic and an angiotensinconverting enzyme inhibitor, but an optimal order for starting these three drugs cannot be specified. Atrial Fibrillation: Digoxin is indicated for the control of ventricular response rate in patients with chronic atrial fibrillation uuid:ae278ec8-a5e7-4483-8801-62a31a7eb8af biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:82866 biolink:treats MONDO:0005984 PMID:41385096 "[{""id"":""uuid:a472e44c-0d0b-4f41-85e5-45b0b6b04ac4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a105d264-4603-4dca-b5d2-011fe442e29d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ERTACZO ® (sertaconazole nitrate) Cream, 2%, is indicated for the topical treatment of interdigital tinea pedis in immunocompetent patients 12 years of age and older, caused by: Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum (see CLINICAL STUDIES Section). uuid:11b05fc8-124c-43eb-9068-bbe7a813c0f2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17026 biolink:treats MONDO:0005047 PMID:41385096 "[{""id"":""uuid:215f3c88-07df-433d-af71-6cc3ff472ada"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:64f89d8e-5252-4714-b915-55dfe7def6f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:28d2381e-0b94-435a-a15a-c6498ac7a375"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Crinone ® 8% is indicated for progesterone supplementation or replacement as part of an Assisted Reproductive Technology (""ART"") treatment for infertile women with progesterone deficiency.|[PMDA] A drug with a new route of administration indicated for luteal support as part of assisted reproductive technology for infertile women." uuid:25cdfb08-1914-4876-abaf-3fc33139392a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17026 biolink:treats UMLS:C5848632 PMID:41385096 "[{""id"":""uuid:30c69a82-060f-49ab-816f-06c61b433336"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c6cf0c09-7b59-4f69-bb37-7a1f4deab6fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Crinone ® 8% is indicated for progesterone supplementation or replacement as part of an Assisted Reproductive Technology (""ART"") treatment for infertile women with progesterone deficiency." uuid:c25d3cb5-5494-4ae5-b223-6902e1c94cd9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17347 biolink:treats MONDO:0009420 PMID:41385096 "[{""id"":""uuid:6ad5f9cc-5498-4e65-ac01-c90ac1e74d15"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:84842991-8cb7-4769-8ae3-adcfdd235c1e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Striant ® is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired) - testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchidectomy, Klinefelter's syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone levels and gonadotropins (FSH, LH) above the normal range. Hypogonadotropic hypogonadism (congenital or acquired) -- idiopathic gonadotropin or LHRH deficiency, or pituitary hypothalamic injury from tumors, trauma, or radiation. These patients have low serum testosterone levels but have gonadotropins in the normal or low range. uuid:f479abc9-0e17-446d-9672-d97eeb4ec826 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17347 biolink:treats MONDO:0023554 PMID:41385096 "[{""id"":""uuid:c2fd0093-b820-4ab0-bcb0-87bb1411b0ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b7657dba-5686-4e22-99ed-52cb49b786a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Striant ® is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired) - testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchidectomy, Klinefelter's syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone levels and gonadotropins (FSH, LH) above the normal range. Hypogonadotropic hypogonadism (congenital or acquired) -- idiopathic gonadotropin or LHRH deficiency, or pituitary hypothalamic injury from tumors, trauma, or radiation. These patients have low serum testosterone levels but have gonadotropins in the normal or low range. uuid:4d4791df-d297-4385-92d0-26150ede3ae8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17347 biolink:treats MONDO:8000015 PMID:41385096 "[{""id"":""uuid:c4e5704f-0fef-4531-a400-768f24a5ff66"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:defdd624-5ade-4d8b-9629-afd79348df8d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Striant ® is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired) - testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchidectomy, Klinefelter's syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone levels and gonadotropins (FSH, LH) above the normal range. Hypogonadotropic hypogonadism (congenital or acquired) -- idiopathic gonadotropin or LHRH deficiency, or pituitary hypothalamic injury from tumors, trauma, or radiation. These patients have low serum testosterone levels but have gonadotropins in the normal or low range. uuid:e589085f-e647-4516-bd93-bf6f8bf896f5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17347 biolink:treats MONDO:0018555 PMID:41385096 "[{""id"":""uuid:3ba2db70-c46c-44fb-a0c3-363c6fd7a0be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:69199ca0-6316-4d4c-9979-638197e49f70"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Striant ® is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired) - testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchidectomy, Klinefelter's syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone levels and gonadotropins (FSH, LH) above the normal range. Hypogonadotropic hypogonadism (congenital or acquired) -- idiopathic gonadotropin or LHRH deficiency, or pituitary hypothalamic injury from tumors, trauma, or radiation. These patients have low serum testosterone levels but have gonadotropins in the normal or low range. uuid:7b826c72-be5b-4b91-b494-db7d276d6682 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17347 biolink:treats MONDO:0013914 PMID:41385096 "[{""id"":""uuid:8abc8347-71eb-40d6-92c1-a0b77944f027"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aa9931bd-096f-438c-8859-f6821a296c45"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Striant ® is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired) - testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchidectomy, Klinefelter's syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone levels and gonadotropins (FSH, LH) above the normal range. Hypogonadotropic hypogonadism (congenital or acquired) -- idiopathic gonadotropin or LHRH deficiency, or pituitary hypothalamic injury from tumors, trauma, or radiation. These patients have low serum testosterone levels but have gonadotropins in the normal or low range. uuid:9da64d21-12bb-4d7e-add5-4b2b29a1a1ad biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17347 biolink:treats MONDO:0043459 PMID:41385096 "[{""id"":""uuid:89103039-e6f6-491a-aa87-ee981a42f748"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0fc7572d-0e1e-404f-ad29-40984b99300c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Striant ® is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired) - testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchidectomy, Klinefelter's syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone levels and gonadotropins (FSH, LH) above the normal range. Hypogonadotropic hypogonadism (congenital or acquired) -- idiopathic gonadotropin or LHRH deficiency, or pituitary hypothalamic injury from tumors, trauma, or radiation. These patients have low serum testosterone levels but have gonadotropins in the normal or low range. uuid:4f8fd5b2-5328-4853-86ab-fb84ddc3c5c0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:40279 biolink:treats MONDO:0005393 PMID:41385096 "[{""id"":""uuid:2c2e15a4-b0cb-482d-92ac-3055de2b26bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:388f6c97-64aa-457f-84fc-0119db63b079"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] THIS IS NOT AN INNOCUOUS DRUG. IT IS NOT RECOMMENDED FOR THE TREATMENT OF ASYMPTOMATIC HYPERURICEMIA. ZYLOPRIM reduces serum and urinary uric acid concentrations. Its use should be individualized for each patient and requires an understanding of its mode of action and pharmacokinetics (see CLINICAL PHARMACOLOGY , CONTRAINDICATIONS , WARNINGS , and PRECAUTIONS ). ZYLOPRIM is indicated in: the management of patients with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy). the management of patients with leukemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. Treatment with ZYLOPRIM should be discontinued when the potential for overproduction of uric acid is no longer present. the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients. Therapy in such patients should be carefully assessed initially and reassessed periodically to determine in each case that treatment is beneficial and that the benefits outweigh the risks. uuid:bd603f7a-fe55-47f2-bbd4-3ee9b4b92eb9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:40279 biolink:treats MONDO:0008629 PMID:41385096 "[{""id"":""uuid:0924d5b4-6e57-4fc1-a134-150114cb313c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:468c94ad-b63e-42f3-a97f-9e66210f8fd8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] THIS IS NOT AN INNOCUOUS DRUG. IT IS NOT RECOMMENDED FOR THE TREATMENT OF ASYMPTOMATIC HYPERURICEMIA. ZYLOPRIM reduces serum and urinary uric acid concentrations. Its use should be individualized for each patient and requires an understanding of its mode of action and pharmacokinetics (see CLINICAL PHARMACOLOGY , CONTRAINDICATIONS , WARNINGS , and PRECAUTIONS ). ZYLOPRIM is indicated in: the management of patients with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy). the management of patients with leukemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. Treatment with ZYLOPRIM should be discontinued when the potential for overproduction of uric acid is no longer present. the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients. Therapy in such patients should be carefully assessed initially and reassessed periodically to determine in each case that treatment is beneficial and that the benefits outweigh the risks. uuid:19274c70-a38e-481f-82ed-d12b0b7beca8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:40279 biolink:treats MONDO:0005059 PMID:41385096 "[{""id"":""uuid:22068b3b-e830-469a-8431-c2c52c92ea34"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:581b550d-84dd-4513-9ebf-f7bc70a64819"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] THIS IS NOT AN INNOCUOUS DRUG. IT IS NOT RECOMMENDED FOR THE TREATMENT OF ASYMPTOMATIC HYPERURICEMIA. ZYLOPRIM reduces serum and urinary uric acid concentrations. Its use should be individualized for each patient and requires an understanding of its mode of action and pharmacokinetics (see CLINICAL PHARMACOLOGY , CONTRAINDICATIONS , WARNINGS , and PRECAUTIONS ). ZYLOPRIM is indicated in: the management of patients with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy). the management of patients with leukemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. Treatment with ZYLOPRIM should be discontinued when the potential for overproduction of uric acid is no longer present. the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients. Therapy in such patients should be carefully assessed initially and reassessed periodically to determine in each case that treatment is beneficial and that the benefits outweigh the risks. uuid:d50bf692-2812-4111-ad85-aa51c8fbdf64 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:40279 biolink:treats MONDO:0005062 PMID:41385096 "[{""id"":""uuid:6fd9dded-3264-4218-b3f1-3ea9c9f8a134"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:58314765-827e-4176-9f1e-1988441aa411"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] THIS IS NOT AN INNOCUOUS DRUG. IT IS NOT RECOMMENDED FOR THE TREATMENT OF ASYMPTOMATIC HYPERURICEMIA. ZYLOPRIM reduces serum and urinary uric acid concentrations. Its use should be individualized for each patient and requires an understanding of its mode of action and pharmacokinetics (see CLINICAL PHARMACOLOGY , CONTRAINDICATIONS , WARNINGS , and PRECAUTIONS ). ZYLOPRIM is indicated in: the management of patients with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy). the management of patients with leukemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. Treatment with ZYLOPRIM should be discontinued when the potential for overproduction of uric acid is no longer present. the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients. Therapy in such patients should be carefully assessed initially and reassessed periodically to determine in each case that treatment is beneficial and that the benefits outweigh the risks. uuid:362f2e9b-deb2-4a2e-8337-c985ace6e4b5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:40279 biolink:treats MONDO:0004992 PMID:41385096 "[{""id"":""uuid:31f2f2dd-ec49-4da7-b6f8-d6e095a3fc96"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ce6c14b2-d335-451b-99a5-ccc11fb2fdb9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] THIS IS NOT AN INNOCUOUS DRUG. IT IS NOT RECOMMENDED FOR THE TREATMENT OF ASYMPTOMATIC HYPERURICEMIA. ZYLOPRIM reduces serum and urinary uric acid concentrations. Its use should be individualized for each patient and requires an understanding of its mode of action and pharmacokinetics (see CLINICAL PHARMACOLOGY , CONTRAINDICATIONS , WARNINGS , and PRECAUTIONS ). ZYLOPRIM is indicated in: the management of patients with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy). the management of patients with leukemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. Treatment with ZYLOPRIM should be discontinued when the potential for overproduction of uric acid is no longer present. the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients. Therapy in such patients should be carefully assessed initially and reassessed periodically to determine in each case that treatment is beneficial and that the benefits outweigh the risks. uuid:9abdfd68-660b-4fa3-a8ca-8110b3435715 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:40279 biolink:treats MONDO:0957318 PMID:41385096 "[{""id"":""uuid:b80535dd-6e6f-4f9b-b34f-f8ef9f44efe6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:42244a13-e0f2-4dc4-a73f-ef5d86e620d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] THIS IS NOT AN INNOCUOUS DRUG. IT IS NOT RECOMMENDED FOR THE TREATMENT OF ASYMPTOMATIC HYPERURICEMIA. ZYLOPRIM reduces serum and urinary uric acid concentrations. Its use should be individualized for each patient and requires an understanding of its mode of action and pharmacokinetics (see CLINICAL PHARMACOLOGY , CONTRAINDICATIONS , WARNINGS , and PRECAUTIONS ). ZYLOPRIM is indicated in: the management of patients with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy). the management of patients with leukemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. Treatment with ZYLOPRIM should be discontinued when the potential for overproduction of uric acid is no longer present. the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients. Therapy in such patients should be carefully assessed initially and reassessed periodically to determine in each case that treatment is beneficial and that the benefits outweigh the risks. uuid:d2221615-1094-4dc0-b240-43a529829e8f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1162650 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:94e3cc26-6120-45cd-9e10-7333e952c0c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:97216a41-f5c1-4cfc-9230-192d0e8c0a1e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Enalapril maleate and hydrochlorothiazide tablets are indicated for the treatment of hypertension. These fixed dose combinations are not indicated for initial treatment (see DOSAGE AND ADMINISTRATION ). In using enalapril maleate and hydrochlorothiazide tablets, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalapril does not have a similar risk (see WARNINGS ). In considering use of enalapril maleate and hydrochlorothiazide tablets, it should be noted that black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks (see WARNINGS: Angioedema ). uuid:8bc53526-be23-405c-a442-9bd60ff8496c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1162650 biolink:treats MONDO:0001609 PMID:41385096 "[{""id"":""uuid:1b8d1a38-e579-4597-866f-0cd00f46dfb5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:675872e0-0d3d-4930-a8c4-2351c48b9b4f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Enalapril maleate and hydrochlorothiazide tablets are indicated for the treatment of hypertension. These fixed dose combinations are not indicated for initial treatment (see DOSAGE AND ADMINISTRATION ). In using enalapril maleate and hydrochlorothiazide tablets, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalapril does not have a similar risk (see WARNINGS ). In considering use of enalapril maleate and hydrochlorothiazide tablets, it should be noted that black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks (see WARNINGS: Angioedema ). uuid:1d7826bf-3fd2-4489-8a41-f0fe38844a08 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1162650 biolink:treats MONDO:0001343 PMID:41385096 "[{""id"":""uuid:4ae8aaef-b5db-4ee2-a0f3-5a859f86ad24"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c1f7fc37-cd14-42f9-a71b-5ee7cc2b61a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Enalapril maleate and hydrochlorothiazide tablets are indicated for the treatment of hypertension. These fixed dose combinations are not indicated for initial treatment (see DOSAGE AND ADMINISTRATION ). In using enalapril maleate and hydrochlorothiazide tablets, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalapril does not have a similar risk (see WARNINGS ). In considering use of enalapril maleate and hydrochlorothiazide tablets, it should be noted that black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks (see WARNINGS: Angioedema ). uuid:dfb84dfe-2cef-4448-a2d1-1781c5a4c380 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1162650 biolink:treats MONDO:0010481 PMID:41385096 "[{""id"":""uuid:87903c58-8194-4dc3-837e-c7cbc1d584a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:53d23bcc-16b9-4474-93ed-3f48503e3fe9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Enalapril maleate and hydrochlorothiazide tablets are indicated for the treatment of hypertension. These fixed dose combinations are not indicated for initial treatment (see DOSAGE AND ADMINISTRATION ). In using enalapril maleate and hydrochlorothiazide tablets, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalapril does not have a similar risk (see WARNINGS ). In considering use of enalapril maleate and hydrochlorothiazide tablets, it should be noted that black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks (see WARNINGS: Angioedema ). uuid:8a31b5ff-5cf9-485f-b724-6fef9a9e124c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:453011 biolink:treats MONDO:0001628 PMID:41385096 "[{""id"":""uuid:092e5b14-13b8-47d3-a914-62d5c6e6e73a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4e4307b0-4194-4852-a654-7725b52185e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] (To understand fully the indication for this product, please read the entire INDICATIONS AND USAGE section of the labeling.) Ciclopirox Topical Solution, 8% (Nail Lacquer) as a component of a comprehensive management program, is indicated as topical treatment in immunocompetent patients with mild to moderate onychomycosis of fingernails and toenails without lunula involvement, due to Tricho-phyto rubrum . The comprehensive management program includes removal of the unattached, infected nails as frequently as monthly, by a health care professional who has special competence in the diagnosis and treatment of nail disorders, including minor nail procedures. No studies have been conducted to determine whether ciclopirox might reduce the effectiveness of systemic antifungal agents for onychomycosis. Therefore, the concomitant use of 8% ciclopirox topical solution and systemic antifungal agents for onychomycosis, is not recommended. Ciclopirox Topical Solution, 8% (Nail Lacquer) should be used only under medical supervision as described above. The effectiveness and safety of Ciclopirox Topical Solution, 8% (Nail Lacquer) in the following populations has not been studied.The clinical trials with use of Ciclopirox Topical Solution, 8% (Nail Lacquer) excluded patients who: were pregnant or nursing, planned to become pregnant, had a history of immunosuppression (e.g., extensive, persistent, or unusual distribution of dermatomycoses, extensive seborrheic dermatitis, recent or recurring herpes zoster, or persistent herpes simplex), were HIV seropositive, received organ transplant, required medication to control epilepsy, were insulin dependent diabetics or had diabetic neuropathy. Patients with severe plantar (moccasin) tinea pedis were also excluded. The safety and efficacy of using Ciclopirox Topical Solution, 8% (Nail Lacquer) daily for greater than 48 weeks have not been established. uuid:10859d1b-85fe-4c9c-936a-11388c1a4db2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:453011 biolink:treats UMLS:C1274470 PMID:41385096 "[{""id"":""uuid:7abfa398-7760-44f3-9eac-c7ba017e8824"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:96462ed5-4ef6-45f4-acaf-ef13de99634b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] (To understand fully the indication for this product, please read the entire INDICATIONS AND USAGE section of the labeling.) Ciclopirox Topical Solution, 8% (Nail Lacquer) as a component of a comprehensive management program, is indicated as topical treatment in immunocompetent patients with mild to moderate onychomycosis of fingernails and toenails without lunula involvement, due to Tricho-phyto rubrum . The comprehensive management program includes removal of the unattached, infected nails as frequently as monthly, by a health care professional who has special competence in the diagnosis and treatment of nail disorders, including minor nail procedures. No studies have been conducted to determine whether ciclopirox might reduce the effectiveness of systemic antifungal agents for onychomycosis. Therefore, the concomitant use of 8% ciclopirox topical solution and systemic antifungal agents for onychomycosis, is not recommended. Ciclopirox Topical Solution, 8% (Nail Lacquer) should be used only under medical supervision as described above. The effectiveness and safety of Ciclopirox Topical Solution, 8% (Nail Lacquer) in the following populations has not been studied.The clinical trials with use of Ciclopirox Topical Solution, 8% (Nail Lacquer) excluded patients who: were pregnant or nursing, planned to become pregnant, had a history of immunosuppression (e.g., extensive, persistent, or unusual distribution of dermatomycoses, extensive seborrheic dermatitis, recent or recurring herpes zoster, or persistent herpes simplex), were HIV seropositive, received organ transplant, required medication to control epilepsy, were insulin dependent diabetics or had diabetic neuropathy. Patients with severe plantar (moccasin) tinea pedis were also excluded. The safety and efficacy of using Ciclopirox Topical Solution, 8% (Nail Lacquer) daily for greater than 48 weeks have not been established. uuid:98805e6b-f84a-4a9d-851f-0323be37856c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:453011 biolink:treats MONDO:0002040 PMID:41385096 "[{""id"":""uuid:19a7e83d-7ce2-4eea-b78f-cd19103401d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9b851485-c907-46d0-be17-4f17d4985452"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] (To understand fully the indication for this product, please read the entire INDICATIONS AND USAGE section of the labeling.) Ciclopirox Topical Solution, 8% (Nail Lacquer) as a component of a comprehensive management program, is indicated as topical treatment in immunocompetent patients with mild to moderate onychomycosis of fingernails and toenails without lunula involvement, due to Tricho-phyto rubrum . The comprehensive management program includes removal of the unattached, infected nails as frequently as monthly, by a health care professional who has special competence in the diagnosis and treatment of nail disorders, including minor nail procedures. No studies have been conducted to determine whether ciclopirox might reduce the effectiveness of systemic antifungal agents for onychomycosis. Therefore, the concomitant use of 8% ciclopirox topical solution and systemic antifungal agents for onychomycosis, is not recommended. Ciclopirox Topical Solution, 8% (Nail Lacquer) should be used only under medical supervision as described above. The effectiveness and safety of Ciclopirox Topical Solution, 8% (Nail Lacquer) in the following populations has not been studied.The clinical trials with use of Ciclopirox Topical Solution, 8% (Nail Lacquer) excluded patients who: were pregnant or nursing, planned to become pregnant, had a history of immunosuppression (e.g., extensive, persistent, or unusual distribution of dermatomycoses, extensive seborrheic dermatitis, recent or recurring herpes zoster, or persistent herpes simplex), were HIV seropositive, received organ transplant, required medication to control epilepsy, were insulin dependent diabetics or had diabetic neuropathy. Patients with severe plantar (moccasin) tinea pedis were also excluded. The safety and efficacy of using Ciclopirox Topical Solution, 8% (Nail Lacquer) daily for greater than 48 weeks have not been established. uuid:429c7e07-c5e0-4625-9de4-4170639b9eae biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:453011 biolink:treats MONDO:0006608 PMID:41385096 "[{""id"":""uuid:bc501171-1415-4c86-b6aa-25d461fe2773"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6ad67a67-28d2-415d-83fa-648a0781a81d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] (To understand fully the indication for this product, please read the entire INDICATIONS AND USAGE section of the labeling.) Ciclopirox Topical Solution, 8% (Nail Lacquer) as a component of a comprehensive management program, is indicated as topical treatment in immunocompetent patients with mild to moderate onychomycosis of fingernails and toenails without lunula involvement, due to Tricho-phyto rubrum . The comprehensive management program includes removal of the unattached, infected nails as frequently as monthly, by a health care professional who has special competence in the diagnosis and treatment of nail disorders, including minor nail procedures. No studies have been conducted to determine whether ciclopirox might reduce the effectiveness of systemic antifungal agents for onychomycosis. Therefore, the concomitant use of 8% ciclopirox topical solution and systemic antifungal agents for onychomycosis, is not recommended. Ciclopirox Topical Solution, 8% (Nail Lacquer) should be used only under medical supervision as described above. The effectiveness and safety of Ciclopirox Topical Solution, 8% (Nail Lacquer) in the following populations has not been studied.The clinical trials with use of Ciclopirox Topical Solution, 8% (Nail Lacquer) excluded patients who: were pregnant or nursing, planned to become pregnant, had a history of immunosuppression (e.g., extensive, persistent, or unusual distribution of dermatomycoses, extensive seborrheic dermatitis, recent or recurring herpes zoster, or persistent herpes simplex), were HIV seropositive, received organ transplant, required medication to control epilepsy, were insulin dependent diabetics or had diabetic neuropathy. Patients with severe plantar (moccasin) tinea pedis were also excluded. The safety and efficacy of using Ciclopirox Topical Solution, 8% (Nail Lacquer) daily for greater than 48 weeks have not been established. uuid:e0bd0e70-ccdb-464e-a88a-d6f30e371a05 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:453011 biolink:treats MONDO:0005609 PMID:41385096 "[{""id"":""uuid:0c46fa36-7db7-4eb3-bce8-52defe60d57c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2441b07d-95e8-4c61-aa1a-7fb8fd120011"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] (To understand fully the indication for this product, please read the entire INDICATIONS AND USAGE section of the labeling.) Ciclopirox Topical Solution, 8% (Nail Lacquer) as a component of a comprehensive management program, is indicated as topical treatment in immunocompetent patients with mild to moderate onychomycosis of fingernails and toenails without lunula involvement, due to Tricho-phyto rubrum . The comprehensive management program includes removal of the unattached, infected nails as frequently as monthly, by a health care professional who has special competence in the diagnosis and treatment of nail disorders, including minor nail procedures. No studies have been conducted to determine whether ciclopirox might reduce the effectiveness of systemic antifungal agents for onychomycosis. Therefore, the concomitant use of 8% ciclopirox topical solution and systemic antifungal agents for onychomycosis, is not recommended. Ciclopirox Topical Solution, 8% (Nail Lacquer) should be used only under medical supervision as described above. The effectiveness and safety of Ciclopirox Topical Solution, 8% (Nail Lacquer) in the following populations has not been studied.The clinical trials with use of Ciclopirox Topical Solution, 8% (Nail Lacquer) excluded patients who: were pregnant or nursing, planned to become pregnant, had a history of immunosuppression (e.g., extensive, persistent, or unusual distribution of dermatomycoses, extensive seborrheic dermatitis, recent or recurring herpes zoster, or persistent herpes simplex), were HIV seropositive, received organ transplant, required medication to control epilepsy, were insulin dependent diabetics or had diabetic neuropathy. Patients with severe plantar (moccasin) tinea pedis were also excluded. The safety and efficacy of using Ciclopirox Topical Solution, 8% (Nail Lacquer) daily for greater than 48 weeks have not been established. uuid:4abc0c63-a099-498d-a124-13e67ab64647 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:453011 biolink:treats MONDO:0004609 PMID:41385096 "[{""id"":""uuid:ff23b944-ecb2-4bf3-8a6e-99a6fabb75a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2e554cf9-19e1-43a6-8030-5844e472871b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] (To understand fully the indication for this product, please read the entire INDICATIONS AND USAGE section of the labeling.) Ciclopirox Topical Solution, 8% (Nail Lacquer) as a component of a comprehensive management program, is indicated as topical treatment in immunocompetent patients with mild to moderate onychomycosis of fingernails and toenails without lunula involvement, due to Tricho-phyto rubrum . The comprehensive management program includes removal of the unattached, infected nails as frequently as monthly, by a health care professional who has special competence in the diagnosis and treatment of nail disorders, including minor nail procedures. No studies have been conducted to determine whether ciclopirox might reduce the effectiveness of systemic antifungal agents for onychomycosis. Therefore, the concomitant use of 8% ciclopirox topical solution and systemic antifungal agents for onychomycosis, is not recommended. Ciclopirox Topical Solution, 8% (Nail Lacquer) should be used only under medical supervision as described above. The effectiveness and safety of Ciclopirox Topical Solution, 8% (Nail Lacquer) in the following populations has not been studied.The clinical trials with use of Ciclopirox Topical Solution, 8% (Nail Lacquer) excluded patients who: were pregnant or nursing, planned to become pregnant, had a history of immunosuppression (e.g., extensive, persistent, or unusual distribution of dermatomycoses, extensive seborrheic dermatitis, recent or recurring herpes zoster, or persistent herpes simplex), were HIV seropositive, received organ transplant, required medication to control epilepsy, were insulin dependent diabetics or had diabetic neuropathy. Patients with severe plantar (moccasin) tinea pedis were also excluded. The safety and efficacy of using Ciclopirox Topical Solution, 8% (Nail Lacquer) daily for greater than 48 weeks have not been established. uuid:972e1ea2-6fa6-46cc-9707-74f21ffd45c1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:453011 biolink:treats MONDO:0005984 PMID:41385096 "[{""id"":""uuid:fadd4e63-c9cc-4e6f-954a-30af44673a48"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f963c321-5ee2-44db-b7ac-7852d9fa178f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] (To understand fully the indication for this product, please read the entire INDICATIONS AND USAGE section of the labeling.) Ciclopirox Topical Solution, 8% (Nail Lacquer) as a component of a comprehensive management program, is indicated as topical treatment in immunocompetent patients with mild to moderate onychomycosis of fingernails and toenails without lunula involvement, due to Tricho-phyto rubrum . The comprehensive management program includes removal of the unattached, infected nails as frequently as monthly, by a health care professional who has special competence in the diagnosis and treatment of nail disorders, including minor nail procedures. No studies have been conducted to determine whether ciclopirox might reduce the effectiveness of systemic antifungal agents for onychomycosis. Therefore, the concomitant use of 8% ciclopirox topical solution and systemic antifungal agents for onychomycosis, is not recommended. Ciclopirox Topical Solution, 8% (Nail Lacquer) should be used only under medical supervision as described above. The effectiveness and safety of Ciclopirox Topical Solution, 8% (Nail Lacquer) in the following populations has not been studied.The clinical trials with use of Ciclopirox Topical Solution, 8% (Nail Lacquer) excluded patients who: were pregnant or nursing, planned to become pregnant, had a history of immunosuppression (e.g., extensive, persistent, or unusual distribution of dermatomycoses, extensive seborrheic dermatitis, recent or recurring herpes zoster, or persistent herpes simplex), were HIV seropositive, received organ transplant, required medication to control epilepsy, were insulin dependent diabetics or had diabetic neuropathy. Patients with severe plantar (moccasin) tinea pedis were also excluded. The safety and efficacy of using Ciclopirox Topical Solution, 8% (Nail Lacquer) daily for greater than 48 weeks have not been established. uuid:80d1b8ac-f699-4bd6-b22a-2e0773682f77 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB10385 biolink:treats MONDO:0005271 PMID:41385096 "[{""id"":""uuid:baf35d26-38eb-4cff-aa33-c9d071d0d3b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f6973dde-7395-45f0-885f-3bb49cb9d30c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergenic extracts are indicated for use in diagnostic testing and as part of a treatment regime for allergic disease, as established by allergy history and skin test reactivity. Allergenic extracts are indicated for the treatment of allergen specific allergic disease for use as hyposensitization or immunotherapy when avoidance of specific allergens can not be attained. The use of allergenic extracts for therapeutic purpose has been established by well-controlled clinical studies. Allergenic extracts may be used as adjunctive therapy along with pharmacotherapy which includes antihistamines, corticosteroids, and cromoglycate, and avoidance measures. Allergenic extracts for therapeutic use should be given using only the allergen selection to which the patient is allergic, has a history of exposure and are likely to be exposed to again. uuid:69ae9873-3fb1-42ab-a7d1-5ae1273c3c09 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB10400 biolink:treats HP:0410324 PMID:41385096 "[{""id"":""uuid:16a63d55-49cf-40cf-8e6a-394b60b2aba9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fa1016d7-ad39-4bea-81c8-d71b4f33c280"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Standardized mite allergenic extracts are intended for use in the diagnosis and therapy of D.farinae and D.pteronyssinus mite allergy, as established by allergy history and skin test reactivity (6,10) . Standardized Mite extracts are not interchangeable with non standardized mite extracts. To select patients for a confirmation of allergic disease diagnosis and/or treatment with allergen extracts, screening tests should be done using in vivo identification testing methods (i.e. scratch or intradermal testing). (13) Standardized mite extract containing equal parts of D.farinae and D.pteronyssinus is intended for therapy only. The use of standardized mites extract is indicated for hypersensitization treatment and may be used as part of the over-all management of the allergic patient. This treatment is particularly to be recommended when a patient's sensitivity to mite has been determined initially by scratch or intradermal skin tests. uuid:2ee32ecf-bc85-4cd5-8d19-0a771a20b1da biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB10535 biolink:treats MONDO:0005271 PMID:41385096 "[{""id"":""uuid:c0b6001f-4197-4be9-bd4d-c3780a4f78a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:10a76382-5a3f-4f4a-a7ae-c6ba4e205121"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergenic extracts are indicated for use in diagnostic testing and as part of a treatment regime for allergic disease, as established by allergy history and skin test reactivity. Allergenic extracts are indicated for the treatment of allergen specific allergic disease for use as hyposensitization or immunotherapy when avoidance of specific allergens can not be attained. The use of allergenic extracts for therapeutic purpose has been established by well-controlled clinical studies. Allergenic extracts may be used as adjunctive therapy along with pharmacotherapy which includes antihistamines, corticosteroids, and cromoglycate, and avoidance measures. Allergenic extracts for therapeutic use should be given using only the allergen selection to which the patient is allergic, has a history of exposure and are likely to be exposed to again. uuid:8cd806a5-41b0-4792-a55a-e5f3c511aef2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB10394 biolink:treats MONDO:0005324 PMID:41385096 "[{""id"":""uuid:bb324a17-b0b3-4756-a5a8-62092ae9ad6b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4099cd3b-33a8-4bbe-ae1f-9aaa69fa589c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Standardized Pollen Extract is intended for use in the diagnosis and therapy of pollen allergic patients as established by allergy history and skin test reactivity. Standardized Grass Pollen extracts labeled in BAU/mL are not interchangeable with Grass Pollen extracts labeled in AU/mL or with non-standardized Grass Pollen extracts. The 10,000 BAU/mL dose form is indicated for percutaneous testing. If negative, 100,000 BAU/mL dose form can be used for percutaneous testing. For immunotherapy, availability of 10,000 and 100,000 BAU/mL dosages facilitates safe switching. (See Dosage & Administration) The use of standardized grass pollen extracts is indicated for hyposensitization treatment and may be used as part of the over-all management of the allergic patient. Treatment of grass sensitive patients consists of using specific standardized grass products of up to and including doses of 100,000 BAU/mL (up to 10,000 BAU/mL for Bermuda grass) or stock mixtures of standardized grass products. Stock mixtures of standardized grass extracts are particularly useful in hyposensitization treatment when multiple allergies to grasses are diagnosed. For previously untreated patients, the 10,000 BAU/mL concentrates can be used to formulate dosages. If tolerated, the concentrates can be inceased to 100,000 BAU/mL dose formulation. uuid:72a2321c-c45d-462b-9cdd-52bd25b3b999 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB10388 biolink:treats MONDO:0005271 PMID:41385096 "[{""id"":""uuid:a83f7338-3dc1-4759-b74e-358cfccda536"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3054aee8-94ca-4c8f-810d-ec61bf67c720"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergenic extracts are indicated for use in diagnostic testing and as part of a treatment regime for allergic disease, as established by allergy history and skin test reactivity. Allergenic extracts are indicated for the treatment of allergen specific allergic disease for use as hyposensitization or immunotherapy when avoidance of specific allergens can not be attained. The use of allergenic extracts for therapeutic purpose has been established by well-controlled clinical studies. Allergenic extracts may be used as adjunctive therapy along with pharmacotherapy which includes antihistamines, corticosteroids, and cromoglycate, and avoidance measures. Allergenic extracts for therapeutic use should be given using only the allergen selection to which the patient is allergic, has a history of exposure and are likely to be exposed to again. uuid:1fe0b5ab-f528-41c9-a1e9-ccdeda3449d0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB10410 biolink:treats MONDO:0005271 PMID:41385096 "[{""id"":""uuid:88dd3a8b-c0fc-4826-b984-5fd384ede6ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:966ac58d-ee41-4481-abec-3a016f5877c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergenic extracts are indicated for use in diagnostic testing and as part of a treatment regime for allergic disease, as established by allergy history and skin test reactivity. Allergenic extracts are indicated for the treatment of allergen specific allergic disease for use as hyposensitization or immunotherapy when avoidance of specific allergens can not be attained. The use of allergenic extracts for therapeutic purpose has been established by well-controlled clinical studies. Allergenic extracts may be used as adjunctive therapy along with pharmacotherapy which includes antihistamines, corticosteroids, and cromoglycate, and avoidance measures. Allergenic extracts for therapeutic use should be given using only the allergen selection to which the patient is allergic, has a history of exposure and are likely to be exposed to again. uuid:d33e5a76-fb43-436a-9c00-fa9b8d196bd1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB10620 biolink:treats MONDO:0005271 PMID:41385096 "[{""id"":""uuid:d6176cf3-0305-4a21-b43a-b7405d7ecc24"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3bae9845-7d0a-425b-8cde-33ffbc87478f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergenic extracts are indicated for use in diagnostic testing and as part of a treatment regime for allergic disease, as established by allergy history and skin test reactivity. Allergenic extracts are indicated for the treatment of allergen specific allergic disease for use as hyposensitization or immunotherapy when avoidance of specific allergens can not be attained. The use of allergenic extracts for therapeutic purpose has been established by well-controlled clinical studies. Allergenic extracts may be used as adjunctive therapy along with pharmacotherapy which includes antihistamines, corticosteroids, and cromoglycate, and avoidance measures. Allergenic extracts for therapeutic use should be given using only the allergen selection to which the patient is allergic, has a history of exposure and are likely to be exposed to again. uuid:ccbd7c55-44ae-4b21-99bc-5f66541bbb15 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB10349 biolink:treats MONDO:0005271 PMID:41385096 "[{""id"":""uuid:34321447-03c1-485a-b2c5-56dfff457071"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ca49022b-dd38-4d41-a7ee-4e5af30fb675"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergenic extracts are indicated for use in diagnostic testing and as part of a treatment regime for allergic disease, as established by allergy history and skin test reactivity. Allergenic extracts are indicated for the treatment of allergen specific allergic disease for use as hyposensitization or immunotherapy when avoidance of specific allergens can not be attained. The use of allergenic extracts for therapeutic purpose has been established by well-controlled clinical studies. Allergenic extracts may be used as adjunctive therapy along with pharmacotherapy which includes antihistamines, corticosteroids, and cromoglycate, and avoidance measures. Allergenic extracts for therapeutic use should be given using only the allergen selection to which the patient is allergic, has a history of exposure and are likely to be exposed to again. uuid:aee15fae-54b0-48d1-af92-424ce1761355 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB10411 biolink:treats MONDO:0005271 PMID:41385096 "[{""id"":""uuid:69516557-5f59-499f-83db-38692a7f39f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f607764f-78bb-4095-873b-9baab93cdfbb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergenic extracts are indicated for use in diagnostic testing and as part of a treatment regime for allergic disease, as established by allergy history and skin test reactivity. Allergenic extracts are indicated for the treatment of allergen specific allergic disease for use as hyposensitization or immunotherapy when avoidance of specific allergens can not be attained. The use of allergenic extracts for therapeutic purpose has been established by well-controlled clinical studies. Allergenic extracts may be used as adjunctive therapy along with pharmacotherapy which includes antihistamines, corticosteroids, and cromoglycate, and avoidance measures. Allergenic extracts for therapeutic use should be given using only the allergen selection to which the patient is allergic, has a history of exposure and are likely to be exposed to again. uuid:69b73206-8858-41fa-a8e3-165cd73d8e79 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB10419 biolink:treats MONDO:0005271 PMID:41385096 "[{""id"":""uuid:0d7b6a88-1558-4646-a51e-c02c11847e18"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5a59c9ae-4c84-4409-ba2a-2ef745d01351"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergenic extracts are indicated for use in diagnostic testing and as part of a treatment regime for allergic disease, as established by allergy history and skin test reactivity. Allergenic extracts are indicated for the treatment of allergen specific allergic disease for use as hyposensitization or immunotherapy when avoidance of specific allergens can not be attained. The use of allergenic extracts for therapeutic purpose has been established by well-controlled clinical studies. Allergenic extracts may be used as adjunctive therapy along with pharmacotherapy which includes antihistamines, corticosteroids, and cromoglycate, and avoidance measures. Allergenic extracts for therapeutic use should be given using only the allergen selection to which the patient is allergic, has a history of exposure and are likely to be exposed to again. uuid:3c14abd8-ce17-4a44-a29a-041ccdb59ce7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB10464 biolink:treats MONDO:0005271 PMID:41385096 "[{""id"":""uuid:0eb4af37-64a7-42f1-abbc-3f506fa29e1d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:33729514-d03c-48d6-bfa3-8f71f02eff4e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergenic extracts are indicated for use in diagnostic testing and as part of a treatment regime for allergic disease, as established by allergy history and skin test reactivity. Allergenic extracts are indicated for the treatment of allergen specific allergic disease for use as hyposensitization or immunotherapy when avoidance of specific allergens can not be attained. The use of allergenic extracts for therapeutic purpose has been established by well-controlled clinical studies. Allergenic extracts may be used as adjunctive therapy along with pharmacotherapy which includes antihistamines, corticosteroids, and cromoglycate, and avoidance measures. Allergenic extracts for therapeutic use should be given using only the allergen selection to which the patient is allergic, has a history of exposure and are likely to be exposed to again. uuid:29057e78-1037-42e2-8138-bea1583d17f6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB10426 biolink:treats MONDO:0005271 PMID:41385096 "[{""id"":""uuid:1257eb12-0ef4-4d18-bc92-9663b32caad5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b7684092-f30b-4514-a022-cfc4f0dc8799"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergenic extracts are indicated for use in diagnostic testing and as part of a treatment regime for allergic disease, as established by allergy history and skin test reactivity. Allergenic extracts are indicated for the treatment of allergen specific allergic disease for use as hyposensitization or immunotherapy when avoidance of specific allergens can not be attained. The use of allergenic extracts for therapeutic purpose has been established by well-controlled clinical studies. Allergenic extracts may be used as adjunctive therapy along with pharmacotherapy which includes antihistamines, corticosteroids, and cromoglycate, and avoidance measures. Allergenic extracts for therapeutic use should be given using only the allergen selection to which the patient is allergic, has a history of exposure and are likely to be exposed to again. uuid:009dc565-bb6d-46a0-951c-a2b70a033bc7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB10708 biolink:treats MONDO:0005271 PMID:41385096 "[{""id"":""uuid:545e2938-6bc1-4849-be57-4937f3d3d5bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ce65fd14-c47d-4c98-b103-fe70033a5885"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergenic extracts are indicated for use in diagnostic testing and as part of a treatment regime for allergic disease, as established by allergy history and skin test reactivity. Allergenic extracts are indicated for the treatment of allergen specific allergic disease for use as hyposensitization or immunotherapy when avoidance of specific allergens can not be attained. The use of allergenic extracts for therapeutic purpose has been established by well-controlled clinical studies. Allergenic extracts may be used as adjunctive therapy along with pharmacotherapy which includes antihistamines, corticosteroids, and cromoglycate, and avoidance measures. Allergenic extracts for therapeutic use should be given using only the allergen selection to which the patient is allergic, has a history of exposure and are likely to be exposed to again. uuid:edd6cc0b-295c-43ca-8b3a-1756d4082287 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB10543 biolink:treats MONDO:0005271 PMID:41385096 "[{""id"":""uuid:0aabdb6b-81b4-4ed4-835e-4cf9b83b9f6d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3dac5d02-3b2b-4b92-b98b-10d076fb3f29"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergenic extracts are indicated for use in diagnostic testing and as part of a treatment regime for allergic disease, as established by allergy history and skin test reactivity. Allergenic extracts are indicated for the treatment of allergen specific allergic disease for use as hyposensitization or immunotherapy when avoidance of specific allergens can not be attained. The use of allergenic extracts for therapeutic purpose has been established by well-controlled clinical studies. Allergenic extracts may be used as adjunctive therapy along with pharmacotherapy which includes antihistamines, corticosteroids, and cromoglycate, and avoidance measures. Allergenic extracts for therapeutic use should be given using only the allergen selection to which the patient is allergic, has a history of exposure and are likely to be exposed to again. uuid:d425eaf2-5dbf-4b92-acb1-8f008ccedf53 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7825 biolink:treats MONDO:0005984 PMID:41385096 "[{""id"":""uuid:6b643d2f-8bdd-4d33-8b7f-bd17775a4918"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e67aed12-bbf9-4fc2-bfb6-322c0b42951a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OXISTAT ® Cream and Lotion are indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris, and tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes, or Epidermophyton floccosum. OXISTAT ® Cream is indicated for the topical treatment of tinea (pityriasis) versicolor due to Malassezia furfur (see DOSAGE AND ADMINISTRATION and CLINICAL STUDIES ). OXISTAT ® Cream may be used in pediatric patients for tinea corporis, tinea cruris, tinea pedis, and tinea (pityriasis) versicolor; however, these indications for which OXISTAT ® Cream has been shown to be effective rarely occur in children below the age of 12. uuid:5367c62f-48e6-408c-bc22-763d2056f213 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7825 biolink:treats MONDO:0001405 PMID:41385096 "[{""id"":""uuid:be6f99bb-c180-4bf7-801d-61b690ca3eac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f72bf573-017b-4ac0-a9ef-7561a446a264"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OXISTAT ® Cream and Lotion are indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris, and tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes, or Epidermophyton floccosum. OXISTAT ® Cream is indicated for the topical treatment of tinea (pityriasis) versicolor due to Malassezia furfur (see DOSAGE AND ADMINISTRATION and CLINICAL STUDIES ). OXISTAT ® Cream may be used in pediatric patients for tinea corporis, tinea cruris, tinea pedis, and tinea (pityriasis) versicolor; however, these indications for which OXISTAT ® Cream has been shown to be effective rarely occur in children below the age of 12. uuid:c1717dcd-360d-4307-b319-fae8f2f71ce3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7825 biolink:treats MONDO:0001461 PMID:41385096 "[{""id"":""uuid:903d1325-8e27-42b4-b8b6-e5a0b9463b8c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b790a906-eab0-4933-b4bd-62038dc48fcf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OXISTAT ® Cream and Lotion are indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris, and tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes, or Epidermophyton floccosum. OXISTAT ® Cream is indicated for the topical treatment of tinea (pityriasis) versicolor due to Malassezia furfur (see DOSAGE AND ADMINISTRATION and CLINICAL STUDIES ). OXISTAT ® Cream may be used in pediatric patients for tinea corporis, tinea cruris, tinea pedis, and tinea (pityriasis) versicolor; however, these indications for which OXISTAT ® Cream has been shown to be effective rarely occur in children below the age of 12. uuid:f18d9274-3b15-4cd1-8786-a786ff68afec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7825 biolink:treats MONDO:0005915 PMID:41385096 "[{""id"":""uuid:96451c5d-7716-4c0f-9569-6bc7e492889e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4daed4f9-55d4-46ac-8138-37ba60c149bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OXISTAT ® Cream and Lotion are indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris, and tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes, or Epidermophyton floccosum. OXISTAT ® Cream is indicated for the topical treatment of tinea (pityriasis) versicolor due to Malassezia furfur (see DOSAGE AND ADMINISTRATION and CLINICAL STUDIES ). OXISTAT ® Cream may be used in pediatric patients for tinea corporis, tinea cruris, tinea pedis, and tinea (pityriasis) versicolor; however, these indications for which OXISTAT ® Cream has been shown to be effective rarely occur in children below the age of 12. uuid:32ffc3dc-f19b-4a37-914e-29cd32650a45 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB10666 biolink:treats MONDO:0005271 PMID:41385096 "[{""id"":""uuid:bb890520-6bee-4ce0-bf36-cc8888d4a64a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3258d0f7-3170-436b-a430-29ca3c4932c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergenic extracts are indicated for use in diagnostic testing and as part of a treatment regime for allergic disease, as established by allergy history and skin test reactivity. Allergenic extracts are indicated for the treatment of allergen specific allergic disease for use as hyposensitization or immunotherapy when avoidance of specific allergens can not be attained. The use of allergenic extracts for therapeutic purpose has been established by well-controlled clinical studies. Allergenic extracts may be used as adjunctive therapy along with pharmacotherapy which includes antihistamines, corticosteroids, and cromoglycate, and avoidance measures. Allergenic extracts for therapeutic use should be given using only the allergen selection to which the patient is allergic, has a history of exposure and are likely to be exposed to again. uuid:ddcff289-1ae5-42e3-9a8d-e9ece3400013 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB10611 biolink:treats MONDO:0005271 PMID:41385096 "[{""id"":""uuid:23ff63dc-22ec-4a33-a0da-b7739d356613"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ac9dfb88-ba69-4f76-824b-dbb23e67e735"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergenic extracts are indicated for use in diagnostic testing and as part of a treatment regime for allergic disease, as established by allergy history and skin test reactivity. Allergenic extracts are indicated for the treatment of allergen specific allergic disease for use as hyposensitization or immunotherapy when avoidance of specific allergens can not be attained. The use of allergenic extracts for therapeutic purpose has been established by well-controlled clinical studies. Allergenic extracts may be used as adjunctive therapy along with pharmacotherapy which includes antihistamines, corticosteroids, and cromoglycate, and avoidance measures. Allergenic extracts for therapeutic use should be given using only the allergen selection to which the patient is allergic, has a history of exposure and are likely to be exposed to again. uuid:c890ccbe-5f63-46c0-8f4a-1e305265a6ff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:144551 biolink:treats UMLS:C0392115 PMID:41385096 "[{""id"":""uuid:279777cb-5cab-4787-b0b9-02331647da83"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0ee425f5-5f00-49a7-8b95-671e634431a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxybutynin chloride tablets are indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria). uuid:7a7b5429-7d9e-4bc6-bc7d-b846a9ffb2b8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:144551 biolink:treats HP:0000011 PMID:41385096 "[{""id"":""uuid:aebcfac9-9f74-43a2-a3ee-e8d4002a2c5e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:66d0e3e5-edd5-4ca6-b3cb-63604b5ffc26"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxybutynin chloride tablets are indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria). uuid:b2026337-47a0-4377-93f4-f79615b7a24a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10102 biolink:treats MONDO:0013600 PMID:41385096 "[{""id"":""uuid:dc73cdf3-8e6d-4475-ad9b-89c3640f3dd6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f92d8140-1db6-4bb9-84c0-505897a752b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Zaleplon is indicated for the short-term treatment of insomnia. Zaleplon has been shown to decrease the time to sleep onset for up to 30 days in controlled clinical studies (see Clinical Trials under CLINICAL PHARMACOLOGY ). It has not been shown to increase total sleep time or decrease the number of awakenings. The clinical trials performed in support of efficacy ranged from a single night to 5 weeks in duration. The final formal assessments of sleep latency were performed at the end of treatment. uuid:45306742-1f37-4def-9a14-5d9407c700e9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB10686 biolink:treats MONDO:0005271 PMID:41385096 "[{""id"":""uuid:b96836d0-4c8b-4b62-9bab-5354c860734e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:069e4341-c384-4e51-8107-b193eb8bdbb3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergenic extracts are indicated for use in diagnostic testing and as part of a treatment regime for allergic disease, as established by allergy history and skin test reactivity. Allergenic extracts are indicated for the treatment of allergen specific allergic disease for use as hyposensitization or immunotherapy when avoidance of specific allergens can not be attained. The use of allergenic extracts for therapeutic purpose has been established by well-controlled clinical studies. Allergenic extracts may be used as adjunctive therapy along with pharmacotherapy which includes antihistamines, corticosteroids, and cromoglycate, and avoidance measures. Allergenic extracts for therapeutic use should be given using only the allergen selection to which the patient is allergic, has a history of exposure and are likely to be exposed to again. uuid:31c3d9ae-2e08-463f-87cf-5f85a9256e48 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6359 biolink:treats MONDO:0002203 PMID:41385096 "[{""id"":""uuid:0a1d6d48-f78e-4d91-922e-90f83ef4e624"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:498e5417-19eb-4a9b-aad8-f2f958f6ae5d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the treatment of constipation. In patients with a history of chronic constipation, lactulose solution therapy increases the number of bowel movements per day and the number of days on which bowel movements occur. uuid:04ad4166-8e73-4644-9f5b-4a7049dd01e4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6359 biolink:treats HP:0012450 PMID:41385096 "[{""id"":""uuid:022671dd-c141-4560-a752-c3ed1b1c9f76"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ff97eb1a-a0d4-49a7-8fbf-bdabc0c73c74"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:a315a9c8-0e8a-4231-82ec-47fdbec6a5d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the treatment of constipation. In patients with a history of chronic constipation, lactulose solution therapy increases the number of bowel movements per day and the number of days on which bowel movements occur.|[PMDA] A drug with a new additional indication and a new dosage in an additional dosage form indicated for the treatment of chronic constipation (excluding constipation due to organic diseases). uuid:1fcc2143-0d01-4262-bfd8-69734d532b43 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4514 biolink:treats MONDO:0005052 PMID:41385096 "[{""id"":""uuid:e3386ed9-ab44-4590-8a78-1a836576842a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f396de8f-527c-4fe5-b362-effb2b6b56b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the treatment of functional bowel/irritable bowel syndrome. uuid:5d46e3ef-03aa-403c-926c-b103f1dc02ae biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27796 biolink:treats EFO:0004888 PMID:41385096 "[{""id"":""uuid:9a1e0982-8e68-4e60-b8de-e21876255018"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e24ad763-5b08-4e60-81f2-3c9cda9c3960"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Trimethobenzamide hydrochloride capsules are indicated for the treatment of postoperative nausea and vomiting and for nausea associated with gastroenteritis. uuid:273a0873-be3c-4611-bdc6-cdf3dee36f17 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27796 biolink:treats MONDO:0002269 PMID:41385096 "[{""id"":""uuid:961d6518-44cd-4e40-bc45-d7bae27a838b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ebc5d2a7-fd55-428b-97e2-6e86bce6635d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Trimethobenzamide hydrochloride capsules are indicated for the treatment of postoperative nausea and vomiting and for nausea associated with gastroenteritis. uuid:00319f13-27a3-4e51-9b8a-5407b8be9f2c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB10581 biolink:treats MONDO:0005271 PMID:41385096 "[{""id"":""uuid:d3ea1681-4341-427d-acc4-57fc8a3b8241"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9556797d-8bcc-4fa7-9ef6-d53554bbe74c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergenic extracts are indicated for use in diagnostic testing and as part of a treatment regime for allergic disease, as established by allergy history and skin test reactivity. Allergenic extracts are indicated for the treatment of allergen specific allergic disease for use as hyposensitization or immunotherapy when avoidance of specific allergens can not be attained. The use of allergenic extracts for therapeutic purpose has been established by well-controlled clinical studies. Allergenic extracts may be used as adjunctive therapy along with pharmacotherapy which includes antihistamines, corticosteroids, and cromoglycate, and avoidance measures. Allergenic extracts for therapeutic use should be given using only the allergen selection to which the patient is allergic, has a history of exposure and are likely to be exposed to again. uuid:6bfb6a24-8a6e-484f-aa86-8d81dd49b678 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB10634 biolink:treats MONDO:0005271 PMID:41385096 "[{""id"":""uuid:1858bb15-b9ee-42ea-8a18-76577ba63f69"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2fdc8176-9498-4906-8fca-6b722ba1a35f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergenic extracts are indicated for use in diagnostic testing and as part of a treatment regime for allergic disease, as established by allergy history and skin test reactivity. Allergenic extracts are indicated for the treatment of allergen specific allergic disease for use as hyposensitization or immunotherapy when avoidance of specific allergens can not be attained. The use of allergenic extracts for therapeutic purpose has been established by well-controlled clinical studies. Allergenic extracts may be used as adjunctive therapy along with pharmacotherapy which includes antihistamines, corticosteroids, and cromoglycate, and avoidance measures. Allergenic extracts for therapeutic use should be given using only the allergen selection to which the patient is allergic, has a history of exposure and are likely to be exposed to again. uuid:0a8d872a-16e5-4ef7-bec8-8ba23f6288d1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB10761 biolink:treats MONDO:0005271 PMID:41385096 "[{""id"":""uuid:fb3cfcff-b5bc-4790-899d-bede067d3b95"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e6b5ee04-29f7-4ade-8cf1-b21cee01b0cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergenic extracts are indicated for use in diagnostic testing and as part of a treatment regime for allergic disease, as established by allergy history and skin test reactivity. Allergenic extracts are indicated for the treatment of allergen specific allergic disease for use as hyposensitization or immunotherapy when avoidance of specific allergens can not be attained. The use of allergenic extracts for therapeutic purpose has been established by well-controlled clinical studies. Allergenic extracts may be used as adjunctive therapy along with pharmacotherapy which includes antihistamines, corticosteroids, and cromoglycate, and avoidance measures. Allergenic extracts for therapeutic use should be given using only the allergen selection to which the patient is allergic, has a history of exposure and are likely to be exposed to again. uuid:e9fdd50c-8b4d-4ced-8c8b-0e994463019e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB10716 biolink:treats MONDO:0005271 PMID:41385096 "[{""id"":""uuid:63c8c718-398a-4165-a017-9ac045eceec0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a49b6d4b-7e14-40c4-aa9a-209800992c81"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergenic extracts are indicated for use in diagnostic testing and as part of a treatment regime for allergic disease, as established by allergy history and skin test reactivity. Allergenic extracts are indicated for the treatment of allergen specific allergic disease for use as hyposensitization or immunotherapy when avoidance of specific allergens can not be attained. The use of allergenic extracts for therapeutic purpose has been established by well-controlled clinical studies. Allergenic extracts may be used as adjunctive therapy along with pharmacotherapy which includes antihistamines, corticosteroids, and cromoglycate, and avoidance measures. Allergenic extracts for therapeutic use should be given using only the allergen selection to which the patient is allergic, has a history of exposure and are likely to be exposed to again. uuid:cd899c5a-52c2-4785-8d8e-3af48bc6bc61 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16755 biolink:treats MONDO:0024647 PMID:41385096 "[{""id"":""uuid:139d16e3-1cf8-4100-816b-e202d981e36d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f0764fc5-2393-4b84-89e3-134c8ee2ac37"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Chenodal (chenodiol tablets) is indicated for patients with radiolucent stones in well-opacifying gallbladders, in whom selective surgery would be undertaken except for the presence of increased surgical risk due to systemic disease or age. The likelihood of successful dissolution is far greater if the stones are floatable or small. For patients with nonfloatable stones, dissolution is less likely and added weight should be given to the risk that more emergent surgery might result form a delay due to unsuccessful treatment. Safety of use beyond 24 months is not established. Chenodiol will not dissolve calcified (radiopaque) or radiolucent bile pigment stones. uuid:e41ff4c0-f9a5-43cc-861b-8daf8f26ee8e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16755 biolink:treats MONDO:0012672 PMID:41385096 "[{""id"":""uuid:2e6a32cd-3df2-4a4c-ba66-2ed0680b87be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:22688a99-680a-472e-a16c-03d91771f5ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Chenodal (chenodiol tablets) is indicated for patients with radiolucent stones in well-opacifying gallbladders, in whom selective surgery would be undertaken except for the presence of increased surgical risk due to systemic disease or age. The likelihood of successful dissolution is far greater if the stones are floatable or small. For patients with nonfloatable stones, dissolution is less likely and added weight should be given to the risk that more emergent surgery might result form a delay due to unsuccessful treatment. Safety of use beyond 24 months is not established. Chenodiol will not dissolve calcified (radiopaque) or radiolucent bile pigment stones. uuid:d3719ca0-9e54-4b9a-bbe9-dfd26da21400 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5134 biolink:treats MONDO:0005324 PMID:41385096 "[{""id"":""uuid:0fb452d1-b6a8-46b7-91ca-71973d891d43"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f09700d7-8705-48d6-88ee-6e6af1bdab9c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fluticasone Propionate Nasal Spray is indicated for the management of the nasal symptoms of seasonal and perennial allergic and nonallergic rhinitis in adults and pediatric patients 4 years of age and older. Safety and effectiveness of Fluticasone Propionate Nasal Spray in children below 4 years of age have not been adequately established. uuid:1f36ea04-30a2-4e57-ba3c-566432120590 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5134 biolink:treats MONDO:0024332 PMID:41385096 "[{""id"":""uuid:fb8f86ee-fb02-4e9e-ae34-ec22d7533404"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:682cef34-bb0f-4332-877c-7d4c2bc149c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fluticasone Propionate Nasal Spray is indicated for the management of the nasal symptoms of seasonal and perennial allergic and nonallergic rhinitis in adults and pediatric patients 4 years of age and older. Safety and effectiveness of Fluticasone Propionate Nasal Spray in children below 4 years of age have not been adequately established. uuid:a160d8c1-9c9c-4004-808b-a2b30138d7c6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5134 biolink:treats MONDO:0006004 PMID:41385096 "[{""id"":""uuid:7daa69a2-b430-4d40-9b9d-911729b3b933"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3092c2a3-e30c-4d3f-be42-d4de86c71c16"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fluticasone Propionate Nasal Spray is indicated for the management of the nasal symptoms of seasonal and perennial allergic and nonallergic rhinitis in adults and pediatric patients 4 years of age and older. Safety and effectiveness of Fluticasone Propionate Nasal Spray in children below 4 years of age have not been adequately established. uuid:0d2fceb3-4d54-49d0-96f1-da60470ddfdb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6909 biolink:treats UMLS:C0343734 PMID:41385096 "[{""id"":""uuid:11a67f81-9bb9-4657-ab98-66fbe0f35edf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fb6cf7aa-8a46-4130-ac13-dd0509b59e44"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Symptomatic Trichomoniasis: Metronidazole is indicated for the treatment of symptomatic trichomoniasis in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures). Asymptomatic Trichomoniasis: Metronidazole is indicated in the treatment of asymptomatic females when the organism is associated with endocervicitis, cervicitis, or cervical erosion.Since there is evidence that presence of the trichomonad can interfere with accurate assessment of abnormal cytological smears, additional smears should be performed after eradication of the parasite. Treatment of Asymptomatic Consorts: T. vaginalis infection is a venereal disease. Therefore, asymptomatic sexual partners of treated patients should be treated simultaneously if the organism has been found to be present, in order to prevent reinfection of the partner. The decision as to whether to treat an asymptomatic male partner who has a negative culture or one for whom no culture has been attempted is an individual one. In making this decision, it should be noted that there is evidence that a woman may become reinfected if her consort is not treated. Also, since there can be considerable difficulty in isolating the organism from the asymptomatic male carrier, negative smears and cultures cannot be relied upon in this regard. In any event, the consort should be treated with metronidazole in cases of reinfection. Amebiasis: Metronidazole is indicated in the treatment of acute intestinal amebiasis (amebic dysentery) and amebic liver abscess. In amebic liver abscess, metronidazole therapy does not obviate the need for aspiration or drainage of pus. Anaerobic Bacterial Infections: Metronidazole is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Indicated surgical procedures should be performed in conjunction with metronidazole therapy. In a mixed aerobic and anaerobic infection, antimicrobials appropriate for the treatment of the aerobic infection should be used in addition to metronidazole. In the treatment of most serious anaerobic infections, the intravenous form of metronidazole is usually administered initially. This may be followed by oral therapy with metronidazole at the discretion of the physician. Intra-Abdominal Infections, including peritonitis, intra-abdominal abscess, and liver abscess, caused by Bacteroides species, including the B. fragilis group, ( B. fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron, B. vulgatus ), Clostridium species, Eubacterium species, Peptococcus niger, and Peptostreptococcus species. Skin and Skin Structure Infections caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus niger, Peptostreptococcus species, and Fusobacterium species. Gynecologic Infections , including endometritis, endomyometritis, tubo-ovarian abscess, and postsurgical vaginal cuff infection, caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus niger and Peptostreptococcus species. Bacterial Septicemia caused by Bacteroides species including the B. fragilis group and Clostridium species. Bone and Joint Infections, as adjunctive therapy, caused by Bacteroides species, including the B. fragilis group. Central Nervous System (CNS) Infection , including meningitis and brain abscess, caused by Bacteroides species, including the B. fragilis group. Lower Respiratory Tract Infections , including pneumonia, empyema, and lung abscess, caused by Bacteroides species including the B. fragilis group. Endocarditis caused by Bacteroides species including the B. fragilis group. uuid:33039635-c8ff-40f9-b27a-4b0f39382a99 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6909 biolink:treats MONDO:0003632 PMID:41385096 "[{""id"":""uuid:2183c31f-feb9-46f0-9d72-4fe1a667d96d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5c13ac16-1774-41da-9e83-9f5e6617c4e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Symptomatic Trichomoniasis: Metronidazole is indicated for the treatment of symptomatic trichomoniasis in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures). Asymptomatic Trichomoniasis: Metronidazole is indicated in the treatment of asymptomatic females when the organism is associated with endocervicitis, cervicitis, or cervical erosion.Since there is evidence that presence of the trichomonad can interfere with accurate assessment of abnormal cytological smears, additional smears should be performed after eradication of the parasite. Treatment of Asymptomatic Consorts: T. vaginalis infection is a venereal disease. Therefore, asymptomatic sexual partners of treated patients should be treated simultaneously if the organism has been found to be present, in order to prevent reinfection of the partner. The decision as to whether to treat an asymptomatic male partner who has a negative culture or one for whom no culture has been attempted is an individual one. In making this decision, it should be noted that there is evidence that a woman may become reinfected if her consort is not treated. Also, since there can be considerable difficulty in isolating the organism from the asymptomatic male carrier, negative smears and cultures cannot be relied upon in this regard. In any event, the consort should be treated with metronidazole in cases of reinfection. Amebiasis: Metronidazole is indicated in the treatment of acute intestinal amebiasis (amebic dysentery) and amebic liver abscess. In amebic liver abscess, metronidazole therapy does not obviate the need for aspiration or drainage of pus. Anaerobic Bacterial Infections: Metronidazole is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Indicated surgical procedures should be performed in conjunction with metronidazole therapy. In a mixed aerobic and anaerobic infection, antimicrobials appropriate for the treatment of the aerobic infection should be used in addition to metronidazole. In the treatment of most serious anaerobic infections, the intravenous form of metronidazole is usually administered initially. This may be followed by oral therapy with metronidazole at the discretion of the physician. Intra-Abdominal Infections, including peritonitis, intra-abdominal abscess, and liver abscess, caused by Bacteroides species, including the B. fragilis group, ( B. fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron, B. vulgatus ), Clostridium species, Eubacterium species, Peptococcus niger, and Peptostreptococcus species. Skin and Skin Structure Infections caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus niger, Peptostreptococcus species, and Fusobacterium species. Gynecologic Infections , including endometritis, endomyometritis, tubo-ovarian abscess, and postsurgical vaginal cuff infection, caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus niger and Peptostreptococcus species. Bacterial Septicemia caused by Bacteroides species including the B. fragilis group and Clostridium species. Bone and Joint Infections, as adjunctive therapy, caused by Bacteroides species, including the B. fragilis group. Central Nervous System (CNS) Infection , including meningitis and brain abscess, caused by Bacteroides species, including the B. fragilis group. Lower Respiratory Tract Infections , including pneumonia, empyema, and lung abscess, caused by Bacteroides species including the B. fragilis group. Endocarditis caused by Bacteroides species including the B. fragilis group. uuid:e59f22f3-58ff-4b5d-a7dd-1b79f3c26f07 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6909 biolink:treats MONDO:0002345 PMID:41385096 "[{""id"":""uuid:bd980afd-8e69-4729-a4b6-e9eea3ccc165"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8032b559-2293-40fc-b266-98fbbebd903d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Symptomatic Trichomoniasis: Metronidazole is indicated for the treatment of symptomatic trichomoniasis in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures). Asymptomatic Trichomoniasis: Metronidazole is indicated in the treatment of asymptomatic females when the organism is associated with endocervicitis, cervicitis, or cervical erosion.Since there is evidence that presence of the trichomonad can interfere with accurate assessment of abnormal cytological smears, additional smears should be performed after eradication of the parasite. Treatment of Asymptomatic Consorts: T. vaginalis infection is a venereal disease. Therefore, asymptomatic sexual partners of treated patients should be treated simultaneously if the organism has been found to be present, in order to prevent reinfection of the partner. The decision as to whether to treat an asymptomatic male partner who has a negative culture or one for whom no culture has been attempted is an individual one. In making this decision, it should be noted that there is evidence that a woman may become reinfected if her consort is not treated. Also, since there can be considerable difficulty in isolating the organism from the asymptomatic male carrier, negative smears and cultures cannot be relied upon in this regard. In any event, the consort should be treated with metronidazole in cases of reinfection. Amebiasis: Metronidazole is indicated in the treatment of acute intestinal amebiasis (amebic dysentery) and amebic liver abscess. In amebic liver abscess, metronidazole therapy does not obviate the need for aspiration or drainage of pus. Anaerobic Bacterial Infections: Metronidazole is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Indicated surgical procedures should be performed in conjunction with metronidazole therapy. In a mixed aerobic and anaerobic infection, antimicrobials appropriate for the treatment of the aerobic infection should be used in addition to metronidazole. In the treatment of most serious anaerobic infections, the intravenous form of metronidazole is usually administered initially. This may be followed by oral therapy with metronidazole at the discretion of the physician. Intra-Abdominal Infections, including peritonitis, intra-abdominal abscess, and liver abscess, caused by Bacteroides species, including the B. fragilis group, ( B. fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron, B. vulgatus ), Clostridium species, Eubacterium species, Peptococcus niger, and Peptostreptococcus species. Skin and Skin Structure Infections caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus niger, Peptostreptococcus species, and Fusobacterium species. Gynecologic Infections , including endometritis, endomyometritis, tubo-ovarian abscess, and postsurgical vaginal cuff infection, caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus niger and Peptostreptococcus species. Bacterial Septicemia caused by Bacteroides species including the B. fragilis group and Clostridium species. Bone and Joint Infections, as adjunctive therapy, caused by Bacteroides species, including the B. fragilis group. Central Nervous System (CNS) Infection , including meningitis and brain abscess, caused by Bacteroides species, including the B. fragilis group. Lower Respiratory Tract Infections , including pneumonia, empyema, and lung abscess, caused by Bacteroides species including the B. fragilis group. Endocarditis caused by Bacteroides species including the B. fragilis group. uuid:d1ea4926-e22b-4fbb-93ca-e58d7c7994f9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6909 biolink:treats MONDO:0006696 PMID:41385096 "[{""id"":""uuid:9c58eab1-e4ba-47bf-8f4e-68ae375353ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:95b2588e-630b-4f81-be4b-f47dc7808a4c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Symptomatic Trichomoniasis: Metronidazole is indicated for the treatment of symptomatic trichomoniasis in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures). Asymptomatic Trichomoniasis: Metronidazole is indicated in the treatment of asymptomatic females when the organism is associated with endocervicitis, cervicitis, or cervical erosion.Since there is evidence that presence of the trichomonad can interfere with accurate assessment of abnormal cytological smears, additional smears should be performed after eradication of the parasite. Treatment of Asymptomatic Consorts: T. vaginalis infection is a venereal disease. Therefore, asymptomatic sexual partners of treated patients should be treated simultaneously if the organism has been found to be present, in order to prevent reinfection of the partner. The decision as to whether to treat an asymptomatic male partner who has a negative culture or one for whom no culture has been attempted is an individual one. In making this decision, it should be noted that there is evidence that a woman may become reinfected if her consort is not treated. Also, since there can be considerable difficulty in isolating the organism from the asymptomatic male carrier, negative smears and cultures cannot be relied upon in this regard. In any event, the consort should be treated with metronidazole in cases of reinfection. Amebiasis: Metronidazole is indicated in the treatment of acute intestinal amebiasis (amebic dysentery) and amebic liver abscess. In amebic liver abscess, metronidazole therapy does not obviate the need for aspiration or drainage of pus. Anaerobic Bacterial Infections: Metronidazole is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Indicated surgical procedures should be performed in conjunction with metronidazole therapy. In a mixed aerobic and anaerobic infection, antimicrobials appropriate for the treatment of the aerobic infection should be used in addition to metronidazole. In the treatment of most serious anaerobic infections, the intravenous form of metronidazole is usually administered initially. This may be followed by oral therapy with metronidazole at the discretion of the physician. Intra-Abdominal Infections, including peritonitis, intra-abdominal abscess, and liver abscess, caused by Bacteroides species, including the B. fragilis group, ( B. fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron, B. vulgatus ), Clostridium species, Eubacterium species, Peptococcus niger, and Peptostreptococcus species. Skin and Skin Structure Infections caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus niger, Peptostreptococcus species, and Fusobacterium species. Gynecologic Infections , including endometritis, endomyometritis, tubo-ovarian abscess, and postsurgical vaginal cuff infection, caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus niger and Peptostreptococcus species. Bacterial Septicemia caused by Bacteroides species including the B. fragilis group and Clostridium species. Bone and Joint Infections, as adjunctive therapy, caused by Bacteroides species, including the B. fragilis group. Central Nervous System (CNS) Infection , including meningitis and brain abscess, caused by Bacteroides species, including the B. fragilis group. Lower Respiratory Tract Infections , including pneumonia, empyema, and lung abscess, caused by Bacteroides species including the B. fragilis group. Endocarditis caused by Bacteroides species including the B. fragilis group. uuid:2e9cdcea-2636-4d43-a43b-0d000b938105 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6909 biolink:treats MONDO:0005644 PMID:41385096 "[{""id"":""uuid:bb3233b1-5fe8-4ee0-ab75-94d709bcea58"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9692f326-5bbe-402c-a262-45e451713d0d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Symptomatic Trichomoniasis: Metronidazole is indicated for the treatment of symptomatic trichomoniasis in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures). Asymptomatic Trichomoniasis: Metronidazole is indicated in the treatment of asymptomatic females when the organism is associated with endocervicitis, cervicitis, or cervical erosion.Since there is evidence that presence of the trichomonad can interfere with accurate assessment of abnormal cytological smears, additional smears should be performed after eradication of the parasite. Treatment of Asymptomatic Consorts: T. vaginalis infection is a venereal disease. Therefore, asymptomatic sexual partners of treated patients should be treated simultaneously if the organism has been found to be present, in order to prevent reinfection of the partner. The decision as to whether to treat an asymptomatic male partner who has a negative culture or one for whom no culture has been attempted is an individual one. In making this decision, it should be noted that there is evidence that a woman may become reinfected if her consort is not treated. Also, since there can be considerable difficulty in isolating the organism from the asymptomatic male carrier, negative smears and cultures cannot be relied upon in this regard. In any event, the consort should be treated with metronidazole in cases of reinfection. Amebiasis: Metronidazole is indicated in the treatment of acute intestinal amebiasis (amebic dysentery) and amebic liver abscess. In amebic liver abscess, metronidazole therapy does not obviate the need for aspiration or drainage of pus. Anaerobic Bacterial Infections: Metronidazole is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Indicated surgical procedures should be performed in conjunction with metronidazole therapy. In a mixed aerobic and anaerobic infection, antimicrobials appropriate for the treatment of the aerobic infection should be used in addition to metronidazole. In the treatment of most serious anaerobic infections, the intravenous form of metronidazole is usually administered initially. This may be followed by oral therapy with metronidazole at the discretion of the physician. Intra-Abdominal Infections, including peritonitis, intra-abdominal abscess, and liver abscess, caused by Bacteroides species, including the B. fragilis group, ( B. fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron, B. vulgatus ), Clostridium species, Eubacterium species, Peptococcus niger, and Peptostreptococcus species. Skin and Skin Structure Infections caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus niger, Peptostreptococcus species, and Fusobacterium species. Gynecologic Infections , including endometritis, endomyometritis, tubo-ovarian abscess, and postsurgical vaginal cuff infection, caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus niger and Peptostreptococcus species. Bacterial Septicemia caused by Bacteroides species including the B. fragilis group and Clostridium species. Bone and Joint Infections, as adjunctive therapy, caused by Bacteroides species, including the B. fragilis group. Central Nervous System (CNS) Infection , including meningitis and brain abscess, caused by Bacteroides species, including the B. fragilis group. Lower Respiratory Tract Infections , including pneumonia, empyema, and lung abscess, caused by Bacteroides species including the B. fragilis group. Endocarditis caused by Bacteroides species including the B. fragilis group. uuid:dd21a2ab-e05e-48c7-af30-ca367a79081f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6909 biolink:treats MONDO:0024275 PMID:41385096 "[{""id"":""uuid:68cefe61-71b5-45e3-b83e-9bf6b5e00a37"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:19e66400-760c-48ed-806a-0f4c543dfd60"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:66e8cb7e-5c0c-4c59-92d4-b649989d24ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Symptomatic Trichomoniasis: Metronidazole is indicated for the treatment of symptomatic trichomoniasis in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures). Asymptomatic Trichomoniasis: Metronidazole is indicated in the treatment of asymptomatic females when the organism is associated with endocervicitis, cervicitis, or cervical erosion.Since there is evidence that presence of the trichomonad can interfere with accurate assessment of abnormal cytological smears, additional smears should be performed after eradication of the parasite. Treatment of Asymptomatic Consorts: T. vaginalis infection is a venereal disease. Therefore, asymptomatic sexual partners of treated patients should be treated simultaneously if the organism has been found to be present, in order to prevent reinfection of the partner. The decision as to whether to treat an asymptomatic male partner who has a negative culture or one for whom no culture has been attempted is an individual one. In making this decision, it should be noted that there is evidence that a woman may become reinfected if her consort is not treated. Also, since there can be considerable difficulty in isolating the organism from the asymptomatic male carrier, negative smears and cultures cannot be relied upon in this regard. In any event, the consort should be treated with metronidazole in cases of reinfection. Amebiasis: Metronidazole is indicated in the treatment of acute intestinal amebiasis (amebic dysentery) and amebic liver abscess. In amebic liver abscess, metronidazole therapy does not obviate the need for aspiration or drainage of pus. Anaerobic Bacterial Infections: Metronidazole is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Indicated surgical procedures should be performed in conjunction with metronidazole therapy. In a mixed aerobic and anaerobic infection, antimicrobials appropriate for the treatment of the aerobic infection should be used in addition to metronidazole. In the treatment of most serious anaerobic infections, the intravenous form of metronidazole is usually administered initially. This may be followed by oral therapy with metronidazole at the discretion of the physician. Intra-Abdominal Infections, including peritonitis, intra-abdominal abscess, and liver abscess, caused by Bacteroides species, including the B. fragilis group, ( B. fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron, B. vulgatus ), Clostridium species, Eubacterium species, Peptococcus niger, and Peptostreptococcus species. Skin and Skin Structure Infections caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus niger, Peptostreptococcus species, and Fusobacterium species. Gynecologic Infections , including endometritis, endomyometritis, tubo-ovarian abscess, and postsurgical vaginal cuff infection, caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus niger and Peptostreptococcus species. Bacterial Septicemia caused by Bacteroides species including the B. fragilis group and Clostridium species. Bone and Joint Infections, as adjunctive therapy, caused by Bacteroides species, including the B. fragilis group. Central Nervous System (CNS) Infection , including meningitis and brain abscess, caused by Bacteroides species, including the B. fragilis group. Lower Respiratory Tract Infections , including pneumonia, empyema, and lung abscess, caused by Bacteroides species including the B. fragilis group. Endocarditis caused by Bacteroides species including the B. fragilis group.|[PMDA] A drug with a new route of administration indicated for the treatment of different kinds of anaerobic bacterial infections, infectious enteritis, and amebic dysentery. uuid:c8356036-f548-4963-8862-c43be7509d19 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6909 biolink:treats UMLS:C0023886 PMID:41385096 "[{""id"":""uuid:1d4c7c2e-279f-41bd-b25c-6b6e21d8134e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e6f3bae4-b3ed-4b4a-afb8-59bfc1cec651"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Symptomatic Trichomoniasis: Metronidazole is indicated for the treatment of symptomatic trichomoniasis in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures). Asymptomatic Trichomoniasis: Metronidazole is indicated in the treatment of asymptomatic females when the organism is associated with endocervicitis, cervicitis, or cervical erosion.Since there is evidence that presence of the trichomonad can interfere with accurate assessment of abnormal cytological smears, additional smears should be performed after eradication of the parasite. Treatment of Asymptomatic Consorts: T. vaginalis infection is a venereal disease. Therefore, asymptomatic sexual partners of treated patients should be treated simultaneously if the organism has been found to be present, in order to prevent reinfection of the partner. The decision as to whether to treat an asymptomatic male partner who has a negative culture or one for whom no culture has been attempted is an individual one. In making this decision, it should be noted that there is evidence that a woman may become reinfected if her consort is not treated. Also, since there can be considerable difficulty in isolating the organism from the asymptomatic male carrier, negative smears and cultures cannot be relied upon in this regard. In any event, the consort should be treated with metronidazole in cases of reinfection. Amebiasis: Metronidazole is indicated in the treatment of acute intestinal amebiasis (amebic dysentery) and amebic liver abscess. In amebic liver abscess, metronidazole therapy does not obviate the need for aspiration or drainage of pus. Anaerobic Bacterial Infections: Metronidazole is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Indicated surgical procedures should be performed in conjunction with metronidazole therapy. In a mixed aerobic and anaerobic infection, antimicrobials appropriate for the treatment of the aerobic infection should be used in addition to metronidazole. In the treatment of most serious anaerobic infections, the intravenous form of metronidazole is usually administered initially. This may be followed by oral therapy with metronidazole at the discretion of the physician. Intra-Abdominal Infections, including peritonitis, intra-abdominal abscess, and liver abscess, caused by Bacteroides species, including the B. fragilis group, ( B. fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron, B. vulgatus ), Clostridium species, Eubacterium species, Peptococcus niger, and Peptostreptococcus species. Skin and Skin Structure Infections caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus niger, Peptostreptococcus species, and Fusobacterium species. Gynecologic Infections , including endometritis, endomyometritis, tubo-ovarian abscess, and postsurgical vaginal cuff infection, caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus niger and Peptostreptococcus species. Bacterial Septicemia caused by Bacteroides species including the B. fragilis group and Clostridium species. Bone and Joint Infections, as adjunctive therapy, caused by Bacteroides species, including the B. fragilis group. Central Nervous System (CNS) Infection , including meningitis and brain abscess, caused by Bacteroides species, including the B. fragilis group. Lower Respiratory Tract Infections , including pneumonia, empyema, and lung abscess, caused by Bacteroides species including the B. fragilis group. Endocarditis caused by Bacteroides species including the B. fragilis group. uuid:bac5d44f-82f6-4e7e-9b32-3a0c73490828 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6909 biolink:treats MONDO:0004522 PMID:41385096 "[{""id"":""uuid:8865fd68-ad73-41b3-bade-7ac71a478e7b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:435a109a-2d46-4c88-a586-ff6b915da488"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Symptomatic Trichomoniasis: Metronidazole is indicated for the treatment of symptomatic trichomoniasis in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures). Asymptomatic Trichomoniasis: Metronidazole is indicated in the treatment of asymptomatic females when the organism is associated with endocervicitis, cervicitis, or cervical erosion.Since there is evidence that presence of the trichomonad can interfere with accurate assessment of abnormal cytological smears, additional smears should be performed after eradication of the parasite. Treatment of Asymptomatic Consorts: T. vaginalis infection is a venereal disease. Therefore, asymptomatic sexual partners of treated patients should be treated simultaneously if the organism has been found to be present, in order to prevent reinfection of the partner. The decision as to whether to treat an asymptomatic male partner who has a negative culture or one for whom no culture has been attempted is an individual one. In making this decision, it should be noted that there is evidence that a woman may become reinfected if her consort is not treated. Also, since there can be considerable difficulty in isolating the organism from the asymptomatic male carrier, negative smears and cultures cannot be relied upon in this regard. In any event, the consort should be treated with metronidazole in cases of reinfection. Amebiasis: Metronidazole is indicated in the treatment of acute intestinal amebiasis (amebic dysentery) and amebic liver abscess. In amebic liver abscess, metronidazole therapy does not obviate the need for aspiration or drainage of pus. Anaerobic Bacterial Infections: Metronidazole is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Indicated surgical procedures should be performed in conjunction with metronidazole therapy. In a mixed aerobic and anaerobic infection, antimicrobials appropriate for the treatment of the aerobic infection should be used in addition to metronidazole. In the treatment of most serious anaerobic infections, the intravenous form of metronidazole is usually administered initially. This may be followed by oral therapy with metronidazole at the discretion of the physician. Intra-Abdominal Infections, including peritonitis, intra-abdominal abscess, and liver abscess, caused by Bacteroides species, including the B. fragilis group, ( B. fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron, B. vulgatus ), Clostridium species, Eubacterium species, Peptococcus niger, and Peptostreptococcus species. Skin and Skin Structure Infections caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus niger, Peptostreptococcus species, and Fusobacterium species. Gynecologic Infections , including endometritis, endomyometritis, tubo-ovarian abscess, and postsurgical vaginal cuff infection, caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus niger and Peptostreptococcus species. Bacterial Septicemia caused by Bacteroides species including the B. fragilis group and Clostridium species. Bone and Joint Infections, as adjunctive therapy, caused by Bacteroides species, including the B. fragilis group. Central Nervous System (CNS) Infection , including meningitis and brain abscess, caused by Bacteroides species, including the B. fragilis group. Lower Respiratory Tract Infections , including pneumonia, empyema, and lung abscess, caused by Bacteroides species including the B. fragilis group. Endocarditis caused by Bacteroides species including the B. fragilis group. uuid:6760b663-258f-412d-a166-98c57ef17591 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6909 biolink:treats MONDO:0700051 PMID:41385096 "[{""id"":""uuid:89f6c3cf-67a0-4b33-b927-93848e0ddb11"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bcb40903-deeb-4580-b285-7e0343690b5f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Symptomatic Trichomoniasis: Metronidazole is indicated for the treatment of symptomatic trichomoniasis in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures). Asymptomatic Trichomoniasis: Metronidazole is indicated in the treatment of asymptomatic females when the organism is associated with endocervicitis, cervicitis, or cervical erosion.Since there is evidence that presence of the trichomonad can interfere with accurate assessment of abnormal cytological smears, additional smears should be performed after eradication of the parasite. Treatment of Asymptomatic Consorts: T. vaginalis infection is a venereal disease. Therefore, asymptomatic sexual partners of treated patients should be treated simultaneously if the organism has been found to be present, in order to prevent reinfection of the partner. The decision as to whether to treat an asymptomatic male partner who has a negative culture or one for whom no culture has been attempted is an individual one. In making this decision, it should be noted that there is evidence that a woman may become reinfected if her consort is not treated. Also, since there can be considerable difficulty in isolating the organism from the asymptomatic male carrier, negative smears and cultures cannot be relied upon in this regard. In any event, the consort should be treated with metronidazole in cases of reinfection. Amebiasis: Metronidazole is indicated in the treatment of acute intestinal amebiasis (amebic dysentery) and amebic liver abscess. In amebic liver abscess, metronidazole therapy does not obviate the need for aspiration or drainage of pus. Anaerobic Bacterial Infections: Metronidazole is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Indicated surgical procedures should be performed in conjunction with metronidazole therapy. In a mixed aerobic and anaerobic infection, antimicrobials appropriate for the treatment of the aerobic infection should be used in addition to metronidazole. In the treatment of most serious anaerobic infections, the intravenous form of metronidazole is usually administered initially. This may be followed by oral therapy with metronidazole at the discretion of the physician. Intra-Abdominal Infections, including peritonitis, intra-abdominal abscess, and liver abscess, caused by Bacteroides species, including the B. fragilis group, ( B. fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron, B. vulgatus ), Clostridium species, Eubacterium species, Peptococcus niger, and Peptostreptococcus species. Skin and Skin Structure Infections caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus niger, Peptostreptococcus species, and Fusobacterium species. Gynecologic Infections , including endometritis, endomyometritis, tubo-ovarian abscess, and postsurgical vaginal cuff infection, caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus niger and Peptostreptococcus species. Bacterial Septicemia caused by Bacteroides species including the B. fragilis group and Clostridium species. Bone and Joint Infections, as adjunctive therapy, caused by Bacteroides species, including the B. fragilis group. Central Nervous System (CNS) Infection , including meningitis and brain abscess, caused by Bacteroides species, including the B. fragilis group. Lower Respiratory Tract Infections , including pneumonia, empyema, and lung abscess, caused by Bacteroides species including the B. fragilis group. Endocarditis caused by Bacteroides species including the B. fragilis group. uuid:763a961a-7b3d-48b5-823d-9aca4f629a13 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6909 biolink:treats MONDO:0000918 PMID:41385096 "[{""id"":""uuid:e14f8f55-5d30-414b-a812-ad73283f0297"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:88b0ad5f-71f4-43ad-b354-165e356dec20"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Symptomatic Trichomoniasis: Metronidazole is indicated for the treatment of symptomatic trichomoniasis in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures). Asymptomatic Trichomoniasis: Metronidazole is indicated in the treatment of asymptomatic females when the organism is associated with endocervicitis, cervicitis, or cervical erosion.Since there is evidence that presence of the trichomonad can interfere with accurate assessment of abnormal cytological smears, additional smears should be performed after eradication of the parasite. Treatment of Asymptomatic Consorts: T. vaginalis infection is a venereal disease. Therefore, asymptomatic sexual partners of treated patients should be treated simultaneously if the organism has been found to be present, in order to prevent reinfection of the partner. The decision as to whether to treat an asymptomatic male partner who has a negative culture or one for whom no culture has been attempted is an individual one. In making this decision, it should be noted that there is evidence that a woman may become reinfected if her consort is not treated. Also, since there can be considerable difficulty in isolating the organism from the asymptomatic male carrier, negative smears and cultures cannot be relied upon in this regard. In any event, the consort should be treated with metronidazole in cases of reinfection. Amebiasis: Metronidazole is indicated in the treatment of acute intestinal amebiasis (amebic dysentery) and amebic liver abscess. In amebic liver abscess, metronidazole therapy does not obviate the need for aspiration or drainage of pus. Anaerobic Bacterial Infections: Metronidazole is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Indicated surgical procedures should be performed in conjunction with metronidazole therapy. In a mixed aerobic and anaerobic infection, antimicrobials appropriate for the treatment of the aerobic infection should be used in addition to metronidazole. In the treatment of most serious anaerobic infections, the intravenous form of metronidazole is usually administered initially. This may be followed by oral therapy with metronidazole at the discretion of the physician. Intra-Abdominal Infections, including peritonitis, intra-abdominal abscess, and liver abscess, caused by Bacteroides species, including the B. fragilis group, ( B. fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron, B. vulgatus ), Clostridium species, Eubacterium species, Peptococcus niger, and Peptostreptococcus species. Skin and Skin Structure Infections caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus niger, Peptostreptococcus species, and Fusobacterium species. Gynecologic Infections , including endometritis, endomyometritis, tubo-ovarian abscess, and postsurgical vaginal cuff infection, caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus niger and Peptostreptococcus species. Bacterial Septicemia caused by Bacteroides species including the B. fragilis group and Clostridium species. Bone and Joint Infections, as adjunctive therapy, caused by Bacteroides species, including the B. fragilis group. Central Nervous System (CNS) Infection , including meningitis and brain abscess, caused by Bacteroides species, including the B. fragilis group. Lower Respiratory Tract Infections , including pneumonia, empyema, and lung abscess, caused by Bacteroides species including the B. fragilis group. Endocarditis caused by Bacteroides species including the B. fragilis group. uuid:c959d0a8-0f50-4f6c-8a16-7efec6706c6e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6909 biolink:treats MONDO:0042451 PMID:41385096 "[{""id"":""uuid:f8855e84-feec-4b27-a6da-f2529549c903"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aac760ca-ca33-434e-b1ed-62a3b03a86e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Symptomatic Trichomoniasis: Metronidazole is indicated for the treatment of symptomatic trichomoniasis in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures). Asymptomatic Trichomoniasis: Metronidazole is indicated in the treatment of asymptomatic females when the organism is associated with endocervicitis, cervicitis, or cervical erosion.Since there is evidence that presence of the trichomonad can interfere with accurate assessment of abnormal cytological smears, additional smears should be performed after eradication of the parasite. Treatment of Asymptomatic Consorts: T. vaginalis infection is a venereal disease. Therefore, asymptomatic sexual partners of treated patients should be treated simultaneously if the organism has been found to be present, in order to prevent reinfection of the partner. The decision as to whether to treat an asymptomatic male partner who has a negative culture or one for whom no culture has been attempted is an individual one. In making this decision, it should be noted that there is evidence that a woman may become reinfected if her consort is not treated. Also, since there can be considerable difficulty in isolating the organism from the asymptomatic male carrier, negative smears and cultures cannot be relied upon in this regard. In any event, the consort should be treated with metronidazole in cases of reinfection. Amebiasis: Metronidazole is indicated in the treatment of acute intestinal amebiasis (amebic dysentery) and amebic liver abscess. In amebic liver abscess, metronidazole therapy does not obviate the need for aspiration or drainage of pus. Anaerobic Bacterial Infections: Metronidazole is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Indicated surgical procedures should be performed in conjunction with metronidazole therapy. In a mixed aerobic and anaerobic infection, antimicrobials appropriate for the treatment of the aerobic infection should be used in addition to metronidazole. In the treatment of most serious anaerobic infections, the intravenous form of metronidazole is usually administered initially. This may be followed by oral therapy with metronidazole at the discretion of the physician. Intra-Abdominal Infections, including peritonitis, intra-abdominal abscess, and liver abscess, caused by Bacteroides species, including the B. fragilis group, ( B. fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron, B. vulgatus ), Clostridium species, Eubacterium species, Peptococcus niger, and Peptostreptococcus species. Skin and Skin Structure Infections caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus niger, Peptostreptococcus species, and Fusobacterium species. Gynecologic Infections , including endometritis, endomyometritis, tubo-ovarian abscess, and postsurgical vaginal cuff infection, caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus niger and Peptostreptococcus species. Bacterial Septicemia caused by Bacteroides species including the B. fragilis group and Clostridium species. Bone and Joint Infections, as adjunctive therapy, caused by Bacteroides species, including the B. fragilis group. Central Nervous System (CNS) Infection , including meningitis and brain abscess, caused by Bacteroides species, including the B. fragilis group. Lower Respiratory Tract Infections , including pneumonia, empyema, and lung abscess, caused by Bacteroides species including the B. fragilis group. Endocarditis caused by Bacteroides species including the B. fragilis group. uuid:7bdcef18-f5cd-478a-a50d-31d87f4fb912 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6909 biolink:treats HP:0034493 PMID:41385096 "[{""id"":""uuid:d46c4d6a-e6df-419c-955a-04021356ee5e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:928d7b01-7fc5-4555-8c7c-5c0ffd73f0d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Symptomatic Trichomoniasis: Metronidazole is indicated for the treatment of symptomatic trichomoniasis in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures). Asymptomatic Trichomoniasis: Metronidazole is indicated in the treatment of asymptomatic females when the organism is associated with endocervicitis, cervicitis, or cervical erosion.Since there is evidence that presence of the trichomonad can interfere with accurate assessment of abnormal cytological smears, additional smears should be performed after eradication of the parasite. Treatment of Asymptomatic Consorts: T. vaginalis infection is a venereal disease. Therefore, asymptomatic sexual partners of treated patients should be treated simultaneously if the organism has been found to be present, in order to prevent reinfection of the partner. The decision as to whether to treat an asymptomatic male partner who has a negative culture or one for whom no culture has been attempted is an individual one. In making this decision, it should be noted that there is evidence that a woman may become reinfected if her consort is not treated. Also, since there can be considerable difficulty in isolating the organism from the asymptomatic male carrier, negative smears and cultures cannot be relied upon in this regard. In any event, the consort should be treated with metronidazole in cases of reinfection. Amebiasis: Metronidazole is indicated in the treatment of acute intestinal amebiasis (amebic dysentery) and amebic liver abscess. In amebic liver abscess, metronidazole therapy does not obviate the need for aspiration or drainage of pus. Anaerobic Bacterial Infections: Metronidazole is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Indicated surgical procedures should be performed in conjunction with metronidazole therapy. In a mixed aerobic and anaerobic infection, antimicrobials appropriate for the treatment of the aerobic infection should be used in addition to metronidazole. In the treatment of most serious anaerobic infections, the intravenous form of metronidazole is usually administered initially. This may be followed by oral therapy with metronidazole at the discretion of the physician. Intra-Abdominal Infections, including peritonitis, intra-abdominal abscess, and liver abscess, caused by Bacteroides species, including the B. fragilis group, ( B. fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron, B. vulgatus ), Clostridium species, Eubacterium species, Peptococcus niger, and Peptostreptococcus species. Skin and Skin Structure Infections caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus niger, Peptostreptococcus species, and Fusobacterium species. Gynecologic Infections , including endometritis, endomyometritis, tubo-ovarian abscess, and postsurgical vaginal cuff infection, caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus niger and Peptostreptococcus species. Bacterial Septicemia caused by Bacteroides species including the B. fragilis group and Clostridium species. Bone and Joint Infections, as adjunctive therapy, caused by Bacteroides species, including the B. fragilis group. Central Nervous System (CNS) Infection , including meningitis and brain abscess, caused by Bacteroides species, including the B. fragilis group. Lower Respiratory Tract Infections , including pneumonia, empyema, and lung abscess, caused by Bacteroides species including the B. fragilis group. Endocarditis caused by Bacteroides species including the B. fragilis group. uuid:369183a0-b16d-42d8-a5d1-43c79978d2e8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6909 biolink:treats UMLS:C0684256 PMID:41385096 "[{""id"":""uuid:33fccb8b-cb81-46e7-89a6-69f145fb28b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:61544fd8-bca8-4af4-a9a5-9589f389c619"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Symptomatic Trichomoniasis: Metronidazole is indicated for the treatment of symptomatic trichomoniasis in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures). Asymptomatic Trichomoniasis: Metronidazole is indicated in the treatment of asymptomatic females when the organism is associated with endocervicitis, cervicitis, or cervical erosion.Since there is evidence that presence of the trichomonad can interfere with accurate assessment of abnormal cytological smears, additional smears should be performed after eradication of the parasite. Treatment of Asymptomatic Consorts: T. vaginalis infection is a venereal disease. Therefore, asymptomatic sexual partners of treated patients should be treated simultaneously if the organism has been found to be present, in order to prevent reinfection of the partner. The decision as to whether to treat an asymptomatic male partner who has a negative culture or one for whom no culture has been attempted is an individual one. In making this decision, it should be noted that there is evidence that a woman may become reinfected if her consort is not treated. Also, since there can be considerable difficulty in isolating the organism from the asymptomatic male carrier, negative smears and cultures cannot be relied upon in this regard. In any event, the consort should be treated with metronidazole in cases of reinfection. Amebiasis: Metronidazole is indicated in the treatment of acute intestinal amebiasis (amebic dysentery) and amebic liver abscess. In amebic liver abscess, metronidazole therapy does not obviate the need for aspiration or drainage of pus. Anaerobic Bacterial Infections: Metronidazole is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Indicated surgical procedures should be performed in conjunction with metronidazole therapy. In a mixed aerobic and anaerobic infection, antimicrobials appropriate for the treatment of the aerobic infection should be used in addition to metronidazole. In the treatment of most serious anaerobic infections, the intravenous form of metronidazole is usually administered initially. This may be followed by oral therapy with metronidazole at the discretion of the physician. Intra-Abdominal Infections, including peritonitis, intra-abdominal abscess, and liver abscess, caused by Bacteroides species, including the B. fragilis group, ( B. fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron, B. vulgatus ), Clostridium species, Eubacterium species, Peptococcus niger, and Peptostreptococcus species. Skin and Skin Structure Infections caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus niger, Peptostreptococcus species, and Fusobacterium species. Gynecologic Infections , including endometritis, endomyometritis, tubo-ovarian abscess, and postsurgical vaginal cuff infection, caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus niger and Peptostreptococcus species. Bacterial Septicemia caused by Bacteroides species including the B. fragilis group and Clostridium species. Bone and Joint Infections, as adjunctive therapy, caused by Bacteroides species, including the B. fragilis group. Central Nervous System (CNS) Infection , including meningitis and brain abscess, caused by Bacteroides species, including the B. fragilis group. Lower Respiratory Tract Infections , including pneumonia, empyema, and lung abscess, caused by Bacteroides species including the B. fragilis group. Endocarditis caused by Bacteroides species including the B. fragilis group. uuid:b950ec75-1fa7-4fc7-ab44-9e298235a434 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6909 biolink:treats MONDO:0021108 PMID:41385096 "[{""id"":""uuid:4d1fa4c5-96fb-48fc-b3da-6ea4426d8a76"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f2c47b31-310d-46e4-83ef-c395774b3254"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Symptomatic Trichomoniasis: Metronidazole is indicated for the treatment of symptomatic trichomoniasis in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures). Asymptomatic Trichomoniasis: Metronidazole is indicated in the treatment of asymptomatic females when the organism is associated with endocervicitis, cervicitis, or cervical erosion.Since there is evidence that presence of the trichomonad can interfere with accurate assessment of abnormal cytological smears, additional smears should be performed after eradication of the parasite. Treatment of Asymptomatic Consorts: T. vaginalis infection is a venereal disease. Therefore, asymptomatic sexual partners of treated patients should be treated simultaneously if the organism has been found to be present, in order to prevent reinfection of the partner. The decision as to whether to treat an asymptomatic male partner who has a negative culture or one for whom no culture has been attempted is an individual one. In making this decision, it should be noted that there is evidence that a woman may become reinfected if her consort is not treated. Also, since there can be considerable difficulty in isolating the organism from the asymptomatic male carrier, negative smears and cultures cannot be relied upon in this regard. In any event, the consort should be treated with metronidazole in cases of reinfection. Amebiasis: Metronidazole is indicated in the treatment of acute intestinal amebiasis (amebic dysentery) and amebic liver abscess. In amebic liver abscess, metronidazole therapy does not obviate the need for aspiration or drainage of pus. Anaerobic Bacterial Infections: Metronidazole is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Indicated surgical procedures should be performed in conjunction with metronidazole therapy. In a mixed aerobic and anaerobic infection, antimicrobials appropriate for the treatment of the aerobic infection should be used in addition to metronidazole. In the treatment of most serious anaerobic infections, the intravenous form of metronidazole is usually administered initially. This may be followed by oral therapy with metronidazole at the discretion of the physician. Intra-Abdominal Infections, including peritonitis, intra-abdominal abscess, and liver abscess, caused by Bacteroides species, including the B. fragilis group, ( B. fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron, B. vulgatus ), Clostridium species, Eubacterium species, Peptococcus niger, and Peptostreptococcus species. Skin and Skin Structure Infections caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus niger, Peptostreptococcus species, and Fusobacterium species. Gynecologic Infections , including endometritis, endomyometritis, tubo-ovarian abscess, and postsurgical vaginal cuff infection, caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus niger and Peptostreptococcus species. Bacterial Septicemia caused by Bacteroides species including the B. fragilis group and Clostridium species. Bone and Joint Infections, as adjunctive therapy, caused by Bacteroides species, including the B. fragilis group. Central Nervous System (CNS) Infection , including meningitis and brain abscess, caused by Bacteroides species, including the B. fragilis group. Lower Respiratory Tract Infections , including pneumonia, empyema, and lung abscess, caused by Bacteroides species including the B. fragilis group. Endocarditis caused by Bacteroides species including the B. fragilis group. uuid:4813b931-5403-43de-bb0c-903c9153d436 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6909 biolink:treats HP:0030049 PMID:41385096 "[{""id"":""uuid:82280148-dac2-4d26-9d42-1955f3088963"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c5c38b9f-2ae6-4a3c-90c4-2bfc3b3daea5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Symptomatic Trichomoniasis: Metronidazole is indicated for the treatment of symptomatic trichomoniasis in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures). Asymptomatic Trichomoniasis: Metronidazole is indicated in the treatment of asymptomatic females when the organism is associated with endocervicitis, cervicitis, or cervical erosion.Since there is evidence that presence of the trichomonad can interfere with accurate assessment of abnormal cytological smears, additional smears should be performed after eradication of the parasite. Treatment of Asymptomatic Consorts: T. vaginalis infection is a venereal disease. Therefore, asymptomatic sexual partners of treated patients should be treated simultaneously if the organism has been found to be present, in order to prevent reinfection of the partner. The decision as to whether to treat an asymptomatic male partner who has a negative culture or one for whom no culture has been attempted is an individual one. In making this decision, it should be noted that there is evidence that a woman may become reinfected if her consort is not treated. Also, since there can be considerable difficulty in isolating the organism from the asymptomatic male carrier, negative smears and cultures cannot be relied upon in this regard. In any event, the consort should be treated with metronidazole in cases of reinfection. Amebiasis: Metronidazole is indicated in the treatment of acute intestinal amebiasis (amebic dysentery) and amebic liver abscess. In amebic liver abscess, metronidazole therapy does not obviate the need for aspiration or drainage of pus. Anaerobic Bacterial Infections: Metronidazole is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Indicated surgical procedures should be performed in conjunction with metronidazole therapy. In a mixed aerobic and anaerobic infection, antimicrobials appropriate for the treatment of the aerobic infection should be used in addition to metronidazole. In the treatment of most serious anaerobic infections, the intravenous form of metronidazole is usually administered initially. This may be followed by oral therapy with metronidazole at the discretion of the physician. Intra-Abdominal Infections, including peritonitis, intra-abdominal abscess, and liver abscess, caused by Bacteroides species, including the B. fragilis group, ( B. fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron, B. vulgatus ), Clostridium species, Eubacterium species, Peptococcus niger, and Peptostreptococcus species. Skin and Skin Structure Infections caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus niger, Peptostreptococcus species, and Fusobacterium species. Gynecologic Infections , including endometritis, endomyometritis, tubo-ovarian abscess, and postsurgical vaginal cuff infection, caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus niger and Peptostreptococcus species. Bacterial Septicemia caused by Bacteroides species including the B. fragilis group and Clostridium species. Bone and Joint Infections, as adjunctive therapy, caused by Bacteroides species, including the B. fragilis group. Central Nervous System (CNS) Infection , including meningitis and brain abscess, caused by Bacteroides species, including the B. fragilis group. Lower Respiratory Tract Infections , including pneumonia, empyema, and lung abscess, caused by Bacteroides species including the B. fragilis group. Endocarditis caused by Bacteroides species including the B. fragilis group. uuid:94954d63-41f8-4748-8579-e4d8b3c7a875 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6909 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:d34716a1-7f02-4264-950e-f4093ba65e1a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e9149ca1-bb76-413f-ad1a-7c199692d4bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Symptomatic Trichomoniasis: Metronidazole is indicated for the treatment of symptomatic trichomoniasis in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures). Asymptomatic Trichomoniasis: Metronidazole is indicated in the treatment of asymptomatic females when the organism is associated with endocervicitis, cervicitis, or cervical erosion.Since there is evidence that presence of the trichomonad can interfere with accurate assessment of abnormal cytological smears, additional smears should be performed after eradication of the parasite. Treatment of Asymptomatic Consorts: T. vaginalis infection is a venereal disease. Therefore, asymptomatic sexual partners of treated patients should be treated simultaneously if the organism has been found to be present, in order to prevent reinfection of the partner. The decision as to whether to treat an asymptomatic male partner who has a negative culture or one for whom no culture has been attempted is an individual one. In making this decision, it should be noted that there is evidence that a woman may become reinfected if her consort is not treated. Also, since there can be considerable difficulty in isolating the organism from the asymptomatic male carrier, negative smears and cultures cannot be relied upon in this regard. In any event, the consort should be treated with metronidazole in cases of reinfection. Amebiasis: Metronidazole is indicated in the treatment of acute intestinal amebiasis (amebic dysentery) and amebic liver abscess. In amebic liver abscess, metronidazole therapy does not obviate the need for aspiration or drainage of pus. Anaerobic Bacterial Infections: Metronidazole is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Indicated surgical procedures should be performed in conjunction with metronidazole therapy. In a mixed aerobic and anaerobic infection, antimicrobials appropriate for the treatment of the aerobic infection should be used in addition to metronidazole. In the treatment of most serious anaerobic infections, the intravenous form of metronidazole is usually administered initially. This may be followed by oral therapy with metronidazole at the discretion of the physician. Intra-Abdominal Infections, including peritonitis, intra-abdominal abscess, and liver abscess, caused by Bacteroides species, including the B. fragilis group, ( B. fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron, B. vulgatus ), Clostridium species, Eubacterium species, Peptococcus niger, and Peptostreptococcus species. Skin and Skin Structure Infections caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus niger, Peptostreptococcus species, and Fusobacterium species. Gynecologic Infections , including endometritis, endomyometritis, tubo-ovarian abscess, and postsurgical vaginal cuff infection, caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus niger and Peptostreptococcus species. Bacterial Septicemia caused by Bacteroides species including the B. fragilis group and Clostridium species. Bone and Joint Infections, as adjunctive therapy, caused by Bacteroides species, including the B. fragilis group. Central Nervous System (CNS) Infection , including meningitis and brain abscess, caused by Bacteroides species, including the B. fragilis group. Lower Respiratory Tract Infections , including pneumonia, empyema, and lung abscess, caused by Bacteroides species including the B. fragilis group. Endocarditis caused by Bacteroides species including the B. fragilis group. uuid:45a09873-a38e-4923-9b20-6ff5a7fdd776 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6909 biolink:treats MONDO:0005242 PMID:41385096 "[{""id"":""uuid:a3c19f12-5e14-4420-90de-09bc16d8315a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7949cb1d-04c4-4776-a3e9-60f3730389d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Symptomatic Trichomoniasis: Metronidazole is indicated for the treatment of symptomatic trichomoniasis in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures). Asymptomatic Trichomoniasis: Metronidazole is indicated in the treatment of asymptomatic females when the organism is associated with endocervicitis, cervicitis, or cervical erosion.Since there is evidence that presence of the trichomonad can interfere with accurate assessment of abnormal cytological smears, additional smears should be performed after eradication of the parasite. Treatment of Asymptomatic Consorts: T. vaginalis infection is a venereal disease. Therefore, asymptomatic sexual partners of treated patients should be treated simultaneously if the organism has been found to be present, in order to prevent reinfection of the partner. The decision as to whether to treat an asymptomatic male partner who has a negative culture or one for whom no culture has been attempted is an individual one. In making this decision, it should be noted that there is evidence that a woman may become reinfected if her consort is not treated. Also, since there can be considerable difficulty in isolating the organism from the asymptomatic male carrier, negative smears and cultures cannot be relied upon in this regard. In any event, the consort should be treated with metronidazole in cases of reinfection. Amebiasis: Metronidazole is indicated in the treatment of acute intestinal amebiasis (amebic dysentery) and amebic liver abscess. In amebic liver abscess, metronidazole therapy does not obviate the need for aspiration or drainage of pus. Anaerobic Bacterial Infections: Metronidazole is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Indicated surgical procedures should be performed in conjunction with metronidazole therapy. In a mixed aerobic and anaerobic infection, antimicrobials appropriate for the treatment of the aerobic infection should be used in addition to metronidazole. In the treatment of most serious anaerobic infections, the intravenous form of metronidazole is usually administered initially. This may be followed by oral therapy with metronidazole at the discretion of the physician. Intra-Abdominal Infections, including peritonitis, intra-abdominal abscess, and liver abscess, caused by Bacteroides species, including the B. fragilis group, ( B. fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron, B. vulgatus ), Clostridium species, Eubacterium species, Peptococcus niger, and Peptostreptococcus species. Skin and Skin Structure Infections caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus niger, Peptostreptococcus species, and Fusobacterium species. Gynecologic Infections , including endometritis, endomyometritis, tubo-ovarian abscess, and postsurgical vaginal cuff infection, caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus niger and Peptostreptococcus species. Bacterial Septicemia caused by Bacteroides species including the B. fragilis group and Clostridium species. Bone and Joint Infections, as adjunctive therapy, caused by Bacteroides species, including the B. fragilis group. Central Nervous System (CNS) Infection , including meningitis and brain abscess, caused by Bacteroides species, including the B. fragilis group. Lower Respiratory Tract Infections , including pneumonia, empyema, and lung abscess, caused by Bacteroides species including the B. fragilis group. Endocarditis caused by Bacteroides species including the B. fragilis group. uuid:3e7d326b-dfc4-4745-98d6-f37b3dc299ec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6909 biolink:treats MONDO:0000744 PMID:41385096 "[{""id"":""uuid:1953b4b5-d99e-441c-97c3-ccd3ddfd4d77"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:541b12e5-119a-4831-ac0d-d845d48dedb1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Symptomatic Trichomoniasis: Metronidazole is indicated for the treatment of symptomatic trichomoniasis in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures). Asymptomatic Trichomoniasis: Metronidazole is indicated in the treatment of asymptomatic females when the organism is associated with endocervicitis, cervicitis, or cervical erosion.Since there is evidence that presence of the trichomonad can interfere with accurate assessment of abnormal cytological smears, additional smears should be performed after eradication of the parasite. Treatment of Asymptomatic Consorts: T. vaginalis infection is a venereal disease. Therefore, asymptomatic sexual partners of treated patients should be treated simultaneously if the organism has been found to be present, in order to prevent reinfection of the partner. The decision as to whether to treat an asymptomatic male partner who has a negative culture or one for whom no culture has been attempted is an individual one. In making this decision, it should be noted that there is evidence that a woman may become reinfected if her consort is not treated. Also, since there can be considerable difficulty in isolating the organism from the asymptomatic male carrier, negative smears and cultures cannot be relied upon in this regard. In any event, the consort should be treated with metronidazole in cases of reinfection. Amebiasis: Metronidazole is indicated in the treatment of acute intestinal amebiasis (amebic dysentery) and amebic liver abscess. In amebic liver abscess, metronidazole therapy does not obviate the need for aspiration or drainage of pus. Anaerobic Bacterial Infections: Metronidazole is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Indicated surgical procedures should be performed in conjunction with metronidazole therapy. In a mixed aerobic and anaerobic infection, antimicrobials appropriate for the treatment of the aerobic infection should be used in addition to metronidazole. In the treatment of most serious anaerobic infections, the intravenous form of metronidazole is usually administered initially. This may be followed by oral therapy with metronidazole at the discretion of the physician. Intra-Abdominal Infections, including peritonitis, intra-abdominal abscess, and liver abscess, caused by Bacteroides species, including the B. fragilis group, ( B. fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron, B. vulgatus ), Clostridium species, Eubacterium species, Peptococcus niger, and Peptostreptococcus species. Skin and Skin Structure Infections caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus niger, Peptostreptococcus species, and Fusobacterium species. Gynecologic Infections , including endometritis, endomyometritis, tubo-ovarian abscess, and postsurgical vaginal cuff infection, caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus niger and Peptostreptococcus species. Bacterial Septicemia caused by Bacteroides species including the B. fragilis group and Clostridium species. Bone and Joint Infections, as adjunctive therapy, caused by Bacteroides species, including the B. fragilis group. Central Nervous System (CNS) Infection , including meningitis and brain abscess, caused by Bacteroides species, including the B. fragilis group. Lower Respiratory Tract Infections , including pneumonia, empyema, and lung abscess, caused by Bacteroides species including the B. fragilis group. Endocarditis caused by Bacteroides species including the B. fragilis group. uuid:91fbcfc6-c9a1-406f-a8b1-38c4105f1fba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6909 biolink:treats MONDO:0005025 PMID:41385096 "[{""id"":""uuid:b00eaaf7-c729-43a7-a4f5-aeb8665e97e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6bfd4b67-ee99-43ab-807d-5b234d0610ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Symptomatic Trichomoniasis: Metronidazole is indicated for the treatment of symptomatic trichomoniasis in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures). Asymptomatic Trichomoniasis: Metronidazole is indicated in the treatment of asymptomatic females when the organism is associated with endocervicitis, cervicitis, or cervical erosion.Since there is evidence that presence of the trichomonad can interfere with accurate assessment of abnormal cytological smears, additional smears should be performed after eradication of the parasite. Treatment of Asymptomatic Consorts: T. vaginalis infection is a venereal disease. Therefore, asymptomatic sexual partners of treated patients should be treated simultaneously if the organism has been found to be present, in order to prevent reinfection of the partner. The decision as to whether to treat an asymptomatic male partner who has a negative culture or one for whom no culture has been attempted is an individual one. In making this decision, it should be noted that there is evidence that a woman may become reinfected if her consort is not treated. Also, since there can be considerable difficulty in isolating the organism from the asymptomatic male carrier, negative smears and cultures cannot be relied upon in this regard. In any event, the consort should be treated with metronidazole in cases of reinfection. Amebiasis: Metronidazole is indicated in the treatment of acute intestinal amebiasis (amebic dysentery) and amebic liver abscess. In amebic liver abscess, metronidazole therapy does not obviate the need for aspiration or drainage of pus. Anaerobic Bacterial Infections: Metronidazole is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Indicated surgical procedures should be performed in conjunction with metronidazole therapy. In a mixed aerobic and anaerobic infection, antimicrobials appropriate for the treatment of the aerobic infection should be used in addition to metronidazole. In the treatment of most serious anaerobic infections, the intravenous form of metronidazole is usually administered initially. This may be followed by oral therapy with metronidazole at the discretion of the physician. Intra-Abdominal Infections, including peritonitis, intra-abdominal abscess, and liver abscess, caused by Bacteroides species, including the B. fragilis group, ( B. fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron, B. vulgatus ), Clostridium species, Eubacterium species, Peptococcus niger, and Peptostreptococcus species. Skin and Skin Structure Infections caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus niger, Peptostreptococcus species, and Fusobacterium species. Gynecologic Infections , including endometritis, endomyometritis, tubo-ovarian abscess, and postsurgical vaginal cuff infection, caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus niger and Peptostreptococcus species. Bacterial Septicemia caused by Bacteroides species including the B. fragilis group and Clostridium species. Bone and Joint Infections, as adjunctive therapy, caused by Bacteroides species, including the B. fragilis group. Central Nervous System (CNS) Infection , including meningitis and brain abscess, caused by Bacteroides species, including the B. fragilis group. Lower Respiratory Tract Infections , including pneumonia, empyema, and lung abscess, caused by Bacteroides species including the B. fragilis group. Endocarditis caused by Bacteroides species including the B. fragilis group. uuid:3730058b-4f6c-4bf5-93f4-7526a504c0f2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:51173 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:b04691f6-b9da-49b7-b469-866ec40c4737"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9f9319b5-18bc-4ac9-bd4d-53678c0bdb2b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATION Propoxyphene hydrochloride capsules are indicated for the relief of mild to moderate pain. uuid:ff966efe-f78f-4247-8da6-820d52ccf1c9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63681 biolink:treats MONDO:0005136 PMID:41385096 "[{""id"":""uuid:172796bb-a0b6-4e2f-ae9a-df70b9e3e6be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:89ecf72c-aa61-4920-94bb-7a9bda946be2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Treatment of Acute Malaria Infections Mefloquine hydrochloride tablets are indicated for the treatment of mild to moderate acute malaria caused by mefloquine-susceptible strains of P. falciparum (both chloroquine-susceptible and resistant strains) or by Plasmodium vivax . There are insufficient clinical data to document the effect of mefloquine in malaria caused by P. ovale or P. malariae . Note: Patients with acute P. vivax malaria, treated with mefloquine, are at high risk of relapse because mefloquine does not eliminate exoerythrocytic (hepatic phase) parasites. To avoid relapse, after initial treatment of the acute infection with mefloquine, patients should subsequently be treated with an 8-aminoquinoline derivative (e.g., primaquine). Prevention of Malaria Mefloquine hydrochloride tablets are indicated for the prophylaxis of P. falciparum and P. vivax malaria infections, including prophylaxis of chloroquine-resistant strains of P. falciparum . uuid:747891c8-4d5b-4d9d-bb6a-423a1e201b2b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63681 biolink:treats MONDO:0005920 PMID:41385096 "[{""id"":""uuid:5659f11d-8893-4dab-83f1-7851ed480064"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e22183b5-616d-43ce-b936-90e9664c5bb5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Treatment of Acute Malaria Infections Mefloquine hydrochloride tablets are indicated for the treatment of mild to moderate acute malaria caused by mefloquine-susceptible strains of P. falciparum (both chloroquine-susceptible and resistant strains) or by Plasmodium vivax . There are insufficient clinical data to document the effect of mefloquine in malaria caused by P. ovale or P. malariae . Note: Patients with acute P. vivax malaria, treated with mefloquine, are at high risk of relapse because mefloquine does not eliminate exoerythrocytic (hepatic phase) parasites. To avoid relapse, after initial treatment of the acute infection with mefloquine, patients should subsequently be treated with an 8-aminoquinoline derivative (e.g., primaquine). Prevention of Malaria Mefloquine hydrochloride tablets are indicated for the prophylaxis of P. falciparum and P. vivax malaria infections, including prophylaxis of chloroquine-resistant strains of P. falciparum . uuid:ac9e2ca7-5a48-41e2-b9d7-5ee3a2bc6f87 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63681 biolink:treats MONDO:0005921 PMID:41385096 "[{""id"":""uuid:b14220ed-211a-419e-9abd-43d7cbd4e7d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3ae882e2-1216-4ba4-9db5-313a1991a726"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Treatment of Acute Malaria Infections Mefloquine hydrochloride tablets are indicated for the treatment of mild to moderate acute malaria caused by mefloquine-susceptible strains of P. falciparum (both chloroquine-susceptible and resistant strains) or by Plasmodium vivax . There are insufficient clinical data to document the effect of mefloquine in malaria caused by P. ovale or P. malariae . Note: Patients with acute P. vivax malaria, treated with mefloquine, are at high risk of relapse because mefloquine does not eliminate exoerythrocytic (hepatic phase) parasites. To avoid relapse, after initial treatment of the acute infection with mefloquine, patients should subsequently be treated with an 8-aminoquinoline derivative (e.g., primaquine). Prevention of Malaria Mefloquine hydrochloride tablets are indicated for the prophylaxis of P. falciparum and P. vivax malaria infections, including prophylaxis of chloroquine-resistant strains of P. falciparum . uuid:bcc7725f-dace-4c59-86d4-70e4c19e0ffe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63681 biolink:treats MONDO:0001601 PMID:41385096 "[{""id"":""uuid:184d1b5f-bc37-4003-a545-f256b8622cfb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f511b38a-c735-407d-99a9-36cbb617e14a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Treatment of Acute Malaria Infections Mefloquine hydrochloride tablets are indicated for the treatment of mild to moderate acute malaria caused by mefloquine-susceptible strains of P. falciparum (both chloroquine-susceptible and resistant strains) or by Plasmodium vivax . There are insufficient clinical data to document the effect of mefloquine in malaria caused by P. ovale or P. malariae . Note: Patients with acute P. vivax malaria, treated with mefloquine, are at high risk of relapse because mefloquine does not eliminate exoerythrocytic (hepatic phase) parasites. To avoid relapse, after initial treatment of the acute infection with mefloquine, patients should subsequently be treated with an 8-aminoquinoline derivative (e.g., primaquine). Prevention of Malaria Mefloquine hydrochloride tablets are indicated for the prophylaxis of P. falciparum and P. vivax malaria infections, including prophylaxis of chloroquine-resistant strains of P. falciparum . uuid:47de44a3-1082-4127-b4a1-c21adcaa8df0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63681 biolink:treats MONDO:0001943 PMID:41385096 "[{""id"":""uuid:92e34cd2-b196-4b9e-a650-4e4be515b1b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:493ba7bb-6d62-4402-b3fc-356260ad1bb6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Treatment of Acute Malaria Infections Mefloquine hydrochloride tablets are indicated for the treatment of mild to moderate acute malaria caused by mefloquine-susceptible strains of P. falciparum (both chloroquine-susceptible and resistant strains) or by Plasmodium vivax . There are insufficient clinical data to document the effect of mefloquine in malaria caused by P. ovale or P. malariae . Note: Patients with acute P. vivax malaria, treated with mefloquine, are at high risk of relapse because mefloquine does not eliminate exoerythrocytic (hepatic phase) parasites. To avoid relapse, after initial treatment of the acute infection with mefloquine, patients should subsequently be treated with an 8-aminoquinoline derivative (e.g., primaquine). Prevention of Malaria Mefloquine hydrochloride tablets are indicated for the prophylaxis of P. falciparum and P. vivax malaria infections, including prophylaxis of chloroquine-resistant strains of P. falciparum . uuid:92aba355-d75d-410b-b766-2450823496cc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7852 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:e5ccb4c2-aa21-451a-92eb-8a7a26c4b143"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:26b7a3f2-634a-4eaf-8927-0b5ec7845718"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxycodone hydrochloride tablets, USP, are an immediate-release oral formulation of oxycodone hydrochloride indicated for the management of moderate to severe pain where the use of an opioid analgesic is appropriate. uuid:0b149021-864c-47a4-aa25-16248c29ee5b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:166679 biolink:treats MONDO:0004592 PMID:41385096 "[{""id"":""uuid:bb88cae0-d305-42e7-9f5b-ade3c5e7c449"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6cebdcbb-fdc1-4094-9e0c-6052dda31d7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ALTABAX is indicated for use in adults and pediatric patients aged 9 months and older for the topical treatment of impetigo (up to 100 cm 2 in total area in adults or 2% total body surface area in pediatric patients aged 9 months or older) due to Staphylococcus aureus (methicillin-susceptible isolates only) or Streptococcus pyogenes [see Clinical Studies (14)] . To reduce the development of drug-resistant bacteria and maintain the effectiveness of ALTABAX and other antibacterial drugs, ALTABAX should uuid:5e1644c4-4f23-4fc3-8f56-da6cd7de9274 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3510 biolink:treats UMLS:C0853854 PMID:41385096 "[{""id"":""uuid:ac465981-475c-47fa-8a32-5c8f29c4da9e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9dc8d43d-294d-45d5-b7aa-97df3e6df8a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CEDAX (ceftibuten) is indicated for the treatment of individuals with mild-to-moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below (see DOSAGE AND ADMINISTRATION and CLINICAL STUDIES sections). Acute Bacterial Exacerbations of Chronic Bronchitis due to Haemophilus influenzae (including β-lactamase-producing strains), Moraxella catarrhalis (including β-lactamase-producing strains), or Streptococcus pneumoniae (penicillin-susceptible strains only). uuid:c48a10cd-7ca1-484c-be9f-ca0d8c402b95 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7565 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:d90e2f11-ba01-4e59-9e2e-8636e07e891c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:cf27e0b6-9a9b-4740-b972-9e2c68d94746"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:26a5e6fa-5440-4d6c-9081-422ba12901bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ADALAT CC is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents|[PMDA] Drugs with a new dosage indicated for the treatment of hypertension. uuid:3e749878-9a08-450c-b636-866ba8d66981 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:109549 biolink:treats MONDO:0013600 PMID:41385096 "[{""id"":""uuid:c63e55e4-fa8c-474a-ba57-40bd6587bef5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8d620c5d-2367-4fb9-80f1-7c41f78d4871"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:8a270ad1-dfa1-4fc6-91c2-7f1f038319b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ROZEREM is indicated for the treatment of insomnia characterized by difficulty with sleep onset. The clinical trials performed in support of efficacy were up to 6 months in duration. The final formal assessments of sleep latency were performed after 2 days of treatment during the crossover study (elderly only), at 5 weeks in the 6-week studies (adults and elderly), and at the end of the 6-month study (adults and elderly) [see Clinical Studies (14) ] .|[PMDA] A drug with a new active ingredient indicated for the improvement of difficulty with sleep onset in insomnia. uuid:4cca973d-ca44-44fa-b8a9-ba150d7167a0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7601 biolink:treats MONDO:0005412 PMID:41385096 "[{""id"":""uuid:36371144-4636-4e89-bc27-299d5b5c5a0e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4f4d2367-2387-48d6-8c8b-5e9e98745643"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Nizatidine is indicated for up to 8 weeks for the treatment of active duodenal ulcer. In most patients, the ulcer will heal within 4 weeks. Nizatidine is indicated for maintenance therapy for duodenal ulcer patients, at a reduced dosage of 150 mg h.s. after healing of an active duodenal ulcer. The consequences of continuous therapy with nizatidine for longer than 1 year are not known. Nizatidine is indicated for up to 12 weeks for the treatment of endoscopically diagnosed esophagitis, including erosive and ulcerative esophagitis, and associated heartburn due to GERD. Nizatidine is indicated for up to 8 weeks for the treatment of active benign gastric ulcer. Before initiating therapy, care should be taken to exclude the possibility of malignant gastric ulceration. uuid:8262b182-3c24-4cae-a738-5aa61e3851fc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7601 biolink:treats MONDO:0001409 PMID:41385096 "[{""id"":""uuid:c30887ca-e3f7-4838-9a4a-c1833d6d6782"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:11cf2f94-2d44-4a9f-8b3e-52def08f5116"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Nizatidine is indicated for up to 8 weeks for the treatment of active duodenal ulcer. In most patients, the ulcer will heal within 4 weeks. Nizatidine is indicated for maintenance therapy for duodenal ulcer patients, at a reduced dosage of 150 mg h.s. after healing of an active duodenal ulcer. The consequences of continuous therapy with nizatidine for longer than 1 year are not known. Nizatidine is indicated for up to 12 weeks for the treatment of endoscopically diagnosed esophagitis, including erosive and ulcerative esophagitis, and associated heartburn due to GERD. Nizatidine is indicated for up to 8 weeks for the treatment of active benign gastric ulcer. Before initiating therapy, care should be taken to exclude the possibility of malignant gastric ulceration. uuid:28ace776-db86-4ab1-9719-6c89a351c5ce biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7601 biolink:treats UMLS:C0267055 PMID:41385096 "[{""id"":""uuid:3e264b1e-e03b-4299-b928-2ef9ba498460"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:370364c8-207c-4e94-8fa5-41a8ddd69608"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Nizatidine is indicated for up to 8 weeks for the treatment of active duodenal ulcer. In most patients, the ulcer will heal within 4 weeks. Nizatidine is indicated for maintenance therapy for duodenal ulcer patients, at a reduced dosage of 150 mg h.s. after healing of an active duodenal ulcer. The consequences of continuous therapy with nizatidine for longer than 1 year are not known. Nizatidine is indicated for up to 12 weeks for the treatment of endoscopically diagnosed esophagitis, including erosive and ulcerative esophagitis, and associated heartburn due to GERD. Nizatidine is indicated for up to 8 weeks for the treatment of active benign gastric ulcer. Before initiating therapy, care should be taken to exclude the possibility of malignant gastric ulceration. uuid:9704c373-db70-464f-8e49-1c8adb8c2a64 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7601 biolink:treats UMLS:C2586050 PMID:41385096 "[{""id"":""uuid:66502524-67de-4a69-ad7d-f3c5a59422f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:25c80143-ace7-4f80-b53c-e8e48b8fc194"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Nizatidine is indicated for up to 8 weeks for the treatment of active duodenal ulcer. In most patients, the ulcer will heal within 4 weeks. Nizatidine is indicated for maintenance therapy for duodenal ulcer patients, at a reduced dosage of 150 mg h.s. after healing of an active duodenal ulcer. The consequences of continuous therapy with nizatidine for longer than 1 year are not known. Nizatidine is indicated for up to 12 weeks for the treatment of endoscopically diagnosed esophagitis, including erosive and ulcerative esophagitis, and associated heartburn due to GERD. Nizatidine is indicated for up to 8 weeks for the treatment of active benign gastric ulcer. Before initiating therapy, care should be taken to exclude the possibility of malignant gastric ulceration. uuid:3e0ba374-566b-48ae-8dea-145fb70e0ba1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7601 biolink:treats MONDO:0007186 PMID:41385096 "[{""id"":""uuid:28f6919a-6391-4253-8007-89f02693a517"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:490d4572-e421-45c4-8e92-f9670b8e7919"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Nizatidine is indicated for up to 8 weeks for the treatment of active duodenal ulcer. In most patients, the ulcer will heal within 4 weeks. Nizatidine is indicated for maintenance therapy for duodenal ulcer patients, at a reduced dosage of 150 mg h.s. after healing of an active duodenal ulcer. The consequences of continuous therapy with nizatidine for longer than 1 year are not known. Nizatidine is indicated for up to 12 weeks for the treatment of endoscopically diagnosed esophagitis, including erosive and ulcerative esophagitis, and associated heartburn due to GERD. Nizatidine is indicated for up to 8 weeks for the treatment of active benign gastric ulcer. Before initiating therapy, care should be taken to exclude the possibility of malignant gastric ulceration. uuid:497bc2b2-d56c-4c2b-b375-fafc2a64bfdb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7601 biolink:treats MONDO:0001126 PMID:41385096 "[{""id"":""uuid:77188c7f-9210-4dbf-b9bc-d441b950f383"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5bd4a86f-86b6-4201-b5f8-856e192cffc1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Nizatidine is indicated for up to 8 weeks for the treatment of active duodenal ulcer. In most patients, the ulcer will heal within 4 weeks. Nizatidine is indicated for maintenance therapy for duodenal ulcer patients, at a reduced dosage of 150 mg h.s. after healing of an active duodenal ulcer. The consequences of continuous therapy with nizatidine for longer than 1 year are not known. Nizatidine is indicated for up to 12 weeks for the treatment of endoscopically diagnosed esophagitis, including erosive and ulcerative esophagitis, and associated heartburn due to GERD. Nizatidine is indicated for up to 8 weeks for the treatment of active benign gastric ulcer. Before initiating therapy, care should be taken to exclude the possibility of malignant gastric ulceration. uuid:c9c02077-db99-4ef2-9b79-a4d0114ecfbd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:144551 biolink:treats EFO:0006865 PMID:41385096 "[{""id"":""uuid:ffe87245-b2fd-4ddc-b028-44abb52b5029"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f32a212b-be41-4358-b100-2695f9fa1524"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:b6b76b54-1f38-420e-a314-8a0dc6e6beff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxybutynin chloride extended-release tablets are once daily controlled-release tablets indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. Pediatric use information for the treatment of patients aged 6 years and older with symptoms of detrusor overactivity associated with a neurological condition (e.g., spina bifida) is approved for Alza Corporation’s oxybutynin extended-release tablets. However, due to Alza Corporation’s marketing exclusivity rights, this drug product is not labeled for pediatric use.|[PMDA] A drug with a new route of administration and new indications for the treatment of urinary urgency, urinary frequency, and urge urinary incontinence associated with overactive bladder. uuid:66ce8989-3cba-444c-86ea-32c54258a281 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:144551 biolink:treats UMLS:C0341736 PMID:41385096 "[{""id"":""uuid:b4cefe19-1859-4015-b15f-83c4022c718d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6026b429-fd0c-46ca-926f-8b4721d3c2f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxybutynin chloride extended-release tablets are once daily controlled-release tablets indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. Pediatric use information for the treatment of patients aged 6 years and older with symptoms of detrusor overactivity associated with a neurological condition (e.g., spina bifida) is approved for Alza Corporation’s oxybutynin extended-release tablets. However, due to Alza Corporation’s marketing exclusivity rights, this drug product is not labeled for pediatric use. uuid:33fca596-9b6e-45b6-b7b8-ec71167f1a4d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:144551 biolink:treats MONDO:0008449 PMID:41385096 "[{""id"":""uuid:84dd4a81-44e5-4e2e-9d9a-e760899db866"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3f079b7f-69ad-414c-b8e1-6ae868d5c491"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxybutynin chloride extended-release tablets are once daily controlled-release tablets indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. Pediatric use information for the treatment of patients aged 6 years and older with symptoms of detrusor overactivity associated with a neurological condition (e.g., spina bifida) is approved for Alza Corporation’s oxybutynin extended-release tablets. However, due to Alza Corporation’s marketing exclusivity rights, this drug product is not labeled for pediatric use. uuid:4ff7b320-0871-47bf-acba-c189e0efa740 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1165009 biolink:treats MONDO:0005324 PMID:41385096 "[{""id"":""uuid:2d55da06-c7d6-489d-bd10-3fbcb5250860"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:43dfcd20-6923-431f-a9fc-cd883fca8e4f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride Extended-Release Tablets are indicated for the relief of symptoms associated with seasonal allergic rhinitis in adults and children 12 years of age and older. Symptoms treated effectively include sneezing, rhinorrhea, itchy nose/palate/ and/or throat, itchy/watery/red eyes, and nasal congestion. Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride Extended-Release Tablets should be administered when both the antihistaminic properties of fexofenadine hydrochloride and the nasal decongestant properties of pseudoephedrine hydrochloride are desired (see CLINICAL PHARMACOLOGY ). uuid:18e2cc0b-63c0-4e64-a745-0192c549524f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:393371 biolink:treats MONDO:0005271 PMID:41385096 "[{""id"":""uuid:4cb9309d-3b58-42da-99aa-2fe4ee92990f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5714cbf7-ea48-48ea-9898-df275e10f505"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Promethazine hydrochloride and dextromethorphan hydrobromide syrup is indicated for the temporary relief of coughs and upper respiratory symptoms associated with allergy or the common cold. uuid:4d45949a-d7e4-4a2f-84c7-4babcfe90054 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:393371 biolink:treats MONDO:0005709 PMID:41385096 "[{""id"":""uuid:ffda8b51-1cc3-4d51-9be1-b9f26ffcb636"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ca0ff515-fa73-41af-8410-315fe3d8e968"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Promethazine hydrochloride and dextromethorphan hydrobromide syrup is indicated for the temporary relief of coughs and upper respiratory symptoms associated with allergy or the common cold. uuid:99a7575f-54d2-45ed-b598-01aab92f1d21 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:216653 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:eceeb6e5-2312-40dc-a0c2-95cb7af626d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c205b8ee-f993-4422-8789-0ccc5e7e3cb9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Diovan HCT (valsartan and hydrochlorothiazide, USP) is indicated for the treatment of hypertension. Diovan HCT may be used in patients whose blood pressure is not adequately controlled on monotherapy. Diovan HCT may be used as initial therapy in patients who are likely to need multiple drugs to achieve blood pressure goals. The choice of Diovan HCT as initial therapy for hypertension should be based on an assessment of potential benefits and risks. Patients with stage 2 hypertension are at a relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. The decision to use a combination as initial therapy should be individualized and should be shaped by considerations such as baseline blood pressure, the target goal and the incremental likelihood of achieving goal with a combination compared to monotherapy. Individual blood pressure goals may vary based upon the patient’s risk. Data from the high dose multifactorial trial [See Clinical Studies (14.1)] provides estimates of the probability of reaching a target blood pressure with Diovan HCT compared to valsartan or hydrochlorothiazide monotherapy. The figures below provide estimates of the likelihood of achieving systolic or diastolic blood pressure control with Diovan HCT 320/25 mg, based upon baseline systolic or diastolic blood pressure. The curve of each treatment group was estimated by logistic regression modeling. The estimated likelihood at the right tail of each curve is less reliable due to small numbers of subjects with high baseline blood pressures. For example, a patient with a baseline blood pressure of 160/100 mmHg has about a 41% likelihood of achieving a goal of less than 140 mmHg (systolic) and 60% likelihood of achieving less than 90 mmHg (diastolic) on valsartan alone and the likelihood of achieving these goals on HCTZ alone is about 50% (systolic) or 57% (diastolic). The likelihood of achieving these goals on Diovan HCT rises to about 84% (systolic) or 80% (diastolic). The likelihood of achieving these goals on placebo is about 23% (systolic) or 36% (diastolic). uuid:333bf072-ab8b-466a-8574-d99a190e5767 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:216653 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:de035066-7134-4e5d-80bd-570fd4f91fdb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1a27a803-ac10-4acb-9841-9b9a1af079de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Diovan HCT (valsartan and hydrochlorothiazide, USP) is indicated for the treatment of hypertension. Diovan HCT may be used in patients whose blood pressure is not adequately controlled on monotherapy. Diovan HCT may be used as initial therapy in patients who are likely to need multiple drugs to achieve blood pressure goals. The choice of Diovan HCT as initial therapy for hypertension should be based on an assessment of potential benefits and risks. Patients with stage 2 hypertension are at a relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. The decision to use a combination as initial therapy should be individualized and should be shaped by considerations such as baseline blood pressure, the target goal and the incremental likelihood of achieving goal with a combination compared to monotherapy. Individual blood pressure goals may vary based upon the patient’s risk. Data from the high dose multifactorial trial [See Clinical Studies (14.1)] provides estimates of the probability of reaching a target blood pressure with Diovan HCT compared to valsartan or hydrochlorothiazide monotherapy. The figures below provide estimates of the likelihood of achieving systolic or diastolic blood pressure control with Diovan HCT 320/25 mg, based upon baseline systolic or diastolic blood pressure. The curve of each treatment group was estimated by logistic regression modeling. The estimated likelihood at the right tail of each curve is less reliable due to small numbers of subjects with high baseline blood pressures. For example, a patient with a baseline blood pressure of 160/100 mmHg has about a 41% likelihood of achieving a goal of less than 140 mmHg (systolic) and 60% likelihood of achieving less than 90 mmHg (diastolic) on valsartan alone and the likelihood of achieving these goals on HCTZ alone is about 50% (systolic) or 57% (diastolic). The likelihood of achieving these goals on Diovan HCT rises to about 84% (systolic) or 80% (diastolic). The likelihood of achieving these goals on placebo is about 23% (systolic) or 36% (diastolic). uuid:58c076a5-027c-41de-a33b-61e8f1a356e1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:216653 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:c82e95e7-205f-4108-827c-ff7194b5aae6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9208170e-f8d9-4e0b-a3a0-f75c1e533043"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Diovan HCT (valsartan and hydrochlorothiazide, USP) is indicated for the treatment of hypertension. Diovan HCT may be used in patients whose blood pressure is not adequately controlled on monotherapy. Diovan HCT may be used as initial therapy in patients who are likely to need multiple drugs to achieve blood pressure goals. The choice of Diovan HCT as initial therapy for hypertension should be based on an assessment of potential benefits and risks. Patients with stage 2 hypertension are at a relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. The decision to use a combination as initial therapy should be individualized and should be shaped by considerations such as baseline blood pressure, the target goal and the incremental likelihood of achieving goal with a combination compared to monotherapy. Individual blood pressure goals may vary based upon the patient’s risk. Data from the high dose multifactorial trial [See Clinical Studies (14.1)] provides estimates of the probability of reaching a target blood pressure with Diovan HCT compared to valsartan or hydrochlorothiazide monotherapy. The figures below provide estimates of the likelihood of achieving systolic or diastolic blood pressure control with Diovan HCT 320/25 mg, based upon baseline systolic or diastolic blood pressure. The curve of each treatment group was estimated by logistic regression modeling. The estimated likelihood at the right tail of each curve is less reliable due to small numbers of subjects with high baseline blood pressures. For example, a patient with a baseline blood pressure of 160/100 mmHg has about a 41% likelihood of achieving a goal of less than 140 mmHg (systolic) and 60% likelihood of achieving less than 90 mmHg (diastolic) on valsartan alone and the likelihood of achieving these goals on HCTZ alone is about 50% (systolic) or 57% (diastolic). The likelihood of achieving these goals on Diovan HCT rises to about 84% (systolic) or 80% (diastolic). The likelihood of achieving these goals on placebo is about 23% (systolic) or 36% (diastolic). uuid:9a2c9b18-9cff-47b8-ac2b-f61242f47a8c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:216653 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:1db68a0b-fde9-4c56-9fca-3f510511b1c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:170721d6-07fb-499c-9106-1d54712d01da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Diovan HCT (valsartan and hydrochlorothiazide, USP) is indicated for the treatment of hypertension. Diovan HCT may be used in patients whose blood pressure is not adequately controlled on monotherapy. Diovan HCT may be used as initial therapy in patients who are likely to need multiple drugs to achieve blood pressure goals. The choice of Diovan HCT as initial therapy for hypertension should be based on an assessment of potential benefits and risks. Patients with stage 2 hypertension are at a relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. The decision to use a combination as initial therapy should be individualized and should be shaped by considerations such as baseline blood pressure, the target goal and the incremental likelihood of achieving goal with a combination compared to monotherapy. Individual blood pressure goals may vary based upon the patient’s risk. Data from the high dose multifactorial trial [See Clinical Studies (14.1)] provides estimates of the probability of reaching a target blood pressure with Diovan HCT compared to valsartan or hydrochlorothiazide monotherapy. The figures below provide estimates of the likelihood of achieving systolic or diastolic blood pressure control with Diovan HCT 320/25 mg, based upon baseline systolic or diastolic blood pressure. The curve of each treatment group was estimated by logistic regression modeling. The estimated likelihood at the right tail of each curve is less reliable due to small numbers of subjects with high baseline blood pressures. For example, a patient with a baseline blood pressure of 160/100 mmHg has about a 41% likelihood of achieving a goal of less than 140 mmHg (systolic) and 60% likelihood of achieving less than 90 mmHg (diastolic) on valsartan alone and the likelihood of achieving these goals on HCTZ alone is about 50% (systolic) or 57% (diastolic). The likelihood of achieving these goals on Diovan HCT rises to about 84% (systolic) or 80% (diastolic). The likelihood of achieving these goals on placebo is about 23% (systolic) or 36% (diastolic). uuid:7fee3ce5-1851-406f-8572-9b34809d00ff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:216653 biolink:treats MONDO:0001106 PMID:41385096 "[{""id"":""uuid:13614e71-7161-4912-84d8-5e559417bea0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:44dbea00-50e0-4ed5-a2d6-8ae3221bdc60"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Diovan HCT (valsartan and hydrochlorothiazide, USP) is indicated for the treatment of hypertension. Diovan HCT may be used in patients whose blood pressure is not adequately controlled on monotherapy. Diovan HCT may be used as initial therapy in patients who are likely to need multiple drugs to achieve blood pressure goals. The choice of Diovan HCT as initial therapy for hypertension should be based on an assessment of potential benefits and risks. Patients with stage 2 hypertension are at a relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. The decision to use a combination as initial therapy should be individualized and should be shaped by considerations such as baseline blood pressure, the target goal and the incremental likelihood of achieving goal with a combination compared to monotherapy. Individual blood pressure goals may vary based upon the patient’s risk. Data from the high dose multifactorial trial [See Clinical Studies (14.1)] provides estimates of the probability of reaching a target blood pressure with Diovan HCT compared to valsartan or hydrochlorothiazide monotherapy. The figures below provide estimates of the likelihood of achieving systolic or diastolic blood pressure control with Diovan HCT 320/25 mg, based upon baseline systolic or diastolic blood pressure. The curve of each treatment group was estimated by logistic regression modeling. The estimated likelihood at the right tail of each curve is less reliable due to small numbers of subjects with high baseline blood pressures. For example, a patient with a baseline blood pressure of 160/100 mmHg has about a 41% likelihood of achieving a goal of less than 140 mmHg (systolic) and 60% likelihood of achieving less than 90 mmHg (diastolic) on valsartan alone and the likelihood of achieving these goals on HCTZ alone is about 50% (systolic) or 57% (diastolic). The likelihood of achieving these goals on Diovan HCT rises to about 84% (systolic) or 80% (diastolic). The likelihood of achieving these goals on placebo is about 23% (systolic) or 36% (diastolic). uuid:80c86428-903d-4702-a94f-1c11a0b89057 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47381 biolink:treats MONDO:0005178 PMID:41385096 "[{""id"":""uuid:260b97cd-f642-4eb5-998d-cb23fb8a2c63"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:73216c8f-576e-4bc2-9b04-17fe617ef9e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of diclofenac sodium extended-release and other treatment options before deciding to use diclofenac sodium extended-release. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Diclofenac sodium extended-release tablets are indicated: • For relief of signs and symptoms of osteoarthritis • For relief of signs and symptoms of rheumatoid arthritis uuid:ad87cd74-7f51-42b0-b2fa-dfcfe43599c6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47381 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:a1dcf493-356a-4dd4-b4a3-5185d955c59c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:86c618d7-17ca-40e8-ba2e-246aaa23857f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:372d2e91-366c-44c2-9ff1-73d4c58fab01"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Carefully consider the potential benefits and risks of diclofenac sodium extended-release and other treatment options before deciding to use diclofenac sodium extended-release. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Diclofenac sodium extended-release tablets are indicated: • For relief of signs and symptoms of osteoarthritis • For relief of signs and symptoms of rheumatoid arthritis|[PMDA] A new indication for the treatment of “toothache”, the format of the indication for ""rheumatoid arthritis"" was coordinated. [Notification of off label use]" uuid:659d9f86-5a98-4b68-af4e-ab057bc25c6d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8080 biolink:treats NCIT:C120380 PMID:41385096 "[{""id"":""uuid:e45cc442-5e02-4c13-80c1-a2828e64bc61"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1ba8a6dc-586e-42a3-853c-4f82de0d5d24"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Phentermine hydrochloride is indicated as a short-term (a few weeks) adjunct in a regimen of weight reduction based on exercise, behavioral modification and caloric restriction in the management of exogenous obesity for patients with an initial body mass index ≥30 kg/m 2 , or ≥27 kg/m 2 in the presence of other risk factors (e. g., hypertension, diabetes, hyperlipidemia). Below is a chart of Body Mass Index (BMI) based on various heights and weights. BMI is calculated by taking the patient's weight, in kilograms (kg), divided by the patient's height, in meters (m), squared. Metric conversions are as follows; pounds ÷ 2.2 = kg; inches × 0.0254 = meters. BODY MASS INDEX (BMI), kg/m 2 Height (feet, inches) Weight (pounds) 5'0"" 5'3"" 5'6"" 5'9"" 6'0"" 6'3"" 140 27 25 23 21 19 18 150 29 27 24 22 20 19 160 31 28 26 24 22 20 170 33 30 28 25 23 21 180 35 32 29 27 25 23 190 37 34 31 28 26 24 200 39 36 32 30 27 25 210 41 37 34 31 29 26 220 43 39 36 33 30 28 230 45 41 37 34 31 29 240 47 43 39 36 33 30 250 49 44 40 37 34 31 The limited usefulness of agents of this class (see CLINICAL PHARMACOLOGY ) should be measured against possible risk factors inherent in their use such as those described below." uuid:5448b39e-05a9-4b2f-b5a2-92d5f8003a60 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8080 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:6c52a61f-1621-4404-8337-114bb5898748"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4e6d5879-3a1a-431c-aa89-348b293b5b8e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Phentermine hydrochloride is indicated as a short-term (a few weeks) adjunct in a regimen of weight reduction based on exercise, behavioral modification and caloric restriction in the management of exogenous obesity for patients with an initial body mass index ≥30 kg/m 2 , or ≥27 kg/m 2 in the presence of other risk factors (e. g., hypertension, diabetes, hyperlipidemia). Below is a chart of Body Mass Index (BMI) based on various heights and weights. BMI is calculated by taking the patient's weight, in kilograms (kg), divided by the patient's height, in meters (m), squared. Metric conversions are as follows; pounds ÷ 2.2 = kg; inches × 0.0254 = meters. BODY MASS INDEX (BMI), kg/m 2 Height (feet, inches) Weight (pounds) 5'0"" 5'3"" 5'6"" 5'9"" 6'0"" 6'3"" 140 27 25 23 21 19 18 150 29 27 24 22 20 19 160 31 28 26 24 22 20 170 33 30 28 25 23 21 180 35 32 29 27 25 23 190 37 34 31 28 26 24 200 39 36 32 30 27 25 210 41 37 34 31 29 26 220 43 39 36 33 30 28 230 45 41 37 34 31 29 240 47 43 39 36 33 30 250 49 44 40 37 34 31 The limited usefulness of agents of this class (see CLINICAL PHARMACOLOGY ) should be measured against possible risk factors inherent in their use such as those described below." uuid:497b6b9f-e57a-40fc-8050-7ccc0612302d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8080 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:7e0c0009-1d50-43ff-b5cb-2fc35f3f5cd2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:13bb2db4-a52f-4db1-9907-24666c9d30cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Phentermine hydrochloride is indicated as a short-term (a few weeks) adjunct in a regimen of weight reduction based on exercise, behavioral modification and caloric restriction in the management of exogenous obesity for patients with an initial body mass index ≥30 kg/m 2 , or ≥27 kg/m 2 in the presence of other risk factors (e. g., hypertension, diabetes, hyperlipidemia). Below is a chart of Body Mass Index (BMI) based on various heights and weights. BMI is calculated by taking the patient's weight, in kilograms (kg), divided by the patient's height, in meters (m), squared. Metric conversions are as follows; pounds ÷ 2.2 = kg; inches × 0.0254 = meters. BODY MASS INDEX (BMI), kg/m 2 Height (feet, inches) Weight (pounds) 5'0"" 5'3"" 5'6"" 5'9"" 6'0"" 6'3"" 140 27 25 23 21 19 18 150 29 27 24 22 20 19 160 31 28 26 24 22 20 170 33 30 28 25 23 21 180 35 32 29 27 25 23 190 37 34 31 28 26 24 200 39 36 32 30 27 25 210 41 37 34 31 29 26 220 43 39 36 33 30 28 230 45 41 37 34 31 29 240 47 43 39 36 33 30 250 49 44 40 37 34 31 The limited usefulness of agents of this class (see CLINICAL PHARMACOLOGY ) should be measured against possible risk factors inherent in their use such as those described below." uuid:ecc34023-477a-47e9-895b-4f5d3481971a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8080 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:a14ef0ec-2519-449b-84e8-0eb0093eb0f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:df798439-2c37-4f84-9011-b653435fa431"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Phentermine hydrochloride is indicated as a short-term (a few weeks) adjunct in a regimen of weight reduction based on exercise, behavioral modification and caloric restriction in the management of exogenous obesity for patients with an initial body mass index ≥30 kg/m 2 , or ≥27 kg/m 2 in the presence of other risk factors (e. g., hypertension, diabetes, hyperlipidemia). Below is a chart of Body Mass Index (BMI) based on various heights and weights. BMI is calculated by taking the patient's weight, in kilograms (kg), divided by the patient's height, in meters (m), squared. Metric conversions are as follows; pounds ÷ 2.2 = kg; inches × 0.0254 = meters. BODY MASS INDEX (BMI), kg/m 2 Height (feet, inches) Weight (pounds) 5'0"" 5'3"" 5'6"" 5'9"" 6'0"" 6'3"" 140 27 25 23 21 19 18 150 29 27 24 22 20 19 160 31 28 26 24 22 20 170 33 30 28 25 23 21 180 35 32 29 27 25 23 190 37 34 31 28 26 24 200 39 36 32 30 27 25 210 41 37 34 31 29 26 220 43 39 36 33 30 28 230 45 41 37 34 31 29 240 47 43 39 36 33 30 250 49 44 40 37 34 31 The limited usefulness of agents of this class (see CLINICAL PHARMACOLOGY ) should be measured against possible risk factors inherent in their use such as those described below." uuid:def581b9-19f9-422e-9228-2ae99d477721 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7852 biolink:treats NCIT:C34887 PMID:41385096 "[{""id"":""uuid:7af85bfc-53da-4f89-9012-5ac9912a815e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d6abd58e-ddd1-4a27-ba0b-1c9b3d7fa682"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxycodone HCl Controlled-Release Tablets are a controlled-release oral formulation of oxycodone hydrochloride indicated for the management of moderate to severe pain when a continuous, around-the-clock analgesic is needed for an extended period of time. Oxycodone HCl Controlled-Release Tablets are NOT intended for use as a prn analgesic. Physicians should individualize treatment in every case, initiating therapy at the appropriate point along a progression from non-opioid analgesics, such as non-steroidal anti-inflammatory drugs and acetaminophen to opioids in a plan of pain management such as outlined by the World Health Organization, the Agency for Healthcare Research and Quality (formerly known as the Agency for Health Care Policy and Research), the Federation of State Medical Boards Model Guidelines, or the American Pain Society. Oxycodone HCl Controlled-Release Tablets are not indicated for pain in the immediate postoperative period (the first 12-24 hours following surgery), or if the pain is mild, or not expected to persist for an extended period of time. Oxycodone HCl Controlled-Release Tablets are only indicated for postoperative use if the patient is already receiving the drug prior to surgery or if the postoperative pain is expected to be moderate to severe and persist for an extended period of time. Physicians should individualize treatment, moving from parenteral to oral analgesics as appropriate. (See American Pain Society guidelines.) uuid:ab8c3c25-ccf9-4eec-8e86-f23d725e8cb4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10650 biolink:treats MONDO:0005475 PMID:41385096 "[{""id"":""uuid:308efb10-a635-40b2-8a98-6f8ea0a22488"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8ac08440-dbaf-486b-b1d5-c1c415faa731"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Sumatriptan Succinate Tablets are indicated for the acute treatment of migraine attacks with or without aura in adults. Sumatriptan Succinate Tablets are not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS). Safety and effectiveness of Sumatriptan Succinate Tablets have not been established for cluster headache, which is present in an older, predominantly male population. uuid:1f8b258a-b707-4bf1-b3f5-ccbd6af75626 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10650 biolink:treats MONDO:0100431 PMID:41385096 "[{""id"":""uuid:61e254fd-bd41-4f25-9e1b-d46e29388535"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:89374a8a-abfe-461c-8f14-111e24f0b5e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Sumatriptan Succinate Tablets are indicated for the acute treatment of migraine attacks with or without aura in adults. Sumatriptan Succinate Tablets are not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS). Safety and effectiveness of Sumatriptan Succinate Tablets have not been established for cluster headache, which is present in an older, predominantly male population. uuid:19b39c99-9292-4ad0-a325-b401274faa67 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10650 biolink:treats MONDO:0018925 PMID:41385096 "[{""id"":""uuid:2ba84f71-7171-4b31-9f1b-e4d03db4d179"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dbc0c980-0895-415e-8b1f-cd6ebebf047b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Sumatriptan Succinate Tablets are indicated for the acute treatment of migraine attacks with or without aura in adults. Sumatriptan Succinate Tablets are not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS). Safety and effectiveness of Sumatriptan Succinate Tablets have not been established for cluster headache, which is present in an older, predominantly male population. uuid:eae47d35-5ece-4587-ad88-5ef40103e3ac biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10650 biolink:treats MONDO:0043219 PMID:41385096 "[{""id"":""uuid:5a3d58da-2cb5-4aef-9ea0-f0ba7cf03a07"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c621164a-f85f-48eb-874f-6176e96c3265"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Sumatriptan Succinate Tablets are indicated for the acute treatment of migraine attacks with or without aura in adults. Sumatriptan Succinate Tablets are not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS). Safety and effectiveness of Sumatriptan Succinate Tablets have not been established for cluster headache, which is present in an older, predominantly male population. uuid:9fe0d6d3-36d0-4116-883a-068397df22b0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10650 biolink:treats MONDO:0043537 PMID:41385096 "[{""id"":""uuid:f6e57e7a-d631-4d9f-a5a5-87aab40d263d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:936c0c62-c41f-41f0-9cbf-780f3508f851"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Sumatriptan Succinate Tablets are indicated for the acute treatment of migraine attacks with or without aura in adults. Sumatriptan Succinate Tablets are not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS). Safety and effectiveness of Sumatriptan Succinate Tablets have not been established for cluster headache, which is present in an older, predominantly male population. uuid:64307d1c-2a92-4669-8679-1b77e294ea81 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2676 biolink:treats UMLS:C0852158 PMID:41385096 "[{""id"":""uuid:fc06c6b0-3e74-4474-a8c4-2420654eb502"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b7854cf9-fe6c-4ba1-a06a-372aa0eaca3d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amoxicillin is indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) strains of the designated microorganisms in the conditions listed below: Infections of the ear, nose, and throat – due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae , Staphylococcus spp., or H. influenzae . Infections of the genitourinary tract – due to E. coli, P. mirabilis , or E. faecalis . Infections of the skin and skin structure – due to Streptococcus spp. (α- and β-hemolytic strains only), Staphylococcus spp., or E. coli . Infections of the lower respiratory tract – due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae . Gonorrhea, acute uncomplicated (ano-genital and urethral infections) – due to N. gonorrhoeae (males and females). uuid:289569b5-4747-465f-9cf1-5e2233ef878d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7773 biolink:treats HP:0002018 PMID:41385096 "[{""id"":""uuid:ef13f4ed-a77f-46ac-a827-ff4bbaaebc42"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:984f5414-5b1d-410a-bf39-003a50e8754a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e13c51ef-8688-4e07-ae43-7c97095120ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including high-dose cisplatin. Efficacy of the 32-mg single dose beyond 24 hours in these patients has not been established.|[PMDA] A drug with a new indication and a new dosage for the treatment of digestive symptoms (nausea and vomiting) after surgery. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:72d5f2c7-dd35-419a-b402-9a5b84ae2326 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7773 biolink:treats HP:0002013 PMID:41385096 "[{""id"":""uuid:1b5c2493-9875-4e31-b9be-7d5cc0c71b91"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2bc052bf-750b-4c9c-b692-01e5e0f0a8d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:5dc125bc-6fd3-45d0-8c3e-054e38365cb4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including high-dose cisplatin. Efficacy of the 32-mg single dose beyond 24 hours in these patients has not been established.|[PMDA] A drug with a new indication and a new dosage for the treatment of digestive symptoms (nausea and vomiting) after surgery. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:2de3d6df-e709-4f4c-a086-ff59babbe835 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6909 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:fea20b63-4290-420b-a6f1-ef5a2d4a3da0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:30809539-f188-4032-a669-b234982f1dba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Metronidazole Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Indicated surgical procedures should be performed in conjunction with Metronidazole Injection, USP therapy. In a mixed aerobic and anaerobic infection, antibiotics appropriate for the treatment of the aerobic infection should be used in addition to Metronidazole Injection, USP. Metronidazole Injection, USP is effective in Bacteroides fragilis infections resistant to clindamycin, chloramphenicol and penicillin. Intra-Abdominal Infections , including peritonitis, intra-abdominal abscess and liver abscess, caused by Bacteroides species including the B. fragilis group ( B. fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron, B. vulgatus ), Clostridium species, Eubacterium species, Peptococcus species and Peptostreptococcus species. Skin and Skin Structure Infections caused by Bacteroides species including the B. fragilis group, Clostridium species , Peptococcus species, Peptostreptococcus species and Fusobacterium species. Gynecologic Infections , including endometritis, endomyometritis, tubo-ovarian abscess and postsurgical vaginal cuff infection, caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptostreptococcus species and Fusobacterium species. Bacterial Septicemia caused by Bacteroides species including the B. fragilis group and Clostridium species. Bone and Joint Infections , as adjunctive therapy, caused by Bacteroides species including the B. fragilis group. Central Nervous System (CNS) Infections , including meningitis and brain abscess, caused by Bacteroides species including the B. fragilis group. Lower Respiratory Tract Infections , including pneumonia, empyema and lung abscess, caused by Bacteroides species including the B. fragilis group. Endocarditis caused by Bacteroides species including the B. fragilis group. uuid:c9ae8f85-1b05-4654-9f5d-ed74ba5fd477 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6909 biolink:treats UMLS:C0851989 PMID:41385096 "[{""id"":""uuid:6340b3fb-bda2-420c-a70a-73e814c240d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:05eb6ad8-1aa4-4287-8e24-57486c9f693b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Metronidazole Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Indicated surgical procedures should be performed in conjunction with Metronidazole Injection, USP therapy. In a mixed aerobic and anaerobic infection, antibiotics appropriate for the treatment of the aerobic infection should be used in addition to Metronidazole Injection, USP. Metronidazole Injection, USP is effective in Bacteroides fragilis infections resistant to clindamycin, chloramphenicol and penicillin. Intra-Abdominal Infections , including peritonitis, intra-abdominal abscess and liver abscess, caused by Bacteroides species including the B. fragilis group ( B. fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron, B. vulgatus ), Clostridium species, Eubacterium species, Peptococcus species and Peptostreptococcus species. Skin and Skin Structure Infections caused by Bacteroides species including the B. fragilis group, Clostridium species , Peptococcus species, Peptostreptococcus species and Fusobacterium species. Gynecologic Infections , including endometritis, endomyometritis, tubo-ovarian abscess and postsurgical vaginal cuff infection, caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptostreptococcus species and Fusobacterium species. Bacterial Septicemia caused by Bacteroides species including the B. fragilis group and Clostridium species. Bone and Joint Infections , as adjunctive therapy, caused by Bacteroides species including the B. fragilis group. Central Nervous System (CNS) Infections , including meningitis and brain abscess, caused by Bacteroides species including the B. fragilis group. Lower Respiratory Tract Infections , including pneumonia, empyema and lung abscess, caused by Bacteroides species including the B. fragilis group. Endocarditis caused by Bacteroides species including the B. fragilis group. uuid:09172dc1-582a-4ca4-94ff-07be1886e455 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:308714 biolink:treats MONDO:0005984 PMID:41385096 "[{""id"":""uuid:4a81f414-90b7-4f9b-9df5-5d94f37110e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2ec5ae04-8653-498d-ad36-f8f9bcb30652"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Clotrimazole and betamethasone dipropionate cream is indicated in patients 17 years and older for the topical treatment of symptomatic inflammatory tinea pedis, tinea cruris and tinea corporis due to Epidermophyton floccosum , Trichophyton mentagrophytes , and Trichophyton rubrum . Effective treatment without the risks associated with topical corticosteroid use may be obtained using a topical antifungal agent that does not contain a corticosteroid, especially for noninflammatory tinea infections. The efficacy of clotrimazole and betamethasone dipropionate cream for the treatment of infections caused by zoophilic dermatophytes (e.g., Microsporum canis ) has not been established. Several cases of treatment failure of clotrimazole and betamethasone dipropionate cream in the treatment of infections caused by Microsporum canis have been reported. uuid:3929e28f-8df8-4405-8250-92c6cef06f74 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:308714 biolink:treats MONDO:0001405 PMID:41385096 "[{""id"":""uuid:e69f54df-f4bd-4d63-81a5-b91fc12d8e69"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:57528d06-b98d-4ecb-aa00-5eba3b5e53e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Clotrimazole and betamethasone dipropionate cream is indicated in patients 17 years and older for the topical treatment of symptomatic inflammatory tinea pedis, tinea cruris and tinea corporis due to Epidermophyton floccosum , Trichophyton mentagrophytes , and Trichophyton rubrum . Effective treatment without the risks associated with topical corticosteroid use may be obtained using a topical antifungal agent that does not contain a corticosteroid, especially for noninflammatory tinea infections. The efficacy of clotrimazole and betamethasone dipropionate cream for the treatment of infections caused by zoophilic dermatophytes (e.g., Microsporum canis ) has not been established. Several cases of treatment failure of clotrimazole and betamethasone dipropionate cream in the treatment of infections caused by Microsporum canis have been reported. uuid:d849cf39-f6b8-46cb-93c7-f0f91380c526 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:308714 biolink:treats MONDO:0001461 PMID:41385096 "[{""id"":""uuid:ce77a7f3-83e3-48ac-bd38-233cb0a29fc3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:874eb60e-9c6f-4632-b14c-5e29e0d74e68"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Clotrimazole and betamethasone dipropionate cream is indicated in patients 17 years and older for the topical treatment of symptomatic inflammatory tinea pedis, tinea cruris and tinea corporis due to Epidermophyton floccosum , Trichophyton mentagrophytes , and Trichophyton rubrum . Effective treatment without the risks associated with topical corticosteroid use may be obtained using a topical antifungal agent that does not contain a corticosteroid, especially for noninflammatory tinea infections. The efficacy of clotrimazole and betamethasone dipropionate cream for the treatment of infections caused by zoophilic dermatophytes (e.g., Microsporum canis ) has not been established. Several cases of treatment failure of clotrimazole and betamethasone dipropionate cream in the treatment of infections caused by Microsporum canis have been reported. uuid:54457a39-4585-424a-a5f8-329a91d76e4b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0041052 PMID:41385096 "[{""id"":""uuid:68e28e42-a92c-4534-9ee5-f09a49cdd4fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:826b8c8b-fd86-4523-9870-7f6b71c8ea38"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LIDODERM is indicated for relief of pain associated with post-herpetic neuralgia. It should be applied only to intact skin . uuid:721507c4-d30d-4172-8bb3-b99daec8336f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3746 biolink:treats MONDO:0005242 PMID:41385096 "[{""id"":""uuid:d1553b94-c511-4b09-96c5-885d12c4bbcb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:78258b97-faad-48fe-a5e0-bb8b8cd225b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin hydrochloride capsules and other antibacterial drugs, clindamycin hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis and postsurgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. uuid:feb276d2-7e09-447b-8a34-76574caff41e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3746 biolink:treats MONDO:0004649 PMID:41385096 "[{""id"":""uuid:07f457de-dfc6-4ea2-8b71-530bf5308ff3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a004536f-2b05-47a5-b367-7df618b9e178"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin hydrochloride capsules and other antibacterial drugs, clindamycin hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis and postsurgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. uuid:a55d5db0-570f-4d35-82d1-39ffb7235b55 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3746 biolink:treats MONDO:0000744 PMID:41385096 "[{""id"":""uuid:3491b1c5-1e91-4bad-9e2b-30c4a797fc6b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7dfbd34f-7202-4f4b-8b43-e305190020c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin hydrochloride capsules and other antibacterial drugs, clindamycin hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis and postsurgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. uuid:3ae09a9b-18fa-4abc-b5dc-845bb76abe87 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3746 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:6f2ca8fa-6109-44e7-bb6b-fd04c88aa4b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f35a1ccd-124c-49ca-b1d4-11bc30cb3935"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin hydrochloride capsules and other antibacterial drugs, clindamycin hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis and postsurgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. uuid:08a4747c-404f-4576-930a-27b00dc44171 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3746 biolink:treats MONDO:0700217 PMID:41385096 "[{""id"":""uuid:c51c4411-faf2-47b3-aa7f-58349ab83ef4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:61bcdba3-2bd7-49de-b577-93d7f74821bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin hydrochloride capsules and other antibacterial drugs, clindamycin hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis and postsurgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. uuid:2141dc56-8941-4c4d-8a0c-fa64b9741b84 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3746 biolink:treats MONDO:0004522 PMID:41385096 "[{""id"":""uuid:77549c36-956e-4652-a4f9-0f1c943e2f90"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2a7fdc59-f435-4079-a3e1-d57734324208"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin hydrochloride capsules and other antibacterial drugs, clindamycin hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis and postsurgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. uuid:de4e44dd-ce8b-4420-88f6-4c7f59dbe74e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3746 biolink:treats MONDO:0000918 PMID:41385096 "[{""id"":""uuid:ed2967d1-9c1b-4bc7-8bca-e4a68a8000c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d08bc9eb-b825-44c6-93db-db0e4dd56d02"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin hydrochloride capsules and other antibacterial drugs, clindamycin hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis and postsurgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. uuid:9996ed73-de67-4833-877a-3a014136c746 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3746 biolink:treats HP:0034493 PMID:41385096 "[{""id"":""uuid:7baf0da2-62eb-4e08-a9e7-bdf4569925d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:73d6e993-7186-436b-91a1-be3b2d6c7157"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin hydrochloride capsules and other antibacterial drugs, clindamycin hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis and postsurgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. uuid:f550ef0a-910e-47f5-ad01-9129356714bb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3746 biolink:treats MONDO:0006887 PMID:41385096 "[{""id"":""uuid:53249270-6246-45c4-9dd6-45180dff49f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:47f79e46-a4f6-42a7-8ec6-2bec3e7a7ecc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin hydrochloride capsules and other antibacterial drugs, clindamycin hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis and postsurgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. uuid:55933f59-b4ea-42b8-87ab-c9bb8cc3e60d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3746 biolink:treats MONDO:0024355 PMID:41385096 "[{""id"":""uuid:3fbeb728-b9bb-4428-acaa-fa6467c8abf9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:185688a7-1d0c-4499-8023-35b0f7c71c38"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin hydrochloride capsules and other antibacterial drugs, clindamycin hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis and postsurgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. uuid:44e3dab0-fca6-45df-b4e8-f8cd72f6d619 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0006604 PMID:41385096 "[{""id"":""uuid:cdc03728-0117-4253-bb76-f32c0681f113"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:df0d37e6-be46-4df8-841f-84a6d3509f42"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ORACEA is indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients. No meaningful effect was demonstrated for generalized erythema (redness) of rosacea. ORACEA has not been evaluated for the treatment of the erythematous, telangiectatic, or ocular components of rosacea. Efficacy of ORACEA beyond 16 weeks and safety beyond 9 months have not been established. This formulation of doxycycline has not been evaluated in the treatment or prevention of infections. ORACEA should not be used for treating bacterial infections, providing antibacterial prophylaxis, or reducing the numbers or eliminating microorganisms associated with any bacterial disease. To reduce the development of drug-resistant bacteria as well as to maintain the effectiveness of other antibacterial drugs, ORACEA should be used only as indicated. uuid:235377d1-da59-4405-8c50-6a25ae0f1934 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0005113 PMID:41385096 "[{""id"":""uuid:74cc7dd5-9106-4a60-bf4a-36ffecfebc2c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f381ce3d-5163-4cd2-b055-8364ed4d2525"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ORACEA is indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients. No meaningful effect was demonstrated for generalized erythema (redness) of rosacea. ORACEA has not been evaluated for the treatment of the erythematous, telangiectatic, or ocular components of rosacea. Efficacy of ORACEA beyond 16 weeks and safety beyond 9 months have not been established. This formulation of doxycycline has not been evaluated in the treatment or prevention of infections. ORACEA should not be used for treating bacterial infections, providing antibacterial prophylaxis, or reducing the numbers or eliminating microorganisms associated with any bacterial disease. To reduce the development of drug-resistant bacteria as well as to maintain the effectiveness of other antibacterial drugs, ORACEA should be used only as indicated. uuid:dad53c93-192d-4030-b73c-89e4e08c34ca biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2955 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:c8bbe748-7978-4250-b839-ae37840f896d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a3cb9309-0b1a-4352-9593-fdc32b67b8db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:9b0953f2-2e88-4ace-a3e8-4d9b2e6d6c5a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azithromycin tablets are indicated for the treatment of patients with mild to moderate infections (pneumonia: see WARNINGS ) caused by susceptible strains of the designated microorganisms in the specific conditions listed below. As recommended dosages, durations of therapy and applicable patient populations vary among these infections, please see DOSAGE AND ADMINISTRATION for specific dosing recommendations.|[PMDA] A drug with a new route of administration indicated for the treatment of pneumonia. uuid:6063f391-34fe-47cf-8b1d-9c7e5768e5f3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8249 biolink:treats MONDO:0005178 PMID:41385096 "[{""id"":""uuid:9b40a12a-ce51-46c7-905b-98cf785b4a51"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:36d167e6-4bac-4353-96e2-fed3da2f5d2d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of piroxicam capsules and other treatment options before deciding to use piroxicam capsules. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Piroxicam capsules are indicated: For relief of the signs and symptoms of osteoarthritis. For relief of the signs and symptoms of rheumatoid arthritis. uuid:f70daad7-2a32-4977-8384-48e39bc4adef biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8249 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:0597de6a-29b8-4bdd-8828-7b9b8c25f0f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5a7b021a-dc60-4a3d-8b4f-adec910f9c14"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of piroxicam capsules and other treatment options before deciding to use piroxicam capsules. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Piroxicam capsules are indicated: For relief of the signs and symptoms of osteoarthritis. For relief of the signs and symptoms of rheumatoid arthritis. uuid:1eebda25-5558-480a-9f67-2760c47d9321 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18258 biolink:treats MONDO:0005420 PMID:41385096 "[{""id"":""uuid:b5c42583-fa06-42cb-aff4-c0bb51712a75"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aada2165-be21-4dc5-b063-9d6dac7f7d35"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Thyroid hormone drugs are indicated: As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema and ordinary hypothyroidism in patients of any age (pediatric patients, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary) or tertiary (hypothalamic) hypothyroidism (see WARNINGS ). As pituitary thyroid-stimulating hormone (TSH) suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto's) and multinodular goiter. As diagnostic agents in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy. Liothyronine Sodium Tablets, USP can be used in patients allergic to desiccated thyroid or thyroid extract derived from pork or beef. uuid:cddfa4ec-8d6d-4546-971c-2d59c4852466 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18258 biolink:treats MONDO:0018612 PMID:41385096 "[{""id"":""uuid:de49e8a1-53e2-48c2-875c-e6a287849e2b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bf677a5b-d442-472b-b5c3-53c3f0451656"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Thyroid hormone drugs are indicated: As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema and ordinary hypothyroidism in patients of any age (pediatric patients, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary) or tertiary (hypothalamic) hypothyroidism (see WARNINGS ). As pituitary thyroid-stimulating hormone (TSH) suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto's) and multinodular goiter. As diagnostic agents in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy. Liothyronine Sodium Tablets, USP can be used in patients allergic to desiccated thyroid or thyroid extract derived from pork or beef. uuid:f6f6b1ff-cc1c-4b81-8b7c-3f2ef94527df biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18258 biolink:treats MONDO:0009718 PMID:41385096 "[{""id"":""uuid:9e2ed25a-ec57-4608-b74b-228a4a01c8c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0e46d9db-459f-4d6f-af62-38b025ba72ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Thyroid hormone drugs are indicated: As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema and ordinary hypothyroidism in patients of any age (pediatric patients, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary) or tertiary (hypothalamic) hypothyroidism (see WARNINGS ). As pituitary thyroid-stimulating hormone (TSH) suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto's) and multinodular goiter. As diagnostic agents in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy. Liothyronine Sodium Tablets, USP can be used in patients allergic to desiccated thyroid or thyroid extract derived from pork or beef. uuid:0b58d609-5a87-4116-b337-b2f58ad63815 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18258 biolink:treats MONDO:0001658 PMID:41385096 "[{""id"":""uuid:3eabf61a-1574-4fc2-a4a3-342338f076aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6f08ed3d-419e-48ba-8a53-feb134e186c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Thyroid hormone drugs are indicated: As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema and ordinary hypothyroidism in patients of any age (pediatric patients, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary) or tertiary (hypothalamic) hypothyroidism (see WARNINGS ). As pituitary thyroid-stimulating hormone (TSH) suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto's) and multinodular goiter. As diagnostic agents in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy. Liothyronine Sodium Tablets, USP can be used in patients allergic to desiccated thyroid or thyroid extract derived from pork or beef. uuid:2325457c-b36e-471f-8a89-da0652589901 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18258 biolink:treats HP:0025388 PMID:41385096 "[{""id"":""uuid:cbafdbcb-7dbc-4719-bae5-0bcfc8a86ef5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:81215313-090d-4734-9d09-356146006f9c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Thyroid hormone drugs are indicated: As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema and ordinary hypothyroidism in patients of any age (pediatric patients, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary) or tertiary (hypothalamic) hypothyroidism (see WARNINGS ). As pituitary thyroid-stimulating hormone (TSH) suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto's) and multinodular goiter. As diagnostic agents in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy. Liothyronine Sodium Tablets, USP can be used in patients allergic to desiccated thyroid or thyroid extract derived from pork or beef. uuid:dadf6019-f41f-45d3-82d9-6784bbd9fae6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18258 biolink:treats MONDO:0007699 PMID:41385096 "[{""id"":""uuid:b71f5b26-6089-4da0-9431-ec97884a1435"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a315be43-3144-4495-b646-112c97716805"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Thyroid hormone drugs are indicated: As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema and ordinary hypothyroidism in patients of any age (pediatric patients, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary) or tertiary (hypothalamic) hypothyroidism (see WARNINGS ). As pituitary thyroid-stimulating hormone (TSH) suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto's) and multinodular goiter. As diagnostic agents in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy. Liothyronine Sodium Tablets, USP can be used in patients allergic to desiccated thyroid or thyroid extract derived from pork or beef. uuid:e1a9f296-8220-4ed3-ac02-4673f5420457 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18258 biolink:treats MONDO:0000334 PMID:41385096 "[{""id"":""uuid:b7705cf7-5095-4850-8153-f209eed8aeeb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f605b182-92f0-48ab-a0c8-fb3a1acbd849"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Thyroid hormone drugs are indicated: As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema and ordinary hypothyroidism in patients of any age (pediatric patients, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary) or tertiary (hypothalamic) hypothyroidism (see WARNINGS ). As pituitary thyroid-stimulating hormone (TSH) suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto's) and multinodular goiter. As diagnostic agents in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy. Liothyronine Sodium Tablets, USP can be used in patients allergic to desiccated thyroid or thyroid extract derived from pork or beef. uuid:ce293569-9950-4cb6-8082-099c73e8a314 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18258 biolink:treats MONDO:0004425 PMID:41385096 "[{""id"":""uuid:07d4e40e-2aee-48a4-a452-286153c1fbeb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:46e6d4bc-78a4-4d71-8a06-2c27349b5c6a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Thyroid hormone drugs are indicated: As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema and ordinary hypothyroidism in patients of any age (pediatric patients, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary) or tertiary (hypothalamic) hypothyroidism (see WARNINGS ). As pituitary thyroid-stimulating hormone (TSH) suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto's) and multinodular goiter. As diagnostic agents in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy. Liothyronine Sodium Tablets, USP can be used in patients allergic to desiccated thyroid or thyroid extract derived from pork or beef. uuid:21c70f21-e7ea-4ff4-8810-aa7845bf1c1f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:192254 biolink:treats MONDO:0004951 PMID:41385096 "[{""id"":""uuid:e377491d-dad5-4c47-9d6d-a30727b33c24"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fa97a2ad-fd85-45d2-94f2-b22ebf9b5077"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1 INDICATIONS AND USAGE COMBIVIR, a combination of two nucleoside analogues, is indicated in combination with other antiretrovirals for the treatment of HIV-1 infection. uuid:00693c0c-f7a1-44d8-9d77-2ec7c2dfe8c3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0010643 PMID:41385096 "[{""id"":""uuid:6fb6f226-7ad0-4e6a-918b-376ba2e02feb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:df5d7244-3201-43b7-8369-1319249583b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Prednisolone Oral Solution is indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice: synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. In addition to the above indications Prednisolone Oral Solution is indicated for systemic dermatomyositis (polymyositis). uuid:793c5336-f3b6-4901-9fdd-fff33d4413f6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0033816 PMID:41385096 "[{""id"":""uuid:7fc5c9b5-f088-4aad-8ae5-b5cc6096d062"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:660b495d-b75b-4dda-8847-22097bf4dd96"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE For the treatment of the following conditions: Ophthalmic Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe, such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitis when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical or thermal burns, or penetration of foreign bodies. Otic Steroid responsive inflammatory conditions of the external auditory meatus, such as allergic otitis externa, selected purulent and nonpurulent infective otitis externa when the hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation. uuid:fabe0b0b-03ad-4b51-8073-2a36ebcc35e3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats UMLS:C0497209 PMID:41385096 "[{""id"":""uuid:e2f5f49f-ea5f-4b7d-88b0-87dc47b64cfd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9966571e-7c33-4671-8a87-4f305501eeaf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE For the treatment of the following conditions: Ophthalmic Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe, such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitis when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical or thermal burns, or penetration of foreign bodies. Otic Steroid responsive inflammatory conditions of the external auditory meatus, such as allergic otitis externa, selected purulent and nonpurulent infective otitis externa when the hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation. uuid:f20de48e-5c54-43d8-8e9a-59c97124d623 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats UMLS:C1320547 PMID:41385096 "[{""id"":""uuid:d23ff4b3-896b-4e92-b391-7b678723f36f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0fc83cd6-135b-49c1-8483-89159f4da4ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE For the treatment of the following conditions: Ophthalmic Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe, such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitis when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical or thermal burns, or penetration of foreign bodies. Otic Steroid responsive inflammatory conditions of the external auditory meatus, such as allergic otitis externa, selected purulent and nonpurulent infective otitis externa when the hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation. uuid:09ff6be7-8448-47b5-9ac8-15220cdc2504 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0004795 PMID:41385096 "[{""id"":""uuid:850a6f56-2ee1-463b-a8ab-6115cf4ade57"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:11a22133-2842-4923-907e-87702768889e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE For the treatment of the following conditions: Ophthalmic Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe, such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitis when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical or thermal burns, or penetration of foreign bodies. Otic Steroid responsive inflammatory conditions of the external auditory meatus, such as allergic otitis externa, selected purulent and nonpurulent infective otitis externa when the hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation. uuid:7fbd6d67-ae3e-4686-8646-bba2d278b798 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75722 biolink:treats HP:0012532 PMID:41385096 "[{""id"":""uuid:9dac4bfe-aad5-4a54-bab5-3e026fb9299a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7cdae925-3713-46b8-a9eb-16e51a207167"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:11a98fa4-412e-4a4c-936c-f936f76864af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Tramadol hydrochloride ER tablets are indicated for the management of moderate to moderately severe chronic pain in adults who require around-the-clock treatment of their pain for an extended period of time|[PMDA] A drug in a new dosage form indicated for analgesia in patients with cancers-associated pain or chronic pain, which cannot be managed by treatments with non-opioid analgesics. uuid:2494a8b9-168e-46cb-8fcb-c0d55c80fee9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75722 biolink:treats MONDO:0024317 PMID:41385096 "[{""id"":""uuid:4c1d50d5-0f80-44e8-ab19-423785831b9e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8c97d61d-e81e-4da0-9763-4ff16f10220e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Tramadol hydrochloride ER tablets are indicated for the management of moderate to moderately severe chronic pain in adults who require around-the-clock treatment of their pain for an extended period of time uuid:e4d80611-f47b-46ed-ac98-021e36c2296f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7822 biolink:treats MONDO:0005178 PMID:41385096 "[{""id"":""uuid:605b395a-6e83-43ce-8dd5-b61a5d8799cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2f94f1ba-d392-40b1-abc6-e8293b4f74e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of oxaprozin tablet, USP and other treatment options before deciding to use oxaprozin tablet, USP. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Oxaprozin Tablet, USP is indicated: For relief of the signs and symptoms of osteoarthritis For relief of the signs and symptoms of rheumatoid arthritis For relief of the signs and symptoms of juvenile rheumatoid arthritis uuid:3d6fd0b1-690d-4d84-8ea6-fc0d3ce1a685 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7822 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:25740fee-12b5-4fcb-bb41-4d719447b1dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:40d808f9-ca3e-46ca-be7c-854d6f76a5cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of oxaprozin tablet, USP and other treatment options before deciding to use oxaprozin tablet, USP. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Oxaprozin Tablet, USP is indicated: For relief of the signs and symptoms of osteoarthritis For relief of the signs and symptoms of rheumatoid arthritis For relief of the signs and symptoms of juvenile rheumatoid arthritis uuid:6b9df377-3b87-4216-9af1-e44468de3fc3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7822 biolink:treats MONDO:0011429 PMID:41385096 "[{""id"":""uuid:99990205-791d-4c4c-85e3-762d01dd26b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:18f6b69c-5048-4cba-b0bb-c6af9b2e9a5b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of oxaprozin tablet, USP and other treatment options before deciding to use oxaprozin tablet, USP. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Oxaprozin Tablet, USP is indicated: For relief of the signs and symptoms of osteoarthritis For relief of the signs and symptoms of rheumatoid arthritis For relief of the signs and symptoms of juvenile rheumatoid arthritis uuid:f6cf2e84-9441-481f-8cdc-d95afb7e0420 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16469 biolink:treats UMLS:C5442256 PMID:41385096 "[{""id"":""uuid:86df09ce-9498-4d9d-a57f-ed0a3ddcc04d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8094b157-b00a-4e9b-8c03-24690e637639"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE: Estradiol Tablets, USP are indicated in the: Treatment of moderate to severe vasomotor symptoms associated with the menopause. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. Treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. Treatment of breast cancer (for palliation only) in appropriately selected women and men with metastatic disease. Treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only). Prevention of osteoporosis. When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and for whom non-estrogen medications are not considered to be appropriate. (See CLINICAL PHARMACOLOGY , Clinical Studies .) The mainstays for decreasing the risk of postmenopausal osteoporosis are weight bearing exercise, adequate calcium and vitamin D intake, and when indicated, pharmacologic therapy. Postmenopausal women require an average of 500 mg/day of elemental calcium. Therefore, when not contraindicated, calcium supplementation may be helpful for women with suboptimal dietary intake. Vitamin D supplementation of 400-800 IU/day may also be required to ensure adequate daily intake in postmenopausal women. uuid:87ba49d9-4d0f-4015-805e-5a479f23c4bd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16469 biolink:treats MONDO:0001932 PMID:41385096 "[{""id"":""uuid:b26a8686-e486-4c3c-a8e4-5ee20a27a212"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e9e41830-6b0c-4a79-bf7a-9cb692dc70e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE: Estradiol Tablets, USP are indicated in the: Treatment of moderate to severe vasomotor symptoms associated with the menopause. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. Treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. Treatment of breast cancer (for palliation only) in appropriately selected women and men with metastatic disease. Treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only). Prevention of osteoporosis. When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and for whom non-estrogen medications are not considered to be appropriate. (See CLINICAL PHARMACOLOGY , Clinical Studies .) The mainstays for decreasing the risk of postmenopausal osteoporosis are weight bearing exercise, adequate calcium and vitamin D intake, and when indicated, pharmacologic therapy. Postmenopausal women require an average of 500 mg/day of elemental calcium. Therefore, when not contraindicated, calcium supplementation may be helpful for women with suboptimal dietary intake. Vitamin D supplementation of 400-800 IU/day may also be required to ensure adequate daily intake in postmenopausal women. DOID:14275 uuid:385eaf49-ffa8-47cb-912f-6973b04a1ee1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16469 biolink:treats MONDO:0018555 PMID:41385096 "[{""id"":""uuid:3695e3d3-0dd7-454d-bfce-103899a3f0f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:61350fac-85e3-4370-966c-7d90a2cb8224"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE: Estradiol Tablets, USP are indicated in the: Treatment of moderate to severe vasomotor symptoms associated with the menopause. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. Treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. Treatment of breast cancer (for palliation only) in appropriately selected women and men with metastatic disease. Treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only). Prevention of osteoporosis. When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and for whom non-estrogen medications are not considered to be appropriate. (See CLINICAL PHARMACOLOGY , Clinical Studies .) The mainstays for decreasing the risk of postmenopausal osteoporosis are weight bearing exercise, adequate calcium and vitamin D intake, and when indicated, pharmacologic therapy. Postmenopausal women require an average of 500 mg/day of elemental calcium. Therefore, when not contraindicated, calcium supplementation may be helpful for women with suboptimal dietary intake. Vitamin D supplementation of 400-800 IU/day may also be required to ensure adequate daily intake in postmenopausal women. uuid:ed4b1275-1429-4d2c-8f6b-dedcb52dd261 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16469 biolink:treats MONDO:0005387 PMID:41385096 "[{""id"":""uuid:5749de03-b817-4c86-b60f-c9c549594f78"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:202997fb-1569-4aaa-9f3e-6440c6cd9aff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:333da9a2-508f-4141-9ab9-fe8d77f56726"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE: Estradiol Tablets, USP are indicated in the: Treatment of moderate to severe vasomotor symptoms associated with the menopause. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. Treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. Treatment of breast cancer (for palliation only) in appropriately selected women and men with metastatic disease. Treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only). Prevention of osteoporosis. When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and for whom non-estrogen medications are not considered to be appropriate. (See CLINICAL PHARMACOLOGY , Clinical Studies .) The mainstays for decreasing the risk of postmenopausal osteoporosis are weight bearing exercise, adequate calcium and vitamin D intake, and when indicated, pharmacologic therapy. Postmenopausal women require an average of 500 mg/day of elemental calcium. Therefore, when not contraindicated, calcium supplementation may be helpful for women with suboptimal dietary intake. Vitamin D supplementation of 400-800 IU/day may also be required to ensure adequate daily intake in postmenopausal women.|[PMDA] A drug with a new route of administration indicated for the treatment of vasomotor symptoms (hot flushes and sweating) and vaginal atrophy symptoms associated with climacteric disturbance and ovarian deficiency symptoms. uuid:ffc04b2a-923d-42bd-82a6-02fa2ce4919c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16469 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:873ba8a3-6731-471d-b1f4-d658162d077f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9081aa4f-ac6c-411e-8cde-f7262a67ce7d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE: Estradiol Tablets, USP are indicated in the: Treatment of moderate to severe vasomotor symptoms associated with the menopause. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. Treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. Treatment of breast cancer (for palliation only) in appropriately selected women and men with metastatic disease. Treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only). Prevention of osteoporosis. When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and for whom non-estrogen medications are not considered to be appropriate. (See CLINICAL PHARMACOLOGY , Clinical Studies .) The mainstays for decreasing the risk of postmenopausal osteoporosis are weight bearing exercise, adequate calcium and vitamin D intake, and when indicated, pharmacologic therapy. Postmenopausal women require an average of 500 mg/day of elemental calcium. Therefore, when not contraindicated, calcium supplementation may be helpful for women with suboptimal dietary intake. Vitamin D supplementation of 400-800 IU/day may also be required to ensure adequate daily intake in postmenopausal women. uuid:f234093d-9618-408b-a958-a6545fc115f8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16469 biolink:treats MONDO:0850353 PMID:41385096 "[{""id"":""uuid:463f9738-ec39-45ed-a92a-891d07282677"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7ead1fd3-39b4-4157-a7f0-8991fdeb18e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE: Estradiol Tablets, USP are indicated in the: Treatment of moderate to severe vasomotor symptoms associated with the menopause. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. Treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. Treatment of breast cancer (for palliation only) in appropriately selected women and men with metastatic disease. Treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only). Prevention of osteoporosis. When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and for whom non-estrogen medications are not considered to be appropriate. (See CLINICAL PHARMACOLOGY , Clinical Studies .) The mainstays for decreasing the risk of postmenopausal osteoporosis are weight bearing exercise, adequate calcium and vitamin D intake, and when indicated, pharmacologic therapy. Postmenopausal women require an average of 500 mg/day of elemental calcium. Therefore, when not contraindicated, calcium supplementation may be helpful for women with suboptimal dietary intake. Vitamin D supplementation of 400-800 IU/day may also be required to ensure adequate daily intake in postmenopausal women. uuid:cc20189e-09bd-43f5-a950-4da9a3a3728e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16469 biolink:treats MONDO:0005298 PMID:41385096 "[{""id"":""uuid:2e7bbcf9-2799-4b9e-a04c-aab4667208e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0d23936a-1a06-4c55-8d69-8f94360bf48d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE: Estradiol Tablets, USP are indicated in the: Treatment of moderate to severe vasomotor symptoms associated with the menopause. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. Treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. Treatment of breast cancer (for palliation only) in appropriately selected women and men with metastatic disease. Treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only). Prevention of osteoporosis. When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and for whom non-estrogen medications are not considered to be appropriate. (See CLINICAL PHARMACOLOGY , Clinical Studies .) The mainstays for decreasing the risk of postmenopausal osteoporosis are weight bearing exercise, adequate calcium and vitamin D intake, and when indicated, pharmacologic therapy. Postmenopausal women require an average of 500 mg/day of elemental calcium. Therefore, when not contraindicated, calcium supplementation may be helpful for women with suboptimal dietary intake. Vitamin D supplementation of 400-800 IU/day may also be required to ensure adequate daily intake in postmenopausal women. uuid:dc8d37aa-ad7e-49dc-a38d-693f3e18f98c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7823 biolink:treats MONDO:0005618 PMID:41385096 "[{""id"":""uuid:4f6e330c-b23c-45b8-8de4-96967d1f12bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c9df4e92-76a5-4126-9d2b-c213ae7bead8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Oxazepam is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. Anxiety associated with depression is also responsive to Oxazepam therapy. This product has been found particularly useful in the management of anxiety, tension, agitation, and irritability in older patients. Alcoholics with acute tremulousness, inebriation, or with anxiety, associated with alcohol withdrawal are responsive to therapy. The effectiveness of Oxazepam in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient. uuid:a1aa6277-f07f-4272-aa03-4eb46b496419 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7823 biolink:treats MONDO:0011918 PMID:41385096 "[{""id"":""uuid:7c50bec0-0cc9-4fa8-841e-1cacb0173bb8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0553a85d-3180-49ab-8952-38c8fe096b9e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Oxazepam is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. Anxiety associated with depression is also responsive to Oxazepam therapy. This product has been found particularly useful in the management of anxiety, tension, agitation, and irritability in older patients. Alcoholics with acute tremulousness, inebriation, or with anxiety, associated with alcohol withdrawal are responsive to therapy. The effectiveness of Oxazepam in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient. uuid:fe668dbb-85e0-40f2-b36c-11a710e75e14 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7823 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:99fc94e9-ab66-4a49-b3cf-89ccc66398a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b4b416db-c653-4581-a2e7-ef6d332dc5bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Oxazepam is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. Anxiety associated with depression is also responsive to Oxazepam therapy. This product has been found particularly useful in the management of anxiety, tension, agitation, and irritability in older patients. Alcoholics with acute tremulousness, inebriation, or with anxiety, associated with alcohol withdrawal are responsive to therapy. The effectiveness of Oxazepam in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient. uuid:e305c0dd-46c3-4ad7-b9a6-6105c2a77a54 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7823 biolink:treats UMLS:C0001969 PMID:41385096 "[{""id"":""uuid:44e94f83-de70-4074-b6fb-e3166f86e917"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:65310a58-c7c3-476b-9a8a-6ab117e7abb6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Oxazepam is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. Anxiety associated with depression is also responsive to Oxazepam therapy. This product has been found particularly useful in the management of anxiety, tension, agitation, and irritability in older patients. Alcoholics with acute tremulousness, inebriation, or with anxiety, associated with alcohol withdrawal are responsive to therapy. The effectiveness of Oxazepam in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient. uuid:9b8a0fd2-5afe-43bb-8110-3d9157cc3e69 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7823 biolink:treats MONDO:0005433 PMID:41385096 "[{""id"":""uuid:78a59753-b59a-4fa9-bffb-22378c7af7ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cc3793e5-cbc1-43d8-b920-e27f67283d50"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Oxazepam is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. Anxiety associated with depression is also responsive to Oxazepam therapy. This product has been found particularly useful in the management of anxiety, tension, agitation, and irritability in older patients. Alcoholics with acute tremulousness, inebriation, or with anxiety, associated with alcohol withdrawal are responsive to therapy. The effectiveness of Oxazepam in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient. uuid:63b00e27-279e-499b-86ce-892be993c670 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5050 biolink:treats MONDO:0005324 PMID:41385096 "[{""id"":""uuid:24657b1d-a9c2-4460-bdd1-4e953226b7ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6d31b956-6c09-47c2-9952-ce8121462f6f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Seasonal Allergic Rhinitis Fexofenadine Hydrochloride Tablets are indicated for the relief of symptoms associated with seasonal allergic rhinitis in adults and children 6 years of age and older. Symptoms treated effectively were sneezing, rhinorrhea, itchy nose/palate/throat, itchy/watery/red eyes. Chronic Idiopathic Urticaria Fexofenadine Hydrochloride Tablets are indicated for treatment of uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children 6 years of age and older. It significantly reduces pruritus and the number of wheals. uuid:fca04bd3-c91e-428b-9c08-5f86a8128942 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5050 biolink:treats MONDO:0044212 PMID:41385096 "[{""id"":""uuid:5f2a9023-6099-4fd3-9113-33e141b583ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c37fce99-e8e4-4813-8fec-24efbcd987ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Seasonal Allergic Rhinitis Fexofenadine Hydrochloride Tablets are indicated for the relief of symptoms associated with seasonal allergic rhinitis in adults and children 6 years of age and older. Symptoms treated effectively were sneezing, rhinorrhea, itchy nose/palate/throat, itchy/watery/red eyes. Chronic Idiopathic Urticaria Fexofenadine Hydrochloride Tablets are indicated for treatment of uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children 6 years of age and older. It significantly reduces pruritus and the number of wheals. uuid:c892cbae-9ab9-4ed7-bcb2-59ae4941749f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3996 biolink:treats HP:0003394 PMID:41385096 "[{""id"":""uuid:f7d5bc0d-1064-4137-abab-56d73bfdbb42"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:02cdf222-7210-42a3-94e4-cef21563d55e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cyclobenzaprine hydrochloride is indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine hydrochloride should be used only for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride has not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy. uuid:44438e49-da68-4682-b8e2-720e988131c0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3996 biolink:treats MONDO:0006497 PMID:41385096 "[{""id"":""uuid:796b7ec8-f5f0-4685-b20c-571be0533616"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:edd8deb4-5735-44d7-806e-13c52d25ff2b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cyclobenzaprine hydrochloride is indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine hydrochloride should be used only for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride has not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy. uuid:3ffbc1cc-93da-4377-9311-9b2005f0b624 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3996 biolink:treats MONDO:0002545 PMID:41385096 "[{""id"":""uuid:8cb3060d-e94b-4196-a4d5-e7417a3b25ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2c331c11-a0d7-4132-8cba-b1173fc70064"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cyclobenzaprine hydrochloride is indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine hydrochloride should be used only for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride has not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy. uuid:79765b20-06c9-4793-adda-8c5c2c7e26bb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2666 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:91fac4b3-27b5-4ecd-a88f-a31302ffeacb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2ad438a7-5895-48e5-9dbb-45612d2a1fff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the relief of symptoms of depression. Endogenous depression is more likely to be alleviated than are other depressive states. uuid:af18c30d-1b3e-4db6-a3e1-25f58ffec9b7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2666 biolink:treats MONDO:0012048 PMID:41385096 "[{""id"":""uuid:f247e19f-a7a7-4558-b143-85c6a342c5b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:20be1570-8901-41ea-86a2-ffd63bf86f68"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the relief of symptoms of depression. Endogenous depression is more likely to be alleviated than are other depressive states. uuid:1455f3b2-8e0b-4422-8096-615ea620f18f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5118 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:4560d2c2-0af3-4abf-acb2-34181bfaf7e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6e4f53d3-4419-415b-838b-71537689f826"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Major Depressive Disorder Prozac is indicated for the treatment of major depressive disorder. Adult — The efficacy of Prozac was established in 5– and 6–week trials with depressed adult and geriatric outpatients (≥18 years of age) whose diagnoses corresponded most closely to the DSM–III (currently DSM–IV) category of major depressive disorder ( see CLINICAL TRIALS ). A major depressive episode (DSM–IV) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least 5 of the following 9 symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. The effects of Prozac in hospitalized depressed patients have not been adequately studied. The efficacy of Prozac 20 mg once daily in maintaining a response in major depressive disorder for up to 38 weeks following 12 weeks of open–label acute treatment (50 weeks total) was demonstrated in a placebo–controlled trial. The efficacy of Prozac Weekly once weekly in maintaining a response in major depressive disorder has been demonstrated in a placebo–controlled trial for up to 25 weeks following open–label acute treatment of 13 weeks with Prozac 20 mg daily for a total treatment of 38 weeks. However, it is unknown whether or not Prozac Weekly given on a once–weekly basis provides the same level of protection from relapse as that provided by Prozac 20 mg daily ( see CLINICAL TRIALS ). Pediatric (children and adolescents) — The efficacy of Prozac in children and adolescents was established in two 8– to 9–week placebo–controlled clinical trials in depressed outpatients whose diagnoses corresponded most closely to the DSM–III–R or DSM–IV category of major depressive disorder ( see CLINICAL TRIALS ). The usefulness of the drug in adult and pediatric patients receiving fluoxetine for extended periods should be reevaluated periodically. Obsessive Compulsive Disorder Adult — Prozac is indicated for the treatment of obsessions and compulsions in patients with obsessive compulsive disorder (OCD), as defined in the DSM–III–R; i.e., the obsessions or compulsions cause marked distress, are time–consuming, or significantly interfere with social or occupational functioning. The efficacy of Prozac was established in 13–week trials with obsessive compulsive outpatients whose diagnoses corresponded most closely to the DSM–III–R category of OCD ( see CLINICAL TRIALS ). OCD is characterized by recurrent and persistent ideas, thoughts, impulses, or images (obsessions) that are ego–dystonic and/or repetitive, purposeful, and intentional behaviors (compulsions) that are recognized by the person as excessive or unreasonable. The effectiveness of Prozac in long–term use, i.e., for more than 13 weeks, has not been systematically evaluated in placebo–controlled trials. Therefore, the physician who elects to use Prozac for extended periods should periodically reevaluate the long–term usefulness of the drug for the individual patient ( see DOSAGE AND ADMINISTRATION ). Pediatric (children and adolescents) — The efficacy of Prozac in children and adolescents was established in a 13–week, dose titration, clinical trial in patients with OCD, as defined in DSM–IV ( see CLINICAL TRIALS ). Bulimia Nervosa Prozac is indicated for the treatment of binge–eating and vomiting behaviors in patients with moderate to severe bulimia nervosa. The efficacy of Prozac was established in 8– to 16–week trials for adult outpatients with moderate to severe bulimia nervosa, i.e., at least 3 bulimic episodes per week for 6 months ( see CLINICAL TRIALS ). The efficacy of Prozac 60 mg/day in maintaining a response, in patients with bulimia who responded during an 8–week acute treatment phase while taking Prozac 60 mg/day and were then observed for relapse during a period of up to 52 weeks, was demonstrated in a placebo–controlled trial ( see CLINICAL TRIALS ). Nevertheless, the physician who elects to use Prozac for extended periods should periodically reevaluate the long–term usefulness of the drug for the individual patient ( see DOSAGE AND ADMINISTRATION ). Panic Disorder Prozac is indicated for the treatment of panic disorder, with or without agoraphobia, as defined in DSM–IV. Panic disorder is characterized by the occurrence of unexpected panic attacks, and associated concern about having additional attacks, worry about the implications or consequences of the attacks, and/or a significant change in behavior related to the attacks. The efficacy of Prozac was established in two 12–week clinical trials in patients whose diagnoses corresponded to the DSM–IV category of panic disorder ( see CLINICAL TRIALS ). Panic disorder (DSM–IV) is characterized by recurrent, unexpected panic attacks, i.e., a discrete period of intense fear or discomfort in which 4 or more of the following symptoms develop abruptly and reach a peak within 10 minutes: 1) palpitations, pounding heart, or accelerated heart rate; 2) sweating; 3) trembling or shaking; 4) sensations of shortness of breath or smothering; 5) feeling of choking; 6) chest pain or discomfort; 7) nausea or abdominal distress; 8) feeling dizzy, unsteady, lightheaded, or faint; 9) fear of losing control; 10) fear of dying; 11) paresthesias (numbness or tingling sensations); 12) chills or hot flashes. The effectiveness of Prozac in long–term use, i.e., for more than 12 weeks, has not been established in placebo–controlled trials. Therefore, the physician who elects to use Prozac for extended periods should periodically reevaluate the long–term usefulness of the drug for the individual patient ( see DOSAGE AND ADMINISTRATION ). uuid:6c70a5a0-5bae-4db2-ad19-e1dfce9d9351 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5118 biolink:treats MONDO:0005452 PMID:41385096 "[{""id"":""uuid:f535b5eb-1ffe-476b-9aab-d8e9b7d39564"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:62537dc3-1781-453f-b850-38069e309245"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Major Depressive Disorder Prozac is indicated for the treatment of major depressive disorder. Adult — The efficacy of Prozac was established in 5– and 6–week trials with depressed adult and geriatric outpatients (≥18 years of age) whose diagnoses corresponded most closely to the DSM–III (currently DSM–IV) category of major depressive disorder ( see CLINICAL TRIALS ). A major depressive episode (DSM–IV) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least 5 of the following 9 symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. The effects of Prozac in hospitalized depressed patients have not been adequately studied. The efficacy of Prozac 20 mg once daily in maintaining a response in major depressive disorder for up to 38 weeks following 12 weeks of open–label acute treatment (50 weeks total) was demonstrated in a placebo–controlled trial. The efficacy of Prozac Weekly once weekly in maintaining a response in major depressive disorder has been demonstrated in a placebo–controlled trial for up to 25 weeks following open–label acute treatment of 13 weeks with Prozac 20 mg daily for a total treatment of 38 weeks. However, it is unknown whether or not Prozac Weekly given on a once–weekly basis provides the same level of protection from relapse as that provided by Prozac 20 mg daily ( see CLINICAL TRIALS ). Pediatric (children and adolescents) — The efficacy of Prozac in children and adolescents was established in two 8– to 9–week placebo–controlled clinical trials in depressed outpatients whose diagnoses corresponded most closely to the DSM–III–R or DSM–IV category of major depressive disorder ( see CLINICAL TRIALS ). The usefulness of the drug in adult and pediatric patients receiving fluoxetine for extended periods should be reevaluated periodically. Obsessive Compulsive Disorder Adult — Prozac is indicated for the treatment of obsessions and compulsions in patients with obsessive compulsive disorder (OCD), as defined in the DSM–III–R; i.e., the obsessions or compulsions cause marked distress, are time–consuming, or significantly interfere with social or occupational functioning. The efficacy of Prozac was established in 13–week trials with obsessive compulsive outpatients whose diagnoses corresponded most closely to the DSM–III–R category of OCD ( see CLINICAL TRIALS ). OCD is characterized by recurrent and persistent ideas, thoughts, impulses, or images (obsessions) that are ego–dystonic and/or repetitive, purposeful, and intentional behaviors (compulsions) that are recognized by the person as excessive or unreasonable. The effectiveness of Prozac in long–term use, i.e., for more than 13 weeks, has not been systematically evaluated in placebo–controlled trials. Therefore, the physician who elects to use Prozac for extended periods should periodically reevaluate the long–term usefulness of the drug for the individual patient ( see DOSAGE AND ADMINISTRATION ). Pediatric (children and adolescents) — The efficacy of Prozac in children and adolescents was established in a 13–week, dose titration, clinical trial in patients with OCD, as defined in DSM–IV ( see CLINICAL TRIALS ). Bulimia Nervosa Prozac is indicated for the treatment of binge–eating and vomiting behaviors in patients with moderate to severe bulimia nervosa. The efficacy of Prozac was established in 8– to 16–week trials for adult outpatients with moderate to severe bulimia nervosa, i.e., at least 3 bulimic episodes per week for 6 months ( see CLINICAL TRIALS ). The efficacy of Prozac 60 mg/day in maintaining a response, in patients with bulimia who responded during an 8–week acute treatment phase while taking Prozac 60 mg/day and were then observed for relapse during a period of up to 52 weeks, was demonstrated in a placebo–controlled trial ( see CLINICAL TRIALS ). Nevertheless, the physician who elects to use Prozac for extended periods should periodically reevaluate the long–term usefulness of the drug for the individual patient ( see DOSAGE AND ADMINISTRATION ). Panic Disorder Prozac is indicated for the treatment of panic disorder, with or without agoraphobia, as defined in DSM–IV. Panic disorder is characterized by the occurrence of unexpected panic attacks, and associated concern about having additional attacks, worry about the implications or consequences of the attacks, and/or a significant change in behavior related to the attacks. The efficacy of Prozac was established in two 12–week clinical trials in patients whose diagnoses corresponded to the DSM–IV category of panic disorder ( see CLINICAL TRIALS ). Panic disorder (DSM–IV) is characterized by recurrent, unexpected panic attacks, i.e., a discrete period of intense fear or discomfort in which 4 or more of the following symptoms develop abruptly and reach a peak within 10 minutes: 1) palpitations, pounding heart, or accelerated heart rate; 2) sweating; 3) trembling or shaking; 4) sensations of shortness of breath or smothering; 5) feeling of choking; 6) chest pain or discomfort; 7) nausea or abdominal distress; 8) feeling dizzy, unsteady, lightheaded, or faint; 9) fear of losing control; 10) fear of dying; 11) paresthesias (numbness or tingling sensations); 12) chills or hot flashes. The effectiveness of Prozac in long–term use, i.e., for more than 12 weeks, has not been established in placebo–controlled trials. Therefore, the physician who elects to use Prozac for extended periods should periodically reevaluate the long–term usefulness of the drug for the individual patient ( see DOSAGE AND ADMINISTRATION ). uuid:fadb19b4-bad3-4495-b59f-57a5100339e5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5118 biolink:treats MONDO:0005383 PMID:41385096 "[{""id"":""uuid:331d8ac0-2d7d-4bbb-8e68-3f59985c351b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3bd38037-e3d3-4dcf-abfa-586e0cecf2f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Major Depressive Disorder Prozac is indicated for the treatment of major depressive disorder. Adult — The efficacy of Prozac was established in 5– and 6–week trials with depressed adult and geriatric outpatients (≥18 years of age) whose diagnoses corresponded most closely to the DSM–III (currently DSM–IV) category of major depressive disorder ( see CLINICAL TRIALS ). A major depressive episode (DSM–IV) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least 5 of the following 9 symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. The effects of Prozac in hospitalized depressed patients have not been adequately studied. The efficacy of Prozac 20 mg once daily in maintaining a response in major depressive disorder for up to 38 weeks following 12 weeks of open–label acute treatment (50 weeks total) was demonstrated in a placebo–controlled trial. The efficacy of Prozac Weekly once weekly in maintaining a response in major depressive disorder has been demonstrated in a placebo–controlled trial for up to 25 weeks following open–label acute treatment of 13 weeks with Prozac 20 mg daily for a total treatment of 38 weeks. However, it is unknown whether or not Prozac Weekly given on a once–weekly basis provides the same level of protection from relapse as that provided by Prozac 20 mg daily ( see CLINICAL TRIALS ). Pediatric (children and adolescents) — The efficacy of Prozac in children and adolescents was established in two 8– to 9–week placebo–controlled clinical trials in depressed outpatients whose diagnoses corresponded most closely to the DSM–III–R or DSM–IV category of major depressive disorder ( see CLINICAL TRIALS ). The usefulness of the drug in adult and pediatric patients receiving fluoxetine for extended periods should be reevaluated periodically. Obsessive Compulsive Disorder Adult — Prozac is indicated for the treatment of obsessions and compulsions in patients with obsessive compulsive disorder (OCD), as defined in the DSM–III–R; i.e., the obsessions or compulsions cause marked distress, are time–consuming, or significantly interfere with social or occupational functioning. The efficacy of Prozac was established in 13–week trials with obsessive compulsive outpatients whose diagnoses corresponded most closely to the DSM–III–R category of OCD ( see CLINICAL TRIALS ). OCD is characterized by recurrent and persistent ideas, thoughts, impulses, or images (obsessions) that are ego–dystonic and/or repetitive, purposeful, and intentional behaviors (compulsions) that are recognized by the person as excessive or unreasonable. The effectiveness of Prozac in long–term use, i.e., for more than 13 weeks, has not been systematically evaluated in placebo–controlled trials. Therefore, the physician who elects to use Prozac for extended periods should periodically reevaluate the long–term usefulness of the drug for the individual patient ( see DOSAGE AND ADMINISTRATION ). Pediatric (children and adolescents) — The efficacy of Prozac in children and adolescents was established in a 13–week, dose titration, clinical trial in patients with OCD, as defined in DSM–IV ( see CLINICAL TRIALS ). Bulimia Nervosa Prozac is indicated for the treatment of binge–eating and vomiting behaviors in patients with moderate to severe bulimia nervosa. The efficacy of Prozac was established in 8– to 16–week trials for adult outpatients with moderate to severe bulimia nervosa, i.e., at least 3 bulimic episodes per week for 6 months ( see CLINICAL TRIALS ). The efficacy of Prozac 60 mg/day in maintaining a response, in patients with bulimia who responded during an 8–week acute treatment phase while taking Prozac 60 mg/day and were then observed for relapse during a period of up to 52 weeks, was demonstrated in a placebo–controlled trial ( see CLINICAL TRIALS ). Nevertheless, the physician who elects to use Prozac for extended periods should periodically reevaluate the long–term usefulness of the drug for the individual patient ( see DOSAGE AND ADMINISTRATION ). Panic Disorder Prozac is indicated for the treatment of panic disorder, with or without agoraphobia, as defined in DSM–IV. Panic disorder is characterized by the occurrence of unexpected panic attacks, and associated concern about having additional attacks, worry about the implications or consequences of the attacks, and/or a significant change in behavior related to the attacks. The efficacy of Prozac was established in two 12–week clinical trials in patients whose diagnoses corresponded to the DSM–IV category of panic disorder ( see CLINICAL TRIALS ). Panic disorder (DSM–IV) is characterized by recurrent, unexpected panic attacks, i.e., a discrete period of intense fear or discomfort in which 4 or more of the following symptoms develop abruptly and reach a peak within 10 minutes: 1) palpitations, pounding heart, or accelerated heart rate; 2) sweating; 3) trembling or shaking; 4) sensations of shortness of breath or smothering; 5) feeling of choking; 6) chest pain or discomfort; 7) nausea or abdominal distress; 8) feeling dizzy, unsteady, lightheaded, or faint; 9) fear of losing control; 10) fear of dying; 11) paresthesias (numbness or tingling sensations); 12) chills or hot flashes. The effectiveness of Prozac in long–term use, i.e., for more than 12 weeks, has not been established in placebo–controlled trials. Therefore, the physician who elects to use Prozac for extended periods should periodically reevaluate the long–term usefulness of the drug for the individual patient ( see DOSAGE AND ADMINISTRATION ). uuid:d2c58e94-89fd-4dcb-9d7e-ba748c81254a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:43755 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:cebe9e3e-9453-42b1-bb94-fcfe0dd8a783"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c6a22825-2506-4efd-b7d1-5cad4b6d5e04"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e71c2aa3-f39c-452a-b6b4-a0bef578c8d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lisinopril tablets, USP is indicated for the treatment of hypertension. It may be used alone as initial therapy or concomitantly with other classes of antihypertensive agents.|[PMDA] Drugs with a new additional pediatric dosage. These drugs are indicated for the treatment of hypertension. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:b8fcf71a-c430-4eb9-badd-1de7f0d3a083 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0001051 PMID:41385096 "[{""id"":""uuid:2c13281b-ecc8-447d-8f42-66e59e428833"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3cb44659-b983-41d6-b0e9-41373d6efb7c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE CIPRO ® HC OTIC is indicated for the treatment of acute otitis externa in adult and pediatric patients, one year and older, due to susceptible strains of Pseudomonas aeruginosa, Staphylococcus aureus, and Proteus mirabilis. uuid:7190ae08-d9b1-4603-9c7f-efb5f8682da9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2567 biolink:treats MONDO:0005298 PMID:41385096 "[{""id"":""uuid:b3d5d1e3-f86c-4425-a46c-18f136b7f297"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:83c90416-dfc7-4e3e-b77e-fd62860ce467"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:4303e642-89e1-472b-b984-0d1a75fe45ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Alendronate sodium tablets, USP are indicated for: Treatment and prevention of osteoporosis in postmenopausal women For the treatment of osteoporosis, alendronate sodium tablets, USP increase bone mass and reduce the incidence of fractures, including those of the hip and spine (vertebral compression fractures). Osteoporosis may be confirmed by the finding of low bone mass (for example, at least 2 standard deviations below the premenopausal mean) or by the presence or history of osteoporotic fracture. (See CLINICAL PHARMACOLOGY, Pharmacodynamics .) For the prevention of osteoporosis, alendronate sodium tablets, USP may be considered in postmenopausal women who are at risk of developing osteoporosis and for whom the desired clinical outcome is to maintain bone mass and to reduce the risk of future fracture. Bone loss is particularly rapid in postmenopausal women younger than age 60. Risk factors often associated with the development of postmenopausal osteoporosis include early menopause; moderately low bone mass (for example, at least 1 standard deviation below the mean for healthy young adult women); thin body build; Caucasian or Asian race; and family history of osteoporosis. The presence of such risk factors may be important when considering the use of alendronate sodium tablets, USP for prevention of osteoporosis. Treatment to increase bone mass in men with osteoporosis. Treatment of glucocorticoid-induced osteoporosis in men and women receiving glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and who have low bone mineral density (see PRECAUTIONS, Glucocorticoid-induced osteoporosis ). Patients treated with glucocorticoids should receive adequate amounts of calcium and vitamin D. Treatment of Paget's disease of bone in men and women Treatment is indicated in patients with Paget's disease of bone having alkaline phosphatase at least two times the upper limit of normal, or those who are symptomatic, or those at risk for future complications from their disease.|[PMDA] A drug with a new dosage in a new additional dosage form indicated for the treatment of osteoporosis (not in the reexamination period). uuid:404925c5-e297-49ff-b2cf-60bb9e275f46 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2567 biolink:treats UMLS:C0521170 PMID:41385096 "[{""id"":""uuid:9f9bb92d-9135-43b7-a2fe-3a1a987166a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4d282553-de37-41b8-8b11-196789e04dbc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Alendronate sodium tablets, USP are indicated for: Treatment and prevention of osteoporosis in postmenopausal women For the treatment of osteoporosis, alendronate sodium tablets, USP increase bone mass and reduce the incidence of fractures, including those of the hip and spine (vertebral compression fractures). Osteoporosis may be confirmed by the finding of low bone mass (for example, at least 2 standard deviations below the premenopausal mean) or by the presence or history of osteoporotic fracture. (See CLINICAL PHARMACOLOGY, Pharmacodynamics .) For the prevention of osteoporosis, alendronate sodium tablets, USP may be considered in postmenopausal women who are at risk of developing osteoporosis and for whom the desired clinical outcome is to maintain bone mass and to reduce the risk of future fracture. Bone loss is particularly rapid in postmenopausal women younger than age 60. Risk factors often associated with the development of postmenopausal osteoporosis include early menopause; moderately low bone mass (for example, at least 1 standard deviation below the mean for healthy young adult women); thin body build; Caucasian or Asian race; and family history of osteoporosis. The presence of such risk factors may be important when considering the use of alendronate sodium tablets, USP for prevention of osteoporosis. Treatment to increase bone mass in men with osteoporosis. Treatment of glucocorticoid-induced osteoporosis in men and women receiving glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and who have low bone mineral density (see PRECAUTIONS, Glucocorticoid-induced osteoporosis ). Patients treated with glucocorticoids should receive adequate amounts of calcium and vitamin D. Treatment of Paget's disease of bone in men and women Treatment is indicated in patients with Paget's disease of bone having alkaline phosphatase at least two times the upper limit of normal, or those who are symptomatic, or those at risk for future complications from their disease. uuid:4d2c3029-afbd-441f-a79e-5a745f4f6ae6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2567 biolink:treats MONDO:0024651 PMID:41385096 "[{""id"":""uuid:b28ecf25-f6d7-4bdd-a187-0e9aaf754bc6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3677d472-081e-477f-92f6-edac7bfb1b18"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Alendronate sodium tablets, USP are indicated for: Treatment and prevention of osteoporosis in postmenopausal women For the treatment of osteoporosis, alendronate sodium tablets, USP increase bone mass and reduce the incidence of fractures, including those of the hip and spine (vertebral compression fractures). Osteoporosis may be confirmed by the finding of low bone mass (for example, at least 2 standard deviations below the premenopausal mean) or by the presence or history of osteoporotic fracture. (See CLINICAL PHARMACOLOGY, Pharmacodynamics .) For the prevention of osteoporosis, alendronate sodium tablets, USP may be considered in postmenopausal women who are at risk of developing osteoporosis and for whom the desired clinical outcome is to maintain bone mass and to reduce the risk of future fracture. Bone loss is particularly rapid in postmenopausal women younger than age 60. Risk factors often associated with the development of postmenopausal osteoporosis include early menopause; moderately low bone mass (for example, at least 1 standard deviation below the mean for healthy young adult women); thin body build; Caucasian or Asian race; and family history of osteoporosis. The presence of such risk factors may be important when considering the use of alendronate sodium tablets, USP for prevention of osteoporosis. Treatment to increase bone mass in men with osteoporosis. Treatment of glucocorticoid-induced osteoporosis in men and women receiving glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and who have low bone mineral density (see PRECAUTIONS, Glucocorticoid-induced osteoporosis ). Patients treated with glucocorticoids should receive adequate amounts of calcium and vitamin D. Treatment of Paget's disease of bone in men and women Treatment is indicated in patients with Paget's disease of bone having alkaline phosphatase at least two times the upper limit of normal, or those who are symptomatic, or those at risk for future complications from their disease. uuid:2f6c571e-8a88-4410-abb0-94fca70a7eaa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2567 biolink:treats MONDO:0005382 PMID:41385096 "[{""id"":""uuid:6d106d04-a3f6-4450-aa62-5e3ad6019361"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3afd335d-b657-4d8e-860d-5db5df360d52"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Alendronate sodium tablets, USP are indicated for: Treatment and prevention of osteoporosis in postmenopausal women For the treatment of osteoporosis, alendronate sodium tablets, USP increase bone mass and reduce the incidence of fractures, including those of the hip and spine (vertebral compression fractures). Osteoporosis may be confirmed by the finding of low bone mass (for example, at least 2 standard deviations below the premenopausal mean) or by the presence or history of osteoporotic fracture. (See CLINICAL PHARMACOLOGY, Pharmacodynamics .) For the prevention of osteoporosis, alendronate sodium tablets, USP may be considered in postmenopausal women who are at risk of developing osteoporosis and for whom the desired clinical outcome is to maintain bone mass and to reduce the risk of future fracture. Bone loss is particularly rapid in postmenopausal women younger than age 60. Risk factors often associated with the development of postmenopausal osteoporosis include early menopause; moderately low bone mass (for example, at least 1 standard deviation below the mean for healthy young adult women); thin body build; Caucasian or Asian race; and family history of osteoporosis. The presence of such risk factors may be important when considering the use of alendronate sodium tablets, USP for prevention of osteoporosis. Treatment to increase bone mass in men with osteoporosis. Treatment of glucocorticoid-induced osteoporosis in men and women receiving glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and who have low bone mineral density (see PRECAUTIONS, Glucocorticoid-induced osteoporosis ). Patients treated with glucocorticoids should receive adequate amounts of calcium and vitamin D. Treatment of Paget's disease of bone in men and women Treatment is indicated in patients with Paget's disease of bone having alkaline phosphatase at least two times the upper limit of normal, or those who are symptomatic, or those at risk for future complications from their disease. uuid:bf8b217a-d694-46dd-a0f2-32833d8c0fc4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6874 biolink:treats UMLS:C5906822 PMID:41385096 "[{""id"":""uuid:7f831ee6-3e23-4d74-b87a-752b054c50c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:89295491-3e55-4f74-ae08-2d71747ac707"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For routine management after delivery of the placenta; postpartum atony and hemorrhage; subinvolution. Under full obstetric supervision, it may be given in the second stage of labor following delivery of the anterior shoulder. uuid:f8143afb-8842-4f42-9790-a79a4fd1fea9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6874 biolink:treats NCIT:C26791 PMID:41385096 "[{""id"":""uuid:1143ae6d-ee42-4b47-99af-756b251a66bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:808f3ad2-e992-40bc-9225-28454b9e6722"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For routine management after delivery of the placenta; postpartum atony and hemorrhage; subinvolution. Under full obstetric supervision, it may be given in the second stage of labor following delivery of the anterior shoulder. uuid:d0c753f8-a622-458b-8971-d092c4d92b94 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6874 biolink:treats MONDO:0001808 PMID:41385096 "[{""id"":""uuid:3dd023da-18d2-4a62-b30a-ba6adc7e7989"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0a7739c7-e8ac-456f-8b24-f08aa0c302b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For routine management after delivery of the placenta; postpartum atony and hemorrhage; subinvolution. Under full obstetric supervision, it may be given in the second stage of labor following delivery of the anterior shoulder. uuid:50be2f30-98b8-4905-9bd9-b982e592918f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50122 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:4471381c-3f49-44cf-ae10-cc8e5e1189c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2bc27f8a-7e64-4cb6-86ca-f574699984ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Monotherapy and Combination Therapy AVANDIA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. 1.2 Important Limitations of Use Due to its mechanism of action, AVANDIA is active only in the presence of endogenous insulin. Therefore, AVANDIA should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. The coadministration of AVANDIA and insulin is not recommended. The use of AVANDIA with nitrates is not recommended. uuid:0c2d5a2e-f5d3-4790-8cd4-a3f95964d6bc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50122 biolink:treats MONDO:0005147 PMID:41385096 "[{""id"":""uuid:f0dc7e0d-f389-420a-934f-7926e4224595"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7911c66e-b9d1-4382-9bc1-934de9e551a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Monotherapy and Combination Therapy AVANDIA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. 1.2 Important Limitations of Use Due to its mechanism of action, AVANDIA is active only in the presence of endogenous insulin. Therefore, AVANDIA should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. The coadministration of AVANDIA and insulin is not recommended. The use of AVANDIA with nitrates is not recommended. uuid:3e22e372-c37e-4192-a91d-00f0fd9a2a29 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50122 biolink:treats MONDO:0012819 PMID:41385096 "[{""id"":""uuid:076f5a4a-eafb-4110-939b-ed4669cbfc6d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:86aff652-a625-49bb-9ab4-be80d2ae5f87"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Monotherapy and Combination Therapy AVANDIA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. 1.2 Important Limitations of Use Due to its mechanism of action, AVANDIA is active only in the presence of endogenous insulin. Therefore, AVANDIA should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. The coadministration of AVANDIA and insulin is not recommended. The use of AVANDIA with nitrates is not recommended. uuid:66c95f2b-4317-41d9-a7f7-40d822f65f91 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4953 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:697a3af7-ed70-40b3-82b2-3a38aa7f5193"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f7e4ca22-1398-45a7-840a-18d6c46ab29a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AROMASIN is indicated for adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to AROMASIN for completion of a total of five consecutive years of adjuvant hormonal therapy. AROMASIN is indicated for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy. uuid:1dd3074c-603c-4444-a1f8-d940af4d8f25 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4953 biolink:treats UMLS:C3495917 PMID:41385096 "[{""id"":""uuid:9e2cb265-ef8c-4257-9013-c29a84d0f449"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:24d91fad-9f67-4392-990f-8c5de71d0424"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AROMASIN is indicated for adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to AROMASIN for completion of a total of five consecutive years of adjuvant hormonal therapy. AROMASIN is indicated for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy. uuid:2f757f21-6413-40e8-80bd-8b37c97c3883 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3647 biolink:treats MONDO:0005485 PMID:41385096 "[{""id"":""uuid:f7494296-4930-4469-a993-90ccf4e58d61"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a4f9d00d-7c45-4a3d-b378-06863f9998ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the management of manifestations of psychotic disorders. For the treatment of schizophrenia. To control nausea and vomiting. For relief of restlessness and apprehension before surgery. For acute intermittent porphyria. As an adjunct in the treatment of tetanus. To control the manifestations of the manic type of manic-depressive illness. For relief of intractable hiccups. For the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability and poor frustration tolerance. uuid:784ec260-1254-42a7-ad89-51f6d12c4a2c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3647 biolink:treats MONDO:0005090 PMID:41385096 "[{""id"":""uuid:b8df6c6f-f234-47d0-a17b-8c6b675d3bc0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cde08c6e-4aea-41d1-a026-4356d3ff1746"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the management of manifestations of psychotic disorders. For the treatment of schizophrenia. To control nausea and vomiting. For relief of restlessness and apprehension before surgery. For acute intermittent porphyria. As an adjunct in the treatment of tetanus. To control the manifestations of the manic type of manic-depressive illness. For relief of intractable hiccups. For the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability and poor frustration tolerance. uuid:073bc4de-baca-4eaf-b855-4539cbd53eb1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3647 biolink:treats MONDO:0008294 PMID:41385096 "[{""id"":""uuid:a5cc97dc-cf23-4a23-9759-0eedc7da0ee7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2053d8ad-462f-45b2-863f-ba38c967c84b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the management of manifestations of psychotic disorders. For the treatment of schizophrenia. To control nausea and vomiting. For relief of restlessness and apprehension before surgery. For acute intermittent porphyria. As an adjunct in the treatment of tetanus. To control the manifestations of the manic type of manic-depressive illness. For relief of intractable hiccups. For the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability and poor frustration tolerance. uuid:77ad8c10-db56-4df5-9cdc-fe6de1079529 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3647 biolink:treats MONDO:0005526 PMID:41385096 "[{""id"":""uuid:f86888d3-2597-4cc9-a95b-72e8a6891ed6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b2161a58-c95a-423f-89a2-5cc803e36ffe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the management of manifestations of psychotic disorders. For the treatment of schizophrenia. To control nausea and vomiting. For relief of restlessness and apprehension before surgery. For acute intermittent porphyria. As an adjunct in the treatment of tetanus. To control the manifestations of the manic type of manic-depressive illness. For relief of intractable hiccups. For the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability and poor frustration tolerance. uuid:a7171796-b77e-451b-945a-6e6e68468247 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3647 biolink:treats MONDO:0004985 PMID:41385096 "[{""id"":""uuid:cf6f0071-5c38-4ce7-a6dd-89005d343512"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e3c152f1-d3d3-432c-92b2-77ccfa85bcf6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the management of manifestations of psychotic disorders. For the treatment of schizophrenia. To control nausea and vomiting. For relief of restlessness and apprehension before surgery. For acute intermittent porphyria. As an adjunct in the treatment of tetanus. To control the manifestations of the manic type of manic-depressive illness. For relief of intractable hiccups. For the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability and poor frustration tolerance. uuid:83372c91-c5db-468c-bf44-68d6bdbe55f5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3647 biolink:treats MONDO:0035133 PMID:41385096 "[{""id"":""uuid:c7d63989-982d-43c7-80e8-e020885d59e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d861842f-b9dd-4a35-a3b3-cdeec8c6a30e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the management of manifestations of psychotic disorders. For the treatment of schizophrenia. To control nausea and vomiting. For relief of restlessness and apprehension before surgery. For acute intermittent porphyria. As an adjunct in the treatment of tetanus. To control the manifestations of the manic type of manic-depressive illness. For relief of intractable hiccups. For the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability and poor frustration tolerance. uuid:a018d971-1bcc-42e1-98a9-3dbefc06b25f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3647 biolink:treats MONDO:0005352 PMID:41385096 "[{""id"":""uuid:f9f6ba0f-40d7-465f-b3a6-bee4a7556c07"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2c2e7e69-a37c-4f1f-b45d-f9004b281465"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the management of manifestations of psychotic disorders. For the treatment of schizophrenia. To control nausea and vomiting. For relief of restlessness and apprehension before surgery. For acute intermittent porphyria. As an adjunct in the treatment of tetanus. To control the manifestations of the manic type of manic-depressive illness. For relief of intractable hiccups. For the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability and poor frustration tolerance. uuid:e4e9caf9-09ac-4929-b908-f82c4ad41d2b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8435 biolink:treats HP:0002017 PMID:41385096 "[{""id"":""uuid:f1a01fa1-38c6-472d-b549-53f6a6ef7276"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bddad57c-b44e-485a-8127-b33203800c63"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE For control of severe nausea and vomiting. For the treatment of schizophrenia. Prochlorperazine is effective for the short-term treatment of generalized non-psychotic anxiety. However, prochlorperazine is not the first drug to be used in therapy for most patients with non-psychotic anxiety, because certain risks associated with its use are not shared by common alternative treatments (e.g., benzodiazepines). When used in the treatment of non-psychotic anxiety, prochlorperazine should not be administered at doses of more than 20 mg per day or for longer than 12 weeks, because the use of prochlorperazine at higher doses or for longer intervals may cause persistent tardive dyskinesia that may prove irreversible (see WARNINGS ). The effectiveness of prochlorperazine as treatment for non-psychotic anxiety was established in 4 week clinical studies of outpatients with generalized anxiety disorder. This evidence does not predict that prochlorperazine will be useful in patients with other non-psychotic conditions in which anxiety, or signs that mimic anxiety, are found (e.g., physical illness, organic mental conditions, agitated depression, character pathologies, etc.). Prochlorperazine has not been shown effective in the management of behavioral complications in patients with mental retardation. uuid:026ced87-c4cd-48fa-b24e-e8b2df1ca1b1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8435 biolink:treats MONDO:0005090 PMID:41385096 "[{""id"":""uuid:1b5430ac-a1eb-478e-aa39-9ae242805a91"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5cc53353-3188-4269-9eda-ddc0f174fefd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE For control of severe nausea and vomiting. For the treatment of schizophrenia. Prochlorperazine is effective for the short-term treatment of generalized non-psychotic anxiety. However, prochlorperazine is not the first drug to be used in therapy for most patients with non-psychotic anxiety, because certain risks associated with its use are not shared by common alternative treatments (e.g., benzodiazepines). When used in the treatment of non-psychotic anxiety, prochlorperazine should not be administered at doses of more than 20 mg per day or for longer than 12 weeks, because the use of prochlorperazine at higher doses or for longer intervals may cause persistent tardive dyskinesia that may prove irreversible (see WARNINGS ). The effectiveness of prochlorperazine as treatment for non-psychotic anxiety was established in 4 week clinical studies of outpatients with generalized anxiety disorder. This evidence does not predict that prochlorperazine will be useful in patients with other non-psychotic conditions in which anxiety, or signs that mimic anxiety, are found (e.g., physical illness, organic mental conditions, agitated depression, character pathologies, etc.). Prochlorperazine has not been shown effective in the management of behavioral complications in patients with mental retardation. uuid:5316d456-991a-4626-a2e3-a6bb9d19b3bb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8435 biolink:treats MONDO:0001942 PMID:41385096 "[{""id"":""uuid:209f87a5-02ea-49a0-b851-a50f80bd7671"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:554729d3-ab87-4b34-9f00-e5769ffdf46f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE For control of severe nausea and vomiting. For the treatment of schizophrenia. Prochlorperazine is effective for the short-term treatment of generalized non-psychotic anxiety. However, prochlorperazine is not the first drug to be used in therapy for most patients with non-psychotic anxiety, because certain risks associated with its use are not shared by common alternative treatments (e.g., benzodiazepines). When used in the treatment of non-psychotic anxiety, prochlorperazine should not be administered at doses of more than 20 mg per day or for longer than 12 weeks, because the use of prochlorperazine at higher doses or for longer intervals may cause persistent tardive dyskinesia that may prove irreversible (see WARNINGS ). The effectiveness of prochlorperazine as treatment for non-psychotic anxiety was established in 4 week clinical studies of outpatients with generalized anxiety disorder. This evidence does not predict that prochlorperazine will be useful in patients with other non-psychotic conditions in which anxiety, or signs that mimic anxiety, are found (e.g., physical illness, organic mental conditions, agitated depression, character pathologies, etc.). Prochlorperazine has not been shown effective in the management of behavioral complications in patients with mental retardation. uuid:f7c2b5b1-b444-41e9-b7db-6a1f6d65101d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8435 biolink:treats MONDO:0010096 PMID:41385096 "[{""id"":""uuid:cde12531-9367-47c7-b8f5-2df456af7565"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8e94c3f0-395f-4488-a85f-f68afdaab563"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE For control of severe nausea and vomiting. For the treatment of schizophrenia. Prochlorperazine is effective for the short-term treatment of generalized non-psychotic anxiety. However, prochlorperazine is not the first drug to be used in therapy for most patients with non-psychotic anxiety, because certain risks associated with its use are not shared by common alternative treatments (e.g., benzodiazepines). When used in the treatment of non-psychotic anxiety, prochlorperazine should not be administered at doses of more than 20 mg per day or for longer than 12 weeks, because the use of prochlorperazine at higher doses or for longer intervals may cause persistent tardive dyskinesia that may prove irreversible (see WARNINGS ). The effectiveness of prochlorperazine as treatment for non-psychotic anxiety was established in 4 week clinical studies of outpatients with generalized anxiety disorder. This evidence does not predict that prochlorperazine will be useful in patients with other non-psychotic conditions in which anxiety, or signs that mimic anxiety, are found (e.g., physical illness, organic mental conditions, agitated depression, character pathologies, etc.). Prochlorperazine has not been shown effective in the management of behavioral complications in patients with mental retardation. uuid:6fb56700-5242-4422-ba9d-b103f99d3c9f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63611 biolink:treats UMLS:C0275556 PMID:41385096 "[{""id"":""uuid:c67732b1-b633-4c7b-bd7e-20cb12868af6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f69421ea-a652-4c8c-ad65-9cec34f42af9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE AVELOX Tablets and I.V. are indicated for the treatment of adults (≥ 18 years of age) with infections caused by susceptible strains of the designated microorganisms in the conditions listed below. (See DOSAGE AND ADMINISTRATION for specific recommendations. In addition, for I.V. use, see PRECAUTIONS, Geriatric Use .) Acute Bacterial Sinusitis caused by Streptococcus pneumoniae, Haemophilus influenzae , or Moraxella catarrhalis . Acute Bacterial Exacerbation of Chronic Bronchitis caused by Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, methicillin-susceptible Staphylococcus aureus, or Moraxella catarrhalis. Community Acquired Pneumonia caused by Streptococcus pneumoniae (including multi-drug resistant strains*), Haemophilus influenzae, Moraxella catarrhalis, methicillin-susceptible Staphylococcus aureus, Klebsiella pneumoniae, Mycoplasma pneumoniae, or Chlamydia pneumoniae . * MDRSP, Multi-drug resistant Streptococcus pneumoniae includes isolates previously known as PRSP (Penicillin-resistant S. pneumoniae ), and are strains resistant to two or more of the following antibiotics: penicillin (MIC ≥ 2 µg/mL), 2 nd generation cephalosporins (e.g., cefuroxime), macrolides, tetracyclines, and trimethoprim/sulfamethoxazole. Uncomplicated Skin and Skin Structure Infections caused by methicillin-susceptible Staphylococcus aureus or Streptococcus pyogenes . Complicated Intra-Abdominal Infections including polymicrobial infections such as abscess caused by Escherichia coli, Bacteroides fragilis, Streptococcus anginosus, Streptococcus constellatus, Enterococcus faecalis, Proteus mirabilis, Clostridium perfringens, Bacteroides thetaiotaomicron, or Peptostreptococcus species . Complicated Skin and Skin Structure Infections caused by methicillin-susceptible Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, or Enterobacter cloacae (See Clinical Studies ). Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to moxifloxacin. Therapy with AVELOX may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. To reduce the development of drug-resistant bacteria and maintain the effectiveness of AVELOX and other antibacterial drugs, AVELOX should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:b74e5c1e-c0a2-4bf2-96d7-91a821dc9cd1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63611 biolink:treats UMLS:C1735365 PMID:41385096 "[{""id"":""uuid:2556977f-d665-43a6-8d08-a1e96b2aa138"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ca0a3191-4292-43bb-b602-e22b33ba666d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE AVELOX Tablets and I.V. are indicated for the treatment of adults (≥ 18 years of age) with infections caused by susceptible strains of the designated microorganisms in the conditions listed below. (See DOSAGE AND ADMINISTRATION for specific recommendations. In addition, for I.V. use, see PRECAUTIONS, Geriatric Use .) Acute Bacterial Sinusitis caused by Streptococcus pneumoniae, Haemophilus influenzae , or Moraxella catarrhalis . Acute Bacterial Exacerbation of Chronic Bronchitis caused by Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, methicillin-susceptible Staphylococcus aureus, or Moraxella catarrhalis. Community Acquired Pneumonia caused by Streptococcus pneumoniae (including multi-drug resistant strains*), Haemophilus influenzae, Moraxella catarrhalis, methicillin-susceptible Staphylococcus aureus, Klebsiella pneumoniae, Mycoplasma pneumoniae, or Chlamydia pneumoniae . * MDRSP, Multi-drug resistant Streptococcus pneumoniae includes isolates previously known as PRSP (Penicillin-resistant S. pneumoniae ), and are strains resistant to two or more of the following antibiotics: penicillin (MIC ≥ 2 µg/mL), 2 nd generation cephalosporins (e.g., cefuroxime), macrolides, tetracyclines, and trimethoprim/sulfamethoxazole. Uncomplicated Skin and Skin Structure Infections caused by methicillin-susceptible Staphylococcus aureus or Streptococcus pyogenes . Complicated Intra-Abdominal Infections including polymicrobial infections such as abscess caused by Escherichia coli, Bacteroides fragilis, Streptococcus anginosus, Streptococcus constellatus, Enterococcus faecalis, Proteus mirabilis, Clostridium perfringens, Bacteroides thetaiotaomicron, or Peptostreptococcus species . Complicated Skin and Skin Structure Infections caused by methicillin-susceptible Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, or Enterobacter cloacae (See Clinical Studies ). Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to moxifloxacin. Therapy with AVELOX may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. To reduce the development of drug-resistant bacteria and maintain the effectiveness of AVELOX and other antibacterial drugs, AVELOX should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:2044e250-f614-492c-bc0d-921d6f70b45b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63611 biolink:treats UMLS:C0694549 PMID:41385096 "[{""id"":""uuid:068ae00d-dbb8-4512-bc69-2380a5f6352a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5e8a666c-f509-4588-9d34-62c68da46094"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE AVELOX Tablets and I.V. are indicated for the treatment of adults (≥ 18 years of age) with infections caused by susceptible strains of the designated microorganisms in the conditions listed below. (See DOSAGE AND ADMINISTRATION for specific recommendations. In addition, for I.V. use, see PRECAUTIONS, Geriatric Use .) Acute Bacterial Sinusitis caused by Streptococcus pneumoniae, Haemophilus influenzae , or Moraxella catarrhalis . Acute Bacterial Exacerbation of Chronic Bronchitis caused by Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, methicillin-susceptible Staphylococcus aureus, or Moraxella catarrhalis. Community Acquired Pneumonia caused by Streptococcus pneumoniae (including multi-drug resistant strains*), Haemophilus influenzae, Moraxella catarrhalis, methicillin-susceptible Staphylococcus aureus, Klebsiella pneumoniae, Mycoplasma pneumoniae, or Chlamydia pneumoniae . * MDRSP, Multi-drug resistant Streptococcus pneumoniae includes isolates previously known as PRSP (Penicillin-resistant S. pneumoniae ), and are strains resistant to two or more of the following antibiotics: penicillin (MIC ≥ 2 µg/mL), 2 nd generation cephalosporins (e.g., cefuroxime), macrolides, tetracyclines, and trimethoprim/sulfamethoxazole. Uncomplicated Skin and Skin Structure Infections caused by methicillin-susceptible Staphylococcus aureus or Streptococcus pyogenes . Complicated Intra-Abdominal Infections including polymicrobial infections such as abscess caused by Escherichia coli, Bacteroides fragilis, Streptococcus anginosus, Streptococcus constellatus, Enterococcus faecalis, Proteus mirabilis, Clostridium perfringens, Bacteroides thetaiotaomicron, or Peptostreptococcus species . Complicated Skin and Skin Structure Infections caused by methicillin-susceptible Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, or Enterobacter cloacae (See Clinical Studies ). Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to moxifloxacin. Therapy with AVELOX may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. To reduce the development of drug-resistant bacteria and maintain the effectiveness of AVELOX and other antibacterial drugs, AVELOX should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:061d9c7d-5674-4568-a1e5-35252645ce56 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63611 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:09844ca2-5998-474f-ab95-230ed703516b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1feddbe2-c26a-4772-a8f1-c187c0ac2065"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE AVELOX Tablets and I.V. are indicated for the treatment of adults (≥ 18 years of age) with infections caused by susceptible strains of the designated microorganisms in the conditions listed below. (See DOSAGE AND ADMINISTRATION for specific recommendations. In addition, for I.V. use, see PRECAUTIONS, Geriatric Use .) Acute Bacterial Sinusitis caused by Streptococcus pneumoniae, Haemophilus influenzae , or Moraxella catarrhalis . Acute Bacterial Exacerbation of Chronic Bronchitis caused by Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, methicillin-susceptible Staphylococcus aureus, or Moraxella catarrhalis. Community Acquired Pneumonia caused by Streptococcus pneumoniae (including multi-drug resistant strains*), Haemophilus influenzae, Moraxella catarrhalis, methicillin-susceptible Staphylococcus aureus, Klebsiella pneumoniae, Mycoplasma pneumoniae, or Chlamydia pneumoniae . * MDRSP, Multi-drug resistant Streptococcus pneumoniae includes isolates previously known as PRSP (Penicillin-resistant S. pneumoniae ), and are strains resistant to two or more of the following antibiotics: penicillin (MIC ≥ 2 µg/mL), 2 nd generation cephalosporins (e.g., cefuroxime), macrolides, tetracyclines, and trimethoprim/sulfamethoxazole. Uncomplicated Skin and Skin Structure Infections caused by methicillin-susceptible Staphylococcus aureus or Streptococcus pyogenes . Complicated Intra-Abdominal Infections including polymicrobial infections such as abscess caused by Escherichia coli, Bacteroides fragilis, Streptococcus anginosus, Streptococcus constellatus, Enterococcus faecalis, Proteus mirabilis, Clostridium perfringens, Bacteroides thetaiotaomicron, or Peptostreptococcus species . Complicated Skin and Skin Structure Infections caused by methicillin-susceptible Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, or Enterobacter cloacae (See Clinical Studies ). Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to moxifloxacin. Therapy with AVELOX may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. To reduce the development of drug-resistant bacteria and maintain the effectiveness of AVELOX and other antibacterial drugs, AVELOX should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:61740812-2802-492c-84f7-a456f4b5dfdf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3219 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:15251fff-08df-4d47-bf18-0c27bd99b8cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2947c812-33d6-434b-9cbb-9ba94948121f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bupropion hydrochloride tablets are indicated for the treatment of major depressive disorder. A physician considering bupropion for the management of a patient’s first episode of depression should be aware that the drug may cause generalized seizures in a dose dependent manner with an approximate incidence of 0.4% (4/1,000). This incidence of seizures may exceed that of other marketed antidepressants by as much as 4-fold. This relative risk is only an approximate estimate because no direct comparative studies have been conducted (see WARNINGS ). The efficacy of bupropion has been established in three placebo-controlled trials, including two of approximately 3 weeks’ duration in depressed inpatients and one of approximately 6 weeks’ duration in depressed outpatients. The depressive disorder of the patients studied corresponds most closely to the Major Depression category of the APA Diagnostic and Statistical Manual III. Major depression implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks); it should include at least four of the following eight symptoms: change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigability, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and suicidal ideation or attempts. Effectiveness of bupropion in long-term use, that is, for more than 6 weeks, has not been systematically evaluated in controlled trials. Therefore, the physician who elects to use bupropion for extended periods should periodically reevaluate the long-term usefulness of the drug for the individual patient. uuid:b8028463-2b7e-4c15-a86e-730053331c16 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3175 biolink:treats MONDO:0005338 PMID:41385096 "[{""id"":""uuid:d0894bfa-7d39-47bb-950f-58e64a554e41"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3ba7b8b2-bedd-482f-a706-8d87cf9c34b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Brimonidine Tartrate Ophthalmic Solution, 0.15% is indicated for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. uuid:a2a3128c-2643-4320-99fa-2d8f0fe38ee8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3175 biolink:treats MONDO:0006875 PMID:41385096 "[{""id"":""uuid:36949bdf-f3b9-455d-b64b-a204853508b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8a73e559-1636-444d-b213-9f2df82fb6a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Brimonidine Tartrate Ophthalmic Solution, 0.15% is indicated for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. uuid:5b89acda-e755-413d-9add-2da0aa4f4bd7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9622 biolink:treats EFO:0006865 PMID:41385096 "[{""id"":""uuid:15cf3ff0-1ae5-49a5-b955-8bcee88f6f2a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:71f08682-27a1-4b23-97c0-da9f747cff06"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:b4665f78-7aef-4daf-8e46-76b79b285444"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1 INDICATIONS AND USAGE DETROL LA Capsules is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency [see CLINICAL STUDIES (14) ].|[PMDA] Drugs with a new active ingredient indicated for treatment of urinary urgency, urinary frequency, and urge urinary incontinence associated with overactive bladder. uuid:5c70a35d-211b-4a83-aa16-edb5181a6588 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:37941 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:0d63a19a-a8d0-4923-acd8-664491d20e0b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:03ad1113-76bc-4597-be67-638ee6acbb9c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE PLAVIX (clopidogrel bisulfate) is indicated for the reduction of atherothrombotic events as follows: Recent MI, Recent Stroke or Established Peripheral Arterial Disease For patients with a history of recent myocardial infarction (MI), recent stroke, or established peripheral arterial disease, PLAVIX has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death. Acute Coronary Syndrome - For patients with non-ST-segment elevation acute coronary syndrome (unstable angina/non-Q-wave MI) including patients who are to be managed medically and those who are to be managed with percutaneous coronary intervention (with or without stent) or CABG, PLAVIX has been shown to decrease the rate of a combined endpoint of cardiovascular death, MI, or stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or refractory ischemia. - For patients with ST-segment elevation acute myocardial infarction, PLAVIX has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction or stroke. This benefit is not known to pertain to patients who receive primary angioplasty uuid:6e5cd589-3117-4b49-9d5f-869e61595950 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:37941 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:601de139-db86-4320-a2e3-03e1a94e3b30"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3b1d052a-0436-41f6-b0c4-42b13c8c6992"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE PLAVIX (clopidogrel bisulfate) is indicated for the reduction of atherothrombotic events as follows: Recent MI, Recent Stroke or Established Peripheral Arterial Disease For patients with a history of recent myocardial infarction (MI), recent stroke, or established peripheral arterial disease, PLAVIX has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death. Acute Coronary Syndrome - For patients with non-ST-segment elevation acute coronary syndrome (unstable angina/non-Q-wave MI) including patients who are to be managed medically and those who are to be managed with percutaneous coronary intervention (with or without stent) or CABG, PLAVIX has been shown to decrease the rate of a combined endpoint of cardiovascular death, MI, or stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or refractory ischemia. - For patients with ST-segment elevation acute myocardial infarction, PLAVIX has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction or stroke. This benefit is not known to pertain to patients who receive primary angioplasty uuid:966f4351-92f1-4b1e-99d3-cabde952e5fc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:37941 biolink:treats MONDO:0005386 PMID:41385096 "[{""id"":""uuid:937760f1-d05f-4750-95b4-48053ef720a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:06503a70-574c-4a84-a34e-ae832bc0ee18"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE PLAVIX (clopidogrel bisulfate) is indicated for the reduction of atherothrombotic events as follows: Recent MI, Recent Stroke or Established Peripheral Arterial Disease For patients with a history of recent myocardial infarction (MI), recent stroke, or established peripheral arterial disease, PLAVIX has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death. Acute Coronary Syndrome - For patients with non-ST-segment elevation acute coronary syndrome (unstable angina/non-Q-wave MI) including patients who are to be managed medically and those who are to be managed with percutaneous coronary intervention (with or without stent) or CABG, PLAVIX has been shown to decrease the rate of a combined endpoint of cardiovascular death, MI, or stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or refractory ischemia. - For patients with ST-segment elevation acute myocardial infarction, PLAVIX has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction or stroke. This benefit is not known to pertain to patients who receive primary angioplasty uuid:656cc8a1-6151-433d-be53-902f334c25f7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:37941 biolink:treats MONDO:0006805 PMID:41385096 "[{""id"":""uuid:f3d37694-ffc6-44fa-8252-7549a6215216"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:040ecba7-ad4c-41ef-a2a7-b5b610beb6a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:3c3d1a93-ef20-4882-81e0-25b482f79f9e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE PLAVIX (clopidogrel bisulfate) is indicated for the reduction of atherothrombotic events as follows: Recent MI, Recent Stroke or Established Peripheral Arterial Disease For patients with a history of recent myocardial infarction (MI), recent stroke, or established peripheral arterial disease, PLAVIX has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death. Acute Coronary Syndrome - For patients with non-ST-segment elevation acute coronary syndrome (unstable angina/non-Q-wave MI) including patients who are to be managed medically and those who are to be managed with percutaneous coronary intervention (with or without stent) or CABG, PLAVIX has been shown to decrease the rate of a combined endpoint of cardiovascular death, MI, or stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or refractory ischemia. - For patients with ST-segment elevation acute myocardial infarction, PLAVIX has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction or stroke. This benefit is not known to pertain to patients who receive primary angioplasty|[PMDA] A new combination drug indicated for the treatment of ischemic heart diseases (acute coronary syndrome [unstable angina, non-ST-segment elevation myocardial infarction, ST-segment elevation myocardial infarction], stable angina, old myocardial infarction) to which percutaneous coronary intervention (PCI) is applicable. uuid:5e16a907-c2b2-4c03-9295-72c8fae8dd96 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:37941 biolink:treats MONDO:0041656 PMID:41385096 "[{""id"":""uuid:65a87d22-d6d9-4443-b6b5-1865caeca28b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:49f88c92-89a5-414b-8c58-4656c2bf0710"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:effcc48f-eb49-4772-8487-4d137188ce5d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE PLAVIX (clopidogrel bisulfate) is indicated for the reduction of atherothrombotic events as follows: Recent MI, Recent Stroke or Established Peripheral Arterial Disease For patients with a history of recent myocardial infarction (MI), recent stroke, or established peripheral arterial disease, PLAVIX has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death. Acute Coronary Syndrome - For patients with non-ST-segment elevation acute coronary syndrome (unstable angina/non-Q-wave MI) including patients who are to be managed medically and those who are to be managed with percutaneous coronary intervention (with or without stent) or CABG, PLAVIX has been shown to decrease the rate of a combined endpoint of cardiovascular death, MI, or stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or refractory ischemia. - For patients with ST-segment elevation acute myocardial infarction, PLAVIX has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction or stroke. This benefit is not known to pertain to patients who receive primary angioplasty|[PMDA] A new combination drug indicated for the treatment of ischemic heart diseases (acute coronary syndrome [unstable angina, non-ST-segment elevation myocardial infarction, ST-segment elevation myocardial infarction], stable angina, old myocardial infarction) to which percutaneous coronary intervention (PCI) is applicable. uuid:e3861f33-c40e-4657-80cf-bc7fd5c0c94f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:37941 biolink:treats UMLS:C1112767 PMID:41385096 "[{""id"":""uuid:f76f3580-ec1b-4dc0-b0a3-91fc3302e73e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:87fce9c6-22d7-4b46-92f7-b08fe85b4a1e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE PLAVIX (clopidogrel bisulfate) is indicated for the reduction of atherothrombotic events as follows: Recent MI, Recent Stroke or Established Peripheral Arterial Disease For patients with a history of recent myocardial infarction (MI), recent stroke, or established peripheral arterial disease, PLAVIX has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death. Acute Coronary Syndrome - For patients with non-ST-segment elevation acute coronary syndrome (unstable angina/non-Q-wave MI) including patients who are to be managed medically and those who are to be managed with percutaneous coronary intervention (with or without stent) or CABG, PLAVIX has been shown to decrease the rate of a combined endpoint of cardiovascular death, MI, or stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or refractory ischemia. - For patients with ST-segment elevation acute myocardial infarction, PLAVIX has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction or stroke. This benefit is not known to pertain to patients who receive primary angioplasty uuid:cf47c3b2-56c7-4134-bbf5-1fae9f460912 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7915 biolink:treats UMLS:C0267055 PMID:41385096 "[{""id"":""uuid:1254150b-9d41-4d95-8c7f-f63cf84fba97"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e67e149e-6f0c-4600-aba7-5b90b14d7a2b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pantoprazole sodium delayed-release tablets are indicated for the short-term treatment (up to 8 weeks) in the healing and symptomatic relief of erosive esophagitis. For those patients who have not healed after 8 weeks of treatment, an additional 8-week course of pantoprazole sodium may be considered. uuid:cd780e34-9fd3-4f66-b9f1-294784dd0975 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50730 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:22261f67-427f-45c0-b84e-e0e7f093fc5b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:95bda2e9-bd15-4aa9-8bf4-d3428a8b0b6e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:bb3ac72b-5814-4ab7-8f00-56eea4165ed5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SINGULAIR is indicated for the prophylaxis and chronic treatment of asthma in adults and pediatric patients 12 months of age and older. SINGULAIR is indicated for prevention of exercise-induced bronchoconstriction in patients 15 years of age and older. SINGULAIR is indicated for the relief of symptoms of allergic rhinitis (seasonal allergic rhinitis in adults and pediatric patients 2 years of age and older, and perennial allergic rhinitis in adults and pediatric patients 6 months of age and older).|[PMDA] Drugs with a new dosage and in a new dosage form, or fine granules, indicated for the treatment of asthma in children aged 1 or more and less than 6 years. uuid:02cdbf4a-c3f8-4f45-b211-eff8e01e96fd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50730 biolink:treats MONDO:0850286 PMID:41385096 "[{""id"":""uuid:f8c86eae-bc4d-4ef7-a4a3-d9fd8117355d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:303f307b-ca6c-4810-ae37-22fd8e66acce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SINGULAIR is indicated for the prophylaxis and chronic treatment of asthma in adults and pediatric patients 12 months of age and older. SINGULAIR is indicated for prevention of exercise-induced bronchoconstriction in patients 15 years of age and older. SINGULAIR is indicated for the relief of symptoms of allergic rhinitis (seasonal allergic rhinitis in adults and pediatric patients 2 years of age and older, and perennial allergic rhinitis in adults and pediatric patients 6 months of age and older). uuid:77a2dc58-73e1-496d-8931-2c38ac186257 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50730 biolink:treats MONDO:0011786 PMID:41385096 "[{""id"":""uuid:7712be2b-1443-4f21-b17a-a7302363ee0a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0b81aaef-88bf-41c6-9a77-6d44b81724fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f03df48d-72d2-4ee3-baee-dc2af7dcf53d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SINGULAIR is indicated for the prophylaxis and chronic treatment of asthma in adults and pediatric patients 12 months of age and older. SINGULAIR is indicated for prevention of exercise-induced bronchoconstriction in patients 15 years of age and older. SINGULAIR is indicated for the relief of symptoms of allergic rhinitis (seasonal allergic rhinitis in adults and pediatric patients 2 years of age and older, and perennial allergic rhinitis in adults and pediatric patients 6 months of age and older).|[PMDA] Drugs with a new indication and dosage and in a new dosge form for the treatment of allergic rhinitis. uuid:2b6a07ba-4411-4b30-9b64-41dea296938d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50730 biolink:treats MONDO:0005324 PMID:41385096 "[{""id"":""uuid:be06ccd5-d262-4c31-adee-00661fbf9619"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8e8471cb-ce4d-4907-b396-4c4eb18d4ba2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SINGULAIR is indicated for the prophylaxis and chronic treatment of asthma in adults and pediatric patients 12 months of age and older. SINGULAIR is indicated for prevention of exercise-induced bronchoconstriction in patients 15 years of age and older. SINGULAIR is indicated for the relief of symptoms of allergic rhinitis (seasonal allergic rhinitis in adults and pediatric patients 2 years of age and older, and perennial allergic rhinitis in adults and pediatric patients 6 months of age and older). uuid:503245e9-b027-4017-a323-173a6f99e5bd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50730 biolink:treats MONDO:0024332 PMID:41385096 "[{""id"":""uuid:aba9d733-dc1a-4b96-b0db-ae5b7aed3fba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2e40246c-5c38-4b6e-b121-282f5c5b2749"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SINGULAIR is indicated for the prophylaxis and chronic treatment of asthma in adults and pediatric patients 12 months of age and older. SINGULAIR is indicated for prevention of exercise-induced bronchoconstriction in patients 15 years of age and older. SINGULAIR is indicated for the relief of symptoms of allergic rhinitis (seasonal allergic rhinitis in adults and pediatric patients 2 years of age and older, and perennial allergic rhinitis in adults and pediatric patients 6 months of age and older). uuid:81aa4abc-3bf7-4561-882b-833c4d200bf5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50663 biolink:treats MONDO:0005812 PMID:41385096 "[{""id"":""uuid:b3f70e6b-011c-4168-b420-6aca3ccfd983"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8f83677b-2af5-4333-9a39-da41565829d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:60969f4e-a4f6-4e3f-91d6-fb8a9f076965"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/dectova""]},{""id"":""uuid:7ad04817-1b3a-4cc2-83e6-ea0b0deeaae5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RELENZA, an influenza neuraminidase inhibitor, is indicated for: Treatment of influenza in patients 7 years of age and older who have been symptomatic for no more than 2 days. (1.1) Prophylaxis of influenza in patients 5 years of age and older. (1.2) Important Limitations on Use of RELENZA: Not recommended for treatment or prophylaxis of influenza in: Individuals with underlying airways disease. (5.1) Not proven effective for: Treatment in individuals with underlying airways disease. (1.3) Prophylaxis in nursing home residents. (1.3) Not a substitute for annual influenza vaccination. (1.3) Consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use RELENZA. (1.3)|[EMA] Dectova is indicated for the treatment of complicated and potentially life-threatening influenza A or B virus infection in adult and paediatric patients (aged ≥6 months) when:The patient’s influenza virus is known or suspected to be resistant to anti-influenza medicinal products other than zanamivir, and/orOther anti-viral medicinal products for treatment of influenza, including inhaled zanamivir, are not suitable for the individual patient.Dectova should be used in accordance with official guidance.|[PMDA] Addition of a new indication for prophylaxis of influenza typeA or typeB infections. [Expedited Review] uuid:3846bcee-b6f3-4770-9eb1-344b05787a39 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8461 biolink:treats MONDO:0005271 PMID:41385096 "[{""id"":""uuid:85df86a3-8d96-4f15-96b1-737d80fa207a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7e695724-3b81-4313-9b0f-f4f2a2d0f5ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Promethazine hydrochloride injection is indicated for the following conditions: Amelioration of allergic reactions to blood or plasma. In anaphylaxis as an adjunct to epinephrine and other standard measures after the acute symptoms have been controlled. For other uncomplicated allergic conditions of the immediate type when oral therapy is impossible or contraindicated. For sedation and relief of apprehension and to produce light sleep from which the patient can be easily aroused. Active treatment of motion sickness. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. As an adjunct to analgesics for the control of postoperative pain. Preoperative, postoperative, and obstetric (during labor) sedation. Intravenously in special surgical situations, such as repeated bronchoscopy, ophthalmic surgery, and poor-risk patients, with reduced amounts of meperidine or other narcotic analgesic as an adjunct to anesthesia and analgesia. uuid:f9f1da6c-f8e8-4f96-b93d-c22ab3dc3454 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8461 biolink:treats UMLS:C0851444 PMID:41385096 "[{""id"":""uuid:7993605d-2bb1-4762-a729-3bc78c28a54d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aee2dcb2-202d-4a17-9009-420d375c1cd0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Promethazine hydrochloride injection is indicated for the following conditions: Amelioration of allergic reactions to blood or plasma. In anaphylaxis as an adjunct to epinephrine and other standard measures after the acute symptoms have been controlled. For other uncomplicated allergic conditions of the immediate type when oral therapy is impossible or contraindicated. For sedation and relief of apprehension and to produce light sleep from which the patient can be easily aroused. Active treatment of motion sickness. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. As an adjunct to analgesics for the control of postoperative pain. Preoperative, postoperative, and obstetric (during labor) sedation. Intravenously in special surgical situations, such as repeated bronchoscopy, ophthalmic surgery, and poor-risk patients, with reduced amounts of meperidine or other narcotic analgesic as an adjunct to anesthesia and analgesia. uuid:113653f7-fd49-41dd-a5a9-0715af34e6b4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation MESH:C075654 biolink:treats MONDO:0005344 PMID:41385096 "[{""id"":""uuid:9f84cafb-3171-4059-859d-570c33c1ba33"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:35ea67f5-6173-4e30-83a4-76ee48800b06"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e09aeead-b170-47ed-91d3-169845ec0bc7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/prehevbri""]},{""id"":""uuid:fc39df26-9774-4342-b9cb-e335cffe267a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ENGERIX-B is indicated for immunization against infection caused by all known subtypes of hepatitis B virus. As hepatitis D (caused by the delta virus) does not occur in the absence of hepatitis B infection, it can be expected that hepatitis D will also be prevented by ENGERIX-B vaccination. ENGERIX-B will not prevent hepatitis caused by other agents, such as hepatitis A, C, and E viruses, or other pathogens known to infect the liver. Immunization is recommended in persons of all ages, especially those who are, or will be, at increased risk of exposure to hepatitis B virus, 1 for example: Infants, Including Those Born of HBsAg-Positive Mothers (See DOSAGE AND ADMINISTRATION.) Adolescents (See CLINICAL PHARMACOLOGY.) Healthcare Personnel: Dentists and oral surgeons. Dental, medical, and nursing students. Physicians, surgeons, and podiatrists. Nurses. Paramedical and ambulance personnel and custodial staff who may be exposed to the virus via blood or other patient specimens. Dental hygienists and dental nurses. Laboratory and blood bank personnel handling blood, blood products, and other patient specimens. Hospital cleaning staff who handle waste. Selected Patients and Patient Contacts: Patients and staff in hemodialysis units and hematology/oncology units. Patients requiring frequent and/or large volume blood transfusions or clotting factor concentrates (e.g., persons with hemophilia, thalassemia, sickle cell anemia, cirrhosis). Clients (residents) and staff of institutions for the mentally handicapped. Classroom contacts of deinstitutionalized mentally handicapped persons who have persistent hepatitis B surface antigenemia and who show aggressive behavior. Household and other intimate contacts of persons with persistent hepatitis B surface antigenemia. Subpopulations With a Known High Incidence of the Disease, such as: Alaskan Eskimos. Pacific Islanders. Indochinese immigrants. Haitian immigrants. Refugees from other HBV-endemic areas. All infants of women born in areas where the infection is highly endemic. Individuals With Chronic Hepatitis C: Risk factors for hepatitis C are similar to those for hepatitis B. Consequently, immunization with hepatitis B vaccine is recommended for individuals with chronic hepatitis C. Persons Who May Be Exposed to the Hepatitis B Virus by Travel to High-Risk Areas (See ACIP Guidelines, 1990.) Military Personnel Identified as Being at Increased Risk Morticians and Embalmers Persons at Increased Risk of the Disease Due to Their Sexual Practices, 1,16 such as: Persons with more than 1 sexual partner in a 6-month period. Persons who have contracted a sexually transmitted disease. Homosexually active males. Female prostitutes. Prisoners Users of Illicit Injectable Drugs Others: Police and fire department personnel who render first aid or medical assistance, and any others who, through their work or personal life-style, may be exposed to the hepatitis B virus. Adoptees from countries of high HBV endemicity.|[EMA] PreHevbri is indicated for active immunisation against infection caused by all known subtypes of the hepatitis B virus in adults., , It can be expected that hepatitis D will also be prevented by immunisation with PreHevbri as hepatitis D (caused by the delta agent) does not occur in the absence of hepatitis B infection., , The use of PreHevbri should be in accordance with official recommendations.,|[PMDA] Drugs with a revised dosage indicated for the prevention of perinatal hepatitis B virus infection (concomitant use with anti-Hepatitis B surface [HBs] human immunoglobulin). [Public knowledge-based application after PAFSC's preliminary assessment] uuid:7d768268-1c11-4d78-b8dd-dbb884a64466 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation MESH:C075654 biolink:treats MONDO:0005789 PMID:41385096 "[{""id"":""uuid:954b31dc-dc3f-4c08-9301-b51a9028a3cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d228c7d1-3abe-4eb9-9910-8eca160d294e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:dc5c2893-f95c-4f7a-a813-21aa62a8d713"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/prehevbri""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] ENGERIX-B is indicated for immunization against infection caused by all known subtypes of hepatitis B virus. As hepatitis D (caused by the delta virus) does not occur in the absence of hepatitis B infection, it can be expected that hepatitis D will also be prevented by ENGERIX-B vaccination. ENGERIX-B will not prevent hepatitis caused by other agents, such as hepatitis A, C, and E viruses, or other pathogens known to infect the liver. Immunization is recommended in persons of all ages, especially those who are, or will be, at increased risk of exposure to hepatitis B virus, 1 for example: Infants, Including Those Born of HBsAg-Positive Mothers (See DOSAGE AND ADMINISTRATION.) Adolescents (See CLINICAL PHARMACOLOGY.) Healthcare Personnel: Dentists and oral surgeons. Dental, medical, and nursing students. Physicians, surgeons, and podiatrists. Nurses. Paramedical and ambulance personnel and custodial staff who may be exposed to the virus via blood or other patient specimens. Dental hygienists and dental nurses. Laboratory and blood bank personnel handling blood, blood products, and other patient specimens. Hospital cleaning staff who handle waste. Selected Patients and Patient Contacts: Patients and staff in hemodialysis units and hematology/oncology units. Patients requiring frequent and/or large volume blood transfusions or clotting factor concentrates (e.g., persons with hemophilia, thalassemia, sickle cell anemia, cirrhosis). Clients (residents) and staff of institutions for the mentally handicapped. Classroom contacts of deinstitutionalized mentally handicapped persons who have persistent hepatitis B surface antigenemia and who show aggressive behavior. Household and other intimate contacts of persons with persistent hepatitis B surface antigenemia. Subpopulations With a Known High Incidence of the Disease, such as: Alaskan Eskimos. Pacific Islanders. Indochinese immigrants. Haitian immigrants. Refugees from other HBV-endemic areas. All infants of women born in areas where the infection is highly endemic. Individuals With Chronic Hepatitis C: Risk factors for hepatitis C are similar to those for hepatitis B. Consequently, immunization with hepatitis B vaccine is recommended for individuals with chronic hepatitis C. Persons Who May Be Exposed to the Hepatitis B Virus by Travel to High-Risk Areas (See ACIP Guidelines, 1990.) Military Personnel Identified as Being at Increased Risk Morticians and Embalmers Persons at Increased Risk of the Disease Due to Their Sexual Practices, 1,16 such as: Persons with more than 1 sexual partner in a 6-month period. Persons who have contracted a sexually transmitted disease. Homosexually active males. Female prostitutes. Prisoners Users of Illicit Injectable Drugs Others: Police and fire department personnel who render first aid or medical assistance, and any others who, through their work or personal life-style, may be exposed to the hepatitis B virus. Adoptees from countries of high HBV endemicity.|[EMA] PreHevbri is indicated for active immunisation against infection caused by all known subtypes of the hepatitis B virus in adults., , It can be expected that hepatitis D will also be prevented by immunisation with PreHevbri as hepatitis D (caused by the delta agent) does not occur in the absence of hepatitis B infection., , The use of PreHevbri should be in accordance with official recommendations., uuid:65830e62-b89f-453d-a3bf-68157f26a806 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation MESH:C075654 biolink:treats MONDO:0018660 PMID:41385096 "[{""id"":""uuid:77b5bb5c-353d-4950-8025-7ab6c70d466c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:238920ae-4281-4431-82b8-1077435d0f64"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ENGERIX-B is indicated for immunization against infection caused by all known subtypes of hepatitis B virus. As hepatitis D (caused by the delta virus) does not occur in the absence of hepatitis B infection, it can be expected that hepatitis D will also be prevented by ENGERIX-B vaccination. ENGERIX-B will not prevent hepatitis caused by other agents, such as hepatitis A, C, and E viruses, or other pathogens known to infect the liver. Immunization is recommended in persons of all ages, especially those who are, or will be, at increased risk of exposure to hepatitis B virus, 1 for example: Infants, Including Those Born of HBsAg-Positive Mothers (See DOSAGE AND ADMINISTRATION.) Adolescents (See CLINICAL PHARMACOLOGY.) Healthcare Personnel: Dentists and oral surgeons. Dental, medical, and nursing students. Physicians, surgeons, and podiatrists. Nurses. Paramedical and ambulance personnel and custodial staff who may be exposed to the virus via blood or other patient specimens. Dental hygienists and dental nurses. Laboratory and blood bank personnel handling blood, blood products, and other patient specimens. Hospital cleaning staff who handle waste. Selected Patients and Patient Contacts: Patients and staff in hemodialysis units and hematology/oncology units. Patients requiring frequent and/or large volume blood transfusions or clotting factor concentrates (e.g., persons with hemophilia, thalassemia, sickle cell anemia, cirrhosis). Clients (residents) and staff of institutions for the mentally handicapped. Classroom contacts of deinstitutionalized mentally handicapped persons who have persistent hepatitis B surface antigenemia and who show aggressive behavior. Household and other intimate contacts of persons with persistent hepatitis B surface antigenemia. Subpopulations With a Known High Incidence of the Disease, such as: Alaskan Eskimos. Pacific Islanders. Indochinese immigrants. Haitian immigrants. Refugees from other HBV-endemic areas. All infants of women born in areas where the infection is highly endemic. Individuals With Chronic Hepatitis C: Risk factors for hepatitis C are similar to those for hepatitis B. Consequently, immunization with hepatitis B vaccine is recommended for individuals with chronic hepatitis C. Persons Who May Be Exposed to the Hepatitis B Virus by Travel to High-Risk Areas (See ACIP Guidelines, 1990.) Military Personnel Identified as Being at Increased Risk Morticians and Embalmers Persons at Increased Risk of the Disease Due to Their Sexual Practices, 1,16 such as: Persons with more than 1 sexual partner in a 6-month period. Persons who have contracted a sexually transmitted disease. Homosexually active males. Female prostitutes. Prisoners Users of Illicit Injectable Drugs Others: Police and fire department personnel who render first aid or medical assistance, and any others who, through their work or personal life-style, may be exposed to the hepatitis B virus. Adoptees from countries of high HBV endemicity. uuid:da925578-118f-4880-b3a9-ad882533a154 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation MESH:C075654 biolink:treats MONDO:0000984 PMID:41385096 "[{""id"":""uuid:d776f05d-5d57-4b48-977f-a78fe5ea2a1a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c0dab67a-f4ca-4e32-8da9-ffe8274d075f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ENGERIX-B is indicated for immunization against infection caused by all known subtypes of hepatitis B virus. As hepatitis D (caused by the delta virus) does not occur in the absence of hepatitis B infection, it can be expected that hepatitis D will also be prevented by ENGERIX-B vaccination. ENGERIX-B will not prevent hepatitis caused by other agents, such as hepatitis A, C, and E viruses, or other pathogens known to infect the liver. Immunization is recommended in persons of all ages, especially those who are, or will be, at increased risk of exposure to hepatitis B virus, 1 for example: Infants, Including Those Born of HBsAg-Positive Mothers (See DOSAGE AND ADMINISTRATION.) Adolescents (See CLINICAL PHARMACOLOGY.) Healthcare Personnel: Dentists and oral surgeons. Dental, medical, and nursing students. Physicians, surgeons, and podiatrists. Nurses. Paramedical and ambulance personnel and custodial staff who may be exposed to the virus via blood or other patient specimens. Dental hygienists and dental nurses. Laboratory and blood bank personnel handling blood, blood products, and other patient specimens. Hospital cleaning staff who handle waste. Selected Patients and Patient Contacts: Patients and staff in hemodialysis units and hematology/oncology units. Patients requiring frequent and/or large volume blood transfusions or clotting factor concentrates (e.g., persons with hemophilia, thalassemia, sickle cell anemia, cirrhosis). Clients (residents) and staff of institutions for the mentally handicapped. Classroom contacts of deinstitutionalized mentally handicapped persons who have persistent hepatitis B surface antigenemia and who show aggressive behavior. Household and other intimate contacts of persons with persistent hepatitis B surface antigenemia. Subpopulations With a Known High Incidence of the Disease, such as: Alaskan Eskimos. Pacific Islanders. Indochinese immigrants. Haitian immigrants. Refugees from other HBV-endemic areas. All infants of women born in areas where the infection is highly endemic. Individuals With Chronic Hepatitis C: Risk factors for hepatitis C are similar to those for hepatitis B. Consequently, immunization with hepatitis B vaccine is recommended for individuals with chronic hepatitis C. Persons Who May Be Exposed to the Hepatitis B Virus by Travel to High-Risk Areas (See ACIP Guidelines, 1990.) Military Personnel Identified as Being at Increased Risk Morticians and Embalmers Persons at Increased Risk of the Disease Due to Their Sexual Practices, 1,16 such as: Persons with more than 1 sexual partner in a 6-month period. Persons who have contracted a sexually transmitted disease. Homosexually active males. Female prostitutes. Prisoners Users of Illicit Injectable Drugs Others: Police and fire department personnel who render first aid or medical assistance, and any others who, through their work or personal life-style, may be exposed to the hepatitis B virus. Adoptees from countries of high HBV endemicity. uuid:4cb4acaf-20f2-40a0-b9f8-76474a7555aa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation MESH:C075654 biolink:treats MONDO:0011382 PMID:41385096 "[{""id"":""uuid:2d29f767-abd6-483b-b32c-6cd5832198b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f19ac613-e8bf-4062-b1fc-4bb0627b8b03"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ENGERIX-B is indicated for immunization against infection caused by all known subtypes of hepatitis B virus. As hepatitis D (caused by the delta virus) does not occur in the absence of hepatitis B infection, it can be expected that hepatitis D will also be prevented by ENGERIX-B vaccination. ENGERIX-B will not prevent hepatitis caused by other agents, such as hepatitis A, C, and E viruses, or other pathogens known to infect the liver. Immunization is recommended in persons of all ages, especially those who are, or will be, at increased risk of exposure to hepatitis B virus, 1 for example: Infants, Including Those Born of HBsAg-Positive Mothers (See DOSAGE AND ADMINISTRATION.) Adolescents (See CLINICAL PHARMACOLOGY.) Healthcare Personnel: Dentists and oral surgeons. Dental, medical, and nursing students. Physicians, surgeons, and podiatrists. Nurses. Paramedical and ambulance personnel and custodial staff who may be exposed to the virus via blood or other patient specimens. Dental hygienists and dental nurses. Laboratory and blood bank personnel handling blood, blood products, and other patient specimens. Hospital cleaning staff who handle waste. Selected Patients and Patient Contacts: Patients and staff in hemodialysis units and hematology/oncology units. Patients requiring frequent and/or large volume blood transfusions or clotting factor concentrates (e.g., persons with hemophilia, thalassemia, sickle cell anemia, cirrhosis). Clients (residents) and staff of institutions for the mentally handicapped. Classroom contacts of deinstitutionalized mentally handicapped persons who have persistent hepatitis B surface antigenemia and who show aggressive behavior. Household and other intimate contacts of persons with persistent hepatitis B surface antigenemia. Subpopulations With a Known High Incidence of the Disease, such as: Alaskan Eskimos. Pacific Islanders. Indochinese immigrants. Haitian immigrants. Refugees from other HBV-endemic areas. All infants of women born in areas where the infection is highly endemic. Individuals With Chronic Hepatitis C: Risk factors for hepatitis C are similar to those for hepatitis B. Consequently, immunization with hepatitis B vaccine is recommended for individuals with chronic hepatitis C. Persons Who May Be Exposed to the Hepatitis B Virus by Travel to High-Risk Areas (See ACIP Guidelines, 1990.) Military Personnel Identified as Being at Increased Risk Morticians and Embalmers Persons at Increased Risk of the Disease Due to Their Sexual Practices, 1,16 such as: Persons with more than 1 sexual partner in a 6-month period. Persons who have contracted a sexually transmitted disease. Homosexually active males. Female prostitutes. Prisoners Users of Illicit Injectable Drugs Others: Police and fire department personnel who render first aid or medical assistance, and any others who, through their work or personal life-style, may be exposed to the hepatitis B virus. Adoptees from countries of high HBV endemicity. uuid:2f699b84-8cf6-4268-bc9d-a954418831b1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation MESH:C075654 biolink:treats MONDO:0005155 PMID:41385096 "[{""id"":""uuid:5f4b9da1-c5b7-43de-a95b-a9eda3b17b4b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:db14cef2-1af5-42a5-8ff1-c8e67d3ca26e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ENGERIX-B is indicated for immunization against infection caused by all known subtypes of hepatitis B virus. As hepatitis D (caused by the delta virus) does not occur in the absence of hepatitis B infection, it can be expected that hepatitis D will also be prevented by ENGERIX-B vaccination. ENGERIX-B will not prevent hepatitis caused by other agents, such as hepatitis A, C, and E viruses, or other pathogens known to infect the liver. Immunization is recommended in persons of all ages, especially those who are, or will be, at increased risk of exposure to hepatitis B virus, 1 for example: Infants, Including Those Born of HBsAg-Positive Mothers (See DOSAGE AND ADMINISTRATION.) Adolescents (See CLINICAL PHARMACOLOGY.) Healthcare Personnel: Dentists and oral surgeons. Dental, medical, and nursing students. Physicians, surgeons, and podiatrists. Nurses. Paramedical and ambulance personnel and custodial staff who may be exposed to the virus via blood or other patient specimens. Dental hygienists and dental nurses. Laboratory and blood bank personnel handling blood, blood products, and other patient specimens. Hospital cleaning staff who handle waste. Selected Patients and Patient Contacts: Patients and staff in hemodialysis units and hematology/oncology units. Patients requiring frequent and/or large volume blood transfusions or clotting factor concentrates (e.g., persons with hemophilia, thalassemia, sickle cell anemia, cirrhosis). Clients (residents) and staff of institutions for the mentally handicapped. Classroom contacts of deinstitutionalized mentally handicapped persons who have persistent hepatitis B surface antigenemia and who show aggressive behavior. Household and other intimate contacts of persons with persistent hepatitis B surface antigenemia. Subpopulations With a Known High Incidence of the Disease, such as: Alaskan Eskimos. Pacific Islanders. Indochinese immigrants. Haitian immigrants. Refugees from other HBV-endemic areas. All infants of women born in areas where the infection is highly endemic. Individuals With Chronic Hepatitis C: Risk factors for hepatitis C are similar to those for hepatitis B. Consequently, immunization with hepatitis B vaccine is recommended for individuals with chronic hepatitis C. Persons Who May Be Exposed to the Hepatitis B Virus by Travel to High-Risk Areas (See ACIP Guidelines, 1990.) Military Personnel Identified as Being at Increased Risk Morticians and Embalmers Persons at Increased Risk of the Disease Due to Their Sexual Practices, 1,16 such as: Persons with more than 1 sexual partner in a 6-month period. Persons who have contracted a sexually transmitted disease. Homosexually active males. Female prostitutes. Prisoners Users of Illicit Injectable Drugs Others: Police and fire department personnel who render first aid or medical assistance, and any others who, through their work or personal life-style, may be exposed to the hepatitis B virus. Adoptees from countries of high HBV endemicity. uuid:ada554c3-fe3f-496b-8889-0c0df11fc744 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation MESH:C075654 biolink:treats MONDO:0005354 PMID:41385096 "[{""id"":""uuid:a9ba0263-4811-45e7-a5ca-b48e57c02e64"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6450f0af-443e-44e0-928f-2776479e180f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ENGERIX-B is indicated for immunization against infection caused by all known subtypes of hepatitis B virus. As hepatitis D (caused by the delta virus) does not occur in the absence of hepatitis B infection, it can be expected that hepatitis D will also be prevented by ENGERIX-B vaccination. ENGERIX-B will not prevent hepatitis caused by other agents, such as hepatitis A, C, and E viruses, or other pathogens known to infect the liver. Immunization is recommended in persons of all ages, especially those who are, or will be, at increased risk of exposure to hepatitis B virus, 1 for example: Infants, Including Those Born of HBsAg-Positive Mothers (See DOSAGE AND ADMINISTRATION.) Adolescents (See CLINICAL PHARMACOLOGY.) Healthcare Personnel: Dentists and oral surgeons. Dental, medical, and nursing students. Physicians, surgeons, and podiatrists. Nurses. Paramedical and ambulance personnel and custodial staff who may be exposed to the virus via blood or other patient specimens. Dental hygienists and dental nurses. Laboratory and blood bank personnel handling blood, blood products, and other patient specimens. Hospital cleaning staff who handle waste. Selected Patients and Patient Contacts: Patients and staff in hemodialysis units and hematology/oncology units. Patients requiring frequent and/or large volume blood transfusions or clotting factor concentrates (e.g., persons with hemophilia, thalassemia, sickle cell anemia, cirrhosis). Clients (residents) and staff of institutions for the mentally handicapped. Classroom contacts of deinstitutionalized mentally handicapped persons who have persistent hepatitis B surface antigenemia and who show aggressive behavior. Household and other intimate contacts of persons with persistent hepatitis B surface antigenemia. Subpopulations With a Known High Incidence of the Disease, such as: Alaskan Eskimos. Pacific Islanders. Indochinese immigrants. Haitian immigrants. Refugees from other HBV-endemic areas. All infants of women born in areas where the infection is highly endemic. Individuals With Chronic Hepatitis C: Risk factors for hepatitis C are similar to those for hepatitis B. Consequently, immunization with hepatitis B vaccine is recommended for individuals with chronic hepatitis C. Persons Who May Be Exposed to the Hepatitis B Virus by Travel to High-Risk Areas (See ACIP Guidelines, 1990.) Military Personnel Identified as Being at Increased Risk Morticians and Embalmers Persons at Increased Risk of the Disease Due to Their Sexual Practices, 1,16 such as: Persons with more than 1 sexual partner in a 6-month period. Persons who have contracted a sexually transmitted disease. Homosexually active males. Female prostitutes. Prisoners Users of Illicit Injectable Drugs Others: Police and fire department personnel who render first aid or medical assistance, and any others who, through their work or personal life-style, may be exposed to the hepatitis B virus. Adoptees from countries of high HBV endemicity. uuid:1f12c9f7-6ac4-48b2-8393-f04440bce977 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46081 biolink:treats UMLS:C0006852 PMID:41385096 "[{""id"":""uuid:d3fe30dd-077f-4403-84a3-02b685df6c59"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3aea944a-7946-43db-875f-2bebfbb91e29"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fluconazole is indicated for the treatment of: Vaginal candidiasis (vaginal yeast infections due to Candida ). Oropharyngeal and esophageal candidiasis. In open noncomparative studies of relatively small numbers of patients, fluconazole was also effective for the treatment of Candida urinary tract infections, peritonitis, and systemic Candida infections including candidemia, disseminated candidiasis, and pneumonia. Cryptococcal meningitis. Before prescribing fluconazole for AIDS patients with cryptococcal meningitis, please see CLINICAL STUDIES section. Studies comparing fluconazole to amphotericin B in non-HIV infected patients have not been conducted. Prophylaxis. Fluconazole is also indicated to decrease the incidence of candidiasis in patients undergoing bone marrow transplantation who receive cytotoxic chemotherapy and/or radiation therapy. Specimens for fungal culture and other relevant laboratory studies (serology, histopathology) should be obtained prior to therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly. uuid:9e6e7634-8c27-40fe-99fc-0fd31419153d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46081 biolink:treats UMLS:C0919659 PMID:41385096 "[{""id"":""uuid:24b6f467-a484-4cd3-92fe-e5a5800607ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:01817a82-ec5c-46d7-a873-4c37e38466fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fluconazole is indicated for the treatment of: Vaginal candidiasis (vaginal yeast infections due to Candida ). Oropharyngeal and esophageal candidiasis. In open noncomparative studies of relatively small numbers of patients, fluconazole was also effective for the treatment of Candida urinary tract infections, peritonitis, and systemic Candida infections including candidemia, disseminated candidiasis, and pneumonia. Cryptococcal meningitis. Before prescribing fluconazole for AIDS patients with cryptococcal meningitis, please see CLINICAL STUDIES section. Studies comparing fluconazole to amphotericin B in non-HIV infected patients have not been conducted. Prophylaxis. Fluconazole is also indicated to decrease the incidence of candidiasis in patients undergoing bone marrow transplantation who receive cytotoxic chemotherapy and/or radiation therapy. Specimens for fungal culture and other relevant laboratory studies (serology, histopathology) should be obtained prior to therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly. uuid:7faf26fa-5bf8-4f50-b6a6-0df5ebddc6f9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46081 biolink:treats MONDO:0001648 PMID:41385096 "[{""id"":""uuid:20b36824-2e0a-417d-bf32-1b76046e9426"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0d4adda5-df4b-496a-b849-04a402487a4a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fluconazole is indicated for the treatment of: Vaginal candidiasis (vaginal yeast infections due to Candida ). Oropharyngeal and esophageal candidiasis. In open noncomparative studies of relatively small numbers of patients, fluconazole was also effective for the treatment of Candida urinary tract infections, peritonitis, and systemic Candida infections including candidemia, disseminated candidiasis, and pneumonia. Cryptococcal meningitis. Before prescribing fluconazole for AIDS patients with cryptococcal meningitis, please see CLINICAL STUDIES section. Studies comparing fluconazole to amphotericin B in non-HIV infected patients have not been conducted. Prophylaxis. Fluconazole is also indicated to decrease the incidence of candidiasis in patients undergoing bone marrow transplantation who receive cytotoxic chemotherapy and/or radiation therapy. Specimens for fungal culture and other relevant laboratory studies (serology, histopathology) should be obtained prior to therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly. uuid:fa673376-6f0c-44cd-9e9d-e2bc319c579d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46081 biolink:treats MONDO:0002026 PMID:41385096 "[{""id"":""uuid:d21c9e4d-f3b6-433e-a22f-4d34bcc569d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7531b482-c0e6-44de-b284-27ccc8fdf3ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fluconazole is indicated for the treatment of: Vaginal candidiasis (vaginal yeast infections due to Candida ). Oropharyngeal and esophageal candidiasis. In open noncomparative studies of relatively small numbers of patients, fluconazole was also effective for the treatment of Candida urinary tract infections, peritonitis, and systemic Candida infections including candidemia, disseminated candidiasis, and pneumonia. Cryptococcal meningitis. Before prescribing fluconazole for AIDS patients with cryptococcal meningitis, please see CLINICAL STUDIES section. Studies comparing fluconazole to amphotericin B in non-HIV infected patients have not been conducted. Prophylaxis. Fluconazole is also indicated to decrease the incidence of candidiasis in patients undergoing bone marrow transplantation who receive cytotoxic chemotherapy and/or radiation therapy. Specimens for fungal culture and other relevant laboratory studies (serology, histopathology) should be obtained prior to therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly. uuid:321c7d81-0e96-4894-9954-dfe6a26fa9a6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46081 biolink:treats MONDO:0004522 PMID:41385096 "[{""id"":""uuid:d90969ac-1214-498a-8329-58c9fab012ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b7f24334-d4b1-4f69-a139-b19143ecddd8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fluconazole is indicated for the treatment of: Vaginal candidiasis (vaginal yeast infections due to Candida ). Oropharyngeal and esophageal candidiasis. In open noncomparative studies of relatively small numbers of patients, fluconazole was also effective for the treatment of Candida urinary tract infections, peritonitis, and systemic Candida infections including candidemia, disseminated candidiasis, and pneumonia. Cryptococcal meningitis. Before prescribing fluconazole for AIDS patients with cryptococcal meningitis, please see CLINICAL STUDIES section. Studies comparing fluconazole to amphotericin B in non-HIV infected patients have not been conducted. Prophylaxis. Fluconazole is also indicated to decrease the incidence of candidiasis in patients undergoing bone marrow transplantation who receive cytotoxic chemotherapy and/or radiation therapy. Specimens for fungal culture and other relevant laboratory studies (serology, histopathology) should be obtained prior to therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly. uuid:cf146546-f56f-4242-8d12-8b153181887e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46081 biolink:treats MONDO:0042233 PMID:41385096 "[{""id"":""uuid:010d7084-58fa-4e04-834c-c678d73978dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:84bbb83c-8777-45c8-ab90-b2be4c4fdd4d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fluconazole is indicated for the treatment of: Vaginal candidiasis (vaginal yeast infections due to Candida ). Oropharyngeal and esophageal candidiasis. In open noncomparative studies of relatively small numbers of patients, fluconazole was also effective for the treatment of Candida urinary tract infections, peritonitis, and systemic Candida infections including candidemia, disseminated candidiasis, and pneumonia. Cryptococcal meningitis. Before prescribing fluconazole for AIDS patients with cryptococcal meningitis, please see CLINICAL STUDIES section. Studies comparing fluconazole to amphotericin B in non-HIV infected patients have not been conducted. Prophylaxis. Fluconazole is also indicated to decrease the incidence of candidiasis in patients undergoing bone marrow transplantation who receive cytotoxic chemotherapy and/or radiation therapy. Specimens for fungal culture and other relevant laboratory studies (serology, histopathology) should be obtained prior to therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly. uuid:d9f92575-45cf-465c-9675-bf6621287cbb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46081 biolink:treats MONDO:0044070 PMID:41385096 "[{""id"":""uuid:dec0855b-f752-4cc1-ab53-a4158e1b29c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bce45039-a736-4133-b133-0f20a2022561"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fluconazole is indicated for the treatment of: Vaginal candidiasis (vaginal yeast infections due to Candida ). Oropharyngeal and esophageal candidiasis. In open noncomparative studies of relatively small numbers of patients, fluconazole was also effective for the treatment of Candida urinary tract infections, peritonitis, and systemic Candida infections including candidemia, disseminated candidiasis, and pneumonia. Cryptococcal meningitis. Before prescribing fluconazole for AIDS patients with cryptococcal meningitis, please see CLINICAL STUDIES section. Studies comparing fluconazole to amphotericin B in non-HIV infected patients have not been conducted. Prophylaxis. Fluconazole is also indicated to decrease the incidence of candidiasis in patients undergoing bone marrow transplantation who receive cytotoxic chemotherapy and/or radiation therapy. Specimens for fungal culture and other relevant laboratory studies (serology, histopathology) should be obtained prior to therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly. uuid:151b3f7f-8199-43b0-865c-3ec05c8163d7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46081 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:e87ff3bb-3e17-4a29-b7ca-89863472d3d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:53d1259b-2bf8-412f-a5a5-5d8946b8de3e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fluconazole is indicated for the treatment of: Vaginal candidiasis (vaginal yeast infections due to Candida ). Oropharyngeal and esophageal candidiasis. In open noncomparative studies of relatively small numbers of patients, fluconazole was also effective for the treatment of Candida urinary tract infections, peritonitis, and systemic Candida infections including candidemia, disseminated candidiasis, and pneumonia. Cryptococcal meningitis. Before prescribing fluconazole for AIDS patients with cryptococcal meningitis, please see CLINICAL STUDIES section. Studies comparing fluconazole to amphotericin B in non-HIV infected patients have not been conducted. Prophylaxis. Fluconazole is also indicated to decrease the incidence of candidiasis in patients undergoing bone marrow transplantation who receive cytotoxic chemotherapy and/or radiation therapy. Specimens for fungal culture and other relevant laboratory studies (serology, histopathology) should be obtained prior to therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly. uuid:4e21084d-c8bd-4035-b3d0-30810989b76e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46081 biolink:treats MONDO:0005723 PMID:41385096 "[{""id"":""uuid:972e95c0-3f59-402a-96d5-f0af23ed8f49"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:668c4aa7-4c04-4937-bcfe-eb528699f9b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fluconazole is indicated for the treatment of: Vaginal candidiasis (vaginal yeast infections due to Candida ). Oropharyngeal and esophageal candidiasis. In open noncomparative studies of relatively small numbers of patients, fluconazole was also effective for the treatment of Candida urinary tract infections, peritonitis, and systemic Candida infections including candidemia, disseminated candidiasis, and pneumonia. Cryptococcal meningitis. Before prescribing fluconazole for AIDS patients with cryptococcal meningitis, please see CLINICAL STUDIES section. Studies comparing fluconazole to amphotericin B in non-HIV infected patients have not been conducted. Prophylaxis. Fluconazole is also indicated to decrease the incidence of candidiasis in patients undergoing bone marrow transplantation who receive cytotoxic chemotherapy and/or radiation therapy. Specimens for fungal culture and other relevant laboratory studies (serology, histopathology) should be obtained prior to therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly. uuid:03c81491-7954-4a58-a93a-0cc6d5b7bf80 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0000004 PMID:41385096 "[{""id"":""uuid:d2a6558a-6090-4357-a033-04616952c71d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f1acd2bb-9a38-4e05-8958-04b786299c65"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:b07734b6-53eb-4540-bcc3-09f8f2c7ba1f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0018479 PMID:41385096 "[{""id"":""uuid:15a4cae2-6783-4910-91b5-5fc32f9a989d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5b1ef47c-675c-4e80-8924-c0aa31dac285"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:ba43d6e1-1c22-45fe-ac6a-90cad57e33f8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0006982 PMID:41385096 "[{""id"":""uuid:5638d3f1-d169-47de-900b-32a690e1d80b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a2cf721d-35e9-4170-a863-3a2cf1252262"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:61b5cb3f-35b8-4b2e-b3a1-ba0d151a90b9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0043455 PMID:41385096 "[{""id"":""uuid:fca32366-ca28-4251-9e32-94e33ffbd771"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2b1c9996-c630-4549-914e-96bd4d903aa5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:13368a25-0cdc-4f50-a182-21b616465ae8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:083766d0-ae32-4602-ab64-bd7d30902632"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ff14f1dd-6590-45be-a3f3-982336626af9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:eb1f4540-9873-4875-885d-04299d8a6601 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0011429 PMID:41385096 "[{""id"":""uuid:be55d9bb-f0f6-4a70-bdc4-d657b7d8bbeb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2dbbc87b-c047-4025-844b-5178185b3964"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:33e3bb44-f035-4e3c-9049-d035924a0969 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0005306 PMID:41385096 "[{""id"":""uuid:7e86e2f2-8f34-40eb-80d6-05b99ea86433"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7ae6584b-f41c-46f2-8690-9ed4b3e10722"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:6018f338-35cf-4472-a58b-7efe9d0777fb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats UMLS:C1290158 PMID:41385096 "[{""id"":""uuid:035f62c7-d230-4184-bc5b-ed297e4ee0f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3bc825a3-5a88-4692-8fa1-e431a1a99838"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:c44745db-4c9f-46ac-8fa0-881c0bcdb0e3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0040698 PMID:41385096 "[{""id"":""uuid:63e32431-0402-45ed-a1a5-9907579325ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b7b419c5-1f01-42be-9ebd-9d7ec6cd76ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:c6de8eed-953f-4b04-b60f-0ef081ac8bb6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0005178 PMID:41385096 "[{""id"":""uuid:9426abd6-f149-4b66-a246-c6937a1d2d16"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dd82c935-6793-4d0e-bab8-d7883fb34132"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:b69140f3-9673-4476-8471-4d619972c8b1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0004855 PMID:41385096 "[{""id"":""uuid:7557df9f-c2e1-428b-b310-bde5053fab7f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:29171acb-2953-4c0f-b105-a482b0b1fa07"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:8693b177-a3e1-4dea-9f18-0997b97d3341 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0011849 PMID:41385096 "[{""id"":""uuid:3a8246c0-5b64-45a6-833d-01758ca40352"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2798dc76-bf53-4100-a4b3-128f273df0cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:a830732c-dc11-41ed-82eb-a55766bc5337 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0001875 PMID:41385096 "[{""id"":""uuid:9c13ee4d-bbd3-4662-b9dd-cbbbd17581cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4337a33e-231f-4cc5-b09b-afb4c1e48146"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:ba1c1cf8-1663-4885-8178-d6fa5505b1fd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats UMLS:C0149896 PMID:41385096 "[{""id"":""uuid:89bd283d-7ef2-4519-9cb9-64aa9a23ee11"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4746464f-877f-4a9e-b951-1234ca0ed2f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:66f30870-9197-4411-af9c-9d5db4235be1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0016367 PMID:41385096 "[{""id"":""uuid:c801fe3d-a5cf-4acd-bea1-42c6a2897e03"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3edee1b5-95f5-41a4-bc60-6bd8d2a2b335"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f904aaa5-d4c7-4a2d-a990-18b616c4bf93"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement.|[PMDA] Drugs with new additional indications and a new dosage for the treatment of the following treatment- resistant rheumatic diseases: systemic vasculitis (including microscopic polyangiitis, Wegener's granulomatosis, polyarteritis nodosa, Churg- Strauss syndrome, aortitis syndrome), systemic lupus erythematosus, polymyositis, dermatomyositis, scleroderma, mixed connective tissue disease, and refractory rheumatic disease. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:8b2898e4-ff76-4902-9977-1bd8af4b20c4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0019127 PMID:41385096 "[{""id"":""uuid:4a19cdec-46c1-4296-a2e9-fc49ba881551"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:94cd8a70-cf86-4b40-8373-ddde86260db1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:471f6d6c-dd34-4d8d-a370-3c7bf2229b93"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement.|[PMDA] Drugs with new additional indications and a new dosage for the treatment of the following treatment- resistant rheumatic diseases: systemic vasculitis (including microscopic polyangiitis, Wegener's granulomatosis, polyarteritis nodosa, Churg- Strauss syndrome, aortitis syndrome), systemic lupus erythematosus, polymyositis, dermatomyositis, scleroderma, mixed connective tissue disease, and refractory rheumatic disease. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:3ace3992-9bfc-4a56-a9d5-a482669824f2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats UMLS:C5441648 PMID:41385096 "[{""id"":""uuid:89da49e2-5188-488e-aac7-23c4f90205fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:531bad8b-c3fd-4708-955e-6fc5a659a4e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:20565441-4b0f-4990-a025-486c5828306c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0015614 PMID:41385096 "[{""id"":""uuid:215f6b5a-a491-47f8-b5ef-42d000c7895e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5dac9bde-1548-4ea6-8e1a-99de54634f56"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:07885c2e-e83a-4805-9072-4848e8b4c0e9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0006545 PMID:41385096 "[{""id"":""uuid:cb8266ea-0a3c-44f7-a14c-43dbc8fbcf8a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3225fc92-f08a-4737-875d-2f11dbf1087c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:3931cc49-e637-48dd-a295-4b59a92c73c8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0018229 PMID:41385096 "[{""id"":""uuid:689cba5e-5fca-4a62-a752-5ecc60522a1a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:403283b4-dade-4eb8-9698-2efce9f01100"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:14648fe1-16b0-4ef2-8cbd-de025474034f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0006608 PMID:41385096 "[{""id"":""uuid:846a88a5-cf85-4e0f-a0c4-2eb07748934f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:628a64f4-eaee-4f67-a289-86f093321f20"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:9b276cbd-1605-41d9-9b04-382befdd63cd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0043233 PMID:41385096 "[{""id"":""uuid:a1d0cee4-22f6-4a85-8a02-bbabba63ec80"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:90617ece-416a-4ace-b708-7a9d0d951195"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:d7b6b2a2-341d-4888-89f1-132e836a15b5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0009691 PMID:41385096 "[{""id"":""uuid:90fcd55f-13b7-4441-991f-b356d9b0d990"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:44ab6ea8-0d16-4a3c-bb60-762bbcfefdad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:169c6915-2c4e-4a7d-b932-8edea656d778 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0006594 PMID:41385096 "[{""id"":""uuid:1806583a-cc04-49e2-a002-7c400dcaca92"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:af6bcb10-d141-4fcf-b2ed-99b65c71dafc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:3b501384-dc19-413e-bf52-87723ef6894a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0005083 PMID:41385096 "[{""id"":""uuid:74e66fbe-c99c-432c-8037-7d88309b1644"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d594eb4d-25ff-4b37-8bea-e4be86432ea4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:d79bdacd-a50d-4822-8f78-b3c1bc295a4d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0005324 PMID:41385096 "[{""id"":""uuid:66f1de61-53c8-4086-ad49-e129d0433b5e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a8050d0f-d0f6-4d1c-b0f6-c0f42674ee0d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:87e120f2-e17c-48c7-a88b-7b8aad449282 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0024332 PMID:41385096 "[{""id"":""uuid:564cfefe-564e-4e0d-b199-b8b5e1daab46"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5f263e2a-edad-4561-99b8-558014afb75f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:a59909d6-f0f9-475e-ac1a-733923619071 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0000775 PMID:41385096 "[{""id"":""uuid:596488c9-d588-40fc-afce-ec0b743c13e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:410c615a-e4ff-464b-be56-e394fe2c3b36"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:032c05cb-a8f0-4a39-b3ba-1e05251909ed biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0043789 PMID:41385096 "[{""id"":""uuid:ece51cbe-1e9d-4dc7-b02f-4753d566c1db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:99a842ad-15eb-48a6-a27d-234326b27b74"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:fc62f1cd-d366-4d5b-9535-9f8575e34b22 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0005480 PMID:41385096 "[{""id"":""uuid:9aecdb53-9f0c-4e06-b563-d23c00785c30"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dc4734b7-972b-48aa-b882-3d772e953d0c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:2fd5c556-212a-4c1a-9faf-572f6c5222fd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:4e3bbdf2-cc91-4055-aff4-0d4fa77dde33"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ccf75f2d-262e-4af4-ba71-28ba7400058f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:0670077a-9c7b-445c-93cc-79bd95655b68 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:868f8733-6874-40cb-af74-d830076e60b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8aabe04e-97d8-45c3-a927-5435c119e008"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:cf01ae8c-a4ea-4425-a899-bc7fffc4bd87 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0001034 PMID:41385096 "[{""id"":""uuid:f9cd098f-4076-4f99-9ab6-0275e3df433f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:630456b6-014e-4a31-912c-b3738e3779f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:72ab74bb-e09b-4a57-a3cf-832e373c1e42 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0005883 PMID:41385096 "[{""id"":""uuid:fcc06079-28c3-4a7f-a0aa-ee936919bcda"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4f2054ba-4661-4bab-bb43-095723660407"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:1c577a35-e921-4bf9-b49c-8f3fc9ecd2a8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0006651 PMID:41385096 "[{""id"":""uuid:5f54c66d-ecb5-4a4c-ad87-94c7b5ba9349"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:87efb64a-4fc2-43ee-a410-f6582a4085a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:648ef4f1-44da-4b56-a360-268b7a66d9ba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0006918 PMID:41385096 "[{""id"":""uuid:5fdc772b-5f88-42ac-a0e7-2e5057fe69a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:200b28ce-90be-4752-a41d-3aca462c6475"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:91390777-0b4b-417e-bb23-0e2dc3c740d0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0001280 PMID:41385096 "[{""id"":""uuid:62efc6a4-f5a7-4bce-9cd8-de1330ce44d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b5e707f7-94ae-4bd2-bd3c-87e2e0350aae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:5a42ab36-7e72-4c2f-93d5-8389198c3e5c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0019198 PMID:41385096 "[{""id"":""uuid:dcc464bb-6e59-401f-9bbf-c5dee40606ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e27e5277-2c27-4bcd-a3fa-8ec396662436"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:af64c492-33e6-401e-b15d-aa05ae1e1f68 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0003085 PMID:41385096 "[{""id"":""uuid:696cde48-3db5-4f7d-86f6-3b8125604b29"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cb1d73e1-9ed5-4911-bcf3-0d0189c39a85"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:752511eb-31b9-440a-8980-41645bc09dc0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0005885 PMID:41385096 "[{""id"":""uuid:2f35beef-ceaf-47c7-ba02-1d6ad01a1d61"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dca6cce6-7dc0-4c76-8925-5c35777bc1b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:f9a9ac5a-7f89-4166-873f-5c08c3e3c9ff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0004674 PMID:41385096 "[{""id"":""uuid:ba9e93a6-0620-4418-9472-cd81d621ab9d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:11c44a80-96f1-43f0-ab24-e2ad3a4105cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:d71b9536-f97c-4678-a858-35fcf92f34d5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0006814 PMID:41385096 "[{""id"":""uuid:b8d8cc00-42ee-4f6f-95da-5778e2188d6c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c8eb15d5-22a2-4f73-906f-602f7665d4d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:faf726e3-2c96-4ae6-aea7-9e4e1d1830de biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0004773 PMID:41385096 "[{""id"":""uuid:562ee6ac-dc81-4ad7-9045-60ac8d18f0c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:04892cc2-358c-4986-a787-912551d4ca19"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:cd1ff419-f4b2-40f6-acc6-391fc0e9f3ef biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0019338 PMID:41385096 "[{""id"":""uuid:fba58b92-4406-4d7a-8ecb-33b8ba1d740e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:40f84914-52a3-424d-a8ac-11e101d02905"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:987c0beb-c4fa-4993-b00c-558601aedfb5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0015274 PMID:41385096 "[{""id"":""uuid:3a116cb3-0dd9-458a-8a1c-0f9e1b121c1c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eff58f92-c897-43ff-a563-d2fb24022990"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:05e4dd28-98f9-4aa4-a549-b4dcf0decd74 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0006052 PMID:41385096 "[{""id"":""uuid:9a60b93c-dfc9-420a-b663-06c7c23fda82"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:76627a1e-998c-473a-b5c2-5d02138a2ca1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:823771c4-b8e6-43ac-a868-e808ee2ddb43 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0005848 PMID:41385096 "[{""id"":""uuid:f022c527-86a1-4009-b21b-9b604b7649c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6f74834b-cb46-4e15-8bae-35e434a002a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:dbab55c1-0693-4da0-b0d8-16bb23d03ec9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0002572 PMID:41385096 "[{""id"":""uuid:0887f04a-fbc3-4fc8-a1b2-8e70c48f2013"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2a1ddad3-ecd4-4213-85d2-5b4513aef480"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:1081baaa-6483-437d-837c-83e3e37ac202 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0019098 PMID:41385096 "[{""id"":""uuid:4ee62df9-7f50-492d-9616-7b80dddabe99"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9bf674b5-0406-41bf-b919-e852bafa517a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:d6560ae9-e9f2-4392-9fce-4c975e41b8ed biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0001198 PMID:41385096 "[{""id"":""uuid:81473dc8-1c7c-4b71-aa18-b6469a630c69"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:78b2c3c1-a5c1-49ba-ab82-3e508a3177a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:4092de4b-f211-4156-9ac4-d9231ee7274b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats UMLS:C0002879 PMID:41385096 "[{""id"":""uuid:e6c7ecad-68c1-4032-bd10-8deacf63ef3d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b8bae12f-efb0-46b1-9595-0d186f125394"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:9991c8e7-dbdb-4dee-a909-175af2a9f9a4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0020108 PMID:41385096 "[{""id"":""uuid:bc31212c-93ab-47ad-bbe7-7f59125566e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9a198ef0-4016-47aa-bc86-b6c9360d5172"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:1eafe81b-2229-4e9c-bd50-36d365811b4e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0002280 PMID:41385096 "[{""id"":""uuid:9a02eeae-3db1-4cee-99a4-371055fa89aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c5c0ef77-d8ac-4d9d-bec2-bd9166f03b9e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:5ae2f1d1-85a3-453e-82ae-9bd83b54d47d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0015253 PMID:41385096 "[{""id"":""uuid:2a6c87c9-1d76-4ae9-a667-5a2a39b13d16"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:27005d78-4e8f-4c5c-a751-e399529c8639"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:255c0dfb-29af-48e8-9681-d54764735154 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats HP:0001908 PMID:41385096 "[{""id"":""uuid:2fd72384-c890-4132-8b96-c8a231d92f9e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d5eed5f7-2225-4f72-80b4-037ea4fb3c12"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:3fac7d6a-fb80-422a-bb8e-1da96e82f261 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0005059 PMID:41385096 "[{""id"":""uuid:73970a73-130f-4efe-802d-b498dd1399aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f696d24c-7392-49fe-96c3-843fc65eaf75"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:681b6b39-7fd2-4713-b358-6b7cb414018b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0004095 PMID:41385096 "[{""id"":""uuid:34fefabd-de66-44c9-bf3a-ce3fa8eda077"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eeff5477-b60d-42f8-b6bf-1e3b637fcd91"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:ddfd3bc6-0ac5-4f41-b489-c7c36c7f82f2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0004355 PMID:41385096 "[{""id"":""uuid:6cbd2d34-ef39-41d3-bacc-6cfe610c6e1e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:14e14927-4286-4430-b931-85fd14a54a28"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:7e27d882-b253-40ce-a973-0667669fbe19 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0005377 PMID:41385096 "[{""id"":""uuid:b73c1124-5aaa-43c5-a1e5-ddbbc801a437"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:daddcfb0-ae5e-44a1-95ee-0fd8fccb9beb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:d3274736-867b-49fc-98f0-3cbdf785f9c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement.|[PMDA] Drugs with a new additional indication and a new dosage for the treatment of nephrotic syndrome. [Public knowledge-based application after preliminary assessment by the Pharmaceutical Affairs and Food Sanitation Council (PAFSC)] uuid:02c7e647-7913-47b3-bbed-874a4b20f259 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0005101 PMID:41385096 "[{""id"":""uuid:c3e6d2c7-8a85-47b0-ac96-94332ef89d85"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:09168ade-cc88-406d-be1d-791b78e8b04b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:ff7a39a0-85c3-4a8a-86af-f4a68513bada biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats UMLS:C0678202 PMID:41385096 "[{""id"":""uuid:38f10870-4f1e-40b8-9737-c1a01ae8f1c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:679ff1cb-27b7-4e2a-810a-224f2be9c926"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:d7de98de-eacc-4b0c-ac1b-df4825f310cc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0005301 PMID:41385096 "[{""id"":""uuid:644fc9c1-c0d1-4d62-9abc-9f0f91b5d4e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f3af82ad-8319-4926-85b7-782ce4cd2088"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:66d34c81-33c7-4153-8e4b-c1fed4a57dda"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement.|[PMDA] Drugs with a new additional indication and a new dosage for the treatment of acute exacerbation of multiple sclerosis. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:072a7fc3-e78b-47b6-ad8d-3bd8a055bd25 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0006042 PMID:41385096 "[{""id"":""uuid:699c3bc4-4cbb-4a59-b245-83de31c5ec0d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b52cab43-c3b7-49be-a929-0f35aab8823f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:23bbecef-8bb8-4e27-8e77-b27e82e504b9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0019444 PMID:41385096 "[{""id"":""uuid:91ba8ba9-eed4-4fba-b6c9-fde5fe4c67c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9e399566-96e3-4a73-8600-8cf9384b3d3e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:e39eeb74-71fb-4bb0-9d9f-d26a6c89921f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:51209 biolink:treats MONDO:0005709 PMID:41385096 "[{""id"":""uuid:d4e465b8-1d18-46b5-b677-bee1b850b75c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8ab83c91-faf2-42de-80fa-b22f68758a34"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] helps loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive temporarily relieves nasal congestion due to: common cold hay fever upper respiratory allergies temporarily restores freer breathing through the nose promotes nasal and/or sinus drainage temporarily relieves sinus congestion and pressure uuid:2400c055-d778-4b7c-b69a-3ea011cb2192 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:51209 biolink:treats MONDO:0005324 PMID:41385096 "[{""id"":""uuid:2f76244e-34f3-47f0-b9c5-03e389d66f9a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4931d3c3-cceb-491f-baba-b8f70546695d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] helps loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive temporarily relieves nasal congestion due to: common cold hay fever upper respiratory allergies temporarily restores freer breathing through the nose promotes nasal and/or sinus drainage temporarily relieves sinus congestion and pressure uuid:24787f27-443e-4ea7-9f6a-dd415c34bf3b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:51209 biolink:treats MONDO:0004867 PMID:41385096 "[{""id"":""uuid:4a14695d-bad3-4118-8bf2-cc0b0c54e02b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:678d3d69-8de9-40a5-ac00-4d3ebc4338e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] helps loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive temporarily relieves nasal congestion due to: common cold hay fever upper respiratory allergies temporarily restores freer breathing through the nose promotes nasal and/or sinus drainage temporarily relieves sinus congestion and pressure uuid:bbdb1dfd-2253-4548-a8bf-4a2d58336ecf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:51209 biolink:treats UMLS:C0152029 PMID:41385096 "[{""id"":""uuid:98e48d6e-7a94-4395-8f63-db8988fb6bb4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d58a4d97-0e13-4680-a4d1-dbe7bedb4020"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] helps loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive temporarily relieves nasal congestion due to: common cold hay fever upper respiratory allergies temporarily restores freer breathing through the nose promotes nasal and/or sinus drainage temporarily relieves sinus congestion and pressure uuid:20a4672e-4d85-49ca-95a0-beebf20230b8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1165654 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:6b9e3969-ab16-40a6-815a-5d6f903203db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:83c64a01-972a-4041-a7ad-da4b87fee3fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:53799d30-6b88-4a6b-a5c1-c1e90888f7c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/bropair-spiromax""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] ADVAIR DISKUS is a combination product containing a corticosteroid and a long-acting beta 2 -adrenergic agonist indicated for: Maintenance treatment of asthma in patients aged 4 years and older. (1.1) Maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD). (1.2) Important limitations: Not indicated for patients whose asthma can be managed by inhaled corticosteroids with occasional use of inhaled short-acting beta 2 -agonists. (1.1) Not indicated for the relief of acute bronchospasm. (1.1, 1.2)|[EMA] BroPair Spiromax is indicated in the regular treatment of asthma in adults and adolescents aged 12 years and older not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short-acting β₂ agonists. uuid:36495cbb-f0bf-4c0a-a355-41520de55214 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1165654 biolink:treats MONDO:0005002 PMID:41385096 "[{""id"":""uuid:c1e5d1ca-1973-4301-aed6-9271442dbebc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f2bb3ad8-6152-4a8c-a5f0-dc404faf74b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ADVAIR DISKUS is a combination product containing a corticosteroid and a long-acting beta 2 -adrenergic agonist indicated for: Maintenance treatment of asthma in patients aged 4 years and older. (1.1) Maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD). (1.2) Important limitations: Not indicated for patients whose asthma can be managed by inhaled corticosteroids with occasional use of inhaled short-acting beta 2 -agonists. (1.1) Not indicated for the relief of acute bronchospasm. (1.1, 1.2) uuid:cede98da-ca2b-4902-92f7-bd985ee6b949 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9609 biolink:treats HP:0001257 PMID:41385096 "[{""id"":""uuid:c3d19ea6-2d25-4a6a-a68f-9f95710d3bf1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:767ea4ea-c3a0-49cc-8d58-338025d1d7a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tizanidine is a short-acting drug for the management of spasticity. Because of the short duration of effect, treatment with tizanidine should be reserved for those daily activities and times when relief of spasticity is most important (see DOSAGE AND ADMINISTRATION ). uuid:965b30f0-5f32-4898-b316-cb6776cd47b5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:56841598 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:e6398b15-f677-4db9-8f2a-3749b45778e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:50053650-2ad3-4976-944f-8c07da40bb56"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1 INDICATIONS AND USAGE EMBEDA is an extended-release oral formulation of morphine sulfate and naltrexone hydrochloride indicated for the management of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time. EMBEDA is NOT intended for use as a prn analgesic. EMBEDA is not indicated for acute/postoperative pain or if the pain is mild or not expected to persist for an extended period of time. EMBEDA is only indicated for postoperative use if the patient is already receiving chronic opioid therapy prior to surgery or if the postoperative pain is expected to be moderate to severe and persist for an extended period of time. Physicians should individualize treatment, moving from parenteral to oral analgesics as appropriate uuid:c604b1b5-72f7-4bb1-a6e9-76f61bdffb5d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:42797 biolink:treats MONDO:0005027 PMID:41385096 "[{""id"":""uuid:1031cddc-685c-422e-aa0d-bda5dbab7cdc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:164a299a-1f99-443c-a3cd-07c542f351ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:22edf42b-583e-45bf-a191-ee607dd38ae6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Postherpetic Neuralgia Gabapentin is indicated for the management of postherpetic neuralgia in adults. Epilepsy Gabapentin is indicated as adjunctive therapy in the treatment of partial seizures with and without secondary generalization in patients over 12 years of age with epilepsy. Gabapentin is also indicated as adjunctive therapy in the treatment of partial seizures in pediatric patients age 3 – 12 years.|[PMDA] Drugs containing a new active ingredient indicated for use as adjunctive therapy with other antiepileptic drugs to treat partial seizures (including secondarily generalized seizure) in patients with epilepsy, to whom other antiepileptic therapies are not sufficiently effective. uuid:e75b1cd2-8b40-4eef-89e7-fef805e501e5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:42797 biolink:treats HP:0007359 PMID:41385096 "[{""id"":""uuid:db415cd5-c8c9-4c6e-ad2d-aea8fe811957"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:39236f08-fee8-4300-b2b7-d4fa71c1f002"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ec0882ee-b7e0-47d8-86fa-479abd5b7110"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Postherpetic Neuralgia Gabapentin is indicated for the management of postherpetic neuralgia in adults. Epilepsy Gabapentin is indicated as adjunctive therapy in the treatment of partial seizures with and without secondary generalization in patients over 12 years of age with epilepsy. Gabapentin is also indicated as adjunctive therapy in the treatment of partial seizures in pediatric patients age 3 – 12 years.|[PMDA] Drugs containing a new active ingredient indicated for use as adjunctive therapy with other antiepileptic drugs to treat partial seizures (including secondarily generalized seizure) in patients with epilepsy, to whom other antiepileptic therapies are not sufficiently effective. uuid:8e214be4-833c-434f-bd01-e24b1452bc2c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2955 biolink:treats UMLS:C0275556 PMID:41385096 "[{""id"":""uuid:ab00bb69-6122-4bc8-ba35-754f5487049a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7fc99d02-bb8f-4993-99d7-43494d16a8aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azithromycin is indicated for the treatment of patients with mild to moderate infections (pneumonia: see WARNINGS ) caused by susceptible strains of the designated microorganisms in the specific conditions listed below. As recommended dosages, durations of therapy and applicable patient populations vary among these infections, please see DOSAGE AND ADMINISTRATION for specific dosing recommendations . Adults Acute bacterial exacerbations of chronic obstructive pulmonary disease due to Haemophilus influenzae, Moraxella catarrhalis or Streptococcus pneumoniae . Acute bacterial sinusitis due to Haemophilus influenzae , Moraxella catarrhalis or Streptococcus pneumoniae . Community -acquired pneumonia due to Chlamydia pneumoniae , Haemophilus influenzae , Mycoplasma pneumoniae or Streptococcus pneumoniae in patients appropriate for oral therapy. NOTE: Azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomially acquired infections, patients with known or suspected bacteremia, patients requiring hospitalization, elderly or debilitated patients, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. NOTE: Penicillin by the intramuscular route is the usual drug of choice in the treatment of Streptococcus pyogenes infection and the prophylaxis of rheumatic fever. Azithromycin is often effective in the eradication of susceptible strains of Streptococcus pyogenes from the nasopharynx. Because some strains are resistant to azithromycin, susceptibility tests should be performed when patients are treated with azithromycin. Data establishing efficacy of azithromycin in subsequent prevention of rheumatic fever are not available. Uncomplicated skin and skin structure infections due to Staphylococcus aureus , Streptococcus pyogenes , or Streptococcus agalactiae . Abscesses usually require surgical drainage. Urethritis and cervicitis due to Chlamydia trachomatis or Neisseria gonorrhoeae . Genital ulcer disease in men due to Haemophilus ducreyi (chancroid). Due to the small number of women included in clinical trials, the efficacy of azithromycin in the treatment of chancroid in women has not been established. Azithromycin, at the recommended dose, should not be relied upon to treat syphilis. Antimicrobial agents used in high doses for short periods of time to treat non-gonococcal urethritis may mask or delay the symptoms of incubating syphilis. All patients with sexually-transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate cultures for gonorrhea performed at the time of diagnosis. Appropriate antimicrobial therapy and follow-up tests for these diseases should be initiated if infection is confirmed. Appropriate culture and susceptibility tests should be performed before treatment to determine the causative organism and its susceptibility to azithromycin. Therapy with azithromycin may be initiated before results of these tests are known; once the results become available, antimicrobial therapy should be adjusted accordingly. To reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin and other antibacterial drugs, azithromycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Pediatric Patients (See PRECAUTIONS—Pediatric Use and CLINICAL STUDIES IN PEDIATRIC PATIENTS .) Acute otitis media caused by Haemophilus influenzae , Moraxella catarrhalis or Streptococcus pneumoniae . (For specific dosage recommendation, see DOSAGE AND ADMINISTRATION .) Community-acquired pneumonia due to Chlamydia pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae or Streptococcus pneumoniae in patients appropriate for oral therapy. (For specific dosage recommendation, see DOSAGE AND ADMINISTRATION .) NOTE: Azithromycin should not be used in pediatric patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomially acquired infections, patients with known or suspected bacteremia, patients requiring hospitalization, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. (For specific dosage recommendation, see DOSAGE AND ADMINISTRATION .) NOTE: Penicillin by the intramuscular route is the usual drug of choice in the treatment of Streptococcus pyogenes infection and the prophylaxis of rheumatic fever. Azithromycin is often effective in the eradication of susceptible strains of Streptococcus pyogenes from the nasopharynx. Because some strains are resistant to azithromycin, susceptibility tests should be performed when patients are treated with azithromycin. Data establishing efficacy of azithromycin in subsequent prevention of rheumatic fever are not available. Appropriate culture and susceptibility tests should be performed before treatment to determine the causative organism and its susceptibility to azithromycin. Therapy with azithromycin may be initiated before results of these tests are known; once the results become available, antimicrobial therapy should be adjusted accordingly. uuid:679e3eea-4a38-4e00-bf3a-adff23518581 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2955 biolink:treats MONDO:0002258 PMID:41385096 "[{""id"":""uuid:b5b7e5c0-6ac5-4785-b072-0a6abe87bd47"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:44a9c226-90f8-4419-91d4-b2aad6063ff7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azithromycin is indicated for the treatment of patients with mild to moderate infections (pneumonia: see WARNINGS ) caused by susceptible strains of the designated microorganisms in the specific conditions listed below. As recommended dosages, durations of therapy and applicable patient populations vary among these infections, please see DOSAGE AND ADMINISTRATION for specific dosing recommendations . Adults Acute bacterial exacerbations of chronic obstructive pulmonary disease due to Haemophilus influenzae, Moraxella catarrhalis or Streptococcus pneumoniae . Acute bacterial sinusitis due to Haemophilus influenzae , Moraxella catarrhalis or Streptococcus pneumoniae . Community -acquired pneumonia due to Chlamydia pneumoniae , Haemophilus influenzae , Mycoplasma pneumoniae or Streptococcus pneumoniae in patients appropriate for oral therapy. NOTE: Azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomially acquired infections, patients with known or suspected bacteremia, patients requiring hospitalization, elderly or debilitated patients, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. NOTE: Penicillin by the intramuscular route is the usual drug of choice in the treatment of Streptococcus pyogenes infection and the prophylaxis of rheumatic fever. Azithromycin is often effective in the eradication of susceptible strains of Streptococcus pyogenes from the nasopharynx. Because some strains are resistant to azithromycin, susceptibility tests should be performed when patients are treated with azithromycin. Data establishing efficacy of azithromycin in subsequent prevention of rheumatic fever are not available. Uncomplicated skin and skin structure infections due to Staphylococcus aureus , Streptococcus pyogenes , or Streptococcus agalactiae . Abscesses usually require surgical drainage. Urethritis and cervicitis due to Chlamydia trachomatis or Neisseria gonorrhoeae . Genital ulcer disease in men due to Haemophilus ducreyi (chancroid). Due to the small number of women included in clinical trials, the efficacy of azithromycin in the treatment of chancroid in women has not been established. Azithromycin, at the recommended dose, should not be relied upon to treat syphilis. Antimicrobial agents used in high doses for short periods of time to treat non-gonococcal urethritis may mask or delay the symptoms of incubating syphilis. All patients with sexually-transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate cultures for gonorrhea performed at the time of diagnosis. Appropriate antimicrobial therapy and follow-up tests for these diseases should be initiated if infection is confirmed. Appropriate culture and susceptibility tests should be performed before treatment to determine the causative organism and its susceptibility to azithromycin. Therapy with azithromycin may be initiated before results of these tests are known; once the results become available, antimicrobial therapy should be adjusted accordingly. To reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin and other antibacterial drugs, azithromycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Pediatric Patients (See PRECAUTIONS—Pediatric Use and CLINICAL STUDIES IN PEDIATRIC PATIENTS .) Acute otitis media caused by Haemophilus influenzae , Moraxella catarrhalis or Streptococcus pneumoniae . (For specific dosage recommendation, see DOSAGE AND ADMINISTRATION .) Community-acquired pneumonia due to Chlamydia pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae or Streptococcus pneumoniae in patients appropriate for oral therapy. (For specific dosage recommendation, see DOSAGE AND ADMINISTRATION .) NOTE: Azithromycin should not be used in pediatric patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomially acquired infections, patients with known or suspected bacteremia, patients requiring hospitalization, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. (For specific dosage recommendation, see DOSAGE AND ADMINISTRATION .) NOTE: Penicillin by the intramuscular route is the usual drug of choice in the treatment of Streptococcus pyogenes infection and the prophylaxis of rheumatic fever. Azithromycin is often effective in the eradication of susceptible strains of Streptococcus pyogenes from the nasopharynx. Because some strains are resistant to azithromycin, susceptibility tests should be performed when patients are treated with azithromycin. Data establishing efficacy of azithromycin in subsequent prevention of rheumatic fever are not available. Appropriate culture and susceptibility tests should be performed before treatment to determine the causative organism and its susceptibility to azithromycin. Therapy with azithromycin may be initiated before results of these tests are known; once the results become available, antimicrobial therapy should be adjusted accordingly. uuid:daaffff5-97d0-4d16-a98e-e1de60ad9c93 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2955 biolink:treats MONDO:0001039 PMID:41385096 "[{""id"":""uuid:187a4c81-d3e2-4d8e-9832-68b5e4937388"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:381d97d7-4af5-4e68-a3bf-fcad0f423afb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azithromycin is indicated for the treatment of patients with mild to moderate infections (pneumonia: see WARNINGS ) caused by susceptible strains of the designated microorganisms in the specific conditions listed below. As recommended dosages, durations of therapy and applicable patient populations vary among these infections, please see DOSAGE AND ADMINISTRATION for specific dosing recommendations . Adults Acute bacterial exacerbations of chronic obstructive pulmonary disease due to Haemophilus influenzae, Moraxella catarrhalis or Streptococcus pneumoniae . Acute bacterial sinusitis due to Haemophilus influenzae , Moraxella catarrhalis or Streptococcus pneumoniae . Community -acquired pneumonia due to Chlamydia pneumoniae , Haemophilus influenzae , Mycoplasma pneumoniae or Streptococcus pneumoniae in patients appropriate for oral therapy. NOTE: Azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomially acquired infections, patients with known or suspected bacteremia, patients requiring hospitalization, elderly or debilitated patients, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. NOTE: Penicillin by the intramuscular route is the usual drug of choice in the treatment of Streptococcus pyogenes infection and the prophylaxis of rheumatic fever. Azithromycin is often effective in the eradication of susceptible strains of Streptococcus pyogenes from the nasopharynx. Because some strains are resistant to azithromycin, susceptibility tests should be performed when patients are treated with azithromycin. Data establishing efficacy of azithromycin in subsequent prevention of rheumatic fever are not available. Uncomplicated skin and skin structure infections due to Staphylococcus aureus , Streptococcus pyogenes , or Streptococcus agalactiae . Abscesses usually require surgical drainage. Urethritis and cervicitis due to Chlamydia trachomatis or Neisseria gonorrhoeae . Genital ulcer disease in men due to Haemophilus ducreyi (chancroid). Due to the small number of women included in clinical trials, the efficacy of azithromycin in the treatment of chancroid in women has not been established. Azithromycin, at the recommended dose, should not be relied upon to treat syphilis. Antimicrobial agents used in high doses for short periods of time to treat non-gonococcal urethritis may mask or delay the symptoms of incubating syphilis. All patients with sexually-transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate cultures for gonorrhea performed at the time of diagnosis. Appropriate antimicrobial therapy and follow-up tests for these diseases should be initiated if infection is confirmed. Appropriate culture and susceptibility tests should be performed before treatment to determine the causative organism and its susceptibility to azithromycin. Therapy with azithromycin may be initiated before results of these tests are known; once the results become available, antimicrobial therapy should be adjusted accordingly. To reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin and other antibacterial drugs, azithromycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Pediatric Patients (See PRECAUTIONS—Pediatric Use and CLINICAL STUDIES IN PEDIATRIC PATIENTS .) Acute otitis media caused by Haemophilus influenzae , Moraxella catarrhalis or Streptococcus pneumoniae . (For specific dosage recommendation, see DOSAGE AND ADMINISTRATION .) Community-acquired pneumonia due to Chlamydia pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae or Streptococcus pneumoniae in patients appropriate for oral therapy. (For specific dosage recommendation, see DOSAGE AND ADMINISTRATION .) NOTE: Azithromycin should not be used in pediatric patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomially acquired infections, patients with known or suspected bacteremia, patients requiring hospitalization, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. (For specific dosage recommendation, see DOSAGE AND ADMINISTRATION .) NOTE: Penicillin by the intramuscular route is the usual drug of choice in the treatment of Streptococcus pyogenes infection and the prophylaxis of rheumatic fever. Azithromycin is often effective in the eradication of susceptible strains of Streptococcus pyogenes from the nasopharynx. Because some strains are resistant to azithromycin, susceptibility tests should be performed when patients are treated with azithromycin. Data establishing efficacy of azithromycin in subsequent prevention of rheumatic fever are not available. Appropriate culture and susceptibility tests should be performed before treatment to determine the causative organism and its susceptibility to azithromycin. Therapy with azithromycin may be initiated before results of these tests are known; once the results become available, antimicrobial therapy should be adjusted accordingly. uuid:2b6c9e0e-0a8c-4359-908f-07e693013746 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2955 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:cade7a62-b470-4f6a-ab27-2bd0922b4476"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8a388aef-1319-4980-9208-efac77adbaf1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azithromycin is indicated for the treatment of patients with mild to moderate infections (pneumonia: see WARNINGS ) caused by susceptible strains of the designated microorganisms in the specific conditions listed below. As recommended dosages, durations of therapy and applicable patient populations vary among these infections, please see DOSAGE AND ADMINISTRATION for specific dosing recommendations . Adults Acute bacterial exacerbations of chronic obstructive pulmonary disease due to Haemophilus influenzae, Moraxella catarrhalis or Streptococcus pneumoniae . Acute bacterial sinusitis due to Haemophilus influenzae , Moraxella catarrhalis or Streptococcus pneumoniae . Community -acquired pneumonia due to Chlamydia pneumoniae , Haemophilus influenzae , Mycoplasma pneumoniae or Streptococcus pneumoniae in patients appropriate for oral therapy. NOTE: Azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomially acquired infections, patients with known or suspected bacteremia, patients requiring hospitalization, elderly or debilitated patients, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. NOTE: Penicillin by the intramuscular route is the usual drug of choice in the treatment of Streptococcus pyogenes infection and the prophylaxis of rheumatic fever. Azithromycin is often effective in the eradication of susceptible strains of Streptococcus pyogenes from the nasopharynx. Because some strains are resistant to azithromycin, susceptibility tests should be performed when patients are treated with azithromycin. Data establishing efficacy of azithromycin in subsequent prevention of rheumatic fever are not available. Uncomplicated skin and skin structure infections due to Staphylococcus aureus , Streptococcus pyogenes , or Streptococcus agalactiae . Abscesses usually require surgical drainage. Urethritis and cervicitis due to Chlamydia trachomatis or Neisseria gonorrhoeae . Genital ulcer disease in men due to Haemophilus ducreyi (chancroid). Due to the small number of women included in clinical trials, the efficacy of azithromycin in the treatment of chancroid in women has not been established. Azithromycin, at the recommended dose, should not be relied upon to treat syphilis. Antimicrobial agents used in high doses for short periods of time to treat non-gonococcal urethritis may mask or delay the symptoms of incubating syphilis. All patients with sexually-transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate cultures for gonorrhea performed at the time of diagnosis. Appropriate antimicrobial therapy and follow-up tests for these diseases should be initiated if infection is confirmed. Appropriate culture and susceptibility tests should be performed before treatment to determine the causative organism and its susceptibility to azithromycin. Therapy with azithromycin may be initiated before results of these tests are known; once the results become available, antimicrobial therapy should be adjusted accordingly. To reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin and other antibacterial drugs, azithromycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Pediatric Patients (See PRECAUTIONS—Pediatric Use and CLINICAL STUDIES IN PEDIATRIC PATIENTS .) Acute otitis media caused by Haemophilus influenzae , Moraxella catarrhalis or Streptococcus pneumoniae . (For specific dosage recommendation, see DOSAGE AND ADMINISTRATION .) Community-acquired pneumonia due to Chlamydia pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae or Streptococcus pneumoniae in patients appropriate for oral therapy. (For specific dosage recommendation, see DOSAGE AND ADMINISTRATION .) NOTE: Azithromycin should not be used in pediatric patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomially acquired infections, patients with known or suspected bacteremia, patients requiring hospitalization, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. (For specific dosage recommendation, see DOSAGE AND ADMINISTRATION .) NOTE: Penicillin by the intramuscular route is the usual drug of choice in the treatment of Streptococcus pyogenes infection and the prophylaxis of rheumatic fever. Azithromycin is often effective in the eradication of susceptible strains of Streptococcus pyogenes from the nasopharynx. Because some strains are resistant to azithromycin, susceptibility tests should be performed when patients are treated with azithromycin. Data establishing efficacy of azithromycin in subsequent prevention of rheumatic fever are not available. Appropriate culture and susceptibility tests should be performed before treatment to determine the causative organism and its susceptibility to azithromycin. Therapy with azithromycin may be initiated before results of these tests are known; once the results become available, antimicrobial therapy should be adjusted accordingly. uuid:6374a16e-1608-4d57-914c-7bc016c94e6c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2955 biolink:treats MONDO:0005297 PMID:41385096 "[{""id"":""uuid:b78af896-4634-48f5-899a-b1368cb7c719"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:72ae2da0-182d-4bc9-b62c-8177c8b47684"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f8cdaa6e-fe1d-4c37-9e03-25e8c3838412"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azithromycin is indicated for the treatment of patients with mild to moderate infections (pneumonia: see WARNINGS ) caused by susceptible strains of the designated microorganisms in the specific conditions listed below. As recommended dosages, durations of therapy and applicable patient populations vary among these infections, please see DOSAGE AND ADMINISTRATION for specific dosing recommendations . Adults Acute bacterial exacerbations of chronic obstructive pulmonary disease due to Haemophilus influenzae, Moraxella catarrhalis or Streptococcus pneumoniae . Acute bacterial sinusitis due to Haemophilus influenzae , Moraxella catarrhalis or Streptococcus pneumoniae . Community -acquired pneumonia due to Chlamydia pneumoniae , Haemophilus influenzae , Mycoplasma pneumoniae or Streptococcus pneumoniae in patients appropriate for oral therapy. NOTE: Azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomially acquired infections, patients with known or suspected bacteremia, patients requiring hospitalization, elderly or debilitated patients, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. NOTE: Penicillin by the intramuscular route is the usual drug of choice in the treatment of Streptococcus pyogenes infection and the prophylaxis of rheumatic fever. Azithromycin is often effective in the eradication of susceptible strains of Streptococcus pyogenes from the nasopharynx. Because some strains are resistant to azithromycin, susceptibility tests should be performed when patients are treated with azithromycin. Data establishing efficacy of azithromycin in subsequent prevention of rheumatic fever are not available. Uncomplicated skin and skin structure infections due to Staphylococcus aureus , Streptococcus pyogenes , or Streptococcus agalactiae . Abscesses usually require surgical drainage. Urethritis and cervicitis due to Chlamydia trachomatis or Neisseria gonorrhoeae . Genital ulcer disease in men due to Haemophilus ducreyi (chancroid). Due to the small number of women included in clinical trials, the efficacy of azithromycin in the treatment of chancroid in women has not been established. Azithromycin, at the recommended dose, should not be relied upon to treat syphilis. Antimicrobial agents used in high doses for short periods of time to treat non-gonococcal urethritis may mask or delay the symptoms of incubating syphilis. All patients with sexually-transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate cultures for gonorrhea performed at the time of diagnosis. Appropriate antimicrobial therapy and follow-up tests for these diseases should be initiated if infection is confirmed. Appropriate culture and susceptibility tests should be performed before treatment to determine the causative organism and its susceptibility to azithromycin. Therapy with azithromycin may be initiated before results of these tests are known; once the results become available, antimicrobial therapy should be adjusted accordingly. To reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin and other antibacterial drugs, azithromycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Pediatric Patients (See PRECAUTIONS—Pediatric Use and CLINICAL STUDIES IN PEDIATRIC PATIENTS .) Acute otitis media caused by Haemophilus influenzae , Moraxella catarrhalis or Streptococcus pneumoniae . (For specific dosage recommendation, see DOSAGE AND ADMINISTRATION .) Community-acquired pneumonia due to Chlamydia pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae or Streptococcus pneumoniae in patients appropriate for oral therapy. (For specific dosage recommendation, see DOSAGE AND ADMINISTRATION .) NOTE: Azithromycin should not be used in pediatric patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomially acquired infections, patients with known or suspected bacteremia, patients requiring hospitalization, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. (For specific dosage recommendation, see DOSAGE AND ADMINISTRATION .) NOTE: Penicillin by the intramuscular route is the usual drug of choice in the treatment of Streptococcus pyogenes infection and the prophylaxis of rheumatic fever. Azithromycin is often effective in the eradication of susceptible strains of Streptococcus pyogenes from the nasopharynx. Because some strains are resistant to azithromycin, susceptibility tests should be performed when patients are treated with azithromycin. Data establishing efficacy of azithromycin in subsequent prevention of rheumatic fever are not available. Appropriate culture and susceptibility tests should be performed before treatment to determine the causative organism and its susceptibility to azithromycin. Therapy with azithromycin may be initiated before results of these tests are known; once the results become available, antimicrobial therapy should be adjusted accordingly.|[PMDA] Addition of indications for Chlamydia trachomatis, urethritis and uterine cervicitis and to dosage regimen. uuid:637cd0c2-3b00-4a05-b1d8-552301926cdd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2955 biolink:treats MONDO:0002345 PMID:41385096 "[{""id"":""uuid:98315965-048a-4c88-acec-30a50f8088d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0997cd51-27e0-4c0f-a5ad-860bd1dea193"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e300b64e-a3ae-44f2-9fdc-4e2f313a0d13"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azithromycin is indicated for the treatment of patients with mild to moderate infections (pneumonia: see WARNINGS ) caused by susceptible strains of the designated microorganisms in the specific conditions listed below. As recommended dosages, durations of therapy and applicable patient populations vary among these infections, please see DOSAGE AND ADMINISTRATION for specific dosing recommendations . Adults Acute bacterial exacerbations of chronic obstructive pulmonary disease due to Haemophilus influenzae, Moraxella catarrhalis or Streptococcus pneumoniae . Acute bacterial sinusitis due to Haemophilus influenzae , Moraxella catarrhalis or Streptococcus pneumoniae . Community -acquired pneumonia due to Chlamydia pneumoniae , Haemophilus influenzae , Mycoplasma pneumoniae or Streptococcus pneumoniae in patients appropriate for oral therapy. NOTE: Azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomially acquired infections, patients with known or suspected bacteremia, patients requiring hospitalization, elderly or debilitated patients, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. NOTE: Penicillin by the intramuscular route is the usual drug of choice in the treatment of Streptococcus pyogenes infection and the prophylaxis of rheumatic fever. Azithromycin is often effective in the eradication of susceptible strains of Streptococcus pyogenes from the nasopharynx. Because some strains are resistant to azithromycin, susceptibility tests should be performed when patients are treated with azithromycin. Data establishing efficacy of azithromycin in subsequent prevention of rheumatic fever are not available. Uncomplicated skin and skin structure infections due to Staphylococcus aureus , Streptococcus pyogenes , or Streptococcus agalactiae . Abscesses usually require surgical drainage. Urethritis and cervicitis due to Chlamydia trachomatis or Neisseria gonorrhoeae . Genital ulcer disease in men due to Haemophilus ducreyi (chancroid). Due to the small number of women included in clinical trials, the efficacy of azithromycin in the treatment of chancroid in women has not been established. Azithromycin, at the recommended dose, should not be relied upon to treat syphilis. Antimicrobial agents used in high doses for short periods of time to treat non-gonococcal urethritis may mask or delay the symptoms of incubating syphilis. All patients with sexually-transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate cultures for gonorrhea performed at the time of diagnosis. Appropriate antimicrobial therapy and follow-up tests for these diseases should be initiated if infection is confirmed. Appropriate culture and susceptibility tests should be performed before treatment to determine the causative organism and its susceptibility to azithromycin. Therapy with azithromycin may be initiated before results of these tests are known; once the results become available, antimicrobial therapy should be adjusted accordingly. To reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin and other antibacterial drugs, azithromycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Pediatric Patients (See PRECAUTIONS—Pediatric Use and CLINICAL STUDIES IN PEDIATRIC PATIENTS .) Acute otitis media caused by Haemophilus influenzae , Moraxella catarrhalis or Streptococcus pneumoniae . (For specific dosage recommendation, see DOSAGE AND ADMINISTRATION .) Community-acquired pneumonia due to Chlamydia pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae or Streptococcus pneumoniae in patients appropriate for oral therapy. (For specific dosage recommendation, see DOSAGE AND ADMINISTRATION .) NOTE: Azithromycin should not be used in pediatric patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomially acquired infections, patients with known or suspected bacteremia, patients requiring hospitalization, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. (For specific dosage recommendation, see DOSAGE AND ADMINISTRATION .) NOTE: Penicillin by the intramuscular route is the usual drug of choice in the treatment of Streptococcus pyogenes infection and the prophylaxis of rheumatic fever. Azithromycin is often effective in the eradication of susceptible strains of Streptococcus pyogenes from the nasopharynx. Because some strains are resistant to azithromycin, susceptibility tests should be performed when patients are treated with azithromycin. Data establishing efficacy of azithromycin in subsequent prevention of rheumatic fever are not available. Appropriate culture and susceptibility tests should be performed before treatment to determine the causative organism and its susceptibility to azithromycin. Therapy with azithromycin may be initiated before results of these tests are known; once the results become available, antimicrobial therapy should be adjusted accordingly.|[PMDA] Addition of indications for Chlamydia trachomatis, urethritis and uterine cervicitis and to dosage regimen. uuid:03da5b70-0b52-4cdb-be09-a9627262de0b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2955 biolink:treats MONDO:0001797 PMID:41385096 "[{""id"":""uuid:6608e1a5-ad0a-48c1-bc81-c2cbef92928a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0ce48d89-aec7-436c-b820-c625b25727c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azithromycin is indicated for the treatment of patients with mild to moderate infections (pneumonia: see WARNINGS ) caused by susceptible strains of the designated microorganisms in the specific conditions listed below. As recommended dosages, durations of therapy and applicable patient populations vary among these infections, please see DOSAGE AND ADMINISTRATION for specific dosing recommendations . Adults Acute bacterial exacerbations of chronic obstructive pulmonary disease due to Haemophilus influenzae, Moraxella catarrhalis or Streptococcus pneumoniae . Acute bacterial sinusitis due to Haemophilus influenzae , Moraxella catarrhalis or Streptococcus pneumoniae . Community -acquired pneumonia due to Chlamydia pneumoniae , Haemophilus influenzae , Mycoplasma pneumoniae or Streptococcus pneumoniae in patients appropriate for oral therapy. NOTE: Azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomially acquired infections, patients with known or suspected bacteremia, patients requiring hospitalization, elderly or debilitated patients, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. NOTE: Penicillin by the intramuscular route is the usual drug of choice in the treatment of Streptococcus pyogenes infection and the prophylaxis of rheumatic fever. Azithromycin is often effective in the eradication of susceptible strains of Streptococcus pyogenes from the nasopharynx. Because some strains are resistant to azithromycin, susceptibility tests should be performed when patients are treated with azithromycin. Data establishing efficacy of azithromycin in subsequent prevention of rheumatic fever are not available. Uncomplicated skin and skin structure infections due to Staphylococcus aureus , Streptococcus pyogenes , or Streptococcus agalactiae . Abscesses usually require surgical drainage. Urethritis and cervicitis due to Chlamydia trachomatis or Neisseria gonorrhoeae . Genital ulcer disease in men due to Haemophilus ducreyi (chancroid). Due to the small number of women included in clinical trials, the efficacy of azithromycin in the treatment of chancroid in women has not been established. Azithromycin, at the recommended dose, should not be relied upon to treat syphilis. Antimicrobial agents used in high doses for short periods of time to treat non-gonococcal urethritis may mask or delay the symptoms of incubating syphilis. All patients with sexually-transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate cultures for gonorrhea performed at the time of diagnosis. Appropriate antimicrobial therapy and follow-up tests for these diseases should be initiated if infection is confirmed. Appropriate culture and susceptibility tests should be performed before treatment to determine the causative organism and its susceptibility to azithromycin. Therapy with azithromycin may be initiated before results of these tests are known; once the results become available, antimicrobial therapy should be adjusted accordingly. To reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin and other antibacterial drugs, azithromycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Pediatric Patients (See PRECAUTIONS—Pediatric Use and CLINICAL STUDIES IN PEDIATRIC PATIENTS .) Acute otitis media caused by Haemophilus influenzae , Moraxella catarrhalis or Streptococcus pneumoniae . (For specific dosage recommendation, see DOSAGE AND ADMINISTRATION .) Community-acquired pneumonia due to Chlamydia pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae or Streptococcus pneumoniae in patients appropriate for oral therapy. (For specific dosage recommendation, see DOSAGE AND ADMINISTRATION .) NOTE: Azithromycin should not be used in pediatric patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomially acquired infections, patients with known or suspected bacteremia, patients requiring hospitalization, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. (For specific dosage recommendation, see DOSAGE AND ADMINISTRATION .) NOTE: Penicillin by the intramuscular route is the usual drug of choice in the treatment of Streptococcus pyogenes infection and the prophylaxis of rheumatic fever. Azithromycin is often effective in the eradication of susceptible strains of Streptococcus pyogenes from the nasopharynx. Because some strains are resistant to azithromycin, susceptibility tests should be performed when patients are treated with azithromycin. Data establishing efficacy of azithromycin in subsequent prevention of rheumatic fever are not available. Appropriate culture and susceptibility tests should be performed before treatment to determine the causative organism and its susceptibility to azithromycin. Therapy with azithromycin may be initiated before results of these tests are known; once the results become available, antimicrobial therapy should be adjusted accordingly. uuid:1f7d7787-7188-40b3-b9e6-0bdb65894590 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2955 biolink:treats HP:0000371 PMID:41385096 "[{""id"":""uuid:2bc6eaf4-f0b4-4ddc-a1a5-40bdcd253d79"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:582aa9d8-9d10-4074-a404-5634eafe670b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azithromycin is indicated for the treatment of patients with mild to moderate infections (pneumonia: see WARNINGS ) caused by susceptible strains of the designated microorganisms in the specific conditions listed below. As recommended dosages, durations of therapy and applicable patient populations vary among these infections, please see DOSAGE AND ADMINISTRATION for specific dosing recommendations . Adults Acute bacterial exacerbations of chronic obstructive pulmonary disease due to Haemophilus influenzae, Moraxella catarrhalis or Streptococcus pneumoniae . Acute bacterial sinusitis due to Haemophilus influenzae , Moraxella catarrhalis or Streptococcus pneumoniae . Community -acquired pneumonia due to Chlamydia pneumoniae , Haemophilus influenzae , Mycoplasma pneumoniae or Streptococcus pneumoniae in patients appropriate for oral therapy. NOTE: Azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomially acquired infections, patients with known or suspected bacteremia, patients requiring hospitalization, elderly or debilitated patients, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. NOTE: Penicillin by the intramuscular route is the usual drug of choice in the treatment of Streptococcus pyogenes infection and the prophylaxis of rheumatic fever. Azithromycin is often effective in the eradication of susceptible strains of Streptococcus pyogenes from the nasopharynx. Because some strains are resistant to azithromycin, susceptibility tests should be performed when patients are treated with azithromycin. Data establishing efficacy of azithromycin in subsequent prevention of rheumatic fever are not available. Uncomplicated skin and skin structure infections due to Staphylococcus aureus , Streptococcus pyogenes , or Streptococcus agalactiae . Abscesses usually require surgical drainage. Urethritis and cervicitis due to Chlamydia trachomatis or Neisseria gonorrhoeae . Genital ulcer disease in men due to Haemophilus ducreyi (chancroid). Due to the small number of women included in clinical trials, the efficacy of azithromycin in the treatment of chancroid in women has not been established. Azithromycin, at the recommended dose, should not be relied upon to treat syphilis. Antimicrobial agents used in high doses for short periods of time to treat non-gonococcal urethritis may mask or delay the symptoms of incubating syphilis. All patients with sexually-transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate cultures for gonorrhea performed at the time of diagnosis. Appropriate antimicrobial therapy and follow-up tests for these diseases should be initiated if infection is confirmed. Appropriate culture and susceptibility tests should be performed before treatment to determine the causative organism and its susceptibility to azithromycin. Therapy with azithromycin may be initiated before results of these tests are known; once the results become available, antimicrobial therapy should be adjusted accordingly. To reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin and other antibacterial drugs, azithromycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Pediatric Patients (See PRECAUTIONS—Pediatric Use and CLINICAL STUDIES IN PEDIATRIC PATIENTS .) Acute otitis media caused by Haemophilus influenzae , Moraxella catarrhalis or Streptococcus pneumoniae . (For specific dosage recommendation, see DOSAGE AND ADMINISTRATION .) Community-acquired pneumonia due to Chlamydia pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae or Streptococcus pneumoniae in patients appropriate for oral therapy. (For specific dosage recommendation, see DOSAGE AND ADMINISTRATION .) NOTE: Azithromycin should not be used in pediatric patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomially acquired infections, patients with known or suspected bacteremia, patients requiring hospitalization, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. (For specific dosage recommendation, see DOSAGE AND ADMINISTRATION .) NOTE: Penicillin by the intramuscular route is the usual drug of choice in the treatment of Streptococcus pyogenes infection and the prophylaxis of rheumatic fever. Azithromycin is often effective in the eradication of susceptible strains of Streptococcus pyogenes from the nasopharynx. Because some strains are resistant to azithromycin, susceptibility tests should be performed when patients are treated with azithromycin. Data establishing efficacy of azithromycin in subsequent prevention of rheumatic fever are not available. Appropriate culture and susceptibility tests should be performed before treatment to determine the causative organism and its susceptibility to azithromycin. Therapy with azithromycin may be initiated before results of these tests are known; once the results become available, antimicrobial therapy should be adjusted accordingly. uuid:0457c7f8-9086-409a-bae7-aa6c7b4cf9da biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:101278 biolink:treats MONDO:0005356 PMID:41385096 "[{""id"":""uuid:001c1ea1-7abc-4e8c-aed6-54d41c170d6d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c1b59f45-446b-4ee3-bf1f-397fc5a75426"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diltiazem hydrochloride extended-release capsules are indicated for the treatment of hypertension. They may be used alone or in combination with other antihypertensive medications. Diltiazem hydrochloride extended-release capsules are indicated for the management of chronic stable angina and angina due to coronary artery spasm. uuid:51726b07-d5e3-447a-bf15-45d4f06bb99b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17823 biolink:treats MONDO:0006964 PMID:41385096 "[{""id"":""uuid:72fd8fb4-a982-4fce-9b16-b518c115ca1b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5bd56712-cd08-4cd1-9543-fd1f34dd4775"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Predialysis Patients Calcitriol is indicated in the management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure (C cr 15 to 55 mL/min) not yet on dialysis. In children, the creatinine clearance value must be corrected for a surface area of 1.73 square meters. A serum iPTH level of ≥ 100 pg/mL is strongly suggestive of secondary hyperparathyroidism. Dialysis Patients Calcitriol is indicated in the management of hypocalcemia and the resultant metabolic bone disease in patients undergoing chronic renal dialysis. In these patients, calcitriol administration enhances calcium absorption, reduces serum alkaline phosphatase levels, and may reduce elevated parathyroid hormone levels and the histological manifestations of osteitis fibrosa cystica and defective mineralization. Hypoparathydroidism Patients Calcitriol is also indicated in the management of hypocalcemia and its clinical manifestations in patients with postsurgical hypoparathyroidism, idiopathic hypoparathyroidism, and pseudohypoparathyroidism. uuid:d1f53fcc-a5a5-4f5c-9d60-c6fe130ffd13 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17823 biolink:treats MONDO:0800486 PMID:41385096 "[{""id"":""uuid:3d7d3db6-c8f5-4013-9d3b-cb395dd6901b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7b14cf30-0dbf-47b5-a22f-f04e0fa6b7e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Predialysis Patients Calcitriol is indicated in the management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure (C cr 15 to 55 mL/min) not yet on dialysis. In children, the creatinine clearance value must be corrected for a surface area of 1.73 square meters. A serum iPTH level of ≥ 100 pg/mL is strongly suggestive of secondary hyperparathyroidism. Dialysis Patients Calcitriol is indicated in the management of hypocalcemia and the resultant metabolic bone disease in patients undergoing chronic renal dialysis. In these patients, calcitriol administration enhances calcium absorption, reduces serum alkaline phosphatase levels, and may reduce elevated parathyroid hormone levels and the histological manifestations of osteitis fibrosa cystica and defective mineralization. Hypoparathydroidism Patients Calcitriol is also indicated in the management of hypocalcemia and its clinical manifestations in patients with postsurgical hypoparathyroidism, idiopathic hypoparathyroidism, and pseudohypoparathyroidism. uuid:9d35d352-b445-4986-9523-56a5fa7c5bef biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17823 biolink:treats UMLS:C0342342 PMID:41385096 "[{""id"":""uuid:17d8ed57-2426-4cd2-95ff-1d22a2b63a18"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7302a303-a813-440d-ad36-fd9b2ce7098b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Predialysis Patients Calcitriol is indicated in the management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure (C cr 15 to 55 mL/min) not yet on dialysis. In children, the creatinine clearance value must be corrected for a surface area of 1.73 square meters. A serum iPTH level of ≥ 100 pg/mL is strongly suggestive of secondary hyperparathyroidism. Dialysis Patients Calcitriol is indicated in the management of hypocalcemia and the resultant metabolic bone disease in patients undergoing chronic renal dialysis. In these patients, calcitriol administration enhances calcium absorption, reduces serum alkaline phosphatase levels, and may reduce elevated parathyroid hormone levels and the histological manifestations of osteitis fibrosa cystica and defective mineralization. Hypoparathydroidism Patients Calcitriol is also indicated in the management of hypocalcemia and its clinical manifestations in patients with postsurgical hypoparathyroidism, idiopathic hypoparathyroidism, and pseudohypoparathyroidism. uuid:bcca0e44-9ce3-4574-ad40-d4f9cae2a2b7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17823 biolink:treats MONDO:0019992 PMID:41385096 "[{""id"":""uuid:4a82f42a-fce1-4d0e-bb21-d5f82ff58320"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e5104124-a0e2-463a-a33d-7444037a06dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Predialysis Patients Calcitriol is indicated in the management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure (C cr 15 to 55 mL/min) not yet on dialysis. In children, the creatinine clearance value must be corrected for a surface area of 1.73 square meters. A serum iPTH level of ≥ 100 pg/mL is strongly suggestive of secondary hyperparathyroidism. Dialysis Patients Calcitriol is indicated in the management of hypocalcemia and the resultant metabolic bone disease in patients undergoing chronic renal dialysis. In these patients, calcitriol administration enhances calcium absorption, reduces serum alkaline phosphatase levels, and may reduce elevated parathyroid hormone levels and the histological manifestations of osteitis fibrosa cystica and defective mineralization. Hypoparathydroidism Patients Calcitriol is also indicated in the management of hypocalcemia and its clinical manifestations in patients with postsurgical hypoparathyroidism, idiopathic hypoparathyroidism, and pseudohypoparathyroidism. uuid:1ca3b9cb-8844-4e42-9039-b437b07f2500 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2567 biolink:treats HP:0002953 PMID:41385096 "[{""id"":""uuid:fe0ceb5a-9dfd-4b42-a67f-3e899f2e03b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7b379a00-e9df-4780-8db4-ec7bec96fd3a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FOSAMAX is indicated for: Treatment and prevention of osteoporosis in postmenopausal women For the treatment of osteoporosis, FOSAMAX increases bone mass and reduces the incidence of fractures, including those of the hip and spine (vertebral compression fractures). Osteoporosis may be confirmed by the finding of low bone mass (for example, at least 2 standard deviations below the premenopausal mean) or by the presence or history of osteoporotic fracture. (See CLINICAL PHARMACOLOGY, Pharmacodynamics .) For the prevention of osteoporosis, FOSAMAX may be considered in postmenopausal women who are at risk of developing osteoporosis and for whom the desired clinical outcome is to maintain bone mass and to reduce the risk of future fracture. Bone loss is particularly rapid in postmenopausal women younger than age 60. Risk factors often associated with the development of postmenopausal osteoporosis include early menopause; moderately low bone mass (for example, at least 1 standard deviation below the mean for healthy young adult women); thin body build; Caucasian or Asian race; and family history of osteoporosis. The presence of such risk factors may be important when considering the use of FOSAMAX for prevention of osteoporosis. Treatment to increase bone mass in men with osteoporosis Treatment of glucocorticoid-induced osteoporosis in men and women receiving glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and who have low bone mineral density (see PRECAUTIONS, Glucocorticoid-induced osteoporosis ). Patients treated with glucocorticoids should receive adequate amounts of calcium and vitamin D. Treatment of Paget's disease of bone in men and women Treatment is indicated in patients with Paget's disease of bone having alkaline phosphatase at least two times the upper limit of normal, or those who are symptomatic, or those at risk for future complications from their disease. uuid:1c96ab98-186e-4163-8ea4-e99d0946f8e2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8746 biolink:treats MONDO:0001358 PMID:41385096 "[{""id"":""uuid:920caba7-625a-47ba-98dc-25d2d26932cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e01ef20b-aaae-4da4-bee8-a1b1ccf4d00c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Xopenex (levalbuterol HCl) Inhalation Solution is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease. uuid:c8f2a341-0698-4b9c-bba6-755757b60d1a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8746 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:71ee2cc5-b121-402c-a5bf-5345ac17f5c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e762d64f-9b67-4a2f-b0e0-cda339f3b67f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Xopenex (levalbuterol HCl) Inhalation Solution is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease. uuid:c9d00345-25bd-46f6-8144-c235980bcea4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50749 biolink:treats MONDO:0005083 PMID:41385096 "[{""id"":""uuid:89a033b1-a017-4777-8d3e-baf244a11315"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:def36986-ea54-4a0d-a064-ca72df32e56e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dovonex ® (calcipotriene solution) Scalp Solution, 0.005%, is indicated for the topical treatment of chronic, moderately severe psoriasis of the scalp. The safety and effectiveness of topical calcipotriene in dermatoses other than psoriasis have not been established. uuid:3ebfcd9b-7906-4cd8-8a66-10ada336710f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2948 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:baa61ee1-45e0-4afd-aa2c-6a53b648f71f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:6949772d-d488-4b3d-9d03-be80686a32a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ccd53f84-e037-4faf-9c04-9e02884857e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/jayempi""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azathioprine tablets are indicated as an adjunct for the prevention of rejection in renal homotransplantation. It is also indicated for the management of active rheumatoid arthritis to reduce signs and symptoms.|[EMA] Jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. Azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression).Jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response.Jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – DMARDs)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidBehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm IgG antibodieschronic refractory idiopathic thrombocytopenic purpuraJayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (IBD) (Crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice.It is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3Jayempi is indicated for the treatment of generalised myasthenia gravis. Depending on the severity of the disease, Jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment. uuid:c671b268-ffd7-4eb7-83a3-3b761d73cc16 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:119915 biolink:treats HP:0012532 PMID:41385096 "[{""id"":""uuid:50ccbcf9-efd9-420c-9fa5-95640fbb077f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:fd3dca24-b21d-4dfc-848c-04ddf4982cae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:2df8bddb-4363-478a-be10-a232b2e5b8a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fentanyl transdermal system is indicated for management of persistent, moderate to severe chronic pain that: requires continuous, around-the-clock opioid administration for an extended period of time, and cannot be managed by other means such as non-steroidal analgesics, opioid combination products, or immediate-release opioids Fentanyl transdermal system should ONLY be used in patients who are already receiving opioid therapy, who have demonstrated opioid tolerance, and who require a total daily dose at least equivalent to fentanyl transdermal system 25 mcg/hr (see DOSAGE AND ADMINISTRATION ). Patients who are considered opioid-tolerant are those who have been taking, for a week or longer, at least 60 mg of morphine daily, or at least 30 mg of oral oxycodone daily, or at least 8 mg of oral hydromorphone daily, or an equianalgesic dose of another opioid. Because serious or life-threatening hypoventilation could result, fentanyl transdermal system is contraindicated for use on an as needed basis (i.e., prn), for the management of post-operative or acute pain, or in patients who are not opioid-tolerant or who require opioid analgesia for a short period of time (see BOX WARNING and CONTRAINDICATIONS ). An evaluation of the appropriateness and adequacy of treating with immediate-release opioids is advisable prior to initiating therapy with any modified-release opioid. Prescribers should individualize treatment in every case, initiating therapy at the appropriate point along a progression from non-opioid analgesics, such as non-steroidal anti-inflammatory drugs and acetaminophen, to opioids, in a plan of pain management such as outlined by the World Health Organization, the Agency for Health Research and Quality, the Federation of State Medical Boards Model Policy, or the American Pain Society. Patients should be assessed for their clinical risks for opioid abuse or addiction prior to being prescribed opioids. Patients receiving opioids should be routinely monitored for signs of misuse, abuse, and addiction. Persons at increased risk for opioid abuse include those with a personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (e.g., major depression). Patients at increased risk may still be appropriately treated with modified-release opioid formulations; however these patients will require intensive monitoring for signs of misuse, abuse, or addiction.|[PMDA] Drugs with a new dosage and in additional dosage form indicated for: (1) analgesia in various types of cancer with moderate to severe pain that cannot be managed with non-opioid analgesics or weak opioid analgesics (for use only in patients who switch from other opioid analgesics); or (2) analgesia in moderate to severe chronic pain (for use only in patients who switch from other opioid analgesics). uuid:07ca0093-ed43-41c5-9b61-31836a04c722 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:51141 biolink:treats MONDO:0010811 PMID:41385096 "[{""id"":""uuid:3e6df228-43d5-4b5b-ab6b-92e6ee55035c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3203332b-66bc-4167-81c7-c00912853eac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1 INDICATIONS AND USAGE UROXATRAL is indicated for the treatment of signs and symptoms of benign prostatic hyperplasia. UROXATRAL is not indicated for the treatment of hypertension. 2 DOSAGE AND ADMINISTRATION The recommended dosage is one 10 mg UROXATRAL (alfuzosin HCl) extended-release tablet once daily. The extent of absorption of Uroxatral is 50% lower under fasting conditions. Therefore, Uroxatral should be taken immediately after the same meal each day. The tablets should not be chewed or crushed. 3 DOSAGE FORMS AND STRENGTHS UROXATRAL (alfuzosin HCl) extended-release tablet 10 mg is available as a round, three-layer tablet: one white layer between two yellow layers, debossed with X10. 4 CONTRAINDICATIONS UROXATRAL is contraindicated for use in patients with moderate or severe hepatic impairment (Childs-Pugh categories B and C), since alfuzosin blood levels are increased in these patients. [see Clinical Pharmacology (12.3) ]. UROXATRAL is contraindicated for use with potent CYP3A4 inhibitors such as ketoconazole, itraconazole, and ritonavir, since alfuzosin blood levels are increased. [see Clinical Pharmacology (12.3) ] . UROXATRAL is contraindicated in patients known to be hypersensitive to alfuzosin hydrochloride or any component of UROXATRAL tablets. uuid:cd449623-f41f-4858-9c0d-34c05b2cf883 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:51141 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:692ab241-45ea-4233-b29a-9d3d1e6814a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:242afb48-7c17-407a-ba18-7e89f0c5d58a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1 INDICATIONS AND USAGE UROXATRAL is indicated for the treatment of signs and symptoms of benign prostatic hyperplasia. UROXATRAL is not indicated for the treatment of hypertension. 2 DOSAGE AND ADMINISTRATION The recommended dosage is one 10 mg UROXATRAL (alfuzosin HCl) extended-release tablet once daily. The extent of absorption of Uroxatral is 50% lower under fasting conditions. Therefore, Uroxatral should be taken immediately after the same meal each day. The tablets should not be chewed or crushed. 3 DOSAGE FORMS AND STRENGTHS UROXATRAL (alfuzosin HCl) extended-release tablet 10 mg is available as a round, three-layer tablet: one white layer between two yellow layers, debossed with X10. 4 CONTRAINDICATIONS UROXATRAL is contraindicated for use in patients with moderate or severe hepatic impairment (Childs-Pugh categories B and C), since alfuzosin blood levels are increased in these patients. [see Clinical Pharmacology (12.3) ]. UROXATRAL is contraindicated for use with potent CYP3A4 inhibitors such as ketoconazole, itraconazole, and ritonavir, since alfuzosin blood levels are increased. [see Clinical Pharmacology (12.3) ] . UROXATRAL is contraindicated in patients known to be hypersensitive to alfuzosin hydrochloride or any component of UROXATRAL tablets. uuid:4f41bc36-8bb4-42dd-b595-9c10a4ed4842 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:51141 biolink:treats UMLS:C0948807 PMID:41385096 "[{""id"":""uuid:cc0f23bf-59fa-4b3d-be0b-cf245ec12171"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8dc546c6-d497-4b8c-8eb5-427ffb1e32b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1 INDICATIONS AND USAGE UROXATRAL is indicated for the treatment of signs and symptoms of benign prostatic hyperplasia. UROXATRAL is not indicated for the treatment of hypertension. 2 DOSAGE AND ADMINISTRATION The recommended dosage is one 10 mg UROXATRAL (alfuzosin HCl) extended-release tablet once daily. The extent of absorption of Uroxatral is 50% lower under fasting conditions. Therefore, Uroxatral should be taken immediately after the same meal each day. The tablets should not be chewed or crushed. 3 DOSAGE FORMS AND STRENGTHS UROXATRAL (alfuzosin HCl) extended-release tablet 10 mg is available as a round, three-layer tablet: one white layer between two yellow layers, debossed with X10. 4 CONTRAINDICATIONS UROXATRAL is contraindicated for use in patients with moderate or severe hepatic impairment (Childs-Pugh categories B and C), since alfuzosin blood levels are increased in these patients. [see Clinical Pharmacology (12.3) ]. UROXATRAL is contraindicated for use with potent CYP3A4 inhibitors such as ketoconazole, itraconazole, and ritonavir, since alfuzosin blood levels are increased. [see Clinical Pharmacology (12.3) ] . UROXATRAL is contraindicated in patients known to be hypersensitive to alfuzosin hydrochloride or any component of UROXATRAL tablets. uuid:47e960ca-6ab7-4f19-9871-1fd13de02baa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0003634 PMID:41385096 "[{""id"":""uuid:92b10ec7-f027-41c1-bf4f-091dfae4b16e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4baac563-dd90-4733-91f5-bdda50998686"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PredniSONE Tablets are indicated in the following conditions: Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Aspiration pneumonitis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Nervous System Acute exacerbations of multiple sclerosis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:7f22930a-5fac-4186-b26d-0902a1dd5b4c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0005314 PMID:41385096 "[{""id"":""uuid:c476b3cb-faa7-40e3-be88-0356b27ea88d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:79b384c6-11dc-411b-9a51-1fc4b2940b76"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PredniSONE Tablets are indicated in the following conditions: Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Aspiration pneumonitis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Nervous System Acute exacerbations of multiple sclerosis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:5b481a89-efd3-40d8-8d4f-29d97f58d574 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63631 biolink:treats HP:0007359 PMID:41385096 "[{""id"":""uuid:14b7256b-c1fc-4590-a32b-11854e4ddd50"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:54f159bb-5515-4a53-9d00-7a102b428a89"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:80c766ca-9f5f-4b8b-9657-85547332b5e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Topiramate tablets are indicated as initial monotherapy in patients 10 years of age and older with partial onset or primary generalized tonic-clonic seizures. Effectiveness was demonstrated in a controlled trial in patients with epilepsy who had no more than 2 seizures in the 3 months prior to enrollment. Safety and effectiveness in patients who were converted to monotherapy from a previous regimen of other anticonvulsant drugs have not been established in controlled trials.|[PMDA] A drug with a new additional pediatric dosage in an additional dosage form. The drug is indicated for use as an adjunctive therapy with other antiepileptic drugs to treat partial seizures (including secondary generalized seizures) in patients with epilepsy who have not responded sufficiently to other antiepileptic drugs. uuid:7173ed8a-6c93-44ff-b475-9bd6b0436ca9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63631 biolink:treats MONDO:0005754 PMID:41385096 "[{""id"":""uuid:be56ba7d-0bb5-45e7-b10c-09d8808f569c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2fd09f03-b857-4557-bcdf-6516e73bdd95"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Topiramate tablets are indicated as initial monotherapy in patients 10 years of age and older with partial onset or primary generalized tonic-clonic seizures. Effectiveness was demonstrated in a controlled trial in patients with epilepsy who had no more than 2 seizures in the 3 months prior to enrollment. Safety and effectiveness in patients who were converted to monotherapy from a previous regimen of other anticonvulsant drugs have not been established in controlled trials. uuid:385b28c5-5c1f-4dfd-9c6e-1accd3b99e27 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63631 biolink:treats MONDO:0005027 PMID:41385096 "[{""id"":""uuid:370c9678-dda7-4e5e-99b4-f65d63145869"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:effd9cfe-e59f-4056-8792-7ab5b343bee4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:32cc7780-09cd-4c81-9cdb-371c730dd8d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Topiramate tablets are indicated as initial monotherapy in patients 10 years of age and older with partial onset or primary generalized tonic-clonic seizures. Effectiveness was demonstrated in a controlled trial in patients with epilepsy who had no more than 2 seizures in the 3 months prior to enrollment. Safety and effectiveness in patients who were converted to monotherapy from a previous regimen of other anticonvulsant drugs have not been established in controlled trials.|[PMDA] A drug with a new additional pediatric dosage in an additional dosage form. The drug is indicated for use as an adjunctive therapy with other antiepileptic drugs to treat partial seizures (including secondary generalized seizures) in patients with epilepsy who have not responded sufficiently to other antiepileptic drugs. uuid:c964e752-5582-46ef-ba2b-b014228cbd33 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49575 biolink:treats MONDO:0005618 PMID:41385096 "[{""id"":""uuid:6b1a0f94-478c-4fbf-bba2-28aabaa9af25"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c0294787-059f-42a4-8a4a-c549296f79f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diazepam Tablets USP are indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. In acute alcohol withdrawal, diazepam may be useful in the symptomatic relief of acute agitation, tremor, impending or acute delirium tremens and hallucinosis. Diazepam is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology (such as inflammation of the muscles or joints, or secondary to trauma), spasticity caused by upper motor neuron disorders (such as cerebral palsy and paraplegia), athetosis, and stiff-man syndrome. Oral diazepam may be used adjunctively in convulsive disorders, although it has not proved useful as the sole therapy. The effectiveness of diazepam in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient. uuid:b4b5e025-b11e-4347-96f9-147719e78f96 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49575 biolink:treats HP:0000713 PMID:41385096 "[{""id"":""uuid:ad5c7c26-d65f-4246-aa45-c8b3865eef1a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:58604f4f-e408-4e63-bc50-04b40bc9b8e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diazepam Tablets USP are indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. In acute alcohol withdrawal, diazepam may be useful in the symptomatic relief of acute agitation, tremor, impending or acute delirium tremens and hallucinosis. Diazepam is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology (such as inflammation of the muscles or joints, or secondary to trauma), spasticity caused by upper motor neuron disorders (such as cerebral palsy and paraplegia), athetosis, and stiff-man syndrome. Oral diazepam may be used adjunctively in convulsive disorders, although it has not proved useful as the sole therapy. The effectiveness of diazepam in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient. uuid:84cb8f42-ec0d-460d-9697-5fd1c4979a84 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49575 biolink:treats HP:0001337 PMID:41385096 "[{""id"":""uuid:81c8c0a7-b4fa-4593-855d-3fdcbcc32938"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:622e97eb-7104-4290-a712-30fd85dbff58"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diazepam Tablets USP are indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. In acute alcohol withdrawal, diazepam may be useful in the symptomatic relief of acute agitation, tremor, impending or acute delirium tremens and hallucinosis. Diazepam is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology (such as inflammation of the muscles or joints, or secondary to trauma), spasticity caused by upper motor neuron disorders (such as cerebral palsy and paraplegia), athetosis, and stiff-man syndrome. Oral diazepam may be used adjunctively in convulsive disorders, although it has not proved useful as the sole therapy. The effectiveness of diazepam in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient. uuid:0cb0d582-d6fe-4abb-bfb5-18fb304da1c0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49575 biolink:treats MONDO:0006642 PMID:41385096 "[{""id"":""uuid:57867703-5f61-42b5-9ff4-e506af38446b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:df05034f-4de4-4080-a564-4be08b41f82c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diazepam Tablets USP are indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. In acute alcohol withdrawal, diazepam may be useful in the symptomatic relief of acute agitation, tremor, impending or acute delirium tremens and hallucinosis. Diazepam is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology (such as inflammation of the muscles or joints, or secondary to trauma), spasticity caused by upper motor neuron disorders (such as cerebral palsy and paraplegia), athetosis, and stiff-man syndrome. Oral diazepam may be used adjunctively in convulsive disorders, although it has not proved useful as the sole therapy. The effectiveness of diazepam in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient. uuid:7d51de52-602d-4dce-a607-9e7e15c02c7f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49575 biolink:treats UMLS:C0233777 PMID:41385096 "[{""id"":""uuid:c695c76a-263d-41ce-9fe4-5cdf191fb0b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e32aa483-8879-4663-beda-6294529ae880"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diazepam Tablets USP are indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. In acute alcohol withdrawal, diazepam may be useful in the symptomatic relief of acute agitation, tremor, impending or acute delirium tremens and hallucinosis. Diazepam is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology (such as inflammation of the muscles or joints, or secondary to trauma), spasticity caused by upper motor neuron disorders (such as cerebral palsy and paraplegia), athetosis, and stiff-man syndrome. Oral diazepam may be used adjunctively in convulsive disorders, although it has not proved useful as the sole therapy. The effectiveness of diazepam in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient. uuid:c36b4d06-34ce-4067-b8dc-5ca8a4fa0aa0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49575 biolink:treats HP:0003394 PMID:41385096 "[{""id"":""uuid:8263115a-4a2d-45f4-b4c8-a735dda726aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c77a9c08-2cde-457d-a8cf-90ea5f301445"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diazepam Tablets USP are indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. In acute alcohol withdrawal, diazepam may be useful in the symptomatic relief of acute agitation, tremor, impending or acute delirium tremens and hallucinosis. Diazepam is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology (such as inflammation of the muscles or joints, or secondary to trauma), spasticity caused by upper motor neuron disorders (such as cerebral palsy and paraplegia), athetosis, and stiff-man syndrome. Oral diazepam may be used adjunctively in convulsive disorders, although it has not proved useful as the sole therapy. The effectiveness of diazepam in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient. uuid:37294aff-abae-4875-b380-e059a7cd2cb8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49575 biolink:treats MONDO:0005578 PMID:41385096 "[{""id"":""uuid:2a84b5f5-070d-4166-831c-a0af5043137c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f79bc142-dbee-4ec4-970e-3a1c87449b13"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diazepam Tablets USP are indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. In acute alcohol withdrawal, diazepam may be useful in the symptomatic relief of acute agitation, tremor, impending or acute delirium tremens and hallucinosis. Diazepam is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology (such as inflammation of the muscles or joints, or secondary to trauma), spasticity caused by upper motor neuron disorders (such as cerebral palsy and paraplegia), athetosis, and stiff-man syndrome. Oral diazepam may be used adjunctively in convulsive disorders, although it has not proved useful as the sole therapy. The effectiveness of diazepam in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient. uuid:eee3f65e-a49c-40ec-b2d3-956764ffdaf4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49575 biolink:treats MONDO:0006497 PMID:41385096 "[{""id"":""uuid:5ef63df4-0630-44d2-8400-a3d3af8a33dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:41cb9c20-b501-4354-8857-59478006cd8f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diazepam Tablets USP are indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. In acute alcohol withdrawal, diazepam may be useful in the symptomatic relief of acute agitation, tremor, impending or acute delirium tremens and hallucinosis. Diazepam is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology (such as inflammation of the muscles or joints, or secondary to trauma), spasticity caused by upper motor neuron disorders (such as cerebral palsy and paraplegia), athetosis, and stiff-man syndrome. Oral diazepam may be used adjunctively in convulsive disorders, although it has not proved useful as the sole therapy. The effectiveness of diazepam in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient. uuid:17652b6d-a20b-4eb6-8a3a-7e46263af0ea biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49575 biolink:treats MONDO:0003757 PMID:41385096 "[{""id"":""uuid:0b210d60-fb05-45f4-a458-28492e85c31f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:45f6bd92-9a50-4af2-a304-49bf1f4a378e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diazepam Tablets USP are indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. In acute alcohol withdrawal, diazepam may be useful in the symptomatic relief of acute agitation, tremor, impending or acute delirium tremens and hallucinosis. Diazepam is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology (such as inflammation of the muscles or joints, or secondary to trauma), spasticity caused by upper motor neuron disorders (such as cerebral palsy and paraplegia), athetosis, and stiff-man syndrome. Oral diazepam may be used adjunctively in convulsive disorders, although it has not proved useful as the sole therapy. The effectiveness of diazepam in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient. uuid:423d4db8-a166-44b0-9b13-c7deeaae7c11 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49575 biolink:treats HP:0002305 PMID:41385096 "[{""id"":""uuid:6b8a0c8b-ce4f-4249-9390-cfb0513f8203"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f0e34b01-49f8-4105-8fa2-90fbe1bef012"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diazepam Tablets USP are indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. In acute alcohol withdrawal, diazepam may be useful in the symptomatic relief of acute agitation, tremor, impending or acute delirium tremens and hallucinosis. Diazepam is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology (such as inflammation of the muscles or joints, or secondary to trauma), spasticity caused by upper motor neuron disorders (such as cerebral palsy and paraplegia), athetosis, and stiff-man syndrome. Oral diazepam may be used adjunctively in convulsive disorders, although it has not proved useful as the sole therapy. The effectiveness of diazepam in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient. uuid:db0e9e67-28dd-44e0-83a1-7c947767f1a1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49575 biolink:treats MONDO:0008491 PMID:41385096 "[{""id"":""uuid:7291299e-0084-4ae4-9287-5a5b32fb08e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7e611924-6b8e-408c-9a96-4dd1ff21016b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diazepam Tablets USP are indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. In acute alcohol withdrawal, diazepam may be useful in the symptomatic relief of acute agitation, tremor, impending or acute delirium tremens and hallucinosis. Diazepam is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology (such as inflammation of the muscles or joints, or secondary to trauma), spasticity caused by upper motor neuron disorders (such as cerebral palsy and paraplegia), athetosis, and stiff-man syndrome. Oral diazepam may be used adjunctively in convulsive disorders, although it has not proved useful as the sole therapy. The effectiveness of diazepam in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient. uuid:2886b417-cc3b-4caf-8c63-ed9bfbeeee41 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49575 biolink:treats UMLS:C0234972 PMID:41385096 "[{""id"":""uuid:140cdc9c-1739-4a9f-9517-f0de1bcd81ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fbcecc4b-b399-4269-945c-55663d555b88"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diazepam Tablets USP are indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. In acute alcohol withdrawal, diazepam may be useful in the symptomatic relief of acute agitation, tremor, impending or acute delirium tremens and hallucinosis. Diazepam is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology (such as inflammation of the muscles or joints, or secondary to trauma), spasticity caused by upper motor neuron disorders (such as cerebral palsy and paraplegia), athetosis, and stiff-man syndrome. Oral diazepam may be used adjunctively in convulsive disorders, although it has not proved useful as the sole therapy. The effectiveness of diazepam in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient. uuid:5268073b-f61c-4c7c-9533-a00d6b656469 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9943 biolink:treats MONDO:0001942 PMID:41385096 "[{""id"":""uuid:437c4a54-1305-4334-86ec-f0402a8a02a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:46e12e25-490a-47f8-80b4-80b4a1f1efd2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Major Depressive Disorder Effexor XR (venlafaxine hydrochloride) extended-release capsules is indicated for the treatment of major depressive disorder. The efficacy of Effexor XR in the treatment of major depressive disorder was established in 8- and 12-week controlled trials of adult outpatients whose diagnoses corresponded most closely to the DSM-III-R or DSM-IV category of major depressive disorder (see Clinical Trials ). A major depressive episode (DSM-IV) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed mood or the loss of interest or pleasure in nearly all activities, representing a change from previous functioning, and includes the presence of at least five of the following nine symptoms during the same two-week period: depressed mood, markedly diminished interest or pleasure in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. The efficacy of Effexor (immediate release) in the treatment of major depressive disorder in adult inpatients meeting diagnostic criteria for major depressive disorder with melancholia was established in a 4-week controlled trial (see Clinical Trials ). The safety and efficacy of Effexor XR in hospitalized depressed patients have not been adequately studied. The efficacy of Effexor XR in maintaining a response in major depressive disorder for up to 26 weeks following 8 weeks of acute treatment was demonstrated in a placebo-controlled trial. The efficacy of Effexor (immediate release) in maintaining a response in patients with recurrent major depressive disorder who had responded and continued to be improved during an initial 26 weeks of treatment and were then followed for a period of up to 52 weeks was demonstrated in a second placebo-controlled trial (see Clinical Trials ). Nevertheless, the physician who elects to use Effexor/Effexor XR for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION ). Generalized Anxiety Disorder Effexor XR is indicated for the treatment of Generalized Anxiety Disorder (GAD) as defined in DSM-IV. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The efficacy of Effexor XR in the treatment of GAD was established in 8-week and 6-month placebo-controlled trials in adult outpatients diagnosed with GAD according to DSM-IV criteria (see Clinical Trials ). Generalized Anxiety Disorder (DSM-IV) is characterized by excessive anxiety and worry (apprehensive expectation) that is persistent for at least 6 months and which the person finds difficult to control. It must be associated with at least 3 of the following 6 symptoms: restlessness or feeling keyed up or on edge, being easily fatigued, difficulty concentrating or mind going blank, irritability, muscle tension, sleep disturbance. Although the effectiveness of Effexor XR has been demonstrated in 6-month clinical trials in patients with GAD, the physician who elects to use Effexor XR for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION ). Social Anxiety Disorder Effexor XR is indicated for the treatment of Social Anxiety Disorder, also known as Social Phobia, as defined in DSM-IV (300.23). Social Anxiety Disorder (DSM-IV) is characterized by a marked and persistent fear of 1 or more social or performance situations in which the person is exposed to unfamiliar people or to possible scrutiny by others. Exposure to the feared situation almost invariably provokes anxiety, which may approach the intensity of a panic attack. The feared situations are avoided or endured with intense anxiety or distress. The avoidance, anxious anticipation, or distress in the feared situation(s) interferes significantly with the person's normal routine, occupational or academic functioning, or social activities or relationships, or there is a marked distress about having the phobias. Lesser degrees of performance anxiety or shyness generally do not require psychopharmacological treatment. The efficacy of Effexor XR in the treatment of Social Anxiety Disorder was established in four 12-week and one 6-month placebo-controlled trials in adult outpatients with Social Anxiety Disorder (DSM-IV) (see Clinical Trials ). Although the effectiveness of Effexor XR has been demonstrated in a 6-month clinical trial in patients with Social Anxiety Disorder, the physician who elects to use Effexor XR for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION ). Panic Disorder Effexor XR is indicated for the treatment of panic disorder, with or without agoraphobia, as defined in DSM-IV. Panic disorder is characterized by the occurrence of unexpected panic attacks and associated concern about having additional attacks, worry about the implications or consequences of the attacks, and/or a significant change in behavior related to the attacks. Panic disorder (DSM-IV) is characterized by recurrent, unexpected panic attacks, ie, a discrete period of intense fear or discomfort, in which four (or more) of the following symptoms develop abruptly and reach a peak within 10 minutes: 1) palpitations, pounding heart, or accelerated heart rate; 2) sweating; 3) trembling or shaking; 4) sensations of shortness of breath or smothering; 5) feeling of choking; 6) chest pain or discomfort; 7) nausea or abdominal distress; 8) feeling dizzy, unsteady, lightheaded, or faint; 9) derealization (feelings of unreality) or depersonalization (being detached from oneself); 10) fear of losing control; 11) fear of dying; 12) paresthesias (numbness or tingling sensations); 13) chills or hot flushes. The efficacy of Effexor XR in the treatment of panic disorder was established in two 12-week placebo-controlled trials in adult outpatients with panic disorder (DSM-IV). The efficacy of Effexor XR in prolonging time to relapse in panic disorder among responders following 12 weeks of open-label acute treatment was demonstrated in a placebo-controlled study (see CLINICAL PHARMACOLOGY, Clinical Trials ). Nevertheless, the physician who elects to use Effexor XR for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION ). uuid:d01b26fa-e408-4b0f-ad1f-1d5c5e668f78 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9943 biolink:treats MONDO:0005383 PMID:41385096 "[{""id"":""uuid:5ba353d2-4b6b-452f-8e2b-3c4acbbed8c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d3acc69d-fb90-4614-af7c-393e23882e10"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Major Depressive Disorder Effexor XR (venlafaxine hydrochloride) extended-release capsules is indicated for the treatment of major depressive disorder. The efficacy of Effexor XR in the treatment of major depressive disorder was established in 8- and 12-week controlled trials of adult outpatients whose diagnoses corresponded most closely to the DSM-III-R or DSM-IV category of major depressive disorder (see Clinical Trials ). A major depressive episode (DSM-IV) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed mood or the loss of interest or pleasure in nearly all activities, representing a change from previous functioning, and includes the presence of at least five of the following nine symptoms during the same two-week period: depressed mood, markedly diminished interest or pleasure in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. The efficacy of Effexor (immediate release) in the treatment of major depressive disorder in adult inpatients meeting diagnostic criteria for major depressive disorder with melancholia was established in a 4-week controlled trial (see Clinical Trials ). The safety and efficacy of Effexor XR in hospitalized depressed patients have not been adequately studied. The efficacy of Effexor XR in maintaining a response in major depressive disorder for up to 26 weeks following 8 weeks of acute treatment was demonstrated in a placebo-controlled trial. The efficacy of Effexor (immediate release) in maintaining a response in patients with recurrent major depressive disorder who had responded and continued to be improved during an initial 26 weeks of treatment and were then followed for a period of up to 52 weeks was demonstrated in a second placebo-controlled trial (see Clinical Trials ). Nevertheless, the physician who elects to use Effexor/Effexor XR for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION ). Generalized Anxiety Disorder Effexor XR is indicated for the treatment of Generalized Anxiety Disorder (GAD) as defined in DSM-IV. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The efficacy of Effexor XR in the treatment of GAD was established in 8-week and 6-month placebo-controlled trials in adult outpatients diagnosed with GAD according to DSM-IV criteria (see Clinical Trials ). Generalized Anxiety Disorder (DSM-IV) is characterized by excessive anxiety and worry (apprehensive expectation) that is persistent for at least 6 months and which the person finds difficult to control. It must be associated with at least 3 of the following 6 symptoms: restlessness or feeling keyed up or on edge, being easily fatigued, difficulty concentrating or mind going blank, irritability, muscle tension, sleep disturbance. Although the effectiveness of Effexor XR has been demonstrated in 6-month clinical trials in patients with GAD, the physician who elects to use Effexor XR for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION ). Social Anxiety Disorder Effexor XR is indicated for the treatment of Social Anxiety Disorder, also known as Social Phobia, as defined in DSM-IV (300.23). Social Anxiety Disorder (DSM-IV) is characterized by a marked and persistent fear of 1 or more social or performance situations in which the person is exposed to unfamiliar people or to possible scrutiny by others. Exposure to the feared situation almost invariably provokes anxiety, which may approach the intensity of a panic attack. The feared situations are avoided or endured with intense anxiety or distress. The avoidance, anxious anticipation, or distress in the feared situation(s) interferes significantly with the person's normal routine, occupational or academic functioning, or social activities or relationships, or there is a marked distress about having the phobias. Lesser degrees of performance anxiety or shyness generally do not require psychopharmacological treatment. The efficacy of Effexor XR in the treatment of Social Anxiety Disorder was established in four 12-week and one 6-month placebo-controlled trials in adult outpatients with Social Anxiety Disorder (DSM-IV) (see Clinical Trials ). Although the effectiveness of Effexor XR has been demonstrated in a 6-month clinical trial in patients with Social Anxiety Disorder, the physician who elects to use Effexor XR for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION ). Panic Disorder Effexor XR is indicated for the treatment of panic disorder, with or without agoraphobia, as defined in DSM-IV. Panic disorder is characterized by the occurrence of unexpected panic attacks and associated concern about having additional attacks, worry about the implications or consequences of the attacks, and/or a significant change in behavior related to the attacks. Panic disorder (DSM-IV) is characterized by recurrent, unexpected panic attacks, ie, a discrete period of intense fear or discomfort, in which four (or more) of the following symptoms develop abruptly and reach a peak within 10 minutes: 1) palpitations, pounding heart, or accelerated heart rate; 2) sweating; 3) trembling or shaking; 4) sensations of shortness of breath or smothering; 5) feeling of choking; 6) chest pain or discomfort; 7) nausea or abdominal distress; 8) feeling dizzy, unsteady, lightheaded, or faint; 9) derealization (feelings of unreality) or depersonalization (being detached from oneself); 10) fear of losing control; 11) fear of dying; 12) paresthesias (numbness or tingling sensations); 13) chills or hot flushes. The efficacy of Effexor XR in the treatment of panic disorder was established in two 12-week placebo-controlled trials in adult outpatients with panic disorder (DSM-IV). The efficacy of Effexor XR in prolonging time to relapse in panic disorder among responders following 12 weeks of open-label acute treatment was demonstrated in a placebo-controlled study (see CLINICAL PHARMACOLOGY, Clinical Trials ). Nevertheless, the physician who elects to use Effexor XR for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION ). uuid:55a41eac-43a9-4531-97e2-d0531affb8e8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9943 biolink:treats MONDO:0044144 PMID:41385096 "[{""id"":""uuid:5fd8773e-72d5-4854-afa2-63685c75adea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:050921c9-4f01-414f-931d-3eb4c5dc372b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Major Depressive Disorder Effexor XR (venlafaxine hydrochloride) extended-release capsules is indicated for the treatment of major depressive disorder. The efficacy of Effexor XR in the treatment of major depressive disorder was established in 8- and 12-week controlled trials of adult outpatients whose diagnoses corresponded most closely to the DSM-III-R or DSM-IV category of major depressive disorder (see Clinical Trials ). A major depressive episode (DSM-IV) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed mood or the loss of interest or pleasure in nearly all activities, representing a change from previous functioning, and includes the presence of at least five of the following nine symptoms during the same two-week period: depressed mood, markedly diminished interest or pleasure in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. The efficacy of Effexor (immediate release) in the treatment of major depressive disorder in adult inpatients meeting diagnostic criteria for major depressive disorder with melancholia was established in a 4-week controlled trial (see Clinical Trials ). The safety and efficacy of Effexor XR in hospitalized depressed patients have not been adequately studied. The efficacy of Effexor XR in maintaining a response in major depressive disorder for up to 26 weeks following 8 weeks of acute treatment was demonstrated in a placebo-controlled trial. The efficacy of Effexor (immediate release) in maintaining a response in patients with recurrent major depressive disorder who had responded and continued to be improved during an initial 26 weeks of treatment and were then followed for a period of up to 52 weeks was demonstrated in a second placebo-controlled trial (see Clinical Trials ). Nevertheless, the physician who elects to use Effexor/Effexor XR for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION ). Generalized Anxiety Disorder Effexor XR is indicated for the treatment of Generalized Anxiety Disorder (GAD) as defined in DSM-IV. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The efficacy of Effexor XR in the treatment of GAD was established in 8-week and 6-month placebo-controlled trials in adult outpatients diagnosed with GAD according to DSM-IV criteria (see Clinical Trials ). Generalized Anxiety Disorder (DSM-IV) is characterized by excessive anxiety and worry (apprehensive expectation) that is persistent for at least 6 months and which the person finds difficult to control. It must be associated with at least 3 of the following 6 symptoms: restlessness or feeling keyed up or on edge, being easily fatigued, difficulty concentrating or mind going blank, irritability, muscle tension, sleep disturbance. Although the effectiveness of Effexor XR has been demonstrated in 6-month clinical trials in patients with GAD, the physician who elects to use Effexor XR for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION ). Social Anxiety Disorder Effexor XR is indicated for the treatment of Social Anxiety Disorder, also known as Social Phobia, as defined in DSM-IV (300.23). Social Anxiety Disorder (DSM-IV) is characterized by a marked and persistent fear of 1 or more social or performance situations in which the person is exposed to unfamiliar people or to possible scrutiny by others. Exposure to the feared situation almost invariably provokes anxiety, which may approach the intensity of a panic attack. The feared situations are avoided or endured with intense anxiety or distress. The avoidance, anxious anticipation, or distress in the feared situation(s) interferes significantly with the person's normal routine, occupational or academic functioning, or social activities or relationships, or there is a marked distress about having the phobias. Lesser degrees of performance anxiety or shyness generally do not require psychopharmacological treatment. The efficacy of Effexor XR in the treatment of Social Anxiety Disorder was established in four 12-week and one 6-month placebo-controlled trials in adult outpatients with Social Anxiety Disorder (DSM-IV) (see Clinical Trials ). Although the effectiveness of Effexor XR has been demonstrated in a 6-month clinical trial in patients with Social Anxiety Disorder, the physician who elects to use Effexor XR for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION ). Panic Disorder Effexor XR is indicated for the treatment of panic disorder, with or without agoraphobia, as defined in DSM-IV. Panic disorder is characterized by the occurrence of unexpected panic attacks and associated concern about having additional attacks, worry about the implications or consequences of the attacks, and/or a significant change in behavior related to the attacks. Panic disorder (DSM-IV) is characterized by recurrent, unexpected panic attacks, ie, a discrete period of intense fear or discomfort, in which four (or more) of the following symptoms develop abruptly and reach a peak within 10 minutes: 1) palpitations, pounding heart, or accelerated heart rate; 2) sweating; 3) trembling or shaking; 4) sensations of shortness of breath or smothering; 5) feeling of choking; 6) chest pain or discomfort; 7) nausea or abdominal distress; 8) feeling dizzy, unsteady, lightheaded, or faint; 9) derealization (feelings of unreality) or depersonalization (being detached from oneself); 10) fear of losing control; 11) fear of dying; 12) paresthesias (numbness or tingling sensations); 13) chills or hot flushes. The efficacy of Effexor XR in the treatment of panic disorder was established in two 12-week placebo-controlled trials in adult outpatients with panic disorder (DSM-IV). The efficacy of Effexor XR in prolonging time to relapse in panic disorder among responders following 12 weeks of open-label acute treatment was demonstrated in a placebo-controlled study (see CLINICAL PHARMACOLOGY, Clinical Trials ). Nevertheless, the physician who elects to use Effexor XR for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION ). uuid:66eb061d-c6ce-4155-b55b-aecb5266ef7f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8024 biolink:treats MONDO:0021661 PMID:41385096 "[{""id"":""uuid:6a37a476-23c5-4002-8e8d-e63f8237bbee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:93e72311-1d68-498e-a4c7-0174bc35588b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Stable Coronary Artery Disease Perindopril erbumine tablets are indicated in patients with stable coronary artery disease to reduce the risk of cardiovascular mortality or non-fatal myocardial infarction. Perindopril erbumine tablets can be used with conventional treatment for management of coronary artery disease, such as antiplatelet, antihypertensive or lipid-lowering therapy. Hypertension Perindopril erbumine tablets are indicated for the treatment of patients with essential hypertension. Perindopril erbumine tablets may be used alone or given with other classes of antihypertensives, especially thiazide diuretics. When using perindopril erbumine tablets, consideration should be given to the fact that another angiotensin converting enzyme inhibitor (captopril) has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease. Available data are insufficient to determine whether perindopril erbumine tablets has a similar potential. (See WARNINGS .) In considering use of perindopril erbumine tablets, it should be noted that in controlled trials ACE inhibitors have an effect on blood pressure that is less in black patients than in nonblacks. In addition, it should be noted that black patients receiving ACE inhibitor monotherapy have been reported to have a higher incidence of angioedema compared to nonblacks. (See WARNINGS : Head and Neck Angioedema .) uuid:e98da6bb-70fb-4c94-8d69-5ab0b403f381 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8024 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:702f5fab-5a3f-4dd0-97a8-e5887bca85bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:47c5bf70-f4f6-4658-9610-6e10050ee6aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Stable Coronary Artery Disease Perindopril erbumine tablets are indicated in patients with stable coronary artery disease to reduce the risk of cardiovascular mortality or non-fatal myocardial infarction. Perindopril erbumine tablets can be used with conventional treatment for management of coronary artery disease, such as antiplatelet, antihypertensive or lipid-lowering therapy. Hypertension Perindopril erbumine tablets are indicated for the treatment of patients with essential hypertension. Perindopril erbumine tablets may be used alone or given with other classes of antihypertensives, especially thiazide diuretics. When using perindopril erbumine tablets, consideration should be given to the fact that another angiotensin converting enzyme inhibitor (captopril) has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease. Available data are insufficient to determine whether perindopril erbumine tablets has a similar potential. (See WARNINGS .) In considering use of perindopril erbumine tablets, it should be noted that in controlled trials ACE inhibitors have an effect on blood pressure that is less in black patients than in nonblacks. In addition, it should be noted that black patients receiving ACE inhibitor monotherapy have been reported to have a higher incidence of angioedema compared to nonblacks. (See WARNINGS : Head and Neck Angioedema .) uuid:75a3d2f1-8e7b-42bb-8486-d02c1c00a934 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8024 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:65565ac3-8341-43fe-acb7-76d3c123d715"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cfa5e756-d556-4b8f-b3f6-3956012683d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Stable Coronary Artery Disease Perindopril erbumine tablets are indicated in patients with stable coronary artery disease to reduce the risk of cardiovascular mortality or non-fatal myocardial infarction. Perindopril erbumine tablets can be used with conventional treatment for management of coronary artery disease, such as antiplatelet, antihypertensive or lipid-lowering therapy. Hypertension Perindopril erbumine tablets are indicated for the treatment of patients with essential hypertension. Perindopril erbumine tablets may be used alone or given with other classes of antihypertensives, especially thiazide diuretics. When using perindopril erbumine tablets, consideration should be given to the fact that another angiotensin converting enzyme inhibitor (captopril) has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease. Available data are insufficient to determine whether perindopril erbumine tablets has a similar potential. (See WARNINGS .) In considering use of perindopril erbumine tablets, it should be noted that in controlled trials ACE inhibitors have an effect on blood pressure that is less in black patients than in nonblacks. In addition, it should be noted that black patients receiving ACE inhibitor monotherapy have been reported to have a higher incidence of angioedema compared to nonblacks. (See WARNINGS : Head and Neck Angioedema .) uuid:2908d9bc-f012-47a0-8cf7-8ceb52b6007f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8024 biolink:treats MONDO:0001134 PMID:41385096 "[{""id"":""uuid:53f60df0-c7c4-4b10-9e0c-d4e366ff364e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3cb7b65c-aa8d-48f2-9dfc-ccb900c29607"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Stable Coronary Artery Disease Perindopril erbumine tablets are indicated in patients with stable coronary artery disease to reduce the risk of cardiovascular mortality or non-fatal myocardial infarction. Perindopril erbumine tablets can be used with conventional treatment for management of coronary artery disease, such as antiplatelet, antihypertensive or lipid-lowering therapy. Hypertension Perindopril erbumine tablets are indicated for the treatment of patients with essential hypertension. Perindopril erbumine tablets may be used alone or given with other classes of antihypertensives, especially thiazide diuretics. When using perindopril erbumine tablets, consideration should be given to the fact that another angiotensin converting enzyme inhibitor (captopril) has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease. Available data are insufficient to determine whether perindopril erbumine tablets has a similar potential. (See WARNINGS .) In considering use of perindopril erbumine tablets, it should be noted that in controlled trials ACE inhibitors have an effect on blood pressure that is less in black patients than in nonblacks. In addition, it should be noted that black patients receiving ACE inhibitor monotherapy have been reported to have a higher incidence of angioedema compared to nonblacks. (See WARNINGS : Head and Neck Angioedema .) uuid:55a40021-6a64-4703-9389-4d998891ec08 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8024 biolink:treats MONDO:0001609 PMID:41385096 "[{""id"":""uuid:f698ca7c-58ab-4ef8-aa6d-c6595a559115"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:84053196-f24e-4698-8d1f-b22908563f50"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Stable Coronary Artery Disease Perindopril erbumine tablets are indicated in patients with stable coronary artery disease to reduce the risk of cardiovascular mortality or non-fatal myocardial infarction. Perindopril erbumine tablets can be used with conventional treatment for management of coronary artery disease, such as antiplatelet, antihypertensive or lipid-lowering therapy. Hypertension Perindopril erbumine tablets are indicated for the treatment of patients with essential hypertension. Perindopril erbumine tablets may be used alone or given with other classes of antihypertensives, especially thiazide diuretics. When using perindopril erbumine tablets, consideration should be given to the fact that another angiotensin converting enzyme inhibitor (captopril) has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease. Available data are insufficient to determine whether perindopril erbumine tablets has a similar potential. (See WARNINGS .) In considering use of perindopril erbumine tablets, it should be noted that in controlled trials ACE inhibitors have an effect on blood pressure that is less in black patients than in nonblacks. In addition, it should be noted that black patients receiving ACE inhibitor monotherapy have been reported to have a higher incidence of angioedema compared to nonblacks. (See WARNINGS : Head and Neck Angioedema .) uuid:e1424b1e-9560-4bae-8c47-02b6a1d52d2d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8024 biolink:treats MONDO:0001343 PMID:41385096 "[{""id"":""uuid:c6b0b6a1-26bc-41d4-b3ee-60e086d9eaaa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aa89274c-30cb-4896-af4d-ba72466187db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Stable Coronary Artery Disease Perindopril erbumine tablets are indicated in patients with stable coronary artery disease to reduce the risk of cardiovascular mortality or non-fatal myocardial infarction. Perindopril erbumine tablets can be used with conventional treatment for management of coronary artery disease, such as antiplatelet, antihypertensive or lipid-lowering therapy. Hypertension Perindopril erbumine tablets are indicated for the treatment of patients with essential hypertension. Perindopril erbumine tablets may be used alone or given with other classes of antihypertensives, especially thiazide diuretics. When using perindopril erbumine tablets, consideration should be given to the fact that another angiotensin converting enzyme inhibitor (captopril) has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease. Available data are insufficient to determine whether perindopril erbumine tablets has a similar potential. (See WARNINGS .) In considering use of perindopril erbumine tablets, it should be noted that in controlled trials ACE inhibitors have an effect on blood pressure that is less in black patients than in nonblacks. In addition, it should be noted that black patients receiving ACE inhibitor monotherapy have been reported to have a higher incidence of angioedema compared to nonblacks. (See WARNINGS : Head and Neck Angioedema .) uuid:03c14b46-6fa0-4747-a2ea-6950564c6257 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8024 biolink:treats MONDO:0010481 PMID:41385096 "[{""id"":""uuid:019be501-5b33-47b8-889e-c803d650bc23"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:80e094f2-eb8e-4484-813e-5bce84d1742d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Stable Coronary Artery Disease Perindopril erbumine tablets are indicated in patients with stable coronary artery disease to reduce the risk of cardiovascular mortality or non-fatal myocardial infarction. Perindopril erbumine tablets can be used with conventional treatment for management of coronary artery disease, such as antiplatelet, antihypertensive or lipid-lowering therapy. Hypertension Perindopril erbumine tablets are indicated for the treatment of patients with essential hypertension. Perindopril erbumine tablets may be used alone or given with other classes of antihypertensives, especially thiazide diuretics. When using perindopril erbumine tablets, consideration should be given to the fact that another angiotensin converting enzyme inhibitor (captopril) has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease. Available data are insufficient to determine whether perindopril erbumine tablets has a similar potential. (See WARNINGS .) In considering use of perindopril erbumine tablets, it should be noted that in controlled trials ACE inhibitors have an effect on blood pressure that is less in black patients than in nonblacks. In addition, it should be noted that black patients receiving ACE inhibitor monotherapy have been reported to have a higher incidence of angioedema compared to nonblacks. (See WARNINGS : Head and Neck Angioedema .) uuid:0a241a79-882e-4b31-890c-acaaf87d16d0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17347 biolink:treats MONDO:0009047 PMID:41385096 "[{""id"":""uuid:ae7817d1-6ee0-4ad7-9972-b98f66bf8e14"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:25a5b730-3b02-4ed2-8f6c-879a1125f403"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Testim ® is indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired): testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter's syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone levels and gonadotropins (FSH, LH) above the normal range. Hypogonadotropic hypogonadism (congenital or acquired): idiopathic gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation. These men have low testosterone serum levels but have gonadotropins in the normal or low range. Testim ® has not been clinically evaluated in males under 18 years of age. uuid:d2749b69-ca37-45c4-9ac1-5e1085d63f19 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17347 biolink:treats MONDO:0008573 PMID:41385096 "[{""id"":""uuid:911fc3c2-f7d7-4dfe-ba47-03b2429ba034"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5e1ce1f1-c58b-4b3b-9f84-b8e03ddc3bbb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Testim ® is indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired): testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter's syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone levels and gonadotropins (FSH, LH) above the normal range. Hypogonadotropic hypogonadism (congenital or acquired): idiopathic gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation. These men have low testosterone serum levels but have gonadotropins in the normal or low range. Testim ® has not been clinically evaluated in males under 18 years of age. uuid:6109db94-1ceb-4287-8151-c895fb1b4c78 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17347 biolink:treats MONDO:0006882 PMID:41385096 "[{""id"":""uuid:595239ce-8a2b-40e6-9a04-1b40baa4175a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b9e67434-ff41-4f41-aa81-3cdc8b0eed51"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Testim ® is indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired): testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter's syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone levels and gonadotropins (FSH, LH) above the normal range. Hypogonadotropic hypogonadism (congenital or acquired): idiopathic gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation. These men have low testosterone serum levels but have gonadotropins in the normal or low range. Testim ® has not been clinically evaluated in males under 18 years of age. uuid:71bde8e1-00ed-404d-a405-2073b054a0d2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47381 biolink:treats MONDO:1060206 PMID:41385096 "[{""id"":""uuid:5b992664-506e-434b-b699-0e66ceee356f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b70165ad-ed92-4855-8fd7-3f30fdb21ed1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Carefully consider the potential benefits and risks of diclofenac potassium immediate-release tablets and other treatment options before deciding to use diclofenac potassium immediate-release tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS). Diclofenac potassium immediate-release tablets are indicated: For treatment of primary dysmenorrhea For relief of mild to moderate pain For relief of the signs and symptoms of osteoarthritis For relief of the signs and symptoms of rheumatoid arthritis UMLS:C0149875 uuid:488b7c1d-1082-4f12-8c9f-f701ae2c02cf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47381 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:8075dc81-7f41-4bbd-b521-3cbfc4c9d161"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:464e1d74-7261-4aef-b19e-9728ba9f2464"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Carefully consider the potential benefits and risks of diclofenac potassium immediate-release tablets and other treatment options before deciding to use diclofenac potassium immediate-release tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS). Diclofenac potassium immediate-release tablets are indicated: For treatment of primary dysmenorrhea For relief of mild to moderate pain For relief of the signs and symptoms of osteoarthritis For relief of the signs and symptoms of rheumatoid arthritis uuid:3afa1ce4-0b93-47f0-baf5-51444dde3497 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47381 biolink:treats MONDO:0005306 PMID:41385096 "[{""id"":""uuid:292f95d3-aca1-48b3-89e0-0b7d79abcc05"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f77ed670-a443-4875-abf6-c5af71cd33c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Carefully consider the potential benefits and risks of diclofenac sodium delayed-release tablets and other treatment options before deciding to use diclofenac sodium delayed-release tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Diclofenac sodium delayed-release tablets, are indicated: For relief of signs and symptoms of osteoarthritis For relief of signs and symptoms of rheumatoid arthritis For acute or long-term use in the relief of signs and symptoms of ankylosing spondylitis uuid:e41c1004-c725-43d8-a955-e41bc37423b0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:36791 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:640a03cc-2a78-4c5a-85be-79a591122665"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2e8865a5-f85b-45e4-82b6-d2a8df0f729f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Major Depressive Disorder Lexapro (escitalopram) is indicated for the acute and maintenance treatment of major depressive disorder in adults and in adolescents 12 to 17 years of age [ see Clinical Studies ( 14.1 ) ]. A major depressive episode (DSM-IV) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least five of the following nine symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. 1.2 Generalized Anxiety Disorder Lexapro is indicated for the acute treatment of Generalized Anxiety Disorder (GAD) in adults [ see Clinical Studies ( 14.2 ) ]. Generalized Anxiety Disorder (DSM-IV) is characterized by excessive anxiety and worry (apprehensive expectation) that is persistent for at least 6 months and which the person finds difficult to control. It must be associated with at least 3 of the following symptoms: restlessness or feeling keyed up or on edge, being easily fatigued, difficulty concentrating or mind going blank, irritability, muscle tension, and sleep disturbance. uuid:364cbe5b-3619-4b49-8f63-25eda77a24cb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:36791 biolink:treats MONDO:0001942 PMID:41385096 "[{""id"":""uuid:3760d6fd-72f3-4a6a-ae5f-71766d58587b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1a107b42-d528-41ee-ab99-5e431cbee823"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Major Depressive Disorder Lexapro (escitalopram) is indicated for the acute and maintenance treatment of major depressive disorder in adults and in adolescents 12 to 17 years of age [ see Clinical Studies ( 14.1 ) ]. A major depressive episode (DSM-IV) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least five of the following nine symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. 1.2 Generalized Anxiety Disorder Lexapro is indicated for the acute treatment of Generalized Anxiety Disorder (GAD) in adults [ see Clinical Studies ( 14.2 ) ]. Generalized Anxiety Disorder (DSM-IV) is characterized by excessive anxiety and worry (apprehensive expectation) that is persistent for at least 6 months and which the person finds difficult to control. It must be associated with at least 3 of the following symptoms: restlessness or feeling keyed up or on edge, being easily fatigued, difficulty concentrating or mind going blank, irritability, muscle tension, and sleep disturbance. uuid:aaaed45d-7919-4523-9fa1-f789cf363f58 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:3081207 biolink:treats HP:0012228 PMID:41385096 "[{""id"":""uuid:33114792-289f-4bf6-a2c9-c80de1ef6be3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c3de2b08-b225-4dae-a78c-ce765fdfd7dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules is indicated for the relief of the symptom complex of tension (or muscle contraction) headache. Evidence supporting the efficacy and safety of Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules in the treatment of multiple recurrent headaches is unavailable. Caution in this regard is required because codeine and butalbital are habit-forming and potentially abusable. uuid:99e57739-a878-41e0-8418-8d850cf513e2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63618 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:e50a9c04-829e-4391-8f77-3341461bfc39"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:136e8410-ff8e-41c8-a586-12b61ba18359"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with pravastatin sodium tablets should be considered in those individuals at increased risk for atherosclerosis-related clinical events as a function of cholesterol level, the presence or absence of coronary heart disease, and other risk factors. Primary Prevention of Coronary Events In hypercholesterolemic patients without clinically evident coronary heart disease, pravastatin sodium tablets are indicated to: - Reduce the risk of myocardial infarction - Reduce the risk of undergoing myocardial revascularization procedures - Reduce the risk of cardiovascular mortality with no increase in death from non-cardiovascular causes Hyperlipidemia Pravastatin sodium tablets are indicated as an adjunct to diet to reduce elevated Total-C, LDL-C, ApoB, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson Type IIa and IIb). 6 Pravastatin sodium tablets are indicated as adjunctive therapy to diet for the treatment of patients with elevated serum triglyceride levels (Fredrickson Type IV). Pravastatin sodium tablets are indicated for the treatment of patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet. Pravastatin sodium tablets are indicated as an adjunct to diet and lifestyle modification for treatment of HeFH in children and adolescent patients ages 8 years and older if after an adequate trial of diet the following findings are present: LDL-C remains greater than or equal to 190 mg/dL or LDL-C remains greater than or equal to 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the patient. Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when the response to diet and other nonpharmacological measures alone has been inadequate (see NCEP Treatment Guidelines below). Prior to initiating therapy with pravastatin, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure Total-C, HDL-C, and TG. For patients with triglycerides (TG) less than 400 mg/dL (less than 4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = Total-C - HDL-C - 1/5 TG For TG levels greater than 400 mg/dL (greater than 4.5 mmol/L), this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In many hypertriglyceridemic patients, LDL-C may be low or normal despite elevated Total-C. In such cases, HMG-CoA reductase inhibitors are not indicated. Lipid determinations should be performed at intervals of no less than four weeks and dosage adjusted according to the patient’s response to therapy. The National Cholesterol Education Program’s Treatment Guidelines are summarized below: Table 5: NCEP Treatment Guidelines: LDL-C Goals and Cutpoints for Therapeutic Lifestyle Changes and Drug Therapy in Different Risk Categories Risk Category LDL Goal (mg/dL) LDL Level at Which to Initiate Therapeutic Lifestyle Changes (mg/dL) LDL Level at Which to Consider Drug Therapy (mg/dL) CHD a or CHD risk equivalents (10 year risk greater than 20%) less than 100 greater than or equal to 100 greater than or equal to 130 (100 to 129: drug optional) b 2+ Risk factors (10 year risk less than or equal to 20%) less than 130 greater than or equal to 130 10 year risk 10% to 20%: greater than 130 10 year risk less than 10%: greater than or equal to 160 0 to 1 Risk factor c less than 160 greater than or equal to 160 greater than or equal to 190 (160 to 189: LDL- lowering drug optional) a CHD, coronary heart disease. b Some authorities recommend use of LDL-lowering drugs in this category if an LDL-C level of less than 100 mg/dL cannot be achieved by therapeutic lifestyle changes. Others prefer use of drugs that primarily modify triglycerides and HDL-C, e.g., nicotinic acid or fibrate. Clinical judgement also may call for deferring drug therapy in this subcategory. c Almost all people with 0 to 1 risk factor have 10 year risk less than 10%; thus, 10 year risk assessment in people with 0 to 1 risk factor is not necessary. After the LDL-C goal has been achieved, if the TG is still greater than or equal to 200 mg/dL, non-HDL-C (Total-C minus HDL-C) becomes a secondary target of therapy. Non-HDL-C goals are set 30 mg/dL higher than LDL-C goals for each risk category. At the time of hospitalization for an acute coronary event, consideration can be given to initiating drug therapy at discharge if the LDL-C is greater than or equal to 130 mg/dL (see NCEP Treatment Guidelines , above). Since the goal of treatment is to lower LDL-C, the NCEP recommends that LDL-C levels be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the Total-C be used to monitor therapy. As with other lipid-lowering therapy, pravastatin sodium tablets are not indicated when hypercholesterolemia is due to hyperalphalipoproteinemia (elevated HDL-C). The NCEP classification of cholesterol levels in pediatric patients with a familial history of hypercholesterolemia or premature cardiovascular disease is summarized below: Category Total-C (mg/dL) LDL-C (mg/dL) Acceptable less than 170 less than 110 Borderline 170 to 199 110 to 129 High greater than or equal to200 greater than or equal to 130 uuid:7a6763d3-5797-459f-82b1-cc457540b8b7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63618 biolink:treats HP:0003124 PMID:41385096 "[{""id"":""uuid:580635c3-c7bc-4471-9f4b-6d8d1780a16b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:38bf029e-aeab-401c-b659-c11fa07f8542"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with pravastatin sodium tablets should be considered in those individuals at increased risk for atherosclerosis-related clinical events as a function of cholesterol level, the presence or absence of coronary heart disease, and other risk factors. Primary Prevention of Coronary Events In hypercholesterolemic patients without clinically evident coronary heart disease, pravastatin sodium tablets are indicated to: - Reduce the risk of myocardial infarction - Reduce the risk of undergoing myocardial revascularization procedures - Reduce the risk of cardiovascular mortality with no increase in death from non-cardiovascular causes Hyperlipidemia Pravastatin sodium tablets are indicated as an adjunct to diet to reduce elevated Total-C, LDL-C, ApoB, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson Type IIa and IIb). 6 Pravastatin sodium tablets are indicated as adjunctive therapy to diet for the treatment of patients with elevated serum triglyceride levels (Fredrickson Type IV). Pravastatin sodium tablets are indicated for the treatment of patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet. Pravastatin sodium tablets are indicated as an adjunct to diet and lifestyle modification for treatment of HeFH in children and adolescent patients ages 8 years and older if after an adequate trial of diet the following findings are present: LDL-C remains greater than or equal to 190 mg/dL or LDL-C remains greater than or equal to 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the patient. Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when the response to diet and other nonpharmacological measures alone has been inadequate (see NCEP Treatment Guidelines below). Prior to initiating therapy with pravastatin, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure Total-C, HDL-C, and TG. For patients with triglycerides (TG) less than 400 mg/dL (less than 4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = Total-C - HDL-C - 1/5 TG For TG levels greater than 400 mg/dL (greater than 4.5 mmol/L), this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In many hypertriglyceridemic patients, LDL-C may be low or normal despite elevated Total-C. In such cases, HMG-CoA reductase inhibitors are not indicated. Lipid determinations should be performed at intervals of no less than four weeks and dosage adjusted according to the patient’s response to therapy. The National Cholesterol Education Program’s Treatment Guidelines are summarized below: Table 5: NCEP Treatment Guidelines: LDL-C Goals and Cutpoints for Therapeutic Lifestyle Changes and Drug Therapy in Different Risk Categories Risk Category LDL Goal (mg/dL) LDL Level at Which to Initiate Therapeutic Lifestyle Changes (mg/dL) LDL Level at Which to Consider Drug Therapy (mg/dL) CHD a or CHD risk equivalents (10 year risk greater than 20%) less than 100 greater than or equal to 100 greater than or equal to 130 (100 to 129: drug optional) b 2+ Risk factors (10 year risk less than or equal to 20%) less than 130 greater than or equal to 130 10 year risk 10% to 20%: greater than 130 10 year risk less than 10%: greater than or equal to 160 0 to 1 Risk factor c less than 160 greater than or equal to 160 greater than or equal to 190 (160 to 189: LDL- lowering drug optional) a CHD, coronary heart disease. b Some authorities recommend use of LDL-lowering drugs in this category if an LDL-C level of less than 100 mg/dL cannot be achieved by therapeutic lifestyle changes. Others prefer use of drugs that primarily modify triglycerides and HDL-C, e.g., nicotinic acid or fibrate. Clinical judgement also may call for deferring drug therapy in this subcategory. c Almost all people with 0 to 1 risk factor have 10 year risk less than 10%; thus, 10 year risk assessment in people with 0 to 1 risk factor is not necessary. After the LDL-C goal has been achieved, if the TG is still greater than or equal to 200 mg/dL, non-HDL-C (Total-C minus HDL-C) becomes a secondary target of therapy. Non-HDL-C goals are set 30 mg/dL higher than LDL-C goals for each risk category. At the time of hospitalization for an acute coronary event, consideration can be given to initiating drug therapy at discharge if the LDL-C is greater than or equal to 130 mg/dL (see NCEP Treatment Guidelines , above). Since the goal of treatment is to lower LDL-C, the NCEP recommends that LDL-C levels be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the Total-C be used to monitor therapy. As with other lipid-lowering therapy, pravastatin sodium tablets are not indicated when hypercholesterolemia is due to hyperalphalipoproteinemia (elevated HDL-C). The NCEP classification of cholesterol levels in pediatric patients with a familial history of hypercholesterolemia or premature cardiovascular disease is summarized below: Category Total-C (mg/dL) LDL-C (mg/dL) Acceptable less than 170 less than 110 Borderline 170 to 199 110 to 129 High greater than or equal to200 greater than or equal to 130 uuid:cfc6c42f-d3da-4336-8c00-364e67cbd7f5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63618 biolink:treats HP:0003119 PMID:41385096 "[{""id"":""uuid:cf8d833b-71fa-45eb-9eb6-cdecaaadb9db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2a3e6c0b-053c-4d9e-b221-ae4aad9b1fa7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with pravastatin sodium tablets should be considered in those individuals at increased risk for atherosclerosis-related clinical events as a function of cholesterol level, the presence or absence of coronary heart disease, and other risk factors. Primary Prevention of Coronary Events In hypercholesterolemic patients without clinically evident coronary heart disease, pravastatin sodium tablets are indicated to: - Reduce the risk of myocardial infarction - Reduce the risk of undergoing myocardial revascularization procedures - Reduce the risk of cardiovascular mortality with no increase in death from non-cardiovascular causes Hyperlipidemia Pravastatin sodium tablets are indicated as an adjunct to diet to reduce elevated Total-C, LDL-C, ApoB, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson Type IIa and IIb). 6 Pravastatin sodium tablets are indicated as adjunctive therapy to diet for the treatment of patients with elevated serum triglyceride levels (Fredrickson Type IV). Pravastatin sodium tablets are indicated for the treatment of patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet. Pravastatin sodium tablets are indicated as an adjunct to diet and lifestyle modification for treatment of HeFH in children and adolescent patients ages 8 years and older if after an adequate trial of diet the following findings are present: LDL-C remains greater than or equal to 190 mg/dL or LDL-C remains greater than or equal to 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the patient. Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when the response to diet and other nonpharmacological measures alone has been inadequate (see NCEP Treatment Guidelines below). Prior to initiating therapy with pravastatin, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure Total-C, HDL-C, and TG. For patients with triglycerides (TG) less than 400 mg/dL (less than 4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = Total-C - HDL-C - 1/5 TG For TG levels greater than 400 mg/dL (greater than 4.5 mmol/L), this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In many hypertriglyceridemic patients, LDL-C may be low or normal despite elevated Total-C. In such cases, HMG-CoA reductase inhibitors are not indicated. Lipid determinations should be performed at intervals of no less than four weeks and dosage adjusted according to the patient’s response to therapy. The National Cholesterol Education Program’s Treatment Guidelines are summarized below: Table 5: NCEP Treatment Guidelines: LDL-C Goals and Cutpoints for Therapeutic Lifestyle Changes and Drug Therapy in Different Risk Categories Risk Category LDL Goal (mg/dL) LDL Level at Which to Initiate Therapeutic Lifestyle Changes (mg/dL) LDL Level at Which to Consider Drug Therapy (mg/dL) CHD a or CHD risk equivalents (10 year risk greater than 20%) less than 100 greater than or equal to 100 greater than or equal to 130 (100 to 129: drug optional) b 2+ Risk factors (10 year risk less than or equal to 20%) less than 130 greater than or equal to 130 10 year risk 10% to 20%: greater than 130 10 year risk less than 10%: greater than or equal to 160 0 to 1 Risk factor c less than 160 greater than or equal to 160 greater than or equal to 190 (160 to 189: LDL- lowering drug optional) a CHD, coronary heart disease. b Some authorities recommend use of LDL-lowering drugs in this category if an LDL-C level of less than 100 mg/dL cannot be achieved by therapeutic lifestyle changes. Others prefer use of drugs that primarily modify triglycerides and HDL-C, e.g., nicotinic acid or fibrate. Clinical judgement also may call for deferring drug therapy in this subcategory. c Almost all people with 0 to 1 risk factor have 10 year risk less than 10%; thus, 10 year risk assessment in people with 0 to 1 risk factor is not necessary. After the LDL-C goal has been achieved, if the TG is still greater than or equal to 200 mg/dL, non-HDL-C (Total-C minus HDL-C) becomes a secondary target of therapy. Non-HDL-C goals are set 30 mg/dL higher than LDL-C goals for each risk category. At the time of hospitalization for an acute coronary event, consideration can be given to initiating drug therapy at discharge if the LDL-C is greater than or equal to 130 mg/dL (see NCEP Treatment Guidelines , above). Since the goal of treatment is to lower LDL-C, the NCEP recommends that LDL-C levels be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the Total-C be used to monitor therapy. As with other lipid-lowering therapy, pravastatin sodium tablets are not indicated when hypercholesterolemia is due to hyperalphalipoproteinemia (elevated HDL-C). The NCEP classification of cholesterol levels in pediatric patients with a familial history of hypercholesterolemia or premature cardiovascular disease is summarized below: Category Total-C (mg/dL) LDL-C (mg/dL) Acceptable less than 170 less than 110 Borderline 170 to 199 110 to 129 High greater than or equal to200 greater than or equal to 130 uuid:023deea3-066a-4fc2-8169-80ab7c611f1f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63618 biolink:treats UMLS:C0342879 PMID:41385096 "[{""id"":""uuid:be29503e-0110-4308-ba14-4726dfb8537c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:999b93a7-a166-4f8c-bfeb-eb97c8d8e78c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with pravastatin sodium tablets should be considered in those individuals at increased risk for atherosclerosis-related clinical events as a function of cholesterol level, the presence or absence of coronary heart disease, and other risk factors. Primary Prevention of Coronary Events In hypercholesterolemic patients without clinically evident coronary heart disease, pravastatin sodium tablets are indicated to: - Reduce the risk of myocardial infarction - Reduce the risk of undergoing myocardial revascularization procedures - Reduce the risk of cardiovascular mortality with no increase in death from non-cardiovascular causes Hyperlipidemia Pravastatin sodium tablets are indicated as an adjunct to diet to reduce elevated Total-C, LDL-C, ApoB, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson Type IIa and IIb). 6 Pravastatin sodium tablets are indicated as adjunctive therapy to diet for the treatment of patients with elevated serum triglyceride levels (Fredrickson Type IV). Pravastatin sodium tablets are indicated for the treatment of patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet. Pravastatin sodium tablets are indicated as an adjunct to diet and lifestyle modification for treatment of HeFH in children and adolescent patients ages 8 years and older if after an adequate trial of diet the following findings are present: LDL-C remains greater than or equal to 190 mg/dL or LDL-C remains greater than or equal to 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the patient. Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when the response to diet and other nonpharmacological measures alone has been inadequate (see NCEP Treatment Guidelines below). Prior to initiating therapy with pravastatin, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure Total-C, HDL-C, and TG. For patients with triglycerides (TG) less than 400 mg/dL (less than 4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = Total-C - HDL-C - 1/5 TG For TG levels greater than 400 mg/dL (greater than 4.5 mmol/L), this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In many hypertriglyceridemic patients, LDL-C may be low or normal despite elevated Total-C. In such cases, HMG-CoA reductase inhibitors are not indicated. Lipid determinations should be performed at intervals of no less than four weeks and dosage adjusted according to the patient’s response to therapy. The National Cholesterol Education Program’s Treatment Guidelines are summarized below: Table 5: NCEP Treatment Guidelines: LDL-C Goals and Cutpoints for Therapeutic Lifestyle Changes and Drug Therapy in Different Risk Categories Risk Category LDL Goal (mg/dL) LDL Level at Which to Initiate Therapeutic Lifestyle Changes (mg/dL) LDL Level at Which to Consider Drug Therapy (mg/dL) CHD a or CHD risk equivalents (10 year risk greater than 20%) less than 100 greater than or equal to 100 greater than or equal to 130 (100 to 129: drug optional) b 2+ Risk factors (10 year risk less than or equal to 20%) less than 130 greater than or equal to 130 10 year risk 10% to 20%: greater than 130 10 year risk less than 10%: greater than or equal to 160 0 to 1 Risk factor c less than 160 greater than or equal to 160 greater than or equal to 190 (160 to 189: LDL- lowering drug optional) a CHD, coronary heart disease. b Some authorities recommend use of LDL-lowering drugs in this category if an LDL-C level of less than 100 mg/dL cannot be achieved by therapeutic lifestyle changes. Others prefer use of drugs that primarily modify triglycerides and HDL-C, e.g., nicotinic acid or fibrate. Clinical judgement also may call for deferring drug therapy in this subcategory. c Almost all people with 0 to 1 risk factor have 10 year risk less than 10%; thus, 10 year risk assessment in people with 0 to 1 risk factor is not necessary. After the LDL-C goal has been achieved, if the TG is still greater than or equal to 200 mg/dL, non-HDL-C (Total-C minus HDL-C) becomes a secondary target of therapy. Non-HDL-C goals are set 30 mg/dL higher than LDL-C goals for each risk category. At the time of hospitalization for an acute coronary event, consideration can be given to initiating drug therapy at discharge if the LDL-C is greater than or equal to 130 mg/dL (see NCEP Treatment Guidelines , above). Since the goal of treatment is to lower LDL-C, the NCEP recommends that LDL-C levels be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the Total-C be used to monitor therapy. As with other lipid-lowering therapy, pravastatin sodium tablets are not indicated when hypercholesterolemia is due to hyperalphalipoproteinemia (elevated HDL-C). The NCEP classification of cholesterol levels in pediatric patients with a familial history of hypercholesterolemia or premature cardiovascular disease is summarized below: Category Total-C (mg/dL) LDL-C (mg/dL) Acceptable less than 170 less than 110 Borderline 170 to 199 110 to 129 High greater than or equal to200 greater than or equal to 130 uuid:a52e15f0-7acb-4508-9ebe-cfe78af6c5b0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63618 biolink:treats MONDO:0018473 PMID:41385096 "[{""id"":""uuid:ee0c8d6a-c712-4a09-9c6e-66e5fbf294d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:06feed8d-4771-43ca-8412-fce97133a695"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with pravastatin sodium tablets should be considered in those individuals at increased risk for atherosclerosis-related clinical events as a function of cholesterol level, the presence or absence of coronary heart disease, and other risk factors. Primary Prevention of Coronary Events In hypercholesterolemic patients without clinically evident coronary heart disease, pravastatin sodium tablets are indicated to: - Reduce the risk of myocardial infarction - Reduce the risk of undergoing myocardial revascularization procedures - Reduce the risk of cardiovascular mortality with no increase in death from non-cardiovascular causes Hyperlipidemia Pravastatin sodium tablets are indicated as an adjunct to diet to reduce elevated Total-C, LDL-C, ApoB, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson Type IIa and IIb). 6 Pravastatin sodium tablets are indicated as adjunctive therapy to diet for the treatment of patients with elevated serum triglyceride levels (Fredrickson Type IV). Pravastatin sodium tablets are indicated for the treatment of patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet. Pravastatin sodium tablets are indicated as an adjunct to diet and lifestyle modification for treatment of HeFH in children and adolescent patients ages 8 years and older if after an adequate trial of diet the following findings are present: LDL-C remains greater than or equal to 190 mg/dL or LDL-C remains greater than or equal to 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the patient. Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when the response to diet and other nonpharmacological measures alone has been inadequate (see NCEP Treatment Guidelines below). Prior to initiating therapy with pravastatin, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure Total-C, HDL-C, and TG. For patients with triglycerides (TG) less than 400 mg/dL (less than 4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = Total-C - HDL-C - 1/5 TG For TG levels greater than 400 mg/dL (greater than 4.5 mmol/L), this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In many hypertriglyceridemic patients, LDL-C may be low or normal despite elevated Total-C. In such cases, HMG-CoA reductase inhibitors are not indicated. Lipid determinations should be performed at intervals of no less than four weeks and dosage adjusted according to the patient’s response to therapy. The National Cholesterol Education Program’s Treatment Guidelines are summarized below: Table 5: NCEP Treatment Guidelines: LDL-C Goals and Cutpoints for Therapeutic Lifestyle Changes and Drug Therapy in Different Risk Categories Risk Category LDL Goal (mg/dL) LDL Level at Which to Initiate Therapeutic Lifestyle Changes (mg/dL) LDL Level at Which to Consider Drug Therapy (mg/dL) CHD a or CHD risk equivalents (10 year risk greater than 20%) less than 100 greater than or equal to 100 greater than or equal to 130 (100 to 129: drug optional) b 2+ Risk factors (10 year risk less than or equal to 20%) less than 130 greater than or equal to 130 10 year risk 10% to 20%: greater than 130 10 year risk less than 10%: greater than or equal to 160 0 to 1 Risk factor c less than 160 greater than or equal to 160 greater than or equal to 190 (160 to 189: LDL- lowering drug optional) a CHD, coronary heart disease. b Some authorities recommend use of LDL-lowering drugs in this category if an LDL-C level of less than 100 mg/dL cannot be achieved by therapeutic lifestyle changes. Others prefer use of drugs that primarily modify triglycerides and HDL-C, e.g., nicotinic acid or fibrate. Clinical judgement also may call for deferring drug therapy in this subcategory. c Almost all people with 0 to 1 risk factor have 10 year risk less than 10%; thus, 10 year risk assessment in people with 0 to 1 risk factor is not necessary. After the LDL-C goal has been achieved, if the TG is still greater than or equal to 200 mg/dL, non-HDL-C (Total-C minus HDL-C) becomes a secondary target of therapy. Non-HDL-C goals are set 30 mg/dL higher than LDL-C goals for each risk category. At the time of hospitalization for an acute coronary event, consideration can be given to initiating drug therapy at discharge if the LDL-C is greater than or equal to 130 mg/dL (see NCEP Treatment Guidelines , above). Since the goal of treatment is to lower LDL-C, the NCEP recommends that LDL-C levels be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the Total-C be used to monitor therapy. As with other lipid-lowering therapy, pravastatin sodium tablets are not indicated when hypercholesterolemia is due to hyperalphalipoproteinemia (elevated HDL-C). The NCEP classification of cholesterol levels in pediatric patients with a familial history of hypercholesterolemia or premature cardiovascular disease is summarized below: Category Total-C (mg/dL) LDL-C (mg/dL) Acceptable less than 170 less than 110 Borderline 170 to 199 110 to 129 High greater than or equal to200 greater than or equal to 130 uuid:292150e1-1c1c-4d76-80a1-659bc0ab5feb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63618 biolink:treats MONDO:0005420 PMID:41385096 "[{""id"":""uuid:f70218aa-9865-4f2e-8a6d-d1a93b8ebcf0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3efa0a35-80de-4a1c-97c7-0a322bf5ad9d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with pravastatin sodium tablets should be considered in those individuals at increased risk for atherosclerosis-related clinical events as a function of cholesterol level, the presence or absence of coronary heart disease, and other risk factors. Primary Prevention of Coronary Events In hypercholesterolemic patients without clinically evident coronary heart disease, pravastatin sodium tablets are indicated to: - Reduce the risk of myocardial infarction - Reduce the risk of undergoing myocardial revascularization procedures - Reduce the risk of cardiovascular mortality with no increase in death from non-cardiovascular causes Hyperlipidemia Pravastatin sodium tablets are indicated as an adjunct to diet to reduce elevated Total-C, LDL-C, ApoB, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson Type IIa and IIb). 6 Pravastatin sodium tablets are indicated as adjunctive therapy to diet for the treatment of patients with elevated serum triglyceride levels (Fredrickson Type IV). Pravastatin sodium tablets are indicated for the treatment of patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet. Pravastatin sodium tablets are indicated as an adjunct to diet and lifestyle modification for treatment of HeFH in children and adolescent patients ages 8 years and older if after an adequate trial of diet the following findings are present: LDL-C remains greater than or equal to 190 mg/dL or LDL-C remains greater than or equal to 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the patient. Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when the response to diet and other nonpharmacological measures alone has been inadequate (see NCEP Treatment Guidelines below). Prior to initiating therapy with pravastatin, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure Total-C, HDL-C, and TG. For patients with triglycerides (TG) less than 400 mg/dL (less than 4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = Total-C - HDL-C - 1/5 TG For TG levels greater than 400 mg/dL (greater than 4.5 mmol/L), this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In many hypertriglyceridemic patients, LDL-C may be low or normal despite elevated Total-C. In such cases, HMG-CoA reductase inhibitors are not indicated. Lipid determinations should be performed at intervals of no less than four weeks and dosage adjusted according to the patient’s response to therapy. The National Cholesterol Education Program’s Treatment Guidelines are summarized below: Table 5: NCEP Treatment Guidelines: LDL-C Goals and Cutpoints for Therapeutic Lifestyle Changes and Drug Therapy in Different Risk Categories Risk Category LDL Goal (mg/dL) LDL Level at Which to Initiate Therapeutic Lifestyle Changes (mg/dL) LDL Level at Which to Consider Drug Therapy (mg/dL) CHD a or CHD risk equivalents (10 year risk greater than 20%) less than 100 greater than or equal to 100 greater than or equal to 130 (100 to 129: drug optional) b 2+ Risk factors (10 year risk less than or equal to 20%) less than 130 greater than or equal to 130 10 year risk 10% to 20%: greater than 130 10 year risk less than 10%: greater than or equal to 160 0 to 1 Risk factor c less than 160 greater than or equal to 160 greater than or equal to 190 (160 to 189: LDL- lowering drug optional) a CHD, coronary heart disease. b Some authorities recommend use of LDL-lowering drugs in this category if an LDL-C level of less than 100 mg/dL cannot be achieved by therapeutic lifestyle changes. Others prefer use of drugs that primarily modify triglycerides and HDL-C, e.g., nicotinic acid or fibrate. Clinical judgement also may call for deferring drug therapy in this subcategory. c Almost all people with 0 to 1 risk factor have 10 year risk less than 10%; thus, 10 year risk assessment in people with 0 to 1 risk factor is not necessary. After the LDL-C goal has been achieved, if the TG is still greater than or equal to 200 mg/dL, non-HDL-C (Total-C minus HDL-C) becomes a secondary target of therapy. Non-HDL-C goals are set 30 mg/dL higher than LDL-C goals for each risk category. At the time of hospitalization for an acute coronary event, consideration can be given to initiating drug therapy at discharge if the LDL-C is greater than or equal to 130 mg/dL (see NCEP Treatment Guidelines , above). Since the goal of treatment is to lower LDL-C, the NCEP recommends that LDL-C levels be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the Total-C be used to monitor therapy. As with other lipid-lowering therapy, pravastatin sodium tablets are not indicated when hypercholesterolemia is due to hyperalphalipoproteinemia (elevated HDL-C). The NCEP classification of cholesterol levels in pediatric patients with a familial history of hypercholesterolemia or premature cardiovascular disease is summarized below: Category Total-C (mg/dL) LDL-C (mg/dL) Acceptable less than 170 less than 110 Borderline 170 to 199 110 to 129 High greater than or equal to200 greater than or equal to 130 uuid:8b49b71c-6ac0-4fc4-adec-824b3f510ff7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63618 biolink:treats MONDO:0005377 PMID:41385096 "[{""id"":""uuid:f9c3e027-9624-42a5-ac04-384fd17b2ba5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:69c253a8-282f-409d-93c6-8114e28aa5b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with pravastatin sodium tablets should be considered in those individuals at increased risk for atherosclerosis-related clinical events as a function of cholesterol level, the presence or absence of coronary heart disease, and other risk factors. Primary Prevention of Coronary Events In hypercholesterolemic patients without clinically evident coronary heart disease, pravastatin sodium tablets are indicated to: - Reduce the risk of myocardial infarction - Reduce the risk of undergoing myocardial revascularization procedures - Reduce the risk of cardiovascular mortality with no increase in death from non-cardiovascular causes Hyperlipidemia Pravastatin sodium tablets are indicated as an adjunct to diet to reduce elevated Total-C, LDL-C, ApoB, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson Type IIa and IIb). 6 Pravastatin sodium tablets are indicated as adjunctive therapy to diet for the treatment of patients with elevated serum triglyceride levels (Fredrickson Type IV). Pravastatin sodium tablets are indicated for the treatment of patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet. Pravastatin sodium tablets are indicated as an adjunct to diet and lifestyle modification for treatment of HeFH in children and adolescent patients ages 8 years and older if after an adequate trial of diet the following findings are present: LDL-C remains greater than or equal to 190 mg/dL or LDL-C remains greater than or equal to 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the patient. Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when the response to diet and other nonpharmacological measures alone has been inadequate (see NCEP Treatment Guidelines below). Prior to initiating therapy with pravastatin, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure Total-C, HDL-C, and TG. For patients with triglycerides (TG) less than 400 mg/dL (less than 4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = Total-C - HDL-C - 1/5 TG For TG levels greater than 400 mg/dL (greater than 4.5 mmol/L), this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In many hypertriglyceridemic patients, LDL-C may be low or normal despite elevated Total-C. In such cases, HMG-CoA reductase inhibitors are not indicated. Lipid determinations should be performed at intervals of no less than four weeks and dosage adjusted according to the patient’s response to therapy. The National Cholesterol Education Program’s Treatment Guidelines are summarized below: Table 5: NCEP Treatment Guidelines: LDL-C Goals and Cutpoints for Therapeutic Lifestyle Changes and Drug Therapy in Different Risk Categories Risk Category LDL Goal (mg/dL) LDL Level at Which to Initiate Therapeutic Lifestyle Changes (mg/dL) LDL Level at Which to Consider Drug Therapy (mg/dL) CHD a or CHD risk equivalents (10 year risk greater than 20%) less than 100 greater than or equal to 100 greater than or equal to 130 (100 to 129: drug optional) b 2+ Risk factors (10 year risk less than or equal to 20%) less than 130 greater than or equal to 130 10 year risk 10% to 20%: greater than 130 10 year risk less than 10%: greater than or equal to 160 0 to 1 Risk factor c less than 160 greater than or equal to 160 greater than or equal to 190 (160 to 189: LDL- lowering drug optional) a CHD, coronary heart disease. b Some authorities recommend use of LDL-lowering drugs in this category if an LDL-C level of less than 100 mg/dL cannot be achieved by therapeutic lifestyle changes. Others prefer use of drugs that primarily modify triglycerides and HDL-C, e.g., nicotinic acid or fibrate. Clinical judgement also may call for deferring drug therapy in this subcategory. c Almost all people with 0 to 1 risk factor have 10 year risk less than 10%; thus, 10 year risk assessment in people with 0 to 1 risk factor is not necessary. After the LDL-C goal has been achieved, if the TG is still greater than or equal to 200 mg/dL, non-HDL-C (Total-C minus HDL-C) becomes a secondary target of therapy. Non-HDL-C goals are set 30 mg/dL higher than LDL-C goals for each risk category. At the time of hospitalization for an acute coronary event, consideration can be given to initiating drug therapy at discharge if the LDL-C is greater than or equal to 130 mg/dL (see NCEP Treatment Guidelines , above). Since the goal of treatment is to lower LDL-C, the NCEP recommends that LDL-C levels be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the Total-C be used to monitor therapy. As with other lipid-lowering therapy, pravastatin sodium tablets are not indicated when hypercholesterolemia is due to hyperalphalipoproteinemia (elevated HDL-C). The NCEP classification of cholesterol levels in pediatric patients with a familial history of hypercholesterolemia or premature cardiovascular disease is summarized below: Category Total-C (mg/dL) LDL-C (mg/dL) Acceptable less than 170 less than 110 Borderline 170 to 199 110 to 129 High greater than or equal to200 greater than or equal to 130 uuid:508cfab6-439e-40d2-be3d-2f35965a4b31 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63618 biolink:treats UMLS:C0259744 PMID:41385096 "[{""id"":""uuid:bd50792b-cda8-4cc7-8871-7bcc723e4fb1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fe40b31e-7889-4016-acf9-005709242bbd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with pravastatin sodium tablets should be considered in those individuals at increased risk for atherosclerosis-related clinical events as a function of cholesterol level, the presence or absence of coronary heart disease, and other risk factors. Primary Prevention of Coronary Events In hypercholesterolemic patients without clinically evident coronary heart disease, pravastatin sodium tablets are indicated to: - Reduce the risk of myocardial infarction - Reduce the risk of undergoing myocardial revascularization procedures - Reduce the risk of cardiovascular mortality with no increase in death from non-cardiovascular causes Hyperlipidemia Pravastatin sodium tablets are indicated as an adjunct to diet to reduce elevated Total-C, LDL-C, ApoB, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson Type IIa and IIb). 6 Pravastatin sodium tablets are indicated as adjunctive therapy to diet for the treatment of patients with elevated serum triglyceride levels (Fredrickson Type IV). Pravastatin sodium tablets are indicated for the treatment of patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet. Pravastatin sodium tablets are indicated as an adjunct to diet and lifestyle modification for treatment of HeFH in children and adolescent patients ages 8 years and older if after an adequate trial of diet the following findings are present: LDL-C remains greater than or equal to 190 mg/dL or LDL-C remains greater than or equal to 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the patient. Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when the response to diet and other nonpharmacological measures alone has been inadequate (see NCEP Treatment Guidelines below). Prior to initiating therapy with pravastatin, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure Total-C, HDL-C, and TG. For patients with triglycerides (TG) less than 400 mg/dL (less than 4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = Total-C - HDL-C - 1/5 TG For TG levels greater than 400 mg/dL (greater than 4.5 mmol/L), this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In many hypertriglyceridemic patients, LDL-C may be low or normal despite elevated Total-C. In such cases, HMG-CoA reductase inhibitors are not indicated. Lipid determinations should be performed at intervals of no less than four weeks and dosage adjusted according to the patient’s response to therapy. The National Cholesterol Education Program’s Treatment Guidelines are summarized below: Table 5: NCEP Treatment Guidelines: LDL-C Goals and Cutpoints for Therapeutic Lifestyle Changes and Drug Therapy in Different Risk Categories Risk Category LDL Goal (mg/dL) LDL Level at Which to Initiate Therapeutic Lifestyle Changes (mg/dL) LDL Level at Which to Consider Drug Therapy (mg/dL) CHD a or CHD risk equivalents (10 year risk greater than 20%) less than 100 greater than or equal to 100 greater than or equal to 130 (100 to 129: drug optional) b 2+ Risk factors (10 year risk less than or equal to 20%) less than 130 greater than or equal to 130 10 year risk 10% to 20%: greater than 130 10 year risk less than 10%: greater than or equal to 160 0 to 1 Risk factor c less than 160 greater than or equal to 160 greater than or equal to 190 (160 to 189: LDL- lowering drug optional) a CHD, coronary heart disease. b Some authorities recommend use of LDL-lowering drugs in this category if an LDL-C level of less than 100 mg/dL cannot be achieved by therapeutic lifestyle changes. Others prefer use of drugs that primarily modify triglycerides and HDL-C, e.g., nicotinic acid or fibrate. Clinical judgement also may call for deferring drug therapy in this subcategory. c Almost all people with 0 to 1 risk factor have 10 year risk less than 10%; thus, 10 year risk assessment in people with 0 to 1 risk factor is not necessary. After the LDL-C goal has been achieved, if the TG is still greater than or equal to 200 mg/dL, non-HDL-C (Total-C minus HDL-C) becomes a secondary target of therapy. Non-HDL-C goals are set 30 mg/dL higher than LDL-C goals for each risk category. At the time of hospitalization for an acute coronary event, consideration can be given to initiating drug therapy at discharge if the LDL-C is greater than or equal to 130 mg/dL (see NCEP Treatment Guidelines , above). Since the goal of treatment is to lower LDL-C, the NCEP recommends that LDL-C levels be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the Total-C be used to monitor therapy. As with other lipid-lowering therapy, pravastatin sodium tablets are not indicated when hypercholesterolemia is due to hyperalphalipoproteinemia (elevated HDL-C). The NCEP classification of cholesterol levels in pediatric patients with a familial history of hypercholesterolemia or premature cardiovascular disease is summarized below: Category Total-C (mg/dL) LDL-C (mg/dL) Acceptable less than 170 less than 110 Borderline 170 to 199 110 to 129 High greater than or equal to200 greater than or equal to 130 uuid:7aa8f914-c3e5-49e1-8deb-13712c32032a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63618 biolink:treats MONDO:0006874 PMID:41385096 "[{""id"":""uuid:d30d5d14-ad70-4861-8b64-8afc0ec86c06"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2b984147-fb96-42a2-b780-6a2e5cb81987"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with pravastatin sodium tablets should be considered in those individuals at increased risk for atherosclerosis-related clinical events as a function of cholesterol level, the presence or absence of coronary heart disease, and other risk factors. Primary Prevention of Coronary Events In hypercholesterolemic patients without clinically evident coronary heart disease, pravastatin sodium tablets are indicated to: - Reduce the risk of myocardial infarction - Reduce the risk of undergoing myocardial revascularization procedures - Reduce the risk of cardiovascular mortality with no increase in death from non-cardiovascular causes Hyperlipidemia Pravastatin sodium tablets are indicated as an adjunct to diet to reduce elevated Total-C, LDL-C, ApoB, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson Type IIa and IIb). 6 Pravastatin sodium tablets are indicated as adjunctive therapy to diet for the treatment of patients with elevated serum triglyceride levels (Fredrickson Type IV). Pravastatin sodium tablets are indicated for the treatment of patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet. Pravastatin sodium tablets are indicated as an adjunct to diet and lifestyle modification for treatment of HeFH in children and adolescent patients ages 8 years and older if after an adequate trial of diet the following findings are present: LDL-C remains greater than or equal to 190 mg/dL or LDL-C remains greater than or equal to 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the patient. Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when the response to diet and other nonpharmacological measures alone has been inadequate (see NCEP Treatment Guidelines below). Prior to initiating therapy with pravastatin, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure Total-C, HDL-C, and TG. For patients with triglycerides (TG) less than 400 mg/dL (less than 4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = Total-C - HDL-C - 1/5 TG For TG levels greater than 400 mg/dL (greater than 4.5 mmol/L), this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In many hypertriglyceridemic patients, LDL-C may be low or normal despite elevated Total-C. In such cases, HMG-CoA reductase inhibitors are not indicated. Lipid determinations should be performed at intervals of no less than four weeks and dosage adjusted according to the patient’s response to therapy. The National Cholesterol Education Program’s Treatment Guidelines are summarized below: Table 5: NCEP Treatment Guidelines: LDL-C Goals and Cutpoints for Therapeutic Lifestyle Changes and Drug Therapy in Different Risk Categories Risk Category LDL Goal (mg/dL) LDL Level at Which to Initiate Therapeutic Lifestyle Changes (mg/dL) LDL Level at Which to Consider Drug Therapy (mg/dL) CHD a or CHD risk equivalents (10 year risk greater than 20%) less than 100 greater than or equal to 100 greater than or equal to 130 (100 to 129: drug optional) b 2+ Risk factors (10 year risk less than or equal to 20%) less than 130 greater than or equal to 130 10 year risk 10% to 20%: greater than 130 10 year risk less than 10%: greater than or equal to 160 0 to 1 Risk factor c less than 160 greater than or equal to 160 greater than or equal to 190 (160 to 189: LDL- lowering drug optional) a CHD, coronary heart disease. b Some authorities recommend use of LDL-lowering drugs in this category if an LDL-C level of less than 100 mg/dL cannot be achieved by therapeutic lifestyle changes. Others prefer use of drugs that primarily modify triglycerides and HDL-C, e.g., nicotinic acid or fibrate. Clinical judgement also may call for deferring drug therapy in this subcategory. c Almost all people with 0 to 1 risk factor have 10 year risk less than 10%; thus, 10 year risk assessment in people with 0 to 1 risk factor is not necessary. After the LDL-C goal has been achieved, if the TG is still greater than or equal to 200 mg/dL, non-HDL-C (Total-C minus HDL-C) becomes a secondary target of therapy. Non-HDL-C goals are set 30 mg/dL higher than LDL-C goals for each risk category. At the time of hospitalization for an acute coronary event, consideration can be given to initiating drug therapy at discharge if the LDL-C is greater than or equal to 130 mg/dL (see NCEP Treatment Guidelines , above). Since the goal of treatment is to lower LDL-C, the NCEP recommends that LDL-C levels be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the Total-C be used to monitor therapy. As with other lipid-lowering therapy, pravastatin sodium tablets are not indicated when hypercholesterolemia is due to hyperalphalipoproteinemia (elevated HDL-C). The NCEP classification of cholesterol levels in pediatric patients with a familial history of hypercholesterolemia or premature cardiovascular disease is summarized below: Category Total-C (mg/dL) LDL-C (mg/dL) Acceptable less than 170 less than 110 Borderline 170 to 199 110 to 129 High greater than or equal to200 greater than or equal to 130 uuid:1aa6e4b4-54d3-418c-89a0-62ff50de4fd6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63618 biolink:treats MONDO:0005347 PMID:41385096 "[{""id"":""uuid:021e6e83-6efa-4228-9e36-202059ad8e69"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ea6182ae-8e48-4fb1-a521-c8f0c7c6c2d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with pravastatin sodium tablets should be considered in those individuals at increased risk for atherosclerosis-related clinical events as a function of cholesterol level, the presence or absence of coronary heart disease, and other risk factors. Primary Prevention of Coronary Events In hypercholesterolemic patients without clinically evident coronary heart disease, pravastatin sodium tablets are indicated to: - Reduce the risk of myocardial infarction - Reduce the risk of undergoing myocardial revascularization procedures - Reduce the risk of cardiovascular mortality with no increase in death from non-cardiovascular causes Hyperlipidemia Pravastatin sodium tablets are indicated as an adjunct to diet to reduce elevated Total-C, LDL-C, ApoB, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson Type IIa and IIb). 6 Pravastatin sodium tablets are indicated as adjunctive therapy to diet for the treatment of patients with elevated serum triglyceride levels (Fredrickson Type IV). Pravastatin sodium tablets are indicated for the treatment of patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet. Pravastatin sodium tablets are indicated as an adjunct to diet and lifestyle modification for treatment of HeFH in children and adolescent patients ages 8 years and older if after an adequate trial of diet the following findings are present: LDL-C remains greater than or equal to 190 mg/dL or LDL-C remains greater than or equal to 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the patient. Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when the response to diet and other nonpharmacological measures alone has been inadequate (see NCEP Treatment Guidelines below). Prior to initiating therapy with pravastatin, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure Total-C, HDL-C, and TG. For patients with triglycerides (TG) less than 400 mg/dL (less than 4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = Total-C - HDL-C - 1/5 TG For TG levels greater than 400 mg/dL (greater than 4.5 mmol/L), this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In many hypertriglyceridemic patients, LDL-C may be low or normal despite elevated Total-C. In such cases, HMG-CoA reductase inhibitors are not indicated. Lipid determinations should be performed at intervals of no less than four weeks and dosage adjusted according to the patient’s response to therapy. The National Cholesterol Education Program’s Treatment Guidelines are summarized below: Table 5: NCEP Treatment Guidelines: LDL-C Goals and Cutpoints for Therapeutic Lifestyle Changes and Drug Therapy in Different Risk Categories Risk Category LDL Goal (mg/dL) LDL Level at Which to Initiate Therapeutic Lifestyle Changes (mg/dL) LDL Level at Which to Consider Drug Therapy (mg/dL) CHD a or CHD risk equivalents (10 year risk greater than 20%) less than 100 greater than or equal to 100 greater than or equal to 130 (100 to 129: drug optional) b 2+ Risk factors (10 year risk less than or equal to 20%) less than 130 greater than or equal to 130 10 year risk 10% to 20%: greater than 130 10 year risk less than 10%: greater than or equal to 160 0 to 1 Risk factor c less than 160 greater than or equal to 160 greater than or equal to 190 (160 to 189: LDL- lowering drug optional) a CHD, coronary heart disease. b Some authorities recommend use of LDL-lowering drugs in this category if an LDL-C level of less than 100 mg/dL cannot be achieved by therapeutic lifestyle changes. Others prefer use of drugs that primarily modify triglycerides and HDL-C, e.g., nicotinic acid or fibrate. Clinical judgement also may call for deferring drug therapy in this subcategory. c Almost all people with 0 to 1 risk factor have 10 year risk less than 10%; thus, 10 year risk assessment in people with 0 to 1 risk factor is not necessary. After the LDL-C goal has been achieved, if the TG is still greater than or equal to 200 mg/dL, non-HDL-C (Total-C minus HDL-C) becomes a secondary target of therapy. Non-HDL-C goals are set 30 mg/dL higher than LDL-C goals for each risk category. At the time of hospitalization for an acute coronary event, consideration can be given to initiating drug therapy at discharge if the LDL-C is greater than or equal to 130 mg/dL (see NCEP Treatment Guidelines , above). Since the goal of treatment is to lower LDL-C, the NCEP recommends that LDL-C levels be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the Total-C be used to monitor therapy. As with other lipid-lowering therapy, pravastatin sodium tablets are not indicated when hypercholesterolemia is due to hyperalphalipoproteinemia (elevated HDL-C). The NCEP classification of cholesterol levels in pediatric patients with a familial history of hypercholesterolemia or premature cardiovascular disease is summarized below: Category Total-C (mg/dL) LDL-C (mg/dL) Acceptable less than 170 less than 110 Borderline 170 to 199 110 to 129 High greater than or equal to200 greater than or equal to 130 uuid:be6b25fd-121c-4f31-b8b2-255fef51076c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63618 biolink:treats MONDO:0015903 PMID:41385096 "[{""id"":""uuid:3dcf7530-66aa-4d8e-a682-439746b90269"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bbd40173-087a-4b02-aeb7-cf193bda5438"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with pravastatin sodium tablets should be considered in those individuals at increased risk for atherosclerosis-related clinical events as a function of cholesterol level, the presence or absence of coronary heart disease, and other risk factors. Primary Prevention of Coronary Events In hypercholesterolemic patients without clinically evident coronary heart disease, pravastatin sodium tablets are indicated to: - Reduce the risk of myocardial infarction - Reduce the risk of undergoing myocardial revascularization procedures - Reduce the risk of cardiovascular mortality with no increase in death from non-cardiovascular causes Hyperlipidemia Pravastatin sodium tablets are indicated as an adjunct to diet to reduce elevated Total-C, LDL-C, ApoB, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson Type IIa and IIb). 6 Pravastatin sodium tablets are indicated as adjunctive therapy to diet for the treatment of patients with elevated serum triglyceride levels (Fredrickson Type IV). Pravastatin sodium tablets are indicated for the treatment of patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet. Pravastatin sodium tablets are indicated as an adjunct to diet and lifestyle modification for treatment of HeFH in children and adolescent patients ages 8 years and older if after an adequate trial of diet the following findings are present: LDL-C remains greater than or equal to 190 mg/dL or LDL-C remains greater than or equal to 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the patient. Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when the response to diet and other nonpharmacological measures alone has been inadequate (see NCEP Treatment Guidelines below). Prior to initiating therapy with pravastatin, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure Total-C, HDL-C, and TG. For patients with triglycerides (TG) less than 400 mg/dL (less than 4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = Total-C - HDL-C - 1/5 TG For TG levels greater than 400 mg/dL (greater than 4.5 mmol/L), this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In many hypertriglyceridemic patients, LDL-C may be low or normal despite elevated Total-C. In such cases, HMG-CoA reductase inhibitors are not indicated. Lipid determinations should be performed at intervals of no less than four weeks and dosage adjusted according to the patient’s response to therapy. The National Cholesterol Education Program’s Treatment Guidelines are summarized below: Table 5: NCEP Treatment Guidelines: LDL-C Goals and Cutpoints for Therapeutic Lifestyle Changes and Drug Therapy in Different Risk Categories Risk Category LDL Goal (mg/dL) LDL Level at Which to Initiate Therapeutic Lifestyle Changes (mg/dL) LDL Level at Which to Consider Drug Therapy (mg/dL) CHD a or CHD risk equivalents (10 year risk greater than 20%) less than 100 greater than or equal to 100 greater than or equal to 130 (100 to 129: drug optional) b 2+ Risk factors (10 year risk less than or equal to 20%) less than 130 greater than or equal to 130 10 year risk 10% to 20%: greater than 130 10 year risk less than 10%: greater than or equal to 160 0 to 1 Risk factor c less than 160 greater than or equal to 160 greater than or equal to 190 (160 to 189: LDL- lowering drug optional) a CHD, coronary heart disease. b Some authorities recommend use of LDL-lowering drugs in this category if an LDL-C level of less than 100 mg/dL cannot be achieved by therapeutic lifestyle changes. Others prefer use of drugs that primarily modify triglycerides and HDL-C, e.g., nicotinic acid or fibrate. Clinical judgement also may call for deferring drug therapy in this subcategory. c Almost all people with 0 to 1 risk factor have 10 year risk less than 10%; thus, 10 year risk assessment in people with 0 to 1 risk factor is not necessary. After the LDL-C goal has been achieved, if the TG is still greater than or equal to 200 mg/dL, non-HDL-C (Total-C minus HDL-C) becomes a secondary target of therapy. Non-HDL-C goals are set 30 mg/dL higher than LDL-C goals for each risk category. At the time of hospitalization for an acute coronary event, consideration can be given to initiating drug therapy at discharge if the LDL-C is greater than or equal to 130 mg/dL (see NCEP Treatment Guidelines , above). Since the goal of treatment is to lower LDL-C, the NCEP recommends that LDL-C levels be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the Total-C be used to monitor therapy. As with other lipid-lowering therapy, pravastatin sodium tablets are not indicated when hypercholesterolemia is due to hyperalphalipoproteinemia (elevated HDL-C). The NCEP classification of cholesterol levels in pediatric patients with a familial history of hypercholesterolemia or premature cardiovascular disease is summarized below: Category Total-C (mg/dL) LDL-C (mg/dL) Acceptable less than 170 less than 110 Borderline 170 to 199 110 to 129 High greater than or equal to200 greater than or equal to 130 uuid:faeb6a2c-137e-4313-a010-82f3de09833f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135931 biolink:treats UMLS:C0267055 PMID:41385096 "[{""id"":""uuid:9dc9db7c-f686-4a85-ba1d-a33cb6ddee61"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0c1929ad-5554-496d-b00a-cc8bbd295942"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Healing of Erosive Esophagitis KAPIDEX is indicated for healing of all grades of erosive esophagitis (EE) for up to 8 weeks. 1.2 Maintenance of Healed Erosive Esophagitis KAPIDEX is indicated to maintain healing of EE for up to 6 months. 1.3 Symptomatic Non-Erosive Gastroesophageal Reflux Disease KAPIDEX is indicated for the treatment of heartburn associated with non-erosive gastroesophageal reflux disease (GERD) for 4 weeks. uuid:02faad08-2f57-4747-ac6e-c7ab21eb1d5a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats MONDO:0024355 PMID:41385096 "[{""id"":""uuid:5368f7a6-590e-42cd-946f-15359e831fe0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8769fec8-c86e-4c81-a4a3-8a0040c80177"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp.) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis or ornithosis caused by Chlamydia Psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Calymmatobacterium granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli , Klebsiella , etc. Other infections caused by susceptible gram-negative organisms such as E. coli , Enterobacter aerogenes, Shigella sp., Acinetobacter sp., Klebsiella sp., and Bacteroides sp. In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent’s infection caused by Fusobacterium fusiforme , infections caused by Neisseria gonorrhoeae , anthrax caused by Bacillus anthracis , infections due to Listeria monocytogenes , actinomycosis caused by Actinomyces species, infections due to Clostridium species. uuid:e05be5b5-bef9-45e5-9323-f3e01eebb88e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:313655a7-38dd-4a99-bbe9-a8c10b8ef4ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a2b0179d-03e6-4395-83d8-42af81e6b29c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp.) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis or ornithosis caused by Chlamydia Psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Calymmatobacterium granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli , Klebsiella , etc. Other infections caused by susceptible gram-negative organisms such as E. coli , Enterobacter aerogenes, Shigella sp., Acinetobacter sp., Klebsiella sp., and Bacteroides sp. In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent’s infection caused by Fusobacterium fusiforme , infections caused by Neisseria gonorrhoeae , anthrax caused by Bacillus anthracis , infections due to Listeria monocytogenes , actinomycosis caused by Actinomyces species, infections due to Clostridium species. uuid:a66f5c94-3aa7-4897-8a59-518eb598c53b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats MONDO:0019359 PMID:41385096 "[{""id"":""uuid:78632e56-271d-4761-a4d7-e1bb15273609"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:685acf92-444b-43bf-8b9f-b19f83b26176"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp.) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis or ornithosis caused by Chlamydia Psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Calymmatobacterium granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli , Klebsiella , etc. Other infections caused by susceptible gram-negative organisms such as E. coli , Enterobacter aerogenes, Shigella sp., Acinetobacter sp., Klebsiella sp., and Bacteroides sp. In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent’s infection caused by Fusobacterium fusiforme , infections caused by Neisseria gonorrhoeae , anthrax caused by Bacillus anthracis , infections due to Listeria monocytogenes , actinomycosis caused by Actinomyces species, infections due to Clostridium species. uuid:fcd85903-dd02-47d8-a152-e42e4d110fc0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats MONDO:0001246 PMID:41385096 "[{""id"":""uuid:13b94a0a-039a-4d26-b681-1a4ff950223f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b12abac6-203b-4626-97f8-d3eeebbf6962"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp.) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis or ornithosis caused by Chlamydia Psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Calymmatobacterium granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli , Klebsiella , etc. Other infections caused by susceptible gram-negative organisms such as E. coli , Enterobacter aerogenes, Shigella sp., Acinetobacter sp., Klebsiella sp., and Bacteroides sp. In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent’s infection caused by Fusobacterium fusiforme , infections caused by Neisseria gonorrhoeae , anthrax caused by Bacillus anthracis , infections due to Listeria monocytogenes , actinomycosis caused by Actinomyces species, infections due to Clostridium species. uuid:fba8707a-1f53-4852-bed7-4ebf2aec5202 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats MONDO:0019186 PMID:41385096 "[{""id"":""uuid:8b4b853b-9147-4ce4-863a-100d8fe2c6f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7083e9d1-f84e-4f5c-99ed-e6f644ca5566"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp.) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis or ornithosis caused by Chlamydia Psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Calymmatobacterium granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli , Klebsiella , etc. Other infections caused by susceptible gram-negative organisms such as E. coli , Enterobacter aerogenes, Shigella sp., Acinetobacter sp., Klebsiella sp., and Bacteroides sp. In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent’s infection caused by Fusobacterium fusiforme , infections caused by Neisseria gonorrhoeae , anthrax caused by Bacillus anthracis , infections due to Listeria monocytogenes , actinomycosis caused by Actinomyces species, infections due to Clostridium species. uuid:74938a62-c3b3-46dd-ac2d-f70c63ecd3ca biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats MONDO:0019360 PMID:41385096 "[{""id"":""uuid:23ec5d57-1e50-4a60-a4cf-f546890a589b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5bb67ed1-03d3-4fc5-8c57-d017ef2f3273"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp.) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis or ornithosis caused by Chlamydia Psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Calymmatobacterium granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli , Klebsiella , etc. Other infections caused by susceptible gram-negative organisms such as E. coli , Enterobacter aerogenes, Shigella sp., Acinetobacter sp., Klebsiella sp., and Bacteroides sp. In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent’s infection caused by Fusobacterium fusiforme , infections caused by Neisseria gonorrhoeae , anthrax caused by Bacillus anthracis , infections due to Listeria monocytogenes , actinomycosis caused by Actinomyces species, infections due to Clostridium species. uuid:220e6834-188e-423b-aed1-0501dad5165c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats MONDO:0005888 PMID:41385096 "[{""id"":""uuid:505fb633-5ce8-4106-aa01-fe57961d2c9e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bfee4658-b83d-4925-b7d1-0d4c6f354846"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp.) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis or ornithosis caused by Chlamydia Psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Calymmatobacterium granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli , Klebsiella , etc. Other infections caused by susceptible gram-negative organisms such as E. coli , Enterobacter aerogenes, Shigella sp., Acinetobacter sp., Klebsiella sp., and Bacteroides sp. In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent’s infection caused by Fusobacterium fusiforme , infections caused by Neisseria gonorrhoeae , anthrax caused by Bacillus anthracis , infections due to Listeria monocytogenes , actinomycosis caused by Actinomyces species, infections due to Clostridium species. uuid:c25a05af-5732-4a75-9ded-4372bdd6be68 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats MONDO:0005808 PMID:41385096 "[{""id"":""uuid:bfae447b-35c5-4cdd-bec3-237ccb09573c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dec22fd3-6637-4a1d-93e6-39be403dacaa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp.) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis or ornithosis caused by Chlamydia Psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Calymmatobacterium granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli , Klebsiella , etc. Other infections caused by susceptible gram-negative organisms such as E. coli , Enterobacter aerogenes, Shigella sp., Acinetobacter sp., Klebsiella sp., and Bacteroides sp. In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent’s infection caused by Fusobacterium fusiforme , infections caused by Neisseria gonorrhoeae , anthrax caused by Bacillus anthracis , infections due to Listeria monocytogenes , actinomycosis caused by Actinomyces species, infections due to Clostridium species. uuid:d009a6d0-a9f6-413b-8658-07870f290621 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats MONDO:0001249 PMID:41385096 "[{""id"":""uuid:53a02fab-846c-4112-9d17-6ccd664c1cdd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3ed8b795-2f98-4206-a3fd-9f76c8b4d5b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp.) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis or ornithosis caused by Chlamydia Psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Calymmatobacterium granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli , Klebsiella , etc. Other infections caused by susceptible gram-negative organisms such as E. coli , Enterobacter aerogenes, Shigella sp., Acinetobacter sp., Klebsiella sp., and Bacteroides sp. In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent’s infection caused by Fusobacterium fusiforme , infections caused by Neisseria gonorrhoeae , anthrax caused by Bacillus anthracis , infections due to Listeria monocytogenes , actinomycosis caused by Actinomyces species, infections due to Clostridium species. uuid:f741b391-b779-4aaf-938c-db4af1fd324c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats MONDO:0005834 PMID:41385096 "[{""id"":""uuid:d2e04099-96ea-4ff7-af15-87bf01ef559b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a4aad18f-c043-4b23-86ea-0fea79e2d90d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp.) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis or ornithosis caused by Chlamydia Psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Calymmatobacterium granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli , Klebsiella , etc. Other infections caused by susceptible gram-negative organisms such as E. coli , Enterobacter aerogenes, Shigella sp., Acinetobacter sp., Klebsiella sp., and Bacteroides sp. In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent’s infection caused by Fusobacterium fusiforme , infections caused by Neisseria gonorrhoeae , anthrax caused by Bacillus anthracis , infections due to Listeria monocytogenes , actinomycosis caused by Actinomyces species, infections due to Clostridium species. uuid:d5e67bb4-aa55-495b-b1fc-e9e250126994 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats MONDO:0005777 PMID:41385096 "[{""id"":""uuid:a91a8660-ce6c-4bf1-a7a9-354421f70249"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7b3871b7-048a-460e-ac28-d7ceb1ebb5ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp.) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis or ornithosis caused by Chlamydia Psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Calymmatobacterium granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli , Klebsiella , etc. Other infections caused by susceptible gram-negative organisms such as E. coli , Enterobacter aerogenes, Shigella sp., Acinetobacter sp., Klebsiella sp., and Bacteroides sp. In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent’s infection caused by Fusobacterium fusiforme , infections caused by Neisseria gonorrhoeae , anthrax caused by Bacillus anthracis , infections due to Listeria monocytogenes , actinomycosis caused by Actinomyces species, infections due to Clostridium species. uuid:5b25ce5c-7658-451c-8e08-09a7f5faf00c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats MONDO:0019633 PMID:41385096 "[{""id"":""uuid:dd271d52-561f-4988-826f-9104ec6754d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5032034e-eafd-44f2-b12f-9232b0c5d9b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp.) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis or ornithosis caused by Chlamydia Psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Calymmatobacterium granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli , Klebsiella , etc. Other infections caused by susceptible gram-negative organisms such as E. coli , Enterobacter aerogenes, Shigella sp., Acinetobacter sp., Klebsiella sp., and Bacteroides sp. In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent’s infection caused by Fusobacterium fusiforme , infections caused by Neisseria gonorrhoeae , anthrax caused by Bacillus anthracis , infections due to Listeria monocytogenes , actinomycosis caused by Actinomyces species, infections due to Clostridium species. uuid:afcf9262-4276-4c8d-b260-52efa1a946a0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats MONDO:0005664 PMID:41385096 "[{""id"":""uuid:d2de2e5e-3ed4-4cb4-915b-a8e9e1ee2f0a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:663f1eca-e55e-4e8e-b7ea-514bd74f783b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp.) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis or ornithosis caused by Chlamydia Psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Calymmatobacterium granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli , Klebsiella , etc. Other infections caused by susceptible gram-negative organisms such as E. coli , Enterobacter aerogenes, Shigella sp., Acinetobacter sp., Klebsiella sp., and Bacteroides sp. In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent’s infection caused by Fusobacterium fusiforme , infections caused by Neisseria gonorrhoeae , anthrax caused by Bacillus anthracis , infections due to Listeria monocytogenes , actinomycosis caused by Actinomyces species, infections due to Clostridium species. uuid:0025fcf4-4ec0-4ead-a273-e998027e88bc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats MONDO:0001797 PMID:41385096 "[{""id"":""uuid:a3a598b2-a998-4d42-9db9-1a3918b24209"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ad934601-ba1e-4ada-ad3a-aa59f11daa6b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp.) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis or ornithosis caused by Chlamydia Psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Calymmatobacterium granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli , Klebsiella , etc. Other infections caused by susceptible gram-negative organisms such as E. coli , Enterobacter aerogenes, Shigella sp., Acinetobacter sp., Klebsiella sp., and Bacteroides sp. In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent’s infection caused by Fusobacterium fusiforme , infections caused by Neisseria gonorrhoeae , anthrax caused by Bacillus anthracis , infections due to Listeria monocytogenes , actinomycosis caused by Actinomyces species, infections due to Clostridium species. uuid:5a69d260-2cf1-4aec-a80f-76be8af10f0f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats MONDO:0018077 PMID:41385096 "[{""id"":""uuid:5ff64624-12e3-45ee-ac93-78ec10d4b6d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a11582da-b423-43e5-a364-c00eb675087d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp.) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis or ornithosis caused by Chlamydia Psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Calymmatobacterium granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli , Klebsiella , etc. Other infections caused by susceptible gram-negative organisms such as E. coli , Enterobacter aerogenes, Shigella sp., Acinetobacter sp., Klebsiella sp., and Bacteroides sp. In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent’s infection caused by Fusobacterium fusiforme , infections caused by Neisseria gonorrhoeae , anthrax caused by Bacillus anthracis , infections due to Listeria monocytogenes , actinomycosis caused by Actinomyces species, infections due to Clostridium species. uuid:779c6ff3-a90a-4ffc-88b3-c0e7c7f2bb57 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats MONDO:0015766 PMID:41385096 "[{""id"":""uuid:b4f641f7-dd58-4069-8e4b-08ec0d4a6783"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:46230ca5-9ee5-400f-a161-56e186c28ebe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp.) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis or ornithosis caused by Chlamydia Psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Calymmatobacterium granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli , Klebsiella , etc. Other infections caused by susceptible gram-negative organisms such as E. coli , Enterobacter aerogenes, Shigella sp., Acinetobacter sp., Klebsiella sp., and Bacteroides sp. In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent’s infection caused by Fusobacterium fusiforme , infections caused by Neisseria gonorrhoeae , anthrax caused by Bacillus anthracis , infections due to Listeria monocytogenes , actinomycosis caused by Actinomyces species, infections due to Clostridium species. uuid:0af83578-520c-4ed5-a615-ac8fe6f799f4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats MONDO:0005683 PMID:41385096 "[{""id"":""uuid:3bd69875-6e16-4e26-8048-0cd278517b09"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:88373f25-6222-49e1-8a73-f3726cb24afc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp.) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis or ornithosis caused by Chlamydia Psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Calymmatobacterium granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli , Klebsiella , etc. Other infections caused by susceptible gram-negative organisms such as E. coli , Enterobacter aerogenes, Shigella sp., Acinetobacter sp., Klebsiella sp., and Bacteroides sp. In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent’s infection caused by Fusobacterium fusiforme , infections caused by Neisseria gonorrhoeae , anthrax caused by Bacillus anthracis , infections due to Listeria monocytogenes , actinomycosis caused by Actinomyces species, infections due to Clostridium species. uuid:bb86e1a7-ad70-4a0c-8a26-c95ddfc84992 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats MONDO:0005644 PMID:41385096 "[{""id"":""uuid:dee31414-7a3e-4edc-8d42-e2cc3c8b9bbf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:30022597-4d79-401b-9fbf-38caffbea428"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp.) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis or ornithosis caused by Chlamydia Psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Calymmatobacterium granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli , Klebsiella , etc. Other infections caused by susceptible gram-negative organisms such as E. coli , Enterobacter aerogenes, Shigella sp., Acinetobacter sp., Klebsiella sp., and Bacteroides sp. In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent’s infection caused by Fusobacterium fusiforme , infections caused by Neisseria gonorrhoeae , anthrax caused by Bacillus anthracis , infections due to Listeria monocytogenes , actinomycosis caused by Actinomyces species, infections due to Clostridium species. uuid:c29a08d7-798b-4a4a-b7af-6bd8c82925fd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:25eed2ce-a77f-4b04-b9a0-230725af0aea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4020deda-6c4c-4fcd-8d44-e4602846fe5e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp.) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis or ornithosis caused by Chlamydia Psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Calymmatobacterium granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli , Klebsiella , etc. Other infections caused by susceptible gram-negative organisms such as E. coli , Enterobacter aerogenes, Shigella sp., Acinetobacter sp., Klebsiella sp., and Bacteroides sp. In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent’s infection caused by Fusobacterium fusiforme , infections caused by Neisseria gonorrhoeae , anthrax caused by Bacillus anthracis , infections due to Listeria monocytogenes , actinomycosis caused by Actinomyces species, infections due to Clostridium species. uuid:970e0d9b-4454-4550-9e96-c6ea942775fa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats MONDO:0011438 PMID:41385096 "[{""id"":""uuid:623e7182-60be-4ac1-baa1-cc04f7d1041c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3fcc21ef-53e0-455c-b8b9-a7e498e3fc12"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp.) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis or ornithosis caused by Chlamydia Psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Calymmatobacterium granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli , Klebsiella , etc. Other infections caused by susceptible gram-negative organisms such as E. coli , Enterobacter aerogenes, Shigella sp., Acinetobacter sp., Klebsiella sp., and Bacteroides sp. In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent’s infection caused by Fusobacterium fusiforme , infections caused by Neisseria gonorrhoeae , anthrax caused by Bacillus anthracis , infections due to Listeria monocytogenes , actinomycosis caused by Actinomyces species, infections due to Clostridium species. uuid:d534a07b-7ad9-4c68-bb9e-e31b76d8ca76 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats MONDO:0005976 PMID:41385096 "[{""id"":""uuid:eb1caf0e-ba09-4c9e-8a45-47ff8f38e015"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a79023ab-93c8-436b-9dd9-bac7706c3006"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp.) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis or ornithosis caused by Chlamydia Psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Calymmatobacterium granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli , Klebsiella , etc. Other infections caused by susceptible gram-negative organisms such as E. coli , Enterobacter aerogenes, Shigella sp., Acinetobacter sp., Klebsiella sp., and Bacteroides sp. In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent’s infection caused by Fusobacterium fusiforme , infections caused by Neisseria gonorrhoeae , anthrax caused by Bacillus anthracis , infections due to Listeria monocytogenes , actinomycosis caused by Actinomyces species, infections due to Clostridium species. uuid:8683bcfd-1539-4ffe-b127-9e42a92f81dd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats MONDO:0006019 PMID:41385096 "[{""id"":""uuid:15028fe3-62da-4de9-839d-db151e2da471"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:935f1996-d814-4b0a-8e0f-59cd8ad58ca3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp.) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis or ornithosis caused by Chlamydia Psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Calymmatobacterium granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli , Klebsiella , etc. Other infections caused by susceptible gram-negative organisms such as E. coli , Enterobacter aerogenes, Shigella sp., Acinetobacter sp., Klebsiella sp., and Bacteroides sp. In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent’s infection caused by Fusobacterium fusiforme , infections caused by Neisseria gonorrhoeae , anthrax caused by Bacillus anthracis , infections due to Listeria monocytogenes , actinomycosis caused by Actinomyces species, infections due to Clostridium species. uuid:b079f5a3-e387-4ce3-b22c-6d45d6cfa149 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats MONDO:0005119 PMID:41385096 "[{""id"":""uuid:e92b6c18-a832-466b-9f37-f11540917595"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4b29020e-53d3-4701-a989-796d752ae0d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp.) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis or ornithosis caused by Chlamydia Psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Calymmatobacterium granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli , Klebsiella , etc. Other infections caused by susceptible gram-negative organisms such as E. coli , Enterobacter aerogenes, Shigella sp., Acinetobacter sp., Klebsiella sp., and Bacteroides sp. In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent’s infection caused by Fusobacterium fusiforme , infections caused by Neisseria gonorrhoeae , anthrax caused by Bacillus anthracis , infections due to Listeria monocytogenes , actinomycosis caused by Actinomyces species, infections due to Clostridium species. uuid:9390dd1f-4fac-472b-8a56-b5de64d05f14 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats MONDO:0005631 PMID:41385096 "[{""id"":""uuid:e2112961-720c-44e6-9338-25f044686324"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8bc76d88-25bf-4964-9664-f3a81dc03b01"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp.) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis or ornithosis caused by Chlamydia Psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Calymmatobacterium granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli , Klebsiella , etc. Other infections caused by susceptible gram-negative organisms such as E. coli , Enterobacter aerogenes, Shigella sp., Acinetobacter sp., Klebsiella sp., and Bacteroides sp. In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent’s infection caused by Fusobacterium fusiforme , infections caused by Neisseria gonorrhoeae , anthrax caused by Bacillus anthracis , infections due to Listeria monocytogenes , actinomycosis caused by Actinomyces species, infections due to Clostridium species. uuid:128635ac-d26f-41f7-bc79-04929f20fa69 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7476 biolink:treats MONDO:0004857 PMID:41385096 "[{""id"":""uuid:dcd5c74f-535c-4e7c-8289-e40ebe65f126"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:95d3b2bb-1ccd-4890-a0cd-200233d25687"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of naproxen, naproxen sodium and other treatment options before deciding to use naproxen and naproxen sodium tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Naproxen as naproxen or naproxen sodium tablets are indicated: For the relief of the signs and symptoms of rheumatoid arthritis For the relief of the signs and symptoms of osteoarthritis For the relief of the signs and symptoms of ankylosing spondylitis For the relief of the signs and symptoms of juvenile arthritis Naproxen as naproxen suspension is recommended for juvenile rheumatoid arthritis in order to obtain the maximum dosage flexibility based on the patient’s weight. Naproxen as naproxen and naproxen sodium tablets are also indicated: For relief of the signs and symptoms of tendonitis For relief of the signs and symptoms of bursitis For relief of the signs and symptoms of acute gout For the management of pain For the management of primary dysmenorrhea uuid:0fa56695-1ae9-46cf-95e1-fbaa93919089 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7476 biolink:treats MONDO:0002471 PMID:41385096 "[{""id"":""uuid:75bac7e4-69a8-4755-9998-28f42dee3a15"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:618cf7da-c5e9-4e96-9718-cdd6c5e7c8aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of naproxen, naproxen sodium and other treatment options before deciding to use naproxen and naproxen sodium tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Naproxen as naproxen or naproxen sodium tablets are indicated: For the relief of the signs and symptoms of rheumatoid arthritis For the relief of the signs and symptoms of osteoarthritis For the relief of the signs and symptoms of ankylosing spondylitis For the relief of the signs and symptoms of juvenile arthritis Naproxen as naproxen suspension is recommended for juvenile rheumatoid arthritis in order to obtain the maximum dosage flexibility based on the patient’s weight. Naproxen as naproxen and naproxen sodium tablets are also indicated: For relief of the signs and symptoms of tendonitis For relief of the signs and symptoms of bursitis For relief of the signs and symptoms of acute gout For the management of pain For the management of primary dysmenorrhea uuid:553a5998-1c53-4338-9aa4-cbdc52ed67c2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7476 biolink:treats MONDO:0005393 PMID:41385096 "[{""id"":""uuid:086b7c6e-18af-4090-b364-340ebf99a97e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eabd7a04-686e-4e2f-b0c7-0a50c71fe735"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of naproxen, naproxen sodium and other treatment options before deciding to use naproxen and naproxen sodium tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Naproxen as naproxen or naproxen sodium tablets are indicated: For the relief of the signs and symptoms of rheumatoid arthritis For the relief of the signs and symptoms of osteoarthritis For the relief of the signs and symptoms of ankylosing spondylitis For the relief of the signs and symptoms of juvenile arthritis Naproxen as naproxen suspension is recommended for juvenile rheumatoid arthritis in order to obtain the maximum dosage flexibility based on the patient’s weight. Naproxen as naproxen and naproxen sodium tablets are also indicated: For relief of the signs and symptoms of tendonitis For relief of the signs and symptoms of bursitis For relief of the signs and symptoms of acute gout For the management of pain For the management of primary dysmenorrhea uuid:4f74a75b-d284-4df7-ad53-fd1cf5b76e1a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PVI5M0M1GW biolink:treats MONDO:0004992 PMID:41385096 "[{""id"":""uuid:5da478ed-077e-4cc0-a6f3-cd77b0e4d615"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ff0cc8cf-0d63-4ace-9239-b44ad202f49b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:64cee7e7-8bab-4188-9510-81591a54a689"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/filgrastim-hexal""]},{""id"":""uuid:4d95ab89-e3c0-4774-885c-e576e661308e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cancer Patients Receiving Myelosuppressive Chemotherapy NEUPOGEN ® is indicated to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever (see CLINICAL EXPERIENCE ). A complete blood count (CBC) and platelet count should be obtained prior to chemotherapy‚ and twice per week (see LABORATORY MONITORING ) during NEUPOGEN ® therapy to avoid leukocytosis and to monitor the neutrophil count. In phase 3 clinical studies‚ NEUPOGEN ® therapy was discontinued when the ANC was ≥ 10‚000/mm 3 after the expected chemotherapy-induced nadir. Patients With Acute Myeloid Leukemia Receiving Induction or Consolidation Chemotherapy NEUPOGEN ® is indicated for reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of adults with AML. Cancer Patients Receiving Bone Marrow Transplant NEUPOGEN ® is indicated to reduce the duration of neutropenia and neutropenia-related clinical sequelae‚ eg‚ febrile neutropenia‚ in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by marrow transplantation (see CLINICAL EXPERIENCE ). It is recommended that CBCs and platelet counts be obtained at a minimum of 3 times per week (see LABORATORY MONITORING ) following marrow infusion to monitor the recovery of marrow reconstitution. Patients Undergoing Peripheral Blood Progenitor Cell Collection and Therapy NEUPOGEN ® is indicated for the mobilization of hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis. Mobilization allows for the collection of increased numbers of progenitor cells capable of engraftment compared with collection by leukapheresis without mobilization or bone marrow harvest. After myeloablative chemotherapy‚ the transplantation of an increased number of progenitor cells can lead to more rapid engraftment‚ which may result in a decreased need for supportive care (see CLINICAL EXPERIENCE ). Patients With Severe Chronic Neutropenia NEUPOGEN ® is indicated for chronic administration to reduce the incidence and duration of sequelae of neutropenia (eg‚ fever‚ infections‚ oropharyngeal ulcers) in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia (see CLINICAL EXPERIENCE ). It is essential that serial CBCs with differential and platelet counts‚ and an evaluation of bone marrow morphology and karyotype be performed prior to initiation of NEUPOGEN ® therapy (see WARNINGS ). The use of NEUPOGEN ® prior to confirmation of SCN may impair diagnostic efforts and may thus impair or delay evaluation and treatment of an underlying condition‚ other than SCN‚ causing the neutropenia.|[EMA] Reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone-marrow transplantation considered to be at increased risk of prolonged severe neutropenia.The safety and efficacy of filgrastim are similar in adults and children receiving cytotoxic chemotherapy.Mobilisation of peripheral blood progenitor cells (PBPCs).In children and adults with severe congenital, cyclic, or idiopathic neutropenia with an absolute neutrophil count (ANC) of of ≤ 0.5 x 109/l, and a history of severe or recurrent infections, long-term administration of filgrastim is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.Treatment of persistent neutropenia (ANC ≤ 0.5 x 109/l), and a history of severe or recurrent infections, long-term administration of filgrastim is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.in patients with advanced HIV infection, in order to reduce the risk of bacterial infections when other therapeutic options are inappropriate.|[PMDA] Follow-on biologics indicated for mobilization of hematopoietic stem cell to peripheral blood, promotion of increase in neutrophil count at the time of hematopoietic stem cell transplantation, and the treatment of neutropenia caused by cancer chemotherapy, neutropenia which affects the treatment of human immunodeficiency virus (HIV) infection, neutropenia associated with myelodysplastic syndrome, neutropenia associated with aplastic anemia and congenital/idiopathic neutropenia. uuid:25198dff-8ec7-43b3-bc60-89a506a5d464 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PVI5M0M1GW biolink:treats MONDO:0018874 PMID:41385096 "[{""id"":""uuid:8cbdc7aa-52cb-452e-bc59-87abd023cca7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a0aeb889-dff8-4d4b-92a7-be398d3afdbd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:a47b95f6-dfeb-4932-b500-4c880e3ad1b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cancer Patients Receiving Myelosuppressive Chemotherapy NEUPOGEN ® is indicated to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever (see CLINICAL EXPERIENCE ). A complete blood count (CBC) and platelet count should be obtained prior to chemotherapy‚ and twice per week (see LABORATORY MONITORING ) during NEUPOGEN ® therapy to avoid leukocytosis and to monitor the neutrophil count. In phase 3 clinical studies‚ NEUPOGEN ® therapy was discontinued when the ANC was ≥ 10‚000/mm 3 after the expected chemotherapy-induced nadir. Patients With Acute Myeloid Leukemia Receiving Induction or Consolidation Chemotherapy NEUPOGEN ® is indicated for reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of adults with AML. Cancer Patients Receiving Bone Marrow Transplant NEUPOGEN ® is indicated to reduce the duration of neutropenia and neutropenia-related clinical sequelae‚ eg‚ febrile neutropenia‚ in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by marrow transplantation (see CLINICAL EXPERIENCE ). It is recommended that CBCs and platelet counts be obtained at a minimum of 3 times per week (see LABORATORY MONITORING ) following marrow infusion to monitor the recovery of marrow reconstitution. Patients Undergoing Peripheral Blood Progenitor Cell Collection and Therapy NEUPOGEN ® is indicated for the mobilization of hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis. Mobilization allows for the collection of increased numbers of progenitor cells capable of engraftment compared with collection by leukapheresis without mobilization or bone marrow harvest. After myeloablative chemotherapy‚ the transplantation of an increased number of progenitor cells can lead to more rapid engraftment‚ which may result in a decreased need for supportive care (see CLINICAL EXPERIENCE ). Patients With Severe Chronic Neutropenia NEUPOGEN ® is indicated for chronic administration to reduce the incidence and duration of sequelae of neutropenia (eg‚ fever‚ infections‚ oropharyngeal ulcers) in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia (see CLINICAL EXPERIENCE ). It is essential that serial CBCs with differential and platelet counts‚ and an evaluation of bone marrow morphology and karyotype be performed prior to initiation of NEUPOGEN ® therapy (see WARNINGS ). The use of NEUPOGEN ® prior to confirmation of SCN may impair diagnostic efforts and may thus impair or delay evaluation and treatment of an underlying condition‚ other than SCN‚ causing the neutropenia.|[PMDA] Drugs with a new indication and a new dosage for use as an adjunctive therapy with antineoplastic agents for the treatment of relapsed or refractory acute myeloid leukemia. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:dbc4e3e7-2ec7-4134-8642-0c2951360fe3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PVI5M0M1GW biolink:treats MONDO:0018542 PMID:41385096 "[{""id"":""uuid:f6c81c12-6961-41e6-940c-c9789add0923"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a24be924-485e-4936-9eff-25b1ff739bab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:b7d66083-ce2b-4c7d-a3f1-b25f8f34789c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/filgrastim-hexal""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cancer Patients Receiving Myelosuppressive Chemotherapy NEUPOGEN ® is indicated to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever (see CLINICAL EXPERIENCE ). A complete blood count (CBC) and platelet count should be obtained prior to chemotherapy‚ and twice per week (see LABORATORY MONITORING ) during NEUPOGEN ® therapy to avoid leukocytosis and to monitor the neutrophil count. In phase 3 clinical studies‚ NEUPOGEN ® therapy was discontinued when the ANC was ≥ 10‚000/mm 3 after the expected chemotherapy-induced nadir. Patients With Acute Myeloid Leukemia Receiving Induction or Consolidation Chemotherapy NEUPOGEN ® is indicated for reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of adults with AML. Cancer Patients Receiving Bone Marrow Transplant NEUPOGEN ® is indicated to reduce the duration of neutropenia and neutropenia-related clinical sequelae‚ eg‚ febrile neutropenia‚ in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by marrow transplantation (see CLINICAL EXPERIENCE ). It is recommended that CBCs and platelet counts be obtained at a minimum of 3 times per week (see LABORATORY MONITORING ) following marrow infusion to monitor the recovery of marrow reconstitution. Patients Undergoing Peripheral Blood Progenitor Cell Collection and Therapy NEUPOGEN ® is indicated for the mobilization of hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis. Mobilization allows for the collection of increased numbers of progenitor cells capable of engraftment compared with collection by leukapheresis without mobilization or bone marrow harvest. After myeloablative chemotherapy‚ the transplantation of an increased number of progenitor cells can lead to more rapid engraftment‚ which may result in a decreased need for supportive care (see CLINICAL EXPERIENCE ). Patients With Severe Chronic Neutropenia NEUPOGEN ® is indicated for chronic administration to reduce the incidence and duration of sequelae of neutropenia (eg‚ fever‚ infections‚ oropharyngeal ulcers) in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia (see CLINICAL EXPERIENCE ). It is essential that serial CBCs with differential and platelet counts‚ and an evaluation of bone marrow morphology and karyotype be performed prior to initiation of NEUPOGEN ® therapy (see WARNINGS ). The use of NEUPOGEN ® prior to confirmation of SCN may impair diagnostic efforts and may thus impair or delay evaluation and treatment of an underlying condition‚ other than SCN‚ causing the neutropenia.|[EMA] Reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone-marrow transplantation considered to be at increased risk of prolonged severe neutropenia.The safety and efficacy of filgrastim are similar in adults and children receiving cytotoxic chemotherapy.Mobilisation of peripheral blood progenitor cells (PBPCs).In children and adults with severe congenital, cyclic, or idiopathic neutropenia with an absolute neutrophil count (ANC) of of ≤ 0.5 x 109/l, and a history of severe or recurrent infections, long-term administration of filgrastim is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.Treatment of persistent neutropenia (ANC ≤ 0.5 x 109/l), and a history of severe or recurrent infections, long-term administration of filgrastim is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.in patients with advanced HIV infection, in order to reduce the risk of bacterial infections when other therapeutic options are inappropriate. uuid:99cfbf5a-b5e7-4ee4-89e4-d1a4c87ae123 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PVI5M0M1GW biolink:treats MONDO:0008090 PMID:41385096 "[{""id"":""uuid:035d9429-334d-4d5f-8f5a-563c3bb23f11"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:86e0ed87-7ffd-44e2-92c2-86af5a5ae9d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:0e528735-4de1-46cd-8777-98c08bbebddf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/filgrastim-hexal""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cancer Patients Receiving Myelosuppressive Chemotherapy NEUPOGEN ® is indicated to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever (see CLINICAL EXPERIENCE ). A complete blood count (CBC) and platelet count should be obtained prior to chemotherapy‚ and twice per week (see LABORATORY MONITORING ) during NEUPOGEN ® therapy to avoid leukocytosis and to monitor the neutrophil count. In phase 3 clinical studies‚ NEUPOGEN ® therapy was discontinued when the ANC was ≥ 10‚000/mm 3 after the expected chemotherapy-induced nadir. Patients With Acute Myeloid Leukemia Receiving Induction or Consolidation Chemotherapy NEUPOGEN ® is indicated for reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of adults with AML. Cancer Patients Receiving Bone Marrow Transplant NEUPOGEN ® is indicated to reduce the duration of neutropenia and neutropenia-related clinical sequelae‚ eg‚ febrile neutropenia‚ in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by marrow transplantation (see CLINICAL EXPERIENCE ). It is recommended that CBCs and platelet counts be obtained at a minimum of 3 times per week (see LABORATORY MONITORING ) following marrow infusion to monitor the recovery of marrow reconstitution. Patients Undergoing Peripheral Blood Progenitor Cell Collection and Therapy NEUPOGEN ® is indicated for the mobilization of hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis. Mobilization allows for the collection of increased numbers of progenitor cells capable of engraftment compared with collection by leukapheresis without mobilization or bone marrow harvest. After myeloablative chemotherapy‚ the transplantation of an increased number of progenitor cells can lead to more rapid engraftment‚ which may result in a decreased need for supportive care (see CLINICAL EXPERIENCE ). Patients With Severe Chronic Neutropenia NEUPOGEN ® is indicated for chronic administration to reduce the incidence and duration of sequelae of neutropenia (eg‚ fever‚ infections‚ oropharyngeal ulcers) in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia (see CLINICAL EXPERIENCE ). It is essential that serial CBCs with differential and platelet counts‚ and an evaluation of bone marrow morphology and karyotype be performed prior to initiation of NEUPOGEN ® therapy (see WARNINGS ). The use of NEUPOGEN ® prior to confirmation of SCN may impair diagnostic efforts and may thus impair or delay evaluation and treatment of an underlying condition‚ other than SCN‚ causing the neutropenia.|[EMA] Reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone-marrow transplantation considered to be at increased risk of prolonged severe neutropenia.The safety and efficacy of filgrastim are similar in adults and children receiving cytotoxic chemotherapy.Mobilisation of peripheral blood progenitor cells (PBPCs).In children and adults with severe congenital, cyclic, or idiopathic neutropenia with an absolute neutrophil count (ANC) of of ≤ 0.5 x 109/l, and a history of severe or recurrent infections, long-term administration of filgrastim is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.Treatment of persistent neutropenia (ANC ≤ 0.5 x 109/l), and a history of severe or recurrent infections, long-term administration of filgrastim is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.in patients with advanced HIV infection, in order to reduce the risk of bacterial infections when other therapeutic options are inappropriate. uuid:cef7b3d9-038b-45f7-ac47-b68138acdc78 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PVI5M0M1GW biolink:treats UMLS:C0948109 PMID:41385096 "[{""id"":""uuid:837f317d-8151-4f9e-9871-15a7135ccee1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9443b125-2fb5-46f5-b5ac-4acbdf472fc8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cancer Patients Receiving Myelosuppressive Chemotherapy NEUPOGEN ® is indicated to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever (see CLINICAL EXPERIENCE ). A complete blood count (CBC) and platelet count should be obtained prior to chemotherapy‚ and twice per week (see LABORATORY MONITORING ) during NEUPOGEN ® therapy to avoid leukocytosis and to monitor the neutrophil count. In phase 3 clinical studies‚ NEUPOGEN ® therapy was discontinued when the ANC was ≥ 10‚000/mm 3 after the expected chemotherapy-induced nadir. Patients With Acute Myeloid Leukemia Receiving Induction or Consolidation Chemotherapy NEUPOGEN ® is indicated for reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of adults with AML. Cancer Patients Receiving Bone Marrow Transplant NEUPOGEN ® is indicated to reduce the duration of neutropenia and neutropenia-related clinical sequelae‚ eg‚ febrile neutropenia‚ in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by marrow transplantation (see CLINICAL EXPERIENCE ). It is recommended that CBCs and platelet counts be obtained at a minimum of 3 times per week (see LABORATORY MONITORING ) following marrow infusion to monitor the recovery of marrow reconstitution. Patients Undergoing Peripheral Blood Progenitor Cell Collection and Therapy NEUPOGEN ® is indicated for the mobilization of hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis. Mobilization allows for the collection of increased numbers of progenitor cells capable of engraftment compared with collection by leukapheresis without mobilization or bone marrow harvest. After myeloablative chemotherapy‚ the transplantation of an increased number of progenitor cells can lead to more rapid engraftment‚ which may result in a decreased need for supportive care (see CLINICAL EXPERIENCE ). Patients With Severe Chronic Neutropenia NEUPOGEN ® is indicated for chronic administration to reduce the incidence and duration of sequelae of neutropenia (eg‚ fever‚ infections‚ oropharyngeal ulcers) in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia (see CLINICAL EXPERIENCE ). It is essential that serial CBCs with differential and platelet counts‚ and an evaluation of bone marrow morphology and karyotype be performed prior to initiation of NEUPOGEN ® therapy (see WARNINGS ). The use of NEUPOGEN ® prior to confirmation of SCN may impair diagnostic efforts and may thus impair or delay evaluation and treatment of an underlying condition‚ other than SCN‚ causing the neutropenia. uuid:e54def66-56a1-48cb-ada8-99bd04cbf94e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7936 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:a4bb94de-e819-4269-979f-cc54ab8e73cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b4a41f7f-133d-4dfb-b347-9c2c4e4329ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Major Depressive Disorder PAXIL CR is indicated for the treatment of major depressive disorder. The efficacy of PAXIL CR in the treatment of a major depressive episode was established in two 12-week controlled trials of outpatients whose diagnoses corresponded to the DSM-IV category of major depressive disorder (see CLINICAL PHARMACOLOGY—Clinical Trials). A major depressive episode (DSM-IV) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed mood or loss of interest or pleasure in nearly all activities, representing a change from previous functioning, and includes the presence of at least 5 of the following 9 symptoms during the same 2-week period: Depressed mood, markedly diminished interest or pleasure in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt, or suicidal ideation. The antidepressant action of paroxetine in hospitalized depressed patients has not been adequately studied. PAXIL CR has not been systematically evaluated beyond 12 weeks in controlled clinical trials; however, the effectiveness of immediate-release paroxetine hydrochloride in maintaining a response in major depressive disorder for up to 1 year has been demonstrated in a placebo-controlled trial (see CLINICAL PHARMACOLOGY—Clinical Trials). The physician who elects to use PAXIL CR for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient. Panic Disorder PAXIL CR is indicated for the treatment of panic disorder, with or without agoraphobia, as defined in DSM-IV. Panic disorder is characterized by the occurrence of unexpected panic attacks and associated concern about having additional attacks, worry about the implications or consequences of the attacks, and/or a significant change in behavior related to the attacks. The efficacy of PAXIL CR controlled-release tablets was established in two 10-week trials in panic disorder patients whose diagnoses corresponded to the DSM-IV category of panic disorder (see CLINICAL PHARMACOLOGY—Clinical Trials). Panic disorder (DSM-IV) is characterized by recurrent unexpected panic attacks, i.e., a discrete period of intense fear or discomfort in which 4 (or more) of the following symptoms develop abruptly and reach a peak within 10 minutes: (1) palpitations, pounding heart, or accelerated heart rate; (2) sweating; (3) trembling or shaking; (4) sensations of shortness of breath or smothering; (5) feeling of choking; (6) chest pain or discomfort; (7) nausea or abdominal distress; (8) feeling dizzy, unsteady, lightheaded, or faint; (9) derealization (feelings of unreality) or depersonalization (being detached from oneself); (10) fear of losing control; (11) fear of dying; (12) paresthesias (numbness or tingling sensations); (13) chills or hot flushes. Long-term maintenance of efficacy with the immediate-release formulation of paroxetine was demonstrated in a 3-month relapse prevention trial. In this trial, patients with panic disorder assigned to immediate-release paroxetine demonstrated a lower relapse rate compared to patients on placebo (see CLINICAL PHARMACOLOGY—Clinical Trials). Nevertheless, the physician who prescribes PAXIL CR for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient. Social Anxiety Disorder PAXIL CR is indicated for the treatment of social anxiety disorder, also known as social phobia, as defined in DSM-IV (300.23). Social anxiety disorder is characterized by a marked and persistent fear of 1 or more social or performance situations in which the person is exposed to unfamiliar people or to possible scrutiny by others. Exposure to the feared situation almost invariably provokes anxiety, which may approach the intensity of a panic attack. The feared situations are avoided or endured with intense anxiety or distress. The avoidance, anxious anticipation, or distress in the feared situation(s) interferes significantly with the person's normal routine, occupational or academic functioning, or social activities or relationships, or there is marked distress about having the phobias. Lesser degrees of performance anxiety or shyness generally do not require psychopharmacological treatment. The efficacy of PAXIL CR as a treatment for social anxiety disorder has been established, in part, on the basis of extrapolation from the established effectiveness of the immediate-release formulation of paroxetine. In addition, the efficacy of PAXIL CR was established in a 12-week trial, in adult outpatients with social anxiety disorder (DSM-IV). PAXIL CR has not been studied in children or adolescents with social phobia (see CLINICAL PHARMACOLOGY—Clinical Trials). The effectiveness of PAXIL CR in long-term treatment of social anxiety disorder, i.e., for more than 12 weeks, has not been systematically evaluated in adequate and well-controlled trials. Therefore, the physician who elects to prescribe PAXIL CR for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION). Premenstrual Dysphoric Disorder PAXIL CR is indicated for the treatment of PMDD. The efficacy of PAXIL CR in the treatment of PMDD has been established in 3 placebo-controlled trials (see CLINICAL PHARMACOLOGY—Clinical Trials). The essential features of PMDD, according to DSM-IV, include markedly depressed mood, anxiety or tension, affective lability, and persistent anger or irritability. Other features include decreased interest in usual activities, difficulty concentrating, lack of energy, change in appetite or sleep, and feeling out of control. Physical symptoms associated with PMDD include breast tenderness, headache, joint and muscle pain, bloating, and weight gain. These symptoms occur regularly during the luteal phase and remit within a few days following the onset of menses; the disturbance markedly interferes with work or school or with usual social activities and relationships with others. In making the diagnosis, care should be taken to rule out other cyclical mood disorders that may be exacerbated by treatment with an antidepressant. The effectiveness of PAXIL CR in long-term use, that is, for more than 3 menstrual cycles, has not been systematically evaluated in controlled trials. Therefore, the physician who elects to use PAXIL CR for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient. uuid:f23315d8-a608-4d1a-9dca-8391dc759744 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7936 biolink:treats MONDO:0005383 PMID:41385096 "[{""id"":""uuid:44643dc6-ed8c-4aa0-8e3d-c35ce953766f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:05d19643-0f83-4235-876d-d5e44d61dc60"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Major Depressive Disorder PAXIL CR is indicated for the treatment of major depressive disorder. The efficacy of PAXIL CR in the treatment of a major depressive episode was established in two 12-week controlled trials of outpatients whose diagnoses corresponded to the DSM-IV category of major depressive disorder (see CLINICAL PHARMACOLOGY—Clinical Trials). A major depressive episode (DSM-IV) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed mood or loss of interest or pleasure in nearly all activities, representing a change from previous functioning, and includes the presence of at least 5 of the following 9 symptoms during the same 2-week period: Depressed mood, markedly diminished interest or pleasure in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt, or suicidal ideation. The antidepressant action of paroxetine in hospitalized depressed patients has not been adequately studied. PAXIL CR has not been systematically evaluated beyond 12 weeks in controlled clinical trials; however, the effectiveness of immediate-release paroxetine hydrochloride in maintaining a response in major depressive disorder for up to 1 year has been demonstrated in a placebo-controlled trial (see CLINICAL PHARMACOLOGY—Clinical Trials). The physician who elects to use PAXIL CR for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient. Panic Disorder PAXIL CR is indicated for the treatment of panic disorder, with or without agoraphobia, as defined in DSM-IV. Panic disorder is characterized by the occurrence of unexpected panic attacks and associated concern about having additional attacks, worry about the implications or consequences of the attacks, and/or a significant change in behavior related to the attacks. The efficacy of PAXIL CR controlled-release tablets was established in two 10-week trials in panic disorder patients whose diagnoses corresponded to the DSM-IV category of panic disorder (see CLINICAL PHARMACOLOGY—Clinical Trials). Panic disorder (DSM-IV) is characterized by recurrent unexpected panic attacks, i.e., a discrete period of intense fear or discomfort in which 4 (or more) of the following symptoms develop abruptly and reach a peak within 10 minutes: (1) palpitations, pounding heart, or accelerated heart rate; (2) sweating; (3) trembling or shaking; (4) sensations of shortness of breath or smothering; (5) feeling of choking; (6) chest pain or discomfort; (7) nausea or abdominal distress; (8) feeling dizzy, unsteady, lightheaded, or faint; (9) derealization (feelings of unreality) or depersonalization (being detached from oneself); (10) fear of losing control; (11) fear of dying; (12) paresthesias (numbness or tingling sensations); (13) chills or hot flushes. Long-term maintenance of efficacy with the immediate-release formulation of paroxetine was demonstrated in a 3-month relapse prevention trial. In this trial, patients with panic disorder assigned to immediate-release paroxetine demonstrated a lower relapse rate compared to patients on placebo (see CLINICAL PHARMACOLOGY—Clinical Trials). Nevertheless, the physician who prescribes PAXIL CR for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient. Social Anxiety Disorder PAXIL CR is indicated for the treatment of social anxiety disorder, also known as social phobia, as defined in DSM-IV (300.23). Social anxiety disorder is characterized by a marked and persistent fear of 1 or more social or performance situations in which the person is exposed to unfamiliar people or to possible scrutiny by others. Exposure to the feared situation almost invariably provokes anxiety, which may approach the intensity of a panic attack. The feared situations are avoided or endured with intense anxiety or distress. The avoidance, anxious anticipation, or distress in the feared situation(s) interferes significantly with the person's normal routine, occupational or academic functioning, or social activities or relationships, or there is marked distress about having the phobias. Lesser degrees of performance anxiety or shyness generally do not require psychopharmacological treatment. The efficacy of PAXIL CR as a treatment for social anxiety disorder has been established, in part, on the basis of extrapolation from the established effectiveness of the immediate-release formulation of paroxetine. In addition, the efficacy of PAXIL CR was established in a 12-week trial, in adult outpatients with social anxiety disorder (DSM-IV). PAXIL CR has not been studied in children or adolescents with social phobia (see CLINICAL PHARMACOLOGY—Clinical Trials). The effectiveness of PAXIL CR in long-term treatment of social anxiety disorder, i.e., for more than 12 weeks, has not been systematically evaluated in adequate and well-controlled trials. Therefore, the physician who elects to prescribe PAXIL CR for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION). Premenstrual Dysphoric Disorder PAXIL CR is indicated for the treatment of PMDD. The efficacy of PAXIL CR in the treatment of PMDD has been established in 3 placebo-controlled trials (see CLINICAL PHARMACOLOGY—Clinical Trials). The essential features of PMDD, according to DSM-IV, include markedly depressed mood, anxiety or tension, affective lability, and persistent anger or irritability. Other features include decreased interest in usual activities, difficulty concentrating, lack of energy, change in appetite or sleep, and feeling out of control. Physical symptoms associated with PMDD include breast tenderness, headache, joint and muscle pain, bloating, and weight gain. These symptoms occur regularly during the luteal phase and remit within a few days following the onset of menses; the disturbance markedly interferes with work or school or with usual social activities and relationships with others. In making the diagnosis, care should be taken to rule out other cyclical mood disorders that may be exacerbated by treatment with an antidepressant. The effectiveness of PAXIL CR in long-term use, that is, for more than 3 menstrual cycles, has not been systematically evaluated in controlled trials. Therefore, the physician who elects to use PAXIL CR for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient. uuid:767ef148-15ba-49f1-9a98-e3d936e7faa1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7936 biolink:treats MONDO:0003709 PMID:41385096 "[{""id"":""uuid:c6c7a1ac-321e-4676-a1bc-37efc84526dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:531dbd9e-030b-4884-ad33-bf6307d1e539"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Major Depressive Disorder PAXIL CR is indicated for the treatment of major depressive disorder. The efficacy of PAXIL CR in the treatment of a major depressive episode was established in two 12-week controlled trials of outpatients whose diagnoses corresponded to the DSM-IV category of major depressive disorder (see CLINICAL PHARMACOLOGY—Clinical Trials). A major depressive episode (DSM-IV) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed mood or loss of interest or pleasure in nearly all activities, representing a change from previous functioning, and includes the presence of at least 5 of the following 9 symptoms during the same 2-week period: Depressed mood, markedly diminished interest or pleasure in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt, or suicidal ideation. The antidepressant action of paroxetine in hospitalized depressed patients has not been adequately studied. PAXIL CR has not been systematically evaluated beyond 12 weeks in controlled clinical trials; however, the effectiveness of immediate-release paroxetine hydrochloride in maintaining a response in major depressive disorder for up to 1 year has been demonstrated in a placebo-controlled trial (see CLINICAL PHARMACOLOGY—Clinical Trials). The physician who elects to use PAXIL CR for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient. Panic Disorder PAXIL CR is indicated for the treatment of panic disorder, with or without agoraphobia, as defined in DSM-IV. Panic disorder is characterized by the occurrence of unexpected panic attacks and associated concern about having additional attacks, worry about the implications or consequences of the attacks, and/or a significant change in behavior related to the attacks. The efficacy of PAXIL CR controlled-release tablets was established in two 10-week trials in panic disorder patients whose diagnoses corresponded to the DSM-IV category of panic disorder (see CLINICAL PHARMACOLOGY—Clinical Trials). Panic disorder (DSM-IV) is characterized by recurrent unexpected panic attacks, i.e., a discrete period of intense fear or discomfort in which 4 (or more) of the following symptoms develop abruptly and reach a peak within 10 minutes: (1) palpitations, pounding heart, or accelerated heart rate; (2) sweating; (3) trembling or shaking; (4) sensations of shortness of breath or smothering; (5) feeling of choking; (6) chest pain or discomfort; (7) nausea or abdominal distress; (8) feeling dizzy, unsteady, lightheaded, or faint; (9) derealization (feelings of unreality) or depersonalization (being detached from oneself); (10) fear of losing control; (11) fear of dying; (12) paresthesias (numbness or tingling sensations); (13) chills or hot flushes. Long-term maintenance of efficacy with the immediate-release formulation of paroxetine was demonstrated in a 3-month relapse prevention trial. In this trial, patients with panic disorder assigned to immediate-release paroxetine demonstrated a lower relapse rate compared to patients on placebo (see CLINICAL PHARMACOLOGY—Clinical Trials). Nevertheless, the physician who prescribes PAXIL CR for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient. Social Anxiety Disorder PAXIL CR is indicated for the treatment of social anxiety disorder, also known as social phobia, as defined in DSM-IV (300.23). Social anxiety disorder is characterized by a marked and persistent fear of 1 or more social or performance situations in which the person is exposed to unfamiliar people or to possible scrutiny by others. Exposure to the feared situation almost invariably provokes anxiety, which may approach the intensity of a panic attack. The feared situations are avoided or endured with intense anxiety or distress. The avoidance, anxious anticipation, or distress in the feared situation(s) interferes significantly with the person's normal routine, occupational or academic functioning, or social activities or relationships, or there is marked distress about having the phobias. Lesser degrees of performance anxiety or shyness generally do not require psychopharmacological treatment. The efficacy of PAXIL CR as a treatment for social anxiety disorder has been established, in part, on the basis of extrapolation from the established effectiveness of the immediate-release formulation of paroxetine. In addition, the efficacy of PAXIL CR was established in a 12-week trial, in adult outpatients with social anxiety disorder (DSM-IV). PAXIL CR has not been studied in children or adolescents with social phobia (see CLINICAL PHARMACOLOGY—Clinical Trials). The effectiveness of PAXIL CR in long-term treatment of social anxiety disorder, i.e., for more than 12 weeks, has not been systematically evaluated in adequate and well-controlled trials. Therefore, the physician who elects to prescribe PAXIL CR for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION). Premenstrual Dysphoric Disorder PAXIL CR is indicated for the treatment of PMDD. The efficacy of PAXIL CR in the treatment of PMDD has been established in 3 placebo-controlled trials (see CLINICAL PHARMACOLOGY—Clinical Trials). The essential features of PMDD, according to DSM-IV, include markedly depressed mood, anxiety or tension, affective lability, and persistent anger or irritability. Other features include decreased interest in usual activities, difficulty concentrating, lack of energy, change in appetite or sleep, and feeling out of control. Physical symptoms associated with PMDD include breast tenderness, headache, joint and muscle pain, bloating, and weight gain. These symptoms occur regularly during the luteal phase and remit within a few days following the onset of menses; the disturbance markedly interferes with work or school or with usual social activities and relationships with others. In making the diagnosis, care should be taken to rule out other cyclical mood disorders that may be exacerbated by treatment with an antidepressant. The effectiveness of PAXIL CR in long-term use, that is, for more than 3 menstrual cycles, has not been systematically evaluated in controlled trials. Therefore, the physician who elects to use PAXIL CR for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient. uuid:da725ed1-f607-4bfc-911d-9064a5757eb9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7936 biolink:treats MONDO:0001247 PMID:41385096 "[{""id"":""uuid:85b530db-7ccc-4240-8324-95ce1ae5a09a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:aeb3eb46-a4fe-4c2a-b922-045585f35156"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f02165fb-6029-49e2-bb05-990caf861bab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Major Depressive Disorder PAXIL CR is indicated for the treatment of major depressive disorder. The efficacy of PAXIL CR in the treatment of a major depressive episode was established in two 12-week controlled trials of outpatients whose diagnoses corresponded to the DSM-IV category of major depressive disorder (see CLINICAL PHARMACOLOGY—Clinical Trials). A major depressive episode (DSM-IV) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed mood or loss of interest or pleasure in nearly all activities, representing a change from previous functioning, and includes the presence of at least 5 of the following 9 symptoms during the same 2-week period: Depressed mood, markedly diminished interest or pleasure in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt, or suicidal ideation. The antidepressant action of paroxetine in hospitalized depressed patients has not been adequately studied. PAXIL CR has not been systematically evaluated beyond 12 weeks in controlled clinical trials; however, the effectiveness of immediate-release paroxetine hydrochloride in maintaining a response in major depressive disorder for up to 1 year has been demonstrated in a placebo-controlled trial (see CLINICAL PHARMACOLOGY—Clinical Trials). The physician who elects to use PAXIL CR for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient. Panic Disorder PAXIL CR is indicated for the treatment of panic disorder, with or without agoraphobia, as defined in DSM-IV. Panic disorder is characterized by the occurrence of unexpected panic attacks and associated concern about having additional attacks, worry about the implications or consequences of the attacks, and/or a significant change in behavior related to the attacks. The efficacy of PAXIL CR controlled-release tablets was established in two 10-week trials in panic disorder patients whose diagnoses corresponded to the DSM-IV category of panic disorder (see CLINICAL PHARMACOLOGY—Clinical Trials). Panic disorder (DSM-IV) is characterized by recurrent unexpected panic attacks, i.e., a discrete period of intense fear or discomfort in which 4 (or more) of the following symptoms develop abruptly and reach a peak within 10 minutes: (1) palpitations, pounding heart, or accelerated heart rate; (2) sweating; (3) trembling or shaking; (4) sensations of shortness of breath or smothering; (5) feeling of choking; (6) chest pain or discomfort; (7) nausea or abdominal distress; (8) feeling dizzy, unsteady, lightheaded, or faint; (9) derealization (feelings of unreality) or depersonalization (being detached from oneself); (10) fear of losing control; (11) fear of dying; (12) paresthesias (numbness or tingling sensations); (13) chills or hot flushes. Long-term maintenance of efficacy with the immediate-release formulation of paroxetine was demonstrated in a 3-month relapse prevention trial. In this trial, patients with panic disorder assigned to immediate-release paroxetine demonstrated a lower relapse rate compared to patients on placebo (see CLINICAL PHARMACOLOGY—Clinical Trials). Nevertheless, the physician who prescribes PAXIL CR for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient. Social Anxiety Disorder PAXIL CR is indicated for the treatment of social anxiety disorder, also known as social phobia, as defined in DSM-IV (300.23). Social anxiety disorder is characterized by a marked and persistent fear of 1 or more social or performance situations in which the person is exposed to unfamiliar people or to possible scrutiny by others. Exposure to the feared situation almost invariably provokes anxiety, which may approach the intensity of a panic attack. The feared situations are avoided or endured with intense anxiety or distress. The avoidance, anxious anticipation, or distress in the feared situation(s) interferes significantly with the person's normal routine, occupational or academic functioning, or social activities or relationships, or there is marked distress about having the phobias. Lesser degrees of performance anxiety or shyness generally do not require psychopharmacological treatment. The efficacy of PAXIL CR as a treatment for social anxiety disorder has been established, in part, on the basis of extrapolation from the established effectiveness of the immediate-release formulation of paroxetine. In addition, the efficacy of PAXIL CR was established in a 12-week trial, in adult outpatients with social anxiety disorder (DSM-IV). PAXIL CR has not been studied in children or adolescents with social phobia (see CLINICAL PHARMACOLOGY—Clinical Trials). The effectiveness of PAXIL CR in long-term treatment of social anxiety disorder, i.e., for more than 12 weeks, has not been systematically evaluated in adequate and well-controlled trials. Therefore, the physician who elects to prescribe PAXIL CR for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION). Premenstrual Dysphoric Disorder PAXIL CR is indicated for the treatment of PMDD. The efficacy of PAXIL CR in the treatment of PMDD has been established in 3 placebo-controlled trials (see CLINICAL PHARMACOLOGY—Clinical Trials). The essential features of PMDD, according to DSM-IV, include markedly depressed mood, anxiety or tension, affective lability, and persistent anger or irritability. Other features include decreased interest in usual activities, difficulty concentrating, lack of energy, change in appetite or sleep, and feeling out of control. Physical symptoms associated with PMDD include breast tenderness, headache, joint and muscle pain, bloating, and weight gain. These symptoms occur regularly during the luteal phase and remit within a few days following the onset of menses; the disturbance markedly interferes with work or school or with usual social activities and relationships with others. In making the diagnosis, care should be taken to rule out other cyclical mood disorders that may be exacerbated by treatment with an antidepressant. The effectiveness of PAXIL CR in long-term use, that is, for more than 3 menstrual cycles, has not been systematically evaluated in controlled trials. Therefore, the physician who elects to use PAXIL CR for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient.|[PMDA] Drugs with a new additional indication and a new dosage for the treatment of social anxiety disorder. uuid:ec184ecf-dd66-45ed-911a-b2508ad52a83 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7936 biolink:treats MONDO:1010182 PMID:41385096 "[{""id"":""uuid:82c7da3c-e4e5-4366-af0f-dcebc48e4be8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dcd5f233-08ee-4bd3-b82c-2cfefde261a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Major Depressive Disorder PAXIL CR is indicated for the treatment of major depressive disorder. The efficacy of PAXIL CR in the treatment of a major depressive episode was established in two 12-week controlled trials of outpatients whose diagnoses corresponded to the DSM-IV category of major depressive disorder (see CLINICAL PHARMACOLOGY—Clinical Trials). A major depressive episode (DSM-IV) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed mood or loss of interest or pleasure in nearly all activities, representing a change from previous functioning, and includes the presence of at least 5 of the following 9 symptoms during the same 2-week period: Depressed mood, markedly diminished interest or pleasure in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt, or suicidal ideation. The antidepressant action of paroxetine in hospitalized depressed patients has not been adequately studied. PAXIL CR has not been systematically evaluated beyond 12 weeks in controlled clinical trials; however, the effectiveness of immediate-release paroxetine hydrochloride in maintaining a response in major depressive disorder for up to 1 year has been demonstrated in a placebo-controlled trial (see CLINICAL PHARMACOLOGY—Clinical Trials). The physician who elects to use PAXIL CR for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient. Panic Disorder PAXIL CR is indicated for the treatment of panic disorder, with or without agoraphobia, as defined in DSM-IV. Panic disorder is characterized by the occurrence of unexpected panic attacks and associated concern about having additional attacks, worry about the implications or consequences of the attacks, and/or a significant change in behavior related to the attacks. The efficacy of PAXIL CR controlled-release tablets was established in two 10-week trials in panic disorder patients whose diagnoses corresponded to the DSM-IV category of panic disorder (see CLINICAL PHARMACOLOGY—Clinical Trials). Panic disorder (DSM-IV) is characterized by recurrent unexpected panic attacks, i.e., a discrete period of intense fear or discomfort in which 4 (or more) of the following symptoms develop abruptly and reach a peak within 10 minutes: (1) palpitations, pounding heart, or accelerated heart rate; (2) sweating; (3) trembling or shaking; (4) sensations of shortness of breath or smothering; (5) feeling of choking; (6) chest pain or discomfort; (7) nausea or abdominal distress; (8) feeling dizzy, unsteady, lightheaded, or faint; (9) derealization (feelings of unreality) or depersonalization (being detached from oneself); (10) fear of losing control; (11) fear of dying; (12) paresthesias (numbness or tingling sensations); (13) chills or hot flushes. Long-term maintenance of efficacy with the immediate-release formulation of paroxetine was demonstrated in a 3-month relapse prevention trial. In this trial, patients with panic disorder assigned to immediate-release paroxetine demonstrated a lower relapse rate compared to patients on placebo (see CLINICAL PHARMACOLOGY—Clinical Trials). Nevertheless, the physician who prescribes PAXIL CR for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient. Social Anxiety Disorder PAXIL CR is indicated for the treatment of social anxiety disorder, also known as social phobia, as defined in DSM-IV (300.23). Social anxiety disorder is characterized by a marked and persistent fear of 1 or more social or performance situations in which the person is exposed to unfamiliar people or to possible scrutiny by others. Exposure to the feared situation almost invariably provokes anxiety, which may approach the intensity of a panic attack. The feared situations are avoided or endured with intense anxiety or distress. The avoidance, anxious anticipation, or distress in the feared situation(s) interferes significantly with the person's normal routine, occupational or academic functioning, or social activities or relationships, or there is marked distress about having the phobias. Lesser degrees of performance anxiety or shyness generally do not require psychopharmacological treatment. The efficacy of PAXIL CR as a treatment for social anxiety disorder has been established, in part, on the basis of extrapolation from the established effectiveness of the immediate-release formulation of paroxetine. In addition, the efficacy of PAXIL CR was established in a 12-week trial, in adult outpatients with social anxiety disorder (DSM-IV). PAXIL CR has not been studied in children or adolescents with social phobia (see CLINICAL PHARMACOLOGY—Clinical Trials). The effectiveness of PAXIL CR in long-term treatment of social anxiety disorder, i.e., for more than 12 weeks, has not been systematically evaluated in adequate and well-controlled trials. Therefore, the physician who elects to prescribe PAXIL CR for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION). Premenstrual Dysphoric Disorder PAXIL CR is indicated for the treatment of PMDD. The efficacy of PAXIL CR in the treatment of PMDD has been established in 3 placebo-controlled trials (see CLINICAL PHARMACOLOGY—Clinical Trials). The essential features of PMDD, according to DSM-IV, include markedly depressed mood, anxiety or tension, affective lability, and persistent anger or irritability. Other features include decreased interest in usual activities, difficulty concentrating, lack of energy, change in appetite or sleep, and feeling out of control. Physical symptoms associated with PMDD include breast tenderness, headache, joint and muscle pain, bloating, and weight gain. These symptoms occur regularly during the luteal phase and remit within a few days following the onset of menses; the disturbance markedly interferes with work or school or with usual social activities and relationships with others. In making the diagnosis, care should be taken to rule out other cyclical mood disorders that may be exacerbated by treatment with an antidepressant. The effectiveness of PAXIL CR in long-term use, that is, for more than 3 menstrual cycles, has not been systematically evaluated in controlled trials. Therefore, the physician who elects to use PAXIL CR for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient. UMLS:C0520676 uuid:da286ebd-a03e-4fff-b026-9c81ba8768d1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64312 biolink:treats MONDO:0004975 PMID:41385096 "[{""id"":""uuid:38585cf9-620e-4cdb-83f2-33df2ede5931"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:48474a98-8ecd-4faf-ad36-ef582605a180"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e6018c8a-ed1a-4d26-bab1-e95a5c70dab9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/nemdatine""]},{""id"":""uuid:1fb75afe-f12d-4944-8554-6dd1aae18daf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Namenda (memantine hydrochloride) is indicated for the treatment of moderate to severe dementia of the Alzheimer's type.|[EMA] Treatment of patients with moderate to severe Alzheimer’s disease.|[PMDA] Drugs with a new active ingredient indicated for inhibition of progression of symptoms of dementia in moderate and severe Alzheimer's dementia. uuid:b6ffb45c-0c46-484b-b0a5-94ee99604499 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:43755 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:e6a8acef-aa2d-4c6a-b21a-ca25728bd549"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:34247c54-847e-4e28-b477-ea8e5babb249"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension: Lisinopril tablets are indicated for the treatment of hypertension. It may be used alone as initial therapy or concomitantly with other classes of antihypertensive agents. Heart Failure: Lisinopril tablets are indicated as adjunctive therapy in the management of heart failure in patients who are not responding adequately to diuretics and digitalis. Acute Myocardial Infarction: Lisinopril tablets are indicated for the treatment of hemodynamically stable patients within 24 hours of acute myocardial infarction, to improve survival. Patients should receive, as appropriate, the standard recommended treatments such as thrombolytics, aspirin and beta blockers. In using lisinopril tablets, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that lisinopril does not have a similar risk. (See WARNINGS .) In considering the use of lisinopril tablets, it should be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in Black patients than in non-Blacks. In addition, ACE inhibitors have been associated with a higher rate of angioedema in Black than in non-Black patients (see WARNINGS, Anaphylactoid and Possibly Related Reactions ). uuid:13f5aef5-b893-4c4c-9f30-a888f0792d29 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:43755 biolink:treats MONDO:0004781 PMID:41385096 "[{""id"":""uuid:49423360-b5c0-4f35-afef-3fdaa4b213f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e6c2ca47-8fff-44f5-86d6-4ec075a1c34f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension: Lisinopril tablets are indicated for the treatment of hypertension. It may be used alone as initial therapy or concomitantly with other classes of antihypertensive agents. Heart Failure: Lisinopril tablets are indicated as adjunctive therapy in the management of heart failure in patients who are not responding adequately to diuretics and digitalis. Acute Myocardial Infarction: Lisinopril tablets are indicated for the treatment of hemodynamically stable patients within 24 hours of acute myocardial infarction, to improve survival. Patients should receive, as appropriate, the standard recommended treatments such as thrombolytics, aspirin and beta blockers. In using lisinopril tablets, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that lisinopril does not have a similar risk. (See WARNINGS .) In considering the use of lisinopril tablets, it should be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in Black patients than in non-Blacks. In addition, ACE inhibitors have been associated with a higher rate of angioedema in Black than in non-Black patients (see WARNINGS, Anaphylactoid and Possibly Related Reactions ). uuid:b5be6211-d176-49a2-ad14-e5ece91e4e13 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6775 biolink:treats MONDO:0005101 PMID:41385096 "[{""id"":""uuid:532cf89b-0c21-4841-83c0-e67ce22945a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:86742fcb-397f-4dc8-aab6-be3ab2260011"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:8bc4997e-e0ea-4460-979e-69175da9d754"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Asacol tablets are indicated for the treatment of mildly to moderately active ulcerative colitis and for the maintenance of remission of ulcerative colitis.|[PMDA] A drug in a new dosage form indicated for the treatment of ulcerative colitis (excluding severe cases). uuid:7390f6ed-0064-4ac8-b4b7-f04f4c6a26a3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3614 biolink:treats MONDO:0009850 PMID:41385096 "[{""id"":""uuid:c7fc3a5a-9078-4a12-bfd1-acd6e0ab72e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:68ba28d8-9a0b-4500-ac1b-8aead06d604b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PerioChip is indicated as an adjunct to scaling and root planing procedures for reduction of pocket depth in patients with adult periodontitis. PerioChip may be used as a part of a periodontal maintenance program, which includes good oral hygiene and scaling and root planing. uuid:ecadccd6-d48e-406b-a6da-65465854f597 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3048 biolink:treats MONDO:0021095 PMID:41385096 "[{""id"":""uuid:3ff63b68-8b38-4beb-95bc-bebf69f7d207"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:da20f130-456b-4bc5-96cf-62674b143459"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For use as an adjunct in the therapy of all forms of parkinsonism. Useful also in the control of extrapyramidal disorders (except tardive dyskinesia - see PRECAUTIONS ) due to neuroleptic drugs (e.g., phenothiazines). uuid:9b654094-e9cd-48c5-bfe8-d710d332e18d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3048 biolink:treats HP:0002071 PMID:41385096 "[{""id"":""uuid:b6053271-40bb-4946-bfc1-d416f95f726a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:17ada979-85ce-408f-89ac-037bc79ce2c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For use as an adjunct in the therapy of all forms of parkinsonism. Useful also in the control of extrapyramidal disorders (except tardive dyskinesia - see PRECAUTIONS ) due to neuroleptic drugs (e.g., phenothiazines). uuid:2f591bc3-07d5-4306-a317-1f47cf982658 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3048 biolink:treats MONDO:0010096 PMID:41385096 "[{""id"":""uuid:0ece8368-a51a-4c86-afe5-7f08d9d3ff71"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:adf2900c-a595-40a2-a685-2bc591775cf2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For use as an adjunct in the therapy of all forms of parkinsonism. Useful also in the control of extrapyramidal disorders (except tardive dyskinesia - see PRECAUTIONS ) due to neuroleptic drugs (e.g., phenothiazines). uuid:dda799de-5e7e-4269-be90-45399276728e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8874 biolink:treats MONDO:0004975 PMID:41385096 "[{""id"":""uuid:61ff6183-97c2-458a-b95d-c88da52f9b92"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b9d2be6a-aa53-4eb4-8cec-76e5610f90cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:50984212-5630-4972-994b-c2200ea5eba2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/prometax""]},{""id"":""uuid:bedb50e0-b4d4-43e3-9b52-4052eaad4916"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Alzheimer’s Disease Exelon Patch (rivastigmine transdermal system) is indicated for the treatment of mild to moderate dementia of the Alzheimer’s type. 1.2 Parkinson’s Disease Dementia Exelon Patch (rivastigmine transdermal system) is indicated for the treatment of mild to moderate dementia associated with Parkinson’s disease. The dementia of Parkinson’s disease is purportedly characterized by impairments in executive function, memory retrieval, and attention in patients with an established diagnosis of Parkinson’s disease. The diagnosis of dementia of Parkinson’s disease can be made reliably in patients in whom a progressive dementia syndrome occurs (without the necessity to document the specific deficits described above) at least 2 years after a diagnosis of Parkinson’s disease has been made, and in whom other causes of dementia have been ruled out.|[EMA] Symptomatic treatment of mild to moderately severe Alzheimer's dementia.Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.|[PMDA] Drugs with a new active ingredient indicated for inhibition of progression of symptoms of dementia in mild and moderate Alzheimer's dementia. uuid:46a96ac6-3959-461f-8eb8-6fe273d8ac32 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8874 biolink:treats UMLS:C0236960 PMID:41385096 "[{""id"":""uuid:cdf15fb9-b161-494b-bc78-aada00ca056e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c2a11dd2-0196-487d-954f-6baf2d687b7d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Alzheimer’s Disease Exelon Patch (rivastigmine transdermal system) is indicated for the treatment of mild to moderate dementia of the Alzheimer’s type. 1.2 Parkinson’s Disease Dementia Exelon Patch (rivastigmine transdermal system) is indicated for the treatment of mild to moderate dementia associated with Parkinson’s disease. The dementia of Parkinson’s disease is purportedly characterized by impairments in executive function, memory retrieval, and attention in patients with an established diagnosis of Parkinson’s disease. The diagnosis of dementia of Parkinson’s disease can be made reliably in patients in whom a progressive dementia syndrome occurs (without the necessity to document the specific deficits described above) at least 2 years after a diagnosis of Parkinson’s disease has been made, and in whom other causes of dementia have been ruled out. uuid:4fb8d947-2177-4af2-9f11-57aa14a6c54b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5109 biolink:treats MONDO:0005093 PMID:41385096 "[{""id"":""uuid:d89af6c9-3ece-46a6-82e7-5220d44d0c65"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:130f7041-f478-46f4-9e89-35d511a56f15"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fluocinonide Cream is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. uuid:b51093ae-0d81-4513-9f43-e3e8020087ab biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1162789 biolink:treats NCIT:C27003 PMID:41385096 "[{""id"":""uuid:af6417c2-2fb1-4835-bb34-f9b1edbd83c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7a925a15-cece-417c-b8b6-3d373363b297"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of hydrocodone bitartrate and ibuprofen tablets and other treatment options before deciding to use hydrocodone bitartrate and ibuprofen tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Hydrocodone bitartrate and ibuprofen tablets are indicated for the short-term (generally less than 10 days) management of acute pain. Hydrocodone bitartrate and ibuprofen tablets are not indicated for the treatment of such conditions as osteoarthritis or rheumatoid arthritis. uuid:b2d6c6fd-5493-49c7-8ef7-fb381949f523 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1162789 biolink:treats MONDO:0005178 PMID:41385096 "[{""id"":""uuid:7d50bbb7-316c-4556-a600-dd0c18a986d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:71993012-5763-4683-b8ec-b8df78dfb8b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of hydrocodone bitartrate and ibuprofen tablets and other treatment options before deciding to use hydrocodone bitartrate and ibuprofen tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Hydrocodone bitartrate and ibuprofen tablets are indicated for the short-term (generally less than 10 days) management of acute pain. Hydrocodone bitartrate and ibuprofen tablets are not indicated for the treatment of such conditions as osteoarthritis or rheumatoid arthritis. uuid:4090f193-de26-44b1-95b4-529db452fd56 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1162789 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:f52c0147-5b30-4eac-8d14-da3c5bc102cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ad971a19-6448-464b-ace7-e7fcdf46ddce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of hydrocodone bitartrate and ibuprofen tablets and other treatment options before deciding to use hydrocodone bitartrate and ibuprofen tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Hydrocodone bitartrate and ibuprofen tablets are indicated for the short-term (generally less than 10 days) management of acute pain. Hydrocodone bitartrate and ibuprofen tablets are not indicated for the treatment of such conditions as osteoarthritis or rheumatoid arthritis. uuid:cbc94619-6000-40bc-ba72-fa624a353880 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6722 biolink:treats MONDO:0012268 PMID:41385096 "[{""id"":""uuid:e74874b9-ef8a-436e-b526-cf9cdf37c773"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9ec907d0-19ce-4671-be9c-ff42d964a0c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Megace ® ES (megestrol acetate) oral suspension is indicated for the treatment of anorexia, cachexia, or an unexplained, significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (AIDS). uuid:5f116e89-4027-4131-adde-1cb290d4f24d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6722 biolink:treats MONDO:0005351 PMID:41385096 "[{""id"":""uuid:2946db0d-e7f0-403d-9477-b8fc6a453020"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ccebbc8b-6a38-44aa-aa17-80ee6b159f37"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Megace ® ES (megestrol acetate) oral suspension is indicated for the treatment of anorexia, cachexia, or an unexplained, significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (AIDS). uuid:2f79c274-ccf1-4797-927e-29d01a5a2337 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16469 biolink:treats MONDO:0008159 PMID:41385096 "[{""id"":""uuid:cb3597c4-4c86-446c-b29b-61941fe9db86"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4896f92f-a1d9-4535-9b4a-5672a99e1755"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c79857ff-d6f4-440d-849a-c596fcdcd078"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Estradiol Transdermal System Continuous Delivery (Once-Weekly), USP is indicated in the: Treatment of moderate to severe vasomotor symptoms associated with the menopause. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. Treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. Prevention of postmenopausal osteoporosis. When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and non-estrogen medications should be carefully considered. The mainstays for decreasing the risk of postmenopausal osteoporosis are weight bearing exercise, adequate calcium and vitamin D intake, and when indicated, pharmacologic therapy. Postmenopausal women require an average of 1500 mg/day of elemental calcium. Therefore, when not contraindicated, calcium supplementation may be helpful for women with suboptimal dietary intake. Vitamin D supplementation of 400 IU/day to 800 IU/day may also be required to ensure adequate daily intake in postmenopausal women.|[PMDA] A new combination drug and 2) a drug with a new indication and a new dosage for the treatment of postmenopausal osteoporosis. uuid:1aac720f-e231-4bde-af8c-09e7143b53ca biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:40279 biolink:treats HP:0033073 PMID:41385096 "[{""id"":""uuid:7709bd71-304e-483a-93e8-1bd76d7eb77d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:60c8dba8-ae02-4dcf-a08c-69f9d555c09e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] THIS IS NOT AN INNOCUOUS DRUG. IT IS NOT RECOMMENDED FOR THE TREATMENT OF ASYMPTOMATIC HYPERURICEMIA. Allopurinol reduces serum and urinary uric acid concentrations. Its use should be individualized for each patient and requires an understanding of its mode of action and pharmacokinetics (see CLINICAL PHARMACOLOGY , CONTRAINDICATIONS , WARNINGS and PRECAUTIONS ). Allopurinol is indicated in: the management of patients with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy). the management of patients with leukemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. Allopurinol treatment should be discontinued when the potential for overproduction of uric acid is no longer present. the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients. Therapy in such patients should be carefully assessed initially and reassessed periodically to determine in each case that treatment is beneficial and that the benefits outweigh the risks. uuid:21be4fd7-1760-4a51-afbb-9752a8ab6754 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:40279 biolink:treats UMLS:C0541875 PMID:41385096 "[{""id"":""uuid:c4fff5d1-6726-4337-9215-bb2277f4f7da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d5b265ec-f261-4631-83cf-298425d53228"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] THIS IS NOT AN INNOCUOUS DRUG. IT IS NOT RECOMMENDED FOR THE TREATMENT OF ASYMPTOMATIC HYPERURICEMIA. Allopurinol reduces serum and urinary uric acid concentrations. Its use should be individualized for each patient and requires an understanding of its mode of action and pharmacokinetics (see CLINICAL PHARMACOLOGY , CONTRAINDICATIONS , WARNINGS and PRECAUTIONS ). Allopurinol is indicated in: the management of patients with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy). the management of patients with leukemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. Allopurinol treatment should be discontinued when the potential for overproduction of uric acid is no longer present. the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients. Therapy in such patients should be carefully assessed initially and reassessed periodically to determine in each case that treatment is beneficial and that the benefits outweigh the risks. uuid:aafb3dae-e5b3-490b-aaf1-68644f20a11e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71940 biolink:treats NCIT:C55615 PMID:41385096 "[{""id"":""uuid:5a8c5df4-ec62-4a22-b123-c5a81bda7a79"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6020fd6e-d955-42ea-9109-e713e0edf863"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e84be322-b02d-4c67-9a9e-d36eeed6a37d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CIALIS ® is a phosphodiesterase 5 (PDE5) inhibitor indicated for erectile dysfunction (ED) ( 1.1 ).|[PMDA] Drugs containing a new active ingredient indicated for the treatment of erectile dysfunction (patients unable to obtain or maintain erections sufficient for satisfactory sexual activity). uuid:01ccd156-5cca-43aa-841c-299e0368258f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71940 biolink:treats MONDO:0020740 PMID:41385096 "[{""id"":""uuid:3d06272d-46be-4005-b679-2375244f407f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2452a6c2-738f-4951-bd40-f7a38fa2ad27"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CIALIS ® is a phosphodiesterase 5 (PDE5) inhibitor indicated for erectile dysfunction (ED) ( 1.1 ). uuid:e27b27c1-9db3-4a9c-a4e0-d7cd72208e12 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:404914 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:463a0bd3-1105-4862-8e62-31528b7feaeb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d1a2e43b-08c7-4254-9270-f9cc0f4c961d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:b18bcb68-0685-4633-88c4-5efc6d1fc2b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CADUET (amlodipine and atorvastatin) is indicated in patients for whom treatment with both amlodipine and atorvastatin is appropriate. Amlodipine1. Hypertension : Amlodipine is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents; 2. Coronary Artery Disease (CAD) Chronic Stable Angina: Amlodipine is indicated for the treatment of chronic stable angina. Amlodipine may be used alone or in combination with other antianginal or antihypertensive agents; Vasospastic Angina (Prinzmetal's or Variant Angina): Amlodipine is indicated for the treatment of confirmed or suspected vasospastic angina. Amlodipine may be used as monotherapy or in combination with other antianginal drugs. Angiographically Documented CAD: In patients with recently documented CAD by angiography and without heart failure or an ejection fraction less than 40%, amlodipine is indicated to reduce the risk of hospitalization due to angina and to reduce the risk of a coronary revascularization procedure. AND Atorvastatin Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, the atorvastatin component of CADUET can be started simultaneously with diet restriction. 1. Prevention of Cardiovascular Disease: In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, LIPITOR is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke; In patients with clinically evident coronary heart disease, LIPITOR is indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 2. Heterozygous Familial and Nonfamilial Hyperlipidemia : Atorvastatin is indicated as an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia ( Fredrickson Types IIa and IIb); 3. Elevated Serum TG Levels : Atorvastatin is indicated as an adjunct to diet for the treatment of patients with elevated serum TG levels ( Fredrickson Type IV); 4. Primary Dysbetalipoproteinemia : Atorvastatin is indicated for the treatment of patients with primary dysbetalipoproteinemia ( Fredrickson Type III) who do not respond adequately to diet; 5. Homozygous Familial Hypercholesterolemia : Atorvastatin is indicated to reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; 6. Pediatric Patients : Atorvastatin is indicated as an adjunct to diet to reduce total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: LDL-C remains greater than or equal to 190 mg/dL or LDL-C remains greater than or equal to 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patients. The antidyslipidemic component of CADUET has not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons ( Fredrickson Types I and V).|[PMDA] A drug with a new dosage in an additional dosage form for the treatment of hypertension. uuid:248f8986-1c54-4664-b0a6-d1d72d4651e3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:404914 biolink:treats MONDO:0005010 PMID:41385096 "[{""id"":""uuid:e583aa1c-982f-4a6e-80b4-3b3c634d45a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a63255b6-2f11-4a7d-a067-afc1dd976da1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CADUET (amlodipine and atorvastatin) is indicated in patients for whom treatment with both amlodipine and atorvastatin is appropriate. Amlodipine1. Hypertension : Amlodipine is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents; 2. Coronary Artery Disease (CAD) Chronic Stable Angina: Amlodipine is indicated for the treatment of chronic stable angina. Amlodipine may be used alone or in combination with other antianginal or antihypertensive agents; Vasospastic Angina (Prinzmetal's or Variant Angina): Amlodipine is indicated for the treatment of confirmed or suspected vasospastic angina. Amlodipine may be used as monotherapy or in combination with other antianginal drugs. Angiographically Documented CAD: In patients with recently documented CAD by angiography and without heart failure or an ejection fraction less than 40%, amlodipine is indicated to reduce the risk of hospitalization due to angina and to reduce the risk of a coronary revascularization procedure. AND Atorvastatin Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, the atorvastatin component of CADUET can be started simultaneously with diet restriction. 1. Prevention of Cardiovascular Disease: In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, LIPITOR is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke; In patients with clinically evident coronary heart disease, LIPITOR is indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 2. Heterozygous Familial and Nonfamilial Hyperlipidemia : Atorvastatin is indicated as an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia ( Fredrickson Types IIa and IIb); 3. Elevated Serum TG Levels : Atorvastatin is indicated as an adjunct to diet for the treatment of patients with elevated serum TG levels ( Fredrickson Type IV); 4. Primary Dysbetalipoproteinemia : Atorvastatin is indicated for the treatment of patients with primary dysbetalipoproteinemia ( Fredrickson Type III) who do not respond adequately to diet; 5. Homozygous Familial Hypercholesterolemia : Atorvastatin is indicated to reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; 6. Pediatric Patients : Atorvastatin is indicated as an adjunct to diet to reduce total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: LDL-C remains greater than or equal to 190 mg/dL or LDL-C remains greater than or equal to 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patients. The antidyslipidemic component of CADUET has not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons ( Fredrickson Types I and V). uuid:09516544-1537-4424-b772-8bab9e759eff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:404914 biolink:treats MONDO:0006021 PMID:41385096 "[{""id"":""uuid:3d1b3897-3384-4b81-923b-e3521647c26b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:158c299e-60bc-4c4f-8ce1-6185816f4b13"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CADUET (amlodipine and atorvastatin) is indicated in patients for whom treatment with both amlodipine and atorvastatin is appropriate. Amlodipine1. Hypertension : Amlodipine is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents; 2. Coronary Artery Disease (CAD) Chronic Stable Angina: Amlodipine is indicated for the treatment of chronic stable angina. Amlodipine may be used alone or in combination with other antianginal or antihypertensive agents; Vasospastic Angina (Prinzmetal's or Variant Angina): Amlodipine is indicated for the treatment of confirmed or suspected vasospastic angina. Amlodipine may be used as monotherapy or in combination with other antianginal drugs. Angiographically Documented CAD: In patients with recently documented CAD by angiography and without heart failure or an ejection fraction less than 40%, amlodipine is indicated to reduce the risk of hospitalization due to angina and to reduce the risk of a coronary revascularization procedure. AND Atorvastatin Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, the atorvastatin component of CADUET can be started simultaneously with diet restriction. 1. Prevention of Cardiovascular Disease: In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, LIPITOR is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke; In patients with clinically evident coronary heart disease, LIPITOR is indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 2. Heterozygous Familial and Nonfamilial Hyperlipidemia : Atorvastatin is indicated as an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia ( Fredrickson Types IIa and IIb); 3. Elevated Serum TG Levels : Atorvastatin is indicated as an adjunct to diet for the treatment of patients with elevated serum TG levels ( Fredrickson Type IV); 4. Primary Dysbetalipoproteinemia : Atorvastatin is indicated for the treatment of patients with primary dysbetalipoproteinemia ( Fredrickson Type III) who do not respond adequately to diet; 5. Homozygous Familial Hypercholesterolemia : Atorvastatin is indicated to reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; 6. Pediatric Patients : Atorvastatin is indicated as an adjunct to diet to reduce total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: LDL-C remains greater than or equal to 190 mg/dL or LDL-C remains greater than or equal to 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patients. The antidyslipidemic component of CADUET has not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons ( Fredrickson Types I and V). uuid:c7153b10-ecec-435f-844d-c1edda0aafa0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:404914 biolink:treats HP:0003124 PMID:41385096 "[{""id"":""uuid:ea8a3c2f-cac5-4062-b344-9e857d1ab521"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7c16d07d-825f-44a7-996d-fdab31b0da55"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:7481cf27-5abb-41e7-a7fc-e6c42673427d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CADUET (amlodipine and atorvastatin) is indicated in patients for whom treatment with both amlodipine and atorvastatin is appropriate. Amlodipine1. Hypertension : Amlodipine is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents; 2. Coronary Artery Disease (CAD) Chronic Stable Angina: Amlodipine is indicated for the treatment of chronic stable angina. Amlodipine may be used alone or in combination with other antianginal or antihypertensive agents; Vasospastic Angina (Prinzmetal's or Variant Angina): Amlodipine is indicated for the treatment of confirmed or suspected vasospastic angina. Amlodipine may be used as monotherapy or in combination with other antianginal drugs. Angiographically Documented CAD: In patients with recently documented CAD by angiography and without heart failure or an ejection fraction less than 40%, amlodipine is indicated to reduce the risk of hospitalization due to angina and to reduce the risk of a coronary revascularization procedure. AND Atorvastatin Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, the atorvastatin component of CADUET can be started simultaneously with diet restriction. 1. Prevention of Cardiovascular Disease: In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, LIPITOR is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke; In patients with clinically evident coronary heart disease, LIPITOR is indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 2. Heterozygous Familial and Nonfamilial Hyperlipidemia : Atorvastatin is indicated as an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia ( Fredrickson Types IIa and IIb); 3. Elevated Serum TG Levels : Atorvastatin is indicated as an adjunct to diet for the treatment of patients with elevated serum TG levels ( Fredrickson Type IV); 4. Primary Dysbetalipoproteinemia : Atorvastatin is indicated for the treatment of patients with primary dysbetalipoproteinemia ( Fredrickson Type III) who do not respond adequately to diet; 5. Homozygous Familial Hypercholesterolemia : Atorvastatin is indicated to reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; 6. Pediatric Patients : Atorvastatin is indicated as an adjunct to diet to reduce total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: LDL-C remains greater than or equal to 190 mg/dL or LDL-C remains greater than or equal to 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patients. The antidyslipidemic component of CADUET has not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons ( Fredrickson Types I and V).|[PMDA] New combination drugs indicated for the treatment of comorbidity of hypertension or angina pectoris and hypercholesterolemia or familial hypercholesterolemia. uuid:36512500-0fd0-4457-8cd0-b7c2e74bc89d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:404914 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:2f4d9465-10b1-4d7b-8703-a7b69c604b3d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fa3da720-0f0e-4e02-abce-34e65117754e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CADUET (amlodipine and atorvastatin) is indicated in patients for whom treatment with both amlodipine and atorvastatin is appropriate. Amlodipine1. Hypertension : Amlodipine is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents; 2. Coronary Artery Disease (CAD) Chronic Stable Angina: Amlodipine is indicated for the treatment of chronic stable angina. Amlodipine may be used alone or in combination with other antianginal or antihypertensive agents; Vasospastic Angina (Prinzmetal's or Variant Angina): Amlodipine is indicated for the treatment of confirmed or suspected vasospastic angina. Amlodipine may be used as monotherapy or in combination with other antianginal drugs. Angiographically Documented CAD: In patients with recently documented CAD by angiography and without heart failure or an ejection fraction less than 40%, amlodipine is indicated to reduce the risk of hospitalization due to angina and to reduce the risk of a coronary revascularization procedure. AND Atorvastatin Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, the atorvastatin component of CADUET can be started simultaneously with diet restriction. 1. Prevention of Cardiovascular Disease: In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, LIPITOR is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke; In patients with clinically evident coronary heart disease, LIPITOR is indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 2. Heterozygous Familial and Nonfamilial Hyperlipidemia : Atorvastatin is indicated as an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia ( Fredrickson Types IIa and IIb); 3. Elevated Serum TG Levels : Atorvastatin is indicated as an adjunct to diet for the treatment of patients with elevated serum TG levels ( Fredrickson Type IV); 4. Primary Dysbetalipoproteinemia : Atorvastatin is indicated for the treatment of patients with primary dysbetalipoproteinemia ( Fredrickson Type III) who do not respond adequately to diet; 5. Homozygous Familial Hypercholesterolemia : Atorvastatin is indicated to reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; 6. Pediatric Patients : Atorvastatin is indicated as an adjunct to diet to reduce total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: LDL-C remains greater than or equal to 190 mg/dL or LDL-C remains greater than or equal to 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patients. The antidyslipidemic component of CADUET has not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons ( Fredrickson Types I and V). uuid:279bff29-a2d1-4fc3-a255-e80b250fab4a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:404914 biolink:treats HP:0012592 PMID:41385096 "[{""id"":""uuid:187baa06-4f88-428c-b4bc-ab632af393ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cf422a15-3eba-425f-974b-ad600159b570"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CADUET (amlodipine and atorvastatin) is indicated in patients for whom treatment with both amlodipine and atorvastatin is appropriate. Amlodipine1. Hypertension : Amlodipine is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents; 2. Coronary Artery Disease (CAD) Chronic Stable Angina: Amlodipine is indicated for the treatment of chronic stable angina. Amlodipine may be used alone or in combination with other antianginal or antihypertensive agents; Vasospastic Angina (Prinzmetal's or Variant Angina): Amlodipine is indicated for the treatment of confirmed or suspected vasospastic angina. Amlodipine may be used as monotherapy or in combination with other antianginal drugs. Angiographically Documented CAD: In patients with recently documented CAD by angiography and without heart failure or an ejection fraction less than 40%, amlodipine is indicated to reduce the risk of hospitalization due to angina and to reduce the risk of a coronary revascularization procedure. AND Atorvastatin Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, the atorvastatin component of CADUET can be started simultaneously with diet restriction. 1. Prevention of Cardiovascular Disease: In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, LIPITOR is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke; In patients with clinically evident coronary heart disease, LIPITOR is indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 2. Heterozygous Familial and Nonfamilial Hyperlipidemia : Atorvastatin is indicated as an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia ( Fredrickson Types IIa and IIb); 3. Elevated Serum TG Levels : Atorvastatin is indicated as an adjunct to diet for the treatment of patients with elevated serum TG levels ( Fredrickson Type IV); 4. Primary Dysbetalipoproteinemia : Atorvastatin is indicated for the treatment of patients with primary dysbetalipoproteinemia ( Fredrickson Type III) who do not respond adequately to diet; 5. Homozygous Familial Hypercholesterolemia : Atorvastatin is indicated to reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; 6. Pediatric Patients : Atorvastatin is indicated as an adjunct to diet to reduce total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: LDL-C remains greater than or equal to 190 mg/dL or LDL-C remains greater than or equal to 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patients. The antidyslipidemic component of CADUET has not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons ( Fredrickson Types I and V). uuid:e2f1e166-eb59-442d-b656-d7e8a1b48e9e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:404914 biolink:treats MONDO:0001336 PMID:41385096 "[{""id"":""uuid:72263e15-b5af-47b8-95e4-99f4b102d7b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4398a3b1-4be7-4d40-8d9a-2909953d612e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CADUET (amlodipine and atorvastatin) is indicated in patients for whom treatment with both amlodipine and atorvastatin is appropriate. Amlodipine1. Hypertension : Amlodipine is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents; 2. Coronary Artery Disease (CAD) Chronic Stable Angina: Amlodipine is indicated for the treatment of chronic stable angina. Amlodipine may be used alone or in combination with other antianginal or antihypertensive agents; Vasospastic Angina (Prinzmetal's or Variant Angina): Amlodipine is indicated for the treatment of confirmed or suspected vasospastic angina. Amlodipine may be used as monotherapy or in combination with other antianginal drugs. Angiographically Documented CAD: In patients with recently documented CAD by angiography and without heart failure or an ejection fraction less than 40%, amlodipine is indicated to reduce the risk of hospitalization due to angina and to reduce the risk of a coronary revascularization procedure. AND Atorvastatin Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, the atorvastatin component of CADUET can be started simultaneously with diet restriction. 1. Prevention of Cardiovascular Disease: In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, LIPITOR is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke; In patients with clinically evident coronary heart disease, LIPITOR is indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 2. Heterozygous Familial and Nonfamilial Hyperlipidemia : Atorvastatin is indicated as an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia ( Fredrickson Types IIa and IIb); 3. Elevated Serum TG Levels : Atorvastatin is indicated as an adjunct to diet for the treatment of patients with elevated serum TG levels ( Fredrickson Type IV); 4. Primary Dysbetalipoproteinemia : Atorvastatin is indicated for the treatment of patients with primary dysbetalipoproteinemia ( Fredrickson Type III) who do not respond adequately to diet; 5. Homozygous Familial Hypercholesterolemia : Atorvastatin is indicated to reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; 6. Pediatric Patients : Atorvastatin is indicated as an adjunct to diet to reduce total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: LDL-C remains greater than or equal to 190 mg/dL or LDL-C remains greater than or equal to 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patients. The antidyslipidemic component of CADUET has not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons ( Fredrickson Types I and V). uuid:712f7db7-db76-4c95-b05b-1372154b08a7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:404914 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:b51f6c0f-6aab-46d0-ae89-47eb81c1f379"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3720e840-8961-444f-a997-0651480660fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CADUET (amlodipine and atorvastatin) is indicated in patients for whom treatment with both amlodipine and atorvastatin is appropriate. Amlodipine1. Hypertension : Amlodipine is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents; 2. Coronary Artery Disease (CAD) Chronic Stable Angina: Amlodipine is indicated for the treatment of chronic stable angina. Amlodipine may be used alone or in combination with other antianginal or antihypertensive agents; Vasospastic Angina (Prinzmetal's or Variant Angina): Amlodipine is indicated for the treatment of confirmed or suspected vasospastic angina. Amlodipine may be used as monotherapy or in combination with other antianginal drugs. Angiographically Documented CAD: In patients with recently documented CAD by angiography and without heart failure or an ejection fraction less than 40%, amlodipine is indicated to reduce the risk of hospitalization due to angina and to reduce the risk of a coronary revascularization procedure. AND Atorvastatin Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, the atorvastatin component of CADUET can be started simultaneously with diet restriction. 1. Prevention of Cardiovascular Disease: In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, LIPITOR is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke; In patients with clinically evident coronary heart disease, LIPITOR is indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 2. Heterozygous Familial and Nonfamilial Hyperlipidemia : Atorvastatin is indicated as an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia ( Fredrickson Types IIa and IIb); 3. Elevated Serum TG Levels : Atorvastatin is indicated as an adjunct to diet for the treatment of patients with elevated serum TG levels ( Fredrickson Type IV); 4. Primary Dysbetalipoproteinemia : Atorvastatin is indicated for the treatment of patients with primary dysbetalipoproteinemia ( Fredrickson Type III) who do not respond adequately to diet; 5. Homozygous Familial Hypercholesterolemia : Atorvastatin is indicated to reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; 6. Pediatric Patients : Atorvastatin is indicated as an adjunct to diet to reduce total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: LDL-C remains greater than or equal to 190 mg/dL or LDL-C remains greater than or equal to 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patients. The antidyslipidemic component of CADUET has not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons ( Fredrickson Types I and V). uuid:c1afb0d5-2e38-47bf-8948-c302b4ede749 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:404914 biolink:treats HP:0003119 PMID:41385096 "[{""id"":""uuid:adae6685-7bae-42f0-81f7-3e1f842d7879"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:664a229d-088e-4f1e-98ba-1fd553623fc9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CADUET (amlodipine and atorvastatin) is indicated in patients for whom treatment with both amlodipine and atorvastatin is appropriate. Amlodipine1. Hypertension : Amlodipine is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents; 2. Coronary Artery Disease (CAD) Chronic Stable Angina: Amlodipine is indicated for the treatment of chronic stable angina. Amlodipine may be used alone or in combination with other antianginal or antihypertensive agents; Vasospastic Angina (Prinzmetal's or Variant Angina): Amlodipine is indicated for the treatment of confirmed or suspected vasospastic angina. Amlodipine may be used as monotherapy or in combination with other antianginal drugs. Angiographically Documented CAD: In patients with recently documented CAD by angiography and without heart failure or an ejection fraction less than 40%, amlodipine is indicated to reduce the risk of hospitalization due to angina and to reduce the risk of a coronary revascularization procedure. AND Atorvastatin Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, the atorvastatin component of CADUET can be started simultaneously with diet restriction. 1. Prevention of Cardiovascular Disease: In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, LIPITOR is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke; In patients with clinically evident coronary heart disease, LIPITOR is indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 2. Heterozygous Familial and Nonfamilial Hyperlipidemia : Atorvastatin is indicated as an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia ( Fredrickson Types IIa and IIb); 3. Elevated Serum TG Levels : Atorvastatin is indicated as an adjunct to diet for the treatment of patients with elevated serum TG levels ( Fredrickson Type IV); 4. Primary Dysbetalipoproteinemia : Atorvastatin is indicated for the treatment of patients with primary dysbetalipoproteinemia ( Fredrickson Type III) who do not respond adequately to diet; 5. Homozygous Familial Hypercholesterolemia : Atorvastatin is indicated to reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; 6. Pediatric Patients : Atorvastatin is indicated as an adjunct to diet to reduce total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: LDL-C remains greater than or equal to 190 mg/dL or LDL-C remains greater than or equal to 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patients. The antidyslipidemic component of CADUET has not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons ( Fredrickson Types I and V). uuid:0f85c3c3-09f6-42ae-8b6c-70ed29fa8b3f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:404914 biolink:treats MONDO:0005347 PMID:41385096 "[{""id"":""uuid:63eba2d0-d8c6-4140-b6a1-57001cf21b68"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3254a6ff-c8da-4ad7-aa7b-f4a216bd2609"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CADUET (amlodipine and atorvastatin) is indicated in patients for whom treatment with both amlodipine and atorvastatin is appropriate. Amlodipine1. Hypertension : Amlodipine is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents; 2. Coronary Artery Disease (CAD) Chronic Stable Angina: Amlodipine is indicated for the treatment of chronic stable angina. Amlodipine may be used alone or in combination with other antianginal or antihypertensive agents; Vasospastic Angina (Prinzmetal's or Variant Angina): Amlodipine is indicated for the treatment of confirmed or suspected vasospastic angina. Amlodipine may be used as monotherapy or in combination with other antianginal drugs. Angiographically Documented CAD: In patients with recently documented CAD by angiography and without heart failure or an ejection fraction less than 40%, amlodipine is indicated to reduce the risk of hospitalization due to angina and to reduce the risk of a coronary revascularization procedure. AND Atorvastatin Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, the atorvastatin component of CADUET can be started simultaneously with diet restriction. 1. Prevention of Cardiovascular Disease: In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, LIPITOR is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke; In patients with clinically evident coronary heart disease, LIPITOR is indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 2. Heterozygous Familial and Nonfamilial Hyperlipidemia : Atorvastatin is indicated as an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia ( Fredrickson Types IIa and IIb); 3. Elevated Serum TG Levels : Atorvastatin is indicated as an adjunct to diet for the treatment of patients with elevated serum TG levels ( Fredrickson Type IV); 4. Primary Dysbetalipoproteinemia : Atorvastatin is indicated for the treatment of patients with primary dysbetalipoproteinemia ( Fredrickson Type III) who do not respond adequately to diet; 5. Homozygous Familial Hypercholesterolemia : Atorvastatin is indicated to reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; 6. Pediatric Patients : Atorvastatin is indicated as an adjunct to diet to reduce total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: LDL-C remains greater than or equal to 190 mg/dL or LDL-C remains greater than or equal to 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patients. The antidyslipidemic component of CADUET has not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons ( Fredrickson Types I and V). uuid:ac8b735b-774e-453b-8b38-49ac1dd8ec89 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:404914 biolink:treats MONDO:0018473 PMID:41385096 "[{""id"":""uuid:b4868295-ffe2-4262-9324-ec4b8a730309"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ec5dceaf-6733-4dea-8478-303cb0549fbc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CADUET (amlodipine and atorvastatin) is indicated in patients for whom treatment with both amlodipine and atorvastatin is appropriate. Amlodipine1. Hypertension : Amlodipine is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents; 2. Coronary Artery Disease (CAD) Chronic Stable Angina: Amlodipine is indicated for the treatment of chronic stable angina. Amlodipine may be used alone or in combination with other antianginal or antihypertensive agents; Vasospastic Angina (Prinzmetal's or Variant Angina): Amlodipine is indicated for the treatment of confirmed or suspected vasospastic angina. Amlodipine may be used as monotherapy or in combination with other antianginal drugs. Angiographically Documented CAD: In patients with recently documented CAD by angiography and without heart failure or an ejection fraction less than 40%, amlodipine is indicated to reduce the risk of hospitalization due to angina and to reduce the risk of a coronary revascularization procedure. AND Atorvastatin Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, the atorvastatin component of CADUET can be started simultaneously with diet restriction. 1. Prevention of Cardiovascular Disease: In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, LIPITOR is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke; In patients with clinically evident coronary heart disease, LIPITOR is indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 2. Heterozygous Familial and Nonfamilial Hyperlipidemia : Atorvastatin is indicated as an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia ( Fredrickson Types IIa and IIb); 3. Elevated Serum TG Levels : Atorvastatin is indicated as an adjunct to diet for the treatment of patients with elevated serum TG levels ( Fredrickson Type IV); 4. Primary Dysbetalipoproteinemia : Atorvastatin is indicated for the treatment of patients with primary dysbetalipoproteinemia ( Fredrickson Type III) who do not respond adequately to diet; 5. Homozygous Familial Hypercholesterolemia : Atorvastatin is indicated to reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; 6. Pediatric Patients : Atorvastatin is indicated as an adjunct to diet to reduce total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: LDL-C remains greater than or equal to 190 mg/dL or LDL-C remains greater than or equal to 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patients. The antidyslipidemic component of CADUET has not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons ( Fredrickson Types I and V). uuid:936b318e-6c5e-4452-be42-44db9fcd59e6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:404914 biolink:treats MONDO:0018328 PMID:41385096 "[{""id"":""uuid:4a316f6e-b150-4754-9fdf-2831eade3baa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d5b2eaf0-b888-4f82-8d4d-046ee64a8df1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CADUET (amlodipine and atorvastatin) is indicated in patients for whom treatment with both amlodipine and atorvastatin is appropriate. Amlodipine1. Hypertension : Amlodipine is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents; 2. Coronary Artery Disease (CAD) Chronic Stable Angina: Amlodipine is indicated for the treatment of chronic stable angina. Amlodipine may be used alone or in combination with other antianginal or antihypertensive agents; Vasospastic Angina (Prinzmetal's or Variant Angina): Amlodipine is indicated for the treatment of confirmed or suspected vasospastic angina. Amlodipine may be used as monotherapy or in combination with other antianginal drugs. Angiographically Documented CAD: In patients with recently documented CAD by angiography and without heart failure or an ejection fraction less than 40%, amlodipine is indicated to reduce the risk of hospitalization due to angina and to reduce the risk of a coronary revascularization procedure. AND Atorvastatin Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, the atorvastatin component of CADUET can be started simultaneously with diet restriction. 1. Prevention of Cardiovascular Disease: In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, LIPITOR is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke; In patients with clinically evident coronary heart disease, LIPITOR is indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 2. Heterozygous Familial and Nonfamilial Hyperlipidemia : Atorvastatin is indicated as an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia ( Fredrickson Types IIa and IIb); 3. Elevated Serum TG Levels : Atorvastatin is indicated as an adjunct to diet for the treatment of patients with elevated serum TG levels ( Fredrickson Type IV); 4. Primary Dysbetalipoproteinemia : Atorvastatin is indicated for the treatment of patients with primary dysbetalipoproteinemia ( Fredrickson Type III) who do not respond adequately to diet; 5. Homozygous Familial Hypercholesterolemia : Atorvastatin is indicated to reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; 6. Pediatric Patients : Atorvastatin is indicated as an adjunct to diet to reduce total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: LDL-C remains greater than or equal to 190 mg/dL or LDL-C remains greater than or equal to 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patients. The antidyslipidemic component of CADUET has not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons ( Fredrickson Types I and V). uuid:a893b006-c278-49dc-908f-1fe8f2d16f68 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2611 biolink:treats MONDO:0005618 PMID:41385096 "[{""id"":""uuid:a7a34490-e1c2-45da-88de-7d124f9db17b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:130cbffa-07ef-4fc3-9f9f-f88f72818575"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Alprazolam tablets are indicated for the management of anxiety disorder (a condition corresponding most closely to the APA Diagnostic and Statistical Manual [DSM-III-R] diagnosis of generalized anxiety disorder) or the short-term relief of symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. Generalized anxiety disorder is characterized by unrealistic or excessive anxiety and worry (apprehensive expectation) about two or more life circumstances, for a period of six months or longer, during which the person has been bothered more days than not by these concerns. At least 6 of the following 18 symptoms are often present in these patients: Motor Tension (trembling, twitching, or feeling shaky; muscle tension, aches, or soreness; restlessness; easy fatigability); Autonomic Hyperactivity (shortness of breath or smothering sensations; palpitations or accelerated heart rate; sweating, or cold clammy hands; dry mouth; dizziness or light-headedness; nausea, diarrhea, or other abdominal distress; flushes or chills; frequent urination; trouble swallowing or ‘lump in throat’); Vigilance and Scanning (feeling keyed up or on edge; exaggerated startle response; difficulty concentrating or ‘mind going blank’ because of anxiety; trouble falling or staying asleep; irritability). These symptoms must not be secondary to another psychiatric disorder or caused by some organic factor. Anxiety associated with depression is responsive to alprazolam. uuid:49116d5b-689c-430f-9c5e-20f6903eb978 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2611 biolink:treats MONDO:0001942 PMID:41385096 "[{""id"":""uuid:1a1a7cef-935f-4e72-a7eb-7cada93b90bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:94979cc5-b82c-4f79-b6a3-e7017d7a242d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Alprazolam tablets are indicated for the management of anxiety disorder (a condition corresponding most closely to the APA Diagnostic and Statistical Manual [DSM-III-R] diagnosis of generalized anxiety disorder) or the short-term relief of symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. Generalized anxiety disorder is characterized by unrealistic or excessive anxiety and worry (apprehensive expectation) about two or more life circumstances, for a period of six months or longer, during which the person has been bothered more days than not by these concerns. At least 6 of the following 18 symptoms are often present in these patients: Motor Tension (trembling, twitching, or feeling shaky; muscle tension, aches, or soreness; restlessness; easy fatigability); Autonomic Hyperactivity (shortness of breath or smothering sensations; palpitations or accelerated heart rate; sweating, or cold clammy hands; dry mouth; dizziness or light-headedness; nausea, diarrhea, or other abdominal distress; flushes or chills; frequent urination; trouble swallowing or ‘lump in throat’); Vigilance and Scanning (feeling keyed up or on edge; exaggerated startle response; difficulty concentrating or ‘mind going blank’ because of anxiety; trouble falling or staying asleep; irritability). These symptoms must not be secondary to another psychiatric disorder or caused by some organic factor. Anxiety associated with depression is responsive to alprazolam. uuid:f8b8e49b-2609-4097-a5df-39081996c438 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2611 biolink:treats MONDO:0011918 PMID:41385096 "[{""id"":""uuid:e09ec4fd-ebed-407b-92dd-02931ea905f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:60ac6da7-3644-49f4-b62f-483ac5e94e9e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Alprazolam tablets are indicated for the management of anxiety disorder (a condition corresponding most closely to the APA Diagnostic and Statistical Manual [DSM-III-R] diagnosis of generalized anxiety disorder) or the short-term relief of symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. Generalized anxiety disorder is characterized by unrealistic or excessive anxiety and worry (apprehensive expectation) about two or more life circumstances, for a period of six months or longer, during which the person has been bothered more days than not by these concerns. At least 6 of the following 18 symptoms are often present in these patients: Motor Tension (trembling, twitching, or feeling shaky; muscle tension, aches, or soreness; restlessness; easy fatigability); Autonomic Hyperactivity (shortness of breath or smothering sensations; palpitations or accelerated heart rate; sweating, or cold clammy hands; dry mouth; dizziness or light-headedness; nausea, diarrhea, or other abdominal distress; flushes or chills; frequent urination; trouble swallowing or ‘lump in throat’); Vigilance and Scanning (feeling keyed up or on edge; exaggerated startle response; difficulty concentrating or ‘mind going blank’ because of anxiety; trouble falling or staying asleep; irritability). These symptoms must not be secondary to another psychiatric disorder or caused by some organic factor. Anxiety associated with depression is responsive to alprazolam. uuid:0b74bc00-f350-4b43-bec2-c9f17b385424 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2611 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:9f5bf331-9a01-4de3-8632-325b99585cd0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2d4871c8-8b01-41f1-bf03-3a0c554257cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Alprazolam tablets are indicated for the management of anxiety disorder (a condition corresponding most closely to the APA Diagnostic and Statistical Manual [DSM-III-R] diagnosis of generalized anxiety disorder) or the short-term relief of symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. Generalized anxiety disorder is characterized by unrealistic or excessive anxiety and worry (apprehensive expectation) about two or more life circumstances, for a period of six months or longer, during which the person has been bothered more days than not by these concerns. At least 6 of the following 18 symptoms are often present in these patients: Motor Tension (trembling, twitching, or feeling shaky; muscle tension, aches, or soreness; restlessness; easy fatigability); Autonomic Hyperactivity (shortness of breath or smothering sensations; palpitations or accelerated heart rate; sweating, or cold clammy hands; dry mouth; dizziness or light-headedness; nausea, diarrhea, or other abdominal distress; flushes or chills; frequent urination; trouble swallowing or ‘lump in throat’); Vigilance and Scanning (feeling keyed up or on edge; exaggerated startle response; difficulty concentrating or ‘mind going blank’ because of anxiety; trouble falling or staying asleep; irritability). These symptoms must not be secondary to another psychiatric disorder or caused by some organic factor. Anxiety associated with depression is responsive to alprazolam. uuid:08631d79-fa26-442b-8270-344bd0939532 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2668 biolink:treats MONDO:0005010 PMID:41385096 "[{""id"":""uuid:41952d1a-32e9-4cba-be38-3f23e795060e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:05c0d98a-c528-4050-a1f7-36249517cf50"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension Amlodipine is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents. Coronary Artery Disease (CAD) Chronic Stable Angina Amlodipine is indicated for the symptomatic treatment of chronic stable angina. Amlodipine may be used alone or in combination with other antianginal agents. Vasospastic Angina (Prinzmetal's or Variant Angina) Amlodipine is indicated for the treatment of confirmed or suspected vasospastic angina. Amlodipine may be used as monotherapy or in combination with other antianginal drugs. Angiographically Documented CAD In patients with recently documented CAD by angiography and without heart failure or an ejection fraction <40%, amlodipine besylate tablets are indicated to reduce the risk of hospitalization due to angina and to reduce the risk of a coronary revascularization procedure. uuid:d89356c5-f325-481e-99dc-6b4e62fa4bb6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135935 biolink:treats NCIT:C27003 PMID:41385096 "[{""id"":""uuid:4745977e-abe2-40ce-a241-58eae80d62e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1a81b16e-0628-45c6-a5cc-2a7b21f8df33"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NUCYNTA™ (tapentadol) is indicated for the relief of moderate to severe acute pain in patients 18 years of age or older. uuid:4208ff1a-c7bb-42ae-9b9d-c92bf52a41ad biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63610 biolink:treats UMLS:C0341178 PMID:41385096 "[{""id"":""uuid:397f1b76-022c-4eb5-8635-473780f7b817"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:905ae8af-10dc-49ee-be3c-90b890343bc0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Misoprostol tablets are indicated for reducing the risk of NSAID (nonsteroidal anti-inflammatory drugs, including aspirin)–induced gastric ulcers in patients at high risk of complications from gastric ulcer, e.g., the elderly and patients with concomitant debilitating disease, as well as patients at high risk of developing gastric ulceration, such as patients with a history of ulcer. Misoprostol has not been shown to reduce the risk of duodenal ulcers in patients taking NSAIDs. Misoprostol should be taken for the duration of NSAID therapy. Misoprostol has been shown to reduce the risk of gastric ulcers in controlled studies of 3 months’ duration. It had no effect, compared to placebo, on gastrointestinal pain or discomfort associated with NSAID use. uuid:a0cbc2d4-595e-437b-86de-a40e4daab935 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63610 biolink:treats MONDO:0005412 PMID:41385096 "[{""id"":""uuid:8fcdc83a-b734-4b45-a02a-822a089efd9f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3c940268-0108-4a84-9337-bec7adc6d7ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Misoprostol tablets are indicated for reducing the risk of NSAID (nonsteroidal anti-inflammatory drugs, including aspirin)–induced gastric ulcers in patients at high risk of complications from gastric ulcer, e.g., the elderly and patients with concomitant debilitating disease, as well as patients at high risk of developing gastric ulceration, such as patients with a history of ulcer. Misoprostol has not been shown to reduce the risk of duodenal ulcers in patients taking NSAIDs. Misoprostol should be taken for the duration of NSAID therapy. Misoprostol has been shown to reduce the risk of gastric ulcers in controlled studies of 3 months’ duration. It had no effect, compared to placebo, on gastrointestinal pain or discomfort associated with NSAID use. uuid:da4b6d5f-53a8-4b50-8a1b-19cf15bf8906 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3223 biolink:treats UMLS:C0086132 PMID:41385096 "[{""id"":""uuid:a292c704-831f-4d54-b0bf-7e1033f9426e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2a683a78-610a-4202-abde-d520e58be16d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Buspirone hydrochloride tablets are indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The efficacy of buspirone has been demonstrated in controlled clinical trials of outpatients whose diagnosis roughly corresponds to Generalized Anxiety Disorder (GAD). Many of the patients enrolled in these studies also had coexisting depressive symptoms and buspirone relieved anxiety in the presence of these coexisting depressive symptoms. The patients evaluated in these studies had experienced symptoms for periods of 1 month to over 1 year prior to the study, with an average symptom duration of 6 months. Generalized Anxiety Disorder (300.02) is described in the American Psychiatric Association’s Diagnostic and Statistical Manual, III 1 as follows: Generalized, persistent anxiety (of at least 1 month continual duration), manifested by symptoms from three of the four following categories: Motor tension: shakiness, jitteriness, jumpiness, trembling, tension, muscle aches, fatigability, inability to relax, eyelid twitch, furrowed brow, strained face, fidgeting, restlessness, easy startle. Autonomic hyperactivity: sweating, heart pounding or racing, cold, clammy hands, dry mouth, dizziness, lightheadedness, paresthesias (tingling in hands or feet), upset stomach, hot or cold spells, frequent urination, diarrhea, discomfort in the pit of the stomach, lump in the throat, flushing, pallor, high resting pulse, and respiration rate. Apprehensive expectation: anxiety, worry, fear, rumination, and anticipation of misfortune to self or others. Vigilance and scanning: hyperattentiveness resulting in distractibility, difficulty in concentrating, insomnia, feeling “on edge,” irritability, impatience. The above symptoms would not be due to another mental disorder, such as a depressive disorder or schizophrenia. However, mild depressive symptoms are common in GAD. The effectiveness of buspirone in long-term use, that is, for more than 3 to 4 weeks, has not been demonstrated in controlled trials. There is no body of evidence available that systematically addresses the appropriate duration of treatment for GAD. However, in a study of long-term use, 264 patients were treated with buspirone for 1 year without ill effect. Therefore, the physician who elects to use buspirone for extended periods should periodically reassess the usefulness of the drug for the individual patient. uuid:73e89e63-ea0c-4617-9480-07de3757d888 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:39867 biolink:treats MONDO:0006710 PMID:41385096 "[{""id"":""uuid:b6626224-ac50-49eb-9392-a65d266846d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aa42c772-b020-4e8c-a958-c90b1bd09c16"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Valproic Acid is indicated as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures that occur either in isolation or in association with other types of seizures. Valproic Acid is indicated for use as sole and adjunctive therapy in the treatment of simple and complex absence seizures, and adjunctively in patients with multiple seizure types which include absence seizures. Simple absence is defined as very brief clouding of the sensorium or loss of consciousness accompanied by certain generalized epileptic discharges without other detectable clinical signs. Complex absence is the term used when other signs are also present. SEE WARNINGS FOR STATEMENT REGARDING FATAL HEPATIC DYSFUNCTION. uuid:ede31840-3fb6-461f-a44d-b6e0552bfdc9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:39867 biolink:treats MONDO:0010826 PMID:41385096 "[{""id"":""uuid:14543d59-6a3e-4560-82d1-1662c34f1afa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:234fe533-442a-4f80-b671-d5d84b4063b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Valproic Acid is indicated as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures that occur either in isolation or in association with other types of seizures. Valproic Acid is indicated for use as sole and adjunctive therapy in the treatment of simple and complex absence seizures, and adjunctively in patients with multiple seizure types which include absence seizures. Simple absence is defined as very brief clouding of the sensorium or loss of consciousness accompanied by certain generalized epileptic discharges without other detectable clinical signs. Complex absence is the term used when other signs are also present. SEE WARNINGS FOR STATEMENT REGARDING FATAL HEPATIC DYSFUNCTION. uuid:c5bdbd79-e1e5-4702-9269-2bfa7d875a91 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:39867 biolink:treats MONDO:0005027 PMID:41385096 "[{""id"":""uuid:e1701b2d-7e79-496b-ae08-e5901f350d7c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3313f408-92b5-4441-8c90-576bf2082685"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Valproic Acid is indicated as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures that occur either in isolation or in association with other types of seizures. Valproic Acid is indicated for use as sole and adjunctive therapy in the treatment of simple and complex absence seizures, and adjunctively in patients with multiple seizure types which include absence seizures. Simple absence is defined as very brief clouding of the sensorium or loss of consciousness accompanied by certain generalized epileptic discharges without other detectable clinical signs. Complex absence is the term used when other signs are also present. SEE WARNINGS FOR STATEMENT REGARDING FATAL HEPATIC DYSFUNCTION. uuid:c42bde9b-d047-48ca-8d1d-77e32224765c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5384 biolink:treats MONDO:0002909 PMID:41385096 "[{""id"":""uuid:cfbffcd1-fd73-42d2-9e03-4c6820b28b8d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1d9302dd-46e9-4ea4-b7e2-9eb239680361"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Glipizide tablets are indicated as an adjunct to diet for the control of hyperglycemia and its associated symptomatology in patients with non-insulin-dependent diabetes mellitus (NIDDM; type II), formerly known as maturity-onset diabetes, after an adequate trial of dietary therapy has proved unsatisfactory. In initiating treatment for non-insulin-dependent diabetes, diet should be emphasized as the primary form of treatment. Caloric restriction and weight loss are essential in the obese diabetic patient. Proper dietary management alone may be effective in controlling the blood glucose and symptoms of hyperglycemia. The importance of regular physical activity should also be stressed, and cardiovascular risk factors should be identified, and corrective measures taken where possible. If this treatment program fails to reduce symptoms and/or blood glucose, the use of an oral sulfonylurea or insulin should be considered. Use of glipizide must be viewed by both the physician and patient as a treatment in addition to diet, and not as a substitute for diet or as a convenient mechanism for avoiding dietary restraint. Furthermore, loss of blood glucose control on diet alone also may be transient, thus requiring only short-term administration of glipizide. During maintenance programs, glipizide should be discontinued if satisfactory lowering of blood glucose is no longer achieved. Judgements should be based on regular clinical and laboratory evaluations. In considering the use of glipizide in asymptomatic patients, it should be recognized that controlling the blood glucose in non-insulin-dependent diabetes has not been definitely established to be effective in preventing the long-term cardiovascular or neural complications of diabetes. uuid:6e29c0eb-9d5c-433a-9ea6-714322774529 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5384 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:c42719b0-2c96-4abd-b530-b91b93912126"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:80f73a3b-1786-4c9c-a966-beeb7c6d97ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Glipizide tablets are indicated as an adjunct to diet for the control of hyperglycemia and its associated symptomatology in patients with non-insulin-dependent diabetes mellitus (NIDDM; type II), formerly known as maturity-onset diabetes, after an adequate trial of dietary therapy has proved unsatisfactory. In initiating treatment for non-insulin-dependent diabetes, diet should be emphasized as the primary form of treatment. Caloric restriction and weight loss are essential in the obese diabetic patient. Proper dietary management alone may be effective in controlling the blood glucose and symptoms of hyperglycemia. The importance of regular physical activity should also be stressed, and cardiovascular risk factors should be identified, and corrective measures taken where possible. If this treatment program fails to reduce symptoms and/or blood glucose, the use of an oral sulfonylurea or insulin should be considered. Use of glipizide must be viewed by both the physician and patient as a treatment in addition to diet, and not as a substitute for diet or as a convenient mechanism for avoiding dietary restraint. Furthermore, loss of blood glucose control on diet alone also may be transient, thus requiring only short-term administration of glipizide. During maintenance programs, glipizide should be discontinued if satisfactory lowering of blood glucose is no longer achieved. Judgements should be based on regular clinical and laboratory evaluations. In considering the use of glipizide in asymptomatic patients, it should be recognized that controlling the blood glucose in non-insulin-dependent diabetes has not been definitely established to be effective in preventing the long-term cardiovascular or neural complications of diabetes. uuid:e5e65a38-5259-42b7-a2b1-360906e1345b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8107 biolink:treats MONDO:0005754 PMID:41385096 "[{""id"":""uuid:b6246ace-5745-4e80-be04-ff4ec6052379"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2816c9dc-e3d1-460f-a52c-fce563014ca3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Extended Phenytoin Sodium Capsules USP, 100 mg are indicated for the control of generalized tonic-clonic (grand mal) and complex partial (psychomotor, temporal lobe) seizures and prevention and treatment of seizures occurring during or following neurosurgery. Phenytoin serum level determinations may be necessary for optimal dosage adjustments (see DOSAGE AND ADMINISTRATION and CLINICAL PHARMACOLOGY ). uuid:c1a4cc7b-ddc5-4f43-b3d1-6b6a090d210d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8107 biolink:treats MONDO:0015638 PMID:41385096 "[{""id"":""uuid:368ed5dd-7f36-454f-a144-ea42c0dc591f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cbf16d5d-cb73-46b3-b62a-c843fe502708"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Extended Phenytoin Sodium Capsules USP, 100 mg are indicated for the control of generalized tonic-clonic (grand mal) and complex partial (psychomotor, temporal lobe) seizures and prevention and treatment of seizures occurring during or following neurosurgery. Phenytoin serum level determinations may be necessary for optimal dosage adjustments (see DOSAGE AND ADMINISTRATION and CLINICAL PHARMACOLOGY ). uuid:dbc2ae97-1bf3-48ec-bb54-79556adfb9b4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8028 biolink:treats MONDO:0005090 PMID:41385096 "[{""id"":""uuid:db23ee3f-09d9-4222-ba3a-4f061f349127"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:190cb11a-b551-43d9-8d43-ee01ddaf380d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Perphenazine is indicated for use in the treatment of schizophrenia and for the control of severe nausea and vomiting in adults. Perphenazine has not been shown effective for the management of behavioral complications in patients with mental retardation. uuid:a8fd1e55-b957-4dd3-a759-72a78e0533ca biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8028 biolink:treats HP:0002017 PMID:41385096 "[{""id"":""uuid:abf85190-9c2a-4276-baaa-4b7ca72a2b42"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0464048a-3a7f-46c9-9802-9ab97800cb4b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Perphenazine is indicated for use in the treatment of schizophrenia and for the control of severe nausea and vomiting in adults. Perphenazine has not been shown effective for the management of behavioral complications in patients with mental retardation. uuid:f4b45f26-77f7-4424-ae6d-d5d9d89471e0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7565 biolink:treats MONDO:0006021 PMID:41385096 "[{""id"":""uuid:87b3c89c-655b-4789-90fb-7d1aa83244ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0f83e14f-e642-4776-bf7d-f6c47df65ec6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nifedipine extended-release tablets are indicated for the management of vasospastic angina confirmed by any of the following criteria: 1) classical pattern of angina at rest accompanied by ST segment elevation, 2) angina or coronary artery spasm provoked by ergonovine, or 3) angiographically demonstrated coronary artery spasm. In those patients who have had angiography, the presence of significant fixed obstructive disease is not incompatible with the diagnosis of vasospastic angina, provided that the above criteria are satisfied. Nifedipine extended-release may also be used where the clinical presentation suggests a possible vasospastic component but where vasospasm has not been confirmed, e.g., where pain has a variable threshold on exertion or in unstable angina where electrocardiographic findings are compatible with intermittent vasospasm, or when angina is refractory to nitrates and/or adequate doses of beta blockers. uuid:bb1c2565-410f-4eab-80f5-922046697ece biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7565 biolink:treats MONDO:0006805 PMID:41385096 "[{""id"":""uuid:98420710-18a3-4ff5-a15a-84baabddd12e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c917b667-7c70-4d2c-a12a-37ed987cef33"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nifedipine extended-release tablets are indicated for the management of vasospastic angina confirmed by any of the following criteria: 1) classical pattern of angina at rest accompanied by ST segment elevation, 2) angina or coronary artery spasm provoked by ergonovine, or 3) angiographically demonstrated coronary artery spasm. In those patients who have had angiography, the presence of significant fixed obstructive disease is not incompatible with the diagnosis of vasospastic angina, provided that the above criteria are satisfied. Nifedipine extended-release may also be used where the clinical presentation suggests a possible vasospastic component but where vasospasm has not been confirmed, e.g., where pain has a variable threshold on exertion or in unstable angina where electrocardiographic findings are compatible with intermittent vasospasm, or when angina is refractory to nitrates and/or adequate doses of beta blockers. uuid:a6a3db59-33ae-48d6-8a47-b0b7afe24a31 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7565 biolink:treats HP:0001681 PMID:41385096 "[{""id"":""uuid:993cbe52-9a73-4aac-9473-cc8dae862dda"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a14fd701-66aa-47ad-8e46-d3f704dc29a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nifedipine extended-release tablets are indicated for the management of vasospastic angina confirmed by any of the following criteria: 1) classical pattern of angina at rest accompanied by ST segment elevation, 2) angina or coronary artery spasm provoked by ergonovine, or 3) angiographically demonstrated coronary artery spasm. In those patients who have had angiography, the presence of significant fixed obstructive disease is not incompatible with the diagnosis of vasospastic angina, provided that the above criteria are satisfied. Nifedipine extended-release may also be used where the clinical presentation suggests a possible vasospastic component but where vasospasm has not been confirmed, e.g., where pain has a variable threshold on exertion or in unstable angina where electrocardiographic findings are compatible with intermittent vasospasm, or when angina is refractory to nitrates and/or adequate doses of beta blockers. uuid:432667ec-c598-43a5-8e27-f6ad568140df biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5441 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:016bb7ac-4a9e-4dc4-8193-005e0581b7e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ee4c9274-c8e1-4207-8c33-334eecb4fd97"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Glyburide tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. uuid:c5d61569-ebd1-41cc-9f12-ed1efa0d88a0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29103 biolink:treats UMLS:C0151595 PMID:41385096 "[{""id"":""uuid:ab22d445-42a4-48b2-8305-dffe911456ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:69839a9a-3ea7-44b4-823c-c92342407ff5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BECAUSE OF REPORTS OF INTESTINAL AND GASTRIC ULCERATION AND BLEEDING WITH EXTENDED-RELEASE POTASSIUM CHLORIDE PREPARATIONS, THESE DRUGS SHOULD BE RESERVED FOR THOSE PATIENTS WHO CANNOT TOLERATE OR REFUSE TO TAKE LIQUID OR EFFERVESCENT POTASSIUM PREPARATIONS OR FOR PATIENTS IN WHOM THERE IS A PROBLEM OF COMPLIANCE WITH THESE PREPARATIONS. For the therapeutic use of patients with hypokalemia, with or without metabolic alkalosis; in digitalis intoxication; and in patients with hypokalemic familial periodic paralysis. If hypokalemia is the result of diuretic therapy, consideration should be given to the use of a lower dose of diuretic, which may be sufficient without leading to hypokalemia. For the prevention of hypokalemia in patients who would be at particular risk if hypokalemia were to develop, e.g., digitalized patients or patients with significant cardiac arrhythmias. The use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension is often unnecessary when such patients have a normal dietary pattern and when low doses of the diuretic are used. Serum potassium should be checked periodically, however, and if hypokalemia occurs, dietary supplementation with potassium-containing foods may be adequate to control milder cases. In more severe cases, and if dose adjustment of the diuretic is ineffective or unwarranted, supplementation with potassium salts may be indicated. uuid:ed1358e1-68ca-4d39-8cbc-1aa3d4074f58 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49040 biolink:treats MONDO:0005311 PMID:41385096 "[{""id"":""uuid:82b5162f-38a1-4fc2-9b27-cdbaaab6fa6f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cb6e4d13-d923-41f9-bf03-b787d021915e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. 1.1 Primary Hyperlipidemia Monotherapy ZETIA 1 , administered alone, is indicated as adjunctive therapy to diet for the reduction of elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), and apolipoprotein B (Apo B) in patients with primary (heterozygous familial and non-familial) hyperlipidemia. 1 COPYRIGHT © 2001, 2002, 2005, 2007, 2008 Merck/Schering-Plough Pharmaceuticals. All rights reserved. Combination Therapy with HMG-CoA Reductase Inhibitors (Statins) ZETIA, administered in combination with a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor (statin), is indicated as adjunctive therapy to diet for the reduction of elevated total-C, LDL-C, and Apo B in patients with primary (heterozygous familial and non-familial) hyperlipidemia. Combination Therapy with Fenofibrate ZETIA, administered in combination with fenofibrate, is indicated as adjunctive therapy to diet for the reduction of elevated total-C, LDL-C, Apo B, and non-high-density lipoprotein cholesterol (non-HDL-C) in adult patients with mixed hyperlipidemia. 1.2 Homozygous Familial Hypercholesterolemia (HoFH) The combination of ZETIA and atorvastatin or simvastatin is indicated for the reduction of elevated total-C and LDL-C levels in patients with HoFH, as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable. 1.3 Homozygous Sitosterolemia ZETIA is indicated as adjunctive therapy to diet for the reduction of elevated sitosterol and campesterol levels in patients with homozygous familial sitosterolemia. 1.4 Limitations of Use The effect of ZETIA on cardiovascular morbidity and mortality has not been determined. ZETIA has not been studied in Fredrickson Type I, III, IV, and V dyslipidemias. uuid:ad3a947c-6a94-4d98-846d-f6cb2d6360ab biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49040 biolink:treats HP:0003124 PMID:41385096 "[{""id"":""uuid:76693863-b152-4e3e-8b0b-726ed4d6c02e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:522737cc-9e8f-4341-ad6d-c8c0b6546e2a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:00e87732-831c-41b8-9315-08ffee396354"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. 1.1 Primary Hyperlipidemia Monotherapy ZETIA 1 , administered alone, is indicated as adjunctive therapy to diet for the reduction of elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), and apolipoprotein B (Apo B) in patients with primary (heterozygous familial and non-familial) hyperlipidemia. 1 COPYRIGHT © 2001, 2002, 2005, 2007, 2008 Merck/Schering-Plough Pharmaceuticals. All rights reserved. Combination Therapy with HMG-CoA Reductase Inhibitors (Statins) ZETIA, administered in combination with a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor (statin), is indicated as adjunctive therapy to diet for the reduction of elevated total-C, LDL-C, and Apo B in patients with primary (heterozygous familial and non-familial) hyperlipidemia. Combination Therapy with Fenofibrate ZETIA, administered in combination with fenofibrate, is indicated as adjunctive therapy to diet for the reduction of elevated total-C, LDL-C, Apo B, and non-high-density lipoprotein cholesterol (non-HDL-C) in adult patients with mixed hyperlipidemia. 1.2 Homozygous Familial Hypercholesterolemia (HoFH) The combination of ZETIA and atorvastatin or simvastatin is indicated for the reduction of elevated total-C and LDL-C levels in patients with HoFH, as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable. 1.3 Homozygous Sitosterolemia ZETIA is indicated as adjunctive therapy to diet for the reduction of elevated sitosterol and campesterol levels in patients with homozygous familial sitosterolemia. 1.4 Limitations of Use The effect of ZETIA on cardiovascular morbidity and mortality has not been determined. ZETIA has not been studied in Fredrickson Type I, III, IV, and V dyslipidemias.|[PMDA] A drug containing a new active ingredient indicated for the inhibition of cholesterol absorption. uuid:88b4869a-19db-4f36-95a0-13a47843476e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49040 biolink:treats MONDO:0001336 PMID:41385096 "[{""id"":""uuid:4c116b3f-1f0d-4aae-8f1d-d549e1ab13f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d0bf9135-7c42-4f20-aef7-33dd55796e45"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. 1.1 Primary Hyperlipidemia Monotherapy ZETIA 1 , administered alone, is indicated as adjunctive therapy to diet for the reduction of elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), and apolipoprotein B (Apo B) in patients with primary (heterozygous familial and non-familial) hyperlipidemia. 1 COPYRIGHT © 2001, 2002, 2005, 2007, 2008 Merck/Schering-Plough Pharmaceuticals. All rights reserved. Combination Therapy with HMG-CoA Reductase Inhibitors (Statins) ZETIA, administered in combination with a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor (statin), is indicated as adjunctive therapy to diet for the reduction of elevated total-C, LDL-C, and Apo B in patients with primary (heterozygous familial and non-familial) hyperlipidemia. Combination Therapy with Fenofibrate ZETIA, administered in combination with fenofibrate, is indicated as adjunctive therapy to diet for the reduction of elevated total-C, LDL-C, Apo B, and non-high-density lipoprotein cholesterol (non-HDL-C) in adult patients with mixed hyperlipidemia. 1.2 Homozygous Familial Hypercholesterolemia (HoFH) The combination of ZETIA and atorvastatin or simvastatin is indicated for the reduction of elevated total-C and LDL-C levels in patients with HoFH, as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable. 1.3 Homozygous Sitosterolemia ZETIA is indicated as adjunctive therapy to diet for the reduction of elevated sitosterol and campesterol levels in patients with homozygous familial sitosterolemia. 1.4 Limitations of Use The effect of ZETIA on cardiovascular morbidity and mortality has not been determined. ZETIA has not been studied in Fredrickson Type I, III, IV, and V dyslipidemias. uuid:86fefc36-93d4-4bcc-a45c-803b217afd95 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49040 biolink:treats NCIT:C34821 PMID:41385096 "[{""id"":""uuid:3b7a943a-3c2b-424d-80a9-06f94d5d3343"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6167b3fe-6109-4c61-b502-3604562ed6b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. 1.1 Primary Hyperlipidemia Monotherapy ZETIA 1 , administered alone, is indicated as adjunctive therapy to diet for the reduction of elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), and apolipoprotein B (Apo B) in patients with primary (heterozygous familial and non-familial) hyperlipidemia. 1 COPYRIGHT © 2001, 2002, 2005, 2007, 2008 Merck/Schering-Plough Pharmaceuticals. All rights reserved. Combination Therapy with HMG-CoA Reductase Inhibitors (Statins) ZETIA, administered in combination with a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor (statin), is indicated as adjunctive therapy to diet for the reduction of elevated total-C, LDL-C, and Apo B in patients with primary (heterozygous familial and non-familial) hyperlipidemia. Combination Therapy with Fenofibrate ZETIA, administered in combination with fenofibrate, is indicated as adjunctive therapy to diet for the reduction of elevated total-C, LDL-C, Apo B, and non-high-density lipoprotein cholesterol (non-HDL-C) in adult patients with mixed hyperlipidemia. 1.2 Homozygous Familial Hypercholesterolemia (HoFH) The combination of ZETIA and atorvastatin or simvastatin is indicated for the reduction of elevated total-C and LDL-C levels in patients with HoFH, as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable. 1.3 Homozygous Sitosterolemia ZETIA is indicated as adjunctive therapy to diet for the reduction of elevated sitosterol and campesterol levels in patients with homozygous familial sitosterolemia. 1.4 Limitations of Use The effect of ZETIA on cardiovascular morbidity and mortality has not been determined. ZETIA has not been studied in Fredrickson Type I, III, IV, and V dyslipidemias. uuid:2ec60571-31eb-4f3e-9464-3fd7336c70de biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49040 biolink:treats MONDO:0018328 PMID:41385096 "[{""id"":""uuid:eec16c82-71f6-4382-9337-fc217ce90991"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1cc358ec-29e1-415f-a30a-b5d9b0759160"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. 1.1 Primary Hyperlipidemia Monotherapy ZETIA 1 , administered alone, is indicated as adjunctive therapy to diet for the reduction of elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), and apolipoprotein B (Apo B) in patients with primary (heterozygous familial and non-familial) hyperlipidemia. 1 COPYRIGHT © 2001, 2002, 2005, 2007, 2008 Merck/Schering-Plough Pharmaceuticals. All rights reserved. Combination Therapy with HMG-CoA Reductase Inhibitors (Statins) ZETIA, administered in combination with a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor (statin), is indicated as adjunctive therapy to diet for the reduction of elevated total-C, LDL-C, and Apo B in patients with primary (heterozygous familial and non-familial) hyperlipidemia. Combination Therapy with Fenofibrate ZETIA, administered in combination with fenofibrate, is indicated as adjunctive therapy to diet for the reduction of elevated total-C, LDL-C, Apo B, and non-high-density lipoprotein cholesterol (non-HDL-C) in adult patients with mixed hyperlipidemia. 1.2 Homozygous Familial Hypercholesterolemia (HoFH) The combination of ZETIA and atorvastatin or simvastatin is indicated for the reduction of elevated total-C and LDL-C levels in patients with HoFH, as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable. 1.3 Homozygous Sitosterolemia ZETIA is indicated as adjunctive therapy to diet for the reduction of elevated sitosterol and campesterol levels in patients with homozygous familial sitosterolemia. 1.4 Limitations of Use The effect of ZETIA on cardiovascular morbidity and mortality has not been determined. ZETIA has not been studied in Fredrickson Type I, III, IV, and V dyslipidemias. uuid:f578ad21-3fed-4df9-8f4e-14c46e5799e4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49040 biolink:treats MONDO:0008863 PMID:41385096 "[{""id"":""uuid:5ad6052e-bc8a-4a57-8cfe-478162407e6b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1182eb06-26c2-41ef-b454-78860c2ef91f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. 1.1 Primary Hyperlipidemia Monotherapy ZETIA 1 , administered alone, is indicated as adjunctive therapy to diet for the reduction of elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), and apolipoprotein B (Apo B) in patients with primary (heterozygous familial and non-familial) hyperlipidemia. 1 COPYRIGHT © 2001, 2002, 2005, 2007, 2008 Merck/Schering-Plough Pharmaceuticals. All rights reserved. Combination Therapy with HMG-CoA Reductase Inhibitors (Statins) ZETIA, administered in combination with a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor (statin), is indicated as adjunctive therapy to diet for the reduction of elevated total-C, LDL-C, and Apo B in patients with primary (heterozygous familial and non-familial) hyperlipidemia. Combination Therapy with Fenofibrate ZETIA, administered in combination with fenofibrate, is indicated as adjunctive therapy to diet for the reduction of elevated total-C, LDL-C, Apo B, and non-high-density lipoprotein cholesterol (non-HDL-C) in adult patients with mixed hyperlipidemia. 1.2 Homozygous Familial Hypercholesterolemia (HoFH) The combination of ZETIA and atorvastatin or simvastatin is indicated for the reduction of elevated total-C and LDL-C levels in patients with HoFH, as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable. 1.3 Homozygous Sitosterolemia ZETIA is indicated as adjunctive therapy to diet for the reduction of elevated sitosterol and campesterol levels in patients with homozygous familial sitosterolemia. 1.4 Limitations of Use The effect of ZETIA on cardiovascular morbidity and mortality has not been determined. ZETIA has not been studied in Fredrickson Type I, III, IV, and V dyslipidemias. uuid:c08bb980-2d91-4afc-92e1-0b8eedfb9c92 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49040 biolink:treats MONDO:0007788 PMID:41385096 "[{""id"":""uuid:b92f8559-da92-433d-80d3-dba2e3e5009c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9c9e9131-c084-4a05-8b8b-c92c2c4a602b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. 1.1 Primary Hyperlipidemia Monotherapy ZETIA 1 , administered alone, is indicated as adjunctive therapy to diet for the reduction of elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), and apolipoprotein B (Apo B) in patients with primary (heterozygous familial and non-familial) hyperlipidemia. 1 COPYRIGHT © 2001, 2002, 2005, 2007, 2008 Merck/Schering-Plough Pharmaceuticals. All rights reserved. Combination Therapy with HMG-CoA Reductase Inhibitors (Statins) ZETIA, administered in combination with a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor (statin), is indicated as adjunctive therapy to diet for the reduction of elevated total-C, LDL-C, and Apo B in patients with primary (heterozygous familial and non-familial) hyperlipidemia. Combination Therapy with Fenofibrate ZETIA, administered in combination with fenofibrate, is indicated as adjunctive therapy to diet for the reduction of elevated total-C, LDL-C, Apo B, and non-high-density lipoprotein cholesterol (non-HDL-C) in adult patients with mixed hyperlipidemia. 1.2 Homozygous Familial Hypercholesterolemia (HoFH) The combination of ZETIA and atorvastatin or simvastatin is indicated for the reduction of elevated total-C and LDL-C levels in patients with HoFH, as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable. 1.3 Homozygous Sitosterolemia ZETIA is indicated as adjunctive therapy to diet for the reduction of elevated sitosterol and campesterol levels in patients with homozygous familial sitosterolemia. 1.4 Limitations of Use The effect of ZETIA on cardiovascular morbidity and mortality has not been determined. ZETIA has not been studied in Fredrickson Type I, III, IV, and V dyslipidemias. uuid:212c12e6-6c9c-44fa-bea6-81b56f293610 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49040 biolink:treats MONDO:0018473 PMID:41385096 "[{""id"":""uuid:d419b871-32b6-467c-b9b6-35fc32353468"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d623a646-1e02-41ff-bf6f-45232b9c53ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. 1.1 Primary Hyperlipidemia Monotherapy ZETIA 1 , administered alone, is indicated as adjunctive therapy to diet for the reduction of elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), and apolipoprotein B (Apo B) in patients with primary (heterozygous familial and non-familial) hyperlipidemia. 1 COPYRIGHT © 2001, 2002, 2005, 2007, 2008 Merck/Schering-Plough Pharmaceuticals. All rights reserved. Combination Therapy with HMG-CoA Reductase Inhibitors (Statins) ZETIA, administered in combination with a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor (statin), is indicated as adjunctive therapy to diet for the reduction of elevated total-C, LDL-C, and Apo B in patients with primary (heterozygous familial and non-familial) hyperlipidemia. Combination Therapy with Fenofibrate ZETIA, administered in combination with fenofibrate, is indicated as adjunctive therapy to diet for the reduction of elevated total-C, LDL-C, Apo B, and non-high-density lipoprotein cholesterol (non-HDL-C) in adult patients with mixed hyperlipidemia. 1.2 Homozygous Familial Hypercholesterolemia (HoFH) The combination of ZETIA and atorvastatin or simvastatin is indicated for the reduction of elevated total-C and LDL-C levels in patients with HoFH, as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable. 1.3 Homozygous Sitosterolemia ZETIA is indicated as adjunctive therapy to diet for the reduction of elevated sitosterol and campesterol levels in patients with homozygous familial sitosterolemia. 1.4 Limitations of Use The effect of ZETIA on cardiovascular morbidity and mortality has not been determined. ZETIA has not been studied in Fredrickson Type I, III, IV, and V dyslipidemias. uuid:57b2cdd8-f6ae-47e1-8594-6a6232ec9059 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49040 biolink:treats MONDO:0007762 PMID:41385096 "[{""id"":""uuid:38d23407-df41-4920-b5b4-771bc93b6fe7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:06503854-c509-4ec5-a8ba-de5948428fe7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. 1.1 Primary Hyperlipidemia Monotherapy ZETIA 1 , administered alone, is indicated as adjunctive therapy to diet for the reduction of elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), and apolipoprotein B (Apo B) in patients with primary (heterozygous familial and non-familial) hyperlipidemia. 1 COPYRIGHT © 2001, 2002, 2005, 2007, 2008 Merck/Schering-Plough Pharmaceuticals. All rights reserved. Combination Therapy with HMG-CoA Reductase Inhibitors (Statins) ZETIA, administered in combination with a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor (statin), is indicated as adjunctive therapy to diet for the reduction of elevated total-C, LDL-C, and Apo B in patients with primary (heterozygous familial and non-familial) hyperlipidemia. Combination Therapy with Fenofibrate ZETIA, administered in combination with fenofibrate, is indicated as adjunctive therapy to diet for the reduction of elevated total-C, LDL-C, Apo B, and non-high-density lipoprotein cholesterol (non-HDL-C) in adult patients with mixed hyperlipidemia. 1.2 Homozygous Familial Hypercholesterolemia (HoFH) The combination of ZETIA and atorvastatin or simvastatin is indicated for the reduction of elevated total-C and LDL-C levels in patients with HoFH, as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable. 1.3 Homozygous Sitosterolemia ZETIA is indicated as adjunctive therapy to diet for the reduction of elevated sitosterol and campesterol levels in patients with homozygous familial sitosterolemia. 1.4 Limitations of Use The effect of ZETIA on cardiovascular morbidity and mortality has not been determined. ZETIA has not been studied in Fredrickson Type I, III, IV, and V dyslipidemias. uuid:eacc6352-81a1-433b-9703-7169d780ced6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7496 biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:ed6c3256-a543-4c2a-86dd-6dc5766115e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dd07ce8d-bb0e-425f-912e-c35819ad5b80"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VIRACEPT in combination with other antiretroviral agents is indicated for the treatment of HIV infection. uuid:51ebba7e-c064-4efa-a49b-4e0d6658aab7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:11954236 biolink:treats MONDO:0004951 PMID:41385096 "[{""id"":""uuid:90c19687-d99e-44d9-89bd-4678e9f1e378"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:da35780c-6503-4d9f-92e1-fc8c5fee717c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TRUVADA ® , a combination of EMTRIVA ® and VIREAD ® , is indicated in combination with other antiretroviral agents (such as non-nucleoside reverse transcriptase inhibitors or protease inhibitors) for the treatment of HIV-1 infection in adults. The following points should be considered when initiating therapy with TRUVADA for the treatment of HIV-1 infection: It is not recommended that TRUVADA be used as a component of a triple nucleoside regimen. TRUVADA should not be coadministered with ATRIPLA ® , EMTRIVA, VIREAD or lamivudine-containing products [See Warnings and Precautions (5.4) ] . In treatment experienced patients, the use of TRUVADA should be guided by laboratory testing and treatment history [See Clinical Pharmacology (12.4) ] . uuid:89a2b861-2ce5-4444-beb6-f56f840fb40c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9352 biolink:treats MONDO:0005178 PMID:41385096 "[{""id"":""uuid:4bc99f52-83dd-4f59-a297-07763f570808"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:db6c8998-2af2-4935-ad43-77c025232b2f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of sulindac and other treatment options before deciding to use sulindac. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Sulindac tablets are indicated for acute long-term use in the relief of signs and symptoms of the following: Osteoarthritis Rheumatoid arthritis * Ankylosing spondylitis Acute painful shoulder (Acute subacromial bursitis/supraspinatus tendinitis) Acute gouty arthritis uuid:e1db2612-87df-4d16-8ff0-b106c170a60c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9352 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:5ebe7ffe-83f7-4730-8b02-9dbab9748b7b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dd9121c3-1fff-4d2d-889f-5cdbd5db33c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of sulindac and other treatment options before deciding to use sulindac. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Sulindac tablets are indicated for acute long-term use in the relief of signs and symptoms of the following: Osteoarthritis Rheumatoid arthritis * Ankylosing spondylitis Acute painful shoulder (Acute subacromial bursitis/supraspinatus tendinitis) Acute gouty arthritis uuid:26b9b65b-f368-4555-b41b-d2f791b2e8de biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9352 biolink:treats MONDO:0005306 PMID:41385096 "[{""id"":""uuid:516ed892-7bbf-4206-8dae-8460a78a1a0f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9a7a7be7-4ddd-476a-b61d-71f77e2ee64e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of sulindac and other treatment options before deciding to use sulindac. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Sulindac tablets are indicated for acute long-term use in the relief of signs and symptoms of the following: Osteoarthritis Rheumatoid arthritis * Ankylosing spondylitis Acute painful shoulder (Acute subacromial bursitis/supraspinatus tendinitis) Acute gouty arthritis uuid:1fcb4614-cf1e-4a90-b659-2a2250c04f87 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9352 biolink:treats UMLS:C0149896 PMID:41385096 "[{""id"":""uuid:a726f138-a34a-4d01-8152-f9ef41889bf0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4e8c9da3-ebb9-43b1-a4eb-f5c67c4aeec3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of sulindac and other treatment options before deciding to use sulindac. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Sulindac tablets are indicated for acute long-term use in the relief of signs and symptoms of the following: Osteoarthritis Rheumatoid arthritis * Ankylosing spondylitis Acute painful shoulder (Acute subacromial bursitis/supraspinatus tendinitis) Acute gouty arthritis uuid:b5fb11f4-705e-4e75-b84d-6675da5bfda5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63625 biolink:treats MONDO:0004951 PMID:41385096 "[{""id"":""uuid:82ae55f4-ddc6-4e65-bf1a-bf659cb436a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:101f9adf-d623-4b4f-9a29-f2e94b947128"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VIREAD is a nucleotide analog HIV-1 reverse transcriptase and HBV polymerase inhibitor. Viread is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults. ( 1 ) Viread is indicated for the treatment of chronic hepatitis B in adults. ( 1 ) uuid:3095b09e-95d3-4450-bb18-0ee3f236bd74 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63625 biolink:treats MONDO:0005366 PMID:41385096 "[{""id"":""uuid:6237eb32-6c8b-402c-b6f7-8f4f44724753"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2d13cbf4-4199-4caf-ba2c-3e18fc03a3a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VIREAD is a nucleotide analog HIV-1 reverse transcriptase and HBV polymerase inhibitor. Viread is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults. ( 1 ) Viread is indicated for the treatment of chronic hepatitis B in adults. ( 1 ) uuid:f6391558-c996-45d9-b86f-1780f56fddc3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9398 biolink:treats MONDO:0010811 PMID:41385096 "[{""id"":""uuid:9f16a0fe-51d3-477d-bb4b-213b18709cef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:47eef8dc-28d7-4015-8dfe-3e9bfc27cfd7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Flomax ® (tamsulosin hydrochloride) capsules are indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH) [ see Clinical Studies (14) ]. FLOMAX capsules are not indicated for the treatment of hypertension. uuid:596bcbcb-5b34-43db-9c56-609049a1d638 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9398 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:1abeb475-b063-4d26-b68e-a84e3b7ed030"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:af27559b-bc06-4e78-a29c-4dee2f5b42f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Flomax ® (tamsulosin hydrochloride) capsules are indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH) [ see Clinical Studies (14) ]. FLOMAX capsules are not indicated for the treatment of hypertension. uuid:3b440cec-770a-4a4d-bed3-714135fc8b6a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31401 biolink:treats MONDO:0005295 PMID:41385096 "[{""id"":""uuid:6c549935-9e2f-4158-b3f7-2d8a6ab12215"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:98bc805e-731b-4c76-8e02-67092676f899"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cilostazol tablets are indicated for the reduction of symptoms of intermittent claudication, as indicated by an increased walking distance. uuid:80a0dc05-9eda-4d26-a6ab-f3398ac3739c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49662 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:51e49ce6-5258-4cd9-89e1-cfa1af445031"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7211df80-a0cd-481f-9ecf-3194002a9795"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of indomethacin capsules and other treatment options before deciding to use indomethacin. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS) Indomethacin has been found effective in active stages of the following: Moderate to severe rheumatoid arthritis including acute flares of chronic disease. Moderate to severe ankylosing spondylitis. Moderate to severe osteoarthritis. Acute painful shoulder (bursitis and/or tendinitis). Acute gouty arthritis. uuid:cf75c5a8-4c04-4084-ad80-33574ee6a897 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49662 biolink:treats MONDO:0005306 PMID:41385096 "[{""id"":""uuid:5721e424-f2ef-4672-b1e6-c6b2d1659e3d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a87d5169-f97b-4e14-8a38-705ed28c3cf9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of indomethacin capsules and other treatment options before deciding to use indomethacin. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS) Indomethacin has been found effective in active stages of the following: Moderate to severe rheumatoid arthritis including acute flares of chronic disease. Moderate to severe ankylosing spondylitis. Moderate to severe osteoarthritis. Acute painful shoulder (bursitis and/or tendinitis). Acute gouty arthritis. uuid:f627a080-646a-4e2a-b4ba-ca4a65a66527 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49662 biolink:treats MONDO:0005178 PMID:41385096 "[{""id"":""uuid:b9ae870a-feb9-445d-b738-a3e2277b3cd3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:88eed098-2ac2-498e-bfd7-88addf2b8502"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of indomethacin capsules and other treatment options before deciding to use indomethacin. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS) Indomethacin has been found effective in active stages of the following: Moderate to severe rheumatoid arthritis including acute flares of chronic disease. Moderate to severe ankylosing spondylitis. Moderate to severe osteoarthritis. Acute painful shoulder (bursitis and/or tendinitis). Acute gouty arthritis. uuid:5a466813-7184-4ef1-afcd-1a176a8c5e86 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49662 biolink:treats MONDO:0002471 PMID:41385096 "[{""id"":""uuid:1b5c3caf-8518-4fd1-a516-f3027ea442d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f5e863c0-36bc-48de-a7b6-95753d75e055"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of indomethacin capsules and other treatment options before deciding to use indomethacin. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS) Indomethacin has been found effective in active stages of the following: Moderate to severe rheumatoid arthritis including acute flares of chronic disease. Moderate to severe ankylosing spondylitis. Moderate to severe osteoarthritis. Acute painful shoulder (bursitis and/or tendinitis). Acute gouty arthritis. uuid:ee2f8d69-7152-4cca-828f-16d168f63f42 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49662 biolink:treats MONDO:0004857 PMID:41385096 "[{""id"":""uuid:7628928d-fd72-4177-a25c-1a8053425956"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e5a48e79-7991-4942-b1ea-c8301aad7499"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of indomethacin capsules and other treatment options before deciding to use indomethacin. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS) Indomethacin has been found effective in active stages of the following: Moderate to severe rheumatoid arthritis including acute flares of chronic disease. Moderate to severe ankylosing spondylitis. Moderate to severe osteoarthritis. Acute painful shoulder (bursitis and/or tendinitis). Acute gouty arthritis. uuid:3cb39af1-ce71-4d53-ba03-89aba38d2b25 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49662 biolink:treats MONDO:0005393 PMID:41385096 "[{""id"":""uuid:1dbb512a-9712-424f-a19b-76859b3aaf2a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:34de5591-c839-4032-a303-fb70ad8d99dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of indomethacin capsules and other treatment options before deciding to use indomethacin. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS) Indomethacin has been found effective in active stages of the following: Moderate to severe rheumatoid arthritis including acute flares of chronic disease. Moderate to severe ankylosing spondylitis. Moderate to severe osteoarthritis. Acute painful shoulder (bursitis and/or tendinitis). Acute gouty arthritis. uuid:250ca7cb-665f-4bb5-a945-829004eeb186 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6030 biolink:treats MONDO:0018076 PMID:41385096 "[{""id"":""uuid:618d2806-d399-4ec2-8090-970f9e7a4f48"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3d6a076a-564e-492a-a485-567d4c6f4b18"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Isoniazid is recommended for all forms of tuberculosis in which organisms are susceptible. However, active tuberculosis must be treated with multiple concomitant antituberculosis medications to prevent the emergence of drug resistance. Single-drug treatment of active tuberculosis with isoniazid, or any other medication, is inadequate therapy. Isoniazid is recommended as preventive therapy for the following groups, regardless of age. (Note: the criterion for a positive reaction to a skin test (in millimeters of induration) for each group is given in parenthesis): Persons with human immunodeficiency virus (HIV) infection (≥ 5 mm) and persons with risk factors for HIV infection whose HIV infection status is unknown but who are suspected of having HIV infection. Preventive therapy may be considered for HIV infected persons who are tuberculin-negative but belong to groups in which the prevalence of tuberculosis infection is high. Candidates for preventive therapy who have HIV infection should have a minimum of 12 months of therapy. Close contacts of persons with newly diagnosed infectious tuberculosis (≥ 5 mm). In addition, tuberculin-negative (< 5 mm) children and adolescents who have been close contacts of infectious persons within the past 3 months are candidates for preventive therapy until a repeat tuberculin skin test is done 12 weeks after contact with the infectious source. If the repeat skin test is positive (> 5 mm), therapy should be continued. Recent converters, as indicated by a tuberculin skin test (≥ 10 mm increase within a 2-year period for those < 35 years old; ≥ 15 mm increase for those ≥ 35 years of age). All infants and children younger than 4 years of age with a > 10 mm skin test are included in this category. Persons with abnormal chest radiographs that show fibrotic lesions likely to represent old healed tuberculosis (≥ 5 mm). Candidates for preventive therapy who have fibrotic pulmonary lesions consistent with healed tuberculosis or who have pulmonary silicosis should have 12 months of isoniazid or 4 months of isoniazid and rifampin, concomitantly. Intravenous drug users known to be HIV-seronegative (> 10 mm). Persons with the following medical conditions that have been reported to increase the risk of tuberculosis (≥ 10 mm): silicosis; diabetes mellitus; prolonged therapy with adrenocorticosteroids; immunosuppressive therapy; some hematologic and reticuloendothelial diseases, such as leukemia or Hodgkin's disease; end-stage renal disease; clinical situations associated with substantial rapid weight loss or chronic undernutrition (including: intestinal bypass surgery for obesity, the postgastrectomy state (with or without weight loss), chronic peptic ulcer disease, chronic malabsorption syndromes, and carcinomas of the oropharynx and upper gastrointestinal tract that prevent adequate nutritional intake). Candidates for preventive therapy who have fibrotic pulmonary lesions consistent with healed tuberculosis or who have pulmonary silicosis should have 12 months of isoniazid or 4 months of isoniazid and rifampin, concomitantly. Additionally, in the absence of any of the above risk factors, persons under the age of 35 with a tuberculin skin test reaction of 10 mm or more are also appropriate candidates for preventive therapy if they are a member of any of the following high-incidence groups: Foreign-born persons from high-prevalence countries who never received BCG vaccine. Medically underserved low-income populations, including high-risk racial or ethnic minority populations, especially blacks, Hispanics, and Native Americans. Residents of facilities for long-term care (e.g., correctional institutions, nursing homes, and mental institutions). Children who are less than 4 years old are candidates for isoniazid preventive therapy if they have >10 mm induration from a PPD Mantoux tuberculin skin test. Finally, persons under the age of 35 who a) have none of the above risk factors (1-6); b) belong to none of the high-incidence groups; and c) have a tuberculin skin test reaction of 15 mm or more, are appropriate candidates for preventive therapy. The risk of hepatitis must be weighed against the risk of tuberculosis in positive tuberculin reactors over the age of 35. However, the use of isoniazid is recommended for those with the additional risk factors listed above (1-6) and on an individual basis in situations where there is likelihood of serious consequences to contacts who may become infected. uuid:2fcd336b-9479-48f7-9367-ecbe2d5cbcf3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6030 biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:11959b94-c11b-4c7e-87b5-001786547604"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0ecb77fb-dbc0-4046-9d8f-09f76d9c011f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Isoniazid is recommended for all forms of tuberculosis in which organisms are susceptible. However, active tuberculosis must be treated with multiple concomitant antituberculosis medications to prevent the emergence of drug resistance. Single-drug treatment of active tuberculosis with isoniazid, or any other medication, is inadequate therapy. Isoniazid is recommended as preventive therapy for the following groups, regardless of age. (Note: the criterion for a positive reaction to a skin test (in millimeters of induration) for each group is given in parenthesis): Persons with human immunodeficiency virus (HIV) infection (≥ 5 mm) and persons with risk factors for HIV infection whose HIV infection status is unknown but who are suspected of having HIV infection. Preventive therapy may be considered for HIV infected persons who are tuberculin-negative but belong to groups in which the prevalence of tuberculosis infection is high. Candidates for preventive therapy who have HIV infection should have a minimum of 12 months of therapy. Close contacts of persons with newly diagnosed infectious tuberculosis (≥ 5 mm). In addition, tuberculin-negative (< 5 mm) children and adolescents who have been close contacts of infectious persons within the past 3 months are candidates for preventive therapy until a repeat tuberculin skin test is done 12 weeks after contact with the infectious source. If the repeat skin test is positive (> 5 mm), therapy should be continued. Recent converters, as indicated by a tuberculin skin test (≥ 10 mm increase within a 2-year period for those < 35 years old; ≥ 15 mm increase for those ≥ 35 years of age). All infants and children younger than 4 years of age with a > 10 mm skin test are included in this category. Persons with abnormal chest radiographs that show fibrotic lesions likely to represent old healed tuberculosis (≥ 5 mm). Candidates for preventive therapy who have fibrotic pulmonary lesions consistent with healed tuberculosis or who have pulmonary silicosis should have 12 months of isoniazid or 4 months of isoniazid and rifampin, concomitantly. Intravenous drug users known to be HIV-seronegative (> 10 mm). Persons with the following medical conditions that have been reported to increase the risk of tuberculosis (≥ 10 mm): silicosis; diabetes mellitus; prolonged therapy with adrenocorticosteroids; immunosuppressive therapy; some hematologic and reticuloendothelial diseases, such as leukemia or Hodgkin's disease; end-stage renal disease; clinical situations associated with substantial rapid weight loss or chronic undernutrition (including: intestinal bypass surgery for obesity, the postgastrectomy state (with or without weight loss), chronic peptic ulcer disease, chronic malabsorption syndromes, and carcinomas of the oropharynx and upper gastrointestinal tract that prevent adequate nutritional intake). Candidates for preventive therapy who have fibrotic pulmonary lesions consistent with healed tuberculosis or who have pulmonary silicosis should have 12 months of isoniazid or 4 months of isoniazid and rifampin, concomitantly. Additionally, in the absence of any of the above risk factors, persons under the age of 35 with a tuberculin skin test reaction of 10 mm or more are also appropriate candidates for preventive therapy if they are a member of any of the following high-incidence groups: Foreign-born persons from high-prevalence countries who never received BCG vaccine. Medically underserved low-income populations, including high-risk racial or ethnic minority populations, especially blacks, Hispanics, and Native Americans. Residents of facilities for long-term care (e.g., correctional institutions, nursing homes, and mental institutions). Children who are less than 4 years old are candidates for isoniazid preventive therapy if they have >10 mm induration from a PPD Mantoux tuberculin skin test. Finally, persons under the age of 35 who a) have none of the above risk factors (1-6); b) belong to none of the high-incidence groups; and c) have a tuberculin skin test reaction of 15 mm or more, are appropriate candidates for preventive therapy. The risk of hepatitis must be weighed against the risk of tuberculosis in positive tuberculin reactors over the age of 35. However, the use of isoniazid is recommended for those with the additional risk factors listed above (1-6) and on an individual basis in situations where there is likelihood of serious consequences to contacts who may become infected. uuid:639a5813-b678-48d8-ab3a-bde164bb21c0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6030 biolink:treats MONDO:0005960 PMID:41385096 "[{""id"":""uuid:8ef5738f-2142-4c62-b7ff-f778d772fa96"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7cb4dd3e-30aa-4a1c-b2f4-6e3d5b773bc3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Isoniazid is recommended for all forms of tuberculosis in which organisms are susceptible. However, active tuberculosis must be treated with multiple concomitant antituberculosis medications to prevent the emergence of drug resistance. Single-drug treatment of active tuberculosis with isoniazid, or any other medication, is inadequate therapy. Isoniazid is recommended as preventive therapy for the following groups, regardless of age. (Note: the criterion for a positive reaction to a skin test (in millimeters of induration) for each group is given in parenthesis): Persons with human immunodeficiency virus (HIV) infection (≥ 5 mm) and persons with risk factors for HIV infection whose HIV infection status is unknown but who are suspected of having HIV infection. Preventive therapy may be considered for HIV infected persons who are tuberculin-negative but belong to groups in which the prevalence of tuberculosis infection is high. Candidates for preventive therapy who have HIV infection should have a minimum of 12 months of therapy. Close contacts of persons with newly diagnosed infectious tuberculosis (≥ 5 mm). In addition, tuberculin-negative (< 5 mm) children and adolescents who have been close contacts of infectious persons within the past 3 months are candidates for preventive therapy until a repeat tuberculin skin test is done 12 weeks after contact with the infectious source. If the repeat skin test is positive (> 5 mm), therapy should be continued. Recent converters, as indicated by a tuberculin skin test (≥ 10 mm increase within a 2-year period for those < 35 years old; ≥ 15 mm increase for those ≥ 35 years of age). All infants and children younger than 4 years of age with a > 10 mm skin test are included in this category. Persons with abnormal chest radiographs that show fibrotic lesions likely to represent old healed tuberculosis (≥ 5 mm). Candidates for preventive therapy who have fibrotic pulmonary lesions consistent with healed tuberculosis or who have pulmonary silicosis should have 12 months of isoniazid or 4 months of isoniazid and rifampin, concomitantly. Intravenous drug users known to be HIV-seronegative (> 10 mm). Persons with the following medical conditions that have been reported to increase the risk of tuberculosis (≥ 10 mm): silicosis; diabetes mellitus; prolonged therapy with adrenocorticosteroids; immunosuppressive therapy; some hematologic and reticuloendothelial diseases, such as leukemia or Hodgkin's disease; end-stage renal disease; clinical situations associated with substantial rapid weight loss or chronic undernutrition (including: intestinal bypass surgery for obesity, the postgastrectomy state (with or without weight loss), chronic peptic ulcer disease, chronic malabsorption syndromes, and carcinomas of the oropharynx and upper gastrointestinal tract that prevent adequate nutritional intake). Candidates for preventive therapy who have fibrotic pulmonary lesions consistent with healed tuberculosis or who have pulmonary silicosis should have 12 months of isoniazid or 4 months of isoniazid and rifampin, concomitantly. Additionally, in the absence of any of the above risk factors, persons under the age of 35 with a tuberculin skin test reaction of 10 mm or more are also appropriate candidates for preventive therapy if they are a member of any of the following high-incidence groups: Foreign-born persons from high-prevalence countries who never received BCG vaccine. Medically underserved low-income populations, including high-risk racial or ethnic minority populations, especially blacks, Hispanics, and Native Americans. Residents of facilities for long-term care (e.g., correctional institutions, nursing homes, and mental institutions). Children who are less than 4 years old are candidates for isoniazid preventive therapy if they have >10 mm induration from a PPD Mantoux tuberculin skin test. Finally, persons under the age of 35 who a) have none of the above risk factors (1-6); b) belong to none of the high-incidence groups; and c) have a tuberculin skin test reaction of 15 mm or more, are appropriate candidates for preventive therapy. The risk of hepatitis must be weighed against the risk of tuberculosis in positive tuberculin reactors over the age of 35. However, the use of isoniazid is recommended for those with the additional risk factors listed above (1-6) and on an individual basis in situations where there is likelihood of serious consequences to contacts who may become infected. uuid:2b8b638a-7b48-4477-bba9-edddbd4ed0be biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6030 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:a92e3c0e-552f-4157-8c58-0edc204704fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f8d03af4-84e1-4cd6-8eec-13249e53e771"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Isoniazid is recommended for all forms of tuberculosis in which organisms are susceptible. However, active tuberculosis must be treated with multiple concomitant antituberculosis medications to prevent the emergence of drug resistance. Single-drug treatment of active tuberculosis with isoniazid, or any other medication, is inadequate therapy. Isoniazid is recommended as preventive therapy for the following groups, regardless of age. (Note: the criterion for a positive reaction to a skin test (in millimeters of induration) for each group is given in parenthesis): Persons with human immunodeficiency virus (HIV) infection (≥ 5 mm) and persons with risk factors for HIV infection whose HIV infection status is unknown but who are suspected of having HIV infection. Preventive therapy may be considered for HIV infected persons who are tuberculin-negative but belong to groups in which the prevalence of tuberculosis infection is high. Candidates for preventive therapy who have HIV infection should have a minimum of 12 months of therapy. Close contacts of persons with newly diagnosed infectious tuberculosis (≥ 5 mm). In addition, tuberculin-negative (< 5 mm) children and adolescents who have been close contacts of infectious persons within the past 3 months are candidates for preventive therapy until a repeat tuberculin skin test is done 12 weeks after contact with the infectious source. If the repeat skin test is positive (> 5 mm), therapy should be continued. Recent converters, as indicated by a tuberculin skin test (≥ 10 mm increase within a 2-year period for those < 35 years old; ≥ 15 mm increase for those ≥ 35 years of age). All infants and children younger than 4 years of age with a > 10 mm skin test are included in this category. Persons with abnormal chest radiographs that show fibrotic lesions likely to represent old healed tuberculosis (≥ 5 mm). Candidates for preventive therapy who have fibrotic pulmonary lesions consistent with healed tuberculosis or who have pulmonary silicosis should have 12 months of isoniazid or 4 months of isoniazid and rifampin, concomitantly. Intravenous drug users known to be HIV-seronegative (> 10 mm). Persons with the following medical conditions that have been reported to increase the risk of tuberculosis (≥ 10 mm): silicosis; diabetes mellitus; prolonged therapy with adrenocorticosteroids; immunosuppressive therapy; some hematologic and reticuloendothelial diseases, such as leukemia or Hodgkin's disease; end-stage renal disease; clinical situations associated with substantial rapid weight loss or chronic undernutrition (including: intestinal bypass surgery for obesity, the postgastrectomy state (with or without weight loss), chronic peptic ulcer disease, chronic malabsorption syndromes, and carcinomas of the oropharynx and upper gastrointestinal tract that prevent adequate nutritional intake). Candidates for preventive therapy who have fibrotic pulmonary lesions consistent with healed tuberculosis or who have pulmonary silicosis should have 12 months of isoniazid or 4 months of isoniazid and rifampin, concomitantly. Additionally, in the absence of any of the above risk factors, persons under the age of 35 with a tuberculin skin test reaction of 10 mm or more are also appropriate candidates for preventive therapy if they are a member of any of the following high-incidence groups: Foreign-born persons from high-prevalence countries who never received BCG vaccine. Medically underserved low-income populations, including high-risk racial or ethnic minority populations, especially blacks, Hispanics, and Native Americans. Residents of facilities for long-term care (e.g., correctional institutions, nursing homes, and mental institutions). Children who are less than 4 years old are candidates for isoniazid preventive therapy if they have >10 mm induration from a PPD Mantoux tuberculin skin test. Finally, persons under the age of 35 who a) have none of the above risk factors (1-6); b) belong to none of the high-incidence groups; and c) have a tuberculin skin test reaction of 15 mm or more, are appropriate candidates for preventive therapy. The risk of hepatitis must be weighed against the risk of tuberculosis in positive tuberculin reactors over the age of 35. However, the use of isoniazid is recommended for those with the additional risk factors listed above (1-6) and on an individual basis in situations where there is likelihood of serious consequences to contacts who may become infected. uuid:caba5ef2-6935-44a9-8793-26e6f7a4cb6e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6030 biolink:treats MONDO:0005059 PMID:41385096 "[{""id"":""uuid:535b5a46-ccd0-4def-b894-bdf8e8aef47a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5bd17c15-7928-4bc8-9a00-92ae926a5731"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Isoniazid is recommended for all forms of tuberculosis in which organisms are susceptible. However, active tuberculosis must be treated with multiple concomitant antituberculosis medications to prevent the emergence of drug resistance. Single-drug treatment of active tuberculosis with isoniazid, or any other medication, is inadequate therapy. Isoniazid is recommended as preventive therapy for the following groups, regardless of age. (Note: the criterion for a positive reaction to a skin test (in millimeters of induration) for each group is given in parenthesis): Persons with human immunodeficiency virus (HIV) infection (≥ 5 mm) and persons with risk factors for HIV infection whose HIV infection status is unknown but who are suspected of having HIV infection. Preventive therapy may be considered for HIV infected persons who are tuberculin-negative but belong to groups in which the prevalence of tuberculosis infection is high. Candidates for preventive therapy who have HIV infection should have a minimum of 12 months of therapy. Close contacts of persons with newly diagnosed infectious tuberculosis (≥ 5 mm). In addition, tuberculin-negative (< 5 mm) children and adolescents who have been close contacts of infectious persons within the past 3 months are candidates for preventive therapy until a repeat tuberculin skin test is done 12 weeks after contact with the infectious source. If the repeat skin test is positive (> 5 mm), therapy should be continued. Recent converters, as indicated by a tuberculin skin test (≥ 10 mm increase within a 2-year period for those < 35 years old; ≥ 15 mm increase for those ≥ 35 years of age). All infants and children younger than 4 years of age with a > 10 mm skin test are included in this category. Persons with abnormal chest radiographs that show fibrotic lesions likely to represent old healed tuberculosis (≥ 5 mm). Candidates for preventive therapy who have fibrotic pulmonary lesions consistent with healed tuberculosis or who have pulmonary silicosis should have 12 months of isoniazid or 4 months of isoniazid and rifampin, concomitantly. Intravenous drug users known to be HIV-seronegative (> 10 mm). Persons with the following medical conditions that have been reported to increase the risk of tuberculosis (≥ 10 mm): silicosis; diabetes mellitus; prolonged therapy with adrenocorticosteroids; immunosuppressive therapy; some hematologic and reticuloendothelial diseases, such as leukemia or Hodgkin's disease; end-stage renal disease; clinical situations associated with substantial rapid weight loss or chronic undernutrition (including: intestinal bypass surgery for obesity, the postgastrectomy state (with or without weight loss), chronic peptic ulcer disease, chronic malabsorption syndromes, and carcinomas of the oropharynx and upper gastrointestinal tract that prevent adequate nutritional intake). Candidates for preventive therapy who have fibrotic pulmonary lesions consistent with healed tuberculosis or who have pulmonary silicosis should have 12 months of isoniazid or 4 months of isoniazid and rifampin, concomitantly. Additionally, in the absence of any of the above risk factors, persons under the age of 35 with a tuberculin skin test reaction of 10 mm or more are also appropriate candidates for preventive therapy if they are a member of any of the following high-incidence groups: Foreign-born persons from high-prevalence countries who never received BCG vaccine. Medically underserved low-income populations, including high-risk racial or ethnic minority populations, especially blacks, Hispanics, and Native Americans. Residents of facilities for long-term care (e.g., correctional institutions, nursing homes, and mental institutions). Children who are less than 4 years old are candidates for isoniazid preventive therapy if they have >10 mm induration from a PPD Mantoux tuberculin skin test. Finally, persons under the age of 35 who a) have none of the above risk factors (1-6); b) belong to none of the high-incidence groups; and c) have a tuberculin skin test reaction of 15 mm or more, are appropriate candidates for preventive therapy. The risk of hepatitis must be weighed against the risk of tuberculosis in positive tuberculin reactors over the age of 35. However, the use of isoniazid is recommended for those with the additional risk factors listed above (1-6) and on an individual basis in situations where there is likelihood of serious consequences to contacts who may become infected. uuid:e7a3cde4-0168-4886-9b1d-c0b190354048 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6030 biolink:treats MONDO:0009348 PMID:41385096 "[{""id"":""uuid:fadf9499-68ea-4cb2-92af-039568a27d92"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c7a00923-d89c-45d1-afad-d01778eaa5bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Isoniazid is recommended for all forms of tuberculosis in which organisms are susceptible. However, active tuberculosis must be treated with multiple concomitant antituberculosis medications to prevent the emergence of drug resistance. Single-drug treatment of active tuberculosis with isoniazid, or any other medication, is inadequate therapy. Isoniazid is recommended as preventive therapy for the following groups, regardless of age. (Note: the criterion for a positive reaction to a skin test (in millimeters of induration) for each group is given in parenthesis): Persons with human immunodeficiency virus (HIV) infection (≥ 5 mm) and persons with risk factors for HIV infection whose HIV infection status is unknown but who are suspected of having HIV infection. Preventive therapy may be considered for HIV infected persons who are tuberculin-negative but belong to groups in which the prevalence of tuberculosis infection is high. Candidates for preventive therapy who have HIV infection should have a minimum of 12 months of therapy. Close contacts of persons with newly diagnosed infectious tuberculosis (≥ 5 mm). In addition, tuberculin-negative (< 5 mm) children and adolescents who have been close contacts of infectious persons within the past 3 months are candidates for preventive therapy until a repeat tuberculin skin test is done 12 weeks after contact with the infectious source. If the repeat skin test is positive (> 5 mm), therapy should be continued. Recent converters, as indicated by a tuberculin skin test (≥ 10 mm increase within a 2-year period for those < 35 years old; ≥ 15 mm increase for those ≥ 35 years of age). All infants and children younger than 4 years of age with a > 10 mm skin test are included in this category. Persons with abnormal chest radiographs that show fibrotic lesions likely to represent old healed tuberculosis (≥ 5 mm). Candidates for preventive therapy who have fibrotic pulmonary lesions consistent with healed tuberculosis or who have pulmonary silicosis should have 12 months of isoniazid or 4 months of isoniazid and rifampin, concomitantly. Intravenous drug users known to be HIV-seronegative (> 10 mm). Persons with the following medical conditions that have been reported to increase the risk of tuberculosis (≥ 10 mm): silicosis; diabetes mellitus; prolonged therapy with adrenocorticosteroids; immunosuppressive therapy; some hematologic and reticuloendothelial diseases, such as leukemia or Hodgkin's disease; end-stage renal disease; clinical situations associated with substantial rapid weight loss or chronic undernutrition (including: intestinal bypass surgery for obesity, the postgastrectomy state (with or without weight loss), chronic peptic ulcer disease, chronic malabsorption syndromes, and carcinomas of the oropharynx and upper gastrointestinal tract that prevent adequate nutritional intake). Candidates for preventive therapy who have fibrotic pulmonary lesions consistent with healed tuberculosis or who have pulmonary silicosis should have 12 months of isoniazid or 4 months of isoniazid and rifampin, concomitantly. Additionally, in the absence of any of the above risk factors, persons under the age of 35 with a tuberculin skin test reaction of 10 mm or more are also appropriate candidates for preventive therapy if they are a member of any of the following high-incidence groups: Foreign-born persons from high-prevalence countries who never received BCG vaccine. Medically underserved low-income populations, including high-risk racial or ethnic minority populations, especially blacks, Hispanics, and Native Americans. Residents of facilities for long-term care (e.g., correctional institutions, nursing homes, and mental institutions). Children who are less than 4 years old are candidates for isoniazid preventive therapy if they have >10 mm induration from a PPD Mantoux tuberculin skin test. Finally, persons under the age of 35 who a) have none of the above risk factors (1-6); b) belong to none of the high-incidence groups; and c) have a tuberculin skin test reaction of 15 mm or more, are appropriate candidates for preventive therapy. The risk of hepatitis must be weighed against the risk of tuberculosis in positive tuberculin reactors over the age of 35. However, the use of isoniazid is recommended for those with the additional risk factors listed above (1-6) and on an individual basis in situations where there is likelihood of serious consequences to contacts who may become infected. uuid:5db29e4d-1c79-4e40-b4b4-cf47becc263b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6030 biolink:treats MONDO:0004375 PMID:41385096 "[{""id"":""uuid:5719d678-2454-4602-b532-e2be6cbfab63"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e74ff370-2aa0-4b8c-86d5-ef0d1545e253"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Isoniazid is recommended for all forms of tuberculosis in which organisms are susceptible. However, active tuberculosis must be treated with multiple concomitant antituberculosis medications to prevent the emergence of drug resistance. Single-drug treatment of active tuberculosis with isoniazid, or any other medication, is inadequate therapy. Isoniazid is recommended as preventive therapy for the following groups, regardless of age. (Note: the criterion for a positive reaction to a skin test (in millimeters of induration) for each group is given in parenthesis): Persons with human immunodeficiency virus (HIV) infection (≥ 5 mm) and persons with risk factors for HIV infection whose HIV infection status is unknown but who are suspected of having HIV infection. Preventive therapy may be considered for HIV infected persons who are tuberculin-negative but belong to groups in which the prevalence of tuberculosis infection is high. Candidates for preventive therapy who have HIV infection should have a minimum of 12 months of therapy. Close contacts of persons with newly diagnosed infectious tuberculosis (≥ 5 mm). In addition, tuberculin-negative (< 5 mm) children and adolescents who have been close contacts of infectious persons within the past 3 months are candidates for preventive therapy until a repeat tuberculin skin test is done 12 weeks after contact with the infectious source. If the repeat skin test is positive (> 5 mm), therapy should be continued. Recent converters, as indicated by a tuberculin skin test (≥ 10 mm increase within a 2-year period for those < 35 years old; ≥ 15 mm increase for those ≥ 35 years of age). All infants and children younger than 4 years of age with a > 10 mm skin test are included in this category. Persons with abnormal chest radiographs that show fibrotic lesions likely to represent old healed tuberculosis (≥ 5 mm). Candidates for preventive therapy who have fibrotic pulmonary lesions consistent with healed tuberculosis or who have pulmonary silicosis should have 12 months of isoniazid or 4 months of isoniazid and rifampin, concomitantly. Intravenous drug users known to be HIV-seronegative (> 10 mm). Persons with the following medical conditions that have been reported to increase the risk of tuberculosis (≥ 10 mm): silicosis; diabetes mellitus; prolonged therapy with adrenocorticosteroids; immunosuppressive therapy; some hematologic and reticuloendothelial diseases, such as leukemia or Hodgkin's disease; end-stage renal disease; clinical situations associated with substantial rapid weight loss or chronic undernutrition (including: intestinal bypass surgery for obesity, the postgastrectomy state (with or without weight loss), chronic peptic ulcer disease, chronic malabsorption syndromes, and carcinomas of the oropharynx and upper gastrointestinal tract that prevent adequate nutritional intake). Candidates for preventive therapy who have fibrotic pulmonary lesions consistent with healed tuberculosis or who have pulmonary silicosis should have 12 months of isoniazid or 4 months of isoniazid and rifampin, concomitantly. Additionally, in the absence of any of the above risk factors, persons under the age of 35 with a tuberculin skin test reaction of 10 mm or more are also appropriate candidates for preventive therapy if they are a member of any of the following high-incidence groups: Foreign-born persons from high-prevalence countries who never received BCG vaccine. Medically underserved low-income populations, including high-risk racial or ethnic minority populations, especially blacks, Hispanics, and Native Americans. Residents of facilities for long-term care (e.g., correctional institutions, nursing homes, and mental institutions). Children who are less than 4 years old are candidates for isoniazid preventive therapy if they have >10 mm induration from a PPD Mantoux tuberculin skin test. Finally, persons under the age of 35 who a) have none of the above risk factors (1-6); b) belong to none of the high-incidence groups; and c) have a tuberculin skin test reaction of 15 mm or more, are appropriate candidates for preventive therapy. The risk of hepatitis must be weighed against the risk of tuberculosis in positive tuberculin reactors over the age of 35. However, the use of isoniazid is recommended for those with the additional risk factors listed above (1-6) and on an individual basis in situations where there is likelihood of serious consequences to contacts who may become infected. uuid:219a5e55-6474-447a-8c42-fe352892338f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6030 biolink:treats MONDO:0004608 PMID:41385096 "[{""id"":""uuid:16f1afa1-3689-4add-b559-81f2a1c0e2ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ce979d98-29ab-4c9e-b269-8b24c9e84a8f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Isoniazid is recommended for all forms of tuberculosis in which organisms are susceptible. However, active tuberculosis must be treated with multiple concomitant antituberculosis medications to prevent the emergence of drug resistance. Single-drug treatment of active tuberculosis with isoniazid, or any other medication, is inadequate therapy. Isoniazid is recommended as preventive therapy for the following groups, regardless of age. (Note: the criterion for a positive reaction to a skin test (in millimeters of induration) for each group is given in parenthesis): Persons with human immunodeficiency virus (HIV) infection (≥ 5 mm) and persons with risk factors for HIV infection whose HIV infection status is unknown but who are suspected of having HIV infection. Preventive therapy may be considered for HIV infected persons who are tuberculin-negative but belong to groups in which the prevalence of tuberculosis infection is high. Candidates for preventive therapy who have HIV infection should have a minimum of 12 months of therapy. Close contacts of persons with newly diagnosed infectious tuberculosis (≥ 5 mm). In addition, tuberculin-negative (< 5 mm) children and adolescents who have been close contacts of infectious persons within the past 3 months are candidates for preventive therapy until a repeat tuberculin skin test is done 12 weeks after contact with the infectious source. If the repeat skin test is positive (> 5 mm), therapy should be continued. Recent converters, as indicated by a tuberculin skin test (≥ 10 mm increase within a 2-year period for those < 35 years old; ≥ 15 mm increase for those ≥ 35 years of age). All infants and children younger than 4 years of age with a > 10 mm skin test are included in this category. Persons with abnormal chest radiographs that show fibrotic lesions likely to represent old healed tuberculosis (≥ 5 mm). Candidates for preventive therapy who have fibrotic pulmonary lesions consistent with healed tuberculosis or who have pulmonary silicosis should have 12 months of isoniazid or 4 months of isoniazid and rifampin, concomitantly. Intravenous drug users known to be HIV-seronegative (> 10 mm). Persons with the following medical conditions that have been reported to increase the risk of tuberculosis (≥ 10 mm): silicosis; diabetes mellitus; prolonged therapy with adrenocorticosteroids; immunosuppressive therapy; some hematologic and reticuloendothelial diseases, such as leukemia or Hodgkin's disease; end-stage renal disease; clinical situations associated with substantial rapid weight loss or chronic undernutrition (including: intestinal bypass surgery for obesity, the postgastrectomy state (with or without weight loss), chronic peptic ulcer disease, chronic malabsorption syndromes, and carcinomas of the oropharynx and upper gastrointestinal tract that prevent adequate nutritional intake). Candidates for preventive therapy who have fibrotic pulmonary lesions consistent with healed tuberculosis or who have pulmonary silicosis should have 12 months of isoniazid or 4 months of isoniazid and rifampin, concomitantly. Additionally, in the absence of any of the above risk factors, persons under the age of 35 with a tuberculin skin test reaction of 10 mm or more are also appropriate candidates for preventive therapy if they are a member of any of the following high-incidence groups: Foreign-born persons from high-prevalence countries who never received BCG vaccine. Medically underserved low-income populations, including high-risk racial or ethnic minority populations, especially blacks, Hispanics, and Native Americans. Residents of facilities for long-term care (e.g., correctional institutions, nursing homes, and mental institutions). Children who are less than 4 years old are candidates for isoniazid preventive therapy if they have >10 mm induration from a PPD Mantoux tuberculin skin test. Finally, persons under the age of 35 who a) have none of the above risk factors (1-6); b) belong to none of the high-incidence groups; and c) have a tuberculin skin test reaction of 15 mm or more, are appropriate candidates for preventive therapy. The risk of hepatitis must be weighed against the risk of tuberculosis in positive tuberculin reactors over the age of 35. However, the use of isoniazid is recommended for those with the additional risk factors listed above (1-6) and on an individual basis in situations where there is likelihood of serious consequences to contacts who may become infected. uuid:3bf1008d-52b3-49a9-a4e8-f065357e7d14 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6030 biolink:treats MONDO:0006181 PMID:41385096 "[{""id"":""uuid:803b36a9-4255-4299-a15a-7979cee58f47"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:51bb6ef9-97e6-4b19-aca4-1a5f6c091342"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Isoniazid is recommended for all forms of tuberculosis in which organisms are susceptible. However, active tuberculosis must be treated with multiple concomitant antituberculosis medications to prevent the emergence of drug resistance. Single-drug treatment of active tuberculosis with isoniazid, or any other medication, is inadequate therapy. Isoniazid is recommended as preventive therapy for the following groups, regardless of age. (Note: the criterion for a positive reaction to a skin test (in millimeters of induration) for each group is given in parenthesis): Persons with human immunodeficiency virus (HIV) infection (≥ 5 mm) and persons with risk factors for HIV infection whose HIV infection status is unknown but who are suspected of having HIV infection. Preventive therapy may be considered for HIV infected persons who are tuberculin-negative but belong to groups in which the prevalence of tuberculosis infection is high. Candidates for preventive therapy who have HIV infection should have a minimum of 12 months of therapy. Close contacts of persons with newly diagnosed infectious tuberculosis (≥ 5 mm). In addition, tuberculin-negative (< 5 mm) children and adolescents who have been close contacts of infectious persons within the past 3 months are candidates for preventive therapy until a repeat tuberculin skin test is done 12 weeks after contact with the infectious source. If the repeat skin test is positive (> 5 mm), therapy should be continued. Recent converters, as indicated by a tuberculin skin test (≥ 10 mm increase within a 2-year period for those < 35 years old; ≥ 15 mm increase for those ≥ 35 years of age). All infants and children younger than 4 years of age with a > 10 mm skin test are included in this category. Persons with abnormal chest radiographs that show fibrotic lesions likely to represent old healed tuberculosis (≥ 5 mm). Candidates for preventive therapy who have fibrotic pulmonary lesions consistent with healed tuberculosis or who have pulmonary silicosis should have 12 months of isoniazid or 4 months of isoniazid and rifampin, concomitantly. Intravenous drug users known to be HIV-seronegative (> 10 mm). Persons with the following medical conditions that have been reported to increase the risk of tuberculosis (≥ 10 mm): silicosis; diabetes mellitus; prolonged therapy with adrenocorticosteroids; immunosuppressive therapy; some hematologic and reticuloendothelial diseases, such as leukemia or Hodgkin's disease; end-stage renal disease; clinical situations associated with substantial rapid weight loss or chronic undernutrition (including: intestinal bypass surgery for obesity, the postgastrectomy state (with or without weight loss), chronic peptic ulcer disease, chronic malabsorption syndromes, and carcinomas of the oropharynx and upper gastrointestinal tract that prevent adequate nutritional intake). Candidates for preventive therapy who have fibrotic pulmonary lesions consistent with healed tuberculosis or who have pulmonary silicosis should have 12 months of isoniazid or 4 months of isoniazid and rifampin, concomitantly. Additionally, in the absence of any of the above risk factors, persons under the age of 35 with a tuberculin skin test reaction of 10 mm or more are also appropriate candidates for preventive therapy if they are a member of any of the following high-incidence groups: Foreign-born persons from high-prevalence countries who never received BCG vaccine. Medically underserved low-income populations, including high-risk racial or ethnic minority populations, especially blacks, Hispanics, and Native Americans. Residents of facilities for long-term care (e.g., correctional institutions, nursing homes, and mental institutions). Children who are less than 4 years old are candidates for isoniazid preventive therapy if they have >10 mm induration from a PPD Mantoux tuberculin skin test. Finally, persons under the age of 35 who a) have none of the above risk factors (1-6); b) belong to none of the high-incidence groups; and c) have a tuberculin skin test reaction of 15 mm or more, are appropriate candidates for preventive therapy. The risk of hepatitis must be weighed against the risk of tuberculosis in positive tuberculin reactors over the age of 35. However, the use of isoniazid is recommended for those with the additional risk factors listed above (1-6) and on an individual basis in situations where there is likelihood of serious consequences to contacts who may become infected. uuid:c0bb7f4f-05c0-48fc-9da1-b7233ac4f142 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7443 biolink:treats MONDO:0005178 PMID:41385096 "[{""id"":""uuid:00c2ca32-49e2-4f38-b90f-426bc02f8aa3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:18b75b18-688c-424f-9b4d-992405656736"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of nabumetone and other treatment options before deciding to use nabumetone. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Nabumetone tablets are indicated for relief of signs and symptoms of osteoarthritis and rheumatoid arthritis. uuid:4c478429-a50d-413b-b5b1-2172c915049f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7443 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:76f43dea-e17c-497f-8b7e-d9f42f9e3148"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:36240dcf-861c-4cbd-8cf4-db298ffd933e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of nabumetone and other treatment options before deciding to use nabumetone. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Nabumetone tablets are indicated for relief of signs and symptoms of osteoarthritis and rheumatoid arthritis. uuid:ecc76f45-80c8-4394-b293-be6914e533ab biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:39867 biolink:treats HP:0100754 PMID:41385096 "[{""id"":""uuid:52c177a3-cc8c-4588-a87f-debcad4f6e2e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c5b8b022-905a-49d7-bd0b-51e29c709c7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Divalproex sodium delayed-release tablets (divalproex sodium) are indicated for the treatment of the manic episodes associated with bipolar disorder. A manic episode is a distinct period of abnormally and persistently elevated, expansive, or irritable mood. Typical symptoms of mania include pressure of speech, motor hyperactivity, reduced need for sleep, flight of ideas, grandiosity, poor judgement, aggressiveness, and possible hostility. The efficacy of divalproex sodium delayed-release tablets was established in 3 week trials with patients meeting DSM-III-R criteria for bipolar disorder who were hospitalized for acute mania (see Clinical Trials under CLINICAL PHARMACOLOGY ). The safety and effectiveness of divalproex sodium delayed-release tablets for long-term use in mania, i.e., more than 3 weeks, has not been systematically evaluated in controlled clinical trials. Therefore, healthcare providers who elect to use divalproex sodium delayed-release tablets for extended periods should continually reevaluate the long-term usefulness of the drug for the individual patient. uuid:0759b190-37d9-4b62-bf61-e3f2dca17a59 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:36795 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:22eec059-aa3b-4c2d-9e21-ced265addcf5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:2cdb9c02-8806-4d9a-b062-7fc59b06c89e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:44084961-cfd1-4c93-a775-80099928e837"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/duloxetine-mylan""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Major Depressive Disorder Cymbalta is indicated for the treatment of major depressive disorder (MDD). The efficacy of Cymbalta was established in four short term and one maintenance trial in adults [see Clinical Studies ( 14.1 )] . A major depressive episode (DSM-IV) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least 5 of the following 9 symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, or a suicide attempt or suicidal ideation. 1.2 Generalized Anxiety Disorder Cymbalta is indicated for the treatment of generalized anxiety disorder (GAD). The efficacy of Cymbalta was established in three short-term trials and one maintenance trial in adults [see Clinical Studies ( 14.2 )] . Generalized anxiety disorder is defined by the DSM-IV as excessive anxiety and worry, present more days than not, for at least 6 months. The excessive anxiety and worry must be difficult to control and must cause significant distress or impairment in normal functioning. It must be associated with at least 3 of the following 6 symptoms: restlessness or feeling keyed up or on edge, being easily fatigued, difficulty concentrating or mind going blank, irritability, muscle tension, and/or sleep disturbance. 1.3 Diabetic Peripheral Neuropathic Pain Cymbalta is indicated for the management of neuropathic pain (DPNP) associated with diabetic peripheral neuropathy [see Clinical Studies ( 14.3 )] . 1.4 Fibromyalgia Cymbalta is indicated for the management of fibromyalgia (FM) [see Clinical Studies ( 14.4 )] .|[EMA] Treatment of major depressive disorder;Treatment of diabetic peripheral neuropathic pain;Treatment of generalised anxiety disorder;Duloxetine Mylan is indicated in adults. uuid:0ef7422a-0e34-4bf5-90fe-59950a68c67e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:36795 biolink:treats MONDO:0001942 PMID:41385096 "[{""id"":""uuid:e762e988-8fc7-443d-9d67-61ea274da7ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:7649d01a-4e71-428e-9a87-9268ad525748"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:de51b289-c710-49c5-92db-18395dbebddb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/duloxetine-mylan""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Major Depressive Disorder Cymbalta is indicated for the treatment of major depressive disorder (MDD). The efficacy of Cymbalta was established in four short term and one maintenance trial in adults [see Clinical Studies ( 14.1 )] . A major depressive episode (DSM-IV) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least 5 of the following 9 symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, or a suicide attempt or suicidal ideation. 1.2 Generalized Anxiety Disorder Cymbalta is indicated for the treatment of generalized anxiety disorder (GAD). The efficacy of Cymbalta was established in three short-term trials and one maintenance trial in adults [see Clinical Studies ( 14.2 )] . Generalized anxiety disorder is defined by the DSM-IV as excessive anxiety and worry, present more days than not, for at least 6 months. The excessive anxiety and worry must be difficult to control and must cause significant distress or impairment in normal functioning. It must be associated with at least 3 of the following 6 symptoms: restlessness or feeling keyed up or on edge, being easily fatigued, difficulty concentrating or mind going blank, irritability, muscle tension, and/or sleep disturbance. 1.3 Diabetic Peripheral Neuropathic Pain Cymbalta is indicated for the management of neuropathic pain (DPNP) associated with diabetic peripheral neuropathy [see Clinical Studies ( 14.3 )] . 1.4 Fibromyalgia Cymbalta is indicated for the management of fibromyalgia (FM) [see Clinical Studies ( 14.4 )] .|[EMA] Treatment of major depressive disorder;Treatment of diabetic peripheral neuropathic pain;Treatment of generalised anxiety disorder;Duloxetine Mylan is indicated in adults. uuid:4f68d183-02b8-43d9-b9e9-f0bb05a3e67b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:36795 biolink:treats MONDO:0001583 PMID:41385096 "[{""id"":""uuid:1b7754b8-c1bc-4f51-bd09-a3e87b714d41"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5ddda533-9a48-4e41-9648-58c0501ed23f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Major Depressive Disorder Cymbalta is indicated for the treatment of major depressive disorder (MDD). The efficacy of Cymbalta was established in four short term and one maintenance trial in adults [see Clinical Studies ( 14.1 )] . A major depressive episode (DSM-IV) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least 5 of the following 9 symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, or a suicide attempt or suicidal ideation. 1.2 Generalized Anxiety Disorder Cymbalta is indicated for the treatment of generalized anxiety disorder (GAD). The efficacy of Cymbalta was established in three short-term trials and one maintenance trial in adults [see Clinical Studies ( 14.2 )] . Generalized anxiety disorder is defined by the DSM-IV as excessive anxiety and worry, present more days than not, for at least 6 months. The excessive anxiety and worry must be difficult to control and must cause significant distress or impairment in normal functioning. It must be associated with at least 3 of the following 6 symptoms: restlessness or feeling keyed up or on edge, being easily fatigued, difficulty concentrating or mind going blank, irritability, muscle tension, and/or sleep disturbance. 1.3 Diabetic Peripheral Neuropathic Pain Cymbalta is indicated for the management of neuropathic pain (DPNP) associated with diabetic peripheral neuropathy [see Clinical Studies ( 14.3 )] . 1.4 Fibromyalgia Cymbalta is indicated for the management of fibromyalgia (FM) [see Clinical Studies ( 14.4 )] . uuid:6d531d52-865c-4ecd-a2db-2eb7dbf51f2e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:36795 biolink:treats MONDO:0005546 PMID:41385096 "[{""id"":""uuid:6cc1d4c4-936e-4ed6-b989-c9dbf5a74a7b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0150d8f8-5489-4df4-9529-b89c53d0cc83"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:a5a19a88-4786-4cd9-9764-3fed9b0c9eed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Major Depressive Disorder Cymbalta is indicated for the treatment of major depressive disorder (MDD). The efficacy of Cymbalta was established in four short term and one maintenance trial in adults [see Clinical Studies ( 14.1 )] . A major depressive episode (DSM-IV) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least 5 of the following 9 symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, or a suicide attempt or suicidal ideation. 1.2 Generalized Anxiety Disorder Cymbalta is indicated for the treatment of generalized anxiety disorder (GAD). The efficacy of Cymbalta was established in three short-term trials and one maintenance trial in adults [see Clinical Studies ( 14.2 )] . Generalized anxiety disorder is defined by the DSM-IV as excessive anxiety and worry, present more days than not, for at least 6 months. The excessive anxiety and worry must be difficult to control and must cause significant distress or impairment in normal functioning. It must be associated with at least 3 of the following 6 symptoms: restlessness or feeling keyed up or on edge, being easily fatigued, difficulty concentrating or mind going blank, irritability, muscle tension, and/or sleep disturbance. 1.3 Diabetic Peripheral Neuropathic Pain Cymbalta is indicated for the management of neuropathic pain (DPNP) associated with diabetic peripheral neuropathy [see Clinical Studies ( 14.3 )] . 1.4 Fibromyalgia Cymbalta is indicated for the management of fibromyalgia (FM) [see Clinical Studies ( 14.4 )] .|[PMDA] Drugs with a new additional indication and a new dosage for the treatment of pain associated with fibromyalgia. uuid:5ceb2e2b-6062-4d11-9fb1-b340f0b49960 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:175184 biolink:treats HP:0012228 PMID:41385096 "[{""id"":""uuid:3ca0e7c1-48a8-404a-82b6-dbabc6262b27"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3d2db985-af31-4bd9-9cb2-9f1bc257f11d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ORBIVAN™ Butalbital, Acetaminophen and Caffeine capsules are indicated for the relief of the symptom complex of tension (or muscle contraction) headache. Evidence supporting the efficacy and safety of this combination product in the treatment of multiple recurrent headaches is unavailable. Caution in this regard is required because butalbital is habit-forming and potentially abusable. uuid:d16b6e01-c036-4b88-a164-99911be0ca5f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:175184 biolink:treats UMLS:C0393736 PMID:41385096 "[{""id"":""uuid:6b475be0-ff63-4fa2-b81f-c5c94733d378"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8ebbd642-37d5-45f6-9854-08d405b66e6a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ORBIVAN™ Butalbital, Acetaminophen and Caffeine capsules are indicated for the relief of the symptom complex of tension (or muscle contraction) headache. Evidence supporting the efficacy and safety of this combination product in the treatment of multiple recurrent headaches is unavailable. Caution in this regard is required because butalbital is habit-forming and potentially abusable. uuid:b110ce23-6836-4f79-ac7f-f14735eb98e3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28971 biolink:treats MONDO:0024355 PMID:41385096 "[{""id"":""uuid:909a8501-186f-4f5f-ac8d-d201bb839414"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:72067e96-25a0-4a16-af8a-25769f7cf1b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ampicillin for Injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory tract Infections caused by S. pneumoniae (formerly D. pneumoniae ). Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae, and Group A beta-hemolytic Streptococci. Bacterial Meningitis caused by E. coli, Group B Streptococci, and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus sp., penicillin G-susceptible staphylococci, and enterococci. Gram-negative sepsis caused by E. coli, Proteus mirabilis and Salmonella sp. respond to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptoccoccal endocarditis. Urinary Tract Infections caused by sensitve strains of E. coli and Proteus mirabilis. Gastrointestinal Infections caused by Salmonella typhosa (typhoid fever), other Salmonella sp., and Shigella sp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ampicillin for Injection, USP and other antibacterial drugs, Ampicillin for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Indicated surgical procedures should be performed. uuid:cd94bdff-d35e-4ced-a75f-eed5bf433cfa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28971 biolink:treats MONDO:0006670 PMID:41385096 "[{""id"":""uuid:e9668739-064b-472e-bbfc-db29f5c201d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2a7c26c6-1eda-44cc-a1a0-6a2fa7615b2a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ampicillin for Injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory tract Infections caused by S. pneumoniae (formerly D. pneumoniae ). Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae, and Group A beta-hemolytic Streptococci. Bacterial Meningitis caused by E. coli, Group B Streptococci, and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus sp., penicillin G-susceptible staphylococci, and enterococci. Gram-negative sepsis caused by E. coli, Proteus mirabilis and Salmonella sp. respond to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptoccoccal endocarditis. Urinary Tract Infections caused by sensitve strains of E. coli and Proteus mirabilis. Gastrointestinal Infections caused by Salmonella typhosa (typhoid fever), other Salmonella sp., and Shigella sp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ampicillin for Injection, USP and other antibacterial drugs, Ampicillin for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Indicated surgical procedures should be performed. uuid:d72d23c3-ff72-4894-883f-a76fcdd1e791 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28971 biolink:treats MONDO:0700217 PMID:41385096 "[{""id"":""uuid:080bbb22-27a4-433e-82ae-610c8e9039a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a01a5a68-b67f-4e63-abe8-0affb96f9fb6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ampicillin for Injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory tract Infections caused by S. pneumoniae (formerly D. pneumoniae ). Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae, and Group A beta-hemolytic Streptococci. Bacterial Meningitis caused by E. coli, Group B Streptococci, and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus sp., penicillin G-susceptible staphylococci, and enterococci. Gram-negative sepsis caused by E. coli, Proteus mirabilis and Salmonella sp. respond to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptoccoccal endocarditis. Urinary Tract Infections caused by sensitve strains of E. coli and Proteus mirabilis. Gastrointestinal Infections caused by Salmonella typhosa (typhoid fever), other Salmonella sp., and Shigella sp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ampicillin for Injection, USP and other antibacterial drugs, Ampicillin for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Indicated surgical procedures should be performed. uuid:3810b965-9d04-487b-bfe9-79802608978f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28971 biolink:treats MONDO:0005025 PMID:41385096 "[{""id"":""uuid:74bdecf7-e5e1-47b4-b70d-3b37694a8648"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:10292ab1-5796-47b5-9c70-55b71c8f5296"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ampicillin for Injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory tract Infections caused by S. pneumoniae (formerly D. pneumoniae ). Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae, and Group A beta-hemolytic Streptococci. Bacterial Meningitis caused by E. coli, Group B Streptococci, and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus sp., penicillin G-susceptible staphylococci, and enterococci. Gram-negative sepsis caused by E. coli, Proteus mirabilis and Salmonella sp. respond to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptoccoccal endocarditis. Urinary Tract Infections caused by sensitve strains of E. coli and Proteus mirabilis. Gastrointestinal Infections caused by Salmonella typhosa (typhoid fever), other Salmonella sp., and Shigella sp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ampicillin for Injection, USP and other antibacterial drugs, Ampicillin for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Indicated surgical procedures should be performed. uuid:2138ce89-bcd3-4add-8c35-c0d2b9c09772 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28971 biolink:treats UMLS:C0036685 PMID:41385096 "[{""id"":""uuid:01c0174c-2f1c-4284-89e8-eb772a0982ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:33265a9f-3804-4914-99a0-4b3a277376a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ampicillin for Injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory tract Infections caused by S. pneumoniae (formerly D. pneumoniae ). Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae, and Group A beta-hemolytic Streptococci. Bacterial Meningitis caused by E. coli, Group B Streptococci, and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus sp., penicillin G-susceptible staphylococci, and enterococci. Gram-negative sepsis caused by E. coli, Proteus mirabilis and Salmonella sp. respond to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptoccoccal endocarditis. Urinary Tract Infections caused by sensitve strains of E. coli and Proteus mirabilis. Gastrointestinal Infections caused by Salmonella typhosa (typhoid fever), other Salmonella sp., and Shigella sp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ampicillin for Injection, USP and other antibacterial drugs, Ampicillin for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Indicated surgical procedures should be performed. uuid:f366c5b7-f2e5-4ba5-9bd0-24b3779e4164 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28971 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:f128a812-be01-4abc-b20d-5f2bf57467a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:031169ff-8b0d-4d58-97c0-6200de4f906c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ampicillin for Injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory tract Infections caused by S. pneumoniae (formerly D. pneumoniae ). Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae, and Group A beta-hemolytic Streptococci. Bacterial Meningitis caused by E. coli, Group B Streptococci, and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus sp., penicillin G-susceptible staphylococci, and enterococci. Gram-negative sepsis caused by E. coli, Proteus mirabilis and Salmonella sp. respond to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptoccoccal endocarditis. Urinary Tract Infections caused by sensitve strains of E. coli and Proteus mirabilis. Gastrointestinal Infections caused by Salmonella typhosa (typhoid fever), other Salmonella sp., and Shigella sp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ampicillin for Injection, USP and other antibacterial drugs, Ampicillin for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Indicated surgical procedures should be performed. uuid:18734dc6-4378-40ad-b42e-c7ac56accbeb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28971 biolink:treats MONDO:0043424 PMID:41385096 "[{""id"":""uuid:00f7f450-bc16-4f0d-8d64-a00cb265fc26"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8509e86c-d7f2-4c6e-9eec-b3ea6ea7bb83"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ampicillin for Injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory tract Infections caused by S. pneumoniae (formerly D. pneumoniae ). Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae, and Group A beta-hemolytic Streptococci. Bacterial Meningitis caused by E. coli, Group B Streptococci, and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus sp., penicillin G-susceptible staphylococci, and enterococci. Gram-negative sepsis caused by E. coli, Proteus mirabilis and Salmonella sp. respond to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptoccoccal endocarditis. Urinary Tract Infections caused by sensitve strains of E. coli and Proteus mirabilis. Gastrointestinal Infections caused by Salmonella typhosa (typhoid fever), other Salmonella sp., and Shigella sp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ampicillin for Injection, USP and other antibacterial drugs, Ampicillin for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Indicated surgical procedures should be performed. uuid:d7393d8f-8444-4425-a43e-c5977ab05d95 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28971 biolink:treats MONDO:0005619 PMID:41385096 "[{""id"":""uuid:eea74d4d-ce01-4a06-9913-7899340a626a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dfda5fb0-6867-4a56-8dd0-cde99336937e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ampicillin for Injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory tract Infections caused by S. pneumoniae (formerly D. pneumoniae ). Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae, and Group A beta-hemolytic Streptococci. Bacterial Meningitis caused by E. coli, Group B Streptococci, and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus sp., penicillin G-susceptible staphylococci, and enterococci. Gram-negative sepsis caused by E. coli, Proteus mirabilis and Salmonella sp. respond to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptoccoccal endocarditis. Urinary Tract Infections caused by sensitve strains of E. coli and Proteus mirabilis. Gastrointestinal Infections caused by Salmonella typhosa (typhoid fever), other Salmonella sp., and Shigella sp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ampicillin for Injection, USP and other antibacterial drugs, Ampicillin for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Indicated surgical procedures should be performed. uuid:b28a026b-defa-43eb-95e4-628638728846 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28971 biolink:treats MONDO:0001517 PMID:41385096 "[{""id"":""uuid:3da00cd9-cdad-4802-8efb-7bb76c9c40ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b4af8cd1-99d7-4b40-a0df-ae414f181454"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ampicillin for Injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory tract Infections caused by S. pneumoniae (formerly D. pneumoniae ). Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae, and Group A beta-hemolytic Streptococci. Bacterial Meningitis caused by E. coli, Group B Streptococci, and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus sp., penicillin G-susceptible staphylococci, and enterococci. Gram-negative sepsis caused by E. coli, Proteus mirabilis and Salmonella sp. respond to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptoccoccal endocarditis. Urinary Tract Infections caused by sensitve strains of E. coli and Proteus mirabilis. Gastrointestinal Infections caused by Salmonella typhosa (typhoid fever), other Salmonella sp., and Shigella sp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ampicillin for Injection, USP and other antibacterial drugs, Ampicillin for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Indicated surgical procedures should be performed. uuid:377d2788-497f-43b3-b1c1-a3271aa0491a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3996 biolink:treats MONDO:0014115 PMID:41385096 "[{""id"":""uuid:6aef76f0-eff2-4e8d-9b4d-7848eb77be02"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:21a75d0f-6107-4cfa-bf62-c8880bea6694"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cyclobenzaprine HCl tablets are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine HCl tablets should be used only for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine HCl tablets have not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy. uuid:bf3885bf-00b8-480a-8495-3941a0892054 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:194135 biolink:treats MONDO:0003799 PMID:41385096 "[{""id"":""uuid:f392ff09-fbd9-4728-968e-960b9c10b1b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:345921da-01c8-4a6f-82c0-f3ff40f573b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ofloxacin ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below: CONJUNCTIVITIS: Gram-positive bacteria: Gram-negative bacteria: Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae Enterobacter cloacae Haemophilus influenzae Proteus mirabilis Pseudomonas aeruginosa CORNEAL ULCERS: Gram-positive bacteria: Gram-negative bacteria: Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae Pseudomonas aeruginosa Serratia marcescens* Anaerobic species: Propionibacterium acnes *Efficacy for this organism was studied in fewer than 10 infections uuid:8cd92135-8bca-4ecb-a65e-3421eb3635aa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:194135 biolink:treats MONDO:0004577 PMID:41385096 "[{""id"":""uuid:11bb2f68-6853-4c2a-9774-b6c83c018473"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:540bd1e9-7d9b-46d1-871d-4d49def87338"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ofloxacin ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below: CONJUNCTIVITIS: Gram-positive bacteria: Gram-negative bacteria: Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae Enterobacter cloacae Haemophilus influenzae Proteus mirabilis Pseudomonas aeruginosa CORNEAL ULCERS: Gram-positive bacteria: Gram-negative bacteria: Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae Pseudomonas aeruginosa Serratia marcescens* Anaerobic species: Propionibacterium acnes *Efficacy for this organism was studied in fewer than 10 infections uuid:fafde1af-6659-4863-aff2-3bc8900fa54e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75722 biolink:treats UMLS:C0278139 PMID:41385096 "[{""id"":""uuid:b2fbac5d-f984-4b11-9a52-bc5d8bbe0c49"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8b28493e-edea-40b0-a729-c3a08517efe4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tramadol hydrochloride is indicated for the management of moderate to moderately severe pain in adults. uuid:e15d0e72-9b4c-4f46-b167-a575f3b64d8b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:151399 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:15f6d691-7973-4321-a209-ba2fc295438f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:178287fd-a987-4284-846a-ebdfe93d2a13"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Sulfamethoxazole and Trimethoprim Oral Suspension and other antibacterial drugs, Sulfamethoxazole and Trimethoprim Oral Suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Urinary Tract Infections: For the treatment of urinary tract infections due to susceptible strains of the following organisms: Escherichia coli , Klebsiella species, Enterobacter species, Morganella morganii , Proteus mirabilis and Proteus vulgaris . It is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. Acute Otitis Media: For the treatment of acute otitis media in children due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when in the judgment of the physician this combination offers some advantage over the use of other antimicrobial agents. To date, there are limited data on the safety of repeated use of sulfamethoxazole and trimethoprim in children under two years of age. This product is not indicated for prophylactic or prolonged administration in otitis media at any age. Acute Exacerbations Of Chronic Bronchitis In Adults: For the treatment of acute exacerbations of chronic bronchitis due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when in the judgment of the physician, this combination offers some advantage over the use of a single antimicrobial agent. Shigellosis: For the treatment of enteritis caused by susceptible strains of Shigella flexneri and Shigella sonnei when antibacterial therapy is indicated. Pneumocystis Carinii Pneumonia: For the treatment of documented Pneumocystis carinii pneumonia. For prophylaxis against Pneumocystis carinii pneumonia in individuals who are immunosuppressed and considered to be at an increased risk of developing Pneumocystis carinii pneumonia. Travelers’ Diarrhea In Adults: For the treatment of travelers’ diarrhea due to susceptible strains of enterotoxigenic E. coli. uuid:5d730f0f-5c92-499a-9833-6895e9e3b209 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:151399 biolink:treats HP:0000371 PMID:41385096 "[{""id"":""uuid:198db526-274c-430b-93ac-094bcb1985ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ac839853-b627-42ab-8e98-e5578d5533f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Sulfamethoxazole and Trimethoprim Oral Suspension and other antibacterial drugs, Sulfamethoxazole and Trimethoprim Oral Suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Urinary Tract Infections: For the treatment of urinary tract infections due to susceptible strains of the following organisms: Escherichia coli , Klebsiella species, Enterobacter species, Morganella morganii , Proteus mirabilis and Proteus vulgaris . It is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. Acute Otitis Media: For the treatment of acute otitis media in children due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when in the judgment of the physician this combination offers some advantage over the use of other antimicrobial agents. To date, there are limited data on the safety of repeated use of sulfamethoxazole and trimethoprim in children under two years of age. This product is not indicated for prophylactic or prolonged administration in otitis media at any age. Acute Exacerbations Of Chronic Bronchitis In Adults: For the treatment of acute exacerbations of chronic bronchitis due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when in the judgment of the physician, this combination offers some advantage over the use of a single antimicrobial agent. Shigellosis: For the treatment of enteritis caused by susceptible strains of Shigella flexneri and Shigella sonnei when antibacterial therapy is indicated. Pneumocystis Carinii Pneumonia: For the treatment of documented Pneumocystis carinii pneumonia. For prophylaxis against Pneumocystis carinii pneumonia in individuals who are immunosuppressed and considered to be at an increased risk of developing Pneumocystis carinii pneumonia. Travelers’ Diarrhea In Adults: For the treatment of travelers’ diarrhea due to susceptible strains of enterotoxigenic E. coli. uuid:4e0c7c0a-45d7-42c9-9f51-b737ab060419 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:151399 biolink:treats UMLS:C0853854 PMID:41385096 "[{""id"":""uuid:ed816b85-55f9-41f5-aad7-f01cd193e350"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2bc8bff4-f052-428a-9b4e-7a1d5efc7f0a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Sulfamethoxazole and Trimethoprim Oral Suspension and other antibacterial drugs, Sulfamethoxazole and Trimethoprim Oral Suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Urinary Tract Infections: For the treatment of urinary tract infections due to susceptible strains of the following organisms: Escherichia coli , Klebsiella species, Enterobacter species, Morganella morganii , Proteus mirabilis and Proteus vulgaris . It is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. Acute Otitis Media: For the treatment of acute otitis media in children due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when in the judgment of the physician this combination offers some advantage over the use of other antimicrobial agents. To date, there are limited data on the safety of repeated use of sulfamethoxazole and trimethoprim in children under two years of age. This product is not indicated for prophylactic or prolonged administration in otitis media at any age. Acute Exacerbations Of Chronic Bronchitis In Adults: For the treatment of acute exacerbations of chronic bronchitis due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when in the judgment of the physician, this combination offers some advantage over the use of a single antimicrobial agent. Shigellosis: For the treatment of enteritis caused by susceptible strains of Shigella flexneri and Shigella sonnei when antibacterial therapy is indicated. Pneumocystis Carinii Pneumonia: For the treatment of documented Pneumocystis carinii pneumonia. For prophylaxis against Pneumocystis carinii pneumonia in individuals who are immunosuppressed and considered to be at an increased risk of developing Pneumocystis carinii pneumonia. Travelers’ Diarrhea In Adults: For the treatment of travelers’ diarrhea due to susceptible strains of enterotoxigenic E. coli. uuid:35864d9b-aee9-4193-bb02-30992ad70d58 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:151399 biolink:treats MONDO:0019345 PMID:41385096 "[{""id"":""uuid:6434d498-121f-4f06-b34f-d3f1b22fc1cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:015c7827-a62f-4090-9492-198d51ab600d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Sulfamethoxazole and Trimethoprim Oral Suspension and other antibacterial drugs, Sulfamethoxazole and Trimethoprim Oral Suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Urinary Tract Infections: For the treatment of urinary tract infections due to susceptible strains of the following organisms: Escherichia coli , Klebsiella species, Enterobacter species, Morganella morganii , Proteus mirabilis and Proteus vulgaris . It is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. Acute Otitis Media: For the treatment of acute otitis media in children due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when in the judgment of the physician this combination offers some advantage over the use of other antimicrobial agents. To date, there are limited data on the safety of repeated use of sulfamethoxazole and trimethoprim in children under two years of age. This product is not indicated for prophylactic or prolonged administration in otitis media at any age. Acute Exacerbations Of Chronic Bronchitis In Adults: For the treatment of acute exacerbations of chronic bronchitis due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when in the judgment of the physician, this combination offers some advantage over the use of a single antimicrobial agent. Shigellosis: For the treatment of enteritis caused by susceptible strains of Shigella flexneri and Shigella sonnei when antibacterial therapy is indicated. Pneumocystis Carinii Pneumonia: For the treatment of documented Pneumocystis carinii pneumonia. For prophylaxis against Pneumocystis carinii pneumonia in individuals who are immunosuppressed and considered to be at an increased risk of developing Pneumocystis carinii pneumonia. Travelers’ Diarrhea In Adults: For the treatment of travelers’ diarrhea due to susceptible strains of enterotoxigenic E. coli. uuid:691a8936-7bd0-4f2f-9f4f-4641e3ffb66a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:151399 biolink:treats MONDO:0019121 PMID:41385096 "[{""id"":""uuid:99c41a3e-8f02-4e4c-b5a3-f55cf2df93b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:19b4bd8b-6f77-4637-9fe2-94b15bdf8922"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:a117e3f3-621d-42a9-9005-9d1e117cee2b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Sulfamethoxazole and Trimethoprim Oral Suspension and other antibacterial drugs, Sulfamethoxazole and Trimethoprim Oral Suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Urinary Tract Infections: For the treatment of urinary tract infections due to susceptible strains of the following organisms: Escherichia coli , Klebsiella species, Enterobacter species, Morganella morganii , Proteus mirabilis and Proteus vulgaris . It is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. Acute Otitis Media: For the treatment of acute otitis media in children due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when in the judgment of the physician this combination offers some advantage over the use of other antimicrobial agents. To date, there are limited data on the safety of repeated use of sulfamethoxazole and trimethoprim in children under two years of age. This product is not indicated for prophylactic or prolonged administration in otitis media at any age. Acute Exacerbations Of Chronic Bronchitis In Adults: For the treatment of acute exacerbations of chronic bronchitis due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when in the judgment of the physician, this combination offers some advantage over the use of a single antimicrobial agent. Shigellosis: For the treatment of enteritis caused by susceptible strains of Shigella flexneri and Shigella sonnei when antibacterial therapy is indicated. Pneumocystis Carinii Pneumonia: For the treatment of documented Pneumocystis carinii pneumonia. For prophylaxis against Pneumocystis carinii pneumonia in individuals who are immunosuppressed and considered to be at an increased risk of developing Pneumocystis carinii pneumonia. Travelers’ Diarrhea In Adults: For the treatment of travelers’ diarrhea due to susceptible strains of enterotoxigenic E. coli.|[PMDA] Drugs with a new additional indication and a new dosage for the treatment and prevention of Pneumocystis pneumonia. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:fecc65aa-7d70-4d1a-b0b9-21354472d7fd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:151399 biolink:treats UMLS:C0277528 PMID:41385096 "[{""id"":""uuid:489f7e43-b805-4253-bdb2-9a27b90a1cdc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:786a387d-1f97-40ee-ae1b-b42fb61a93c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Sulfamethoxazole and Trimethoprim Oral Suspension and other antibacterial drugs, Sulfamethoxazole and Trimethoprim Oral Suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Urinary Tract Infections: For the treatment of urinary tract infections due to susceptible strains of the following organisms: Escherichia coli , Klebsiella species, Enterobacter species, Morganella morganii , Proteus mirabilis and Proteus vulgaris . It is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. Acute Otitis Media: For the treatment of acute otitis media in children due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when in the judgment of the physician this combination offers some advantage over the use of other antimicrobial agents. To date, there are limited data on the safety of repeated use of sulfamethoxazole and trimethoprim in children under two years of age. This product is not indicated for prophylactic or prolonged administration in otitis media at any age. Acute Exacerbations Of Chronic Bronchitis In Adults: For the treatment of acute exacerbations of chronic bronchitis due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when in the judgment of the physician, this combination offers some advantage over the use of a single antimicrobial agent. Shigellosis: For the treatment of enteritis caused by susceptible strains of Shigella flexneri and Shigella sonnei when antibacterial therapy is indicated. Pneumocystis Carinii Pneumonia: For the treatment of documented Pneumocystis carinii pneumonia. For prophylaxis against Pneumocystis carinii pneumonia in individuals who are immunosuppressed and considered to be at an increased risk of developing Pneumocystis carinii pneumonia. Travelers’ Diarrhea In Adults: For the treatment of travelers’ diarrhea due to susceptible strains of enterotoxigenic E. coli. uuid:8196ee0c-6b8d-4ad1-943b-dc871f27da74 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9599 biolink:treats MONDO:0006875 PMID:41385096 "[{""id"":""uuid:28bbfa4e-0f95-4df1-80e1-076b79cba9ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:17b6f91a-bf65-45f1-92ba-89cc16ca9022"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Betimol ® is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. uuid:f34b548d-5b23-49dc-ac54-bc624940f911 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9599 biolink:treats MONDO:0005338 PMID:41385096 "[{""id"":""uuid:289c129a-d1ae-4d41-95d9-0ec202aed63e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d2d2eeb4-d7a1-4e9b-a2bc-f16c00fc77b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Betimol ® is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. uuid:177018f1-3a40-4cac-affa-8a8cd0ae255e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:87681 biolink:treats HP:0001681 PMID:41385096 "[{""id"":""uuid:998dd602-fda4-4a31-b2cc-dc24d968507e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:00831e05-714d-43b3-ae99-19b16cec232d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ranexa is indicated for the treatment of chronic angina. Ranexa may be used with beta-blockers, nitrates, calcium channel blockers, anti-platelet therapy, lipid-lowering therapy, ACE inhibitors, and angiotensin receptor blockers. uuid:9a091a5c-10af-40dd-be11-8fbadc7c1309 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4B33BGI082 biolink:treats UMLS:C0342879 PMID:41385096 "[{""id"":""uuid:7fcf170d-b153-4a7b-abff-a6e5264bf2df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2e90ead1-ecfb-4702-93e1-cf29d41a4b27"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1) Cholestyramine for Oral Suspension USP is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet. Cholestyramine may be useful to lower LDL cholesterol in patients who also have hypertriglyceridemia, but it is not indicated where hypertriglyceridemia is the abnormality of most concern. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Treatment should begin and continue with dietary therapy specific for the type of hyperlipoproteinemia determined prior to initiation of drug therapy. Excess body weight may be an important factor and caloric restriction for weight normalization should be addressed prior to drug therapy in the overweight. Prior to initiating therapy with Cholestyramine, secondary causes of hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism), should be excluded, and a lipid profile performed to assess Total cholesterol, HDL-C, and triglycerides (TG). For individuals with TG less than 400 mg/dL (less than 4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = Total cholesterol – [(TG/5) + HDL-C] For TG levels >400 mg/dL, this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated Total-C. In such cases Cholestyramine may not be indicated. Serum cholesterol and triglyceride levels should be determined periodically based on NCEP guidelines to confirm initial and adequate long-term response. A favorable trend in cholesterol reduction should occur during the first month of Cholestyramine therapy. The therapy should be continued to sustain cholesterol reduction. If adequate cholesterol reduction is not attained, increasing the dosage of Cholestyramine or adding other lipid-lowering agents in combination with Cholestyramine should be considered. Since the goal of treatment is to lower LDL-C, the NCEP 4 recommends that LDL-C levels be used to initiate and assess treatment response. If LDL-C levels are not available then Total-C alone may be used to monitor long-term therapy. A lipoprotein analysis (including LDL-C determination) should be carried out once a year. The NCEP treatment guidelines are summarized below. LDL-Cholesterol mg/dL (mmol/L) Definite Atherosclerotic Disease* Two or More Other Risk Factors** Initiation Level Goal NO NO Greater Than or Equal to 190 (Greater Than or Equal To 4.9) Less Than 160 (Less Than 4.1) NO YES Greater Than or Equal To 160 (Greater Than or Equal To 4.1) Less Than 130 (Less Than 3.4) YES YES or NO Greater Than or Equal To 130 (Greater Than or Equal To 3.4) Less Than or Equal To 100 (Less Than or Equal To 2.6) * Coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease). ** Other risk factors for coronary heart disease (CHD) include: age (males greater than or equal to 45 years; females greater than or equal to 55 years or premature menopause without estrogen replacement therapy); family history of premature CHD; current cigarette smoking; hypertension; confirmed HDL-C less than 35 mg/dL (less than 0.91 mmol/L); and diabetes mellitus. Subtract one risk factor if HDL-C is greater than or equal to 60 mg/dL (greater than or equal to 1.6 mmol/L). Cholestyramine monotherapy has been demonstrated to retard the rate of progression 2,3 and increase the rate of regression 3 of coronary atherosclerosis. 2) Cholestyramine for oral suspension is indicated for the relief of pruritus associated with partial biliary obstruction. Cholestyramine for oral suspension has been shown to have a variable effect on serum cholesterol in these patients. Patients with primary biliary cirrhosis may exhibit an elevated cholesterol as part of their disease. uuid:45bf1ca4-a669-4846-949a-1f17c9ab7d52 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4B33BGI082 biolink:treats MONDO:0005347 PMID:41385096 "[{""id"":""uuid:b2043f74-0d6d-48e3-b9c5-099cb981cf9d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:86793aca-4d58-4917-8f21-287e26cd4653"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1) Cholestyramine for Oral Suspension USP is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet. Cholestyramine may be useful to lower LDL cholesterol in patients who also have hypertriglyceridemia, but it is not indicated where hypertriglyceridemia is the abnormality of most concern. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Treatment should begin and continue with dietary therapy specific for the type of hyperlipoproteinemia determined prior to initiation of drug therapy. Excess body weight may be an important factor and caloric restriction for weight normalization should be addressed prior to drug therapy in the overweight. Prior to initiating therapy with Cholestyramine, secondary causes of hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism), should be excluded, and a lipid profile performed to assess Total cholesterol, HDL-C, and triglycerides (TG). For individuals with TG less than 400 mg/dL (less than 4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = Total cholesterol – [(TG/5) + HDL-C] For TG levels >400 mg/dL, this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated Total-C. In such cases Cholestyramine may not be indicated. Serum cholesterol and triglyceride levels should be determined periodically based on NCEP guidelines to confirm initial and adequate long-term response. A favorable trend in cholesterol reduction should occur during the first month of Cholestyramine therapy. The therapy should be continued to sustain cholesterol reduction. If adequate cholesterol reduction is not attained, increasing the dosage of Cholestyramine or adding other lipid-lowering agents in combination with Cholestyramine should be considered. Since the goal of treatment is to lower LDL-C, the NCEP 4 recommends that LDL-C levels be used to initiate and assess treatment response. If LDL-C levels are not available then Total-C alone may be used to monitor long-term therapy. A lipoprotein analysis (including LDL-C determination) should be carried out once a year. The NCEP treatment guidelines are summarized below. LDL-Cholesterol mg/dL (mmol/L) Definite Atherosclerotic Disease* Two or More Other Risk Factors** Initiation Level Goal NO NO Greater Than or Equal to 190 (Greater Than or Equal To 4.9) Less Than 160 (Less Than 4.1) NO YES Greater Than or Equal To 160 (Greater Than or Equal To 4.1) Less Than 130 (Less Than 3.4) YES YES or NO Greater Than or Equal To 130 (Greater Than or Equal To 3.4) Less Than or Equal To 100 (Less Than or Equal To 2.6) * Coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease). ** Other risk factors for coronary heart disease (CHD) include: age (males greater than or equal to 45 years; females greater than or equal to 55 years or premature menopause without estrogen replacement therapy); family history of premature CHD; current cigarette smoking; hypertension; confirmed HDL-C less than 35 mg/dL (less than 0.91 mmol/L); and diabetes mellitus. Subtract one risk factor if HDL-C is greater than or equal to 60 mg/dL (greater than or equal to 1.6 mmol/L). Cholestyramine monotherapy has been demonstrated to retard the rate of progression 2,3 and increase the rate of regression 3 of coronary atherosclerosis. 2) Cholestyramine for oral suspension is indicated for the relief of pruritus associated with partial biliary obstruction. Cholestyramine for oral suspension has been shown to have a variable effect on serum cholesterol in these patients. Patients with primary biliary cirrhosis may exhibit an elevated cholesterol as part of their disease. uuid:b9544ab3-a329-44b6-a517-5af0f0a52d1b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4B33BGI082 biolink:treats MONDO:0005311 PMID:41385096 "[{""id"":""uuid:bcd69235-c3ca-443d-b6df-7e028ce07f2c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ef3c5d4e-c072-4ae3-ab7d-d3d9a1a4a10a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1) Cholestyramine for Oral Suspension USP is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet. Cholestyramine may be useful to lower LDL cholesterol in patients who also have hypertriglyceridemia, but it is not indicated where hypertriglyceridemia is the abnormality of most concern. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Treatment should begin and continue with dietary therapy specific for the type of hyperlipoproteinemia determined prior to initiation of drug therapy. Excess body weight may be an important factor and caloric restriction for weight normalization should be addressed prior to drug therapy in the overweight. Prior to initiating therapy with Cholestyramine, secondary causes of hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism), should be excluded, and a lipid profile performed to assess Total cholesterol, HDL-C, and triglycerides (TG). For individuals with TG less than 400 mg/dL (less than 4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = Total cholesterol – [(TG/5) + HDL-C] For TG levels >400 mg/dL, this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated Total-C. In such cases Cholestyramine may not be indicated. Serum cholesterol and triglyceride levels should be determined periodically based on NCEP guidelines to confirm initial and adequate long-term response. A favorable trend in cholesterol reduction should occur during the first month of Cholestyramine therapy. The therapy should be continued to sustain cholesterol reduction. If adequate cholesterol reduction is not attained, increasing the dosage of Cholestyramine or adding other lipid-lowering agents in combination with Cholestyramine should be considered. Since the goal of treatment is to lower LDL-C, the NCEP 4 recommends that LDL-C levels be used to initiate and assess treatment response. If LDL-C levels are not available then Total-C alone may be used to monitor long-term therapy. A lipoprotein analysis (including LDL-C determination) should be carried out once a year. The NCEP treatment guidelines are summarized below. LDL-Cholesterol mg/dL (mmol/L) Definite Atherosclerotic Disease* Two or More Other Risk Factors** Initiation Level Goal NO NO Greater Than or Equal to 190 (Greater Than or Equal To 4.9) Less Than 160 (Less Than 4.1) NO YES Greater Than or Equal To 160 (Greater Than or Equal To 4.1) Less Than 130 (Less Than 3.4) YES YES or NO Greater Than or Equal To 130 (Greater Than or Equal To 3.4) Less Than or Equal To 100 (Less Than or Equal To 2.6) * Coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease). ** Other risk factors for coronary heart disease (CHD) include: age (males greater than or equal to 45 years; females greater than or equal to 55 years or premature menopause without estrogen replacement therapy); family history of premature CHD; current cigarette smoking; hypertension; confirmed HDL-C less than 35 mg/dL (less than 0.91 mmol/L); and diabetes mellitus. Subtract one risk factor if HDL-C is greater than or equal to 60 mg/dL (greater than or equal to 1.6 mmol/L). Cholestyramine monotherapy has been demonstrated to retard the rate of progression 2,3 and increase the rate of regression 3 of coronary atherosclerosis. 2) Cholestyramine for oral suspension is indicated for the relief of pruritus associated with partial biliary obstruction. Cholestyramine for oral suspension has been shown to have a variable effect on serum cholesterol in these patients. Patients with primary biliary cirrhosis may exhibit an elevated cholesterol as part of their disease. uuid:5e8a865e-5ac9-409e-b08e-7727921f1ede biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4B33BGI082 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:e0e2cf8c-c404-4502-a254-6f6e0824a2cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0804a934-cb9f-4068-862d-1ed297251809"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1) Cholestyramine for Oral Suspension USP is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet. Cholestyramine may be useful to lower LDL cholesterol in patients who also have hypertriglyceridemia, but it is not indicated where hypertriglyceridemia is the abnormality of most concern. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Treatment should begin and continue with dietary therapy specific for the type of hyperlipoproteinemia determined prior to initiation of drug therapy. Excess body weight may be an important factor and caloric restriction for weight normalization should be addressed prior to drug therapy in the overweight. Prior to initiating therapy with Cholestyramine, secondary causes of hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism), should be excluded, and a lipid profile performed to assess Total cholesterol, HDL-C, and triglycerides (TG). For individuals with TG less than 400 mg/dL (less than 4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = Total cholesterol – [(TG/5) + HDL-C] For TG levels >400 mg/dL, this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated Total-C. In such cases Cholestyramine may not be indicated. Serum cholesterol and triglyceride levels should be determined periodically based on NCEP guidelines to confirm initial and adequate long-term response. A favorable trend in cholesterol reduction should occur during the first month of Cholestyramine therapy. The therapy should be continued to sustain cholesterol reduction. If adequate cholesterol reduction is not attained, increasing the dosage of Cholestyramine or adding other lipid-lowering agents in combination with Cholestyramine should be considered. Since the goal of treatment is to lower LDL-C, the NCEP 4 recommends that LDL-C levels be used to initiate and assess treatment response. If LDL-C levels are not available then Total-C alone may be used to monitor long-term therapy. A lipoprotein analysis (including LDL-C determination) should be carried out once a year. The NCEP treatment guidelines are summarized below. LDL-Cholesterol mg/dL (mmol/L) Definite Atherosclerotic Disease* Two or More Other Risk Factors** Initiation Level Goal NO NO Greater Than or Equal to 190 (Greater Than or Equal To 4.9) Less Than 160 (Less Than 4.1) NO YES Greater Than or Equal To 160 (Greater Than or Equal To 4.1) Less Than 130 (Less Than 3.4) YES YES or NO Greater Than or Equal To 130 (Greater Than or Equal To 3.4) Less Than or Equal To 100 (Less Than or Equal To 2.6) * Coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease). ** Other risk factors for coronary heart disease (CHD) include: age (males greater than or equal to 45 years; females greater than or equal to 55 years or premature menopause without estrogen replacement therapy); family history of premature CHD; current cigarette smoking; hypertension; confirmed HDL-C less than 35 mg/dL (less than 0.91 mmol/L); and diabetes mellitus. Subtract one risk factor if HDL-C is greater than or equal to 60 mg/dL (greater than or equal to 1.6 mmol/L). Cholestyramine monotherapy has been demonstrated to retard the rate of progression 2,3 and increase the rate of regression 3 of coronary atherosclerosis. 2) Cholestyramine for oral suspension is indicated for the relief of pruritus associated with partial biliary obstruction. Cholestyramine for oral suspension has been shown to have a variable effect on serum cholesterol in these patients. Patients with primary biliary cirrhosis may exhibit an elevated cholesterol as part of their disease. uuid:83b35435-f08f-4874-aa9f-2283ba5caa3d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4B33BGI082 biolink:treats MONDO:0005420 PMID:41385096 "[{""id"":""uuid:4555b1f6-05d6-4478-8c52-f26a42f7861a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8984d7cc-91b3-4ac5-ada5-40ea3903418a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1) Cholestyramine for Oral Suspension USP is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet. Cholestyramine may be useful to lower LDL cholesterol in patients who also have hypertriglyceridemia, but it is not indicated where hypertriglyceridemia is the abnormality of most concern. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Treatment should begin and continue with dietary therapy specific for the type of hyperlipoproteinemia determined prior to initiation of drug therapy. Excess body weight may be an important factor and caloric restriction for weight normalization should be addressed prior to drug therapy in the overweight. Prior to initiating therapy with Cholestyramine, secondary causes of hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism), should be excluded, and a lipid profile performed to assess Total cholesterol, HDL-C, and triglycerides (TG). For individuals with TG less than 400 mg/dL (less than 4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = Total cholesterol – [(TG/5) + HDL-C] For TG levels >400 mg/dL, this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated Total-C. In such cases Cholestyramine may not be indicated. Serum cholesterol and triglyceride levels should be determined periodically based on NCEP guidelines to confirm initial and adequate long-term response. A favorable trend in cholesterol reduction should occur during the first month of Cholestyramine therapy. The therapy should be continued to sustain cholesterol reduction. If adequate cholesterol reduction is not attained, increasing the dosage of Cholestyramine or adding other lipid-lowering agents in combination with Cholestyramine should be considered. Since the goal of treatment is to lower LDL-C, the NCEP 4 recommends that LDL-C levels be used to initiate and assess treatment response. If LDL-C levels are not available then Total-C alone may be used to monitor long-term therapy. A lipoprotein analysis (including LDL-C determination) should be carried out once a year. The NCEP treatment guidelines are summarized below. LDL-Cholesterol mg/dL (mmol/L) Definite Atherosclerotic Disease* Two or More Other Risk Factors** Initiation Level Goal NO NO Greater Than or Equal to 190 (Greater Than or Equal To 4.9) Less Than 160 (Less Than 4.1) NO YES Greater Than or Equal To 160 (Greater Than or Equal To 4.1) Less Than 130 (Less Than 3.4) YES YES or NO Greater Than or Equal To 130 (Greater Than or Equal To 3.4) Less Than or Equal To 100 (Less Than or Equal To 2.6) * Coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease). ** Other risk factors for coronary heart disease (CHD) include: age (males greater than or equal to 45 years; females greater than or equal to 55 years or premature menopause without estrogen replacement therapy); family history of premature CHD; current cigarette smoking; hypertension; confirmed HDL-C less than 35 mg/dL (less than 0.91 mmol/L); and diabetes mellitus. Subtract one risk factor if HDL-C is greater than or equal to 60 mg/dL (greater than or equal to 1.6 mmol/L). Cholestyramine monotherapy has been demonstrated to retard the rate of progression 2,3 and increase the rate of regression 3 of coronary atherosclerosis. 2) Cholestyramine for oral suspension is indicated for the relief of pruritus associated with partial biliary obstruction. Cholestyramine for oral suspension has been shown to have a variable effect on serum cholesterol in these patients. Patients with primary biliary cirrhosis may exhibit an elevated cholesterol as part of their disease. uuid:e6d9b39c-3c2c-47d7-9277-3fdf471e906c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4B33BGI082 biolink:treats MONDO:0005377 PMID:41385096 "[{""id"":""uuid:e20fc42c-5997-43bd-bcd4-7d8db90d53a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:40b4631c-9d39-4215-864a-ed5cb68f402d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1) Cholestyramine for Oral Suspension USP is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet. Cholestyramine may be useful to lower LDL cholesterol in patients who also have hypertriglyceridemia, but it is not indicated where hypertriglyceridemia is the abnormality of most concern. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Treatment should begin and continue with dietary therapy specific for the type of hyperlipoproteinemia determined prior to initiation of drug therapy. Excess body weight may be an important factor and caloric restriction for weight normalization should be addressed prior to drug therapy in the overweight. Prior to initiating therapy with Cholestyramine, secondary causes of hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism), should be excluded, and a lipid profile performed to assess Total cholesterol, HDL-C, and triglycerides (TG). For individuals with TG less than 400 mg/dL (less than 4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = Total cholesterol – [(TG/5) + HDL-C] For TG levels >400 mg/dL, this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated Total-C. In such cases Cholestyramine may not be indicated. Serum cholesterol and triglyceride levels should be determined periodically based on NCEP guidelines to confirm initial and adequate long-term response. A favorable trend in cholesterol reduction should occur during the first month of Cholestyramine therapy. The therapy should be continued to sustain cholesterol reduction. If adequate cholesterol reduction is not attained, increasing the dosage of Cholestyramine or adding other lipid-lowering agents in combination with Cholestyramine should be considered. Since the goal of treatment is to lower LDL-C, the NCEP 4 recommends that LDL-C levels be used to initiate and assess treatment response. If LDL-C levels are not available then Total-C alone may be used to monitor long-term therapy. A lipoprotein analysis (including LDL-C determination) should be carried out once a year. The NCEP treatment guidelines are summarized below. LDL-Cholesterol mg/dL (mmol/L) Definite Atherosclerotic Disease* Two or More Other Risk Factors** Initiation Level Goal NO NO Greater Than or Equal to 190 (Greater Than or Equal To 4.9) Less Than 160 (Less Than 4.1) NO YES Greater Than or Equal To 160 (Greater Than or Equal To 4.1) Less Than 130 (Less Than 3.4) YES YES or NO Greater Than or Equal To 130 (Greater Than or Equal To 3.4) Less Than or Equal To 100 (Less Than or Equal To 2.6) * Coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease). ** Other risk factors for coronary heart disease (CHD) include: age (males greater than or equal to 45 years; females greater than or equal to 55 years or premature menopause without estrogen replacement therapy); family history of premature CHD; current cigarette smoking; hypertension; confirmed HDL-C less than 35 mg/dL (less than 0.91 mmol/L); and diabetes mellitus. Subtract one risk factor if HDL-C is greater than or equal to 60 mg/dL (greater than or equal to 1.6 mmol/L). Cholestyramine monotherapy has been demonstrated to retard the rate of progression 2,3 and increase the rate of regression 3 of coronary atherosclerosis. 2) Cholestyramine for oral suspension is indicated for the relief of pruritus associated with partial biliary obstruction. Cholestyramine for oral suspension has been shown to have a variable effect on serum cholesterol in these patients. Patients with primary biliary cirrhosis may exhibit an elevated cholesterol as part of their disease. uuid:9f4c64f7-9fbd-4ea1-a576-19a45ac41dce biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4B33BGI082 biolink:treats UMLS:C0259744 PMID:41385096 "[{""id"":""uuid:43c75d0b-5c9e-4828-a85f-12ccfb623489"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:37f3c46d-c695-4721-b5fb-d148f3e54dc1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1) Cholestyramine for Oral Suspension USP is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet. Cholestyramine may be useful to lower LDL cholesterol in patients who also have hypertriglyceridemia, but it is not indicated where hypertriglyceridemia is the abnormality of most concern. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Treatment should begin and continue with dietary therapy specific for the type of hyperlipoproteinemia determined prior to initiation of drug therapy. Excess body weight may be an important factor and caloric restriction for weight normalization should be addressed prior to drug therapy in the overweight. Prior to initiating therapy with Cholestyramine, secondary causes of hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism), should be excluded, and a lipid profile performed to assess Total cholesterol, HDL-C, and triglycerides (TG). For individuals with TG less than 400 mg/dL (less than 4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = Total cholesterol – [(TG/5) + HDL-C] For TG levels >400 mg/dL, this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated Total-C. In such cases Cholestyramine may not be indicated. Serum cholesterol and triglyceride levels should be determined periodically based on NCEP guidelines to confirm initial and adequate long-term response. A favorable trend in cholesterol reduction should occur during the first month of Cholestyramine therapy. The therapy should be continued to sustain cholesterol reduction. If adequate cholesterol reduction is not attained, increasing the dosage of Cholestyramine or adding other lipid-lowering agents in combination with Cholestyramine should be considered. Since the goal of treatment is to lower LDL-C, the NCEP 4 recommends that LDL-C levels be used to initiate and assess treatment response. If LDL-C levels are not available then Total-C alone may be used to monitor long-term therapy. A lipoprotein analysis (including LDL-C determination) should be carried out once a year. The NCEP treatment guidelines are summarized below. LDL-Cholesterol mg/dL (mmol/L) Definite Atherosclerotic Disease* Two or More Other Risk Factors** Initiation Level Goal NO NO Greater Than or Equal to 190 (Greater Than or Equal To 4.9) Less Than 160 (Less Than 4.1) NO YES Greater Than or Equal To 160 (Greater Than or Equal To 4.1) Less Than 130 (Less Than 3.4) YES YES or NO Greater Than or Equal To 130 (Greater Than or Equal To 3.4) Less Than or Equal To 100 (Less Than or Equal To 2.6) * Coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease). ** Other risk factors for coronary heart disease (CHD) include: age (males greater than or equal to 45 years; females greater than or equal to 55 years or premature menopause without estrogen replacement therapy); family history of premature CHD; current cigarette smoking; hypertension; confirmed HDL-C less than 35 mg/dL (less than 0.91 mmol/L); and diabetes mellitus. Subtract one risk factor if HDL-C is greater than or equal to 60 mg/dL (greater than or equal to 1.6 mmol/L). Cholestyramine monotherapy has been demonstrated to retard the rate of progression 2,3 and increase the rate of regression 3 of coronary atherosclerosis. 2) Cholestyramine for oral suspension is indicated for the relief of pruritus associated with partial biliary obstruction. Cholestyramine for oral suspension has been shown to have a variable effect on serum cholesterol in these patients. Patients with primary biliary cirrhosis may exhibit an elevated cholesterol as part of their disease. uuid:57008e62-9a4f-4e6e-a066-9f78004fd5f0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4B33BGI082 biolink:treats MONDO:0006874 PMID:41385096 "[{""id"":""uuid:de55b217-9b5d-416d-834e-aacc20dc0795"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:09083e40-d38e-4bf2-ab67-e0ff9adeb746"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1) Cholestyramine for Oral Suspension USP is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet. Cholestyramine may be useful to lower LDL cholesterol in patients who also have hypertriglyceridemia, but it is not indicated where hypertriglyceridemia is the abnormality of most concern. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Treatment should begin and continue with dietary therapy specific for the type of hyperlipoproteinemia determined prior to initiation of drug therapy. Excess body weight may be an important factor and caloric restriction for weight normalization should be addressed prior to drug therapy in the overweight. Prior to initiating therapy with Cholestyramine, secondary causes of hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism), should be excluded, and a lipid profile performed to assess Total cholesterol, HDL-C, and triglycerides (TG). For individuals with TG less than 400 mg/dL (less than 4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = Total cholesterol – [(TG/5) + HDL-C] For TG levels >400 mg/dL, this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated Total-C. In such cases Cholestyramine may not be indicated. Serum cholesterol and triglyceride levels should be determined periodically based on NCEP guidelines to confirm initial and adequate long-term response. A favorable trend in cholesterol reduction should occur during the first month of Cholestyramine therapy. The therapy should be continued to sustain cholesterol reduction. If adequate cholesterol reduction is not attained, increasing the dosage of Cholestyramine or adding other lipid-lowering agents in combination with Cholestyramine should be considered. Since the goal of treatment is to lower LDL-C, the NCEP 4 recommends that LDL-C levels be used to initiate and assess treatment response. If LDL-C levels are not available then Total-C alone may be used to monitor long-term therapy. A lipoprotein analysis (including LDL-C determination) should be carried out once a year. The NCEP treatment guidelines are summarized below. LDL-Cholesterol mg/dL (mmol/L) Definite Atherosclerotic Disease* Two or More Other Risk Factors** Initiation Level Goal NO NO Greater Than or Equal to 190 (Greater Than or Equal To 4.9) Less Than 160 (Less Than 4.1) NO YES Greater Than or Equal To 160 (Greater Than or Equal To 4.1) Less Than 130 (Less Than 3.4) YES YES or NO Greater Than or Equal To 130 (Greater Than or Equal To 3.4) Less Than or Equal To 100 (Less Than or Equal To 2.6) * Coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease). ** Other risk factors for coronary heart disease (CHD) include: age (males greater than or equal to 45 years; females greater than or equal to 55 years or premature menopause without estrogen replacement therapy); family history of premature CHD; current cigarette smoking; hypertension; confirmed HDL-C less than 35 mg/dL (less than 0.91 mmol/L); and diabetes mellitus. Subtract one risk factor if HDL-C is greater than or equal to 60 mg/dL (greater than or equal to 1.6 mmol/L). Cholestyramine monotherapy has been demonstrated to retard the rate of progression 2,3 and increase the rate of regression 3 of coronary atherosclerosis. 2) Cholestyramine for oral suspension is indicated for the relief of pruritus associated with partial biliary obstruction. Cholestyramine for oral suspension has been shown to have a variable effect on serum cholesterol in these patients. Patients with primary biliary cirrhosis may exhibit an elevated cholesterol as part of their disease. uuid:6c88121c-3cee-4c14-83c0-3a10736fd75c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4B33BGI082 biolink:treats MONDO:0005010 PMID:41385096 "[{""id"":""uuid:a1676b6c-ae26-4797-8fde-bc19796e0937"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fb9379e5-2f16-4cfe-8c00-bfd5e6569cd4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1) Cholestyramine for Oral Suspension USP is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet. Cholestyramine may be useful to lower LDL cholesterol in patients who also have hypertriglyceridemia, but it is not indicated where hypertriglyceridemia is the abnormality of most concern. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Treatment should begin and continue with dietary therapy specific for the type of hyperlipoproteinemia determined prior to initiation of drug therapy. Excess body weight may be an important factor and caloric restriction for weight normalization should be addressed prior to drug therapy in the overweight. Prior to initiating therapy with Cholestyramine, secondary causes of hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism), should be excluded, and a lipid profile performed to assess Total cholesterol, HDL-C, and triglycerides (TG). For individuals with TG less than 400 mg/dL (less than 4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = Total cholesterol – [(TG/5) + HDL-C] For TG levels >400 mg/dL, this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated Total-C. In such cases Cholestyramine may not be indicated. Serum cholesterol and triglyceride levels should be determined periodically based on NCEP guidelines to confirm initial and adequate long-term response. A favorable trend in cholesterol reduction should occur during the first month of Cholestyramine therapy. The therapy should be continued to sustain cholesterol reduction. If adequate cholesterol reduction is not attained, increasing the dosage of Cholestyramine or adding other lipid-lowering agents in combination with Cholestyramine should be considered. Since the goal of treatment is to lower LDL-C, the NCEP 4 recommends that LDL-C levels be used to initiate and assess treatment response. If LDL-C levels are not available then Total-C alone may be used to monitor long-term therapy. A lipoprotein analysis (including LDL-C determination) should be carried out once a year. The NCEP treatment guidelines are summarized below. LDL-Cholesterol mg/dL (mmol/L) Definite Atherosclerotic Disease* Two or More Other Risk Factors** Initiation Level Goal NO NO Greater Than or Equal to 190 (Greater Than or Equal To 4.9) Less Than 160 (Less Than 4.1) NO YES Greater Than or Equal To 160 (Greater Than or Equal To 4.1) Less Than 130 (Less Than 3.4) YES YES or NO Greater Than or Equal To 130 (Greater Than or Equal To 3.4) Less Than or Equal To 100 (Less Than or Equal To 2.6) * Coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease). ** Other risk factors for coronary heart disease (CHD) include: age (males greater than or equal to 45 years; females greater than or equal to 55 years or premature menopause without estrogen replacement therapy); family history of premature CHD; current cigarette smoking; hypertension; confirmed HDL-C less than 35 mg/dL (less than 0.91 mmol/L); and diabetes mellitus. Subtract one risk factor if HDL-C is greater than or equal to 60 mg/dL (greater than or equal to 1.6 mmol/L). Cholestyramine monotherapy has been demonstrated to retard the rate of progression 2,3 and increase the rate of regression 3 of coronary atherosclerosis. 2) Cholestyramine for oral suspension is indicated for the relief of pruritus associated with partial biliary obstruction. Cholestyramine for oral suspension has been shown to have a variable effect on serum cholesterol in these patients. Patients with primary biliary cirrhosis may exhibit an elevated cholesterol as part of their disease. uuid:4ae147b4-faaa-4d70-a164-153926a76240 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4B33BGI082 biolink:treats MONDO:0005294 PMID:41385096 "[{""id"":""uuid:489ee0f1-74ce-461e-9816-faed05c80390"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:96225adc-6db1-4b44-85ba-9c6fe2a6069d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1) Cholestyramine for Oral Suspension USP is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet. Cholestyramine may be useful to lower LDL cholesterol in patients who also have hypertriglyceridemia, but it is not indicated where hypertriglyceridemia is the abnormality of most concern. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Treatment should begin and continue with dietary therapy specific for the type of hyperlipoproteinemia determined prior to initiation of drug therapy. Excess body weight may be an important factor and caloric restriction for weight normalization should be addressed prior to drug therapy in the overweight. Prior to initiating therapy with Cholestyramine, secondary causes of hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism), should be excluded, and a lipid profile performed to assess Total cholesterol, HDL-C, and triglycerides (TG). For individuals with TG less than 400 mg/dL (less than 4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = Total cholesterol – [(TG/5) + HDL-C] For TG levels >400 mg/dL, this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated Total-C. In such cases Cholestyramine may not be indicated. Serum cholesterol and triglyceride levels should be determined periodically based on NCEP guidelines to confirm initial and adequate long-term response. A favorable trend in cholesterol reduction should occur during the first month of Cholestyramine therapy. The therapy should be continued to sustain cholesterol reduction. If adequate cholesterol reduction is not attained, increasing the dosage of Cholestyramine or adding other lipid-lowering agents in combination with Cholestyramine should be considered. Since the goal of treatment is to lower LDL-C, the NCEP 4 recommends that LDL-C levels be used to initiate and assess treatment response. If LDL-C levels are not available then Total-C alone may be used to monitor long-term therapy. A lipoprotein analysis (including LDL-C determination) should be carried out once a year. The NCEP treatment guidelines are summarized below. LDL-Cholesterol mg/dL (mmol/L) Definite Atherosclerotic Disease* Two or More Other Risk Factors** Initiation Level Goal NO NO Greater Than or Equal to 190 (Greater Than or Equal To 4.9) Less Than 160 (Less Than 4.1) NO YES Greater Than or Equal To 160 (Greater Than or Equal To 4.1) Less Than 130 (Less Than 3.4) YES YES or NO Greater Than or Equal To 130 (Greater Than or Equal To 3.4) Less Than or Equal To 100 (Less Than or Equal To 2.6) * Coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease). ** Other risk factors for coronary heart disease (CHD) include: age (males greater than or equal to 45 years; females greater than or equal to 55 years or premature menopause without estrogen replacement therapy); family history of premature CHD; current cigarette smoking; hypertension; confirmed HDL-C less than 35 mg/dL (less than 0.91 mmol/L); and diabetes mellitus. Subtract one risk factor if HDL-C is greater than or equal to 60 mg/dL (greater than or equal to 1.6 mmol/L). Cholestyramine monotherapy has been demonstrated to retard the rate of progression 2,3 and increase the rate of regression 3 of coronary atherosclerosis. 2) Cholestyramine for oral suspension is indicated for the relief of pruritus associated with partial biliary obstruction. Cholestyramine for oral suspension has been shown to have a variable effect on serum cholesterol in these patients. Patients with primary biliary cirrhosis may exhibit an elevated cholesterol as part of their disease. uuid:c8231d75-b2cc-4b8c-a7d1-2fdff3802aa9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4B33BGI082 biolink:treats MONDO:0005269 PMID:41385096 "[{""id"":""uuid:d43a5053-bbdf-483f-99aa-bae7c15585d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0ae3017a-f929-4c60-8687-831e8c348a1a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1) Cholestyramine for Oral Suspension USP is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet. Cholestyramine may be useful to lower LDL cholesterol in patients who also have hypertriglyceridemia, but it is not indicated where hypertriglyceridemia is the abnormality of most concern. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Treatment should begin and continue with dietary therapy specific for the type of hyperlipoproteinemia determined prior to initiation of drug therapy. Excess body weight may be an important factor and caloric restriction for weight normalization should be addressed prior to drug therapy in the overweight. Prior to initiating therapy with Cholestyramine, secondary causes of hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism), should be excluded, and a lipid profile performed to assess Total cholesterol, HDL-C, and triglycerides (TG). For individuals with TG less than 400 mg/dL (less than 4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = Total cholesterol – [(TG/5) + HDL-C] For TG levels >400 mg/dL, this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated Total-C. In such cases Cholestyramine may not be indicated. Serum cholesterol and triglyceride levels should be determined periodically based on NCEP guidelines to confirm initial and adequate long-term response. A favorable trend in cholesterol reduction should occur during the first month of Cholestyramine therapy. The therapy should be continued to sustain cholesterol reduction. If adequate cholesterol reduction is not attained, increasing the dosage of Cholestyramine or adding other lipid-lowering agents in combination with Cholestyramine should be considered. Since the goal of treatment is to lower LDL-C, the NCEP 4 recommends that LDL-C levels be used to initiate and assess treatment response. If LDL-C levels are not available then Total-C alone may be used to monitor long-term therapy. A lipoprotein analysis (including LDL-C determination) should be carried out once a year. The NCEP treatment guidelines are summarized below. LDL-Cholesterol mg/dL (mmol/L) Definite Atherosclerotic Disease* Two or More Other Risk Factors** Initiation Level Goal NO NO Greater Than or Equal to 190 (Greater Than or Equal To 4.9) Less Than 160 (Less Than 4.1) NO YES Greater Than or Equal To 160 (Greater Than or Equal To 4.1) Less Than 130 (Less Than 3.4) YES YES or NO Greater Than or Equal To 130 (Greater Than or Equal To 3.4) Less Than or Equal To 100 (Less Than or Equal To 2.6) * Coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease). ** Other risk factors for coronary heart disease (CHD) include: age (males greater than or equal to 45 years; females greater than or equal to 55 years or premature menopause without estrogen replacement therapy); family history of premature CHD; current cigarette smoking; hypertension; confirmed HDL-C less than 35 mg/dL (less than 0.91 mmol/L); and diabetes mellitus. Subtract one risk factor if HDL-C is greater than or equal to 60 mg/dL (greater than or equal to 1.6 mmol/L). Cholestyramine monotherapy has been demonstrated to retard the rate of progression 2,3 and increase the rate of regression 3 of coronary atherosclerosis. 2) Cholestyramine for oral suspension is indicated for the relief of pruritus associated with partial biliary obstruction. Cholestyramine for oral suspension has been shown to have a variable effect on serum cholesterol in these patients. Patients with primary biliary cirrhosis may exhibit an elevated cholesterol as part of their disease. uuid:dbd72500-18ca-4b05-8691-da4efd298406 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4B33BGI082 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:5e047a92-40b4-47be-8472-688ca5e7ba20"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5bd26d66-5ce5-478f-8800-4d13b2719b3e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1) Cholestyramine for Oral Suspension USP is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet. Cholestyramine may be useful to lower LDL cholesterol in patients who also have hypertriglyceridemia, but it is not indicated where hypertriglyceridemia is the abnormality of most concern. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Treatment should begin and continue with dietary therapy specific for the type of hyperlipoproteinemia determined prior to initiation of drug therapy. Excess body weight may be an important factor and caloric restriction for weight normalization should be addressed prior to drug therapy in the overweight. Prior to initiating therapy with Cholestyramine, secondary causes of hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism), should be excluded, and a lipid profile performed to assess Total cholesterol, HDL-C, and triglycerides (TG). For individuals with TG less than 400 mg/dL (less than 4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = Total cholesterol – [(TG/5) + HDL-C] For TG levels >400 mg/dL, this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated Total-C. In such cases Cholestyramine may not be indicated. Serum cholesterol and triglyceride levels should be determined periodically based on NCEP guidelines to confirm initial and adequate long-term response. A favorable trend in cholesterol reduction should occur during the first month of Cholestyramine therapy. The therapy should be continued to sustain cholesterol reduction. If adequate cholesterol reduction is not attained, increasing the dosage of Cholestyramine or adding other lipid-lowering agents in combination with Cholestyramine should be considered. Since the goal of treatment is to lower LDL-C, the NCEP 4 recommends that LDL-C levels be used to initiate and assess treatment response. If LDL-C levels are not available then Total-C alone may be used to monitor long-term therapy. A lipoprotein analysis (including LDL-C determination) should be carried out once a year. The NCEP treatment guidelines are summarized below. LDL-Cholesterol mg/dL (mmol/L) Definite Atherosclerotic Disease* Two or More Other Risk Factors** Initiation Level Goal NO NO Greater Than or Equal to 190 (Greater Than or Equal To 4.9) Less Than 160 (Less Than 4.1) NO YES Greater Than or Equal To 160 (Greater Than or Equal To 4.1) Less Than 130 (Less Than 3.4) YES YES or NO Greater Than or Equal To 130 (Greater Than or Equal To 3.4) Less Than or Equal To 100 (Less Than or Equal To 2.6) * Coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease). ** Other risk factors for coronary heart disease (CHD) include: age (males greater than or equal to 45 years; females greater than or equal to 55 years or premature menopause without estrogen replacement therapy); family history of premature CHD; current cigarette smoking; hypertension; confirmed HDL-C less than 35 mg/dL (less than 0.91 mmol/L); and diabetes mellitus. Subtract one risk factor if HDL-C is greater than or equal to 60 mg/dL (greater than or equal to 1.6 mmol/L). Cholestyramine monotherapy has been demonstrated to retard the rate of progression 2,3 and increase the rate of regression 3 of coronary atherosclerosis. 2) Cholestyramine for oral suspension is indicated for the relief of pruritus associated with partial biliary obstruction. Cholestyramine for oral suspension has been shown to have a variable effect on serum cholesterol in these patients. Patients with primary biliary cirrhosis may exhibit an elevated cholesterol as part of their disease. uuid:e33fa98b-ae94-489d-9af9-a5b33ff115eb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4B33BGI082 biolink:treats MONDO:0005388 PMID:41385096 "[{""id"":""uuid:9a71ad20-09ff-47f4-afb7-4e26db625afe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ebe1201b-a8ec-409a-9510-5f4f9d9c21bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1) Cholestyramine for Oral Suspension USP is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet. Cholestyramine may be useful to lower LDL cholesterol in patients who also have hypertriglyceridemia, but it is not indicated where hypertriglyceridemia is the abnormality of most concern. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Treatment should begin and continue with dietary therapy specific for the type of hyperlipoproteinemia determined prior to initiation of drug therapy. Excess body weight may be an important factor and caloric restriction for weight normalization should be addressed prior to drug therapy in the overweight. Prior to initiating therapy with Cholestyramine, secondary causes of hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism), should be excluded, and a lipid profile performed to assess Total cholesterol, HDL-C, and triglycerides (TG). For individuals with TG less than 400 mg/dL (less than 4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = Total cholesterol – [(TG/5) + HDL-C] For TG levels >400 mg/dL, this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated Total-C. In such cases Cholestyramine may not be indicated. Serum cholesterol and triglyceride levels should be determined periodically based on NCEP guidelines to confirm initial and adequate long-term response. A favorable trend in cholesterol reduction should occur during the first month of Cholestyramine therapy. The therapy should be continued to sustain cholesterol reduction. If adequate cholesterol reduction is not attained, increasing the dosage of Cholestyramine or adding other lipid-lowering agents in combination with Cholestyramine should be considered. Since the goal of treatment is to lower LDL-C, the NCEP 4 recommends that LDL-C levels be used to initiate and assess treatment response. If LDL-C levels are not available then Total-C alone may be used to monitor long-term therapy. A lipoprotein analysis (including LDL-C determination) should be carried out once a year. The NCEP treatment guidelines are summarized below. LDL-Cholesterol mg/dL (mmol/L) Definite Atherosclerotic Disease* Two or More Other Risk Factors** Initiation Level Goal NO NO Greater Than or Equal to 190 (Greater Than or Equal To 4.9) Less Than 160 (Less Than 4.1) NO YES Greater Than or Equal To 160 (Greater Than or Equal To 4.1) Less Than 130 (Less Than 3.4) YES YES or NO Greater Than or Equal To 130 (Greater Than or Equal To 3.4) Less Than or Equal To 100 (Less Than or Equal To 2.6) * Coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease). ** Other risk factors for coronary heart disease (CHD) include: age (males greater than or equal to 45 years; females greater than or equal to 55 years or premature menopause without estrogen replacement therapy); family history of premature CHD; current cigarette smoking; hypertension; confirmed HDL-C less than 35 mg/dL (less than 0.91 mmol/L); and diabetes mellitus. Subtract one risk factor if HDL-C is greater than or equal to 60 mg/dL (greater than or equal to 1.6 mmol/L). Cholestyramine monotherapy has been demonstrated to retard the rate of progression 2,3 and increase the rate of regression 3 of coronary atherosclerosis. 2) Cholestyramine for oral suspension is indicated for the relief of pruritus associated with partial biliary obstruction. Cholestyramine for oral suspension has been shown to have a variable effect on serum cholesterol in these patients. Patients with primary biliary cirrhosis may exhibit an elevated cholesterol as part of their disease. uuid:11940615-8be5-4bc8-9d98-e5aff65cf9e5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4B33BGI082 biolink:treats MONDO:0006757 PMID:41385096 "[{""id"":""uuid:2bc42073-7ea0-42e0-a0e5-716b510a7041"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5c547464-c7a4-4b1c-bf7e-1a8a09db2cb0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1) Cholestyramine for Oral Suspension USP is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet. Cholestyramine may be useful to lower LDL cholesterol in patients who also have hypertriglyceridemia, but it is not indicated where hypertriglyceridemia is the abnormality of most concern. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Treatment should begin and continue with dietary therapy specific for the type of hyperlipoproteinemia determined prior to initiation of drug therapy. Excess body weight may be an important factor and caloric restriction for weight normalization should be addressed prior to drug therapy in the overweight. Prior to initiating therapy with Cholestyramine, secondary causes of hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism), should be excluded, and a lipid profile performed to assess Total cholesterol, HDL-C, and triglycerides (TG). For individuals with TG less than 400 mg/dL (less than 4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = Total cholesterol – [(TG/5) + HDL-C] For TG levels >400 mg/dL, this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated Total-C. In such cases Cholestyramine may not be indicated. Serum cholesterol and triglyceride levels should be determined periodically based on NCEP guidelines to confirm initial and adequate long-term response. A favorable trend in cholesterol reduction should occur during the first month of Cholestyramine therapy. The therapy should be continued to sustain cholesterol reduction. If adequate cholesterol reduction is not attained, increasing the dosage of Cholestyramine or adding other lipid-lowering agents in combination with Cholestyramine should be considered. Since the goal of treatment is to lower LDL-C, the NCEP 4 recommends that LDL-C levels be used to initiate and assess treatment response. If LDL-C levels are not available then Total-C alone may be used to monitor long-term therapy. A lipoprotein analysis (including LDL-C determination) should be carried out once a year. The NCEP treatment guidelines are summarized below. LDL-Cholesterol mg/dL (mmol/L) Definite Atherosclerotic Disease* Two or More Other Risk Factors** Initiation Level Goal NO NO Greater Than or Equal to 190 (Greater Than or Equal To 4.9) Less Than 160 (Less Than 4.1) NO YES Greater Than or Equal To 160 (Greater Than or Equal To 4.1) Less Than 130 (Less Than 3.4) YES YES or NO Greater Than or Equal To 130 (Greater Than or Equal To 3.4) Less Than or Equal To 100 (Less Than or Equal To 2.6) * Coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease). ** Other risk factors for coronary heart disease (CHD) include: age (males greater than or equal to 45 years; females greater than or equal to 55 years or premature menopause without estrogen replacement therapy); family history of premature CHD; current cigarette smoking; hypertension; confirmed HDL-C less than 35 mg/dL (less than 0.91 mmol/L); and diabetes mellitus. Subtract one risk factor if HDL-C is greater than or equal to 60 mg/dL (greater than or equal to 1.6 mmol/L). Cholestyramine monotherapy has been demonstrated to retard the rate of progression 2,3 and increase the rate of regression 3 of coronary atherosclerosis. 2) Cholestyramine for oral suspension is indicated for the relief of pruritus associated with partial biliary obstruction. Cholestyramine for oral suspension has been shown to have a variable effect on serum cholesterol in these patients. Patients with primary biliary cirrhosis may exhibit an elevated cholesterol as part of their disease. uuid:dbeff1cd-6311-410f-82fc-3865dd13d710 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0015614 PMID:41385096 "[{""id"":""uuid:9915b990-f79c-4b79-bf47-61fa8c0a0d1f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ce928c24-3df0-411b-8d96-1f64788a3bf8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:7746ba9a-dff0-4958-b392-164cf3ec29e3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0043233 PMID:41385096 "[{""id"":""uuid:c608d40e-4596-469f-b2e8-795ff4734b2e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:982f9da5-eab2-45f5-a351-e677aa605528"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:c439ca9b-6531-4c6a-9b83-ca5696b54293 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0009691 PMID:41385096 "[{""id"":""uuid:0df73a2e-2bba-449b-bb4b-6e303c19dd49"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:71e6ce9a-d7a5-404d-85ff-f7d4f1d03f94"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:b995d10a-f1de-4b53-8ded-307b8b43894c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0006594 PMID:41385096 "[{""id"":""uuid:e4872683-95b2-4915-ae32-9921f06cea7d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bb74fafe-9af3-4eb7-8d77-0d633adcdb7d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:824ec46d-3d61-4709-bb45-cd33066f1cb1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0018229 PMID:41385096 "[{""id"":""uuid:a2f5cfb7-5850-4176-b938-2288fdbc6077"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a3a75d35-098f-4031-a87b-44b36ee525ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:9512abfa-9052-46ac-bf5d-384f72fab076 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0000004 PMID:41385096 "[{""id"":""uuid:6b71f6ad-9cef-48c9-bcc2-6c5651dda17e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b1f4e39a-3464-4472-acd6-e48e9fc4a639"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:f6a4dbb1-7802-4368-a1ce-6bb9800015e8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats UMLS:C0678202 PMID:41385096 "[{""id"":""uuid:fbb7895f-fa13-4e3d-8d4d-709803ae8dd8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c30fc184-31a7-43b2-85be-96b5dbec6c74"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:4319b8d6-0698-44de-a362-0166fc5cc6c3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0005101 PMID:41385096 "[{""id"":""uuid:c4e342ef-b42c-4f64-8cf4-8ffdba82c145"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a5843519-1789-4135-9756-f5fdd5835e73"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:e232b200-6606-44ca-9869-796b61aa40f6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0020108 PMID:41385096 "[{""id"":""uuid:7adec86d-17a8-4865-937e-b1959b9e1882"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1ff371ff-238d-4952-ae7b-8bc474c5dc3f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:ade4fa80-aa26-4b59-8fa2-9c118400267f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0001713 PMID:41385096 "[{""id"":""uuid:14f646d2-d0af-4cfa-84fe-9a463de9818a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ff8c111b-2568-468e-aeeb-ed69ed5e1ad2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:54a80b33-7efa-4f68-b9a8-a5390812185c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0019098 PMID:41385096 "[{""id"":""uuid:46b89667-eb2e-45a7-901f-9833bbd09f75"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e7724884-906c-4d84-a568-b2bd2901fcb4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:1d2abc40-3be1-45dc-aef4-de596fc892be biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0001705 PMID:41385096 "[{""id"":""uuid:19a66b26-fbb4-4ebd-9a8e-5ce4909f0f49"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:400974fd-91c6-4014-93d9-e180dfefced0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:eaaa67d1-a0e2-4cf3-b49d-f6f3a29659fa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0001198 PMID:41385096 "[{""id"":""uuid:31b55f35-4f8e-4a07-abb8-6cce9f83027a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c9162756-88ad-4a5c-8b6e-7d99f0ef3d12"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:cdb60987-ea32-47a9-8329-92b0ae6cd28a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0019444 PMID:41385096 "[{""id"":""uuid:64cec8ff-161d-4191-9d64-95169b9cc2d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f0681d32-3120-4884-9943-2e9a39ee553c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:c0472b0a-489f-4346-a202-66602e89e6af biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0006042 PMID:41385096 "[{""id"":""uuid:46e31152-f89a-4a60-842f-94f664126301"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:059e817a-ea49-44b1-af1a-9c0e5b4fb786"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:da9f0eb7-c4f7-425a-8953-41f0dc68c18c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0005059 PMID:41385096 "[{""id"":""uuid:604a7866-9bbd-4573-b862-8a5013012620"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:77128f67-4c72-4e0a-a642-9641fa0d7811"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:407d642e-2c44-4151-b230-bafb8f40b687 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0004095 PMID:41385096 "[{""id"":""uuid:535bb5ca-84b3-4381-8c19-38d48845fe9e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4152ee74-c5c8-4551-966a-f3dea3072fe1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:e6338a6c-75c1-4212-af3b-0ba4919a81d4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0005301 PMID:41385096 "[{""id"":""uuid:94268d33-5f2e-44a6-8909-c5cc8cc3cb1f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dd0fcae5-8288-4de3-8d45-206df8359a50"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:8aa91993-0649-4c0a-b4b5-137fd1a0ffba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0006684 PMID:41385096 "[{""id"":""uuid:df0623a5-d659-4c05-a180-7b2966a396d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3dca5dca-2e64-48ac-a0aa-8bdd340726f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:7bb52f65-42d6-48ee-bacf-4e29040ac88a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0021211 PMID:41385096 "[{""id"":""uuid:b9eb0c88-fa0e-4310-a002-2754a009bae4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7288a08f-060c-43ec-94d7-f822896aab60"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:7cc729f2-8232-4a9c-82dc-6a2f68a51ee9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0019198 PMID:41385096 "[{""id"":""uuid:c7a144c9-809d-4291-86a1-401a41061560"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e4f0eb54-17c9-40aa-a1b2-450d1aba1393"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:2e79185b-2d38-48f3-8e69-a0e6f2ca2560 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0008538 PMID:41385096 "[{""id"":""uuid:eff47318-4929-4ec1-bd9a-3e7f3761160b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c26a30a5-fa66-406f-b0d4-3bf5f61832e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:5dd99c09-61fe-4876-86f9-bc0bbd7b1f8c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0020283 PMID:41385096 "[{""id"":""uuid:23d7c9b4-576c-4eb7-9f88-5406fb44bfb1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:00fb541d-f904-41b2-b1f9-a9aef6664396"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:6fafc4ea-6fd7-45d1-90b5-bb26f3bcbdc5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0018170 PMID:41385096 "[{""id"":""uuid:2423f9f9-6324-4b9c-a11a-87759147b3c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:34848d68-65c5-4ce5-a40b-ffda90e4056c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:4c979fcd-aa09-4e1c-b2a1-5698e1044794 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0004670 PMID:41385096 "[{""id"":""uuid:4dcc97aa-7aff-4536-b090-e6dd67600dfd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5dfec57c-9e67-44e5-be3a-43c448559d3d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:2c32f0fd-2b07-405d-a2f6-24b9df72b98b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0015274 PMID:41385096 "[{""id"":""uuid:418bbd93-b01d-45ed-bfd6-6c9008bf75ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c57f082a-2b76-49f2-8cc8-c9eaa8b58c18"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:8623990d-8da7-453f-aab8-d059ae343834 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0006052 PMID:41385096 "[{""id"":""uuid:cebf85a9-c5ff-400f-8584-c3bc78817409"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:04925474-d9f2-4742-812c-f4bdfe460967"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:54912087-6222-4c04-961b-9db11cea28ba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0015927 PMID:41385096 "[{""id"":""uuid:eec17d17-ed52-42c0-96ea-90b49703d700"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8a4459ed-fb1c-4280-9261-288b78239be7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:3ba8342a-daee-4869-9aa8-9c3ee9659c0f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0019338 PMID:41385096 "[{""id"":""uuid:b182ae05-08aa-492e-8fb1-b4105ba206cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fc5bbd6f-56d7-4ce1-bd3f-3600bf30feb2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:4b3b02c0-3b4a-4636-a77f-050e0eb5e67c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats UMLS:C0149896 PMID:41385096 "[{""id"":""uuid:928074f1-fec4-4387-9eda-115790c14d37"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2900e696-727f-4c95-b082-ea13e816187b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:ec6eb801-f4c8-4be3-b914-71807b71cd3e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats UMLS:C5441648 PMID:41385096 "[{""id"":""uuid:1034dca3-ee4a-41c4-adfa-da4f04fdae39"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0a50f248-9c8c-400d-99ef-de4ae4aaf39d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:f9910887-2360-4b9a-84f6-e2050b73c453 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0005306 PMID:41385096 "[{""id"":""uuid:4dcc39b2-0db1-4db3-86e5-b6e44727ef32"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:885d055a-3e16-482a-b8b4-f38e1d6646f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:bf183ffc-ec45-4d1b-bced-6a803660c3cc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0011849 PMID:41385096 "[{""id"":""uuid:46fec7bb-532b-4314-b243-0b6b33e52145"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6f72786a-6aa3-4399-b79a-9526dacfdae7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:74f7a0b5-9ce8-462a-97da-68706ccf5d12 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:12528ce2-7989-4179-8786-32fb85e8f007"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ccb728cf-353e-4df5-9269-3a87506ea2fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:d1d8df7d-bd90-4994-9ffc-39fb77a3a164 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0011429 PMID:41385096 "[{""id"":""uuid:d03977af-f0b6-4c41-afa4-bd4bc0081113"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a1d1ae23-4b0b-4cfc-b51b-933070041556"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:8838be88-91f5-4a9d-a783-cfbb74ce0145 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0016367 PMID:41385096 "[{""id"":""uuid:90349042-9f0c-4ace-9a64-daf804184adb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a141a54e-4987-4b10-98e5-d06100d84272"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:66233bc5-e5b1-43a0-84e4-f2dd1b0a2bdd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0019127 PMID:41385096 "[{""id"":""uuid:05b27665-3714-4fd3-9cfa-1192f49d1fae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:efb584cc-6d78-4097-af80-cb920b441c95"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:5480d7cf-1af3-4b20-977a-3b65022d8fed biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5778 biolink:treats MONDO:0045048 PMID:41385096 "[{""id"":""uuid:4f44ee9f-36a0-4efd-ba26-67bb40a375c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2d497e6c-aa64-4301-89e7-4ea50c0c9271"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydrochlorothiazide tablets are indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Hydrochlorothiazide tablets have also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. Hydrochlorothiazide tablets are indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension. Use in Pregnancy Routine use of diuretics during normal pregnancy is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy and there is no satisfactory evidence that they are useful in the treatment of toxemia. Edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy. Thiazides are indicated in pregnancy when edema is due to pathologic causes, just as they are in the absence of pregnancy ( see PRECAUTIONS, Pregnancy). Dependent edema in pregnancy, resulting from restriction of venous return by the gravid uterus, is properly treated through elevation of the lower extremities and use of support stockings. Use of diuretics to lower intravascular volume in this instance is illogical and unnecessary. During normal pregnancy there is hypervolemia which is not harmful to the fetus or the mother in the absence of cardiovascular disease. However, it may be associated with edema, rarely generalized edema. If such edema causes discomfort, increased recumbency will often provide relief. Rarely this edema may cause extreme discomfort which is not relieved by rest. In these instances, a short course of diuretic therapy may provide relief and be appropriate. uuid:3236f1db-45d2-443b-b307-4d2fa16789d1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5778 biolink:treats HP:0007430 PMID:41385096 "[{""id"":""uuid:085532ec-9276-4fd6-8126-c6ef1f419dc1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5e940463-c0f2-4627-9202-0b4023a48727"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydrochlorothiazide tablets are indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Hydrochlorothiazide tablets have also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. Hydrochlorothiazide tablets are indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension. Use in Pregnancy Routine use of diuretics during normal pregnancy is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy and there is no satisfactory evidence that they are useful in the treatment of toxemia. Edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy. Thiazides are indicated in pregnancy when edema is due to pathologic causes, just as they are in the absence of pregnancy ( see PRECAUTIONS, Pregnancy). Dependent edema in pregnancy, resulting from restriction of venous return by the gravid uterus, is properly treated through elevation of the lower extremities and use of support stockings. Use of diuretics to lower intravascular volume in this instance is illogical and unnecessary. During normal pregnancy there is hypervolemia which is not harmful to the fetus or the mother in the absence of cardiovascular disease. However, it may be associated with edema, rarely generalized edema. If such edema causes discomfort, increased recumbency will often provide relief. Rarely this edema may cause extreme discomfort which is not relieved by rest. In these instances, a short course of diuretic therapy may provide relief and be appropriate. uuid:0afa9cc1-07d5-4f96-bd38-0bdfc46ce3e9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:91495 biolink:treats MONDO:0005709 PMID:41385096 "[{""id"":""uuid:10001111-3fc8-44c1-9d04-ddd3b3eeadf8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3f937725-86f8-4d4e-819d-d236c5b0ed46"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ipratropium bromide nasal solution 0.06% (Nasal Spray) is indicated for the symptomatic relief of rhinorrhea associated with the common cold for adults and children age 5 years and older. Ipratropium bromide nasal solution 0.06% (Nasal Spray) does not relieve nasal congestion or sneezing associated with the common cold or seasonal allergic rhinitis. The safety and effectiveness of the use of ipratropium bromide nasal solution 0.06% (Nasal Spray) beyond four days in patients with the common cold or beyond three weeks in patients with seasonal allergic rhinitis has not been established. uuid:a91528d1-e16d-4afe-894f-05b77db5deaf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:91495 biolink:treats MONDO:0005324 PMID:41385096 "[{""id"":""uuid:4591df3e-717e-4a88-b690-3a5e34d71d33"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:65b553c3-a900-4685-bc0e-a01bcf050f76"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ipratropium bromide nasal solution 0.06% (Nasal Spray) is indicated for the symptomatic relief of rhinorrhea associated with the common cold for adults and children age 5 years and older. Ipratropium bromide nasal solution 0.06% (Nasal Spray) does not relieve nasal congestion or sneezing associated with the common cold or seasonal allergic rhinitis. The safety and effectiveness of the use of ipratropium bromide nasal solution 0.06% (Nasal Spray) beyond four days in patients with the common cold or beyond three weeks in patients with seasonal allergic rhinitis has not been established. uuid:cce9798d-271f-4a42-9ea2-b9c397ff476f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:151293 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:0d9af03d-a906-4627-ad73-199cf75345c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f4ebc241-5827-447c-aacf-06d16924c28b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Quinapril hydrochloride and hydrochlorothiazide tablets are indicated for the treatment of hypertension. This fixed combination is not indicated for the initial therapy of hypertension (see DOSAGE AND ADMINISTRATION ). In using quinapril hydrochloride and hydrochlorothiazide, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that quinapril does not have a similar risk (see WARNINGS: Neutropenia/Agranulocytosis ). Angioedema in Black Patients: Black patients receiving ACE inhibitor monotherapy have been reported to have a higher incidence of angioedema compared to non-blacks. It should also be noted that in controlled clinical trials, ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. uuid:fbc23e80-3504-4164-b9fb-d347d9575fac biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:151293 biolink:treats MONDO:0001609 PMID:41385096 "[{""id"":""uuid:609bf3ff-a954-42d6-96ba-a3c1377da595"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:23e29905-391e-4691-85e4-b9f12dcd87d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Quinapril hydrochloride and hydrochlorothiazide tablets are indicated for the treatment of hypertension. This fixed combination is not indicated for the initial therapy of hypertension (see DOSAGE AND ADMINISTRATION ). In using quinapril hydrochloride and hydrochlorothiazide, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that quinapril does not have a similar risk (see WARNINGS: Neutropenia/Agranulocytosis ). Angioedema in Black Patients: Black patients receiving ACE inhibitor monotherapy have been reported to have a higher incidence of angioedema compared to non-blacks. It should also be noted that in controlled clinical trials, ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. uuid:75dbfe78-538f-431d-b9bb-2953e6b9b63a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:151293 biolink:treats MONDO:0001343 PMID:41385096 "[{""id"":""uuid:dc6ed34c-2cc2-41fc-b774-782fc87c275a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:14c29ac8-129a-4c67-ab7a-f8333ca0dddc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Quinapril hydrochloride and hydrochlorothiazide tablets are indicated for the treatment of hypertension. This fixed combination is not indicated for the initial therapy of hypertension (see DOSAGE AND ADMINISTRATION ). In using quinapril hydrochloride and hydrochlorothiazide, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that quinapril does not have a similar risk (see WARNINGS: Neutropenia/Agranulocytosis ). Angioedema in Black Patients: Black patients receiving ACE inhibitor monotherapy have been reported to have a higher incidence of angioedema compared to non-blacks. It should also be noted that in controlled clinical trials, ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. uuid:157a4e0f-7ff8-4590-be46-0f41104b6908 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:151293 biolink:treats MONDO:0010481 PMID:41385096 "[{""id"":""uuid:4402fbf2-2a7d-467e-9dff-9c68df1044b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:edfbaa36-b400-4581-9232-61518b148d5d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Quinapril hydrochloride and hydrochlorothiazide tablets are indicated for the treatment of hypertension. This fixed combination is not indicated for the initial therapy of hypertension (see DOSAGE AND ADMINISTRATION ). In using quinapril hydrochloride and hydrochlorothiazide, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that quinapril does not have a similar risk (see WARNINGS: Neutropenia/Agranulocytosis ). Angioedema in Black Patients: Black patients receiving ACE inhibitor monotherapy have been reported to have a higher incidence of angioedema compared to non-blacks. It should also be noted that in controlled clinical trials, ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. uuid:ffd33209-c409-4f77-bf9f-ccfea29f3fad biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1152239 biolink:treats NCIT:C27003 PMID:41385096 "[{""id"":""uuid:894cf652-a168-4e46-901c-29c839a4e9e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:db654f77-ff80-4601-a1be-825a610b3231"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tramadol hydrochloride and acetaminophen tablets, 37.5 mg/325 mg, are indicated for the short-term (five days or less) management of acute pain. uuid:88158882-9999-4a5e-a6e4-f3407263c0b2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63610 biolink:treats MONDO:0001126 PMID:41385096 "[{""id"":""uuid:7b246986-a4ee-44d1-989d-963f02a95d8b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4065cf67-424e-4499-88b6-488de8de8eab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cytotec (misoprostol) is indicated for reducing the risk of NSAID (nonsteroidal anti-inflammatory drugs, including aspirin)–induced gastric ulcers in patients at high risk of complications from gastric ulcer, e.g., the elderly and patients with concomitant debilitating disease, as well as patients at high risk of developing gastric ulceration, such as patients with a history of ulcer. Cytotec has not been shown to reduce the risk of duodenal ulcers in patients taking NSAIDs. Cytotec should be taken for the duration of NSAID therapy. Cytotec has been shown to reduce the risk of gastric ulcers in controlled studies of 3 months' duration. It had no effect, compared to placebo, on gastrointestinal pain or discomfort associated with NSAID use. uuid:8b2dfc04-afc0-43c4-8c76-f8cae9d0e2de biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:91495 biolink:treats MONDO:0011786 PMID:41385096 "[{""id"":""uuid:02c37407-3509-4817-a747-8ced770c08df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:751b5069-c1d6-4a36-ad3b-3073e248d308"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ipratropium bromide nasal solution 0.03% (Nasal Spray) is indicated for the symptomatic relief of rhinorrhea associated with allergic and nonallergic perennial rhinitis in adults and children age 6 years and older. Ipratropium bromide nasal solution 0.03% (Nasal Spray) does not relieve nasal congestion, sneezing, or postnasal drip associated with allergic or nonallergic perennial rhinitis. uuid:bf8b3b98-6405-4e05-98cf-a7743df75521 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:91495 biolink:treats MONDO:0006004 PMID:41385096 "[{""id"":""uuid:a9f0171e-6c80-4914-876d-1a86fd2819b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1c8a5b6e-5c7d-47ef-9e4d-ee702738e966"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ipratropium bromide nasal solution 0.03% (Nasal Spray) is indicated for the symptomatic relief of rhinorrhea associated with allergic and nonallergic perennial rhinitis in adults and children age 6 years and older. Ipratropium bromide nasal solution 0.03% (Nasal Spray) does not relieve nasal congestion, sneezing, or postnasal drip associated with allergic or nonallergic perennial rhinitis. uuid:97af96f8-12e9-4094-b66a-749fff1fa0b1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3387 biolink:treats MONDO:0008599 PMID:41385096 "[{""id"":""uuid:639d8889-4f65-4bab-886a-ea762e1cbbd5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7a4d0a56-2ed2-47e8-adcb-565c63700430"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Epilepsy Carbamazepine is indicated for use as an anticonvulsant drug. Evidence supporting efficacy of carbamazepine as an anticonvulsant was derived from active drug-controlled studies that enrolled patients with the following seizure types: Partial seizures with complex symptomatology (psychomotor, temporal lobe). Patients with these seizures appear to show greater improvement than those with other types. Generalized tonic-clonic seizures (grand mal). Mixed seizure patterns which include the above, or other partial or generalized seizures. Absence seizures (petit mal) do not appear to be controlled by carbamazepine (see PRECAUTIONS, General). Trigeminal Neuralgia Carbamazepine is indicated in the treatment of the pain associated with true trigeminal neuralgia. Beneficial results have also been reported in glossopharyngeal neuralgia. This drug is not a simple analgesic and should not be used for the relief of trivial aches or pains. uuid:fda82d1a-36fa-48d3-891e-b8cca3194ae6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3387 biolink:treats MONDO:0016372 PMID:41385096 "[{""id"":""uuid:6eaad9f5-399e-4a58-9d6a-299511bcf6ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6d48adaa-acd5-4954-b238-e261cd1248a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Epilepsy Carbamazepine is indicated for use as an anticonvulsant drug. Evidence supporting efficacy of carbamazepine as an anticonvulsant was derived from active drug-controlled studies that enrolled patients with the following seizure types: Partial seizures with complex symptomatology (psychomotor, temporal lobe). Patients with these seizures appear to show greater improvement than those with other types. Generalized tonic-clonic seizures (grand mal). Mixed seizure patterns which include the above, or other partial or generalized seizures. Absence seizures (petit mal) do not appear to be controlled by carbamazepine (see PRECAUTIONS, General). Trigeminal Neuralgia Carbamazepine is indicated in the treatment of the pain associated with true trigeminal neuralgia. Beneficial results have also been reported in glossopharyngeal neuralgia. This drug is not a simple analgesic and should not be used for the relief of trivial aches or pains. uuid:f6401451-74fd-4486-9457-36e3a6491b5b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17303 biolink:treats NCIT:C34887 PMID:41385096 "[{""id"":""uuid:a73dbafc-939b-42b2-b919-e1e23b7c8147"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:04898a6e-cbdf-4540-8b5c-73a459128839"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Morphine sulfate extended-release tablets are a controlled-release oral formulation of morphine sulfate indicated for the management of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time. Morphine sulfate extended-release tablets are NOT intended for use as a prn analgesic. Morphine sulfate extended-release 100 mg and 200 mg tablet strengths are high dose, controlled-release, oral morphine formulations indicated for the relief of pain in opioid-tolerant patients only. Morphine sulfate extended-release tablets are not indicated for pain in the immediate postoperative period (the first 12 to 24 hours following surgery) for patients not previously taking the drug, because its safety in this setting has not been established. Morphine sulfate extended-release tablets are not indicated for pain in the postoperative period if the pain is mild, or not expected to persist for an extended period of time. Morphine sulfate extended-release tablets are only indicated for postoperative use if the patient is already receiving the drug prior to surgery or if the postoperative pain is expected to be moderate to severe and persist for an extended period of time. Physicians should individualize treatment, moving from parenteral to oral analgesics as appropriate (see American Pain Society guidelines). uuid:a2cab5c2-d434-48a3-8389-916492e565c7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:61049 biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:70647813-13b8-41de-aba2-e8536944e37b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:c773757d-2f24-4852-b588-43c8de0bc364"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:3016ea04-a1ea-4cab-aef0-a516110a7211"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/advagraf""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] PROTOPIC Ointment, both 0.03% and 0.1% for adults, and only 0.03% for children aged 2 to 15 years, is indicated as second-line therapy for the short-term and non-continuous chronic treatment of moderate to severe atopic dermatitis in non-immunocompromised adults and children who have failed to respond adequately to other topical prescription treatments for atopic dermatitis, or when those treatments are not advisable. PROTOPIC Ointment is not indicated for children younger than 2 years of age (see boxed WARNING, WARNINGS and PRECAUTIONS : Pediatric Use ).|[EMA] Flare treatmentAdults and adolescents (16 years of age and above)Treatment of moderate to severe atopic dermatitis in adults who are not adequately responsive to or are intolerant of conventional therapies such as topical corticosteroids.Children (two years of age and above)Treatment of moderate to severe atopic dermatitis in children (two years of age and above) who failed to respond adequately to conventional therapies such as topical corticosteroids.Maintenance treatmentMaintenance treatment of moderate to severe atopic dermatitis for the prevention of flares and the prolongation of flare-free intervals in patients experiencing a high frequency of disease exacerbations (i.e. occurring four or more times per year) who have had an initial response to a maximum of six weeks treatment of twice daily tacrolimus ointment (lesions cleared, almost cleared or mildly affected). uuid:34e27e22-54ab-4618-bedc-30faa8b336dd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31397 biolink:treats MONDO:0005324 PMID:41385096 "[{""id"":""uuid:d264b116-22c1-4903-8c17-ba3eb0b5aafc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ef10dc8d-c3cf-4825-9e72-0394c2cd8e61"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Seasonal Allergic Rhinitis OMNARIS Nasal Spray is indicated for the treatment of nasal symptoms associated with seasonal allergic rhinitis in adults and children 6 years of age and older. Perennial Allergic Rhinitis OMNARIS Nasal Spray is indicated for the treatment of nasal symptoms associated with perennial allergic rhinitis in adults and adolescents 12 years of age and older. uuid:c9b1b9ca-7861-4cad-ab98-f609ca915ca9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31397 biolink:treats MONDO:0024332 PMID:41385096 "[{""id"":""uuid:79b897a0-a003-4783-a720-f2f09ec13b37"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ced016b6-785f-497c-ad78-5428005c03e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Seasonal Allergic Rhinitis OMNARIS Nasal Spray is indicated for the treatment of nasal symptoms associated with seasonal allergic rhinitis in adults and children 6 years of age and older. Perennial Allergic Rhinitis OMNARIS Nasal Spray is indicated for the treatment of nasal symptoms associated with perennial allergic rhinitis in adults and adolescents 12 years of age and older. uuid:279eae23-4f14-44f9-b38d-3ff21cb3b820 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:40050 biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:24c261e2-fcb6-4528-ad82-ab46ad8b1dd0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3127fa86-0630-4ebe-8776-c555d8c37b10"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LEXIVA ® is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV-1) infection. The following points should be considered when initiating therapy with LEXIVA plus ritonavir in protease inhibitor-experienced patients: The protease inhibitor-experienced patient study was not large enough to reach a definitive conclusion that LEXIVA plus ritonavir and lopinavir plus ritonavir are clinically equivalent [see Clinical Studies (14.2)] . Once-daily administration of LEXIVA plus ritonavir is not recommended for adult protease inhibitor-experienced patients or any pediatric patients. uuid:5a766273-e130-4835-a200-dd433f995b79 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63577 biolink:treats MONDO:0004951 PMID:41385096 "[{""id"":""uuid:dde9f521-4170-44ff-9eb7-20240fc6597b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eb5792bf-486a-4edc-8d9c-202695b8e3d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EPIVIR is a nucleoside analogue indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV-1) infection. Limitation of use: The dosage of this product is for HIV-1 and not for HBV. uuid:ea52ec04-590a-4d28-a3dd-c6d978d29885 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9150 biolink:treats HP:0003124 PMID:41385096 "[{""id"":""uuid:56ff95c0-ff04-4fed-b3f8-90a27c8a8d87"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:45a3caa9-0561-421f-8f62-515f4fea53c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with coronary heart disease (CHD) or at high risk of CHD, simvastatin tablets can be started simultaneously with diet. uuid:9aee8051-839a-4717-91d2-dd776130ed36 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134751 biolink:treats MONDO:0005326 PMID:41385096 "[{""id"":""uuid:6c665975-ac34-4415-b7b8-a1612c301e28"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9f49d14c-9c59-4761-85e3-edc5ca0bee7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Uses -helps prevent sunburn -for skin that burns easily -provides moderate protection against sunburn -higher SPF gives more sunburn protection Directions -for external use only -when using this product keep out of eyes -rinse with water to remove -stop use and ask doctor if rash or irritation develops and lasts -keep out of reach of children -do not use on infants under 6 months of age uuid:a5afdf0c-6ca5-47cb-8ef1-fae6dbb2add5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134751 biolink:treats MONDO:0006547 PMID:41385096 "[{""id"":""uuid:9f4f31f0-2198-4a72-8895-c11d29599056"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:826a47c5-452a-4fc0-b06b-0356857c74a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Uses -helps prevent sunburn -for skin that burns easily -provides moderate protection against sunburn -higher SPF gives more sunburn protection Directions -for external use only -when using this product keep out of eyes -rinse with water to remove -stop use and ask doctor if rash or irritation develops and lasts -keep out of reach of children -do not use on infants under 6 months of age uuid:bb9d2e52-40ca-4bab-b72f-7f53596fb839 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134751 biolink:treats NCIT:C50624 PMID:41385096 "[{""id"":""uuid:3d7d7be1-d95e-4637-8bfb-0897cf2bac8a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:857c064f-3f00-4030-a452-3d97485ad1fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Uses -helps prevent sunburn -for skin that burns easily -provides moderate protection against sunburn -higher SPF gives more sunburn protection Directions -for external use only -when using this product keep out of eyes -rinse with water to remove -stop use and ask doctor if rash or irritation develops and lasts -keep out of reach of children -do not use on infants under 6 months of age uuid:d3c86340-1ee2-4f84-a017-fe70be6aaa9a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:421707 biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:239161a7-de1c-4821-a51d-757cfb4afce9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a06d4dee-5ce1-4fcc-abe6-2a465ae45ab8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:0db3e138-a51f-4176-96c3-b7fc2ff845c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ziagen""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZIAGEN Tablets and Oral Solution, in combination with other antiretroviral agents, are indicated for the treatment of human immunodeficiency virus (HIV-1) infection. Additional important information on the use of ZIAGEN for treatment of HIV-1 infection: ZIAGEN is one of multiple products containing abacavir. Before starting ZIAGEN, review medical history for prior exposure to any abacavir-containing product in order to avoid reintroduction in a patient with a history of hypersensitivity to abacavir.|[EMA] Ziagen is indicated in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infection in adults, adolescents and children.The demonstration of the benefit of Ziagen is mainly based on results of studies performed with a twice daily regimen, in treatment-naïve adult patients on combination therapy.Before initiating treatment with abacavir, screening for carriage of the HLA-B*5701 allele should be performed in any HIV-infected patient, irrespective of racial origin. Abacavir should not be used in patients known to carry the HLA-B*5701 allele. uuid:44665590-05f7-4fd2-9a2d-0b2e94bf2134 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15854 biolink:treats MONDO:0005920 PMID:41385096 "[{""id"":""uuid:a2a3977b-11d7-4f66-ab26-6c4ad9a8a5d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d831ca83-e1f8-4ce1-90c4-d04640d145b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] QUALAQUIN (quinine sulfate) is an antimalarial drug indicated only for treatment of uncomplicated Plasmodium falciparum malaria. Quinine sulfate has been shown to be effective in geographical regions where resistance to chloroquine has been documented [ see Clinical Studies (14) ]. QUALAQUIN oral capsules are not approved for: Treatment of severe or complicated P. falciparum malaria. Prevention of malaria. Treatment or prevention of nocturnal leg cramps [ see Warnings and Precautions (5.1) ]. uuid:a4660664-81e2-4f4e-bf8b-2612b5aabfb3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15854 biolink:treats UMLS:C0860058 PMID:41385096 "[{""id"":""uuid:dee353c2-a624-42d2-a190-be0e94271c88"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:21784d78-70db-4a1a-b8e4-9d6000576fdc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] QUALAQUIN (quinine sulfate) is an antimalarial drug indicated only for treatment of uncomplicated Plasmodium falciparum malaria. Quinine sulfate has been shown to be effective in geographical regions where resistance to chloroquine has been documented [ see Clinical Studies (14) ]. QUALAQUIN oral capsules are not approved for: Treatment of severe or complicated P. falciparum malaria. Prevention of malaria. Treatment or prevention of nocturnal leg cramps [ see Warnings and Precautions (5.1) ]. uuid:24fbda0c-0389-44bf-b93d-262b9724d7a6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29103 biolink:treats MONDO:0006919 PMID:41385096 "[{""id"":""uuid:52c58216-fd30-407d-b4fe-03c9f51cd964"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:39a2b2d4-93fe-41bf-aa47-ac1ee4948950"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Potassium Chloride for Injection Concentrate, USP is indicated in the treatment of potassium deficiency states when oral replacement is not feasible. uuid:c2b4eaad-0365-449f-9b52-16d735506b15 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6933 biolink:treats MONDO:0005469 PMID:41385096 "[{""id"":""uuid:7935117f-a616-43f0-bd62-c000ef00149b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d32e49d5-419f-4387-b9e1-0d6f4283045d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ProAmatine ® is indicated for the treatment of symptomatic orthostatic hypotension (OH). Because ProAmatine ® can cause marked elevation of supine blood pressure (BP>200 mmHg systolic), it should be used in patients whose lives are considerably impaired despite standard clinical care, including non-pharmacologic treatment (such as support stockings), fluid expansion, and lifestyle alterations. The indication is based on ProAmatine ® 's effect on increases in 1-minute standing systolic blood pressure, a surrogate marker considered likely to correspond to a clinical benefit. At present, however, clinical benefits of ProAmatine ® , principally improved ability to perform life activities, have not been established. Further clinical trials are underway to verify and describe the clinical benefits of ProAmatine ® . After initiation of treatment, ProAmatine ® should be continued only for patients who report significant symptomatic improvement. uuid:56f1c8c8-c894-46e9-921b-cda0197a7db9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8499 biolink:treats HP:0005115 PMID:41385096 "[{""id"":""uuid:cc7e23e0-3bed-466f-8397-c95f8a9296f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:55cacf39-f14b-4dd1-9ca7-a3832a075314"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cardiac Arrhythmias Intravenous administration is usually reserved for life-threatening arrhythmias or those occurring under anesthesia. Supraventricular arrhythmias Intravenous propranolol is indicated for the short-term treatment of supraventricular tachycardia, including Wolff-Parkinson-White syndrome and thyrotoxicosis, to decrease ventricular rate. Use in patients with atrial flutter or atrial fibrillation should be reserved for arrythmias unresponsive to standard therapy or when more prolonged control is required. Reversion to normal sinus rhythm has occasionally been observed, predominantly in patients with sinus or atrial tachycardia. Ventricular tachycardias With the exception of those induced by catecholamines or digitalis, propranolol is not the drug of first choice. In critical situations when cardioversion techniques or other drugs are not indicated or are not effective, propranolol may be considered. If, after consideration of the risks involved, propranolol is used, it should be given intravenously in low dosage and very slowly, as the failing heart requires some sympathetic drive for maintenance of myocardial tone. (See DOSAGE AND ADMINISTRATION ). Some patients may respond with complete reversion to normal sinus rhythm, but reduction in ventricular rate is more likely. Ventricular arrhythmias do not respond to propranolol as predictably as do the supraventricular arrhythmias. Intravenous propranolol is indicated for the treatment of persistent premature ventricular extrasystoles that impair the well-being of the patient and do not respond to conventional measures. Tachyarrhythmias of digitalis intoxication Intravenous propranolol is indicated to control ventricular rate in life-threatening digitalis-induced arrhythmias. Severe bradycardia may occur. (See OVERDOSAGE ). Resistant tachyarrhythmias due to excessive catecholamine action during anesthesia Intravenous propranolol is indicated to abolish tachyarrhythmias due to excessive catecholamine action during anesthesia when other measures fail. These arrhythmias may arise because of release of endogenous catecholamines or administration of catecholamines. All general inhalation anesthetics produce some degree of myocardial depression. Therefore, when propranolol is used to treat arrhythmias during anesthesia, it should be used with extreme caution, usually with constant monitoring of the ECG and central venous pressure. (See WARNINGS ). uuid:3864b3e9-bb7d-40b1-bd49-5d945825db06 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8499 biolink:treats MONDO:0005477 PMID:41385096 "[{""id"":""uuid:31fbea9c-be3f-4764-bc53-a582a16a6b61"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7e41c645-9257-4736-9207-4f036f0ba84b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cardiac Arrhythmias Intravenous administration is usually reserved for life-threatening arrhythmias or those occurring under anesthesia. Supraventricular arrhythmias Intravenous propranolol is indicated for the short-term treatment of supraventricular tachycardia, including Wolff-Parkinson-White syndrome and thyrotoxicosis, to decrease ventricular rate. Use in patients with atrial flutter or atrial fibrillation should be reserved for arrythmias unresponsive to standard therapy or when more prolonged control is required. Reversion to normal sinus rhythm has occasionally been observed, predominantly in patients with sinus or atrial tachycardia. Ventricular tachycardias With the exception of those induced by catecholamines or digitalis, propranolol is not the drug of first choice. In critical situations when cardioversion techniques or other drugs are not indicated or are not effective, propranolol may be considered. If, after consideration of the risks involved, propranolol is used, it should be given intravenously in low dosage and very slowly, as the failing heart requires some sympathetic drive for maintenance of myocardial tone. (See DOSAGE AND ADMINISTRATION ). Some patients may respond with complete reversion to normal sinus rhythm, but reduction in ventricular rate is more likely. Ventricular arrhythmias do not respond to propranolol as predictably as do the supraventricular arrhythmias. Intravenous propranolol is indicated for the treatment of persistent premature ventricular extrasystoles that impair the well-being of the patient and do not respond to conventional measures. Tachyarrhythmias of digitalis intoxication Intravenous propranolol is indicated to control ventricular rate in life-threatening digitalis-induced arrhythmias. Severe bradycardia may occur. (See OVERDOSAGE ). Resistant tachyarrhythmias due to excessive catecholamine action during anesthesia Intravenous propranolol is indicated to abolish tachyarrhythmias due to excessive catecholamine action during anesthesia when other measures fail. These arrhythmias may arise because of release of endogenous catecholamines or administration of catecholamines. All general inhalation anesthetics produce some degree of myocardial depression. Therefore, when propranolol is used to treat arrhythmias during anesthesia, it should be used with extreme caution, usually with constant monitoring of the ECG and central venous pressure. (See WARNINGS ). uuid:3cb2d2ca-56f3-445b-9878-0942d16e8915 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8499 biolink:treats MONDO:0017863 PMID:41385096 "[{""id"":""uuid:ce85ce6b-c54a-4238-b07b-cf28b15257ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e739c39b-52db-4ad0-b71b-3f323c59dd97"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cardiac Arrhythmias Intravenous administration is usually reserved for life-threatening arrhythmias or those occurring under anesthesia. Supraventricular arrhythmias Intravenous propranolol is indicated for the short-term treatment of supraventricular tachycardia, including Wolff-Parkinson-White syndrome and thyrotoxicosis, to decrease ventricular rate. Use in patients with atrial flutter or atrial fibrillation should be reserved for arrythmias unresponsive to standard therapy or when more prolonged control is required. Reversion to normal sinus rhythm has occasionally been observed, predominantly in patients with sinus or atrial tachycardia. Ventricular tachycardias With the exception of those induced by catecholamines or digitalis, propranolol is not the drug of first choice. In critical situations when cardioversion techniques or other drugs are not indicated or are not effective, propranolol may be considered. If, after consideration of the risks involved, propranolol is used, it should be given intravenously in low dosage and very slowly, as the failing heart requires some sympathetic drive for maintenance of myocardial tone. (See DOSAGE AND ADMINISTRATION ). Some patients may respond with complete reversion to normal sinus rhythm, but reduction in ventricular rate is more likely. Ventricular arrhythmias do not respond to propranolol as predictably as do the supraventricular arrhythmias. Intravenous propranolol is indicated for the treatment of persistent premature ventricular extrasystoles that impair the well-being of the patient and do not respond to conventional measures. Tachyarrhythmias of digitalis intoxication Intravenous propranolol is indicated to control ventricular rate in life-threatening digitalis-induced arrhythmias. Severe bradycardia may occur. (See OVERDOSAGE ). Resistant tachyarrhythmias due to excessive catecholamine action during anesthesia Intravenous propranolol is indicated to abolish tachyarrhythmias due to excessive catecholamine action during anesthesia when other measures fail. These arrhythmias may arise because of release of endogenous catecholamines or administration of catecholamines. All general inhalation anesthetics produce some degree of myocardial depression. Therefore, when propranolol is used to treat arrhythmias during anesthesia, it should be used with extreme caution, usually with constant monitoring of the ECG and central venous pressure. (See WARNINGS ). uuid:079a5cca-5cb6-4605-9cfa-c37be87dbe1d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8499 biolink:treats MONDO:0018493 PMID:41385096 "[{""id"":""uuid:70a04733-28e2-4aa3-b8c5-09552ed0ede0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6ab3553e-471f-489e-9a96-d1b088f0fa1a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cardiac Arrhythmias Intravenous administration is usually reserved for life-threatening arrhythmias or those occurring under anesthesia. Supraventricular arrhythmias Intravenous propranolol is indicated for the short-term treatment of supraventricular tachycardia, including Wolff-Parkinson-White syndrome and thyrotoxicosis, to decrease ventricular rate. Use in patients with atrial flutter or atrial fibrillation should be reserved for arrythmias unresponsive to standard therapy or when more prolonged control is required. Reversion to normal sinus rhythm has occasionally been observed, predominantly in patients with sinus or atrial tachycardia. Ventricular tachycardias With the exception of those induced by catecholamines or digitalis, propranolol is not the drug of first choice. In critical situations when cardioversion techniques or other drugs are not indicated or are not effective, propranolol may be considered. If, after consideration of the risks involved, propranolol is used, it should be given intravenously in low dosage and very slowly, as the failing heart requires some sympathetic drive for maintenance of myocardial tone. (See DOSAGE AND ADMINISTRATION ). Some patients may respond with complete reversion to normal sinus rhythm, but reduction in ventricular rate is more likely. Ventricular arrhythmias do not respond to propranolol as predictably as do the supraventricular arrhythmias. Intravenous propranolol is indicated for the treatment of persistent premature ventricular extrasystoles that impair the well-being of the patient and do not respond to conventional measures. Tachyarrhythmias of digitalis intoxication Intravenous propranolol is indicated to control ventricular rate in life-threatening digitalis-induced arrhythmias. Severe bradycardia may occur. (See OVERDOSAGE ). Resistant tachyarrhythmias due to excessive catecholamine action during anesthesia Intravenous propranolol is indicated to abolish tachyarrhythmias due to excessive catecholamine action during anesthesia when other measures fail. These arrhythmias may arise because of release of endogenous catecholamines or administration of catecholamines. All general inhalation anesthetics produce some degree of myocardial depression. Therefore, when propranolol is used to treat arrhythmias during anesthesia, it should be used with extreme caution, usually with constant monitoring of the ECG and central venous pressure. (See WARNINGS ). uuid:27965db7-fa9a-4a4f-931b-495011dc200e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8499 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:b0cc5413-c196-44cd-ac01-1894c2014e70"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:662f9b6f-716b-4e77-a561-29b584f613c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension Propranolol hydrochloride tablets are indicated in the management of hypertension. They may be used alone or used in combination with other antihypertensive agents, particularly a thiazide diuretic. Propranolol hydrochloride tablets are not indicated in the management of hypertensive emergencies. Angina Pectoris Due to Coronary Atherosclerosis Propranolol hydrochloride tablets are indicated to decrease angina frequency and increase exercise tolerance in patients with angina pectoris. Atrial Fibrillation Propranolol hydrochloride tablets are indicated to control ventricular rate in patients with atrial fibrillation and a rapid ventricular response. Myocardial Infarction Propranolol hydrochloride tablets are indicated to reduce cardiovascular mortality in patients who have survived the acute phase of myocardial infarction and are clinically stable. Migraine Propranolol hydrochloride tablets are indicated for the prophylaxis of common migraine headache. The efficacy of propranolol in the treatment of a migraine attack that has started has not been established, and propranolol is not indicated for such use. Essential Tremor Propranolol hydrochloride tablets are indicated in the management of familial or hereditary essential tremor. Familial or essential tremor consists of involuntary, rhythmic, oscillatory movements, usually limited to the upper limbs. It is absent at rest, but occurs when the limb is held in a fixed posture or position against gravity and during active movement. Propranolol hydrochloride tablets, USP causes a reduction in the tremor amplitude but not in the tremor frequency. Propranolol hydrochloride tablets are not indicated for the treatment of tremor associated with Parkinsonism. Hypertrophic Subaortic Stenosis Propranolol hydrochloride tablets improve NYHA functional class in symptomatic patients with hypertrophic subaortic stenosis. Pheochromocytoma Propranolol hydrochloride tablets are indicated as an adjunct to alpha-adrenergic blockade to control blood pressure and reduce symptoms of catecholamine-secreting tumors. uuid:892ff5ec-1f10-4c0b-9f1c-ea6ee72b93a4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8499 biolink:treats HP:0001681 PMID:41385096 "[{""id"":""uuid:a1f8a1f2-7bc5-4e1b-b1bd-f184df8c1757"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:740cbfcb-8238-46b0-913a-5341b68f999d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension Propranolol hydrochloride tablets are indicated in the management of hypertension. They may be used alone or used in combination with other antihypertensive agents, particularly a thiazide diuretic. Propranolol hydrochloride tablets are not indicated in the management of hypertensive emergencies. Angina Pectoris Due to Coronary Atherosclerosis Propranolol hydrochloride tablets are indicated to decrease angina frequency and increase exercise tolerance in patients with angina pectoris. Atrial Fibrillation Propranolol hydrochloride tablets are indicated to control ventricular rate in patients with atrial fibrillation and a rapid ventricular response. Myocardial Infarction Propranolol hydrochloride tablets are indicated to reduce cardiovascular mortality in patients who have survived the acute phase of myocardial infarction and are clinically stable. Migraine Propranolol hydrochloride tablets are indicated for the prophylaxis of common migraine headache. The efficacy of propranolol in the treatment of a migraine attack that has started has not been established, and propranolol is not indicated for such use. Essential Tremor Propranolol hydrochloride tablets are indicated in the management of familial or hereditary essential tremor. Familial or essential tremor consists of involuntary, rhythmic, oscillatory movements, usually limited to the upper limbs. It is absent at rest, but occurs when the limb is held in a fixed posture or position against gravity and during active movement. Propranolol hydrochloride tablets, USP causes a reduction in the tremor amplitude but not in the tremor frequency. Propranolol hydrochloride tablets are not indicated for the treatment of tremor associated with Parkinsonism. Hypertrophic Subaortic Stenosis Propranolol hydrochloride tablets improve NYHA functional class in symptomatic patients with hypertrophic subaortic stenosis. Pheochromocytoma Propranolol hydrochloride tablets are indicated as an adjunct to alpha-adrenergic blockade to control blood pressure and reduce symptoms of catecholamine-secreting tumors. uuid:59b7bbfb-3546-4b31-96c5-331bb47ceb04 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8499 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:5ea80553-bc94-4b39-9804-ef91b58bff47"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:abce36d0-6cff-4ed6-86a3-b20d5bf49240"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension Propranolol hydrochloride tablets are indicated in the management of hypertension. They may be used alone or used in combination with other antihypertensive agents, particularly a thiazide diuretic. Propranolol hydrochloride tablets are not indicated in the management of hypertensive emergencies. Angina Pectoris Due to Coronary Atherosclerosis Propranolol hydrochloride tablets are indicated to decrease angina frequency and increase exercise tolerance in patients with angina pectoris. Atrial Fibrillation Propranolol hydrochloride tablets are indicated to control ventricular rate in patients with atrial fibrillation and a rapid ventricular response. Myocardial Infarction Propranolol hydrochloride tablets are indicated to reduce cardiovascular mortality in patients who have survived the acute phase of myocardial infarction and are clinically stable. Migraine Propranolol hydrochloride tablets are indicated for the prophylaxis of common migraine headache. The efficacy of propranolol in the treatment of a migraine attack that has started has not been established, and propranolol is not indicated for such use. Essential Tremor Propranolol hydrochloride tablets are indicated in the management of familial or hereditary essential tremor. Familial or essential tremor consists of involuntary, rhythmic, oscillatory movements, usually limited to the upper limbs. It is absent at rest, but occurs when the limb is held in a fixed posture or position against gravity and during active movement. Propranolol hydrochloride tablets, USP causes a reduction in the tremor amplitude but not in the tremor frequency. Propranolol hydrochloride tablets are not indicated for the treatment of tremor associated with Parkinsonism. Hypertrophic Subaortic Stenosis Propranolol hydrochloride tablets improve NYHA functional class in symptomatic patients with hypertrophic subaortic stenosis. Pheochromocytoma Propranolol hydrochloride tablets are indicated as an adjunct to alpha-adrenergic blockade to control blood pressure and reduce symptoms of catecholamine-secreting tumors. uuid:c475bb1f-6628-49ff-a283-c4ef0cae85b0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8499 biolink:treats MONDO:0005277 PMID:41385096 "[{""id"":""uuid:41bddc4e-747e-4874-9668-45405c8dc2ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7a1f6947-fcd9-4e5d-9b89-844aafc650ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:596838b8-0f21-44e0-8d5d-a4586ab75e96"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension Propranolol hydrochloride tablets are indicated in the management of hypertension. They may be used alone or used in combination with other antihypertensive agents, particularly a thiazide diuretic. Propranolol hydrochloride tablets are not indicated in the management of hypertensive emergencies. Angina Pectoris Due to Coronary Atherosclerosis Propranolol hydrochloride tablets are indicated to decrease angina frequency and increase exercise tolerance in patients with angina pectoris. Atrial Fibrillation Propranolol hydrochloride tablets are indicated to control ventricular rate in patients with atrial fibrillation and a rapid ventricular response. Myocardial Infarction Propranolol hydrochloride tablets are indicated to reduce cardiovascular mortality in patients who have survived the acute phase of myocardial infarction and are clinically stable. Migraine Propranolol hydrochloride tablets are indicated for the prophylaxis of common migraine headache. The efficacy of propranolol in the treatment of a migraine attack that has started has not been established, and propranolol is not indicated for such use. Essential Tremor Propranolol hydrochloride tablets are indicated in the management of familial or hereditary essential tremor. Familial or essential tremor consists of involuntary, rhythmic, oscillatory movements, usually limited to the upper limbs. It is absent at rest, but occurs when the limb is held in a fixed posture or position against gravity and during active movement. Propranolol hydrochloride tablets, USP causes a reduction in the tremor amplitude but not in the tremor frequency. Propranolol hydrochloride tablets are not indicated for the treatment of tremor associated with Parkinsonism. Hypertrophic Subaortic Stenosis Propranolol hydrochloride tablets improve NYHA functional class in symptomatic patients with hypertrophic subaortic stenosis. Pheochromocytoma Propranolol hydrochloride tablets are indicated as an adjunct to alpha-adrenergic blockade to control blood pressure and reduce symptoms of catecholamine-secreting tumors.|[PMDA] Drugs with a new additional indication and a new dosage for the prevention of migraine attack. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:774758cd-82af-4b5e-8f43-604b544a7544 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8499 biolink:treats MONDO:0008590 PMID:41385096 "[{""id"":""uuid:2e0d30e5-3ad6-4109-a44e-d024e54201ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b403d752-37c1-4d0c-87eb-5ff843d1b12b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension Propranolol hydrochloride tablets are indicated in the management of hypertension. They may be used alone or used in combination with other antihypertensive agents, particularly a thiazide diuretic. Propranolol hydrochloride tablets are not indicated in the management of hypertensive emergencies. Angina Pectoris Due to Coronary Atherosclerosis Propranolol hydrochloride tablets are indicated to decrease angina frequency and increase exercise tolerance in patients with angina pectoris. Atrial Fibrillation Propranolol hydrochloride tablets are indicated to control ventricular rate in patients with atrial fibrillation and a rapid ventricular response. Myocardial Infarction Propranolol hydrochloride tablets are indicated to reduce cardiovascular mortality in patients who have survived the acute phase of myocardial infarction and are clinically stable. Migraine Propranolol hydrochloride tablets are indicated for the prophylaxis of common migraine headache. The efficacy of propranolol in the treatment of a migraine attack that has started has not been established, and propranolol is not indicated for such use. Essential Tremor Propranolol hydrochloride tablets are indicated in the management of familial or hereditary essential tremor. Familial or essential tremor consists of involuntary, rhythmic, oscillatory movements, usually limited to the upper limbs. It is absent at rest, but occurs when the limb is held in a fixed posture or position against gravity and during active movement. Propranolol hydrochloride tablets, USP causes a reduction in the tremor amplitude but not in the tremor frequency. Propranolol hydrochloride tablets are not indicated for the treatment of tremor associated with Parkinsonism. Hypertrophic Subaortic Stenosis Propranolol hydrochloride tablets improve NYHA functional class in symptomatic patients with hypertrophic subaortic stenosis. Pheochromocytoma Propranolol hydrochloride tablets are indicated as an adjunct to alpha-adrenergic blockade to control blood pressure and reduce symptoms of catecholamine-secreting tumors. uuid:cd93e9cd-a240-4eea-9255-1adec0714a36 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8499 biolink:treats MONDO:0008647 PMID:41385096 "[{""id"":""uuid:b07e42d5-1627-46b9-9986-c2326428952c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d757f513-8245-4fd1-9cde-eef8de7cab2d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension Propranolol hydrochloride tablets are indicated in the management of hypertension. They may be used alone or used in combination with other antihypertensive agents, particularly a thiazide diuretic. Propranolol hydrochloride tablets are not indicated in the management of hypertensive emergencies. Angina Pectoris Due to Coronary Atherosclerosis Propranolol hydrochloride tablets are indicated to decrease angina frequency and increase exercise tolerance in patients with angina pectoris. Atrial Fibrillation Propranolol hydrochloride tablets are indicated to control ventricular rate in patients with atrial fibrillation and a rapid ventricular response. Myocardial Infarction Propranolol hydrochloride tablets are indicated to reduce cardiovascular mortality in patients who have survived the acute phase of myocardial infarction and are clinically stable. Migraine Propranolol hydrochloride tablets are indicated for the prophylaxis of common migraine headache. The efficacy of propranolol in the treatment of a migraine attack that has started has not been established, and propranolol is not indicated for such use. Essential Tremor Propranolol hydrochloride tablets are indicated in the management of familial or hereditary essential tremor. Familial or essential tremor consists of involuntary, rhythmic, oscillatory movements, usually limited to the upper limbs. It is absent at rest, but occurs when the limb is held in a fixed posture or position against gravity and during active movement. Propranolol hydrochloride tablets, USP causes a reduction in the tremor amplitude but not in the tremor frequency. Propranolol hydrochloride tablets are not indicated for the treatment of tremor associated with Parkinsonism. Hypertrophic Subaortic Stenosis Propranolol hydrochloride tablets improve NYHA functional class in symptomatic patients with hypertrophic subaortic stenosis. Pheochromocytoma Propranolol hydrochloride tablets are indicated as an adjunct to alpha-adrenergic blockade to control blood pressure and reduce symptoms of catecholamine-secreting tumors. uuid:1475a6e0-9a8c-434a-a9bd-b48b44182137 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8499 biolink:treats MONDO:0008233 PMID:41385096 "[{""id"":""uuid:ac6055d8-7251-4982-aa5e-69163aefc6d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5387bbef-f9a6-477b-adf9-3811acdf8334"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension Propranolol hydrochloride tablets are indicated in the management of hypertension. They may be used alone or used in combination with other antihypertensive agents, particularly a thiazide diuretic. Propranolol hydrochloride tablets are not indicated in the management of hypertensive emergencies. Angina Pectoris Due to Coronary Atherosclerosis Propranolol hydrochloride tablets are indicated to decrease angina frequency and increase exercise tolerance in patients with angina pectoris. Atrial Fibrillation Propranolol hydrochloride tablets are indicated to control ventricular rate in patients with atrial fibrillation and a rapid ventricular response. Myocardial Infarction Propranolol hydrochloride tablets are indicated to reduce cardiovascular mortality in patients who have survived the acute phase of myocardial infarction and are clinically stable. Migraine Propranolol hydrochloride tablets are indicated for the prophylaxis of common migraine headache. The efficacy of propranolol in the treatment of a migraine attack that has started has not been established, and propranolol is not indicated for such use. Essential Tremor Propranolol hydrochloride tablets are indicated in the management of familial or hereditary essential tremor. Familial or essential tremor consists of involuntary, rhythmic, oscillatory movements, usually limited to the upper limbs. It is absent at rest, but occurs when the limb is held in a fixed posture or position against gravity and during active movement. Propranolol hydrochloride tablets, USP causes a reduction in the tremor amplitude but not in the tremor frequency. Propranolol hydrochloride tablets are not indicated for the treatment of tremor associated with Parkinsonism. Hypertrophic Subaortic Stenosis Propranolol hydrochloride tablets improve NYHA functional class in symptomatic patients with hypertrophic subaortic stenosis. Pheochromocytoma Propranolol hydrochloride tablets are indicated as an adjunct to alpha-adrenergic blockade to control blood pressure and reduce symptoms of catecholamine-secreting tumors. uuid:4af8ca34-3135-44ce-bedf-cd2a4d81c16d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:17276 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:7161a87b-d1e8-45d0-bef6-2a7123ae1637"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5f672ed9-c5c6-49dd-bb89-52a5b36428ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Spironolactone has been shown to be a tumorigen in chronic toxicity studies in rats (see PRECAUTIONS section). Spironolactone and hydrochlorothiazide tablets should be used only in those conditions described below. Unnecessary use of this drug should be avoided. Spironolactone and Hydrochlorothiazide Tablets are Indicated for: Edematous Conditions for Patients with: Congestive Heart Failure For the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures. The treatment of diuretic-induced hypokalemia in patients with congestive heart failure when other measures are considered inappropriate. The treatment of patients with congestive heart failure taking digitalis when other therapies are considered inadequate or inappropriate. Cirrhosis of the Liver Accompanied by Edema and/or Ascites Aldosterone levels may be exceptionally high in this condition. Spironolactone and hydrochlorothiazide tablets are indicated for maintenance therapy together with bed rest and the restriction of fluid and sodium. The Nephrotic Syndrome For nephrotic patients when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics do not provide an adequate response. Essential Hypertension For patients with essential hypertension in whom other measures are considered inadequate or inappropriate. In hypertensive patients for the treatment of a diuretic-induced hypokalemia when other measures are considered inappropriate. Usage in Pregnancy The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developing toxemia. Edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy. Spironolactone and hydrochlorothiazide tablets are indicated in pregnancy when edema is due to pathologic causes just as it is in the absence of pregnancy (however, see PRECAUTIONS: Pregnancy ). Dependent edema in pregnancy, resulting from restriction of venous return by the expanded uterus, is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is unsupported and unnecessary. There is hypervolemia during normal pregnancy which is not harmful to either the fetus or the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema, in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances, this edema may cause extreme discomfort which is not relieved by rest. In these cases, a short course of diuretics may provide relief and may be appropriate. uuid:41811550-d0a9-4afe-89b4-ab1babf76646 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:17276 biolink:treats MONDO:0005155 PMID:41385096 "[{""id"":""uuid:fd002ab2-19d9-42a0-9aaa-fb9a9e58bf83"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cfdc2c48-a1f9-4f57-9a84-d7b2d7ec61f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Spironolactone has been shown to be a tumorigen in chronic toxicity studies in rats (see PRECAUTIONS section). Spironolactone and hydrochlorothiazide tablets should be used only in those conditions described below. Unnecessary use of this drug should be avoided. Spironolactone and Hydrochlorothiazide Tablets are Indicated for: Edematous Conditions for Patients with: Congestive Heart Failure For the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures. The treatment of diuretic-induced hypokalemia in patients with congestive heart failure when other measures are considered inappropriate. The treatment of patients with congestive heart failure taking digitalis when other therapies are considered inadequate or inappropriate. Cirrhosis of the Liver Accompanied by Edema and/or Ascites Aldosterone levels may be exceptionally high in this condition. Spironolactone and hydrochlorothiazide tablets are indicated for maintenance therapy together with bed rest and the restriction of fluid and sodium. The Nephrotic Syndrome For nephrotic patients when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics do not provide an adequate response. Essential Hypertension For patients with essential hypertension in whom other measures are considered inadequate or inappropriate. In hypertensive patients for the treatment of a diuretic-induced hypokalemia when other measures are considered inappropriate. Usage in Pregnancy The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developing toxemia. Edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy. Spironolactone and hydrochlorothiazide tablets are indicated in pregnancy when edema is due to pathologic causes just as it is in the absence of pregnancy (however, see PRECAUTIONS: Pregnancy ). Dependent edema in pregnancy, resulting from restriction of venous return by the expanded uterus, is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is unsupported and unnecessary. There is hypervolemia during normal pregnancy which is not harmful to either the fetus or the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema, in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances, this edema may cause extreme discomfort which is not relieved by rest. In these cases, a short course of diuretics may provide relief and may be appropriate. uuid:f3be67f5-69d9-41cf-b9f8-7aac3c1c58a9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:17276 biolink:treats MONDO:0005377 PMID:41385096 "[{""id"":""uuid:1f981b66-02a9-4b52-aa9b-e43534260f25"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:02a80340-874f-4857-b91b-1fa5265bddbd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Spironolactone has been shown to be a tumorigen in chronic toxicity studies in rats (see PRECAUTIONS section). Spironolactone and hydrochlorothiazide tablets should be used only in those conditions described below. Unnecessary use of this drug should be avoided. Spironolactone and Hydrochlorothiazide Tablets are Indicated for: Edematous Conditions for Patients with: Congestive Heart Failure For the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures. The treatment of diuretic-induced hypokalemia in patients with congestive heart failure when other measures are considered inappropriate. The treatment of patients with congestive heart failure taking digitalis when other therapies are considered inadequate or inappropriate. Cirrhosis of the Liver Accompanied by Edema and/or Ascites Aldosterone levels may be exceptionally high in this condition. Spironolactone and hydrochlorothiazide tablets are indicated for maintenance therapy together with bed rest and the restriction of fluid and sodium. The Nephrotic Syndrome For nephrotic patients when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics do not provide an adequate response. Essential Hypertension For patients with essential hypertension in whom other measures are considered inadequate or inappropriate. In hypertensive patients for the treatment of a diuretic-induced hypokalemia when other measures are considered inappropriate. Usage in Pregnancy The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developing toxemia. Edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy. Spironolactone and hydrochlorothiazide tablets are indicated in pregnancy when edema is due to pathologic causes just as it is in the absence of pregnancy (however, see PRECAUTIONS: Pregnancy ). Dependent edema in pregnancy, resulting from restriction of venous return by the expanded uterus, is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is unsupported and unnecessary. There is hypervolemia during normal pregnancy which is not harmful to either the fetus or the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema, in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances, this edema may cause extreme discomfort which is not relieved by rest. In these cases, a short course of diuretics may provide relief and may be appropriate. uuid:5054277d-841d-41b3-8ddb-981eb207dfb1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:17276 biolink:treats MONDO:0001134 PMID:41385096 "[{""id"":""uuid:4c8426fc-a223-48af-8322-65dd2f5403a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:54ec516c-726d-43c6-8ae2-184921bd8b75"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Spironolactone has been shown to be a tumorigen in chronic toxicity studies in rats (see PRECAUTIONS section). Spironolactone and hydrochlorothiazide tablets should be used only in those conditions described below. Unnecessary use of this drug should be avoided. Spironolactone and Hydrochlorothiazide Tablets are Indicated for: Edematous Conditions for Patients with: Congestive Heart Failure For the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures. The treatment of diuretic-induced hypokalemia in patients with congestive heart failure when other measures are considered inappropriate. The treatment of patients with congestive heart failure taking digitalis when other therapies are considered inadequate or inappropriate. Cirrhosis of the Liver Accompanied by Edema and/or Ascites Aldosterone levels may be exceptionally high in this condition. Spironolactone and hydrochlorothiazide tablets are indicated for maintenance therapy together with bed rest and the restriction of fluid and sodium. The Nephrotic Syndrome For nephrotic patients when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics do not provide an adequate response. Essential Hypertension For patients with essential hypertension in whom other measures are considered inadequate or inappropriate. In hypertensive patients for the treatment of a diuretic-induced hypokalemia when other measures are considered inappropriate. Usage in Pregnancy The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developing toxemia. Edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy. Spironolactone and hydrochlorothiazide tablets are indicated in pregnancy when edema is due to pathologic causes just as it is in the absence of pregnancy (however, see PRECAUTIONS: Pregnancy ). Dependent edema in pregnancy, resulting from restriction of venous return by the expanded uterus, is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is unsupported and unnecessary. There is hypervolemia during normal pregnancy which is not harmful to either the fetus or the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema, in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances, this edema may cause extreme discomfort which is not relieved by rest. In these cases, a short course of diuretics may provide relief and may be appropriate. uuid:c6605eac-e34c-4894-a26a-893fa062952c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:17276 biolink:treats MONDO:0045048 PMID:41385096 "[{""id"":""uuid:832655c7-4b5b-41b6-b1b7-684d8da082b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b6a3b0b4-3c05-4af4-8ec7-48302c3d1b14"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Spironolactone has been shown to be a tumorigen in chronic toxicity studies in rats (see PRECAUTIONS section). Spironolactone and hydrochlorothiazide tablets should be used only in those conditions described below. Unnecessary use of this drug should be avoided. Spironolactone and Hydrochlorothiazide Tablets are Indicated for: Edematous Conditions for Patients with: Congestive Heart Failure For the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures. The treatment of diuretic-induced hypokalemia in patients with congestive heart failure when other measures are considered inappropriate. The treatment of patients with congestive heart failure taking digitalis when other therapies are considered inadequate or inappropriate. Cirrhosis of the Liver Accompanied by Edema and/or Ascites Aldosterone levels may be exceptionally high in this condition. Spironolactone and hydrochlorothiazide tablets are indicated for maintenance therapy together with bed rest and the restriction of fluid and sodium. The Nephrotic Syndrome For nephrotic patients when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics do not provide an adequate response. Essential Hypertension For patients with essential hypertension in whom other measures are considered inadequate or inappropriate. In hypertensive patients for the treatment of a diuretic-induced hypokalemia when other measures are considered inappropriate. Usage in Pregnancy The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developing toxemia. Edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy. Spironolactone and hydrochlorothiazide tablets are indicated in pregnancy when edema is due to pathologic causes just as it is in the absence of pregnancy (however, see PRECAUTIONS: Pregnancy ). Dependent edema in pregnancy, resulting from restriction of venous return by the expanded uterus, is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is unsupported and unnecessary. There is hypervolemia during normal pregnancy which is not harmful to either the fetus or the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema, in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances, this edema may cause extreme discomfort which is not relieved by rest. In these cases, a short course of diuretics may provide relief and may be appropriate. uuid:03698174-ab78-4f94-9ce3-46ec0f97015b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47381 biolink:treats UMLS:C0038045 PMID:41385096 "[{""id"":""uuid:311470d6-cc94-4a1c-b856-5c2f216efbf0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1fe5a99b-8e57-4c1c-a6aa-93be8434e078"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of Flector® Patch and other treatment options before deciding to use Flector® Patch. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Flector® Patch is indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions. uuid:97879a3a-87ff-4940-86b1-7f6d9e9bb1bd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47381 biolink:treats UMLS:C0009938 PMID:41385096 "[{""id"":""uuid:57b8c377-10e5-4e0d-b63a-a29286d71811"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fe677fa3-d09c-4eb4-99dd-3ec512ffc9bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of Flector® Patch and other treatment options before deciding to use Flector® Patch. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Flector® Patch is indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions. uuid:447d43ee-6edf-452f-96cd-78411b060dec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:453011 biolink:treats MONDO:0006626 PMID:41385096 "[{""id"":""uuid:02b8d051-d3fa-43ca-ade4-19b7b839ca74"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d90abfb9-e5fe-4f6e-92f3-ad899daf94d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] (To understand fully the indication for this product, please read the entire INDICATIONS AND USAGE section of the labeling.) Ciclopirox topical solution, 8% (nail lacquer), as a component of a comprehensive management program, is indicated as topical treatment in immunocompetent patients with mild to moderate onychomycosis of fingernails and toenails without lunula involvement, due to Trichophyton rubrum . The comprehensive management program includes removal of the unattached, infected nails as frequently as monthly, by a health care professional who has special competence in the diagnosis and treatment of nail disorders, including minor nail procedures. No studies have been conducted to determine whether ciclopirox might reduce the effectiveness of systemic antifungal agents for onychomycosis. Therefore, the concomitant use of 8% ciclopirox topical solution and systemic antifungal agents for onychomycosis, is not recommended. Ciclopirox topical solution, 8% (nail lacquer), should be used only under medical supervision as described above. The effectiveness and safety of ciclopirox topical solution, 8% (nail lacquer), in the following populations has not been studied. The clinical trials with use of ciclopirox topical solution, 8% (nail lacquer), excluded patients who: were pregnant or nursing, planned to become pregnant, had a history of immunosuppression (e.g., extensive, persistent, or unusual distribution of dermatomycoses, extensive seborrheic dermatitis, recent or recurring herpes zoster, or persistent herpes simplex), were HIV seropositive, received organ transplant, required medication to control epilepsy, were insulin dependent diabetics or had diabetic neuropathy. Patients with severe plantar (moccasin) tinea pedis were also excluded. The safety and efficacy of using ciclopirox topical solution, 8% (nail lacquer), daily for greater than 48 weeks have not been established. Clinical Trials Data The results of use of ciclopirox topical solution, 8% (nail lacquer), in treatment of onychomycosis of the toenail without lunula involvement were obtained from two double-blind, placebo-controlled studies conducted in the US. In these studies, patients with onychomycosis of the great toenails without lunula involvement were treated with ciclopirox topical solution, 8% (nail lacquer) in conjunction with monthly removal of the unattached, infected toenail by the investigator. Ciclopirox topical solution, 8% (nail lacquer), was applied for 48 weeks. At baseline, patients had 20 to 65% involvement of the target great toenail plate. Statistical significance was demonstrated in one of two studies for the endpoint “complete cure” (clear nail and negative mycology), and in two studies for the endpoint “almost clear” (≤ 10% nail involvement and negative mycology) at the end of study. These results are presented below. At Week 48 (plus Last Observation Carried Forward) for the Intent-to-Treat (ITT) Population Study 312 Study 313 Active Vehicle Active Vehicle CompleteCure* 6/110 (5.5%) 1/109 (0.9%) 10/118 (8.5%) 0/117 (0%) AlmostClear** 7/107 (6.5%) 1/108 (0.9%) 14/116 (12%) 1/115 (0.9%) Negative MycologyAlone*** 30/105 (29%) 12/106 (11%) 41/115 (36%) 10/114 (9%) * Clear nail and negative mycology ** ≤ 10% nail involvement and negative mycology *** Negative KOH and negative culture The summary of reported patient outcomes for the ITT population at 12 weeks following the end of treatment are presented below. Note that post-treatment efficacy assessments were scheduled only for patients who achieved a complete cure. Post-Treatment Week 12 Data for Patients Who Achieved Complete Cure at Week 48 Study 312 Study 313 Active Vehicle Active Vehicle Number of Treated Patients 112 111 119 118 Complete Cure at Week 48 6 1 10 0 Post-Treatment Week 12 Outcomes: Patients Missing All Week 12 Assessments 2 0 2 0 Patients with Week 12 Assessments 4 1 8 0 Complete Cure 3 1 4 0 Almost Clear 2* 1 1* 0 Negative Mycology 3 1 5 0 * Four patients (from studies 312 and 313) who were completely cured did not have post-treatment Week 12 planimetry data. uuid:7effe798-1258-4197-8f81-09dfcb9c25bf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:453011 biolink:treats MONDO:0005027 PMID:41385096 "[{""id"":""uuid:f5b0bd27-d365-4461-85be-72ca09ff07ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0f0eb571-b462-42c6-ba1e-db5eef5ddfc6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] (To understand fully the indication for this product, please read the entire INDICATIONS AND USAGE section of the labeling.) Ciclopirox topical solution, 8% (nail lacquer), as a component of a comprehensive management program, is indicated as topical treatment in immunocompetent patients with mild to moderate onychomycosis of fingernails and toenails without lunula involvement, due to Trichophyton rubrum . The comprehensive management program includes removal of the unattached, infected nails as frequently as monthly, by a health care professional who has special competence in the diagnosis and treatment of nail disorders, including minor nail procedures. No studies have been conducted to determine whether ciclopirox might reduce the effectiveness of systemic antifungal agents for onychomycosis. Therefore, the concomitant use of 8% ciclopirox topical solution and systemic antifungal agents for onychomycosis, is not recommended. Ciclopirox topical solution, 8% (nail lacquer), should be used only under medical supervision as described above. The effectiveness and safety of ciclopirox topical solution, 8% (nail lacquer), in the following populations has not been studied. The clinical trials with use of ciclopirox topical solution, 8% (nail lacquer), excluded patients who: were pregnant or nursing, planned to become pregnant, had a history of immunosuppression (e.g., extensive, persistent, or unusual distribution of dermatomycoses, extensive seborrheic dermatitis, recent or recurring herpes zoster, or persistent herpes simplex), were HIV seropositive, received organ transplant, required medication to control epilepsy, were insulin dependent diabetics or had diabetic neuropathy. Patients with severe plantar (moccasin) tinea pedis were also excluded. The safety and efficacy of using ciclopirox topical solution, 8% (nail lacquer), daily for greater than 48 weeks have not been established. Clinical Trials Data The results of use of ciclopirox topical solution, 8% (nail lacquer), in treatment of onychomycosis of the toenail without lunula involvement were obtained from two double-blind, placebo-controlled studies conducted in the US. In these studies, patients with onychomycosis of the great toenails without lunula involvement were treated with ciclopirox topical solution, 8% (nail lacquer) in conjunction with monthly removal of the unattached, infected toenail by the investigator. Ciclopirox topical solution, 8% (nail lacquer), was applied for 48 weeks. At baseline, patients had 20 to 65% involvement of the target great toenail plate. Statistical significance was demonstrated in one of two studies for the endpoint “complete cure” (clear nail and negative mycology), and in two studies for the endpoint “almost clear” (≤ 10% nail involvement and negative mycology) at the end of study. These results are presented below. At Week 48 (plus Last Observation Carried Forward) for the Intent-to-Treat (ITT) Population Study 312 Study 313 Active Vehicle Active Vehicle CompleteCure* 6/110 (5.5%) 1/109 (0.9%) 10/118 (8.5%) 0/117 (0%) AlmostClear** 7/107 (6.5%) 1/108 (0.9%) 14/116 (12%) 1/115 (0.9%) Negative MycologyAlone*** 30/105 (29%) 12/106 (11%) 41/115 (36%) 10/114 (9%) * Clear nail and negative mycology ** ≤ 10% nail involvement and negative mycology *** Negative KOH and negative culture The summary of reported patient outcomes for the ITT population at 12 weeks following the end of treatment are presented below. Note that post-treatment efficacy assessments were scheduled only for patients who achieved a complete cure. Post-Treatment Week 12 Data for Patients Who Achieved Complete Cure at Week 48 Study 312 Study 313 Active Vehicle Active Vehicle Number of Treated Patients 112 111 119 118 Complete Cure at Week 48 6 1 10 0 Post-Treatment Week 12 Outcomes: Patients Missing All Week 12 Assessments 2 0 2 0 Patients with Week 12 Assessments 4 1 8 0 Complete Cure 3 1 4 0 Almost Clear 2* 1 1* 0 Negative Mycology 3 1 5 0 * Four patients (from studies 312 and 313) who were completely cured did not have post-treatment Week 12 planimetry data. uuid:7bbd9490-e0a1-416b-a86a-f59388470210 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9649 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:db79d735-d674-4606-8815-b257802235dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0d2913b4-259b-4402-bb92-de32f4c60ce8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension: Trandolapril tablets are indicated for the treatment of hypertension. They may be used alone or in combination with other antihypertensive medication such as hydrochlorothiazide. In considering the use of trandolapril tablets, it should be noted that in controlled trials ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients. (See Warnings: Angioedema .) When using trandolapril tablets, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that trandolapril tablets do not have a similar risk. (See WARNINGS .) uuid:26ae7b13-8ad0-4a06-8c35-1a7470b88f23 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9649 biolink:treats MONDO:0010481 PMID:41385096 "[{""id"":""uuid:36ce09ce-eba2-4234-a25d-11a246ab561d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0184e8c8-4bed-495b-87ce-9d037adb89e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension: Trandolapril tablets are indicated for the treatment of hypertension. They may be used alone or in combination with other antihypertensive medication such as hydrochlorothiazide. In considering the use of trandolapril tablets, it should be noted that in controlled trials ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients. (See Warnings: Angioedema .) When using trandolapril tablets, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that trandolapril tablets do not have a similar risk. (See WARNINGS .) uuid:2e61140c-ad35-479c-8867-8718da08f703 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9649 biolink:treats MONDO:0001609 PMID:41385096 "[{""id"":""uuid:058249f6-5812-428b-8a78-a25b26b86cb3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9da92aa7-0c4d-49ef-9fbf-4580439ce358"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension: Trandolapril tablets are indicated for the treatment of hypertension. They may be used alone or in combination with other antihypertensive medication such as hydrochlorothiazide. In considering the use of trandolapril tablets, it should be noted that in controlled trials ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients. (See Warnings: Angioedema .) When using trandolapril tablets, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that trandolapril tablets do not have a similar risk. (See WARNINGS .) uuid:42eed0f6-05cb-45f2-9052-16a49de89da8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9649 biolink:treats MONDO:0001343 PMID:41385096 "[{""id"":""uuid:d482bc76-e14f-410c-93f2-a8c15e997b56"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:592a998a-ce70-460e-88c5-8be46545d7ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension: Trandolapril tablets are indicated for the treatment of hypertension. They may be used alone or in combination with other antihypertensive medication such as hydrochlorothiazide. In considering the use of trandolapril tablets, it should be noted that in controlled trials ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients. (See Warnings: Angioedema .) When using trandolapril tablets, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that trandolapril tablets do not have a similar risk. (See WARNINGS .) uuid:2a563e0f-0268-4199-b85f-db9f437068f1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats MONDO:0003799 PMID:41385096 "[{""id"":""uuid:70acf640-978b-4fd0-8a56-96187cae5e97"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9945efe6-ea79-4b71-945b-02df5d8df03c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gentamicin Sulfate Ophthalmic Ointment is indicated in the topical treatment of ocular bacterial infections, including conjunctivitis, keratitis, keratoconjunctivitis, corneal ulcers, blepharitis, blepharoconjunctivitis, acute meibomianitis, and dacryocystitis caused by susceptible strains of the following microorganisms: Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus pneumoniae, Enterobacter aerogenes, Escherichia coli, Haemophilus influenzae, Klebsiella pneumoniae, Neisseria gonorrhoeae, Pseudomonas aeruginosa, and Serratia marcescens. uuid:56f76028-2682-4b13-a96b-cee08d94197a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats MONDO:0003085 PMID:41385096 "[{""id"":""uuid:ec5ef87a-9450-46b2-aeac-6c60117d157a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bc0a6f34-4ab1-4607-8035-6d2c74b00a07"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gentamicin Sulfate Ophthalmic Ointment is indicated in the topical treatment of ocular bacterial infections, including conjunctivitis, keratitis, keratoconjunctivitis, corneal ulcers, blepharitis, blepharoconjunctivitis, acute meibomianitis, and dacryocystitis caused by susceptible strains of the following microorganisms: Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus pneumoniae, Enterobacter aerogenes, Escherichia coli, Haemophilus influenzae, Klebsiella pneumoniae, Neisseria gonorrhoeae, Pseudomonas aeruginosa, and Serratia marcescens. uuid:8718fa2d-5e2d-4f6a-aeed-4b7908714a58 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats MONDO:0004768 PMID:41385096 "[{""id"":""uuid:82af337a-b333-41de-aceb-013222845efc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3afeb249-1318-48ac-9fc8-905a3f4c1e7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gentamicin Sulfate Ophthalmic Ointment is indicated in the topical treatment of ocular bacterial infections, including conjunctivitis, keratitis, keratoconjunctivitis, corneal ulcers, blepharitis, blepharoconjunctivitis, acute meibomianitis, and dacryocystitis caused by susceptible strains of the following microorganisms: Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus pneumoniae, Enterobacter aerogenes, Escherichia coli, Haemophilus influenzae, Klebsiella pneumoniae, Neisseria gonorrhoeae, Pseudomonas aeruginosa, and Serratia marcescens. uuid:2a160415-2333-4919-ad93-8e524b03ab98 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats MONDO:0004577 PMID:41385096 "[{""id"":""uuid:8f955f1c-b201-49ff-942d-c94cfbf1f999"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:86267201-bf43-47fc-999d-232e454a965b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gentamicin Sulfate Ophthalmic Ointment is indicated in the topical treatment of ocular bacterial infections, including conjunctivitis, keratitis, keratoconjunctivitis, corneal ulcers, blepharitis, blepharoconjunctivitis, acute meibomianitis, and dacryocystitis caused by susceptible strains of the following microorganisms: Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus pneumoniae, Enterobacter aerogenes, Escherichia coli, Haemophilus influenzae, Klebsiella pneumoniae, Neisseria gonorrhoeae, Pseudomonas aeruginosa, and Serratia marcescens. uuid:12f93055-930e-47e3-ad13-3e1c7cf4b265 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats MONDO:0004785 PMID:41385096 "[{""id"":""uuid:2875c59c-79c6-4c2b-95df-2fa24eaed1f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:abee180d-921c-4a9c-89f5-45e73b7a61ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gentamicin Sulfate Ophthalmic Ointment is indicated in the topical treatment of ocular bacterial infections, including conjunctivitis, keratitis, keratoconjunctivitis, corneal ulcers, blepharitis, blepharoconjunctivitis, acute meibomianitis, and dacryocystitis caused by susceptible strains of the following microorganisms: Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus pneumoniae, Enterobacter aerogenes, Escherichia coli, Haemophilus influenzae, Klebsiella pneumoniae, Neisseria gonorrhoeae, Pseudomonas aeruginosa, and Serratia marcescens. uuid:e77ebb41-ac5e-4cdb-acd3-8713d31b6c9d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats MONDO:0002307 PMID:41385096 "[{""id"":""uuid:2b64988a-4b4b-4839-8abd-fa270708cb1a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:df390e3a-ecdf-46c1-8815-c0d7a3081012"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gentamicin Sulfate Ophthalmic Ointment is indicated in the topical treatment of ocular bacterial infections, including conjunctivitis, keratitis, keratoconjunctivitis, corneal ulcers, blepharitis, blepharoconjunctivitis, acute meibomianitis, and dacryocystitis caused by susceptible strains of the following microorganisms: Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus pneumoniae, Enterobacter aerogenes, Escherichia coli, Haemophilus influenzae, Klebsiella pneumoniae, Neisseria gonorrhoeae, Pseudomonas aeruginosa, and Serratia marcescens. uuid:e202fd42-8835-4322-8582-f039f7e98cae biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats MONDO:0004926 PMID:41385096 "[{""id"":""uuid:0a97b8be-06c6-4e7e-8a1e-539d646171ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:15134ec0-8349-4c7f-87bd-f64611baad81"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gentamicin Sulfate Ophthalmic Ointment is indicated in the topical treatment of ocular bacterial infections, including conjunctivitis, keratitis, keratoconjunctivitis, corneal ulcers, blepharitis, blepharoconjunctivitis, acute meibomianitis, and dacryocystitis caused by susceptible strains of the following microorganisms: Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus pneumoniae, Enterobacter aerogenes, Escherichia coli, Haemophilus influenzae, Klebsiella pneumoniae, Neisseria gonorrhoeae, Pseudomonas aeruginosa, and Serratia marcescens. uuid:f3f90c61-cd9a-4866-a714-6b9d8317c491 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8874 biolink:treats MONDO:0019977 PMID:41385096 "[{""id"":""uuid:0ded9c40-2bda-477e-a115-140a1163e660"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:97e39b0c-334c-4f93-9fed-45a4ad123964"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Exelon ® (rivastigmine tartrate) is indicated for the treatment of mild to moderate dementia of the Alzheimer's type. Exelon ® (rivastigmine tartrate) is indicated for the treatment of mild to moderate dementia associated with Parkinson’s disease. The dementia of Parkinson’s disease is purportedly characterized by impairments in executive function, memory retrieval, and attention in patients with an established diagnosis of Parkinson’s disease. The diagnosis of the dementia of Parkinson’s disease, however, can reliably be made in patients in whom a progressive dementia syndrome occurs (without the necessity to document the specific deficits described above) at least 2 years after a diagnosis of Parkinson’s disease has been made, and in whom other causes of dementia have been ruled out (see CLINICAL PHARMACOLOGY, Clinical Trial Data). uuid:0859a1f8-e757-4c42-95b8-ca6df381cb47 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8874 biolink:treats MONDO:0005180 PMID:41385096 "[{""id"":""uuid:c4e99b4b-8b1f-43d3-96ea-d2e9d73d2476"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:924698f7-6ee0-463c-9891-e6322feea6b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:39114fc4-fca1-4a56-994b-369ec7827800"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/prometax""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Exelon ® (rivastigmine tartrate) is indicated for the treatment of mild to moderate dementia of the Alzheimer's type. Exelon ® (rivastigmine tartrate) is indicated for the treatment of mild to moderate dementia associated with Parkinson’s disease. The dementia of Parkinson’s disease is purportedly characterized by impairments in executive function, memory retrieval, and attention in patients with an established diagnosis of Parkinson’s disease. The diagnosis of the dementia of Parkinson’s disease, however, can reliably be made in patients in whom a progressive dementia syndrome occurs (without the necessity to document the specific deficits described above) at least 2 years after a diagnosis of Parkinson’s disease has been made, and in whom other causes of dementia have been ruled out (see CLINICAL PHARMACOLOGY, Clinical Trial Data).|[EMA] Symptomatic treatment of mild to moderately severe Alzheimer's dementia.Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease. uuid:94697986-b9e0-46b4-a9d9-26e2fac533fb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:37941 biolink:treats MONDO:0000990 PMID:41385096 "[{""id"":""uuid:1013e814-f363-435c-92db-a812038d0b77"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a976d55c-771c-4602-b353-c4ae343dd421"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:2a0bb5bd-27d3-4f24-97bc-a6ccce523ddd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Plavix is a P2Y 12 platelet inhibitor indicated for: Acute coronary syndrome - For patients with non-ST-segment elevation ACS [unstable angina (UA)/non-ST-elevation myocardial infarction (NSTEMI)] including patients who are to be managed medically and those who are to be managed with coronary revascularization, Plavix has been shown to decrease the rate of a combined endpoint of cardiovascular death, myocardial infarction (MI), or stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or refractory ischemia. ( 1.1 ) - For patients with ST-elevation myocardial infarction (STEMI), Plavix has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction, or stroke. The benefit for patients who undergo primary PCI is unknown. ( 1.1 ) Recent myocardial infarction (MI), recent stroke, or established peripheral arterial disease. Plavix has been shown to reduce the combined endpoint of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death. ( 1.2 )|[PMDA] A new combination drug indicated for the treatment of ischemic heart diseases (acute coronary syndrome [unstable angina, non-ST-segment elevation myocardial infarction, ST-segment elevation myocardial infarction], stable angina, old myocardial infarction) to which percutaneous coronary intervention (PCI) is applicable. uuid:a1da9834-3fa5-4548-95ad-347bdb863619 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:37941 biolink:treats UMLS:C1998297 PMID:41385096 "[{""id"":""uuid:f226f7a1-6365-47ee-a157-88b70f8b77c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7b756b42-da93-4731-be8b-7b182714ce99"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Plavix is a P2Y 12 platelet inhibitor indicated for: Acute coronary syndrome - For patients with non-ST-segment elevation ACS [unstable angina (UA)/non-ST-elevation myocardial infarction (NSTEMI)] including patients who are to be managed medically and those who are to be managed with coronary revascularization, Plavix has been shown to decrease the rate of a combined endpoint of cardiovascular death, myocardial infarction (MI), or stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or refractory ischemia. ( 1.1 ) - For patients with ST-elevation myocardial infarction (STEMI), Plavix has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction, or stroke. The benefit for patients who undergo primary PCI is unknown. ( 1.1 ) Recent myocardial infarction (MI), recent stroke, or established peripheral arterial disease. Plavix has been shown to reduce the combined endpoint of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death. ( 1.2 ) uuid:874d1910-5c6c-402f-bfa3-d2976717083e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:37941 biolink:treats HP:0002140 PMID:41385096 "[{""id"":""uuid:bc7cd821-2429-41fb-a5a8-37d62990adef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ec606474-ea4a-44b8-9875-694c5e3cb979"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Plavix is a P2Y 12 platelet inhibitor indicated for: Acute coronary syndrome - For patients with non-ST-segment elevation ACS [unstable angina (UA)/non-ST-elevation myocardial infarction (NSTEMI)] including patients who are to be managed medically and those who are to be managed with coronary revascularization, Plavix has been shown to decrease the rate of a combined endpoint of cardiovascular death, myocardial infarction (MI), or stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or refractory ischemia. ( 1.1 ) - For patients with ST-elevation myocardial infarction (STEMI), Plavix has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction, or stroke. The benefit for patients who undergo primary PCI is unknown. ( 1.1 ) Recent myocardial infarction (MI), recent stroke, or established peripheral arterial disease. Plavix has been shown to reduce the combined endpoint of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death. ( 1.2 ) uuid:c3b53feb-4c54-474b-9dda-2edcd12eb102 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8389 biolink:treats MONDO:0018555 PMID:41385096 "[{""id"":""uuid:c6930531-7a73-42aa-a981-1894ac30a09e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eb5cd76a-9fc9-4791-9a5f-e0f9b8e6f4df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PREMARIN therapy is indicated in the: Treatment of moderate to severe vasomotor symptoms due to menopause. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. Treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. Treatment of breast cancer (for palliation only) in appropriately selected women and men with metastatic disease. Treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only). Prevention of postmenopausal osteoporosis. When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and for whom non-estrogen medications are not considered to be appropriate. (See CLINICAL STUDIES .) The mainstays for decreasing the risk of postmenopausal osteoporosis are weight-bearing exercise, adequate calcium and vitamin D intake, and when indicated, pharmacologic therapy. Postmenopausal women require an average of 1500 mg/day of elemental calcium. Therefore, when not contraindicated, calcium supplementation may be helpful for women with suboptimal dietary intake. Vitamin D supplementation of 400-800 IU/day may also be required to ensure adequate daily intake in postmenopausal women. uuid:6332d55b-3da6-440a-9917-f5eac4886351 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8389 biolink:treats MONDO:0005387 PMID:41385096 "[{""id"":""uuid:0bfd58ae-db00-4293-958e-e5108a26411d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:93e4c31a-8b6d-4d26-be4e-11c2e1e6f828"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PREMARIN therapy is indicated in the: Treatment of moderate to severe vasomotor symptoms due to menopause. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. Treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. Treatment of breast cancer (for palliation only) in appropriately selected women and men with metastatic disease. Treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only). Prevention of postmenopausal osteoporosis. When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and for whom non-estrogen medications are not considered to be appropriate. (See CLINICAL STUDIES .) The mainstays for decreasing the risk of postmenopausal osteoporosis are weight-bearing exercise, adequate calcium and vitamin D intake, and when indicated, pharmacologic therapy. Postmenopausal women require an average of 1500 mg/day of elemental calcium. Therefore, when not contraindicated, calcium supplementation may be helpful for women with suboptimal dietary intake. Vitamin D supplementation of 400-800 IU/day may also be required to ensure adequate daily intake in postmenopausal women. uuid:ede1df03-e014-424e-9d6a-64551edf4902 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8389 biolink:treats UMLS:C0278488 PMID:41385096 "[{""id"":""uuid:92b6b8be-8158-4c13-9cc6-f92e8cacd71e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:77ffe741-1532-4629-b724-8e03bbca9e75"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PREMARIN therapy is indicated in the: Treatment of moderate to severe vasomotor symptoms due to menopause. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. Treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. Treatment of breast cancer (for palliation only) in appropriately selected women and men with metastatic disease. Treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only). Prevention of postmenopausal osteoporosis. When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and for whom non-estrogen medications are not considered to be appropriate. (See CLINICAL STUDIES .) The mainstays for decreasing the risk of postmenopausal osteoporosis are weight-bearing exercise, adequate calcium and vitamin D intake, and when indicated, pharmacologic therapy. Postmenopausal women require an average of 1500 mg/day of elemental calcium. Therefore, when not contraindicated, calcium supplementation may be helpful for women with suboptimal dietary intake. Vitamin D supplementation of 400-800 IU/day may also be required to ensure adequate daily intake in postmenopausal women. uuid:6f64d6c2-8e23-45ed-9c41-51366ae6b4af biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8389 biolink:treats MONDO:0850353 PMID:41385096 "[{""id"":""uuid:54e6e80c-8260-4025-a338-22f011fb2b46"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5e1b296d-d06c-4162-b28e-17754b14e352"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PREMARIN therapy is indicated in the: Treatment of moderate to severe vasomotor symptoms due to menopause. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. Treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. Treatment of breast cancer (for palliation only) in appropriately selected women and men with metastatic disease. Treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only). Prevention of postmenopausal osteoporosis. When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and for whom non-estrogen medications are not considered to be appropriate. (See CLINICAL STUDIES .) The mainstays for decreasing the risk of postmenopausal osteoporosis are weight-bearing exercise, adequate calcium and vitamin D intake, and when indicated, pharmacologic therapy. Postmenopausal women require an average of 1500 mg/day of elemental calcium. Therefore, when not contraindicated, calcium supplementation may be helpful for women with suboptimal dietary intake. Vitamin D supplementation of 400-800 IU/day may also be required to ensure adequate daily intake in postmenopausal women. uuid:8f1e0a51-1ec1-44f4-bea6-fd8e15fdf6fc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8389 biolink:treats MONDO:0008159 PMID:41385096 "[{""id"":""uuid:cfef1162-f447-4a6b-8f20-eab243d3fc68"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:48b02d39-b708-4640-b60a-6a20447d93c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PREMARIN therapy is indicated in the: Treatment of moderate to severe vasomotor symptoms due to menopause. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. Treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. Treatment of breast cancer (for palliation only) in appropriately selected women and men with metastatic disease. Treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only). Prevention of postmenopausal osteoporosis. When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and for whom non-estrogen medications are not considered to be appropriate. (See CLINICAL STUDIES .) The mainstays for decreasing the risk of postmenopausal osteoporosis are weight-bearing exercise, adequate calcium and vitamin D intake, and when indicated, pharmacologic therapy. Postmenopausal women require an average of 1500 mg/day of elemental calcium. Therefore, when not contraindicated, calcium supplementation may be helpful for women with suboptimal dietary intake. Vitamin D supplementation of 400-800 IU/day may also be required to ensure adequate daily intake in postmenopausal women. uuid:1df62be0-573a-411f-afd2-fb388596af56 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16914 biolink:treats MONDO:0011438 PMID:41385096 "[{""id"":""uuid:9d1a54c7-9c05-46a1-880b-22bf6115a5dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6a859792-09f3-49bc-b304-872e465d7835"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Uses: -For the treatment of acne -Helps prevent new acne blemishes Directions -Cleanse skin thoroughly before applying -Apply to cotton pad and wipe over skin, avoiding eye area. uuid:b881e939-dcfa-458f-8947-533e6b333efa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9449 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:ed4c3d0e-f2de-4bc0-8cc6-b248753bf5bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5253d492-972a-4c74-9512-6fcb4c95b83f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Terbutaline sulfate is indicated for the prevention and reversal of bronchospasm in patients 12 years of age and older with asthma and reversible bronchospasm associated with bronchitis and emphysema. uuid:c48ace3a-cc21-480b-9c9d-66df3edfb468 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9449 biolink:treats MONDO:0003781 PMID:41385096 "[{""id"":""uuid:8482f43f-6a10-4505-8e24-d5941f0d5423"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4e51d461-0390-4f17-a1c9-e2660f48e35a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Terbutaline sulfate is indicated for the prevention and reversal of bronchospasm in patients 12 years of age and older with asthma and reversible bronchospasm associated with bronchitis and emphysema. uuid:a4736915-636c-41a2-8e8c-d47cb06f81e5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9449 biolink:treats MONDO:0004849 PMID:41385096 "[{""id"":""uuid:bd39941b-3c9d-4e86-9a18-9488b7a87f2c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a827bacd-4d6c-4588-a5b4-c2ad64b62f46"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Terbutaline sulfate is indicated for the prevention and reversal of bronchospasm in patients 12 years of age and older with asthma and reversible bronchospasm associated with bronchitis and emphysema. uuid:1a49dd7d-a30e-4a0b-9b92-bd0270f6ced8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4046 biolink:treats MONDO:0024332 PMID:41385096 "[{""id"":""uuid:bfcee535-658f-4a3c-9139-f1939eaff46e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:37dde03d-af05-48c5-bfe9-0b737d04d510"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Perennial and seasonal allergic rhinitis Vasomotor rhinitis Allergic conjunctivitis due to inhalant allergens and foods Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma Cold urticaria Dermatographism As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled. uuid:9a9f457a-bca4-4f38-856a-fd180708db0e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4046 biolink:treats MONDO:0005324 PMID:41385096 "[{""id"":""uuid:5e34043f-65d2-432e-994b-24db4545a500"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f9b7b495-e1da-4e68-bc63-451cbd7329ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Perennial and seasonal allergic rhinitis Vasomotor rhinitis Allergic conjunctivitis due to inhalant allergens and foods Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma Cold urticaria Dermatographism As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled. uuid:1be2bee3-c684-46c1-ad89-09bb3fdc3550 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4046 biolink:treats MONDO:0006004 PMID:41385096 "[{""id"":""uuid:0339e03f-a057-4084-9c16-046b615d352e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f3e139b1-ea50-4f1f-b3e9-bfaa8b353a4c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Perennial and seasonal allergic rhinitis Vasomotor rhinitis Allergic conjunctivitis due to inhalant allergens and foods Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma Cold urticaria Dermatographism As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled. uuid:320a8bc8-737f-401d-8b2b-73f92c50cb36 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4046 biolink:treats MONDO:0005492 PMID:41385096 "[{""id"":""uuid:7b5fdf02-7b4f-4cb5-8300-3b0be5b235f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ba94ce5c-5e81-4aa7-af76-d74da6e58911"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Perennial and seasonal allergic rhinitis Vasomotor rhinitis Allergic conjunctivitis due to inhalant allergens and foods Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma Cold urticaria Dermatographism As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled. uuid:34d11e75-9962-4c17-92e4-97f3b09705a4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4046 biolink:treats MONDO:0010481 PMID:41385096 "[{""id"":""uuid:60c8e37a-cd66-4526-8e15-3e64a8b30669"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8c0e541a-4213-46d3-b8a8-e994f94d23d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Perennial and seasonal allergic rhinitis Vasomotor rhinitis Allergic conjunctivitis due to inhalant allergens and foods Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma Cold urticaria Dermatographism As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled. uuid:61f12c2a-1dfa-4b60-ba86-3fbceafe2c92 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4046 biolink:treats MONDO:0022799 PMID:41385096 "[{""id"":""uuid:1c0517f2-e60d-4423-a6e9-877f78701936"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2403632d-ca35-4ca4-8208-68e6efeca10f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Perennial and seasonal allergic rhinitis Vasomotor rhinitis Allergic conjunctivitis due to inhalant allergens and foods Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma Cold urticaria Dermatographism As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled. uuid:8cc18ee0-2574-496f-b866-cb0aa0353905 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4046 biolink:treats MONDO:0007448 PMID:41385096 "[{""id"":""uuid:32f86749-9f9a-496e-b14e-a46b90de9691"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a71b468b-b6da-443a-b5db-b9f78074d026"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Perennial and seasonal allergic rhinitis Vasomotor rhinitis Allergic conjunctivitis due to inhalant allergens and foods Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma Cold urticaria Dermatographism As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled. uuid:78c0ef18-4b10-4799-85ea-cc7666c129ee biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4046 biolink:treats MONDO:0100053 PMID:41385096 "[{""id"":""uuid:8bd4d47a-2078-4a20-a500-0992150968b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:79cb9964-e4e5-4db4-8b52-fc1b81b28cca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Perennial and seasonal allergic rhinitis Vasomotor rhinitis Allergic conjunctivitis due to inhalant allergens and foods Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma Cold urticaria Dermatographism As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled. uuid:e4b05c5e-b8f7-4c2b-9ea9-f3044b061001 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63613 biolink:treats MONDO:0004951 PMID:41385096 "[{""id"":""uuid:dd55fd4c-36e2-4be1-a17b-4f566dba9735"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f9787d3d-f76d-47af-b1c2-105cf5b47483"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VIRAMUNE is indicated for use in combination with other antiretroviral agents for the treatment of HIV-1 infection. This indication is based on one principal clinical trial (BI 1090) that demonstrated prolonged suppression of HIV-1 RNA and two smaller supportive studies, one of which (BI 1046) is described below. Additional important information regarding the use of VIRAMUNE for the treatment of HIV-1 infection: Based on serious and life-threatening hepatotoxicity observed in controlled and uncontrolled studies, VIRAMUNE should not be initiated in adult females with CD4 + cell counts greater than 250 cells/mm 3 or in adult males with CD4 + cell counts greater than 400 cells/mm 3 unless the benefit outweighs the risk [ see Boxed Warning and Warnings and Precautions (5.1) ]. The 14-day lead-in period with VIRAMUNE 200 mg daily dosing has been demonstrated to reduce the frequency of rash [ see Dosage and Administration (2.4) and Warnings and Precautions (5.2) ]. If rash persists beyond the 14-day lead-in period, do not dose escalate to 200 mg twice daily. The 200 mg once-daily dosing regimen should not be continued beyond 28 days, at which point an alternative regimen should be sought. uuid:fb4e1125-fe44-4511-9b26-8f8756fce83d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6437 biolink:treats MONDO:0005027 PMID:41385096 "[{""id"":""uuid:95d7fe8c-2b76-4e8a-bffc-29611762e97c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e1dcfe1f-7251-4836-80c1-aed9432644fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:63c8cbc9-8edc-49e0-82a9-4c6d58b267a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/levetiracetam-sun""]},{""id"":""uuid:c107aa17-7c19-417d-b5a1-aa4bfde6023a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levetiracetam is indicated as adjunctive therapy in the treatment of partial onset seizures in adults and children 4 years of age and older with epilepsy.|[EMA] Levetiracetam Sun is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.Levetiracetam Sun is indicated as adjunctive therapy:in the treatment of partial-onset seizures with or without secondary generalisation in adults and children from four years of age with epilepsy;in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy;in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.Levetiracetam Sun concentrate is an alternative for patients when oral administration is temporarily not feasible.|[PMDA] A drug with a new route of administration indicated for use as an adjunctive therapy with other antiepileptic drugs to treat partial seizure (including secondary generalized seizure) in patients with epilepsy who have not responded sufficiently to other antiepileptic drugs. It is used as an alternative therapy for levetiracetam oral formulation in patients who are temporarily unable to be administered orally. uuid:921f54a8-317d-4058-a64a-7fc801e3427a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6437 biolink:treats HP:0007359 PMID:41385096 "[{""id"":""uuid:9342e97d-7668-47b4-bc8c-57801b4b6f86"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:560c59f9-22c0-43c6-9f19-8547e94a10a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:08e677b7-b95f-4e48-af28-2a96a47d2836"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/levetiracetam-sun""]},{""id"":""uuid:218d40fa-7e91-437a-8e0e-5fd8fd7b6af6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levetiracetam is indicated as adjunctive therapy in the treatment of partial onset seizures in adults and children 4 years of age and older with epilepsy.|[EMA] Levetiracetam Sun is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.Levetiracetam Sun is indicated as adjunctive therapy:in the treatment of partial-onset seizures with or without secondary generalisation in adults and children from four years of age with epilepsy;in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy;in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.Levetiracetam Sun concentrate is an alternative for patients when oral administration is temporarily not feasible.|[PMDA] A drug with a new additional pediatric dosage in an additional dosage form indicated for use as an adjunctive therapy with other antiepileptic drugs to treat partial seizures (including secondary generalized seizures) in patients with epilepsy who have not responded sufficiently to other antiepileptic drugs. uuid:c1754355-4acf-4ff4-8ae7-58adf3bbfd90 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats MONDO:0004592 PMID:41385096 "[{""id"":""uuid:469837bc-d634-4a85-b089-3c1d832d9dcd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e3d8d008-bdc7-4847-8a1b-e67706daa19a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Primary skin infections: Impetigo contagiosa, superficial folliculitis, ecthyma, furunculosis, sycosis barbae, and pyoderma gangrenosum. Secondary skin infections: Infectious eczematoid dermatitis, pustular acne, pustular psoriasis, infected seborrheic dermatitis, infected contact dermatitis (including poison ivy), infected excoriations, and bacterial super-infections of fungal or viral infections. Please Note: Gentamicin sulfate is a bactericidal agent that is not effective against viruses or fungi in skin infections. Gentamicin sulfate is useful in the treatment of infected skin cysts and certain other skin abscesses when preceded by incision and drainage to permit adequate contact between the antibiotic and the infecting bacteria. Good results have been obtained in the treatment of infected stasis and other skin ulcers , infected superficial burns, paronychia, infected insect bites and stings, infected lacerations and abrasions, and wounds from minor surgery. Patients sensitive to neomycin can be treated with gentamicin sulfate, although regular observation of patients sensitive to topical antibiotics is advisable when such patients are treated with any topical antibiotic. Gentamicin Sulfate Ointment helps retain moisture and has been useful in infection on dry eczematous or psoriatic skin. Gentamicin Sulfate Ointment may be used in children over one year of age as well as in adults. uuid:c0785246-0596-4b6a-89bb-721e32035c63 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats UMLS:C0302160 PMID:41385096 "[{""id"":""uuid:421a8e43-5280-4dd9-94a0-654a009eb5c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d30e5d0b-3d5d-409a-8645-f7e19b8c36d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Primary skin infections: Impetigo contagiosa, superficial folliculitis, ecthyma, furunculosis, sycosis barbae, and pyoderma gangrenosum. Secondary skin infections: Infectious eczematoid dermatitis, pustular acne, pustular psoriasis, infected seborrheic dermatitis, infected contact dermatitis (including poison ivy), infected excoriations, and bacterial super-infections of fungal or viral infections. Please Note: Gentamicin sulfate is a bactericidal agent that is not effective against viruses or fungi in skin infections. Gentamicin sulfate is useful in the treatment of infected skin cysts and certain other skin abscesses when preceded by incision and drainage to permit adequate contact between the antibiotic and the infecting bacteria. Good results have been obtained in the treatment of infected stasis and other skin ulcers , infected superficial burns, paronychia, infected insect bites and stings, infected lacerations and abrasions, and wounds from minor surgery. Patients sensitive to neomycin can be treated with gentamicin sulfate, although regular observation of patients sensitive to topical antibiotics is advisable when such patients are treated with any topical antibiotic. Gentamicin Sulfate Ointment helps retain moisture and has been useful in infection on dry eczematous or psoriatic skin. Gentamicin Sulfate Ointment may be used in children over one year of age as well as in adults. uuid:0b682a63-a026-419a-baaa-3c597a90aa1e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats MONDO:0001404 PMID:41385096 "[{""id"":""uuid:810f598f-f4ac-4974-a9f2-3bee37541867"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:633cd4d2-bcb4-4163-8add-23e395e0adf7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Primary skin infections: Impetigo contagiosa, superficial folliculitis, ecthyma, furunculosis, sycosis barbae, and pyoderma gangrenosum. Secondary skin infections: Infectious eczematoid dermatitis, pustular acne, pustular psoriasis, infected seborrheic dermatitis, infected contact dermatitis (including poison ivy), infected excoriations, and bacterial super-infections of fungal or viral infections. Please Note: Gentamicin sulfate is a bactericidal agent that is not effective against viruses or fungi in skin infections. Gentamicin sulfate is useful in the treatment of infected skin cysts and certain other skin abscesses when preceded by incision and drainage to permit adequate contact between the antibiotic and the infecting bacteria. Good results have been obtained in the treatment of infected stasis and other skin ulcers , infected superficial burns, paronychia, infected insect bites and stings, infected lacerations and abrasions, and wounds from minor surgery. Patients sensitive to neomycin can be treated with gentamicin sulfate, although regular observation of patients sensitive to topical antibiotics is advisable when such patients are treated with any topical antibiotic. Gentamicin Sulfate Ointment helps retain moisture and has been useful in infection on dry eczematous or psoriatic skin. Gentamicin Sulfate Ointment may be used in children over one year of age as well as in adults. uuid:dcca4aab-67cc-4648-bba0-2165a9955288 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats MONDO:0100595 PMID:41385096 "[{""id"":""uuid:be3c6605-4e16-4b41-9ae7-df1848c9087d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e6db0efb-78bf-4125-93ab-68c2e1f6e37d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Primary skin infections: Impetigo contagiosa, superficial folliculitis, ecthyma, furunculosis, sycosis barbae, and pyoderma gangrenosum. Secondary skin infections: Infectious eczematoid dermatitis, pustular acne, pustular psoriasis, infected seborrheic dermatitis, infected contact dermatitis (including poison ivy), infected excoriations, and bacterial super-infections of fungal or viral infections. Please Note: Gentamicin sulfate is a bactericidal agent that is not effective against viruses or fungi in skin infections. Gentamicin sulfate is useful in the treatment of infected skin cysts and certain other skin abscesses when preceded by incision and drainage to permit adequate contact between the antibiotic and the infecting bacteria. Good results have been obtained in the treatment of infected stasis and other skin ulcers , infected superficial burns, paronychia, infected insect bites and stings, infected lacerations and abrasions, and wounds from minor surgery. Patients sensitive to neomycin can be treated with gentamicin sulfate, although regular observation of patients sensitive to topical antibiotics is advisable when such patients are treated with any topical antibiotic. Gentamicin Sulfate Ointment helps retain moisture and has been useful in infection on dry eczematous or psoriatic skin. Gentamicin Sulfate Ointment may be used in children over one year of age as well as in adults. uuid:a0f0f2cf-4339-45ad-a315-43a25fe3b792 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats MONDO:1050000 PMID:41385096 "[{""id"":""uuid:c3fb96d8-d93a-4ca5-898a-0729e2fffcb0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6e24f10d-ed4a-4c4d-af3a-7e3b6818eef5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Primary skin infections: Impetigo contagiosa, superficial folliculitis, ecthyma, furunculosis, sycosis barbae, and pyoderma gangrenosum. Secondary skin infections: Infectious eczematoid dermatitis, pustular acne, pustular psoriasis, infected seborrheic dermatitis, infected contact dermatitis (including poison ivy), infected excoriations, and bacterial super-infections of fungal or viral infections. Please Note: Gentamicin sulfate is a bactericidal agent that is not effective against viruses or fungi in skin infections. Gentamicin sulfate is useful in the treatment of infected skin cysts and certain other skin abscesses when preceded by incision and drainage to permit adequate contact between the antibiotic and the infecting bacteria. Good results have been obtained in the treatment of infected stasis and other skin ulcers , infected superficial burns, paronychia, infected insect bites and stings, infected lacerations and abrasions, and wounds from minor surgery. Patients sensitive to neomycin can be treated with gentamicin sulfate, although regular observation of patients sensitive to topical antibiotics is advisable when such patients are treated with any topical antibiotic. Gentamicin Sulfate Ointment helps retain moisture and has been useful in infection on dry eczematous or psoriatic skin. Gentamicin Sulfate Ointment may be used in children over one year of age as well as in adults. uuid:cb233824-7c2e-4921-bf95-6c68fc8d4bef biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats MONDO:0018824 PMID:41385096 "[{""id"":""uuid:a56d9b74-776d-48f9-8319-8fefd4d0f6c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:01c9e545-6d0d-48b3-94e9-229b055ab416"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Primary skin infections: Impetigo contagiosa, superficial folliculitis, ecthyma, furunculosis, sycosis barbae, and pyoderma gangrenosum. Secondary skin infections: Infectious eczematoid dermatitis, pustular acne, pustular psoriasis, infected seborrheic dermatitis, infected contact dermatitis (including poison ivy), infected excoriations, and bacterial super-infections of fungal or viral infections. Please Note: Gentamicin sulfate is a bactericidal agent that is not effective against viruses or fungi in skin infections. Gentamicin sulfate is useful in the treatment of infected skin cysts and certain other skin abscesses when preceded by incision and drainage to permit adequate contact between the antibiotic and the infecting bacteria. Good results have been obtained in the treatment of infected stasis and other skin ulcers , infected superficial burns, paronychia, infected insect bites and stings, infected lacerations and abrasions, and wounds from minor surgery. Patients sensitive to neomycin can be treated with gentamicin sulfate, although regular observation of patients sensitive to topical antibiotics is advisable when such patients are treated with any topical antibiotic. Gentamicin Sulfate Ointment helps retain moisture and has been useful in infection on dry eczematous or psoriatic skin. Gentamicin Sulfate Ointment may be used in children over one year of age as well as in adults. uuid:db8c32d8-0eb8-48dd-bd43-bce290811221 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats UMLS:C0263443 PMID:41385096 "[{""id"":""uuid:a49b2c4a-fd37-4e99-b922-33a63842ff1e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cd768b28-2738-4bb5-b7fe-133cb5047bf2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Primary skin infections: Impetigo contagiosa, superficial folliculitis, ecthyma, furunculosis, sycosis barbae, and pyoderma gangrenosum. Secondary skin infections: Infectious eczematoid dermatitis, pustular acne, pustular psoriasis, infected seborrheic dermatitis, infected contact dermatitis (including poison ivy), infected excoriations, and bacterial super-infections of fungal or viral infections. Please Note: Gentamicin sulfate is a bactericidal agent that is not effective against viruses or fungi in skin infections. Gentamicin sulfate is useful in the treatment of infected skin cysts and certain other skin abscesses when preceded by incision and drainage to permit adequate contact between the antibiotic and the infecting bacteria. Good results have been obtained in the treatment of infected stasis and other skin ulcers , infected superficial burns, paronychia, infected insect bites and stings, infected lacerations and abrasions, and wounds from minor surgery. Patients sensitive to neomycin can be treated with gentamicin sulfate, although regular observation of patients sensitive to topical antibiotics is advisable when such patients are treated with any topical antibiotic. Gentamicin Sulfate Ointment helps retain moisture and has been useful in infection on dry eczematous or psoriatic skin. Gentamicin Sulfate Ointment may be used in children over one year of age as well as in adults. uuid:83287ffc-8fa7-4c61-8393-85a5f3c8393c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats MONDO:0022205 PMID:41385096 "[{""id"":""uuid:d656f52b-6f4d-441c-bf10-f52b1b6b1896"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:98bae1aa-fc0e-4750-812d-4d694858bc7c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Primary skin infections: Impetigo contagiosa, superficial folliculitis, ecthyma, furunculosis, sycosis barbae, and pyoderma gangrenosum. Secondary skin infections: Infectious eczematoid dermatitis, pustular acne, pustular psoriasis, infected seborrheic dermatitis, infected contact dermatitis (including poison ivy), infected excoriations, and bacterial super-infections of fungal or viral infections. Please Note: Gentamicin sulfate is a bactericidal agent that is not effective against viruses or fungi in skin infections. Gentamicin sulfate is useful in the treatment of infected skin cysts and certain other skin abscesses when preceded by incision and drainage to permit adequate contact between the antibiotic and the infecting bacteria. Good results have been obtained in the treatment of infected stasis and other skin ulcers , infected superficial burns, paronychia, infected insect bites and stings, infected lacerations and abrasions, and wounds from minor surgery. Patients sensitive to neomycin can be treated with gentamicin sulfate, although regular observation of patients sensitive to topical antibiotics is advisable when such patients are treated with any topical antibiotic. Gentamicin Sulfate Ointment helps retain moisture and has been useful in infection on dry eczematous or psoriatic skin. Gentamicin Sulfate Ointment may be used in children over one year of age as well as in adults. uuid:52a1636e-64e8-487e-ac93-e06a61816e79 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats MONDO:0006608 PMID:41385096 "[{""id"":""uuid:bcb67cd4-ace3-415e-9f72-fa419bdb0285"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a2a13e97-cfa0-4e18-9628-4829ba0c2cb0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Primary skin infections: Impetigo contagiosa, superficial folliculitis, ecthyma, furunculosis, sycosis barbae, and pyoderma gangrenosum. Secondary skin infections: Infectious eczematoid dermatitis, pustular acne, pustular psoriasis, infected seborrheic dermatitis, infected contact dermatitis (including poison ivy), infected excoriations, and bacterial super-infections of fungal or viral infections. Please Note: Gentamicin sulfate is a bactericidal agent that is not effective against viruses or fungi in skin infections. Gentamicin sulfate is useful in the treatment of infected skin cysts and certain other skin abscesses when preceded by incision and drainage to permit adequate contact between the antibiotic and the infecting bacteria. Good results have been obtained in the treatment of infected stasis and other skin ulcers , infected superficial burns, paronychia, infected insect bites and stings, infected lacerations and abrasions, and wounds from minor surgery. Patients sensitive to neomycin can be treated with gentamicin sulfate, although regular observation of patients sensitive to topical antibiotics is advisable when such patients are treated with any topical antibiotic. Gentamicin Sulfate Ointment helps retain moisture and has been useful in infection on dry eczematous or psoriatic skin. Gentamicin Sulfate Ointment may be used in children over one year of age as well as in adults. uuid:f9cc450a-df8d-4eac-a095-5006814a2c08 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats UMLS:C0162451 PMID:41385096 "[{""id"":""uuid:c16aa72d-7c93-4534-a033-80f90afc7d97"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1db06d67-1f1e-4377-9f59-e1d3477b389e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Primary skin infections: Impetigo contagiosa, superficial folliculitis, ecthyma, furunculosis, sycosis barbae, and pyoderma gangrenosum. Secondary skin infections: Infectious eczematoid dermatitis, pustular acne, pustular psoriasis, infected seborrheic dermatitis, infected contact dermatitis (including poison ivy), infected excoriations, and bacterial super-infections of fungal or viral infections. Please Note: Gentamicin sulfate is a bactericidal agent that is not effective against viruses or fungi in skin infections. Gentamicin sulfate is useful in the treatment of infected skin cysts and certain other skin abscesses when preceded by incision and drainage to permit adequate contact between the antibiotic and the infecting bacteria. Good results have been obtained in the treatment of infected stasis and other skin ulcers , infected superficial burns, paronychia, infected insect bites and stings, infected lacerations and abrasions, and wounds from minor surgery. Patients sensitive to neomycin can be treated with gentamicin sulfate, although regular observation of patients sensitive to topical antibiotics is advisable when such patients are treated with any topical antibiotic. Gentamicin Sulfate Ointment helps retain moisture and has been useful in infection on dry eczematous or psoriatic skin. Gentamicin Sulfate Ointment may be used in children over one year of age as well as in adults. uuid:642cac3f-5046-4b8d-b737-b534ee563114 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats HP:0031292 PMID:41385096 "[{""id"":""uuid:a8210a21-bb7f-411b-9e42-8cd9f5f61857"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0b08399a-a04b-402f-aecc-5e2d2f8a0fed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Primary skin infections: Impetigo contagiosa, superficial folliculitis, ecthyma, furunculosis, sycosis barbae, and pyoderma gangrenosum. Secondary skin infections: Infectious eczematoid dermatitis, pustular acne, pustular psoriasis, infected seborrheic dermatitis, infected contact dermatitis (including poison ivy), infected excoriations, and bacterial super-infections of fungal or viral infections. Please Note: Gentamicin sulfate is a bactericidal agent that is not effective against viruses or fungi in skin infections. Gentamicin sulfate is useful in the treatment of infected skin cysts and certain other skin abscesses when preceded by incision and drainage to permit adequate contact between the antibiotic and the infecting bacteria. Good results have been obtained in the treatment of infected stasis and other skin ulcers , infected superficial burns, paronychia, infected insect bites and stings, infected lacerations and abrasions, and wounds from minor surgery. Patients sensitive to neomycin can be treated with gentamicin sulfate, although regular observation of patients sensitive to topical antibiotics is advisable when such patients are treated with any topical antibiotic. Gentamicin Sulfate Ointment helps retain moisture and has been useful in infection on dry eczematous or psoriatic skin. Gentamicin Sulfate Ointment may be used in children over one year of age as well as in adults. uuid:a0dfa545-a8d9-4a99-9e13-3539e7b8cabd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats HP:0200042 PMID:41385096 "[{""id"":""uuid:852e33e1-a2ff-4fa8-8183-e0e0d7a11ece"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b8061832-e934-43fe-8075-517b99ad72ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Primary skin infections: Impetigo contagiosa, superficial folliculitis, ecthyma, furunculosis, sycosis barbae, and pyoderma gangrenosum. Secondary skin infections: Infectious eczematoid dermatitis, pustular acne, pustular psoriasis, infected seborrheic dermatitis, infected contact dermatitis (including poison ivy), infected excoriations, and bacterial super-infections of fungal or viral infections. Please Note: Gentamicin sulfate is a bactericidal agent that is not effective against viruses or fungi in skin infections. Gentamicin sulfate is useful in the treatment of infected skin cysts and certain other skin abscesses when preceded by incision and drainage to permit adequate contact between the antibiotic and the infecting bacteria. Good results have been obtained in the treatment of infected stasis and other skin ulcers , infected superficial burns, paronychia, infected insect bites and stings, infected lacerations and abrasions, and wounds from minor surgery. Patients sensitive to neomycin can be treated with gentamicin sulfate, although regular observation of patients sensitive to topical antibiotics is advisable when such patients are treated with any topical antibiotic. Gentamicin Sulfate Ointment helps retain moisture and has been useful in infection on dry eczematous or psoriatic skin. Gentamicin Sulfate Ointment may be used in children over one year of age as well as in adults. uuid:1e8f94d0-b01d-4c55-af73-d11a9402cae0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats MONDO:0005898 PMID:41385096 "[{""id"":""uuid:12e4e92c-108c-49ce-a719-be6e44127d9f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e41ee414-2090-4889-9053-07ed001cb4c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Primary skin infections: Impetigo contagiosa, superficial folliculitis, ecthyma, furunculosis, sycosis barbae, and pyoderma gangrenosum. Secondary skin infections: Infectious eczematoid dermatitis, pustular acne, pustular psoriasis, infected seborrheic dermatitis, infected contact dermatitis (including poison ivy), infected excoriations, and bacterial super-infections of fungal or viral infections. Please Note: Gentamicin sulfate is a bactericidal agent that is not effective against viruses or fungi in skin infections. Gentamicin sulfate is useful in the treatment of infected skin cysts and certain other skin abscesses when preceded by incision and drainage to permit adequate contact between the antibiotic and the infecting bacteria. Good results have been obtained in the treatment of infected stasis and other skin ulcers , infected superficial burns, paronychia, infected insect bites and stings, infected lacerations and abrasions, and wounds from minor surgery. Patients sensitive to neomycin can be treated with gentamicin sulfate, although regular observation of patients sensitive to topical antibiotics is advisable when such patients are treated with any topical antibiotic. Gentamicin Sulfate Ointment helps retain moisture and has been useful in infection on dry eczematous or psoriatic skin. Gentamicin Sulfate Ointment may be used in children over one year of age as well as in adults. uuid:1e8fafa0-f918-4c27-bcd0-dc6fb84872dd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:b57fc2e8-9e99-4b72-b63f-f0633b22a2db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b62f39dd-3504-408d-9756-1fc7c908eff6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Primary skin infections: Impetigo contagiosa, superficial folliculitis, ecthyma, furunculosis, sycosis barbae, and pyoderma gangrenosum. Secondary skin infections: Infectious eczematoid dermatitis, pustular acne, pustular psoriasis, infected seborrheic dermatitis, infected contact dermatitis (including poison ivy), infected excoriations, and bacterial super-infections of fungal or viral infections. Please Note: Gentamicin sulfate is a bactericidal agent that is not effective against viruses or fungi in skin infections. Gentamicin sulfate is useful in the treatment of infected skin cysts and certain other skin abscesses when preceded by incision and drainage to permit adequate contact between the antibiotic and the infecting bacteria. Good results have been obtained in the treatment of infected stasis and other skin ulcers , infected superficial burns, paronychia, infected insect bites and stings, infected lacerations and abrasions, and wounds from minor surgery. Patients sensitive to neomycin can be treated with gentamicin sulfate, although regular observation of patients sensitive to topical antibiotics is advisable when such patients are treated with any topical antibiotic. Gentamicin Sulfate Ointment helps retain moisture and has been useful in infection on dry eczematous or psoriatic skin. Gentamicin Sulfate Ointment may be used in children over one year of age as well as in adults. uuid:fe9bdfb3-0e85-4eed-8439-d837dcd09344 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10033 biolink:treats MONDO:0005279 PMID:41385096 "[{""id"":""uuid:72169281-0181-480a-b8d8-f1518e5cdcde"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1cecddbd-4601-4d26-8c3f-2d8952273059"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:966fdffe-ef01-4973-972d-235cf53bad39"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Warfarin sodium tablets, USP are indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, and pulmonary embolism. Warfarin sodium tablets, USP are indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement. Warfarin sodium tablets, USP are indicated to reduce the risk of death, recurrent myocardial infarction, and thromboembolic events such as stroke or systemic embolization after myocardial infarction.|[PMDA] Drugs with new additional pediatric dosages. These drugs are indicated for the treatment and prophylaxis of thromboembolism (e.g., phlebothrombosis, myocardial infarction, pulmonary embolism, brain embolism, slowly- progressive cerebral thrombosis). [Public knowledge-based application after PAFSC's preliminary assessment] uuid:07ab2080-b233-41f6-bfc5-9c09833a2b45 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10033 biolink:treats MONDO:0004981 PMID:41385096 "[{""id"":""uuid:a81231aa-fe11-44d7-bcf4-b683ee6095f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:698f8d53-d493-470f-bd11-b6af1980d713"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Warfarin sodium tablets, USP are indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, and pulmonary embolism. Warfarin sodium tablets, USP are indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement. Warfarin sodium tablets, USP are indicated to reduce the risk of death, recurrent myocardial infarction, and thromboembolic events such as stroke or systemic embolization after myocardial infarction. uuid:bbff7c7d-0eb3-4c39-bfac-d0d14511189c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10033 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:e386271a-cc22-492f-9564-e533ecb815d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aa525489-bcbf-42fd-8caf-d8dce6a047ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Warfarin sodium tablets, USP are indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, and pulmonary embolism. Warfarin sodium tablets, USP are indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement. Warfarin sodium tablets, USP are indicated to reduce the risk of death, recurrent myocardial infarction, and thromboembolic events such as stroke or systemic embolization after myocardial infarction. uuid:94b418ca-909f-481c-8f52-a2a684346c5d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10033 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:2944b4f4-86b1-48bc-a97a-1efcfc1e74af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:39c9b8de-b056-4d5e-8f0b-5ef4f1a1b685"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:816b05d8-e6e3-4d84-9f4f-a0d9958ddb94"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Warfarin sodium tablets, USP are indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, and pulmonary embolism. Warfarin sodium tablets, USP are indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement. Warfarin sodium tablets, USP are indicated to reduce the risk of death, recurrent myocardial infarction, and thromboembolic events such as stroke or systemic embolization after myocardial infarction.|[PMDA] Drugs with new additional pediatric dosages. These drugs are indicated for the treatment and prophylaxis of thromboembolism (e.g., phlebothrombosis, myocardial infarction, pulmonary embolism, brain embolism, slowly- progressive cerebral thrombosis). [Public knowledge-based application after PAFSC's preliminary assessment] uuid:f4475a84-5fbf-4d69-b6f0-13d35cbe6183 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:107736 biolink:treats UMLS:C0341117 PMID:41385096 "[{""id"":""uuid:06f80aaa-d5b9-4132-aa2f-ef31ba565674"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:922c2723-f94d-4976-a932-f4c900a95288"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Symptomatic Gastroesophageal Reflux: Metoclopramide tablets are indicated as short-term (4 to 12 weeks) therapy for adults with symptomatic, documented gastroesophageal reflux who fail to respond to conventional therapy. The principal effect of metoclopramide is on symptoms of postprandial and daytime heartburn with less observed effect on nocturnal symptoms. If symptoms are confined to particular situations, such as following the evening meal, use of metoclopramide as single doses prior to the provocative situation should be considered, rather than using the drug throughout the day. Healing of esophageal ulcers and erosions has been endoscopically demonstrated at the end of a 12-week trial using doses of 15 mg q.i.d. As there is no documented correlation between symptoms and healing of esophageal lesions, patients with documented lesions should be monitored endoscopically. Diabetic Gastroparesis (Diabetic Gastric Stasis): Metoclopramide is indicated for the relief of symptoms associated with acute and recurrent diabetic gastric stasis. The usual manifestations of delayed gastric emptying (e.g., nausea, vomiting, heartburn, persistent fullness after meals, and anorexia) appear to respond to metoclopramide within different time intervals. Significant relief of nausea occurs early and continues to improve over a three week period. Relief of vomiting and anorexia may precede the relief of abdominal fullness by one week or more. uuid:6f30d7ba-e7f2-4d46-a008-cd33ed023ed0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:107736 biolink:treats UMLS:C0267176 PMID:41385096 "[{""id"":""uuid:05e4cfd1-9825-4471-b1fb-7c47fc5f96c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ae196b88-6988-498c-a06f-d51a99ab6ffa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Symptomatic Gastroesophageal Reflux: Metoclopramide tablets are indicated as short-term (4 to 12 weeks) therapy for adults with symptomatic, documented gastroesophageal reflux who fail to respond to conventional therapy. The principal effect of metoclopramide is on symptoms of postprandial and daytime heartburn with less observed effect on nocturnal symptoms. If symptoms are confined to particular situations, such as following the evening meal, use of metoclopramide as single doses prior to the provocative situation should be considered, rather than using the drug throughout the day. Healing of esophageal ulcers and erosions has been endoscopically demonstrated at the end of a 12-week trial using doses of 15 mg q.i.d. As there is no documented correlation between symptoms and healing of esophageal lesions, patients with documented lesions should be monitored endoscopically. Diabetic Gastroparesis (Diabetic Gastric Stasis): Metoclopramide is indicated for the relief of symptoms associated with acute and recurrent diabetic gastric stasis. The usual manifestations of delayed gastric emptying (e.g., nausea, vomiting, heartburn, persistent fullness after meals, and anorexia) appear to respond to metoclopramide within different time intervals. Significant relief of nausea occurs early and continues to improve over a three week period. Relief of vomiting and anorexia may precede the relief of abdominal fullness by one week or more. uuid:53083dd3-a3cc-437c-a1bf-00065c8f9804 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:107736 biolink:treats MONDO:0006769 PMID:41385096 "[{""id"":""uuid:577e2b89-8f36-48b3-b24b-6bea6e56f9d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b34736ed-3330-4cb1-895a-7d501d861bcb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Symptomatic Gastroesophageal Reflux: Metoclopramide tablets are indicated as short-term (4 to 12 weeks) therapy for adults with symptomatic, documented gastroesophageal reflux who fail to respond to conventional therapy. The principal effect of metoclopramide is on symptoms of postprandial and daytime heartburn with less observed effect on nocturnal symptoms. If symptoms are confined to particular situations, such as following the evening meal, use of metoclopramide as single doses prior to the provocative situation should be considered, rather than using the drug throughout the day. Healing of esophageal ulcers and erosions has been endoscopically demonstrated at the end of a 12-week trial using doses of 15 mg q.i.d. As there is no documented correlation between symptoms and healing of esophageal lesions, patients with documented lesions should be monitored endoscopically. Diabetic Gastroparesis (Diabetic Gastric Stasis): Metoclopramide is indicated for the relief of symptoms associated with acute and recurrent diabetic gastric stasis. The usual manifestations of delayed gastric emptying (e.g., nausea, vomiting, heartburn, persistent fullness after meals, and anorexia) appear to respond to metoclopramide within different time intervals. Significant relief of nausea occurs early and continues to improve over a three week period. Relief of vomiting and anorexia may precede the relief of abdominal fullness by one week or more. uuid:7ccfe711-a431-4ef3-979b-9e988b9bf533 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9352 biolink:treats UMLS:C0410022 PMID:41385096 "[{""id"":""uuid:7d583fc8-f8f9-4795-8365-6fdb0bc21408"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:31a66e38-3993-4b9f-9cc8-f0e7564668f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of sulindac tablets and other treatment options before deciding to use sulindac tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Sulindac tablets are indicated for acute or long-term use in the relief of signs and symptoms of the following: Osteoarthritis Rheumatoid arthritis The safety and effectiveness of sulindac tablets have not been established in rheumatoid arthritis patients who are designated in the American Rheumatism Association classification as Functional Class IV (incapacitated, largely or wholly bedridden, or confined to wheelchair; little or no self-care). Ankylosing spondylitis Acute painful shoulder (Acute subacromial bursitis/supraspinatus tendinitis) Acute gouty arthritis uuid:eb954847-7f4e-4ccb-a41a-fee1a9ec93fe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:48390 biolink:treats MONDO:0006964 PMID:41385096 "[{""id"":""uuid:0c4a1abf-99b5-4781-8bb3-3ab84d563bdc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:97e55dcc-8f91-441f-aaec-5459acec7a68"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:4cab64d5-28cb-4ad7-86ab-416e8cda3ecf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c2d1162d-0a59-4233-aded-b0e015fe3a27"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sensipar ® is indicated for the treatment of secondary hyperparathyroidism in patients with Chronic Kidney Disease on dialysis. Sensipar ® is indicated for the treatment of hypercalcemia in patients with parathyroid carcinoma.|[EMA] Secondary hyperparathyroidismAdultsTreatment of secondary hyperparathyroidism (HPT) in adult patients with end-stage renal disease (ESRD) on maintenance dialysis therapy.Paediatric populationTreatment of secondary hyperparathyroidism (HPT) in children aged 3 years and older with end-stage renal disease (ESRD) on maintenance dialysis therapy in whom secondary HPT is not adequately controlled with standard of care therapy (see section 4.4).Cinacalcet Accordpharma may be used as part of a therapeutic regimen including phosphate binders and/or Vitamin D sterols, as appropriate (see section 5.1).Parathyroid carcinoma and primary hyperparathyroidism in adultsReduction of hypercalcaemia in adult patients with:parathyroid carcinoma.primary HPT for whom parathyroidectomy would be indicated on the basis of serum calcium levels (as defined by relevant treatment guidelines), but in whom parathyroidectomy is not clinically appropriate or is contraindicated.|[PMDA] A drug containing a new active ingredient indicated for the treatment of secondary hyperparathyroidism in patients on maintenance dialysis. uuid:ac52b244-0f0f-4ea1-9ef7-f72b982025b4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:48390 biolink:treats MONDO:0001566 PMID:41385096 "[{""id"":""uuid:96792ba3-461a-432e-9f71-ad4b5e74eaad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:fb590169-9523-4401-89c7-18ec96f3c631"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c5998e17-2e8c-4a3f-ab45-2c9f4c1bf76b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:1012bb2e-7182-48f4-a8bf-d7b62d7667b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sensipar ® is indicated for the treatment of secondary hyperparathyroidism in patients with Chronic Kidney Disease on dialysis. Sensipar ® is indicated for the treatment of hypercalcemia in patients with parathyroid carcinoma.|[EMA] Treatment of secondary hyperparathyroidism (HPT) in patients with end-stage renal disease (ESRD) on maintenance dialysis therapy.Cinacalcet Mylan may be used as part of a therapeutic regimen including phosphate binders and/or vitamin D sterols, as appropriate.Reduction of hypercalcaemia in patients with:parathyroid carcinomaprimary HPT for whom parathyroidectomywould be indicated on the basis of serum calcium levels (as defined by relevant treatment guidelines), but in whom parathyroidectomy is not clinically appropriate or is contraindicated.|[PMDA] Drugs with a new additional indication and a new dosage for the treatment of hypercalcemia in patients with parathyroid carcinoma, and hypercalcemia in patients with primary hyperparathyroidism (HPT) who are unable to undergo parathyroidectomy or who experience recurrent primary HPT after the surgery. [Orphan drug] uuid:5fac5a33-d062-4203-8f3b-b0b1726fb4ff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6722 biolink:treats MONDO:0006256 PMID:41385096 "[{""id"":""uuid:31d553d8-71f3-4b37-8033-5df488306fb9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:df236a91-4ac8-4877-aeac-f15ce23cbb20"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Megestrol acetate tablets are indicated for the palliative treatment of advanced carcinoma of the breast or endometrium (i.e., recurrent, inoperable, or metastatic disease). It should not be used in lieu of currently accepted procedures such as surgery, radiation, or chemotherapy. uuid:395f7fe5-9f91-4ce2-9617-11cf77540cb0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6722 biolink:treats MONDO:0002447 PMID:41385096 "[{""id"":""uuid:1f87f40b-5924-4d76-9d09-95ffabfeacd9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:72e42889-aefb-409f-8fb2-97655cf4db42"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Megestrol acetate tablets are indicated for the palliative treatment of advanced carcinoma of the breast or endometrium (i.e., recurrent, inoperable, or metastatic disease). It should not be used in lieu of currently accepted procedures such as surgery, radiation, or chemotherapy. uuid:e3d1078d-038c-4342-99c8-67aa9d9cd9b9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27779 biolink:treats MONDO:0001461 PMID:41385096 "[{""id"":""uuid:6455046f-f4d1-4dd3-91d5-9636e73c53ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:96ffed12-e336-413e-9cbb-5c327f5881e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gris-PEG ® (griseofulvin ultramicrosize) is indicated for the treatment of the following ringworm infections; tinea corporis (ringworm of the body), tinea pedis (athlete's foot), tinea cruris (ringworm of the groin and thigh), tinea barbae (barber's itch), tinea capitis (ringworm of the scalp), and tinea unguium (onychomycosis, ringworm of the nails), when caused by one or more of the following genera of fungi: Trichophyton rubrum, Trichophyton tonsurans, Trichophyton mentagrophytes, Trichophyton interdigitalis,Trichophyton verrucosum, Trichophyton megnini, Trichophyton gallinae, Trichophyton crateriform, Trichophyton sulphureum, Trichophyton schoenleini, Microsporum audouini, Microsporum canis, Microsporum gypseum and Epidermophyton floccosum . NOTE: Prior to therapy, the type of fungi responsible for the infection should be identified. The use of the drug is not justified in minor or trivial infections which will respond to topical agents alone. Griseofulvin is not effective in the following: bacterial infections, candidiasis (moniliasis), histoplasmosis, actinomycosis, sporotrichosis, chromoblastomycosis, coccidioidomycosis, North American blastomycosis, cryptococcosis (torulosis), tinea versicolor and nocardiosis. uuid:f02baa4f-9ac8-405d-89db-2a12fd3b50a6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27779 biolink:treats MONDO:0005984 PMID:41385096 "[{""id"":""uuid:1b8c431d-3a39-4de1-894f-cdde7b664c49"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:db02dba5-4e1f-4d4a-8441-44730613c088"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gris-PEG ® (griseofulvin ultramicrosize) is indicated for the treatment of the following ringworm infections; tinea corporis (ringworm of the body), tinea pedis (athlete's foot), tinea cruris (ringworm of the groin and thigh), tinea barbae (barber's itch), tinea capitis (ringworm of the scalp), and tinea unguium (onychomycosis, ringworm of the nails), when caused by one or more of the following genera of fungi: Trichophyton rubrum, Trichophyton tonsurans, Trichophyton mentagrophytes, Trichophyton interdigitalis,Trichophyton verrucosum, Trichophyton megnini, Trichophyton gallinae, Trichophyton crateriform, Trichophyton sulphureum, Trichophyton schoenleini, Microsporum audouini, Microsporum canis, Microsporum gypseum and Epidermophyton floccosum . NOTE: Prior to therapy, the type of fungi responsible for the infection should be identified. The use of the drug is not justified in minor or trivial infections which will respond to topical agents alone. Griseofulvin is not effective in the following: bacterial infections, candidiasis (moniliasis), histoplasmosis, actinomycosis, sporotrichosis, chromoblastomycosis, coccidioidomycosis, North American blastomycosis, cryptococcosis (torulosis), tinea versicolor and nocardiosis. uuid:be06d51b-ef28-49a8-99d6-c27bce4db646 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27779 biolink:treats MONDO:0001405 PMID:41385096 "[{""id"":""uuid:ed6b1cbf-a6bd-412a-b769-c8bfd80f0949"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:000abf85-f4bc-4676-9fa3-d8db023120e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gris-PEG ® (griseofulvin ultramicrosize) is indicated for the treatment of the following ringworm infections; tinea corporis (ringworm of the body), tinea pedis (athlete's foot), tinea cruris (ringworm of the groin and thigh), tinea barbae (barber's itch), tinea capitis (ringworm of the scalp), and tinea unguium (onychomycosis, ringworm of the nails), when caused by one or more of the following genera of fungi: Trichophyton rubrum, Trichophyton tonsurans, Trichophyton mentagrophytes, Trichophyton interdigitalis,Trichophyton verrucosum, Trichophyton megnini, Trichophyton gallinae, Trichophyton crateriform, Trichophyton sulphureum, Trichophyton schoenleini, Microsporum audouini, Microsporum canis, Microsporum gypseum and Epidermophyton floccosum . NOTE: Prior to therapy, the type of fungi responsible for the infection should be identified. The use of the drug is not justified in minor or trivial infections which will respond to topical agents alone. Griseofulvin is not effective in the following: bacterial infections, candidiasis (moniliasis), histoplasmosis, actinomycosis, sporotrichosis, chromoblastomycosis, coccidioidomycosis, North American blastomycosis, cryptococcosis (torulosis), tinea versicolor and nocardiosis. uuid:f89ddcf8-34d2-47f1-ae69-bb2e6d5d2a89 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27779 biolink:treats MONDO:0000242 PMID:41385096 "[{""id"":""uuid:006c535b-c7c4-4b91-9c69-b71a24a4daf1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:979d4e63-8e3f-4856-99aa-42bea1faa9a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gris-PEG ® (griseofulvin ultramicrosize) is indicated for the treatment of the following ringworm infections; tinea corporis (ringworm of the body), tinea pedis (athlete's foot), tinea cruris (ringworm of the groin and thigh), tinea barbae (barber's itch), tinea capitis (ringworm of the scalp), and tinea unguium (onychomycosis, ringworm of the nails), when caused by one or more of the following genera of fungi: Trichophyton rubrum, Trichophyton tonsurans, Trichophyton mentagrophytes, Trichophyton interdigitalis,Trichophyton verrucosum, Trichophyton megnini, Trichophyton gallinae, Trichophyton crateriform, Trichophyton sulphureum, Trichophyton schoenleini, Microsporum audouini, Microsporum canis, Microsporum gypseum and Epidermophyton floccosum . NOTE: Prior to therapy, the type of fungi responsible for the infection should be identified. The use of the drug is not justified in minor or trivial infections which will respond to topical agents alone. Griseofulvin is not effective in the following: bacterial infections, candidiasis (moniliasis), histoplasmosis, actinomycosis, sporotrichosis, chromoblastomycosis, coccidioidomycosis, North American blastomycosis, cryptococcosis (torulosis), tinea versicolor and nocardiosis. uuid:bd45f077-fa36-4b21-b20a-ef6a2ccb94a0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27779 biolink:treats MONDO:0002967 PMID:41385096 "[{""id"":""uuid:b3dc4e35-e92e-4285-86d7-c40ab57c6c77"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d992f077-5808-40c2-bdff-1fdcd8855be0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gris-PEG ® (griseofulvin ultramicrosize) is indicated for the treatment of the following ringworm infections; tinea corporis (ringworm of the body), tinea pedis (athlete's foot), tinea cruris (ringworm of the groin and thigh), tinea barbae (barber's itch), tinea capitis (ringworm of the scalp), and tinea unguium (onychomycosis, ringworm of the nails), when caused by one or more of the following genera of fungi: Trichophyton rubrum, Trichophyton tonsurans, Trichophyton mentagrophytes, Trichophyton interdigitalis,Trichophyton verrucosum, Trichophyton megnini, Trichophyton gallinae, Trichophyton crateriform, Trichophyton sulphureum, Trichophyton schoenleini, Microsporum audouini, Microsporum canis, Microsporum gypseum and Epidermophyton floccosum . NOTE: Prior to therapy, the type of fungi responsible for the infection should be identified. The use of the drug is not justified in minor or trivial infections which will respond to topical agents alone. Griseofulvin is not effective in the following: bacterial infections, candidiasis (moniliasis), histoplasmosis, actinomycosis, sporotrichosis, chromoblastomycosis, coccidioidomycosis, North American blastomycosis, cryptococcosis (torulosis), tinea versicolor and nocardiosis. uuid:0117a2aa-dffc-4a16-ad60-03f39dfd931e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27779 biolink:treats MONDO:0001628 PMID:41385096 "[{""id"":""uuid:8e96ac55-ade6-43d1-8e41-d739a825d6b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bccf9899-b431-42ed-b0bf-b6c7fcef2598"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gris-PEG ® (griseofulvin ultramicrosize) is indicated for the treatment of the following ringworm infections; tinea corporis (ringworm of the body), tinea pedis (athlete's foot), tinea cruris (ringworm of the groin and thigh), tinea barbae (barber's itch), tinea capitis (ringworm of the scalp), and tinea unguium (onychomycosis, ringworm of the nails), when caused by one or more of the following genera of fungi: Trichophyton rubrum, Trichophyton tonsurans, Trichophyton mentagrophytes, Trichophyton interdigitalis,Trichophyton verrucosum, Trichophyton megnini, Trichophyton gallinae, Trichophyton crateriform, Trichophyton sulphureum, Trichophyton schoenleini, Microsporum audouini, Microsporum canis, Microsporum gypseum and Epidermophyton floccosum . NOTE: Prior to therapy, the type of fungi responsible for the infection should be identified. The use of the drug is not justified in minor or trivial infections which will respond to topical agents alone. Griseofulvin is not effective in the following: bacterial infections, candidiasis (moniliasis), histoplasmosis, actinomycosis, sporotrichosis, chromoblastomycosis, coccidioidomycosis, North American blastomycosis, cryptococcosis (torulosis), tinea versicolor and nocardiosis. uuid:08de74f4-0685-4f79-8fd5-be87d312838e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27779 biolink:treats MONDO:0005113 PMID:41385096 "[{""id"":""uuid:b89dffae-45f6-487d-b2ac-a33f62755515"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:61e38997-01d6-4003-8209-e2d4b5fa3c12"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gris-PEG ® (griseofulvin ultramicrosize) is indicated for the treatment of the following ringworm infections; tinea corporis (ringworm of the body), tinea pedis (athlete's foot), tinea cruris (ringworm of the groin and thigh), tinea barbae (barber's itch), tinea capitis (ringworm of the scalp), and tinea unguium (onychomycosis, ringworm of the nails), when caused by one or more of the following genera of fungi: Trichophyton rubrum, Trichophyton tonsurans, Trichophyton mentagrophytes, Trichophyton interdigitalis,Trichophyton verrucosum, Trichophyton megnini, Trichophyton gallinae, Trichophyton crateriform, Trichophyton sulphureum, Trichophyton schoenleini, Microsporum audouini, Microsporum canis, Microsporum gypseum and Epidermophyton floccosum . NOTE: Prior to therapy, the type of fungi responsible for the infection should be identified. The use of the drug is not justified in minor or trivial infections which will respond to topical agents alone. Griseofulvin is not effective in the following: bacterial infections, candidiasis (moniliasis), histoplasmosis, actinomycosis, sporotrichosis, chromoblastomycosis, coccidioidomycosis, North American blastomycosis, cryptococcosis (torulosis), tinea versicolor and nocardiosis. uuid:3ccdc074-c4b9-4f58-95ca-3146bdefd1a6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27779 biolink:treats MONDO:0002026 PMID:41385096 "[{""id"":""uuid:02192ba7-04a8-43e8-b99e-1291be50db3d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9f7f8990-580c-4d83-ae2e-2e8a80c93a0e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gris-PEG ® (griseofulvin ultramicrosize) is indicated for the treatment of the following ringworm infections; tinea corporis (ringworm of the body), tinea pedis (athlete's foot), tinea cruris (ringworm of the groin and thigh), tinea barbae (barber's itch), tinea capitis (ringworm of the scalp), and tinea unguium (onychomycosis, ringworm of the nails), when caused by one or more of the following genera of fungi: Trichophyton rubrum, Trichophyton tonsurans, Trichophyton mentagrophytes, Trichophyton interdigitalis,Trichophyton verrucosum, Trichophyton megnini, Trichophyton gallinae, Trichophyton crateriform, Trichophyton sulphureum, Trichophyton schoenleini, Microsporum audouini, Microsporum canis, Microsporum gypseum and Epidermophyton floccosum . NOTE: Prior to therapy, the type of fungi responsible for the infection should be identified. The use of the drug is not justified in minor or trivial infections which will respond to topical agents alone. Griseofulvin is not effective in the following: bacterial infections, candidiasis (moniliasis), histoplasmosis, actinomycosis, sporotrichosis, chromoblastomycosis, coccidioidomycosis, North American blastomycosis, cryptococcosis (torulosis), tinea versicolor and nocardiosis. uuid:ca29af89-ef98-44df-9d81-f41ed43c544d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27779 biolink:treats UMLS:C0343886 PMID:41385096 "[{""id"":""uuid:cf6f9fd2-7041-49d2-aa1a-24fbbb3ef639"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eaf7cfc1-949c-4569-b573-094d02d6e821"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gris-PEG ® (griseofulvin ultramicrosize) is indicated for the treatment of the following ringworm infections; tinea corporis (ringworm of the body), tinea pedis (athlete's foot), tinea cruris (ringworm of the groin and thigh), tinea barbae (barber's itch), tinea capitis (ringworm of the scalp), and tinea unguium (onychomycosis, ringworm of the nails), when caused by one or more of the following genera of fungi: Trichophyton rubrum, Trichophyton tonsurans, Trichophyton mentagrophytes, Trichophyton interdigitalis,Trichophyton verrucosum, Trichophyton megnini, Trichophyton gallinae, Trichophyton crateriform, Trichophyton sulphureum, Trichophyton schoenleini, Microsporum audouini, Microsporum canis, Microsporum gypseum and Epidermophyton floccosum . NOTE: Prior to therapy, the type of fungi responsible for the infection should be identified. The use of the drug is not justified in minor or trivial infections which will respond to topical agents alone. Griseofulvin is not effective in the following: bacterial infections, candidiasis (moniliasis), histoplasmosis, actinomycosis, sporotrichosis, chromoblastomycosis, coccidioidomycosis, North American blastomycosis, cryptococcosis (torulosis), tinea versicolor and nocardiosis. uuid:513b1afe-0300-422f-a924-aabd5614a192 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27779 biolink:treats MONDO:0018312 PMID:41385096 "[{""id"":""uuid:4f899c9c-e694-4c62-9cc6-be2ef7ab12da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bf3cad1b-f248-4543-b3c4-7766aae97f62"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gris-PEG ® (griseofulvin ultramicrosize) is indicated for the treatment of the following ringworm infections; tinea corporis (ringworm of the body), tinea pedis (athlete's foot), tinea cruris (ringworm of the groin and thigh), tinea barbae (barber's itch), tinea capitis (ringworm of the scalp), and tinea unguium (onychomycosis, ringworm of the nails), when caused by one or more of the following genera of fungi: Trichophyton rubrum, Trichophyton tonsurans, Trichophyton mentagrophytes, Trichophyton interdigitalis,Trichophyton verrucosum, Trichophyton megnini, Trichophyton gallinae, Trichophyton crateriform, Trichophyton sulphureum, Trichophyton schoenleini, Microsporum audouini, Microsporum canis, Microsporum gypseum and Epidermophyton floccosum . NOTE: Prior to therapy, the type of fungi responsible for the infection should be identified. The use of the drug is not justified in minor or trivial infections which will respond to topical agents alone. Griseofulvin is not effective in the following: bacterial infections, candidiasis (moniliasis), histoplasmosis, actinomycosis, sporotrichosis, chromoblastomycosis, coccidioidomycosis, North American blastomycosis, cryptococcosis (torulosis), tinea versicolor and nocardiosis. uuid:f0baab88-51e0-43ef-aeb7-442dc4756cc9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27779 biolink:treats MONDO:0005631 PMID:41385096 "[{""id"":""uuid:e69fc713-84df-418b-ba99-325ba58bfbf8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:896c0852-3b25-4b72-ba02-143bfdcfe006"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gris-PEG ® (griseofulvin ultramicrosize) is indicated for the treatment of the following ringworm infections; tinea corporis (ringworm of the body), tinea pedis (athlete's foot), tinea cruris (ringworm of the groin and thigh), tinea barbae (barber's itch), tinea capitis (ringworm of the scalp), and tinea unguium (onychomycosis, ringworm of the nails), when caused by one or more of the following genera of fungi: Trichophyton rubrum, Trichophyton tonsurans, Trichophyton mentagrophytes, Trichophyton interdigitalis,Trichophyton verrucosum, Trichophyton megnini, Trichophyton gallinae, Trichophyton crateriform, Trichophyton sulphureum, Trichophyton schoenleini, Microsporum audouini, Microsporum canis, Microsporum gypseum and Epidermophyton floccosum . NOTE: Prior to therapy, the type of fungi responsible for the infection should be identified. The use of the drug is not justified in minor or trivial infections which will respond to topical agents alone. Griseofulvin is not effective in the following: bacterial infections, candidiasis (moniliasis), histoplasmosis, actinomycosis, sporotrichosis, chromoblastomycosis, coccidioidomycosis, North American blastomycosis, cryptococcosis (torulosis), tinea versicolor and nocardiosis. uuid:689d20bd-6502-492c-b936-a7ce77a2c75f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27779 biolink:treats MONDO:0005968 PMID:41385096 "[{""id"":""uuid:645dc658-ded4-4019-8e5a-a696ad6bf3b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5daa5a7c-5f23-453c-9fce-2087439a0d39"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gris-PEG ® (griseofulvin ultramicrosize) is indicated for the treatment of the following ringworm infections; tinea corporis (ringworm of the body), tinea pedis (athlete's foot), tinea cruris (ringworm of the groin and thigh), tinea barbae (barber's itch), tinea capitis (ringworm of the scalp), and tinea unguium (onychomycosis, ringworm of the nails), when caused by one or more of the following genera of fungi: Trichophyton rubrum, Trichophyton tonsurans, Trichophyton mentagrophytes, Trichophyton interdigitalis,Trichophyton verrucosum, Trichophyton megnini, Trichophyton gallinae, Trichophyton crateriform, Trichophyton sulphureum, Trichophyton schoenleini, Microsporum audouini, Microsporum canis, Microsporum gypseum and Epidermophyton floccosum . NOTE: Prior to therapy, the type of fungi responsible for the infection should be identified. The use of the drug is not justified in minor or trivial infections which will respond to topical agents alone. Griseofulvin is not effective in the following: bacterial infections, candidiasis (moniliasis), histoplasmosis, actinomycosis, sporotrichosis, chromoblastomycosis, coccidioidomycosis, North American blastomycosis, cryptococcosis (torulosis), tinea versicolor and nocardiosis. uuid:c6064a33-72e0-448d-8dd7-84aec3cd6721 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27779 biolink:treats MONDO:0015908 PMID:41385096 "[{""id"":""uuid:80293997-19e7-4ffa-972d-fa6739627c24"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a4a4921d-c086-4963-8bf7-90b02a243c5b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gris-PEG ® (griseofulvin ultramicrosize) is indicated for the treatment of the following ringworm infections; tinea corporis (ringworm of the body), tinea pedis (athlete's foot), tinea cruris (ringworm of the groin and thigh), tinea barbae (barber's itch), tinea capitis (ringworm of the scalp), and tinea unguium (onychomycosis, ringworm of the nails), when caused by one or more of the following genera of fungi: Trichophyton rubrum, Trichophyton tonsurans, Trichophyton mentagrophytes, Trichophyton interdigitalis,Trichophyton verrucosum, Trichophyton megnini, Trichophyton gallinae, Trichophyton crateriform, Trichophyton sulphureum, Trichophyton schoenleini, Microsporum audouini, Microsporum canis, Microsporum gypseum and Epidermophyton floccosum . NOTE: Prior to therapy, the type of fungi responsible for the infection should be identified. The use of the drug is not justified in minor or trivial infections which will respond to topical agents alone. Griseofulvin is not effective in the following: bacterial infections, candidiasis (moniliasis), histoplasmosis, actinomycosis, sporotrichosis, chromoblastomycosis, coccidioidomycosis, North American blastomycosis, cryptococcosis (torulosis), tinea versicolor and nocardiosis. uuid:17fe4031-5c73-4a61-9a79-9f7ef1cf9a32 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27779 biolink:treats MONDO:0005706 PMID:41385096 "[{""id"":""uuid:05097cb9-f68f-40cc-81cc-f6de1e9703e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3ac665d0-4c5b-4b7a-b0ae-6ac7a4f532ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gris-PEG ® (griseofulvin ultramicrosize) is indicated for the treatment of the following ringworm infections; tinea corporis (ringworm of the body), tinea pedis (athlete's foot), tinea cruris (ringworm of the groin and thigh), tinea barbae (barber's itch), tinea capitis (ringworm of the scalp), and tinea unguium (onychomycosis, ringworm of the nails), when caused by one or more of the following genera of fungi: Trichophyton rubrum, Trichophyton tonsurans, Trichophyton mentagrophytes, Trichophyton interdigitalis,Trichophyton verrucosum, Trichophyton megnini, Trichophyton gallinae, Trichophyton crateriform, Trichophyton sulphureum, Trichophyton schoenleini, Microsporum audouini, Microsporum canis, Microsporum gypseum and Epidermophyton floccosum . NOTE: Prior to therapy, the type of fungi responsible for the infection should be identified. The use of the drug is not justified in minor or trivial infections which will respond to topical agents alone. Griseofulvin is not effective in the following: bacterial infections, candidiasis (moniliasis), histoplasmosis, actinomycosis, sporotrichosis, chromoblastomycosis, coccidioidomycosis, North American blastomycosis, cryptococcosis (torulosis), tinea versicolor and nocardiosis. uuid:3d7cb974-9f91-41f8-b55c-79a3fd433723 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27779 biolink:treats MONDO:0005672 PMID:41385096 "[{""id"":""uuid:873e2105-db62-42dd-bdbf-f315216c6b44"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:66017e64-a661-4b2e-a59e-6876f397f3b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gris-PEG ® (griseofulvin ultramicrosize) is indicated for the treatment of the following ringworm infections; tinea corporis (ringworm of the body), tinea pedis (athlete's foot), tinea cruris (ringworm of the groin and thigh), tinea barbae (barber's itch), tinea capitis (ringworm of the scalp), and tinea unguium (onychomycosis, ringworm of the nails), when caused by one or more of the following genera of fungi: Trichophyton rubrum, Trichophyton tonsurans, Trichophyton mentagrophytes, Trichophyton interdigitalis,Trichophyton verrucosum, Trichophyton megnini, Trichophyton gallinae, Trichophyton crateriform, Trichophyton sulphureum, Trichophyton schoenleini, Microsporum audouini, Microsporum canis, Microsporum gypseum and Epidermophyton floccosum . NOTE: Prior to therapy, the type of fungi responsible for the infection should be identified. The use of the drug is not justified in minor or trivial infections which will respond to topical agents alone. Griseofulvin is not effective in the following: bacterial infections, candidiasis (moniliasis), histoplasmosis, actinomycosis, sporotrichosis, chromoblastomycosis, coccidioidomycosis, North American blastomycosis, cryptococcosis (torulosis), tinea versicolor and nocardiosis. uuid:9dac8f56-41cf-4ed9-a912-f5f2c412fa1b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27779 biolink:treats MONDO:0005724 PMID:41385096 "[{""id"":""uuid:cd09c132-cc74-4427-b104-62df9c21f479"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9c9833b4-dfe8-40c8-8c08-5d666b2f3f7f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gris-PEG ® (griseofulvin ultramicrosize) is indicated for the treatment of the following ringworm infections; tinea corporis (ringworm of the body), tinea pedis (athlete's foot), tinea cruris (ringworm of the groin and thigh), tinea barbae (barber's itch), tinea capitis (ringworm of the scalp), and tinea unguium (onychomycosis, ringworm of the nails), when caused by one or more of the following genera of fungi: Trichophyton rubrum, Trichophyton tonsurans, Trichophyton mentagrophytes, Trichophyton interdigitalis,Trichophyton verrucosum, Trichophyton megnini, Trichophyton gallinae, Trichophyton crateriform, Trichophyton sulphureum, Trichophyton schoenleini, Microsporum audouini, Microsporum canis, Microsporum gypseum and Epidermophyton floccosum . NOTE: Prior to therapy, the type of fungi responsible for the infection should be identified. The use of the drug is not justified in minor or trivial infections which will respond to topical agents alone. Griseofulvin is not effective in the following: bacterial infections, candidiasis (moniliasis), histoplasmosis, actinomycosis, sporotrichosis, chromoblastomycosis, coccidioidomycosis, North American blastomycosis, cryptococcosis (torulosis), tinea versicolor and nocardiosis. uuid:75443728-6cca-4e7c-b188-69eae3d8a525 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27779 biolink:treats MONDO:0005915 PMID:41385096 "[{""id"":""uuid:37cbc84a-ce82-475b-b6ec-32dde869a29c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9366311c-18a4-460f-9a66-b7e22982ffcf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gris-PEG ® (griseofulvin ultramicrosize) is indicated for the treatment of the following ringworm infections; tinea corporis (ringworm of the body), tinea pedis (athlete's foot), tinea cruris (ringworm of the groin and thigh), tinea barbae (barber's itch), tinea capitis (ringworm of the scalp), and tinea unguium (onychomycosis, ringworm of the nails), when caused by one or more of the following genera of fungi: Trichophyton rubrum, Trichophyton tonsurans, Trichophyton mentagrophytes, Trichophyton interdigitalis,Trichophyton verrucosum, Trichophyton megnini, Trichophyton gallinae, Trichophyton crateriform, Trichophyton sulphureum, Trichophyton schoenleini, Microsporum audouini, Microsporum canis, Microsporum gypseum and Epidermophyton floccosum . NOTE: Prior to therapy, the type of fungi responsible for the infection should be identified. The use of the drug is not justified in minor or trivial infections which will respond to topical agents alone. Griseofulvin is not effective in the following: bacterial infections, candidiasis (moniliasis), histoplasmosis, actinomycosis, sporotrichosis, chromoblastomycosis, coccidioidomycosis, North American blastomycosis, cryptococcosis (torulosis), tinea versicolor and nocardiosis. uuid:cefa867f-ae39-4ff7-b707-7e2939085a31 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27779 biolink:treats MONDO:0017776 PMID:41385096 "[{""id"":""uuid:1258b58b-c5f2-4d0f-87f6-f906aa87baa5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8b74ed79-be17-4f2b-85b6-032c2afcc71b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gris-PEG ® (griseofulvin ultramicrosize) is indicated for the treatment of the following ringworm infections; tinea corporis (ringworm of the body), tinea pedis (athlete's foot), tinea cruris (ringworm of the groin and thigh), tinea barbae (barber's itch), tinea capitis (ringworm of the scalp), and tinea unguium (onychomycosis, ringworm of the nails), when caused by one or more of the following genera of fungi: Trichophyton rubrum, Trichophyton tonsurans, Trichophyton mentagrophytes, Trichophyton interdigitalis,Trichophyton verrucosum, Trichophyton megnini, Trichophyton gallinae, Trichophyton crateriform, Trichophyton sulphureum, Trichophyton schoenleini, Microsporum audouini, Microsporum canis, Microsporum gypseum and Epidermophyton floccosum . NOTE: Prior to therapy, the type of fungi responsible for the infection should be identified. The use of the drug is not justified in minor or trivial infections which will respond to topical agents alone. Griseofulvin is not effective in the following: bacterial infections, candidiasis (moniliasis), histoplasmosis, actinomycosis, sporotrichosis, chromoblastomycosis, coccidioidomycosis, North American blastomycosis, cryptococcosis (torulosis), tinea versicolor and nocardiosis. uuid:0e9b74b6-cb18-4945-926a-c437d7186c5a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31348 biolink:treats UMLS:C0278480 PMID:41385096 "[{""id"":""uuid:9dd0c8ec-cfe8-494c-b95e-710b6df5b56c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:39aa7101-710e-46be-a1ff-17258f201861"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XELODA is indicated as a single agent for adjuvant treatment in patients with Dukes' C colon cancer who have undergone complete resection of the primary tumor when treatment with fluoropyrimidine therapy alone is preferred. XELODA was non-inferior to 5-fluorouracil and leucovorin (5-FU/LV) for disease-free survival (DFS). Although neither XELODA nor combination chemotherapy prolongs overall survival (OS), combination chemotherapy has been demonstrated to improve disease-free survival compared to 5-FU/LV. Physicians should consider these results when prescribing single-agent XELODA in the adjuvant treatment of Dukes' C colon cancer. XELODA is indicated as first-line treatment of patients with metastatic colorectal carcinoma when treatment with fluoropyrimidine therapy alone is preferred. Combination chemotherapy has shown a survival benefit compared to 5-FU/LV alone. A survival benefit over 5-FU/LV has not been demonstrated with XELODA monotherapy. Use of XELODA instead of 5-FU/LV in combinations has not been adequately studied to assure safety or preservation of the survival advantage. uuid:2c7b7510-c680-4cc9-af34-cc2882f1035f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31348 biolink:treats UMLS:C4744564 PMID:41385096 "[{""id"":""uuid:f0c84e2a-b8c1-42a0-9f31-9bb272014686"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ebfe386d-87a6-4474-a11a-565203f9cb7d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XELODA is indicated as a single agent for adjuvant treatment in patients with Dukes' C colon cancer who have undergone complete resection of the primary tumor when treatment with fluoropyrimidine therapy alone is preferred. XELODA was non-inferior to 5-fluorouracil and leucovorin (5-FU/LV) for disease-free survival (DFS). Although neither XELODA nor combination chemotherapy prolongs overall survival (OS), combination chemotherapy has been demonstrated to improve disease-free survival compared to 5-FU/LV. Physicians should consider these results when prescribing single-agent XELODA in the adjuvant treatment of Dukes' C colon cancer. XELODA is indicated as first-line treatment of patients with metastatic colorectal carcinoma when treatment with fluoropyrimidine therapy alone is preferred. Combination chemotherapy has shown a survival benefit compared to 5-FU/LV alone. A survival benefit over 5-FU/LV has not been demonstrated with XELODA monotherapy. Use of XELODA instead of 5-FU/LV in combinations has not been adequately studied to assure safety or preservation of the survival advantage. uuid:0eabcf6d-cb9d-44d5-8e3c-f6ea3e971df4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9674 biolink:treats MONDO:0013600 PMID:41385096 "[{""id"":""uuid:a7137ca5-acab-468d-a56f-054295d974e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a42e3133-4e5a-47e2-8406-ef7c1e103921"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Triazolam is indicated for the short-term treatment of insomnia (generally 7–10 days). Use for more than 2–3 weeks requires complete reevaluation of the patient (see WARNINGS ). Prescriptions for triazolam should be written for short-term use (7–10 days) and it should not be prescribed in quantities exceeding a 1-month supply. uuid:2338bfdb-5a43-48dc-a9da-8e875d9da838 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28077 biolink:treats MONDO:0018076 PMID:41385096 "[{""id"":""uuid:82aa5a8d-fecd-48b7-96b7-82725e69f02f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:984ac037-7417-4f7a-a9b3-4b78007bbc80"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In the treatment of both tuberculosis and the meningococcal carrier state, the small number of resistant cells present within large populations of susceptible cells can rapidly become the predominant type. Bacteriologic cultures should be obtained before the start of therapy to confirm the susceptibility of the organism to rifampin and they should be repeated throughout therapy to monitor the response to treatment. Since resistance can emerge rapidly, susceptibility tests should be performed in the event of persistent positive cultures during the course of treatment. If test results show resistance to rifampin and the patient is not responding to therapy, the drug regimen should be modified. uuid:5da20916-9f49-4e73-a347-43ed98238329 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9313 biolink:treats MONDO:0005412 PMID:41385096 "[{""id"":""uuid:81034902-aecc-4418-981d-935b1e1b1a12"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eb376fdc-cf71-48fb-9d2f-7fdd536f83b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sucralfate is indicated in: Short-term treatment (up to 8 weeks) of active duodenal ulcer. While healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. UNII:XX73205DH5 uuid:4bf8b7d3-f395-477f-a252-3dd7d4d34cad biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63581 biolink:treats MONDO:0004951 PMID:41385096 "[{""id"":""uuid:83c9d4f3-a48e-48d7-a565-db2e708b9522"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:05bbe399-a2e2-48f5-9124-06e467f22d16"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Stavudine capsules , in combination with other antiretroviral agents, is indicated for the treatment of HIV-1 infection (see Clinical Studies ). uuid:20d8ea0e-7b9b-48cf-aa3c-3aeece90193d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5384 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:3f19567c-46c5-4783-81f9-05e0988c5a07"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9d74ba6b-cffa-49e5-9fea-b7e1a898c52b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Glipizide Tablets USP are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. uuid:3beb78e1-6826-43b6-a592-4f4d1a11c926 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4877 biolink:treats MONDO:0006052 PMID:41385096 "[{""id"":""uuid:1bbcda4d-e260-41f8-bc13-280da8426fba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:26b3308f-2a69-47e7-99a0-fcc1f5856e99"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ethambutol Hydrochloride Tablets are indicated for the treatment of pulmonary tuberculosis. It should not be used as the sole antituberculous drug, but should be used in conjunction with at least one other antituberculous drug. Selection of the companion drug should be based on clinical experience, considerations of comparative safety and appropriate in vitro susceptibility studies. In patients who have not received previous antituberculous therapy, i.e., initial treatment, the most frequently used regimens have been the following: Ethambutol plus isoniazid Ethambutol plus isoniazid plus streptomycin. In patients who have received previous antituberculous therapy, mycobacterial resistance to other drugs used in initial therapy is frequent. Consequently, in such retreatment patients, ethambutol should be combined with at least one of the second line drugs not previously administered to the patient and to which bacterial susceptibility has been indicated by appropriate in vitro studies. Antituberculous drugs used with ethambutol have included cycloserine, ethionamide, pyrazinamide, viomycin, and other drugs. Isoniazid, aminosalicylic acid, and streptomycin have also been used in multiple drug regimens. Alternating drug regimens have also been utilized. uuid:23487edc-3061-4d9f-a127-6fb5a6324d15 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6950 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:7dfdc850-7a35-4af5-aeb2-9368739ecc26"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:80f05ed9-073c-43f3-8a96-c87c41f9d632"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mirtazapine tablets, USP are indicated for the treatment of major depressive disorder. The efficacy of mirtazapine tablets, USP in the treatment of major depressive disorder was established in six week controlled trials of outpatients whose diagnoses corresponded most closely to the Diagnostic and Statistical Manual of Mental Disorders - 3rd edition (DSM-lll) category of major depressive disorder (see CLINICAL PHARMACOLOGY ). A major depressive episode (DSM-IV) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least five of the following nine symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. The effectiveness of mirtazapine in hospitalized depressed patients has not been adequately studied. The efficacy of mirtazapine, USP in maintaining a response in patients with major depressive disorder for up to 40 weeks following 8–12 weeks of initial open-label treatment was demonstrated in a placebo-controlled trial. Nevertheless, the physician who elects to use mirtazapine, USP for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see CLINICAL PHARMACOLOGY ). uuid:1556a2c5-dc1a-47d1-8838-2a432b0c5a93 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47381 biolink:treats MONDO:0005416 PMID:41385096 "[{""id"":""uuid:0fc2672c-9c62-44f3-98f2-45a9161494d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:71bf13cc-d9e2-4484-a7cf-18d1cb3458d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Voltaren® Gel is indicated for the relief of the pain of osteoarthritis of joints amenable to topical treatment, such as the knees and those of the hands. Voltaren® Gel has not been evaluated for use on the spine, hip, or shoulder. uuid:c525dbe0-e8c7-419a-880f-ba30ed8d87a9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47381 biolink:treats MONDO:0006632 PMID:41385096 "[{""id"":""uuid:02f8b34c-c7f0-478f-8e13-5fdbdeb1630a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:43d5c557-48a2-4781-9e6a-792b0a2a2d1a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Voltaren® Gel is indicated for the relief of the pain of osteoarthritis of joints amenable to topical treatment, such as the knees and those of the hands. Voltaren® Gel has not been evaluated for use on the spine, hip, or shoulder. uuid:5fd0071d-5dcf-4826-9e36-76b37d5c96d4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8871 biolink:treats MONDO:0005090 PMID:41385096 "[{""id"":""uuid:907abdc4-f104-4c10-bdac-bf34295437ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:2e9bdf72-1d6a-4a65-a71b-5941b66a4805"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:552fc904-0057-4067-a0d6-677b10905208"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/okedi""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Risperidone is an atypical antipsychotic agent indicated for: Treatment of schizophrenia in adults ( 1.1 ) Alone, or in combination with lithium or valproate, for the short-term treatment of acute manic or mixed episodes associated with Bipolar I Disorder in adults ( 1.2 ) Treatment of irritability associated with autistic disorder in children and adolescents aged 5 to 16 years ( 1.3 )|[EMA] Treatment of schizophrenia in adults for whom tolerability and effectiveness has been established with oral risperidone. uuid:352dd504-9dc0-4f9e-acb6-a043469bf59e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8871 biolink:treats MONDO:0001866 PMID:41385096 "[{""id"":""uuid:d9898c0b-d5db-42a4-b11d-ea478bb8e0da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d69ee776-1537-4e03-966a-9a9980861954"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Risperidone is an atypical antipsychotic agent indicated for: Treatment of schizophrenia in adults ( 1.1 ) Alone, or in combination with lithium or valproate, for the short-term treatment of acute manic or mixed episodes associated with Bipolar I Disorder in adults ( 1.2 ) Treatment of irritability associated with autistic disorder in children and adolescents aged 5 to 16 years ( 1.3 ) uuid:726fbd2d-abb5-4b28-bc29-7f9fcdce6eff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8871 biolink:treats MONDO:0005258 PMID:41385096 "[{""id"":""uuid:50e97c27-4000-44c2-b1da-ae12493b7ae7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1152b49f-5966-4346-bf77-7994f80cbe28"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Risperidone is an atypical antipsychotic agent indicated for: Treatment of schizophrenia in adults ( 1.1 ) Alone, or in combination with lithium or valproate, for the short-term treatment of acute manic or mixed episodes associated with Bipolar I Disorder in adults ( 1.2 ) Treatment of irritability associated with autistic disorder in children and adolescents aged 5 to 16 years ( 1.3 ) uuid:c28dc1c3-45b7-4147-b1e2-3754d44b0cd3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8499 biolink:treats HP:0100735 PMID:41385096 "[{""id"":""uuid:9fe6abb2-538d-40b9-9d2f-8dd6f3458fa9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:866fb257-0386-4c18-91a4-ef0f7e8efc12"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Propranolol hydrochloride tablets are indicated in the management of hypertension. They may be used alone or used in combination with other antihypertensive agents, particularly a thiazide diuretic. Propranolol hydrochloride tablets are not indicated in the management of hypertensive emergencies. uuid:3bb6b15b-5f0e-4a87-bddb-fb2952a20e24 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1163424 biolink:treats MONDO:0006668 PMID:41385096 "[{""id"":""uuid:0ea58fb7-3f30-4d81-a634-b36da0a82440"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:81b503c8-4a5f-447d-a582-eae60e0c34e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Neomycin and Polymyxin B Sulfates and Hydrocortisone Ophthalmic Suspension is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. Ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe where the inherent risk of corticosteroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye (See CLINICAL PHARMACOLOGY: Microbiology ). The particular anti-infective drugs in this product are active against the following common bacterial eye pathogens: Staphylococcus aureus , Escherichia coli , Haemophilus influenzae , Klebsiella/Enterobacter species, Neisseria species, and Pseudomonas aeruginosa . The product does not provide adequate coverage against Serratia marcescens and streptococci, including Streptococcus pneumoniae . uuid:cc99e764-a105-48f5-8830-46c882ea56e5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1163424 biolink:treats UMLS:C0008690 PMID:41385096 "[{""id"":""uuid:89d07382-d8ff-41a0-b308-02bc0362a729"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0d38ffe9-0355-4920-964f-03195b1883b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Neomycin and Polymyxin B Sulfates and Hydrocortisone Ophthalmic Suspension is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. Ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe where the inherent risk of corticosteroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye (See CLINICAL PHARMACOLOGY: Microbiology ). The particular anti-infective drugs in this product are active against the following common bacterial eye pathogens: Staphylococcus aureus , Escherichia coli , Haemophilus influenzae , Klebsiella/Enterobacter species, Neisseria species, and Pseudomonas aeruginosa . The product does not provide adequate coverage against Serratia marcescens and streptococci, including Streptococcus pneumoniae . uuid:9c5fa2e8-8061-44af-a42f-608df3fda31d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1163424 biolink:treats UMLS:C0339289 PMID:41385096 "[{""id"":""uuid:cf14b777-d4dd-4660-a492-c029c806caa7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3680ed52-834c-4f66-bf61-e7c2b8c4c1a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Neomycin and Polymyxin B Sulfates and Hydrocortisone Ophthalmic Suspension is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. Ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe where the inherent risk of corticosteroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye (See CLINICAL PHARMACOLOGY: Microbiology ). The particular anti-infective drugs in this product are active against the following common bacterial eye pathogens: Staphylococcus aureus , Escherichia coli , Haemophilus influenzae , Klebsiella/Enterobacter species, Neisseria species, and Pseudomonas aeruginosa . The product does not provide adequate coverage against Serratia marcescens and streptococci, including Streptococcus pneumoniae . uuid:419cc9c1-3b29-4ceb-935e-f51d476fff09 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7986 biolink:treats MONDO:0005295 PMID:41385096 "[{""id"":""uuid:263bd41e-6796-450f-ae51-74faacd94328"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:64300211-9bbf-442b-ab90-021ae50029b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pentoxifylline extended-release Tablet is indicated for the treatment of patients with intermittent claudication on the basis of chronic occlusive arterial disease of the limbs. Pentoxifylline extended-release Tablet can improve function and symptoms but is not intended to replace more definitive therapy, such as surgical bypass, or removal of arterial obstructions when treating peripheral vascular disease. uuid:a61c6de6-bcf7-4489-b0fc-302707dacd1b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7986 biolink:treats MONDO:0005294 PMID:41385096 "[{""id"":""uuid:75cfa057-8cba-4474-8b0b-fa0f041432f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0090375b-8a67-4805-a3b9-38efa9bbcecb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pentoxifylline extended-release Tablet is indicated for the treatment of patients with intermittent claudication on the basis of chronic occlusive arterial disease of the limbs. Pentoxifylline extended-release Tablet can improve function and symptoms but is not intended to replace more definitive therapy, such as surgical bypass, or removal of arterial obstructions when treating peripheral vascular disease. uuid:8ca7b5c2-b53b-4894-b337-0f27ca34a935 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5613 biolink:treats MONDO:0005485 PMID:41385096 "[{""id"":""uuid:59599add-3fcf-424b-be6a-57a558890b9a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3720b0c4-c6d6-4023-b576-487d79db7d76"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Haloperidol is indicated for use in the management of manifestations of psychotic disorders. Haloperidol is indicated for the control of tics and vocal utterances of Tourette’s Disorder in children and adults. Haloperidol is effective for the treatment of severe behavior problems in children of combative, explosive hyperexcitability (which cannot be accounted for by immediate provocation). Haloperidol is also effective in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability, and poor frustration tolerance. Haloperidol should be reserved for these two groups of children only after failure to respond to psychotherapy or medications other than antipsychotics. uuid:c51b8be4-a698-4335-9ddc-a1dbd0d0f327 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5613 biolink:treats MONDO:0007661 PMID:41385096 "[{""id"":""uuid:f3f2a913-16ca-4e96-a386-424848f2549c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e79d2b44-63f7-44af-adfb-df0d2dead439"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Haloperidol is indicated for use in the management of manifestations of psychotic disorders. Haloperidol is indicated for the control of tics and vocal utterances of Tourette’s Disorder in children and adults. Haloperidol is effective for the treatment of severe behavior problems in children of combative, explosive hyperexcitability (which cannot be accounted for by immediate provocation). Haloperidol is also effective in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability, and poor frustration tolerance. Haloperidol should be reserved for these two groups of children only after failure to respond to psychotherapy or medications other than antipsychotics. uuid:69d9ef81-ae90-4033-9800-8897bbefe9c6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5613 biolink:treats HP:0000718 PMID:41385096 "[{""id"":""uuid:5aaf1c03-e232-4d50-a8b7-ea7baa1186ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e8ea5ae8-9af4-4774-b785-f1fa8791320d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Haloperidol is indicated for use in the management of manifestations of psychotic disorders. Haloperidol is indicated for the control of tics and vocal utterances of Tourette’s Disorder in children and adults. Haloperidol is effective for the treatment of severe behavior problems in children of combative, explosive hyperexcitability (which cannot be accounted for by immediate provocation). Haloperidol is also effective in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability, and poor frustration tolerance. Haloperidol should be reserved for these two groups of children only after failure to respond to psychotherapy or medications other than antipsychotics. uuid:6bc2ea44-67a0-41a6-a9c2-ca9f4c71e77f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5613 biolink:treats MONDO:0005352 PMID:41385096 "[{""id"":""uuid:ce3bffa7-8f6e-41a6-a24b-b060954ea7aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:74ca84e5-1d8e-4a47-8362-277d157b25f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Haloperidol is indicated for use in the management of manifestations of psychotic disorders. Haloperidol is indicated for the control of tics and vocal utterances of Tourette’s Disorder in children and adults. Haloperidol is effective for the treatment of severe behavior problems in children of combative, explosive hyperexcitability (which cannot be accounted for by immediate provocation). Haloperidol is also effective in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability, and poor frustration tolerance. Haloperidol should be reserved for these two groups of children only after failure to respond to psychotherapy or medications other than antipsychotics. uuid:4151c294-523b-4e34-a00f-3b740108ab71 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7735 biolink:treats MONDO:0005090 PMID:41385096 "[{""id"":""uuid:50f92b84-4e31-46a1-aa4a-b92e81e54426"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:4e8b6bd2-1773-400b-8dbd-9778f22e7750"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:37641472-7c1e-42f7-860b-9a78efdea23e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/olanzapine-teva""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Schizophrenia Oral ZYPREXA is indicated for acute and maintenance treatment of Schizophrenia in adults. 1.2 Bipolar I Disorder (Manic or Mixed Episodes) Monotherapy — Oral ZYPREXA is indicated for acute treatment of manic or mixed episodes associated with Bipolar I Disorder (monotherapy and in combination with lithium or valproate) and maintenance treatment of Bipolar I Disorder (monotherapy) in adults. Combination Therapy — The combination of oral ZYPREXA with lithium or valproate is indicated for the short-term treatment of acute manic or mixed episodes associated with Bipolar I Disorder in adults [see Clinical Studies ( 14.2 )] . 1.3 ZYPREXA IntraMuscular: Agitation Associated with Schizophrenia and Bipolar I Mania ZYPREXA IntraMuscular is indicated for the treatment of acute agitation associated with Schizophrenia and Bipolar I Mania. “Psychomotor agitation” is defined in DSM-IV as “excessive motor activity associated with a feeling of inner tension.” Patients experiencing agitation often manifest behaviors that interfere with their diagnosis and care, e.g., threatening behaviors, escalating or urgently distressing behavior, or self-exhausting behavior, leading clinicians to the use of intramuscular antipsychotic medications to achieve immediate control of the agitation [see Clinical Studies ( 14.3 )] . 1.4 ZYPREXA and Fluoxetine in Combination: Depressive Episodes Associated with Bipolar I Disorder When using ZYPREXA and fluoxetine in combination, also refer to the Clinical Studies section of the package insert for Symbyax. Oral ZYPREXA and fluoxetine in combination is indicated for the acute treatment of depressive episodes associated with Bipolar I Disorder in adult patients. ZYPREXA monotherapy is not indicated for the treatment of depressive episodes associated with Bipolar I Disorder. 1.5 ZYPREXA and Fluoxetine in Combination: Treatment Resistant Depression When using ZYPREXA and fluoxetine in combination, also refer to the Indications and Usage section of the package insert for Symbyax. Oral ZYPREXA and fluoxetine in combination is indicated for the acute treatment of treatment resistant depression (Major Depressive Disorder in adult patients who do not respond to 2 separate trials of different antidepressants of adequate dose and duration in the current episode). ZYPREXA monotherapy is not indicated for the treatment of treatment resistant depression.|[EMA] AdultsOlanzapine is indicated for the treatment of schizophrenia.Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.Olanzapine is indicated for the treatment of moderate to severe manic episode.In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder. uuid:565747e1-d079-4cf8-83e8-81974009e07b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7735 biolink:treats MONDO:0001866 PMID:41385096 "[{""id"":""uuid:45fce0f7-c180-4cdb-8856-4fac52a41e82"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0bfc3fbf-02bf-462c-81d6-9ee1c72e80e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Schizophrenia Oral ZYPREXA is indicated for acute and maintenance treatment of Schizophrenia in adults. 1.2 Bipolar I Disorder (Manic or Mixed Episodes) Monotherapy — Oral ZYPREXA is indicated for acute treatment of manic or mixed episodes associated with Bipolar I Disorder (monotherapy and in combination with lithium or valproate) and maintenance treatment of Bipolar I Disorder (monotherapy) in adults. Combination Therapy — The combination of oral ZYPREXA with lithium or valproate is indicated for the short-term treatment of acute manic or mixed episodes associated with Bipolar I Disorder in adults [see Clinical Studies ( 14.2 )] . 1.3 ZYPREXA IntraMuscular: Agitation Associated with Schizophrenia and Bipolar I Mania ZYPREXA IntraMuscular is indicated for the treatment of acute agitation associated with Schizophrenia and Bipolar I Mania. “Psychomotor agitation” is defined in DSM-IV as “excessive motor activity associated with a feeling of inner tension.” Patients experiencing agitation often manifest behaviors that interfere with their diagnosis and care, e.g., threatening behaviors, escalating or urgently distressing behavior, or self-exhausting behavior, leading clinicians to the use of intramuscular antipsychotic medications to achieve immediate control of the agitation [see Clinical Studies ( 14.3 )] . 1.4 ZYPREXA and Fluoxetine in Combination: Depressive Episodes Associated with Bipolar I Disorder When using ZYPREXA and fluoxetine in combination, also refer to the Clinical Studies section of the package insert for Symbyax. Oral ZYPREXA and fluoxetine in combination is indicated for the acute treatment of depressive episodes associated with Bipolar I Disorder in adult patients. ZYPREXA monotherapy is not indicated for the treatment of depressive episodes associated with Bipolar I Disorder. 1.5 ZYPREXA and Fluoxetine in Combination: Treatment Resistant Depression When using ZYPREXA and fluoxetine in combination, also refer to the Indications and Usage section of the package insert for Symbyax. Oral ZYPREXA and fluoxetine in combination is indicated for the acute treatment of treatment resistant depression (Major Depressive Disorder in adult patients who do not respond to 2 separate trials of different antidepressants of adequate dose and duration in the current episode). ZYPREXA monotherapy is not indicated for the treatment of treatment resistant depression. uuid:9abe32e3-b6a5-491f-8fcc-d60ad4dc137e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7735 biolink:treats HP:0100754 PMID:41385096 "[{""id"":""uuid:67eb4fa9-1d4b-4ffc-9e0e-7fce03404ad3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:18b432bf-05ce-4c65-b480-2088cfd05142"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:07382c3a-68ec-486a-949a-5a8ff35a2994"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/olanzapine-teva""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Schizophrenia Oral ZYPREXA is indicated for acute and maintenance treatment of Schizophrenia in adults. 1.2 Bipolar I Disorder (Manic or Mixed Episodes) Monotherapy — Oral ZYPREXA is indicated for acute treatment of manic or mixed episodes associated with Bipolar I Disorder (monotherapy and in combination with lithium or valproate) and maintenance treatment of Bipolar I Disorder (monotherapy) in adults. Combination Therapy — The combination of oral ZYPREXA with lithium or valproate is indicated for the short-term treatment of acute manic or mixed episodes associated with Bipolar I Disorder in adults [see Clinical Studies ( 14.2 )] . 1.3 ZYPREXA IntraMuscular: Agitation Associated with Schizophrenia and Bipolar I Mania ZYPREXA IntraMuscular is indicated for the treatment of acute agitation associated with Schizophrenia and Bipolar I Mania. “Psychomotor agitation” is defined in DSM-IV as “excessive motor activity associated with a feeling of inner tension.” Patients experiencing agitation often manifest behaviors that interfere with their diagnosis and care, e.g., threatening behaviors, escalating or urgently distressing behavior, or self-exhausting behavior, leading clinicians to the use of intramuscular antipsychotic medications to achieve immediate control of the agitation [see Clinical Studies ( 14.3 )] . 1.4 ZYPREXA and Fluoxetine in Combination: Depressive Episodes Associated with Bipolar I Disorder When using ZYPREXA and fluoxetine in combination, also refer to the Clinical Studies section of the package insert for Symbyax. Oral ZYPREXA and fluoxetine in combination is indicated for the acute treatment of depressive episodes associated with Bipolar I Disorder in adult patients. ZYPREXA monotherapy is not indicated for the treatment of depressive episodes associated with Bipolar I Disorder. 1.5 ZYPREXA and Fluoxetine in Combination: Treatment Resistant Depression When using ZYPREXA and fluoxetine in combination, also refer to the Indications and Usage section of the package insert for Symbyax. Oral ZYPREXA and fluoxetine in combination is indicated for the acute treatment of treatment resistant depression (Major Depressive Disorder in adult patients who do not respond to 2 separate trials of different antidepressants of adequate dose and duration in the current episode). ZYPREXA monotherapy is not indicated for the treatment of treatment resistant depression.|[EMA] AdultsOlanzapine is indicated for the treatment of schizophrenia.Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.Olanzapine is indicated for the treatment of moderate to severe manic episode.In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder. uuid:eaa2c962-affa-43aa-83c9-5949abcccb3e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7735 biolink:treats UMLS:C2063866 PMID:41385096 "[{""id"":""uuid:171c66ee-24df-4a90-8c95-79afb23fbb03"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:af899dc6-a503-46c1-9536-e10ef07c7453"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Schizophrenia Oral ZYPREXA is indicated for acute and maintenance treatment of Schizophrenia in adults. 1.2 Bipolar I Disorder (Manic or Mixed Episodes) Monotherapy — Oral ZYPREXA is indicated for acute treatment of manic or mixed episodes associated with Bipolar I Disorder (monotherapy and in combination with lithium or valproate) and maintenance treatment of Bipolar I Disorder (monotherapy) in adults. Combination Therapy — The combination of oral ZYPREXA with lithium or valproate is indicated for the short-term treatment of acute manic or mixed episodes associated with Bipolar I Disorder in adults [see Clinical Studies ( 14.2 )] . 1.3 ZYPREXA IntraMuscular: Agitation Associated with Schizophrenia and Bipolar I Mania ZYPREXA IntraMuscular is indicated for the treatment of acute agitation associated with Schizophrenia and Bipolar I Mania. “Psychomotor agitation” is defined in DSM-IV as “excessive motor activity associated with a feeling of inner tension.” Patients experiencing agitation often manifest behaviors that interfere with their diagnosis and care, e.g., threatening behaviors, escalating or urgently distressing behavior, or self-exhausting behavior, leading clinicians to the use of intramuscular antipsychotic medications to achieve immediate control of the agitation [see Clinical Studies ( 14.3 )] . 1.4 ZYPREXA and Fluoxetine in Combination: Depressive Episodes Associated with Bipolar I Disorder When using ZYPREXA and fluoxetine in combination, also refer to the Clinical Studies section of the package insert for Symbyax. Oral ZYPREXA and fluoxetine in combination is indicated for the acute treatment of depressive episodes associated with Bipolar I Disorder in adult patients. ZYPREXA monotherapy is not indicated for the treatment of depressive episodes associated with Bipolar I Disorder. 1.5 ZYPREXA and Fluoxetine in Combination: Treatment Resistant Depression When using ZYPREXA and fluoxetine in combination, also refer to the Indications and Usage section of the package insert for Symbyax. Oral ZYPREXA and fluoxetine in combination is indicated for the acute treatment of treatment resistant depression (Major Depressive Disorder in adult patients who do not respond to 2 separate trials of different antidepressants of adequate dose and duration in the current episode). ZYPREXA monotherapy is not indicated for the treatment of treatment resistant depression. uuid:881363a2-f8a2-4faa-9ff9-14971573f28c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7735 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:702c138e-22ad-4a67-988e-f129a541ab55"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1f2c8e51-d45b-4dc6-abb8-5d365be7313b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Schizophrenia Oral ZYPREXA is indicated for acute and maintenance treatment of Schizophrenia in adults. 1.2 Bipolar I Disorder (Manic or Mixed Episodes) Monotherapy — Oral ZYPREXA is indicated for acute treatment of manic or mixed episodes associated with Bipolar I Disorder (monotherapy and in combination with lithium or valproate) and maintenance treatment of Bipolar I Disorder (monotherapy) in adults. Combination Therapy — The combination of oral ZYPREXA with lithium or valproate is indicated for the short-term treatment of acute manic or mixed episodes associated with Bipolar I Disorder in adults [see Clinical Studies ( 14.2 )] . 1.3 ZYPREXA IntraMuscular: Agitation Associated with Schizophrenia and Bipolar I Mania ZYPREXA IntraMuscular is indicated for the treatment of acute agitation associated with Schizophrenia and Bipolar I Mania. “Psychomotor agitation” is defined in DSM-IV as “excessive motor activity associated with a feeling of inner tension.” Patients experiencing agitation often manifest behaviors that interfere with their diagnosis and care, e.g., threatening behaviors, escalating or urgently distressing behavior, or self-exhausting behavior, leading clinicians to the use of intramuscular antipsychotic medications to achieve immediate control of the agitation [see Clinical Studies ( 14.3 )] . 1.4 ZYPREXA and Fluoxetine in Combination: Depressive Episodes Associated with Bipolar I Disorder When using ZYPREXA and fluoxetine in combination, also refer to the Clinical Studies section of the package insert for Symbyax. Oral ZYPREXA and fluoxetine in combination is indicated for the acute treatment of depressive episodes associated with Bipolar I Disorder in adult patients. ZYPREXA monotherapy is not indicated for the treatment of depressive episodes associated with Bipolar I Disorder. 1.5 ZYPREXA and Fluoxetine in Combination: Treatment Resistant Depression When using ZYPREXA and fluoxetine in combination, also refer to the Indications and Usage section of the package insert for Symbyax. Oral ZYPREXA and fluoxetine in combination is indicated for the acute treatment of treatment resistant depression (Major Depressive Disorder in adult patients who do not respond to 2 separate trials of different antidepressants of adequate dose and duration in the current episode). ZYPREXA monotherapy is not indicated for the treatment of treatment resistant depression. uuid:28bcae73-fba5-40f3-8d06-7c15ece8ac49 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2469 biolink:treats MONDO:0005366 PMID:41385096 "[{""id"":""uuid:05b9b580-7330-41f1-9d71-2d2cc869286f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bc7a144a-5775-4da7-8be3-9b9e6e865672"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] HEPSERA is indicated for the treatment of chronic hepatitis B in patients 12 years of age and older with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease. This indication is based on histological, virological, biochemical, and serological responses in adult patients with HBeAg+ and HBeAg- chronic hepatitis B with compensated liver function, and with clinical evidence of lamivudine-resistant hepatitis B virus with either compensated or decompensated liver function. For patients 12 to <18 years of age, the indication is based on virological and biochemical responses in patients with HBeAg+ chronic hepatitis B virus infection with compensated liver function. uuid:5ccb6f1f-fe15-40bd-b008-fdeb2a6f7abb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:36795 biolink:treats UMLS:C1963916 PMID:41385096 "[{""id"":""uuid:eaec647a-07c4-4770-a9b9-a741790757d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:754fe31a-1602-4b34-bf96-d9815977faf3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cymbalta ® is a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for: Major Depressive Disorder (MDD) ( 1.1 ) Efficacy was established in 4 short-term and one maintenance trial in adults ( 14.1 ). Generalized Anxiety Disorder (GAD) ( 1.2 ) Efficacy was established in 3 short-term and one maintenance trial in adults ( 14.2 ). Diabetic Peripheral Neuropathic Pain (DPNP) ( 1.3 ) Fibromyalgia (FM) ( 1.4 ) uuid:6e4f4a21-3969-4cc8-a54e-859b172262d6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134991 biolink:treats MONDO:0005475 PMID:41385096 "[{""id"":""uuid:cef8b9b4-aa93-4df3-a7b4-169b293bb6a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b48c998f-eba9-4862-9f77-7be376141732"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FROVA is indicated for the acute treatment of migraine attacks with or without aura in adults. FROVA is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS ). The safety and effectiveness of FROVA have not been established for cluster headache, which is present in an older, predominately male, population. uuid:b4c014dd-3b61-4bd1-ac84-f2718f9de898 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134991 biolink:treats MONDO:0100431 PMID:41385096 "[{""id"":""uuid:2e466d45-78a7-46e5-8a54-4dbea531d42f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:343d1dd6-9e7c-463c-b1d5-b29a974545ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FROVA is indicated for the acute treatment of migraine attacks with or without aura in adults. FROVA is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS ). The safety and effectiveness of FROVA have not been established for cluster headache, which is present in an older, predominately male, population. uuid:660f8e48-9c29-4a6a-84de-5dcc5d5997eb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134991 biolink:treats MONDO:0018925 PMID:41385096 "[{""id"":""uuid:ffa215bd-5c65-4bc2-8b85-752a239df632"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fcb8cdd5-33d2-4c59-ae49-9af64daf4da0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FROVA is indicated for the acute treatment of migraine attacks with or without aura in adults. FROVA is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS ). The safety and effectiveness of FROVA have not been established for cluster headache, which is present in an older, predominately male, population. uuid:6d1f4d89-1f8b-4e65-9fa7-8ca214ff1c19 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134991 biolink:treats MONDO:0043219 PMID:41385096 "[{""id"":""uuid:dc23e399-6733-4ae3-ad7a-9a0966f26743"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fcf102e7-8d58-430d-b45a-812d5d3f48fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FROVA is indicated for the acute treatment of migraine attacks with or without aura in adults. FROVA is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS ). The safety and effectiveness of FROVA have not been established for cluster headache, which is present in an older, predominately male, population. uuid:0285a2c5-bb89-4f64-bc4a-d82ba1540db0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134991 biolink:treats MONDO:0043537 PMID:41385096 "[{""id"":""uuid:4f617ed7-a3dd-4c30-97ef-28b4c937a339"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ea5daa6f-d7fa-43dc-9662-3303002407fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FROVA is indicated for the acute treatment of migraine attacks with or without aura in adults. FROVA is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS ). The safety and effectiveness of FROVA have not been established for cluster headache, which is present in an older, predominately male, population. uuid:a2c89bcc-2689-4786-9f46-9ff9bc968d1d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31859 biolink:treats MONDO:0021107 PMID:41385096 "[{""id"":""uuid:cf3f47cf-95dc-4c01-80d7-4826448c0328"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6cc70dd0-0ef5-4013-bb4a-c3ad79c97a30"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:130960b1-0ad2-40f9-a8b2-ecd2ceee6d40"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PROVIGIL is indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnea/hypopnea syndrome, and shift work sleep disorder. In OSAHS, PROVIGIL is indicated as an adjunct to standard treatment(s) for the underlying obstruction. If continuous positive airway pressure (CPAP) is the treatment of choice for a patient, a maximal effort to treat with CPAP for an adequate period of time should be made prior to initiating PROVIGIL. If PROVIGIL is used adjunctively with CPAP, the encouragement of and periodic assessment of CPAP compliance is necessary. In all cases, careful attention to the diagnosis and treatment of the underlying sleep disorder(s) is of utmost importance. Prescribers should be aware that some patients may have more than one sleep disorder contributing to their excessive sleepiness. The effectiveness of modafinil in long-term use (greater than 9 weeks in Narcolepsy clinical trials and 12 weeks in OSAHS and SWSD clinical trials) has not been systematically evaluated in placebo-controlled trials. The physician who elects to prescribe PROVIGIL for an extended time in patients with Narcolepsy, OSAHS, or SWSD should periodically reevaluate long-term usefulness for the individual patient.|[PMDA] Drugs containing a new active ingredient indicated for treatment of excessive daytime sleepiness associated with narcolepsy. [Orphan Drug] uuid:e30cd236-6c2a-4177-ae12-4a252bdd8d2e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31859 biolink:treats MONDO:0007147 PMID:41385096 "[{""id"":""uuid:6d6a7dcb-2bb3-4fb8-bbf2-3a712e276028"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9291ecff-5458-41a2-9c60-24f84038e601"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:2b3753c9-eea1-488f-b724-e78bac7cbaac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PROVIGIL is indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnea/hypopnea syndrome, and shift work sleep disorder. In OSAHS, PROVIGIL is indicated as an adjunct to standard treatment(s) for the underlying obstruction. If continuous positive airway pressure (CPAP) is the treatment of choice for a patient, a maximal effort to treat with CPAP for an adequate period of time should be made prior to initiating PROVIGIL. If PROVIGIL is used adjunctively with CPAP, the encouragement of and periodic assessment of CPAP compliance is necessary. In all cases, careful attention to the diagnosis and treatment of the underlying sleep disorder(s) is of utmost importance. Prescribers should be aware that some patients may have more than one sleep disorder contributing to their excessive sleepiness. The effectiveness of modafinil in long-term use (greater than 9 weeks in Narcolepsy clinical trials and 12 weeks in OSAHS and SWSD clinical trials) has not been systematically evaluated in placebo-controlled trials. The physician who elects to prescribe PROVIGIL for an extended time in patients with Narcolepsy, OSAHS, or SWSD should periodically reevaluate long-term usefulness for the individual patient.|[PMDA] A drug with a new additional indication for the treatment of excessive daytime sleepiness in patients with obstructive sleep apnea syndrome who receive treatment of airway obstruction with continuous positive airway pressure (CPAP) therapy, etc. uuid:6cfd0814-273a-4501-b4b3-aec110a72f42 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31859 biolink:treats MONDO:0024382 PMID:41385096 "[{""id"":""uuid:554a0373-d879-4893-9b99-27913f4f817c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0dbc9ca3-209a-4b55-93c4-e6e4954d0a79"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PROVIGIL is indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnea/hypopnea syndrome, and shift work sleep disorder. In OSAHS, PROVIGIL is indicated as an adjunct to standard treatment(s) for the underlying obstruction. If continuous positive airway pressure (CPAP) is the treatment of choice for a patient, a maximal effort to treat with CPAP for an adequate period of time should be made prior to initiating PROVIGIL. If PROVIGIL is used adjunctively with CPAP, the encouragement of and periodic assessment of CPAP compliance is necessary. In all cases, careful attention to the diagnosis and treatment of the underlying sleep disorder(s) is of utmost importance. Prescribers should be aware that some patients may have more than one sleep disorder contributing to their excessive sleepiness. The effectiveness of modafinil in long-term use (greater than 9 weeks in Narcolepsy clinical trials and 12 weeks in OSAHS and SWSD clinical trials) has not been systematically evaluated in placebo-controlled trials. The physician who elects to prescribe PROVIGIL for an extended time in patients with Narcolepsy, OSAHS, or SWSD should periodically reevaluate long-term usefulness for the individual patient. uuid:c2e95702-0411-4980-9a87-250640ae51b5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29103 biolink:treats MONDO:0001909 PMID:41385096 "[{""id"":""uuid:3fb884d2-9ce7-48f1-a9ad-97c96ccfaae9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7b15915a-df32-4db6-906b-53e5c4260b15"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Potassium citrate extended-release tablets are indicated for the management of renal tubular acidosis (RTA) with calcium stones, hypocitraturic calcium oxalate nephrolithiasis of any etiology, and uric acid lithiasis with or without calcium stones. uuid:596bb7d6-9ac1-4a40-bb05-a13e85cf4e10 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29103 biolink:treats MONDO:0957318 PMID:41385096 "[{""id"":""uuid:a75e19e0-5f24-4d0c-8b0d-25588fa766b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4d9f3339-6250-4993-bb27-77c69594e3a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Potassium citrate extended-release tablets are indicated for the management of renal tubular acidosis (RTA) with calcium stones, hypocitraturic calcium oxalate nephrolithiasis of any etiology, and uric acid lithiasis with or without calcium stones. uuid:f1b0350c-ee72-476a-9ec6-3340bb8568d9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29103 biolink:treats MONDO:0008629 PMID:41385096 "[{""id"":""uuid:d2dfecc9-8a17-42a6-91f2-125da200fb25"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:74715d33-0d9f-448e-8980-62d61b924ce1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Potassium citrate extended-release tablets are indicated for the management of renal tubular acidosis (RTA) with calcium stones, hypocitraturic calcium oxalate nephrolithiasis of any etiology, and uric acid lithiasis with or without calcium stones. uuid:f76e3947-b2d8-4f51-b4ae-b8567d18c777 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31536 biolink:treats MONDO:0004951 PMID:41385096 "[{""id"":""uuid:1899694a-2533-47ac-93e6-14dcd816e1c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7df66bfa-1066-4d6c-8119-db5bdb063c72"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EMTRIVA ® is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. Additional important information regarding the use of EMTRIVA for the treatment of HIV-1 Infection: EMTRIVA should not be coadministered with ATRIPLA ® , TRUVADA ® , or lamivudine-containing products [See Warnings and Precautions (5.3) ] . In treatment-experienced patients, the use of EMTRIVA should be guided by laboratory testing and treatment history [See Clinical Pharmacology (12.4) ] . uuid:d40eca77-001e-4acc-b4cd-9105a90dbad5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8059 biolink:treats NCIT:C120380 PMID:41385096 "[{""id"":""uuid:732b91a6-80ac-484e-b764-962dcb1e6cc3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6663acd8-19d9-41e1-bb89-c2095694c00b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Phendimetrazine tartrate tablets are indicated in the management of exogenous obesity as a short term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction. The limited usefulness of agents of this class (see CLINICAL PHARMACOLOGY ) should be measured against possible risk factors inherent in their use such as those described below. uuid:7a16d985-47ce-4660-a0e1-58feaacee667 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6539 biolink:treats MONDO:0005618 PMID:41385096 "[{""id"":""uuid:582cd8dd-ed97-47e6-b759-43868583e66b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0184d952-d7f3-4c7e-a678-effeefe08c49"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lorazepam is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety or anxiety associated with depressive symptoms. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The effectiveness of lorazepam in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient. uuid:a7769e52-5964-40dd-9d70-ce0a4ea52b2a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6539 biolink:treats MONDO:0041086 PMID:41385096 "[{""id"":""uuid:0421b632-f3cf-4003-b8e5-9871a86ef5f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4df29453-95d5-4553-a8a6-c6148d1f4be2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lorazepam is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety or anxiety associated with depressive symptoms. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The effectiveness of lorazepam in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient. uuid:0f2d440a-7c75-4f30-99df-25fc79360efe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9907 biolink:treats MONDO:0006698 PMID:41385096 "[{""id"":""uuid:9ae37cc1-70d8-4e67-b326-c03e963ee330"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:71db1925-c82e-47ad-be3f-3304ddd05470"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ursodiol is indicated for patients with radiolucent, noncalcified gallbladder stones < 20 mm in greatest diameter in whom elective cholecystectomy would be undertaken except for the presence of increased surgical risk due to systemic disease, advanced age, idiosyncratic reaction to general anesthesia, or for those patients who refuse surgery. Safety of use of ursodiol beyond 24 months is not established. Ursodiol is indicated for the prevention of gallstone formation in obese patients experiencing rapid weight loss. uuid:4c4babba-fe83-443c-a76c-ec201cc52be6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9907 biolink:treats MONDO:0012672 PMID:41385096 "[{""id"":""uuid:b9257469-5a9b-4445-b32f-933f63dcc433"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b2dbbe3c-c834-44d0-84f8-2f0666706267"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ursodiol is indicated for patients with radiolucent, noncalcified gallbladder stones < 20 mm in greatest diameter in whom elective cholecystectomy would be undertaken except for the presence of increased surgical risk due to systemic disease, advanced age, idiosyncratic reaction to general anesthesia, or for those patients who refuse surgery. Safety of use of ursodiol beyond 24 months is not established. Ursodiol is indicated for the prevention of gallstone formation in obese patients experiencing rapid weight loss. uuid:cc07799b-ddbf-4377-9804-ab1a6187dece biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7451 biolink:treats MONDO:0005984 PMID:41385096 "[{""id"":""uuid:79d7cba6-84cd-46d8-9034-bac082c64fca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ba3b82c7-14be-419f-a422-efacbb52b7e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Naftin ® Cream, 1% is indicated for the topical treatment of tinea pedis, tinea cruris and tinea corporis caused by the organisms Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum. uuid:4e5c4de0-79e9-4cb1-ad6c-4585352a95ef biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7451 biolink:treats MONDO:0001405 PMID:41385096 "[{""id"":""uuid:ae013537-27e3-4a55-ae67-7806c503d3eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c5d80bd6-38b0-4206-9af6-f9a0e00eedf0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Naftin ® Cream, 1% is indicated for the topical treatment of tinea pedis, tinea cruris and tinea corporis caused by the organisms Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum. uuid:83db8b02-c447-4bde-9d04-45613624c3ae biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7451 biolink:treats MONDO:0001461 PMID:41385096 "[{""id"":""uuid:6aa7e93b-a79c-471d-901f-4cc141e0bf53"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dda4906a-594d-462a-a522-413e746f05fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Naftin ® Cream, 1% is indicated for the topical treatment of tinea pedis, tinea cruris and tinea corporis caused by the organisms Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum. uuid:23e199a6-72d5-4f4a-a12f-8ecc9348107f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17439 biolink:treats MONDO:0400000 PMID:41385096 "[{""id"":""uuid:508266ca-6a4e-4871-8d0a-f68be00616d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3238fc61-05f8-46a5-9357-1b74c50507eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cyanocobalamin is indicated for vitamin B 12 deficiencies due to malabsorption which may be associated with the following conditions: Addisonian (pernicious) anemia Gastrointestinal pathology, dysfunction, or surgery, including gluten enteropathy or sprue, small bowel bacteria overgrowth, total or partial gastrectomy Fish tapeworm infestation Malignancy of pancreas or bowel Folic acid deficiency It may be possible to treat the underlying disease by surgical correction of anatomic lesions leading to small bowel bacterial overgrowth, expulsion of fish tapeworm, discontinuation of drugs leading to vitamin malabsorption (see Drug Interactions ), use of a gluten-free diet in nontropical sprue, or administration of antibiotics in tropical sprue. Such measures remove the need for long-term administration of cyanocobalamin. Requirements of vitamin B 12 in excess of normal (due to pregnancy, thyrotoxicosis, hemolytic anemia, hemorrhage, malignancy, hepatic and renal disease) can usually be met with oral supplementation. Cyanocobalamin Injection, USP is also suitable for the vitamin B 12 absorption test ( Schilling test ). uuid:2b3436cc-4de6-459f-ad91-f6bcf29655e6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17439 biolink:treats MONDO:0015260 PMID:41385096 "[{""id"":""uuid:c6715de2-3f1e-4fc5-ad8a-774a4c8f5fb1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:00e48f58-0a6f-46b8-b318-befebd3840f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cyanocobalamin is indicated for vitamin B 12 deficiencies due to malabsorption which may be associated with the following conditions: Addisonian (pernicious) anemia Gastrointestinal pathology, dysfunction, or surgery, including gluten enteropathy or sprue, small bowel bacteria overgrowth, total or partial gastrectomy Fish tapeworm infestation Malignancy of pancreas or bowel Folic acid deficiency It may be possible to treat the underlying disease by surgical correction of anatomic lesions leading to small bowel bacterial overgrowth, expulsion of fish tapeworm, discontinuation of drugs leading to vitamin malabsorption (see Drug Interactions ), use of a gluten-free diet in nontropical sprue, or administration of antibiotics in tropical sprue. Such measures remove the need for long-term administration of cyanocobalamin. Requirements of vitamin B 12 in excess of normal (due to pregnancy, thyrotoxicosis, hemolytic anemia, hemorrhage, malignancy, hepatic and renal disease) can usually be met with oral supplementation. Cyanocobalamin Injection, USP is also suitable for the vitamin B 12 absorption test ( Schilling test ). uuid:b766a116-5401-4de8-97f1-934e303de6c1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17439 biolink:treats MONDO:0009831 PMID:41385096 "[{""id"":""uuid:1c5581fa-e9ae-4e78-a51c-cffdb44c63e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:11100a87-f7ad-48d1-83b2-0c4cb4dc1452"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cyanocobalamin is indicated for vitamin B 12 deficiencies due to malabsorption which may be associated with the following conditions: Addisonian (pernicious) anemia Gastrointestinal pathology, dysfunction, or surgery, including gluten enteropathy or sprue, small bowel bacteria overgrowth, total or partial gastrectomy Fish tapeworm infestation Malignancy of pancreas or bowel Folic acid deficiency It may be possible to treat the underlying disease by surgical correction of anatomic lesions leading to small bowel bacterial overgrowth, expulsion of fish tapeworm, discontinuation of drugs leading to vitamin malabsorption (see Drug Interactions ), use of a gluten-free diet in nontropical sprue, or administration of antibiotics in tropical sprue. Such measures remove the need for long-term administration of cyanocobalamin. Requirements of vitamin B 12 in excess of normal (due to pregnancy, thyrotoxicosis, hemolytic anemia, hemorrhage, malignancy, hepatic and renal disease) can usually be met with oral supplementation. Cyanocobalamin Injection, USP is also suitable for the vitamin B 12 absorption test ( Schilling test ). uuid:efbde9b0-e6b1-4d28-83f8-05d8a9641aa4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17439 biolink:treats MONDO:0005008 PMID:41385096 "[{""id"":""uuid:1c621749-60c8-464a-bd7c-c1c9fa972fad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4b070426-fe44-44aa-8c2d-318cfa7dd96d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cyanocobalamin is indicated for vitamin B 12 deficiencies due to malabsorption which may be associated with the following conditions: Addisonian (pernicious) anemia Gastrointestinal pathology, dysfunction, or surgery, including gluten enteropathy or sprue, small bowel bacteria overgrowth, total or partial gastrectomy Fish tapeworm infestation Malignancy of pancreas or bowel Folic acid deficiency It may be possible to treat the underlying disease by surgical correction of anatomic lesions leading to small bowel bacterial overgrowth, expulsion of fish tapeworm, discontinuation of drugs leading to vitamin malabsorption (see Drug Interactions ), use of a gluten-free diet in nontropical sprue, or administration of antibiotics in tropical sprue. Such measures remove the need for long-term administration of cyanocobalamin. Requirements of vitamin B 12 in excess of normal (due to pregnancy, thyrotoxicosis, hemolytic anemia, hemorrhage, malignancy, hepatic and renal disease) can usually be met with oral supplementation. Cyanocobalamin Injection, USP is also suitable for the vitamin B 12 absorption test ( Schilling test ). uuid:f1fec83d-4fac-42bc-a77f-f46d744948ef biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17439 biolink:treats MONDO:0001860 PMID:41385096 "[{""id"":""uuid:cc13a1ff-dcee-484d-898f-bff54a697eca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4825af38-4bf4-4139-8c5e-981c7c45bb68"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cyanocobalamin is indicated for vitamin B 12 deficiencies due to malabsorption which may be associated with the following conditions: Addisonian (pernicious) anemia Gastrointestinal pathology, dysfunction, or surgery, including gluten enteropathy or sprue, small bowel bacteria overgrowth, total or partial gastrectomy Fish tapeworm infestation Malignancy of pancreas or bowel Folic acid deficiency It may be possible to treat the underlying disease by surgical correction of anatomic lesions leading to small bowel bacterial overgrowth, expulsion of fish tapeworm, discontinuation of drugs leading to vitamin malabsorption (see Drug Interactions ), use of a gluten-free diet in nontropical sprue, or administration of antibiotics in tropical sprue. Such measures remove the need for long-term administration of cyanocobalamin. Requirements of vitamin B 12 in excess of normal (due to pregnancy, thyrotoxicosis, hemolytic anemia, hemorrhage, malignancy, hepatic and renal disease) can usually be met with oral supplementation. Cyanocobalamin Injection, USP is also suitable for the vitamin B 12 absorption test ( Schilling test ). uuid:9777bf27-52ec-4436-a6c9-0ba0f6c1ad2e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32234 biolink:treats MONDO:0005326 PMID:41385096 "[{""id"":""uuid:3b090b01-702d-4d6f-823d-becd37ab0e61"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9ffb95a9-a1cd-4910-9dbd-be26841a22b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] USES Helps prevent sunburns Higher SPF gives more sunburn protection Apply liberally as needed 15 to 20 minutes before sun exposure Reapply as needed or after swimming, perspiring or towel drying Children under 6 months of age: ask doctor uuid:19fe017f-4ec6-482f-8bad-75ccc44bcbce biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90959 biolink:treats MONDO:0005002 PMID:41385096 "[{""id"":""uuid:948b482e-b2d2-44b8-b8a2-b0cf8b2c4389"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:850c7e52-be09-4665-992f-0efa3b900e6f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SPIRIVA HandiHaler (tiotropium bromide inhalation powder) is indicated for the long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. SPIRIVA HandiHaler is indicated to reduce exacerbations in COPD patients. uuid:ffa79dc6-4033-4b76-9152-c6b99ba55e34 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90959 biolink:treats MONDO:0005607 PMID:41385096 "[{""id"":""uuid:2d1fc80d-56ea-4906-a4d5-87fd7fd68347"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4e03ae4c-5486-423d-9859-e250a6fb102a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SPIRIVA HandiHaler (tiotropium bromide inhalation powder) is indicated for the long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. SPIRIVA HandiHaler is indicated to reduce exacerbations in COPD patients. uuid:8048dbaa-c59a-4b2c-a74d-e0a07fa8bdad biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90959 biolink:treats MONDO:0004849 PMID:41385096 "[{""id"":""uuid:c0129bc3-4b5b-4cc3-b812-a96b1bb887af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:19e03bc1-d5f7-4e64-a33e-deee87b03a4e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SPIRIVA HandiHaler (tiotropium bromide inhalation powder) is indicated for the long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. SPIRIVA HandiHaler is indicated to reduce exacerbations in COPD patients. uuid:55ccf27e-9c81-4616-98bb-ea7078d1ac8d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3219 biolink:treats MONDO:0000694 PMID:41385096 "[{""id"":""uuid:37ae162d-ea5c-41ef-b0e6-2d18b57c192f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9d3948ee-b6be-4b34-920a-996e16ae19ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Major Depressive Disorder: Bupropion hydrochloride extended-release tablets (XL) are indicated for the treatment of major depressive disorder. The efficacy of bupropion in the treatment of a major depressive episode was established in two 4-week controlled trials of inpatients and in one 6-week controlled trial of outpatients whose diagnoses corresponded most closely to the Major Depression category of the APA Diagnostic and Statistical Manual (DSM) (see CLINICAL TRIALS ). A major depressive episode (DSM-IV) implies the presence of 1) depressed mood or 2) loss of interest or pleasure; in addition, at least 5 of the following symptoms have been present during the same 2-week period and represent a change from previous functioning: depressed mood, markedly diminished interest or pleasure in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt, or suicidal ideation. The efficacy of bupropion in maintaining an antidepressant response for up to 44 weeks following 8 weeks of acute treatment was demonstrated in a placebo-controlled trial with the sustained-release formulation of bupropion (see CLINICAL TRIALS ). Nevertheless, the physician who elects to use bupropion hydrochloride extended-release tablets (XL) for extended periods should periodically reevaluate the long-term usefulness of the drug for the individual patient. Seasonal Affective Disorder: Bupropion hydrochloride extended-release tablets (XL) are indicated for the prevention of seasonal major depressive episodes in patients with a diagnosis of seasonal affective disorder. The efficacy of bupropion hydrochloride extended-release tablets (XL) for the prevention of seasonal major depressive episodes was established in 3 controlled trials of adult outpatients with a history of major depressive disorder with an autumn-winter seasonal pattern as defined by Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) criteria (see CLINICAL TRIALS ). Seasonal affective disorder is characterized by recurrent major depressive episodes, most commonly occurring during the autumn and/or winter months. Episodes may last up to 6 months in duration, typically beginning in the autumn and remitting in the springtime. Although patients with seasonal affective disorder may have depressive episodes during other times of the year, the diagnosis of seasonal affective disorder requires that the number of seasonal episodes substantially outnumber the number of non-seasonal episodes during the individual's lifetime. uuid:4963d806-9c86-43cd-afa2-8c9be73a3d9c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:378730 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:07733002-2ac2-47c5-8822-d26f5829f618"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:013507f3-3491-4674-aa6b-a2c0a43ad0d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Glipizide and metformin hydrochloride tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. uuid:ac670c9f-6210-42ea-8a26-dddb43ecfb5e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2453 biolink:treats MONDO:0005609 PMID:41385096 "[{""id"":""uuid:0ac57b22-9873-47e9-8da6-25a01ded479a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:80589453-ac38-4f11-b24f-ffed5bfeb258"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ecfa9642-245f-4114-b6e6-6bf5b6262d3f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Herpes Zoster Infections: Acyclovir oral suspension, USP is indicated for the acute treatment of herpes zoster (shingles). Genital Herpes: Acyclovir oral suspension, USP is indicated for the treatment of initial episodes and the management of recurrent episodes of genital herpes. Chickenpox: Acyclovir oral suspension, USP is indicated for the treatment of chickenpox (varicella).|[PMDA] Drugs with new additional indications and a new additional dosage for herpes simplex, prevention of herpes simplex virus infection in hematopoietic stem cell transplantation, herpes zoster, and prevention of recurrence of genital herpes (oral dosage form), and neonatal herpes simplex virus infection (injectable dosage form) based on the discussion of the Investigational Committee on Pediatric Drug Therapies. uuid:45bfe28f-c157-4461-90b7-4a4f92601273 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2453 biolink:treats MONDO:0005770 PMID:41385096 "[{""id"":""uuid:8016de66-da7b-4948-9543-038e5afafd14"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:bfcfa247-9295-4273-bd43-3a086bbf1fe5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:3343921b-ac16-475a-bab4-a5ef862153d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Herpes Zoster Infections: Acyclovir oral suspension, USP is indicated for the acute treatment of herpes zoster (shingles). Genital Herpes: Acyclovir oral suspension, USP is indicated for the treatment of initial episodes and the management of recurrent episodes of genital herpes. Chickenpox: Acyclovir oral suspension, USP is indicated for the treatment of chickenpox (varicella).|[PMDA] Drugs with new additional indications and a new additional dosage for herpes simplex, prevention of herpes simplex virus infection in hematopoietic stem cell transplantation, herpes zoster, and prevention of recurrence of genital herpes (oral dosage form), and neonatal herpes simplex virus infection (injectable dosage form) based on the discussion of the Investigational Committee on Pediatric Drug Therapies. uuid:85887cd0-9eab-44b9-ac57-f852296dc352 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2453 biolink:treats MONDO:0005700 PMID:41385096 "[{""id"":""uuid:73334d81-e274-4064-bea4-cb36fcd0947b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3bf3d212-d41d-4734-8fef-d4be00145694"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Herpes Zoster Infections: Acyclovir oral suspension, USP is indicated for the acute treatment of herpes zoster (shingles). Genital Herpes: Acyclovir oral suspension, USP is indicated for the treatment of initial episodes and the management of recurrent episodes of genital herpes. Chickenpox: Acyclovir oral suspension, USP is indicated for the treatment of chickenpox (varicella). uuid:599f700a-bbb5-4e02-93ee-e582eed9b986 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5950 biolink:treats MONDO:0005480 PMID:41385096 "[{""id"":""uuid:bedc0ad8-98d7-4678-aecc-65e2bca93d05"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ff60ca0e-3298-4f67-b1af-f300b600552f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); monliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:ffb46329-8ebd-415f-ae13-8a5719702fe2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5950 biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:ad96bd32-e1bc-4006-9aaf-4db4ec9a480f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:08ebdfd8-278c-49f9-bda5-84caf142a211"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); monliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:c2bc3cb3-3da7-4b32-bc51-4976671096dd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5950 biolink:treats MONDO:0002406 PMID:41385096 "[{""id"":""uuid:289df9ef-eb03-4fe2-864d-368912c86d4b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7d125066-82fb-4d38-b0c8-b1125fd32a81"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); monliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:7a2ec222-47c8-48e5-a951-0fdaa1e44a8d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5950 biolink:treats HP:0033120 PMID:41385096 "[{""id"":""uuid:f20e2d78-ccd2-4cb0-aa74-d5e73c4c742f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e26df92c-f797-45c7-abee-2812aea7aedd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); monliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:9c964224-1aa8-41c5-98c2-26c785358034 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5950 biolink:treats HP:0033564 PMID:41385096 "[{""id"":""uuid:5742672f-58e9-46b6-8714-1c9373622dec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4e64cf82-a38e-4d28-85af-d14650503a0c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); monliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:d661e691-ebce-48c1-a5f2-b370acad5d40 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5950 biolink:treats MONDO:0002922 PMID:41385096 "[{""id"":""uuid:f7f279d5-1d0e-41a3-b973-6e6c4876d500"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ffcd7217-bfc6-4104-98a1-239b4a227936"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); monliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:23f567de-4902-4e4b-8082-307093779441 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5950 biolink:treats MONDO:0004795 PMID:41385096 "[{""id"":""uuid:7ba2f474-42ac-400a-b489-7198d256c170"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c6f507fb-9d2f-46d2-b4e7-36eacff0eeb6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); monliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:f78fff6d-fbb0-46a2-b992-712eff1e580d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5950 biolink:treats UMLS:C0406297 PMID:41385096 "[{""id"":""uuid:c4a9d2bb-5433-4827-8299-9c18847669fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d04c2353-ca9e-494a-bdec-0a71d67bc24f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); monliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:c44bef04-c66b-49ea-82f1-8a87b78585ab biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5950 biolink:treats MONDO:0006585 PMID:41385096 "[{""id"":""uuid:a27f78b3-9f16-4cdc-98b8-5cccfec689ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:15cf5830-eb72-4c65-ab54-2e3c166fed37"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); monliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:b923792d-7d52-43ea-945c-ca2e067e47e8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5950 biolink:treats UMLS:C0149922 PMID:41385096 "[{""id"":""uuid:761bc98a-5445-4399-98e0-848731c29d7c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0f06912b-e12b-4922-b2d0-a591a18aea8b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); monliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:8afe5abe-97d5-4734-b06d-b71751210c1f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5950 biolink:treats UMLS:C0003107 PMID:41385096 "[{""id"":""uuid:e819b92c-6a23-4ca7-84c1-6b4f303c7dd9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b740966e-0f1f-4c7f-84ee-6c7123a432ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); monliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:ea73e859-b999-40e4-a520-cbebab226e0a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5950 biolink:treats HP:0032004 PMID:41385096 "[{""id"":""uuid:6fdfb207-8fd8-4507-a186-32d6cf76965d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:55eadd05-02de-45dc-8565-9678f92e4c41"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); monliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:bfcde6c5-3c2f-4e92-9662-241353043ba4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5950 biolink:treats UMLS:C0451941 PMID:41385096 "[{""id"":""uuid:03732c3e-1419-4afd-b044-ded1870668ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b8ae6ee0-b7f2-4b76-a05a-6214d8b34b64"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); monliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:4c67cc37-18d0-4407-b5cc-e4fda98a5392 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5950 biolink:treats UMLS:C0033775 PMID:41385096 "[{""id"":""uuid:d8e0214e-41ee-4d2f-821c-e023e43a05ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c309badb-5061-499b-a9e6-a098c7ba4573"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); monliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:fdd343f9-0119-4a38-8562-486eb8d4fcbe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5950 biolink:treats MONDO:0006552 PMID:41385096 "[{""id"":""uuid:28c91f8e-5e16-4ae0-8fe4-8314b6c97e30"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fdef6eaf-7704-4060-a27f-d9eb74e36881"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); monliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:ffe228b3-1d26-4e31-b49b-7df73025616a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5950 biolink:treats MONDO:0002967 PMID:41385096 "[{""id"":""uuid:1dc01d4c-48c3-4e93-a7ce-e452a66b2c54"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2f2f0271-28d1-4cae-8a24-8414c32795cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); monliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:e73f3168-8b6f-4d5b-9cc3-a239fd11c330 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5950 biolink:treats MONDO:0001405 PMID:41385096 "[{""id"":""uuid:1ffc445d-5613-433a-a531-fbbb6335e82c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dc2e2300-9841-4e9f-94db-d67fedc20938"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); monliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:84295fc3-70c9-4778-af3b-f2aee9fc8cb8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5950 biolink:treats MONDO:0001461 PMID:41385096 "[{""id"":""uuid:96e4ae00-f120-4cb0-a5e9-cd4c270a59ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b496238e-57d4-4675-8d5b-2c61aeae0628"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); monliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:1b7cc389-29ce-43a4-849d-2bea7e92ca97 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5950 biolink:treats MONDO:0005984 PMID:41385096 "[{""id"":""uuid:c76260d9-3e40-458c-8226-fc73e3508e22"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4d208f7d-4a16-4d45-a07c-aca841580cc8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); monliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:df41b1d1-ea35-491e-ba11-bb2c9370f558 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5950 biolink:treats MONDO:0021340 PMID:41385096 "[{""id"":""uuid:4707766b-7760-43af-afec-a6ddc7f82479"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9875040d-d587-4a9c-a242-438fce398ea4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); monliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:f95298f9-c62e-4ecf-a22f-d0e976c9c565 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17051 biolink:treats MONDO:0005276 PMID:41385096 "[{""id"":""uuid:c9547535-ccf0-4898-9fe4-c6f7c71da1ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:efab967a-4f58-4777-9d8b-a0986716e31b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATION AND USE: A topically-applied foaming solution to aid in the prevention of dental caries. uuid:e4858378-c1c3-435c-9c34-764aecd6b6a2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:82405 biolink:treats MONDO:0011438 PMID:41385096 "[{""id"":""uuid:2e713f87-13ff-4078-9951-e9cbb93d585d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b78b4617-280e-46f8-9251-5a93f0c6b068"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:1a8868f5-c1dc-4eae-ad66-895f01636eee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NeoBenz® Micro, NeoBenz® Micro SD and NeoBenz® Micro Wash are indicated for use in the topical treatment of mild to moderated acne vulgaris.|[PMDA] A drug with a new active ingredient indicated for the treatment of acne vulgaris. uuid:9fd0a212-4346-4199-8360-b9904e09135d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0002406 PMID:41385096 "[{""id"":""uuid:ef768bce-2bb6-479d-8ab4-26782747e9f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:881efa38-6bf8-4a2c-a021-4d7c4717652d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); monliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:bf5ed6fa-8641-4510-ad78-d4602367e6cf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats HP:0033120 PMID:41385096 "[{""id"":""uuid:65eb265c-708e-4de6-86f3-f8ab413d1787"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:23a3d6c5-b55a-45d3-bf06-46006f214bbd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); monliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:e4a1dfd7-5853-4bed-83e8-bb01163534c2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats HP:0033564 PMID:41385096 "[{""id"":""uuid:aa3f406b-4875-4633-b5c3-eac29abdebe2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6b1be4b8-68ac-4489-95f4-312dfd85b70b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); monliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:08f05f21-4f49-4463-be0a-d588181f46d7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0002922 PMID:41385096 "[{""id"":""uuid:f3f64391-2786-4517-a7d1-208917bd0f60"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:67d6245c-fc10-46e0-8cea-2306f5a88032"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); monliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:d2c19ead-8eed-4ebb-8a6d-a3071a874896 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0004795 PMID:41385096 "[{""id"":""uuid:817f88f5-97eb-4663-8a2e-54cc25d8d8f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b1505abc-0761-49ad-b30d-7b1e88e81d9b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); monliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:e42abf63-3402-4983-9d36-a64290b87f93 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats UMLS:C0406297 PMID:41385096 "[{""id"":""uuid:c4571d22-88b8-451f-ba6e-401796fc6f47"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9c690de8-416b-45e7-8de9-28463e5d7901"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); monliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:05fa45b4-e00f-48f3-91b2-6b43c9519f7b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0006585 PMID:41385096 "[{""id"":""uuid:e96d5772-0b9e-43a6-af9b-7cf0a423b52e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f6721771-0a17-4c04-b459-b58243e82ed1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); monliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:b92f6790-f93a-4f86-a249-a678369666d3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats UMLS:C0149922 PMID:41385096 "[{""id"":""uuid:27b59d9d-d0e2-4d12-88d1-c0ff2a22fbc9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c1a20ba5-c3e6-4836-bad9-e8a52f680ad6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); monliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:396faa8b-dd84-4873-b7ff-7b20c2246d7e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats UMLS:C0003107 PMID:41385096 "[{""id"":""uuid:fe516bb0-2bf6-439c-ae12-b36170585d66"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:691c19e8-b125-46bd-b2e8-51e63e76a805"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); monliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:77cd5b15-bce7-4b92-8234-dc10d68c2a4c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats HP:0032004 PMID:41385096 "[{""id"":""uuid:1c7fabe8-8277-4504-ab3a-2c7442dc8819"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3fee286a-0c46-4cdc-bc04-724cec42b353"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); monliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:1ef4d050-ac52-4004-a807-6dfbe8e591a9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats UMLS:C0451941 PMID:41385096 "[{""id"":""uuid:419a20f6-8aac-4e30-b133-eb3f7aa045c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:52ac16ae-dd60-408c-b4cf-cc80067f6e80"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); monliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:9af6d36a-1fa1-4ab9-9875-49ae20b59c3d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats UMLS:C0033775 PMID:41385096 "[{""id"":""uuid:4e5c3c61-982b-4a23-b2b4-b26c88fcaa9c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d6218399-fd0f-4bfd-b683-ad45a6110b46"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); monliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:8d21797c-4275-4cd2-bb68-350b01759f17 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0006552 PMID:41385096 "[{""id"":""uuid:bc264fca-84f3-40f6-b5cf-f5e103e07c1c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:36ec2475-1769-4c0f-bd98-4752a38a81de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); monliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:b3ee9e51-1771-487c-9396-1fee9fe86a13 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0002967 PMID:41385096 "[{""id"":""uuid:adb19f12-283c-4b00-9649-1f2e565d8991"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:be7c163f-1bcd-4b66-abcb-a0efc138ab3f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); monliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:344f7fae-0ed0-4fe8-906c-f82af25232ba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0001405 PMID:41385096 "[{""id"":""uuid:75cf2c51-0f53-436b-9f40-a48344cbc17b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:32c32715-be06-427a-b5de-ba847d567ea7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); monliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:45cfd84d-697c-49b7-b824-4ec868947e11 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0001461 PMID:41385096 "[{""id"":""uuid:cafa8d3c-9184-4d11-8bd8-d51a09f27b35"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ebbc9779-62b6-4617-ac9f-48c480c96085"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); monliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:9a68b274-7f84-4eda-9b4a-597aa4a82604 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0005984 PMID:41385096 "[{""id"":""uuid:9abb95e3-0c8d-4cec-849c-a59acebe54b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:20a8793a-4278-4803-8ae4-9b5894a44231"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); monliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:12974264-979d-4a96-91b7-121a63d376af biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0021340 PMID:41385096 "[{""id"":""uuid:90a333bf-0bc6-40cc-9ae8-5dee2397f337"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:90496381-8244-45c5-a708-2ebc4a0f4da1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); monliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:eab6e228-622f-4fa6-94a9-63e4fe733a06 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:37510 biolink:treats UMLS:C0406317 PMID:41385096 "[{""id"":""uuid:21d27c10-83a9-40f1-b147-adf35dd0c350"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2477248c-8e1c-4ac9-84b3-3aaf5dc9631d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the topical treatment of patients with stable plaque psoriasis. uuid:be06a871-428a-4cf4-bc6a-d9999ffb02c8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1152833 biolink:treats MONDO:0021146 PMID:41385096 "[{""id"":""uuid:a465e065-0dee-41d3-baf5-fd6355df73bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f65d2b20-0095-4549-88dc-d1c8d5d4997d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the temporary relief of minor aches and pains associated with headaches, backache, muscular aches, the menstrual and premenstrual periods, colds, the flu, toothaches, as well as for minor pain from arthritis, and to reduce fever. uuid:98b08997-87c4-4158-9f18-e0fceefd05c6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1152833 biolink:treats HP:0003418 PMID:41385096 "[{""id"":""uuid:7355ff41-da14-4819-a116-215cc67d1eef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a8d8f1e9-27ea-4e3f-859f-0e82de7efc16"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the temporary relief of minor aches and pains associated with headaches, backache, muscular aches, the menstrual and premenstrual periods, colds, the flu, toothaches, as well as for minor pain from arthritis, and to reduce fever. uuid:05b7e9b8-0821-4da4-8874-591d8bf1103c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1152833 biolink:treats HP:0003326 PMID:41385096 "[{""id"":""uuid:eed45f4c-8176-429b-96fc-5a9b59ba060e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f2c868c8-f79b-4c01-a317-305959e06215"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the temporary relief of minor aches and pains associated with headaches, backache, muscular aches, the menstrual and premenstrual periods, colds, the flu, toothaches, as well as for minor pain from arthritis, and to reduce fever. uuid:e887af7b-ff19-4ace-90e0-ce72445f4ead biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1152833 biolink:treats MONDO:0005709 PMID:41385096 "[{""id"":""uuid:1467ba33-43ab-46ba-a983-3fd6bbff6017"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c9922150-3683-4ab8-ad26-e9c624fc1b34"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the temporary relief of minor aches and pains associated with headaches, backache, muscular aches, the menstrual and premenstrual periods, colds, the flu, toothaches, as well as for minor pain from arthritis, and to reduce fever. uuid:3033050f-b012-488d-9838-00fa3095b86d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1152833 biolink:treats MONDO:0005812 PMID:41385096 "[{""id"":""uuid:e2660c1d-f94f-4529-bd01-94b62932fb4c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7c02d686-7e74-4674-8f86-11acaf0fadfd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the temporary relief of minor aches and pains associated with headaches, backache, muscular aches, the menstrual and premenstrual periods, colds, the flu, toothaches, as well as for minor pain from arthritis, and to reduce fever. uuid:3d2f7502-7097-4f53-ac05-1f14ac8f9ded biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1152833 biolink:treats EFO:0010072 PMID:41385096 "[{""id"":""uuid:d08e4822-e764-49fa-9a28-27e2e3fd7df8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2cfc9938-897e-49c7-b1b7-e53afb85082d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the temporary relief of minor aches and pains associated with headaches, backache, muscular aches, the menstrual and premenstrual periods, colds, the flu, toothaches, as well as for minor pain from arthritis, and to reduce fever. uuid:4d46e5f9-5fbb-4500-a204-8d41083638dc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1152833 biolink:treats MONDO:0005578 PMID:41385096 "[{""id"":""uuid:0a9742eb-29ea-480c-9695-cb95baf900b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9e161a2c-7f20-41f0-a158-bd001d0d719d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the temporary relief of minor aches and pains associated with headaches, backache, muscular aches, the menstrual and premenstrual periods, colds, the flu, toothaches, as well as for minor pain from arthritis, and to reduce fever. uuid:09cf1900-72de-4f32-a273-f511d51c7e46 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9327 biolink:treats MONDO:0011438 PMID:41385096 "[{""id"":""uuid:31fdc2f4-4116-4603-af64-c0d8c5a9c5db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9934eed1-c5df-4f41-b47e-cc6b734ee072"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Sulfacetamide Medicated Pads are indicated in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis. uuid:82142c46-6c44-4972-86d9-9db265b79377 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9327 biolink:treats MONDO:0006604 PMID:41385096 "[{""id"":""uuid:8aff771f-ee28-4567-9884-88c64fcee573"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d0a0ed7f-d81c-48b7-aff8-ad0901369518"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Sulfacetamide Medicated Pads are indicated in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis. uuid:9f9c2476-592c-436f-bcaa-be6f957483a6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9327 biolink:treats MONDO:0006608 PMID:41385096 "[{""id"":""uuid:2c78663a-c21b-494c-bbc8-0acd64aaa795"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:93910834-2154-46d3-8010-ed1bf4e7c14d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Sulfacetamide Medicated Pads are indicated in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis. uuid:a997b61d-b950-4a5f-93ae-7f0c1fa7bb5a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9014 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:0467b59f-48a1-47ce-a9ec-f3d5012e6c48"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ae87094f-f915-4d78-87cc-39761bb39d21"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of Salsalate tablets, USP and other treatment options before deciding to use Salsalate tablets, USP. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Salsalate is indicated for relief of the signs and symptoms of rheumatoid arthritis, osteoarthritis and related rheumatic disorder. uuid:45038547-6d51-4f59-9657-5d5d0dd27943 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9014 biolink:treats MONDO:0005178 PMID:41385096 "[{""id"":""uuid:daaa962b-9e25-43d5-9d50-39a37d95d03a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:30e62a39-0195-4545-a23f-0892ff3d22c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of Salsalate tablets, USP and other treatment options before deciding to use Salsalate tablets, USP. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Salsalate is indicated for relief of the signs and symptoms of rheumatoid arthritis, osteoarthritis and related rheumatic disorder. uuid:731a2125-ac57-45f2-a2ae-106178caf640 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9014 biolink:treats MONDO:0005554 PMID:41385096 "[{""id"":""uuid:cd11e335-b797-4d61-966b-14968097c9b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:55416d2d-ad97-40a2-8221-455b93626c0e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of Salsalate tablets, USP and other treatment options before deciding to use Salsalate tablets, USP. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Salsalate is indicated for relief of the signs and symptoms of rheumatoid arthritis, osteoarthritis and related rheumatic disorder. uuid:2a7c863c-80fc-4967-80fb-d90c8d7dd8e7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0981911 biolink:treats MONDO:0005271 PMID:41385096 "[{""id"":""uuid:7fc2e030-cb6f-4d52-b517-c5b381085080"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:db944012-0e51-44f4-97e6-e3629293ef21"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergenic extracts are indicated for use in diagnostic testing and as part of a treatment regime for allergic disease, as established by allergy history and skin test reactivity. Allergenic extracts are indicated for the treatment of allergen specific allergic disease for use as hyposensitization or immunotherapy when avoidance of specific allergens can not be attained. The use of allergenic extracts for therapeutic purpose has been established by well-controlled clinical studies. Allergenic extracts may be used as adjunctive therapy along with pharmacotherapy which includes antihistamines, corticosteroids, and cromoglycate, and avoidance measures. Allergenic extracts for therapeutic use should be given using only the allergen selection to which the patient is allergic, has a history of exposure and are likely to be exposed to again. DRUGBANK:DB10345 uuid:bfa062a4-6531-47dc-aaf8-7039f96706de biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1154173 biolink:treats MONDO:0005961 PMID:41385096 "[{""id"":""uuid:4b2b1864-b475-4501-8a15-c6d0f7d47315"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2deeef3c-afde-4823-98c9-f5490b8cb80b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Atuss® DS Tannate Suspension is indicated for temporary relief of nasal congestion and cough associated with respiratory tract infections and related conditions such as sinusitis, pharyngitis, bronchitis and asthma when these conditions are complicated by tenacious mucus and/or mucous plugs and congestion. Atuss® DS Tannate Suspension is effective in a productive as well as a nonproductive cough, but is of particular value in a dry nonproductive cough which tends to injure the mucous membrane of the air passages. uuid:b2d6dd9e-b319-4712-834e-ef6a28386804 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1154173 biolink:treats MONDO:0002258 PMID:41385096 "[{""id"":""uuid:f2e34ff1-229d-453b-8e48-67e3ef5f50d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eab0bed8-541b-461b-bf3c-3d2d3f737ad3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Atuss® DS Tannate Suspension is indicated for temporary relief of nasal congestion and cough associated with respiratory tract infections and related conditions such as sinusitis, pharyngitis, bronchitis and asthma when these conditions are complicated by tenacious mucus and/or mucous plugs and congestion. Atuss® DS Tannate Suspension is effective in a productive as well as a nonproductive cough, but is of particular value in a dry nonproductive cough which tends to injure the mucous membrane of the air passages. uuid:835a7289-0155-4b0c-9d60-c839a54703fc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1154173 biolink:treats MONDO:0003781 PMID:41385096 "[{""id"":""uuid:79d79bc1-2134-4c31-a3b3-3c8cc179c955"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:90ef138f-f745-43de-8c89-a92169eed126"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Atuss® DS Tannate Suspension is indicated for temporary relief of nasal congestion and cough associated with respiratory tract infections and related conditions such as sinusitis, pharyngitis, bronchitis and asthma when these conditions are complicated by tenacious mucus and/or mucous plugs and congestion. Atuss® DS Tannate Suspension is effective in a productive as well as a nonproductive cough, but is of particular value in a dry nonproductive cough which tends to injure the mucous membrane of the air passages. uuid:33a1ede6-0eef-4268-9066-78ab94400541 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1154173 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:58547283-54ea-4180-85ee-96db5ca379a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ea1cffa1-ed0f-49bd-9495-6324f652bea3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Atuss® DS Tannate Suspension is indicated for temporary relief of nasal congestion and cough associated with respiratory tract infections and related conditions such as sinusitis, pharyngitis, bronchitis and asthma when these conditions are complicated by tenacious mucus and/or mucous plugs and congestion. Atuss® DS Tannate Suspension is effective in a productive as well as a nonproductive cough, but is of particular value in a dry nonproductive cough which tends to injure the mucous membrane of the air passages. uuid:ad756851-7f76-4379-8570-03b4a1dc9758 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1156977 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:164bae1d-2cc8-4fd3-b2c3-49c4352b8c29"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:30f2948f-dafe-49f6-932d-7531b6008c18"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Pentazocine and naloxone hydrochlorides tablets are intended for oral use only. Severe, potentially lethal, reactions may result from misuse of pentazocine and naloxone hydrochlorides tablets by injection either alone or in combination with other substances. (See DRUG ABUSE AND DEPENDENCE section.) Pentazocine and naloxone hydrochlorides tablets are indicated for the relief of moderate to severe pain. Pentazocine and naloxone hydrochlorides tablets are indicated for oral use only. uuid:b1c94712-3f81-4c75-bbeb-85580aef8c5e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:37789 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:deb0a0c3-32e3-43b1-884d-215a7246d340"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8e3e868e-98f2-4dd5-bc26-549b14f4cdf9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Atenolol and chlorthalidone tablets are indicated in the treatment of hypertension. This fixed dose combination drug is not indicated for initial therapy of hypertension. If the fixed dose combination represents the dose appropriate to the individual patient’s needs, it may be more convenient than the separate components. uuid:d988c6e5-44cd-4330-b9ba-f4274a062c3f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31174 biolink:treats MONDO:0011438 PMID:41385096 "[{""id"":""uuid:7c1295bd-a7a1-42dd-92f4-1e32cc62af3e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:269c3ec6-4528-4461-ae2d-7c57601c740e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:6d5f97a8-3f9c-458c-84b1-40f25973f9ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Adapalene Gel is indicated for the topical treatment of acne vulgaris.|[PMDA] A drug containing a new active ingredient indicated for the treatment of acne vulgaris. uuid:3f9afd4e-5fa1-4f85-995b-9dfc1810bfe7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:39867 biolink:treats MONDO:0005277 PMID:41385096 "[{""id"":""uuid:fa94d60c-22c5-49f1-b42b-d001c44ceb93"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9199291f-1780-4e14-a2c6-7371bcc48731"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Divalproex sodium extended-release tablets are indicated for: Acute treatment of manic or mixed episodes associated with bipolar disorder, with or without psychotic features (1.1) Monotherapy and adjunctive therapy of complex partial seizures and simple and complex absence seizures; adjunctive therapy in patients with multiple seizure types that include absence seizures (1.2) Prophylaxis of migraine headaches (1.3) uuid:d0466c89-b804-47ea-8eec-5da9cf000da2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:352990 biolink:treats MONDO:0005530 PMID:41385096 "[{""id"":""uuid:4a38af5b-7498-4f7e-be38-30fcb874ed25"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:dcc64882-6713-479a-8809-d17ef57076ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:4850a993-b114-4538-ba06-d3965d0ac7dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/suboxone""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] SUBOXONE and SUBUTEX are indicated for the treatment of opioid dependence.|[EMA] Substitution treatment for opioid-drug dependence, within a framework of medical, social and psychological treatment. The intention of the naloxone component is to deter intravenous misuse. Treatment is intended for use in adults and adolescents over 15 years of age who have agreed to be treated for addiction. uuid:8af39b4f-6cb7-487c-806f-abd6dcfbf65d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:8NZ41MIK1O biolink:treats HP:0002625 PMID:41385096 "[{""id"":""uuid:f482c1b7-472d-44cf-a635-d731cbc94511"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:7c32a763-1cfc-4c17-99aa-eb353b399c9a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:81facb3b-7741-43a2-b007-c62f8cccab69"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/inhixa""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lovenox is a low molecular weight heparin [LMWH] indicated for: Prophylaxis of deep vein thrombosis (DVT) in abdominal surgery, hip replacement surgery, knee replacement surgery, or medical patients with severely restricted mobility during acute illness ( 1.1 ) Inpatient treatment of acute DVT with or without pulmonary embolism ( 1.2 ) Outpatient treatment of acute DVT without pulmonary embolism. ( 1.2 ) Prophylaxis of ischemic complications of unstable angina and non-Q-wave myocardial infarction [MI] ( 1.3 ) Treatment of acute ST-segment elevation myocardial infarction [STEMI] managed medically or with subsequent percutaneous coronary intervention [PCI] ( 1.4 )|[EMA] Inhixa is indicated for adults for:Prophylaxis of venous thromboembolism, particularly in patients undergoing orthopaedic, general or oncological surgery.Prophylaxis of venous thromboembolism in patients bedridden due to acute illnesses including acute heart failure, acute respiratory failure, severe infections, as well as exacerbation of rheumatic diseases causing immobilisation of the patient (applies to strengths of 40 mg/0.4 mL).Treatment of deep vein thrombosis (DVT), complicated or uncomplicated by pulmonary embolism.Treatment of unstable angina and non Q wave myocardial infarction, in combination with acetylsalicylic acid (ASA).Treatment of acute ST segment elevation myocardial infarction (STEMI) including patients who will be treated conservatively or who will later undergo percutaneous coronary angioplasty (applies to strengths of 60 mg/0.6 mL, 80 mg/0.8 mL, and 100 mg/1 mL).Blood clot prevention in the extracorporeal circulation during haemodialysis. uuid:21379a9d-71d4-42a1-ac79-be16d6fdfa81 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:8NZ41MIK1O biolink:treats MONDO:0005279 PMID:41385096 "[{""id"":""uuid:fdaca33d-49f5-4247-badd-6af23fb58e84"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:b00f6617-b369-499e-a710-8693aa23bec2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:82e5c5d0-0ee4-45cd-a8f8-59d5d0f3fc0b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/inhixa""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lovenox is a low molecular weight heparin [LMWH] indicated for: Prophylaxis of deep vein thrombosis (DVT) in abdominal surgery, hip replacement surgery, knee replacement surgery, or medical patients with severely restricted mobility during acute illness ( 1.1 ) Inpatient treatment of acute DVT with or without pulmonary embolism ( 1.2 ) Outpatient treatment of acute DVT without pulmonary embolism. ( 1.2 ) Prophylaxis of ischemic complications of unstable angina and non-Q-wave myocardial infarction [MI] ( 1.3 ) Treatment of acute ST-segment elevation myocardial infarction [STEMI] managed medically or with subsequent percutaneous coronary intervention [PCI] ( 1.4 )|[EMA] Inhixa is indicated for adults for:Prophylaxis of venous thromboembolism, particularly in patients undergoing orthopaedic, general or oncological surgery.Prophylaxis of venous thromboembolism in patients bedridden due to acute illnesses including acute heart failure, acute respiratory failure, severe infections, as well as exacerbation of rheumatic diseases causing immobilisation of the patient (applies to strengths of 40 mg/0.4 mL).Treatment of deep vein thrombosis (DVT), complicated or uncomplicated by pulmonary embolism.Treatment of unstable angina and non Q wave myocardial infarction, in combination with acetylsalicylic acid (ASA).Treatment of acute ST segment elevation myocardial infarction (STEMI) including patients who will be treated conservatively or who will later undergo percutaneous coronary angioplasty (applies to strengths of 60 mg/0.6 mL, 80 mg/0.8 mL, and 100 mg/1 mL).Blood clot prevention in the extracorporeal circulation during haemodialysis. uuid:93acc9cb-b83d-4748-bbb4-b0201576835d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:8NZ41MIK1O biolink:treats MONDO:0006805 PMID:41385096 "[{""id"":""uuid:d678fe6c-9af8-42fb-9c42-6537e69adfb3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:c55d8cf4-6ace-470c-96fa-70ef9f832b3b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:10eee8b3-980a-4436-8a95-d8a9639bc93a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/inhixa""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lovenox is a low molecular weight heparin [LMWH] indicated for: Prophylaxis of deep vein thrombosis (DVT) in abdominal surgery, hip replacement surgery, knee replacement surgery, or medical patients with severely restricted mobility during acute illness ( 1.1 ) Inpatient treatment of acute DVT with or without pulmonary embolism ( 1.2 ) Outpatient treatment of acute DVT without pulmonary embolism. ( 1.2 ) Prophylaxis of ischemic complications of unstable angina and non-Q-wave myocardial infarction [MI] ( 1.3 ) Treatment of acute ST-segment elevation myocardial infarction [STEMI] managed medically or with subsequent percutaneous coronary intervention [PCI] ( 1.4 )|[EMA] Inhixa is indicated for adults for:Prophylaxis of venous thromboembolism, particularly in patients undergoing orthopaedic, general or oncological surgery.Prophylaxis of venous thromboembolism in patients bedridden due to acute illnesses including acute heart failure, acute respiratory failure, severe infections, as well as exacerbation of rheumatic diseases causing immobilisation of the patient (applies to strengths of 40 mg/0.4 mL).Treatment of deep vein thrombosis (DVT), complicated or uncomplicated by pulmonary embolism.Treatment of unstable angina and non Q wave myocardial infarction, in combination with acetylsalicylic acid (ASA).Treatment of acute ST segment elevation myocardial infarction (STEMI) including patients who will be treated conservatively or who will later undergo percutaneous coronary angioplasty (applies to strengths of 60 mg/0.6 mL, 80 mg/0.8 mL, and 100 mg/1 mL).Blood clot prevention in the extracorporeal circulation during haemodialysis. uuid:4ecc5c6f-667b-41d7-aa2b-03051368a9f4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:8NZ41MIK1O biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:aeec769e-7de0-4bef-954e-7c16965662ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:247bd118-76dd-437f-a5e1-ac8a72c1d6bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lovenox is a low molecular weight heparin [LMWH] indicated for: Prophylaxis of deep vein thrombosis (DVT) in abdominal surgery, hip replacement surgery, knee replacement surgery, or medical patients with severely restricted mobility during acute illness ( 1.1 ) Inpatient treatment of acute DVT with or without pulmonary embolism ( 1.2 ) Outpatient treatment of acute DVT without pulmonary embolism. ( 1.2 ) Prophylaxis of ischemic complications of unstable angina and non-Q-wave myocardial infarction [MI] ( 1.3 ) Treatment of acute ST-segment elevation myocardial infarction [STEMI] managed medically or with subsequent percutaneous coronary intervention [PCI] ( 1.4 ) uuid:933dac1f-529e-4c40-9a73-5298c97b2bc3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:8NZ41MIK1O biolink:treats MONDO:0041656 PMID:41385096 "[{""id"":""uuid:44e30eaa-7ff3-46a2-8325-ecc8cf614a7b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:b30838b4-cb7d-4d82-9f13-229974faebac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:dc6aa4b2-3750-42a0-b1c8-e80e61d6b29f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/inhixa""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lovenox is a low molecular weight heparin [LMWH] indicated for: Prophylaxis of deep vein thrombosis (DVT) in abdominal surgery, hip replacement surgery, knee replacement surgery, or medical patients with severely restricted mobility during acute illness ( 1.1 ) Inpatient treatment of acute DVT with or without pulmonary embolism ( 1.2 ) Outpatient treatment of acute DVT without pulmonary embolism. ( 1.2 ) Prophylaxis of ischemic complications of unstable angina and non-Q-wave myocardial infarction [MI] ( 1.3 ) Treatment of acute ST-segment elevation myocardial infarction [STEMI] managed medically or with subsequent percutaneous coronary intervention [PCI] ( 1.4 )|[EMA] Inhixa is indicated for adults for:Prophylaxis of venous thromboembolism, particularly in patients undergoing orthopaedic, general or oncological surgery.Prophylaxis of venous thromboembolism in patients bedridden due to acute illnesses including acute heart failure, acute respiratory failure, severe infections, as well as exacerbation of rheumatic diseases causing immobilisation of the patient (applies to strengths of 40 mg/0.4 mL).Treatment of deep vein thrombosis (DVT), complicated or uncomplicated by pulmonary embolism.Treatment of unstable angina and non Q wave myocardial infarction, in combination with acetylsalicylic acid (ASA).Treatment of acute ST segment elevation myocardial infarction (STEMI) including patients who will be treated conservatively or who will later undergo percutaneous coronary angioplasty (applies to strengths of 60 mg/0.6 mL, 80 mg/0.8 mL, and 100 mg/1 mL).Blood clot prevention in the extracorporeal circulation during haemodialysis. uuid:02c231dd-f328-4ec7-8d78-8315b7d86596 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5118 biolink:treats MONDO:0001866 PMID:41385096 "[{""id"":""uuid:22cdca74-c283-4a52-a18f-3d0207f71b41"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f8f27895-dbba-4038-9996-c0076e806ba1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fluoxetine is a selective serotonin reuptake inhibitor indicated for: Acute and maintenance treatment of Major Depressive Disorder (MDD) in adult and pediatric patients aged 8 to 18 years ( 1.1 ) Acute and maintenance treatment of Obsessive Compulsive Disorder (OCD) in adult and pediatric patients aged 7 to 17 years ( 1.2 ) Acute and maintenance treatment of Bulimia Nervosa in adult patients ( 1.3 ) Acute treatment of Panic Disorder, with or without agoraphobia, in adult patients ( 1.4 ) Fluoxetine and olanzapine in combination for: Acute treatment of Depressive Episodes Associated with Bipolar I Disorder in adults ( 1.5 ) uuid:4b49adaa-827b-498e-ae25-7fc917eaa098 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63580 biolink:treats MONDO:0005354 PMID:41385096 "[{""id"":""uuid:e9617d38-2b97-4be8-bdfd-13feaa9bc9c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:126bce85-b52a-4578-92d3-0acdf27c95b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:bf76b045-8e85-464b-b98b-746885f87310"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ribavirin tablets in combination with peginterferon alfa-2a are indicated for the treatment of adults with chronic hepatitis C virus infection who have compensated liver disease and have not been previously treated with interferon alpha. Patients in whom efficacy was demonstrated included patients with compensated liver disease and histological evidence of cirrhosis (Child-Pugh class A) and patients with HIV disease that is clinically stable (e.g., antiretroviral therapy not required or receiving stable antiretroviral therapy).|[PMDA] New drug application for Copegus to treat the following conditions, and additional indications and dosages for Pegasys. Ribavirin In combination with peginterferon alfa-2a , Ribavirin is indicated for the treatment of either of the following viremia in chronic hepatitis C. Patients with a high viral RNA load of HCV serogroup 1 (genotype I (1a) or II (1b)). Patients who are not responding to or relapsing after interferon monotherapy. PEG-IFNα-2a In combination with Ribavirin, peginterferon alfa-2a is indicated for the treatment of either of the following viremia in chronic hepatitis C. Patients with a high viral RNA load of HCV serogroup 1 (genotype I (1a) or II (1b)). Patients who are not responding to or relapsing after interferon monotherapy. (the above is the added part of labeling) uuid:027e7a7a-a5f7-4375-82d0-98e11c6b62b9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63580 biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:8514a1ed-963a-41d0-b50f-536e48a002fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9463cc43-e0ce-42d6-9f8a-1f505e3e8733"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ribavirin tablets in combination with peginterferon alfa-2a are indicated for the treatment of adults with chronic hepatitis C virus infection who have compensated liver disease and have not been previously treated with interferon alpha. Patients in whom efficacy was demonstrated included patients with compensated liver disease and histological evidence of cirrhosis (Child-Pugh class A) and patients with HIV disease that is clinically stable (e.g., antiretroviral therapy not required or receiving stable antiretroviral therapy). uuid:132a4700-2ebf-48a9-b48f-72f5c18de8c3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9445 biolink:treats MONDO:0010811 PMID:41385096 "[{""id"":""uuid:47567133-8b50-48bd-8892-75eb42687d5e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6c50c73e-4ef6-48d9-a317-037e0f505375"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Terazosin hydrochloride is indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH). There is a rapid response, with approximately 70% of patients experiencing an increase in urinary flow and improvement in symptoms of BPH when treated with terazosin hydrochloride. The long-term effects of terazosin hydrochloride on the incidence of surgery, acute urinary obstruction or other complications of BPH are yet to be determined. Terazosin hydrochloride is also indicated for the treatment of hypertension. It can be used alone or in combination with other antihypertensive agents such as diuretics or beta-adrenergic blocking agents. uuid:4eb2015e-ce0f-4dd1-8f0a-a21c84936406 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9445 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:b8f089a0-2445-4739-96e7-fb544ec0eeae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5696e8af-2e76-4d8b-84e3-456c7a9d3894"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Terazosin hydrochloride is indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH). There is a rapid response, with approximately 70% of patients experiencing an increase in urinary flow and improvement in symptoms of BPH when treated with terazosin hydrochloride. The long-term effects of terazosin hydrochloride on the incidence of surgery, acute urinary obstruction or other complications of BPH are yet to be determined. Terazosin hydrochloride is also indicated for the treatment of hypertension. It can be used alone or in combination with other antihypertensive agents such as diuretics or beta-adrenergic blocking agents. uuid:64ea454a-5eb6-4cfd-8490-12203d7c117b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:39867 biolink:treats MONDO:0001866 PMID:41385096 "[{""id"":""uuid:c729b69c-3418-4639-9644-e9466c9f35da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:83f5543e-4d55-48c9-86fb-d181d2a932d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Divalproex sodium delayed-release tablets are indicated for the treatment of the manic episodes associated with bipolar disorder. A manic episode is a distinct period of abnormally and persistently elevated, expansive, or irritable mood. Typical symptoms of mania include pressure of speech, motor hyperactivity, reduced need for sleep, flight of ideas, grandiosity, poor judgement, aggressiveness, and possible hostility. The efficacy of divalproex sodium delayed-release tablets was established in 3-week trials with patients meeting DSMIII-R criteria for bipolar disorder who were hospitalized for acute mania (see Clinical Trials under CLINICAL PHARMACOLOGY ). The safety and effectiveness of divalproex sodium delayed-release tablets for long-term use in mania, i.e., more than 3 weeks, has not been systematically evaluated in controlled clinical trials. Therefore, healthcare providers who elect to use divalproex sodium delayed-release tablets for extended periods should continually reevaluate the long-term usefulness of the drug for the individual patient. uuid:07714711-866d-40c3-b9d7-b71aec8f3de6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3380 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:b935ecd0-287f-4982-8879-86c5d6d65ddb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:73f8c114-99f7-4a4a-81e5-94f833a8e379"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Captopril tablets are indicated for the treatment of hypertension. In using captopril, consideration should be given to the risk of neutropenia/agranulocytosis (see WARNINGS ). Captopril may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. In patients with impaired renal function, particularly those with collagen vascular disease, captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations. Captopril is effective alone and in combination with other antihypertensive agents, especially thiazide-type diuretics. The blood pressure lowering effects of captopril and thiazides are approximately additive. uuid:1ee7d2fd-8932-439c-bc85-38e21583d747 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10100 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:497ef78b-c053-4eea-9995-94826597200a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:26bf5d69-976c-4d3e-bfa8-44e8240e6848"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ACCOLATE is indicated for the prophylaxis and chronic treatment of asthma in adults and children 5 years of age and older. uuid:88728592-4217-495e-8cca-9887f2eb1c81 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3387 biolink:treats MONDO:0005115 PMID:41385096 "[{""id"":""uuid:2033612e-8ff9-4c9b-9f4a-6762120f5724"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4c020b22-1186-4f76-b369-18903d2a3ed9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Epilepsy: Carbamazepine tablets are indicated for use as an anticonvulsant drug. Evidence supporting efficacy of carbamazepine as an anticonvulsant was derived from active drug-controlled studies that enrolled patients with the following seizure types: 1. Partial seizures with complex symptomatology (psychomotor, temporal lobe). Patients with these seizures appear to show greater improvement than those with other types. 2. Generalized tonic-clonic seizures (grand mal). 3. Mixed seizure patterns which include the above, or other partial or generalized seizures. Absence seizures (petit mal) do not appear to be controlled by carbamazepine (see PRECAUTIONS, General ). Trigeminal Neuralgia: Carbamazepine tablets are indicated in the treatment of the pain associated with true trigeminal neuralgia. Beneficial results have also been reported in glossopharyngeal neuralgia. This drug is not a simple analgesic and should not be used for the relief of trivial aches or pains. uuid:9c41d1a9-1144-4274-bb99-69524168b3de biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3387 biolink:treats HP:0002069 PMID:41385096 "[{""id"":""uuid:0c71dac6-c05a-4e35-921e-44993cba4810"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6ea8cd72-0c61-443e-8089-497b1b2aac13"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Epilepsy: Carbamazepine tablets are indicated for use as an anticonvulsant drug. Evidence supporting efficacy of carbamazepine as an anticonvulsant was derived from active drug-controlled studies that enrolled patients with the following seizure types: 1. Partial seizures with complex symptomatology (psychomotor, temporal lobe). Patients with these seizures appear to show greater improvement than those with other types. 2. Generalized tonic-clonic seizures (grand mal). 3. Mixed seizure patterns which include the above, or other partial or generalized seizures. Absence seizures (petit mal) do not appear to be controlled by carbamazepine (see PRECAUTIONS, General ). Trigeminal Neuralgia: Carbamazepine tablets are indicated in the treatment of the pain associated with true trigeminal neuralgia. Beneficial results have also been reported in glossopharyngeal neuralgia. This drug is not a simple analgesic and should not be used for the relief of trivial aches or pains. uuid:9e18c51a-6440-4a5d-a536-9a5141cd0db3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3441 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:53d557ad-842f-4c78-905d-361190a2d2ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:99bd00a8-5ea0-4068-81e5-8bb3f6d7f328"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carvedilol is an alpha/beta-adrenergic blocking agent indicated for the treatment of: Mild to severe chronic heart failure (1.1) Left ventricular dysfunction following myocardial infarction in clinically stable patients (1.2) Hypertension (1.3) uuid:593e5e45-70a4-4f9b-a4a6-07569c4bd647 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3441 biolink:treats HP:0005162 PMID:41385096 "[{""id"":""uuid:39ac0085-d85d-4089-ab34-bc0d77693057"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:69dbd989-e638-4c88-b7bf-1e58e855f6e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carvedilol is an alpha/beta-adrenergic blocking agent indicated for the treatment of: Mild to severe chronic heart failure (1.1) Left ventricular dysfunction following myocardial infarction in clinically stable patients (1.2) Hypertension (1.3) uuid:f3d63b95-046c-486d-9bce-06369ef845b9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63589 biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:87925ed4-4717-4321-a573-25eb24075477"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:05c4cf85-01e8-4af0-9d10-4b7ded665cec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INTELENCE ® Registered trademark of Tibotec Pharmaceuticals , in combination with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-experienced adult patients, who have evidence of viral replication and HIV-1 strains resistant to a non-nucleoside reverse transcriptase inhibitor (NNRTI) and other antiretroviral agents. This indication is based on Week 48 analyses from 2 randomized, double-blind, placebo-controlled trials of INTELENCE ® . Both studies were conducted in clinically advanced, 3-class antiretroviral (NNRTI, N[t]RTI, PI) treatment-experienced adults. The following points should be considered when initiating therapy with INTELENCE ® : Treatment history and, when available, resistance testing, should guide the use of INTELENCE ® . The use of other active antiretroviral agents with INTELENCE ® is associated with an increased likelihood of treatment response. In patients who have experienced virologic failure on an NNRTI-containing regimen, do not use INTELENCE ® in combination with only N[t]RTIs [ see Clinical Studies (14) ]. The risks and benefits of INTELENCE ® have not been established in pediatric patients or in treatment-naïve adult patients. uuid:fbdd643b-2f73-49ab-ae7a-e0258a528d28 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:42355 biolink:treats MONDO:0024355 PMID:41385096 "[{""id"":""uuid:823490ee-db49-48f9-9ecc-286712b8d340"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ee0a5beb-cf58-4d9d-b214-edf9202c73c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin ethylsuccinate tablets and other antibacterial drugs, erythromycin ethylsuccinate tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Erythromycin ethylsuccinate tablets are indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes , Streptococcus pneumoniae , or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.) Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumoniae or Streptococcus pyogenes . Listeriosis caused by Listeria monocytogenes . Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: Infections due to Corynebacterium diphtheriae , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma: In the treatment of infections due to Corynebacterium minutissimum . Intestinal amebiasis caused by Entamoeba histolytica (oral erythromycins only). Extraenteric amebiasis requires treatment with other agents. Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae: As an alternative drug in treatment of acute pelvic inflammatory disease caused by N. gonorrhoeae in female patients with a history of sensitivity to penicillin. Patients should have a serologic test for syphilis before receiving erythromycin as treatment of gonorrhea and a follow-up serologic test for syphilis after 3 months. Syphilis Caused by Treponema Pallidum : Erythromycin is an alternate choice of treatment for primary syphilis in penicillin-allergic patients. In primary syphilis, spinal fluid examinations should be done before treatment and as part of follow-up after therapy. Erythromycins are indicated for the treatment of the following infections caused by Chlamydia trachomatis: Conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections during pregnancy. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to Chlamydia trachomatis . When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of nongonococcal urethritis caused by Ureaplasma urealyticum . Legionnaires' Disease caused by Legionella pneumophila . Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires' Disease. Prophylaxis Prevention of Initial Attacks of Rheumatic Fever Penicillin is considered by the American Heart Association to be the drug of choice in the prevention of initial attacks of rheumatic fever (treatment of Streptococcus pyogenes infections of the upper respiratory tract, e.g., tonsillitis or pharyngitis). Erythromycin is indicated for the treatment of penicillin-allergic patients. 3 The therapeutic dose should be administered for 10 days. Prevention of Recurrent Attacks of Rheumatic Fever Penicillin or sulfonamides are considered by the American Heart Association to be the drugs of choice in the prevention of recurrent attacks of rheumatic fever. In patients who are allergic to penicillin and sulfonamides, oral erythromycin is recommended by the American Heart Association in the long-term prophylaxis of streptococcal pharyngitis (for the prevention of recurrent attacks of rheumatic fever). 3 uuid:4a491846-24ad-4e59-b371-06f5812ac8d7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:42355 biolink:treats MONDO:0005828 PMID:41385096 "[{""id"":""uuid:49b50674-496d-430d-8edc-58a01f7f5703"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d14ea084-e3af-4dfc-9652-615ebd265715"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin ethylsuccinate tablets and other antibacterial drugs, erythromycin ethylsuccinate tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Erythromycin ethylsuccinate tablets are indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes , Streptococcus pneumoniae , or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.) Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumoniae or Streptococcus pyogenes . Listeriosis caused by Listeria monocytogenes . Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: Infections due to Corynebacterium diphtheriae , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma: In the treatment of infections due to Corynebacterium minutissimum . Intestinal amebiasis caused by Entamoeba histolytica (oral erythromycins only). Extraenteric amebiasis requires treatment with other agents. Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae: As an alternative drug in treatment of acute pelvic inflammatory disease caused by N. gonorrhoeae in female patients with a history of sensitivity to penicillin. Patients should have a serologic test for syphilis before receiving erythromycin as treatment of gonorrhea and a follow-up serologic test for syphilis after 3 months. Syphilis Caused by Treponema Pallidum : Erythromycin is an alternate choice of treatment for primary syphilis in penicillin-allergic patients. In primary syphilis, spinal fluid examinations should be done before treatment and as part of follow-up after therapy. Erythromycins are indicated for the treatment of the following infections caused by Chlamydia trachomatis: Conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections during pregnancy. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to Chlamydia trachomatis . When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of nongonococcal urethritis caused by Ureaplasma urealyticum . Legionnaires' Disease caused by Legionella pneumophila . Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires' Disease. Prophylaxis Prevention of Initial Attacks of Rheumatic Fever Penicillin is considered by the American Heart Association to be the drug of choice in the prevention of initial attacks of rheumatic fever (treatment of Streptococcus pyogenes infections of the upper respiratory tract, e.g., tonsillitis or pharyngitis). Erythromycin is indicated for the treatment of penicillin-allergic patients. 3 The therapeutic dose should be administered for 10 days. Prevention of Recurrent Attacks of Rheumatic Fever Penicillin or sulfonamides are considered by the American Heart Association to be the drugs of choice in the prevention of recurrent attacks of rheumatic fever. In patients who are allergic to penicillin and sulfonamides, oral erythromycin is recommended by the American Heart Association in the long-term prophylaxis of streptococcal pharyngitis (for the prevention of recurrent attacks of rheumatic fever). 3 uuid:7443fc13-dfaa-47df-b5fe-7cff71382374 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:42355 biolink:treats MONDO:0005077 PMID:41385096 "[{""id"":""uuid:89120c28-bfd8-421a-9373-b3adfa5a40de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e4525c44-e3f1-4fc3-b2f4-7584e65cc0d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin ethylsuccinate tablets and other antibacterial drugs, erythromycin ethylsuccinate tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Erythromycin ethylsuccinate tablets are indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes , Streptococcus pneumoniae , or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.) Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumoniae or Streptococcus pyogenes . Listeriosis caused by Listeria monocytogenes . Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: Infections due to Corynebacterium diphtheriae , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma: In the treatment of infections due to Corynebacterium minutissimum . Intestinal amebiasis caused by Entamoeba histolytica (oral erythromycins only). Extraenteric amebiasis requires treatment with other agents. Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae: As an alternative drug in treatment of acute pelvic inflammatory disease caused by N. gonorrhoeae in female patients with a history of sensitivity to penicillin. Patients should have a serologic test for syphilis before receiving erythromycin as treatment of gonorrhea and a follow-up serologic test for syphilis after 3 months. Syphilis Caused by Treponema Pallidum : Erythromycin is an alternate choice of treatment for primary syphilis in penicillin-allergic patients. In primary syphilis, spinal fluid examinations should be done before treatment and as part of follow-up after therapy. Erythromycins are indicated for the treatment of the following infections caused by Chlamydia trachomatis: Conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections during pregnancy. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to Chlamydia trachomatis . When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of nongonococcal urethritis caused by Ureaplasma urealyticum . Legionnaires' Disease caused by Legionella pneumophila . Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires' Disease. Prophylaxis Prevention of Initial Attacks of Rheumatic Fever Penicillin is considered by the American Heart Association to be the drug of choice in the prevention of initial attacks of rheumatic fever (treatment of Streptococcus pyogenes infections of the upper respiratory tract, e.g., tonsillitis or pharyngitis). Erythromycin is indicated for the treatment of penicillin-allergic patients. 3 The therapeutic dose should be administered for 10 days. Prevention of Recurrent Attacks of Rheumatic Fever Penicillin or sulfonamides are considered by the American Heart Association to be the drugs of choice in the prevention of recurrent attacks of rheumatic fever. In patients who are allergic to penicillin and sulfonamides, oral erythromycin is recommended by the American Heart Association in the long-term prophylaxis of streptococcal pharyngitis (for the prevention of recurrent attacks of rheumatic fever). 3 uuid:3ee2fb96-70a6-42fb-8d00-0052e9d283bc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:42355 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:8142dd0b-b72d-464e-b346-7c50856a877d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:de332d70-8cfd-4ac5-b60c-b1fc0d3f5e17"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin ethylsuccinate tablets and other antibacterial drugs, erythromycin ethylsuccinate tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Erythromycin ethylsuccinate tablets are indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes , Streptococcus pneumoniae , or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.) Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumoniae or Streptococcus pyogenes . Listeriosis caused by Listeria monocytogenes . Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: Infections due to Corynebacterium diphtheriae , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma: In the treatment of infections due to Corynebacterium minutissimum . Intestinal amebiasis caused by Entamoeba histolytica (oral erythromycins only). Extraenteric amebiasis requires treatment with other agents. Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae: As an alternative drug in treatment of acute pelvic inflammatory disease caused by N. gonorrhoeae in female patients with a history of sensitivity to penicillin. Patients should have a serologic test for syphilis before receiving erythromycin as treatment of gonorrhea and a follow-up serologic test for syphilis after 3 months. Syphilis Caused by Treponema Pallidum : Erythromycin is an alternate choice of treatment for primary syphilis in penicillin-allergic patients. In primary syphilis, spinal fluid examinations should be done before treatment and as part of follow-up after therapy. Erythromycins are indicated for the treatment of the following infections caused by Chlamydia trachomatis: Conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections during pregnancy. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to Chlamydia trachomatis . When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of nongonococcal urethritis caused by Ureaplasma urealyticum . Legionnaires' Disease caused by Legionella pneumophila . Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires' Disease. Prophylaxis Prevention of Initial Attacks of Rheumatic Fever Penicillin is considered by the American Heart Association to be the drug of choice in the prevention of initial attacks of rheumatic fever (treatment of Streptococcus pyogenes infections of the upper respiratory tract, e.g., tonsillitis or pharyngitis). Erythromycin is indicated for the treatment of penicillin-allergic patients. 3 The therapeutic dose should be administered for 10 days. Prevention of Recurrent Attacks of Rheumatic Fever Penicillin or sulfonamides are considered by the American Heart Association to be the drugs of choice in the prevention of recurrent attacks of rheumatic fever. In patients who are allergic to penicillin and sulfonamides, oral erythromycin is recommended by the American Heart Association in the long-term prophylaxis of streptococcal pharyngitis (for the prevention of recurrent attacks of rheumatic fever). 3 uuid:d62bca2b-bb60-46fa-9191-530d68cf95bf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:42355 biolink:treats MONDO:0005504 PMID:41385096 "[{""id"":""uuid:17c94071-9f90-44a1-a36d-cc50a3fe9261"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:78f29642-daf1-494b-a4b2-af957ef19008"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin ethylsuccinate tablets and other antibacterial drugs, erythromycin ethylsuccinate tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Erythromycin ethylsuccinate tablets are indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes , Streptococcus pneumoniae , or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.) Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumoniae or Streptococcus pyogenes . Listeriosis caused by Listeria monocytogenes . Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: Infections due to Corynebacterium diphtheriae , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma: In the treatment of infections due to Corynebacterium minutissimum . Intestinal amebiasis caused by Entamoeba histolytica (oral erythromycins only). Extraenteric amebiasis requires treatment with other agents. Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae: As an alternative drug in treatment of acute pelvic inflammatory disease caused by N. gonorrhoeae in female patients with a history of sensitivity to penicillin. Patients should have a serologic test for syphilis before receiving erythromycin as treatment of gonorrhea and a follow-up serologic test for syphilis after 3 months. Syphilis Caused by Treponema Pallidum : Erythromycin is an alternate choice of treatment for primary syphilis in penicillin-allergic patients. In primary syphilis, spinal fluid examinations should be done before treatment and as part of follow-up after therapy. Erythromycins are indicated for the treatment of the following infections caused by Chlamydia trachomatis: Conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections during pregnancy. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to Chlamydia trachomatis . When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of nongonococcal urethritis caused by Ureaplasma urealyticum . Legionnaires' Disease caused by Legionella pneumophila . Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires' Disease. Prophylaxis Prevention of Initial Attacks of Rheumatic Fever Penicillin is considered by the American Heart Association to be the drug of choice in the prevention of initial attacks of rheumatic fever (treatment of Streptococcus pyogenes infections of the upper respiratory tract, e.g., tonsillitis or pharyngitis). Erythromycin is indicated for the treatment of penicillin-allergic patients. 3 The therapeutic dose should be administered for 10 days. Prevention of Recurrent Attacks of Rheumatic Fever Penicillin or sulfonamides are considered by the American Heart Association to be the drugs of choice in the prevention of recurrent attacks of rheumatic fever. In patients who are allergic to penicillin and sulfonamides, oral erythromycin is recommended by the American Heart Association in the long-term prophylaxis of streptococcal pharyngitis (for the prevention of recurrent attacks of rheumatic fever). 3 uuid:c27720ef-49a4-46b3-a6a0-e5ec54e4c0d4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:42355 biolink:treats MONDO:0002885 PMID:41385096 "[{""id"":""uuid:9c1c9885-aa5b-49ad-816a-2349bdc68e59"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:662af153-9466-4164-bbc5-6ff4b0453145"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin ethylsuccinate tablets and other antibacterial drugs, erythromycin ethylsuccinate tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Erythromycin ethylsuccinate tablets are indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes , Streptococcus pneumoniae , or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.) Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumoniae or Streptococcus pyogenes . Listeriosis caused by Listeria monocytogenes . Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: Infections due to Corynebacterium diphtheriae , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma: In the treatment of infections due to Corynebacterium minutissimum . Intestinal amebiasis caused by Entamoeba histolytica (oral erythromycins only). Extraenteric amebiasis requires treatment with other agents. Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae: As an alternative drug in treatment of acute pelvic inflammatory disease caused by N. gonorrhoeae in female patients with a history of sensitivity to penicillin. Patients should have a serologic test for syphilis before receiving erythromycin as treatment of gonorrhea and a follow-up serologic test for syphilis after 3 months. Syphilis Caused by Treponema Pallidum : Erythromycin is an alternate choice of treatment for primary syphilis in penicillin-allergic patients. In primary syphilis, spinal fluid examinations should be done before treatment and as part of follow-up after therapy. Erythromycins are indicated for the treatment of the following infections caused by Chlamydia trachomatis: Conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections during pregnancy. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to Chlamydia trachomatis . When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of nongonococcal urethritis caused by Ureaplasma urealyticum . Legionnaires' Disease caused by Legionella pneumophila . Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires' Disease. Prophylaxis Prevention of Initial Attacks of Rheumatic Fever Penicillin is considered by the American Heart Association to be the drug of choice in the prevention of initial attacks of rheumatic fever (treatment of Streptococcus pyogenes infections of the upper respiratory tract, e.g., tonsillitis or pharyngitis). Erythromycin is indicated for the treatment of penicillin-allergic patients. 3 The therapeutic dose should be administered for 10 days. Prevention of Recurrent Attacks of Rheumatic Fever Penicillin or sulfonamides are considered by the American Heart Association to be the drugs of choice in the prevention of recurrent attacks of rheumatic fever. In patients who are allergic to penicillin and sulfonamides, oral erythromycin is recommended by the American Heart Association in the long-term prophylaxis of streptococcal pharyngitis (for the prevention of recurrent attacks of rheumatic fever). 3 uuid:eedafa16-566a-400a-9b5e-6c592111fb0b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:42355 biolink:treats MONDO:0005644 PMID:41385096 "[{""id"":""uuid:bf1cf301-3030-454c-ba1e-d0854430307f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:96a424d9-f067-4ffa-a39d-02b97c0cca01"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin ethylsuccinate tablets and other antibacterial drugs, erythromycin ethylsuccinate tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Erythromycin ethylsuccinate tablets are indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes , Streptococcus pneumoniae , or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.) Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumoniae or Streptococcus pyogenes . Listeriosis caused by Listeria monocytogenes . Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: Infections due to Corynebacterium diphtheriae , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma: In the treatment of infections due to Corynebacterium minutissimum . Intestinal amebiasis caused by Entamoeba histolytica (oral erythromycins only). Extraenteric amebiasis requires treatment with other agents. Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae: As an alternative drug in treatment of acute pelvic inflammatory disease caused by N. gonorrhoeae in female patients with a history of sensitivity to penicillin. Patients should have a serologic test for syphilis before receiving erythromycin as treatment of gonorrhea and a follow-up serologic test for syphilis after 3 months. Syphilis Caused by Treponema Pallidum : Erythromycin is an alternate choice of treatment for primary syphilis in penicillin-allergic patients. In primary syphilis, spinal fluid examinations should be done before treatment and as part of follow-up after therapy. Erythromycins are indicated for the treatment of the following infections caused by Chlamydia trachomatis: Conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections during pregnancy. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to Chlamydia trachomatis . When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of nongonococcal urethritis caused by Ureaplasma urealyticum . Legionnaires' Disease caused by Legionella pneumophila . Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires' Disease. Prophylaxis Prevention of Initial Attacks of Rheumatic Fever Penicillin is considered by the American Heart Association to be the drug of choice in the prevention of initial attacks of rheumatic fever (treatment of Streptococcus pyogenes infections of the upper respiratory tract, e.g., tonsillitis or pharyngitis). Erythromycin is indicated for the treatment of penicillin-allergic patients. 3 The therapeutic dose should be administered for 10 days. Prevention of Recurrent Attacks of Rheumatic Fever Penicillin or sulfonamides are considered by the American Heart Association to be the drugs of choice in the prevention of recurrent attacks of rheumatic fever. In patients who are allergic to penicillin and sulfonamides, oral erythromycin is recommended by the American Heart Association in the long-term prophylaxis of streptococcal pharyngitis (for the prevention of recurrent attacks of rheumatic fever). 3 uuid:b0a52cd6-5104-4f51-a29e-5c7bc945c1de biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:42355 biolink:treats UMLS:C0149959 PMID:41385096 "[{""id"":""uuid:33cc3a9c-50e2-43a8-9f53-8081033b1706"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c3604cf1-bb51-43e0-b4be-9fad9b632642"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin ethylsuccinate tablets and other antibacterial drugs, erythromycin ethylsuccinate tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Erythromycin ethylsuccinate tablets are indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes , Streptococcus pneumoniae , or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.) Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumoniae or Streptococcus pyogenes . Listeriosis caused by Listeria monocytogenes . Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: Infections due to Corynebacterium diphtheriae , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma: In the treatment of infections due to Corynebacterium minutissimum . Intestinal amebiasis caused by Entamoeba histolytica (oral erythromycins only). Extraenteric amebiasis requires treatment with other agents. Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae: As an alternative drug in treatment of acute pelvic inflammatory disease caused by N. gonorrhoeae in female patients with a history of sensitivity to penicillin. Patients should have a serologic test for syphilis before receiving erythromycin as treatment of gonorrhea and a follow-up serologic test for syphilis after 3 months. Syphilis Caused by Treponema Pallidum : Erythromycin is an alternate choice of treatment for primary syphilis in penicillin-allergic patients. In primary syphilis, spinal fluid examinations should be done before treatment and as part of follow-up after therapy. Erythromycins are indicated for the treatment of the following infections caused by Chlamydia trachomatis: Conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections during pregnancy. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to Chlamydia trachomatis . When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of nongonococcal urethritis caused by Ureaplasma urealyticum . Legionnaires' Disease caused by Legionella pneumophila . Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires' Disease. Prophylaxis Prevention of Initial Attacks of Rheumatic Fever Penicillin is considered by the American Heart Association to be the drug of choice in the prevention of initial attacks of rheumatic fever (treatment of Streptococcus pyogenes infections of the upper respiratory tract, e.g., tonsillitis or pharyngitis). Erythromycin is indicated for the treatment of penicillin-allergic patients. 3 The therapeutic dose should be administered for 10 days. Prevention of Recurrent Attacks of Rheumatic Fever Penicillin or sulfonamides are considered by the American Heart Association to be the drugs of choice in the prevention of recurrent attacks of rheumatic fever. In patients who are allergic to penicillin and sulfonamides, oral erythromycin is recommended by the American Heart Association in the long-term prophylaxis of streptococcal pharyngitis (for the prevention of recurrent attacks of rheumatic fever). 3 uuid:bdc64bab-1174-46d0-ae38-f0596f357314 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:42355 biolink:treats MONDO:0005976 PMID:41385096 "[{""id"":""uuid:5da5924e-2356-4d09-8718-124e2bd8badb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:783e0b44-0169-40e1-a072-005a91a3de59"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin ethylsuccinate tablets and other antibacterial drugs, erythromycin ethylsuccinate tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Erythromycin ethylsuccinate tablets are indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes , Streptococcus pneumoniae , or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.) Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumoniae or Streptococcus pyogenes . Listeriosis caused by Listeria monocytogenes . Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: Infections due to Corynebacterium diphtheriae , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma: In the treatment of infections due to Corynebacterium minutissimum . Intestinal amebiasis caused by Entamoeba histolytica (oral erythromycins only). Extraenteric amebiasis requires treatment with other agents. Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae: As an alternative drug in treatment of acute pelvic inflammatory disease caused by N. gonorrhoeae in female patients with a history of sensitivity to penicillin. Patients should have a serologic test for syphilis before receiving erythromycin as treatment of gonorrhea and a follow-up serologic test for syphilis after 3 months. Syphilis Caused by Treponema Pallidum : Erythromycin is an alternate choice of treatment for primary syphilis in penicillin-allergic patients. In primary syphilis, spinal fluid examinations should be done before treatment and as part of follow-up after therapy. Erythromycins are indicated for the treatment of the following infections caused by Chlamydia trachomatis: Conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections during pregnancy. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to Chlamydia trachomatis . When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of nongonococcal urethritis caused by Ureaplasma urealyticum . Legionnaires' Disease caused by Legionella pneumophila . Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires' Disease. Prophylaxis Prevention of Initial Attacks of Rheumatic Fever Penicillin is considered by the American Heart Association to be the drug of choice in the prevention of initial attacks of rheumatic fever (treatment of Streptococcus pyogenes infections of the upper respiratory tract, e.g., tonsillitis or pharyngitis). Erythromycin is indicated for the treatment of penicillin-allergic patients. 3 The therapeutic dose should be administered for 10 days. Prevention of Recurrent Attacks of Rheumatic Fever Penicillin or sulfonamides are considered by the American Heart Association to be the drugs of choice in the prevention of recurrent attacks of rheumatic fever. In patients who are allergic to penicillin and sulfonamides, oral erythromycin is recommended by the American Heart Association in the long-term prophylaxis of streptococcal pharyngitis (for the prevention of recurrent attacks of rheumatic fever). 3 uuid:99008c60-deee-4c28-9c20-d8c144399204 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:42355 biolink:treats MONDO:0004854 PMID:41385096 "[{""id"":""uuid:733bd21d-17ec-4c8d-ae17-c253d77523ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6e141ac7-ba6e-45f0-bdc2-42fe76cff689"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin ethylsuccinate tablets and other antibacterial drugs, erythromycin ethylsuccinate tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Erythromycin ethylsuccinate tablets are indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes , Streptococcus pneumoniae , or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.) Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumoniae or Streptococcus pyogenes . Listeriosis caused by Listeria monocytogenes . Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: Infections due to Corynebacterium diphtheriae , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma: In the treatment of infections due to Corynebacterium minutissimum . Intestinal amebiasis caused by Entamoeba histolytica (oral erythromycins only). Extraenteric amebiasis requires treatment with other agents. Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae: As an alternative drug in treatment of acute pelvic inflammatory disease caused by N. gonorrhoeae in female patients with a history of sensitivity to penicillin. Patients should have a serologic test for syphilis before receiving erythromycin as treatment of gonorrhea and a follow-up serologic test for syphilis after 3 months. Syphilis Caused by Treponema Pallidum : Erythromycin is an alternate choice of treatment for primary syphilis in penicillin-allergic patients. In primary syphilis, spinal fluid examinations should be done before treatment and as part of follow-up after therapy. Erythromycins are indicated for the treatment of the following infections caused by Chlamydia trachomatis: Conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections during pregnancy. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to Chlamydia trachomatis . When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of nongonococcal urethritis caused by Ureaplasma urealyticum . Legionnaires' Disease caused by Legionella pneumophila . Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires' Disease. Prophylaxis Prevention of Initial Attacks of Rheumatic Fever Penicillin is considered by the American Heart Association to be the drug of choice in the prevention of initial attacks of rheumatic fever (treatment of Streptococcus pyogenes infections of the upper respiratory tract, e.g., tonsillitis or pharyngitis). Erythromycin is indicated for the treatment of penicillin-allergic patients. 3 The therapeutic dose should be administered for 10 days. Prevention of Recurrent Attacks of Rheumatic Fever Penicillin or sulfonamides are considered by the American Heart Association to be the drugs of choice in the prevention of recurrent attacks of rheumatic fever. In patients who are allergic to penicillin and sulfonamides, oral erythromycin is recommended by the American Heart Association in the long-term prophylaxis of streptococcal pharyngitis (for the prevention of recurrent attacks of rheumatic fever). 3 uuid:cf320a45-2272-4f13-92b7-8716d88b55e1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:42355 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:6be92b05-119d-4f63-9953-d262a070f1ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9b156590-d55f-4445-84b8-4f88ae088e54"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin ethylsuccinate tablets and other antibacterial drugs, erythromycin ethylsuccinate tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Erythromycin ethylsuccinate tablets are indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes , Streptococcus pneumoniae , or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.) Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumoniae or Streptococcus pyogenes . Listeriosis caused by Listeria monocytogenes . Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: Infections due to Corynebacterium diphtheriae , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma: In the treatment of infections due to Corynebacterium minutissimum . Intestinal amebiasis caused by Entamoeba histolytica (oral erythromycins only). Extraenteric amebiasis requires treatment with other agents. Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae: As an alternative drug in treatment of acute pelvic inflammatory disease caused by N. gonorrhoeae in female patients with a history of sensitivity to penicillin. Patients should have a serologic test for syphilis before receiving erythromycin as treatment of gonorrhea and a follow-up serologic test for syphilis after 3 months. Syphilis Caused by Treponema Pallidum : Erythromycin is an alternate choice of treatment for primary syphilis in penicillin-allergic patients. In primary syphilis, spinal fluid examinations should be done before treatment and as part of follow-up after therapy. Erythromycins are indicated for the treatment of the following infections caused by Chlamydia trachomatis: Conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections during pregnancy. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to Chlamydia trachomatis . When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of nongonococcal urethritis caused by Ureaplasma urealyticum . Legionnaires' Disease caused by Legionella pneumophila . Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires' Disease. Prophylaxis Prevention of Initial Attacks of Rheumatic Fever Penicillin is considered by the American Heart Association to be the drug of choice in the prevention of initial attacks of rheumatic fever (treatment of Streptococcus pyogenes infections of the upper respiratory tract, e.g., tonsillitis or pharyngitis). Erythromycin is indicated for the treatment of penicillin-allergic patients. 3 The therapeutic dose should be administered for 10 days. Prevention of Recurrent Attacks of Rheumatic Fever Penicillin or sulfonamides are considered by the American Heart Association to be the drugs of choice in the prevention of recurrent attacks of rheumatic fever. In patients who are allergic to penicillin and sulfonamides, oral erythromycin is recommended by the American Heart Association in the long-term prophylaxis of streptococcal pharyngitis (for the prevention of recurrent attacks of rheumatic fever). 3 uuid:99df440c-ea72-47e6-ba2f-c25689b695d9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:42355 biolink:treats MONDO:0005297 PMID:41385096 "[{""id"":""uuid:beb44432-fade-4433-9f62-414a07779595"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ccb399d5-327c-4f2b-875d-9e2aaf2de9e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin ethylsuccinate tablets and other antibacterial drugs, erythromycin ethylsuccinate tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Erythromycin ethylsuccinate tablets are indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes , Streptococcus pneumoniae , or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.) Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumoniae or Streptococcus pyogenes . Listeriosis caused by Listeria monocytogenes . Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: Infections due to Corynebacterium diphtheriae , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma: In the treatment of infections due to Corynebacterium minutissimum . Intestinal amebiasis caused by Entamoeba histolytica (oral erythromycins only). Extraenteric amebiasis requires treatment with other agents. Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae: As an alternative drug in treatment of acute pelvic inflammatory disease caused by N. gonorrhoeae in female patients with a history of sensitivity to penicillin. Patients should have a serologic test for syphilis before receiving erythromycin as treatment of gonorrhea and a follow-up serologic test for syphilis after 3 months. Syphilis Caused by Treponema Pallidum : Erythromycin is an alternate choice of treatment for primary syphilis in penicillin-allergic patients. In primary syphilis, spinal fluid examinations should be done before treatment and as part of follow-up after therapy. Erythromycins are indicated for the treatment of the following infections caused by Chlamydia trachomatis: Conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections during pregnancy. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to Chlamydia trachomatis . When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of nongonococcal urethritis caused by Ureaplasma urealyticum . Legionnaires' Disease caused by Legionella pneumophila . Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires' Disease. Prophylaxis Prevention of Initial Attacks of Rheumatic Fever Penicillin is considered by the American Heart Association to be the drug of choice in the prevention of initial attacks of rheumatic fever (treatment of Streptococcus pyogenes infections of the upper respiratory tract, e.g., tonsillitis or pharyngitis). Erythromycin is indicated for the treatment of penicillin-allergic patients. 3 The therapeutic dose should be administered for 10 days. Prevention of Recurrent Attacks of Rheumatic Fever Penicillin or sulfonamides are considered by the American Heart Association to be the drugs of choice in the prevention of recurrent attacks of rheumatic fever. In patients who are allergic to penicillin and sulfonamides, oral erythromycin is recommended by the American Heart Association in the long-term prophylaxis of streptococcal pharyngitis (for the prevention of recurrent attacks of rheumatic fever). 3 uuid:9760f09d-02ad-4fca-a29d-97753e9039ab biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:42355 biolink:treats MONDO:0005824 PMID:41385096 "[{""id"":""uuid:5c93fb57-d1e7-4009-a209-5fcdad121250"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:371bba55-f5bb-465a-a203-9020180d3108"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin ethylsuccinate tablets and other antibacterial drugs, erythromycin ethylsuccinate tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Erythromycin ethylsuccinate tablets are indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes , Streptococcus pneumoniae , or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.) Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumoniae or Streptococcus pyogenes . Listeriosis caused by Listeria monocytogenes . Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: Infections due to Corynebacterium diphtheriae , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma: In the treatment of infections due to Corynebacterium minutissimum . Intestinal amebiasis caused by Entamoeba histolytica (oral erythromycins only). Extraenteric amebiasis requires treatment with other agents. Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae: As an alternative drug in treatment of acute pelvic inflammatory disease caused by N. gonorrhoeae in female patients with a history of sensitivity to penicillin. Patients should have a serologic test for syphilis before receiving erythromycin as treatment of gonorrhea and a follow-up serologic test for syphilis after 3 months. Syphilis Caused by Treponema Pallidum : Erythromycin is an alternate choice of treatment for primary syphilis in penicillin-allergic patients. In primary syphilis, spinal fluid examinations should be done before treatment and as part of follow-up after therapy. Erythromycins are indicated for the treatment of the following infections caused by Chlamydia trachomatis: Conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections during pregnancy. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to Chlamydia trachomatis . When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of nongonococcal urethritis caused by Ureaplasma urealyticum . Legionnaires' Disease caused by Legionella pneumophila . Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires' Disease. Prophylaxis Prevention of Initial Attacks of Rheumatic Fever Penicillin is considered by the American Heart Association to be the drug of choice in the prevention of initial attacks of rheumatic fever (treatment of Streptococcus pyogenes infections of the upper respiratory tract, e.g., tonsillitis or pharyngitis). Erythromycin is indicated for the treatment of penicillin-allergic patients. 3 The therapeutic dose should be administered for 10 days. Prevention of Recurrent Attacks of Rheumatic Fever Penicillin or sulfonamides are considered by the American Heart Association to be the drugs of choice in the prevention of recurrent attacks of rheumatic fever. In patients who are allergic to penicillin and sulfonamides, oral erythromycin is recommended by the American Heart Association in the long-term prophylaxis of streptococcal pharyngitis (for the prevention of recurrent attacks of rheumatic fever). 3 uuid:ef67e976-9a2c-4eb2-b78b-5cbe92c63d27 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:42355 biolink:treats MONDO:0017767 PMID:41385096 "[{""id"":""uuid:3c72e40e-8b5d-4e9f-862a-6a29be52b759"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7c32abd3-5190-49f6-bec5-c2ab7c2ae3c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin ethylsuccinate tablets and other antibacterial drugs, erythromycin ethylsuccinate tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Erythromycin ethylsuccinate tablets are indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes , Streptococcus pneumoniae , or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.) Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumoniae or Streptococcus pyogenes . Listeriosis caused by Listeria monocytogenes . Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: Infections due to Corynebacterium diphtheriae , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma: In the treatment of infections due to Corynebacterium minutissimum . Intestinal amebiasis caused by Entamoeba histolytica (oral erythromycins only). Extraenteric amebiasis requires treatment with other agents. Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae: As an alternative drug in treatment of acute pelvic inflammatory disease caused by N. gonorrhoeae in female patients with a history of sensitivity to penicillin. Patients should have a serologic test for syphilis before receiving erythromycin as treatment of gonorrhea and a follow-up serologic test for syphilis after 3 months. Syphilis Caused by Treponema Pallidum : Erythromycin is an alternate choice of treatment for primary syphilis in penicillin-allergic patients. In primary syphilis, spinal fluid examinations should be done before treatment and as part of follow-up after therapy. Erythromycins are indicated for the treatment of the following infections caused by Chlamydia trachomatis: Conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections during pregnancy. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to Chlamydia trachomatis . When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of nongonococcal urethritis caused by Ureaplasma urealyticum . Legionnaires' Disease caused by Legionella pneumophila . Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires' Disease. Prophylaxis Prevention of Initial Attacks of Rheumatic Fever Penicillin is considered by the American Heart Association to be the drug of choice in the prevention of initial attacks of rheumatic fever (treatment of Streptococcus pyogenes infections of the upper respiratory tract, e.g., tonsillitis or pharyngitis). Erythromycin is indicated for the treatment of penicillin-allergic patients. 3 The therapeutic dose should be administered for 10 days. Prevention of Recurrent Attacks of Rheumatic Fever Penicillin or sulfonamides are considered by the American Heart Association to be the drugs of choice in the prevention of recurrent attacks of rheumatic fever. In patients who are allergic to penicillin and sulfonamides, oral erythromycin is recommended by the American Heart Association in the long-term prophylaxis of streptococcal pharyngitis (for the prevention of recurrent attacks of rheumatic fever). 3 uuid:cdd076f7-79cc-4ed0-ac9f-df3f57d0cf69 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:42355 biolink:treats MONDO:0001039 PMID:41385096 "[{""id"":""uuid:7ac13423-13ca-41ba-9fa7-72a51ecc14f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:43e52240-e050-4725-baa7-99c027e25e7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin ethylsuccinate tablets and other antibacterial drugs, erythromycin ethylsuccinate tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Erythromycin ethylsuccinate tablets are indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes , Streptococcus pneumoniae , or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.) Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumoniae or Streptococcus pyogenes . Listeriosis caused by Listeria monocytogenes . Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: Infections due to Corynebacterium diphtheriae , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma: In the treatment of infections due to Corynebacterium minutissimum . Intestinal amebiasis caused by Entamoeba histolytica (oral erythromycins only). Extraenteric amebiasis requires treatment with other agents. Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae: As an alternative drug in treatment of acute pelvic inflammatory disease caused by N. gonorrhoeae in female patients with a history of sensitivity to penicillin. Patients should have a serologic test for syphilis before receiving erythromycin as treatment of gonorrhea and a follow-up serologic test for syphilis after 3 months. Syphilis Caused by Treponema Pallidum : Erythromycin is an alternate choice of treatment for primary syphilis in penicillin-allergic patients. In primary syphilis, spinal fluid examinations should be done before treatment and as part of follow-up after therapy. Erythromycins are indicated for the treatment of the following infections caused by Chlamydia trachomatis: Conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections during pregnancy. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to Chlamydia trachomatis . When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of nongonococcal urethritis caused by Ureaplasma urealyticum . Legionnaires' Disease caused by Legionella pneumophila . Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires' Disease. Prophylaxis Prevention of Initial Attacks of Rheumatic Fever Penicillin is considered by the American Heart Association to be the drug of choice in the prevention of initial attacks of rheumatic fever (treatment of Streptococcus pyogenes infections of the upper respiratory tract, e.g., tonsillitis or pharyngitis). Erythromycin is indicated for the treatment of penicillin-allergic patients. 3 The therapeutic dose should be administered for 10 days. Prevention of Recurrent Attacks of Rheumatic Fever Penicillin or sulfonamides are considered by the American Heart Association to be the drugs of choice in the prevention of recurrent attacks of rheumatic fever. In patients who are allergic to penicillin and sulfonamides, oral erythromycin is recommended by the American Heart Association in the long-term prophylaxis of streptococcal pharyngitis (for the prevention of recurrent attacks of rheumatic fever). 3 uuid:e23fa973-a486-4d13-b839-b633214d6687 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:42355 biolink:treats MONDO:0002258 PMID:41385096 "[{""id"":""uuid:b7e4bf6f-2694-44d8-8598-2d92298417f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:abbbfd60-f892-483d-af90-32550758dd52"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin ethylsuccinate tablets and other antibacterial drugs, erythromycin ethylsuccinate tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Erythromycin ethylsuccinate tablets are indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes , Streptococcus pneumoniae , or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.) Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumoniae or Streptococcus pyogenes . Listeriosis caused by Listeria monocytogenes . Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: Infections due to Corynebacterium diphtheriae , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma: In the treatment of infections due to Corynebacterium minutissimum . Intestinal amebiasis caused by Entamoeba histolytica (oral erythromycins only). Extraenteric amebiasis requires treatment with other agents. Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae: As an alternative drug in treatment of acute pelvic inflammatory disease caused by N. gonorrhoeae in female patients with a history of sensitivity to penicillin. Patients should have a serologic test for syphilis before receiving erythromycin as treatment of gonorrhea and a follow-up serologic test for syphilis after 3 months. Syphilis Caused by Treponema Pallidum : Erythromycin is an alternate choice of treatment for primary syphilis in penicillin-allergic patients. In primary syphilis, spinal fluid examinations should be done before treatment and as part of follow-up after therapy. Erythromycins are indicated for the treatment of the following infections caused by Chlamydia trachomatis: Conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections during pregnancy. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to Chlamydia trachomatis . When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of nongonococcal urethritis caused by Ureaplasma urealyticum . Legionnaires' Disease caused by Legionella pneumophila . Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires' Disease. Prophylaxis Prevention of Initial Attacks of Rheumatic Fever Penicillin is considered by the American Heart Association to be the drug of choice in the prevention of initial attacks of rheumatic fever (treatment of Streptococcus pyogenes infections of the upper respiratory tract, e.g., tonsillitis or pharyngitis). Erythromycin is indicated for the treatment of penicillin-allergic patients. 3 The therapeutic dose should be administered for 10 days. Prevention of Recurrent Attacks of Rheumatic Fever Penicillin or sulfonamides are considered by the American Heart Association to be the drugs of choice in the prevention of recurrent attacks of rheumatic fever. In patients who are allergic to penicillin and sulfonamides, oral erythromycin is recommended by the American Heart Association in the long-term prophylaxis of streptococcal pharyngitis (for the prevention of recurrent attacks of rheumatic fever). 3 uuid:386cea67-68dd-4384-b927-6a53dce7d7c0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:42355 biolink:treats MONDO:0021783 PMID:41385096 "[{""id"":""uuid:359be4db-5ab6-450f-a37a-ca5caf9d9c45"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:20525816-364a-4242-aec4-aff48d09495a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin ethylsuccinate tablets and other antibacterial drugs, erythromycin ethylsuccinate tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Erythromycin ethylsuccinate tablets are indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes , Streptococcus pneumoniae , or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.) Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumoniae or Streptococcus pyogenes . Listeriosis caused by Listeria monocytogenes . Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: Infections due to Corynebacterium diphtheriae , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma: In the treatment of infections due to Corynebacterium minutissimum . Intestinal amebiasis caused by Entamoeba histolytica (oral erythromycins only). Extraenteric amebiasis requires treatment with other agents. Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae: As an alternative drug in treatment of acute pelvic inflammatory disease caused by N. gonorrhoeae in female patients with a history of sensitivity to penicillin. Patients should have a serologic test for syphilis before receiving erythromycin as treatment of gonorrhea and a follow-up serologic test for syphilis after 3 months. Syphilis Caused by Treponema Pallidum : Erythromycin is an alternate choice of treatment for primary syphilis in penicillin-allergic patients. In primary syphilis, spinal fluid examinations should be done before treatment and as part of follow-up after therapy. Erythromycins are indicated for the treatment of the following infections caused by Chlamydia trachomatis: Conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections during pregnancy. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to Chlamydia trachomatis . When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of nongonococcal urethritis caused by Ureaplasma urealyticum . Legionnaires' Disease caused by Legionella pneumophila . Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires' Disease. Prophylaxis Prevention of Initial Attacks of Rheumatic Fever Penicillin is considered by the American Heart Association to be the drug of choice in the prevention of initial attacks of rheumatic fever (treatment of Streptococcus pyogenes infections of the upper respiratory tract, e.g., tonsillitis or pharyngitis). Erythromycin is indicated for the treatment of penicillin-allergic patients. 3 The therapeutic dose should be administered for 10 days. Prevention of Recurrent Attacks of Rheumatic Fever Penicillin or sulfonamides are considered by the American Heart Association to be the drugs of choice in the prevention of recurrent attacks of rheumatic fever. In patients who are allergic to penicillin and sulfonamides, oral erythromycin is recommended by the American Heart Association in the long-term prophylaxis of streptococcal pharyngitis (for the prevention of recurrent attacks of rheumatic fever). 3 uuid:913276ca-83c9-4582-88dd-c26f87c0994b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:391960 biolink:treats EFO:0006865 PMID:41385096 "[{""id"":""uuid:357a1325-617c-439d-a26f-b5cdef8ef176"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b9342a4d-e108-47d0-a2ef-8cc7c6005cc0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ENABLEX ® (darifenacin) extended-release tablets are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency. uuid:4411a20d-1472-4b2b-994b-dea9dd2c064c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:42355 biolink:treats MONDO:0043885 PMID:41385096 "[{""id"":""uuid:7b888abb-2f05-46be-b091-1b0fcd157760"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4fb0c69e-10f2-49f2-8ef1-035a86a99d66"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the treatment of superficial ocular infections involving the conjunctiva and/or cornea caused by organisms susceptible to erythromycin. For prophylaxis of ophthalmia neonatorum due to N. gonorrhoeae or C. trachomatis . The effectiveness of erythromycin in the prevention of ophthalmia caused by penicillinase-producing N. gonorrhoeae is not established. For infants born to mothers with clinically apparent gonorrhea, intravenous or intramuscular injections of aqueous crystalline penicillin G should be given; a single dose of 50,000 units for term infants or 20,000 units for infants of low birth weight. Topical prophylaxis alone is inadequate for these infants. uuid:a7fa1356-8a33-4419-8181-063eb3a12895 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:42355 biolink:treats MONDO:0004277 PMID:41385096 "[{""id"":""uuid:70ca3aef-5a9c-4fa6-b235-4e0317a13a36"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:093dc623-7807-4903-8776-d19e5a6b719b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the treatment of superficial ocular infections involving the conjunctiva and/or cornea caused by organisms susceptible to erythromycin. For prophylaxis of ophthalmia neonatorum due to N. gonorrhoeae or C. trachomatis . The effectiveness of erythromycin in the prevention of ophthalmia caused by penicillinase-producing N. gonorrhoeae is not established. For infants born to mothers with clinically apparent gonorrhea, intravenous or intramuscular injections of aqueous crystalline penicillin G should be given; a single dose of 50,000 units for term infants or 20,000 units for infants of low birth weight. Topical prophylaxis alone is inadequate for these infants. uuid:f3896a2b-f085-4242-bf2d-24c4a2ffe535 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:602393 biolink:treats MONDO:0004951 PMID:41385096 "[{""id"":""uuid:3e3eb33c-432d-41a4-9279-2694f0a21aae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ef2ba16d-506e-42bb-b0f0-0f681ccc016d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EPZICOM Tablets, in combination with other antiretroviral agents, are indicated for the treatment of HIV-1 infection. Additional important information on the use of EPZICOM for treatment of HIV-1 infection: EPZICOM is one of multiple products containing abacavir. Before starting EPZICOM, review medical history for prior exposure to any abacavir-containing product in order to avoid reintroduction in a patient with a history of hypersensitivity to abacavir. In one controlled study (CNA30021), more patients taking ZIAGEN 600 mg once daily had severe hypersensitivity reactions compared with patients taking ZIAGEN 300 mg twice daily. As part of a triple-drug regimen, EPZICOM Tablets are recommended for use with antiretroviral agents from different pharmacological classes and not with other nucleoside/nucleotide reverse transcriptase inhibitors. See WARNINGS, ADVERSE REACTIONS, and Description of Clinical Studies. uuid:6ee47fc8-00af-4a7e-be37-d24ca8b2512c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2647689 biolink:treats HP:0000371 PMID:41385096 "[{""id"":""uuid:2d005e5d-4941-4999-a02c-2af9fa0a3fb5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dab0afeb-a6d6-4851-948f-4c07f665c8dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For treatment of ACUTE OTITIS MEDIA in children that is caused by susceptible strains of Haemophilus influenzae . uuid:54d9c688-856a-469d-a06b-0799caae2347 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3746 biolink:treats MONDO:0018602 PMID:41385096 "[{""id"":""uuid:d4175961-21f6-4442-8675-e025db11d6c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:de8386bd-385d-4648-b573-e5695e9c5673"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis and postsurgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin hydrochloride and other antibacterial drugs, clindamycin hydrochloride should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:d4068909-a685-4cb7-9783-29a33f362111 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:187893 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:7dc02957-b094-45f8-87dd-0e00210dbbae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1f0e5580-e111-49f7-b9bc-8abacadfc7cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS Baclofen is useful for the alleviation of signs and symptoms of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity. Patients should have reversible spasticity so that baclofen treatment will aid in restoring residual function. Baclofen may also be of some value in patients with spinal cord injuries and other spinal cord diseases. Baclofen is not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders. The efficacy of baclofen in stroke, cerebral palsy, and Parkinson’s disease has not been established and, therefore, it is not recommended for these conditions. uuid:cce76b53-3c64-4716-9642-79708e891043 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:490877 biolink:treats MONDO:0004951 PMID:41385096 "[{""id"":""uuid:0373b04d-8700-4291-94aa-ccf056ae2a0d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1a4d27ae-1a3f-49f6-b941-940506d0243d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Didanosine delayed-release capsules, also known as ddI, in combination with other antiretroviral agents is indicated for the treatment of human immunodeficiency virus (HIV)-1 infection [ see Clinical Studies ( 14 ) ]. uuid:3f0da3f3-3b05-40f7-a513-c585dce5c427 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:82960 biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:2d05a1ba-fe93-40b3-96f5-0fbc752e853e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f5970400-24ad-4ca0-9a3b-3e33e3c00568"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:b66ac358-47de-4396-8e7c-b42ccb5385d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/isentress""]},{""id"":""uuid:5f988286-565f-40dc-a4fb-2e118888bf20"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ISENTRESS Registered trademark of MERCK & CO., Inc. COPYRIGHT © 2007, 2009 MERCK & CO., Inc. All rights reserved is indicated in combination with other anti-retroviral agents for the treatment of human immunodeficiency virus (HIV-1) infection in adult patients. This indication is based on analyses of plasma HIV-1 RNA levels up through 48 weeks in three double-blind controlled studies of ISENTRESS. Two of these studies were conducted in clinically advanced, 3-class antiretroviral (NNRTI, NRTI, PI) treatment-experienced adults and one was conducted in treatment-naïve adults. The use of other active agents with ISENTRESS is associated with a greater likelihood of treatment response [see Clinical Studies (14) ] . The safety and efficacy of ISENTRESS have not been established in pediatric patients.|[EMA] Isentress is indicated in combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (HIV 1) infection.|[PMDA] A drug with a new dosage and in an additional dosage form indicated for the treatment of HIV infection. [Orphan drug] uuid:d9819130-68e5-472b-a03b-7ff548639c76 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8107 biolink:treats MONDO:0006710 PMID:41385096 "[{""id"":""uuid:be3ea244-0f2b-4511-a427-6780a9070894"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:16968310-e1fa-451b-bba6-3303e9a0dcb9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Extended phenytoin sodium capsules are indicated for the control of generalized tonic-clonic (grand mal) and complex partial (psychomotor, temporal lobe) seizures and prevention and treatment of seizures occurring during or following neurosurgery. Phenytoin serum level determinations may be necessary for optimal dosage adjustments (see DOSAGE AND ADMINISTRATION and CLINICAL PHARMACOLOGY ). uuid:0bd30f2d-f228-4da6-9c8a-e313ad329874 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10119 biolink:treats MONDO:0005090 PMID:41385096 "[{""id"":""uuid:1f467cca-0226-466a-a2ce-1a8dc661a3eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:21208572-4e6a-4ed1-9f52-09239e1d54d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] GEODON is indicated for the treatment of schizophrenia, as monotherapy for the acute treatment of bipolar manic or mixed episodes, and as an adjunct to lithium or valproate for the maintenance treatment of bipolar disorder. GEODON intramuscular is indicated for acute agitation in schizophrenic patients. When deciding among the alternative treatments available for the condition needing treatment, the prescriber should consider the finding of ziprasidone's greater capacity to prolong the QT/QTc interval compared to several other antipsychotic drugs [ see Warnings and Precautions (5.2) ]. Prolongation of the QTc interval is associated in some other drugs with the ability to cause torsade de pointes-type arrhythmia, a potentially fatal polymorphic ventricular tachycardia, and sudden death. In many cases this would lead to the conclusion that other drugs should be tried first. Whether ziprasidone will cause torsade de pointes or increase the rate of sudden death is not yet known [see Warnings and Precautions (5.2) ] uuid:5cceee2b-b540-49f0-b162-f01e6afbd681 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10119 biolink:treats MONDO:0024612 PMID:41385096 "[{""id"":""uuid:1227f914-3da7-4fcb-9830-539c41d88083"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:386f3e85-5e57-4b99-9e4b-0dea1fdabc62"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] GEODON is indicated for the treatment of schizophrenia, as monotherapy for the acute treatment of bipolar manic or mixed episodes, and as an adjunct to lithium or valproate for the maintenance treatment of bipolar disorder. GEODON intramuscular is indicated for acute agitation in schizophrenic patients. When deciding among the alternative treatments available for the condition needing treatment, the prescriber should consider the finding of ziprasidone's greater capacity to prolong the QT/QTc interval compared to several other antipsychotic drugs [ see Warnings and Precautions (5.2) ]. Prolongation of the QTc interval is associated in some other drugs with the ability to cause torsade de pointes-type arrhythmia, a potentially fatal polymorphic ventricular tachycardia, and sudden death. In many cases this would lead to the conclusion that other drugs should be tried first. Whether ziprasidone will cause torsade de pointes or increase the rate of sudden death is not yet known [see Warnings and Precautions (5.2) ] uuid:d6a9460a-1e72-4813-a248-9ba50c0ca895 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10119 biolink:treats MONDO:0004985 PMID:41385096 "[{""id"":""uuid:fb1335fa-992a-4a08-9a13-540784dcac8a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e8c0b3b6-3d01-49ef-83d6-af8e249f299f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] GEODON is indicated for the treatment of schizophrenia, as monotherapy for the acute treatment of bipolar manic or mixed episodes, and as an adjunct to lithium or valproate for the maintenance treatment of bipolar disorder. GEODON intramuscular is indicated for acute agitation in schizophrenic patients. When deciding among the alternative treatments available for the condition needing treatment, the prescriber should consider the finding of ziprasidone's greater capacity to prolong the QT/QTc interval compared to several other antipsychotic drugs [ see Warnings and Precautions (5.2) ]. Prolongation of the QTc interval is associated in some other drugs with the ability to cause torsade de pointes-type arrhythmia, a potentially fatal polymorphic ventricular tachycardia, and sudden death. In many cases this would lead to the conclusion that other drugs should be tried first. Whether ziprasidone will cause torsade de pointes or increase the rate of sudden death is not yet known [see Warnings and Precautions (5.2) ] uuid:b71fd511-f3bf-4b1b-bd43-82c22ddde962 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7662KG2R6K biolink:treats UMLS:C0267509 PMID:41385096 "[{""id"":""uuid:ff208404-b4c3-4feb-a2b1-219b9a8ee324"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:55ba9f07-b7b0-48d0-b205-a858e0cf52b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amitiza is a chloride channel activator indicated for: Treatment of chronic idiopathic constipation in adults (1.1) Treatment of irritable bowel syndrome with constipation in women ≥ 18 years old (1.2) uuid:c1e25c10-cf73-4714-8485-564c7e2dcaa1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7662KG2R6K biolink:treats MONDO:0005052 PMID:41385096 "[{""id"":""uuid:a6d5a187-f224-47e3-ad05-f0a0431a44cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:080db5f4-2d15-4ec8-8a44-75d9710c655b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amitiza is a chloride channel activator indicated for: Treatment of chronic idiopathic constipation in adults (1.1) Treatment of irritable bowel syndrome with constipation in women ≥ 18 years old (1.2) uuid:de9430a8-e44d-43e3-a0a0-86694a2138c6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:375719 biolink:treats MONDO:0005271 PMID:41385096 "[{""id"":""uuid:d8d6149d-d179-48fe-aed3-af994a9e774c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:deb87361-e9c4-4802-a0ef-a1bfe626e9e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Promethazine with codeine syrup is indicated for the temporary relief of coughs and upper respiratory symptoms associated with allergy or the common cold. uuid:58b6d7ee-5635-424e-9b77-457f7fcbdb90 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:375719 biolink:treats MONDO:0005709 PMID:41385096 "[{""id"":""uuid:318ad566-9922-4122-82a2-98cef8d18d87"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2e80cd21-f80d-4e63-a91b-54f586ef24bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Promethazine with codeine syrup is indicated for the temporary relief of coughs and upper respiratory symptoms associated with allergy or the common cold. uuid:3aedd667-a5e3-45e1-8ae3-389c44732652 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8435 biolink:treats HP:0002018 PMID:41385096 "[{""id"":""uuid:bdf7ff85-f41b-4e4e-b952-b235e7d03e31"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e40ca079-beef-45ff-87b0-43f952ba132b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prochlorperazine 25 mg suppositories are indicated in the control of severe nausea and vomiting in adults. uuid:7f9bb0a2-b63d-4315-a16c-b7769239b4fc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8435 biolink:treats HP:0002013 PMID:41385096 "[{""id"":""uuid:dac83766-ac84-4510-a26e-905a4677468d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3cf6f52e-b619-4215-91cb-f8744a552806"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prochlorperazine 25 mg suppositories are indicated in the control of severe nausea and vomiting in adults. uuid:9e774798-7afd-45c5-afb0-8157d9afd304 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:NQX9KB6PCL biolink:treats MONDO:0018997 PMID:41385096 "[{""id"":""uuid:2281bc55-7a4b-4c50-8666-6d6906fb451c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:fe14bbd3-9bbf-45ec-9e8f-8d2ebdfd9276"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:9de4406f-4914-417d-a664-47f02c9c0f11"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Norditropin is a recombinant human growth hormone indicated for: Pediatric : Treatment of children with growth failure due to growth hormone deficiency (GHD), short stature associated with Noonan syndrome, short stature associated with Turner syndrome and short stature born SGA with no catch-up growth by age 2-4 years ( 1.1 ) Adult : Treatment of adults with either adult onset or childhood onset GHD ( 1.2 )|[PMDA] Drugs with a new additional indication for the treatment of short stature associated with Noonan syndrome with no epiphyseal closure. uuid:27e7ca1a-b2d4-4876-92a7-4dc15b14e7f3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:100241 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:db13ca05-cfa8-4898-9d8f-9878559a982a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:833c80d7-024e-4ac7-b0ce-b35b515c5b2d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Proquin XR is indicated only for the treatment of uncomplicated urinary tract infections (acute cystitis) caused by susceptible strains of the designated microorganisms listed below. Proquin XR is not interchangeable with other ciprofloxacin extended-release or immediate release oral formulations. See DOSAGE AND ADMINISTRATION for specific recommendations. Uncomplicated urinary tract infections (acute cystitis) caused by Escherichia coli and Klebsiella pneumoniae . THE SAFETY AND EFFICACY OF PROQUIN XR IN TREATING PYELONEPHRITIS, COMPLICATED URINARY TRACT INFECTIONS, AND INFECTIONS OTHER THAN UNCOMPLICATED URINARY TRACT INFECTIONS HAVE NOT BEEN DEMONSTRATED. Alternative therapy should be considered for patients who remain symptomatic or develop fever and back pain while on treatment with Proquin XR. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Proquin XR and other antibacterial drugs, Proquin XR should only be used to treat uncomplicated urinary tract infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and sensitivity information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:1a27f463-34b4-46dd-a59b-29e2b6f3de8e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:100241 biolink:treats MONDO:0001650 PMID:41385096 "[{""id"":""uuid:9963e8b7-f13b-40b8-b618-450f1e54e57e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0ce61ea1-6f7b-4125-8a20-9314ff584bd1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Proquin XR is indicated only for the treatment of uncomplicated urinary tract infections (acute cystitis) caused by susceptible strains of the designated microorganisms listed below. Proquin XR is not interchangeable with other ciprofloxacin extended-release or immediate release oral formulations. See DOSAGE AND ADMINISTRATION for specific recommendations. Uncomplicated urinary tract infections (acute cystitis) caused by Escherichia coli and Klebsiella pneumoniae . THE SAFETY AND EFFICACY OF PROQUIN XR IN TREATING PYELONEPHRITIS, COMPLICATED URINARY TRACT INFECTIONS, AND INFECTIONS OTHER THAN UNCOMPLICATED URINARY TRACT INFECTIONS HAVE NOT BEEN DEMONSTRATED. Alternative therapy should be considered for patients who remain symptomatic or develop fever and back pain while on treatment with Proquin XR. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Proquin XR and other antibacterial drugs, Proquin XR should only be used to treat uncomplicated urinary tract infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and sensitivity information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:80b6bb21-c4ab-40c5-b5c7-e296251da62f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47781 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:713c26bc-b47e-4ecb-8ea1-8d16bac88b65"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1e498e17-d0cc-4d4e-bce3-6e4ef187af30"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Desipramine hydrochloride is indicated for the treatment of depression. uuid:a27226fe-7ed2-4759-87d4-1e9e9a8aa687 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:261454 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:db97f072-affb-49ee-beca-7215f806fca9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1ef93778-2ac5-4df9-912a-cdec6e0a17b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:a1272c67-a893-4267-9b4f-f70168b8c848"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AVALIDE ® (irbesartan-hydrochlorothiazide) Tablets is indicated for the treatment of hypertension. AVALIDE may be used in patients whose blood pressure is not adequately controlled on monotherapy. AVALIDE may also be used as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals. The choice of AVALIDE as initial therapy for hypertension should be based on an assessment of potential benefits and risks. Patients with stage 2 (moderate or severe) hypertension are at relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. The decision to use a combination as initial therapy should be individualized and may be shaped by considerations such as the baseline blood pressure, the target goal, and the incremental likelihood of achieving goal with a combination compared with monotherapy. Data from Studies V and VI [see Clinical Studies (14.2) ] provide estimates of the probability of reaching a blood pressure goal with AVALIDE compared to irbesartan or HCTZ monotherapy. The relationship between baseline blood pressure and achievement of a SeSBP less than 140 or less than 130 mmHg or SeDBP less than 90 or less than 80 mmHg in patients treated with AVALIDE compared to patients treated with irbesartan or HCTZ monotherapy are shown in Figures 1a through 2b. Figure 1a: Probability of Achieving SBP less than 140 mmHg in Patients from Initial Therapy Studies V (Week 8) and VI (Week 7)* Figure 1b: Probability of Achieving SBP less than 130 mmHg in Patients from Initial Therapy Studies V (Week 8) and VI (Week 7)* Figure 2a: Probability of Achieving DBP less than 90 mmHg in Patients from Initial Therapy Studies V (Week 8) and VI (Week 7)* Figure 2b: Probability of Achieving DBP less than 80 mmHg in Patients from Initial Therapy Studies V (Week 8) and VI (Week 7)* *For all probability curves, patients without blood pressure measurements at Week 7 (Study VI) and Week 8 (Study V) were counted as not reaching goal (intent-to-treat analysis). The above graphs provide a rough approximation of the likelihood of reaching a targeted blood pressure goal (eg, Week 8 sitting systolic blood pressure less than or equal to 140 mmHg) for the treatment groups. The curve of each treatment group in each study was estimated by logistic regression modeling from all available data of that treatment group. The estimated likelihood at the right tail of each curve is less reliable due to small numbers of subjects with high baseline blood pressures. For example, a patient with a blood pressure of 180/105 mmHg has about a 25% likelihood of achieving a goal of less than 140 mmHg (systolic) and 50% likelihood of achieving less than 90 mmHg (diastolic) on irbesartan alone (and lower still likelihoods on HCTZ alone). The likelihood of achieving these goals on AVALIDE rises to about 40% (systolic) or 70% (diastolic).|[PMDA] New combination drugs indicated for the treatment of hypertension. uuid:1dd4ea95-5719-4d06-8323-4f39ad86f3d2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:261454 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:617b4a56-b7ef-461d-b4a5-25363fefc49a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:95426e02-be95-419f-a3ff-b7d39c1d8e3b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AVALIDE ® (irbesartan-hydrochlorothiazide) Tablets is indicated for the treatment of hypertension. AVALIDE may be used in patients whose blood pressure is not adequately controlled on monotherapy. AVALIDE may also be used as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals. The choice of AVALIDE as initial therapy for hypertension should be based on an assessment of potential benefits and risks. Patients with stage 2 (moderate or severe) hypertension are at relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. The decision to use a combination as initial therapy should be individualized and may be shaped by considerations such as the baseline blood pressure, the target goal, and the incremental likelihood of achieving goal with a combination compared with monotherapy. Data from Studies V and VI [see Clinical Studies (14.2) ] provide estimates of the probability of reaching a blood pressure goal with AVALIDE compared to irbesartan or HCTZ monotherapy. The relationship between baseline blood pressure and achievement of a SeSBP less than 140 or less than 130 mmHg or SeDBP less than 90 or less than 80 mmHg in patients treated with AVALIDE compared to patients treated with irbesartan or HCTZ monotherapy are shown in Figures 1a through 2b. Figure 1a: Probability of Achieving SBP less than 140 mmHg in Patients from Initial Therapy Studies V (Week 8) and VI (Week 7)* Figure 1b: Probability of Achieving SBP less than 130 mmHg in Patients from Initial Therapy Studies V (Week 8) and VI (Week 7)* Figure 2a: Probability of Achieving DBP less than 90 mmHg in Patients from Initial Therapy Studies V (Week 8) and VI (Week 7)* Figure 2b: Probability of Achieving DBP less than 80 mmHg in Patients from Initial Therapy Studies V (Week 8) and VI (Week 7)* *For all probability curves, patients without blood pressure measurements at Week 7 (Study VI) and Week 8 (Study V) were counted as not reaching goal (intent-to-treat analysis). The above graphs provide a rough approximation of the likelihood of reaching a targeted blood pressure goal (eg, Week 8 sitting systolic blood pressure less than or equal to 140 mmHg) for the treatment groups. The curve of each treatment group in each study was estimated by logistic regression modeling from all available data of that treatment group. The estimated likelihood at the right tail of each curve is less reliable due to small numbers of subjects with high baseline blood pressures. For example, a patient with a blood pressure of 180/105 mmHg has about a 25% likelihood of achieving a goal of less than 140 mmHg (systolic) and 50% likelihood of achieving less than 90 mmHg (diastolic) on irbesartan alone (and lower still likelihoods on HCTZ alone). The likelihood of achieving these goals on AVALIDE rises to about 40% (systolic) or 70% (diastolic). uuid:47cdd063-da1f-4537-bf09-3ab9948f26a5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:261454 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:4cc096c5-3dc4-4ab0-a8b6-bdb08b949fd8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0cacaa29-24e3-4ad0-821a-3ee1b70a8981"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AVALIDE ® (irbesartan-hydrochlorothiazide) Tablets is indicated for the treatment of hypertension. AVALIDE may be used in patients whose blood pressure is not adequately controlled on monotherapy. AVALIDE may also be used as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals. The choice of AVALIDE as initial therapy for hypertension should be based on an assessment of potential benefits and risks. Patients with stage 2 (moderate or severe) hypertension are at relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. The decision to use a combination as initial therapy should be individualized and may be shaped by considerations such as the baseline blood pressure, the target goal, and the incremental likelihood of achieving goal with a combination compared with monotherapy. Data from Studies V and VI [see Clinical Studies (14.2) ] provide estimates of the probability of reaching a blood pressure goal with AVALIDE compared to irbesartan or HCTZ monotherapy. The relationship between baseline blood pressure and achievement of a SeSBP less than 140 or less than 130 mmHg or SeDBP less than 90 or less than 80 mmHg in patients treated with AVALIDE compared to patients treated with irbesartan or HCTZ monotherapy are shown in Figures 1a through 2b. Figure 1a: Probability of Achieving SBP less than 140 mmHg in Patients from Initial Therapy Studies V (Week 8) and VI (Week 7)* Figure 1b: Probability of Achieving SBP less than 130 mmHg in Patients from Initial Therapy Studies V (Week 8) and VI (Week 7)* Figure 2a: Probability of Achieving DBP less than 90 mmHg in Patients from Initial Therapy Studies V (Week 8) and VI (Week 7)* Figure 2b: Probability of Achieving DBP less than 80 mmHg in Patients from Initial Therapy Studies V (Week 8) and VI (Week 7)* *For all probability curves, patients without blood pressure measurements at Week 7 (Study VI) and Week 8 (Study V) were counted as not reaching goal (intent-to-treat analysis). The above graphs provide a rough approximation of the likelihood of reaching a targeted blood pressure goal (eg, Week 8 sitting systolic blood pressure less than or equal to 140 mmHg) for the treatment groups. The curve of each treatment group in each study was estimated by logistic regression modeling from all available data of that treatment group. The estimated likelihood at the right tail of each curve is less reliable due to small numbers of subjects with high baseline blood pressures. For example, a patient with a blood pressure of 180/105 mmHg has about a 25% likelihood of achieving a goal of less than 140 mmHg (systolic) and 50% likelihood of achieving less than 90 mmHg (diastolic) on irbesartan alone (and lower still likelihoods on HCTZ alone). The likelihood of achieving these goals on AVALIDE rises to about 40% (systolic) or 70% (diastolic). uuid:92587a7c-71af-4947-97b2-87f71a8120de biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:261454 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:7b3435dc-7dd5-4b0a-96db-9fcf62d6cf64"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cb609086-553d-4a2e-9cae-a9b190b1df3e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AVALIDE ® (irbesartan-hydrochlorothiazide) Tablets is indicated for the treatment of hypertension. AVALIDE may be used in patients whose blood pressure is not adequately controlled on monotherapy. AVALIDE may also be used as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals. The choice of AVALIDE as initial therapy for hypertension should be based on an assessment of potential benefits and risks. Patients with stage 2 (moderate or severe) hypertension are at relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. The decision to use a combination as initial therapy should be individualized and may be shaped by considerations such as the baseline blood pressure, the target goal, and the incremental likelihood of achieving goal with a combination compared with monotherapy. Data from Studies V and VI [see Clinical Studies (14.2) ] provide estimates of the probability of reaching a blood pressure goal with AVALIDE compared to irbesartan or HCTZ monotherapy. The relationship between baseline blood pressure and achievement of a SeSBP less than 140 or less than 130 mmHg or SeDBP less than 90 or less than 80 mmHg in patients treated with AVALIDE compared to patients treated with irbesartan or HCTZ monotherapy are shown in Figures 1a through 2b. Figure 1a: Probability of Achieving SBP less than 140 mmHg in Patients from Initial Therapy Studies V (Week 8) and VI (Week 7)* Figure 1b: Probability of Achieving SBP less than 130 mmHg in Patients from Initial Therapy Studies V (Week 8) and VI (Week 7)* Figure 2a: Probability of Achieving DBP less than 90 mmHg in Patients from Initial Therapy Studies V (Week 8) and VI (Week 7)* Figure 2b: Probability of Achieving DBP less than 80 mmHg in Patients from Initial Therapy Studies V (Week 8) and VI (Week 7)* *For all probability curves, patients without blood pressure measurements at Week 7 (Study VI) and Week 8 (Study V) were counted as not reaching goal (intent-to-treat analysis). The above graphs provide a rough approximation of the likelihood of reaching a targeted blood pressure goal (eg, Week 8 sitting systolic blood pressure less than or equal to 140 mmHg) for the treatment groups. The curve of each treatment group in each study was estimated by logistic regression modeling from all available data of that treatment group. The estimated likelihood at the right tail of each curve is less reliable due to small numbers of subjects with high baseline blood pressures. For example, a patient with a blood pressure of 180/105 mmHg has about a 25% likelihood of achieving a goal of less than 140 mmHg (systolic) and 50% likelihood of achieving less than 90 mmHg (diastolic) on irbesartan alone (and lower still likelihoods on HCTZ alone). The likelihood of achieving these goals on AVALIDE rises to about 40% (systolic) or 70% (diastolic). uuid:893b4f71-f48b-48d6-8283-b2551709c2eb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:261454 biolink:treats MONDO:0001106 PMID:41385096 "[{""id"":""uuid:474df473-0f09-477c-9559-8e40506497d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0a39b64f-a78f-4084-98fa-7fceb9431848"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AVALIDE ® (irbesartan-hydrochlorothiazide) Tablets is indicated for the treatment of hypertension. AVALIDE may be used in patients whose blood pressure is not adequately controlled on monotherapy. AVALIDE may also be used as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals. The choice of AVALIDE as initial therapy for hypertension should be based on an assessment of potential benefits and risks. Patients with stage 2 (moderate or severe) hypertension are at relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. The decision to use a combination as initial therapy should be individualized and may be shaped by considerations such as the baseline blood pressure, the target goal, and the incremental likelihood of achieving goal with a combination compared with monotherapy. Data from Studies V and VI [see Clinical Studies (14.2) ] provide estimates of the probability of reaching a blood pressure goal with AVALIDE compared to irbesartan or HCTZ monotherapy. The relationship between baseline blood pressure and achievement of a SeSBP less than 140 or less than 130 mmHg or SeDBP less than 90 or less than 80 mmHg in patients treated with AVALIDE compared to patients treated with irbesartan or HCTZ monotherapy are shown in Figures 1a through 2b. Figure 1a: Probability of Achieving SBP less than 140 mmHg in Patients from Initial Therapy Studies V (Week 8) and VI (Week 7)* Figure 1b: Probability of Achieving SBP less than 130 mmHg in Patients from Initial Therapy Studies V (Week 8) and VI (Week 7)* Figure 2a: Probability of Achieving DBP less than 90 mmHg in Patients from Initial Therapy Studies V (Week 8) and VI (Week 7)* Figure 2b: Probability of Achieving DBP less than 80 mmHg in Patients from Initial Therapy Studies V (Week 8) and VI (Week 7)* *For all probability curves, patients without blood pressure measurements at Week 7 (Study VI) and Week 8 (Study V) were counted as not reaching goal (intent-to-treat analysis). The above graphs provide a rough approximation of the likelihood of reaching a targeted blood pressure goal (eg, Week 8 sitting systolic blood pressure less than or equal to 140 mmHg) for the treatment groups. The curve of each treatment group in each study was estimated by logistic regression modeling from all available data of that treatment group. The estimated likelihood at the right tail of each curve is less reliable due to small numbers of subjects with high baseline blood pressures. For example, a patient with a blood pressure of 180/105 mmHg has about a 25% likelihood of achieving a goal of less than 140 mmHg (systolic) and 50% likelihood of achieving less than 90 mmHg (diastolic) on irbesartan alone (and lower still likelihoods on HCTZ alone). The likelihood of achieving these goals on AVALIDE rises to about 40% (systolic) or 70% (diastolic). uuid:53393e4c-c770-4732-935d-818562b2d528 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:44032 biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:29300602-cbb0-43d4-aa92-9200311f2841"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9dbeb3b7-f16c-41cb-83d3-2750173a2bad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CRIXIVAN in combination with antiretroviral agents is indicated for the treatment of HIV infection. This indication is based on two clinical trials of approximately 1 year duration that demonstrated: 1) a reduction in the risk of AIDS-defining illnesses or death; 2) a prolonged suppression of HIV RNA. uuid:839ab8e9-f6c5-44fb-a7c9-457331b17fd3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:44032 biolink:treats UMLS:C0740842 PMID:41385096 "[{""id"":""uuid:6acf646b-9645-4e3e-bca9-930bbb615d1f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c12b606c-c0ce-405d-8cc6-407044faed13"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CRIXIVAN in combination with antiretroviral agents is indicated for the treatment of HIV infection. This indication is based on two clinical trials of approximately 1 year duration that demonstrated: 1) a reduction in the risk of AIDS-defining illnesses or death; 2) a prolonged suppression of HIV RNA. uuid:1bda4fde-88e6-4b68-9393-a7040d444edc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:578771 biolink:treats MONDO:0005093 PMID:41385096 "[{""id"":""uuid:f0a0e53a-e9d4-4e0c-851f-9b220c3cd38a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c56e992e-cede-40ab-aa8b-a2418f3a9193"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of cortico-steroid-responsive dermatoses. uuid:525f52ea-d4b2-4051-9f55-d44fc278995a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46345 biolink:treats MONDO:0005173 PMID:41385096 "[{""id"":""uuid:b46d0d82-188b-4925-a33a-d0de65f1c1e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:575ce7ba-affd-49bd-b3dd-76199195f4a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fluorouracil is recommended for the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Safety and efficacy in other indications have not been established. The diagnosis should be established prior to treatment, since this method has not been proven effective in other types of basal cell carcinomas. With isolated, easily accessible basal cell carcinomas, surgery is preferred since success with such lesions is almost 100%. The success rate with Fluorouracil Cream and Solution is approximately 93%, based on 113 lesions in 54 patients. Twenty-five lesions treated with the solution produced 1 failure and 88 lesions treated with the cream produced 7 failures. uuid:c27a73a3-1fe5-4a72-bb2d-5d08984d0f7f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46345 biolink:treats UMLS:C1274598 PMID:41385096 "[{""id"":""uuid:fbd71984-87a6-47b2-a63f-5391f6abafdd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:98a6e2fd-d24b-456a-b0d7-03769eeeb26b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fluorouracil is recommended for the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Safety and efficacy in other indications have not been established. The diagnosis should be established prior to treatment, since this method has not been proven effective in other types of basal cell carcinomas. With isolated, easily accessible basal cell carcinomas, surgery is preferred since success with such lesions is almost 100%. The success rate with Fluorouracil Cream and Solution is approximately 93%, based on 113 lesions in 54 patients. Twenty-five lesions treated with the solution produced 1 failure and 88 lesions treated with the cream produced 7 failures. uuid:50013eb7-3a1f-46ea-b893-d285014627c9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46345 biolink:treats MONDO:0002954 PMID:41385096 "[{""id"":""uuid:366cb7e8-4534-4165-8046-b36035ad3a86"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2e8ea295-fae3-4c79-9f3a-0825de93975b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fluorouracil is recommended for the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Safety and efficacy in other indications have not been established. The diagnosis should be established prior to treatment, since this method has not been proven effective in other types of basal cell carcinomas. With isolated, easily accessible basal cell carcinomas, surgery is preferred since success with such lesions is almost 100%. The success rate with Fluorouracil Cream and Solution is approximately 93%, based on 113 lesions in 54 patients. Twenty-five lesions treated with the solution produced 1 failure and 88 lesions treated with the cream produced 7 failures. uuid:4cd46587-1c8c-4f14-bee5-e43f48c3fa62 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46345 biolink:treats MONDO:0005341 PMID:41385096 "[{""id"":""uuid:2217dd18-d6e8-4db1-b30e-cba18427c7df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3beb139b-4c69-41ac-b5d3-ff1c83beeab7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fluorouracil is recommended for the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Safety and efficacy in other indications have not been established. The diagnosis should be established prior to treatment, since this method has not been proven effective in other types of basal cell carcinomas. With isolated, easily accessible basal cell carcinomas, surgery is preferred since success with such lesions is almost 100%. The success rate with Fluorouracil Cream and Solution is approximately 93%, based on 113 lesions in 54 patients. Twenty-five lesions treated with the solution produced 1 failure and 88 lesions treated with the cream produced 7 failures. uuid:220f9a08-fc71-4865-8428-cc8451306300 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6909 biolink:treats MONDO:0006604 PMID:41385096 "[{""id"":""uuid:0dd20ebf-1ab8-407d-8317-fac59cc16c56"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9339b1d4-7b9e-4eea-b75e-e35ef58006f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:b0abf3a2-b15b-4ad7-8434-535e6b3fbb58"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Metronidazole Topical Cream is indicated for topical application in the treatment of inflammatory papules and pustules of rosacea.|[PMDA] A drug with a new indication and a new dosage for the treatment of rosacea. uuid:893854bd-2691-4aae-a40e-60d6d595352a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:367163 biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:1487886f-6581-4a08-8d0e-af5eabc495dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d880a4ca-eec0-410a-a392-d64aabcfa60b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:45b7d6bd-29a1-40f8-80b1-e50f945ee2de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/darunavir-mylan""]},{""id"":""uuid:cbefd968-a98b-4df5-91f8-03d79ff50d6f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PREZISTA is a human immunodeficiency virus (HIV-1) protease inhibitor indicated for the treatment of HIV infection in adult patients. PREZISTA is also indicated for the treatment of HIV infection in pediatric patients 6 years of age and older. PREZISTA must be co-administered with ritonavir (PREZISTA/ritonavir) and with other antiretroviral agents. ( 1 )|[EMA] Darunavir, co-administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (HIV-1) infection (see section 4.2).Darunavir Mylan 75 mg, 150 mg, 300 mg and 600 mg tablets may be used to provide suitable dose regimens (see section 4.2):For the treatment of HIV-1 infection in antiretroviral treatment (ART)-experienced adult patients, including those that have been highly pre-treated.For the treatment of HIV-1 infection in paediatric patients from the age of 3 years and at least 15 kg body weight.In deciding to initiate treatment with darunavir co-administered with low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. Genotypic or phenotypic testing (when available) and treatment history should guide the use of darunavir (see sections 4.2, 4.4 and 5.1).Darunavir co-administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (HIV-1) infection. Darunavir co-administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg) (see section 4.2). Darunavir Mylan 400 mg and 800 mg tablets may be used to provide suitable dose regimens for the treatment of HIV-1 infection in adult and paediatric patients from the age of 3 years and at least 40 kg body weight who are: antiretroviral therapy (ART)-naïve (see section 4.2). ART-experienced with no darunavir resistance associated mutations (DRV-RAMs) and who have plasma HIV-1 RNA < 100,000 copies/ml and CD4+ cell count ≥ 100 cells x 10⁶/L. In deciding to initiate treatment with darunavir in such ART-experienced patients, genotypic testing should guide the use of darunavir (see sections 4.2, 4.3, 4.4 and 5.1).|[PMDA] A drug with a new dosage indicated for the treatment of HIV infection. [Orphan drug] uuid:53560049-8e0b-4279-bd1c-b614b142f3f1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6775 biolink:treats UMLS:C5779507 PMID:41385096 "[{""id"":""uuid:df6294a6-ee09-4553-92db-dce9175097ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:828ac027-4d47-4b97-936f-8c4651a2a452"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CANASA ® 1000 mg Suppositories are indicated for the treatment of active ulcerative proctitis. uuid:042d2e1f-9c16-4e0c-82f8-ebbcaf77fc65 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8871 biolink:treats HP:0100754 PMID:41385096 "[{""id"":""uuid:95be5f0b-2752-46d8-abb5-bfaf13ef65c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:26d66ff0-5cf2-4425-9a57-11b5f912b5b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RISPERIDONE is an atypical antipsychotic agent indicated for: Treatment of schizophrenia in adults ( 1.1 ) Alone, or in combination with lithium or valproate, for the short-term treatment of acute manic or mixed episodes associated with Bipolar I Disorder in adults ( 1.2 ) Due to Janssen Pharmaceuticals Corporation's marketing exclusivity rights, this drug product is not labeled for use in pediatric patients with schizophrenia, bipolar mania or autistic disorder. ( 1.1 , 1.2 , 1.3 ) uuid:711bb579-9e28-442a-b8bb-ff759581d9a0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:375581 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:eea79bde-dc6c-4394-bba0-7c007034d71a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2ecc0c2e-2719-4711-b6f9-e36ce682299d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxycodone and acetaminophen tablets USP are indicated for the relief of moderate to moderately severe pain. uuid:8c405f13-5aff-478b-9eae-7f92adfbf18d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:37941 biolink:treats MONDO:0005542 PMID:41385096 "[{""id"":""uuid:6750a3f5-7ff4-4d44-b8b4-24de39e0fcde"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6261874d-b750-4555-83a4-6bdb4045fe92"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Plavix is a P2Y 12 platelet inhibitor indicated for: Acute coronary syndrome Recent myocardial infarction (MI), recent stroke, or established peripheral arterial disease. Plavix has been shown to reduce the combined endpoint of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death. ( 1.2 ) uuid:81a28cdf-fefa-4fe4-a188-e9d671032183 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5778 biolink:treats HP:0000969 PMID:41385096 "[{""id"":""uuid:c3e4455e-48ce-45bc-8837-1e7afd12ee89"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c33597cb-d0fd-46e6-bf84-cdb16229e217"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydrochlorothiazide is indicated in the management of hypertension either as the sole therapeutic agent, or in combination with other antihypertensives. Unlike potassium sparing combination diuretic products, hydrochlorothiazide may be used in those patients in whom the development of hyperkalemia cannot be risked, including patients taking ACE inhibitors. Usage in Pregnancy: The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developed toxemia. Edema during pregnancy may arise from pathological causes or from the physiologic and mechanical consequences of pregnancy. Diuretics are indicated in pregnancy when edema is due to pathologic causes, just as they are in the absence of pregnancy. Dependent edema in pregnancy resulting from restriction of venous return by the expanded uterus is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is illogical and unnecessary. There is hypervolemia during normal pregnancy which is harmful to neither the fetus nor the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances this edema may cause extreme discomfort which is not relieved by rest. In these cases a short course of diuretics may provide relief and may be appropriate. uuid:2fa3e3f3-c084-46c3-b926-8356bf64d2d7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1157355 biolink:treats UMLS:C5442256 PMID:41385096 "[{""id"":""uuid:81624264-c18c-4161-9ca0-3f30e9fb4ca3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b1e65893-7585-43dd-8fa0-08316e185cf5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] femhrt is indicated in women with an intact uterus for the: Treatment of moderate to severe vasomotor symptoms associated with the menopause. Prevention of postmenopausal osteoporosis. When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis. Non-estrogen medications should be carefully considered. The mainstays for decreasing the risk of postmenopausal osteoporosis are weight-bearing exercise, adequate calcium and vitamin D intake, and when indicated, pharmacologic therapy. Postmenopausal women require an average of 1500 mg/day of elemental calcium. Therefore, when not contraindicated, calcium supplementation may be helpful for women with suboptimal dietary intake. Vitamin D supplementation of 400-800 IU/day may also be required to ensure adequate daily intake in postmenopausal women. Risk factors for osteoporosis include low bone mineral density, low estrogen levels, family history of osteoporosis, previous fracture, small frame (low BMI), light skin color, smoking, and alcohol intake. Response to therapy can be predicted by pre-treatment serum estradiol, and can be assessed during treatment by measuring biochemical markers of bone formation/resorption, and/or bone mineral density. Estrogen therapy reduces bone resorption and retards or halts postmenopausal bone loss. Studies have shown a risk ratio of about 0.4 for hip and wrist fractures in women whose estrogen therapy was begun within a few years of menopause, compared to women taking calcium and vitamin D alone. Studies also suggest that estrogen reduces the rate of vertebral fractures. Even when started as late as 6 years after menopause, estrogen reduces further loss of bone mass for as long as treatment is continued. When estrogen therapy is discontinued, bone mass declines at a rate comparable to the immediate postmenopausal period. Data from the Women's Health Initiative study showed that use of estrogen-plus-progestin (dose equivalent to 0.625 mg CE and 2.5 mg MPA) resulted in about 5 less hip fractures per 10,000 women-years, compared to use of placebo (risk ratio about 0.66). uuid:12f35abe-132a-4b83-83b3-cb3d26044e85 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1157355 biolink:treats MONDO:0008159 PMID:41385096 "[{""id"":""uuid:fdadc2f4-5ef0-4ea2-a834-ce618d716f89"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:baecdff8-d7d9-4892-953b-4b71fbb25fe4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] femhrt is indicated in women with an intact uterus for the: Treatment of moderate to severe vasomotor symptoms associated with the menopause. Prevention of postmenopausal osteoporosis. When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis. Non-estrogen medications should be carefully considered. The mainstays for decreasing the risk of postmenopausal osteoporosis are weight-bearing exercise, adequate calcium and vitamin D intake, and when indicated, pharmacologic therapy. Postmenopausal women require an average of 1500 mg/day of elemental calcium. Therefore, when not contraindicated, calcium supplementation may be helpful for women with suboptimal dietary intake. Vitamin D supplementation of 400-800 IU/day may also be required to ensure adequate daily intake in postmenopausal women. Risk factors for osteoporosis include low bone mineral density, low estrogen levels, family history of osteoporosis, previous fracture, small frame (low BMI), light skin color, smoking, and alcohol intake. Response to therapy can be predicted by pre-treatment serum estradiol, and can be assessed during treatment by measuring biochemical markers of bone formation/resorption, and/or bone mineral density. Estrogen therapy reduces bone resorption and retards or halts postmenopausal bone loss. Studies have shown a risk ratio of about 0.4 for hip and wrist fractures in women whose estrogen therapy was begun within a few years of menopause, compared to women taking calcium and vitamin D alone. Studies also suggest that estrogen reduces the rate of vertebral fractures. Even when started as late as 6 years after menopause, estrogen reduces further loss of bone mass for as long as treatment is continued. When estrogen therapy is discontinued, bone mass declines at a rate comparable to the immediate postmenopausal period. Data from the Women's Health Initiative study showed that use of estrogen-plus-progestin (dose equivalent to 0.625 mg CE and 2.5 mg MPA) resulted in about 5 less hip fractures per 10,000 women-years, compared to use of placebo (risk ratio about 0.66). uuid:d7c15661-ab77-4ef3-9b76-85491ba8f25e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1157355 biolink:treats HP:6000655 PMID:41385096 "[{""id"":""uuid:22b4ab39-dc97-4d51-844f-58f64076fff2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a6106f2b-8529-40ae-95ae-626570dd5bde"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] femhrt is indicated in women with an intact uterus for the: Treatment of moderate to severe vasomotor symptoms associated with the menopause. Prevention of postmenopausal osteoporosis. When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis. Non-estrogen medications should be carefully considered. The mainstays for decreasing the risk of postmenopausal osteoporosis are weight-bearing exercise, adequate calcium and vitamin D intake, and when indicated, pharmacologic therapy. Postmenopausal women require an average of 1500 mg/day of elemental calcium. Therefore, when not contraindicated, calcium supplementation may be helpful for women with suboptimal dietary intake. Vitamin D supplementation of 400-800 IU/day may also be required to ensure adequate daily intake in postmenopausal women. Risk factors for osteoporosis include low bone mineral density, low estrogen levels, family history of osteoporosis, previous fracture, small frame (low BMI), light skin color, smoking, and alcohol intake. Response to therapy can be predicted by pre-treatment serum estradiol, and can be assessed during treatment by measuring biochemical markers of bone formation/resorption, and/or bone mineral density. Estrogen therapy reduces bone resorption and retards or halts postmenopausal bone loss. Studies have shown a risk ratio of about 0.4 for hip and wrist fractures in women whose estrogen therapy was begun within a few years of menopause, compared to women taking calcium and vitamin D alone. Studies also suggest that estrogen reduces the rate of vertebral fractures. Even when started as late as 6 years after menopause, estrogen reduces further loss of bone mass for as long as treatment is continued. When estrogen therapy is discontinued, bone mass declines at a rate comparable to the immediate postmenopausal period. Data from the Women's Health Initiative study showed that use of estrogen-plus-progestin (dose equivalent to 0.625 mg CE and 2.5 mg MPA) resulted in about 5 less hip fractures per 10,000 women-years, compared to use of placebo (risk ratio about 0.66). uuid:fbed10e8-ad8d-4004-a909-b53ec11e41dc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1157355 biolink:treats EFO:0009515 PMID:41385096 "[{""id"":""uuid:9081de9e-6e48-45df-ba9f-ebd6f4a5adfd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:095459ab-4171-480a-84a6-91ce3d53e0ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] femhrt is indicated in women with an intact uterus for the: Treatment of moderate to severe vasomotor symptoms associated with the menopause. Prevention of postmenopausal osteoporosis. When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis. Non-estrogen medications should be carefully considered. The mainstays for decreasing the risk of postmenopausal osteoporosis are weight-bearing exercise, adequate calcium and vitamin D intake, and when indicated, pharmacologic therapy. Postmenopausal women require an average of 1500 mg/day of elemental calcium. Therefore, when not contraindicated, calcium supplementation may be helpful for women with suboptimal dietary intake. Vitamin D supplementation of 400-800 IU/day may also be required to ensure adequate daily intake in postmenopausal women. Risk factors for osteoporosis include low bone mineral density, low estrogen levels, family history of osteoporosis, previous fracture, small frame (low BMI), light skin color, smoking, and alcohol intake. Response to therapy can be predicted by pre-treatment serum estradiol, and can be assessed during treatment by measuring biochemical markers of bone formation/resorption, and/or bone mineral density. Estrogen therapy reduces bone resorption and retards or halts postmenopausal bone loss. Studies have shown a risk ratio of about 0.4 for hip and wrist fractures in women whose estrogen therapy was begun within a few years of menopause, compared to women taking calcium and vitamin D alone. Studies also suggest that estrogen reduces the rate of vertebral fractures. Even when started as late as 6 years after menopause, estrogen reduces further loss of bone mass for as long as treatment is continued. When estrogen therapy is discontinued, bone mass declines at a rate comparable to the immediate postmenopausal period. Data from the Women's Health Initiative study showed that use of estrogen-plus-progestin (dose equivalent to 0.625 mg CE and 2.5 mg MPA) resulted in about 5 less hip fractures per 10,000 women-years, compared to use of placebo (risk ratio about 0.66). uuid:cb8bda47-5a91-4ce0-9e5f-b84bfb0401bb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1157355 biolink:treats HP:0041166 PMID:41385096 "[{""id"":""uuid:0b0248c8-1ad2-4af5-ab38-bafb88f57a3d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cb152c28-26dd-4ba4-8503-90ad1e00260f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] femhrt is indicated in women with an intact uterus for the: Treatment of moderate to severe vasomotor symptoms associated with the menopause. Prevention of postmenopausal osteoporosis. When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis. Non-estrogen medications should be carefully considered. The mainstays for decreasing the risk of postmenopausal osteoporosis are weight-bearing exercise, adequate calcium and vitamin D intake, and when indicated, pharmacologic therapy. Postmenopausal women require an average of 1500 mg/day of elemental calcium. Therefore, when not contraindicated, calcium supplementation may be helpful for women with suboptimal dietary intake. Vitamin D supplementation of 400-800 IU/day may also be required to ensure adequate daily intake in postmenopausal women. Risk factors for osteoporosis include low bone mineral density, low estrogen levels, family history of osteoporosis, previous fracture, small frame (low BMI), light skin color, smoking, and alcohol intake. Response to therapy can be predicted by pre-treatment serum estradiol, and can be assessed during treatment by measuring biochemical markers of bone formation/resorption, and/or bone mineral density. Estrogen therapy reduces bone resorption and retards or halts postmenopausal bone loss. Studies have shown a risk ratio of about 0.4 for hip and wrist fractures in women whose estrogen therapy was begun within a few years of menopause, compared to women taking calcium and vitamin D alone. Studies also suggest that estrogen reduces the rate of vertebral fractures. Even when started as late as 6 years after menopause, estrogen reduces further loss of bone mass for as long as treatment is continued. When estrogen therapy is discontinued, bone mass declines at a rate comparable to the immediate postmenopausal period. Data from the Women's Health Initiative study showed that use of estrogen-plus-progestin (dose equivalent to 0.625 mg CE and 2.5 mg MPA) resulted in about 5 less hip fractures per 10,000 women-years, compared to use of placebo (risk ratio about 0.66). uuid:1086ceba-93ac-43e0-88c3-c66f0ca2a853 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16469 biolink:treats NCIT:C50476 PMID:41385096 "[{""id"":""uuid:79945396-d253-4421-8759-c7b1b3e4f1ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c8e265bf-e453-4949-9542-340e8e33a175"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ESTRING (estradiol vaginal ring) is an estrogen indicated for the treatment of moderate to severe urogenital symptoms due to postmenopausal atrophy of the vagina (such as dryness, burning, pruritus and dyspareunia) and/or the lower urinary tract (urinary urgency and dysuria). uuid:f64e5df5-a186-45c9-811a-af717ad81246 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16469 biolink:treats HP:0000989 PMID:41385096 "[{""id"":""uuid:ace969a1-97ea-4ecd-8b2a-b0c6c7f3771a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:23555bf8-dcd5-4af3-9808-98567e329f2f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ESTRING (estradiol vaginal ring) is an estrogen indicated for the treatment of moderate to severe urogenital symptoms due to postmenopausal atrophy of the vagina (such as dryness, burning, pruritus and dyspareunia) and/or the lower urinary tract (urinary urgency and dysuria). uuid:eff7b1ac-446b-418e-af0c-707b4e904df2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16469 biolink:treats UMLS:C0423747 PMID:41385096 "[{""id"":""uuid:f8228a1b-384e-4fe8-b629-0493a79b4861"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eccf19e2-eeb3-4d44-8d26-538cfea033c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ESTRING (estradiol vaginal ring) is an estrogen indicated for the treatment of moderate to severe urogenital symptoms due to postmenopausal atrophy of the vagina (such as dryness, burning, pruritus and dyspareunia) and/or the lower urinary tract (urinary urgency and dysuria). uuid:e280bdb6-766f-4e59-a84a-60c368d5a4b0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16469 biolink:treats MONDO:0006624 PMID:41385096 "[{""id"":""uuid:84e5ab48-8e7c-4376-92bf-3cf4579945be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8ecccf11-fd86-4a40-a3ff-d65ba4335c0c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ESTRING (estradiol vaginal ring) is an estrogen indicated for the treatment of moderate to severe urogenital symptoms due to postmenopausal atrophy of the vagina (such as dryness, burning, pruritus and dyspareunia) and/or the lower urinary tract (urinary urgency and dysuria). uuid:693b04ab-1978-441f-b1aa-659c6134b4f1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16469 biolink:treats HP:0100518 PMID:41385096 "[{""id"":""uuid:409a1a4e-6480-40bf-930f-cf06ec7a5e60"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:69459fba-7cec-4a1c-b902-c7c9be645ea9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ESTRING (estradiol vaginal ring) is an estrogen indicated for the treatment of moderate to severe urogenital symptoms due to postmenopausal atrophy of the vagina (such as dryness, burning, pruritus and dyspareunia) and/or the lower urinary tract (urinary urgency and dysuria). uuid:afc3a324-dfba-4be8-b38e-dc884b535534 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:82980 biolink:treats MONDO:0006014 PMID:41385096 "[{""id"":""uuid:bc6ebae0-4b05-47a0-b44c-4f740a18c987"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ac4dafe1-ba87-4301-9c4f-e77258fe994a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Terconazole vaginal cream 0.4% is indicated for the local treatment of vulvovaginal candidiasis (moniliasis). As terconazole vaginal cream 0.4% is effective only for vulvovaginitis caused by the genus Candida, the diagnosis should be confirmed by KOH smears and/or cultures. uuid:65ad64dc-4ecd-4d83-9101-40cb781a6f76 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:82980 biolink:treats UMLS:C0343886 PMID:41385096 "[{""id"":""uuid:2b20b343-875d-4c27-b59e-f02bcab56d6a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:52c7eabe-9d31-4dae-9366-5f5075e8c33c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Terconazole vaginal cream 0.4% is indicated for the local treatment of vulvovaginal candidiasis (moniliasis). As terconazole vaginal cream 0.4% is effective only for vulvovaginitis caused by the genus Candida, the diagnosis should be confirmed by KOH smears and/or cultures. uuid:f8cf1f85-3a81-46bb-bc27-4b5ac19b3c10 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:82980 biolink:treats MONDO:0007019 PMID:41385096 "[{""id"":""uuid:00194a06-43dd-453e-a7ac-b8bc1b214712"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e888a3d6-83e1-4de9-b309-bbf6b738f199"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Terconazole vaginal cream 0.4% is indicated for the local treatment of vulvovaginal candidiasis (moniliasis). As terconazole vaginal cream 0.4% is effective only for vulvovaginitis caused by the genus Candida, the diagnosis should be confirmed by KOH smears and/or cultures. uuid:605bb87a-7f83-45cd-8139-469a5655ac8f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:48131 biolink:treats MONDO:0006604 PMID:41385096 "[{""id"":""uuid:3315c03f-8a0f-4765-9da0-d1fb88ae143f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:06be2e0e-8914-4bfa-a60a-e774b283c231"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FINACEA Gel, 15%, is indicated for topical treatment of inflammatory papules and pustules of mild to moderate rosacea. Although some reduction of erythema which was present in patients with papules and pustules of rosacea occurred in clinical studies, efficacy for treatment of erythema in rosacea in the absence of papules and pustules has not been evaluated. Patients should be instructed to avoid spicy foods, thermally hot foods and drinks, alcoholic beverages and to use only very mild soaps or soapless cleansing lotion for facial cleansing. uuid:50a9b16c-a500-4f5a-a772-aa2a914b68d7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135888 biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:6a317f3b-793f-4028-b6cb-06b2b663f85b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a99ca9e2-e87e-4cd5-9b3d-14a9ab96a9d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ELIDEL ® (pimecrolimus) Cream 1% is indicated as second-line therapy for the short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adults and children 2 years of age and older, who have failed to respond adequately to other topical prescription treatments, or when those treatments are not advisable. ELIDEL Cream is not indicated for use in children less than 2 years of age (see WARNINGS, boxed WARNING, and PRECAUTIONS, Pediatric Use). uuid:b791a75c-a856-4b6a-829b-df3e883c79bb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17026 biolink:treats MONDO:0006193 PMID:41385096 "[{""id"":""uuid:a72b1920-1fc7-4641-8d53-3034270e65ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:00af4091-008d-4cca-b707-a86d6a6ff3df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PROMETRIUM Capsules are indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving conjugated estrogens tablets. They are also indicated for use in secondary amenorrhea. uuid:7f3fc653-2a5c-4b18-a926-bdaea1c67107 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17026 biolink:treats HP:0000869 PMID:41385096 "[{""id"":""uuid:121254b7-3742-4920-9953-f847c97acb4e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7d170346-0707-4f40-906c-228560b8b9ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PROMETRIUM Capsules are indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving conjugated estrogens tablets. They are also indicated for use in secondary amenorrhea. uuid:5a2adadc-db40-4747-97cd-1972c8dd1e3c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31236 biolink:treats MONDO:0005090 PMID:41385096 "[{""id"":""uuid:bb2f041e-e925-4baa-a923-dbf1f0366466"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f13dce24-e7d8-47d3-b74b-a12091e7fc41"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:11cc88b5-3f5c-4d89-a8aa-ce0080f61b64"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/aripiprazole-mylan-pharma""]},{""id"":""uuid:ef6137e7-6d08-4412-a385-73a8fee10507"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ABILIFY is an atypical antipsychotic indicated as oral formulations for the: Treatment of schizophrenia (1.1) Adults: Efficacy was established in four 4-6 week trials and one maintenance trial in patients with schizophrenia (14.1) Adolescents (ages 13-17): Efficacy was established in one 6-week trial in patients with schizophrenia (14.1) Acute treatment of manic or mixed episodes associated with bipolar I disorder as monotherapy and as an adjunct to lithium or valproate (1.2) Adults: Efficacy was established in four 3-week monotherapy trials and one 6-week adjunctive trial in patients with manic or mixed episodes (14.2) Pediatric Patients (ages 10-17): Efficacy was established in one 4-week monotherapy trial in patients with manic or mixed episodes (14.2) Maintenance treatment of bipolar I disorder (1.2) Adults: Efficacy was established in one maintenance trial (14.2) Adjunctive treatment of major depressive disorder (MDD) (1.3) Adults: Efficacy was established in two 6-week trials in patients with MDD who had an inadequate response to antidepressant therapy during the current episode (14.3) Treatment of irritability associated with autistic disorder (1.4) Pediatric Patients (ages 6-17 years): Efficacy was established in two 8-week trials in patients with autistic disorder (14.4) as an injection for the: Acute treatment of agitation associated with schizophrenia or bipolar I disorder (1.5) Adults: Efficacy was established in three 24-hour trials in agitated patients with schizophrenia or manic/mixed episodes of bipolar I disorder (14.5)|[EMA] Aripiprazole Mylan Pharma is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older.Aripiprazole Mylan Pharma is indicated for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment.Aripiprazole Mylan Pharma is indicated for the treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 years and older.|[PMDA] Drugs with a new route of administration indicated for the treatment of schizophrenia. uuid:8bebf67e-3567-49e8-b762-ad957627c61b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31236 biolink:treats MONDO:0024612 PMID:41385096 "[{""id"":""uuid:226ade30-162f-4ad7-bc89-1318a3d5322f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:50c4b355-c4dc-43fc-91cb-2323204dc81b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:9f739e76-c703-4d96-99de-272cf1852aef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/aripiprazole-mylan-pharma""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] ABILIFY is an atypical antipsychotic indicated as oral formulations for the: Treatment of schizophrenia (1.1) Adults: Efficacy was established in four 4-6 week trials and one maintenance trial in patients with schizophrenia (14.1) Adolescents (ages 13-17): Efficacy was established in one 6-week trial in patients with schizophrenia (14.1) Acute treatment of manic or mixed episodes associated with bipolar I disorder as monotherapy and as an adjunct to lithium or valproate (1.2) Adults: Efficacy was established in four 3-week monotherapy trials and one 6-week adjunctive trial in patients with manic or mixed episodes (14.2) Pediatric Patients (ages 10-17): Efficacy was established in one 4-week monotherapy trial in patients with manic or mixed episodes (14.2) Maintenance treatment of bipolar I disorder (1.2) Adults: Efficacy was established in one maintenance trial (14.2) Adjunctive treatment of major depressive disorder (MDD) (1.3) Adults: Efficacy was established in two 6-week trials in patients with MDD who had an inadequate response to antidepressant therapy during the current episode (14.3) Treatment of irritability associated with autistic disorder (1.4) Pediatric Patients (ages 6-17 years): Efficacy was established in two 8-week trials in patients with autistic disorder (14.4) as an injection for the: Acute treatment of agitation associated with schizophrenia or bipolar I disorder (1.5) Adults: Efficacy was established in three 24-hour trials in agitated patients with schizophrenia or manic/mixed episodes of bipolar I disorder (14.5)|[EMA] Aripiprazole Mylan Pharma is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older.Aripiprazole Mylan Pharma is indicated for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment.Aripiprazole Mylan Pharma is indicated for the treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 years and older. uuid:a8338790-d920-4d59-b15c-6b9958e38523 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31236 biolink:treats MONDO:0001866 PMID:41385096 "[{""id"":""uuid:eb026ced-67c4-4082-a8ff-e708b9a5d916"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:907c0378-a4c1-433e-9043-5ab13b9a7530"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e86d681c-25f6-4b90-b0e9-f5ee9b4f4a14"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/aripiprazole-mylan-pharma""]},{""id"":""uuid:c52674d9-a4d0-442c-b811-d2c773df62fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ABILIFY is an atypical antipsychotic indicated as oral formulations for the: Treatment of schizophrenia (1.1) Adults: Efficacy was established in four 4-6 week trials and one maintenance trial in patients with schizophrenia (14.1) Adolescents (ages 13-17): Efficacy was established in one 6-week trial in patients with schizophrenia (14.1) Acute treatment of manic or mixed episodes associated with bipolar I disorder as monotherapy and as an adjunct to lithium or valproate (1.2) Adults: Efficacy was established in four 3-week monotherapy trials and one 6-week adjunctive trial in patients with manic or mixed episodes (14.2) Pediatric Patients (ages 10-17): Efficacy was established in one 4-week monotherapy trial in patients with manic or mixed episodes (14.2) Maintenance treatment of bipolar I disorder (1.2) Adults: Efficacy was established in one maintenance trial (14.2) Adjunctive treatment of major depressive disorder (MDD) (1.3) Adults: Efficacy was established in two 6-week trials in patients with MDD who had an inadequate response to antidepressant therapy during the current episode (14.3) Treatment of irritability associated with autistic disorder (1.4) Pediatric Patients (ages 6-17 years): Efficacy was established in two 8-week trials in patients with autistic disorder (14.4) as an injection for the: Acute treatment of agitation associated with schizophrenia or bipolar I disorder (1.5) Adults: Efficacy was established in three 24-hour trials in agitated patients with schizophrenia or manic/mixed episodes of bipolar I disorder (14.5)|[EMA] Aripiprazole Mylan Pharma is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older.Aripiprazole Mylan Pharma is indicated for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment.Aripiprazole Mylan Pharma is indicated for the treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 years and older.|[PMDA] Drugs with a new indication for the prevention of recurrence/relapse of mood episodes in patients with bipolar I disorder. uuid:bc73436c-9f29-483e-83bd-be35ba486a99 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31236 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:88c6db63-42ec-45f8-8597-364ef23deed3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ec626039-0465-4e9a-a37d-b6f63538a93e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ABILIFY is an atypical antipsychotic indicated as oral formulations for the: Treatment of schizophrenia (1.1) Adults: Efficacy was established in four 4-6 week trials and one maintenance trial in patients with schizophrenia (14.1) Adolescents (ages 13-17): Efficacy was established in one 6-week trial in patients with schizophrenia (14.1) Acute treatment of manic or mixed episodes associated with bipolar I disorder as monotherapy and as an adjunct to lithium or valproate (1.2) Adults: Efficacy was established in four 3-week monotherapy trials and one 6-week adjunctive trial in patients with manic or mixed episodes (14.2) Pediatric Patients (ages 10-17): Efficacy was established in one 4-week monotherapy trial in patients with manic or mixed episodes (14.2) Maintenance treatment of bipolar I disorder (1.2) Adults: Efficacy was established in one maintenance trial (14.2) Adjunctive treatment of major depressive disorder (MDD) (1.3) Adults: Efficacy was established in two 6-week trials in patients with MDD who had an inadequate response to antidepressant therapy during the current episode (14.3) Treatment of irritability associated with autistic disorder (1.4) Pediatric Patients (ages 6-17 years): Efficacy was established in two 8-week trials in patients with autistic disorder (14.4) as an injection for the: Acute treatment of agitation associated with schizophrenia or bipolar I disorder (1.5) Adults: Efficacy was established in three 24-hour trials in agitated patients with schizophrenia or manic/mixed episodes of bipolar I disorder (14.5) uuid:8f8980dd-1b1f-4213-a174-8235878c141f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31236 biolink:treats MONDO:0005258 PMID:41385096 "[{""id"":""uuid:c8754dbc-0911-4222-86ca-c0a311b108fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:86145532-7308-4528-a801-d14fe865d454"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ABILIFY is an atypical antipsychotic indicated as oral formulations for the: Treatment of schizophrenia (1.1) Adults: Efficacy was established in four 4-6 week trials and one maintenance trial in patients with schizophrenia (14.1) Adolescents (ages 13-17): Efficacy was established in one 6-week trial in patients with schizophrenia (14.1) Acute treatment of manic or mixed episodes associated with bipolar I disorder as monotherapy and as an adjunct to lithium or valproate (1.2) Adults: Efficacy was established in four 3-week monotherapy trials and one 6-week adjunctive trial in patients with manic or mixed episodes (14.2) Pediatric Patients (ages 10-17): Efficacy was established in one 4-week monotherapy trial in patients with manic or mixed episodes (14.2) Maintenance treatment of bipolar I disorder (1.2) Adults: Efficacy was established in one maintenance trial (14.2) Adjunctive treatment of major depressive disorder (MDD) (1.3) Adults: Efficacy was established in two 6-week trials in patients with MDD who had an inadequate response to antidepressant therapy during the current episode (14.3) Treatment of irritability associated with autistic disorder (1.4) Pediatric Patients (ages 6-17 years): Efficacy was established in two 8-week trials in patients with autistic disorder (14.4) as an injection for the: Acute treatment of agitation associated with schizophrenia or bipolar I disorder (1.5) Adults: Efficacy was established in three 24-hour trials in agitated patients with schizophrenia or manic/mixed episodes of bipolar I disorder (14.5) uuid:4da484d2-5ea4-470a-91eb-9e580d6a7de0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31236 biolink:treats HP:0000713 PMID:41385096 "[{""id"":""uuid:29f8be8a-bf50-4cc7-9e17-fc50e77cf1cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:94a8b6a6-a2fa-4994-a8f6-c47da83ba585"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ABILIFY is an atypical antipsychotic indicated as oral formulations for the: Treatment of schizophrenia (1.1) Adults: Efficacy was established in four 4-6 week trials and one maintenance trial in patients with schizophrenia (14.1) Adolescents (ages 13-17): Efficacy was established in one 6-week trial in patients with schizophrenia (14.1) Acute treatment of manic or mixed episodes associated with bipolar I disorder as monotherapy and as an adjunct to lithium or valproate (1.2) Adults: Efficacy was established in four 3-week monotherapy trials and one 6-week adjunctive trial in patients with manic or mixed episodes (14.2) Pediatric Patients (ages 10-17): Efficacy was established in one 4-week monotherapy trial in patients with manic or mixed episodes (14.2) Maintenance treatment of bipolar I disorder (1.2) Adults: Efficacy was established in one maintenance trial (14.2) Adjunctive treatment of major depressive disorder (MDD) (1.3) Adults: Efficacy was established in two 6-week trials in patients with MDD who had an inadequate response to antidepressant therapy during the current episode (14.3) Treatment of irritability associated with autistic disorder (1.4) Pediatric Patients (ages 6-17 years): Efficacy was established in two 8-week trials in patients with autistic disorder (14.4) as an injection for the: Acute treatment of agitation associated with schizophrenia or bipolar I disorder (1.5) Adults: Efficacy was established in three 24-hour trials in agitated patients with schizophrenia or manic/mixed episodes of bipolar I disorder (14.5) uuid:b75041ce-9968-4eac-af64-1be6870c3a99 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:137329 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:cd8965c5-7113-4b6b-93a5-0f2fe47d5aba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2c834f86-dae3-4097-b36e-17a35f5c9d60"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AGGRENOX is indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis. uuid:6a920331-9cee-49b9-bf0a-7dd52a590b0e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:137329 biolink:treats MONDO:0005299 PMID:41385096 "[{""id"":""uuid:15fdf462-4d31-4b75-994e-01339e95783a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:26f9ed7a-11d4-46ae-91b0-01aaf3aa48b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AGGRENOX is indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis. uuid:99ed65cd-7e6c-4608-9ef6-04254a8e480a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6129 biolink:treats UMLS:C0339164 PMID:41385096 "[{""id"":""uuid:2d8bf9b5-9750-42c6-8639-dcb901852e5d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:72a6e845-3ef4-46e0-958d-b15a7fdb282e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE ACULAR ® ophthalmic solution is indicated for the temporary relief of ocular itching due to seasonal allergic conjunctivitis. ACULAR ® ophthalmic solution is also indicated for the treatment of postoperative inflammation in patients who have undergone cataract extraction. uuid:ddd8ab6c-b8be-4090-82e9-2ce912132c3d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8228 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:1a9293b3-ef9a-48b8-a834-3b8eb557e0bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:81b80fbb-ee03-425e-adfa-cb8bb2a8332b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:1670fc4d-1e37-4d65-9d96-d96a4e7cf1ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:9a9a7611-09ba-4b46-b2f4-13207a095c4d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ACTOS is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.|[EMA] Pioglitazone is indicated in the treatment of type-2 diabetes mellitus:as monotherapy:in patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance;as dual oral therapy in combination with:metformin, in patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin;a sulphonylurea, only in patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea;as triple oral therapy in combination with:metformin and a sulphonylurea, in patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy.Pioglitazone is also indicated for combination with insulin in type-2 diabetes mellitus patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance.|[PMDA] Drugs with a new additional indication for the treatment of Type 2 diabetes mellitus (for use only in patients in whom treatment with biguanides in conjunction with dietary and exercise regimens is not sufficiently effective, and insulin resistance is suspected). uuid:7bca6625-f57b-4f82-bee7-a953d13a889d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50885 biolink:treats MONDO:0015129 PMID:41385096 "[{""id"":""uuid:e94266b4-dee7-4fd2-9b45-d8048550d094"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bff32e2a-8cef-40b1-a0eb-8d4141364ac4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fludrocortisone acetate tablets USP, 0.1 mg are indicated as partial replacement therapy for primary and secondary adrenocortical insufficiency in Addison's disease and for the treatment of salt-losing adrenogenital syndrome. uuid:a5df314a-30bf-473e-ba36-863129a2c180 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50885 biolink:treats MONDO:0018479 PMID:41385096 "[{""id"":""uuid:af8fae56-c84a-414f-846e-2193b2b9ffcd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6fcbfe49-fe06-41d1-9510-c9e37c03ba6e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fludrocortisone acetate tablets USP, 0.1 mg are indicated as partial replacement therapy for primary and secondary adrenocortical insufficiency in Addison's disease and for the treatment of salt-losing adrenogenital syndrome. uuid:3c7f314f-be8a-46ac-a223-965885e73f41 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:129011819 biolink:treats MONDO:0008159 PMID:41385096 "[{""id"":""uuid:d74ee602-9655-4357-afa7-fd33effbaff3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f2b14c8b-ab5b-4653-ac15-33e9561b3f44"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FORTICAL ® calcitonin-salmon (rDNA origin) Nasal Spray is indicated for the treatment of postmenopausal osteoporosis in women greater than 5 years postmenopause with low bone mass relative to healthy premenopausal women. Use of FORTICAL ® calcitonin-salmon (rDNA origin) Nasal Spray is recommended in conjunction with an adequate calcium (at least 1000 mg elemental calcium per day) and Vitamin D (400 International Units per day) intake to retard the progressive loss of bone mass. The evidence of efficacy for calcitonin-salmon is based on increases in spinal bone mineral density (BMD) observed in clinical trials. Two randomized, placebo-controlled trials were conducted in 325 postmenopausal women (227 treated with calcitonin-salmon nasal spray and 98 treated with placebo) with spinal, forearm or femoral BMD at least one standard deviation below the normal value for healthy premenopausal women. These studies conducted over two years demonstrated that 200 International Units daily of calcitonin-salmon nasal spray increases lumbar vertebral BMD relative to baseline and relative to placebo in osteoporotic women who were greater than 5 years postmenopause. Calcitonin-salmon nasal spray produced statistically significant increases in lumbar vertebral BMD compared to placebo as early as 6 months after initiation of therapy with persistence of this level for up to 2 years of observation. No effects of calcitonin-salmon nasal spray on cortical bone of the forearm or hip were demonstrated. However, in one study, BMD of the hip showed a statistically significant increase compared with placebo in a region composed of predominantly trabecular bone after 1 year of treatment changing to a trend at 2 years that was no longer statistically significant. uuid:8bdcf1ce-521e-4c4e-9dd0-4fa9ed032454 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3001 biolink:treats MONDO:0005324 PMID:41385096 "[{""id"":""uuid:0b9c9adc-bbba-4d6d-9a0f-7f19b25ec20c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a8f76c87-5b6e-47bf-b879-65d639305fcb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE BECONASE AQ Nasal Spray is indicated for the relief of the symptoms of seasonal or perennial allergic and nonallergic (vasomotor) rhinitis. Results from 2 clinical trials have shown that significant symptomatic relief was obtained within 3 days. However, symptomatic relief may not occur in some patients for as long as 2 weeks. BECONASE AQ Nasal Spray should not be continued beyond 3 weeks in the absence of significant symptomatic improvement. BECONASE AQ Nasal Spray should not be used in the presence of untreated localized infection involving the nasal mucosa. BECONASE AQ Nasal Spray is also indicated for the prevention of recurrence of nasal polyps following surgical removal. Clinical studies have shown that treatment of the symptoms associated with nasal polyps may have to be continued for several weeks or more before a therapeutic result can be fully assessed. Recurrence of symptoms due to polyps can occur after stopping treatment, depending on the severity of the disease. uuid:3f145748-c00f-4789-8b4d-f6a991e7f46d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3001 biolink:treats MONDO:0024332 PMID:41385096 "[{""id"":""uuid:f6490608-890b-420c-ba68-7df9a435da6d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e5d86cb5-aa0d-4f51-b558-4bba319a509a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE BECONASE AQ Nasal Spray is indicated for the relief of the symptoms of seasonal or perennial allergic and nonallergic (vasomotor) rhinitis. Results from 2 clinical trials have shown that significant symptomatic relief was obtained within 3 days. However, symptomatic relief may not occur in some patients for as long as 2 weeks. BECONASE AQ Nasal Spray should not be continued beyond 3 weeks in the absence of significant symptomatic improvement. BECONASE AQ Nasal Spray should not be used in the presence of untreated localized infection involving the nasal mucosa. BECONASE AQ Nasal Spray is also indicated for the prevention of recurrence of nasal polyps following surgical removal. Clinical studies have shown that treatment of the symptoms associated with nasal polyps may have to be continued for several weeks or more before a therapeutic result can be fully assessed. Recurrence of symptoms due to polyps can occur after stopping treatment, depending on the severity of the disease. uuid:fcd90b0b-609b-4bd4-b7d7-956858f570fc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3001 biolink:treats MONDO:0006004 PMID:41385096 "[{""id"":""uuid:945047b4-4c57-4d09-8514-4423b5ad73a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e6e7b317-4210-4fcf-9ec1-47c6abc119ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE BECONASE AQ Nasal Spray is indicated for the relief of the symptoms of seasonal or perennial allergic and nonallergic (vasomotor) rhinitis. Results from 2 clinical trials have shown that significant symptomatic relief was obtained within 3 days. However, symptomatic relief may not occur in some patients for as long as 2 weeks. BECONASE AQ Nasal Spray should not be continued beyond 3 weeks in the absence of significant symptomatic improvement. BECONASE AQ Nasal Spray should not be used in the presence of untreated localized infection involving the nasal mucosa. BECONASE AQ Nasal Spray is also indicated for the prevention of recurrence of nasal polyps following surgical removal. Clinical studies have shown that treatment of the symptoms associated with nasal polyps may have to be continued for several weeks or more before a therapeutic result can be fully assessed. Recurrence of symptoms due to polyps can occur after stopping treatment, depending on the severity of the disease. uuid:0bdb2a27-11a8-4499-979b-d9c40f69530d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3001 biolink:treats MONDO:0006314 PMID:41385096 "[{""id"":""uuid:bef639f5-b22a-4245-be0c-a571e79d768d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4dd644ad-db4b-4d21-869a-0d0971580359"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE BECONASE AQ Nasal Spray is indicated for the relief of the symptoms of seasonal or perennial allergic and nonallergic (vasomotor) rhinitis. Results from 2 clinical trials have shown that significant symptomatic relief was obtained within 3 days. However, symptomatic relief may not occur in some patients for as long as 2 weeks. BECONASE AQ Nasal Spray should not be continued beyond 3 weeks in the absence of significant symptomatic improvement. BECONASE AQ Nasal Spray should not be used in the presence of untreated localized infection involving the nasal mucosa. BECONASE AQ Nasal Spray is also indicated for the prevention of recurrence of nasal polyps following surgical removal. Clinical studies have shown that treatment of the symptoms associated with nasal polyps may have to be continued for several weeks or more before a therapeutic result can be fully assessed. Recurrence of symptoms due to polyps can occur after stopping treatment, depending on the severity of the disease. uuid:0fa0ddfb-9211-4b96-822f-daf783cd4764 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:119915 biolink:treats NCIT:C34887 PMID:41385096 "[{""id"":""uuid:8e6166e6-212e-47f6-9e90-6f5bf77740b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6f4a4cd2-1f53-45bc-b417-004b82538127"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fentanyl transdermal system is indicated for management of persistent , moderate to severe chronic pain that: requires continuous, around-the-clock opioid administration for an extended period of time, and cannot be managed by other means such as non-steroidal analgesics, opioid combination products, or immediate-release opioids Fentanyl transdermal system should ONLY be used in patients who are already receiving opioid therapy, who have demonstrated opioid tolerance, and who require a total daily dose at least equivalent to fentanyl transdermal system 25 mcg/hr (see DOSAGE AND ADMINISTRATION ). Patients who are considered opioid-tolerant are those who have been taking, for a week or longer, at least 60 mg of morphine daily, or at least 30 mg of oral oxycodone daily, or at least 8 mg of oral hydromorphone daily, or an equianalgesic dose of another opioid. Because serious or life-threatening hypoventilation could result, fentanyl transdermal system is contraindicated for use on an as needed basis (i.e., prn), for the management of postoperative or acute pain, or in patients who are not opioid-tolerant or who require opioid analgesia for a short period of time (see BOX WARNING and CONTRAINDICATIONS ). An evaluation of the appropriateness and adequacy of treating with immediate-release opioids is advisable prior to initiating therapy with any modified-release opioid. Prescribers should individualize treatment in every case, initiating therapy at the appropriate point along a progression from non-opioid analgesics, such as non-steroidal anti-inflammatory drugs and acetaminophen, to opioids, in a plan of pain management such as outlined by the World Health Organization, the Agency for Health Research and Quality, the Federation of State Medical Boards Model Policy, or the American Pain Society. Patients should be assessed for their clinical risks for opioid abuse or addiction prior to being prescribed opioids. Patients receiving opioids should be routinely monitored for signs of misuse, abuse, and addiction. Persons at increased risk for opioid abuse include those with a personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (e.g., major depression). Patients at increased risk may still be appropriately treated with modified-release opioid formulations; however these patients will require intensive monitoring for signs of misuse, abuse, or addiction. uuid:895a0684-4fbf-420f-8b9e-f243077073bb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:119915 biolink:treats NCIT:C27003 PMID:41385096 "[{""id"":""uuid:9ca777f7-15d5-44c7-884f-fbd8b57d842b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0c8fea53-68fd-46b6-bca4-0b5f8ec278d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fentanyl transdermal system is indicated for management of persistent , moderate to severe chronic pain that: requires continuous, around-the-clock opioid administration for an extended period of time, and cannot be managed by other means such as non-steroidal analgesics, opioid combination products, or immediate-release opioids Fentanyl transdermal system should ONLY be used in patients who are already receiving opioid therapy, who have demonstrated opioid tolerance, and who require a total daily dose at least equivalent to fentanyl transdermal system 25 mcg/hr (see DOSAGE AND ADMINISTRATION ). Patients who are considered opioid-tolerant are those who have been taking, for a week or longer, at least 60 mg of morphine daily, or at least 30 mg of oral oxycodone daily, or at least 8 mg of oral hydromorphone daily, or an equianalgesic dose of another opioid. Because serious or life-threatening hypoventilation could result, fentanyl transdermal system is contraindicated for use on an as needed basis (i.e., prn), for the management of postoperative or acute pain, or in patients who are not opioid-tolerant or who require opioid analgesia for a short period of time (see BOX WARNING and CONTRAINDICATIONS ). An evaluation of the appropriateness and adequacy of treating with immediate-release opioids is advisable prior to initiating therapy with any modified-release opioid. Prescribers should individualize treatment in every case, initiating therapy at the appropriate point along a progression from non-opioid analgesics, such as non-steroidal anti-inflammatory drugs and acetaminophen, to opioids, in a plan of pain management such as outlined by the World Health Organization, the Agency for Health Research and Quality, the Federation of State Medical Boards Model Policy, or the American Pain Society. Patients should be assessed for their clinical risks for opioid abuse or addiction prior to being prescribed opioids. Patients receiving opioids should be routinely monitored for signs of misuse, abuse, and addiction. Persons at increased risk for opioid abuse include those with a personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (e.g., major depression). Patients at increased risk may still be appropriately treated with modified-release opioid formulations; however these patients will require intensive monitoring for signs of misuse, abuse, or addiction. uuid:b9950f31-c55e-4858-a809-fc0b7aac56e8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6887 biolink:treats MONDO:0021107 PMID:41385096 "[{""id"":""uuid:c5312156-7ef0-4cb6-b803-416cd76bcf0d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:28bab2be-1a6d-4cf8-af3d-2d3b64769768"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Attention Deficit Disorders, Narcolepsy Attention Deficit Disorders (previously known as Minimal Brain Dysfunction in Children). Other terms being used to describe the behavioral syndrome below include: Hyperkinetic Child Syndrome, Minimal Brain Damage, Minimal Cerebral Dysfunction, Minor Cerebral Dysfunction. Methylphenidate hydrochloride is indicated as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate-to-severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. The diagnosis of this syndrome should not be made with finality when these symptoms are only of comparatively recent origin. Nonlocalizing (soft) neurological signs, learning disability, and abnormal EEG may or may not be present, and a diagnosis of central nervous system dysfunction may or may not be warranted. Special Diagnostic Considerations Specific etiology of this syndrome is unknown, and there is no single diagnostic test. Adequate diagnosis requires the use not only of medical but of special psychological, educational, and social resources. Characteristics commonly reported include: chronic history of short attention span, distractibility, emotional lability, impulsivity, and moderate-to-severe hyperactivity; minor neurological signs and abnormal EEG. Learning may or may not be impaired. The diagnosis must be based upon a complete history and evaluation of the child and not solely on the presence of one or more of these characteristics. Drug treatment is not indicated for all children with this syndrome. Stimulants are not intended for use in the child who exhibits symptoms secondary to environmental factors and/or primary psychiatric disorders, including psychosis. Appropriate educational placement is essential and psychosocial intervention is generally necessary. When remedial measures alone are insufficient, the decision to prescribe stimulant medication will depend upon the physician’s assessment of the chronicity and severity of the child’s symptoms. uuid:01f0fd06-6aa7-4e3d-a48a-7d008935496f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63621 biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:b3a4ddb2-fc91-4cd4-a9b6-392595485a31"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7c479151-5ad2-473e-b8d8-06d61ebf18a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:884626c3-69de-4156-a985-95d765e173cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INVIRASE in combination with ritonavir and other antiretroviral agents is indicated for the treatment of HIV infection. The twice daily administration of INVIRASE in combination with ritonavir is supported by safety data from the MaxCmin 1 study (see Table 6 ) and pharmacokinetic data (see Table 1 ). The efficacy of INVIRASE with ritonavir has not been compared against the efficacy of antiretroviral regimens currently considered standard of care.|[PMDA] Addition of a new dosage and dosage form of 500mg tablets, indicated for treatment of HIV infection. [Orphan Drug] uuid:23a46a59-ddc4-4e34-b55b-0e885e772a42 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats UMLS:C0268732 PMID:41385096 "[{""id"":""uuid:6014da32-feab-4166-86f7-777dd87c74f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:89e0c745-b82d-4b7e-9a0b-a1cfcd1b05ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prednisone tablets are indicated in the following conditions: Endocrine disorders: primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, nonsuppurative thyroiditis, hypercalcemia associated with cancer. Rheumatic disorders: as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; post-traumatic osteoarthritis; synovitis of osteoarthritis; epicondylitis. Collagen diseases: during an exacerbation or as maintenance therapy in selected cases of: systemic lupus erythematosus, systemic dermatomyositis (polymyositis), acute rheumatic carditis. Dermatologic diseases: pemphigus, bullous dermatitis herpetiformis, severe erythema multiforme (Stevens-Johnson syndrome), exfoliative dermatitis, mycosis fungoides, severe psoriasis, severe seborrheic dermatitis. Allergic states: control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: seasonal or perennial allergic rhinitis, serum sickness, bronchial asthma, contact dermatitis, atopic dermatitis, drug hypersensitivity reactions. Ophthalmic diseases: severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: allergic conjunctivitis, keratitis, allergic corneal marginal ulcers, herpes zoster ophthalmicus, iritis and iridocyclitis, chorioretinitis, anterior segment inflammation, diffuse posterior uveitis and choroiditis, optic neuritis, sympathetic ophthalmia. Respiratory diseases: symptomatic sarcoidosis, Loeffler’s syndrome not manageable by other means, berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, aspiration pneumonitis. Hematologic disorders: Idiopathic thrombocytopenic purpura in adults, secondary thrombocytopenia in adults, acquired (autoimmune) hemolytic anemia, eythroblastopenia (RBC anemia), congenital (erythroid) hypoplastic anemia. Neoplastic diseases: for palliative management of: leukemias and lymphomas in adults, acute leukemia of childhood. Edematous states: to induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. Gastrointestinal diseases: to tide the patient over a critical period of the disease in: ulcerative colitis, regional enteritis. Miscellaneous: tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy, trichinosis with neurologic or myocardial involvement. uuid:52e8dcfb-969e-4f64-9c9b-a1fb76f4a9af biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0004670 PMID:41385096 "[{""id"":""uuid:b0897d67-8f58-4f8e-9a4e-28f67c8eafd3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6b6f85b3-356b-41f6-9f10-b2bf1dc88314"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prednisone tablets are indicated in the following conditions: Endocrine disorders: primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, nonsuppurative thyroiditis, hypercalcemia associated with cancer. Rheumatic disorders: as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; post-traumatic osteoarthritis; synovitis of osteoarthritis; epicondylitis. Collagen diseases: during an exacerbation or as maintenance therapy in selected cases of: systemic lupus erythematosus, systemic dermatomyositis (polymyositis), acute rheumatic carditis. Dermatologic diseases: pemphigus, bullous dermatitis herpetiformis, severe erythema multiforme (Stevens-Johnson syndrome), exfoliative dermatitis, mycosis fungoides, severe psoriasis, severe seborrheic dermatitis. Allergic states: control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: seasonal or perennial allergic rhinitis, serum sickness, bronchial asthma, contact dermatitis, atopic dermatitis, drug hypersensitivity reactions. Ophthalmic diseases: severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: allergic conjunctivitis, keratitis, allergic corneal marginal ulcers, herpes zoster ophthalmicus, iritis and iridocyclitis, chorioretinitis, anterior segment inflammation, diffuse posterior uveitis and choroiditis, optic neuritis, sympathetic ophthalmia. Respiratory diseases: symptomatic sarcoidosis, Loeffler’s syndrome not manageable by other means, berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, aspiration pneumonitis. Hematologic disorders: Idiopathic thrombocytopenic purpura in adults, secondary thrombocytopenia in adults, acquired (autoimmune) hemolytic anemia, eythroblastopenia (RBC anemia), congenital (erythroid) hypoplastic anemia. Neoplastic diseases: for palliative management of: leukemias and lymphomas in adults, acute leukemia of childhood. Edematous states: to induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. Gastrointestinal diseases: to tide the patient over a critical period of the disease in: ulcerative colitis, regional enteritis. Miscellaneous: tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy, trichinosis with neurologic or myocardial involvement. uuid:fd4e3e1b-df81-4b6b-b40c-e41c123115b5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3764 biolink:treats MONDO:0002026 PMID:41385096 "[{""id"":""uuid:a7930a3d-6ad8-47a6-8ee7-c8ea9ed9d65e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4c505b17-7b4a-49cb-88e4-2a9a00e49cbb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clotrimazole Cream is indicated for the topical treatment of candidiasis due to Candida albicans and tinea versicolor due to Malassezia furfur . Clotrimazole is also available as a nonprescription item which is indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris, and tinea corporis due to Trichophyton rubrum , Trichophyton mentagrophytes , Epidermophyton floccosum , and Microsporum canis . uuid:1992e1a7-440d-4938-b3f9-50e50cac7408 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3764 biolink:treats MONDO:0005915 PMID:41385096 "[{""id"":""uuid:e3ade59f-cc4c-453d-8154-76027434c910"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:06cd7eea-8078-4baa-9d01-47d693c4b088"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clotrimazole Cream is indicated for the topical treatment of candidiasis due to Candida albicans and tinea versicolor due to Malassezia furfur . Clotrimazole is also available as a nonprescription item which is indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris, and tinea corporis due to Trichophyton rubrum , Trichophyton mentagrophytes , Epidermophyton floccosum , and Microsporum canis . uuid:9efbd714-ff2f-4bb1-b1e4-b90d4d2ea31a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3764 biolink:treats MONDO:0005984 PMID:41385096 "[{""id"":""uuid:462143fa-3ae2-4977-b073-5222395b22ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:75618bc3-f516-4259-8e0c-cf2d8fb3f22f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clotrimazole Cream is indicated for the topical treatment of candidiasis due to Candida albicans and tinea versicolor due to Malassezia furfur . Clotrimazole is also available as a nonprescription item which is indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris, and tinea corporis due to Trichophyton rubrum , Trichophyton mentagrophytes , Epidermophyton floccosum , and Microsporum canis . uuid:309c8a0b-7b0d-4c7c-aa42-c51eb10295f2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3764 biolink:treats MONDO:0001405 PMID:41385096 "[{""id"":""uuid:93722e02-18a3-4a8c-85de-5bcfd958f68a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:05b542f9-30fa-4955-85dc-7662a62a64e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clotrimazole Cream is indicated for the topical treatment of candidiasis due to Candida albicans and tinea versicolor due to Malassezia furfur . Clotrimazole is also available as a nonprescription item which is indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris, and tinea corporis due to Trichophyton rubrum , Trichophyton mentagrophytes , Epidermophyton floccosum , and Microsporum canis . uuid:d9c2d0e9-7775-42f1-8195-56362c3c8bdf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3764 biolink:treats MONDO:0001461 PMID:41385096 "[{""id"":""uuid:a5aa4b8a-0f7b-4284-9f4c-711d7abee200"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c66c85f2-27f8-4a4d-a48d-900a801634a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clotrimazole Cream is indicated for the topical treatment of candidiasis due to Candida albicans and tinea versicolor due to Malassezia furfur . Clotrimazole is also available as a nonprescription item which is indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris, and tinea corporis due to Trichophyton rubrum , Trichophyton mentagrophytes , Epidermophyton floccosum , and Microsporum canis . uuid:500c4210-77e9-426b-9454-6a173684f99f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:8L6LAK9BTR biolink:treats UMLS:C5442256 PMID:41385096 "[{""id"":""uuid:00865bce-9b68-423f-9293-43162fc148b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:10310709-c4e5-45a6-bb0b-088fb399a1dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ENJUVIA tablets are indicated in the: Treatment of moderate to severe vasomotor symptoms associated with menopause. Treatment of moderate to severe vaginal dryness and pain with intercourse, symptoms of vulvar and vaginal atrophy, associated with menopause. When prescribing solely for the treatment of moderate to severe vaginal dryness and pain with intercourse, topical vaginal products should be considered. uuid:0d864642-3f1a-4e10-a3af-27a38de1c34d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:8L6LAK9BTR biolink:treats HP:0031088 PMID:41385096 "[{""id"":""uuid:865f8952-ee2d-4720-89dd-6e5a52dda5ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:653c2768-226b-44c9-8550-13b1cce055a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ENJUVIA tablets are indicated in the: Treatment of moderate to severe vasomotor symptoms associated with menopause. Treatment of moderate to severe vaginal dryness and pain with intercourse, symptoms of vulvar and vaginal atrophy, associated with menopause. When prescribing solely for the treatment of moderate to severe vaginal dryness and pain with intercourse, topical vaginal products should be considered. uuid:ebd692bc-fde4-43f6-9c37-26e816014cf9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:8L6LAK9BTR biolink:treats MONDO:0001932 PMID:41385096 "[{""id"":""uuid:1a8c4fa0-a1ff-49fd-8c5d-ea2bae6989f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aa06aa22-a468-462d-afde-9997bf441bfd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ENJUVIA tablets are indicated in the: Treatment of moderate to severe vasomotor symptoms associated with menopause. Treatment of moderate to severe vaginal dryness and pain with intercourse, symptoms of vulvar and vaginal atrophy, associated with menopause. When prescribing solely for the treatment of moderate to severe vaginal dryness and pain with intercourse, topical vaginal products should be considered. DOID:14275 uuid:4ff3a7b3-4f48-4708-a1a7-129a5b66c55e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15640 biolink:treats MONDO:0034212 PMID:41385096 "[{""id"":""uuid:0cbf81c1-ad40-40e1-8ba1-928e446d9036"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0d9666b1-86f6-4aa2-bcb2-0355e6011381"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Leucovorin Calcium Tablets USP are indicated to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists. uuid:42210b1e-6273-41e9-99ce-d7f1b21df9ff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6402 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:187fec53-a90c-4ee7-8e98-a75075b467e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:425450d5-2a2c-43db-bd37-487164947388"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:bff38c17-7f5b-4d5f-b790-a429ad9762ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/leflunomide-medac""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Leflunomide is indicated in adults for the treatment of active rheumatoid arthritis (RA): to reduce signs and symptoms to inhibit structural damage as evidenced by X-ray erosions and joint space narrowing to improve physical function (see CLINICAL STUDIES ). Aspirin, nonsteroidal anti-inflammatory agents and/or low dose corticosteroids may be continued during treatment with leflunomide (see PRECAUTIONS: Drug Interactions: NSAIDs ). The combined use of leflunomide with antimalarials, intramuscular or oral gold, D penicillamine, azathioprine, or methotrexate has not been adequately studied (see WARNINGS: Immunosuppression Potential/Bone Marrow Suppression ).|[EMA] Leflunomide is indicated for the treatment of adult patients with:active rheumatoid arthritis as a 'disease-modifying antirheumatic drug' (DMARD).Recent or concurrent treatment with hepatotoxic or haematotoxic DMARDs (e.g. methotrexate) may result in an increased risk of serious adverse reactions, therefore, the initiation of leflunomide treatment has to be carefully considered regarding these benefit / risk aspects.Moreover, switching from leflunomide to another DMARD without following the washout procedure may also increase the risk of serious adverse reactions even for a long time after the switching. uuid:c91001c3-5f1f-478c-9393-64e1d74b5c0c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:184555 biolink:treats MONDO:0018301 PMID:41385096 "[{""id"":""uuid:bc156cd4-d18e-46fa-856d-2bac4e184e3d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:71f70ca5-8de5-4faa-8865-4963199da29c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:da31e0e4-e03e-48cb-8c02-02d25d90cd85"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/elmiron""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] ELMIRON ® (pentosan polysulfate sodium) is indicated for the relief of bladder pain or discomfort associated with interstitial cystitis.|[EMA] Elmiron is indicated for the treatment of bladder pain syndrome characterized by either glomerulations or Hunner’s lesions in adults with moderate to severe pain, urgency and frequency of micturition., uuid:5a8e2297-5c49-4334-b3e5-6f0360c0b126 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:36704 biolink:treats MONDO:0005173 PMID:41385096 "[{""id"":""uuid:3a9827d8-acbb-4382-8f5a-3588d80c325a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:77c45a0c-20ed-43bb-85f9-632d58b0a323"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:4c54c894-c77f-4ebf-9d75-a39b65648458"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/zyclara""]},{""id"":""uuid:996fb79c-1185-4dd1-889d-57a9b3e91e8b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Imiquimod Cream is indicated for the topical treatment of: Clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses (AK) on the face or scalp in immunocompetent adults ( 1.1 ) External genital and perianal warts/condyloma acuminata in patients 12 years old or older ( 1.3 ) Limitations of Use: Efficacy was not demonstrated for molluscum contagiosum in children aged 2-12 ( 1.4 , 8.4 )|[EMA] Zyclara is indicated for the topical treatment of clinically typical, non-hyperkeratotic, non-hypertrophic, visible or palpable actinic keratosis of the full face or balding scalp in immunocompetent adults when other topical treatment options are contraindicated or less appropriate.|[PMDA] A drug with a new additional indication and a new dosage for the treatment of actinic keratosis (limited to the face or baldness). uuid:d931b898-e374-4e7d-9c54-294a416f5078 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:36704 biolink:treats MONDO:0005647 PMID:41385096 "[{""id"":""uuid:6a37d103-d5bd-473b-8cae-80e80d43b757"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:1164e42c-02dd-4fa9-9532-e5965f4ddf01"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:51b32dbf-61e0-4693-89e4-62dc0f5724e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/zyclara""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Imiquimod Cream is indicated for the topical treatment of: Clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses (AK) on the face or scalp in immunocompetent adults ( 1.1 ) External genital and perianal warts/condyloma acuminata in patients 12 years old or older ( 1.3 ) Limitations of Use: Efficacy was not demonstrated for molluscum contagiosum in children aged 2-12 ( 1.4 , 8.4 )|[EMA] Imiquimod cream is indicated for the topical treatment of :External genital and perianal warts (condylomata acuminata) in adults.Small superficial basal cell carcinomas (sBCCs) in adults.Clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses (AKs) on the face or scalp in immunocompetent adult patients when size or number of lesions limit the efficacy and/or acceptability of cryotherapy and other topical treatment options are contraindicated or less appropriate. uuid:cf2cc6c1-ddd0-498d-97de-9ffc66dc6cf7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:36704 biolink:treats MONDO:0005855 PMID:41385096 "[{""id"":""uuid:26e7c42c-11cb-4097-84b0-8c11d7f08f08"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c0fa8dd0-01ca-4dc4-b015-d6a4759cbaaa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Imiquimod Cream is indicated for the topical treatment of: Clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses (AK) on the face or scalp in immunocompetent adults ( 1.1 ) External genital and perianal warts/condyloma acuminata in patients 12 years old or older ( 1.3 ) Limitations of Use: Efficacy was not demonstrated for molluscum contagiosum in children aged 2-12 ( 1.4 , 8.4 ) uuid:affd5e9f-2546-475c-b740-4c294db2dbb1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1158109 biolink:treats HP:0003124 PMID:41385096 "[{""id"":""uuid:cc2fa1cd-be41-4a66-9ebd-dbf1a49347df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dc706c08-c5f6-40f3-98a2-217c65373ba3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. uuid:19fbb3de-adc0-4b8b-84f6-7004048ac21f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1158109 biolink:treats MONDO:0005311 PMID:41385096 "[{""id"":""uuid:8d1530b7-7c55-4b87-ba64-49f6af0f82ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dea923bd-2e9e-4dc6-8e2b-67052395e8c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. uuid:e8664a0c-e488-494f-abe2-ec36ae051425 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:116962 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:734481fe-0a9b-429d-b35e-fd96070f800f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3ea4f64f-dacc-49fb-89fc-81274592ec5b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fosinopril sodium and hydrochlorothiazide tablets are indicated for the treatment of hypertension. These fixed dose combinations are not indicated for initial therapy. (See DOSAGE AND ADMINISTRATION .) In using fosinopril sodium and hydrochlorothiazide tablets, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that fosinopril does not have a similar risk (see WARNINGS: Neutropenia/Agranulocytosis ). ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients (see WARNINGS: Head and Neck Angioedema and Intestinal Angioedema: ). uuid:5b28a945-33be-43a2-a405-56fe9039131f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:116962 biolink:treats MONDO:0001609 PMID:41385096 "[{""id"":""uuid:dfbfb2b9-3aea-4dc5-a025-b28e15697306"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1d9ae46b-059f-41b4-843f-6554dd4b9ea1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fosinopril sodium and hydrochlorothiazide tablets are indicated for the treatment of hypertension. These fixed dose combinations are not indicated for initial therapy. (See DOSAGE AND ADMINISTRATION .) In using fosinopril sodium and hydrochlorothiazide tablets, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that fosinopril does not have a similar risk (see WARNINGS: Neutropenia/Agranulocytosis ). ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients (see WARNINGS: Head and Neck Angioedema and Intestinal Angioedema: ). uuid:6352a6f4-8d64-42f7-a6af-f4bcd243caa3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:116962 biolink:treats MONDO:0001343 PMID:41385096 "[{""id"":""uuid:ec0b6438-28cd-482e-8fd0-3cb322150ff9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1959fe22-bb82-4235-b26d-85ed9d0e92c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fosinopril sodium and hydrochlorothiazide tablets are indicated for the treatment of hypertension. These fixed dose combinations are not indicated for initial therapy. (See DOSAGE AND ADMINISTRATION .) In using fosinopril sodium and hydrochlorothiazide tablets, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that fosinopril does not have a similar risk (see WARNINGS: Neutropenia/Agranulocytosis ). ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients (see WARNINGS: Head and Neck Angioedema and Intestinal Angioedema: ). uuid:b04992e6-2416-4ccf-a66e-ba6bdf598d25 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:116962 biolink:treats MONDO:0010481 PMID:41385096 "[{""id"":""uuid:a1bd59d8-535d-4bd3-9b45-1b80a24a595c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:91935756-15cb-4b98-9fc6-3b20608a1642"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fosinopril sodium and hydrochlorothiazide tablets are indicated for the treatment of hypertension. These fixed dose combinations are not indicated for initial therapy. (See DOSAGE AND ADMINISTRATION .) In using fosinopril sodium and hydrochlorothiazide tablets, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that fosinopril does not have a similar risk (see WARNINGS: Neutropenia/Agranulocytosis ). ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients (see WARNINGS: Head and Neck Angioedema and Intestinal Angioedema: ). uuid:402e90d5-e79d-4483-b035-c4092ad807ba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9327 biolink:treats MONDO:0043885 PMID:41385096 "[{""id"":""uuid:bc69a681-46a2-4077-8440-82abdc90e501"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d8f86530-ccdb-4528-a32d-53d0367d8be4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sulfacetamide Sodium Ophthalmic Solution USP, 10% is indicated for the treatment of conjunctivitis and other superficial ocular infections due to susceptible microorganisms, and as an adjunctive in systemic sulfonamide therapy of trachoma: Escherichia coli, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus (viridans group), Haemophilus influenzae, Klebsiella species, and Enterobacter species. Topically applied sulfonamides do not provide adequate coverage against Neisseria species, Serratia marcescens and Pseudomonas aeruginosa. A significant percentage of staphylococcal isolates are completely resistant to sulfa drugs. uuid:e592167e-a5d6-4831-8e9d-4b795c78b648 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3699 biolink:treats MONDO:0006896 PMID:41385096 "[{""id"":""uuid:d77161d5-0fd7-48d7-90b2-d46d9e0facc7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3fdb8a63-079f-4671-85ef-72d312b707db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cimetidine tablets are indicated in: 1) Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks and there is rarely reason to use cimetidine at full dosage for longer than 6 to 8 weeks (see DOSAGE AND ADMINISTRATION , Duodenal Ulcer ). Concomitant antacids should be given as needed for relief of pain. However, simultaneous administration of oral cimetidine and antacids is not recommended, since antacids have been reported to interfere with the absorption of oral cimetidine. 2) Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of active ulcer. Patients have been maintained on continued treatment with cimetidine 400 mg at bedtime for periods of up to five years. 3) Short-term treatment of active benign gastric ulcer. There is no information concerning usefulness of treatment periods of longer than eight weeks. 4) Erosive gastroesophageal reflux disease (GERD). Erosive esophagitis diagnosed by endoscopy. Treatment is indicated for twelve weeks for healing of lesions and control of symptoms. The use of cimetidine beyond twelve weeks has not been established (see DOSAGE AND ADMINISTRATION , GERD ). 5) The treatment of pathological hypersecretory conditions (i.e., Zollinger-Ellison Syndrome, systemic mastocytosis, multiple endocrine adenomas). uuid:4b84d94a-0a4f-4581-af3a-b74b605b3281 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3699 biolink:treats UMLS:C0267055 PMID:41385096 "[{""id"":""uuid:32672d5b-8d0f-4ffa-89f8-76cf78a7287f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:df6f9837-d62b-4999-a688-93ce5a9982fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cimetidine tablets are indicated in: 1) Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks and there is rarely reason to use cimetidine at full dosage for longer than 6 to 8 weeks (see DOSAGE AND ADMINISTRATION , Duodenal Ulcer ). Concomitant antacids should be given as needed for relief of pain. However, simultaneous administration of oral cimetidine and antacids is not recommended, since antacids have been reported to interfere with the absorption of oral cimetidine. 2) Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of active ulcer. Patients have been maintained on continued treatment with cimetidine 400 mg at bedtime for periods of up to five years. 3) Short-term treatment of active benign gastric ulcer. There is no information concerning usefulness of treatment periods of longer than eight weeks. 4) Erosive gastroesophageal reflux disease (GERD). Erosive esophagitis diagnosed by endoscopy. Treatment is indicated for twelve weeks for healing of lesions and control of symptoms. The use of cimetidine beyond twelve weeks has not been established (see DOSAGE AND ADMINISTRATION , GERD ). 5) The treatment of pathological hypersecretory conditions (i.e., Zollinger-Ellison Syndrome, systemic mastocytosis, multiple endocrine adenomas). uuid:35f5cb76-a3ed-4da6-aa7a-ef6e30659df4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4754 biolink:treats MONDO:0005984 PMID:41385096 "[{""id"":""uuid:f6a30453-df59-496e-939e-0ac32823a05b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c5be3e0b-fda5-4c76-bf9b-7a293e50b38c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Econazole Nitrate Cream, 1% is indicated for topical application in the treatment of tinea pedis, tinea cruris, and tinea corporis caused by Trichophyton rubrum, Trichophyton mentagrophytes, Trichophyton tonsurans, Microsporum canis, Microsporum audouini, Microsporum gypseum, and Epidermophyton floccosum, in the treatment of cutaneous candidiasis, and in the treatment of tinea versicolor. uuid:b846db26-62a3-4437-af8f-72597a360569 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4754 biolink:treats MONDO:0001405 PMID:41385096 "[{""id"":""uuid:eb7cdb53-ca9a-4ca1-8207-c7ba2874fadc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:af3988e7-6d1c-4c4f-a912-50986345358d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Econazole Nitrate Cream, 1% is indicated for topical application in the treatment of tinea pedis, tinea cruris, and tinea corporis caused by Trichophyton rubrum, Trichophyton mentagrophytes, Trichophyton tonsurans, Microsporum canis, Microsporum audouini, Microsporum gypseum, and Epidermophyton floccosum, in the treatment of cutaneous candidiasis, and in the treatment of tinea versicolor. uuid:a18c2293-6d72-4000-8a69-f5bbbd4fa753 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4754 biolink:treats MONDO:0001461 PMID:41385096 "[{""id"":""uuid:4f8ea248-7eda-4dc0-a6f0-b3589ab0db9c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dc243c54-34f9-48ec-be39-edd7836fbcc0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Econazole Nitrate Cream, 1% is indicated for topical application in the treatment of tinea pedis, tinea cruris, and tinea corporis caused by Trichophyton rubrum, Trichophyton mentagrophytes, Trichophyton tonsurans, Microsporum canis, Microsporum audouini, Microsporum gypseum, and Epidermophyton floccosum, in the treatment of cutaneous candidiasis, and in the treatment of tinea versicolor. uuid:1eaea3c6-8983-4fe6-b8e0-08e79e506ec2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4754 biolink:treats MONDO:0000879 PMID:41385096 "[{""id"":""uuid:b3e0a0e3-4047-4b83-930c-fbfa784d1dc9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3e8b6001-02e3-4223-bc8f-e79e9cad1f03"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Econazole Nitrate Cream, 1% is indicated for topical application in the treatment of tinea pedis, tinea cruris, and tinea corporis caused by Trichophyton rubrum, Trichophyton mentagrophytes, Trichophyton tonsurans, Microsporum canis, Microsporum audouini, Microsporum gypseum, and Epidermophyton floccosum, in the treatment of cutaneous candidiasis, and in the treatment of tinea versicolor. uuid:0800f859-5bfd-49bc-9444-e5f905fb99ea biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4754 biolink:treats MONDO:0005915 PMID:41385096 "[{""id"":""uuid:7c99fda6-f604-49e8-aac4-c2e5522e16b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ddd19096-b0fb-4a47-8ce7-1c4530c1697a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Econazole Nitrate Cream, 1% is indicated for topical application in the treatment of tinea pedis, tinea cruris, and tinea corporis caused by Trichophyton rubrum, Trichophyton mentagrophytes, Trichophyton tonsurans, Microsporum canis, Microsporum audouini, Microsporum gypseum, and Epidermophyton floccosum, in the treatment of cutaneous candidiasis, and in the treatment of tinea versicolor. uuid:5e758fa8-31bb-4839-9120-5ec9850a52d0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:375581 biolink:treats UMLS:C0278139 PMID:41385096 "[{""id"":""uuid:ec5b19ad-83ec-4d4b-82dc-f080d749531a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:beda18a0-286c-49c0-ae2f-5fe8e1912556"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxycodone and Acetaminophen Tablets, USP are indicated for the relief of moderate to moderately severe pain. uuid:8acfcd14-1bfc-4023-872f-8c6e041c4989 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5551 biolink:treats MONDO:0005607 PMID:41385096 "[{""id"":""uuid:3716a49f-29a2-4e98-a714-f2afe1ad9a0d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aa009705-8fbe-4b4e-b6f9-88edc5e68851"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Helps loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus, drain bronchial tubes and make coughs more productive. Helps loosen phlegm and thin bronchial secretions in patients with stable chronic bronchitis. uuid:90129217-2502-4e85-88a9-58920e73fdeb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:9874151 biolink:treats MONDO:0001932 PMID:41385096 "[{""id"":""uuid:a120529f-8923-4331-a49a-fd3a13ae37dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5ecf5480-145a-4ecb-80ce-6eba4b6eca2f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ANGELIQ is indicated in women who have a uterus for the: 1. Treatment of moderate to severe vasomotor symptoms associated with the menopause. 2. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. DOID:14275 uuid:e869c1da-bb1b-40ae-92ce-e23f9e174b85 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46295 biolink:treats NCIT:C55615 PMID:41385096 "[{""id"":""uuid:b64a3d7b-9d91-49f8-bd7a-97f42e06aba7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9206cf60-e488-4fcc-b29a-608ad42d80f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:30c539b7-1f15-4779-8095-6e5f2da05be3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LEVITRA is indicated for the treatment of erectile dysfunction.|[PMDA] A drugs containing a new active ingredient with indications for phosphodiesterase-5 inhibitor in erectile dysfunction. uuid:e7a731d5-a330-4930-a617-5d2117ea5b82 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:42355 biolink:treats MONDO:0002896 PMID:41385096 "[{""id"":""uuid:e846e8c2-06f6-411d-aa60-25c4c0e0cb8d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3525e450-a621-40f2-afbe-d85ea03b597c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Erythromycin Base Filmtab tablets and other antibacterial drugs, Erythromycin Base Filmtab tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Erythromycin Base Filmtab tablets are indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes ; Streptococcus pneumoniae ; Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.) Lower respiratory tract infections of mild to moderate severity caused by Streptococcus pyogenes or Streptococcus pneumoniae . Listeriosis caused by Listeria monocytogenes . Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals, rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Diphtheria: Infections due to Corynebacterium diphtheriae , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma - In the treatment of infections due to Corynebacterium minutissimum . Intestinal amebiasis caused by Entamoeba histolytica (oral erythromycins only). Extraenteric amebiasis requires treatment with other agents. Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae : Erythrocin ® Lactobionate-I.V. (erythromycin lactobionate for injection, USP) followed by erythromycin base orally, as an alternative drug in treatment of acute pelvic inflammatory disease caused by N. gonorrhoeae in female patients with a history of sensitivity to penicillin. Patients should have a serologic test for syphilis before receiving erythromycin as treatment of gonorrhea and a follow-up serologic test for syphilis after 3 months. Erythromycins are indicated for treatment of the following infections caused by Chlamydia trachomatis : conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections during pregnancy. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to Chlamydia trachomatis . 3 When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of nongonococcal urethritis caused by Ureaplasma urealyticum . 3 Primary syphilis caused by Treponema pallidum . Erythromycin (oral forms only) is an alternative choice of treatment for primary syphilis in patients allergic to the penicillins. In treatment of primary syphilis, spinal fluid should be examined before treatment and as part of the follow-up after therapy. Legionnaires' Disease caused by Legionella pneumophila . Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires' Disease. Prophylaxis Prevention of Initial Attacks of Rheumatic Fever Penicillin is considered by the American Heart Association to be the drug of choice in the prevention of initial attacks of rheumatic fever (treatment of Streptococcus pyogenes infections of the upper respiratory tract e.g., tonsillitis, or pharyngitis). 3 Erythromycin is indicated for the treatment of penicillin-allergic patients. The therapeutic dose should be administered for ten days. Prevention of Recurrent Attacks of Rheumatic Fever Penicillin or sulfonamides are considered by the American Heart Association to be the drugs of choice in the prevention of recurrent attacks of rheumatic fever. In patients who are allergic to penicillin and sulfonamides, oral erythromycin is recommended by the American Heart Association in the long-term prophylaxis of streptococcal pharyngitis (for the prevention of recurrent attacks of rheumatic fever). 3 uuid:5438d624-5f48-4121-8adc-db35100b3057 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3746 biolink:treats MONDO:0005316 PMID:41385096 "[{""id"":""uuid:924b471a-bdad-45f3-80ae-1c4f6d00fc6c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f5c77fb0-b2c4-4175-a6c7-43f83fe5bd53"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Clindamycin phosphate vaginal cream 2%, is indicated in the treatment of bacterial vaginosis (formerly referred to as Haemophilus vaginitis, Gardnerella vaginitis, nonspecific vaginitis, Corynebacterium vaginitis, or anaerobic vaginosis). Clindamycin phosphate vaginal cream 2%, can be used to treat non-pregnant women and pregnant women during the second and third trimester. (See CLINICAL STUDIES. ) NOTE: For purposes of this indication, a clinical diagnosis of bacterial vaginosis is usually defined by the presence of a homogeneous vaginal discharge that (a) has a pH of greater than 4.5, (b) emits a ""fishy"" amine odor when mixed with a 10% KOH solution, and (c) contains clue cells on microscopic examination. Gram's stain results consistent with a diagnosis of bacterial vaginosis include (a) markedly reduced or absent Lactobacillus morphology, (b) predominance of Gardnerella morphotype, and (c) absent or few white blood cells. Other pathogens commonly associated with vulvovaginitis, e.g., Trichomonas vaginalis , Chlamydia trachomatis, N. gonorrhoeae, Candida albicans , and Herpes simplex virus should be ruled out." uuid:ea1a4475-8bea-49a1-965b-94f799d73f6a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3746 biolink:treats UMLS:C1622505 PMID:41385096 "[{""id"":""uuid:79741581-3a72-416b-b6d1-6273f800b3f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:62cfcd68-d414-4845-b415-e2fdb86157bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Clindamycin phosphate vaginal cream 2%, is indicated in the treatment of bacterial vaginosis (formerly referred to as Haemophilus vaginitis, Gardnerella vaginitis, nonspecific vaginitis, Corynebacterium vaginitis, or anaerobic vaginosis). Clindamycin phosphate vaginal cream 2%, can be used to treat non-pregnant women and pregnant women during the second and third trimester. (See CLINICAL STUDIES. ) NOTE: For purposes of this indication, a clinical diagnosis of bacterial vaginosis is usually defined by the presence of a homogeneous vaginal discharge that (a) has a pH of greater than 4.5, (b) emits a ""fishy"" amine odor when mixed with a 10% KOH solution, and (c) contains clue cells on microscopic examination. Gram's stain results consistent with a diagnosis of bacterial vaginosis include (a) markedly reduced or absent Lactobacillus morphology, (b) predominance of Gardnerella morphotype, and (c) absent or few white blood cells. Other pathogens commonly associated with vulvovaginitis, e.g., Trichomonas vaginalis , Chlamydia trachomatis, N. gonorrhoeae, Candida albicans , and Herpes simplex virus should be ruled out." uuid:dd599315-6410-4741-a20d-6ba91aaf8cdc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3746 biolink:treats MONDO:0023557 PMID:41385096 "[{""id"":""uuid:009daea4-d8e1-4f8a-93b0-27489481f24e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c01b56af-7b2e-43bb-866d-b16b84fc0a8a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Clindamycin phosphate vaginal cream 2%, is indicated in the treatment of bacterial vaginosis (formerly referred to as Haemophilus vaginitis, Gardnerella vaginitis, nonspecific vaginitis, Corynebacterium vaginitis, or anaerobic vaginosis). Clindamycin phosphate vaginal cream 2%, can be used to treat non-pregnant women and pregnant women during the second and third trimester. (See CLINICAL STUDIES. ) NOTE: For purposes of this indication, a clinical diagnosis of bacterial vaginosis is usually defined by the presence of a homogeneous vaginal discharge that (a) has a pH of greater than 4.5, (b) emits a ""fishy"" amine odor when mixed with a 10% KOH solution, and (c) contains clue cells on microscopic examination. Gram's stain results consistent with a diagnosis of bacterial vaginosis include (a) markedly reduced or absent Lactobacillus morphology, (b) predominance of Gardnerella morphotype, and (c) absent or few white blood cells. Other pathogens commonly associated with vulvovaginitis, e.g., Trichomonas vaginalis , Chlamydia trachomatis, N. gonorrhoeae, Candida albicans , and Herpes simplex virus should be ruled out." uuid:27bf214e-7b2f-43b5-86b8-9b8ea53fa6b6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DrugCentral:3875 biolink:treats MONDO:0011438 PMID:41385096 "[{""id"":""uuid:5b8d2d96-3d28-40a5-b0c4-20e28afc7247"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:17b463d5-dd75-4db0-ad7a-d8e335ed4afa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Erythromycin-Benzoyl Peroxide Topical Gel is indicated for the topical treatment of acne vulgaris. uuid:d0a758a5-1ee9-4c85-990b-b66c32b79215 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3814 biolink:treats UMLS:C0342879 PMID:41385096 "[{""id"":""uuid:73bba23f-1be7-44fa-b0e4-435d0a21b819"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:56e0a858-1c6e-4c52-8e82-a755ad866296"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Since no drug is innocuous, strict attention should be paid to the indications and contraindications, particularly when selecting drugs for chronic long-term use. Micronized colestipol hydrochloride tablets are indicated as adjunctive therapy to diet for the reduction of elevated serum total and LDL-C in patients with primary hypercholesterolemia (elevated LDL-C) who do not respond adequately to diet. Generally, micronized colestipol hydrochloride tablets have no clinically significant effect on serum triglycerides, but with their use, triglyceride levels may be raised in some patients. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Treatment should begin and continue with dietary therapy (see NCEP guidelines ). A minimum of six months of intensive dietary therapy and counseling should be carried out prior to initiation of drug therapy. Shorter periods may be considered in patients with severe elevations of LDL-C or with definite CHD. According to the NCEP guidelines, the goal of treatment is to lower LDL-C, and LDL-C is to be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the Total-C be used to monitor therapy. The NCEP treatment guidelines are shown below. LDL-Cholesterol mg/dL (mmol/L) Definite Atherosclerotic Disease Coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease). Two or More Other Risk Factors Other risk factors for coronary heart disease (CHD) include: age (males: ≥45 years; female: ≥55 years or premature menopause without estrogen replacement therapy); family history of premature CHD; current cigarette smoking; hypertension; confirmed HDL-C <35 mg/dL (0.91 mmol/L); and diabetes mellitus. Subtract one risk factor if HDL-C is ≥60 mg/dL (1.6 mmol/L). Initiation Level Goal No No ≥190 (≥4.9) <160 (<4.1) No Yes ≥160 (≥4.1) <130 (<3.4) Yes Yes or No ≥130 (≥3.4) ≤100 (≤2.6) uuid:70b6a28e-4a05-4ab2-8561-9d038344e91c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3814 biolink:treats MONDO:0005311 PMID:41385096 "[{""id"":""uuid:a6e19ed5-e2e4-446a-946b-3482d1881973"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:21c88511-d133-4437-9fa5-54ab71be6a44"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Since no drug is innocuous, strict attention should be paid to the indications and contraindications, particularly when selecting drugs for chronic long-term use. Micronized colestipol hydrochloride tablets are indicated as adjunctive therapy to diet for the reduction of elevated serum total and LDL-C in patients with primary hypercholesterolemia (elevated LDL-C) who do not respond adequately to diet. Generally, micronized colestipol hydrochloride tablets have no clinically significant effect on serum triglycerides, but with their use, triglyceride levels may be raised in some patients. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Treatment should begin and continue with dietary therapy (see NCEP guidelines ). A minimum of six months of intensive dietary therapy and counseling should be carried out prior to initiation of drug therapy. Shorter periods may be considered in patients with severe elevations of LDL-C or with definite CHD. According to the NCEP guidelines, the goal of treatment is to lower LDL-C, and LDL-C is to be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the Total-C be used to monitor therapy. The NCEP treatment guidelines are shown below. LDL-Cholesterol mg/dL (mmol/L) Definite Atherosclerotic Disease Coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease). Two or More Other Risk Factors Other risk factors for coronary heart disease (CHD) include: age (males: ≥45 years; female: ≥55 years or premature menopause without estrogen replacement therapy); family history of premature CHD; current cigarette smoking; hypertension; confirmed HDL-C <35 mg/dL (0.91 mmol/L); and diabetes mellitus. Subtract one risk factor if HDL-C is ≥60 mg/dL (1.6 mmol/L). Initiation Level Goal No No ≥190 (≥4.9) <160 (<4.1) No Yes ≥160 (≥4.1) <130 (<3.4) Yes Yes or No ≥130 (≥3.4) ≤100 (≤2.6) uuid:a9ed7bd6-3544-46ba-a12a-88f4ad8b7a4d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3814 biolink:treats MONDO:0005010 PMID:41385096 "[{""id"":""uuid:f0005019-a420-4af8-9026-cdc14d718f2f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0d2d38af-7e2f-438f-9842-9e0e6dae358e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Since no drug is innocuous, strict attention should be paid to the indications and contraindications, particularly when selecting drugs for chronic long-term use. Micronized colestipol hydrochloride tablets are indicated as adjunctive therapy to diet for the reduction of elevated serum total and LDL-C in patients with primary hypercholesterolemia (elevated LDL-C) who do not respond adequately to diet. Generally, micronized colestipol hydrochloride tablets have no clinically significant effect on serum triglycerides, but with their use, triglyceride levels may be raised in some patients. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Treatment should begin and continue with dietary therapy (see NCEP guidelines ). A minimum of six months of intensive dietary therapy and counseling should be carried out prior to initiation of drug therapy. Shorter periods may be considered in patients with severe elevations of LDL-C or with definite CHD. According to the NCEP guidelines, the goal of treatment is to lower LDL-C, and LDL-C is to be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the Total-C be used to monitor therapy. The NCEP treatment guidelines are shown below. LDL-Cholesterol mg/dL (mmol/L) Definite Atherosclerotic Disease Coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease). Two or More Other Risk Factors Other risk factors for coronary heart disease (CHD) include: age (males: ≥45 years; female: ≥55 years or premature menopause without estrogen replacement therapy); family history of premature CHD; current cigarette smoking; hypertension; confirmed HDL-C <35 mg/dL (0.91 mmol/L); and diabetes mellitus. Subtract one risk factor if HDL-C is ≥60 mg/dL (1.6 mmol/L). Initiation Level Goal No No ≥190 (≥4.9) <160 (<4.1) No Yes ≥160 (≥4.1) <130 (<3.4) Yes Yes or No ≥130 (≥3.4) ≤100 (≤2.6) uuid:af97f7ab-256d-4b09-980e-6a5a2f4942fe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3814 biolink:treats MONDO:0005294 PMID:41385096 "[{""id"":""uuid:23f5e38a-e08d-4c97-849a-a8599aa1483a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e00c9344-35ca-4565-858d-ed44dcf0cd6e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Since no drug is innocuous, strict attention should be paid to the indications and contraindications, particularly when selecting drugs for chronic long-term use. Micronized colestipol hydrochloride tablets are indicated as adjunctive therapy to diet for the reduction of elevated serum total and LDL-C in patients with primary hypercholesterolemia (elevated LDL-C) who do not respond adequately to diet. Generally, micronized colestipol hydrochloride tablets have no clinically significant effect on serum triglycerides, but with their use, triglyceride levels may be raised in some patients. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Treatment should begin and continue with dietary therapy (see NCEP guidelines ). A minimum of six months of intensive dietary therapy and counseling should be carried out prior to initiation of drug therapy. Shorter periods may be considered in patients with severe elevations of LDL-C or with definite CHD. According to the NCEP guidelines, the goal of treatment is to lower LDL-C, and LDL-C is to be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the Total-C be used to monitor therapy. The NCEP treatment guidelines are shown below. LDL-Cholesterol mg/dL (mmol/L) Definite Atherosclerotic Disease Coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease). Two or More Other Risk Factors Other risk factors for coronary heart disease (CHD) include: age (males: ≥45 years; female: ≥55 years or premature menopause without estrogen replacement therapy); family history of premature CHD; current cigarette smoking; hypertension; confirmed HDL-C <35 mg/dL (0.91 mmol/L); and diabetes mellitus. Subtract one risk factor if HDL-C is ≥60 mg/dL (1.6 mmol/L). Initiation Level Goal No No ≥190 (≥4.9) <160 (<4.1) No Yes ≥160 (≥4.1) <130 (<3.4) Yes Yes or No ≥130 (≥3.4) ≤100 (≤2.6) uuid:9f739081-6671-4bb6-a660-780be6f34637 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3814 biolink:treats MONDO:0005269 PMID:41385096 "[{""id"":""uuid:76e22042-50f6-43cc-82da-85b778826ef6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a89bf89e-6532-40de-b57e-c9ca1a631745"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Since no drug is innocuous, strict attention should be paid to the indications and contraindications, particularly when selecting drugs for chronic long-term use. Micronized colestipol hydrochloride tablets are indicated as adjunctive therapy to diet for the reduction of elevated serum total and LDL-C in patients with primary hypercholesterolemia (elevated LDL-C) who do not respond adequately to diet. Generally, micronized colestipol hydrochloride tablets have no clinically significant effect on serum triglycerides, but with their use, triglyceride levels may be raised in some patients. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Treatment should begin and continue with dietary therapy (see NCEP guidelines ). A minimum of six months of intensive dietary therapy and counseling should be carried out prior to initiation of drug therapy. Shorter periods may be considered in patients with severe elevations of LDL-C or with definite CHD. According to the NCEP guidelines, the goal of treatment is to lower LDL-C, and LDL-C is to be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the Total-C be used to monitor therapy. The NCEP treatment guidelines are shown below. LDL-Cholesterol mg/dL (mmol/L) Definite Atherosclerotic Disease Coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease). Two or More Other Risk Factors Other risk factors for coronary heart disease (CHD) include: age (males: ≥45 years; female: ≥55 years or premature menopause without estrogen replacement therapy); family history of premature CHD; current cigarette smoking; hypertension; confirmed HDL-C <35 mg/dL (0.91 mmol/L); and diabetes mellitus. Subtract one risk factor if HDL-C is ≥60 mg/dL (1.6 mmol/L). Initiation Level Goal No No ≥190 (≥4.9) <160 (<4.1) No Yes ≥160 (≥4.1) <130 (<3.4) Yes Yes or No ≥130 (≥3.4) ≤100 (≤2.6) uuid:dd8696c3-72fc-405f-8ef0-b03e365f3757 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3814 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:159eb296-a092-4a00-a1b3-061aa530ea0b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:79dcb6e5-0e52-41c6-b5db-50bc60e50f97"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Since no drug is innocuous, strict attention should be paid to the indications and contraindications, particularly when selecting drugs for chronic long-term use. Micronized colestipol hydrochloride tablets are indicated as adjunctive therapy to diet for the reduction of elevated serum total and LDL-C in patients with primary hypercholesterolemia (elevated LDL-C) who do not respond adequately to diet. Generally, micronized colestipol hydrochloride tablets have no clinically significant effect on serum triglycerides, but with their use, triglyceride levels may be raised in some patients. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Treatment should begin and continue with dietary therapy (see NCEP guidelines ). A minimum of six months of intensive dietary therapy and counseling should be carried out prior to initiation of drug therapy. Shorter periods may be considered in patients with severe elevations of LDL-C or with definite CHD. According to the NCEP guidelines, the goal of treatment is to lower LDL-C, and LDL-C is to be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the Total-C be used to monitor therapy. The NCEP treatment guidelines are shown below. LDL-Cholesterol mg/dL (mmol/L) Definite Atherosclerotic Disease Coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease). Two or More Other Risk Factors Other risk factors for coronary heart disease (CHD) include: age (males: ≥45 years; female: ≥55 years or premature menopause without estrogen replacement therapy); family history of premature CHD; current cigarette smoking; hypertension; confirmed HDL-C <35 mg/dL (0.91 mmol/L); and diabetes mellitus. Subtract one risk factor if HDL-C is ≥60 mg/dL (1.6 mmol/L). Initiation Level Goal No No ≥190 (≥4.9) <160 (<4.1) No Yes ≥160 (≥4.1) <130 (<3.4) Yes Yes or No ≥130 (≥3.4) ≤100 (≤2.6) uuid:54a6b324-41d0-4bd2-91ac-8758ffdd9bde biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3814 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:23e6f723-dd59-412a-a3a0-d2d5ee050164"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:708aa32d-28a8-43ff-8555-38226a4b47a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Since no drug is innocuous, strict attention should be paid to the indications and contraindications, particularly when selecting drugs for chronic long-term use. Micronized colestipol hydrochloride tablets are indicated as adjunctive therapy to diet for the reduction of elevated serum total and LDL-C in patients with primary hypercholesterolemia (elevated LDL-C) who do not respond adequately to diet. Generally, micronized colestipol hydrochloride tablets have no clinically significant effect on serum triglycerides, but with their use, triglyceride levels may be raised in some patients. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Treatment should begin and continue with dietary therapy (see NCEP guidelines ). A minimum of six months of intensive dietary therapy and counseling should be carried out prior to initiation of drug therapy. Shorter periods may be considered in patients with severe elevations of LDL-C or with definite CHD. According to the NCEP guidelines, the goal of treatment is to lower LDL-C, and LDL-C is to be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the Total-C be used to monitor therapy. The NCEP treatment guidelines are shown below. LDL-Cholesterol mg/dL (mmol/L) Definite Atherosclerotic Disease Coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease). Two or More Other Risk Factors Other risk factors for coronary heart disease (CHD) include: age (males: ≥45 years; female: ≥55 years or premature menopause without estrogen replacement therapy); family history of premature CHD; current cigarette smoking; hypertension; confirmed HDL-C <35 mg/dL (0.91 mmol/L); and diabetes mellitus. Subtract one risk factor if HDL-C is ≥60 mg/dL (1.6 mmol/L). Initiation Level Goal No No ≥190 (≥4.9) <160 (<4.1) No Yes ≥160 (≥4.1) <130 (<3.4) Yes Yes or No ≥130 (≥3.4) ≤100 (≤2.6) uuid:929dce28-e3ae-4c77-8e83-46e69c4dcc7c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3746 biolink:treats MONDO:0011438 PMID:41385096 "[{""id"":""uuid:360826c0-3491-4181-b294-d468838dd886"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1e8426a6-a4e5-4a68-887e-808ae5159963"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clindamycin Phosphate Topical Solution, Clindamycin Phosphate Gel, and Clindamycin Phosphate Lotion are indicated in the treatment of acne vulgaris. In view of the potential for diarrhea, bloody diarrhea and pseudomembranous colitis, the physician should consider whether other agents are more appropriate. (See CONTRAINDICATIONS , WARNINGS and ADVERSE REACTIONS. ) uuid:285e1016-c328-4257-bfa8-35afad05bca0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3746 biolink:treats MONDO:0001673 PMID:41385096 "[{""id"":""uuid:2bad19dc-5138-4f63-a359-c4e66c29e001"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5087d8e1-0934-48e8-a2ff-6e8df5d588c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clindamycin Phosphate Topical Solution, Clindamycin Phosphate Gel, and Clindamycin Phosphate Lotion are indicated in the treatment of acne vulgaris. In view of the potential for diarrhea, bloody diarrhea and pseudomembranous colitis, the physician should consider whether other agents are more appropriate. (See CONTRAINDICATIONS , WARNINGS and ADVERSE REACTIONS. ) uuid:d7a42919-d0a3-459e-9273-4f4e7208ce1b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3746 biolink:treats HP:0025085 PMID:41385096 "[{""id"":""uuid:4ec9107d-1fa9-4cc2-814f-29f3ba1f3011"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e19a2b73-4b64-4cda-b708-d182ef0c1814"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clindamycin Phosphate Topical Solution, Clindamycin Phosphate Gel, and Clindamycin Phosphate Lotion are indicated in the treatment of acne vulgaris. In view of the potential for diarrhea, bloody diarrhea and pseudomembranous colitis, the physician should consider whether other agents are more appropriate. (See CONTRAINDICATIONS , WARNINGS and ADVERSE REACTIONS. ) uuid:4ca02fea-ba73-4b20-9c83-6a9c914fcb11 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3746 biolink:treats MONDO:0000705 PMID:41385096 "[{""id"":""uuid:ba778f32-99c5-4448-ab36-872d15fe2bd0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b7f8212c-0bee-40a5-b967-40098bd779f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clindamycin Phosphate Topical Solution, Clindamycin Phosphate Gel, and Clindamycin Phosphate Lotion are indicated in the treatment of acne vulgaris. In view of the potential for diarrhea, bloody diarrhea and pseudomembranous colitis, the physician should consider whether other agents are more appropriate. (See CONTRAINDICATIONS , WARNINGS and ADVERSE REACTIONS. ) uuid:32055139-aee0-4851-be1f-f948d4a7fe3f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31854 biolink:treats MONDO:0005546 PMID:41385096 "[{""id"":""uuid:2ba19a67-5876-435b-8915-13c6ab640bd8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a94f55ae-4108-49dc-a59a-6f5cb644214b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Savella is indicated for the management of fibromyalgia. Savella is not approved for use in pediatric patients [ see Use in Specific Populations ( 8.4 ) ]. uuid:43181eb4-fe34-4923-8a41-64fa9091f42e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32184 biolink:treats UMLS:C1304119 PMID:41385096 "[{""id"":""uuid:69610b00-9b25-4266-88a1-6cd984e881e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8d6c983c-7af0-4209-a6e9-53e15aa27c05"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TAZORAC ® (tazarotene) Gel 0.05% and 0.1% are indicated for the topical treatment of patients with stable plaque psoriasis of up to 20% body surface area involvement. TAZORAC ® (tazarotene) Gel 0.1% is also indicated for the topical treatment of patients with facial acne vulgaris of mild to moderate severity. The efficacy of TAZORAC ® Gel in the treatment of acne previously treated with other retinoids or resistant to oral antibiotics has not been established. uuid:e8357fac-8db7-4dba-bb52-2ab383e477e8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32184 biolink:treats MONDO:0011438 PMID:41385096 "[{""id"":""uuid:5f72b3b8-eabb-4e70-b70c-82d696fb065d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:10c44651-a0ad-4ea2-8092-a4f10747909d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TAZORAC ® (tazarotene) Gel 0.05% and 0.1% are indicated for the topical treatment of patients with stable plaque psoriasis of up to 20% body surface area involvement. TAZORAC ® (tazarotene) Gel 0.1% is also indicated for the topical treatment of patients with facial acne vulgaris of mild to moderate severity. The efficacy of TAZORAC ® Gel in the treatment of acne previously treated with other retinoids or resistant to oral antibiotics has not been established. uuid:079d44c3-fca2-48d1-851c-2085500d747a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5558 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:eb35ad95-6b1e-48e3-b4f8-68898a9d2b0a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:70f50bfd-1f23-419d-874e-018dd1877cf6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Guanfacine tablets are indicated in the management of hypertension. Guanfacine may be given alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. uuid:43380a92-4ef8-406d-b632-53d5e6fc11ed biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8356 biolink:treats MONDO:0005180 PMID:41385096 "[{""id"":""uuid:136da4a2-5a2e-49f1-9d8f-a5ed35265523"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0e7627b7-558e-4f82-b05b-5f6c35fa2146"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:9379090a-7abf-4e02-bf89-18fa13c2f97b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:4dbe0507-b2f2-4c72-9fe4-2812dc8c5ae8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Pramipexole dihydrochloride tablets are indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease. The effectiveness of pramipexole dihydrochloride tablets was demonstrated in randomized, controlled trials in patients with early Parkinson's disease who were not receiving concomitant levodopa therapy as well as in patients with advanced disease on concomitant levodopa (see CLINICAL STUDIES ).|[EMA] Oprymea is indicated for treatment of the signs and symptoms of idiopathic Parkinson's disease, alone (without levodopa) or in combination with levodopa, i.e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end of dose or ""on off"" fluctuations).Oprymea is indicated in adults for symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome in doses up to 0.54 mg of base (0.75 mg of salt) (see section 4.2).|[PMDA] Drugs in new dosage forms and with new dosages indicated for the treatment of Parkinson's disease." uuid:ac97140d-0360-43c1-b101-b64613a62767 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7025 biolink:treats MONDO:0021680 PMID:41385096 "[{""id"":""uuid:8f9a19c4-24da-454e-b823-22c9d0c20ba3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:af043a3f-2966-4e33-a16a-6da30b67e5f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Mupirocin Ointment USP, 2% is indicated for the topical treatment of impetigo due to: Staphylococcus aureus and Streptococcus pyogenes . uuid:f8cf4929-68ae-45ee-8f18-57030426a6bd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:56841899 biolink:treats MONDO:0006668 PMID:41385096 "[{""id"":""uuid:8452afd7-8fea-4965-be4d-ec9da51f485b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:83008dc2-7099-45d4-8eee-28f47edb8709"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. Ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of corticosteroids use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns; or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus, Escherichia coli, Haemophilus influenzae, Klebsiella/Enterobacter species, Neisseria species, and Pseudomonas aeruginosa. This product does not provide adequate coverage against: Serratia marcescens and streptococci, including Streptococcus pneumoniae. uuid:7116750c-2557-4c79-9bc5-5dd55845c1ff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:56841899 biolink:treats UMLS:C0008690 PMID:41385096 "[{""id"":""uuid:44b2777b-3d00-4bff-a4b2-8695a050cf02"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:21b3706e-4164-4171-80be-0e22e82432c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. Ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of corticosteroids use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns; or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus, Escherichia coli, Haemophilus influenzae, Klebsiella/Enterobacter species, Neisseria species, and Pseudomonas aeruginosa. This product does not provide adequate coverage against: Serratia marcescens and streptococci, including Streptococcus pneumoniae. uuid:ff172ec1-f114-4137-83c0-ca047867f939 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:56841899 biolink:treats UMLS:C0339289 PMID:41385096 "[{""id"":""uuid:25aceee5-fb22-4f20-addc-2302f48bbf3f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:69b5e9ff-0d19-4ab2-bf89-349390818478"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. Ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of corticosteroids use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns; or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus, Escherichia coli, Haemophilus influenzae, Klebsiella/Enterobacter species, Neisseria species, and Pseudomonas aeruginosa. This product does not provide adequate coverage against: Serratia marcescens and streptococci, including Streptococcus pneumoniae. uuid:70b8c1cf-52f2-43b3-8ff8-d319d88d12f5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5296 biolink:treats MONDO:0037748 PMID:41385096 "[{""id"":""uuid:d1a8e9fd-a618-43fd-b5fe-7827771b599c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a7c0d013-af0b-44cb-b5df-5bf70228b205"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gemfibrozil Tablets, USP are indicated as adjunctive therapy to diet for: 1. Treatment of adult patients with very high elevations of serum triglyceride levels (Types IV and V hyperlipidemia) who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Patients who present such risk typically have serum triglycerides over 2000 mg/dL and have elevations of VLDL-cholesterol as well as fasting chylomicrons (Type V hyperlipidemia). Subjects who consistently have total serum or plasma triglycerides below 1000 mg/dL are unlikely to present a risk of pancreatitis. Gemfibrozil tablets, USP therapy may be considered for those subjects with triglyceride elevations between 1000 and 2000 mg/dL who have a history of pancreatitis or of recurrent abdominal pain typical of pancreatitis. It is recognized that some Type IV patients with triglycerides under 1000 mg/dL may, through dietary or alcoholic indiscretion, convert to a Type V pattern with massive triglyceride elevations accompanying fasting chylomicronemia, but the influence of gemfibrozil tablets, USP therapy on the risk of pancreatitis in such situations has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of very low density lipoprotein (VLDL). Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV, and V hyperlipoproteinemia. 2. Reducing the risk of developing coronary heart disease only in Type IIb patients without history of or symptoms of existing coronary heart disease who have had an inadequate response to weight loss, dietary therapy, exercise, and other pharmacologic agents (such as bile acid sequestrants and nicotinic acid, known to reduce LDL- and raise HDL-cholesterol) and who have the following triad of lipid abnormalities: low HDL-cholesterol levels in addition to elevated LDL-cholesterol and elevated triglycerides (see WARNINGS , PRECAUTIONS , and CLINICAL PHARMACOLOGY ). The National Cholesterol Education Program has defined a serum HDL-cholesterol value that is consistently below 35 mg/dL as constituting an independent risk factor for coronary heart disease. Patients with significantly elevated triglycerides should be closely observed when treated with gemfibrozil. In some patients with high triglyceride levels, treatment with gemfibrozil is associated with a significant increase in LDL-cholesterol. BECAUSE OF POTENTIAL TOXICITY SUCH AS MALIGNANCY, GALLBLADDER DISEASE, ABDOMINAL PAIN LEADING TO APPENDECTOMY AND OTHER ABDOMINAL SURGERIES, AN INCREASED INCIDENCE IN NON-CORONARY MORTALITY, AND THE 44% RELATIVE INCREASE DURING THE TRIAL PERIOD IN AGE-ADJUSTED ALL-CAUSE MORTALITY SEEN WITH THE CHEMICALLY AND PHARMACOLOGICALLY RELATED DRUG, CLOFIBRATE, THE POTENTIAL BENEFIT OF GEMFIBROZIL IN TREATING TYPE IIA PATIENTS WITH ELEVATIONS OF LDL-CHOLESTEROL ONLY IS NOT LIKELY TO OUTWEIGH THE RISKS. GEMFIBROZIL TABLETS, USP ARE ALSO NOT INDICATED FOR THE TREATMENT OF PATIENTS WITH LOW HDL-CHOLESTEROL AS THEIR ONLY LIPID ABNORMALITY. In a subgroup analysis of patients in the Helsinki Heart Study with above-median HDL-cholesterol values at baseline (greater than 46.4 mg/dL), the incidence of serious coronary events was similar for gemfibrozil and placebo subgroups (see Table I). The initial treatment for dyslipidemia is dietary therapy specific for the type of lipoprotein abnormality. Excess body weight and excess alcohol intake may be important factors in hypertriglyceridemia and should be managed prior to any drug therapy. Physical exercise can be an important ancillary measure, and has been associated with rises in HDL-cholesterol. Diseases contributory to hyperlipidemia such as hypothyroidism or diabetes mellitus should be looked for and adequately treated. Estrogen therapy is sometimes associated with massive rises in plasma triglycerides, especially in subjects with familial hypertriglyceridemia. In such cases, discontinuation of estrogen therapy may obviate the need for specific drug therapy of hypertriglyceridemia. The use of drugs should be considered only when reasonable attempts have been made to obtain satisfactory results with nondrug methods. If the decision is made to use drugs, the patient should be instructed that this does not reduce the importance of adhering to diet. uuid:5882ac47-b518-4d8b-ba49-996577a800f5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:129316490 biolink:treats MONDO:0000879 PMID:41385096 "[{""id"":""uuid:36dcf101-80d7-4abb-bb88-c313e193cd4f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4847601e-4081-4afd-8f16-9f91cf4dedda"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Nystatin and Triamcinolone Acetonide Cream and Ointment are indicated for the treatment of cutaneous candidiasis; it has been demonstrated that the nystatin-steroid combination provides greater benefit than the nystatin component alone during the first few days of treatment. uuid:50dec7be-652d-4034-855f-133bee5b6c09 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1154771 biolink:treats MONDO:0005271 PMID:41385096 "[{""id"":""uuid:f1e44012-d1ad-4b5e-9684-dd687204e832"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7aed5132-2519-4ab4-a073-ea1cfb6a733a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydrocodone polistirex and chlorpheniramine polistirex ER oral suspension is indicated for relief of cough and upper respiratory symptoms associated with allergy or a cold in adults and children 6 years of age and older. uuid:c25d0f99-ff90-4cfe-9b79-2e44bcfa3d7f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1154771 biolink:treats MONDO:0005709 PMID:41385096 "[{""id"":""uuid:28ad1a75-5021-4cff-9181-c1aa7bd9c1bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:105f72d1-1aa2-4ed3-b108-2e4b7cbd11c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydrocodone polistirex and chlorpheniramine polistirex ER oral suspension is indicated for relief of cough and upper respiratory symptoms associated with allergy or a cold in adults and children 6 years of age and older. uuid:5761fa09-0618-4910-ba75-4f95001cdb6d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:56841573 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:a73c4c31-7449-44fe-9c26-341a7fcc13f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ffd44643-53ce-4a6f-be00-e97e548b0693"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tekturna HCT is indicated for the treatment of hypertension. Add-On Therapy A patient whose blood pressure is not adequately controlled with aliskiren alone or hydrochlorothiazide alone may be switched to combination therapy with Tekturna HCT. A patient whose blood pressure is controlled with hydrochlorothiazide alone but who experiences hypokalemia may be switched to combination therapy with Tekturna HCT. A patient who experiences dose-limiting adverse reactions on either component alone may be switched to Tekturna HCT containing a lower dose of that component in combination with the other to achieve similar blood pressure reductions. Replacement Therapy Tekturna HCT may be substituted for the titrated components. Initial Therapy Tekturna HCT may be used as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals. The choice of Tekturna HCT as initial therapy should be based on an assessment of potential benefits and risks. Patients with Stage 2 hypertension are at a relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. The decision to use a combination as initial therapy should be individualized and should be shaped by considerations such as baseline blood pressure, the target goal, and the incremental likelihood of achieving goal with a combination compared to monotherapy. Individual blood pressure goals may vary based upon the patient’s risk. Data from the high-dose multifactorial study [ see Clinical Studies (14) ] provides estimates of the probability of reaching a target blood pressure with Tekturna HCT compared to aliskiren or hydrochlorothiazide monotherapy. The figures below provide estimates of the likelihood of achieving systolic or diastolic blood pressure control with Tekturna HCT 300/25 mg, based upon baseline systolic or diastolic blood pressure. The curve of each treatment group was estimated by logistic regression modeling. The estimated likelihood at the right tail of each curve is less reliable because of small numbers of subjects with high baseline blood pressures. Figure 1: Probability of Achieving Systolic Blood Pressure (SBP) <140 mmHg Figure 2: Probability of Achieving Systolic Blood Pressure (SBP) <130 mmHg Figure 3: Probability of Achieving Diastolic Blood Pressure (DBP) <90 mmHg Figure 4: Probability of Achieving Diastolic Blood Pressure (DBP) <80 mmHg At all levels of baseline blood pressure, the probability of achieving any given diastolic or systolic goal is greater with the combination than for either monotherapy. For example, the mean baseline msSBP/msDBP for patients participating in this multifactorial study was 154/99 mmHg. A patient with a baseline blood pressure of 154/99 mmHg has about a 62% chance of achieving a goal of <140 mmHg (systolic) and 61% chance of achieving <90 mmHg (diastolic) on aliskiren alone, and the chance of achieving these goals on hydrochlorothiazide alone is about 54% (systolic) and 49% (diastolic). The chance of achieving these goals on Tekturna HCT rises to about 77% (systolic) and 74% (diastolic). The chance of achieving these goals on placebo is about 34% (systolic) and 37% (diastolic). [See Dosage and Administration (2) and Clinical Studies (14) . ] uuid:946ed8bb-9bb9-4e49-827d-baaac329b486 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:56841573 biolink:treats MONDO:0003019 PMID:41385096 "[{""id"":""uuid:c9afca8b-2ec4-4e64-bc9a-d556861d9301"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9bb8f769-80a5-4017-8ea4-a1c250b11cf0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tekturna HCT is indicated for the treatment of hypertension. Add-On Therapy A patient whose blood pressure is not adequately controlled with aliskiren alone or hydrochlorothiazide alone may be switched to combination therapy with Tekturna HCT. A patient whose blood pressure is controlled with hydrochlorothiazide alone but who experiences hypokalemia may be switched to combination therapy with Tekturna HCT. A patient who experiences dose-limiting adverse reactions on either component alone may be switched to Tekturna HCT containing a lower dose of that component in combination with the other to achieve similar blood pressure reductions. Replacement Therapy Tekturna HCT may be substituted for the titrated components. Initial Therapy Tekturna HCT may be used as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals. The choice of Tekturna HCT as initial therapy should be based on an assessment of potential benefits and risks. Patients with Stage 2 hypertension are at a relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. The decision to use a combination as initial therapy should be individualized and should be shaped by considerations such as baseline blood pressure, the target goal, and the incremental likelihood of achieving goal with a combination compared to monotherapy. Individual blood pressure goals may vary based upon the patient’s risk. Data from the high-dose multifactorial study [ see Clinical Studies (14) ] provides estimates of the probability of reaching a target blood pressure with Tekturna HCT compared to aliskiren or hydrochlorothiazide monotherapy. The figures below provide estimates of the likelihood of achieving systolic or diastolic blood pressure control with Tekturna HCT 300/25 mg, based upon baseline systolic or diastolic blood pressure. The curve of each treatment group was estimated by logistic regression modeling. The estimated likelihood at the right tail of each curve is less reliable because of small numbers of subjects with high baseline blood pressures. Figure 1: Probability of Achieving Systolic Blood Pressure (SBP) <140 mmHg Figure 2: Probability of Achieving Systolic Blood Pressure (SBP) <130 mmHg Figure 3: Probability of Achieving Diastolic Blood Pressure (DBP) <90 mmHg Figure 4: Probability of Achieving Diastolic Blood Pressure (DBP) <80 mmHg At all levels of baseline blood pressure, the probability of achieving any given diastolic or systolic goal is greater with the combination than for either monotherapy. For example, the mean baseline msSBP/msDBP for patients participating in this multifactorial study was 154/99 mmHg. A patient with a baseline blood pressure of 154/99 mmHg has about a 62% chance of achieving a goal of <140 mmHg (systolic) and 61% chance of achieving <90 mmHg (diastolic) on aliskiren alone, and the chance of achieving these goals on hydrochlorothiazide alone is about 54% (systolic) and 49% (diastolic). The chance of achieving these goals on Tekturna HCT rises to about 77% (systolic) and 74% (diastolic). The chance of achieving these goals on placebo is about 34% (systolic) and 37% (diastolic). [See Dosage and Administration (2) and Clinical Studies (14) . ] uuid:603033fe-5085-4f0c-83fa-2feab864426b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:56841573 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:3e601218-506c-4f50-be35-5152cf0b197d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c1c2b238-3d71-4935-b63a-a90a326f31e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tekturna HCT is indicated for the treatment of hypertension. Add-On Therapy A patient whose blood pressure is not adequately controlled with aliskiren alone or hydrochlorothiazide alone may be switched to combination therapy with Tekturna HCT. A patient whose blood pressure is controlled with hydrochlorothiazide alone but who experiences hypokalemia may be switched to combination therapy with Tekturna HCT. A patient who experiences dose-limiting adverse reactions on either component alone may be switched to Tekturna HCT containing a lower dose of that component in combination with the other to achieve similar blood pressure reductions. Replacement Therapy Tekturna HCT may be substituted for the titrated components. Initial Therapy Tekturna HCT may be used as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals. The choice of Tekturna HCT as initial therapy should be based on an assessment of potential benefits and risks. Patients with Stage 2 hypertension are at a relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. The decision to use a combination as initial therapy should be individualized and should be shaped by considerations such as baseline blood pressure, the target goal, and the incremental likelihood of achieving goal with a combination compared to monotherapy. Individual blood pressure goals may vary based upon the patient’s risk. Data from the high-dose multifactorial study [ see Clinical Studies (14) ] provides estimates of the probability of reaching a target blood pressure with Tekturna HCT compared to aliskiren or hydrochlorothiazide monotherapy. The figures below provide estimates of the likelihood of achieving systolic or diastolic blood pressure control with Tekturna HCT 300/25 mg, based upon baseline systolic or diastolic blood pressure. The curve of each treatment group was estimated by logistic regression modeling. The estimated likelihood at the right tail of each curve is less reliable because of small numbers of subjects with high baseline blood pressures. Figure 1: Probability of Achieving Systolic Blood Pressure (SBP) <140 mmHg Figure 2: Probability of Achieving Systolic Blood Pressure (SBP) <130 mmHg Figure 3: Probability of Achieving Diastolic Blood Pressure (DBP) <90 mmHg Figure 4: Probability of Achieving Diastolic Blood Pressure (DBP) <80 mmHg At all levels of baseline blood pressure, the probability of achieving any given diastolic or systolic goal is greater with the combination than for either monotherapy. For example, the mean baseline msSBP/msDBP for patients participating in this multifactorial study was 154/99 mmHg. A patient with a baseline blood pressure of 154/99 mmHg has about a 62% chance of achieving a goal of <140 mmHg (systolic) and 61% chance of achieving <90 mmHg (diastolic) on aliskiren alone, and the chance of achieving these goals on hydrochlorothiazide alone is about 54% (systolic) and 49% (diastolic). The chance of achieving these goals on Tekturna HCT rises to about 77% (systolic) and 74% (diastolic). The chance of achieving these goals on placebo is about 34% (systolic) and 37% (diastolic). [See Dosage and Administration (2) and Clinical Studies (14) . ] uuid:c7f6b284-81a7-46e4-a83f-9ac6c1eab735 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:56841573 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:b97bb6a4-8fd1-4ca3-8105-8623ba69e020"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3f1e15f7-9149-4020-9882-d9fbb914c134"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tekturna HCT is indicated for the treatment of hypertension. Add-On Therapy A patient whose blood pressure is not adequately controlled with aliskiren alone or hydrochlorothiazide alone may be switched to combination therapy with Tekturna HCT. A patient whose blood pressure is controlled with hydrochlorothiazide alone but who experiences hypokalemia may be switched to combination therapy with Tekturna HCT. A patient who experiences dose-limiting adverse reactions on either component alone may be switched to Tekturna HCT containing a lower dose of that component in combination with the other to achieve similar blood pressure reductions. Replacement Therapy Tekturna HCT may be substituted for the titrated components. Initial Therapy Tekturna HCT may be used as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals. The choice of Tekturna HCT as initial therapy should be based on an assessment of potential benefits and risks. Patients with Stage 2 hypertension are at a relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. The decision to use a combination as initial therapy should be individualized and should be shaped by considerations such as baseline blood pressure, the target goal, and the incremental likelihood of achieving goal with a combination compared to monotherapy. Individual blood pressure goals may vary based upon the patient’s risk. Data from the high-dose multifactorial study [ see Clinical Studies (14) ] provides estimates of the probability of reaching a target blood pressure with Tekturna HCT compared to aliskiren or hydrochlorothiazide monotherapy. The figures below provide estimates of the likelihood of achieving systolic or diastolic blood pressure control with Tekturna HCT 300/25 mg, based upon baseline systolic or diastolic blood pressure. The curve of each treatment group was estimated by logistic regression modeling. The estimated likelihood at the right tail of each curve is less reliable because of small numbers of subjects with high baseline blood pressures. Figure 1: Probability of Achieving Systolic Blood Pressure (SBP) <140 mmHg Figure 2: Probability of Achieving Systolic Blood Pressure (SBP) <130 mmHg Figure 3: Probability of Achieving Diastolic Blood Pressure (DBP) <90 mmHg Figure 4: Probability of Achieving Diastolic Blood Pressure (DBP) <80 mmHg At all levels of baseline blood pressure, the probability of achieving any given diastolic or systolic goal is greater with the combination than for either monotherapy. For example, the mean baseline msSBP/msDBP for patients participating in this multifactorial study was 154/99 mmHg. A patient with a baseline blood pressure of 154/99 mmHg has about a 62% chance of achieving a goal of <140 mmHg (systolic) and 61% chance of achieving <90 mmHg (diastolic) on aliskiren alone, and the chance of achieving these goals on hydrochlorothiazide alone is about 54% (systolic) and 49% (diastolic). The chance of achieving these goals on Tekturna HCT rises to about 77% (systolic) and 74% (diastolic). The chance of achieving these goals on placebo is about 34% (systolic) and 37% (diastolic). [See Dosage and Administration (2) and Clinical Studies (14) . ] uuid:c3608f6f-88d2-486f-a5c6-67b07d7025bb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:56841573 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:f6d567c8-e524-4b87-98ec-51e348ed0817"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bf1ba930-72f3-4aaf-9ebc-1b3f6047c724"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tekturna HCT is indicated for the treatment of hypertension. Add-On Therapy A patient whose blood pressure is not adequately controlled with aliskiren alone or hydrochlorothiazide alone may be switched to combination therapy with Tekturna HCT. A patient whose blood pressure is controlled with hydrochlorothiazide alone but who experiences hypokalemia may be switched to combination therapy with Tekturna HCT. A patient who experiences dose-limiting adverse reactions on either component alone may be switched to Tekturna HCT containing a lower dose of that component in combination with the other to achieve similar blood pressure reductions. Replacement Therapy Tekturna HCT may be substituted for the titrated components. Initial Therapy Tekturna HCT may be used as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals. The choice of Tekturna HCT as initial therapy should be based on an assessment of potential benefits and risks. Patients with Stage 2 hypertension are at a relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. The decision to use a combination as initial therapy should be individualized and should be shaped by considerations such as baseline blood pressure, the target goal, and the incremental likelihood of achieving goal with a combination compared to monotherapy. Individual blood pressure goals may vary based upon the patient’s risk. Data from the high-dose multifactorial study [ see Clinical Studies (14) ] provides estimates of the probability of reaching a target blood pressure with Tekturna HCT compared to aliskiren or hydrochlorothiazide monotherapy. The figures below provide estimates of the likelihood of achieving systolic or diastolic blood pressure control with Tekturna HCT 300/25 mg, based upon baseline systolic or diastolic blood pressure. The curve of each treatment group was estimated by logistic regression modeling. The estimated likelihood at the right tail of each curve is less reliable because of small numbers of subjects with high baseline blood pressures. Figure 1: Probability of Achieving Systolic Blood Pressure (SBP) <140 mmHg Figure 2: Probability of Achieving Systolic Blood Pressure (SBP) <130 mmHg Figure 3: Probability of Achieving Diastolic Blood Pressure (DBP) <90 mmHg Figure 4: Probability of Achieving Diastolic Blood Pressure (DBP) <80 mmHg At all levels of baseline blood pressure, the probability of achieving any given diastolic or systolic goal is greater with the combination than for either monotherapy. For example, the mean baseline msSBP/msDBP for patients participating in this multifactorial study was 154/99 mmHg. A patient with a baseline blood pressure of 154/99 mmHg has about a 62% chance of achieving a goal of <140 mmHg (systolic) and 61% chance of achieving <90 mmHg (diastolic) on aliskiren alone, and the chance of achieving these goals on hydrochlorothiazide alone is about 54% (systolic) and 49% (diastolic). The chance of achieving these goals on Tekturna HCT rises to about 77% (systolic) and 74% (diastolic). The chance of achieving these goals on placebo is about 34% (systolic) and 37% (diastolic). [See Dosage and Administration (2) and Clinical Studies (14) . ] uuid:ab206cbb-ef96-4340-aafe-be7cd34ecdf6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:56841573 biolink:treats MONDO:0001106 PMID:41385096 "[{""id"":""uuid:c7aba235-d562-4074-b128-c8a62e469fce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:406f9694-1121-4789-9035-c1e3c20aede8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tekturna HCT is indicated for the treatment of hypertension. Add-On Therapy A patient whose blood pressure is not adequately controlled with aliskiren alone or hydrochlorothiazide alone may be switched to combination therapy with Tekturna HCT. A patient whose blood pressure is controlled with hydrochlorothiazide alone but who experiences hypokalemia may be switched to combination therapy with Tekturna HCT. A patient who experiences dose-limiting adverse reactions on either component alone may be switched to Tekturna HCT containing a lower dose of that component in combination with the other to achieve similar blood pressure reductions. Replacement Therapy Tekturna HCT may be substituted for the titrated components. Initial Therapy Tekturna HCT may be used as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals. The choice of Tekturna HCT as initial therapy should be based on an assessment of potential benefits and risks. Patients with Stage 2 hypertension are at a relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. The decision to use a combination as initial therapy should be individualized and should be shaped by considerations such as baseline blood pressure, the target goal, and the incremental likelihood of achieving goal with a combination compared to monotherapy. Individual blood pressure goals may vary based upon the patient’s risk. Data from the high-dose multifactorial study [ see Clinical Studies (14) ] provides estimates of the probability of reaching a target blood pressure with Tekturna HCT compared to aliskiren or hydrochlorothiazide monotherapy. The figures below provide estimates of the likelihood of achieving systolic or diastolic blood pressure control with Tekturna HCT 300/25 mg, based upon baseline systolic or diastolic blood pressure. The curve of each treatment group was estimated by logistic regression modeling. The estimated likelihood at the right tail of each curve is less reliable because of small numbers of subjects with high baseline blood pressures. Figure 1: Probability of Achieving Systolic Blood Pressure (SBP) <140 mmHg Figure 2: Probability of Achieving Systolic Blood Pressure (SBP) <130 mmHg Figure 3: Probability of Achieving Diastolic Blood Pressure (DBP) <90 mmHg Figure 4: Probability of Achieving Diastolic Blood Pressure (DBP) <80 mmHg At all levels of baseline blood pressure, the probability of achieving any given diastolic or systolic goal is greater with the combination than for either monotherapy. For example, the mean baseline msSBP/msDBP for patients participating in this multifactorial study was 154/99 mmHg. A patient with a baseline blood pressure of 154/99 mmHg has about a 62% chance of achieving a goal of <140 mmHg (systolic) and 61% chance of achieving <90 mmHg (diastolic) on aliskiren alone, and the chance of achieving these goals on hydrochlorothiazide alone is about 54% (systolic) and 49% (diastolic). The chance of achieving these goals on Tekturna HCT rises to about 77% (systolic) and 74% (diastolic). The chance of achieving these goals on placebo is about 34% (systolic) and 37% (diastolic). [See Dosage and Administration (2) and Clinical Studies (14) . ] uuid:dfb3b3e7-4e1d-4633-aefa-a10946331403 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10125 biolink:treats HP:0031354 PMID:41385096 "[{""id"":""uuid:77bdec2f-0e40-4c16-8fa5-2a22eb8687a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:47e33361-7c40-4575-b63a-cde8771d5412"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Zolpidem tartrate extended-release tablets are indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance (as measured by wake time after sleep onset). The clinical trials performed in support of efficacy were up to 3 weeks (using polysomnography measurement up to 2 weeks in both adult and elderly patients) and 24 weeks (using patient-reported assessment in adult patients only) in duration [see Clinical Studies (14) ]. uuid:ee0e574d-e7f1-4f1d-a5e7-7b36d6a7907c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10125 biolink:treats HP:0031355 PMID:41385096 "[{""id"":""uuid:941efe02-39fb-4496-b7a5-8c729e4a63c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4f5e7a38-fc2a-45ac-8e5f-1797d6716271"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Zolpidem tartrate extended-release tablets are indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance (as measured by wake time after sleep onset). The clinical trials performed in support of efficacy were up to 3 weeks (using polysomnography measurement up to 2 weeks in both adult and elderly patients) and 24 weeks (using patient-reported assessment in adult patients only) in duration [see Clinical Studies (14) ]. uuid:172fc5d3-b4d0-4897-92e1-f2ebd5b40254 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2376 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:3956712f-9e57-429e-93ec-c21696e04ef8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3ee32988-7eaa-49b8-99e8-b8ee27ab7dc6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Acarbose Tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. uuid:21aa61a2-44f2-4f5b-97b6-9af5303b2147 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:151539 biolink:treats MONDO:0011751 PMID:41385096 "[{""id"":""uuid:84ff5088-bc7e-46d9-b373-74acd334c6c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:76ec31aa-8066-4960-8cc3-361dc6a23407"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ipratropium Bromide and Albuterol Sulfate is indicated for the treatment of bronchospasm associated with COPD in patients requiring more than one bronchodilator. uuid:98dbe9bf-9df1-480d-8c9a-b084c6653fb5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:151539 biolink:treats MONDO:0001358 PMID:41385096 "[{""id"":""uuid:11102de7-6fe6-4589-9fcb-126159f01737"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7ddc8f7d-7cbf-43cf-b3e2-ca511602a72a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ipratropium Bromide and Albuterol Sulfate is indicated for the treatment of bronchospasm associated with COPD in patients requiring more than one bronchodilator. uuid:d99460c7-4cef-407e-a774-b52d89bef7fc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16335 biolink:treats HP:0004763 PMID:41385096 "[{""id"":""uuid:5e0b2c91-0673-4a41-b2ad-a2f78b1d578d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d8cbee64-3d83-4e24-9ae4-8559bc2d67d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Adenosine injection is indicated for the following. Conversion to sinus rhythm of paroxysmal supraventricular tachycardia (PSVT), including that associated with accessory bypass tracts (Wolff-Parkinson-White Syndrome). When clinically advisable, appropriate vagal maneuvers (e.g., Valsalva maneuver), should be attempted prior to adenosine administration. It is important to be sure the adenosine solution actually reaches the systemic circulation (see DOSAGE AND ADMINISTRATION ). Adenosine does not convert atrial flutter, atrial fibrillation, or ventricular tachycardia to normal sinus rhythm. In the presence of atrial flutter or atrial fibrillation, a transient modest slowing of ventricular response may occur immediately following adenosine administration. uuid:387da761-4ee9-41c6-bae4-004df2e285de biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16335 biolink:treats MONDO:0008685 PMID:41385096 "[{""id"":""uuid:c715a0c1-81ff-4bc2-9381-5dc6538f70d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:40561e71-f42f-421c-8d89-243bb7bbfd7b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Adenosine injection is indicated for the following. Conversion to sinus rhythm of paroxysmal supraventricular tachycardia (PSVT), including that associated with accessory bypass tracts (Wolff-Parkinson-White Syndrome). When clinically advisable, appropriate vagal maneuvers (e.g., Valsalva maneuver), should be attempted prior to adenosine administration. It is important to be sure the adenosine solution actually reaches the systemic circulation (see DOSAGE AND ADMINISTRATION ). Adenosine does not convert atrial flutter, atrial fibrillation, or ventricular tachycardia to normal sinus rhythm. In the presence of atrial flutter or atrial fibrillation, a transient modest slowing of ventricular response may occur immediately following adenosine administration. uuid:c81fbb36-2a95-44e4-8348-eba78d6b5f50 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16335 biolink:treats MONDO:0005310 PMID:41385096 "[{""id"":""uuid:a5ed3d20-4cf7-4e00-acd0-d07ed5118e58"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fb9e4aac-7540-4304-8e28-c5f71ba6a3fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Adenosine injection is indicated for the following. Conversion to sinus rhythm of paroxysmal supraventricular tachycardia (PSVT), including that associated with accessory bypass tracts (Wolff-Parkinson-White Syndrome). When clinically advisable, appropriate vagal maneuvers (e.g., Valsalva maneuver), should be attempted prior to adenosine administration. It is important to be sure the adenosine solution actually reaches the systemic circulation (see DOSAGE AND ADMINISTRATION ). Adenosine does not convert atrial flutter, atrial fibrillation, or ventricular tachycardia to normal sinus rhythm. In the presence of atrial flutter or atrial fibrillation, a transient modest slowing of ventricular response may occur immediately following adenosine administration. uuid:755e985c-48d3-4022-ab71-0099b200f6d3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16335 biolink:treats MONDO:0004981 PMID:41385096 "[{""id"":""uuid:045d8848-cca2-4d87-a271-2d9f633415f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:491f5b40-8639-4dc3-9463-1090d43f3e14"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Adenosine injection is indicated for the following. Conversion to sinus rhythm of paroxysmal supraventricular tachycardia (PSVT), including that associated with accessory bypass tracts (Wolff-Parkinson-White Syndrome). When clinically advisable, appropriate vagal maneuvers (e.g., Valsalva maneuver), should be attempted prior to adenosine administration. It is important to be sure the adenosine solution actually reaches the systemic circulation (see DOSAGE AND ADMINISTRATION ). Adenosine does not convert atrial flutter, atrial fibrillation, or ventricular tachycardia to normal sinus rhythm. In the presence of atrial flutter or atrial fibrillation, a transient modest slowing of ventricular response may occur immediately following adenosine administration. uuid:706e33eb-14df-463c-9983-dc349c02b7d1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16335 biolink:treats MONDO:0005477 PMID:41385096 "[{""id"":""uuid:f33206bd-05ca-410e-b527-2f88c7f938aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b25f4be4-0466-48da-bb36-d3b87c02f20b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Adenosine injection is indicated for the following. Conversion to sinus rhythm of paroxysmal supraventricular tachycardia (PSVT), including that associated with accessory bypass tracts (Wolff-Parkinson-White Syndrome). When clinically advisable, appropriate vagal maneuvers (e.g., Valsalva maneuver), should be attempted prior to adenosine administration. It is important to be sure the adenosine solution actually reaches the systemic circulation (see DOSAGE AND ADMINISTRATION ). Adenosine does not convert atrial flutter, atrial fibrillation, or ventricular tachycardia to normal sinus rhythm. In the presence of atrial flutter or atrial fibrillation, a transient modest slowing of ventricular response may occur immediately following adenosine administration. uuid:df2399ea-0dc3-4064-a9ae-e157e7896869 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2663 biolink:treats UMLS:C1739149 PMID:41385096 "[{""id"":""uuid:e75dd8ec-0aa0-4b91-a739-2b695886ac2f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:350c66aa-775c-492f-bb53-10fad07c0560"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Because of its life-threatening side effects and the substantial management difficulties associated with its use (see WARNINGS below), amiodarone is indicated only for the treatment of the following documented, life-threatening recurrent ventricular arrhythmias when these have not responded to documented adequate doses of other available antiarrhythmics or when alternative agents could not be tolerated. Recurrent ventricular fibrillation. Recurrent hemodynamically unstable ventricular tachycardia. As is the case for other antiarrhythmic agents, there is no evidence from controlled trials that the use of amiodarone hydrochloride tablets favorably affects survival. Amiodarone should be used only by physicians familiar with and with access to (directly or through referral) the use of all available modalities for treating recurrent life-threatening ventricular arrhythmias, and who have access to appropriate monitoring facilities, including in-hospital and ambulatory continuous electrocardiographic monitoring and electrophysiologic techniques. Because of the life-threatening nature of the arrhythmias treated, potential interactions with prior therapy, and potential exacerbation of the arrhythmia, initiation of therapy with amiodarone should be carried out in the hospital. uuid:f0ef457f-0153-40fb-a02e-2d4c168fe61a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2663 biolink:treats MONDO:0005477 PMID:41385096 "[{""id"":""uuid:6caf80d5-cad5-4df8-8d4e-6b0722aff5ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b2bcdbcd-123e-4c57-9a38-4050cf133f56"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:896e6297-bb18-49e8-b99e-79b7a89931ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Because of its life-threatening side effects and the substantial management difficulties associated with its use (see WARNINGS below), amiodarone is indicated only for the treatment of the following documented, life-threatening recurrent ventricular arrhythmias when these have not responded to documented adequate doses of other available antiarrhythmics or when alternative agents could not be tolerated. Recurrent ventricular fibrillation. Recurrent hemodynamically unstable ventricular tachycardia. As is the case for other antiarrhythmic agents, there is no evidence from controlled trials that the use of amiodarone hydrochloride tablets favorably affects survival. Amiodarone should be used only by physicians familiar with and with access to (directly or through referral) the use of all available modalities for treating recurrent life-threatening ventricular arrhythmias, and who have access to appropriate monitoring facilities, including in-hospital and ambulatory continuous electrocardiographic monitoring and electrophysiologic techniques. Because of the life-threatening nature of the arrhythmias treated, potential interactions with prior therapy, and potential exacerbation of the arrhythmia, initiation of therapy with amiodarone should be carried out in the hospital.|[PMDA] Drug with a new route of administration, used for emergency treatment of refractory arrhythmias (ventricular fibrillation and hemodynamically unstable ventricular tachycardia). [Orphan Drug] uuid:0c445c79-c9b5-4bd9-be52-7548235cb11f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2618 biolink:treats UMLS:C0858004 PMID:41385096 "[{""id"":""uuid:bea08c5d-4f54-4a79-830d-daeb4e4ccb01"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:087a76a0-79dd-464d-8976-9cc69a2b0a97"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amantadine hydrochloride syrup (amantadine hydrochloride oral solution, USP) is indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus. Amantadine hydrochloride is also indicated in the treatment of parkinsonism and drug-induced extrapyramidal reactions. Influenza A Prophylaxis Amantadine hydrochloride is indicated for chemoprophylaxis against signs and symptoms of influenza A virus infection when early vaccination is not feasible or when the vaccine is contraindicated or not available. In the prophylaxis of influenza, early vaccination on an annual basis as recommended by the Centers for Disease Control's Immunization Practices Advisory Committee is the method of choice. Because amantadine does not completely prevent the host immune response to influenza A infection, individuals who take this drug may still develop immune responses to natural disease or vaccination and may be protected when later exposed to antigenically related viruses. Following vaccination during an influenza A outbreak, amantadine prophylaxis should be considered for the 2-to 4-week time period required to develop an antibody response. Influenza A Treatment Amantadine hydrochloride is also indicated in the treatment of uncomplicated respiratory tract illness caused by influenza A virus strains especially when administered early in the course of illness. There are no well-controlled clinical studies demonstrating that treatment with amantadine will avoid the development of influenza A virus pneumonitis or other complications in high risk patients. There is no clinical evidence indicating that amantadine is effective in the prophylaxis or treatment of viral respiratory tract illnesses other than those caused by influenza A virus strains. Parkinson's Disease/Syndrome Amantadine is indicated in the treatment of idiopathic Parkinson's disease (Paralysis Agitans), postencephalitic parkinsonism, and symptomatic parkinsonism which may follow injury to the nervous system by carbon monoxide intoxication. It is indicated in those elderly patients believed to develop parkinsonism in association with cerebral arteriosclerosis. In the treatment of Parkinson's disease, amantadine is less effective than levodopa, (-)-3-(3,4-dihydroxyphenyl)-L-alanine, and its efficacy in comparison with the anticholinergic antiparkinson drugs has not yet been established. Drug-Induced Extrapyramidal Reactions Amantadine hydrochloride is indicated in the treatment of drug-induced extrapyramidal reactions. Although anticholinergic-type side effects have been noted with amantadine when used in patients with drug-induced extrapyramidal reactions, there is a lower incidence of these side effects than that observed with the anticholinergic antiparkinson drugs. uuid:54d15ab7-ff63-495e-900f-0028a999db8b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2618 biolink:treats MONDO:0021095 PMID:41385096 "[{""id"":""uuid:2ba2c535-b864-4c63-87ed-6d0b0a602c9a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4ec6ed1f-4834-4640-8000-286d39c2564a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amantadine hydrochloride syrup (amantadine hydrochloride oral solution, USP) is indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus. Amantadine hydrochloride is also indicated in the treatment of parkinsonism and drug-induced extrapyramidal reactions. Influenza A Prophylaxis Amantadine hydrochloride is indicated for chemoprophylaxis against signs and symptoms of influenza A virus infection when early vaccination is not feasible or when the vaccine is contraindicated or not available. In the prophylaxis of influenza, early vaccination on an annual basis as recommended by the Centers for Disease Control's Immunization Practices Advisory Committee is the method of choice. Because amantadine does not completely prevent the host immune response to influenza A infection, individuals who take this drug may still develop immune responses to natural disease or vaccination and may be protected when later exposed to antigenically related viruses. Following vaccination during an influenza A outbreak, amantadine prophylaxis should be considered for the 2-to 4-week time period required to develop an antibody response. Influenza A Treatment Amantadine hydrochloride is also indicated in the treatment of uncomplicated respiratory tract illness caused by influenza A virus strains especially when administered early in the course of illness. There are no well-controlled clinical studies demonstrating that treatment with amantadine will avoid the development of influenza A virus pneumonitis or other complications in high risk patients. There is no clinical evidence indicating that amantadine is effective in the prophylaxis or treatment of viral respiratory tract illnesses other than those caused by influenza A virus strains. Parkinson's Disease/Syndrome Amantadine is indicated in the treatment of idiopathic Parkinson's disease (Paralysis Agitans), postencephalitic parkinsonism, and symptomatic parkinsonism which may follow injury to the nervous system by carbon monoxide intoxication. It is indicated in those elderly patients believed to develop parkinsonism in association with cerebral arteriosclerosis. In the treatment of Parkinson's disease, amantadine is less effective than levodopa, (-)-3-(3,4-dihydroxyphenyl)-L-alanine, and its efficacy in comparison with the anticholinergic antiparkinson drugs has not yet been established. Drug-Induced Extrapyramidal Reactions Amantadine hydrochloride is indicated in the treatment of drug-induced extrapyramidal reactions. Although anticholinergic-type side effects have been noted with amantadine when used in patients with drug-induced extrapyramidal reactions, there is a lower incidence of these side effects than that observed with the anticholinergic antiparkinson drugs. uuid:53f9d590-9e32-444a-8d83-8c18f711a0a6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2618 biolink:treats MONDO:0001815 PMID:41385096 "[{""id"":""uuid:630d6156-b4ad-45cd-8d55-260017c1f83b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:777e9094-3b91-4118-be43-ca240cf1ab90"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amantadine hydrochloride syrup (amantadine hydrochloride oral solution, USP) is indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus. Amantadine hydrochloride is also indicated in the treatment of parkinsonism and drug-induced extrapyramidal reactions. Influenza A Prophylaxis Amantadine hydrochloride is indicated for chemoprophylaxis against signs and symptoms of influenza A virus infection when early vaccination is not feasible or when the vaccine is contraindicated or not available. In the prophylaxis of influenza, early vaccination on an annual basis as recommended by the Centers for Disease Control's Immunization Practices Advisory Committee is the method of choice. Because amantadine does not completely prevent the host immune response to influenza A infection, individuals who take this drug may still develop immune responses to natural disease or vaccination and may be protected when later exposed to antigenically related viruses. Following vaccination during an influenza A outbreak, amantadine prophylaxis should be considered for the 2-to 4-week time period required to develop an antibody response. Influenza A Treatment Amantadine hydrochloride is also indicated in the treatment of uncomplicated respiratory tract illness caused by influenza A virus strains especially when administered early in the course of illness. There are no well-controlled clinical studies demonstrating that treatment with amantadine will avoid the development of influenza A virus pneumonitis or other complications in high risk patients. There is no clinical evidence indicating that amantadine is effective in the prophylaxis or treatment of viral respiratory tract illnesses other than those caused by influenza A virus strains. Parkinson's Disease/Syndrome Amantadine is indicated in the treatment of idiopathic Parkinson's disease (Paralysis Agitans), postencephalitic parkinsonism, and symptomatic parkinsonism which may follow injury to the nervous system by carbon monoxide intoxication. It is indicated in those elderly patients believed to develop parkinsonism in association with cerebral arteriosclerosis. In the treatment of Parkinson's disease, amantadine is less effective than levodopa, (-)-3-(3,4-dihydroxyphenyl)-L-alanine, and its efficacy in comparison with the anticholinergic antiparkinson drugs has not yet been established. Drug-Induced Extrapyramidal Reactions Amantadine hydrochloride is indicated in the treatment of drug-induced extrapyramidal reactions. Although anticholinergic-type side effects have been noted with amantadine when used in patients with drug-induced extrapyramidal reactions, there is a lower incidence of these side effects than that observed with the anticholinergic antiparkinson drugs. uuid:78b74518-be4d-45c0-9b16-d93139d389c7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2618 biolink:treats MONDO:0005180 PMID:41385096 "[{""id"":""uuid:337baa71-06fc-4653-8328-21279bbc1759"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ac260339-648c-4946-b562-4a87dd9f3189"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amantadine hydrochloride syrup (amantadine hydrochloride oral solution, USP) is indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus. Amantadine hydrochloride is also indicated in the treatment of parkinsonism and drug-induced extrapyramidal reactions. Influenza A Prophylaxis Amantadine hydrochloride is indicated for chemoprophylaxis against signs and symptoms of influenza A virus infection when early vaccination is not feasible or when the vaccine is contraindicated or not available. In the prophylaxis of influenza, early vaccination on an annual basis as recommended by the Centers for Disease Control's Immunization Practices Advisory Committee is the method of choice. Because amantadine does not completely prevent the host immune response to influenza A infection, individuals who take this drug may still develop immune responses to natural disease or vaccination and may be protected when later exposed to antigenically related viruses. Following vaccination during an influenza A outbreak, amantadine prophylaxis should be considered for the 2-to 4-week time period required to develop an antibody response. Influenza A Treatment Amantadine hydrochloride is also indicated in the treatment of uncomplicated respiratory tract illness caused by influenza A virus strains especially when administered early in the course of illness. There are no well-controlled clinical studies demonstrating that treatment with amantadine will avoid the development of influenza A virus pneumonitis or other complications in high risk patients. There is no clinical evidence indicating that amantadine is effective in the prophylaxis or treatment of viral respiratory tract illnesses other than those caused by influenza A virus strains. Parkinson's Disease/Syndrome Amantadine is indicated in the treatment of idiopathic Parkinson's disease (Paralysis Agitans), postencephalitic parkinsonism, and symptomatic parkinsonism which may follow injury to the nervous system by carbon monoxide intoxication. It is indicated in those elderly patients believed to develop parkinsonism in association with cerebral arteriosclerosis. In the treatment of Parkinson's disease, amantadine is less effective than levodopa, (-)-3-(3,4-dihydroxyphenyl)-L-alanine, and its efficacy in comparison with the anticholinergic antiparkinson drugs has not yet been established. Drug-Induced Extrapyramidal Reactions Amantadine hydrochloride is indicated in the treatment of drug-induced extrapyramidal reactions. Although anticholinergic-type side effects have been noted with amantadine when used in patients with drug-induced extrapyramidal reactions, there is a lower incidence of these side effects than that observed with the anticholinergic antiparkinson drugs. uuid:666f76bb-0ade-47d9-8a64-07f895d961c3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2618 biolink:treats MONDO:0008193 PMID:41385096 "[{""id"":""uuid:dcc13bf8-daff-40da-b15f-e59b98e402b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:44269a97-6e4e-44f1-8c98-37ec05742895"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amantadine hydrochloride syrup (amantadine hydrochloride oral solution, USP) is indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus. Amantadine hydrochloride is also indicated in the treatment of parkinsonism and drug-induced extrapyramidal reactions. Influenza A Prophylaxis Amantadine hydrochloride is indicated for chemoprophylaxis against signs and symptoms of influenza A virus infection when early vaccination is not feasible or when the vaccine is contraindicated or not available. In the prophylaxis of influenza, early vaccination on an annual basis as recommended by the Centers for Disease Control's Immunization Practices Advisory Committee is the method of choice. Because amantadine does not completely prevent the host immune response to influenza A infection, individuals who take this drug may still develop immune responses to natural disease or vaccination and may be protected when later exposed to antigenically related viruses. Following vaccination during an influenza A outbreak, amantadine prophylaxis should be considered for the 2-to 4-week time period required to develop an antibody response. Influenza A Treatment Amantadine hydrochloride is also indicated in the treatment of uncomplicated respiratory tract illness caused by influenza A virus strains especially when administered early in the course of illness. There are no well-controlled clinical studies demonstrating that treatment with amantadine will avoid the development of influenza A virus pneumonitis or other complications in high risk patients. There is no clinical evidence indicating that amantadine is effective in the prophylaxis or treatment of viral respiratory tract illnesses other than those caused by influenza A virus strains. Parkinson's Disease/Syndrome Amantadine is indicated in the treatment of idiopathic Parkinson's disease (Paralysis Agitans), postencephalitic parkinsonism, and symptomatic parkinsonism which may follow injury to the nervous system by carbon monoxide intoxication. It is indicated in those elderly patients believed to develop parkinsonism in association with cerebral arteriosclerosis. In the treatment of Parkinson's disease, amantadine is less effective than levodopa, (-)-3-(3,4-dihydroxyphenyl)-L-alanine, and its efficacy in comparison with the anticholinergic antiparkinson drugs has not yet been established. Drug-Induced Extrapyramidal Reactions Amantadine hydrochloride is indicated in the treatment of drug-induced extrapyramidal reactions. Although anticholinergic-type side effects have been noted with amantadine when used in patients with drug-induced extrapyramidal reactions, there is a lower incidence of these side effects than that observed with the anticholinergic antiparkinson drugs. uuid:e46aa3c6-b4ea-428c-964b-69b9e07fd36a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2618 biolink:treats MONDO:0001945 PMID:41385096 "[{""id"":""uuid:f7d8b205-4960-4480-a265-db1d1d0f6eb2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1fbded8a-cd2f-4911-978b-f46913b3603e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amantadine hydrochloride syrup (amantadine hydrochloride oral solution, USP) is indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus. Amantadine hydrochloride is also indicated in the treatment of parkinsonism and drug-induced extrapyramidal reactions. Influenza A Prophylaxis Amantadine hydrochloride is indicated for chemoprophylaxis against signs and symptoms of influenza A virus infection when early vaccination is not feasible or when the vaccine is contraindicated or not available. In the prophylaxis of influenza, early vaccination on an annual basis as recommended by the Centers for Disease Control's Immunization Practices Advisory Committee is the method of choice. Because amantadine does not completely prevent the host immune response to influenza A infection, individuals who take this drug may still develop immune responses to natural disease or vaccination and may be protected when later exposed to antigenically related viruses. Following vaccination during an influenza A outbreak, amantadine prophylaxis should be considered for the 2-to 4-week time period required to develop an antibody response. Influenza A Treatment Amantadine hydrochloride is also indicated in the treatment of uncomplicated respiratory tract illness caused by influenza A virus strains especially when administered early in the course of illness. There are no well-controlled clinical studies demonstrating that treatment with amantadine will avoid the development of influenza A virus pneumonitis or other complications in high risk patients. There is no clinical evidence indicating that amantadine is effective in the prophylaxis or treatment of viral respiratory tract illnesses other than those caused by influenza A virus strains. Parkinson's Disease/Syndrome Amantadine is indicated in the treatment of idiopathic Parkinson's disease (Paralysis Agitans), postencephalitic parkinsonism, and symptomatic parkinsonism which may follow injury to the nervous system by carbon monoxide intoxication. It is indicated in those elderly patients believed to develop parkinsonism in association with cerebral arteriosclerosis. In the treatment of Parkinson's disease, amantadine is less effective than levodopa, (-)-3-(3,4-dihydroxyphenyl)-L-alanine, and its efficacy in comparison with the anticholinergic antiparkinson drugs has not yet been established. Drug-Induced Extrapyramidal Reactions Amantadine hydrochloride is indicated in the treatment of drug-induced extrapyramidal reactions. Although anticholinergic-type side effects have been noted with amantadine when used in patients with drug-induced extrapyramidal reactions, there is a lower incidence of these side effects than that observed with the anticholinergic antiparkinson drugs. uuid:e0bf92f9-0594-4b73-839e-fe1482476b0f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2618 biolink:treats UMLS:C0007020 PMID:41385096 "[{""id"":""uuid:123d4f17-a392-4edb-aec3-b41d54350938"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a32c428c-b433-44ee-acdf-981e9b1df2bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amantadine hydrochloride syrup (amantadine hydrochloride oral solution, USP) is indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus. Amantadine hydrochloride is also indicated in the treatment of parkinsonism and drug-induced extrapyramidal reactions. Influenza A Prophylaxis Amantadine hydrochloride is indicated for chemoprophylaxis against signs and symptoms of influenza A virus infection when early vaccination is not feasible or when the vaccine is contraindicated or not available. In the prophylaxis of influenza, early vaccination on an annual basis as recommended by the Centers for Disease Control's Immunization Practices Advisory Committee is the method of choice. Because amantadine does not completely prevent the host immune response to influenza A infection, individuals who take this drug may still develop immune responses to natural disease or vaccination and may be protected when later exposed to antigenically related viruses. Following vaccination during an influenza A outbreak, amantadine prophylaxis should be considered for the 2-to 4-week time period required to develop an antibody response. Influenza A Treatment Amantadine hydrochloride is also indicated in the treatment of uncomplicated respiratory tract illness caused by influenza A virus strains especially when administered early in the course of illness. There are no well-controlled clinical studies demonstrating that treatment with amantadine will avoid the development of influenza A virus pneumonitis or other complications in high risk patients. There is no clinical evidence indicating that amantadine is effective in the prophylaxis or treatment of viral respiratory tract illnesses other than those caused by influenza A virus strains. Parkinson's Disease/Syndrome Amantadine is indicated in the treatment of idiopathic Parkinson's disease (Paralysis Agitans), postencephalitic parkinsonism, and symptomatic parkinsonism which may follow injury to the nervous system by carbon monoxide intoxication. It is indicated in those elderly patients believed to develop parkinsonism in association with cerebral arteriosclerosis. In the treatment of Parkinson's disease, amantadine is less effective than levodopa, (-)-3-(3,4-dihydroxyphenyl)-L-alanine, and its efficacy in comparison with the anticholinergic antiparkinson drugs has not yet been established. Drug-Induced Extrapyramidal Reactions Amantadine hydrochloride is indicated in the treatment of drug-induced extrapyramidal reactions. Although anticholinergic-type side effects have been noted with amantadine when used in patients with drug-induced extrapyramidal reactions, there is a lower incidence of these side effects than that observed with the anticholinergic antiparkinson drugs. uuid:ced33714-34e8-4b93-b9b0-d4afc7aa74d1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5130 biolink:treats HP:0000616 PMID:41385096 "[{""id"":""uuid:28f7ed10-6c14-4ebd-892d-e17926c664c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c777d24c-c297-4c3b-bf40-2fc104f58196"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Flurbiprofen sodium ophthalmic solution is indicated for the inhibition of intraoperative miosis. uuid:980e55c1-ce56-4b9a-a7b1-8551f88a1ec9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:194135 biolink:treats MONDO:0005545 PMID:41385096 "[{""id"":""uuid:495a5275-f970-4017-b478-5325b4164c8e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:36cef8e4-73a6-45b8-8091-8fbd4e16ef08"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ofloxacin ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below: CONJUNCTIVITIS: Gram-positive bacteria: Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae Gram-negative bacteria: Enterobacter cloacae Haemophilus influenzae Proteus mirabilis Pseudomonas aeruginosa CORNEAL ULCERS: Gram-positive bacteria: Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae Gram-negative bacteria: Pseudomonas aeruginosa Serratia marcescens* Anaerobic species: Propionibacterium acnes *Efficacy for this organism was studied in fewer than 10 infections uuid:3d583a37-4f58-4188-9f42-0a55f3af88e7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:194135 biolink:treats UMLS:C1096572 PMID:41385096 "[{""id"":""uuid:bfa66acb-b73b-4119-98ec-ee6ac3d2bc0c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c2bb8896-b126-4994-bb2e-0a35215b91fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ofloxacin ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below: CONJUNCTIVITIS: Gram-positive bacteria: Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae Gram-negative bacteria: Enterobacter cloacae Haemophilus influenzae Proteus mirabilis Pseudomonas aeruginosa CORNEAL ULCERS: Gram-positive bacteria: Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae Gram-negative bacteria: Pseudomonas aeruginosa Serratia marcescens* Anaerobic species: Propionibacterium acnes *Efficacy for this organism was studied in fewer than 10 infections uuid:1164c0d6-330a-4f77-8503-30b80527896e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:194135 biolink:treats MONDO:0005114 PMID:41385096 "[{""id"":""uuid:0617c272-8b50-4a8b-9aea-adc611f32640"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a4c45a76-aec6-43ee-aee0-fc760fc3912f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ofloxacin ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below: CONJUNCTIVITIS: Gram-positive bacteria: Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae Gram-negative bacteria: Enterobacter cloacae Haemophilus influenzae Proteus mirabilis Pseudomonas aeruginosa CORNEAL ULCERS: Gram-positive bacteria: Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae Gram-negative bacteria: Pseudomonas aeruginosa Serratia marcescens* Anaerobic species: Propionibacterium acnes *Efficacy for this organism was studied in fewer than 10 infections uuid:6dadbfbe-03ff-4ca1-9000-d664c47999de biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:194135 biolink:treats UMLS:C1096729 PMID:41385096 "[{""id"":""uuid:04331e53-b27b-44bb-8a7c-db6a17b3c643"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:790d291c-db80-41f2-aec7-b290026211a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ofloxacin ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below: CONJUNCTIVITIS: Gram-positive bacteria: Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae Gram-negative bacteria: Enterobacter cloacae Haemophilus influenzae Proteus mirabilis Pseudomonas aeruginosa CORNEAL ULCERS: Gram-positive bacteria: Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae Gram-negative bacteria: Pseudomonas aeruginosa Serratia marcescens* Anaerobic species: Propionibacterium acnes *Efficacy for this organism was studied in fewer than 10 infections uuid:cb75b47f-1eae-4036-a679-faa72a68f0eb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:194135 biolink:treats UMLS:C0348321 PMID:41385096 "[{""id"":""uuid:c03f6f99-366a-4161-b908-e6a14e74e8d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6c1d2030-82f4-40c2-8dba-3185c340acad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ofloxacin ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below: CONJUNCTIVITIS: Gram-positive bacteria: Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae Gram-negative bacteria: Enterobacter cloacae Haemophilus influenzae Proteus mirabilis Pseudomonas aeruginosa CORNEAL ULCERS: Gram-positive bacteria: Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae Gram-negative bacteria: Pseudomonas aeruginosa Serratia marcescens* Anaerobic species: Propionibacterium acnes *Efficacy for this organism was studied in fewer than 10 infections uuid:f401892c-a89d-4301-af40-db0a7ddea9d0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:194135 biolink:treats UMLS:C0276078 PMID:41385096 "[{""id"":""uuid:9488e5e0-0364-4ca0-baf6-df38947665a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:53330183-f2fc-4a46-9d0f-3113ac7bed56"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ofloxacin ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below: CONJUNCTIVITIS: Gram-positive bacteria: Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae Gram-negative bacteria: Enterobacter cloacae Haemophilus influenzae Proteus mirabilis Pseudomonas aeruginosa CORNEAL ULCERS: Gram-positive bacteria: Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae Gram-negative bacteria: Pseudomonas aeruginosa Serratia marcescens* Anaerobic species: Propionibacterium acnes *Efficacy for this organism was studied in fewer than 10 infections uuid:85cf018e-cec5-4d38-ae7e-c644ef437cf6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:194135 biolink:treats UMLS:C0854135 PMID:41385096 "[{""id"":""uuid:76f23274-99be-41ef-8f14-87916b993a33"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e45851b7-f92b-46f6-afe1-579e1c2454ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ofloxacin ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below: CONJUNCTIVITIS: Gram-positive bacteria: Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae Gram-negative bacteria: Enterobacter cloacae Haemophilus influenzae Proteus mirabilis Pseudomonas aeruginosa CORNEAL ULCERS: Gram-positive bacteria: Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae Gram-negative bacteria: Pseudomonas aeruginosa Serratia marcescens* Anaerobic species: Propionibacterium acnes *Efficacy for this organism was studied in fewer than 10 infections uuid:44e7e3e9-1481-4947-8d39-7a38d2f5c485 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:194135 biolink:treats UMLS:C1096571 PMID:41385096 "[{""id"":""uuid:01e16a59-0a3e-4ac0-9ac2-ecfc9652f79b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:90eac29a-ec04-4f6f-91d3-e2f137487130"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ofloxacin ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below: CONJUNCTIVITIS: Gram-positive bacteria: Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae Gram-negative bacteria: Enterobacter cloacae Haemophilus influenzae Proteus mirabilis Pseudomonas aeruginosa CORNEAL ULCERS: Gram-positive bacteria: Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae Gram-negative bacteria: Pseudomonas aeruginosa Serratia marcescens* Anaerobic species: Propionibacterium acnes *Efficacy for this organism was studied in fewer than 10 infections uuid:310ccaa5-46fb-4c0c-b3b6-d58070d56f95 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6129 biolink:treats HP:0200026 PMID:41385096 "[{""id"":""uuid:6b0c7a1e-860e-4db7-ad15-26d66ad50d0b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e0979f4d-dc5f-4b27-a6bd-7e82d901736b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ketorolac Tromethamine Ophthalmic Solution, 0.4% is indicated for the reduction of ocular pain and burning/stinging following corneal refractive surgery. uuid:87cb6503-a5d5-4140-924d-43ad38b48d7d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:34911 biolink:treats MONDO:0004525 PMID:41385096 "[{""id"":""uuid:6c2b75bb-e5b9-4499-a1e4-d4fd47a862a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7337c19c-9ac4-499c-b1cc-5709eeb1e49f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Permethrin cream, 5% is indicated for the treatment of infestation with Sarcoptes scabiei (scabies). uuid:a7493a9f-3bde-49ea-b042-66d249bfcb0a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4909 biolink:treats MONDO:0005178 PMID:41385096 "[{""id"":""uuid:50bdb9bb-1e1d-4256-b9a9-7c323333d34f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ab70081c-43b7-4302-8d32-f609a5387d35"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of etodolac capsules and tablets, USP, and other treatment options before deciding to use etodolac capsules and tablets, USP. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Etodolac Capsules and Tablets, USP are indicated: For acute and long-term use in the management of signs and symptoms of the following: Osteoarthritis Rheumatoid arthritis For the management of acute pain uuid:b06b5c25-4dca-4f47-9494-8ef474a78d11 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4909 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:d7c52953-c0b5-4b80-80b7-5970ae807ee7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8a95c4e7-5ebe-458e-897d-b01007a7257e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of etodolac capsules and tablets, USP, and other treatment options before deciding to use etodolac capsules and tablets, USP. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Etodolac Capsules and Tablets, USP are indicated: For acute and long-term use in the management of signs and symptoms of the following: Osteoarthritis Rheumatoid arthritis For the management of acute pain uuid:b777d229-9bc1-480f-a389-ca7c0fe74cb6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4909 biolink:treats NCIT:C27003 PMID:41385096 "[{""id"":""uuid:42d1dfff-36ee-4bcb-9798-f348554686bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:33d16a13-c473-403d-827c-3bc48cf7ebae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of etodolac capsules and tablets, USP, and other treatment options before deciding to use etodolac capsules and tablets, USP. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Etodolac Capsules and Tablets, USP are indicated: For acute and long-term use in the management of signs and symptoms of the following: Osteoarthritis Rheumatoid arthritis For the management of acute pain uuid:fc2455c9-7692-4d56-b7cd-e7e3ab89aebc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31397 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:100ddc76-9477-4a65-835e-dfddad3ddd3d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:82de43d4-afc2-4de8-bf51-7cbb9d0fc3eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:47808a4c-e5df-4742-afcc-795b5d00b1db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ALVESCO is an inhaled corticosteroid indicated for: Maintenance treatment of asthma as prophylactic therapy in adult and adolescent patients 12 years of age and older. ( 1 ) ALVESCO is NOT indicated for the relief of acute bronchospasm. ( 1 )|[PMDA] Drugs containing a new active ingredient indicated for the treatment of asthma. uuid:57c90153-ee3f-415c-a18a-4c040d16917e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47519 biolink:treats MONDO:0002026 PMID:41385096 "[{""id"":""uuid:5f756d43-7305-4f1f-9eb7-d02f2e3b76f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c1533a58-7e7c-44c5-84bd-5d80eb47bfa1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ketoconazole tablets are indicated for the treatment of the following systemic fungal infections: candidiasis, chronic mucocutaneous candidiasis, oral thrush, candiduria, blastomycosis, coccidioidomycosis, histoplasmosis, chromomycosis, and paracoccidioidomycosis. Ketoconazole tablets should not be used for fungal meningitis because it penetrates poorly into the cerebral-spinal fluid. Ketoconazole tablets are also indicated for the treatment of patients with severe recalcitrant cutaneous dermatophyte infections who have not responded to topical therapy or oral griseofulvin, or who are unable to take griseofulvin. uuid:00696c08-1599-4719-87b2-75b0e841ccfc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47519 biolink:treats MONDO:0015279 PMID:41385096 "[{""id"":""uuid:5f45c1de-8c18-41c7-a154-6b4b936002ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:99c32b79-a6ac-4479-9794-5b22f32fac0b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ketoconazole tablets are indicated for the treatment of the following systemic fungal infections: candidiasis, chronic mucocutaneous candidiasis, oral thrush, candiduria, blastomycosis, coccidioidomycosis, histoplasmosis, chromomycosis, and paracoccidioidomycosis. Ketoconazole tablets should not be used for fungal meningitis because it penetrates poorly into the cerebral-spinal fluid. Ketoconazole tablets are also indicated for the treatment of patients with severe recalcitrant cutaneous dermatophyte infections who have not responded to topical therapy or oral griseofulvin, or who are unable to take griseofulvin. uuid:ee125785-63a6-4769-8eb4-970c0fa583ea biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47519 biolink:treats MONDO:0005886 PMID:41385096 "[{""id"":""uuid:1d68837b-80b9-4cfc-be33-54f877df87b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:80112c09-2353-47b8-b4b7-d9ed5ce3ae06"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ketoconazole tablets are indicated for the treatment of the following systemic fungal infections: candidiasis, chronic mucocutaneous candidiasis, oral thrush, candiduria, blastomycosis, coccidioidomycosis, histoplasmosis, chromomycosis, and paracoccidioidomycosis. Ketoconazole tablets should not be used for fungal meningitis because it penetrates poorly into the cerebral-spinal fluid. Ketoconazole tablets are also indicated for the treatment of patients with severe recalcitrant cutaneous dermatophyte infections who have not responded to topical therapy or oral griseofulvin, or who are unable to take griseofulvin. uuid:887203ab-f930-4877-9ff6-5f793e6b243f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47519 biolink:treats UMLS:C0403723 PMID:41385096 "[{""id"":""uuid:19d3f63d-ac0c-451b-909b-200042638244"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:da71171b-219d-4588-9b8e-f62bbfb2eb2e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ketoconazole tablets are indicated for the treatment of the following systemic fungal infections: candidiasis, chronic mucocutaneous candidiasis, oral thrush, candiduria, blastomycosis, coccidioidomycosis, histoplasmosis, chromomycosis, and paracoccidioidomycosis. Ketoconazole tablets should not be used for fungal meningitis because it penetrates poorly into the cerebral-spinal fluid. Ketoconazole tablets are also indicated for the treatment of patients with severe recalcitrant cutaneous dermatophyte infections who have not responded to topical therapy or oral griseofulvin, or who are unable to take griseofulvin. uuid:08c7e7b9-c87a-4314-b28a-ca4cbc1712e9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47519 biolink:treats MONDO:0005672 PMID:41385096 "[{""id"":""uuid:d6fa9f09-dfaf-4c53-a7cc-bdf9b8ac0fa3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:14eb4441-7c48-42a4-9eb8-4907e3644a31"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ketoconazole tablets are indicated for the treatment of the following systemic fungal infections: candidiasis, chronic mucocutaneous candidiasis, oral thrush, candiduria, blastomycosis, coccidioidomycosis, histoplasmosis, chromomycosis, and paracoccidioidomycosis. Ketoconazole tablets should not be used for fungal meningitis because it penetrates poorly into the cerebral-spinal fluid. Ketoconazole tablets are also indicated for the treatment of patients with severe recalcitrant cutaneous dermatophyte infections who have not responded to topical therapy or oral griseofulvin, or who are unable to take griseofulvin. uuid:fab9f043-6153-4d57-8dc0-579f1518307c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47519 biolink:treats MONDO:0005706 PMID:41385096 "[{""id"":""uuid:ca061b41-3378-497c-931b-a5878f766239"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3497b8d9-a7d7-4af8-8e95-f55be77bb247"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ketoconazole tablets are indicated for the treatment of the following systemic fungal infections: candidiasis, chronic mucocutaneous candidiasis, oral thrush, candiduria, blastomycosis, coccidioidomycosis, histoplasmosis, chromomycosis, and paracoccidioidomycosis. Ketoconazole tablets should not be used for fungal meningitis because it penetrates poorly into the cerebral-spinal fluid. Ketoconazole tablets are also indicated for the treatment of patients with severe recalcitrant cutaneous dermatophyte infections who have not responded to topical therapy or oral griseofulvin, or who are unable to take griseofulvin. uuid:cdf5ecfb-3b92-4615-ac38-c600908eae8a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47519 biolink:treats MONDO:0018312 PMID:41385096 "[{""id"":""uuid:cbf46c6d-c5cd-43f8-aaf9-bf91de26719a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cc623bd4-ff2f-44c5-a707-8bcc90da3483"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ketoconazole tablets are indicated for the treatment of the following systemic fungal infections: candidiasis, chronic mucocutaneous candidiasis, oral thrush, candiduria, blastomycosis, coccidioidomycosis, histoplasmosis, chromomycosis, and paracoccidioidomycosis. Ketoconazole tablets should not be used for fungal meningitis because it penetrates poorly into the cerebral-spinal fluid. Ketoconazole tablets are also indicated for the treatment of patients with severe recalcitrant cutaneous dermatophyte infections who have not responded to topical therapy or oral griseofulvin, or who are unable to take griseofulvin. uuid:4073eec8-1e61-4a7b-9dee-f4ae26f272e9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47519 biolink:treats MONDO:0015908 PMID:41385096 "[{""id"":""uuid:2ca1d427-eea0-4578-97c8-4743dcb01ece"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:72242e3c-fd3e-452c-b861-779170d52c4a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ketoconazole tablets are indicated for the treatment of the following systemic fungal infections: candidiasis, chronic mucocutaneous candidiasis, oral thrush, candiduria, blastomycosis, coccidioidomycosis, histoplasmosis, chromomycosis, and paracoccidioidomycosis. Ketoconazole tablets should not be used for fungal meningitis because it penetrates poorly into the cerebral-spinal fluid. Ketoconazole tablets are also indicated for the treatment of patients with severe recalcitrant cutaneous dermatophyte infections who have not responded to topical therapy or oral griseofulvin, or who are unable to take griseofulvin. uuid:878d8ff1-9176-4576-97c9-54742ddd88c9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47519 biolink:treats MONDO:0005894 PMID:41385096 "[{""id"":""uuid:2490929c-9b22-46eb-87ba-f32618cc1ce0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:98a16f66-adf6-436c-b2fb-e44d6eef18aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ketoconazole tablets are indicated for the treatment of the following systemic fungal infections: candidiasis, chronic mucocutaneous candidiasis, oral thrush, candiduria, blastomycosis, coccidioidomycosis, histoplasmosis, chromomycosis, and paracoccidioidomycosis. Ketoconazole tablets should not be used for fungal meningitis because it penetrates poorly into the cerebral-spinal fluid. Ketoconazole tablets are also indicated for the treatment of patients with severe recalcitrant cutaneous dermatophyte infections who have not responded to topical therapy or oral griseofulvin, or who are unable to take griseofulvin. uuid:23d24e2e-9895-46a0-884e-d1d804e01d22 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8207 biolink:treats MONDO:0010030 PMID:41385096 "[{""id"":""uuid:128e995f-17f5-4c88-9e55-2b159c5089a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9344ee23-b23f-46e1-97a4-c1b641c96d32"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:77155cda-2007-4ef3-ad8d-fd08cd246e20"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pilocarpine HCl Tablets are indicated for 1) the treatment of symptoms of dry mouth from salivary gland hypofunction caused by radiotherapy for cancer of the head and neck; and 2) the treatment of symptoms of dry mouth in patients with Sjogren's syndrome.|[PMDA] A drug with a new indication for the treatment of oral dryness in patients with Sjögren’s syndrome. uuid:902a62f2-68e5-4038-86c6-6a2a1c667c90 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8207 biolink:treats MONDO:0005627 PMID:41385096 "[{""id"":""uuid:73da57d5-315d-498b-815d-ff495f3f9c64"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a2c63395-75d4-4edc-9a25-9269a3d2579f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e3700b47-e405-4032-a881-44d319ad15f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pilocarpine HCl Tablets are indicated for 1) the treatment of symptoms of dry mouth from salivary gland hypofunction caused by radiotherapy for cancer of the head and neck; and 2) the treatment of symptoms of dry mouth in patients with Sjogren's syndrome.|[PMDA] Drug with a new route of oral administration indicated for the treatment of symptoms of dry mouth caused by radiotherapy for head and neck cancer uuid:84ab0ea8-4c3f-489b-ad59-e3e2c002fe27 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50305 biolink:treats MONDO:0005647 PMID:41385096 "[{""id"":""uuid:a8668c2b-7d40-40cc-82ac-0f4c4acff86c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d03543f7-c87c-4340-9099-1e8767ee2f09"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Podofilox 0.5% Solution is indicated for the topical treatment of external genital warts (Condyloma acuminatum). This product is not indicated in the treatment of perianal or mucous membrane warts (see PRECAUTIONS ). uuid:f53d7143-8c4f-4bfb-846d-763fa8f2d5e5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:370638 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:32638d61-55a8-4899-851b-3e429a4d4c17"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cfe09d34-8eaa-47ba-91e8-e75769c1791e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amiloride hydrochloride and hydrochlorothiazide tablets are indicated in those patients with hypertension or with congestive heart failure who develop hypokalemia when thiazides or other kaliuretic diuretics are used alone, or in whom maintenance of normal serum potassium levels is considered to be clinically important, e.g., digitalized patients, or patients with significant cardiac arrhythmias. The use of potassium-conserving agents is often unnecessary in patients receiving diuretics for uncomplicated essential hypertension when such patients have a normal diet. Amiloride hydrochloride and hydrochlorothiazide tablets may be used alone or as an adjunct to other antihypertensive drugs, such as methyldopa or beta blockers. Since amiloride hydrochloride and hydrochlorothiazide enhances the action of these agents, dosage adjustments may be necessary to avoid an excessive fall in blood pressure and other unwanted side effects. This fixed combination drug is not indicated for the initial therapy of edema or hypertension except in individuals in whom the development of hypokalemia cannot be risked. uuid:060e72ca-10fc-44aa-99f6-a69d35a70a82 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:370638 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:3e7b8cca-bd48-4659-b46a-97507f3bf0fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:851fff4f-a7a1-4fc4-a7cb-2a5ad013465e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amiloride hydrochloride and hydrochlorothiazide tablets are indicated in those patients with hypertension or with congestive heart failure who develop hypokalemia when thiazides or other kaliuretic diuretics are used alone, or in whom maintenance of normal serum potassium levels is considered to be clinically important, e.g., digitalized patients, or patients with significant cardiac arrhythmias. The use of potassium-conserving agents is often unnecessary in patients receiving diuretics for uncomplicated essential hypertension when such patients have a normal diet. Amiloride hydrochloride and hydrochlorothiazide tablets may be used alone or as an adjunct to other antihypertensive drugs, such as methyldopa or beta blockers. Since amiloride hydrochloride and hydrochlorothiazide enhances the action of these agents, dosage adjustments may be necessary to avoid an excessive fall in blood pressure and other unwanted side effects. This fixed combination drug is not indicated for the initial therapy of edema or hypertension except in individuals in whom the development of hypokalemia cannot be risked. uuid:7fe6f315-6c1d-4c51-a8cf-be96dea3917b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:370638 biolink:treats MONDO:0003019 PMID:41385096 "[{""id"":""uuid:fea07a0d-1d54-446e-ad55-afa253fbbb5f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:11e4c69d-2a0a-4ff0-98f3-26a48383a196"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amiloride hydrochloride and hydrochlorothiazide tablets are indicated in those patients with hypertension or with congestive heart failure who develop hypokalemia when thiazides or other kaliuretic diuretics are used alone, or in whom maintenance of normal serum potassium levels is considered to be clinically important, e.g., digitalized patients, or patients with significant cardiac arrhythmias. The use of potassium-conserving agents is often unnecessary in patients receiving diuretics for uncomplicated essential hypertension when such patients have a normal diet. Amiloride hydrochloride and hydrochlorothiazide tablets may be used alone or as an adjunct to other antihypertensive drugs, such as methyldopa or beta blockers. Since amiloride hydrochloride and hydrochlorothiazide enhances the action of these agents, dosage adjustments may be necessary to avoid an excessive fall in blood pressure and other unwanted side effects. This fixed combination drug is not indicated for the initial therapy of edema or hypertension except in individuals in whom the development of hypokalemia cannot be risked. uuid:ed91924a-9b41-4769-bc46-d04cfaed054d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:370638 biolink:treats MONDO:0007263 PMID:41385096 "[{""id"":""uuid:ad17368d-e4c5-4283-9f72-436b41558743"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dc69a9d7-cec3-430a-9edf-284a64c8f81a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amiloride hydrochloride and hydrochlorothiazide tablets are indicated in those patients with hypertension or with congestive heart failure who develop hypokalemia when thiazides or other kaliuretic diuretics are used alone, or in whom maintenance of normal serum potassium levels is considered to be clinically important, e.g., digitalized patients, or patients with significant cardiac arrhythmias. The use of potassium-conserving agents is often unnecessary in patients receiving diuretics for uncomplicated essential hypertension when such patients have a normal diet. Amiloride hydrochloride and hydrochlorothiazide tablets may be used alone or as an adjunct to other antihypertensive drugs, such as methyldopa or beta blockers. Since amiloride hydrochloride and hydrochlorothiazide enhances the action of these agents, dosage adjustments may be necessary to avoid an excessive fall in blood pressure and other unwanted side effects. This fixed combination drug is not indicated for the initial therapy of edema or hypertension except in individuals in whom the development of hypokalemia cannot be risked. uuid:38d3ce4e-15e7-4f7d-aba0-a35d9bccb1c2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:370638 biolink:treats HP:0000969 PMID:41385096 "[{""id"":""uuid:30604d1e-c259-4119-88d8-5e440221e35d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5dee3a2d-c7c4-4bc7-bcb2-a51a783b6e48"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amiloride hydrochloride and hydrochlorothiazide tablets are indicated in those patients with hypertension or with congestive heart failure who develop hypokalemia when thiazides or other kaliuretic diuretics are used alone, or in whom maintenance of normal serum potassium levels is considered to be clinically important, e.g., digitalized patients, or patients with significant cardiac arrhythmias. The use of potassium-conserving agents is often unnecessary in patients receiving diuretics for uncomplicated essential hypertension when such patients have a normal diet. Amiloride hydrochloride and hydrochlorothiazide tablets may be used alone or as an adjunct to other antihypertensive drugs, such as methyldopa or beta blockers. Since amiloride hydrochloride and hydrochlorothiazide enhances the action of these agents, dosage adjustments may be necessary to avoid an excessive fall in blood pressure and other unwanted side effects. This fixed combination drug is not indicated for the initial therapy of edema or hypertension except in individuals in whom the development of hypokalemia cannot be risked. uuid:5c281859-0c45-4b75-bed6-6785c97fc944 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:370638 biolink:treats MONDO:0001134 PMID:41385096 "[{""id"":""uuid:e128d6da-320a-44c8-9fff-00c6d7236700"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ff48aa4d-fa73-4cd2-a878-74e4fb22ad82"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amiloride hydrochloride and hydrochlorothiazide tablets are indicated in those patients with hypertension or with congestive heart failure who develop hypokalemia when thiazides or other kaliuretic diuretics are used alone, or in whom maintenance of normal serum potassium levels is considered to be clinically important, e.g., digitalized patients, or patients with significant cardiac arrhythmias. The use of potassium-conserving agents is often unnecessary in patients receiving diuretics for uncomplicated essential hypertension when such patients have a normal diet. Amiloride hydrochloride and hydrochlorothiazide tablets may be used alone or as an adjunct to other antihypertensive drugs, such as methyldopa or beta blockers. Since amiloride hydrochloride and hydrochlorothiazide enhances the action of these agents, dosage adjustments may be necessary to avoid an excessive fall in blood pressure and other unwanted side effects. This fixed combination drug is not indicated for the initial therapy of edema or hypertension except in individuals in whom the development of hypokalemia cannot be risked. uuid:dae8778e-2536-4a23-b654-b62de141fb33 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:151392 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:692f20ee-be5b-4174-a72a-67072001a2a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7090fe72-18e9-46c3-a2c7-d3eeb1d349f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AUGMENTIN XR Extended Release Tablets are indicated for the treatment of patients with community-acquired pneumonia or acute bacterial sinusitis due to confirmed, or suspected β-lactamase−producing pathogens (i.e., H. influenzae , M. catarrhalis , H. parainfluenzae , K. pneumoniae , or methicillin-susceptible S. aureus ) and S. pneumoniae with reduced susceptibility to penicillin (i.e., penicillin MICs = 2 mcg/mL). AUGMENTIN XR is not indicated for the treatment of infections due to S. pneumoniae with penicillin MICs ≥ 4 mcg/mL. Data are limited with regard to infections due to S. pneumoniae with penicillin MICs ≥ 4 mcg/mL (see CLINICAL STUDIES). Of the common epidemiological risk factors for patients with resistant pneumococcal infections, only age > 65 years was studied. Patients with other common risk factors for resistant pneumococcal infections (e.g., alcoholism, immune-suppressive illness, and presence of multiple co-morbid conditions) were not studied. In patients with community-acquired pneumonia in whom penicillin-resistant S. pneumoniae is suspected, bacteriological studies should be performed to determine the causative organisms and their susceptibility when AUGMENTIN XR is prescribed. Acute bacterial sinusitis or community-acquired pneumonia due to a penicillin-susceptible strain of S. pneumoniae plus a β-lactamase−producing pathogen can be treated with another AUGMENTIN ® (amoxicillin/clavulanate potassium) product containing lower daily doses of amoxicillin (i.e., 500 mg every 8 hours or 875 mg every 12 hours). Acute bacterial sinusitis or community-acquired pneumonia due to S. pneumoniae alone can be treated with amoxicillin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of AUGMENTIN XR and other antibacterial drugs, AUGMENTIN XR should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:2019c419-68ee-4448-8a95-c33adf3a1cef biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:151392 biolink:treats UMLS:C0275556 PMID:41385096 "[{""id"":""uuid:05a9db87-d897-4128-b3b0-041a72d166cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:139ae2a4-4c94-40c3-ae2f-ec2ea94c5656"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AUGMENTIN XR Extended Release Tablets are indicated for the treatment of patients with community-acquired pneumonia or acute bacterial sinusitis due to confirmed, or suspected β-lactamase−producing pathogens (i.e., H. influenzae , M. catarrhalis , H. parainfluenzae , K. pneumoniae , or methicillin-susceptible S. aureus ) and S. pneumoniae with reduced susceptibility to penicillin (i.e., penicillin MICs = 2 mcg/mL). AUGMENTIN XR is not indicated for the treatment of infections due to S. pneumoniae with penicillin MICs ≥ 4 mcg/mL. Data are limited with regard to infections due to S. pneumoniae with penicillin MICs ≥ 4 mcg/mL (see CLINICAL STUDIES). Of the common epidemiological risk factors for patients with resistant pneumococcal infections, only age > 65 years was studied. Patients with other common risk factors for resistant pneumococcal infections (e.g., alcoholism, immune-suppressive illness, and presence of multiple co-morbid conditions) were not studied. In patients with community-acquired pneumonia in whom penicillin-resistant S. pneumoniae is suspected, bacteriological studies should be performed to determine the causative organisms and their susceptibility when AUGMENTIN XR is prescribed. Acute bacterial sinusitis or community-acquired pneumonia due to a penicillin-susceptible strain of S. pneumoniae plus a β-lactamase−producing pathogen can be treated with another AUGMENTIN ® (amoxicillin/clavulanate potassium) product containing lower daily doses of amoxicillin (i.e., 500 mg every 8 hours or 875 mg every 12 hours). Acute bacterial sinusitis or community-acquired pneumonia due to S. pneumoniae alone can be treated with amoxicillin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of AUGMENTIN XR and other antibacterial drugs, AUGMENTIN XR should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:84b862ef-2d38-4409-b255-6a2a7c0de93a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:100241 biolink:treats MONDO:0004577 PMID:41385096 "[{""id"":""uuid:604acbc8-d521-4a89-85f1-843a7c855dd1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3db043e9-8618-4b17-b784-e6348800efef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ciprofloxacin Hydrochloride Ophthalmic Solution is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions listed below: Corneal Ulcers: Pseudomonas aeruginosa Serratia marcescens* Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae Streptococcus (Viridans Group)* Conjunctivitis: Haemophilus influenzae Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae *Efficacy for this organism was studied in fewer than 10 infections. uuid:c040b022-9eb6-442d-8eee-2cf8ae07d9fe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:100241 biolink:treats MONDO:0003799 PMID:41385096 "[{""id"":""uuid:3f56396f-0f07-4190-a946-89a24b96702e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6fb5a920-dda3-4e65-a010-18625adc82d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ciprofloxacin Hydrochloride Ophthalmic Solution is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions listed below: Corneal Ulcers: Pseudomonas aeruginosa Serratia marcescens* Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae Streptococcus (Viridans Group)* Conjunctivitis: Haemophilus influenzae Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae *Efficacy for this organism was studied in fewer than 10 infections. uuid:d95e0b19-453f-4a66-a05d-fcdc084d5e35 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3752 biolink:treats HP:0000869 PMID:41385096 "[{""id"":""uuid:973e1afe-64c3-4231-a61b-d5869d0a7285"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e1a12f82-cae9-4169-85a1-08e08d49b324"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clomiphene citrate is indicated for the treatment of ovulatory dysfunction in women desiring pregnancy. Impediments to achieving pregnancy must be excluded or adequately treated before beginning clomiphene citrate therapy. Those patients most likely to achieve success with clomiphene therapy include patients with polycystic ovary syndrome (see WARNINGS : Ovarian Hyperstimulation Syndrome ), amenorrhea-galactorrhea syndrome, psychogenic amenorrhea, post-oral-contraceptive amenorrhea, and certain cases of secondary amenorrhea of undetermined etiology. Properly timed coitus in relationship to ovulation is important. A basal body temperature graph or other appropriate tests may help the patient and her physician determine if ovulation occurred. Once ovulation has been established, each course of clomiphene citrate should be started on or about the 5th day of the cycle. Long-term cyclic therapy is not recommended beyond a total of about six cycles (including three ovulatory cycles). (See DOSAGE AND ADMINISTRATION and PRECAUTIONS .) Clomiphene citrate is indicated only in patients with demonstrated ovulatory dysfunction who meet the conditions described below (see CONTRAINDICATIONS ): Patients who are not pregnant. Patients without ovarian cysts. Clomiphene citrate should not be used in patients with ovarian enlargement except those with polycystic ovary syndrome. Pelvic examination is necessary prior to the first and each subsequent course of clomiphene citrate treatment. Patients without abnormal vaginal bleeding. If abnormal vaginal bleeding is present, the patient should be carefully evaluated to ensure that neoplastic lesions are not present. Patients with normal liver function. In addition, patients selected for clomiphene citrate therapy should be evaluated in regard to the following: Estrogen Levels. Patients should have adequate levels of endogenous estrogen (as estimated from vaginal smears, endometrial biopsy, assay of urinary estrogen, or from bleeding in response to progesterone). Reduced estrogen levels, while less favorable, do not preclude successful therapy. Primary Pituitary or Ovarian Failure. Clomiphene citrate therapy cannot be expected to substitute for specific treatment of other causes of ovulatory failure. Endometriosis and Endometrial Carcinoma. The incidence of endometriosis and endometrial carcinoma increases with age as does the incidence of ovulatory disorders. Endometrial biopsy should always be performed prior to clomiphene citrate therapy in this population. Other Impediments to Pregnancy. Impediments to pregnancy can include thyroid disorders, adrenal disorders, hyperprolactinemia, and male factor infertility. Uterine Fibroids. Caution should be exercised when using clomiphene citrate in patients with uterine fibroids due to the potential for further enlargement of the fibroids. There are no adequate or well-controlled studies that demonstrate the effectiveness of clomiphene citrate in the treatment of male infertility. In addition, testicular tumors and gynecomastia have been reported in males using clomiphene. The cause and effect relationship between reports of testicular tumors and the administration of clomiphene citrate is not known. Although the medical literature suggests various methods, there is no universally accepted standard regimen for combined therapy (i.e., clomiphene citrate in conjunction with other ovulation-inducing drugs). Similarly, there is no standard clomiphene citrate regimen for ovulation induction in vitro fertilization programs to produce ova for fertilization and reintroduction. Therefore, clomiphene citrate is not recommended for these uses. uuid:14f6e2e3-8147-49f8-8240-61bec845a96a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3752 biolink:treats MONDO:0005133 PMID:41385096 "[{""id"":""uuid:7097872b-f46b-4404-a503-38ee98150f62"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:99046d08-dc29-400c-9182-ac25d377d7d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clomiphene citrate is indicated for the treatment of ovulatory dysfunction in women desiring pregnancy. Impediments to achieving pregnancy must be excluded or adequately treated before beginning clomiphene citrate therapy. Those patients most likely to achieve success with clomiphene therapy include patients with polycystic ovary syndrome (see WARNINGS : Ovarian Hyperstimulation Syndrome ), amenorrhea-galactorrhea syndrome, psychogenic amenorrhea, post-oral-contraceptive amenorrhea, and certain cases of secondary amenorrhea of undetermined etiology. Properly timed coitus in relationship to ovulation is important. A basal body temperature graph or other appropriate tests may help the patient and her physician determine if ovulation occurred. Once ovulation has been established, each course of clomiphene citrate should be started on or about the 5th day of the cycle. Long-term cyclic therapy is not recommended beyond a total of about six cycles (including three ovulatory cycles). (See DOSAGE AND ADMINISTRATION and PRECAUTIONS .) Clomiphene citrate is indicated only in patients with demonstrated ovulatory dysfunction who meet the conditions described below (see CONTRAINDICATIONS ): Patients who are not pregnant. Patients without ovarian cysts. Clomiphene citrate should not be used in patients with ovarian enlargement except those with polycystic ovary syndrome. Pelvic examination is necessary prior to the first and each subsequent course of clomiphene citrate treatment. Patients without abnormal vaginal bleeding. If abnormal vaginal bleeding is present, the patient should be carefully evaluated to ensure that neoplastic lesions are not present. Patients with normal liver function. In addition, patients selected for clomiphene citrate therapy should be evaluated in regard to the following: Estrogen Levels. Patients should have adequate levels of endogenous estrogen (as estimated from vaginal smears, endometrial biopsy, assay of urinary estrogen, or from bleeding in response to progesterone). Reduced estrogen levels, while less favorable, do not preclude successful therapy. Primary Pituitary or Ovarian Failure. Clomiphene citrate therapy cannot be expected to substitute for specific treatment of other causes of ovulatory failure. Endometriosis and Endometrial Carcinoma. The incidence of endometriosis and endometrial carcinoma increases with age as does the incidence of ovulatory disorders. Endometrial biopsy should always be performed prior to clomiphene citrate therapy in this population. Other Impediments to Pregnancy. Impediments to pregnancy can include thyroid disorders, adrenal disorders, hyperprolactinemia, and male factor infertility. Uterine Fibroids. Caution should be exercised when using clomiphene citrate in patients with uterine fibroids due to the potential for further enlargement of the fibroids. There are no adequate or well-controlled studies that demonstrate the effectiveness of clomiphene citrate in the treatment of male infertility. In addition, testicular tumors and gynecomastia have been reported in males using clomiphene. The cause and effect relationship between reports of testicular tumors and the administration of clomiphene citrate is not known. Although the medical literature suggests various methods, there is no universally accepted standard regimen for combined therapy (i.e., clomiphene citrate in conjunction with other ovulation-inducing drugs). Similarly, there is no standard clomiphene citrate regimen for ovulation induction in vitro fertilization programs to produce ova for fertilization and reintroduction. Therefore, clomiphene citrate is not recommended for these uses. uuid:45705861-2fe4-4d56-afc4-6733356abf20 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3752 biolink:treats MONDO:0002447 PMID:41385096 "[{""id"":""uuid:5cf517f4-05ad-4bd2-9edb-d330f35f79e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5dce79c7-4a88-4dd7-947d-2bdcd30c0abd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clomiphene citrate is indicated for the treatment of ovulatory dysfunction in women desiring pregnancy. Impediments to achieving pregnancy must be excluded or adequately treated before beginning clomiphene citrate therapy. Those patients most likely to achieve success with clomiphene therapy include patients with polycystic ovary syndrome (see WARNINGS : Ovarian Hyperstimulation Syndrome ), amenorrhea-galactorrhea syndrome, psychogenic amenorrhea, post-oral-contraceptive amenorrhea, and certain cases of secondary amenorrhea of undetermined etiology. Properly timed coitus in relationship to ovulation is important. A basal body temperature graph or other appropriate tests may help the patient and her physician determine if ovulation occurred. Once ovulation has been established, each course of clomiphene citrate should be started on or about the 5th day of the cycle. Long-term cyclic therapy is not recommended beyond a total of about six cycles (including three ovulatory cycles). (See DOSAGE AND ADMINISTRATION and PRECAUTIONS .) Clomiphene citrate is indicated only in patients with demonstrated ovulatory dysfunction who meet the conditions described below (see CONTRAINDICATIONS ): Patients who are not pregnant. Patients without ovarian cysts. Clomiphene citrate should not be used in patients with ovarian enlargement except those with polycystic ovary syndrome. Pelvic examination is necessary prior to the first and each subsequent course of clomiphene citrate treatment. Patients without abnormal vaginal bleeding. If abnormal vaginal bleeding is present, the patient should be carefully evaluated to ensure that neoplastic lesions are not present. Patients with normal liver function. In addition, patients selected for clomiphene citrate therapy should be evaluated in regard to the following: Estrogen Levels. Patients should have adequate levels of endogenous estrogen (as estimated from vaginal smears, endometrial biopsy, assay of urinary estrogen, or from bleeding in response to progesterone). Reduced estrogen levels, while less favorable, do not preclude successful therapy. Primary Pituitary or Ovarian Failure. Clomiphene citrate therapy cannot be expected to substitute for specific treatment of other causes of ovulatory failure. Endometriosis and Endometrial Carcinoma. The incidence of endometriosis and endometrial carcinoma increases with age as does the incidence of ovulatory disorders. Endometrial biopsy should always be performed prior to clomiphene citrate therapy in this population. Other Impediments to Pregnancy. Impediments to pregnancy can include thyroid disorders, adrenal disorders, hyperprolactinemia, and male factor infertility. Uterine Fibroids. Caution should be exercised when using clomiphene citrate in patients with uterine fibroids due to the potential for further enlargement of the fibroids. There are no adequate or well-controlled studies that demonstrate the effectiveness of clomiphene citrate in the treatment of male infertility. In addition, testicular tumors and gynecomastia have been reported in males using clomiphene. The cause and effect relationship between reports of testicular tumors and the administration of clomiphene citrate is not known. Although the medical literature suggests various methods, there is no universally accepted standard regimen for combined therapy (i.e., clomiphene citrate in conjunction with other ovulation-inducing drugs). Similarly, there is no standard clomiphene citrate regimen for ovulation induction in vitro fertilization programs to produce ova for fertilization and reintroduction. Therefore, clomiphene citrate is not recommended for these uses. uuid:499cbdad-7a13-49f4-8e41-869c240bf2f6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3752 biolink:treats MONDO:0003240 PMID:41385096 "[{""id"":""uuid:bb6cb42f-668f-4fab-91cd-8176939a2cc7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:79c53613-ac5c-4f92-8421-812e744df8ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clomiphene citrate is indicated for the treatment of ovulatory dysfunction in women desiring pregnancy. Impediments to achieving pregnancy must be excluded or adequately treated before beginning clomiphene citrate therapy. Those patients most likely to achieve success with clomiphene therapy include patients with polycystic ovary syndrome (see WARNINGS : Ovarian Hyperstimulation Syndrome ), amenorrhea-galactorrhea syndrome, psychogenic amenorrhea, post-oral-contraceptive amenorrhea, and certain cases of secondary amenorrhea of undetermined etiology. Properly timed coitus in relationship to ovulation is important. A basal body temperature graph or other appropriate tests may help the patient and her physician determine if ovulation occurred. Once ovulation has been established, each course of clomiphene citrate should be started on or about the 5th day of the cycle. Long-term cyclic therapy is not recommended beyond a total of about six cycles (including three ovulatory cycles). (See DOSAGE AND ADMINISTRATION and PRECAUTIONS .) Clomiphene citrate is indicated only in patients with demonstrated ovulatory dysfunction who meet the conditions described below (see CONTRAINDICATIONS ): Patients who are not pregnant. Patients without ovarian cysts. Clomiphene citrate should not be used in patients with ovarian enlargement except those with polycystic ovary syndrome. Pelvic examination is necessary prior to the first and each subsequent course of clomiphene citrate treatment. Patients without abnormal vaginal bleeding. If abnormal vaginal bleeding is present, the patient should be carefully evaluated to ensure that neoplastic lesions are not present. Patients with normal liver function. In addition, patients selected for clomiphene citrate therapy should be evaluated in regard to the following: Estrogen Levels. Patients should have adequate levels of endogenous estrogen (as estimated from vaginal smears, endometrial biopsy, assay of urinary estrogen, or from bleeding in response to progesterone). Reduced estrogen levels, while less favorable, do not preclude successful therapy. Primary Pituitary or Ovarian Failure. Clomiphene citrate therapy cannot be expected to substitute for specific treatment of other causes of ovulatory failure. Endometriosis and Endometrial Carcinoma. The incidence of endometriosis and endometrial carcinoma increases with age as does the incidence of ovulatory disorders. Endometrial biopsy should always be performed prior to clomiphene citrate therapy in this population. Other Impediments to Pregnancy. Impediments to pregnancy can include thyroid disorders, adrenal disorders, hyperprolactinemia, and male factor infertility. Uterine Fibroids. Caution should be exercised when using clomiphene citrate in patients with uterine fibroids due to the potential for further enlargement of the fibroids. There are no adequate or well-controlled studies that demonstrate the effectiveness of clomiphene citrate in the treatment of male infertility. In addition, testicular tumors and gynecomastia have been reported in males using clomiphene. The cause and effect relationship between reports of testicular tumors and the administration of clomiphene citrate is not known. Although the medical literature suggests various methods, there is no universally accepted standard regimen for combined therapy (i.e., clomiphene citrate in conjunction with other ovulation-inducing drugs). Similarly, there is no standard clomiphene citrate regimen for ovulation induction in vitro fertilization programs to produce ova for fertilization and reintroduction. Therefore, clomiphene citrate is not recommended for these uses. uuid:882a1e4d-5679-426b-97ec-d952e81bc8a9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3752 biolink:treats MONDO:0005495 PMID:41385096 "[{""id"":""uuid:1073260b-f7cb-4c35-b858-41384b054db6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:81e511fa-70fb-499e-85eb-ac5d9a165c6d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clomiphene citrate is indicated for the treatment of ovulatory dysfunction in women desiring pregnancy. Impediments to achieving pregnancy must be excluded or adequately treated before beginning clomiphene citrate therapy. Those patients most likely to achieve success with clomiphene therapy include patients with polycystic ovary syndrome (see WARNINGS : Ovarian Hyperstimulation Syndrome ), amenorrhea-galactorrhea syndrome, psychogenic amenorrhea, post-oral-contraceptive amenorrhea, and certain cases of secondary amenorrhea of undetermined etiology. Properly timed coitus in relationship to ovulation is important. A basal body temperature graph or other appropriate tests may help the patient and her physician determine if ovulation occurred. Once ovulation has been established, each course of clomiphene citrate should be started on or about the 5th day of the cycle. Long-term cyclic therapy is not recommended beyond a total of about six cycles (including three ovulatory cycles). (See DOSAGE AND ADMINISTRATION and PRECAUTIONS .) Clomiphene citrate is indicated only in patients with demonstrated ovulatory dysfunction who meet the conditions described below (see CONTRAINDICATIONS ): Patients who are not pregnant. Patients without ovarian cysts. Clomiphene citrate should not be used in patients with ovarian enlargement except those with polycystic ovary syndrome. Pelvic examination is necessary prior to the first and each subsequent course of clomiphene citrate treatment. Patients without abnormal vaginal bleeding. If abnormal vaginal bleeding is present, the patient should be carefully evaluated to ensure that neoplastic lesions are not present. Patients with normal liver function. In addition, patients selected for clomiphene citrate therapy should be evaluated in regard to the following: Estrogen Levels. Patients should have adequate levels of endogenous estrogen (as estimated from vaginal smears, endometrial biopsy, assay of urinary estrogen, or from bleeding in response to progesterone). Reduced estrogen levels, while less favorable, do not preclude successful therapy. Primary Pituitary or Ovarian Failure. Clomiphene citrate therapy cannot be expected to substitute for specific treatment of other causes of ovulatory failure. Endometriosis and Endometrial Carcinoma. The incidence of endometriosis and endometrial carcinoma increases with age as does the incidence of ovulatory disorders. Endometrial biopsy should always be performed prior to clomiphene citrate therapy in this population. Other Impediments to Pregnancy. Impediments to pregnancy can include thyroid disorders, adrenal disorders, hyperprolactinemia, and male factor infertility. Uterine Fibroids. Caution should be exercised when using clomiphene citrate in patients with uterine fibroids due to the potential for further enlargement of the fibroids. There are no adequate or well-controlled studies that demonstrate the effectiveness of clomiphene citrate in the treatment of male infertility. In addition, testicular tumors and gynecomastia have been reported in males using clomiphene. The cause and effect relationship between reports of testicular tumors and the administration of clomiphene citrate is not known. Although the medical literature suggests various methods, there is no universally accepted standard regimen for combined therapy (i.e., clomiphene citrate in conjunction with other ovulation-inducing drugs). Similarly, there is no standard clomiphene citrate regimen for ovulation induction in vitro fertilization programs to produce ova for fertilization and reintroduction. Therefore, clomiphene citrate is not recommended for these uses. uuid:8952e5c6-781b-4db1-9acc-6eb815280a3e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3752 biolink:treats MONDO:0005804 PMID:41385096 "[{""id"":""uuid:fe14dab0-a7ad-4120-92aa-026504280429"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5f3b4e9c-70a1-4c1a-81c4-83b417267507"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clomiphene citrate is indicated for the treatment of ovulatory dysfunction in women desiring pregnancy. Impediments to achieving pregnancy must be excluded or adequately treated before beginning clomiphene citrate therapy. Those patients most likely to achieve success with clomiphene therapy include patients with polycystic ovary syndrome (see WARNINGS : Ovarian Hyperstimulation Syndrome ), amenorrhea-galactorrhea syndrome, psychogenic amenorrhea, post-oral-contraceptive amenorrhea, and certain cases of secondary amenorrhea of undetermined etiology. Properly timed coitus in relationship to ovulation is important. A basal body temperature graph or other appropriate tests may help the patient and her physician determine if ovulation occurred. Once ovulation has been established, each course of clomiphene citrate should be started on or about the 5th day of the cycle. Long-term cyclic therapy is not recommended beyond a total of about six cycles (including three ovulatory cycles). (See DOSAGE AND ADMINISTRATION and PRECAUTIONS .) Clomiphene citrate is indicated only in patients with demonstrated ovulatory dysfunction who meet the conditions described below (see CONTRAINDICATIONS ): Patients who are not pregnant. Patients without ovarian cysts. Clomiphene citrate should not be used in patients with ovarian enlargement except those with polycystic ovary syndrome. Pelvic examination is necessary prior to the first and each subsequent course of clomiphene citrate treatment. Patients without abnormal vaginal bleeding. If abnormal vaginal bleeding is present, the patient should be carefully evaluated to ensure that neoplastic lesions are not present. Patients with normal liver function. In addition, patients selected for clomiphene citrate therapy should be evaluated in regard to the following: Estrogen Levels. Patients should have adequate levels of endogenous estrogen (as estimated from vaginal smears, endometrial biopsy, assay of urinary estrogen, or from bleeding in response to progesterone). Reduced estrogen levels, while less favorable, do not preclude successful therapy. Primary Pituitary or Ovarian Failure. Clomiphene citrate therapy cannot be expected to substitute for specific treatment of other causes of ovulatory failure. Endometriosis and Endometrial Carcinoma. The incidence of endometriosis and endometrial carcinoma increases with age as does the incidence of ovulatory disorders. Endometrial biopsy should always be performed prior to clomiphene citrate therapy in this population. Other Impediments to Pregnancy. Impediments to pregnancy can include thyroid disorders, adrenal disorders, hyperprolactinemia, and male factor infertility. Uterine Fibroids. Caution should be exercised when using clomiphene citrate in patients with uterine fibroids due to the potential for further enlargement of the fibroids. There are no adequate or well-controlled studies that demonstrate the effectiveness of clomiphene citrate in the treatment of male infertility. In addition, testicular tumors and gynecomastia have been reported in males using clomiphene. The cause and effect relationship between reports of testicular tumors and the administration of clomiphene citrate is not known. Although the medical literature suggests various methods, there is no universally accepted standard regimen for combined therapy (i.e., clomiphene citrate in conjunction with other ovulation-inducing drugs). Similarly, there is no standard clomiphene citrate regimen for ovulation induction in vitro fertilization programs to produce ova for fertilization and reintroduction. Therefore, clomiphene citrate is not recommended for these uses. uuid:3b67e3ba-3f0e-4c9a-bc69-dacc4b127c4e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3752 biolink:treats MONDO:0005372 PMID:41385096 "[{""id"":""uuid:f2381df7-ab7d-4220-aebd-b92e6a6ba86c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:05e894fc-efd6-4cf4-8cd9-5094ae15aa03"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clomiphene citrate is indicated for the treatment of ovulatory dysfunction in women desiring pregnancy. Impediments to achieving pregnancy must be excluded or adequately treated before beginning clomiphene citrate therapy. Those patients most likely to achieve success with clomiphene therapy include patients with polycystic ovary syndrome (see WARNINGS : Ovarian Hyperstimulation Syndrome ), amenorrhea-galactorrhea syndrome, psychogenic amenorrhea, post-oral-contraceptive amenorrhea, and certain cases of secondary amenorrhea of undetermined etiology. Properly timed coitus in relationship to ovulation is important. A basal body temperature graph or other appropriate tests may help the patient and her physician determine if ovulation occurred. Once ovulation has been established, each course of clomiphene citrate should be started on or about the 5th day of the cycle. Long-term cyclic therapy is not recommended beyond a total of about six cycles (including three ovulatory cycles). (See DOSAGE AND ADMINISTRATION and PRECAUTIONS .) Clomiphene citrate is indicated only in patients with demonstrated ovulatory dysfunction who meet the conditions described below (see CONTRAINDICATIONS ): Patients who are not pregnant. Patients without ovarian cysts. Clomiphene citrate should not be used in patients with ovarian enlargement except those with polycystic ovary syndrome. Pelvic examination is necessary prior to the first and each subsequent course of clomiphene citrate treatment. Patients without abnormal vaginal bleeding. If abnormal vaginal bleeding is present, the patient should be carefully evaluated to ensure that neoplastic lesions are not present. Patients with normal liver function. In addition, patients selected for clomiphene citrate therapy should be evaluated in regard to the following: Estrogen Levels. Patients should have adequate levels of endogenous estrogen (as estimated from vaginal smears, endometrial biopsy, assay of urinary estrogen, or from bleeding in response to progesterone). Reduced estrogen levels, while less favorable, do not preclude successful therapy. Primary Pituitary or Ovarian Failure. Clomiphene citrate therapy cannot be expected to substitute for specific treatment of other causes of ovulatory failure. Endometriosis and Endometrial Carcinoma. The incidence of endometriosis and endometrial carcinoma increases with age as does the incidence of ovulatory disorders. Endometrial biopsy should always be performed prior to clomiphene citrate therapy in this population. Other Impediments to Pregnancy. Impediments to pregnancy can include thyroid disorders, adrenal disorders, hyperprolactinemia, and male factor infertility. Uterine Fibroids. Caution should be exercised when using clomiphene citrate in patients with uterine fibroids due to the potential for further enlargement of the fibroids. There are no adequate or well-controlled studies that demonstrate the effectiveness of clomiphene citrate in the treatment of male infertility. In addition, testicular tumors and gynecomastia have been reported in males using clomiphene. The cause and effect relationship between reports of testicular tumors and the administration of clomiphene citrate is not known. Although the medical literature suggests various methods, there is no universally accepted standard regimen for combined therapy (i.e., clomiphene citrate in conjunction with other ovulation-inducing drugs). Similarly, there is no standard clomiphene citrate regimen for ovulation induction in vitro fertilization programs to produce ova for fertilization and reintroduction. Therefore, clomiphene citrate is not recommended for these uses. uuid:99962185-489a-402b-8910-8069fa0939aa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1163424 biolink:treats MONDO:0004795 PMID:41385096 "[{""id"":""uuid:07ea65e0-ebf2-4ed1-ab10-8fa323c0805f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0ee2c11d-2917-4a29-9722-11b5f0a35b8b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the treatment of superficial bacterial infections of the external auditory canal caused by organisms susceptible to the action of the antibiotics, and for the treatment of infections of mastoidectomy and fenestration cavities caused by organisms susceptible to the antibiotics. uuid:3f3f6d76-4093-4191-9c98-80e7976e9914 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1163424 biolink:treats MONDO:0021666 PMID:41385096 "[{""id"":""uuid:74d26dc9-952e-4335-a988-b210090f59fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6d427a16-08bd-4e83-b23e-8c4304ad2583"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the treatment of superficial bacterial infections of the external auditory canal caused by organisms susceptible to the action of the antibiotics, and for the treatment of infections of mastoidectomy and fenestration cavities caused by organisms susceptible to the antibiotics. uuid:5e922fc1-cadd-431b-9ef7-a134d453f07f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47381 biolink:treats HP:0000613 PMID:41385096 "[{""id"":""uuid:a2d3171c-da84-4142-ad0a-abf3cd3980cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7b2089a2-ac83-4ba8-a945-e90bb7cc7630"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diclofenac Sodium Ophthalmic is indicated for the treatment of postoperative inflammation in patients who have undergone cataract extraction and for the temporary relief of pain and photophobia in patients undergoing corneal refractive surgery. uuid:2f9b24c9-3cbe-4812-bb8e-914a9d3140b7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:151392 biolink:treats HP:0000371 PMID:41385096 "[{""id"":""uuid:fa67d7f7-2b52-427c-975d-49e2e85fecff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ee7b6c43-5783-4605-8bec-5df4dfb8f7bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amoxicillin and Clavulanate Potassium for Oral Suspension USP, 600 mg/5 mL is indicated for the treatment of pediatric patients with recurrent or persistent acute otitis media due to S. pneumoniae (penicillin MICs ≤ 2 mcg/mL), H. influenzae (including β-lactamase-producing strains), or M. catarrhalis (including β-lactamase-producing strains) characterized by the following risk factors: • antibiotic exposure for acute otitis media within the preceding 3 months, and either of the following: - age ≤ 2 years - daycare attendance [See CLINICAL PHARMACOLOGY , Microbiology .] NOTE: Acute otitis media due to S. pneumoniae alone can be treated with amoxicillin. Amoxicillin and Clavulanate Potassium for Oral Suspension is not indicated for the treatment of acute otitis media due to S. pneumoniae with penicillin MIC ≥ 4 mcg /mL. Therapy may be instituted prior to obtaining the results from bacteriological studies when there is reason to believe the infection may involve both S. pneumoniae (penicillin MIC ≤ 2 mcg/mL) and the β-lactamase-producing organisms listed above. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Amoxicillin and Clavulanate Potassium for Oral Suspension 600 mg/42.9 mg per 5 mL and other antibacterial drugs, Amoxicillin and Clavulanate Potassium for Oral Suspension 600 mg/42.9 mg per 5 mL should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:1d9b76cf-a6b2-4dce-817b-b77ebb627b60 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:308714 biolink:treats UMLS:C0276733 PMID:41385096 "[{""id"":""uuid:ae6ad692-28a3-4ae0-8bec-9aecd15b0d07"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:df4eeff2-a64c-4972-abdf-c02b93d87d0f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clotrimazole and Betamethasone Dipropionate Cream and Lotion are indicated in patients 17 years and older for the topical treatment of symptomatic inflammatory tinea pedis, tinea cruris, and tinea corporis due to Epidermophyton floccosum, Trichophyton mentagrophytes and Trichophyton rubrum. Effective treatment without the risks associated with topical corticosteroid use may be obtained using a topical antifungal agent that does not contain a corticosteroid, especially for noninflammatory tinea infections. The efficacy of Clotrimazole and Betamethasone Dipropionate Cream or Lotion for the treatment of infections caused by zoophilic dermatophytes (e.g. Microsporum canis ) has not been established. Several cases of treatment failure of Clotrimazole and Betamethasone Dipropionate Cream, USP in the treatment of infections caused by Microsporum canis have been reported. uuid:d3ca8212-6f7b-47ab-824f-b3dbda8f2748 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6970 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:c6fef69a-2001-4174-a4d9-fa504686187c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ff2160a5-1ee7-4b2a-89ce-d9d6a256d31d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ASMANEX TWISTHALER is a corticosteroid indicated for: Maintenance treatment of asthma as prophylactic therapy in patients 4 years of age and older. ( 1.1 ) ASMANEX TWISTHALER is NOT indicated for the relief of acute bronchospasm ( 1.1 , 5.2 ) or in children less than 4 years of age ( 1.1 , 8.4 ). uuid:de559c22-0958-4650-bc42-d11df4eb34ed biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:84500 biolink:treats MONDO:0008575 PMID:41385096 "[{""id"":""uuid:2e91fd00-4306-4682-bc6c-409f043d38fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d3e94689-ac46-4e01-9317-bfa8b80365d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:81371cfd-dc64-4c8b-985b-7368b823efcf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CHANTIX is indicated for use as an aid to smoking cessation treatment.|[PMDA] Drugs containing a new active ingredient indicated as a smoking-cessation aid for nicotine-dependent smokers. Expedited review. uuid:d84c1ce1-9b6f-4c1f-9a52-ad777c1dee46 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5855 biolink:treats HP:0001945 PMID:41385096 "[{""id"":""uuid:8146007e-e4bf-4b94-95a0-e4fd0ceba629"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:13e493c7-60c3-4114-a1b4-5aa70604d17e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of ibuprofen suspension and other treatment options before deciding to use ibuprofen suspension. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). In Pediatric Patients , ibuprofen suspension is indicated: For reduction of fever in patients aged 6 months up to 2 years of age. For relief of mild to moderate pain in patients aged 6 months up to 2 years of age. For relief of signs and symptoms of juvenile arthritis. In Adults , ibuprofen is indicated: For treatment of primary dysmenorrhea. For relief of the signs and symptoms of rheumatoid arthritis and osteoarthritis. Since there have been no controlled trials to demonstrate whether there is any beneficial effect or harmful interaction with the use of ibuprofen in conjunction with aspirin, the combination cannot be recommended. (See PRECAUTIONS - Drug Interactions ). uuid:095e284c-dcc6-419e-b935-fca176477913 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5855 biolink:treats MONDO:0011429 PMID:41385096 "[{""id"":""uuid:2be806be-2f00-45d9-b619-61ba4b80704d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fa931968-a465-41bf-93a1-ded6e56911b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of ibuprofen suspension and other treatment options before deciding to use ibuprofen suspension. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). In Pediatric Patients , ibuprofen suspension is indicated: For reduction of fever in patients aged 6 months up to 2 years of age. For relief of mild to moderate pain in patients aged 6 months up to 2 years of age. For relief of signs and symptoms of juvenile arthritis. In Adults , ibuprofen is indicated: For treatment of primary dysmenorrhea. For relief of the signs and symptoms of rheumatoid arthritis and osteoarthritis. Since there have been no controlled trials to demonstrate whether there is any beneficial effect or harmful interaction with the use of ibuprofen in conjunction with aspirin, the combination cannot be recommended. (See PRECAUTIONS - Drug Interactions ). uuid:3fed2a16-473c-4ddc-8268-987405e9750b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2955 biolink:treats MONDO:0005866 PMID:41385096 "[{""id"":""uuid:20b5ba88-92b2-49bd-a3f7-3e86785354af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7f737567-293a-4add-8763-2a949fe030cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azithromycin tablets are indicated for the treatment of patients with mild to moderate infections (pneumonia: see WARNINGS) caused by susceptible strains of the designated microorganisms in the specific conditions listed below. Mycobacterial Infections Prophylaxis of Disseminated M ycobacterium avium complex (MAC) Disease Azithromycin tablet, taken alone or in combination with rifabutin at its approved dose, is indicated for the prevention of disseminated Mycobacterium avium complex (MAC) disease in persons with advanced HIV infection. (See DOSAGE AND ADMINISTRATION, CLINICAL STUDIES) Treatment of Disseminated Mycobacterium avium complex (MAC) Disease Azithromycin tablet, taken in combination with ethambutol, is indicated for the treatment of disseminated MAC infections in persons with advanced HIV infection. (See DOSAGE AND ADMINISTRATION, CLINICAL STUDIES) uuid:bdcb02e5-c2bc-4b37-9b14-7df7a922b30d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8774 biolink:treats MONDO:0005010 PMID:41385096 "[{""id"":""uuid:63378eb8-47b5-4223-a611-dec17d26b7d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:67399135-2407-48ed-b02e-484acb870475"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ramipril capsules are indicated in patients 55 years or older at high risk of developing a major cardiovascular event because of a history of coronary artery disease, stroke, peripheral vascular disease, or diabetes that is accompanied by at least one other cardiovascular risk factor (hypertension, elevated total cholesterol levels, low HDL levels, cigarette smoking, or documented microalbuminuria), to reduce the risk of myocardial infarction, stroke, or death from cardiovascular causes. Ramipril capsules can be used in addition to other needed treatment (such as antihypertensive, antiplatelet or lipid-lowering therapy). uuid:191b636e-e2e0-4419-af29-cec51fd549d7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8774 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:428e5726-2dec-4e0d-a288-dd4f6322849a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a583252c-dad4-41e8-a3f8-7eb48d655972"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ramipril capsules are indicated in patients 55 years or older at high risk of developing a major cardiovascular event because of a history of coronary artery disease, stroke, peripheral vascular disease, or diabetes that is accompanied by at least one other cardiovascular risk factor (hypertension, elevated total cholesterol levels, low HDL levels, cigarette smoking, or documented microalbuminuria), to reduce the risk of myocardial infarction, stroke, or death from cardiovascular causes. Ramipril capsules can be used in addition to other needed treatment (such as antihypertensive, antiplatelet or lipid-lowering therapy). uuid:4e860b77-8986-48ab-82b9-2db3ce702c42 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8774 biolink:treats MONDO:0005294 PMID:41385096 "[{""id"":""uuid:f71c4f69-f760-4aa6-8149-86a37e8415b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:103ff602-d009-4a73-a612-4f42d90edd3c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ramipril capsules are indicated in patients 55 years or older at high risk of developing a major cardiovascular event because of a history of coronary artery disease, stroke, peripheral vascular disease, or diabetes that is accompanied by at least one other cardiovascular risk factor (hypertension, elevated total cholesterol levels, low HDL levels, cigarette smoking, or documented microalbuminuria), to reduce the risk of myocardial infarction, stroke, or death from cardiovascular causes. Ramipril capsules can be used in addition to other needed treatment (such as antihypertensive, antiplatelet or lipid-lowering therapy). uuid:fa174445-6130-462d-a969-914101ad1935 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8774 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:ed523af3-146d-4818-9776-f482e66c3d9f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7a90e283-984b-4fab-b4c0-417126c749b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ramipril capsules are indicated in patients 55 years or older at high risk of developing a major cardiovascular event because of a history of coronary artery disease, stroke, peripheral vascular disease, or diabetes that is accompanied by at least one other cardiovascular risk factor (hypertension, elevated total cholesterol levels, low HDL levels, cigarette smoking, or documented microalbuminuria), to reduce the risk of myocardial infarction, stroke, or death from cardiovascular causes. Ramipril capsules can be used in addition to other needed treatment (such as antihypertensive, antiplatelet or lipid-lowering therapy). uuid:324cde57-6df4-486b-9f01-684221066252 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8774 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:5b45f67a-a6a5-47ae-af28-b81645e5280f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ec3bf9b8-5993-4457-992d-6fc9516a1216"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ramipril capsules are indicated in patients 55 years or older at high risk of developing a major cardiovascular event because of a history of coronary artery disease, stroke, peripheral vascular disease, or diabetes that is accompanied by at least one other cardiovascular risk factor (hypertension, elevated total cholesterol levels, low HDL levels, cigarette smoking, or documented microalbuminuria), to reduce the risk of myocardial infarction, stroke, or death from cardiovascular causes. Ramipril capsules can be used in addition to other needed treatment (such as antihypertensive, antiplatelet or lipid-lowering therapy). uuid:52e40a07-f337-418f-ac67-3ed358344ab0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8888 biolink:treats MONDO:0005180 PMID:41385096 "[{""id"":""uuid:2561aee9-2bee-48bd-8d28-cf568a8adf6a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:396af787-4aee-4461-9b0c-11f379511842"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:cec03c48-1cd5-4b5a-9648-eca48c3b0f34"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Parkinson's Disease: Ropinirole hydrochloride tablets are indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease. The effectiveness of ropinirole hydrochloride tablets was demonstrated in randomized, controlled trials in patients with early Parkinson's disease who were not receiving concomitant L-dopa therapy as well as in patients with advanced disease on concomitant L-dopa (see CLINICAL PHARMACOLOGY, Clinical Trials ).|[PMDA] Drugs in new dosage forms and with a new dosage. These drugs are indicated for the treatment of Parkinson's disease. uuid:2584a624-8790-458b-956a-6a5a592b54f1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:53760 biolink:treats MONDO:0013600 PMID:41385096 "[{""id"":""uuid:069bc389-f5af-4cb9-b397-4dd04c8b58cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7924a0e9-f3aa-4236-8390-f055a3c4efa9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c771d0ef-e3d6-42a7-9c42-259ec3cd4887"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LUNESTA is indicated for the treatment of insomnia. In controlled outpatient and sleep laboratory studies, LUNESTA administered at bedtime decreased sleep latency and improved sleep maintenance. The clinical trials performed in support of efficacy were up to 6 months in duration. The final formal assessments of sleep latency and maintenance were performed at 4 weeks in the 6-week study (adults only), at the end of both 2-week studies (elderly only) and at the end of the 6-month study (adults only).|[PMDA] Drugs with a new active ingredient indicated for the treatment of insomnia. uuid:3e5e3415-a03e-4eea-9311-5dcdbf41388b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0007008 PMID:41385096 "[{""id"":""uuid:4c2171da-a4cb-4960-93a6-3e7f308dff64"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:39ea1395-bc5d-4bb1-a512-1bb677638b15"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prednisolone Oral Solution is indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice: synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. In addition to the above indications Prednisolone Oral Solution is indicated for systemic dermatomyositis (polymyositis). uuid:f21bec56-96cd-45b2-942b-f32f92ece05b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27446 biolink:treats MONDO:0021680 PMID:41385096 "[{""id"":""uuid:e9b3ac23-c904-465b-80c1-597a470846e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:96a26673-08e0-444c-85cb-15e78d961292"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin V potassium tablets, penicillin V potassium for oral solution, and other antibacterial drugs, penicillin V potassium tablets and penicillin V potassium for oral solution should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Penicillin V potassium tablets and penicillin V potassium for oral solution are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with penicillin V during the acute stage. Indicated surgical procedures should be performed. The following infections will usually respond to adequate dosage of penicillin V. Streptococcal infections (without bacteremia). Mild-to-moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas. NOTE: Streptococci in groups A, C, G, H, L, and M are very sensitive to penicillin. Other groups, including group D (enterococcus), are resistant. Pneumococcal infections. Mild to moderately severe infections of the respiratory tract. Staphylococcal infections —penicillin G-sensitive. Mild infections of the skin and soft tissues. NOTE: Reports indicate an increasing number of strains of staphylococci resistant to penicillin G, emphasizing the need for culture and sensitivity studies in treating suspected staphylococcal infections. Fusospirochetosis (Vincent's gingivitis and pharyngitis)— Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin. NOTE: Necessary dental care should be accomplished in infections involving the gum tissue. Medical conditions in which oral penicillin therapy is indicated as prophylaxis: For the prevention of recurrence following rheumatic fever and/or chorea: Prophylaxis with oral penicillin on a continuing basis has proven effective in preventing recurrence of these conditions. Although no controlled clinical efficacy studies have been conducted, penicillin V has been suggested by the American Heart Association and the American Dental Association for use as an oral regimen for prophylaxis against bacterial endocarditis in patients who have congenital heart disease or rheumatic or other acquired valvular heart disease when they undergo dental procedures and surgical procedures of the upper respiratory tract. 1 Oral penicillin should not be used in those patients at particularly high risk for endocarditis (e.g., those with prosthetic heart valves or surgically constructed systemic pulmonary shunts). Penicillin V should not be used as adjunctive prophylaxis for genitourinary instrumentation or surgery, lower-intestinal-tract surgery, sigmoidoscopy, and childbirth. Since it may happen that alpha hemolytic streptococci relatively resistant to penicillin may be found when patients are receiving continuous oral penicillin for secondary prevention of rheumatic fever, prophylactic agents other than penicillin may be chosen for these patients and prescribed in addition to their continuous rheumatic fever prophylactic regimen. NOTE: When selecting antibiotics for the prevention of bacterial endocarditis, the physician or dentist should read the full joint statement of the American Heart Association and the American Dental Association. 1 uuid:21dcde8f-c430-4f96-a204-4936c7813306 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27446 biolink:treats MONDO:0005952 PMID:41385096 "[{""id"":""uuid:c628ce6f-d344-48c3-a49b-a9c38af902b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6e45fd7d-caef-47e0-83ca-5e2a20dbab14"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin V potassium tablets, penicillin V potassium for oral solution, and other antibacterial drugs, penicillin V potassium tablets and penicillin V potassium for oral solution should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Penicillin V potassium tablets and penicillin V potassium for oral solution are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with penicillin V during the acute stage. Indicated surgical procedures should be performed. The following infections will usually respond to adequate dosage of penicillin V. Streptococcal infections (without bacteremia). Mild-to-moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas. NOTE: Streptococci in groups A, C, G, H, L, and M are very sensitive to penicillin. Other groups, including group D (enterococcus), are resistant. Pneumococcal infections. Mild to moderately severe infections of the respiratory tract. Staphylococcal infections —penicillin G-sensitive. Mild infections of the skin and soft tissues. NOTE: Reports indicate an increasing number of strains of staphylococci resistant to penicillin G, emphasizing the need for culture and sensitivity studies in treating suspected staphylococcal infections. Fusospirochetosis (Vincent's gingivitis and pharyngitis)— Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin. NOTE: Necessary dental care should be accomplished in infections involving the gum tissue. Medical conditions in which oral penicillin therapy is indicated as prophylaxis: For the prevention of recurrence following rheumatic fever and/or chorea: Prophylaxis with oral penicillin on a continuing basis has proven effective in preventing recurrence of these conditions. Although no controlled clinical efficacy studies have been conducted, penicillin V has been suggested by the American Heart Association and the American Dental Association for use as an oral regimen for prophylaxis against bacterial endocarditis in patients who have congenital heart disease or rheumatic or other acquired valvular heart disease when they undergo dental procedures and surgical procedures of the upper respiratory tract. 1 Oral penicillin should not be used in those patients at particularly high risk for endocarditis (e.g., those with prosthetic heart valves or surgically constructed systemic pulmonary shunts). Penicillin V should not be used as adjunctive prophylaxis for genitourinary instrumentation or surgery, lower-intestinal-tract surgery, sigmoidoscopy, and childbirth. Since it may happen that alpha hemolytic streptococci relatively resistant to penicillin may be found when patients are receiving continuous oral penicillin for secondary prevention of rheumatic fever, prophylactic agents other than penicillin may be chosen for these patients and prescribed in addition to their continuous rheumatic fever prophylactic regimen. NOTE: When selecting antibiotics for the prevention of bacterial endocarditis, the physician or dentist should read the full joint statement of the American Heart Association and the American Dental Association. 1 uuid:dff4f75b-f1dd-46a2-92a1-33855ea0185c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27446 biolink:treats MONDO:0001266 PMID:41385096 "[{""id"":""uuid:b5552682-ad73-4704-89e4-d5152e73af75"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:56ab0778-aef5-4532-b28c-debbe5f81629"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin V potassium tablets, penicillin V potassium for oral solution, and other antibacterial drugs, penicillin V potassium tablets and penicillin V potassium for oral solution should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Penicillin V potassium tablets and penicillin V potassium for oral solution are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with penicillin V during the acute stage. Indicated surgical procedures should be performed. The following infections will usually respond to adequate dosage of penicillin V. Streptococcal infections (without bacteremia). Mild-to-moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas. NOTE: Streptococci in groups A, C, G, H, L, and M are very sensitive to penicillin. Other groups, including group D (enterococcus), are resistant. Pneumococcal infections. Mild to moderately severe infections of the respiratory tract. Staphylococcal infections —penicillin G-sensitive. Mild infections of the skin and soft tissues. NOTE: Reports indicate an increasing number of strains of staphylococci resistant to penicillin G, emphasizing the need for culture and sensitivity studies in treating suspected staphylococcal infections. Fusospirochetosis (Vincent's gingivitis and pharyngitis)— Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin. NOTE: Necessary dental care should be accomplished in infections involving the gum tissue. Medical conditions in which oral penicillin therapy is indicated as prophylaxis: For the prevention of recurrence following rheumatic fever and/or chorea: Prophylaxis with oral penicillin on a continuing basis has proven effective in preventing recurrence of these conditions. Although no controlled clinical efficacy studies have been conducted, penicillin V has been suggested by the American Heart Association and the American Dental Association for use as an oral regimen for prophylaxis against bacterial endocarditis in patients who have congenital heart disease or rheumatic or other acquired valvular heart disease when they undergo dental procedures and surgical procedures of the upper respiratory tract. 1 Oral penicillin should not be used in those patients at particularly high risk for endocarditis (e.g., those with prosthetic heart valves or surgically constructed systemic pulmonary shunts). Penicillin V should not be used as adjunctive prophylaxis for genitourinary instrumentation or surgery, lower-intestinal-tract surgery, sigmoidoscopy, and childbirth. Since it may happen that alpha hemolytic streptococci relatively resistant to penicillin may be found when patients are receiving continuous oral penicillin for secondary prevention of rheumatic fever, prophylactic agents other than penicillin may be chosen for these patients and prescribed in addition to their continuous rheumatic fever prophylactic regimen. NOTE: When selecting antibiotics for the prevention of bacterial endocarditis, the physician or dentist should read the full joint statement of the American Heart Association and the American Dental Association. 1 uuid:6c569088-cf70-456e-ab47-7c0be40b0e1b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27446 biolink:treats MONDO:0005114 PMID:41385096 "[{""id"":""uuid:6d75e42f-c371-4029-9c36-0e1bfbf2ff23"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c7763aeb-24b5-4c96-b3e5-b643545f3991"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin V potassium tablets, penicillin V potassium for oral solution, and other antibacterial drugs, penicillin V potassium tablets and penicillin V potassium for oral solution should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Penicillin V potassium tablets and penicillin V potassium for oral solution are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with penicillin V during the acute stage. Indicated surgical procedures should be performed. The following infections will usually respond to adequate dosage of penicillin V. Streptococcal infections (without bacteremia). Mild-to-moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas. NOTE: Streptococci in groups A, C, G, H, L, and M are very sensitive to penicillin. Other groups, including group D (enterococcus), are resistant. Pneumococcal infections. Mild to moderately severe infections of the respiratory tract. Staphylococcal infections —penicillin G-sensitive. Mild infections of the skin and soft tissues. NOTE: Reports indicate an increasing number of strains of staphylococci resistant to penicillin G, emphasizing the need for culture and sensitivity studies in treating suspected staphylococcal infections. Fusospirochetosis (Vincent's gingivitis and pharyngitis)— Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin. NOTE: Necessary dental care should be accomplished in infections involving the gum tissue. Medical conditions in which oral penicillin therapy is indicated as prophylaxis: For the prevention of recurrence following rheumatic fever and/or chorea: Prophylaxis with oral penicillin on a continuing basis has proven effective in preventing recurrence of these conditions. Although no controlled clinical efficacy studies have been conducted, penicillin V has been suggested by the American Heart Association and the American Dental Association for use as an oral regimen for prophylaxis against bacterial endocarditis in patients who have congenital heart disease or rheumatic or other acquired valvular heart disease when they undergo dental procedures and surgical procedures of the upper respiratory tract. 1 Oral penicillin should not be used in those patients at particularly high risk for endocarditis (e.g., those with prosthetic heart valves or surgically constructed systemic pulmonary shunts). Penicillin V should not be used as adjunctive prophylaxis for genitourinary instrumentation or surgery, lower-intestinal-tract surgery, sigmoidoscopy, and childbirth. Since it may happen that alpha hemolytic streptococci relatively resistant to penicillin may be found when patients are receiving continuous oral penicillin for secondary prevention of rheumatic fever, prophylactic agents other than penicillin may be chosen for these patients and prescribed in addition to their continuous rheumatic fever prophylactic regimen. NOTE: When selecting antibiotics for the prevention of bacterial endocarditis, the physician or dentist should read the full joint statement of the American Heart Association and the American Dental Association. 1 uuid:c888232e-a8bc-4b8f-bd56-2f7a6bed4752 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27446 biolink:treats MONDO:0024313 PMID:41385096 "[{""id"":""uuid:2a371995-8dfd-4f1a-9eff-b51fa65739bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:45862d04-e2cf-4626-9c62-b1a338699a63"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin V potassium tablets, penicillin V potassium for oral solution, and other antibacterial drugs, penicillin V potassium tablets and penicillin V potassium for oral solution should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Penicillin V potassium tablets and penicillin V potassium for oral solution are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with penicillin V during the acute stage. Indicated surgical procedures should be performed. The following infections will usually respond to adequate dosage of penicillin V. Streptococcal infections (without bacteremia). Mild-to-moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas. NOTE: Streptococci in groups A, C, G, H, L, and M are very sensitive to penicillin. Other groups, including group D (enterococcus), are resistant. Pneumococcal infections. Mild to moderately severe infections of the respiratory tract. Staphylococcal infections —penicillin G-sensitive. Mild infections of the skin and soft tissues. NOTE: Reports indicate an increasing number of strains of staphylococci resistant to penicillin G, emphasizing the need for culture and sensitivity studies in treating suspected staphylococcal infections. Fusospirochetosis (Vincent's gingivitis and pharyngitis)— Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin. NOTE: Necessary dental care should be accomplished in infections involving the gum tissue. Medical conditions in which oral penicillin therapy is indicated as prophylaxis: For the prevention of recurrence following rheumatic fever and/or chorea: Prophylaxis with oral penicillin on a continuing basis has proven effective in preventing recurrence of these conditions. Although no controlled clinical efficacy studies have been conducted, penicillin V has been suggested by the American Heart Association and the American Dental Association for use as an oral regimen for prophylaxis against bacterial endocarditis in patients who have congenital heart disease or rheumatic or other acquired valvular heart disease when they undergo dental procedures and surgical procedures of the upper respiratory tract. 1 Oral penicillin should not be used in those patients at particularly high risk for endocarditis (e.g., those with prosthetic heart valves or surgically constructed systemic pulmonary shunts). Penicillin V should not be used as adjunctive prophylaxis for genitourinary instrumentation or surgery, lower-intestinal-tract surgery, sigmoidoscopy, and childbirth. Since it may happen that alpha hemolytic streptococci relatively resistant to penicillin may be found when patients are receiving continuous oral penicillin for secondary prevention of rheumatic fever, prophylactic agents other than penicillin may be chosen for these patients and prescribed in addition to their continuous rheumatic fever prophylactic regimen. NOTE: When selecting antibiotics for the prevention of bacterial endocarditis, the physician or dentist should read the full joint statement of the American Heart Association and the American Dental Association. 1 uuid:dd0017d1-4bcf-496b-ab20-7b4034344362 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27446 biolink:treats MONDO:0006865 PMID:41385096 "[{""id"":""uuid:edb6cf75-de19-4c41-9a8b-2a3d6279e9f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d98d3b7b-d860-4064-af0f-e277964f9963"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin V potassium tablets, penicillin V potassium for oral solution, and other antibacterial drugs, penicillin V potassium tablets and penicillin V potassium for oral solution should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Penicillin V potassium tablets and penicillin V potassium for oral solution are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with penicillin V during the acute stage. Indicated surgical procedures should be performed. The following infections will usually respond to adequate dosage of penicillin V. Streptococcal infections (without bacteremia). Mild-to-moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas. NOTE: Streptococci in groups A, C, G, H, L, and M are very sensitive to penicillin. Other groups, including group D (enterococcus), are resistant. Pneumococcal infections. Mild to moderately severe infections of the respiratory tract. Staphylococcal infections —penicillin G-sensitive. Mild infections of the skin and soft tissues. NOTE: Reports indicate an increasing number of strains of staphylococci resistant to penicillin G, emphasizing the need for culture and sensitivity studies in treating suspected staphylococcal infections. Fusospirochetosis (Vincent's gingivitis and pharyngitis)— Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin. NOTE: Necessary dental care should be accomplished in infections involving the gum tissue. Medical conditions in which oral penicillin therapy is indicated as prophylaxis: For the prevention of recurrence following rheumatic fever and/or chorea: Prophylaxis with oral penicillin on a continuing basis has proven effective in preventing recurrence of these conditions. Although no controlled clinical efficacy studies have been conducted, penicillin V has been suggested by the American Heart Association and the American Dental Association for use as an oral regimen for prophylaxis against bacterial endocarditis in patients who have congenital heart disease or rheumatic or other acquired valvular heart disease when they undergo dental procedures and surgical procedures of the upper respiratory tract. 1 Oral penicillin should not be used in those patients at particularly high risk for endocarditis (e.g., those with prosthetic heart valves or surgically constructed systemic pulmonary shunts). Penicillin V should not be used as adjunctive prophylaxis for genitourinary instrumentation or surgery, lower-intestinal-tract surgery, sigmoidoscopy, and childbirth. Since it may happen that alpha hemolytic streptococci relatively resistant to penicillin may be found when patients are receiving continuous oral penicillin for secondary prevention of rheumatic fever, prophylactic agents other than penicillin may be chosen for these patients and prescribed in addition to their continuous rheumatic fever prophylactic regimen. NOTE: When selecting antibiotics for the prevention of bacterial endocarditis, the physician or dentist should read the full joint statement of the American Heart Association and the American Dental Association. 1 uuid:7a19ba5c-8faa-4649-81b6-3f64fa716858 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27446 biolink:treats MONDO:0002258 PMID:41385096 "[{""id"":""uuid:75e85898-0c0d-4e0e-a460-ed1214143bcf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6aac5a85-d086-4332-a54d-fa467b2f458e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin V potassium tablets, penicillin V potassium for oral solution, and other antibacterial drugs, penicillin V potassium tablets and penicillin V potassium for oral solution should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Penicillin V potassium tablets and penicillin V potassium for oral solution are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with penicillin V during the acute stage. Indicated surgical procedures should be performed. The following infections will usually respond to adequate dosage of penicillin V. Streptococcal infections (without bacteremia). Mild-to-moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas. NOTE: Streptococci in groups A, C, G, H, L, and M are very sensitive to penicillin. Other groups, including group D (enterococcus), are resistant. Pneumococcal infections. Mild to moderately severe infections of the respiratory tract. Staphylococcal infections —penicillin G-sensitive. Mild infections of the skin and soft tissues. NOTE: Reports indicate an increasing number of strains of staphylococci resistant to penicillin G, emphasizing the need for culture and sensitivity studies in treating suspected staphylococcal infections. Fusospirochetosis (Vincent's gingivitis and pharyngitis)— Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin. NOTE: Necessary dental care should be accomplished in infections involving the gum tissue. Medical conditions in which oral penicillin therapy is indicated as prophylaxis: For the prevention of recurrence following rheumatic fever and/or chorea: Prophylaxis with oral penicillin on a continuing basis has proven effective in preventing recurrence of these conditions. Although no controlled clinical efficacy studies have been conducted, penicillin V has been suggested by the American Heart Association and the American Dental Association for use as an oral regimen for prophylaxis against bacterial endocarditis in patients who have congenital heart disease or rheumatic or other acquired valvular heart disease when they undergo dental procedures and surgical procedures of the upper respiratory tract. 1 Oral penicillin should not be used in those patients at particularly high risk for endocarditis (e.g., those with prosthetic heart valves or surgically constructed systemic pulmonary shunts). Penicillin V should not be used as adjunctive prophylaxis for genitourinary instrumentation or surgery, lower-intestinal-tract surgery, sigmoidoscopy, and childbirth. Since it may happen that alpha hemolytic streptococci relatively resistant to penicillin may be found when patients are receiving continuous oral penicillin for secondary prevention of rheumatic fever, prophylactic agents other than penicillin may be chosen for these patients and prescribed in addition to their continuous rheumatic fever prophylactic regimen. NOTE: When selecting antibiotics for the prevention of bacterial endocarditis, the physician or dentist should read the full joint statement of the American Heart Association and the American Dental Association. 1 uuid:ad3a25ad-c861-4dcc-a8d3-26d07e6c5fe5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27446 biolink:treats MONDO:0017767 PMID:41385096 "[{""id"":""uuid:9f5e9ad8-dc23-470a-a14f-b6284c3a605b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d138d1e2-add6-42f2-9bf3-62756eeed40f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin V potassium tablets, penicillin V potassium for oral solution, and other antibacterial drugs, penicillin V potassium tablets and penicillin V potassium for oral solution should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Penicillin V potassium tablets and penicillin V potassium for oral solution are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with penicillin V during the acute stage. Indicated surgical procedures should be performed. The following infections will usually respond to adequate dosage of penicillin V. Streptococcal infections (without bacteremia). Mild-to-moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas. NOTE: Streptococci in groups A, C, G, H, L, and M are very sensitive to penicillin. Other groups, including group D (enterococcus), are resistant. Pneumococcal infections. Mild to moderately severe infections of the respiratory tract. Staphylococcal infections —penicillin G-sensitive. Mild infections of the skin and soft tissues. NOTE: Reports indicate an increasing number of strains of staphylococci resistant to penicillin G, emphasizing the need for culture and sensitivity studies in treating suspected staphylococcal infections. Fusospirochetosis (Vincent's gingivitis and pharyngitis)— Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin. NOTE: Necessary dental care should be accomplished in infections involving the gum tissue. Medical conditions in which oral penicillin therapy is indicated as prophylaxis: For the prevention of recurrence following rheumatic fever and/or chorea: Prophylaxis with oral penicillin on a continuing basis has proven effective in preventing recurrence of these conditions. Although no controlled clinical efficacy studies have been conducted, penicillin V has been suggested by the American Heart Association and the American Dental Association for use as an oral regimen for prophylaxis against bacterial endocarditis in patients who have congenital heart disease or rheumatic or other acquired valvular heart disease when they undergo dental procedures and surgical procedures of the upper respiratory tract. 1 Oral penicillin should not be used in those patients at particularly high risk for endocarditis (e.g., those with prosthetic heart valves or surgically constructed systemic pulmonary shunts). Penicillin V should not be used as adjunctive prophylaxis for genitourinary instrumentation or surgery, lower-intestinal-tract surgery, sigmoidoscopy, and childbirth. Since it may happen that alpha hemolytic streptococci relatively resistant to penicillin may be found when patients are receiving continuous oral penicillin for secondary prevention of rheumatic fever, prophylactic agents other than penicillin may be chosen for these patients and prescribed in addition to their continuous rheumatic fever prophylactic regimen. NOTE: When selecting antibiotics for the prevention of bacterial endocarditis, the physician or dentist should read the full joint statement of the American Heart Association and the American Dental Association. 1 uuid:412ebe5f-1b92-4060-b509-3ca1c61ce519 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27446 biolink:treats MONDO:0001595 PMID:41385096 "[{""id"":""uuid:2c7cced1-c6e5-444d-ae44-2cd8c8086fee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d3d892fe-b62e-4a9f-b6e6-27e038b85ab9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin V potassium tablets, penicillin V potassium for oral solution, and other antibacterial drugs, penicillin V potassium tablets and penicillin V potassium for oral solution should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Penicillin V potassium tablets and penicillin V potassium for oral solution are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with penicillin V during the acute stage. Indicated surgical procedures should be performed. The following infections will usually respond to adequate dosage of penicillin V. Streptococcal infections (without bacteremia). Mild-to-moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas. NOTE: Streptococci in groups A, C, G, H, L, and M are very sensitive to penicillin. Other groups, including group D (enterococcus), are resistant. Pneumococcal infections. Mild to moderately severe infections of the respiratory tract. Staphylococcal infections —penicillin G-sensitive. Mild infections of the skin and soft tissues. NOTE: Reports indicate an increasing number of strains of staphylococci resistant to penicillin G, emphasizing the need for culture and sensitivity studies in treating suspected staphylococcal infections. Fusospirochetosis (Vincent's gingivitis and pharyngitis)— Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin. NOTE: Necessary dental care should be accomplished in infections involving the gum tissue. Medical conditions in which oral penicillin therapy is indicated as prophylaxis: For the prevention of recurrence following rheumatic fever and/or chorea: Prophylaxis with oral penicillin on a continuing basis has proven effective in preventing recurrence of these conditions. Although no controlled clinical efficacy studies have been conducted, penicillin V has been suggested by the American Heart Association and the American Dental Association for use as an oral regimen for prophylaxis against bacterial endocarditis in patients who have congenital heart disease or rheumatic or other acquired valvular heart disease when they undergo dental procedures and surgical procedures of the upper respiratory tract. 1 Oral penicillin should not be used in those patients at particularly high risk for endocarditis (e.g., those with prosthetic heart valves or surgically constructed systemic pulmonary shunts). Penicillin V should not be used as adjunctive prophylaxis for genitourinary instrumentation or surgery, lower-intestinal-tract surgery, sigmoidoscopy, and childbirth. Since it may happen that alpha hemolytic streptococci relatively resistant to penicillin may be found when patients are receiving continuous oral penicillin for secondary prevention of rheumatic fever, prophylactic agents other than penicillin may be chosen for these patients and prescribed in addition to their continuous rheumatic fever prophylactic regimen. NOTE: When selecting antibiotics for the prevention of bacterial endocarditis, the physician or dentist should read the full joint statement of the American Heart Association and the American Dental Association. 1 uuid:26a63193-0438-48ae-a478-de27363acd33 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27446 biolink:treats MONDO:0006669 PMID:41385096 "[{""id"":""uuid:42df6015-bdd3-4b7b-915f-f7d7834f72c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:67452fa0-5c1f-4d50-84cb-938385ea8612"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin V potassium tablets, penicillin V potassium for oral solution, and other antibacterial drugs, penicillin V potassium tablets and penicillin V potassium for oral solution should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Penicillin V potassium tablets and penicillin V potassium for oral solution are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with penicillin V during the acute stage. Indicated surgical procedures should be performed. The following infections will usually respond to adequate dosage of penicillin V. Streptococcal infections (without bacteremia). Mild-to-moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas. NOTE: Streptococci in groups A, C, G, H, L, and M are very sensitive to penicillin. Other groups, including group D (enterococcus), are resistant. Pneumococcal infections. Mild to moderately severe infections of the respiratory tract. Staphylococcal infections —penicillin G-sensitive. Mild infections of the skin and soft tissues. NOTE: Reports indicate an increasing number of strains of staphylococci resistant to penicillin G, emphasizing the need for culture and sensitivity studies in treating suspected staphylococcal infections. Fusospirochetosis (Vincent's gingivitis and pharyngitis)— Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin. NOTE: Necessary dental care should be accomplished in infections involving the gum tissue. Medical conditions in which oral penicillin therapy is indicated as prophylaxis: For the prevention of recurrence following rheumatic fever and/or chorea: Prophylaxis with oral penicillin on a continuing basis has proven effective in preventing recurrence of these conditions. Although no controlled clinical efficacy studies have been conducted, penicillin V has been suggested by the American Heart Association and the American Dental Association for use as an oral regimen for prophylaxis against bacterial endocarditis in patients who have congenital heart disease or rheumatic or other acquired valvular heart disease when they undergo dental procedures and surgical procedures of the upper respiratory tract. 1 Oral penicillin should not be used in those patients at particularly high risk for endocarditis (e.g., those with prosthetic heart valves or surgically constructed systemic pulmonary shunts). Penicillin V should not be used as adjunctive prophylaxis for genitourinary instrumentation or surgery, lower-intestinal-tract surgery, sigmoidoscopy, and childbirth. Since it may happen that alpha hemolytic streptococci relatively resistant to penicillin may be found when patients are receiving continuous oral penicillin for secondary prevention of rheumatic fever, prophylactic agents other than penicillin may be chosen for these patients and prescribed in addition to their continuous rheumatic fever prophylactic regimen. NOTE: When selecting antibiotics for the prevention of bacterial endocarditis, the physician or dentist should read the full joint statement of the American Heart Association and the American Dental Association. 1 uuid:4ebb990f-4e1d-4f57-b285-1b7765805ed1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27446 biolink:treats MONDO:0005453 PMID:41385096 "[{""id"":""uuid:9471742a-6790-4f2d-8cea-819c9f69f1ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6c7e0269-c920-4a56-81d4-59c4c57c3ae1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin V potassium tablets, penicillin V potassium for oral solution, and other antibacterial drugs, penicillin V potassium tablets and penicillin V potassium for oral solution should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Penicillin V potassium tablets and penicillin V potassium for oral solution are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with penicillin V during the acute stage. Indicated surgical procedures should be performed. The following infections will usually respond to adequate dosage of penicillin V. Streptococcal infections (without bacteremia). Mild-to-moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas. NOTE: Streptococci in groups A, C, G, H, L, and M are very sensitive to penicillin. Other groups, including group D (enterococcus), are resistant. Pneumococcal infections. Mild to moderately severe infections of the respiratory tract. Staphylococcal infections —penicillin G-sensitive. Mild infections of the skin and soft tissues. NOTE: Reports indicate an increasing number of strains of staphylococci resistant to penicillin G, emphasizing the need for culture and sensitivity studies in treating suspected staphylococcal infections. Fusospirochetosis (Vincent's gingivitis and pharyngitis)— Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin. NOTE: Necessary dental care should be accomplished in infections involving the gum tissue. Medical conditions in which oral penicillin therapy is indicated as prophylaxis: For the prevention of recurrence following rheumatic fever and/or chorea: Prophylaxis with oral penicillin on a continuing basis has proven effective in preventing recurrence of these conditions. Although no controlled clinical efficacy studies have been conducted, penicillin V has been suggested by the American Heart Association and the American Dental Association for use as an oral regimen for prophylaxis against bacterial endocarditis in patients who have congenital heart disease or rheumatic or other acquired valvular heart disease when they undergo dental procedures and surgical procedures of the upper respiratory tract. 1 Oral penicillin should not be used in those patients at particularly high risk for endocarditis (e.g., those with prosthetic heart valves or surgically constructed systemic pulmonary shunts). Penicillin V should not be used as adjunctive prophylaxis for genitourinary instrumentation or surgery, lower-intestinal-tract surgery, sigmoidoscopy, and childbirth. Since it may happen that alpha hemolytic streptococci relatively resistant to penicillin may be found when patients are receiving continuous oral penicillin for secondary prevention of rheumatic fever, prophylactic agents other than penicillin may be chosen for these patients and prescribed in addition to their continuous rheumatic fever prophylactic regimen. NOTE: When selecting antibiotics for the prevention of bacterial endocarditis, the physician or dentist should read the full joint statement of the American Heart Association and the American Dental Association. 1 uuid:c2925b9b-2e13-467e-a05f-c2161029744f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27446 biolink:treats MONDO:0006955 PMID:41385096 "[{""id"":""uuid:6d5a83d0-41c8-4335-bfd2-ce2acf08910e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6e147e55-2cbf-4557-b0cf-55558fb66bf6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin V potassium tablets, penicillin V potassium for oral solution, and other antibacterial drugs, penicillin V potassium tablets and penicillin V potassium for oral solution should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Penicillin V potassium tablets and penicillin V potassium for oral solution are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with penicillin V during the acute stage. Indicated surgical procedures should be performed. The following infections will usually respond to adequate dosage of penicillin V. Streptococcal infections (without bacteremia). Mild-to-moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas. NOTE: Streptococci in groups A, C, G, H, L, and M are very sensitive to penicillin. Other groups, including group D (enterococcus), are resistant. Pneumococcal infections. Mild to moderately severe infections of the respiratory tract. Staphylococcal infections —penicillin G-sensitive. Mild infections of the skin and soft tissues. NOTE: Reports indicate an increasing number of strains of staphylococci resistant to penicillin G, emphasizing the need for culture and sensitivity studies in treating suspected staphylococcal infections. Fusospirochetosis (Vincent's gingivitis and pharyngitis)— Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin. NOTE: Necessary dental care should be accomplished in infections involving the gum tissue. Medical conditions in which oral penicillin therapy is indicated as prophylaxis: For the prevention of recurrence following rheumatic fever and/or chorea: Prophylaxis with oral penicillin on a continuing basis has proven effective in preventing recurrence of these conditions. Although no controlled clinical efficacy studies have been conducted, penicillin V has been suggested by the American Heart Association and the American Dental Association for use as an oral regimen for prophylaxis against bacterial endocarditis in patients who have congenital heart disease or rheumatic or other acquired valvular heart disease when they undergo dental procedures and surgical procedures of the upper respiratory tract. 1 Oral penicillin should not be used in those patients at particularly high risk for endocarditis (e.g., those with prosthetic heart valves or surgically constructed systemic pulmonary shunts). Penicillin V should not be used as adjunctive prophylaxis for genitourinary instrumentation or surgery, lower-intestinal-tract surgery, sigmoidoscopy, and childbirth. Since it may happen that alpha hemolytic streptococci relatively resistant to penicillin may be found when patients are receiving continuous oral penicillin for secondary prevention of rheumatic fever, prophylactic agents other than penicillin may be chosen for these patients and prescribed in addition to their continuous rheumatic fever prophylactic regimen. NOTE: When selecting antibiotics for the prevention of bacterial endocarditis, the physician or dentist should read the full joint statement of the American Heart Association and the American Dental Association. 1 uuid:525923fa-329b-4f7d-841c-d4b8ee1b099c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27446 biolink:treats MONDO:0002869 PMID:41385096 "[{""id"":""uuid:ba98a969-d3c3-4931-872e-8e9a55751b49"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:da35912d-6092-475b-8d60-8427da5c6e0b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin V potassium tablets, penicillin V potassium for oral solution, and other antibacterial drugs, penicillin V potassium tablets and penicillin V potassium for oral solution should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Penicillin V potassium tablets and penicillin V potassium for oral solution are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with penicillin V during the acute stage. Indicated surgical procedures should be performed. The following infections will usually respond to adequate dosage of penicillin V. Streptococcal infections (without bacteremia). Mild-to-moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas. NOTE: Streptococci in groups A, C, G, H, L, and M are very sensitive to penicillin. Other groups, including group D (enterococcus), are resistant. Pneumococcal infections. Mild to moderately severe infections of the respiratory tract. Staphylococcal infections —penicillin G-sensitive. Mild infections of the skin and soft tissues. NOTE: Reports indicate an increasing number of strains of staphylococci resistant to penicillin G, emphasizing the need for culture and sensitivity studies in treating suspected staphylococcal infections. Fusospirochetosis (Vincent's gingivitis and pharyngitis)— Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin. NOTE: Necessary dental care should be accomplished in infections involving the gum tissue. Medical conditions in which oral penicillin therapy is indicated as prophylaxis: For the prevention of recurrence following rheumatic fever and/or chorea: Prophylaxis with oral penicillin on a continuing basis has proven effective in preventing recurrence of these conditions. Although no controlled clinical efficacy studies have been conducted, penicillin V has been suggested by the American Heart Association and the American Dental Association for use as an oral regimen for prophylaxis against bacterial endocarditis in patients who have congenital heart disease or rheumatic or other acquired valvular heart disease when they undergo dental procedures and surgical procedures of the upper respiratory tract. 1 Oral penicillin should not be used in those patients at particularly high risk for endocarditis (e.g., those with prosthetic heart valves or surgically constructed systemic pulmonary shunts). Penicillin V should not be used as adjunctive prophylaxis for genitourinary instrumentation or surgery, lower-intestinal-tract surgery, sigmoidoscopy, and childbirth. Since it may happen that alpha hemolytic streptococci relatively resistant to penicillin may be found when patients are receiving continuous oral penicillin for secondary prevention of rheumatic fever, prophylactic agents other than penicillin may be chosen for these patients and prescribed in addition to their continuous rheumatic fever prophylactic regimen. NOTE: When selecting antibiotics for the prevention of bacterial endocarditis, the physician or dentist should read the full joint statement of the American Heart Association and the American Dental Association. 1 uuid:77ddafcd-17b7-4dee-8026-59dcae177be7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:122707137 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:56ddd29c-c5db-4935-a7d3-7fc017f6604e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d6deb1f6-8360-42f6-9701-6744489ada70"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pentazocine hydrochloride and acetaminophen tablets are indicated for the relief of mild to moderate pain. uuid:e7cc2845-f9ff-4b5f-a55a-4ec0396b5d2f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:56841899 biolink:treats UMLS:C0497209 PMID:41385096 "[{""id"":""uuid:52c84d8e-0a0d-4716-81ee-683f6da08177"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9aabf355-7861-4b6e-b718-e4629f20d24b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitis is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus, Escherichia coli, Haemophilus influenzae, Klebsiella/Enterobacter species, Neisseria species, Pseudomonas aeruginosa . This product does not provide adequate coverage against Serratia marcescens , and Streptococci, including Streptococcus pneumoniae . uuid:e3e9c73b-86ce-436e-b8a8-e401ac16c272 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:54955 biolink:treats MONDO:0043885 PMID:41385096 "[{""id"":""uuid:78fdf72c-71b0-4ff1-860c-cd9196476d05"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eee1fc81-5ebd-4123-ab55-0c7010b6927c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the treatment of superficial ocular infections involving the conjunctiva and/or cornea caused by organisms susceptible to bacitracin zinc and polymyxin B sulfate. uuid:c907c33c-bd8c-4ee4-abaa-f03d421bd1e6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:54955 biolink:treats MONDO:0023865 PMID:41385096 "[{""id"":""uuid:d5fe5a37-fb13-42b3-9afe-1b4a40c9fa36"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a71f780c-a069-4c2f-8c71-fe89e3162bd7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the treatment of superficial ocular infections involving the conjunctiva and/or cornea caused by organisms susceptible to bacitracin zinc and polymyxin B sulfate. uuid:3f216ca3-cdb8-4697-b0ee-39bc762aabb7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:184381 biolink:treats MONDO:0043885 PMID:41385096 "[{""id"":""uuid:e95f02bb-9149-4bd8-b477-ee0e2256e394"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6cb72c59-8030-4e63-9cc2-2f74a7c964b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the treatment of superficial ocular infections involving the conjunctiva and/or cornea caused by Bacitracin susceptible organisms. CHEBI:28669 uuid:aa9ae8bd-19e2-4b2d-8e94-dc49d809d85e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:184381 biolink:treats MONDO:0003799 PMID:41385096 "[{""id"":""uuid:1adcc54e-f1f9-4952-9676-dc3e767af49c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:148c1284-1d4a-4d7c-acc5-3d41a23c7b45"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the treatment of superficial ocular infections involving the conjunctiva and/or cornea caused by Bacitracin susceptible organisms. CHEBI:28669 uuid:04b1161c-a07a-436a-b161-d13e6874fc36 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:184381 biolink:treats MONDO:0023865 PMID:41385096 "[{""id"":""uuid:d8f86524-931f-4881-b2a0-935a0aa06024"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cdaacd5d-c483-4f8c-8200-080d52ed014c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the treatment of superficial ocular infections involving the conjunctiva and/or cornea caused by Bacitracin susceptible organisms. CHEBI:28669 uuid:8cff8615-7b14-424d-a111-9e28103651cf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats UMLS:C0497209 PMID:41385096 "[{""id"":""uuid:1a832a42-a361-4be5-b8ce-6b8a40f930ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:24d6a6de-56f9-4cbb-bb65-fe7eadedd4c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prednisolone Sodium Phosphate Ophthalmic Solution 1% or 1/8% is for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe, such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitis when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation, corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. Prednisolone Sodium Phosphate Ophthalmic Solution, 1%, is recommended for moderate to severe inflammations, particularly when unusually rapid control is desired. In stubborn cases of anterior segment eye disease, systemic adrenocortical hormone therapy may be required. When deeper ocular structures are involved, systemic therapy is necessary. uuid:029ca0e8-1c02-4749-97d1-56a18d0f5cb8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2950 biolink:treats MONDO:0005324 PMID:41385096 "[{""id"":""uuid:f17a1272-9074-4f93-af3f-80009f95c3e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:09e443a8-cd03-467a-b4dc-a5d947e8ca4d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Astelin ® Nasal Spray is indicated for the treatment of the symptoms of seasonal allergic rhinitis such as rhinorrhea, sneezing, and nasal pruritus in adults and children 5 years and older, and for the treatment of the symptoms of vasomotor rhinitis, such as rhinorrhea, nasal congestion and postnasal drip in adults and children 12 years and older. uuid:1d9bfae4-1e46-4076-a847-ff3baf89a51f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2950 biolink:treats MONDO:0006004 PMID:41385096 "[{""id"":""uuid:8eebec96-59b0-48b8-bc01-f8ead52bc4bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c4a80302-9583-49b3-b015-2f517235f202"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Astelin ® Nasal Spray is indicated for the treatment of the symptoms of seasonal allergic rhinitis such as rhinorrhea, sneezing, and nasal pruritus in adults and children 5 years and older, and for the treatment of the symptoms of vasomotor rhinitis, such as rhinorrhea, nasal congestion and postnasal drip in adults and children 12 years and older. uuid:e32ec1a5-b200-4286-a8f9-017a1b11ed49 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31932 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:a2011223-efa1-426e-8daf-b3f8cf05c729"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8ce0a50c-5357-4c72-be44-5efc309aa69e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Benicar is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents. uuid:71b9e3a4-f9d5-4985-a265-56efce3f881c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9435 biolink:treats MONDO:0013600 PMID:41385096 "[{""id"":""uuid:e33c733d-65ac-46df-be06-f426d55498e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e8296046-b7eb-4923-97f8-22671b662010"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Temazepam Capsules, USP are indicated for the short-term treatment of insomnia (generally 7 to 10 days). For patients with short-term insomnia, instructions in the prescription should indicate that Temazepam Capsules should be used for short periods of time (7 to 10 days). The clinical trials performed in support of efficacy were 2 weeks in duration with the final formal assessment of sleep latency performed at the end of treatment. uuid:35b90c0f-e5f5-4a59-8cb2-f52a9019161d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9435 biolink:treats UMLS:C0393759 PMID:41385096 "[{""id"":""uuid:e268c68e-71e1-4402-85d7-5de4b08a5b12"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ac5a119c-746c-422a-8b25-57463b85451b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Temazepam Capsules, USP are indicated for the short-term treatment of insomnia (generally 7 to 10 days). For patients with short-term insomnia, instructions in the prescription should indicate that Temazepam Capsules should be used for short periods of time (7 to 10 days). The clinical trials performed in support of efficacy were 2 weeks in duration with the final formal assessment of sleep latency performed at the end of treatment. uuid:e3ecb726-6385-454e-9a78-8fde437347e0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49575 biolink:treats HP:0001257 PMID:41385096 "[{""id"":""uuid:19a80c10-e5c6-404a-8677-cc24aa5de90a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a4d98e3d-86df-4856-926a-8bce00384151"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diazepam Tablets USP are indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. In acute alcohol withdrawal, diazepam may be useful in the symptomatic relief of acute agitation, tremor, impending or acute delirium tremens and hallucinosis. Diazepam is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology (such as inflammation of the muscles or joints, or secondary to trauma); spasticity caused by upper motor neuron disorders (such as cerebral palsy and paraplegia); athetosis; and stiff-man syndrome. Oral diazepam may be used adjunctively in convulsive disorders, although it has not proved useful as the sole therapy. The effectiveness of diazepam in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient. uuid:b4c12ead-2621-42fb-8766-870e126a29f8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28864 biolink:treats MONDO:0043885 PMID:41385096 "[{""id"":""uuid:3ea33abe-624f-4733-8e25-8fa701cd737a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fccfebfb-d7b2-497e-beb2-86e19d91a6a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TOBREX (tobramycin ophthalmic ointment) 0.3 % is a topical antibiotic indicated in the treatment of external infections of the eye and its adnexa caused by susceptible bacteria. Appropriate monitoring of bacterial response to topical antibiotic therapy should accompany the use of TOBREX (tobramycin ophthalmic ointment) 0.3%. Clinical studies have shown tobramycin to be safe and effective for use in children. uuid:355ca8ea-ae50-4d81-ad05-bb965e946838 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63622 biolink:treats UMLS:C2919575 PMID:41385096 "[{""id"":""uuid:0111d304-edc3-4d66-938d-f64617838355"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c1a1cfa2-bb2b-4a2c-b406-4097b01f44ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sotalol hydrochloride tablets USP are indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that in the judgment of the physician are life-threatening. Because of the proarrhythmic effects of sotalol hydrochloride tablets (see WARNINGS ), including a 1.5% to 2% rate of torsade de pointes or new VT/VF in patients with either NSVT or supraventricular arrhythmias, its use in patients with less severe arrhythmias, even if the patients are symptomatic, is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of sotalol hydrochloride tablet USP treatment or increasing doses, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. The response to treatment should then be evaluated by a suitable method (e.g., PES or Holter monitoring) prior to continuing the patient on chronic therapy. Various approaches have been used to determine the response to antiarrhythmic therapy, including sotalol hydrochloride tablets USP. In the ESVEM Trial, response by Holter monitoring was tentatively defined as 100% suppression of ventricular tachycardia, 90% suppression of non-sustained VT, 80% suppression of paired VPCs and 75% suppression of total VPCs in patients who had at least 10 VPCs/hour at baseline; this tentative response was confirmed if VT lasting 5 or more beats was not observed during treadmill exercise testing using a standard Bruce protocol. The PES protocol utilized a maximum of three extrastimuli at three pacing cycle lengths and two right ventricular pacing sites. Response to PES was defined as prevention of induction of the following: 1) monomorphic VT lasting over 15 seconds; 2) non-sustained polymorphic VT containing more than 15 beats of monomorphic VT in patients with a history of monomorphic VT; 3) polymorphic VT or VF greater than 15 beats in patients with VF or a history of aborted sudden death without monomorphic VT; and 4) two episodes of polymorphic VT or VF of greater than 15 beats in a patient presenting with monomorphic VT. Sustained VT or NSVT producing hypotension during the final treadmill test was considered a drug failure. In a multicenter open-label long-term study of sotalol hydrochloride tablets USP in patients with life-threatening ventricular arrhythmias which had proven refractory to other antiarrhythmic medications, response by Holter monitoring was defined as in ESVEM. Response by PES was defined as non-inducibility of sustained VT by at least double extrastimuli delivered at a pacing cycle length of 400 msec. Overall survival and arrhythmia recurrence rates in this study were similar to those seen in ESVEM, although there was no comparative group to allow a definitive assessment of outcome. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias. Sotalol is also indicated for the maintenance of normal sinus rhythm [delay in time to recurrence of atrial fibrillation/atrial flutter (AFIB/AFL)] in patients with symptomatic AFIB/AFL who are currently in sinus rhythm and is marketed under the brand name BETAPACE AF TM . Sotalol hydrochloride tablets USP are not approved for the AFIB/AFL indication and should not be substituted for BETAPACE AF TM because only BETAPACE AF TM is distributed with a patient package insert that is appropriate for patients with AFIB/AFL. uuid:63559d2e-4cb0-43f8-9815-ed2359c96e6a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63622 biolink:treats HP:0005115 PMID:41385096 "[{""id"":""uuid:7541fc21-1089-4ae6-8b87-a03e4e0431a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f9607287-ef79-4c96-96df-1b41a4e7e812"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sotalol hydrochloride tablets USP are indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that in the judgment of the physician are life-threatening. Because of the proarrhythmic effects of sotalol hydrochloride tablets (see WARNINGS ), including a 1.5% to 2% rate of torsade de pointes or new VT/VF in patients with either NSVT or supraventricular arrhythmias, its use in patients with less severe arrhythmias, even if the patients are symptomatic, is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of sotalol hydrochloride tablet USP treatment or increasing doses, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. The response to treatment should then be evaluated by a suitable method (e.g., PES or Holter monitoring) prior to continuing the patient on chronic therapy. Various approaches have been used to determine the response to antiarrhythmic therapy, including sotalol hydrochloride tablets USP. In the ESVEM Trial, response by Holter monitoring was tentatively defined as 100% suppression of ventricular tachycardia, 90% suppression of non-sustained VT, 80% suppression of paired VPCs and 75% suppression of total VPCs in patients who had at least 10 VPCs/hour at baseline; this tentative response was confirmed if VT lasting 5 or more beats was not observed during treadmill exercise testing using a standard Bruce protocol. The PES protocol utilized a maximum of three extrastimuli at three pacing cycle lengths and two right ventricular pacing sites. Response to PES was defined as prevention of induction of the following: 1) monomorphic VT lasting over 15 seconds; 2) non-sustained polymorphic VT containing more than 15 beats of monomorphic VT in patients with a history of monomorphic VT; 3) polymorphic VT or VF greater than 15 beats in patients with VF or a history of aborted sudden death without monomorphic VT; and 4) two episodes of polymorphic VT or VF of greater than 15 beats in a patient presenting with monomorphic VT. Sustained VT or NSVT producing hypotension during the final treadmill test was considered a drug failure. In a multicenter open-label long-term study of sotalol hydrochloride tablets USP in patients with life-threatening ventricular arrhythmias which had proven refractory to other antiarrhythmic medications, response by Holter monitoring was defined as in ESVEM. Response by PES was defined as non-inducibility of sustained VT by at least double extrastimuli delivered at a pacing cycle length of 400 msec. Overall survival and arrhythmia recurrence rates in this study were similar to those seen in ESVEM, although there was no comparative group to allow a definitive assessment of outcome. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias. Sotalol is also indicated for the maintenance of normal sinus rhythm [delay in time to recurrence of atrial fibrillation/atrial flutter (AFIB/AFL)] in patients with symptomatic AFIB/AFL who are currently in sinus rhythm and is marketed under the brand name BETAPACE AF TM . Sotalol hydrochloride tablets USP are not approved for the AFIB/AFL indication and should not be substituted for BETAPACE AF TM because only BETAPACE AF TM is distributed with a patient package insert that is appropriate for patients with AFIB/AFL. uuid:4b4ecd07-321c-4d9b-9162-78437373e063 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63622 biolink:treats HP:0006682 PMID:41385096 "[{""id"":""uuid:d1b41216-d5d9-47bb-8751-7ed7d4d58e83"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3a36ec5f-ca1f-417c-a50e-70c402a19c62"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sotalol hydrochloride tablets USP are indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that in the judgment of the physician are life-threatening. Because of the proarrhythmic effects of sotalol hydrochloride tablets (see WARNINGS ), including a 1.5% to 2% rate of torsade de pointes or new VT/VF in patients with either NSVT or supraventricular arrhythmias, its use in patients with less severe arrhythmias, even if the patients are symptomatic, is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of sotalol hydrochloride tablet USP treatment or increasing doses, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. The response to treatment should then be evaluated by a suitable method (e.g., PES or Holter monitoring) prior to continuing the patient on chronic therapy. Various approaches have been used to determine the response to antiarrhythmic therapy, including sotalol hydrochloride tablets USP. In the ESVEM Trial, response by Holter monitoring was tentatively defined as 100% suppression of ventricular tachycardia, 90% suppression of non-sustained VT, 80% suppression of paired VPCs and 75% suppression of total VPCs in patients who had at least 10 VPCs/hour at baseline; this tentative response was confirmed if VT lasting 5 or more beats was not observed during treadmill exercise testing using a standard Bruce protocol. The PES protocol utilized a maximum of three extrastimuli at three pacing cycle lengths and two right ventricular pacing sites. Response to PES was defined as prevention of induction of the following: 1) monomorphic VT lasting over 15 seconds; 2) non-sustained polymorphic VT containing more than 15 beats of monomorphic VT in patients with a history of monomorphic VT; 3) polymorphic VT or VF greater than 15 beats in patients with VF or a history of aborted sudden death without monomorphic VT; and 4) two episodes of polymorphic VT or VF of greater than 15 beats in a patient presenting with monomorphic VT. Sustained VT or NSVT producing hypotension during the final treadmill test was considered a drug failure. In a multicenter open-label long-term study of sotalol hydrochloride tablets USP in patients with life-threatening ventricular arrhythmias which had proven refractory to other antiarrhythmic medications, response by Holter monitoring was defined as in ESVEM. Response by PES was defined as non-inducibility of sustained VT by at least double extrastimuli delivered at a pacing cycle length of 400 msec. Overall survival and arrhythmia recurrence rates in this study were similar to those seen in ESVEM, although there was no comparative group to allow a definitive assessment of outcome. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias. Sotalol is also indicated for the maintenance of normal sinus rhythm [delay in time to recurrence of atrial fibrillation/atrial flutter (AFIB/AFL)] in patients with symptomatic AFIB/AFL who are currently in sinus rhythm and is marketed under the brand name BETAPACE AF TM . Sotalol hydrochloride tablets USP are not approved for the AFIB/AFL indication and should not be substituted for BETAPACE AF TM because only BETAPACE AF TM is distributed with a patient package insert that is appropriate for patients with AFIB/AFL. uuid:8ebda383-f927-4c24-8fb5-d62995bd1b50 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:476348 biolink:treats HP:0003124 PMID:41385096 "[{""id"":""uuid:718f3304-af2f-4c79-9c86-887e7f0d1f50"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:da3588c7-4726-4e26-a6fb-3abda04acc70"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. uuid:8f56e8c0-4790-4aab-a4d1-42cc43e636e7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:476348 biolink:treats MONDO:0005311 PMID:41385096 "[{""id"":""uuid:4272a433-f44b-450c-898e-966243b82870"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4ad260e3-cc4c-466f-8960-c3fccc4abde7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. uuid:e876b386-2131-4c8d-85cd-50f99fc05f55 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9241 biolink:treats MONDO:0001422 PMID:41385096 "[{""id"":""uuid:64f2b364-9ab4-4872-bdfc-8c98ea4250f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:2b8216b6-05ca-4a31-bb74-062855ac3509"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:dbe7ccea-d931-4fc0-a83b-ea826e0de793"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/qaialdo""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Spironolactone is indicated in the management of: Primary hyperaldosteronism for: Establishing the diagnosis of primary hyperaldosteronism by therapeutic trial. Short-term preoperative treatment of patients with primary hyperaldosteronism. Long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are judged to be poor operative risks or who decline surgery. Long-term maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). Edematous conditions for patients with: Congestive heart failure: For the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures. Spironolactone is also indicated for patients with congestive heart failure taking digitalis when other therapies are considered inappropriate. Cirrhosis of the liver accompanied by edema and/or ascites: Aldosterone levels may be exceptionally high in this condition. Spironolactone is indicated for maintenance therapy together with bed rest and the restriction of fluid and sodium. The nephrotic syndrome: For nephrotic patients when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics do not provide an adequate response.|[EMA] In the management of refractory oedema associated with congestive cardiac failure; hepatic cirrhosis with ascites and oedema, malignant ascites, nephrotic syndrome, diagnosis and treatment of primary aldosteronism, essential hypertension.Neonates, children and adolescents should only be treated under guidance of a paediatric specialist (see sections 5.1 and 5.2). uuid:e8a0eff2-feae-44d9-b6c3-fbc14f40893b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9241 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:3066b033-2843-4fab-83a8-73cae442d7b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:b3c089c8-c1c5-42c5-9a1b-57ab3cb0475d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:83238ead-945f-4572-8e2d-c3dd79d958ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/qaialdo""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Spironolactone is indicated in the management of: Primary hyperaldosteronism for: Establishing the diagnosis of primary hyperaldosteronism by therapeutic trial. Short-term preoperative treatment of patients with primary hyperaldosteronism. Long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are judged to be poor operative risks or who decline surgery. Long-term maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). Edematous conditions for patients with: Congestive heart failure: For the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures. Spironolactone is also indicated for patients with congestive heart failure taking digitalis when other therapies are considered inappropriate. Cirrhosis of the liver accompanied by edema and/or ascites: Aldosterone levels may be exceptionally high in this condition. Spironolactone is indicated for maintenance therapy together with bed rest and the restriction of fluid and sodium. The nephrotic syndrome: For nephrotic patients when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics do not provide an adequate response.|[EMA] In the management of refractory oedema associated with congestive cardiac failure; hepatic cirrhosis with ascites and oedema, malignant ascites, nephrotic syndrome, diagnosis and treatment of primary aldosteronism, essential hypertension.Neonates, children and adolescents should only be treated under guidance of a paediatric specialist (see sections 5.1 and 5.2). uuid:b713d846-f034-4b32-a5e7-97fb0866e42a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9241 biolink:treats MONDO:0005155 PMID:41385096 "[{""id"":""uuid:bc2aa356-468b-4065-b397-321290ce2cff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:8ec4b8ac-426f-41e2-8e3b-5bfe92fb9182"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f1030109-a022-4a30-8ac9-3c6bef741b27"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/qaialdo""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Spironolactone is indicated in the management of: Primary hyperaldosteronism for: Establishing the diagnosis of primary hyperaldosteronism by therapeutic trial. Short-term preoperative treatment of patients with primary hyperaldosteronism. Long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are judged to be poor operative risks or who decline surgery. Long-term maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). Edematous conditions for patients with: Congestive heart failure: For the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures. Spironolactone is also indicated for patients with congestive heart failure taking digitalis when other therapies are considered inappropriate. Cirrhosis of the liver accompanied by edema and/or ascites: Aldosterone levels may be exceptionally high in this condition. Spironolactone is indicated for maintenance therapy together with bed rest and the restriction of fluid and sodium. The nephrotic syndrome: For nephrotic patients when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics do not provide an adequate response.|[EMA] In the management of refractory oedema associated with congestive cardiac failure; hepatic cirrhosis with ascites and oedema, malignant ascites, nephrotic syndrome, diagnosis and treatment of primary aldosteronism, essential hypertension.Neonates, children and adolescents should only be treated under guidance of a paediatric specialist (see sections 5.1 and 5.2). uuid:a3ec5396-5d39-4732-b015-2865c507cd2a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9241 biolink:treats MONDO:0005377 PMID:41385096 "[{""id"":""uuid:2983a5f9-8925-4b1b-af8b-2b7d241deae9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:1d8a2a47-ee36-4803-b34d-685f83480dc7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:a5646d7b-dc8e-452e-971a-68b6dc7639e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/qaialdo""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Spironolactone is indicated in the management of: Primary hyperaldosteronism for: Establishing the diagnosis of primary hyperaldosteronism by therapeutic trial. Short-term preoperative treatment of patients with primary hyperaldosteronism. Long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are judged to be poor operative risks or who decline surgery. Long-term maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). Edematous conditions for patients with: Congestive heart failure: For the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures. Spironolactone is also indicated for patients with congestive heart failure taking digitalis when other therapies are considered inappropriate. Cirrhosis of the liver accompanied by edema and/or ascites: Aldosterone levels may be exceptionally high in this condition. Spironolactone is indicated for maintenance therapy together with bed rest and the restriction of fluid and sodium. The nephrotic syndrome: For nephrotic patients when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics do not provide an adequate response.|[EMA] In the management of refractory oedema associated with congestive cardiac failure; hepatic cirrhosis with ascites and oedema, malignant ascites, nephrotic syndrome, diagnosis and treatment of primary aldosteronism, essential hypertension.Neonates, children and adolescents should only be treated under guidance of a paediatric specialist (see sections 5.1 and 5.2). uuid:1c24346a-970f-401b-82a1-c52d91006ce8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77733 biolink:treats HP:0001681 PMID:41385096 "[{""id"":""uuid:c7226fd3-1756-4c9b-b89b-07102432cd40"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:42608258-3d39-4d28-8e65-2b35d21e08dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Verapamil Hydrochloride Tablets are indicated for the treatment of the following: Angina 1. Angina at rest including: – Vasospastic (Prinzmetal’s variant) angina – Unstable (crescendo, pre-infarction) angina 2. Chronic stable angina (classic effort-associated angina) Arrhythmias 1. In association with digitalis for the control of ventricular rate at rest and during stress in patients with chronic atrial flutter and/or atrial fibrillation (see WARNINGS; Accessory Bypass Tract) 2. Prophylaxis of repetitive paroxysmal supraventricular tachycardia Essential Hypertension uuid:07e108b0-04a3-4e5a-a88e-f7dcdaf3dff2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77733 biolink:treats MONDO:0006021 PMID:41385096 "[{""id"":""uuid:bfdc0ea4-a7b6-46cb-9b8f-1f65b1449ca3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:29fa16ff-2b2c-4be6-9d39-2e860d053c47"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Verapamil Hydrochloride Tablets are indicated for the treatment of the following: Angina 1. Angina at rest including: – Vasospastic (Prinzmetal’s variant) angina – Unstable (crescendo, pre-infarction) angina 2. Chronic stable angina (classic effort-associated angina) Arrhythmias 1. In association with digitalis for the control of ventricular rate at rest and during stress in patients with chronic atrial flutter and/or atrial fibrillation (see WARNINGS; Accessory Bypass Tract) 2. Prophylaxis of repetitive paroxysmal supraventricular tachycardia Essential Hypertension uuid:7e7f98cf-bc7f-42a1-9eca-bfaff0dda427 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77733 biolink:treats MONDO:0006805 PMID:41385096 "[{""id"":""uuid:59fb432d-0d33-46f5-a2a0-8cc4aa78b868"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7b8fafb9-28bb-4202-8728-064214c21353"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Verapamil Hydrochloride Tablets are indicated for the treatment of the following: Angina 1. Angina at rest including: – Vasospastic (Prinzmetal’s variant) angina – Unstable (crescendo, pre-infarction) angina 2. Chronic stable angina (classic effort-associated angina) Arrhythmias 1. In association with digitalis for the control of ventricular rate at rest and during stress in patients with chronic atrial flutter and/or atrial fibrillation (see WARNINGS; Accessory Bypass Tract) 2. Prophylaxis of repetitive paroxysmal supraventricular tachycardia Essential Hypertension uuid:2e7658f7-001d-44fb-ba4a-a37067a41686 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15940 biolink:treats MONDO:0005311 PMID:41385096 "[{""id"":""uuid:e6df1c50-acd3-44af-ae2b-6a9bc16ae18b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a90e4e73-4c3e-4196-8acc-6ca66169c760"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hyperlipidemia. Niacin therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. NIASPAN is indicated to reduce elevated TC, LDL-C, Apo B and TG levels, and to increase HDL-C in patients with primary hyperlipidemia and mixed dyslipidemia. NIASPAN in combination with simvastatin or lovastatin is indicated for the treatment of primary hyperlipidemia and mixed dyslipidemia when treatment with NIASPAN, simvastatin, or lovastatin monotherapy is considered inadequate. In patients with a history of myocardial infarction and hyperlipidemia, niacin is indicated to reduce the risk of recurrent nonfatal myocardial infarction. In patients with a history of coronary artery disease (CAD) and hyperlipidemia, niacin, in combination with a bile acid binding resin, is indicated to slow progression or promote regression of atherosclerotic disease. NIASPAN in combination with a bile acid binding resin is indicated to reduce elevated TC and LDL-C levels in adult patients with primary hyperlipidemia. Niacin is also indicated as adjunctive therapy for treatment of adult patients with severe hypertriglyceridemia who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Limitations of Use No incremental benefit of NIASPAN coadministered with simvastatin or lovastatin on cardiovascular morbidity and mortality over and above that demonstrated for niacin, simvastatin, or lovastatin monotherapy has been established. uuid:80402fe4-57b7-436b-9894-01759d795b1b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15940 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:21298d3b-e84c-49f4-bd82-15a841388ac6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3c907387-d61a-402a-bfaa-09af44f1eff1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hyperlipidemia. Niacin therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. NIASPAN is indicated to reduce elevated TC, LDL-C, Apo B and TG levels, and to increase HDL-C in patients with primary hyperlipidemia and mixed dyslipidemia. NIASPAN in combination with simvastatin or lovastatin is indicated for the treatment of primary hyperlipidemia and mixed dyslipidemia when treatment with NIASPAN, simvastatin, or lovastatin monotherapy is considered inadequate. In patients with a history of myocardial infarction and hyperlipidemia, niacin is indicated to reduce the risk of recurrent nonfatal myocardial infarction. In patients with a history of coronary artery disease (CAD) and hyperlipidemia, niacin, in combination with a bile acid binding resin, is indicated to slow progression or promote regression of atherosclerotic disease. NIASPAN in combination with a bile acid binding resin is indicated to reduce elevated TC and LDL-C levels in adult patients with primary hyperlipidemia. Niacin is also indicated as adjunctive therapy for treatment of adult patients with severe hypertriglyceridemia who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Limitations of Use No incremental benefit of NIASPAN coadministered with simvastatin or lovastatin on cardiovascular morbidity and mortality over and above that demonstrated for niacin, simvastatin, or lovastatin monotherapy has been established. uuid:ca585dc7-26e8-4ff9-90be-97bcb92546e2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15940 biolink:treats HP:0003119 PMID:41385096 "[{""id"":""uuid:e56be699-6e4a-40f8-9541-628b8726e4de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7a0eb1cd-46e4-4407-8ccc-b766da9d3077"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hyperlipidemia. Niacin therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. NIASPAN is indicated to reduce elevated TC, LDL-C, Apo B and TG levels, and to increase HDL-C in patients with primary hyperlipidemia and mixed dyslipidemia. NIASPAN in combination with simvastatin or lovastatin is indicated for the treatment of primary hyperlipidemia and mixed dyslipidemia when treatment with NIASPAN, simvastatin, or lovastatin monotherapy is considered inadequate. In patients with a history of myocardial infarction and hyperlipidemia, niacin is indicated to reduce the risk of recurrent nonfatal myocardial infarction. In patients with a history of coronary artery disease (CAD) and hyperlipidemia, niacin, in combination with a bile acid binding resin, is indicated to slow progression or promote regression of atherosclerotic disease. NIASPAN in combination with a bile acid binding resin is indicated to reduce elevated TC and LDL-C levels in adult patients with primary hyperlipidemia. Niacin is also indicated as adjunctive therapy for treatment of adult patients with severe hypertriglyceridemia who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Limitations of Use No incremental benefit of NIASPAN coadministered with simvastatin or lovastatin on cardiovascular morbidity and mortality over and above that demonstrated for niacin, simvastatin, or lovastatin monotherapy has been established. uuid:c9eeed0f-fd1d-45c3-accd-48a527e519e5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15940 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:3fa9501f-56a9-4777-8b82-524532f74c8e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d0329369-4b50-4e2d-a97f-b4a1b40ad19f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hyperlipidemia. Niacin therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. NIASPAN is indicated to reduce elevated TC, LDL-C, Apo B and TG levels, and to increase HDL-C in patients with primary hyperlipidemia and mixed dyslipidemia. NIASPAN in combination with simvastatin or lovastatin is indicated for the treatment of primary hyperlipidemia and mixed dyslipidemia when treatment with NIASPAN, simvastatin, or lovastatin monotherapy is considered inadequate. In patients with a history of myocardial infarction and hyperlipidemia, niacin is indicated to reduce the risk of recurrent nonfatal myocardial infarction. In patients with a history of coronary artery disease (CAD) and hyperlipidemia, niacin, in combination with a bile acid binding resin, is indicated to slow progression or promote regression of atherosclerotic disease. NIASPAN in combination with a bile acid binding resin is indicated to reduce elevated TC and LDL-C levels in adult patients with primary hyperlipidemia. Niacin is also indicated as adjunctive therapy for treatment of adult patients with severe hypertriglyceridemia who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Limitations of Use No incremental benefit of NIASPAN coadministered with simvastatin or lovastatin on cardiovascular morbidity and mortality over and above that demonstrated for niacin, simvastatin, or lovastatin monotherapy has been established. uuid:b9494a98-7b50-4f48-a8db-bc8487f3c339 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15940 biolink:treats MONDO:0005010 PMID:41385096 "[{""id"":""uuid:0c49d176-7bc5-4bb9-bfca-f39d02d6d99d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:069bd6b3-0788-4280-b5f6-012c3ecb71af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hyperlipidemia. Niacin therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. NIASPAN is indicated to reduce elevated TC, LDL-C, Apo B and TG levels, and to increase HDL-C in patients with primary hyperlipidemia and mixed dyslipidemia. NIASPAN in combination with simvastatin or lovastatin is indicated for the treatment of primary hyperlipidemia and mixed dyslipidemia when treatment with NIASPAN, simvastatin, or lovastatin monotherapy is considered inadequate. In patients with a history of myocardial infarction and hyperlipidemia, niacin is indicated to reduce the risk of recurrent nonfatal myocardial infarction. In patients with a history of coronary artery disease (CAD) and hyperlipidemia, niacin, in combination with a bile acid binding resin, is indicated to slow progression or promote regression of atherosclerotic disease. NIASPAN in combination with a bile acid binding resin is indicated to reduce elevated TC and LDL-C levels in adult patients with primary hyperlipidemia. Niacin is also indicated as adjunctive therapy for treatment of adult patients with severe hypertriglyceridemia who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Limitations of Use No incremental benefit of NIASPAN coadministered with simvastatin or lovastatin on cardiovascular morbidity and mortality over and above that demonstrated for niacin, simvastatin, or lovastatin monotherapy has been established. uuid:90aa4e6b-0d3f-4f3f-9423-a8cf6d5a5e03 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15940 biolink:treats MONDO:0005347 PMID:41385096 "[{""id"":""uuid:afd5ef27-1832-4612-bdad-2c2623cf2d2d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fcb56534-722a-4ceb-b4c5-8f85f1618358"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hyperlipidemia. Niacin therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. NIASPAN is indicated to reduce elevated TC, LDL-C, Apo B and TG levels, and to increase HDL-C in patients with primary hyperlipidemia and mixed dyslipidemia. NIASPAN in combination with simvastatin or lovastatin is indicated for the treatment of primary hyperlipidemia and mixed dyslipidemia when treatment with NIASPAN, simvastatin, or lovastatin monotherapy is considered inadequate. In patients with a history of myocardial infarction and hyperlipidemia, niacin is indicated to reduce the risk of recurrent nonfatal myocardial infarction. In patients with a history of coronary artery disease (CAD) and hyperlipidemia, niacin, in combination with a bile acid binding resin, is indicated to slow progression or promote regression of atherosclerotic disease. NIASPAN in combination with a bile acid binding resin is indicated to reduce elevated TC and LDL-C levels in adult patients with primary hyperlipidemia. Niacin is also indicated as adjunctive therapy for treatment of adult patients with severe hypertriglyceridemia who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Limitations of Use No incremental benefit of NIASPAN coadministered with simvastatin or lovastatin on cardiovascular morbidity and mortality over and above that demonstrated for niacin, simvastatin, or lovastatin monotherapy has been established. uuid:20e9aa2d-88dc-4233-8aa4-92ddb310f4d3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1155751 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:fb93995c-7d1b-423e-ad4e-7c3106a582d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:99a9e878-3fd8-4db1-bca2-b3a4b677f813"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Captopril and Hydrochlorothiazide tablets are indicated for the treatment of hypertension. The blood pressure lowering effects of captopril and thiazides are approximately additive. This fixed combination drug may be used as initial therapy or substituted for previously titrated doses of the individual components. When captopril and hydrochlorothiazide are given together it may not be necessary to administer captopril in divided doses to attain blood pressure control at trough (before the next dose). Also, with such a combination, a daily dose of 15 mg of hydrochlorothiazide may be adequate. Treatment may, therefore, be initiated with Captopril and Hydrochlorothiazide tablets 25 mg/15 mg once daily. Subsequent titration should be with additional doses of the components (captopril, hydrochlorothiazide) as single agents or as Captopril and Hydrochlorothiazide tablets 50 mg/15 mg, 25 mg/25 mg, or 50 mg/25 mg (see DOSAGE AND ADMINISTRATION ). In using Captopril and Hydrochlorothiazide, consideration should be given to the risk of neutropenia/agranulocytosis (see WARNINGS ). Captopril and Hydrochlorothiazide may be used for patients with normal renal function, in whom the risk is relatively low. In patients with impaired renal function, particularly those with collagen vascular disease, Captopril and Hydrochlorothiazide should be reserved for hypertensives who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to other drug combinations. ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients (see WARNINGS: Captopril: Head and Neck Angioedema and Intestinal Angioedema ). uuid:22b6a55c-72b6-46f3-b160-f399a7d94f23 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3478 biolink:treats MONDO:0005441 PMID:41385096 "[{""id"":""uuid:d2e6bfe8-a3eb-4ac7-9176-69dfd9ee7bac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:50bf9988-b6f6-40b9-8684-37a571708662"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefaclor is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: Otitis media caused by Streptococcus pneumoniae, Haemophilus influenzae , staphylococci, and Streptococcus pyogenes Note: β-lactamase-negative, ampicillin-resistant (BLNAR) strains of Haemophilus influenzae should be considered resistant to cefaclor despite apparent in vitro susceptibility of some BLNAR strains. Lower respiratory tract infections , including pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae , and Streptococcus. Note: β-lactamase-negative, ampicillin-resistant (BLNAR) strains of Haemophilus influenzae should be considered resistant to cefaclor despite apparent in vitro susceptibility of some BLNAR strains. Pharyngitis and Tonsillitis , caused by Streptococcus pyogenes Note : Penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cefaclor is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefaclor in the subsequent prevention of rheumatic fever are not available at present. Urinary tract infections , including pyelonephritis and cystitis, caused by Escherichia coli, Proteus mirabilis, Klebsiella spp., and coagulase-negative staphylococci Skin and skin structure infections caused by Staphylococcus aureus and Streptococcus pyogenes Appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefaclor. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefaclor Capsules and Cefaclor for Oral Suspension and other antibacterial drugs, Cefaclor Capsules and Cefaclor for Oral Suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:5867af65-8433-4318-a4ca-f79483b289b4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3478 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:102bd467-5e9d-4ded-979e-bd82bd1c91ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c28cfe4b-1186-4b60-a45e-b023839549b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefaclor is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: Otitis media caused by Streptococcus pneumoniae, Haemophilus influenzae , staphylococci, and Streptococcus pyogenes Note: β-lactamase-negative, ampicillin-resistant (BLNAR) strains of Haemophilus influenzae should be considered resistant to cefaclor despite apparent in vitro susceptibility of some BLNAR strains. Lower respiratory tract infections , including pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae , and Streptococcus. Note: β-lactamase-negative, ampicillin-resistant (BLNAR) strains of Haemophilus influenzae should be considered resistant to cefaclor despite apparent in vitro susceptibility of some BLNAR strains. Pharyngitis and Tonsillitis , caused by Streptococcus pyogenes Note : Penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cefaclor is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefaclor in the subsequent prevention of rheumatic fever are not available at present. Urinary tract infections , including pyelonephritis and cystitis, caused by Escherichia coli, Proteus mirabilis, Klebsiella spp., and coagulase-negative staphylococci Skin and skin structure infections caused by Staphylococcus aureus and Streptococcus pyogenes Appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefaclor. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefaclor Capsules and Cefaclor for Oral Suspension and other antibacterial drugs, Cefaclor Capsules and Cefaclor for Oral Suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:f368d84f-cc49-4f89-9149-23db3367c7c5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3478 biolink:treats MONDO:0002258 PMID:41385096 "[{""id"":""uuid:13df82aa-cdf6-4270-b08c-ecff1dd10511"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:28bc929d-31fa-42e7-afdf-d9d1c8a307f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefaclor is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: Otitis media caused by Streptococcus pneumoniae, Haemophilus influenzae , staphylococci, and Streptococcus pyogenes Note: β-lactamase-negative, ampicillin-resistant (BLNAR) strains of Haemophilus influenzae should be considered resistant to cefaclor despite apparent in vitro susceptibility of some BLNAR strains. Lower respiratory tract infections , including pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae , and Streptococcus. Note: β-lactamase-negative, ampicillin-resistant (BLNAR) strains of Haemophilus influenzae should be considered resistant to cefaclor despite apparent in vitro susceptibility of some BLNAR strains. Pharyngitis and Tonsillitis , caused by Streptococcus pyogenes Note : Penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cefaclor is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefaclor in the subsequent prevention of rheumatic fever are not available at present. Urinary tract infections , including pyelonephritis and cystitis, caused by Escherichia coli, Proteus mirabilis, Klebsiella spp., and coagulase-negative staphylococci Skin and skin structure infections caused by Staphylococcus aureus and Streptococcus pyogenes Appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefaclor. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefaclor Capsules and Cefaclor for Oral Suspension and other antibacterial drugs, Cefaclor Capsules and Cefaclor for Oral Suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:250bb574-0fc8-4a75-b968-94c02d007577 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3478 biolink:treats MONDO:0001039 PMID:41385096 "[{""id"":""uuid:93f3fe14-04df-4de9-891b-dc5c9086ed93"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e75a094f-998f-403d-a206-a1aa3a4e51ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefaclor is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: Otitis media caused by Streptococcus pneumoniae, Haemophilus influenzae , staphylococci, and Streptococcus pyogenes Note: β-lactamase-negative, ampicillin-resistant (BLNAR) strains of Haemophilus influenzae should be considered resistant to cefaclor despite apparent in vitro susceptibility of some BLNAR strains. Lower respiratory tract infections , including pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae , and Streptococcus. Note: β-lactamase-negative, ampicillin-resistant (BLNAR) strains of Haemophilus influenzae should be considered resistant to cefaclor despite apparent in vitro susceptibility of some BLNAR strains. Pharyngitis and Tonsillitis , caused by Streptococcus pyogenes Note : Penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cefaclor is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefaclor in the subsequent prevention of rheumatic fever are not available at present. Urinary tract infections , including pyelonephritis and cystitis, caused by Escherichia coli, Proteus mirabilis, Klebsiella spp., and coagulase-negative staphylococci Skin and skin structure infections caused by Staphylococcus aureus and Streptococcus pyogenes Appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefaclor. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefaclor Capsules and Cefaclor for Oral Suspension and other antibacterial drugs, Cefaclor Capsules and Cefaclor for Oral Suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:4fb0fe44-bcac-4e9a-9404-c88a07992e45 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3478 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:1374d86e-1498-45f4-bd70-2b3084145542"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ac9a5769-1ef6-4413-aaa3-de6eedeccd9f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefaclor is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: Otitis media caused by Streptococcus pneumoniae, Haemophilus influenzae , staphylococci, and Streptococcus pyogenes Note: β-lactamase-negative, ampicillin-resistant (BLNAR) strains of Haemophilus influenzae should be considered resistant to cefaclor despite apparent in vitro susceptibility of some BLNAR strains. Lower respiratory tract infections , including pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae , and Streptococcus. Note: β-lactamase-negative, ampicillin-resistant (BLNAR) strains of Haemophilus influenzae should be considered resistant to cefaclor despite apparent in vitro susceptibility of some BLNAR strains. Pharyngitis and Tonsillitis , caused by Streptococcus pyogenes Note : Penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cefaclor is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefaclor in the subsequent prevention of rheumatic fever are not available at present. Urinary tract infections , including pyelonephritis and cystitis, caused by Escherichia coli, Proteus mirabilis, Klebsiella spp., and coagulase-negative staphylococci Skin and skin structure infections caused by Staphylococcus aureus and Streptococcus pyogenes Appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefaclor. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefaclor Capsules and Cefaclor for Oral Suspension and other antibacterial drugs, Cefaclor Capsules and Cefaclor for Oral Suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:e6b3586b-af9d-4535-8f8d-fb16daabb43f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3478 biolink:treats MONDO:0006939 PMID:41385096 "[{""id"":""uuid:d2f258e6-30bf-4a54-93e9-739feb6dab49"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:015af225-ee57-4c33-8c8b-70983146f346"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefaclor is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: Otitis media caused by Streptococcus pneumoniae, Haemophilus influenzae , staphylococci, and Streptococcus pyogenes Note: β-lactamase-negative, ampicillin-resistant (BLNAR) strains of Haemophilus influenzae should be considered resistant to cefaclor despite apparent in vitro susceptibility of some BLNAR strains. Lower respiratory tract infections , including pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae , and Streptococcus. Note: β-lactamase-negative, ampicillin-resistant (BLNAR) strains of Haemophilus influenzae should be considered resistant to cefaclor despite apparent in vitro susceptibility of some BLNAR strains. Pharyngitis and Tonsillitis , caused by Streptococcus pyogenes Note : Penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cefaclor is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefaclor in the subsequent prevention of rheumatic fever are not available at present. Urinary tract infections , including pyelonephritis and cystitis, caused by Escherichia coli, Proteus mirabilis, Klebsiella spp., and coagulase-negative staphylococci Skin and skin structure infections caused by Staphylococcus aureus and Streptococcus pyogenes Appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefaclor. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefaclor Capsules and Cefaclor for Oral Suspension and other antibacterial drugs, Cefaclor Capsules and Cefaclor for Oral Suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:e642b823-95d7-4a2c-8fce-5b17a79340ae biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3478 biolink:treats MONDO:0006032 PMID:41385096 "[{""id"":""uuid:1680413e-4a36-4c5e-938b-d617434c3e72"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1ec1c797-a7b7-47a9-bb99-5b27ddf5963e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefaclor is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: Otitis media caused by Streptococcus pneumoniae, Haemophilus influenzae , staphylococci, and Streptococcus pyogenes Note: β-lactamase-negative, ampicillin-resistant (BLNAR) strains of Haemophilus influenzae should be considered resistant to cefaclor despite apparent in vitro susceptibility of some BLNAR strains. Lower respiratory tract infections , including pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae , and Streptococcus. Note: β-lactamase-negative, ampicillin-resistant (BLNAR) strains of Haemophilus influenzae should be considered resistant to cefaclor despite apparent in vitro susceptibility of some BLNAR strains. Pharyngitis and Tonsillitis , caused by Streptococcus pyogenes Note : Penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cefaclor is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefaclor in the subsequent prevention of rheumatic fever are not available at present. Urinary tract infections , including pyelonephritis and cystitis, caused by Escherichia coli, Proteus mirabilis, Klebsiella spp., and coagulase-negative staphylococci Skin and skin structure infections caused by Staphylococcus aureus and Streptococcus pyogenes Appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefaclor. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefaclor Capsules and Cefaclor for Oral Suspension and other antibacterial drugs, Cefaclor Capsules and Cefaclor for Oral Suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:365913e3-07ad-4821-873f-9111a27af258 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3478 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:479989a1-6c66-46fc-84e3-7117d1d60ecb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d72c8e7d-ae80-453e-9dc5-be733b7d2365"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefaclor is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: Otitis media caused by Streptococcus pneumoniae, Haemophilus influenzae , staphylococci, and Streptococcus pyogenes Note: β-lactamase-negative, ampicillin-resistant (BLNAR) strains of Haemophilus influenzae should be considered resistant to cefaclor despite apparent in vitro susceptibility of some BLNAR strains. Lower respiratory tract infections , including pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae , and Streptococcus. Note: β-lactamase-negative, ampicillin-resistant (BLNAR) strains of Haemophilus influenzae should be considered resistant to cefaclor despite apparent in vitro susceptibility of some BLNAR strains. Pharyngitis and Tonsillitis , caused by Streptococcus pyogenes Note : Penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cefaclor is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefaclor in the subsequent prevention of rheumatic fever are not available at present. Urinary tract infections , including pyelonephritis and cystitis, caused by Escherichia coli, Proteus mirabilis, Klebsiella spp., and coagulase-negative staphylococci Skin and skin structure infections caused by Staphylococcus aureus and Streptococcus pyogenes Appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefaclor. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefaclor Capsules and Cefaclor for Oral Suspension and other antibacterial drugs, Cefaclor Capsules and Cefaclor for Oral Suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:7c3fb82e-08d1-4a68-bf28-e33b94a4623e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29103 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:e4afb324-00a1-4bbb-b635-e5b6014d01d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0b7b6359-f030-49bd-ad57-b2b89d0aa207"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AN USAGE: 1. For therapeutic use in patients with hypokalemia with or without metabolic alkalosis; in digitalis intoxication and in patients with hypokalemic familial periodic paralysis. 2. For prevention of potassium depletion when the dietary intake of potassium is inadequate in the following conditions; patients receiving digitalis and diuretics for congestive heart failure; hepatic cirrhosis with ascites; states of aldosterone excess with normal renal function; potassium-losing nephropathy, and certain diarrheal states. 3. The use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension is often unnecessary when such patients have a normal dietary pattern. Serum potassium should be checked periodically, however, and, if hypokalemia occurs, dietary supplementation with potassium-containing foods may be adequate to control milder cases. In more severe cases supplementation with potassium salts may be indicated. uuid:2445dc10-7237-44af-acda-3b2ab4cbe926 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29103 biolink:treats MONDO:0003009 PMID:41385096 "[{""id"":""uuid:17caff96-f38e-434e-9933-e43a2cd98634"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d1ec9f02-132d-4cb3-9219-e365cbb3f915"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AN USAGE: 1. For therapeutic use in patients with hypokalemia with or without metabolic alkalosis; in digitalis intoxication and in patients with hypokalemic familial periodic paralysis. 2. For prevention of potassium depletion when the dietary intake of potassium is inadequate in the following conditions; patients receiving digitalis and diuretics for congestive heart failure; hepatic cirrhosis with ascites; states of aldosterone excess with normal renal function; potassium-losing nephropathy, and certain diarrheal states. 3. The use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension is often unnecessary when such patients have a normal dietary pattern. Serum potassium should be checked periodically, however, and, if hypokalemia occurs, dietary supplementation with potassium-containing foods may be adequate to control milder cases. In more severe cases supplementation with potassium salts may be indicated. uuid:521b1307-521c-4ee3-83a4-63daf7d7ab99 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50690 biolink:treats MONDO:0005311 PMID:41385096 "[{""id"":""uuid:968b5921-f7a2-4172-95ff-97be93170f3a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dbc6dfa5-fdc1-444d-b0cf-e280fda54f39"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, LIPITOR can be started simultaneously with diet. uuid:60cd585b-5fc6-4d79-8ce7-e90093756092 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50690 biolink:treats HP:0003124 PMID:41385096 "[{""id"":""uuid:333012ec-da8c-4a34-bbfd-818ccf5f5c01"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aa0bbfc3-d13c-456c-9335-7f33c5e209f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, LIPITOR can be started simultaneously with diet. uuid:cc5af5eb-1cce-4540-a286-73bd2e897456 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50690 biolink:treats MONDO:0005010 PMID:41385096 "[{""id"":""uuid:2052b6eb-21c4-41d3-b91f-3ca278579bab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c334fa86-3caa-486a-9ff6-f835f519a0d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, LIPITOR can be started simultaneously with diet. uuid:e8dfcd88-8265-4e5b-8783-921b142e2d4a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:JM2621P2LS biolink:treats UMLS:C5442256 PMID:41385096 "[{""id"":""uuid:17a373f1-3ab7-44ac-8a92-fb43f55a2eba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b032922f-d33c-43c1-9058-64cdd9e47e02"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cenestin therapy is indicated for the: 1. Treatment of moderate-to-severe vasomotor symptoms associated with the menopause. 0.45 mg Cenestin 0.625 mg Cenestin 0.9 mg Cenestin 1.25 mg Cenestin 2. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. 0.3 mg Cenestin uuid:acd9a755-ff11-4f53-9184-c6797d061231 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:JM2621P2LS biolink:treats MONDO:0001932 PMID:41385096 "[{""id"":""uuid:d37dcaaf-aefb-4981-9a9d-5ec15c9fa9d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:571aa7b7-d320-43dd-bdd4-519c9c8c45f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cenestin therapy is indicated for the: 1. Treatment of moderate-to-severe vasomotor symptoms associated with the menopause. 0.45 mg Cenestin 0.625 mg Cenestin 0.9 mg Cenestin 1.25 mg Cenestin 2. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. 0.3 mg Cenestin DOID:14275 uuid:9f3764a5-32b1-4314-bc11-1ff129eb6154 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:404930 biolink:treats HP:0000371 PMID:41385096 "[{""id"":""uuid:7af28f52-0915-4d00-aa86-69a6c2470d9e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:531070ec-77b4-4930-9e9d-8a88e009e860"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CIPRODEX® Otic is indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in the specific conditions listed below: Acute Otitis Media in pediatric patients (age 6 months and older) with tympanostomy tubes due to Staphylococcus aureus , Streptococcus pneumoniae , Haemophilus influenzae , Moraxella catarrhalis , and Pseudomonas aeruginosa . Acute Otitis Externa in pediatric (age 6 months and older), adult and elderly patients due to Staphylococcus aureus and Pseudomonas aeruginosa . uuid:252a5344-8eca-45ed-af25-db741d71cc34 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:404930 biolink:treats MONDO:0001051 PMID:41385096 "[{""id"":""uuid:dabd8daf-9239-4a55-a858-ef25c40c0024"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2da69b91-e259-4b70-b4f1-56d478486d5d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CIPRODEX® Otic is indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in the specific conditions listed below: Acute Otitis Media in pediatric patients (age 6 months and older) with tympanostomy tubes due to Staphylococcus aureus , Streptococcus pneumoniae , Haemophilus influenzae , Moraxella catarrhalis , and Pseudomonas aeruginosa . Acute Otitis Externa in pediatric (age 6 months and older), adult and elderly patients due to Staphylococcus aureus and Pseudomonas aeruginosa . uuid:108ee66b-46aa-4c34-ae28-a441981bd7b2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:291342 biolink:treats MONDO:0005324 PMID:41385096 "[{""id"":""uuid:37043d91-a1a5-4ecb-b27c-89c089b988df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:878b0fa0-b02e-41f8-94ff-34fc4f3060fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Seasonal Allergic Rhinitis CLARINEX is indicated for the relief of the nasal and non-nasal symptoms of seasonal allergic rhinitis in patients 2 years of age and older. Perennial Allergic Rhinitis CLARINEX is indicated for the relief of the nasal and non-nasal symptoms of perennial allergic rhinitis in patients 6 months of age and older. Chronic Idiopathic Urticaria CLARINEX is indicated for the symptomatic relief of pruritus, reduction in the number of hives, and size of hives, in patients with chronic idiopathic urticaria 6 months of age and older. uuid:1259828b-30ae-443a-9c9c-40032840cf20 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:291342 biolink:treats MONDO:0024332 PMID:41385096 "[{""id"":""uuid:1e18d645-f235-42ab-910e-ebbb8612e024"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2cf8a12a-707f-47a5-b052-8b67d30c8c1d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Seasonal Allergic Rhinitis CLARINEX is indicated for the relief of the nasal and non-nasal symptoms of seasonal allergic rhinitis in patients 2 years of age and older. Perennial Allergic Rhinitis CLARINEX is indicated for the relief of the nasal and non-nasal symptoms of perennial allergic rhinitis in patients 6 months of age and older. Chronic Idiopathic Urticaria CLARINEX is indicated for the symptomatic relief of pruritus, reduction in the number of hives, and size of hives, in patients with chronic idiopathic urticaria 6 months of age and older. uuid:e019831d-d762-41ca-b705-0713f2230de6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:291342 biolink:treats MONDO:0044212 PMID:41385096 "[{""id"":""uuid:89905c58-1756-4ee4-b7ae-8ffdfa5a6da8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d312f42a-0be3-4f6c-bbb1-5009b6864e6f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:586e7b5d-d040-49c7-a37a-2e6e2e18179e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/neoclarityn""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Seasonal Allergic Rhinitis CLARINEX is indicated for the relief of the nasal and non-nasal symptoms of seasonal allergic rhinitis in patients 2 years of age and older. Perennial Allergic Rhinitis CLARINEX is indicated for the relief of the nasal and non-nasal symptoms of perennial allergic rhinitis in patients 6 months of age and older. Chronic Idiopathic Urticaria CLARINEX is indicated for the symptomatic relief of pruritus, reduction in the number of hives, and size of hives, in patients with chronic idiopathic urticaria 6 months of age and older.|[EMA] Desloratadine ratiopharm is indicated in adults for the relief of symptoms associated with:allergic rhinitischronic idiopathic urticaria as initially diagnosed by a physician uuid:6b56395b-8009-4d4a-8a0a-e7ed31b1fb65 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3216 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:ce09b7ce-af18-460f-9ee7-2c258f6c3f89"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6394c547-dd8e-49fd-b468-68924f241842"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Buprenorphine hydrochloride injection is indicated for the relief of moderate to severe pain. uuid:a0331535-b825-4edd-b842-2e667a6a49b5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75984 biolink:treats HP:0004763 PMID:41385096 "[{""id"":""uuid:fd908c05-4b6b-4e1f-afb5-f849ea682943"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f1957d30-052e-4c59-929d-3f3a671350eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:347aaf0d-dacd-4196-85a7-30f20cc3e8c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In patients without structural heart disease, Flecainide Acetate Tablets, USP are indicated for the prevention of: •paroxysmal supraventricular tachycardias (PSVT), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms •paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms Flecainide Acetate Tablets, USP are also indicated for the prevention of: •documented ventricular arrhythmias, such as sustained ventricular tachycardia ( sustained VT), that in the judgment of the physician are life-threatening. Use of Flecainide Acetate Tablets, USP for the treatment of sustained VT, like other antiarrhythmics, should be initiated in the hospital. The use of flecainide acetate is not recommended in patients with less severe ventricular arrhythmias even if the patients are symptomatic. Because of the proarrhythmic effects of Flecainide Acetate Tablets, USP, its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment outweigh the risks. Flecainide Acetate Tablets, USP should not be used in patients with recent myocardial infarction. (See Boxed WARNINGS .) Use of Flecainide Acetate Tablets, USP in chronic atrial fibrillation has not been adequately studied and is not recommended. (See Boxed WARNINGS .) As is the case for other antiarrhythmic agents, there is no evidence from controlled trials that the use of flecainide acetate favorably affects survival or the incidence of sudden death.|[PMDA] Drugs with a new additional indication and a new dosage for the treatment of tachyarrhythmia (paroxysmal atrial fibrillation/flutter, paroxysmal supraventricular tachycardia, ventricular tachycardia) in children. [Expedited review] uuid:802a817b-7423-4bbf-9ee1-b2ef39df63c0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75984 biolink:treats UMLS:C0039232 PMID:41385096 "[{""id"":""uuid:e3b230aa-0d99-4125-955f-9cd6d0419536"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d8cb15c2-4c2e-4207-8111-535e1db17fea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In patients without structural heart disease, Flecainide Acetate Tablets, USP are indicated for the prevention of: •paroxysmal supraventricular tachycardias (PSVT), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms •paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms Flecainide Acetate Tablets, USP are also indicated for the prevention of: •documented ventricular arrhythmias, such as sustained ventricular tachycardia ( sustained VT), that in the judgment of the physician are life-threatening. Use of Flecainide Acetate Tablets, USP for the treatment of sustained VT, like other antiarrhythmics, should be initiated in the hospital. The use of flecainide acetate is not recommended in patients with less severe ventricular arrhythmias even if the patients are symptomatic. Because of the proarrhythmic effects of Flecainide Acetate Tablets, USP, its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment outweigh the risks. Flecainide Acetate Tablets, USP should not be used in patients with recent myocardial infarction. (See Boxed WARNINGS .) Use of Flecainide Acetate Tablets, USP in chronic atrial fibrillation has not been adequately studied and is not recommended. (See Boxed WARNINGS .) As is the case for other antiarrhythmic agents, there is no evidence from controlled trials that the use of flecainide acetate favorably affects survival or the incidence of sudden death. uuid:356b39f5-8f1d-4139-b55d-760993e199c7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75984 biolink:treats HP:0011717 PMID:41385096 "[{""id"":""uuid:06ed4101-4c2d-4d08-8bf0-102b784d6ae3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ce577e05-638d-4356-a6d4-7b1b9d8b297f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In patients without structural heart disease, Flecainide Acetate Tablets, USP are indicated for the prevention of: •paroxysmal supraventricular tachycardias (PSVT), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms •paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms Flecainide Acetate Tablets, USP are also indicated for the prevention of: •documented ventricular arrhythmias, such as sustained ventricular tachycardia ( sustained VT), that in the judgment of the physician are life-threatening. Use of Flecainide Acetate Tablets, USP for the treatment of sustained VT, like other antiarrhythmics, should be initiated in the hospital. The use of flecainide acetate is not recommended in patients with less severe ventricular arrhythmias even if the patients are symptomatic. Because of the proarrhythmic effects of Flecainide Acetate Tablets, USP, its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment outweigh the risks. Flecainide Acetate Tablets, USP should not be used in patients with recent myocardial infarction. (See Boxed WARNINGS .) Use of Flecainide Acetate Tablets, USP in chronic atrial fibrillation has not been adequately studied and is not recommended. (See Boxed WARNINGS .) As is the case for other antiarrhythmic agents, there is no evidence from controlled trials that the use of flecainide acetate favorably affects survival or the incidence of sudden death. uuid:f7cc39b2-5fa1-4d18-b31f-5471774d2818 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75984 biolink:treats HP:0004755 PMID:41385096 "[{""id"":""uuid:8581fd6c-6795-49a1-acba-8cfeeb58c782"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:51726db8-c9cb-4681-946f-db3eb1009e46"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In patients without structural heart disease, Flecainide Acetate Tablets, USP are indicated for the prevention of: •paroxysmal supraventricular tachycardias (PSVT), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms •paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms Flecainide Acetate Tablets, USP are also indicated for the prevention of: •documented ventricular arrhythmias, such as sustained ventricular tachycardia ( sustained VT), that in the judgment of the physician are life-threatening. Use of Flecainide Acetate Tablets, USP for the treatment of sustained VT, like other antiarrhythmics, should be initiated in the hospital. The use of flecainide acetate is not recommended in patients with less severe ventricular arrhythmias even if the patients are symptomatic. Because of the proarrhythmic effects of Flecainide Acetate Tablets, USP, its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment outweigh the risks. Flecainide Acetate Tablets, USP should not be used in patients with recent myocardial infarction. (See Boxed WARNINGS .) Use of Flecainide Acetate Tablets, USP in chronic atrial fibrillation has not been adequately studied and is not recommended. (See Boxed WARNINGS .) As is the case for other antiarrhythmic agents, there is no evidence from controlled trials that the use of flecainide acetate favorably affects survival or the incidence of sudden death. uuid:e7541427-581b-4792-9be5-c710825670cf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75984 biolink:treats MONDO:1030011 PMID:41385096 "[{""id"":""uuid:cbd496e8-f643-46fa-bb64-624b0028b602"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2a1c5621-7822-4ad5-bbbc-94233bd3592f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:d08d3384-fd72-4bdb-b338-eb82551ad669"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In patients without structural heart disease, Flecainide Acetate Tablets, USP are indicated for the prevention of: •paroxysmal supraventricular tachycardias (PSVT), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms •paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms Flecainide Acetate Tablets, USP are also indicated for the prevention of: •documented ventricular arrhythmias, such as sustained ventricular tachycardia ( sustained VT), that in the judgment of the physician are life-threatening. Use of Flecainide Acetate Tablets, USP for the treatment of sustained VT, like other antiarrhythmics, should be initiated in the hospital. The use of flecainide acetate is not recommended in patients with less severe ventricular arrhythmias even if the patients are symptomatic. Because of the proarrhythmic effects of Flecainide Acetate Tablets, USP, its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment outweigh the risks. Flecainide Acetate Tablets, USP should not be used in patients with recent myocardial infarction. (See Boxed WARNINGS .) Use of Flecainide Acetate Tablets, USP in chronic atrial fibrillation has not been adequately studied and is not recommended. (See Boxed WARNINGS .) As is the case for other antiarrhythmic agents, there is no evidence from controlled trials that the use of flecainide acetate favorably affects survival or the incidence of sudden death.|[PMDA] Drugs with a new additional indication and a new dosage for the treatment of tachyarrhythmia (paroxysmal atrial fibrillation/flutter, paroxysmal supraventricular tachycardia, ventricular tachycardia) in children. [Expedited review] uuid:a65eb719-7681-4cd8-8089-7cd038b38f70 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75984 biolink:treats UMLS:C0741292 PMID:41385096 "[{""id"":""uuid:266ebe56-9390-4137-b42d-ae9968613f15"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:719e2a50-1d1f-4ae7-917c-f41ba52d3f6a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In patients without structural heart disease, Flecainide Acetate Tablets, USP are indicated for the prevention of: •paroxysmal supraventricular tachycardias (PSVT), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms •paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms Flecainide Acetate Tablets, USP are also indicated for the prevention of: •documented ventricular arrhythmias, such as sustained ventricular tachycardia ( sustained VT), that in the judgment of the physician are life-threatening. Use of Flecainide Acetate Tablets, USP for the treatment of sustained VT, like other antiarrhythmics, should be initiated in the hospital. The use of flecainide acetate is not recommended in patients with less severe ventricular arrhythmias even if the patients are symptomatic. Because of the proarrhythmic effects of Flecainide Acetate Tablets, USP, its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment outweigh the risks. Flecainide Acetate Tablets, USP should not be used in patients with recent myocardial infarction. (See Boxed WARNINGS .) Use of Flecainide Acetate Tablets, USP in chronic atrial fibrillation has not been adequately studied and is not recommended. (See Boxed WARNINGS .) As is the case for other antiarrhythmic agents, there is no evidence from controlled trials that the use of flecainide acetate favorably affects survival or the incidence of sudden death. uuid:ddc7e563-1e83-4e24-b9e7-5c29ad9dde20 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75984 biolink:treats HP:0004308 PMID:41385096 "[{""id"":""uuid:fbf9a6ec-4053-4a92-bb3d-fa328dbc0eac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bad5f777-e93d-4d28-acea-c94687ca872c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In patients without structural heart disease, Flecainide Acetate Tablets, USP are indicated for the prevention of: •paroxysmal supraventricular tachycardias (PSVT), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms •paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms Flecainide Acetate Tablets, USP are also indicated for the prevention of: •documented ventricular arrhythmias, such as sustained ventricular tachycardia ( sustained VT), that in the judgment of the physician are life-threatening. Use of Flecainide Acetate Tablets, USP for the treatment of sustained VT, like other antiarrhythmics, should be initiated in the hospital. The use of flecainide acetate is not recommended in patients with less severe ventricular arrhythmias even if the patients are symptomatic. Because of the proarrhythmic effects of Flecainide Acetate Tablets, USP, its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment outweigh the risks. Flecainide Acetate Tablets, USP should not be used in patients with recent myocardial infarction. (See Boxed WARNINGS .) Use of Flecainide Acetate Tablets, USP in chronic atrial fibrillation has not been adequately studied and is not recommended. (See Boxed WARNINGS .) As is the case for other antiarrhythmic agents, there is no evidence from controlled trials that the use of flecainide acetate favorably affects survival or the incidence of sudden death. uuid:fb55cc02-8749-4fc6-9029-1fdf7c6889f5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75984 biolink:treats UMLS:C0750197 PMID:41385096 "[{""id"":""uuid:06d5c102-f4f4-4dda-964f-9a028bbac24d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:49b1ef3c-aec9-4053-97be-da61280fd54f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In patients without structural heart disease, Flecainide Acetate Tablets, USP are indicated for the prevention of: •paroxysmal supraventricular tachycardias (PSVT), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms •paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms Flecainide Acetate Tablets, USP are also indicated for the prevention of: •documented ventricular arrhythmias, such as sustained ventricular tachycardia ( sustained VT), that in the judgment of the physician are life-threatening. Use of Flecainide Acetate Tablets, USP for the treatment of sustained VT, like other antiarrhythmics, should be initiated in the hospital. The use of flecainide acetate is not recommended in patients with less severe ventricular arrhythmias even if the patients are symptomatic. Because of the proarrhythmic effects of Flecainide Acetate Tablets, USP, its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment outweigh the risks. Flecainide Acetate Tablets, USP should not be used in patients with recent myocardial infarction. (See Boxed WARNINGS .) Use of Flecainide Acetate Tablets, USP in chronic atrial fibrillation has not been adequately studied and is not recommended. (See Boxed WARNINGS .) As is the case for other antiarrhythmic agents, there is no evidence from controlled trials that the use of flecainide acetate favorably affects survival or the incidence of sudden death. uuid:78dfd4cc-1d0d-433c-9844-7b534e74fc72 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3761 biolink:treats MONDO:0005618 PMID:41385096 "[{""id"":""uuid:07b6f914-60a7-4f15-bdbb-7698a2d31603"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7b190883-bcab-4575-9643-8a5a7efa2c19"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clorazepate dipotassium is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. Clorazepate dipotassium tablets are indicated as adjunctive therapy in the management of partial seizures. The effectiveness of clorazepate dipotassium tablets in long-term management of anxiety, that is, more than 4 months, has not been assessed by systematic clinical studies. Long-term studies in epileptic patients, however, have shown continued therapeutic activity. The physician should reassess periodically the usefulness of the drug for the individual patient. Clorazepate dipotassium tablets are indicated for the symptomatic relief of acute alcohol withdrawal. uuid:928697de-afa5-4b32-8e48-d41850002e9a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3761 biolink:treats HP:0007359 PMID:41385096 "[{""id"":""uuid:d64ae101-9a4a-40c8-b5fb-43e363e743d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b934ee27-675b-414f-8b9e-eb59a01cc49a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clorazepate dipotassium is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. Clorazepate dipotassium tablets are indicated as adjunctive therapy in the management of partial seizures. The effectiveness of clorazepate dipotassium tablets in long-term management of anxiety, that is, more than 4 months, has not been assessed by systematic clinical studies. Long-term studies in epileptic patients, however, have shown continued therapeutic activity. The physician should reassess periodically the usefulness of the drug for the individual patient. Clorazepate dipotassium tablets are indicated for the symptomatic relief of acute alcohol withdrawal. uuid:34988215-ffa6-4579-9978-f56f231ee23a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3761 biolink:treats MONDO:0005433 PMID:41385096 "[{""id"":""uuid:4fe1da77-7e3c-4039-8980-f89bb0e634bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6996c10e-406d-4436-9194-bcb8f3cc2778"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clorazepate dipotassium is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. Clorazepate dipotassium tablets are indicated as adjunctive therapy in the management of partial seizures. The effectiveness of clorazepate dipotassium tablets in long-term management of anxiety, that is, more than 4 months, has not been assessed by systematic clinical studies. Long-term studies in epileptic patients, however, have shown continued therapeutic activity. The physician should reassess periodically the usefulness of the drug for the individual patient. Clorazepate dipotassium tablets are indicated for the symptomatic relief of acute alcohol withdrawal. uuid:eff844c1-44c3-40f5-890c-e93b3599a553 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3654 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:a78268de-9582-4a10-81a6-d4927b460eae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:002581f4-a2f3-4efe-a67d-ad4d7792ddbc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diuretics such as chlorthalidone are indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertension. Chlorthalidone is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Chlorthalidone has also been found useful in edema due to various forms of renal dysfunction, such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. uuid:2309a5ec-bdf3-4eba-95da-7fcf4dab1f02 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3654 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:f2088f36-57a3-43ea-bb02-bf8d515d61c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f63af317-cf0d-466d-a72e-3d0509a73723"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diuretics such as chlorthalidone are indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertension. Chlorthalidone is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Chlorthalidone has also been found useful in edema due to various forms of renal dysfunction, such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. uuid:81cc80bb-b505-48e0-b53a-09c1a6cbfd58 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3654 biolink:treats MONDO:0005155 PMID:41385096 "[{""id"":""uuid:552d0dcf-c1f5-4ffa-b704-f09d17fe9df3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0d152736-071f-4ee3-b23a-691dbcf2ab75"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diuretics such as chlorthalidone are indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertension. Chlorthalidone is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Chlorthalidone has also been found useful in edema due to various forms of renal dysfunction, such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. uuid:f37289df-9e08-46ca-a295-f409bbc5cd69 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3654 biolink:treats MONDO:0005377 PMID:41385096 "[{""id"":""uuid:b264121f-8135-469c-b342-1512c25d8237"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b7324a0a-727d-4183-a1c7-4cf0240c247c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diuretics such as chlorthalidone are indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertension. Chlorthalidone is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Chlorthalidone has also been found useful in edema due to various forms of renal dysfunction, such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. uuid:1cffc17f-32c3-4e98-a8b6-bea0931f42e8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3654 biolink:treats UMLS:C0156221 PMID:41385096 "[{""id"":""uuid:27a728ac-e0e8-456a-a2e2-0ba009e6d548"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c5fb3b37-db6b-4243-b9e8-ea9af3120a68"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diuretics such as chlorthalidone are indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertension. Chlorthalidone is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Chlorthalidone has also been found useful in edema due to various forms of renal dysfunction, such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. uuid:ac6de59a-9b31-4e91-a0e2-52208bf85920 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3654 biolink:treats MONDO:0005300 PMID:41385096 "[{""id"":""uuid:49983e45-89c2-4e7e-9c03-b92aab6450ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:17b0561c-9c7c-4df2-9049-24e2de601d98"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diuretics such as chlorthalidone are indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertension. Chlorthalidone is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Chlorthalidone has also been found useful in edema due to various forms of renal dysfunction, such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. uuid:db057a6b-bb12-49b8-b045-bfb9654e3416 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3506 biolink:treats MONDO:0002258 PMID:41385096 "[{""id"":""uuid:c5af3290-7c0f-4778-8c71-86286b136004"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3470e5ad-f180-4ed1-91d2-97aa238f0b2a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefprozil for oral suspension is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below: Upper Respiratory Tract: Pharyngitis/Tonsillitis: Caused by Streptococcus pyogenes . NOTE: The usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. Cefprozil is generally effective in the eradication of Streptococcus pyogenes from the nasopharynx; however, substantial data establishing the efficacy of cefprozil in the subsequent prevention of rheumatic fever are not available at present. Otitis Media: Caused by Streptococcus pneumoniae, Haemophilus influenzae (including ß-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). (See CLINICAL STUDIES .) NOTE: In the treatment of otitis media due to ß-lactamase producing organisms, cefprozil had bacteriologic eradication rates somewhat lower than those observed with a product containing a specific ß-lactamase inhibitor. In considering the use of cefprozil, lower overall eradication rates should be balanced against the susceptibility patterns of the common microbes in a given geographic area and the increased potential for toxicity with products containing ß-lactamase inhibitors. Acute Sinusitis: Caused by Streptococcus pneumoniae, Haemophilus influenzae (including ß-lactamase producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). Lower Respiratory Tract: Secondary Bacterial Infection of Acute Bronchitis and Acute Bacterial Exacerbation of Chronic Bronchitis: Caused by Streptococcus pneumoniae , Haemophilus influenzae (including ß-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). Skin And Skin Structure: Uncomplicated Skin and Skin-Structure Infections: Caused by Staphylococcus aureus (including penicillinase producing strains) and Streptococcus pyogenes . Abscesses usually require surgical drainage. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefprozil for oral suspension and other antibacterial drugs, cefprozil for oral suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:d193f679-469b-49a0-893b-06322576c5a4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3506 biolink:treats MONDO:0001039 PMID:41385096 "[{""id"":""uuid:a7b01640-82b8-4837-8b40-c8fe81f949c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:94f6a42f-1fb1-45eb-b93a-bab537a2bdb3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefprozil for oral suspension is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below: Upper Respiratory Tract: Pharyngitis/Tonsillitis: Caused by Streptococcus pyogenes . NOTE: The usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. Cefprozil is generally effective in the eradication of Streptococcus pyogenes from the nasopharynx; however, substantial data establishing the efficacy of cefprozil in the subsequent prevention of rheumatic fever are not available at present. Otitis Media: Caused by Streptococcus pneumoniae, Haemophilus influenzae (including ß-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). (See CLINICAL STUDIES .) NOTE: In the treatment of otitis media due to ß-lactamase producing organisms, cefprozil had bacteriologic eradication rates somewhat lower than those observed with a product containing a specific ß-lactamase inhibitor. In considering the use of cefprozil, lower overall eradication rates should be balanced against the susceptibility patterns of the common microbes in a given geographic area and the increased potential for toxicity with products containing ß-lactamase inhibitors. Acute Sinusitis: Caused by Streptococcus pneumoniae, Haemophilus influenzae (including ß-lactamase producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). Lower Respiratory Tract: Secondary Bacterial Infection of Acute Bronchitis and Acute Bacterial Exacerbation of Chronic Bronchitis: Caused by Streptococcus pneumoniae , Haemophilus influenzae (including ß-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). Skin And Skin Structure: Uncomplicated Skin and Skin-Structure Infections: Caused by Staphylococcus aureus (including penicillinase producing strains) and Streptococcus pyogenes . Abscesses usually require surgical drainage. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefprozil for oral suspension and other antibacterial drugs, cefprozil for oral suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:71bfd668-f5c1-4b3c-825d-0cacbd9c3364 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3506 biolink:treats MONDO:0005441 PMID:41385096 "[{""id"":""uuid:63b30792-b3d1-429c-a9be-f37b92e9b6d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8b5a9431-bfc3-4847-a5c4-8072e63cb738"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefprozil for oral suspension is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below: Upper Respiratory Tract: Pharyngitis/Tonsillitis: Caused by Streptococcus pyogenes . NOTE: The usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. Cefprozil is generally effective in the eradication of Streptococcus pyogenes from the nasopharynx; however, substantial data establishing the efficacy of cefprozil in the subsequent prevention of rheumatic fever are not available at present. Otitis Media: Caused by Streptococcus pneumoniae, Haemophilus influenzae (including ß-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). (See CLINICAL STUDIES .) NOTE: In the treatment of otitis media due to ß-lactamase producing organisms, cefprozil had bacteriologic eradication rates somewhat lower than those observed with a product containing a specific ß-lactamase inhibitor. In considering the use of cefprozil, lower overall eradication rates should be balanced against the susceptibility patterns of the common microbes in a given geographic area and the increased potential for toxicity with products containing ß-lactamase inhibitors. Acute Sinusitis: Caused by Streptococcus pneumoniae, Haemophilus influenzae (including ß-lactamase producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). Lower Respiratory Tract: Secondary Bacterial Infection of Acute Bronchitis and Acute Bacterial Exacerbation of Chronic Bronchitis: Caused by Streptococcus pneumoniae , Haemophilus influenzae (including ß-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). Skin And Skin Structure: Uncomplicated Skin and Skin-Structure Infections: Caused by Staphylococcus aureus (including penicillinase producing strains) and Streptococcus pyogenes . Abscesses usually require surgical drainage. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefprozil for oral suspension and other antibacterial drugs, cefprozil for oral suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:32f5b747-cb89-49f8-bf6e-6f2a91cb28d5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3506 biolink:treats HP:0000255 PMID:41385096 "[{""id"":""uuid:e2a7cd4c-6e8a-42a7-8f69-1ccc7e4bad87"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fd797eae-06be-4676-a263-b4ee7e14bf75"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefprozil for oral suspension is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below: Upper Respiratory Tract: Pharyngitis/Tonsillitis: Caused by Streptococcus pyogenes . NOTE: The usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. Cefprozil is generally effective in the eradication of Streptococcus pyogenes from the nasopharynx; however, substantial data establishing the efficacy of cefprozil in the subsequent prevention of rheumatic fever are not available at present. Otitis Media: Caused by Streptococcus pneumoniae, Haemophilus influenzae (including ß-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). (See CLINICAL STUDIES .) NOTE: In the treatment of otitis media due to ß-lactamase producing organisms, cefprozil had bacteriologic eradication rates somewhat lower than those observed with a product containing a specific ß-lactamase inhibitor. In considering the use of cefprozil, lower overall eradication rates should be balanced against the susceptibility patterns of the common microbes in a given geographic area and the increased potential for toxicity with products containing ß-lactamase inhibitors. Acute Sinusitis: Caused by Streptococcus pneumoniae, Haemophilus influenzae (including ß-lactamase producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). Lower Respiratory Tract: Secondary Bacterial Infection of Acute Bronchitis and Acute Bacterial Exacerbation of Chronic Bronchitis: Caused by Streptococcus pneumoniae , Haemophilus influenzae (including ß-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). Skin And Skin Structure: Uncomplicated Skin and Skin-Structure Infections: Caused by Staphylococcus aureus (including penicillinase producing strains) and Streptococcus pyogenes . Abscesses usually require surgical drainage. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefprozil for oral suspension and other antibacterial drugs, cefprozil for oral suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:c9f515e4-ec0b-4458-b657-5b27001bdf13 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3506 biolink:treats UMLS:C1735365 PMID:41385096 "[{""id"":""uuid:3f2b7627-2e67-4eec-832f-438692ae7511"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1b9d0052-c301-4adf-9fd3-515c2c15bab1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefprozil for oral suspension is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below: Upper Respiratory Tract: Pharyngitis/Tonsillitis: Caused by Streptococcus pyogenes . NOTE: The usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. Cefprozil is generally effective in the eradication of Streptococcus pyogenes from the nasopharynx; however, substantial data establishing the efficacy of cefprozil in the subsequent prevention of rheumatic fever are not available at present. Otitis Media: Caused by Streptococcus pneumoniae, Haemophilus influenzae (including ß-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). (See CLINICAL STUDIES .) NOTE: In the treatment of otitis media due to ß-lactamase producing organisms, cefprozil had bacteriologic eradication rates somewhat lower than those observed with a product containing a specific ß-lactamase inhibitor. In considering the use of cefprozil, lower overall eradication rates should be balanced against the susceptibility patterns of the common microbes in a given geographic area and the increased potential for toxicity with products containing ß-lactamase inhibitors. Acute Sinusitis: Caused by Streptococcus pneumoniae, Haemophilus influenzae (including ß-lactamase producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). Lower Respiratory Tract: Secondary Bacterial Infection of Acute Bronchitis and Acute Bacterial Exacerbation of Chronic Bronchitis: Caused by Streptococcus pneumoniae , Haemophilus influenzae (including ß-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). Skin And Skin Structure: Uncomplicated Skin and Skin-Structure Infections: Caused by Staphylococcus aureus (including penicillinase producing strains) and Streptococcus pyogenes . Abscesses usually require surgical drainage. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefprozil for oral suspension and other antibacterial drugs, cefprozil for oral suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:d58911a7-d25b-4486-ab4b-b758dd0b717e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3506 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:e9864344-9132-4d03-b6b4-0c28434aadd7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:11896764-4027-42a9-9599-d57a3cb65dc2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefprozil for oral suspension is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below: Upper Respiratory Tract: Pharyngitis/Tonsillitis: Caused by Streptococcus pyogenes . NOTE: The usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. Cefprozil is generally effective in the eradication of Streptococcus pyogenes from the nasopharynx; however, substantial data establishing the efficacy of cefprozil in the subsequent prevention of rheumatic fever are not available at present. Otitis Media: Caused by Streptococcus pneumoniae, Haemophilus influenzae (including ß-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). (See CLINICAL STUDIES .) NOTE: In the treatment of otitis media due to ß-lactamase producing organisms, cefprozil had bacteriologic eradication rates somewhat lower than those observed with a product containing a specific ß-lactamase inhibitor. In considering the use of cefprozil, lower overall eradication rates should be balanced against the susceptibility patterns of the common microbes in a given geographic area and the increased potential for toxicity with products containing ß-lactamase inhibitors. Acute Sinusitis: Caused by Streptococcus pneumoniae, Haemophilus influenzae (including ß-lactamase producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). Lower Respiratory Tract: Secondary Bacterial Infection of Acute Bronchitis and Acute Bacterial Exacerbation of Chronic Bronchitis: Caused by Streptococcus pneumoniae , Haemophilus influenzae (including ß-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). Skin And Skin Structure: Uncomplicated Skin and Skin-Structure Infections: Caused by Staphylococcus aureus (including penicillinase producing strains) and Streptococcus pyogenes . Abscesses usually require surgical drainage. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefprozil for oral suspension and other antibacterial drugs, cefprozil for oral suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:2dc4f70d-3ffa-4787-a2c2-522708827cc4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1162777 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:7385b68d-f332-4847-ad66-eae9af49fa67"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4b61f81d-c993-40aa-b8fa-f58e0fbb0a22"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BENICAR HCT ® is indicated for the treatment of hypertension. This fixed dose combination is not indicated for initial therapy (see DOSAGE AND ADMINISTRATION ). uuid:ae32195b-dc61-4291-be0a-842a96ac8820 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63620 biolink:treats MONDO:0005180 PMID:41385096 "[{""id"":""uuid:8464a5e9-5540-4957-b346-857f1df76cd9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e0bccffb-a23d-4c27-8917-2e0927eb3b1f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:0067fe1d-d7ab-4c8c-92cd-3b83c47c56c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/azilect""]},{""id"":""uuid:79025f6b-466d-48ce-8100-4f2cd7f97859"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AZILECT (rasagiline tablets) is indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease as initial monotherapy and as adjunct therapy to levodopa. The effectiveness of AZILECT was demonstrated in patients with early Parkinson's disease who were receiving AZILECT as monotherapy and who were not receiving any concomitant dopaminergic therapy. The effectiveness of AZILECT as adjunct therapy was demonstrated in patients with Parkinson's disease who were treated with levodopa.|[EMA] Azilect is indicated for the treatment of idiopathic Parkinson's disease (PD) as monotherapy (without levodopa) or as adjunct therapy (with levodopa) in patients with end-of-dose fluctuations.|[PMDA] Drugs with a new active ingredient indicated for the treatment of Parkinson’s disease. uuid:c4b2c32d-1747-481a-8c30-9e2fc8c739cd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8713 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:5142a831-b422-4978-8696-bbd590c6cd18"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:adbd9412-b987-49b8-aaf1-eb06d96b756f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension Quinapril hydrochloride tablets are indicated for the treatment of hypertension. It may be used alone or in combination with thiazide diuretics. In using quinapril hydrochloride tablets, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease. Available data are insufficient to show that quinapril hydrochloride tablets do not have a similar risk (see WARNINGS ). Angioedema in Black Patients Black patients receiving ACE inhibitor monotherapy have been reported to have a higher incidence of angioedema compared to non-blacks. It should also be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. uuid:40aaa438-e887-4500-876b-c8b73c57a16e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8713 biolink:treats MONDO:0001609 PMID:41385096 "[{""id"":""uuid:ff186f37-3c22-4504-bb9e-1213f361d8e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5aa9857d-31e8-4e77-9309-fe6f54b0c303"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension Quinapril hydrochloride tablets are indicated for the treatment of hypertension. It may be used alone or in combination with thiazide diuretics. In using quinapril hydrochloride tablets, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease. Available data are insufficient to show that quinapril hydrochloride tablets do not have a similar risk (see WARNINGS ). Angioedema in Black Patients Black patients receiving ACE inhibitor monotherapy have been reported to have a higher incidence of angioedema compared to non-blacks. It should also be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. uuid:af76b374-d1ba-4644-8bd1-624f7d96cb1b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8713 biolink:treats MONDO:0001343 PMID:41385096 "[{""id"":""uuid:1242041d-e339-4f54-a5f0-b0109c73d58e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6bca949b-f49a-4afa-9057-4ee3e870fdd6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension Quinapril hydrochloride tablets are indicated for the treatment of hypertension. It may be used alone or in combination with thiazide diuretics. In using quinapril hydrochloride tablets, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease. Available data are insufficient to show that quinapril hydrochloride tablets do not have a similar risk (see WARNINGS ). Angioedema in Black Patients Black patients receiving ACE inhibitor monotherapy have been reported to have a higher incidence of angioedema compared to non-blacks. It should also be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. uuid:dcd7ac6d-4c5b-4bea-84ba-4b9044464d11 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8713 biolink:treats MONDO:0010481 PMID:41385096 "[{""id"":""uuid:e44411a0-8057-4fd2-a95d-9cec051d8d13"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c6cb7845-6764-4ef2-bf24-f6675861f0bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension Quinapril hydrochloride tablets are indicated for the treatment of hypertension. It may be used alone or in combination with thiazide diuretics. In using quinapril hydrochloride tablets, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease. Available data are insufficient to show that quinapril hydrochloride tablets do not have a similar risk (see WARNINGS ). Angioedema in Black Patients Black patients receiving ACE inhibitor monotherapy have been reported to have a higher incidence of angioedema compared to non-blacks. It should also be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. uuid:42a4dcfa-5246-4fa8-9051-7d11452b3fa3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5128 biolink:treats MONDO:0013600 PMID:41385096 "[{""id"":""uuid:82e1e736-ac40-427c-beb2-250d4b0b0e72"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d24a9997-07cb-4467-bb42-76463655ac2f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Flurazepam Hydrochloride Capsules are a hypnotic agent useful for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakening. Flurazepam Hydrochloride Capsules can be used effectively in patients with recurring insomnia or poor sleeping habits, and in acute or chronic medical situations requiring restful sleep. Sleep laboratory studies have objectively determined that Flurazepam Hydrochloride Capsules are effective for at least 28 consecutive nights of drug administration. Since insomnia is often transient and intermittent short-term use is usually sufficient. Prolonged use of hypnotics is usually not indicated and should only be undertaken concomitantly with appropriate evaluation of the patient. uuid:25d4d22b-6acc-4bd9-a2e7-1722676add08 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:52017 biolink:treats MONDO:0024313 PMID:41385096 "[{""id"":""uuid:93270a2e-cb82-4115-b430-ebb3a070fdad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bbe9667f-b60a-47a1-91de-c7abcfb26883"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The penicillinase-resistant penicillins are indicated in the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drugs. Cultures and susceptibility tests should be performed initially to determine the causative organism and their sensitivity to the drug (see CLINICAL PHARMACOLOGY – Susceptibility Testing ). The penicillinase-resistant penicillins may be used to initiate therapy in suspected cases of resistant staphylococcal infections prior to the availability of laboratory test results. The penicillinase-resistant penicillins should not be used in infections caused by organisms susceptible to penicillin G. If the susceptibility tests indicate that the infection is due to an organism other than a resistant staphylococcus, therapy should not be continued with a penicillinase-resistant penicillin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of dicloxacillin sodium capsules and other antibacterial drugs, dicloxacillin sodium capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:f94ea815-9fa6-4fcf-813a-c023b2b19143 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:52017 biolink:treats MONDO:0100073 PMID:41385096 "[{""id"":""uuid:633e8504-733c-4f77-9e4f-576cdedbd09b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b95fb888-fec7-4817-b5b2-95f0cb7392ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The penicillinase-resistant penicillins are indicated in the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drugs. Cultures and susceptibility tests should be performed initially to determine the causative organism and their sensitivity to the drug (see CLINICAL PHARMACOLOGY – Susceptibility Testing ). The penicillinase-resistant penicillins may be used to initiate therapy in suspected cases of resistant staphylococcal infections prior to the availability of laboratory test results. The penicillinase-resistant penicillins should not be used in infections caused by organisms susceptible to penicillin G. If the susceptibility tests indicate that the infection is due to an organism other than a resistant staphylococcus, therapy should not be continued with a penicillinase-resistant penicillin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of dicloxacillin sodium capsules and other antibacterial drugs, dicloxacillin sodium capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:cf807919-26cf-41ed-afae-37995d4aee79 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49575 biolink:treats MONDO:0005526 PMID:41385096 "[{""id"":""uuid:22dc629e-a513-4759-ad1a-60e4f8d51901"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9e031a3b-d4a7-43eb-8651-0a5f2413e889"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diazepam is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. In acute alcohol withdrawal, diazepam may be useful in the symptomatic relief of acute agitation, tremor, impending or acute delirium tremens and hallucinosis. As an adjunct prior to endoscopic procedures if apprehension, anxiety or acute stress reactions are present, and to diminish the patient’s recall of the procedures. (See WARNINGS.) Diazepam is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology (such as inflammation of the muscles or joints, or secondary to trauma); spasticity caused by upper motor neuron disorders (such as cerebral palsy and paraplegia); athetosis; stiff-man syndrome; and tetanus. Diazepam is a useful adjunct in status epilepticus and severe recurrent convulsive seizures. Diazepam is a useful premedication (the I.M. route is preferred) for relief of anxiety and tension in patients who are to undergo surgical procedures. Intravenously, prior to cardioversion for the relief of anxiety and tension and to diminish the patient’s recall of the procedure. uuid:96ba926e-5dbe-481a-a594-6c874c01ef91 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49575 biolink:treats MONDO:0002125 PMID:41385096 "[{""id"":""uuid:e5767644-a861-4e7b-ba3d-62c6c4bdb841"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:50e46788-1bc0-4e5a-b322-53a7349a00c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diazepam is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. In acute alcohol withdrawal, diazepam may be useful in the symptomatic relief of acute agitation, tremor, impending or acute delirium tremens and hallucinosis. As an adjunct prior to endoscopic procedures if apprehension, anxiety or acute stress reactions are present, and to diminish the patient’s recall of the procedures. (See WARNINGS.) Diazepam is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology (such as inflammation of the muscles or joints, or secondary to trauma); spasticity caused by upper motor neuron disorders (such as cerebral palsy and paraplegia); athetosis; stiff-man syndrome; and tetanus. Diazepam is a useful adjunct in status epilepticus and severe recurrent convulsive seizures. Diazepam is a useful premedication (the I.M. route is preferred) for relief of anxiety and tension in patients who are to undergo surgical procedures. Intravenously, prior to cardioversion for the relief of anxiety and tension and to diminish the patient’s recall of the procedure. uuid:9bd3ca77-8c08-437e-85cf-dcab614239be biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49575 biolink:treats MONDO:0005754 PMID:41385096 "[{""id"":""uuid:e34ef641-b4af-4db2-8fe4-a8830816dad9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ad6a7057-b06d-4495-93b1-2c2cf103acb5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diazepam is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. In acute alcohol withdrawal, diazepam may be useful in the symptomatic relief of acute agitation, tremor, impending or acute delirium tremens and hallucinosis. As an adjunct prior to endoscopic procedures if apprehension, anxiety or acute stress reactions are present, and to diminish the patient’s recall of the procedures. (See WARNINGS.) Diazepam is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology (such as inflammation of the muscles or joints, or secondary to trauma); spasticity caused by upper motor neuron disorders (such as cerebral palsy and paraplegia); athetosis; stiff-man syndrome; and tetanus. Diazepam is a useful adjunct in status epilepticus and severe recurrent convulsive seizures. Diazepam is a useful premedication (the I.M. route is preferred) for relief of anxiety and tension in patients who are to undergo surgical procedures. Intravenously, prior to cardioversion for the relief of anxiety and tension and to diminish the patient’s recall of the procedure. uuid:10b5caf0-39a0-490a-8c45-ea39cf5281f3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49575 biolink:treats MONDO:0005433 PMID:41385096 "[{""id"":""uuid:0251b27d-e9ab-45aa-a5de-ffb458077228"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:40c173d5-8c26-4fcd-9375-2c8fdade685e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diazepam is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. In acute alcohol withdrawal, diazepam may be useful in the symptomatic relief of acute agitation, tremor, impending or acute delirium tremens and hallucinosis. As an adjunct prior to endoscopic procedures if apprehension, anxiety or acute stress reactions are present, and to diminish the patient’s recall of the procedures. (See WARNINGS.) Diazepam is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology (such as inflammation of the muscles or joints, or secondary to trauma); spasticity caused by upper motor neuron disorders (such as cerebral palsy and paraplegia); athetosis; stiff-man syndrome; and tetanus. Diazepam is a useful adjunct in status epilepticus and severe recurrent convulsive seizures. Diazepam is a useful premedication (the I.M. route is preferred) for relief of anxiety and tension in patients who are to undergo surgical procedures. Intravenously, prior to cardioversion for the relief of anxiety and tension and to diminish the patient’s recall of the procedure. uuid:825065a6-b714-4c88-a47c-f66eecf00cc3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6367 biolink:treats HP:0007359 PMID:41385096 "[{""id"":""uuid:02659e7c-acb0-4c63-81a4-499e84063960"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:69dd4688-1061-48c0-b876-e406d20992c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:a613b0b7-ba21-401f-934c-fe47c7cc6927"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LAMICTAL is an antiepileptic drug (AED) indicated for: Epilepsy—adjunctive therapy in patients ≥2 years of age: (1.1) partial seizures. primary generalized tonic-clonic seizures. generalized seizures of Lennox-Gastaut syndrome. Epilepsy—monotherapy in patients ≥16 years of age: conversion to monotherapy in patients with partial seizures who are receiving treatment with carbamazepine, phenobarbital, phenytoin, primidone, or valproate as the single AED. (1.1) Bipolar Disorder in patients ≥18 years of age: maintenance treatment of Bipolar I Disorder to delay the time to occurrence of mood episodes in patients treated for acute mood episodes with standard therapy. (1.2)|[PMDA] Drugs containing a new active ingredient indicated for use as adjunctive treatment with other antiepileptic drugs for partial seizures (including secondary generalized seizures), tonic-clonic seizures, and generalized seizures associated with Lennox-Gastaut syndrome in patients with epilepsy for whom other antiepileptic drugs are not sufficiently effective. uuid:1d7d7046-dda0-44f5-9d5f-d2bb84e43188 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6367 biolink:treats MONDO:0005754 PMID:41385096 "[{""id"":""uuid:258cfb66-46bb-4364-8655-d3b890c9217a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:07df328f-0046-4189-ab0c-c94ddc077ae0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f50a15c0-d937-475d-9f98-4f94d040a90a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LAMICTAL is an antiepileptic drug (AED) indicated for: Epilepsy—adjunctive therapy in patients ≥2 years of age: (1.1) partial seizures. primary generalized tonic-clonic seizures. generalized seizures of Lennox-Gastaut syndrome. Epilepsy—monotherapy in patients ≥16 years of age: conversion to monotherapy in patients with partial seizures who are receiving treatment with carbamazepine, phenobarbital, phenytoin, primidone, or valproate as the single AED. (1.1) Bipolar Disorder in patients ≥18 years of age: maintenance treatment of Bipolar I Disorder to delay the time to occurrence of mood episodes in patients treated for acute mood episodes with standard therapy. (1.2)|[PMDA] Drugs containing a new active ingredient indicated for use as adjunctive treatment with other antiepileptic drugs for partial seizures (including secondary generalized seizures), tonic-clonic seizures, and generalized seizures associated with Lennox-Gastaut syndrome in patients with epilepsy for whom other antiepileptic drugs are not sufficiently effective. uuid:8030f64e-928d-432c-89e2-a64814243527 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6367 biolink:treats MONDO:0001866 PMID:41385096 "[{""id"":""uuid:370f5ea8-873e-4ab0-9bea-8f5667e698cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:82b2cfc0-ee85-4973-8a6c-870f2af71fed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LAMICTAL is an antiepileptic drug (AED) indicated for: Epilepsy—adjunctive therapy in patients ≥2 years of age: (1.1) partial seizures. primary generalized tonic-clonic seizures. generalized seizures of Lennox-Gastaut syndrome. Epilepsy—monotherapy in patients ≥16 years of age: conversion to monotherapy in patients with partial seizures who are receiving treatment with carbamazepine, phenobarbital, phenytoin, primidone, or valproate as the single AED. (1.1) Bipolar Disorder in patients ≥18 years of age: maintenance treatment of Bipolar I Disorder to delay the time to occurrence of mood episodes in patients treated for acute mood episodes with standard therapy. (1.2) uuid:2a54843c-7c05-41df-9e39-be984c881a65 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9571 biolink:treats MONDO:0005090 PMID:41385096 "[{""id"":""uuid:f1bfb5d9-151e-4a16-a90a-872e662edf03"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:71a9cff5-08a0-40ba-9968-f4d45ffecda2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Thiothixene is effective in the management of schizophrenia. Thiothixene has not been evaluated in the management of behavioral complications in patients with mental retardation. uuid:3c575a37-1d7b-4085-a139-ddc1959e6956 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63631 biolink:treats MONDO:0005277 PMID:41385096 "[{""id"":""uuid:297c8416-94a1-44a1-9832-ec7f7cc0cf01"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:32108f7c-363f-4cc5-a543-44fe378d3e83"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TOPAMAX ® is an antiepileptic (AED) agent indicated for: Monotherapy epilepsy: Initial monotherapy in patients ≥10 years of age with partial onset or primary generalized tonic-clonic seizures ( 1.1 ). Adjunctive therapy epilepsy: Adjunctive therapy for adults and pediatric patients (2 to 16 years of age) with partial onset seizures or primary generalized tonic-clonic seizures, and in patients ≥2 years of age with seizures associated with Lennox-Gastaut syndrome (LGS) ( 1.2 ). Migraine: Treatment for adults for prophylaxis of migraine headache ( 1.3 ). uuid:34ef2770-18b4-4434-829e-eda3ff72f593 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:284756 biolink:treats MONDO:0004951 PMID:41385096 "[{""id"":""uuid:ee9e27fb-2480-4425-a4c6-56de6da53fa1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d0617253-8aa3-488a-bad1-138a19a8f832"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KALETRA is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. The following points should be considered when initiating therapy with KALETRA: The use of other active agents with KALETRA is associated with a greater likelihood of treatment response [see Clinical Pharmacology ( 12.4 ) and Clinical Studies ( 14 )] . Genotypic or phenotypic testing and/or treatment history should guide the use of KALETRA [see Clinical Pharmacology ( 12.4 )] . The number of baseline lopinavir resistance-associated substitutions affects the virologic response to KALETRA [see Clinical Pharmacology ( 12.4 )] . Once daily administration of KALETRA is not recommended for any pediatric patients. uuid:f522069f-6586-4f62-839d-ddc49f5022a5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:11949636 biolink:treats MONDO:0006668 PMID:41385096 "[{""id"":""uuid:e1f586cb-53eb-42e6-8290-ea35f9ab2f7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ce80a4bf-58ae-4862-b64b-4cbab633c6a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TOBRADEX Ophthalmic Suspension is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococci, including S. aureus and S. epidermidis (coagulase-positive and coagulase-negative), including penicillin-resistant strains. Streptococci, including some of the Group A-beta-hemolytic species, some nonhemolytic species, and some Streptococcus pneumoniae. Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, Proteus mirabilis, Morganella morganii, most Proteus vulgaris strains, Haemophilus influenzae and H. aegyptius, Moraxella lacunata, Acinetobacter calcoaceticus and some Neisseria species. uuid:3530e936-d6b0-48a0-9bde-f486e3c4576f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:11949636 biolink:treats UMLS:C0008690 PMID:41385096 "[{""id"":""uuid:473d7c55-9569-4a82-ac64-28c865e1e79b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:80f99a35-88ef-46c6-ad0d-36a94c70090d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TOBRADEX Ophthalmic Suspension is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococci, including S. aureus and S. epidermidis (coagulase-positive and coagulase-negative), including penicillin-resistant strains. Streptococci, including some of the Group A-beta-hemolytic species, some nonhemolytic species, and some Streptococcus pneumoniae. Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, Proteus mirabilis, Morganella morganii, most Proteus vulgaris strains, Haemophilus influenzae and H. aegyptius, Moraxella lacunata, Acinetobacter calcoaceticus and some Neisseria species. uuid:2661d45a-011e-4868-8045-a5212c8e3ec1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:11949636 biolink:treats UMLS:C0339289 PMID:41385096 "[{""id"":""uuid:45b08467-6109-4d49-9315-ae4d19556831"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:071cf2a3-7c81-4626-bc28-9ee832063f88"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TOBRADEX Ophthalmic Suspension is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococci, including S. aureus and S. epidermidis (coagulase-positive and coagulase-negative), including penicillin-resistant strains. Streptococci, including some of the Group A-beta-hemolytic species, some nonhemolytic species, and some Streptococcus pneumoniae. Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, Proteus mirabilis, Morganella morganii, most Proteus vulgaris strains, Haemophilus influenzae and H. aegyptius, Moraxella lacunata, Acinetobacter calcoaceticus and some Neisseria species. uuid:378b26de-bd1c-4a3b-b7b1-564765f7d194 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18067 biolink:treats MONDO:0016990 PMID:41385096 "[{""id"":""uuid:8233901d-0c39-4816-9fb4-ec464eb7e283"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:756021cb-4b0c-4842-8513-a1ff1b464abc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MEPHYTON is indicated in the following coagulation disorders which are due to faulty formation of factors II, VII, IX and X when caused by vitamin K deficiency or interference with vitamin K activity. MEPHYTON tablets are indicated in: anticoagulant-induced prothrombin deficiency caused by coumarin or indanedione derivatives; hypoprothrombinemia secondary to antibacterial therapy; hypoprothrombinemia secondary to administration of salicylates; hypoprothrombinemia secondary to obstructive jaundice or biliary fistulas but only if bile salts are administered concurrently, since otherwise the oral vitamin K will not be absorbed. uuid:f2333eee-99e4-4a84-ad88-fda6135edfb2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9139 biolink:treats NCIT:C55615 PMID:41385096 "[{""id"":""uuid:720b2e98-653d-47ec-a744-a9177400fbd1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:57449441-5e30-4991-9493-200522507d30"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VIAGRA is indicated for the treatment of erectile dysfunction. uuid:85ae8049-5f42-4a85-a078-aa1d4dc06dc6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50922 biolink:treats MONDO:0005475 PMID:41385096 "[{""id"":""uuid:0deca7b3-ddd8-451b-883a-d13978de6bf3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7a7d3557-0b14-4f17-9c00-ecf7dbd40917"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RELPAX is indicated for the acute treatment of migraine with or without aura in adults. RELPAX is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS ). Safety and effectiveness of RELPAX Tablets have not been established for cluster headache, which is present in an older, predominantly male population. uuid:436ec9f9-4aea-4666-9ea0-0551b86680d4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50922 biolink:treats MONDO:0100431 PMID:41385096 "[{""id"":""uuid:1c71e960-5581-43fe-9dbc-d594fb48c5e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4110cdb8-0401-461f-ae30-6c0e5816d16c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RELPAX is indicated for the acute treatment of migraine with or without aura in adults. RELPAX is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS ). Safety and effectiveness of RELPAX Tablets have not been established for cluster headache, which is present in an older, predominantly male population. uuid:54430ca3-d2dd-4c7e-840f-52e5ca734a21 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50922 biolink:treats MONDO:0018925 PMID:41385096 "[{""id"":""uuid:d7c41e9a-6fdd-457c-9483-3fbdcfa7dbac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e293393a-ecac-4c10-aeb4-43ac5e4bfe72"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RELPAX is indicated for the acute treatment of migraine with or without aura in adults. RELPAX is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS ). Safety and effectiveness of RELPAX Tablets have not been established for cluster headache, which is present in an older, predominantly male population. uuid:7497f745-8a17-4e13-8ab6-27283154bccc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50922 biolink:treats MONDO:0043219 PMID:41385096 "[{""id"":""uuid:a58466a7-f196-4e71-b613-25a18c856669"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a239fc35-e81a-44de-8f78-1c7af057c8d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RELPAX is indicated for the acute treatment of migraine with or without aura in adults. RELPAX is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS ). Safety and effectiveness of RELPAX Tablets have not been established for cluster headache, which is present in an older, predominantly male population. uuid:73e0520f-1221-44c9-82e4-fd4f135cd419 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50922 biolink:treats MONDO:0043537 PMID:41385096 "[{""id"":""uuid:edfbd849-cd0e-4bd0-a5e0-95980ecc6862"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c8c8cdd7-7fff-4b07-b332-bfee8f34c221"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RELPAX is indicated for the acute treatment of migraine with or without aura in adults. RELPAX is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS ). Safety and effectiveness of RELPAX Tablets have not been established for cluster headache, which is present in an older, predominantly male population. uuid:6514e593-5fb6-4c45-b1a3-e323cbda74f9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:83804 biolink:treats MONDO:0005090 PMID:41385096 "[{""id"":""uuid:7b0b59ab-35c0-4668-a043-2ed3343ae9dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:33d055d7-0bb7-454d-88d0-79d1489f566a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:1632a94a-0f94-4684-86c4-147108a5ada8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:94e5074e-806d-4b3b-8796-c14e2a98f311"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INVEGA ® is an atypical antipsychotic agent indicated for the acute and maintenance treatment of schizophrenia ( 1.1 ) acute treatment of schizoaffective disorder as monotherapy ( 1.2 ) acute treatment of schizoaffective disorder as an adjunct to mood stabilizers and/or antidepressants ( 1.2 )|[EMA] Xeplion is indicated for maintenance treatment of schizophrenia in adult patients stabilised with paliperidone or risperidone.In selected adult patients with schizophrenia and previous responsiveness to oral paliperidone or risperidone, Xeplion may be used without prior stabilisation with oral treatment if psychotic symptoms are mild to moderate and a long-acting injectable treatment is needed.|[PMDA] Drugs with a new active ingredient indicated for the treatment of schizophrenia. uuid:11364e24-1f4b-4b07-8740-6a690e7dad15 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:83804 biolink:treats MONDO:0005487 PMID:41385096 "[{""id"":""uuid:122bf6e0-1b50-4784-a9d4-77eef75a9f1b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:53489aea-5c5b-4e20-85a4-0c461ec36e97"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:d4fa7021-3d2e-4884-b19e-c0fded539251"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INVEGA ® is an atypical antipsychotic agent indicated for the acute and maintenance treatment of schizophrenia ( 1.1 ) acute treatment of schizoaffective disorder as monotherapy ( 1.2 ) acute treatment of schizoaffective disorder as an adjunct to mood stabilizers and/or antidepressants ( 1.2 )|[EMA] Invega is indicated for the treatment of schizophrenia in adults and in adolescents 15 years and older.Invega is indicated for the treatment of schizoaffective disorder in adults. uuid:2e28fe67-05d9-412f-a4ca-479567ebae8c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5893 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:4fedd986-9c01-4b5b-92cb-ef64a8297767"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4f436353-05e5-4b57-8109-7637cb9ff05b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Indapamide tablets are indicated for the treatment of hypertension, alone or in combination with other antihypertensive drugs. Indapamide tablets are also indicated for the treatment of salt and fluid retention associated with congestive heart failure. uuid:d4fde1a7-6d9d-4cc9-aecf-28b3cf08aea4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5893 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:e1fe476f-9f8b-494f-8861-0a73fc8cf180"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:91b441a6-d802-42a9-af0d-a22416f0044a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Indapamide tablets are indicated for the treatment of hypertension, alone or in combination with other antihypertensive drugs. Indapamide tablets are also indicated for the treatment of salt and fluid retention associated with congestive heart failure. uuid:dbdfdd69-4f3f-4e57-b59a-75667c11d000 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6128 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:30b1cabb-c615-4888-8830-c493ade24c57"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:bc863b19-6288-4c46-a052-6989278fae02"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:04e5cb1d-089b-4592-89d1-56a99ef61235"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of ketoprofen immediate-release capsules and ketoprofen extended-release capsules before deciding to use ketoprofen immediate-release capsules and ketoprofen extended-release capsules. Use of the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Ketoprofen immediate-release capsules and ketoprofen extended-release capsules are indicated for the management of the signs and symptoms of rheumatoid arthritis and osteoarthritis. Ketoprofen extended-release capsules are not recommended for treatment of acute pain because of its extended-release characteristics (see CLINICAL PHARMACOLOGY: Pharmacokinetics ). Ketoprofen immediate-release capsules are indicated for the management of pain. Ketoprofen immediate-release capsules are also indicated for treatment of primary dysmenorrhea.|[PMDA] Drugs with a new additional indication for relief of local pain associated with rheumatoid arthritis. uuid:7fd9ee6c-8ca7-4785-b049-6c97a773fc80 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6128 biolink:treats MONDO:0005178 PMID:41385096 "[{""id"":""uuid:ef109ca9-b666-42ce-bc61-0968f41473aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:44440d9d-5841-4231-9f07-25c925b4f211"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of ketoprofen immediate-release capsules and ketoprofen extended-release capsules before deciding to use ketoprofen immediate-release capsules and ketoprofen extended-release capsules. Use of the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Ketoprofen immediate-release capsules and ketoprofen extended-release capsules are indicated for the management of the signs and symptoms of rheumatoid arthritis and osteoarthritis. Ketoprofen extended-release capsules are not recommended for treatment of acute pain because of its extended-release characteristics (see CLINICAL PHARMACOLOGY: Pharmacokinetics ). Ketoprofen immediate-release capsules are indicated for the management of pain. Ketoprofen immediate-release capsules are also indicated for treatment of primary dysmenorrhea. uuid:1fd85116-3e44-4d14-8bfb-0ed6dd71c318 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6128 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:459eb35f-3d67-4023-98f1-84f4fc98cf07"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:708d348f-039e-42ba-9c4a-46d2e3816013"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of ketoprofen immediate-release capsules and ketoprofen extended-release capsules before deciding to use ketoprofen immediate-release capsules and ketoprofen extended-release capsules. Use of the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Ketoprofen immediate-release capsules and ketoprofen extended-release capsules are indicated for the management of the signs and symptoms of rheumatoid arthritis and osteoarthritis. Ketoprofen extended-release capsules are not recommended for treatment of acute pain because of its extended-release characteristics (see CLINICAL PHARMACOLOGY: Pharmacokinetics ). Ketoprofen immediate-release capsules are indicated for the management of pain. Ketoprofen immediate-release capsules are also indicated for treatment of primary dysmenorrhea. uuid:0cb16c19-3e3a-4cb9-a3b3-dcaeea154834 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6128 biolink:treats MONDO:1060206 PMID:41385096 "[{""id"":""uuid:007d49dc-8aeb-4276-996d-9bb18412de31"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0e6b7a59-9a99-4138-af51-3a53213bc985"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of ketoprofen immediate-release capsules and ketoprofen extended-release capsules before deciding to use ketoprofen immediate-release capsules and ketoprofen extended-release capsules. Use of the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Ketoprofen immediate-release capsules and ketoprofen extended-release capsules are indicated for the management of the signs and symptoms of rheumatoid arthritis and osteoarthritis. Ketoprofen extended-release capsules are not recommended for treatment of acute pain because of its extended-release characteristics (see CLINICAL PHARMACOLOGY: Pharmacokinetics ). Ketoprofen immediate-release capsules are indicated for the management of pain. Ketoprofen immediate-release capsules are also indicated for treatment of primary dysmenorrhea. UMLS:C0149875 uuid:f9473063-6da0-4808-8c57-3ab701f15585 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7444 biolink:treats HP:0001681 PMID:41385096 "[{""id"":""uuid:31efe7ce-0bb2-4eb7-b7f9-0b1d6e747182"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3e5a5de3-b953-4bfd-ac9f-7bb40bd9d046"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nadolol tablets are indicated for the long-term management of patients with angina pectoris. uuid:93dae400-3e69-448c-b9e1-83713c0328e8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31596 biolink:treats MONDO:0005393 PMID:41385096 "[{""id"":""uuid:d2d13055-ae05-4eb6-8261-c1b881409840"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5824a9a2-10b8-4976-9286-15f9e09805e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:3cceecb8-f89d-48f9-9ec6-f1e356e029f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/febuxostat-mylan""]},{""id"":""uuid:58b5b9d3-1a6b-4b66-b983-752161cf80e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ULORIC ® is a xanthine oxidase (XO) inhibitor indicated for the chronic management of hyperuricemia in patients with gout. ULORIC is not recommended for the treatment of asymptomatic hyperuricemia.|[EMA] Febuxostat Mylan is indicated for the prevention and treatment of hyperuricaemia in adult patients undergoing chemotherapy for haematologic malignancies at intermediate to high risk of Tumor Lysis Syndrome (TLS).Febuxostat Mylan is indicated for the treatment of chronic hyperuricaemia in conditions where urate deposition has already occurred (including a history, or presence of, tophus and/or gouty arthritis).Febuxostat Mylan is indicated in adults.|[PMDA] Drugs with a new active ingredient indicated for the treatment of gout and hyperuricemia. uuid:cf60fdd7-405c-4023-9e4d-d39ecdfc6986 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31596 biolink:treats HP:0002149 PMID:41385096 "[{""id"":""uuid:8fb774a8-a07f-4be1-896e-7f9ff458c207"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:32c60017-ad00-4b6a-b157-111007bde295"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:15cf1bbd-20bd-46b0-b72b-653a881be756"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ULORIC ® is a xanthine oxidase (XO) inhibitor indicated for the chronic management of hyperuricemia in patients with gout. ULORIC is not recommended for the treatment of asymptomatic hyperuricemia.|[PMDA] Drugs with a new active ingredient indicated for the treatment of gout and hyperuricemia. uuid:d0943821-784b-43ec-8acf-ccc0bd13fd6c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31547 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:faccf920-a45b-44c4-8fca-f7203a25603f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9916a981-7886-4109-8fd9-e0a4024201a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:54aa0b16-ef46-4467-9f9d-52350850ed3b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INSPRA is an aldosterone antagonist indicated for: Improving survival of stable patients with LV systolic dysfunction (LVEF ≤40%) and CHF after an acute myocardial infarction. ( 1.2 ) Hypertension, alone or combined with other agents. ( 1.3 )|[PMDA] Drugs with a new additional indication and a new dosage for the treatment of chronic heart failure in patients receiving basic treatment with angiotensin converting enzyme inhibitors or angiotensin II receptor antagonists, β-blockers, diuretics, etc. uuid:174f3407-d6dc-4b63-a1f8-abe6c275c08c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31547 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:f2eb1b02-f8e5-4a12-9883-2a4d437ca612"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:98f3ae43-ebee-4986-82c6-62ca6f4c345f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e4a6ba21-b004-4840-86e7-b5caad37316a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INSPRA is an aldosterone antagonist indicated for: Improving survival of stable patients with LV systolic dysfunction (LVEF ≤40%) and CHF after an acute myocardial infarction. ( 1.2 ) Hypertension, alone or combined with other agents. ( 1.3 )|[PMDA] Drugs containing a new active ingredient indicated for the treatment of hypertension. uuid:1e4e944e-05db-41d5-b079-45f53d0218de biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6437 biolink:treats HP:0032794 PMID:41385096 "[{""id"":""uuid:f9450bbc-74b0-4fab-b578-31d098a1f3b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:bd950e79-b874-4647-ba81-7027cabcca5a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:0ba9f6fd-b85b-4781-869e-9b4f65a065a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/levetiracetam-sun""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] KEPPRA is indicated as adjunctive therapy in the treatment of partial onset seizures in adults and children 4 years of age and older with epilepsy. KEPPRA is indicated as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents 12 years of age and older with juvenile myoclonic epilepsy. KEPPRA is indicated as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in adults and children 6 years of age and older with idiopathic generalized epilepsy.|[EMA] Levetiracetam Sun is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.Levetiracetam Sun is indicated as adjunctive therapy:in the treatment of partial-onset seizures with or without secondary generalisation in adults and children from four years of age with epilepsy;in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy;in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.Levetiracetam Sun concentrate is an alternative for patients when oral administration is temporarily not feasible. uuid:864bc78e-a358-4c54-9df7-bbb11ba5d84a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6437 biolink:treats MONDO:0009696 PMID:41385096 "[{""id"":""uuid:9e9bac1f-8b8f-408d-9cab-d7eebf04517f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:2cba0926-07ee-4fb5-8763-02018664c673"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:24661b3d-c24d-4839-bd90-1c2a956e30e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/levetiracetam-sun""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] KEPPRA is indicated as adjunctive therapy in the treatment of partial onset seizures in adults and children 4 years of age and older with epilepsy. KEPPRA is indicated as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents 12 years of age and older with juvenile myoclonic epilepsy. KEPPRA is indicated as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in adults and children 6 years of age and older with idiopathic generalized epilepsy.|[EMA] Levetiracetam Sun is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.Levetiracetam Sun is indicated as adjunctive therapy:in the treatment of partial-onset seizures with or without secondary generalisation in adults and children from four years of age with epilepsy;in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy;in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.Levetiracetam Sun concentrate is an alternative for patients when oral administration is temporarily not feasible. uuid:ed73eaae-3c2b-4615-8430-19c9e4117a5f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6437 biolink:treats MONDO:0005754 PMID:41385096 "[{""id"":""uuid:b5023dae-7824-4604-9402-1705cf0fe0b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7f29d16d-622b-4fef-b329-6ff0365e1c1a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ceed28e1-afa5-4d23-8589-6faf90066856"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/levetiracetam-sun""]},{""id"":""uuid:92a231ef-a249-45f6-b9cb-90347c5c4c11"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KEPPRA is indicated as adjunctive therapy in the treatment of partial onset seizures in adults and children 4 years of age and older with epilepsy. KEPPRA is indicated as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents 12 years of age and older with juvenile myoclonic epilepsy. KEPPRA is indicated as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in adults and children 6 years of age and older with idiopathic generalized epilepsy.|[EMA] Levetiracetam Sun is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.Levetiracetam Sun is indicated as adjunctive therapy:in the treatment of partial-onset seizures with or without secondary generalisation in adults and children from four years of age with epilepsy;in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy;in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.Levetiracetam Sun concentrate is an alternative for patients when oral administration is temporarily not feasible.|[PMDA] Drugs with a new additional indication for use as an adjunctive therapy with other antiepileptic drugs to treat tonic-clonic seizures in patients with epilepsy who have not responded sufficiently to other antiepileptic drugs. uuid:a084f082-f7c9-4f41-a67a-1b451245f15c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6437 biolink:treats MONDO:0005579 PMID:41385096 "[{""id"":""uuid:c82eec79-df22-48c5-a8e4-9fdbbdbd1e48"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:b68994f5-4956-434f-93ac-21a6b2804fcc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:4e448efb-623a-44c1-bb4f-48ed33ae3ce5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/levetiracetam-sun""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] KEPPRA is indicated as adjunctive therapy in the treatment of partial onset seizures in adults and children 4 years of age and older with epilepsy. KEPPRA is indicated as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents 12 years of age and older with juvenile myoclonic epilepsy. KEPPRA is indicated as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in adults and children 6 years of age and older with idiopathic generalized epilepsy.|[EMA] Levetiracetam Sun is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.Levetiracetam Sun is indicated as adjunctive therapy:in the treatment of partial-onset seizures with or without secondary generalisation in adults and children from four years of age with epilepsy;in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy;in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.Levetiracetam Sun concentrate is an alternative for patients when oral administration is temporarily not feasible. uuid:c3ea80cf-339f-4092-9dde-4ab371129ebf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:61049 biolink:treats UMLS:C0345468 PMID:41385096 "[{""id"":""uuid:3ccdde4d-e8fc-4387-9161-d49b808fa17f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:54680111-1c96-4233-a98f-72a16db6138f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:bd9b495b-6d49-4e06-880b-3796d80616a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/advagraf""]},{""id"":""uuid:4842e175-9139-4fe3-a099-5c483fd9b724"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prograf is indicated for the prophylaxis of organ rejection in patients receiving allogeneic liver, kidney, or heart transplants. It is recommended that Prograf be used concomitantly with adrenal corticosteroids. Because of the risk of anaphylaxis, Prograf injection should be reserved for patients unable to take Prograf capsules orally. In heart and kidney transplant recipients, it is recommended that Prograf be used in conjunction with azathioprine or mycophenolate mofetil (MMF). The safety and efficacy of the use of Prograf with sirolimus has not been established (see CLINICAL STUDIES ).|[EMA] Prophylaxis of transplant rejection in adult kidney or liver allograft recipients.Treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adult patients.|[PMDA] Drugs in a new dosage form indicated for suppression of organ rejection in renal, liver, heart, lung, and pancreatic transplantation, as well as for suppression of graft rejection and graft versus host disease (GVHD) in bone marrow transplantation. uuid:e950743c-2482-452d-98c8-848d1543e089 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:61049 biolink:treats UMLS:C0400968 PMID:41385096 "[{""id"":""uuid:942dcdcc-d51b-4fcf-8cbb-a98cf5e49e49"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3485c23b-2e0e-45ce-af30-ea4a1174b6b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prograf is indicated for the prophylaxis of organ rejection in patients receiving allogeneic liver, kidney, or heart transplants. It is recommended that Prograf be used concomitantly with adrenal corticosteroids. Because of the risk of anaphylaxis, Prograf injection should be reserved for patients unable to take Prograf capsules orally. In heart and kidney transplant recipients, it is recommended that Prograf be used in conjunction with azathioprine or mycophenolate mofetil (MMF). The safety and efficacy of the use of Prograf with sirolimus has not been established (see CLINICAL STUDIES ). uuid:6c0f1287-3358-45e0-9e9b-ce9afca41de0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:61049 biolink:treats UMLS:C0238217 PMID:41385096 "[{""id"":""uuid:ef8147d7-0d60-4246-9340-37386237fea9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:68a48625-e784-4a92-a876-7547cae4ec4f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e82c6f94-d9ce-4161-ac21-1e612c07f166"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prograf is indicated for the prophylaxis of organ rejection in patients receiving allogeneic liver, kidney, or heart transplants. It is recommended that Prograf be used concomitantly with adrenal corticosteroids. Because of the risk of anaphylaxis, Prograf injection should be reserved for patients unable to take Prograf capsules orally. In heart and kidney transplant recipients, it is recommended that Prograf be used in conjunction with azathioprine or mycophenolate mofetil (MMF). The safety and efficacy of the use of Prograf with sirolimus has not been established (see CLINICAL STUDIES ).|[PMDA] Drugs with a new dosage indicated for the suppression of rejection reaction associated with kidney transplantation. [Orphan drug] uuid:69be3f20-1b76-4153-8410-34f05ce38f53 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:61049 biolink:treats UMLS:C0340530 PMID:41385096 "[{""id"":""uuid:52b11421-914f-4c7b-87a4-3ebbc0501be0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6deaab27-1a6f-45ab-95f3-34008c08705a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prograf is indicated for the prophylaxis of organ rejection in patients receiving allogeneic liver, kidney, or heart transplants. It is recommended that Prograf be used concomitantly with adrenal corticosteroids. Because of the risk of anaphylaxis, Prograf injection should be reserved for patients unable to take Prograf capsules orally. In heart and kidney transplant recipients, it is recommended that Prograf be used in conjunction with azathioprine or mycophenolate mofetil (MMF). The safety and efficacy of the use of Prograf with sirolimus has not been established (see CLINICAL STUDIES ). uuid:1227ca46-3c42-4853-a35a-5e0177b33d38 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB09381 biolink:treats HP:0000134 PMID:41385096 "[{""id"":""uuid:3babb201-211c-4146-97f2-baf390e5c11b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:32c18a4a-484a-44e8-b2cf-956be1f26669"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Menest is indicated in the: Treatment of moderate to severe vasomotor symptoms associated with the menopause. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. Female hypogonadism. Female castration. Primary ovarian failure. Breast cancer (for palliation only) in appropriately selected women and men with metastatic disease. Prostatic carcinoma - palliative therapy of advanced disease. uuid:1f82ab37-825a-4647-b4fd-1034f9665c86 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB09381 biolink:treats MONDO:0005387 PMID:41385096 "[{""id"":""uuid:393c1610-4d74-448e-b0bd-9b1fb9b9dd1a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a60ecb12-b5d6-47c1-bb75-e383fed6b831"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Menest is indicated in the: Treatment of moderate to severe vasomotor symptoms associated with the menopause. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. Female hypogonadism. Female castration. Primary ovarian failure. Breast cancer (for palliation only) in appropriately selected women and men with metastatic disease. Prostatic carcinoma - palliative therapy of advanced disease. uuid:33242d52-130e-48f7-90f1-8e7433ed9470 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB09381 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:c32b41b9-8911-45d3-936f-d9f5727b7097"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:38158aa7-ef02-460b-834e-76ea40a3395d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Menest is indicated in the: Treatment of moderate to severe vasomotor symptoms associated with the menopause. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. Female hypogonadism. Female castration. Primary ovarian failure. Breast cancer (for palliation only) in appropriately selected women and men with metastatic disease. Prostatic carcinoma - palliative therapy of advanced disease. uuid:1aa67b07-c496-45a0-ac6b-b98674914f07 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB09381 biolink:treats MONDO:0005159 PMID:41385096 "[{""id"":""uuid:6c402e31-500d-4a20-bc73-2eb8cab1d5de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9a1e7dbb-963d-49b0-83ce-cb01b0a27b16"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Menest is indicated in the: Treatment of moderate to severe vasomotor symptoms associated with the menopause. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. Female hypogonadism. Female castration. Primary ovarian failure. Breast cancer (for palliation only) in appropriately selected women and men with metastatic disease. Prostatic carcinoma - palliative therapy of advanced disease. uuid:641e8dcd-fb5c-4a34-83e1-172b3ad1b840 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:216244 biolink:treats MONDO:0004795 PMID:41385096 "[{""id"":""uuid:eb206e8c-aa9b-4d8a-af49-52a63e298b30"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:08c0e4b0-48c2-4aec-9b15-f0efcf58c17c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cortisporin ® -TC Otic Suspension is indicated for the treatment of superficial bacterial infections of the external auditory canal, caused by organisms susceptible to the action of the antibiotics; and for the treatment of infections of mastoidectomy and fenestration cavities, caused by organisms susceptible to the antibiotics. uuid:e0f133fb-ef3d-4887-b82b-a33ab866a10c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:216244 biolink:treats MONDO:0021666 PMID:41385096 "[{""id"":""uuid:72f73629-6c4b-4dfd-97b6-324ddc2979b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fb3f2f9d-0aed-4a85-848a-43e05209913e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cortisporin ® -TC Otic Suspension is indicated for the treatment of superficial bacterial infections of the external auditory canal, caused by organisms susceptible to the action of the antibiotics; and for the treatment of infections of mastoidectomy and fenestration cavities, caused by organisms susceptible to the antibiotics. uuid:6d664eea-811b-4ae2-848f-9fb6bcca9aca biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:205919 biolink:treats MONDO:0006605 PMID:41385096 "[{""id"":""uuid:0922ada2-0cb4-4395-ac7c-152348a08027"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7592cbc7-bd97-49fb-9353-f9285834a7ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:92ca3fd4-43f4-4dda-8e1d-181449312c3b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clobetasol propionate topical solution is indicated for shortterm topical treatment of inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp. Treatment beyond 2 consecutive weeks is not recommended, and the total dosage should not exceed 50 mL/week because of the potential for the drug to suppress the HPA axis. This product is not recommended for use in pediatric patients under 12 years of age.|[PMDA] A drug with a new indication for the treatment of eczema/dermatitis of the scalp. uuid:053e7ced-65a6-4f8d-859b-944d38061c7f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7956 biolink:treats MONDO:0043653 PMID:41385096 "[{""id"":""uuid:cdd6f6e8-497a-496b-adee-8d6e690acaa8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ca05d232-50a8-4b88-aebc-71be15dc5da8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Denavir (penciclovir cream) is indicated for the treatment of recurrent herpes labialis (cold sores) in adults and children 12 years of age and older. uuid:bcff8e7f-06de-4342-9c97-66738b8d4a61 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:3263 biolink:treats MONDO:0018555 PMID:41385096 "[{""id"":""uuid:3b39c526-dbe9-4c8a-8f1d-9b006bf8b068"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:328f922f-fc01-4bd4-bedc-5508094b825e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DEPO-Estradiol Injection is indicated in the treatment of: Moderate to severe vasomotor symptoms associated with the menopause. Hypoestrogenism due to hypogonadism. uuid:8af3c532-ca28-4148-9437-be3368e23680 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:56841571 biolink:treats MONDO:0005338 PMID:41385096 "[{""id"":""uuid:4d90e390-9fdd-445f-8e53-24035171dfe9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6bdf7bec-3934-4362-85f2-a6ddce4ee720"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] COSOPT is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta-blockers (failed to achieve target IOP determined after multiple measurements over time). The IOP-lowering of COSOPT b.i.d. was slightly less than that seen with the concomitant administration of 0.5% timolol b.i.d. and 2.0% dorzolamide t.i.d. (see CLINICAL PHARMACOLOGY, Clinical Studies ). uuid:04419118-960a-4faa-9277-44f939b4a7c6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:56841571 biolink:treats MONDO:0006875 PMID:41385096 "[{""id"":""uuid:8549c608-d6d7-4915-b617-b1b513d6f31c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4d666303-d947-431f-99eb-bf73c2da9364"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] COSOPT is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta-blockers (failed to achieve target IOP determined after multiple measurements over time). The IOP-lowering of COSOPT b.i.d. was slightly less than that seen with the concomitant administration of 0.5% timolol b.i.d. and 2.0% dorzolamide t.i.d. (see CLINICAL PHARMACOLOGY, Clinical Studies ). uuid:4157b26a-c25b-4530-b8c7-a4054f66fda4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:127342 biolink:treats MONDO:0005302 PMID:41385096 "[{""id"":""uuid:fd5163e1-c68b-4220-90e9-b9a554decd9d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f23bc28a-2ef1-4eb8-893b-29139fe5b8f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:2e84815b-07e4-4ff4-8f12-b66118431f46"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Atomoxetine hydrochloride is a selective norepinephrine reuptake inhibitor indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD). (1.1)|[PMDA] Drugs with a new active ingredient indicated for the treatment of attention-deficit/hyperactivity disorder (AD/HD) in children. [Expedited review] uuid:acc4be40-c818-4dfa-8083-2afc4c9ac08a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45367 biolink:treats MONDO:0005866 PMID:41385096 "[{""id"":""uuid:9c82fb1d-40af-4032-9c89-13cc7e27ad04"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:292ecdc2-f834-4eef-bb58-b3c15c24533e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:be878547-fa30-4193-b608-653562b27cba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MYCOBUTIN Capsules are indicated for the prevention of disseminated Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection.|[PMDA] A drug containing a new active ingredient indicated for the treatment of 1) tuberculosis, 2) non-tuberculous mycobacteriosis including mycobacterium avium complex (MAC) infections, and 3) prophylaxis of disseminated MAC infections in patients with HIV disease. uuid:a5869d8b-e10a-4ff2-aa22-cbf62046763a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5062 biolink:treats MONDO:0010811 PMID:41385096 "[{""id"":""uuid:1584e368-4046-4857-b98b-288ceb6a5206"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3741c4f3-9d6a-48c8-805e-bf6dcffaa652"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Finasteride tablets USP are indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to: -Improve symptoms -Reduce the risk of the need for surgery including transurethral resection of the prostate (TURP) and prostatectomy. uuid:3eca50b1-d812-405b-bd25-4869baf25579 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18258 biolink:treats MONDO:0006982 PMID:41385096 "[{""id"":""uuid:c1e44549-cdd7-4f98-a3bc-1782be016d2e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:99a337dd-bf7a-49c7-a7e1-252295038f8a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Thyroid hormone drugs are indicated: As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema and ordinary hypothyroidism in patients of any age (pediatric patients, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary) or tertiary (hypothalamic) hypothyroidism (see WARNINGS ). As pituitary thyroid-stimulating hormone (TSH) suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto’s) and multinodular goiter. As diagnostic agents in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy. Cytomel (liothyronine sodium) Tablets can be used in patients allergic to desiccated thyroid or thyroid extract derived from pork or beef. uuid:c6f00679-4754-4262-b968-5dbadeffe394 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1163424 biolink:treats UMLS:C0442886 PMID:41385096 "[{""id"":""uuid:ce3bfa22-9aa9-4f85-83c1-4a8dab59e8e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:abfa6884-76d2-452f-9b67-45ac56afbf43"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the treatment of corticosteroid-responsive dermatoses with secondary infection. It has not been demonstrated that this steroid-antibiotic combination provides greater benefit than the steroid component alone after 7 days of treatment (see WARNINGS ). uuid:be9cca63-7168-4037-93ba-a9e95f1c406f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6887 biolink:treats MONDO:0005302 PMID:41385096 "[{""id"":""uuid:1ed128e7-9afb-4a7b-8920-2e7cdf95ff09"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:948651a9-a345-414c-b072-888eb1e51303"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:4e2d788a-0b62-4a5f-be00-247e7c18e698"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] CONCERTA ® is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children 6 years of age and older, adolescents, and adults up to the age of 65 [see Clinical Studies (14) ] . A diagnosis of Attention Deficit Hyperactivity Disorder (ADHD; DSM-IV) implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years. The symptoms must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and be present in two or more settings, e.g., school (or work) and at home. The symptoms must not be better accounted for by another mental disorder. For the Inattentive Type, at least six of the following symptoms must have persisted for at least 6 months: lack of attention to details/careless mistakes; lack of sustained attention; poor listener; failure to follow through on tasks; poor organization; avoids tasks requiring sustained mental effort; loses things; easily distracted; forgetful. For the Hyperactive-Impulsive Type, at least six of the following symptoms must have persisted for at least 6 months: fidgeting/squirming; leaving seat; inappropriate running/climbing; difficulty with quiet activities; ""on the go;"" excessive talking; blurting answers; can't wait turn; intrusive. The Combined Type requires both inattentive and hyperactive-impulsive criteria to be met.|[PMDA] A drug with a new indication and a new dosage in an additional dosage form indicated for the treatment of attention deficit/hyperactivity disorder (AD/HD) in adults." uuid:277f3904-2904-45e5-a1ca-6b857c6aeeb5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4325 biolink:treats MONDO:0015614 PMID:41385096 "[{""id"":""uuid:3d3d14f1-cfdd-4401-893e-781007679863"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bbee11b3-ea78-4360-8356-b0eca40a5e1e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dermatitis herpetiformis: (D.H.) Leprosy: All forms of leprosy except for cases of proven Dapsone resistance. uuid:58e715e9-6152-4ba9-ae2e-7972efc59018 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4325 biolink:treats MONDO:0005124 PMID:41385096 "[{""id"":""uuid:63a764b9-d5c8-4ee4-8e57-34ed19436252"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:00399b20-347a-4124-a030-d11b7af99910"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dermatitis herpetiformis: (D.H.) Leprosy: All forms of leprosy except for cases of proven Dapsone resistance. uuid:d9968625-596e-43a1-9a31-cad3cb72fea5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1162127 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:7ccc9a80-fee4-4aba-b817-1b3c1b995c2f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f81c99d1-9ecb-4bcd-b252-6995587d73f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] HYZAAR is indicated for the treatment of hypertension. This fixed dose combination is not indicated for initial therapy of hypertension, except when the hypertension is severe enough that the value of achieving prompt blood pressure control exceeds the risk of initiating combination therapy in these patients (see CLINICAL PHARMACOLOGY, Pharmacodynamics and Clinical Effects , and DOSAGE AND ADMINISTRATION ). uuid:27ce9e13-5f0f-4fac-87e6-7d3d2ba815e0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1152284 biolink:treats NCIT:C50995 PMID:41385096 "[{""id"":""uuid:ebbafff6-5e8c-4e93-be55-c934e02eb7d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bcedef60-83c3-4b90-ac8b-39236b0b488a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] {template} uuid:09a2f354-5572-45b0-928a-099f4e8079cf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7660 biolink:treats MONDO:0002026 PMID:41385096 "[{""id"":""uuid:83e13dd6-6d5f-42d3-a985-1b8b5d99ed5f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5606c15d-4d96-47c2-8e79-95a288ae36df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nystatin Oral Suspension is indicated for the treatment of candidiasis in the oral cavity. uuid:dd088a5f-c5cd-41b7-8f05-0509568175ed biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7660 biolink:treats MONDO:0005886 PMID:41385096 "[{""id"":""uuid:2e1de2db-898c-45d8-a84e-b02e20b533b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fcb871f0-12fa-4331-a94c-3719a370e5d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nystatin Oral Suspension is indicated for the treatment of candidiasis in the oral cavity. uuid:178a64cb-7395-43e2-a66e-87225a5c1036 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6541 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:025e0c0e-d393-4b72-a873-b0ae72cbf75b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:297a9b12-eb18-43e3-9149-d55bc3f5c194"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Losartan potassium tablets are indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents, including diuretics. uuid:72fe3322-48bc-492b-bbed-f91beaa910de biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:40303 biolink:treats HP:0003119 PMID:41385096 "[{""id"":""uuid:f74c6a5c-b940-476d-8b5e-718e710cb44c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6bea57ff-b25b-43dc-8a82-da166a5f6393"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lovastatin tablets should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin tablets should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C, and below average HDL-C, lovastatin tablets are indicated to reduce the risk of: - Myocardial infarction - Unstable angina - Coronary revascularization procedures (See CLINICAL PHARMACOLOGY, Clinical Studies .) Coronary Heart Disease Lovastatin tablets are indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Lovastatin tablets are indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb***), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. *** Classification of Hyperlipoproteinemias IDL = intermediate-density lipoprotein Type Lipoproteins elevated Lipid Elevations major minor I Chylomicrons TG ↑ →C IIa LDL C — IIb LDL, VLDL C TG III (rare) IDL C/TG — IV VLDL TG ↑ →C V (rare) Chylomicrons, VLDL TG ↑ →C Adolescent Patients with Heterozygous Familial Hypercholesterolemia Lovastatin tablets are indicated as an adjunct to diet to reduce total-C, LDL-C and apolipoprotein B levels in adolescent boys and girls who are at least one year post-menarche, 10-17 years of age, with heFH if after an adequate trial of diet therapy the following findings are present: LDL-C remains >189 mg/dL or LDL-C remains >160 mg/dL and: • there is a positive family history of premature cardiovascular disease or • two or more other CVD risk factors are present in the adolescent patient General Recommendations Prior to initiating therapy with lovastatin, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure total-C, HDL-C, and TG. For patients with TG less than 400 mg / dL (<4.5 mmol / L), LDL-C can be estimated using the following equation: LDL-C = total-C – [0.2 x (TG) + HDL-C] For TG levels >400 mg/dL (>4.5 mmol/L), this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated total-C. In such cases, lovastatin tablets are not indicated. The National Cholesterol Education Program (NCEP) Treatment Guidelines are summarized below: NCEP Treatment Guidelines: LDL-C Goals and Cutpoints for Therapeutic Lifestyle Changes and Drug Therapy in Different Risk Categories Risk Category LDL Goal (mg/dL) LDL Level at Which to Initiate Therapeutic Lifestyle Changes (mg/dL) LDL Level at Which to Consider Drug Therapy (mg/dL) CHD CHD, coronary heart disease or CHD risk equivalence (10-year risk >20%) <100 ≥100 ≥130 (100-129: drug optional) Some authorities recommend use of LDL-lowering drugs in this category if an LDL-C level of <100 mg/dL cannot be achieved by therapeutic lifestyle changes. Others prefer use of drugs that primarily modify triglycerides and HDL-C, e.g., nicotinic acid or fibrate. Clinical judgment also may call for deferring drug therapy in this subcategory. 2+ Risk factors (10-year risk ≤20%) <130 ≥130 10-year risk 10-20%: ≥130 10-year risk<10%: ≥160 0-1 Risk factor Almost all people with 0-1 risk factor have a 10-year risk <10%; thus, 10-year risk assessment in people with 0-1 risk factor is not necessary. <160 ≥160 ≥190 (160-189: LDL-lowering drug optional) After the LDL-C goal has been achieved, if the TG is still ≥200 mg/dL, non-HDL-C (total-C minus HDLC) becomes a secondary target of therapy. Non-HDL-C goals are set 30 mg/dL higher than LDL-C goals for each risk category. At the time of hospitalization for an acute coronary event, consideration can be given to initiating drug therapy at discharge if the LDL-C is ≥130 mg/dL (see NCEP Guidelines above). Since the goal of treatment is to lower LDL-C, the NCEP recommends that LDL-C levels be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the total-C be used to monitor therapy. Although lovastatin tablets may be useful to reduce elevated LDL-C levels in patients with combined hypercholesterolemia and hypertriglyceridemia where hypercholesterolemia is the major abnormality (Type IIb hyperlipoproteinemia), it has not been studied in conditions where the major abnormality is elevation of chylomicrons, VLDL or IDL (i.e., hyperlipoproteinemia types I, III, IV, or V).*** The NCEP classification of cholesterol levels in pediatric patients with a familial history of hypercholesterolemia or premature cardiovascular disease is summarized below: Category Total-C (mg/dL) LDL-C (mg/dL) Acceptable <170 <110 Borderline 170-199 110-129 High ≥200 ≥130 Children treated with lovastatin in adolescence should be re-evaluated in adulthood and appropriate changes made to their cholesterol-lowering regimen to achieve adult goals for LDL-C. uuid:f16d78af-7ced-4faa-ac88-721c4c614732 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:40303 biolink:treats MONDO:0005311 PMID:41385096 "[{""id"":""uuid:9e056fd0-288d-4322-8916-e419f5451d8f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:11ea75c7-d0a9-413d-9955-ef6a6bc9165b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lovastatin tablets should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin tablets should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C, and below average HDL-C, lovastatin tablets are indicated to reduce the risk of: - Myocardial infarction - Unstable angina - Coronary revascularization procedures (See CLINICAL PHARMACOLOGY, Clinical Studies .) Coronary Heart Disease Lovastatin tablets are indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Lovastatin tablets are indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb***), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. *** Classification of Hyperlipoproteinemias IDL = intermediate-density lipoprotein Type Lipoproteins elevated Lipid Elevations major minor I Chylomicrons TG ↑ →C IIa LDL C — IIb LDL, VLDL C TG III (rare) IDL C/TG — IV VLDL TG ↑ →C V (rare) Chylomicrons, VLDL TG ↑ →C Adolescent Patients with Heterozygous Familial Hypercholesterolemia Lovastatin tablets are indicated as an adjunct to diet to reduce total-C, LDL-C and apolipoprotein B levels in adolescent boys and girls who are at least one year post-menarche, 10-17 years of age, with heFH if after an adequate trial of diet therapy the following findings are present: LDL-C remains >189 mg/dL or LDL-C remains >160 mg/dL and: • there is a positive family history of premature cardiovascular disease or • two or more other CVD risk factors are present in the adolescent patient General Recommendations Prior to initiating therapy with lovastatin, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure total-C, HDL-C, and TG. For patients with TG less than 400 mg / dL (<4.5 mmol / L), LDL-C can be estimated using the following equation: LDL-C = total-C – [0.2 x (TG) + HDL-C] For TG levels >400 mg/dL (>4.5 mmol/L), this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated total-C. In such cases, lovastatin tablets are not indicated. The National Cholesterol Education Program (NCEP) Treatment Guidelines are summarized below: NCEP Treatment Guidelines: LDL-C Goals and Cutpoints for Therapeutic Lifestyle Changes and Drug Therapy in Different Risk Categories Risk Category LDL Goal (mg/dL) LDL Level at Which to Initiate Therapeutic Lifestyle Changes (mg/dL) LDL Level at Which to Consider Drug Therapy (mg/dL) CHD CHD, coronary heart disease or CHD risk equivalence (10-year risk >20%) <100 ≥100 ≥130 (100-129: drug optional) Some authorities recommend use of LDL-lowering drugs in this category if an LDL-C level of <100 mg/dL cannot be achieved by therapeutic lifestyle changes. Others prefer use of drugs that primarily modify triglycerides and HDL-C, e.g., nicotinic acid or fibrate. Clinical judgment also may call for deferring drug therapy in this subcategory. 2+ Risk factors (10-year risk ≤20%) <130 ≥130 10-year risk 10-20%: ≥130 10-year risk<10%: ≥160 0-1 Risk factor Almost all people with 0-1 risk factor have a 10-year risk <10%; thus, 10-year risk assessment in people with 0-1 risk factor is not necessary. <160 ≥160 ≥190 (160-189: LDL-lowering drug optional) After the LDL-C goal has been achieved, if the TG is still ≥200 mg/dL, non-HDL-C (total-C minus HDLC) becomes a secondary target of therapy. Non-HDL-C goals are set 30 mg/dL higher than LDL-C goals for each risk category. At the time of hospitalization for an acute coronary event, consideration can be given to initiating drug therapy at discharge if the LDL-C is ≥130 mg/dL (see NCEP Guidelines above). Since the goal of treatment is to lower LDL-C, the NCEP recommends that LDL-C levels be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the total-C be used to monitor therapy. Although lovastatin tablets may be useful to reduce elevated LDL-C levels in patients with combined hypercholesterolemia and hypertriglyceridemia where hypercholesterolemia is the major abnormality (Type IIb hyperlipoproteinemia), it has not been studied in conditions where the major abnormality is elevation of chylomicrons, VLDL or IDL (i.e., hyperlipoproteinemia types I, III, IV, or V).*** The NCEP classification of cholesterol levels in pediatric patients with a familial history of hypercholesterolemia or premature cardiovascular disease is summarized below: Category Total-C (mg/dL) LDL-C (mg/dL) Acceptable <170 <110 Borderline 170-199 110-129 High ≥200 ≥130 Children treated with lovastatin in adolescence should be re-evaluated in adulthood and appropriate changes made to their cholesterol-lowering regimen to achieve adult goals for LDL-C. uuid:d170c095-91af-4fdf-92e0-77efa70491b2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:40303 biolink:treats MONDO:0005010 PMID:41385096 "[{""id"":""uuid:15fdcbea-4a6f-4a77-813b-de119565e66e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:994f81d8-dbb0-4c98-8ccd-4f75d96252ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lovastatin tablets should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin tablets should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C, and below average HDL-C, lovastatin tablets are indicated to reduce the risk of: - Myocardial infarction - Unstable angina - Coronary revascularization procedures (See CLINICAL PHARMACOLOGY, Clinical Studies .) Coronary Heart Disease Lovastatin tablets are indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Lovastatin tablets are indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb***), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. *** Classification of Hyperlipoproteinemias IDL = intermediate-density lipoprotein Type Lipoproteins elevated Lipid Elevations major minor I Chylomicrons TG ↑ →C IIa LDL C — IIb LDL, VLDL C TG III (rare) IDL C/TG — IV VLDL TG ↑ →C V (rare) Chylomicrons, VLDL TG ↑ →C Adolescent Patients with Heterozygous Familial Hypercholesterolemia Lovastatin tablets are indicated as an adjunct to diet to reduce total-C, LDL-C and apolipoprotein B levels in adolescent boys and girls who are at least one year post-menarche, 10-17 years of age, with heFH if after an adequate trial of diet therapy the following findings are present: LDL-C remains >189 mg/dL or LDL-C remains >160 mg/dL and: • there is a positive family history of premature cardiovascular disease or • two or more other CVD risk factors are present in the adolescent patient General Recommendations Prior to initiating therapy with lovastatin, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure total-C, HDL-C, and TG. For patients with TG less than 400 mg / dL (<4.5 mmol / L), LDL-C can be estimated using the following equation: LDL-C = total-C – [0.2 x (TG) + HDL-C] For TG levels >400 mg/dL (>4.5 mmol/L), this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated total-C. In such cases, lovastatin tablets are not indicated. The National Cholesterol Education Program (NCEP) Treatment Guidelines are summarized below: NCEP Treatment Guidelines: LDL-C Goals and Cutpoints for Therapeutic Lifestyle Changes and Drug Therapy in Different Risk Categories Risk Category LDL Goal (mg/dL) LDL Level at Which to Initiate Therapeutic Lifestyle Changes (mg/dL) LDL Level at Which to Consider Drug Therapy (mg/dL) CHD CHD, coronary heart disease or CHD risk equivalence (10-year risk >20%) <100 ≥100 ≥130 (100-129: drug optional) Some authorities recommend use of LDL-lowering drugs in this category if an LDL-C level of <100 mg/dL cannot be achieved by therapeutic lifestyle changes. Others prefer use of drugs that primarily modify triglycerides and HDL-C, e.g., nicotinic acid or fibrate. Clinical judgment also may call for deferring drug therapy in this subcategory. 2+ Risk factors (10-year risk ≤20%) <130 ≥130 10-year risk 10-20%: ≥130 10-year risk<10%: ≥160 0-1 Risk factor Almost all people with 0-1 risk factor have a 10-year risk <10%; thus, 10-year risk assessment in people with 0-1 risk factor is not necessary. <160 ≥160 ≥190 (160-189: LDL-lowering drug optional) After the LDL-C goal has been achieved, if the TG is still ≥200 mg/dL, non-HDL-C (total-C minus HDLC) becomes a secondary target of therapy. Non-HDL-C goals are set 30 mg/dL higher than LDL-C goals for each risk category. At the time of hospitalization for an acute coronary event, consideration can be given to initiating drug therapy at discharge if the LDL-C is ≥130 mg/dL (see NCEP Guidelines above). Since the goal of treatment is to lower LDL-C, the NCEP recommends that LDL-C levels be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the total-C be used to monitor therapy. Although lovastatin tablets may be useful to reduce elevated LDL-C levels in patients with combined hypercholesterolemia and hypertriglyceridemia where hypercholesterolemia is the major abnormality (Type IIb hyperlipoproteinemia), it has not been studied in conditions where the major abnormality is elevation of chylomicrons, VLDL or IDL (i.e., hyperlipoproteinemia types I, III, IV, or V).*** The NCEP classification of cholesterol levels in pediatric patients with a familial history of hypercholesterolemia or premature cardiovascular disease is summarized below: Category Total-C (mg/dL) LDL-C (mg/dL) Acceptable <170 <110 Borderline 170-199 110-129 High ≥200 ≥130 Children treated with lovastatin in adolescence should be re-evaluated in adulthood and appropriate changes made to their cholesterol-lowering regimen to achieve adult goals for LDL-C. uuid:ff32718b-cb48-4e75-92b5-a95068c5c3c9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:40303 biolink:treats MONDO:0021661 PMID:41385096 "[{""id"":""uuid:51e88902-346d-4cf1-abfb-b26f858bc08a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:65949ce7-6ee1-445a-b4de-0bbf1e30e860"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lovastatin tablets should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin tablets should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C, and below average HDL-C, lovastatin tablets are indicated to reduce the risk of: - Myocardial infarction - Unstable angina - Coronary revascularization procedures (See CLINICAL PHARMACOLOGY, Clinical Studies .) Coronary Heart Disease Lovastatin tablets are indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Lovastatin tablets are indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb***), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. *** Classification of Hyperlipoproteinemias IDL = intermediate-density lipoprotein Type Lipoproteins elevated Lipid Elevations major minor I Chylomicrons TG ↑ →C IIa LDL C — IIb LDL, VLDL C TG III (rare) IDL C/TG — IV VLDL TG ↑ →C V (rare) Chylomicrons, VLDL TG ↑ →C Adolescent Patients with Heterozygous Familial Hypercholesterolemia Lovastatin tablets are indicated as an adjunct to diet to reduce total-C, LDL-C and apolipoprotein B levels in adolescent boys and girls who are at least one year post-menarche, 10-17 years of age, with heFH if after an adequate trial of diet therapy the following findings are present: LDL-C remains >189 mg/dL or LDL-C remains >160 mg/dL and: • there is a positive family history of premature cardiovascular disease or • two or more other CVD risk factors are present in the adolescent patient General Recommendations Prior to initiating therapy with lovastatin, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure total-C, HDL-C, and TG. For patients with TG less than 400 mg / dL (<4.5 mmol / L), LDL-C can be estimated using the following equation: LDL-C = total-C – [0.2 x (TG) + HDL-C] For TG levels >400 mg/dL (>4.5 mmol/L), this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated total-C. In such cases, lovastatin tablets are not indicated. The National Cholesterol Education Program (NCEP) Treatment Guidelines are summarized below: NCEP Treatment Guidelines: LDL-C Goals and Cutpoints for Therapeutic Lifestyle Changes and Drug Therapy in Different Risk Categories Risk Category LDL Goal (mg/dL) LDL Level at Which to Initiate Therapeutic Lifestyle Changes (mg/dL) LDL Level at Which to Consider Drug Therapy (mg/dL) CHD CHD, coronary heart disease or CHD risk equivalence (10-year risk >20%) <100 ≥100 ≥130 (100-129: drug optional) Some authorities recommend use of LDL-lowering drugs in this category if an LDL-C level of <100 mg/dL cannot be achieved by therapeutic lifestyle changes. Others prefer use of drugs that primarily modify triglycerides and HDL-C, e.g., nicotinic acid or fibrate. Clinical judgment also may call for deferring drug therapy in this subcategory. 2+ Risk factors (10-year risk ≤20%) <130 ≥130 10-year risk 10-20%: ≥130 10-year risk<10%: ≥160 0-1 Risk factor Almost all people with 0-1 risk factor have a 10-year risk <10%; thus, 10-year risk assessment in people with 0-1 risk factor is not necessary. <160 ≥160 ≥190 (160-189: LDL-lowering drug optional) After the LDL-C goal has been achieved, if the TG is still ≥200 mg/dL, non-HDL-C (total-C minus HDLC) becomes a secondary target of therapy. Non-HDL-C goals are set 30 mg/dL higher than LDL-C goals for each risk category. At the time of hospitalization for an acute coronary event, consideration can be given to initiating drug therapy at discharge if the LDL-C is ≥130 mg/dL (see NCEP Guidelines above). Since the goal of treatment is to lower LDL-C, the NCEP recommends that LDL-C levels be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the total-C be used to monitor therapy. Although lovastatin tablets may be useful to reduce elevated LDL-C levels in patients with combined hypercholesterolemia and hypertriglyceridemia where hypercholesterolemia is the major abnormality (Type IIb hyperlipoproteinemia), it has not been studied in conditions where the major abnormality is elevation of chylomicrons, VLDL or IDL (i.e., hyperlipoproteinemia types I, III, IV, or V).*** The NCEP classification of cholesterol levels in pediatric patients with a familial history of hypercholesterolemia or premature cardiovascular disease is summarized below: Category Total-C (mg/dL) LDL-C (mg/dL) Acceptable <170 <110 Borderline 170-199 110-129 High ≥200 ≥130 Children treated with lovastatin in adolescence should be re-evaluated in adulthood and appropriate changes made to their cholesterol-lowering regimen to achieve adult goals for LDL-C. uuid:04c4e576-604c-473e-8bbb-8b20f4025c15 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:40303 biolink:treats HP:0003124 PMID:41385096 "[{""id"":""uuid:0707cf96-1a7f-46a3-bbed-4f013e73efbd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:97292ebc-01c2-43ad-ac7e-e316fd63fb3d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lovastatin tablets should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin tablets should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C, and below average HDL-C, lovastatin tablets are indicated to reduce the risk of: - Myocardial infarction - Unstable angina - Coronary revascularization procedures (See CLINICAL PHARMACOLOGY, Clinical Studies .) Coronary Heart Disease Lovastatin tablets are indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Lovastatin tablets are indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb***), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. *** Classification of Hyperlipoproteinemias IDL = intermediate-density lipoprotein Type Lipoproteins elevated Lipid Elevations major minor I Chylomicrons TG ↑ →C IIa LDL C — IIb LDL, VLDL C TG III (rare) IDL C/TG — IV VLDL TG ↑ →C V (rare) Chylomicrons, VLDL TG ↑ →C Adolescent Patients with Heterozygous Familial Hypercholesterolemia Lovastatin tablets are indicated as an adjunct to diet to reduce total-C, LDL-C and apolipoprotein B levels in adolescent boys and girls who are at least one year post-menarche, 10-17 years of age, with heFH if after an adequate trial of diet therapy the following findings are present: LDL-C remains >189 mg/dL or LDL-C remains >160 mg/dL and: • there is a positive family history of premature cardiovascular disease or • two or more other CVD risk factors are present in the adolescent patient General Recommendations Prior to initiating therapy with lovastatin, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure total-C, HDL-C, and TG. For patients with TG less than 400 mg / dL (<4.5 mmol / L), LDL-C can be estimated using the following equation: LDL-C = total-C – [0.2 x (TG) + HDL-C] For TG levels >400 mg/dL (>4.5 mmol/L), this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated total-C. In such cases, lovastatin tablets are not indicated. The National Cholesterol Education Program (NCEP) Treatment Guidelines are summarized below: NCEP Treatment Guidelines: LDL-C Goals and Cutpoints for Therapeutic Lifestyle Changes and Drug Therapy in Different Risk Categories Risk Category LDL Goal (mg/dL) LDL Level at Which to Initiate Therapeutic Lifestyle Changes (mg/dL) LDL Level at Which to Consider Drug Therapy (mg/dL) CHD CHD, coronary heart disease or CHD risk equivalence (10-year risk >20%) <100 ≥100 ≥130 (100-129: drug optional) Some authorities recommend use of LDL-lowering drugs in this category if an LDL-C level of <100 mg/dL cannot be achieved by therapeutic lifestyle changes. Others prefer use of drugs that primarily modify triglycerides and HDL-C, e.g., nicotinic acid or fibrate. Clinical judgment also may call for deferring drug therapy in this subcategory. 2+ Risk factors (10-year risk ≤20%) <130 ≥130 10-year risk 10-20%: ≥130 10-year risk<10%: ≥160 0-1 Risk factor Almost all people with 0-1 risk factor have a 10-year risk <10%; thus, 10-year risk assessment in people with 0-1 risk factor is not necessary. <160 ≥160 ≥190 (160-189: LDL-lowering drug optional) After the LDL-C goal has been achieved, if the TG is still ≥200 mg/dL, non-HDL-C (total-C minus HDLC) becomes a secondary target of therapy. Non-HDL-C goals are set 30 mg/dL higher than LDL-C goals for each risk category. At the time of hospitalization for an acute coronary event, consideration can be given to initiating drug therapy at discharge if the LDL-C is ≥130 mg/dL (see NCEP Guidelines above). Since the goal of treatment is to lower LDL-C, the NCEP recommends that LDL-C levels be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the total-C be used to monitor therapy. Although lovastatin tablets may be useful to reduce elevated LDL-C levels in patients with combined hypercholesterolemia and hypertriglyceridemia where hypercholesterolemia is the major abnormality (Type IIb hyperlipoproteinemia), it has not been studied in conditions where the major abnormality is elevation of chylomicrons, VLDL or IDL (i.e., hyperlipoproteinemia types I, III, IV, or V).*** The NCEP classification of cholesterol levels in pediatric patients with a familial history of hypercholesterolemia or premature cardiovascular disease is summarized below: Category Total-C (mg/dL) LDL-C (mg/dL) Acceptable <170 <110 Borderline 170-199 110-129 High ≥200 ≥130 Children treated with lovastatin in adolescence should be re-evaluated in adulthood and appropriate changes made to their cholesterol-lowering regimen to achieve adult goals for LDL-C. uuid:b8ff875a-219d-417c-9954-ebf3bfdc6e0e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:40303 biolink:treats UMLS:C0342879 PMID:41385096 "[{""id"":""uuid:45ac022b-4da2-4228-b482-f06b77f48d9f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0810db2f-dc5e-445e-a313-6c7b3e82e94d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lovastatin tablets should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin tablets should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C, and below average HDL-C, lovastatin tablets are indicated to reduce the risk of: - Myocardial infarction - Unstable angina - Coronary revascularization procedures (See CLINICAL PHARMACOLOGY, Clinical Studies .) Coronary Heart Disease Lovastatin tablets are indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Lovastatin tablets are indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb***), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. *** Classification of Hyperlipoproteinemias IDL = intermediate-density lipoprotein Type Lipoproteins elevated Lipid Elevations major minor I Chylomicrons TG ↑ →C IIa LDL C — IIb LDL, VLDL C TG III (rare) IDL C/TG — IV VLDL TG ↑ →C V (rare) Chylomicrons, VLDL TG ↑ →C Adolescent Patients with Heterozygous Familial Hypercholesterolemia Lovastatin tablets are indicated as an adjunct to diet to reduce total-C, LDL-C and apolipoprotein B levels in adolescent boys and girls who are at least one year post-menarche, 10-17 years of age, with heFH if after an adequate trial of diet therapy the following findings are present: LDL-C remains >189 mg/dL or LDL-C remains >160 mg/dL and: • there is a positive family history of premature cardiovascular disease or • two or more other CVD risk factors are present in the adolescent patient General Recommendations Prior to initiating therapy with lovastatin, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure total-C, HDL-C, and TG. For patients with TG less than 400 mg / dL (<4.5 mmol / L), LDL-C can be estimated using the following equation: LDL-C = total-C – [0.2 x (TG) + HDL-C] For TG levels >400 mg/dL (>4.5 mmol/L), this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated total-C. In such cases, lovastatin tablets are not indicated. The National Cholesterol Education Program (NCEP) Treatment Guidelines are summarized below: NCEP Treatment Guidelines: LDL-C Goals and Cutpoints for Therapeutic Lifestyle Changes and Drug Therapy in Different Risk Categories Risk Category LDL Goal (mg/dL) LDL Level at Which to Initiate Therapeutic Lifestyle Changes (mg/dL) LDL Level at Which to Consider Drug Therapy (mg/dL) CHD CHD, coronary heart disease or CHD risk equivalence (10-year risk >20%) <100 ≥100 ≥130 (100-129: drug optional) Some authorities recommend use of LDL-lowering drugs in this category if an LDL-C level of <100 mg/dL cannot be achieved by therapeutic lifestyle changes. Others prefer use of drugs that primarily modify triglycerides and HDL-C, e.g., nicotinic acid or fibrate. Clinical judgment also may call for deferring drug therapy in this subcategory. 2+ Risk factors (10-year risk ≤20%) <130 ≥130 10-year risk 10-20%: ≥130 10-year risk<10%: ≥160 0-1 Risk factor Almost all people with 0-1 risk factor have a 10-year risk <10%; thus, 10-year risk assessment in people with 0-1 risk factor is not necessary. <160 ≥160 ≥190 (160-189: LDL-lowering drug optional) After the LDL-C goal has been achieved, if the TG is still ≥200 mg/dL, non-HDL-C (total-C minus HDLC) becomes a secondary target of therapy. Non-HDL-C goals are set 30 mg/dL higher than LDL-C goals for each risk category. At the time of hospitalization for an acute coronary event, consideration can be given to initiating drug therapy at discharge if the LDL-C is ≥130 mg/dL (see NCEP Guidelines above). Since the goal of treatment is to lower LDL-C, the NCEP recommends that LDL-C levels be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the total-C be used to monitor therapy. Although lovastatin tablets may be useful to reduce elevated LDL-C levels in patients with combined hypercholesterolemia and hypertriglyceridemia where hypercholesterolemia is the major abnormality (Type IIb hyperlipoproteinemia), it has not been studied in conditions where the major abnormality is elevation of chylomicrons, VLDL or IDL (i.e., hyperlipoproteinemia types I, III, IV, or V).*** The NCEP classification of cholesterol levels in pediatric patients with a familial history of hypercholesterolemia or premature cardiovascular disease is summarized below: Category Total-C (mg/dL) LDL-C (mg/dL) Acceptable <170 <110 Borderline 170-199 110-129 High ≥200 ≥130 Children treated with lovastatin in adolescence should be re-evaluated in adulthood and appropriate changes made to their cholesterol-lowering regimen to achieve adult goals for LDL-C. uuid:bce92e8b-c7fa-478c-9786-da4692b1c808 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:40303 biolink:treats UMLS:C0342882 PMID:41385096 "[{""id"":""uuid:351b7ba1-c019-47a1-907a-6cb2c67ed1db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2950383a-2aa8-42f9-8e72-4bbe9a9f4426"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lovastatin tablets should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin tablets should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C, and below average HDL-C, lovastatin tablets are indicated to reduce the risk of: - Myocardial infarction - Unstable angina - Coronary revascularization procedures (See CLINICAL PHARMACOLOGY, Clinical Studies .) Coronary Heart Disease Lovastatin tablets are indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Lovastatin tablets are indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb***), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. *** Classification of Hyperlipoproteinemias IDL = intermediate-density lipoprotein Type Lipoproteins elevated Lipid Elevations major minor I Chylomicrons TG ↑ →C IIa LDL C — IIb LDL, VLDL C TG III (rare) IDL C/TG — IV VLDL TG ↑ →C V (rare) Chylomicrons, VLDL TG ↑ →C Adolescent Patients with Heterozygous Familial Hypercholesterolemia Lovastatin tablets are indicated as an adjunct to diet to reduce total-C, LDL-C and apolipoprotein B levels in adolescent boys and girls who are at least one year post-menarche, 10-17 years of age, with heFH if after an adequate trial of diet therapy the following findings are present: LDL-C remains >189 mg/dL or LDL-C remains >160 mg/dL and: • there is a positive family history of premature cardiovascular disease or • two or more other CVD risk factors are present in the adolescent patient General Recommendations Prior to initiating therapy with lovastatin, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure total-C, HDL-C, and TG. For patients with TG less than 400 mg / dL (<4.5 mmol / L), LDL-C can be estimated using the following equation: LDL-C = total-C – [0.2 x (TG) + HDL-C] For TG levels >400 mg/dL (>4.5 mmol/L), this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated total-C. In such cases, lovastatin tablets are not indicated. The National Cholesterol Education Program (NCEP) Treatment Guidelines are summarized below: NCEP Treatment Guidelines: LDL-C Goals and Cutpoints for Therapeutic Lifestyle Changes and Drug Therapy in Different Risk Categories Risk Category LDL Goal (mg/dL) LDL Level at Which to Initiate Therapeutic Lifestyle Changes (mg/dL) LDL Level at Which to Consider Drug Therapy (mg/dL) CHD CHD, coronary heart disease or CHD risk equivalence (10-year risk >20%) <100 ≥100 ≥130 (100-129: drug optional) Some authorities recommend use of LDL-lowering drugs in this category if an LDL-C level of <100 mg/dL cannot be achieved by therapeutic lifestyle changes. Others prefer use of drugs that primarily modify triglycerides and HDL-C, e.g., nicotinic acid or fibrate. Clinical judgment also may call for deferring drug therapy in this subcategory. 2+ Risk factors (10-year risk ≤20%) <130 ≥130 10-year risk 10-20%: ≥130 10-year risk<10%: ≥160 0-1 Risk factor Almost all people with 0-1 risk factor have a 10-year risk <10%; thus, 10-year risk assessment in people with 0-1 risk factor is not necessary. <160 ≥160 ≥190 (160-189: LDL-lowering drug optional) After the LDL-C goal has been achieved, if the TG is still ≥200 mg/dL, non-HDL-C (total-C minus HDLC) becomes a secondary target of therapy. Non-HDL-C goals are set 30 mg/dL higher than LDL-C goals for each risk category. At the time of hospitalization for an acute coronary event, consideration can be given to initiating drug therapy at discharge if the LDL-C is ≥130 mg/dL (see NCEP Guidelines above). Since the goal of treatment is to lower LDL-C, the NCEP recommends that LDL-C levels be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the total-C be used to monitor therapy. Although lovastatin tablets may be useful to reduce elevated LDL-C levels in patients with combined hypercholesterolemia and hypertriglyceridemia where hypercholesterolemia is the major abnormality (Type IIb hyperlipoproteinemia), it has not been studied in conditions where the major abnormality is elevation of chylomicrons, VLDL or IDL (i.e., hyperlipoproteinemia types I, III, IV, or V).*** The NCEP classification of cholesterol levels in pediatric patients with a familial history of hypercholesterolemia or premature cardiovascular disease is summarized below: Category Total-C (mg/dL) LDL-C (mg/dL) Acceptable <170 <110 Borderline 170-199 110-129 High ≥200 ≥130 Children treated with lovastatin in adolescence should be re-evaluated in adulthood and appropriate changes made to their cholesterol-lowering regimen to achieve adult goals for LDL-C. uuid:c9741124-3f38-438b-af2c-84ae8f9e821a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:40303 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:dfcca009-8f0c-4ac7-a108-a77ac37c087a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:69ff39eb-699c-47bd-9ac8-4dc3aa01c7dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lovastatin tablets should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin tablets should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C, and below average HDL-C, lovastatin tablets are indicated to reduce the risk of: - Myocardial infarction - Unstable angina - Coronary revascularization procedures (See CLINICAL PHARMACOLOGY, Clinical Studies .) Coronary Heart Disease Lovastatin tablets are indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Lovastatin tablets are indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb***), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. *** Classification of Hyperlipoproteinemias IDL = intermediate-density lipoprotein Type Lipoproteins elevated Lipid Elevations major minor I Chylomicrons TG ↑ →C IIa LDL C — IIb LDL, VLDL C TG III (rare) IDL C/TG — IV VLDL TG ↑ →C V (rare) Chylomicrons, VLDL TG ↑ →C Adolescent Patients with Heterozygous Familial Hypercholesterolemia Lovastatin tablets are indicated as an adjunct to diet to reduce total-C, LDL-C and apolipoprotein B levels in adolescent boys and girls who are at least one year post-menarche, 10-17 years of age, with heFH if after an adequate trial of diet therapy the following findings are present: LDL-C remains >189 mg/dL or LDL-C remains >160 mg/dL and: • there is a positive family history of premature cardiovascular disease or • two or more other CVD risk factors are present in the adolescent patient General Recommendations Prior to initiating therapy with lovastatin, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure total-C, HDL-C, and TG. For patients with TG less than 400 mg / dL (<4.5 mmol / L), LDL-C can be estimated using the following equation: LDL-C = total-C – [0.2 x (TG) + HDL-C] For TG levels >400 mg/dL (>4.5 mmol/L), this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated total-C. In such cases, lovastatin tablets are not indicated. The National Cholesterol Education Program (NCEP) Treatment Guidelines are summarized below: NCEP Treatment Guidelines: LDL-C Goals and Cutpoints for Therapeutic Lifestyle Changes and Drug Therapy in Different Risk Categories Risk Category LDL Goal (mg/dL) LDL Level at Which to Initiate Therapeutic Lifestyle Changes (mg/dL) LDL Level at Which to Consider Drug Therapy (mg/dL) CHD CHD, coronary heart disease or CHD risk equivalence (10-year risk >20%) <100 ≥100 ≥130 (100-129: drug optional) Some authorities recommend use of LDL-lowering drugs in this category if an LDL-C level of <100 mg/dL cannot be achieved by therapeutic lifestyle changes. Others prefer use of drugs that primarily modify triglycerides and HDL-C, e.g., nicotinic acid or fibrate. Clinical judgment also may call for deferring drug therapy in this subcategory. 2+ Risk factors (10-year risk ≤20%) <130 ≥130 10-year risk 10-20%: ≥130 10-year risk<10%: ≥160 0-1 Risk factor Almost all people with 0-1 risk factor have a 10-year risk <10%; thus, 10-year risk assessment in people with 0-1 risk factor is not necessary. <160 ≥160 ≥190 (160-189: LDL-lowering drug optional) After the LDL-C goal has been achieved, if the TG is still ≥200 mg/dL, non-HDL-C (total-C minus HDLC) becomes a secondary target of therapy. Non-HDL-C goals are set 30 mg/dL higher than LDL-C goals for each risk category. At the time of hospitalization for an acute coronary event, consideration can be given to initiating drug therapy at discharge if the LDL-C is ≥130 mg/dL (see NCEP Guidelines above). Since the goal of treatment is to lower LDL-C, the NCEP recommends that LDL-C levels be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the total-C be used to monitor therapy. Although lovastatin tablets may be useful to reduce elevated LDL-C levels in patients with combined hypercholesterolemia and hypertriglyceridemia where hypercholesterolemia is the major abnormality (Type IIb hyperlipoproteinemia), it has not been studied in conditions where the major abnormality is elevation of chylomicrons, VLDL or IDL (i.e., hyperlipoproteinemia types I, III, IV, or V).*** The NCEP classification of cholesterol levels in pediatric patients with a familial history of hypercholesterolemia or premature cardiovascular disease is summarized below: Category Total-C (mg/dL) LDL-C (mg/dL) Acceptable <170 <110 Borderline 170-199 110-129 High ≥200 ≥130 Children treated with lovastatin in adolescence should be re-evaluated in adulthood and appropriate changes made to their cholesterol-lowering regimen to achieve adult goals for LDL-C. uuid:48889c67-2374-447d-bf2d-bf3161bd4931 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:40303 biolink:treats MONDO:0005420 PMID:41385096 "[{""id"":""uuid:e4b15c2f-dde7-4bd6-a29a-2a8fc1696866"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6664dbca-86df-4fec-86db-acf2fc0c4e1d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lovastatin tablets should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin tablets should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C, and below average HDL-C, lovastatin tablets are indicated to reduce the risk of: - Myocardial infarction - Unstable angina - Coronary revascularization procedures (See CLINICAL PHARMACOLOGY, Clinical Studies .) Coronary Heart Disease Lovastatin tablets are indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Lovastatin tablets are indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb***), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. *** Classification of Hyperlipoproteinemias IDL = intermediate-density lipoprotein Type Lipoproteins elevated Lipid Elevations major minor I Chylomicrons TG ↑ →C IIa LDL C — IIb LDL, VLDL C TG III (rare) IDL C/TG — IV VLDL TG ↑ →C V (rare) Chylomicrons, VLDL TG ↑ →C Adolescent Patients with Heterozygous Familial Hypercholesterolemia Lovastatin tablets are indicated as an adjunct to diet to reduce total-C, LDL-C and apolipoprotein B levels in adolescent boys and girls who are at least one year post-menarche, 10-17 years of age, with heFH if after an adequate trial of diet therapy the following findings are present: LDL-C remains >189 mg/dL or LDL-C remains >160 mg/dL and: • there is a positive family history of premature cardiovascular disease or • two or more other CVD risk factors are present in the adolescent patient General Recommendations Prior to initiating therapy with lovastatin, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure total-C, HDL-C, and TG. For patients with TG less than 400 mg / dL (<4.5 mmol / L), LDL-C can be estimated using the following equation: LDL-C = total-C – [0.2 x (TG) + HDL-C] For TG levels >400 mg/dL (>4.5 mmol/L), this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated total-C. In such cases, lovastatin tablets are not indicated. The National Cholesterol Education Program (NCEP) Treatment Guidelines are summarized below: NCEP Treatment Guidelines: LDL-C Goals and Cutpoints for Therapeutic Lifestyle Changes and Drug Therapy in Different Risk Categories Risk Category LDL Goal (mg/dL) LDL Level at Which to Initiate Therapeutic Lifestyle Changes (mg/dL) LDL Level at Which to Consider Drug Therapy (mg/dL) CHD CHD, coronary heart disease or CHD risk equivalence (10-year risk >20%) <100 ≥100 ≥130 (100-129: drug optional) Some authorities recommend use of LDL-lowering drugs in this category if an LDL-C level of <100 mg/dL cannot be achieved by therapeutic lifestyle changes. Others prefer use of drugs that primarily modify triglycerides and HDL-C, e.g., nicotinic acid or fibrate. Clinical judgment also may call for deferring drug therapy in this subcategory. 2+ Risk factors (10-year risk ≤20%) <130 ≥130 10-year risk 10-20%: ≥130 10-year risk<10%: ≥160 0-1 Risk factor Almost all people with 0-1 risk factor have a 10-year risk <10%; thus, 10-year risk assessment in people with 0-1 risk factor is not necessary. <160 ≥160 ≥190 (160-189: LDL-lowering drug optional) After the LDL-C goal has been achieved, if the TG is still ≥200 mg/dL, non-HDL-C (total-C minus HDLC) becomes a secondary target of therapy. Non-HDL-C goals are set 30 mg/dL higher than LDL-C goals for each risk category. At the time of hospitalization for an acute coronary event, consideration can be given to initiating drug therapy at discharge if the LDL-C is ≥130 mg/dL (see NCEP Guidelines above). Since the goal of treatment is to lower LDL-C, the NCEP recommends that LDL-C levels be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the total-C be used to monitor therapy. Although lovastatin tablets may be useful to reduce elevated LDL-C levels in patients with combined hypercholesterolemia and hypertriglyceridemia where hypercholesterolemia is the major abnormality (Type IIb hyperlipoproteinemia), it has not been studied in conditions where the major abnormality is elevation of chylomicrons, VLDL or IDL (i.e., hyperlipoproteinemia types I, III, IV, or V).*** The NCEP classification of cholesterol levels in pediatric patients with a familial history of hypercholesterolemia or premature cardiovascular disease is summarized below: Category Total-C (mg/dL) LDL-C (mg/dL) Acceptable <170 <110 Borderline 170-199 110-129 High ≥200 ≥130 Children treated with lovastatin in adolescence should be re-evaluated in adulthood and appropriate changes made to their cholesterol-lowering regimen to achieve adult goals for LDL-C. uuid:576260d6-9ae5-4309-b7f3-92827d93a2bf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:40303 biolink:treats MONDO:0005377 PMID:41385096 "[{""id"":""uuid:e4a9e0c3-79e8-4d2d-9dda-e0c66fafddda"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e827e967-ff31-46fd-a749-7de87203b066"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lovastatin tablets should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin tablets should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C, and below average HDL-C, lovastatin tablets are indicated to reduce the risk of: - Myocardial infarction - Unstable angina - Coronary revascularization procedures (See CLINICAL PHARMACOLOGY, Clinical Studies .) Coronary Heart Disease Lovastatin tablets are indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Lovastatin tablets are indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb***), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. *** Classification of Hyperlipoproteinemias IDL = intermediate-density lipoprotein Type Lipoproteins elevated Lipid Elevations major minor I Chylomicrons TG ↑ →C IIa LDL C — IIb LDL, VLDL C TG III (rare) IDL C/TG — IV VLDL TG ↑ →C V (rare) Chylomicrons, VLDL TG ↑ →C Adolescent Patients with Heterozygous Familial Hypercholesterolemia Lovastatin tablets are indicated as an adjunct to diet to reduce total-C, LDL-C and apolipoprotein B levels in adolescent boys and girls who are at least one year post-menarche, 10-17 years of age, with heFH if after an adequate trial of diet therapy the following findings are present: LDL-C remains >189 mg/dL or LDL-C remains >160 mg/dL and: • there is a positive family history of premature cardiovascular disease or • two or more other CVD risk factors are present in the adolescent patient General Recommendations Prior to initiating therapy with lovastatin, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure total-C, HDL-C, and TG. For patients with TG less than 400 mg / dL (<4.5 mmol / L), LDL-C can be estimated using the following equation: LDL-C = total-C – [0.2 x (TG) + HDL-C] For TG levels >400 mg/dL (>4.5 mmol/L), this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated total-C. In such cases, lovastatin tablets are not indicated. The National Cholesterol Education Program (NCEP) Treatment Guidelines are summarized below: NCEP Treatment Guidelines: LDL-C Goals and Cutpoints for Therapeutic Lifestyle Changes and Drug Therapy in Different Risk Categories Risk Category LDL Goal (mg/dL) LDL Level at Which to Initiate Therapeutic Lifestyle Changes (mg/dL) LDL Level at Which to Consider Drug Therapy (mg/dL) CHD CHD, coronary heart disease or CHD risk equivalence (10-year risk >20%) <100 ≥100 ≥130 (100-129: drug optional) Some authorities recommend use of LDL-lowering drugs in this category if an LDL-C level of <100 mg/dL cannot be achieved by therapeutic lifestyle changes. Others prefer use of drugs that primarily modify triglycerides and HDL-C, e.g., nicotinic acid or fibrate. Clinical judgment also may call for deferring drug therapy in this subcategory. 2+ Risk factors (10-year risk ≤20%) <130 ≥130 10-year risk 10-20%: ≥130 10-year risk<10%: ≥160 0-1 Risk factor Almost all people with 0-1 risk factor have a 10-year risk <10%; thus, 10-year risk assessment in people with 0-1 risk factor is not necessary. <160 ≥160 ≥190 (160-189: LDL-lowering drug optional) After the LDL-C goal has been achieved, if the TG is still ≥200 mg/dL, non-HDL-C (total-C minus HDLC) becomes a secondary target of therapy. Non-HDL-C goals are set 30 mg/dL higher than LDL-C goals for each risk category. At the time of hospitalization for an acute coronary event, consideration can be given to initiating drug therapy at discharge if the LDL-C is ≥130 mg/dL (see NCEP Guidelines above). Since the goal of treatment is to lower LDL-C, the NCEP recommends that LDL-C levels be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the total-C be used to monitor therapy. Although lovastatin tablets may be useful to reduce elevated LDL-C levels in patients with combined hypercholesterolemia and hypertriglyceridemia where hypercholesterolemia is the major abnormality (Type IIb hyperlipoproteinemia), it has not been studied in conditions where the major abnormality is elevation of chylomicrons, VLDL or IDL (i.e., hyperlipoproteinemia types I, III, IV, or V).*** The NCEP classification of cholesterol levels in pediatric patients with a familial history of hypercholesterolemia or premature cardiovascular disease is summarized below: Category Total-C (mg/dL) LDL-C (mg/dL) Acceptable <170 <110 Borderline 170-199 110-129 High ≥200 ≥130 Children treated with lovastatin in adolescence should be re-evaluated in adulthood and appropriate changes made to their cholesterol-lowering regimen to achieve adult goals for LDL-C. uuid:b66c4709-60eb-4f47-9795-d439c78a7d68 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:40303 biolink:treats UMLS:C0259744 PMID:41385096 "[{""id"":""uuid:caa8e488-235b-4ae4-80d2-acab91926be6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f004fc45-d0f7-45ad-8590-af30c8e17929"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lovastatin tablets should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin tablets should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C, and below average HDL-C, lovastatin tablets are indicated to reduce the risk of: - Myocardial infarction - Unstable angina - Coronary revascularization procedures (See CLINICAL PHARMACOLOGY, Clinical Studies .) Coronary Heart Disease Lovastatin tablets are indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Lovastatin tablets are indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb***), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. *** Classification of Hyperlipoproteinemias IDL = intermediate-density lipoprotein Type Lipoproteins elevated Lipid Elevations major minor I Chylomicrons TG ↑ →C IIa LDL C — IIb LDL, VLDL C TG III (rare) IDL C/TG — IV VLDL TG ↑ →C V (rare) Chylomicrons, VLDL TG ↑ →C Adolescent Patients with Heterozygous Familial Hypercholesterolemia Lovastatin tablets are indicated as an adjunct to diet to reduce total-C, LDL-C and apolipoprotein B levels in adolescent boys and girls who are at least one year post-menarche, 10-17 years of age, with heFH if after an adequate trial of diet therapy the following findings are present: LDL-C remains >189 mg/dL or LDL-C remains >160 mg/dL and: • there is a positive family history of premature cardiovascular disease or • two or more other CVD risk factors are present in the adolescent patient General Recommendations Prior to initiating therapy with lovastatin, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure total-C, HDL-C, and TG. For patients with TG less than 400 mg / dL (<4.5 mmol / L), LDL-C can be estimated using the following equation: LDL-C = total-C – [0.2 x (TG) + HDL-C] For TG levels >400 mg/dL (>4.5 mmol/L), this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated total-C. In such cases, lovastatin tablets are not indicated. The National Cholesterol Education Program (NCEP) Treatment Guidelines are summarized below: NCEP Treatment Guidelines: LDL-C Goals and Cutpoints for Therapeutic Lifestyle Changes and Drug Therapy in Different Risk Categories Risk Category LDL Goal (mg/dL) LDL Level at Which to Initiate Therapeutic Lifestyle Changes (mg/dL) LDL Level at Which to Consider Drug Therapy (mg/dL) CHD CHD, coronary heart disease or CHD risk equivalence (10-year risk >20%) <100 ≥100 ≥130 (100-129: drug optional) Some authorities recommend use of LDL-lowering drugs in this category if an LDL-C level of <100 mg/dL cannot be achieved by therapeutic lifestyle changes. Others prefer use of drugs that primarily modify triglycerides and HDL-C, e.g., nicotinic acid or fibrate. Clinical judgment also may call for deferring drug therapy in this subcategory. 2+ Risk factors (10-year risk ≤20%) <130 ≥130 10-year risk 10-20%: ≥130 10-year risk<10%: ≥160 0-1 Risk factor Almost all people with 0-1 risk factor have a 10-year risk <10%; thus, 10-year risk assessment in people with 0-1 risk factor is not necessary. <160 ≥160 ≥190 (160-189: LDL-lowering drug optional) After the LDL-C goal has been achieved, if the TG is still ≥200 mg/dL, non-HDL-C (total-C minus HDLC) becomes a secondary target of therapy. Non-HDL-C goals are set 30 mg/dL higher than LDL-C goals for each risk category. At the time of hospitalization for an acute coronary event, consideration can be given to initiating drug therapy at discharge if the LDL-C is ≥130 mg/dL (see NCEP Guidelines above). Since the goal of treatment is to lower LDL-C, the NCEP recommends that LDL-C levels be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the total-C be used to monitor therapy. Although lovastatin tablets may be useful to reduce elevated LDL-C levels in patients with combined hypercholesterolemia and hypertriglyceridemia where hypercholesterolemia is the major abnormality (Type IIb hyperlipoproteinemia), it has not been studied in conditions where the major abnormality is elevation of chylomicrons, VLDL or IDL (i.e., hyperlipoproteinemia types I, III, IV, or V).*** The NCEP classification of cholesterol levels in pediatric patients with a familial history of hypercholesterolemia or premature cardiovascular disease is summarized below: Category Total-C (mg/dL) LDL-C (mg/dL) Acceptable <170 <110 Borderline 170-199 110-129 High ≥200 ≥130 Children treated with lovastatin in adolescence should be re-evaluated in adulthood and appropriate changes made to their cholesterol-lowering regimen to achieve adult goals for LDL-C. uuid:cc023c1a-d500-4388-82cf-32c1d3f48131 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:40303 biolink:treats MONDO:0006874 PMID:41385096 "[{""id"":""uuid:9b08b25c-9b8d-43ce-8045-a9a871eee5dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ad9a1d70-36dc-498b-82e5-a4bed009007a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lovastatin tablets should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin tablets should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C, and below average HDL-C, lovastatin tablets are indicated to reduce the risk of: - Myocardial infarction - Unstable angina - Coronary revascularization procedures (See CLINICAL PHARMACOLOGY, Clinical Studies .) Coronary Heart Disease Lovastatin tablets are indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Lovastatin tablets are indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb***), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. *** Classification of Hyperlipoproteinemias IDL = intermediate-density lipoprotein Type Lipoproteins elevated Lipid Elevations major minor I Chylomicrons TG ↑ →C IIa LDL C — IIb LDL, VLDL C TG III (rare) IDL C/TG — IV VLDL TG ↑ →C V (rare) Chylomicrons, VLDL TG ↑ →C Adolescent Patients with Heterozygous Familial Hypercholesterolemia Lovastatin tablets are indicated as an adjunct to diet to reduce total-C, LDL-C and apolipoprotein B levels in adolescent boys and girls who are at least one year post-menarche, 10-17 years of age, with heFH if after an adequate trial of diet therapy the following findings are present: LDL-C remains >189 mg/dL or LDL-C remains >160 mg/dL and: • there is a positive family history of premature cardiovascular disease or • two or more other CVD risk factors are present in the adolescent patient General Recommendations Prior to initiating therapy with lovastatin, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure total-C, HDL-C, and TG. For patients with TG less than 400 mg / dL (<4.5 mmol / L), LDL-C can be estimated using the following equation: LDL-C = total-C – [0.2 x (TG) + HDL-C] For TG levels >400 mg/dL (>4.5 mmol/L), this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated total-C. In such cases, lovastatin tablets are not indicated. The National Cholesterol Education Program (NCEP) Treatment Guidelines are summarized below: NCEP Treatment Guidelines: LDL-C Goals and Cutpoints for Therapeutic Lifestyle Changes and Drug Therapy in Different Risk Categories Risk Category LDL Goal (mg/dL) LDL Level at Which to Initiate Therapeutic Lifestyle Changes (mg/dL) LDL Level at Which to Consider Drug Therapy (mg/dL) CHD CHD, coronary heart disease or CHD risk equivalence (10-year risk >20%) <100 ≥100 ≥130 (100-129: drug optional) Some authorities recommend use of LDL-lowering drugs in this category if an LDL-C level of <100 mg/dL cannot be achieved by therapeutic lifestyle changes. Others prefer use of drugs that primarily modify triglycerides and HDL-C, e.g., nicotinic acid or fibrate. Clinical judgment also may call for deferring drug therapy in this subcategory. 2+ Risk factors (10-year risk ≤20%) <130 ≥130 10-year risk 10-20%: ≥130 10-year risk<10%: ≥160 0-1 Risk factor Almost all people with 0-1 risk factor have a 10-year risk <10%; thus, 10-year risk assessment in people with 0-1 risk factor is not necessary. <160 ≥160 ≥190 (160-189: LDL-lowering drug optional) After the LDL-C goal has been achieved, if the TG is still ≥200 mg/dL, non-HDL-C (total-C minus HDLC) becomes a secondary target of therapy. Non-HDL-C goals are set 30 mg/dL higher than LDL-C goals for each risk category. At the time of hospitalization for an acute coronary event, consideration can be given to initiating drug therapy at discharge if the LDL-C is ≥130 mg/dL (see NCEP Guidelines above). Since the goal of treatment is to lower LDL-C, the NCEP recommends that LDL-C levels be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the total-C be used to monitor therapy. Although lovastatin tablets may be useful to reduce elevated LDL-C levels in patients with combined hypercholesterolemia and hypertriglyceridemia where hypercholesterolemia is the major abnormality (Type IIb hyperlipoproteinemia), it has not been studied in conditions where the major abnormality is elevation of chylomicrons, VLDL or IDL (i.e., hyperlipoproteinemia types I, III, IV, or V).*** The NCEP classification of cholesterol levels in pediatric patients with a familial history of hypercholesterolemia or premature cardiovascular disease is summarized below: Category Total-C (mg/dL) LDL-C (mg/dL) Acceptable <170 <110 Borderline 170-199 110-129 High ≥200 ≥130 Children treated with lovastatin in adolescence should be re-evaluated in adulthood and appropriate changes made to their cholesterol-lowering regimen to achieve adult goals for LDL-C. uuid:350953b0-748d-4bba-bb6f-fc3e4ea19bed biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:40303 biolink:treats MONDO:0005347 PMID:41385096 "[{""id"":""uuid:6d42b006-fb32-443e-9be0-5d731b04d0ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4e817059-3576-4e52-b4ae-4fd5cfcb0593"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lovastatin tablets should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin tablets should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C, and below average HDL-C, lovastatin tablets are indicated to reduce the risk of: - Myocardial infarction - Unstable angina - Coronary revascularization procedures (See CLINICAL PHARMACOLOGY, Clinical Studies .) Coronary Heart Disease Lovastatin tablets are indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Lovastatin tablets are indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb***), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. *** Classification of Hyperlipoproteinemias IDL = intermediate-density lipoprotein Type Lipoproteins elevated Lipid Elevations major minor I Chylomicrons TG ↑ →C IIa LDL C — IIb LDL, VLDL C TG III (rare) IDL C/TG — IV VLDL TG ↑ →C V (rare) Chylomicrons, VLDL TG ↑ →C Adolescent Patients with Heterozygous Familial Hypercholesterolemia Lovastatin tablets are indicated as an adjunct to diet to reduce total-C, LDL-C and apolipoprotein B levels in adolescent boys and girls who are at least one year post-menarche, 10-17 years of age, with heFH if after an adequate trial of diet therapy the following findings are present: LDL-C remains >189 mg/dL or LDL-C remains >160 mg/dL and: • there is a positive family history of premature cardiovascular disease or • two or more other CVD risk factors are present in the adolescent patient General Recommendations Prior to initiating therapy with lovastatin, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure total-C, HDL-C, and TG. For patients with TG less than 400 mg / dL (<4.5 mmol / L), LDL-C can be estimated using the following equation: LDL-C = total-C – [0.2 x (TG) + HDL-C] For TG levels >400 mg/dL (>4.5 mmol/L), this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated total-C. In such cases, lovastatin tablets are not indicated. The National Cholesterol Education Program (NCEP) Treatment Guidelines are summarized below: NCEP Treatment Guidelines: LDL-C Goals and Cutpoints for Therapeutic Lifestyle Changes and Drug Therapy in Different Risk Categories Risk Category LDL Goal (mg/dL) LDL Level at Which to Initiate Therapeutic Lifestyle Changes (mg/dL) LDL Level at Which to Consider Drug Therapy (mg/dL) CHD CHD, coronary heart disease or CHD risk equivalence (10-year risk >20%) <100 ≥100 ≥130 (100-129: drug optional) Some authorities recommend use of LDL-lowering drugs in this category if an LDL-C level of <100 mg/dL cannot be achieved by therapeutic lifestyle changes. Others prefer use of drugs that primarily modify triglycerides and HDL-C, e.g., nicotinic acid or fibrate. Clinical judgment also may call for deferring drug therapy in this subcategory. 2+ Risk factors (10-year risk ≤20%) <130 ≥130 10-year risk 10-20%: ≥130 10-year risk<10%: ≥160 0-1 Risk factor Almost all people with 0-1 risk factor have a 10-year risk <10%; thus, 10-year risk assessment in people with 0-1 risk factor is not necessary. <160 ≥160 ≥190 (160-189: LDL-lowering drug optional) After the LDL-C goal has been achieved, if the TG is still ≥200 mg/dL, non-HDL-C (total-C minus HDLC) becomes a secondary target of therapy. Non-HDL-C goals are set 30 mg/dL higher than LDL-C goals for each risk category. At the time of hospitalization for an acute coronary event, consideration can be given to initiating drug therapy at discharge if the LDL-C is ≥130 mg/dL (see NCEP Guidelines above). Since the goal of treatment is to lower LDL-C, the NCEP recommends that LDL-C levels be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the total-C be used to monitor therapy. Although lovastatin tablets may be useful to reduce elevated LDL-C levels in patients with combined hypercholesterolemia and hypertriglyceridemia where hypercholesterolemia is the major abnormality (Type IIb hyperlipoproteinemia), it has not been studied in conditions where the major abnormality is elevation of chylomicrons, VLDL or IDL (i.e., hyperlipoproteinemia types I, III, IV, or V).*** The NCEP classification of cholesterol levels in pediatric patients with a familial history of hypercholesterolemia or premature cardiovascular disease is summarized below: Category Total-C (mg/dL) LDL-C (mg/dL) Acceptable <170 <110 Borderline 170-199 110-129 High ≥200 ≥130 Children treated with lovastatin in adolescence should be re-evaluated in adulthood and appropriate changes made to their cholesterol-lowering regimen to achieve adult goals for LDL-C. uuid:0e1bd019-0d60-46fc-a3c6-6e7f7c79ecbd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:40303 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:93309a84-de97-42b5-9a01-31143fe09094"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d8b04e79-d45a-4042-8894-de47762283ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lovastatin tablets should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin tablets should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C, and below average HDL-C, lovastatin tablets are indicated to reduce the risk of: - Myocardial infarction - Unstable angina - Coronary revascularization procedures (See CLINICAL PHARMACOLOGY, Clinical Studies .) Coronary Heart Disease Lovastatin tablets are indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Lovastatin tablets are indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb***), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. *** Classification of Hyperlipoproteinemias IDL = intermediate-density lipoprotein Type Lipoproteins elevated Lipid Elevations major minor I Chylomicrons TG ↑ →C IIa LDL C — IIb LDL, VLDL C TG III (rare) IDL C/TG — IV VLDL TG ↑ →C V (rare) Chylomicrons, VLDL TG ↑ →C Adolescent Patients with Heterozygous Familial Hypercholesterolemia Lovastatin tablets are indicated as an adjunct to diet to reduce total-C, LDL-C and apolipoprotein B levels in adolescent boys and girls who are at least one year post-menarche, 10-17 years of age, with heFH if after an adequate trial of diet therapy the following findings are present: LDL-C remains >189 mg/dL or LDL-C remains >160 mg/dL and: • there is a positive family history of premature cardiovascular disease or • two or more other CVD risk factors are present in the adolescent patient General Recommendations Prior to initiating therapy with lovastatin, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure total-C, HDL-C, and TG. For patients with TG less than 400 mg / dL (<4.5 mmol / L), LDL-C can be estimated using the following equation: LDL-C = total-C – [0.2 x (TG) + HDL-C] For TG levels >400 mg/dL (>4.5 mmol/L), this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated total-C. In such cases, lovastatin tablets are not indicated. The National Cholesterol Education Program (NCEP) Treatment Guidelines are summarized below: NCEP Treatment Guidelines: LDL-C Goals and Cutpoints for Therapeutic Lifestyle Changes and Drug Therapy in Different Risk Categories Risk Category LDL Goal (mg/dL) LDL Level at Which to Initiate Therapeutic Lifestyle Changes (mg/dL) LDL Level at Which to Consider Drug Therapy (mg/dL) CHD CHD, coronary heart disease or CHD risk equivalence (10-year risk >20%) <100 ≥100 ≥130 (100-129: drug optional) Some authorities recommend use of LDL-lowering drugs in this category if an LDL-C level of <100 mg/dL cannot be achieved by therapeutic lifestyle changes. Others prefer use of drugs that primarily modify triglycerides and HDL-C, e.g., nicotinic acid or fibrate. Clinical judgment also may call for deferring drug therapy in this subcategory. 2+ Risk factors (10-year risk ≤20%) <130 ≥130 10-year risk 10-20%: ≥130 10-year risk<10%: ≥160 0-1 Risk factor Almost all people with 0-1 risk factor have a 10-year risk <10%; thus, 10-year risk assessment in people with 0-1 risk factor is not necessary. <160 ≥160 ≥190 (160-189: LDL-lowering drug optional) After the LDL-C goal has been achieved, if the TG is still ≥200 mg/dL, non-HDL-C (total-C minus HDLC) becomes a secondary target of therapy. Non-HDL-C goals are set 30 mg/dL higher than LDL-C goals for each risk category. At the time of hospitalization for an acute coronary event, consideration can be given to initiating drug therapy at discharge if the LDL-C is ≥130 mg/dL (see NCEP Guidelines above). Since the goal of treatment is to lower LDL-C, the NCEP recommends that LDL-C levels be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the total-C be used to monitor therapy. Although lovastatin tablets may be useful to reduce elevated LDL-C levels in patients with combined hypercholesterolemia and hypertriglyceridemia where hypercholesterolemia is the major abnormality (Type IIb hyperlipoproteinemia), it has not been studied in conditions where the major abnormality is elevation of chylomicrons, VLDL or IDL (i.e., hyperlipoproteinemia types I, III, IV, or V).*** The NCEP classification of cholesterol levels in pediatric patients with a familial history of hypercholesterolemia or premature cardiovascular disease is summarized below: Category Total-C (mg/dL) LDL-C (mg/dL) Acceptable <170 <110 Borderline 170-199 110-129 High ≥200 ≥130 Children treated with lovastatin in adolescence should be re-evaluated in adulthood and appropriate changes made to their cholesterol-lowering regimen to achieve adult goals for LDL-C. uuid:1f00880a-11f9-4ecb-99cc-ed957d3a63de biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:40303 biolink:treats MONDO:0006805 PMID:41385096 "[{""id"":""uuid:a6d8eeaf-ce08-47a1-9ba2-9cfe122e594c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:58f7bbdb-e0df-46a4-9c6d-f33f830a67aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lovastatin tablets should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin tablets should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C, and below average HDL-C, lovastatin tablets are indicated to reduce the risk of: - Myocardial infarction - Unstable angina - Coronary revascularization procedures (See CLINICAL PHARMACOLOGY, Clinical Studies .) Coronary Heart Disease Lovastatin tablets are indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Lovastatin tablets are indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb***), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. *** Classification of Hyperlipoproteinemias IDL = intermediate-density lipoprotein Type Lipoproteins elevated Lipid Elevations major minor I Chylomicrons TG ↑ →C IIa LDL C — IIb LDL, VLDL C TG III (rare) IDL C/TG — IV VLDL TG ↑ →C V (rare) Chylomicrons, VLDL TG ↑ →C Adolescent Patients with Heterozygous Familial Hypercholesterolemia Lovastatin tablets are indicated as an adjunct to diet to reduce total-C, LDL-C and apolipoprotein B levels in adolescent boys and girls who are at least one year post-menarche, 10-17 years of age, with heFH if after an adequate trial of diet therapy the following findings are present: LDL-C remains >189 mg/dL or LDL-C remains >160 mg/dL and: • there is a positive family history of premature cardiovascular disease or • two or more other CVD risk factors are present in the adolescent patient General Recommendations Prior to initiating therapy with lovastatin, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure total-C, HDL-C, and TG. For patients with TG less than 400 mg / dL (<4.5 mmol / L), LDL-C can be estimated using the following equation: LDL-C = total-C – [0.2 x (TG) + HDL-C] For TG levels >400 mg/dL (>4.5 mmol/L), this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated total-C. In such cases, lovastatin tablets are not indicated. The National Cholesterol Education Program (NCEP) Treatment Guidelines are summarized below: NCEP Treatment Guidelines: LDL-C Goals and Cutpoints for Therapeutic Lifestyle Changes and Drug Therapy in Different Risk Categories Risk Category LDL Goal (mg/dL) LDL Level at Which to Initiate Therapeutic Lifestyle Changes (mg/dL) LDL Level at Which to Consider Drug Therapy (mg/dL) CHD CHD, coronary heart disease or CHD risk equivalence (10-year risk >20%) <100 ≥100 ≥130 (100-129: drug optional) Some authorities recommend use of LDL-lowering drugs in this category if an LDL-C level of <100 mg/dL cannot be achieved by therapeutic lifestyle changes. Others prefer use of drugs that primarily modify triglycerides and HDL-C, e.g., nicotinic acid or fibrate. Clinical judgment also may call for deferring drug therapy in this subcategory. 2+ Risk factors (10-year risk ≤20%) <130 ≥130 10-year risk 10-20%: ≥130 10-year risk<10%: ≥160 0-1 Risk factor Almost all people with 0-1 risk factor have a 10-year risk <10%; thus, 10-year risk assessment in people with 0-1 risk factor is not necessary. <160 ≥160 ≥190 (160-189: LDL-lowering drug optional) After the LDL-C goal has been achieved, if the TG is still ≥200 mg/dL, non-HDL-C (total-C minus HDLC) becomes a secondary target of therapy. Non-HDL-C goals are set 30 mg/dL higher than LDL-C goals for each risk category. At the time of hospitalization for an acute coronary event, consideration can be given to initiating drug therapy at discharge if the LDL-C is ≥130 mg/dL (see NCEP Guidelines above). Since the goal of treatment is to lower LDL-C, the NCEP recommends that LDL-C levels be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the total-C be used to monitor therapy. Although lovastatin tablets may be useful to reduce elevated LDL-C levels in patients with combined hypercholesterolemia and hypertriglyceridemia where hypercholesterolemia is the major abnormality (Type IIb hyperlipoproteinemia), it has not been studied in conditions where the major abnormality is elevation of chylomicrons, VLDL or IDL (i.e., hyperlipoproteinemia types I, III, IV, or V).*** The NCEP classification of cholesterol levels in pediatric patients with a familial history of hypercholesterolemia or premature cardiovascular disease is summarized below: Category Total-C (mg/dL) LDL-C (mg/dL) Acceptable <170 <110 Borderline 170-199 110-129 High ≥200 ≥130 Children treated with lovastatin in adolescence should be re-evaluated in adulthood and appropriate changes made to their cholesterol-lowering regimen to achieve adult goals for LDL-C. uuid:8da108ba-1213-4770-ba1b-73149c4698bb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2704 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:cc599000-faec-4ded-8d57-c1b13151dc79"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:71d648fc-dbc0-49ec-9176-15921019da5c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Anastrozole tablets are an aromatase inhibitor indicated for: • Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1) • First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer ( 1.2) • Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets ( 1.3) uuid:41715a3f-2e1f-4a6f-bf85-58edc1ac08ce biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2704 biolink:treats UMLS:C3495949 PMID:41385096 "[{""id"":""uuid:d9428126-b6c4-4b54-8132-164127088736"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e16f4663-703c-49f4-a83a-50053ca19d32"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Anastrozole tablets are an aromatase inhibitor indicated for: • Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1) • First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer ( 1.2) • Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets ( 1.3) uuid:b52aa96e-7b82-4bb4-bbe3-7e69d897312e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2704 biolink:treats UMLS:C0278488 PMID:41385096 "[{""id"":""uuid:6e3974ca-051a-46d2-b039-e15371169c84"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:17bdb7b8-b487-4f0b-b31b-d0520fde9449"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Anastrozole tablets are an aromatase inhibitor indicated for: • Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1) • First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer ( 1.2) • Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets ( 1.3) uuid:3f6f66b4-c190-4686-b855-3e4f74e18b4e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2704 biolink:treats UMLS:C3495917 PMID:41385096 "[{""id"":""uuid:7cb4eea9-0d1e-4935-b692-d4f741b2ad32"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7bcdfe8e-719d-4db9-8d5b-ae9876a9e010"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Anastrozole tablets are an aromatase inhibitor indicated for: • Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1) • First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer ( 1.2) • Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets ( 1.3) uuid:48882dfa-e03b-4e02-84c7-d3be763adc65 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:D87YGH4Z0Q biolink:treats MONDO:0005347 PMID:41385096 "[{""id"":""uuid:c0e96637-f7f1-4dff-afb0-65af9a679bdd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6e55f2a0-8819-4c58-89b8-3dd65e5ee15b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LOVAZA ® (omega-3-acid ethyl esters) is indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia. Usage Considerations: Patients should be placed on an appropriate lipid-lowering diet before receiving LOVAZA and should continue this diet during treatment with LOVAZA. Laboratory studies should be done to ascertain that the lipid levels are consistently abnormal before instituting LOVAZA therapy. Every attempt should be made to control serum lipids with appropriate diet, exercise, weight loss in obese patients, and control of any medical problems such as diabetes mellitus and hypothyroidism that are contributing to the lipid abnormalities. Medications known to exacerbate hypertriglyceridemia (such as beta blockers, thiazides, estrogens) should be discontinued or changed if possible prior to consideration of triglyceride-lowering drug therapy. Limitations of Use: The effect of LOVAZA on cardiovascular mortality and morbidity in patients with elevated triglycerides has not been determined. uuid:991a3497-8e90-4deb-90fe-8fcd397676bb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:D87YGH4Z0Q biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:8c5f02a0-21ef-4b30-ae61-4abccc1d1eab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0b1e63b1-8fac-4047-bf83-269cf350b57c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LOVAZA ® (omega-3-acid ethyl esters) is indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia. Usage Considerations: Patients should be placed on an appropriate lipid-lowering diet before receiving LOVAZA and should continue this diet during treatment with LOVAZA. Laboratory studies should be done to ascertain that the lipid levels are consistently abnormal before instituting LOVAZA therapy. Every attempt should be made to control serum lipids with appropriate diet, exercise, weight loss in obese patients, and control of any medical problems such as diabetes mellitus and hypothyroidism that are contributing to the lipid abnormalities. Medications known to exacerbate hypertriglyceridemia (such as beta blockers, thiazides, estrogens) should be discontinued or changed if possible prior to consideration of triglyceride-lowering drug therapy. Limitations of Use: The effect of LOVAZA on cardiovascular mortality and morbidity in patients with elevated triglycerides has not been determined. uuid:9db16ec3-906e-456b-a793-1a2d09a33142 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:D87YGH4Z0Q biolink:treats MONDO:0005420 PMID:41385096 "[{""id"":""uuid:d0dc00da-c6a7-4617-8974-79a92609ab8d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0894f504-d6ea-4b8e-953c-e99bdaefe275"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LOVAZA ® (omega-3-acid ethyl esters) is indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia. Usage Considerations: Patients should be placed on an appropriate lipid-lowering diet before receiving LOVAZA and should continue this diet during treatment with LOVAZA. Laboratory studies should be done to ascertain that the lipid levels are consistently abnormal before instituting LOVAZA therapy. Every attempt should be made to control serum lipids with appropriate diet, exercise, weight loss in obese patients, and control of any medical problems such as diabetes mellitus and hypothyroidism that are contributing to the lipid abnormalities. Medications known to exacerbate hypertriglyceridemia (such as beta blockers, thiazides, estrogens) should be discontinued or changed if possible prior to consideration of triglyceride-lowering drug therapy. Limitations of Use: The effect of LOVAZA on cardiovascular mortality and morbidity in patients with elevated triglycerides has not been determined. uuid:15b346d0-3eb0-4145-b58a-6f6619775bbf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3746 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:ecf850b7-1c3e-4b67-af7f-eb9fdc70fbcc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1a050b0f-3be8-446f-9b59-10df04314575"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibiotic therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae , other streptococci (except E. faecalis ), and Staphylococcus aureus . Skin and skin structure infections caused by Streptococcus pyogenes , Staphylococcus aureus , and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus , streptococci (except Enterococcus faecalis ), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin and other antibacterial drugs, clindamycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:053943d1-c6a8-4406-a87f-c4e196f899c1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3746 biolink:treats UMLS:C1112209 PMID:41385096 "[{""id"":""uuid:1efdb36a-3f91-47d1-b106-da41f915d5fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0f6ebbf2-7b0c-47af-bb86-7c619e4a66a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibiotic therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae , other streptococci (except E. faecalis ), and Staphylococcus aureus . Skin and skin structure infections caused by Streptococcus pyogenes , Staphylococcus aureus , and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus , streptococci (except Enterococcus faecalis ), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin and other antibacterial drugs, clindamycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:5653bb2b-f316-4e5e-aa2a-7219ec4c305c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3746 biolink:treats UMLS:C0851989 PMID:41385096 "[{""id"":""uuid:726e7730-4c9a-4f11-8129-cae37c29691e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7fafe2e0-bbe1-41f6-8faf-b18037e054bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibiotic therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae , other streptococci (except E. faecalis ), and Staphylococcus aureus . Skin and skin structure infections caused by Streptococcus pyogenes , Staphylococcus aureus , and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus , streptococci (except Enterococcus faecalis ), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin and other antibacterial drugs, clindamycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:60d5ad46-74c3-4023-a81d-61ba00eaffe0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3746 biolink:treats UMLS:C0600123 PMID:41385096 "[{""id"":""uuid:e53798b4-8b37-4e20-96e9-0ed636b965b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0c0885da-8f45-41c7-a239-af0d04860c62"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibiotic therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae , other streptococci (except E. faecalis ), and Staphylococcus aureus . Skin and skin structure infections caused by Streptococcus pyogenes , Staphylococcus aureus , and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus , streptococci (except Enterococcus faecalis ), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin and other antibacterial drugs, clindamycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:8bcc43dc-5c06-4ed4-9934-549e71d5c895 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3746 biolink:treats MONDO:0005246 PMID:41385096 "[{""id"":""uuid:53ca40cc-cdda-4c36-bffe-a37b8a30450f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ed110a96-82ea-4b9b-9072-76a0f9e02230"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibiotic therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae , other streptococci (except E. faecalis ), and Staphylococcus aureus . Skin and skin structure infections caused by Streptococcus pyogenes , Staphylococcus aureus , and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus , streptococci (except Enterococcus faecalis ), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin and other antibacterial drugs, clindamycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:8aa5cac9-f6ec-42f3-8f00-a1f22c088c58 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4450 biolink:treats MONDO:0015790 PMID:41385096 "[{""id"":""uuid:9633e238-6f2f-47cc-8a5d-ee68088f837a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1916e015-425c-4d93-a6ba-401fa5312bf0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Central Diabetes Insipidus Desmopressin acetate tablets are indicated as antidiuretic replacement therapy in the management of central diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. Desmopressin acetate is ineffective for the treatment of nephrogenic diabetes insipidus. Patients were selected for therapy based on the diagnosis by means of the water deprivation test, the hypertonic saline infusion test, and/or response to antidiuretic hormone. Continued response to desmopressin acetate can be monitored by measuring urine volume and osmolality. Primary Nocturnal Enuresis Desmopressin acetate tablets are indicated for the management of primary nocturnal enuresis. Desmopressin acetate may be used alone or as an adjunct to behavioral conditioning or other non-pharmacologic intervention. uuid:d44a58f9-8a69-41c4-a273-70f1460d1938 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4450 biolink:treats HP:0000103 PMID:41385096 "[{""id"":""uuid:d00155b1-2964-4b2d-ae41-afe34e1112d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e8eb9966-d077-4f16-ace2-1245890fe628"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Central Diabetes Insipidus Desmopressin acetate tablets are indicated as antidiuretic replacement therapy in the management of central diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. Desmopressin acetate is ineffective for the treatment of nephrogenic diabetes insipidus. Patients were selected for therapy based on the diagnosis by means of the water deprivation test, the hypertonic saline infusion test, and/or response to antidiuretic hormone. Continued response to desmopressin acetate can be monitored by measuring urine volume and osmolality. Primary Nocturnal Enuresis Desmopressin acetate tablets are indicated for the management of primary nocturnal enuresis. Desmopressin acetate may be used alone or as an adjunct to behavioral conditioning or other non-pharmacologic intervention. uuid:862c7c5c-488c-4f08-ad65-6e8e69c109db biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4450 biolink:treats MONDO:0040871 PMID:41385096 "[{""id"":""uuid:0a62a1c6-e80e-4bb9-ab3b-e7be68a737d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8a87ee73-7fe0-4059-978c-11dfc10c11e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Central Diabetes Insipidus Desmopressin acetate tablets are indicated as antidiuretic replacement therapy in the management of central diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. Desmopressin acetate is ineffective for the treatment of nephrogenic diabetes insipidus. Patients were selected for therapy based on the diagnosis by means of the water deprivation test, the hypertonic saline infusion test, and/or response to antidiuretic hormone. Continued response to desmopressin acetate can be monitored by measuring urine volume and osmolality. Primary Nocturnal Enuresis Desmopressin acetate tablets are indicated for the management of primary nocturnal enuresis. Desmopressin acetate may be used alone or as an adjunct to behavioral conditioning or other non-pharmacologic intervention. uuid:b575df1e-79e2-4975-ae99-b3e9c2649c22 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4450 biolink:treats UMLS:C2228139 PMID:41385096 "[{""id"":""uuid:403525f4-77e2-45b7-a077-9e009d3f7dcf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9fbefe28-3862-4b13-ac2f-c1ce86823129"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Central Diabetes Insipidus Desmopressin acetate tablets are indicated as antidiuretic replacement therapy in the management of central diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. Desmopressin acetate is ineffective for the treatment of nephrogenic diabetes insipidus. Patients were selected for therapy based on the diagnosis by means of the water deprivation test, the hypertonic saline infusion test, and/or response to antidiuretic hormone. Continued response to desmopressin acetate can be monitored by measuring urine volume and osmolality. Primary Nocturnal Enuresis Desmopressin acetate tablets are indicated for the management of primary nocturnal enuresis. Desmopressin acetate may be used alone or as an adjunct to behavioral conditioning or other non-pharmacologic intervention. uuid:8ca240c2-de83-4cb1-ac35-a2e952401050 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6715 biolink:treats MONDO:0002447 PMID:41385096 "[{""id"":""uuid:fad06876-8a23-4722-9273-c84d452b1bb1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9d15d57f-b7ff-463f-9bff-91391fe41184"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Adjunctive therapy and palliative treatment of inoperable, recurrent, and metastatic endometrial or renal carcinoma. uuid:0ffdc9bb-66e0-427e-8054-643e6b5d8e35 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6715 biolink:treats MONDO:0005206 PMID:41385096 "[{""id"":""uuid:d114e4e5-111e-4beb-9ed4-045b129e484d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7675b492-4efb-44cd-a4b8-5330d8b985b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Adjunctive therapy and palliative treatment of inoperable, recurrent, and metastatic endometrial or renal carcinoma. uuid:88103366-dc30-4d1f-8f35-db45a9b5030c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17234 biolink:treats UMLS:C0858734 PMID:41385096 "[{""id"":""uuid:87345ea5-6494-498e-827b-8f867b9dfe4d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:14e9e1cb-2d49-427e-a3b2-7e26d9e4a95c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 50% Dextrose Injection is indicated in the treatment of insulin hypoglycemia (hyperinsulinemia or insulin shock) to restore blood glucose levels. The solution is also indicated, after dilution, for intravenous infusion as a source of carbohydrate calories in patients whose oral intake is restricted or inadequate to maintain nutritional requirements. Slow infusion of hypertonic solutions is essential to insure proper utilization of dextrose and avoid production of hyperglycemia. uuid:e185578d-a6e5-4094-9a6c-57e06f8d0646 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17234 biolink:treats NCIT:C113104 PMID:41385096 "[{""id"":""uuid:5ab2f614-d99b-4b35-97df-c9b96a5fd9e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2c87f218-1e32-41fe-a7ae-0b17bbca5894"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 50% Dextrose Injection is indicated in the treatment of insulin hypoglycemia (hyperinsulinemia or insulin shock) to restore blood glucose levels. The solution is also indicated, after dilution, for intravenous infusion as a source of carbohydrate calories in patients whose oral intake is restricted or inadequate to maintain nutritional requirements. Slow infusion of hypertonic solutions is essential to insure proper utilization of dextrose and avoid production of hyperglycemia. uuid:06d27c54-7b6f-4858-a642-59d7d054b916 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17234 biolink:treats UMLS:C1527401 PMID:41385096 "[{""id"":""uuid:ef5e128e-1955-4fcd-9436-15ef82b56734"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f471052b-2c6e-439c-b0e5-1d28df760552"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 50% Dextrose Injection is indicated in the treatment of insulin hypoglycemia (hyperinsulinemia or insulin shock) to restore blood glucose levels. The solution is also indicated, after dilution, for intravenous infusion as a source of carbohydrate calories in patients whose oral intake is restricted or inadequate to maintain nutritional requirements. Slow infusion of hypertonic solutions is essential to insure proper utilization of dextrose and avoid production of hyperglycemia. uuid:d24310b6-61c3-403b-84cd-340d1183718f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17234 biolink:treats MONDO:0002909 PMID:41385096 "[{""id"":""uuid:0b20c760-463a-43eb-8861-b748e9810750"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:39745f49-f121-40b2-931b-55aec7d16280"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 50% Dextrose Injection is indicated in the treatment of insulin hypoglycemia (hyperinsulinemia or insulin shock) to restore blood glucose levels. The solution is also indicated, after dilution, for intravenous infusion as a source of carbohydrate calories in patients whose oral intake is restricted or inadequate to maintain nutritional requirements. Slow infusion of hypertonic solutions is essential to insure proper utilization of dextrose and avoid production of hyperglycemia. uuid:ae39861c-a113-47b6-87d3-5a2b7b7db49f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47519 biolink:treats MONDO:0001461 PMID:41385096 "[{""id"":""uuid:b6f8964f-0be2-4dd3-9fd5-d59d167cf9fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1bfa8d17-3115-4764-b7ef-3ae1478ec634"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ketoconazole cream, 2% is indicated for the topical treatment of tinea corporis, tinea cruris and tinea pedis caused by Trichophyton rubrum, T. mentagrophytes and Epidermophyton floccosum; in the treatment of tinea (pityriasis) versicolor caused by Malassezia furfur (Pityrosporum orbiculare); in the treatment of cutaneous candidiasis caused by Candida spp. and in the treatment of seborrheic dermatitis. uuid:20441e8c-15fb-42b0-ba8d-3b0bc4f0c061 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47519 biolink:treats MONDO:0001405 PMID:41385096 "[{""id"":""uuid:ca567c56-d63f-4e91-896e-e1f7a416c87f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c4aaf081-8500-4bf7-8e4f-2bd0c0fc7c12"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ketoconazole cream, 2% is indicated for the topical treatment of tinea corporis, tinea cruris and tinea pedis caused by Trichophyton rubrum, T. mentagrophytes and Epidermophyton floccosum; in the treatment of tinea (pityriasis) versicolor caused by Malassezia furfur (Pityrosporum orbiculare); in the treatment of cutaneous candidiasis caused by Candida spp. and in the treatment of seborrheic dermatitis. uuid:00feca0d-35b4-43c6-9f67-7dfba1a32023 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47519 biolink:treats MONDO:0005984 PMID:41385096 "[{""id"":""uuid:25f2a009-48ef-41d8-9db2-a0fae4486608"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:13fc0ff9-6c38-44e9-a787-fdf9fb103321"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ketoconazole cream, 2% is indicated for the topical treatment of tinea corporis, tinea cruris and tinea pedis caused by Trichophyton rubrum, T. mentagrophytes and Epidermophyton floccosum; in the treatment of tinea (pityriasis) versicolor caused by Malassezia furfur (Pityrosporum orbiculare); in the treatment of cutaneous candidiasis caused by Candida spp. and in the treatment of seborrheic dermatitis. uuid:a06fe950-fee5-4801-9b1b-4c6032082681 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47519 biolink:treats MONDO:0005915 PMID:41385096 "[{""id"":""uuid:55e34d11-9b04-4cce-90eb-fa00f58bf05c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:93669860-9197-438e-ac13-6685dfed5f02"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ketoconazole cream, 2% is indicated for the topical treatment of tinea corporis, tinea cruris and tinea pedis caused by Trichophyton rubrum, T. mentagrophytes and Epidermophyton floccosum; in the treatment of tinea (pityriasis) versicolor caused by Malassezia furfur (Pityrosporum orbiculare); in the treatment of cutaneous candidiasis caused by Candida spp. and in the treatment of seborrheic dermatitis. uuid:4dd3b8f4-ee34-410a-bbc1-48877db207c8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47519 biolink:treats MONDO:0000879 PMID:41385096 "[{""id"":""uuid:3ec51f12-a888-4f23-9668-c97349ff7f1d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0d45c1e2-2fb4-4817-8fd1-2c9721ac1370"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ketoconazole cream, 2% is indicated for the topical treatment of tinea corporis, tinea cruris and tinea pedis caused by Trichophyton rubrum, T. mentagrophytes and Epidermophyton floccosum; in the treatment of tinea (pityriasis) versicolor caused by Malassezia furfur (Pityrosporum orbiculare); in the treatment of cutaneous candidiasis caused by Candida spp. and in the treatment of seborrheic dermatitis. uuid:c5631eaa-eac0-4bc6-b0f5-97adaf193050 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47519 biolink:treats MONDO:0006608 PMID:41385096 "[{""id"":""uuid:e42fe3d1-cd85-482e-80b5-16fa2f269924"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:60d36367-79d8-4c1e-ae92-a9c40338deeb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ketoconazole cream, 2% is indicated for the topical treatment of tinea corporis, tinea cruris and tinea pedis caused by Trichophyton rubrum, T. mentagrophytes and Epidermophyton floccosum; in the treatment of tinea (pityriasis) versicolor caused by Malassezia furfur (Pityrosporum orbiculare); in the treatment of cutaneous candidiasis caused by Candida spp. and in the treatment of seborrheic dermatitis. uuid:cf44b879-390d-46dc-9cec-b2df67351a76 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17347 biolink:treats MONDO:0043510 PMID:41385096 "[{""id"":""uuid:6b60792e-606a-4120-8b9d-c1fe8e1afe87"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0ae76bb2-799a-4ed8-beae-008a1b992717"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DEPO-Testosterone Injection is indicated for replacement therapy in the male in conditions associated with symptoms of deficiency or absence of endogenous testosterone. 1. Primary hypogonadism (congenital or acquired)-testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome; or orchidectomy. 2. Hypogonadotropic hypogonadism (congenital or acquired)-idiopathic gonadotropin or LHRH deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation. uuid:2f74bc9f-ea06-441b-80f8-ecdd94ebaed5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:205919 biolink:treats UMLS:C0406317 PMID:41385096 "[{""id"":""uuid:d7d2097d-064e-4f28-9b21-d3cb4d86597f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:252b0255-6cdb-45e3-82f2-dfd7e7980db6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CLOBEX ® (clobetasol propionate) Spray, 0.05% is a super-high potent topical corticosteroid formulation indicated for the treatment of moderate to severe plaque psoriasis affecting up to 20% body surface area (BSA) in patients 18 years of age or older (see PRECAUTIONS ). Treatment should be limited to 4 consecutive weeks. The total dosage should not exceed 50 g (59 mL or 2 fl. oz.) per week. Before prescribing for more than 2 weeks, any additional benefits of extending treatment to 4 weeks should be weighed against the risk of HPA axis suppression. Patients should be instructed to use CLOBEX ® (clobetasol propionate) Spray, 0.05% for the minimum amount of time necessary to achieve the desired results (see PRECAUTIONS ). Use in patients under 18 years of age is not recommended because safety has not been established and because numerically high rates of HPA axis suppression were seen with other clobetasol propionate topical formulations (see PRECAUTIONS: Pediatric Use ). uuid:bdc67c99-cda8-40c5-961e-2208a2a72c00 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27300 biolink:treats MONDO:0001220 PMID:41385096 "[{""id"":""uuid:213a3748-fbc0-4d9c-aecd-0504f9563b52"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b35adac9-296c-4ddd-8dda-bcf2b9787b3d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ergocalciferol Capsules, USP are indicated for use in the treatment of hypoparathyroidism, refractory rickets, also known as vitamin D resistant rickets, and familial hypophosphatemia. CHEBI:28934 uuid:25682075-11ec-45a9-9328-11f0a356e594 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27300 biolink:treats MONDO:0024300 PMID:41385096 "[{""id"":""uuid:027ffbde-f561-493c-8e0b-82d3519f4cf4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:15b191a1-6feb-4e32-8775-f229f3d83a02"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ergocalciferol Capsules, USP are indicated for use in the treatment of hypoparathyroidism, refractory rickets, also known as vitamin D resistant rickets, and familial hypophosphatemia. CHEBI:28934 uuid:1825936a-3328-4d0b-abe2-d7473ffff444 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27300 biolink:treats MONDO:0010619 PMID:41385096 "[{""id"":""uuid:ed333354-0e0f-436c-a615-92401a8d8cae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ab3b0e92-fb1d-4c05-81fc-735ce0e06cc1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ergocalciferol Capsules, USP are indicated for use in the treatment of hypoparathyroidism, refractory rickets, also known as vitamin D resistant rickets, and familial hypophosphatemia. CHEBI:28934 uuid:97e49af2-420a-448f-96ca-089f4d691d90 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27300 biolink:treats UMLS:C0020631 PMID:41385096 "[{""id"":""uuid:8bc9f350-e190-4271-b62b-36992d1c5dc4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4e723920-4303-43ee-883d-3895048e2159"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ergocalciferol Capsules, USP are indicated for use in the treatment of hypoparathyroidism, refractory rickets, also known as vitamin D resistant rickets, and familial hypophosphatemia. CHEBI:28934 uuid:82e05d60-8f66-487f-9d41-a70c320d0a22 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63607 biolink:treats MONDO:0021679 PMID:41385096 "[{""id"":""uuid:5da9910b-0a6b-457e-8b28-f7760605ac26"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:576aad2d-6ab3-4e9a-8dd7-ec1a8691dff4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZYVOX formulations are indicated in the treatment of the following infections caused by susceptible strains of the designated microorganisms (see PRECAUTIONS, Pediatric Use and DOSAGE AND ADMINISTRATION and CLINICAL STUDIES ). Linezolid is not indicated for the treatment of Gram-negative infections. It is critical that specific Gram-negative therapy be initiated immediately if a concomitant Gram-negative pathogen is documented or suspected (see WARNINGS ). Vancomycin-Resistant Enterococcus faecium infections, including cases with concurrent bacteremia. (see CLINICAL STUDIES ) Nosocomial pneumonia caused by Staphylococcus aureus (methicillin-susceptible and -resistant strains), or Streptococcus pneumoniae (including multi-drug resistant strains [MDRSP]). Complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis , caused by Staphylococcus aureus (methicillin-susceptible and -resistant strains), Streptococcus pyogenes, or Streptococcus agalactiae . ZYVOX has not been studied in the treatment of decubitus ulcers. Uncomplicated skin and skin structure infections caused by Staphylococcus aureus (methicillin-susceptible only) or Streptococcus pyogenes . Community-acquired pneumonia caused by Streptococcus pneumoniae (including multi-drug resistant strains [MDRSP] MDRSP refers to isolates resistant to two or more of the following antibiotics: penicillin, second-generation cephalosporins, macrolides, tetracycline, and trimethoprim/sulfamethoxazole. ), including cases with concurrent bacteremia, or Staphylococcus aureus (methicillin-susceptible strains only). To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZYVOX and other antibacterial drugs, ZYVOX should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:88c771ba-8d8b-4847-b712-8e0371d7d354 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63607 biolink:treats MONDO:0005229 PMID:41385096 "[{""id"":""uuid:9acf22de-0bad-47e3-842b-84e3d67c5c28"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9fe68598-853a-44ca-b3b5-e25c8cb7bd11"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZYVOX formulations are indicated in the treatment of the following infections caused by susceptible strains of the designated microorganisms (see PRECAUTIONS, Pediatric Use and DOSAGE AND ADMINISTRATION and CLINICAL STUDIES ). Linezolid is not indicated for the treatment of Gram-negative infections. It is critical that specific Gram-negative therapy be initiated immediately if a concomitant Gram-negative pathogen is documented or suspected (see WARNINGS ). Vancomycin-Resistant Enterococcus faecium infections, including cases with concurrent bacteremia. (see CLINICAL STUDIES ) Nosocomial pneumonia caused by Staphylococcus aureus (methicillin-susceptible and -resistant strains), or Streptococcus pneumoniae (including multi-drug resistant strains [MDRSP]). Complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis , caused by Staphylococcus aureus (methicillin-susceptible and -resistant strains), Streptococcus pyogenes, or Streptococcus agalactiae . ZYVOX has not been studied in the treatment of decubitus ulcers. Uncomplicated skin and skin structure infections caused by Staphylococcus aureus (methicillin-susceptible only) or Streptococcus pyogenes . Community-acquired pneumonia caused by Streptococcus pneumoniae (including multi-drug resistant strains [MDRSP] MDRSP refers to isolates resistant to two or more of the following antibiotics: penicillin, second-generation cephalosporins, macrolides, tetracycline, and trimethoprim/sulfamethoxazole. ), including cases with concurrent bacteremia, or Staphylococcus aureus (methicillin-susceptible strains only). To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZYVOX and other antibacterial drugs, ZYVOX should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:dcb5bd83-9a8e-42a6-9b6e-bfeb5fd8d302 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63607 biolink:treats UMLS:C0949083 PMID:41385096 "[{""id"":""uuid:023e6f8e-af6a-4ac7-a4de-d53c02a5a88a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bf9fbd0e-c119-4f74-bb9b-b5cdee1e2370"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZYVOX formulations are indicated in the treatment of the following infections caused by susceptible strains of the designated microorganisms (see PRECAUTIONS, Pediatric Use and DOSAGE AND ADMINISTRATION and CLINICAL STUDIES ). Linezolid is not indicated for the treatment of Gram-negative infections. It is critical that specific Gram-negative therapy be initiated immediately if a concomitant Gram-negative pathogen is documented or suspected (see WARNINGS ). Vancomycin-Resistant Enterococcus faecium infections, including cases with concurrent bacteremia. (see CLINICAL STUDIES ) Nosocomial pneumonia caused by Staphylococcus aureus (methicillin-susceptible and -resistant strains), or Streptococcus pneumoniae (including multi-drug resistant strains [MDRSP]). Complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis , caused by Staphylococcus aureus (methicillin-susceptible and -resistant strains), Streptococcus pyogenes, or Streptococcus agalactiae . ZYVOX has not been studied in the treatment of decubitus ulcers. Uncomplicated skin and skin structure infections caused by Staphylococcus aureus (methicillin-susceptible only) or Streptococcus pyogenes . Community-acquired pneumonia caused by Streptococcus pneumoniae (including multi-drug resistant strains [MDRSP] MDRSP refers to isolates resistant to two or more of the following antibiotics: penicillin, second-generation cephalosporins, macrolides, tetracycline, and trimethoprim/sulfamethoxazole. ), including cases with concurrent bacteremia, or Staphylococcus aureus (methicillin-susceptible strains only). To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZYVOX and other antibacterial drugs, ZYVOX should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:986cbe1e-05d8-4bfa-9dd8-7c854e42cfae biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63607 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:78c4365b-25c4-449d-a4ee-80d0edd9ed6c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a113400d-a37b-4e62-8a01-29a6c78b1778"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:58830cb3-b974-4e26-8e7a-c189f4ebdcb2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZYVOX formulations are indicated in the treatment of the following infections caused by susceptible strains of the designated microorganisms (see PRECAUTIONS, Pediatric Use and DOSAGE AND ADMINISTRATION and CLINICAL STUDIES ). Linezolid is not indicated for the treatment of Gram-negative infections. It is critical that specific Gram-negative therapy be initiated immediately if a concomitant Gram-negative pathogen is documented or suspected (see WARNINGS ). Vancomycin-Resistant Enterococcus faecium infections, including cases with concurrent bacteremia. (see CLINICAL STUDIES ) Nosocomial pneumonia caused by Staphylococcus aureus (methicillin-susceptible and -resistant strains), or Streptococcus pneumoniae (including multi-drug resistant strains [MDRSP]). Complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis , caused by Staphylococcus aureus (methicillin-susceptible and -resistant strains), Streptococcus pyogenes, or Streptococcus agalactiae . ZYVOX has not been studied in the treatment of decubitus ulcers. Uncomplicated skin and skin structure infections caused by Staphylococcus aureus (methicillin-susceptible only) or Streptococcus pyogenes . Community-acquired pneumonia caused by Streptococcus pneumoniae (including multi-drug resistant strains [MDRSP] MDRSP refers to isolates resistant to two or more of the following antibiotics: penicillin, second-generation cephalosporins, macrolides, tetracycline, and trimethoprim/sulfamethoxazole. ), including cases with concurrent bacteremia, or Staphylococcus aureus (methicillin-susceptible strains only). To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZYVOX and other antibacterial drugs, ZYVOX should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.|[PMDA] Drugs with a new additional pediatric dosage. These drugs are indicated for sepsis, deep skin infection, chronic pyoderma, secondary infection of trauma, burn, and surgical wounds, and pneumonia. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:e3e2fe79-c300-4d30-8c53-a28af498b2c9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63607 biolink:treats UMLS:C0744130 PMID:41385096 "[{""id"":""uuid:ec28336c-ddf7-4f4a-a56c-c321c7046060"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:de1c5ed2-ae53-4c40-a63d-c6513b666527"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZYVOX formulations are indicated in the treatment of the following infections caused by susceptible strains of the designated microorganisms (see PRECAUTIONS, Pediatric Use and DOSAGE AND ADMINISTRATION and CLINICAL STUDIES ). Linezolid is not indicated for the treatment of Gram-negative infections. It is critical that specific Gram-negative therapy be initiated immediately if a concomitant Gram-negative pathogen is documented or suspected (see WARNINGS ). Vancomycin-Resistant Enterococcus faecium infections, including cases with concurrent bacteremia. (see CLINICAL STUDIES ) Nosocomial pneumonia caused by Staphylococcus aureus (methicillin-susceptible and -resistant strains), or Streptococcus pneumoniae (including multi-drug resistant strains [MDRSP]). Complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis , caused by Staphylococcus aureus (methicillin-susceptible and -resistant strains), Streptococcus pyogenes, or Streptococcus agalactiae . ZYVOX has not been studied in the treatment of decubitus ulcers. Uncomplicated skin and skin structure infections caused by Staphylococcus aureus (methicillin-susceptible only) or Streptococcus pyogenes . Community-acquired pneumonia caused by Streptococcus pneumoniae (including multi-drug resistant strains [MDRSP] MDRSP refers to isolates resistant to two or more of the following antibiotics: penicillin, second-generation cephalosporins, macrolides, tetracycline, and trimethoprim/sulfamethoxazole. ), including cases with concurrent bacteremia, or Staphylococcus aureus (methicillin-susceptible strains only). To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZYVOX and other antibacterial drugs, ZYVOX should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:98b96009-1107-4088-a3aa-5614e27b2518 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63607 biolink:treats MONDO:0005246 PMID:41385096 "[{""id"":""uuid:99aeb4d8-0791-455e-a6fd-c11e1167e93f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7bf991f2-777a-44a1-867f-ba544d844a1f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZYVOX formulations are indicated in the treatment of the following infections caused by susceptible strains of the designated microorganisms (see PRECAUTIONS, Pediatric Use and DOSAGE AND ADMINISTRATION and CLINICAL STUDIES ). Linezolid is not indicated for the treatment of Gram-negative infections. It is critical that specific Gram-negative therapy be initiated immediately if a concomitant Gram-negative pathogen is documented or suspected (see WARNINGS ). Vancomycin-Resistant Enterococcus faecium infections, including cases with concurrent bacteremia. (see CLINICAL STUDIES ) Nosocomial pneumonia caused by Staphylococcus aureus (methicillin-susceptible and -resistant strains), or Streptococcus pneumoniae (including multi-drug resistant strains [MDRSP]). Complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis , caused by Staphylococcus aureus (methicillin-susceptible and -resistant strains), Streptococcus pyogenes, or Streptococcus agalactiae . ZYVOX has not been studied in the treatment of decubitus ulcers. Uncomplicated skin and skin structure infections caused by Staphylococcus aureus (methicillin-susceptible only) or Streptococcus pyogenes . Community-acquired pneumonia caused by Streptococcus pneumoniae (including multi-drug resistant strains [MDRSP] MDRSP refers to isolates resistant to two or more of the following antibiotics: penicillin, second-generation cephalosporins, macrolides, tetracycline, and trimethoprim/sulfamethoxazole. ), including cases with concurrent bacteremia, or Staphylococcus aureus (methicillin-susceptible strains only). To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZYVOX and other antibacterial drugs, ZYVOX should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:7406a14a-58e7-4f00-8adf-47ea58994795 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63607 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:21902993-3c45-4d30-b8b1-87b9caa7fd8b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:06065610-2815-4441-afc5-be7b3d982955"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:3a7b98d6-046a-4ca3-9aff-82fef66cfb7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZYVOX formulations are indicated in the treatment of the following infections caused by susceptible strains of the designated microorganisms (see PRECAUTIONS, Pediatric Use and DOSAGE AND ADMINISTRATION and CLINICAL STUDIES ). Linezolid is not indicated for the treatment of Gram-negative infections. It is critical that specific Gram-negative therapy be initiated immediately if a concomitant Gram-negative pathogen is documented or suspected (see WARNINGS ). Vancomycin-Resistant Enterococcus faecium infections, including cases with concurrent bacteremia. (see CLINICAL STUDIES ) Nosocomial pneumonia caused by Staphylococcus aureus (methicillin-susceptible and -resistant strains), or Streptococcus pneumoniae (including multi-drug resistant strains [MDRSP]). Complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis , caused by Staphylococcus aureus (methicillin-susceptible and -resistant strains), Streptococcus pyogenes, or Streptococcus agalactiae . ZYVOX has not been studied in the treatment of decubitus ulcers. Uncomplicated skin and skin structure infections caused by Staphylococcus aureus (methicillin-susceptible only) or Streptococcus pyogenes . Community-acquired pneumonia caused by Streptococcus pneumoniae (including multi-drug resistant strains [MDRSP] MDRSP refers to isolates resistant to two or more of the following antibiotics: penicillin, second-generation cephalosporins, macrolides, tetracycline, and trimethoprim/sulfamethoxazole. ), including cases with concurrent bacteremia, or Staphylococcus aureus (methicillin-susceptible strains only). To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZYVOX and other antibacterial drugs, ZYVOX should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.|[PMDA] Drugs with a new additional pediatric dosage. These drugs are indicated for sepsis, deep skin infection, chronic pyoderma, secondary infection of trauma, burn, and surgical wounds, and pneumonia. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:29aed84d-951a-46ac-98ed-2101e0c49732 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59594 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:e512db67-4e00-4a9d-9df9-a54933fdebe5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e822a81a-1bc2-433c-af78-b5b5e8f42740"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] WELCHOL is a bile acid sequestrant indicated as an adjunct to diet and exercise to reduce elevated low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia as monotherapy or in combination with an hydroxymethyl-glutaryl-coenzyme A (HMG CoA) reductase inhibitor (statin) (1.1) . reduce LDL-C levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia as monotherapy or in combination with a statin after failing an adequate trial of diet therapy improve glycemic control in adults with type 2 diabetes mellitus (1.2) . Important Limitations of Use (1.3) : Do not use for glycemic control in type 1 diabetes or for treating diabetic ketoacidosis. WELCHOL has not been studied in type 2 diabetes as monotherapy or in combination with a dipeptidyl peptidase 4 inhibitor and has not been extensively studied in combination with thiazolidinediones. WELCHOL has not been studied in Fredrickson Type I, III, IV, and V dyslipidemias. WELCHOL has not been studied in children younger than 10 years of age or in pre-menarchal girls. uuid:576b803d-64a4-4cd7-8500-9b31cfe48b22 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59594 biolink:treats UMLS:C0342882 PMID:41385096 "[{""id"":""uuid:ea638f4b-f905-44bc-9464-b0b7e23e26b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:752bebbc-ac86-4664-be50-f5fab83b7e6e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] WELCHOL is a bile acid sequestrant indicated as an adjunct to diet and exercise to reduce elevated low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia as monotherapy or in combination with an hydroxymethyl-glutaryl-coenzyme A (HMG CoA) reductase inhibitor (statin) (1.1) . reduce LDL-C levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia as monotherapy or in combination with a statin after failing an adequate trial of diet therapy improve glycemic control in adults with type 2 diabetes mellitus (1.2) . Important Limitations of Use (1.3) : Do not use for glycemic control in type 1 diabetes or for treating diabetic ketoacidosis. WELCHOL has not been studied in type 2 diabetes as monotherapy or in combination with a dipeptidyl peptidase 4 inhibitor and has not been extensively studied in combination with thiazolidinediones. WELCHOL has not been studied in Fredrickson Type I, III, IV, and V dyslipidemias. WELCHOL has not been studied in children younger than 10 years of age or in pre-menarchal girls. uuid:53cdc922-8ed9-40d5-b5de-486b38bcf73a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59594 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:5e6811da-9dac-403e-a857-cd1506d040f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:66bf8ab5-3290-46db-a530-f8e777d8dfdb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] WELCHOL is a bile acid sequestrant indicated as an adjunct to diet and exercise to reduce elevated low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia as monotherapy or in combination with an hydroxymethyl-glutaryl-coenzyme A (HMG CoA) reductase inhibitor (statin) (1.1) . reduce LDL-C levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia as monotherapy or in combination with a statin after failing an adequate trial of diet therapy improve glycemic control in adults with type 2 diabetes mellitus (1.2) . Important Limitations of Use (1.3) : Do not use for glycemic control in type 1 diabetes or for treating diabetic ketoacidosis. WELCHOL has not been studied in type 2 diabetes as monotherapy or in combination with a dipeptidyl peptidase 4 inhibitor and has not been extensively studied in combination with thiazolidinediones. WELCHOL has not been studied in Fredrickson Type I, III, IV, and V dyslipidemias. WELCHOL has not been studied in children younger than 10 years of age or in pre-menarchal girls. uuid:8acd4ee1-461b-4758-a0d8-1f15b23e3b2f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59594 biolink:treats MONDO:0012819 PMID:41385096 "[{""id"":""uuid:1a5e3b85-c87c-4dd8-b9f5-3949d1304d51"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:54d2ac8c-1ae7-4cff-b5cb-f0e52e6ff6e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] WELCHOL is a bile acid sequestrant indicated as an adjunct to diet and exercise to reduce elevated low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia as monotherapy or in combination with an hydroxymethyl-glutaryl-coenzyme A (HMG CoA) reductase inhibitor (statin) (1.1) . reduce LDL-C levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia as monotherapy or in combination with a statin after failing an adequate trial of diet therapy improve glycemic control in adults with type 2 diabetes mellitus (1.2) . Important Limitations of Use (1.3) : Do not use for glycemic control in type 1 diabetes or for treating diabetic ketoacidosis. WELCHOL has not been studied in type 2 diabetes as monotherapy or in combination with a dipeptidyl peptidase 4 inhibitor and has not been extensively studied in combination with thiazolidinediones. WELCHOL has not been studied in Fredrickson Type I, III, IV, and V dyslipidemias. WELCHOL has not been studied in children younger than 10 years of age or in pre-menarchal girls. uuid:372a1e96-2fa2-488f-80d9-d8932d0057a0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59594 biolink:treats MONDO:0007788 PMID:41385096 "[{""id"":""uuid:dc2f651a-5a47-42e9-b1ba-5b528067ee90"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c391a3ba-10d0-4bc5-908d-68c7deab7d25"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] WELCHOL is a bile acid sequestrant indicated as an adjunct to diet and exercise to reduce elevated low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia as monotherapy or in combination with an hydroxymethyl-glutaryl-coenzyme A (HMG CoA) reductase inhibitor (statin) (1.1) . reduce LDL-C levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia as monotherapy or in combination with a statin after failing an adequate trial of diet therapy improve glycemic control in adults with type 2 diabetes mellitus (1.2) . Important Limitations of Use (1.3) : Do not use for glycemic control in type 1 diabetes or for treating diabetic ketoacidosis. WELCHOL has not been studied in type 2 diabetes as monotherapy or in combination with a dipeptidyl peptidase 4 inhibitor and has not been extensively studied in combination with thiazolidinediones. WELCHOL has not been studied in Fredrickson Type I, III, IV, and V dyslipidemias. WELCHOL has not been studied in children younger than 10 years of age or in pre-menarchal girls. uuid:ea88f3e3-36ce-48aa-b8dc-67ef14e4ff58 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59594 biolink:treats MONDO:0018473 PMID:41385096 "[{""id"":""uuid:f3b72110-4574-4d59-882c-f3b5bf34940c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1512b195-7070-4c1b-92cb-f96fb7f54228"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] WELCHOL is a bile acid sequestrant indicated as an adjunct to diet and exercise to reduce elevated low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia as monotherapy or in combination with an hydroxymethyl-glutaryl-coenzyme A (HMG CoA) reductase inhibitor (statin) (1.1) . reduce LDL-C levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia as monotherapy or in combination with a statin after failing an adequate trial of diet therapy improve glycemic control in adults with type 2 diabetes mellitus (1.2) . Important Limitations of Use (1.3) : Do not use for glycemic control in type 1 diabetes or for treating diabetic ketoacidosis. WELCHOL has not been studied in type 2 diabetes as monotherapy or in combination with a dipeptidyl peptidase 4 inhibitor and has not been extensively studied in combination with thiazolidinediones. WELCHOL has not been studied in Fredrickson Type I, III, IV, and V dyslipidemias. WELCHOL has not been studied in children younger than 10 years of age or in pre-menarchal girls. uuid:2562a60f-a2ae-4749-9025-d51ab7058ba5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59594 biolink:treats MONDO:0007762 PMID:41385096 "[{""id"":""uuid:5ddb8d6e-cf43-462a-b0e7-4749f8676a43"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:faf247d2-1bb8-4452-bdb9-48d0ef9fd796"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] WELCHOL is a bile acid sequestrant indicated as an adjunct to diet and exercise to reduce elevated low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia as monotherapy or in combination with an hydroxymethyl-glutaryl-coenzyme A (HMG CoA) reductase inhibitor (statin) (1.1) . reduce LDL-C levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia as monotherapy or in combination with a statin after failing an adequate trial of diet therapy improve glycemic control in adults with type 2 diabetes mellitus (1.2) . Important Limitations of Use (1.3) : Do not use for glycemic control in type 1 diabetes or for treating diabetic ketoacidosis. WELCHOL has not been studied in type 2 diabetes as monotherapy or in combination with a dipeptidyl peptidase 4 inhibitor and has not been extensively studied in combination with thiazolidinediones. WELCHOL has not been studied in Fredrickson Type I, III, IV, and V dyslipidemias. WELCHOL has not been studied in children younger than 10 years of age or in pre-menarchal girls. uuid:147471e9-183d-4c4d-9ec3-c9a8b54b254a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0005093 PMID:41385096 "[{""id"":""uuid:4be283f0-6cb8-4a40-a435-407a6aaf70d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a732ed2c-7304-4f60-88ca-9283c14f1012"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Triamcinolone acetonide cream is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. uuid:949376ae-7d9c-4af4-a300-bc29ff8c4564 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10110 biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:b80ede99-5959-47e4-98e7-381aec3c09e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fdca7275-70db-4bec-beec-ab37ee9a82ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Zidovudine tablets are a nucleoside analogue reverse transcriptase inhibitor indicated for: Treatment of Human Immunodeficiency Virus (HIV-1) infection in combination with other antiretroviral agents. (1.1) Prevention of maternal-fetal HIV-1 transmission. (1.2) uuid:019cb732-b571-4779-b44a-808859ee2ff3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10110 biolink:treats UMLS:C0242648 PMID:41385096 "[{""id"":""uuid:42d31a48-ec7e-4acc-a524-525817ae3015"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4be413ec-6dbb-4f39-9412-e35c5c47a5ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Zidovudine tablets are a nucleoside analogue reverse transcriptase inhibitor indicated for: Treatment of Human Immunodeficiency Virus (HIV-1) infection in combination with other antiretroviral agents. (1.1) Prevention of maternal-fetal HIV-1 transmission. (1.2) uuid:185e5b40-c50e-439c-82ff-d7128b80ba44 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation MESH:C069202 biolink:treats MONDO:0005052 PMID:41385096 "[{""id"":""uuid:3dc00942-2f4b-452f-9663-1e58b4e99230"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:26a33332-ddd1-4e90-aa19-bdc191f1bd90"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FDA has classified the following indications as “possibly” effective: For use as adjunctive therapy in the treatment of irritable bowel syndrome (irritable colon, spastic colon, mucous colitis) and acute enterocolitis. May also be useful as adjunctive therapy in the treatment of duodenal ulcer. IT HAS NOT BEEN SHOWN CONCLUSIVELY WHETHER ANTICHOLINERGIC/ ANTISPASMODIC DRUGS AID IN THE HEALING OF A DUODENAL ULCER, DECREASE THE RATE OF RECURRENCES OR PREVENT COMPLICATIONS. uuid:39909624-f244-41f6-be25-00582cd950ca biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation MESH:C069202 biolink:treats UMLS:C0856217 PMID:41385096 "[{""id"":""uuid:32404ea3-0e58-455b-827d-b325fc8d166a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:02082f0c-bd56-4b21-adac-db21ec071109"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FDA has classified the following indications as “possibly” effective: For use as adjunctive therapy in the treatment of irritable bowel syndrome (irritable colon, spastic colon, mucous colitis) and acute enterocolitis. May also be useful as adjunctive therapy in the treatment of duodenal ulcer. IT HAS NOT BEEN SHOWN CONCLUSIVELY WHETHER ANTICHOLINERGIC/ ANTISPASMODIC DRUGS AID IN THE HEALING OF A DUODENAL ULCER, DECREASE THE RATE OF RECURRENCES OR PREVENT COMPLICATIONS. uuid:a3ce01b9-69fc-4385-98ed-6bcdde209d69 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation MESH:C069202 biolink:treats UMLS:C3203466 PMID:41385096 "[{""id"":""uuid:44b4c3e4-6626-416c-bac5-b762ab8f8888"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8ef9a59f-1222-4bf3-b74a-64f7442c5353"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FDA has classified the following indications as “possibly” effective: For use as adjunctive therapy in the treatment of irritable bowel syndrome (irritable colon, spastic colon, mucous colitis) and acute enterocolitis. May also be useful as adjunctive therapy in the treatment of duodenal ulcer. IT HAS NOT BEEN SHOWN CONCLUSIVELY WHETHER ANTICHOLINERGIC/ ANTISPASMODIC DRUGS AID IN THE HEALING OF A DUODENAL ULCER, DECREASE THE RATE OF RECURRENCES OR PREVENT COMPLICATIONS. uuid:58cffbdb-6062-40b1-a6f8-52ec4284b088 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation MESH:C069202 biolink:treats MONDO:0005412 PMID:41385096 "[{""id"":""uuid:a1d870ca-1f9b-4235-a5d5-cf29b882654f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c5cbd3fc-c2ad-41c6-b21b-2e46f82a7cd9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FDA has classified the following indications as “possibly” effective: For use as adjunctive therapy in the treatment of irritable bowel syndrome (irritable colon, spastic colon, mucous colitis) and acute enterocolitis. May also be useful as adjunctive therapy in the treatment of duodenal ulcer. IT HAS NOT BEEN SHOWN CONCLUSIVELY WHETHER ANTICHOLINERGIC/ ANTISPASMODIC DRUGS AID IN THE HEALING OF A DUODENAL ULCER, DECREASE THE RATE OF RECURRENCES OR PREVENT COMPLICATIONS. uuid:a74a254e-e82b-476c-a75d-d15f4f6d4a4c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:11949636 biolink:treats UMLS:C0015404 PMID:41385096 "[{""id"":""uuid:e41b55a6-0441-4c3d-806d-4d1147ec58b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3c3d9a0b-fa16-426a-9667-16398b3d3af6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tobramycin and dexamethasone ophthalmic suspension is indicated for steroid responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococci, including S. aureus and S. epidermidis (coagulase-positive and coagulase-negative), including penicillin-resistant strains. Streptococci, including some of the Group A-beta-hemolytic species, some nonhemolytic species, and some Streptococcus pneumoniae . Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, Proteus mirabilis, Morganella morganii, most Proteus vulgaris strains , Haemophilus influenzae and H. aegyptius, Moraxella lacunata, Acinetobacter calcoaceticus and some Neisseria species. uuid:d64659fe-3e91-46ca-aca0-131f04fb6f60 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0005324 PMID:41385096 "[{""id"":""uuid:cb6f7da1-29ae-4b2b-bd03-b749e9a0d59a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8e5a0a02-c407-467d-a71d-1460bf8771f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AllerNaze is indicated for the treatment of the nasal symptoms of seasonal and perennial allergic rhinitis in adults and children 12 years of age or older. uuid:6303469e-7b07-4489-b593-64d52249d565 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0024332 PMID:41385096 "[{""id"":""uuid:ec64f15f-53fa-4230-a55a-fa4746bb8225"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ed3c6a3c-3609-4274-9b65-7203fc718f3e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AllerNaze is indicated for the treatment of the nasal symptoms of seasonal and perennial allergic rhinitis in adults and children 12 years of age or older. uuid:0f734359-3aa1-44de-8880-ee0ef4a782a6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:215703 biolink:treats MONDO:0006668 PMID:41385096 "[{""id"":""uuid:7d184336-6a70-411d-981f-5d8d7d3cdce1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:66655ea3-a1ef-4bb2-90d7-8f12970e990a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sulfacetamide sodium and prednisolone sodium phosphate ophthalmic solution is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where a superficial bacterial ocular infection or a risk of bacterial ocular infection exists. Ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of corticosteroid use in certain infective conjunctivitides is accepted to obtain diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular antibacterial drug in this product is active against the following common bacterial eye pathogens: Escherichia coli, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus (viridans group), Haemophilus influenzae, Klebsiella species, and Enterobacter species. The product does not provide adequate coverage against: Neisseria species, Pseudomonas species, Serratia marcescens . A significant percentage of staphylococcal isolates are completely resistant to sulfa drugs. uuid:8d239c14-133f-4a30-a27e-92cd5c3cd008 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:215703 biolink:treats UMLS:C0008690 PMID:41385096 "[{""id"":""uuid:441a9f3b-7c78-4dfb-9f23-bf828daa3f95"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d2f553d6-906b-4350-8c03-3a6787be6600"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sulfacetamide sodium and prednisolone sodium phosphate ophthalmic solution is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where a superficial bacterial ocular infection or a risk of bacterial ocular infection exists. Ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of corticosteroid use in certain infective conjunctivitides is accepted to obtain diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular antibacterial drug in this product is active against the following common bacterial eye pathogens: Escherichia coli, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus (viridans group), Haemophilus influenzae, Klebsiella species, and Enterobacter species. The product does not provide adequate coverage against: Neisseria species, Pseudomonas species, Serratia marcescens . A significant percentage of staphylococcal isolates are completely resistant to sulfa drugs. uuid:1ade709b-9892-4497-a374-4487e2962a60 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:215703 biolink:treats UMLS:C0339289 PMID:41385096 "[{""id"":""uuid:40b9fbab-6623-4b91-978b-3ca876efad5c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7d94e7aa-d998-4d65-9332-9b7c44dbcde8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sulfacetamide sodium and prednisolone sodium phosphate ophthalmic solution is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where a superficial bacterial ocular infection or a risk of bacterial ocular infection exists. Ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of corticosteroid use in certain infective conjunctivitides is accepted to obtain diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular antibacterial drug in this product is active against the following common bacterial eye pathogens: Escherichia coli, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus (viridans group), Haemophilus influenzae, Klebsiella species, and Enterobacter species. The product does not provide adequate coverage against: Neisseria species, Pseudomonas species, Serratia marcescens . A significant percentage of staphylococcal isolates are completely resistant to sulfa drugs. uuid:e04bd98d-65d6-45cd-a83a-03fa26cfd9a3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:40237 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:3cb16592-f6cc-46a7-8283-f337f3e63ce9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:34bfc980-74e9-4212-b2e6-5c363e7e780a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:1206186c-1cb7-49fa-874a-765c218cf45b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/xelevia""]},{""id"":""uuid:56b66c33-af09-4bf4-8210-31a7c78974c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] JANUVIA is a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1.1 ) Important Limitations of Use: JANUVIA should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. ( 1.2 ) JANUVIA has not been studied in patients with a history of pancreatitis. ( 1.2 , 5.1 )|[EMA] For adult patients with type-2 diabetes mellitus, Xelevia is indicated to improve glycaemic control:as monotherapy:in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance;as dual oral therapy in combination with:metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control;a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance;a peroxisome proliferator-activated receptor gamma (PPARγ) agonist (i.e. a thiazolidinedione) when use of a PPARγ agonist is appropriate and when diet and exercise plus the PPARγ agonist alone do not provide adequate glycaemic control;as triple oral therapy in combination with:a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control;a PPARγ agonist and metformin when use of a PPARγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.Xelevia is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.|[PMDA] Drugs with a new active ingredient indicated for the treatment of type 2 diabetes mellitus (for use only in patients who do not sufficiently respond to any one of the following treatments): Dietary therapy and/or exercise therapy only Use of sulfonylureas in addition to dietary therapy and/or exercise therapy Use of thiazolidinediones in addition to dietary therapy and/or exercise therapy Use of biguanides in addition to dietary therapy and/or exercise therapy uuid:05945162-9a4d-46d9-98e6-c5d20f2eac44 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:40237 biolink:treats MONDO:0012819 PMID:41385096 "[{""id"":""uuid:dcacbc29-b6b6-4271-bc28-028abe2b7931"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5de7cd30-7a13-424b-b871-cd9d5c2479ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] JANUVIA is a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1.1 ) Important Limitations of Use: JANUVIA should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. ( 1.2 ) JANUVIA has not been studied in patients with a history of pancreatitis. ( 1.2 , 5.1 ) uuid:fc14e6c3-905f-454d-bfd3-27a570543a7f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:40237 biolink:treats MONDO:0004982 PMID:41385096 "[{""id"":""uuid:3cd5f80d-629b-4494-aec0-c52695762300"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:de978d2e-091a-4d83-b95f-d17cb00ec73a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] JANUVIA is a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1.1 ) Important Limitations of Use: JANUVIA should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. ( 1.2 ) JANUVIA has not been studied in patients with a history of pancreatitis. ( 1.2 , 5.1 ) uuid:331b0fb1-ce33-4eab-beda-e785d2039ccb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50749 biolink:treats UMLS:C0406317 PMID:41385096 "[{""id"":""uuid:5fdcf531-2953-44ea-8fe5-be0bc52c8754"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9b74b9c1-6789-4b61-b318-7c9fb5113bea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dovonex ® (calcipotriene cream) Cream, 0.005%, is indicated for the treatment of plaque psoriasis. The safety and effectiveness of topical calcipotriene in dermatoses other than psoriasis have not been established. uuid:d32c74b4-cf45-4f4e-a63c-222c5dbfd147 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4670 biolink:treats UMLS:C1740826 PMID:41385096 "[{""id"":""uuid:4cde52ad-f061-4221-9e35-481e6ef3c814"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0da02fff-a8a8-430b-996c-1bf983baf541"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dobutamine injection is indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of adults with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures. In patients who have atrial fibrillation with rapid ventricular response, a digitalis preparation should be used prior to institution of therapy with dobutamine hydrochloride. uuid:8fc41ae2-3a1f-41d3-b79e-795d7f82be47 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4670 biolink:treats MONDO:0005267 PMID:41385096 "[{""id"":""uuid:71fdd089-e5f8-441c-85cc-6f0b3161315d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:be2740f4-cfde-4e93-9fe4-462bc330770e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dobutamine injection is indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of adults with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures. In patients who have atrial fibrillation with rapid ventricular response, a digitalis preparation should be used prior to institution of therapy with dobutamine hydrochloride. uuid:7cb0d48f-7798-4f28-884e-0fffb163f6cb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4670 biolink:treats MONDO:0004981 PMID:41385096 "[{""id"":""uuid:d2063090-413f-4cb9-b8ff-6fc12bf29e17"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9ef82bbe-a9ee-4b8a-9830-0ce558c9ff8a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dobutamine injection is indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of adults with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures. In patients who have atrial fibrillation with rapid ventricular response, a digitalis preparation should be used prior to institution of therapy with dobutamine hydrochloride. uuid:d2199c6b-016b-41b1-92ef-06dda7f58a7e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4670 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:e67a9340-7fe8-4fd4-83ca-a431fe8229ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7b6391db-9982-4787-afa0-6c60f4340328"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dobutamine in 5% Dextrose Injection, USP is indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures. Experience with intravenous dobutamine in controlled trials does not extend beyond 48 hours of repeated boluses and/or continuous infusions. Whether given orally, continuously intravenously, or intermittently intravenously, neither dobutamine nor any other cyclic-AMP-dependent inotrope has been shown in controlled trials to be safe or effective in the long-term treatment of congestive heart failure. In controlled trials of chronic oral therapy with various such agents, symptoms were not consistently alleviated, and the cyclic-AMP-dependent inotropes were consistently associated with increased risks of hospitalization and death. Patients with NYHA Class IV symptoms appeared to be at particular risk. uuid:19594abe-e0d2-49d0-9f45-f9be11d68ccd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9448 biolink:treats MONDO:0001628 PMID:41385096 "[{""id"":""uuid:6a4cdaa3-5006-4f26-99b8-a6bfc8ebe622"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9c1d8abf-3bc4-422e-9a3f-dabef43636be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Terbinafine hydrochloride tablets are indicated for the treatment of onychomycosis of the toenail or fingernail due to dermatophytes (tinea unguium) (see DOSAGE AND ADMINISTRATION and CLINICAL STUDIES ). Prior to initiating treatment, appropriate nail specimens for laboratory testing (KOH preparation, fungal culture, or nail biopsy) should be obtained to confirm the diagnosis of onychomycosis. uuid:6635a5bf-a140-435d-acd4-a52257a2dee8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3219 biolink:treats MONDO:0002050 PMID:41385096 "[{""id"":""uuid:145f8bb4-ce73-49ae-9907-78df9952a87f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:82f0f74a-2bfd-4f43-9f6d-00b99e2fe6ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Aplenzin™ (bupropion hydrobromide extended-release tablets) is indicated for the treatment of major depressive disorder. The efficacy of bupropion in the treatment of a major depressive episode was established in two 4-week controlled trials of inpatients and in one 6-week controlled trial of outpatients whose diagnoses corresponded most closely to the Major Depression category of the APA Diagnostic and Statistical Manual (DSM) [see CLINICAL STUDIES (14) ] . A major depressive episode (DSM-IV) implies the presence of 1) depressed mood or 2) loss of interest or pleasure; in addition, at least 5 of the following symptoms have been present during the same 2-week period and represent a change from previous functioning: depressed mood, markedly diminished interest or pleasure in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt, or suicidal ideation. The efficacy of bupropion in maintaining an antidepressant response for up to 44 weeks following 8 weeks of acute treatment was demonstrated in a placebo-controlled trial with the sustained-release formulation of bupropion [see CLINICAL STUDIES (14) ] . Nevertheless, the physician who elects to use Aplenzin for extended periods should periodically reevaluate the long-term usefulness of the drug for the individual patient. uuid:6975d755-2d4d-4810-be3d-ad7ce1279fe4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3219 biolink:treats MONDO:0013600 PMID:41385096 "[{""id"":""uuid:a59cf484-5062-4130-9f6c-850f5d64acf5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:94ec436e-16c7-4ba4-8598-8a8a2ece1567"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Aplenzin™ (bupropion hydrobromide extended-release tablets) is indicated for the treatment of major depressive disorder. The efficacy of bupropion in the treatment of a major depressive episode was established in two 4-week controlled trials of inpatients and in one 6-week controlled trial of outpatients whose diagnoses corresponded most closely to the Major Depression category of the APA Diagnostic and Statistical Manual (DSM) [see CLINICAL STUDIES (14) ] . A major depressive episode (DSM-IV) implies the presence of 1) depressed mood or 2) loss of interest or pleasure; in addition, at least 5 of the following symptoms have been present during the same 2-week period and represent a change from previous functioning: depressed mood, markedly diminished interest or pleasure in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt, or suicidal ideation. The efficacy of bupropion in maintaining an antidepressant response for up to 44 weeks following 8 weeks of acute treatment was demonstrated in a placebo-controlled trial with the sustained-release formulation of bupropion [see CLINICAL STUDIES (14) ] . Nevertheless, the physician who elects to use Aplenzin for extended periods should periodically reevaluate the long-term usefulness of the drug for the individual patient. uuid:b20268fd-c3bf-461b-b107-961ca8ed6a67 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3219 biolink:treats MONDO:0005466 PMID:41385096 "[{""id"":""uuid:b2ac8a04-bc76-4d5f-b795-add883a47e81"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f8007dd8-487c-4cf0-a228-be09bbbc7e3f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Aplenzin™ (bupropion hydrobromide extended-release tablets) is indicated for the treatment of major depressive disorder. The efficacy of bupropion in the treatment of a major depressive episode was established in two 4-week controlled trials of inpatients and in one 6-week controlled trial of outpatients whose diagnoses corresponded most closely to the Major Depression category of the APA Diagnostic and Statistical Manual (DSM) [see CLINICAL STUDIES (14) ] . A major depressive episode (DSM-IV) implies the presence of 1) depressed mood or 2) loss of interest or pleasure; in addition, at least 5 of the following symptoms have been present during the same 2-week period and represent a change from previous functioning: depressed mood, markedly diminished interest or pleasure in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt, or suicidal ideation. The efficacy of bupropion in maintaining an antidepressant response for up to 44 weeks following 8 weeks of acute treatment was demonstrated in a placebo-controlled trial with the sustained-release formulation of bupropion [see CLINICAL STUDIES (14) ] . Nevertheless, the physician who elects to use Aplenzin for extended periods should periodically reevaluate the long-term usefulness of the drug for the individual patient. uuid:5106f257-c927-4c6c-9d9d-6fc0c57a1d81 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71253 biolink:treats MONDO:0005090 PMID:41385096 "[{""id"":""uuid:700e8113-494f-422e-85fd-fdab4ef4c8a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:25be2832-1738-4b3c-901d-56620090d269"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:470b3388-6fd2-45bb-acc3-ec12a4941fb3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SAPHRIS is an atypical antipsychotic indicated for: Treatment of schizophrenia. ( 1.1 ) Efficacy was established in two 6-week clinical trials and one maintenance trial in patients with schizophrenia in adults. ( 14.1 ) Acute treatment, as monotherapy or adjunctive therapy, of manic or mixed episodes associated with bipolar I disorder. ( 1.2 ) Efficacy was established in two 3-week monotherapy trials and in one 3-week adjunctive trial in patients with manic or mixed episodes associated with bipolar I disorder in adults. ( 14.2 )|[PMDA] Drugs with a new active ingredient indicated for the treatment of schizophrenia. uuid:12d9d093-318d-4548-ab37-bad7ffa8dcc2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71253 biolink:treats MONDO:0001866 PMID:41385096 "[{""id"":""uuid:801c8e45-9d59-47bb-b189-f4c8f43f6db0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4b5db1be-a9dc-40f3-8a41-bd42ced01038"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SAPHRIS is an atypical antipsychotic indicated for: Treatment of schizophrenia. ( 1.1 ) Efficacy was established in two 6-week clinical trials and one maintenance trial in patients with schizophrenia in adults. ( 14.1 ) Acute treatment, as monotherapy or adjunctive therapy, of manic or mixed episodes associated with bipolar I disorder. ( 1.2 ) Efficacy was established in two 3-week monotherapy trials and in one 3-week adjunctive trial in patients with manic or mixed episodes associated with bipolar I disorder in adults. ( 14.2 ) uuid:6b5b8c01-6683-4135-a0cf-500a1ac041ff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C4277251 biolink:treats MONDO:0005147 PMID:41385096 "[{""id"":""uuid:dd4ff209-961c-449d-a144-df70477486d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f1e60491-b2b3-4199-a279-d259cbe62a65"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LANTUS is indicated to improve glycemic control in adults and children with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. Important Limitations of Use: LANTUS is not recommended for the treatment of diabetic ketoacidosis. Intravenous short-acting insulin is the preferred treatment for this condition. MESH:C000606659 uuid:1421d5c6-b9ff-4b27-86ca-a6d182d5df9c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C4277251 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:32b24fa8-f12d-4d63-8c89-1b38a90230eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:87f45ca7-fd21-439b-b351-3997aea739b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LANTUS is indicated to improve glycemic control in adults and children with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. Important Limitations of Use: LANTUS is not recommended for the treatment of diabetic ketoacidosis. Intravenous short-acting insulin is the preferred treatment for this condition. MESH:C000606659 uuid:918f8229-ab79-4267-8c63-66fc4258aefb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C4277251 biolink:treats MONDO:0012819 PMID:41385096 "[{""id"":""uuid:84ec6b7f-dde3-47df-9460-2790c3b643fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:797fe3da-61f5-4398-ac6c-11c22569a92d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LANTUS is indicated to improve glycemic control in adults and children with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. Important Limitations of Use: LANTUS is not recommended for the treatment of diabetic ketoacidosis. Intravenous short-acting insulin is the preferred treatment for this condition. MESH:C000606659 uuid:4aaf848e-11c2-42f6-86cd-4ed3ae5a3d87 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:42944 biolink:treats MONDO:0004975 PMID:41385096 "[{""id"":""uuid:96efaf40-7f42-4fe4-b2f1-f7fa7352474f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5a09a830-34bd-4708-94c9-338a2df7494d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:460a996e-d6b8-4a23-8ab5-446328b46806"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RAZADYNE ® ER/RAZADYNE ® (galantamine hydrobromide) is indicated for the treatment of mild to moderate dementia of the Alzheimer's type.|[PMDA] Drugs with a new active ingredient indicated for inhibition of progression of symptoms of dementia in mild and moderate Alzheimer's dementia. uuid:8cad32e2-6c8c-4425-8463-c38b0523021b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:56841818 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:df49046c-35ef-4179-bdb2-ea27b79a4f08"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4b3c3ff6-0aae-495b-9aba-ea68028483dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Acetaminophen, caffeine, and dihydrocodeine bitartrate tablets are indicated for the relief of moderate to moderately severe pain. uuid:491ad359-d2b4-449a-8de7-46d6f4474859 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10127 biolink:treats MONDO:0005027 PMID:41385096 "[{""id"":""uuid:3179419d-086b-4fe5-87a1-11232a9a623f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:dde79985-da11-4c22-aa39-a9d6c8462354"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:bded3c3f-136c-4560-a587-086e9f76fd39"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/zonisamide-mylan""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Zonisamide capsules are indicated as adjunctive therapy in the treatment of partial seizures in adults with epilepsy.|[EMA] Monotherapy in the treatment of partial seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy;adjunctive therapy in the treatment of partial seizures, with or without secondary generalisation, in adults, adolescents, and children aged 6 years and above. uuid:07c2e96b-5a3f-4963-870d-47c23163d1d2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10127 biolink:treats HP:0007359 PMID:41385096 "[{""id"":""uuid:4c1b1da2-3351-48db-ad2a-cf160263768f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:48bc56d5-7348-4945-bee1-9479452f6ec4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:2d8670c9-be25-432e-b14e-4f0247f4aaf7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/zonisamide-mylan""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Zonisamide capsules are indicated as adjunctive therapy in the treatment of partial seizures in adults with epilepsy.|[EMA] Monotherapy in the treatment of partial seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy;adjunctive therapy in the treatment of partial seizures, with or without secondary generalisation, in adults, adolescents, and children aged 6 years and above. uuid:f2c83e1e-60e4-4eb8-a0ce-0b57b031c58b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29108 biolink:treats MONDO:0000328 PMID:41385096 "[{""id"":""uuid:df359734-d488-4384-88d1-139034a1ccea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7696ec71-c73b-4680-9936-c9398cbd0ce7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PhosLo is indicated for the control of hyperphosphatemia in end stage renal failure and does not promote aluminum absorption. uuid:1174a1a5-c519-410b-8245-9790b7b69fd5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29108 biolink:treats MONDO:0004375 PMID:41385096 "[{""id"":""uuid:34b60860-19d2-4f8f-9465-86b383ac2079"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fdc154ed-5ef8-41d8-99d7-606bfd241ab4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PhosLo is indicated for the control of hyperphosphatemia in end stage renal failure and does not promote aluminum absorption. uuid:4f1bbd3a-8d7e-411a-b029-a49004810b4e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats UMLS:C0433042 PMID:41385096 "[{""id"":""uuid:b0462f24-47c2-4155-a924-d1c9a6fdf42c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c6e47504-2aeb-4ff7-bb5c-f8d64abb9514"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Primary skin infections: Impetigo contagiosa, superficial folliculitis, ecthyma, furunculosis, sycosis barbae, and pyoderma gangrenosum. Secondary skin infections: Infectious eczematoid dermatitis, pustular acne, pustular psoriasis, infected seborrheic dermatitis, infected contact dermatitis (including poison ivy), infected excoriations, and bacterial superinfections of fungal or viral infections. NOTE: Gentamicin is a bactericidal agent that is not effective against viruses or fungi in skin infections. It is useful in the treatment of infected skin cysts and certain other skin abscesses when preceded by incision and drainage to permit adequate contact between the antibiotic and the infecting bacteria. Good results have been obtained in the treatment of infected stasis and other skin ulcers, infected superficial burns, paronychia, infected insect bites and stings, infected lacerations and abrasions and wounds from minor surgery. Patients sensitive to neomycin can be treated with GENTAMICIN, although regular observation of patients sensitive to topical antibiotics is advisable when such patients are treated with any topical antibiotic. GENTAMICIN CREAM is recommended for wet, oozing primary infections, and greasy, secondary infections, such as pustular acne or infected seborrheic dermatitis, and where a water washable cream preparation is desired. GENTAMICIN OINTMENT helps retain moisture and has been useful in infection on dry eczematous or psoriatic skin. GENTAMICIN CREAM and OINTMENT have been used successfully in infants over one year of age as well as in adults and children. uuid:2709256c-690a-4ee7-9cea-c95caf859565 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats UMLS:C0043241 PMID:41385096 "[{""id"":""uuid:ef781a3e-86f5-4700-ab00-ae0d730cbc45"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4a96e558-813a-477e-a244-02e01e2a41f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Primary skin infections: Impetigo contagiosa, superficial folliculitis, ecthyma, furunculosis, sycosis barbae, and pyoderma gangrenosum. Secondary skin infections: Infectious eczematoid dermatitis, pustular acne, pustular psoriasis, infected seborrheic dermatitis, infected contact dermatitis (including poison ivy), infected excoriations, and bacterial superinfections of fungal or viral infections. NOTE: Gentamicin is a bactericidal agent that is not effective against viruses or fungi in skin infections. It is useful in the treatment of infected skin cysts and certain other skin abscesses when preceded by incision and drainage to permit adequate contact between the antibiotic and the infecting bacteria. Good results have been obtained in the treatment of infected stasis and other skin ulcers, infected superficial burns, paronychia, infected insect bites and stings, infected lacerations and abrasions and wounds from minor surgery. Patients sensitive to neomycin can be treated with GENTAMICIN, although regular observation of patients sensitive to topical antibiotics is advisable when such patients are treated with any topical antibiotic. GENTAMICIN CREAM is recommended for wet, oozing primary infections, and greasy, secondary infections, such as pustular acne or infected seborrheic dermatitis, and where a water washable cream preparation is desired. GENTAMICIN OINTMENT helps retain moisture and has been useful in infection on dry eczematous or psoriatic skin. GENTAMICIN CREAM and OINTMENT have been used successfully in infants over one year of age as well as in adults and children. uuid:4ed9850b-7b28-45a5-89e1-768247722450 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1162127 biolink:treats MONDO:0001302 PMID:41385096 "[{""id"":""uuid:ec6d4dbe-bc3f-4aea-b17e-190b3f97bd22"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c3c4c0d9-776b-4e27-aff9-8ea94ec37284"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension Losartan potassium and hydrochlorothiazide tablets are indicated for the treatment of hypertension. This fixed dose combination is not indicated for initial therapy of hypertension, except when the hypertension is severe enough that the value of achieving prompt blood pressure control exceeds the risk of initiating combination therapy in these patients (see CLINICAL PHARMACOLOGY , Pharmacodynamics and Clinical Effects and DOSAGE AND ADMINISTRATION ). Hypertensive Patients with Left Ventricular Hypertrophy Losartan potassium and hydrochlorothiazide tablets are indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to Black patients (see PRECAUTIONS , Race ; CLINICAL PHARMACOLOGY , Pharmacodynamics and Clinical Effects , Losartan Potassium , Reduction in the risk of stroke , Race ; and DOSAGE AND ADMINISTRATION ). uuid:00b9a2d2-fe40-4693-985e-f29cd6c90fc1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1162127 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:0afd8284-b92a-48a8-8b03-15eace0cf8ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c1f4077d-59ed-4ef8-8172-c7cfdea2e577"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension Losartan potassium and hydrochlorothiazide tablets are indicated for the treatment of hypertension. This fixed dose combination is not indicated for initial therapy of hypertension, except when the hypertension is severe enough that the value of achieving prompt blood pressure control exceeds the risk of initiating combination therapy in these patients (see CLINICAL PHARMACOLOGY , Pharmacodynamics and Clinical Effects and DOSAGE AND ADMINISTRATION ). Hypertensive Patients with Left Ventricular Hypertrophy Losartan potassium and hydrochlorothiazide tablets are indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to Black patients (see PRECAUTIONS , Race ; CLINICAL PHARMACOLOGY , Pharmacodynamics and Clinical Effects , Losartan Potassium , Reduction in the risk of stroke , Race ; and DOSAGE AND ADMINISTRATION ). uuid:f7fed5e1-1b71-436d-9cd4-b5210f74a52f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:1678OK0E08 biolink:treats MONDO:0007743 PMID:41385096 "[{""id"":""uuid:e7a7647c-05bf-4546-ad68-85701987264d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8d60aa98-64c4-47ee-99d2-6ef2f3c91d08"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Focalin XR is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients aged 6 years and older. The effectiveness of Focalin XR in the treatment of ADHD in patients aged 6 years and older was established in two placebo-controlled studies in patients meeting DSM-IV criteria for ADHD [ see Clinical Studies (14) ]. A diagnosis of Attention Deficit Hyperactivity Disorder (ADHD; DSM-IV) implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years. The symptoms must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and be present in two or more settings, e.g., school (or work) and at home. The symptoms must not be better accounted for by another mental disorder. For the Inattentive Type, at least six of the following symptoms must have persisted for at least 6 months: lack of attention to details/careless mistakes; lack of sustained attention; poor listener; failure to follow through on tasks; poor organization; avoids tasks requiring sustained mental effort; loses things; easily distracted; forgetful. For the Hyperactive-Impulsive Type, at least six of the following symptoms must have persisted for at least 6 months: fidgeting/squirming; leaving seat; inappropriate running/climbing; difficulty with quiet activities; “on the go”; excessive talking; blurting answers; can’t wait turn; intrusive. The Combined Types requires both inattentive and hyperactive-impulsive criteria to be met. Special Diagnostic Considerations Specific etiology of this syndrome is unknown, and there is no single diagnostic test. Adequate diagnosis requires the use not only of medical but of special psychological, educational, and social resources. Learning may or may not be impaired. The diagnosis must be based upon a complete history and evaluation of the child and not solely on the presence of the required number of DSM-IV characteristics. Need for Comprehensive Treatment Program Focalin XR is indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational, social) for patients with this syndrome. Drug treatment may not be indicated for all children with this syndrome. Stimulants are not intended for use in the child who exhibits symptoms secondary to environmental factors and/or other primary psychiatric disorders, including psychosis. Appropriate educational placement is essential and psychosocial intervention is often helpful. When remedial measures alone are insufficient, the decision to prescribe stimulant medication will depend upon the physician’s assessment of the chronicity and severity of the child’s symptoms. Long-Term Use The effectiveness of Focalin XR for long-term use, i.e., for more than 7 weeks, has not been systematically evaluated in controlled trials. Therefore, the physician who elects to use Focalin XR for extended periods should periodically reevaluate the long-term usefulness of the drug for the individual patient [ see Dosage a nd Administration (2.3) ]. CHEMBL.COMPOUND:CHEMBL904 uuid:6ce9a947-77d5-492b-95fb-12dc76757421 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9150 biolink:treats MONDO:0005311 PMID:41385096 "[{""id"":""uuid:614c99b6-5c4a-422b-a1e2-a7d07c10530a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f28b17cb-ceb0-45bc-8f3a-6a384664e46d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with coronary heart disease (CHD) or at high risk of CHD, simvastatin can be started simultaneously with diet. 1.1 Reductions in Risk of CHD Mortality and Cardiovascular Events In patients at high risk of coronary events because of existing coronary heart disease, diabetes, peripheral vessel disease, history of stroke or other cerebrovascular disease, simvastatin tablets, USP are indicated to: Reduce the risk of total mortality by reducing CHD deaths. Reduce the risk of non-fatal myocardial infarction and stroke. Reduce the need for coronary and non-coronary revascularization procedures. 1.2 Hyperlipidemia Simvastatin tablets, USP are indicated to: Reduce elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), and triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary hyperlipidemia (Fredrickson type IIa, heterozygous familial and nonfamilial) or mixed dyslipidemia (Fredrickson type IIb). Reduce elevated TG in patients with hypertriglyceridemia (Fredrickson type lV hyperlipidemia). Reduce elevated TG and VLDL-C in patients with primary dysbetalipoproteinemia (Fredrickson type III hyperlipidemia). Reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable. 1.3 Adolescent Patients with Heterozygous Familial Hypercholesterolemia (HeFH) Simvastatin tablets, USP are indicated as an adjunct to diet to reduce total-C, LDL-C, and Apo B levels in adolescent boys and girls who are at least one year post-menarche, 10-17 years of age, with HeFH, if after an adequate trial of diet therapy the following findings are present: LDL cholesterol remains greater than or equal to 190 mg/dL; or LDL cholesterol remains greater than or equal to 160 mg/dL and There is a positive family history of premature cardiovascular disease (CVD) or Two or more other CVD risk factors are present in the adolescent patient. The minimum goal of treatment in pediatric and adolescent patients is to achieve a mean LDL-C less than 130 mg/dL. The optimal age at which to initiate lipid-lowering therapy to decrease the risk of symptomatic adulthood CAD has not been determined. 1.4 Limitations of Use Simvastatin tablets, USP have not been studied in conditions where the major abnormality is elevation of chylomicrons (i.e., hyperlipidemia Fredrickson types I and V). uuid:e5607d23-d137-4a6f-aa29-9e4d0d1f44cb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9150 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:49c1ab96-eaee-4244-9e65-5fa4ad7101cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:29a98a39-2508-41a7-99bc-6ff6ed345b9e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with coronary heart disease (CHD) or at high risk of CHD, simvastatin can be started simultaneously with diet. 1.1 Reductions in Risk of CHD Mortality and Cardiovascular Events In patients at high risk of coronary events because of existing coronary heart disease, diabetes, peripheral vessel disease, history of stroke or other cerebrovascular disease, simvastatin tablets, USP are indicated to: Reduce the risk of total mortality by reducing CHD deaths. Reduce the risk of non-fatal myocardial infarction and stroke. Reduce the need for coronary and non-coronary revascularization procedures. 1.2 Hyperlipidemia Simvastatin tablets, USP are indicated to: Reduce elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), and triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary hyperlipidemia (Fredrickson type IIa, heterozygous familial and nonfamilial) or mixed dyslipidemia (Fredrickson type IIb). Reduce elevated TG in patients with hypertriglyceridemia (Fredrickson type lV hyperlipidemia). Reduce elevated TG and VLDL-C in patients with primary dysbetalipoproteinemia (Fredrickson type III hyperlipidemia). Reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable. 1.3 Adolescent Patients with Heterozygous Familial Hypercholesterolemia (HeFH) Simvastatin tablets, USP are indicated as an adjunct to diet to reduce total-C, LDL-C, and Apo B levels in adolescent boys and girls who are at least one year post-menarche, 10-17 years of age, with HeFH, if after an adequate trial of diet therapy the following findings are present: LDL cholesterol remains greater than or equal to 190 mg/dL; or LDL cholesterol remains greater than or equal to 160 mg/dL and There is a positive family history of premature cardiovascular disease (CVD) or Two or more other CVD risk factors are present in the adolescent patient. The minimum goal of treatment in pediatric and adolescent patients is to achieve a mean LDL-C less than 130 mg/dL. The optimal age at which to initiate lipid-lowering therapy to decrease the risk of symptomatic adulthood CAD has not been determined. 1.4 Limitations of Use Simvastatin tablets, USP have not been studied in conditions where the major abnormality is elevation of chylomicrons (i.e., hyperlipidemia Fredrickson types I and V). uuid:3d8e05fe-a35f-4363-8214-cd071407a4e9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9150 biolink:treats MONDO:0005294 PMID:41385096 "[{""id"":""uuid:54e1883e-4181-4abb-8c72-d87fc7dd7858"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0234d833-4a5d-4931-aca6-3a135e421fdf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with coronary heart disease (CHD) or at high risk of CHD, simvastatin can be started simultaneously with diet. 1.1 Reductions in Risk of CHD Mortality and Cardiovascular Events In patients at high risk of coronary events because of existing coronary heart disease, diabetes, peripheral vessel disease, history of stroke or other cerebrovascular disease, simvastatin tablets, USP are indicated to: Reduce the risk of total mortality by reducing CHD deaths. Reduce the risk of non-fatal myocardial infarction and stroke. Reduce the need for coronary and non-coronary revascularization procedures. 1.2 Hyperlipidemia Simvastatin tablets, USP are indicated to: Reduce elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), and triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary hyperlipidemia (Fredrickson type IIa, heterozygous familial and nonfamilial) or mixed dyslipidemia (Fredrickson type IIb). Reduce elevated TG in patients with hypertriglyceridemia (Fredrickson type lV hyperlipidemia). Reduce elevated TG and VLDL-C in patients with primary dysbetalipoproteinemia (Fredrickson type III hyperlipidemia). Reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable. 1.3 Adolescent Patients with Heterozygous Familial Hypercholesterolemia (HeFH) Simvastatin tablets, USP are indicated as an adjunct to diet to reduce total-C, LDL-C, and Apo B levels in adolescent boys and girls who are at least one year post-menarche, 10-17 years of age, with HeFH, if after an adequate trial of diet therapy the following findings are present: LDL cholesterol remains greater than or equal to 190 mg/dL; or LDL cholesterol remains greater than or equal to 160 mg/dL and There is a positive family history of premature cardiovascular disease (CVD) or Two or more other CVD risk factors are present in the adolescent patient. The minimum goal of treatment in pediatric and adolescent patients is to achieve a mean LDL-C less than 130 mg/dL. The optimal age at which to initiate lipid-lowering therapy to decrease the risk of symptomatic adulthood CAD has not been determined. 1.4 Limitations of Use Simvastatin tablets, USP have not been studied in conditions where the major abnormality is elevation of chylomicrons (i.e., hyperlipidemia Fredrickson types I and V). uuid:728a2ee1-2a0b-4ab6-ab5b-3a018917599a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9150 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:bef16f9a-d690-4033-a219-96f96edbb798"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0eb7c470-4a71-46e0-b065-73d6cb7d1c92"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with coronary heart disease (CHD) or at high risk of CHD, simvastatin can be started simultaneously with diet. 1.1 Reductions in Risk of CHD Mortality and Cardiovascular Events In patients at high risk of coronary events because of existing coronary heart disease, diabetes, peripheral vessel disease, history of stroke or other cerebrovascular disease, simvastatin tablets, USP are indicated to: Reduce the risk of total mortality by reducing CHD deaths. Reduce the risk of non-fatal myocardial infarction and stroke. Reduce the need for coronary and non-coronary revascularization procedures. 1.2 Hyperlipidemia Simvastatin tablets, USP are indicated to: Reduce elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), and triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary hyperlipidemia (Fredrickson type IIa, heterozygous familial and nonfamilial) or mixed dyslipidemia (Fredrickson type IIb). Reduce elevated TG in patients with hypertriglyceridemia (Fredrickson type lV hyperlipidemia). Reduce elevated TG and VLDL-C in patients with primary dysbetalipoproteinemia (Fredrickson type III hyperlipidemia). Reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable. 1.3 Adolescent Patients with Heterozygous Familial Hypercholesterolemia (HeFH) Simvastatin tablets, USP are indicated as an adjunct to diet to reduce total-C, LDL-C, and Apo B levels in adolescent boys and girls who are at least one year post-menarche, 10-17 years of age, with HeFH, if after an adequate trial of diet therapy the following findings are present: LDL cholesterol remains greater than or equal to 190 mg/dL; or LDL cholesterol remains greater than or equal to 160 mg/dL and There is a positive family history of premature cardiovascular disease (CVD) or Two or more other CVD risk factors are present in the adolescent patient. The minimum goal of treatment in pediatric and adolescent patients is to achieve a mean LDL-C less than 130 mg/dL. The optimal age at which to initiate lipid-lowering therapy to decrease the risk of symptomatic adulthood CAD has not been determined. 1.4 Limitations of Use Simvastatin tablets, USP have not been studied in conditions where the major abnormality is elevation of chylomicrons (i.e., hyperlipidemia Fredrickson types I and V). uuid:5e40e43a-ac83-493e-9a8c-d3a8adce9512 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9150 biolink:treats MONDO:0011057 PMID:41385096 "[{""id"":""uuid:218a730d-65d1-4a92-8c6f-a4a6a1f02cf0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e8f2b950-a2ac-4768-add1-73efd5b80d9a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with coronary heart disease (CHD) or at high risk of CHD, simvastatin can be started simultaneously with diet. 1.1 Reductions in Risk of CHD Mortality and Cardiovascular Events In patients at high risk of coronary events because of existing coronary heart disease, diabetes, peripheral vessel disease, history of stroke or other cerebrovascular disease, simvastatin tablets, USP are indicated to: Reduce the risk of total mortality by reducing CHD deaths. Reduce the risk of non-fatal myocardial infarction and stroke. Reduce the need for coronary and non-coronary revascularization procedures. 1.2 Hyperlipidemia Simvastatin tablets, USP are indicated to: Reduce elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), and triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary hyperlipidemia (Fredrickson type IIa, heterozygous familial and nonfamilial) or mixed dyslipidemia (Fredrickson type IIb). Reduce elevated TG in patients with hypertriglyceridemia (Fredrickson type lV hyperlipidemia). Reduce elevated TG and VLDL-C in patients with primary dysbetalipoproteinemia (Fredrickson type III hyperlipidemia). Reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable. 1.3 Adolescent Patients with Heterozygous Familial Hypercholesterolemia (HeFH) Simvastatin tablets, USP are indicated as an adjunct to diet to reduce total-C, LDL-C, and Apo B levels in adolescent boys and girls who are at least one year post-menarche, 10-17 years of age, with HeFH, if after an adequate trial of diet therapy the following findings are present: LDL cholesterol remains greater than or equal to 190 mg/dL; or LDL cholesterol remains greater than or equal to 160 mg/dL and There is a positive family history of premature cardiovascular disease (CVD) or Two or more other CVD risk factors are present in the adolescent patient. The minimum goal of treatment in pediatric and adolescent patients is to achieve a mean LDL-C less than 130 mg/dL. The optimal age at which to initiate lipid-lowering therapy to decrease the risk of symptomatic adulthood CAD has not been determined. 1.4 Limitations of Use Simvastatin tablets, USP have not been studied in conditions where the major abnormality is elevation of chylomicrons (i.e., hyperlipidemia Fredrickson types I and V). uuid:d3ab6150-456c-4228-9d3a-a4af04254295 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9150 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:f4764445-2003-45f1-8b92-c63f614004b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:11c764f4-8af9-4f1a-b7d6-db75d98343d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with coronary heart disease (CHD) or at high risk of CHD, simvastatin can be started simultaneously with diet. 1.1 Reductions in Risk of CHD Mortality and Cardiovascular Events In patients at high risk of coronary events because of existing coronary heart disease, diabetes, peripheral vessel disease, history of stroke or other cerebrovascular disease, simvastatin tablets, USP are indicated to: Reduce the risk of total mortality by reducing CHD deaths. Reduce the risk of non-fatal myocardial infarction and stroke. Reduce the need for coronary and non-coronary revascularization procedures. 1.2 Hyperlipidemia Simvastatin tablets, USP are indicated to: Reduce elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), and triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary hyperlipidemia (Fredrickson type IIa, heterozygous familial and nonfamilial) or mixed dyslipidemia (Fredrickson type IIb). Reduce elevated TG in patients with hypertriglyceridemia (Fredrickson type lV hyperlipidemia). Reduce elevated TG and VLDL-C in patients with primary dysbetalipoproteinemia (Fredrickson type III hyperlipidemia). Reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable. 1.3 Adolescent Patients with Heterozygous Familial Hypercholesterolemia (HeFH) Simvastatin tablets, USP are indicated as an adjunct to diet to reduce total-C, LDL-C, and Apo B levels in adolescent boys and girls who are at least one year post-menarche, 10-17 years of age, with HeFH, if after an adequate trial of diet therapy the following findings are present: LDL cholesterol remains greater than or equal to 190 mg/dL; or LDL cholesterol remains greater than or equal to 160 mg/dL and There is a positive family history of premature cardiovascular disease (CVD) or Two or more other CVD risk factors are present in the adolescent patient. The minimum goal of treatment in pediatric and adolescent patients is to achieve a mean LDL-C less than 130 mg/dL. The optimal age at which to initiate lipid-lowering therapy to decrease the risk of symptomatic adulthood CAD has not been determined. 1.4 Limitations of Use Simvastatin tablets, USP have not been studied in conditions where the major abnormality is elevation of chylomicrons (i.e., hyperlipidemia Fredrickson types I and V). uuid:910fc34e-430b-456d-8d75-3b65eca32d5a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9150 biolink:treats HP:0003119 PMID:41385096 "[{""id"":""uuid:09909d83-a31b-451f-986a-e2f74e2a3031"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a70f717d-b56f-4bbe-80cb-fef488e7c685"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with coronary heart disease (CHD) or at high risk of CHD, simvastatin can be started simultaneously with diet. 1.1 Reductions in Risk of CHD Mortality and Cardiovascular Events In patients at high risk of coronary events because of existing coronary heart disease, diabetes, peripheral vessel disease, history of stroke or other cerebrovascular disease, simvastatin tablets, USP are indicated to: Reduce the risk of total mortality by reducing CHD deaths. Reduce the risk of non-fatal myocardial infarction and stroke. Reduce the need for coronary and non-coronary revascularization procedures. 1.2 Hyperlipidemia Simvastatin tablets, USP are indicated to: Reduce elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), and triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary hyperlipidemia (Fredrickson type IIa, heterozygous familial and nonfamilial) or mixed dyslipidemia (Fredrickson type IIb). Reduce elevated TG in patients with hypertriglyceridemia (Fredrickson type lV hyperlipidemia). Reduce elevated TG and VLDL-C in patients with primary dysbetalipoproteinemia (Fredrickson type III hyperlipidemia). Reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable. 1.3 Adolescent Patients with Heterozygous Familial Hypercholesterolemia (HeFH) Simvastatin tablets, USP are indicated as an adjunct to diet to reduce total-C, LDL-C, and Apo B levels in adolescent boys and girls who are at least one year post-menarche, 10-17 years of age, with HeFH, if after an adequate trial of diet therapy the following findings are present: LDL cholesterol remains greater than or equal to 190 mg/dL; or LDL cholesterol remains greater than or equal to 160 mg/dL and There is a positive family history of premature cardiovascular disease (CVD) or Two or more other CVD risk factors are present in the adolescent patient. The minimum goal of treatment in pediatric and adolescent patients is to achieve a mean LDL-C less than 130 mg/dL. The optimal age at which to initiate lipid-lowering therapy to decrease the risk of symptomatic adulthood CAD has not been determined. 1.4 Limitations of Use Simvastatin tablets, USP have not been studied in conditions where the major abnormality is elevation of chylomicrons (i.e., hyperlipidemia Fredrickson types I and V). uuid:17b71f33-d082-4c14-bfd1-f928e4a6ff59 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9150 biolink:treats MONDO:0005347 PMID:41385096 "[{""id"":""uuid:c1898bea-a60b-4b12-a25a-11ae7e079b84"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f9a1df13-c719-42aa-88f1-214c502f8964"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with coronary heart disease (CHD) or at high risk of CHD, simvastatin can be started simultaneously with diet. 1.1 Reductions in Risk of CHD Mortality and Cardiovascular Events In patients at high risk of coronary events because of existing coronary heart disease, diabetes, peripheral vessel disease, history of stroke or other cerebrovascular disease, simvastatin tablets, USP are indicated to: Reduce the risk of total mortality by reducing CHD deaths. Reduce the risk of non-fatal myocardial infarction and stroke. Reduce the need for coronary and non-coronary revascularization procedures. 1.2 Hyperlipidemia Simvastatin tablets, USP are indicated to: Reduce elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), and triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary hyperlipidemia (Fredrickson type IIa, heterozygous familial and nonfamilial) or mixed dyslipidemia (Fredrickson type IIb). Reduce elevated TG in patients with hypertriglyceridemia (Fredrickson type lV hyperlipidemia). Reduce elevated TG and VLDL-C in patients with primary dysbetalipoproteinemia (Fredrickson type III hyperlipidemia). Reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable. 1.3 Adolescent Patients with Heterozygous Familial Hypercholesterolemia (HeFH) Simvastatin tablets, USP are indicated as an adjunct to diet to reduce total-C, LDL-C, and Apo B levels in adolescent boys and girls who are at least one year post-menarche, 10-17 years of age, with HeFH, if after an adequate trial of diet therapy the following findings are present: LDL cholesterol remains greater than or equal to 190 mg/dL; or LDL cholesterol remains greater than or equal to 160 mg/dL and There is a positive family history of premature cardiovascular disease (CVD) or Two or more other CVD risk factors are present in the adolescent patient. The minimum goal of treatment in pediatric and adolescent patients is to achieve a mean LDL-C less than 130 mg/dL. The optimal age at which to initiate lipid-lowering therapy to decrease the risk of symptomatic adulthood CAD has not been determined. 1.4 Limitations of Use Simvastatin tablets, USP have not been studied in conditions where the major abnormality is elevation of chylomicrons (i.e., hyperlipidemia Fredrickson types I and V). uuid:0518356c-7f1b-4845-8a30-e2ec1fe10b8a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9150 biolink:treats MONDO:0018473 PMID:41385096 "[{""id"":""uuid:10c80ac3-e5b6-4b65-a432-d43512e1c5d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:32204f87-3d2a-49de-ad65-a26a98909496"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with coronary heart disease (CHD) or at high risk of CHD, simvastatin can be started simultaneously with diet. 1.1 Reductions in Risk of CHD Mortality and Cardiovascular Events In patients at high risk of coronary events because of existing coronary heart disease, diabetes, peripheral vessel disease, history of stroke or other cerebrovascular disease, simvastatin tablets, USP are indicated to: Reduce the risk of total mortality by reducing CHD deaths. Reduce the risk of non-fatal myocardial infarction and stroke. Reduce the need for coronary and non-coronary revascularization procedures. 1.2 Hyperlipidemia Simvastatin tablets, USP are indicated to: Reduce elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), and triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary hyperlipidemia (Fredrickson type IIa, heterozygous familial and nonfamilial) or mixed dyslipidemia (Fredrickson type IIb). Reduce elevated TG in patients with hypertriglyceridemia (Fredrickson type lV hyperlipidemia). Reduce elevated TG and VLDL-C in patients with primary dysbetalipoproteinemia (Fredrickson type III hyperlipidemia). Reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable. 1.3 Adolescent Patients with Heterozygous Familial Hypercholesterolemia (HeFH) Simvastatin tablets, USP are indicated as an adjunct to diet to reduce total-C, LDL-C, and Apo B levels in adolescent boys and girls who are at least one year post-menarche, 10-17 years of age, with HeFH, if after an adequate trial of diet therapy the following findings are present: LDL cholesterol remains greater than or equal to 190 mg/dL; or LDL cholesterol remains greater than or equal to 160 mg/dL and There is a positive family history of premature cardiovascular disease (CVD) or Two or more other CVD risk factors are present in the adolescent patient. The minimum goal of treatment in pediatric and adolescent patients is to achieve a mean LDL-C less than 130 mg/dL. The optimal age at which to initiate lipid-lowering therapy to decrease the risk of symptomatic adulthood CAD has not been determined. 1.4 Limitations of Use Simvastatin tablets, USP have not been studied in conditions where the major abnormality is elevation of chylomicrons (i.e., hyperlipidemia Fredrickson types I and V). uuid:91ee0134-ab2b-4345-93b7-7d62b22d19f8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9150 biolink:treats MONDO:0018328 PMID:41385096 "[{""id"":""uuid:e7ef0671-2913-4715-ae0c-8f4e43914a46"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:73682d76-761f-4fe3-b5bc-e4c1c3d81a91"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with coronary heart disease (CHD) or at high risk of CHD, simvastatin can be started simultaneously with diet. 1.1 Reductions in Risk of CHD Mortality and Cardiovascular Events In patients at high risk of coronary events because of existing coronary heart disease, diabetes, peripheral vessel disease, history of stroke or other cerebrovascular disease, simvastatin tablets, USP are indicated to: Reduce the risk of total mortality by reducing CHD deaths. Reduce the risk of non-fatal myocardial infarction and stroke. Reduce the need for coronary and non-coronary revascularization procedures. 1.2 Hyperlipidemia Simvastatin tablets, USP are indicated to: Reduce elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), and triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary hyperlipidemia (Fredrickson type IIa, heterozygous familial and nonfamilial) or mixed dyslipidemia (Fredrickson type IIb). Reduce elevated TG in patients with hypertriglyceridemia (Fredrickson type lV hyperlipidemia). Reduce elevated TG and VLDL-C in patients with primary dysbetalipoproteinemia (Fredrickson type III hyperlipidemia). Reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable. 1.3 Adolescent Patients with Heterozygous Familial Hypercholesterolemia (HeFH) Simvastatin tablets, USP are indicated as an adjunct to diet to reduce total-C, LDL-C, and Apo B levels in adolescent boys and girls who are at least one year post-menarche, 10-17 years of age, with HeFH, if after an adequate trial of diet therapy the following findings are present: LDL cholesterol remains greater than or equal to 190 mg/dL; or LDL cholesterol remains greater than or equal to 160 mg/dL and There is a positive family history of premature cardiovascular disease (CVD) or Two or more other CVD risk factors are present in the adolescent patient. The minimum goal of treatment in pediatric and adolescent patients is to achieve a mean LDL-C less than 130 mg/dL. The optimal age at which to initiate lipid-lowering therapy to decrease the risk of symptomatic adulthood CAD has not been determined. 1.4 Limitations of Use Simvastatin tablets, USP have not been studied in conditions where the major abnormality is elevation of chylomicrons (i.e., hyperlipidemia Fredrickson types I and V). uuid:a4726155-23c6-4048-ab59-0b6fa8038075 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9150 biolink:treats UMLS:C0342882 PMID:41385096 "[{""id"":""uuid:4888b695-d104-46ae-b470-eb57a50f4458"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bcb47d48-da9e-4ce7-b3fc-adc84b564dcf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with coronary heart disease (CHD) or at high risk of CHD, simvastatin can be started simultaneously with diet. 1.1 Reductions in Risk of CHD Mortality and Cardiovascular Events In patients at high risk of coronary events because of existing coronary heart disease, diabetes, peripheral vessel disease, history of stroke or other cerebrovascular disease, simvastatin tablets, USP are indicated to: Reduce the risk of total mortality by reducing CHD deaths. Reduce the risk of non-fatal myocardial infarction and stroke. Reduce the need for coronary and non-coronary revascularization procedures. 1.2 Hyperlipidemia Simvastatin tablets, USP are indicated to: Reduce elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), and triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary hyperlipidemia (Fredrickson type IIa, heterozygous familial and nonfamilial) or mixed dyslipidemia (Fredrickson type IIb). Reduce elevated TG in patients with hypertriglyceridemia (Fredrickson type lV hyperlipidemia). Reduce elevated TG and VLDL-C in patients with primary dysbetalipoproteinemia (Fredrickson type III hyperlipidemia). Reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable. 1.3 Adolescent Patients with Heterozygous Familial Hypercholesterolemia (HeFH) Simvastatin tablets, USP are indicated as an adjunct to diet to reduce total-C, LDL-C, and Apo B levels in adolescent boys and girls who are at least one year post-menarche, 10-17 years of age, with HeFH, if after an adequate trial of diet therapy the following findings are present: LDL cholesterol remains greater than or equal to 190 mg/dL; or LDL cholesterol remains greater than or equal to 160 mg/dL and There is a positive family history of premature cardiovascular disease (CVD) or Two or more other CVD risk factors are present in the adolescent patient. The minimum goal of treatment in pediatric and adolescent patients is to achieve a mean LDL-C less than 130 mg/dL. The optimal age at which to initiate lipid-lowering therapy to decrease the risk of symptomatic adulthood CAD has not been determined. 1.4 Limitations of Use Simvastatin tablets, USP have not been studied in conditions where the major abnormality is elevation of chylomicrons (i.e., hyperlipidemia Fredrickson types I and V). uuid:73beb140-2983-4572-ab04-d90cd9a3e2b7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats UMLS:C0149896 PMID:41385096 "[{""id"":""uuid:21b0a7e6-89ff-4536-a04d-8b41638ca505"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:422e75d9-b92e-4443-9a27-cf57822ee940"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The intra-articular or soft tissue administration of Kenalog-10 Injection (triamcinolone acetonide injectable suspension, USP) is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis, or osteoarthritis. uuid:a7bb6d1c-1794-4ba9-afc9-abfbadf2454f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0040698 PMID:41385096 "[{""id"":""uuid:194b47ac-bba9-4898-8c2a-075813b463d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bb0aa5f8-0cef-4d95-bb62-d489cd97962d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The intra-articular or soft tissue administration of Kenalog-10 Injection (triamcinolone acetonide injectable suspension, USP) is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis, or osteoarthritis. uuid:1665fa49-dd59-411e-b6d6-177907dab429 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0004855 PMID:41385096 "[{""id"":""uuid:b74e37b9-c4f5-41a7-b058-73c32987db78"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a20bff4c-429d-4c5b-9f94-5e57c1809135"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The intra-articular or soft tissue administration of Kenalog-10 Injection (triamcinolone acetonide injectable suspension, USP) is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis, or osteoarthritis. uuid:8d5e6a42-e304-47ac-a7de-f5a9feea2737 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0001875 PMID:41385096 "[{""id"":""uuid:c8f5cd56-e304-44b5-a919-c4dc863e8cc5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:16c6184f-9580-42a3-8c56-0f6d7c805f1e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The intra-articular or soft tissue administration of Kenalog-10 Injection (triamcinolone acetonide injectable suspension, USP) is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis, or osteoarthritis. uuid:d818576f-3862-4f30-bea6-473a49da41bb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:794ef661-28e9-49fa-a194-f35c56ad7e3a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2330ba6d-23c1-4a8e-8456-dfd4ba0fc4cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The intra-articular or soft tissue administration of Kenalog-10 Injection (triamcinolone acetonide injectable suspension, USP) is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis, or osteoarthritis. uuid:a16f9a47-8762-42be-b034-1cb62ecf58e1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0002400 PMID:41385096 "[{""id"":""uuid:ec892bda-be0a-41f8-a688-7a3a856de551"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c020429a-b38f-42b6-a8c7-3a01aab60e39"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The intra-articular or soft tissue administration of Kenalog-10 Injection (triamcinolone acetonide injectable suspension, USP) is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis, or osteoarthritis. uuid:fde9ae79-0707-4782-a4f5-d76a6673e6e3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0005178 PMID:41385096 "[{""id"":""uuid:7def1492-dd13-4e05-9611-8f9b171e6d6f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:77162347-6538-41ac-abe3-26cd080f5d4f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The intra-articular or soft tissue administration of Kenalog-10 Injection (triamcinolone acetonide injectable suspension, USP) is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis, or osteoarthritis. uuid:d27428d4-36ae-4cc2-a164-0c69f2e02a05 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:151875 biolink:treats HP:0012735 PMID:41385096 "[{""id"":""uuid:15b89a3d-2ecb-4472-8c9d-569ecc215d5e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cf19a427-2221-41ec-86ec-4f81c3753eea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydrocodone bitartrate and homatropine methylbromide syrup is indicated for the symptomatic relief of cough. uuid:f1175b42-22d6-4812-96af-e2adeca248f1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8207 biolink:treats MONDO:0005041 PMID:41385096 "[{""id"":""uuid:c9450f2d-0a17-4c9a-ba31-7bec5375a824"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:77b044ed-ca2d-400a-a68e-3a05e124f611"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pilocarpine hydrochloride can be used in the medical management of glaucoma, especially open-angle glaucoma, in those cases in which the intraocular pressure can be controlled adequately by the topical administration of pilocarpine. In acute (closed-angle) glaucoma, pilocarpine hydrochloride may be used alone, or in combination with other cholinergic agents or carbonic anhydrase inhibitors, to relieve tension prior to emergency surgery. Patients may be maintained on pilocarpine hydrochloride as long as intraocular pressure is controlled and there is no deterioration in the visual fields. The choice of concentration should be determined by the severity of the condition and the response of the patient. Pilocarpine hydrochloride is also indicated to counter the effects of cycloplegics and mydriatics following surgery or ophthalmoscopic examination. uuid:b0e9235e-ecab-40e5-ba9e-bbd5a0f568bf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8207 biolink:treats MONDO:0005338 PMID:41385096 "[{""id"":""uuid:2e811078-5f5b-490f-b0cb-165515b72b1f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:29abd8ef-2202-4d02-b4a0-4c4c3cefe4e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pilocarpine hydrochloride can be used in the medical management of glaucoma, especially open-angle glaucoma, in those cases in which the intraocular pressure can be controlled adequately by the topical administration of pilocarpine. In acute (closed-angle) glaucoma, pilocarpine hydrochloride may be used alone, or in combination with other cholinergic agents or carbonic anhydrase inhibitors, to relieve tension prior to emergency surgery. Patients may be maintained on pilocarpine hydrochloride as long as intraocular pressure is controlled and there is no deterioration in the visual fields. The choice of concentration should be determined by the severity of the condition and the response of the patient. Pilocarpine hydrochloride is also indicated to counter the effects of cycloplegics and mydriatics following surgery or ophthalmoscopic examination. uuid:0584cda0-2a12-45d2-82d9-9d6b02d7169f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8207 biolink:treats MONDO:0001817 PMID:41385096 "[{""id"":""uuid:181a35db-5e32-4293-b967-96debb165839"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:926a3218-5190-49bc-8fb9-316b72d3a575"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pilocarpine hydrochloride can be used in the medical management of glaucoma, especially open-angle glaucoma, in those cases in which the intraocular pressure can be controlled adequately by the topical administration of pilocarpine. In acute (closed-angle) glaucoma, pilocarpine hydrochloride may be used alone, or in combination with other cholinergic agents or carbonic anhydrase inhibitors, to relieve tension prior to emergency surgery. Patients may be maintained on pilocarpine hydrochloride as long as intraocular pressure is controlled and there is no deterioration in the visual fields. The choice of concentration should be determined by the severity of the condition and the response of the patient. Pilocarpine hydrochloride is also indicated to counter the effects of cycloplegics and mydriatics following surgery or ophthalmoscopic examination. uuid:0c37584d-c9f7-4e9e-909d-83bdc59e4c55 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:87715 biolink:treats MONDO:0006805 PMID:41385096 "[{""id"":""uuid:99671a82-8204-4ecd-81ee-31127e2e153e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:dcd1cea6-1899-4557-b329-2de2d9a024b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:b0f6b160-2ac3-4349-8538-993eaabf66e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/efient""]},{""id"":""uuid:f9709e4e-77e8-4895-baae-4cbff845f7ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Effient is a P2Y 12 platelet inhibitor indicated for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndrome who are to be managed with PCI as follows: Patients with unstable angina or, non-ST-elevation myocardial infarction (NSTEMI) ( 1.1 ). Patients with ST-elevation myocardial infarction (STEMI) when managed with either primary or delayed PCI ( 1.1 ).|[EMA] Efient, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in patients with acute coronary syndrome (i.e. unstable angina, non-ST-segment-elevation myocardial infarction [UA / NSTEMI] or ST-segment-elevation myocardial infarction [STEMI]) undergoing primary or delayed percutaneous coronary intervention (PCI).|[PMDA] Drugs with a new active ingredient indicated for the treatment of the following ischemic heart diseases managed with percutaneous coronary intervention (PCI): acute coronary syndrome (unstable angina, non ST-segment elevation myocardial infarction, ST- segment elevation myocardial infarction), stable angina, old myocardial infarction. uuid:2df5790b-9be2-4091-acb6-0b23ada9f2ac biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:87715 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:7956b389-0ab0-4e1c-9288-47a4f200396a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9eb8927f-f72f-48cb-a4a2-9bd01f675b11"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:dbe5e332-0cd4-4c4b-9288-c5abc72f40df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Effient is a P2Y 12 platelet inhibitor indicated for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndrome who are to be managed with PCI as follows: Patients with unstable angina or, non-ST-elevation myocardial infarction (NSTEMI) ( 1.1 ). Patients with ST-elevation myocardial infarction (STEMI) when managed with either primary or delayed PCI ( 1.1 ).|[PMDA] Drugs with a new active ingredient indicated for the treatment of the following ischemic heart diseases managed with percutaneous coronary intervention (PCI): acute coronary syndrome (unstable angina, non ST-segment elevation myocardial infarction, ST- segment elevation myocardial infarction), stable angina, old myocardial infarction. uuid:5536ec70-bd09-4596-8997-8d72d7a6ed07 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:87715 biolink:treats UMLS:C3897493 PMID:41385096 "[{""id"":""uuid:c3cb2089-9cfb-4c43-bd71-8b5dc17ad999"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:110154b6-e207-4dff-a06c-f08e0a404f79"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Effient is a P2Y 12 platelet inhibitor indicated for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndrome who are to be managed with PCI as follows: Patients with unstable angina or, non-ST-elevation myocardial infarction (NSTEMI) ( 1.1 ). Patients with ST-elevation myocardial infarction (STEMI) when managed with either primary or delayed PCI ( 1.1 ). uuid:630a8f59-3955-47e2-b21b-403f67ca1f83 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:40a0b1a7-a24d-4a68-b31b-e534132a55c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:82fc40f2-6d03-4ab8-907d-a232d2bdea84"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:a6e40012-77ac-48c1-86c5-8227cfe6721a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:9b39a117-0c15-4061-b0e9-8cdcb476019f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1e7d18fe-79f8-402f-8a84-3fcbcaa45c0b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:df023679-93b8-4e86-bdfb-9ebd7e410b54 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0005480 PMID:41385096 "[{""id"":""uuid:84fcf2f1-9d3a-45da-843d-4d64e2bebdf5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c8b1fccb-4a00-4193-8feb-f5d962f54d6a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:5c5c7d2f-7b0d-49c5-ab40-27cf0bfa1a27 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0000775 PMID:41385096 "[{""id"":""uuid:c8f4fd20-89e6-4428-b294-084bb5bd899d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:516a608b-70aa-4dc1-bb39-efe54286d428"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:8d6a0ecf-bc03-4aa7-b7e4-128504e8c9ad biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0043789 PMID:41385096 "[{""id"":""uuid:977e9255-59dc-4c37-8db9-268e02129db0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:97cd4e8d-17ce-43fb-b3ac-4439710c97ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:dad5ba17-ef4a-41d2-b28b-98317918bc4f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats UMLS:C0274435 PMID:41385096 "[{""id"":""uuid:026bbea5-7ba8-48c0-b69b-848ed09962c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ef25f420-da2c-4abc-afd5-4b72fceb73e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:bc59cbd3-1a50-4c61-ade2-be91a21b4eec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0015614 PMID:41385096 "[{""id"":""uuid:0ed7052c-ed2e-4bdf-8dd4-87ed9e3062ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:56c2229d-379d-46f4-8c15-2876071839b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:7dc318e4-d3af-4103-b056-bcba8182be09 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0043233 PMID:41385096 "[{""id"":""uuid:e0898f3f-c564-405b-8142-f17671cd7c7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f9370c56-c2dd-4ab8-a569-48360606310b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:d1f00994-bf0f-4189-92f2-363e5d83e747 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0009691 PMID:41385096 "[{""id"":""uuid:876660f5-fda9-4b63-b9ce-88e77dabf9e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0174bcd2-3349-450d-974c-77fde5d74b76"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:4eb2eb4b-8123-4a98-b5af-00ea24999b32 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0006594 PMID:41385096 "[{""id"":""uuid:49026b27-a920-43e1-9935-de0215f0b2c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:59d7f423-9f7c-4266-aa8c-49d20d99a2a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:3322babb-ef87-4f8e-9864-88eef34028a8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0018229 PMID:41385096 "[{""id"":""uuid:cdafd4f4-c70a-44bb-9f43-01f948c4fb0b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:354631b3-1223-4d07-803e-56a84586a9b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:c5faccd9-698d-4bd6-8aec-52a3e7a164ed biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0015129 PMID:41385096 "[{""id"":""uuid:dd3e371d-bd57-4e2f-9b1d-4a8403f7592e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3969b9f5-a28d-432d-bb26-db6fa24a7c66"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:0a69299c-4837-4de2-82bc-28b6181487e5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0043370 PMID:41385096 "[{""id"":""uuid:b848c831-4855-4558-8d56-8ce4cd1337d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:04ea0b74-cf2e-43ae-96e2-139bb40edc4a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:afd4c3d6-a5b5-4f01-ab91-d10db2b7104c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0018479 PMID:41385096 "[{""id"":""uuid:23178209-ebde-45ac-9010-f7666083cb1a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4026ae6e-976d-4c36-8437-c628ea441f6e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:54800f82-6f8b-47b4-b7f5-526024bf67e7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0043455 PMID:41385096 "[{""id"":""uuid:0fe3fb2b-f2dc-411c-9b0c-23f95b6fe08f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6f06ce37-02f3-462f-9991-ac2e546c0f55"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:579a7a4d-133a-4707-a64a-cab35abc3529 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0006982 PMID:41385096 "[{""id"":""uuid:0575eaf4-370b-4557-81cd-7a32ca0411a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:39d54481-1e3d-4b59-884c-febd431ebc71"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:5b44fc3b-b836-4922-8d84-23c1b3527993 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats UMLS:C0678202 PMID:41385096 "[{""id"":""uuid:dcff129e-fa6e-4fcb-81ab-197f829a7cb9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bdebbbc2-c405-4daa-8554-4e243617f4fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:00306be0-0147-4759-8ba3-31ed12ac06a9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0005101 PMID:41385096 "[{""id"":""uuid:3426bfd3-6ca7-4ba7-8071-7406f3365a1a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b670e9fa-7883-4de9-8cfb-1c7c078a9b8a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:f83289f9-267d-4a22-a413-06cca58988c3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0020108 PMID:41385096 "[{""id"":""uuid:ca2ea439-07d8-4c78-b8d4-1254d3a36e98"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:350cd8ff-dc66-4af2-9582-bfabf4ece5f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:d686b358-d5c6-454a-b0c7-79c1fbafc13f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0015253 PMID:41385096 "[{""id"":""uuid:c24a44aa-de97-4096-9090-0e6dfbeb36cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b6a58a26-134d-40e5-92b5-7bad1e74720e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:5bf784b8-24d9-49f8-b617-41fe79376fad biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0001705 PMID:41385096 "[{""id"":""uuid:2d491ddf-8e26-4e4b-ba6f-7823748125d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e6ec8b03-7434-4800-ac26-beb3f204be96"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:fb40e8b1-becd-4120-8aec-4b06812a28c0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0001198 PMID:41385096 "[{""id"":""uuid:752130b0-90ff-453b-8b3a-fb3549630ff8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:228d2b30-c976-4c83-8a7d-6e3e50bc8809"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:77072301-47e0-4b09-8415-67781a7e2c82 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0019444 PMID:41385096 "[{""id"":""uuid:92ad829b-e2c2-46b9-9a14-e90f970c1037"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c64ddc9d-1b0d-41bb-9abf-b28cbddda216"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:5a4dc080-5717-4be6-bcdb-715070dcc4f8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0006042 PMID:41385096 "[{""id"":""uuid:32c76db6-0c01-4132-b34f-dc254b383028"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0e9e7fd4-dff2-41ad-a7bb-4070f64457de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:911dda69-f1e2-4e2e-8289-87b35bda881c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0005059 PMID:41385096 "[{""id"":""uuid:0c9dde78-54c1-44b5-8bc0-d157e4c1cb32"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:060a1388-01a7-445d-ac44-e7498eb6a347"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:38470326-1bd3-49d5-8af4-191f297503ad biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0004095 PMID:41385096 "[{""id"":""uuid:b50ffae8-ca66-45f2-aad7-428fc368b407"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dfdf4676-6a1d-41dd-a8d4-1d2761f7de0c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:ea773474-010e-473a-b9e4-050a1dd12aaf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0005301 PMID:41385096 "[{""id"":""uuid:d62f868e-c5c4-410c-8bf4-9d0545f692ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:211835fe-34c5-4cca-a426-7ea1c585a5f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:11727b0b-7cc1-4f88-b039-4e401182658b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0006684 PMID:41385096 "[{""id"":""uuid:6ffec1e9-3827-44d4-a476-32be75130f2e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:704f403c-fad1-4b5a-a61e-52e0a1130b2c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:618d44a5-2ded-4302-804d-ef3985ffa93e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0021211 PMID:41385096 "[{""id"":""uuid:470ab540-a419-475d-a4b7-1c46cce3c422"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:be0bc55c-866c-4185-a15f-395d10433751"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:7bdc71b8-0bee-4279-9078-f1900efc80e0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0019198 PMID:41385096 "[{""id"":""uuid:f8ccc042-aa05-4096-ad99-50aeba726666"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0b71072f-cb17-47eb-a1cb-e030c1f24f6a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:2550e926-f40b-444c-825f-0e1c34801394 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0008538 PMID:41385096 "[{""id"":""uuid:f608b555-773b-4dbe-a712-15cf303058bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:38600eea-9842-4ab3-8ef6-73d8d536e278"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:4137e1a9-cf13-41af-8667-254c458a5b29 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0020283 PMID:41385096 "[{""id"":""uuid:e41730fd-a853-4ad1-968f-ed1cef367771"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2d3299d3-ba7b-4f99-bc55-55145795f369"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:871da257-0809-4109-878e-7041825d0cda biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0008109 PMID:41385096 "[{""id"":""uuid:23672af3-aa58-400f-bb2a-f668e7e6021b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:495808be-fd6d-45eb-8d48-58a06b99b08d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:f914144d-496e-459d-a1da-7edb008a32c7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0018170 PMID:41385096 "[{""id"":""uuid:9b72bb56-b266-49fd-85db-9b44751ea280"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:264f3a46-0bfe-48c3-a0db-fb0ca8fd929f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:069ef272-5015-4c2a-b800-bc3b94e013f7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0004670 PMID:41385096 "[{""id"":""uuid:0c72959c-b6bf-4d0d-95e7-4ea2f82c4ade"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6d7466a4-a46f-4879-b7fb-4f1ad392c44d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:5bd08e09-2c36-426e-9023-a735e08d6eb6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0015274 PMID:41385096 "[{""id"":""uuid:5f1aa0ef-19dd-4ca5-8d69-c67fc7ef2a52"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a82c97db-4c6b-4a81-9e61-5121af70e571"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:55c78560-1693-4923-ab3f-0dac29ea68ac biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0006052 PMID:41385096 "[{""id"":""uuid:bf7834db-5476-4500-986e-9f75c4e33d2f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0d03a2f0-05ee-4384-ad95-4d97e26381f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:b62b6e4a-b355-40e3-b84b-8badb9aeb034 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0005848 PMID:41385096 "[{""id"":""uuid:3236803d-fc38-4418-b807-cd4b3372d575"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:992f0388-ca6b-491d-9acf-266b00fecb8e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:1ba29c2f-cd5b-4f17-900a-8fb0ec99e190 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0015927 PMID:41385096 "[{""id"":""uuid:c10b1703-0318-4f0f-8429-a040272c631f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8599c065-9b05-4df5-92b2-bbd7b8168d0b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:6fa5b8d0-99a0-478f-a588-d2c447b42ba7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0019338 PMID:41385096 "[{""id"":""uuid:09f2b0d9-8b3d-4136-8a25-af233fc56944"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f9f9fb77-2ec6-420b-8789-cbdce647398c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:d0f99bc5-5667-4625-a531-4539c2cb4d68 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats UMLS:C5441648 PMID:41385096 "[{""id"":""uuid:bba44816-96e5-4d32-9a63-347487fc6a23"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eae777e5-f02d-4408-bd29-df1b2821fad9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:ddf3c884-15ed-4ebd-a776-f0d81b5904b9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0005306 PMID:41385096 "[{""id"":""uuid:5bfdd20e-02e4-464a-80f9-38b660385431"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ceee7fa2-0e25-400c-9e4f-6819807b234a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:ec46c890-d0b1-42df-b7ca-b0f9f097341a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0011849 PMID:41385096 "[{""id"":""uuid:9d8ed58b-f730-4b64-b084-311f2edbde04"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4eb3ffd6-debd-4896-a3a3-209102212f92"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:6e318668-f28c-4ac6-a01d-f70707219e0f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0011429 PMID:41385096 "[{""id"":""uuid:ce9a00df-f097-4d90-ae7a-400312a3d09c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6869dab0-b34c-4516-99ac-f1ca310ba1aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:aedccfcd-7892-4417-8854-11271be78581 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0016367 PMID:41385096 "[{""id"":""uuid:d5ac7433-1697-4fef-8576-c4e9fe1b93d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:93e19f61-8263-47cb-86bd-405443e169e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:0ef5579b-0bfb-456d-a4e4-2984b2cdad81 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0019127 PMID:41385096 "[{""id"":""uuid:47fbdf48-fd16-4d88-9cf7-12ef742726e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1d472dd2-e0dc-4bc2-9566-eafafdf4e4ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:c747b5d3-bb9b-453c-9e9b-c309b03acb45 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59164 biolink:treats MONDO:0005101 PMID:41385096 "[{""id"":""uuid:debeced5-e00a-47bd-9783-9abbfdb4c59c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:58e304f6-81a3-436f-8fb5-ac4b8a848249"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Balsalazide Disodium Capsules are indicated for the treatment of mildly to moderately active ulcerative colitis in adults. Safety and effectiveness of Balsalazide Disodium Capsules beyond 12 weeks in adults have not been established. uuid:520b463e-959e-4fce-941f-7b92787a78bb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4450 biolink:treats MONDO:0016383 PMID:41385096 "[{""id"":""uuid:95d46d35-4410-4351-827a-2b5808001f60"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:920fc2ef-b3a3-4b1a-99a6-1d4c10cd203b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Desmopressin acetate nasal solution is indicated as antidiuretic replacement therapy in the management of central cranial diabetes insipidus and for management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. It is ineffective for the treatment of nephrogenic diabetes insipidus. The use of desmopressin acetate nasal solution in patients with an established diagnosis will result in a reduction in urinary output with increase in urine osmolality and a decrease in plasma osmolality. This will allow the resumption of a more normal life-style with a decrease in urinary frequency and nocturia. There are reports of an occasional change in response with time, usually greater than 6 months. Some patients may show a decreased responsiveness, others a shortened duration of effect. There is no evidence this effect is due to the development of binding antibodies but may be due to a local inactivation of the peptide. Patients are selected for therapy by establishing the diagnosis by means of the water deprivation test, the hypertonic saline infusion test, and/or the response to antidiuretic hormone. Continued response to intranasal desmopressin acetate can be monitored by urine volume and osmolality. Desmopressin acetate nasal solution is also available as a solution for injection when the intranasal route may be compromised. These situations include nasal congestion and blockage, nasal discharge, atrophy of nasal mucosa, and severe atrophic rhinitis. Intranasal delivery may also be inappropriate where there is an impaired level of consciousness. In addition, cranial surgical procedures, such as transsphenoidal hypophysectomy create situations where an alternative route of administration is needed as in cases of nasal packing or recovery from surgery. uuid:ebe2608a-4e56-44b0-8218-dffbf9b9f3b8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4450 biolink:treats MONDO:0005659 PMID:41385096 "[{""id"":""uuid:a34143a8-a6c7-4a9f-bf86-fb6285b193d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1fb924a5-26c1-4190-813b-51f3ccb36667"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Desmopressin acetate nasal solution is indicated as antidiuretic replacement therapy in the management of central cranial diabetes insipidus and for management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. It is ineffective for the treatment of nephrogenic diabetes insipidus. The use of desmopressin acetate nasal solution in patients with an established diagnosis will result in a reduction in urinary output with increase in urine osmolality and a decrease in plasma osmolality. This will allow the resumption of a more normal life-style with a decrease in urinary frequency and nocturia. There are reports of an occasional change in response with time, usually greater than 6 months. Some patients may show a decreased responsiveness, others a shortened duration of effect. There is no evidence this effect is due to the development of binding antibodies but may be due to a local inactivation of the peptide. Patients are selected for therapy by establishing the diagnosis by means of the water deprivation test, the hypertonic saline infusion test, and/or the response to antidiuretic hormone. Continued response to intranasal desmopressin acetate can be monitored by urine volume and osmolality. Desmopressin acetate nasal solution is also available as a solution for injection when the intranasal route may be compromised. These situations include nasal congestion and blockage, nasal discharge, atrophy of nasal mucosa, and severe atrophic rhinitis. Intranasal delivery may also be inappropriate where there is an impaired level of consciousness. In addition, cranial surgical procedures, such as transsphenoidal hypophysectomy create situations where an alternative route of administration is needed as in cases of nasal packing or recovery from surgery. uuid:a67cc0e0-33bb-4293-a201-a1c4d9d1c3f9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:691037 biolink:treats MONDO:0005093 PMID:41385096 "[{""id"":""uuid:ca5b05cc-cb41-4044-ac8f-6708f4cdb7bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:df55dd22-6639-4a95-a602-1910f2d043b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Desoximetasone ointment USP, 0.25% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. uuid:3c494ea5-388d-45a3-9fbb-ba5a7c180881 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats HP:0025245 PMID:41385096 "[{""id"":""uuid:dd8b42e3-2d9f-45e1-b22c-6c26e7589526"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8b4ce7c6-ee84-4125-b497-6b99c188bda8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Primary skin infections: Impetigo contagiosa, superficial folliculitis, ecthyma, furunculosis, sycosis barbae, and pyoderma gangrenosum. Secondary skin infections: Infectious eczematoid dermatitis, pustular acne, pustular psoriasis, infected seborrheic dermatitis, infected contact dermatitis (including poison ivy), infected excoriations, and bacterial super-infections of fungal or viral infections. Please Note: Gentamicin sulfate is a bactericidal agent that is not effective against viruses or fungi in skin infections. Gentamicin sulfate is useful in the treatment of infected skin cysts and certain other skin abscesses when preceded by incision and drainage to permit adequate contact between the antibiotic and the infecting bacteria. Good results have been obtained in the treatment of infected stasis and other skin ulcers , infected superficial burns, paronychia, infected insect bites and stings, infected lacerations and abrasions, and wounds from minor surgery. Patients sensitive to neomycin can be treated with gentamicin sulfate, although regular observation of patients sensitive to topical antibiotics is advisable when such patients are treated with any topical antibiotic. Gentamicin sulfate cream is recommended for wet, oozing primary infections, and greasy, secondary infections, such as pustular acne or infected seborrheic dermatitis. If a water-washable preparation is desired, the cream is preferable. Gentamicin sulfate cream has been used successfully in infants over one year of age, as well as in adults and children. uuid:d2c90633-6e34-42c2-b999-cc90749c5bb4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5537 biolink:treats HP:0002017 PMID:41385096 "[{""id"":""uuid:14721568-cceb-4999-838a-651e4acf91b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6f22d6c7-08f2-4ff9-9880-a238e8750932"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Granisetron HCl is indicated for the prevention of : Nausea and vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin. Nausea and vomiting associated with radiation, including total body irradiation and fractionated abdominal radiation. uuid:48846bf1-34c8-451c-921d-bf968d68d18a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5537 biolink:treats EFO:0006911 PMID:41385096 "[{""id"":""uuid:7bc78100-cc85-4428-8603-5a2c10526ae0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e0922194-48ca-4baf-ae4e-3843484339a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Granisetron HCl is indicated for the prevention of : Nausea and vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin. Nausea and vomiting associated with radiation, including total body irradiation and fractionated abdominal radiation. uuid:b83055b0-d7ce-45e6-8f1d-ca05d1de69ef biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5537 biolink:treats EFO:0006912 PMID:41385096 "[{""id"":""uuid:786e01ad-d99f-48d6-8991-ab53bf4299a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:04adac8b-2135-4289-9c58-61a713638fbb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Granisetron HCl is indicated for the prevention of : Nausea and vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin. Nausea and vomiting associated with radiation, including total body irradiation and fractionated abdominal radiation. uuid:155eedf5-c524-4b97-ac07-d21d56142e61 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:119915 biolink:treats UMLS:C2721580 PMID:41385096 "[{""id"":""uuid:8cb4cda2-7945-4c32-8eb8-156765e1c73d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ffc3eed6-1a4b-4df6-85b4-2cb2a2186619"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oral Transmucosal Fentanyl Citrate (OTFC) is indicated only for the management of breakthrough cancer pain in patients 16 and older with malignancies who are already receiving and who are tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain . Patients considered opioid tolerant are those who are taking around-the-clock medicine consisting of at least 60 mg of oral morphine daily, at least 25 mcg of transdermal fentanyl/hour, at least 30 mg of oral oxycodone daily, at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid daily for a week or longer. Patients must remain on around-the-clock opioids when taking OTFC. This product must not be used in opioid non-tolerant patients because life-threatening respiratory depression and death could occur at any dose in patients not on a chronic regimen of opioids. For this reason, OTFC is contraindicated in the management of acute or postoperative pain. OTFC is intended to be used only in the care of cancer patients and only by oncologists and pain specialists who are knowledgeable of and skilled in the use of Schedule II opioids to treat cancer pain. uuid:88f7ad40-8791-48ed-b179-01fbf53f09c5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:119915 biolink:treats EFO:0801084 PMID:41385096 "[{""id"":""uuid:39b84ccc-aa95-45e7-8262-d999f7938a4e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b0855a65-1086-4db0-8b0b-e1140654ff1d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:2a95f5e9-a5ea-480f-ac52-a055898825ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oral Transmucosal Fentanyl Citrate (OTFC) is indicated only for the management of breakthrough cancer pain in patients 16 and older with malignancies who are already receiving and who are tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain . Patients considered opioid tolerant are those who are taking around-the-clock medicine consisting of at least 60 mg of oral morphine daily, at least 25 mcg of transdermal fentanyl/hour, at least 30 mg of oral oxycodone daily, at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid daily for a week or longer. Patients must remain on around-the-clock opioids when taking OTFC. This product must not be used in opioid non-tolerant patients because life-threatening respiratory depression and death could occur at any dose in patients not on a chronic regimen of opioids. For this reason, OTFC is contraindicated in the management of acute or postoperative pain. OTFC is intended to be used only in the care of cancer patients and only by oncologists and pain specialists who are knowledgeable of and skilled in the use of Schedule II opioids to treat cancer pain.|[PMDA] Drugs with a new dosage in a new dosage form indicated for analgesia of breakthrough pain in patients with cancer receiving a potent opioid analgesic at fixed time. uuid:6ccb9c52-4498-479b-b521-cd1582f63989 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:61058 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:aa5fb458-6150-467d-928f-759be52de21e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:85757e45-a2b8-4d48-80fa-28613e5efab5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension. uuid:765bc9fa-1649-4f22-a23a-879ab57d7103 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:13422922 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:ec024033-62e9-45e2-822b-f929382de606"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ad709c96-307e-41d4-9e1e-39a0dfee58a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] QVAR is indicated in the maintenance treatment of asthma as prophylactic therapy in patients 5 years of age and older. QVAR is also indicated for asthma patients who require systemic corticosteroid administration, where adding QVAR may reduce or eliminate the need for the systemic corticosteroids. Beclomethasone dipropionate is NOT indicated for the relief of acute bronchospasm. uuid:6531136d-8608-4bad-bc0b-1a8a831c6c44 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7773 biolink:treats UMLS:C0520904 PMID:41385096 "[{""id"":""uuid:729049d1-801d-410a-be59-b97033c58b59"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a552d47f-353b-4d9b-885b-166a8a2e2582"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin ≥ 50 mg/m 2 . 2. Prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy. 3. Prevention of nausea and vomiting associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen. 4. Prevention of postoperative nausea and/or vomiting. As with other antiemetics, routine prophylaxis is not recommended for patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. In patients where nausea and/or vomiting must be avoided postoperatively, ondansetron hydrochloride tablets, ondansetron orally disintegrating tablets, and ondansetron hydrochloride oral solution are recommended even where the incidence of postoperative nausea and/or vomiting is low. uuid:26884068-9f6e-4679-87f2-70bc56805577 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7773 biolink:treats UMLS:C0520905 PMID:41385096 "[{""id"":""uuid:fce227bb-d2fe-46fd-9595-dd700632c7d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1480ec30-2db6-472d-b903-dfae1a6752e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin ≥ 50 mg/m 2 . 2. Prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy. 3. Prevention of nausea and vomiting associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen. 4. Prevention of postoperative nausea and/or vomiting. As with other antiemetics, routine prophylaxis is not recommended for patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. In patients where nausea and/or vomiting must be avoided postoperatively, ondansetron hydrochloride tablets, ondansetron orally disintegrating tablets, and ondansetron hydrochloride oral solution are recommended even where the incidence of postoperative nausea and/or vomiting is low. uuid:5055cd8a-a1bc-4748-8de1-2c6e52e02e7e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45951 biolink:treats MONDO:0005090 PMID:41385096 "[{""id"":""uuid:e140fe14-76e5-4fee-a82b-9dc3494731a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ca8109b5-83fd-41e0-825a-e34705d34ddd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the management of schizophrenia. Trifluoperazine HCl is effective for the short-term treatment of generalized non-psychotic anxiety. However, trifluoperazine HCl is not the first drug to be used in therapy for most patients with non-psychotic anxiety because certain risks associated with its use are not shared by common alternative treatments (i.e., benzodiazepines). When used in the treatment of non-psychotic anxiety, trifluoperazine HCl should not be administered at doses of more than 6 mg per day or for longer than 12 weeks because the use of trifluoperazine HCl at higher doses or for longer intervals may cause persistent tardive dyskinesia that may prove irreversible (see WARNINGS ). The effectiveness of trifluoperazine HCl as a treatment for non-psychotic anxiety was established in a four-week clinical multicenter study of outpatients with generalized anxiety disorder (DSM-III). This evidence does not predict that trifluoperazine HCl will be useful in patients with other non-psychotic conditions in which anxiety, or signs that mimic anxiety, are found (i.e., physical illness, organic mental conditions, agitated depression, character pathologies, etc.). Trifluoperazine HCl has not been shown effective in the management of behavioral complications in patients with mental retardation. uuid:5a112e33-5489-4747-8564-101fd422006d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45951 biolink:treats MONDO:0001942 PMID:41385096 "[{""id"":""uuid:fd851a4b-7cec-4152-8af2-b7db9c83c938"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d2b08756-57e6-4902-9ea5-f6083f790d76"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the management of schizophrenia. Trifluoperazine HCl is effective for the short-term treatment of generalized non-psychotic anxiety. However, trifluoperazine HCl is not the first drug to be used in therapy for most patients with non-psychotic anxiety because certain risks associated with its use are not shared by common alternative treatments (i.e., benzodiazepines). When used in the treatment of non-psychotic anxiety, trifluoperazine HCl should not be administered at doses of more than 6 mg per day or for longer than 12 weeks because the use of trifluoperazine HCl at higher doses or for longer intervals may cause persistent tardive dyskinesia that may prove irreversible (see WARNINGS ). The effectiveness of trifluoperazine HCl as a treatment for non-psychotic anxiety was established in a four-week clinical multicenter study of outpatients with generalized anxiety disorder (DSM-III). This evidence does not predict that trifluoperazine HCl will be useful in patients with other non-psychotic conditions in which anxiety, or signs that mimic anxiety, are found (i.e., physical illness, organic mental conditions, agitated depression, character pathologies, etc.). Trifluoperazine HCl has not been shown effective in the management of behavioral complications in patients with mental retardation. uuid:65fb79b0-abe5-4b43-8584-445165bdd749 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0006605 PMID:41385096 "[{""id"":""uuid:355bce95-31e1-4da4-8d5a-013872633500"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:80cc1f85-3c86-4f6a-8277-5e8a3d59c7c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Luxíq is a medium potency topical corticosteroid indicated for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses of the scalp. uuid:eb4f33c7-6180-47d7-b367-eba56c54b7cb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6715 biolink:treats HP:0000869 PMID:41385096 "[{""id"":""uuid:1c3f2345-6dde-4df9-8100-6d48ad7e19c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6965cc3e-98c2-4cc0-b5fc-2fed3e7dd2cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Medroxyprogesterone acetate tablets contain a progestin indicated for the treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer. Medroxyprogesterone acetate is also indicated to reduce the incidence of endometrial hyperplasia in nonhysterectomized postmenopausal women receiving daily oral conjugated estrogens 0.625 mg tablets. uuid:c840e306-606d-4b1c-b344-3026aa1f4a00 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6715 biolink:treats UMLS:C3650625 PMID:41385096 "[{""id"":""uuid:b69c2b01-75d0-4fc3-a27e-ebfd128a0ed6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1ed80f67-b04b-4387-a089-e684b4022eb6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Medroxyprogesterone acetate tablets contain a progestin indicated for the treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer. Medroxyprogesterone acetate is also indicated to reduce the incidence of endometrial hyperplasia in nonhysterectomized postmenopausal women receiving daily oral conjugated estrogens 0.625 mg tablets. uuid:2b4383ad-7310-43c5-9efc-1dc360bb3310 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6715 biolink:treats MONDO:0006193 PMID:41385096 "[{""id"":""uuid:71430e1a-3ad9-4e13-bf6a-db1884f76097"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:87850427-34fe-4362-818b-00ba3f1ae1a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Medroxyprogesterone acetate tablets contain a progestin indicated for the treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer. Medroxyprogesterone acetate is also indicated to reduce the incidence of endometrial hyperplasia in nonhysterectomized postmenopausal women receiving daily oral conjugated estrogens 0.625 mg tablets. uuid:a684e5f7-6f1f-4d88-9751-443863a6be78 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:40303 biolink:treats MONDO:0037748 PMID:41385096 "[{""id"":""uuid:062e25b0-bd3e-458e-bf51-1dbce1538504"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f63ae358-e0d0-4f6f-8978-ea5903f915f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lovastatin tablets should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin tablets should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C, and below average HDL-C, lovastatin tablets are indicated to reduce the risk of: - Myocardial infarction - Unstable angina - Coronary revascularization procedures (See CLINICAL PHARMACOLOGY, Clinical Studies .) Coronary Heart Disease Lovastatin tablets are indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Lovastatin tablets are indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb***), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. *** Classification of Hyperlipoproteinemias IDL = intermediate-density lipoprotein Type Lipoproteins elevated Lipid Elevations major minor I Chylomicrons TG ↑ →C IIa LDL C — IIb LDL, VLDL C TG III (rare) IDL C/TG — IV VLDL TG ↑ →C V (rare) Chylomicrons, VLDL TG ↑ →C Adolescent Patients with Heterozygous Familial Hypercholesterolemia Lovastatin tablets are indicated as an adjunct to diet to reduce total-C, LDL-C and apolipoprotein B levels in adolescent boys and girls who are at least one year post-menarche, 10-17 years of age, with heFH if after an adequate trial of diet therapy the following findings are present: LDL-C remains >189 mg/dL or LDL-C remains >160 mg/dL and: • there is a positive family history of premature cardiovascular disease or • two or more other CVD risk factors are present in the adolescent patient General Recommendations Prior to initiating therapy with lovastatin, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure total-C, HDL-C, and TG. For patients with TG less than 400 mg / dL (<4.5 mmol / L), LDL-C can be estimated using the following equation: LDL-C = total-C – [0.2 x (TG) + HDL-C] For TG levels >400 mg/dL (>4.5 mmol/L), this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated total-C. In such cases, lovastatin tablets are not indicated. The National Cholesterol Education Program (NCEP) Treatment Guidelines are summarized below: NCEP Treatment Guidelines: LDL-C Goals and Cutpoints for Therapeutic Lifestyle Changes and Drug Therapy in Different Risk Categories Risk Category LDL Goal (mg/dL) LDL Level at Which to Initiate Therapeutic Lifestyle Changes (mg/dL) LDL Level at Which to Consider Drug Therapy (mg/dL) CHD or CHD risk equivalence (10-year risk >20%) <100 ≥100 ≥130 (100-129: drug optional) 2+ Risk factors (10-year risk ≤20%) <130 ≥130 10-year risk 10-20%: ≥130 10-year risk<10%: ≥160 0-1 Risk factor <160 ≥160 ≥190 (160-189: LDL-lowering drug optional) After the LDL-C goal has been achieved, if the TG is still ≥200 mg/dL, non-HDL-C (total-C minus HDLC) becomes a secondary target of therapy. Non-HDL-C goals are set 30 mg/dL higher than LDL-C goals for each risk category. At the time of hospitalization for an acute coronary event, consideration can be given to initiating drug therapy at discharge if the LDL-C is ≥130 mg/dL (see NCEP Guidelines above). Since the goal of treatment is to lower LDL-C, the NCEP recommends that LDL-C levels be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the total-C be used to monitor therapy. Although lovastatin tablets may be useful to reduce elevated LDL-C levels in patients with combined hypercholesterolemia and hypertriglyceridemia where hypercholesterolemia is the major abnormality (Type IIb hyperlipoproteinemia), it has not been studied in conditions where the major abnormality is elevation of chylomicrons, VLDL or IDL (i.e., hyperlipoproteinemia types I, III, IV, or V).*** The NCEP classification of cholesterol levels in pediatric patients with a familial history of hypercholesterolemia or premature cardiovascular disease is summarized below: Category Total-C (mg/dL) LDL-C (mg/dL) Acceptable <170 <110 Borderline 170-199 110-129 High ≥200 ≥130 Children treated with lovastatin in adolescence should be re-evaluated in adulthood and appropriate changes made to their cholesterol-lowering regimen to achieve adult goals for LDL-C. uuid:b6b1c9ca-cd60-42db-b39a-35390ad6f53f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6704 biolink:treats MONDO:0005746 PMID:41385096 "[{""id"":""uuid:6e637e06-1b22-4a13-9ab9-ed78b23d524f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f0c0fb40-ed4a-45d8-bd6b-b555f6a38abd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mebendazole tablets are indicated for the treatment of Enterobius vermicularis (pinworm), Trichuris trichiura (whipworm), Ascaris lumbricoides (common roundworm), Ancylostoma duodenale (common hookworm), Necator americanus (American hookworm) in single or mixed infections. Efficacy varies as a function of such factors as preexisting diarrhea and gastrointestinal transit time, degree of infection, and helminth strains. Efficacy rates derived from various studies are shown in the table below: Pinworm (enterobiasis) Whipworm (trichuriasis) Common Roundworm (ascariasis) Hookworm Cure rates mean 95% 68% 98% 96% Egg reduction mean — 93% 99% 99% uuid:e817e785-35b1-4e46-b67d-d68f74508c33 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6704 biolink:treats MONDO:0005996 PMID:41385096 "[{""id"":""uuid:b56c12ae-513f-4a7b-adde-89ead5f03c27"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:82115d84-0e8d-4255-9476-6143485e7a13"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mebendazole tablets are indicated for the treatment of Enterobius vermicularis (pinworm), Trichuris trichiura (whipworm), Ascaris lumbricoides (common roundworm), Ancylostoma duodenale (common hookworm), Necator americanus (American hookworm) in single or mixed infections. Efficacy varies as a function of such factors as preexisting diarrhea and gastrointestinal transit time, degree of infection, and helminth strains. Efficacy rates derived from various studies are shown in the table below: Pinworm (enterobiasis) Whipworm (trichuriasis) Common Roundworm (ascariasis) Hookworm Cure rates mean 95% 68% 98% 96% Egg reduction mean — 93% 99% 99% uuid:37084a01-abb3-4771-a87e-2e5e12245186 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6704 biolink:treats MONDO:0011427 PMID:41385096 "[{""id"":""uuid:231f2f9a-0e11-4782-afec-11f2b75aea08"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:27385a5d-4906-4c18-b524-c294e3a5aa1d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mebendazole tablets are indicated for the treatment of Enterobius vermicularis (pinworm), Trichuris trichiura (whipworm), Ascaris lumbricoides (common roundworm), Ancylostoma duodenale (common hookworm), Necator americanus (American hookworm) in single or mixed infections. Efficacy varies as a function of such factors as preexisting diarrhea and gastrointestinal transit time, degree of infection, and helminth strains. Efficacy rates derived from various studies are shown in the table below: Pinworm (enterobiasis) Whipworm (trichuriasis) Common Roundworm (ascariasis) Hookworm Cure rates mean 95% 68% 98% 96% Egg reduction mean — 93% 99% 99% uuid:707a505f-89bc-47ae-a2c1-7bf0ebb0a126 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6704 biolink:treats MONDO:0005654 PMID:41385096 "[{""id"":""uuid:68c6ff94-2af1-4b40-8d84-01f39f479744"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6a48cec9-4529-43c6-a7e4-4a8bb454b856"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mebendazole tablets are indicated for the treatment of Enterobius vermicularis (pinworm), Trichuris trichiura (whipworm), Ascaris lumbricoides (common roundworm), Ancylostoma duodenale (common hookworm), Necator americanus (American hookworm) in single or mixed infections. Efficacy varies as a function of such factors as preexisting diarrhea and gastrointestinal transit time, degree of infection, and helminth strains. Efficacy rates derived from various studies are shown in the table below: Pinworm (enterobiasis) Whipworm (trichuriasis) Common Roundworm (ascariasis) Hookworm Cure rates mean 95% 68% 98% 96% Egg reduction mean — 93% 99% 99% uuid:26072c42-df9c-49f1-9e25-9c945d5034c1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6704 biolink:treats MONDO:0005645 PMID:41385096 "[{""id"":""uuid:6554e689-14f7-46cf-9086-6eab09db466a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5f4ca816-4032-4a1e-b4ba-097f3493175a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mebendazole tablets are indicated for the treatment of Enterobius vermicularis (pinworm), Trichuris trichiura (whipworm), Ascaris lumbricoides (common roundworm), Ancylostoma duodenale (common hookworm), Necator americanus (American hookworm) in single or mixed infections. Efficacy varies as a function of such factors as preexisting diarrhea and gastrointestinal transit time, degree of infection, and helminth strains. Efficacy rates derived from various studies are shown in the table below: Pinworm (enterobiasis) Whipworm (trichuriasis) Common Roundworm (ascariasis) Hookworm Cure rates mean 95% 68% 98% 96% Egg reduction mean — 93% 99% 99% uuid:e07bee78-3d36-4ed3-912e-385f5e584e0c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6704 biolink:treats MONDO:0005799 PMID:41385096 "[{""id"":""uuid:5eea42ec-d104-4aa2-9e6c-ecd8116db80f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ded40269-a5ed-4397-99f0-9c7b53083f43"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mebendazole tablets are indicated for the treatment of Enterobius vermicularis (pinworm), Trichuris trichiura (whipworm), Ascaris lumbricoides (common roundworm), Ancylostoma duodenale (common hookworm), Necator americanus (American hookworm) in single or mixed infections. Efficacy varies as a function of such factors as preexisting diarrhea and gastrointestinal transit time, degree of infection, and helminth strains. Efficacy rates derived from various studies are shown in the table below: Pinworm (enterobiasis) Whipworm (trichuriasis) Common Roundworm (ascariasis) Hookworm Cure rates mean 95% 68% 98% 96% Egg reduction mean — 93% 99% 99% uuid:b7894d72-72cd-4535-a137-b5acb2ba1b73 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6704 biolink:treats UMLS:C0027529 PMID:41385096 "[{""id"":""uuid:551de8ac-6f31-4c73-9c4d-22f13f510260"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:83a237bc-1a09-4f79-80ac-84ea65d85aa4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mebendazole tablets are indicated for the treatment of Enterobius vermicularis (pinworm), Trichuris trichiura (whipworm), Ascaris lumbricoides (common roundworm), Ancylostoma duodenale (common hookworm), Necator americanus (American hookworm) in single or mixed infections. Efficacy varies as a function of such factors as preexisting diarrhea and gastrointestinal transit time, degree of infection, and helminth strains. Efficacy rates derived from various studies are shown in the table below: Pinworm (enterobiasis) Whipworm (trichuriasis) Common Roundworm (ascariasis) Hookworm Cure rates mean 95% 68% 98% 96% Egg reduction mean — 93% 99% 99% uuid:9934c693-7178-4b26-8368-7dad1d1a57ed biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:38562 biolink:treats MONDO:0005439 PMID:41385096 "[{""id"":""uuid:7c5b0b8f-e08b-42b7-895d-453437fe9492"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:38e00d48-41f6-46ce-9a98-178ae64da5f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol (see National Cholesterol Education Program [NCEP] Treatment Guidelines, below). Hypercholesterolemia (heterozygous familial and nonfamilial) and Mixed Dyslipidemia Lescol ® (fluvastatin sodium) and Lescol ® XL (fluvastatin sodium) are indicated to reduce elevated total cholesterol (Total-C), LDL-C, TG and Apo B levels, and to increase HDL-C in patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson Type IIa and IIb) whose response to dietary restriction of saturated fat and cholesterol and other nonpharmacological measures has not been adequate. Heterozygous Familial Hypercholesterolemia in Pediatric Patients Lescol and Lescol XL are indicated as an adjunct to diet to reduce Total-C, LDL-C, and Apo B levels in adolescent boys and girls who are at least one year post-menarche, 10-16 years of age, with heterozygous familial hypercholesterolemia whose response to dietary restriction has not been adequate and the following findings are present: LDL-C remains > 190 mg/dL or LDL-C remains > 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other cardiovascular disease risk factors are present. Therapy with lipid-altering agents should be considered only after secondary causes for hyperlipidemia such as poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other medication, or alcoholism, have been excluded. Prior to initiation of fluvastatin sodium, a lipid profile should be performed to measure Total-C, HDL-C and TG. For patients with TG <400 mg/dL (<4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = Total-C - HDL-C - 1/5 TG For TG levels >400 mg/dL (>4.5 mmol/L), this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In many hypertriglyceridemic patients LDL-C may be low or normal despite elevated Total-C. In such cases, Lescol is not indicated. Lipid determinations should be performed at intervals of no less than 4 weeks and dosage adjusted according to the patient’s response to therapy. The National Cholesterol Education Program (NCEP) Treatment Guidelines are summarized below: Table 3 NCEP Treatment Guidelines: LDL-C Goals and Cutpoints for Therapeutic Lifestyle Changes and Drug Therapy in Different Risk Categories Risk Category LDL Goal (mg/dL) LDL Level at Which to Initiate Therapeutic Lifestyle Changes (mg/dL) LDL Level at Which to Consider Drug Therapy (mg/dL) CHD† or CHD risk equivalents (10-year risk >20%) <100 > 100 > 130 (100-129: drug optional)†† 2+ Risk factors (10-year risk < 20%) <130 > 130 10-year risk 10%-20%: >130 10-year risk <10%: > 160 0-1 Risk factor††† <160 > 160 > 190 (160-189: LDL-lowering drug optional) † CHD, coronary heart disease †† Some authorities recommend use of LDL-lowering drugs in this category if an LDL-C level of <100mg/dL cannot be achieved by therapeutic lifestyle changes. Others prefer use of drugs that primarily modify triglycerides and HDL-C, e.g. , nicotinic acid or fibrate. Clinical judgement also may call for deferring drug therapy in this subcategory. ††† Almost all people with 0-1 risk factor have 10-year risk <10%; thus, 10-year risk assessment in people with 0 -1 risk factor is not necessary. After the LDL-C goal has been achieved, if the TG is still > 200 mg/dL, non-HDL-C (Total-C minus HDL-C) becomes a secondary target of therapy. Non-HDL-C goals are set 30 mg/dL higher than LDL-C goals for each risk category. At the time of hospitalization for an acute coronary event, consideration can be given to initiating drug therapy at discharge if the LDL-C level is > 130 mg/dL (NCEP-ATP II). Since the goal of treatment is to lower LDL-C, the NCEP recommends that the LDL-C levels be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the Total-C be used to monitor therapy. Table 4 Classification of Hyperlipoproteinemias Lipid Elevations Type Lipoproteins Elevated Major Minor I (rare) Chylomicrons TG ↑→C IIa LDL C – IIb LDL, VLDL C TG III (rare) IDL C/TG – IV VLDL TG ↑→C V (rare) Chylomicrons, VLDL TG ↑→C C = cholesterol, TG = triglycerides, LDL = low density lipoprotein, VLDL = very low density lipoprotein, IDL = intermediate density lipoprotein Neither Lescol nor Lescol XL have been studied in conditions where the major abnormality is elevation of chylomicrons, VLDL, or IDL (i.e., hyperlipoproteinemia Types I, III, IV, or V). The NCEP classification of cholesterol levels in pediatric patients with a familial history of hypercholesterolemia or premature cardiovascular disease is summarized below: Category Total-C (mg/dL) LDL-C (mg/dL) Acceptable Borderline High <170 170-199 > 200 <110 110-129 > 130 Children treated with fluvastatin in adolescence should be re-evaluated in adulthood and appropriate changes made to their cholesterol-lowering regimen to achieve adult treatment goals. Secondary Prevention of Coronary Events In patients with coronary heart disease, Lescol and Lescol XL are indicated to reduce the risk of undergoing coronary revascularization procedures. Atherosclerosis Lescol and Lescol XL are also indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total and LDL cholesterol to target levels. uuid:6d5c9d8a-101e-4b4d-bbfc-99f844467f05 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:38562 biolink:treats HP:0003119 PMID:41385096 "[{""id"":""uuid:3534aa8b-c84b-4781-ad76-faa41e6b7d1e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2d80e747-90fc-47c0-8632-9be18b688666"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol (see National Cholesterol Education Program [NCEP] Treatment Guidelines, below). Hypercholesterolemia (heterozygous familial and nonfamilial) and Mixed Dyslipidemia Lescol ® (fluvastatin sodium) and Lescol ® XL (fluvastatin sodium) are indicated to reduce elevated total cholesterol (Total-C), LDL-C, TG and Apo B levels, and to increase HDL-C in patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson Type IIa and IIb) whose response to dietary restriction of saturated fat and cholesterol and other nonpharmacological measures has not been adequate. Heterozygous Familial Hypercholesterolemia in Pediatric Patients Lescol and Lescol XL are indicated as an adjunct to diet to reduce Total-C, LDL-C, and Apo B levels in adolescent boys and girls who are at least one year post-menarche, 10-16 years of age, with heterozygous familial hypercholesterolemia whose response to dietary restriction has not been adequate and the following findings are present: LDL-C remains > 190 mg/dL or LDL-C remains > 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other cardiovascular disease risk factors are present. Therapy with lipid-altering agents should be considered only after secondary causes for hyperlipidemia such as poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other medication, or alcoholism, have been excluded. Prior to initiation of fluvastatin sodium, a lipid profile should be performed to measure Total-C, HDL-C and TG. For patients with TG <400 mg/dL (<4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = Total-C - HDL-C - 1/5 TG For TG levels >400 mg/dL (>4.5 mmol/L), this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In many hypertriglyceridemic patients LDL-C may be low or normal despite elevated Total-C. In such cases, Lescol is not indicated. Lipid determinations should be performed at intervals of no less than 4 weeks and dosage adjusted according to the patient’s response to therapy. The National Cholesterol Education Program (NCEP) Treatment Guidelines are summarized below: Table 3 NCEP Treatment Guidelines: LDL-C Goals and Cutpoints for Therapeutic Lifestyle Changes and Drug Therapy in Different Risk Categories Risk Category LDL Goal (mg/dL) LDL Level at Which to Initiate Therapeutic Lifestyle Changes (mg/dL) LDL Level at Which to Consider Drug Therapy (mg/dL) CHD† or CHD risk equivalents (10-year risk >20%) <100 > 100 > 130 (100-129: drug optional)†† 2+ Risk factors (10-year risk < 20%) <130 > 130 10-year risk 10%-20%: >130 10-year risk <10%: > 160 0-1 Risk factor††† <160 > 160 > 190 (160-189: LDL-lowering drug optional) † CHD, coronary heart disease †† Some authorities recommend use of LDL-lowering drugs in this category if an LDL-C level of <100mg/dL cannot be achieved by therapeutic lifestyle changes. Others prefer use of drugs that primarily modify triglycerides and HDL-C, e.g. , nicotinic acid or fibrate. Clinical judgement also may call for deferring drug therapy in this subcategory. ††† Almost all people with 0-1 risk factor have 10-year risk <10%; thus, 10-year risk assessment in people with 0 -1 risk factor is not necessary. After the LDL-C goal has been achieved, if the TG is still > 200 mg/dL, non-HDL-C (Total-C minus HDL-C) becomes a secondary target of therapy. Non-HDL-C goals are set 30 mg/dL higher than LDL-C goals for each risk category. At the time of hospitalization for an acute coronary event, consideration can be given to initiating drug therapy at discharge if the LDL-C level is > 130 mg/dL (NCEP-ATP II). Since the goal of treatment is to lower LDL-C, the NCEP recommends that the LDL-C levels be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the Total-C be used to monitor therapy. Table 4 Classification of Hyperlipoproteinemias Lipid Elevations Type Lipoproteins Elevated Major Minor I (rare) Chylomicrons TG ↑→C IIa LDL C – IIb LDL, VLDL C TG III (rare) IDL C/TG – IV VLDL TG ↑→C V (rare) Chylomicrons, VLDL TG ↑→C C = cholesterol, TG = triglycerides, LDL = low density lipoprotein, VLDL = very low density lipoprotein, IDL = intermediate density lipoprotein Neither Lescol nor Lescol XL have been studied in conditions where the major abnormality is elevation of chylomicrons, VLDL, or IDL (i.e., hyperlipoproteinemia Types I, III, IV, or V). The NCEP classification of cholesterol levels in pediatric patients with a familial history of hypercholesterolemia or premature cardiovascular disease is summarized below: Category Total-C (mg/dL) LDL-C (mg/dL) Acceptable Borderline High <170 170-199 > 200 <110 110-129 > 130 Children treated with fluvastatin in adolescence should be re-evaluated in adulthood and appropriate changes made to their cholesterol-lowering regimen to achieve adult treatment goals. Secondary Prevention of Coronary Events In patients with coronary heart disease, Lescol and Lescol XL are indicated to reduce the risk of undergoing coronary revascularization procedures. Atherosclerosis Lescol and Lescol XL are also indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total and LDL cholesterol to target levels. uuid:cce3a8b8-976a-4703-9c51-070007635967 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:38562 biolink:treats UMLS:C0342882 PMID:41385096 "[{""id"":""uuid:0b8339f4-d265-4b54-93e6-3a5f07fc94e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cdd45a6e-6f7a-4986-aa6a-ddaef3b1f371"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol (see National Cholesterol Education Program [NCEP] Treatment Guidelines, below). Hypercholesterolemia (heterozygous familial and nonfamilial) and Mixed Dyslipidemia Lescol ® (fluvastatin sodium) and Lescol ® XL (fluvastatin sodium) are indicated to reduce elevated total cholesterol (Total-C), LDL-C, TG and Apo B levels, and to increase HDL-C in patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson Type IIa and IIb) whose response to dietary restriction of saturated fat and cholesterol and other nonpharmacological measures has not been adequate. Heterozygous Familial Hypercholesterolemia in Pediatric Patients Lescol and Lescol XL are indicated as an adjunct to diet to reduce Total-C, LDL-C, and Apo B levels in adolescent boys and girls who are at least one year post-menarche, 10-16 years of age, with heterozygous familial hypercholesterolemia whose response to dietary restriction has not been adequate and the following findings are present: LDL-C remains > 190 mg/dL or LDL-C remains > 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other cardiovascular disease risk factors are present. Therapy with lipid-altering agents should be considered only after secondary causes for hyperlipidemia such as poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other medication, or alcoholism, have been excluded. Prior to initiation of fluvastatin sodium, a lipid profile should be performed to measure Total-C, HDL-C and TG. For patients with TG <400 mg/dL (<4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = Total-C - HDL-C - 1/5 TG For TG levels >400 mg/dL (>4.5 mmol/L), this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In many hypertriglyceridemic patients LDL-C may be low or normal despite elevated Total-C. In such cases, Lescol is not indicated. Lipid determinations should be performed at intervals of no less than 4 weeks and dosage adjusted according to the patient’s response to therapy. The National Cholesterol Education Program (NCEP) Treatment Guidelines are summarized below: Table 3 NCEP Treatment Guidelines: LDL-C Goals and Cutpoints for Therapeutic Lifestyle Changes and Drug Therapy in Different Risk Categories Risk Category LDL Goal (mg/dL) LDL Level at Which to Initiate Therapeutic Lifestyle Changes (mg/dL) LDL Level at Which to Consider Drug Therapy (mg/dL) CHD† or CHD risk equivalents (10-year risk >20%) <100 > 100 > 130 (100-129: drug optional)†† 2+ Risk factors (10-year risk < 20%) <130 > 130 10-year risk 10%-20%: >130 10-year risk <10%: > 160 0-1 Risk factor††† <160 > 160 > 190 (160-189: LDL-lowering drug optional) † CHD, coronary heart disease †† Some authorities recommend use of LDL-lowering drugs in this category if an LDL-C level of <100mg/dL cannot be achieved by therapeutic lifestyle changes. Others prefer use of drugs that primarily modify triglycerides and HDL-C, e.g. , nicotinic acid or fibrate. Clinical judgement also may call for deferring drug therapy in this subcategory. ††† Almost all people with 0-1 risk factor have 10-year risk <10%; thus, 10-year risk assessment in people with 0 -1 risk factor is not necessary. After the LDL-C goal has been achieved, if the TG is still > 200 mg/dL, non-HDL-C (Total-C minus HDL-C) becomes a secondary target of therapy. Non-HDL-C goals are set 30 mg/dL higher than LDL-C goals for each risk category. At the time of hospitalization for an acute coronary event, consideration can be given to initiating drug therapy at discharge if the LDL-C level is > 130 mg/dL (NCEP-ATP II). Since the goal of treatment is to lower LDL-C, the NCEP recommends that the LDL-C levels be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the Total-C be used to monitor therapy. Table 4 Classification of Hyperlipoproteinemias Lipid Elevations Type Lipoproteins Elevated Major Minor I (rare) Chylomicrons TG ↑→C IIa LDL C – IIb LDL, VLDL C TG III (rare) IDL C/TG – IV VLDL TG ↑→C V (rare) Chylomicrons, VLDL TG ↑→C C = cholesterol, TG = triglycerides, LDL = low density lipoprotein, VLDL = very low density lipoprotein, IDL = intermediate density lipoprotein Neither Lescol nor Lescol XL have been studied in conditions where the major abnormality is elevation of chylomicrons, VLDL, or IDL (i.e., hyperlipoproteinemia Types I, III, IV, or V). The NCEP classification of cholesterol levels in pediatric patients with a familial history of hypercholesterolemia or premature cardiovascular disease is summarized below: Category Total-C (mg/dL) LDL-C (mg/dL) Acceptable Borderline High <170 170-199 > 200 <110 110-129 > 130 Children treated with fluvastatin in adolescence should be re-evaluated in adulthood and appropriate changes made to their cholesterol-lowering regimen to achieve adult treatment goals. Secondary Prevention of Coronary Events In patients with coronary heart disease, Lescol and Lescol XL are indicated to reduce the risk of undergoing coronary revascularization procedures. Atherosclerosis Lescol and Lescol XL are also indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total and LDL cholesterol to target levels. uuid:67cc5780-3718-4cf3-a307-6421f8a35018 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:38562 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:9b5ba5b8-7507-49a3-be77-64cca24e0e63"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8eaad9cc-59c0-4e18-a7cd-56f33d9f39e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol (see National Cholesterol Education Program [NCEP] Treatment Guidelines, below). Hypercholesterolemia (heterozygous familial and nonfamilial) and Mixed Dyslipidemia Lescol ® (fluvastatin sodium) and Lescol ® XL (fluvastatin sodium) are indicated to reduce elevated total cholesterol (Total-C), LDL-C, TG and Apo B levels, and to increase HDL-C in patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson Type IIa and IIb) whose response to dietary restriction of saturated fat and cholesterol and other nonpharmacological measures has not been adequate. Heterozygous Familial Hypercholesterolemia in Pediatric Patients Lescol and Lescol XL are indicated as an adjunct to diet to reduce Total-C, LDL-C, and Apo B levels in adolescent boys and girls who are at least one year post-menarche, 10-16 years of age, with heterozygous familial hypercholesterolemia whose response to dietary restriction has not been adequate and the following findings are present: LDL-C remains > 190 mg/dL or LDL-C remains > 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other cardiovascular disease risk factors are present. Therapy with lipid-altering agents should be considered only after secondary causes for hyperlipidemia such as poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other medication, or alcoholism, have been excluded. Prior to initiation of fluvastatin sodium, a lipid profile should be performed to measure Total-C, HDL-C and TG. For patients with TG <400 mg/dL (<4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = Total-C - HDL-C - 1/5 TG For TG levels >400 mg/dL (>4.5 mmol/L), this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In many hypertriglyceridemic patients LDL-C may be low or normal despite elevated Total-C. In such cases, Lescol is not indicated. Lipid determinations should be performed at intervals of no less than 4 weeks and dosage adjusted according to the patient’s response to therapy. The National Cholesterol Education Program (NCEP) Treatment Guidelines are summarized below: Table 3 NCEP Treatment Guidelines: LDL-C Goals and Cutpoints for Therapeutic Lifestyle Changes and Drug Therapy in Different Risk Categories Risk Category LDL Goal (mg/dL) LDL Level at Which to Initiate Therapeutic Lifestyle Changes (mg/dL) LDL Level at Which to Consider Drug Therapy (mg/dL) CHD† or CHD risk equivalents (10-year risk >20%) <100 > 100 > 130 (100-129: drug optional)†† 2+ Risk factors (10-year risk < 20%) <130 > 130 10-year risk 10%-20%: >130 10-year risk <10%: > 160 0-1 Risk factor††† <160 > 160 > 190 (160-189: LDL-lowering drug optional) † CHD, coronary heart disease †† Some authorities recommend use of LDL-lowering drugs in this category if an LDL-C level of <100mg/dL cannot be achieved by therapeutic lifestyle changes. Others prefer use of drugs that primarily modify triglycerides and HDL-C, e.g. , nicotinic acid or fibrate. Clinical judgement also may call for deferring drug therapy in this subcategory. ††† Almost all people with 0-1 risk factor have 10-year risk <10%; thus, 10-year risk assessment in people with 0 -1 risk factor is not necessary. After the LDL-C goal has been achieved, if the TG is still > 200 mg/dL, non-HDL-C (Total-C minus HDL-C) becomes a secondary target of therapy. Non-HDL-C goals are set 30 mg/dL higher than LDL-C goals for each risk category. At the time of hospitalization for an acute coronary event, consideration can be given to initiating drug therapy at discharge if the LDL-C level is > 130 mg/dL (NCEP-ATP II). Since the goal of treatment is to lower LDL-C, the NCEP recommends that the LDL-C levels be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the Total-C be used to monitor therapy. Table 4 Classification of Hyperlipoproteinemias Lipid Elevations Type Lipoproteins Elevated Major Minor I (rare) Chylomicrons TG ↑→C IIa LDL C – IIb LDL, VLDL C TG III (rare) IDL C/TG – IV VLDL TG ↑→C V (rare) Chylomicrons, VLDL TG ↑→C C = cholesterol, TG = triglycerides, LDL = low density lipoprotein, VLDL = very low density lipoprotein, IDL = intermediate density lipoprotein Neither Lescol nor Lescol XL have been studied in conditions where the major abnormality is elevation of chylomicrons, VLDL, or IDL (i.e., hyperlipoproteinemia Types I, III, IV, or V). The NCEP classification of cholesterol levels in pediatric patients with a familial history of hypercholesterolemia or premature cardiovascular disease is summarized below: Category Total-C (mg/dL) LDL-C (mg/dL) Acceptable Borderline High <170 170-199 > 200 <110 110-129 > 130 Children treated with fluvastatin in adolescence should be re-evaluated in adulthood and appropriate changes made to their cholesterol-lowering regimen to achieve adult treatment goals. Secondary Prevention of Coronary Events In patients with coronary heart disease, Lescol and Lescol XL are indicated to reduce the risk of undergoing coronary revascularization procedures. Atherosclerosis Lescol and Lescol XL are also indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total and LDL cholesterol to target levels. uuid:b317302a-0b6b-41ea-ab7f-0e53f1cc95d1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:38562 biolink:treats MONDO:0005010 PMID:41385096 "[{""id"":""uuid:938e2dd0-3f2f-454e-9983-4a18765ad0e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:749faad3-0a4d-418a-8542-979a381d89f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol (see National Cholesterol Education Program [NCEP] Treatment Guidelines, below). Hypercholesterolemia (heterozygous familial and nonfamilial) and Mixed Dyslipidemia Lescol ® (fluvastatin sodium) and Lescol ® XL (fluvastatin sodium) are indicated to reduce elevated total cholesterol (Total-C), LDL-C, TG and Apo B levels, and to increase HDL-C in patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson Type IIa and IIb) whose response to dietary restriction of saturated fat and cholesterol and other nonpharmacological measures has not been adequate. Heterozygous Familial Hypercholesterolemia in Pediatric Patients Lescol and Lescol XL are indicated as an adjunct to diet to reduce Total-C, LDL-C, and Apo B levels in adolescent boys and girls who are at least one year post-menarche, 10-16 years of age, with heterozygous familial hypercholesterolemia whose response to dietary restriction has not been adequate and the following findings are present: LDL-C remains > 190 mg/dL or LDL-C remains > 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other cardiovascular disease risk factors are present. Therapy with lipid-altering agents should be considered only after secondary causes for hyperlipidemia such as poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other medication, or alcoholism, have been excluded. Prior to initiation of fluvastatin sodium, a lipid profile should be performed to measure Total-C, HDL-C and TG. For patients with TG <400 mg/dL (<4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = Total-C - HDL-C - 1/5 TG For TG levels >400 mg/dL (>4.5 mmol/L), this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In many hypertriglyceridemic patients LDL-C may be low or normal despite elevated Total-C. In such cases, Lescol is not indicated. Lipid determinations should be performed at intervals of no less than 4 weeks and dosage adjusted according to the patient’s response to therapy. The National Cholesterol Education Program (NCEP) Treatment Guidelines are summarized below: Table 3 NCEP Treatment Guidelines: LDL-C Goals and Cutpoints for Therapeutic Lifestyle Changes and Drug Therapy in Different Risk Categories Risk Category LDL Goal (mg/dL) LDL Level at Which to Initiate Therapeutic Lifestyle Changes (mg/dL) LDL Level at Which to Consider Drug Therapy (mg/dL) CHD† or CHD risk equivalents (10-year risk >20%) <100 > 100 > 130 (100-129: drug optional)†† 2+ Risk factors (10-year risk < 20%) <130 > 130 10-year risk 10%-20%: >130 10-year risk <10%: > 160 0-1 Risk factor††† <160 > 160 > 190 (160-189: LDL-lowering drug optional) † CHD, coronary heart disease †† Some authorities recommend use of LDL-lowering drugs in this category if an LDL-C level of <100mg/dL cannot be achieved by therapeutic lifestyle changes. Others prefer use of drugs that primarily modify triglycerides and HDL-C, e.g. , nicotinic acid or fibrate. Clinical judgement also may call for deferring drug therapy in this subcategory. ††† Almost all people with 0-1 risk factor have 10-year risk <10%; thus, 10-year risk assessment in people with 0 -1 risk factor is not necessary. After the LDL-C goal has been achieved, if the TG is still > 200 mg/dL, non-HDL-C (Total-C minus HDL-C) becomes a secondary target of therapy. Non-HDL-C goals are set 30 mg/dL higher than LDL-C goals for each risk category. At the time of hospitalization for an acute coronary event, consideration can be given to initiating drug therapy at discharge if the LDL-C level is > 130 mg/dL (NCEP-ATP II). Since the goal of treatment is to lower LDL-C, the NCEP recommends that the LDL-C levels be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the Total-C be used to monitor therapy. Table 4 Classification of Hyperlipoproteinemias Lipid Elevations Type Lipoproteins Elevated Major Minor I (rare) Chylomicrons TG ↑→C IIa LDL C – IIb LDL, VLDL C TG III (rare) IDL C/TG – IV VLDL TG ↑→C V (rare) Chylomicrons, VLDL TG ↑→C C = cholesterol, TG = triglycerides, LDL = low density lipoprotein, VLDL = very low density lipoprotein, IDL = intermediate density lipoprotein Neither Lescol nor Lescol XL have been studied in conditions where the major abnormality is elevation of chylomicrons, VLDL, or IDL (i.e., hyperlipoproteinemia Types I, III, IV, or V). The NCEP classification of cholesterol levels in pediatric patients with a familial history of hypercholesterolemia or premature cardiovascular disease is summarized below: Category Total-C (mg/dL) LDL-C (mg/dL) Acceptable Borderline High <170 170-199 > 200 <110 110-129 > 130 Children treated with fluvastatin in adolescence should be re-evaluated in adulthood and appropriate changes made to their cholesterol-lowering regimen to achieve adult treatment goals. Secondary Prevention of Coronary Events In patients with coronary heart disease, Lescol and Lescol XL are indicated to reduce the risk of undergoing coronary revascularization procedures. Atherosclerosis Lescol and Lescol XL are also indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total and LDL cholesterol to target levels. uuid:27089b9d-7305-46c8-9dab-7977fa8848bb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:38562 biolink:treats MONDO:0021661 PMID:41385096 "[{""id"":""uuid:27f43bae-af6a-4dc8-8ceb-fa772b201346"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:020810aa-4610-4e35-8a4f-0cf065fbe2ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol (see National Cholesterol Education Program [NCEP] Treatment Guidelines, below). Hypercholesterolemia (heterozygous familial and nonfamilial) and Mixed Dyslipidemia Lescol ® (fluvastatin sodium) and Lescol ® XL (fluvastatin sodium) are indicated to reduce elevated total cholesterol (Total-C), LDL-C, TG and Apo B levels, and to increase HDL-C in patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson Type IIa and IIb) whose response to dietary restriction of saturated fat and cholesterol and other nonpharmacological measures has not been adequate. Heterozygous Familial Hypercholesterolemia in Pediatric Patients Lescol and Lescol XL are indicated as an adjunct to diet to reduce Total-C, LDL-C, and Apo B levels in adolescent boys and girls who are at least one year post-menarche, 10-16 years of age, with heterozygous familial hypercholesterolemia whose response to dietary restriction has not been adequate and the following findings are present: LDL-C remains > 190 mg/dL or LDL-C remains > 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other cardiovascular disease risk factors are present. Therapy with lipid-altering agents should be considered only after secondary causes for hyperlipidemia such as poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other medication, or alcoholism, have been excluded. Prior to initiation of fluvastatin sodium, a lipid profile should be performed to measure Total-C, HDL-C and TG. For patients with TG <400 mg/dL (<4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = Total-C - HDL-C - 1/5 TG For TG levels >400 mg/dL (>4.5 mmol/L), this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In many hypertriglyceridemic patients LDL-C may be low or normal despite elevated Total-C. In such cases, Lescol is not indicated. Lipid determinations should be performed at intervals of no less than 4 weeks and dosage adjusted according to the patient’s response to therapy. The National Cholesterol Education Program (NCEP) Treatment Guidelines are summarized below: Table 3 NCEP Treatment Guidelines: LDL-C Goals and Cutpoints for Therapeutic Lifestyle Changes and Drug Therapy in Different Risk Categories Risk Category LDL Goal (mg/dL) LDL Level at Which to Initiate Therapeutic Lifestyle Changes (mg/dL) LDL Level at Which to Consider Drug Therapy (mg/dL) CHD† or CHD risk equivalents (10-year risk >20%) <100 > 100 > 130 (100-129: drug optional)†† 2+ Risk factors (10-year risk < 20%) <130 > 130 10-year risk 10%-20%: >130 10-year risk <10%: > 160 0-1 Risk factor††† <160 > 160 > 190 (160-189: LDL-lowering drug optional) † CHD, coronary heart disease †† Some authorities recommend use of LDL-lowering drugs in this category if an LDL-C level of <100mg/dL cannot be achieved by therapeutic lifestyle changes. Others prefer use of drugs that primarily modify triglycerides and HDL-C, e.g. , nicotinic acid or fibrate. Clinical judgement also may call for deferring drug therapy in this subcategory. ††† Almost all people with 0-1 risk factor have 10-year risk <10%; thus, 10-year risk assessment in people with 0 -1 risk factor is not necessary. After the LDL-C goal has been achieved, if the TG is still > 200 mg/dL, non-HDL-C (Total-C minus HDL-C) becomes a secondary target of therapy. Non-HDL-C goals are set 30 mg/dL higher than LDL-C goals for each risk category. At the time of hospitalization for an acute coronary event, consideration can be given to initiating drug therapy at discharge if the LDL-C level is > 130 mg/dL (NCEP-ATP II). Since the goal of treatment is to lower LDL-C, the NCEP recommends that the LDL-C levels be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the Total-C be used to monitor therapy. Table 4 Classification of Hyperlipoproteinemias Lipid Elevations Type Lipoproteins Elevated Major Minor I (rare) Chylomicrons TG ↑→C IIa LDL C – IIb LDL, VLDL C TG III (rare) IDL C/TG – IV VLDL TG ↑→C V (rare) Chylomicrons, VLDL TG ↑→C C = cholesterol, TG = triglycerides, LDL = low density lipoprotein, VLDL = very low density lipoprotein, IDL = intermediate density lipoprotein Neither Lescol nor Lescol XL have been studied in conditions where the major abnormality is elevation of chylomicrons, VLDL, or IDL (i.e., hyperlipoproteinemia Types I, III, IV, or V). The NCEP classification of cholesterol levels in pediatric patients with a familial history of hypercholesterolemia or premature cardiovascular disease is summarized below: Category Total-C (mg/dL) LDL-C (mg/dL) Acceptable Borderline High <170 170-199 > 200 <110 110-129 > 130 Children treated with fluvastatin in adolescence should be re-evaluated in adulthood and appropriate changes made to their cholesterol-lowering regimen to achieve adult treatment goals. Secondary Prevention of Coronary Events In patients with coronary heart disease, Lescol and Lescol XL are indicated to reduce the risk of undergoing coronary revascularization procedures. Atherosclerosis Lescol and Lescol XL are also indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total and LDL cholesterol to target levels. uuid:3911c84b-cc15-4b38-a881-2cdd420688ac biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50848 biolink:treats MONDO:0006604 PMID:41385096 "[{""id"":""uuid:c050d4b9-6dfe-42cf-a096-5d39587728f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:22c1dc36-f8b6-4e69-a73f-7e2d3edfd46e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LOTEMAX is indicated for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation. LOTEMAX is less effective than prednisolone acetate 1% in two 28-day controlled clinical studies in acute anterior uveitis, where 72% of patients treated with LOTEMAX experienced resolution of anterior chamber cells, compared to 87% of patients treated with prednisolone acetate 1%. The incidence of patients with clinically significant increases in IOP (≥10 mmHg) was 1% with LOTEMAX and 6% with prednisolone acetate 1%. LOTEMAX should not be used in patients who require a more potent corticosteroid for this indication. LOTEMAX is also indicated for the treatment of post-operative inflammation following ocular surgery. uuid:0e90604e-2132-4b1c-9586-1328ee81539d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50848 biolink:treats MONDO:0033816 PMID:41385096 "[{""id"":""uuid:4fc8f33f-6210-481f-86e6-e2dec95efe2f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:477cebb1-35ee-46da-b311-dc77542f0b54"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LOTEMAX is indicated for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation. LOTEMAX is less effective than prednisolone acetate 1% in two 28-day controlled clinical studies in acute anterior uveitis, where 72% of patients treated with LOTEMAX experienced resolution of anterior chamber cells, compared to 87% of patients treated with prednisolone acetate 1%. The incidence of patients with clinically significant increases in IOP (≥10 mmHg) was 1% with LOTEMAX and 6% with prednisolone acetate 1%. LOTEMAX should not be used in patients who require a more potent corticosteroid for this indication. LOTEMAX is also indicated for the treatment of post-operative inflammation following ocular surgery. uuid:898d962c-9526-4f2a-a7d9-e68ec24bca4c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50848 biolink:treats UMLS:C1275687 PMID:41385096 "[{""id"":""uuid:0dd3f405-a4ad-4ef6-bf4f-cd892a8b652c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4ed8d90c-5f99-47f2-a176-6823d2f6062f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LOTEMAX is indicated for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation. LOTEMAX is less effective than prednisolone acetate 1% in two 28-day controlled clinical studies in acute anterior uveitis, where 72% of patients treated with LOTEMAX experienced resolution of anterior chamber cells, compared to 87% of patients treated with prednisolone acetate 1%. The incidence of patients with clinically significant increases in IOP (≥10 mmHg) was 1% with LOTEMAX and 6% with prednisolone acetate 1%. LOTEMAX should not be used in patients who require a more potent corticosteroid for this indication. LOTEMAX is also indicated for the treatment of post-operative inflammation following ocular surgery. uuid:f522e524-87c6-4c2a-ab18-3d0dc0ff92ec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50848 biolink:treats MONDO:0006814 PMID:41385096 "[{""id"":""uuid:083b97c4-556c-47b1-ab09-bd9e68cb770f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:114a1f04-c974-4818-832a-60d63bdb5da3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LOTEMAX is indicated for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation. LOTEMAX is less effective than prednisolone acetate 1% in two 28-day controlled clinical studies in acute anterior uveitis, where 72% of patients treated with LOTEMAX experienced resolution of anterior chamber cells, compared to 87% of patients treated with prednisolone acetate 1%. The incidence of patients with clinically significant increases in IOP (≥10 mmHg) was 1% with LOTEMAX and 6% with prednisolone acetate 1%. LOTEMAX should not be used in patients who require a more potent corticosteroid for this indication. LOTEMAX is also indicated for the treatment of post-operative inflammation following ocular surgery. uuid:ae6a66da-68b8-4968-84e6-39498f7b5182 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50848 biolink:treats UMLS:C0010543 PMID:41385096 "[{""id"":""uuid:9d312a54-1445-4ad2-8fb8-a836a4a51041"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b8e256ae-b955-4f1b-ae1f-6e854ec8a1ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LOTEMAX is indicated for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation. LOTEMAX is less effective than prednisolone acetate 1% in two 28-day controlled clinical studies in acute anterior uveitis, where 72% of patients treated with LOTEMAX experienced resolution of anterior chamber cells, compared to 87% of patients treated with prednisolone acetate 1%. The incidence of patients with clinically significant increases in IOP (≥10 mmHg) was 1% with LOTEMAX and 6% with prednisolone acetate 1%. LOTEMAX should not be used in patients who require a more potent corticosteroid for this indication. LOTEMAX is also indicated for the treatment of post-operative inflammation following ocular surgery. uuid:0742359d-6a35-45b8-88c5-c9466ee95627 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50848 biolink:treats MONDO:0006668 PMID:41385096 "[{""id"":""uuid:2c9da5d8-ed2c-43dd-a886-d0b5f575d465"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4912a096-3c74-43ab-a858-7a6517db0948"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LOTEMAX is indicated for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation. LOTEMAX is less effective than prednisolone acetate 1% in two 28-day controlled clinical studies in acute anterior uveitis, where 72% of patients treated with LOTEMAX experienced resolution of anterior chamber cells, compared to 87% of patients treated with prednisolone acetate 1%. The incidence of patients with clinically significant increases in IOP (≥10 mmHg) was 1% with LOTEMAX and 6% with prednisolone acetate 1%. LOTEMAX should not be used in patients who require a more potent corticosteroid for this indication. LOTEMAX is also indicated for the treatment of post-operative inflammation following ocular surgery. uuid:a8e0e51f-477c-4528-8fd6-7d55cf34775b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50848 biolink:treats MONDO:0006651 PMID:41385096 "[{""id"":""uuid:79537bcf-16c4-4bb1-9435-780437da1ec0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:94cbd405-8761-42e6-aa58-36ec9ef9b58a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LOTEMAX is indicated for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation. LOTEMAX is less effective than prednisolone acetate 1% in two 28-day controlled clinical studies in acute anterior uveitis, where 72% of patients treated with LOTEMAX experienced resolution of anterior chamber cells, compared to 87% of patients treated with prednisolone acetate 1%. The incidence of patients with clinically significant increases in IOP (≥10 mmHg) was 1% with LOTEMAX and 6% with prednisolone acetate 1%. LOTEMAX should not be used in patients who require a more potent corticosteroid for this indication. LOTEMAX is also indicated for the treatment of post-operative inflammation following ocular surgery. uuid:424ce6ca-df44-4cce-a859-8585c8da17fe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49713 biolink:treats HP:0100754 PMID:41385096 "[{""id"":""uuid:18ce6316-8d7c-4516-945d-6c06a844a8c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f5f6f764-3617-46b7-86c5-b706619cda74"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lithium carbonate is indicated in the treatment of manic episodes of manic-depressive illness. Maintenance therapy prevents or diminishes the intensity of subsequent episodes in those manic-depressive patients with a history of mania. Typical symptoms of mania include pressure of speech, motor hyperactivity, reduced need for sleep, flight of ideas, grandiosity, elation, poor judgment, aggressiveness and possibly hostility. When given to a patient experiencing a manic episode, lithium carbonate may produce a normalization of symptomatology within 1 to 3 weeks. uuid:35d9edd8-697c-4d32-8267-b9826f8ec6ef biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:372890 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:8bf2a149-d61a-4fe2-b5d8-930ba7570dd2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bf287aad-26de-4aa7-bd1f-1817e809ed72"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Metoprolol tartrate and hydrochlorothiazide tablets are indicated for the management of hypertension. This fixed-combination drug is not indicated for initial therapy of hypertension. If the fixed combination represents the dose titrated to the individual patient's needs, therapy with the fixed combination may be more convenient than with the separate components. uuid:98fdea18-b730-4496-92fb-f67398b395b8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0005314 PMID:41385096 "[{""id"":""uuid:00ecd8a4-a485-400f-8613-237170b626e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c6348695-941f-456d-9a79-71c9ccc4d7e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Nervous System Acute exacerbations of multiple sclerosis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:9836155c-a360-456f-a914-138b7e10e014 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6909 biolink:treats MONDO:0005316 PMID:41385096 "[{""id"":""uuid:f348732e-9174-4403-bf6b-c0c7e75dc43e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:44297732-8dd3-47ce-aeac-dd5e5185dda1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:4c1f3972-3f55-4f24-bfcf-8fd109bf5d4c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] METROGEL-VAGINAL is indicated in the treatment of bacterial vaginosis (formerly referred to as Haemophilus vaginitis, ­Gardnerella vaginitis, nonspecific vaginitis, Corynebacterium vaginitis, or anaerobic vaginosis). NOTE: For purposes of this indication, a clinical diagnosis of bacterial vaginosis is usually defined by the presence of a homogeneous vaginal discharge that (a) has a pH of greater than 4.5, (b) emits a “fishy” amine odor when mixed with a 10% KOH solution, and (c) contains clue cells on microscopic examination. Gram’s stain results consistent with a diagnosis of bacterial vaginosis include (a) markedly reduced or absent Lactobacillus morphology, (b) predominance of Gardnerella morphotype, and (c) absent or few white blood cells. Other pathogens commonly associated with vulvovaginitis, e.g., Trichomonas vaginalis , Chlamydia trachomatis , ­ N. gonorrhoeae , Candida albicans , and Herpes simplex virus should be ruled out.|[PMDA] Drugs with a new indication and new dosages for the treatment of bacterial vaginosis. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:bc9464bf-476e-4627-be6f-dd633d791876 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6909 biolink:treats UMLS:C1622505 PMID:41385096 "[{""id"":""uuid:51b7cad0-543d-41ae-8fdb-7329b3365ba8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c80db1a3-a462-4cb9-9067-f9844e5369ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] METROGEL-VAGINAL is indicated in the treatment of bacterial vaginosis (formerly referred to as Haemophilus vaginitis, ­Gardnerella vaginitis, nonspecific vaginitis, Corynebacterium vaginitis, or anaerobic vaginosis). NOTE: For purposes of this indication, a clinical diagnosis of bacterial vaginosis is usually defined by the presence of a homogeneous vaginal discharge that (a) has a pH of greater than 4.5, (b) emits a “fishy” amine odor when mixed with a 10% KOH solution, and (c) contains clue cells on microscopic examination. Gram’s stain results consistent with a diagnosis of bacterial vaginosis include (a) markedly reduced or absent Lactobacillus morphology, (b) predominance of Gardnerella morphotype, and (c) absent or few white blood cells. Other pathogens commonly associated with vulvovaginitis, e.g., Trichomonas vaginalis , Chlamydia trachomatis , ­ N. gonorrhoeae , Candida albicans , and Herpes simplex virus should be ruled out. uuid:d8467127-fa88-42fd-a00c-24d3a577cad9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6909 biolink:treats MONDO:0023557 PMID:41385096 "[{""id"":""uuid:391275e6-7f75-4569-9790-7419d9eeae17"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b01da79a-b8e4-4e0a-825b-b09c93f568dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] METROGEL-VAGINAL is indicated in the treatment of bacterial vaginosis (formerly referred to as Haemophilus vaginitis, ­Gardnerella vaginitis, nonspecific vaginitis, Corynebacterium vaginitis, or anaerobic vaginosis). NOTE: For purposes of this indication, a clinical diagnosis of bacterial vaginosis is usually defined by the presence of a homogeneous vaginal discharge that (a) has a pH of greater than 4.5, (b) emits a “fishy” amine odor when mixed with a 10% KOH solution, and (c) contains clue cells on microscopic examination. Gram’s stain results consistent with a diagnosis of bacterial vaginosis include (a) markedly reduced or absent Lactobacillus morphology, (b) predominance of Gardnerella morphotype, and (c) absent or few white blood cells. Other pathogens commonly associated with vulvovaginitis, e.g., Trichomonas vaginalis , Chlamydia trachomatis , ­ N. gonorrhoeae , Candida albicans , and Herpes simplex virus should be ruled out. uuid:e788fd05-e78b-4275-a407-7d1429d13a3b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6909 biolink:treats MONDO:0007019 PMID:41385096 "[{""id"":""uuid:81d17e12-54ff-4096-bad1-31b39299d31a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ce19201f-a3c7-4516-8d60-a708857eb3b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] METROGEL-VAGINAL is indicated in the treatment of bacterial vaginosis (formerly referred to as Haemophilus vaginitis, ­Gardnerella vaginitis, nonspecific vaginitis, Corynebacterium vaginitis, or anaerobic vaginosis). NOTE: For purposes of this indication, a clinical diagnosis of bacterial vaginosis is usually defined by the presence of a homogeneous vaginal discharge that (a) has a pH of greater than 4.5, (b) emits a “fishy” amine odor when mixed with a 10% KOH solution, and (c) contains clue cells on microscopic examination. Gram’s stain results consistent with a diagnosis of bacterial vaginosis include (a) markedly reduced or absent Lactobacillus morphology, (b) predominance of Gardnerella morphotype, and (c) absent or few white blood cells. Other pathogens commonly associated with vulvovaginitis, e.g., Trichomonas vaginalis , Chlamydia trachomatis , ­ N. gonorrhoeae , Candida albicans , and Herpes simplex virus should be ruled out. uuid:1bcf59d6-f92f-474e-baf9-71f3e048ecf1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29103 biolink:treats MONDO:0012692 PMID:41385096 "[{""id"":""uuid:c6ca700c-b29c-43ad-b180-601a162ba18b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4f7a0e6e-a932-4ae7-a28d-3a34d608320a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Urocit ® -K is a citrate salt of potassium indicated for the management of: Renal tubular acidosis (RTA) with calcium stones ( 1.1 ) Hypocitraturic calcium oxalate nephrolithiasis of any etiology ( 1.2 ) Uric acid lithiasis with or without calcium stones ( 1.3 ) uuid:c6529ebc-8e3a-4ab0-a21c-c74ee4807adf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29103 biolink:treats MONDO:0024647 PMID:41385096 "[{""id"":""uuid:68cfbfeb-dc7a-4731-a5df-0194e5bd371d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6b645c6f-470d-4374-a283-8e6ca9dc99f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Urocit ® -K is a citrate salt of potassium indicated for the management of: Renal tubular acidosis (RTA) with calcium stones ( 1.1 ) Hypocitraturic calcium oxalate nephrolithiasis of any etiology ( 1.2 ) Uric acid lithiasis with or without calcium stones ( 1.3 ) uuid:a4d51df8-fc1d-40ac-a98e-eb4bafc199aa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6822 biolink:treats MONDO:0005338 PMID:41385096 "[{""id"":""uuid:b7965fc1-46fa-45d4-82a2-d66c183ee116"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:709b67c0-dc06-4bb4-96ac-8580b784a18c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methazolamide is indicated in the treatment of ocular conditions where lowering intraocular pressure is likely to be of therapeutic benefit, such as chronic open-angle glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where lowering the intraocular pressure is desired before surgery. uuid:0dc439d7-9ae4-4dd1-bbf3-0f958b6bc79a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6822 biolink:treats UMLS:C0149893 PMID:41385096 "[{""id"":""uuid:7e29b5e6-57d7-4eb0-84bf-cafb22c2f831"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f79a0910-ff2e-45b4-b8c6-f0c74f6e7583"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methazolamide is indicated in the treatment of ocular conditions where lowering intraocular pressure is likely to be of therapeutic benefit, such as chronic open-angle glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where lowering the intraocular pressure is desired before surgery. uuid:7942b3eb-fa7b-464e-bdd4-829e9553118a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6822 biolink:treats MONDO:0001817 PMID:41385096 "[{""id"":""uuid:0c7fc4c8-cdc0-4336-958e-b32798f77d31"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9509f4b3-1f48-4f11-a0a6-268efbd642e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methazolamide is indicated in the treatment of ocular conditions where lowering intraocular pressure is likely to be of therapeutic benefit, such as chronic open-angle glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where lowering the intraocular pressure is desired before surgery. uuid:42feaf40-79fc-4a2e-aee6-53a4fc845d18 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0015129 PMID:41385096 "[{""id"":""uuid:e5f8d174-722c-427b-88aa-c828e976f4bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a25c9d05-e3a6-43c3-a376-c854e9cb84e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone tablets are indicated in the following conditions: Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoid where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis Collagen Diseases : During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis Dermatologic Diseases : Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases : Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis Respiratory Diseases : Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis Hematologic Disorders : Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Diseases : For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States : To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases : To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Nervous System: Acute exacerbations of multiple sclerosis Miscellaneous : Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:a3adb1cb-cfae-48e9-9017-e85174db206e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0043370 PMID:41385096 "[{""id"":""uuid:d4b3ceb7-ab4e-4761-9b76-40d2cea37e9a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f9aea55f-9d3e-43b5-ab2a-70dec3cbeee6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone tablets are indicated in the following conditions: Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoid where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis Collagen Diseases : During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis Dermatologic Diseases : Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases : Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis Respiratory Diseases : Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis Hematologic Disorders : Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Diseases : For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States : To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases : To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Nervous System: Acute exacerbations of multiple sclerosis Miscellaneous : Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:76f4fd43-cfdb-4a36-92e5-3f48aa8992e0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:24847953 biolink:treats HP:0005202 PMID:41385096 "[{""id"":""uuid:f9c1673d-fad2-47c2-90f8-b6eaa4220fc7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:70308f2c-41df-4f4e-8090-d7e5d7f0ede7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c0d63c1c-f29c-4208-85d1-f253e7a2e5ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The components in PREVPAC (PREVACID, amoxicillin, and clarithromycin) are indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or one-year history of a duodenal ulcer) to eradicate H. pylori . Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence (see CLINICAL STUDIES and DOSAGE AND ADMINISTRATION ) . To reduce the development of drug-resistant bacteria and maintain the effectiveness of PREVPAC and other antibacterial drugs, PREVPAC should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Please refer to the full prescribing information for amoxicillin and clarithromycin.|[PMDA] Revision of the dosage for a combination therapy of amoxicillin, clarithromycin, and omeprazole indicated for treatment of Helicobacter pylori infections in patients with gastric ulcer or duodenal ulcer. uuid:8ade0a98-0aca-45e8-a518-946794a0623f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:24847953 biolink:treats MONDO:0005412 PMID:41385096 "[{""id"":""uuid:d24b475e-4f3e-408e-bec7-1f1d80e9d195"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7cdb0a71-3c8f-401e-b61c-ec8d54ce2958"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ac994ec8-e093-470d-9c2d-1686b9967d45"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The components in PREVPAC (PREVACID, amoxicillin, and clarithromycin) are indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or one-year history of a duodenal ulcer) to eradicate H. pylori . Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence (see CLINICAL STUDIES and DOSAGE AND ADMINISTRATION ) . To reduce the development of drug-resistant bacteria and maintain the effectiveness of PREVPAC and other antibacterial drugs, PREVPAC should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Please refer to the full prescribing information for amoxicillin and clarithromycin.|[PMDA] Addition of a new dosage indicated for a combination therapy with sodium rabeprazole, amoxicillin, and clarithromycin to eradicate Helicobacter pylori in patients with gastric or duodenal ulcer. uuid:6718d013-8b54-44e9-a666-0fdfcc12f537 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:9874151 biolink:treats MONDO:0011438 PMID:41385096 "[{""id"":""uuid:8ff2659b-def9-488c-9ba7-c4ef4ea3decd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8ce38d96-8d9c-4ec8-9df9-d9d64ad180be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gianvi™ (drospirenone and ethinyl estradiol tablets) 3 mg/0.02 mg is indicated for the prevention of pregnancy in women who elect to use an oral contraceptive. Oral contraceptives are highly effective. Table II lists the typical unintended pregnancy rates for users of combination oral contraceptives and other methods of contraception. The efficacy of these contraceptive methods, except sterilization and contraceptive implants and IUDs, depends upon the reliability with which they are used. Correct and consistent use of methods can result in lower failure rates. Gianvi™ (drospirenone and ethinyl estradiol tablets) is indicated for the treatment of moderate acne vulgaris in women at least 14 years of age, who have no known contraindications to oral contraceptive therapy and have achieved menarche. Gianvi™ (drospirenone and ethinyl estradiol tablets) should be used for the treatment of acne only if the patient desires an oral contraceptive for birth control. TABLE II: PERCENTAGE OF WOMEN EXPERIENCING AN UNINTENDED PREGNANCY DURING THE FIRST YEAR OF TYPICAL USE AND FIRST YEAR OF PERFECT USE OF CONTRACEPTION AND THE PERCENTAGE CONTINUING USE AT THE END OF THE FIRST YEAR: UNITED STATES. % of Women Experiencing an Unintended Pregnancy Within the First Year of Use % of Women Continuing Use at One Year Method (1) Typical Use (2) Perfect Use (3) (4) Chance 85 85 40 Spermicides 26 6 63 Periodic abstinence 25 Calendar 9 Ovulation method 3 Sympto-thermal 2 Post-ovulation 1 Withdrawal 19 4 Cap With spermicidal cream or jelly. Parous women 40 26 42 Nulliparous women 20 9 56 Sponge Parous women 40 20 42 Nulliparous women 20 9 56 Diaphragm 20 6 56 Condom Female (Reality) 21 5 56 Male 14 3 61 Pill 5 71 progestin only 0.5 combined 0.1 IUD Progesterone T 2 1.5 81 Copper T 380A 0.8 0.6 78 Lng 20 0.1 0.1 81 Depo Provera 0.3 0.3 70 Norplant and Norplant-2 0.05 0.05 88 Female sterilization 0.5 0.5 100 Male sterilization 0.15 0.1 100 Emergency Contraceptive Pills: Treatment initiated within 72 hours after unprotected intercourse reduces the risk of pregnancy by at least 75%. Lactational Amenorrhea Method: LAM is a highly effective, temporary method of contraception. Source: Trussell J, Contraceptive efficacy. In Hatcher RA, Trussell J, Stewart F, Cates W, Stewart GK, Guest F, Kowal D, Contraceptive Technology: Seventeenth Revised Edition . New York NY: Irvington Publishers, 1998. uuid:ed85e205-4690-4f29-891d-eced663a5a89 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17303 biolink:treats MONDO:0043775 PMID:41385096 "[{""id"":""uuid:8877f759-660f-4b2e-b02d-32b8d7972c60"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:73a374e7-6aab-446e-9f95-bf3652794b0c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Morphine sulfate oral solution (10 mg per 5 mL and 20 mg per 5 mL) are formulations of morphine, an opioid analgesic, indicated for the relief of moderate to severe acute and chronic pain where use of an opioid analgesic is appropriate. Morphine sulfate oral solution 100 mg per 5 mL (20 mg/mL) is an opioid analgesic indicated for the relief of moderate to severe acute and chronic pain in opioid-tolerant patients. Morphine sulfate oral solution 100 mg per 5 mL (20 mg/mL) may cause fatal respiratory depression when administered to patients not previously exposed to opioids. Patients considered to be opioid tolerant are those who are taking at least 60 mg oral morphine per day, or at least 30 mg of oral oxycodone per day, or at least 12 mg hydromorphone per day, or an equianalgesic dose of another opioid, for a week or longer. uuid:eefaffe4-7b0b-4675-846f-7cd223003c03 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3127 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:f9b4c800-30d8-4f2c-a8d5-78cff28303c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:540b783d-d123-4a21-b6d4-5777949e49c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BISOPROLOL FUMARATE is indicated in the management of hypertension. It may be used alone or in combination with other antihypertensive agents. uuid:986d83f8-82bd-445a-bbd6-161c7d87382b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:24783652 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:539c0ff7-d23e-4253-a552-c701f782cdc6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:50f87846-5784-4cd3-812e-27b2de40f86f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ceabe985-05a0-43e1-bcc2-1ea502432948"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Losartan potassium and hydrochlorothiazide tablets are indicated for the treatment of hypertension. This fixed dose combination is not indicated for initial therapy of hypertension, except when the hypertension is severe enough that the value of achieving prompt blood pressure control exceeds the risk of initiating combination therapy in these patients (see CLINICAL PHARMACOLOGY , Pharmacodynamics and Clinical Effects , and DOSAGE AND ADMINISTRATION ).|[PMDA] A drug with a new dosage in an additional dosage form. The drug is indicated for the treatment of hypertension. uuid:9c8069b3-666f-4b8d-8f0a-0573f7558078 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1154168 biolink:treats MONDO:0005271 PMID:41385096 "[{""id"":""uuid:b84e19da-2cec-4516-9550-7fb5b0ab802a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:232f9c51-9da8-4e9e-be2e-22532cc33325"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For relief of coughs and upper respiratory symptoms, including nasal congestion, associated with allergy or the common cold. uuid:7d2bec51-759b-4194-bd47-f6e84d1b2913 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1154168 biolink:treats MONDO:0005709 PMID:41385096 "[{""id"":""uuid:6f51810e-849d-4ea5-81f3-154724ab69c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:75e006e9-7712-4453-8efc-312616657a70"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For relief of coughs and upper respiratory symptoms, including nasal congestion, associated with allergy or the common cold. uuid:6e4d2641-d768-4fc2-a4bf-ad962c3e40d4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:70746 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:4e9c2cd1-5cdd-4063-a117-57d092c8c070"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:0346b974-1c91-4888-afe3-beb6fc7bb500"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:0a3cdd56-1bca-44d1-a1f3-39c4e955dabb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PRADAXA is indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.|[EMA] Pradaxa 75 mgPrimary prevention of venous thromboembolic events in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery.Pradaxa 110 mgPrimary prevention of venous thromboembolic events in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery.Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischemic attack (TIA); age ≥ 75 years; heart failure (NYHA Class ≥ II); diabetes mellitus; hypertension.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.Pradaxa 150 mgPrevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischemic attack (TIA); age ≥ 75 years; heart failure (NYHA Class ≥ II); diabetes mellitus; hypertension.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. uuid:aac9cbe2-cc75-47dc-9a88-026c03186b4e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:70746 biolink:treats UMLS:C5400523 PMID:41385096 "[{""id"":""uuid:5fd7b6a2-b0fa-43ca-8710-1f54330adcb2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:94871d79-73fe-429a-9ddf-3f9885e46e97"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:07c5e40b-4882-4cb6-bbaf-f743050cb8e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PRADAXA is indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.|[PMDA] Drugs with a new active ingredient indicated for prevention of ischemic stroke and systemic embolism in patients with nonvalvular atrial fibrillation. uuid:a1298d7a-2d4a-4df4-8108-980d63971751 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:70746 biolink:treats MONDO:0004981 PMID:41385096 "[{""id"":""uuid:7a07f015-46d9-4a52-9336-1b460ac32628"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8a52a1f2-6cc5-441f-a93e-840367eb3e07"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PRADAXA is indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation. uuid:80f48b21-16cd-4ea3-9b5b-24f45ca9b9d8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28001 biolink:treats UMLS:C0520767 PMID:41385096 "[{""id"":""uuid:1bc8b705-8736-4f02-8ecd-f0b22a13835c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4660920b-a452-4391-9333-a2cd03e55a93"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vancomycin is indicated for the treatment of serious or severe infections caused by susceptible strains of methicillin-resistant (beta-lactam-resistant) staphylococci. It is indicated for penicillin-allergic patients, for patients who cannot receive or who have failed to respond to other drugs, including the penicillins or cephalosporins, and for infections caused by vancomycin-susceptible organisms that are resistant to other antimicrobial drugs. Vancomycin is indicated for initial therapy when methicillin-resistant staphylococci are suspected, but after susceptibility data are available, therapy should be adjusted accordingly. Vancomycin hydrochloride is effective in the treatment of staphylococcal endocarditis. Its effectiveness has been documented in other infections due to staphylococci, including septicemia, bone infections, lower respiratory tract infections, and skin and skin-structure infections. When staphylococcal infections are localized and purulent, antibiotics are used as adjuncts to appropriate surgical measures. Vancomycin hydrochloride has been reported to be effective alone or in combination with an aminoglycoside for endocarditis caused by S. viridans or S. bovis . For endocarditis caused by enterococci (e.g., E. faecalis ), vancomycin hydrochloride has been reported to be effective only in combination with an aminoglycoside. Vancomycin has been reported to be effective for the treatment of diphtheroid endocarditis. Vancomycin has been used successfully in combination with either rifampin, an aminoglycoside, or both in early-onset prosthetic valve endocarditis caused by S. epidermidis or diphtheroids. Specimens for bacteriologic cultures should be obtained in order to isolate and identify causative organisms and to determine their susceptibilities to vancomycin. The parenteral form of Sterile Vancomycin Hydrochloride may be administered orally for treatment of antibiotic-associated pseudomembranous colitis produced by C. difficile and for staphylococcal enterocolitis. Parenteral administration of vancomycin hydrochloride alone is of unproven benefit for these indications. Vancomycin is not effective by the oral route for other types of infection. To reduce the development of drug-resistant bacteria and maintain the effectiveness of vancomycin and other antibacterial drugs, vancomycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:8ecdd447-3ac1-4321-9e28-eb02d92e9342 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28001 biolink:treats MONDO:0700217 PMID:41385096 "[{""id"":""uuid:e4b14ce6-fd77-4bda-b5a8-78df1db02fce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b77a2d49-ef50-4339-9b95-3f2e7f563b25"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vancomycin is indicated for the treatment of serious or severe infections caused by susceptible strains of methicillin-resistant (beta-lactam-resistant) staphylococci. It is indicated for penicillin-allergic patients, for patients who cannot receive or who have failed to respond to other drugs, including the penicillins or cephalosporins, and for infections caused by vancomycin-susceptible organisms that are resistant to other antimicrobial drugs. Vancomycin is indicated for initial therapy when methicillin-resistant staphylococci are suspected, but after susceptibility data are available, therapy should be adjusted accordingly. Vancomycin hydrochloride is effective in the treatment of staphylococcal endocarditis. Its effectiveness has been documented in other infections due to staphylococci, including septicemia, bone infections, lower respiratory tract infections, and skin and skin-structure infections. When staphylococcal infections are localized and purulent, antibiotics are used as adjuncts to appropriate surgical measures. Vancomycin hydrochloride has been reported to be effective alone or in combination with an aminoglycoside for endocarditis caused by S. viridans or S. bovis . For endocarditis caused by enterococci (e.g., E. faecalis ), vancomycin hydrochloride has been reported to be effective only in combination with an aminoglycoside. Vancomycin has been reported to be effective for the treatment of diphtheroid endocarditis. Vancomycin has been used successfully in combination with either rifampin, an aminoglycoside, or both in early-onset prosthetic valve endocarditis caused by S. epidermidis or diphtheroids. Specimens for bacteriologic cultures should be obtained in order to isolate and identify causative organisms and to determine their susceptibilities to vancomycin. The parenteral form of Sterile Vancomycin Hydrochloride may be administered orally for treatment of antibiotic-associated pseudomembranous colitis produced by C. difficile and for staphylococcal enterocolitis. Parenteral administration of vancomycin hydrochloride alone is of unproven benefit for these indications. Vancomycin is not effective by the oral route for other types of infection. To reduce the development of drug-resistant bacteria and maintain the effectiveness of vancomycin and other antibacterial drugs, vancomycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:799b140c-8bb5-4bf1-866d-2be75158a288 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28001 biolink:treats MONDO:0005246 PMID:41385096 "[{""id"":""uuid:f968e13b-510a-4e1f-9c8a-3db1a2546ad5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6202fef7-5f0d-42a6-b382-8738be638fc0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:030966b2-2e2a-40b5-bc75-26d66a38bfb8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vancomycin is indicated for the treatment of serious or severe infections caused by susceptible strains of methicillin-resistant (beta-lactam-resistant) staphylococci. It is indicated for penicillin-allergic patients, for patients who cannot receive or who have failed to respond to other drugs, including the penicillins or cephalosporins, and for infections caused by vancomycin-susceptible organisms that are resistant to other antimicrobial drugs. Vancomycin is indicated for initial therapy when methicillin-resistant staphylococci are suspected, but after susceptibility data are available, therapy should be adjusted accordingly. Vancomycin hydrochloride is effective in the treatment of staphylococcal endocarditis. Its effectiveness has been documented in other infections due to staphylococci, including septicemia, bone infections, lower respiratory tract infections, and skin and skin-structure infections. When staphylococcal infections are localized and purulent, antibiotics are used as adjuncts to appropriate surgical measures. Vancomycin hydrochloride has been reported to be effective alone or in combination with an aminoglycoside for endocarditis caused by S. viridans or S. bovis . For endocarditis caused by enterococci (e.g., E. faecalis ), vancomycin hydrochloride has been reported to be effective only in combination with an aminoglycoside. Vancomycin has been reported to be effective for the treatment of diphtheroid endocarditis. Vancomycin has been used successfully in combination with either rifampin, an aminoglycoside, or both in early-onset prosthetic valve endocarditis caused by S. epidermidis or diphtheroids. Specimens for bacteriologic cultures should be obtained in order to isolate and identify causative organisms and to determine their susceptibilities to vancomycin. The parenteral form of Sterile Vancomycin Hydrochloride may be administered orally for treatment of antibiotic-associated pseudomembranous colitis produced by C. difficile and for staphylococcal enterocolitis. Parenteral administration of vancomycin hydrochloride alone is of unproven benefit for these indications. Vancomycin is not effective by the oral route for other types of infection. To reduce the development of drug-resistant bacteria and maintain the effectiveness of vancomycin and other antibacterial drugs, vancomycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.|[PMDA] A drug with new additional indications for the treatment of: sepsis, infective endocarditis, secondary infection of trauma, burn or surgical wounds, osteomyelitis, arthritis, peritonitis and purulent meningitis caused by vancomycin-sensitive methicillin-resistant coagulase-negative Staphylococcus (MRCNS); or febrile neutropenia which is suspected of MRSA or MRCNS infection. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:79b0f973-f72a-4f82-9fe7-f5a3df36c264 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28001 biolink:treats MONDO:0024355 PMID:41385096 "[{""id"":""uuid:b2938720-1a78-4d19-826a-b76d38be3050"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:76b142c5-c0cb-4567-9b48-41014914ed80"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vancomycin is indicated for the treatment of serious or severe infections caused by susceptible strains of methicillin-resistant (beta-lactam-resistant) staphylococci. It is indicated for penicillin-allergic patients, for patients who cannot receive or who have failed to respond to other drugs, including the penicillins or cephalosporins, and for infections caused by vancomycin-susceptible organisms that are resistant to other antimicrobial drugs. Vancomycin is indicated for initial therapy when methicillin-resistant staphylococci are suspected, but after susceptibility data are available, therapy should be adjusted accordingly. Vancomycin hydrochloride is effective in the treatment of staphylococcal endocarditis. Its effectiveness has been documented in other infections due to staphylococci, including septicemia, bone infections, lower respiratory tract infections, and skin and skin-structure infections. When staphylococcal infections are localized and purulent, antibiotics are used as adjuncts to appropriate surgical measures. Vancomycin hydrochloride has been reported to be effective alone or in combination with an aminoglycoside for endocarditis caused by S. viridans or S. bovis . For endocarditis caused by enterococci (e.g., E. faecalis ), vancomycin hydrochloride has been reported to be effective only in combination with an aminoglycoside. Vancomycin has been reported to be effective for the treatment of diphtheroid endocarditis. Vancomycin has been used successfully in combination with either rifampin, an aminoglycoside, or both in early-onset prosthetic valve endocarditis caused by S. epidermidis or diphtheroids. Specimens for bacteriologic cultures should be obtained in order to isolate and identify causative organisms and to determine their susceptibilities to vancomycin. The parenteral form of Sterile Vancomycin Hydrochloride may be administered orally for treatment of antibiotic-associated pseudomembranous colitis produced by C. difficile and for staphylococcal enterocolitis. Parenteral administration of vancomycin hydrochloride alone is of unproven benefit for these indications. Vancomycin is not effective by the oral route for other types of infection. To reduce the development of drug-resistant bacteria and maintain the effectiveness of vancomycin and other antibacterial drugs, vancomycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:8b32b8ac-26d6-4bfa-8943-508877baa2ab biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28001 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:143e1e99-ce81-4563-9df9-7d9a574e448c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:56dd0e29-8f49-4af9-b9e0-bc1c333f824a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vancomycin is indicated for the treatment of serious or severe infections caused by susceptible strains of methicillin-resistant (beta-lactam-resistant) staphylococci. It is indicated for penicillin-allergic patients, for patients who cannot receive or who have failed to respond to other drugs, including the penicillins or cephalosporins, and for infections caused by vancomycin-susceptible organisms that are resistant to other antimicrobial drugs. Vancomycin is indicated for initial therapy when methicillin-resistant staphylococci are suspected, but after susceptibility data are available, therapy should be adjusted accordingly. Vancomycin hydrochloride is effective in the treatment of staphylococcal endocarditis. Its effectiveness has been documented in other infections due to staphylococci, including septicemia, bone infections, lower respiratory tract infections, and skin and skin-structure infections. When staphylococcal infections are localized and purulent, antibiotics are used as adjuncts to appropriate surgical measures. Vancomycin hydrochloride has been reported to be effective alone or in combination with an aminoglycoside for endocarditis caused by S. viridans or S. bovis . For endocarditis caused by enterococci (e.g., E. faecalis ), vancomycin hydrochloride has been reported to be effective only in combination with an aminoglycoside. Vancomycin has been reported to be effective for the treatment of diphtheroid endocarditis. Vancomycin has been used successfully in combination with either rifampin, an aminoglycoside, or both in early-onset prosthetic valve endocarditis caused by S. epidermidis or diphtheroids. Specimens for bacteriologic cultures should be obtained in order to isolate and identify causative organisms and to determine their susceptibilities to vancomycin. The parenteral form of Sterile Vancomycin Hydrochloride may be administered orally for treatment of antibiotic-associated pseudomembranous colitis produced by C. difficile and for staphylococcal enterocolitis. Parenteral administration of vancomycin hydrochloride alone is of unproven benefit for these indications. Vancomycin is not effective by the oral route for other types of infection. To reduce the development of drug-resistant bacteria and maintain the effectiveness of vancomycin and other antibacterial drugs, vancomycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:153220ad-4871-4891-82ad-59df2513cc5e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28001 biolink:treats MONDO:0005025 PMID:41385096 "[{""id"":""uuid:d0315ad5-1066-46e1-958d-b2746bdd91fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:548a958a-5e64-4145-a89b-ac7230fa8ad2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vancomycin is indicated for the treatment of serious or severe infections caused by susceptible strains of methicillin-resistant (beta-lactam-resistant) staphylococci. It is indicated for penicillin-allergic patients, for patients who cannot receive or who have failed to respond to other drugs, including the penicillins or cephalosporins, and for infections caused by vancomycin-susceptible organisms that are resistant to other antimicrobial drugs. Vancomycin is indicated for initial therapy when methicillin-resistant staphylococci are suspected, but after susceptibility data are available, therapy should be adjusted accordingly. Vancomycin hydrochloride is effective in the treatment of staphylococcal endocarditis. Its effectiveness has been documented in other infections due to staphylococci, including septicemia, bone infections, lower respiratory tract infections, and skin and skin-structure infections. When staphylococcal infections are localized and purulent, antibiotics are used as adjuncts to appropriate surgical measures. Vancomycin hydrochloride has been reported to be effective alone or in combination with an aminoglycoside for endocarditis caused by S. viridans or S. bovis . For endocarditis caused by enterococci (e.g., E. faecalis ), vancomycin hydrochloride has been reported to be effective only in combination with an aminoglycoside. Vancomycin has been reported to be effective for the treatment of diphtheroid endocarditis. Vancomycin has been used successfully in combination with either rifampin, an aminoglycoside, or both in early-onset prosthetic valve endocarditis caused by S. epidermidis or diphtheroids. Specimens for bacteriologic cultures should be obtained in order to isolate and identify causative organisms and to determine their susceptibilities to vancomycin. The parenteral form of Sterile Vancomycin Hydrochloride may be administered orally for treatment of antibiotic-associated pseudomembranous colitis produced by C. difficile and for staphylococcal enterocolitis. Parenteral administration of vancomycin hydrochloride alone is of unproven benefit for these indications. Vancomycin is not effective by the oral route for other types of infection. To reduce the development of drug-resistant bacteria and maintain the effectiveness of vancomycin and other antibacterial drugs, vancomycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:207d86a4-8772-43d3-b05d-e7e73fe13379 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28001 biolink:treats MONDO:0006669 PMID:41385096 "[{""id"":""uuid:83f489a1-b675-494a-91f4-6d631639f2cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d2c8ec34-95c9-4fe8-a48a-01f80dcf62e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vancomycin is indicated for the treatment of serious or severe infections caused by susceptible strains of methicillin-resistant (beta-lactam-resistant) staphylococci. It is indicated for penicillin-allergic patients, for patients who cannot receive or who have failed to respond to other drugs, including the penicillins or cephalosporins, and for infections caused by vancomycin-susceptible organisms that are resistant to other antimicrobial drugs. Vancomycin is indicated for initial therapy when methicillin-resistant staphylococci are suspected, but after susceptibility data are available, therapy should be adjusted accordingly. Vancomycin hydrochloride is effective in the treatment of staphylococcal endocarditis. Its effectiveness has been documented in other infections due to staphylococci, including septicemia, bone infections, lower respiratory tract infections, and skin and skin-structure infections. When staphylococcal infections are localized and purulent, antibiotics are used as adjuncts to appropriate surgical measures. Vancomycin hydrochloride has been reported to be effective alone or in combination with an aminoglycoside for endocarditis caused by S. viridans or S. bovis . For endocarditis caused by enterococci (e.g., E. faecalis ), vancomycin hydrochloride has been reported to be effective only in combination with an aminoglycoside. Vancomycin has been reported to be effective for the treatment of diphtheroid endocarditis. Vancomycin has been used successfully in combination with either rifampin, an aminoglycoside, or both in early-onset prosthetic valve endocarditis caused by S. epidermidis or diphtheroids. Specimens for bacteriologic cultures should be obtained in order to isolate and identify causative organisms and to determine their susceptibilities to vancomycin. The parenteral form of Sterile Vancomycin Hydrochloride may be administered orally for treatment of antibiotic-associated pseudomembranous colitis produced by C. difficile and for staphylococcal enterocolitis. Parenteral administration of vancomycin hydrochloride alone is of unproven benefit for these indications. Vancomycin is not effective by the oral route for other types of infection. To reduce the development of drug-resistant bacteria and maintain the effectiveness of vancomycin and other antibacterial drugs, vancomycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:88ebee1a-32b1-4ceb-af86-cd43d8bcbb3a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28001 biolink:treats MONDO:0000565 PMID:41385096 "[{""id"":""uuid:f2a77a13-00fc-4117-a4f3-a4e7189ebf48"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c6e85484-0498-4d6d-b174-cfb990075e4a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c66450c5-fa75-4d37-877b-6eca51c433f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vancomycin is indicated for the treatment of serious or severe infections caused by susceptible strains of methicillin-resistant (beta-lactam-resistant) staphylococci. It is indicated for penicillin-allergic patients, for patients who cannot receive or who have failed to respond to other drugs, including the penicillins or cephalosporins, and for infections caused by vancomycin-susceptible organisms that are resistant to other antimicrobial drugs. Vancomycin is indicated for initial therapy when methicillin-resistant staphylococci are suspected, but after susceptibility data are available, therapy should be adjusted accordingly. Vancomycin hydrochloride is effective in the treatment of staphylococcal endocarditis. Its effectiveness has been documented in other infections due to staphylococci, including septicemia, bone infections, lower respiratory tract infections, and skin and skin-structure infections. When staphylococcal infections are localized and purulent, antibiotics are used as adjuncts to appropriate surgical measures. Vancomycin hydrochloride has been reported to be effective alone or in combination with an aminoglycoside for endocarditis caused by S. viridans or S. bovis . For endocarditis caused by enterococci (e.g., E. faecalis ), vancomycin hydrochloride has been reported to be effective only in combination with an aminoglycoside. Vancomycin has been reported to be effective for the treatment of diphtheroid endocarditis. Vancomycin has been used successfully in combination with either rifampin, an aminoglycoside, or both in early-onset prosthetic valve endocarditis caused by S. epidermidis or diphtheroids. Specimens for bacteriologic cultures should be obtained in order to isolate and identify causative organisms and to determine their susceptibilities to vancomycin. The parenteral form of Sterile Vancomycin Hydrochloride may be administered orally for treatment of antibiotic-associated pseudomembranous colitis produced by C. difficile and for staphylococcal enterocolitis. Parenteral administration of vancomycin hydrochloride alone is of unproven benefit for these indications. Vancomycin is not effective by the oral route for other types of infection. To reduce the development of drug-resistant bacteria and maintain the effectiveness of vancomycin and other antibacterial drugs, vancomycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.|[PMDA] A drug with new additional indications for the treatment of: sepsis, infective endocarditis, secondary infection of trauma, burn or surgical wounds, osteomyelitis, arthritis, peritonitis and purulent meningitis caused by vancomycin-sensitive methicillin-resistant coagulase-negative Staphylococcus (MRCNS); or febrile neutropenia which is suspected of MRSA or MRCNS infection. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:7115ffcd-b692-4d45-a590-22dc2bfaa40c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28001 biolink:treats MONDO:0000705 PMID:41385096 "[{""id"":""uuid:76fe83f7-7733-4720-b694-e0b2141b2276"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a11eb6a7-e6de-4822-b191-652910c13920"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vancomycin is indicated for the treatment of serious or severe infections caused by susceptible strains of methicillin-resistant (beta-lactam-resistant) staphylococci. It is indicated for penicillin-allergic patients, for patients who cannot receive or who have failed to respond to other drugs, including the penicillins or cephalosporins, and for infections caused by vancomycin-susceptible organisms that are resistant to other antimicrobial drugs. Vancomycin is indicated for initial therapy when methicillin-resistant staphylococci are suspected, but after susceptibility data are available, therapy should be adjusted accordingly. Vancomycin hydrochloride is effective in the treatment of staphylococcal endocarditis. Its effectiveness has been documented in other infections due to staphylococci, including septicemia, bone infections, lower respiratory tract infections, and skin and skin-structure infections. When staphylococcal infections are localized and purulent, antibiotics are used as adjuncts to appropriate surgical measures. Vancomycin hydrochloride has been reported to be effective alone or in combination with an aminoglycoside for endocarditis caused by S. viridans or S. bovis . For endocarditis caused by enterococci (e.g., E. faecalis ), vancomycin hydrochloride has been reported to be effective only in combination with an aminoglycoside. Vancomycin has been reported to be effective for the treatment of diphtheroid endocarditis. Vancomycin has been used successfully in combination with either rifampin, an aminoglycoside, or both in early-onset prosthetic valve endocarditis caused by S. epidermidis or diphtheroids. Specimens for bacteriologic cultures should be obtained in order to isolate and identify causative organisms and to determine their susceptibilities to vancomycin. The parenteral form of Sterile Vancomycin Hydrochloride may be administered orally for treatment of antibiotic-associated pseudomembranous colitis produced by C. difficile and for staphylococcal enterocolitis. Parenteral administration of vancomycin hydrochloride alone is of unproven benefit for these indications. Vancomycin is not effective by the oral route for other types of infection. To reduce the development of drug-resistant bacteria and maintain the effectiveness of vancomycin and other antibacterial drugs, vancomycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:35ee6fb9-f791-41f7-a471-0f835c6fc677 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28001 biolink:treats UMLS:C0038157 PMID:41385096 "[{""id"":""uuid:a38acb99-3d9a-4289-a33d-9115fd57f89d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:43e4ee40-6d01-486d-916d-ca987ff08e3b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vancomycin is indicated for the treatment of serious or severe infections caused by susceptible strains of methicillin-resistant (beta-lactam-resistant) staphylococci. It is indicated for penicillin-allergic patients, for patients who cannot receive or who have failed to respond to other drugs, including the penicillins or cephalosporins, and for infections caused by vancomycin-susceptible organisms that are resistant to other antimicrobial drugs. Vancomycin is indicated for initial therapy when methicillin-resistant staphylococci are suspected, but after susceptibility data are available, therapy should be adjusted accordingly. Vancomycin hydrochloride is effective in the treatment of staphylococcal endocarditis. Its effectiveness has been documented in other infections due to staphylococci, including septicemia, bone infections, lower respiratory tract infections, and skin and skin-structure infections. When staphylococcal infections are localized and purulent, antibiotics are used as adjuncts to appropriate surgical measures. Vancomycin hydrochloride has been reported to be effective alone or in combination with an aminoglycoside for endocarditis caused by S. viridans or S. bovis . For endocarditis caused by enterococci (e.g., E. faecalis ), vancomycin hydrochloride has been reported to be effective only in combination with an aminoglycoside. Vancomycin has been reported to be effective for the treatment of diphtheroid endocarditis. Vancomycin has been used successfully in combination with either rifampin, an aminoglycoside, or both in early-onset prosthetic valve endocarditis caused by S. epidermidis or diphtheroids. Specimens for bacteriologic cultures should be obtained in order to isolate and identify causative organisms and to determine their susceptibilities to vancomycin. The parenteral form of Sterile Vancomycin Hydrochloride may be administered orally for treatment of antibiotic-associated pseudomembranous colitis produced by C. difficile and for staphylococcal enterocolitis. Parenteral administration of vancomycin hydrochloride alone is of unproven benefit for these indications. Vancomycin is not effective by the oral route for other types of infection. To reduce the development of drug-resistant bacteria and maintain the effectiveness of vancomycin and other antibacterial drugs, vancomycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:9ed0f555-a10a-45ec-bb9a-bfb70810d606 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2668 biolink:treats MONDO:0021661 PMID:41385096 "[{""id"":""uuid:42fdfbc3-9e88-4a96-83b9-2df5c0815125"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:888f0298-8eb8-4307-a8a4-243883d15f69"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NORVASC is a calcium channel blocker and may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of: Hypertension ( 1.1 ) Coronary Artery Disease ( 1.2 ) Chronic Stable Angina Vasospastic Angina (Prinzmetal's or Variant Angina) Angiographically Documented Coronary Artery Disease in patients without heart failure or an ejection fraction < 40% uuid:e0ee9e6f-d5a0-4cb5-8edf-b5957c66339f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:H3753190JS biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:a51c668b-d6d0-4fda-9eb7-c8c5f6087dff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:99cdde38-8102-4048-96ab-8c18467e7764"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Moexipril hydrochloride is indicated for treatment of patients with hypertension. It may be used alone or in combination with thiazide diuretics. In using moexipril hydrochloride, consideration should be given to the fact that another ACE inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that moexipril hydrochloride does not have a similar risk (see WARNINGS ). In considering use of moexipril hydrochloride, it should be noted that in controlled trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients (see WARNINGS , Angioedema ). uuid:2481dec2-7d20-4e2f-9a16-142b97717a99 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:H3753190JS biolink:treats MONDO:0001609 PMID:41385096 "[{""id"":""uuid:d635c0de-8bc1-4ed9-8fce-8f7def2327bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9b74b912-f2ed-4a3c-b8d4-2a46faae531d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Moexipril hydrochloride is indicated for treatment of patients with hypertension. It may be used alone or in combination with thiazide diuretics. In using moexipril hydrochloride, consideration should be given to the fact that another ACE inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that moexipril hydrochloride does not have a similar risk (see WARNINGS ). In considering use of moexipril hydrochloride, it should be noted that in controlled trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients (see WARNINGS , Angioedema ). uuid:7495305d-3d39-4513-bc99-79a9b0f676d5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:H3753190JS biolink:treats MONDO:0001343 PMID:41385096 "[{""id"":""uuid:c3a10aa9-09cb-4d10-8bdb-209fcb569dda"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7e9a8703-7dd1-4e50-9299-aab41e25d117"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Moexipril hydrochloride is indicated for treatment of patients with hypertension. It may be used alone or in combination with thiazide diuretics. In using moexipril hydrochloride, consideration should be given to the fact that another ACE inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that moexipril hydrochloride does not have a similar risk (see WARNINGS ). In considering use of moexipril hydrochloride, it should be noted that in controlled trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients (see WARNINGS , Angioedema ). uuid:96f3737c-59bd-4b86-9cef-ced9d5297e33 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:H3753190JS biolink:treats MONDO:0010481 PMID:41385096 "[{""id"":""uuid:61c50248-a5bb-44a0-8d2b-ce6845d3a5f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6946f614-ba7b-4bb7-a7fd-9e5a1adf546d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Moexipril hydrochloride is indicated for treatment of patients with hypertension. It may be used alone or in combination with thiazide diuretics. In using moexipril hydrochloride, consideration should be given to the fact that another ACE inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that moexipril hydrochloride does not have a similar risk (see WARNINGS ). In considering use of moexipril hydrochloride, it should be noted that in controlled trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients (see WARNINGS , Angioedema ). uuid:dfd04738-c293-408e-bed2-34044c2497ad biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2639 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:716d8ed1-eb09-409b-818d-584e6ec9510b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:782326b6-6cd5-4946-ba82-8d77424008a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amiloride HCl is indicated as adjunctive treatment with thiazide diuretics or other kaliuretic-diuretic agents in congestive heart failure or hypertension to: help restore normal serum potassium levels in patients who develop hypokalemia on the kaliuretic diuretic prevent development of hypokalemia in patients who would be exposed to particular risk if hypokalemia were to develop, e.g., digitalized patients or patients with significant cardiac arrhythmias. The use of potassium-conserving agents is often unnecessary in patients receiving diuretics for uncomplicated essential hypertension when such patients have a normal diet. Amiloride HCl has little additive diuretic or antihypertensive effect when added to a thiazide diuretic. Amiloride HCl should rarely be used alone. It has weak (compared with thiazides) diuretic and antihypertensive effects. Used as single agents, potassium sparing diuretics, including amiloride HCl, result in an increased risk of hyperkalemia (approximately 10% with amiloride). Amiloride HCl should be used alone only when persistent hypokalemia has been documented and only with careful titration of the dose and close monitoring of serum electrolytes. uuid:b85d06ea-c0f3-4208-9cac-cf9c9502ed0f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2639 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:077a2b37-c21e-4fe3-8387-9ad3b2a3d857"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bf48c64f-dc82-4593-8dc2-480c54317607"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amiloride HCl is indicated as adjunctive treatment with thiazide diuretics or other kaliuretic-diuretic agents in congestive heart failure or hypertension to: help restore normal serum potassium levels in patients who develop hypokalemia on the kaliuretic diuretic prevent development of hypokalemia in patients who would be exposed to particular risk if hypokalemia were to develop, e.g., digitalized patients or patients with significant cardiac arrhythmias. The use of potassium-conserving agents is often unnecessary in patients receiving diuretics for uncomplicated essential hypertension when such patients have a normal diet. Amiloride HCl has little additive diuretic or antihypertensive effect when added to a thiazide diuretic. Amiloride HCl should rarely be used alone. It has weak (compared with thiazides) diuretic and antihypertensive effects. Used as single agents, potassium sparing diuretics, including amiloride HCl, result in an increased risk of hyperkalemia (approximately 10% with amiloride). Amiloride HCl should be used alone only when persistent hypokalemia has been documented and only with careful titration of the dose and close monitoring of serum electrolytes. uuid:1604a508-1f7d-4848-85ac-75cba574d05a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2639 biolink:treats MONDO:0003019 PMID:41385096 "[{""id"":""uuid:c8f9892a-ca9a-4145-9aa7-6c401621957e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b7beb405-5375-4410-bfde-2cb4f07d8bed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amiloride HCl is indicated as adjunctive treatment with thiazide diuretics or other kaliuretic-diuretic agents in congestive heart failure or hypertension to: help restore normal serum potassium levels in patients who develop hypokalemia on the kaliuretic diuretic prevent development of hypokalemia in patients who would be exposed to particular risk if hypokalemia were to develop, e.g., digitalized patients or patients with significant cardiac arrhythmias. The use of potassium-conserving agents is often unnecessary in patients receiving diuretics for uncomplicated essential hypertension when such patients have a normal diet. Amiloride HCl has little additive diuretic or antihypertensive effect when added to a thiazide diuretic. Amiloride HCl should rarely be used alone. It has weak (compared with thiazides) diuretic and antihypertensive effects. Used as single agents, potassium sparing diuretics, including amiloride HCl, result in an increased risk of hyperkalemia (approximately 10% with amiloride). Amiloride HCl should be used alone only when persistent hypokalemia has been documented and only with careful titration of the dose and close monitoring of serum electrolytes. uuid:4f29b03b-bfe7-445b-b29b-6a5e15a792d4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2639 biolink:treats MONDO:0007263 PMID:41385096 "[{""id"":""uuid:a58073e6-c6dd-4661-bb1d-aa013af9d3b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ddddfb8a-0df6-430c-ac85-531e68baaf62"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amiloride HCl is indicated as adjunctive treatment with thiazide diuretics or other kaliuretic-diuretic agents in congestive heart failure or hypertension to: help restore normal serum potassium levels in patients who develop hypokalemia on the kaliuretic diuretic prevent development of hypokalemia in patients who would be exposed to particular risk if hypokalemia were to develop, e.g., digitalized patients or patients with significant cardiac arrhythmias. The use of potassium-conserving agents is often unnecessary in patients receiving diuretics for uncomplicated essential hypertension when such patients have a normal diet. Amiloride HCl has little additive diuretic or antihypertensive effect when added to a thiazide diuretic. Amiloride HCl should rarely be used alone. It has weak (compared with thiazides) diuretic and antihypertensive effects. Used as single agents, potassium sparing diuretics, including amiloride HCl, result in an increased risk of hyperkalemia (approximately 10% with amiloride). Amiloride HCl should be used alone only when persistent hypokalemia has been documented and only with careful titration of the dose and close monitoring of serum electrolytes. uuid:f1e0dfdd-828f-4efe-bec7-ad390f9c5530 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2639 biolink:treats MONDO:0001134 PMID:41385096 "[{""id"":""uuid:5e0ddf4d-180a-4d41-9ad1-6c3e9961626f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:93c32834-fa55-4802-8eaa-9663dd73025f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amiloride HCl is indicated as adjunctive treatment with thiazide diuretics or other kaliuretic-diuretic agents in congestive heart failure or hypertension to: help restore normal serum potassium levels in patients who develop hypokalemia on the kaliuretic diuretic prevent development of hypokalemia in patients who would be exposed to particular risk if hypokalemia were to develop, e.g., digitalized patients or patients with significant cardiac arrhythmias. The use of potassium-conserving agents is often unnecessary in patients receiving diuretics for uncomplicated essential hypertension when such patients have a normal diet. Amiloride HCl has little additive diuretic or antihypertensive effect when added to a thiazide diuretic. Amiloride HCl should rarely be used alone. It has weak (compared with thiazides) diuretic and antihypertensive effects. Used as single agents, potassium sparing diuretics, including amiloride HCl, result in an increased risk of hyperkalemia (approximately 10% with amiloride). Amiloride HCl should be used alone only when persistent hypokalemia has been documented and only with careful titration of the dose and close monitoring of serum electrolytes. uuid:92f86264-f106-4488-8322-d527e0645855 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2639 biolink:treats HP:0002153 PMID:41385096 "[{""id"":""uuid:32f65244-7a13-4e38-abe4-a56caecea204"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b24b28a1-e3fb-4aa8-849f-cc244402c7bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amiloride HCl is indicated as adjunctive treatment with thiazide diuretics or other kaliuretic-diuretic agents in congestive heart failure or hypertension to: help restore normal serum potassium levels in patients who develop hypokalemia on the kaliuretic diuretic prevent development of hypokalemia in patients who would be exposed to particular risk if hypokalemia were to develop, e.g., digitalized patients or patients with significant cardiac arrhythmias. The use of potassium-conserving agents is often unnecessary in patients receiving diuretics for uncomplicated essential hypertension when such patients have a normal diet. Amiloride HCl has little additive diuretic or antihypertensive effect when added to a thiazide diuretic. Amiloride HCl should rarely be used alone. It has weak (compared with thiazides) diuretic and antihypertensive effects. Used as single agents, potassium sparing diuretics, including amiloride HCl, result in an increased risk of hyperkalemia (approximately 10% with amiloride). Amiloride HCl should be used alone only when persistent hypokalemia has been documented and only with careful titration of the dose and close monitoring of serum electrolytes. uuid:c787fc05-a7ac-405c-9c2e-b71dfb0bbe20 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6970 biolink:treats MONDO:0011786 PMID:41385096 "[{""id"":""uuid:4c49eeaa-3ecb-4068-a90b-dd3fe7ac44d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:82e03293-4d9d-4d88-9bad-0bf906eefe48"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:b105afe0-6e4f-4d07-a609-59505423d113"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NASONEX is a corticosteroid indicated for: Treatment of Nasal Symptoms of Allergic Rhinitis in patients ≥2 years of age ( 1.1 ) Treatment of Nasal Congestion Associated with Seasonal Allergic Rhinitis in patients ≥2 years of age ( 1.2 ) Prophylaxis of Seasonal Allergic Rhinitis in patients ≥12 years of age ( 1.3 ) Treatment of Nasal Polyps in patients ≥18 years of age ( 1.4 )|[PMDA] Drugs containing a new active ingredient indicated for the treatment of allergic rhinitis. uuid:53de9cd0-552d-4f45-af5d-9efefdf09e68 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6970 biolink:treats MONDO:0005324 PMID:41385096 "[{""id"":""uuid:dd62a517-e31d-4961-b426-fa7aa535d5ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:31a8a818-4abe-456f-abbd-6c323ab49575"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NASONEX is a corticosteroid indicated for: Treatment of Nasal Symptoms of Allergic Rhinitis in patients ≥2 years of age ( 1.1 ) Treatment of Nasal Congestion Associated with Seasonal Allergic Rhinitis in patients ≥2 years of age ( 1.2 ) Prophylaxis of Seasonal Allergic Rhinitis in patients ≥12 years of age ( 1.3 ) Treatment of Nasal Polyps in patients ≥18 years of age ( 1.4 ) uuid:48896f3b-e34f-4599-b8bc-a4c193baf94f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6970 biolink:treats MONDO:0006314 PMID:41385096 "[{""id"":""uuid:1c321cdd-9cae-41c1-8ece-df80551df275"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0a560767-e478-4e65-9997-bf5b4d93c04d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NASONEX is a corticosteroid indicated for: Treatment of Nasal Symptoms of Allergic Rhinitis in patients ≥2 years of age ( 1.1 ) Treatment of Nasal Congestion Associated with Seasonal Allergic Rhinitis in patients ≥2 years of age ( 1.2 ) Prophylaxis of Seasonal Allergic Rhinitis in patients ≥12 years of age ( 1.3 ) Treatment of Nasal Polyps in patients ≥18 years of age ( 1.4 ) uuid:deafec1f-f6f4-43ed-a4cf-03c894dbf4e1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28918 biolink:treats MONDO:0600005 PMID:41385096 "[{""id"":""uuid:63c56707-b9f0-4997-a079-46e8fbd9e1f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a2aba715-66f7-448e-b69a-d81042a8748d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Epinephrine auto-injector is indicated in the emergency treatment of severe allergic reactions (Type I) including anaphylaxis to stinging insects (e.g. order Hymenoptera, which includes bees, wasps, hornets, yellow jackets and fire ants), and biting insects (e.g. triatoma, mosquitos), allergen immunotherapy, foods, drugs, diagnostic testing substances (e.g. radiocontrast media), and other allergens, as well as anaphylaxis to unknown substances (idiopathic anaphylaxis) or exercise-induced anaphylaxis. Epinephrine auto-injector is intended for immediate administration in patients with a history of anaphylactic reactions. Selection of the appropriate dosage strength is determined according to patient body weight (See DOSAGE AND ADMINISTRATION section). Such reactions may occur within minutes after exposure and consist of flushing, apprehension, syncope, tachycardia, thready or unobtainable pulse associated with a fall in blood pressure, convulsions, vomiting, diarrhea and abdominal cramps, involuntary voiding, wheezing, dyspnea due to laryngeal spasm, pruritus, rashes, urticaria, or angioedema. Epinephrine auto-injector is designed as emergency supportive therapy only and is not a replacement or substitute for immediate medical care. uuid:f4d3ff54-9e47-4f9a-a6a8-b80c4c72785e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28918 biolink:treats HP:0500096 PMID:41385096 "[{""id"":""uuid:1b5e3b2f-a8fe-496e-8bf6-34b814006207"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5bbd7a50-b276-47b6-bdf0-5a17389cd18e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Epinephrine auto-injector is indicated in the emergency treatment of severe allergic reactions (Type I) including anaphylaxis to stinging insects (e.g. order Hymenoptera, which includes bees, wasps, hornets, yellow jackets and fire ants), and biting insects (e.g. triatoma, mosquitos), allergen immunotherapy, foods, drugs, diagnostic testing substances (e.g. radiocontrast media), and other allergens, as well as anaphylaxis to unknown substances (idiopathic anaphylaxis) or exercise-induced anaphylaxis. Epinephrine auto-injector is intended for immediate administration in patients with a history of anaphylactic reactions. Selection of the appropriate dosage strength is determined according to patient body weight (See DOSAGE AND ADMINISTRATION section). Such reactions may occur within minutes after exposure and consist of flushing, apprehension, syncope, tachycardia, thready or unobtainable pulse associated with a fall in blood pressure, convulsions, vomiting, diarrhea and abdominal cramps, involuntary voiding, wheezing, dyspnea due to laryngeal spasm, pruritus, rashes, urticaria, or angioedema. Epinephrine auto-injector is designed as emergency supportive therapy only and is not a replacement or substitute for immediate medical care. uuid:bbde9152-7764-4bc8-ad5d-123e6f8cb619 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28918 biolink:treats HP:0500095 PMID:41385096 "[{""id"":""uuid:f046fe5d-659c-4809-8327-0f1d28abdf72"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:925a2164-9027-4ccf-9aa1-fbe48b245049"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Epinephrine auto-injector is indicated in the emergency treatment of severe allergic reactions (Type I) including anaphylaxis to stinging insects (e.g. order Hymenoptera, which includes bees, wasps, hornets, yellow jackets and fire ants), and biting insects (e.g. triatoma, mosquitos), allergen immunotherapy, foods, drugs, diagnostic testing substances (e.g. radiocontrast media), and other allergens, as well as anaphylaxis to unknown substances (idiopathic anaphylaxis) or exercise-induced anaphylaxis. Epinephrine auto-injector is intended for immediate administration in patients with a history of anaphylactic reactions. Selection of the appropriate dosage strength is determined according to patient body weight (See DOSAGE AND ADMINISTRATION section). Such reactions may occur within minutes after exposure and consist of flushing, apprehension, syncope, tachycardia, thready or unobtainable pulse associated with a fall in blood pressure, convulsions, vomiting, diarrhea and abdominal cramps, involuntary voiding, wheezing, dyspnea due to laryngeal spasm, pruritus, rashes, urticaria, or angioedema. Epinephrine auto-injector is designed as emergency supportive therapy only and is not a replacement or substitute for immediate medical care. uuid:07387a08-9261-4c2b-83e0-5813bbdfb3f4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28918 biolink:treats HP:0410149 PMID:41385096 "[{""id"":""uuid:3517989b-23f7-40ab-95af-82ee92c1214f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:00db3f17-59ec-48db-a121-4ae2f0e29309"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Epinephrine auto-injector is indicated in the emergency treatment of severe allergic reactions (Type I) including anaphylaxis to stinging insects (e.g. order Hymenoptera, which includes bees, wasps, hornets, yellow jackets and fire ants), and biting insects (e.g. triatoma, mosquitos), allergen immunotherapy, foods, drugs, diagnostic testing substances (e.g. radiocontrast media), and other allergens, as well as anaphylaxis to unknown substances (idiopathic anaphylaxis) or exercise-induced anaphylaxis. Epinephrine auto-injector is intended for immediate administration in patients with a history of anaphylactic reactions. Selection of the appropriate dosage strength is determined according to patient body weight (See DOSAGE AND ADMINISTRATION section). Such reactions may occur within minutes after exposure and consist of flushing, apprehension, syncope, tachycardia, thready or unobtainable pulse associated with a fall in blood pressure, convulsions, vomiting, diarrhea and abdominal cramps, involuntary voiding, wheezing, dyspnea due to laryngeal spasm, pruritus, rashes, urticaria, or angioedema. Epinephrine auto-injector is designed as emergency supportive therapy only and is not a replacement or substitute for immediate medical care. uuid:202f7c74-84b0-4941-be2b-afc6ef01a4bf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28918 biolink:treats MONDO:0100053 PMID:41385096 "[{""id"":""uuid:54b0ff04-204c-4337-835b-379e244d0f9b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:59c9ac81-21ce-48d9-bccc-4d7dc1776e37"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:1a667243-9abe-4a5f-a72c-cbce8ea66ffb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Epinephrine auto-injector is indicated in the emergency treatment of severe allergic reactions (Type I) including anaphylaxis to stinging insects (e.g. order Hymenoptera, which includes bees, wasps, hornets, yellow jackets and fire ants), and biting insects (e.g. triatoma, mosquitos), allergen immunotherapy, foods, drugs, diagnostic testing substances (e.g. radiocontrast media), and other allergens, as well as anaphylaxis to unknown substances (idiopathic anaphylaxis) or exercise-induced anaphylaxis. Epinephrine auto-injector is intended for immediate administration in patients with a history of anaphylactic reactions. Selection of the appropriate dosage strength is determined according to patient body weight (See DOSAGE AND ADMINISTRATION section). Such reactions may occur within minutes after exposure and consist of flushing, apprehension, syncope, tachycardia, thready or unobtainable pulse associated with a fall in blood pressure, convulsions, vomiting, diarrhea and abdominal cramps, involuntary voiding, wheezing, dyspnea due to laryngeal spasm, pruritus, rashes, urticaria, or angioedema. Epinephrine auto-injector is designed as emergency supportive therapy only and is not a replacement or substitute for immediate medical care.|[PMDA] Addition of its pediatric application and indications for adjunctive therapy for anaphylactic reaction induced by food, drug and others. uuid:3945469e-ebef-4991-ba86-36d1b0baad63 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28918 biolink:treats MONDO:0100054 PMID:41385096 "[{""id"":""uuid:6584eff8-d70e-4c55-adbb-6cdce1a6e5cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2e06ba53-9165-413e-a15c-c42ff0d1af3c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Epinephrine auto-injector is indicated in the emergency treatment of severe allergic reactions (Type I) including anaphylaxis to stinging insects (e.g. order Hymenoptera, which includes bees, wasps, hornets, yellow jackets and fire ants), and biting insects (e.g. triatoma, mosquitos), allergen immunotherapy, foods, drugs, diagnostic testing substances (e.g. radiocontrast media), and other allergens, as well as anaphylaxis to unknown substances (idiopathic anaphylaxis) or exercise-induced anaphylaxis. Epinephrine auto-injector is intended for immediate administration in patients with a history of anaphylactic reactions. Selection of the appropriate dosage strength is determined according to patient body weight (See DOSAGE AND ADMINISTRATION section). Such reactions may occur within minutes after exposure and consist of flushing, apprehension, syncope, tachycardia, thready or unobtainable pulse associated with a fall in blood pressure, convulsions, vomiting, diarrhea and abdominal cramps, involuntary voiding, wheezing, dyspnea due to laryngeal spasm, pruritus, rashes, urticaria, or angioedema. Epinephrine auto-injector is designed as emergency supportive therapy only and is not a replacement or substitute for immediate medical care. uuid:7b26c43f-d168-4181-b611-a9aab39e5066 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28918 biolink:treats MONDO:0100056 PMID:41385096 "[{""id"":""uuid:7c6c55be-38a1-4835-acd5-c47dfab693e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:014b7bc3-7445-4ee3-8b12-1d34ac1b0bc5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Epinephrine auto-injector is indicated in the emergency treatment of severe allergic reactions (Type I) including anaphylaxis to stinging insects (e.g. order Hymenoptera, which includes bees, wasps, hornets, yellow jackets and fire ants), and biting insects (e.g. triatoma, mosquitos), allergen immunotherapy, foods, drugs, diagnostic testing substances (e.g. radiocontrast media), and other allergens, as well as anaphylaxis to unknown substances (idiopathic anaphylaxis) or exercise-induced anaphylaxis. Epinephrine auto-injector is intended for immediate administration in patients with a history of anaphylactic reactions. Selection of the appropriate dosage strength is determined according to patient body weight (See DOSAGE AND ADMINISTRATION section). Such reactions may occur within minutes after exposure and consist of flushing, apprehension, syncope, tachycardia, thready or unobtainable pulse associated with a fall in blood pressure, convulsions, vomiting, diarrhea and abdominal cramps, involuntary voiding, wheezing, dyspnea due to laryngeal spasm, pruritus, rashes, urticaria, or angioedema. Epinephrine auto-injector is designed as emergency supportive therapy only and is not a replacement or substitute for immediate medical care. uuid:1dbd255e-a8c1-4842-b23f-14e6dc04a11b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7459 biolink:treats MONDO:0043775 PMID:41385096 "[{""id"":""uuid:bddcc511-2b06-446e-bd1e-d04a6586678f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bd5851ef-7e99-4de7-a382-6a4e0a8b71c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Naloxone Hydrochloride Injection is indicated for the complete or partial reversal of opioid depression, including respiratory depression, induced by natural and synthetic opioids including propoxyphene, methadone, and certain mixed agonist-antagonist analgesics: nalbuphine, pentazocine, butorphanol and cyclazocine. Naloxone hydrochloride is also indicated for the diagnosis of suspected or known acute opioid overdosage. Naloxone may be useful as an adjunctive agent to increase blood pressure in the management of septic shock (see CLINICAL PHARMACOLOGY, Adjunctive Use in Septic Shock ). uuid:8343c2d3-083b-48b0-9474-fa500f9f5d8f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7459 biolink:treats MONDO:0001881 PMID:41385096 "[{""id"":""uuid:7e4a5732-43ef-4c9b-bda5-d9c315c8651f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9545cd56-1e49-4edc-82e3-a93bd5951717"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Naloxone Hydrochloride Injection is indicated for the complete or partial reversal of opioid depression, including respiratory depression, induced by natural and synthetic opioids including propoxyphene, methadone, and certain mixed agonist-antagonist analgesics: nalbuphine, pentazocine, butorphanol and cyclazocine. Naloxone hydrochloride is also indicated for the diagnosis of suspected or known acute opioid overdosage. Naloxone may be useful as an adjunctive agent to increase blood pressure in the management of septic shock (see CLINICAL PHARMACOLOGY, Adjunctive Use in Septic Shock ). uuid:4f545acd-d6fa-4109-b52d-f5d2d5ecc5ae biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3380 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:61b44cf4-7227-496b-bd9c-b0222c2fcd7f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f2b07bde-b4e9-4eb1-9fea-f0f578d0beed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension : Captopril tablets USP are indicated for the treatment of hypertension. In using captopril, consideration should be given to the risk of neutropenia/ agranulocytosis (see WARNINGS ). Captopril may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. In patients with impaired renal function, particularly those with collagen vascular disease, captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations. Captopril is effective alone and in combination with other antihypertensive agents, especially thiazide-type diuretics. The blood pressure lowering effects of captopril and thiazides are approximately additive. Heart Failure : Captopril tablets are indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis. The beneficial effect of captopril in heart failure does not require the presence of digitalis, however, most controlled clinical trial experience with captopril has been in patients receiving digitalis, as well as diuretic treatment. Left Ventricular Dysfunction After Myocardial Infarction : Captopril tablets are indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction <40% and to reduce the incidence of overt heart failure and subsequent hospitalizations for congestive heart failure in these patients. Diabetic Nephropathy : Captopril tablets are indicated for the treatment of diabetic nephropathy (proteinuria > 500 mg/day) in patients with type I insulin-dependent diabetes mellitus and retinopathy. Captopril tablets decreases the rate of progression of renal insufficiency and development of serious adverse clinical outcomes (death or need for renal transplantation or dialysis). In considering use of captopril tablets, it should be noted that in controlled trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients (see WARNINGS : Angioedema ). uuid:4e360608-a925-4689-83c9-bf9f4e2a09e7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3380 biolink:treats MONDO:0005016 PMID:41385096 "[{""id"":""uuid:f8ec0d8d-6f8e-4a4b-be86-4aed4471d650"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9b373cc1-c703-4d86-9900-8377a0c33a13"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension : Captopril tablets USP are indicated for the treatment of hypertension. In using captopril, consideration should be given to the risk of neutropenia/ agranulocytosis (see WARNINGS ). Captopril may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. In patients with impaired renal function, particularly those with collagen vascular disease, captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations. Captopril is effective alone and in combination with other antihypertensive agents, especially thiazide-type diuretics. The blood pressure lowering effects of captopril and thiazides are approximately additive. Heart Failure : Captopril tablets are indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis. The beneficial effect of captopril in heart failure does not require the presence of digitalis, however, most controlled clinical trial experience with captopril has been in patients receiving digitalis, as well as diuretic treatment. Left Ventricular Dysfunction After Myocardial Infarction : Captopril tablets are indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction <40% and to reduce the incidence of overt heart failure and subsequent hospitalizations for congestive heart failure in these patients. Diabetic Nephropathy : Captopril tablets are indicated for the treatment of diabetic nephropathy (proteinuria > 500 mg/day) in patients with type I insulin-dependent diabetes mellitus and retinopathy. Captopril tablets decreases the rate of progression of renal insufficiency and development of serious adverse clinical outcomes (death or need for renal transplantation or dialysis). In considering use of captopril tablets, it should be noted that in controlled trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients (see WARNINGS : Angioedema ). uuid:020cdca2-dfbd-478f-a94d-b85179de9800 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3380 biolink:treats MONDO:0001106 PMID:41385096 "[{""id"":""uuid:1c760d6a-2dd0-40b8-b35e-694b3da1b302"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fb327830-8c85-4e5c-8bf6-23957dce3aa5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension : Captopril tablets USP are indicated for the treatment of hypertension. In using captopril, consideration should be given to the risk of neutropenia/ agranulocytosis (see WARNINGS ). Captopril may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. In patients with impaired renal function, particularly those with collagen vascular disease, captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations. Captopril is effective alone and in combination with other antihypertensive agents, especially thiazide-type diuretics. The blood pressure lowering effects of captopril and thiazides are approximately additive. Heart Failure : Captopril tablets are indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis. The beneficial effect of captopril in heart failure does not require the presence of digitalis, however, most controlled clinical trial experience with captopril has been in patients receiving digitalis, as well as diuretic treatment. Left Ventricular Dysfunction After Myocardial Infarction : Captopril tablets are indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction <40% and to reduce the incidence of overt heart failure and subsequent hospitalizations for congestive heart failure in these patients. Diabetic Nephropathy : Captopril tablets are indicated for the treatment of diabetic nephropathy (proteinuria > 500 mg/day) in patients with type I insulin-dependent diabetes mellitus and retinopathy. Captopril tablets decreases the rate of progression of renal insufficiency and development of serious adverse clinical outcomes (death or need for renal transplantation or dialysis). In considering use of captopril tablets, it should be noted that in controlled trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients (see WARNINGS : Angioedema ). uuid:5d162044-1794-4afd-a695-d24ff1a2ba99 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90972 biolink:treats MONDO:0007263 PMID:41385096 "[{""id"":""uuid:5a2a7f52-774f-4a92-9c4f-22b492e33edc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:99c894ca-9c28-4e11-8c4c-5fdafff19072"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Glycopyrrolate Injection is indicated for use as a preoperative antimuscarinic to reduce salivary, tracheobronchial, and pharyngeal secretions; to reduce the volume and free acidity of gastric secretions; and to block cardiac vagal inhibitory reflexes during induction of anesthesia and intubation. When indicated, Glycopyrrolate Injection may be used intraoperatively to counteract surgically or drug-induced or vagal reflexes associated arrhythmias. Glycopyrrolate protects against the peripheral muscarinic effects (e.g., bradycardia and excessive secretions) of cholinergic agents such as neostigmine and pyridostigmine given to reverse the neuromuscular blockade due to non-depolarizing muscle relaxants. uuid:97ef9105-9760-4fbe-8bf8-b59f8d4b6583 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28918 biolink:treats EFO:0020918 PMID:41385096 "[{""id"":""uuid:c487141f-c779-4e59-ba5f-1151eb9ee2cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bc145db9-9d6b-44dc-9035-238077ad290b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Epinephrine Injection, USP is indicated for intravenous injection in (1) treatment of acute hypersensitivity (anaphylactoid reactions to drugs, animal serums and other allergens), (2) treatment of acute asthmatic attacks to relieve bronchospasm not controlled by inhalation or subcutaneous administration of other solutions of the drug and (3) treatment and prophylaxis of cardiac arrest and attacks of transitory atrioventricular (A-V) heart block with syncopal seizures (Stokes-Adams Syndrome). In acute attacks of ventricular standstill, physical measures should be applied first. When external cardiac compression and attempts to restore the circulation by electrical defibrillation or use of a pacemaker fail, intracardiac puncture and intramyocardial injection of epinephrine may be effective. uuid:2b083bea-2812-4669-9277-6e5833f59fc7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28918 biolink:treats MONDO:0004766 PMID:41385096 "[{""id"":""uuid:66626b16-9dce-44ff-990f-aaf5b617ed7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f04dd4e2-77ec-4baf-989a-d0e19cf47177"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Epinephrine Injection, USP is indicated for intravenous injection in (1) treatment of acute hypersensitivity (anaphylactoid reactions to drugs, animal serums and other allergens), (2) treatment of acute asthmatic attacks to relieve bronchospasm not controlled by inhalation or subcutaneous administration of other solutions of the drug and (3) treatment and prophylaxis of cardiac arrest and attacks of transitory atrioventricular (A-V) heart block with syncopal seizures (Stokes-Adams Syndrome). In acute attacks of ventricular standstill, physical measures should be applied first. When external cardiac compression and attempts to restore the circulation by electrical defibrillation or use of a pacemaker fail, intracardiac puncture and intramyocardial injection of epinephrine may be effective. uuid:eaef8a9a-18fe-45f2-860c-50a341d30122 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28918 biolink:treats MONDO:0000745 PMID:41385096 "[{""id"":""uuid:2776d45c-8e38-4bf1-ad51-5a7c22643af1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:799f465f-f4ba-4eb9-a544-a600589394e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Epinephrine Injection, USP is indicated for intravenous injection in (1) treatment of acute hypersensitivity (anaphylactoid reactions to drugs, animal serums and other allergens), (2) treatment of acute asthmatic attacks to relieve bronchospasm not controlled by inhalation or subcutaneous administration of other solutions of the drug and (3) treatment and prophylaxis of cardiac arrest and attacks of transitory atrioventricular (A-V) heart block with syncopal seizures (Stokes-Adams Syndrome). In acute attacks of ventricular standstill, physical measures should be applied first. When external cardiac compression and attempts to restore the circulation by electrical defibrillation or use of a pacemaker fail, intracardiac puncture and intramyocardial injection of epinephrine may be effective. uuid:99c49a62-dc65-4efb-aee1-b8c7249bbe08 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28918 biolink:treats MONDO:0000465 PMID:41385096 "[{""id"":""uuid:b9359a02-ae95-4013-b17a-1bfacf645d84"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a5fc66c2-b96d-424b-a300-f71a11b069c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Epinephrine Injection, USP is indicated for intravenous injection in (1) treatment of acute hypersensitivity (anaphylactoid reactions to drugs, animal serums and other allergens), (2) treatment of acute asthmatic attacks to relieve bronchospasm not controlled by inhalation or subcutaneous administration of other solutions of the drug and (3) treatment and prophylaxis of cardiac arrest and attacks of transitory atrioventricular (A-V) heart block with syncopal seizures (Stokes-Adams Syndrome). In acute attacks of ventricular standstill, physical measures should be applied first. When external cardiac compression and attempts to restore the circulation by electrical defibrillation or use of a pacemaker fail, intracardiac puncture and intramyocardial injection of epinephrine may be effective. uuid:0cdc0a6e-aead-4afb-8f67-1c14df30a3ce biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28918 biolink:treats UMLS:C4285916 PMID:41385096 "[{""id"":""uuid:89acfe18-cca3-486d-b117-273310e86667"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c7db9d80-93dd-4507-9362-fa4445058374"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Epinephrine Injection, USP is indicated for intravenous injection in (1) treatment of acute hypersensitivity (anaphylactoid reactions to drugs, animal serums and other allergens), (2) treatment of acute asthmatic attacks to relieve bronchospasm not controlled by inhalation or subcutaneous administration of other solutions of the drug and (3) treatment and prophylaxis of cardiac arrest and attacks of transitory atrioventricular (A-V) heart block with syncopal seizures (Stokes-Adams Syndrome). In acute attacks of ventricular standstill, physical measures should be applied first. When external cardiac compression and attempts to restore the circulation by electrical defibrillation or use of a pacemaker fail, intracardiac puncture and intramyocardial injection of epinephrine may be effective. uuid:1dcb803c-c7ad-4ffc-bfde-04e49c81afb0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6539 biolink:treats UMLS:C0086132 PMID:41385096 "[{""id"":""uuid:551736a4-86da-49eb-96bb-f920f299805d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e53626f8-c039-4a67-a7b2-613cd05e0ea5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lorazepam is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety associated with depressive symptoms. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The effectiveness of lorazepam in long-term use, that is more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient. uuid:cb6ce781-cd5c-4641-889b-136f2fbe6bae biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2675 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:5b4f69f8-1c6e-424c-952d-c79434856404"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a81afabe-7d53-4e60-a721-a7a481a212f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amoxapine is indicated for the relief of symptoms of depression in patients with neurotic or reactive depressive disorders as well as endogenous and psychotic depressions. It is indicated for depression accompanied by anxiety or agitation. uuid:1cd60be0-993c-4ba6-aed1-f328f476fdaf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2675 biolink:treats MONDO:0024614 PMID:41385096 "[{""id"":""uuid:462a1292-f03b-4689-8888-223ffff4b19c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8baed407-5b6d-4a84-a67c-694f59de012d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amoxapine is indicated for the relief of symptoms of depression in patients with neurotic or reactive depressive disorders as well as endogenous and psychotic depressions. It is indicated for depression accompanied by anxiety or agitation. uuid:3d3c3275-ae9b-4664-9c4e-db951ae39b70 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2675 biolink:treats MONDO:0003265 PMID:41385096 "[{""id"":""uuid:34de38eb-b37e-4a3e-87d7-d78f367aa2ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:33756dcd-37e3-402a-98aa-180aa7fe38bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amoxapine is indicated for the relief of symptoms of depression in patients with neurotic or reactive depressive disorders as well as endogenous and psychotic depressions. It is indicated for depression accompanied by anxiety or agitation. uuid:8ede7f0b-a7c0-4690-874c-2100d018373c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2675 biolink:treats MONDO:0012048 PMID:41385096 "[{""id"":""uuid:e5f66e74-e4c0-423d-ac83-a67c73333796"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1d09080b-855e-43ea-a9c0-bb65668516e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amoxapine is indicated for the relief of symptoms of depression in patients with neurotic or reactive depressive disorders as well as endogenous and psychotic depressions. It is indicated for depression accompanied by anxiety or agitation. uuid:7fc42f28-3add-4b43-a67a-d09a2fbe1034 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2675 biolink:treats UMLS:C0743072 PMID:41385096 "[{""id"":""uuid:7b84bfcb-b10c-49c9-8dce-a9e617618958"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:01043b29-7c0a-47cc-bdef-c4d0ade6fe71"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amoxapine is indicated for the relief of symptoms of depression in patients with neurotic or reactive depressive disorders as well as endogenous and psychotic depressions. It is indicated for depression accompanied by anxiety or agitation. uuid:377d0d5e-5544-43e8-b0b7-bad5ffa34379 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2675 biolink:treats MONDO:0041086 PMID:41385096 "[{""id"":""uuid:3f46714c-9b6b-49a2-84b3-411f8abc4ad9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:88753150-04cc-492b-b49e-c4f8e5c8d7ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amoxapine is indicated for the relief of symptoms of depression in patients with neurotic or reactive depressive disorders as well as endogenous and psychotic depressions. It is indicated for depression accompanied by anxiety or agitation. uuid:ab1a35c1-3a74-496f-92f7-e8c0a78ef70b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2675 biolink:treats UMLS:C0235136 PMID:41385096 "[{""id"":""uuid:40350c46-0690-42e2-b861-8e1342db3a47"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fb894b8c-328d-4bb2-bbfd-e7e013c43a87"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amoxapine is indicated for the relief of symptoms of depression in patients with neurotic or reactive depressive disorders as well as endogenous and psychotic depressions. It is indicated for depression accompanied by anxiety or agitation. uuid:5c5d99d9-01c9-461e-9200-cb5c2914bfe6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5001 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:806600a8-53d9-4194-850a-f9f82b505eb4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:36495bd4-e1f4-4f6e-8464-f82a6134c559"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:3e35d2b1-aba5-417e-8884-109e7276a92a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fenoglide is a peroxisome proliferator receptor alpha (PPARα) activator indicated: as an adjunct to diet to reduce elevated LDL-C, Total-C, TG, and Apo B, and to increase HDL-C in patients with primary hyperlipidemia or mixed dyslipidemia when response to diet and non-pharmacological interventions alone has been inadequate. ( 1.1 ) as an adjunct to diet to treat patients with hypertriglyceridemia. Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually obviate the need for pharmacologic intervention. ( 1.2 ) Fenofibrate was not shown to reduce coronary heart disease morbidity and mortality in a large, randomized controlled trial of patients with type 2 diabetes mellitus. ( 1.3 )|[PMDA] Pulverization enables a reduction in the dosage to two thirds of the current dosage for hyperlipidemia (including familial hyperlipidemia). uuid:d78abbd6-a18c-415b-9a93-2a210da0bb59 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5001 biolink:treats MONDO:0005347 PMID:41385096 "[{""id"":""uuid:e1c2bf7a-2156-46db-aabb-14649f512bb3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d586c9df-d937-43b0-9ea0-50de3877c83a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fenoglide is a peroxisome proliferator receptor alpha (PPARα) activator indicated: as an adjunct to diet to reduce elevated LDL-C, Total-C, TG, and Apo B, and to increase HDL-C in patients with primary hyperlipidemia or mixed dyslipidemia when response to diet and non-pharmacological interventions alone has been inadequate. ( 1.1 ) as an adjunct to diet to treat patients with hypertriglyceridemia. Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually obviate the need for pharmacologic intervention. ( 1.2 ) Fenofibrate was not shown to reduce coronary heart disease morbidity and mortality in a large, randomized controlled trial of patients with type 2 diabetes mellitus. ( 1.3 ) uuid:8cad0dcd-cf5e-49cd-ae66-f902637c7d01 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5001 biolink:treats MONDO:0018637 PMID:41385096 "[{""id"":""uuid:94399be9-9032-4bd1-9ba7-4c51b6039bd1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:af030f0c-88bb-4c76-a226-f6e85ce68dee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fenoglide is a peroxisome proliferator receptor alpha (PPARα) activator indicated: as an adjunct to diet to reduce elevated LDL-C, Total-C, TG, and Apo B, and to increase HDL-C in patients with primary hyperlipidemia or mixed dyslipidemia when response to diet and non-pharmacological interventions alone has been inadequate. ( 1.1 ) as an adjunct to diet to treat patients with hypertriglyceridemia. Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually obviate the need for pharmacologic intervention. ( 1.2 ) Fenofibrate was not shown to reduce coronary heart disease morbidity and mortality in a large, randomized controlled trial of patients with type 2 diabetes mellitus. ( 1.3 ) uuid:a1a9ed99-a9cc-4bd9-abc3-9fb41fddfda5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5001 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:247dd331-8286-42de-9b2f-a63ae689b174"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f5be6cbd-dc73-49e9-85b1-e9801cd4a41e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fenoglide is a peroxisome proliferator receptor alpha (PPARα) activator indicated: as an adjunct to diet to reduce elevated LDL-C, Total-C, TG, and Apo B, and to increase HDL-C in patients with primary hyperlipidemia or mixed dyslipidemia when response to diet and non-pharmacological interventions alone has been inadequate. ( 1.1 ) as an adjunct to diet to treat patients with hypertriglyceridemia. Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually obviate the need for pharmacologic intervention. ( 1.2 ) Fenofibrate was not shown to reduce coronary heart disease morbidity and mortality in a large, randomized controlled trial of patients with type 2 diabetes mellitus. ( 1.3 ) uuid:51cb4d41-4ecc-4984-bc54-fe4ead97567c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:204734 biolink:treats MONDO:0005093 PMID:41385096 "[{""id"":""uuid:47d78e92-d204-4d58-9a8e-44c3bbe10a51"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7ff97097-9800-4e9c-9065-195b1e26777e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Desonide cream and ointment are low to medium potency corticosteroids indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. uuid:c57ca9fa-4e79-4fc1-8c0b-ea8a1904ae1b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:100241 biolink:treats UMLS:C1720797 PMID:41385096 "[{""id"":""uuid:aee73aba-91d9-4f94-a1e9-317154d57f55"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:136c36b2-b48c-472f-83f3-955c302c560e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ciprofloxacin tablets are indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions and patient populations listed below. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Adult Patients Urinary Tract Infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Serratia marcescens, Proteus mirabilis, Providencia rettgeri, Morganella morganii, Citrobacter diversus, Citrobacter freundii, Pseudomonas aeruginosa, methicillin-susceptible Staphylococcus epidermidis, Staphylococcus saprophyticus, or Enterococcus faecalis. Acute Uncomplicated Cystitis in females caused by Escherichia coli or Staphylococcus saprophyticus. Chronic Bacterial Prostatitis caused by Escherichia coli or Proteus mirabilis. Lower Respiratory Tract Infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Pseudomonas aeruginosa, Haemophilus influenzae, Haemophilus parainfluenzae, or penicillin-susceptible Streptococcus pneumoniae. Also, Moraxella catarrhalis for the treatment of acute exacerbations of chronic bronchitis. NOTE: Although effective in clinical trials, ciprofloxacin is not a drug of first choice in the treatment of presumed or confirmed pneumonia secondary to Streptococcus pneumoniae. Acute Sinusitis caused by Haemophilus influenzae, penicillin-susceptible Streptococcus pneumoniae, or Moraxella catarrhalis. Skin and Skin Structure Infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Proteus vulgaris, Providencia stuartii, Morganella morganii, Citrobacter freundii, Pseudomonas aeruginosa, methicillin-susceptible, Staphylococcus aureus, methicillin-susceptible Staphylococcus epidermidis, or Streptococcus pyogenes. Bone and Joint Infections caused by Enterobacter cloacae, Serratia marcescens, or Pseudomonas aeruginosa. Complicated Intra-Abdominal Infections (used in combination with metronidazole) caused by Escherichia coli, Pseudomonas aeruginosa, Proteus mirabilis, Klebsiella pneumoniae, or Bacteroides fragilis. Infectious Diarrhea caused by Escherichia coli (enterotoxigenic strains), Campylobacter jejuni, Shigella boydii 1 , Shigella dysenteriae, Shigella flexneri or Shigella sonnei 1 when antibacterial therapy is indicated. Typhoid Fever (Enteric Fever) caused by Salmonella typhi. NOTE: The efficacy of ciprofloxacin in the eradication of the chronic typhoid carrier state has not been demonstrated. Uncomplicated cervical and urethral gonorrhea due to Neisseria gonorrhoeae. 1 Although treatment of infections due to this organism in this organ system demonstrated a clinically significant outcome, efficacy was studied in fewer than 10 patients. Pediatric Patients (1 to 17 years of age) Complicated Urinary Tract Infections and Pyelonephritis due to Escherichia coli. Ciprofloxacin is not a drug of first choice in the pediatric population due to an increased incidence of adverse events compared to controls, including events related to joints and/or surrounding tissues. (See WARNINGS , PRECAUTIONS, Pediatric Use , ADVERSE REACTIONS and CLINICAL STUDIES .) Ciprofloxacin, like other fluoroquinolones, is associated with arthropathy and histopathological changes in weight-bearing joints of juvenile animals. (See ANIMAL PHARMACOLOGY .) Adult and Pediatric Patients Inhalational anthrax (post-exposure): To reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. Ciprofloxacin serum concentrations achieved in humans served as a surrogate endpoint reasonably likely to predict clinical benefit and provided the initial basis for approval of this indication.5 Supportive clinical information for ciprofloxacin for anthrax post-exposure prophylaxis was obtained during the anthrax bioterror attacks of October 2001. (See also, INHALATIONAL ANTHRAX - ADDITIONAL INFORMATION ). If anaerobic organisms are suspected of contributing to the infection, appropriate therapy should be administered. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to ciprofloxacin. Therapy with ciprofloxacin hydrochloride may be initiated before results of these tests are known; once results become available appropriate therapy should be continued. As with other drugs, some strains of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with ciprofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information not only on the therapeutic effect of the antimicrobial agent but also on the possible emergence of bacterial resistance. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ciprofloxacin tablets and other antibacterial drugs, ciprofloxacin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:bf6016fc-b0d4-4c10-a52d-7114c53eee8e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:100241 biolink:treats MONDO:0024355 PMID:41385096 "[{""id"":""uuid:879075d4-71ea-41e1-9aa8-9eb12b525f67"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8ddba8bd-3081-4622-8879-20dc864ad7b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ciprofloxacin tablets are indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions and patient populations listed below. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Adult Patients Urinary Tract Infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Serratia marcescens, Proteus mirabilis, Providencia rettgeri, Morganella morganii, Citrobacter diversus, Citrobacter freundii, Pseudomonas aeruginosa, methicillin-susceptible Staphylococcus epidermidis, Staphylococcus saprophyticus, or Enterococcus faecalis. Acute Uncomplicated Cystitis in females caused by Escherichia coli or Staphylococcus saprophyticus. Chronic Bacterial Prostatitis caused by Escherichia coli or Proteus mirabilis. Lower Respiratory Tract Infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Pseudomonas aeruginosa, Haemophilus influenzae, Haemophilus parainfluenzae, or penicillin-susceptible Streptococcus pneumoniae. Also, Moraxella catarrhalis for the treatment of acute exacerbations of chronic bronchitis. NOTE: Although effective in clinical trials, ciprofloxacin is not a drug of first choice in the treatment of presumed or confirmed pneumonia secondary to Streptococcus pneumoniae. Acute Sinusitis caused by Haemophilus influenzae, penicillin-susceptible Streptococcus pneumoniae, or Moraxella catarrhalis. Skin and Skin Structure Infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Proteus vulgaris, Providencia stuartii, Morganella morganii, Citrobacter freundii, Pseudomonas aeruginosa, methicillin-susceptible, Staphylococcus aureus, methicillin-susceptible Staphylococcus epidermidis, or Streptococcus pyogenes. Bone and Joint Infections caused by Enterobacter cloacae, Serratia marcescens, or Pseudomonas aeruginosa. Complicated Intra-Abdominal Infections (used in combination with metronidazole) caused by Escherichia coli, Pseudomonas aeruginosa, Proteus mirabilis, Klebsiella pneumoniae, or Bacteroides fragilis. Infectious Diarrhea caused by Escherichia coli (enterotoxigenic strains), Campylobacter jejuni, Shigella boydii 1 , Shigella dysenteriae, Shigella flexneri or Shigella sonnei 1 when antibacterial therapy is indicated. Typhoid Fever (Enteric Fever) caused by Salmonella typhi. NOTE: The efficacy of ciprofloxacin in the eradication of the chronic typhoid carrier state has not been demonstrated. Uncomplicated cervical and urethral gonorrhea due to Neisseria gonorrhoeae. 1 Although treatment of infections due to this organism in this organ system demonstrated a clinically significant outcome, efficacy was studied in fewer than 10 patients. Pediatric Patients (1 to 17 years of age) Complicated Urinary Tract Infections and Pyelonephritis due to Escherichia coli. Ciprofloxacin is not a drug of first choice in the pediatric population due to an increased incidence of adverse events compared to controls, including events related to joints and/or surrounding tissues. (See WARNINGS , PRECAUTIONS, Pediatric Use , ADVERSE REACTIONS and CLINICAL STUDIES .) Ciprofloxacin, like other fluoroquinolones, is associated with arthropathy and histopathological changes in weight-bearing joints of juvenile animals. (See ANIMAL PHARMACOLOGY .) Adult and Pediatric Patients Inhalational anthrax (post-exposure): To reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. Ciprofloxacin serum concentrations achieved in humans served as a surrogate endpoint reasonably likely to predict clinical benefit and provided the initial basis for approval of this indication.5 Supportive clinical information for ciprofloxacin for anthrax post-exposure prophylaxis was obtained during the anthrax bioterror attacks of October 2001. (See also, INHALATIONAL ANTHRAX - ADDITIONAL INFORMATION ). If anaerobic organisms are suspected of contributing to the infection, appropriate therapy should be administered. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to ciprofloxacin. Therapy with ciprofloxacin hydrochloride may be initiated before results of these tests are known; once results become available appropriate therapy should be continued. As with other drugs, some strains of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with ciprofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information not only on the therapeutic effect of the antimicrobial agent but also on the possible emergence of bacterial resistance. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ciprofloxacin tablets and other antibacterial drugs, ciprofloxacin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:692593df-d848-42b6-9161-dd6d3a6ada96 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:100241 biolink:treats UMLS:C0853854 PMID:41385096 "[{""id"":""uuid:84f281eb-5bc4-4f59-b7a1-5f5ece4a5638"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f9fe452c-b27e-4d12-a359-ab3a92fe7c1b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ciprofloxacin tablets are indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions and patient populations listed below. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Adult Patients Urinary Tract Infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Serratia marcescens, Proteus mirabilis, Providencia rettgeri, Morganella morganii, Citrobacter diversus, Citrobacter freundii, Pseudomonas aeruginosa, methicillin-susceptible Staphylococcus epidermidis, Staphylococcus saprophyticus, or Enterococcus faecalis. Acute Uncomplicated Cystitis in females caused by Escherichia coli or Staphylococcus saprophyticus. Chronic Bacterial Prostatitis caused by Escherichia coli or Proteus mirabilis. Lower Respiratory Tract Infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Pseudomonas aeruginosa, Haemophilus influenzae, Haemophilus parainfluenzae, or penicillin-susceptible Streptococcus pneumoniae. Also, Moraxella catarrhalis for the treatment of acute exacerbations of chronic bronchitis. NOTE: Although effective in clinical trials, ciprofloxacin is not a drug of first choice in the treatment of presumed or confirmed pneumonia secondary to Streptococcus pneumoniae. Acute Sinusitis caused by Haemophilus influenzae, penicillin-susceptible Streptococcus pneumoniae, or Moraxella catarrhalis. Skin and Skin Structure Infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Proteus vulgaris, Providencia stuartii, Morganella morganii, Citrobacter freundii, Pseudomonas aeruginosa, methicillin-susceptible, Staphylococcus aureus, methicillin-susceptible Staphylococcus epidermidis, or Streptococcus pyogenes. Bone and Joint Infections caused by Enterobacter cloacae, Serratia marcescens, or Pseudomonas aeruginosa. Complicated Intra-Abdominal Infections (used in combination with metronidazole) caused by Escherichia coli, Pseudomonas aeruginosa, Proteus mirabilis, Klebsiella pneumoniae, or Bacteroides fragilis. Infectious Diarrhea caused by Escherichia coli (enterotoxigenic strains), Campylobacter jejuni, Shigella boydii 1 , Shigella dysenteriae, Shigella flexneri or Shigella sonnei 1 when antibacterial therapy is indicated. Typhoid Fever (Enteric Fever) caused by Salmonella typhi. NOTE: The efficacy of ciprofloxacin in the eradication of the chronic typhoid carrier state has not been demonstrated. Uncomplicated cervical and urethral gonorrhea due to Neisseria gonorrhoeae. 1 Although treatment of infections due to this organism in this organ system demonstrated a clinically significant outcome, efficacy was studied in fewer than 10 patients. Pediatric Patients (1 to 17 years of age) Complicated Urinary Tract Infections and Pyelonephritis due to Escherichia coli. Ciprofloxacin is not a drug of first choice in the pediatric population due to an increased incidence of adverse events compared to controls, including events related to joints and/or surrounding tissues. (See WARNINGS , PRECAUTIONS, Pediatric Use , ADVERSE REACTIONS and CLINICAL STUDIES .) Ciprofloxacin, like other fluoroquinolones, is associated with arthropathy and histopathological changes in weight-bearing joints of juvenile animals. (See ANIMAL PHARMACOLOGY .) Adult and Pediatric Patients Inhalational anthrax (post-exposure): To reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. Ciprofloxacin serum concentrations achieved in humans served as a surrogate endpoint reasonably likely to predict clinical benefit and provided the initial basis for approval of this indication.5 Supportive clinical information for ciprofloxacin for anthrax post-exposure prophylaxis was obtained during the anthrax bioterror attacks of October 2001. (See also, INHALATIONAL ANTHRAX - ADDITIONAL INFORMATION ). If anaerobic organisms are suspected of contributing to the infection, appropriate therapy should be administered. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to ciprofloxacin. Therapy with ciprofloxacin hydrochloride may be initiated before results of these tests are known; once results become available appropriate therapy should be continued. As with other drugs, some strains of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with ciprofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information not only on the therapeutic effect of the antimicrobial agent but also on the possible emergence of bacterial resistance. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ciprofloxacin tablets and other antibacterial drugs, ciprofloxacin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:e127b490-383a-4ad5-a4a6-a9de879e4fff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:100241 biolink:treats HP:0000255 PMID:41385096 "[{""id"":""uuid:cd613fff-febc-4e43-bf21-48a945895007"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2c5c84fd-7e4d-4951-bd5f-87e45100d500"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ciprofloxacin tablets are indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions and patient populations listed below. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Adult Patients Urinary Tract Infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Serratia marcescens, Proteus mirabilis, Providencia rettgeri, Morganella morganii, Citrobacter diversus, Citrobacter freundii, Pseudomonas aeruginosa, methicillin-susceptible Staphylococcus epidermidis, Staphylococcus saprophyticus, or Enterococcus faecalis. Acute Uncomplicated Cystitis in females caused by Escherichia coli or Staphylococcus saprophyticus. Chronic Bacterial Prostatitis caused by Escherichia coli or Proteus mirabilis. Lower Respiratory Tract Infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Pseudomonas aeruginosa, Haemophilus influenzae, Haemophilus parainfluenzae, or penicillin-susceptible Streptococcus pneumoniae. Also, Moraxella catarrhalis for the treatment of acute exacerbations of chronic bronchitis. NOTE: Although effective in clinical trials, ciprofloxacin is not a drug of first choice in the treatment of presumed or confirmed pneumonia secondary to Streptococcus pneumoniae. Acute Sinusitis caused by Haemophilus influenzae, penicillin-susceptible Streptococcus pneumoniae, or Moraxella catarrhalis. Skin and Skin Structure Infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Proteus vulgaris, Providencia stuartii, Morganella morganii, Citrobacter freundii, Pseudomonas aeruginosa, methicillin-susceptible, Staphylococcus aureus, methicillin-susceptible Staphylococcus epidermidis, or Streptococcus pyogenes. Bone and Joint Infections caused by Enterobacter cloacae, Serratia marcescens, or Pseudomonas aeruginosa. Complicated Intra-Abdominal Infections (used in combination with metronidazole) caused by Escherichia coli, Pseudomonas aeruginosa, Proteus mirabilis, Klebsiella pneumoniae, or Bacteroides fragilis. Infectious Diarrhea caused by Escherichia coli (enterotoxigenic strains), Campylobacter jejuni, Shigella boydii 1 , Shigella dysenteriae, Shigella flexneri or Shigella sonnei 1 when antibacterial therapy is indicated. Typhoid Fever (Enteric Fever) caused by Salmonella typhi. NOTE: The efficacy of ciprofloxacin in the eradication of the chronic typhoid carrier state has not been demonstrated. Uncomplicated cervical and urethral gonorrhea due to Neisseria gonorrhoeae. 1 Although treatment of infections due to this organism in this organ system demonstrated a clinically significant outcome, efficacy was studied in fewer than 10 patients. Pediatric Patients (1 to 17 years of age) Complicated Urinary Tract Infections and Pyelonephritis due to Escherichia coli. Ciprofloxacin is not a drug of first choice in the pediatric population due to an increased incidence of adverse events compared to controls, including events related to joints and/or surrounding tissues. (See WARNINGS , PRECAUTIONS, Pediatric Use , ADVERSE REACTIONS and CLINICAL STUDIES .) Ciprofloxacin, like other fluoroquinolones, is associated with arthropathy and histopathological changes in weight-bearing joints of juvenile animals. (See ANIMAL PHARMACOLOGY .) Adult and Pediatric Patients Inhalational anthrax (post-exposure): To reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. Ciprofloxacin serum concentrations achieved in humans served as a surrogate endpoint reasonably likely to predict clinical benefit and provided the initial basis for approval of this indication.5 Supportive clinical information for ciprofloxacin for anthrax post-exposure prophylaxis was obtained during the anthrax bioterror attacks of October 2001. (See also, INHALATIONAL ANTHRAX - ADDITIONAL INFORMATION ). If anaerobic organisms are suspected of contributing to the infection, appropriate therapy should be administered. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to ciprofloxacin. Therapy with ciprofloxacin hydrochloride may be initiated before results of these tests are known; once results become available appropriate therapy should be continued. As with other drugs, some strains of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with ciprofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information not only on the therapeutic effect of the antimicrobial agent but also on the possible emergence of bacterial resistance. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ciprofloxacin tablets and other antibacterial drugs, ciprofloxacin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:83235773-d9cf-4ac1-9a6c-9c2bfad6398a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:100241 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:efe45542-1492-4fe9-92f9-8fd5689fd9f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:faae3157-3ff9-494e-8a4e-053f3e949341"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ciprofloxacin tablets are indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions and patient populations listed below. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Adult Patients Urinary Tract Infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Serratia marcescens, Proteus mirabilis, Providencia rettgeri, Morganella morganii, Citrobacter diversus, Citrobacter freundii, Pseudomonas aeruginosa, methicillin-susceptible Staphylococcus epidermidis, Staphylococcus saprophyticus, or Enterococcus faecalis. Acute Uncomplicated Cystitis in females caused by Escherichia coli or Staphylococcus saprophyticus. Chronic Bacterial Prostatitis caused by Escherichia coli or Proteus mirabilis. Lower Respiratory Tract Infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Pseudomonas aeruginosa, Haemophilus influenzae, Haemophilus parainfluenzae, or penicillin-susceptible Streptococcus pneumoniae. Also, Moraxella catarrhalis for the treatment of acute exacerbations of chronic bronchitis. NOTE: Although effective in clinical trials, ciprofloxacin is not a drug of first choice in the treatment of presumed or confirmed pneumonia secondary to Streptococcus pneumoniae. Acute Sinusitis caused by Haemophilus influenzae, penicillin-susceptible Streptococcus pneumoniae, or Moraxella catarrhalis. Skin and Skin Structure Infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Proteus vulgaris, Providencia stuartii, Morganella morganii, Citrobacter freundii, Pseudomonas aeruginosa, methicillin-susceptible, Staphylococcus aureus, methicillin-susceptible Staphylococcus epidermidis, or Streptococcus pyogenes. Bone and Joint Infections caused by Enterobacter cloacae, Serratia marcescens, or Pseudomonas aeruginosa. Complicated Intra-Abdominal Infections (used in combination with metronidazole) caused by Escherichia coli, Pseudomonas aeruginosa, Proteus mirabilis, Klebsiella pneumoniae, or Bacteroides fragilis. Infectious Diarrhea caused by Escherichia coli (enterotoxigenic strains), Campylobacter jejuni, Shigella boydii 1 , Shigella dysenteriae, Shigella flexneri or Shigella sonnei 1 when antibacterial therapy is indicated. Typhoid Fever (Enteric Fever) caused by Salmonella typhi. NOTE: The efficacy of ciprofloxacin in the eradication of the chronic typhoid carrier state has not been demonstrated. Uncomplicated cervical and urethral gonorrhea due to Neisseria gonorrhoeae. 1 Although treatment of infections due to this organism in this organ system demonstrated a clinically significant outcome, efficacy was studied in fewer than 10 patients. Pediatric Patients (1 to 17 years of age) Complicated Urinary Tract Infections and Pyelonephritis due to Escherichia coli. Ciprofloxacin is not a drug of first choice in the pediatric population due to an increased incidence of adverse events compared to controls, including events related to joints and/or surrounding tissues. (See WARNINGS , PRECAUTIONS, Pediatric Use , ADVERSE REACTIONS and CLINICAL STUDIES .) Ciprofloxacin, like other fluoroquinolones, is associated with arthropathy and histopathological changes in weight-bearing joints of juvenile animals. (See ANIMAL PHARMACOLOGY .) Adult and Pediatric Patients Inhalational anthrax (post-exposure): To reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. Ciprofloxacin serum concentrations achieved in humans served as a surrogate endpoint reasonably likely to predict clinical benefit and provided the initial basis for approval of this indication.5 Supportive clinical information for ciprofloxacin for anthrax post-exposure prophylaxis was obtained during the anthrax bioterror attacks of October 2001. (See also, INHALATIONAL ANTHRAX - ADDITIONAL INFORMATION ). If anaerobic organisms are suspected of contributing to the infection, appropriate therapy should be administered. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to ciprofloxacin. Therapy with ciprofloxacin hydrochloride may be initiated before results of these tests are known; once results become available appropriate therapy should be continued. As with other drugs, some strains of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with ciprofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information not only on the therapeutic effect of the antimicrobial agent but also on the possible emergence of bacterial resistance. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ciprofloxacin tablets and other antibacterial drugs, ciprofloxacin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:58d0052c-1225-4224-8811-218b0d085786 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:100241 biolink:treats UMLS:C0851989 PMID:41385096 "[{""id"":""uuid:c8e34523-0a1d-4cb6-a733-a6e412fa4f94"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f57acb10-142e-4dd3-b01a-d62af8c7086d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ciprofloxacin tablets are indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions and patient populations listed below. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Adult Patients Urinary Tract Infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Serratia marcescens, Proteus mirabilis, Providencia rettgeri, Morganella morganii, Citrobacter diversus, Citrobacter freundii, Pseudomonas aeruginosa, methicillin-susceptible Staphylococcus epidermidis, Staphylococcus saprophyticus, or Enterococcus faecalis. Acute Uncomplicated Cystitis in females caused by Escherichia coli or Staphylococcus saprophyticus. Chronic Bacterial Prostatitis caused by Escherichia coli or Proteus mirabilis. Lower Respiratory Tract Infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Pseudomonas aeruginosa, Haemophilus influenzae, Haemophilus parainfluenzae, or penicillin-susceptible Streptococcus pneumoniae. Also, Moraxella catarrhalis for the treatment of acute exacerbations of chronic bronchitis. NOTE: Although effective in clinical trials, ciprofloxacin is not a drug of first choice in the treatment of presumed or confirmed pneumonia secondary to Streptococcus pneumoniae. Acute Sinusitis caused by Haemophilus influenzae, penicillin-susceptible Streptococcus pneumoniae, or Moraxella catarrhalis. Skin and Skin Structure Infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Proteus vulgaris, Providencia stuartii, Morganella morganii, Citrobacter freundii, Pseudomonas aeruginosa, methicillin-susceptible, Staphylococcus aureus, methicillin-susceptible Staphylococcus epidermidis, or Streptococcus pyogenes. Bone and Joint Infections caused by Enterobacter cloacae, Serratia marcescens, or Pseudomonas aeruginosa. Complicated Intra-Abdominal Infections (used in combination with metronidazole) caused by Escherichia coli, Pseudomonas aeruginosa, Proteus mirabilis, Klebsiella pneumoniae, or Bacteroides fragilis. Infectious Diarrhea caused by Escherichia coli (enterotoxigenic strains), Campylobacter jejuni, Shigella boydii 1 , Shigella dysenteriae, Shigella flexneri or Shigella sonnei 1 when antibacterial therapy is indicated. Typhoid Fever (Enteric Fever) caused by Salmonella typhi. NOTE: The efficacy of ciprofloxacin in the eradication of the chronic typhoid carrier state has not been demonstrated. Uncomplicated cervical and urethral gonorrhea due to Neisseria gonorrhoeae. 1 Although treatment of infections due to this organism in this organ system demonstrated a clinically significant outcome, efficacy was studied in fewer than 10 patients. Pediatric Patients (1 to 17 years of age) Complicated Urinary Tract Infections and Pyelonephritis due to Escherichia coli. Ciprofloxacin is not a drug of first choice in the pediatric population due to an increased incidence of adverse events compared to controls, including events related to joints and/or surrounding tissues. (See WARNINGS , PRECAUTIONS, Pediatric Use , ADVERSE REACTIONS and CLINICAL STUDIES .) Ciprofloxacin, like other fluoroquinolones, is associated with arthropathy and histopathological changes in weight-bearing joints of juvenile animals. (See ANIMAL PHARMACOLOGY .) Adult and Pediatric Patients Inhalational anthrax (post-exposure): To reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. Ciprofloxacin serum concentrations achieved in humans served as a surrogate endpoint reasonably likely to predict clinical benefit and provided the initial basis for approval of this indication.5 Supportive clinical information for ciprofloxacin for anthrax post-exposure prophylaxis was obtained during the anthrax bioterror attacks of October 2001. (See also, INHALATIONAL ANTHRAX - ADDITIONAL INFORMATION ). If anaerobic organisms are suspected of contributing to the infection, appropriate therapy should be administered. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to ciprofloxacin. Therapy with ciprofloxacin hydrochloride may be initiated before results of these tests are known; once results become available appropriate therapy should be continued. As with other drugs, some strains of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with ciprofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information not only on the therapeutic effect of the antimicrobial agent but also on the possible emergence of bacterial resistance. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ciprofloxacin tablets and other antibacterial drugs, ciprofloxacin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:fe9ead64-b0dd-499d-a679-e6030f02cf0a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:100241 biolink:treats MONDO:0001517 PMID:41385096 "[{""id"":""uuid:7da5f86e-e4ba-4560-951b-d480d800f99f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:66ff118c-1e8e-4e13-9b81-388cdf8accde"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ciprofloxacin tablets are indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions and patient populations listed below. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Adult Patients Urinary Tract Infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Serratia marcescens, Proteus mirabilis, Providencia rettgeri, Morganella morganii, Citrobacter diversus, Citrobacter freundii, Pseudomonas aeruginosa, methicillin-susceptible Staphylococcus epidermidis, Staphylococcus saprophyticus, or Enterococcus faecalis. Acute Uncomplicated Cystitis in females caused by Escherichia coli or Staphylococcus saprophyticus. Chronic Bacterial Prostatitis caused by Escherichia coli or Proteus mirabilis. Lower Respiratory Tract Infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Pseudomonas aeruginosa, Haemophilus influenzae, Haemophilus parainfluenzae, or penicillin-susceptible Streptococcus pneumoniae. Also, Moraxella catarrhalis for the treatment of acute exacerbations of chronic bronchitis. NOTE: Although effective in clinical trials, ciprofloxacin is not a drug of first choice in the treatment of presumed or confirmed pneumonia secondary to Streptococcus pneumoniae. Acute Sinusitis caused by Haemophilus influenzae, penicillin-susceptible Streptococcus pneumoniae, or Moraxella catarrhalis. Skin and Skin Structure Infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Proteus vulgaris, Providencia stuartii, Morganella morganii, Citrobacter freundii, Pseudomonas aeruginosa, methicillin-susceptible, Staphylococcus aureus, methicillin-susceptible Staphylococcus epidermidis, or Streptococcus pyogenes. Bone and Joint Infections caused by Enterobacter cloacae, Serratia marcescens, or Pseudomonas aeruginosa. Complicated Intra-Abdominal Infections (used in combination with metronidazole) caused by Escherichia coli, Pseudomonas aeruginosa, Proteus mirabilis, Klebsiella pneumoniae, or Bacteroides fragilis. Infectious Diarrhea caused by Escherichia coli (enterotoxigenic strains), Campylobacter jejuni, Shigella boydii 1 , Shigella dysenteriae, Shigella flexneri or Shigella sonnei 1 when antibacterial therapy is indicated. Typhoid Fever (Enteric Fever) caused by Salmonella typhi. NOTE: The efficacy of ciprofloxacin in the eradication of the chronic typhoid carrier state has not been demonstrated. Uncomplicated cervical and urethral gonorrhea due to Neisseria gonorrhoeae. 1 Although treatment of infections due to this organism in this organ system demonstrated a clinically significant outcome, efficacy was studied in fewer than 10 patients. Pediatric Patients (1 to 17 years of age) Complicated Urinary Tract Infections and Pyelonephritis due to Escherichia coli. Ciprofloxacin is not a drug of first choice in the pediatric population due to an increased incidence of adverse events compared to controls, including events related to joints and/or surrounding tissues. (See WARNINGS , PRECAUTIONS, Pediatric Use , ADVERSE REACTIONS and CLINICAL STUDIES .) Ciprofloxacin, like other fluoroquinolones, is associated with arthropathy and histopathological changes in weight-bearing joints of juvenile animals. (See ANIMAL PHARMACOLOGY .) Adult and Pediatric Patients Inhalational anthrax (post-exposure): To reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. Ciprofloxacin serum concentrations achieved in humans served as a surrogate endpoint reasonably likely to predict clinical benefit and provided the initial basis for approval of this indication.5 Supportive clinical information for ciprofloxacin for anthrax post-exposure prophylaxis was obtained during the anthrax bioterror attacks of October 2001. (See also, INHALATIONAL ANTHRAX - ADDITIONAL INFORMATION ). If anaerobic organisms are suspected of contributing to the infection, appropriate therapy should be administered. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to ciprofloxacin. Therapy with ciprofloxacin hydrochloride may be initiated before results of these tests are known; once results become available appropriate therapy should be continued. As with other drugs, some strains of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with ciprofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information not only on the therapeutic effect of the antimicrobial agent but also on the possible emergence of bacterial resistance. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ciprofloxacin tablets and other antibacterial drugs, ciprofloxacin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:a402473b-ee17-4d40-adcc-d9a82f5cb8e5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:100241 biolink:treats MONDO:0005619 PMID:41385096 "[{""id"":""uuid:543db72e-7d40-48f6-9d8c-289be294a568"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:22eb8126-0312-438e-926e-412578a818cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ciprofloxacin tablets are indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions and patient populations listed below. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Adult Patients Urinary Tract Infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Serratia marcescens, Proteus mirabilis, Providencia rettgeri, Morganella morganii, Citrobacter diversus, Citrobacter freundii, Pseudomonas aeruginosa, methicillin-susceptible Staphylococcus epidermidis, Staphylococcus saprophyticus, or Enterococcus faecalis. Acute Uncomplicated Cystitis in females caused by Escherichia coli or Staphylococcus saprophyticus. Chronic Bacterial Prostatitis caused by Escherichia coli or Proteus mirabilis. Lower Respiratory Tract Infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Pseudomonas aeruginosa, Haemophilus influenzae, Haemophilus parainfluenzae, or penicillin-susceptible Streptococcus pneumoniae. Also, Moraxella catarrhalis for the treatment of acute exacerbations of chronic bronchitis. NOTE: Although effective in clinical trials, ciprofloxacin is not a drug of first choice in the treatment of presumed or confirmed pneumonia secondary to Streptococcus pneumoniae. Acute Sinusitis caused by Haemophilus influenzae, penicillin-susceptible Streptococcus pneumoniae, or Moraxella catarrhalis. Skin and Skin Structure Infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Proteus vulgaris, Providencia stuartii, Morganella morganii, Citrobacter freundii, Pseudomonas aeruginosa, methicillin-susceptible, Staphylococcus aureus, methicillin-susceptible Staphylococcus epidermidis, or Streptococcus pyogenes. Bone and Joint Infections caused by Enterobacter cloacae, Serratia marcescens, or Pseudomonas aeruginosa. Complicated Intra-Abdominal Infections (used in combination with metronidazole) caused by Escherichia coli, Pseudomonas aeruginosa, Proteus mirabilis, Klebsiella pneumoniae, or Bacteroides fragilis. Infectious Diarrhea caused by Escherichia coli (enterotoxigenic strains), Campylobacter jejuni, Shigella boydii 1 , Shigella dysenteriae, Shigella flexneri or Shigella sonnei 1 when antibacterial therapy is indicated. Typhoid Fever (Enteric Fever) caused by Salmonella typhi. NOTE: The efficacy of ciprofloxacin in the eradication of the chronic typhoid carrier state has not been demonstrated. Uncomplicated cervical and urethral gonorrhea due to Neisseria gonorrhoeae. 1 Although treatment of infections due to this organism in this organ system demonstrated a clinically significant outcome, efficacy was studied in fewer than 10 patients. Pediatric Patients (1 to 17 years of age) Complicated Urinary Tract Infections and Pyelonephritis due to Escherichia coli. Ciprofloxacin is not a drug of first choice in the pediatric population due to an increased incidence of adverse events compared to controls, including events related to joints and/or surrounding tissues. (See WARNINGS , PRECAUTIONS, Pediatric Use , ADVERSE REACTIONS and CLINICAL STUDIES .) Ciprofloxacin, like other fluoroquinolones, is associated with arthropathy and histopathological changes in weight-bearing joints of juvenile animals. (See ANIMAL PHARMACOLOGY .) Adult and Pediatric Patients Inhalational anthrax (post-exposure): To reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. Ciprofloxacin serum concentrations achieved in humans served as a surrogate endpoint reasonably likely to predict clinical benefit and provided the initial basis for approval of this indication.5 Supportive clinical information for ciprofloxacin for anthrax post-exposure prophylaxis was obtained during the anthrax bioterror attacks of October 2001. (See also, INHALATIONAL ANTHRAX - ADDITIONAL INFORMATION ). If anaerobic organisms are suspected of contributing to the infection, appropriate therapy should be administered. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to ciprofloxacin. Therapy with ciprofloxacin hydrochloride may be initiated before results of these tests are known; once results become available appropriate therapy should be continued. As with other drugs, some strains of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with ciprofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information not only on the therapeutic effect of the antimicrobial agent but also on the possible emergence of bacterial resistance. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ciprofloxacin tablets and other antibacterial drugs, ciprofloxacin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:a31c5e19-bfae-4b5d-a635-a644e06dc711 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:100241 biolink:treats MONDO:0004277 PMID:41385096 "[{""id"":""uuid:010c1e1b-2b54-40e4-808a-1543dd8a695d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:16de69e4-2b7f-4cfe-b6b5-2b8d4e2b3c1a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ciprofloxacin tablets are indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions and patient populations listed below. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Adult Patients Urinary Tract Infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Serratia marcescens, Proteus mirabilis, Providencia rettgeri, Morganella morganii, Citrobacter diversus, Citrobacter freundii, Pseudomonas aeruginosa, methicillin-susceptible Staphylococcus epidermidis, Staphylococcus saprophyticus, or Enterococcus faecalis. Acute Uncomplicated Cystitis in females caused by Escherichia coli or Staphylococcus saprophyticus. Chronic Bacterial Prostatitis caused by Escherichia coli or Proteus mirabilis. Lower Respiratory Tract Infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Pseudomonas aeruginosa, Haemophilus influenzae, Haemophilus parainfluenzae, or penicillin-susceptible Streptococcus pneumoniae. Also, Moraxella catarrhalis for the treatment of acute exacerbations of chronic bronchitis. NOTE: Although effective in clinical trials, ciprofloxacin is not a drug of first choice in the treatment of presumed or confirmed pneumonia secondary to Streptococcus pneumoniae. Acute Sinusitis caused by Haemophilus influenzae, penicillin-susceptible Streptococcus pneumoniae, or Moraxella catarrhalis. Skin and Skin Structure Infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Proteus vulgaris, Providencia stuartii, Morganella morganii, Citrobacter freundii, Pseudomonas aeruginosa, methicillin-susceptible, Staphylococcus aureus, methicillin-susceptible Staphylococcus epidermidis, or Streptococcus pyogenes. Bone and Joint Infections caused by Enterobacter cloacae, Serratia marcescens, or Pseudomonas aeruginosa. Complicated Intra-Abdominal Infections (used in combination with metronidazole) caused by Escherichia coli, Pseudomonas aeruginosa, Proteus mirabilis, Klebsiella pneumoniae, or Bacteroides fragilis. Infectious Diarrhea caused by Escherichia coli (enterotoxigenic strains), Campylobacter jejuni, Shigella boydii 1 , Shigella dysenteriae, Shigella flexneri or Shigella sonnei 1 when antibacterial therapy is indicated. Typhoid Fever (Enteric Fever) caused by Salmonella typhi. NOTE: The efficacy of ciprofloxacin in the eradication of the chronic typhoid carrier state has not been demonstrated. Uncomplicated cervical and urethral gonorrhea due to Neisseria gonorrhoeae. 1 Although treatment of infections due to this organism in this organ system demonstrated a clinically significant outcome, efficacy was studied in fewer than 10 patients. Pediatric Patients (1 to 17 years of age) Complicated Urinary Tract Infections and Pyelonephritis due to Escherichia coli. Ciprofloxacin is not a drug of first choice in the pediatric population due to an increased incidence of adverse events compared to controls, including events related to joints and/or surrounding tissues. (See WARNINGS , PRECAUTIONS, Pediatric Use , ADVERSE REACTIONS and CLINICAL STUDIES .) Ciprofloxacin, like other fluoroquinolones, is associated with arthropathy and histopathological changes in weight-bearing joints of juvenile animals. (See ANIMAL PHARMACOLOGY .) Adult and Pediatric Patients Inhalational anthrax (post-exposure): To reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. Ciprofloxacin serum concentrations achieved in humans served as a surrogate endpoint reasonably likely to predict clinical benefit and provided the initial basis for approval of this indication.5 Supportive clinical information for ciprofloxacin for anthrax post-exposure prophylaxis was obtained during the anthrax bioterror attacks of October 2001. (See also, INHALATIONAL ANTHRAX - ADDITIONAL INFORMATION ). If anaerobic organisms are suspected of contributing to the infection, appropriate therapy should be administered. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to ciprofloxacin. Therapy with ciprofloxacin hydrochloride may be initiated before results of these tests are known; once results become available appropriate therapy should be continued. As with other drugs, some strains of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with ciprofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information not only on the therapeutic effect of the antimicrobial agent but also on the possible emergence of bacterial resistance. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ciprofloxacin tablets and other antibacterial drugs, ciprofloxacin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:3153b72c-b580-4a85-bb89-edc0ca104268 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:100241 biolink:treats MONDO:0006939 PMID:41385096 "[{""id"":""uuid:f53c93bd-5cf2-4947-a266-9be5dd1b4d58"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:327c91b0-3cf7-4b02-856a-56acfc9c54aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:3dd1d227-cb14-4a2e-8051-1e12e7eba054"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ciprofloxacin tablets are indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions and patient populations listed below. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Adult Patients Urinary Tract Infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Serratia marcescens, Proteus mirabilis, Providencia rettgeri, Morganella morganii, Citrobacter diversus, Citrobacter freundii, Pseudomonas aeruginosa, methicillin-susceptible Staphylococcus epidermidis, Staphylococcus saprophyticus, or Enterococcus faecalis. Acute Uncomplicated Cystitis in females caused by Escherichia coli or Staphylococcus saprophyticus. Chronic Bacterial Prostatitis caused by Escherichia coli or Proteus mirabilis. Lower Respiratory Tract Infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Pseudomonas aeruginosa, Haemophilus influenzae, Haemophilus parainfluenzae, or penicillin-susceptible Streptococcus pneumoniae. Also, Moraxella catarrhalis for the treatment of acute exacerbations of chronic bronchitis. NOTE: Although effective in clinical trials, ciprofloxacin is not a drug of first choice in the treatment of presumed or confirmed pneumonia secondary to Streptococcus pneumoniae. Acute Sinusitis caused by Haemophilus influenzae, penicillin-susceptible Streptococcus pneumoniae, or Moraxella catarrhalis. Skin and Skin Structure Infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Proteus vulgaris, Providencia stuartii, Morganella morganii, Citrobacter freundii, Pseudomonas aeruginosa, methicillin-susceptible, Staphylococcus aureus, methicillin-susceptible Staphylococcus epidermidis, or Streptococcus pyogenes. Bone and Joint Infections caused by Enterobacter cloacae, Serratia marcescens, or Pseudomonas aeruginosa. Complicated Intra-Abdominal Infections (used in combination with metronidazole) caused by Escherichia coli, Pseudomonas aeruginosa, Proteus mirabilis, Klebsiella pneumoniae, or Bacteroides fragilis. Infectious Diarrhea caused by Escherichia coli (enterotoxigenic strains), Campylobacter jejuni, Shigella boydii 1 , Shigella dysenteriae, Shigella flexneri or Shigella sonnei 1 when antibacterial therapy is indicated. Typhoid Fever (Enteric Fever) caused by Salmonella typhi. NOTE: The efficacy of ciprofloxacin in the eradication of the chronic typhoid carrier state has not been demonstrated. Uncomplicated cervical and urethral gonorrhea due to Neisseria gonorrhoeae. 1 Although treatment of infections due to this organism in this organ system demonstrated a clinically significant outcome, efficacy was studied in fewer than 10 patients. Pediatric Patients (1 to 17 years of age) Complicated Urinary Tract Infections and Pyelonephritis due to Escherichia coli. Ciprofloxacin is not a drug of first choice in the pediatric population due to an increased incidence of adverse events compared to controls, including events related to joints and/or surrounding tissues. (See WARNINGS , PRECAUTIONS, Pediatric Use , ADVERSE REACTIONS and CLINICAL STUDIES .) Ciprofloxacin, like other fluoroquinolones, is associated with arthropathy and histopathological changes in weight-bearing joints of juvenile animals. (See ANIMAL PHARMACOLOGY .) Adult and Pediatric Patients Inhalational anthrax (post-exposure): To reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. Ciprofloxacin serum concentrations achieved in humans served as a surrogate endpoint reasonably likely to predict clinical benefit and provided the initial basis for approval of this indication.5 Supportive clinical information for ciprofloxacin for anthrax post-exposure prophylaxis was obtained during the anthrax bioterror attacks of October 2001. (See also, INHALATIONAL ANTHRAX - ADDITIONAL INFORMATION ). If anaerobic organisms are suspected of contributing to the infection, appropriate therapy should be administered. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to ciprofloxacin. Therapy with ciprofloxacin hydrochloride may be initiated before results of these tests are known; once results become available appropriate therapy should be continued. As with other drugs, some strains of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with ciprofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information not only on the therapeutic effect of the antimicrobial agent but also on the possible emergence of bacterial resistance. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ciprofloxacin tablets and other antibacterial drugs, ciprofloxacin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.|[PMDA] A drug with a new increased dose for adults indicated for the treatment of sepsis, pneumonia, etc., and also with new indications and new dosages for children for both the treatment of complicated cystitis, pyelonephritis and anthrax, and the improvement of symptoms associated with respiratory infection caused by Pseudomonas aeruginosa in cystic fibrosis. uuid:9605e3fe-57ad-4785-8dc5-6da8c9fcd0c6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:100241 biolink:treats MONDO:0016595 PMID:41385096 "[{""id"":""uuid:90c7fc69-3cdf-4ba7-8e61-8be6d7fef3fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aafd0e5e-e3e0-4c43-9d52-0299c8fd02f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ciprofloxacin tablets are indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions and patient populations listed below. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Adult Patients Urinary Tract Infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Serratia marcescens, Proteus mirabilis, Providencia rettgeri, Morganella morganii, Citrobacter diversus, Citrobacter freundii, Pseudomonas aeruginosa, methicillin-susceptible Staphylococcus epidermidis, Staphylococcus saprophyticus, or Enterococcus faecalis. Acute Uncomplicated Cystitis in females caused by Escherichia coli or Staphylococcus saprophyticus. Chronic Bacterial Prostatitis caused by Escherichia coli or Proteus mirabilis. Lower Respiratory Tract Infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Pseudomonas aeruginosa, Haemophilus influenzae, Haemophilus parainfluenzae, or penicillin-susceptible Streptococcus pneumoniae. Also, Moraxella catarrhalis for the treatment of acute exacerbations of chronic bronchitis. NOTE: Although effective in clinical trials, ciprofloxacin is not a drug of first choice in the treatment of presumed or confirmed pneumonia secondary to Streptococcus pneumoniae. Acute Sinusitis caused by Haemophilus influenzae, penicillin-susceptible Streptococcus pneumoniae, or Moraxella catarrhalis. Skin and Skin Structure Infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Proteus vulgaris, Providencia stuartii, Morganella morganii, Citrobacter freundii, Pseudomonas aeruginosa, methicillin-susceptible, Staphylococcus aureus, methicillin-susceptible Staphylococcus epidermidis, or Streptococcus pyogenes. Bone and Joint Infections caused by Enterobacter cloacae, Serratia marcescens, or Pseudomonas aeruginosa. Complicated Intra-Abdominal Infections (used in combination with metronidazole) caused by Escherichia coli, Pseudomonas aeruginosa, Proteus mirabilis, Klebsiella pneumoniae, or Bacteroides fragilis. Infectious Diarrhea caused by Escherichia coli (enterotoxigenic strains), Campylobacter jejuni, Shigella boydii 1 , Shigella dysenteriae, Shigella flexneri or Shigella sonnei 1 when antibacterial therapy is indicated. Typhoid Fever (Enteric Fever) caused by Salmonella typhi. NOTE: The efficacy of ciprofloxacin in the eradication of the chronic typhoid carrier state has not been demonstrated. Uncomplicated cervical and urethral gonorrhea due to Neisseria gonorrhoeae. 1 Although treatment of infections due to this organism in this organ system demonstrated a clinically significant outcome, efficacy was studied in fewer than 10 patients. Pediatric Patients (1 to 17 years of age) Complicated Urinary Tract Infections and Pyelonephritis due to Escherichia coli. Ciprofloxacin is not a drug of first choice in the pediatric population due to an increased incidence of adverse events compared to controls, including events related to joints and/or surrounding tissues. (See WARNINGS , PRECAUTIONS, Pediatric Use , ADVERSE REACTIONS and CLINICAL STUDIES .) Ciprofloxacin, like other fluoroquinolones, is associated with arthropathy and histopathological changes in weight-bearing joints of juvenile animals. (See ANIMAL PHARMACOLOGY .) Adult and Pediatric Patients Inhalational anthrax (post-exposure): To reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. Ciprofloxacin serum concentrations achieved in humans served as a surrogate endpoint reasonably likely to predict clinical benefit and provided the initial basis for approval of this indication.5 Supportive clinical information for ciprofloxacin for anthrax post-exposure prophylaxis was obtained during the anthrax bioterror attacks of October 2001. (See also, INHALATIONAL ANTHRAX - ADDITIONAL INFORMATION ). If anaerobic organisms are suspected of contributing to the infection, appropriate therapy should be administered. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to ciprofloxacin. Therapy with ciprofloxacin hydrochloride may be initiated before results of these tests are known; once results become available appropriate therapy should be continued. As with other drugs, some strains of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with ciprofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information not only on the therapeutic effect of the antimicrobial agent but also on the possible emergence of bacterial resistance. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ciprofloxacin tablets and other antibacterial drugs, ciprofloxacin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:ab4dca68-9f82-4e1d-8b12-ffbd0ac75ce6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:168396 biolink:treats UMLS:C0345468 PMID:41385096 "[{""id"":""uuid:6c11647a-4361-4a9d-bab9-7fd91f49706f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ada575ab-c2fe-4a66-b00d-3696b908aa1d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CellCept is indicated for the prophylaxis of organ rejection in patients receiving allogeneic renal, cardiac or hepatic transplants. CellCept should be used concomitantly with cyclosporine and corticosteroids. CellCept Intravenous is an alternative dosage form to CellCept capsules, tablets and oral suspension. CellCept Intravenous should be administered within 24 hours following transplantation. CellCept Intravenous can be administered for up to 14 days; patients should be switched to oral CellCept as soon as they can tolerate oral medication. uuid:6de5b15e-e0e7-47b9-8cde-156e221ec52a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:168396 biolink:treats UMLS:C0238217 PMID:41385096 "[{""id"":""uuid:ad848742-570f-405c-ba66-65f069725abc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:de861e09-f349-4819-9805-fcfd14336731"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CellCept is indicated for the prophylaxis of organ rejection in patients receiving allogeneic renal, cardiac or hepatic transplants. CellCept should be used concomitantly with cyclosporine and corticosteroids. CellCept Intravenous is an alternative dosage form to CellCept capsules, tablets and oral suspension. CellCept Intravenous should be administered within 24 hours following transplantation. CellCept Intravenous can be administered for up to 14 days; patients should be switched to oral CellCept as soon as they can tolerate oral medication. uuid:e0e886b1-9349-4d14-a970-09f2c9d16a1d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:168396 biolink:treats UMLS:C0340530 PMID:41385096 "[{""id"":""uuid:52686517-0484-416d-a750-439e154d72f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c304328d-9948-4832-a099-60ae1e849dfe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CellCept is indicated for the prophylaxis of organ rejection in patients receiving allogeneic renal, cardiac or hepatic transplants. CellCept should be used concomitantly with cyclosporine and corticosteroids. CellCept Intravenous is an alternative dosage form to CellCept capsules, tablets and oral suspension. CellCept Intravenous should be administered within 24 hours following transplantation. CellCept Intravenous can be administered for up to 14 days; patients should be switched to oral CellCept as soon as they can tolerate oral medication. uuid:9f9a5c2b-b423-4435-ae7e-07eee731e4fa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:168396 biolink:treats UMLS:C0400968 PMID:41385096 "[{""id"":""uuid:09949382-7483-4e1f-8829-327bcd7b6b87"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0aa4faa9-24bd-4cb5-99cd-64ff36be5252"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CellCept is indicated for the prophylaxis of organ rejection in patients receiving allogeneic renal, cardiac or hepatic transplants. CellCept should be used concomitantly with cyclosporine and corticosteroids. CellCept Intravenous is an alternative dosage form to CellCept capsules, tablets and oral suspension. CellCept Intravenous should be administered within 24 hours following transplantation. CellCept Intravenous can be administered for up to 14 days; patients should be switched to oral CellCept as soon as they can tolerate oral medication. uuid:a0086e32-b806-4af5-8977-ab4caa2f30db biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1153750 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:1fd9bc1b-28ff-4842-8646-6e8a583792b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:248294de-3b1f-495e-b6b4-d69e59eca27a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ENDODAN tablets are indicated for the management of moderate to moderately severe pain. uuid:f4ae3676-b032-4e54-be44-def3c1244d6d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7865 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:ee551aeb-3be9-4101-8334-68103addbdac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f14602a9-9fb5-4760-91d9-4d860d445a42"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OPANA ER is indicated for the relief of moderate to severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time. OPANA ER is not intended for use as a prn analgesic. OPANA ER is not indicated for pain in the immediate post-operative period (12-24 hours following surgery) for patients not previously taking opioids because of the risk of oversedation and respiratory depression requiring reversal with opioid antagonists. OPANA ER is not indicated for pain in the post-operative period if the pain is mild or not expected to persist for an extended period of time. uuid:31adefaf-a01f-4895-8732-85ba5f8890fd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:173924 biolink:treats HP:0000371 PMID:41385096 "[{""id"":""uuid:24866a66-8b32-40dd-a84b-97cbd0dcdcbb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1296bb11-3676-442f-a6a1-c17c000d8afc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Acute Otitis media of various etiologies -prompt relief of pain and reduction of inflammation in the congestive and serous stages. -adjuvant therapy during systemic antibiotic administration for resolution of the infection. Because of the close anatomical relationship of the eustachian tube to the nasal cavity, otitis media is a frequent problem, especially in children in whom the tube is shorter, wider, and more horizontal than in adults. Removal of Cerumen -facilitates the removal of excessive or impacted cerumen. uuid:94571fb5-8db6-4624-a616-40d1e40329fa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:173924 biolink:treats MONDO:0005441 PMID:41385096 "[{""id"":""uuid:b34c4118-24b4-4c99-bf36-ac584feb86e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f999ad2f-7a88-4379-8a64-0178233695cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Acute Otitis media of various etiologies -prompt relief of pain and reduction of inflammation in the congestive and serous stages. -adjuvant therapy during systemic antibiotic administration for resolution of the infection. Because of the close anatomical relationship of the eustachian tube to the nasal cavity, otitis media is a frequent problem, especially in children in whom the tube is shorter, wider, and more horizontal than in adults. Removal of Cerumen -facilitates the removal of excessive or impacted cerumen. uuid:19c78a19-74b5-4ba2-928f-850b900476ef biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0004872 PMID:41385096 "[{""id"":""uuid:12a20dd5-5bf9-465b-984e-1bdbf43e2747"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:de93872d-df07-4186-ac32-d575ba64baf3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For use in inflamed hemorrhoids, postirradiation (factitial) proctitis; as an adjunct in the treatment of chronic ulcerative colitis; cryptitis; and other inflammatory conditions of anorectum and pruritus ani. uuid:7ca29544-41ff-455f-be27-537ccd66e5a2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0019084 PMID:41385096 "[{""id"":""uuid:9ff60317-e7b4-47c2-a1c8-d620f494d679"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d853a438-bcb8-41f3-a081-183a598aed06"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For use in inflamed hemorrhoids, postirradiation (factitial) proctitis; as an adjunct in the treatment of chronic ulcerative colitis; cryptitis; and other inflammatory conditions of anorectum and pruritus ani. uuid:1d67f188-6008-4bf8-9d45-7080c3ee9355 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats UMLS:C2919828 PMID:41385096 "[{""id"":""uuid:d2bce7e5-7a02-4762-a54d-7bb1c206cdf3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ad22a7a6-1b26-47b5-a216-a065bd19e9ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For use in inflamed hemorrhoids, postirradiation (factitial) proctitis; as an adjunct in the treatment of chronic ulcerative colitis; cryptitis; and other inflammatory conditions of anorectum and pruritus ani. uuid:9e66bb09-4f28-455b-8211-86aa2589a38b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats UMLS:C1394254 PMID:41385096 "[{""id"":""uuid:a012f26d-9f40-4726-a8c7-53e6584ae505"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:82a5e73b-93e0-4565-9149-1fab26376ab4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For use in inflamed hemorrhoids, postirradiation (factitial) proctitis; as an adjunct in the treatment of chronic ulcerative colitis; cryptitis; and other inflammatory conditions of anorectum and pruritus ani. uuid:de91e414-f9e8-4844-8f1e-cc3d41d459a0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:370748 biolink:treats MONDO:0005618 PMID:41385096 "[{""id"":""uuid:504b3004-fe81-415e-96be-8c37faae90fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:664ffcd6-1cdb-4ddd-84e0-e7f9d66bf21a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lorazepam is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety or anxiety associated with depressive symptoms. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The effectiveness of lorazepam in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient. uuid:4823b2eb-f7d9-473f-ad36-3c926f3b7c76 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:370748 biolink:treats MONDO:0011918 PMID:41385096 "[{""id"":""uuid:95b30259-4295-4004-8c4e-0e764023e981"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5f2c8453-b2f1-485d-95af-8c53dbf075e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lorazepam is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety or anxiety associated with depressive symptoms. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The effectiveness of lorazepam in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient. uuid:eb1e08af-c958-4720-912b-d258e9f720dc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:370748 biolink:treats MONDO:0041086 PMID:41385096 "[{""id"":""uuid:2dddac0d-294b-49c8-9a84-d4685a98ff37"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:07de409e-1370-4b1e-95b0-d64ea6e9657a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lorazepam is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety or anxiety associated with depressive symptoms. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The effectiveness of lorazepam in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient. uuid:59589eb3-f3e4-4b86-8033-2a28470ec8b5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29007 biolink:treats MONDO:0024355 PMID:41385096 "[{""id"":""uuid:42914f19-89fb-4bac-b799-4a6bcb3657a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:85e77df7-05e3-42f7-9db4-e0e8eedb7ad7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Before instituting treatment with ceftriaxone, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. Therapy may be instituted prior to obtaining results of susceptibility testing. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftriaxone for injection and other antibacterial drugs, ceftriaxone for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ceftriaxone sodium is indicated for the treatment of the following infections when caused by susceptible organisms: Lower Respiratory Tract Infections caused by Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Escherichia coli, Enterobacter aerogenes, Proteus mirabilis or Serratia marcescens. Acute Bacterial Otitis Media caused by Streptococcus pneumoniae, Haemophilus influenzae (including beta-lactamase producing strains) or Moraxella catarrhalis (including beta-lactamase producing strains). NOTE: In one study lower clinical cure rates were observed with a single dose of ceftriaxone sodium compared to 10 days of oral therapy. In a second study comparable cure rates were observed between single dose ceftriaxone sodium and the comparator. The potentially lower clinical cure rate of ceftriaxone should be balanced against the potential advantages of parenteral therapy (see CLINICAL STUDIES ). Skin And Skin Structure Infections caused by Staphylococcus aureus , Staphylococcus epidermidis , Streptococcus pyogenes , Viridans group streptococci, Escherichia coli , Enterobacter cloacae , Klebsiella oxytoca , Klebsiella pneumoniae , Proteus mirabilis , Morganella morganii Efficacy for this organism in this organ system was studied in fewer than ten infections. , Pseudomonas aeruginosa , Serratia marcescens , Acinetobacter calcoaceticus , Bacteroides fragilis Efficacy for this organism in this organ system was studied in fewer than ten infections. or Peptostreptococcus species. Urinary Tract Infections ( complicated and uncomplicated ) caused by Escherichia coli, Proteus mirabilis, Proteus vulgaris, Morganella morganii or Klebsiella pneumoniae. Uncomplicated Gonorrhea ( cervical/urethral and rectal ) caused by Neisseria gonorrhoeae , including both penicillinase- and nonpenicillinase-producing strains, and pharyngeal gonorrhea caused by nonpenicillinase-producing strains of Neisseria gonorrhoeae . Pelvic Inflammatory Disease caused by Neisseria gonorrhoeae . Ceftriaxone sodium, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and Chlamydia trachomatis is one of the suspected pathogens, appropriate antichlamydial coverage should be added. Bacterial Septicemia caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae or Klebsiella pneumoniae. Bone And Joint Infections caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae or Enterobacter species. Intra-Abdominal Infections caused by Escherichia coli, Klebsiella pneumoniae , Bacteroides fragilis , Clostridium species (Note: most strains of Clostridium difficile are resistant) or Peptostreptococcus species. Meningitis caused by Haemophilus influenzae, Neisseria meningitidis or Streptococcus pneumoniae. Ceftriaxone has also been used successfully in a limited number of cases of meningitis and shunt infection caused by Staphylococcus epidermidis Efficacy for this organism in this organ system was studied in fewer than ten infections. and Escherichia coli Efficacy for this organism in this organ system was studied in fewer than ten infections. . Surgical Prophylaxis: The preoperative administration of a single 1 gm dose of ceftriaxone sodium may reduce the incidence of postoperative infections in patients undergoing surgical procedures classified as contaminated or potentially contaminated (e.g., vaginal or abdominal hysterectomy or cholecystectomy for chronic calculous cholecystitis in high-risk patients, such as those over 70 years of age, with acute cholecystitis not requiring therapeutic antimicrobials, obstructive jaundice or common duct bile stones) and in surgical patients for whom infection at the operative site would present serious risk (e.g., during coronary artery bypass surgery). Although ceftriaxone has been shown to have been as effective as cefazolin in the prevention of infection following coronary artery bypass surgery, no placebo-controlled trials have been conducted to evaluate any cephalosporin antibiotic in the prevention of infection following coronary artery bypass surgery. When administered prior to surgical procedures for which it is indicated, a single 1 gm dose of ceftriaxone sodium provides protection from most infections due to susceptible organisms throughout the course of the procedure. uuid:31b01070-cec2-46a7-af2c-92d19adfaed0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29007 biolink:treats MONDO:0001031 PMID:41385096 "[{""id"":""uuid:53268d41-6c53-4637-9f7b-02538fb594a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5e41888e-3cac-47e6-97ae-48d38870febd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Before instituting treatment with ceftriaxone, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. Therapy may be instituted prior to obtaining results of susceptibility testing. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftriaxone for injection and other antibacterial drugs, ceftriaxone for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ceftriaxone sodium is indicated for the treatment of the following infections when caused by susceptible organisms: Lower Respiratory Tract Infections caused by Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Escherichia coli, Enterobacter aerogenes, Proteus mirabilis or Serratia marcescens. Acute Bacterial Otitis Media caused by Streptococcus pneumoniae, Haemophilus influenzae (including beta-lactamase producing strains) or Moraxella catarrhalis (including beta-lactamase producing strains). NOTE: In one study lower clinical cure rates were observed with a single dose of ceftriaxone sodium compared to 10 days of oral therapy. In a second study comparable cure rates were observed between single dose ceftriaxone sodium and the comparator. The potentially lower clinical cure rate of ceftriaxone should be balanced against the potential advantages of parenteral therapy (see CLINICAL STUDIES ). Skin And Skin Structure Infections caused by Staphylococcus aureus , Staphylococcus epidermidis , Streptococcus pyogenes , Viridans group streptococci, Escherichia coli , Enterobacter cloacae , Klebsiella oxytoca , Klebsiella pneumoniae , Proteus mirabilis , Morganella morganii Efficacy for this organism in this organ system was studied in fewer than ten infections. , Pseudomonas aeruginosa , Serratia marcescens , Acinetobacter calcoaceticus , Bacteroides fragilis Efficacy for this organism in this organ system was studied in fewer than ten infections. or Peptostreptococcus species. Urinary Tract Infections ( complicated and uncomplicated ) caused by Escherichia coli, Proteus mirabilis, Proteus vulgaris, Morganella morganii or Klebsiella pneumoniae. Uncomplicated Gonorrhea ( cervical/urethral and rectal ) caused by Neisseria gonorrhoeae , including both penicillinase- and nonpenicillinase-producing strains, and pharyngeal gonorrhea caused by nonpenicillinase-producing strains of Neisseria gonorrhoeae . Pelvic Inflammatory Disease caused by Neisseria gonorrhoeae . Ceftriaxone sodium, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and Chlamydia trachomatis is one of the suspected pathogens, appropriate antichlamydial coverage should be added. Bacterial Septicemia caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae or Klebsiella pneumoniae. Bone And Joint Infections caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae or Enterobacter species. Intra-Abdominal Infections caused by Escherichia coli, Klebsiella pneumoniae , Bacteroides fragilis , Clostridium species (Note: most strains of Clostridium difficile are resistant) or Peptostreptococcus species. Meningitis caused by Haemophilus influenzae, Neisseria meningitidis or Streptococcus pneumoniae. Ceftriaxone has also been used successfully in a limited number of cases of meningitis and shunt infection caused by Staphylococcus epidermidis Efficacy for this organism in this organ system was studied in fewer than ten infections. and Escherichia coli Efficacy for this organism in this organ system was studied in fewer than ten infections. . Surgical Prophylaxis: The preoperative administration of a single 1 gm dose of ceftriaxone sodium may reduce the incidence of postoperative infections in patients undergoing surgical procedures classified as contaminated or potentially contaminated (e.g., vaginal or abdominal hysterectomy or cholecystectomy for chronic calculous cholecystitis in high-risk patients, such as those over 70 years of age, with acute cholecystitis not requiring therapeutic antimicrobials, obstructive jaundice or common duct bile stones) and in surgical patients for whom infection at the operative site would present serious risk (e.g., during coronary artery bypass surgery). Although ceftriaxone has been shown to have been as effective as cefazolin in the prevention of infection following coronary artery bypass surgery, no placebo-controlled trials have been conducted to evaluate any cephalosporin antibiotic in the prevention of infection following coronary artery bypass surgery. When administered prior to surgical procedures for which it is indicated, a single 1 gm dose of ceftriaxone sodium provides protection from most infections due to susceptible organisms throughout the course of the procedure. uuid:456bc6d0-cfe1-47fa-b596-688c9c6891ac biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29007 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:42ac48ff-6bb9-4ebe-96fd-e801fc20b071"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0f94d038-ffe9-467e-8166-8e96ba281fc6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Before instituting treatment with ceftriaxone, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. Therapy may be instituted prior to obtaining results of susceptibility testing. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftriaxone for injection and other antibacterial drugs, ceftriaxone for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ceftriaxone sodium is indicated for the treatment of the following infections when caused by susceptible organisms: Lower Respiratory Tract Infections caused by Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Escherichia coli, Enterobacter aerogenes, Proteus mirabilis or Serratia marcescens. Acute Bacterial Otitis Media caused by Streptococcus pneumoniae, Haemophilus influenzae (including beta-lactamase producing strains) or Moraxella catarrhalis (including beta-lactamase producing strains). NOTE: In one study lower clinical cure rates were observed with a single dose of ceftriaxone sodium compared to 10 days of oral therapy. In a second study comparable cure rates were observed between single dose ceftriaxone sodium and the comparator. The potentially lower clinical cure rate of ceftriaxone should be balanced against the potential advantages of parenteral therapy (see CLINICAL STUDIES ). Skin And Skin Structure Infections caused by Staphylococcus aureus , Staphylococcus epidermidis , Streptococcus pyogenes , Viridans group streptococci, Escherichia coli , Enterobacter cloacae , Klebsiella oxytoca , Klebsiella pneumoniae , Proteus mirabilis , Morganella morganii Efficacy for this organism in this organ system was studied in fewer than ten infections. , Pseudomonas aeruginosa , Serratia marcescens , Acinetobacter calcoaceticus , Bacteroides fragilis Efficacy for this organism in this organ system was studied in fewer than ten infections. or Peptostreptococcus species. Urinary Tract Infections ( complicated and uncomplicated ) caused by Escherichia coli, Proteus mirabilis, Proteus vulgaris, Morganella morganii or Klebsiella pneumoniae. Uncomplicated Gonorrhea ( cervical/urethral and rectal ) caused by Neisseria gonorrhoeae , including both penicillinase- and nonpenicillinase-producing strains, and pharyngeal gonorrhea caused by nonpenicillinase-producing strains of Neisseria gonorrhoeae . Pelvic Inflammatory Disease caused by Neisseria gonorrhoeae . Ceftriaxone sodium, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and Chlamydia trachomatis is one of the suspected pathogens, appropriate antichlamydial coverage should be added. Bacterial Septicemia caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae or Klebsiella pneumoniae. Bone And Joint Infections caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae or Enterobacter species. Intra-Abdominal Infections caused by Escherichia coli, Klebsiella pneumoniae , Bacteroides fragilis , Clostridium species (Note: most strains of Clostridium difficile are resistant) or Peptostreptococcus species. Meningitis caused by Haemophilus influenzae, Neisseria meningitidis or Streptococcus pneumoniae. Ceftriaxone has also been used successfully in a limited number of cases of meningitis and shunt infection caused by Staphylococcus epidermidis Efficacy for this organism in this organ system was studied in fewer than ten infections. and Escherichia coli Efficacy for this organism in this organ system was studied in fewer than ten infections. . Surgical Prophylaxis: The preoperative administration of a single 1 gm dose of ceftriaxone sodium may reduce the incidence of postoperative infections in patients undergoing surgical procedures classified as contaminated or potentially contaminated (e.g., vaginal or abdominal hysterectomy or cholecystectomy for chronic calculous cholecystitis in high-risk patients, such as those over 70 years of age, with acute cholecystitis not requiring therapeutic antimicrobials, obstructive jaundice or common duct bile stones) and in surgical patients for whom infection at the operative site would present serious risk (e.g., during coronary artery bypass surgery). Although ceftriaxone has been shown to have been as effective as cefazolin in the prevention of infection following coronary artery bypass surgery, no placebo-controlled trials have been conducted to evaluate any cephalosporin antibiotic in the prevention of infection following coronary artery bypass surgery. When administered prior to surgical procedures for which it is indicated, a single 1 gm dose of ceftriaxone sodium provides protection from most infections due to susceptible organisms throughout the course of the procedure. uuid:02d12962-acce-41a9-92ed-f198941dc9ea biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29007 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:da210858-a4ea-41cb-ba40-a46b65c8e85d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e66f0d27-c06d-4198-9ad8-676d478e5cce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Before instituting treatment with ceftriaxone, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. Therapy may be instituted prior to obtaining results of susceptibility testing. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftriaxone for injection and other antibacterial drugs, ceftriaxone for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ceftriaxone sodium is indicated for the treatment of the following infections when caused by susceptible organisms: Lower Respiratory Tract Infections caused by Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Escherichia coli, Enterobacter aerogenes, Proteus mirabilis or Serratia marcescens. Acute Bacterial Otitis Media caused by Streptococcus pneumoniae, Haemophilus influenzae (including beta-lactamase producing strains) or Moraxella catarrhalis (including beta-lactamase producing strains). NOTE: In one study lower clinical cure rates were observed with a single dose of ceftriaxone sodium compared to 10 days of oral therapy. In a second study comparable cure rates were observed between single dose ceftriaxone sodium and the comparator. The potentially lower clinical cure rate of ceftriaxone should be balanced against the potential advantages of parenteral therapy (see CLINICAL STUDIES ). Skin And Skin Structure Infections caused by Staphylococcus aureus , Staphylococcus epidermidis , Streptococcus pyogenes , Viridans group streptococci, Escherichia coli , Enterobacter cloacae , Klebsiella oxytoca , Klebsiella pneumoniae , Proteus mirabilis , Morganella morganii Efficacy for this organism in this organ system was studied in fewer than ten infections. , Pseudomonas aeruginosa , Serratia marcescens , Acinetobacter calcoaceticus , Bacteroides fragilis Efficacy for this organism in this organ system was studied in fewer than ten infections. or Peptostreptococcus species. Urinary Tract Infections ( complicated and uncomplicated ) caused by Escherichia coli, Proteus mirabilis, Proteus vulgaris, Morganella morganii or Klebsiella pneumoniae. Uncomplicated Gonorrhea ( cervical/urethral and rectal ) caused by Neisseria gonorrhoeae , including both penicillinase- and nonpenicillinase-producing strains, and pharyngeal gonorrhea caused by nonpenicillinase-producing strains of Neisseria gonorrhoeae . Pelvic Inflammatory Disease caused by Neisseria gonorrhoeae . Ceftriaxone sodium, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and Chlamydia trachomatis is one of the suspected pathogens, appropriate antichlamydial coverage should be added. Bacterial Septicemia caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae or Klebsiella pneumoniae. Bone And Joint Infections caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae or Enterobacter species. Intra-Abdominal Infections caused by Escherichia coli, Klebsiella pneumoniae , Bacteroides fragilis , Clostridium species (Note: most strains of Clostridium difficile are resistant) or Peptostreptococcus species. Meningitis caused by Haemophilus influenzae, Neisseria meningitidis or Streptococcus pneumoniae. Ceftriaxone has also been used successfully in a limited number of cases of meningitis and shunt infection caused by Staphylococcus epidermidis Efficacy for this organism in this organ system was studied in fewer than ten infections. and Escherichia coli Efficacy for this organism in this organ system was studied in fewer than ten infections. . Surgical Prophylaxis: The preoperative administration of a single 1 gm dose of ceftriaxone sodium may reduce the incidence of postoperative infections in patients undergoing surgical procedures classified as contaminated or potentially contaminated (e.g., vaginal or abdominal hysterectomy or cholecystectomy for chronic calculous cholecystitis in high-risk patients, such as those over 70 years of age, with acute cholecystitis not requiring therapeutic antimicrobials, obstructive jaundice or common duct bile stones) and in surgical patients for whom infection at the operative site would present serious risk (e.g., during coronary artery bypass surgery). Although ceftriaxone has been shown to have been as effective as cefazolin in the prevention of infection following coronary artery bypass surgery, no placebo-controlled trials have been conducted to evaluate any cephalosporin antibiotic in the prevention of infection following coronary artery bypass surgery. When administered prior to surgical procedures for which it is indicated, a single 1 gm dose of ceftriaxone sodium provides protection from most infections due to susceptible organisms throughout the course of the procedure. uuid:2c47f5e4-9698-43f9-9eb0-30b645cee2fd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29007 biolink:treats MONDO:0004277 PMID:41385096 "[{""id"":""uuid:45d493d8-f808-4291-8162-bbc3316dac4d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0c3e2065-a1ba-4f5f-8e2b-e08f2a8a065a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Before instituting treatment with ceftriaxone, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. Therapy may be instituted prior to obtaining results of susceptibility testing. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftriaxone for injection and other antibacterial drugs, ceftriaxone for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ceftriaxone sodium is indicated for the treatment of the following infections when caused by susceptible organisms: Lower Respiratory Tract Infections caused by Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Escherichia coli, Enterobacter aerogenes, Proteus mirabilis or Serratia marcescens. Acute Bacterial Otitis Media caused by Streptococcus pneumoniae, Haemophilus influenzae (including beta-lactamase producing strains) or Moraxella catarrhalis (including beta-lactamase producing strains). NOTE: In one study lower clinical cure rates were observed with a single dose of ceftriaxone sodium compared to 10 days of oral therapy. In a second study comparable cure rates were observed between single dose ceftriaxone sodium and the comparator. The potentially lower clinical cure rate of ceftriaxone should be balanced against the potential advantages of parenteral therapy (see CLINICAL STUDIES ). Skin And Skin Structure Infections caused by Staphylococcus aureus , Staphylococcus epidermidis , Streptococcus pyogenes , Viridans group streptococci, Escherichia coli , Enterobacter cloacae , Klebsiella oxytoca , Klebsiella pneumoniae , Proteus mirabilis , Morganella morganii Efficacy for this organism in this organ system was studied in fewer than ten infections. , Pseudomonas aeruginosa , Serratia marcescens , Acinetobacter calcoaceticus , Bacteroides fragilis Efficacy for this organism in this organ system was studied in fewer than ten infections. or Peptostreptococcus species. Urinary Tract Infections ( complicated and uncomplicated ) caused by Escherichia coli, Proteus mirabilis, Proteus vulgaris, Morganella morganii or Klebsiella pneumoniae. Uncomplicated Gonorrhea ( cervical/urethral and rectal ) caused by Neisseria gonorrhoeae , including both penicillinase- and nonpenicillinase-producing strains, and pharyngeal gonorrhea caused by nonpenicillinase-producing strains of Neisseria gonorrhoeae . Pelvic Inflammatory Disease caused by Neisseria gonorrhoeae . Ceftriaxone sodium, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and Chlamydia trachomatis is one of the suspected pathogens, appropriate antichlamydial coverage should be added. Bacterial Septicemia caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae or Klebsiella pneumoniae. Bone And Joint Infections caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae or Enterobacter species. Intra-Abdominal Infections caused by Escherichia coli, Klebsiella pneumoniae , Bacteroides fragilis , Clostridium species (Note: most strains of Clostridium difficile are resistant) or Peptostreptococcus species. Meningitis caused by Haemophilus influenzae, Neisseria meningitidis or Streptococcus pneumoniae. Ceftriaxone has also been used successfully in a limited number of cases of meningitis and shunt infection caused by Staphylococcus epidermidis Efficacy for this organism in this organ system was studied in fewer than ten infections. and Escherichia coli Efficacy for this organism in this organ system was studied in fewer than ten infections. . Surgical Prophylaxis: The preoperative administration of a single 1 gm dose of ceftriaxone sodium may reduce the incidence of postoperative infections in patients undergoing surgical procedures classified as contaminated or potentially contaminated (e.g., vaginal or abdominal hysterectomy or cholecystectomy for chronic calculous cholecystitis in high-risk patients, such as those over 70 years of age, with acute cholecystitis not requiring therapeutic antimicrobials, obstructive jaundice or common duct bile stones) and in surgical patients for whom infection at the operative site would present serious risk (e.g., during coronary artery bypass surgery). Although ceftriaxone has been shown to have been as effective as cefazolin in the prevention of infection following coronary artery bypass surgery, no placebo-controlled trials have been conducted to evaluate any cephalosporin antibiotic in the prevention of infection following coronary artery bypass surgery. When administered prior to surgical procedures for which it is indicated, a single 1 gm dose of ceftriaxone sodium provides protection from most infections due to susceptible organisms throughout the course of the procedure. uuid:375952ae-0ba5-426f-aa10-32d8ecdcf6c4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29007 biolink:treats MONDO:0000922 PMID:41385096 "[{""id"":""uuid:e73d1a29-a1d8-419f-8eea-2717cc2d5e2c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a885812d-9675-4e68-b219-bb23fd351237"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Before instituting treatment with ceftriaxone, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. Therapy may be instituted prior to obtaining results of susceptibility testing. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftriaxone for injection and other antibacterial drugs, ceftriaxone for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ceftriaxone sodium is indicated for the treatment of the following infections when caused by susceptible organisms: Lower Respiratory Tract Infections caused by Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Escherichia coli, Enterobacter aerogenes, Proteus mirabilis or Serratia marcescens. Acute Bacterial Otitis Media caused by Streptococcus pneumoniae, Haemophilus influenzae (including beta-lactamase producing strains) or Moraxella catarrhalis (including beta-lactamase producing strains). NOTE: In one study lower clinical cure rates were observed with a single dose of ceftriaxone sodium compared to 10 days of oral therapy. In a second study comparable cure rates were observed between single dose ceftriaxone sodium and the comparator. The potentially lower clinical cure rate of ceftriaxone should be balanced against the potential advantages of parenteral therapy (see CLINICAL STUDIES ). Skin And Skin Structure Infections caused by Staphylococcus aureus , Staphylococcus epidermidis , Streptococcus pyogenes , Viridans group streptococci, Escherichia coli , Enterobacter cloacae , Klebsiella oxytoca , Klebsiella pneumoniae , Proteus mirabilis , Morganella morganii Efficacy for this organism in this organ system was studied in fewer than ten infections. , Pseudomonas aeruginosa , Serratia marcescens , Acinetobacter calcoaceticus , Bacteroides fragilis Efficacy for this organism in this organ system was studied in fewer than ten infections. or Peptostreptococcus species. Urinary Tract Infections ( complicated and uncomplicated ) caused by Escherichia coli, Proteus mirabilis, Proteus vulgaris, Morganella morganii or Klebsiella pneumoniae. Uncomplicated Gonorrhea ( cervical/urethral and rectal ) caused by Neisseria gonorrhoeae , including both penicillinase- and nonpenicillinase-producing strains, and pharyngeal gonorrhea caused by nonpenicillinase-producing strains of Neisseria gonorrhoeae . Pelvic Inflammatory Disease caused by Neisseria gonorrhoeae . Ceftriaxone sodium, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and Chlamydia trachomatis is one of the suspected pathogens, appropriate antichlamydial coverage should be added. Bacterial Septicemia caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae or Klebsiella pneumoniae. Bone And Joint Infections caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae or Enterobacter species. Intra-Abdominal Infections caused by Escherichia coli, Klebsiella pneumoniae , Bacteroides fragilis , Clostridium species (Note: most strains of Clostridium difficile are resistant) or Peptostreptococcus species. Meningitis caused by Haemophilus influenzae, Neisseria meningitidis or Streptococcus pneumoniae. Ceftriaxone has also been used successfully in a limited number of cases of meningitis and shunt infection caused by Staphylococcus epidermidis Efficacy for this organism in this organ system was studied in fewer than ten infections. and Escherichia coli Efficacy for this organism in this organ system was studied in fewer than ten infections. . Surgical Prophylaxis: The preoperative administration of a single 1 gm dose of ceftriaxone sodium may reduce the incidence of postoperative infections in patients undergoing surgical procedures classified as contaminated or potentially contaminated (e.g., vaginal or abdominal hysterectomy or cholecystectomy for chronic calculous cholecystitis in high-risk patients, such as those over 70 years of age, with acute cholecystitis not requiring therapeutic antimicrobials, obstructive jaundice or common duct bile stones) and in surgical patients for whom infection at the operative site would present serious risk (e.g., during coronary artery bypass surgery). Although ceftriaxone has been shown to have been as effective as cefazolin in the prevention of infection following coronary artery bypass surgery, no placebo-controlled trials have been conducted to evaluate any cephalosporin antibiotic in the prevention of infection following coronary artery bypass surgery. When administered prior to surgical procedures for which it is indicated, a single 1 gm dose of ceftriaxone sodium provides protection from most infections due to susceptible organisms throughout the course of the procedure. uuid:a6ab2154-d8c8-47dc-8f17-c3e134fc3f18 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29007 biolink:treats UMLS:C0684256 PMID:41385096 "[{""id"":""uuid:056ae102-d342-4725-9228-cab7f753373c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9af6e7f0-23bc-4547-8eb6-3eab77446a5a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Before instituting treatment with ceftriaxone, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. Therapy may be instituted prior to obtaining results of susceptibility testing. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftriaxone for injection and other antibacterial drugs, ceftriaxone for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ceftriaxone sodium is indicated for the treatment of the following infections when caused by susceptible organisms: Lower Respiratory Tract Infections caused by Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Escherichia coli, Enterobacter aerogenes, Proteus mirabilis or Serratia marcescens. Acute Bacterial Otitis Media caused by Streptococcus pneumoniae, Haemophilus influenzae (including beta-lactamase producing strains) or Moraxella catarrhalis (including beta-lactamase producing strains). NOTE: In one study lower clinical cure rates were observed with a single dose of ceftriaxone sodium compared to 10 days of oral therapy. In a second study comparable cure rates were observed between single dose ceftriaxone sodium and the comparator. The potentially lower clinical cure rate of ceftriaxone should be balanced against the potential advantages of parenteral therapy (see CLINICAL STUDIES ). Skin And Skin Structure Infections caused by Staphylococcus aureus , Staphylococcus epidermidis , Streptococcus pyogenes , Viridans group streptococci, Escherichia coli , Enterobacter cloacae , Klebsiella oxytoca , Klebsiella pneumoniae , Proteus mirabilis , Morganella morganii Efficacy for this organism in this organ system was studied in fewer than ten infections. , Pseudomonas aeruginosa , Serratia marcescens , Acinetobacter calcoaceticus , Bacteroides fragilis Efficacy for this organism in this organ system was studied in fewer than ten infections. or Peptostreptococcus species. Urinary Tract Infections ( complicated and uncomplicated ) caused by Escherichia coli, Proteus mirabilis, Proteus vulgaris, Morganella morganii or Klebsiella pneumoniae. Uncomplicated Gonorrhea ( cervical/urethral and rectal ) caused by Neisseria gonorrhoeae , including both penicillinase- and nonpenicillinase-producing strains, and pharyngeal gonorrhea caused by nonpenicillinase-producing strains of Neisseria gonorrhoeae . Pelvic Inflammatory Disease caused by Neisseria gonorrhoeae . Ceftriaxone sodium, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and Chlamydia trachomatis is one of the suspected pathogens, appropriate antichlamydial coverage should be added. Bacterial Septicemia caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae or Klebsiella pneumoniae. Bone And Joint Infections caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae or Enterobacter species. Intra-Abdominal Infections caused by Escherichia coli, Klebsiella pneumoniae , Bacteroides fragilis , Clostridium species (Note: most strains of Clostridium difficile are resistant) or Peptostreptococcus species. Meningitis caused by Haemophilus influenzae, Neisseria meningitidis or Streptococcus pneumoniae. Ceftriaxone has also been used successfully in a limited number of cases of meningitis and shunt infection caused by Staphylococcus epidermidis Efficacy for this organism in this organ system was studied in fewer than ten infections. and Escherichia coli Efficacy for this organism in this organ system was studied in fewer than ten infections. . Surgical Prophylaxis: The preoperative administration of a single 1 gm dose of ceftriaxone sodium may reduce the incidence of postoperative infections in patients undergoing surgical procedures classified as contaminated or potentially contaminated (e.g., vaginal or abdominal hysterectomy or cholecystectomy for chronic calculous cholecystitis in high-risk patients, such as those over 70 years of age, with acute cholecystitis not requiring therapeutic antimicrobials, obstructive jaundice or common duct bile stones) and in surgical patients for whom infection at the operative site would present serious risk (e.g., during coronary artery bypass surgery). Although ceftriaxone has been shown to have been as effective as cefazolin in the prevention of infection following coronary artery bypass surgery, no placebo-controlled trials have been conducted to evaluate any cephalosporin antibiotic in the prevention of infection following coronary artery bypass surgery. When administered prior to surgical procedures for which it is indicated, a single 1 gm dose of ceftriaxone sodium provides protection from most infections due to susceptible organisms throughout the course of the procedure. uuid:f5b8af3b-024c-44d3-82c7-619a9f2a9617 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29007 biolink:treats UMLS:C0851989 PMID:41385096 "[{""id"":""uuid:bea4582a-0863-4687-8a82-d4f6c1fdafda"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:790c3d91-003d-401c-ae4d-970b29ba51bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Before instituting treatment with ceftriaxone, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. Therapy may be instituted prior to obtaining results of susceptibility testing. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftriaxone for injection and other antibacterial drugs, ceftriaxone for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ceftriaxone sodium is indicated for the treatment of the following infections when caused by susceptible organisms: Lower Respiratory Tract Infections caused by Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Escherichia coli, Enterobacter aerogenes, Proteus mirabilis or Serratia marcescens. Acute Bacterial Otitis Media caused by Streptococcus pneumoniae, Haemophilus influenzae (including beta-lactamase producing strains) or Moraxella catarrhalis (including beta-lactamase producing strains). NOTE: In one study lower clinical cure rates were observed with a single dose of ceftriaxone sodium compared to 10 days of oral therapy. In a second study comparable cure rates were observed between single dose ceftriaxone sodium and the comparator. The potentially lower clinical cure rate of ceftriaxone should be balanced against the potential advantages of parenteral therapy (see CLINICAL STUDIES ). Skin And Skin Structure Infections caused by Staphylococcus aureus , Staphylococcus epidermidis , Streptococcus pyogenes , Viridans group streptococci, Escherichia coli , Enterobacter cloacae , Klebsiella oxytoca , Klebsiella pneumoniae , Proteus mirabilis , Morganella morganii Efficacy for this organism in this organ system was studied in fewer than ten infections. , Pseudomonas aeruginosa , Serratia marcescens , Acinetobacter calcoaceticus , Bacteroides fragilis Efficacy for this organism in this organ system was studied in fewer than ten infections. or Peptostreptococcus species. Urinary Tract Infections ( complicated and uncomplicated ) caused by Escherichia coli, Proteus mirabilis, Proteus vulgaris, Morganella morganii or Klebsiella pneumoniae. Uncomplicated Gonorrhea ( cervical/urethral and rectal ) caused by Neisseria gonorrhoeae , including both penicillinase- and nonpenicillinase-producing strains, and pharyngeal gonorrhea caused by nonpenicillinase-producing strains of Neisseria gonorrhoeae . Pelvic Inflammatory Disease caused by Neisseria gonorrhoeae . Ceftriaxone sodium, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and Chlamydia trachomatis is one of the suspected pathogens, appropriate antichlamydial coverage should be added. Bacterial Septicemia caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae or Klebsiella pneumoniae. Bone And Joint Infections caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae or Enterobacter species. Intra-Abdominal Infections caused by Escherichia coli, Klebsiella pneumoniae , Bacteroides fragilis , Clostridium species (Note: most strains of Clostridium difficile are resistant) or Peptostreptococcus species. Meningitis caused by Haemophilus influenzae, Neisseria meningitidis or Streptococcus pneumoniae. Ceftriaxone has also been used successfully in a limited number of cases of meningitis and shunt infection caused by Staphylococcus epidermidis Efficacy for this organism in this organ system was studied in fewer than ten infections. and Escherichia coli Efficacy for this organism in this organ system was studied in fewer than ten infections. . Surgical Prophylaxis: The preoperative administration of a single 1 gm dose of ceftriaxone sodium may reduce the incidence of postoperative infections in patients undergoing surgical procedures classified as contaminated or potentially contaminated (e.g., vaginal or abdominal hysterectomy or cholecystectomy for chronic calculous cholecystitis in high-risk patients, such as those over 70 years of age, with acute cholecystitis not requiring therapeutic antimicrobials, obstructive jaundice or common duct bile stones) and in surgical patients for whom infection at the operative site would present serious risk (e.g., during coronary artery bypass surgery). Although ceftriaxone has been shown to have been as effective as cefazolin in the prevention of infection following coronary artery bypass surgery, no placebo-controlled trials have been conducted to evaluate any cephalosporin antibiotic in the prevention of infection following coronary artery bypass surgery. When administered prior to surgical procedures for which it is indicated, a single 1 gm dose of ceftriaxone sodium provides protection from most infections due to susceptible organisms throughout the course of the procedure. uuid:82d59893-dc05-415f-8d65-a24df3300530 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29007 biolink:treats UMLS:C1112209 PMID:41385096 "[{""id"":""uuid:3f13e9f3-6ead-4df6-840f-bef0fec0e0ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ac8b6ba5-8762-46aa-ad3d-c3c40ec959f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Before instituting treatment with ceftriaxone, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. Therapy may be instituted prior to obtaining results of susceptibility testing. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftriaxone for injection and other antibacterial drugs, ceftriaxone for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ceftriaxone sodium is indicated for the treatment of the following infections when caused by susceptible organisms: Lower Respiratory Tract Infections caused by Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Escherichia coli, Enterobacter aerogenes, Proteus mirabilis or Serratia marcescens. Acute Bacterial Otitis Media caused by Streptococcus pneumoniae, Haemophilus influenzae (including beta-lactamase producing strains) or Moraxella catarrhalis (including beta-lactamase producing strains). NOTE: In one study lower clinical cure rates were observed with a single dose of ceftriaxone sodium compared to 10 days of oral therapy. In a second study comparable cure rates were observed between single dose ceftriaxone sodium and the comparator. The potentially lower clinical cure rate of ceftriaxone should be balanced against the potential advantages of parenteral therapy (see CLINICAL STUDIES ). Skin And Skin Structure Infections caused by Staphylococcus aureus , Staphylococcus epidermidis , Streptococcus pyogenes , Viridans group streptococci, Escherichia coli , Enterobacter cloacae , Klebsiella oxytoca , Klebsiella pneumoniae , Proteus mirabilis , Morganella morganii Efficacy for this organism in this organ system was studied in fewer than ten infections. , Pseudomonas aeruginosa , Serratia marcescens , Acinetobacter calcoaceticus , Bacteroides fragilis Efficacy for this organism in this organ system was studied in fewer than ten infections. or Peptostreptococcus species. Urinary Tract Infections ( complicated and uncomplicated ) caused by Escherichia coli, Proteus mirabilis, Proteus vulgaris, Morganella morganii or Klebsiella pneumoniae. Uncomplicated Gonorrhea ( cervical/urethral and rectal ) caused by Neisseria gonorrhoeae , including both penicillinase- and nonpenicillinase-producing strains, and pharyngeal gonorrhea caused by nonpenicillinase-producing strains of Neisseria gonorrhoeae . Pelvic Inflammatory Disease caused by Neisseria gonorrhoeae . Ceftriaxone sodium, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and Chlamydia trachomatis is one of the suspected pathogens, appropriate antichlamydial coverage should be added. Bacterial Septicemia caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae or Klebsiella pneumoniae. Bone And Joint Infections caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae or Enterobacter species. Intra-Abdominal Infections caused by Escherichia coli, Klebsiella pneumoniae , Bacteroides fragilis , Clostridium species (Note: most strains of Clostridium difficile are resistant) or Peptostreptococcus species. Meningitis caused by Haemophilus influenzae, Neisseria meningitidis or Streptococcus pneumoniae. Ceftriaxone has also been used successfully in a limited number of cases of meningitis and shunt infection caused by Staphylococcus epidermidis Efficacy for this organism in this organ system was studied in fewer than ten infections. and Escherichia coli Efficacy for this organism in this organ system was studied in fewer than ten infections. . Surgical Prophylaxis: The preoperative administration of a single 1 gm dose of ceftriaxone sodium may reduce the incidence of postoperative infections in patients undergoing surgical procedures classified as contaminated or potentially contaminated (e.g., vaginal or abdominal hysterectomy or cholecystectomy for chronic calculous cholecystitis in high-risk patients, such as those over 70 years of age, with acute cholecystitis not requiring therapeutic antimicrobials, obstructive jaundice or common duct bile stones) and in surgical patients for whom infection at the operative site would present serious risk (e.g., during coronary artery bypass surgery). Although ceftriaxone has been shown to have been as effective as cefazolin in the prevention of infection following coronary artery bypass surgery, no placebo-controlled trials have been conducted to evaluate any cephalosporin antibiotic in the prevention of infection following coronary artery bypass surgery. When administered prior to surgical procedures for which it is indicated, a single 1 gm dose of ceftriaxone sodium provides protection from most infections due to susceptible organisms throughout the course of the procedure. uuid:57fccfbb-df67-4e2e-a899-54b5566b02fc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29007 biolink:treats MONDO:0021108 PMID:41385096 "[{""id"":""uuid:e396d5e3-40a3-4679-a1cc-b360af6702ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d7965006-ed3a-4c99-90c4-41a0229e2071"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Before instituting treatment with ceftriaxone, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. Therapy may be instituted prior to obtaining results of susceptibility testing. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftriaxone for injection and other antibacterial drugs, ceftriaxone for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ceftriaxone sodium is indicated for the treatment of the following infections when caused by susceptible organisms: Lower Respiratory Tract Infections caused by Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Escherichia coli, Enterobacter aerogenes, Proteus mirabilis or Serratia marcescens. Acute Bacterial Otitis Media caused by Streptococcus pneumoniae, Haemophilus influenzae (including beta-lactamase producing strains) or Moraxella catarrhalis (including beta-lactamase producing strains). NOTE: In one study lower clinical cure rates were observed with a single dose of ceftriaxone sodium compared to 10 days of oral therapy. In a second study comparable cure rates were observed between single dose ceftriaxone sodium and the comparator. The potentially lower clinical cure rate of ceftriaxone should be balanced against the potential advantages of parenteral therapy (see CLINICAL STUDIES ). Skin And Skin Structure Infections caused by Staphylococcus aureus , Staphylococcus epidermidis , Streptococcus pyogenes , Viridans group streptococci, Escherichia coli , Enterobacter cloacae , Klebsiella oxytoca , Klebsiella pneumoniae , Proteus mirabilis , Morganella morganii Efficacy for this organism in this organ system was studied in fewer than ten infections. , Pseudomonas aeruginosa , Serratia marcescens , Acinetobacter calcoaceticus , Bacteroides fragilis Efficacy for this organism in this organ system was studied in fewer than ten infections. or Peptostreptococcus species. Urinary Tract Infections ( complicated and uncomplicated ) caused by Escherichia coli, Proteus mirabilis, Proteus vulgaris, Morganella morganii or Klebsiella pneumoniae. Uncomplicated Gonorrhea ( cervical/urethral and rectal ) caused by Neisseria gonorrhoeae , including both penicillinase- and nonpenicillinase-producing strains, and pharyngeal gonorrhea caused by nonpenicillinase-producing strains of Neisseria gonorrhoeae . Pelvic Inflammatory Disease caused by Neisseria gonorrhoeae . Ceftriaxone sodium, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and Chlamydia trachomatis is one of the suspected pathogens, appropriate antichlamydial coverage should be added. Bacterial Septicemia caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae or Klebsiella pneumoniae. Bone And Joint Infections caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae or Enterobacter species. Intra-Abdominal Infections caused by Escherichia coli, Klebsiella pneumoniae , Bacteroides fragilis , Clostridium species (Note: most strains of Clostridium difficile are resistant) or Peptostreptococcus species. Meningitis caused by Haemophilus influenzae, Neisseria meningitidis or Streptococcus pneumoniae. Ceftriaxone has also been used successfully in a limited number of cases of meningitis and shunt infection caused by Staphylococcus epidermidis Efficacy for this organism in this organ system was studied in fewer than ten infections. and Escherichia coli Efficacy for this organism in this organ system was studied in fewer than ten infections. . Surgical Prophylaxis: The preoperative administration of a single 1 gm dose of ceftriaxone sodium may reduce the incidence of postoperative infections in patients undergoing surgical procedures classified as contaminated or potentially contaminated (e.g., vaginal or abdominal hysterectomy or cholecystectomy for chronic calculous cholecystitis in high-risk patients, such as those over 70 years of age, with acute cholecystitis not requiring therapeutic antimicrobials, obstructive jaundice or common duct bile stones) and in surgical patients for whom infection at the operative site would present serious risk (e.g., during coronary artery bypass surgery). Although ceftriaxone has been shown to have been as effective as cefazolin in the prevention of infection following coronary artery bypass surgery, no placebo-controlled trials have been conducted to evaluate any cephalosporin antibiotic in the prevention of infection following coronary artery bypass surgery. When administered prior to surgical procedures for which it is indicated, a single 1 gm dose of ceftriaxone sodium provides protection from most infections due to susceptible organisms throughout the course of the procedure. uuid:8338f724-c2d2-482d-8fd5-80069042874b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29007 biolink:treats MONDO:0021839 PMID:41385096 "[{""id"":""uuid:9b7e9ac7-dfc5-4a22-92be-916d13b84d6b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e3751e26-e3d5-4989-a853-eb1fe30f2a69"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Before instituting treatment with ceftriaxone, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. Therapy may be instituted prior to obtaining results of susceptibility testing. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftriaxone for injection and other antibacterial drugs, ceftriaxone for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ceftriaxone sodium is indicated for the treatment of the following infections when caused by susceptible organisms: Lower Respiratory Tract Infections caused by Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Escherichia coli, Enterobacter aerogenes, Proteus mirabilis or Serratia marcescens. Acute Bacterial Otitis Media caused by Streptococcus pneumoniae, Haemophilus influenzae (including beta-lactamase producing strains) or Moraxella catarrhalis (including beta-lactamase producing strains). NOTE: In one study lower clinical cure rates were observed with a single dose of ceftriaxone sodium compared to 10 days of oral therapy. In a second study comparable cure rates were observed between single dose ceftriaxone sodium and the comparator. The potentially lower clinical cure rate of ceftriaxone should be balanced against the potential advantages of parenteral therapy (see CLINICAL STUDIES ). Skin And Skin Structure Infections caused by Staphylococcus aureus , Staphylococcus epidermidis , Streptococcus pyogenes , Viridans group streptococci, Escherichia coli , Enterobacter cloacae , Klebsiella oxytoca , Klebsiella pneumoniae , Proteus mirabilis , Morganella morganii Efficacy for this organism in this organ system was studied in fewer than ten infections. , Pseudomonas aeruginosa , Serratia marcescens , Acinetobacter calcoaceticus , Bacteroides fragilis Efficacy for this organism in this organ system was studied in fewer than ten infections. or Peptostreptococcus species. Urinary Tract Infections ( complicated and uncomplicated ) caused by Escherichia coli, Proteus mirabilis, Proteus vulgaris, Morganella morganii or Klebsiella pneumoniae. Uncomplicated Gonorrhea ( cervical/urethral and rectal ) caused by Neisseria gonorrhoeae , including both penicillinase- and nonpenicillinase-producing strains, and pharyngeal gonorrhea caused by nonpenicillinase-producing strains of Neisseria gonorrhoeae . Pelvic Inflammatory Disease caused by Neisseria gonorrhoeae . Ceftriaxone sodium, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and Chlamydia trachomatis is one of the suspected pathogens, appropriate antichlamydial coverage should be added. Bacterial Septicemia caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae or Klebsiella pneumoniae. Bone And Joint Infections caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae or Enterobacter species. Intra-Abdominal Infections caused by Escherichia coli, Klebsiella pneumoniae , Bacteroides fragilis , Clostridium species (Note: most strains of Clostridium difficile are resistant) or Peptostreptococcus species. Meningitis caused by Haemophilus influenzae, Neisseria meningitidis or Streptococcus pneumoniae. Ceftriaxone has also been used successfully in a limited number of cases of meningitis and shunt infection caused by Staphylococcus epidermidis Efficacy for this organism in this organ system was studied in fewer than ten infections. and Escherichia coli Efficacy for this organism in this organ system was studied in fewer than ten infections. . Surgical Prophylaxis: The preoperative administration of a single 1 gm dose of ceftriaxone sodium may reduce the incidence of postoperative infections in patients undergoing surgical procedures classified as contaminated or potentially contaminated (e.g., vaginal or abdominal hysterectomy or cholecystectomy for chronic calculous cholecystitis in high-risk patients, such as those over 70 years of age, with acute cholecystitis not requiring therapeutic antimicrobials, obstructive jaundice or common duct bile stones) and in surgical patients for whom infection at the operative site would present serious risk (e.g., during coronary artery bypass surgery). Although ceftriaxone has been shown to have been as effective as cefazolin in the prevention of infection following coronary artery bypass surgery, no placebo-controlled trials have been conducted to evaluate any cephalosporin antibiotic in the prevention of infection following coronary artery bypass surgery. When administered prior to surgical procedures for which it is indicated, a single 1 gm dose of ceftriaxone sodium provides protection from most infections due to susceptible organisms throughout the course of the procedure. uuid:b34ef2a1-4243-46ee-913f-4b154d066102 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29007 biolink:treats MONDO:0043994 PMID:41385096 "[{""id"":""uuid:a44d46b1-3122-450d-aa39-9440992448db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:34945de7-c44c-42ac-ac9b-effe0aab07ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Before instituting treatment with ceftriaxone, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. Therapy may be instituted prior to obtaining results of susceptibility testing. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftriaxone for injection and other antibacterial drugs, ceftriaxone for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ceftriaxone sodium is indicated for the treatment of the following infections when caused by susceptible organisms: Lower Respiratory Tract Infections caused by Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Escherichia coli, Enterobacter aerogenes, Proteus mirabilis or Serratia marcescens. Acute Bacterial Otitis Media caused by Streptococcus pneumoniae, Haemophilus influenzae (including beta-lactamase producing strains) or Moraxella catarrhalis (including beta-lactamase producing strains). NOTE: In one study lower clinical cure rates were observed with a single dose of ceftriaxone sodium compared to 10 days of oral therapy. In a second study comparable cure rates were observed between single dose ceftriaxone sodium and the comparator. The potentially lower clinical cure rate of ceftriaxone should be balanced against the potential advantages of parenteral therapy (see CLINICAL STUDIES ). Skin And Skin Structure Infections caused by Staphylococcus aureus , Staphylococcus epidermidis , Streptococcus pyogenes , Viridans group streptococci, Escherichia coli , Enterobacter cloacae , Klebsiella oxytoca , Klebsiella pneumoniae , Proteus mirabilis , Morganella morganii Efficacy for this organism in this organ system was studied in fewer than ten infections. , Pseudomonas aeruginosa , Serratia marcescens , Acinetobacter calcoaceticus , Bacteroides fragilis Efficacy for this organism in this organ system was studied in fewer than ten infections. or Peptostreptococcus species. Urinary Tract Infections ( complicated and uncomplicated ) caused by Escherichia coli, Proteus mirabilis, Proteus vulgaris, Morganella morganii or Klebsiella pneumoniae. Uncomplicated Gonorrhea ( cervical/urethral and rectal ) caused by Neisseria gonorrhoeae , including both penicillinase- and nonpenicillinase-producing strains, and pharyngeal gonorrhea caused by nonpenicillinase-producing strains of Neisseria gonorrhoeae . Pelvic Inflammatory Disease caused by Neisseria gonorrhoeae . Ceftriaxone sodium, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and Chlamydia trachomatis is one of the suspected pathogens, appropriate antichlamydial coverage should be added. Bacterial Septicemia caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae or Klebsiella pneumoniae. Bone And Joint Infections caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae or Enterobacter species. Intra-Abdominal Infections caused by Escherichia coli, Klebsiella pneumoniae , Bacteroides fragilis , Clostridium species (Note: most strains of Clostridium difficile are resistant) or Peptostreptococcus species. Meningitis caused by Haemophilus influenzae, Neisseria meningitidis or Streptococcus pneumoniae. Ceftriaxone has also been used successfully in a limited number of cases of meningitis and shunt infection caused by Staphylococcus epidermidis Efficacy for this organism in this organ system was studied in fewer than ten infections. and Escherichia coli Efficacy for this organism in this organ system was studied in fewer than ten infections. . Surgical Prophylaxis: The preoperative administration of a single 1 gm dose of ceftriaxone sodium may reduce the incidence of postoperative infections in patients undergoing surgical procedures classified as contaminated or potentially contaminated (e.g., vaginal or abdominal hysterectomy or cholecystectomy for chronic calculous cholecystitis in high-risk patients, such as those over 70 years of age, with acute cholecystitis not requiring therapeutic antimicrobials, obstructive jaundice or common duct bile stones) and in surgical patients for whom infection at the operative site would present serious risk (e.g., during coronary artery bypass surgery). Although ceftriaxone has been shown to have been as effective as cefazolin in the prevention of infection following coronary artery bypass surgery, no placebo-controlled trials have been conducted to evaluate any cephalosporin antibiotic in the prevention of infection following coronary artery bypass surgery. When administered prior to surgical procedures for which it is indicated, a single 1 gm dose of ceftriaxone sodium provides protection from most infections due to susceptible organisms throughout the course of the procedure. uuid:438f8d7e-3d92-465f-a83f-b170409bf8d0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29007 biolink:treats MONDO:0006874 PMID:41385096 "[{""id"":""uuid:02d0891b-c4f9-4d7d-af20-892435b2c0ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a9c6bf08-9726-4b6e-9227-c1b76b8063a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Before instituting treatment with ceftriaxone, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. Therapy may be instituted prior to obtaining results of susceptibility testing. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftriaxone for injection and other antibacterial drugs, ceftriaxone for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ceftriaxone sodium is indicated for the treatment of the following infections when caused by susceptible organisms: Lower Respiratory Tract Infections caused by Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Escherichia coli, Enterobacter aerogenes, Proteus mirabilis or Serratia marcescens. Acute Bacterial Otitis Media caused by Streptococcus pneumoniae, Haemophilus influenzae (including beta-lactamase producing strains) or Moraxella catarrhalis (including beta-lactamase producing strains). NOTE: In one study lower clinical cure rates were observed with a single dose of ceftriaxone sodium compared to 10 days of oral therapy. In a second study comparable cure rates were observed between single dose ceftriaxone sodium and the comparator. The potentially lower clinical cure rate of ceftriaxone should be balanced against the potential advantages of parenteral therapy (see CLINICAL STUDIES ). Skin And Skin Structure Infections caused by Staphylococcus aureus , Staphylococcus epidermidis , Streptococcus pyogenes , Viridans group streptococci, Escherichia coli , Enterobacter cloacae , Klebsiella oxytoca , Klebsiella pneumoniae , Proteus mirabilis , Morganella morganii Efficacy for this organism in this organ system was studied in fewer than ten infections. , Pseudomonas aeruginosa , Serratia marcescens , Acinetobacter calcoaceticus , Bacteroides fragilis Efficacy for this organism in this organ system was studied in fewer than ten infections. or Peptostreptococcus species. Urinary Tract Infections ( complicated and uncomplicated ) caused by Escherichia coli, Proteus mirabilis, Proteus vulgaris, Morganella morganii or Klebsiella pneumoniae. Uncomplicated Gonorrhea ( cervical/urethral and rectal ) caused by Neisseria gonorrhoeae , including both penicillinase- and nonpenicillinase-producing strains, and pharyngeal gonorrhea caused by nonpenicillinase-producing strains of Neisseria gonorrhoeae . Pelvic Inflammatory Disease caused by Neisseria gonorrhoeae . Ceftriaxone sodium, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and Chlamydia trachomatis is one of the suspected pathogens, appropriate antichlamydial coverage should be added. Bacterial Septicemia caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae or Klebsiella pneumoniae. Bone And Joint Infections caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae or Enterobacter species. Intra-Abdominal Infections caused by Escherichia coli, Klebsiella pneumoniae , Bacteroides fragilis , Clostridium species (Note: most strains of Clostridium difficile are resistant) or Peptostreptococcus species. Meningitis caused by Haemophilus influenzae, Neisseria meningitidis or Streptococcus pneumoniae. Ceftriaxone has also been used successfully in a limited number of cases of meningitis and shunt infection caused by Staphylococcus epidermidis Efficacy for this organism in this organ system was studied in fewer than ten infections. and Escherichia coli Efficacy for this organism in this organ system was studied in fewer than ten infections. . Surgical Prophylaxis: The preoperative administration of a single 1 gm dose of ceftriaxone sodium may reduce the incidence of postoperative infections in patients undergoing surgical procedures classified as contaminated or potentially contaminated (e.g., vaginal or abdominal hysterectomy or cholecystectomy for chronic calculous cholecystitis in high-risk patients, such as those over 70 years of age, with acute cholecystitis not requiring therapeutic antimicrobials, obstructive jaundice or common duct bile stones) and in surgical patients for whom infection at the operative site would present serious risk (e.g., during coronary artery bypass surgery). Although ceftriaxone has been shown to have been as effective as cefazolin in the prevention of infection following coronary artery bypass surgery, no placebo-controlled trials have been conducted to evaluate any cephalosporin antibiotic in the prevention of infection following coronary artery bypass surgery. When administered prior to surgical procedures for which it is indicated, a single 1 gm dose of ceftriaxone sodium provides protection from most infections due to susceptible organisms throughout the course of the procedure. uuid:e7922997-3128-4791-9523-81dedbe483ab biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29007 biolink:treats MONDO:0006699 PMID:41385096 "[{""id"":""uuid:b95fa09d-2dc0-402a-8cde-7c6568e40a3c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f542fa74-94b4-433d-b581-b1489a63caf5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Before instituting treatment with ceftriaxone, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. Therapy may be instituted prior to obtaining results of susceptibility testing. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftriaxone for injection and other antibacterial drugs, ceftriaxone for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ceftriaxone sodium is indicated for the treatment of the following infections when caused by susceptible organisms: Lower Respiratory Tract Infections caused by Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Escherichia coli, Enterobacter aerogenes, Proteus mirabilis or Serratia marcescens. Acute Bacterial Otitis Media caused by Streptococcus pneumoniae, Haemophilus influenzae (including beta-lactamase producing strains) or Moraxella catarrhalis (including beta-lactamase producing strains). NOTE: In one study lower clinical cure rates were observed with a single dose of ceftriaxone sodium compared to 10 days of oral therapy. In a second study comparable cure rates were observed between single dose ceftriaxone sodium and the comparator. The potentially lower clinical cure rate of ceftriaxone should be balanced against the potential advantages of parenteral therapy (see CLINICAL STUDIES ). Skin And Skin Structure Infections caused by Staphylococcus aureus , Staphylococcus epidermidis , Streptococcus pyogenes , Viridans group streptococci, Escherichia coli , Enterobacter cloacae , Klebsiella oxytoca , Klebsiella pneumoniae , Proteus mirabilis , Morganella morganii Efficacy for this organism in this organ system was studied in fewer than ten infections. , Pseudomonas aeruginosa , Serratia marcescens , Acinetobacter calcoaceticus , Bacteroides fragilis Efficacy for this organism in this organ system was studied in fewer than ten infections. or Peptostreptococcus species. Urinary Tract Infections ( complicated and uncomplicated ) caused by Escherichia coli, Proteus mirabilis, Proteus vulgaris, Morganella morganii or Klebsiella pneumoniae. Uncomplicated Gonorrhea ( cervical/urethral and rectal ) caused by Neisseria gonorrhoeae , including both penicillinase- and nonpenicillinase-producing strains, and pharyngeal gonorrhea caused by nonpenicillinase-producing strains of Neisseria gonorrhoeae . Pelvic Inflammatory Disease caused by Neisseria gonorrhoeae . Ceftriaxone sodium, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and Chlamydia trachomatis is one of the suspected pathogens, appropriate antichlamydial coverage should be added. Bacterial Septicemia caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae or Klebsiella pneumoniae. Bone And Joint Infections caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae or Enterobacter species. Intra-Abdominal Infections caused by Escherichia coli, Klebsiella pneumoniae , Bacteroides fragilis , Clostridium species (Note: most strains of Clostridium difficile are resistant) or Peptostreptococcus species. Meningitis caused by Haemophilus influenzae, Neisseria meningitidis or Streptococcus pneumoniae. Ceftriaxone has also been used successfully in a limited number of cases of meningitis and shunt infection caused by Staphylococcus epidermidis Efficacy for this organism in this organ system was studied in fewer than ten infections. and Escherichia coli Efficacy for this organism in this organ system was studied in fewer than ten infections. . Surgical Prophylaxis: The preoperative administration of a single 1 gm dose of ceftriaxone sodium may reduce the incidence of postoperative infections in patients undergoing surgical procedures classified as contaminated or potentially contaminated (e.g., vaginal or abdominal hysterectomy or cholecystectomy for chronic calculous cholecystitis in high-risk patients, such as those over 70 years of age, with acute cholecystitis not requiring therapeutic antimicrobials, obstructive jaundice or common duct bile stones) and in surgical patients for whom infection at the operative site would present serious risk (e.g., during coronary artery bypass surgery). Although ceftriaxone has been shown to have been as effective as cefazolin in the prevention of infection following coronary artery bypass surgery, no placebo-controlled trials have been conducted to evaluate any cephalosporin antibiotic in the prevention of infection following coronary artery bypass surgery. When administered prior to surgical procedures for which it is indicated, a single 1 gm dose of ceftriaxone sodium provides protection from most infections due to susceptible organisms throughout the course of the procedure. uuid:eac87899-a5ac-49ce-8cc1-1e2d38b9876f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0005556 PMID:41385096 "[{""id"":""uuid:e780dd81-7569-499c-adf1-92c574ae9c68"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2975f03f-e5f5-4637-aee2-f8ea4dd2afe4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:9874df59-9b75-4ce9-a0b7-7e20ac9f263f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4858 biolink:treats MONDO:0013600 PMID:41385096 "[{""id"":""uuid:215b70d6-30c0-4645-a2ef-c9f4ec0723f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6c8e5954-b189-4878-9597-b809389cb08e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Estazolam tablets are indicated for the short-term management of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. Both out-patient studies and a sleep laboratory study have shown that estazolam administered at bedtime improved sleep induction and sleep maintenance (see CLINICAL PHARMACOLOGY ). Because insomnia is often transient and intermittent, the prolonged administration of estazolam is generally neither necessary nor recommended. Since insomnia may be a symptom of several other disorders, the possibility that the complaint may be related to a condition for which there is a more specific treatment should be considered. There is evidence to support the ability of estazolam to enhance the duration and quality of sleep for intervals up to 12 weeks (see CLINICAL PHARMACOLOGY ). uuid:498ac9cc-dc9e-45e6-b06f-3a9c2b839650 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:38545 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:e272f7f1-5ed4-4a15-a2eb-ae62299c519d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a748fe40-aff8-463e-af04-f0630c5d92e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Hyperlipidemia and Mixed Dyslipidemia CRESTOR is indicated as adjunctive therapy to diet to reduce elevated total-C, LDL-C, ApoB, nonHDL-C, and triglycerides and to increase HDL-C in adult patients with primary hyperlipidemia or mixed dyslipidemia. Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and non-pharmacological interventions alone has been inadequate. 1.2 Hypertriglyceridemia CRESTOR is indicated as adjunctive therapy to diet for the treatment of adult patients with hypertriglyceridemia. 1.3 Primary Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) CRESTOR is indicated as an adjunct to diet for the treatment of patients with primary dysbetalipoproteinemia (Type III Hyperlipoproteinemia). 1.4 Homozygous Familial Hypercholesterolemia CRESTOR is indicated as adjunctive therapy to other lipid-lowering treatments (e.g., LDL apheresis) or alone if such treatments are unavailable to reduce LDL-C, Total-C, and ApoB in adult patients with homozygous familial hypercholesterolemia. 1.5 Slowing of the Progression of Atherosclerosis CRESTOR is indicated as adjunctive therapy to diet to slow the progression of atherosclerosis in adult patients as part of a treatment strategy to lower Total-C and LDL-C to target levels. 1.6 Limitations of Use The effect of CRESTOR on cardiovascular morbidity and mortality has not been determined. CRESTOR has not been studied in Fredrickson Type I and V dyslipidemias. uuid:61185ae4-5f6d-4188-ac22-ab2ca8c40712 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:38545 biolink:treats HP:0003119 PMID:41385096 "[{""id"":""uuid:9f7409c1-3363-44cd-b6c9-55e3cb6f3f76"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a8acf5f2-7f82-4b80-b752-3036d39ed6e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Hyperlipidemia and Mixed Dyslipidemia CRESTOR is indicated as adjunctive therapy to diet to reduce elevated total-C, LDL-C, ApoB, nonHDL-C, and triglycerides and to increase HDL-C in adult patients with primary hyperlipidemia or mixed dyslipidemia. Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and non-pharmacological interventions alone has been inadequate. 1.2 Hypertriglyceridemia CRESTOR is indicated as adjunctive therapy to diet for the treatment of adult patients with hypertriglyceridemia. 1.3 Primary Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) CRESTOR is indicated as an adjunct to diet for the treatment of patients with primary dysbetalipoproteinemia (Type III Hyperlipoproteinemia). 1.4 Homozygous Familial Hypercholesterolemia CRESTOR is indicated as adjunctive therapy to other lipid-lowering treatments (e.g., LDL apheresis) or alone if such treatments are unavailable to reduce LDL-C, Total-C, and ApoB in adult patients with homozygous familial hypercholesterolemia. 1.5 Slowing of the Progression of Atherosclerosis CRESTOR is indicated as adjunctive therapy to diet to slow the progression of atherosclerosis in adult patients as part of a treatment strategy to lower Total-C and LDL-C to target levels. 1.6 Limitations of Use The effect of CRESTOR on cardiovascular morbidity and mortality has not been determined. CRESTOR has not been studied in Fredrickson Type I and V dyslipidemias. uuid:7d2a588b-6194-4953-a6cf-701dd2e540f3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:38545 biolink:treats MONDO:0005347 PMID:41385096 "[{""id"":""uuid:522f1c3d-be9a-4099-ae70-4a899ede84da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6551347f-9c42-44b9-af23-1e1e7c8b0f15"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Hyperlipidemia and Mixed Dyslipidemia CRESTOR is indicated as adjunctive therapy to diet to reduce elevated total-C, LDL-C, ApoB, nonHDL-C, and triglycerides and to increase HDL-C in adult patients with primary hyperlipidemia or mixed dyslipidemia. Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and non-pharmacological interventions alone has been inadequate. 1.2 Hypertriglyceridemia CRESTOR is indicated as adjunctive therapy to diet for the treatment of adult patients with hypertriglyceridemia. 1.3 Primary Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) CRESTOR is indicated as an adjunct to diet for the treatment of patients with primary dysbetalipoproteinemia (Type III Hyperlipoproteinemia). 1.4 Homozygous Familial Hypercholesterolemia CRESTOR is indicated as adjunctive therapy to other lipid-lowering treatments (e.g., LDL apheresis) or alone if such treatments are unavailable to reduce LDL-C, Total-C, and ApoB in adult patients with homozygous familial hypercholesterolemia. 1.5 Slowing of the Progression of Atherosclerosis CRESTOR is indicated as adjunctive therapy to diet to slow the progression of atherosclerosis in adult patients as part of a treatment strategy to lower Total-C and LDL-C to target levels. 1.6 Limitations of Use The effect of CRESTOR on cardiovascular morbidity and mortality has not been determined. CRESTOR has not been studied in Fredrickson Type I and V dyslipidemias. uuid:a871d254-3659-4cf8-8d6a-565091a76862 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:38545 biolink:treats MONDO:0018473 PMID:41385096 "[{""id"":""uuid:37036040-9a37-43b7-ad45-fc9b44af5ede"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aa06636f-aa4d-4421-a206-2be1d76aa61f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Hyperlipidemia and Mixed Dyslipidemia CRESTOR is indicated as adjunctive therapy to diet to reduce elevated total-C, LDL-C, ApoB, nonHDL-C, and triglycerides and to increase HDL-C in adult patients with primary hyperlipidemia or mixed dyslipidemia. Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and non-pharmacological interventions alone has been inadequate. 1.2 Hypertriglyceridemia CRESTOR is indicated as adjunctive therapy to diet for the treatment of adult patients with hypertriglyceridemia. 1.3 Primary Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) CRESTOR is indicated as an adjunct to diet for the treatment of patients with primary dysbetalipoproteinemia (Type III Hyperlipoproteinemia). 1.4 Homozygous Familial Hypercholesterolemia CRESTOR is indicated as adjunctive therapy to other lipid-lowering treatments (e.g., LDL apheresis) or alone if such treatments are unavailable to reduce LDL-C, Total-C, and ApoB in adult patients with homozygous familial hypercholesterolemia. 1.5 Slowing of the Progression of Atherosclerosis CRESTOR is indicated as adjunctive therapy to diet to slow the progression of atherosclerosis in adult patients as part of a treatment strategy to lower Total-C and LDL-C to target levels. 1.6 Limitations of Use The effect of CRESTOR on cardiovascular morbidity and mortality has not been determined. CRESTOR has not been studied in Fredrickson Type I and V dyslipidemias. uuid:278c3765-19a9-4130-9ab0-1a3e4b252469 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:38545 biolink:treats MONDO:0018328 PMID:41385096 "[{""id"":""uuid:854967d2-4442-4908-befa-7048eb25cc22"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:32eb7ada-045a-46af-9fe7-be58e402f37f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Hyperlipidemia and Mixed Dyslipidemia CRESTOR is indicated as adjunctive therapy to diet to reduce elevated total-C, LDL-C, ApoB, nonHDL-C, and triglycerides and to increase HDL-C in adult patients with primary hyperlipidemia or mixed dyslipidemia. Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and non-pharmacological interventions alone has been inadequate. 1.2 Hypertriglyceridemia CRESTOR is indicated as adjunctive therapy to diet for the treatment of adult patients with hypertriglyceridemia. 1.3 Primary Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) CRESTOR is indicated as an adjunct to diet for the treatment of patients with primary dysbetalipoproteinemia (Type III Hyperlipoproteinemia). 1.4 Homozygous Familial Hypercholesterolemia CRESTOR is indicated as adjunctive therapy to other lipid-lowering treatments (e.g., LDL apheresis) or alone if such treatments are unavailable to reduce LDL-C, Total-C, and ApoB in adult patients with homozygous familial hypercholesterolemia. 1.5 Slowing of the Progression of Atherosclerosis CRESTOR is indicated as adjunctive therapy to diet to slow the progression of atherosclerosis in adult patients as part of a treatment strategy to lower Total-C and LDL-C to target levels. 1.6 Limitations of Use The effect of CRESTOR on cardiovascular morbidity and mortality has not been determined. CRESTOR has not been studied in Fredrickson Type I and V dyslipidemias. uuid:b235ae7d-c362-4927-86f0-f68571fa55a1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:38545 biolink:treats MONDO:0005311 PMID:41385096 "[{""id"":""uuid:a81ce445-7119-4b27-9da5-e66ab0232b98"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:08fb7683-ae03-4f9c-8ec4-73cd8cbd59b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Hyperlipidemia and Mixed Dyslipidemia CRESTOR is indicated as adjunctive therapy to diet to reduce elevated total-C, LDL-C, ApoB, nonHDL-C, and triglycerides and to increase HDL-C in adult patients with primary hyperlipidemia or mixed dyslipidemia. Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and non-pharmacological interventions alone has been inadequate. 1.2 Hypertriglyceridemia CRESTOR is indicated as adjunctive therapy to diet for the treatment of adult patients with hypertriglyceridemia. 1.3 Primary Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) CRESTOR is indicated as an adjunct to diet for the treatment of patients with primary dysbetalipoproteinemia (Type III Hyperlipoproteinemia). 1.4 Homozygous Familial Hypercholesterolemia CRESTOR is indicated as adjunctive therapy to other lipid-lowering treatments (e.g., LDL apheresis) or alone if such treatments are unavailable to reduce LDL-C, Total-C, and ApoB in adult patients with homozygous familial hypercholesterolemia. 1.5 Slowing of the Progression of Atherosclerosis CRESTOR is indicated as adjunctive therapy to diet to slow the progression of atherosclerosis in adult patients as part of a treatment strategy to lower Total-C and LDL-C to target levels. 1.6 Limitations of Use The effect of CRESTOR on cardiovascular morbidity and mortality has not been determined. CRESTOR has not been studied in Fredrickson Type I and V dyslipidemias. uuid:74c2ae26-5841-4be7-ac1e-07201bd11310 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8888 biolink:treats MONDO:0005391 PMID:41385096 "[{""id"":""uuid:82c9b918-4220-4924-90cb-e8417f0729c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:df14dc30-a5f3-4cf0-b54b-66f33c9e401f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Parkinson's Disease Ropinirole hydrochloride tablets are indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease. The effectiveness of ropinirole hydrochloride tablets was demonstrated in randomized, controlled trials in patients with early Parkinson's disease who were not receiving concomitant L-dopa therapy as well as in patients with advanced disease on concomitant L-dopa (see CLINICAL PHARMACOLOGY: Clinical Trials ). Restless Legs Syndrome Ropinirole hydrochloride tablets are indicated for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS). Key diagnostic criteria for RLS are: an urge to move the legs usually accompanied or caused by uncomfortable and unpleasant leg sensations; symptoms begin or worsen during periods of rest or inactivity such as lying or sitting; symptoms are partially or totally relieved by movement such as walking or stretching at least as long as the activity continues; and symptoms are worse or occur only in the evening or night. Difficulty falling asleep may frequently be associated with moderate-to-severe RLS. uuid:93a26832-1bdf-432a-b3af-346a2c395df1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats UMLS:C0274435 PMID:41385096 "[{""id"":""uuid:3e7276c5-b595-41ce-a5e8-5a58ac24d5cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:17269152-03f4-45ff-a50d-f2d76d54ff36"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal Diseases: To tide the patient over a critical period of the disease in regional enteritis (systemic therapy), ulcerative colitis. Hematologic Disorders: Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases: For palliative management of leukemias and lymphomas. Nervous System: Acute exacerbations of multiple sclerosis. Cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases: Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases: Berylliosis, symptomatic sarcoidosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:14830316-9fa2-40e4-b7f4-ad789454241b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0001705 PMID:41385096 "[{""id"":""uuid:0c391a86-9637-44f8-b1c7-989a37863bc8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a6f30edd-dd5e-45af-b72e-0623048b4606"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal Diseases: To tide the patient over a critical period of the disease in regional enteritis (systemic therapy), ulcerative colitis. Hematologic Disorders: Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases: For palliative management of leukemias and lymphomas. Nervous System: Acute exacerbations of multiple sclerosis. Cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases: Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases: Berylliosis, symptomatic sarcoidosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:21a4577d-fd26-4c9c-9fa3-3108602d06e1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0006684 PMID:41385096 "[{""id"":""uuid:8312ef8e-bbbb-4c3f-ac0b-7cd807c408a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:88accc73-d878-4328-aee9-f45cd6fba9b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal Diseases: To tide the patient over a critical period of the disease in regional enteritis (systemic therapy), ulcerative colitis. Hematologic Disorders: Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases: For palliative management of leukemias and lymphomas. Nervous System: Acute exacerbations of multiple sclerosis. Cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases: Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases: Berylliosis, symptomatic sarcoidosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:155dff49-4507-4dc6-88d4-11886cf0beb7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0008538 PMID:41385096 "[{""id"":""uuid:6a7cb81c-02b3-44a3-ba65-8d8084b51e71"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d6df5a75-352b-4077-825e-17fb4ff15986"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal Diseases: To tide the patient over a critical period of the disease in regional enteritis (systemic therapy), ulcerative colitis. Hematologic Disorders: Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases: For palliative management of leukemias and lymphomas. Nervous System: Acute exacerbations of multiple sclerosis. Cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases: Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases: Berylliosis, symptomatic sarcoidosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:50530da6-55bc-4e17-877d-09e4389c7e80 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0020283 PMID:41385096 "[{""id"":""uuid:6602f86d-760a-492b-93b2-c7cdd0e6d941"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:28199f86-a7de-4167-aa09-094838125a5a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal Diseases: To tide the patient over a critical period of the disease in regional enteritis (systemic therapy), ulcerative colitis. Hematologic Disorders: Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases: For palliative management of leukemias and lymphomas. Nervous System: Acute exacerbations of multiple sclerosis. Cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases: Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases: Berylliosis, symptomatic sarcoidosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:c8b6f927-10de-4761-b6ed-3f375457d9d1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0018170 PMID:41385096 "[{""id"":""uuid:78d499aa-9d5d-4471-bd6c-39d690d6ff39"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3845cc12-5224-49e6-a8d2-e0102e55c6d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal Diseases: To tide the patient over a critical period of the disease in regional enteritis (systemic therapy), ulcerative colitis. Hematologic Disorders: Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases: For palliative management of leukemias and lymphomas. Nervous System: Acute exacerbations of multiple sclerosis. Cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases: Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases: Berylliosis, symptomatic sarcoidosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:7c7e915a-a7b0-497c-9640-398edbf9ac10 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0005556 PMID:41385096 "[{""id"":""uuid:bfa389e0-53f2-4514-928d-9139b355488d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7f4c850b-b6c0-4b30-b6d6-9859ed9e4dc8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal Diseases: To tide the patient over a critical period of the disease in regional enteritis (systemic therapy), ulcerative colitis. Hematologic Disorders: Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases: For palliative management of leukemias and lymphomas. Nervous System: Acute exacerbations of multiple sclerosis. Cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases: Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases: Berylliosis, symptomatic sarcoidosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:f2aa4024-1c9b-44e6-8552-98c0dd1dc0e2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0015927 PMID:41385096 "[{""id"":""uuid:ac018956-66c0-4b3f-bd89-ba43e1a01ddb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:80da28a0-c3cc-4ebc-8cec-21eb8e410c4c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal Diseases: To tide the patient over a critical period of the disease in regional enteritis (systemic therapy), ulcerative colitis. Hematologic Disorders: Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases: For palliative management of leukemias and lymphomas. Nervous System: Acute exacerbations of multiple sclerosis. Cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases: Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases: Berylliosis, symptomatic sarcoidosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:93a2aef4-44a4-4b9c-9077-19a45930d60d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:100241 biolink:treats UMLS:C0949083 PMID:41385096 "[{""id"":""uuid:a184ea7e-fb59-4294-b8e4-d68a5d31c0ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:13bb7168-b67b-42f3-bdd0-dfa7aad3fc3b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ciprofloxacin Injection, USP is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions and patient populations listed below when the intravenous administration offers a route of administration advantageous to the patient. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Adult Patients: Urinary Tract Infections caused by Escherichia coli (including cases with secondary bacteremia), Klebsiella pneumoniae subspecies pneumoniae , Enterobacter cloacae , Serratia marcescens , Proteus mirabilis , Providencia rettgeri , Morganella morganii , Citrobacter diversus , Citrobacter freundii , Pseudomonas aeruginosa , methicillin-susceptible Staphylococcus epidermidis , Staphylococcus saprophyticus , or Enterococcus faecalis . Lower Respiratory Infections caused by Escherichia coli , Klebsiella pneumoniae subspecies pneumoniae , Enterobacter cloacae , Proteus mirabilis , Pseudomonas aeruginosa , Haemophilus influenzae , Haemophilus parainfluenzae , or penicillin-susceptible Streptococcus pneumoniae . Also, Moraxella catarrhalis for the treatment of acute exacerbations of chronic bronchitis. NOTE: Although effective in clinical trials, ciprofloxacin is not a drug of first choice in the treatment of presumed or confirmed pneumonia secondary to Streptococcus pneumoniae . Nosocomial Pneumonia caused by Haemophilus influenzae or Klebsiella pneumoniae . Skin and Skin Structure Infections caused by Escherichia coli , Klebsiella pneumoniae subspecies pneumoniae , Enterobacter cloacae , Proteus mirabilis , Proteus vulgaris , Providencia stuartii , Morganella morganii , Citrobacter freundii , Pseudomonas aeruginosa , methicillin-susceptible Staphylococcus aureus , methicillin-susceptible Staphylococcus epidermidis , or Streptococcus pyogenes . Bone and Joint Infections caused by Enterobacter cloacae , Serratia marcescens , or Pseudomonas aeruginosa . Complicated Intra-Abdominal Infections (used in conjunction with metronidazole) caused by Escherichia coli , Pseudomonas aeruginosa , Proteus mirabilis , Klebsiella pneumoniae , or Bacteroides fragilis . Acute Sinusitis caused by Haemophilus influenzae , penicillin-susceptible Streptococcus pneumoniae , or Moraxella catarrhalis . Chronic Bacterial Prostatitis caused by Escherichia coli or Proteus mirabilis . Empirical Therapy for Febrile Neutropenic Patients in combination with piperacillin sodium. (See CLINICAL STUDIES .) Pediatric Patients (1 to 17 years of age): Complicated Urinary Tract Infections and Pyelonephritis due to Escherichia coli. NOTE: Although effective in clinical trials, ciprofloxacin is not a drug of first choice in the pediatric population due to an increased incidence of adverse events compared to controls, including events related to joints and/or surrounding tissues. (See WARNINGS , PRECAUTIONS: Pediatric Use , ADVERSE REACTIONS , and CLINICAL STUDIES .) Ciprofloxacin, like other fluoroquinolones, is associated with arthropathy and histopathological changes in weight-bearing joints of juvenile animals. (See ANIMAL PHARMACOLOGY .) Adult and Pediatric Patients: Inhalational anthrax (post-exposure): To reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . Ciprofloxacin serum concentrations achieved in humans served as a surrogate endpoint reasonably likely to predict clinical benefit and provided the initial basis for approval of this indication. 4 Supportive clinical information for ciprofloxacin for anthrax post-exposure prophylaxis was obtained during the anthrax bioterror attacks of October 2001. (See also, INHALATIONAL ANTHRAX – ADDITIONAL INFORMATION .) If anaerobic organisms are suspected of contributing to the infection, appropriate therapy should be administered. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to ciprofloxacin. Therapy with Ciprofloxacin Injection, USP may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. As with other drugs, some strains of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with ciprofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information not only on the therapeutic effect of the antimicrobial agent but also on the possible emergence of bacterial resistance. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ciprofloxacin Injection, USP and other antibacterial drugs, Ciprofloxacin Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:8f3432a3-3899-49e2-a699-43554c9ea9e6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:100241 biolink:treats UMLS:C0746883 PMID:41385096 "[{""id"":""uuid:2aa67d20-7818-42f7-9e63-c54690dcc7ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0125b019-13d5-415e-96a6-55c59768f57e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ciprofloxacin Injection, USP is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions and patient populations listed below when the intravenous administration offers a route of administration advantageous to the patient. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Adult Patients: Urinary Tract Infections caused by Escherichia coli (including cases with secondary bacteremia), Klebsiella pneumoniae subspecies pneumoniae , Enterobacter cloacae , Serratia marcescens , Proteus mirabilis , Providencia rettgeri , Morganella morganii , Citrobacter diversus , Citrobacter freundii , Pseudomonas aeruginosa , methicillin-susceptible Staphylococcus epidermidis , Staphylococcus saprophyticus , or Enterococcus faecalis . Lower Respiratory Infections caused by Escherichia coli , Klebsiella pneumoniae subspecies pneumoniae , Enterobacter cloacae , Proteus mirabilis , Pseudomonas aeruginosa , Haemophilus influenzae , Haemophilus parainfluenzae , or penicillin-susceptible Streptococcus pneumoniae . Also, Moraxella catarrhalis for the treatment of acute exacerbations of chronic bronchitis. NOTE: Although effective in clinical trials, ciprofloxacin is not a drug of first choice in the treatment of presumed or confirmed pneumonia secondary to Streptococcus pneumoniae . Nosocomial Pneumonia caused by Haemophilus influenzae or Klebsiella pneumoniae . Skin and Skin Structure Infections caused by Escherichia coli , Klebsiella pneumoniae subspecies pneumoniae , Enterobacter cloacae , Proteus mirabilis , Proteus vulgaris , Providencia stuartii , Morganella morganii , Citrobacter freundii , Pseudomonas aeruginosa , methicillin-susceptible Staphylococcus aureus , methicillin-susceptible Staphylococcus epidermidis , or Streptococcus pyogenes . Bone and Joint Infections caused by Enterobacter cloacae , Serratia marcescens , or Pseudomonas aeruginosa . Complicated Intra-Abdominal Infections (used in conjunction with metronidazole) caused by Escherichia coli , Pseudomonas aeruginosa , Proteus mirabilis , Klebsiella pneumoniae , or Bacteroides fragilis . Acute Sinusitis caused by Haemophilus influenzae , penicillin-susceptible Streptococcus pneumoniae , or Moraxella catarrhalis . Chronic Bacterial Prostatitis caused by Escherichia coli or Proteus mirabilis . Empirical Therapy for Febrile Neutropenic Patients in combination with piperacillin sodium. (See CLINICAL STUDIES .) Pediatric Patients (1 to 17 years of age): Complicated Urinary Tract Infections and Pyelonephritis due to Escherichia coli. NOTE: Although effective in clinical trials, ciprofloxacin is not a drug of first choice in the pediatric population due to an increased incidence of adverse events compared to controls, including events related to joints and/or surrounding tissues. (See WARNINGS , PRECAUTIONS: Pediatric Use , ADVERSE REACTIONS , and CLINICAL STUDIES .) Ciprofloxacin, like other fluoroquinolones, is associated with arthropathy and histopathological changes in weight-bearing joints of juvenile animals. (See ANIMAL PHARMACOLOGY .) Adult and Pediatric Patients: Inhalational anthrax (post-exposure): To reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . Ciprofloxacin serum concentrations achieved in humans served as a surrogate endpoint reasonably likely to predict clinical benefit and provided the initial basis for approval of this indication. 4 Supportive clinical information for ciprofloxacin for anthrax post-exposure prophylaxis was obtained during the anthrax bioterror attacks of October 2001. (See also, INHALATIONAL ANTHRAX – ADDITIONAL INFORMATION .) If anaerobic organisms are suspected of contributing to the infection, appropriate therapy should be administered. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to ciprofloxacin. Therapy with Ciprofloxacin Injection, USP may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. As with other drugs, some strains of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with ciprofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information not only on the therapeutic effect of the antimicrobial agent but also on the possible emergence of bacterial resistance. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ciprofloxacin Injection, USP and other antibacterial drugs, Ciprofloxacin Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:7e76a4f2-904b-4065-a4cd-dc518d9801ba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:39669 biolink:treats MONDO:0005178 PMID:41385096 "[{""id"":""uuid:d642d649-ab23-4a4d-a5b3-b46e4d1504ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1d6cd5b1-ce6a-47c0-8776-b2db56b5667a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of diflunisal tablets and other treatment options before deciding to use diflunisal tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Diflunisal tablets are indicated for acute or long-term use for symptomatic treatment of the following: Mild to moderate pain Osteoarthritis Rheumatoid arthritis uuid:a906fe8e-1861-47a6-87a7-0a956f71309d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:39669 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:324a999a-c734-4670-a51e-b65f8c7b3dc8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5be9689d-5d62-4a35-9f67-2a2a90a9bfcf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of diflunisal tablets and other treatment options before deciding to use diflunisal tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Diflunisal tablets are indicated for acute or long-term use for symptomatic treatment of the following: Mild to moderate pain Osteoarthritis Rheumatoid arthritis uuid:19c36de0-11d2-4eb6-a6b5-6ff79bce9f8b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5775 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:a3290007-fe60-48be-a9fd-dd541270fac2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:62932ee8-c30f-4f3c-85ab-5724bc68d618"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Severe essential hypertension when the drug cannot be given orally or when there is an urgent need to lower blood pressure. uuid:9a752f1c-21fb-40e0-9969-a412507a64ec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4031 biolink:treats MONDO:0006733 PMID:41385096 "[{""id"":""uuid:ebf88a13-8f75-4dc9-8aa6-f947013ea10c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:449c188e-3dd6-4cf6-85a0-9bb33ca1d976"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:9a266996-2d07-4d4f-bf5a-430063665172"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/verkazia""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] RESTASIS ® ophthalmic emulsion is indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca. Increased tear production was not seen in patients currently taking topical anti-inflammatory drugs or using punctal plugs.|[EMA] Treatment of severe keratitis in adult patients with dry eye disease, which has not improved despite treatment with tear substitutes. uuid:2f4cf4ce-0b93-4f90-bfe0-bfba342e8952 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5062 biolink:treats UMLS:C0426732 PMID:41385096 "[{""id"":""uuid:cd71bf19-4f62-47c2-ac8c-879f08b281f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:51b86a88-0b0d-4142-a04c-490766c445ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Finasteride is indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to: -Improve symptoms -Reduce the risk of the need for surgery including transurethral resection of the prostate (TURP) and prostatectomy. uuid:63fcde55-2d17-48cb-bd91-13d9ff46dbe7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1157355 biolink:treats MONDO:0011438 PMID:41385096 "[{""id"":""uuid:69439b3a-a2df-4860-8473-f55cf5f78679"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c84d5d7a-c50f-40ff-8d11-5dcbdda03998"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tilia™ Fe is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. Tilia™ Fe is indicated for the treatment of moderate acne vulgaris in females, ≥15 years of age, who have no known contraindications to oral contraceptive therapy, desire oral contraception, have achieved menarche, and are unresponsive to topical anti-acne medications. Tilia™ Fe should be used for the treatment of acne only if the patient desires an oral contraceptive for birth control and plans to stay on it for at least 6 months. Oral contraceptives are highly effective for pregnancy prevention. Table 2 lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. The efficacy of these contraceptive methods, except sterilization, depends upon the reliability with which they are used. Correct and consistent use of methods can result in lower failure rates. Table 2 Percentage of Women Experiencing an Unintended Pregnancy During the First Year of Typical Use and the First Year of Perfect Use of Contraception and the Percentage Continuing Use at the End of the First Year (United States). % of Women Experiencing an Unintended Pregnancy within the First Year of Use % of Women Continuing Use at One Year 3 Emergency Contraceptives Pills: Treatment initiated within 72 hours after unprotected intercourse reduces the risk of pregnancy by at least 75%. 9 Lactational Amenorrhea Method: LAM is a highly effective, temporary method of contraception. 10 Source: Trussell J, The Essentials of Contraception. In Hatcher RA, Trussell J, Stewart F, Cates W, Stewart GK, Kowel D, Guest F, Contraceptive Technology : Seventeenth Revised Edition. New York NY: Irvington Publishers, 1998. 1 Among typical couples who initiate use of a method (not necessarily for the first time), the percentage who experience an accidental pregnancy during the first year if they do not stop use for any other reason. 2 Among couples who initiate use of a method (not necessarily for the first time) and who use it perfectly (both consistently and correctly), the percentage who experience an accidental pregnancy during the first year if they do not stop use for any other reason. 3 Among couples attempting to avoid pregnancy, the percentage who continue to use a method for 1 year. 4 The percentages becoming pregnant in columns (2) and (3) are based on data from populations where contraception is not used and from women who cease using contraception in order to become pregnant. Among such populations, about 89% become pregnant within one year. This estimate was lowered slightly (to 85%) to represent the percent who would become pregnant within one year among women now relying on reversible methods of contraception if they abandoned contraception altogether. 5 Foams, creams, gels, vaginal suppositories, and vaginal film. 6 Cervical mucus (ovulation) method supplemented by calendar in the pre-ovulatory and basal body temperature in the post-ovulatory phases. 7 With spermicidal cream or jelly. 8 Without spermicides. 9 The treatment schedule is one dose within 72 hours after unprotected intercourse, and a second dose 12 hours after the first dose. The Food and Drug Administration has declared the following brands of oral contraceptives to be safe and effective for emergency contraception: Ovral ®† (1 dose is 2 white pills), Alesse ®† (1 dose is 5 pink pills), Nordette ®† or Levlen ®† (1 dose is 4 light-orange pills), Lo-Ovral ®† (1 dose is 4 white pills), Triphasil ®† or Tri-Levlen ®† (1 dose is 4 yellow pills). 10 However, to maintain effective protection against pregnancy, another method of contraception must be used as soon as menstruation resumes, the frequency or duration of breastfeeds is reduced, bottle feeds are introduced, or the baby reaches 6 months of age. Method Typical Use 1 Perfect Use 2 (1) (2) (3) (4) Chance 4 85 85 Spermicides 5 26 6 40 Periodic Abstinence 25 63 Calendar 9 Ovulation Method 3 Symptothermal 6 2 Post-ovulation 1 Cap 7 Parous Women 40 26 42 Nulliparous Women 20 9 56 Sponge Parous Women 40 20 42 Nulliparous Women 20 9 56 Diaphragm 7 20 6 56 Withdrawal 19 4 Condom 8 Female (Reality ®† ) 21 5 56 Male 14 3 61 Pill 5 71 Progestin only 0.5 Combined 0.1 IUD Progesterone T 2.0 1.5 81 Copper T380A 0.8 0.6 78 LNg 20 0.1 0.1 81 Injectable progestogen 0.3 0.3 70 Implants 0.05 0.05 88 Female Sterilization 0.5 0.5 100 Male Sterilization 0.15 0.10 100 Norethindrone acetate and ethinyl estradiol tablets were evaluated for the treatment of acne vulgaris in two randomized, double-blind, placebo-controlled, multicenter, Phase 3, six (28 day) cycle studies. A total of 295 patients received norethindrone acetate and ethinyl estradiol tablets and 296 received placebo. Mean age at enrollment for both groups was 24 years. At six months each study demonstrated a statistically significant difference between norethindrone acetate and ethinyl estradiol tablets and placebo for mean change from baseline in lesion counts (see Table 3 and Figure 2). Each study also demonstrated overall treatment success in the investigator’s global evaluation. Patients with severe androgen excess were not studied. Table 3: Acne Vulgaris Indication Pooled Data 376-403 and 376-404 Observed Means at Six Months and at Baseline* Intent To Treat Population Norethindrone Acetate and Ethinyl Estradiol Tablets N=296 Placebo N=295 Difference in Counts Between Norethindrone Acetate and Ethinyl Estradiol Tablets and Placebo at Six Months (95% CI)** Number of Lesions Counts % reduction Counts % reduction * Numbers rounded to nearest integer ** Limits for 95% Confidence Interval; not adjusted for baseline differences INFLAMMATORY LESIONS Baseline Mean 29 29 Sixth Month Mean 14 52% 17 41% 3 (± 2) NON-INFLAMMATORY Baseline Mean 44 43 Sixth Month Mean 27 38% 32 25% 5 (± 3.5) TOTAL LESIONS Baseline Mean 74 72 Sixth Month Mean 42 43% 49 32% 7 (± 5) Norethindrone acetate and ethinyl estradiol tablets users who started with about 74 acne lesions had about 42 lesions after 6 months of treatment. Placebo users who started with about 72 acne lesions had about 49 lesions after the same duration of treatment. uuid:695c4b4e-75ae-4991-9b04-0ae19af576e4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2611 biolink:treats MONDO:0044144 PMID:41385096 "[{""id"":""uuid:2c0ea0af-4fc2-4ae5-b00c-bc0fc8575485"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7ba80e92-75c2-492c-906b-e36ed392de96"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Anxiety Disorders Alprazolam tablets are indicated for the management of anxiety disorder (a condition corresponding most closely to the APA Diagnostic and Statistical Manual [DSM-III-R] diagnosis of generalized anxiety disorder) or the short-term relief of symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. Generalized anxiety disorder is characterized by unrealistic or excessive anxiety and worry (apprehensive expectation) about two or more life circumstances, for a period of six months or longer, during which the person has been bothered more days than not by these concerns. At least 6 of the following 18 symptoms are often present in these patients: Motor Tension (trembling, twitching, or feeling shaky; muscle tension, aches, or soreness; restlessness; easy fatigability); Autonomic Hyperactivity (shortness of breath or smothering sensations; palpitations or accelerated heart rate; sweating, or cold clammy hands; dry mouth; dizziness or light-headedness; nausea, diarrhea, or other abdominal distress; flushes or chills; frequent urination; trouble swallowing or ‘lump in throat’); Vigilance and Scanning (feeling keyed up or on edge; exaggerated startle response; difficulty concentrating or ‘mind going blank’ because of anxiety; trouble falling or staying asleep; irritability). These symptoms must not be secondary to another psychiatric disorder or caused by some organic factor. Anxiety associated with depression is responsive to alprazolam. Panic Disorder Alprazolam is also indicated for the treatment of panic disorder, with or without agoraphobia. Studies supporting this claim were conducted in patients whose diagnoses corresponded closely to the DSM-III-R/IV criteria for panic disorder (see CLINICAL STUDIES ). Panic disorder (DSM-IV) is characterized by recurrent unexpected panic attacks, ie, a discrete period of intense fear or discomfort in which four (or more) of the following symptoms develop abruptly and reach a peak within 10 minutes: (1) palpitations, pounding heart, or accelerated heart rate; (2) sweating; (3) trembling or shaking; (4) sensations of shortness of breath or smothering; (5) feeling of choking; (6) chest pain or discomfort; (7) nausea or abdominal distress; (8) feeling dizzy, unsteady, lightheaded, or faint; (9) derealization (feelings of unreality) or depersonalization (being detached from oneself); (10) fear of losing control; (11) fear of dying; (12) paresthesias (numbness or tingling sensations); (13) chills or hot flushes. Demonstrations of the effectiveness of alprazolam by systematic clinical study are limited to 4 months duration for anxiety disorder and 4 to 10 weeks duration for panic disorder; however, patients with panic disorder have been treated on an open basis for up to 8 months without apparent loss of benefit. The physician should periodically reassess the usefulness of the drug for the individual patient. uuid:1f286575-62e9-4a5d-ad65-f993cedb2215 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2611 biolink:treats MONDO:0041086 PMID:41385096 "[{""id"":""uuid:248f7e63-5226-4a3c-a67f-5d1e88f33c19"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fdb7f6e5-3bf4-4d1e-b916-c698102f0fe8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Anxiety Disorders Alprazolam tablets are indicated for the management of anxiety disorder (a condition corresponding most closely to the APA Diagnostic and Statistical Manual [DSM-III-R] diagnosis of generalized anxiety disorder) or the short-term relief of symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. Generalized anxiety disorder is characterized by unrealistic or excessive anxiety and worry (apprehensive expectation) about two or more life circumstances, for a period of six months or longer, during which the person has been bothered more days than not by these concerns. At least 6 of the following 18 symptoms are often present in these patients: Motor Tension (trembling, twitching, or feeling shaky; muscle tension, aches, or soreness; restlessness; easy fatigability); Autonomic Hyperactivity (shortness of breath or smothering sensations; palpitations or accelerated heart rate; sweating, or cold clammy hands; dry mouth; dizziness or light-headedness; nausea, diarrhea, or other abdominal distress; flushes or chills; frequent urination; trouble swallowing or ‘lump in throat’); Vigilance and Scanning (feeling keyed up or on edge; exaggerated startle response; difficulty concentrating or ‘mind going blank’ because of anxiety; trouble falling or staying asleep; irritability). These symptoms must not be secondary to another psychiatric disorder or caused by some organic factor. Anxiety associated with depression is responsive to alprazolam. Panic Disorder Alprazolam is also indicated for the treatment of panic disorder, with or without agoraphobia. Studies supporting this claim were conducted in patients whose diagnoses corresponded closely to the DSM-III-R/IV criteria for panic disorder (see CLINICAL STUDIES ). Panic disorder (DSM-IV) is characterized by recurrent unexpected panic attacks, ie, a discrete period of intense fear or discomfort in which four (or more) of the following symptoms develop abruptly and reach a peak within 10 minutes: (1) palpitations, pounding heart, or accelerated heart rate; (2) sweating; (3) trembling or shaking; (4) sensations of shortness of breath or smothering; (5) feeling of choking; (6) chest pain or discomfort; (7) nausea or abdominal distress; (8) feeling dizzy, unsteady, lightheaded, or faint; (9) derealization (feelings of unreality) or depersonalization (being detached from oneself); (10) fear of losing control; (11) fear of dying; (12) paresthesias (numbness or tingling sensations); (13) chills or hot flushes. Demonstrations of the effectiveness of alprazolam by systematic clinical study are limited to 4 months duration for anxiety disorder and 4 to 10 weeks duration for panic disorder; however, patients with panic disorder have been treated on an open basis for up to 8 months without apparent loss of benefit. The physician should periodically reassess the usefulness of the drug for the individual patient. uuid:33177bc7-efd7-4982-a701-115cd038faf9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6413 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:32edcbea-af75-4454-9328-79fd214d8cab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e6990923-563b-4607-9510-5151904da30f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:767bb2d9-37e9-4144-b435-daf86e6a84bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Letrozole tablets are an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer ( 1.1 ) Extended adjuvant treatment of postmenopausal women with early breast cancer who have received prior standard adjuvant tamoxifen therapy ( 1.2 ) First and second-line treatment of postmenopausal women with hormone receptor positive or unknown advanced breast cancer ( 1.3 )|[PMDA] Drugs containing a new active ingredient indicated for the treatment of post-menopausal breast cancer uuid:1e013caf-59a7-4e8f-a180-224b8dca41e4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6413 biolink:treats UMLS:C3495917 PMID:41385096 "[{""id"":""uuid:9dd96823-c685-46f6-80ee-a88e22bf8e25"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1d2d3ff4-313e-45ea-bfdc-c337ab8ab8d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Letrozole tablets are an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer ( 1.1 ) Extended adjuvant treatment of postmenopausal women with early breast cancer who have received prior standard adjuvant tamoxifen therapy ( 1.2 ) First and second-line treatment of postmenopausal women with hormone receptor positive or unknown advanced breast cancer ( 1.3 ) uuid:a503887e-da9e-4f50-a642-6b5cbeacb56c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4W0459ZA4V biolink:treats MONDO:0002258 PMID:41385096 "[{""id"":""uuid:e1d0c3e0-eed9-46ff-b30d-8d37c9eb3215"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:20d0a58c-17e6-4341-a33b-efc02abe76c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefprozil tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below: Upper Respiratory Tract: Pharyngitis/Tonsillitis: Caused by Streptococcus pyogenes . NOTE: The usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. Cefprozil is generally effective in the eradication of Streptococcus pyogenes from the nasopharynx; however, substantial data establishing the efficacy of cefprozil in the subsequent prevention of rheumatic fever are not available at present. Otitis Media: Caused by Streptococcus pneumoniae, Haemophilus influenzae (including ß-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). (See CLINICAL STUDIES .) NOTE: In the treatment of otitis media due to ß-lactamase producing organisms, cefprozil had bacteriologic eradication rates somewhat lower than those observed with a product containing a specific ß-lactamase inhibitor. In considering the use of cefprozil, lower overall eradication rates should be balanced against the susceptibility patterns of the common microbes in a given geographic area and the increased potential for toxicity with products containing ß-lactamase inhibitors. Acute Sinusitis: Caused by Streptococcus pneumoniae , Haemophilus influenzae (including ß-lactamase producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). Lower Respiratory Tract: Secondary Bacterial Infection of Acute Bronchitis and Acute Bacterial Exacerbation of Chronic Bronchitis: Caused by Streptococcus pneumoniae, Haemophilus influenzae (including ß-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). Skin and Skin Structure: Uncomplicated Skin and Skin-Structure Infections: Caused by Staphylococcus aureus (including penicillinase producing strains) and Streptococcus pyogenes . Abscesses usually require surgical drainage. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefprozil tablets and other antibacterial drugs, cefprozil tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:802412d8-419f-4e97-9ff1-7098fc8e3f9d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4W0459ZA4V biolink:treats MONDO:0001039 PMID:41385096 "[{""id"":""uuid:d7eaaabc-0f83-4713-9765-3adab8ba8c8c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:90db40a8-5802-4cbb-a21b-98161312bf80"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefprozil tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below: Upper Respiratory Tract: Pharyngitis/Tonsillitis: Caused by Streptococcus pyogenes . NOTE: The usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. Cefprozil is generally effective in the eradication of Streptococcus pyogenes from the nasopharynx; however, substantial data establishing the efficacy of cefprozil in the subsequent prevention of rheumatic fever are not available at present. Otitis Media: Caused by Streptococcus pneumoniae, Haemophilus influenzae (including ß-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). (See CLINICAL STUDIES .) NOTE: In the treatment of otitis media due to ß-lactamase producing organisms, cefprozil had bacteriologic eradication rates somewhat lower than those observed with a product containing a specific ß-lactamase inhibitor. In considering the use of cefprozil, lower overall eradication rates should be balanced against the susceptibility patterns of the common microbes in a given geographic area and the increased potential for toxicity with products containing ß-lactamase inhibitors. Acute Sinusitis: Caused by Streptococcus pneumoniae , Haemophilus influenzae (including ß-lactamase producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). Lower Respiratory Tract: Secondary Bacterial Infection of Acute Bronchitis and Acute Bacterial Exacerbation of Chronic Bronchitis: Caused by Streptococcus pneumoniae, Haemophilus influenzae (including ß-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). Skin and Skin Structure: Uncomplicated Skin and Skin-Structure Infections: Caused by Staphylococcus aureus (including penicillinase producing strains) and Streptococcus pyogenes . Abscesses usually require surgical drainage. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefprozil tablets and other antibacterial drugs, cefprozil tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:f0ada286-89b9-4091-82b6-4ad9387d5b2f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4W0459ZA4V biolink:treats MONDO:0021680 PMID:41385096 "[{""id"":""uuid:6ee1f1a2-6b8c-466b-b1fd-0ad666cdde9b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:89772f97-fbbb-4a5f-bd7a-ae50ae6d69c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefprozil tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below: Upper Respiratory Tract: Pharyngitis/Tonsillitis: Caused by Streptococcus pyogenes . NOTE: The usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. Cefprozil is generally effective in the eradication of Streptococcus pyogenes from the nasopharynx; however, substantial data establishing the efficacy of cefprozil in the subsequent prevention of rheumatic fever are not available at present. Otitis Media: Caused by Streptococcus pneumoniae, Haemophilus influenzae (including ß-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). (See CLINICAL STUDIES .) NOTE: In the treatment of otitis media due to ß-lactamase producing organisms, cefprozil had bacteriologic eradication rates somewhat lower than those observed with a product containing a specific ß-lactamase inhibitor. In considering the use of cefprozil, lower overall eradication rates should be balanced against the susceptibility patterns of the common microbes in a given geographic area and the increased potential for toxicity with products containing ß-lactamase inhibitors. Acute Sinusitis: Caused by Streptococcus pneumoniae , Haemophilus influenzae (including ß-lactamase producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). Lower Respiratory Tract: Secondary Bacterial Infection of Acute Bronchitis and Acute Bacterial Exacerbation of Chronic Bronchitis: Caused by Streptococcus pneumoniae, Haemophilus influenzae (including ß-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). Skin and Skin Structure: Uncomplicated Skin and Skin-Structure Infections: Caused by Staphylococcus aureus (including penicillinase producing strains) and Streptococcus pyogenes . Abscesses usually require surgical drainage. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefprozil tablets and other antibacterial drugs, cefprozil tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:b54ee1fd-e727-469d-aed7-26dd79968515 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4W0459ZA4V biolink:treats MONDO:0017767 PMID:41385096 "[{""id"":""uuid:ed13d3c1-1e8a-4c14-a2c1-a566fc859008"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:884a7e3b-1c31-46df-a733-4e9218569311"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefprozil tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below: Upper Respiratory Tract: Pharyngitis/Tonsillitis: Caused by Streptococcus pyogenes . NOTE: The usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. Cefprozil is generally effective in the eradication of Streptococcus pyogenes from the nasopharynx; however, substantial data establishing the efficacy of cefprozil in the subsequent prevention of rheumatic fever are not available at present. Otitis Media: Caused by Streptococcus pneumoniae, Haemophilus influenzae (including ß-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). (See CLINICAL STUDIES .) NOTE: In the treatment of otitis media due to ß-lactamase producing organisms, cefprozil had bacteriologic eradication rates somewhat lower than those observed with a product containing a specific ß-lactamase inhibitor. In considering the use of cefprozil, lower overall eradication rates should be balanced against the susceptibility patterns of the common microbes in a given geographic area and the increased potential for toxicity with products containing ß-lactamase inhibitors. Acute Sinusitis: Caused by Streptococcus pneumoniae , Haemophilus influenzae (including ß-lactamase producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). Lower Respiratory Tract: Secondary Bacterial Infection of Acute Bronchitis and Acute Bacterial Exacerbation of Chronic Bronchitis: Caused by Streptococcus pneumoniae, Haemophilus influenzae (including ß-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). Skin and Skin Structure: Uncomplicated Skin and Skin-Structure Infections: Caused by Staphylococcus aureus (including penicillinase producing strains) and Streptococcus pyogenes . Abscesses usually require surgical drainage. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefprozil tablets and other antibacterial drugs, cefprozil tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:d1987e0b-c48f-444e-b40f-3a59109764d2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4W0459ZA4V biolink:treats MONDO:0005441 PMID:41385096 "[{""id"":""uuid:cd75eacb-ffc4-4456-b552-2e385e33f6a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:939c0c1c-f970-42de-932e-82a5de17873d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefprozil tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below: Upper Respiratory Tract: Pharyngitis/Tonsillitis: Caused by Streptococcus pyogenes . NOTE: The usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. Cefprozil is generally effective in the eradication of Streptococcus pyogenes from the nasopharynx; however, substantial data establishing the efficacy of cefprozil in the subsequent prevention of rheumatic fever are not available at present. Otitis Media: Caused by Streptococcus pneumoniae, Haemophilus influenzae (including ß-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). (See CLINICAL STUDIES .) NOTE: In the treatment of otitis media due to ß-lactamase producing organisms, cefprozil had bacteriologic eradication rates somewhat lower than those observed with a product containing a specific ß-lactamase inhibitor. In considering the use of cefprozil, lower overall eradication rates should be balanced against the susceptibility patterns of the common microbes in a given geographic area and the increased potential for toxicity with products containing ß-lactamase inhibitors. Acute Sinusitis: Caused by Streptococcus pneumoniae , Haemophilus influenzae (including ß-lactamase producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). Lower Respiratory Tract: Secondary Bacterial Infection of Acute Bronchitis and Acute Bacterial Exacerbation of Chronic Bronchitis: Caused by Streptococcus pneumoniae, Haemophilus influenzae (including ß-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). Skin and Skin Structure: Uncomplicated Skin and Skin-Structure Infections: Caused by Staphylococcus aureus (including penicillinase producing strains) and Streptococcus pyogenes . Abscesses usually require surgical drainage. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefprozil tablets and other antibacterial drugs, cefprozil tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:98e80635-b342-476a-b5d2-f0c4ba10ce50 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4W0459ZA4V biolink:treats HP:0000255 PMID:41385096 "[{""id"":""uuid:37f711b6-ff4a-4037-8d7b-8f11d38e6a41"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:25fb5cf9-50c2-495f-952c-b880aae8c1f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefprozil tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below: Upper Respiratory Tract: Pharyngitis/Tonsillitis: Caused by Streptococcus pyogenes . NOTE: The usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. Cefprozil is generally effective in the eradication of Streptococcus pyogenes from the nasopharynx; however, substantial data establishing the efficacy of cefprozil in the subsequent prevention of rheumatic fever are not available at present. Otitis Media: Caused by Streptococcus pneumoniae, Haemophilus influenzae (including ß-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). (See CLINICAL STUDIES .) NOTE: In the treatment of otitis media due to ß-lactamase producing organisms, cefprozil had bacteriologic eradication rates somewhat lower than those observed with a product containing a specific ß-lactamase inhibitor. In considering the use of cefprozil, lower overall eradication rates should be balanced against the susceptibility patterns of the common microbes in a given geographic area and the increased potential for toxicity with products containing ß-lactamase inhibitors. Acute Sinusitis: Caused by Streptococcus pneumoniae , Haemophilus influenzae (including ß-lactamase producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). Lower Respiratory Tract: Secondary Bacterial Infection of Acute Bronchitis and Acute Bacterial Exacerbation of Chronic Bronchitis: Caused by Streptococcus pneumoniae, Haemophilus influenzae (including ß-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). Skin and Skin Structure: Uncomplicated Skin and Skin-Structure Infections: Caused by Staphylococcus aureus (including penicillinase producing strains) and Streptococcus pyogenes . Abscesses usually require surgical drainage. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefprozil tablets and other antibacterial drugs, cefprozil tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:d6dd1be0-e6f8-49e4-a45b-239c5c4a228a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4W0459ZA4V biolink:treats HP:0012388 PMID:41385096 "[{""id"":""uuid:9609e52b-7c7e-4aa5-b741-04a973dabe4d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3282d034-3ae1-4ad6-a776-63fcde77d7c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefprozil tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below: Upper Respiratory Tract: Pharyngitis/Tonsillitis: Caused by Streptococcus pyogenes . NOTE: The usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. Cefprozil is generally effective in the eradication of Streptococcus pyogenes from the nasopharynx; however, substantial data establishing the efficacy of cefprozil in the subsequent prevention of rheumatic fever are not available at present. Otitis Media: Caused by Streptococcus pneumoniae, Haemophilus influenzae (including ß-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). (See CLINICAL STUDIES .) NOTE: In the treatment of otitis media due to ß-lactamase producing organisms, cefprozil had bacteriologic eradication rates somewhat lower than those observed with a product containing a specific ß-lactamase inhibitor. In considering the use of cefprozil, lower overall eradication rates should be balanced against the susceptibility patterns of the common microbes in a given geographic area and the increased potential for toxicity with products containing ß-lactamase inhibitors. Acute Sinusitis: Caused by Streptococcus pneumoniae , Haemophilus influenzae (including ß-lactamase producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). Lower Respiratory Tract: Secondary Bacterial Infection of Acute Bronchitis and Acute Bacterial Exacerbation of Chronic Bronchitis: Caused by Streptococcus pneumoniae, Haemophilus influenzae (including ß-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). Skin and Skin Structure: Uncomplicated Skin and Skin-Structure Infections: Caused by Staphylococcus aureus (including penicillinase producing strains) and Streptococcus pyogenes . Abscesses usually require surgical drainage. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefprozil tablets and other antibacterial drugs, cefprozil tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:f3267e0c-a2ce-498c-b9a0-2ad9d37f617b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4W0459ZA4V biolink:treats MONDO:0005607 PMID:41385096 "[{""id"":""uuid:60dc60ad-fb30-4bcc-9ef9-4ad8e671c3ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:10c873b3-434a-4788-ba59-e6ed8478e49b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefprozil tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below: Upper Respiratory Tract: Pharyngitis/Tonsillitis: Caused by Streptococcus pyogenes . NOTE: The usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. Cefprozil is generally effective in the eradication of Streptococcus pyogenes from the nasopharynx; however, substantial data establishing the efficacy of cefprozil in the subsequent prevention of rheumatic fever are not available at present. Otitis Media: Caused by Streptococcus pneumoniae, Haemophilus influenzae (including ß-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). (See CLINICAL STUDIES .) NOTE: In the treatment of otitis media due to ß-lactamase producing organisms, cefprozil had bacteriologic eradication rates somewhat lower than those observed with a product containing a specific ß-lactamase inhibitor. In considering the use of cefprozil, lower overall eradication rates should be balanced against the susceptibility patterns of the common microbes in a given geographic area and the increased potential for toxicity with products containing ß-lactamase inhibitors. Acute Sinusitis: Caused by Streptococcus pneumoniae , Haemophilus influenzae (including ß-lactamase producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). Lower Respiratory Tract: Secondary Bacterial Infection of Acute Bronchitis and Acute Bacterial Exacerbation of Chronic Bronchitis: Caused by Streptococcus pneumoniae, Haemophilus influenzae (including ß-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). Skin and Skin Structure: Uncomplicated Skin and Skin-Structure Infections: Caused by Staphylococcus aureus (including penicillinase producing strains) and Streptococcus pyogenes . Abscesses usually require surgical drainage. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefprozil tablets and other antibacterial drugs, cefprozil tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:09614d7b-f18b-414e-b7f4-b9f452dc6549 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4W0459ZA4V biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:7e816357-e5d4-4d73-9918-a88dc71a708d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:74e2d849-973d-455e-b7e7-b46320e63b8c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefprozil tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below: Upper Respiratory Tract: Pharyngitis/Tonsillitis: Caused by Streptococcus pyogenes . NOTE: The usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. Cefprozil is generally effective in the eradication of Streptococcus pyogenes from the nasopharynx; however, substantial data establishing the efficacy of cefprozil in the subsequent prevention of rheumatic fever are not available at present. Otitis Media: Caused by Streptococcus pneumoniae, Haemophilus influenzae (including ß-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). (See CLINICAL STUDIES .) NOTE: In the treatment of otitis media due to ß-lactamase producing organisms, cefprozil had bacteriologic eradication rates somewhat lower than those observed with a product containing a specific ß-lactamase inhibitor. In considering the use of cefprozil, lower overall eradication rates should be balanced against the susceptibility patterns of the common microbes in a given geographic area and the increased potential for toxicity with products containing ß-lactamase inhibitors. Acute Sinusitis: Caused by Streptococcus pneumoniae , Haemophilus influenzae (including ß-lactamase producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). Lower Respiratory Tract: Secondary Bacterial Infection of Acute Bronchitis and Acute Bacterial Exacerbation of Chronic Bronchitis: Caused by Streptococcus pneumoniae, Haemophilus influenzae (including ß-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). Skin and Skin Structure: Uncomplicated Skin and Skin-Structure Infections: Caused by Staphylococcus aureus (including penicillinase producing strains) and Streptococcus pyogenes . Abscesses usually require surgical drainage. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefprozil tablets and other antibacterial drugs, cefprozil tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:19dc9423-93d5-4d60-adac-94c3785280df biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8207 biolink:treats HP:0000217 PMID:41385096 "[{""id"":""uuid:df9c8217-f0a0-4c62-b89d-cb7615e003cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f1b311f5-fa27-4afa-a834-f5876ff7b921"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:6a0c01ce-494c-49fd-853a-ea8ad8a33577"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pilocarpine hydrochloride tablets are indicated for 1) the treatment of symptoms of dry mouth from salivary gland hypofunction caused by radiotherapy for cancer of the head and neck; and 2) the treatment of symptoms of dry mouth in patients with Sjogren's syndrome.|[PMDA] Drug with a new route of oral administration indicated for the treatment of symptoms of dry mouth caused by radiotherapy for head and neck cancer uuid:eba349c5-49a1-4f81-8688-bb479f6af33d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135622 biolink:treats MONDO:0006668 PMID:41385096 "[{""id"":""uuid:d39a78d8-458b-4e5a-a841-9346d3ffb7d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:06dc2660-55d2-4f46-bc2a-dbd35b03d53e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Besivance™ (besifloxacin ophthalmic suspension) 0.6%, is indicated for the treatment of bacterial conjunctivitis caused by susceptible isolates of the following bacteria: CDC coryneform group G Corynebacterium pseudodiphtheriticum* Corynebacterium striatum* Haemophilus influenzae Moraxella lacunata* Staphylococcus aureus Staphylococcus epidermidis Staphylococcus hominis* Staphylococcus lugdunensis* Streptococcus mitis group Streptococcus oralis Streptococcus pneumoniae Streptococcus salivarius* *Efficacy for this organism was studied in fewer than 10 infections. uuid:274d64f7-dab2-46a3-94fa-d000a8ed5de7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47426 biolink:treats MONDO:0002476 PMID:41385096 "[{""id"":""uuid:c3bd645c-02f7-4e0c-a3f6-f501b4bb62a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9596d4b1-c1ab-44bf-b070-0993d75050e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Edema Furosemide tablets, USP is indicated in adults and pediatric patients for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. Furosemide is particularly useful when an agent with greater diuretic potential is desired. Hypertension Furosemide tablets, USP may be used in adults for the treatment of hypertension alone or in combination with other antihypertensive agents. Hypertensive patients who cannot be adequately controlled with thiazides will probably also not be adequately controlled with furosemide alone. CONTRAINDICATIONS Furosemide tablets are contraindicated in patients with anuria and in patients with a history of hypersensitivity to furosemide. uuid:a5ab176c-67a9-4abf-9aa3-21e6823b9fc6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:36795 biolink:treats UMLS:C0746683 PMID:41385096 "[{""id"":""uuid:3c47151d-c728-47ab-a391-2d84766f3e57"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:69be5c28-3a68-410f-99c3-8b3e690b1f83"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cymbalta ® is a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for: Major Depressive Disorder (MDD). ( 1.1 ) Efficacy was established in four short-term and one maintenance trial in adults. ( 14.1 ) Generalized Anxiety Disorder (GAD). ( 1.2 ) Efficacy was established in three short-term and one maintenance trial in adults. ( 14.2 ) Diabetic Peripheral Neuropathic Pain (DPNP). ( 1.3 ) Fibromyalgia (FM). ( 1.4 ) Chronic Musculoskeletal Pain. ( 1.5 ) uuid:c87a2034-2e91-42dc-9d67-f9161e3d2866 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6129 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:f714cb48-fa49-41cc-ab7e-e8897e79a4a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8c699f91-f577-4158-8055-4ab0bea45c18"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SPRIX is indicated in adult patients for the short term (up to 5 days) management of moderate to moderately severe pain that requires analgesia at the opioid level. uuid:526176cc-9fda-4575-adc7-c5061bcc2f85 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9927 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:12d79a4b-4c8d-4837-9ac8-bfa7512e7c28"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7ebb8381-e680-4585-b115-9158f03bf335"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:5aa9cc31-c63c-4e82-8586-52423680604e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diovan is an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension (1.1) Treatment of heart failure (NYHA class II-IV); Diovan significantly reduced hospitalization for heart failure (1.2) Reduction of cardiovascular mortality in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction (1.3)|[PMDA] Drugs with a new additional pediatric dosage. These drugs are indicated for the treatment of hypertension. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:c9eecf33-795d-48ca-bb6d-090d1959d88a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9927 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:3e4198b7-1c0f-47f9-8540-a082ac9e899f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3bd64e71-c7f2-49b8-b1e3-a6274a892c53"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diovan is an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension (1.1) Treatment of heart failure (NYHA class II-IV); Diovan significantly reduced hospitalization for heart failure (1.2) Reduction of cardiovascular mortality in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction (1.3) uuid:297b0ed3-3f1a-44dd-958f-c999d992b1f9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9927 biolink:treats HP:0025169 PMID:41385096 "[{""id"":""uuid:6004aca8-d109-4fcf-b705-b8cdef51e605"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ebc8f3a4-2161-4e3d-a0d9-670e137b1b16"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diovan is an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension (1.1) Treatment of heart failure (NYHA class II-IV); Diovan significantly reduced hospitalization for heart failure (1.2) Reduction of cardiovascular mortality in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction (1.3) uuid:5b3eb746-f304-48c1-bd2f-4c2c5ce65a9c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4031 biolink:treats UMLS:C0345468 PMID:41385096 "[{""id"":""uuid:91f5f3b5-b249-4813-95e9-5ae88e168d39"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:85ab5736-497f-45fa-ba4b-17e2caa68234"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cyclosporine Capsules USP MODIFIED are indicated for the prophylaxis of organ rejection in kidney, liver, and heart allogeneic transplants. Cyclosporine Capsules USP MODIFIED have been used in combination with azathioprine and corticosteroids. uuid:6e15761f-6f36-488f-87c6-72c4e5a1b289 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3568 biolink:treats MONDO:0010030 PMID:41385096 "[{""id"":""uuid:b8e67c1f-1ed2-4fca-9cbc-fc2a7c90aa91"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b5a29ca0-8eaa-430f-9ac6-1fab56269ccc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cevimeline is indicated for the treatment of symptoms of dry mouth in patients with Sjögren’s Syndrome. uuid:fedae834-d640-467a-bb96-48a8cc3e8860 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3568 biolink:treats HP:0000217 PMID:41385096 "[{""id"":""uuid:fb4ab309-f283-42dd-ae8e-da590aa87343"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aacdebf7-e87a-44a6-86cb-a6e6740bb3a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cevimeline is indicated for the treatment of symptoms of dry mouth in patients with Sjögren’s Syndrome. uuid:ef3f46e8-13c5-4e32-ab9c-21fe1dadaae0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27690 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:ad37b2e6-491c-45cc-993a-493d10aefd0c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c733f53e-2e05-4baa-af04-ad53c74ab1ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For adjunctive treatment of: edema due to congestive heart failure; drug-induced edema; centrencephalic epilepsies (petit mal, unlocalized seizures); chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure. AcetaZOLAMIDE is also indicated for the prevention or amelioration of symptoms associated with acute mountain sickness in climbers attempting rapid ascent and in those who are very susceptible to acute mountain sickness despite gradual ascent. uuid:38512ff9-5185-48d7-afbb-2184c2cec80c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27690 biolink:treats MONDO:0010826 PMID:41385096 "[{""id"":""uuid:04de1d0f-7e9a-400d-a76a-bffd86076a65"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c06d1a82-2503-4fa6-9660-1e945577b232"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For adjunctive treatment of: edema due to congestive heart failure; drug-induced edema; centrencephalic epilepsies (petit mal, unlocalized seizures); chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure. AcetaZOLAMIDE is also indicated for the prevention or amelioration of symptoms associated with acute mountain sickness in climbers attempting rapid ascent and in those who are very susceptible to acute mountain sickness despite gradual ascent. uuid:43b72261-7328-4de1-a482-2f7e2786fad4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27690 biolink:treats MONDO:0005338 PMID:41385096 "[{""id"":""uuid:b80233c6-2959-4dff-ab7c-81e340920b8f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ed5b0d0a-fa7c-4fc8-a5ce-5d1a6357bcfc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For adjunctive treatment of: edema due to congestive heart failure; drug-induced edema; centrencephalic epilepsies (petit mal, unlocalized seizures); chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure. AcetaZOLAMIDE is also indicated for the prevention or amelioration of symptoms associated with acute mountain sickness in climbers attempting rapid ascent and in those who are very susceptible to acute mountain sickness despite gradual ascent. uuid:2c30a228-dae5-449d-b328-ed24f1655973 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27690 biolink:treats UMLS:C0149893 PMID:41385096 "[{""id"":""uuid:c6d6d043-4bb4-47d1-bd8b-7fa98a2cfab2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a5a7fde9-2f7b-43e1-a983-fa96dbecdcd9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For adjunctive treatment of: edema due to congestive heart failure; drug-induced edema; centrencephalic epilepsies (petit mal, unlocalized seizures); chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure. AcetaZOLAMIDE is also indicated for the prevention or amelioration of symptoms associated with acute mountain sickness in climbers attempting rapid ascent and in those who are very susceptible to acute mountain sickness despite gradual ascent. uuid:f8cf24d2-fd0f-4aaa-8fb4-0d4c262392dc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27690 biolink:treats MONDO:0001817 PMID:41385096 "[{""id"":""uuid:ca7dab26-8cd0-4524-aba5-51d5c3dd1456"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2da7388a-6d78-4afe-b9fd-b8f8339d2ceb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For adjunctive treatment of: edema due to congestive heart failure; drug-induced edema; centrencephalic epilepsies (petit mal, unlocalized seizures); chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure. AcetaZOLAMIDE is also indicated for the prevention or amelioration of symptoms associated with acute mountain sickness in climbers attempting rapid ascent and in those who are very susceptible to acute mountain sickness despite gradual ascent. uuid:6841ae2b-d998-4cdc-b887-baed499d8db1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27690 biolink:treats MONDO:0021811 PMID:41385096 "[{""id"":""uuid:aee5f886-a931-44b4-95b5-9c27d72cd7c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1d74a0c3-7ba1-4603-9f9c-c3ab40af6a9e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For adjunctive treatment of: edema due to congestive heart failure; drug-induced edema; centrencephalic epilepsies (petit mal, unlocalized seizures); chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure. AcetaZOLAMIDE is also indicated for the prevention or amelioration of symptoms associated with acute mountain sickness in climbers attempting rapid ascent and in those who are very susceptible to acute mountain sickness despite gradual ascent. uuid:6d0c8d1a-ae02-4d27-8248-3e1c32ea5d8a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15354 biolink:treats MONDO:0850282 PMID:41385096 "[{""id"":""uuid:7d663af6-fdb2-425f-a8bb-905708f9269a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:66f47641-604c-4042-965d-9f6648c1f675"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Theophylline extended-release tablets are indicated for the treatment of the symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, e.g., emphysema and chronic bronchitis. uuid:be5f83c2-83a1-40df-8073-5b32120218f9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15354 biolink:treats MONDO:0004849 PMID:41385096 "[{""id"":""uuid:13c636a2-c4d0-4f14-9654-2eafb51a3ba2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:64eb96ff-5e5a-458b-b74d-a335ad356bb1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Theophylline extended-release tablets are indicated for the treatment of the symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, e.g., emphysema and chronic bronchitis. uuid:42596af1-fd98-4332-9ad7-c8e837bdaeff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15354 biolink:treats MONDO:0005607 PMID:41385096 "[{""id"":""uuid:ebffe064-ffbe-4998-bf0e-021213a50c97"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6d561a57-86a9-433a-9ab4-48ca755423d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Theophylline extended-release tablets are indicated for the treatment of the symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, e.g., emphysema and chronic bronchitis. uuid:5b016b96-1a0c-4b8a-9d15-2d0dce735824 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1151549 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:8072fd1f-7f71-44d3-8ada-9a88581e674a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e42d22ea-c5c3-4b9a-94ba-625258a10cdd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydrocodone and acetaminophen tablets are indicated for the relief of moderate to moderately severe pain. uuid:7110acab-9eca-40df-a86f-7d0a7a350f47 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9943 biolink:treats MONDO:0002444 PMID:41385096 "[{""id"":""uuid:9b9da34b-2057-4308-9727-2e4f59cfdf3f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4abf9664-e2a3-4ec8-9567-aed63091d3f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Venlafaxine hydrochloride tablets are indicated for the treatment of major depressive disorder. The efficacy of venlafaxine hydrochloride in the treatment of major depressive disorder was established in 6-week controlled trials of adult outpatients whose diagnoses corresponded most closely to the DSM-III or DSM-III-R category of major depression and in a 4-week controlled trial of inpatients meeting diagnostic criteria for major depression with melancholia (see CLINICAL TRIALS ). A major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks); it should include at least 4 of the following 8 symptoms: change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suicide attempt or suicidal ideation. The efficacy of venlafaxine extended-release capsules in maintaining an antidepressant response for up to 26 weeks following 8 weeks of acute treatment was demonstrated in a placebo-controlled trial. The efficacy of venlafaxine hydrochloride in maintaining an antidepressant response in patients with recurrent depression who had responded and continued to be improved during an initial 26 weeks of treatment and were then followed for a period of up to 52 weeks was demonstrated in a second placebo-controlled trial (see CLINICAL TRIALS ). Nevertheless, the physician who elects to use venlafaxine hydrochloride tablets/ venlafaxine hydrochloride extended-release capsules for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient. uuid:88f051f2-056f-41fb-bf3b-4d657258a513 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9943 biolink:treats UMLS:C0221480 PMID:41385096 "[{""id"":""uuid:4b9def03-7e8f-4045-a0a5-146186069ac8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8940e391-2338-4204-a12d-93133be06db7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Venlafaxine hydrochloride tablets are indicated for the treatment of major depressive disorder. The efficacy of venlafaxine hydrochloride in the treatment of major depressive disorder was established in 6-week controlled trials of adult outpatients whose diagnoses corresponded most closely to the DSM-III or DSM-III-R category of major depression and in a 4-week controlled trial of inpatients meeting diagnostic criteria for major depression with melancholia (see CLINICAL TRIALS ). A major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks); it should include at least 4 of the following 8 symptoms: change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suicide attempt or suicidal ideation. The efficacy of venlafaxine extended-release capsules in maintaining an antidepressant response for up to 26 weeks following 8 weeks of acute treatment was demonstrated in a placebo-controlled trial. The efficacy of venlafaxine hydrochloride in maintaining an antidepressant response in patients with recurrent depression who had responded and continued to be improved during an initial 26 weeks of treatment and were then followed for a period of up to 52 weeks was demonstrated in a second placebo-controlled trial (see CLINICAL TRIALS ). Nevertheless, the physician who elects to use venlafaxine hydrochloride tablets/ venlafaxine hydrochloride extended-release capsules for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient. uuid:0bfaf1dd-dad4-4ed3-9998-3d830bf1bf8b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:92609 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:abb2c35a-e42c-409d-95fa-cbd5bc48b731"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7a0415cb-7b25-411b-9288-d9dfbf651e92"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:672e0e8c-30cf-471e-946f-aa3025aef17f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Glimepiride tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (see DOSAGE AND ADMINISTRATION ).|[PMDA] Drugs with a new dosage indicated for the treatment of type 2 diabetes mellitus (for use only in patients who have not responded sufficiently to diet and exercise therapies alone). uuid:dec20cbe-8b2d-4cf2-8437-43203af13d20 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16467 biolink:treats UMLS:C0858004 PMID:41385096 "[{""id"":""uuid:ba433ddf-85a6-444c-a5b8-475cf45dfcc8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:42cb908d-cc8f-4fd1-acc6-7f3786906316"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Rimantadine hydrochloride tablet is indicated for the prophylaxis and treatment of illness caused by various strains of influenza A virus in adults (17 years and older). Rimantadine hydrochloride tablet is indicated for prophylaxis against influenza A virus in children (1 year to 16 years of age). PROPHYLAXIS In controlled studies of children (1 year to 16 years of age), healthy adults (17 years and older), and elderly patients (65 years of age and older), rimantadine hydrochloride has been shown to be safe and effective in preventing signs and symptoms of infection caused by various strains of influenza A virus. Since rimantadine hydrochloride does not completely prevent the host immune response to influenza A infection, individuals who take this drug may still develop immune responses to natural disease or vaccination and may be protected when later exposed to antigenically-related viruses. Following vaccination during an influenza outbreak, rimantadine hydrochloride prophylaxis should be considered for the 2 to 4 week time period required to develop an antibody response. However, the safety and effectiveness of rimantadine hydrochloride prophylaxis have not been demonstrated for longer than 6 weeks. TREATMENT Rimantadine hydrochloride therapy should be considered for adults (17 years and older) who develop an influenza-like illness during known or suspected influenza A infection in the community. When administered within 48 hours after onset of signs and symptoms of infection caused by influenza A virus strains, rimantadine hydrochloride has been shown to reduce the duration of fever and systemic symptoms. The following points should be considered before initiating treatment or prophylaxis with rimantadine hydrochloride: - Rimantadine hydrochloride is not a substitute for early vaccination on an annual basis as recommended by the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices - Influenza viruses change over time. Emergence of resistance mutations could decrease drug effectiveness. Other factors (for example, changes in viral virulence) might also diminish clinical benefit of antiviral drugs. Prescribers should consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use rimantadine hydrochloride. uuid:3c61dd0e-c140-4f48-8970-df407f7be88b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16467 biolink:treats UMLS:C0521839 PMID:41385096 "[{""id"":""uuid:6c435848-0c20-4c8e-8f72-baf1decadd28"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:009b048f-bc59-4ed3-9e24-da0bafb6bf29"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Rimantadine hydrochloride tablet is indicated for the prophylaxis and treatment of illness caused by various strains of influenza A virus in adults (17 years and older). Rimantadine hydrochloride tablet is indicated for prophylaxis against influenza A virus in children (1 year to 16 years of age). PROPHYLAXIS In controlled studies of children (1 year to 16 years of age), healthy adults (17 years and older), and elderly patients (65 years of age and older), rimantadine hydrochloride has been shown to be safe and effective in preventing signs and symptoms of infection caused by various strains of influenza A virus. Since rimantadine hydrochloride does not completely prevent the host immune response to influenza A infection, individuals who take this drug may still develop immune responses to natural disease or vaccination and may be protected when later exposed to antigenically-related viruses. Following vaccination during an influenza outbreak, rimantadine hydrochloride prophylaxis should be considered for the 2 to 4 week time period required to develop an antibody response. However, the safety and effectiveness of rimantadine hydrochloride prophylaxis have not been demonstrated for longer than 6 weeks. TREATMENT Rimantadine hydrochloride therapy should be considered for adults (17 years and older) who develop an influenza-like illness during known or suspected influenza A infection in the community. When administered within 48 hours after onset of signs and symptoms of infection caused by influenza A virus strains, rimantadine hydrochloride has been shown to reduce the duration of fever and systemic symptoms. The following points should be considered before initiating treatment or prophylaxis with rimantadine hydrochloride: - Rimantadine hydrochloride is not a substitute for early vaccination on an annual basis as recommended by the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices - Influenza viruses change over time. Emergence of resistance mutations could decrease drug effectiveness. Other factors (for example, changes in viral virulence) might also diminish clinical benefit of antiviral drugs. Prescribers should consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use rimantadine hydrochloride. uuid:b6a6064e-e5e6-4b31-8a86-36ab9e8c885c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6904 biolink:treats HP:0001681 PMID:41385096 "[{""id"":""uuid:be568c13-3d7c-47dd-b854-49920ba1cfeb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:755384bb-98db-4b06-994f-2a9a43a7dfc2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Hypertension Metoprolol tartrate tablets are indicated for the treatment of hypertension. They may be used alone or in combination with other antihypertensive agents. Angina Pectoris Metoprolol tartrate tablets are indicated in the long-term treatment of angina pectoris. Myocardial Infarction Metoprolol tartrate tablets are indicated in the treatment of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce cardiovascular mortality. Treatment with intravenous metoprolol tartrate can be initiated as soon as the patient's clinical condition allows (see DOSAGE AND ADMINISTRATION, CONTRAINDICATIONS, and WARNINGS). Alternatively, treatment can begin within 3 to 10 days of the acute event (see DOSAGE AND ADMINISTRATION). uuid:d18c8ed9-317c-4f9a-af03-55323e4cd895 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9123 biolink:treats MONDO:0005383 PMID:41385096 "[{""id"":""uuid:b2aeaf7e-2dd1-4952-b31c-0ebc04044862"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b7e02b41-9d99-49fb-8a6d-633cd9763628"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:3a38eb2f-58bd-40fb-8fb7-a3c2cdb766f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Major Depressive Disorder Sertraline hydrochloride tablets are indicated for the treatment of major depressive disorder in adults. The efficacy of sertraline hydrochloride tablets in the treatment of a major depressive episode was established in six to eight week controlled trials of adult outpatients whose diagnoses corresponded most closely to the DSM-III category of major depressive disorder (see Clinical Trials under CLINICAL PHARMACOLOGY ). A major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks); it should include at least 4 of the following 8 symptoms: change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suicide attempt or suicidal ideation. The antidepressant action of sertraline hydrochloride tablets in hospitalized depressed patients has not been adequately studied. The efficacy of sertraline hydrochloride tablets in maintaining an antidepressant response for up to 44 weeks following 8 weeks of open-label acute treatment (52 weeks total) was demonstrated in a placebo-controlled trial. The usefulness of the drug in patients receiving sertraline hydrochloride tablets for extended periods should be reevaluated periodically (see Clinical Trials under CLINICAL PHARMACOLOGY ). Obsessive-Compulsive Disorder Sertraline hydrochloride tablets are indicated for the treatment of obsessions and compulsions in patients with obsessive-compulsive disorder (OCD), as defined in the DSM-III-R; i.e., the obsessions or compulsions cause marked distress, are time-consuming, or significantly interfere with social or occupational functioning. The efficacy of sertraline hydrochloride tablets were established in 12-week trials with obsessive-compulsive outpatients having diagnoses of obsessive-compulsive disorder as defined according to DSM-III or DSM-III-R criteria (see Clinical Trials under CLINICAL PHARMACOLOGY ). Obsessive-compulsive disorder is characterized by recurrent and persistent ideas, thoughts, impulses, or images (obsessions) that are ego-dystonic and/or repetitive, purposeful, and intentional behaviors (compulsions) that are recognized by the person as excessive or unreasonable. The efficacy of sertraline hydrochloride tablets in maintaining a response, in patients with OCD who responded during a 52-week treatment phase while taking sertraline hydrochloride tablets and were then observed for relapse during a period of up to 28 weeks, was demonstrated in a placebo-controlled trial (see Clinical Trials under CLINICAL PHARMACOLOGY ). Nevertheless, the physician who elects to use sertraline hydrochloride tablets for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION ). Panic Disorder Sertraline hydrochloride tablets are indicated for the treatment of panic disorder in adults, with or without agoraphobia, as defined in DSM-IV. Panic disorder is characterized by the occurrence of unexpected panic attacks and associated concern about having additional attacks, worry about the implications or consequences of the attacks, and/or a significant change in behavior related to the attacks. The efficacy of sertraline hydrochloride tablets were established in three 10 to 12 week trials in adult panic disorder patients whose diagnoses corresponded to the DSM-III-R category of panic disorder (see Clinical Trials under CLINICAL PHARMACOLOGY ). Panic disorder (DSM-IV) is characterized by recurrent unexpected panic attacks, i.e., a discrete period of intense fear or discomfort in which four (or more) of the following symptoms develop abruptly and reach a peak within 10 minutes: (1) palpitations, pounding heart, or accelerated heart rate; (2) sweating; (3) trembling or shaking; (4) sensations of shortness of breath or smothering; (5) feeling of choking; (6) chest pain or discomfort; (7) nausea or abdominal distress; (8) feeling dizzy, unsteady, lightheaded, or faint; (9) derealization (feelings of unreality) or depersonalization (being detached from oneself); (10) fear of losing control; (11) fear of dying; (12) paresthesias (numbness or tingling sensations); (13) chills or hot flushes. The efficacy of sertraline hydrochloride tablets in maintaining a response, in adult patients with panic disorder who responded during a 52-week treatment phase while taking sertraline hydrochloride tablets and were then observed for relapse during a period of up to 28 weeks, was demonstrated in a placebo-controlled trial (see Clinical Trials under CLINICAL PHARMACOLOGY ). Nevertheless, the physician who elects to use sertraline hydrochloride tablets for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION ). Posttraumatic Stress Disorder (PTSD) Sertraline hydrochloride tablets are indicated for the treatment of posttraumatic stress disorder in adults. The efficacy of sertraline hydrochloride tablets in the treatment of PTSD was established in two 12-week placebo-controlled trials of adult outpatients whose diagnosis met criteria for the DSM-III-R category of PTSD (see Clinical Trials under CLINICAL PHARMACOLOGY ). PTSD, as defined by DSM-III-R/IV, requires exposure to a traumatic event that involved actual or threatened death or serious injury, or threat to the physical integrity of self or others, and a response which involves intense fear, helplessness, or horror. Symptoms that occur as a result of exposure to the traumatic event include reexperiencing of the event in the form of intrusive thoughts, flashbacks or dreams, and intense psychological distress and physiological reactivity on exposure to cues to the event; avoidance of situations reminiscent of the traumatic event, inability to recall details of the event, and/or numbing of general responsiveness manifested as diminished interest in significant activities, estrangement from others, restricted range of affect, or sense of foreshortened future; and symptoms of autonomic arousal including hypervigilance, exaggerated startle response, sleep disturbance, impaired concentration, and irritability or outbursts of anger. A PTSD diagnosis requires that the symptoms are present for at least a month and that they cause clinically significant distress or impairment in social, occupational, or other important areas of functioning. The efficacy of sertraline hydrochloride tablets in maintaining a response in adult patients with PTSD for up to 28 weeks following 24 weeks of open-label treatment was demonstrated in a placebo-controlled trial. Nevertheless, the physician who elects to use sertraline hydrochloride tablets for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION ). Premenstrual Dysphoric Disorder (PMDD) Sertraline hydrochloride tablets are indicated for the treatment of premenstrual dysphoric disorder (PMDD) in adults. The efficacy of sertraline hydrochloride tablets in the treatment of PMDD was established in 2 placebo-controlled trials of female adult outpatients treated for 3 menstrual cycles who met criteria for the DSM-III-R/IV category of PMDD (see Clinical Trials under CLINICAL PHARMACOLOGY ). The essential features of PMDD include markedly depressed mood, anxiety or tension, affective lability, and persistent anger or irritability. Other features include decreased interest in activities, difficulty concentrating, lack of energy, change in appetite or sleep, and feeling out of control. Physical symptoms associated with PMDD include breast tenderness, headache, joint and muscle pain, bloating and weight gain. These symptoms occur regularly during the luteal phase and remit within a few days following onset of menses; the disturbance markedly interferes with work or school or with usual social activities and relationships with others. In making the diagnosis, care should be taken to rule out other cyclical mood disorders that may be exacerbated by treatment with an antidepressant. The effectiveness of sertraline hydrochloride tablets in long-term use, that is, for more than 3 menstrual cycles, has not been systematically evaluated in controlled trials. Therefore, the physician who elects to use sertraline hydrochloride tablets for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION ). Social Anxiety Disorder Sertraline hydrochloride tablets are indicated for the treatment of social anxiety disorder, also known as social phobia in adults. The efficacy of sertraline hydrochloride tablets in the treatment of social anxiety disorder was established in two placebo-controlled trials of adult outpatients with a diagnosis of social anxiety disorder as defined by DSM-IV criteria (see Clinical Trials under CLINICAL PHARMACOLOGY ). Social anxiety disorder, as defined by DSM-IV, is characterized by marked and persistent fear of social or performance situations involving exposure to unfamiliar people or possible scrutiny by others and by fears of acting in a humiliating or embarrassing way. Exposure to the feared social situation almost always provokes anxiety and feared social or performance situations are avoided or else are endured with intense anxiety or distress. In addition, patients recognize that the fear is excessive or unreasonable and the avoidance and anticipatory anxiety of the feared situation is associated with functional impairment or marked distress. The efficacy of sertraline hydrochloride tablets in maintaining a response in adult patients with social anxiety disorder for up to 24 weeks following 20 weeks of sertraline hydrochloride tablets treatment was demonstrated in a placebo-controlled trial. Physicians who prescribe sertraline hydrochloride tablets for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see Clinical Trials under CLINICAL PHARMACOLOGY ).|[PMDA] Drugs containing a new active ingredient, indicated for depression and panic disorder. uuid:46548cb1-d0ff-4697-9754-84f28d9f9b71 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9123 biolink:treats MONDO:0005146 PMID:41385096 "[{""id"":""uuid:526a5f06-fcfa-4412-9d5f-d1a230c3cbc6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d5343296-c689-4192-9773-1d1b210182ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:aceab642-cb07-4ab7-92da-c8c189c8290e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Major Depressive Disorder Sertraline hydrochloride tablets are indicated for the treatment of major depressive disorder in adults. The efficacy of sertraline hydrochloride tablets in the treatment of a major depressive episode was established in six to eight week controlled trials of adult outpatients whose diagnoses corresponded most closely to the DSM-III category of major depressive disorder (see Clinical Trials under CLINICAL PHARMACOLOGY ). A major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks); it should include at least 4 of the following 8 symptoms: change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suicide attempt or suicidal ideation. The antidepressant action of sertraline hydrochloride tablets in hospitalized depressed patients has not been adequately studied. The efficacy of sertraline hydrochloride tablets in maintaining an antidepressant response for up to 44 weeks following 8 weeks of open-label acute treatment (52 weeks total) was demonstrated in a placebo-controlled trial. The usefulness of the drug in patients receiving sertraline hydrochloride tablets for extended periods should be reevaluated periodically (see Clinical Trials under CLINICAL PHARMACOLOGY ). Obsessive-Compulsive Disorder Sertraline hydrochloride tablets are indicated for the treatment of obsessions and compulsions in patients with obsessive-compulsive disorder (OCD), as defined in the DSM-III-R; i.e., the obsessions or compulsions cause marked distress, are time-consuming, or significantly interfere with social or occupational functioning. The efficacy of sertraline hydrochloride tablets were established in 12-week trials with obsessive-compulsive outpatients having diagnoses of obsessive-compulsive disorder as defined according to DSM-III or DSM-III-R criteria (see Clinical Trials under CLINICAL PHARMACOLOGY ). Obsessive-compulsive disorder is characterized by recurrent and persistent ideas, thoughts, impulses, or images (obsessions) that are ego-dystonic and/or repetitive, purposeful, and intentional behaviors (compulsions) that are recognized by the person as excessive or unreasonable. The efficacy of sertraline hydrochloride tablets in maintaining a response, in patients with OCD who responded during a 52-week treatment phase while taking sertraline hydrochloride tablets and were then observed for relapse during a period of up to 28 weeks, was demonstrated in a placebo-controlled trial (see Clinical Trials under CLINICAL PHARMACOLOGY ). Nevertheless, the physician who elects to use sertraline hydrochloride tablets for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION ). Panic Disorder Sertraline hydrochloride tablets are indicated for the treatment of panic disorder in adults, with or without agoraphobia, as defined in DSM-IV. Panic disorder is characterized by the occurrence of unexpected panic attacks and associated concern about having additional attacks, worry about the implications or consequences of the attacks, and/or a significant change in behavior related to the attacks. The efficacy of sertraline hydrochloride tablets were established in three 10 to 12 week trials in adult panic disorder patients whose diagnoses corresponded to the DSM-III-R category of panic disorder (see Clinical Trials under CLINICAL PHARMACOLOGY ). Panic disorder (DSM-IV) is characterized by recurrent unexpected panic attacks, i.e., a discrete period of intense fear or discomfort in which four (or more) of the following symptoms develop abruptly and reach a peak within 10 minutes: (1) palpitations, pounding heart, or accelerated heart rate; (2) sweating; (3) trembling or shaking; (4) sensations of shortness of breath or smothering; (5) feeling of choking; (6) chest pain or discomfort; (7) nausea or abdominal distress; (8) feeling dizzy, unsteady, lightheaded, or faint; (9) derealization (feelings of unreality) or depersonalization (being detached from oneself); (10) fear of losing control; (11) fear of dying; (12) paresthesias (numbness or tingling sensations); (13) chills or hot flushes. The efficacy of sertraline hydrochloride tablets in maintaining a response, in adult patients with panic disorder who responded during a 52-week treatment phase while taking sertraline hydrochloride tablets and were then observed for relapse during a period of up to 28 weeks, was demonstrated in a placebo-controlled trial (see Clinical Trials under CLINICAL PHARMACOLOGY ). Nevertheless, the physician who elects to use sertraline hydrochloride tablets for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION ). Posttraumatic Stress Disorder (PTSD) Sertraline hydrochloride tablets are indicated for the treatment of posttraumatic stress disorder in adults. The efficacy of sertraline hydrochloride tablets in the treatment of PTSD was established in two 12-week placebo-controlled trials of adult outpatients whose diagnosis met criteria for the DSM-III-R category of PTSD (see Clinical Trials under CLINICAL PHARMACOLOGY ). PTSD, as defined by DSM-III-R/IV, requires exposure to a traumatic event that involved actual or threatened death or serious injury, or threat to the physical integrity of self or others, and a response which involves intense fear, helplessness, or horror. Symptoms that occur as a result of exposure to the traumatic event include reexperiencing of the event in the form of intrusive thoughts, flashbacks or dreams, and intense psychological distress and physiological reactivity on exposure to cues to the event; avoidance of situations reminiscent of the traumatic event, inability to recall details of the event, and/or numbing of general responsiveness manifested as diminished interest in significant activities, estrangement from others, restricted range of affect, or sense of foreshortened future; and symptoms of autonomic arousal including hypervigilance, exaggerated startle response, sleep disturbance, impaired concentration, and irritability or outbursts of anger. A PTSD diagnosis requires that the symptoms are present for at least a month and that they cause clinically significant distress or impairment in social, occupational, or other important areas of functioning. The efficacy of sertraline hydrochloride tablets in maintaining a response in adult patients with PTSD for up to 28 weeks following 24 weeks of open-label treatment was demonstrated in a placebo-controlled trial. Nevertheless, the physician who elects to use sertraline hydrochloride tablets for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION ). Premenstrual Dysphoric Disorder (PMDD) Sertraline hydrochloride tablets are indicated for the treatment of premenstrual dysphoric disorder (PMDD) in adults. The efficacy of sertraline hydrochloride tablets in the treatment of PMDD was established in 2 placebo-controlled trials of female adult outpatients treated for 3 menstrual cycles who met criteria for the DSM-III-R/IV category of PMDD (see Clinical Trials under CLINICAL PHARMACOLOGY ). The essential features of PMDD include markedly depressed mood, anxiety or tension, affective lability, and persistent anger or irritability. Other features include decreased interest in activities, difficulty concentrating, lack of energy, change in appetite or sleep, and feeling out of control. Physical symptoms associated with PMDD include breast tenderness, headache, joint and muscle pain, bloating and weight gain. These symptoms occur regularly during the luteal phase and remit within a few days following onset of menses; the disturbance markedly interferes with work or school or with usual social activities and relationships with others. In making the diagnosis, care should be taken to rule out other cyclical mood disorders that may be exacerbated by treatment with an antidepressant. The effectiveness of sertraline hydrochloride tablets in long-term use, that is, for more than 3 menstrual cycles, has not been systematically evaluated in controlled trials. Therefore, the physician who elects to use sertraline hydrochloride tablets for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION ). Social Anxiety Disorder Sertraline hydrochloride tablets are indicated for the treatment of social anxiety disorder, also known as social phobia in adults. The efficacy of sertraline hydrochloride tablets in the treatment of social anxiety disorder was established in two placebo-controlled trials of adult outpatients with a diagnosis of social anxiety disorder as defined by DSM-IV criteria (see Clinical Trials under CLINICAL PHARMACOLOGY ). Social anxiety disorder, as defined by DSM-IV, is characterized by marked and persistent fear of social or performance situations involving exposure to unfamiliar people or possible scrutiny by others and by fears of acting in a humiliating or embarrassing way. Exposure to the feared social situation almost always provokes anxiety and feared social or performance situations are avoided or else are endured with intense anxiety or distress. In addition, patients recognize that the fear is excessive or unreasonable and the avoidance and anticipatory anxiety of the feared situation is associated with functional impairment or marked distress. The efficacy of sertraline hydrochloride tablets in maintaining a response in adult patients with social anxiety disorder for up to 24 weeks following 20 weeks of sertraline hydrochloride tablets treatment was demonstrated in a placebo-controlled trial. Physicians who prescribe sertraline hydrochloride tablets for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see Clinical Trials under CLINICAL PHARMACOLOGY ).|[PMDA] Drugs with a new additional indication for the treatment of posttraumatic stress disorder. uuid:87bfbd85-3da7-4158-b024-bdddee4699ba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9123 biolink:treats MONDO:1010182 PMID:41385096 "[{""id"":""uuid:b2437d07-a072-4d76-acc0-2cc35d32f8d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:74c4daf5-b638-49d2-8aa3-e4bb8c541948"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Major Depressive Disorder Sertraline hydrochloride tablets are indicated for the treatment of major depressive disorder in adults. The efficacy of sertraline hydrochloride tablets in the treatment of a major depressive episode was established in six to eight week controlled trials of adult outpatients whose diagnoses corresponded most closely to the DSM-III category of major depressive disorder (see Clinical Trials under CLINICAL PHARMACOLOGY ). A major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks); it should include at least 4 of the following 8 symptoms: change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suicide attempt or suicidal ideation. The antidepressant action of sertraline hydrochloride tablets in hospitalized depressed patients has not been adequately studied. The efficacy of sertraline hydrochloride tablets in maintaining an antidepressant response for up to 44 weeks following 8 weeks of open-label acute treatment (52 weeks total) was demonstrated in a placebo-controlled trial. The usefulness of the drug in patients receiving sertraline hydrochloride tablets for extended periods should be reevaluated periodically (see Clinical Trials under CLINICAL PHARMACOLOGY ). Obsessive-Compulsive Disorder Sertraline hydrochloride tablets are indicated for the treatment of obsessions and compulsions in patients with obsessive-compulsive disorder (OCD), as defined in the DSM-III-R; i.e., the obsessions or compulsions cause marked distress, are time-consuming, or significantly interfere with social or occupational functioning. The efficacy of sertraline hydrochloride tablets were established in 12-week trials with obsessive-compulsive outpatients having diagnoses of obsessive-compulsive disorder as defined according to DSM-III or DSM-III-R criteria (see Clinical Trials under CLINICAL PHARMACOLOGY ). Obsessive-compulsive disorder is characterized by recurrent and persistent ideas, thoughts, impulses, or images (obsessions) that are ego-dystonic and/or repetitive, purposeful, and intentional behaviors (compulsions) that are recognized by the person as excessive or unreasonable. The efficacy of sertraline hydrochloride tablets in maintaining a response, in patients with OCD who responded during a 52-week treatment phase while taking sertraline hydrochloride tablets and were then observed for relapse during a period of up to 28 weeks, was demonstrated in a placebo-controlled trial (see Clinical Trials under CLINICAL PHARMACOLOGY ). Nevertheless, the physician who elects to use sertraline hydrochloride tablets for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION ). Panic Disorder Sertraline hydrochloride tablets are indicated for the treatment of panic disorder in adults, with or without agoraphobia, as defined in DSM-IV. Panic disorder is characterized by the occurrence of unexpected panic attacks and associated concern about having additional attacks, worry about the implications or consequences of the attacks, and/or a significant change in behavior related to the attacks. The efficacy of sertraline hydrochloride tablets were established in three 10 to 12 week trials in adult panic disorder patients whose diagnoses corresponded to the DSM-III-R category of panic disorder (see Clinical Trials under CLINICAL PHARMACOLOGY ). Panic disorder (DSM-IV) is characterized by recurrent unexpected panic attacks, i.e., a discrete period of intense fear or discomfort in which four (or more) of the following symptoms develop abruptly and reach a peak within 10 minutes: (1) palpitations, pounding heart, or accelerated heart rate; (2) sweating; (3) trembling or shaking; (4) sensations of shortness of breath or smothering; (5) feeling of choking; (6) chest pain or discomfort; (7) nausea or abdominal distress; (8) feeling dizzy, unsteady, lightheaded, or faint; (9) derealization (feelings of unreality) or depersonalization (being detached from oneself); (10) fear of losing control; (11) fear of dying; (12) paresthesias (numbness or tingling sensations); (13) chills or hot flushes. The efficacy of sertraline hydrochloride tablets in maintaining a response, in adult patients with panic disorder who responded during a 52-week treatment phase while taking sertraline hydrochloride tablets and were then observed for relapse during a period of up to 28 weeks, was demonstrated in a placebo-controlled trial (see Clinical Trials under CLINICAL PHARMACOLOGY ). Nevertheless, the physician who elects to use sertraline hydrochloride tablets for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION ). Posttraumatic Stress Disorder (PTSD) Sertraline hydrochloride tablets are indicated for the treatment of posttraumatic stress disorder in adults. The efficacy of sertraline hydrochloride tablets in the treatment of PTSD was established in two 12-week placebo-controlled trials of adult outpatients whose diagnosis met criteria for the DSM-III-R category of PTSD (see Clinical Trials under CLINICAL PHARMACOLOGY ). PTSD, as defined by DSM-III-R/IV, requires exposure to a traumatic event that involved actual or threatened death or serious injury, or threat to the physical integrity of self or others, and a response which involves intense fear, helplessness, or horror. Symptoms that occur as a result of exposure to the traumatic event include reexperiencing of the event in the form of intrusive thoughts, flashbacks or dreams, and intense psychological distress and physiological reactivity on exposure to cues to the event; avoidance of situations reminiscent of the traumatic event, inability to recall details of the event, and/or numbing of general responsiveness manifested as diminished interest in significant activities, estrangement from others, restricted range of affect, or sense of foreshortened future; and symptoms of autonomic arousal including hypervigilance, exaggerated startle response, sleep disturbance, impaired concentration, and irritability or outbursts of anger. A PTSD diagnosis requires that the symptoms are present for at least a month and that they cause clinically significant distress or impairment in social, occupational, or other important areas of functioning. The efficacy of sertraline hydrochloride tablets in maintaining a response in adult patients with PTSD for up to 28 weeks following 24 weeks of open-label treatment was demonstrated in a placebo-controlled trial. Nevertheless, the physician who elects to use sertraline hydrochloride tablets for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION ). Premenstrual Dysphoric Disorder (PMDD) Sertraline hydrochloride tablets are indicated for the treatment of premenstrual dysphoric disorder (PMDD) in adults. The efficacy of sertraline hydrochloride tablets in the treatment of PMDD was established in 2 placebo-controlled trials of female adult outpatients treated for 3 menstrual cycles who met criteria for the DSM-III-R/IV category of PMDD (see Clinical Trials under CLINICAL PHARMACOLOGY ). The essential features of PMDD include markedly depressed mood, anxiety or tension, affective lability, and persistent anger or irritability. Other features include decreased interest in activities, difficulty concentrating, lack of energy, change in appetite or sleep, and feeling out of control. Physical symptoms associated with PMDD include breast tenderness, headache, joint and muscle pain, bloating and weight gain. These symptoms occur regularly during the luteal phase and remit within a few days following onset of menses; the disturbance markedly interferes with work or school or with usual social activities and relationships with others. In making the diagnosis, care should be taken to rule out other cyclical mood disorders that may be exacerbated by treatment with an antidepressant. The effectiveness of sertraline hydrochloride tablets in long-term use, that is, for more than 3 menstrual cycles, has not been systematically evaluated in controlled trials. Therefore, the physician who elects to use sertraline hydrochloride tablets for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION ). Social Anxiety Disorder Sertraline hydrochloride tablets are indicated for the treatment of social anxiety disorder, also known as social phobia in adults. The efficacy of sertraline hydrochloride tablets in the treatment of social anxiety disorder was established in two placebo-controlled trials of adult outpatients with a diagnosis of social anxiety disorder as defined by DSM-IV criteria (see Clinical Trials under CLINICAL PHARMACOLOGY ). Social anxiety disorder, as defined by DSM-IV, is characterized by marked and persistent fear of social or performance situations involving exposure to unfamiliar people or possible scrutiny by others and by fears of acting in a humiliating or embarrassing way. Exposure to the feared social situation almost always provokes anxiety and feared social or performance situations are avoided or else are endured with intense anxiety or distress. In addition, patients recognize that the fear is excessive or unreasonable and the avoidance and anticipatory anxiety of the feared situation is associated with functional impairment or marked distress. The efficacy of sertraline hydrochloride tablets in maintaining a response in adult patients with social anxiety disorder for up to 24 weeks following 20 weeks of sertraline hydrochloride tablets treatment was demonstrated in a placebo-controlled trial. Physicians who prescribe sertraline hydrochloride tablets for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see Clinical Trials under CLINICAL PHARMACOLOGY ). UMLS:C0520676 uuid:eae46644-9f63-4b17-916e-96654fb09c4c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9123 biolink:treats MONDO:0001247 PMID:41385096 "[{""id"":""uuid:a9e6ce94-b04c-4b6d-b318-a2dfc6dd32e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:16a108da-e896-42d6-bae0-823697b0bb2f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Major Depressive Disorder Sertraline hydrochloride tablets are indicated for the treatment of major depressive disorder in adults. The efficacy of sertraline hydrochloride tablets in the treatment of a major depressive episode was established in six to eight week controlled trials of adult outpatients whose diagnoses corresponded most closely to the DSM-III category of major depressive disorder (see Clinical Trials under CLINICAL PHARMACOLOGY ). A major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks); it should include at least 4 of the following 8 symptoms: change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suicide attempt or suicidal ideation. The antidepressant action of sertraline hydrochloride tablets in hospitalized depressed patients has not been adequately studied. The efficacy of sertraline hydrochloride tablets in maintaining an antidepressant response for up to 44 weeks following 8 weeks of open-label acute treatment (52 weeks total) was demonstrated in a placebo-controlled trial. The usefulness of the drug in patients receiving sertraline hydrochloride tablets for extended periods should be reevaluated periodically (see Clinical Trials under CLINICAL PHARMACOLOGY ). Obsessive-Compulsive Disorder Sertraline hydrochloride tablets are indicated for the treatment of obsessions and compulsions in patients with obsessive-compulsive disorder (OCD), as defined in the DSM-III-R; i.e., the obsessions or compulsions cause marked distress, are time-consuming, or significantly interfere with social or occupational functioning. The efficacy of sertraline hydrochloride tablets were established in 12-week trials with obsessive-compulsive outpatients having diagnoses of obsessive-compulsive disorder as defined according to DSM-III or DSM-III-R criteria (see Clinical Trials under CLINICAL PHARMACOLOGY ). Obsessive-compulsive disorder is characterized by recurrent and persistent ideas, thoughts, impulses, or images (obsessions) that are ego-dystonic and/or repetitive, purposeful, and intentional behaviors (compulsions) that are recognized by the person as excessive or unreasonable. The efficacy of sertraline hydrochloride tablets in maintaining a response, in patients with OCD who responded during a 52-week treatment phase while taking sertraline hydrochloride tablets and were then observed for relapse during a period of up to 28 weeks, was demonstrated in a placebo-controlled trial (see Clinical Trials under CLINICAL PHARMACOLOGY ). Nevertheless, the physician who elects to use sertraline hydrochloride tablets for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION ). Panic Disorder Sertraline hydrochloride tablets are indicated for the treatment of panic disorder in adults, with or without agoraphobia, as defined in DSM-IV. Panic disorder is characterized by the occurrence of unexpected panic attacks and associated concern about having additional attacks, worry about the implications or consequences of the attacks, and/or a significant change in behavior related to the attacks. The efficacy of sertraline hydrochloride tablets were established in three 10 to 12 week trials in adult panic disorder patients whose diagnoses corresponded to the DSM-III-R category of panic disorder (see Clinical Trials under CLINICAL PHARMACOLOGY ). Panic disorder (DSM-IV) is characterized by recurrent unexpected panic attacks, i.e., a discrete period of intense fear or discomfort in which four (or more) of the following symptoms develop abruptly and reach a peak within 10 minutes: (1) palpitations, pounding heart, or accelerated heart rate; (2) sweating; (3) trembling or shaking; (4) sensations of shortness of breath or smothering; (5) feeling of choking; (6) chest pain or discomfort; (7) nausea or abdominal distress; (8) feeling dizzy, unsteady, lightheaded, or faint; (9) derealization (feelings of unreality) or depersonalization (being detached from oneself); (10) fear of losing control; (11) fear of dying; (12) paresthesias (numbness or tingling sensations); (13) chills or hot flushes. The efficacy of sertraline hydrochloride tablets in maintaining a response, in adult patients with panic disorder who responded during a 52-week treatment phase while taking sertraline hydrochloride tablets and were then observed for relapse during a period of up to 28 weeks, was demonstrated in a placebo-controlled trial (see Clinical Trials under CLINICAL PHARMACOLOGY ). Nevertheless, the physician who elects to use sertraline hydrochloride tablets for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION ). Posttraumatic Stress Disorder (PTSD) Sertraline hydrochloride tablets are indicated for the treatment of posttraumatic stress disorder in adults. The efficacy of sertraline hydrochloride tablets in the treatment of PTSD was established in two 12-week placebo-controlled trials of adult outpatients whose diagnosis met criteria for the DSM-III-R category of PTSD (see Clinical Trials under CLINICAL PHARMACOLOGY ). PTSD, as defined by DSM-III-R/IV, requires exposure to a traumatic event that involved actual or threatened death or serious injury, or threat to the physical integrity of self or others, and a response which involves intense fear, helplessness, or horror. Symptoms that occur as a result of exposure to the traumatic event include reexperiencing of the event in the form of intrusive thoughts, flashbacks or dreams, and intense psychological distress and physiological reactivity on exposure to cues to the event; avoidance of situations reminiscent of the traumatic event, inability to recall details of the event, and/or numbing of general responsiveness manifested as diminished interest in significant activities, estrangement from others, restricted range of affect, or sense of foreshortened future; and symptoms of autonomic arousal including hypervigilance, exaggerated startle response, sleep disturbance, impaired concentration, and irritability or outbursts of anger. A PTSD diagnosis requires that the symptoms are present for at least a month and that they cause clinically significant distress or impairment in social, occupational, or other important areas of functioning. The efficacy of sertraline hydrochloride tablets in maintaining a response in adult patients with PTSD for up to 28 weeks following 24 weeks of open-label treatment was demonstrated in a placebo-controlled trial. Nevertheless, the physician who elects to use sertraline hydrochloride tablets for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION ). Premenstrual Dysphoric Disorder (PMDD) Sertraline hydrochloride tablets are indicated for the treatment of premenstrual dysphoric disorder (PMDD) in adults. The efficacy of sertraline hydrochloride tablets in the treatment of PMDD was established in 2 placebo-controlled trials of female adult outpatients treated for 3 menstrual cycles who met criteria for the DSM-III-R/IV category of PMDD (see Clinical Trials under CLINICAL PHARMACOLOGY ). The essential features of PMDD include markedly depressed mood, anxiety or tension, affective lability, and persistent anger or irritability. Other features include decreased interest in activities, difficulty concentrating, lack of energy, change in appetite or sleep, and feeling out of control. Physical symptoms associated with PMDD include breast tenderness, headache, joint and muscle pain, bloating and weight gain. These symptoms occur regularly during the luteal phase and remit within a few days following onset of menses; the disturbance markedly interferes with work or school or with usual social activities and relationships with others. In making the diagnosis, care should be taken to rule out other cyclical mood disorders that may be exacerbated by treatment with an antidepressant. The effectiveness of sertraline hydrochloride tablets in long-term use, that is, for more than 3 menstrual cycles, has not been systematically evaluated in controlled trials. Therefore, the physician who elects to use sertraline hydrochloride tablets for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION ). Social Anxiety Disorder Sertraline hydrochloride tablets are indicated for the treatment of social anxiety disorder, also known as social phobia in adults. The efficacy of sertraline hydrochloride tablets in the treatment of social anxiety disorder was established in two placebo-controlled trials of adult outpatients with a diagnosis of social anxiety disorder as defined by DSM-IV criteria (see Clinical Trials under CLINICAL PHARMACOLOGY ). Social anxiety disorder, as defined by DSM-IV, is characterized by marked and persistent fear of social or performance situations involving exposure to unfamiliar people or possible scrutiny by others and by fears of acting in a humiliating or embarrassing way. Exposure to the feared social situation almost always provokes anxiety and feared social or performance situations are avoided or else are endured with intense anxiety or distress. In addition, patients recognize that the fear is excessive or unreasonable and the avoidance and anticipatory anxiety of the feared situation is associated with functional impairment or marked distress. The efficacy of sertraline hydrochloride tablets in maintaining a response in adult patients with social anxiety disorder for up to 24 weeks following 20 weeks of sertraline hydrochloride tablets treatment was demonstrated in a placebo-controlled trial. Physicians who prescribe sertraline hydrochloride tablets for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see Clinical Trials under CLINICAL PHARMACOLOGY ). uuid:510dc780-7cb7-4291-b068-10869e123495 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46195 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:7182b583-dada-4746-9f37-de8de55e5118"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e9e91f58-168a-4af1-b31c-cd85d961388e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:b0396b6a-eb99-41bc-8f88-af1af1950489"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Acetaminophen and codeine phosphate tablets are indicated for the relief of mild to moderately severe pain.|[PMDA] A drug with a new route of administration indicated for the treatment of pain and pyrexia which cannnot be managed by oral preparations and suppositories. uuid:0f28fc4a-1268-4402-97ba-67f6a5d026b9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:375910 biolink:treats MONDO:0005271 PMID:41385096 "[{""id"":""uuid:1248e2c3-3d5c-48aa-9016-e1ea92b3e687"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:34712fe8-e262-4cae-b74e-f917ee91aeaa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Promethazine hydrochloride and phenylephrine hydrochloride syrup is indicated for the temporary relief of upper respiratory symptoms, including nasal congestion, associated with allergy or the common cold. uuid:0d554143-1d10-4191-94ae-3acc73352f0d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:375910 biolink:treats MONDO:0005709 PMID:41385096 "[{""id"":""uuid:eca4ef8a-ca99-4365-87fd-3cdc6c496ac6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5b71c54f-f5d6-4656-bb94-6363f5c01c5c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Promethazine hydrochloride and phenylephrine hydrochloride syrup is indicated for the temporary relief of upper respiratory symptoms, including nasal congestion, associated with allergy or the common cold. uuid:a125a8b0-cf77-4dbc-adbe-7a318e5e2996 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8875 biolink:treats MONDO:0005475 PMID:41385096 "[{""id"":""uuid:58b3bed8-23e9-4619-af69-89aaa87ed266"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:da9c875d-f5fd-4d54-add2-7600abe99630"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MAXALT is indicated for the acute treatment of migraine attacks with or without aura in adults. MAXALT is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS ). Safety and effectiveness of MAXALT have not been established for cluster headache, which is present in an older, predominantly male population. uuid:fffb750c-7fa0-44e8-95ea-199dc0ead2a2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8875 biolink:treats MONDO:0100431 PMID:41385096 "[{""id"":""uuid:e7d6eabe-bdd3-4a46-87ac-9ed0d4e4590d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:56ccc92e-d5d7-4797-871e-bef054f991d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MAXALT is indicated for the acute treatment of migraine attacks with or without aura in adults. MAXALT is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS ). Safety and effectiveness of MAXALT have not been established for cluster headache, which is present in an older, predominantly male population. uuid:80ad9e13-41fd-4c4e-8820-556255d880fd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8875 biolink:treats MONDO:0018925 PMID:41385096 "[{""id"":""uuid:ef07ce3e-97b2-4bda-b5ac-65541c405fdd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2eb79615-72e7-4c5c-8841-b03175d1215e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MAXALT is indicated for the acute treatment of migraine attacks with or without aura in adults. MAXALT is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS ). Safety and effectiveness of MAXALT have not been established for cluster headache, which is present in an older, predominantly male population. uuid:0b6f8af2-9fd7-4aa0-b5fe-4ce3df894ce1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8875 biolink:treats MONDO:0043219 PMID:41385096 "[{""id"":""uuid:65cba4e2-e724-4828-a61c-62ca3f454610"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c7334dac-0bb2-4445-9ac7-3d742e70fca5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MAXALT is indicated for the acute treatment of migraine attacks with or without aura in adults. MAXALT is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS ). Safety and effectiveness of MAXALT have not been established for cluster headache, which is present in an older, predominantly male population. uuid:60c86c00-7fda-4604-be92-4b1c77ee543e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8875 biolink:treats MONDO:0043537 PMID:41385096 "[{""id"":""uuid:6f428fc7-75c8-45f4-b868-494220d811a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:32013283-f885-41f6-a650-d42fafd84eb9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MAXALT is indicated for the acute treatment of migraine attacks with or without aura in adults. MAXALT is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS ). Safety and effectiveness of MAXALT have not been established for cluster headache, which is present in an older, predominantly male population. uuid:bc70c77b-5913-46a8-b244-73b966cd56aa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:205919 biolink:treats MONDO:0005083 PMID:41385096 "[{""id"":""uuid:cb7e2c15-465a-4365-a2b2-0a9df70dc6d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f85ba2db-d6da-464a-86c7-0b0b8e7212c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clobetasol propionate foam, 0.05% is a super-potent topical corticosteroid indicated for short-term topical treatment of the inflammatory and pruritic manifestations of moderate to severe corticosteroid- responsive dermatoses of the scalp, and for short-term topical treatment of mild to moderate plaque-type psoriasis on non-scalp regions excluding the face and intertriginous areas. Treatment beyond 2 consecutive weeks is not recommended and the total dosage should not exceed 50 g per week because of the potential for the drug to suppress the hypothalamic-pituitary-adrenal (HPA) axis. In a controlled pharmacokinetic study, some subjects experienced reversible suppression of the adrenals following 14 days of clobetasol propionate foam, 0.05% therapy (See ADVERSE REACTIONS ). Use in children under 12 years of age is not recommended. uuid:a071834f-80d1-49fd-8871-d0bc340b6879 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:194135 biolink:treats MONDO:0004795 PMID:41385096 "[{""id"":""uuid:b4e16ca7-0e97-412d-9755-2cef4fef30e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:45130111-03c2-47b6-911f-b94e0ba41f9a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ofloxacin Otic Solution 0.3% is indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in the specific conditions listed below: Otitis Externa in adults and pediatric patients, 6 months and older, due to Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus aereus . Chronic Suppurative Otitis Media in patients 12 years and older with perforated tympanic membranes due to Proteus mirabilis, Pseudomonas aeruginosa and Staphylococcus aureus . Acute Otitis Media in pediatric patients one year and older with tympanostomy tubes due to Haemophilus influenzae, Moraxella catarrhalis, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae . uuid:fc57141a-24f8-4e02-9516-f2a19ddfa828 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:194135 biolink:treats MONDO:0001920 PMID:41385096 "[{""id"":""uuid:ac28d1d6-03e4-4131-8d77-810ec38e3e1f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9f71ab22-8663-4488-94f3-07f9d6147e2c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ofloxacin Otic Solution 0.3% is indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in the specific conditions listed below: Otitis Externa in adults and pediatric patients, 6 months and older, due to Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus aereus . Chronic Suppurative Otitis Media in patients 12 years and older with perforated tympanic membranes due to Proteus mirabilis, Pseudomonas aeruginosa and Staphylococcus aureus . Acute Otitis Media in pediatric patients one year and older with tympanostomy tubes due to Haemophilus influenzae, Moraxella catarrhalis, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae . uuid:97f4274a-cc02-43da-8b7f-213df405acef biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:194135 biolink:treats HP:0000371 PMID:41385096 "[{""id"":""uuid:370ba9bd-8e86-4c38-b5c2-d5882b638e99"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:381561d5-5663-450a-b242-c807b40d8259"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ofloxacin Otic Solution 0.3% is indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in the specific conditions listed below: Otitis Externa in adults and pediatric patients, 6 months and older, due to Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus aereus . Chronic Suppurative Otitis Media in patients 12 years and older with perforated tympanic membranes due to Proteus mirabilis, Pseudomonas aeruginosa and Staphylococcus aureus . Acute Otitis Media in pediatric patients one year and older with tympanostomy tubes due to Haemophilus influenzae, Moraxella catarrhalis, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae . uuid:a7e059dc-ec3e-441d-9b5a-c3e0156399f8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:30742 biolink:treats MONDO:0002203 PMID:41385096 "[{""id"":""uuid:27c2c805-c100-4fdc-81d8-958caafa189c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c03ba389-fadb-4660-8869-fdb277d5f2cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the treatment of occasional constipation. This product should be used for 2 weeks or less or as directed by a physician. uuid:c39f7c16-63f7-47b5-a24a-2b7e16954b87 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9586 biolink:treats HP:0007359 PMID:41385096 "[{""id"":""uuid:a9b118bd-63e2-4b05-b676-035b43b147ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1eddff2c-0b16-43b3-b336-1696bf82c89e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] GABITRIL (tiagabine hydrochloride) is indicated as adjunctive therapy in adults and children 12 years and older in the treatment of partial seizures. uuid:29b21b2a-afdd-49d2-bc18-b10995215d51 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47499 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:2bacd8c4-b4a2-4e7c-bab7-59fc5c618574"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1c3c9202-a376-4d46-9659-4b4c30e27573"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the relief of symptoms of depression. Endogenous depression is more likely to be alleviated than other depressive states. One to three weeks of treatment may be needed before optimal therapeutic effects are evident. uuid:461210ba-05d2-4f25-bf08-f0fdeff9defe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47499 biolink:treats MONDO:0012048 PMID:41385096 "[{""id"":""uuid:06a45dee-7f42-46e7-8dfc-e4155762a4bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bda3a615-3c32-4c71-be6f-31984be00949"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the relief of symptoms of depression. Endogenous depression is more likely to be alleviated than other depressive states. One to three weeks of treatment may be needed before optimal therapeutic effects are evident. uuid:ffd4b044-2355-4009-a956-26d7d3f2308c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9619 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:23cc1e7c-9dc2-4b32-afaa-74eccaedc428"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:58ba1781-8032-4dac-b1a9-6b1a7928003f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of tolmetin sodium tablets and other treatment options before deciding to use tolmetin sodium tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Tolmetin sodium tablets are indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis. Tolmetin is indicated in the treatment of acute flares and the long-term management of the chronic disease. Tolmetin is also indicated for treatment of juvenile rheumatoid arthritis. The safety and effectiveness of tolmetin have not been established in pediatric patients under 2 years of age (see PRECAUTIONS: Pediatric Use and DOSAGE AND ADMINISTRATION ). uuid:14ed0482-d825-45e4-bc02-f9f532922df1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9619 biolink:treats MONDO:0005178 PMID:41385096 "[{""id"":""uuid:aec107c2-2340-43ac-8e88-47b9b2dd3e48"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:22ac9e0a-d33e-4fdc-8007-95e842edd7e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of tolmetin sodium tablets and other treatment options before deciding to use tolmetin sodium tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Tolmetin sodium tablets are indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis. Tolmetin is indicated in the treatment of acute flares and the long-term management of the chronic disease. Tolmetin is also indicated for treatment of juvenile rheumatoid arthritis. The safety and effectiveness of tolmetin have not been established in pediatric patients under 2 years of age (see PRECAUTIONS: Pediatric Use and DOSAGE AND ADMINISTRATION ). uuid:3f0e2003-aaf6-4257-9934-2195d040dd6c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9619 biolink:treats MONDO:0011429 PMID:41385096 "[{""id"":""uuid:f5314124-6004-44c1-bf72-0578a0492ba2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ae708f19-0d6e-43ce-bc92-f2760c9cf58d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of tolmetin sodium tablets and other treatment options before deciding to use tolmetin sodium tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Tolmetin sodium tablets are indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis. Tolmetin is indicated in the treatment of acute flares and the long-term management of the chronic disease. Tolmetin is also indicated for treatment of juvenile rheumatoid arthritis. The safety and effectiveness of tolmetin have not been established in pediatric patients under 2 years of age (see PRECAUTIONS: Pediatric Use and DOSAGE AND ADMINISTRATION ). uuid:7ad57a1a-112c-4aae-a1d3-97c4ef33a18d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75922 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:2ccaca7b-f7fb-49b7-a12d-9659bf0a2ecc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ba5dd7b4-9df4-410d-96a0-e3cc93e45bf4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NEVANAC ® ophthalmic suspension is indicated for the treatment of pain and inflammation associated with cataract surgery. uuid:790019f9-6751-4a5c-a5e4-ce070249bd76 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75922 biolink:treats NCIT:C3137 PMID:41385096 "[{""id"":""uuid:d9b3018c-4950-4713-a6e9-7eb627dcec86"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8e453acf-e146-46cd-9733-92e68daa6633"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NEVANAC ® ophthalmic suspension is indicated for the treatment of pain and inflammation associated with cataract surgery. uuid:b474816e-ab26-455f-ad1f-29be0c8c25bb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:577093 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:c14034e6-a21a-4c28-b170-ec4f153ac986"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f748da39-77b0-4d31-b1c4-d830760c2924"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c931c594-0252-488f-b242-66b1a4cf120a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/competact""]},{""id"":""uuid:c1e16fd5-bb1d-4f03-b3af-ce4aef5c9299"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ACTOPLUS MET is a thiazolidinedione and biguanide combination product indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who are already treated with a thiazolidinedione and metformin or who have inadequate glycemic control on a thiazolidinedione alone or metformin alone.|[EMA] Competact is indicated in the treatment of type 2 diabetes mellitus patients, particularly overweight patients, who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone.|[PMDA] New combination drugs indicated for the treatment of type 2 diabetes (only when a concomitant use of pioglitazone hydrochloride with metformin hydrochloride is deemed appropriate). uuid:8a89b30a-a68f-4386-8c56-d4897cd82b1c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1163093 biolink:treats MONDO:0005041 PMID:41385096 "[{""id"":""uuid:8fd86cc5-ed66-4686-a415-185e6bda85b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3e1b3d4a-814f-4ad5-936c-502ee3918ac5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] COMBIGAN ® (brimonidine tartrate/timolol maleate ophthalmic solution) 0.2%/0.5% is an alpha adrenergic receptor agonist with a beta adrenergic receptor inhibitor indicated for the reduction of elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled IOP; the IOP-lowering of COMBIGAN ® dosed twice a day was slightly less than that seen with the concomitant administration of 0.5% timolol maleate ophthalmic solution dosed twice a day and 0.2% brimonidine tartrate ophthalmic solution dosed three times per day. uuid:b134c34e-ba45-4d4c-b378-4b627a9f8cb2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1163093 biolink:treats MONDO:0006875 PMID:41385096 "[{""id"":""uuid:57669e91-a154-483b-852a-4f6276c808ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e2628cbb-867a-44cf-a76c-b8a92e380bc1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] COMBIGAN ® (brimonidine tartrate/timolol maleate ophthalmic solution) 0.2%/0.5% is an alpha adrenergic receptor agonist with a beta adrenergic receptor inhibitor indicated for the reduction of elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled IOP; the IOP-lowering of COMBIGAN ® dosed twice a day was slightly less than that seen with the concomitant administration of 0.5% timolol maleate ophthalmic solution dosed twice a day and 0.2% brimonidine tartrate ophthalmic solution dosed three times per day. uuid:111ca1d5-165a-47ba-ae41-63e031b40ae6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18420 biolink:treats MONDO:0006844 PMID:41385096 "[{""id"":""uuid:c385b2a0-78b7-4322-a11d-f87f8b4b04a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0f119612-67b8-495d-b21a-8757fa379aea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Magnesium Sulfate Injection, USP is suitable for replacement therapy in magnesium deficiency, especially in acute hypomagnesemia accompanied by signs of tetany similar to those observed in hypocalcemia. In such cases, the serum magnesium (Mg ++ ) level is usually below the lower limit of normal (1.5 to 2.5 mEq/liter) and the serum calcium (Ca ++ ) level is normal (4.3 to 5.3 mEq/liter) or elevated. In total parenteral nutrition (TPN), magnesium sulfate may be added to the nutrient admixture to correct or prevent hypomagnesemia which can arise during the course of therapy. Magnesium Sulfate Injection, USP is also indicated as a parenteral anticonvulsant for the prevention and control of seizures (convulsions) in severe toxemia of pregnancy. It effectively prevents and controls the convulsions of eclampsia without producing deleterious depression of the central nervous system of the mother or infant. However, other effective drugs are available for this purpose. uuid:43891518-160f-4ffe-aa7d-58a5c1a3c6a9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18420 biolink:treats MONDO:0018100 PMID:41385096 "[{""id"":""uuid:f5d22faf-e377-446b-9e39-53a84e9e0c68"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c78001c8-9f3c-423c-bdbb-39656020131d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Magnesium Sulfate Injection, USP is suitable for replacement therapy in magnesium deficiency, especially in acute hypomagnesemia accompanied by signs of tetany similar to those observed in hypocalcemia. In such cases, the serum magnesium (Mg ++ ) level is usually below the lower limit of normal (1.5 to 2.5 mEq/liter) and the serum calcium (Ca ++ ) level is normal (4.3 to 5.3 mEq/liter) or elevated. In total parenteral nutrition (TPN), magnesium sulfate may be added to the nutrient admixture to correct or prevent hypomagnesemia which can arise during the course of therapy. Magnesium Sulfate Injection, USP is also indicated as a parenteral anticonvulsant for the prevention and control of seizures (convulsions) in severe toxemia of pregnancy. It effectively prevents and controls the convulsions of eclampsia without producing deleterious depression of the central nervous system of the mother or infant. However, other effective drugs are available for this purpose. uuid:a37452b7-947c-4d0e-999b-aba4bda58008 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18420 biolink:treats HP:0001281 PMID:41385096 "[{""id"":""uuid:e9e49aa1-c2ea-44b6-89ba-637861766c5b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:56de6a30-7ca7-43e6-ab59-8da47d7cce24"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Magnesium Sulfate Injection, USP is suitable for replacement therapy in magnesium deficiency, especially in acute hypomagnesemia accompanied by signs of tetany similar to those observed in hypocalcemia. In such cases, the serum magnesium (Mg ++ ) level is usually below the lower limit of normal (1.5 to 2.5 mEq/liter) and the serum calcium (Ca ++ ) level is normal (4.3 to 5.3 mEq/liter) or elevated. In total parenteral nutrition (TPN), magnesium sulfate may be added to the nutrient admixture to correct or prevent hypomagnesemia which can arise during the course of therapy. Magnesium Sulfate Injection, USP is also indicated as a parenteral anticonvulsant for the prevention and control of seizures (convulsions) in severe toxemia of pregnancy. It effectively prevents and controls the convulsions of eclampsia without producing deleterious depression of the central nervous system of the mother or infant. However, other effective drugs are available for this purpose. uuid:6eac23ab-5766-46eb-8e63-8ce954282f8c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18420 biolink:treats HP:0002901 PMID:41385096 "[{""id"":""uuid:d2b0ea0a-4b52-49cf-b4af-9d8b55204af0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:18852620-3b05-42e7-9db0-d3840a173a53"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Magnesium Sulfate Injection, USP is suitable for replacement therapy in magnesium deficiency, especially in acute hypomagnesemia accompanied by signs of tetany similar to those observed in hypocalcemia. In such cases, the serum magnesium (Mg ++ ) level is usually below the lower limit of normal (1.5 to 2.5 mEq/liter) and the serum calcium (Ca ++ ) level is normal (4.3 to 5.3 mEq/liter) or elevated. In total parenteral nutrition (TPN), magnesium sulfate may be added to the nutrient admixture to correct or prevent hypomagnesemia which can arise during the course of therapy. Magnesium Sulfate Injection, USP is also indicated as a parenteral anticonvulsant for the prevention and control of seizures (convulsions) in severe toxemia of pregnancy. It effectively prevents and controls the convulsions of eclampsia without producing deleterious depression of the central nervous system of the mother or infant. However, other effective drugs are available for this purpose. uuid:0e6172f1-9185-434e-acbe-fac94600962d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18420 biolink:treats MONDO:0045048 PMID:41385096 "[{""id"":""uuid:2629242d-851a-491c-983b-693daf9486b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cbeb2394-5e22-47c7-abbe-17c5dcea5bec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Magnesium Sulfate Injection, USP is suitable for replacement therapy in magnesium deficiency, especially in acute hypomagnesemia accompanied by signs of tetany similar to those observed in hypocalcemia. In such cases, the serum magnesium (Mg ++ ) level is usually below the lower limit of normal (1.5 to 2.5 mEq/liter) and the serum calcium (Ca ++ ) level is normal (4.3 to 5.3 mEq/liter) or elevated. In total parenteral nutrition (TPN), magnesium sulfate may be added to the nutrient admixture to correct or prevent hypomagnesemia which can arise during the course of therapy. Magnesium Sulfate Injection, USP is also indicated as a parenteral anticonvulsant for the prevention and control of seizures (convulsions) in severe toxemia of pregnancy. It effectively prevents and controls the convulsions of eclampsia without producing deleterious depression of the central nervous system of the mother or infant. However, other effective drugs are available for this purpose. uuid:7e4c2108-4a54-4aa9-a890-d4f0f4d1e164 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18420 biolink:treats MONDO:0001754 PMID:41385096 "[{""id"":""uuid:cb5e0a08-d247-411f-98e9-c005b9cd8b5a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c2f75d5e-4d02-46a3-90bf-d1ffa6bf0d16"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Magnesium Sulfate Injection, USP is suitable for replacement therapy in magnesium deficiency, especially in acute hypomagnesemia accompanied by signs of tetany similar to those observed in hypocalcemia. In such cases, the serum magnesium (Mg ++ ) level is usually below the lower limit of normal (1.5 to 2.5 mEq/liter) and the serum calcium (Ca ++ ) level is normal (4.3 to 5.3 mEq/liter) or elevated. In total parenteral nutrition (TPN), magnesium sulfate may be added to the nutrient admixture to correct or prevent hypomagnesemia which can arise during the course of therapy. Magnesium Sulfate Injection, USP is also indicated as a parenteral anticonvulsant for the prevention and control of seizures (convulsions) in severe toxemia of pregnancy. It effectively prevents and controls the convulsions of eclampsia without producing deleterious depression of the central nervous system of the mother or infant. However, other effective drugs are available for this purpose. uuid:72acc8a4-ced6-4bf6-9789-6a39bc306707 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63611 biolink:treats MONDO:0006668 PMID:41385096 "[{""id"":""uuid:b38aec64-e3e3-4f93-9cf9-c40758efcb74"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1f58d773-1c63-4dfe-b6da-d38cca98fcb5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VIGAMOX® solution is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Aerobic Gram-positive microorganisms : Corynebacterium species* Micrococcus luteus* Staphylococcus aureus Staphylococcus epidermidis Staphylococcus haemolyticus Staphylococcus hominis Staphylococcus warneri* Streptococcus pneumoniae Streptococcus viridans group Aerobic Gram-negative microorganisms : Acinetobacter lwoffii* Haemophilus influenzae Haemophilus parainfluenzae * Other microorganisms : Chlamydia trachomatis *Efficacy for this organism was studied in fewer than 10 infections. uuid:304285e5-42c6-4ccb-847e-089a1f57f025 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:9571023 biolink:treats MONDO:0011438 PMID:41385096 "[{""id"":""uuid:e51abba0-6489-4570-a5f7-213b8d69ae7f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4fcf99fe-1518-46f6-a4e0-71f0dc74160f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Tri-Sprintec Tablets are indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. Tri-Sprintec Tablets are indicated for the treatment of moderate acne vulgaris in females, ≥15 years of age, who have no known contraindications to oral contraceptive therapy, desire contraception, have achieved menarche and are unresponsive to topical anti-acne medications. Oral contraceptives are highly effective. Table I lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. The efficacy of these contraceptive methods, except sterilization, depends upon the reliability with which they are used. Correct and consistent use of methods can result in lower failure rates. TABLE I: PERCENTAGE OF WOMEN EXPERIENCING AN UNINTENDED PREGNANCY DURING THE FIRST YEAR OF TYPICAL USE AND THE FIRST YEAR OF PERFECT USE OF CONTRACEPTION AND THE PERCENTAGE CONTINUING USE AT THE END OF THE FIRST YEAR. UNITED STATES. % of Women Experiencing an Unintended Pregnancy within the First Year of Use % of Women Continuing Use at One Year Among couples attempting to avoid pregnancy, the percentage who continue to use a method for one year. Method Typical Use Among typical couples who initiate use of a method (not necessarily for the first time), the percentage who experience an accidental pregnancy during the first year if they do not stop use for any other reason. Perfect Use Among couples who initiate use of a method (not necessarily for the first time) and who use it perfectly (both consistently and correctly), the percentage who experience an accidental pregnancy during the first year if they do not stop use for any other reason. (1) (2) (3) (4) Chance The percents becoming pregnant in columns (2) and (3) are based on data from populations where contraception is not used and from women who cease using contraception in order to become pregnant. Among such populations, about 89% become pregnant within one year. This estimate was lowered slightly (to 85%) to represent the percent who would become pregnant within one year among women now relying on reversible methods of contraception if they abandoned contraception altogether. 85 85 Spermicides Foams, creams, gels, vaginal suppositories, and vaginal film. 26 6 40 Periodic abstinence 25 63 Calendar 9 Ovulation Method 3 Sympto-Thermal Cervical mucus (ovulation) method supplemented by calendar in the pre-ovulatory and basal body temperature in the post-ovulatory phases. 2 Post-Ovulation 1 Withdrawal 19 4 Cap With spermicidal cream or jelly. Parous Women 40 26 42 Nulliparous Women 20 9 56 Sponge Parous Women 40 20 42 Nulliparous Women 20 9 56 Diaphragm 20 6 56 Condom Without spermicides. Female (Reality) 21 5 56 Male 14 3 61 Pill 5 71 Progestin Only 0.5 Combined 0.1 IUD Progesterone T 2 1.5 81 Copper T380A 0.8 0.6 78 LNg 20 0.1 0.1 81 Depo-Provera 0.3 0.3 70 Norplant and Norplant-2 0.05 0.05 88 Female Sterilization 0.5 0.5 100 Male Sterilization 0.15 0.10 100 Adapted from Hatcher et al., 1998 Ref. #1. In four clinical trials with norgestimate and ethinyl estradiol, the use-efficacy pregnancy rate ranged from 0.68 to 1.47 per 100 women-years. In total, 4,756 subjects completed 45,244 cycles and a total of 42 pregnancies were reported. This represents an overall use-efficacy rate of 1.21 per 100 women-years. One of these 4 studies was a randomized comparative clinical trial in which 4,633 subjects completed 22,312 cycles. Of the 2,312 patients on norgestimate and ethinyl estradiol, 8 pregnancies were reported. This represents an overall use-efficacy pregnancy rate of 0.94 per 100 women-years. In two double-blind, placebo-controlled, six month, multicenter clinical trials, norgestimate and ethinyl estradiol showed a statistically significant decrease in inflammatory lesion count and total lesion count (TABLE II). The adverse reaction profile of norgestimate and ethinyl estradiol from these two controlled clinical trials is consistent with what has been noted from previous studies involving norgestimate and ethinyl estradiol and are the known risks associated with oral contraceptives. TABLE II: Acne Vulgaris Indication Combined Results: Two Multicenter, Placebo-Controlled Trials Primary Efficacy Variables: Evaluable-for-Efficacy Population Norgestimate and Ethinyl Estradiol Placebo N=163 N=161 Mean Age at Enrollment 27.3 years 28 Inflammatory Lesions - 56.6 36.6 Mean Percent Reduction Total Lesions - 49.6 30.3 Mean Percent Reduction" uuid:64f94585-6fda-487a-89c0-afabe3f670cc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1157512 biolink:treats MONDO:0005475 PMID:41385096 "[{""id"":""uuid:392a79de-3aef-4b0d-94a2-03f85258b269"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8ed01d1b-db1d-42fb-80ed-8d7036e1cd10"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TREXIMET is indicated for the acute treatment of migraine attacks with or without aura in adults. Carefully consider the potential benefits and risks of TREXIMET and other treatment options when deciding to use TREXIMET. TREXIMET is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS). Safety and effectiveness of TREXIMET have not been established for cluster headache. uuid:4fdbb83a-e2bb-4805-9fce-99e394891eea biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1157512 biolink:treats MONDO:0100431 PMID:41385096 "[{""id"":""uuid:68a52225-808b-4d83-a8e4-bb2e7255bbba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:83eef067-dd77-499f-97be-97683e435c40"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TREXIMET is indicated for the acute treatment of migraine attacks with or without aura in adults. Carefully consider the potential benefits and risks of TREXIMET and other treatment options when deciding to use TREXIMET. TREXIMET is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS). Safety and effectiveness of TREXIMET have not been established for cluster headache. uuid:663ce653-d61d-4b6a-8a5d-21fa67d31000 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1157512 biolink:treats MONDO:0018925 PMID:41385096 "[{""id"":""uuid:8129cace-080d-46d8-a275-96e9228c3b79"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7a681ca3-bb29-41f9-b5e6-65b0f6eb4b17"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TREXIMET is indicated for the acute treatment of migraine attacks with or without aura in adults. Carefully consider the potential benefits and risks of TREXIMET and other treatment options when deciding to use TREXIMET. TREXIMET is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS). Safety and effectiveness of TREXIMET have not been established for cluster headache. uuid:41119ece-ee42-4b7f-895f-9f2514125c22 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1157512 biolink:treats MONDO:0043219 PMID:41385096 "[{""id"":""uuid:10cc01ad-a416-49d7-a3d0-de8e240b0642"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b3cd821d-3984-4e54-bced-efccbe598280"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TREXIMET is indicated for the acute treatment of migraine attacks with or without aura in adults. Carefully consider the potential benefits and risks of TREXIMET and other treatment options when deciding to use TREXIMET. TREXIMET is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS). Safety and effectiveness of TREXIMET have not been established for cluster headache. uuid:8611a067-b3eb-4722-a628-fff567a0a917 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1157512 biolink:treats MONDO:0043537 PMID:41385096 "[{""id"":""uuid:4ad3b6b7-77ea-4c32-9009-62d086449a6d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5837edcb-d4b2-4d7d-89fe-0482ff5061f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TREXIMET is indicated for the acute treatment of migraine attacks with or without aura in adults. Carefully consider the potential benefits and risks of TREXIMET and other treatment options when deciding to use TREXIMET. TREXIMET is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS). Safety and effectiveness of TREXIMET have not been established for cluster headache. uuid:45d37654-e34e-4967-b4fd-60e232b05c32 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8228 biolink:treats MONDO:0005147 PMID:41385096 "[{""id"":""uuid:fab8d801-ecdd-46ba-b6f7-6009cd440e03"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:10cb7bf0-f7b9-4c1a-9b43-1af03704f069"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ACTOS is a thiazolidinedione and an agonist for peroxisome proliferator-activated receptor (PPAR) gamma indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings. ( 1.1 , 14 ) Important Limitation of Use: Not for treatment of type 1 diabetes or diabetic ketoacidosis. ( 1.2 ) uuid:c523d76f-fe97-4cd5-a70a-b5817407be58 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8228 biolink:treats MONDO:0012819 PMID:41385096 "[{""id"":""uuid:330ac144-9b3d-47c6-814f-d222c4c76b90"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ddb5ec96-e663-4f49-a625-09057d041478"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ACTOS is a thiazolidinedione and an agonist for peroxisome proliferator-activated receptor (PPAR) gamma indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings. ( 1.1 , 14 ) Important Limitation of Use: Not for treatment of type 1 diabetes or diabetic ketoacidosis. ( 1.2 ) uuid:38260465-83ee-4f36-8af6-040df752464a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0008558 PMID:41385096 "[{""id"":""uuid:74086e39-041b-4d58-9624-8b78db664e87"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bb660135-95c9-4f1f-b190-fa9a16446b9d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MethylPREDNISolone Tablets are indicated in the following conditions: Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Psoriatic arthritis Epicondylitis Acute gouty arthritis Post-traumatic osteoarthritis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Contact dermatitis Drug hypersensitivity reactions Bronchial asthma Atopic dermatitis Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Anterior segment inflammation Sympathetic ophthalmia Keratitis Optic neuritis Iritis and iridocyclitis Herpes zoster ophthalmicus Diffuse posterior uveitis and choroiditis Allergic conjunctivitis Chorioretinitis Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis Berylliosis Hematologic Disorders Idiopathic thrombocytopenia purpura in adults Acquired (autoimmune) hemolytic anemia Congenital (erythroid) hypoplastic anemia Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Nervous System Acute exacerbations of multiple sclerosis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:8d912dca-4f0c-4cfb-8f11-cadc05c98b3f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49662 biolink:treats UMLS:C0149896 PMID:41385096 "[{""id"":""uuid:77c05294-f264-484d-8db4-ccec5190398e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9e30dbd1-efbd-4013-93ab-d7fd95dfd14b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of Indomethacin Extended-Release Capsules, USP and other treatment options before deciding to use Indomethacin Extended-Release Capsules, USP. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Indomethacin Extended-Release Capsules, USP have been found effective in active stages of the following: 1. Moderate to severe rheumatoid arthritis including acute flares of chronic disease. 2. Moderate to severe ankylosing spondylitis. 3. Moderate to sever osteoarthritis. 4. Acute painful shoulder (bursitis and/or tendonitis). Indomethacin Extended-Release Capsules, USP are not recommended for the treatment of acute gouty arthritis. Indomethacin may enable the reduction of steroid dosage in patients receiving steroids for the more sever forms of rheumatoid arthritis. In such instances the steroid dosage should be reduced slowly and the patients followed very closely for any possible adverse effects. The use of indomethacin in conjunction with aspirin or other salicylates is not recommended. Controlled clinical studies have shown that the combined use of indomethacin and aspirin does not product any greater therapeutic effect than the use of indomethacin alone. Furthermore, in one of these clinical studies, the incidence of gastrointestinal side effects was significantly increased with combined therapy. (see PRECAUTIONS, Drug Interactions ). uuid:21833fe1-99d3-4823-807d-f06d4620b152 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:240107 biolink:treats HP:0200026 PMID:41385096 "[{""id"":""uuid:3b00703b-b471-42cc-a171-0d9f59f0574c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a2133e38-0697-4574-b705-286009f32da6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bromday™ (bromfenac ophthalmic solution) 0.09% is indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery. uuid:574e8689-1362-4bd6-a07f-d9af4b30d1be biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:3081207 biolink:treats UMLS:C0393736 PMID:41385096 "[{""id"":""uuid:057c5ff2-b6ec-49d0-bff3-0b1f5ceb3f2b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:84953a7a-6d65-42c1-869b-898524e1a1b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules are indicated for the relief of the symptom complex of tension (or muscle contraction) headache. Evidence supporting the efficacy and safety of Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules in the treatment of multiple recurrent headaches is unavailable. Caution in this regard is required because codeine and butalbital are habit-forming and potentially abusable. uuid:a5fb0f22-6765-4ca4-b720-8af149dade51 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10124 biolink:treats MONDO:0005277 PMID:41385096 "[{""id"":""uuid:e62ba3a9-b70e-40d8-9a59-a68d7408b566"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cab1c8d5-b5e8-416c-be47-1303709005ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZOMIG is indicated for the acute treatment of migraine with or without aura in adults. ZOMIG should only be used where a clear diagnosis of migraine has been established. ZOMIG is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS ). Safety and effectiveness of ZOMIG have not been established for cluster headache, which is present in an older, predominantly male population. uuid:59c7835b-ae2d-49c6-be66-61019e5aa515 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10124 biolink:treats MONDO:0005475 PMID:41385096 "[{""id"":""uuid:a40f8296-fc61-48c4-8655-9b05222780c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cef01a74-2947-4eed-a259-01d6f60753c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZOMIG is indicated for the acute treatment of migraine with or without aura in adults. ZOMIG should only be used where a clear diagnosis of migraine has been established. ZOMIG is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS ). Safety and effectiveness of ZOMIG have not been established for cluster headache, which is present in an older, predominantly male population. uuid:74fa75b3-23e5-41b6-bb70-51dff551321c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10124 biolink:treats MONDO:0018925 PMID:41385096 "[{""id"":""uuid:c88b5cba-8ebb-41f1-8e71-7ec481eda9a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f1572b99-eeb3-4121-80cf-0afb340f9ed8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZOMIG is indicated for the acute treatment of migraine with or without aura in adults. ZOMIG should only be used where a clear diagnosis of migraine has been established. ZOMIG is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS ). Safety and effectiveness of ZOMIG have not been established for cluster headache, which is present in an older, predominantly male population. uuid:d955c13b-1970-4149-92a5-57495cad52fe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10124 biolink:treats MONDO:0043219 PMID:41385096 "[{""id"":""uuid:8bac2c65-3538-4960-b127-acfe1adbfe57"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:87329e0d-5447-4308-9c6e-f0bb39e4f6c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZOMIG is indicated for the acute treatment of migraine with or without aura in adults. ZOMIG should only be used where a clear diagnosis of migraine has been established. ZOMIG is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS ). Safety and effectiveness of ZOMIG have not been established for cluster headache, which is present in an older, predominantly male population. uuid:df33d8a2-ade4-432a-b0de-9dbfcfeda406 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10124 biolink:treats MONDO:0043537 PMID:41385096 "[{""id"":""uuid:dc078003-b894-4d22-bb96-7386dc82d922"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:06cacc14-caf2-4aee-9569-5e49b9c2ab06"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZOMIG is indicated for the acute treatment of migraine with or without aura in adults. ZOMIG should only be used where a clear diagnosis of migraine has been established. ZOMIG is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS ). Safety and effectiveness of ZOMIG have not been established for cluster headache, which is present in an older, predominantly male population. uuid:e5fdd4d5-e552-4f2f-80e4-ae7c6ea6bed4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:376076 biolink:treats MONDO:0005271 PMID:41385096 "[{""id"":""uuid:3b1ff9fd-4cf8-4d3b-9c61-e562b12a59e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ad8ad349-f1a0-46f6-88d3-aa7e4b74b6b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Promethazine HCl, phenylephrine HCl and codeine phosphate syrup is indicated for the temporary relief of coughs and upper respiratory symptoms, including nasal congestion, associated with allergy or the common cold. uuid:68522001-7cd1-4054-a23a-c1e6d99fcaf3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:376076 biolink:treats MONDO:0005709 PMID:41385096 "[{""id"":""uuid:0b3b7776-6692-48ae-9cc1-3ab255cda396"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ff75e5d4-8d7e-40e2-95ce-6e649503efcc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Promethazine HCl, phenylephrine HCl and codeine phosphate syrup is indicated for the temporary relief of coughs and upper respiratory symptoms, including nasal congestion, associated with allergy or the common cold. uuid:fa82554e-5073-4906-ab6c-995b4093846c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16199 biolink:treats MONDO:0002406 PMID:41385096 "[{""id"":""uuid:99f840d4-b25b-4116-9989-f86e8eb31991"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a9355b3e-8778-4002-9258-81388b73923b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For debridement and promotion of normal healing of hyperkeratotic surface lesions, particularly where healing is retarded by local infection, necrotic tissue, fibrinous or purulent debris or eschar. Urea is useful for the treatment of hyperkeratotic conditions such as dry, rough skin, dermatitis, psoriasis, xerosis, ichthyosis, eczema, keratosis, keratoderma, corns and calluses, as well as damaged, devitalized and ingrown nails. uuid:70898b87-d3dc-4afb-a157-fa31713f111d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16199 biolink:treats MONDO:0005083 PMID:41385096 "[{""id"":""uuid:a2bb6fa4-0be4-41a5-98b1-6a2588641ed0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:31ae220d-38e5-4ea7-887f-a20c28d0ee42"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For debridement and promotion of normal healing of hyperkeratotic surface lesions, particularly where healing is retarded by local infection, necrotic tissue, fibrinous or purulent debris or eschar. Urea is useful for the treatment of hyperkeratotic conditions such as dry, rough skin, dermatitis, psoriasis, xerosis, ichthyosis, eczema, keratosis, keratoderma, corns and calluses, as well as damaged, devitalized and ingrown nails. uuid:f816e1c2-f105-4547-92a6-4a99faecd4d7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16199 biolink:treats HP:0000958 PMID:41385096 "[{""id"":""uuid:c5b1cf22-35bf-4830-bc6a-aa1a50f4ffbe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:edbe4141-bf56-4bbb-8d7f-fac2bb60e94e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For debridement and promotion of normal healing of hyperkeratotic surface lesions, particularly where healing is retarded by local infection, necrotic tissue, fibrinous or purulent debris or eschar. Urea is useful for the treatment of hyperkeratotic conditions such as dry, rough skin, dermatitis, psoriasis, xerosis, ichthyosis, eczema, keratosis, keratoderma, corns and calluses, as well as damaged, devitalized and ingrown nails. uuid:1d24463f-04cb-4cc6-bd4f-124bebc1cb87 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16199 biolink:treats MONDO:0019269 PMID:41385096 "[{""id"":""uuid:bd46f79f-b921-4079-b6fa-d35e61135e6b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:64d074db-1e4d-43e5-ae51-84e33b0a2b52"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For debridement and promotion of normal healing of hyperkeratotic surface lesions, particularly where healing is retarded by local infection, necrotic tissue, fibrinous or purulent debris or eschar. Urea is useful for the treatment of hyperkeratotic conditions such as dry, rough skin, dermatitis, psoriasis, xerosis, ichthyosis, eczema, keratosis, keratoderma, corns and calluses, as well as damaged, devitalized and ingrown nails. uuid:6a0ffc80-f853-4c34-ba4c-3814157f7b21 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16199 biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:a7d4474a-7281-4f91-bb9b-79e5493adc30"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:76d3ab76-0013-40bc-9da8-206097bf5a12"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For debridement and promotion of normal healing of hyperkeratotic surface lesions, particularly where healing is retarded by local infection, necrotic tissue, fibrinous or purulent debris or eschar. Urea is useful for the treatment of hyperkeratotic conditions such as dry, rough skin, dermatitis, psoriasis, xerosis, ichthyosis, eczema, keratosis, keratoderma, corns and calluses, as well as damaged, devitalized and ingrown nails. uuid:77e6d1a6-3870-49de-bbb6-027be0faa16e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16199 biolink:treats MONDO:0006566 PMID:41385096 "[{""id"":""uuid:14979924-1dbe-458e-be9c-ac32ddcd535f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6c9a63df-4478-43a3-ae64-aba25e8ae1bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For debridement and promotion of normal healing of hyperkeratotic surface lesions, particularly where healing is retarded by local infection, necrotic tissue, fibrinous or purulent debris or eschar. Urea is useful for the treatment of hyperkeratotic conditions such as dry, rough skin, dermatitis, psoriasis, xerosis, ichthyosis, eczema, keratosis, keratoderma, corns and calluses, as well as damaged, devitalized and ingrown nails. uuid:0f97e541-a422-4236-a422-8b7bdfaf16de biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16199 biolink:treats MONDO:0019272 PMID:41385096 "[{""id"":""uuid:2ac3fec1-ae28-4589-afa6-37b8c535b552"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6825d1b5-5ec2-4a82-a11a-0511e581b59c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For debridement and promotion of normal healing of hyperkeratotic surface lesions, particularly where healing is retarded by local infection, necrotic tissue, fibrinous or purulent debris or eschar. Urea is useful for the treatment of hyperkeratotic conditions such as dry, rough skin, dermatitis, psoriasis, xerosis, ichthyosis, eczema, keratosis, keratoderma, corns and calluses, as well as damaged, devitalized and ingrown nails. uuid:743ba89b-adaa-470b-8226-5f3bb393ef7c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16199 biolink:treats HP:6000789 PMID:41385096 "[{""id"":""uuid:b3f8456f-86e9-4f84-87b9-981b146bff30"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8f91cd8f-b366-41df-a355-9b7d3dfce3a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For debridement and promotion of normal healing of hyperkeratotic surface lesions, particularly where healing is retarded by local infection, necrotic tissue, fibrinous or purulent debris or eschar. Urea is useful for the treatment of hyperkeratotic conditions such as dry, rough skin, dermatitis, psoriasis, xerosis, ichthyosis, eczema, keratosis, keratoderma, corns and calluses, as well as damaged, devitalized and ingrown nails. uuid:5ee846cd-2e6d-4c76-a664-2bde722891e1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16199 biolink:treats MONDO:0007758 PMID:41385096 "[{""id"":""uuid:7b66a60a-4192-4b21-9f3b-47c91ab7319a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a58bdbba-e965-4061-82fd-11d454d93851"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For debridement and promotion of normal healing of hyperkeratotic surface lesions, particularly where healing is retarded by local infection, necrotic tissue, fibrinous or purulent debris or eschar. Urea is useful for the treatment of hyperkeratotic conditions such as dry, rough skin, dermatitis, psoriasis, xerosis, ichthyosis, eczema, keratosis, keratoderma, corns and calluses, as well as damaged, devitalized and ingrown nails. uuid:3630f9e0-02d3-4155-8a2e-76ef79caa7bf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16199 biolink:treats HP:0012710 PMID:41385096 "[{""id"":""uuid:0e5fa5b7-ede9-42fd-a694-430a66e3c492"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a51b4246-dabf-4f79-a752-df0cd35bccad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For debridement and promotion of normal healing of hyperkeratotic surface lesions, particularly where healing is retarded by local infection, necrotic tissue, fibrinous or purulent debris or eschar. Urea is useful for the treatment of hyperkeratotic conditions such as dry, rough skin, dermatitis, psoriasis, xerosis, ichthyosis, eczema, keratosis, keratoderma, corns and calluses, as well as damaged, devitalized and ingrown nails. uuid:d08354ee-2a34-4dac-9152-08f1e10c7759 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9327 biolink:treats MONDO:0006609 PMID:41385096 "[{""id"":""uuid:058864ac-92c3-48c4-a0aa-2bd284b885a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8eb215c7-3d04-4aca-9903-5268ffe7b392"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE: Sodium Sulfacetamide 10% Wash is intended for topical application in the following scaling dematoses: seborrheic dermatitis and sebonthea sicca (dandruff). It also is indicated for the treatment of secondary bacterial infections of the skin due to organisms susceptible to sulfonamides. uuid:f6df57d9-6523-44f1-85ca-81d9cb40c722 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9327 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:8d2012dc-40f7-4929-9458-301c5598e9bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e6daa56f-a25e-48fb-b50d-2d34924396a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE: Sodium Sulfacetamide 10% Wash is intended for topical application in the following scaling dematoses: seborrheic dermatitis and sebonthea sicca (dandruff). It also is indicated for the treatment of secondary bacterial infections of the skin due to organisms susceptible to sulfonamides. uuid:6ff9f52a-f4d3-4d77-ba70-88205c160a15 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:379230 biolink:treats MONDO:0011438 PMID:41385096 "[{""id"":""uuid:3f6633e4-536d-4610-8328-94ecd93baceb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ebb36e37-3ab2-40cb-bd16-b863ec6d4686"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS: Sodium Sulfacetamide 10% & Sulfur 5% Cleanser is indicated in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis. uuid:99f64e41-387e-4997-b721-6fe77e313817 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:379230 biolink:treats MONDO:0006604 PMID:41385096 "[{""id"":""uuid:c7d47438-988b-4d28-a683-12cfc9e8c1c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8dca1bdd-2f0f-4338-a106-d8204a957466"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS: Sodium Sulfacetamide 10% & Sulfur 5% Cleanser is indicated in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis. uuid:c3d6e476-d73f-4d26-95c4-a317dca0b583 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:379230 biolink:treats MONDO:0006608 PMID:41385096 "[{""id"":""uuid:7928e9a0-0d6b-4835-bd2a-beb5df4d5913"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ca284a69-8bdb-4a1b-b9d3-266b989f35d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS: Sodium Sulfacetamide 10% & Sulfur 5% Cleanser is indicated in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis. uuid:8abf1e16-7c62-4ab3-8782-216f3b21f3eb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7824 biolink:treats MONDO:0005027 PMID:41385096 "[{""id"":""uuid:52c679d3-42e7-417d-9124-8450fcaef41b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5b618039-c069-442e-a8bc-7317a2588cda"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:9e5a54ae-d708-45eb-be6a-b5c1ab48f3c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxcarbazepine is indicated for use as monotherapy or adjunctive therapy in the treatment of partial seizures in adults and as monotherapy in the treatment of partial seizures in children aged 4years and above with epilepsy, and as adjunctive therapy in children aged 2 years and above with epilepsy.|[PMDA] Drugs with a new active ingredient indicated for the use as an adjunctive therapy with other antiepileptic drugs to treat partial seizures (including secondary generalized seizures) in patients with epilepsy who have not responded sufficiently to other antiepileptic drugs. uuid:f9702270-508c-414a-8770-ba80df2b5304 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7824 biolink:treats HP:0007359 PMID:41385096 "[{""id"":""uuid:3c56e61e-4efb-4d2b-b4d4-1a7d74890879"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0fe72824-13c2-4ae4-8c50-8aa8a07156ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:02127b34-65ec-4e60-ac3d-50a9aa88a9b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxcarbazepine is indicated for use as monotherapy or adjunctive therapy in the treatment of partial seizures in adults and as monotherapy in the treatment of partial seizures in children aged 4years and above with epilepsy, and as adjunctive therapy in children aged 2 years and above with epilepsy.|[PMDA] Drugs with a new active ingredient indicated for the use as an adjunctive therapy with other antiepileptic drugs to treat partial seizures (including secondary generalized seizures) in patients with epilepsy who have not responded sufficiently to other antiepileptic drugs. uuid:4f664ef5-2597-4716-83ac-0c4c1e53aaa5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6541 biolink:treats HP:0001712 PMID:41385096 "[{""id"":""uuid:ea9ff3a4-71a3-4d0f-aa30-d923eb128229"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:74a932cb-01c6-47a0-8592-63fd5984e8ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension Losartan potassium tablets are indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents, including diuretics. Hypertensive Patients with Left Ventricular Hypertrophy Losartan potassium tablets are indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to Black patients. (See and , PRECAUTIONS Race , CLINICAL PHARMACOLOGY , , .) Pharmacodynamics and Clinical Effects Reduction in the Risk of Stroke Race in 2 Patients Nephropathy Type Diabetic Losartan potassium tablets are indicated for the treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria (urinary albumin to creatinine ratio ≥300 mg/g) in patients with type 2 diabetes and a history of hypertension. In this population, losartan potassium tablets reduce the rate of progression of nephropathy as measured by the occurrence of doubling of serum creatinine or end stage renal disease (need for dialysis or renal transplantation) (see , CLINICAL PHARMACOLOGY ). Pharmacodynamics and Clinical Effects uuid:aaa035c4-2c8b-4cad-99f0-e660f03a7b37 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6541 biolink:treats MONDO:0005016 PMID:41385096 "[{""id"":""uuid:e54af882-2250-4021-afca-1bb0ca0c0067"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:57a29036-9864-493f-b1fd-7635fc8a6902"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:96a02bb0-fb3b-4d1c-af6e-f8b0ceb65154"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension Losartan potassium tablets are indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents, including diuretics. Hypertensive Patients with Left Ventricular Hypertrophy Losartan potassium tablets are indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to Black patients. (See and , PRECAUTIONS Race , CLINICAL PHARMACOLOGY , , .) Pharmacodynamics and Clinical Effects Reduction in the Risk of Stroke Race in 2 Patients Nephropathy Type Diabetic Losartan potassium tablets are indicated for the treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria (urinary albumin to creatinine ratio ≥300 mg/g) in patients with type 2 diabetes and a history of hypertension. In this population, losartan potassium tablets reduce the rate of progression of nephropathy as measured by the occurrence of doubling of serum creatinine or end stage renal disease (need for dialysis or renal transplantation) (see , CLINICAL PHARMACOLOGY ). Pharmacodynamics and Clinical Effects|[PMDA] Addition of a new indication for diabetic nephropathy in patients with type2 diabetes, hypertension, and proteinuria. uuid:113b6ba5-e2c6-4902-81c7-e48232b26339 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6541 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:93b9f3d2-55b8-471f-b27c-35580424d023"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:76e85652-55ab-4cf6-aa78-7b8b16e639d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension Losartan potassium tablets are indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents, including diuretics. Hypertensive Patients with Left Ventricular Hypertrophy Losartan potassium tablets are indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to Black patients. (See and , PRECAUTIONS Race , CLINICAL PHARMACOLOGY , , .) Pharmacodynamics and Clinical Effects Reduction in the Risk of Stroke Race in 2 Patients Nephropathy Type Diabetic Losartan potassium tablets are indicated for the treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria (urinary albumin to creatinine ratio ≥300 mg/g) in patients with type 2 diabetes and a history of hypertension. In this population, losartan potassium tablets reduce the rate of progression of nephropathy as measured by the occurrence of doubling of serum creatinine or end stage renal disease (need for dialysis or renal transplantation) (see , CLINICAL PHARMACOLOGY ). Pharmacodynamics and Clinical Effects uuid:ed4f30ca-6d6f-470e-ba75-bf93b4aa57d4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6541 biolink:treats MONDO:0004375 PMID:41385096 "[{""id"":""uuid:0623e82a-446b-4294-903c-03ea6b691fd5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:673e27df-c7eb-424e-aebe-ec9810e05078"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension Losartan potassium tablets are indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents, including diuretics. Hypertensive Patients with Left Ventricular Hypertrophy Losartan potassium tablets are indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to Black patients. (See and , PRECAUTIONS Race , CLINICAL PHARMACOLOGY , , .) Pharmacodynamics and Clinical Effects Reduction in the Risk of Stroke Race in 2 Patients Nephropathy Type Diabetic Losartan potassium tablets are indicated for the treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria (urinary albumin to creatinine ratio ≥300 mg/g) in patients with type 2 diabetes and a history of hypertension. In this population, losartan potassium tablets reduce the rate of progression of nephropathy as measured by the occurrence of doubling of serum creatinine or end stage renal disease (need for dialysis or renal transplantation) (see , CLINICAL PHARMACOLOGY ). Pharmacodynamics and Clinical Effects uuid:cf99e00f-14d7-4271-b109-2ca65b8a46e2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0018059 PMID:41385096 "[{""id"":""uuid:e92948ca-a271-49e9-bfe0-0247e331b105"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d314bfa5-2499-4a49-b3b1-b865cb72aae1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Minocycline hydrochloride tablets, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (Ornithosis) due to Chlamydia psittaci. Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis. Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Calymmatobacterium granulomatis. Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Enterobacter aerogenes. Shigella species . Acinetobacter species . Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species . Minocycline hydrochloride tablets, USP are indicated for the treatment of infections caused by the following gram-positive microorganism when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection). When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal infections. Infections in women caused by Neisseria gonorrhoeae. Syphilis caused by Treponema pallidum subspecies pallidum. Yaws caused by Treponema pallidum subspecies pertenue. Listeriosis due to Listeria monocytogenes. Anthrax due to Bacillus anthracis. Vincent’s infection caused by Fusobacterium fusiforme. Actinomycosis caused by Actinomyces israelii. Infections caused by Clostridium species . In acute intestinal amebiasis , minocycline may be a useful adjunct to amebicides. In severe acne , minocycline may be useful adjunctive therapy. Oral minocycline is indicated in the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum . To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride tablets, USP and other antibacterial drugs, minocycline hydrochloride tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:05ef5817-3b2c-489f-a385-4d2fbc204866 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0005373 PMID:41385096 "[{""id"":""uuid:1dc318a4-f3da-4657-9815-247ddedb4308"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:93c0aee3-3554-4c51-9a36-eeb0a1dbfe4a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Minocycline hydrochloride tablets, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (Ornithosis) due to Chlamydia psittaci. Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis. Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Calymmatobacterium granulomatis. Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Enterobacter aerogenes. Shigella species . Acinetobacter species . Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species . Minocycline hydrochloride tablets, USP are indicated for the treatment of infections caused by the following gram-positive microorganism when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection). When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal infections. Infections in women caused by Neisseria gonorrhoeae. Syphilis caused by Treponema pallidum subspecies pallidum. Yaws caused by Treponema pallidum subspecies pertenue. Listeriosis due to Listeria monocytogenes. Anthrax due to Bacillus anthracis. Vincent’s infection caused by Fusobacterium fusiforme. Actinomycosis caused by Actinomyces israelii. Infections caused by Clostridium species . In acute intestinal amebiasis , minocycline may be a useful adjunct to amebicides. In severe acne , minocycline may be useful adjunctive therapy. Oral minocycline is indicated in the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum . To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride tablets, USP and other antibacterial drugs, minocycline hydrochloride tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:24465f3a-5a80-4afa-b1e1-44d3d3c651bb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18332 biolink:treats MONDO:0005420 PMID:41385096 "[{""id"":""uuid:b816bb2c-9346-404c-9b99-fe3ecdd0aa90"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4129d66a-949a-4b42-81f6-a96a5d041d62"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:5e21a510-8f3c-4b2a-ac39-a7719795354f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levothyroxine sodium is used for the following indications: Hypothyroidism As replacement or supplemental therapy in congenital or acquired hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. Specific indications include: primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) hypothyroidism and subclinical hypothyroidism. Primary hypothyroidism may result from functional deficiency, primary atrophy, partial or total congenital absence of the thyroid gland, or from the effects of surgery, radiation, or drugs, with or without the presence of goiter. Pituitary TSH Suppression In the treatment or prevention of various types of euthyroid goiters (see WARNINGS and PRECAUTIONS ), including thyroid nodules (see WARNINGS and PRECAUTIONS ), subacute or chronic lymphocytic thyroiditis (Hashimoto’s thyroiditis), multinodular goiter (see WARNINGS and PRECAUTIONS ) and, as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well differentiated thyroid cancer.|[PMDA] A drug with a new route of administration indicated for the treatment of myxedema coma and hypothyroidism (for hypothyroidism, only in patients ineligible for oral levothyroxine sodium therapy). uuid:2624853b-c283-464e-9a2d-83f8e52c77c4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18332 biolink:treats MONDO:0018612 PMID:41385096 "[{""id"":""uuid:f7e23506-e2cd-4111-bbcf-29a462f97620"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f6148ad6-7cb2-4b7e-a7dc-de4b89c29a46"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levothyroxine sodium is used for the following indications: Hypothyroidism As replacement or supplemental therapy in congenital or acquired hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. Specific indications include: primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) hypothyroidism and subclinical hypothyroidism. Primary hypothyroidism may result from functional deficiency, primary atrophy, partial or total congenital absence of the thyroid gland, or from the effects of surgery, radiation, or drugs, with or without the presence of goiter. Pituitary TSH Suppression In the treatment or prevention of various types of euthyroid goiters (see WARNINGS and PRECAUTIONS ), including thyroid nodules (see WARNINGS and PRECAUTIONS ), subacute or chronic lymphocytic thyroiditis (Hashimoto’s thyroiditis), multinodular goiter (see WARNINGS and PRECAUTIONS ) and, as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well differentiated thyroid cancer. uuid:47195684-2c3b-48f1-a595-3815c6a60af5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18332 biolink:treats HP:0000832 PMID:41385096 "[{""id"":""uuid:202d94a1-ffa0-45c8-a25a-46dca1becc8e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d53819aa-c6f9-44d3-8978-6fefb96e19cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levothyroxine sodium is used for the following indications: Hypothyroidism As replacement or supplemental therapy in congenital or acquired hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. Specific indications include: primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) hypothyroidism and subclinical hypothyroidism. Primary hypothyroidism may result from functional deficiency, primary atrophy, partial or total congenital absence of the thyroid gland, or from the effects of surgery, radiation, or drugs, with or without the presence of goiter. Pituitary TSH Suppression In the treatment or prevention of various types of euthyroid goiters (see WARNINGS and PRECAUTIONS ), including thyroid nodules (see WARNINGS and PRECAUTIONS ), subacute or chronic lymphocytic thyroiditis (Hashimoto’s thyroiditis), multinodular goiter (see WARNINGS and PRECAUTIONS ) and, as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well differentiated thyroid cancer. uuid:33e0e9f8-5084-40c7-9ad5-9dc5cfdaaf25 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18332 biolink:treats UMLS:C0854492 PMID:41385096 "[{""id"":""uuid:734d6a39-3490-487f-83a2-e909a8926d48"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1d745bfb-36cb-4394-93ab-5db4d930c653"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levothyroxine sodium is used for the following indications: Hypothyroidism As replacement or supplemental therapy in congenital or acquired hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. Specific indications include: primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) hypothyroidism and subclinical hypothyroidism. Primary hypothyroidism may result from functional deficiency, primary atrophy, partial or total congenital absence of the thyroid gland, or from the effects of surgery, radiation, or drugs, with or without the presence of goiter. Pituitary TSH Suppression In the treatment or prevention of various types of euthyroid goiters (see WARNINGS and PRECAUTIONS ), including thyroid nodules (see WARNINGS and PRECAUTIONS ), subacute or chronic lymphocytic thyroiditis (Hashimoto’s thyroiditis), multinodular goiter (see WARNINGS and PRECAUTIONS ) and, as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well differentiated thyroid cancer. uuid:474862b0-5f7f-41a7-868c-f5d60dd54c51 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18332 biolink:treats HP:0008223 PMID:41385096 "[{""id"":""uuid:666f8f93-97fc-4e10-98c6-f58a67750163"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6c5ffd9a-5667-43a9-9200-4cfa041c5183"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levothyroxine sodium is used for the following indications: Hypothyroidism As replacement or supplemental therapy in congenital or acquired hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. Specific indications include: primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) hypothyroidism and subclinical hypothyroidism. Primary hypothyroidism may result from functional deficiency, primary atrophy, partial or total congenital absence of the thyroid gland, or from the effects of surgery, radiation, or drugs, with or without the presence of goiter. Pituitary TSH Suppression In the treatment or prevention of various types of euthyroid goiters (see WARNINGS and PRECAUTIONS ), including thyroid nodules (see WARNINGS and PRECAUTIONS ), subacute or chronic lymphocytic thyroiditis (Hashimoto’s thyroiditis), multinodular goiter (see WARNINGS and PRECAUTIONS ) and, as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well differentiated thyroid cancer. uuid:b92171cf-4e13-452b-a05f-cae1d4049062 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18332 biolink:treats MONDO:0001658 PMID:41385096 "[{""id"":""uuid:12e5dfd7-418c-4655-8d53-a040526fecbd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b78d3162-0284-4054-814c-c6fb604b1184"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levothyroxine sodium is used for the following indications: Hypothyroidism As replacement or supplemental therapy in congenital or acquired hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. Specific indications include: primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) hypothyroidism and subclinical hypothyroidism. Primary hypothyroidism may result from functional deficiency, primary atrophy, partial or total congenital absence of the thyroid gland, or from the effects of surgery, radiation, or drugs, with or without the presence of goiter. Pituitary TSH Suppression In the treatment or prevention of various types of euthyroid goiters (see WARNINGS and PRECAUTIONS ), including thyroid nodules (see WARNINGS and PRECAUTIONS ), subacute or chronic lymphocytic thyroiditis (Hashimoto’s thyroiditis), multinodular goiter (see WARNINGS and PRECAUTIONS ) and, as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well differentiated thyroid cancer. uuid:e96ac681-d11f-49e4-8147-0297b0fa2bbf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18332 biolink:treats HP:0025388 PMID:41385096 "[{""id"":""uuid:06149bbf-d324-46a7-88fa-b9c4960e7a14"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9a6ecb62-1fea-41b3-8bfe-dfbdab0f3ee8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levothyroxine sodium is used for the following indications: Hypothyroidism As replacement or supplemental therapy in congenital or acquired hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. Specific indications include: primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) hypothyroidism and subclinical hypothyroidism. Primary hypothyroidism may result from functional deficiency, primary atrophy, partial or total congenital absence of the thyroid gland, or from the effects of surgery, radiation, or drugs, with or without the presence of goiter. Pituitary TSH Suppression In the treatment or prevention of various types of euthyroid goiters (see WARNINGS and PRECAUTIONS ), including thyroid nodules (see WARNINGS and PRECAUTIONS ), subacute or chronic lymphocytic thyroiditis (Hashimoto’s thyroiditis), multinodular goiter (see WARNINGS and PRECAUTIONS ) and, as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well differentiated thyroid cancer. uuid:50efbad4-c085-46ef-a305-a50f39aad714 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18332 biolink:treats MONDO:0007699 PMID:41385096 "[{""id"":""uuid:35a8250d-8ca6-4b62-aac5-ed1b176751ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2e7e82b6-8d30-4fe2-8846-baa4170e7de1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levothyroxine sodium is used for the following indications: Hypothyroidism As replacement or supplemental therapy in congenital or acquired hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. Specific indications include: primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) hypothyroidism and subclinical hypothyroidism. Primary hypothyroidism may result from functional deficiency, primary atrophy, partial or total congenital absence of the thyroid gland, or from the effects of surgery, radiation, or drugs, with or without the presence of goiter. Pituitary TSH Suppression In the treatment or prevention of various types of euthyroid goiters (see WARNINGS and PRECAUTIONS ), including thyroid nodules (see WARNINGS and PRECAUTIONS ), subacute or chronic lymphocytic thyroiditis (Hashimoto’s thyroiditis), multinodular goiter (see WARNINGS and PRECAUTIONS ) and, as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well differentiated thyroid cancer. uuid:4246d43f-f135-4ced-bea0-6570d3d38f00 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18332 biolink:treats MONDO:0000334 PMID:41385096 "[{""id"":""uuid:e3ef1c54-0384-47fd-b1b3-07f604eb910d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:af5cca72-2375-462e-94c0-4c27fa1e75ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levothyroxine sodium is used for the following indications: Hypothyroidism As replacement or supplemental therapy in congenital or acquired hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. Specific indications include: primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) hypothyroidism and subclinical hypothyroidism. Primary hypothyroidism may result from functional deficiency, primary atrophy, partial or total congenital absence of the thyroid gland, or from the effects of surgery, radiation, or drugs, with or without the presence of goiter. Pituitary TSH Suppression In the treatment or prevention of various types of euthyroid goiters (see WARNINGS and PRECAUTIONS ), including thyroid nodules (see WARNINGS and PRECAUTIONS ), subacute or chronic lymphocytic thyroiditis (Hashimoto’s thyroiditis), multinodular goiter (see WARNINGS and PRECAUTIONS ) and, as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well differentiated thyroid cancer. uuid:84ec1c9b-b407-453d-8ac2-05e4d8bc95dd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18332 biolink:treats MONDO:0015447 PMID:41385096 "[{""id"":""uuid:5629d654-01fb-4372-b0af-f8989dc79712"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:449303a1-d0a5-4564-861a-9eecb1fbe393"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levothyroxine sodium is used for the following indications: Hypothyroidism As replacement or supplemental therapy in congenital or acquired hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. Specific indications include: primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) hypothyroidism and subclinical hypothyroidism. Primary hypothyroidism may result from functional deficiency, primary atrophy, partial or total congenital absence of the thyroid gland, or from the effects of surgery, radiation, or drugs, with or without the presence of goiter. Pituitary TSH Suppression In the treatment or prevention of various types of euthyroid goiters (see WARNINGS and PRECAUTIONS ), including thyroid nodules (see WARNINGS and PRECAUTIONS ), subacute or chronic lymphocytic thyroiditis (Hashimoto’s thyroiditis), multinodular goiter (see WARNINGS and PRECAUTIONS ) and, as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well differentiated thyroid cancer. uuid:13e8a0f6-ac9c-41de-ac87-a41dd287c7ed biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5537 biolink:treats HP:0002018 PMID:41385096 "[{""id"":""uuid:6a9a013a-320a-4abd-8df3-5366ec383449"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:54e29ff4-32d1-4502-9e13-4319976aeccd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:874cbe94-eb17-4bea-ac1b-c2ff8c35261e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/sancuso""]},{""id"":""uuid:6e600038-7f67-4419-be91-edba58c1e6e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sancuso ® (Granisetron Transdermal System) is indicated for the prevention of nausea and vomiting in patients receiving moderately and/or highly emetogenic chemotherapy regimens of up to 5 consecutive days duration.|[EMA] Prevention of nausea and vomiting in patients receiving moderately or highly emetogenic chemotherapy, with or without cisplatin, for up to five consecutive days.Sancuso may be used in patients receiving their first chemotherapy regimen or in patients who have previously received chemotherapy.|[PMDA] Drugs with a new indication and a new dosage for the treatment of digestive symptoms (nausea and vomiting) after surgery. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:e311d4cb-dcf7-4ee2-877e-7a46780411ef biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5537 biolink:treats HP:0002013 PMID:41385096 "[{""id"":""uuid:65c73d5d-69a7-4783-abed-47d600220299"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:43377b87-72b5-4ba6-b574-de0d2b5e2db0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:de5a009d-3015-4bf1-8513-170b1cf1df3a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/sancuso""]},{""id"":""uuid:2c391fda-a1c3-45cd-846c-b46b4163e6ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sancuso ® (Granisetron Transdermal System) is indicated for the prevention of nausea and vomiting in patients receiving moderately and/or highly emetogenic chemotherapy regimens of up to 5 consecutive days duration.|[EMA] Prevention of nausea and vomiting in patients receiving moderately or highly emetogenic chemotherapy, with or without cisplatin, for up to five consecutive days.Sancuso may be used in patients receiving their first chemotherapy regimen or in patients who have previously received chemotherapy.|[PMDA] Drugs with a new indication and a new dosage for the treatment of digestive symptoms (nausea and vomiting) after surgery. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:f80740e1-9ed7-416b-a47c-23cd932bf698 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31159 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:7aa0f79f-8b3a-410f-9fd2-0cd355ce4d2f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a5a6b8a7-7c4e-415c-a3c8-fb6ea41ed126"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS CLANZA CR is indicated for Rheumatoid arthritis, ankylosing spondylitis, osteoarthritis and periarthritis of scapulohumerous, lumbago, ischiadynia, pain caused by nonaticular rheutism. uuid:7bf5026f-426a-474e-b737-8f2cba1af677 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31159 biolink:treats MONDO:0005306 PMID:41385096 "[{""id"":""uuid:4ca3b72a-9fe0-44b7-8b42-b011a9ba857d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:12c153c7-7463-4cdc-8f52-b8a1739ab579"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS CLANZA CR is indicated for Rheumatoid arthritis, ankylosing spondylitis, osteoarthritis and periarthritis of scapulohumerous, lumbago, ischiadynia, pain caused by nonaticular rheutism. uuid:2de85226-8b4e-4da7-a613-f901e31073b2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31159 biolink:treats MONDO:0005178 PMID:41385096 "[{""id"":""uuid:f22bb8cd-7e53-4c33-8775-4ccf79aed726"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e4831b24-1440-4182-92af-cdac710cecdc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS CLANZA CR is indicated for Rheumatoid arthritis, ankylosing spondylitis, osteoarthritis and periarthritis of scapulohumerous, lumbago, ischiadynia, pain caused by nonaticular rheutism. uuid:3a7e6eae-2698-470d-8348-55658b81beec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31159 biolink:treats MONDO:0006898 PMID:41385096 "[{""id"":""uuid:dd3e30a0-b496-406b-9974-db39978131e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5fd505f3-7067-4d57-bc56-3b7dd7968811"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS CLANZA CR is indicated for Rheumatoid arthritis, ankylosing spondylitis, osteoarthritis and periarthritis of scapulohumerous, lumbago, ischiadynia, pain caused by nonaticular rheutism. uuid:5aba13be-7479-4c82-b406-6305b1d37b89 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31159 biolink:treats HP:0003419 PMID:41385096 "[{""id"":""uuid:04867597-c922-4341-9267-041dd46898f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0bd7e658-9734-4317-bf84-5d300a5a3192"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS CLANZA CR is indicated for Rheumatoid arthritis, ankylosing spondylitis, osteoarthritis and periarthritis of scapulohumerous, lumbago, ischiadynia, pain caused by nonaticular rheutism. uuid:e22f7e33-8007-4bf4-842c-ac2bd00ed0db biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41774 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:98c7914e-d84f-4dc1-b7d9-08884dcbb7dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8068f094-6b03-4b59-8533-e639ce551486"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tamoxifen citrate tablets are effective in the treatment of metastatic breast cancer in women and men. In premenopausal women with metastatic breast cancer, tamoxifen is an alternative to oophorectomy or ovarian irradiation. Available evidence indicates that patients whose tumors are estrogen receptor positive are more likely to benefit from tamoxifen therapy. uuid:9f6e52f6-2759-459d-a9c8-6c51ea68e002 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8107 biolink:treats HP:0002069 PMID:41385096 "[{""id"":""uuid:0cdde879-9cdc-4b51-b31b-18f1105a1982"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4d6c542f-5d55-4571-b99c-201f7b07db5e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Phenytoin Oral Suspension is indicated for the control of tonic-clonic (grand mal) and psychomotor (temporal lobe) seizures. Phenytoin serum level determinations may be necessary for optimal dosage adjustments (see DOSAGE AND ADMINISTRATION and CLINICAL PHARMACOLOGY sections). uuid:2fbf3d08-e705-4216-98fc-8dea736b4848 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8107 biolink:treats MONDO:0005115 PMID:41385096 "[{""id"":""uuid:36aa7c54-d1eb-456b-b93d-55c47d7186f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:35b3995b-fd08-4861-91b0-faf4238f31c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Phenytoin Oral Suspension is indicated for the control of tonic-clonic (grand mal) and psychomotor (temporal lobe) seizures. Phenytoin serum level determinations may be necessary for optimal dosage adjustments (see DOSAGE AND ADMINISTRATION and CLINICAL PHARMACOLOGY sections). uuid:933f9d57-e923-4afd-90c8-4c66beb7332b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50693 biolink:treats UMLS:C1609524 PMID:41385096 "[{""id"":""uuid:54e36032-61d0-41ff-8619-9e5705d59d60"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:987b42fb-e76a-4e1c-bc69-06f646895b9d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Milrinone Lactate Injection is indicated for the short-term intravenous treatment of patients with acute decompensated heart failure. Patients receiving milrinone should be observed closely with appropriate electrocardiographic equipment. The facility for immediate treatment of potential cardiac events, which may include life-threatening ventricular arrhythmias, must be available. The majority of experience with intravenous milrinone has been in patients receiving digoxin and diuretics. There is no experience in controlled trials with infusions of milrinone for periods exceeding 48 hours. uuid:a4bb750c-848c-4d1a-8658-d49d0e2ceb77 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50693 biolink:treats HP:0004308 PMID:41385096 "[{""id"":""uuid:13ac1a3e-6beb-4c45-a5ea-9f5d9d31ef55"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4413b525-b44b-472a-b3b0-427ff05d2144"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Milrinone Lactate Injection is indicated for the short-term intravenous treatment of patients with acute decompensated heart failure. Patients receiving milrinone should be observed closely with appropriate electrocardiographic equipment. The facility for immediate treatment of potential cardiac events, which may include life-threatening ventricular arrhythmias, must be available. The majority of experience with intravenous milrinone has been in patients receiving digoxin and diuretics. There is no experience in controlled trials with infusions of milrinone for periods exceeding 48 hours. uuid:807e5f05-1983-4757-a647-bbdeb59880b6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:51230 biolink:treats MONDO:0005338 PMID:41385096 "[{""id"":""uuid:48db23b4-da28-4a5c-9145-eb39c2672413"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:2e685e1c-2f17-434f-98fb-73304b0c6971"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:0c1ffa26-ee8d-43a0-871c-e191f0d63b62"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/lumigan""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] LUMIGAN ® 0.01% and 0.03% (bimatoprost ophthalmic solution) is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension.|[EMA] Reduction of elevated intraocular pressure in chronic open-angle glaucoma and ocular hypertension (as monotherapy or as adjunctive therapy to beta-blockers)., uuid:ea6bdece-c916-432d-b7e6-da32c937be2e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:51230 biolink:treats MONDO:0006875 PMID:41385096 "[{""id"":""uuid:525b0ef1-b60b-45d8-a8c4-c106ed9d68d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f1d82ce6-3468-4e6d-9071-f67e17bc2d7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:01f1522f-8400-45c7-8cc4-c0a2e3823401"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/lumigan""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] LUMIGAN ® 0.01% and 0.03% (bimatoprost ophthalmic solution) is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension.|[EMA] Reduction of elevated intraocular pressure in chronic open-angle glaucoma and ocular hypertension (as monotherapy or as adjunctive therapy to beta-blockers)., uuid:5ab71360-1e49-4cb9-a9b9-7d56b3eadb89 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9919 biolink:treats MONDO:0043653 PMID:41385096 "[{""id"":""uuid:5525f5d4-b528-4081-ad2a-9d9e1f5f2a70"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:334200ad-c51b-4fa4-9b52-6cc703831a5c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Valacyclovir hydrochloride tablets are a nucleoside analogue DNA polymerase inhibitor indicated for: Adult Patients ( 1.1 ) Cold Sores (Herpes Labialis) Genital Herpes Treatment in immunocompetent patients (initial or recurrent episode) Suppression in immunocompetent or HIV-infected patients Reduction of transmission Herpes Zoster Pediatric Patients ( 1.2 ) Cold Sores (Herpes Labialis) Limitations of Use ( 1.3 ) The efficacy and safety of valacyclovir hydrochloride tablets have not been established in immunocompromised patients other than for the suppression of genital herpes in HIV-infected patients. uuid:844e712b-b778-454c-b572-d7cbad8822c8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9919 biolink:treats MONDO:0005770 PMID:41385096 "[{""id"":""uuid:4e3cd11c-170a-410e-a5ea-d8dc1cda3628"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ae2263f5-c4cc-4c73-a05e-c586974848b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Valacyclovir hydrochloride tablets are a nucleoside analogue DNA polymerase inhibitor indicated for: Adult Patients ( 1.1 ) Cold Sores (Herpes Labialis) Genital Herpes Treatment in immunocompetent patients (initial or recurrent episode) Suppression in immunocompetent or HIV-infected patients Reduction of transmission Herpes Zoster Pediatric Patients ( 1.2 ) Cold Sores (Herpes Labialis) Limitations of Use ( 1.3 ) The efficacy and safety of valacyclovir hydrochloride tablets have not been established in immunocompromised patients other than for the suppression of genital herpes in HIV-infected patients. uuid:08e324f1-273a-4410-a792-1343706cae98 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9919 biolink:treats MONDO:0005609 PMID:41385096 "[{""id"":""uuid:ce0f08e1-c985-4a4f-901a-47448b8f6b32"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7b403138-6860-4ee1-858b-54fc8865708e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:6c4d0357-175d-4263-9732-ec36af380be3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Valacyclovir hydrochloride tablets are a nucleoside analogue DNA polymerase inhibitor indicated for: Adult Patients ( 1.1 ) Cold Sores (Herpes Labialis) Genital Herpes Treatment in immunocompetent patients (initial or recurrent episode) Suppression in immunocompetent or HIV-infected patients Reduction of transmission Herpes Zoster Pediatric Patients ( 1.2 ) Cold Sores (Herpes Labialis) Limitations of Use ( 1.3 ) The efficacy and safety of valacyclovir hydrochloride tablets have not been established in immunocompromised patients other than for the suppression of genital herpes in HIV-infected patients.|[PMDA] Drugs with a new additional indication and revised indications with a new dosage for prevention of herpes simplex virus infection in adult or pediatric haematopoietic stem cell transplant patients, for treatment of herpes simplex /herpes zoster, and for prevention of recurrent genital herpes in pediatric patients. uuid:0bc40521-3869-4625-8d05-295300d847eb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31547 biolink:treats MONDO:0004781 PMID:41385096 "[{""id"":""uuid:627a42a0-4b90-48ef-8c88-e8607ae148d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6534c6af-0852-468f-8600-0f51c2de4d83"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Eplerenone is an aldosterone antagonist indicated for: Improving survival of stable patients with LV systolic dysfunction (LVEF ≤40%) and CHF after an acute myocardial infarction. (1.2) Hypertension, alone or combined with other agents. (1.3) uuid:be8f2702-0191-4040-8407-8f2cf6e640a7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6904 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:48021edb-9006-4d64-855f-9ec40aac9db8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:165edecc-7a94-4230-936f-321fc04fce93"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Metoprolol succinate is a beta1-selective adrenoceptor blocking agent. Metoprolol succinate extended-release tablets USP are indicated for the treatment of: Hypertension ( 1.1 ) Angina Pectoris ( 1.2 ) Heart Failure - for the treatment of stable, symptomatic (NYHA Class II or III) heart failure of ischemic, hypertensive, or cardiomyopathic origin.( 1.3 ) uuid:d7c6beeb-40cc-4925-b15f-1d3765cb0848 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0003799 PMID:41385096 "[{""id"":""uuid:faf97113-436f-42b0-bbce-f718be65d1ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:31b93b52-9261-47e3-8229-97d9f9858ec8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prednisolone acetate ophthalmic suspension 1.0% is indicated for the treatment of steroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe. uuid:e851bc9f-d3bf-4624-9d0c-01bd0bc565ab biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71419 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:b08477e9-9dcc-4389-b818-daa9cc220fd1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:23e4800d-eddb-4622-b076-16f6ed6f3623"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Phenazopyridine HCl is indicated for the symptomatic relief of pain, burning, urgency, frequency, and other discomforts arising from irritation of the lower urinary tract mucosa caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters. The use of Phenazopyridine HCl for relief of symptoms should not delay definitive diagnosis and treatment of causative conditions. Because it provides only symptomatic relief, prompt appropriate treatment of the cause of pain must be instituted and Phenazopyridine HCl should be discontinued when symptoms are controlled. The analgesic action may reduce or eliminate the need for systemic analgesics or narcotics. It is, however, compatible with antibacterial therapy and can help to relieve pain and discomfort during the interval before antibacterial therapy controls the infection. Treatment of a urinary tract infection with Phenazopyridine HCl should not exceed 2 days because there is a lack of evidence that the combined administration of Phenazopyridine HCl and an antibacterial provides greater benefit than administration of the antibacterial alone after 2 days. (See DOSAGE AND ADMINISTRATION section.) uuid:f2975096-8b47-4d8c-b9ff-809b5d0c4882 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8502 biolink:treats MONDO:0005364 PMID:41385096 "[{""id"":""uuid:bc688239-df21-4b9f-adbb-648d23acd90a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b7c020b5-9078-4926-a824-0199286e88f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Propylthiouracil is indicated: in patients with Graves' disease with hyperthyroidism or toxic multinodular goiter who are intolerant of methimazole and for whom surgery or radioactive iodine therapy is not an appropriate treatment option. to ameliorate symptoms of hyperthyroidism in preparation for thyroidectomy or radioactive iodine therapy in patients who are intolerant of methimazole. uuid:8ddf4372-d00f-47cd-b5d3-82e658c9b5bf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8502 biolink:treats MONDO:0001252 PMID:41385096 "[{""id"":""uuid:4b482ec5-45d1-49a7-a96d-09cb702c8ed2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d921ba6f-c21c-42f4-8ecb-b5d8864f64b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Propylthiouracil is indicated: in patients with Graves' disease with hyperthyroidism or toxic multinodular goiter who are intolerant of methimazole and for whom surgery or radioactive iodine therapy is not an appropriate treatment option. to ameliorate symptoms of hyperthyroidism in preparation for thyroidectomy or radioactive iodine therapy in patients who are intolerant of methimazole. uuid:e7b145f1-ae04-485e-aa92-b518c9bb46cd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8502 biolink:treats MONDO:0004425 PMID:41385096 "[{""id"":""uuid:e2232241-af48-468b-b67d-88693b3b94ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b49e29c9-5e22-402d-ae62-189127d0a513"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Propylthiouracil is indicated: in patients with Graves' disease with hyperthyroidism or toxic multinodular goiter who are intolerant of methimazole and for whom surgery or radioactive iodine therapy is not an appropriate treatment option. to ameliorate symptoms of hyperthyroidism in preparation for thyroidectomy or radioactive iodine therapy in patients who are intolerant of methimazole. uuid:5f14306c-2c2d-4ed3-aeb7-1b013e11d747 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6715 biolink:treats HP:0000938 PMID:41385096 "[{""id"":""uuid:aca51a7d-1966-453c-992c-c6ac31874ce3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ccc226c3-0e4d-46bc-bf34-eb01b53a8282"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Medroxyprogesterone Acetate Injectable Suspension, USP is indicated only for the prevention of pregnancy. The loss of bone mineral density (BMD) in women of all ages and the impact on peak bone mass in adolescents should be considered, along with the decrease in BMD that occurs during pregnancy and/or lactation, in the risk/benefit assessment for women who use Medroxyprogesterone Acetate Injectable Suspension, USP long-term [see Warnings and Precautions (5.1) ]. uuid:ecbe42bf-f430-441c-9185-bca348c86bf6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32293 biolink:treats MONDO:0005150 PMID:41385096 "[{""id"":""uuid:1b0ddce7-3162-48e8-b98e-19f1d3f2d52c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:b3e2651f-291c-4227-af33-4b24958fd97e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:20f089bd-8182-4d9c-b187-cbcf43563ae3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/visudyne""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Visudyne ® (verteporfin for injection) therapy is indicated for the treatment of patients with predominantly classic subfoveal choroidal neovascularization due to age-related macular degeneration, pathologic myopia or presumed ocular histoplasmosis. There is insufficient evidence to indicate Visudyne for the treatment of predominantly occult subfoveal choroidal neovascularization.|[EMA] Visudyne is indicated for the treatment of:adults with exudative (wet) age-related macular degeneration (AMD) with predominantly classic subfoveal choroidal neovascularisation (CNV) or;adults with subfoveal choroidal neovascularisation secondary to pathological myopia. uuid:939e1d51-efa8-4e59-80f9-50e3f232d8c4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32293 biolink:treats UMLS:C3537442 PMID:41385096 "[{""id"":""uuid:2ce08ee6-3e27-4be4-ae6c-74654768f494"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:56154655-d0f1-4f04-9448-aa5f1967ca0d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Visudyne ® (verteporfin for injection) therapy is indicated for the treatment of patients with predominantly classic subfoveal choroidal neovascularization due to age-related macular degeneration, pathologic myopia or presumed ocular histoplasmosis. There is insufficient evidence to indicate Visudyne for the treatment of predominantly occult subfoveal choroidal neovascularization. uuid:ff8c8df1-c0dc-4aac-ad59-7aaed678ebaa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32293 biolink:treats UMLS:C0339403 PMID:41385096 "[{""id"":""uuid:5b6a41a3-c824-4f22-9625-904bc0a4e531"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:72f6b6cc-7d86-4792-ac6b-50a24b10fe2c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Visudyne ® (verteporfin for injection) therapy is indicated for the treatment of patients with predominantly classic subfoveal choroidal neovascularization due to age-related macular degeneration, pathologic myopia or presumed ocular histoplasmosis. There is insufficient evidence to indicate Visudyne for the treatment of predominantly occult subfoveal choroidal neovascularization. uuid:881f9090-b548-46c2-bde8-8fdc949d25df biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16914 biolink:treats MONDO:0001209 PMID:41385096 "[{""id"":""uuid:f37c2726-4ef4-4640-aa35-6e2e6a205f49"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e30b0d25-f4bd-4ed4-88e0-e88bf01606b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For Dermatologic Use: SA 6% is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders including verrucae, and the various ichthyoses (vulgaris, sex-linked and lamellar), keratosis palmaris and plantaris keratosis pilaris, pityriasis rubra pilaris, and psoriasis (including body, scalp, palms and soles). For Podiatric Use: SA 6% is a topical aid in the removal of excessive keratin on dorsal and plantar hyperkeratotic lesions. Topical preparations of 6% salicylic acid have been reported to be useful adjunctive therapy for verrucae plantares. uuid:50be1275-ec4c-44ea-b39a-63212f3f4b3a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16914 biolink:treats MONDO:0024304 PMID:41385096 "[{""id"":""uuid:6749caef-78aa-4952-92ae-e103a32a045a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b05218d0-f61e-4f74-849b-37387ed3a845"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For Dermatologic Use: SA 6% is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders including verrucae, and the various ichthyoses (vulgaris, sex-linked and lamellar), keratosis palmaris and plantaris keratosis pilaris, pityriasis rubra pilaris, and psoriasis (including body, scalp, palms and soles). For Podiatric Use: SA 6% is a topical aid in the removal of excessive keratin on dorsal and plantar hyperkeratotic lesions. Topical preparations of 6% salicylic acid have been reported to be useful adjunctive therapy for verrucae plantares. uuid:48ba255b-8524-4c88-be99-8f8c85cdaff3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16914 biolink:treats MONDO:0010622 PMID:41385096 "[{""id"":""uuid:cfa072da-58b7-4b51-b89a-363cdc41a081"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:29ea1ea0-89ec-409b-9f5c-1521fbd59918"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For Dermatologic Use: SA 6% is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders including verrucae, and the various ichthyoses (vulgaris, sex-linked and lamellar), keratosis palmaris and plantaris keratosis pilaris, pityriasis rubra pilaris, and psoriasis (including body, scalp, palms and soles). For Podiatric Use: SA 6% is a topical aid in the removal of excessive keratin on dorsal and plantar hyperkeratotic lesions. Topical preparations of 6% salicylic acid have been reported to be useful adjunctive therapy for verrucae plantares. uuid:420658b3-47a0-4b9f-8fe9-69cb8fcf4106 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16914 biolink:treats MONDO:0017778 PMID:41385096 "[{""id"":""uuid:1c6eb1f7-4ae5-45df-a904-63b2fa08a99a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7f9c7dc1-336e-4a83-9054-2a6ff28acc42"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For Dermatologic Use: SA 6% is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders including verrucae, and the various ichthyoses (vulgaris, sex-linked and lamellar), keratosis palmaris and plantaris keratosis pilaris, pityriasis rubra pilaris, and psoriasis (including body, scalp, palms and soles). For Podiatric Use: SA 6% is a topical aid in the removal of excessive keratin on dorsal and plantar hyperkeratotic lesions. Topical preparations of 6% salicylic acid have been reported to be useful adjunctive therapy for verrucae plantares. uuid:5eae2f36-8372-42a5-9001-282068bd0ec0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16914 biolink:treats UMLS:C0856543 PMID:41385096 "[{""id"":""uuid:8c79bbe8-7e54-49fc-8b09-0ecdefb37f94"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4d589cb8-ebca-4826-ad92-32681b56a0f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For Dermatologic Use: SA 6% is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders including verrucae, and the various ichthyoses (vulgaris, sex-linked and lamellar), keratosis palmaris and plantaris keratosis pilaris, pityriasis rubra pilaris, and psoriasis (including body, scalp, palms and soles). For Podiatric Use: SA 6% is a topical aid in the removal of excessive keratin on dorsal and plantar hyperkeratotic lesions. Topical preparations of 6% salicylic acid have been reported to be useful adjunctive therapy for verrucae plantares. uuid:cf89ed22-243e-431b-b2b0-afc3522fc252 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16914 biolink:treats MONDO:0006590 PMID:41385096 "[{""id"":""uuid:9bab6c02-ea60-47ce-a086-4b0c7015b1ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:89ca9ec1-1a95-444d-927f-33490220d053"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For Dermatologic Use: SA 6% is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders including verrucae, and the various ichthyoses (vulgaris, sex-linked and lamellar), keratosis palmaris and plantaris keratosis pilaris, pityriasis rubra pilaris, and psoriasis (including body, scalp, palms and soles). For Podiatric Use: SA 6% is a topical aid in the removal of excessive keratin on dorsal and plantar hyperkeratotic lesions. Topical preparations of 6% salicylic acid have been reported to be useful adjunctive therapy for verrucae plantares. uuid:d70d1e58-5651-4522-9030-d91ed0db6f1f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16914 biolink:treats MONDO:0021036 PMID:41385096 "[{""id"":""uuid:8a00be3e-3285-4c58-81f4-65a65a6492ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b7ada894-33eb-4ccf-8ce6-95cfc397369e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For Dermatologic Use: SA 6% is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders including verrucae, and the various ichthyoses (vulgaris, sex-linked and lamellar), keratosis palmaris and plantaris keratosis pilaris, pityriasis rubra pilaris, and psoriasis (including body, scalp, palms and soles). For Podiatric Use: SA 6% is a topical aid in the removal of excessive keratin on dorsal and plantar hyperkeratotic lesions. Topical preparations of 6% salicylic acid have been reported to be useful adjunctive therapy for verrucae plantares. uuid:d88da777-5a3b-4036-bbdc-9be63420f0db biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16914 biolink:treats MONDO:0100017 PMID:41385096 "[{""id"":""uuid:d100f649-fe05-48fe-a94d-91739f756fba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:89695516-8583-45ca-9a22-c8ee1944c62d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For Dermatologic Use: SA 6% is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders including verrucae, and the various ichthyoses (vulgaris, sex-linked and lamellar), keratosis palmaris and plantaris keratosis pilaris, pityriasis rubra pilaris, and psoriasis (including body, scalp, palms and soles). For Podiatric Use: SA 6% is a topical aid in the removal of excessive keratin on dorsal and plantar hyperkeratotic lesions. Topical preparations of 6% salicylic acid have been reported to be useful adjunctive therapy for verrucae plantares. uuid:2b636ac3-071f-453f-9334-9547505c3abb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16914 biolink:treats MONDO:0005083 PMID:41385096 "[{""id"":""uuid:3d5904d5-96f6-469c-930c-a8c3638b781b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d3591d33-c72c-40f8-bde2-ee9e6ea642f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For Dermatologic Use: SA 6% is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders including verrucae, and the various ichthyoses (vulgaris, sex-linked and lamellar), keratosis palmaris and plantaris keratosis pilaris, pityriasis rubra pilaris, and psoriasis (including body, scalp, palms and soles). For Podiatric Use: SA 6% is a topical aid in the removal of excessive keratin on dorsal and plantar hyperkeratotic lesions. Topical preparations of 6% salicylic acid have been reported to be useful adjunctive therapy for verrucae plantares. uuid:d191a47a-49f5-4a5f-9edf-7529a23f623f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16914 biolink:treats MONDO:0001795 PMID:41385096 "[{""id"":""uuid:57ecf70c-354e-4783-88b5-5bfbb4cf11f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:03b47feb-b6b8-41d3-af67-071832a1a931"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For Dermatologic Use: SA 6% is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders including verrucae, and the various ichthyoses (vulgaris, sex-linked and lamellar), keratosis palmaris and plantaris keratosis pilaris, pityriasis rubra pilaris, and psoriasis (including body, scalp, palms and soles). For Podiatric Use: SA 6% is a topical aid in the removal of excessive keratin on dorsal and plantar hyperkeratotic lesions. Topical preparations of 6% salicylic acid have been reported to be useful adjunctive therapy for verrucae plantares. uuid:29492cfe-0342-46e6-a0d0-faffa523e499 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5790 biolink:treats NCIT:C34887 PMID:41385096 "[{""id"":""uuid:95d0368d-8e88-4b87-8c0b-60f80339cb73"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:98402ea4-4a54-4247-9117-1d51af452521"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EXALGO is an extended-release oral formulation of hydromorphone hydrochloride indicated for the management of moderate to severe pain in opioid tolerant patients requiring continuous, around-the-clock opioid analgesia for an extended period of time. Patients considered opioid tolerant are those who are taking at least 60 mg oral morphine per day, 25 mcg transdermal fentanyl/hour, 30 mg oral oxycodone/day, 8 mg oral hydromorphone/day, 25 mg oral oxymorphone/day or an equianalgesic dose of another opioid, for a week or longer. EXALGO is NOT intended for use as an as-needed analgesic. EXALGO is not indicated for the management of acute or postoperative pain. uuid:72739459-ad6d-4380-b8b8-f47c04f74344 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1090966 biolink:treats MONDO:0005276 PMID:41385096 "[{""id"":""uuid:41031e3c-9506-40aa-9b25-2f9b386fdb17"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:af89c0b7-f7e9-4a0f-abf0-679084f813fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Supplementation of the diet with vitamins A, C and D. Multi-Vitamin Fluoride Drops 0.25 mg also provide fluoride for caries prophylaxis. The American Academy of Pediatrics recommends that children up to age 16, in areas where drinking water contains less than optimal levels of fluoride, receive daily fluoride supplementation. The American Academy of Pediatrics recommend that infants and young children 6 months to 3 years of age, in areas where drinking water contains less than 0.3 ppm of fluoride, and children 3-6 years of age, in areas where the drinking water contains 0.3 through 0.6 ppm of fluoride, receive 0.25 mg of supplemental fluoride daily which is provided in a dose of 1 mL of Multi-Vitamin Fluoride 0.25 mg drops. (see Dosage and Administration ). Multi-Vitamin Fluoride 0.25 mg drops supply significant amounts of vitamins A, C and D to supplement the diet, and to help assure that nutritional deficiencies of these vitamins will not develop. Thus, in a single easy-to-use preparation, children obtain essential vitamins and fluoride. uuid:afc85fdb-7c92-4df9-b88e-30b3f65234be biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2922 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:4f4028c4-9b59-40fb-87be-b04e45e8a1d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c5f48a21-10ef-4513-92ba-a40d85916670"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RIDAURA (auranofin) is indicated in the management of adults with active classical or definite rheumatoid arthritis (ARA criteria) who have had an insufficient therapeutic response to, or are intolerant of, an adequate trial of full doses of one or more nonsteroidal anti-inflammatory drugs. RIDAURA should be added to a comprehensive baseline program, including non-drug therapies. Unlike anti-inflammatory drugs, RIDAURA does not produce an immediate response. Therapeutic effects may be seen after three to four months of treatment, although improvement has not been seen in some patients before six months. When cartilage and bone damage has already occurred, gold cannot reverse structural damage to joints caused by previous disease. The greatest potential benefit occurs in patients with active synovitis, particularly in its early stage. In controlled clinical trials comparing RIDAURA with injectable gold, RIDAURA was associated with fewer dropouts due to adverse reactions, while injectable gold was associated with fewer dropouts for inadequate or poor therapeutic effect. Physicians should consider these findings when deciding on the use of RIDAURA in patients who are candidates for chrysotherapy. uuid:0d625b16-1a65-486d-a182-7af6bc08a153 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71940 biolink:treats MONDO:0010811 PMID:41385096 "[{""id"":""uuid:254d9c6b-3800-4d7a-8bd0-542011842ce3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a49fb50b-390a-464b-8a54-3bcd38cba72b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:5f4371c6-ec1c-48f4-b44b-2fffb96be228"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/cialis""]},{""id"":""uuid:f36b3123-8a2f-4d07-b054-c48c2d13751d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CIALIS ® is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of: erectile dysfunction (ED) ( 1.1 ) the signs and symptoms of benign prostatic hyperplasia (BPH) ( 1.2 ) ED and the signs and symptoms of BPH (ED/BPH) ( 1.3 )|[EMA] Treatment of erectile dysfunction in adult males.In order for tadalafil to be effective, sexual stimulation is required.Tadalafil Lilly is not indicated for use by women.Treatment of the signs and symptoms of benign prostatic hyperplasia in adult males.|[PMDA] Drugs with a new indication and a new dosage in a new additional dosage form indicated for the treatment of dysuria associated with benign prostatic hypertrophy. uuid:c4b57dca-ef33-4700-af0b-92c89882165d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:11949636 biolink:treats MONDO:0043885 PMID:41385096 "[{""id"":""uuid:75893b54-f0f3-47a8-8e1d-20dd7b4a09f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5b05a108-12e9-4788-bbf3-88a2d6774995"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tobramycin and Dexamethasone Ophthalmic Suspension is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococci, including S. aureus and S. epidermidis (coagulase-positive and coagulase-negative), including penicillin-resistant strains. Streptococci, including some of the Group A-beta-hemolytic species, some nonhemolytic species, and some Streptococcus pneumoniae . Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, Proteus mirabilis, Morganella morganii, most Proteus vulgaris strains, Haemophilus influenzae and H. aegyptius, Moraxella lacunata, Acinetobacter calcoaceticus and some Neisseria species . uuid:23baa622-798d-4dbb-9faa-16eb628a2fb3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31897 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:bb56c8c5-3d94-4427-b69e-e1511a3c8500"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:51d492c5-02bb-4b86-8c57-eda306797bb7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:bce0cf61-910d-4ff8-bb51-fb0dfdcc8e92"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nateglinide Tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus.|[PMDA] Drugs with a new additional indication for the treatment of postprandial glucose excursions in Type 2 diabetes mellitus (for use only when treatment with thiazolidines in conjunction with dietary and exercise regimens is not sufficiently effective). uuid:4b106638-bae0-4ae8-b6ec-186c1fe7b237 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77590 biolink:treats MONDO:0007147 PMID:41385096 "[{""id"":""uuid:8fa69ea8-e863-4bc9-b868-5148121eee8e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bd75633a-920f-4aae-ac14-ea576f48ed04"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NUVIGIL is indicated to improve wakefulness in patients with excessive sleepiness associated with obstructive sleep apnea, narcolepsy and shift work disorder. In OSA, NUVIGIL is indicated as an adjunct to standard treatment(s) for the underlying obstruction. If continuous positive airway pressure (CPAP) is the treatment of choice for a patient, a maximal effort to treat with CPAP for an adequate period of time should be made prior to initiating NUVIGIL. If NUVIGIL is used adjunctively with CPAP, the encouragement of and periodic assessment of CPAP compliance is necessary. In all cases, careful attention to the diagnosis and treatment of the underlying sleep disorder(s) is of utmost importance. Prescribers should be aware that some patients may have more than one sleep disorder contributing to their excessive sleepiness. The effectiveness of NUVIGIL in long-term use (greater than 12 weeks) has not been systematically evaluated in placebo-controlled trials. The physician who elects to prescribe NUVIGIL for an extended time in patients should periodically re-evaluate long-term usefulness for the individual patient. uuid:ea01876b-2760-4890-9497-68b8a05d58cc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77590 biolink:treats MONDO:0021107 PMID:41385096 "[{""id"":""uuid:371ed4b1-b2a7-4cf8-a016-25e10229dcf3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f1c72c0d-1ad1-48ea-a16d-9852ecfb3e64"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NUVIGIL is indicated to improve wakefulness in patients with excessive sleepiness associated with obstructive sleep apnea, narcolepsy and shift work disorder. In OSA, NUVIGIL is indicated as an adjunct to standard treatment(s) for the underlying obstruction. If continuous positive airway pressure (CPAP) is the treatment of choice for a patient, a maximal effort to treat with CPAP for an adequate period of time should be made prior to initiating NUVIGIL. If NUVIGIL is used adjunctively with CPAP, the encouragement of and periodic assessment of CPAP compliance is necessary. In all cases, careful attention to the diagnosis and treatment of the underlying sleep disorder(s) is of utmost importance. Prescribers should be aware that some patients may have more than one sleep disorder contributing to their excessive sleepiness. The effectiveness of NUVIGIL in long-term use (greater than 12 weeks) has not been systematically evaluated in placebo-controlled trials. The physician who elects to prescribe NUVIGIL for an extended time in patients should periodically re-evaluate long-term usefulness for the individual patient. uuid:b9e30167-e6e6-4ad9-a2bb-a860a5d8b9ea biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77590 biolink:treats UMLS:C4087539 PMID:41385096 "[{""id"":""uuid:18472561-9c74-4772-9d15-4f42b1e457c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ca38a040-79ba-45a3-9614-2ef40af84bbd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NUVIGIL is indicated to improve wakefulness in patients with excessive sleepiness associated with obstructive sleep apnea, narcolepsy and shift work disorder. In OSA, NUVIGIL is indicated as an adjunct to standard treatment(s) for the underlying obstruction. If continuous positive airway pressure (CPAP) is the treatment of choice for a patient, a maximal effort to treat with CPAP for an adequate period of time should be made prior to initiating NUVIGIL. If NUVIGIL is used adjunctively with CPAP, the encouragement of and periodic assessment of CPAP compliance is necessary. In all cases, careful attention to the diagnosis and treatment of the underlying sleep disorder(s) is of utmost importance. Prescribers should be aware that some patients may have more than one sleep disorder contributing to their excessive sleepiness. The effectiveness of NUVIGIL in long-term use (greater than 12 weeks) has not been systematically evaluated in placebo-controlled trials. The physician who elects to prescribe NUVIGIL for an extended time in patients should periodically re-evaluate long-term usefulness for the individual patient. uuid:7d5b74e8-3116-4476-b140-5528b628c913 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50275 biolink:treats MONDO:0001126 PMID:41385096 "[{""id"":""uuid:4af1db8c-9d64-4b20-964c-be9df94b5b9c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7dc106bd-7d99-4c62-a66b-eca97f9ef624"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:5f2d4b7e-37bb-4818-82f3-242c69a0bdeb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NEXIUM is a proton pump inhibitor indicated for the following: Treatment of gastroesophageal reflux disease (GERD) (1.1) Risk reduction of NSAID-associated gastric ulcer (1.2) H. pylori eradication to reduce the risk of duodenal ulcer recurrence (1.3) Pathological hypersecretory conditions, including Zollinger-Ellison syndrome (1.4)|[PMDA] A drug with a new active ingredient indicated for the treatment of gastric ulcer, duodenal ulcer, anastomotic ulcer, reflux esophagitis, non-erosive reflux disease and Zollinger-Ellison syndrome, prevention of recurrence of gastric ulcer or duodenal ulcer in patients treated with nonsteroidal antiinflammatory drugs, and aid to eradication of Helicobacter pylori in patients with gastric ulcer, duodenal ulcer, gastric MALT lymphoma, idiopathic thrombocytopenic purpura, and stomach after endoscopic treatment for early gastric cancer. uuid:8a9c795d-e25e-407e-b70e-19954e642902 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50275 biolink:treats MONDO:0005412 PMID:41385096 "[{""id"":""uuid:f62db8dd-8651-414f-bca4-2eedd6202d16"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1a47b2e6-c414-44d3-a443-820c7856c4cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:170dc23c-344b-413a-a735-3e4a5de168f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NEXIUM is a proton pump inhibitor indicated for the following: Treatment of gastroesophageal reflux disease (GERD) (1.1) Risk reduction of NSAID-associated gastric ulcer (1.2) H. pylori eradication to reduce the risk of duodenal ulcer recurrence (1.3) Pathological hypersecretory conditions, including Zollinger-Ellison syndrome (1.4)|[PMDA] A drug with a new active ingredient indicated for the treatment of gastric ulcer, duodenal ulcer, anastomotic ulcer, reflux esophagitis, non-erosive reflux disease and Zollinger-Ellison syndrome, prevention of recurrence of gastric ulcer or duodenal ulcer in patients treated with nonsteroidal antiinflammatory drugs, and aid to eradication of Helicobacter pylori in patients with gastric ulcer, duodenal ulcer, gastric MALT lymphoma, idiopathic thrombocytopenic purpura, and stomach after endoscopic treatment for early gastric cancer. uuid:08927c08-ee8e-45f1-bba8-13da641513cc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:521033 biolink:treats MONDO:0010811 PMID:41385096 "[{""id"":""uuid:98a40b05-2258-4b34-afce-eb81be235051"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:afe0c6ac-5306-48d8-920a-36b8bc059ea5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:a9838f21-5123-439f-b2a5-6642e29f905d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AVODART is a 5 alpha-reductase inhibitor indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to: (1.1) improve symptoms, reduce the risk of acute urinary retention, and reduce the risk of the need for BPH-related surgery. AVODART in combination with the alpha adrenergic antagonist, tamsulosin, is indicated for the treatment of symptomatic BPH in men with an enlarged prostate. (1.2) Limitations of Use: AVODART is not approved for the prevention of prostate cancer. (1.3)|[PMDA] A drug with a new active ingredient indicated for the treatment of benign prostatic hyperplasia. uuid:95207305-a63c-4fee-8e64-17c60f836cff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:521033 biolink:treats UMLS:C0341742 PMID:41385096 "[{""id"":""uuid:99fda4c0-3f4c-43db-93a5-350b6c6e9d8a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a851bc64-a77b-467c-b8fa-d5cb8973ed5f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AVODART is a 5 alpha-reductase inhibitor indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to: (1.1) improve symptoms, reduce the risk of acute urinary retention, and reduce the risk of the need for BPH-related surgery. AVODART in combination with the alpha adrenergic antagonist, tamsulosin, is indicated for the treatment of symptomatic BPH in men with an enlarged prostate. (1.2) Limitations of Use: AVODART is not approved for the prevention of prostate cancer. (1.3) uuid:f4055363-4711-4742-89e8-3d62d6fe1625 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:9874151 biolink:treats MONDO:1010182 PMID:41385096 "[{""id"":""uuid:34f39b0f-a342-4337-8229-bf42a81852f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1afe153a-4082-4778-8a37-1d8f184ee5f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gianvi is indicated for the prevention of pregnancy in women who elect to use an oral contraceptive. Oral contraceptives are highly effective. Table II lists the typical unintended pregnancy rates for users of combination oral contraceptives and other methods of contraception. The efficacy of these contraceptive methods, except sterilization and contraceptive implants and IUDs, depends upon the reliability with which they are used. Correct and consistent use of methods can result in lower failure rates. Gianvi is also indicated for the treatment of symptoms of premenstrual dysphoric disorder (PMDD) in women who choose to use an oral contraceptive as their method of contraception. The effectiveness of Gianvi for PMDD when used for more than three menstrual cycles has not been evaluated. The essential features of PMDD according to the Diagnostic and Statistical Manual-4 th edition (DSM-IV) include markedly depressed mood, anxiety or tension, affective lability, and persistent anger or irritability. Other features include decreased interest in usual activities, difficulty concentrating, lack of energy, change in appetite or sleep, and feeling out of control. Physical symptoms associated with PMDD include breast tenderness, headache, joint and muscle pain, bloating and weight gain. In this disorder, these symptoms occur regularly during the luteal phase and remit within a few days following onset of menses; the disturbance markedly interferes with work or school, or with usual social activities and relationships with others. Diagnosis is made by healthcare providers according to DSM-IV criteria, with symptomatology assessed prospectively over at least two menstrual cycles. In making the diagnosis, care should be taken to rule out other cyclical mood disorders. Gianvi has not been evaluated for the treatment of premenstrual syndrome (PMS). Gianvi is indicated for the treatment of moderate acne vulgaris in women at least 14 years of age, who have no known contraindications to oral contraceptive therapy and have achieved menarche. Gianvi should be used for the treatment of acne only if the patient desires an oral contraceptive for birth control. TABLE II: Percentage of women experiencing an unintended pregnancy during the first year of typical use and first year of perfect use of contraception and the percentage continuing use at the end of the first year: United States. Source: Trussell J, Contraceptive efficacy. In Hatcher RA, Trussell J, Stewart F, Cates W, Stewart GK, Guest F, Kowal D, Contraceptive Technology: Seventeenth Revised Edition. New York NY: Irvington Publishers, 1998. % of Women Experiencing an Unintended Pregnancy Within the First Year of Use % of Women Continuing Use at One Year Among couples attempting to avoid pregnancy, the percentage who continue to use a method for one year. Method (1) Typical Use Among typical couples who initiate use of a method (not necessarily for the first time), the percentage who experience an accidental pregnancy during the first year if they do not stop use for any other reason. (2) Perfect Use Among couples who initiate use of a method (not necessarily for the first time) and who use it perfectly (both consistently and correctly). The percentage who experience an accidental pregnancy during the first year if they do not stop use for any reason. (3) (4) Chance The percents becoming pregnant in columns (2) and (3) are based on data from populations where contraception is not used and from women who cease using contraception in order to become pregnant. Among such populations, about 89% become pregnant within one year. This estimate was lowered slightly (to 85%) to represent the percentage who would become pregnant within one year among women now relying on reversible methods of contraception if they abandoned contraception altogether. 85 85 Spermicides Foams, creams, gels vaginal suppositories, and vaginal film. 26 6 40 Periodic abstinence 25 63 Calendar 9 Ovulation method 3 Sympto-thermal Cervical mucus (ovulation) method supplemented by calendar in the pre-ovulatory and basal body temperature in the post-ovulatory phases. 2 Post-ovulation 1 Withdrawal 19 4 Cap With spermicidal cream or jelly. Parous women 40 26 42 Nulliparous women 20 9 56 Sponge Parous women 40 20 42 Nulliparous women 20 9 56 Diaphragm 20 6 56 Condom Without spermicides. Female (Reality) 21 5 56 Male 14 3 61 Pill 5 71 progestin only 0.5 combined 0.1 IUD: Progesterone T 2 1.5 81 Copper T 380A 0.8 0.6 78 Lng 20 0.1 0.1 81 Depo Provera 0.3 0.3 70 Norplant and Norplant-2 0.05 0.05 88 Female sterilization 0.5 0.5 100 Male sterilization 0.15 0.1 100 Emergency Contraceptive Pills: Treatment initiated within 72 hours after unprotected intercourse reduces the risk of pregnancy by at least 75%. The treatment schedule is one dose within 72 hours after unprotected intercourse, and a second dose 12 hours after the first dose. The Food and Drug Administration has declared the following brands of oral contraceptives to be safe and effective for emergency contraception: Ovral (1 dose is 2 white pills), Alesse (1 dose is 5 pink pills), Nordette or Levlen (1 dose is 2 light-orange pills), Lo/Ovral (1 dose is 4 white pills), Triphasil or Tri-Levlen (1 dose is 4 yellow pills). Lactational Amenorrhea Method: LAM is a highly effective, temporary method of contraception. However, to maintain effective protection against pregnancy, another method of contraception must be used as soon as menstruation resumes, the frequency or duration of breastfeeds is reduced, bottle feeds are introduced, or the baby reaches six months of age. UMLS:C0520676 uuid:37551e16-5c4c-4a0a-9c80-ae47d917ac6a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6129 biolink:treats NCIT:C50476 PMID:41385096 "[{""id"":""uuid:79470d51-6de2-4d52-bb53-1e89ed7a7b8b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c6c99aca-4def-4b54-a7d1-3e73642236fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ketorolac tromethamine ophthalmic solution is indicated for the reduction of ocular pain and burning/stinging following corneal refraction surgery. uuid:bed2e0e3-8e23-48b1-86ca-89c2a6fa8e75 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6129 biolink:treats UMLS:C0677500 PMID:41385096 "[{""id"":""uuid:cb5592bd-b7fc-4e68-9b05-fae4fed66fe3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7ee7ed20-5b79-4257-bd07-adc0df552689"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ketorolac tromethamine ophthalmic solution is indicated for the reduction of ocular pain and burning/stinging following corneal refraction surgery. uuid:7aa7e47c-e0f5-492f-b073-fe9a42bb81dc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5959 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:94f365c6-fe9b-4d0c-acb4-f9e652408952"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:29085937-ad27-48da-8df7-5100ef9e6abf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:9205eb25-4de8-45e6-9a8c-d35066f9aced"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AVAPRO (irbesartan) is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents.|[PMDA] Drugs containing a new active ingredient indicated for the treatment of hypertension. uuid:8026f64b-d8ff-4c02-b9fa-956a4e2e9cf7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4909 biolink:treats MONDO:0011429 PMID:41385096 "[{""id"":""uuid:6339c10c-930c-404a-a9b9-a046dc6dea3d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ee6e79d1-793c-45ff-abd1-7cce46349b52"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of etodolac extended-release tablets and other treatment options before deciding to use etodolac extended-release tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Etodolac extended-release tablets are indicated: * For relief of signs and symptoms of juvenile arthritis * For relief of the signs and symptoms of rheumatoid arthritis * For relief of the signs and symptoms of osteoarthritis uuid:c78a59b2-0012-4000-af6b-2653498a11fd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7798 biolink:treats MONDO:0005812 PMID:41385096 "[{""id"":""uuid:05c51b9d-7483-4f86-81ea-78f24cc31dfa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9670ed6a-e77d-4be3-b1b8-d46cc8252c6b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:673ebb13-2924-4330-8b0e-491fcb9dffce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ebilfumin""]},{""id"":""uuid:ead84e06-3f9b-49ed-92fd-a8690d3ca865"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TAMIFLU is an influenza neuraminidase inhibitor indicated for: Treatment of influenza in patients 1 year and older who have been symptomatic for no more than 2 days. ( 1.1 ) Prophylaxis of influenza in patients 1 year and older. ( 1.2 ) Important Limitations of Use : Efficacy not established in patients who begin therapy after 48 hours of symptoms. ( 1.3 ) Not a substitute for annual influenza vaccination. ( 1.3 ) No evidence of efficacy for illness from agents other than influenza viruses types A and B. ( 1.3 ) Consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use. ( 1.3 )|[EMA] Treatment of influenzaIn patients one year of age and older who present with symptoms typical of influenza, when influenza virus is circulating in the community.Ebilfumin is indicated for the treatment of infants less than 1 year of age during a pandemic influenza outbreak (see section 5.2 of the SmPC). The treating physician should take into account the pathogenicity of the circulating strain and the underlying condition of the patient to ensure there is a potential benefit to the child.Prevention of influenzaPost-exposure prevention in individuals 1 year of age or older following contact with a clinically diagnosed influenza case when influenza virus is circulating in the community.The appropriate use of Ebilfumin for prevention of influenza should be determined on a case by case basis by the circumstances and the population requiring protection. In exceptional situations (e.g. in case of a mismatch between the circulating and vaccine virus strains, and a pandemic situation) seasonal prevention could be considered in individuals one year of age or older.Ebilfumin is indicated for post-exposure prevention of influenza in infants less than 1 year of age during a pandemic influenza outbreak (see section 5.2 of the SmPC).Ebilfumin is not a substitute for influenza vaccination.|[PMDA] Drugs with a new additional indication and a new dosage for prophylaxis of influenza A or B virus infections. uuid:13de3b71-ab22-4da4-88aa-ff7544ff1ac7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4974 biolink:treats MONDO:0043653 PMID:41385096 "[{""id"":""uuid:d59faaf6-dcd8-403a-8fc5-66c70eba526b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9e230f1e-228b-4eb4-85e8-aa34b844ccbd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Famciclovir tablets, a prodrug of penciclovir, is a nucleoside analog DNA polymerase inhibitor indicated for: Immunocompetent Adult Patients ( 1.1 ) Herpes labialis (cold sores) Treatment of recurrent episodes Genital herpes Treatment of recurrent episodes Suppressive therapy of recurrent episodes Herpes zoster (shingles) HIV-Infected Adult Patients ( 1.2 ) Treatment of recurrent episodes of orolabial or genital herpes Limitation of Use ( 1.3 ) The efficacy and safety of famciclovir tablets has not been established for: Patients < 18 years of age Immunocompromised patients other than for the treatment of recurrent episodes of orolabial or genital herpes in HIV-infected patients Black and African American patients with recurrent genital herpes uuid:a4d311e3-f5d0-4f00-b73e-3b8cc018440c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4974 biolink:treats MONDO:0005770 PMID:41385096 "[{""id"":""uuid:1cf88bac-7112-4fa8-982c-c23fee386257"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:afc53123-1af2-488b-9b49-a67a0eda53f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Famciclovir tablets, a prodrug of penciclovir, is a nucleoside analog DNA polymerase inhibitor indicated for: Immunocompetent Adult Patients ( 1.1 ) Herpes labialis (cold sores) Treatment of recurrent episodes Genital herpes Treatment of recurrent episodes Suppressive therapy of recurrent episodes Herpes zoster (shingles) HIV-Infected Adult Patients ( 1.2 ) Treatment of recurrent episodes of orolabial or genital herpes Limitation of Use ( 1.3 ) The efficacy and safety of famciclovir tablets has not been established for: Patients < 18 years of age Immunocompromised patients other than for the treatment of recurrent episodes of orolabial or genital herpes in HIV-infected patients Black and African American patients with recurrent genital herpes uuid:d894e9da-98b7-4c61-a678-f188d5544af2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4974 biolink:treats MONDO:0005609 PMID:41385096 "[{""id"":""uuid:4fdff029-76aa-4bcb-a2b5-25c7f42dd7dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:497642a0-233c-4bf1-87d5-6767838a8a63"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:833cfd44-2dce-4955-8d98-aa89d87b88ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Famciclovir tablets, a prodrug of penciclovir, is a nucleoside analog DNA polymerase inhibitor indicated for: Immunocompetent Adult Patients ( 1.1 ) Herpes labialis (cold sores) Treatment of recurrent episodes Genital herpes Treatment of recurrent episodes Suppressive therapy of recurrent episodes Herpes zoster (shingles) HIV-Infected Adult Patients ( 1.2 ) Treatment of recurrent episodes of orolabial or genital herpes Limitation of Use ( 1.3 ) The efficacy and safety of famciclovir tablets has not been established for: Patients < 18 years of age Immunocompromised patients other than for the treatment of recurrent episodes of orolabial or genital herpes in HIV-infected patients Black and African American patients with recurrent genital herpes|[PMDA] A drug containing a new active ingredient indicated for the treatment of herpes zoster. uuid:bd285197-12ef-4391-9a47-482b7ffaa2d7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:848151 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:c81f1a19-8864-427d-a1c9-49e3f823022f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:af25a911-5a41-49e8-9181-e221021221e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Exforge HCT (amlodipine, valsartan, hydrochlorothiazide) is indicated for the treatment of hypertension. This fixed combination drug is not indicated for the initial therapy of hypertension [see Dosage and Administration (2)]. uuid:48c02326-ca21-4ad6-b9cd-2081f7da4c7c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:284544 biolink:treats MONDO:0011438 PMID:41385096 "[{""id"":""uuid:d47f4648-a43c-46da-b07c-b7bbd4325225"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1572e654-4180-47a3-878a-4d10b25cd659"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BenzaClin Topical Gel is indicated for the topical treatment of acne vulgaris. uuid:f21c149c-90fe-49e7-829c-05fffb36500d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17594 biolink:treats MONDO:0000736 PMID:41385096 "[{""id"":""uuid:cdf1275a-07af-44f9-8012-6dfae190a17c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cc85ee90-dc12-4b10-a9ca-319dc8933469"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The gradual bleaching of hyperpigmented skin conditions such as chloasma, melasma, freckles, senile lentigines, and other unwanted areas of melanin hyperpigmentation. uuid:e7f01f57-0866-46b5-9d42-fcb3af37b16b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17594 biolink:treats MONDO:0021582 PMID:41385096 "[{""id"":""uuid:158bfa68-3558-4b95-b4f6-a92d014efd88"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8f432af4-cf12-496d-932f-8a421b4dd5c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The gradual bleaching of hyperpigmented skin conditions such as chloasma, melasma, freckles, senile lentigines, and other unwanted areas of melanin hyperpigmentation. uuid:bc3055b0-2d43-499d-874c-33eed931acb2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8865 biolink:treats MONDO:0005812 PMID:41385096 "[{""id"":""uuid:1186cead-67d9-435d-96df-b524481a988b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:224a3088-5214-44e8-86b5-91539ced4e43"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Rimantadine hydrochloride tablet is indicated for the prophylaxis and treatment of illness caused by various strains of influenza A virus in adults (17 years and older). Rimantadine hydrochloride tablet is indicated for prophylaxis against influenza A virus in children (1 year to 16 years of age). uuid:39c59844-c08b-41b8-b619-916788b9a890 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8865 biolink:treats UMLS:C0858004 PMID:41385096 "[{""id"":""uuid:51a46b3f-476d-49ef-bd02-2bd5fc728396"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ee946fd4-e0c6-4fa5-984e-4b732bfc7836"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Rimantadine hydrochloride tablet is indicated for the prophylaxis and treatment of illness caused by various strains of influenza A virus in adults (17 years and older). Rimantadine hydrochloride tablet is indicated for prophylaxis against influenza A virus in children (1 year to 16 years of age). uuid:8477fff2-7cfd-4230-9488-576ee66846fa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50659 biolink:treats MONDO:0004981 PMID:41385096 "[{""id"":""uuid:57a601da-39dc-4fc1-9f1b-760db62cb8ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:42acac26-478b-4349-926a-5950811d5d80"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:a75260ab-2658-4c6d-ac20-805a575d26d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/multaq-0""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] MULTAQ ® is indicated to reduce the risk of hospitalization for atrial fibrillation in patients in sinus rhythm with a history of paroxysmal or persistent atrial fibrillation (AF) [see Clinical Studies (14) ].|[EMA] Multaq is indicated for the maintenance of sinus rhythm after successful cardioversion in adult clinically stable patients with paroxysmal or persistent atrial fibrillation (AF). Due to its safety profile, Multaq should only be prescribed after alternative treatment options have been considered.Multaq should not be given to patients with left ventricular systolic dysfunction or to patients with current or previous episodes of heart failure. uuid:a4d475fc-f989-4083-a137-951b7b8acb9d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3515 biolink:treats MONDO:0021680 PMID:41385096 "[{""id"":""uuid:0ad23246-536f-40cf-bb94-0199c583c196"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:45111099-e949-43b6-824d-4722067665e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefuroxime axetil and other antibacterial drugs, cefuroxime axetil should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. NOTE: CEFUROXIME AXETIL TABLETS AND CEFUROXIME AXETIL FOR ORAL SUSPENSION ARE NOT BIO­EQUIVALENT AND ARE NOT SUBSTITUTABLE ON A MILLIGRAM-PER-MILLIGRAM BASIS (SEE CLINICAL PHARMACOLOGY ). Cefuroxime Axetil Tablets Cefuroxime axetil tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below: Pharyngitis/Tonsillitis caused by Streptococcus pyogenes. NOTE: The usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. Cefuroxime axetil tablets are generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefuroxime in the subsequent prevention of rheumatic fever are not available. Please also note that in all clinical trials, all isolates had to be sensitive to both penicillin and cefuroxime. There are no data from adequate and well-controlled trials to demonstrate the effectiveness of cefuroxime in the treatment of penicillin-resistant strains of Streptococcus pyogenes. Acute Bacterial Otitis Media caused by Streptococcus pneumoniae , Haemophilus influenzae (including beta-lactamase–producing strains), Moraxella catarrhalis (including beta-lactamase–producing strains), or Streptococcus pyogenes. Acute Bacterial Maxillary Sinusitis caused by Streptococcus pneumoniae or Haemophilus influenzae (non-beta-lactamase–producing strains only). (See CLINICAL STUDIES section.) NOTE: In view of the insufficient numbers of isolates of beta-lactamase–producing strains of Haemophilus influenzae and Moraxella catarrhalis that were obtained from clinical trials with cefuroxime axetil tablets for patients with acute bacterial maxillary sinusitis, it was not possible to adequately evaluate the effectiveness of cefuroxime axetil tablets for sinus infections known, suspected, or considered potentially to be caused by beta-lactamase–producing Haemophilus influenzae or Moraxella catarrhalis . Acute Bacterial Exacerbations of Chronic Bronchitis and Secondary Bacterial Infections of Acute Bronchitis caused by Streptococcus pneumoniae , Haemophilus influenzae (beta-lactamase negative strains), or Haemophilus parainfluenzae (beta-lactamase negative strains). (See DOSAGE AND ADMINISTRATION section and CLINICAL STUDIES section.) Uncomplicated Skin and Skin-Structure Infections caused by Staphylococcus aureus (including beta-lactamase–producing strains) or Streptococcus pyogenes. Uncomplicated Urinary Tract Infections caused by Escherichia coli or Klebsiella pneumoniae . Uncomplicated Gonorrhea, urethral and endocervical, caused by penicillinase-producing and non-penicillinase–producing strains of Neisseria gonorrhoeae and uncomplicated gonorrhea, rectal, in females, caused by non-penicillinase–producing strains of Neisseria gonorrhoeae . Early Lyme Disease (erythema migrans) caused by Borrelia burgdorferi. uuid:4bb1be59-490d-4d56-8727-2dbfb2074ec0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3515 biolink:treats MONDO:0017767 PMID:41385096 "[{""id"":""uuid:3590c71d-20c7-409b-8f68-43f7602e5f81"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1566a94a-6b02-4856-8ccd-59887afd64d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefuroxime axetil and other antibacterial drugs, cefuroxime axetil should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. NOTE: CEFUROXIME AXETIL TABLETS AND CEFUROXIME AXETIL FOR ORAL SUSPENSION ARE NOT BIO­EQUIVALENT AND ARE NOT SUBSTITUTABLE ON A MILLIGRAM-PER-MILLIGRAM BASIS (SEE CLINICAL PHARMACOLOGY ). Cefuroxime Axetil Tablets Cefuroxime axetil tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below: Pharyngitis/Tonsillitis caused by Streptococcus pyogenes. NOTE: The usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. Cefuroxime axetil tablets are generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefuroxime in the subsequent prevention of rheumatic fever are not available. Please also note that in all clinical trials, all isolates had to be sensitive to both penicillin and cefuroxime. There are no data from adequate and well-controlled trials to demonstrate the effectiveness of cefuroxime in the treatment of penicillin-resistant strains of Streptococcus pyogenes. Acute Bacterial Otitis Media caused by Streptococcus pneumoniae , Haemophilus influenzae (including beta-lactamase–producing strains), Moraxella catarrhalis (including beta-lactamase–producing strains), or Streptococcus pyogenes. Acute Bacterial Maxillary Sinusitis caused by Streptococcus pneumoniae or Haemophilus influenzae (non-beta-lactamase–producing strains only). (See CLINICAL STUDIES section.) NOTE: In view of the insufficient numbers of isolates of beta-lactamase–producing strains of Haemophilus influenzae and Moraxella catarrhalis that were obtained from clinical trials with cefuroxime axetil tablets for patients with acute bacterial maxillary sinusitis, it was not possible to adequately evaluate the effectiveness of cefuroxime axetil tablets for sinus infections known, suspected, or considered potentially to be caused by beta-lactamase–producing Haemophilus influenzae or Moraxella catarrhalis . Acute Bacterial Exacerbations of Chronic Bronchitis and Secondary Bacterial Infections of Acute Bronchitis caused by Streptococcus pneumoniae , Haemophilus influenzae (beta-lactamase negative strains), or Haemophilus parainfluenzae (beta-lactamase negative strains). (See DOSAGE AND ADMINISTRATION section and CLINICAL STUDIES section.) Uncomplicated Skin and Skin-Structure Infections caused by Staphylococcus aureus (including beta-lactamase–producing strains) or Streptococcus pyogenes. Uncomplicated Urinary Tract Infections caused by Escherichia coli or Klebsiella pneumoniae . Uncomplicated Gonorrhea, urethral and endocervical, caused by penicillinase-producing and non-penicillinase–producing strains of Neisseria gonorrhoeae and uncomplicated gonorrhea, rectal, in females, caused by non-penicillinase–producing strains of Neisseria gonorrhoeae . Early Lyme Disease (erythema migrans) caused by Borrelia burgdorferi. uuid:e74e12cc-d772-4561-923f-e93be15412da biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17303 biolink:treats NCIT:C27003 PMID:41385096 "[{""id"":""uuid:5c818371-24ba-4453-b080-2a14f9d2d0d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bd69283f-97a2-4967-bdbf-9b95ef1a98f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Morphine sulfate tablets contain morphine, an opioid analgesic, indicated for the relief of moderate to severe acute and chronic pain where use of an opioid analgesic is appropriate. uuid:66052a17-b513-4b60-88e6-aecbc057ac53 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17303 biolink:treats HP:0012532 PMID:41385096 "[{""id"":""uuid:0b1519ba-2e11-47ca-a388-509fd127a792"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b90d2983-7687-4034-87eb-7cf948790e73"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Morphine sulfate tablets contain morphine, an opioid analgesic, indicated for the relief of moderate to severe acute and chronic pain where use of an opioid analgesic is appropriate. uuid:ef5075ce-753c-4090-a8cc-20cc151222ea biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:46878853 biolink:treats HP:0003119 PMID:41385096 "[{""id"":""uuid:89406c50-ffd4-4956-8893-3bb06356ba6f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:51847e9b-49dc-417f-8a56-00729737d2a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Trilipix is a peroxisome proliferator receptor alpha (PPARα) activator indicated: In combination with a statin to reduce TG and increase HDL-C in patients with mixed dyslipidemia and CHD or a CHD risk equivalent who are on optimal statin therapy to achieve their LDL-C goal ( 1.1 ). As monotherapy to reduce TG in patients with severe hypertriglyceridemia ( 1.2 ). As monotherapy to reduce elevated LDL-C, Total-C, TG and Apo B, and to increase HDL-C in patients with primary hyperlipidemia or mixed dyslipidemia ( 1.3 ). Important Limitations of Use: No incremental benefit of Trilipix on cardiovascular morbidity and mortality over and above that demonstrated for statin monotherapy has been established. Fenofibrate at a dose equivalent to 135 mg of Trilipix was not shown to reduce coronary heart disease morbidity and mortality in 2 large, randomized controlled trials of patients with type 2 diabetes mellitus. uuid:27d6ea33-c756-4c7f-bf85-7c1f99926cbc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:46878853 biolink:treats MONDO:0005010 PMID:41385096 "[{""id"":""uuid:6743d68a-6d63-4bd2-b93d-da8a00081e41"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bcd6e22e-5519-4711-b01e-d0868a7a276f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Trilipix is a peroxisome proliferator receptor alpha (PPARα) activator indicated: In combination with a statin to reduce TG and increase HDL-C in patients with mixed dyslipidemia and CHD or a CHD risk equivalent who are on optimal statin therapy to achieve their LDL-C goal ( 1.1 ). As monotherapy to reduce TG in patients with severe hypertriglyceridemia ( 1.2 ). As monotherapy to reduce elevated LDL-C, Total-C, TG and Apo B, and to increase HDL-C in patients with primary hyperlipidemia or mixed dyslipidemia ( 1.3 ). Important Limitations of Use: No incremental benefit of Trilipix on cardiovascular morbidity and mortality over and above that demonstrated for statin monotherapy has been established. Fenofibrate at a dose equivalent to 135 mg of Trilipix was not shown to reduce coronary heart disease morbidity and mortality in 2 large, randomized controlled trials of patients with type 2 diabetes mellitus. uuid:014cc9b9-1605-4634-a08f-d2ce395168c5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:46878853 biolink:treats MONDO:0005347 PMID:41385096 "[{""id"":""uuid:78655d10-69b8-483e-bf25-14b237f1df09"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5c7e62ea-7104-45bb-a476-31681906c11c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Trilipix is a peroxisome proliferator receptor alpha (PPARα) activator indicated: In combination with a statin to reduce TG and increase HDL-C in patients with mixed dyslipidemia and CHD or a CHD risk equivalent who are on optimal statin therapy to achieve their LDL-C goal ( 1.1 ). As monotherapy to reduce TG in patients with severe hypertriglyceridemia ( 1.2 ). As monotherapy to reduce elevated LDL-C, Total-C, TG and Apo B, and to increase HDL-C in patients with primary hyperlipidemia or mixed dyslipidemia ( 1.3 ). Important Limitations of Use: No incremental benefit of Trilipix on cardiovascular morbidity and mortality over and above that demonstrated for statin monotherapy has been established. Fenofibrate at a dose equivalent to 135 mg of Trilipix was not shown to reduce coronary heart disease morbidity and mortality in 2 large, randomized controlled trials of patients with type 2 diabetes mellitus. uuid:60647b5d-81d4-4c7a-9eb8-07c88f991232 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:46878853 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:7335c131-13b0-4482-a421-97cfbf431689"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3116f26a-5aef-4815-bbe2-b9a7e4d5a9a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Trilipix is a peroxisome proliferator receptor alpha (PPARα) activator indicated: In combination with a statin to reduce TG and increase HDL-C in patients with mixed dyslipidemia and CHD or a CHD risk equivalent who are on optimal statin therapy to achieve their LDL-C goal ( 1.1 ). As monotherapy to reduce TG in patients with severe hypertriglyceridemia ( 1.2 ). As monotherapy to reduce elevated LDL-C, Total-C, TG and Apo B, and to increase HDL-C in patients with primary hyperlipidemia or mixed dyslipidemia ( 1.3 ). Important Limitations of Use: No incremental benefit of Trilipix on cardiovascular morbidity and mortality over and above that demonstrated for statin monotherapy has been established. Fenofibrate at a dose equivalent to 135 mg of Trilipix was not shown to reduce coronary heart disease morbidity and mortality in 2 large, randomized controlled trials of patients with type 2 diabetes mellitus. uuid:b76dcb75-6be5-47e4-9acb-9237acf6dae2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:46878853 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:1463c606-8205-4f9c-8a5b-a30945ca9b10"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ebe6a9b9-687d-4c88-a79e-a0abb6bd5e10"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Trilipix is a peroxisome proliferator receptor alpha (PPARα) activator indicated: In combination with a statin to reduce TG and increase HDL-C in patients with mixed dyslipidemia and CHD or a CHD risk equivalent who are on optimal statin therapy to achieve their LDL-C goal ( 1.1 ). As monotherapy to reduce TG in patients with severe hypertriglyceridemia ( 1.2 ). As monotherapy to reduce elevated LDL-C, Total-C, TG and Apo B, and to increase HDL-C in patients with primary hyperlipidemia or mixed dyslipidemia ( 1.3 ). Important Limitations of Use: No incremental benefit of Trilipix on cardiovascular morbidity and mortality over and above that demonstrated for statin monotherapy has been established. Fenofibrate at a dose equivalent to 135 mg of Trilipix was not shown to reduce coronary heart disease morbidity and mortality in 2 large, randomized controlled trials of patients with type 2 diabetes mellitus. uuid:2d3f2180-4b30-4851-88cd-1ee3ac80028c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2648852 biolink:treats MONDO:0010602 PMID:41385096 "[{""id"":""uuid:df9b2f88-319c-4390-a405-1e6edff7aee4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:409b2570-2f8b-4b6c-8906-38d9942c4fd4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The use of RECOMBINATE [Antihemophilic Factor (Recombinant)] is indicated in hemophilia A (classical hemophilia) for the prevention and control of hemorrhagic episodes. 2 RECOMBINATE is also indicated in the perioperative management of patients with hemophilia A (classical hemophilia). RECOMBINATE can be of therapeutic value in patients with acquired Factor VIII inhibitors not exceeding 10 Bethesda Units per mL. 3 In clinical studies with RECOMBINATE, patients with inhibitors who were entered into the previously treated patient trial and those previously untreated children who have developed inhibitor activity on study, showed clinical hemostatic response when the titer of inhibitor was less than 10 Bethesda Units per mL. However, in such uses, the dosage of RECOMBINATE should be controlled by frequent laboratory determinations of circulating Factor VIII levels as well as the clinical status of the patient. RECOMBINATE is not indicated in von Willebrand’s disease. uuid:c8297427-751a-4b5e-8f80-d3db313de615 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2648852 biolink:treats MONDO:0035735 PMID:41385096 "[{""id"":""uuid:f3ba1647-0301-4d19-b1fa-5c8003e5e13c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9b87d9e6-48d0-438e-8af4-59fdf33e4f39"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The use of RECOMBINATE [Antihemophilic Factor (Recombinant)] is indicated in hemophilia A (classical hemophilia) for the prevention and control of hemorrhagic episodes. 2 RECOMBINATE is also indicated in the perioperative management of patients with hemophilia A (classical hemophilia). RECOMBINATE can be of therapeutic value in patients with acquired Factor VIII inhibitors not exceeding 10 Bethesda Units per mL. 3 In clinical studies with RECOMBINATE, patients with inhibitors who were entered into the previously treated patient trial and those previously untreated children who have developed inhibitor activity on study, showed clinical hemostatic response when the titer of inhibitor was less than 10 Bethesda Units per mL. However, in such uses, the dosage of RECOMBINATE should be controlled by frequent laboratory determinations of circulating Factor VIII levels as well as the clinical status of the patient. RECOMBINATE is not indicated in von Willebrand’s disease. uuid:d217cd42-e49a-4de8-a64f-ee6ecd2e3047 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2648852 biolink:treats MONDO:0024574 PMID:41385096 "[{""id"":""uuid:2297dfbd-85b2-4368-b4f6-56e95e5fd55a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:acf7ea28-4501-4d1f-9a82-2631b939985b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The use of RECOMBINATE [Antihemophilic Factor (Recombinant)] is indicated in hemophilia A (classical hemophilia) for the prevention and control of hemorrhagic episodes. 2 RECOMBINATE is also indicated in the perioperative management of patients with hemophilia A (classical hemophilia). RECOMBINATE can be of therapeutic value in patients with acquired Factor VIII inhibitors not exceeding 10 Bethesda Units per mL. 3 In clinical studies with RECOMBINATE, patients with inhibitors who were entered into the previously treated patient trial and those previously untreated children who have developed inhibitor activity on study, showed clinical hemostatic response when the titer of inhibitor was less than 10 Bethesda Units per mL. However, in such uses, the dosage of RECOMBINATE should be controlled by frequent laboratory determinations of circulating Factor VIII levels as well as the clinical status of the patient. RECOMBINATE is not indicated in von Willebrand’s disease. uuid:c9568a5c-9eec-4655-91d4-c40e093432b6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:56841546 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:b3dd4f13-4100-4b31-925d-815a4da0d89f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:007f500e-ca17-4499-bab9-f393bc32a2f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TEVETEN ® HCT is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensives such as calcium channel blockers. This fixed dose combination is not indicated for initial therapy (see DOSAGE AND ADMINISTRATION ). uuid:628f5cc0-590a-4090-b122-bda2e91411be biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:189563 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:e932a637-6623-44aa-a214-ba8825516511"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bc69dade-9c30-48dd-b97c-5dad9a611298"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BYSTOLIC is a beta-adrenergic blocking agent indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) uuid:5cfd00eb-e4b9-4a2a-8219-0bf67cbf7bb8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:189563 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:30659029-8eb1-4b68-a2c9-bfd4c7328a8f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:40225798-7ee1-4d8a-aecc-7ad3d9975a19"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BYSTOLIC is a beta-adrenergic blocking agent indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) uuid:7881bd78-b76c-4aef-9021-5b0ea24225cb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:189563 biolink:treats MONDO:0006652 PMID:41385096 "[{""id"":""uuid:6f06ac19-923e-4148-8e51-4631e3221163"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:70a32a1e-53f3-4cea-a234-abf8c2eec1b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BYSTOLIC is a beta-adrenergic blocking agent indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) uuid:787d5819-2478-4fa0-882f-9e3a92b15d7b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:216653 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:07841c87-85cc-45fb-aa66-b6127c7d1256"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e1ec6693-4cb4-47ff-a685-867a23bd05d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diovan HCT (valsartan and hydrochlorothiazide, USP) is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including hydrochlorothiazide and the ARB class to which valsartan principally belongs. There are no controlled trials demonstrating risk reduction with Diovan HCT. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Diovan HCT may be used in patients whose blood pressure is not adequately controlled on monotherapy. Diovan HCT may be used as initial therapy in patients who are likely to need multiple drugs to achieve blood pressure goals. The choice of Diovan HCT as initial therapy for hypertension should be based on an assessment of potential benefits and risks. Patients with stage 2 hypertension are at a relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. The decision to use a combination as initial therapy should be individualized and should be shaped by considerations such as baseline blood pressure, the target goal and the incremental likelihood of achieving goal with a combination compared to monotherapy. Individual blood pressure goals may vary based upon the patient’s risk. Data from the high dose multifactorial trial [ see Clinical Studies (14.1)] provides estimates of the probability of reaching a target blood pressure with Diovan HCT compared to valsartan or hydrochlorothiazide monotherapy. The figures below provide estimates of the likelihood of achieving systolic or diastolic blood pressure control with Diovan HCT 320/25 mg, based upon baseline systolic or diastolic blood pressure. The curve of each treatment group was estimated by logistic regression modeling. The estimated likelihood at the right tail of each curve is less reliable due to small numbers of subjects with high baseline blood pressures. Figure 1 : Probability of Achieving Systolic Blood Pressure <140 mmHg at Week 8 Figure 2 : Probability of Achieving Diastolic Blood Pressure <90 mmHg at Week 8 Figure 3 : Probability of Achieving Systolic Blood Pressure <130 mmHg at Week 8 Figure 4 : Probability of Achieving Diastolic Blood Pressure <80 mmHg at Week 8 For example, a patient with a baseline blood pressure of 160/100 mmHg has about a 41% likelihood of achieving a goal of <140 mmHg (systolic) and 60% likelihood of achieving <90 mmHg (diastolic) on valsartan alone and the likelihood of achieving these goals on HCTZ alone is about 50% (systolic) or 57% (diastolic). The likelihood of achieving these goals on Diovan HCT rises to about 84% (systolic) or 80% (diastolic). The likelihood of achieving these goals on placebo is about 23% (systolic) or 36% (diastolic). uuid:86f5687a-d0a7-49f2-b6af-7a278aac22c3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:216653 biolink:treats MONDO:0005016 PMID:41385096 "[{""id"":""uuid:9acdc5ed-2875-4576-9ba4-db3747a006b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fbd908de-b190-4d92-a3cc-fce720d435bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diovan HCT (valsartan and hydrochlorothiazide, USP) is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including hydrochlorothiazide and the ARB class to which valsartan principally belongs. There are no controlled trials demonstrating risk reduction with Diovan HCT. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Diovan HCT may be used in patients whose blood pressure is not adequately controlled on monotherapy. Diovan HCT may be used as initial therapy in patients who are likely to need multiple drugs to achieve blood pressure goals. The choice of Diovan HCT as initial therapy for hypertension should be based on an assessment of potential benefits and risks. Patients with stage 2 hypertension are at a relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. The decision to use a combination as initial therapy should be individualized and should be shaped by considerations such as baseline blood pressure, the target goal and the incremental likelihood of achieving goal with a combination compared to monotherapy. Individual blood pressure goals may vary based upon the patient’s risk. Data from the high dose multifactorial trial [ see Clinical Studies (14.1)] provides estimates of the probability of reaching a target blood pressure with Diovan HCT compared to valsartan or hydrochlorothiazide monotherapy. The figures below provide estimates of the likelihood of achieving systolic or diastolic blood pressure control with Diovan HCT 320/25 mg, based upon baseline systolic or diastolic blood pressure. The curve of each treatment group was estimated by logistic regression modeling. The estimated likelihood at the right tail of each curve is less reliable due to small numbers of subjects with high baseline blood pressures. Figure 1 : Probability of Achieving Systolic Blood Pressure <140 mmHg at Week 8 Figure 2 : Probability of Achieving Diastolic Blood Pressure <90 mmHg at Week 8 Figure 3 : Probability of Achieving Systolic Blood Pressure <130 mmHg at Week 8 Figure 4 : Probability of Achieving Diastolic Blood Pressure <80 mmHg at Week 8 For example, a patient with a baseline blood pressure of 160/100 mmHg has about a 41% likelihood of achieving a goal of <140 mmHg (systolic) and 60% likelihood of achieving <90 mmHg (diastolic) on valsartan alone and the likelihood of achieving these goals on HCTZ alone is about 50% (systolic) or 57% (diastolic). The likelihood of achieving these goals on Diovan HCT rises to about 84% (systolic) or 80% (diastolic). The likelihood of achieving these goals on placebo is about 23% (systolic) or 36% (diastolic). uuid:35e0bc53-7cee-49eb-8e7a-c96068a6317d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:216653 biolink:treats HP:0001681 PMID:41385096 "[{""id"":""uuid:16bf7d38-5d7c-45ea-8696-df3f5814dc01"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:47ba8240-a5a9-4a31-bdb8-d1b38d3533af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diovan HCT (valsartan and hydrochlorothiazide, USP) is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including hydrochlorothiazide and the ARB class to which valsartan principally belongs. There are no controlled trials demonstrating risk reduction with Diovan HCT. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Diovan HCT may be used in patients whose blood pressure is not adequately controlled on monotherapy. Diovan HCT may be used as initial therapy in patients who are likely to need multiple drugs to achieve blood pressure goals. The choice of Diovan HCT as initial therapy for hypertension should be based on an assessment of potential benefits and risks. Patients with stage 2 hypertension are at a relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. The decision to use a combination as initial therapy should be individualized and should be shaped by considerations such as baseline blood pressure, the target goal and the incremental likelihood of achieving goal with a combination compared to monotherapy. Individual blood pressure goals may vary based upon the patient’s risk. Data from the high dose multifactorial trial [ see Clinical Studies (14.1)] provides estimates of the probability of reaching a target blood pressure with Diovan HCT compared to valsartan or hydrochlorothiazide monotherapy. The figures below provide estimates of the likelihood of achieving systolic or diastolic blood pressure control with Diovan HCT 320/25 mg, based upon baseline systolic or diastolic blood pressure. The curve of each treatment group was estimated by logistic regression modeling. The estimated likelihood at the right tail of each curve is less reliable due to small numbers of subjects with high baseline blood pressures. Figure 1 : Probability of Achieving Systolic Blood Pressure <140 mmHg at Week 8 Figure 2 : Probability of Achieving Diastolic Blood Pressure <90 mmHg at Week 8 Figure 3 : Probability of Achieving Systolic Blood Pressure <130 mmHg at Week 8 Figure 4 : Probability of Achieving Diastolic Blood Pressure <80 mmHg at Week 8 For example, a patient with a baseline blood pressure of 160/100 mmHg has about a 41% likelihood of achieving a goal of <140 mmHg (systolic) and 60% likelihood of achieving <90 mmHg (diastolic) on valsartan alone and the likelihood of achieving these goals on HCTZ alone is about 50% (systolic) or 57% (diastolic). The likelihood of achieving these goals on Diovan HCT rises to about 84% (systolic) or 80% (diastolic). The likelihood of achieving these goals on placebo is about 23% (systolic) or 36% (diastolic). uuid:fd87efb6-4fd0-4fd5-abd6-a37ba5c541e2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:216653 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:444c4201-a177-42f9-8e52-a8ca4aa2b8d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7978ad09-4369-4734-88d3-a1051ffa7d01"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diovan HCT (valsartan and hydrochlorothiazide, USP) is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including hydrochlorothiazide and the ARB class to which valsartan principally belongs. There are no controlled trials demonstrating risk reduction with Diovan HCT. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Diovan HCT may be used in patients whose blood pressure is not adequately controlled on monotherapy. Diovan HCT may be used as initial therapy in patients who are likely to need multiple drugs to achieve blood pressure goals. The choice of Diovan HCT as initial therapy for hypertension should be based on an assessment of potential benefits and risks. Patients with stage 2 hypertension are at a relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. The decision to use a combination as initial therapy should be individualized and should be shaped by considerations such as baseline blood pressure, the target goal and the incremental likelihood of achieving goal with a combination compared to monotherapy. Individual blood pressure goals may vary based upon the patient’s risk. Data from the high dose multifactorial trial [ see Clinical Studies (14.1)] provides estimates of the probability of reaching a target blood pressure with Diovan HCT compared to valsartan or hydrochlorothiazide monotherapy. The figures below provide estimates of the likelihood of achieving systolic or diastolic blood pressure control with Diovan HCT 320/25 mg, based upon baseline systolic or diastolic blood pressure. The curve of each treatment group was estimated by logistic regression modeling. The estimated likelihood at the right tail of each curve is less reliable due to small numbers of subjects with high baseline blood pressures. Figure 1 : Probability of Achieving Systolic Blood Pressure <140 mmHg at Week 8 Figure 2 : Probability of Achieving Diastolic Blood Pressure <90 mmHg at Week 8 Figure 3 : Probability of Achieving Systolic Blood Pressure <130 mmHg at Week 8 Figure 4 : Probability of Achieving Diastolic Blood Pressure <80 mmHg at Week 8 For example, a patient with a baseline blood pressure of 160/100 mmHg has about a 41% likelihood of achieving a goal of <140 mmHg (systolic) and 60% likelihood of achieving <90 mmHg (diastolic) on valsartan alone and the likelihood of achieving these goals on HCTZ alone is about 50% (systolic) or 57% (diastolic). The likelihood of achieving these goals on Diovan HCT rises to about 84% (systolic) or 80% (diastolic). The likelihood of achieving these goals on placebo is about 23% (systolic) or 36% (diastolic). uuid:8af817aa-6c38-44ea-972d-9f2216f263f9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1152286 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:b6b336ba-a406-401d-8225-a76677f97d99"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ffc7fcce-4909-4a8a-be32-660ca040ccf5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azor is indicated for the treatment of hypertension, alone or with other antihypertensive agents , to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Azor. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Azor may also be used as initial therapy in patients who are likely to need multiple antihypertensive agents to achieve their blood pressure goals. Patients with moderate or severe hypertension are at relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. The decision to use a combination as initial therapy should be individualized and should be shaped by considerations such as baseline blood pressure, the target goal, and the incremental likelihood of achieving goal with a combination compared to monotherapy. Individual blood pressure goals may vary based upon the patient’s risk. Data from an 8-week, placebo-controlled, parallel-group factorial study [see Clinical Studies (14.1) ] provide estimates of the probability of reaching a blood pressure goal with Azor compared to amlodipine or olmesartan medoxomil monotherapy. The figures below provide estimates of the likelihood of achieving the targeted systolic or diastolic blood pressure goals with Azor 10/40 mg compared with amlodipine or olmesartan medoxomil monotherapy, based upon baseline systolic or diastolic blood pressure. The curve of each treatment group was estimated by logistic regression modeling from all available data of that treatment group. The right tail of each curve is less reliable because of small numbers of subjects with high baseline blood pressures. Figure 1: Probability of Achieving Systolic Blood Pressure (SBP) <140 mmHg at Week 8 With LOCF Figure 2: Probability of Achieving Diastolic Blood Pressure (DBP) <90 mmHg at Week 8 With LOCF Figure 3: Probability of Achieving Systolic Blood Pressure (SBP) <130 mmHg at Week 8 With LOCF Figure 4: Probability of Achieving Diastolic Blood Pressure (DBP) <80 mmHg at Week 8 With LOCF The figures above provide an approximation of the likelihood of reaching a targeted blood pressure goal (e.g., Week 8 SBP <140 mmHg or <130 mmHg or a DBP <90 mmHg or <80 mmHg) for the high-dose treatment groups evaluated in the study. Azor 5/20 mg, the lowest dose combination treatment group, increases the probability of reaching blood pressure goal compared with the highest dose monotherapies, amlodipine 10 mg and olmesartan medoxomil 40 mg. For example, a patient with a baseline blood pressure of 160/100 mmHg has about a 48% likelihood of achieving a goal of <140 mmHg (systolic) and a 51% likelihood of achieving a goal of <90 mmHg (diastolic) on monotherapy with olmesartan medoxomil 40 mg, and about a 46% likelihood of achieving a goal of <140 mmHg (systolic) and a 60% likelihood of achieving a goal of <90 mmHg (diastolic) on monotherapy with amlodipine 10 mg. The likelihood of achieving these same goals increases to 63% (systolic) and 71% (diastolic) on Azor 5/20 mg, and to 68% (systolic) and 85% (diastolic) on Azor 10/40 mg. uuid:df268caf-fffa-4a31-b7d2-03d830de20b8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1152286 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:87f7735f-837b-4407-9662-58b6bcb8d977"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:da1f3385-2001-4314-b859-e60217be2fec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azor is indicated for the treatment of hypertension, alone or with other antihypertensive agents , to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Azor. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Azor may also be used as initial therapy in patients who are likely to need multiple antihypertensive agents to achieve their blood pressure goals. Patients with moderate or severe hypertension are at relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. The decision to use a combination as initial therapy should be individualized and should be shaped by considerations such as baseline blood pressure, the target goal, and the incremental likelihood of achieving goal with a combination compared to monotherapy. Individual blood pressure goals may vary based upon the patient’s risk. Data from an 8-week, placebo-controlled, parallel-group factorial study [see Clinical Studies (14.1) ] provide estimates of the probability of reaching a blood pressure goal with Azor compared to amlodipine or olmesartan medoxomil monotherapy. The figures below provide estimates of the likelihood of achieving the targeted systolic or diastolic blood pressure goals with Azor 10/40 mg compared with amlodipine or olmesartan medoxomil monotherapy, based upon baseline systolic or diastolic blood pressure. The curve of each treatment group was estimated by logistic regression modeling from all available data of that treatment group. The right tail of each curve is less reliable because of small numbers of subjects with high baseline blood pressures. Figure 1: Probability of Achieving Systolic Blood Pressure (SBP) <140 mmHg at Week 8 With LOCF Figure 2: Probability of Achieving Diastolic Blood Pressure (DBP) <90 mmHg at Week 8 With LOCF Figure 3: Probability of Achieving Systolic Blood Pressure (SBP) <130 mmHg at Week 8 With LOCF Figure 4: Probability of Achieving Diastolic Blood Pressure (DBP) <80 mmHg at Week 8 With LOCF The figures above provide an approximation of the likelihood of reaching a targeted blood pressure goal (e.g., Week 8 SBP <140 mmHg or <130 mmHg or a DBP <90 mmHg or <80 mmHg) for the high-dose treatment groups evaluated in the study. Azor 5/20 mg, the lowest dose combination treatment group, increases the probability of reaching blood pressure goal compared with the highest dose monotherapies, amlodipine 10 mg and olmesartan medoxomil 40 mg. For example, a patient with a baseline blood pressure of 160/100 mmHg has about a 48% likelihood of achieving a goal of <140 mmHg (systolic) and a 51% likelihood of achieving a goal of <90 mmHg (diastolic) on monotherapy with olmesartan medoxomil 40 mg, and about a 46% likelihood of achieving a goal of <140 mmHg (systolic) and a 60% likelihood of achieving a goal of <90 mmHg (diastolic) on monotherapy with amlodipine 10 mg. The likelihood of achieving these same goals increases to 63% (systolic) and 71% (diastolic) on Azor 5/20 mg, and to 68% (systolic) and 85% (diastolic) on Azor 10/40 mg. uuid:c70bf636-971d-4e0b-b0d9-8c282c03d98d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1152286 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:bb5ceda3-cdc5-4156-835a-dcd85c372e5f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b56851d5-6c22-4c43-925c-654f33a2eb8c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azor is indicated for the treatment of hypertension, alone or with other antihypertensive agents , to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Azor. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Azor may also be used as initial therapy in patients who are likely to need multiple antihypertensive agents to achieve their blood pressure goals. Patients with moderate or severe hypertension are at relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. The decision to use a combination as initial therapy should be individualized and should be shaped by considerations such as baseline blood pressure, the target goal, and the incremental likelihood of achieving goal with a combination compared to monotherapy. Individual blood pressure goals may vary based upon the patient’s risk. Data from an 8-week, placebo-controlled, parallel-group factorial study [see Clinical Studies (14.1) ] provide estimates of the probability of reaching a blood pressure goal with Azor compared to amlodipine or olmesartan medoxomil monotherapy. The figures below provide estimates of the likelihood of achieving the targeted systolic or diastolic blood pressure goals with Azor 10/40 mg compared with amlodipine or olmesartan medoxomil monotherapy, based upon baseline systolic or diastolic blood pressure. The curve of each treatment group was estimated by logistic regression modeling from all available data of that treatment group. The right tail of each curve is less reliable because of small numbers of subjects with high baseline blood pressures. Figure 1: Probability of Achieving Systolic Blood Pressure (SBP) <140 mmHg at Week 8 With LOCF Figure 2: Probability of Achieving Diastolic Blood Pressure (DBP) <90 mmHg at Week 8 With LOCF Figure 3: Probability of Achieving Systolic Blood Pressure (SBP) <130 mmHg at Week 8 With LOCF Figure 4: Probability of Achieving Diastolic Blood Pressure (DBP) <80 mmHg at Week 8 With LOCF The figures above provide an approximation of the likelihood of reaching a targeted blood pressure goal (e.g., Week 8 SBP <140 mmHg or <130 mmHg or a DBP <90 mmHg or <80 mmHg) for the high-dose treatment groups evaluated in the study. Azor 5/20 mg, the lowest dose combination treatment group, increases the probability of reaching blood pressure goal compared with the highest dose monotherapies, amlodipine 10 mg and olmesartan medoxomil 40 mg. For example, a patient with a baseline blood pressure of 160/100 mmHg has about a 48% likelihood of achieving a goal of <140 mmHg (systolic) and a 51% likelihood of achieving a goal of <90 mmHg (diastolic) on monotherapy with olmesartan medoxomil 40 mg, and about a 46% likelihood of achieving a goal of <140 mmHg (systolic) and a 60% likelihood of achieving a goal of <90 mmHg (diastolic) on monotherapy with amlodipine 10 mg. The likelihood of achieving these same goals increases to 63% (systolic) and 71% (diastolic) on Azor 5/20 mg, and to 68% (systolic) and 85% (diastolic) on Azor 10/40 mg. uuid:27c078dd-62ff-4c6c-80bc-003273ee485d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1152286 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:b984f79c-7ab7-449b-aa64-4a872a1fe467"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7ccb3a5b-aa21-42d7-b17c-8b1d6a6c166b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azor is indicated for the treatment of hypertension, alone or with other antihypertensive agents , to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Azor. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Azor may also be used as initial therapy in patients who are likely to need multiple antihypertensive agents to achieve their blood pressure goals. Patients with moderate or severe hypertension are at relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. The decision to use a combination as initial therapy should be individualized and should be shaped by considerations such as baseline blood pressure, the target goal, and the incremental likelihood of achieving goal with a combination compared to monotherapy. Individual blood pressure goals may vary based upon the patient’s risk. Data from an 8-week, placebo-controlled, parallel-group factorial study [see Clinical Studies (14.1) ] provide estimates of the probability of reaching a blood pressure goal with Azor compared to amlodipine or olmesartan medoxomil monotherapy. The figures below provide estimates of the likelihood of achieving the targeted systolic or diastolic blood pressure goals with Azor 10/40 mg compared with amlodipine or olmesartan medoxomil monotherapy, based upon baseline systolic or diastolic blood pressure. The curve of each treatment group was estimated by logistic regression modeling from all available data of that treatment group. The right tail of each curve is less reliable because of small numbers of subjects with high baseline blood pressures. Figure 1: Probability of Achieving Systolic Blood Pressure (SBP) <140 mmHg at Week 8 With LOCF Figure 2: Probability of Achieving Diastolic Blood Pressure (DBP) <90 mmHg at Week 8 With LOCF Figure 3: Probability of Achieving Systolic Blood Pressure (SBP) <130 mmHg at Week 8 With LOCF Figure 4: Probability of Achieving Diastolic Blood Pressure (DBP) <80 mmHg at Week 8 With LOCF The figures above provide an approximation of the likelihood of reaching a targeted blood pressure goal (e.g., Week 8 SBP <140 mmHg or <130 mmHg or a DBP <90 mmHg or <80 mmHg) for the high-dose treatment groups evaluated in the study. Azor 5/20 mg, the lowest dose combination treatment group, increases the probability of reaching blood pressure goal compared with the highest dose monotherapies, amlodipine 10 mg and olmesartan medoxomil 40 mg. For example, a patient with a baseline blood pressure of 160/100 mmHg has about a 48% likelihood of achieving a goal of <140 mmHg (systolic) and a 51% likelihood of achieving a goal of <90 mmHg (diastolic) on monotherapy with olmesartan medoxomil 40 mg, and about a 46% likelihood of achieving a goal of <140 mmHg (systolic) and a 60% likelihood of achieving a goal of <90 mmHg (diastolic) on monotherapy with amlodipine 10 mg. The likelihood of achieving these same goals increases to 63% (systolic) and 71% (diastolic) on Azor 5/20 mg, and to 68% (systolic) and 85% (diastolic) on Azor 10/40 mg. uuid:e20fde07-4d51-4594-ac95-0e219583862f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1152286 biolink:treats MONDO:0005016 PMID:41385096 "[{""id"":""uuid:dc0f67f1-2925-496d-af39-016912d32fe6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3a33761d-4d10-454b-8d4a-ad4f7b75b430"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azor is indicated for the treatment of hypertension, alone or with other antihypertensive agents , to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Azor. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Azor may also be used as initial therapy in patients who are likely to need multiple antihypertensive agents to achieve their blood pressure goals. Patients with moderate or severe hypertension are at relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. The decision to use a combination as initial therapy should be individualized and should be shaped by considerations such as baseline blood pressure, the target goal, and the incremental likelihood of achieving goal with a combination compared to monotherapy. Individual blood pressure goals may vary based upon the patient’s risk. Data from an 8-week, placebo-controlled, parallel-group factorial study [see Clinical Studies (14.1) ] provide estimates of the probability of reaching a blood pressure goal with Azor compared to amlodipine or olmesartan medoxomil monotherapy. The figures below provide estimates of the likelihood of achieving the targeted systolic or diastolic blood pressure goals with Azor 10/40 mg compared with amlodipine or olmesartan medoxomil monotherapy, based upon baseline systolic or diastolic blood pressure. The curve of each treatment group was estimated by logistic regression modeling from all available data of that treatment group. The right tail of each curve is less reliable because of small numbers of subjects with high baseline blood pressures. Figure 1: Probability of Achieving Systolic Blood Pressure (SBP) <140 mmHg at Week 8 With LOCF Figure 2: Probability of Achieving Diastolic Blood Pressure (DBP) <90 mmHg at Week 8 With LOCF Figure 3: Probability of Achieving Systolic Blood Pressure (SBP) <130 mmHg at Week 8 With LOCF Figure 4: Probability of Achieving Diastolic Blood Pressure (DBP) <80 mmHg at Week 8 With LOCF The figures above provide an approximation of the likelihood of reaching a targeted blood pressure goal (e.g., Week 8 SBP <140 mmHg or <130 mmHg or a DBP <90 mmHg or <80 mmHg) for the high-dose treatment groups evaluated in the study. Azor 5/20 mg, the lowest dose combination treatment group, increases the probability of reaching blood pressure goal compared with the highest dose monotherapies, amlodipine 10 mg and olmesartan medoxomil 40 mg. For example, a patient with a baseline blood pressure of 160/100 mmHg has about a 48% likelihood of achieving a goal of <140 mmHg (systolic) and a 51% likelihood of achieving a goal of <90 mmHg (diastolic) on monotherapy with olmesartan medoxomil 40 mg, and about a 46% likelihood of achieving a goal of <140 mmHg (systolic) and a 60% likelihood of achieving a goal of <90 mmHg (diastolic) on monotherapy with amlodipine 10 mg. The likelihood of achieving these same goals increases to 63% (systolic) and 71% (diastolic) on Azor 5/20 mg, and to 68% (systolic) and 85% (diastolic) on Azor 10/40 mg. uuid:309ce4d4-5855-4acd-b9cf-4b99d61ba6a0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1152286 biolink:treats HP:0001681 PMID:41385096 "[{""id"":""uuid:baad2d04-8152-461b-bcdf-169f822006ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:52864b0a-07da-4479-a87e-d559794623c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azor is indicated for the treatment of hypertension, alone or with other antihypertensive agents , to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Azor. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Azor may also be used as initial therapy in patients who are likely to need multiple antihypertensive agents to achieve their blood pressure goals. Patients with moderate or severe hypertension are at relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. The decision to use a combination as initial therapy should be individualized and should be shaped by considerations such as baseline blood pressure, the target goal, and the incremental likelihood of achieving goal with a combination compared to monotherapy. Individual blood pressure goals may vary based upon the patient’s risk. Data from an 8-week, placebo-controlled, parallel-group factorial study [see Clinical Studies (14.1) ] provide estimates of the probability of reaching a blood pressure goal with Azor compared to amlodipine or olmesartan medoxomil monotherapy. The figures below provide estimates of the likelihood of achieving the targeted systolic or diastolic blood pressure goals with Azor 10/40 mg compared with amlodipine or olmesartan medoxomil monotherapy, based upon baseline systolic or diastolic blood pressure. The curve of each treatment group was estimated by logistic regression modeling from all available data of that treatment group. The right tail of each curve is less reliable because of small numbers of subjects with high baseline blood pressures. Figure 1: Probability of Achieving Systolic Blood Pressure (SBP) <140 mmHg at Week 8 With LOCF Figure 2: Probability of Achieving Diastolic Blood Pressure (DBP) <90 mmHg at Week 8 With LOCF Figure 3: Probability of Achieving Systolic Blood Pressure (SBP) <130 mmHg at Week 8 With LOCF Figure 4: Probability of Achieving Diastolic Blood Pressure (DBP) <80 mmHg at Week 8 With LOCF The figures above provide an approximation of the likelihood of reaching a targeted blood pressure goal (e.g., Week 8 SBP <140 mmHg or <130 mmHg or a DBP <90 mmHg or <80 mmHg) for the high-dose treatment groups evaluated in the study. Azor 5/20 mg, the lowest dose combination treatment group, increases the probability of reaching blood pressure goal compared with the highest dose monotherapies, amlodipine 10 mg and olmesartan medoxomil 40 mg. For example, a patient with a baseline blood pressure of 160/100 mmHg has about a 48% likelihood of achieving a goal of <140 mmHg (systolic) and a 51% likelihood of achieving a goal of <90 mmHg (diastolic) on monotherapy with olmesartan medoxomil 40 mg, and about a 46% likelihood of achieving a goal of <140 mmHg (systolic) and a 60% likelihood of achieving a goal of <90 mmHg (diastolic) on monotherapy with amlodipine 10 mg. The likelihood of achieving these same goals increases to 63% (systolic) and 71% (diastolic) on Azor 5/20 mg, and to 68% (systolic) and 85% (diastolic) on Azor 10/40 mg. uuid:4252de35-1893-4c12-8778-2a854ebe3745 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1152286 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:bac0dcdf-2f8a-4d14-90ea-ebfd9406cedb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ba9ed286-3c4c-4eaf-9307-56fbe9134830"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azor is indicated for the treatment of hypertension, alone or with other antihypertensive agents , to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Azor. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Azor may also be used as initial therapy in patients who are likely to need multiple antihypertensive agents to achieve their blood pressure goals. Patients with moderate or severe hypertension are at relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. The decision to use a combination as initial therapy should be individualized and should be shaped by considerations such as baseline blood pressure, the target goal, and the incremental likelihood of achieving goal with a combination compared to monotherapy. Individual blood pressure goals may vary based upon the patient’s risk. Data from an 8-week, placebo-controlled, parallel-group factorial study [see Clinical Studies (14.1) ] provide estimates of the probability of reaching a blood pressure goal with Azor compared to amlodipine or olmesartan medoxomil monotherapy. The figures below provide estimates of the likelihood of achieving the targeted systolic or diastolic blood pressure goals with Azor 10/40 mg compared with amlodipine or olmesartan medoxomil monotherapy, based upon baseline systolic or diastolic blood pressure. The curve of each treatment group was estimated by logistic regression modeling from all available data of that treatment group. The right tail of each curve is less reliable because of small numbers of subjects with high baseline blood pressures. Figure 1: Probability of Achieving Systolic Blood Pressure (SBP) <140 mmHg at Week 8 With LOCF Figure 2: Probability of Achieving Diastolic Blood Pressure (DBP) <90 mmHg at Week 8 With LOCF Figure 3: Probability of Achieving Systolic Blood Pressure (SBP) <130 mmHg at Week 8 With LOCF Figure 4: Probability of Achieving Diastolic Blood Pressure (DBP) <80 mmHg at Week 8 With LOCF The figures above provide an approximation of the likelihood of reaching a targeted blood pressure goal (e.g., Week 8 SBP <140 mmHg or <130 mmHg or a DBP <90 mmHg or <80 mmHg) for the high-dose treatment groups evaluated in the study. Azor 5/20 mg, the lowest dose combination treatment group, increases the probability of reaching blood pressure goal compared with the highest dose monotherapies, amlodipine 10 mg and olmesartan medoxomil 40 mg. For example, a patient with a baseline blood pressure of 160/100 mmHg has about a 48% likelihood of achieving a goal of <140 mmHg (systolic) and a 51% likelihood of achieving a goal of <90 mmHg (diastolic) on monotherapy with olmesartan medoxomil 40 mg, and about a 46% likelihood of achieving a goal of <140 mmHg (systolic) and a 60% likelihood of achieving a goal of <90 mmHg (diastolic) on monotherapy with amlodipine 10 mg. The likelihood of achieving these same goals increases to 63% (systolic) and 71% (diastolic) on Azor 5/20 mg, and to 68% (systolic) and 85% (diastolic) on Azor 10/40 mg. uuid:4309df4d-c205-4895-beb0-3a2106ba75a2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1152286 biolink:treats MONDO:0001106 PMID:41385096 "[{""id"":""uuid:f8aa11bd-6964-4da4-a0be-6999661c5f34"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dea40980-2e17-4dce-bc8c-a7f3f7cb1eca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azor is indicated for the treatment of hypertension, alone or with other antihypertensive agents , to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Azor. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Azor may also be used as initial therapy in patients who are likely to need multiple antihypertensive agents to achieve their blood pressure goals. Patients with moderate or severe hypertension are at relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. The decision to use a combination as initial therapy should be individualized and should be shaped by considerations such as baseline blood pressure, the target goal, and the incremental likelihood of achieving goal with a combination compared to monotherapy. Individual blood pressure goals may vary based upon the patient’s risk. Data from an 8-week, placebo-controlled, parallel-group factorial study [see Clinical Studies (14.1) ] provide estimates of the probability of reaching a blood pressure goal with Azor compared to amlodipine or olmesartan medoxomil monotherapy. The figures below provide estimates of the likelihood of achieving the targeted systolic or diastolic blood pressure goals with Azor 10/40 mg compared with amlodipine or olmesartan medoxomil monotherapy, based upon baseline systolic or diastolic blood pressure. The curve of each treatment group was estimated by logistic regression modeling from all available data of that treatment group. The right tail of each curve is less reliable because of small numbers of subjects with high baseline blood pressures. Figure 1: Probability of Achieving Systolic Blood Pressure (SBP) <140 mmHg at Week 8 With LOCF Figure 2: Probability of Achieving Diastolic Blood Pressure (DBP) <90 mmHg at Week 8 With LOCF Figure 3: Probability of Achieving Systolic Blood Pressure (SBP) <130 mmHg at Week 8 With LOCF Figure 4: Probability of Achieving Diastolic Blood Pressure (DBP) <80 mmHg at Week 8 With LOCF The figures above provide an approximation of the likelihood of reaching a targeted blood pressure goal (e.g., Week 8 SBP <140 mmHg or <130 mmHg or a DBP <90 mmHg or <80 mmHg) for the high-dose treatment groups evaluated in the study. Azor 5/20 mg, the lowest dose combination treatment group, increases the probability of reaching blood pressure goal compared with the highest dose monotherapies, amlodipine 10 mg and olmesartan medoxomil 40 mg. For example, a patient with a baseline blood pressure of 160/100 mmHg has about a 48% likelihood of achieving a goal of <140 mmHg (systolic) and a 51% likelihood of achieving a goal of <90 mmHg (diastolic) on monotherapy with olmesartan medoxomil 40 mg, and about a 46% likelihood of achieving a goal of <140 mmHg (systolic) and a 60% likelihood of achieving a goal of <90 mmHg (diastolic) on monotherapy with amlodipine 10 mg. The likelihood of achieving these same goals increases to 63% (systolic) and 71% (diastolic) on Azor 5/20 mg, and to 68% (systolic) and 85% (diastolic) on Azor 10/40 mg. uuid:ffe726dd-49df-4ca9-b5dc-f9258ed9a6a5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1152286 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:b5fe1d22-cb80-4c6b-8c50-7a5e3f7192fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dde66b4b-1f1a-4a65-9b78-2ed5f5f8a3f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azor is indicated for the treatment of hypertension, alone or with other antihypertensive agents , to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Azor. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Azor may also be used as initial therapy in patients who are likely to need multiple antihypertensive agents to achieve their blood pressure goals. Patients with moderate or severe hypertension are at relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. The decision to use a combination as initial therapy should be individualized and should be shaped by considerations such as baseline blood pressure, the target goal, and the incremental likelihood of achieving goal with a combination compared to monotherapy. Individual blood pressure goals may vary based upon the patient’s risk. Data from an 8-week, placebo-controlled, parallel-group factorial study [see Clinical Studies (14.1) ] provide estimates of the probability of reaching a blood pressure goal with Azor compared to amlodipine or olmesartan medoxomil monotherapy. The figures below provide estimates of the likelihood of achieving the targeted systolic or diastolic blood pressure goals with Azor 10/40 mg compared with amlodipine or olmesartan medoxomil monotherapy, based upon baseline systolic or diastolic blood pressure. The curve of each treatment group was estimated by logistic regression modeling from all available data of that treatment group. The right tail of each curve is less reliable because of small numbers of subjects with high baseline blood pressures. Figure 1: Probability of Achieving Systolic Blood Pressure (SBP) <140 mmHg at Week 8 With LOCF Figure 2: Probability of Achieving Diastolic Blood Pressure (DBP) <90 mmHg at Week 8 With LOCF Figure 3: Probability of Achieving Systolic Blood Pressure (SBP) <130 mmHg at Week 8 With LOCF Figure 4: Probability of Achieving Diastolic Blood Pressure (DBP) <80 mmHg at Week 8 With LOCF The figures above provide an approximation of the likelihood of reaching a targeted blood pressure goal (e.g., Week 8 SBP <140 mmHg or <130 mmHg or a DBP <90 mmHg or <80 mmHg) for the high-dose treatment groups evaluated in the study. Azor 5/20 mg, the lowest dose combination treatment group, increases the probability of reaching blood pressure goal compared with the highest dose monotherapies, amlodipine 10 mg and olmesartan medoxomil 40 mg. For example, a patient with a baseline blood pressure of 160/100 mmHg has about a 48% likelihood of achieving a goal of <140 mmHg (systolic) and a 51% likelihood of achieving a goal of <90 mmHg (diastolic) on monotherapy with olmesartan medoxomil 40 mg, and about a 46% likelihood of achieving a goal of <140 mmHg (systolic) and a 60% likelihood of achieving a goal of <90 mmHg (diastolic) on monotherapy with amlodipine 10 mg. The likelihood of achieving these same goals increases to 63% (systolic) and 71% (diastolic) on Azor 5/20 mg, and to 68% (systolic) and 85% (diastolic) on Azor 10/40 mg. uuid:bf239862-ccc5-4811-ba40-004902cd8189 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9927 biolink:treats HP:0005162 PMID:41385096 "[{""id"":""uuid:3335d7a2-85b4-41ce-b918-b45f494771ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:806acc00-991b-40da-aea3-e35c97095b27"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diovan is an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension , to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.1 ) Treatment of heart failure (NYHA class II-IV); Diovan significantly reduced hospitalization for heart failure ( 1.2 ) Reduction of cardiovascular mortality in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction ( 1.3 ) uuid:1c8423b1-3828-4a00-a178-6653c123c0c3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9927 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:06f4a8df-be9e-475d-8892-125e89037033"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6016f8f7-06c3-492f-993c-7df89d188019"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diovan is an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension , to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.1 ) Treatment of heart failure (NYHA class II-IV); Diovan significantly reduced hospitalization for heart failure ( 1.2 ) Reduction of cardiovascular mortality in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction ( 1.3 ) uuid:ac0f6c48-9d8d-4a9d-8b4a-dc66611dbc34 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:722125 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:f0355a13-a1d4-4a35-81d2-fde4681e5a36"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:97137df4-25ba-4344-af7b-d99909454c86"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:3d9cb4a9-4b93-446b-8afe-005a25fdbbf4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Exforge is the combination tablet of amlodipine, a dihydropyridine calcium channel blocker (DHP CCB), and valsartan, an angiotensin II receptor blocker (ARB). Exforge is indicated for the treatment of hypertension: In patients not adequately controlled on monotherapy (1) As initial therapy in patients likely to need multiple drugs to achieve their blood pressure goals (1).|[PMDA] A new combination drug indicated for the treatment of hypertension. uuid:86d6f75c-09c2-4576-979e-0e0617cec9db biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31933 biolink:treats MONDO:0005324 PMID:41385096 "[{""id"":""uuid:d6c00ae0-8ab4-4f0a-bfc7-ed5104da810a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:49199251-956b-4b6a-8a35-72a3dc4d2ede"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PATANASE Nasal Spray is an H 1 receptor antagonist indicated for the relief of the symptoms of seasonal allergic rhinitis in adults and children 6 years of age and older. (1) uuid:7c1c3413-65a1-43dd-a7a2-3ef4b30d5403 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7865 biolink:treats NCIT:C27003 PMID:41385096 "[{""id"":""uuid:fcba43f2-ea0a-4af9-ba3b-ee0c9bc645da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d9b8ecf3-2e83-4ee4-8da1-b05a773ab5bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OPANA is indicated for the relief of moderate to severe acute pain where the use of an opioid is appropriate. uuid:b7095a77-a5ac-425d-80d5-bbcfd0ad2537 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:601027 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:e6fb9f5b-74d3-44bf-9bcb-064e04994352"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:88e4f1f5-0cdf-4df8-bee2-ea44f7f75116"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e9611902-be32-43e1-9912-910a0fc6a133"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tekturna is a renin inhibitor (RI) indicated for: The treatment of hypertension, to lower blood pressure (1.1) Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.|[PMDA] A drug with a new active ingredient indicated for the treatment of hypertension. uuid:cc4fcdb1-f322-4240-9a1c-330facbd80b3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5134 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:966def80-8bb8-4c61-bf74-1e39225dca20"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:53ba6359-af19-40dc-8f84-0117d352b6ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FLOVENT ® HFA Inhalation Aerosol is indicated for the maintenance treatment of asthma as prophylactic therapy in patients aged 4 years and older. It is also indicated for patients requiring oral corticosteroid therapy for asthma. Many of these patients may be able to reduce or eliminate their requirement for oral corticosteroids over time. FLOVENT HFA Inhalation Aerosol is NOT indicated for the relief of acute bronchospasm. uuid:a8432271-e7c5-420e-9750-510ca39ba809 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3207 biolink:treats MONDO:0005011 PMID:41385096 "[{""id"":""uuid:16606e05-5f34-4b03-99fe-3f2e2f497070"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:140ff1fd-07ae-414c-a76d-597e9f231774"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ENTOCORT EC is indicated for the treatment of mild to moderate active Crohn's disease involving the iluem and/or the ascending colon and the maintenance of clinical remission of mild to moderate Crohn's disease involving the ileum and/or the ascending colon for up to 3 months. uuid:b01f807b-6fec-461e-8bab-7a8622cc163b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5088 biolink:treats MONDO:0006032 PMID:41385096 "[{""id"":""uuid:027e9fdf-7427-4b27-8582-5c42bfb98503"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8051821c-1aa6-4e48-84cd-1c116f8fa0a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Flavoxate hydrochloride tablets are indicated for symptomatic relief of dysuria, urgency, nocturia, suprapubic pain, frequency and incontinence as may occur in cystitis, prostatitis, urethritis, urethrocystitis/urethrotrigonitis. Flavoxate hydrochloride tablets are not indicated for definitive treatment, but are compatible with drugs used for the treatment of urinary tract infections. uuid:e4c55bb9-ccbf-41f7-bf45-f153041636fe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5088 biolink:treats MONDO:0005280 PMID:41385096 "[{""id"":""uuid:f8f73258-3c99-4c07-b789-d450f2703464"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6caf32de-a991-483c-a02d-8110c48a3fc3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Flavoxate hydrochloride tablets are indicated for symptomatic relief of dysuria, urgency, nocturia, suprapubic pain, frequency and incontinence as may occur in cystitis, prostatitis, urethritis, urethrocystitis/urethrotrigonitis. Flavoxate hydrochloride tablets are not indicated for definitive treatment, but are compatible with drugs used for the treatment of urinary tract infections. uuid:93206914-9006-4cc3-9167-17dadf8e0d18 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5088 biolink:treats MONDO:0005297 PMID:41385096 "[{""id"":""uuid:b4cdb3f4-8da0-4b3c-856a-8cf8a7cdd9c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:44b05102-4675-456c-81f9-6d347ca1e587"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Flavoxate hydrochloride tablets are indicated for symptomatic relief of dysuria, urgency, nocturia, suprapubic pain, frequency and incontinence as may occur in cystitis, prostatitis, urethritis, urethrocystitis/urethrotrigonitis. Flavoxate hydrochloride tablets are not indicated for definitive treatment, but are compatible with drugs used for the treatment of urinary tract infections. uuid:7941f2db-e7d3-4b07-815e-8c373c4c8035 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:66964 biolink:treats MONDO:0024571 PMID:41385096 "[{""id"":""uuid:c260efb0-ca40-4f4c-b0df-dd64289d8d8f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4e950aff-1a1a-4726-8d00-b2d6dd3aa392"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dronabinol capsules are indicated for the treatment of: anorexia associated with weight loss in patients with AIDS; and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. uuid:2c340db0-b529-46a3-8411-061a3a2968fa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:66964 biolink:treats EFO:0006911 PMID:41385096 "[{""id"":""uuid:cbce6aa2-9fed-46c4-91e7-7033c096ba7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9cd069a1-ced6-4f78-b964-c56bc50fd495"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dronabinol capsules are indicated for the treatment of: anorexia associated with weight loss in patients with AIDS; and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. uuid:c46dfbbe-a15a-44d6-875c-3a79f2eb7c27 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4027 biolink:treats MONDO:0005062 PMID:41385096 "[{""id"":""uuid:4b034a8f-88fe-4c06-9986-b1449eee0b9c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:966ed6b4-6057-4f3d-8ee4-9cb3bc67d489"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:3346bcdc-0870-4b6b-938b-e87697a328a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cyclophosphamide Tablets USP, 25 mg and 50 mg, although effective alone in susceptible malignancies, are more frequently used concurrently or sequentially with other antineoplastic drugs. The following malignancies are often susceptible to cyclophosphamide treatment: Malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin’s disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma. Multiple myeloma. Leukemias: Chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia in children (cyclophosphamide given during remission is effective in prolonging its duration). Mycosis fungoides (advanced disease). Neuroblastoma (disseminated disease). Adenocarcinoma of the ovary. Retinoblastoma. Carcinoma of the breast.|[PMDA] Drugs with a revised indication and a new dosage for the relief of symptoms of malignant lymphoma. [Expedited review] uuid:05605a08-e2ec-4606-bb38-88b9f82e7a95 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4027 biolink:treats MONDO:0009348 PMID:41385096 "[{""id"":""uuid:568beff9-7ed1-427f-862e-0a35537aa454"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3d87225a-7239-4ff7-b998-a06433e88a8a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cyclophosphamide Tablets USP, 25 mg and 50 mg, although effective alone in susceptible malignancies, are more frequently used concurrently or sequentially with other antineoplastic drugs. The following malignancies are often susceptible to cyclophosphamide treatment: Malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin’s disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma. Multiple myeloma. Leukemias: Chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia in children (cyclophosphamide given during remission is effective in prolonging its duration). Mycosis fungoides (advanced disease). Neuroblastoma (disseminated disease). Adenocarcinoma of the ovary. Retinoblastoma. Carcinoma of the breast. uuid:16c225a2-bdf1-477c-9428-e2fe22feec82 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4027 biolink:treats MONDO:0003864 PMID:41385096 "[{""id"":""uuid:9b6ab9d1-0dff-4634-b5be-884ab6d58ea4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c7b17167-2b16-4f4a-bab7-81228adb494e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cyclophosphamide Tablets USP, 25 mg and 50 mg, although effective alone in susceptible malignancies, are more frequently used concurrently or sequentially with other antineoplastic drugs. The following malignancies are often susceptible to cyclophosphamide treatment: Malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin’s disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma. Multiple myeloma. Leukemias: Chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia in children (cyclophosphamide given during remission is effective in prolonging its duration). Mycosis fungoides (advanced disease). Neuroblastoma (disseminated disease). Adenocarcinoma of the ovary. Retinoblastoma. Carcinoma of the breast. uuid:1ef3221b-c389-4c66-8bb9-f8f0a72376d5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4027 biolink:treats MONDO:0004633 PMID:41385096 "[{""id"":""uuid:7bd3f138-3978-40db-bd53-47f17f2107a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:51379b3a-ceed-41f8-a9cd-0daf7bd20a6b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cyclophosphamide Tablets USP, 25 mg and 50 mg, although effective alone in susceptible malignancies, are more frequently used concurrently or sequentially with other antineoplastic drugs. The following malignancies are often susceptible to cyclophosphamide treatment: Malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin’s disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma. Multiple myeloma. Leukemias: Chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia in children (cyclophosphamide given during remission is effective in prolonging its duration). Mycosis fungoides (advanced disease). Neuroblastoma (disseminated disease). Adenocarcinoma of the ovary. Retinoblastoma. Carcinoma of the breast. uuid:e0cbf744-2a61-40f8-85b8-eaf0197b1fba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4027 biolink:treats MONDO:0004604 PMID:41385096 "[{""id"":""uuid:1bc7e3ac-d77b-4cdb-af8c-00ed563de60b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6a3362cc-be79-4922-9f30-1f036485e84a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cyclophosphamide Tablets USP, 25 mg and 50 mg, although effective alone in susceptible malignancies, are more frequently used concurrently or sequentially with other antineoplastic drugs. The following malignancies are often susceptible to cyclophosphamide treatment: Malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin’s disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma. Multiple myeloma. Leukemias: Chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia in children (cyclophosphamide given during remission is effective in prolonging its duration). Mycosis fungoides (advanced disease). Neuroblastoma (disseminated disease). Adenocarcinoma of the ovary. Retinoblastoma. Carcinoma of the breast. uuid:ac0d92dd-94b6-4b2b-ae8f-0f7c6a376c0c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4027 biolink:treats MONDO:0006150 PMID:41385096 "[{""id"":""uuid:6a3acc92-6c58-4f3c-8662-47b2c684f9e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9f012c7e-c906-47ea-aa51-4d3993f28bee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cyclophosphamide Tablets USP, 25 mg and 50 mg, although effective alone in susceptible malignancies, are more frequently used concurrently or sequentially with other antineoplastic drugs. The following malignancies are often susceptible to cyclophosphamide treatment: Malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin’s disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma. Multiple myeloma. Leukemias: Chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia in children (cyclophosphamide given during remission is effective in prolonging its duration). Mycosis fungoides (advanced disease). Neuroblastoma (disseminated disease). Adenocarcinoma of the ovary. Retinoblastoma. Carcinoma of the breast. uuid:b788e33f-8a5f-4628-809e-764232c1dd19 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4027 biolink:treats MONDO:0009693 PMID:41385096 "[{""id"":""uuid:cea75ba9-0a4e-4441-b2df-ed21ef35154d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:13e34aeb-fa51-457b-86b1-11acd557b4c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cyclophosphamide Tablets USP, 25 mg and 50 mg, although effective alone in susceptible malignancies, are more frequently used concurrently or sequentially with other antineoplastic drugs. The following malignancies are often susceptible to cyclophosphamide treatment: Malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin’s disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma. Multiple myeloma. Leukemias: Chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia in children (cyclophosphamide given during remission is effective in prolonging its duration). Mycosis fungoides (advanced disease). Neuroblastoma (disseminated disease). Adenocarcinoma of the ovary. Retinoblastoma. Carcinoma of the breast. uuid:9aa31a99-40d2-4a4c-b959-2b0adbf3b715 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4027 biolink:treats MONDO:0004948 PMID:41385096 "[{""id"":""uuid:30a16487-4b63-44a8-8133-7d3fdacfcf0e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0f2e52f4-45ea-49fe-9c6b-0b934062b303"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cyclophosphamide Tablets USP, 25 mg and 50 mg, although effective alone in susceptible malignancies, are more frequently used concurrently or sequentially with other antineoplastic drugs. The following malignancies are often susceptible to cyclophosphamide treatment: Malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin’s disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma. Multiple myeloma. Leukemias: Chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia in children (cyclophosphamide given during remission is effective in prolonging its duration). Mycosis fungoides (advanced disease). Neuroblastoma (disseminated disease). Adenocarcinoma of the ovary. Retinoblastoma. Carcinoma of the breast. uuid:c9fb3773-ea67-437a-b63d-09076f7b692a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4027 biolink:treats MONDO:0011996 PMID:41385096 "[{""id"":""uuid:b343ff4e-b364-444e-be82-19f6c3de351d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:33739961-fc95-46d7-b214-5d094bbb0beb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cyclophosphamide Tablets USP, 25 mg and 50 mg, although effective alone in susceptible malignancies, are more frequently used concurrently or sequentially with other antineoplastic drugs. The following malignancies are often susceptible to cyclophosphamide treatment: Malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin’s disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma. Multiple myeloma. Leukemias: Chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia in children (cyclophosphamide given during remission is effective in prolonging its duration). Mycosis fungoides (advanced disease). Neuroblastoma (disseminated disease). Adenocarcinoma of the ovary. Retinoblastoma. Carcinoma of the breast. uuid:9cf86b3d-c838-4c8f-8cb4-35a1e53fee60 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4027 biolink:treats MONDO:0018871 PMID:41385096 "[{""id"":""uuid:6dcbf083-83ad-4918-82d4-d818e0d816ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8d5901c9-4a77-4f08-926a-3128d6a481a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cyclophosphamide Tablets USP, 25 mg and 50 mg, although effective alone in susceptible malignancies, are more frequently used concurrently or sequentially with other antineoplastic drugs. The following malignancies are often susceptible to cyclophosphamide treatment: Malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin’s disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma. Multiple myeloma. Leukemias: Chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia in children (cyclophosphamide given during remission is effective in prolonging its duration). Mycosis fungoides (advanced disease). Neuroblastoma (disseminated disease). Adenocarcinoma of the ovary. Retinoblastoma. Carcinoma of the breast. uuid:d51dc72a-f8bc-4cb7-9895-5a507ca711fc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4027 biolink:treats MONDO:0004967 PMID:41385096 "[{""id"":""uuid:2153172e-bdda-4574-86e3-bdd71d424037"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2db8342f-5063-4f82-9e55-cd931f731b62"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cyclophosphamide Tablets USP, 25 mg and 50 mg, although effective alone in susceptible malignancies, are more frequently used concurrently or sequentially with other antineoplastic drugs. The following malignancies are often susceptible to cyclophosphamide treatment: Malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin’s disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma. Multiple myeloma. Leukemias: Chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia in children (cyclophosphamide given during remission is effective in prolonging its duration). Mycosis fungoides (advanced disease). Neuroblastoma (disseminated disease). Adenocarcinoma of the ovary. Retinoblastoma. Carcinoma of the breast. uuid:83b8a6aa-f876-484a-9c4b-9d5d46fb1183 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4027 biolink:treats MONDO:0009691 PMID:41385096 "[{""id"":""uuid:8d7baa56-cffa-48d9-97f7-027ff454b633"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7e4a545b-8b6f-4e45-abe1-ae1ce22af9ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cyclophosphamide Tablets USP, 25 mg and 50 mg, although effective alone in susceptible malignancies, are more frequently used concurrently or sequentially with other antineoplastic drugs. The following malignancies are often susceptible to cyclophosphamide treatment: Malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin’s disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma. Multiple myeloma. Leukemias: Chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia in children (cyclophosphamide given during remission is effective in prolonging its duration). Mycosis fungoides (advanced disease). Neuroblastoma (disseminated disease). Adenocarcinoma of the ovary. Retinoblastoma. Carcinoma of the breast. uuid:731ae977-3532-4f5d-ac36-1b4757785dd4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4027 biolink:treats MONDO:0005072 PMID:41385096 "[{""id"":""uuid:83008595-43e3-4b9a-bce2-052544b1ec22"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d397a975-fa01-4066-b256-5189754a936b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cyclophosphamide Tablets USP, 25 mg and 50 mg, although effective alone in susceptible malignancies, are more frequently used concurrently or sequentially with other antineoplastic drugs. The following malignancies are often susceptible to cyclophosphamide treatment: Malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin’s disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma. Multiple myeloma. Leukemias: Chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia in children (cyclophosphamide given during remission is effective in prolonging its duration). Mycosis fungoides (advanced disease). Neuroblastoma (disseminated disease). Adenocarcinoma of the ovary. Retinoblastoma. Carcinoma of the breast. uuid:18e6acf8-422f-4c2e-addb-fc5c42463b6e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4027 biolink:treats MONDO:0002752 PMID:41385096 "[{""id"":""uuid:86ef254c-d177-4cac-8b98-e7a67d3cdb00"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c2814c91-4a7f-47f4-84bd-9c38eee2e911"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cyclophosphamide Tablets USP, 25 mg and 50 mg, although effective alone in susceptible malignancies, are more frequently used concurrently or sequentially with other antineoplastic drugs. The following malignancies are often susceptible to cyclophosphamide treatment: Malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin’s disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma. Multiple myeloma. Leukemias: Chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia in children (cyclophosphamide given during remission is effective in prolonging its duration). Mycosis fungoides (advanced disease). Neuroblastoma (disseminated disease). Adenocarcinoma of the ovary. Retinoblastoma. Carcinoma of the breast. uuid:2cef8d44-e6a6-40a4-8edb-d85c1caf8152 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4027 biolink:treats MONDO:0008380 PMID:41385096 "[{""id"":""uuid:89328e88-86a2-4ece-a4c9-ba608cdb3af2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a1821621-3629-45e0-95a4-e63281accdb8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cyclophosphamide Tablets USP, 25 mg and 50 mg, although effective alone in susceptible malignancies, are more frequently used concurrently or sequentially with other antineoplastic drugs. The following malignancies are often susceptible to cyclophosphamide treatment: Malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin’s disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma. Multiple myeloma. Leukemias: Chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia in children (cyclophosphamide given during remission is effective in prolonging its duration). Mycosis fungoides (advanced disease). Neuroblastoma (disseminated disease). Adenocarcinoma of the ovary. Retinoblastoma. Carcinoma of the breast. uuid:29e45ff3-52bf-4644-83dd-9e3cc56fa997 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4027 biolink:treats MONDO:0004989 PMID:41385096 "[{""id"":""uuid:0f6c7800-8f14-48d8-8bbf-80bb5a616721"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a840f083-a90b-46b8-9af0-cd233e0869b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cyclophosphamide Tablets USP, 25 mg and 50 mg, although effective alone in susceptible malignancies, are more frequently used concurrently or sequentially with other antineoplastic drugs. The following malignancies are often susceptible to cyclophosphamide treatment: Malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin’s disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma. Multiple myeloma. Leukemias: Chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia in children (cyclophosphamide given during remission is effective in prolonging its duration). Mycosis fungoides (advanced disease). Neuroblastoma (disseminated disease). Adenocarcinoma of the ovary. Retinoblastoma. Carcinoma of the breast. uuid:b71df74a-1fee-4614-8df4-69531e74184b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:61033 biolink:treats HP:0002625 PMID:41385096 "[{""id"":""uuid:236995df-4346-4897-91fd-4b74865b15b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:0d58b039-0d11-468d-8207-63ffdd2b4ea4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:1029e06e-b0c6-4591-bb65-e9e9df0018e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/arixtra""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] ARIXTRA is a Factor Xa inhibitor (anticoagulant) indicated for: Prophylaxis of deep vein thrombosis (DVT) in patients undergoing hip fracture surgery (including extended prophylaxis), hip replacement surgery, knee replacement surgery, or abdominal surgery. (1.1) Treatment of DVT or acute pulmonary embolism (PE) when administered in conjunction with warfarin. (1.2, 1.3)|[EMA] 1.5-mg/0.3-ml and 2.5-mg/0.5-ml solution for injectionPrevention of venous thromboembolic events (VTE) in adults undergoing major orthopaedic surgery of the lower limbs such as hip fracture, major knee surgery or hip-replacement surgery.Prevention of VTE in adults undergoing abdominal surgery who are judged to be at high risk of thromboembolic complications, such as patients undergoing abdominal cancer surgery.Prevention of VTE in adult medical patients who are judged to be at high risk for VTE and who are immobilised due to acute illness such as cardiac insufficiency and / or acute respiratory disorders, and / or acute infectious or inflammatory disease.Treatment of adults with acute symptomatic spontaneous superficial-vein thrombosis of the lower limbs without concomitant deep-vein thrombosis.2.5-mg/0.5-ml solution for injectionTreatment of unstable angina or non-ST-segment-elevation myocardial infarction (UA/NSTEMI) in adult patients for whom urgent (< 120 mins) invasive management (PCI) is not indicated.infarction (STEMI) in adult patients who are managed with thrombolytics or who initially are to receive no other form of reperfusion therapy.5-mg/0.4-ml, 7.5-mg/0.6-ml and 10-mg/0.8-ml solution for injectionTreatment of adults with acute deep-vein thrombosis (DVT) and treatment of acute pulmonary embolism (PE), except in haemodynamically unstable patients or patients who require thrombolysis or pulmonary embolectomy. uuid:14fcbd01-3753-4dd3-b119-c071efb0987b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:61033 biolink:treats UMLS:C2882221 PMID:41385096 "[{""id"":""uuid:80f56b25-b2e6-4c1f-967e-68927a5824be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:58b0bf4b-8952-4f09-bca5-d51779216fc9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ARIXTRA is a Factor Xa inhibitor (anticoagulant) indicated for: Prophylaxis of deep vein thrombosis (DVT) in patients undergoing hip fracture surgery (including extended prophylaxis), hip replacement surgery, knee replacement surgery, or abdominal surgery. (1.1) Treatment of DVT or acute pulmonary embolism (PE) when administered in conjunction with warfarin. (1.2, 1.3) uuid:306cd941-236c-46fe-a340-190895cb124d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7447 biolink:treats MONDO:0100073 PMID:41385096 "[{""id"":""uuid:0e90bf51-0448-47f6-9f35-1e55980ecb92"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c8112bf9-8af9-47ae-ab97-adb2579fb8d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nafcillin is indicated in the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug. Culture and susceptibility tests should be performed initially to determine the causative organism and its susceptibility to the drug (see CLINICAL PHARMACOLOGY - Susceptibility Tests ). Nafcillin may be used to initiate therapy in suspected cases of resistant staphylococcal infections prior to the availability of susceptibility test results. Nafcillin should not be used in infections caused by organisms susceptible to penicillin G. If the susceptibility tests indicate that the infection is due to an organism other than a resistant Staphylococcus , therapy should not be continued with Nafcillin for Injection, USP. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Nafcillin for Injection and other antibacterial drugs, Nafcillin for Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:34198549-aa75-49ba-84b8-9eb02019b8de biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18385 biolink:treats MONDO:0006676 PMID:41385096 "[{""id"":""uuid:dc2ccd7e-8d70-4718-bade-d4411293ceb9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9a3a784f-ab9f-4af5-8f9e-d0bf67434fa9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Thiamine hydrochloride injection is effective for the treatment of thiamine deficiency or beriberi whether of the dry (major symptoms related to the nervous system) or wet (major symptoms related to the cardiovascular system) variety. Thiamine hydrochloride injection should be used where rapid restoration of thiamine is necessary, as in Wernicke’s encephalopathy, infantile beriberi with acute collapse, cardiovascular disease due to thiamine deficiency, or neuritis of pregnancy if vomiting is severe. It is also indicated when giving IV dextrose to individuals with marginal thiamine status to avoid precipitation of heart failure. Thiamine hydrochloride injection is also indicated in patients with established thiamine deficiency who cannot take thiamine orally due to coexisting severe anorexia, nausea, vomiting, or malabsorption. Thiamine hydrochloride injection is not usually indicated for conditions of decreased oral intake or decreased gastrointestinal absorption, because multiple vitamins should usually be given uuid:2dc0a8ab-2852-45c4-b0ce-ab0d6b07a161 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18385 biolink:treats MONDO:0007020 PMID:41385096 "[{""id"":""uuid:de317be1-3f1e-4934-93c9-d8074f04f923"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9ab0964f-452f-41c5-8bb3-186beeac42d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Thiamine hydrochloride injection is effective for the treatment of thiamine deficiency or beriberi whether of the dry (major symptoms related to the nervous system) or wet (major symptoms related to the cardiovascular system) variety. Thiamine hydrochloride injection should be used where rapid restoration of thiamine is necessary, as in Wernicke’s encephalopathy, infantile beriberi with acute collapse, cardiovascular disease due to thiamine deficiency, or neuritis of pregnancy if vomiting is severe. It is also indicated when giving IV dextrose to individuals with marginal thiamine status to avoid precipitation of heart failure. Thiamine hydrochloride injection is also indicated in patients with established thiamine deficiency who cannot take thiamine orally due to coexisting severe anorexia, nausea, vomiting, or malabsorption. Thiamine hydrochloride injection is not usually indicated for conditions of decreased oral intake or decreased gastrointestinal absorption, because multiple vitamins should usually be given uuid:39bb94f9-9dbf-4aaa-9278-1f760c274192 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18385 biolink:treats MONDO:0024183 PMID:41385096 "[{""id"":""uuid:43881f7e-8ffd-4301-916c-9cdf630fcd7c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f34ad06e-d2b8-436d-bf41-32f6c40de318"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Thiamine hydrochloride injection is effective for the treatment of thiamine deficiency or beriberi whether of the dry (major symptoms related to the nervous system) or wet (major symptoms related to the cardiovascular system) variety. Thiamine hydrochloride injection should be used where rapid restoration of thiamine is necessary, as in Wernicke’s encephalopathy, infantile beriberi with acute collapse, cardiovascular disease due to thiamine deficiency, or neuritis of pregnancy if vomiting is severe. It is also indicated when giving IV dextrose to individuals with marginal thiamine status to avoid precipitation of heart failure. Thiamine hydrochloride injection is also indicated in patients with established thiamine deficiency who cannot take thiamine orally due to coexisting severe anorexia, nausea, vomiting, or malabsorption. Thiamine hydrochloride injection is not usually indicated for conditions of decreased oral intake or decreased gastrointestinal absorption, because multiple vitamins should usually be given uuid:2eac3a70-0a9c-4a9e-8b5e-71f7b831aadd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5280 biolink:treats MONDO:0006668 PMID:41385096 "[{""id"":""uuid:12dd3431-0b8d-4e02-ac5a-50b9beaefa6d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ebc1c110-fa28-4fe0-98b4-e2f1c72f09db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZYMAXID ® (gatifloxacin ophthalmic solution) 0.5% solution is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Aerobic Gram-Positive Bacteria: Staphylococcus aureus Staphylococcus epidermidis Streptococcus mitis group * Streptococcus oralis * Streptococcus pneumoniae Aerobic Gram-Negative Bacteria: Haemophilus influenzae * Efficacy for this organism was studied in fewer than 10 infections. uuid:daa0f8a0-6f6b-4cca-aa6f-c018dcb3f640 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3084 biolink:treats HP:0000016 PMID:41385096 "[{""id"":""uuid:6bdf40bc-437a-443d-8498-0655e3af1ff3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fd7afea8-1f67-46e8-bcf3-87a093d7e26d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bethanechol chloride is indicated for the treatment of acute postoperative and postpartum nonobstructive (functional) urinary retention and for neurogenic atony of the urinary bladder with retention. uuid:d2cecf9d-f956-4add-95b5-8719b9819076 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3084 biolink:treats HP:0000011 PMID:41385096 "[{""id"":""uuid:a9e3888b-e841-4d95-be58-b3551992acf1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4ed1d139-f145-4e87-b4d9-cdb118b4c5f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bethanechol chloride is indicated for the treatment of acute postoperative and postpartum nonobstructive (functional) urinary retention and for neurogenic atony of the urinary bladder with retention. uuid:6f09efb7-fee9-41c3-bca7-93cfc54b5d95 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1156610 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:4a94e6dc-83bf-4ab3-9ac7-34028b34e246"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4adc7bbc-c513-4e65-8efb-cfc9a3dd4fb1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:6c1e2c34-94e8-4d59-825e-9066375a06c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ATACAND HCT is indicated for the treatment of hypertension. This fixed dose combination is not indicated for initial therapy (see DOSAGE AND ADMINISTRATION ).|[PMDA] New combination drugs indicated for the treatment of hypertension. uuid:ce0bfd2a-0de0-4c04-bbe7-548772a9967a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3732 biolink:treats MONDO:0002258 PMID:41385096 "[{""id"":""uuid:e96c5c8a-0929-46ad-bce2-949440a86432"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:03f02a96-e521-47d0-afa0-d2fa9899551c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clarithromycin tablets are indicated for the treatment of mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions as listed below: Adults Pharyngitis/Tonsillitis due to Streptococcus pyogenes (The usual drug of choice in the treatment and prevention of streptococcal infections and the prophylaxis of rheumatic fever is penicillin administered by either the intramuscular or the oral route. Clarithromycin is generally effective in the eradication of S. pyogenes from the nasopharynx; however, data establishing the efficacy of clarithromycin in the subsequent prevention of rheumatic fever are not available at present.) Acute maxillary sinusitis due to Haemophilus influenzae, Moraxella catarrhalis , or Streptococcus pneumoniae Acute bacterial exacerbation of chronic bronchitis due to Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis, or Streptococcus pneumoniae Community-Acquired Pneumonia due to Haemophilus influenzae, Mycoplasma pneumoniae, Streptococcus pneumoniae, or Chlamydia pneumoniae (TWAR) Uncomplicated skin and skin structure infections due to Staphylococcus aureus, or Streptococcus pyogenes (Abscesses usually require surgical drainage.) Disseminated mycobacterial infections due to Mycobacterium avium, or Mycobacterium intracellulare Clarithromycin tablets in combination with amoxicillin and lansoprazole or omeprazole delayed-release capsules, as triple therapy, are indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or five-year history of duodenal ulcer) to eradicate H. pylori. Clarithromycin tablets in combination with omeprazole capsules or ranitidine bismuth citrate tablets are also indicated for the treatment of patients with an active duodenal ulcer associated with H. pylori infection. However, regimens which contain clarithromycin as the single antimicrobial agent are more likely to be associated with the development of clarithromycin resistance among patients who fail therapy. Clarithromycin-containing regimens should not be used in patients with known or suspected clarithromycin resistant isolates because the efficacy of treatment is reduced in this setting. In patients who fail therapy, susceptibility testing should be done if possible. If resistance to clarithromycin is demonstrated, a non-clarithromycin-containing therapy is recommended. (For information on development of resistance see Microbiology section.) The eradication of H. pylori has been demonstrated to reduce the risk of duodenal ulcer recurrence. Children Pharyngitis/Tonsillitis due to Streptococcus pyogenes Community-Acquired Pneumonia due to Mycoplasma pneumoniae, Streptococcus pneumoniae, or Chlamydia pneumoniae (TWAR) Acute maxillary sinusitis due to Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae Acute otitis media due to Haemophilus influenzae, Moraxella catarrhalis ,or Streptococcus pneumoniae NOTE: For information on otitis media, see CLINICAL STUDIES: Otitis Media . Uncomplicated skin and skin structure infections due to Staphylococcus aureus, or Streptococcus pyogenes (Abscesses usually require surgical drainage.) Disseminated mycobacterial infections due to Mycobacterium avium, or Mycobacterium intracellulare Prophylaxis Clarithromycin tablets are indicated for the prevention of disseminated Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clarithromycin tablets and other antibacterial drugs, clarithromycin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:f68b1e59-df49-4964-831e-8fdfd1e87b05 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3732 biolink:treats MONDO:0001039 PMID:41385096 "[{""id"":""uuid:a6066815-111b-4767-894b-c187588bc56c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bac24f7b-4711-4c03-8875-5e756030f177"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clarithromycin tablets are indicated for the treatment of mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions as listed below: Adults Pharyngitis/Tonsillitis due to Streptococcus pyogenes (The usual drug of choice in the treatment and prevention of streptococcal infections and the prophylaxis of rheumatic fever is penicillin administered by either the intramuscular or the oral route. Clarithromycin is generally effective in the eradication of S. pyogenes from the nasopharynx; however, data establishing the efficacy of clarithromycin in the subsequent prevention of rheumatic fever are not available at present.) Acute maxillary sinusitis due to Haemophilus influenzae, Moraxella catarrhalis , or Streptococcus pneumoniae Acute bacterial exacerbation of chronic bronchitis due to Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis, or Streptococcus pneumoniae Community-Acquired Pneumonia due to Haemophilus influenzae, Mycoplasma pneumoniae, Streptococcus pneumoniae, or Chlamydia pneumoniae (TWAR) Uncomplicated skin and skin structure infections due to Staphylococcus aureus, or Streptococcus pyogenes (Abscesses usually require surgical drainage.) Disseminated mycobacterial infections due to Mycobacterium avium, or Mycobacterium intracellulare Clarithromycin tablets in combination with amoxicillin and lansoprazole or omeprazole delayed-release capsules, as triple therapy, are indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or five-year history of duodenal ulcer) to eradicate H. pylori. Clarithromycin tablets in combination with omeprazole capsules or ranitidine bismuth citrate tablets are also indicated for the treatment of patients with an active duodenal ulcer associated with H. pylori infection. However, regimens which contain clarithromycin as the single antimicrobial agent are more likely to be associated with the development of clarithromycin resistance among patients who fail therapy. Clarithromycin-containing regimens should not be used in patients with known or suspected clarithromycin resistant isolates because the efficacy of treatment is reduced in this setting. In patients who fail therapy, susceptibility testing should be done if possible. If resistance to clarithromycin is demonstrated, a non-clarithromycin-containing therapy is recommended. (For information on development of resistance see Microbiology section.) The eradication of H. pylori has been demonstrated to reduce the risk of duodenal ulcer recurrence. Children Pharyngitis/Tonsillitis due to Streptococcus pyogenes Community-Acquired Pneumonia due to Mycoplasma pneumoniae, Streptococcus pneumoniae, or Chlamydia pneumoniae (TWAR) Acute maxillary sinusitis due to Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae Acute otitis media due to Haemophilus influenzae, Moraxella catarrhalis ,or Streptococcus pneumoniae NOTE: For information on otitis media, see CLINICAL STUDIES: Otitis Media . Uncomplicated skin and skin structure infections due to Staphylococcus aureus, or Streptococcus pyogenes (Abscesses usually require surgical drainage.) Disseminated mycobacterial infections due to Mycobacterium avium, or Mycobacterium intracellulare Prophylaxis Clarithromycin tablets are indicated for the prevention of disseminated Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clarithromycin tablets and other antibacterial drugs, clarithromycin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:897999fc-ccb2-4354-b5b9-fa3576a1ad3b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3732 biolink:treats MONDO:0002186 PMID:41385096 "[{""id"":""uuid:1fd4b692-471e-4e8a-b31e-de8f8970be67"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9f5f6054-5d20-4fc9-9a1a-a8dbd8a7cf9b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clarithromycin tablets are indicated for the treatment of mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions as listed below: Adults Pharyngitis/Tonsillitis due to Streptococcus pyogenes (The usual drug of choice in the treatment and prevention of streptococcal infections and the prophylaxis of rheumatic fever is penicillin administered by either the intramuscular or the oral route. Clarithromycin is generally effective in the eradication of S. pyogenes from the nasopharynx; however, data establishing the efficacy of clarithromycin in the subsequent prevention of rheumatic fever are not available at present.) Acute maxillary sinusitis due to Haemophilus influenzae, Moraxella catarrhalis , or Streptococcus pneumoniae Acute bacterial exacerbation of chronic bronchitis due to Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis, or Streptococcus pneumoniae Community-Acquired Pneumonia due to Haemophilus influenzae, Mycoplasma pneumoniae, Streptococcus pneumoniae, or Chlamydia pneumoniae (TWAR) Uncomplicated skin and skin structure infections due to Staphylococcus aureus, or Streptococcus pyogenes (Abscesses usually require surgical drainage.) Disseminated mycobacterial infections due to Mycobacterium avium, or Mycobacterium intracellulare Clarithromycin tablets in combination with amoxicillin and lansoprazole or omeprazole delayed-release capsules, as triple therapy, are indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or five-year history of duodenal ulcer) to eradicate H. pylori. Clarithromycin tablets in combination with omeprazole capsules or ranitidine bismuth citrate tablets are also indicated for the treatment of patients with an active duodenal ulcer associated with H. pylori infection. However, regimens which contain clarithromycin as the single antimicrobial agent are more likely to be associated with the development of clarithromycin resistance among patients who fail therapy. Clarithromycin-containing regimens should not be used in patients with known or suspected clarithromycin resistant isolates because the efficacy of treatment is reduced in this setting. In patients who fail therapy, susceptibility testing should be done if possible. If resistance to clarithromycin is demonstrated, a non-clarithromycin-containing therapy is recommended. (For information on development of resistance see Microbiology section.) The eradication of H. pylori has been demonstrated to reduce the risk of duodenal ulcer recurrence. Children Pharyngitis/Tonsillitis due to Streptococcus pyogenes Community-Acquired Pneumonia due to Mycoplasma pneumoniae, Streptococcus pneumoniae, or Chlamydia pneumoniae (TWAR) Acute maxillary sinusitis due to Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae Acute otitis media due to Haemophilus influenzae, Moraxella catarrhalis ,or Streptococcus pneumoniae NOTE: For information on otitis media, see CLINICAL STUDIES: Otitis Media . Uncomplicated skin and skin structure infections due to Staphylococcus aureus, or Streptococcus pyogenes (Abscesses usually require surgical drainage.) Disseminated mycobacterial infections due to Mycobacterium avium, or Mycobacterium intracellulare Prophylaxis Clarithromycin tablets are indicated for the prevention of disseminated Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clarithromycin tablets and other antibacterial drugs, clarithromycin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:a52d5935-fc48-4e85-ad45-7afb5d09ed27 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3732 biolink:treats UMLS:C1735365 PMID:41385096 "[{""id"":""uuid:052bb5ca-dd15-4420-a2a6-41230b6ae2ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b58afef7-df55-4652-b689-8543a38ec42d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clarithromycin tablets are indicated for the treatment of mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions as listed below: Adults Pharyngitis/Tonsillitis due to Streptococcus pyogenes (The usual drug of choice in the treatment and prevention of streptococcal infections and the prophylaxis of rheumatic fever is penicillin administered by either the intramuscular or the oral route. Clarithromycin is generally effective in the eradication of S. pyogenes from the nasopharynx; however, data establishing the efficacy of clarithromycin in the subsequent prevention of rheumatic fever are not available at present.) Acute maxillary sinusitis due to Haemophilus influenzae, Moraxella catarrhalis , or Streptococcus pneumoniae Acute bacterial exacerbation of chronic bronchitis due to Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis, or Streptococcus pneumoniae Community-Acquired Pneumonia due to Haemophilus influenzae, Mycoplasma pneumoniae, Streptococcus pneumoniae, or Chlamydia pneumoniae (TWAR) Uncomplicated skin and skin structure infections due to Staphylococcus aureus, or Streptococcus pyogenes (Abscesses usually require surgical drainage.) Disseminated mycobacterial infections due to Mycobacterium avium, or Mycobacterium intracellulare Clarithromycin tablets in combination with amoxicillin and lansoprazole or omeprazole delayed-release capsules, as triple therapy, are indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or five-year history of duodenal ulcer) to eradicate H. pylori. Clarithromycin tablets in combination with omeprazole capsules or ranitidine bismuth citrate tablets are also indicated for the treatment of patients with an active duodenal ulcer associated with H. pylori infection. However, regimens which contain clarithromycin as the single antimicrobial agent are more likely to be associated with the development of clarithromycin resistance among patients who fail therapy. Clarithromycin-containing regimens should not be used in patients with known or suspected clarithromycin resistant isolates because the efficacy of treatment is reduced in this setting. In patients who fail therapy, susceptibility testing should be done if possible. If resistance to clarithromycin is demonstrated, a non-clarithromycin-containing therapy is recommended. (For information on development of resistance see Microbiology section.) The eradication of H. pylori has been demonstrated to reduce the risk of duodenal ulcer recurrence. Children Pharyngitis/Tonsillitis due to Streptococcus pyogenes Community-Acquired Pneumonia due to Mycoplasma pneumoniae, Streptococcus pneumoniae, or Chlamydia pneumoniae (TWAR) Acute maxillary sinusitis due to Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae Acute otitis media due to Haemophilus influenzae, Moraxella catarrhalis ,or Streptococcus pneumoniae NOTE: For information on otitis media, see CLINICAL STUDIES: Otitis Media . Uncomplicated skin and skin structure infections due to Staphylococcus aureus, or Streptococcus pyogenes (Abscesses usually require surgical drainage.) Disseminated mycobacterial infections due to Mycobacterium avium, or Mycobacterium intracellulare Prophylaxis Clarithromycin tablets are indicated for the prevention of disseminated Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clarithromycin tablets and other antibacterial drugs, clarithromycin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:73792ece-6481-4c4c-99c2-28c4d1ecf9bd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3732 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:df0246c5-3556-4b65-9383-4160206112e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c3d30b7d-f25e-460d-9545-4a9e672393ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clarithromycin tablets are indicated for the treatment of mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions as listed below: Adults Pharyngitis/Tonsillitis due to Streptococcus pyogenes (The usual drug of choice in the treatment and prevention of streptococcal infections and the prophylaxis of rheumatic fever is penicillin administered by either the intramuscular or the oral route. Clarithromycin is generally effective in the eradication of S. pyogenes from the nasopharynx; however, data establishing the efficacy of clarithromycin in the subsequent prevention of rheumatic fever are not available at present.) Acute maxillary sinusitis due to Haemophilus influenzae, Moraxella catarrhalis , or Streptococcus pneumoniae Acute bacterial exacerbation of chronic bronchitis due to Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis, or Streptococcus pneumoniae Community-Acquired Pneumonia due to Haemophilus influenzae, Mycoplasma pneumoniae, Streptococcus pneumoniae, or Chlamydia pneumoniae (TWAR) Uncomplicated skin and skin structure infections due to Staphylococcus aureus, or Streptococcus pyogenes (Abscesses usually require surgical drainage.) Disseminated mycobacterial infections due to Mycobacterium avium, or Mycobacterium intracellulare Clarithromycin tablets in combination with amoxicillin and lansoprazole or omeprazole delayed-release capsules, as triple therapy, are indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or five-year history of duodenal ulcer) to eradicate H. pylori. Clarithromycin tablets in combination with omeprazole capsules or ranitidine bismuth citrate tablets are also indicated for the treatment of patients with an active duodenal ulcer associated with H. pylori infection. However, regimens which contain clarithromycin as the single antimicrobial agent are more likely to be associated with the development of clarithromycin resistance among patients who fail therapy. Clarithromycin-containing regimens should not be used in patients with known or suspected clarithromycin resistant isolates because the efficacy of treatment is reduced in this setting. In patients who fail therapy, susceptibility testing should be done if possible. If resistance to clarithromycin is demonstrated, a non-clarithromycin-containing therapy is recommended. (For information on development of resistance see Microbiology section.) The eradication of H. pylori has been demonstrated to reduce the risk of duodenal ulcer recurrence. Children Pharyngitis/Tonsillitis due to Streptococcus pyogenes Community-Acquired Pneumonia due to Mycoplasma pneumoniae, Streptococcus pneumoniae, or Chlamydia pneumoniae (TWAR) Acute maxillary sinusitis due to Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae Acute otitis media due to Haemophilus influenzae, Moraxella catarrhalis ,or Streptococcus pneumoniae NOTE: For information on otitis media, see CLINICAL STUDIES: Otitis Media . Uncomplicated skin and skin structure infections due to Staphylococcus aureus, or Streptococcus pyogenes (Abscesses usually require surgical drainage.) Disseminated mycobacterial infections due to Mycobacterium avium, or Mycobacterium intracellulare Prophylaxis Clarithromycin tablets are indicated for the prevention of disseminated Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clarithromycin tablets and other antibacterial drugs, clarithromycin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:5f2f1048-2558-4385-8468-e30979c11c13 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3732 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:3fbf775f-c8e5-48fd-be27-0f0631effd33"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e6cb9762-d39b-4170-95b3-ebb8890bf866"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clarithromycin tablets are indicated for the treatment of mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions as listed below: Adults Pharyngitis/Tonsillitis due to Streptococcus pyogenes (The usual drug of choice in the treatment and prevention of streptococcal infections and the prophylaxis of rheumatic fever is penicillin administered by either the intramuscular or the oral route. Clarithromycin is generally effective in the eradication of S. pyogenes from the nasopharynx; however, data establishing the efficacy of clarithromycin in the subsequent prevention of rheumatic fever are not available at present.) Acute maxillary sinusitis due to Haemophilus influenzae, Moraxella catarrhalis , or Streptococcus pneumoniae Acute bacterial exacerbation of chronic bronchitis due to Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis, or Streptococcus pneumoniae Community-Acquired Pneumonia due to Haemophilus influenzae, Mycoplasma pneumoniae, Streptococcus pneumoniae, or Chlamydia pneumoniae (TWAR) Uncomplicated skin and skin structure infections due to Staphylococcus aureus, or Streptococcus pyogenes (Abscesses usually require surgical drainage.) Disseminated mycobacterial infections due to Mycobacterium avium, or Mycobacterium intracellulare Clarithromycin tablets in combination with amoxicillin and lansoprazole or omeprazole delayed-release capsules, as triple therapy, are indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or five-year history of duodenal ulcer) to eradicate H. pylori. Clarithromycin tablets in combination with omeprazole capsules or ranitidine bismuth citrate tablets are also indicated for the treatment of patients with an active duodenal ulcer associated with H. pylori infection. However, regimens which contain clarithromycin as the single antimicrobial agent are more likely to be associated with the development of clarithromycin resistance among patients who fail therapy. Clarithromycin-containing regimens should not be used in patients with known or suspected clarithromycin resistant isolates because the efficacy of treatment is reduced in this setting. In patients who fail therapy, susceptibility testing should be done if possible. If resistance to clarithromycin is demonstrated, a non-clarithromycin-containing therapy is recommended. (For information on development of resistance see Microbiology section.) The eradication of H. pylori has been demonstrated to reduce the risk of duodenal ulcer recurrence. Children Pharyngitis/Tonsillitis due to Streptococcus pyogenes Community-Acquired Pneumonia due to Mycoplasma pneumoniae, Streptococcus pneumoniae, or Chlamydia pneumoniae (TWAR) Acute maxillary sinusitis due to Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae Acute otitis media due to Haemophilus influenzae, Moraxella catarrhalis ,or Streptococcus pneumoniae NOTE: For information on otitis media, see CLINICAL STUDIES: Otitis Media . Uncomplicated skin and skin structure infections due to Staphylococcus aureus, or Streptococcus pyogenes (Abscesses usually require surgical drainage.) Disseminated mycobacterial infections due to Mycobacterium avium, or Mycobacterium intracellulare Prophylaxis Clarithromycin tablets are indicated for the prevention of disseminated Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clarithromycin tablets and other antibacterial drugs, clarithromycin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:d34584ed-995f-49f9-8fa1-f3a166418a1b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3732 biolink:treats MONDO:0020590 PMID:41385096 "[{""id"":""uuid:7c6f8933-35e5-4bce-b169-636484f3238d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1b1442a1-d4ae-418a-930d-f5be58885c57"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clarithromycin tablets are indicated for the treatment of mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions as listed below: Adults Pharyngitis/Tonsillitis due to Streptococcus pyogenes (The usual drug of choice in the treatment and prevention of streptococcal infections and the prophylaxis of rheumatic fever is penicillin administered by either the intramuscular or the oral route. Clarithromycin is generally effective in the eradication of S. pyogenes from the nasopharynx; however, data establishing the efficacy of clarithromycin in the subsequent prevention of rheumatic fever are not available at present.) Acute maxillary sinusitis due to Haemophilus influenzae, Moraxella catarrhalis , or Streptococcus pneumoniae Acute bacterial exacerbation of chronic bronchitis due to Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis, or Streptococcus pneumoniae Community-Acquired Pneumonia due to Haemophilus influenzae, Mycoplasma pneumoniae, Streptococcus pneumoniae, or Chlamydia pneumoniae (TWAR) Uncomplicated skin and skin structure infections due to Staphylococcus aureus, or Streptococcus pyogenes (Abscesses usually require surgical drainage.) Disseminated mycobacterial infections due to Mycobacterium avium, or Mycobacterium intracellulare Clarithromycin tablets in combination with amoxicillin and lansoprazole or omeprazole delayed-release capsules, as triple therapy, are indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or five-year history of duodenal ulcer) to eradicate H. pylori. Clarithromycin tablets in combination with omeprazole capsules or ranitidine bismuth citrate tablets are also indicated for the treatment of patients with an active duodenal ulcer associated with H. pylori infection. However, regimens which contain clarithromycin as the single antimicrobial agent are more likely to be associated with the development of clarithromycin resistance among patients who fail therapy. Clarithromycin-containing regimens should not be used in patients with known or suspected clarithromycin resistant isolates because the efficacy of treatment is reduced in this setting. In patients who fail therapy, susceptibility testing should be done if possible. If resistance to clarithromycin is demonstrated, a non-clarithromycin-containing therapy is recommended. (For information on development of resistance see Microbiology section.) The eradication of H. pylori has been demonstrated to reduce the risk of duodenal ulcer recurrence. Children Pharyngitis/Tonsillitis due to Streptococcus pyogenes Community-Acquired Pneumonia due to Mycoplasma pneumoniae, Streptococcus pneumoniae, or Chlamydia pneumoniae (TWAR) Acute maxillary sinusitis due to Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae Acute otitis media due to Haemophilus influenzae, Moraxella catarrhalis ,or Streptococcus pneumoniae NOTE: For information on otitis media, see CLINICAL STUDIES: Otitis Media . Uncomplicated skin and skin structure infections due to Staphylococcus aureus, or Streptococcus pyogenes (Abscesses usually require surgical drainage.) Disseminated mycobacterial infections due to Mycobacterium avium, or Mycobacterium intracellulare Prophylaxis Clarithromycin tablets are indicated for the prevention of disseminated Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clarithromycin tablets and other antibacterial drugs, clarithromycin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:74dae665-f48b-44b7-b853-a243321449ed biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3732 biolink:treats HP:0005202 PMID:41385096 "[{""id"":""uuid:846cb6c0-14a3-4a41-b315-042a0c257896"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1c0b7b7d-20f0-473c-9a14-ac9d448f3399"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clarithromycin tablets are indicated for the treatment of mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions as listed below: Adults Pharyngitis/Tonsillitis due to Streptococcus pyogenes (The usual drug of choice in the treatment and prevention of streptococcal infections and the prophylaxis of rheumatic fever is penicillin administered by either the intramuscular or the oral route. Clarithromycin is generally effective in the eradication of S. pyogenes from the nasopharynx; however, data establishing the efficacy of clarithromycin in the subsequent prevention of rheumatic fever are not available at present.) Acute maxillary sinusitis due to Haemophilus influenzae, Moraxella catarrhalis , or Streptococcus pneumoniae Acute bacterial exacerbation of chronic bronchitis due to Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis, or Streptococcus pneumoniae Community-Acquired Pneumonia due to Haemophilus influenzae, Mycoplasma pneumoniae, Streptococcus pneumoniae, or Chlamydia pneumoniae (TWAR) Uncomplicated skin and skin structure infections due to Staphylococcus aureus, or Streptococcus pyogenes (Abscesses usually require surgical drainage.) Disseminated mycobacterial infections due to Mycobacterium avium, or Mycobacterium intracellulare Clarithromycin tablets in combination with amoxicillin and lansoprazole or omeprazole delayed-release capsules, as triple therapy, are indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or five-year history of duodenal ulcer) to eradicate H. pylori. Clarithromycin tablets in combination with omeprazole capsules or ranitidine bismuth citrate tablets are also indicated for the treatment of patients with an active duodenal ulcer associated with H. pylori infection. However, regimens which contain clarithromycin as the single antimicrobial agent are more likely to be associated with the development of clarithromycin resistance among patients who fail therapy. Clarithromycin-containing regimens should not be used in patients with known or suspected clarithromycin resistant isolates because the efficacy of treatment is reduced in this setting. In patients who fail therapy, susceptibility testing should be done if possible. If resistance to clarithromycin is demonstrated, a non-clarithromycin-containing therapy is recommended. (For information on development of resistance see Microbiology section.) The eradication of H. pylori has been demonstrated to reduce the risk of duodenal ulcer recurrence. Children Pharyngitis/Tonsillitis due to Streptococcus pyogenes Community-Acquired Pneumonia due to Mycoplasma pneumoniae, Streptococcus pneumoniae, or Chlamydia pneumoniae (TWAR) Acute maxillary sinusitis due to Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae Acute otitis media due to Haemophilus influenzae, Moraxella catarrhalis ,or Streptococcus pneumoniae NOTE: For information on otitis media, see CLINICAL STUDIES: Otitis Media . Uncomplicated skin and skin structure infections due to Staphylococcus aureus, or Streptococcus pyogenes (Abscesses usually require surgical drainage.) Disseminated mycobacterial infections due to Mycobacterium avium, or Mycobacterium intracellulare Prophylaxis Clarithromycin tablets are indicated for the prevention of disseminated Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clarithromycin tablets and other antibacterial drugs, clarithromycin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:1a08371a-0138-49e0-afcf-de5439ae98a5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3732 biolink:treats MONDO:0005412 PMID:41385096 "[{""id"":""uuid:7dafd923-8808-4036-9479-6b107a9c4356"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1fa0037f-2d09-4a80-81af-497f0a37d7f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clarithromycin tablets are indicated for the treatment of mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions as listed below: Adults Pharyngitis/Tonsillitis due to Streptococcus pyogenes (The usual drug of choice in the treatment and prevention of streptococcal infections and the prophylaxis of rheumatic fever is penicillin administered by either the intramuscular or the oral route. Clarithromycin is generally effective in the eradication of S. pyogenes from the nasopharynx; however, data establishing the efficacy of clarithromycin in the subsequent prevention of rheumatic fever are not available at present.) Acute maxillary sinusitis due to Haemophilus influenzae, Moraxella catarrhalis , or Streptococcus pneumoniae Acute bacterial exacerbation of chronic bronchitis due to Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis, or Streptococcus pneumoniae Community-Acquired Pneumonia due to Haemophilus influenzae, Mycoplasma pneumoniae, Streptococcus pneumoniae, or Chlamydia pneumoniae (TWAR) Uncomplicated skin and skin structure infections due to Staphylococcus aureus, or Streptococcus pyogenes (Abscesses usually require surgical drainage.) Disseminated mycobacterial infections due to Mycobacterium avium, or Mycobacterium intracellulare Clarithromycin tablets in combination with amoxicillin and lansoprazole or omeprazole delayed-release capsules, as triple therapy, are indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or five-year history of duodenal ulcer) to eradicate H. pylori. Clarithromycin tablets in combination with omeprazole capsules or ranitidine bismuth citrate tablets are also indicated for the treatment of patients with an active duodenal ulcer associated with H. pylori infection. However, regimens which contain clarithromycin as the single antimicrobial agent are more likely to be associated with the development of clarithromycin resistance among patients who fail therapy. Clarithromycin-containing regimens should not be used in patients with known or suspected clarithromycin resistant isolates because the efficacy of treatment is reduced in this setting. In patients who fail therapy, susceptibility testing should be done if possible. If resistance to clarithromycin is demonstrated, a non-clarithromycin-containing therapy is recommended. (For information on development of resistance see Microbiology section.) The eradication of H. pylori has been demonstrated to reduce the risk of duodenal ulcer recurrence. Children Pharyngitis/Tonsillitis due to Streptococcus pyogenes Community-Acquired Pneumonia due to Mycoplasma pneumoniae, Streptococcus pneumoniae, or Chlamydia pneumoniae (TWAR) Acute maxillary sinusitis due to Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae Acute otitis media due to Haemophilus influenzae, Moraxella catarrhalis ,or Streptococcus pneumoniae NOTE: For information on otitis media, see CLINICAL STUDIES: Otitis Media . Uncomplicated skin and skin structure infections due to Staphylococcus aureus, or Streptococcus pyogenes (Abscesses usually require surgical drainage.) Disseminated mycobacterial infections due to Mycobacterium avium, or Mycobacterium intracellulare Prophylaxis Clarithromycin tablets are indicated for the prevention of disseminated Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clarithromycin tablets and other antibacterial drugs, clarithromycin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:3a4ac6a2-0e43-4fb9-9f38-6c30ac1e3c13 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3732 biolink:treats HP:0000371 PMID:41385096 "[{""id"":""uuid:b9baf1bf-f2e2-4a88-bc59-ae8017282c13"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ddb30604-2407-4dc0-92ef-4b5aced7d118"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clarithromycin tablets are indicated for the treatment of mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions as listed below: Adults Pharyngitis/Tonsillitis due to Streptococcus pyogenes (The usual drug of choice in the treatment and prevention of streptococcal infections and the prophylaxis of rheumatic fever is penicillin administered by either the intramuscular or the oral route. Clarithromycin is generally effective in the eradication of S. pyogenes from the nasopharynx; however, data establishing the efficacy of clarithromycin in the subsequent prevention of rheumatic fever are not available at present.) Acute maxillary sinusitis due to Haemophilus influenzae, Moraxella catarrhalis , or Streptococcus pneumoniae Acute bacterial exacerbation of chronic bronchitis due to Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis, or Streptococcus pneumoniae Community-Acquired Pneumonia due to Haemophilus influenzae, Mycoplasma pneumoniae, Streptococcus pneumoniae, or Chlamydia pneumoniae (TWAR) Uncomplicated skin and skin structure infections due to Staphylococcus aureus, or Streptococcus pyogenes (Abscesses usually require surgical drainage.) Disseminated mycobacterial infections due to Mycobacterium avium, or Mycobacterium intracellulare Clarithromycin tablets in combination with amoxicillin and lansoprazole or omeprazole delayed-release capsules, as triple therapy, are indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or five-year history of duodenal ulcer) to eradicate H. pylori. Clarithromycin tablets in combination with omeprazole capsules or ranitidine bismuth citrate tablets are also indicated for the treatment of patients with an active duodenal ulcer associated with H. pylori infection. However, regimens which contain clarithromycin as the single antimicrobial agent are more likely to be associated with the development of clarithromycin resistance among patients who fail therapy. Clarithromycin-containing regimens should not be used in patients with known or suspected clarithromycin resistant isolates because the efficacy of treatment is reduced in this setting. In patients who fail therapy, susceptibility testing should be done if possible. If resistance to clarithromycin is demonstrated, a non-clarithromycin-containing therapy is recommended. (For information on development of resistance see Microbiology section.) The eradication of H. pylori has been demonstrated to reduce the risk of duodenal ulcer recurrence. Children Pharyngitis/Tonsillitis due to Streptococcus pyogenes Community-Acquired Pneumonia due to Mycoplasma pneumoniae, Streptococcus pneumoniae, or Chlamydia pneumoniae (TWAR) Acute maxillary sinusitis due to Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae Acute otitis media due to Haemophilus influenzae, Moraxella catarrhalis ,or Streptococcus pneumoniae NOTE: For information on otitis media, see CLINICAL STUDIES: Otitis Media . Uncomplicated skin and skin structure infections due to Staphylococcus aureus, or Streptococcus pyogenes (Abscesses usually require surgical drainage.) Disseminated mycobacterial infections due to Mycobacterium avium, or Mycobacterium intracellulare Prophylaxis Clarithromycin tablets are indicated for the prevention of disseminated Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clarithromycin tablets and other antibacterial drugs, clarithromycin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:409f75b7-2719-4701-a274-e23023ea6959 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3732 biolink:treats MONDO:0005866 PMID:41385096 "[{""id"":""uuid:5452f2f2-b738-4814-8401-b9710ad29c51"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:67a1e4fb-6190-44a4-a5ae-659c3a80b071"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:2a511336-c7b6-45df-b785-f983e5ba8ed9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clarithromycin tablets are indicated for the treatment of mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions as listed below: Adults Pharyngitis/Tonsillitis due to Streptococcus pyogenes (The usual drug of choice in the treatment and prevention of streptococcal infections and the prophylaxis of rheumatic fever is penicillin administered by either the intramuscular or the oral route. Clarithromycin is generally effective in the eradication of S. pyogenes from the nasopharynx; however, data establishing the efficacy of clarithromycin in the subsequent prevention of rheumatic fever are not available at present.) Acute maxillary sinusitis due to Haemophilus influenzae, Moraxella catarrhalis , or Streptococcus pneumoniae Acute bacterial exacerbation of chronic bronchitis due to Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis, or Streptococcus pneumoniae Community-Acquired Pneumonia due to Haemophilus influenzae, Mycoplasma pneumoniae, Streptococcus pneumoniae, or Chlamydia pneumoniae (TWAR) Uncomplicated skin and skin structure infections due to Staphylococcus aureus, or Streptococcus pyogenes (Abscesses usually require surgical drainage.) Disseminated mycobacterial infections due to Mycobacterium avium, or Mycobacterium intracellulare Clarithromycin tablets in combination with amoxicillin and lansoprazole or omeprazole delayed-release capsules, as triple therapy, are indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or five-year history of duodenal ulcer) to eradicate H. pylori. Clarithromycin tablets in combination with omeprazole capsules or ranitidine bismuth citrate tablets are also indicated for the treatment of patients with an active duodenal ulcer associated with H. pylori infection. However, regimens which contain clarithromycin as the single antimicrobial agent are more likely to be associated with the development of clarithromycin resistance among patients who fail therapy. Clarithromycin-containing regimens should not be used in patients with known or suspected clarithromycin resistant isolates because the efficacy of treatment is reduced in this setting. In patients who fail therapy, susceptibility testing should be done if possible. If resistance to clarithromycin is demonstrated, a non-clarithromycin-containing therapy is recommended. (For information on development of resistance see Microbiology section.) The eradication of H. pylori has been demonstrated to reduce the risk of duodenal ulcer recurrence. Children Pharyngitis/Tonsillitis due to Streptococcus pyogenes Community-Acquired Pneumonia due to Mycoplasma pneumoniae, Streptococcus pneumoniae, or Chlamydia pneumoniae (TWAR) Acute maxillary sinusitis due to Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae Acute otitis media due to Haemophilus influenzae, Moraxella catarrhalis ,or Streptococcus pneumoniae NOTE: For information on otitis media, see CLINICAL STUDIES: Otitis Media . Uncomplicated skin and skin structure infections due to Staphylococcus aureus, or Streptococcus pyogenes (Abscesses usually require surgical drainage.) Disseminated mycobacterial infections due to Mycobacterium avium, or Mycobacterium intracellulare Prophylaxis Clarithromycin tablets are indicated for the prevention of disseminated Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clarithromycin tablets and other antibacterial drugs, clarithromycin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.|[PMDA] Drugs with a new indication and a new dosage for non-tuberculous mycobacteriosis including mycobacterium avium complex (MAC) infections. uuid:41b0f80c-6245-4dee-baf0-c0eb5e483cbe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:82960 biolink:treats MONDO:0004951 PMID:41385096 "[{""id"":""uuid:4ed9c212-0508-4f22-86a8-8c0f3ddbb375"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:46afc53f-f747-4156-8db5-22b250bf9543"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ISENTRESS is a human immunodeficiency virus integrase strand transfer inhibitor (HIV-1 INSTI) indicated: In combination with other antiretroviral agents for the treatment of HIV-1 infection ( 1 ). The safety and efficacy of ISENTRESS have not been established in children less than 2 years of age ( 1.2 ). uuid:d83fbdbd-5b05-49c7-ad71-0bb3168a7c41 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:24847846 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:f1d07654-5cf5-4124-955e-4af03e149e81"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:55f33b6f-4f36-48a9-b765-447911d6b4f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TARKA is indicated for the treatment of hypertension. This fixed combination drug is not indicated for the initial therapy of hypertension (see DOSAGE and ADMINISTRATION). In using TARKA, consideration should be given to the fact that an angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that trandolapril does not have similar risk (see WARNINGS -Neutropenia/Agranulocytosis ). uuid:128fe8e8-76ba-4b6a-967f-860322728d73 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:24847846 biolink:treats MONDO:0001609 PMID:41385096 "[{""id"":""uuid:3e234887-3a67-4590-9e61-a8a0de05ed15"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b540ca9b-d4ce-4118-a995-9fbcdf117331"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TARKA is indicated for the treatment of hypertension. This fixed combination drug is not indicated for the initial therapy of hypertension (see DOSAGE and ADMINISTRATION). In using TARKA, consideration should be given to the fact that an angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that trandolapril does not have similar risk (see WARNINGS -Neutropenia/Agranulocytosis ). uuid:a2f77f8c-9ce3-40c4-9ec2-a9858543d1ea biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:829538 biolink:treats MONDO:0011438 PMID:41385096 "[{""id"":""uuid:e75b06dd-3606-4c32-b552-54c0907abf88"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:896653ae-0cdd-4286-a2fb-ac755a47004a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:040cfb49-c8b5-40cc-b350-5b2e56baa42a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EPIDUO gel is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older.|[PMDA] A new combination drug indicated for the treatment of acne vulgaris. uuid:fe607747-b752-41c7-aea4-b514cd42628f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:81916 biolink:treats MONDO:0001684 PMID:41385096 "[{""id"":""uuid:5ca7e57d-e927-4da2-8121-24edb0e6fec5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d42f955c-b703-468a-85ec-f5c946c51c7d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f0f08c00-38fd-468a-b20e-f2c3301b7f13"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CREON ® (pancrelipase) is indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis, chronic pancreatitis, pancreatectomy, or other conditions.|[PMDA] Drugs with a new active ingredient indicated for the replacement of pancreatic digestive enzymes in pancreatic exocrine insufficiency. uuid:abbbe017-94a7-4faf-96f7-f37c92979a86 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:81916 biolink:treats MONDO:0009061 PMID:41385096 "[{""id"":""uuid:45e9d505-3dba-4879-9f91-5a5cc22644dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0c7a04c5-5b0d-4c2f-8592-e0760141bef2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CREON ® (pancrelipase) is indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis, chronic pancreatitis, pancreatectomy, or other conditions. uuid:cfe2fe45-737c-4ad0-b105-d481fdf2a5d4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:81916 biolink:treats MONDO:0005003 PMID:41385096 "[{""id"":""uuid:6d1c1f94-a6dd-40be-8a9e-aba129854b01"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3fa0e9d0-3bc8-41ec-877a-224a242aaa90"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CREON ® (pancrelipase) is indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis, chronic pancreatitis, pancreatectomy, or other conditions. uuid:4fdf5b79-2001-49d8-b843-f28a45b0dc8d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:97af1ae9-1c48-4936-b19e-3ad687f80567"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e6ad5799-daac-4a6c-b2d9-c37077e937f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of Doxycycline Monohydrate Capsules and other antibacterial drugs, Doxycycline Monohydrate Capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydia psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis (formerly Pasteurella pestis ). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis ). Cholera caused by Vibrio cholerae (formerly Vibrio comma ). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus ). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes ( formerly Aerobacter aerogenes) Shigella species Acinetobacter species (formerly Mima species and Herellea species) Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus pneumoniae ). Skin and skin structure infections caused by Staphylococcus aureus . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . Doxycycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent’s infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species . In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:b5857f16-2198-4f1d-b4c5-4fe5fa971630 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0016595 PMID:41385096 "[{""id"":""uuid:5d9b62cc-b0b3-48be-9fae-e814de7ca252"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9a8b5b91-1135-4525-a8f4-de7f91228d86"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of Doxycycline Monohydrate Capsules and other antibacterial drugs, Doxycycline Monohydrate Capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydia psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis (formerly Pasteurella pestis ). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis ). Cholera caused by Vibrio cholerae (formerly Vibrio comma ). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus ). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes ( formerly Aerobacter aerogenes) Shigella species Acinetobacter species (formerly Mima species and Herellea species) Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus pneumoniae ). Skin and skin structure infections caused by Staphylococcus aureus . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . Doxycycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent’s infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species . In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:57492b95-0971-4ac5-8a18-012b80a5491d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:141521 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:85487bbd-5a7c-4ca5-aaf2-eae12273a897"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f495259a-0212-4b8e-b69f-8da28f2ef8c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MAVIK is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive medication such as hydrochlorothiazide. uuid:ba9b9772-c517-4853-a29a-09f005bc2001 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135931 biolink:treats MONDO:0007186 PMID:41385096 "[{""id"":""uuid:b7fcf259-f063-4145-b63c-5e0e3c98da91"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4a81d05a-2432-45b4-9f79-236916056571"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DEXILANT is a proton pump inhibitor (PPI) indicated for: Healing of all grades of erosive esophagitis (EE). ( 1.1 ) Maintaining healing of EE and relief of heartburn. ( 1.2 ) Treating heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD). ( 1.3 ) uuid:0948f178-d674-467f-b15a-9c1a1fb28e60 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6709 biolink:treats MONDO:0008015 PMID:41385096 "[{""id"":""uuid:eb06811f-553e-4378-9727-7a9b45d1da16"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fad56006-487f-4a5c-a70c-5cf70837c0bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the management of nausea and vomiting, and dizziness associated with motion sickness. uuid:630dc01e-c473-4142-b08a-53a7793c82ac biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63681 biolink:treats UMLS:C2930826 PMID:41385096 "[{""id"":""uuid:f3f00c3d-4325-4be3-8811-5b6d4a181ad1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:01d8cbaf-7fcd-44fb-b90a-25467d091825"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mefloquine Hydrochloride Tablets are indicated for the treatment of mild to moderate acute malaria caused by mefloquine-susceptible strains of P. falciparum (both chloroquine-susceptible and resistant strains) or by Plasmodium vivax . There are insufficient clinical data to document the effect of mefloquine in malaria caused by P. ovale or P. malariae . Note: Patients with acute P. vivax malaria, treated with Mefloquine Hydrochloride Tablets, are at high risk of relapse because Mefloquine Hydrochloride Tablets do not eliminate exoerythrocytic (hepatic phase) parasites. To avoid relapse, after initial treatment of the acute infection with mefloquine, patients should subsequently be treated with an 8-aminoquinoline derivative (e.g., primaquine). uuid:2b042b38-5e72-42b2-a33d-b1f903b8e5c1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60311 biolink:treats MONDO:0005420 PMID:41385096 "[{""id"":""uuid:e3c36fd0-2dad-4cdb-9ad8-956cb82c0738"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a0974b62-3ced-4226-9028-2980e945b0fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Armour Thyroid tablets are indicated: As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (See WARNINGS ). As pituitary TSH suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic Iymphocytic thyroiditis (Hashimoto's), multinodular goiter, and in the management of thyroid cancer. PUBCHEM.COMPOUND:53462828 uuid:ace49300-975d-4155-b835-956df8ab227a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60311 biolink:treats MONDO:0018612 PMID:41385096 "[{""id"":""uuid:d691086b-bdea-40a0-b352-cf055c9de7da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:50865b77-3fa3-4622-a442-bfa0b1000149"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Armour Thyroid tablets are indicated: As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (See WARNINGS ). As pituitary TSH suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic Iymphocytic thyroiditis (Hashimoto's), multinodular goiter, and in the management of thyroid cancer. PUBCHEM.COMPOUND:53462828 uuid:96f3a4d8-aa7e-400b-ae61-44a353788282 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60311 biolink:treats MONDO:0009718 PMID:41385096 "[{""id"":""uuid:85e48bc0-13c0-4e20-811e-c367f9afc8a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4c3b2f46-9243-4ea7-a4e5-79905b2d31ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Armour Thyroid tablets are indicated: As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (See WARNINGS ). As pituitary TSH suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic Iymphocytic thyroiditis (Hashimoto's), multinodular goiter, and in the management of thyroid cancer. PUBCHEM.COMPOUND:53462828 uuid:9134aacb-70a5-40df-9e8c-15e919d06693 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60311 biolink:treats MONDO:0001658 PMID:41385096 "[{""id"":""uuid:29ceb97c-6f8e-4947-8be5-ade16ee7dc6d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5fc176fa-3b15-450b-9032-88a791d07ffd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Armour Thyroid tablets are indicated: As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (See WARNINGS ). As pituitary TSH suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic Iymphocytic thyroiditis (Hashimoto's), multinodular goiter, and in the management of thyroid cancer. PUBCHEM.COMPOUND:53462828 uuid:2be0fbc1-3130-492a-86f3-1ce21b802462 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60311 biolink:treats HP:0025388 PMID:41385096 "[{""id"":""uuid:65f5c408-bf9b-4c08-9812-53f7a1bc08a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6f9609a0-059d-46bc-a06c-4f86e780a102"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Armour Thyroid tablets are indicated: As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (See WARNINGS ). As pituitary TSH suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic Iymphocytic thyroiditis (Hashimoto's), multinodular goiter, and in the management of thyroid cancer. PUBCHEM.COMPOUND:53462828 uuid:b4637474-3428-4973-b293-b016f29ade7d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60311 biolink:treats MONDO:0007699 PMID:41385096 "[{""id"":""uuid:889323c7-7556-4893-b90a-5571e5425944"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8c256c98-a972-4d7d-b053-34b470a25976"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Armour Thyroid tablets are indicated: As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (See WARNINGS ). As pituitary TSH suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic Iymphocytic thyroiditis (Hashimoto's), multinodular goiter, and in the management of thyroid cancer. PUBCHEM.COMPOUND:53462828 uuid:c580cd41-09b0-4480-b2a9-e01236f7c6e2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60311 biolink:treats MONDO:0000334 PMID:41385096 "[{""id"":""uuid:2fe8cc97-0f2f-42a2-9f8c-44f1ff54292a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f65f6d38-1d12-4124-9518-cab26474d6b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Armour Thyroid tablets are indicated: As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (See WARNINGS ). As pituitary TSH suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic Iymphocytic thyroiditis (Hashimoto's), multinodular goiter, and in the management of thyroid cancer. PUBCHEM.COMPOUND:53462828 uuid:0ce5bbac-9169-4dde-ae76-9c5a968b9783 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60311 biolink:treats MONDO:0002108 PMID:41385096 "[{""id"":""uuid:bfaf14fd-a2d0-4da5-985e-3857286c7014"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:11c5cf77-3bd4-404f-bc52-455af607825f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Armour Thyroid tablets are indicated: As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (See WARNINGS ). As pituitary TSH suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic Iymphocytic thyroiditis (Hashimoto's), multinodular goiter, and in the management of thyroid cancer. PUBCHEM.COMPOUND:53462828 uuid:8c4d77c5-a4b1-43ef-8251-62d3c347c8ee biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15366 biolink:treats MONDO:0004795 PMID:41385096 "[{""id"":""uuid:920a3413-4e87-4fe4-9275-871762d11978"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1d5d1663-4247-4930-ab76-922ab596c432"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the treatment of superficial infections of the external auditory canal caused by organisms susceptible to the action of the antimicrobial. uuid:3a8c839b-9c9d-4cbf-a097-3d01a687e202 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:37924 biolink:treats MONDO:0004951 PMID:41385096 "[{""id"":""uuid:5812e68b-5301-4a61-a136-7970151c49bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:79aa3aa0-1fb2-46c1-96d2-f298d7bfb11b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] REYATAZ ® (atazanavir sulfate) is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. This indication is based on analyses of plasma HIV-1 RNA levels and CD4+ cell counts from controlled studies of 96 weeks duration in antiretroviral-naive and 48 weeks duration in antiretroviral-treatment-experienced adult and pediatric patients at least 6 years of age. The following points should be considered when initiating therapy with REYATAZ: In Study AI424-045, REYATAZ/ritonavir and lopinavir/ritonavir were similar for the primary efficacy outcome measure of time-averaged difference in change from baseline in HIV RNA level. This study was not large enough to reach a definitive conclusion that REYATAZ/ritonavir and lopinavir/ritonavir are equivalent on the secondary efficacy outcome measure of proportions below the HIV RNA lower limit of detection [see Clinical Studies (14.2) ]. The number of baseline primary protease inhibitor mutations affects the virologic response to REYATAZ/ritonavir [see Clinical Pharmacology (12.4) ]. uuid:7d127d36-8383-41a3-81db-9bba56b72cd4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:100241 biolink:treats MONDO:0003529 PMID:41385096 "[{""id"":""uuid:fc76f6c5-e280-46ff-9833-b8ebb8abd1e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4ca1b249-0381-490f-bae6-91421a939516"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ciprofloxacin extended-release tablets are indicated only for the treatment of urinary tract infections, including acute uncomplicated pyelonephritis, caused by susceptible strains of the designated microorganisms as listed below. Ciprofloxacin extended-release tablets and ciprofloxacin immediate-release tablets are not interchangeable. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Uncomplicated Urinary Tract Infections (Acute Cystitis) caused by Escherichia coli, Proteus mirabilis, Enterococcus faecalis, or Staphylococcus saprophyticus Treatment of infections due to this organism in the organ system was studied in fewer than 10 patients. . Complicated Urinary Tract Infections caused by Escherichia coli, Klebsiella pneumoniae, Enterococcus faecalis, Proteus mirabilis, or Pseudomonas aeruginosa . Acute Uncomplicated Pyelonephritis caused by Escherichia coli. THE SAFETY AND EFFICACY OF CIPROFLOXACIN EXTENDED-RELEASE TABLETS IN TREATING INFECTIONS OTHER THAN URINARY TRACT INFECTIONS HAS NOT BEEN DEMONSTRATED. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to ciprofloxacin. Therapy with ciprofloxacin extended-release tablets may be initiated before results of these tests are known; once results become available appropriate therapy should be continued. Culture and susceptibility testing performed periodically during therapy will provide information not only on the therapeutic effect of the antimicrobial agent but also on the possible emergence of bacterial resistance. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ciprofloxacin extended-release tablets and other antibacterial drugs, ciprofloxacin extended-release tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:d7717cc7-4c88-40ba-93cf-f7f2ff65cd8f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:284780 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:f8e30ef1-82aa-4724-85bf-2212c6361d1e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:eced6f70-0b36-4ef0-8efb-8948b3757deb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c4d72b3b-5300-4865-aa2d-e2bb1deaa419"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Micardis® HCT (telmisartan and hydrochlorothiazide) tablets are indicated for the treatment of hypertension. This fixed dose combination is not indicated for initial therapy (see DOSAGE AND ADMINISTRATION ).|[PMDA] A new combination drug indicated for the treatment of hypertension. uuid:df247467-16ba-4753-a4c5-2e111f602b71 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135929 biolink:treats MONDO:0010811 PMID:41385096 "[{""id"":""uuid:abc31a9a-e089-4cc7-8073-9239f76856f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6bbe32d1-00e9-4bee-93c9-ebe7efb0bf26"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:0c5e5747-47ac-45c2-8b69-2ba15611f5ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/silodosin-recordati""]},{""id"":""uuid:d6c6400c-2171-4b37-a5de-20b567392b78"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RAPAFLO, a selective alpha-1 adrenergic receptor antagonist, is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH) [ see Clinical Studies (14) ]. RAPAFLO is not indicated for the treatment of hypertension.|[EMA] Treatment of the signs and symptoms of benign prostatic hyperplasia (BPH) in adult men.|[PMDA] Drugs containing a new active ingredient indicated for the treatment of urination disorder associated with prostatic hypertrophy uuid:d74a57ef-8c83-4365-8ec9-5d3cbb43726c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8426 biolink:treats MONDO:0005393 PMID:41385096 "[{""id"":""uuid:8cae9b3a-02ef-4088-b844-bd49b10c4613"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ce2dcb6b-bd8c-4a91-832a-cc1d0ad9f85e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For treatment of the hyperuricemia associated with gout and gouty arthritis. As an adjuvant to therapy with penicillin or with ampicillin, methicillin, oxacillin, cloxacillin, or nafcillin, for elevation and prolongation of plasma levels by whatever route the antibiotic is given. uuid:98ee4775-b0bd-4012-b668-3ce546a9cb32 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8426 biolink:treats HP:0002149 PMID:41385096 "[{""id"":""uuid:a7c3adb2-1bc5-42a8-b042-7527c6aff040"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:63941efb-a46b-42de-a28d-68eebdf94216"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For treatment of the hyperuricemia associated with gout and gouty arthritis. As an adjuvant to therapy with penicillin or with ampicillin, methicillin, oxacillin, cloxacillin, or nafcillin, for elevation and prolongation of plasma levels by whatever route the antibiotic is given. uuid:bc35c961-2cd3-4fd3-af93-6b3002587eae biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5147 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:85b7dd4e-7465-43bc-82cd-24345cf3f454"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e32642bf-9563-4baa-a112-c63c2c798fac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FORADIL AEROLIZER is indicated for the treatment of asthma and in the prevention of bronchospasm only as concomitant therapy with a long-term asthma control medication, such as an inhaled corticosteroid, in adults and children 5 years of age and older with reversible obstructive airways disease, including patients with symptoms of nocturnal asthma. Long-acting beta 2 -adrenergic agonists (LABA), such as formoterol, the active ingredient in FORADIL AEROLIZER, increase the risk of asthma-related death (see WARNINGS). Use of FORADIL AEROLIZER for the treatment of asthma without concomitant use of a long-term asthma control medication, such as an inhaled corticosteroid, is contraindicated. Use FORADIL AEROLIZER only as additional therapy for patients with asthma who are currently taking but are inadequately controlled on a long-term asthma control medication, such as an inhaled corticosteroid. Once asthma control is achieved and maintained, assess the patient at regular intervals and step down therapy (e.g. discontinue FORADIL AEROLIZER) if possible without loss of asthma control, and maintain the patient on a long-term asthma control medication, such as an inhaled corticosteroid. Do not use FORADIL AEROLIZER for patients whose asthma is adequately controlled on low or medium dose inhaled corticosteroids. uuid:f65e0991-759e-49ed-9d7f-a326d717f428 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5147 biolink:treats MONDO:0001358 PMID:41385096 "[{""id"":""uuid:1db14c5b-c3bc-459a-af09-e99e0d937ef5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:58ab4957-fb5f-4795-91c2-58608a9f7ded"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FORADIL AEROLIZER is indicated for the treatment of asthma and in the prevention of bronchospasm only as concomitant therapy with a long-term asthma control medication, such as an inhaled corticosteroid, in adults and children 5 years of age and older with reversible obstructive airways disease, including patients with symptoms of nocturnal asthma. Long-acting beta 2 -adrenergic agonists (LABA), such as formoterol, the active ingredient in FORADIL AEROLIZER, increase the risk of asthma-related death (see WARNINGS). Use of FORADIL AEROLIZER for the treatment of asthma without concomitant use of a long-term asthma control medication, such as an inhaled corticosteroid, is contraindicated. Use FORADIL AEROLIZER only as additional therapy for patients with asthma who are currently taking but are inadequately controlled on a long-term asthma control medication, such as an inhaled corticosteroid. Once asthma control is achieved and maintained, assess the patient at regular intervals and step down therapy (e.g. discontinue FORADIL AEROLIZER) if possible without loss of asthma control, and maintain the patient on a long-term asthma control medication, such as an inhaled corticosteroid. Do not use FORADIL AEROLIZER for patients whose asthma is adequately controlled on low or medium dose inhaled corticosteroids. uuid:ae9c7eb6-c259-4d56-9bb1-1d0bea0d8fdc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5147 biolink:treats MONDO:0956979 PMID:41385096 "[{""id"":""uuid:651b6aec-fa42-4112-8d99-e4d234c2ee5b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e26e4847-8dc6-4d27-ac46-3ca995177353"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FORADIL AEROLIZER is indicated for the treatment of asthma and in the prevention of bronchospasm only as concomitant therapy with a long-term asthma control medication, such as an inhaled corticosteroid, in adults and children 5 years of age and older with reversible obstructive airways disease, including patients with symptoms of nocturnal asthma. Long-acting beta 2 -adrenergic agonists (LABA), such as formoterol, the active ingredient in FORADIL AEROLIZER, increase the risk of asthma-related death (see WARNINGS). Use of FORADIL AEROLIZER for the treatment of asthma without concomitant use of a long-term asthma control medication, such as an inhaled corticosteroid, is contraindicated. Use FORADIL AEROLIZER only as additional therapy for patients with asthma who are currently taking but are inadequately controlled on a long-term asthma control medication, such as an inhaled corticosteroid. Once asthma control is achieved and maintained, assess the patient at regular intervals and step down therapy (e.g. discontinue FORADIL AEROLIZER) if possible without loss of asthma control, and maintain the patient on a long-term asthma control medication, such as an inhaled corticosteroid. Do not use FORADIL AEROLIZER for patients whose asthma is adequately controlled on low or medium dose inhaled corticosteroids. uuid:ce90f87b-615c-49b7-9861-5f75c6c242ab biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10650 biolink:treats MONDO:0005277 PMID:41385096 "[{""id"":""uuid:786b28c7-97bb-463e-84a3-7b115d8d6ff9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0561232b-8400-4c35-aead-4ba84e03b091"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sumatriptan succinate injection is indicated for 1) the acute treatment of migraine attacks with or without aura and 2) the acute treatment of cluster headache episodes. Sumatriptan succinate injection is not for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS ). uuid:2129992e-c6d8-4276-a995-0411ad2f2667 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1152283 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:28839ebd-3627-475c-973c-8ec7ebf98b37"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a01f5519-76b9-449a-afdb-57445522d4f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lotrel is a combination tablet of amlodipine, a dihydropyridine calcium channel blocker (DHP CCB) and benazepril, an angiotensin converting enzyme (ACE) inhibitor. Lotrel is indicated for the treatment of hypertension in patients not adequately controlled on monotherapy with either agent ( 1 ) uuid:893f6433-c217-403f-a7be-fb43c468a0be biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6942 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:295c873c-61ec-433b-a8d5-cd35b7a78226"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ccba6da2-bcec-4561-846f-7c91a55eaa9f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Because of the potential for serious adverse effects, minoxidil tablets are indicated only in the treatment of hypertension that is symptomatic or associated with target organ damage and is not manageable with maximum therapeutic doses of a diuretic plus two other antihypertensive drugs. At the present time use in milder degrees of hypertension is not recommended because the benefit-risk relationship in such patients has not been defined. Minoxidil reduced supine diastolic blood pressure by 20 mm Hg or to 90 mm Hg or less in approximately 75% of patients, most of whom had hypertension that could not be controlled by other drugs. uuid:13291a5b-5c64-4549-abcb-758f23c3bd5c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4975 biolink:treats UMLS:C0267055 PMID:41385096 "[{""id"":""uuid:14c243b4-9631-477d-bfbe-609f31cb1a8e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0a4284bc-83ad-4057-acf2-3c50d5e2c0c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Famotidine is indicated in: 1. Short-term treatment of active duodenal ulcer. Most adult patients heal within 4 weeks; there is rarely reason to use famotidine at full dosage for longer than 6 to 8 weeks. Studies have not assessed the safety of famotidine in uncomplicated active duodenal ulcer for periods of more than eight weeks. 2. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of an active ulcer. Controlled studies in adults have not extended beyond one year. 3. Short-term treatment of active benign gastric ulcer. Most adult patients heal within 6 weeks. Studies have not assessed the safety or efficacy of famotidine in uncomplicated active benign gastric ulcer for periods of more than 8 weeks. 4. Short-term treatment of gastroesophageal reflux disease (GERD). Famotidine is indicated for short-term treatment of patients with symptoms of GERD (see CLINICAL PHARMACOLOGY IN ADULTS, Clinical Studies ). Famotidine is also indicated for the short-term treatment of esophagitis due to GERD including erosive or ulcerative disease diagnosed by endoscopy (see CLINICAL PHARMACOLOGY IN ADULTS, Clinical Studies ). 5. Treatment of pathological hypersecretory conditions (e. g., Zollinger-Ellison Syndrome, multiple endocrine adenomas ) (see CLINICAL PHARMACOLOGY IN ADULTS, Clinical Studies ) . uuid:5b5986eb-1bbd-47a9-bed2-85aa804c35f9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1154384 biolink:treats MONDO:0005136 PMID:41385096 "[{""id"":""uuid:55981584-5e91-4299-a1a6-d4bc8421964d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:48d28534-488e-46e1-a6fc-2121346a76ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:fbb30d0e-fef4-4f5a-bdd8-7886f1458f52"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prevention of Malaria: Atovaquone and proguanil hydrochloride tablets are indicated for the prophylaxis of P. falciparum malaria, including in areas where chloroquine resistance has been reported (see CLINICAL STUDIES ).|[PMDA] A new combination drug with a new active ingredient indicated for the treatment and prevention of malaria. [Priority review] uuid:7a7eda33-e93f-4ade-8bcd-d201c548a1b8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats UMLS:C0332686 PMID:41385096 "[{""id"":""uuid:955f6514-1312-47a6-8587-2a4175e63708"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:07387c46-56ae-47e1-ad69-8c3102f0815e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the temporary relief of pain and itching due to: ■ minor burns ■ minor skin irritations ■ scrapes ■ minor cuts ■ sunburn ■ insect bites uuid:d435dd81-6283-4af6-85a8-3a59e641e5e0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0005093 PMID:41385096 "[{""id"":""uuid:029985f0-22e5-4f43-9435-7287ca5d3c01"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:29cffd05-6e5f-4cde-b0c5-4a8a92517265"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the temporary relief of pain and itching due to: ■ minor burns ■ minor skin irritations ■ scrapes ■ minor cuts ■ sunburn ■ insect bites uuid:59da9b95-5b61-4cfd-84de-acce6d4f5c51 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0005326 PMID:41385096 "[{""id"":""uuid:6e53d9aa-a7aa-4a3f-8f28-0f742d8168eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f2b34d1c-f94c-4823-b180-0db2a185d836"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the temporary relief of pain and itching due to: ■ minor burns ■ minor skin irritations ■ scrapes ■ minor cuts ■ sunburn ■ insect bites uuid:5983ad64-2d86-462a-adc9-2b97f7b39c64 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats UMLS:C0021564 PMID:41385096 "[{""id"":""uuid:c99bf73c-1905-491c-ac95-29538b81db0c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ff7741dd-3fe4-4460-8be1-309a636c9c82"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the temporary relief of pain and itching due to: ■ minor burns ■ minor skin irritations ■ scrapes ■ minor cuts ■ sunburn ■ insect bites uuid:abab4582-f34b-4a99-8977-937306850201 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:9P1872D4OL biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:1800c150-8fc5-40aa-9619-b29f664e05f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:02a01c11-1fe1-44a0-82d9-f7739e65e3fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:4b0affc7-f1aa-426f-82a2-242ad979da6a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/bydureon""]},{""id"":""uuid:a36f7c0d-84f9-4b68-b363-fb77110c7955"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BYETTA is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Important Limitations of Use Not a substitute for insulin. BYETTA should not be used for the treatment of type 1 diabetes or diabetic ketoacidosis ( 1.2 ). Concurrent use with prandial insulin has not been studied and cannot be recommended ( 1.2 ). Has not been studied in patients with a history of pancreatitis. Consider other antidiabetic therapies in patients with a history of pancreatitis ( 1.2 ).|[EMA] Bydureon is indicated in adults 18 years and older with type 2 diabetes mellitus to improve glycaemic control in combination with other glucose lowering medicinal products when the therapy in use, together with diet and exercise, does not provide adequate glycaemic control (see section 4.4, 4.5 and 5.1 for available data on different combinations).Bydureon is indicated for treatment of type 2 diabetes mellitus in combination with:MetforminSulphonylureaThiazolidinedioneMetformin and sulphonylureaMetformin and thiazolidinedionein adults who have not achieved adequate glycaemic control on maximally tolerated doses of these oral therapies.|[PMDA] A drug with a new additional indication and a new dosage in a new dosage form for the treatment of type 2 diabetes mellitus. uuid:827ebb17-8ae3-480d-b068-966664beaf34 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:9P1872D4OL biolink:treats MONDO:0005147 PMID:41385096 "[{""id"":""uuid:b48b1260-4da5-4afb-8bbe-2557f3bbf5db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0ceefac8-689f-41e9-8f21-d8214b0e6e18"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BYETTA is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Important Limitations of Use Not a substitute for insulin. BYETTA should not be used for the treatment of type 1 diabetes or diabetic ketoacidosis ( 1.2 ). Concurrent use with prandial insulin has not been studied and cannot be recommended ( 1.2 ). Has not been studied in patients with a history of pancreatitis. Consider other antidiabetic therapies in patients with a history of pancreatitis ( 1.2 ). uuid:64fbee4f-7c48-41d7-bbaa-9aa3d28a6b70 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:9P1872D4OL biolink:treats MONDO:0012819 PMID:41385096 "[{""id"":""uuid:a17b5750-799c-4304-9251-45d71bb4935b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:453393df-50f9-4976-b63e-d3217e8d0a97"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BYETTA is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Important Limitations of Use Not a substitute for insulin. BYETTA should not be used for the treatment of type 1 diabetes or diabetic ketoacidosis ( 1.2 ). Concurrent use with prandial insulin has not been studied and cannot be recommended ( 1.2 ). Has not been studied in patients with a history of pancreatitis. Consider other antidiabetic therapies in patients with a history of pancreatitis ( 1.2 ). uuid:bbb91d0c-2f0e-449d-a365-95a3ee2a601a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:9P1872D4OL biolink:treats MONDO:0004982 PMID:41385096 "[{""id"":""uuid:d7073a7d-bb1f-4074-9ad5-d82020cfccc8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e14c98f2-e622-4921-b90f-7736594183c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BYETTA is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Important Limitations of Use Not a substitute for insulin. BYETTA should not be used for the treatment of type 1 diabetes or diabetic ketoacidosis ( 1.2 ). Concurrent use with prandial insulin has not been studied and cannot be recommended ( 1.2 ). Has not been studied in patients with a history of pancreatitis. Consider other antidiabetic therapies in patients with a history of pancreatitis ( 1.2 ). uuid:4941e2a2-2369-411b-8096-80d1913d458e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32151 biolink:treats EFO:0006865 PMID:41385096 "[{""id"":""uuid:c38e1c0d-2608-4efe-a0af-91e62458a805"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ac6eccbf-b417-4a5f-9c5b-12931b5725cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:622371d4-dc09-4c5f-afb2-8df115498bd2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VESIcare is a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.|[PMDA] Drugs with a new active ingredient indicated for treatment of urinary urgency, urinary frequency, and urge urinary incontinence associated with overactive bladder. uuid:be0dfd56-0c74-4acb-9019-24edd9443f9e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32151 biolink:treats HP:0100515 PMID:41385096 "[{""id"":""uuid:f12aaa44-587d-4ea9-bb40-2552ebd34ea2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f76ac5ff-6f7a-43ef-ae57-e541fce389df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:fdce8d91-0e8b-44d7-976e-a7c9ad21d715"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VESIcare is a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.|[PMDA] Drugs with a new active ingredient indicated for treatment of urinary urgency, urinary frequency, and urge urinary incontinence associated with overactive bladder. uuid:9444206e-dd3a-4e11-9d58-c41de4d94b85 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5062 biolink:treats MONDO:0008315 PMID:41385096 "[{""id"":""uuid:034b510a-95cb-4adf-993c-24ce82042fe3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4ce32a87-ea96-4cd1-be5c-b6704bb17aeb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Finasteride tablets USP, is a 5α-reductase inhibitor, indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to ( 1.1 ): •Improve symptoms • Reduce the risk of the need for surgery including transurethral resection of the prostate (TURP) and prostatectomy. Limitations of Use: Finasteride tablets USP is not approved for the prevention of prostate cancer ( 1.3 ). uuid:bdaf00fe-4d68-47c6-b6fe-7533c5d2fdb0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:84043 biolink:treats MONDO:0043455 PMID:41385096 "[{""id"":""uuid:4296ad3e-9f39-4cf1-bef4-af4fa9095468"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9e0599be-d022-4254-9a32-e6dc706cd8f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ganite is indicated for the treatment of clearly symptomatic cancer-related hypercalcemia that has not responded to adequate hydration. In general, patients with a serum calcium (corrected for albumin) < 12 mg/dL would not be expected to be symptomatic. Mild or asymptomatic hypercalcemia may be treated with conservative measures (i.e., saline hydration, with or without diuretics). In the treatment of cancer-related hypercalcemia, it is important first to establish adequate hydration, preferably with intravenous saline, in order to increase the renal excretion of calcium and correct dehydration caused by hypercalcemia. uuid:661fd7a6-083a-45f3-a6e9-dc3ae2deb313 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4873 biolink:treats MONDO:0001932 PMID:41385096 "[{""id"":""uuid:dabfc4e8-c81d-42a8-ba54-d58518a8210b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6badca0f-86bf-4caf-83e2-f2bdddd367fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Estropipate tablets are indicated in the: Treatment of moderate to severe vasomotor symptoms associated with the menopause. Treatment of moderate to severe symptoms of vulval and vaginal atrophy associated with the menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. Treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. Prevention of postmenopausal osteoporosis. When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and for whom non-estrogen medications are not considered to be appropriate. The mainstays for decreasing the risk of postmenopausal osteoporosis are weight-bearing exercise, adequate calcium and vitamin D intake, and when indicated, pharmacologic therapy. Postmenopausal women require an average of 1500 mg/day of elemental calcium. Therefore, when not contraindicated, calcium supplementation may be helpful for women with suboptimal dietary intake. Vitamin D supplementation of 400-800 IU/day may also be required to ensure adequate daily intake in postmenopausal women. DOID:14275 uuid:3ec77c2e-7eb6-423c-a698-a1ecd8a1a339 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4873 biolink:treats MONDO:0018555 PMID:41385096 "[{""id"":""uuid:ce0c80cf-802f-45c5-a629-ceefe2803f18"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6aada529-c012-449f-bd62-dbf473e8ac7e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Estropipate tablets are indicated in the: Treatment of moderate to severe vasomotor symptoms associated with the menopause. Treatment of moderate to severe symptoms of vulval and vaginal atrophy associated with the menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. Treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. Prevention of postmenopausal osteoporosis. When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and for whom non-estrogen medications are not considered to be appropriate. The mainstays for decreasing the risk of postmenopausal osteoporosis are weight-bearing exercise, adequate calcium and vitamin D intake, and when indicated, pharmacologic therapy. Postmenopausal women require an average of 1500 mg/day of elemental calcium. Therefore, when not contraindicated, calcium supplementation may be helpful for women with suboptimal dietary intake. Vitamin D supplementation of 400-800 IU/day may also be required to ensure adequate daily intake in postmenopausal women. uuid:25cf0901-67f6-4a46-96b4-09bfc3b0d0f9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4873 biolink:treats MONDO:0005387 PMID:41385096 "[{""id"":""uuid:e61df45c-2331-4ff1-b4a5-0ddea0cefa4b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:005c7d90-c7dd-408c-a436-2babcff71773"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Estropipate tablets are indicated in the: Treatment of moderate to severe vasomotor symptoms associated with the menopause. Treatment of moderate to severe symptoms of vulval and vaginal atrophy associated with the menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. Treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. Prevention of postmenopausal osteoporosis. When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and for whom non-estrogen medications are not considered to be appropriate. The mainstays for decreasing the risk of postmenopausal osteoporosis are weight-bearing exercise, adequate calcium and vitamin D intake, and when indicated, pharmacologic therapy. Postmenopausal women require an average of 1500 mg/day of elemental calcium. Therefore, when not contraindicated, calcium supplementation may be helpful for women with suboptimal dietary intake. Vitamin D supplementation of 400-800 IU/day may also be required to ensure adequate daily intake in postmenopausal women. uuid:591c6bbe-9650-4543-b922-7da682020c17 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4873 biolink:treats MONDO:0008159 PMID:41385096 "[{""id"":""uuid:888bcdd8-d486-4af7-8a92-8eccfbde1f46"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3ab2fefb-79a9-48dd-87c4-a89177c6f1c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Estropipate tablets are indicated in the: Treatment of moderate to severe vasomotor symptoms associated with the menopause. Treatment of moderate to severe symptoms of vulval and vaginal atrophy associated with the menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. Treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. Prevention of postmenopausal osteoporosis. When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and for whom non-estrogen medications are not considered to be appropriate. The mainstays for decreasing the risk of postmenopausal osteoporosis are weight-bearing exercise, adequate calcium and vitamin D intake, and when indicated, pharmacologic therapy. Postmenopausal women require an average of 1500 mg/day of elemental calcium. Therefore, when not contraindicated, calcium supplementation may be helpful for women with suboptimal dietary intake. Vitamin D supplementation of 400-800 IU/day may also be required to ensure adequate daily intake in postmenopausal women. uuid:067b05e0-9962-4dfd-9f4c-a6575f5de59e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8875 biolink:treats MONDO:0005277 PMID:41385096 "[{""id"":""uuid:58c0c500-1032-4ee2-85b8-4ab1bd59e897"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f02a7998-c3c5-42ed-88e7-a33e5b77111c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MAXALT ® and MAXALT-MLT ® are indicated for the acute treatment of migraine with or without aura in adults and in pediatric patients 6 to 17 years old. Limitations of Use MAXALT should only be used where a clear diagnosis of migraine has been established. If a patient has no response for the first migraine attack treated with MAXALT, the diagnosis of migraine should be reconsidered before MAXALT is administered to treat any subsequent attacks. MAXALT is not indicated for use in the management of hemiplegic or basilar migraine [see Contraindications (4) ] . MAXALT is not indicated for the prevention of migraine attacks. Safety and effectiveness of MAXALT have not been established for cluster headache. uuid:6c50be3d-868c-479f-9e78-e355f9ab3832 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4702 biolink:treats MONDO:0006875 PMID:41385096 "[{""id"":""uuid:b4f3f6d6-5c2c-4160-a789-83dfe9621f68"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c87c2561-68cd-4c96-b85f-a37cbd54c04d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dorzolamide HCl Ophthalmic Solution is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. uuid:0dd22d44-1706-42a4-ac49-f97fab68a3d7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4702 biolink:treats MONDO:0005338 PMID:41385096 "[{""id"":""uuid:38c8a410-4935-4193-b019-8376d3382dc6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4b076cb1-3cd8-4d85-b1b5-a4033b81f291"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dorzolamide HCl Ophthalmic Solution is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. uuid:6ff95ab1-fa3e-40e1-b6a4-8eb712549df0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16469 biolink:treats MONDO:0001410 PMID:41385096 "[{""id"":""uuid:07409e90-b6c4-46b4-bd43-7fcbe6ef601f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c712ffd0-0e75-4cb4-8cd9-b6399bc2857a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vagifem is an estrogen (estradiol) indicated for the treatment of atrophic vaginitis due to menopause ( 1 ). uuid:bec5775a-7713-46ca-9518-d560ba55d419 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2663 biolink:treats MONDO:0000190 PMID:41385096 "[{""id"":""uuid:85cd7f75-848d-46c3-9b09-70fcbc02fd02"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1ea48535-7dca-44dd-a5e7-3db37335b78b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:4b9f2c68-2b02-4fe5-afba-2cc2c57e38e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amiodarone injection is indicated for initiation of treatment and prophylaxis of frequently recurring ventricular fibrillation (VF) and hemodynamically unstable ventricular tachycardia (VT) in patients refractory to other therapy. Amiodarone also can be used to treat patients with VT/VF for whom oral amiodarone is indicated, but who are unable to take oral medication. During or after treatment with amiodarone, patients may be transferred to oral amiodarone therapy [see Dosage and Administration (2) ] . Use amiodarone for acute treatment until the patient's ventricular arrhythmias are stabilized. Most patients will require this therapy for 48 to 96 hours, but amiodarone may be safely administered for longer periods if necessary.|[PMDA] Drug with a new route of administration, used for emergency treatment of refractory arrhythmias (ventricular fibrillation and hemodynamically unstable ventricular tachycardia). [Orphan Drug] uuid:8b87cc49-58d1-4b31-bd2c-70e545fca8c3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:a71b2f42-487f-460c-a668-f3dd7be029d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3ef97e43-a3b4-4638-88f3-199b23e481bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:cf2ce35a-f2b9-4180-8c06-8ba424738e14"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lidocaine HCl 2% Jelly is indicated for prevention and control of pain in procedures involving the male and female urethra, for topical treatment of painful urethritis, and as an anesthetic lubricant for endotracheal intubation (oral and nasal).|[PMDA] A drug with a new additional indication and a new dosage for pain relief at the resection of molluscum contagiosum. uuid:71582533-a484-4b3f-8043-d800a2ae4290 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0005297 PMID:41385096 "[{""id"":""uuid:3f324ba8-b5ce-41f6-8a2c-bf8410e1c78e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2faf9a37-38d2-4ebf-b91b-49132476488b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lidocaine HCl 2% Jelly is indicated for prevention and control of pain in procedures involving the male and female urethra, for topical treatment of painful urethritis, and as an anesthetic lubricant for endotracheal intubation (oral and nasal). uuid:79c2ef80-08c5-447c-a3da-15135a95a44d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47381 biolink:treats MONDO:0005475 PMID:41385096 "[{""id"":""uuid:04e31991-d703-460b-8151-40e3921d4998"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6d7cf63c-b0ea-4013-aba8-dac6fad422b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CAMBIA is a non-steroidal anti-inflammatory (NSAID) drug indicated for the acute treatment of migraine attacks with or without aura in adults 18 years of age or older ( 1.1 ) Important Limitations ( 1.2 ): CAMBIA is not indicated for the prophylactic therapy of migraine Safety and effectiveness of CAMBIA not established for cluster headache, which is present in an older, predominantly male population uuid:34b0d326-21a8-401f-a010-d7f93fcea92c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47381 biolink:treats MONDO:0100431 PMID:41385096 "[{""id"":""uuid:ac00572b-2aa1-4449-865e-8125b9145d1a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a3bd6c16-1cdb-4fc9-b49f-4d308efab923"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CAMBIA is a non-steroidal anti-inflammatory (NSAID) drug indicated for the acute treatment of migraine attacks with or without aura in adults 18 years of age or older ( 1.1 ) Important Limitations ( 1.2 ): CAMBIA is not indicated for the prophylactic therapy of migraine Safety and effectiveness of CAMBIA not established for cluster headache, which is present in an older, predominantly male population uuid:b199a53d-0fa5-409f-bc1a-98b9543ca697 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47381 biolink:treats MONDO:0043537 PMID:41385096 "[{""id"":""uuid:07903007-b61e-4cfc-93ed-00d351c571db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e11699b5-a394-443d-bf05-77d07f24f311"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CAMBIA is a non-steroidal anti-inflammatory (NSAID) drug indicated for the acute treatment of migraine attacks with or without aura in adults 18 years of age or older ( 1.1 ) Important Limitations ( 1.2 ): CAMBIA is not indicated for the prophylactic therapy of migraine Safety and effectiveness of CAMBIA not established for cluster headache, which is present in an older, predominantly male population uuid:4e2b2d66-4f95-4755-87f7-d02a0a49f685 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0009850 PMID:41385096 "[{""id"":""uuid:d290a77e-4649-4144-8c77-3340d4a63830"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cce137d7-2e6c-408b-aabf-0ecb5b8d0809"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Doxycycline hyclate is indicated for use as an adjunct to scaling and root planing to promote attachment level gain and to reduce pocket depth in patients with adult periodontitis. uuid:62df8091-44dc-4495-be4d-417e0a255748 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2453 biolink:treats MONDO:0043653 PMID:41385096 "[{""id"":""uuid:7a9da75f-73bf-40ca-a271-663aa58d1b08"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:97e4f119-0542-4ef8-a62e-44033cc040d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZOVIRAX Cream is indicated for the treatment of recurrent herpes labialis (cold sores) in adults and adolescents (12 years of age and older). uuid:18a4d044-9a2f-429e-924a-bad324923365 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90972 biolink:treats MONDO:0004247 PMID:41385096 "[{""id"":""uuid:25d659fb-4a28-42ea-b129-26f7f87000fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5d5ef1fb-e799-4fb2-8a9e-a7e871fbf835"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For use as adjunctive therapy in the treatment of peptic ulcer. uuid:b224e664-90ec-49bd-997f-69888d2255ef biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8059 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:e879778d-4c82-40a3-8f4a-7cdcc27a1829"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8bc2ad9b-ddd1-4b89-a494-f96775011898"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Phendimetrazine tartrate extended-release capsules are indicated in the management of exogenous obesity as a short term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction in patients with an initial body mass index (BMI) of greater than or equal to 30 kg/m2 or greater than or equal to 27 kg/m2 in the presence of other risk factors (e.g., controlled hypertension, diabetes, hyperlipidemia) who have not responded to appropriate weight reducing regimen (diet and/or exercise) alone. Below is a chart of Body Mass Index (BMI) based on various heights and weights. BMI is calculated by taking the patient's weight, in kilograms (kg), divided by the patient's height, in meters (m), squared. Metric conversions are as follows: pounds ÷ 2.2 = kg; inches × 0.0254 = meters BODY MASS INDEX (BMI), kg/m 2 Height (feet, inches) The usefulness of agents of this class (see CLINICAL PHARMACOLOGY) should be measured against possible risk factors inherent in their use such as those described below. Phendimetrazine tartrate is indicated for use as monotherapy only. uuid:7bd9e573-1f1e-46cb-91a2-e0e453465147 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8059 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:adc71c55-4409-4901-870f-0692b1cd14ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2df14aaa-7430-4f83-9d24-bd2e4a39ee38"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Phendimetrazine tartrate extended-release capsules are indicated in the management of exogenous obesity as a short term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction in patients with an initial body mass index (BMI) of greater than or equal to 30 kg/m2 or greater than or equal to 27 kg/m2 in the presence of other risk factors (e.g., controlled hypertension, diabetes, hyperlipidemia) who have not responded to appropriate weight reducing regimen (diet and/or exercise) alone. Below is a chart of Body Mass Index (BMI) based on various heights and weights. BMI is calculated by taking the patient's weight, in kilograms (kg), divided by the patient's height, in meters (m), squared. Metric conversions are as follows: pounds ÷ 2.2 = kg; inches × 0.0254 = meters BODY MASS INDEX (BMI), kg/m 2 Height (feet, inches) The usefulness of agents of this class (see CLINICAL PHARMACOLOGY) should be measured against possible risk factors inherent in their use such as those described below. Phendimetrazine tartrate is indicated for use as monotherapy only. uuid:a23a33fc-af9b-4def-9822-bfe66c293a40 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8059 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:ed799f24-da57-41f3-affb-b44c8d3e6ca2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b8912ac2-91ac-43ad-a45f-ad7d0de570e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Phendimetrazine tartrate extended-release capsules are indicated in the management of exogenous obesity as a short term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction in patients with an initial body mass index (BMI) of greater than or equal to 30 kg/m2 or greater than or equal to 27 kg/m2 in the presence of other risk factors (e.g., controlled hypertension, diabetes, hyperlipidemia) who have not responded to appropriate weight reducing regimen (diet and/or exercise) alone. Below is a chart of Body Mass Index (BMI) based on various heights and weights. BMI is calculated by taking the patient's weight, in kilograms (kg), divided by the patient's height, in meters (m), squared. Metric conversions are as follows: pounds ÷ 2.2 = kg; inches × 0.0254 = meters BODY MASS INDEX (BMI), kg/m 2 Height (feet, inches) The usefulness of agents of this class (see CLINICAL PHARMACOLOGY) should be measured against possible risk factors inherent in their use such as those described below. Phendimetrazine tartrate is indicated for use as monotherapy only. uuid:f6b0f4ab-5d72-4b88-a9f1-172dddd20732 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135920 biolink:treats EFO:0006865 PMID:41385096 "[{""id"":""uuid:069e1069-57ae-486d-b2a6-7c0057e5fff6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4186321a-2c91-4804-bc7a-4a1e90446601"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:b530b35b-4475-4d05-ae4b-33dc031357fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Toviaz ® is a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.|[PMDA] Drugs with a new active ingredient indicated for the treatment of urinary urgency, urinary frequency, and urge urinary incontinence associated with overactive bladder. uuid:9e4fa8f1-cadc-4c33-af7d-72ee6f97cbac biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4659 biolink:treats MONDO:0007079 PMID:41385096 "[{""id"":""uuid:7c68a42a-585d-4150-8e38-88c637111a8c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c9332b69-2a82-4319-9b9a-e56ed55e6132"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Disulfiram is an aid in the management of selected chronic alcohol patients who want to remain in a state of enforced sobriety so that supportive and psychotherapeutic treatment may be applied to best advantage. Disulfiram is not a cure for alcoholism. When used alone, without proper motivation and supportive therapy, it is unlikely that it will have any substantive effect on the drinking pattern of the chronic alcoholic. uuid:7bfd2416-efce-47c7-87a1-06dd331d6e7b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15367 biolink:treats MONDO:0005173 PMID:41385096 "[{""id"":""uuid:c8453eef-5ba0-46ba-b43a-156058ad4dd1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:488547c4-2b4f-484b-a090-1fc405694125"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] (To understand fully the indication for this product, please read the entire INDICATIONS AND USAGE section of the labeling.) RENOVA ® (tretinoin cream) 0.02% is indicated as an adjunctive agent (see second bullet point below) for use in the mitigation (palliation) of fine facial wrinkles in patients who use comprehensive skin care and sunlight avoidance programs. RENOVA ® (tretinoin cream) 0.02% DOES NOT ELIMINATE WRINKLES, REPAIR SUN-DAMAGED SKIN, REVERSE PHOTOAGING, or RESTORE MORE YOUTHFUL or YOUNGER SKIN. In double-blinded, vehicle-controlled clinical studies, many patients in the vehicle group achieved desired palliative effects on fine wrinkling of facial skin with the use of comprehensive skin care and sunlight avoidance programs including sunscreens, protective clothing, and non-prescription emollient creams. RENOVA ® (tretinoin cream) 0.02% has NOT DEMONSTRATED A MITIGATING EFFECT on significant signs of chronic sunlight exposure such as coarse or deep wrinkling, tactile roughness, mottled hyperpigmentation, lentigines, telangiectasia, skin laxity, keratinocytic atypia, melanocytic atypia, or dermal elastosis. RENOVA ® (tretinoin cream) 0.02% should be used under medical supervision as an adjunct to a comprehensive skin care and sunlight avoidance program that includes the use of effective sunscreens (minimum SPF of 15) and protective clothing. Patients with visible actinic keratoses and patients with a history of skin cancer were excluded from clinical trials of RENOVA ® (tretinoin cream) 0.02%. Thus the effectiveness and safety of RENOVA ® (tretinoin cream) 0.02% in these populations are not known at this time. Neither the safety nor the effectiveness of RENOVA ® (tretinoin cream) 0.02% for the prevention or treatment of actinic keratoses or skin neoplasms has been established. Neither the safety nor the efficacy of RENOVA ® (tretinoin cream) 0.02% daily for greater than 52 weeks has been established, and daily use beyond 52 weeks has not been systematically and histologically investigated in adequate and well-controlled trials. (See WARNINGS section.) uuid:ff85f3f3-1e1f-48b1-a713-3e15c201a2ac biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15367 biolink:treats MONDO:0002898 PMID:41385096 "[{""id"":""uuid:985d12c9-b082-424c-883a-c921473c8535"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9477152c-dd04-4fe3-a0b1-465d1dd5a89f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] (To understand fully the indication for this product, please read the entire INDICATIONS AND USAGE section of the labeling.) RENOVA ® (tretinoin cream) 0.02% is indicated as an adjunctive agent (see second bullet point below) for use in the mitigation (palliation) of fine facial wrinkles in patients who use comprehensive skin care and sunlight avoidance programs. RENOVA ® (tretinoin cream) 0.02% DOES NOT ELIMINATE WRINKLES, REPAIR SUN-DAMAGED SKIN, REVERSE PHOTOAGING, or RESTORE MORE YOUTHFUL or YOUNGER SKIN. In double-blinded, vehicle-controlled clinical studies, many patients in the vehicle group achieved desired palliative effects on fine wrinkling of facial skin with the use of comprehensive skin care and sunlight avoidance programs including sunscreens, protective clothing, and non-prescription emollient creams. RENOVA ® (tretinoin cream) 0.02% has NOT DEMONSTRATED A MITIGATING EFFECT on significant signs of chronic sunlight exposure such as coarse or deep wrinkling, tactile roughness, mottled hyperpigmentation, lentigines, telangiectasia, skin laxity, keratinocytic atypia, melanocytic atypia, or dermal elastosis. RENOVA ® (tretinoin cream) 0.02% should be used under medical supervision as an adjunct to a comprehensive skin care and sunlight avoidance program that includes the use of effective sunscreens (minimum SPF of 15) and protective clothing. Patients with visible actinic keratoses and patients with a history of skin cancer were excluded from clinical trials of RENOVA ® (tretinoin cream) 0.02%. Thus the effectiveness and safety of RENOVA ® (tretinoin cream) 0.02% in these populations are not known at this time. Neither the safety nor the effectiveness of RENOVA ® (tretinoin cream) 0.02% for the prevention or treatment of actinic keratoses or skin neoplasms has been established. Neither the safety nor the efficacy of RENOVA ® (tretinoin cream) 0.02% daily for greater than 52 weeks has been established, and daily use beyond 52 weeks has not been systematically and histologically investigated in adequate and well-controlled trials. (See WARNINGS section.) uuid:7229f693-6c62-465e-8ffe-8f0b346d8b91 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15367 biolink:treats MONDO:0002531 PMID:41385096 "[{""id"":""uuid:d3c030af-f87c-4160-bff1-77e0cbfdeb2f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d3c8ed0a-658e-417e-9232-ebd0b78e5b9c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] (To understand fully the indication for this product, please read the entire INDICATIONS AND USAGE section of the labeling.) RENOVA ® (tretinoin cream) 0.02% is indicated as an adjunctive agent (see second bullet point below) for use in the mitigation (palliation) of fine facial wrinkles in patients who use comprehensive skin care and sunlight avoidance programs. RENOVA ® (tretinoin cream) 0.02% DOES NOT ELIMINATE WRINKLES, REPAIR SUN-DAMAGED SKIN, REVERSE PHOTOAGING, or RESTORE MORE YOUTHFUL or YOUNGER SKIN. In double-blinded, vehicle-controlled clinical studies, many patients in the vehicle group achieved desired palliative effects on fine wrinkling of facial skin with the use of comprehensive skin care and sunlight avoidance programs including sunscreens, protective clothing, and non-prescription emollient creams. RENOVA ® (tretinoin cream) 0.02% has NOT DEMONSTRATED A MITIGATING EFFECT on significant signs of chronic sunlight exposure such as coarse or deep wrinkling, tactile roughness, mottled hyperpigmentation, lentigines, telangiectasia, skin laxity, keratinocytic atypia, melanocytic atypia, or dermal elastosis. RENOVA ® (tretinoin cream) 0.02% should be used under medical supervision as an adjunct to a comprehensive skin care and sunlight avoidance program that includes the use of effective sunscreens (minimum SPF of 15) and protective clothing. Patients with visible actinic keratoses and patients with a history of skin cancer were excluded from clinical trials of RENOVA ® (tretinoin cream) 0.02%. Thus the effectiveness and safety of RENOVA ® (tretinoin cream) 0.02% in these populations are not known at this time. Neither the safety nor the effectiveness of RENOVA ® (tretinoin cream) 0.02% for the prevention or treatment of actinic keratoses or skin neoplasms has been established. Neither the safety nor the efficacy of RENOVA ® (tretinoin cream) 0.02% daily for greater than 52 weeks has been established, and daily use beyond 52 weeks has not been systematically and histologically investigated in adequate and well-controlled trials. (See WARNINGS section.) uuid:8d57cca2-3061-42e5-b841-9e4188674ac0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18332 biolink:treats MONDO:0002108 PMID:41385096 "[{""id"":""uuid:f5c2b3be-e50e-4f10-ae7d-2afdf20ec23a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:490d6935-2ffe-459d-ba1d-532acdf3e7d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levothyroxine sodium is used for the following indications: Hypothyroidism - As replacement or supplemental therapy in congenital or acquired hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. Specific indications include: primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) hypothyroidism and subclinical hypothyroidism. Primary hypothyroidism may result from functional deficiency, primary atrophy, partial or total congenital absence of the thyroid gland, or from the effects of surgery, radiation, or drugs, with or without the presence of goiter. Pituitary TSH Suppression - In the treatment or prevention of various types of euthyroid goiters (see WARNINGS and PRECAUTIONS ), including thyroid nodules (see WARNINGS and PRECAUTIONS ), subacute or chronic Iymphocytic thyroiditis (Hashimoto's thyroiditis), multinodular goiter (see WARNINGS and PRECAUTIONS ), and, as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer. uuid:0de05877-7177-4c86-9c09-4a1aa9ad9f90 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5391 biolink:treats UMLS:C4728082 PMID:41385096 "[{""id"":""uuid:38f4b048-41ee-4747-8fed-ab9dfb41b4a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1b1cbe51-42db-4e23-b25f-cd439db00625"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Glucagon is indicated as a treatment for severe hypoglycemia. Because patients with type 1 diabetes may have less of an increase in blood glucose levels compared with a stable type 2 patient, supplementary carbohydrate should be given as soon as possible, especially to a pediatric patient. uuid:ba78d566-8732-4074-8fb0-6b17664fed60 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5391 biolink:treats MONDO:0005147 PMID:41385096 "[{""id"":""uuid:f7f168a4-50dd-4a38-adec-278e55a5d600"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cc75c46b-afe2-44fb-92ad-bbad6784cd6a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Glucagon is indicated as a treatment for severe hypoglycemia. Because patients with type 1 diabetes may have less of an increase in blood glucose levels compared with a stable type 2 patient, supplementary carbohydrate should be given as soon as possible, especially to a pediatric patient. uuid:e345aedb-09ea-4c08-8586-39672c251cd5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5391 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:003e68a9-b598-4bf8-9ac5-17163727e9eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:13b8c7bf-cb2a-465a-883b-3a08eb45579a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Glucagon is indicated as a treatment for severe hypoglycemia. Because patients with type 1 diabetes may have less of an increase in blood glucose levels compared with a stable type 2 patient, supplementary carbohydrate should be given as soon as possible, especially to a pediatric patient. uuid:8f10d9d9-bcc6-4bda-a68b-0a4e7b3eecf2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1152283 biolink:treats NCIT:C50995 PMID:41385096 "[{""id"":""uuid:3eadb43d-5135-4125-a305-55beff3280f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1e53b23d-3dc0-43b3-a533-c3a32373f1ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] {template} uuid:7dcac7a9-a159-49da-a31e-62680138c5f3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27882 biolink:treats MONDO:0005393 PMID:41385096 "[{""id"":""uuid:b23cfa18-1a04-4223-9cfd-174b4f03276a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3546950f-8312-4921-be99-9fd07e3ae3f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] COLCRYS (colchicine, USP) tablets are an alkaloid indicated for: Prophylaxis and Treatment of Gout Flares in adults ( 1.1 ). Familial Mediterranean fever (FMF) in adults and children 4 years or older ( 1.2 ). COLCRYS is not an analgesic medication and should not be used to treat pain from other causes. uuid:516d4a90-2971-4a98-a8ec-579ee7603b1c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27882 biolink:treats MONDO:0018088 PMID:41385096 "[{""id"":""uuid:217cdf6b-db61-442e-b732-fbf1f62473c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5f0d4058-43aa-43ae-9999-c23de85cf08e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:0a4da194-804d-48ea-8cd0-bf152efbd122"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] COLCRYS (colchicine, USP) tablets are an alkaloid indicated for: Prophylaxis and Treatment of Gout Flares in adults ( 1.1 ). Familial Mediterranean fever (FMF) in adults and children 4 years or older ( 1.2 ). COLCRYS is not an analgesic medication and should not be used to treat pain from other causes.|[PMDA] A drug with a new additional indication and a new dosage for the treatment of familial Mediterranean fever. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:f625a75a-6d7a-49c6-afeb-d04d37ef095f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64354 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:685bdd42-d47f-44d4-b821-9cbd3e4137dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0c549945-262a-484f-af10-e0b5d27afb52"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Metolazone tablets USP are indicated for the treatment of salt and water retention including: • edema accompanying congestive heart failure; • edema accompanying renal diseases, including the nephrotic syndrome and states of diminished renal function. Metolazone tablets USP are also indicated for the treatment of hypertension, alone or in combination with other antihypertensive drugs of a different class. Mykrox ® tablets, a more rapidly available form of metolazone, are intended for the treatment of new patients with mild to moderate hypertension. A dose titration is necessary if Mykrox ® tablets are to be substituted for Zaroxolyn ® tablets and other formulations of metolazone that share its slow and incomplete bioavailability, in the treatment of hypertension. uuid:26264254-da23-4fe6-8801-22a6d6f8d9c1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64354 biolink:treats MONDO:0005240 PMID:41385096 "[{""id"":""uuid:d6e05e14-8063-4db8-8de8-fefdd8de6b27"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a2766969-f03d-4a57-bca6-258047dd32f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Metolazone tablets USP are indicated for the treatment of salt and water retention including: • edema accompanying congestive heart failure; • edema accompanying renal diseases, including the nephrotic syndrome and states of diminished renal function. Metolazone tablets USP are also indicated for the treatment of hypertension, alone or in combination with other antihypertensive drugs of a different class. Mykrox ® tablets, a more rapidly available form of metolazone, are intended for the treatment of new patients with mild to moderate hypertension. A dose titration is necessary if Mykrox ® tablets are to be substituted for Zaroxolyn ® tablets and other formulations of metolazone that share its slow and incomplete bioavailability, in the treatment of hypertension. uuid:e58fcc4b-77f0-48bb-80b8-411f19522e40 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64354 biolink:treats MONDO:0005377 PMID:41385096 "[{""id"":""uuid:3acbbf76-5b5d-4a09-9a38-895aae8ac3a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cecc31e3-89f2-477b-9779-1321bcce6c7b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Metolazone tablets USP are indicated for the treatment of salt and water retention including: • edema accompanying congestive heart failure; • edema accompanying renal diseases, including the nephrotic syndrome and states of diminished renal function. Metolazone tablets USP are also indicated for the treatment of hypertension, alone or in combination with other antihypertensive drugs of a different class. Mykrox ® tablets, a more rapidly available form of metolazone, are intended for the treatment of new patients with mild to moderate hypertension. A dose titration is necessary if Mykrox ® tablets are to be substituted for Zaroxolyn ® tablets and other formulations of metolazone that share its slow and incomplete bioavailability, in the treatment of hypertension. uuid:a85fcc53-60f4-4017-87af-997920788429 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64354 biolink:treats MONDO:0005300 PMID:41385096 "[{""id"":""uuid:e240f4ba-a286-4d0c-a235-05c3d15b6d48"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b8cdc33e-38d8-47d2-a68c-52bc046d4329"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Metolazone tablets USP are indicated for the treatment of salt and water retention including: • edema accompanying congestive heart failure; • edema accompanying renal diseases, including the nephrotic syndrome and states of diminished renal function. Metolazone tablets USP are also indicated for the treatment of hypertension, alone or in combination with other antihypertensive drugs of a different class. Mykrox ® tablets, a more rapidly available form of metolazone, are intended for the treatment of new patients with mild to moderate hypertension. A dose titration is necessary if Mykrox ® tablets are to be substituted for Zaroxolyn ® tablets and other formulations of metolazone that share its slow and incomplete bioavailability, in the treatment of hypertension. uuid:b2c5d6e7-f8e6-4ac8-99bb-01a297d52e18 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2567 biolink:treats MONDO:0008159 PMID:41385096 "[{""id"":""uuid:ee7c1ae6-6313-4234-ae31-e18af646c0ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:03e6bcdc-dace-4f19-bc13-925f107c08d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Alendronate sodium tablets are indicated for: Treatment and prevention of osteoporosis in postmenopausal women For the treatment of osteoporosis, alendronate sodium tablets increase bone mass and reduce the incidence of fractures, including those of the hip and spine (vertebral compression fractures). Osteoporosis may be confirmed by the finding of low bone mass (for example, at least 2 standard deviations below the premenopausal mean) or by the presence or history of osteoporotic fracture (see CLINICAL PHARMACOLOGY , Pharmacodynamics ). For the prevention of osteoporosis, alendronate sodium tablets may be considered in postmenopausal women who are at risk of developing osteoporosis and for whom the desired clinical outcome is to maintain bone mass and to reduce the risk of future fracture. Bone loss is particularly rapid in postmenopausal women younger than age 60. Risk factors often associated with the development of postmenopausal osteoporosis include early menopause; moderately low bone mass (for example, at least 1 standard deviation below the mean for healthy young adult women); thin body build; Caucasian or Asian race; and family history of osteoporosis. The presence of such risk factors may be important when considering the use of alendronate sodium for prevention of osteoporosis. Treatment to increase bone mass in men with osteoporosis Treatment of glucocorticoid-induced osteoporosis in men and women receiving glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and who have low bone mineral density (see PRECAUTIONS , Glucocorticoid-induced osteoporosis ). Patients treated with glucocorticoids should receive adequate amounts of calcium and vitamin D. Treatment of Paget’s disease of bone in men and women Treatment is indicated in patients with Paget’s disease of bone having alkaline phosphatase at least two times the upper limit of normal, or those who are symptomatic, or those at risk for future complications from their disease. The safety and effectiveness of alendronate sodium tablets for the treatment of osteoporosis are based on clinical data of four years duration. The optimal duration of use has not been determined. All patients on bisphosphonate therapy should have the need for continued therapy re-evaluated on a periodic basis. uuid:656f4dcb-59ec-48d7-a4ce-febf145b3ee9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0004670 PMID:41385096 "[{""id"":""uuid:9e205b0d-0b62-4eaa-8e4b-f18cd15f29de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:33092639-18a9-47b0-86fb-159ae56c375b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prednisolone Sodium Phosphate Oral Solution is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under “Allergic States”), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren’s syndrome, relapsing polychrondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents). uuid:ae5993a9-9405-4a1d-a771-2a2b9fa181a6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0018170 PMID:41385096 "[{""id"":""uuid:8449546d-f41c-4626-a9da-303cbaaeca9b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aa160a90-02b0-4ec9-bafc-960b9fbc6373"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prednisolone Sodium Phosphate Oral Solution is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under “Allergic States”), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren’s syndrome, relapsing polychrondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents). uuid:cda9cfc4-e2bd-49d9-964c-2c16a4c70e6e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0001705 PMID:41385096 "[{""id"":""uuid:26d03363-2cb2-4029-8d87-901ab014f8da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:81cbf581-03b1-4c49-a142-5437cd9a1ff9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prednisolone Sodium Phosphate Oral Solution is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under “Allergic States”), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren’s syndrome, relapsing polychrondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents). uuid:baf51eca-2b8b-41f2-b7df-8a227911798d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0017595 PMID:41385096 "[{""id"":""uuid:79abfd81-89c7-47fc-9a47-c2e261d81979"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:305470ad-8590-48c7-93c3-3acfd4b9c5f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prednisolone Sodium Phosphate Oral Solution is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under “Allergic States”), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren’s syndrome, relapsing polychrondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents). uuid:bfe96f3b-033b-4890-b5ae-0f11c5279c74 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0020283 PMID:41385096 "[{""id"":""uuid:8ab5e24f-020a-4dd1-96f8-9e0b8367b529"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:26b64a39-3162-4104-88ec-e0bd5612fa8b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prednisolone Sodium Phosphate Oral Solution is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under “Allergic States”), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren’s syndrome, relapsing polychrondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents). uuid:b70bfa7f-3530-4f7f-8f36-aa64fabcb098 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0008538 PMID:41385096 "[{""id"":""uuid:50560c6f-7c84-48f8-aeb1-2bd74fd2981a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f9c1255e-6de6-49a0-94ac-55f9b495a923"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prednisolone Sodium Phosphate Oral Solution is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under “Allergic States”), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren’s syndrome, relapsing polychrondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents). uuid:c8af29cd-1319-41fe-8914-fc9b496c5a63 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0015927 PMID:41385096 "[{""id"":""uuid:ead86c9d-2858-4d04-8aa2-1a7fe2664728"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2f2757f0-5557-400e-a6b7-4ced0d589415"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prednisolone Sodium Phosphate Oral Solution is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under “Allergic States”), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren’s syndrome, relapsing polychrondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents). uuid:968e5a9f-e4d3-4dc9-a230-6be1b3bb1202 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0017853 PMID:41385096 "[{""id"":""uuid:d3e27dcb-14d7-4e56-b4f8-9dc878511aea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8f0ecc83-08cc-4ab5-a79d-18420979b451"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prednisolone Sodium Phosphate Oral Solution is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under “Allergic States”), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren’s syndrome, relapsing polychrondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents). uuid:3b7838fe-1df2-43ad-9c00-b5950eda348d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0002771 PMID:41385096 "[{""id"":""uuid:e3e6f02d-3c63-43f6-b529-fecd618c90e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:831c5556-70d3-4d27-a952-06043c230eeb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prednisolone Sodium Phosphate Oral Solution is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under “Allergic States”), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren’s syndrome, relapsing polychrondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents). uuid:7ff9b2f4-e465-4fef-bcd3-16fe039ec177 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats UMLS:C0340044 PMID:41385096 "[{""id"":""uuid:9b9dd481-d43f-42ca-a99e-7434b22b0eed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:df8972fd-d1e5-40f3-9aee-3794bdc91196"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prednisolone Sodium Phosphate Oral Solution is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under “Allergic States”), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren’s syndrome, relapsing polychrondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents). uuid:3a768a7e-6afa-4b61-96a9-e87c2855db34 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0019121 PMID:41385096 "[{""id"":""uuid:323cf75c-3769-41b4-8d3a-808c859dd1f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c1da6120-9a5f-48fe-8454-6ce80021f9bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prednisolone Sodium Phosphate Oral Solution is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under “Allergic States”), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren’s syndrome, relapsing polychrondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents). uuid:ac650dbd-0a84-40e9-8069-1a63aafa8e67 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0015243 PMID:41385096 "[{""id"":""uuid:ff9c9827-dc30-497e-ac31-98d7e9979573"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a5069f9f-cc8b-4315-ac90-caa70b843b4d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prednisolone Sodium Phosphate Oral Solution is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under “Allergic States”), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren’s syndrome, relapsing polychrondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents). uuid:b5b3e2c5-2a79-4638-a2e8-cf2bdecbac67 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0015264 PMID:41385096 "[{""id"":""uuid:2a42556a-c90c-4133-9543-5a4127c3479d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5321b3b3-4d1e-452e-90dc-6eb7d4d18f52"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prednisolone Sodium Phosphate Oral Solution is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under “Allergic States”), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren’s syndrome, relapsing polychrondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents). uuid:0e022091-aeb1-4dec-852f-d7191ddc44ef biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0019735 PMID:41385096 "[{""id"":""uuid:85c5134a-29f3-4f33-83ce-8914654a5eb8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:20642b7b-e1a2-46f7-ab0d-5075773ff925"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prednisolone Sodium Phosphate Oral Solution is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under “Allergic States”), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren’s syndrome, relapsing polychrondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents). uuid:d77d9fe6-6731-4878-bbe4-e7cbb131a558 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0010030 PMID:41385096 "[{""id"":""uuid:d3275c3f-528f-406b-a67a-c7a94645ebb8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7ed20b99-00d2-4936-8cbc-8b25b65ed057"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prednisolone Sodium Phosphate Oral Solution is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under “Allergic States”), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren’s syndrome, relapsing polychrondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents). uuid:ca0f0584-4d3a-49b7-a5de-3d1f89f73c83 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0019125 PMID:41385096 "[{""id"":""uuid:0281e4d0-9b80-4faa-bdda-bb44a654a12b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d982fb4e-89bc-4067-b3a7-889d1abe8acd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prednisolone Sodium Phosphate Oral Solution is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under “Allergic States”), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren’s syndrome, relapsing polychrondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents). uuid:bbea3955-e949-4ed2-b209-f12fd12d4b84 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0018882 PMID:41385096 "[{""id"":""uuid:0597cb4c-b4bf-49f3-b4f8-126480d4003b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a0292bd8-77e1-4a01-8a3a-1975e6ec9cca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prednisolone Sodium Phosphate Oral Solution is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under “Allergic States”), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren’s syndrome, relapsing polychrondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents). uuid:2d15cd48-5073-475f-888c-bd6b69105996 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0018310 PMID:41385096 "[{""id"":""uuid:e06e59df-fd23-4fa0-b862-60e240d6221d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:858da91f-2486-4fa8-976f-317ca8196024"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prednisolone Sodium Phosphate Oral Solution is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under “Allergic States”), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren’s syndrome, relapsing polychrondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents). uuid:0df0a723-7a81-4ba2-93bd-c947cb60917d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0005922 PMID:41385096 "[{""id"":""uuid:2ed70f64-7522-4621-954f-04cbe4f71d16"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0c22ba12-d770-4f8c-9369-f46d6916a871"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prednisolone Sodium Phosphate Oral Solution is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under “Allergic States”), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren’s syndrome, relapsing polychrondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents). uuid:e136c96e-cfaf-4663-a628-ea77538aeb82 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0005903 PMID:41385096 "[{""id"":""uuid:c4799544-3c7a-4fb7-9dc0-687e490490f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:263f405d-f7d3-448f-b86e-f961e106ee67"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prednisolone Sodium Phosphate Oral Solution is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under “Allergic States”), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren’s syndrome, relapsing polychrondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents). uuid:1d5f1fd8-6719-435c-a57e-afa811e4981c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:142290 biolink:treats MONDO:0008554 PMID:41385096 "[{""id"":""uuid:34dc2ef8-c1b4-4c18-b96a-1617b3aedc8c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e94918fe-3fdd-4f91-8b03-95d379cb470b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Anagrelide hydrochloride capsules are indicated for the treatment of patients with thrombocythemia, secondary to myeloproliferative disorders, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms including thrombo-hemorrhagic events (see CLINICAL STUDIES , DOSAGE AND ADMINISTRATION ). uuid:25479f64-cc97-4e85-8483-c4ed3ee23cd9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:142290 biolink:treats MONDO:0000831 PMID:41385096 "[{""id"":""uuid:96d43779-2180-40de-8a55-d1ac406f7711"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6a860566-49c4-4307-b433-8d9b938880d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Anagrelide hydrochloride capsules are indicated for the treatment of patients with thrombocythemia, secondary to myeloproliferative disorders, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms including thrombo-hemorrhagic events (see CLINICAL STUDIES , DOSAGE AND ADMINISTRATION ). uuid:e12edd27-ea93-4862-b1f5-391b73c4dd94 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:142290 biolink:treats UMLS:C1868936 PMID:41385096 "[{""id"":""uuid:0b8f0d5b-219a-41c8-9ef7-fb0e5530608f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6b28f483-9005-480d-86cf-104b2e0730d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Anagrelide hydrochloride capsules are indicated for the treatment of patients with thrombocythemia, secondary to myeloproliferative disorders, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms including thrombo-hemorrhagic events (see CLINICAL STUDIES , DOSAGE AND ADMINISTRATION ). uuid:9165263a-5274-4c1f-a799-5377212ed30f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3207 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:83597393-02e0-4ae0-9650-0bccd47289d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a735fe56-8266-412e-ba14-7bad379d676d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:30775a32-8416-450a-bb3f-9a42718ded35"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Budesonide inhalation suspension is an inhaled corticosteroid indicated for: Maintenance treatment of asthma and as prophylactic therapy in children 12 months to 8 years of age ( 1.1 ) Important Limitations of Use : Not indicated for the relief of acute bronchospasm ( 1.1 )|[PMDA] Drugs with new dosages and dosage forms indicated for use in children from 6 months and under 5 years of age to treat asthma. [Expedited Review] uuid:0b7a7820-0465-4545-874b-b0b51e095481 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7465 biolink:treats MONDO:0007079 PMID:41385096 "[{""id"":""uuid:92ef806f-5db4-4222-a617-0c0a97b07b71"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d7a62f17-0996-4feb-94a0-cea6b197e3ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Naltrexone hydrochloride tablets are indicated in the treatment of alcohol dependence and for the blockade of the effects of exogenously administered opioids. Naltrexone has not been shown to provide any therapeutic benefit except as part of an appropriate plan of management for the addictions. uuid:002b8193-e606-4f45-bed7-cee39eafb5fc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7465 biolink:treats MONDO:0005530 PMID:41385096 "[{""id"":""uuid:1d715423-32a2-49d5-afbd-4f44a7723731"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cb3385ac-cd19-4277-983c-32034a97faf9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Naltrexone hydrochloride tablets are indicated in the treatment of alcohol dependence and for the blockade of the effects of exogenously administered opioids. Naltrexone has not been shown to provide any therapeutic benefit except as part of an appropriate plan of management for the addictions. uuid:41d08b5d-036e-4259-b47e-8f35936abcba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3181 biolink:treats MONDO:0001836 PMID:41385096 "[{""id"":""uuid:697ec1d3-6662-4560-8043-15efa2a2f16d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c59e9d46-4d66-4fd4-94b7-d1792d4be5f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bromocriptine mesylate tablets and capsules are indicated for the treatment of dysfunctions associated with hyperprolactinemia including amenorrhea with or without galactorrhea, infertility or hypogonadism . Bromocriptine treatment is indicated in patients with prolactin-secreting adenomas , which may be the basic underlying endocrinopathy contributing to the above clinical presentations. Reduction in tumor size has been demonstrated in both male and female patients with macroadenomas. In cases where adenectomy is elected, a course of bromocriptine therapy may be used to reduce the tumor mass prior to surgery. uuid:fdfddbe2-c9b2-4639-9789-85ea6211ae68 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3181 biolink:treats MONDO:0009256 PMID:41385096 "[{""id"":""uuid:4b56b3db-8be9-485e-a964-8cc3212956e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4341eca2-450d-402b-ae81-c52082d30492"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bromocriptine mesylate tablets and capsules are indicated for the treatment of dysfunctions associated with hyperprolactinemia including amenorrhea with or without galactorrhea, infertility or hypogonadism . Bromocriptine treatment is indicated in patients with prolactin-secreting adenomas , which may be the basic underlying endocrinopathy contributing to the above clinical presentations. Reduction in tumor size has been demonstrated in both male and female patients with macroadenomas. In cases where adenectomy is elected, a course of bromocriptine therapy may be used to reduce the tumor mass prior to surgery. uuid:aa400bad-6ae2-4ddf-8b07-bdf4f79ee492 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3181 biolink:treats MONDO:0005047 PMID:41385096 "[{""id"":""uuid:0f88c1e6-dbd8-4a3c-8d7d-2f1c9e12e46c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:348b1fbc-5899-467a-a2d4-7159fcf50cf4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bromocriptine mesylate tablets and capsules are indicated for the treatment of dysfunctions associated with hyperprolactinemia including amenorrhea with or without galactorrhea, infertility or hypogonadism . Bromocriptine treatment is indicated in patients with prolactin-secreting adenomas , which may be the basic underlying endocrinopathy contributing to the above clinical presentations. Reduction in tumor size has been demonstrated in both male and female patients with macroadenomas. In cases where adenectomy is elected, a course of bromocriptine therapy may be used to reduce the tumor mass prior to surgery. uuid:8d639cea-a459-4d0f-94ae-4cbdcb7536f2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3181 biolink:treats MONDO:0002146 PMID:41385096 "[{""id"":""uuid:ad726711-7ba1-423c-a17b-1964f9eae1b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a9525425-f6b1-4921-aed9-cad7ef16d84c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bromocriptine mesylate tablets and capsules are indicated for the treatment of dysfunctions associated with hyperprolactinemia including amenorrhea with or without galactorrhea, infertility or hypogonadism . Bromocriptine treatment is indicated in patients with prolactin-secreting adenomas , which may be the basic underlying endocrinopathy contributing to the above clinical presentations. Reduction in tumor size has been demonstrated in both male and female patients with macroadenomas. In cases where adenectomy is elected, a course of bromocriptine therapy may be used to reduce the tumor mass prior to surgery. uuid:82e14973-1ac6-4a50-a054-34db622dc2ed biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3181 biolink:treats MONDO:0010911 PMID:41385096 "[{""id"":""uuid:6dcbcfb1-6129-455b-a938-62b5d4592245"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:41a299ed-c82a-441b-9b18-b75022874e49"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bromocriptine mesylate tablets and capsules are indicated for the treatment of dysfunctions associated with hyperprolactinemia including amenorrhea with or without galactorrhea, infertility or hypogonadism . Bromocriptine treatment is indicated in patients with prolactin-secreting adenomas , which may be the basic underlying endocrinopathy contributing to the above clinical presentations. Reduction in tumor size has been demonstrated in both male and female patients with macroadenomas. In cases where adenectomy is elected, a course of bromocriptine therapy may be used to reduce the tumor mass prior to surgery. uuid:89dbfb9c-1d86-49f4-a2c0-d6bf5ea3c708 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3181 biolink:treats HP:0025693 PMID:41385096 "[{""id"":""uuid:946f7686-4b35-4ec1-87ae-2c046117942a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:134de545-3b4a-4a28-b64d-f4a7c4b845da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bromocriptine mesylate tablets and capsules are indicated for the treatment of dysfunctions associated with hyperprolactinemia including amenorrhea with or without galactorrhea, infertility or hypogonadism . Bromocriptine treatment is indicated in patients with prolactin-secreting adenomas , which may be the basic underlying endocrinopathy contributing to the above clinical presentations. Reduction in tumor size has been demonstrated in both male and female patients with macroadenomas. In cases where adenectomy is elected, a course of bromocriptine therapy may be used to reduce the tumor mass prior to surgery. uuid:6e5ad7a7-e46f-4beb-afdf-1d3bf20ba549 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:616538 biolink:treats MONDO:0005412 PMID:41385096 "[{""id"":""uuid:0c4ceed6-1721-4cd9-a5e4-99a38a6bb9d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6e2aba63-ec14-4179-bd72-e2937ca4b82a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZEGERID is a proton pump inhibitor indicated for: Short-term treatment of active duodenal ulcer ( 1.1 ) Short-term treatment of active benign gastric ulcer ( 1.2 ) Treatment of gastroesophageal reflux disease (GERD) ( 1.3 ) Maintenance of healing of erosive esophagitis ( 1.4 ) Reduction of risk of upper GI bleeding in critically ill patients ( 1.5 ) The safety and effectiveness of ZEGERID in pediatric patients (<18 years of age) have not been established. ( 8.4 ) uuid:f04d371b-9584-448e-998a-c6c4df5c67ce biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:616538 biolink:treats MONDO:0001126 PMID:41385096 "[{""id"":""uuid:d60cb20e-dc64-4d5b-a4a9-c123e12274b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6714630f-73b7-40cc-a308-c2db5f067d27"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZEGERID is a proton pump inhibitor indicated for: Short-term treatment of active duodenal ulcer ( 1.1 ) Short-term treatment of active benign gastric ulcer ( 1.2 ) Treatment of gastroesophageal reflux disease (GERD) ( 1.3 ) Maintenance of healing of erosive esophagitis ( 1.4 ) Reduction of risk of upper GI bleeding in critically ill patients ( 1.5 ) The safety and effectiveness of ZEGERID in pediatric patients (<18 years of age) have not been established. ( 8.4 ) uuid:befc9909-ec39-436c-bd22-ad39f934f08a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:616538 biolink:treats UMLS:C0267055 PMID:41385096 "[{""id"":""uuid:2205f84b-0772-4c52-973f-db022b88e7fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dc246929-9ff7-4a9f-9996-4a3c9346d582"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZEGERID is a proton pump inhibitor indicated for: Short-term treatment of active duodenal ulcer ( 1.1 ) Short-term treatment of active benign gastric ulcer ( 1.2 ) Treatment of gastroesophageal reflux disease (GERD) ( 1.3 ) Maintenance of healing of erosive esophagitis ( 1.4 ) Reduction of risk of upper GI bleeding in critically ill patients ( 1.5 ) The safety and effectiveness of ZEGERID in pediatric patients (<18 years of age) have not been established. ( 8.4 ) uuid:4dc7c8c8-7b3d-4b76-b0d0-dc9139d5fbd9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:616538 biolink:treats UMLS:C0041909 PMID:41385096 "[{""id"":""uuid:980097e6-458e-4e9e-b13e-aed68a9cc659"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:227794d4-29fc-4eef-80ff-95d1b1fba42e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZEGERID is a proton pump inhibitor indicated for: Short-term treatment of active duodenal ulcer ( 1.1 ) Short-term treatment of active benign gastric ulcer ( 1.2 ) Treatment of gastroesophageal reflux disease (GERD) ( 1.3 ) Maintenance of healing of erosive esophagitis ( 1.4 ) Reduction of risk of upper GI bleeding in critically ill patients ( 1.5 ) The safety and effectiveness of ZEGERID in pediatric patients (<18 years of age) have not been established. ( 8.4 ) uuid:4f4a9901-e926-47e4-bf20-729ded37c930 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:48390 biolink:treats MONDO:0012004 PMID:41385096 "[{""id"":""uuid:81de09cd-f3e5-45ac-badc-fca0babec5d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c0ef3a22-f93e-4482-bdf2-5586ae872e6e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:180b281d-892c-4592-b21c-8d42b3c8de47"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:44b057a3-d965-4b6d-bbea-eb6defe5a2c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sensipar is a calcium-sensing receptor agonist indicated for: Secondary Hyperparathyroidism (HPT) in patients with chronic kidney disease (CKD) on dialysis. ( 1.1 ) Hypercalcemia in patients with Parathyroid Carcinoma (PC). ( 1.2 ) Severe hypercalcemia in patients with primary HPT who are unable to undergo parathyroidectomy. ( 1.3 )|[EMA] Secondary hyperparathyroidismAdultsTreatment of secondary hyperparathyroidism (HPT) in adult patients with end-stage renal disease (ESRD) on maintenance dialysis therapy.Paediatric populationTreatment of secondary hyperparathyroidism (HPT) in children aged 3 years and older with end-stage renal disease (ESRD) on maintenance dialysis therapy in whom secondary HPT is not adequately controlled with standard of care therapy (see section 4.4).Cinacalcet Accordpharma may be used as part of a therapeutic regimen including phosphate binders and/or Vitamin D sterols, as appropriate (see section 5.1).Parathyroid carcinoma and primary hyperparathyroidism in adultsReduction of hypercalcaemia in adult patients with:parathyroid carcinoma.primary HPT for whom parathyroidectomy would be indicated on the basis of serum calcium levels (as defined by relevant treatment guidelines), but in whom parathyroidectomy is not clinically appropriate or is contraindicated.|[PMDA] Drugs with a new additional indication and a new dosage for the treatment of hypercalcemia in patients with parathyroid carcinoma, and hypercalcemia in patients with primary hyperparathyroidism (HPT) who are unable to undergo parathyroidectomy or who experience recurrent primary HPT after the surgery. [Orphan drug] uuid:6e2eb3d9-43e0-44b6-95a6-c6cedc840653 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:48390 biolink:treats MONDO:0010837 PMID:41385096 "[{""id"":""uuid:8702cd53-e11e-4a2f-ae11-0a3e50b397c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:569b86ac-b5c7-46ff-860d-43ba17219e45"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:398a643e-2571-402a-8bbd-2850dee06b5c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:2c2222ae-835e-4121-a835-ab96aa44c3e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sensipar is a calcium-sensing receptor agonist indicated for: Secondary Hyperparathyroidism (HPT) in patients with chronic kidney disease (CKD) on dialysis. ( 1.1 ) Hypercalcemia in patients with Parathyroid Carcinoma (PC). ( 1.2 ) Severe hypercalcemia in patients with primary HPT who are unable to undergo parathyroidectomy. ( 1.3 )|[EMA] Secondary hyperparathyroidismAdultsTreatment of secondary hyperparathyroidism (HPT) in adult patients with end-stage renal disease (ESRD) on maintenance dialysis therapy.Paediatric populationTreatment of secondary hyperparathyroidism (HPT) in children aged 3 years and older with end-stage renal disease (ESRD) on maintenance dialysis therapy in whom secondary HPT is not adequately controlled with standard of care therapy (see section 4.4).Cinacalcet Accordpharma may be used as part of a therapeutic regimen including phosphate binders and/or Vitamin D sterols, as appropriate (see section 5.1).Parathyroid carcinoma and primary hyperparathyroidism in adultsReduction of hypercalcaemia in adult patients with:parathyroid carcinoma.primary HPT for whom parathyroidectomy would be indicated on the basis of serum calcium levels (as defined by relevant treatment guidelines), but in whom parathyroidectomy is not clinically appropriate or is contraindicated.|[PMDA] Drugs with a new additional indication and a new dosage for the treatment of hypercalcemia in patients with parathyroid carcinoma, and hypercalcemia in patients with primary hyperparathyroidism (HPT) who are unable to undergo parathyroidectomy or who experience recurrent primary HPT after the surgery. [Orphan drug] uuid:61749ae8-2923-4b09-ae3b-5b7266132906 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:36560 biolink:treats MONDO:0000736 PMID:41385096 "[{""id"":""uuid:e4866de3-a591-44cc-b31f-648c12bcdc4a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4560e4f4-5b72-451c-8c80-bc255153d0c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The gradual bleaching of hyperpigmented skin conditions such as chloasma, melasma, freckles, senile lentigines, and other unwanted areas of melanin hyperpigmentation. uuid:d75385a4-6fd4-4dec-8adc-19f1a194046f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:36560 biolink:treats MONDO:0021582 PMID:41385096 "[{""id"":""uuid:7a1821b4-c0f7-41f3-a465-aecde367b9dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:93760708-e21b-4d88-808d-56c83873ea18"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The gradual bleaching of hyperpigmented skin conditions such as chloasma, melasma, freckles, senile lentigines, and other unwanted areas of melanin hyperpigmentation. uuid:7d1f624c-950f-4273-ac40-08a2c3b9724a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29688 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:aa4dfd6b-ac1b-4861-b8d9-c785a5169511"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9148026c-d6f8-44ff-8536-a38b9e843ded"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KETEK tablets are indicated for the treatment of community-acquired pneumonia (of mild to moderate severity) due to Streptococcus pneumoniae , (including multi-drug resistant isolates [MDRSP MDRSP, Multi-drug resistant Streptococcus pneumoniae includes isolates known as PRSP (penicillin-resistant Streptococcus pneumoniae ), and are isolates resistant to two or more of the following antibiotics: penicillin, 2 nd generation cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole. ]), Haemophilus influenzae , Moraxella catarrhalis , Chlamydophila pneumoniae , or Mycoplasma pneumoniae , for patients 18 years old and above. To reduce the development of drug-resistant bacteria and maintain the effectiveness of KETEK and other antibacterial drugs, KETEK should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:cf247a73-ebd8-4528-8e0a-0260ccba9dd1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29688 biolink:treats MONDO:0005114 PMID:41385096 "[{""id"":""uuid:6a4f803c-6205-41f6-b89a-86c1abf759c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:60a96e80-c528-4aea-be31-dc521b1cf628"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KETEK tablets are indicated for the treatment of community-acquired pneumonia (of mild to moderate severity) due to Streptococcus pneumoniae , (including multi-drug resistant isolates [MDRSP MDRSP, Multi-drug resistant Streptococcus pneumoniae includes isolates known as PRSP (penicillin-resistant Streptococcus pneumoniae ), and are isolates resistant to two or more of the following antibiotics: penicillin, 2 nd generation cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole. ]), Haemophilus influenzae , Moraxella catarrhalis , Chlamydophila pneumoniae , or Mycoplasma pneumoniae , for patients 18 years old and above. To reduce the development of drug-resistant bacteria and maintain the effectiveness of KETEK and other antibacterial drugs, KETEK should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:bf507715-ea1a-4580-bb8b-37d7ba0b7276 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29688 biolink:treats MONDO:0006878 PMID:41385096 "[{""id"":""uuid:6b57b3c8-ed6e-41e5-b712-e2e1d23a6ff5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4ce84558-61b3-4865-81b2-605d54e68405"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KETEK tablets are indicated for the treatment of community-acquired pneumonia (of mild to moderate severity) due to Streptococcus pneumoniae , (including multi-drug resistant isolates [MDRSP MDRSP, Multi-drug resistant Streptococcus pneumoniae includes isolates known as PRSP (penicillin-resistant Streptococcus pneumoniae ), and are isolates resistant to two or more of the following antibiotics: penicillin, 2 nd generation cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole. ]), Haemophilus influenzae , Moraxella catarrhalis , Chlamydophila pneumoniae , or Mycoplasma pneumoniae , for patients 18 years old and above. To reduce the development of drug-resistant bacteria and maintain the effectiveness of KETEK and other antibacterial drugs, KETEK should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:5f4ce766-5634-409f-bf57-38806c2d753b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29688 biolink:treats MONDO:0025598 PMID:41385096 "[{""id"":""uuid:b129a0f4-ba0d-4660-b607-ff670c3e4446"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3e501252-46d6-4703-8a03-83d502657923"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KETEK tablets are indicated for the treatment of community-acquired pneumonia (of mild to moderate severity) due to Streptococcus pneumoniae , (including multi-drug resistant isolates [MDRSP MDRSP, Multi-drug resistant Streptococcus pneumoniae includes isolates known as PRSP (penicillin-resistant Streptococcus pneumoniae ), and are isolates resistant to two or more of the following antibiotics: penicillin, 2 nd generation cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole. ]), Haemophilus influenzae , Moraxella catarrhalis , Chlamydophila pneumoniae , or Mycoplasma pneumoniae , for patients 18 years old and above. To reduce the development of drug-resistant bacteria and maintain the effectiveness of KETEK and other antibacterial drugs, KETEK should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:fd5c0ab3-aafa-45db-a9b9-6a432d6720d8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29688 biolink:treats MONDO:0005867 PMID:41385096 "[{""id"":""uuid:37422730-76bd-4b38-87fa-8fd1f913f341"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:55c7b730-6451-4d3d-84ae-d1ce2bb6215e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KETEK tablets are indicated for the treatment of community-acquired pneumonia (of mild to moderate severity) due to Streptococcus pneumoniae , (including multi-drug resistant isolates [MDRSP MDRSP, Multi-drug resistant Streptococcus pneumoniae includes isolates known as PRSP (penicillin-resistant Streptococcus pneumoniae ), and are isolates resistant to two or more of the following antibiotics: penicillin, 2 nd generation cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole. ]), Haemophilus influenzae , Moraxella catarrhalis , Chlamydophila pneumoniae , or Mycoplasma pneumoniae , for patients 18 years old and above. To reduce the development of drug-resistant bacteria and maintain the effectiveness of KETEK and other antibacterial drugs, KETEK should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:b5aa8081-2cd9-499c-af85-3dce93b0c328 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18067 biolink:treats MONDO:0006874 PMID:41385096 "[{""id"":""uuid:3010eeb7-5337-429f-81c4-d9ad83ed9b14"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d2031c40-b82f-4a73-860a-f2762d1e4452"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MEPHYTON is indicated in the following coagulation disorders which are due to faulty formation of factors II,VII, IX and X when caused by vitamin K deficiency or interference with vitamin K activity. MEPHYTON tablets are indicated in: – anticoagulant-induced prothrombin deficiency caused by coumarin or indanedione derivatives; – hypoprothrombinemia secondary to antibacterial therapy; – hypoprothrombinemia secondary to administration of salicylates; – hypoprothrombinemia secondary to obstructive jaundice or biliary fistulas but only if bile salts are administered concurrently, since otherwise the oral vitamin K will not be absorbed. uuid:29299c53-9089-4212-bf1c-e225c2a9df63 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18067 biolink:treats UMLS:C0005417 PMID:41385096 "[{""id"":""uuid:a138c98c-4944-4873-8cf6-e2615f45f8eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cc9c8fc1-beb5-4b05-bbd4-bb0626ffe0de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MEPHYTON is indicated in the following coagulation disorders which are due to faulty formation of factors II,VII, IX and X when caused by vitamin K deficiency or interference with vitamin K activity. MEPHYTON tablets are indicated in: – anticoagulant-induced prothrombin deficiency caused by coumarin or indanedione derivatives; – hypoprothrombinemia secondary to antibacterial therapy; – hypoprothrombinemia secondary to administration of salicylates; – hypoprothrombinemia secondary to obstructive jaundice or biliary fistulas but only if bile salts are administered concurrently, since otherwise the oral vitamin K will not be absorbed. uuid:bbf7d8f6-ecd3-4250-80fd-b2f8a1fd9686 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17051 biolink:treats MONDO:0000605 PMID:41385096 "[{""id"":""uuid:75a90c54-570d-42b0-959a-cf36af44ab74"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6434c846-e581-4ba2-86a7-8956c25ec3de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Helps prevent dental caries and hypersensitivity. uuid:cde2034e-0b33-42a0-8a49-7f301ba8a866 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31859 biolink:treats UMLS:C4087539 PMID:41385096 "[{""id"":""uuid:4163a422-3763-4b05-ae19-47f2926ed5cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a15ceeee-85f4-497f-b2ae-241248097566"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Modafinil is indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnea, and shift work disorder. In OSA, modafinil is indicated as an adjunct to standard treatment(s) for the underlying obstruction. If continuous positive airway pressure (CPAP) is the treatment of choice for a patient, a maximal effort to treat with CPAP for an adequate period of time should be made prior to initiating modafinil. If modafinil is used adjunctively with CPAP, the encouragement of and periodic assessment of CPAP compliance is necessary. In all cases, careful attention to the diagnosis and treatment of the underlying sleep disorder(s) is of utmost importance. Prescribers should be aware that some patients may have more than one sleep disorder contributing to their excessive sleepiness. The effectiveness of modafinil in long-term use (greater than 9 weeks in Narcolepsy clinical trials and 12 weeks in OSA and SWD clinical trials) has not been systematically evaluated in placebo-controlled trials. The physician who elects to prescribe modafinil for an extended time in patients with Narcolepsy, OSA, or SWD should periodically reevaluate long-term usefulness for the individual patient. uuid:407fff3f-ecdd-453c-9283-8e15668e198f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3082 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:46683e16-0244-4feb-9b5e-2c9b15eea57b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:de58dea1-9924-419c-a8e9-a4a159790d8e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Betaxolol is indicated in the management of hypertension. It may be used alone or concomitantly with other antihypertensive agents, particularly thiazide-type diuretics. uuid:dbc5930f-8965-4f03-aa7a-52e066dd5135 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:11679580 biolink:treats MONDO:0010811 PMID:41385096 "[{""id"":""uuid:a448a8f0-c7e9-431e-9fe3-793ad40afcdc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f28e3d77-77fa-40f0-8c14-d7849e831457"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] JALYN is a combination of dutasteride, a 5 alpha-reductase inhibitor, and tamsulosin, an alpha adrenergic antagonist, indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate. (1.1) Limitations of Use: Dutasteride-containing products, including JALYN, are not approved for the prevention of prostate cancer. (1.2) uuid:6bedb929-2a7d-4a5c-b98a-c2f2b4e9b6f8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:11679580 biolink:treats MONDO:0008315 PMID:41385096 "[{""id"":""uuid:cdd3e4d3-ed79-461a-bc93-aa5d837717c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b7b4db62-3304-467e-ad5c-396ab4c11910"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] JALYN is a combination of dutasteride, a 5 alpha-reductase inhibitor, and tamsulosin, an alpha adrenergic antagonist, indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate. (1.1) Limitations of Use: Dutasteride-containing products, including JALYN, are not approved for the prevention of prostate cancer. (1.2) uuid:d1f3126a-791a-4fda-9596-b4e6f5876c66 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8412 biolink:treats HP:0002069 PMID:41385096 "[{""id"":""uuid:6d17a646-7388-4162-b58a-c5f5c45a5c7c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1d0eb8b2-7271-4e26-b37c-f71098364643"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Primidone, used alone or concomitantly with other anticonvulsants, is indicated in the control of grand mal, psychomotor, and focal epileptic seizures. It may control grand mal seizures refractory to other anticonvulsant therapy. uuid:5f6beda1-18d9-4071-b3dc-8da1618dfcbb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8412 biolink:treats MONDO:0006710 PMID:41385096 "[{""id"":""uuid:7e54bf86-03dd-4419-9222-6a75b1999b77"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a2d07d0a-b4fd-4c6a-851c-a1e79ee2f173"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Primidone, used alone or concomitantly with other anticonvulsants, is indicated in the control of grand mal, psychomotor, and focal epileptic seizures. It may control grand mal seizures refractory to other anticonvulsant therapy. uuid:88a9dead-f4aa-49f3-81ea-090e02e32436 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8412 biolink:treats MONDO:0005384 PMID:41385096 "[{""id"":""uuid:bf2186df-9db3-4de1-9bcb-15f724ac64ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cc7d6566-4367-40b8-bc9c-181fcd1b5ad3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Primidone, used alone or concomitantly with other anticonvulsants, is indicated in the control of grand mal, psychomotor, and focal epileptic seizures. It may control grand mal seizures refractory to other anticonvulsant therapy. uuid:76e21ca4-f2fc-4f16-8f1d-643fcece11c6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5108 biolink:treats MONDO:0005083 PMID:41385096 "[{""id"":""uuid:bd59473d-c007-4d4c-9abf-6cb8f2f2940a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0f99f122-e310-4fc7-a669-6a975b3d7090"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fluocinolone Acetonide 0.01% Topical Oil is a low to medium potency corticosteroid indicated: In adult patients for the treatment of psoriasis of the scalp (Scalp Oil). uuid:09c5e02c-0f6d-4d85-9229-a5c99362fa3c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63608 biolink:treats MONDO:0004951 PMID:41385096 "[{""id"":""uuid:82cdda71-00b2-4e9a-ac16-c685e22bf9e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a5e0ad5f-7862-49dc-b3e5-d5fd0103f68b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SELZENTRY, in combination with other antiretroviral agents, is indicated for adult patients infected with only CCR5-tropic HIV-1. This indication is based on analyses of plasma HIV-1 RNA levels in two controlled studies of SELZENTRY in treatment-experienced subjects and one study in treatment-naïve subjects. Both studies in treatment-experienced subjects were conducted in clinically advanced, 3-class antiretroviral-experienced (NRTI, NNRTI, PI, or enfuvirtide) adults with evidence of HIV-1 replication despite ongoing antiretroviral therapy. The following points should be considered when initiating therapy with SELZENTRY: Adult patients infected with only CCR5-tropic HIV-1 should use SELZENTRY. Tropism testing must be conducted with a highly sensitive tropism assay that has demonstrated the ability to identify patients appropriate for SELZENTRY use. Outgrowth of pre-existing low-level CXCR4- or dual/mixed-tropic HIV-1 not detected by tropism testing at screening has been associated with virologic failure on SELZENTRY. [see Microbiology (12.4) Clinical Studies (14.3) ] . Use of SELZENTRY is not recommended in subjects with dual/mixed or CXCR4-tropic HIV-1 as efficacy was not demonstrated in a phase 2 study of this patient group. The safety and efficacy of SELZENTRY have not been established in pediatric patients. In treatment-naïve subjects, more subjects treated with SELZENTRY experienced virologic failure and developed lamivudine resistance compared to efavirenz. [see Microbiology (12.4) Clinical Studies (14.3) ] uuid:d182c845-c52c-4d8d-b2cf-664b3d55241d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17334 biolink:treats MONDO:0024355 PMID:41385096 "[{""id"":""uuid:a7069de8-7fed-4ffd-88e7-994dbd759549"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:92b7bce3-9163-425e-9875-6c0990411d5c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Bicillin C-R and other antibacterial drugs, Bicillin C-R should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. This drug is indicated in the treatment of moderately severe infections due to penicillin-G-susceptible microorganisms that are susceptible to serum levels common to this particular dosage form. Therapy should be guided by bacteriological studies (including susceptibility testing) and by clinical response. Bicillin C-R is indicated in the treatment of the following in adults and pediatric patients: Moderately severe to severe infections of the upper-respiratory tract, scarlet fever, erysipelas, and skin and soft-tissue infections due to susceptible streptococci. NOTE: Streptococci in Groups A, C, G, H, L, and M are very sensitive to penicillin G. Other groups, including Group D (enterococci), are resistant. Penicillin G sodium or potassium is recommended for streptococcal infections with bacteremia. Moderately severe pneumonia and otitis media due to susceptible pneumococci. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, peritonitis, and arthritis of pneumococcal etiology are better treated with penicillin G sodium or potassium during the acute stage. When high, sustained serum levels are required, penicillin G sodium or potassium, either IM or IV, should be used. This drug should not be used in the treatment of venereal diseases, including syphilis, gonorrhea, yaws, bejel, and pinta. CHEBI:18208 uuid:92d72771-9009-4810-833c-1f5146387cd4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17334 biolink:treats MONDO:0005952 PMID:41385096 "[{""id"":""uuid:251704ee-381b-44f7-85fb-58654f040dcf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dacb8b4d-1e2f-4cc9-b594-72b6fa3380f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Bicillin C-R and other antibacterial drugs, Bicillin C-R should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. This drug is indicated in the treatment of moderately severe infections due to penicillin-G-susceptible microorganisms that are susceptible to serum levels common to this particular dosage form. Therapy should be guided by bacteriological studies (including susceptibility testing) and by clinical response. Bicillin C-R is indicated in the treatment of the following in adults and pediatric patients: Moderately severe to severe infections of the upper-respiratory tract, scarlet fever, erysipelas, and skin and soft-tissue infections due to susceptible streptococci. NOTE: Streptococci in Groups A, C, G, H, L, and M are very sensitive to penicillin G. Other groups, including Group D (enterococci), are resistant. Penicillin G sodium or potassium is recommended for streptococcal infections with bacteremia. Moderately severe pneumonia and otitis media due to susceptible pneumococci. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, peritonitis, and arthritis of pneumococcal etiology are better treated with penicillin G sodium or potassium during the acute stage. When high, sustained serum levels are required, penicillin G sodium or potassium, either IM or IV, should be used. This drug should not be used in the treatment of venereal diseases, including syphilis, gonorrhea, yaws, bejel, and pinta. CHEBI:18208 uuid:72e94df8-0950-479d-88e5-e73939bf2f22 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17334 biolink:treats MONDO:0001266 PMID:41385096 "[{""id"":""uuid:8a66f388-d2ef-4645-95a1-8067e4ef272e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:77b80a66-ef63-4952-92d7-5ad7c5db9067"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Bicillin C-R and other antibacterial drugs, Bicillin C-R should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. This drug is indicated in the treatment of moderately severe infections due to penicillin-G-susceptible microorganisms that are susceptible to serum levels common to this particular dosage form. Therapy should be guided by bacteriological studies (including susceptibility testing) and by clinical response. Bicillin C-R is indicated in the treatment of the following in adults and pediatric patients: Moderately severe to severe infections of the upper-respiratory tract, scarlet fever, erysipelas, and skin and soft-tissue infections due to susceptible streptococci. NOTE: Streptococci in Groups A, C, G, H, L, and M are very sensitive to penicillin G. Other groups, including Group D (enterococci), are resistant. Penicillin G sodium or potassium is recommended for streptococcal infections with bacteremia. Moderately severe pneumonia and otitis media due to susceptible pneumococci. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, peritonitis, and arthritis of pneumococcal etiology are better treated with penicillin G sodium or potassium during the acute stage. When high, sustained serum levels are required, penicillin G sodium or potassium, either IM or IV, should be used. This drug should not be used in the treatment of venereal diseases, including syphilis, gonorrhea, yaws, bejel, and pinta. CHEBI:18208 uuid:bb3cbe48-599b-4027-8780-2079bb8ba536 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17334 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:17fb23ab-c9ef-4f0d-a94e-2feaf6080727"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:be29c41a-65af-41ef-83d3-0cf67730f353"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Bicillin C-R and other antibacterial drugs, Bicillin C-R should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. This drug is indicated in the treatment of moderately severe infections due to penicillin-G-susceptible microorganisms that are susceptible to serum levels common to this particular dosage form. Therapy should be guided by bacteriological studies (including susceptibility testing) and by clinical response. Bicillin C-R is indicated in the treatment of the following in adults and pediatric patients: Moderately severe to severe infections of the upper-respiratory tract, scarlet fever, erysipelas, and skin and soft-tissue infections due to susceptible streptococci. NOTE: Streptococci in Groups A, C, G, H, L, and M are very sensitive to penicillin G. Other groups, including Group D (enterococci), are resistant. Penicillin G sodium or potassium is recommended for streptococcal infections with bacteremia. Moderately severe pneumonia and otitis media due to susceptible pneumococci. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, peritonitis, and arthritis of pneumococcal etiology are better treated with penicillin G sodium or potassium during the acute stage. When high, sustained serum levels are required, penicillin G sodium or potassium, either IM or IV, should be used. This drug should not be used in the treatment of venereal diseases, including syphilis, gonorrhea, yaws, bejel, and pinta. CHEBI:18208 uuid:063f4a07-813f-433a-bcd7-78a6b5222ef4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17334 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:ef106a2e-5392-45cb-b85b-6f5cf5bc4410"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:16590281-b192-4979-991f-d9a4814c44a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Bicillin C-R and other antibacterial drugs, Bicillin C-R should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. This drug is indicated in the treatment of moderately severe infections due to penicillin-G-susceptible microorganisms that are susceptible to serum levels common to this particular dosage form. Therapy should be guided by bacteriological studies (including susceptibility testing) and by clinical response. Bicillin C-R is indicated in the treatment of the following in adults and pediatric patients: Moderately severe to severe infections of the upper-respiratory tract, scarlet fever, erysipelas, and skin and soft-tissue infections due to susceptible streptococci. NOTE: Streptococci in Groups A, C, G, H, L, and M are very sensitive to penicillin G. Other groups, including Group D (enterococci), are resistant. Penicillin G sodium or potassium is recommended for streptococcal infections with bacteremia. Moderately severe pneumonia and otitis media due to susceptible pneumococci. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, peritonitis, and arthritis of pneumococcal etiology are better treated with penicillin G sodium or potassium during the acute stage. When high, sustained serum levels are required, penicillin G sodium or potassium, either IM or IV, should be used. This drug should not be used in the treatment of venereal diseases, including syphilis, gonorrhea, yaws, bejel, and pinta. CHEBI:18208 uuid:21661de8-6360-467d-9749-05b97076e8df biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17334 biolink:treats MONDO:0005441 PMID:41385096 "[{""id"":""uuid:b6a5efcb-832d-41f6-8bce-610fe901ee6a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:40d16d2d-3e2c-4190-9724-548c455ee6dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Bicillin C-R and other antibacterial drugs, Bicillin C-R should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. This drug is indicated in the treatment of moderately severe infections due to penicillin-G-susceptible microorganisms that are susceptible to serum levels common to this particular dosage form. Therapy should be guided by bacteriological studies (including susceptibility testing) and by clinical response. Bicillin C-R is indicated in the treatment of the following in adults and pediatric patients: Moderately severe to severe infections of the upper-respiratory tract, scarlet fever, erysipelas, and skin and soft-tissue infections due to susceptible streptococci. NOTE: Streptococci in Groups A, C, G, H, L, and M are very sensitive to penicillin G. Other groups, including Group D (enterococci), are resistant. Penicillin G sodium or potassium is recommended for streptococcal infections with bacteremia. Moderately severe pneumonia and otitis media due to susceptible pneumococci. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, peritonitis, and arthritis of pneumococcal etiology are better treated with penicillin G sodium or potassium during the acute stage. When high, sustained serum levels are required, penicillin G sodium or potassium, either IM or IV, should be used. This drug should not be used in the treatment of venereal diseases, including syphilis, gonorrhea, yaws, bejel, and pinta. CHEBI:18208 uuid:ac9081ac-14a4-4c4a-b9df-33ae78431244 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17334 biolink:treats MONDO:0005976 PMID:41385096 "[{""id"":""uuid:a1d8b839-b6ca-4439-bec1-7440a2d23865"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1d6c0c4d-14f6-4d4e-bb4d-12c158d63fe3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:0b584c04-47db-4f8c-83a5-114a0eaea7ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Bicillin C-R and other antibacterial drugs, Bicillin C-R should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. This drug is indicated in the treatment of moderately severe infections due to penicillin-G-susceptible microorganisms that are susceptible to serum levels common to this particular dosage form. Therapy should be guided by bacteriological studies (including susceptibility testing) and by clinical response. Bicillin C-R is indicated in the treatment of the following in adults and pediatric patients: Moderately severe to severe infections of the upper-respiratory tract, scarlet fever, erysipelas, and skin and soft-tissue infections due to susceptible streptococci. NOTE: Streptococci in Groups A, C, G, H, L, and M are very sensitive to penicillin G. Other groups, including Group D (enterococci), are resistant. Penicillin G sodium or potassium is recommended for streptococcal infections with bacteremia. Moderately severe pneumonia and otitis media due to susceptible pneumococci. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, peritonitis, and arthritis of pneumococcal etiology are better treated with penicillin G sodium or potassium during the acute stage. When high, sustained serum levels are required, penicillin G sodium or potassium, either IM or IV, should be used. This drug should not be used in the treatment of venereal diseases, including syphilis, gonorrhea, yaws, bejel, and pinta.|[PMDA] Drugs with a new route of administration indicated for the treatment of syphilis (excluding neurosyphilis) caused by Treponema pallidum . CHEBI:18208 uuid:7abc195f-3e93-4679-be12-081e6b902a5b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17334 biolink:treats MONDO:0004277 PMID:41385096 "[{""id"":""uuid:495fa7a8-d05b-496f-bfc6-10359d6a25dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:57d66fae-0dcd-4f9e-b6be-d5cc9aa3d9b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Bicillin C-R and other antibacterial drugs, Bicillin C-R should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. This drug is indicated in the treatment of moderately severe infections due to penicillin-G-susceptible microorganisms that are susceptible to serum levels common to this particular dosage form. Therapy should be guided by bacteriological studies (including susceptibility testing) and by clinical response. Bicillin C-R is indicated in the treatment of the following in adults and pediatric patients: Moderately severe to severe infections of the upper-respiratory tract, scarlet fever, erysipelas, and skin and soft-tissue infections due to susceptible streptococci. NOTE: Streptococci in Groups A, C, G, H, L, and M are very sensitive to penicillin G. Other groups, including Group D (enterococci), are resistant. Penicillin G sodium or potassium is recommended for streptococcal infections with bacteremia. Moderately severe pneumonia and otitis media due to susceptible pneumococci. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, peritonitis, and arthritis of pneumococcal etiology are better treated with penicillin G sodium or potassium during the acute stage. When high, sustained serum levels are required, penicillin G sodium or potassium, either IM or IV, should be used. This drug should not be used in the treatment of venereal diseases, including syphilis, gonorrhea, yaws, bejel, and pinta. CHEBI:18208 uuid:ba945c7f-8b8b-4b9f-b48b-e7d261f94bba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17334 biolink:treats MONDO:0006019 PMID:41385096 "[{""id"":""uuid:b01e6ea0-ef02-4cce-aebf-a188056e518f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b05cc784-b777-4d69-89dd-9486d3eae2fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Bicillin C-R and other antibacterial drugs, Bicillin C-R should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. This drug is indicated in the treatment of moderately severe infections due to penicillin-G-susceptible microorganisms that are susceptible to serum levels common to this particular dosage form. Therapy should be guided by bacteriological studies (including susceptibility testing) and by clinical response. Bicillin C-R is indicated in the treatment of the following in adults and pediatric patients: Moderately severe to severe infections of the upper-respiratory tract, scarlet fever, erysipelas, and skin and soft-tissue infections due to susceptible streptococci. NOTE: Streptococci in Groups A, C, G, H, L, and M are very sensitive to penicillin G. Other groups, including Group D (enterococci), are resistant. Penicillin G sodium or potassium is recommended for streptococcal infections with bacteremia. Moderately severe pneumonia and otitis media due to susceptible pneumococci. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, peritonitis, and arthritis of pneumococcal etiology are better treated with penicillin G sodium or potassium during the acute stage. When high, sustained serum levels are required, penicillin G sodium or potassium, either IM or IV, should be used. This drug should not be used in the treatment of venereal diseases, including syphilis, gonorrhea, yaws, bejel, and pinta. CHEBI:18208 uuid:e2ed3374-cb79-4a01-b254-8ae920cdf897 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17334 biolink:treats MONDO:0001714 PMID:41385096 "[{""id"":""uuid:4a1fb9d1-d68d-4398-a047-4c4885198c31"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e6187493-ac58-4209-ae80-f211eb074f66"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Bicillin C-R and other antibacterial drugs, Bicillin C-R should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. This drug is indicated in the treatment of moderately severe infections due to penicillin-G-susceptible microorganisms that are susceptible to serum levels common to this particular dosage form. Therapy should be guided by bacteriological studies (including susceptibility testing) and by clinical response. Bicillin C-R is indicated in the treatment of the following in adults and pediatric patients: Moderately severe to severe infections of the upper-respiratory tract, scarlet fever, erysipelas, and skin and soft-tissue infections due to susceptible streptococci. NOTE: Streptococci in Groups A, C, G, H, L, and M are very sensitive to penicillin G. Other groups, including Group D (enterococci), are resistant. Penicillin G sodium or potassium is recommended for streptococcal infections with bacteremia. Moderately severe pneumonia and otitis media due to susceptible pneumococci. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, peritonitis, and arthritis of pneumococcal etiology are better treated with penicillin G sodium or potassium during the acute stage. When high, sustained serum levels are required, penicillin G sodium or potassium, either IM or IV, should be used. This drug should not be used in the treatment of venereal diseases, including syphilis, gonorrhea, yaws, bejel, and pinta. CHEBI:18208 uuid:c8adcd1e-f353-4d04-88b5-bf3ad0c49f81 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17334 biolink:treats MONDO:0000979 PMID:41385096 "[{""id"":""uuid:c05f7152-560b-4693-bf6f-9b6cd2124e98"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8418b4f2-f1b1-40b2-9928-b9049bc12ade"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Bicillin C-R and other antibacterial drugs, Bicillin C-R should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. This drug is indicated in the treatment of moderately severe infections due to penicillin-G-susceptible microorganisms that are susceptible to serum levels common to this particular dosage form. Therapy should be guided by bacteriological studies (including susceptibility testing) and by clinical response. Bicillin C-R is indicated in the treatment of the following in adults and pediatric patients: Moderately severe to severe infections of the upper-respiratory tract, scarlet fever, erysipelas, and skin and soft-tissue infections due to susceptible streptococci. NOTE: Streptococci in Groups A, C, G, H, L, and M are very sensitive to penicillin G. Other groups, including Group D (enterococci), are resistant. Penicillin G sodium or potassium is recommended for streptococcal infections with bacteremia. Moderately severe pneumonia and otitis media due to susceptible pneumococci. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, peritonitis, and arthritis of pneumococcal etiology are better treated with penicillin G sodium or potassium during the acute stage. When high, sustained serum levels are required, penicillin G sodium or potassium, either IM or IV, should be used. This drug should not be used in the treatment of venereal diseases, including syphilis, gonorrhea, yaws, bejel, and pinta. CHEBI:18208 uuid:c568583c-48bd-47d8-a852-3a36aab39d8d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:9831783 biolink:treats HP:0100660 PMID:41385096 "[{""id"":""uuid:4cc1e4c4-19cd-4d21-b72a-225633e3418a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d0255e20-9ed5-4cfe-9008-5ba96468de19"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] To substitute (with equivalent strength of each of the three components) for immediate-release carbidopa/levodopa and entacapone previously administered as individual products. To replace immediate-release carbidopa/levodopa therapy (without entacapone) when patients experience the signs and symptoms of end-of-dose ""wearing-off"" (only for patients taking a total daily dose of levodopa of 600 mg or less and not experiencing dyskinesias, see DOSAGE AND ADMINISTRATION )." uuid:d4a62568-759e-43f4-84c3-4e7591c3ef23 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45924 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:cff09823-5595-410b-897b-737634e38176"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:72549635-1d4a-4d8a-b672-ced3b9ad83d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the treatment of initial episodes of uncomplicated urinary tract infections due to susceptible strains of the following organisms: Escherichiacoli, Proteus mirabilis, Klebsiella pneumoniae, Enterobacter species and coagulase-negative Staphylococcus species, including S. saprophyticus. Cultures and susceptibility tests should be performed to determine the susceptibility of the bacteria to trimethoprim. Therapy may be initiated prior to obtaining the results of these tests. uuid:5ed087ec-b40d-4dde-86ce-86c2fc4e6926 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45924 biolink:treats MONDO:0020920 PMID:41385096 "[{""id"":""uuid:32346d13-a629-47c5-a1e6-a5c282426c78"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c421ba4e-4e78-4d08-90f5-78e7a88a09ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the treatment of initial episodes of uncomplicated urinary tract infections due to susceptible strains of the following organisms: Escherichiacoli, Proteus mirabilis, Klebsiella pneumoniae, Enterobacter species and coagulase-negative Staphylococcus species, including S. saprophyticus. Cultures and susceptibility tests should be performed to determine the susceptibility of the bacteria to trimethoprim. Therapy may be initiated prior to obtaining the results of these tests. uuid:d27d5b23-89a9-4fcd-a096-c69ed74283ed biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45924 biolink:treats UMLS:C0276078 PMID:41385096 "[{""id"":""uuid:9dd211e4-6791-4db3-876e-ef28397868c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:272714e1-d44f-4b9c-93d7-4ae8ae956500"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the treatment of initial episodes of uncomplicated urinary tract infections due to susceptible strains of the following organisms: Escherichiacoli, Proteus mirabilis, Klebsiella pneumoniae, Enterobacter species and coagulase-negative Staphylococcus species, including S. saprophyticus. Cultures and susceptibility tests should be performed to determine the susceptibility of the bacteria to trimethoprim. Therapy may be initiated prior to obtaining the results of these tests. uuid:9691b62b-c0b6-486c-b20f-032cdb2a2a95 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45924 biolink:treats UMLS:C0948802 PMID:41385096 "[{""id"":""uuid:56d63048-a71c-4837-ab32-1aac1e0cb181"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c77111c6-8c39-4b0b-9d54-0a7382ce1fde"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the treatment of initial episodes of uncomplicated urinary tract infections due to susceptible strains of the following organisms: Escherichiacoli, Proteus mirabilis, Klebsiella pneumoniae, Enterobacter species and coagulase-negative Staphylococcus species, including S. saprophyticus. Cultures and susceptibility tests should be performed to determine the susceptibility of the bacteria to trimethoprim. Therapy may be initiated prior to obtaining the results of these tests. uuid:6e4ba8a6-be2c-4631-a15c-979bf3bcaf42 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45924 biolink:treats UMLS:C0948205 PMID:41385096 "[{""id"":""uuid:42bbb2a7-b74c-4fa8-b4b9-6fbd26e67267"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:05bfb6c5-45d6-4398-8c2d-7dcf35432d0f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the treatment of initial episodes of uncomplicated urinary tract infections due to susceptible strains of the following organisms: Escherichiacoli, Proteus mirabilis, Klebsiella pneumoniae, Enterobacter species and coagulase-negative Staphylococcus species, including S. saprophyticus. Cultures and susceptibility tests should be performed to determine the susceptibility of the bacteria to trimethoprim. Therapy may be initiated prior to obtaining the results of these tests. uuid:754b0355-76f6-455e-a216-bb80382ad6f2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45924 biolink:treats MONDO:0024313 PMID:41385096 "[{""id"":""uuid:abb338be-6237-4c72-ac01-120071124b8c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:75e737b2-97c4-4bbc-8b0e-48f870b26889"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the treatment of initial episodes of uncomplicated urinary tract infections due to susceptible strains of the following organisms: Escherichiacoli, Proteus mirabilis, Klebsiella pneumoniae, Enterobacter species and coagulase-negative Staphylococcus species, including S. saprophyticus. Cultures and susceptibility tests should be performed to determine the susceptibility of the bacteria to trimethoprim. Therapy may be initiated prior to obtaining the results of these tests. uuid:88f6b4bc-ae62-4ee6-901b-4234d9151986 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49375 biolink:treats MONDO:0011996 PMID:41385096 "[{""id"":""uuid:67c05dbb-5a7f-44b0-8d88-30453d665174"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:dd587a96-688c-40b6-807a-e27327cc2e93"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c873e995-99eb-49de-b358-96a2f85f1a1f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f5277568-a13a-4170-8544-8cb7b65f7de9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SPRYCEL ® (dasatinib) is indicated for the treatment of adults with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. The effectiveness of SPRYCEL is based on cytogenetic response and major molecular response rates [see Clinical Studies (14.1) ] . The trial is ongoing and further data will be required to determine long-term outcome. chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.|[EMA] Sprycel is indicated for the treatment of paediatric patients with:newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukaemia in chronic phase (Ph+ CML CP) or Ph+ CML CP resistant or intolerant to prior therapy including imatinib.newly diagnosed Ph+ acute lymphoblastic leukaemia (ALL) in combination with chemotherapy.Sprycel is indicated for the treatment of adult patients with:newly diagnosed Philadelphia-chromosome-positive (Ph+) chronic myelogenous leukaemia (CML) in the chronic phase;chronic, accelerated or blast phase CML with resistance or intolerance to prior therapy including imatinib mesilate;Ph+ acute lymphoblastic leukaemia (ALL) and lymphoid blast CML with resistance or intolerance to prior therapy.Sprycel is indicated for the treatment of paediatric patients with:newly diagnosed Ph+ CML in chronic phase (Ph+ CML-CP) or Ph+ CML-CP resistant or intolerant to prior therapy including imatinib.|[PMDA] Drugs with a new additional indication and a new dosage for the treatment of chronic myelocytic leukemia. uuid:087a8548-a23b-4b7c-b5ad-30b0822b034e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49375 biolink:treats MONDO:0004967 PMID:41385096 "[{""id"":""uuid:d61e9fb0-d3c5-454f-bdf4-b62cc5db4e0a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:fe8b1ad1-1e7b-451f-be86-d12830d879e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:8a11d939-fe60-447a-9d9b-af96b08743cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SPRYCEL ® (dasatinib) is indicated for the treatment of adults with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. The effectiveness of SPRYCEL is based on cytogenetic response and major molecular response rates [see Clinical Studies (14.1) ] . The trial is ongoing and further data will be required to determine long-term outcome. chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.|[EMA] Sprycel is indicated for the treatment of paediatric patients with:newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukaemia in chronic phase (Ph+ CML CP) or Ph+ CML CP resistant or intolerant to prior therapy including imatinib.newly diagnosed Ph+ acute lymphoblastic leukaemia (ALL) in combination with chemotherapy.Sprycel is indicated for the treatment of adult patients with:newly diagnosed Philadelphia-chromosome-positive (Ph+) chronic myelogenous leukaemia (CML) in the chronic phase;chronic, accelerated or blast phase CML with resistance or intolerance to prior therapy including imatinib mesilate;Ph+ acute lymphoblastic leukaemia (ALL) and lymphoid blast CML with resistance or intolerance to prior therapy.Sprycel is indicated for the treatment of paediatric patients with:newly diagnosed Ph+ CML in chronic phase (Ph+ CML-CP) or Ph+ CML-CP resistant or intolerant to prior therapy including imatinib. uuid:3324aa5a-41e6-4278-8753-764661f47f02 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29007 biolink:treats UMLS:C1141920 PMID:41385096 "[{""id"":""uuid:19027df4-4d59-4e9a-bbf8-ba7882c28821"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:035d474e-4218-45b4-9693-c5531a21cbd3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Before instituting treatment with ceftriaxone, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. Therapy may be instituted prior to obtaining results of susceptibility testing. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftriaxone for injection and other antibacterial drugs, ceftriaxone for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ceftriaxone sodium is indicated for the treatment of the following infections when caused by susceptible organisms: Lower Respiratory Tract Infections caused by Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Escherichia coli, Enterobacter aerogenes, Proteus mirabilis or Serratia marcescens. Acute Bacterial Otitis Media caused by Streptococcus pneumoniae, Haemophilus influenzae (including beta-lactamase producing strains) or Moraxella catarrhalis (including beta-lactamase producing strains). NOTE: In one study lower clinical cure rates were observed with a single dose of ceftriaxone sodium compared to 10 days of oral therapy. In a second study comparable cure rates were observed between single dose ceftriaxone sodium and the comparator. The potentially lower clinical cure rate of ceftriaxone should be balanced against the potential advantages of parenteral therapy (see CLINICAL STUDIES ). Skin And Skin Structure Infections caused by Staphylococcus aureus , Staphylococcus epidermidis , Streptococcus pyogenes , Viridans group streptococci, Escherichia coli , Enterobacter cloacae , Klebsiella oxytoca , Klebsiella pneumoniae , Proteus mirabilis , Morganella morganii Efficacy for this organism in this organ system was studied in fewer than ten infections. , Pseudomonas aeruginosa , Serratia marcescens , Acinetobacter calcoaceticus , Bacteroides fragilis or Peptostreptococcus species. Urinary Tract Infections ( complicated and uncomplicated ) caused by Escherichia coli, Proteus mirabilis, Proteus vulgaris, Morganella morganii or Klebsiella pneumoniae. Uncomplicated Gonorrhea ( cervical/urethral and rectal ) caused by Neisseria gonorrhoeae , including both penicillinase- and nonpenicillinase-producing strains, and pharyngeal gonorrhea caused by nonpenicillinase-producing strains of Neisseria gonorrhoeae . Pelvic Inflammatory Disease caused by Neisseria gonorrhoeae . Ceftriaxone sodium, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and Chlamydia trachomatis is one of the suspected pathogens, appropriate antichlamydial coverage should be added. Bacterial Septicemia caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae or Klebsiella pneumoniae. Bone And Joint Infections caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae or Enterobacter species. Intra-Abdominal Infections caused by Escherichia coli, Klebsiella pneumoniae , Bacteroides fragilis , Clostridium species (Note: most strains of Clostridium difficile are resistant) or Peptostreptococcus species. Meningitis caused by Haemophilus influenzae, Neisseria meningitidis or Streptococcus pneumoniae. Ceftriaxone has also been used successfully in a limited number of cases of meningitis and shunt infection caused by Staphylococcus epidermidis and Escherichia coli . Surgical Prophylaxis: The preoperative administration of a single 1 gm dose of ceftriaxone sodium may reduce the incidence of postoperative infections in patients undergoing surgical procedures classified as contaminated or potentially contaminated (e.g., vaginal or abdominal hysterectomy or cholecystectomy for chronic calculous cholecystitis in high-risk patients, such as those over 70 years of age, with acute cholecystitis not requiring therapeutic antimicrobials, obstructive jaundice or common duct bile stones) and in surgical patients for whom infection at the operative site would present serious risk (e.g., during coronary artery bypass surgery). Although ceftriaxone has been shown to have been as effective as cefazolin in the prevention of infection following coronary artery bypass surgery, no placebo-controlled trials have been conducted to evaluate any cephalosporin antibiotic in the prevention of infection following coronary artery bypass surgery. When administered prior to surgical procedures for which it is indicated, a single 1 gm dose of ceftriaxone sodium provides protection from most infections due to susceptible organisms throughout the course of the procedure. uuid:07d32257-8613-4867-af04-e52c84d793cd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31348 biolink:treats MONDO:0021063 PMID:41385096 "[{""id"":""uuid:184a1808-1daa-4069-a895-8da032e9624c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:22f5f7e2-6340-4aea-ad8e-bcba45fd6ef7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XELODA (capecitabine) is a nucleoside metabolic inhibitor with antineoplastic activity indicated for: Adjuvant Colon Cancer ( 1.1 ) – Patients with Dukes' C colon cancer Metastatic Colorectal Cancer ( 1.1 ) – First-line as monotherapy when treatment with fluoropyrimidine therapy alone is preferred Metastatic Breast Cancer ( 1.2 ) – In combination with docetaxel after failure of prior anthracycline-containing therapy – As monotherapy in patients resistant to both paclitaxel and an anthracycline-containing regimen uuid:7b873bcb-9ca7-4763-aec4-5b8503141cfa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31348 biolink:treats EFO:1001480 PMID:41385096 "[{""id"":""uuid:b9f1d1e6-7cf6-40cd-b79d-a1e06a425820"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:14a69158-37fb-4906-b043-895ab3824220"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XELODA (capecitabine) is a nucleoside metabolic inhibitor with antineoplastic activity indicated for: Adjuvant Colon Cancer ( 1.1 ) – Patients with Dukes' C colon cancer Metastatic Colorectal Cancer ( 1.1 ) – First-line as monotherapy when treatment with fluoropyrimidine therapy alone is preferred Metastatic Breast Cancer ( 1.2 ) – In combination with docetaxel after failure of prior anthracycline-containing therapy – As monotherapy in patients resistant to both paclitaxel and an anthracycline-containing regimen uuid:a49fb6f5-d6f4-4067-8c1e-0518bcdfe869 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31348 biolink:treats UMLS:C0278488 PMID:41385096 "[{""id"":""uuid:7172087b-d4c0-4d60-9341-452dfa101a6d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0c96c268-3b2c-4904-ab68-c5808e255733"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XELODA (capecitabine) is a nucleoside metabolic inhibitor with antineoplastic activity indicated for: Adjuvant Colon Cancer ( 1.1 ) – Patients with Dukes' C colon cancer Metastatic Colorectal Cancer ( 1.1 ) – First-line as monotherapy when treatment with fluoropyrimidine therapy alone is preferred Metastatic Breast Cancer ( 1.2 ) – In combination with docetaxel after failure of prior anthracycline-containing therapy – As monotherapy in patients resistant to both paclitaxel and an anthracycline-containing regimen uuid:cf042ab5-0be4-4da2-b767-3a66ee413cbc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:28697 biolink:treats MONDO:0004247 PMID:41385096 "[{""id"":""uuid:cccbc68e-3a5e-4bc3-8edb-57e405152808"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:029a8625-8c6d-4d9e-91eb-2a1ea09df46f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of this drug by the National Academy of Sciences – National Research Council and/or other information, FDA has classified the indications as follows: ""Possibly"" effective: as adjunctive therapy in the treatment of peptic ulcer and in the treatment of the irritable bowel syndrome (irritable colon, spastic colon, mucous colitis) and acute enterocolitis. Final classification of the less-than-effective indications requires further investigation." uuid:a9313471-9a6e-49ac-ab84-d1ca76463de3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:28697 biolink:treats MONDO:0005052 PMID:41385096 "[{""id"":""uuid:4e4929dd-5929-4acd-8a57-e7ee8ec89929"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:63332162-0031-463e-8ea6-5f3ad28bd322"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of this drug by the National Academy of Sciences – National Research Council and/or other information, FDA has classified the indications as follows: ""Possibly"" effective: as adjunctive therapy in the treatment of peptic ulcer and in the treatment of the irritable bowel syndrome (irritable colon, spastic colon, mucous colitis) and acute enterocolitis. Final classification of the less-than-effective indications requires further investigation." uuid:48496549-6077-45b8-80be-0661b47d87fb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:28697 biolink:treats UMLS:C0856217 PMID:41385096 "[{""id"":""uuid:6077811e-5e45-4e2f-b134-889756f1d0bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2cffe50a-305d-401b-afde-037681c09245"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of this drug by the National Academy of Sciences – National Research Council and/or other information, FDA has classified the indications as follows: ""Possibly"" effective: as adjunctive therapy in the treatment of peptic ulcer and in the treatment of the irritable bowel syndrome (irritable colon, spastic colon, mucous colitis) and acute enterocolitis. Final classification of the less-than-effective indications requires further investigation." uuid:1ce4e261-854d-4c44-95a4-1b624dc42609 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:28697 biolink:treats UMLS:C3203466 PMID:41385096 "[{""id"":""uuid:ad592d5e-e698-4426-b206-443904ce966a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:401a20f2-1bdd-4d76-8f47-a014a32711d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of this drug by the National Academy of Sciences – National Research Council and/or other information, FDA has classified the indications as follows: ""Possibly"" effective: as adjunctive therapy in the treatment of peptic ulcer and in the treatment of the irritable bowel syndrome (irritable colon, spastic colon, mucous colitis) and acute enterocolitis. Final classification of the less-than-effective indications requires further investigation." uuid:351c7a60-5047-49ba-8c98-ceb7106f67eb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0010643 PMID:41385096 "[{""id"":""uuid:4bbd84e8-1ba5-4df1-ba0a-9bf7eb26d07d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:af9d0bbd-66b3-4c64-8508-f773e2e499b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prednisone tablets are indicated in the following conditions: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Endocrine disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis Rheumatic disorders During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis Collagen diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Dermatologic diseases Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions Allergic states Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Ophthalmic diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis Respiratory diseases Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Hematologic disorders For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Neoplastic diseases To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Edematous states To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Gastrointestinal diseases Acute exacerbations of multiple sclerosis Nervous System Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement Miscellaneous uuid:acfadef2-6fec-4a65-b099-670d570c6bfb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:44423 biolink:treats MONDO:0005105 PMID:41385096 "[{""id"":""uuid:06d1dada-151c-409c-9577-a0f55b7a40d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0849a82f-d49b-4963-b1fd-2e276c2c1d96"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Significant tumor response to hydroxyurea capsules USP has been demonstrated in melanoma, resistant chronic myelocytic leukemia, and recurrent, metastatic, or inoperable carcinoma of the ovary. Hydroxyurea, USP used concomitantly with irradiation therapy is intended for use in the local control of primary squamous cell (epidermoid) carcinomas of the head and neck, excluding the lip. uuid:5e0f4d3f-a720-4d23-b5bf-cdebd83e8828 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:44423 biolink:treats MONDO:0011996 PMID:41385096 "[{""id"":""uuid:6de70de2-7d11-435a-a438-40f35d7f5a96"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ea036c58-5a7a-4bba-833d-df44477f8589"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Significant tumor response to hydroxyurea capsules USP has been demonstrated in melanoma, resistant chronic myelocytic leukemia, and recurrent, metastatic, or inoperable carcinoma of the ovary. Hydroxyurea, USP used concomitantly with irradiation therapy is intended for use in the local control of primary squamous cell (epidermoid) carcinomas of the head and neck, excluding the lip. uuid:a22f0a39-4c3d-4b36-92aa-f4e6a55ec71e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:44423 biolink:treats MONDO:0005140 PMID:41385096 "[{""id"":""uuid:0c82aca7-dea4-4c99-9412-950c41f43d00"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4247cfd9-886e-4e5f-b0f2-681fa1e04efd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Significant tumor response to hydroxyurea capsules USP has been demonstrated in melanoma, resistant chronic myelocytic leukemia, and recurrent, metastatic, or inoperable carcinoma of the ovary. Hydroxyurea, USP used concomitantly with irradiation therapy is intended for use in the local control of primary squamous cell (epidermoid) carcinomas of the head and neck, excluding the lip. uuid:6cabdab6-f22c-4762-9997-aabccb93a19c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:44423 biolink:treats MONDO:0010150 PMID:41385096 "[{""id"":""uuid:5985210a-8e01-4150-811d-9f15593938c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eca267ad-11b1-41b3-b86c-bee061bfc8e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Significant tumor response to hydroxyurea capsules USP has been demonstrated in melanoma, resistant chronic myelocytic leukemia, and recurrent, metastatic, or inoperable carcinoma of the ovary. Hydroxyurea, USP used concomitantly with irradiation therapy is intended for use in the local control of primary squamous cell (epidermoid) carcinomas of the head and neck, excluding the lip. uuid:a4cafdac-d223-4eb9-a74b-7e8ae4945839 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28971 biolink:treats MONDO:0004277 PMID:41385096 "[{""id"":""uuid:2d2dfefd-a849-41e6-a3a2-c22457290b56"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a384fd6a-4f34-4be2-917e-d039c41f9eff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ampicillin Capsules, USP are indicated in the treatment of infections caused by susceptible strains of the designated organism listed below: INFECTIONS OF THE GENITOURINARY TRACT INCLUDING GONORRHEA: E. coli, P. mirabilis, enterococci, Shigella, S. typhosa and other Salmonella , and nonpenicillinaseproducing N. gonorrhoeae . INFECTIONS OF THE RESPIRATORY TRACT: Nonpenicillinase- producing H. influenzae and staphylococci, and streptococci including streptococcus pneumoniae . INFECTIONS OF THE GASTROINTESTINAL TRACT: Shigella, S. typhosa and other Salmonella, E. coli, P. mirabilis, and enterococci. MENINGITIS: N. Meningitides . To reduce the development of drug-resistant bacteria and maintain the effectiveness of ampicillin and other antibacterial drugs, ampicillin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to the results of susceptibility testing. uuid:ea3cf495-e2b0-4588-a2a8-d1367b023f59 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28971 biolink:treats MONDO:0021108 PMID:41385096 "[{""id"":""uuid:59a33513-07ce-4200-8839-5c9842409ae7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5dcd0457-31dc-4c79-b508-cdaf0a73d9ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ampicillin Capsules, USP are indicated in the treatment of infections caused by susceptible strains of the designated organism listed below: INFECTIONS OF THE GENITOURINARY TRACT INCLUDING GONORRHEA: E. coli, P. mirabilis, enterococci, Shigella, S. typhosa and other Salmonella , and nonpenicillinaseproducing N. gonorrhoeae . INFECTIONS OF THE RESPIRATORY TRACT: Nonpenicillinase- producing H. influenzae and staphylococci, and streptococci including streptococcus pneumoniae . INFECTIONS OF THE GASTROINTESTINAL TRACT: Shigella, S. typhosa and other Salmonella, E. coli, P. mirabilis, and enterococci. MENINGITIS: N. Meningitides . To reduce the development of drug-resistant bacteria and maintain the effectiveness of ampicillin and other antibacterial drugs, ampicillin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to the results of susceptibility testing. uuid:aa59b90b-bde4-40a4-9b0f-6c103c2f9dce biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:48131 biolink:treats MONDO:0011438 PMID:41385096 "[{""id"":""uuid:01460be6-3532-41ec-93bc-841cbc3059e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4bc7bf4b-1eb4-4765-8a58-c03fb7669044"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AZELEX ® Cream is indicated for the topical treatment of mild-to-moderate inflammatory acne vulgaris. uuid:aa4a4f0f-5034-4985-8feb-5adbf16b9034 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6438 biolink:treats MONDO:0005338 PMID:41385096 "[{""id"":""uuid:4065bb72-eb2b-4cb2-a82d-ed912ed2a6c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c88f64cb-ae6f-409e-a0df-75830c578ac0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levobunolol Hydrochloride Ophthalmic Solution has been shown to be effective in lowering intraocular pressure and may be used in patients with chronic open-angle glaucoma or ocular hypertension. uuid:30e44f40-6041-4a25-94c0-b34bac576212 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6438 biolink:treats MONDO:0006875 PMID:41385096 "[{""id"":""uuid:517e2e7f-828b-4d2a-a7bb-663fa01e43fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f7412ab3-033f-4c69-8ffb-b6a5f52bf5d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levobunolol Hydrochloride Ophthalmic Solution has been shown to be effective in lowering intraocular pressure and may be used in patients with chronic open-angle glaucoma or ocular hypertension. uuid:93ca4d4f-512b-460c-a099-b9bafb385cce biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135598 biolink:treats MONDO:0024644 PMID:41385096 "[{""id"":""uuid:ebc62083-a92f-49ff-a2f0-2e9b4f7841c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5a5c26d7-8701-466d-921c-bc84612dbfba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tetrofosmin is a diagnostic agent used to assess areas of reversible myocardial ischemia in the presence or absence of infracted myocardium and is also used to assess ventricular function. PHYSICAL HALF-LIFE & TARGET ORGANS The physical half-life of technetium, Tc99m, is 6 hours and has a principal radiation emission of gamma photons with a mean energy of 140 KeV. Estimated Absorbed Radiation Dose (Technetium Tc99m Tetrofosmin Injection) Absorbed radiation dose Exercise Rest Target organ rad/mCi µGy/MBq rad/mCi µGy/MBq Gall bladder wall 0.123 33.2 0.180 48.6 Upper large intestine 0.075 20.1 0.113 30.4 Bladder wall 0.058 15.6 0.071 19.3 Lower large intestine 0.057 15.3 0.082 22.2 Small intestine 0.045 12.1 0.063 17.0 Kidney 0.039 10.4 0.046 12.5 Salivary glands 0.030 8.04 0.043 11.6 Ovaries 0.029 7.88 0.035 9.55 Uterus 0.027 7.34 0.031 8.36 Bone surface 0.023 6.23 0.021 5.58 Pancreas 0.019 5.00 0.018 4.98 Stomach 0.017 4.60 0.017 4.63 Thyroid 0.016 4.34 0.022 5.83 Adrenals 0.016 4.32 0.015 4.11 Heart wall 0.015 4.14 0.015 3.93 Red marrow 0.015 4.14 0.015 3.97 Spleen 0.015 4.12 0.014 3.82 Muscle 0.013 3.52 0.012 3.32 Testes 0.013 3.41 0.011 3.05 Liver 0.012 3.22 0.015 4.15 Thymus 0.012 3.11 0.009 2.54 Brain 0.010 2.72 0.008 2.15 Lungs 0.008 2.27 0.008 2.08 Skin 0.008 2.22 0.007 1.91 Breasts 0.008 2.22 0.007 1.83 Dose calculations were performed using the standard MIRD method (MIRD Pamphlet No.1 (rev),Society of Nuclear Medicine, 1976). Effective dose equivalents (EDE) were calculated in accordance with ICRP 53 (Ann. ICRP 18 (1-4),1988) and gave values of 8.61 × 10-3 mSV/MBq and 1.12 × 10-2 mSV/MBq after exercise and rest, respectively. uuid:1ae6ac99-defa-43ed-86e6-5273d463660c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135598 biolink:treats MONDO:0024643 PMID:41385096 "[{""id"":""uuid:0aeee268-221c-4124-bad9-e86cf3e73486"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c1ad1f99-8ba8-4c27-9845-c12e04c26f33"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tetrofosmin is a diagnostic agent used to assess areas of reversible myocardial ischemia in the presence or absence of infracted myocardium and is also used to assess ventricular function. PHYSICAL HALF-LIFE & TARGET ORGANS The physical half-life of technetium, Tc99m, is 6 hours and has a principal radiation emission of gamma photons with a mean energy of 140 KeV. Estimated Absorbed Radiation Dose (Technetium Tc99m Tetrofosmin Injection) Absorbed radiation dose Exercise Rest Target organ rad/mCi µGy/MBq rad/mCi µGy/MBq Gall bladder wall 0.123 33.2 0.180 48.6 Upper large intestine 0.075 20.1 0.113 30.4 Bladder wall 0.058 15.6 0.071 19.3 Lower large intestine 0.057 15.3 0.082 22.2 Small intestine 0.045 12.1 0.063 17.0 Kidney 0.039 10.4 0.046 12.5 Salivary glands 0.030 8.04 0.043 11.6 Ovaries 0.029 7.88 0.035 9.55 Uterus 0.027 7.34 0.031 8.36 Bone surface 0.023 6.23 0.021 5.58 Pancreas 0.019 5.00 0.018 4.98 Stomach 0.017 4.60 0.017 4.63 Thyroid 0.016 4.34 0.022 5.83 Adrenals 0.016 4.32 0.015 4.11 Heart wall 0.015 4.14 0.015 3.93 Red marrow 0.015 4.14 0.015 3.97 Spleen 0.015 4.12 0.014 3.82 Muscle 0.013 3.52 0.012 3.32 Testes 0.013 3.41 0.011 3.05 Liver 0.012 3.22 0.015 4.15 Thymus 0.012 3.11 0.009 2.54 Brain 0.010 2.72 0.008 2.15 Lungs 0.008 2.27 0.008 2.08 Skin 0.008 2.22 0.007 1.91 Breasts 0.008 2.22 0.007 1.83 Dose calculations were performed using the standard MIRD method (MIRD Pamphlet No.1 (rev),Society of Nuclear Medicine, 1976). Effective dose equivalents (EDE) were calculated in accordance with ICRP 53 (Ann. ICRP 18 (1-4),1988) and gave values of 8.61 × 10-3 mSV/MBq and 1.12 × 10-2 mSV/MBq after exercise and rest, respectively. uuid:5d80b70a-353e-438c-9ba8-c408882154ca biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31974 biolink:treats MONDO:0008228 PMID:41385096 "[{""id"":""uuid:90a86508-d0db-428e-b919-da2cf23b7cd0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:07ca4733-d42d-4083-b43c-243b410d2725"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Anacidity (diagnosis) —Pentagastrin is indicated as a diagnostic aid for evaluation of gastric acid secretory function. It is effective in testing for anacidity (achlorhydria) in patients with suspected pernicious anemia, atrophic gastritis, or gastric carcinoma. It is also effective in determining the reduction in acid output after operations for peptic ulcer, such as vagotomy or gastric resection. Hypersecretory conditions, gastric (diagnosis) —Pentagastrin is indicated as a diagnostic aid in testing for gastric hypersecretion in patients with suspected duodenal ulcer or postoperative stomal ulcer, and for the diagnosis of Zollinger-Ellison tumor uuid:f2cbae89-52fa-46bc-b983-48418b1e0bce biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31974 biolink:treats MONDO:0006665 PMID:41385096 "[{""id"":""uuid:951ddc9b-5d78-4c5d-ad3c-31d3e034da5a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c16a6e66-bc9b-4e10-9e33-688810c60550"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Anacidity (diagnosis) —Pentagastrin is indicated as a diagnostic aid for evaluation of gastric acid secretory function. It is effective in testing for anacidity (achlorhydria) in patients with suspected pernicious anemia, atrophic gastritis, or gastric carcinoma. It is also effective in determining the reduction in acid output after operations for peptic ulcer, such as vagotomy or gastric resection. Hypersecretory conditions, gastric (diagnosis) —Pentagastrin is indicated as a diagnostic aid in testing for gastric hypersecretion in patients with suspected duodenal ulcer or postoperative stomal ulcer, and for the diagnosis of Zollinger-Ellison tumor uuid:29839559-4570-43ea-861a-5d298e21bce4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31974 biolink:treats MONDO:0004716 PMID:41385096 "[{""id"":""uuid:e2e668a8-12ae-4815-9eed-d373887c7ca1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d42eac50-52a8-4d44-8f08-d163087269bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Anacidity (diagnosis) —Pentagastrin is indicated as a diagnostic aid for evaluation of gastric acid secretory function. It is effective in testing for anacidity (achlorhydria) in patients with suspected pernicious anemia, atrophic gastritis, or gastric carcinoma. It is also effective in determining the reduction in acid output after operations for peptic ulcer, such as vagotomy or gastric resection. Hypersecretory conditions, gastric (diagnosis) —Pentagastrin is indicated as a diagnostic aid in testing for gastric hypersecretion in patients with suspected duodenal ulcer or postoperative stomal ulcer, and for the diagnosis of Zollinger-Ellison tumor uuid:3ca275dc-ada6-4005-8e76-5dd5164ddfc7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31974 biolink:treats MONDO:0004247 PMID:41385096 "[{""id"":""uuid:4acb438f-dfa3-4243-9045-5a13481abba6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ef65a4a1-ce0e-460c-93d4-c5d1128dd92f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Anacidity (diagnosis) —Pentagastrin is indicated as a diagnostic aid for evaluation of gastric acid secretory function. It is effective in testing for anacidity (achlorhydria) in patients with suspected pernicious anemia, atrophic gastritis, or gastric carcinoma. It is also effective in determining the reduction in acid output after operations for peptic ulcer, such as vagotomy or gastric resection. Hypersecretory conditions, gastric (diagnosis) —Pentagastrin is indicated as a diagnostic aid in testing for gastric hypersecretion in patients with suspected duodenal ulcer or postoperative stomal ulcer, and for the diagnosis of Zollinger-Ellison tumor uuid:d8fc805b-c93d-41da-af37-4e72cbae5104 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31974 biolink:treats MONDO:0005412 PMID:41385096 "[{""id"":""uuid:d9df82a9-a378-40dc-8bb7-80868c248835"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7d87706d-2338-43ba-aa13-5affcda6232f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Anacidity (diagnosis) —Pentagastrin is indicated as a diagnostic aid for evaluation of gastric acid secretory function. It is effective in testing for anacidity (achlorhydria) in patients with suspected pernicious anemia, atrophic gastritis, or gastric carcinoma. It is also effective in determining the reduction in acid output after operations for peptic ulcer, such as vagotomy or gastric resection. Hypersecretory conditions, gastric (diagnosis) —Pentagastrin is indicated as a diagnostic aid in testing for gastric hypersecretion in patients with suspected duodenal ulcer or postoperative stomal ulcer, and for the diagnosis of Zollinger-Ellison tumor uuid:7e4919dd-9f02-4ce0-9931-fe8083588d1f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:39N9K8S2A4 biolink:treats MONDO:0019297 PMID:41385096 "[{""id"":""uuid:5b3773ba-8714-401a-8473-d6765d7bf7c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f8f1f37c-9668-4fd9-bf40-0bd40993b3b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Isosulfan Blue 1% Injection delineates the lymphatic vessels following subcutaneous administration. It is an adjunct to lymphography (in primary and secondary lymphedema of the extremities; chyluria, chylous ascites or chylothorax; lymph node involvement by primary or secondary neoplasm; and lymph node response to therapeutic modalities) for visualization to the lymphatic system draining the region of injection uuid:39656087-034d-4dd3-801a-3b77d825d02a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:39N9K8S2A4 biolink:treats UMLS:C0159075 PMID:41385096 "[{""id"":""uuid:3b2f2f69-8bbf-477e-88a4-8a26efb4f0bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ddaf8e44-b591-4dc2-90ec-bfa651568549"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Isosulfan Blue 1% Injection delineates the lymphatic vessels following subcutaneous administration. It is an adjunct to lymphography (in primary and secondary lymphedema of the extremities; chyluria, chylous ascites or chylothorax; lymph node involvement by primary or secondary neoplasm; and lymph node response to therapeutic modalities) for visualization to the lymphatic system draining the region of injection uuid:a183c5aa-c451-4402-8782-a84ae7fb7268 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:39N9K8S2A4 biolink:treats MONDO:0008829 PMID:41385096 "[{""id"":""uuid:ddac8b63-9be5-4b8b-8882-84ae1bcdcadf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4f225980-6bbc-404e-bca5-502529513e3d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Isosulfan Blue 1% Injection delineates the lymphatic vessels following subcutaneous administration. It is an adjunct to lymphography (in primary and secondary lymphedema of the extremities; chyluria, chylous ascites or chylothorax; lymph node involvement by primary or secondary neoplasm; and lymph node response to therapeutic modalities) for visualization to the lymphatic system draining the region of injection uuid:cab977d9-6fc2-4f98-b0cb-118453791b39 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:39N9K8S2A4 biolink:treats HP:0010310 PMID:41385096 "[{""id"":""uuid:677e3c9a-9628-465e-ab42-048a66fda06c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e5692638-d22b-463c-a6db-0fd9d4ffb979"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Isosulfan Blue 1% Injection delineates the lymphatic vessels following subcutaneous administration. It is an adjunct to lymphography (in primary and secondary lymphedema of the extremities; chyluria, chylous ascites or chylothorax; lymph node involvement by primary or secondary neoplasm; and lymph node response to therapeutic modalities) for visualization to the lymphatic system draining the region of injection uuid:484e8234-908a-4b88-8767-dbb2d78b2ed4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:39N9K8S2A4 biolink:treats MONDO:0005438 PMID:41385096 "[{""id"":""uuid:d087eff3-c3e9-4300-8836-685fb80a98a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:210e7874-282a-4ea7-b729-2c4e253b18e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Isosulfan Blue 1% Injection delineates the lymphatic vessels following subcutaneous administration. It is an adjunct to lymphography (in primary and secondary lymphedema of the extremities; chyluria, chylous ascites or chylothorax; lymph node involvement by primary or secondary neoplasm; and lymph node response to therapeutic modalities) for visualization to the lymphatic system draining the region of injection uuid:29fbff2c-beb5-4354-8dc5-aa7f1d48eb7e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:119915 biolink:treats HP:0032149 PMID:41385096 "[{""id"":""uuid:8fbf8ff7-d9b9-4bd7-88b6-bb281bd30210"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a664fee1-57ce-4345-af17-7e8a1382a085"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:9e1b4f8c-bea7-4fc0-9443-6a713be9b775"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lazanda (fentanyl) nasal spray is indicated for the management of breakthrough pain in cancer patients 18 years of age and older who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. Patients considered opioid tolerant are those who are taking at least: 60 mg of oral morphine/day, 25 mcg of transdermal fentanyl/hour, 30 mg oral oxycodone/day, 8 mg oral hydromorphone/day, 25 mg oral oxymorphone/day, or an equianalgesic dose of another opioid for a week or longer. Patients must remain on around-the-clock opioids when taking Lazanda. Lazanda is contraindicated for patients who are not already tolerant to opioids because life-threatening respiratory depression and death could occur in patients not taking chronic opioids. For this reason, Lazanda is contraindicated in the management of acute or postoperative pain, including headache/migraine, or dental pain. [ 4 ] Lazanda is intended to be prescribed only by healthcare professionals who are knowledgeable of and skilled in the use of Schedule II opioids to treat cancer pain.|[PMDA] Drugs with a new dosage in a new dosage form indicated for analgesia of breakthrough pain in patients with cancer receiving a potent opioid analgesic at fixed time. uuid:83ffa1d4-d997-4637-b6fc-feccef605fd5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6030 biolink:treats UMLS:C0343751 PMID:41385096 "[{""id"":""uuid:72a73f0d-94be-4f7a-bd7c-b16e18488435"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d47a9eca-d563-44dd-8c89-d43e14194622"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Isoniazid is recommended for all forms of tuberculosis in which organisms are susceptible. However, active tuberculosis must be treated with multiple concomitant antituberculosis medications to prevent the emergence of drug resistance. Single-drug treatment of active tuberculosis with isoniazid, or any other medication, is inadequate therapy. Isoniazid is recommended as preventive therapy for the following groups, regardless of age. (Note: the criterion for a positive reaction to a skin test (in millimeters of induration) for each group is given in parentheses): Persons with human immunodeficiency virus (HIV) infection (≥ 5 mm) and persons with risk factors for HIV infection whose HIV infection status is unknown but who are suspected of having HIV infection. Preventive therapy may be considered for HIV infected persons who are tuberculin-negative but belong to groups in which the prevalence of tuberculosis infection is high. Candidates for preventive therapy who have HIV infection should have a minimum of 12 months of therapy. Close contacts of persons with newly diagnosed infectious tuberculosis (≥ 5 mm). In addition, tuberculin-negative (< 5 mm) children and adolescents who have been close contacts of infectious persons within the past 3 months are candidates for preventive therapy until a repeat tuberculin skin test is done 12 weeks after contact with the infectious source. If the repeat skin test is positive (> 5 mm), therapy should be continued. Recent converters, as indicated by a tuberculin skin test (≥ 10 mm increase within a 2-year period for those < 35 years old; ≥ 15 mm increase for those ≥ 35 years of age). All infants and children younger than 4 years of age with a > 10 mm skin test are included in this category. Persons with abnormal chest radiographs that show fibrotic lesions likely to represent old healed tuberculosis (≥ 5 mm). Candidates for preventive therapy who have fibrotic pulmonary lesions consistent with healed tuberculosis or who have pulmonary silicosis should have 12 months of isoniazid or 4 months of isoniazid and rifampin, concomitantly. Intravenous drug users known to be HIV-seronegative (> 10 mm). Persons with the following medical conditions that have been reported to increase the risk of tuberculosis (≥ 10 mm): silicosis; diabetes mellitus; prolonged therapy with adrenocorticosteroids; immunosuppressive therapy; some hematologic and reticuloendothelial diseases, such as leukemia or Hodgkin's disease; end-stage renal disease; clinical situations associated with substantial rapid weight loss or chronic under nutrition (including: intestinal bypass surgery for obesity, the postgastrectomy state (with or without weight loss), chronic peptic ulcer disease, chronic malabsorption syndromes, and carcinomas of the oropharynx and upper gastrointestinal tract that prevent adequate nutritional intake). Candidates for preventive therapy who have fibrotic pulmonary lesions consistent with healed tuberculosis or who have pulmonary silicosis should have 12 months of isoniazid or 4 months of isoniazid and rifampin, concomitantly. Additionally, in the absence of any of the above risk factors, persons under the age of 35 with a tuberculin skin test reaction of 10 mm or more are also appropriate candidates for preventive therapy if they are a member of any of the following high-incidence groups: Foreign-born persons from high-prevalence countries who never received BCG vaccine. Medically underserved low-income populations, including high-risk racial or ethnic minority populations, especially blacks, Hispanics, and Native Americans. Residents of facilities for long-term care (e.g., correctional institutions, nursing homes, and mental institutions). Children who are less than 4 years old are candidates for isoniazid preventive therapy if they have > 10 mm induration from a PPD Mantoux tuberculin skin test. Finally, persons under the age of 35 who a) have none of the above risk factors (1-6); b) belong to none of the high-incidence groups; and c) have a tuberculin skin test reaction of 15 mm or more, are appropriate candidates for preventive therapy. The risk of hepatitis must be weighed against the risk of tuberculosis in positive tuberculin reactors over the age of 35. However, the use of isoniazid is recommended for those with the additional risk factors listed above (1-6) and on an individual basis in situations where there is likelihood of serious consequences to contacts who may become infected. uuid:c00d6d6b-ca99-46f2-b5dc-c70ae26671a6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C4534619 biolink:treats MONDO:0002898 PMID:41385096 "[{""id"":""uuid:dbde22cb-7a38-471e-8489-bb390b76b8ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6cab85c8-7ec1-4505-9f84-8eb9a278c235"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Helps prevent sunburn. If used as directed, with other sun protection measures (see Directions ), decreases the risk of skin cancer and early skin aging caused by the sun. uuid:b565ba79-6f93-4a32-80d6-e2e0a95d051a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C4534619 biolink:treats MONDO:0019303 PMID:41385096 "[{""id"":""uuid:e791c546-23fa-4b3e-8f42-5ca25561ffa0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ce84b849-5241-47b8-b282-ce970edee563"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Helps prevent sunburn. If used as directed, with other sun protection measures (see Directions ), decreases the risk of skin cancer and early skin aging caused by the sun. uuid:6c8e4cbd-cfca-4a59-8158-564d5f0f2671 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4856 biolink:treats MONDO:0004981 PMID:41385096 "[{""id"":""uuid:177b130b-67bd-4487-a997-da6ad92c580d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7fff9381-802c-45a9-873b-da7c1cb7952d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Esmolol hydrochloride is indicated for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable. Esmolol hydrochloride is also indicated in noncompensatory sinus tachycardia where, in the physician’s judgment, the rapid heart rate requires specific intervention. Esmolol hydrochloride is not intended for use in chronic settings where transfer to another agent is anticipated. uuid:4adb1c48-4bce-478b-b493-134a83b4bc02 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4856 biolink:treats MONDO:0005310 PMID:41385096 "[{""id"":""uuid:f3f28e80-fa7f-442c-b61f-71c3e133b871"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9feccfae-a833-4958-bc9e-d2efb7e16d35"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Esmolol hydrochloride is indicated for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable. Esmolol hydrochloride is also indicated in noncompensatory sinus tachycardia where, in the physician’s judgment, the rapid heart rate requires specific intervention. Esmolol hydrochloride is not intended for use in chronic settings where transfer to another agent is anticipated. uuid:7eeee66f-80fe-47a8-b251-13b94bdade2d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4856 biolink:treats HP:0040182 PMID:41385096 "[{""id"":""uuid:0b9f8f73-e7b2-4247-a704-d00cc9229441"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4bc0e56c-f0f1-4535-8891-a948ba5ef6df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Esmolol hydrochloride is indicated for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable. Esmolol hydrochloride is also indicated in noncompensatory sinus tachycardia where, in the physician’s judgment, the rapid heart rate requires specific intervention. Esmolol hydrochloride is not intended for use in chronic settings where transfer to another agent is anticipated. uuid:194d39d4-b4e9-4821-8238-083c43d20c7f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8364 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:68c11ab9-49d6-46c5-9f26-4b3d96b7ccd0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:98a8a6fe-b196-4606-9abe-9fbb50f13284"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prazosin hydrochloride capsules are indicated in the treatment of hypertension. They can be used alone or in combination with other antihypertensive drugs such as diuretics or beta-adrenergic blocking agents. uuid:cff18168-7d27-441d-9307-3ee43c90217f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9328 biolink:treats UMLS:C0332687 PMID:41385096 "[{""id"":""uuid:364e74fc-8620-430c-958e-4b68138f6554"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a50a2738-8261-4713-953e-78027a923391"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Silver Sulfadiazine Cream is a topical antimicrobial drug indicated as an adjunct for the prevention and treatment of wound sepsis in patients with second and third degree burns. uuid:768c06a9-3d09-4107-a52e-819999721b1d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9328 biolink:treats UMLS:C0433445 PMID:41385096 "[{""id"":""uuid:bac85a9f-0ecf-44bf-848e-9ff689a6a476"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aa66e345-681b-4204-960d-4a56e46967ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Silver Sulfadiazine Cream is a topical antimicrobial drug indicated as an adjunct for the prevention and treatment of wound sepsis in patients with second and third degree burns. uuid:569bfedd-b0c1-4782-9abe-ccb71d63a9e4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4975 biolink:treats MONDO:0001409 PMID:41385096 "[{""id"":""uuid:856506e4-dfbd-4924-a46c-5d865dce586e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d00fe486-c2a2-4880-b423-940276970ec5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Famotidine tablets are indicated in: 1. Short term treatment of active duodenal ulcer . Most adult patients heal within 4 weeks; there is rarely reason to use famotidine at full dosage for longer than 6 to 8 weeks. Studies have not assessed the safety of famotidine in uncomplicated active duodenal ulcer for periods of more than eight weeks. 2. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of an active ulcer. Controlled studies in adults have not extended beyond one year. 3. Short term treatment of active benign gastric ulcer . Most adult patients heal within 6 weeks. Studies have not assessed the safety or efficacy of famotidine in uncomplicated active benign gastric ulcer for periods of more than 8 weeks. 4. Short term treatment of gastroesophageal reflux disease (GERD). Famotidine is indicated for short term treatment of patients with symptoms of GERD (see CLINICAL PHARMACOLOGY IN ADULTS, Clinical Studies ). Famotidine is also indicated for the short term treatment of esophagitis due to GERD including erosive or ulcerative disease diagnosed by endoscopy (see CLINICAL PHARMACOLOGY IN ADULTS, Clinical Studies ). 5. Treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison Syndrome, multiple endocrine adenomas ) (see CLINICAL PHARMACOLOGY IN ADULTS, Clinical Studies ). uuid:12dbbe1e-8d35-44d5-aace-38194c811e75 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1165173 biolink:treats UMLS:C5442256 PMID:41385096 "[{""id"":""uuid:3a1714a9-4e39-4396-a9a0-17ab19097639"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c63bcabb-e67e-451f-bc32-792171ff8a39"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Estradiol/Norethindrone Acetate Tablets 1.0 mg/0.5 mg and 0.5 mg/0.1 mg are indicated in women who have a uterus for the: Treatment of moderate to severe vasomotor symptoms associated with menopause. Prevention of postmenopausal osteoporosis. When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and non-estrogen medications should be carefully considered. The mainstays for decreasing the risk of postmenopausal osteoporosis are weight bearing exercise, adequate calcium and vitamin D intake, and when indicated, pharmacologic therapy. Postmenopausal women require an average of 1500 mg/day of elemental calcium. Therefore, when not contraindicated, calcium supplementation may be helpful for women with suboptimal dietary intake. Vitamin D supplementation of 400-800 IU/day may also be required to ensure adequate daily intake in postmenopausal women. Estradiol/Norethindrone Acetate Tablets 1.0 mg/0.5 mg is also indicated in women who have a uterus for the: 3. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with menopause. When used solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. uuid:94070262-a338-42d3-81ca-770f2ed80106 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1165173 biolink:treats MONDO:0008159 PMID:41385096 "[{""id"":""uuid:68b1cd76-fffd-4395-bfd1-e0e5b4a55036"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ce46aef3-5d19-45ee-bda8-8afac8291aff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Estradiol/Norethindrone Acetate Tablets 1.0 mg/0.5 mg and 0.5 mg/0.1 mg are indicated in women who have a uterus for the: Treatment of moderate to severe vasomotor symptoms associated with menopause. Prevention of postmenopausal osteoporosis. When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and non-estrogen medications should be carefully considered. The mainstays for decreasing the risk of postmenopausal osteoporosis are weight bearing exercise, adequate calcium and vitamin D intake, and when indicated, pharmacologic therapy. Postmenopausal women require an average of 1500 mg/day of elemental calcium. Therefore, when not contraindicated, calcium supplementation may be helpful for women with suboptimal dietary intake. Vitamin D supplementation of 400-800 IU/day may also be required to ensure adequate daily intake in postmenopausal women. Estradiol/Norethindrone Acetate Tablets 1.0 mg/0.5 mg is also indicated in women who have a uterus for the: 3. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with menopause. When used solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. uuid:c4b6ac24-8fe2-4c07-bc97-f9a5fb297a75 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3419 biolink:treats MONDO:0002081 PMID:41385096 "[{""id"":""uuid:95594879-135d-4292-924f-4263a8653bac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:816b1d01-576c-49f8-adb2-da9f0fa6f1c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carisoprodol Tablets, USP are indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions in adults. Carisoprodol Tablets should only be used for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use has not been established and because acute, painful musculoskeletal conditions are generally of short duration. [see DOSAGE AND ADMINISTRATION (2)]. uuid:cc6b6395-6994-4646-b0de-085cb27a7fa2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9328 biolink:treats UMLS:C1141927 PMID:41385096 "[{""id"":""uuid:7ea8c85e-f213-495c-b409-b11ea25a78a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cb01643b-3bde-4b7a-b3ee-fb9de3e90ede"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Thermazene Cream is a topical antimicrobial drug indicated as an adjunct for the prevention and treatment of wound sepsis in patients with second and third degree burns. uuid:4260f9a7-8587-40cc-ace5-1a79e12820c0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:378729 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:48f6a9c4-83d3-4382-9f7c-5803a63dfff7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6e32869a-d9b6-4a36-b982-872d525ef077"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] After consultation with a healthcare professional who has considered and advised the patient of the risks and benefits of rosiglitazone, AVANDAMET ® is indicated as an adjunct to diet and exercise to improve glycemic control when treatment with both rosiglitazone and metformin is appropriate in adults with type 2 diabetes mellitus who either are: already taking rosiglitazone, or not already taking rosiglitazone and unable to achieve glycemic control on other diabetes medications and, in consultation with their healthcare provider, have decided not to take pioglitazone (ACTOS ® ) or pioglitazone-containing products (ACTOPLUS MET ® , ACTOPLUS MET XR ® , DUETACT ® ) for medical reasons. Other Important Limitations of Use: Due to its mechanism of action, rosiglitazone is active only in the presence of endogenous insulin. Therefore, AVANDAMET should not be used in patients with type 1 diabetes. Coadministration of AVANDAMET with insulin is not recommended [see Warnings and Precautions (5.2, 5.3)] . uuid:0c9b9203-d062-47bf-bc95-d998be3bdbe3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:378729 biolink:treats MONDO:0005147 PMID:41385096 "[{""id"":""uuid:923fa5d9-d4b1-4b0c-8ee8-44ff6e7671a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:af4c38cc-3c17-4f00-9800-c4857e916d03"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] After consultation with a healthcare professional who has considered and advised the patient of the risks and benefits of rosiglitazone, AVANDAMET ® is indicated as an adjunct to diet and exercise to improve glycemic control when treatment with both rosiglitazone and metformin is appropriate in adults with type 2 diabetes mellitus who either are: already taking rosiglitazone, or not already taking rosiglitazone and unable to achieve glycemic control on other diabetes medications and, in consultation with their healthcare provider, have decided not to take pioglitazone (ACTOS ® ) or pioglitazone-containing products (ACTOPLUS MET ® , ACTOPLUS MET XR ® , DUETACT ® ) for medical reasons. Other Important Limitations of Use: Due to its mechanism of action, rosiglitazone is active only in the presence of endogenous insulin. Therefore, AVANDAMET should not be used in patients with type 1 diabetes. Coadministration of AVANDAMET with insulin is not recommended [see Warnings and Precautions (5.2, 5.3)] . uuid:9053e157-96da-401a-8466-90a0c6abab7e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28864 biolink:treats MONDO:0000462 PMID:41385096 "[{""id"":""uuid:91e6a8ad-84cb-4661-b185-f4a065d6883c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6a61d821-0805-4c81-aaac-6c5a41141146"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tobramycin Ophthalmic Solution USP, 0.3% is a topical antibiotic indicated in the treatment of external infections of the eye and its adnexa caused by susceptible bacteria. Appropriate monitoring of bacterial response to topical antibiotic therapy should accompany the use of Tobramycin Ophthalmic Solution USP, 0.3%. Clinical studies have shown tobramycin to be safe and effective for use in pediatric patients. uuid:22e858dd-76b2-4c18-9157-eb1b4061a9b9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16469 biolink:treats MONDO:0005159 PMID:41385096 "[{""id"":""uuid:f3a01529-5ae2-4301-b5fb-a7606cf0326c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:021f58c8-2ade-4573-9244-a72019e14baa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Estradiol tablets are indicated in the: 1. Treatment of moderate to severe vasomotor symptoms associated with the menopause. 2. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. When prescribed solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. 3. Treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. 4. Treatment of breast cancer (for palliation only) in appropriately selected women and men with metastatic disease. 5. Treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only). 6. Prevention of osteoporosis. When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and for whom non-estrogen medications are not considered to be appropriate (See CLINICAL PHARMACOLOGY, Clinical Studies .) The mainstays for decreasing the risk of postmenopausal osteoporosis are weight bearing exercise, adequate calcium and vitamin D intake, and when indicated, pharmacologic therapy. Postmenopausal women require an average of 1500 mg/day of elemental calcium. Therefore, when not contraindicated, calcium supplementation may be helpful for women with suboptimal dietary intake. Vitamin D supplementation of 400 to 800 IU/day may also be required to ensure adequate daily intake in postmenopausal women. uuid:a4e4abd1-ad2e-43ca-843e-54a9cc3666fa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5106 biolink:treats UMLS:C1322281 PMID:41385096 "[{""id"":""uuid:94660785-6241-48f5-b1fe-739c16c08109"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f3840837-7b42-4948-8e2e-b8b510e27147"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Flunisolide nasal solution is indicated for the treatment of the nasal symptoms of seasonal or perennial rhinitis. Flunisolide nasal solution should not be used in the presence of untreated localized infection involving nasal mucosa. uuid:00172b5c-0086-4b31-bef5-f980db457f2f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5106 biolink:treats UMLS:C0848309 PMID:41385096 "[{""id"":""uuid:6679b69a-f005-46b2-8816-404b4902a5b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7aa5b5a9-723a-436e-8896-f44d437ff09f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Flunisolide nasal solution is indicated for the treatment of the nasal symptoms of seasonal or perennial rhinitis. Flunisolide nasal solution should not be used in the presence of untreated localized infection involving nasal mucosa. uuid:50c4498d-b01b-4de1-8bc1-891965f7610d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1154384 biolink:treats MONDO:0005920 PMID:41385096 "[{""id"":""uuid:cc691591-da3e-4600-bb93-b973d16bda33"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:08be4ae7-b710-4f2b-ada8-b88780caf71b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Atovaquone and proguanil hydrochloride tablets are indicated for the prophylaxis of P. falciparum malaria, including in areas where chloroquine resistance has been reported (see CLINICAL STUDIES ). uuid:1a897615-fe31-42fa-86a9-ce620d040d31 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50848 biolink:treats UMLS:C0339164 PMID:41385096 "[{""id"":""uuid:03e801ee-e1b1-4e0e-8f51-1cd25f616343"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:990de8a8-f10e-44be-b3e5-0d15d194966f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ALREX Ophthalmic Suspension is indicated for the temporary relief of the signs and symptoms of seasonal allergic conjunctivitis. uuid:c064f4da-4086-48e1-8c2d-e94aebf28030 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3213 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:348a8a25-7749-491b-99f0-c00fc3ba9319"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:705c6417-2482-4866-95a3-12b510cb000f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bumetanide tablets USP are indicated for the treatment of edema associated with congestive heart failure, hepatic and renal disease, including the nephrotic syndrome. Almost equal diuretic response occurs after oral and parenteral administration of bumetanide. Therefore, if impaired gastrointestinal absorption is suspected or oral administration is not practical, bumetanide should be given by the intramuscular or intravenous route. Successful treatment with bumetanide tablets USP following instances of allergic reactions to furosemide suggests a lack of cross-sensitivity. uuid:a110a45e-ba10-449f-94d7-fb0e020945dc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3213 biolink:treats MONDO:0005154 PMID:41385096 "[{""id"":""uuid:f28d2209-1523-4f21-8b3c-b995e62f6991"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d430a73a-9fb5-49a5-b4ed-258b4df1b537"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bumetanide tablets USP are indicated for the treatment of edema associated with congestive heart failure, hepatic and renal disease, including the nephrotic syndrome. Almost equal diuretic response occurs after oral and parenteral administration of bumetanide. Therefore, if impaired gastrointestinal absorption is suspected or oral administration is not practical, bumetanide should be given by the intramuscular or intravenous route. Successful treatment with bumetanide tablets USP following instances of allergic reactions to furosemide suggests a lack of cross-sensitivity. uuid:8e1afb83-122a-46a4-93b3-2314b9d8a88d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3213 biolink:treats MONDO:0005240 PMID:41385096 "[{""id"":""uuid:0a6493f8-6250-4b01-915e-b37d5f746fe8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4d0a36a9-4d5b-47b7-97f9-1aca9058fd63"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bumetanide tablets USP are indicated for the treatment of edema associated with congestive heart failure, hepatic and renal disease, including the nephrotic syndrome. Almost equal diuretic response occurs after oral and parenteral administration of bumetanide. Therefore, if impaired gastrointestinal absorption is suspected or oral administration is not practical, bumetanide should be given by the intramuscular or intravenous route. Successful treatment with bumetanide tablets USP following instances of allergic reactions to furosemide suggests a lack of cross-sensitivity. uuid:7ab7a8bd-3670-420a-9145-3c9b620539cc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3213 biolink:treats MONDO:0005377 PMID:41385096 "[{""id"":""uuid:43fee364-a797-4603-aced-578c899ca2fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3a586f6a-21fa-41d5-bf73-29e7bf3b8f28"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bumetanide tablets USP are indicated for the treatment of edema associated with congestive heart failure, hepatic and renal disease, including the nephrotic syndrome. Almost equal diuretic response occurs after oral and parenteral administration of bumetanide. Therefore, if impaired gastrointestinal absorption is suspected or oral administration is not practical, bumetanide should be given by the intramuscular or intravenous route. Successful treatment with bumetanide tablets USP following instances of allergic reactions to furosemide suggests a lack of cross-sensitivity. uuid:4e02520d-06cf-4b44-85ce-e365b587ff19 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41948 biolink:treats HP:0001007 PMID:41385096 "[{""id"":""uuid:5908acef-22ee-423a-890f-5d3f22bafd04"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:16101154-ccb3-433d-8035-4c0b93577558"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VANIQA (eflornithine hydrochloride) Cream, 13.9% is indicated for the reduction of unwanted facial hair in women. VANIQA has only been studied on the face and adjacent involved areas under the chin of affected individuals. Usage should be limited to these areas of involvement. uuid:4e840949-db97-49a8-b4b1-d955efd3b425 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6722 biolink:treats MONDO:0004989 PMID:41385096 "[{""id"":""uuid:85bcee09-b363-45bf-8ada-425c30e798a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:91fdd440-ac21-448e-b4c7-def47c2e3d96"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Megestrol acetate tablets are indicated for the palliative treatment of advanced carcinoma of the breast or endometrium (ie, recurrent, inoperable, or metastatic disease). It should not be used in lieu of currently accepted procedures such as surgery, radiation, or chemotherapy. uuid:f4746aa7-80d9-4947-bd26-2f9a445a43c9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2379 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:10df631b-5b62-4f09-98c6-0359e344337f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ab3a0812-98e3-4f56-9965-30ea12438a35"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] HYPERTENSION: Acebutolol hydrochloride capsules are indicated for the management of hypertension in adults. It may be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. VENTRICULAR ARRHYTHMIAS: Acebutolol hydrochloride capsules are indicated in the management of ventricular premature beats; it reduces the total number of premature beats, as well as the number of paired and multiform ventricular ectopic beats, and R-on-T beats. uuid:0e2d344e-ea58-43e2-b24e-51a461f9c4e3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2379 biolink:treats HP:0006682 PMID:41385096 "[{""id"":""uuid:c99db49b-d63b-4dc3-abca-6bb47bff2f25"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:581ba4df-20bb-4fa8-8aad-0412c2650198"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] HYPERTENSION: Acebutolol hydrochloride capsules are indicated for the management of hypertension in adults. It may be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. VENTRICULAR ARRHYTHMIAS: Acebutolol hydrochloride capsules are indicated in the management of ventricular premature beats; it reduces the total number of premature beats, as well as the number of paired and multiform ventricular ectopic beats, and R-on-T beats. uuid:e69ae713-9e2b-44d9-9efb-58b609373076 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28939 biolink:treats UMLS:C1265792 PMID:41385096 "[{""id"":""uuid:46ab723f-5034-4b76-961e-7679b40c6ef9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dd2786ae-ee37-4b6a-a50f-db8156c4ff93"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Acetylcysteine is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as: Chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung) Acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis) Pulmonary complications of cystic fibrosis Tracheostomy care Pulmonary complications associated with surgery Use during anesthesia Post-traumatic chest conditions Atelectasis due to mucous obstruction Diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization) uuid:d65fb0a1-217b-47c0-a121-b043da2c6ea2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28939 biolink:treats UMLS:C0155874 PMID:41385096 "[{""id"":""uuid:a58a5f29-36d2-4b4f-bf07-2d4236dd3bc7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1aabf48c-e716-46a5-9295-04c2c8cb3be7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Acetylcysteine is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as: Chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung) Acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis) Pulmonary complications of cystic fibrosis Tracheostomy care Pulmonary complications associated with surgery Use during anesthesia Post-traumatic chest conditions Atelectasis due to mucous obstruction Diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization) uuid:0a1b1760-4913-403a-94b6-9e9a144dc26c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28939 biolink:treats UMLS:C0264348 PMID:41385096 "[{""id"":""uuid:308dd323-d568-461e-b867-6016a19f5f1e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d5edac3a-fe95-4e4a-9bbc-a50d85b8930b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Acetylcysteine is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as: Chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung) Acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis) Pulmonary complications of cystic fibrosis Tracheostomy care Pulmonary complications associated with surgery Use during anesthesia Post-traumatic chest conditions Atelectasis due to mucous obstruction Diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization) uuid:5284df3b-a3ae-4194-a472-30d6f2e27424 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28939 biolink:treats MONDO:0018076 PMID:41385096 "[{""id"":""uuid:1619c01e-1d13-4367-b68e-868a9cc8a760"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6e3011b1-e3bb-4e48-b36c-ddfdfa4654c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Acetylcysteine is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as: Chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung) Acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis) Pulmonary complications of cystic fibrosis Tracheostomy care Pulmonary complications associated with surgery Use during anesthesia Post-traumatic chest conditions Atelectasis due to mucous obstruction Diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization) uuid:9e88da5b-05c4-4843-80df-761163b5c790 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28939 biolink:treats MONDO:0004822 PMID:41385096 "[{""id"":""uuid:1c047a32-fcf1-4b2b-9186-e60f81be4b11"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8fae90c1-586d-4797-8864-6d9d63ee2afd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Acetylcysteine is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as: Chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung) Acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis) Pulmonary complications of cystic fibrosis Tracheostomy care Pulmonary complications associated with surgery Use during anesthesia Post-traumatic chest conditions Atelectasis due to mucous obstruction Diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization) uuid:5b3158d2-1892-4f6a-aa6a-a40bfdbb2b03 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28939 biolink:treats MONDO:0019438 PMID:41385096 "[{""id"":""uuid:62bf5451-d27f-4a31-944e-76afa525b61c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6041c835-83b5-467c-925a-f55a4ea1806e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Acetylcysteine is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as: Chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung) Acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis) Pulmonary complications of cystic fibrosis Tracheostomy care Pulmonary complications associated with surgery Use during anesthesia Post-traumatic chest conditions Atelectasis due to mucous obstruction Diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization) uuid:5f4c4674-a89b-4abd-ae78-e6d16281dbee biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28939 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:e14ca4e4-74ad-4dc8-a0cd-469ea55228b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8fe9285d-7c56-4643-92d0-c72a67728f6b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Acetylcysteine is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as: Chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung) Acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis) Pulmonary complications of cystic fibrosis Tracheostomy care Pulmonary complications associated with surgery Use during anesthesia Post-traumatic chest conditions Atelectasis due to mucous obstruction Diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization) uuid:49d7fb72-8b71-4e48-8287-b0648c175703 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28939 biolink:treats MONDO:0003781 PMID:41385096 "[{""id"":""uuid:3ca07190-4a23-456b-b739-6a208355c9c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:76204dfa-fdd2-46c5-871c-a920bc9c1b58"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Acetylcysteine is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as: Chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung) Acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis) Pulmonary complications of cystic fibrosis Tracheostomy care Pulmonary complications associated with surgery Use during anesthesia Post-traumatic chest conditions Atelectasis due to mucous obstruction Diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization) uuid:fb8bc50e-c196-4f07-9a99-4bf969c7004e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28939 biolink:treats MONDO:0021925 PMID:41385096 "[{""id"":""uuid:019bbbac-1d65-4453-85bd-97175e49a0ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:80de6245-56dc-4a67-830d-e61cf2610569"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Acetylcysteine is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as: Chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung) Acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis) Pulmonary complications of cystic fibrosis Tracheostomy care Pulmonary complications associated with surgery Use during anesthesia Post-traumatic chest conditions Atelectasis due to mucous obstruction Diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization) uuid:2e80b1b2-d63a-4f70-8945-5a5ac9e80cde biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28939 biolink:treats MONDO:0009061 PMID:41385096 "[{""id"":""uuid:91214363-515b-4b1b-81ee-f91a68391eed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ca5a5657-62f1-4825-b81a-bc20e9df20b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Acetylcysteine is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as: Chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung) Acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis) Pulmonary complications of cystic fibrosis Tracheostomy care Pulmonary complications associated with surgery Use during anesthesia Post-traumatic chest conditions Atelectasis due to mucous obstruction Diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization) uuid:cfc79d06-af2e-42b8-a18b-b47feaeb0252 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9012 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:a5cf6b4d-e0f2-4b79-97a2-6ab15444b72f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f6f4a90d-44c0-4c8d-8b8b-adcec6d8a0ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SEREVENT DISKUS is a LABA indicated for: Treatment of asthma in patients aged 4 years and older. (1.1) Prevention of exercise-induced bronchospasm (EIB) in patients aged 4 years and older. (1.2) Maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD). (1.3) Important limitation: Not indicated for the relief of acute bronchospasm. (1.1, 1.3) uuid:6d01762a-dfaf-45d4-9dc6-7f9f7e69fb67 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9012 biolink:treats MONDO:0850286 PMID:41385096 "[{""id"":""uuid:d0d92809-6d02-4086-803a-60e144d85036"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3df6fe17-71a8-4fd2-aaa8-d8bf19cbec49"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SEREVENT DISKUS is a LABA indicated for: Treatment of asthma in patients aged 4 years and older. (1.1) Prevention of exercise-induced bronchospasm (EIB) in patients aged 4 years and older. (1.2) Maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD). (1.3) Important limitation: Not indicated for the relief of acute bronchospasm. (1.1, 1.3) UMLS:C0015263 uuid:12b880de-d5bd-40d4-ba96-a15e129b7744 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9012 biolink:treats MONDO:0005002 PMID:41385096 "[{""id"":""uuid:642f8117-092b-4061-a5b7-dfe50a9bdeb2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:625a0bb5-962e-454c-8c97-3adae185dfa0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SEREVENT DISKUS is a LABA indicated for: Treatment of asthma in patients aged 4 years and older. (1.1) Prevention of exercise-induced bronchospasm (EIB) in patients aged 4 years and older. (1.2) Maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD). (1.3) Important limitation: Not indicated for the relief of acute bronchospasm. (1.1, 1.3) uuid:b5ae1f6e-6ef3-4056-9ee6-9e51758d173a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7936 biolink:treats MONDO:0001942 PMID:41385096 "[{""id"":""uuid:458b939b-c4d2-420f-aead-3a1354bb238e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5be1b96c-8518-4763-82b6-a5b1e324d8d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Major Depressive Disorder Paroxetine tablets, USP are indicated for the treatment of major depressive disorder. The efficacy of paroxetine in the treatment of a major depressive episode was established in 6-week controlled trials of outpatients whose diagnoses corresponded most closely to the DSM-III category of major depressive disorder (see CLINICAL PHARMACOLOGY: Clinical Trials ). A major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks); it should include at least 4 of the following 8 symptoms: Change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suicide attempt or suicidal ideation. The effects of paroxetine in hospitalized depressed patients have not been adequately studied. The efficacy of paroxetine in maintaining a response in major depressive disorder for up to 1 year was demonstrated in a placebo-controlled trial (see CLINICAL PHARMACOLOGY: Clinical Trials ). Nevertheless, the physician who elects to use paroxetine for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient. Obsessive Compulsive Disorder Paroxetine tablets, USP are indicated for the treatment of obsessions and compulsions in patients with obsessive compulsive disorder (OCD) as defined in the DSM-IV. The obsessions or compulsions cause marked distress, are time-consuming, or significantly interfere with social or occupational functioning. The efficacy of paroxetine was established in two 12-week trials with obsessive compulsive outpatients whose diagnoses corresponded most closely to the DSM-IIIR category of obsessive compulsive disorder (see CLINICAL PHARMACOLOGY: Clinical Trials ). Obsessive compulsive disorder is characterized by recurrent and persistent ideas, thoughts, impulses, or images (obsessions) that are ego-dystonic and/or repetitive, purposeful, and intentional behaviors (compulsions) that are recognized by the person as excessive or unreasonable. Long-term maintenance of efficacy was demonstrated in a 6-month relapse prevention trial. In this trial, patients assigned to paroxetine showed a lower relapse rate compared to patients on placebo (see CLINICAL PHARMACOLOGY: Clinical Trials ). Nevertheless, the physician who elects to use paroxetine for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION ). Panic Disorder Paroxetine tablets, USP are indicated for the treatment of panic disorder, with or without agoraphobia, as defined in DSM-IV. Panic disorder is characterized by the occurrence of unexpected panic attacks and associated concern about having additional attacks, worry about the implications or consequences of the attacks, and/or a significant change in behavior related to the attacks. The efficacy of paroxetine was established in three 10- to 12-week trials in panic disorder patients whose diagnoses corresponded to the DSM-IIIR category of panic disorder (see CLINICAL PHARMACOLOGY: Clinical Trials ). Panic disorder (DSM-IV) is characterized by recurrent unexpected panic attacks, i.e., a discrete period of intense fear or discomfort in which 4 (or more) of the following symptoms develop abruptly and reach a peak within 10 minutes: (1) palpitations, pounding heart, or accelerated heart rate; (2) sweating; (3) trembling or shaking; (4) sensations of shortness of breath or smothering; (5) feeling of choking; (6) chest pain or discomfort; (7) nausea or abdominal distress; (8) feeling dizzy, unsteady, lightheaded, or faint; (9) derealization (feelings of unreality) or depersonalization (being detached from oneself); (10) fear of losing control; (11) fear of dying; (12) paresthesias (numbness or tingling sensations); (13) chills or hot flushes. Long-term maintenance of efficacy was demonstrated in a 3-month relapse prevention trial. In this trial, patients with panic disorder assigned to paroxetine demonstrated a lower relapse rate compared to patients on placebo (see CLINICAL PHARMACOLOGY: Clinical Trials ). Nevertheless, the physician who prescribes paroxetine for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION ). Generalized Anxiety Disorder Paroxetine tablets, USP are indicated for the treatment of Generalized Anxiety Disorder (GAD), as defined in DSM-IV. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The efficacy of paroxetine in the treatment of GAD was established in two 8-week placebo-controlled trials in adults with GAD. Paroxetine has not been studied in children or adolescents with Generalized Anxiety Disorder (see CLINICAL PHARMACOLOGY: Clinical Trials ). Generalized Anxiety Disorder (DSM-IV) is characterized by excessive anxiety and worry (apprehensive expectation) that is persistent for at least 6 months and which the person finds difficult to control. It must be associated with at least 3 of the following 6 symptoms: Restlessness or feeling keyed up or on edge, being easily fatigued, difficulty concentrating or mind going blank, irritability, muscle tension, sleep disturbance. The efficacy of paroxetine in maintaining a response in patients with Generalized Anxiety Disorder, who responded during an 8-week acute treatment phase while taking paroxetine and were then observed for relapse during a period of up to 24 weeks, was demonstrated in a placebo-controlled trial (see CLINICAL PHARMACOLOGY: Clinical Trials ). Nevertheless, the physician who elects to use paroxetine for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION ). uuid:2f70181d-52c0-4bcf-99cd-ec06df193172 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4798 biolink:treats MONDO:0005180 PMID:41385096 "[{""id"":""uuid:1faa9611-53be-41dc-b186-26e3a6dc973c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a5cdd97d-8015-4fe3-a100-cb30fee38d5f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:a28f7f58-3735-4b53-bf9a-46bad83a5682"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/entacapone-orion""]},{""id"":""uuid:057188cb-551c-479d-91a3-587a518a396b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Entacapone Tablets are indicated as an adjunct to levodopa and carbidopa to treat patients with idiopathic Parkinson’s Disease who experience the signs and symptoms of end-of-dose ""wearing-off"" (see CLINICAL PHARMACOLOGY, Clinical Studies ). Entacapone Tablets’ effectiveness has not been systematically evaluated in patients with idiopathic Parkinson’s Disease who do not experience end-of-dose ""wearing-off"".|[EMA] Entacapone is indicated as an adjunct to standard preparations of levodopa / benserazide or levodopa / carbidopa for use in adult patients with Parkinson's disease and end-of-dose motor fluctuations, who cannot be stabilised on those combinations.|[PMDA] Drug containing a new active ingredient used in combination with levodopa/carbidopa or levodopa/benserazide hydrochloride to improve daily fluctuation, or 'wearing-off' phenomena, in Parkinson’ s disease." uuid:e9414a7f-733e-46ed-8c43-bc6e2fa4ea21 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3216 biolink:treats MONDO:0005530 PMID:41385096 "[{""id"":""uuid:e1c023fe-83a8-49a5-89e0-260efb60d6df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:557ffabc-7460-408f-8e28-cddc20618ab0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:89910e39-c3f8-43be-b12b-07be070cd6e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/buvidal""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] SUBOXONE and SUBUTEX are indicated for the treatment of opioid dependence.|[EMA] Treatment of opioid dependence within a framework of medical, social and psychological treatment. Treatment is intended for use in adults and adolescents aged 16 years or over. uuid:61f98bdb-c268-4704-ac12-95bad8f96a2d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:9887103 biolink:treats MONDO:0004247 PMID:41385096 "[{""id"":""uuid:e9f642b9-51a5-4a9d-b9c0-9a1a8821c3bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3ee107a0-4955-4f99-9ab4-e43d52baa646"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For use as adjunctive therapy in the treatment of peptic ulcer. uuid:490386e9-aa3a-44df-8c42-eb75f5b85091 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2208 biolink:treats MONDO:0004967 PMID:41385096 "[{""id"":""uuid:d35478f8-ec54-40de-bac0-af625049caf3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:b089f0fa-f16e-4b15-b1a9-492f8d21619f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:5fb53d58-db25-402c-83dd-7f0d8dc3d241"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mercaptopurine tablets are indicated for maintenance therapy of acute lymphatic (lymphocytic, lymphoblastic) leukemia as part of a combination regimen. The response to this agent depends upon the particular subclassification of acute lymphatic leukemia and the age of the patient (pediatric or adult). Mercaptopurine is not effective for prophylaxis or treatment of central nervous system leukemia. Mercaptopurine is not effective in acute myelogenous leukemia, chronic lymphatic leukemia, the lymphomas (including Hodgkins Disease), or solid tumors.|[EMA] Xaluprine is indicated for the treatment of acute lymphoblastic leukaemia (ALL) in adults, adolescents and children. uuid:e6261f56-7874-4ca5-a629-ae26ba4f7cf4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2208 biolink:treats MONDO:0001606 PMID:41385096 "[{""id"":""uuid:1efb61c8-fbfe-49c6-9481-75cfae6ef880"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3815b757-5c59-431a-82f4-e7ec6ef39f65"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mercaptopurine tablets are indicated for maintenance therapy of acute lymphatic (lymphocytic, lymphoblastic) leukemia as part of a combination regimen. The response to this agent depends upon the particular subclassification of acute lymphatic leukemia and the age of the patient (pediatric or adult). Mercaptopurine is not effective for prophylaxis or treatment of central nervous system leukemia. Mercaptopurine is not effective in acute myelogenous leukemia, chronic lymphatic leukemia, the lymphomas (including Hodgkins Disease), or solid tumors. uuid:53113ea5-b263-497b-99a9-23ae0298ee74 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2208 biolink:treats MONDO:0018874 PMID:41385096 "[{""id"":""uuid:1feb9dd1-bfc2-4464-b5df-0872c8f41342"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2cdf320a-f627-47fc-9f51-16105abc9997"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mercaptopurine tablets are indicated for maintenance therapy of acute lymphatic (lymphocytic, lymphoblastic) leukemia as part of a combination regimen. The response to this agent depends upon the particular subclassification of acute lymphatic leukemia and the age of the patient (pediatric or adult). Mercaptopurine is not effective for prophylaxis or treatment of central nervous system leukemia. Mercaptopurine is not effective in acute myelogenous leukemia, chronic lymphatic leukemia, the lymphomas (including Hodgkins Disease), or solid tumors. uuid:069f3c04-fd5c-4e6c-86b9-0479457a5c5a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2208 biolink:treats MONDO:0004948 PMID:41385096 "[{""id"":""uuid:26c0ace7-b0fa-445b-aa0c-e26f767037d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4437e4ac-c6a9-43a0-86ae-4b9bbd227fdc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mercaptopurine tablets are indicated for maintenance therapy of acute lymphatic (lymphocytic, lymphoblastic) leukemia as part of a combination regimen. The response to this agent depends upon the particular subclassification of acute lymphatic leukemia and the age of the patient (pediatric or adult). Mercaptopurine is not effective for prophylaxis or treatment of central nervous system leukemia. Mercaptopurine is not effective in acute myelogenous leukemia, chronic lymphatic leukemia, the lymphomas (including Hodgkins Disease), or solid tumors. uuid:6ed70a55-ee62-4852-b10b-8fa4a7d2bafa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2208 biolink:treats MONDO:0009348 PMID:41385096 "[{""id"":""uuid:da2cda75-b668-4dc7-ba7e-aeb46494a375"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:085b6e30-6466-47bf-947f-abcfe1a49289"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mercaptopurine tablets are indicated for maintenance therapy of acute lymphatic (lymphocytic, lymphoblastic) leukemia as part of a combination regimen. The response to this agent depends upon the particular subclassification of acute lymphatic leukemia and the age of the patient (pediatric or adult). Mercaptopurine is not effective for prophylaxis or treatment of central nervous system leukemia. Mercaptopurine is not effective in acute myelogenous leukemia, chronic lymphatic leukemia, the lymphomas (including Hodgkins Disease), or solid tumors. uuid:629ae892-01d3-4a9e-af22-6e76f08bd1c9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:453011 biolink:treats MONDO:0001405 PMID:41385096 "[{""id"":""uuid:23656ccb-586d-4c9f-ba81-b37b885b9832"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4a5c8973-7943-4e5a-85be-da117a3a3535"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ciclopirox olamine cream is indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris, and tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum , and Microsporum canis ; candidiasis (moniliasis) due to Candida albicans ; and tinea (pityriasis) vesicolor due to Malassezia furfur. uuid:c8295135-4c1b-4920-8826-243c10b5de01 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:453011 biolink:treats MONDO:0001461 PMID:41385096 "[{""id"":""uuid:b5b5cd5a-4082-4b2f-8c96-936934fa3a3c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:80b86801-0b52-4ebb-8c21-b5574e504207"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ciclopirox olamine cream is indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris, and tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum , and Microsporum canis ; candidiasis (moniliasis) due to Candida albicans ; and tinea (pityriasis) vesicolor due to Malassezia furfur. uuid:77a556e7-c27e-48e7-a8a7-513d46d00e5e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:453011 biolink:treats UMLS:C0343886 PMID:41385096 "[{""id"":""uuid:439b1afd-c8be-4b72-9a3e-98dd3d06debc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:216e9c3a-61a5-42e3-84fa-e8e35bfe5c10"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ciclopirox olamine cream is indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris, and tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum , and Microsporum canis ; candidiasis (moniliasis) due to Candida albicans ; and tinea (pityriasis) vesicolor due to Malassezia furfur. uuid:b5714c6b-2374-48c6-b265-b7981418fcec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:453011 biolink:treats MONDO:0005915 PMID:41385096 "[{""id"":""uuid:792acfc0-d0b3-4569-952e-af1630faeeb8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c45c1ede-c5de-4813-9068-11b9f149b225"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ciclopirox olamine cream is indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris, and tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum , and Microsporum canis ; candidiasis (moniliasis) due to Candida albicans ; and tinea (pityriasis) vesicolor due to Malassezia furfur. uuid:e1247ce8-afe3-4b18-aa02-d3a352bb02f6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7444 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:7b316d64-07ea-428d-8678-e9829eb81f49"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:df200508-0cba-4d0e-b2ae-ba584c151a3b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Angina Pectoris Nadolol tablets are indicated for the long-term management of patients with angina pectoris. Hypertension Nadolol tablets are indicated in the management of hypertension; it may be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. uuid:57fa3e14-0177-45a8-b15f-e2cb37c6b658 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77363 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:cea9512f-0ae5-4973-9300-c4c5c6270d87"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:96194934-faab-4060-81a7-6816f1a73f39"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ramipril Capsules USP are indicated for the treatment of hypertension. It may be used alone or in combination with thiazide diuretics (1.1). uuid:45876c7d-bcfa-4572-bbe6-fb84724d0c84 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:151176 biolink:treats HP:0003124 PMID:41385096 "[{""id"":""uuid:1c390801-1f0c-4da8-b0ce-7a7a2937bde5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:267a2ebd-8413-427f-83f4-8b4159def353"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk-factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate (see also Table 8 and the NCEP treatment guidelines 1 ). uuid:7154046c-5002-4556-b35c-28154b7ae5ba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4887 biolink:treats MONDO:0010826 PMID:41385096 "[{""id"":""uuid:5d6f5f8c-53d8-44c8-bc4c-a3ab39a0f0be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6f76774d-a634-4764-974e-c7fc8e412237"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ethosuximide capsule is indicated for the control of absence (petit mal) epilepsy. uuid:9f9d0190-eb77-4bbf-a223-792575b7bfdc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:36560 biolink:treats MONDO:0002898 PMID:41385096 "[{""id"":""uuid:24258e3c-34be-4a64-b79d-61fd6d860f4b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:775d68ee-c459-4138-b1d4-1201a20df973"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] helps prevent sunburn if used as directed wiht other sun protection measures (see Directions ), decreases the risk of skin cancer and early skin aging caused by the sun. uuid:ebc8cc5f-7bd3-46ad-8e09-fe25a99ffa65 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:36560 biolink:treats MONDO:0019303 PMID:41385096 "[{""id"":""uuid:9ff5a796-ff29-4c80-bc90-ec58a4658199"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:64368d59-9dc5-4bdc-9bf4-98526479b508"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] helps prevent sunburn if used as directed wiht other sun protection measures (see Directions ), decreases the risk of skin cancer and early skin aging caused by the sun. uuid:9a72f9f9-ef8f-43a3-b7f3-4c23babfce59 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:26751 biolink:treats MONDO:0004992 PMID:41385096 "[{""id"":""uuid:d899aeaa-2f06-4787-8ccd-71afbb95a062"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6a400133-11e1-4c95-87f2-7dac7d02f3fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] P32 chromic phosphate is indicated for intracavitary instillation for the treatment of peritoneal or pleural effusions caused by metastatic disease, and may be injected interstitially for the treatment of cancer. It is also used in hemophilia patients for intraarticular injections. uuid:f586be68-6eac-4d39-8171-10825438ce3a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:26751 biolink:treats MONDO:0018660 PMID:41385096 "[{""id"":""uuid:c6a38f90-6a0b-491f-8e46-62f95ecf1b53"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d80c5c59-9582-47f8-8899-025ec70f8051"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] P32 chromic phosphate is indicated for intracavitary instillation for the treatment of peritoneal or pleural effusions caused by metastatic disease, and may be injected interstitially for the treatment of cancer. It is also used in hemophilia patients for intraarticular injections. uuid:ca373e94-b656-44a2-bce0-8c74771e400c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:26751 biolink:treats MONDO:0009891 PMID:41385096 "[{""id"":""uuid:efcc2c8f-9dd1-4011-94fb-e1a62a10ec27"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cc19ffd9-31c7-424a-baee-a71f8656fa52"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] P32 sodium phosphate is indicated for the treatment of polycythemia vera and is effective for the treatment of chronic myelocytic leukemia and chronic lymphocytic leukemia. It may also be used in the palliative treatment of selected patients with multiple areas of skeletal metastases uuid:5a3a5a40-73a7-450b-9aae-68de795253d3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:26751 biolink:treats MONDO:0011996 PMID:41385096 "[{""id"":""uuid:38026e08-3c76-4470-b041-27d8ebe6bc27"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0b847e9f-fcf7-40b0-8671-10d9367a8419"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] P32 sodium phosphate is indicated for the treatment of polycythemia vera and is effective for the treatment of chronic myelocytic leukemia and chronic lymphocytic leukemia. It may also be used in the palliative treatment of selected patients with multiple areas of skeletal metastases uuid:e968fc8e-5099-44ad-acc4-e0eebb5ba228 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:26751 biolink:treats MONDO:0004948 PMID:41385096 "[{""id"":""uuid:66abccc9-8c6a-42e2-ba30-585ca1a165c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0ca3fbe2-7507-4637-8b3b-4154ea8e3f2a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] P32 sodium phosphate is indicated for the treatment of polycythemia vera and is effective for the treatment of chronic myelocytic leukemia and chronic lymphocytic leukemia. It may also be used in the palliative treatment of selected patients with multiple areas of skeletal metastases uuid:ee16d2c0-a8df-4196-9523-74061bc7cee8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:26751 biolink:treats UMLS:C0153690 PMID:41385096 "[{""id"":""uuid:96ca6684-be4a-4fe2-a9ef-95f592044843"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:239f99c6-6a42-4511-bed0-c8dd29b6b370"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] P32 sodium phosphate is indicated for the treatment of polycythemia vera and is effective for the treatment of chronic myelocytic leukemia and chronic lymphocytic leukemia. It may also be used in the palliative treatment of selected patients with multiple areas of skeletal metastases uuid:8eb5ef7a-9f21-48bc-8c97-61c7a1cf52a7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3FYP5M0IJX biolink:treats MONDO:0002203 PMID:41385096 "[{""id"":""uuid:4472a55a-ee33-446b-81e3-dbf903c89dc3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:085e9e9d-ab16-4f8c-84d6-318530c5c126"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] relieves occasional constipation (irregularity) generally produces a bowel movement in 6-12 hours uuid:c838926a-4311-4115-8ec0-2c49b30b761c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:367163 biolink:treats MONDO:0004951 PMID:41385096 "[{""id"":""uuid:e4142500-317c-43c1-9477-ab21d844dfeb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2ee34ac4-e143-4cb0-b93e-a5053324f502"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PREZISTA is a human immunodeficiency virus (HIV-1) protease inhibitor indicated for the treatment of HIV-1 infection in adult patients. PREZISTA is also indicated for the treatment of HIV-1 infection in pediatric patients 3 years of age and older. PREZISTA must be co-administered with ritonavir (PREZISTA/ritonavir) and with other antiretroviral agents. ( 1 ) uuid:7eabadd5-b1f7-413f-86b5-b0aa87af8f57 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:24757947 biolink:treats MONDO:0003664 PMID:41385096 "[{""id"":""uuid:dcbede85-3e73-481f-91d8-c8de98897aec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:194b39e1-7af2-460e-bc7f-af92031289f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cr51 is indicated for use in determining red blood cell volume or mass, studying red blood cell survival time (in conditions such as hemolytic anemia), and evaluating blood loss uuid:1f36c082-7cde-4532-ba5f-ae6ead4000f5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:35940 biolink:treats MONDO:0006869 PMID:41385096 "[{""id"":""uuid:0f922a7c-3737-435a-b462-2dc2ddf9b048"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b1cc7a54-40f5-4bf8-b9d6-ddc76f3b3475"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TRH is indicated as an adjunctive agent in the diagnostic assessment of thyroid function. As an adjunct to other diagnostic procedures, testing with TRH (protirelin) may yield useful information in patients with pituitary or hypothalamic dysfunction. TRH is indicated as an adjunct to evaluate the effectiveness of thyrotropin suppression with a particular dose of T4 in patients with nodular or diffuse goiter. A normal TSH baseline value and a minimal difference between the 30 minute and baseline response to TRH injection would indicate adequate suppression of the pituitary secretion of TSH. TRH may be used, adjunctively, for adjustment of thyroid hormone dosage given to patients with primary hypothyroidism. A normal or slightly blunted TSH response, thirty minutes following TRH injection, would indicate adequate replacement therapy. uuid:1f60e2d6-e099-4255-9353-97c56ba82ca2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:35940 biolink:treats UMLS:C0342114 PMID:41385096 "[{""id"":""uuid:151ded3f-a4fb-4141-af58-7569d3f19204"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:02170a13-0260-4a0c-b03c-08acb3e7b09c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TRH is indicated as an adjunctive agent in the diagnostic assessment of thyroid function. As an adjunct to other diagnostic procedures, testing with TRH (protirelin) may yield useful information in patients with pituitary or hypothalamic dysfunction. TRH is indicated as an adjunct to evaluate the effectiveness of thyrotropin suppression with a particular dose of T4 in patients with nodular or diffuse goiter. A normal TSH baseline value and a minimal difference between the 30 minute and baseline response to TRH injection would indicate adequate suppression of the pituitary secretion of TSH. TRH may be used, adjunctively, for adjustment of thyroid hormone dosage given to patients with primary hypothyroidism. A normal or slightly blunted TSH response, thirty minutes following TRH injection, would indicate adequate replacement therapy. uuid:afc24440-697a-40f8-b762-5454174b5b3d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:35940 biolink:treats HP:0000832 PMID:41385096 "[{""id"":""uuid:e8ff6a84-93c5-4770-a8f9-1dcc469ef666"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:336b4998-3278-4c61-ae19-57cef5563b44"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TRH is indicated as an adjunctive agent in the diagnostic assessment of thyroid function. As an adjunct to other diagnostic procedures, testing with TRH (protirelin) may yield useful information in patients with pituitary or hypothalamic dysfunction. TRH is indicated as an adjunct to evaluate the effectiveness of thyrotropin suppression with a particular dose of T4 in patients with nodular or diffuse goiter. A normal TSH baseline value and a minimal difference between the 30 minute and baseline response to TRH injection would indicate adequate suppression of the pituitary secretion of TSH. TRH may be used, adjunctively, for adjustment of thyroid hormone dosage given to patients with primary hypothyroidism. A normal or slightly blunted TSH response, thirty minutes following TRH injection, would indicate adequate replacement therapy. uuid:494b0e32-c183-45ac-8771-a45170cd3e47 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29101 biolink:treats UMLS:C0948840 PMID:41385096 "[{""id"":""uuid:24c6435e-637a-4eee-8af5-a79c51027a78"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:78cf1839-bcb1-4d81-baa0-56a9ccdd4b2a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Elliotts B Solution is indicated as a diluent for the intrathecal administration of methotrexate sodium and cytarabine for the prevention or treatment of meningeal leukemia or lymphocytic lymphoma. uuid:de5620e9-cbb9-4a33-9cb1-65a1ce0d9385 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29101 biolink:treats MONDO:0003864 PMID:41385096 "[{""id"":""uuid:40d33143-9fcb-4b92-bd8c-77661c05c001"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:82d7e0d6-1bf5-4a32-b3cc-67d93ef0ff77"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Elliotts B Solution is indicated as a diluent for the intrathecal administration of methotrexate sodium and cytarabine for the prevention or treatment of meningeal leukemia or lymphocytic lymphoma. uuid:61d6d203-6143-407e-b27a-298d007c6064 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:520985 biolink:treats MONDO:0005277 PMID:41385096 "[{""id"":""uuid:65ec2b90-451d-4d29-9643-70e0d8aacb87"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b8b69aaf-5cdd-4a8e-b478-ed1adeab9954"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AXERT ® is a 5HT 1B/1D receptor agonist (triptan) indicated for: Acute treatment of migraine attacks in adults with a history of migraine with or without aura ( 1.1 ) Acute treatment of migraine headache pain in adolescents age 12 to 17 years with a history of migraine with or without aura, and who have migraine attacks usually lasting 4 hours or more ( 1.1 ) Important limitations: Use only after a clear diagnosis of migraine has been established ( 1.2 ) In adolescents age 12 to 17 years, efficacy of AXERT ® on migraine-associated symptoms was not established ( 1.2 ) Not intended for the prophylactic therapy of migraine ( 1.2 ) Not indicated for the treatment of cluster headache ( 1.2 ) uuid:9522177e-7a78-4f5e-b953-d739268dd4c4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:520985 biolink:treats MONDO:0043537 PMID:41385096 "[{""id"":""uuid:153a06c0-a67a-4352-99f5-e1f162404643"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4335dcfb-f516-411d-9c81-e3308429dbe7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AXERT ® is a 5HT 1B/1D receptor agonist (triptan) indicated for: Acute treatment of migraine attacks in adults with a history of migraine with or without aura ( 1.1 ) Acute treatment of migraine headache pain in adolescents age 12 to 17 years with a history of migraine with or without aura, and who have migraine attacks usually lasting 4 hours or more ( 1.1 ) Important limitations: Use only after a clear diagnosis of migraine has been established ( 1.2 ) In adolescents age 12 to 17 years, efficacy of AXERT ® on migraine-associated symptoms was not established ( 1.2 ) Not intended for the prophylactic therapy of migraine ( 1.2 ) Not indicated for the treatment of cluster headache ( 1.2 ) uuid:ccdc4a20-96dc-4a05-9273-3d2cfea48681 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7025 biolink:treats MONDO:0100073 PMID:41385096 "[{""id"":""uuid:63404f76-40fd-4c0a-90ee-7af2e4600ac5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:149066e3-7081-4e4b-bc50-ec38fe5c1437"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BACTROBAN NASAL is indicated for the eradication of nasal colonization with methicillin-resistant S. aureus in adult patients and health care workers as part of a comprehensive infection control program to reduce the risk of infection among patients at high risk of methicillin-resistant S. aureus infection during institutional outbreaks of infections with this pathogen. NOTE: There are insufficient data at this time to establish that this product is safe and effective as part of an intervention program to prevent autoinfection of high-risk patients from their own nasal colonization with S. aureus . There are insufficient data at this time to recommend use of BACTROBAN NASAL for general prophylaxis of any infection in any patient population. Greater than 90% of subjects/patients in clinical trials had eradication of nasal colonization 2 to 4 days after therapy was completed. Approximately 30% recolonization was reported in 1 domestic study within 4 weeks after completion of therapy. These eradication rates were clinically and statistically superior to those reported in subjects/patients in the vehicle-treated arms of the adequate and well-controlled studies. Those treated with vehicle had eradication rates of 5% to 30% at 2 to 4 days post-therapy with 85% to 100% recolonization within 4 weeks. All adequate and well-controlled trials of this product were vehicle-controlled; therefore, no data from direct, head-to-head comparisons with other products are available at this time. uuid:fe2bd92f-fbd6-4b03-8c1b-d7767908cb74 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:88667 biolink:treats MONDO:0002898 PMID:41385096 "[{""id"":""uuid:df2cad85-a865-43ec-a388-203b4fc73683"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a1808e8e-c5a4-49ec-97f3-124d377da58f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Directions apply liberally 15 minutes bfore sun exposure reapply at least every 2 hours. use a water resistant sunscreen if swimming or sweating. children under 6 months of age: Ask a doctor. Sun Protection Measures. Spending time in the sun increases your risk of skin cancer and early skin aging. To decrease this risk, regularly use a sunscreen with a Broad Spectrum SPF value of 15 or higher and other sun protection measures including: limit time in the sun, especially from 10 a.m.–2 p.m. wear long-sleeved shirts, pants, hats, and sunglasses uuid:c30a6e58-5360-4e82-8af8-9fe5990d8a53 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:88667 biolink:treats MONDO:0019303 PMID:41385096 "[{""id"":""uuid:3019eb6a-5054-44b0-bb29-3477e72c8cc9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c8f9f2e9-c01f-490a-95c3-586c5941849a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Directions apply liberally 15 minutes bfore sun exposure reapply at least every 2 hours. use a water resistant sunscreen if swimming or sweating. children under 6 months of age: Ask a doctor. Sun Protection Measures. Spending time in the sun increases your risk of skin cancer and early skin aging. To decrease this risk, regularly use a sunscreen with a Broad Spectrum SPF value of 15 or higher and other sun protection measures including: limit time in the sun, especially from 10 a.m.–2 p.m. wear long-sleeved shirts, pants, hats, and sunglasses uuid:4aaf7202-4485-4587-871f-326492823892 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:83527 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:5cbcc653-d143-402e-8ba4-3f4272ce68fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0b1df941-d280-41b9-9763-b0fcd6603bd3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PRISTIQ, a selective serotonin and norepinephrine reuptake inhibitor (SNRI), is indicated for the treatment of major depressive disorder (MDD) [ see Clinical Studies ( 14 ) and Dosage and Administration ( 2.1 ) ]. The efficacy of PRISTIQ has been established in four 8-week, placebo-controlled studies of outpatients who met DSM-IV criteria for major depressive disorder. A major depressive episode (DSM-IV) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least 5 of the following 9 symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, or a suicide attempt or suicidal ideation. uuid:b2d6ae64-aad6-4c07-81f4-39359f069746 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32130 biolink:treats MONDO:0001209 PMID:41385096 "[{""id"":""uuid:19585b27-aa35-42b0-9b1d-43d62bc2123b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0d6f8fb2-8f03-465c-af19-89331e79ae6a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Repara ® ​Silver Nitrate Applicators are useful for cauterization of skin or mucous membrane and for the removal of granulation tissue, warts and verrucae. uuid:1c982867-8f62-4949-836b-cf7c5e777f6a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:RWM8CCW8GP biolink:treats MONDO:0019933 PMID:41385096 "[{""id"":""uuid:10a7cc3e-6994-417d-bf31-9dd24a43849c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f0d52441-468d-4932-9807-c17375039db5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:4bc609ce-435f-4a45-8a78-328d836d5e3a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:9434d283-a89f-4e72-9a48-30546c8d0043"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Octreotide acetate injection is indicated to reduce blood levels of growth hormone and IGF-I (somatomedin C) in acromegaly patients who have had inadequate response to or cannot be treated with surgical resection, pituitary irradiation, and bromocriptine mesylate at maximally tolerated doses. The goal is to achieve normalization of growth hormone and IGF-I (somatomedin C) levels ( see DOSAGE AND ADMINISTRATION ). In patients with acromegaly, octreotide acetate reduces growth hormone to within normal ranges in 50% of patients and reduces IGF-I (somatomedin C) to within normal ranges in 50%-60% of patients. Since the effects of pituitary irradiation may not become maximal for several years, adjunctive therapy with octreotide acetate to reduce blood levels of growth hormone and IGF-I (somatomedin C) offers potential benefit before the effects of irradiation are manifested. Improvement in clinical signs and symptoms or reduction in tumor size or rate of growth were not shown in clinical trials performed with octreotide acetate; these trials were not optimally designed to detect such effects.|[EMA] Mycapssa is indicated for maintenance treatment in adult patients with acromegaly who have responded to and tolerated treatment with somatostatin analogues.|[PMDA] New form drug with a new administration route administered once every four weeks and which has the following indications: alleviation of various symptoms associated with gastrointestinal hormone-producing tumors and alleviation of excessive secretions of growth hormone and somatomedin-C and other various symptoms in acromegaly and pituitary gigantism uuid:52de7048-93d9-45ab-9211-d6ba7178c870 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:378788 biolink:treats MONDO:0008159 PMID:41385096 "[{""id"":""uuid:92a290d0-72cb-4400-8ed3-e622da39db79"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:657695b9-89c2-4e4f-9843-80f342977eb0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PREMPRO/PREMPHASE is an estrogen/progestin indicated in women with intact uteri for: Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause ( 1.1 ) Treatment of Moderate to Severe Vulvar and Vaginal Atrophy due to Menopause ( 1.2 ) Prevention of Postmenopausal Osteoporosis ( 1.3 ) uuid:246aed9b-d31a-4ccd-acfe-12d82e4a0207 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135934 biolink:treats MONDO:0005915 PMID:41385096 "[{""id"":""uuid:540affc9-1c8e-498c-a48a-3e288f30ef07"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:10dc4652-a388-494b-a3be-d9ec32ff1bf6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the treatment of tinea versicolor, seborrheic dermatitis of the scalp, and dandruff. uuid:28952adb-60fd-4cc9-9d70-de16ab0f25f7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135934 biolink:treats MONDO:0006608 PMID:41385096 "[{""id"":""uuid:9ffcadae-1286-43e4-bdb5-7e7f426e5777"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a32faa14-5e30-4000-9e92-ed6817685804"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the treatment of tinea versicolor, seborrheic dermatitis of the scalp, and dandruff. uuid:9b44a53b-ac03-40c8-8962-60ca612a9470 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135934 biolink:treats MONDO:0006609 PMID:41385096 "[{""id"":""uuid:e3d142a2-8104-4ae2-bac2-659cba17b7af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2efe5b46-9228-41c3-829c-a83a94803bd4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the treatment of tinea versicolor, seborrheic dermatitis of the scalp, and dandruff. uuid:f199e76f-097d-4e01-a983-e6a361b66c7e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63618 biolink:treats MONDO:0005311 PMID:41385096 "[{""id"":""uuid:887a55b3-83da-4d9f-8b35-7575dc4d9541"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f3105db2-c37f-4b63-b8e7-86330ca0ddd6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. uuid:8ad81805-4493-49c0-8d8d-fdfbfc7a5518 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17823 biolink:treats MONDO:0005300 PMID:41385096 "[{""id"":""uuid:1e742a90-7aee-4d52-a892-d5d1f4d7999b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:897fecd6-1551-457f-994d-4f27cab6977b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Predialysis Patients Rocaltrol is indicated in the management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure (Ccr 15 to 55 mL/min) not yet on dialysis. In children, the creatinine clearance value must be corrected for a surface area of 1.73 square meters. A serum iPTH level of ≥ 100 pg/mL is strongly suggestive of secondary hyperparathyroidism. Dialysis Patients Rocaltrol is indicated in the management of hypocalcemia and the resultant metabolic bone disease in patients undergoing chronic renal dialysis. In these patients, Rocaltrol administration enhances calcium absorption, reduces serum alkaline phosphatase levels, and may reduce elevated parathyroid hormone levels and the histological manifestations of osteitis fibrosa cystica and defective mineralization. Hypoparathyroidism Patients Rocaltrol is also indicated in the management of hypocalcemia and its clinical manifestations in patients with postsurgical hypoparathyroidism, idiopathic hypoparathyroidism, and pseudohypoparathyroidism. uuid:cd65268c-7da6-45cc-a478-445fdd72fa3f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:e5e20857-1d54-4989-a58f-c85a546b80a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:51dc05a3-43b8-49f0-88ea-d55eb50b39c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:3d5c5269-d3fe-49e4-b7cb-201c7dd771e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levofloxacin is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria ( 1 , 12.4 ). Pneumonia: nosocomial ( 1.1 ) and community acquired ( 1.2 , 1.3 ) Acute bacterial sinusitis ( 1.4 ) Acute bacterial exacerbation of chronic bronchitis ( 1.5 ) Skin and skin structure infections: complicated ( 1.6 ) and uncomplicated ( 1.7 ) Chronic bacterial prostatitis ( 1.8 ) Urinary tract infections: complicated ( 1.9 , 1.10 ) and uncomplicated ( 1.12 ) Acute pyelonephritis ( 1.11 ) Inhalational anthrax, post-exposure ( 1.13 ) Plague ( 1.14 )|[PMDA] Drugs with a new route of administration indicated for the treatment of pneumonia, secondary infection of chronic respiratory disease, typhoid, paratyphoid, anthrax, brucellosis, plague, tularemia and Q fever. uuid:0c2b636b-7ef6-4bd7-a528-04d7abaea6b4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats UMLS:C0949083 PMID:41385096 "[{""id"":""uuid:722efdca-ce9f-4425-aba4-e09edcfa52b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c10a8696-627a-413a-b035-c8c1b4aa684d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levofloxacin is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria ( 1 , 12.4 ). Pneumonia: nosocomial ( 1.1 ) and community acquired ( 1.2 , 1.3 ) Acute bacterial sinusitis ( 1.4 ) Acute bacterial exacerbation of chronic bronchitis ( 1.5 ) Skin and skin structure infections: complicated ( 1.6 ) and uncomplicated ( 1.7 ) Chronic bacterial prostatitis ( 1.8 ) Urinary tract infections: complicated ( 1.9 , 1.10 ) and uncomplicated ( 1.12 ) Acute pyelonephritis ( 1.11 ) Inhalational anthrax, post-exposure ( 1.13 ) Plague ( 1.14 ) uuid:36ed1756-423c-45c4-8948-e47d07c4ebf1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats UMLS:C0694549 PMID:41385096 "[{""id"":""uuid:67031526-4fa5-49ff-ae48-ed8dd2a10d79"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b9ee3ef1-f483-43d9-ab5a-424f3462b42a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levofloxacin is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria ( 1 , 12.4 ). Pneumonia: nosocomial ( 1.1 ) and community acquired ( 1.2 , 1.3 ) Acute bacterial sinusitis ( 1.4 ) Acute bacterial exacerbation of chronic bronchitis ( 1.5 ) Skin and skin structure infections: complicated ( 1.6 ) and uncomplicated ( 1.7 ) Chronic bacterial prostatitis ( 1.8 ) Urinary tract infections: complicated ( 1.9 , 1.10 ) and uncomplicated ( 1.12 ) Acute pyelonephritis ( 1.11 ) Inhalational anthrax, post-exposure ( 1.13 ) Plague ( 1.14 ) uuid:2bcb1479-d7da-4d0e-8149-6004e544d6f2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats UMLS:C0275556 PMID:41385096 "[{""id"":""uuid:2eda81ac-89e4-47b6-b0c7-dd8b26ba2580"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1781d277-3e2b-4c32-8be7-fc863009ecbb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levofloxacin is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria ( 1 , 12.4 ). Pneumonia: nosocomial ( 1.1 ) and community acquired ( 1.2 , 1.3 ) Acute bacterial sinusitis ( 1.4 ) Acute bacterial exacerbation of chronic bronchitis ( 1.5 ) Skin and skin structure infections: complicated ( 1.6 ) and uncomplicated ( 1.7 ) Chronic bacterial prostatitis ( 1.8 ) Urinary tract infections: complicated ( 1.9 , 1.10 ) and uncomplicated ( 1.12 ) Acute pyelonephritis ( 1.11 ) Inhalational anthrax, post-exposure ( 1.13 ) Plague ( 1.14 ) uuid:c686cdbe-d1bb-4d9a-8dc3-6fce7261d4e5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats UMLS:C1735365 PMID:41385096 "[{""id"":""uuid:3a188c96-66ae-4e4b-857e-8254f8384bb1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:be461e53-74bf-4ef9-bff0-6d6a0b7524b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levofloxacin is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria ( 1 , 12.4 ). Pneumonia: nosocomial ( 1.1 ) and community acquired ( 1.2 , 1.3 ) Acute bacterial sinusitis ( 1.4 ) Acute bacterial exacerbation of chronic bronchitis ( 1.5 ) Skin and skin structure infections: complicated ( 1.6 ) and uncomplicated ( 1.7 ) Chronic bacterial prostatitis ( 1.8 ) Urinary tract infections: complicated ( 1.9 , 1.10 ) and uncomplicated ( 1.12 ) Acute pyelonephritis ( 1.11 ) Inhalational anthrax, post-exposure ( 1.13 ) Plague ( 1.14 ) uuid:9c2c1c88-6f26-4c32-b65a-00a128e3f093 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:85b1964c-7f7a-4cf4-b11e-3c5faa047443"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e98b1978-5509-4913-a084-3b1a2a9f8f77"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levofloxacin is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria ( 1 , 12.4 ). Pneumonia: nosocomial ( 1.1 ) and community acquired ( 1.2 , 1.3 ) Acute bacterial sinusitis ( 1.4 ) Acute bacterial exacerbation of chronic bronchitis ( 1.5 ) Skin and skin structure infections: complicated ( 1.6 ) and uncomplicated ( 1.7 ) Chronic bacterial prostatitis ( 1.8 ) Urinary tract infections: complicated ( 1.9 , 1.10 ) and uncomplicated ( 1.12 ) Acute pyelonephritis ( 1.11 ) Inhalational anthrax, post-exposure ( 1.13 ) Plague ( 1.14 ) uuid:3d9a6f0e-7b2b-4bee-accd-62ebbdf53526 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats UMLS:C1720797 PMID:41385096 "[{""id"":""uuid:c5e1584b-b43a-4d2b-bcb0-57aa6d9820bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2bdb1edc-80bc-4e3d-a747-ca3af4e5d26c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levofloxacin is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria ( 1 , 12.4 ). Pneumonia: nosocomial ( 1.1 ) and community acquired ( 1.2 , 1.3 ) Acute bacterial sinusitis ( 1.4 ) Acute bacterial exacerbation of chronic bronchitis ( 1.5 ) Skin and skin structure infections: complicated ( 1.6 ) and uncomplicated ( 1.7 ) Chronic bacterial prostatitis ( 1.8 ) Urinary tract infections: complicated ( 1.9 , 1.10 ) and uncomplicated ( 1.12 ) Acute pyelonephritis ( 1.11 ) Inhalational anthrax, post-exposure ( 1.13 ) Plague ( 1.14 ) uuid:511f7ee7-ad20-4c60-a52a-029ab5260dc3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:0124425f-80b7-42f6-8f86-f1d5d393b33d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4e7d2da5-932b-401e-99f7-c5fcce5432c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levofloxacin is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria ( 1 , 12.4 ). Pneumonia: nosocomial ( 1.1 ) and community acquired ( 1.2 , 1.3 ) Acute bacterial sinusitis ( 1.4 ) Acute bacterial exacerbation of chronic bronchitis ( 1.5 ) Skin and skin structure infections: complicated ( 1.6 ) and uncomplicated ( 1.7 ) Chronic bacterial prostatitis ( 1.8 ) Urinary tract infections: complicated ( 1.9 , 1.10 ) and uncomplicated ( 1.12 ) Acute pyelonephritis ( 1.11 ) Inhalational anthrax, post-exposure ( 1.13 ) Plague ( 1.14 ) uuid:98f4ddd6-d9c5-4b9d-beb3-175dd5d09b9e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats MONDO:0003529 PMID:41385096 "[{""id"":""uuid:05ba6416-e8e8-4e2c-921d-9de3678b18c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:07b8b966-294d-484a-8ba5-2be00316dd1d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levofloxacin is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria ( 1 , 12.4 ). Pneumonia: nosocomial ( 1.1 ) and community acquired ( 1.2 , 1.3 ) Acute bacterial sinusitis ( 1.4 ) Acute bacterial exacerbation of chronic bronchitis ( 1.5 ) Skin and skin structure infections: complicated ( 1.6 ) and uncomplicated ( 1.7 ) Chronic bacterial prostatitis ( 1.8 ) Urinary tract infections: complicated ( 1.9 , 1.10 ) and uncomplicated ( 1.12 ) Acute pyelonephritis ( 1.11 ) Inhalational anthrax, post-exposure ( 1.13 ) Plague ( 1.14 ) uuid:e900ab02-71d2-44d3-bb98-3d27864abfee biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats MONDO:0016595 PMID:41385096 "[{""id"":""uuid:698f8443-bca2-4a18-ac6b-d6aaf724caf4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:30af57c7-5608-4bcf-8373-d4fcc1cb94cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levofloxacin is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria ( 1 , 12.4 ). Pneumonia: nosocomial ( 1.1 ) and community acquired ( 1.2 , 1.3 ) Acute bacterial sinusitis ( 1.4 ) Acute bacterial exacerbation of chronic bronchitis ( 1.5 ) Skin and skin structure infections: complicated ( 1.6 ) and uncomplicated ( 1.7 ) Chronic bacterial prostatitis ( 1.8 ) Urinary tract infections: complicated ( 1.9 , 1.10 ) and uncomplicated ( 1.12 ) Acute pyelonephritis ( 1.11 ) Inhalational anthrax, post-exposure ( 1.13 ) Plague ( 1.14 ) uuid:ea46c723-2de6-420a-9ae2-880002351525 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats MONDO:0019095 PMID:41385096 "[{""id"":""uuid:faeb0775-0d12-4f3c-9ab2-bd1ac2f777df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a9d1ddc7-73b8-44c9-86b5-6907fb3ab069"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:29bf3dee-360e-44bd-a673-fe920d1bcaa5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levofloxacin is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria ( 1 , 12.4 ). Pneumonia: nosocomial ( 1.1 ) and community acquired ( 1.2 , 1.3 ) Acute bacterial sinusitis ( 1.4 ) Acute bacterial exacerbation of chronic bronchitis ( 1.5 ) Skin and skin structure infections: complicated ( 1.6 ) and uncomplicated ( 1.7 ) Chronic bacterial prostatitis ( 1.8 ) Urinary tract infections: complicated ( 1.9 , 1.10 ) and uncomplicated ( 1.12 ) Acute pyelonephritis ( 1.11 ) Inhalational anthrax, post-exposure ( 1.13 ) Plague ( 1.14 )|[PMDA] Drugs with a new route of administration indicated for the treatment of pneumonia, secondary infection of chronic respiratory disease, typhoid, paratyphoid, anthrax, brucellosis, plague, tularemia and Q fever. uuid:f5a9b682-328c-4f15-812c-90e68886f14a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2904 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:281995b4-5168-460c-a87b-c0b52cb096c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f9e52f17-92ed-4081-b690-b8cd55aebde9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Atenolol is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including atenolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Atenolol may be administered with other antihypertensive agents. uuid:08975589-0287-4a92-a030-235d051cb0a2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2904 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:8697f3a0-e667-471a-829e-55d62c83a92d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ba0ca339-127f-4b1b-b9fc-639ffc2aba60"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Atenolol is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including atenolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Atenolol may be administered with other antihypertensive agents. uuid:be5aa634-0fb5-476e-94a8-cdf8c856dfe6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2904 biolink:treats MONDO:0005016 PMID:41385096 "[{""id"":""uuid:37ff61f0-eb52-4fc0-8039-d0ec6e5e41ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d4c7c4e6-4ad7-40b5-9130-2cd946b70da9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Atenolol is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including atenolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Atenolol may be administered with other antihypertensive agents. uuid:16b05524-f15a-4249-abde-6fa76898b4d9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3515 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:a7756bbf-36c6-4360-a17f-9487c8aa1300"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:01120f06-2d2c-4cf6-aab0-1e213e676453"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefuroxime for Injection, USP is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: Lower Respiratory Tract Infections, including pneumonia, caused by Streptococcus pneumoniae, Haemophilus influenzae (including ampicillin-resistant strains), Klebsiella spp., Staphylococcus aureus (penicillinase- and non-penicillinase-producing strains), Streptococcus pyogenes , and Escherichia coli . Urinary Tract Infections caused by Escherichia coli and Klebsiella spp. Skin and Skin Structure Infections caused by Staphylococcus aureus (penicillinase- and non-penicillinase-producing strains), Streptococcus pyogenes , Escherichia coli, Klebsiella spp., and Enterobacter spp. Septicemia caused by Staphylococcus aureus (penicillinase- and non-penicillinase-producing strains), Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae (including ampicillin-resistant strains), and Klebsiella spp. Meningitis caused by Streptococcus pneumoniae, Haemophilus influenzae (including ampicillin-resistant strains), Neisseria meningitidis , and Staphylococcus aureus (penicillinase- and non-penicillinase-producing strains). Gonorrhea: Uncomplicated and disseminated gonococcal infections due to Neisseria gonorrhoeae (penicillinase- and non-penicillinase-producing strains) in both males and females. Bone and Joint Infections caused by Staphylococcus aureus (penicillinase- and non-penicillinase-producing strains). Clinical microbiological studies in skin and skin-structure infections frequently reveal the growth of susceptible strains of both aerobic and anaerobic organisms. Cefuroxime for Injection, USP has been used successfully in these mixed infections in which several organisms have been isolated. In certain cases of confirmed or suspected gram-positive or gram-negative sepsis or in patients with other serious infections in which the causative organism has not been identified, Cefuroxime for Injection may be used concomitantly with an aminoglycoside (see PRECAUTIONS). The recommended doses of both antibiotics may be given depending on the severity of the infection and the patient’s condition. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefuroxime for Injection, USP and other antibacterial drugs, Cefuroxime for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Prevention: The preoperative prophylactic administration of Cefuroxime for Injection, USP may prevent the growth of susceptible disease-causing bacteria and thereby may reduce the incidence of certain postoperative infections in patients undergoing surgical procedures (e.g., vaginal hysterectomy) that are classified as clean-contaminated or potentially contaminated procedures. Effective prophylactic use of antibiotics in surgery depends on the time of administration. Cefuroxime for Injection, USP should usually be given one-half to 1 hour before the operation to allow sufficient time to achieve effective antibiotic concentrations in the wound tissues during the procedure. The dose should be repeated intraoperatively if the surgical procedure is lengthy. Prophylactic administration is usually not required after the surgical procedure ends and should be stopped within 24 hours. In the majority of surgical procedures, continuing prophylactic administration of any antibiotic does not reduce the incidence of subsequent infections but will increase the possibility of adverse reactions and the development of bacterial resistance. The perioperative use of Cefuroxime for Injection, USP has also been effective during open heart surgery for surgical patients in whom infections at the operative site would present a serious risk. For these patients it is recommended that therapy with Cefuroxime for Injection, USP be continued for at least 48 hours after the surgical procedure ends. If an infection is present, specimens for culture should be obtained for the identification of the causative organism, and appropriate antimicrobial therapy should be instituted. uuid:6d475b18-b5b7-4a81-b3fe-2a3cfe161a9d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3515 biolink:treats MONDO:0700217 PMID:41385096 "[{""id"":""uuid:ad86a3a0-581e-48fb-9bb8-3104f63b1a6a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:69e97f43-82cb-4189-98b0-15293b7185a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefuroxime for Injection, USP is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: Lower Respiratory Tract Infections, including pneumonia, caused by Streptococcus pneumoniae, Haemophilus influenzae (including ampicillin-resistant strains), Klebsiella spp., Staphylococcus aureus (penicillinase- and non-penicillinase-producing strains), Streptococcus pyogenes , and Escherichia coli . Urinary Tract Infections caused by Escherichia coli and Klebsiella spp. Skin and Skin Structure Infections caused by Staphylococcus aureus (penicillinase- and non-penicillinase-producing strains), Streptococcus pyogenes , Escherichia coli, Klebsiella spp., and Enterobacter spp. Septicemia caused by Staphylococcus aureus (penicillinase- and non-penicillinase-producing strains), Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae (including ampicillin-resistant strains), and Klebsiella spp. Meningitis caused by Streptococcus pneumoniae, Haemophilus influenzae (including ampicillin-resistant strains), Neisseria meningitidis , and Staphylococcus aureus (penicillinase- and non-penicillinase-producing strains). Gonorrhea: Uncomplicated and disseminated gonococcal infections due to Neisseria gonorrhoeae (penicillinase- and non-penicillinase-producing strains) in both males and females. Bone and Joint Infections caused by Staphylococcus aureus (penicillinase- and non-penicillinase-producing strains). Clinical microbiological studies in skin and skin-structure infections frequently reveal the growth of susceptible strains of both aerobic and anaerobic organisms. Cefuroxime for Injection, USP has been used successfully in these mixed infections in which several organisms have been isolated. In certain cases of confirmed or suspected gram-positive or gram-negative sepsis or in patients with other serious infections in which the causative organism has not been identified, Cefuroxime for Injection may be used concomitantly with an aminoglycoside (see PRECAUTIONS). The recommended doses of both antibiotics may be given depending on the severity of the infection and the patient’s condition. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefuroxime for Injection, USP and other antibacterial drugs, Cefuroxime for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Prevention: The preoperative prophylactic administration of Cefuroxime for Injection, USP may prevent the growth of susceptible disease-causing bacteria and thereby may reduce the incidence of certain postoperative infections in patients undergoing surgical procedures (e.g., vaginal hysterectomy) that are classified as clean-contaminated or potentially contaminated procedures. Effective prophylactic use of antibiotics in surgery depends on the time of administration. Cefuroxime for Injection, USP should usually be given one-half to 1 hour before the operation to allow sufficient time to achieve effective antibiotic concentrations in the wound tissues during the procedure. The dose should be repeated intraoperatively if the surgical procedure is lengthy. Prophylactic administration is usually not required after the surgical procedure ends and should be stopped within 24 hours. In the majority of surgical procedures, continuing prophylactic administration of any antibiotic does not reduce the incidence of subsequent infections but will increase the possibility of adverse reactions and the development of bacterial resistance. The perioperative use of Cefuroxime for Injection, USP has also been effective during open heart surgery for surgical patients in whom infections at the operative site would present a serious risk. For these patients it is recommended that therapy with Cefuroxime for Injection, USP be continued for at least 48 hours after the surgical procedure ends. If an infection is present, specimens for culture should be obtained for the identification of the causative organism, and appropriate antimicrobial therapy should be instituted. uuid:f34aa77a-ee1c-41d3-974a-575e6913e403 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3515 biolink:treats MONDO:0021108 PMID:41385096 "[{""id"":""uuid:dce09b6d-4869-4bab-9c8f-1dd7fcf1acf1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:98bdf2a4-290e-4954-86f1-2687ff6db032"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefuroxime for Injection, USP is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: Lower Respiratory Tract Infections, including pneumonia, caused by Streptococcus pneumoniae, Haemophilus influenzae (including ampicillin-resistant strains), Klebsiella spp., Staphylococcus aureus (penicillinase- and non-penicillinase-producing strains), Streptococcus pyogenes , and Escherichia coli . Urinary Tract Infections caused by Escherichia coli and Klebsiella spp. Skin and Skin Structure Infections caused by Staphylococcus aureus (penicillinase- and non-penicillinase-producing strains), Streptococcus pyogenes , Escherichia coli, Klebsiella spp., and Enterobacter spp. Septicemia caused by Staphylococcus aureus (penicillinase- and non-penicillinase-producing strains), Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae (including ampicillin-resistant strains), and Klebsiella spp. Meningitis caused by Streptococcus pneumoniae, Haemophilus influenzae (including ampicillin-resistant strains), Neisseria meningitidis , and Staphylococcus aureus (penicillinase- and non-penicillinase-producing strains). Gonorrhea: Uncomplicated and disseminated gonococcal infections due to Neisseria gonorrhoeae (penicillinase- and non-penicillinase-producing strains) in both males and females. Bone and Joint Infections caused by Staphylococcus aureus (penicillinase- and non-penicillinase-producing strains). Clinical microbiological studies in skin and skin-structure infections frequently reveal the growth of susceptible strains of both aerobic and anaerobic organisms. Cefuroxime for Injection, USP has been used successfully in these mixed infections in which several organisms have been isolated. In certain cases of confirmed or suspected gram-positive or gram-negative sepsis or in patients with other serious infections in which the causative organism has not been identified, Cefuroxime for Injection may be used concomitantly with an aminoglycoside (see PRECAUTIONS). The recommended doses of both antibiotics may be given depending on the severity of the infection and the patient’s condition. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefuroxime for Injection, USP and other antibacterial drugs, Cefuroxime for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Prevention: The preoperative prophylactic administration of Cefuroxime for Injection, USP may prevent the growth of susceptible disease-causing bacteria and thereby may reduce the incidence of certain postoperative infections in patients undergoing surgical procedures (e.g., vaginal hysterectomy) that are classified as clean-contaminated or potentially contaminated procedures. Effective prophylactic use of antibiotics in surgery depends on the time of administration. Cefuroxime for Injection, USP should usually be given one-half to 1 hour before the operation to allow sufficient time to achieve effective antibiotic concentrations in the wound tissues during the procedure. The dose should be repeated intraoperatively if the surgical procedure is lengthy. Prophylactic administration is usually not required after the surgical procedure ends and should be stopped within 24 hours. In the majority of surgical procedures, continuing prophylactic administration of any antibiotic does not reduce the incidence of subsequent infections but will increase the possibility of adverse reactions and the development of bacterial resistance. The perioperative use of Cefuroxime for Injection, USP has also been effective during open heart surgery for surgical patients in whom infections at the operative site would present a serious risk. For these patients it is recommended that therapy with Cefuroxime for Injection, USP be continued for at least 48 hours after the surgical procedure ends. If an infection is present, specimens for culture should be obtained for the identification of the causative organism, and appropriate antimicrobial therapy should be instituted. uuid:99a1897b-3b71-4076-9e91-56eae7856b75 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3515 biolink:treats UMLS:C0851989 PMID:41385096 "[{""id"":""uuid:06008520-cdaf-4485-a978-072bac7d7513"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:20206bcd-dd6d-4ba0-8037-39626dcb67db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefuroxime for Injection, USP is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: Lower Respiratory Tract Infections, including pneumonia, caused by Streptococcus pneumoniae, Haemophilus influenzae (including ampicillin-resistant strains), Klebsiella spp., Staphylococcus aureus (penicillinase- and non-penicillinase-producing strains), Streptococcus pyogenes , and Escherichia coli . Urinary Tract Infections caused by Escherichia coli and Klebsiella spp. Skin and Skin Structure Infections caused by Staphylococcus aureus (penicillinase- and non-penicillinase-producing strains), Streptococcus pyogenes , Escherichia coli, Klebsiella spp., and Enterobacter spp. Septicemia caused by Staphylococcus aureus (penicillinase- and non-penicillinase-producing strains), Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae (including ampicillin-resistant strains), and Klebsiella spp. Meningitis caused by Streptococcus pneumoniae, Haemophilus influenzae (including ampicillin-resistant strains), Neisseria meningitidis , and Staphylococcus aureus (penicillinase- and non-penicillinase-producing strains). Gonorrhea: Uncomplicated and disseminated gonococcal infections due to Neisseria gonorrhoeae (penicillinase- and non-penicillinase-producing strains) in both males and females. Bone and Joint Infections caused by Staphylococcus aureus (penicillinase- and non-penicillinase-producing strains). Clinical microbiological studies in skin and skin-structure infections frequently reveal the growth of susceptible strains of both aerobic and anaerobic organisms. Cefuroxime for Injection, USP has been used successfully in these mixed infections in which several organisms have been isolated. In certain cases of confirmed or suspected gram-positive or gram-negative sepsis or in patients with other serious infections in which the causative organism has not been identified, Cefuroxime for Injection may be used concomitantly with an aminoglycoside (see PRECAUTIONS). The recommended doses of both antibiotics may be given depending on the severity of the infection and the patient’s condition. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefuroxime for Injection, USP and other antibacterial drugs, Cefuroxime for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Prevention: The preoperative prophylactic administration of Cefuroxime for Injection, USP may prevent the growth of susceptible disease-causing bacteria and thereby may reduce the incidence of certain postoperative infections in patients undergoing surgical procedures (e.g., vaginal hysterectomy) that are classified as clean-contaminated or potentially contaminated procedures. Effective prophylactic use of antibiotics in surgery depends on the time of administration. Cefuroxime for Injection, USP should usually be given one-half to 1 hour before the operation to allow sufficient time to achieve effective antibiotic concentrations in the wound tissues during the procedure. The dose should be repeated intraoperatively if the surgical procedure is lengthy. Prophylactic administration is usually not required after the surgical procedure ends and should be stopped within 24 hours. In the majority of surgical procedures, continuing prophylactic administration of any antibiotic does not reduce the incidence of subsequent infections but will increase the possibility of adverse reactions and the development of bacterial resistance. The perioperative use of Cefuroxime for Injection, USP has also been effective during open heart surgery for surgical patients in whom infections at the operative site would present a serious risk. For these patients it is recommended that therapy with Cefuroxime for Injection, USP be continued for at least 48 hours after the surgical procedure ends. If an infection is present, specimens for culture should be obtained for the identification of the causative organism, and appropriate antimicrobial therapy should be instituted. uuid:376cfafb-4a87-4715-b59a-bd468f211574 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3515 biolink:treats MONDO:0021839 PMID:41385096 "[{""id"":""uuid:acfecd90-cc3e-4dde-8b7d-3297152c5999"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1880861e-c910-4d88-bf79-36fc6824a0e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefuroxime for Injection, USP is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: Lower Respiratory Tract Infections, including pneumonia, caused by Streptococcus pneumoniae, Haemophilus influenzae (including ampicillin-resistant strains), Klebsiella spp., Staphylococcus aureus (penicillinase- and non-penicillinase-producing strains), Streptococcus pyogenes , and Escherichia coli . Urinary Tract Infections caused by Escherichia coli and Klebsiella spp. Skin and Skin Structure Infections caused by Staphylococcus aureus (penicillinase- and non-penicillinase-producing strains), Streptococcus pyogenes , Escherichia coli, Klebsiella spp., and Enterobacter spp. Septicemia caused by Staphylococcus aureus (penicillinase- and non-penicillinase-producing strains), Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae (including ampicillin-resistant strains), and Klebsiella spp. Meningitis caused by Streptococcus pneumoniae, Haemophilus influenzae (including ampicillin-resistant strains), Neisseria meningitidis , and Staphylococcus aureus (penicillinase- and non-penicillinase-producing strains). Gonorrhea: Uncomplicated and disseminated gonococcal infections due to Neisseria gonorrhoeae (penicillinase- and non-penicillinase-producing strains) in both males and females. Bone and Joint Infections caused by Staphylococcus aureus (penicillinase- and non-penicillinase-producing strains). Clinical microbiological studies in skin and skin-structure infections frequently reveal the growth of susceptible strains of both aerobic and anaerobic organisms. Cefuroxime for Injection, USP has been used successfully in these mixed infections in which several organisms have been isolated. In certain cases of confirmed or suspected gram-positive or gram-negative sepsis or in patients with other serious infections in which the causative organism has not been identified, Cefuroxime for Injection may be used concomitantly with an aminoglycoside (see PRECAUTIONS). The recommended doses of both antibiotics may be given depending on the severity of the infection and the patient’s condition. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefuroxime for Injection, USP and other antibacterial drugs, Cefuroxime for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Prevention: The preoperative prophylactic administration of Cefuroxime for Injection, USP may prevent the growth of susceptible disease-causing bacteria and thereby may reduce the incidence of certain postoperative infections in patients undergoing surgical procedures (e.g., vaginal hysterectomy) that are classified as clean-contaminated or potentially contaminated procedures. Effective prophylactic use of antibiotics in surgery depends on the time of administration. Cefuroxime for Injection, USP should usually be given one-half to 1 hour before the operation to allow sufficient time to achieve effective antibiotic concentrations in the wound tissues during the procedure. The dose should be repeated intraoperatively if the surgical procedure is lengthy. Prophylactic administration is usually not required after the surgical procedure ends and should be stopped within 24 hours. In the majority of surgical procedures, continuing prophylactic administration of any antibiotic does not reduce the incidence of subsequent infections but will increase the possibility of adverse reactions and the development of bacterial resistance. The perioperative use of Cefuroxime for Injection, USP has also been effective during open heart surgery for surgical patients in whom infections at the operative site would present a serious risk. For these patients it is recommended that therapy with Cefuroxime for Injection, USP be continued for at least 48 hours after the surgical procedure ends. If an infection is present, specimens for culture should be obtained for the identification of the causative organism, and appropriate antimicrobial therapy should be instituted. uuid:60054b50-84f3-4506-b9a8-88e44275ca17 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:37789 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:df0ddc69-c1bb-4cc1-a254-2ecc00949413"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2ebe3517-5599-4491-9e4f-0c7e0846619b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Atenolol and chlorthalidone tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including atenolol and chlorthalidone. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. This fixed dose combination drug is not indicated for initial therapy of hypertension. If the fixed dose combination represents the dose appropriate to the individual patient's needs, it may be more convenient than the separate components. uuid:7eb30752-ef3b-416b-9b05-5528c3b35c9b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:37789 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:b56616b5-ff34-465a-b379-4b1a1fc0f5a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8c134a63-e0a9-4019-8f71-99ed2d1f840e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Atenolol and chlorthalidone tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including atenolol and chlorthalidone. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. This fixed dose combination drug is not indicated for initial therapy of hypertension. If the fixed dose combination represents the dose appropriate to the individual patient's needs, it may be more convenient than the separate components. uuid:2283b58a-1486-4002-81ff-8e28e89e7892 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:37789 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:7ad090bd-9757-4d4c-852b-dc9f8437bc9c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7a0ffbee-433f-450e-91d8-f5d4b24760df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Atenolol and chlorthalidone tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including atenolol and chlorthalidone. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. This fixed dose combination drug is not indicated for initial therapy of hypertension. If the fixed dose combination represents the dose appropriate to the individual patient's needs, it may be more convenient than the separate components. uuid:a83e0cd8-02de-49dd-be0f-8b198a1eea8a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:37789 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:2e295e5c-c4c4-4979-a432-3b7a1bc2fb57"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:21331cfc-90b6-4628-b8c7-a22908b1c0d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Atenolol and chlorthalidone tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including atenolol and chlorthalidone. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. This fixed dose combination drug is not indicated for initial therapy of hypertension. If the fixed dose combination represents the dose appropriate to the individual patient's needs, it may be more convenient than the separate components. uuid:aabb07d5-3b97-479a-bc24-125c0d5307a9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:37789 biolink:treats HP:0001681 PMID:41385096 "[{""id"":""uuid:6bfbfd75-40b9-471c-ab34-db60da80a92b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:20e3007f-a4e6-4734-93fb-069a7b5b64e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Atenolol and chlorthalidone tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including atenolol and chlorthalidone. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. This fixed dose combination drug is not indicated for initial therapy of hypertension. If the fixed dose combination represents the dose appropriate to the individual patient's needs, it may be more convenient than the separate components. uuid:5ddc7aa0-a83d-41bd-8f15-02dd3029c0f9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:37789 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:b4e59d3f-8b52-439d-9bf8-d5c2f85b1066"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:181fab78-8f05-4577-bc12-18efa4950e99"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Atenolol and chlorthalidone tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including atenolol and chlorthalidone. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. This fixed dose combination drug is not indicated for initial therapy of hypertension. If the fixed dose combination represents the dose appropriate to the individual patient's needs, it may be more convenient than the separate components. uuid:060f6195-4335-49de-b489-83b253dd6fc6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:37789 biolink:treats MONDO:0005016 PMID:41385096 "[{""id"":""uuid:8756e5e6-fadb-4dbb-8904-8fe9e752ffc2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2f1ec543-c99d-4b9c-b043-737c6fee078c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Atenolol and chlorthalidone tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including atenolol and chlorthalidone. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. This fixed dose combination drug is not indicated for initial therapy of hypertension. If the fixed dose combination represents the dose appropriate to the individual patient's needs, it may be more convenient than the separate components. uuid:fa15759a-2733-4656-9ba0-3551209052a9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15367 biolink:treats UMLS:C0344328 PMID:41385096 "[{""id"":""uuid:5f01be39-6b5f-4a77-9d51-a8464cd087b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d9938bcb-d462-4c8b-9451-49cb34bdc4cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] (To understand fully the indication for this product, please read the entire INDICATIONS AND USAGE section of the labeling.) Tretinoin Cream, USP (Emollient) 0.05% is indicated as an adjunctive agent (see second bullet point below) for use in the mitigation (palliation) of fine wrinkles, mottled hyperpigmentation, and tactile roughness of facial skin in patients who use comprehensive skin care and sunlight avoidance programs (see bullet 3 for populations in which effectiveness has not been established ). TRETINOIN CREAM, USP (EMOLLIENT) DOES NOT ELIMINATE WRINKLES, REPAIR SUN-DAMAGED SKIN, REVERSE PHOTOAGING, or RESTORE MORE YOUTHFUL or YOUNGER SKIN . In double-blinded, vehicle-controlled clinical studies, many patients in the vehicle group achieved desired palliative effects on fine wrinkling, mottled hyperpigmentation, and tactile roughness of facial skin with the use of comprehensive skin care and sunlight avoidance programs including sunscreens, protective clothing, and non-prescription emollient creams. Tretinoin Cream, USP (Emollient) 0.05% has NOT DEMONSTRATED A MITIGATING EFFECT on significant signs of chronic sun exposure such as coarse or deep wrinkling, skin yellowing, lentigines, telangiectasia, skin laxity, keratinocytic atypia, melanocytic atypia, or dermal elastosis. Tretinoin Cream, USP (Emollient) 0.05% should be used under medical supervision as an adjunct to a comprehensive skin care and sunlight avoidance program that includes the use of effective sunscreens (minimum SPF of 15) and protective clothing when desired results on fine wrinkles, mottled hyperpigmentation, and roughness of facial skin have not been achieved with a comprehensive skin care and sunlight avoidance program alone. The effectiveness of Tretinoin Cream, USP (Emollient) 0.05% in the mitigation of fine wrinkles, mottled hyperpigmentation, and tactile roughness of facial skin has not been established in people greater than 50 years of age OR in people with moderately to heavily pigmented skin. In addition, patients with visible actinic keratoses and patients with a history of skin cancer were excluded from clinical trials of Tretinoin Cream, USP (Emollient) 0.05%. Thus the effectiveness and safety of Tretinoin Cream, USP (Emollient) 0.05% in these populations are not known at this time. Neither the safety nor the effectiveness of Tretinoin Cream, USP (Emollient) for the prevention or treatment of actinic keratoses or skin neoplasms has been established. Neither the safety nor the efficacy of using Tretinoin Cream, USP (Emollient) 0.05% daily for greater than 48 weeks has been established, and daily use beyond 48 weeks has not been systematically and histologically investigated in adequate and well-controlled trials. (see WARNINGS section.) uuid:0646b613-3916-4433-a995-89597fb59d65 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15367 biolink:treats MONDO:0019289 PMID:41385096 "[{""id"":""uuid:f8ba0a8d-30d8-4028-ae31-fb887efce69a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eb0bce26-b146-4740-901f-77f0602af7c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] (To understand fully the indication for this product, please read the entire INDICATIONS AND USAGE section of the labeling.) Tretinoin Cream, USP (Emollient) 0.05% is indicated as an adjunctive agent (see second bullet point below) for use in the mitigation (palliation) of fine wrinkles, mottled hyperpigmentation, and tactile roughness of facial skin in patients who use comprehensive skin care and sunlight avoidance programs (see bullet 3 for populations in which effectiveness has not been established ). TRETINOIN CREAM, USP (EMOLLIENT) DOES NOT ELIMINATE WRINKLES, REPAIR SUN-DAMAGED SKIN, REVERSE PHOTOAGING, or RESTORE MORE YOUTHFUL or YOUNGER SKIN . In double-blinded, vehicle-controlled clinical studies, many patients in the vehicle group achieved desired palliative effects on fine wrinkling, mottled hyperpigmentation, and tactile roughness of facial skin with the use of comprehensive skin care and sunlight avoidance programs including sunscreens, protective clothing, and non-prescription emollient creams. Tretinoin Cream, USP (Emollient) 0.05% has NOT DEMONSTRATED A MITIGATING EFFECT on significant signs of chronic sun exposure such as coarse or deep wrinkling, skin yellowing, lentigines, telangiectasia, skin laxity, keratinocytic atypia, melanocytic atypia, or dermal elastosis. Tretinoin Cream, USP (Emollient) 0.05% should be used under medical supervision as an adjunct to a comprehensive skin care and sunlight avoidance program that includes the use of effective sunscreens (minimum SPF of 15) and protective clothing when desired results on fine wrinkles, mottled hyperpigmentation, and roughness of facial skin have not been achieved with a comprehensive skin care and sunlight avoidance program alone. The effectiveness of Tretinoin Cream, USP (Emollient) 0.05% in the mitigation of fine wrinkles, mottled hyperpigmentation, and tactile roughness of facial skin has not been established in people greater than 50 years of age OR in people with moderately to heavily pigmented skin. In addition, patients with visible actinic keratoses and patients with a history of skin cancer were excluded from clinical trials of Tretinoin Cream, USP (Emollient) 0.05%. Thus the effectiveness and safety of Tretinoin Cream, USP (Emollient) 0.05% in these populations are not known at this time. Neither the safety nor the effectiveness of Tretinoin Cream, USP (Emollient) for the prevention or treatment of actinic keratoses or skin neoplasms has been established. Neither the safety nor the efficacy of using Tretinoin Cream, USP (Emollient) 0.05% daily for greater than 48 weeks has been established, and daily use beyond 48 weeks has not been systematically and histologically investigated in adequate and well-controlled trials. (see WARNINGS section.) uuid:0a0ae417-50d5-4dd7-8baa-cbd13d98663b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6367 biolink:treats HP:0007334 PMID:41385096 "[{""id"":""uuid:3a1b2347-9a2f-4a0f-a3a0-a60b7906a12e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3a9b0bee-db87-428c-b1c6-c9e132ffc7d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:3e498a50-1b4d-481a-ac1d-f27ee254dd7f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lamotrigine extended-release tablet is an antiepileptic drug (AED) indicated for: adjunctive therapy for partial onset seizures with or without secondary generalization in patients ≥13 years of age. ( 1.1 ) Limitation of use: Safety and effectiveness in patients less than 13 years of age have not been established. (1.3)|[PMDA] Drugs with a new additional indication and a new dosage for use in the monotherapy for treatment of partial seizures (including secondary generalized seizure) and tonic-clonic seizures in patients with epilepsy. uuid:8e27ddce-23dd-471a-a694-15dae70407aa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:81579 biolink:treats UMLS:C5438213 PMID:41385096 "[{""id"":""uuid:63b1ca1b-c6c4-4385-a5d8-7a4e83c7ae79"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:319314d9-1bd6-4ad9-b5a4-7a611643fb74"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PROCRIT is an erythropoiesis-stimulating agent (ESA) indicated for: Treatment of anemia due to - Chronic Kidney Disease (CKD) in patients on dialysis and not on dialysis ( 1.1 ). - Zidovudine in HIV-infected patients ( 1.2 ). - The effects of concomitant myelosuppressive chemotherapy and upon initiation, there is a minimum of two additional months of planned chemotherapy ( 1.3 ). Reduction of allogeneic RBC transfusions in patients undergoing elective, noncardiac, nonvascular surgery ( 1.4 ). Limitations of Use PROCRIT has not been shown to improve quality of life, fatigue, or patient well-being ( 1.5 ). PROCRIT is not indicated for use: In patients with cancer receiving hormonal agents, biologic products, or radiotherapy, unless also receiving concomitant myelosuppressive chemotherapy ( 1.5 ). In patients with cancer receiving myelosuppressive chemotherapy when the anticipated outcome is cure ( 1.5 ). In patients scheduled for surgery who are willing to donate autologous blood ( 1.5 ). In patients undergoing cardiac or vascular surgery ( 1.5 ). As a substitute for RBC transfusions in patients who require immediate correction of anemia ( 1.5 ). uuid:2212cc5a-48f7-465c-94ef-b2548b0a9bfc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5790 biolink:treats NCIT:C27003 PMID:41385096 "[{""id"":""uuid:a3852710-b726-4e18-ad98-02f629177287"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:37749341-44d7-48f4-bcf7-ea5134014ee1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EXALGO is indicated for the management of moderate to severe pain in opioid tolerant patients requiring continuous, around-the-clock opioid analgesia for an extended period of time. Patients considered opioid tolerant are those who are taking at least 60 mg oral morphine per day, 25 mcg transdermal fentanyl/hour, 30 mg oral oxycodone/day, 8 mg oral hydromorphone/day, 25 mg oral oxymorphone/day or an equianalgesic dose of another opioid, for a week or longer. Limitations of Use EXALGO is not for use: As an as-needed (prn) analgesic For pain that is mild or not expected to persist for an extended period of time For acute pain For postoperative pain. uuid:a19d0b9f-0321-49f0-9d79-805ab7d0375c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1155722 biolink:treats MONDO:0005271 PMID:41385096 "[{""id"":""uuid:7507db5f-ba54-4eec-919c-e17f896540e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:de47e305-7e1e-49ee-b881-561dd817b90d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For relief of coughs and upper respiratory symptoms, including nasal congestion, associated with allergy or the common cold. uuid:c3426088-34ca-40b7-9f70-9f734643e5e0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1155722 biolink:treats MONDO:0005709 PMID:41385096 "[{""id"":""uuid:d4adb1c4-0018-4b2d-a78d-5dea4a9c5f0b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:be0aace4-64a4-49c7-8d10-51f09674e0f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For relief of coughs and upper respiratory symptoms, including nasal congestion, associated with allergy or the common cold. uuid:4e4e43ea-853a-41a0-83f7-50e8260a2e04 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50673 biolink:treats MONDO:0005364 PMID:41385096 "[{""id"":""uuid:bef7f4a4-9df9-48f9-b338-c9a6395bea61"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3ae835a1-7ea2-4a4e-bfc7-ebba1fa1a1ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methimazole is indicated: In patients with Graves’ disease with hyperthyroidism or toxic multinodular goiter for whom surgery or radioactive iodine therapy is not an appropriate treatment option To ameliorate symptoms of hyperthyroidism in preparation for thyroidectomy or radioactive iodine therapy uuid:dde1210b-e1f2-4576-a531-e44d57d64308 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50673 biolink:treats MONDO:0001252 PMID:41385096 "[{""id"":""uuid:05477337-e12f-40d5-9bec-faaaba25dfe1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:482aec11-3183-4ad9-9083-228dc5bb4521"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methimazole is indicated: In patients with Graves’ disease with hyperthyroidism or toxic multinodular goiter for whom surgery or radioactive iodine therapy is not an appropriate treatment option To ameliorate symptoms of hyperthyroidism in preparation for thyroidectomy or radioactive iodine therapy uuid:df8b98a0-000e-48a9-b769-34dd8acb8dbd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31932 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:f58c074e-82c8-47b3-860f-7a95509b7e18"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:005a4361-17b5-489b-9d83-7f192b33d183"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Benicar is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Benicar. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. It may be used alone or in combination with other antihypertensive agents. uuid:f8e457bd-efb8-46a0-bca5-31344c38172f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31932 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:3b7dea43-14c4-4a29-9f9e-f2f1684324c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d4e4f011-d1c6-4917-aee0-70b44a170d45"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Benicar is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Benicar. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. It may be used alone or in combination with other antihypertensive agents. uuid:f462b5c5-000d-4e36-a8e4-bfbe91bc0006 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31932 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:b0d3123f-7627-4db9-a5d8-9161117eb749"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:21a4fb03-d05c-4916-8039-b437f8ff41a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Benicar is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Benicar. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. It may be used alone or in combination with other antihypertensive agents. uuid:0a8b8838-06a8-4610-a9a6-317fc71e9b41 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31932 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:9d234ce9-f3bb-4ec4-bd89-b8d6504df887"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4d0f9efd-3a00-4311-a67d-29f60cc34434"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Benicar is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Benicar. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. It may be used alone or in combination with other antihypertensive agents. uuid:a6664c13-f255-4d3d-8bbf-971d3c086aa3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31932 biolink:treats MONDO:0005016 PMID:41385096 "[{""id"":""uuid:cfb7a9e5-a763-4a8a-9317-ff314c6a9b6a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9937a45c-ba7d-461e-a648-022369db5ca5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Benicar is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Benicar. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. It may be used alone or in combination with other antihypertensive agents. uuid:856316c8-ecd3-4031-80f1-158f4c9bab9e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2904 biolink:treats MONDO:0021661 PMID:41385096 "[{""id"":""uuid:fa6c84dc-6f4e-4e3a-ab03-0ae70dca7f0d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3e347e4c-460f-4803-9399-0dbb0ae59179"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension Atenolol tablets, USP are indicated in the management of hypertension. They may be used alone or concomitantly with other antihypertensive agents, particularly with a thiazide-type diuretic. Angina Pectoris Due to Coronary Atherosclerosis Atenolol tablets, USP are indicated for the long-term management of patients with angina pectoris. Acute Myocardial Infarction Atenolol tablets, USP are indicated in the management of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce cardiovascular mortality. Treatment can be initiated as soon as the patient’s clinical condition allows. (See DOSAGE AND ADMINISTRATION , CONTRAINDICATIONS , and WARNINGS .) In general, there is no basis for treating patients like those who were excluded from the ISIS-1 trial (blood pressure less than 100 mmHg systolic, heart rate less than 50 bpm) or have other reasons to avoid beta-blockade. As noted above, some subgroups (e.g., elderly patients with systolic blood pressure below 120 mmHg) seemed less likely to benefit. uuid:5f3e7642-0539-4ad2-b747-64e102612f1a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3380 biolink:treats HP:0005162 PMID:41385096 "[{""id"":""uuid:95838df8-aee8-4cde-88fe-229235849e9c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b637fffe-a3a2-4331-a3d4-4bee8744347d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension: Captopril tablets, USP are indicated for the treatment of hypertension. In using captopril, consideration should be given to the risk of neutropenia/ agranulocytosis (see WARNINGS ). Captopril may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. In patients with impaired renal function, particularly those with collagen vascular disease, captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations. Captopril is effective alone and in combination with other antihypertensive agents, especially thiazide-type diuretics. The blood pressure lowering effects of captopril and thiazides are approximately additive. Heart Failure: Captopril tablets are indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis. The beneficial effect of captopril in heart failure does not require the presence of digitalis, however, most controlled clinical trial experience with captopril has been in patients receiving digitalis, as well as diuretic treatment. Left Ventricular Dysfunction After Myocardial Infarction: Captopril tablets are indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction ≤40% and to reduce the incidence of overt heart failure and subsequent hospitalizations for congestive heart failure in these patients. Diabetic Nephropathy: Captopril tablets are indicated for the treatment of diabetic nephropathy (proteinuria > 500 mg/day) in patients with type I insulin-dependent diabetes mellitus and retinopathy. Captopril tablets decreases the rate of progression of renal insufficiency and development of serious adverse clinical outcomes (death or need for renal transplantation or dialysis). In considering use of captopril tablets, it should be noted that in controlled trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients (see WARNINGS: Head and Neck Angioedema and Intestinal Angioedema ). uuid:844c6863-2a0c-4a87-9d49-e37e44a41f06 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3380 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:99593b99-9057-4bf2-8a2c-3bba61917830"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:91b863f4-bdd1-46bc-ad3a-c704b3aef763"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension: Captopril tablets, USP are indicated for the treatment of hypertension. In using captopril, consideration should be given to the risk of neutropenia/ agranulocytosis (see WARNINGS ). Captopril may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. In patients with impaired renal function, particularly those with collagen vascular disease, captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations. Captopril is effective alone and in combination with other antihypertensive agents, especially thiazide-type diuretics. The blood pressure lowering effects of captopril and thiazides are approximately additive. Heart Failure: Captopril tablets are indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis. The beneficial effect of captopril in heart failure does not require the presence of digitalis, however, most controlled clinical trial experience with captopril has been in patients receiving digitalis, as well as diuretic treatment. Left Ventricular Dysfunction After Myocardial Infarction: Captopril tablets are indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction ≤40% and to reduce the incidence of overt heart failure and subsequent hospitalizations for congestive heart failure in these patients. Diabetic Nephropathy: Captopril tablets are indicated for the treatment of diabetic nephropathy (proteinuria > 500 mg/day) in patients with type I insulin-dependent diabetes mellitus and retinopathy. Captopril tablets decreases the rate of progression of renal insufficiency and development of serious adverse clinical outcomes (death or need for renal transplantation or dialysis). In considering use of captopril tablets, it should be noted that in controlled trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients (see WARNINGS: Head and Neck Angioedema and Intestinal Angioedema ). uuid:cc45d260-fef7-411e-ba1e-74ebc53e9864 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:116962 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:1048667c-0d23-4fa4-b702-b5af60f23b91"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f5fab7b1-cc5d-4250-9416-8027328e41a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fosinopril sodium tablets are indicated for the treatment of hypertension. They may be used alone or in combination with thiazide diuretics. Fosinopril sodium tablets are indicated in the management of heart failure as adjunctive therapy when added to conventional therapy including diuretics with or without digitalis (see DOSAGE AND ADMINISTRATION ). In using fosinopril sodium, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that fosinopril sodium does not have a similar risk (see WARNINGS ). In considering use of fosinopril sodium, it should be noted that in controlled trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients (see WARNINGS , Head and Neck Angioedema and Intestinal Angioedema ). uuid:826d4566-d90e-4c3a-a954-af386e7a390a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27779 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:b4e7091d-509a-4a73-8cb9-520ada1219e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2c9a0eb8-1fbb-4a1f-bc97-c5a1385d775d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Major indications for Griseofulvin Oral Suspension are: Griseofulvin inhibits the growth of those genera of fungi that commonly cause ringworm infections of the hair, skin, and nails, such as: Note: Prior to therapy, the type of fungi responsible for the infection should be identified. The use of the drug is not justified in minor or trivial infections which will respond to topical antifungal agents alone. It is not effective in: uuid:54f7e65c-4377-40db-8aaa-f8ff5bb1bd38 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:119486 biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:c4b2f858-6722-4e59-a82b-488c474538a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:987b98bd-bed6-4076-b1cf-8990860510a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SUSTIVA ® (efavirenz) in combination with other antiretroviral agents is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. This indication is based on two clinical trials of at least one year duration that demonstrated prolonged suppression of HIV RNA [see Clinical Studies (14) ]. uuid:b768a5f9-63ba-49ba-9266-4dc3e9396070 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0005642 PMID:41385096 "[{""id"":""uuid:57a6799e-2928-4497-8ac9-667eeae7dc16"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4e38980b-4e47-41ca-a467-d72565b90905"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PRED MILD ® is indicated for the treatment of mild to moderate noninfectious allergic and inflammatory disorders of the lid, conjunctiva, cornea, and sclera (including chemical and thermal burns). uuid:3a009ab5-b5a7-4105-b502-692c1ab15ece biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0001269 PMID:41385096 "[{""id"":""uuid:77f43585-fd8a-496c-9ae0-a542d42dccbe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:84d480b2-02a9-4b3a-b5cc-b0d061fe9816"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PRED MILD ® is indicated for the treatment of mild to moderate noninfectious allergic and inflammatory disorders of the lid, conjunctiva, cornea, and sclera (including chemical and thermal burns). uuid:82b16c3e-5a5a-4bca-9807-41af9b693cce biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0003382 PMID:41385096 "[{""id"":""uuid:50f1d980-4761-4f6d-89e5-02894ada0a0b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6c8feb77-735d-403a-8a5f-6633f236bd07"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PRED MILD ® is indicated for the treatment of mild to moderate noninfectious allergic and inflammatory disorders of the lid, conjunctiva, cornea, and sclera (including chemical and thermal burns). uuid:a7b4d05e-50d9-4cf1-92fb-523a3ea3cb3e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats UMLS:C0006435 PMID:41385096 "[{""id"":""uuid:5775e2dd-d397-4fea-b9f3-4e61f467e80c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b1961d75-9785-4737-a478-92dce178757f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PRED MILD ® is indicated for the treatment of mild to moderate noninfectious allergic and inflammatory disorders of the lid, conjunctiva, cornea, and sclera (including chemical and thermal burns). uuid:7fa90572-46ed-4578-b365-d89aa26378dd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats UMLS:C0701836 PMID:41385096 "[{""id"":""uuid:a2c50512-fdab-4ac6-a2de-567ab57a46de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0c0f8e49-748c-49ab-8a2b-9888202e735b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PRED MILD ® is indicated for the treatment of mild to moderate noninfectious allergic and inflammatory disorders of the lid, conjunctiva, cornea, and sclera (including chemical and thermal burns). uuid:c5e76012-0cd1-4695-a8d3-81f661aba3f9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:11954236 biolink:treats MONDO:0012268 PMID:41385096 "[{""id"":""uuid:f3f13bf0-dc9e-4fc9-960c-b9f5bc789572"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a26628ee-6328-4189-be82-6f57fc30b2ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TRUVADA is a combination of EMTRIVA and VIREAD, both nucleoside analog HIV-1 reverse transcriptase inhibitors. TRUVADA is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older. ( 1 ) TRUVADA is indicated in combination with safer sex practices for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults at high risk. ( 1 ) uuid:21ccf87e-3776-4a63-a618-4549a406563e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77363 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:457028b7-f627-45e8-8775-61d36892bc40"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c0e019d7-329c-4b6e-8ef0-a045dc19151d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ramipril capsules USP are indicated for the treatment of hypertension. It may be used alone or in combination with thiazide diuretics ( 1.1 ). Ramipril capsules USP are indicated in stable patients who have demonstrated clinical signs of congestive heart failure post-myocardial infarction ( 1.3 ). uuid:1fae5980-44d5-4c20-b051-602d62e422e0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:132041 biolink:treats MONDO:0001134 PMID:41385096 "[{""id"":""uuid:a4eb6577-640e-40e9-bf35-ae0cc3d70eb4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:be428104-36b4-41db-a43c-b4d94ae9e185"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ACEON is indicated for the treatment of patients with essential hypertension ( 1.1 ) ACEON is indicated for treatment of patients with stable coronary artery disease to reduce the risk of cardiovascular mortality or nonfatal myocardial infarction ( 1.2 ) uuid:db225ba7-e95c-4720-90bd-6dfbace8aaa4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:132041 biolink:treats MONDO:0005010 PMID:41385096 "[{""id"":""uuid:e24d2247-1345-4add-9fe2-be38af1ad2b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:10ef39d4-1341-4fee-a471-652efc2be6db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ACEON is indicated for the treatment of patients with essential hypertension ( 1.1 ) ACEON is indicated for treatment of patients with stable coronary artery disease to reduce the risk of cardiovascular mortality or nonfatal myocardial infarction ( 1.2 ) uuid:cced11ad-2ee7-4f40-b50f-a40757da5189 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:132041 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:b52c5937-caf0-466d-a2ac-984655042f78"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e03400eb-e466-4b8a-bcda-23ba202875bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ACEON is indicated for the treatment of patients with essential hypertension ( 1.1 ) ACEON is indicated for treatment of patients with stable coronary artery disease to reduce the risk of cardiovascular mortality or nonfatal myocardial infarction ( 1.2 ) uuid:c31b6173-31d9-4c49-927b-3deb68d6f19f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1145800 biolink:treats MONDO:0004951 PMID:41385096 "[{""id"":""uuid:4da76779-864b-4334-b711-2848f0ea2bf9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8b589937-07d7-43be-9a9f-238d277a97a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] COMPLERA ® (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) is indicated for use as a complete regimen for the treatment of HIV-1 infection in antiretroviral treatment-naive adult patients with HIV-1 RNA less than or equal to 100,000 copies/mL at the start of therapy. This indication is based on safety and efficacy analyses through 96 weeks from 2 randomized, double-blind, active controlled, Phase 3 trials in treatment-naive subjects comparing rilpivirine to efavirenz [See Clinical Studies (14) ] . The following points should be considered when initiating therapy with COMPLERA: More rilpivirine-treated subjects with HIV-1 RNA greater than 100,000 copies/mL at the start of therapy experienced virologic failure (HIV-1 RNA ≥50 copies/mL) compared to rilpivirine-treated subjects with HIV-1 RNA less than or equal to 100,000 copies/mL [See Clinical Studies (14) ] . Regardless of HIV-1 RNA level at the start of therapy, more rilpivirine-treated subjects with CD4+ cell count less than 200 cells/mm 3 experienced virologic failure compared to rilpivirine-treated subjects with CD4+ cell count greater than or equal to 200 cells/mm 3 [See Clinical Studies (14) ] . The observed virologic failure rate in rilpivirine-treated subjects conferred a higher rate of overall treatment resistance and cross-resistance to the NNRTI class compared to efavirenz [See Microbiology (12.4) ] . More subjects treated with rilpivirine developed tenofovir and lamivudine/emtricitabine associated resistance compared to efavirenz [See Microbiology (12.4) ] . COMPLERA is not recommended for patients less than 18 years of age [See Use in Specific Populations (8.4) ]. uuid:58164a98-a4fc-4857-9543-d1dfd286edc1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:46878853 biolink:treats HP:0003124 PMID:41385096 "[{""id"":""uuid:5189bea4-a3ea-4d0b-ad3f-67788aa9811c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0e55ff90-ddc7-44bf-800f-3ce0a6625cd2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FIBRICOR is a peroxisome proliferator receptor alpha (PPARα) activator indicated as an adjunct to diet: to reduce triglyceride (TG) levels in adult patients with severe hypertriglyceridemia (≥ 500 mg/dL) ( 1.1 ). to reduce elevated total cholesterol (TC), low-density-lipoprotein cholesterol (LDL-C), TG and apolipoprotein (Apo) B and to increase high-density lipoprotein cholesterol (HDL-C) in adult patients with primary hypercholesterolemia or mixed dyslipidemia ( 1.2 ). Important Limitations of Use: Fenofibrate was not shown to reduce coronary heart disease morbidity and mortality in patients with type 2 diabetes mellitus ( 1.3 ). uuid:4a47a048-0ab9-49fd-a2ee-ee0a3f4ebc8d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16794 biolink:treats MONDO:0008015 PMID:41385096 "[{""id"":""uuid:a090786e-5eb5-4914-957c-00ecf99e46f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e0e1845d-f0e3-46fb-8d05-bb38233858f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Transderm Scōp is indicated in adults for prevention of nausea and vomiting associated with motion sickness and recovery from anesthesia and surgery. The patch should be applied only to skin in the postauricular area. uuid:0ad679f4-a177-43d4-be93-2e0dbcf06b55 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16794 biolink:treats HP:0002018 PMID:41385096 "[{""id"":""uuid:133156b7-5960-4fc7-a468-96f4961013e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:581bb393-232c-4eef-b2e8-f85dfb6c81d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Transderm Scōp is indicated in adults for prevention of nausea and vomiting associated with motion sickness and recovery from anesthesia and surgery. The patch should be applied only to skin in the postauricular area. uuid:a2fd69b2-e61d-4c02-a5a5-999cbfd64cb6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16794 biolink:treats HP:0002013 PMID:41385096 "[{""id"":""uuid:b441dda4-2ba3-437c-8a5d-b37ac583157e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5fa0fbf6-1943-4e44-a288-da5cab88df96"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Transderm Scōp is indicated in adults for prevention of nausea and vomiting associated with motion sickness and recovery from anesthesia and surgery. The patch should be applied only to skin in the postauricular area. uuid:38ca5fdd-a389-474a-8f23-321741bbf214 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1152398 biolink:treats MONDO:0005277 PMID:41385096 "[{""id"":""uuid:f98651de-2653-497d-93fc-7aa06ca40748"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:36692b4a-768a-459f-a8ef-18e2a1f19e2f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Indicated as therapy to abort or prevent vascular headache, e.g., migraine, migraine variants or so-called “histaminic cephalalgia”. uuid:e3f163e5-4726-4744-9e76-3f5db3e91dc3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1152398 biolink:treats MONDO:0043537 PMID:41385096 "[{""id"":""uuid:aa8b4556-611d-4185-8908-2f2e29a8a60c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9cbccf84-b5df-4dee-bfe9-cf427f4ffa27"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Indicated as therapy to abort or prevent vascular headache, e.g., migraine, migraine variants or so-called “histaminic cephalalgia”. uuid:24481c2f-fa2e-47b2-8d61-1ccd60c80df4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:R581OT55EA biolink:treats MONDO:0005393 PMID:41385096 "[{""id"":""uuid:f1b726ee-e266-4256-9d57-b9eedfa58f67"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7f26ba2b-d9e2-4d02-bc30-cbe0986390bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KRYSTEXXA® (pegloticase) is a PEGylated uric acid specific enzyme indicated for the treatment of chronic gout in adult patients refractory to conventional therapy. Gout refractory to conventional therapy occurs in patients who have failed to normalize serum uric acid and whose signs and symptoms are inadequately controlled with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these drugs are contraindicated. Important Limitations of Use: KRYSTEXXA is not recommended for the treatment of asymptomatic hyperuricemia. uuid:ffbf48cb-be01-4c2e-9e74-dfea6cbad4f8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:R581OT55EA biolink:treats HP:0002149 PMID:41385096 "[{""id"":""uuid:dc8274c9-6474-45f5-9264-21400a0ab8f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b8240dd2-26dd-405a-baab-178718ff31f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KRYSTEXXA® (pegloticase) is a PEGylated uric acid specific enzyme indicated for the treatment of chronic gout in adult patients refractory to conventional therapy. Gout refractory to conventional therapy occurs in patients who have failed to normalize serum uric acid and whose signs and symptoms are inadequately controlled with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these drugs are contraindicated. Important Limitations of Use: KRYSTEXXA is not recommended for the treatment of asymptomatic hyperuricemia. uuid:ae50adf4-ce47-4b83-b69f-5afc75778e05 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8069 biolink:treats MONDO:0005754 PMID:41385096 "[{""id"":""uuid:4bb36dbf-fa6a-4e31-8514-2de831c7f9b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3cd2ffca-ad0c-455e-9f37-a1de925c6d13"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sedative Anticonvulsant – For the treatment of generalized and partial seizures. uuid:169ad9e9-9c57-4ceb-a8ce-c2e6364720a4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8069 biolink:treats HP:0007359 PMID:41385096 "[{""id"":""uuid:45b57bba-50d4-45bc-a79a-7dc3ee57dfc2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9c48abe8-f9cd-4032-946c-a0efa30ba7c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sedative Anticonvulsant – For the treatment of generalized and partial seizures. uuid:2cd030ca-e99e-4455-bb4f-0b7efc22c7ca biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1161287 biolink:treats MONDO:0004951 PMID:41385096 "[{""id"":""uuid:e0ab8ef0-613f-447f-a391-22768dc5eb26"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eb9fbfd1-049a-4183-97ab-45c8eb9135bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ATRIPLA ® is indicated for use alone as a complete regimen or in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older. uuid:c8fefd9a-62d4-4e90-843d-e6504aa078bd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6538 biolink:treats MONDO:0005324 PMID:41385096 "[{""id"":""uuid:1e971022-9d11-43ce-bf47-a8d7616edb81"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:075a964c-a019-4097-bf7c-f0488bd40872"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] temporarily relieves these symptoms due to hay fever or other upper respiratory allergies: runny nose sneezing itchy, watery eyes itching of the nose or throat uuid:1bea9df5-48e3-4280-ad16-86c3aa1b54a4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6538 biolink:treats MONDO:0004867 PMID:41385096 "[{""id"":""uuid:d776d6dd-aa80-4784-81a5-f47172f1aa2f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fa2df5c1-6459-41b8-851b-463e2c80a7b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] temporarily relieves these symptoms due to hay fever or other upper respiratory allergies: runny nose sneezing itchy, watery eyes itching of the nose or throat uuid:bf85fcec-034a-4c43-b868-5e7f8a50cf4e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:116962 biolink:treats UMLS:C3888796 PMID:41385096 "[{""id"":""uuid:5048650b-64e8-40e3-bf39-890d73f6938b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dc183a5d-99d0-4ba5-9f4e-19071a0f7df3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fosinopril sodium tablets are indicated for the treatment of hypertension. It may be used alone or in combination with thiazide diuretics. Fosinopril sodium tablets are indicated in the management of heart failure as adjunctive therapy when added to conventional therapy including diuretics with or without digitalis (see ). DOSAGE AND ADMINISTRATION In using fosinopril sodium, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that fosinopril sodium does not have a similar risk (see ). WARNINGS In considering use of fosinopril sodium, it should be noted that in controlled trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non- blacks. In addition, ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients (see ). WARNINGS : Head and Neck Angioedema and Intestinal Angioedema uuid:035c2866-6141-4b07-acd2-299279839741 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB11601 biolink:treats MONDO:0018076 PMID:41385096 "[{""id"":""uuid:75da96c0-2a94-4f5d-a8dc-b753c0960506"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5bf88ade-41eb-4d49-9119-da51a4860d6d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TUBERSOL, Tuberculin Purified Protein Derivative (Mantoux), is indicated to aid diagnosis of tuberculosis infection (TB) in persons at increased risk of developing active disease. The Centers for Disease Control and Prevention (CDC) have published guidelines regarding populations that would benefit from tuberculin skin testing (TST). Current recommendations can be accessed at: http://www.cdc.gov/tb/publications/factsheets/testing.htm. Previous BCG vaccination is not a contraindication to tuberculin testing. The skin-test results of BCG vaccinated persons can be used to support or exclude the diagnosis of TB infection. However, an FDA-approved interferon gamma release assay is preferred over tuberculin skin test for persons 5 years of age and older who were previously vaccinated with BCG. (9) uuid:ff3e020f-eae5-46a0-807e-483ce61a40f6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3534 biolink:treats MONDO:0005114 PMID:41385096 "[{""id"":""uuid:addb7c72-7146-4e1a-aa4d-81de056a1ac4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a23eed3d-afa1-4549-a137-4b51b6af2601"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cephalexin Capsules USP are indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms: Respiratory tract infections caused by Streptococcus pneumoniae and Streptococcus pyogenes . (Penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cephalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present.) Otitis media due to Streptococcus pneumoniae , Haemophilus influenzae , Staphylococcus aureus , Streptococcus pyogenes , and Moraxella catarrhalis . Skin and skin structure infections caused by Staphylococcus aureus and/or Streptococcus pyogenes . Bone infections caused by Staphylococcus aureus and/or Proteus mirabilis . Genitourinary tract infections, including acute prostatitis, caused by Escherichia coli , Proteus mirabilis , and Klebsiella pneumoniae. Note – Culture and susceptibility tests should be initiated prior to and during therapy. Renal function studies should be performed when indicated. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cephalexin capsules and other antibacterial drugs, cephalexin capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:2d793cba-5832-4630-9e5b-f21bfd38d217 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3534 biolink:treats HP:0005376 PMID:41385096 "[{""id"":""uuid:a590b47e-9abb-42af-829e-91819edb34cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:70e74372-98f6-4a34-87a7-5830853306c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cephalexin Capsules USP are indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms: Respiratory tract infections caused by Streptococcus pneumoniae and Streptococcus pyogenes . (Penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cephalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present.) Otitis media due to Streptococcus pneumoniae , Haemophilus influenzae , Staphylococcus aureus , Streptococcus pyogenes , and Moraxella catarrhalis . Skin and skin structure infections caused by Staphylococcus aureus and/or Streptococcus pyogenes . Bone infections caused by Staphylococcus aureus and/or Proteus mirabilis . Genitourinary tract infections, including acute prostatitis, caused by Escherichia coli , Proteus mirabilis , and Klebsiella pneumoniae. Note – Culture and susceptibility tests should be initiated prior to and during therapy. Renal function studies should be performed when indicated. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cephalexin capsules and other antibacterial drugs, cephalexin capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:f83d464e-e2ae-4b56-8260-98a7c55bd827 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3534 biolink:treats MONDO:0005545 PMID:41385096 "[{""id"":""uuid:b62f165f-0e1e-4edd-9880-9fd0be63c0fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ded316d7-a4dc-4551-b70e-0294316c602a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cephalexin Capsules USP are indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms: Respiratory tract infections caused by Streptococcus pneumoniae and Streptococcus pyogenes . (Penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cephalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present.) Otitis media due to Streptococcus pneumoniae , Haemophilus influenzae , Staphylococcus aureus , Streptococcus pyogenes , and Moraxella catarrhalis . Skin and skin structure infections caused by Staphylococcus aureus and/or Streptococcus pyogenes . Bone infections caused by Staphylococcus aureus and/or Proteus mirabilis . Genitourinary tract infections, including acute prostatitis, caused by Escherichia coli , Proteus mirabilis , and Klebsiella pneumoniae. Note – Culture and susceptibility tests should be initiated prior to and during therapy. Renal function studies should be performed when indicated. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cephalexin capsules and other antibacterial drugs, cephalexin capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:a080f18b-734a-420a-aa32-c6017dd83a86 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3534 biolink:treats UMLS:C0852874 PMID:41385096 "[{""id"":""uuid:08ba24d1-c899-4144-aad3-93b889502a24"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:25201b26-fa1c-4ff2-bf5d-c7c50309aafb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cephalexin Capsules USP are indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms: Respiratory tract infections caused by Streptococcus pneumoniae and Streptococcus pyogenes . (Penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cephalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present.) Otitis media due to Streptococcus pneumoniae , Haemophilus influenzae , Staphylococcus aureus , Streptococcus pyogenes , and Moraxella catarrhalis . Skin and skin structure infections caused by Staphylococcus aureus and/or Streptococcus pyogenes . Bone infections caused by Staphylococcus aureus and/or Proteus mirabilis . Genitourinary tract infections, including acute prostatitis, caused by Escherichia coli , Proteus mirabilis , and Klebsiella pneumoniae. Note – Culture and susceptibility tests should be initiated prior to and during therapy. Renal function studies should be performed when indicated. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cephalexin capsules and other antibacterial drugs, cephalexin capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:555344e2-5cc8-4c5a-aa6e-755add81fa17 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3534 biolink:treats MONDO:0006929 PMID:41385096 "[{""id"":""uuid:0cfb9c45-103e-422d-b855-c1671b7273cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ceab67fd-124c-4657-b066-63e0e8d77d19"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cephalexin Capsules USP are indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms: Respiratory tract infections caused by Streptococcus pneumoniae and Streptococcus pyogenes . (Penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cephalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present.) Otitis media due to Streptococcus pneumoniae , Haemophilus influenzae , Staphylococcus aureus , Streptococcus pyogenes , and Moraxella catarrhalis . Skin and skin structure infections caused by Staphylococcus aureus and/or Streptococcus pyogenes . Bone infections caused by Staphylococcus aureus and/or Proteus mirabilis . Genitourinary tract infections, including acute prostatitis, caused by Escherichia coli , Proteus mirabilis , and Klebsiella pneumoniae. Note – Culture and susceptibility tests should be initiated prior to and during therapy. Renal function studies should be performed when indicated. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cephalexin capsules and other antibacterial drugs, cephalexin capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:b8360d76-f925-44e5-bc6f-21d3f5247172 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3534 biolink:treats MONDO:0020920 PMID:41385096 "[{""id"":""uuid:5556e3dc-1a27-4c99-8f3f-b1717ff9a8ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a5588d30-2155-404e-9952-40990cc91f28"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cephalexin Capsules USP are indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms: Respiratory tract infections caused by Streptococcus pneumoniae and Streptococcus pyogenes . (Penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cephalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present.) Otitis media due to Streptococcus pneumoniae , Haemophilus influenzae , Staphylococcus aureus , Streptococcus pyogenes , and Moraxella catarrhalis . Skin and skin structure infections caused by Staphylococcus aureus and/or Streptococcus pyogenes . Bone infections caused by Staphylococcus aureus and/or Proteus mirabilis . Genitourinary tract infections, including acute prostatitis, caused by Escherichia coli , Proteus mirabilis , and Klebsiella pneumoniae. Note – Culture and susceptibility tests should be initiated prior to and during therapy. Renal function studies should be performed when indicated. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cephalexin capsules and other antibacterial drugs, cephalexin capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:99249e63-9c1c-4fe2-ab95-26b6696ba24b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3534 biolink:treats MONDO:0030602 PMID:41385096 "[{""id"":""uuid:6a9f7bb5-43de-4d60-9fad-2cec0768a419"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:06c972b4-86d5-42c0-a8be-9de0b16e5162"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cephalexin Capsules USP are indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms: Respiratory tract infections caused by Streptococcus pneumoniae and Streptococcus pyogenes . (Penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cephalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present.) Otitis media due to Streptococcus pneumoniae , Haemophilus influenzae , Staphylococcus aureus , Streptococcus pyogenes , and Moraxella catarrhalis . Skin and skin structure infections caused by Staphylococcus aureus and/or Streptococcus pyogenes . Bone infections caused by Staphylococcus aureus and/or Proteus mirabilis . Genitourinary tract infections, including acute prostatitis, caused by Escherichia coli , Proteus mirabilis , and Klebsiella pneumoniae. Note – Culture and susceptibility tests should be initiated prior to and during therapy. Renal function studies should be performed when indicated. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cephalexin capsules and other antibacterial drugs, cephalexin capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:b3869580-c580-4b98-bafe-a551dbeb086e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59343 biolink:treats UMLS:C1735365 PMID:41385096 "[{""id"":""uuid:65c7f63f-43e9-4b7f-a881-ffbef08e4b09"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3b31b417-147a-409a-8045-610481f9690e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SPECTRACEF® (cefditoren pivoxil) is indicated for the treatment of mild to moderate infections in adults and adolescents (12 years of age or older) which are caused by susceptible strains of the designated microorganisms in the conditions listed below. Acute Bacterial Exacerbation of Chronic Bronchitis caused by Haemophilus influenzae (including ß-lactamase-producing strains), Haemophilus parainfluenzae (including ß-lactamase producing strains), Streptococcus pneumoniae (penicillin susceptible strains only), or Moraxella catarrhalis (including ß-lactamase-producing strains). Community-Acquired Pneumonia caused by Haemophilus influenzae (including ß-lactamase-producing strains), Haemophilus parainfluenzae (including ß-lactamase-producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), or Moraxella catarrhalis (including ß-lactamase producing strains). Pharyngitis/Tonsillitis caused by Streptococcus pyogenes . NOTE: SPECTRACEF® is effective in the eradication of Streptococcus pyogenes from the oropharynx. SPECTRACEF® has not been studied for the prevention of rheumatic fever following Streptococcus pyogenes pharyngitis/tonsillitis. Only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever. Uncomplicated Skin and Skin-Structure Infections caused by Staphylococcus aureus (including ß-lactamase-producing strains) or Streptococcus pyogenes. To reduce the development of drug-resistant bacteria and maintain the effectiveness of SPECTRACEF® and other antibacterial drugs, SPECTRACEF® should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:9cc606ac-ee30-4b2f-80ec-f6e1985f28df biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59343 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:a8b6ac91-7453-4c11-81f9-f1a717351e9b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:de5d3258-9902-4edc-ba99-55e332a2d82b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:a06492e4-5171-4ea0-b65e-6fc72d97c3d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SPECTRACEF® (cefditoren pivoxil) is indicated for the treatment of mild to moderate infections in adults and adolescents (12 years of age or older) which are caused by susceptible strains of the designated microorganisms in the conditions listed below. Acute Bacterial Exacerbation of Chronic Bronchitis caused by Haemophilus influenzae (including ß-lactamase-producing strains), Haemophilus parainfluenzae (including ß-lactamase producing strains), Streptococcus pneumoniae (penicillin susceptible strains only), or Moraxella catarrhalis (including ß-lactamase-producing strains). Community-Acquired Pneumonia caused by Haemophilus influenzae (including ß-lactamase-producing strains), Haemophilus parainfluenzae (including ß-lactamase-producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), or Moraxella catarrhalis (including ß-lactamase producing strains). Pharyngitis/Tonsillitis caused by Streptococcus pyogenes . NOTE: SPECTRACEF® is effective in the eradication of Streptococcus pyogenes from the oropharynx. SPECTRACEF® has not been studied for the prevention of rheumatic fever following Streptococcus pyogenes pharyngitis/tonsillitis. Only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever. Uncomplicated Skin and Skin-Structure Infections caused by Staphylococcus aureus (including ß-lactamase-producing strains) or Streptococcus pyogenes. To reduce the development of drug-resistant bacteria and maintain the effectiveness of SPECTRACEF® and other antibacterial drugs, SPECTRACEF® should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.|[PMDA] A drug with a new additional dosage for the treatment of pneumonia, otitis media, and sinusitis. uuid:f8237824-31b1-4244-9e7a-347d631de641 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59343 biolink:treats MONDO:0002258 PMID:41385096 "[{""id"":""uuid:7b4e79e9-eb01-40a0-96ba-8dfd6ae93bb1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a91ebbfd-b09a-4ad3-9b48-d7bbb2436a4c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SPECTRACEF® (cefditoren pivoxil) is indicated for the treatment of mild to moderate infections in adults and adolescents (12 years of age or older) which are caused by susceptible strains of the designated microorganisms in the conditions listed below. Acute Bacterial Exacerbation of Chronic Bronchitis caused by Haemophilus influenzae (including ß-lactamase-producing strains), Haemophilus parainfluenzae (including ß-lactamase producing strains), Streptococcus pneumoniae (penicillin susceptible strains only), or Moraxella catarrhalis (including ß-lactamase-producing strains). Community-Acquired Pneumonia caused by Haemophilus influenzae (including ß-lactamase-producing strains), Haemophilus parainfluenzae (including ß-lactamase-producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), or Moraxella catarrhalis (including ß-lactamase producing strains). Pharyngitis/Tonsillitis caused by Streptococcus pyogenes . NOTE: SPECTRACEF® is effective in the eradication of Streptococcus pyogenes from the oropharynx. SPECTRACEF® has not been studied for the prevention of rheumatic fever following Streptococcus pyogenes pharyngitis/tonsillitis. Only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever. Uncomplicated Skin and Skin-Structure Infections caused by Staphylococcus aureus (including ß-lactamase-producing strains) or Streptococcus pyogenes. To reduce the development of drug-resistant bacteria and maintain the effectiveness of SPECTRACEF® and other antibacterial drugs, SPECTRACEF® should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:5cfbdf52-f7ae-4fab-9205-91a8a1760459 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59343 biolink:treats MONDO:0001039 PMID:41385096 "[{""id"":""uuid:effc511f-ffcc-4669-b37c-db1495ed96a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fe1b7511-6b6b-4fcb-a25f-759081569e85"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SPECTRACEF® (cefditoren pivoxil) is indicated for the treatment of mild to moderate infections in adults and adolescents (12 years of age or older) which are caused by susceptible strains of the designated microorganisms in the conditions listed below. Acute Bacterial Exacerbation of Chronic Bronchitis caused by Haemophilus influenzae (including ß-lactamase-producing strains), Haemophilus parainfluenzae (including ß-lactamase producing strains), Streptococcus pneumoniae (penicillin susceptible strains only), or Moraxella catarrhalis (including ß-lactamase-producing strains). Community-Acquired Pneumonia caused by Haemophilus influenzae (including ß-lactamase-producing strains), Haemophilus parainfluenzae (including ß-lactamase-producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), or Moraxella catarrhalis (including ß-lactamase producing strains). Pharyngitis/Tonsillitis caused by Streptococcus pyogenes . NOTE: SPECTRACEF® is effective in the eradication of Streptococcus pyogenes from the oropharynx. SPECTRACEF® has not been studied for the prevention of rheumatic fever following Streptococcus pyogenes pharyngitis/tonsillitis. Only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever. Uncomplicated Skin and Skin-Structure Infections caused by Staphylococcus aureus (including ß-lactamase-producing strains) or Streptococcus pyogenes. To reduce the development of drug-resistant bacteria and maintain the effectiveness of SPECTRACEF® and other antibacterial drugs, SPECTRACEF® should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:eddadab2-ab71-4151-a50f-6201714b2d73 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59343 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:df9217d0-d691-4b5f-9076-fbdb64a7d8b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bbc7a96f-79b6-4a47-95f6-0dcac811ad11"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SPECTRACEF® (cefditoren pivoxil) is indicated for the treatment of mild to moderate infections in adults and adolescents (12 years of age or older) which are caused by susceptible strains of the designated microorganisms in the conditions listed below. Acute Bacterial Exacerbation of Chronic Bronchitis caused by Haemophilus influenzae (including ß-lactamase-producing strains), Haemophilus parainfluenzae (including ß-lactamase producing strains), Streptococcus pneumoniae (penicillin susceptible strains only), or Moraxella catarrhalis (including ß-lactamase-producing strains). Community-Acquired Pneumonia caused by Haemophilus influenzae (including ß-lactamase-producing strains), Haemophilus parainfluenzae (including ß-lactamase-producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), or Moraxella catarrhalis (including ß-lactamase producing strains). Pharyngitis/Tonsillitis caused by Streptococcus pyogenes . NOTE: SPECTRACEF® is effective in the eradication of Streptococcus pyogenes from the oropharynx. SPECTRACEF® has not been studied for the prevention of rheumatic fever following Streptococcus pyogenes pharyngitis/tonsillitis. Only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever. Uncomplicated Skin and Skin-Structure Infections caused by Staphylococcus aureus (including ß-lactamase-producing strains) or Streptococcus pyogenes. To reduce the development of drug-resistant bacteria and maintain the effectiveness of SPECTRACEF® and other antibacterial drugs, SPECTRACEF® should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:b74c1b4d-6a6f-4159-9ef2-a898c5b197d9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5062 biolink:treats MONDO:0004907 PMID:41385096 "[{""id"":""uuid:4a4e976c-0713-4f1e-8019-7179b7799aba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7b40f617-f343-43a0-999f-178c36516de8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PROPECIA ® is indicated for the treatment of male pattern hair loss (androgenetic alopecia) in MEN ONLY . Efficacy in bitemporal recession has not been established. PROPECIA is not indicated for use in women. uuid:a8e71d55-c0be-4895-9235-09112acaa134 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5062 biolink:treats MONDO:0005339 PMID:41385096 "[{""id"":""uuid:0626cea3-eb6d-466f-8b09-6530f7e0ebdd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2f8fbbf7-b5f2-4962-8191-aebe31b3c37b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:103e83a7-f6d8-48db-915d-d9a9ba52807c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PROPECIA ® is indicated for the treatment of male pattern hair loss (androgenetic alopecia) in MEN ONLY . Efficacy in bitemporal recession has not been established. PROPECIA is not indicated for use in women.|[PMDA] Drugs containing a new active ingredient used for delaying progression of male pattern alopecia in men. uuid:b9a6df38-4c7b-4bee-8532-3977db6da693 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:94559 biolink:treats MONDO:0044212 PMID:41385096 "[{""id"":""uuid:28198e24-a100-4166-83a4-2bb5f1ae20ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cc71cecb-18d3-4636-b392-36e7e96d86bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levocetirizine dihydrochloride tablets are a histamine H 1 -receptor antagonist indicated for: The treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria ( 1.3 ) uuid:66608fea-912d-4015-b276-8efe1da2e5c2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:122173976 biolink:treats UMLS:C0080032 PMID:41385096 "[{""id"":""uuid:ea0c2fb2-3811-4186-bc30-0a04246298d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d54eca7d-5285-4399-acf7-eb902aa8fe69"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c0dc3181-f3e6-48bc-8fe8-34bfaa5beafc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sclerosol® Intrapleural Aerosol, administered by aerosol during thoracoscopy or open thoracotomy, is indicated to prevent recurrence of malignant pleural effusions in symptomatic patients.|[PMDA] A drug with a new active ingredient indicated for the suppression of recurrence of malignant pleural effusions. uuid:0f44a8ec-7ae1-4010-a8c3-f3246beb5b64 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17347 biolink:treats HP:0000823 PMID:41385096 "[{""id"":""uuid:3a0f232e-e388-4f0a-848b-53b001b0f100"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fac7c324-cfe3-48d3-833a-2f533934b802"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MALES Androgens are indicated for replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone. a. Primary hypogonadism (congenital or acquired) - testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testes syndrome; or orchiectomy. b. Hypogonadotrophic hypogonadism (congenital or acquired) - idiopathic or gonadotropic LHRH deficiency, or pituitary - hypothalamic injury from tumors, trauma or radiation. If the above conditions occur prior to puberty, androgen replacement therapy will be needed during the adolescent years for development of secondary sex characteristics. Prolonged androgen treatment will be required to maintain sexual characteristics in these and other males who develop testosterone deficiency after puberty. c. Androgens may be used to stimulate puberty in carefully selected males with clearly delayed puberty. These patients usually have a familial pattern of delayed puberty that is not secondary to a pathological disorder; puberty is expected to occur spontaneously at a relatively late date. Brief treatment with conservative doses may occasionally be justified in these patients if they do not respond to psychological support. The potential adverse effect on bone maturation should be discussed with the patient and parents prior to androgen administration. An x-ray of the hand and wrist to determine bone age should be taken every 6 months to assess the effect of treatment on epiphyseal centers (see WARNINGS ). uuid:0ca178de-e3e1-4215-b2df-dfaeb1e05c67 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17347 biolink:treats UMLS:C1963961 PMID:41385096 "[{""id"":""uuid:ad1c6b16-8867-489b-a447-4184c91ba213"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2b7815bd-f709-470a-937a-aced38f5225c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MALES Androgens are indicated for replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone. a. Primary hypogonadism (congenital or acquired) - testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testes syndrome; or orchiectomy. b. Hypogonadotrophic hypogonadism (congenital or acquired) - idiopathic or gonadotropic LHRH deficiency, or pituitary - hypothalamic injury from tumors, trauma or radiation. If the above conditions occur prior to puberty, androgen replacement therapy will be needed during the adolescent years for development of secondary sex characteristics. Prolonged androgen treatment will be required to maintain sexual characteristics in these and other males who develop testosterone deficiency after puberty. c. Androgens may be used to stimulate puberty in carefully selected males with clearly delayed puberty. These patients usually have a familial pattern of delayed puberty that is not secondary to a pathological disorder; puberty is expected to occur spontaneously at a relatively late date. Brief treatment with conservative doses may occasionally be justified in these patients if they do not respond to psychological support. The potential adverse effect on bone maturation should be discussed with the patient and parents prior to androgen administration. An x-ray of the hand and wrist to determine bone age should be taken every 6 months to assess the effect of treatment on epiphyseal centers (see WARNINGS ). uuid:9530e729-71b7-4f14-9e92-5c923eeba8a7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64356 biolink:treats UMLS:C0740447 PMID:41385096 "[{""id"":""uuid:2294761b-e441-4c5c-ad8b-807f59f0eac7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a4d951d2-1546-47f2-9a2e-fe2d0bebc6ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LYRICA is indicated for: Management of neuropathic pain associated with diabetic peripheral neuropathy Management of postherpetic neuralgia Adjunctive therapy for adult patients with partial onset seizures Management of fibromyalgia Management of neuropathic pain associated with spinal cord injury uuid:8704239a-76c2-4119-85f7-359f3940b98d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64356 biolink:treats MONDO:0041052 PMID:41385096 "[{""id"":""uuid:65254219-7933-4d95-8ae2-233ebc202576"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:41a9521e-d43a-4bb0-ba4b-3fb515f7f7c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:3337e6d7-19fe-45e0-913e-84262bc64a35"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LYRICA is indicated for: Management of neuropathic pain associated with diabetic peripheral neuropathy Management of postherpetic neuralgia Adjunctive therapy for adult patients with partial onset seizures Management of fibromyalgia Management of neuropathic pain associated with spinal cord injury|[PMDA] Drugs with a new active ingredient indicated for the treatment of postherpetic neuralgia. uuid:9dc117bf-25a8-4175-a682-07c2d36d8c62 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64356 biolink:treats HP:0007359 PMID:41385096 "[{""id"":""uuid:d5c5faba-d68c-4a86-9f4b-69bde80469f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b37445b0-a5b3-4248-ae6d-37f2d3d8c8a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LYRICA is indicated for: Management of neuropathic pain associated with diabetic peripheral neuropathy Management of postherpetic neuralgia Adjunctive therapy for adult patients with partial onset seizures Management of fibromyalgia Management of neuropathic pain associated with spinal cord injury uuid:2de3a383-4722-464a-8cbd-a93207953068 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64356 biolink:treats MONDO:0005546 PMID:41385096 "[{""id"":""uuid:14f4a522-03fb-421b-89c1-17aad58be2c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d9411e27-20e4-45b5-ac2b-f1573f8d7769"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:24a49a2b-5223-46ba-83b9-002017ea99fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LYRICA is indicated for: Management of neuropathic pain associated with diabetic peripheral neuropathy Management of postherpetic neuralgia Adjunctive therapy for adult patients with partial onset seizures Management of fibromyalgia Management of neuropathic pain associated with spinal cord injury|[PMDA] Drugs with a new additional indication and a new dosage for the treatment of pain associated with fibromyalgia. [Priority review] uuid:1ac42dae-6a0e-4a60-a45a-d24b0f5731ed biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3996 biolink:treats HP:0001257 PMID:41385096 "[{""id"":""uuid:1c09b9fb-240e-4765-a7b9-c9cb6766841d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:49e06910-e803-4381-b044-95759f6fd2bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cyclobenzaprine hydrochloride tablets, USP are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine hydrochloride tablets, USP should be used only for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride tablets, USP have not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy. uuid:8a575eb1-b467-4d75-991b-3fb342c3ed23 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:85783 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:20e18dc6-a6b8-47dc-9581-a79b685e9b6e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:06fe51ed-26a8-42df-ae12-29daef4e2d48"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lisinopril and hydrochlorothiazide tablets USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including lisinopril and hydrochlorothiazide. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in Black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. These fixed-dose combinations are not indicated for initial therapy (see DOSAGE AND ADMINISTRATION ). In using lisinopril and hydrochlorothiazide, consideration should be given to the fact that an angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that lisinopril does not have a similar risk (see WARNINGS ). In considering the use of lisinopril and hydrochlorothiazide, it should be noted that ACE inhibitors have been associated with a higher rate of angioedema in Black than in non-Black patients (see WARNINGS, Lisinopril ). uuid:b22445eb-95eb-452a-b2fc-100054c4afe3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:85783 biolink:treats MONDO:0006652 PMID:41385096 "[{""id"":""uuid:bcdbaa87-09c2-4f2a-a7e1-d9c4c84bf8da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:580988ef-802e-4eea-889d-019f757931c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lisinopril and hydrochlorothiazide tablets USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including lisinopril and hydrochlorothiazide. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in Black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. These fixed-dose combinations are not indicated for initial therapy (see DOSAGE AND ADMINISTRATION ). In using lisinopril and hydrochlorothiazide, consideration should be given to the fact that an angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that lisinopril does not have a similar risk (see WARNINGS ). In considering the use of lisinopril and hydrochlorothiazide, it should be noted that ACE inhibitors have been associated with a higher rate of angioedema in Black than in non-Black patients (see WARNINGS, Lisinopril ). uuid:6821626b-3c6a-4beb-831d-d769f75b7079 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:85783 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:9cb24e91-3eef-42b3-9ab3-ddf21e7ca2ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1b01731a-e5ae-4165-bdcf-062071f8797e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lisinopril and hydrochlorothiazide tablets USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including lisinopril and hydrochlorothiazide. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in Black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. These fixed-dose combinations are not indicated for initial therapy (see DOSAGE AND ADMINISTRATION ). In using lisinopril and hydrochlorothiazide, consideration should be given to the fact that an angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that lisinopril does not have a similar risk (see WARNINGS ). In considering the use of lisinopril and hydrochlorothiazide, it should be noted that ACE inhibitors have been associated with a higher rate of angioedema in Black than in non-Black patients (see WARNINGS, Lisinopril ). uuid:8b7caf6c-7ba8-4545-a7b2-e2a09d5b0314 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:85783 biolink:treats MONDO:0005016 PMID:41385096 "[{""id"":""uuid:36d686fa-6b5e-46fc-88b8-c9bb228fe5ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3ee24904-580a-432b-b6ff-e437353fd86e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lisinopril and hydrochlorothiazide tablets USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including lisinopril and hydrochlorothiazide. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in Black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. These fixed-dose combinations are not indicated for initial therapy (see DOSAGE AND ADMINISTRATION ). In using lisinopril and hydrochlorothiazide, consideration should be given to the fact that an angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that lisinopril does not have a similar risk (see WARNINGS ). In considering the use of lisinopril and hydrochlorothiazide, it should be noted that ACE inhibitors have been associated with a higher rate of angioedema in Black than in non-Black patients (see WARNINGS, Lisinopril ). uuid:61334e28-19c7-4581-8a33-9684d7ee0181 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:43755 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:97a24421-cda8-469e-8c2f-a0d18e978fcf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e13cebd2-6482-4631-afd4-3c4dd003b8c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lisinopril tablets USP are indicated for the treatment of hypertension to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including lisinopril. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in Black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Lisinopril tablets USP may be administered alone or with other antihypertensive agents. uuid:5c4d48c0-8277-400d-8536-ed7bb422585d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:43755 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:9d557ae8-9088-42b3-bce0-c4f93fa38617"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a880f079-bfe6-45bf-ab3d-ef64473b43b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lisinopril tablets USP are indicated for the treatment of hypertension to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including lisinopril. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in Black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Lisinopril tablets USP may be administered alone or with other antihypertensive agents. uuid:e61d16e7-75ae-4b56-8c52-eb3348b52e86 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:43755 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:3e7b2e36-d840-466b-b526-483896eeb07c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a101d504-6a17-4c87-8819-bf188efc3301"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lisinopril tablets USP are indicated for the treatment of hypertension to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including lisinopril. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in Black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Lisinopril tablets USP may be administered alone or with other antihypertensive agents. uuid:07420380-f039-4c62-af58-1074e40e7e9e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:43755 biolink:treats MONDO:0005016 PMID:41385096 "[{""id"":""uuid:e1d33986-c0f2-46e3-bc30-a878048b734f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dac5e730-f30c-4e59-9fb1-0c8e929459c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lisinopril tablets USP are indicated for the treatment of hypertension to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including lisinopril. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in Black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Lisinopril tablets USP may be administered alone or with other antihypertensive agents. uuid:2091d82a-dc2d-4e93-af57-1ceae8faf956 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:216653 biolink:treats MONDO:0006652 PMID:41385096 "[{""id"":""uuid:723e6c0d-3fdf-44f1-ad11-80773c43391b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:24c1296a-fe7c-48a5-8d7b-b76bd8fc5968"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Valsartan and hydrochlorothiazide tablet USP is the combination tablet of valsartan, an angiotensin II receptor blocker (ARB) and hydrochlorothiazide (HCTZ), a diuretic. Valsartan and hydrochlorothiazide tablet USP is indicated for the treatment of hypertension, to lower blood pressure: In patients not adequately controlled with monotherapy ( 1 ) As initial therapy in patients likely to need multiple drugs to achieve their blood pressure goals ( 1 ) Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. uuid:b7b9ab0d-9518-48bc-838d-ec7f0fd75c3d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3515 biolink:treats MONDO:0004592 PMID:41385096 "[{""id"":""uuid:fc6dfcfb-6e54-4e45-8005-9cb84b2fb744"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a9ae6e97-c616-4d4e-bec5-82176bdbab9b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NOTE: CEFUROXIME AXETIL TABLETS AND CEFUROXIME AXETIL FOR ORAL SUSPENSION ARE NOT BIOEQUIVALENT AND ARE NOT SUBSTITUTABLE ON A MILLIGRAM-PER-MILLIGRAM BASIS (SEE CLINICAL PHARMACOLOGY). Cefuroxime axetil for oral suspension is indicated for the treatment of pediatric patients 3 months to 12 years of age with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. The safety and effectiveness of cefuroxime axetil for oral suspension in the treatment of infections other than those specifically listed below have not been established either by adequate and well-controlled trials or by pharmacokinetic data with which to determine an effective and safe dosing regimen. Pharyngitis/Tonsillitis caused by Streptococcus pyogenes. NOTE: The usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. Cefuroxime axetil for oral suspension is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefuroxime in the subsequent prevention of rheumatic fever are not available. Please also note that in all clinical trials, all isolates had to be sensitive to both penicillin and cefuroxime. There are no data from adequate and well-controlled trials to demonstrate the effectiveness of cefuroxime in the treatment of penicillin-resistant strains of Streptococcus pyogenes. Acute Bacterial Otitis Media caused by Streptococcus pneumoniae, Haemophilus influenzae (including beta-lactamase-producing strains), Moraxella catarrhalis (including beta-lactamase-producing strains), or Streptococcus pyogenes. Impetigo caused by Staphylococcus aureus (including beta-lactamase-producing strains) or Streptococcus pyogenes. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefuroxime axetil for oral suspension and other antibacterial drugs, cefuroxime axetil for oral suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:82536ff7-5e95-4350-90ee-81e54ae24f79 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3996 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:514daf42-f738-4d48-9bef-a0649e322be7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5876c4be-86bc-4ebd-b130-f1a9baed8390"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cyclobenzaprine Hydrochloride Tablets USP are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine Hydrochloride Tablets USP should be used only for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine Hydrochloride Tablets USP have not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy. uuid:2a602de9-7ed3-428c-b4a0-28d54f0307a8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3996 biolink:treats HP:0031058 PMID:41385096 "[{""id"":""uuid:6c056569-5c09-4bd9-aead-0f5d7c6adc04"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:584be1e6-8f81-489a-9cd4-8db89f4dfe37"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cyclobenzaprine Hydrochloride Tablets USP are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine Hydrochloride Tablets USP should be used only for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine Hydrochloride Tablets USP have not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy. uuid:faa52a91-2f9c-46d5-971b-bc1a5da44bc3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6741 biolink:treats MONDO:0011429 PMID:41385096 "[{""id"":""uuid:e09fc035-255a-4126-ab92-758a952cc3e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9f8dcdc4-31dc-4e58-838e-697f1a018d0e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Meloxicam is a non-steroidal anti-inflammatory drug indicated for: • Osteoarthritis (OA) (1.1) • Rheumatoid Arthritis (RA) (1.2) • Juvenile Rheumatoid Arthritis (JRA) in patients 2 years of age or older (1.3) uuid:c907e712-09f6-46bd-965b-aa1dc279d055 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2904 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:6d0160b5-57fa-4324-b498-47c8c4afd751"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1c34261a-f691-4e76-a278-aae440df77bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Atenolol tablets USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including atenolol, USP. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Atenolol tablets USP may be administered with other antihypertensive agents. uuid:c529dea1-82dd-4eac-9ce8-b87d76cd8733 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5818 biolink:treats MONDO:0005492 PMID:41385096 "[{""id"":""uuid:f90c44ab-9c92-4395-b327-b75f41ea3674"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:08b19ca4-44dc-4105-9617-b2cffa7e4533"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested. Useful in the management of pruritus due to allergic conditions such as chronic urticarial and atopic and contact dermatoses and in histamine-mediated pruritus. As a sedative when used as a premedication and following general anesthesia, hydroxyzine may potentiate meperidine and barbiturates , so their use in pre-anesthetic adjunctive therapy should be modified on an individual basis. Atropine and other belladonna alkaloids are not affected by the drug. Hydroxyzine is not known to interfere with the action of digitalis in any way and it may be used concurrently with this agent. The effectiveness of hydroxyzine as an antianxiety agent for long term use, that is more than 4 months, has not been assessed by systematic clinical studies. The physician should reassess periodically the usefulness of the drug for the individual patient. uuid:b01a354f-7208-4170-bddc-de919a97c528 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6709 biolink:treats MONDO:0004900 PMID:41385096 "[{""id"":""uuid:c121a44a-6485-4edd-aec3-dea58203ef4d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3e2aca6a-9e35-4585-9a95-d9ddaf629975"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS Based on a review of this drug by the National Academy of Sciences – National Research Council and/or other information, FDA has classified the indications as follows: Effective: Management of nausea and vomiting, and dizziness associated with motion sickness. Possibly Effective: Management of vertigo associated with diseases affecting the vestibular system. Final classification of the less than effective indications required further investigation. uuid:9072a375-0b5c-45db-b5f8-36e4460da6f3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3696 biolink:treats MONDO:0000878 PMID:41385096 "[{""id"":""uuid:14058311-c745-4993-9403-d71e8e71c47a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:621a0fe1-ef3c-4dc5-ad6c-17ff73c47d18"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VISTIDE is indicated for the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS). THE SAFETY AND EFFICACY OF VISTIDE HAVE NOT BEEN ESTABLISHED FOR TREATMENT OF OTHER CMV INFECTIONS (SUCH AS PNEUMONITIS OR GASTROENTERITIS), CONGENITAL OR NEONATAL CMV DISEASE, OR CMV DISEASE IN NON-HIV-INFECTED INDIVIDUALS. uuid:82a8fcf6-d5af-4c8b-92c7-483eb18112e9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3696 biolink:treats MONDO:0012268 PMID:41385096 "[{""id"":""uuid:39ce0a89-f145-4d41-91a6-ba17cff39fbd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f151f6dc-8109-4e86-81cf-8887439c0a51"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VISTIDE is indicated for the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS). THE SAFETY AND EFFICACY OF VISTIDE HAVE NOT BEEN ESTABLISHED FOR TREATMENT OF OTHER CMV INFECTIONS (SUCH AS PNEUMONITIS OR GASTROENTERITIS), CONGENITAL OR NEONATAL CMV DISEASE, OR CMV DISEASE IN NON-HIV-INFECTED INDIVIDUALS. uuid:4cf2d7d7-11b1-470b-89b9-a3645dff5331 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:215703 biolink:treats MONDO:0020920 PMID:41385096 "[{""id"":""uuid:b5d3c2c2-9a39-4d40-b92e-e490fe29202b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:567503f2-abc3-45d3-a36c-c40eec2a013f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] A steroid/anti-infective combination is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. Ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of corticosteroid use in certain infective conjunctivitides is accepted to obtain diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular antibacterial drug in this product is active against the following common bacterial eye pathogens: Escherichia coli, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus (viridans group ), Haemophilus influenzae, Klebsiella species , and Enterobacter species. This product does not provide adequate coverage against: Neisseria species , Pseudomonas species, and Serratia marcescens . A significant percentage of staphylococcal isolates are completely resistant to sulfa drugs. uuid:fdb562cb-8903-40a5-96a9-5781ba9c2ecc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:215703 biolink:treats MONDO:0005545 PMID:41385096 "[{""id"":""uuid:791f10b4-c226-4988-a9b4-69dd29dc572c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c75e8325-0623-4f4d-b12e-4c3bc7a633ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] A steroid/anti-infective combination is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. Ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of corticosteroid use in certain infective conjunctivitides is accepted to obtain diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular antibacterial drug in this product is active against the following common bacterial eye pathogens: Escherichia coli, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus (viridans group ), Haemophilus influenzae, Klebsiella species , and Enterobacter species. This product does not provide adequate coverage against: Neisseria species , Pseudomonas species, and Serratia marcescens . A significant percentage of staphylococcal isolates are completely resistant to sulfa drugs. uuid:09ea80b6-e1df-42eb-ae10-4863b011c483 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:215703 biolink:treats MONDO:0005114 PMID:41385096 "[{""id"":""uuid:ac3bbb7a-bf88-4513-ba71-02da40548b22"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9007d0d4-354d-4284-87cc-0e35fd587a5f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] A steroid/anti-infective combination is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. Ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of corticosteroid use in certain infective conjunctivitides is accepted to obtain diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular antibacterial drug in this product is active against the following common bacterial eye pathogens: Escherichia coli, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus (viridans group ), Haemophilus influenzae, Klebsiella species , and Enterobacter species. This product does not provide adequate coverage against: Neisseria species , Pseudomonas species, and Serratia marcescens . A significant percentage of staphylococcal isolates are completely resistant to sulfa drugs. uuid:975939a0-9721-4a6e-9104-cad620495254 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:215703 biolink:treats UMLS:C1096266 PMID:41385096 "[{""id"":""uuid:8649e789-4fe1-4419-8802-97f24a42c7bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e3fb22b6-9f50-4960-956d-82ae0954e723"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] A steroid/anti-infective combination is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. Ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of corticosteroid use in certain infective conjunctivitides is accepted to obtain diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular antibacterial drug in this product is active against the following common bacterial eye pathogens: Escherichia coli, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus (viridans group ), Haemophilus influenzae, Klebsiella species , and Enterobacter species. This product does not provide adequate coverage against: Neisseria species , Pseudomonas species, and Serratia marcescens . A significant percentage of staphylococcal isolates are completely resistant to sulfa drugs. uuid:e8f58adf-976e-4ce0-9038-06eef5f67e50 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:215703 biolink:treats UMLS:C0348321 PMID:41385096 "[{""id"":""uuid:dbbad48d-adbf-4424-8489-75220d9c824d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d4298636-19c7-41ce-a949-f645c6c0fe41"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] A steroid/anti-infective combination is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. Ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of corticosteroid use in certain infective conjunctivitides is accepted to obtain diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular antibacterial drug in this product is active against the following common bacterial eye pathogens: Escherichia coli, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus (viridans group ), Haemophilus influenzae, Klebsiella species , and Enterobacter species. This product does not provide adequate coverage against: Neisseria species , Pseudomonas species, and Serratia marcescens . A significant percentage of staphylococcal isolates are completely resistant to sulfa drugs. uuid:d2a94bec-e10d-4f69-959a-22e39c08cd89 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:215703 biolink:treats MONDO:0030603 PMID:41385096 "[{""id"":""uuid:08400a7a-6611-400e-8409-9d4ce8d0cf8c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b9a33e50-73a3-456e-8229-8a5c1d567906"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] A steroid/anti-infective combination is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. Ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of corticosteroid use in certain infective conjunctivitides is accepted to obtain diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular antibacterial drug in this product is active against the following common bacterial eye pathogens: Escherichia coli, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus (viridans group ), Haemophilus influenzae, Klebsiella species , and Enterobacter species. This product does not provide adequate coverage against: Neisseria species , Pseudomonas species, and Serratia marcescens . A significant percentage of staphylococcal isolates are completely resistant to sulfa drugs. uuid:afb534d2-1282-4b55-a4c5-829cbc692508 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1155432 biolink:treats MONDO:0005578 PMID:41385096 "[{""id"":""uuid:938e9f23-a9be-4783-8b5a-39501fc74230"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:410f08f9-6cd8-4e72-807d-2aeb9720bb9e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] USES: FOR THE TEMPORARY RELIEF OF MINOR ACHES AND PAINS OF MUSCLES AND JOINTS ASSOCIATED WITH ARTHRITIS, SIMPLE BACKACHE, STRAINS, SPRAINS, MUSCLE SORENESS AND STIFFNESS. uuid:d8fe4d65-ca2e-4e1d-bbfb-424e8551ce03 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1155432 biolink:treats UMLS:C0038045 PMID:41385096 "[{""id"":""uuid:6e2348e3-95d9-4e18-96b7-2723467e1d52"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:35a7eded-dc78-4d95-91d6-52b91cadc2fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] USES: FOR THE TEMPORARY RELIEF OF MINOR ACHES AND PAINS OF MUSCLES AND JOINTS ASSOCIATED WITH ARTHRITIS, SIMPLE BACKACHE, STRAINS, SPRAINS, MUSCLE SORENESS AND STIFFNESS. uuid:18051fc7-7a29-4e17-b3da-9a31ac3bdfd6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1155432 biolink:treats HP:0003326 PMID:41385096 "[{""id"":""uuid:db29c298-9a38-43d5-a9b4-401e8fc38095"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:224a9569-b5fd-4e67-89f2-0333452d29ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] USES: FOR THE TEMPORARY RELIEF OF MINOR ACHES AND PAINS OF MUSCLES AND JOINTS ASSOCIATED WITH ARTHRITIS, SIMPLE BACKACHE, STRAINS, SPRAINS, MUSCLE SORENESS AND STIFFNESS. uuid:a25c4b2a-05ad-4bca-a6e7-4272ebcaac34 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1155432 biolink:treats HP:0003552 PMID:41385096 "[{""id"":""uuid:2a220cd7-0ee0-4361-b70a-fa5419725b3c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7a064ca3-ef40-477f-82fd-cf5e083d7e5e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] USES: FOR THE TEMPORARY RELIEF OF MINOR ACHES AND PAINS OF MUSCLES AND JOINTS ASSOCIATED WITH ARTHRITIS, SIMPLE BACKACHE, STRAINS, SPRAINS, MUSCLE SORENESS AND STIFFNESS. uuid:2c211e70-107a-46d4-95c3-c3b8502256fd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27446 biolink:treats MONDO:0004867 PMID:41385096 "[{""id"":""uuid:fb4569d4-08ad-493d-9415-0cbb36bded2b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bea178ff-af84-4cc1-8042-b4c34dca3eca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Penicillin V Potassium Tablets, Penicillin V Potassium for Oral Solution and other antibacterial drugs, Penicillin V Potassium Tablets, and Penicillin V Potassium for Oral Solution should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antimicrobial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Penicillin V Potassium Tablets, USP and Penicillin V Potassium for Oral Solution, USP, are indicated in the treatment of mild to moderately severe infections due to penicillin G sensitive microorganisms. Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with penicillin V during the acute stage. Indicated surgical procedures should be performed. The following Infections will usually respond to adequate dosage of Penicillin V: Streptococcal infections (without bacteremia): Mild to moderate infections of the upper respiratory tract, scarlet fever and mild erysipelas. NOTE: Streptococci in groups A, C, G, H, L, and M are very sensitive to penicillin. Other groups, including group D (enterococcus) are resistant. Pneumococcal infections: Mild to moderately severe infections of the respiratory tract. Staphylococcal infections - penicillin G sensitive: Mild infections of the skin and soft tissues. NOTE: Reports indicate an increasing number of strains of staphylococci resistant to penicillin G, emphasizing the need for culture and sensitivity studies in treating suspected staphylococcal infections. Fusospirochetosis (Vincent's gingivitis and pharyngitis): Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin. NOTE: Necessary dental care should be accomplished in infections involving the gum tissue. Medical conditions in which oral penicillin therapy is indicated as prophylaxis: For the prevention of recurrence following rheumatic fever and/or chorea: Prophylaxis with oral penicillin on a continuing basis has proven effective in preventing recurrence of these conditions. Although no controlled clinical efficacy studies have been conducted, penicillin V has been suggested by the American Heart Association and the American Dental Association for use as an oral regimen for prophylaxis against bacterial endocarditis in patients with congenital heart disease or rheumatic or other acquired valvular heart disease when they undergo dental procedures and surgical procedures of the upper respiratory tract. 1 Oral penicillin should not be used in those patients at particularly high risk for endocarditis (e.g. those with prosthetic heart valves or surgically constructed systemic pulmonary shunts). Penicillin V should not be used as adjunctive prophylaxis for genitourinary instrumentation or surgery, lower-intestinal tract surgery, sigmoidoscopy, and childbirth. Since it may happen that alpha haemolytic streptococci relatively resistant to penicillin may be found when patients are receiving continuous oral penicillin for secondary prevention of rheumatic fever, prophylactic agents, other than penicillin may be chosen for these patients and prescribed in addition to their continuous rheumatic fever prophylactic regimen. NOTE: When selecting antibiotics for the prevention of bacterial endocarditis, the physician or dentist should read the full joint statement of the American Heart Association and the American Dental Association. 1 uuid:18ac48c0-1aa8-4382-b9ea-3857371a74b6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27446 biolink:treats MONDO:0024355 PMID:41385096 "[{""id"":""uuid:73535328-99b5-44d4-89c9-fe4ec9e12456"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8a9f15cb-f3ba-48c0-9c88-ab36b7ade4ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Penicillin V Potassium Tablets, Penicillin V Potassium for Oral Solution and other antibacterial drugs, Penicillin V Potassium Tablets, and Penicillin V Potassium for Oral Solution should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antimicrobial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Penicillin V Potassium Tablets, USP and Penicillin V Potassium for Oral Solution, USP, are indicated in the treatment of mild to moderately severe infections due to penicillin G sensitive microorganisms. Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with penicillin V during the acute stage. Indicated surgical procedures should be performed. The following Infections will usually respond to adequate dosage of Penicillin V: Streptococcal infections (without bacteremia): Mild to moderate infections of the upper respiratory tract, scarlet fever and mild erysipelas. NOTE: Streptococci in groups A, C, G, H, L, and M are very sensitive to penicillin. Other groups, including group D (enterococcus) are resistant. Pneumococcal infections: Mild to moderately severe infections of the respiratory tract. Staphylococcal infections - penicillin G sensitive: Mild infections of the skin and soft tissues. NOTE: Reports indicate an increasing number of strains of staphylococci resistant to penicillin G, emphasizing the need for culture and sensitivity studies in treating suspected staphylococcal infections. Fusospirochetosis (Vincent's gingivitis and pharyngitis): Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin. NOTE: Necessary dental care should be accomplished in infections involving the gum tissue. Medical conditions in which oral penicillin therapy is indicated as prophylaxis: For the prevention of recurrence following rheumatic fever and/or chorea: Prophylaxis with oral penicillin on a continuing basis has proven effective in preventing recurrence of these conditions. Although no controlled clinical efficacy studies have been conducted, penicillin V has been suggested by the American Heart Association and the American Dental Association for use as an oral regimen for prophylaxis against bacterial endocarditis in patients with congenital heart disease or rheumatic or other acquired valvular heart disease when they undergo dental procedures and surgical procedures of the upper respiratory tract. 1 Oral penicillin should not be used in those patients at particularly high risk for endocarditis (e.g. those with prosthetic heart valves or surgically constructed systemic pulmonary shunts). Penicillin V should not be used as adjunctive prophylaxis for genitourinary instrumentation or surgery, lower-intestinal tract surgery, sigmoidoscopy, and childbirth. Since it may happen that alpha haemolytic streptococci relatively resistant to penicillin may be found when patients are receiving continuous oral penicillin for secondary prevention of rheumatic fever, prophylactic agents, other than penicillin may be chosen for these patients and prescribed in addition to their continuous rheumatic fever prophylactic regimen. NOTE: When selecting antibiotics for the prevention of bacterial endocarditis, the physician or dentist should read the full joint statement of the American Heart Association and the American Dental Association. 1 uuid:3e2e588c-81ef-4eef-bd10-49668e619391 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27446 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:2530ad57-88c0-4a7d-9647-6f1f4e0dc9cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:59d9d112-9a01-4960-9ccf-e92b91dc2301"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Penicillin V Potassium Tablets, Penicillin V Potassium for Oral Solution and other antibacterial drugs, Penicillin V Potassium Tablets, and Penicillin V Potassium for Oral Solution should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antimicrobial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Penicillin V Potassium Tablets, USP and Penicillin V Potassium for Oral Solution, USP, are indicated in the treatment of mild to moderately severe infections due to penicillin G sensitive microorganisms. Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with penicillin V during the acute stage. Indicated surgical procedures should be performed. The following Infections will usually respond to adequate dosage of Penicillin V: Streptococcal infections (without bacteremia): Mild to moderate infections of the upper respiratory tract, scarlet fever and mild erysipelas. NOTE: Streptococci in groups A, C, G, H, L, and M are very sensitive to penicillin. Other groups, including group D (enterococcus) are resistant. Pneumococcal infections: Mild to moderately severe infections of the respiratory tract. Staphylococcal infections - penicillin G sensitive: Mild infections of the skin and soft tissues. NOTE: Reports indicate an increasing number of strains of staphylococci resistant to penicillin G, emphasizing the need for culture and sensitivity studies in treating suspected staphylococcal infections. Fusospirochetosis (Vincent's gingivitis and pharyngitis): Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin. NOTE: Necessary dental care should be accomplished in infections involving the gum tissue. Medical conditions in which oral penicillin therapy is indicated as prophylaxis: For the prevention of recurrence following rheumatic fever and/or chorea: Prophylaxis with oral penicillin on a continuing basis has proven effective in preventing recurrence of these conditions. Although no controlled clinical efficacy studies have been conducted, penicillin V has been suggested by the American Heart Association and the American Dental Association for use as an oral regimen for prophylaxis against bacterial endocarditis in patients with congenital heart disease or rheumatic or other acquired valvular heart disease when they undergo dental procedures and surgical procedures of the upper respiratory tract. 1 Oral penicillin should not be used in those patients at particularly high risk for endocarditis (e.g. those with prosthetic heart valves or surgically constructed systemic pulmonary shunts). Penicillin V should not be used as adjunctive prophylaxis for genitourinary instrumentation or surgery, lower-intestinal tract surgery, sigmoidoscopy, and childbirth. Since it may happen that alpha haemolytic streptococci relatively resistant to penicillin may be found when patients are receiving continuous oral penicillin for secondary prevention of rheumatic fever, prophylactic agents, other than penicillin may be chosen for these patients and prescribed in addition to their continuous rheumatic fever prophylactic regimen. NOTE: When selecting antibiotics for the prevention of bacterial endocarditis, the physician or dentist should read the full joint statement of the American Heart Association and the American Dental Association. 1 uuid:a9193d14-2f67-40d9-9054-1f051fb33617 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:151399 biolink:treats MONDO:0043579 PMID:41385096 "[{""id"":""uuid:1489aae5-0cd7-4a62-b68c-1d9311e1f964"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1a113a0c-f29e-4ed7-bb32-dcfb13ae76ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim tablets, USP and other antibacterial drugs, sulfamethoxazole and trimethoprim tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Urinary Tract Infections: For the treatment of urinary tract infections due to susceptible strains of the following organisms: Escherichia coli , Klebsiella species, Enterobacter species, Morganella morganii , Proteus mirabilis and Proteus vulgaris . It is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. Acute Otitis Media: For the treatment of acute otitis media in pediatric patients due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when in the judgment of the physician sulfamethoxazole and trimethoprim offers some advantage over the use of other antimicrobial agents. To date, there are limited data on the safety of repeated use of sulfamethoxazole and trimethoprim in pediatric patients under two years of age. Sulfamethoxazole and trimethoprim is not indicated for prophylactic or prolonged administration in otitis media at any age. Acute Exacerbations of Chronic Bronchitis in Adults: For the treatment of acute exacerbations of chronic bronchitis due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when in the judgment of the physician sulfamethoxazole and trimethoprim offers some advantage over the use of a single antimicrobial agent. Shigellosis: For the treatment of enteritis caused by susceptible strains of Shigella flexneri and Shigella sonnei when antibacterial therapy is indicated. Pneumocystis Jiroveci Pneumonia: For the treatment of documented Pneumocystis jiroveci pneumonia and for prophylaxis against Pneumocystis jiroveci pneumonia in individuals who are immunosuppressed and considered to be at an increased risk of developing Pneumocystis jiroveci pneumonia. Traveler’s Diarrhea in Adults: For the treatment of traveler’s diarrhea due to susceptible strains of enterotoxigenic E. coli . uuid:bf919299-0525-4705-aae4-b7bcf5504275 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63619 biolink:treats HP:0001692 PMID:41385096 "[{""id"":""uuid:aba66f1f-02bf-44cf-9ffc-1355f0862291"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:274ccfb4-e46b-4007-bb3b-dbfeeb17eac2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In patients without structural heart disease, propafenone is indicated to prolong the time to recurrence of – paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms. – paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms. As with other agents, some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. Concomitant treatment with drugs that increase the functional AV refractory period is recommended. The use of propafenone HCl in patients with chronic atrial fibrillation has not been evaluated. Propafenone HCl should not be used to control ventricular rate during atrial fibrillation. Propafenone HCl is also indicated for the treatment of – documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening. Because of the proarrhythmic effects of propafenone HCl, its use with lesser ventricular arrhythmias is not recommended, even if patients are symptomatic, and any use of the drug should be reserved for patients in whom, in the opinion of the physician, the potential benefits outweigh the risks. Initiation of propafenone HCl treatment, as with other antiarrhythmics used to treat life-threatening ventricular arrhythmias, should be carried out in the hospital. Propafenone HCl, like other antiarrhythmic drugs, has not been shown to enhance survival in patients with ventricular or atrial arrhythmias. uuid:9ecb3389-0417-4f0e-8df8-89d77e9248b7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:85783 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:35682dd2-227b-40f4-bb87-9a67e7b05972"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fcd95ad1-fdb4-4759-ad45-cbd4e4440803"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lisinopril and hydrochlorothiazide tablets, USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including lisinopril and hydrochlorothiazide. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (eg, on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. These fixed-dose combinations are not indicated for initial therapy (see DOSAGE AND ADMINISTRATION ). In using lisinopril and hydrochlorothiazide tablets, USP, consideration should be given to the fact that an angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that lisinopril does not have a similar risk (See WARNINGS ). In considering the use of lisinopril and hydrochlorothiazide tablets, USP, it should be noted that ACE inhibitors have been associated with a higher rate of angioedema in black than in nonblack patients (see WARNINGS, Lisinopril ). uuid:7a5584ba-3c4e-4778-97b6-0ad1d254f497 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:85783 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:8c7550c0-a82b-4aa7-95d1-1376544a9a53"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:befd374b-c880-4d10-946b-b8094a724c8c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lisinopril and hydrochlorothiazide tablets, USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including lisinopril and hydrochlorothiazide. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (eg, on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. These fixed-dose combinations are not indicated for initial therapy (see DOSAGE AND ADMINISTRATION ). In using lisinopril and hydrochlorothiazide tablets, USP, consideration should be given to the fact that an angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that lisinopril does not have a similar risk (See WARNINGS ). In considering the use of lisinopril and hydrochlorothiazide tablets, USP, it should be noted that ACE inhibitors have been associated with a higher rate of angioedema in black than in nonblack patients (see WARNINGS, Lisinopril ). uuid:6cdee6f5-eacc-48a4-b682-a4c3cb4b57fb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:85783 biolink:treats HP:0001681 PMID:41385096 "[{""id"":""uuid:3978f90c-6e69-4008-9b35-a788fbfa3289"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0227db1f-e2db-42ef-8309-1124c12e262c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lisinopril and hydrochlorothiazide tablets, USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including lisinopril and hydrochlorothiazide. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (eg, on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. These fixed-dose combinations are not indicated for initial therapy (see DOSAGE AND ADMINISTRATION ). In using lisinopril and hydrochlorothiazide tablets, USP, consideration should be given to the fact that an angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that lisinopril does not have a similar risk (See WARNINGS ). In considering the use of lisinopril and hydrochlorothiazide tablets, USP, it should be noted that ACE inhibitors have been associated with a higher rate of angioedema in black than in nonblack patients (see WARNINGS, Lisinopril ). uuid:66757866-cdae-4c3a-84c8-0454667f64f6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:85783 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:6b381d57-2e6b-4497-9b9a-bed8cdb39434"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5d874009-ae22-4fb3-bb30-96086d24e9dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lisinopril and hydrochlorothiazide tablets, USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including lisinopril and hydrochlorothiazide. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (eg, on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. These fixed-dose combinations are not indicated for initial therapy (see DOSAGE AND ADMINISTRATION ). In using lisinopril and hydrochlorothiazide tablets, USP, consideration should be given to the fact that an angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that lisinopril does not have a similar risk (See WARNINGS ). In considering the use of lisinopril and hydrochlorothiazide tablets, USP, it should be noted that ACE inhibitors have been associated with a higher rate of angioedema in black than in nonblack patients (see WARNINGS, Lisinopril ). uuid:dddee218-0a2b-4d60-9e83-e6c6c85e179b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22652 biolink:treats MONDO:0005300 PMID:41385096 "[{""id"":""uuid:0b08674c-76e4-42ff-a22f-41b4e66b77aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:908d3f87-c2cd-4098-a632-42804a34fa58"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In the wasting syndrome in chronic renal failure; uremia; impaired metabolic functions of the kidney and to maintain levels when dietary intake of vitamins is inadequate or excretion or loss in excessive. Also, highly effective as a stress vitamin. uuid:4122e209-f071-4974-bd75-cf524e1c4efb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22652 biolink:treats MONDO:0007008 PMID:41385096 "[{""id"":""uuid:00d76db2-9c70-46a9-bd31-b57fd5f0c4e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:43231d41-218f-4076-b848-ea11960d8dba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In the wasting syndrome in chronic renal failure; uremia; impaired metabolic functions of the kidney and to maintain levels when dietary intake of vitamins is inadequate or excretion or loss in excessive. Also, highly effective as a stress vitamin. uuid:164fa72c-dfdf-4023-a50d-f3d2474184d2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3213 biolink:treats HP:0000969 PMID:41385096 "[{""id"":""uuid:1dda79a6-074b-49dd-941f-a61631b8cc12"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:92eed9df-9729-4ceb-8311-f686c0befd94"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bumetanide tablets are indicated for the treatment of edema associated with congestive heart failure, hepatic and renal disease, including the nephrotic syndrome. Almost equal diuretic response occurs after oral and parenteral administration of bumetanide. Therefore, if impaired gastrointestinal absorption is suspected or oral administration is not practical, bumetanide should be given by the intramuscular or intravenous route. Successful treatment with bumetanide following instances of allergic reactions to furosemide suggests a lack of cross-sensitivity. uuid:77b4490b-a662-4296-bd28-084b6c64925a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3044 biolink:treats NCIT:C120380 PMID:41385096 "[{""id"":""uuid:e1d8b912-c047-4e5e-ab7d-99e3dcdf44a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ec0527c4-820a-4b52-b4a8-f41ae76c1068"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Benzphetamine Hydrochloride Tablets are indicated in the management of exogenous obesity as a short term (a few weeks) adjunct in a regimen of weight reduction based on caloric restriction in patients with an initial body mass index (BMI) of 30 kg/m2 or higher who have not responded to appropriate weight reducing regimen (diet and/or exercise) alone. Below is a chart of Body Mass Index (BMI) based on various heights and weights. BMI is calculated by taking the patient's weight, in kilograms (kg), divided by the patient's height, in meters (m), squared. Metric conversions are as follows: pounds ÷2.2 = kg; inches × 0.0254 = meters. The limited usefulness of agents of this class (See CLINICAL PHARMACOLOGY ) should be weighed against possible risks inherent in their use such as those described below. BODY MASS INDEX (BMI), kg/m 2 Weight (pounds) Height (feet, inches) 5'0"" 5'3"" 5'6"" 5'9"" 6'0"" 6'3"" 140 27 25 23 21 19 18 150 29 27 24 22 20 19 160 31 28 26 24 22 20 170 33 30 28 25 23 21 180 35 32 29 27 25 23 190 37 34 31 28 26 24 200 39 36 32 30 27 25 210 41 37 34 31 29 26 220 43 39 36 33 30 28 230 45 41 37 34 31 29 240 47 43 39 36 33 30 250 49 44 40 37 34 31 Benzphetamine Hydrochloride Tablets are indicated for use as monotherapy only." uuid:aaf1777c-3746-41f8-8c85-ee7231656f21 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5296 biolink:treats MONDO:0007750 PMID:41385096 "[{""id"":""uuid:6562a6c7-4534-4001-b216-b2583ef88ccd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e04a2044-85e8-4a88-a9dc-63ce0f082526"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gemfibrozil tablets, USP are indicated as adjunctive therapy to diet for: Treatment of adult patients with very high elevations of serum triglyceride levels (Types IV and V hyperlipidemia) who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Patients who present such risk typically have serum triglycerides over 2000 mg/dL and have elevations of VLDL-cholesterol as well as fasting chylomicrons (Type V hyperlipidemia). Subjects who consistently have total serum or plasma triglycerides below 1000 mg/dL are unlikely to present a risk of pancreatitis. Gemfibrozil therapy may be considered for those subjects with triglyceride elevations between 1000 and 2000 mg/dL who have a history of pancreatitis or of recurrent abdominal pain typical of pancreatitis. It is recognized that some Type IV patients with triglycerides under 1000 mg/dL may, through dietary or alcoholic indiscretion, convert to a Type V pattern with massive triglyceride elevations accompanying fasting chylomicronemia, but the influence of gemfibrozil therapy on the risk of pancreatitis in such situations has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of very low density lipoprotein (VLDL). Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV, and V hyperlipoproteinemia. Reducing the risk of developing coronary heart disease only in Type IIb patients without history of or symptoms of existing coronary heart disease who have had an inadequate response to weight loss, dietary therapy, exercise, and other pharmacologic agents (such as bile acid sequestrants and nicotinic acid, known to reduce LDL- and raise HDL-cholesterol) and who have the following triad of lipid abnormalities: low HDL-cholesterol levels in addition to elevated LDL-cholesterol and elevated triglycerides (see WARNINGS , PRECAUTIONS , and CLINICAL PHARMACOLOGY ). The National Cholesterol Education Program has defined a serum HDL-cholesterol value that is consistently below 35 mg/dL as constituting an independent risk factor for coronary heart disease. Patients with significantly elevated triglycerides should be closely observed when treated with gemfibrozil. In some patients with high triglyceride levels, treatment with gemfibrozil is associated with a significant increase in LDL-cholesterol. BECAUSE OF POTENTIAL TOXICITY SUCH AS MALIGNANCY, GALLBLADDER DISEASE, ABDOMINAL PAIN LEADING TO APPENDECTOMY AND OTHER ABDOMINAL SURGERIES, AN INCREASED INCIDENCE IN NON-CORONARY MORTALITY, AND THE 44% RELATIVE INCREASE DURING THE TRIAL PERIOD IN AGE-ADJUSTED ALL-CAUSE MORTALITY SEEN WITH THE CHEMICALLY AND PHARMACOLOGICALLY RELATED DRUG, CLOFIBRATE, THE POTENTIAL BENEFIT OF GEMFIBROZIL IN TREATING TYPE IIA PATIENTS WITH ELEVATIONS OF LDL-CHOLESTEROL ONLY IS NOT LIKELY TO OUTWEIGH THE RISKS. GEMFIBROZIL IS ALSO NOT INDICATED FOR THE TREATMENT OF PATIENTS WITH LOW HDL-CHOLESTEROL AS THEIR ONLY LIPID ABNORMALITY. In a subgroup analysis of patients in the Helsinki Heart Study with above-median HDL-cholesterol values at baseline (greater than 46.4 mg/dL), the incidence of serious coronary events was similar for gemfibrozil and placebo subgroups (see Table I). The initial treatment for dyslipidemia is dietary therapy specific for the type of lipoprotein abnormality. Excess body weight and excess alcohol intake may be important factors in hypertriglyceridemia and should be managed prior to any drug therapy. Physical exercise can be an important ancillary measure, and has been associated with rises in HDL-cholesterol. Diseases contributory to hyperlipidemia such as hypothyroidism or diabetes mellitus should be looked for and adequately treated. Estrogen therapy is sometimes associated with massive rises in plasma triglycerides, especially in subjects with familial hypertriglyceridemia. In such cases, discontinuation of estrogen therapy may obviate the need for specific drug therapy of hypertriglyceridemia. The use of drugs should be considered only when reasonable attempts have been made to obtain satisfactory results with nondrug methods. If the decision is made to use drugs, the patient should be instructed that this does not reduce the importance of adhering to diet. uuid:8b4ffb95-c68f-4fc9-b5cd-8930f513d309 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63618 biolink:treats UMLS:C0342882 PMID:41385096 "[{""id"":""uuid:c3c2d09f-22be-423d-a66e-e6130949002b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:20454c76-4912-40a4-b2b8-45a294bf49cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pravastatin sodium tablet is an HMG-CoA reductase inhibitor (statin) indicated as an adjunctive therapy to diet to: Reduce the risk of MI, revascularization, and cardiovascular mortality in hypercholesterolemic patients without clinically evident CHD. ( 1.1 ) Reduce elevated Total-C, LDL-C, ApoB, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia and mixed dyslipidemia. ( 1.2 ) Reduce elevated serum TG levels in patients with hypertriglyceridemia. ( 1.2 ) Treat patients with primary dysbetalipoproteinemia who are not responding to diet. ( 1.2 ) Treat children and adolescent patients ages 8 years and older with heterozygous familial hypercholesterolemia after failing an adequate trial of diet therapy. ( 1.2 ) Limitations of use: Pravastatin sodium tablets have not been studied in Fredrickson Types I and V dyslipidemias. ( 1.3 ) uuid:928644c8-9b19-4aea-9c4e-34b5044bb883 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7660 biolink:treats UMLS:C0343886 PMID:41385096 "[{""id"":""uuid:6b63ef25-6c77-4b59-abc6-1907969f96f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0b9a1145-32d6-4291-a90e-b38ba298bf33"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nystatin tablets are intended for the treatment of non-esophageal mucus membrane gastrointestinal candidiasis. uuid:62b0fc9e-118d-42b6-8b4b-b366122d5399 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:43755 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:5bbe36f5-b554-4a69-a6c3-1ae875908972"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0d73e754-a4ba-405b-bd9e-f8c5865d7eac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lisinopril tablets USP are indicated for the treatment of hypertension to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including lisinopril. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g, on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Lisinopril tablets USP may be administered alone or with other antihypertensive agents. uuid:c45bc418-b09f-412d-a8b8-096f3500026c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:43755 biolink:treats HP:0001681 PMID:41385096 "[{""id"":""uuid:742880d8-2383-43cb-a314-c16d56189b73"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:daaaf327-8666-4f56-8d59-5ec85e73defc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lisinopril tablets USP are indicated for the treatment of hypertension to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including lisinopril. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g, on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Lisinopril tablets USP may be administered alone or with other antihypertensive agents. uuid:358a12d1-e2a3-4083-9ea2-c815a9d831f3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8364 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:e23374fe-82d6-41d2-989b-6dcfec66e474"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:81e0c584-5a68-49f8-9732-a5992349864e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prazosin hydrochloride capsules are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Prazosin hydrochloride capsules can be used alone or in combination with other antihypertensive drugs such as diuretics or beta-adrenergic blocking agents. uuid:2c9ae9d4-3962-4c01-a886-ea5ac997d8ba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8364 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:47e306c5-68df-41c3-8214-646ae821b538"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ef95582e-16a0-4e87-8ef4-f786ebc65a31"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prazosin hydrochloride capsules are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Prazosin hydrochloride capsules can be used alone or in combination with other antihypertensive drugs such as diuretics or beta-adrenergic blocking agents. uuid:de481947-da86-435d-9bab-e353f339bfb0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8364 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:d6a41206-11b8-490a-b3b7-92caddadf0b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ac6d3a8a-daf0-459b-b10b-cad82ad937e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prazosin hydrochloride capsules are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Prazosin hydrochloride capsules can be used alone or in combination with other antihypertensive drugs such as diuretics or beta-adrenergic blocking agents. uuid:e756e799-2513-4a62-8dec-9d2234793639 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8364 biolink:treats MONDO:0005016 PMID:41385096 "[{""id"":""uuid:3218a5da-9e61-4d75-ab9e-499c4a51ef8a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1572defe-25ef-4e39-8444-eea5fd7455fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prazosin hydrochloride capsules are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Prazosin hydrochloride capsules can be used alone or in combination with other antihypertensive drugs such as diuretics or beta-adrenergic blocking agents. uuid:f48f22bd-af1b-4739-8b5f-2b927052f7b7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8364 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:ce629ac0-e9e7-4881-8049-4d552ea52d05"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b31352ef-7b05-4fcc-a048-cb8989ae3af7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prazosin hydrochloride capsules are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Prazosin hydrochloride capsules can be used alone or in combination with other antihypertensive drugs such as diuretics or beta-adrenergic blocking agents. uuid:1fc80ed4-31e8-4063-ab6a-7134ca01bfe4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8364 biolink:treats HP:0001681 PMID:41385096 "[{""id"":""uuid:9bbec5d0-db25-49f7-b331-4c0fb23d6ed7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7e50a2f6-9801-4208-aa71-a91787f53e20"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prazosin hydrochloride capsules are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Prazosin hydrochloride capsules can be used alone or in combination with other antihypertensive drugs such as diuretics or beta-adrenergic blocking agents. uuid:d84c5eeb-8cea-4a3b-b90b-94853b263713 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8364 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:ad5b278b-9754-451c-bb6c-529c05250dc0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9abda8ba-84a9-4ba1-8197-fd5d85baa0ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prazosin hydrochloride capsules are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Prazosin hydrochloride capsules can be used alone or in combination with other antihypertensive drugs such as diuretics or beta-adrenergic blocking agents. uuid:69f9d417-7c7b-42c3-9d9b-a9f83318a3c6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0005136 PMID:41385096 "[{""id"":""uuid:b241244a-f7bd-4e73-8527-796acb637a73"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:60c2d76f-8492-4ded-8916-45d326f60d8e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate tablets and other antibacterial drugs, doxycycline hyclate tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: • Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. • Respiratory tract infections caused by Mycoplasma pneumoniae. • Lymphogranuloma venereum caused by Chlamydia trachomatis . • Psittacosis (ornithosis) caused by Chlamydophila psittaci . • Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. • Inclusion conjunctivitis caused by Chlamydia trachomatis . • Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . • Nongonococcal urethritis caused by Ureaplasma urealyticum . • Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: • Chancroid caused by Haemophilus ducreyi . • Plague due to Yersinia pestis . • Tularemia due to Francisella tularensis . • Cholera caused by Vibrio cholerae . • Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus ). • Brucellosis due to Brucella species (in conjunction with streptomycin). • Bartonellosis due to Bartonella bacilliformis . • Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative bacteria, when bacteriologic testing indicates appropriate susceptibility to the drug: • Escherichia coli . • Enterobacter aerogenes (formerly Aerobacter aerogenes ). • Shigella species. • Acinetobacter species. • Respiratory tract infections caused by Haemophilus influenzae . • Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: • Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus pneumoniae ). • Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: • Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . • Syphilis caused by Treponema pallidum . • Yaws caused by Treponema pertenue . • Listeriosis due to Listeria monocytogenes . • Vincent’s infection caused by Fusobacterium fusiforme . • Actinomycosis caused by Actinomyces israelii . • Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. Prophylaxis: Doxycycline is indicated for the prophylaxis of malaria due to Plasmodium falciparum in short-term travelers (<4 months) to areas with chloroquine and/or pyrimethamine-sulfadoxine resistant strains. (See DOSAGE AND ADMINISTRATION section and Information for Patients subsection of the PRECAUTIONS section.) uuid:b4040a88-7a33-4f53-95f5-a19810a3a085 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77363 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:5b3ca536-307e-435c-9296-934c8dc4124d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:913f890a-18cb-415e-a6f1-fc918a2aad80"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ramipril capsules, USP is an angiotensin converting enzyme (ACE) inhibitor indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. It may be used alone or in combination with thiazide diuretics (1.1) . Ramipril capsules, USP are indicated in stable patients who have demonstrated clinical signs of congestive heart failure post-myocardial infarction (1.3) . uuid:440556b6-4911-4d09-9b92-b305fff0025f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77363 biolink:treats MONDO:0006652 PMID:41385096 "[{""id"":""uuid:67ffab81-7bb5-4d89-93d9-4320b21d18a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c307c6b6-8099-49dd-9903-9d2bf2ead49b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ramipril capsules, USP is an angiotensin converting enzyme (ACE) inhibitor indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. It may be used alone or in combination with thiazide diuretics (1.1) . Ramipril capsules, USP are indicated in stable patients who have demonstrated clinical signs of congestive heart failure post-myocardial infarction (1.3) . uuid:4f8e051d-6cfc-4a8d-b2b4-3dc600c1ecf3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9334 biolink:treats MONDO:0005101 PMID:41385096 "[{""id"":""uuid:9cf4aa52-e166-4a5c-be6f-fef24824992e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:71658077-e89f-4671-93af-98c9f35948d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sulfasalazine tablets, USP are indicated: in the treatment of mild to moderate ulcerative colitis, and as adjunctive therapy in severe ulcerative colitis; and for the prolongation of the remission period between acute attacks of ulcerative colitis. uuid:3a5e41f4-d28d-454d-b37b-ffd0211e6d7b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats HP:0000989 PMID:41385096 "[{""id"":""uuid:11301f7e-5a73-47d2-8edb-74f550308afa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7c60babd-a531-4d37-bbf4-83fa105a004a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Anesthetic for relief of pruritus, pruritic eczemas, abrasions, minor burns, insect bites, pain, soreness and discomfort due to pruritus ani, pruritus vulvae,hemorrhoids, anal fissures, and similar conditions of the skin and mucous membranes. uuid:ce0b3ace-d1ad-4b26-ae02-b1ed9c619b3a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0002406 PMID:41385096 "[{""id"":""uuid:4582ffde-93d4-484f-a2e2-7a02568a07ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:29b88322-d8e7-4146-aa11-4e5c9c24d490"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Anesthetic for relief of pruritus, pruritic eczemas, abrasions, minor burns, insect bites, pain, soreness and discomfort due to pruritus ani, pruritus vulvae,hemorrhoids, anal fissures, and similar conditions of the skin and mucous membranes. uuid:e6c37e8d-6590-4153-b701-174c2bdb10e8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats NCIT:C50748 PMID:41385096 "[{""id"":""uuid:e17ee15a-f0b0-4d6d-95f2-bf53945094cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a1845964-b267-4f89-8dde-e7d04d9ccba0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Anesthetic for relief of pruritus, pruritic eczemas, abrasions, minor burns, insect bites, pain, soreness and discomfort due to pruritus ani, pruritus vulvae,hemorrhoids, anal fissures, and similar conditions of the skin and mucous membranes. uuid:1580aaea-3292-4af4-a49c-ce144873eb67 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0001918 PMID:41385096 "[{""id"":""uuid:7ad1188c-a3f4-41f9-9806-9efad0d6c971"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:22b19afd-c399-4ad2-b0af-dde866aea87f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Anesthetic for relief of pruritus, pruritic eczemas, abrasions, minor burns, insect bites, pain, soreness and discomfort due to pruritus ani, pruritus vulvae,hemorrhoids, anal fissures, and similar conditions of the skin and mucous membranes. uuid:17ff3202-ee4e-4624-a056-081014e5bc71 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats HP:0032004 PMID:41385096 "[{""id"":""uuid:abb7dd6e-a7fe-4b77-8a48-2dcf01b6158a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:af087443-19a1-440e-b3b7-175b8b2ba988"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Anesthetic for relief of pruritus, pruritic eczemas, abrasions, minor burns, insect bites, pain, soreness and discomfort due to pruritus ani, pruritus vulvae,hemorrhoids, anal fissures, and similar conditions of the skin and mucous membranes. uuid:efb9a690-c242-4c80-90bd-3e8bce97a1a1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0004872 PMID:41385096 "[{""id"":""uuid:9bccbb10-ecd2-487d-9562-dc283ef2db5d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4f54c2b6-a047-41c0-ade5-b22e71df15c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Anesthetic for relief of pruritus, pruritic eczemas, abrasions, minor burns, insect bites, pain, soreness and discomfort due to pruritus ani, pruritus vulvae,hemorrhoids, anal fissures, and similar conditions of the skin and mucous membranes. uuid:63cafd0d-7a98-4b48-9b33-314042bfcc7f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats HP:0012390 PMID:41385096 "[{""id"":""uuid:8dec4969-58b6-4b81-973f-aa1029e0f1e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a44577fd-61d0-419e-9e34-6d4e296bef5c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Anesthetic for relief of pruritus, pruritic eczemas, abrasions, minor burns, insect bites, pain, soreness and discomfort due to pruritus ani, pruritus vulvae,hemorrhoids, anal fissures, and similar conditions of the skin and mucous membranes. uuid:ecda8c86-1742-449f-8c87-2641618aea06 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28918 biolink:treats MONDO:0001358 PMID:41385096 "[{""id"":""uuid:59b2d032-8b82-4d1f-bb5e-c9e06781ebbf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8204c1fc-91ed-40a5-8375-4742c263282e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In general, the most common uses of epinephrine are to relieve respiratory distress due to bronchospasm, to provide rapid relief of hypersensitivity reactions to drugs and other allergens, and to prolong the action of infiltration anesthetics. Its cardiac effects may be of use in restoring cardiac rhythm in cardiac arrest due to various causes, but it is not used in cardiac failure or in hemorrhagic, traumatic, or cardiogenic shock. Epinephrine is used as a hemostatic agent. It is also used in treating mucosal congestion of hay fever, rhinitis and acute sinusitis; to relieve bronchial asthmatic paroxysms; in syncope due to complete heart block or carotid sinus hypersensitivity; for symptomatic relief of serum sickness, urticaria, angioneurotic edema; for resuscitation in cardiac arrest following anesthetic accidents; in simple (open angle) glaucoma; for relaxation of uterine musculature and to inhibit uterine contractions. Epinephrine injection can be utilized to prolong the action of local anesthetics (see CONTRAINDICATIONS). uuid:0c3bf552-80fd-469a-bbae-0cbf314f5e58 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28918 biolink:treats MONDO:0000605 PMID:41385096 "[{""id"":""uuid:a4bd6aec-2028-43cd-835b-354c4f8a1c77"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cb6ec86a-268b-4b34-b101-7c34927e8d2d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In general, the most common uses of epinephrine are to relieve respiratory distress due to bronchospasm, to provide rapid relief of hypersensitivity reactions to drugs and other allergens, and to prolong the action of infiltration anesthetics. Its cardiac effects may be of use in restoring cardiac rhythm in cardiac arrest due to various causes, but it is not used in cardiac failure or in hemorrhagic, traumatic, or cardiogenic shock. Epinephrine is used as a hemostatic agent. It is also used in treating mucosal congestion of hay fever, rhinitis and acute sinusitis; to relieve bronchial asthmatic paroxysms; in syncope due to complete heart block or carotid sinus hypersensitivity; for symptomatic relief of serum sickness, urticaria, angioneurotic edema; for resuscitation in cardiac arrest following anesthetic accidents; in simple (open angle) glaucoma; for relaxation of uterine musculature and to inhibit uterine contractions. Epinephrine injection can be utilized to prolong the action of local anesthetics (see CONTRAINDICATIONS). uuid:e68a25f7-b60f-4409-99a0-4d62cac891aa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28918 biolink:treats MONDO:0005324 PMID:41385096 "[{""id"":""uuid:f562cde9-bc6c-4b8e-8e3d-824445529ceb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2126d063-b759-47dc-90bf-ad6de110bb34"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In general, the most common uses of epinephrine are to relieve respiratory distress due to bronchospasm, to provide rapid relief of hypersensitivity reactions to drugs and other allergens, and to prolong the action of infiltration anesthetics. Its cardiac effects may be of use in restoring cardiac rhythm in cardiac arrest due to various causes, but it is not used in cardiac failure or in hemorrhagic, traumatic, or cardiogenic shock. Epinephrine is used as a hemostatic agent. It is also used in treating mucosal congestion of hay fever, rhinitis and acute sinusitis; to relieve bronchial asthmatic paroxysms; in syncope due to complete heart block or carotid sinus hypersensitivity; for symptomatic relief of serum sickness, urticaria, angioneurotic edema; for resuscitation in cardiac arrest following anesthetic accidents; in simple (open angle) glaucoma; for relaxation of uterine musculature and to inhibit uterine contractions. Epinephrine injection can be utilized to prolong the action of local anesthetics (see CONTRAINDICATIONS). uuid:5e4baaf0-a14a-4cc6-a0aa-777b8156952e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28918 biolink:treats MONDO:0003014 PMID:41385096 "[{""id"":""uuid:609f7ccc-3e69-473a-a095-761bf69b87d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8b5ad441-4ab1-426a-a0af-fac506fd11ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In general, the most common uses of epinephrine are to relieve respiratory distress due to bronchospasm, to provide rapid relief of hypersensitivity reactions to drugs and other allergens, and to prolong the action of infiltration anesthetics. Its cardiac effects may be of use in restoring cardiac rhythm in cardiac arrest due to various causes, but it is not used in cardiac failure or in hemorrhagic, traumatic, or cardiogenic shock. Epinephrine is used as a hemostatic agent. It is also used in treating mucosal congestion of hay fever, rhinitis and acute sinusitis; to relieve bronchial asthmatic paroxysms; in syncope due to complete heart block or carotid sinus hypersensitivity; for symptomatic relief of serum sickness, urticaria, angioneurotic edema; for resuscitation in cardiac arrest following anesthetic accidents; in simple (open angle) glaucoma; for relaxation of uterine musculature and to inhibit uterine contractions. Epinephrine injection can be utilized to prolong the action of local anesthetics (see CONTRAINDICATIONS). uuid:c1c5d8de-2ab9-4221-9692-c1ea47dfc8af biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28918 biolink:treats HP:0000255 PMID:41385096 "[{""id"":""uuid:89d606a5-f413-4fd3-8489-6e3def71c781"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:86669d44-b06a-412e-86c4-8177fe440613"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In general, the most common uses of epinephrine are to relieve respiratory distress due to bronchospasm, to provide rapid relief of hypersensitivity reactions to drugs and other allergens, and to prolong the action of infiltration anesthetics. Its cardiac effects may be of use in restoring cardiac rhythm in cardiac arrest due to various causes, but it is not used in cardiac failure or in hemorrhagic, traumatic, or cardiogenic shock. Epinephrine is used as a hemostatic agent. It is also used in treating mucosal congestion of hay fever, rhinitis and acute sinusitis; to relieve bronchial asthmatic paroxysms; in syncope due to complete heart block or carotid sinus hypersensitivity; for symptomatic relief of serum sickness, urticaria, angioneurotic edema; for resuscitation in cardiac arrest following anesthetic accidents; in simple (open angle) glaucoma; for relaxation of uterine musculature and to inhibit uterine contractions. Epinephrine injection can be utilized to prolong the action of local anesthetics (see CONTRAINDICATIONS). uuid:71c4cabd-f801-4477-ba48-4ca14cc1df65 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28918 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:37f5a495-fb5a-4ccd-aef8-e8181acf7af9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1c6f1791-e4be-4a4b-80af-728ec8e344a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In general, the most common uses of epinephrine are to relieve respiratory distress due to bronchospasm, to provide rapid relief of hypersensitivity reactions to drugs and other allergens, and to prolong the action of infiltration anesthetics. Its cardiac effects may be of use in restoring cardiac rhythm in cardiac arrest due to various causes, but it is not used in cardiac failure or in hemorrhagic, traumatic, or cardiogenic shock. Epinephrine is used as a hemostatic agent. It is also used in treating mucosal congestion of hay fever, rhinitis and acute sinusitis; to relieve bronchial asthmatic paroxysms; in syncope due to complete heart block or carotid sinus hypersensitivity; for symptomatic relief of serum sickness, urticaria, angioneurotic edema; for resuscitation in cardiac arrest following anesthetic accidents; in simple (open angle) glaucoma; for relaxation of uterine musculature and to inhibit uterine contractions. Epinephrine injection can be utilized to prolong the action of local anesthetics (see CONTRAINDICATIONS). uuid:4bed95bd-7db3-422c-bb81-8695565837a9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28918 biolink:treats HP:0001279 PMID:41385096 "[{""id"":""uuid:da7e199d-829b-464a-a383-5ef2c2fe8d1f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:31044150-35e7-4a42-b476-bd41fc7c287e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In general, the most common uses of epinephrine are to relieve respiratory distress due to bronchospasm, to provide rapid relief of hypersensitivity reactions to drugs and other allergens, and to prolong the action of infiltration anesthetics. Its cardiac effects may be of use in restoring cardiac rhythm in cardiac arrest due to various causes, but it is not used in cardiac failure or in hemorrhagic, traumatic, or cardiogenic shock. Epinephrine is used as a hemostatic agent. It is also used in treating mucosal congestion of hay fever, rhinitis and acute sinusitis; to relieve bronchial asthmatic paroxysms; in syncope due to complete heart block or carotid sinus hypersensitivity; for symptomatic relief of serum sickness, urticaria, angioneurotic edema; for resuscitation in cardiac arrest following anesthetic accidents; in simple (open angle) glaucoma; for relaxation of uterine musculature and to inhibit uterine contractions. Epinephrine injection can be utilized to prolong the action of local anesthetics (see CONTRAINDICATIONS). uuid:7d7a9529-758f-45d8-9d59-af4ca16795d5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28918 biolink:treats MONDO:0043789 PMID:41385096 "[{""id"":""uuid:ce08fe06-d3fe-467d-83be-5b6a613fb501"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9175447f-2075-4a79-96e3-2bc9317675f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In general, the most common uses of epinephrine are to relieve respiratory distress due to bronchospasm, to provide rapid relief of hypersensitivity reactions to drugs and other allergens, and to prolong the action of infiltration anesthetics. Its cardiac effects may be of use in restoring cardiac rhythm in cardiac arrest due to various causes, but it is not used in cardiac failure or in hemorrhagic, traumatic, or cardiogenic shock. Epinephrine is used as a hemostatic agent. It is also used in treating mucosal congestion of hay fever, rhinitis and acute sinusitis; to relieve bronchial asthmatic paroxysms; in syncope due to complete heart block or carotid sinus hypersensitivity; for symptomatic relief of serum sickness, urticaria, angioneurotic edema; for resuscitation in cardiac arrest following anesthetic accidents; in simple (open angle) glaucoma; for relaxation of uterine musculature and to inhibit uterine contractions. Epinephrine injection can be utilized to prolong the action of local anesthetics (see CONTRAINDICATIONS). uuid:27c5b314-ea0e-4b39-adfc-73cc1a118bb3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28918 biolink:treats MONDO:0005492 PMID:41385096 "[{""id"":""uuid:bfe15629-00dd-4bc0-9302-4bb3ff7a5ef1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:459dd9e1-d9ba-421a-9022-d078ec12775b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In general, the most common uses of epinephrine are to relieve respiratory distress due to bronchospasm, to provide rapid relief of hypersensitivity reactions to drugs and other allergens, and to prolong the action of infiltration anesthetics. Its cardiac effects may be of use in restoring cardiac rhythm in cardiac arrest due to various causes, but it is not used in cardiac failure or in hemorrhagic, traumatic, or cardiogenic shock. Epinephrine is used as a hemostatic agent. It is also used in treating mucosal congestion of hay fever, rhinitis and acute sinusitis; to relieve bronchial asthmatic paroxysms; in syncope due to complete heart block or carotid sinus hypersensitivity; for symptomatic relief of serum sickness, urticaria, angioneurotic edema; for resuscitation in cardiac arrest following anesthetic accidents; in simple (open angle) glaucoma; for relaxation of uterine musculature and to inhibit uterine contractions. Epinephrine injection can be utilized to prolong the action of local anesthetics (see CONTRAINDICATIONS). uuid:979302cd-6d78-4943-9e8c-35c713539b08 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28918 biolink:treats MONDO:0010481 PMID:41385096 "[{""id"":""uuid:947b77d6-9981-4bc0-9ca5-b9eed1efa6d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9583c185-6fb8-4900-af0e-a6b5fca0e41e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In general, the most common uses of epinephrine are to relieve respiratory distress due to bronchospasm, to provide rapid relief of hypersensitivity reactions to drugs and other allergens, and to prolong the action of infiltration anesthetics. Its cardiac effects may be of use in restoring cardiac rhythm in cardiac arrest due to various causes, but it is not used in cardiac failure or in hemorrhagic, traumatic, or cardiogenic shock. Epinephrine is used as a hemostatic agent. It is also used in treating mucosal congestion of hay fever, rhinitis and acute sinusitis; to relieve bronchial asthmatic paroxysms; in syncope due to complete heart block or carotid sinus hypersensitivity; for symptomatic relief of serum sickness, urticaria, angioneurotic edema; for resuscitation in cardiac arrest following anesthetic accidents; in simple (open angle) glaucoma; for relaxation of uterine musculature and to inhibit uterine contractions. Epinephrine injection can be utilized to prolong the action of local anesthetics (see CONTRAINDICATIONS). uuid:cc756859-17d6-4ca8-8b4b-92465bde9e54 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28918 biolink:treats MONDO:0005041 PMID:41385096 "[{""id"":""uuid:c35000fe-6c9c-4bcd-9879-d108b3abb496"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:734657c7-c57e-4fec-953f-2435f9b9ee50"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In general, the most common uses of epinephrine are to relieve respiratory distress due to bronchospasm, to provide rapid relief of hypersensitivity reactions to drugs and other allergens, and to prolong the action of infiltration anesthetics. Its cardiac effects may be of use in restoring cardiac rhythm in cardiac arrest due to various causes, but it is not used in cardiac failure or in hemorrhagic, traumatic, or cardiogenic shock. Epinephrine is used as a hemostatic agent. It is also used in treating mucosal congestion of hay fever, rhinitis and acute sinusitis; to relieve bronchial asthmatic paroxysms; in syncope due to complete heart block or carotid sinus hypersensitivity; for symptomatic relief of serum sickness, urticaria, angioneurotic edema; for resuscitation in cardiac arrest following anesthetic accidents; in simple (open angle) glaucoma; for relaxation of uterine musculature and to inhibit uterine contractions. Epinephrine injection can be utilized to prolong the action of local anesthetics (see CONTRAINDICATIONS). uuid:4e2c1fe4-42c9-45d2-b043-3c69bb1b6cf2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17439 biolink:treats MONDO:0001356 PMID:41385096 "[{""id"":""uuid:53a96746-51c4-4d6e-aab4-1d17b5c02f76"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:03ff768e-c977-49b6-a34b-3105569a473c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Myferon 150 Forte is indicated for the prevention and treatment of iron deficiency anemia and/or nutritional megaloblastic anemias. uuid:b0a51f09-8b13-4f24-b17b-cbb0789a617f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17439 biolink:treats MONDO:0001700 PMID:41385096 "[{""id"":""uuid:98e08a06-8fcb-4c74-8f50-043af4111867"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:32ba3926-5d34-436a-8593-648d29e6e9ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Myferon 150 Forte is indicated for the prevention and treatment of iron deficiency anemia and/or nutritional megaloblastic anemias. uuid:bc948803-4516-43b2-942c-db88c5d1cda2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:421707 biolink:treats MONDO:0004951 PMID:41385096 "[{""id"":""uuid:b41d7af4-d7aa-4513-bce2-a52ecb764f7b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e15ba81a-027d-47f6-b44f-8864570d999a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Abacavir tablets, in combination with other antiretroviral agents, are indicated for the treatment of human immunodeficiency virus (HIV-1) infection. Additional important information on the use of abacavir tablets for treatment of HIV-1 infection: Abacavir tablets are one of multiple products containing abacavir. Before starting abacavir tablets, review medical history for prior exposure to any abacavir-containing product in order to avoid reintroduction in a patient with a history of hypersensitivity to abacavir [see Warnings and Precautions (5.1) , Adverse Reactions (6) ]. uuid:2a29413a-a368-4c80-8eb6-396c5dd61121 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3387 biolink:treats MONDO:0010826 PMID:41385096 "[{""id"":""uuid:1acff2e5-029d-4ba9-b683-9143324623be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c18e815f-1a05-4de8-95da-9098f172dc65"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carbamazepine is indicated for use as an anticonvulsant drug. Evidence supporting efficacy of carbamazepine as an anticonvulsant was derived from active drug-controlled studies that enrolled patients with the following seizure types: 1. Partial seizures with complex symptomatology (psychomotor, temporal lobe). Patients with these seizures appear to show greater improvement than those with other types. 2. Generalized tonic-clonic seizures (grand mal). 3. Mixed seizure patterns which include the above, or other partial or generalized seizures. Absence seizures (petit mal) do not appear to be controlled by carbamazepine (see PRECAUTIONS, General ). uuid:8eafa0d4-20ec-4d8c-b900-6e4fa0823895 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:38545 biolink:treats UMLS:C0342882 PMID:41385096 "[{""id"":""uuid:6dc1b330-ff88-4e95-8465-925cfedc0b00"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:952b22e7-3e92-43b2-849c-3e10ab01cc7f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CRESTOR is an HMG Co‑A reductase inhibitor indicated for: • patients with primary hyperlipidemia and mixed dyslipidemia as an adjunct to diet to reduce elevated total‑C, LDL‑C, ApoB, nonHDL‑C, and TG levels and to increase HDL‑C (1.1) • patients with hypertriglyceridemia as an adjunct to diet (1.2) • patients with primary dysbetalipoproteinemia (Type III hyperlipoproteinemia) as an adjunct to diet (1.3) • patients with homozygous familial hypercholesterolemia (HoFH) to reduce LDL‑C, total-C, and ApoB (1.4) • slowing the progression of atherosclerosis as part of a treatment strategy to lower total‑C and LDL‑C as an adjunct to diet (1.5) • pediatric patients 10 to 17 years of age with heterozygous familial hypercholesterolemia (HeFH) to reduce elevated total‑C, LDL‑C and ApoB after failing an adequate trial of diet therapy (1.1) • risk reduction of MI, stroke, and arterial revascularization procedures in patients without clinically evident CHD, but with multiple risk factors (1.6) Limitations of use (1.7) : • CRESTOR has not been studied in Fredrickson Type I and V dyslipidemias. uuid:6e9b7e37-b178-4b69-bfb5-b76b115c7664 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:144551 biolink:treats HP:0100518 PMID:41385096 "[{""id"":""uuid:9fbaf8bf-0109-42e1-b9d7-cecf0bb15424"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:61256be9-532c-4815-92c2-aa97cba355e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxybutynin chloride is indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria). uuid:ddef3e15-0c77-48a0-b6a0-3c246e2e3bbf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:144551 biolink:treats NCIT:C118167 PMID:41385096 "[{""id"":""uuid:6486f463-c2aa-4376-b16d-ee1723ef45a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:18a7b751-f435-4974-8fc2-024b21549c87"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxybutynin chloride is indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria). uuid:ab47ccca-1c5a-4a99-ad4f-f0972bcc22cd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9150 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:b64fd543-6b8c-4969-bb6a-5bef378fe140"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:13695bda-352e-4b5e-b2e1-c01e94044396"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Simvastatin tablets are an HMG-CoA reductase inhibitor (statin) indicated as an adjunctive therapy to diet to: Reduce the risk of total mortality by reducing CHD deaths and reduce the risk of non-fatal myocardial infarction, stroke, and the need for revascularization procedures in patients at high risk of coronary events. ( 1.1 ) Reduce elevated total-C, LDL-C, Apo B, TG and increase HDL-C in patients with primary hyperlipidemia (heterozygous familial and nonfamilial) and mixed dyslipidemia. ( 1.2 ) Reduce elevated TG in patients with hypertriglyceridemia and reduce TG and VLDL-C in patients with primary dysbetalipoproteinemia. ( 1.2 ) Reduce total-C and LDL-C in adult patients with homozygous familial hypercholesterolemia. ( 1.2 ) Reduce elevated total-C, LDL-C, and Apo B in boys and postmenarchal girls, 10 to 17 years of age with heterozygous familial hypercholesterolemia after failing an adequate trial of diet therapy. ( 1.2 , 1.3 ) Limitations of Use Simvastatin tablets have not been studied in Fredrickson Types I and V dyslipidemias. ( 1.4 ) uuid:8dc8244b-70da-4669-94dd-705f1775aac6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9150 biolink:treats MONDO:0001336 PMID:41385096 "[{""id"":""uuid:9343a49f-8ff2-47ee-b5b1-052423d091d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a26a5b58-e2ed-4ed5-a667-021c06ba63bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Simvastatin tablets are an HMG-CoA reductase inhibitor (statin) indicated as an adjunctive therapy to diet to: Reduce the risk of total mortality by reducing CHD deaths and reduce the risk of non-fatal myocardial infarction, stroke, and the need for revascularization procedures in patients at high risk of coronary events. ( 1.1 ) Reduce elevated total-C, LDL-C, Apo B, TG and increase HDL-C in patients with primary hyperlipidemia (heterozygous familial and nonfamilial) and mixed dyslipidemia. ( 1.2 ) Reduce elevated TG in patients with hypertriglyceridemia and reduce TG and VLDL-C in patients with primary dysbetalipoproteinemia. ( 1.2 ) Reduce total-C and LDL-C in adult patients with homozygous familial hypercholesterolemia. ( 1.2 ) Reduce elevated total-C, LDL-C, and Apo B in boys and postmenarchal girls, 10 to 17 years of age with heterozygous familial hypercholesterolemia after failing an adequate trial of diet therapy. ( 1.2 , 1.3 ) Limitations of Use Simvastatin tablets have not been studied in Fredrickson Types I and V dyslipidemias. ( 1.4 ) uuid:c3388ca2-6d17-46e6-bf31-c22f6272cbe4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9150 biolink:treats MONDO:0007788 PMID:41385096 "[{""id"":""uuid:48433ffa-c445-4a41-9fd0-f007b3274856"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7f49b235-b712-4ac9-b382-69b4e0c38ead"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Simvastatin tablets are an HMG-CoA reductase inhibitor (statin) indicated as an adjunctive therapy to diet to: Reduce the risk of total mortality by reducing CHD deaths and reduce the risk of non-fatal myocardial infarction, stroke, and the need for revascularization procedures in patients at high risk of coronary events. ( 1.1 ) Reduce elevated total-C, LDL-C, Apo B, TG and increase HDL-C in patients with primary hyperlipidemia (heterozygous familial and nonfamilial) and mixed dyslipidemia. ( 1.2 ) Reduce elevated TG in patients with hypertriglyceridemia and reduce TG and VLDL-C in patients with primary dysbetalipoproteinemia. ( 1.2 ) Reduce total-C and LDL-C in adult patients with homozygous familial hypercholesterolemia. ( 1.2 ) Reduce elevated total-C, LDL-C, and Apo B in boys and postmenarchal girls, 10 to 17 years of age with heterozygous familial hypercholesterolemia after failing an adequate trial of diet therapy. ( 1.2 , 1.3 ) Limitations of Use Simvastatin tablets have not been studied in Fredrickson Types I and V dyslipidemias. ( 1.4 ) uuid:042edec2-b532-4b59-95da-7ddd38e4ef07 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9150 biolink:treats MONDO:0007762 PMID:41385096 "[{""id"":""uuid:48055e6f-b415-46e4-af85-3f8179f76ee2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:64948b09-8a37-479f-adbd-3d674139243a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Simvastatin tablets are an HMG-CoA reductase inhibitor (statin) indicated as an adjunctive therapy to diet to: Reduce the risk of total mortality by reducing CHD deaths and reduce the risk of non-fatal myocardial infarction, stroke, and the need for revascularization procedures in patients at high risk of coronary events. ( 1.1 ) Reduce elevated total-C, LDL-C, Apo B, TG and increase HDL-C in patients with primary hyperlipidemia (heterozygous familial and nonfamilial) and mixed dyslipidemia. ( 1.2 ) Reduce elevated TG in patients with hypertriglyceridemia and reduce TG and VLDL-C in patients with primary dysbetalipoproteinemia. ( 1.2 ) Reduce total-C and LDL-C in adult patients with homozygous familial hypercholesterolemia. ( 1.2 ) Reduce elevated total-C, LDL-C, and Apo B in boys and postmenarchal girls, 10 to 17 years of age with heterozygous familial hypercholesterolemia after failing an adequate trial of diet therapy. ( 1.2 , 1.3 ) Limitations of Use Simvastatin tablets have not been studied in Fredrickson Types I and V dyslipidemias. ( 1.4 ) uuid:4dea1f24-7518-45c1-8e85-b4d4f1cae2aa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9720 biolink:treats MONDO:0021095 PMID:41385096 "[{""id"":""uuid:723a4f6f-5e3c-4a5d-b696-0ecfb6645677"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:64e3e6fc-5295-4919-b90a-db7e2ce95d4c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] This drug is indicated as an adjunct in the treatment of all forms of parkinsonism (postencephalitic, arteriosclerotic, and idiopathic). It is often useful as adjuvant therapy when treating these forms of parkinsonism with levodopa. Additionally, it is indicated for the control of extrapyramidal disorders caused by central nervous system drugs such as the dibenzoxazepines, phenothiazines, thioxanthenes, and butyrophenones. uuid:2dda1f15-33b5-4226-beba-9bdd3fb2d054 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9720 biolink:treats MONDO:0001945 PMID:41385096 "[{""id"":""uuid:218873c5-8453-4791-a44d-236e275da667"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c65d5b76-2177-4cc6-9f6e-9a884ec3b216"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] This drug is indicated as an adjunct in the treatment of all forms of parkinsonism (postencephalitic, arteriosclerotic, and idiopathic). It is often useful as adjuvant therapy when treating these forms of parkinsonism with levodopa. Additionally, it is indicated for the control of extrapyramidal disorders caused by central nervous system drugs such as the dibenzoxazepines, phenothiazines, thioxanthenes, and butyrophenones. uuid:6e8ec028-f523-46a0-87cc-bcc89fc79c38 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9720 biolink:treats MONDO:0956980 PMID:41385096 "[{""id"":""uuid:7f5b09ae-e81e-4969-abe9-5d2c97deb9cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c498f20e-595f-4dc1-a12b-3ed0a0b07023"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] This drug is indicated as an adjunct in the treatment of all forms of parkinsonism (postencephalitic, arteriosclerotic, and idiopathic). It is often useful as adjuvant therapy when treating these forms of parkinsonism with levodopa. Additionally, it is indicated for the control of extrapyramidal disorders caused by central nervous system drugs such as the dibenzoxazepines, phenothiazines, thioxanthenes, and butyrophenones. uuid:1f2eb4dd-c35f-44b1-af78-2ef320aa2b70 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9720 biolink:treats MONDO:0005180 PMID:41385096 "[{""id"":""uuid:1ee86f10-4571-42c1-9e36-cfcfe1cec3c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:771cbc82-2fa1-4a56-880d-14ec18d97c7c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] This drug is indicated as an adjunct in the treatment of all forms of parkinsonism (postencephalitic, arteriosclerotic, and idiopathic). It is often useful as adjuvant therapy when treating these forms of parkinsonism with levodopa. Additionally, it is indicated for the control of extrapyramidal disorders caused by central nervous system drugs such as the dibenzoxazepines, phenothiazines, thioxanthenes, and butyrophenones. uuid:7ac844ae-b331-43d0-a445-099fa261eaaa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9720 biolink:treats HP:0002071 PMID:41385096 "[{""id"":""uuid:a7312e7b-1176-4818-9a5c-971e3eaf8a75"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:53e9f374-5348-4900-8a78-ca0efea2c9e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] This drug is indicated as an adjunct in the treatment of all forms of parkinsonism (postencephalitic, arteriosclerotic, and idiopathic). It is often useful as adjuvant therapy when treating these forms of parkinsonism with levodopa. Additionally, it is indicated for the control of extrapyramidal disorders caused by central nervous system drugs such as the dibenzoxazepines, phenothiazines, thioxanthenes, and butyrophenones. uuid:37370d0e-b2c4-4b9e-8c14-80ec7ffd13b5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27446 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:950fa087-fe72-4da3-9a96-0db9b9c3fa71"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4c0137c5-57a7-4760-b2ef-d3b0d8ecc457"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Penicillin V potassium tablets are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with penicillin V during the acute stage. Indicated surgical procedures should be performed. The following infections will usually respond to adequate dosage of penicillin V. uuid:86ae890b-0b4c-4f6c-8384-55eb6959336b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27446 biolink:treats MONDO:0005242 PMID:41385096 "[{""id"":""uuid:aa5a0550-eb40-4b0d-b3f1-3acf5a3f29dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:52688eb9-531e-416a-b8fa-955826d60d9e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Penicillin V potassium tablets are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with penicillin V during the acute stage. Indicated surgical procedures should be performed. The following infections will usually respond to adequate dosage of penicillin V. uuid:390d7c93-6869-4670-be22-f10aea6d2069 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27446 biolink:treats MONDO:0005229 PMID:41385096 "[{""id"":""uuid:f3d6ff91-0b6e-454d-8ef6-537256948656"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4a295612-f32d-45fe-ae90-8b445ea37c9b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Penicillin V potassium tablets are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with penicillin V during the acute stage. Indicated surgical procedures should be performed. The following infections will usually respond to adequate dosage of penicillin V. uuid:e805ca94-20ae-4ae9-ba79-61fc3798df88 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27446 biolink:treats MONDO:0005904 PMID:41385096 "[{""id"":""uuid:ef10c602-babf-4f97-bac4-df285a59915d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6605f416-0aa4-43a3-8f9a-92b17bd9be46"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Penicillin V potassium tablets are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with penicillin V during the acute stage. Indicated surgical procedures should be performed. The following infections will usually respond to adequate dosage of penicillin V. uuid:18fb9a6b-e177-4247-b5a8-1cc4851305e9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27446 biolink:treats MONDO:0021108 PMID:41385096 "[{""id"":""uuid:9631c3e6-3fd8-4de9-8a2a-e6e4a5c5e89f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5285d3cc-a32c-41bd-bf82-951f03e8a205"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Penicillin V potassium tablets are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with penicillin V during the acute stage. Indicated surgical procedures should be performed. The following infections will usually respond to adequate dosage of penicillin V. uuid:3b363a88-87ac-476e-8357-02b9a207e7a4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27446 biolink:treats MONDO:0005578 PMID:41385096 "[{""id"":""uuid:25e57b69-afbe-4e81-bde3-0d5433cc9ab7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4e479e71-865b-4551-a754-0b8aa1b2f366"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Penicillin V potassium tablets are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with penicillin V during the acute stage. Indicated surgical procedures should be performed. The following infections will usually respond to adequate dosage of penicillin V. uuid:10bb820a-cc5e-44ce-86c8-29df006d1a74 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:284904 biolink:treats MONDO:0004951 PMID:41385096 "[{""id"":""uuid:2a1c0a3b-5979-4173-9d68-a6926c897611"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8529ee02-21e8-4143-86cd-10247a5b3df2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TRIZIVIR is indicated in combination with other antiretrovirals or alone for the treatment of HIV-1 infection. Additional important information on the use of TRIZIVIR for treatment of HIV-1 infection: • TRIZIVIR is one of multiple products containing abacavir. Before starting TRIZIVIR, review medical history for prior exposure to any abacavir-containing product in order to avoid reintroduction in a patient with a history of hypersensitivity to abacavir [see Warnings and Precautions (5.1), Adverse Reactions (6)] . • TRIZIVIR is a fixed-dose combination of 3 nucleoside analogues: abacavir, lamivudine, and zidovudine and is intended only for patients whose regimen would otherwise include these 3 components. • Limited data exist on the use of TRIZIVIR alone in patients with higher baseline viral load levels (>100,000 copies/mL) [see Clinical Studies (14)] . uuid:7e3f1008-2f86-4c9d-9a27-5e6109d8ee3e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9241 biolink:treats MONDO:0021511 PMID:41385096 "[{""id"":""uuid:d8c675ab-f2dd-4440-9162-bd983533f800"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dde0cd35-343e-4b68-aff0-4198abc60bc3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Spironolactone tablets, USP are indicated in the management of: Primary hyperaldosteronism for: Establishing the diagnosis of primary hyperaldosteronism by therapeutic trial. Short-term preoperative treatment of patients with primary hyperaldosteronism. Long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are judged to be poor operative risks or who decline surgery. Long-term maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). Edematous conditions for patients with: Congestive heart failure: For the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures. Spironolactone tablets, USP are also indicated for patients with congestive heart failure taking digitalis when other therapies are considered inappropriate. Cirrhosis of the liver accompanied by edema and/or ascites: Aldosterone levels may be exceptionally high in this condition. Spironolactone tablets, USP are indicated for maintenance therapy together with bed rest and the restriction of fluid and sodium. Nephrotic syndrome: For nephrotic patients when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics do not provide an adequate response. Essential hypertension Spironolactone tablets, USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Usually in combination with other drugs, spironolactone tablets, USP are indicated for patients who cannot be treated adequately with other agents or for whom other agents are considered inappropriate. Hypokalemia For the treatment of patients with hypokalemia when other measures are considered inappropriate or inadequate. Spironolactone tablets, USP are also indicated for the prophylaxis of hypokalemia in patients taking digitalis when other measures are considered inadequate or inappropriate. Severe heart failure (NYHA class III – IV) To increase survival, and to reduce the need for hospitalization for heart failure when used in addition to standard therapy. Usage in Pregnancy The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developing toxemia. Edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy. Spironolactone tablets, USP are indicated in pregnancy when edema is due to pathologic causes just as it is in the absence of pregnancy (however, see Precautions: Pregnancy ). Dependent edema in pregnancy, resulting from restriction of venous return by the expanded uterus, is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is unsupported and unnecessary. There is hypervolemia during normal pregnancy which is not harmful to either the fetus or the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema, in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances, this edema may cause extreme discomfort that is not relieved by rest. In these cases, a short course of diuretics may provide relief and may be appropriate. uuid:38c44959-1430-4c4f-b4e3-f1be2070bc8c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9241 biolink:treats HP:0008221 PMID:41385096 "[{""id"":""uuid:8bd47279-2e76-47ae-ba42-251cd88767a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a11a67b5-b442-42ef-b3cb-d83490d3e3ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Spironolactone tablets, USP are indicated in the management of: Primary hyperaldosteronism for: Establishing the diagnosis of primary hyperaldosteronism by therapeutic trial. Short-term preoperative treatment of patients with primary hyperaldosteronism. Long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are judged to be poor operative risks or who decline surgery. Long-term maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). Edematous conditions for patients with: Congestive heart failure: For the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures. Spironolactone tablets, USP are also indicated for patients with congestive heart failure taking digitalis when other therapies are considered inappropriate. Cirrhosis of the liver accompanied by edema and/or ascites: Aldosterone levels may be exceptionally high in this condition. Spironolactone tablets, USP are indicated for maintenance therapy together with bed rest and the restriction of fluid and sodium. Nephrotic syndrome: For nephrotic patients when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics do not provide an adequate response. Essential hypertension Spironolactone tablets, USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Usually in combination with other drugs, spironolactone tablets, USP are indicated for patients who cannot be treated adequately with other agents or for whom other agents are considered inappropriate. Hypokalemia For the treatment of patients with hypokalemia when other measures are considered inappropriate or inadequate. Spironolactone tablets, USP are also indicated for the prophylaxis of hypokalemia in patients taking digitalis when other measures are considered inadequate or inappropriate. Severe heart failure (NYHA class III – IV) To increase survival, and to reduce the need for hospitalization for heart failure when used in addition to standard therapy. Usage in Pregnancy The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developing toxemia. Edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy. Spironolactone tablets, USP are indicated in pregnancy when edema is due to pathologic causes just as it is in the absence of pregnancy (however, see Precautions: Pregnancy ). Dependent edema in pregnancy, resulting from restriction of venous return by the expanded uterus, is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is unsupported and unnecessary. There is hypervolemia during normal pregnancy which is not harmful to either the fetus or the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema, in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances, this edema may cause extreme discomfort that is not relieved by rest. In these cases, a short course of diuretics may provide relief and may be appropriate. uuid:6a9e94aa-dc8f-421d-ba50-726899232449 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9241 biolink:treats MONDO:0001134 PMID:41385096 "[{""id"":""uuid:13c1f424-8712-4172-9b15-7ced96323a1f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:dbc3aa81-714b-4711-9fce-78567e1c6d7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:56f19d0e-b3dc-454d-8d83-d038f29a3f6e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/qaialdo""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Spironolactone tablets, USP are indicated in the management of: Primary hyperaldosteronism for: Establishing the diagnosis of primary hyperaldosteronism by therapeutic trial. Short-term preoperative treatment of patients with primary hyperaldosteronism. Long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are judged to be poor operative risks or who decline surgery. Long-term maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). Edematous conditions for patients with: Congestive heart failure: For the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures. Spironolactone tablets, USP are also indicated for patients with congestive heart failure taking digitalis when other therapies are considered inappropriate. Cirrhosis of the liver accompanied by edema and/or ascites: Aldosterone levels may be exceptionally high in this condition. Spironolactone tablets, USP are indicated for maintenance therapy together with bed rest and the restriction of fluid and sodium. Nephrotic syndrome: For nephrotic patients when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics do not provide an adequate response. Essential hypertension Spironolactone tablets, USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Usually in combination with other drugs, spironolactone tablets, USP are indicated for patients who cannot be treated adequately with other agents or for whom other agents are considered inappropriate. Hypokalemia For the treatment of patients with hypokalemia when other measures are considered inappropriate or inadequate. Spironolactone tablets, USP are also indicated for the prophylaxis of hypokalemia in patients taking digitalis when other measures are considered inadequate or inappropriate. Severe heart failure (NYHA class III – IV) To increase survival, and to reduce the need for hospitalization for heart failure when used in addition to standard therapy. Usage in Pregnancy The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developing toxemia. Edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy. Spironolactone tablets, USP are indicated in pregnancy when edema is due to pathologic causes just as it is in the absence of pregnancy (however, see Precautions: Pregnancy ). Dependent edema in pregnancy, resulting from restriction of venous return by the expanded uterus, is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is unsupported and unnecessary. There is hypervolemia during normal pregnancy which is not harmful to either the fetus or the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema, in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances, this edema may cause extreme discomfort that is not relieved by rest. In these cases, a short course of diuretics may provide relief and may be appropriate.|[EMA] In the management of refractory oedema associated with congestive cardiac failure; hepatic cirrhosis with ascites and oedema, malignant ascites, nephrotic syndrome, diagnosis and treatment of primary aldosteronism, essential hypertension.Neonates, children and adolescents should only be treated under guidance of a paediatric specialist (see sections 5.1 and 5.2). uuid:72c80aa2-35d9-45e9-9edf-a6b68fbfd980 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9241 biolink:treats MONDO:0003019 PMID:41385096 "[{""id"":""uuid:f19eafd2-24b0-4c80-8cea-6bca75ded8bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dc5efb0e-7b8b-4cdd-9e50-ec5934da216b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Spironolactone tablets, USP are indicated in the management of: Primary hyperaldosteronism for: Establishing the diagnosis of primary hyperaldosteronism by therapeutic trial. Short-term preoperative treatment of patients with primary hyperaldosteronism. Long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are judged to be poor operative risks or who decline surgery. Long-term maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). Edematous conditions for patients with: Congestive heart failure: For the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures. Spironolactone tablets, USP are also indicated for patients with congestive heart failure taking digitalis when other therapies are considered inappropriate. Cirrhosis of the liver accompanied by edema and/or ascites: Aldosterone levels may be exceptionally high in this condition. Spironolactone tablets, USP are indicated for maintenance therapy together with bed rest and the restriction of fluid and sodium. Nephrotic syndrome: For nephrotic patients when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics do not provide an adequate response. Essential hypertension Spironolactone tablets, USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Usually in combination with other drugs, spironolactone tablets, USP are indicated for patients who cannot be treated adequately with other agents or for whom other agents are considered inappropriate. Hypokalemia For the treatment of patients with hypokalemia when other measures are considered inappropriate or inadequate. Spironolactone tablets, USP are also indicated for the prophylaxis of hypokalemia in patients taking digitalis when other measures are considered inadequate or inappropriate. Severe heart failure (NYHA class III – IV) To increase survival, and to reduce the need for hospitalization for heart failure when used in addition to standard therapy. Usage in Pregnancy The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developing toxemia. Edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy. Spironolactone tablets, USP are indicated in pregnancy when edema is due to pathologic causes just as it is in the absence of pregnancy (however, see Precautions: Pregnancy ). Dependent edema in pregnancy, resulting from restriction of venous return by the expanded uterus, is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is unsupported and unnecessary. There is hypervolemia during normal pregnancy which is not harmful to either the fetus or the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema, in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances, this edema may cause extreme discomfort that is not relieved by rest. In these cases, a short course of diuretics may provide relief and may be appropriate. uuid:b36352a3-686d-440c-9d83-c9f9c43ee62c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9241 biolink:treats MONDO:0045048 PMID:41385096 "[{""id"":""uuid:2211100f-f965-472f-8a7e-46b6ef4b6f14"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a685b1fe-c6cd-4700-9648-73c341f15dfa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Spironolactone tablets, USP are indicated in the management of: Primary hyperaldosteronism for: Establishing the diagnosis of primary hyperaldosteronism by therapeutic trial. Short-term preoperative treatment of patients with primary hyperaldosteronism. Long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are judged to be poor operative risks or who decline surgery. Long-term maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). Edematous conditions for patients with: Congestive heart failure: For the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures. Spironolactone tablets, USP are also indicated for patients with congestive heart failure taking digitalis when other therapies are considered inappropriate. Cirrhosis of the liver accompanied by edema and/or ascites: Aldosterone levels may be exceptionally high in this condition. Spironolactone tablets, USP are indicated for maintenance therapy together with bed rest and the restriction of fluid and sodium. Nephrotic syndrome: For nephrotic patients when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics do not provide an adequate response. Essential hypertension Spironolactone tablets, USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Usually in combination with other drugs, spironolactone tablets, USP are indicated for patients who cannot be treated adequately with other agents or for whom other agents are considered inappropriate. Hypokalemia For the treatment of patients with hypokalemia when other measures are considered inappropriate or inadequate. Spironolactone tablets, USP are also indicated for the prophylaxis of hypokalemia in patients taking digitalis when other measures are considered inadequate or inappropriate. Severe heart failure (NYHA class III – IV) To increase survival, and to reduce the need for hospitalization for heart failure when used in addition to standard therapy. Usage in Pregnancy The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developing toxemia. Edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy. Spironolactone tablets, USP are indicated in pregnancy when edema is due to pathologic causes just as it is in the absence of pregnancy (however, see Precautions: Pregnancy ). Dependent edema in pregnancy, resulting from restriction of venous return by the expanded uterus, is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is unsupported and unnecessary. There is hypervolemia during normal pregnancy which is not harmful to either the fetus or the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema, in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances, this edema may cause extreme discomfort that is not relieved by rest. In these cases, a short course of diuretics may provide relief and may be appropriate. uuid:993e5f85-c0d1-4fd3-971b-0c08cd08c74d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9241 biolink:treats MONDO:0005081 PMID:41385096 "[{""id"":""uuid:95eae28d-e34e-47e8-ae61-c596083a0610"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:41ca0e82-c700-42e7-bae8-62dfbe5462cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Spironolactone tablets, USP are indicated in the management of: Primary hyperaldosteronism for: Establishing the diagnosis of primary hyperaldosteronism by therapeutic trial. Short-term preoperative treatment of patients with primary hyperaldosteronism. Long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are judged to be poor operative risks or who decline surgery. Long-term maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). Edematous conditions for patients with: Congestive heart failure: For the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures. Spironolactone tablets, USP are also indicated for patients with congestive heart failure taking digitalis when other therapies are considered inappropriate. Cirrhosis of the liver accompanied by edema and/or ascites: Aldosterone levels may be exceptionally high in this condition. Spironolactone tablets, USP are indicated for maintenance therapy together with bed rest and the restriction of fluid and sodium. Nephrotic syndrome: For nephrotic patients when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics do not provide an adequate response. Essential hypertension Spironolactone tablets, USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Usually in combination with other drugs, spironolactone tablets, USP are indicated for patients who cannot be treated adequately with other agents or for whom other agents are considered inappropriate. Hypokalemia For the treatment of patients with hypokalemia when other measures are considered inappropriate or inadequate. Spironolactone tablets, USP are also indicated for the prophylaxis of hypokalemia in patients taking digitalis when other measures are considered inadequate or inappropriate. Severe heart failure (NYHA class III – IV) To increase survival, and to reduce the need for hospitalization for heart failure when used in addition to standard therapy. Usage in Pregnancy The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developing toxemia. Edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy. Spironolactone tablets, USP are indicated in pregnancy when edema is due to pathologic causes just as it is in the absence of pregnancy (however, see Precautions: Pregnancy ). Dependent edema in pregnancy, resulting from restriction of venous return by the expanded uterus, is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is unsupported and unnecessary. There is hypervolemia during normal pregnancy which is not harmful to either the fetus or the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema, in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances, this edema may cause extreme discomfort that is not relieved by rest. In these cases, a short course of diuretics may provide relief and may be appropriate. uuid:be81da44-88dd-4d9e-806e-c47f8e5d6125 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:9YCX42I8IU biolink:treats MONDO:0005300 PMID:41385096 "[{""id"":""uuid:104aa86a-74f8-4d73-bdbf-330172c88e3f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5a29e254-f6ff-4100-b721-12f8d943d82e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RENAGEL ® Renagel is a Registered Trademark of Genzyme Corporation. (sevelamer hydrochloride) is indicated for the control of serum phosphorus in patients with chronic kidney disease (CKD) on dialysis. The safety and efficacy of Renagel in CKD patients who are not on dialysis have not been studied. uuid:05f16058-3b37-4af1-9d94-943cf25de945 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6909 biolink:treats MONDO:0005993 PMID:41385096 "[{""id"":""uuid:7ad10d65-7999-4628-8625-becb2f381c83"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:afc24987-6079-4b66-86b4-ad9023024712"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Metronidazole Tablets USP are indicated for the treatment of T. vaginalis infection in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures). uuid:c823e25c-b937-4eee-81f4-7ae7b003c1ce biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22652 biolink:treats MONDO:0005351 PMID:41385096 "[{""id"":""uuid:2f3858bf-ac3e-4431-b71c-aec909bdb2a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6a55a521-28a2-4e39-b2ab-e6f4626332ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BACMIN is indicated for prophylactic or therapeutic nutritional supplementation in physiologically stressful conditions. These include: Conditions causing depletion, reduced absorption or bioavailability of essential vitamins and minerals- Inadequate intake due to highly restricted or unbalanced diets such as those frequently associated with anorexic conditions and other states of severe malnutrition. Gastrointestinal disorders, chronic alcoholism, chronic or acute infections (especially those involving febrile illness), prolonged or wasting disease, congestive heart failure, hyperthyroidism, poorly controlled diabetes or other physiologic stress. Also, patients on estrogenic oral contraceptives or other estrogen therapy, anti-bacterials which affect intestinal microflora, or other interfering drugs. Certain conditions resulting from severe B-Vitamin or ascorbic acid deficiency- Recovery from surgery or trauma involving severe burns, fractures or other extensive tissue damage. Also, pregnant women and those with heavy menstrual bleeding. uuid:1c5e86d4-181b-4cd7-afe1-da1b85f2a922 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22652 biolink:treats MONDO:0005137 PMID:41385096 "[{""id"":""uuid:04dad37c-bf5c-4e60-ac76-b0486d1f1987"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:49a78323-0b26-4e68-b6d8-f16bb371a805"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BACMIN is indicated for prophylactic or therapeutic nutritional supplementation in physiologically stressful conditions. These include: Conditions causing depletion, reduced absorption or bioavailability of essential vitamins and minerals- Inadequate intake due to highly restricted or unbalanced diets such as those frequently associated with anorexic conditions and other states of severe malnutrition. Gastrointestinal disorders, chronic alcoholism, chronic or acute infections (especially those involving febrile illness), prolonged or wasting disease, congestive heart failure, hyperthyroidism, poorly controlled diabetes or other physiologic stress. Also, patients on estrogenic oral contraceptives or other estrogen therapy, anti-bacterials which affect intestinal microflora, or other interfering drugs. Certain conditions resulting from severe B-Vitamin or ascorbic acid deficiency- Recovery from surgery or trauma involving severe burns, fractures or other extensive tissue damage. Also, pregnant women and those with heavy menstrual bleeding. uuid:b0607ec2-db9c-4332-a544-857bab349fcf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22652 biolink:treats MONDO:0004335 PMID:41385096 "[{""id"":""uuid:d87d8b7a-fe0f-47bf-8e8f-8b7e9ba01c91"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1f213b94-c011-420f-8bb6-8413e721b15d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BACMIN is indicated for prophylactic or therapeutic nutritional supplementation in physiologically stressful conditions. These include: Conditions causing depletion, reduced absorption or bioavailability of essential vitamins and minerals- Inadequate intake due to highly restricted or unbalanced diets such as those frequently associated with anorexic conditions and other states of severe malnutrition. Gastrointestinal disorders, chronic alcoholism, chronic or acute infections (especially those involving febrile illness), prolonged or wasting disease, congestive heart failure, hyperthyroidism, poorly controlled diabetes or other physiologic stress. Also, patients on estrogenic oral contraceptives or other estrogen therapy, anti-bacterials which affect intestinal microflora, or other interfering drugs. Certain conditions resulting from severe B-Vitamin or ascorbic acid deficiency- Recovery from surgery or trauma involving severe burns, fractures or other extensive tissue damage. Also, pregnant women and those with heavy menstrual bleeding. uuid:a67c786f-b741-496c-ab5b-e9357bcfb9e8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22652 biolink:treats MONDO:0007079 PMID:41385096 "[{""id"":""uuid:32029c24-7466-44d9-a832-5b6048802ed4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:40f202ae-b80f-47fa-a492-e0b1d1438646"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BACMIN is indicated for prophylactic or therapeutic nutritional supplementation in physiologically stressful conditions. These include: Conditions causing depletion, reduced absorption or bioavailability of essential vitamins and minerals- Inadequate intake due to highly restricted or unbalanced diets such as those frequently associated with anorexic conditions and other states of severe malnutrition. Gastrointestinal disorders, chronic alcoholism, chronic or acute infections (especially those involving febrile illness), prolonged or wasting disease, congestive heart failure, hyperthyroidism, poorly controlled diabetes or other physiologic stress. Also, patients on estrogenic oral contraceptives or other estrogen therapy, anti-bacterials which affect intestinal microflora, or other interfering drugs. Certain conditions resulting from severe B-Vitamin or ascorbic acid deficiency- Recovery from surgery or trauma involving severe burns, fractures or other extensive tissue damage. Also, pregnant women and those with heavy menstrual bleeding. uuid:8b680c02-bb77-4fd5-b497-d46919ccdcae biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22652 biolink:treats UMLS:C0743841 PMID:41385096 "[{""id"":""uuid:773c4dc5-faf2-4378-b14d-977206696adc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:14ade345-9a88-452c-bb53-d8ea03eb7f47"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BACMIN is indicated for prophylactic or therapeutic nutritional supplementation in physiologically stressful conditions. These include: Conditions causing depletion, reduced absorption or bioavailability of essential vitamins and minerals- Inadequate intake due to highly restricted or unbalanced diets such as those frequently associated with anorexic conditions and other states of severe malnutrition. Gastrointestinal disorders, chronic alcoholism, chronic or acute infections (especially those involving febrile illness), prolonged or wasting disease, congestive heart failure, hyperthyroidism, poorly controlled diabetes or other physiologic stress. Also, patients on estrogenic oral contraceptives or other estrogen therapy, anti-bacterials which affect intestinal microflora, or other interfering drugs. Certain conditions resulting from severe B-Vitamin or ascorbic acid deficiency- Recovery from surgery or trauma involving severe burns, fractures or other extensive tissue damage. Also, pregnant women and those with heavy menstrual bleeding. uuid:7ae1e7b4-e639-4cdb-af83-89df29e6bc8b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22652 biolink:treats MONDO:0001327 PMID:41385096 "[{""id"":""uuid:86e35063-fe4b-4e25-94af-1aef85580c22"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:141d694d-64b1-49b9-afc9-66afbdacbb3d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BACMIN is indicated for prophylactic or therapeutic nutritional supplementation in physiologically stressful conditions. These include: Conditions causing depletion, reduced absorption or bioavailability of essential vitamins and minerals- Inadequate intake due to highly restricted or unbalanced diets such as those frequently associated with anorexic conditions and other states of severe malnutrition. Gastrointestinal disorders, chronic alcoholism, chronic or acute infections (especially those involving febrile illness), prolonged or wasting disease, congestive heart failure, hyperthyroidism, poorly controlled diabetes or other physiologic stress. Also, patients on estrogenic oral contraceptives or other estrogen therapy, anti-bacterials which affect intestinal microflora, or other interfering drugs. Certain conditions resulting from severe B-Vitamin or ascorbic acid deficiency- Recovery from surgery or trauma involving severe burns, fractures or other extensive tissue damage. Also, pregnant women and those with heavy menstrual bleeding. uuid:585e81c1-a2e5-490d-9bd5-c99911390da6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22652 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:7899c253-3c11-48d2-9ad9-231f099a7c69"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:55b89bf9-b045-4e63-a0c0-cee22edc31a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BACMIN is indicated for prophylactic or therapeutic nutritional supplementation in physiologically stressful conditions. These include: Conditions causing depletion, reduced absorption or bioavailability of essential vitamins and minerals- Inadequate intake due to highly restricted or unbalanced diets such as those frequently associated with anorexic conditions and other states of severe malnutrition. Gastrointestinal disorders, chronic alcoholism, chronic or acute infections (especially those involving febrile illness), prolonged or wasting disease, congestive heart failure, hyperthyroidism, poorly controlled diabetes or other physiologic stress. Also, patients on estrogenic oral contraceptives or other estrogen therapy, anti-bacterials which affect intestinal microflora, or other interfering drugs. Certain conditions resulting from severe B-Vitamin or ascorbic acid deficiency- Recovery from surgery or trauma involving severe burns, fractures or other extensive tissue damage. Also, pregnant women and those with heavy menstrual bleeding. uuid:1d749a74-6741-4ba3-ba92-e31bf4d9fc5e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22652 biolink:treats MONDO:0004425 PMID:41385096 "[{""id"":""uuid:47749b8d-0108-47ab-b300-8516369c296c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bdd3a35a-63cc-454c-a901-57d080468bf7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BACMIN is indicated for prophylactic or therapeutic nutritional supplementation in physiologically stressful conditions. These include: Conditions causing depletion, reduced absorption or bioavailability of essential vitamins and minerals- Inadequate intake due to highly restricted or unbalanced diets such as those frequently associated with anorexic conditions and other states of severe malnutrition. Gastrointestinal disorders, chronic alcoholism, chronic or acute infections (especially those involving febrile illness), prolonged or wasting disease, congestive heart failure, hyperthyroidism, poorly controlled diabetes or other physiologic stress. Also, patients on estrogenic oral contraceptives or other estrogen therapy, anti-bacterials which affect intestinal microflora, or other interfering drugs. Certain conditions resulting from severe B-Vitamin or ascorbic acid deficiency- Recovery from surgery or trauma involving severe burns, fractures or other extensive tissue damage. Also, pregnant women and those with heavy menstrual bleeding. uuid:70676d6a-0c37-48be-9a98-f2736bb7a400 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22652 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:2879620d-57ae-4d51-b21c-3f7a62147a8f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ca61645f-2525-4c35-9160-b28ae0b02cce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BACMIN is indicated for prophylactic or therapeutic nutritional supplementation in physiologically stressful conditions. These include: Conditions causing depletion, reduced absorption or bioavailability of essential vitamins and minerals- Inadequate intake due to highly restricted or unbalanced diets such as those frequently associated with anorexic conditions and other states of severe malnutrition. Gastrointestinal disorders, chronic alcoholism, chronic or acute infections (especially those involving febrile illness), prolonged or wasting disease, congestive heart failure, hyperthyroidism, poorly controlled diabetes or other physiologic stress. Also, patients on estrogenic oral contraceptives or other estrogen therapy, anti-bacterials which affect intestinal microflora, or other interfering drugs. Certain conditions resulting from severe B-Vitamin or ascorbic acid deficiency- Recovery from surgery or trauma involving severe burns, fractures or other extensive tissue damage. Also, pregnant women and those with heavy menstrual bleeding. uuid:ce5a736c-a828-448e-a200-da8d306856ea biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22652 biolink:treats HP:0020110 PMID:41385096 "[{""id"":""uuid:a23d0324-a0bd-41d4-9dc7-79d70ee484a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d01f6111-21d5-4c4d-9096-149619ce6e86"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BACMIN is indicated for prophylactic or therapeutic nutritional supplementation in physiologically stressful conditions. These include: Conditions causing depletion, reduced absorption or bioavailability of essential vitamins and minerals- Inadequate intake due to highly restricted or unbalanced diets such as those frequently associated with anorexic conditions and other states of severe malnutrition. Gastrointestinal disorders, chronic alcoholism, chronic or acute infections (especially those involving febrile illness), prolonged or wasting disease, congestive heart failure, hyperthyroidism, poorly controlled diabetes or other physiologic stress. Also, patients on estrogenic oral contraceptives or other estrogen therapy, anti-bacterials which affect intestinal microflora, or other interfering drugs. Certain conditions resulting from severe B-Vitamin or ascorbic acid deficiency- Recovery from surgery or trauma involving severe burns, fractures or other extensive tissue damage. Also, pregnant women and those with heavy menstrual bleeding. uuid:3ef32a95-99d8-44a3-8bc4-7b1403809f11 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8707 biolink:treats MONDO:0005090 PMID:41385096 "[{""id"":""uuid:b410744c-89d5-4158-8f92-3eb1be031c76"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:49e8874f-a528-4648-a437-6b44a4d8c9b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Quetiapine Fumarate Tablets are an atypical antipsychotic indicated for the treatment of: • Schizophrenia ( 1.1 ) • Bipolar I disorder manic episodes ( 1.2 ) • Bipolar disorder, depressive episodes ( 1.2 ) uuid:78a4b73f-8371-4c17-907c-efec599b5cd9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8707 biolink:treats MONDO:0004985 PMID:41385096 "[{""id"":""uuid:194f28f9-2b64-4287-ab3f-4386fd14d36e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f95f8192-2eaf-46a3-b3ae-6ee8ac63f3a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:39e7e943-ef6e-45e5-83a2-81a3b7a00f46"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Quetiapine Fumarate Tablets are an atypical antipsychotic indicated for the treatment of: • Schizophrenia ( 1.1 ) • Bipolar I disorder manic episodes ( 1.2 ) • Bipolar disorder, depressive episodes ( 1.2 )|[PMDA] Drugs with a new indication in new dosage form indicated for the improvement of depressive symptoms in patients with bipolar disorder. uuid:9fb2fd61-5190-455e-8cc0-f2ad74e065ce biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:6473866 biolink:treats UMLS:C0345468 PMID:41385096 "[{""id"":""uuid:0a55da03-be59-433a-a3e8-dea1a10cf2d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5c6d57c1-f28b-4a1e-8867-573d9e415c7e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prograf is a calcineurin-inhibitor immunosuppressant indicated for • Prophylaxis of organ rejection in patients receiving allogeneic liver, kidney or heart transplants ( 1.1 , 1.2 , 1.3 ) • Use concomitantly with adrenal corticosteroids; in kidney and heart transplant, use in conjunction with azathioprine or mycophenolate mofetil (MMF) ( 1.1 , 1.2 , 1.3 ) • Limitations of Use ( 1.4 ): ∘ Do not use simultaneously with cyclosporine ∘ Intravenous use reserved for patients who can not tolerate capsules orally ∘ Use with sirolimus is not recommended in liver and heart transplant; use with sirolimus in kidney transplant has not been established uuid:329e0d62-3a52-447b-ab94-3d6a938aab63 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:967089 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:e94f1fa0-1592-40c3-a27a-27316b6e2ada"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:24404d9a-e6da-445e-8f61-4de3428f2872"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Indicated for the treatment of symptoms of irritative voiding. Indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. Indicated for the relief of urinary tract symptoms caused by diagnostic procedures. uuid:21dbf596-7376-4a5f-bdcf-31efb025ec14 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0023628 PMID:41385096 "[{""id"":""uuid:4c6599fa-7eac-4570-add9-08e695174911"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f352c334-0c67-4c77-a9ae-23782e08bc1c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydrocortisone acetate suppositories are indicated for the use in inflamed hemorrhoids, post-irradiation (factitial) proctitis; as an adjunct in the treatment of chronic ulcerative colitis; cryptitis; and other inflammatory conditions of anorectum and puritus ani. uuid:d3c62f51-36c6-493c-82ff-a8ffc37346ad biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2904 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:514063e6-f5de-47c0-b9cb-fca6489bd6ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5a4750e6-8635-4a6c-81c6-89c959054a58"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Atenolol tablets, USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including atenolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (eg, on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Atenolol tablets, USP may be administered with other antihypertensive agents. uuid:d10a243c-b6f4-4acf-aefb-a090469e9282 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2904 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:afaeaf8f-9078-4348-83df-7d5582160c92"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ba246571-f6a0-4f7a-b383-48362d001caf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Atenolol tablets, USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including atenolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (eg, on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Atenolol tablets, USP may be administered with other antihypertensive agents. uuid:11d5dcdf-363b-47f6-8bef-42e3a2e94ad0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4392 biolink:treats MONDO:0019359 PMID:41385096 "[{""id"":""uuid:2f11e0d3-d9e7-4995-8e86-fd98145f1f49"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6f0f4ce4-2ef9-40f4-868d-734e19ee1a8a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of demeclocycline hydrochloride tablets and other antibacterial drugs, demeclocycline hydrochloride tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Demeclocycline hydrochloride is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by rickettsiae; Respiratory tract infections caused by ; Lymphogranuloma venereum due to ; Psittacosis (Ornithosis) due to ; Trachoma due to , although the infectious agent is not always eliminated, as judged by immunofluorescence; Inclusion conjunctivitis caused by ; Nongonococcal urethritis in adults caused by or ; Relapsing fever due to ; Chancroid caused by ; Plague due to ; Tularemia due to ; Cholera caused by ; Campylobacter fetus infections caused by ; Brucellosis due to species (in conjunction with streptomycin); Bartonellosis due to ; Granuloma inguinale caused by ; Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: ; ; species; species; Respiratory tract infections caused by ; Respiratory tract and urinary tract infections caused by species. Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by pneumoniae; Skin and skin structure infections caused by . (Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, tetracyclines, including demeclocycline hydrochloride, are alternative drugs in the treatment of the following infections: Uncomplicated urethritis in men due to , and for the treatment of other uncomplicated gonococcal infections; Infections in women caused by ; Syphilis caused by subspecies ; Yaws caused by subspecies ; Listeriosis due to ; Anthrax due to ; Vincent’s infection caused by ; Actinomycosis caused by ; Clostridial diseases caused by species. In acute intestinal amebiasis, demeclocycline hydrochloride may be a useful adjunct to amebicides. In severe acne, demeclocycline hydrochloride may be a useful adjunctive therapy. Mycoplasma pneumoniae Chlamydia trachomatis Chlamydia psittaci Chlamydia trachomatis Chlamydia trachomatis Ureaplasma urealyticum Chlamydia trachomatis Borrelia recurrentis Haemophilus ducreyi Yersinia pestis Francisella tularensis Vibrio cholerae Campylobacter fetus Brucella Bartonella bacilliformis Calymmatobacterium granulomatis Escherichia coli Enterobacter aerogenes Shigella Acinetobacter Haemophilus influenzae Klebsiella Streptococcus Staphylococcus aureus Neisseria gonorrhoeae Neisseria gonorrhoeae Treponema pallidum pallidum Treponema pallidum pertenue Listeria monocytogenes Bacillus anthracis Fusobacterium fusiforme Actinomyces israelii Clostridium uuid:6bbd0dd0-1686-4cc1-ad3b-690629fba382 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4392 biolink:treats MONDO:0001246 PMID:41385096 "[{""id"":""uuid:3ce9a52a-3c78-43ad-bf48-53d7d1bbef16"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f2f09e24-9da7-404d-a730-c205743fa4e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of demeclocycline hydrochloride tablets and other antibacterial drugs, demeclocycline hydrochloride tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Demeclocycline hydrochloride is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by rickettsiae; Respiratory tract infections caused by ; Lymphogranuloma venereum due to ; Psittacosis (Ornithosis) due to ; Trachoma due to , although the infectious agent is not always eliminated, as judged by immunofluorescence; Inclusion conjunctivitis caused by ; Nongonococcal urethritis in adults caused by or ; Relapsing fever due to ; Chancroid caused by ; Plague due to ; Tularemia due to ; Cholera caused by ; Campylobacter fetus infections caused by ; Brucellosis due to species (in conjunction with streptomycin); Bartonellosis due to ; Granuloma inguinale caused by ; Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: ; ; species; species; Respiratory tract infections caused by ; Respiratory tract and urinary tract infections caused by species. Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by pneumoniae; Skin and skin structure infections caused by . (Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, tetracyclines, including demeclocycline hydrochloride, are alternative drugs in the treatment of the following infections: Uncomplicated urethritis in men due to , and for the treatment of other uncomplicated gonococcal infections; Infections in women caused by ; Syphilis caused by subspecies ; Yaws caused by subspecies ; Listeriosis due to ; Anthrax due to ; Vincent’s infection caused by ; Actinomycosis caused by ; Clostridial diseases caused by species. In acute intestinal amebiasis, demeclocycline hydrochloride may be a useful adjunct to amebicides. In severe acne, demeclocycline hydrochloride may be a useful adjunctive therapy. Mycoplasma pneumoniae Chlamydia trachomatis Chlamydia psittaci Chlamydia trachomatis Chlamydia trachomatis Ureaplasma urealyticum Chlamydia trachomatis Borrelia recurrentis Haemophilus ducreyi Yersinia pestis Francisella tularensis Vibrio cholerae Campylobacter fetus Brucella Bartonella bacilliformis Calymmatobacterium granulomatis Escherichia coli Enterobacter aerogenes Shigella Acinetobacter Haemophilus influenzae Klebsiella Streptococcus Staphylococcus aureus Neisseria gonorrhoeae Neisseria gonorrhoeae Treponema pallidum pallidum Treponema pallidum pertenue Listeria monocytogenes Bacillus anthracis Fusobacterium fusiforme Actinomyces israelii Clostridium uuid:ac94a87e-7d99-47e8-b628-a46bd1a08461 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4392 biolink:treats MONDO:0019186 PMID:41385096 "[{""id"":""uuid:2f11dfb0-79e7-4c05-8bbc-cab600b71d76"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7c163b16-a312-4ab8-9b7e-abe6106ec8d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of demeclocycline hydrochloride tablets and other antibacterial drugs, demeclocycline hydrochloride tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Demeclocycline hydrochloride is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by rickettsiae; Respiratory tract infections caused by ; Lymphogranuloma venereum due to ; Psittacosis (Ornithosis) due to ; Trachoma due to , although the infectious agent is not always eliminated, as judged by immunofluorescence; Inclusion conjunctivitis caused by ; Nongonococcal urethritis in adults caused by or ; Relapsing fever due to ; Chancroid caused by ; Plague due to ; Tularemia due to ; Cholera caused by ; Campylobacter fetus infections caused by ; Brucellosis due to species (in conjunction with streptomycin); Bartonellosis due to ; Granuloma inguinale caused by ; Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: ; ; species; species; Respiratory tract infections caused by ; Respiratory tract and urinary tract infections caused by species. Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by pneumoniae; Skin and skin structure infections caused by . (Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, tetracyclines, including demeclocycline hydrochloride, are alternative drugs in the treatment of the following infections: Uncomplicated urethritis in men due to , and for the treatment of other uncomplicated gonococcal infections; Infections in women caused by ; Syphilis caused by subspecies ; Yaws caused by subspecies ; Listeriosis due to ; Anthrax due to ; Vincent’s infection caused by ; Actinomycosis caused by ; Clostridial diseases caused by species. In acute intestinal amebiasis, demeclocycline hydrochloride may be a useful adjunct to amebicides. In severe acne, demeclocycline hydrochloride may be a useful adjunctive therapy. Mycoplasma pneumoniae Chlamydia trachomatis Chlamydia psittaci Chlamydia trachomatis Chlamydia trachomatis Ureaplasma urealyticum Chlamydia trachomatis Borrelia recurrentis Haemophilus ducreyi Yersinia pestis Francisella tularensis Vibrio cholerae Campylobacter fetus Brucella Bartonella bacilliformis Calymmatobacterium granulomatis Escherichia coli Enterobacter aerogenes Shigella Acinetobacter Haemophilus influenzae Klebsiella Streptococcus Staphylococcus aureus Neisseria gonorrhoeae Neisseria gonorrhoeae Treponema pallidum pallidum Treponema pallidum pertenue Listeria monocytogenes Bacillus anthracis Fusobacterium fusiforme Actinomyces israelii Clostridium uuid:4cfa4468-79e3-4655-a530-59dbf477c0a2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4392 biolink:treats MONDO:0019360 PMID:41385096 "[{""id"":""uuid:b602bb89-0aee-4d5f-a6e3-557a391c353c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c0fcdb75-acd6-4d4e-8af3-aa60dd2e4e67"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of demeclocycline hydrochloride tablets and other antibacterial drugs, demeclocycline hydrochloride tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Demeclocycline hydrochloride is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by rickettsiae; Respiratory tract infections caused by ; Lymphogranuloma venereum due to ; Psittacosis (Ornithosis) due to ; Trachoma due to , although the infectious agent is not always eliminated, as judged by immunofluorescence; Inclusion conjunctivitis caused by ; Nongonococcal urethritis in adults caused by or ; Relapsing fever due to ; Chancroid caused by ; Plague due to ; Tularemia due to ; Cholera caused by ; Campylobacter fetus infections caused by ; Brucellosis due to species (in conjunction with streptomycin); Bartonellosis due to ; Granuloma inguinale caused by ; Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: ; ; species; species; Respiratory tract infections caused by ; Respiratory tract and urinary tract infections caused by species. Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by pneumoniae; Skin and skin structure infections caused by . (Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, tetracyclines, including demeclocycline hydrochloride, are alternative drugs in the treatment of the following infections: Uncomplicated urethritis in men due to , and for the treatment of other uncomplicated gonococcal infections; Infections in women caused by ; Syphilis caused by subspecies ; Yaws caused by subspecies ; Listeriosis due to ; Anthrax due to ; Vincent’s infection caused by ; Actinomycosis caused by ; Clostridial diseases caused by species. In acute intestinal amebiasis, demeclocycline hydrochloride may be a useful adjunct to amebicides. In severe acne, demeclocycline hydrochloride may be a useful adjunctive therapy. Mycoplasma pneumoniae Chlamydia trachomatis Chlamydia psittaci Chlamydia trachomatis Chlamydia trachomatis Ureaplasma urealyticum Chlamydia trachomatis Borrelia recurrentis Haemophilus ducreyi Yersinia pestis Francisella tularensis Vibrio cholerae Campylobacter fetus Brucella Bartonella bacilliformis Calymmatobacterium granulomatis Escherichia coli Enterobacter aerogenes Shigella Acinetobacter Haemophilus influenzae Klebsiella Streptococcus Staphylococcus aureus Neisseria gonorrhoeae Neisseria gonorrhoeae Treponema pallidum pallidum Treponema pallidum pertenue Listeria monocytogenes Bacillus anthracis Fusobacterium fusiforme Actinomyces israelii Clostridium uuid:9587990b-cf5d-4ee4-b644-004acb7ab12c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4392 biolink:treats MONDO:0025294 PMID:41385096 "[{""id"":""uuid:56b81919-f09b-4524-8bf9-88a72b086264"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ff8e8a6b-d83b-4983-bd11-513e46844055"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of demeclocycline hydrochloride tablets and other antibacterial drugs, demeclocycline hydrochloride tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Demeclocycline hydrochloride is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by rickettsiae; Respiratory tract infections caused by ; Lymphogranuloma venereum due to ; Psittacosis (Ornithosis) due to ; Trachoma due to , although the infectious agent is not always eliminated, as judged by immunofluorescence; Inclusion conjunctivitis caused by ; Nongonococcal urethritis in adults caused by or ; Relapsing fever due to ; Chancroid caused by ; Plague due to ; Tularemia due to ; Cholera caused by ; Campylobacter fetus infections caused by ; Brucellosis due to species (in conjunction with streptomycin); Bartonellosis due to ; Granuloma inguinale caused by ; Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: ; ; species; species; Respiratory tract infections caused by ; Respiratory tract and urinary tract infections caused by species. Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by pneumoniae; Skin and skin structure infections caused by . (Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, tetracyclines, including demeclocycline hydrochloride, are alternative drugs in the treatment of the following infections: Uncomplicated urethritis in men due to , and for the treatment of other uncomplicated gonococcal infections; Infections in women caused by ; Syphilis caused by subspecies ; Yaws caused by subspecies ; Listeriosis due to ; Anthrax due to ; Vincent’s infection caused by ; Actinomycosis caused by ; Clostridial diseases caused by species. In acute intestinal amebiasis, demeclocycline hydrochloride may be a useful adjunct to amebicides. In severe acne, demeclocycline hydrochloride may be a useful adjunctive therapy. Mycoplasma pneumoniae Chlamydia trachomatis Chlamydia psittaci Chlamydia trachomatis Chlamydia trachomatis Ureaplasma urealyticum Chlamydia trachomatis Borrelia recurrentis Haemophilus ducreyi Yersinia pestis Francisella tularensis Vibrio cholerae Campylobacter fetus Brucella Bartonella bacilliformis Calymmatobacterium granulomatis Escherichia coli Enterobacter aerogenes Shigella Acinetobacter Haemophilus influenzae Klebsiella Streptococcus Staphylococcus aureus Neisseria gonorrhoeae Neisseria gonorrhoeae Treponema pallidum pallidum Treponema pallidum pertenue Listeria monocytogenes Bacillus anthracis Fusobacterium fusiforme Actinomyces israelii Clostridium uuid:ce3c1745-366b-4866-8d25-29b6d31ac1ba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4392 biolink:treats MONDO:0024355 PMID:41385096 "[{""id"":""uuid:6a293e54-4119-4616-9ce7-c885697e3619"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cead657c-7f21-4048-8427-8726bd1efe49"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of demeclocycline hydrochloride tablets and other antibacterial drugs, demeclocycline hydrochloride tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Demeclocycline hydrochloride is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by rickettsiae; Respiratory tract infections caused by ; Lymphogranuloma venereum due to ; Psittacosis (Ornithosis) due to ; Trachoma due to , although the infectious agent is not always eliminated, as judged by immunofluorescence; Inclusion conjunctivitis caused by ; Nongonococcal urethritis in adults caused by or ; Relapsing fever due to ; Chancroid caused by ; Plague due to ; Tularemia due to ; Cholera caused by ; Campylobacter fetus infections caused by ; Brucellosis due to species (in conjunction with streptomycin); Bartonellosis due to ; Granuloma inguinale caused by ; Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: ; ; species; species; Respiratory tract infections caused by ; Respiratory tract and urinary tract infections caused by species. Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by pneumoniae; Skin and skin structure infections caused by . (Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, tetracyclines, including demeclocycline hydrochloride, are alternative drugs in the treatment of the following infections: Uncomplicated urethritis in men due to , and for the treatment of other uncomplicated gonococcal infections; Infections in women caused by ; Syphilis caused by subspecies ; Yaws caused by subspecies ; Listeriosis due to ; Anthrax due to ; Vincent’s infection caused by ; Actinomycosis caused by ; Clostridial diseases caused by species. In acute intestinal amebiasis, demeclocycline hydrochloride may be a useful adjunct to amebicides. In severe acne, demeclocycline hydrochloride may be a useful adjunctive therapy. Mycoplasma pneumoniae Chlamydia trachomatis Chlamydia psittaci Chlamydia trachomatis Chlamydia trachomatis Ureaplasma urealyticum Chlamydia trachomatis Borrelia recurrentis Haemophilus ducreyi Yersinia pestis Francisella tularensis Vibrio cholerae Campylobacter fetus Brucella Bartonella bacilliformis Calymmatobacterium granulomatis Escherichia coli Enterobacter aerogenes Shigella Acinetobacter Haemophilus influenzae Klebsiella Streptococcus Staphylococcus aureus Neisseria gonorrhoeae Neisseria gonorrhoeae Treponema pallidum pallidum Treponema pallidum pertenue Listeria monocytogenes Bacillus anthracis Fusobacterium fusiforme Actinomyces israelii Clostridium uuid:52290188-7c40-428e-9c0e-c6cc019761df biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4392 biolink:treats MONDO:0005834 PMID:41385096 "[{""id"":""uuid:832b3743-be7b-48d5-bd2f-8c618c67f0a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8fd37c11-48aa-4164-96e2-6cff6ab30f71"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of demeclocycline hydrochloride tablets and other antibacterial drugs, demeclocycline hydrochloride tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Demeclocycline hydrochloride is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by rickettsiae; Respiratory tract infections caused by ; Lymphogranuloma venereum due to ; Psittacosis (Ornithosis) due to ; Trachoma due to , although the infectious agent is not always eliminated, as judged by immunofluorescence; Inclusion conjunctivitis caused by ; Nongonococcal urethritis in adults caused by or ; Relapsing fever due to ; Chancroid caused by ; Plague due to ; Tularemia due to ; Cholera caused by ; Campylobacter fetus infections caused by ; Brucellosis due to species (in conjunction with streptomycin); Bartonellosis due to ; Granuloma inguinale caused by ; Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: ; ; species; species; Respiratory tract infections caused by ; Respiratory tract and urinary tract infections caused by species. Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by pneumoniae; Skin and skin structure infections caused by . (Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, tetracyclines, including demeclocycline hydrochloride, are alternative drugs in the treatment of the following infections: Uncomplicated urethritis in men due to , and for the treatment of other uncomplicated gonococcal infections; Infections in women caused by ; Syphilis caused by subspecies ; Yaws caused by subspecies ; Listeriosis due to ; Anthrax due to ; Vincent’s infection caused by ; Actinomycosis caused by ; Clostridial diseases caused by species. In acute intestinal amebiasis, demeclocycline hydrochloride may be a useful adjunct to amebicides. In severe acne, demeclocycline hydrochloride may be a useful adjunctive therapy. Mycoplasma pneumoniae Chlamydia trachomatis Chlamydia psittaci Chlamydia trachomatis Chlamydia trachomatis Ureaplasma urealyticum Chlamydia trachomatis Borrelia recurrentis Haemophilus ducreyi Yersinia pestis Francisella tularensis Vibrio cholerae Campylobacter fetus Brucella Bartonella bacilliformis Calymmatobacterium granulomatis Escherichia coli Enterobacter aerogenes Shigella Acinetobacter Haemophilus influenzae Klebsiella Streptococcus Staphylococcus aureus Neisseria gonorrhoeae Neisseria gonorrhoeae Treponema pallidum pallidum Treponema pallidum pertenue Listeria monocytogenes Bacillus anthracis Fusobacterium fusiforme Actinomyces israelii Clostridium uuid:dd817f52-2011-49a7-b8e4-e28683513039 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4392 biolink:treats MONDO:0005888 PMID:41385096 "[{""id"":""uuid:fb062f84-6b49-450d-b0ba-59e4c088cb70"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:14ac169b-7244-49c4-a5ed-b2ed0dcd0ed7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of demeclocycline hydrochloride tablets and other antibacterial drugs, demeclocycline hydrochloride tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Demeclocycline hydrochloride is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by rickettsiae; Respiratory tract infections caused by ; Lymphogranuloma venereum due to ; Psittacosis (Ornithosis) due to ; Trachoma due to , although the infectious agent is not always eliminated, as judged by immunofluorescence; Inclusion conjunctivitis caused by ; Nongonococcal urethritis in adults caused by or ; Relapsing fever due to ; Chancroid caused by ; Plague due to ; Tularemia due to ; Cholera caused by ; Campylobacter fetus infections caused by ; Brucellosis due to species (in conjunction with streptomycin); Bartonellosis due to ; Granuloma inguinale caused by ; Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: ; ; species; species; Respiratory tract infections caused by ; Respiratory tract and urinary tract infections caused by species. Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by pneumoniae; Skin and skin structure infections caused by . (Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, tetracyclines, including demeclocycline hydrochloride, are alternative drugs in the treatment of the following infections: Uncomplicated urethritis in men due to , and for the treatment of other uncomplicated gonococcal infections; Infections in women caused by ; Syphilis caused by subspecies ; Yaws caused by subspecies ; Listeriosis due to ; Anthrax due to ; Vincent’s infection caused by ; Actinomycosis caused by ; Clostridial diseases caused by species. In acute intestinal amebiasis, demeclocycline hydrochloride may be a useful adjunct to amebicides. In severe acne, demeclocycline hydrochloride may be a useful adjunctive therapy. Mycoplasma pneumoniae Chlamydia trachomatis Chlamydia psittaci Chlamydia trachomatis Chlamydia trachomatis Ureaplasma urealyticum Chlamydia trachomatis Borrelia recurrentis Haemophilus ducreyi Yersinia pestis Francisella tularensis Vibrio cholerae Campylobacter fetus Brucella Bartonella bacilliformis Calymmatobacterium granulomatis Escherichia coli Enterobacter aerogenes Shigella Acinetobacter Haemophilus influenzae Klebsiella Streptococcus Staphylococcus aureus Neisseria gonorrhoeae Neisseria gonorrhoeae Treponema pallidum pallidum Treponema pallidum pertenue Listeria monocytogenes Bacillus anthracis Fusobacterium fusiforme Actinomyces israelii Clostridium uuid:6d420648-5673-4e52-9d60-0d7902e308c0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4392 biolink:treats MONDO:0001249 PMID:41385096 "[{""id"":""uuid:c150deeb-bef2-4712-8bc7-bbceb2b0be24"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dbacaf03-33c3-4521-8ff1-e3b214e0f3f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of demeclocycline hydrochloride tablets and other antibacterial drugs, demeclocycline hydrochloride tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Demeclocycline hydrochloride is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by rickettsiae; Respiratory tract infections caused by ; Lymphogranuloma venereum due to ; Psittacosis (Ornithosis) due to ; Trachoma due to , although the infectious agent is not always eliminated, as judged by immunofluorescence; Inclusion conjunctivitis caused by ; Nongonococcal urethritis in adults caused by or ; Relapsing fever due to ; Chancroid caused by ; Plague due to ; Tularemia due to ; Cholera caused by ; Campylobacter fetus infections caused by ; Brucellosis due to species (in conjunction with streptomycin); Bartonellosis due to ; Granuloma inguinale caused by ; Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: ; ; species; species; Respiratory tract infections caused by ; Respiratory tract and urinary tract infections caused by species. Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by pneumoniae; Skin and skin structure infections caused by . (Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, tetracyclines, including demeclocycline hydrochloride, are alternative drugs in the treatment of the following infections: Uncomplicated urethritis in men due to , and for the treatment of other uncomplicated gonococcal infections; Infections in women caused by ; Syphilis caused by subspecies ; Yaws caused by subspecies ; Listeriosis due to ; Anthrax due to ; Vincent’s infection caused by ; Actinomycosis caused by ; Clostridial diseases caused by species. In acute intestinal amebiasis, demeclocycline hydrochloride may be a useful adjunct to amebicides. In severe acne, demeclocycline hydrochloride may be a useful adjunctive therapy. Mycoplasma pneumoniae Chlamydia trachomatis Chlamydia psittaci Chlamydia trachomatis Chlamydia trachomatis Ureaplasma urealyticum Chlamydia trachomatis Borrelia recurrentis Haemophilus ducreyi Yersinia pestis Francisella tularensis Vibrio cholerae Campylobacter fetus Brucella Bartonella bacilliformis Calymmatobacterium granulomatis Escherichia coli Enterobacter aerogenes Shigella Acinetobacter Haemophilus influenzae Klebsiella Streptococcus Staphylococcus aureus Neisseria gonorrhoeae Neisseria gonorrhoeae Treponema pallidum pallidum Treponema pallidum pertenue Listeria monocytogenes Bacillus anthracis Fusobacterium fusiforme Actinomyces israelii Clostridium uuid:f3b31f1c-e90b-47f2-ba4f-496e8f62a202 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4392 biolink:treats MONDO:0005808 PMID:41385096 "[{""id"":""uuid:3bbecffc-4858-48e2-9884-7440436fe420"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dce89dd2-4741-4776-b39f-2869e59f6290"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of demeclocycline hydrochloride tablets and other antibacterial drugs, demeclocycline hydrochloride tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Demeclocycline hydrochloride is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by rickettsiae; Respiratory tract infections caused by ; Lymphogranuloma venereum due to ; Psittacosis (Ornithosis) due to ; Trachoma due to , although the infectious agent is not always eliminated, as judged by immunofluorescence; Inclusion conjunctivitis caused by ; Nongonococcal urethritis in adults caused by or ; Relapsing fever due to ; Chancroid caused by ; Plague due to ; Tularemia due to ; Cholera caused by ; Campylobacter fetus infections caused by ; Brucellosis due to species (in conjunction with streptomycin); Bartonellosis due to ; Granuloma inguinale caused by ; Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: ; ; species; species; Respiratory tract infections caused by ; Respiratory tract and urinary tract infections caused by species. Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by pneumoniae; Skin and skin structure infections caused by . (Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, tetracyclines, including demeclocycline hydrochloride, are alternative drugs in the treatment of the following infections: Uncomplicated urethritis in men due to , and for the treatment of other uncomplicated gonococcal infections; Infections in women caused by ; Syphilis caused by subspecies ; Yaws caused by subspecies ; Listeriosis due to ; Anthrax due to ; Vincent’s infection caused by ; Actinomycosis caused by ; Clostridial diseases caused by species. In acute intestinal amebiasis, demeclocycline hydrochloride may be a useful adjunct to amebicides. In severe acne, demeclocycline hydrochloride may be a useful adjunctive therapy. Mycoplasma pneumoniae Chlamydia trachomatis Chlamydia psittaci Chlamydia trachomatis Chlamydia trachomatis Ureaplasma urealyticum Chlamydia trachomatis Borrelia recurrentis Haemophilus ducreyi Yersinia pestis Francisella tularensis Vibrio cholerae Campylobacter fetus Brucella Bartonella bacilliformis Calymmatobacterium granulomatis Escherichia coli Enterobacter aerogenes Shigella Acinetobacter Haemophilus influenzae Klebsiella Streptococcus Staphylococcus aureus Neisseria gonorrhoeae Neisseria gonorrhoeae Treponema pallidum pallidum Treponema pallidum pertenue Listeria monocytogenes Bacillus anthracis Fusobacterium fusiforme Actinomyces israelii Clostridium uuid:9f66716c-f091-49fe-8988-ec343de220c7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4392 biolink:treats MONDO:0005297 PMID:41385096 "[{""id"":""uuid:27eb6122-9a0c-4b21-b605-3702d3717281"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1f9a8f92-c9e5-4509-a8f1-2ad868b605fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of demeclocycline hydrochloride tablets and other antibacterial drugs, demeclocycline hydrochloride tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Demeclocycline hydrochloride is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by rickettsiae; Respiratory tract infections caused by ; Lymphogranuloma venereum due to ; Psittacosis (Ornithosis) due to ; Trachoma due to , although the infectious agent is not always eliminated, as judged by immunofluorescence; Inclusion conjunctivitis caused by ; Nongonococcal urethritis in adults caused by or ; Relapsing fever due to ; Chancroid caused by ; Plague due to ; Tularemia due to ; Cholera caused by ; Campylobacter fetus infections caused by ; Brucellosis due to species (in conjunction with streptomycin); Bartonellosis due to ; Granuloma inguinale caused by ; Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: ; ; species; species; Respiratory tract infections caused by ; Respiratory tract and urinary tract infections caused by species. Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by pneumoniae; Skin and skin structure infections caused by . (Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, tetracyclines, including demeclocycline hydrochloride, are alternative drugs in the treatment of the following infections: Uncomplicated urethritis in men due to , and for the treatment of other uncomplicated gonococcal infections; Infections in women caused by ; Syphilis caused by subspecies ; Yaws caused by subspecies ; Listeriosis due to ; Anthrax due to ; Vincent’s infection caused by ; Actinomycosis caused by ; Clostridial diseases caused by species. In acute intestinal amebiasis, demeclocycline hydrochloride may be a useful adjunct to amebicides. In severe acne, demeclocycline hydrochloride may be a useful adjunctive therapy. Mycoplasma pneumoniae Chlamydia trachomatis Chlamydia psittaci Chlamydia trachomatis Chlamydia trachomatis Ureaplasma urealyticum Chlamydia trachomatis Borrelia recurrentis Haemophilus ducreyi Yersinia pestis Francisella tularensis Vibrio cholerae Campylobacter fetus Brucella Bartonella bacilliformis Calymmatobacterium granulomatis Escherichia coli Enterobacter aerogenes Shigella Acinetobacter Haemophilus influenzae Klebsiella Streptococcus Staphylococcus aureus Neisseria gonorrhoeae Neisseria gonorrhoeae Treponema pallidum pallidum Treponema pallidum pertenue Listeria monocytogenes Bacillus anthracis Fusobacterium fusiforme Actinomyces israelii Clostridium uuid:b1795872-1ca8-4184-aee3-4a634db4099d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4392 biolink:treats MONDO:0019633 PMID:41385096 "[{""id"":""uuid:4543db07-3d2d-44b9-a3cf-ff7b03627e9e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6d96c243-6455-49c4-af0b-413055e12a2e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of demeclocycline hydrochloride tablets and other antibacterial drugs, demeclocycline hydrochloride tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Demeclocycline hydrochloride is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by rickettsiae; Respiratory tract infections caused by ; Lymphogranuloma venereum due to ; Psittacosis (Ornithosis) due to ; Trachoma due to , although the infectious agent is not always eliminated, as judged by immunofluorescence; Inclusion conjunctivitis caused by ; Nongonococcal urethritis in adults caused by or ; Relapsing fever due to ; Chancroid caused by ; Plague due to ; Tularemia due to ; Cholera caused by ; Campylobacter fetus infections caused by ; Brucellosis due to species (in conjunction with streptomycin); Bartonellosis due to ; Granuloma inguinale caused by ; Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: ; ; species; species; Respiratory tract infections caused by ; Respiratory tract and urinary tract infections caused by species. Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by pneumoniae; Skin and skin structure infections caused by . (Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, tetracyclines, including demeclocycline hydrochloride, are alternative drugs in the treatment of the following infections: Uncomplicated urethritis in men due to , and for the treatment of other uncomplicated gonococcal infections; Infections in women caused by ; Syphilis caused by subspecies ; Yaws caused by subspecies ; Listeriosis due to ; Anthrax due to ; Vincent’s infection caused by ; Actinomycosis caused by ; Clostridial diseases caused by species. In acute intestinal amebiasis, demeclocycline hydrochloride may be a useful adjunct to amebicides. In severe acne, demeclocycline hydrochloride may be a useful adjunctive therapy. Mycoplasma pneumoniae Chlamydia trachomatis Chlamydia psittaci Chlamydia trachomatis Chlamydia trachomatis Ureaplasma urealyticum Chlamydia trachomatis Borrelia recurrentis Haemophilus ducreyi Yersinia pestis Francisella tularensis Vibrio cholerae Campylobacter fetus Brucella Bartonella bacilliformis Calymmatobacterium granulomatis Escherichia coli Enterobacter aerogenes Shigella Acinetobacter Haemophilus influenzae Klebsiella Streptococcus Staphylococcus aureus Neisseria gonorrhoeae Neisseria gonorrhoeae Treponema pallidum pallidum Treponema pallidum pertenue Listeria monocytogenes Bacillus anthracis Fusobacterium fusiforme Actinomyces israelii Clostridium uuid:31227e9f-4e4d-4b09-8db7-fef52c659079 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4392 biolink:treats MONDO:0001797 PMID:41385096 "[{""id"":""uuid:92ae4050-155b-4bd2-a456-f71ec8427507"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:22bab058-f18c-4be2-a6c7-431213abb190"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of demeclocycline hydrochloride tablets and other antibacterial drugs, demeclocycline hydrochloride tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Demeclocycline hydrochloride is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by rickettsiae; Respiratory tract infections caused by ; Lymphogranuloma venereum due to ; Psittacosis (Ornithosis) due to ; Trachoma due to , although the infectious agent is not always eliminated, as judged by immunofluorescence; Inclusion conjunctivitis caused by ; Nongonococcal urethritis in adults caused by or ; Relapsing fever due to ; Chancroid caused by ; Plague due to ; Tularemia due to ; Cholera caused by ; Campylobacter fetus infections caused by ; Brucellosis due to species (in conjunction with streptomycin); Bartonellosis due to ; Granuloma inguinale caused by ; Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: ; ; species; species; Respiratory tract infections caused by ; Respiratory tract and urinary tract infections caused by species. Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by pneumoniae; Skin and skin structure infections caused by . (Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, tetracyclines, including demeclocycline hydrochloride, are alternative drugs in the treatment of the following infections: Uncomplicated urethritis in men due to , and for the treatment of other uncomplicated gonococcal infections; Infections in women caused by ; Syphilis caused by subspecies ; Yaws caused by subspecies ; Listeriosis due to ; Anthrax due to ; Vincent’s infection caused by ; Actinomycosis caused by ; Clostridial diseases caused by species. In acute intestinal amebiasis, demeclocycline hydrochloride may be a useful adjunct to amebicides. In severe acne, demeclocycline hydrochloride may be a useful adjunctive therapy. Mycoplasma pneumoniae Chlamydia trachomatis Chlamydia psittaci Chlamydia trachomatis Chlamydia trachomatis Ureaplasma urealyticum Chlamydia trachomatis Borrelia recurrentis Haemophilus ducreyi Yersinia pestis Francisella tularensis Vibrio cholerae Campylobacter fetus Brucella Bartonella bacilliformis Calymmatobacterium granulomatis Escherichia coli Enterobacter aerogenes Shigella Acinetobacter Haemophilus influenzae Klebsiella Streptococcus Staphylococcus aureus Neisseria gonorrhoeae Neisseria gonorrhoeae Treponema pallidum pallidum Treponema pallidum pertenue Listeria monocytogenes Bacillus anthracis Fusobacterium fusiforme Actinomyces israelii Clostridium uuid:8efaefc0-66c8-4a19-9fbd-41f54c10dc90 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4392 biolink:treats MONDO:0019095 PMID:41385096 "[{""id"":""uuid:2369f2b7-ea74-4e62-99c2-b50c920d0d80"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:af0f29a0-d841-4586-b446-0f4a2edb1f2a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of demeclocycline hydrochloride tablets and other antibacterial drugs, demeclocycline hydrochloride tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Demeclocycline hydrochloride is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by rickettsiae; Respiratory tract infections caused by ; Lymphogranuloma venereum due to ; Psittacosis (Ornithosis) due to ; Trachoma due to , although the infectious agent is not always eliminated, as judged by immunofluorescence; Inclusion conjunctivitis caused by ; Nongonococcal urethritis in adults caused by or ; Relapsing fever due to ; Chancroid caused by ; Plague due to ; Tularemia due to ; Cholera caused by ; Campylobacter fetus infections caused by ; Brucellosis due to species (in conjunction with streptomycin); Bartonellosis due to ; Granuloma inguinale caused by ; Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: ; ; species; species; Respiratory tract infections caused by ; Respiratory tract and urinary tract infections caused by species. Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by pneumoniae; Skin and skin structure infections caused by . (Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, tetracyclines, including demeclocycline hydrochloride, are alternative drugs in the treatment of the following infections: Uncomplicated urethritis in men due to , and for the treatment of other uncomplicated gonococcal infections; Infections in women caused by ; Syphilis caused by subspecies ; Yaws caused by subspecies ; Listeriosis due to ; Anthrax due to ; Vincent’s infection caused by ; Actinomycosis caused by ; Clostridial diseases caused by species. In acute intestinal amebiasis, demeclocycline hydrochloride may be a useful adjunct to amebicides. In severe acne, demeclocycline hydrochloride may be a useful adjunctive therapy. Mycoplasma pneumoniae Chlamydia trachomatis Chlamydia psittaci Chlamydia trachomatis Chlamydia trachomatis Ureaplasma urealyticum Chlamydia trachomatis Borrelia recurrentis Haemophilus ducreyi Yersinia pestis Francisella tularensis Vibrio cholerae Campylobacter fetus Brucella Bartonella bacilliformis Calymmatobacterium granulomatis Escherichia coli Enterobacter aerogenes Shigella Acinetobacter Haemophilus influenzae Klebsiella Streptococcus Staphylococcus aureus Neisseria gonorrhoeae Neisseria gonorrhoeae Treponema pallidum pallidum Treponema pallidum pertenue Listeria monocytogenes Bacillus anthracis Fusobacterium fusiforme Actinomyces israelii Clostridium uuid:abd999a1-03ac-4803-a2b7-ecd6c8d71e9b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4392 biolink:treats MONDO:0018077 PMID:41385096 "[{""id"":""uuid:f9ee999a-098d-43b7-9d88-4f4a514db711"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:890140bb-9133-4c0a-a4ed-b8072c6d9721"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of demeclocycline hydrochloride tablets and other antibacterial drugs, demeclocycline hydrochloride tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Demeclocycline hydrochloride is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by rickettsiae; Respiratory tract infections caused by ; Lymphogranuloma venereum due to ; Psittacosis (Ornithosis) due to ; Trachoma due to , although the infectious agent is not always eliminated, as judged by immunofluorescence; Inclusion conjunctivitis caused by ; Nongonococcal urethritis in adults caused by or ; Relapsing fever due to ; Chancroid caused by ; Plague due to ; Tularemia due to ; Cholera caused by ; Campylobacter fetus infections caused by ; Brucellosis due to species (in conjunction with streptomycin); Bartonellosis due to ; Granuloma inguinale caused by ; Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: ; ; species; species; Respiratory tract infections caused by ; Respiratory tract and urinary tract infections caused by species. Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by pneumoniae; Skin and skin structure infections caused by . (Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, tetracyclines, including demeclocycline hydrochloride, are alternative drugs in the treatment of the following infections: Uncomplicated urethritis in men due to , and for the treatment of other uncomplicated gonococcal infections; Infections in women caused by ; Syphilis caused by subspecies ; Yaws caused by subspecies ; Listeriosis due to ; Anthrax due to ; Vincent’s infection caused by ; Actinomycosis caused by ; Clostridial diseases caused by species. In acute intestinal amebiasis, demeclocycline hydrochloride may be a useful adjunct to amebicides. In severe acne, demeclocycline hydrochloride may be a useful adjunctive therapy. Mycoplasma pneumoniae Chlamydia trachomatis Chlamydia psittaci Chlamydia trachomatis Chlamydia trachomatis Ureaplasma urealyticum Chlamydia trachomatis Borrelia recurrentis Haemophilus ducreyi Yersinia pestis Francisella tularensis Vibrio cholerae Campylobacter fetus Brucella Bartonella bacilliformis Calymmatobacterium granulomatis Escherichia coli Enterobacter aerogenes Shigella Acinetobacter Haemophilus influenzae Klebsiella Streptococcus Staphylococcus aureus Neisseria gonorrhoeae Neisseria gonorrhoeae Treponema pallidum pallidum Treponema pallidum pertenue Listeria monocytogenes Bacillus anthracis Fusobacterium fusiforme Actinomyces israelii Clostridium uuid:5d10eb8d-9f4a-4a08-8355-4c31133c157a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4392 biolink:treats MONDO:0015766 PMID:41385096 "[{""id"":""uuid:50e4c056-6d9a-4954-9c80-b60a5b52a76b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:97e4af16-fb53-4b85-b731-24b80020de9d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of demeclocycline hydrochloride tablets and other antibacterial drugs, demeclocycline hydrochloride tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Demeclocycline hydrochloride is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by rickettsiae; Respiratory tract infections caused by ; Lymphogranuloma venereum due to ; Psittacosis (Ornithosis) due to ; Trachoma due to , although the infectious agent is not always eliminated, as judged by immunofluorescence; Inclusion conjunctivitis caused by ; Nongonococcal urethritis in adults caused by or ; Relapsing fever due to ; Chancroid caused by ; Plague due to ; Tularemia due to ; Cholera caused by ; Campylobacter fetus infections caused by ; Brucellosis due to species (in conjunction with streptomycin); Bartonellosis due to ; Granuloma inguinale caused by ; Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: ; ; species; species; Respiratory tract infections caused by ; Respiratory tract and urinary tract infections caused by species. Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by pneumoniae; Skin and skin structure infections caused by . (Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, tetracyclines, including demeclocycline hydrochloride, are alternative drugs in the treatment of the following infections: Uncomplicated urethritis in men due to , and for the treatment of other uncomplicated gonococcal infections; Infections in women caused by ; Syphilis caused by subspecies ; Yaws caused by subspecies ; Listeriosis due to ; Anthrax due to ; Vincent’s infection caused by ; Actinomycosis caused by ; Clostridial diseases caused by species. In acute intestinal amebiasis, demeclocycline hydrochloride may be a useful adjunct to amebicides. In severe acne, demeclocycline hydrochloride may be a useful adjunctive therapy. Mycoplasma pneumoniae Chlamydia trachomatis Chlamydia psittaci Chlamydia trachomatis Chlamydia trachomatis Ureaplasma urealyticum Chlamydia trachomatis Borrelia recurrentis Haemophilus ducreyi Yersinia pestis Francisella tularensis Vibrio cholerae Campylobacter fetus Brucella Bartonella bacilliformis Calymmatobacterium granulomatis Escherichia coli Enterobacter aerogenes Shigella Acinetobacter Haemophilus influenzae Klebsiella Streptococcus Staphylococcus aureus Neisseria gonorrhoeae Neisseria gonorrhoeae Treponema pallidum pallidum Treponema pallidum pertenue Listeria monocytogenes Bacillus anthracis Fusobacterium fusiforme Actinomyces israelii Clostridium uuid:fd079ad2-db61-41af-9a11-19c4b60b975c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4392 biolink:treats MONDO:0040728 PMID:41385096 "[{""id"":""uuid:7b730bc0-c452-486b-9a3d-0c1079e1e161"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:74f7c164-1a92-4ce7-9f15-2cd286c67720"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of demeclocycline hydrochloride tablets and other antibacterial drugs, demeclocycline hydrochloride tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Demeclocycline hydrochloride is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by rickettsiae; Respiratory tract infections caused by ; Lymphogranuloma venereum due to ; Psittacosis (Ornithosis) due to ; Trachoma due to , although the infectious agent is not always eliminated, as judged by immunofluorescence; Inclusion conjunctivitis caused by ; Nongonococcal urethritis in adults caused by or ; Relapsing fever due to ; Chancroid caused by ; Plague due to ; Tularemia due to ; Cholera caused by ; Campylobacter fetus infections caused by ; Brucellosis due to species (in conjunction with streptomycin); Bartonellosis due to ; Granuloma inguinale caused by ; Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: ; ; species; species; Respiratory tract infections caused by ; Respiratory tract and urinary tract infections caused by species. Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by pneumoniae; Skin and skin structure infections caused by . (Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, tetracyclines, including demeclocycline hydrochloride, are alternative drugs in the treatment of the following infections: Uncomplicated urethritis in men due to , and for the treatment of other uncomplicated gonococcal infections; Infections in women caused by ; Syphilis caused by subspecies ; Yaws caused by subspecies ; Listeriosis due to ; Anthrax due to ; Vincent’s infection caused by ; Actinomycosis caused by ; Clostridial diseases caused by species. In acute intestinal amebiasis, demeclocycline hydrochloride may be a useful adjunct to amebicides. In severe acne, demeclocycline hydrochloride may be a useful adjunctive therapy. Mycoplasma pneumoniae Chlamydia trachomatis Chlamydia psittaci Chlamydia trachomatis Chlamydia trachomatis Ureaplasma urealyticum Chlamydia trachomatis Borrelia recurrentis Haemophilus ducreyi Yersinia pestis Francisella tularensis Vibrio cholerae Campylobacter fetus Brucella Bartonella bacilliformis Calymmatobacterium granulomatis Escherichia coli Enterobacter aerogenes Shigella Acinetobacter Haemophilus influenzae Klebsiella Streptococcus Staphylococcus aureus Neisseria gonorrhoeae Neisseria gonorrhoeae Treponema pallidum pallidum Treponema pallidum pertenue Listeria monocytogenes Bacillus anthracis Fusobacterium fusiforme Actinomyces israelii Clostridium uuid:41712b72-6d38-4323-a5a5-b68a95eebafc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4392 biolink:treats MONDO:0005683 PMID:41385096 "[{""id"":""uuid:df4405c5-e9e8-48ae-95bf-85694b3a0a7e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e3052343-706f-4b75-9ad3-ffad488cb9f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of demeclocycline hydrochloride tablets and other antibacterial drugs, demeclocycline hydrochloride tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Demeclocycline hydrochloride is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by rickettsiae; Respiratory tract infections caused by ; Lymphogranuloma venereum due to ; Psittacosis (Ornithosis) due to ; Trachoma due to , although the infectious agent is not always eliminated, as judged by immunofluorescence; Inclusion conjunctivitis caused by ; Nongonococcal urethritis in adults caused by or ; Relapsing fever due to ; Chancroid caused by ; Plague due to ; Tularemia due to ; Cholera caused by ; Campylobacter fetus infections caused by ; Brucellosis due to species (in conjunction with streptomycin); Bartonellosis due to ; Granuloma inguinale caused by ; Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: ; ; species; species; Respiratory tract infections caused by ; Respiratory tract and urinary tract infections caused by species. Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by pneumoniae; Skin and skin structure infections caused by . (Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, tetracyclines, including demeclocycline hydrochloride, are alternative drugs in the treatment of the following infections: Uncomplicated urethritis in men due to , and for the treatment of other uncomplicated gonococcal infections; Infections in women caused by ; Syphilis caused by subspecies ; Yaws caused by subspecies ; Listeriosis due to ; Anthrax due to ; Vincent’s infection caused by ; Actinomycosis caused by ; Clostridial diseases caused by species. In acute intestinal amebiasis, demeclocycline hydrochloride may be a useful adjunct to amebicides. In severe acne, demeclocycline hydrochloride may be a useful adjunctive therapy. Mycoplasma pneumoniae Chlamydia trachomatis Chlamydia psittaci Chlamydia trachomatis Chlamydia trachomatis Ureaplasma urealyticum Chlamydia trachomatis Borrelia recurrentis Haemophilus ducreyi Yersinia pestis Francisella tularensis Vibrio cholerae Campylobacter fetus Brucella Bartonella bacilliformis Calymmatobacterium granulomatis Escherichia coli Enterobacter aerogenes Shigella Acinetobacter Haemophilus influenzae Klebsiella Streptococcus Staphylococcus aureus Neisseria gonorrhoeae Neisseria gonorrhoeae Treponema pallidum pallidum Treponema pallidum pertenue Listeria monocytogenes Bacillus anthracis Fusobacterium fusiforme Actinomyces israelii Clostridium uuid:c759ba1c-8dbe-4aa9-a50c-7b4e16ad6fcc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4392 biolink:treats MONDO:0005664 PMID:41385096 "[{""id"":""uuid:e259d05e-5f94-4c76-bb75-b32efb05edcb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b6847279-8483-4c98-a652-b9674ee4dd7d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of demeclocycline hydrochloride tablets and other antibacterial drugs, demeclocycline hydrochloride tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Demeclocycline hydrochloride is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by rickettsiae; Respiratory tract infections caused by ; Lymphogranuloma venereum due to ; Psittacosis (Ornithosis) due to ; Trachoma due to , although the infectious agent is not always eliminated, as judged by immunofluorescence; Inclusion conjunctivitis caused by ; Nongonococcal urethritis in adults caused by or ; Relapsing fever due to ; Chancroid caused by ; Plague due to ; Tularemia due to ; Cholera caused by ; Campylobacter fetus infections caused by ; Brucellosis due to species (in conjunction with streptomycin); Bartonellosis due to ; Granuloma inguinale caused by ; Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: ; ; species; species; Respiratory tract infections caused by ; Respiratory tract and urinary tract infections caused by species. Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by pneumoniae; Skin and skin structure infections caused by . (Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, tetracyclines, including demeclocycline hydrochloride, are alternative drugs in the treatment of the following infections: Uncomplicated urethritis in men due to , and for the treatment of other uncomplicated gonococcal infections; Infections in women caused by ; Syphilis caused by subspecies ; Yaws caused by subspecies ; Listeriosis due to ; Anthrax due to ; Vincent’s infection caused by ; Actinomycosis caused by ; Clostridial diseases caused by species. In acute intestinal amebiasis, demeclocycline hydrochloride may be a useful adjunct to amebicides. In severe acne, demeclocycline hydrochloride may be a useful adjunctive therapy. Mycoplasma pneumoniae Chlamydia trachomatis Chlamydia psittaci Chlamydia trachomatis Chlamydia trachomatis Ureaplasma urealyticum Chlamydia trachomatis Borrelia recurrentis Haemophilus ducreyi Yersinia pestis Francisella tularensis Vibrio cholerae Campylobacter fetus Brucella Bartonella bacilliformis Calymmatobacterium granulomatis Escherichia coli Enterobacter aerogenes Shigella Acinetobacter Haemophilus influenzae Klebsiella Streptococcus Staphylococcus aureus Neisseria gonorrhoeae Neisseria gonorrhoeae Treponema pallidum pallidum Treponema pallidum pertenue Listeria monocytogenes Bacillus anthracis Fusobacterium fusiforme Actinomyces israelii Clostridium uuid:e3478250-a0b5-4e82-ad28-584c851f9e3b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4392 biolink:treats MONDO:0005777 PMID:41385096 "[{""id"":""uuid:179840c9-93f3-4721-b3ed-e12884b75e59"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b14e9400-ad35-4dfe-b159-37e1499dccb5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of demeclocycline hydrochloride tablets and other antibacterial drugs, demeclocycline hydrochloride tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Demeclocycline hydrochloride is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by rickettsiae; Respiratory tract infections caused by ; Lymphogranuloma venereum due to ; Psittacosis (Ornithosis) due to ; Trachoma due to , although the infectious agent is not always eliminated, as judged by immunofluorescence; Inclusion conjunctivitis caused by ; Nongonococcal urethritis in adults caused by or ; Relapsing fever due to ; Chancroid caused by ; Plague due to ; Tularemia due to ; Cholera caused by ; Campylobacter fetus infections caused by ; Brucellosis due to species (in conjunction with streptomycin); Bartonellosis due to ; Granuloma inguinale caused by ; Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: ; ; species; species; Respiratory tract infections caused by ; Respiratory tract and urinary tract infections caused by species. Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by pneumoniae; Skin and skin structure infections caused by . (Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, tetracyclines, including demeclocycline hydrochloride, are alternative drugs in the treatment of the following infections: Uncomplicated urethritis in men due to , and for the treatment of other uncomplicated gonococcal infections; Infections in women caused by ; Syphilis caused by subspecies ; Yaws caused by subspecies ; Listeriosis due to ; Anthrax due to ; Vincent’s infection caused by ; Actinomycosis caused by ; Clostridial diseases caused by species. In acute intestinal amebiasis, demeclocycline hydrochloride may be a useful adjunct to amebicides. In severe acne, demeclocycline hydrochloride may be a useful adjunctive therapy. Mycoplasma pneumoniae Chlamydia trachomatis Chlamydia psittaci Chlamydia trachomatis Chlamydia trachomatis Ureaplasma urealyticum Chlamydia trachomatis Borrelia recurrentis Haemophilus ducreyi Yersinia pestis Francisella tularensis Vibrio cholerae Campylobacter fetus Brucella Bartonella bacilliformis Calymmatobacterium granulomatis Escherichia coli Enterobacter aerogenes Shigella Acinetobacter Haemophilus influenzae Klebsiella Streptococcus Staphylococcus aureus Neisseria gonorrhoeae Neisseria gonorrhoeae Treponema pallidum pallidum Treponema pallidum pertenue Listeria monocytogenes Bacillus anthracis Fusobacterium fusiforme Actinomyces israelii Clostridium uuid:c3b7d350-e48e-4712-adcf-d58bee570b46 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4392 biolink:treats UMLS:C0041912 PMID:41385096 "[{""id"":""uuid:99eb2b50-d3cd-4bc4-a72c-ba874a7d5721"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4b901689-7221-4263-843d-483399d727cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of demeclocycline hydrochloride tablets and other antibacterial drugs, demeclocycline hydrochloride tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Demeclocycline hydrochloride is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by rickettsiae; Respiratory tract infections caused by ; Lymphogranuloma venereum due to ; Psittacosis (Ornithosis) due to ; Trachoma due to , although the infectious agent is not always eliminated, as judged by immunofluorescence; Inclusion conjunctivitis caused by ; Nongonococcal urethritis in adults caused by or ; Relapsing fever due to ; Chancroid caused by ; Plague due to ; Tularemia due to ; Cholera caused by ; Campylobacter fetus infections caused by ; Brucellosis due to species (in conjunction with streptomycin); Bartonellosis due to ; Granuloma inguinale caused by ; Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: ; ; species; species; Respiratory tract infections caused by ; Respiratory tract and urinary tract infections caused by species. Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by pneumoniae; Skin and skin structure infections caused by . (Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, tetracyclines, including demeclocycline hydrochloride, are alternative drugs in the treatment of the following infections: Uncomplicated urethritis in men due to , and for the treatment of other uncomplicated gonococcal infections; Infections in women caused by ; Syphilis caused by subspecies ; Yaws caused by subspecies ; Listeriosis due to ; Anthrax due to ; Vincent’s infection caused by ; Actinomycosis caused by ; Clostridial diseases caused by species. In acute intestinal amebiasis, demeclocycline hydrochloride may be a useful adjunct to amebicides. In severe acne, demeclocycline hydrochloride may be a useful adjunctive therapy. Mycoplasma pneumoniae Chlamydia trachomatis Chlamydia psittaci Chlamydia trachomatis Chlamydia trachomatis Ureaplasma urealyticum Chlamydia trachomatis Borrelia recurrentis Haemophilus ducreyi Yersinia pestis Francisella tularensis Vibrio cholerae Campylobacter fetus Brucella Bartonella bacilliformis Calymmatobacterium granulomatis Escherichia coli Enterobacter aerogenes Shigella Acinetobacter Haemophilus influenzae Klebsiella Streptococcus Staphylococcus aureus Neisseria gonorrhoeae Neisseria gonorrhoeae Treponema pallidum pallidum Treponema pallidum pertenue Listeria monocytogenes Bacillus anthracis Fusobacterium fusiforme Actinomyces israelii Clostridium uuid:18efbcfc-2871-4a73-8f05-e78d6c06b037 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4392 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:affbf64a-e092-40a4-a5b1-1b557c16ff9c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1fbaefe1-af5b-4088-a966-c186f80f66c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of demeclocycline hydrochloride tablets and other antibacterial drugs, demeclocycline hydrochloride tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Demeclocycline hydrochloride is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by rickettsiae; Respiratory tract infections caused by ; Lymphogranuloma venereum due to ; Psittacosis (Ornithosis) due to ; Trachoma due to , although the infectious agent is not always eliminated, as judged by immunofluorescence; Inclusion conjunctivitis caused by ; Nongonococcal urethritis in adults caused by or ; Relapsing fever due to ; Chancroid caused by ; Plague due to ; Tularemia due to ; Cholera caused by ; Campylobacter fetus infections caused by ; Brucellosis due to species (in conjunction with streptomycin); Bartonellosis due to ; Granuloma inguinale caused by ; Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: ; ; species; species; Respiratory tract infections caused by ; Respiratory tract and urinary tract infections caused by species. Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by pneumoniae; Skin and skin structure infections caused by . (Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, tetracyclines, including demeclocycline hydrochloride, are alternative drugs in the treatment of the following infections: Uncomplicated urethritis in men due to , and for the treatment of other uncomplicated gonococcal infections; Infections in women caused by ; Syphilis caused by subspecies ; Yaws caused by subspecies ; Listeriosis due to ; Anthrax due to ; Vincent’s infection caused by ; Actinomycosis caused by ; Clostridial diseases caused by species. In acute intestinal amebiasis, demeclocycline hydrochloride may be a useful adjunct to amebicides. In severe acne, demeclocycline hydrochloride may be a useful adjunctive therapy. Mycoplasma pneumoniae Chlamydia trachomatis Chlamydia psittaci Chlamydia trachomatis Chlamydia trachomatis Ureaplasma urealyticum Chlamydia trachomatis Borrelia recurrentis Haemophilus ducreyi Yersinia pestis Francisella tularensis Vibrio cholerae Campylobacter fetus Brucella Bartonella bacilliformis Calymmatobacterium granulomatis Escherichia coli Enterobacter aerogenes Shigella Acinetobacter Haemophilus influenzae Klebsiella Streptococcus Staphylococcus aureus Neisseria gonorrhoeae Neisseria gonorrhoeae Treponema pallidum pallidum Treponema pallidum pertenue Listeria monocytogenes Bacillus anthracis Fusobacterium fusiforme Actinomyces israelii Clostridium uuid:c4c6cdad-8a25-4ed1-b11f-33e84eceec5a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4392 biolink:treats MONDO:0004277 PMID:41385096 "[{""id"":""uuid:8b2621f3-bfa7-4859-83b2-2fcd87c006f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b46e9cac-3354-4da8-b1db-9f47fe005a37"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of demeclocycline hydrochloride tablets and other antibacterial drugs, demeclocycline hydrochloride tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Demeclocycline hydrochloride is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by rickettsiae; Respiratory tract infections caused by ; Lymphogranuloma venereum due to ; Psittacosis (Ornithosis) due to ; Trachoma due to , although the infectious agent is not always eliminated, as judged by immunofluorescence; Inclusion conjunctivitis caused by ; Nongonococcal urethritis in adults caused by or ; Relapsing fever due to ; Chancroid caused by ; Plague due to ; Tularemia due to ; Cholera caused by ; Campylobacter fetus infections caused by ; Brucellosis due to species (in conjunction with streptomycin); Bartonellosis due to ; Granuloma inguinale caused by ; Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: ; ; species; species; Respiratory tract infections caused by ; Respiratory tract and urinary tract infections caused by species. Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by pneumoniae; Skin and skin structure infections caused by . (Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, tetracyclines, including demeclocycline hydrochloride, are alternative drugs in the treatment of the following infections: Uncomplicated urethritis in men due to , and for the treatment of other uncomplicated gonococcal infections; Infections in women caused by ; Syphilis caused by subspecies ; Yaws caused by subspecies ; Listeriosis due to ; Anthrax due to ; Vincent’s infection caused by ; Actinomycosis caused by ; Clostridial diseases caused by species. In acute intestinal amebiasis, demeclocycline hydrochloride may be a useful adjunct to amebicides. In severe acne, demeclocycline hydrochloride may be a useful adjunctive therapy. Mycoplasma pneumoniae Chlamydia trachomatis Chlamydia psittaci Chlamydia trachomatis Chlamydia trachomatis Ureaplasma urealyticum Chlamydia trachomatis Borrelia recurrentis Haemophilus ducreyi Yersinia pestis Francisella tularensis Vibrio cholerae Campylobacter fetus Brucella Bartonella bacilliformis Calymmatobacterium granulomatis Escherichia coli Enterobacter aerogenes Shigella Acinetobacter Haemophilus influenzae Klebsiella Streptococcus Staphylococcus aureus Neisseria gonorrhoeae Neisseria gonorrhoeae Treponema pallidum pallidum Treponema pallidum pertenue Listeria monocytogenes Bacillus anthracis Fusobacterium fusiforme Actinomyces israelii Clostridium uuid:50dcff8d-7d74-4706-9ca1-11dd2c3f21bb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4392 biolink:treats MONDO:0005976 PMID:41385096 "[{""id"":""uuid:c2194e22-8645-48ee-900b-ebf8008ff5f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:16f8cdff-e074-4792-a9c0-49ec4a188fb3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of demeclocycline hydrochloride tablets and other antibacterial drugs, demeclocycline hydrochloride tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Demeclocycline hydrochloride is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by rickettsiae; Respiratory tract infections caused by ; Lymphogranuloma venereum due to ; Psittacosis (Ornithosis) due to ; Trachoma due to , although the infectious agent is not always eliminated, as judged by immunofluorescence; Inclusion conjunctivitis caused by ; Nongonococcal urethritis in adults caused by or ; Relapsing fever due to ; Chancroid caused by ; Plague due to ; Tularemia due to ; Cholera caused by ; Campylobacter fetus infections caused by ; Brucellosis due to species (in conjunction with streptomycin); Bartonellosis due to ; Granuloma inguinale caused by ; Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: ; ; species; species; Respiratory tract infections caused by ; Respiratory tract and urinary tract infections caused by species. Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by pneumoniae; Skin and skin structure infections caused by . (Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, tetracyclines, including demeclocycline hydrochloride, are alternative drugs in the treatment of the following infections: Uncomplicated urethritis in men due to , and for the treatment of other uncomplicated gonococcal infections; Infections in women caused by ; Syphilis caused by subspecies ; Yaws caused by subspecies ; Listeriosis due to ; Anthrax due to ; Vincent’s infection caused by ; Actinomycosis caused by ; Clostridial diseases caused by species. In acute intestinal amebiasis, demeclocycline hydrochloride may be a useful adjunct to amebicides. In severe acne, demeclocycline hydrochloride may be a useful adjunctive therapy. Mycoplasma pneumoniae Chlamydia trachomatis Chlamydia psittaci Chlamydia trachomatis Chlamydia trachomatis Ureaplasma urealyticum Chlamydia trachomatis Borrelia recurrentis Haemophilus ducreyi Yersinia pestis Francisella tularensis Vibrio cholerae Campylobacter fetus Brucella Bartonella bacilliformis Calymmatobacterium granulomatis Escherichia coli Enterobacter aerogenes Shigella Acinetobacter Haemophilus influenzae Klebsiella Streptococcus Staphylococcus aureus Neisseria gonorrhoeae Neisseria gonorrhoeae Treponema pallidum pallidum Treponema pallidum pertenue Listeria monocytogenes Bacillus anthracis Fusobacterium fusiforme Actinomyces israelii Clostridium uuid:c519475e-cabb-4503-a66d-fb92e570e8d9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4392 biolink:treats MONDO:0006019 PMID:41385096 "[{""id"":""uuid:6fa450ae-763a-4fcf-a73f-f45ee1f3a910"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dd76ee5f-f55e-4802-9549-42654fbfa5c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of demeclocycline hydrochloride tablets and other antibacterial drugs, demeclocycline hydrochloride tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Demeclocycline hydrochloride is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by rickettsiae; Respiratory tract infections caused by ; Lymphogranuloma venereum due to ; Psittacosis (Ornithosis) due to ; Trachoma due to , although the infectious agent is not always eliminated, as judged by immunofluorescence; Inclusion conjunctivitis caused by ; Nongonococcal urethritis in adults caused by or ; Relapsing fever due to ; Chancroid caused by ; Plague due to ; Tularemia due to ; Cholera caused by ; Campylobacter fetus infections caused by ; Brucellosis due to species (in conjunction with streptomycin); Bartonellosis due to ; Granuloma inguinale caused by ; Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: ; ; species; species; Respiratory tract infections caused by ; Respiratory tract and urinary tract infections caused by species. Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by pneumoniae; Skin and skin structure infections caused by . (Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, tetracyclines, including demeclocycline hydrochloride, are alternative drugs in the treatment of the following infections: Uncomplicated urethritis in men due to , and for the treatment of other uncomplicated gonococcal infections; Infections in women caused by ; Syphilis caused by subspecies ; Yaws caused by subspecies ; Listeriosis due to ; Anthrax due to ; Vincent’s infection caused by ; Actinomycosis caused by ; Clostridial diseases caused by species. In acute intestinal amebiasis, demeclocycline hydrochloride may be a useful adjunct to amebicides. In severe acne, demeclocycline hydrochloride may be a useful adjunctive therapy. Mycoplasma pneumoniae Chlamydia trachomatis Chlamydia psittaci Chlamydia trachomatis Chlamydia trachomatis Ureaplasma urealyticum Chlamydia trachomatis Borrelia recurrentis Haemophilus ducreyi Yersinia pestis Francisella tularensis Vibrio cholerae Campylobacter fetus Brucella Bartonella bacilliformis Calymmatobacterium granulomatis Escherichia coli Enterobacter aerogenes Shigella Acinetobacter Haemophilus influenzae Klebsiella Streptococcus Staphylococcus aureus Neisseria gonorrhoeae Neisseria gonorrhoeae Treponema pallidum pallidum Treponema pallidum pertenue Listeria monocytogenes Bacillus anthracis Fusobacterium fusiforme Actinomyces israelii Clostridium uuid:5e2a380c-f18c-43a2-989c-95735baaae59 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4392 biolink:treats MONDO:0005828 PMID:41385096 "[{""id"":""uuid:3c11f98d-11ce-402c-975b-4a33d1d65373"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cf9ce0b6-17ae-434f-85a8-1426804a01c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of demeclocycline hydrochloride tablets and other antibacterial drugs, demeclocycline hydrochloride tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Demeclocycline hydrochloride is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by rickettsiae; Respiratory tract infections caused by ; Lymphogranuloma venereum due to ; Psittacosis (Ornithosis) due to ; Trachoma due to , although the infectious agent is not always eliminated, as judged by immunofluorescence; Inclusion conjunctivitis caused by ; Nongonococcal urethritis in adults caused by or ; Relapsing fever due to ; Chancroid caused by ; Plague due to ; Tularemia due to ; Cholera caused by ; Campylobacter fetus infections caused by ; Brucellosis due to species (in conjunction with streptomycin); Bartonellosis due to ; Granuloma inguinale caused by ; Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: ; ; species; species; Respiratory tract infections caused by ; Respiratory tract and urinary tract infections caused by species. Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by pneumoniae; Skin and skin structure infections caused by . (Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, tetracyclines, including demeclocycline hydrochloride, are alternative drugs in the treatment of the following infections: Uncomplicated urethritis in men due to , and for the treatment of other uncomplicated gonococcal infections; Infections in women caused by ; Syphilis caused by subspecies ; Yaws caused by subspecies ; Listeriosis due to ; Anthrax due to ; Vincent’s infection caused by ; Actinomycosis caused by ; Clostridial diseases caused by species. In acute intestinal amebiasis, demeclocycline hydrochloride may be a useful adjunct to amebicides. In severe acne, demeclocycline hydrochloride may be a useful adjunctive therapy. Mycoplasma pneumoniae Chlamydia trachomatis Chlamydia psittaci Chlamydia trachomatis Chlamydia trachomatis Ureaplasma urealyticum Chlamydia trachomatis Borrelia recurrentis Haemophilus ducreyi Yersinia pestis Francisella tularensis Vibrio cholerae Campylobacter fetus Brucella Bartonella bacilliformis Calymmatobacterium granulomatis Escherichia coli Enterobacter aerogenes Shigella Acinetobacter Haemophilus influenzae Klebsiella Streptococcus Staphylococcus aureus Neisseria gonorrhoeae Neisseria gonorrhoeae Treponema pallidum pallidum Treponema pallidum pertenue Listeria monocytogenes Bacillus anthracis Fusobacterium fusiforme Actinomyces israelii Clostridium uuid:7c1975bc-4a0a-41cb-ade0-bef91669657c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4392 biolink:treats MONDO:0005119 PMID:41385096 "[{""id"":""uuid:a4fefdc9-142d-495a-842b-c3b00c299f1e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:748242fc-5ae0-4a3e-b8bd-78d44ce012c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of demeclocycline hydrochloride tablets and other antibacterial drugs, demeclocycline hydrochloride tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Demeclocycline hydrochloride is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by rickettsiae; Respiratory tract infections caused by ; Lymphogranuloma venereum due to ; Psittacosis (Ornithosis) due to ; Trachoma due to , although the infectious agent is not always eliminated, as judged by immunofluorescence; Inclusion conjunctivitis caused by ; Nongonococcal urethritis in adults caused by or ; Relapsing fever due to ; Chancroid caused by ; Plague due to ; Tularemia due to ; Cholera caused by ; Campylobacter fetus infections caused by ; Brucellosis due to species (in conjunction with streptomycin); Bartonellosis due to ; Granuloma inguinale caused by ; Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: ; ; species; species; Respiratory tract infections caused by ; Respiratory tract and urinary tract infections caused by species. Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by pneumoniae; Skin and skin structure infections caused by . (Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, tetracyclines, including demeclocycline hydrochloride, are alternative drugs in the treatment of the following infections: Uncomplicated urethritis in men due to , and for the treatment of other uncomplicated gonococcal infections; Infections in women caused by ; Syphilis caused by subspecies ; Yaws caused by subspecies ; Listeriosis due to ; Anthrax due to ; Vincent’s infection caused by ; Actinomycosis caused by ; Clostridial diseases caused by species. In acute intestinal amebiasis, demeclocycline hydrochloride may be a useful adjunct to amebicides. In severe acne, demeclocycline hydrochloride may be a useful adjunctive therapy. Mycoplasma pneumoniae Chlamydia trachomatis Chlamydia psittaci Chlamydia trachomatis Chlamydia trachomatis Ureaplasma urealyticum Chlamydia trachomatis Borrelia recurrentis Haemophilus ducreyi Yersinia pestis Francisella tularensis Vibrio cholerae Campylobacter fetus Brucella Bartonella bacilliformis Calymmatobacterium granulomatis Escherichia coli Enterobacter aerogenes Shigella Acinetobacter Haemophilus influenzae Klebsiella Streptococcus Staphylococcus aureus Neisseria gonorrhoeae Neisseria gonorrhoeae Treponema pallidum pallidum Treponema pallidum pertenue Listeria monocytogenes Bacillus anthracis Fusobacterium fusiforme Actinomyces israelii Clostridium uuid:f03b5523-726e-4275-8df7-8c138c851475 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4392 biolink:treats MONDO:0005631 PMID:41385096 "[{""id"":""uuid:048b2e12-87f5-4a3c-8bfb-453bac43e1b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ee6acc19-a80b-4355-84a0-e2f7d2860a1d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of demeclocycline hydrochloride tablets and other antibacterial drugs, demeclocycline hydrochloride tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Demeclocycline hydrochloride is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by rickettsiae; Respiratory tract infections caused by ; Lymphogranuloma venereum due to ; Psittacosis (Ornithosis) due to ; Trachoma due to , although the infectious agent is not always eliminated, as judged by immunofluorescence; Inclusion conjunctivitis caused by ; Nongonococcal urethritis in adults caused by or ; Relapsing fever due to ; Chancroid caused by ; Plague due to ; Tularemia due to ; Cholera caused by ; Campylobacter fetus infections caused by ; Brucellosis due to species (in conjunction with streptomycin); Bartonellosis due to ; Granuloma inguinale caused by ; Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: ; ; species; species; Respiratory tract infections caused by ; Respiratory tract and urinary tract infections caused by species. Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by pneumoniae; Skin and skin structure infections caused by . (Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, tetracyclines, including demeclocycline hydrochloride, are alternative drugs in the treatment of the following infections: Uncomplicated urethritis in men due to , and for the treatment of other uncomplicated gonococcal infections; Infections in women caused by ; Syphilis caused by subspecies ; Yaws caused by subspecies ; Listeriosis due to ; Anthrax due to ; Vincent’s infection caused by ; Actinomycosis caused by ; Clostridial diseases caused by species. In acute intestinal amebiasis, demeclocycline hydrochloride may be a useful adjunct to amebicides. In severe acne, demeclocycline hydrochloride may be a useful adjunctive therapy. Mycoplasma pneumoniae Chlamydia trachomatis Chlamydia psittaci Chlamydia trachomatis Chlamydia trachomatis Ureaplasma urealyticum Chlamydia trachomatis Borrelia recurrentis Haemophilus ducreyi Yersinia pestis Francisella tularensis Vibrio cholerae Campylobacter fetus Brucella Bartonella bacilliformis Calymmatobacterium granulomatis Escherichia coli Enterobacter aerogenes Shigella Acinetobacter Haemophilus influenzae Klebsiella Streptococcus Staphylococcus aureus Neisseria gonorrhoeae Neisseria gonorrhoeae Treponema pallidum pallidum Treponema pallidum pertenue Listeria monocytogenes Bacillus anthracis Fusobacterium fusiforme Actinomyces israelii Clostridium uuid:ff1e7dc7-b099-47a8-bb6e-8c1188bc8283 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4392 biolink:treats MONDO:0024388 PMID:41385096 "[{""id"":""uuid:6108ea33-1d12-479c-830b-403d65467e82"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f51f3ac6-596d-4060-90ba-4ae96b23576c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of demeclocycline hydrochloride tablets and other antibacterial drugs, demeclocycline hydrochloride tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Demeclocycline hydrochloride is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by rickettsiae; Respiratory tract infections caused by ; Lymphogranuloma venereum due to ; Psittacosis (Ornithosis) due to ; Trachoma due to , although the infectious agent is not always eliminated, as judged by immunofluorescence; Inclusion conjunctivitis caused by ; Nongonococcal urethritis in adults caused by or ; Relapsing fever due to ; Chancroid caused by ; Plague due to ; Tularemia due to ; Cholera caused by ; Campylobacter fetus infections caused by ; Brucellosis due to species (in conjunction with streptomycin); Bartonellosis due to ; Granuloma inguinale caused by ; Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: ; ; species; species; Respiratory tract infections caused by ; Respiratory tract and urinary tract infections caused by species. Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by pneumoniae; Skin and skin structure infections caused by . (Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, tetracyclines, including demeclocycline hydrochloride, are alternative drugs in the treatment of the following infections: Uncomplicated urethritis in men due to , and for the treatment of other uncomplicated gonococcal infections; Infections in women caused by ; Syphilis caused by subspecies ; Yaws caused by subspecies ; Listeriosis due to ; Anthrax due to ; Vincent’s infection caused by ; Actinomycosis caused by ; Clostridial diseases caused by species. In acute intestinal amebiasis, demeclocycline hydrochloride may be a useful adjunct to amebicides. In severe acne, demeclocycline hydrochloride may be a useful adjunctive therapy. Mycoplasma pneumoniae Chlamydia trachomatis Chlamydia psittaci Chlamydia trachomatis Chlamydia trachomatis Ureaplasma urealyticum Chlamydia trachomatis Borrelia recurrentis Haemophilus ducreyi Yersinia pestis Francisella tularensis Vibrio cholerae Campylobacter fetus Brucella Bartonella bacilliformis Calymmatobacterium granulomatis Escherichia coli Enterobacter aerogenes Shigella Acinetobacter Haemophilus influenzae Klebsiella Streptococcus Staphylococcus aureus Neisseria gonorrhoeae Neisseria gonorrhoeae Treponema pallidum pallidum Treponema pallidum pertenue Listeria monocytogenes Bacillus anthracis Fusobacterium fusiforme Actinomyces israelii Clostridium uuid:694620f5-10a2-4c7d-806a-d180a4e8581d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4392 biolink:treats MONDO:0005644 PMID:41385096 "[{""id"":""uuid:c9a3dbea-f920-4e1c-acb0-f776185fb9da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7a73b320-a3da-40fc-8bc6-2cf61129e52c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of demeclocycline hydrochloride tablets and other antibacterial drugs, demeclocycline hydrochloride tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Demeclocycline hydrochloride is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by rickettsiae; Respiratory tract infections caused by ; Lymphogranuloma venereum due to ; Psittacosis (Ornithosis) due to ; Trachoma due to , although the infectious agent is not always eliminated, as judged by immunofluorescence; Inclusion conjunctivitis caused by ; Nongonococcal urethritis in adults caused by or ; Relapsing fever due to ; Chancroid caused by ; Plague due to ; Tularemia due to ; Cholera caused by ; Campylobacter fetus infections caused by ; Brucellosis due to species (in conjunction with streptomycin); Bartonellosis due to ; Granuloma inguinale caused by ; Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: ; ; species; species; Respiratory tract infections caused by ; Respiratory tract and urinary tract infections caused by species. Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by pneumoniae; Skin and skin structure infections caused by . (Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, tetracyclines, including demeclocycline hydrochloride, are alternative drugs in the treatment of the following infections: Uncomplicated urethritis in men due to , and for the treatment of other uncomplicated gonococcal infections; Infections in women caused by ; Syphilis caused by subspecies ; Yaws caused by subspecies ; Listeriosis due to ; Anthrax due to ; Vincent’s infection caused by ; Actinomycosis caused by ; Clostridial diseases caused by species. In acute intestinal amebiasis, demeclocycline hydrochloride may be a useful adjunct to amebicides. In severe acne, demeclocycline hydrochloride may be a useful adjunctive therapy. Mycoplasma pneumoniae Chlamydia trachomatis Chlamydia psittaci Chlamydia trachomatis Chlamydia trachomatis Ureaplasma urealyticum Chlamydia trachomatis Borrelia recurrentis Haemophilus ducreyi Yersinia pestis Francisella tularensis Vibrio cholerae Campylobacter fetus Brucella Bartonella bacilliformis Calymmatobacterium granulomatis Escherichia coli Enterobacter aerogenes Shigella Acinetobacter Haemophilus influenzae Klebsiella Streptococcus Staphylococcus aureus Neisseria gonorrhoeae Neisseria gonorrhoeae Treponema pallidum pallidum Treponema pallidum pertenue Listeria monocytogenes Bacillus anthracis Fusobacterium fusiforme Actinomyces israelii Clostridium uuid:eb592b33-dd6c-45a4-b985-410e9adae3b2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4392 biolink:treats MONDO:0011438 PMID:41385096 "[{""id"":""uuid:4adecdf5-6216-41b3-88c8-1308c5a3bbd9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6d351d8d-6b64-4d01-9781-e76a7d0801b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of demeclocycline hydrochloride tablets and other antibacterial drugs, demeclocycline hydrochloride tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Demeclocycline hydrochloride is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by rickettsiae; Respiratory tract infections caused by ; Lymphogranuloma venereum due to ; Psittacosis (Ornithosis) due to ; Trachoma due to , although the infectious agent is not always eliminated, as judged by immunofluorescence; Inclusion conjunctivitis caused by ; Nongonococcal urethritis in adults caused by or ; Relapsing fever due to ; Chancroid caused by ; Plague due to ; Tularemia due to ; Cholera caused by ; Campylobacter fetus infections caused by ; Brucellosis due to species (in conjunction with streptomycin); Bartonellosis due to ; Granuloma inguinale caused by ; Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: ; ; species; species; Respiratory tract infections caused by ; Respiratory tract and urinary tract infections caused by species. Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by pneumoniae; Skin and skin structure infections caused by . (Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, tetracyclines, including demeclocycline hydrochloride, are alternative drugs in the treatment of the following infections: Uncomplicated urethritis in men due to , and for the treatment of other uncomplicated gonococcal infections; Infections in women caused by ; Syphilis caused by subspecies ; Yaws caused by subspecies ; Listeriosis due to ; Anthrax due to ; Vincent’s infection caused by ; Actinomycosis caused by ; Clostridial diseases caused by species. In acute intestinal amebiasis, demeclocycline hydrochloride may be a useful adjunct to amebicides. In severe acne, demeclocycline hydrochloride may be a useful adjunctive therapy. Mycoplasma pneumoniae Chlamydia trachomatis Chlamydia psittaci Chlamydia trachomatis Chlamydia trachomatis Ureaplasma urealyticum Chlamydia trachomatis Borrelia recurrentis Haemophilus ducreyi Yersinia pestis Francisella tularensis Vibrio cholerae Campylobacter fetus Brucella Bartonella bacilliformis Calymmatobacterium granulomatis Escherichia coli Enterobacter aerogenes Shigella Acinetobacter Haemophilus influenzae Klebsiella Streptococcus Staphylococcus aureus Neisseria gonorrhoeae Neisseria gonorrhoeae Treponema pallidum pallidum Treponema pallidum pertenue Listeria monocytogenes Bacillus anthracis Fusobacterium fusiforme Actinomyces israelii Clostridium uuid:0da5c298-04cb-4a08-96e0-84b9563e4b79 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17544 biolink:treats MONDO:0000440 PMID:41385096 "[{""id"":""uuid:cd847e93-48f1-4a58-9312-0fc567dc2eae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ae4b004e-3dea-4341-86b4-81255c0f5a6c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of blood pigments. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis ― e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO 2 content is crucial ― e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis. uuid:e6180e7b-2ff0-4809-b372-4dcf3c3bbcc5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17544 biolink:treats MONDO:0001106 PMID:41385096 "[{""id"":""uuid:2fd66965-c37a-476a-a578-748d2c94f5ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e13df51a-858d-4100-86ac-20effab648fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of blood pigments. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis ― e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO 2 content is crucial ― e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis. uuid:06455215-6c8f-4423-90a4-e337d7ef49e6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17544 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:a6621a11-3d00-425d-aece-c46700fb9ca5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2a1d9b1a-5a46-4703-9b09-e8426ba5f4cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of blood pigments. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis ― e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO 2 content is crucial ― e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis. uuid:340ab8b5-cd0a-463c-95a6-0bd0b0e84c7d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17544 biolink:treats HP:0031273 PMID:41385096 "[{""id"":""uuid:d1d33ab4-8719-48bc-af37-ba40d75d0c75"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cf2a3229-d29b-414b-b38e-fae878e6a865"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of blood pigments. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis ― e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO 2 content is crucial ― e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis. uuid:3021ee12-95c7-45f6-b8a7-3fb0311cddd4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17544 biolink:treats UMLS:C3472181 PMID:41385096 "[{""id"":""uuid:0296ca43-c437-4400-a08e-1781a259ac8f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0065d742-af9a-499c-868e-5e8919e8fe6c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of blood pigments. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis ― e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO 2 content is crucial ― e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis. uuid:6d24d306-4975-45c1-9b68-d9733bd85bfe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17544 biolink:treats MONDO:0000745 PMID:41385096 "[{""id"":""uuid:c310fb30-d8ec-4d0c-aa99-1e6e640b979a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:86cb6afe-0850-47b5-9f9f-488467816cc5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of blood pigments. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis ― e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO 2 content is crucial ― e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis. uuid:b357d9e2-7a35-4045-a1ee-52c100f3285b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17544 biolink:treats MONDO:0006040 PMID:41385096 "[{""id"":""uuid:5cfd67f3-9623-48f8-92cc-b7bc2917a39a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:196e07f9-ebbd-430c-b54d-aaec45f68bf9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of blood pigments. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis ― e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO 2 content is crucial ― e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis. uuid:201b5ba9-746b-4c85-a8f6-a255643bd707 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17544 biolink:treats EFO:0009574 PMID:41385096 "[{""id"":""uuid:92b395dd-dddb-4676-a091-717c33735ca0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:02f2467a-d6e0-4c3c-b0f3-35248a8e4c30"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of blood pigments. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis ― e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO 2 content is crucial ― e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis. uuid:e4904f13-3cb8-48d6-bfc5-8b1eab886c20 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17544 biolink:treats UMLS:C0161558 PMID:41385096 "[{""id"":""uuid:407f5a1d-3399-4eac-9f3f-f483c09121f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aa8cc079-022c-4327-99b1-96efda89df8c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of blood pigments. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis ― e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO 2 content is crucial ― e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis. uuid:86de4f0b-daac-4808-ae2c-9cd1f5d81379 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17544 biolink:treats UMLS:C0161544 PMID:41385096 "[{""id"":""uuid:4c9d3b93-1f09-472b-966f-d25af3532238"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1748c3a8-e550-4026-9166-1f41370b04e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of blood pigments. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis ― e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO 2 content is crucial ― e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis. uuid:c1a2cb2f-5a27-4600-864f-315533ae7f3e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17544 biolink:treats UMLS:C0161680 PMID:41385096 "[{""id"":""uuid:59f88449-f7b2-499c-bf84-c3403246c144"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:70480277-4329-4159-8b9d-ac0fb292f092"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of blood pigments. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis ― e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO 2 content is crucial ― e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis. uuid:24791b91-5d95-4961-82f5-6407723231fc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17544 biolink:treats UMLS:C0235575 PMID:41385096 "[{""id"":""uuid:331db8ca-bd17-42fd-b9d4-523744926514"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:04bef8f2-311d-488d-ba66-b4049e9ed5ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of blood pigments. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis ― e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO 2 content is crucial ― e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis. uuid:f19aacf5-f7e6-4897-b0c0-24eeee24fe4f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17544 biolink:treats UMLS:C1443924 PMID:41385096 "[{""id"":""uuid:15a1d865-dfc4-4fe1-8109-e73f698488f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a0200b1c-81dc-4e7b-a766-19529effcfc4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of blood pigments. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis ― e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO 2 content is crucial ― e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis. uuid:7161259c-0c68-496d-b4e9-8539e1a6105d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17544 biolink:treats MONDO:0012819 PMID:41385096 "[{""id"":""uuid:fcdf8151-1768-4ebf-8fab-43af4c199d38"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:71d0e156-2562-4b87-8aa4-07bc4ae25e74"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of blood pigments. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis ― e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO 2 content is crucial ― e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis. uuid:ec7e728e-ba9c-44fc-aad4-6f524e31cbfb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6824 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:69da2057-2666-499d-a5dd-be52f223be89"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3afa7170-2e84-4835-8d42-adbe57bab1e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methenamine hippurate tablets, USP are indicated for prophylactic or suppressive treatment of frequently recurring urinary tract infections when long-term therapy is considered necessary. This drug should only be used after eradication of the infection by other appropriate antimicrobial agents. To reduce the development of drug-resistant bacteria and maintain the effectiveness of methenamine hippurate tablets, USP and other antibacterial drugs, methenamine hippurate tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:ea212f09-d0a2-4fbb-b64e-6dc0caa44930 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4975 biolink:treats MONDO:0043839 PMID:41385096 "[{""id"":""uuid:436bf790-c1d6-422a-b5bf-9aa3ba0f76d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:70c1951b-9f7e-4298-9ba7-b644dca1a095"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Famotidine is indicated in: 1. Most adult patients heal within 4 weeks; there is rarely reason to use famotidine at full dosage for longer than 6 to 8 weeks. Studies have not assessed the safety of famotidine in uncomplicated active duodenal ulcer for periods of more than eight weeks. Short-term treatment of active duodenal ulcer. 2. Controlled studies in adults have not extended beyond one year. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of an active ulcer. 3. Most adult patients heal within 6 weeks. Studies have not assessed the safety or efficacy of famotidine in uncomplicated active benign gastric ulcer for periods of more than 8 weeks. Short-term treatment of active benign gastric ulcer. 4. Famotidine is indicated for short-term treatment of patients with symptoms of GERD (see Famotidine is also indicated for the short-term treatment of esophagitis due to GERD including erosive or ulcerative disease diagnosed by endoscopy (see ). Short-term treatment of gastroesophageal reflux disease (GERD). ). CLINICAL PHARMACOLOGY IN ADULTS, Clinical Studies CLINICAL PHARMACOLOGY IN ADULTS, Clinical Studies 5. (see ) Treatment of pathological hypersecretory conditions (e. g., Zollinger-Ellison Syndrome, multiple endocrine adenomas ) CLINICAL PHARMACOLOGY IN ADULTS, Clinical Studies . uuid:3daf2cc2-5b77-45f9-8bef-8475be457750 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:38562 biolink:treats HP:0003124 PMID:41385096 "[{""id"":""uuid:b075b3b4-f161-4885-8e74-d57dc5526d7d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:93691b61-e505-4e46-935e-b20754b83f27"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other non-pharmacologic measures alone has been inadequate. uuid:f08342a9-958a-4550-8fa2-1ef5616e8e79 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0006926 PMID:41385096 "[{""id"":""uuid:23869d8e-f3ca-42d7-917c-e2f2601e5d2f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c630d70a-150d-4fc2-bc29-9e5b22a74b3f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Minocycline hydrochloride capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (Ornithosis) due to Chlamydia psittaci. Trachoma caused by , although the infectious agent is not always eliminated, as judged by immunofluorescence. Chlamydia trachomatis Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by or Ureaplasma urealyticum Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis. Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to species (in conjunction with streptomycin). Brucella Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Calymmatobacterium granulomatis. Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Enterobacter aerogenes. species. Shigella species. Acinetobacter Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by species. Klebsiella Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by . Streptococcus pneumoniae Skin and skin structure infections caused by (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) Staphylococcus aureus. When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to and for the treatment of other gonococcal infections. Neisseria gonorrhoeae Infections in women caused by . Neisseria gonorrhoeae Syphilis caused by subspecies Treponema pallidum pallidum. Yaws caused by subspecies Treponema pallidum pertenue. Listeriosis due to Listeria monocytogenes. Anthrax due to . Bacillus anthracis Vincent’s infection caused by Fusobacterium fusiforme. Actinomycosis caused by Actinomyces israelii. Infections caused by species Clostridium . In acute minocycline may be a useful adjunct to amebicides. intestinal amebiasis, In severe minocycline may be useful adjunctive therapy. acne, Oral minocycline is indicated in the treatment of asymptomatic carriers of to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Neisseria meningitidis Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:8c6c8d9b-3ba2-4848-ab8e-040aaa1c7e01 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:140296 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:36b1192f-9126-42b8-b168-604aab465f9f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6847e828-bddb-4f55-9162-2c5db3fd3f68"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Quinapril hydrochloride is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with quinapril hydrochloride. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Quinapril hydrochloride may be used alone or in combination with thiazide diuretics. uuid:dececaec-2ab3-4171-abde-3b1d7bcfb541 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:140296 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:985da0ee-d91f-4d90-aa73-cb26409a7ab6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:68ba1530-85e5-42a1-bcaa-df3e5a33bb17"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Quinapril hydrochloride is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with quinapril hydrochloride. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Quinapril hydrochloride may be used alone or in combination with thiazide diuretics. uuid:98cff139-d8f1-4cbb-88e0-3188c176ba7c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:140296 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:7595249e-708b-40f9-8425-28d1f79c0947"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:da5a951a-df5e-4516-91ff-ae2a25148f36"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Quinapril hydrochloride is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with quinapril hydrochloride. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Quinapril hydrochloride may be used alone or in combination with thiazide diuretics. uuid:3d431a11-b077-4eb7-8a12-1d766258245d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:140296 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:073a0580-8a3e-4002-89b6-e4a7dd32cd7b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2b1f6e3c-f512-4f65-8022-2c6f83877218"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Quinapril hydrochloride is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with quinapril hydrochloride. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Quinapril hydrochloride may be used alone or in combination with thiazide diuretics. uuid:dc54493c-c39f-4800-bc06-f442eea1796d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:140296 biolink:treats MONDO:0005016 PMID:41385096 "[{""id"":""uuid:8040d233-883c-4199-8f7e-1e4bc9bac298"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:143ba4ed-d7c5-4618-9fe4-7fa3af7f2fec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Quinapril hydrochloride is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with quinapril hydrochloride. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Quinapril hydrochloride may be used alone or in combination with thiazide diuretics. uuid:74277a75-0b0f-452b-8ef4-7103bf731afe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:140296 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:054fe236-b82b-4bc2-ac58-a4816591476c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:424a17b8-174d-49f8-bb60-39c29e929261"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Quinapril hydrochloride is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with quinapril hydrochloride. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Quinapril hydrochloride may be used alone or in combination with thiazide diuretics. uuid:c90e3b00-b6c9-41fd-b574-bdcef6d5d380 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:140296 biolink:treats HP:0001681 PMID:41385096 "[{""id"":""uuid:75690ab2-c177-44de-84f3-8e06257d0e54"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5e900385-395f-4aa6-84b1-e2e4f36db567"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Quinapril hydrochloride is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with quinapril hydrochloride. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Quinapril hydrochloride may be used alone or in combination with thiazide diuretics. uuid:7d06ee30-4528-4d13-a723-af2d7702aa82 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9014 biolink:treats UMLS:C3495832 PMID:41385096 "[{""id"":""uuid:7ce6f921-8d1b-4db3-845f-3866fec16415"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:18691b23-85bd-48b3-b978-65ab2725e0d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of Salsalate tablets, USP and other treatment options before deciding to use Salsalate tablets, USP. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see ). Salsalate is indicated for relief of the signs and symptoms of rheumatoid arthritis, osteoarthritis and related rheumatic disorder. WARNINGS uuid:248be75d-df0f-4498-8c8b-a3ad3cd6ab7f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4315 biolink:treats MONDO:0005133 PMID:41385096 "[{""id"":""uuid:3cd4a826-90f5-4fae-832c-77482b9ca681"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3973ba65-b888-4556-b4f5-292dcf31a9d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endometriosis Danazol capsules are indicated for the treatment of endometriosis amenable to hormonal management. Fibrocystic Breast Disease Most cases of symptomatic fibrocystic breast disease may be treated by simple measures (e.g., padded brassieres and analgesics). In infrequent patients, symptoms of pain and tenderness may be severe enough to warrant treatment by suppression of ovarian function. Danazol capsules are usually effective in decreasing nodularity, pain, and tenderness. It should be stressed to the patient that this treatment is not innocuous in that it involves considerable alterations of hormone levels and that recurrence of symptoms is very common after cessation of therapy. Hereditary Angioedema Danazol capsules are indicated for the prevention of attacks of angioedema of all types (cutaneous, abdominal, laryngeal) in males and females. uuid:a4b8138e-8a65-4d72-9453-a3d05cad0986 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4315 biolink:treats MONDO:0005219 PMID:41385096 "[{""id"":""uuid:9b847b1f-8023-45fe-806b-8a83f2de8a95"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:236e54a0-fb8b-4b17-8e42-aa204542645b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endometriosis Danazol capsules are indicated for the treatment of endometriosis amenable to hormonal management. Fibrocystic Breast Disease Most cases of symptomatic fibrocystic breast disease may be treated by simple measures (e.g., padded brassieres and analgesics). In infrequent patients, symptoms of pain and tenderness may be severe enough to warrant treatment by suppression of ovarian function. Danazol capsules are usually effective in decreasing nodularity, pain, and tenderness. It should be stressed to the patient that this treatment is not innocuous in that it involves considerable alterations of hormone levels and that recurrence of symptoms is very common after cessation of therapy. Hereditary Angioedema Danazol capsules are indicated for the prevention of attacks of angioedema of all types (cutaneous, abdominal, laryngeal) in males and females. uuid:c9b65694-18ed-4936-81fa-19adaea55483 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4315 biolink:treats MONDO:0019623 PMID:41385096 "[{""id"":""uuid:283b3821-7e0a-430e-9eb0-2d404d014e98"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5e2ec6aa-246c-47f2-8192-7e5202f80d53"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endometriosis Danazol capsules are indicated for the treatment of endometriosis amenable to hormonal management. Fibrocystic Breast Disease Most cases of symptomatic fibrocystic breast disease may be treated by simple measures (e.g., padded brassieres and analgesics). In infrequent patients, symptoms of pain and tenderness may be severe enough to warrant treatment by suppression of ovarian function. Danazol capsules are usually effective in decreasing nodularity, pain, and tenderness. It should be stressed to the patient that this treatment is not innocuous in that it involves considerable alterations of hormone levels and that recurrence of symptoms is very common after cessation of therapy. Hereditary Angioedema Danazol capsules are indicated for the prevention of attacks of angioedema of all types (cutaneous, abdominal, laryngeal) in males and females. uuid:0d4291ad-38b9-4502-a798-87996dcf8783 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6909 biolink:treats MONDO:0030720 PMID:41385096 "[{""id"":""uuid:e37bf722-4266-4256-95fe-0618c3895cae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0c8ad24a-d5b9-4ee0-a055-13cdbd0c258b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Metronidazole Tablets USP are indicated for the treatment of infection in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures). T. vaginalis uuid:bcf45a9d-2f77-46e8-b206-dd0538e2636b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:465284 biolink:treats MONDO:0005132 PMID:41385096 "[{""id"":""uuid:4405d5a0-5fe5-48fa-a36e-573a7badd7f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:770536ff-73b0-44e4-8710-f22b0b18afd6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ganciclovir capsules are indicated for the prevention of CMV disease in solid organ transplant recipients and in individuals with advanced HIV infection at risk for developing CMV disease. Ganciclovir capsules are also indicated as an alternative to the intravenous formulation for maintenance treatment of CMV retinitis in immunocompromised patients, including patients with AIDS, in whom retinitis is stable following appropriate induction therapy and for whom the risk of more rapid progression is balanced by the benefit associated with avoiding daily IV infusions (see CLINICAL TRIALS ). SAFETY AND EFFICACY OF GANCICLOVIR HAVE NOT BEEN ESTABLISHED FOR CONGENITAL OR NEONATAL CMV DISEASE; NOT FOR THE TREATMENT OF ESTABLISHED CMV DISEASE OTHER THAN RETINITIS; NOR FOR USE IN NON-IMMUNOCOMPROMISED INDIVIDUALS. THE SAFETY AND EFFICACY OF GANCICLOVIR CAPSULES HAVE NOT BEEN ESTABLISHED FOR TREATING ANY MANIFESTATION OF CMV DISEASE OTHER THAN MAINTENANCE TREATMENT OF CMV RETINITIS. uuid:2f368d21-bde6-4592-a314-71c2efeddbe2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:465284 biolink:treats MONDO:0000878 PMID:41385096 "[{""id"":""uuid:50f3f790-d5a6-4aa8-8aec-a73dfd68b8ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:162fc32c-b0e9-4e31-930d-d1841a6432b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ganciclovir capsules are indicated for the prevention of CMV disease in solid organ transplant recipients and in individuals with advanced HIV infection at risk for developing CMV disease. Ganciclovir capsules are also indicated as an alternative to the intravenous formulation for maintenance treatment of CMV retinitis in immunocompromised patients, including patients with AIDS, in whom retinitis is stable following appropriate induction therapy and for whom the risk of more rapid progression is balanced by the benefit associated with avoiding daily IV infusions (see CLINICAL TRIALS ). SAFETY AND EFFICACY OF GANCICLOVIR HAVE NOT BEEN ESTABLISHED FOR CONGENITAL OR NEONATAL CMV DISEASE; NOT FOR THE TREATMENT OF ESTABLISHED CMV DISEASE OTHER THAN RETINITIS; NOR FOR USE IN NON-IMMUNOCOMPROMISED INDIVIDUALS. THE SAFETY AND EFFICACY OF GANCICLOVIR CAPSULES HAVE NOT BEEN ESTABLISHED FOR TREATING ANY MANIFESTATION OF CMV DISEASE OTHER THAN MAINTENANCE TREATMENT OF CMV RETINITIS. uuid:98734e0c-ce17-463b-a682-54e1c6945e67 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:465284 biolink:treats MONDO:0012268 PMID:41385096 "[{""id"":""uuid:248a57c5-7f24-4e91-811d-71729ba35497"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c8fcfeeb-7756-4e23-96f7-82b2a7521c0c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ganciclovir capsules are indicated for the prevention of CMV disease in solid organ transplant recipients and in individuals with advanced HIV infection at risk for developing CMV disease. Ganciclovir capsules are also indicated as an alternative to the intravenous formulation for maintenance treatment of CMV retinitis in immunocompromised patients, including patients with AIDS, in whom retinitis is stable following appropriate induction therapy and for whom the risk of more rapid progression is balanced by the benefit associated with avoiding daily IV infusions (see CLINICAL TRIALS ). SAFETY AND EFFICACY OF GANCICLOVIR HAVE NOT BEEN ESTABLISHED FOR CONGENITAL OR NEONATAL CMV DISEASE; NOT FOR THE TREATMENT OF ESTABLISHED CMV DISEASE OTHER THAN RETINITIS; NOR FOR USE IN NON-IMMUNOCOMPROMISED INDIVIDUALS. THE SAFETY AND EFFICACY OF GANCICLOVIR CAPSULES HAVE NOT BEEN ESTABLISHED FOR TREATING ANY MANIFESTATION OF CMV DISEASE OTHER THAN MAINTENANCE TREATMENT OF CMV RETINITIS. uuid:92f2c2de-e38e-461f-bacf-97a0fdfe7aea biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16236 biolink:treats MONDO:0004992 PMID:41385096 "[{""id"":""uuid:bf48921c-3490-4273-9103-264932cea1ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:09eb9948-fc02-4a0d-80c3-7c4350d951ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dehydrated Alcohol Injection is indicated for therapeutic neurolysis of nerves or ganglia for the relief of intractable chronic pain in such conditions as inoperable cancer and trigeminal neuralgia (ticdouloureux), in patients for whom neurosurgical procedures are contraindicated. Relief of trigeminal neuralgia usually is only temporary. Other conditions for which injection of alcohol has been reported include glossopharyngeal neuralgia, angina pectoris and severe claudication due to peripheral vascular insufficiency. Alcohol concentrations of 40 to 50% (prepared by appropriate dilution of dehydrated alcohol) have been used for epidural or individual motor nerve injections to control certain manifestations of cerebral palsy and spastic paraplegia. Similar concentrations also have been injected for celiac plexus block to relieve pain of inoperable upper abdominal cancer, and have been injected intra-and subcutaneously for relief of intractable pruritus ani. uuid:a58d1188-c582-4522-b854-16aafa4866c0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16236 biolink:treats MONDO:0008599 PMID:41385096 "[{""id"":""uuid:648b2b31-1753-40d7-9d40-6d1fb205d0bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d3b47e04-3948-4e61-bfca-361d9e730390"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dehydrated Alcohol Injection is indicated for therapeutic neurolysis of nerves or ganglia for the relief of intractable chronic pain in such conditions as inoperable cancer and trigeminal neuralgia (ticdouloureux), in patients for whom neurosurgical procedures are contraindicated. Relief of trigeminal neuralgia usually is only temporary. Other conditions for which injection of alcohol has been reported include glossopharyngeal neuralgia, angina pectoris and severe claudication due to peripheral vascular insufficiency. Alcohol concentrations of 40 to 50% (prepared by appropriate dilution of dehydrated alcohol) have been used for epidural or individual motor nerve injections to control certain manifestations of cerebral palsy and spastic paraplegia. Similar concentrations also have been injected for celiac plexus block to relieve pain of inoperable upper abdominal cancer, and have been injected intra-and subcutaneously for relief of intractable pruritus ani. uuid:cbd34559-a3b6-418a-b7c3-15adb47bc9a6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16236 biolink:treats MONDO:0016372 PMID:41385096 "[{""id"":""uuid:277fcb83-e5f9-40da-bf54-de7829dcc0af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d59ebb0c-23b7-4274-8d57-c23bbb1b1e24"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dehydrated Alcohol Injection is indicated for therapeutic neurolysis of nerves or ganglia for the relief of intractable chronic pain in such conditions as inoperable cancer and trigeminal neuralgia (ticdouloureux), in patients for whom neurosurgical procedures are contraindicated. Relief of trigeminal neuralgia usually is only temporary. Other conditions for which injection of alcohol has been reported include glossopharyngeal neuralgia, angina pectoris and severe claudication due to peripheral vascular insufficiency. Alcohol concentrations of 40 to 50% (prepared by appropriate dilution of dehydrated alcohol) have been used for epidural or individual motor nerve injections to control certain manifestations of cerebral palsy and spastic paraplegia. Similar concentrations also have been injected for celiac plexus block to relieve pain of inoperable upper abdominal cancer, and have been injected intra-and subcutaneously for relief of intractable pruritus ani. uuid:3307a8ac-7945-4ac9-a572-c13f299c6d0a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16236 biolink:treats HP:0001681 PMID:41385096 "[{""id"":""uuid:99acf30b-cfa0-4fcb-8d4b-7f6d317ccbf3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:877a5b01-6b91-4875-9540-9fa4fb9d97a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dehydrated Alcohol Injection is indicated for therapeutic neurolysis of nerves or ganglia for the relief of intractable chronic pain in such conditions as inoperable cancer and trigeminal neuralgia (ticdouloureux), in patients for whom neurosurgical procedures are contraindicated. Relief of trigeminal neuralgia usually is only temporary. Other conditions for which injection of alcohol has been reported include glossopharyngeal neuralgia, angina pectoris and severe claudication due to peripheral vascular insufficiency. Alcohol concentrations of 40 to 50% (prepared by appropriate dilution of dehydrated alcohol) have been used for epidural or individual motor nerve injections to control certain manifestations of cerebral palsy and spastic paraplegia. Similar concentrations also have been injected for celiac plexus block to relieve pain of inoperable upper abdominal cancer, and have been injected intra-and subcutaneously for relief of intractable pruritus ani. uuid:07ce9586-a0d9-42af-992b-cf4d99257f25 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16236 biolink:treats MONDO:0005294 PMID:41385096 "[{""id"":""uuid:81692916-d68b-4517-b300-f091d1ffeba6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8024744c-971a-42b3-adfa-2b2cb37e2bc3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dehydrated Alcohol Injection is indicated for therapeutic neurolysis of nerves or ganglia for the relief of intractable chronic pain in such conditions as inoperable cancer and trigeminal neuralgia (ticdouloureux), in patients for whom neurosurgical procedures are contraindicated. Relief of trigeminal neuralgia usually is only temporary. Other conditions for which injection of alcohol has been reported include glossopharyngeal neuralgia, angina pectoris and severe claudication due to peripheral vascular insufficiency. Alcohol concentrations of 40 to 50% (prepared by appropriate dilution of dehydrated alcohol) have been used for epidural or individual motor nerve injections to control certain manifestations of cerebral palsy and spastic paraplegia. Similar concentrations also have been injected for celiac plexus block to relieve pain of inoperable upper abdominal cancer, and have been injected intra-and subcutaneously for relief of intractable pruritus ani. uuid:b3a153a0-a193-4cd4-ab88-6cd1bffeb138 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16236 biolink:treats MONDO:0006497 PMID:41385096 "[{""id"":""uuid:e3f2a9ff-9185-4b5f-8209-d4d955694c0b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:21c63cd0-df4a-4f29-9172-cf92ab95f03a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dehydrated Alcohol Injection is indicated for therapeutic neurolysis of nerves or ganglia for the relief of intractable chronic pain in such conditions as inoperable cancer and trigeminal neuralgia (ticdouloureux), in patients for whom neurosurgical procedures are contraindicated. Relief of trigeminal neuralgia usually is only temporary. Other conditions for which injection of alcohol has been reported include glossopharyngeal neuralgia, angina pectoris and severe claudication due to peripheral vascular insufficiency. Alcohol concentrations of 40 to 50% (prepared by appropriate dilution of dehydrated alcohol) have been used for epidural or individual motor nerve injections to control certain manifestations of cerebral palsy and spastic paraplegia. Similar concentrations also have been injected for celiac plexus block to relieve pain of inoperable upper abdominal cancer, and have been injected intra-and subcutaneously for relief of intractable pruritus ani. uuid:f446a26c-0406-4a31-92d6-42006af937f6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16236 biolink:treats HP:0001258 PMID:41385096 "[{""id"":""uuid:1c36bb3c-2eb1-4580-b196-74da3aeae60d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6c03334c-f699-48bb-94c4-b3f3398571e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dehydrated Alcohol Injection is indicated for therapeutic neurolysis of nerves or ganglia for the relief of intractable chronic pain in such conditions as inoperable cancer and trigeminal neuralgia (ticdouloureux), in patients for whom neurosurgical procedures are contraindicated. Relief of trigeminal neuralgia usually is only temporary. Other conditions for which injection of alcohol has been reported include glossopharyngeal neuralgia, angina pectoris and severe claudication due to peripheral vascular insufficiency. Alcohol concentrations of 40 to 50% (prepared by appropriate dilution of dehydrated alcohol) have been used for epidural or individual motor nerve injections to control certain manifestations of cerebral palsy and spastic paraplegia. Similar concentrations also have been injected for celiac plexus block to relieve pain of inoperable upper abdominal cancer, and have been injected intra-and subcutaneously for relief of intractable pruritus ani. uuid:066adacc-44e5-47a4-aa57-c5a846a25be6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3738 biolink:treats MONDO:0011786 PMID:41385096 "[{""id"":""uuid:36daa268-1aac-4426-b2ef-46e6fb5b1250"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c5cd8447-54f0-4091-bedd-a627d8990e21"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clemastine Fumarate Tablets 1.34 mg are indicated for the relief of symptoms associated with allergic rhinitis such as sneezing, rhinorrhea, pruritus, and lacrimation. Clemastine Fumarate Tablets 2.68 mg are indicated for the relief of symptoms associated with allergic rhinitis such as sneezing, rhinorrhea, pruritus, and lacrimation. Clemastine Fumarate Tablets 2.68 mg are also indicated for the relief of mild, uncomplicated allergic skin manifestations of urticaria and angioedema. It should be noted that clemastine fumarate is indicated for the dermatologic indications at the 2.68 mg dosage level only. uuid:e75b4a51-eb0e-40df-a5df-3ada4beb737d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3738 biolink:treats MONDO:0005492 PMID:41385096 "[{""id"":""uuid:a43dfbad-dc04-49f1-a2f4-7e09572cbf94"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3dcd9496-2351-4f10-9581-4b82ec7f644f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clemastine Fumarate Tablets 1.34 mg are indicated for the relief of symptoms associated with allergic rhinitis such as sneezing, rhinorrhea, pruritus, and lacrimation. Clemastine Fumarate Tablets 2.68 mg are indicated for the relief of symptoms associated with allergic rhinitis such as sneezing, rhinorrhea, pruritus, and lacrimation. Clemastine Fumarate Tablets 2.68 mg are also indicated for the relief of mild, uncomplicated allergic skin manifestations of urticaria and angioedema. It should be noted that clemastine fumarate is indicated for the dermatologic indications at the 2.68 mg dosage level only. uuid:9cc9641d-e1c7-491d-afe5-8b9282a2f9d6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3738 biolink:treats MONDO:0010481 PMID:41385096 "[{""id"":""uuid:b8527d99-fd10-463f-a19d-41b962c047ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:35ef7888-2158-466e-9a43-fc437ca87f69"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clemastine Fumarate Tablets 1.34 mg are indicated for the relief of symptoms associated with allergic rhinitis such as sneezing, rhinorrhea, pruritus, and lacrimation. Clemastine Fumarate Tablets 2.68 mg are indicated for the relief of symptoms associated with allergic rhinitis such as sneezing, rhinorrhea, pruritus, and lacrimation. Clemastine Fumarate Tablets 2.68 mg are also indicated for the relief of mild, uncomplicated allergic skin manifestations of urticaria and angioedema. It should be noted that clemastine fumarate is indicated for the dermatologic indications at the 2.68 mg dosage level only. uuid:dea63fc5-a452-4c2e-94ee-5e47338b0584 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63618 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:a16cdabf-7875-4c14-920b-2ae22e9d23eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:88ed5eb6-2b95-418a-bc41-8fffde192e35"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. Prevention of Cardiovascular Disease In hypercholesterolemic patients without clinically evident coronary heart disease (CHD), pravastatin sodium tablets are indicated to: reduce the risk of myocardial infarction (MI). reduce the risk of undergoing myocardial revascularization procedures. reduce the risk of cardiovascular mortality with no increase in death from non-cardiovascular causes. Hyperlipidemia Pravastatin sodium tablets are indicated: as an adjunct to diet to reduce elevated total cholesterol (Total-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (ApoB), and triglyceride (TG) levels and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson Types IIa and IIb).1 as an adjunct to diet for the treatment of patients with elevated serum TG levels (Fredrickson Type IV). for the treatment of patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet. as an adjunct to diet and lifestyle modification for treatment of heterozygous familial hypercholesterolemia (HeFH) in children and adolescent patients ages 8 years and older if after an adequate trial of diet the following findings are present: a. LDL-C remains ≥ 190 mg/dL or b. LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease (CVD) or two or more other CVD risk factors are present in the patient. Limitations of Use Pravastatin sodium has not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V). uuid:6a321c28-f82b-48b4-8984-3e2f2d55399c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7476 biolink:treats MONDO:0005578 PMID:41385096 "[{""id"":""uuid:f647e59e-34b0-49dc-8933-0876b187c7b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:36e44475-a367-42a3-aef4-9ee3b78925f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Active ingredient (in each tablet) Naproxen sodium 220 mg (naproxen 200 mg) (NSAID)* *nonsteroidal anti-inflammatory drug Purpose Pain reliever/fever reducer Uses •temporarily relieves minor aches and pains due to: •minor pain of arthritis •muscular aches •backache •menstrual cramps •headache •toothache •the common cold •temporarily reduces fever uuid:f1916634-9695-4c86-af00-52c68d3c74bd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7476 biolink:treats HP:0003326 PMID:41385096 "[{""id"":""uuid:efe1ef7b-28ae-4965-a27c-e952e84788ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:08a3ef2a-db40-4b47-a9f2-129852ff5f19"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Active ingredient (in each tablet) Naproxen sodium 220 mg (naproxen 200 mg) (NSAID)* *nonsteroidal anti-inflammatory drug Purpose Pain reliever/fever reducer Uses •temporarily relieves minor aches and pains due to: •minor pain of arthritis •muscular aches •backache •menstrual cramps •headache •toothache •the common cold •temporarily reduces fever uuid:e9a94752-20b2-40f9-8545-770fa6fb5094 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7476 biolink:treats HP:0003418 PMID:41385096 "[{""id"":""uuid:20e8189f-a46f-43f1-b000-6701681acecb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:80eea4e1-f4cc-44ee-949d-4a60f991db1f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Active ingredient (in each tablet) Naproxen sodium 220 mg (naproxen 200 mg) (NSAID)* *nonsteroidal anti-inflammatory drug Purpose Pain reliever/fever reducer Uses •temporarily relieves minor aches and pains due to: •minor pain of arthritis •muscular aches •backache •menstrual cramps •headache •toothache •the common cold •temporarily reduces fever uuid:e1c1fa84-ceb9-4c29-9d93-49f721b69f2c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7476 biolink:treats HP:0100607 PMID:41385096 "[{""id"":""uuid:bb53c435-7c34-46a0-be57-eee489a80ae6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7030ea36-5c9b-4b30-9fb1-4b14bee34881"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Active ingredient (in each tablet) Naproxen sodium 220 mg (naproxen 200 mg) (NSAID)* *nonsteroidal anti-inflammatory drug Purpose Pain reliever/fever reducer Uses •temporarily relieves minor aches and pains due to: •minor pain of arthritis •muscular aches •backache •menstrual cramps •headache •toothache •the common cold •temporarily reduces fever uuid:a2ca5962-d48b-4b4b-a3be-b5d258bb2615 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7476 biolink:treats HP:0002315 PMID:41385096 "[{""id"":""uuid:5adad575-0f6e-4d30-b438-223bc1c8c379"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5f04d2da-f24f-4c54-bfe0-e15f2b6ead97"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Active ingredient (in each tablet) Naproxen sodium 220 mg (naproxen 200 mg) (NSAID)* *nonsteroidal anti-inflammatory drug Purpose Pain reliever/fever reducer Uses •temporarily relieves minor aches and pains due to: •minor pain of arthritis •muscular aches •backache •menstrual cramps •headache •toothache •the common cold •temporarily reduces fever uuid:4fb4b616-d9e7-45bf-a3af-12ef4bcc4dd4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7476 biolink:treats EFO:0010072 PMID:41385096 "[{""id"":""uuid:ed416054-ee85-4441-970c-5552d3abf673"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cc0fb6d3-70da-4af1-adb3-3b3d873d6590"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Active ingredient (in each tablet) Naproxen sodium 220 mg (naproxen 200 mg) (NSAID)* *nonsteroidal anti-inflammatory drug Purpose Pain reliever/fever reducer Uses •temporarily relieves minor aches and pains due to: •minor pain of arthritis •muscular aches •backache •menstrual cramps •headache •toothache •the common cold •temporarily reduces fever uuid:a9ac1357-61bf-4582-812f-b2d6b6e9f3c9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7476 biolink:treats MONDO:0005709 PMID:41385096 "[{""id"":""uuid:9f87aa51-ddf5-4820-8f0a-00802862c214"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9704d672-1a27-4155-a650-6e1bea01525a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Active ingredient (in each tablet) Naproxen sodium 220 mg (naproxen 200 mg) (NSAID)* *nonsteroidal anti-inflammatory drug Purpose Pain reliever/fever reducer Uses •temporarily relieves minor aches and pains due to: •minor pain of arthritis •muscular aches •backache •menstrual cramps •headache •toothache •the common cold •temporarily reduces fever uuid:9b3de907-5acf-4d82-b6b2-cb8dbbc4640f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7476 biolink:treats HP:0001945 PMID:41385096 "[{""id"":""uuid:85eb8ba0-d6d2-4221-a7d4-0e22ce7b0802"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:71f9a500-cd06-4d15-8f5a-c28b16fa4d5e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Active ingredient (in each tablet) Naproxen sodium 220 mg (naproxen 200 mg) (NSAID)* *nonsteroidal anti-inflammatory drug Purpose Pain reliever/fever reducer Uses •temporarily relieves minor aches and pains due to: •minor pain of arthritis •muscular aches •backache •menstrual cramps •headache •toothache •the common cold •temporarily reduces fever uuid:cac45d2e-76f6-4c4c-aed2-c791a317ee87 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15940 biolink:treats MONDO:0004995 PMID:41385096 "[{""id"":""uuid:219b5fc1-99a9-4f26-ac98-7c2eb7f3d018"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8087c2e0-98ae-411f-8b88-66a446dfa5d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hyperlipidemia. Niacin therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. NIASPAN is indicated to reduce elevated TC, LDL-C, Apo B and TG levels, and to increase HDL-C in patients with primary hyperlipidemia and mixed dyslipidemia. NIASPAN in combination with simvastatin or lovastatin is indicated for the treatment of primary hyperlipidemia and mixed dyslipidemia when treatment with NIASPAN, simvastatin, or lovastatin monotherapy is considered inadequate. In patients with a history of myocardial infarction and hyperlipidemia, niacin is indicated to reduce the risk of recurrent nonfatal myocardial infarction. In patients with a history of coronary artery disease (CAD) and hyperlipidemia, niacin, in combination with a bile acid binding resin, is indicated to slow progression or promote regression of atherosclerotic disease. NIASPAN in combination with a bile acid binding resin is indicated to reduce elevated TC and LDL-C levels in adult patients with primary hyperlipidemia. Niacin is also indicated as adjunctive therapy for treatment of adult patients with severe hypertriglyceridemia who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Limitations of Use No incremental benefit of NIASPAN coadministered with simvastatin or lovastatin on cardiovascular morbidity and mortality over and above that demonstrated for niacin, simvastatin, or lovastatin monotherapy has been established. NIASPAN, at doses of 1,500-2,000 mg/day, in combination with simvastatin, did not reduce the incidence of cardiovascular events more than simvastatin in a randomized controlled trial of patients with cardiovascular disease and mean baseline LDL-C levels of 74 mg per deciliter . [see Warnings and Precautions ] (5.1) uuid:9f686a05-9186-41b2-8d33-9d5aa7649395 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50841 biolink:treats MONDO:0005090 PMID:41385096 "[{""id"":""uuid:cf12bac9-56c7-43ba-859e-4a581b1aac3a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:4246f988-5cdd-41b6-bc24-e0733e7dffb3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:6d2a2e9f-ec2f-46d7-84e2-a1b3d597ccd9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/adasuve""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Loxapine Capsules USP are indicated for the treatment of schizophrenia. The efficacy of loxapine in schizophrenia was established in clinical studies which enrolled newly hospitalized and chronically hospitalized acutely ill schizophrenic patients as subjects.|[EMA] Adasuve is indicated for the rapid control of mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder. Patients should receive regular treatment immediately after control of acute agitation symptoms. uuid:e41cfe5f-930d-43c8-9a71-c2a5cd2edf58 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7770 biolink:treats MONDO:0005101 PMID:41385096 "[{""id"":""uuid:bcf01e5f-3a58-4f53-9d21-4c2b437ef007"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c746007d-7989-4490-9905-ccd62cb5b480"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Olsalazine is indicated for the maintenance of remission of ulcerative colitis in patients who are intolerant of sulfasalazine. uuid:9dc8b66d-5413-49bb-a4c7-7313605c4203 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47499 biolink:treats MONDO:0000022 PMID:41385096 "[{""id"":""uuid:0267903b-38a2-4f12-a681-cd3c063aa5f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c3276b8f-b26b-4759-be8f-c8877ea98091"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the relief of symptoms of depression. Endogenous depression is more likely to be alleviated than other depressive states. One to three weeks of treatment may be needed before optimal therapeutic effects are evident. Depression: May be useful as temporary adjunctive therapy in reducing enuresis in children aged 6 years and older, after possible organic causes have been excludedby appropriate tests. In patients having daytime symptoms of frequency and urgency, examination should include voiding cystourethrography and cystoscopy, as necessary. The effectiveness of treatment may decrease with continued drug administration. Childhood Enuresis: uuid:fe9d0c77-c9bc-41bd-872c-a190eac0e7a9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7662KG2R6K biolink:treats MONDO:0100187 PMID:41385096 "[{""id"":""uuid:52091cbd-839a-41da-890d-b584eee28886"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5e02824c-f7f5-4937-afe8-743b3b795476"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amitiza is a chloride channel activator indicated for: Treatment of chronic idiopathic constipation in adults • (1.1) Treatment of opioid-induced constipation in adults with chronic, non-cancer pain ( ) • 1.2 Treatment of irritable bowel syndrome with constipation in women ≥ 18 years old • (1.3) Limitations of Use: Effectiveness of Amitiza in the treatment of opioid-induced constipation in patients taking diphenylheptane opioids (e.g., methadone) has not been established ( ) ( ) 1 14.2 uuid:156cb304-3968-460b-906d-ed14d7a40e73 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7565 biolink:treats UMLS:C0577698 PMID:41385096 "[{""id"":""uuid:a9cb30b1-6d20-43a1-ad7d-cf4c3ccaccb6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1f7bdb93-5e06-4716-b969-519fa00e220e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] I. Vasospastic Angina Nifedipine is indicated for the management of vasospastic angina confirmed by any of the following criteria: 1) classical pattern of angina at rest accompanied by ST segment elevation, 2) angina or coronary artery spasm provoked by ergonovine, or 3) angiographically demonstrated coronary artery spasm. In those patients who have had angiography, the presence of significant fixed obstructive disease is not incompatible with the diagnosis of vasospastic angina, provided that the above criteria are satisfied. Nifedipine may also be used where the clinical presentation suggests a possible vasospastic component but where vasospasm has not been confirmed, e.g., where pain has a variable threshold on exertion or when angina is refractory to nitrates and/or adequate doses of beta blockers. II. Chronic Stable Angina (Classical Effort-Associated Angina) Nifedipine is indicated for the management of chronic stable angina (effort-associated angina) without evidence of vasospasm in patients who remain symptomatic despite adequate doses of beta blockers and/or organic nitrates or who cannot tolerate those agents. In chronic stable angina (effort-associated angina) nifedipine has been effective in controlled trials of up to eight weeks duration in reducing angina frequency and increasing exercise tolerance, but confirmation of sustained effectiveness and evaluation of long-term safety in these patients are incomplete. Controlled studies in small numbers of patients suggest concomitant use of nifedipine and betablocking agents may be beneficial in patients with chronic stable angina, but available information is not sufficient to predict with confidence the effects of concurrent treatment, especially in patients with compromised left ventricular function or cardiac conduction abnormalities. When introducing such concomitant therapy, care must be taken to monitor blood pressure closely since severe hypotension can occur from the combined effects of the drugs. (See ). WARNINGS uuid:792d1889-3e04-4202-9e5e-f8740a61e372 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5779 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:e33303a8-eb2f-4d0f-bebb-833e55efc94a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:92643516-d75b-4f3d-91a2-d9011ab01ea6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZOHYDRO ® ER (hydrocodone bitartrate) is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Limitations of Use Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations, reserve ZOHYDRO ER for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. ZOHYDRO ER is not indicated as an as-needed (prn) analgesic. uuid:74fccade-cd54-448d-ad28-bb1cd555361f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6073 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:1e932771-4996-4c0b-8d43-72f0db66b1f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f3d2eff1-1e37-4dd2-884e-fc94125e49ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Isradipine is indicated in the management of hypertension. It may be used alone or concurrently with thiazide-type diuretics. uuid:b6312ef6-1ff4-438f-8e6c-de5df1fbbdd2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49575 biolink:treats MONDO:0011918 PMID:41385096 "[{""id"":""uuid:2e44d81a-2e3b-4fe3-a2a2-7cc8921a5fbe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fee22c72-a2cf-4584-b679-257dd422e660"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diazepam Tablets USP are indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. In acute alcohol withdrawal, Diazepam Tablets USP may be useful in the symptomatic relief of acute agitation, tremor, impending or acute delirium tremens and hallucinosis. Diazepam Tablets USP are a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology (such as inflammation of the muscles or joints, or secondary to trauma), spasticity caused by upper motor neuron disorders (such as cerebral palsy and paraplegia), athetosis, and stiff-man syndrome. Oral diazepam may be used adjunctively in convulsive disorders, although it has not proved useful as the sole therapy. The effectiveness of Diazepam Tablets USP in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient. uuid:592cc149-5879-4dfd-9f17-ac6f7a2f6673 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5123 biolink:treats MONDO:0005485 PMID:41385096 "[{""id"":""uuid:88841db2-966f-4b9a-b2a1-28ffdc2cebfa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:73d8f403-c263-4dd8-b568-8b044896288b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fluphenazine HCl is indicated in the management of manifestations of psychotic disorders. Fluphenazine HCl has not been shown effective in the management of behavioral complications in patients with mental retardation. uuid:7b1d7a9a-1c21-4f43-80a3-118583da308e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5123 biolink:treats MONDO:0001071 PMID:41385096 "[{""id"":""uuid:200d5df5-d5f4-404c-85eb-082e6e958942"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8685cad9-c298-4947-a027-91ed239e4d98"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fluphenazine HCl is indicated in the management of manifestations of psychotic disorders. Fluphenazine HCl has not been shown effective in the management of behavioral complications in patients with mental retardation. uuid:d1955098-20a5-47b1-81da-0d53facc38ec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:42797 biolink:treats MONDO:0021667 PMID:41385096 "[{""id"":""uuid:c9ca4b4a-0e02-4091-a03a-538ec8ac803f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a8dab633-8c82-4026-98d3-7605df033465"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Postherpetic Neuralgia Gabapentin is indicated for the management of postherpetic neuralgia in adults. uuid:f4730cb4-176b-4d22-8b2d-d42ad4e0e190 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3534 biolink:treats MONDO:0006878 PMID:41385096 "[{""id"":""uuid:edd9f51a-0db8-4192-b105-335feeef56b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:28a434f0-2296-4e0d-b28c-b44df446cb91"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cephalexin capsules are indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms: Respiratory tract infections caused by and (Penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cephalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present.) Streptococcus pneumoniae Streptococcus pyogenes Otitis media due to Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, Streptococcus pyogenes, and Moraxella catarrhalis Skin and skin structure infections caused by and/or Staphylococcus aureus Streptococcus pyogenes Bone infections caused by and/or Staphylococcus aureus Proteus mirabilis Genitourinary tract infections, including acute prostatitis, caused by Escherichia coli, Proteus mirabilis, and Klebsiella pneumoniae Culture and susceptibility tests should be initiated prior to and during therapy. Renal function studies should be performed when indicated. Note: To reduce the development of drug-resistant bacteria and maintain the effectiveness of cephalexin and other antibacterial drugs, cephalexin capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:03f19d60-74ed-4fab-b7ea-aa82b48d6fc0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5004 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:30c63580-b718-4f2f-963f-b17071c266cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:139e8fd9-b341-4ff2-8eff-08fe5bf7f0a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of Fenoprofen Calcium and other treatment options before deciding to use Fenoprofen Calcium. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Fenoprofen Calcium is indicated: For relief of mild to moderate pain in adults. For relief of the signs and symptoms of rheumatoid arthritis. For relief of the signs and symptoms of osteoarthritis. uuid:de804c13-4128-428f-afbf-ba8a3fdd111a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5004 biolink:treats MONDO:0005178 PMID:41385096 "[{""id"":""uuid:79750b72-b0d5-449d-9793-43e653913ccc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2f8b7824-f679-47f9-bc4b-bc0d54860543"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of Fenoprofen Calcium and other treatment options before deciding to use Fenoprofen Calcium. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Fenoprofen Calcium is indicated: For relief of mild to moderate pain in adults. For relief of the signs and symptoms of rheumatoid arthritis. For relief of the signs and symptoms of osteoarthritis. uuid:13378b98-bf97-4d7d-acca-cd7bf57022c6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5004 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:b8e8d2b0-b24b-4f79-ae81-e8301235d1f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1a149768-d3b4-40ba-acf7-fd4da34e2542"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of Fenoprofen Calcium and other treatment options before deciding to use Fenoprofen Calcium. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Fenoprofen Calcium is indicated: For relief of mild to moderate pain in adults. For relief of the signs and symptoms of rheumatoid arthritis. For relief of the signs and symptoms of osteoarthritis. uuid:1e81a097-6168-4512-ba6d-7db2ed7e5e24 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10119 biolink:treats MONDO:0005478 PMID:41385096 "[{""id"":""uuid:b265f321-6ded-4533-a1c3-92e60033fb32"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2f2207d6-b362-4418-b0ea-45c99ca56bca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ziprasidone hydrochloride capsules are indicated for the treatment of schizophrenia. When deciding among the alternative treatments available for the condition needing treatment, the prescriber should consider the finding of ziprasidone's greater capacity to prolong the QT/QTc interval compared to several other antipsychotic drugs [see ]. Prolongation of the QTc interval is associated in some other drugs with the ability to cause torsade de pointes-type arrhythmia, a potentially fatal polymorphic ventricular tachycardia, and sudden death. In many cases this would lead to the conclusion that other drugs should be tried first. Whether ziprasidone will cause torsade de pointes or increase the rate of sudden death is not yet known [see ] WARNINGS AND PRECAUTIONS ( ) 5.2 WARNINGS AND PRECAUTIONS ( ) 5.2 uuid:e821828c-9134-42cf-bfd8-7b39a63d1c04 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10119 biolink:treats MONDO:0005477 PMID:41385096 "[{""id"":""uuid:d7fa08c3-ba9c-4423-9ff1-ef948c808b51"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2a6c2e4a-fce5-44fd-bfab-177aa690bf0c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ziprasidone hydrochloride capsules are indicated for the treatment of schizophrenia. When deciding among the alternative treatments available for the condition needing treatment, the prescriber should consider the finding of ziprasidone's greater capacity to prolong the QT/QTc interval compared to several other antipsychotic drugs [see ]. Prolongation of the QTc interval is associated in some other drugs with the ability to cause torsade de pointes-type arrhythmia, a potentially fatal polymorphic ventricular tachycardia, and sudden death. In many cases this would lead to the conclusion that other drugs should be tried first. Whether ziprasidone will cause torsade de pointes or increase the rate of sudden death is not yet known [see ] WARNINGS AND PRECAUTIONS ( ) 5.2 WARNINGS AND PRECAUTIONS ( ) 5.2 uuid:3ccf2c9a-2a45-4a9c-b55d-b905a4fcd034 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3766 biolink:treats MONDO:0005090 PMID:41385096 "[{""id"":""uuid:f7cf9b5f-f39d-4a11-a834-3d08dcb1e7d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2a9b9b1d-b78b-4051-9ec8-7f3815ef4a57"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:39a2f61f-2d8e-4ef3-a651-0b7c9de97e02"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CLOZARIL is an atypical antipsychotic indicated for: Treatment-resistant schizophrenia. Efficacy was established in an active-controlled study. ( , ) 1.1 14.1 Reducing suicidal behavior in patients with schizophrenia or schizoaffective disorder. Efficacy was established in an active-controlled study. ( , ) 1.2 14.2|[PMDA] Drugs with a new active ingredient indicated for the treatment of treatment-resistant schizophrenia. uuid:f4b8e31b-7555-4d38-ad4b-f7347c9b7e88 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3766 biolink:treats MONDO:0005487 PMID:41385096 "[{""id"":""uuid:e3089b0d-177f-44b2-85cb-bd4f3d7f90c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e27d2b71-b591-40c2-b4b8-1df75592425a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CLOZARIL is an atypical antipsychotic indicated for: Treatment-resistant schizophrenia. Efficacy was established in an active-controlled study. ( , ) 1.1 14.1 Reducing suicidal behavior in patients with schizophrenia or schizoaffective disorder. Efficacy was established in an active-controlled study. ( , ) 1.2 14.2 uuid:4a1b2054-6887-4dda-a5ae-0457d6abc251 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3485 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:2bc49312-8747-4b85-95d3-ce127e84c2c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:41af0470-63c1-462e-b4ac-1b6885288ea5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefdinir capsules and other antibacterial drugs, cefdinir capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Cefdinir capsules are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Adults and Adolescents Community-Acquired Pneumonia caused by Haemophilus influenzae (including β-lactamase producing strains), Haemophilus parainfluenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains) (see CLINICAL STUDIES). Acute Exacerbations of Chronic Bronchitis caused by Haemophilus influenzae (including β-lactamase producing strains), Haemophilus parainfluenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains). Acute Maxillary Sinusitis caused by Haemophilus influenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains). NOTE: For information on use in pediatric patients, see Pediatric Use and DOSAGE ANDADMINISTRATION. Pharyngitis/Tonsillitis caused by Streptococcus pyogenes (see CLINICAL STUDIES). NOTE: Cefdinir is effective in the eradication of S. pyogenes from the oropharynx. Cefdinir has not, however, been studied for the prevention of rheumatic fever following S. pyogenes pharyngitis/tonsillitis. Only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever. Uncomplicated Skin and Skin Structure Infections caused by Staphylococcus aureus (including β-lactamase producing strains) and Streptococcus pyogenes. Pediatric Patients Acute Bacterial Otitis Media caused by Haemophilus influenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains). Pharyngitis/Tonsillitis caused by Streptococcus pyogenes (see CLINICAL STUDIES). NOTE: Cefdinir is effective in the eradication of S. pyogenes from the oropharynx. Cefdinir has not, however, been studied for the prevention of rheumatic fever following S. pyogenes pharyngitis/tonsillitis. Only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever. Uncomplicated Skin and Skin Structure Infections caused by Staphylococcus aureus (including β-lactamase producing strains) and Streptococcus pyogenes. uuid:0593a4bb-ddc4-4cb7-9311-7d23d009ffbe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3485 biolink:treats UMLS:C0853854 PMID:41385096 "[{""id"":""uuid:777df6ee-1880-4f6e-bb4e-8d9ae5d718cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8be05314-850c-4f90-990b-c4a106cc7923"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefdinir capsules and other antibacterial drugs, cefdinir capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Cefdinir capsules are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Adults and Adolescents Community-Acquired Pneumonia caused by Haemophilus influenzae (including β-lactamase producing strains), Haemophilus parainfluenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains) (see CLINICAL STUDIES). Acute Exacerbations of Chronic Bronchitis caused by Haemophilus influenzae (including β-lactamase producing strains), Haemophilus parainfluenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains). Acute Maxillary Sinusitis caused by Haemophilus influenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains). NOTE: For information on use in pediatric patients, see Pediatric Use and DOSAGE ANDADMINISTRATION. Pharyngitis/Tonsillitis caused by Streptococcus pyogenes (see CLINICAL STUDIES). NOTE: Cefdinir is effective in the eradication of S. pyogenes from the oropharynx. Cefdinir has not, however, been studied for the prevention of rheumatic fever following S. pyogenes pharyngitis/tonsillitis. Only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever. Uncomplicated Skin and Skin Structure Infections caused by Staphylococcus aureus (including β-lactamase producing strains) and Streptococcus pyogenes. Pediatric Patients Acute Bacterial Otitis Media caused by Haemophilus influenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains). Pharyngitis/Tonsillitis caused by Streptococcus pyogenes (see CLINICAL STUDIES). NOTE: Cefdinir is effective in the eradication of S. pyogenes from the oropharynx. Cefdinir has not, however, been studied for the prevention of rheumatic fever following S. pyogenes pharyngitis/tonsillitis. Only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever. Uncomplicated Skin and Skin Structure Infections caused by Staphylococcus aureus (including β-lactamase producing strains) and Streptococcus pyogenes. uuid:4eb8f550-d646-42b1-85f5-8ee9b522fbf6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3485 biolink:treats MONDO:0002186 PMID:41385096 "[{""id"":""uuid:1da12d00-0e67-4304-a4b8-5190214c25ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c05c5983-88bc-4938-a588-f11f1c3a78ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefdinir capsules and other antibacterial drugs, cefdinir capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Cefdinir capsules are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Adults and Adolescents Community-Acquired Pneumonia caused by Haemophilus influenzae (including β-lactamase producing strains), Haemophilus parainfluenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains) (see CLINICAL STUDIES). Acute Exacerbations of Chronic Bronchitis caused by Haemophilus influenzae (including β-lactamase producing strains), Haemophilus parainfluenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains). Acute Maxillary Sinusitis caused by Haemophilus influenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains). NOTE: For information on use in pediatric patients, see Pediatric Use and DOSAGE ANDADMINISTRATION. Pharyngitis/Tonsillitis caused by Streptococcus pyogenes (see CLINICAL STUDIES). NOTE: Cefdinir is effective in the eradication of S. pyogenes from the oropharynx. Cefdinir has not, however, been studied for the prevention of rheumatic fever following S. pyogenes pharyngitis/tonsillitis. Only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever. Uncomplicated Skin and Skin Structure Infections caused by Staphylococcus aureus (including β-lactamase producing strains) and Streptococcus pyogenes. Pediatric Patients Acute Bacterial Otitis Media caused by Haemophilus influenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains). Pharyngitis/Tonsillitis caused by Streptococcus pyogenes (see CLINICAL STUDIES). NOTE: Cefdinir is effective in the eradication of S. pyogenes from the oropharynx. Cefdinir has not, however, been studied for the prevention of rheumatic fever following S. pyogenes pharyngitis/tonsillitis. Only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever. Uncomplicated Skin and Skin Structure Infections caused by Staphylococcus aureus (including β-lactamase producing strains) and Streptococcus pyogenes. uuid:dce38225-cdd7-4501-b238-f6e7e1273fe7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3485 biolink:treats MONDO:0002258 PMID:41385096 "[{""id"":""uuid:91eb0f9f-2c2c-452a-92d4-62e3faa0a5ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b8c5a1cf-3cf8-4107-9258-9604d9fe96ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefdinir capsules and other antibacterial drugs, cefdinir capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Cefdinir capsules are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Adults and Adolescents Community-Acquired Pneumonia caused by Haemophilus influenzae (including β-lactamase producing strains), Haemophilus parainfluenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains) (see CLINICAL STUDIES). Acute Exacerbations of Chronic Bronchitis caused by Haemophilus influenzae (including β-lactamase producing strains), Haemophilus parainfluenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains). Acute Maxillary Sinusitis caused by Haemophilus influenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains). NOTE: For information on use in pediatric patients, see Pediatric Use and DOSAGE ANDADMINISTRATION. Pharyngitis/Tonsillitis caused by Streptococcus pyogenes (see CLINICAL STUDIES). NOTE: Cefdinir is effective in the eradication of S. pyogenes from the oropharynx. Cefdinir has not, however, been studied for the prevention of rheumatic fever following S. pyogenes pharyngitis/tonsillitis. Only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever. Uncomplicated Skin and Skin Structure Infections caused by Staphylococcus aureus (including β-lactamase producing strains) and Streptococcus pyogenes. Pediatric Patients Acute Bacterial Otitis Media caused by Haemophilus influenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains). Pharyngitis/Tonsillitis caused by Streptococcus pyogenes (see CLINICAL STUDIES). NOTE: Cefdinir is effective in the eradication of S. pyogenes from the oropharynx. Cefdinir has not, however, been studied for the prevention of rheumatic fever following S. pyogenes pharyngitis/tonsillitis. Only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever. Uncomplicated Skin and Skin Structure Infections caused by Staphylococcus aureus (including β-lactamase producing strains) and Streptococcus pyogenes. uuid:b7482c26-8266-43aa-bb97-9ebd027dfda1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3485 biolink:treats MONDO:0001039 PMID:41385096 "[{""id"":""uuid:41d897c8-c631-4234-b0f2-cfe1d2a4024a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6397e7b4-8b31-40b9-a5f1-08a9b558c6a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefdinir capsules and other antibacterial drugs, cefdinir capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Cefdinir capsules are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Adults and Adolescents Community-Acquired Pneumonia caused by Haemophilus influenzae (including β-lactamase producing strains), Haemophilus parainfluenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains) (see CLINICAL STUDIES). Acute Exacerbations of Chronic Bronchitis caused by Haemophilus influenzae (including β-lactamase producing strains), Haemophilus parainfluenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains). Acute Maxillary Sinusitis caused by Haemophilus influenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains). NOTE: For information on use in pediatric patients, see Pediatric Use and DOSAGE ANDADMINISTRATION. Pharyngitis/Tonsillitis caused by Streptococcus pyogenes (see CLINICAL STUDIES). NOTE: Cefdinir is effective in the eradication of S. pyogenes from the oropharynx. Cefdinir has not, however, been studied for the prevention of rheumatic fever following S. pyogenes pharyngitis/tonsillitis. Only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever. Uncomplicated Skin and Skin Structure Infections caused by Staphylococcus aureus (including β-lactamase producing strains) and Streptococcus pyogenes. Pediatric Patients Acute Bacterial Otitis Media caused by Haemophilus influenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains). Pharyngitis/Tonsillitis caused by Streptococcus pyogenes (see CLINICAL STUDIES). NOTE: Cefdinir is effective in the eradication of S. pyogenes from the oropharynx. Cefdinir has not, however, been studied for the prevention of rheumatic fever following S. pyogenes pharyngitis/tonsillitis. Only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever. Uncomplicated Skin and Skin Structure Infections caused by Staphylococcus aureus (including β-lactamase producing strains) and Streptococcus pyogenes. uuid:92d9ebf2-d71e-41f2-8557-763567a5484e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3485 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:3e17153f-6a21-46b8-ab6a-01d45220db48"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4d868f4d-561c-49cc-af91-45734e3f3906"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefdinir capsules and other antibacterial drugs, cefdinir capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Cefdinir capsules are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Adults and Adolescents Community-Acquired Pneumonia caused by Haemophilus influenzae (including β-lactamase producing strains), Haemophilus parainfluenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains) (see CLINICAL STUDIES). Acute Exacerbations of Chronic Bronchitis caused by Haemophilus influenzae (including β-lactamase producing strains), Haemophilus parainfluenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains). Acute Maxillary Sinusitis caused by Haemophilus influenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains). NOTE: For information on use in pediatric patients, see Pediatric Use and DOSAGE ANDADMINISTRATION. Pharyngitis/Tonsillitis caused by Streptococcus pyogenes (see CLINICAL STUDIES). NOTE: Cefdinir is effective in the eradication of S. pyogenes from the oropharynx. Cefdinir has not, however, been studied for the prevention of rheumatic fever following S. pyogenes pharyngitis/tonsillitis. Only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever. Uncomplicated Skin and Skin Structure Infections caused by Staphylococcus aureus (including β-lactamase producing strains) and Streptococcus pyogenes. Pediatric Patients Acute Bacterial Otitis Media caused by Haemophilus influenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains). Pharyngitis/Tonsillitis caused by Streptococcus pyogenes (see CLINICAL STUDIES). NOTE: Cefdinir is effective in the eradication of S. pyogenes from the oropharynx. Cefdinir has not, however, been studied for the prevention of rheumatic fever following S. pyogenes pharyngitis/tonsillitis. Only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever. Uncomplicated Skin and Skin Structure Infections caused by Staphylococcus aureus (including β-lactamase producing strains) and Streptococcus pyogenes. uuid:6c985376-3c5c-49d1-aadb-eeaf0c0355ca biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3485 biolink:treats MONDO:0001031 PMID:41385096 "[{""id"":""uuid:015c17e4-c598-4a21-baa0-4a122b136bdb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f8eb15bd-b52c-47c6-b89f-10840f7693a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefdinir capsules and other antibacterial drugs, cefdinir capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Cefdinir capsules are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Adults and Adolescents Community-Acquired Pneumonia caused by Haemophilus influenzae (including β-lactamase producing strains), Haemophilus parainfluenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains) (see CLINICAL STUDIES). Acute Exacerbations of Chronic Bronchitis caused by Haemophilus influenzae (including β-lactamase producing strains), Haemophilus parainfluenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains). Acute Maxillary Sinusitis caused by Haemophilus influenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains). NOTE: For information on use in pediatric patients, see Pediatric Use and DOSAGE ANDADMINISTRATION. Pharyngitis/Tonsillitis caused by Streptococcus pyogenes (see CLINICAL STUDIES). NOTE: Cefdinir is effective in the eradication of S. pyogenes from the oropharynx. Cefdinir has not, however, been studied for the prevention of rheumatic fever following S. pyogenes pharyngitis/tonsillitis. Only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever. Uncomplicated Skin and Skin Structure Infections caused by Staphylococcus aureus (including β-lactamase producing strains) and Streptococcus pyogenes. Pediatric Patients Acute Bacterial Otitis Media caused by Haemophilus influenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains). Pharyngitis/Tonsillitis caused by Streptococcus pyogenes (see CLINICAL STUDIES). NOTE: Cefdinir is effective in the eradication of S. pyogenes from the oropharynx. Cefdinir has not, however, been studied for the prevention of rheumatic fever following S. pyogenes pharyngitis/tonsillitis. Only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever. Uncomplicated Skin and Skin Structure Infections caused by Staphylococcus aureus (including β-lactamase producing strains) and Streptococcus pyogenes. uuid:8945f9bd-e8e1-4502-9ebc-fea331c3d5b5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3756 biolink:treats MONDO:0003709 PMID:41385096 "[{""id"":""uuid:ccb37f03-f334-4bd8-85e1-a2b3a5e90567"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b30617ff-76ac-4825-b841-66ab492e87bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clonazepam tablets, USP are useful alone or as an adjunct in the treatment of the Lennox-Gastaut syndrome (petit mal variant), akinetic and myoclonic seizures. In patients with absence seizures (petit mal) who have failed to respond to succinimides, clonazepam may be useful. Seizure Disorders: In some studies, up to 30% of patients have shown a loss of anticonvulsant activity, often within 3 months of administration. In some cases, dosage adjustment may reestablish efficacy. Clonazepam tablets, USP are indicated for the treatment of panic disorder, with or without agoraphobia, as defined in DSM-IV. Panic disorder is characterized by the occurrence of unexpected panic attacks and associated concern about having additional attacks, worry about the implications or consequences of the attacks, and/or a significant change in behavior related to the attacks. Panic Disorder: The efficacy of clonazepam was established in two 6- to 9-week trials in panic disorder patients whose diagnoses corresponded to the DSM-IIIR category of panic disorder (see ). CLlNICAL PHARMACOLOGY: Clinical Trials Panic disorder (DSM-IV) is characterized by recurrent unexpected panic attacks, ie, a discrete period of intense fear or discomfort in which four (or more) of the following symptoms develop abruptly and reach a peak within 10 minutes: (1) palpitations, pounding heart or accelerated heart rate; (2) sweating; (3) trembling or shaking; (4) sensations of shortness of breath or smothering; (5) feeling of choking; (6) chest pain or discomfort; (7) nausea or abdominal distress; (8) feeling dizzy, unsteady, lightheaded or faint; (9) derealization (feelings of unreality) or depersonalization (being detached from oneself); (10) fear of losing control; (11) fear of dying; (12) paresthesias (numbness or tingling sensations); (13) chills or hot flushes. The effectiveness of clonazepam in long-term use, that is, for more than 9 weeks, has not been systematically studied in controlled clinical trials. The physician who elects to use clonazepam for extended periods should periodically reevaluate the long-term usefulness of the drug for the individual patient (see ). DOSAGE AND ADMINISTRATION uuid:0dd8d02a-6f38-4fc9-80e9-d8a78c43cfd2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5613 biolink:treats MONDO:0005090 PMID:41385096 "[{""id"":""uuid:f295d61f-739b-4e87-ab64-45de17858d52"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5663d1ab-7161-4b4a-8179-8c11ea8ccc63"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Haloperidol is indicated for use in the treatment of schizophrenia. Haloperidol is indicated for the control of tics and vocal utterances of Tourette's Disorder. uuid:a22adad8-663e-4d7a-8b95-145eafa7b507 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5391 biolink:treats MONDO:0004946 PMID:41385096 "[{""id"":""uuid:6c4c789f-9cfb-4fce-ac0e-77c09f043d4b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b268f5e5-846b-47a8-83bc-da0ab69c4020"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:7f72ee3b-e2fc-4995-b4b5-fa2ed41069f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ogluo""]},{""id"":""uuid:d0c41683-97b1-46f7-b838-92003a5bd00f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the treatment of hypoglycemia: Glucagon is indicated as a treatment for severe hypoglycemia. Because patients with type 1 diabetes may have less of an increase in blood glucose levels compared with a stable type 2 patient, supplementary carbohydrate should be given as soon as possible, especially to a pediatric patient.|[EMA] Ogluo is indicated for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus.|[PMDA] A drug with a new route of administration indicated for the emergency treatment of hypoglycemia. uuid:4be53cf2-c791-40fe-9768-378ed82b0870 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7476 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:d5fcc06e-2218-4f43-939b-eb5cb158c1a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dfa76015-a3d1-4bd4-bf85-94b1545c73be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of Naproxen Sodium Tablets, USP and other treatment options before deciding to use Naproxen Sodium Tablets, USP. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS). Naproxen suspension is recommended for juvenile rheumatoid arthritis in order to obtain the maximum dosage flexibility based on the patient's weight. Naproxen as naproxen sodium tablets are indicated: • For the relief of the signs and symptoms of rheumatoid arthritis • For the relief of the signs and symptoms of osteoarthritis • For the relief of the signs and symptoms of ankylosing spondylitis • For the relief of the signs and symptoms of juvenile arthritis • For relief of the signs and symptoms of tendonitis • For relief of the signs and symptoms of bursitis • For relief of the signs and symptoms of acute gout • For the management of pain • For the management of primary dysmenorrhea uuid:f0acd471-3d97-4beb-8e6d-35e5a9c6893c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:66545969 biolink:treats MONDO:0004951 PMID:41385096 "[{""id"":""uuid:be40985b-6754-4511-b902-f0fb5d721210"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3a43093d-6739-4d8a-bd59-c211385aa579"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] STRIBILD ® is indicated as a complete regimen for the treatment of HIV-1 infection in adults who are antiretroviral treatment-naïve. uuid:c0facaae-c296-4dac-874a-90f278f5eb41 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63577 biolink:treats MONDO:0005366 PMID:41385096 "[{""id"":""uuid:75f4684d-4b11-4d29-899d-e7d7a1690cf5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:375805a7-9701-428d-8dd6-70eba146efae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:011f2576-d51f-4965-aa0e-85ba7abd47d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/lamivudine-teva-pharma-bv""]},{""id"":""uuid:fb533ea4-fb9f-465d-97ad-3d36146c273a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EPIVIR-HBV is indicated for the treatment of chronic hepatitis B virus (HBV) infection associated with evidence of hepatitis B viral replication and active liver inflammation [see Clinical Studies (14.1, 14.2)]. The following points should be considered when initiating therapy with EPIVIR-HBV: • Due to high rates of resistance development in treated patients, initiation of treatment with EPIVIR-HBV should only be considered when the use of an alternative antiviral agent with a higher genetic barrier to resistance is not available or appropriate. • EPIVIR-HBV has not been evaluated in patients co-infected with HIV, hepatitis C virus (HCV), or hepatitis delta virus. • EPIVIR-HBV has not been evaluated in liver transplant recipients or in patients with chronic hepatitis B virus infection with decompensated liver disease. • EPIVIR-HBV has not been evaluated in pediatric patients younger than 2 years of age with chronic HBV infection.|[EMA] Lamivudine Teva is indicated for the treatment of chronic hepatitis B in adults with:compensated liver disease with evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active liver inflammation and / or fibrosis. Initiation of lamivudine treatment should only be considered when the use of an alternative antiviral agent with a higher genetic barrier is not available or appropriate (see in section 5.1).|[PMDA] Addition to indications for improving the levels of viral markers and hepatic function in chronic hepatitis B and hepatitis B cirrhosis in which an abnormality of the hepatic function with persistent regrowth of type B hepatitis viruses has been confirmed during administration of this drug combined with adefovir pivoxil. uuid:8591d1dc-bdca-40b7-b554-9cf97492eeaa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63577 biolink:treats MONDO:0005344 PMID:41385096 "[{""id"":""uuid:8cbdb586-19c1-4e66-98c7-951af1c2025c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2812bfc5-43f0-483e-990e-ce09f9324170"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:b80acfc5-fa99-4ac5-8bf7-3822770c89e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EPIVIR-HBV is indicated for the treatment of chronic hepatitis B virus (HBV) infection associated with evidence of hepatitis B viral replication and active liver inflammation [see Clinical Studies (14.1, 14.2)]. The following points should be considered when initiating therapy with EPIVIR-HBV: • Due to high rates of resistance development in treated patients, initiation of treatment with EPIVIR-HBV should only be considered when the use of an alternative antiviral agent with a higher genetic barrier to resistance is not available or appropriate. • EPIVIR-HBV has not been evaluated in patients co-infected with HIV, hepatitis C virus (HCV), or hepatitis delta virus. • EPIVIR-HBV has not been evaluated in liver transplant recipients or in patients with chronic hepatitis B virus infection with decompensated liver disease. • EPIVIR-HBV has not been evaluated in pediatric patients younger than 2 years of age with chronic HBV infection.|[PMDA] A new indication for “improving viral markers in patients with hepatitis B cirrhosis complicated by proliferation of hepatitis B virus and with abnormal hepatic function to be confirmed” in monotherapy [Priority review] uuid:f51b7643-6213-442a-9004-0156296d52a6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63577 biolink:treats MONDO:0002251 PMID:41385096 "[{""id"":""uuid:1e99e45d-b5cd-4cd6-a234-21ae74c44632"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4def3a37-c411-46a1-a250-67801138a85a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EPIVIR-HBV is indicated for the treatment of chronic hepatitis B virus (HBV) infection associated with evidence of hepatitis B viral replication and active liver inflammation [see Clinical Studies (14.1, 14.2)]. The following points should be considered when initiating therapy with EPIVIR-HBV: • Due to high rates of resistance development in treated patients, initiation of treatment with EPIVIR-HBV should only be considered when the use of an alternative antiviral agent with a higher genetic barrier to resistance is not available or appropriate. • EPIVIR-HBV has not been evaluated in patients co-infected with HIV, hepatitis C virus (HCV), or hepatitis delta virus. • EPIVIR-HBV has not been evaluated in liver transplant recipients or in patients with chronic hepatitis B virus infection with decompensated liver disease. • EPIVIR-HBV has not been evaluated in pediatric patients younger than 2 years of age with chronic HBV infection. uuid:1deb60a2-192c-481b-ae40-2e85400f1a56 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63577 biolink:treats MONDO:0005354 PMID:41385096 "[{""id"":""uuid:9538e5f5-c1e5-4898-86a2-decfe2b494bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:06080985-800e-47cc-a44f-8b3b2ead761f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EPIVIR-HBV is indicated for the treatment of chronic hepatitis B virus (HBV) infection associated with evidence of hepatitis B viral replication and active liver inflammation [see Clinical Studies (14.1, 14.2)]. The following points should be considered when initiating therapy with EPIVIR-HBV: • Due to high rates of resistance development in treated patients, initiation of treatment with EPIVIR-HBV should only be considered when the use of an alternative antiviral agent with a higher genetic barrier to resistance is not available or appropriate. • EPIVIR-HBV has not been evaluated in patients co-infected with HIV, hepatitis C virus (HCV), or hepatitis delta virus. • EPIVIR-HBV has not been evaluated in liver transplant recipients or in patients with chronic hepatitis B virus infection with decompensated liver disease. • EPIVIR-HBV has not been evaluated in pediatric patients younger than 2 years of age with chronic HBV infection. uuid:76ebfee2-fc3e-4e51-a154-f4eef2e2a765 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63577 biolink:treats MONDO:0005789 PMID:41385096 "[{""id"":""uuid:5af2ed79-797e-4f6f-8860-dc193c7b74ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:895d78eb-2890-4387-b93c-9ef9d4a18a74"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EPIVIR-HBV is indicated for the treatment of chronic hepatitis B virus (HBV) infection associated with evidence of hepatitis B viral replication and active liver inflammation [see Clinical Studies (14.1, 14.2)]. The following points should be considered when initiating therapy with EPIVIR-HBV: • Due to high rates of resistance development in treated patients, initiation of treatment with EPIVIR-HBV should only be considered when the use of an alternative antiviral agent with a higher genetic barrier to resistance is not available or appropriate. • EPIVIR-HBV has not been evaluated in patients co-infected with HIV, hepatitis C virus (HCV), or hepatitis delta virus. • EPIVIR-HBV has not been evaluated in liver transplant recipients or in patients with chronic hepatitis B virus infection with decompensated liver disease. • EPIVIR-HBV has not been evaluated in pediatric patients younger than 2 years of age with chronic HBV infection. uuid:62b5b96b-c193-4f48-a12c-2c0ee690db4f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8060 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:98ce181f-4003-4d2f-86b6-a66dd2caa48e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:666670e4-d321-4550-821f-0a7390362be0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Phenelzine Sulfate Tablets, USP has been found to be effective in depressed patients clinically characterized as “atypical,” “nonendogenous,” or “neurotic.” These patients often have mixed anxiety and depression and phobic or hypochondriacal features. There is less conclusive evidence of its usefulness with severely depressed patients with endogenous features. Phenelzine Sulfate Tablets should rarely be the first antidepressant drug used. Rather, it is more suitable for use with patients who have failed to respond to the drugs more commonly used for these conditions. uuid:cae64c5b-be77-4c1e-a7e5-e2f218b18bed biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8060 biolink:treats MONDO:0011918 PMID:41385096 "[{""id"":""uuid:e103354b-2d08-4d0d-8aa5-16e841eee072"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:17f8cf53-e0fb-4da7-ac69-17898a972621"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Phenelzine Sulfate Tablets, USP has been found to be effective in depressed patients clinically characterized as “atypical,” “nonendogenous,” or “neurotic.” These patients often have mixed anxiety and depression and phobic or hypochondriacal features. There is less conclusive evidence of its usefulness with severely depressed patients with endogenous features. Phenelzine Sulfate Tablets should rarely be the first antidepressant drug used. Rather, it is more suitable for use with patients who have failed to respond to the drugs more commonly used for these conditions. uuid:553d74aa-042f-4a22-bf4a-5b0fe87dea53 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8060 biolink:treats MONDO:0003699 PMID:41385096 "[{""id"":""uuid:5f55946c-b955-4e89-a1bd-c4d3b1b53d1e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9f239d96-7835-45f3-8f62-0f0fee6bd40d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Phenelzine Sulfate Tablets, USP has been found to be effective in depressed patients clinically characterized as “atypical,” “nonendogenous,” or “neurotic.” These patients often have mixed anxiety and depression and phobic or hypochondriacal features. There is less conclusive evidence of its usefulness with severely depressed patients with endogenous features. Phenelzine Sulfate Tablets should rarely be the first antidepressant drug used. Rather, it is more suitable for use with patients who have failed to respond to the drugs more commonly used for these conditions. uuid:a638736f-dcc4-4341-8d2e-7e1e63ea4811 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8060 biolink:treats MONDO:0001596 PMID:41385096 "[{""id"":""uuid:a1bdeb27-bd0d-46f1-82d6-6c4fcdbeaace"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c0e8e598-566a-4fa6-8258-5ff6ac5ae468"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Phenelzine Sulfate Tablets, USP has been found to be effective in depressed patients clinically characterized as “atypical,” “nonendogenous,” or “neurotic.” These patients often have mixed anxiety and depression and phobic or hypochondriacal features. There is less conclusive evidence of its usefulness with severely depressed patients with endogenous features. Phenelzine Sulfate Tablets should rarely be the first antidepressant drug used. Rather, it is more suitable for use with patients who have failed to respond to the drugs more commonly used for these conditions. uuid:03df9912-ab8a-41cc-9b71-7f7f6aa35bd3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:37510 biolink:treats UMLS:C0406326 PMID:41385096 "[{""id"":""uuid:f96d8788-66a7-45ae-93f3-b3b611e4f7ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5b2e6df7-3378-4ad8-ac50-8b50eea0fbc4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Zithranol Shampoo for the treatment of scalp psoriasis in subjects 12 years of age and older (see PRECAUTIONS). Patients should be instructed to use Zithranol Shampoo for the minimum time period necessary to achieve the desired results. uuid:8955d3a2-d55b-4b70-aa79-2c830c320c9f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5558 biolink:treats MONDO:0007743 PMID:41385096 "[{""id"":""uuid:ce9e0454-926d-4140-ba71-8fadbf369b11"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:b594529a-def1-4886-8603-7a82c1938186"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:d338d96f-85e5-4eae-bea2-0c3843f5ed3d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INTUNIV is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) as monotherapy and as adjunctive therapy to stimulant medications. The efficacy of INTUNIV was studied for the treatment of ADHD in three controlled monotherapy clinical trials (up to 8 weeks in duration) and one controlled adjunctive trial with psychostimulants (8 weeks in duration) in children and adolescents ages 6-17 who met DSM-IV criteria for ADHD [ ]. The effectiveness of INTUNIV for longer-term use (more than 8 weeks) has not been systematically evaluated in controlled trials. ® ® ® see Clinical Studies (14) ®|[EMA] Intuniv is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents 6 17 years old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective., , Intuniv must be used as a part of a comprehensive ADHD treatment programme, typically including psychological, educational and social measures., uuid:95c96497-aaf8-473b-a5c5-aeca247ac7ec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5558 biolink:treats MONDO:0005302 PMID:41385096 "[{""id"":""uuid:6eaef98c-c57a-46f7-abfb-8847b92d99ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:19432beb-4bc7-4e24-a0af-0e94d0c4acb0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f9b49ab1-35b3-4649-9646-86327f601985"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INTUNIV is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) as monotherapy and as adjunctive therapy to stimulant medications. The efficacy of INTUNIV was studied for the treatment of ADHD in three controlled monotherapy clinical trials (up to 8 weeks in duration) and one controlled adjunctive trial with psychostimulants (8 weeks in duration) in children and adolescents ages 6-17 who met DSM-IV criteria for ADHD [ ]. The effectiveness of INTUNIV for longer-term use (more than 8 weeks) has not been systematically evaluated in controlled trials. ® ® ® see Clinical Studies (14) ®|[PMDA] Drugs with a new active ingredient indicated for the treatment of pediatric attention deficit/hyperactivity disorder (AD/HD). uuid:33e0cab4-1a4b-40df-88ac-aa64f4056a0b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50690 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:d91e31be-82c9-4fe2-b55d-d3753ad61646"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ecbb90cc-b62a-4fdd-8410-77df9af7d9d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin calcium tablets can be started simultaneously with diet. 1.1 Prevention of Cardiovascular Disease In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, Atorvastatin Calcium Tablets is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, Atorvastatin Calcium Tablets is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In patients with clinically evident coronary heart disease, Atorvastatin Calcium Tablets is indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 1.2 Hyperlipidemia Atorvastatin Calcium Tablets is indicated: As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson Types IIa and IIb); As an adjunct to diet for the treatment of patients with elevated serum TG levels (Fredrickson Type IV); For the treatment of patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet; To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; As an adjunct to diet to reduce total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: LDL-C remains ≥ 190 mg/dL or LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient 1.3 Limitations of Use Atorvastatin Calcium Tablets has not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V). uuid:4290db99-e537-4850-a270-c8b1a265e02b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50690 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:666946d1-1dd6-480b-8c51-c163385355fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b305c4b8-6322-4b5e-b5ca-d91aeb1aa8f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin calcium tablets can be started simultaneously with diet. 1.1 Prevention of Cardiovascular Disease In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, Atorvastatin Calcium Tablets is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, Atorvastatin Calcium Tablets is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In patients with clinically evident coronary heart disease, Atorvastatin Calcium Tablets is indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 1.2 Hyperlipidemia Atorvastatin Calcium Tablets is indicated: As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson Types IIa and IIb); As an adjunct to diet for the treatment of patients with elevated serum TG levels (Fredrickson Type IV); For the treatment of patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet; To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; As an adjunct to diet to reduce total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: LDL-C remains ≥ 190 mg/dL or LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient 1.3 Limitations of Use Atorvastatin Calcium Tablets has not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V). uuid:c832fbc5-52fe-4276-a455-99e92a8faef0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50690 biolink:treats HP:0012592 PMID:41385096 "[{""id"":""uuid:8fa712ea-1c40-4fb8-befb-9da8bf4c2566"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:372a2933-980b-4f3c-98bc-c9d0716c9a9e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin calcium tablets can be started simultaneously with diet. 1.1 Prevention of Cardiovascular Disease In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, Atorvastatin Calcium Tablets is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, Atorvastatin Calcium Tablets is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In patients with clinically evident coronary heart disease, Atorvastatin Calcium Tablets is indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 1.2 Hyperlipidemia Atorvastatin Calcium Tablets is indicated: As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson Types IIa and IIb); As an adjunct to diet for the treatment of patients with elevated serum TG levels (Fredrickson Type IV); For the treatment of patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet; To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; As an adjunct to diet to reduce total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: LDL-C remains ≥ 190 mg/dL or LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient 1.3 Limitations of Use Atorvastatin Calcium Tablets has not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V). uuid:dc72fb24-f39c-4904-9cf0-5e50ff93d307 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50690 biolink:treats UMLS:C0342879 PMID:41385096 "[{""id"":""uuid:bd27a85c-2351-4da4-b376-f36640c0d066"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4237a200-ac4f-4f84-b2af-4355f7c04889"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin calcium tablets can be started simultaneously with diet. 1.1 Prevention of Cardiovascular Disease In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, Atorvastatin Calcium Tablets is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, Atorvastatin Calcium Tablets is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In patients with clinically evident coronary heart disease, Atorvastatin Calcium Tablets is indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 1.2 Hyperlipidemia Atorvastatin Calcium Tablets is indicated: As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson Types IIa and IIb); As an adjunct to diet for the treatment of patients with elevated serum TG levels (Fredrickson Type IV); For the treatment of patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet; To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; As an adjunct to diet to reduce total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: LDL-C remains ≥ 190 mg/dL or LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient 1.3 Limitations of Use Atorvastatin Calcium Tablets has not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V). uuid:fc1a20ff-83b0-4206-af55-f08132652f2c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50690 biolink:treats UMLS:C0342882 PMID:41385096 "[{""id"":""uuid:089557af-996c-4dc4-8af0-c92d4c6e5f14"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:daa7fbad-149f-4118-a9e1-7c9ca35e176a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin calcium tablets can be started simultaneously with diet. 1.1 Prevention of Cardiovascular Disease In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, Atorvastatin Calcium Tablets is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, Atorvastatin Calcium Tablets is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In patients with clinically evident coronary heart disease, Atorvastatin Calcium Tablets is indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 1.2 Hyperlipidemia Atorvastatin Calcium Tablets is indicated: As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson Types IIa and IIb); As an adjunct to diet for the treatment of patients with elevated serum TG levels (Fredrickson Type IV); For the treatment of patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet; To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; As an adjunct to diet to reduce total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: LDL-C remains ≥ 190 mg/dL or LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient 1.3 Limitations of Use Atorvastatin Calcium Tablets has not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V). uuid:07e2fa6a-6bfa-44ed-b82b-12aae55c77a2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50690 biolink:treats HP:0003119 PMID:41385096 "[{""id"":""uuid:6c284d3d-895e-482d-a747-8d6df6600fe1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:07005bd5-dc32-412a-9f21-fc6d38dac12d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin calcium tablets can be started simultaneously with diet. 1.1 Prevention of Cardiovascular Disease In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, Atorvastatin Calcium Tablets is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, Atorvastatin Calcium Tablets is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In patients with clinically evident coronary heart disease, Atorvastatin Calcium Tablets is indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 1.2 Hyperlipidemia Atorvastatin Calcium Tablets is indicated: As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson Types IIa and IIb); As an adjunct to diet for the treatment of patients with elevated serum TG levels (Fredrickson Type IV); For the treatment of patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet; To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; As an adjunct to diet to reduce total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: LDL-C remains ≥ 190 mg/dL or LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient 1.3 Limitations of Use Atorvastatin Calcium Tablets has not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V). uuid:814400e9-34ba-4688-b36c-ee66a7ada12e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50690 biolink:treats MONDO:0007750 PMID:41385096 "[{""id"":""uuid:27f20599-4b59-42f3-955a-30fc01ac6891"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fa438d1a-f2a0-478f-a808-d80624753042"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin calcium tablets can be started simultaneously with diet. 1.1 Prevention of Cardiovascular Disease In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, Atorvastatin Calcium Tablets is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, Atorvastatin Calcium Tablets is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In patients with clinically evident coronary heart disease, Atorvastatin Calcium Tablets is indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 1.2 Hyperlipidemia Atorvastatin Calcium Tablets is indicated: As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson Types IIa and IIb); As an adjunct to diet for the treatment of patients with elevated serum TG levels (Fredrickson Type IV); For the treatment of patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet; To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; As an adjunct to diet to reduce total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: LDL-C remains ≥ 190 mg/dL or LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient 1.3 Limitations of Use Atorvastatin Calcium Tablets has not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V). uuid:c187ed6b-7efb-422b-8c65-048c97b67980 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50690 biolink:treats MONDO:0007759 PMID:41385096 "[{""id"":""uuid:20df0e84-1daf-4645-ac4c-985a7ac9cece"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7d2e8da2-ba3e-47e0-af24-dc4c5f684a9f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin calcium tablets can be started simultaneously with diet. 1.1 Prevention of Cardiovascular Disease In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, Atorvastatin Calcium Tablets is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, Atorvastatin Calcium Tablets is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In patients with clinically evident coronary heart disease, Atorvastatin Calcium Tablets is indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 1.2 Hyperlipidemia Atorvastatin Calcium Tablets is indicated: As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson Types IIa and IIb); As an adjunct to diet for the treatment of patients with elevated serum TG levels (Fredrickson Type IV); For the treatment of patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet; To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; As an adjunct to diet to reduce total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: LDL-C remains ≥ 190 mg/dL or LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient 1.3 Limitations of Use Atorvastatin Calcium Tablets has not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V). uuid:29c8cc22-5b64-4116-b838-c6838ed41c49 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50690 biolink:treats MONDO:0037748 PMID:41385096 "[{""id"":""uuid:4a0deb58-59a7-4293-a956-1de3fd86bddd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b9648a74-131e-4cc6-9daa-397cbd2b7a84"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin calcium tablets can be started simultaneously with diet. 1.1 Prevention of Cardiovascular Disease In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, Atorvastatin Calcium Tablets is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, Atorvastatin Calcium Tablets is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In patients with clinically evident coronary heart disease, Atorvastatin Calcium Tablets is indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 1.2 Hyperlipidemia Atorvastatin Calcium Tablets is indicated: As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson Types IIa and IIb); As an adjunct to diet for the treatment of patients with elevated serum TG levels (Fredrickson Type IV); For the treatment of patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet; To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; As an adjunct to diet to reduce total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: LDL-C remains ≥ 190 mg/dL or LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient 1.3 Limitations of Use Atorvastatin Calcium Tablets has not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V). uuid:cb939143-d30b-49f1-a2d1-1e5478e710ed biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50690 biolink:treats MONDO:0018473 PMID:41385096 "[{""id"":""uuid:984fb104-8859-41e4-9f39-8cf1294b05d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:03c3315d-86cd-4726-b3c7-a663a8713f73"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin calcium tablets can be started simultaneously with diet. 1.1 Prevention of Cardiovascular Disease In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, Atorvastatin Calcium Tablets is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, Atorvastatin Calcium Tablets is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In patients with clinically evident coronary heart disease, Atorvastatin Calcium Tablets is indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 1.2 Hyperlipidemia Atorvastatin Calcium Tablets is indicated: As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson Types IIa and IIb); As an adjunct to diet for the treatment of patients with elevated serum TG levels (Fredrickson Type IV); For the treatment of patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet; To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; As an adjunct to diet to reduce total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: LDL-C remains ≥ 190 mg/dL or LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient 1.3 Limitations of Use Atorvastatin Calcium Tablets has not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V). uuid:2b111851-184a-463c-9f31-6e788200667e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50690 biolink:treats MONDO:0018328 PMID:41385096 "[{""id"":""uuid:0d69ce33-a4c7-4010-b855-2786e87df9fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e2db9064-3478-4c64-94a9-fb20cfaec6ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin calcium tablets can be started simultaneously with diet. 1.1 Prevention of Cardiovascular Disease In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, Atorvastatin Calcium Tablets is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, Atorvastatin Calcium Tablets is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In patients with clinically evident coronary heart disease, Atorvastatin Calcium Tablets is indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 1.2 Hyperlipidemia Atorvastatin Calcium Tablets is indicated: As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson Types IIa and IIb); As an adjunct to diet for the treatment of patients with elevated serum TG levels (Fredrickson Type IV); For the treatment of patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet; To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; As an adjunct to diet to reduce total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: LDL-C remains ≥ 190 mg/dL or LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient 1.3 Limitations of Use Atorvastatin Calcium Tablets has not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V). uuid:b9a9d114-7283-44e1-bb6f-b8651261e063 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50690 biolink:treats MONDO:0007788 PMID:41385096 "[{""id"":""uuid:d328792f-a4e2-4c4d-8574-daf731af14af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:50ffff0b-4e48-465e-afe6-a05080cb888e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin calcium tablets can be started simultaneously with diet. 1.1 Prevention of Cardiovascular Disease In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, Atorvastatin Calcium Tablets is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, Atorvastatin Calcium Tablets is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In patients with clinically evident coronary heart disease, Atorvastatin Calcium Tablets is indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 1.2 Hyperlipidemia Atorvastatin Calcium Tablets is indicated: As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson Types IIa and IIb); As an adjunct to diet for the treatment of patients with elevated serum TG levels (Fredrickson Type IV); For the treatment of patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet; To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; As an adjunct to diet to reduce total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: LDL-C remains ≥ 190 mg/dL or LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient 1.3 Limitations of Use Atorvastatin Calcium Tablets has not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V). uuid:f42cf9b1-bd17-40ff-a57d-4e8c25e846a5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50690 biolink:treats MONDO:0007762 PMID:41385096 "[{""id"":""uuid:702f3ab6-063d-44d7-bc88-f650da610f7e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dbc380e9-f592-4efa-8281-8d54f9877d59"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin calcium tablets can be started simultaneously with diet. 1.1 Prevention of Cardiovascular Disease In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, Atorvastatin Calcium Tablets is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, Atorvastatin Calcium Tablets is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In patients with clinically evident coronary heart disease, Atorvastatin Calcium Tablets is indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 1.2 Hyperlipidemia Atorvastatin Calcium Tablets is indicated: As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson Types IIa and IIb); As an adjunct to diet for the treatment of patients with elevated serum TG levels (Fredrickson Type IV); For the treatment of patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet; To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; As an adjunct to diet to reduce total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: LDL-C remains ≥ 190 mg/dL or LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient 1.3 Limitations of Use Atorvastatin Calcium Tablets has not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V). uuid:d46dc3ca-cd96-4bfe-8b58-ffa85d38f018 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3534 biolink:treats MONDO:0030603 PMID:41385096 "[{""id"":""uuid:89e6a19b-be13-4465-b55c-f4f77186beae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f94ee82b-c39a-4fe9-857a-cc4ed9ff4eea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cephalexin Capsules USP are indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms: Respiratory tract infections caused by and . (Penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cephalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present.) Streptococcus pneumoniae Streptococcus pyogenes Otitis media due to , , , , and . Streptococcus pneumoniae Haemophilus influenzae Staphylococcus aureus Streptococcus pyogenes Moraxella catarrhalis Skin and skin structure infections caused by and/or . Staphylococcus aureus Streptococcus pyogenes Bone infections caused by and/or . Staphylococcus aureus Proteus mirabilis Genitourinary tract infections, including acute prostatitis, caused by , , and pneumoniae. Escherichia coli Proteus mirabilis Klebsiella Note – Culture and susceptibility tests should be initiated prior to and during therapy. Renal function studies should be performed when indicated. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cephalexin capsules and other antibacterial drugs, cephalexin capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:060a5010-850e-4c55-b45c-d2bdd50daefa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32016 biolink:treats MONDO:0002771 PMID:41385096 "[{""id"":""uuid:c61bdca7-d4e1-4dfb-b54b-a5150efb7463"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c72c64a6-0a08-46aa-9aed-7bcd0f65e289"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:651a20af-0b1d-4d4c-9454-c4e480da1fbe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/pirfenidone-viatris""]},{""id"":""uuid:9f4d2736-d9a9-46e6-9217-139dcce47d30"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ESBRIET is indicated for the treatment of idiopathic pulmonary fibrosis (IPF).|[EMA] Esbriet is indicated in adults for the treatment of idiopathic pulmonary fibrosis.|[PMDA] A drug containing a new active ingredient indicated for the treatment of idiopathic pulmonary fibrosis. [Orphan drug] uuid:a605ee61-b16b-407c-91dd-9686fdcd0dd7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3647 biolink:treats HP:0002018 PMID:41385096 "[{""id"":""uuid:7cf9b388-5ea6-4683-b0db-2b020c471c96"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:011e270d-a619-4d54-88e6-390530913c73"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the treatment of schizophrenia; to control nausea and vomiting; for relief of restlessness and apprehension before surgery; for acute intermittent porphyria; as an adjunct in the treatment of tetanus; to control the manifestations of the manic type of manic-depressive illness; for relief of intractable hiccups; for the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability, and poor frustration tolerance. uuid:342414fd-ef28-47e6-9f1e-31dc6dfd225c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3647 biolink:treats HP:0002013 PMID:41385096 "[{""id"":""uuid:6ef84bf9-4fb4-4157-a97e-24f40262e141"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bbf0ea18-8f23-42b4-a2bd-0321b37e2ec7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the treatment of schizophrenia; to control nausea and vomiting; for relief of restlessness and apprehension before surgery; for acute intermittent porphyria; as an adjunct in the treatment of tetanus; to control the manifestations of the manic type of manic-depressive illness; for relief of intractable hiccups; for the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability, and poor frustration tolerance. uuid:b1a83887-47a8-40a1-8c9e-53cdfafca790 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3647 biolink:treats UMLS:C0744896 PMID:41385096 "[{""id"":""uuid:a7ab429d-af17-4a49-9629-b69cd1936ee7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bb1a6a24-de01-4e46-992b-3b4091f50eae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the treatment of schizophrenia; to control nausea and vomiting; for relief of restlessness and apprehension before surgery; for acute intermittent porphyria; as an adjunct in the treatment of tetanus; to control the manifestations of the manic type of manic-depressive illness; for relief of intractable hiccups; for the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability, and poor frustration tolerance. uuid:fbd4628f-98e7-4346-a1ef-359099330144 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9139 biolink:treats MONDO:0015924 PMID:41385096 "[{""id"":""uuid:5f269527-c793-4384-aa45-184e4c292a00"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3f14bba4-2e4d-492c-95a6-ad901945dbbd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:3d70e426-d17d-4486-993e-8b3579eac358"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/revatio""]},{""id"":""uuid:7de92a34-9c2a-4d1a-8ed8-c4772cd47bc1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sildenafil tablets are indicated for the treatment of pulmonary arterial hypertension (WHO Group I) in adults to improve exercise ability and delay clinical worsening. The delay in clinical worsening was demonstrated when sildenafil tablets were added to background epoprostenol therapy [see Clinical Studies (14)]. Studies establishing effectiveness were short-term (12 to 16 weeks), and included predominately patients with New York Heart Association (NYHA) Functional Class II-III symptoms and idiopathic etiology (71%) or associated with connective tissue disease (CTD) (25%). Limitation of Use The efficacy of sildenafil tablets in the treatment of pulmonary arterial hypertension (PAH) has not been adequately evaluated in patients taking bosentan.|[EMA] Treatment of adult patients with pulmonary arterial hypertension classified as World Health Organization (WHO) functional class II and III, to improve exercise capacity. Efficacy has been shown in primary pulmonary hypertension and pulmonary hypertension associated with connective tissue disease.Paediatric populationTreatment of paediatric patients aged one year to 17 years old with pulmonary arterial hypertension. Efficacy in terms of improvement of exercise capacity or pulmonary haemodynamics has been shown in primary pulmonary hypertension and pulmonary hypertension associated with congenital heart disease.Revatio solution for injection is for the treatment of adult patients with pulmonary arterial hypertension who are currently prescribed oral Revatio and who are temporarily unable to take oral therapy, but are otherwise clinically and haemodynamically stable.Revatio (oral) is indicated for treatment of adult patients with pulmonary arterial hypertension classified as WHO functional class II and III, to improve exercise capacity. Efficacy has been shown in primary pulmonary hypertension and pulmonary hypertension associated with connective tissue disease.|[PMDA] A drug with a new indication and dosage for the treatment of pulmonary arterial hypertension. [Orphan drug] uuid:1ee969b0-7453-469e-95fb-a16c93e3a5e4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9139 biolink:treats MONDO:0003900 PMID:41385096 "[{""id"":""uuid:61f9a427-149a-4baa-ae68-4ef27e31739f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:336b50d0-f609-4fe6-9766-0932d9b65654"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sildenafil tablets are indicated for the treatment of pulmonary arterial hypertension (WHO Group I) in adults to improve exercise ability and delay clinical worsening. The delay in clinical worsening was demonstrated when sildenafil tablets were added to background epoprostenol therapy [see Clinical Studies (14)]. Studies establishing effectiveness were short-term (12 to 16 weeks), and included predominately patients with New York Heart Association (NYHA) Functional Class II-III symptoms and idiopathic etiology (71%) or associated with connective tissue disease (CTD) (25%). Limitation of Use The efficacy of sildenafil tablets in the treatment of pulmonary arterial hypertension (PAH) has not been adequately evaluated in patients taking bosentan. uuid:8a506bd7-68d9-412c-9d9b-7a106a847b1b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8707 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:ecdcd2cf-8161-45dc-a723-89c8adfd997d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3fba08a5-e46c-471c-b265-d73c466dc87f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SEROQUEL XR is an atypical antipsychotic indicated for the treatment of: Schizophrenia • (1.1) Bipolar I disorder, manic or mixed episodes • (1.2) Bipolar disorder, depressive episodes • (1.2) Major depressive disorder, adjunctive therapy with antidepressants • (1.3) uuid:c13739ba-4f66-4be4-9669-2eda3069e13c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5123 biolink:treats MONDO:0005090 PMID:41385096 "[{""id"":""uuid:5f5044e8-0a0a-4c94-a0db-6698e8d07208"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a8a5f21e-ae87-4faf-9906-e037068e5f55"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fluphenazine Decanoate Injection is a long-acting parenteral antipsychotic drug intended for use in the management of patients requiring prolonged parenteral neuroleptic therapy (e.g., chronic schizophrenics). Fluphenazine Decanoate Injection has not been shown effective in the management of behavioral complications in patients with mental retardation. uuid:96dd4910-cbc7-432f-b8c6-fb4a4b536edf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB09100 biolink:treats MONDO:0005420 PMID:41385096 "[{""id"":""uuid:aad13a52-df1c-4d95-bd2f-0f7ba11d97f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ce0dc7e3-56ae-43e2-830c-47b452f7f186"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Armour Thyroid tablets are indicated: As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (SeeWARNINGS). As pituitary TSH suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic Iymphocytic thyroiditis (Hashimoto's), multinodular goiter, and in the management of thyroid cancer. uuid:b563328c-2c05-481f-a98d-e63d7eb18629 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB09100 biolink:treats MONDO:0018612 PMID:41385096 "[{""id"":""uuid:f80ff8f7-42d1-4ebf-a74c-7c68c7d4094d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:82962835-5e83-4c3e-b42b-a967782249b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Armour Thyroid tablets are indicated: As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (SeeWARNINGS). As pituitary TSH suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic Iymphocytic thyroiditis (Hashimoto's), multinodular goiter, and in the management of thyroid cancer. uuid:c85a910a-83c3-4487-8e24-4978ee73fc45 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB09100 biolink:treats MONDO:0009718 PMID:41385096 "[{""id"":""uuid:b6c3c6ac-3e71-401f-9625-62ef03f28267"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bf3d17eb-cc2b-4922-98d0-78041d3ffb04"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Armour Thyroid tablets are indicated: As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (SeeWARNINGS). As pituitary TSH suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic Iymphocytic thyroiditis (Hashimoto's), multinodular goiter, and in the management of thyroid cancer. uuid:8df2cbec-8592-44c5-ac28-db18a0aadd00 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB09100 biolink:treats MONDO:0001658 PMID:41385096 "[{""id"":""uuid:d83f2da6-c419-44a4-a36f-cb6cee48086c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:876c79ca-7c8e-4c4b-9cdb-2cb1b66ac8ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Armour Thyroid tablets are indicated: As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (SeeWARNINGS). As pituitary TSH suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic Iymphocytic thyroiditis (Hashimoto's), multinodular goiter, and in the management of thyroid cancer. uuid:cc6b8abe-a146-4f58-8b27-d095cf697a44 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB09100 biolink:treats HP:0025388 PMID:41385096 "[{""id"":""uuid:36eae445-cb9e-4f20-87d8-28798e290f1a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6aab010e-7e5a-4722-8426-0a5fd908b3f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Armour Thyroid tablets are indicated: As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (SeeWARNINGS). As pituitary TSH suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic Iymphocytic thyroiditis (Hashimoto's), multinodular goiter, and in the management of thyroid cancer. uuid:9b58aafa-a2d7-4f9d-a95c-3259e1f5c494 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB09100 biolink:treats MONDO:0007699 PMID:41385096 "[{""id"":""uuid:27468a26-6464-4716-b84b-80afe9bc0418"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:59e62940-287f-4ee3-a682-4a8736812361"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Armour Thyroid tablets are indicated: As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (SeeWARNINGS). As pituitary TSH suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic Iymphocytic thyroiditis (Hashimoto's), multinodular goiter, and in the management of thyroid cancer. uuid:381f1cb3-11dc-47dd-8182-4bf1b14526e6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB09100 biolink:treats MONDO:0000334 PMID:41385096 "[{""id"":""uuid:4cf84ef4-868f-4554-8589-d87b5ac181e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3818c25d-2452-4b1c-b100-0d23db7ab559"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Armour Thyroid tablets are indicated: As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (SeeWARNINGS). As pituitary TSH suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic Iymphocytic thyroiditis (Hashimoto's), multinodular goiter, and in the management of thyroid cancer. uuid:abd7e160-babf-4875-bd91-580521aa9cd3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB09100 biolink:treats MONDO:0002108 PMID:41385096 "[{""id"":""uuid:c8d6c0be-0e9f-4780-acbd-487252c42958"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e0287663-c096-48b6-8cb9-3785981fae46"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Armour Thyroid tablets are indicated: As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (SeeWARNINGS). As pituitary TSH suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic Iymphocytic thyroiditis (Hashimoto's), multinodular goiter, and in the management of thyroid cancer. uuid:d80dda1b-42ce-42f1-a5b0-fb99e250857e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1593740 biolink:treats MONDO:0100471 PMID:41385096 "[{""id"":""uuid:ba1d1c0d-f9ea-4b14-b8dc-3baeb570bd0a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1c905ee3-0fde-4a84-a17f-5eb650424b09"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ciferex is indicated for dietary management of patients with unique nutritional needs requiring increased folate levels, Vitamin D deficiency or are in need of Vitamin D supplementation and other nutritional supplementation. uuid:2b78893b-89dd-4a01-8d9e-fcc866ddf7a5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63618 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:d3df7e4a-0233-4f7f-8485-4c01e9b84603"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2b44de8e-1f4c-4aa9-bf11-1a3889e22916"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. 1.1 Prevention of Cardiovascular Disease In hypercholesterolemic patients without clinically evident coronary heart disease (CHD), pravastatin sodium tablets, USP are indicated to: reduce the risk of myocardial infarction (MI). reduce the risk of undergoing myocardial revascularization procedures. reduce the risk of cardiovascular mortality with no increase in death from non-cardiovascular causes. In patients with clinically evident CHD, pravastatin sodium tablet is indicated to: reduce the risk of total mortality by reducing coronary death. reduce the risk of MI. reduce the risk of undergoing myocardial revascularization procedures. reduce the risk of stroke and stroke/transient ischemic attack (TIA). slow the progression of coronary atherosclerosis. 1.2 Hyperlipidemia Pravastatin sodium tablet is indicated: as an adjunct to diet to reduce elevated total cholesterol (Total-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (ApoB), and triglyceride (TG) levels and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson Types IIa and IIb).1 as an adjunct to diet for the treatment of patients with elevated serum TG levels (Fredrickson Type IV). for the treatment of patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet. as an adjunct to diet and lifestyle modification for treatment of heterozygous familial hypercholesterolemia (HeFH) in children and adolescent patients ages 8 years and older if after an adequate trial of diet the following findings are present: a. LDL-C remains ≥ 190 mg/dL or b. LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease (CVD) or two or more other CVD risk factors are present in the patient. 1.3 Limitations of Use Pravastatin sodium has not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V). uuid:3aa6891e-ac7a-4e8c-b55a-0702ac78eb62 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63618 biolink:treats MONDO:0005264 PMID:41385096 "[{""id"":""uuid:6eb3c71f-1822-4d14-b974-3171e68d2b4c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0c20a88e-2b44-419c-a8be-a5d3b25d5cbb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. 1.1 Prevention of Cardiovascular Disease In hypercholesterolemic patients without clinically evident coronary heart disease (CHD), pravastatin sodium tablets, USP are indicated to: reduce the risk of myocardial infarction (MI). reduce the risk of undergoing myocardial revascularization procedures. reduce the risk of cardiovascular mortality with no increase in death from non-cardiovascular causes. In patients with clinically evident CHD, pravastatin sodium tablet is indicated to: reduce the risk of total mortality by reducing coronary death. reduce the risk of MI. reduce the risk of undergoing myocardial revascularization procedures. reduce the risk of stroke and stroke/transient ischemic attack (TIA). slow the progression of coronary atherosclerosis. 1.2 Hyperlipidemia Pravastatin sodium tablet is indicated: as an adjunct to diet to reduce elevated total cholesterol (Total-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (ApoB), and triglyceride (TG) levels and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson Types IIa and IIb).1 as an adjunct to diet for the treatment of patients with elevated serum TG levels (Fredrickson Type IV). for the treatment of patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet. as an adjunct to diet and lifestyle modification for treatment of heterozygous familial hypercholesterolemia (HeFH) in children and adolescent patients ages 8 years and older if after an adequate trial of diet the following findings are present: a. LDL-C remains ≥ 190 mg/dL or b. LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease (CVD) or two or more other CVD risk factors are present in the patient. 1.3 Limitations of Use Pravastatin sodium has not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V). uuid:a5c52005-f1eb-444c-9808-b77e7e113633 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9927 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:3a972eeb-5ca4-42f4-89b6-fbdc0b88657d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:95d0e3c1-5a71-41f4-9d1a-741c8fd6b5af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Hypertension Valsartan tablets, USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which valsartan principally belongs. There are no controlled trials in hypertensive patients demonstrating risk reduction with valsartan tablets, USP. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Valsartan tablets, USP may be used alone or in combination with other antihypertensive agents. 1.2 Heart Failure Valsartan tablets, USP are indicated for the treatment of heart failure (NYHA class II-IV). In a controlled clinical trial, valsartan tablets, USP significantly reduced hospitalizations for heart failure. There is no evidence that valsartan tablets, USP provide added benefits when it is used with an adequate dose of an ACE inhibitor. [See Clinical Studies (14.2)] uuid:daf355e9-b53a-47da-aef4-0801c95b9420 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9927 biolink:treats MONDO:0005016 PMID:41385096 "[{""id"":""uuid:b38fe4b5-7f7a-43ff-bbcc-efdb4e3fa98a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c4c2e7de-c346-4633-afa7-e02b777fb101"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Hypertension Valsartan tablets, USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which valsartan principally belongs. There are no controlled trials in hypertensive patients demonstrating risk reduction with valsartan tablets, USP. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Valsartan tablets, USP may be used alone or in combination with other antihypertensive agents. 1.2 Heart Failure Valsartan tablets, USP are indicated for the treatment of heart failure (NYHA class II-IV). In a controlled clinical trial, valsartan tablets, USP significantly reduced hospitalizations for heart failure. There is no evidence that valsartan tablets, USP provide added benefits when it is used with an adequate dose of an ACE inhibitor. [See Clinical Studies (14.2)] uuid:775a931c-eb05-48b6-b049-55c638fa7d60 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:375139 biolink:treats MONDO:0005093 PMID:41385096 "[{""id"":""uuid:f9dad6dd-d9d3-4afb-9c5c-db84b575a3cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7db78c99-1e69-40d7-b95b-b170689d8cf0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Temporary relief of pain associated with minor cuts, scrapes and minor skin irritations uuid:afadb1af-51a7-4cef-9a82-8b57d4febdab biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7931 biolink:treats MONDO:0006964 PMID:41385096 "[{""id"":""uuid:767f7aeb-4f86-4709-8fb4-3e8d0706f5aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7e6cb669-68c1-4d65-a972-e6b280842035"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Paricalcitol capsules is a vitamin D analog indicated for the prevention and treatment of secondary hyperparathyroidism associated with Chronic kidney disease (CKD) Stages 3 and 4 ( 1.1 ). CKD Stage 5 in patients on hemodialysis (HD) or peritoneal dialysis (PD) ( 1.2 ). uuid:ea8ebcba-48f9-4054-ab99-6987e9bb4f35 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7931 biolink:treats MONDO:0005300 PMID:41385096 "[{""id"":""uuid:5ef2e3fc-a36b-4931-b09b-7a7956f55de7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:028d7c85-1acc-4aa6-9587-5d07b85f9b9f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Paricalcitol capsules is a vitamin D analog indicated for the prevention and treatment of secondary hyperparathyroidism associated with Chronic kidney disease (CKD) Stages 3 and 4 ( 1.1 ). CKD Stage 5 in patients on hemodialysis (HD) or peritoneal dialysis (PD) ( 1.2 ). uuid:4e6160ca-a585-4265-a99a-cf2510441a78 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7931 biolink:treats MONDO:0004375 PMID:41385096 "[{""id"":""uuid:a7353032-d45d-4ac3-ba9d-3b1f85f5d596"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:20c12f4a-94cb-47c2-b222-83f896f34645"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Paricalcitol capsules is a vitamin D analog indicated for the prevention and treatment of secondary hyperparathyroidism associated with Chronic kidney disease (CKD) Stages 3 and 4 ( 1.1 ). CKD Stage 5 in patients on hemodialysis (HD) or peritoneal dialysis (PD) ( 1.2 ). uuid:ec10910c-28cc-4436-ac75-13749da95c9f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4786 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:bdc6de30-6583-4c8a-87a0-9de9b561828a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:18db0417-053e-494b-9f26-1812ce54baba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension Enalapril maleate is indicated for the treatment of hypertension. Enalapril maleate is effective alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. The blood pressure lowering effects of enalapril maleate and thiazides are approximately additive. Heart Failure Enalapril maleate is indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. In these patients enalapril maleate improves symptoms, increases survival, and decreases the frequency of hospitalization (see CLINICAL PHARMACOLOGY, Heart Failure, Mortality Trials for details and limitations of survival trials). Asymptomatic Left Ventricular Dysfunction In clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35 percent), enalapril maleate decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure (see CLINICAL PHARMACOLOGY, Heart Failure, Mortality Trials for details and limitations of survival trials). In using enalapril maleate consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalapril maleate does not have a similar risk (see WARNINGS). In considering use of enalapril maleate it should be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, it should be noted that black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks (see WARNINGS, Head and Neck Angioedema). uuid:72efb76c-eab3-485f-8f84-e0370fbd1c2c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4786 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:c271ec30-34c5-4cda-8d05-316e3d00d477"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f47955d2-6035-4709-8f62-4b4772d54c64"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension Enalapril maleate is indicated for the treatment of hypertension. Enalapril maleate is effective alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. The blood pressure lowering effects of enalapril maleate and thiazides are approximately additive. Heart Failure Enalapril maleate is indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. In these patients enalapril maleate improves symptoms, increases survival, and decreases the frequency of hospitalization (see CLINICAL PHARMACOLOGY, Heart Failure, Mortality Trials for details and limitations of survival trials). Asymptomatic Left Ventricular Dysfunction In clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35 percent), enalapril maleate decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure (see CLINICAL PHARMACOLOGY, Heart Failure, Mortality Trials for details and limitations of survival trials). In using enalapril maleate consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalapril maleate does not have a similar risk (see WARNINGS). In considering use of enalapril maleate it should be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, it should be noted that black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks (see WARNINGS, Head and Neck Angioedema). uuid:2f0aa1e5-dbbc-44e0-9f02-17a9dbe54aa2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2668 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:7749c439-a982-4d7c-93e4-fced503150ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:336eb0ec-5c72-4daa-b152-b1a9e39eb1f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amlodipine besylate tablets USP are a calcium channel blocker and may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of: Hypertension ( 1.1 ) Amlodipine besylate tablets USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. Coronary Artery Disease ( 1.2 ) Chronic Stable Angina Vasospastic Angina (Prinzmetal's or Variant Angina) Angiographically Documented Coronary Artery Disease in patients without heart failure or an ejection fraction < 40% uuid:de5581df-b0e5-473a-b140-41bc9d01f520 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2668 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:70b81291-5600-40d6-a617-5ed2b6cdf111"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:71c558fb-8e81-4b38-8eb6-4f0f556a1901"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amlodipine besylate tablets USP are a calcium channel blocker and may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of: Hypertension ( 1.1 ) Amlodipine besylate tablets USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. Coronary Artery Disease ( 1.2 ) Chronic Stable Angina Vasospastic Angina (Prinzmetal's or Variant Angina) Angiographically Documented Coronary Artery Disease in patients without heart failure or an ejection fraction < 40% uuid:1cf3147a-e8d0-4fdf-9b4c-ec3824e6ff96 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77733 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:c42aa21f-58a7-4764-a612-5de33770097b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c4e9a164-f23c-4305-8d66-90c7c09c2056"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Verapamil hydrochloride extended-release tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. uuid:01e6c83e-9d1f-4118-b8ea-ee95dd33e72a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77733 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:0177d692-3ce8-4d1a-b51b-cc0d6c46732c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1c9ec909-16db-45d5-ab70-5a9158b3fd96"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Verapamil hydrochloride extended-release tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. uuid:13e09f67-73cc-4b53-b898-4152aa1ba06a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77733 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:2f89e496-8a56-49a2-929e-1cbb0ea505ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1411b6d8-84c7-43e5-8553-ac81a0a40a9f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Verapamil hydrochloride extended-release tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. uuid:8af25c39-ce94-441a-9834-ec5e6ab22090 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77733 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:e248c336-cd6b-4f74-9116-6bbb1e7e31b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7d8663c8-8fb6-4715-a474-134401fe3bef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Verapamil hydrochloride extended-release tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. uuid:5755a825-0ccb-481f-8033-6af38ccff576 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77733 biolink:treats MONDO:0005016 PMID:41385096 "[{""id"":""uuid:c946d9fe-7a23-404b-a837-af5ad5a23f89"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:efb03473-11a6-4475-bd4d-c66476d3fdb8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Verapamil hydrochloride extended-release tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. uuid:0d56b9d0-d375-4eee-a731-63ebfcf6fa7c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats MONDO:0005227 PMID:41385096 "[{""id"":""uuid:a76adc6a-771e-4c70-ac84-ed0e0229a4cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:07ad2d55-d6fe-4a9e-b559-092b68762edf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin and other antibacterial drugs, levofloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Levofloxacin tablets are indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. Culture and susceptibility testing Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to levofloxacin [see Microbiology(12.4)]. Therapy with levofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be selected. As with other drugs in this class, some isolates of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with levofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information about the continued susceptibility of the pathogens to the antimicrobial agent and also the possible emergence of bacterial resistance. 1.1 Nosocomial Pneumonia Levofloxacin is indicated for the treatment of nosocomial pneumonia due to methicillinsusceptible Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, or Streptococcus pneumoniae. Adjunctive therapy should be used as clinically indicated. Where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an antipseudomonal β-lactam is recommended [see Clinical Studies (14.1)]. 1.2 Community-Acquired Pneumonia: 7-14 day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae (including multidrug-resistant Streptococcus pneumoniae [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae, Legionella pneumophila, or Mycoplasma pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.2)]. MDRSP isolates are strains resistant to two or more of the following antibacterials: penicillin (MIC ≥2 mcg/mL), 2nd generation cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole. 1.3 Community-Acquired Pneumonia: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to Streptococcus pneumoniae (excluding multi-drug-resistant strains [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Mycoplasma pneumoniae, or Chlamydophila pneumoniae [see Dosage and Administration (2.1)and Clinical Studies (14.3)]. 1.4 Acute Bacterial Sinusitis: 5-day and 10-14 day Treatment Regimens Levofloxacin is indicated for the treatment of acute bacterial sinusitis due to Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis [see Clinical Studies (14.4)]. 1.5 Acute Bacterial Exacerbation of Chronic Bronchitis Levofloxacin is indicated for the treatment of acute bacterial exacerbation of chronic bronchitis due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis. 1.6 Complicated Skin and Skin Structure Infections Levofloxacin is indicated for the treatment of complicated skin and skin structure infections due to methicillin-susceptible Staphylococcus aureus, Enterococcus faecalis, Streptococcus pyogenes, or Proteus mirabilis [see Clinical Studies (14.5)]. 1.7 Uncomplicated Skin and Skin Structure Infections Levofloxacin is indicated for the treatment of uncomplicated skin and skin structure infections (mild to moderate) including abscesses, cellulitis, furuncles, impetigo, pyoderma, wound infections, due to methicillin-susceptible Staphylococcus aureus, or Streptococcus pyogenes. 1.8 Chronic Bacterial Prostatitis Levofloxacin is indicated for the treatment of chronic bacterial prostatitis due to Escherichia coli, Enterococcus faecalis, or methicillin-susceptible Staphylococcus epidermidis [see Clinical Studies (14.6)]. 1.9 Complicated Urinary Tract Infections: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis [see Clinical Studies (14.7)]. 1.10 Complicated Urinary Tract Infections: 10-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections (mild to moderate) due to Enterococcus faecalis, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa [see Clinical Studies (14.8)]. 1.11 Acute Pyelonephritis: 5 or 10-day Treatment Regimen Levofloxacin is indicated for the treatment of acute pyelonephritis caused by Escherichia coli, including cases with concurrent bacteremia [see Clinical Studies(14.7, 14.8)].]. 1.12 Uncomplicated Urinary Tract Infections Levofloxacin is indicated for the treatment of uncomplicated urinary tract infections (mild to moderate) due to Escherichia coli, Klebsiella pneumoniae, or Staphylococcus saprophyticus. 1.13 Inhalational Anthrax (Post-Exposure) Levofloxacin is indicated for inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. The effectiveness of levofloxacin is based on plasma concentrations achieved in humans, a surrogate endpoint reasonably likely to predict clinical benefit. Levofloxacin has not been tested in humans for the post-exposure prevention of inhalation anthrax. The safety of levofloxacin in adults for durations of therapy beyond 28 days or in pediatric patients for durations of therapy beyond 14 days has not been studied. Prolonged levofloxacin therapy should only be used when the benefit outweighs the risk [see Dosage and Administration(2.1, 2.2) and Clinical Studies (14.9)]. 1.14 Plague Levofloxacin is indicated for treatment of plague, including pneumonic and septicemic plague, due to Yersinia pestis (Y. pestis) and prophylaxis for plague in adults and pediatric patients, 6 months of age and older. Efficacy studies of levofloxacin could not be conducted in humans with plague for ethical and feasibility reasons. Therefore, approval of this indication was based on an efficacy study conducted in animals [seeDosage and Administration (2.1, 2.2) and Clinical Studies (14.10)]. uuid:cef5db76-726d-47a6-8cec-3e187018ab5b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats MONDO:0005230 PMID:41385096 "[{""id"":""uuid:840464fc-70b0-4d76-b5b9-b8a1b5e55e57"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e81401e8-af86-4d1a-929c-0d2781bd9032"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin and other antibacterial drugs, levofloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Levofloxacin tablets are indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. Culture and susceptibility testing Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to levofloxacin [see Microbiology(12.4)]. Therapy with levofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be selected. As with other drugs in this class, some isolates of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with levofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information about the continued susceptibility of the pathogens to the antimicrobial agent and also the possible emergence of bacterial resistance. 1.1 Nosocomial Pneumonia Levofloxacin is indicated for the treatment of nosocomial pneumonia due to methicillinsusceptible Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, or Streptococcus pneumoniae. Adjunctive therapy should be used as clinically indicated. Where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an antipseudomonal β-lactam is recommended [see Clinical Studies (14.1)]. 1.2 Community-Acquired Pneumonia: 7-14 day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae (including multidrug-resistant Streptococcus pneumoniae [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae, Legionella pneumophila, or Mycoplasma pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.2)]. MDRSP isolates are strains resistant to two or more of the following antibacterials: penicillin (MIC ≥2 mcg/mL), 2nd generation cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole. 1.3 Community-Acquired Pneumonia: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to Streptococcus pneumoniae (excluding multi-drug-resistant strains [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Mycoplasma pneumoniae, or Chlamydophila pneumoniae [see Dosage and Administration (2.1)and Clinical Studies (14.3)]. 1.4 Acute Bacterial Sinusitis: 5-day and 10-14 day Treatment Regimens Levofloxacin is indicated for the treatment of acute bacterial sinusitis due to Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis [see Clinical Studies (14.4)]. 1.5 Acute Bacterial Exacerbation of Chronic Bronchitis Levofloxacin is indicated for the treatment of acute bacterial exacerbation of chronic bronchitis due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis. 1.6 Complicated Skin and Skin Structure Infections Levofloxacin is indicated for the treatment of complicated skin and skin structure infections due to methicillin-susceptible Staphylococcus aureus, Enterococcus faecalis, Streptococcus pyogenes, or Proteus mirabilis [see Clinical Studies (14.5)]. 1.7 Uncomplicated Skin and Skin Structure Infections Levofloxacin is indicated for the treatment of uncomplicated skin and skin structure infections (mild to moderate) including abscesses, cellulitis, furuncles, impetigo, pyoderma, wound infections, due to methicillin-susceptible Staphylococcus aureus, or Streptococcus pyogenes. 1.8 Chronic Bacterial Prostatitis Levofloxacin is indicated for the treatment of chronic bacterial prostatitis due to Escherichia coli, Enterococcus faecalis, or methicillin-susceptible Staphylococcus epidermidis [see Clinical Studies (14.6)]. 1.9 Complicated Urinary Tract Infections: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis [see Clinical Studies (14.7)]. 1.10 Complicated Urinary Tract Infections: 10-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections (mild to moderate) due to Enterococcus faecalis, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa [see Clinical Studies (14.8)]. 1.11 Acute Pyelonephritis: 5 or 10-day Treatment Regimen Levofloxacin is indicated for the treatment of acute pyelonephritis caused by Escherichia coli, including cases with concurrent bacteremia [see Clinical Studies(14.7, 14.8)].]. 1.12 Uncomplicated Urinary Tract Infections Levofloxacin is indicated for the treatment of uncomplicated urinary tract infections (mild to moderate) due to Escherichia coli, Klebsiella pneumoniae, or Staphylococcus saprophyticus. 1.13 Inhalational Anthrax (Post-Exposure) Levofloxacin is indicated for inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. The effectiveness of levofloxacin is based on plasma concentrations achieved in humans, a surrogate endpoint reasonably likely to predict clinical benefit. Levofloxacin has not been tested in humans for the post-exposure prevention of inhalation anthrax. The safety of levofloxacin in adults for durations of therapy beyond 28 days or in pediatric patients for durations of therapy beyond 14 days has not been studied. Prolonged levofloxacin therapy should only be used when the benefit outweighs the risk [see Dosage and Administration(2.1, 2.2) and Clinical Studies (14.9)]. 1.14 Plague Levofloxacin is indicated for treatment of plague, including pneumonic and septicemic plague, due to Yersinia pestis (Y. pestis) and prophylaxis for plague in adults and pediatric patients, 6 months of age and older. Efficacy studies of levofloxacin could not be conducted in humans with plague for ethical and feasibility reasons. Therefore, approval of this indication was based on an efficacy study conducted in animals [seeDosage and Administration (2.1, 2.2) and Clinical Studies (14.10)]. uuid:df4ee92a-5ba7-42d6-9232-3228f1f24cd1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats HP:0020083 PMID:41385096 "[{""id"":""uuid:1fd7ca9a-ff87-4718-8e90-d20307bf2002"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1f50de6b-5a59-499c-9861-eccf5f106330"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin and other antibacterial drugs, levofloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Levofloxacin tablets are indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. Culture and susceptibility testing Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to levofloxacin [see Microbiology(12.4)]. Therapy with levofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be selected. As with other drugs in this class, some isolates of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with levofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information about the continued susceptibility of the pathogens to the antimicrobial agent and also the possible emergence of bacterial resistance. 1.1 Nosocomial Pneumonia Levofloxacin is indicated for the treatment of nosocomial pneumonia due to methicillinsusceptible Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, or Streptococcus pneumoniae. Adjunctive therapy should be used as clinically indicated. Where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an antipseudomonal β-lactam is recommended [see Clinical Studies (14.1)]. 1.2 Community-Acquired Pneumonia: 7-14 day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae (including multidrug-resistant Streptococcus pneumoniae [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae, Legionella pneumophila, or Mycoplasma pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.2)]. MDRSP isolates are strains resistant to two or more of the following antibacterials: penicillin (MIC ≥2 mcg/mL), 2nd generation cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole. 1.3 Community-Acquired Pneumonia: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to Streptococcus pneumoniae (excluding multi-drug-resistant strains [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Mycoplasma pneumoniae, or Chlamydophila pneumoniae [see Dosage and Administration (2.1)and Clinical Studies (14.3)]. 1.4 Acute Bacterial Sinusitis: 5-day and 10-14 day Treatment Regimens Levofloxacin is indicated for the treatment of acute bacterial sinusitis due to Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis [see Clinical Studies (14.4)]. 1.5 Acute Bacterial Exacerbation of Chronic Bronchitis Levofloxacin is indicated for the treatment of acute bacterial exacerbation of chronic bronchitis due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis. 1.6 Complicated Skin and Skin Structure Infections Levofloxacin is indicated for the treatment of complicated skin and skin structure infections due to methicillin-susceptible Staphylococcus aureus, Enterococcus faecalis, Streptococcus pyogenes, or Proteus mirabilis [see Clinical Studies (14.5)]. 1.7 Uncomplicated Skin and Skin Structure Infections Levofloxacin is indicated for the treatment of uncomplicated skin and skin structure infections (mild to moderate) including abscesses, cellulitis, furuncles, impetigo, pyoderma, wound infections, due to methicillin-susceptible Staphylococcus aureus, or Streptococcus pyogenes. 1.8 Chronic Bacterial Prostatitis Levofloxacin is indicated for the treatment of chronic bacterial prostatitis due to Escherichia coli, Enterococcus faecalis, or methicillin-susceptible Staphylococcus epidermidis [see Clinical Studies (14.6)]. 1.9 Complicated Urinary Tract Infections: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis [see Clinical Studies (14.7)]. 1.10 Complicated Urinary Tract Infections: 10-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections (mild to moderate) due to Enterococcus faecalis, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa [see Clinical Studies (14.8)]. 1.11 Acute Pyelonephritis: 5 or 10-day Treatment Regimen Levofloxacin is indicated for the treatment of acute pyelonephritis caused by Escherichia coli, including cases with concurrent bacteremia [see Clinical Studies(14.7, 14.8)].]. 1.12 Uncomplicated Urinary Tract Infections Levofloxacin is indicated for the treatment of uncomplicated urinary tract infections (mild to moderate) due to Escherichia coli, Klebsiella pneumoniae, or Staphylococcus saprophyticus. 1.13 Inhalational Anthrax (Post-Exposure) Levofloxacin is indicated for inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. The effectiveness of levofloxacin is based on plasma concentrations achieved in humans, a surrogate endpoint reasonably likely to predict clinical benefit. Levofloxacin has not been tested in humans for the post-exposure prevention of inhalation anthrax. The safety of levofloxacin in adults for durations of therapy beyond 28 days or in pediatric patients for durations of therapy beyond 14 days has not been studied. Prolonged levofloxacin therapy should only be used when the benefit outweighs the risk [see Dosage and Administration(2.1, 2.2) and Clinical Studies (14.9)]. 1.14 Plague Levofloxacin is indicated for treatment of plague, including pneumonic and septicemic plague, due to Yersinia pestis (Y. pestis) and prophylaxis for plague in adults and pediatric patients, 6 months of age and older. Efficacy studies of levofloxacin could not be conducted in humans with plague for ethical and feasibility reasons. Therefore, approval of this indication was based on an efficacy study conducted in animals [seeDosage and Administration (2.1, 2.2) and Clinical Studies (14.10)]. uuid:4d709e70-d13d-41c3-b01d-c730366acc5f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats MONDO:0004592 PMID:41385096 "[{""id"":""uuid:7cb0be5d-016e-4544-86f7-b97a86e880ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d6282bf9-b752-453a-b2d6-0b9e52a519c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin and other antibacterial drugs, levofloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Levofloxacin tablets are indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. Culture and susceptibility testing Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to levofloxacin [see Microbiology(12.4)]. Therapy with levofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be selected. As with other drugs in this class, some isolates of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with levofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information about the continued susceptibility of the pathogens to the antimicrobial agent and also the possible emergence of bacterial resistance. 1.1 Nosocomial Pneumonia Levofloxacin is indicated for the treatment of nosocomial pneumonia due to methicillinsusceptible Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, or Streptococcus pneumoniae. Adjunctive therapy should be used as clinically indicated. Where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an antipseudomonal β-lactam is recommended [see Clinical Studies (14.1)]. 1.2 Community-Acquired Pneumonia: 7-14 day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae (including multidrug-resistant Streptococcus pneumoniae [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae, Legionella pneumophila, or Mycoplasma pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.2)]. MDRSP isolates are strains resistant to two or more of the following antibacterials: penicillin (MIC ≥2 mcg/mL), 2nd generation cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole. 1.3 Community-Acquired Pneumonia: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to Streptococcus pneumoniae (excluding multi-drug-resistant strains [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Mycoplasma pneumoniae, or Chlamydophila pneumoniae [see Dosage and Administration (2.1)and Clinical Studies (14.3)]. 1.4 Acute Bacterial Sinusitis: 5-day and 10-14 day Treatment Regimens Levofloxacin is indicated for the treatment of acute bacterial sinusitis due to Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis [see Clinical Studies (14.4)]. 1.5 Acute Bacterial Exacerbation of Chronic Bronchitis Levofloxacin is indicated for the treatment of acute bacterial exacerbation of chronic bronchitis due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis. 1.6 Complicated Skin and Skin Structure Infections Levofloxacin is indicated for the treatment of complicated skin and skin structure infections due to methicillin-susceptible Staphylococcus aureus, Enterococcus faecalis, Streptococcus pyogenes, or Proteus mirabilis [see Clinical Studies (14.5)]. 1.7 Uncomplicated Skin and Skin Structure Infections Levofloxacin is indicated for the treatment of uncomplicated skin and skin structure infections (mild to moderate) including abscesses, cellulitis, furuncles, impetigo, pyoderma, wound infections, due to methicillin-susceptible Staphylococcus aureus, or Streptococcus pyogenes. 1.8 Chronic Bacterial Prostatitis Levofloxacin is indicated for the treatment of chronic bacterial prostatitis due to Escherichia coli, Enterococcus faecalis, or methicillin-susceptible Staphylococcus epidermidis [see Clinical Studies (14.6)]. 1.9 Complicated Urinary Tract Infections: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis [see Clinical Studies (14.7)]. 1.10 Complicated Urinary Tract Infections: 10-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections (mild to moderate) due to Enterococcus faecalis, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa [see Clinical Studies (14.8)]. 1.11 Acute Pyelonephritis: 5 or 10-day Treatment Regimen Levofloxacin is indicated for the treatment of acute pyelonephritis caused by Escherichia coli, including cases with concurrent bacteremia [see Clinical Studies(14.7, 14.8)].]. 1.12 Uncomplicated Urinary Tract Infections Levofloxacin is indicated for the treatment of uncomplicated urinary tract infections (mild to moderate) due to Escherichia coli, Klebsiella pneumoniae, or Staphylococcus saprophyticus. 1.13 Inhalational Anthrax (Post-Exposure) Levofloxacin is indicated for inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. The effectiveness of levofloxacin is based on plasma concentrations achieved in humans, a surrogate endpoint reasonably likely to predict clinical benefit. Levofloxacin has not been tested in humans for the post-exposure prevention of inhalation anthrax. The safety of levofloxacin in adults for durations of therapy beyond 28 days or in pediatric patients for durations of therapy beyond 14 days has not been studied. Prolonged levofloxacin therapy should only be used when the benefit outweighs the risk [see Dosage and Administration(2.1, 2.2) and Clinical Studies (14.9)]. 1.14 Plague Levofloxacin is indicated for treatment of plague, including pneumonic and septicemic plague, due to Yersinia pestis (Y. pestis) and prophylaxis for plague in adults and pediatric patients, 6 months of age and older. Efficacy studies of levofloxacin could not be conducted in humans with plague for ethical and feasibility reasons. Therefore, approval of this indication was based on an efficacy study conducted in animals [seeDosage and Administration (2.1, 2.2) and Clinical Studies (14.10)]. uuid:bc6b06b7-fa36-441e-8929-4437231ac4a4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats MONDO:0002922 PMID:41385096 "[{""id"":""uuid:e2a9ecca-465d-4a56-ba03-4d305d0d1c74"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9adeed73-1734-46b0-b775-227d56f29a0f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin and other antibacterial drugs, levofloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Levofloxacin tablets are indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. Culture and susceptibility testing Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to levofloxacin [see Microbiology(12.4)]. Therapy with levofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be selected. As with other drugs in this class, some isolates of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with levofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information about the continued susceptibility of the pathogens to the antimicrobial agent and also the possible emergence of bacterial resistance. 1.1 Nosocomial Pneumonia Levofloxacin is indicated for the treatment of nosocomial pneumonia due to methicillinsusceptible Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, or Streptococcus pneumoniae. Adjunctive therapy should be used as clinically indicated. Where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an antipseudomonal β-lactam is recommended [see Clinical Studies (14.1)]. 1.2 Community-Acquired Pneumonia: 7-14 day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae (including multidrug-resistant Streptococcus pneumoniae [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae, Legionella pneumophila, or Mycoplasma pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.2)]. MDRSP isolates are strains resistant to two or more of the following antibacterials: penicillin (MIC ≥2 mcg/mL), 2nd generation cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole. 1.3 Community-Acquired Pneumonia: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to Streptococcus pneumoniae (excluding multi-drug-resistant strains [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Mycoplasma pneumoniae, or Chlamydophila pneumoniae [see Dosage and Administration (2.1)and Clinical Studies (14.3)]. 1.4 Acute Bacterial Sinusitis: 5-day and 10-14 day Treatment Regimens Levofloxacin is indicated for the treatment of acute bacterial sinusitis due to Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis [see Clinical Studies (14.4)]. 1.5 Acute Bacterial Exacerbation of Chronic Bronchitis Levofloxacin is indicated for the treatment of acute bacterial exacerbation of chronic bronchitis due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis. 1.6 Complicated Skin and Skin Structure Infections Levofloxacin is indicated for the treatment of complicated skin and skin structure infections due to methicillin-susceptible Staphylococcus aureus, Enterococcus faecalis, Streptococcus pyogenes, or Proteus mirabilis [see Clinical Studies (14.5)]. 1.7 Uncomplicated Skin and Skin Structure Infections Levofloxacin is indicated for the treatment of uncomplicated skin and skin structure infections (mild to moderate) including abscesses, cellulitis, furuncles, impetigo, pyoderma, wound infections, due to methicillin-susceptible Staphylococcus aureus, or Streptococcus pyogenes. 1.8 Chronic Bacterial Prostatitis Levofloxacin is indicated for the treatment of chronic bacterial prostatitis due to Escherichia coli, Enterococcus faecalis, or methicillin-susceptible Staphylococcus epidermidis [see Clinical Studies (14.6)]. 1.9 Complicated Urinary Tract Infections: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis [see Clinical Studies (14.7)]. 1.10 Complicated Urinary Tract Infections: 10-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections (mild to moderate) due to Enterococcus faecalis, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa [see Clinical Studies (14.8)]. 1.11 Acute Pyelonephritis: 5 or 10-day Treatment Regimen Levofloxacin is indicated for the treatment of acute pyelonephritis caused by Escherichia coli, including cases with concurrent bacteremia [see Clinical Studies(14.7, 14.8)].]. 1.12 Uncomplicated Urinary Tract Infections Levofloxacin is indicated for the treatment of uncomplicated urinary tract infections (mild to moderate) due to Escherichia coli, Klebsiella pneumoniae, or Staphylococcus saprophyticus. 1.13 Inhalational Anthrax (Post-Exposure) Levofloxacin is indicated for inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. The effectiveness of levofloxacin is based on plasma concentrations achieved in humans, a surrogate endpoint reasonably likely to predict clinical benefit. Levofloxacin has not been tested in humans for the post-exposure prevention of inhalation anthrax. The safety of levofloxacin in adults for durations of therapy beyond 28 days or in pediatric patients for durations of therapy beyond 14 days has not been studied. Prolonged levofloxacin therapy should only be used when the benefit outweighs the risk [see Dosage and Administration(2.1, 2.2) and Clinical Studies (14.9)]. 1.14 Plague Levofloxacin is indicated for treatment of plague, including pneumonic and septicemic plague, due to Yersinia pestis (Y. pestis) and prophylaxis for plague in adults and pediatric patients, 6 months of age and older. Efficacy studies of levofloxacin could not be conducted in humans with plague for ethical and feasibility reasons. Therefore, approval of this indication was based on an efficacy study conducted in animals [seeDosage and Administration (2.1, 2.2) and Clinical Studies (14.10)]. uuid:6653e8d7-fcb5-4521-b335-51c4494e1cc3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats MONDO:0024313 PMID:41385096 "[{""id"":""uuid:8766fee6-ef3a-4bce-88c9-3472d56f726c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:74d7cc37-6cbb-41ea-bafa-3000d2067bd9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin and other antibacterial drugs, levofloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Levofloxacin tablets are indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. Culture and susceptibility testing Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to levofloxacin [see Microbiology(12.4)]. Therapy with levofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be selected. As with other drugs in this class, some isolates of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with levofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information about the continued susceptibility of the pathogens to the antimicrobial agent and also the possible emergence of bacterial resistance. 1.1 Nosocomial Pneumonia Levofloxacin is indicated for the treatment of nosocomial pneumonia due to methicillinsusceptible Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, or Streptococcus pneumoniae. Adjunctive therapy should be used as clinically indicated. Where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an antipseudomonal β-lactam is recommended [see Clinical Studies (14.1)]. 1.2 Community-Acquired Pneumonia: 7-14 day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae (including multidrug-resistant Streptococcus pneumoniae [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae, Legionella pneumophila, or Mycoplasma pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.2)]. MDRSP isolates are strains resistant to two or more of the following antibacterials: penicillin (MIC ≥2 mcg/mL), 2nd generation cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole. 1.3 Community-Acquired Pneumonia: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to Streptococcus pneumoniae (excluding multi-drug-resistant strains [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Mycoplasma pneumoniae, or Chlamydophila pneumoniae [see Dosage and Administration (2.1)and Clinical Studies (14.3)]. 1.4 Acute Bacterial Sinusitis: 5-day and 10-14 day Treatment Regimens Levofloxacin is indicated for the treatment of acute bacterial sinusitis due to Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis [see Clinical Studies (14.4)]. 1.5 Acute Bacterial Exacerbation of Chronic Bronchitis Levofloxacin is indicated for the treatment of acute bacterial exacerbation of chronic bronchitis due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis. 1.6 Complicated Skin and Skin Structure Infections Levofloxacin is indicated for the treatment of complicated skin and skin structure infections due to methicillin-susceptible Staphylococcus aureus, Enterococcus faecalis, Streptococcus pyogenes, or Proteus mirabilis [see Clinical Studies (14.5)]. 1.7 Uncomplicated Skin and Skin Structure Infections Levofloxacin is indicated for the treatment of uncomplicated skin and skin structure infections (mild to moderate) including abscesses, cellulitis, furuncles, impetigo, pyoderma, wound infections, due to methicillin-susceptible Staphylococcus aureus, or Streptococcus pyogenes. 1.8 Chronic Bacterial Prostatitis Levofloxacin is indicated for the treatment of chronic bacterial prostatitis due to Escherichia coli, Enterococcus faecalis, or methicillin-susceptible Staphylococcus epidermidis [see Clinical Studies (14.6)]. 1.9 Complicated Urinary Tract Infections: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis [see Clinical Studies (14.7)]. 1.10 Complicated Urinary Tract Infections: 10-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections (mild to moderate) due to Enterococcus faecalis, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa [see Clinical Studies (14.8)]. 1.11 Acute Pyelonephritis: 5 or 10-day Treatment Regimen Levofloxacin is indicated for the treatment of acute pyelonephritis caused by Escherichia coli, including cases with concurrent bacteremia [see Clinical Studies(14.7, 14.8)].]. 1.12 Uncomplicated Urinary Tract Infections Levofloxacin is indicated for the treatment of uncomplicated urinary tract infections (mild to moderate) due to Escherichia coli, Klebsiella pneumoniae, or Staphylococcus saprophyticus. 1.13 Inhalational Anthrax (Post-Exposure) Levofloxacin is indicated for inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. The effectiveness of levofloxacin is based on plasma concentrations achieved in humans, a surrogate endpoint reasonably likely to predict clinical benefit. Levofloxacin has not been tested in humans for the post-exposure prevention of inhalation anthrax. The safety of levofloxacin in adults for durations of therapy beyond 28 days or in pediatric patients for durations of therapy beyond 14 days has not been studied. Prolonged levofloxacin therapy should only be used when the benefit outweighs the risk [see Dosage and Administration(2.1, 2.2) and Clinical Studies (14.9)]. 1.14 Plague Levofloxacin is indicated for treatment of plague, including pneumonic and septicemic plague, due to Yersinia pestis (Y. pestis) and prophylaxis for plague in adults and pediatric patients, 6 months of age and older. Efficacy studies of levofloxacin could not be conducted in humans with plague for ethical and feasibility reasons. Therefore, approval of this indication was based on an efficacy study conducted in animals [seeDosage and Administration (2.1, 2.2) and Clinical Studies (14.10)]. uuid:a2c288dd-473c-41a6-ba16-f9eb487ec9f3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats MONDO:0001024 PMID:41385096 "[{""id"":""uuid:7801fc77-a77a-4cf4-a2d6-51249c4bba36"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3c51bfa6-858f-4b86-8bfa-20cc7af2a89f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin and other antibacterial drugs, levofloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Levofloxacin tablets are indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. Culture and susceptibility testing Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to levofloxacin [see Microbiology(12.4)]. Therapy with levofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be selected. As with other drugs in this class, some isolates of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with levofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information about the continued susceptibility of the pathogens to the antimicrobial agent and also the possible emergence of bacterial resistance. 1.1 Nosocomial Pneumonia Levofloxacin is indicated for the treatment of nosocomial pneumonia due to methicillinsusceptible Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, or Streptococcus pneumoniae. Adjunctive therapy should be used as clinically indicated. Where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an antipseudomonal β-lactam is recommended [see Clinical Studies (14.1)]. 1.2 Community-Acquired Pneumonia: 7-14 day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae (including multidrug-resistant Streptococcus pneumoniae [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae, Legionella pneumophila, or Mycoplasma pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.2)]. MDRSP isolates are strains resistant to two or more of the following antibacterials: penicillin (MIC ≥2 mcg/mL), 2nd generation cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole. 1.3 Community-Acquired Pneumonia: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to Streptococcus pneumoniae (excluding multi-drug-resistant strains [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Mycoplasma pneumoniae, or Chlamydophila pneumoniae [see Dosage and Administration (2.1)and Clinical Studies (14.3)]. 1.4 Acute Bacterial Sinusitis: 5-day and 10-14 day Treatment Regimens Levofloxacin is indicated for the treatment of acute bacterial sinusitis due to Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis [see Clinical Studies (14.4)]. 1.5 Acute Bacterial Exacerbation of Chronic Bronchitis Levofloxacin is indicated for the treatment of acute bacterial exacerbation of chronic bronchitis due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis. 1.6 Complicated Skin and Skin Structure Infections Levofloxacin is indicated for the treatment of complicated skin and skin structure infections due to methicillin-susceptible Staphylococcus aureus, Enterococcus faecalis, Streptococcus pyogenes, or Proteus mirabilis [see Clinical Studies (14.5)]. 1.7 Uncomplicated Skin and Skin Structure Infections Levofloxacin is indicated for the treatment of uncomplicated skin and skin structure infections (mild to moderate) including abscesses, cellulitis, furuncles, impetigo, pyoderma, wound infections, due to methicillin-susceptible Staphylococcus aureus, or Streptococcus pyogenes. 1.8 Chronic Bacterial Prostatitis Levofloxacin is indicated for the treatment of chronic bacterial prostatitis due to Escherichia coli, Enterococcus faecalis, or methicillin-susceptible Staphylococcus epidermidis [see Clinical Studies (14.6)]. 1.9 Complicated Urinary Tract Infections: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis [see Clinical Studies (14.7)]. 1.10 Complicated Urinary Tract Infections: 10-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections (mild to moderate) due to Enterococcus faecalis, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa [see Clinical Studies (14.8)]. 1.11 Acute Pyelonephritis: 5 or 10-day Treatment Regimen Levofloxacin is indicated for the treatment of acute pyelonephritis caused by Escherichia coli, including cases with concurrent bacteremia [see Clinical Studies(14.7, 14.8)].]. 1.12 Uncomplicated Urinary Tract Infections Levofloxacin is indicated for the treatment of uncomplicated urinary tract infections (mild to moderate) due to Escherichia coli, Klebsiella pneumoniae, or Staphylococcus saprophyticus. 1.13 Inhalational Anthrax (Post-Exposure) Levofloxacin is indicated for inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. The effectiveness of levofloxacin is based on plasma concentrations achieved in humans, a surrogate endpoint reasonably likely to predict clinical benefit. Levofloxacin has not been tested in humans for the post-exposure prevention of inhalation anthrax. The safety of levofloxacin in adults for durations of therapy beyond 28 days or in pediatric patients for durations of therapy beyond 14 days has not been studied. Prolonged levofloxacin therapy should only be used when the benefit outweighs the risk [see Dosage and Administration(2.1, 2.2) and Clinical Studies (14.9)]. 1.14 Plague Levofloxacin is indicated for treatment of plague, including pneumonic and septicemic plague, due to Yersinia pestis (Y. pestis) and prophylaxis for plague in adults and pediatric patients, 6 months of age and older. Efficacy studies of levofloxacin could not be conducted in humans with plague for ethical and feasibility reasons. Therefore, approval of this indication was based on an efficacy study conducted in animals [seeDosage and Administration (2.1, 2.2) and Clinical Studies (14.10)]. uuid:e26e9e6f-d892-4493-bde1-f466b0930a4d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats MONDO:0005956 PMID:41385096 "[{""id"":""uuid:5ec891a3-c4a5-4ef7-a391-4819f3b50892"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2dfad58a-1ac5-4f71-aa15-42e5864b416c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin and other antibacterial drugs, levofloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Levofloxacin tablets are indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. Culture and susceptibility testing Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to levofloxacin [see Microbiology(12.4)]. Therapy with levofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be selected. As with other drugs in this class, some isolates of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with levofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information about the continued susceptibility of the pathogens to the antimicrobial agent and also the possible emergence of bacterial resistance. 1.1 Nosocomial Pneumonia Levofloxacin is indicated for the treatment of nosocomial pneumonia due to methicillinsusceptible Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, or Streptococcus pneumoniae. Adjunctive therapy should be used as clinically indicated. Where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an antipseudomonal β-lactam is recommended [see Clinical Studies (14.1)]. 1.2 Community-Acquired Pneumonia: 7-14 day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae (including multidrug-resistant Streptococcus pneumoniae [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae, Legionella pneumophila, or Mycoplasma pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.2)]. MDRSP isolates are strains resistant to two or more of the following antibacterials: penicillin (MIC ≥2 mcg/mL), 2nd generation cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole. 1.3 Community-Acquired Pneumonia: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to Streptococcus pneumoniae (excluding multi-drug-resistant strains [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Mycoplasma pneumoniae, or Chlamydophila pneumoniae [see Dosage and Administration (2.1)and Clinical Studies (14.3)]. 1.4 Acute Bacterial Sinusitis: 5-day and 10-14 day Treatment Regimens Levofloxacin is indicated for the treatment of acute bacterial sinusitis due to Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis [see Clinical Studies (14.4)]. 1.5 Acute Bacterial Exacerbation of Chronic Bronchitis Levofloxacin is indicated for the treatment of acute bacterial exacerbation of chronic bronchitis due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis. 1.6 Complicated Skin and Skin Structure Infections Levofloxacin is indicated for the treatment of complicated skin and skin structure infections due to methicillin-susceptible Staphylococcus aureus, Enterococcus faecalis, Streptococcus pyogenes, or Proteus mirabilis [see Clinical Studies (14.5)]. 1.7 Uncomplicated Skin and Skin Structure Infections Levofloxacin is indicated for the treatment of uncomplicated skin and skin structure infections (mild to moderate) including abscesses, cellulitis, furuncles, impetigo, pyoderma, wound infections, due to methicillin-susceptible Staphylococcus aureus, or Streptococcus pyogenes. 1.8 Chronic Bacterial Prostatitis Levofloxacin is indicated for the treatment of chronic bacterial prostatitis due to Escherichia coli, Enterococcus faecalis, or methicillin-susceptible Staphylococcus epidermidis [see Clinical Studies (14.6)]. 1.9 Complicated Urinary Tract Infections: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis [see Clinical Studies (14.7)]. 1.10 Complicated Urinary Tract Infections: 10-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections (mild to moderate) due to Enterococcus faecalis, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa [see Clinical Studies (14.8)]. 1.11 Acute Pyelonephritis: 5 or 10-day Treatment Regimen Levofloxacin is indicated for the treatment of acute pyelonephritis caused by Escherichia coli, including cases with concurrent bacteremia [see Clinical Studies(14.7, 14.8)].]. 1.12 Uncomplicated Urinary Tract Infections Levofloxacin is indicated for the treatment of uncomplicated urinary tract infections (mild to moderate) due to Escherichia coli, Klebsiella pneumoniae, or Staphylococcus saprophyticus. 1.13 Inhalational Anthrax (Post-Exposure) Levofloxacin is indicated for inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. The effectiveness of levofloxacin is based on plasma concentrations achieved in humans, a surrogate endpoint reasonably likely to predict clinical benefit. Levofloxacin has not been tested in humans for the post-exposure prevention of inhalation anthrax. The safety of levofloxacin in adults for durations of therapy beyond 28 days or in pediatric patients for durations of therapy beyond 14 days has not been studied. Prolonged levofloxacin therapy should only be used when the benefit outweighs the risk [see Dosage and Administration(2.1, 2.2) and Clinical Studies (14.9)]. 1.14 Plague Levofloxacin is indicated for treatment of plague, including pneumonic and septicemic plague, due to Yersinia pestis (Y. pestis) and prophylaxis for plague in adults and pediatric patients, 6 months of age and older. Efficacy studies of levofloxacin could not be conducted in humans with plague for ethical and feasibility reasons. Therefore, approval of this indication was based on an efficacy study conducted in animals [seeDosage and Administration (2.1, 2.2) and Clinical Studies (14.10)]. uuid:a41c11f2-8a54-4b19-aa1c-e8ee013cd7c1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77363 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:08acfa3e-8163-473d-8cca-be2d2760ab1b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:75ecfe69-c028-47f0-9b38-80e395b15ac3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension Ramipril capsules USP are indicated for the treatment of hypertension. It may be used alone or in combination with thiazide diuretics. Heart Failure Post-Myocardial Infarction Ramipril capsules USP are indicated in stable patients who have demonstrated clinical signs of congestive heart failure within the first few days after sustaining acute myocardial infarction. Administration of ramipril to such patients has been shown to decrease the risk of death (principally cardiovascular death) and to decrease the risks of failure-related hospitalization and progression to severe/resistant heart failure [see Clinical Studies (14.3)]. uuid:0242ca75-bf55-4baa-860b-e35ec1c57cb8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77363 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:775b8806-05cb-4e12-b78c-6a3e89dcae72"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1252caea-8955-43af-9ba4-0e4c9e6730b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension Ramipril capsules USP are indicated for the treatment of hypertension. It may be used alone or in combination with thiazide diuretics. Heart Failure Post-Myocardial Infarction Ramipril capsules USP are indicated in stable patients who have demonstrated clinical signs of congestive heart failure within the first few days after sustaining acute myocardial infarction. Administration of ramipril to such patients has been shown to decrease the risk of death (principally cardiovascular death) and to decrease the risks of failure-related hospitalization and progression to severe/resistant heart failure [see Clinical Studies (14.3)]. uuid:e4c5a2e4-0d06-4880-a2ed-57c7ac3f0415 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1602752 biolink:treats MONDO:0005420 PMID:41385096 "[{""id"":""uuid:c8a9851a-c42e-4163-96a7-d712dafa91a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:70bf3584-79f0-4dd6-961b-e489335bf9a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE: NP Thyroid tablets (thyroid tablets, USP) are indicated: 1. As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (See WARNINGS). 2. As pituitary TSH suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic Iymphocytic thyroiditis (Hashimoto’s), multinodular goiter, and in the management of thyroid cancer. 3. As diagnostic agents in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy. uuid:0ad8157a-c3e2-4f91-8ca7-dc381994a3ea biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1602752 biolink:treats MONDO:0018612 PMID:41385096 "[{""id"":""uuid:283a855f-6bcc-4e6a-903f-9c1c5c3c8737"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:70e364f1-8373-4740-a295-7d8125ef2293"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE: NP Thyroid tablets (thyroid tablets, USP) are indicated: 1. As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (See WARNINGS). 2. As pituitary TSH suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic Iymphocytic thyroiditis (Hashimoto’s), multinodular goiter, and in the management of thyroid cancer. 3. As diagnostic agents in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy. uuid:008b93cc-b44e-457d-b3e7-a0251bd106e7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1602752 biolink:treats MONDO:0009718 PMID:41385096 "[{""id"":""uuid:e94d6c59-bdb2-4412-a852-d3d2f29d059a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:357fc8b9-352c-4b2d-b6e8-a843af0df0f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE: NP Thyroid tablets (thyroid tablets, USP) are indicated: 1. As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (See WARNINGS). 2. As pituitary TSH suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic Iymphocytic thyroiditis (Hashimoto’s), multinodular goiter, and in the management of thyroid cancer. 3. As diagnostic agents in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy. uuid:0197b113-4757-4dce-81d8-ffce91ccc261 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1602752 biolink:treats MONDO:0001658 PMID:41385096 "[{""id"":""uuid:17e791b4-83c7-4041-bd90-b8c08d0fa31c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e26ea02e-e5ba-4a40-8d6b-2c0c0f39f6db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE: NP Thyroid tablets (thyroid tablets, USP) are indicated: 1. As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (See WARNINGS). 2. As pituitary TSH suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic Iymphocytic thyroiditis (Hashimoto’s), multinodular goiter, and in the management of thyroid cancer. 3. As diagnostic agents in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy. uuid:0a4175a7-57e5-4cf3-9f9d-7f0fcd4dfe6a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1602752 biolink:treats HP:0025388 PMID:41385096 "[{""id"":""uuid:fd27a297-63e6-4fc9-a74c-5f4f16290341"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cd504283-1b50-4920-8506-444f072deeb6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE: NP Thyroid tablets (thyroid tablets, USP) are indicated: 1. As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (See WARNINGS). 2. As pituitary TSH suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic Iymphocytic thyroiditis (Hashimoto’s), multinodular goiter, and in the management of thyroid cancer. 3. As diagnostic agents in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy. uuid:361cc433-e639-4891-8b03-6ff4b0fb0c37 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1602752 biolink:treats MONDO:0007699 PMID:41385096 "[{""id"":""uuid:5afe3567-e74d-4a5a-9b64-6afbf9340fcb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eee30013-87cc-4036-b9ec-bef1bee7cbb9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE: NP Thyroid tablets (thyroid tablets, USP) are indicated: 1. As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (See WARNINGS). 2. As pituitary TSH suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic Iymphocytic thyroiditis (Hashimoto’s), multinodular goiter, and in the management of thyroid cancer. 3. As diagnostic agents in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy. uuid:c8e2c4b1-9948-4d16-8c5b-34438b416e3d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1602752 biolink:treats MONDO:0000334 PMID:41385096 "[{""id"":""uuid:5b3ec423-a7dd-4c6b-9d4d-3c6eee11d1d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e0eaab74-b7b4-431d-bcac-a369e13ea374"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE: NP Thyroid tablets (thyroid tablets, USP) are indicated: 1. As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (See WARNINGS). 2. As pituitary TSH suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic Iymphocytic thyroiditis (Hashimoto’s), multinodular goiter, and in the management of thyroid cancer. 3. As diagnostic agents in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy. uuid:462845ce-197f-4214-a091-fd1cd3e45bbf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1602752 biolink:treats MONDO:0002108 PMID:41385096 "[{""id"":""uuid:9ce98976-95b5-4b6e-8daf-789563e9203f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9940300a-d6c5-4c94-835f-5c1b65692876"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE: NP Thyroid tablets (thyroid tablets, USP) are indicated: 1. As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (See WARNINGS). 2. As pituitary TSH suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic Iymphocytic thyroiditis (Hashimoto’s), multinodular goiter, and in the management of thyroid cancer. 3. As diagnostic agents in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy. uuid:2ab8b977-feb0-4f85-bc97-32d2cb46ff72 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1602752 biolink:treats MONDO:0006982 PMID:41385096 "[{""id"":""uuid:1322cbe4-125f-4f5f-81bc-f05e078a4a99"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0a469ed2-7b8e-4c48-aab0-7a9cab0a40be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE: NP Thyroid tablets (thyroid tablets, USP) are indicated: 1. As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (See WARNINGS). 2. As pituitary TSH suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic Iymphocytic thyroiditis (Hashimoto’s), multinodular goiter, and in the management of thyroid cancer. 3. As diagnostic agents in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy. uuid:0b7f39d2-6c35-4a0e-8562-5d5ad65679d2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1602752 biolink:treats MONDO:0004425 PMID:41385096 "[{""id"":""uuid:1081baf0-1aa8-45ce-9a64-249f3768ddf4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:85d9af7f-4992-400e-baee-693e489d0069"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE: NP Thyroid tablets (thyroid tablets, USP) are indicated: 1. As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (See WARNINGS). 2. As pituitary TSH suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic Iymphocytic thyroiditis (Hashimoto’s), multinodular goiter, and in the management of thyroid cancer. 3. As diagnostic agents in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy. uuid:f3b08ff1-9f3a-4ea7-899e-d01201e526fa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB11218 biolink:treats HP:0002829 PMID:41385096 "[{""id"":""uuid:174ba10f-93d8-4c8a-a025-36ac3fb9c2aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6ea21f3a-ace7-4d63-93d1-2f14d2f115e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the temporary relief of arthritic pain & relief of muscular aches & pains, including symptomatic relief of lower back pains. May also assist with increased joint mobility & reduce inflammation and swelling associated with arthritis and gout. uuid:ead22b14-414e-4be6-8c97-efa74d0e282f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB11218 biolink:treats HP:0003326 PMID:41385096 "[{""id"":""uuid:924eb917-32b3-4b4d-92f9-c7e648954fb7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1b5ba127-a3f8-41b1-9622-4b134ddd7c78"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the temporary relief of arthritic pain & relief of muscular aches & pains, including symptomatic relief of lower back pains. May also assist with increased joint mobility & reduce inflammation and swelling associated with arthritis and gout. uuid:5b9784e8-953f-4ec3-a75a-4ca1f0de7935 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB11218 biolink:treats HP:0003419 PMID:41385096 "[{""id"":""uuid:06df4f57-85a8-451c-90d8-cc7aee290b46"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2f18f10c-64d8-4af6-b2b6-174a3bb26c85"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the temporary relief of arthritic pain & relief of muscular aches & pains, including symptomatic relief of lower back pains. May also assist with increased joint mobility & reduce inflammation and swelling associated with arthritis and gout. uuid:61d8f9ee-8782-49a8-b4f1-f779c2b9e27e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB11218 biolink:treats MONDO:0005578 PMID:41385096 "[{""id"":""uuid:a5657005-8ff5-47cb-9ae5-117d4fb023c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c052083f-bb02-4b22-97f3-29fe52cf1011"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the temporary relief of arthritic pain & relief of muscular aches & pains, including symptomatic relief of lower back pains. May also assist with increased joint mobility & reduce inflammation and swelling associated with arthritis and gout. uuid:1cabce17-3a2c-4998-9694-8e57349c7c86 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB11218 biolink:treats MONDO:0005393 PMID:41385096 "[{""id"":""uuid:33887a6c-0369-451e-ba97-b261ffde1c7b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:23d38a1d-7426-4fec-8454-254b97fba1fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the temporary relief of arthritic pain & relief of muscular aches & pains, including symptomatic relief of lower back pains. May also assist with increased joint mobility & reduce inflammation and swelling associated with arthritis and gout. uuid:fb3334ce-edcf-44b1-b45b-f35a2843be37 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31617 biolink:treats MONDO:0005027 PMID:41385096 "[{""id"":""uuid:4ec2955b-063d-4675-8395-40de8702d2c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2fa0e22a-49d3-473b-a0d0-819c0a401176"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fludeoxyglucose F 18 Injection,USP is indicated in PET (positron emission tomography) for: 1. Identification of regions of abnormal glucose metabolism associated with foci of epileptic seizures. 2. Assessment of abnormal glucose metabolism to assist in the evaluation of malignancy in patients with known or suspected abnormalities found by other testing modalities, or in patients with an existing diagnosis of cancer. 3. Assessment of patients with coronary artery disease and left ventricular dysfunction, when used together with myocardial perfusion imaging, for the identification of left ventricular myocardium with residual glucose metabolism and reversible loss of systolic function. Fludeoxyglucose F 18 Injection, USP is not indicated for distinguishing epileptogenic foci from brain tumors or other brain lesions which may cause seizures. uuid:89627353-380c-4a6a-85eb-103b03b9b52d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31617 biolink:treats MONDO:0004992 PMID:41385096 "[{""id"":""uuid:fe26910a-e3ac-446f-af18-5ce058e37fa2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4aece380-c0b7-4d30-90ec-ae9334672c9a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fludeoxyglucose F 18 Injection,USP is indicated in PET (positron emission tomography) for: 1. Identification of regions of abnormal glucose metabolism associated with foci of epileptic seizures. 2. Assessment of abnormal glucose metabolism to assist in the evaluation of malignancy in patients with known or suspected abnormalities found by other testing modalities, or in patients with an existing diagnosis of cancer. 3. Assessment of patients with coronary artery disease and left ventricular dysfunction, when used together with myocardial perfusion imaging, for the identification of left ventricular myocardium with residual glucose metabolism and reversible loss of systolic function. Fludeoxyglucose F 18 Injection, USP is not indicated for distinguishing epileptogenic foci from brain tumors or other brain lesions which may cause seizures. uuid:e443c38c-66b9-4d3d-acb9-945ef1f66f95 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31617 biolink:treats MONDO:0005010 PMID:41385096 "[{""id"":""uuid:aa3a5096-3db5-40d7-8e56-611890573613"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:45f56570-9d97-4d85-9a02-25dee444b5ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fludeoxyglucose F 18 Injection,USP is indicated in PET (positron emission tomography) for: 1. Identification of regions of abnormal glucose metabolism associated with foci of epileptic seizures. 2. Assessment of abnormal glucose metabolism to assist in the evaluation of malignancy in patients with known or suspected abnormalities found by other testing modalities, or in patients with an existing diagnosis of cancer. 3. Assessment of patients with coronary artery disease and left ventricular dysfunction, when used together with myocardial perfusion imaging, for the identification of left ventricular myocardium with residual glucose metabolism and reversible loss of systolic function. Fludeoxyglucose F 18 Injection, USP is not indicated for distinguishing epileptogenic foci from brain tumors or other brain lesions which may cause seizures. uuid:5866ced8-b469-4bcb-a220-fc0c0fddd546 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31617 biolink:treats HP:0005162 PMID:41385096 "[{""id"":""uuid:c2c35f93-10ed-49c1-8528-e033efda7b44"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:85f3d34b-669e-4cd6-bbf0-ff2b1d8a4bb6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fludeoxyglucose F 18 Injection,USP is indicated in PET (positron emission tomography) for: 1. Identification of regions of abnormal glucose metabolism associated with foci of epileptic seizures. 2. Assessment of abnormal glucose metabolism to assist in the evaluation of malignancy in patients with known or suspected abnormalities found by other testing modalities, or in patients with an existing diagnosis of cancer. 3. Assessment of patients with coronary artery disease and left ventricular dysfunction, when used together with myocardial perfusion imaging, for the identification of left ventricular myocardium with residual glucose metabolism and reversible loss of systolic function. Fludeoxyglucose F 18 Injection, USP is not indicated for distinguishing epileptogenic foci from brain tumors or other brain lesions which may cause seizures. uuid:5cb5670e-21ae-4a8b-aef3-2e5f12b579c9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5296 biolink:treats MONDO:0011817 PMID:41385096 "[{""id"":""uuid:64aeeec2-9a11-4b9f-9e7e-a6be1636665f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d5696cbc-8bd2-48bb-8a1a-a42df1b705a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gemfibrozil (Gemfibrozil tablets, USP) is indicated as adjunctive therapy to diet for: Treatment of adult patients with very high elevations of serum triglyceride levels (Types IV and V hyperlipidemia) who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Patients who present such risk typically have serum triglycerides over 2000 mg/dL and have elevations of VLDL-cholesterol as well as fasting chylomicrons (Type V hyperlipidemia). Subjects who consistently have total serum or plasma triglycerides below 1000 mg/dL are unlikely to present a risk of pancreatitis. Gemfibrozil therapy may be considered for those subjects with triglyceride elevations between 1000 and 2000 mg/dL who have a history of pancreatitis or of recurrent abdominal pain typical of pancreatitis. It is recognized that some Type IV patients with triglycerides under 1000 mg/dL may, through dietary or alcoholic indiscretion, convert to a Type V pattern with massive triglyceride elevations accompanying fasting chylomicronemia, but the influence of Gemfibrozil therapy on the risk of pancreatitis in such situations has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of very low density lipoprotein (VLDL). Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV, and V hyperlipoproteinemia. Reducing the risk of developing coronary heart disease only in Type IIb patients without history of or symptoms of existing coronary heart disease who have had an inadequate response to weight loss, dietary therapy, exercise, and other pharmacologic agents (such as bile acid sequestrants and nicotinic acid, known to reduce LDL- and raise HDL-cholesterol) and who have the following triad of lipid abnormalities: low HDL-cholesterol levels in addition to elevated LDL-cholesterol and elevated triglycerides (see WARNINGS , PRECAUTIONS , and CLINICAL PHARMACOLOGY ). The National Cholesterol Education Program has defined a serum HDL-cholesterol value that is consistently below 35 mg/dL as constituting an independent risk factor for coronary heart disease. Patients with significantly elevated triglycerides should be closely observed when treated with Gemfibrozil. In some patients with high triglyceride levels, treatment with Gemfibrozil is associated with a significant increase in LDL-cholesterol. BECAUSE OF POTENTIAL TOXICITY SUCH AS MALIGNANCY, GALLBLADDER DISEASE, ABDOMINAL PAIN LEADING TO APPENDECTOMY AND OTHER ABDOMINAL SURGERIES, AN INCREASED INCIDENCE IN NON-CORONARY MORTALITY, AND THE 44% RELATIVE INCREASE DURING THE TRIAL PERIOD IN AGE-ADJUSTED ALL-CAUSE MORTALITY SEEN WITH THE CHEMICALLY AND PHARMACOLOGICALLY RELATED DRUG, CLOFIBRATE, THE POTENTIAL BENEFIT OF GEMFIBROZIL IN TREATING TYPE IIA PATIENTS WITH ELEVATIONS OF LDL-CHOLESTEROL ONLY IS NOT LIKELY TO OUTWEIGH THE RISKS. GEMFIBROZIL IS ALSO NOT INDICATED FOR THE TREATMENT OF PATIENTS WITH LOW HDL- CHOLESTEROL AS THEIR ONLY LIPID ABNORMALITY. In a subgroup analysis of patients in the Helsinki Heart Study with above-median HDL-cholesterol values at baseline (greater than 46.4 mg/dL), the incidence of serious coronary events was similar for Gemfibrozil and placebo subgroups (see Table I). The initial treatment for dyslipidemia is dietary therapy specific for the type of lipoprotein abnormality. Excess body weight and excess alcohol intake may be important factors in hypertriglyceridemia and should be managed prior to any drug therapy. Physical exercise can be an important ancillary measure, and has been associated with rises in HDL-cholesterol. Diseases contributory to hyperlipidemia such as hypothyroidism or diabetes mellitus should be looked for and adequately treated. Estrogen therapy is sometimes associated with massive rises in plasma triglycerides, especially in subjects with familial hypertriglyceridemia. In such cases, discontinuation of estrogen therapy may obviate the need for specific drug therapy of hypertriglyceridemia. The use of drugs should be considered only when reasonable attempts have been made to obtain satisfactory results with nondrug methods. If the decision is made to use drugs, the patient should be instructed that this does not reduce the importance of adhering to diet. uuid:bb9c4c14-08fc-4ba1-aa49-f4e674cfd802 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5296 biolink:treats MONDO:0005281 PMID:41385096 "[{""id"":""uuid:ebf7767b-eea9-46c2-ac9a-c7138bfd2685"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ed0c9311-ce6e-4a07-9c1c-eb4817c07e5d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gemfibrozil (Gemfibrozil tablets, USP) is indicated as adjunctive therapy to diet for: Treatment of adult patients with very high elevations of serum triglyceride levels (Types IV and V hyperlipidemia) who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Patients who present such risk typically have serum triglycerides over 2000 mg/dL and have elevations of VLDL-cholesterol as well as fasting chylomicrons (Type V hyperlipidemia). Subjects who consistently have total serum or plasma triglycerides below 1000 mg/dL are unlikely to present a risk of pancreatitis. Gemfibrozil therapy may be considered for those subjects with triglyceride elevations between 1000 and 2000 mg/dL who have a history of pancreatitis or of recurrent abdominal pain typical of pancreatitis. It is recognized that some Type IV patients with triglycerides under 1000 mg/dL may, through dietary or alcoholic indiscretion, convert to a Type V pattern with massive triglyceride elevations accompanying fasting chylomicronemia, but the influence of Gemfibrozil therapy on the risk of pancreatitis in such situations has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of very low density lipoprotein (VLDL). Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV, and V hyperlipoproteinemia. Reducing the risk of developing coronary heart disease only in Type IIb patients without history of or symptoms of existing coronary heart disease who have had an inadequate response to weight loss, dietary therapy, exercise, and other pharmacologic agents (such as bile acid sequestrants and nicotinic acid, known to reduce LDL- and raise HDL-cholesterol) and who have the following triad of lipid abnormalities: low HDL-cholesterol levels in addition to elevated LDL-cholesterol and elevated triglycerides (see WARNINGS , PRECAUTIONS , and CLINICAL PHARMACOLOGY ). The National Cholesterol Education Program has defined a serum HDL-cholesterol value that is consistently below 35 mg/dL as constituting an independent risk factor for coronary heart disease. Patients with significantly elevated triglycerides should be closely observed when treated with Gemfibrozil. In some patients with high triglyceride levels, treatment with Gemfibrozil is associated with a significant increase in LDL-cholesterol. BECAUSE OF POTENTIAL TOXICITY SUCH AS MALIGNANCY, GALLBLADDER DISEASE, ABDOMINAL PAIN LEADING TO APPENDECTOMY AND OTHER ABDOMINAL SURGERIES, AN INCREASED INCIDENCE IN NON-CORONARY MORTALITY, AND THE 44% RELATIVE INCREASE DURING THE TRIAL PERIOD IN AGE-ADJUSTED ALL-CAUSE MORTALITY SEEN WITH THE CHEMICALLY AND PHARMACOLOGICALLY RELATED DRUG, CLOFIBRATE, THE POTENTIAL BENEFIT OF GEMFIBROZIL IN TREATING TYPE IIA PATIENTS WITH ELEVATIONS OF LDL-CHOLESTEROL ONLY IS NOT LIKELY TO OUTWEIGH THE RISKS. GEMFIBROZIL IS ALSO NOT INDICATED FOR THE TREATMENT OF PATIENTS WITH LOW HDL- CHOLESTEROL AS THEIR ONLY LIPID ABNORMALITY. In a subgroup analysis of patients in the Helsinki Heart Study with above-median HDL-cholesterol values at baseline (greater than 46.4 mg/dL), the incidence of serious coronary events was similar for Gemfibrozil and placebo subgroups (see Table I). The initial treatment for dyslipidemia is dietary therapy specific for the type of lipoprotein abnormality. Excess body weight and excess alcohol intake may be important factors in hypertriglyceridemia and should be managed prior to any drug therapy. Physical exercise can be an important ancillary measure, and has been associated with rises in HDL-cholesterol. Diseases contributory to hyperlipidemia such as hypothyroidism or diabetes mellitus should be looked for and adequately treated. Estrogen therapy is sometimes associated with massive rises in plasma triglycerides, especially in subjects with familial hypertriglyceridemia. In such cases, discontinuation of estrogen therapy may obviate the need for specific drug therapy of hypertriglyceridemia. The use of drugs should be considered only when reasonable attempts have been made to obtain satisfactory results with nondrug methods. If the decision is made to use drugs, the patient should be instructed that this does not reduce the importance of adhering to diet. uuid:221d8755-2f1c-4aad-b61b-e24cfdea1abc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:23742 biolink:treats HP:0007430 PMID:41385096 "[{""id"":""uuid:687391a5-d4db-44dd-b3b8-cb26739c4dfb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a94ac330-7c9d-442d-95f3-ba116e9e808c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] This fixed combination drug is not indicated for the initial therapy of edema or hypertension except in individuals in whom the development of hypokalemia cannot be risked. 1. Triamterene and hydrochlorothiazide tablets are indicated for the treatment of hypertension or edema in patients who develop hypokalemia on hydrochlorothiazide alone. 2. Triamterene and hydrochlorothiazide is also indicated for those patients who require a thiazide diuretic and in whom the development of hypokalemia cannot be risked (e.g., patients on concomitant digitalis preparations, or with a history of cardiac arrhythmias, etc.). Triamterene and hydrochlorothiazide may be used alone or in combination with other antihypertensive drugs such as beta-blockers. Since triamterene and hydrochlorothiazide may enhance the actions of these drugs, dosage adjustments may be necessary. Usage in Pregnancy: The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia in pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developed toxemia. Edema during pregnancy may arise from pathological causes or from the physiologic and mechanical consequences of pregnancy. Thiazides are indicated in pregnancy when edema is due to pathologic causes, just as they are in the absence of pregnancy. Dependent edema in pregnancy, resulting from restriction of venous return by the expanded uterus, is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is illogical and unnecessary. There is hypervolemia during normal pregnancy which is harmful to neither the fetus nor the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema, in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances, this edema may cause extreme discomfort which is not relieved by rest. In these cases, a short course of diuretics may provide relief and may be appropriate. uuid:d5188ec7-1899-4a70-82a9-4b9962cf5365 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1155432 biolink:treats UMLS:C0427008 PMID:41385096 "[{""id"":""uuid:3298502f-0e23-4274-abe9-e726dc39216a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:514af7e7-c5b2-4de0-adb5-64c8d263a5f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] USES : Use for temporary relief of minor aches and muscle pains associated with arthritis, simple backache, strains, sprains, muscle soreness and stiffness uuid:081ee8d7-0b84-46eb-b52d-002d6208fc9d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5001 biolink:treats MONDO:0004982 PMID:41385096 "[{""id"":""uuid:fe16c1e4-5b44-403c-b99f-9524f6b0899e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:88056490-5d85-46c2-b892-227a19edcfa5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Treatment of Hypercholesterolemia Fenofibrate tablets, USP are indicated as adjunctive therapy to diet to reduce elevated LDL-C, Total-C, Triglycerides and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb). Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and non-pharmacological interventions alone has been inadequate (See National Cholesterol Education Program [NCEP] Treatment Guidelines, below). Treatment of Hypertriglyceridemia Fenofibrate tablets, USP are also indicated as adjunctive therapy to diet for treatment of adult patients with hypertriglyceridemia (Fredrickson Types IV and V hyperlipidemia). Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually reduce fasting triglycerides and eliminate chylomicronemia thereby obviating the need for pharmacologic intervention. Markedly elevated levels of serum triglycerides (e.g. > 2,000 mg/dL) may increase the risk of developing pancreatitis. The effect of fenofibrate tablet, USP therapy on reducing this risk has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of very low density lipoprotein (VLDL). Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV and V hyperlipoproteinemia2. The initial treatment for dyslipidemia is dietary therapy specific for the type of lipoprotein abnormality. Excess body weight and excess alcoholic intake may be important factors in hypertriglyceridemia and should be addressed prior to any drug therapy. Physical exercise can be an important ancillary measure. Diseases contributory to hyperlipidemia, such as hypothyroidism or diabetes mellitus should be looked for and adequately treated. Estrogen therapy, thiazide diuretics and beta-blockers, are sometimes associated with massive rises in plasma triglycerides, especially in subjects with familial hypertriglyceridemia. In such cases, discontinuation of the specific etiologic agent may obviate the need for specific drug therapy of hypertriglyceridemia. The use of drugs should be considered only when reasonable attempts have been made to obtain satisfactory results with non-drug methods. If the decision is made to use drugs, the patient should be instructed that this does not reduce the importance of adhering to diet. (See WARNINGS and PRECAUTIONS). Please review the manufacturer's complete information (studies, figures, tables) here:http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a9c5062d-e8ad-44e7-a709-af0092f73d52 uuid:c5035cf2-4329-47c9-9643-023c69e94b74 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5001 biolink:treats MONDO:0005420 PMID:41385096 "[{""id"":""uuid:3e8109d9-8e36-475e-8271-874d8b28a78f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dd919ceb-b08d-4fe4-9f1d-51186ba20726"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Treatment of Hypercholesterolemia Fenofibrate tablets, USP are indicated as adjunctive therapy to diet to reduce elevated LDL-C, Total-C, Triglycerides and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb). Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and non-pharmacological interventions alone has been inadequate (See National Cholesterol Education Program [NCEP] Treatment Guidelines, below). Treatment of Hypertriglyceridemia Fenofibrate tablets, USP are also indicated as adjunctive therapy to diet for treatment of adult patients with hypertriglyceridemia (Fredrickson Types IV and V hyperlipidemia). Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually reduce fasting triglycerides and eliminate chylomicronemia thereby obviating the need for pharmacologic intervention. Markedly elevated levels of serum triglycerides (e.g. > 2,000 mg/dL) may increase the risk of developing pancreatitis. The effect of fenofibrate tablet, USP therapy on reducing this risk has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of very low density lipoprotein (VLDL). Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV and V hyperlipoproteinemia2. The initial treatment for dyslipidemia is dietary therapy specific for the type of lipoprotein abnormality. Excess body weight and excess alcoholic intake may be important factors in hypertriglyceridemia and should be addressed prior to any drug therapy. Physical exercise can be an important ancillary measure. Diseases contributory to hyperlipidemia, such as hypothyroidism or diabetes mellitus should be looked for and adequately treated. Estrogen therapy, thiazide diuretics and beta-blockers, are sometimes associated with massive rises in plasma triglycerides, especially in subjects with familial hypertriglyceridemia. In such cases, discontinuation of the specific etiologic agent may obviate the need for specific drug therapy of hypertriglyceridemia. The use of drugs should be considered only when reasonable attempts have been made to obtain satisfactory results with non-drug methods. If the decision is made to use drugs, the patient should be instructed that this does not reduce the importance of adhering to diet. (See WARNINGS and PRECAUTIONS). Please review the manufacturer's complete information (studies, figures, tables) here:http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a9c5062d-e8ad-44e7-a709-af0092f73d52 uuid:ea18823e-8557-49a7-a17c-511bb7fd0698 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5001 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:9885a5db-1832-4cc7-8682-6a19183b6c4c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5654825d-0723-416f-8d2b-b98db1944909"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Treatment of Hypercholesterolemia Fenofibrate tablets, USP are indicated as adjunctive therapy to diet to reduce elevated LDL-C, Total-C, Triglycerides and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb). Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and non-pharmacological interventions alone has been inadequate (See National Cholesterol Education Program [NCEP] Treatment Guidelines, below). Treatment of Hypertriglyceridemia Fenofibrate tablets, USP are also indicated as adjunctive therapy to diet for treatment of adult patients with hypertriglyceridemia (Fredrickson Types IV and V hyperlipidemia). Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually reduce fasting triglycerides and eliminate chylomicronemia thereby obviating the need for pharmacologic intervention. Markedly elevated levels of serum triglycerides (e.g. > 2,000 mg/dL) may increase the risk of developing pancreatitis. The effect of fenofibrate tablet, USP therapy on reducing this risk has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of very low density lipoprotein (VLDL). Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV and V hyperlipoproteinemia2. The initial treatment for dyslipidemia is dietary therapy specific for the type of lipoprotein abnormality. Excess body weight and excess alcoholic intake may be important factors in hypertriglyceridemia and should be addressed prior to any drug therapy. Physical exercise can be an important ancillary measure. Diseases contributory to hyperlipidemia, such as hypothyroidism or diabetes mellitus should be looked for and adequately treated. Estrogen therapy, thiazide diuretics and beta-blockers, are sometimes associated with massive rises in plasma triglycerides, especially in subjects with familial hypertriglyceridemia. In such cases, discontinuation of the specific etiologic agent may obviate the need for specific drug therapy of hypertriglyceridemia. The use of drugs should be considered only when reasonable attempts have been made to obtain satisfactory results with non-drug methods. If the decision is made to use drugs, the patient should be instructed that this does not reduce the importance of adhering to diet. (See WARNINGS and PRECAUTIONS). Please review the manufacturer's complete information (studies, figures, tables) here:http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a9c5062d-e8ad-44e7-a709-af0092f73d52 uuid:38d7b949-cbf6-419d-a271-ad2fb7dcdd4a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3387 biolink:treats HP:0007359 PMID:41385096 "[{""id"":""uuid:e698cb6c-b338-4ec0-9ca4-a12b0426129d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c570b301-6f2e-42df-a8f3-4922de3dd785"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Epilepsy Carbamazepine tablets, USP are indicated for use as an anticonvulsant drug. Evidence supporting efficacy of carbamazepine as an anticonvulsant was derived from active drug-controlled studies that enrolled patients with the following seizure types: Partial seizures with complex symptomatology (psychomotor, temporal lobe). Patients with these seizures appear to show greater improvement than those with other types. Generalized tonic-clonic seizures (grand mal). Mixed seizure patterns which include the above, or other partial or generalized seizures. Absence seizures (petit mal) do not appear to be controlled by carbamazepine (see PRECAUTIONS, General). Trigeminal Neuralgia Carbamazepine tablets, USP are indicated in the treatment of the pain associated with true trigeminal neuralgia. Beneficial results have also been reported in glossopharyngeal neuralgia. This drug is not a simple analgesic and should not be used for the relief of trivial aches or pains. uuid:ed973732-9136-4664-9def-1c90bbf9a151 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16240 biolink:treats HP:0033050 PMID:41385096 "[{""id"":""uuid:0897bb9b-c762-4964-8592-aa71d3390d2e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d954a54d-93a2-4e6d-a1af-13f5c63e0643"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Aids in the removal of phlegm, mucus, or other secretions in the temporary relief of discomfort due to occasional sore throat and sore mouth. uuid:6d67acc9-b34c-4478-a792-d9b69ec7c276 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16240 biolink:treats UMLS:C1579838 PMID:41385096 "[{""id"":""uuid:c53c76b2-24e3-4179-ba46-e5f55ed5e422"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a5f8aeac-cccc-4151-9b9a-684f0b1ca722"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Aids in the removal of phlegm, mucus, or other secretions in the temporary relief of discomfort due to occasional sore throat and sore mouth. uuid:019827d3-4b70-4719-b689-6e46eedc70d8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:241c69a6-de67-402c-8775-b499e1178ba6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a964d7df-ada1-4695-9834-f6dd647cb97c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:2e19a152-e38f-44ea-a1fb-2dc12d5521f1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:fdf75f9e-ee18-47bd-a720-c62191d88471"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e93750b0-bd80-4d2c-979e-eac658079c73"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:f89ef712-2f8d-42d9-ab8a-164299949d9a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0005480 PMID:41385096 "[{""id"":""uuid:e524aea2-a55d-40a8-ae04-a51d9ecfe3b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:21fd5fd4-2769-487f-b6b1-17ab651e7164"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:70b16266-772e-4511-be80-68ec2008b50a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0000775 PMID:41385096 "[{""id"":""uuid:4cf88771-4274-4852-8d37-99ce71787eaa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:451991ed-e23f-4e85-8117-6bce88248b79"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:4acd28eb-ee2b-4aec-ad86-d28453b9fc3d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0005324 PMID:41385096 "[{""id"":""uuid:0f67e34e-b46b-41a4-b670-87dc65f980b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8408616d-d23c-4922-9fdf-5fb1be9c1152"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:179afa0b-3474-4422-a72f-0595960ac1fb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0024332 PMID:41385096 "[{""id"":""uuid:4350c8ba-7289-430d-b509-40d1ee370192"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2b8bf19f-cffc-447f-bd78-dfc097ec6348"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:fa9968f9-237c-4596-992a-57818252d3a9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0043789 PMID:41385096 "[{""id"":""uuid:d67a310a-2806-45fe-87e1-3faab4209554"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9651b991-7d16-4074-a85b-6f415206687c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:3038426b-e1f1-4bd0-9d0d-f490a4eb3325 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats UMLS:C0274435 PMID:41385096 "[{""id"":""uuid:3b506c1a-7fb4-4ea3-93a5-74cf8c42f8f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c9b18280-072e-4097-bfb2-c074b81dc04d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:cfcd619f-1677-4647-8083-feabcefffd2c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0015614 PMID:41385096 "[{""id"":""uuid:6ddb6541-ad29-45a9-943a-76c67ed9c7aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:39da1b02-c6db-482e-8087-dbd4b98c3302"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:066807d4-9902-4e41-bf72-6a4dd058e52b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0043233 PMID:41385096 "[{""id"":""uuid:8264d304-8bd1-4828-8c4b-f44e320dd3d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0a0bbc71-84e7-4715-944f-009830e7c774"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:01999623-07bc-40d7-a38b-4e3b97e25af8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0009691 PMID:41385096 "[{""id"":""uuid:8ebf8997-fad0-4620-8ee3-7f4271813c6a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:34218d0d-2ca0-4587-824b-a2bb921c960e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:1985e6e9-dbaa-4c9a-9fd0-5f781c65ab01 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0006594 PMID:41385096 "[{""id"":""uuid:54368f81-c989-400a-93b4-ecb0bcd70c6b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8b9d7684-0acd-42ce-9a68-44f9dde6fbd8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:98c3f37e-1ca2-40a7-9630-f75c939f5cca biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0018229 PMID:41385096 "[{""id"":""uuid:7e526a47-6b34-4261-917f-3641349a78a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e101aece-dce6-47ca-83ea-de8fb25256a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:0f98897f-f846-4095-95c4-12f5ba79be27 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0015129 PMID:41385096 "[{""id"":""uuid:b5761106-fa8a-42b5-b429-ba2522ee7179"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:074ac841-44b3-411c-b00f-80f37edbbeef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:22b89fdd-a870-43ee-8458-c041b5119094 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0043370 PMID:41385096 "[{""id"":""uuid:7d661e48-9125-4e97-adba-f0478549e7fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9bc892fa-de02-4d0f-94d9-53381e8f9f02"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:46df1396-9b8e-42b1-bf64-7e39a5e0bfc8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0018479 PMID:41385096 "[{""id"":""uuid:ca96614e-3853-40f9-b0dc-bc8f1c8deac4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6aa5e26c-3c55-4057-b34b-277f331b1b18"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:23733c79-b0c6-459f-8c8c-e43d800a0286 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0043455 PMID:41385096 "[{""id"":""uuid:4f2d9c27-895d-4ba2-8e64-189a3ecd9a35"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8db60af0-e01f-4bfa-95bc-2879219a2105"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:b063fb55-4ca9-49f6-a7ae-47b600493bbb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0004126 PMID:41385096 "[{""id"":""uuid:62bd910d-1a40-43fc-9e49-ee9b1f109f00"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6d200db8-32db-44a7-93af-e8eecfc6b496"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:a911d28d-5a06-4d98-a24e-4ec181bfc8fe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats UMLS:C0678202 PMID:41385096 "[{""id"":""uuid:10d6c904-8bf6-4d54-a18a-6a5cc11946a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0b1c11fc-fe68-4659-9eab-803be33dcd01"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:e8038944-d4d2-46e5-b5e0-5ef56e86edc7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0005101 PMID:41385096 "[{""id"":""uuid:54041b22-d75a-4c05-aab7-6e4a179259ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:11013b2f-1ee6-429d-a50e-0296d1564811"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:884699b0-20ca-4c6d-b645-a569743f5818 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0020108 PMID:41385096 "[{""id"":""uuid:d5b0bcd5-6d68-4b79-aba3-0c48bb70abfe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:74dabd82-cde6-46ce-b525-1cb953c51ee3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:36cce6e9-8da7-4484-b12a-72a88d75de32 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0015253 PMID:41385096 "[{""id"":""uuid:c49a7235-b286-4220-a634-7a5a2aa3a58e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d2c2a7d2-4d34-4463-8034-fb307ec55be2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:35fcf040-bf57-4bcd-8e47-faef5ade6aff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0001705 PMID:41385096 "[{""id"":""uuid:0d9dc432-e736-46f3-aac8-1812e7149269"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e72357e7-ffc4-401f-9f9e-a11e0939109b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:292727e9-560f-4cf9-a22f-89924040303a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0001198 PMID:41385096 "[{""id"":""uuid:89302cbe-b704-4770-966a-e13aac90e3e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1522776d-6367-497e-8186-9c5ae6b179f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:6276b227-42c0-4a6c-bfcb-c8537e40f64f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0019444 PMID:41385096 "[{""id"":""uuid:28c27344-5d73-4be3-ae2e-456b04b4e94f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f0d0e18a-824d-4c7e-88e8-f442f96e93a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:02e26136-5743-4888-8a00-59df1d6e5a2b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0006042 PMID:41385096 "[{""id"":""uuid:8b136d59-97ea-4252-8744-b694769b2764"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:88381085-3bcd-459d-96df-48a0f640ecd2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:ceb7ffa2-2ecf-4b33-9f38-a3741a88cd2a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0005059 PMID:41385096 "[{""id"":""uuid:bd3ccf75-c065-4267-9573-af1e4e3771ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:43a2bfc2-d1ef-4e51-8b6b-155abbf85bb0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:db93e258-fd40-4375-9d9a-6f6dd20e0fb3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0004095 PMID:41385096 "[{""id"":""uuid:fd1e6267-1a07-44a0-b0b1-b8c4ce369918"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:baed62ea-f580-4f81-b5a8-c9313b2e5d26"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:dec45555-d062-4d17-8996-e69a7c795e33 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0005314 PMID:41385096 "[{""id"":""uuid:8b621d25-aa71-4081-a31b-2bd3f51f5631"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ace0bca6-4239-4f52-9276-7873cf79206e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:fe2dc9a4-9819-4afc-b00b-41123f822167 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0006684 PMID:41385096 "[{""id"":""uuid:7afa46e6-94cb-403c-942a-2826f6deb86a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:968ebbd1-163b-4077-bd5a-fe614b8addc7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:a331669b-a931-41a3-ba34-28d8b6032940 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0019198 PMID:41385096 "[{""id"":""uuid:1bdcfc3f-a6c6-44d6-9181-e6adc5e90ed1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:00bfb9da-eae6-458c-be2e-2080b01dd91e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:0b166e4b-f890-4563-a283-a1798104592f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0008538 PMID:41385096 "[{""id"":""uuid:bb5e86aa-88de-42cd-9ec9-f60a34350cfc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:777995a5-a9c0-40f5-925f-9822edbcb219"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:ee2f149b-a156-4dc3-953c-c5ae5649dab3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0020283 PMID:41385096 "[{""id"":""uuid:9050c9b8-9c9c-4574-a630-6cb219937dcb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:83e49338-f4a1-4ea2-b33f-3df0abc18220"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:d738b083-1d2a-4718-918e-84a4d66a2325 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0018170 PMID:41385096 "[{""id"":""uuid:50cd143f-5a75-4980-9828-cbd0d6e90f8c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:19aece14-b7eb-4ccb-8826-e333d8638e37"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:2a1ccaf1-5c92-48cf-a5d1-23de6f51e1b8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0005556 PMID:41385096 "[{""id"":""uuid:e9dcb8f0-9597-47c4-8d63-1633b9214e02"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:33b38c0a-3571-4c7a-abcb-9cbb634cf895"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:97df4d08-8357-4ec7-a44f-2328e84a00cd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0015274 PMID:41385096 "[{""id"":""uuid:77607f9f-03d0-4a2f-91ec-29886b6b30b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:72bdeb40-ebe8-40d2-81ff-9d8bdcb13764"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:384bb30b-caee-44cc-b432-4d87909c373f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0006052 PMID:41385096 "[{""id"":""uuid:4bda8e2e-d00c-4d6a-9892-d1d4d5c671cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ae8173ec-7bc7-4b66-879d-22db989d5ee6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:736a8236-c561-4bc1-bdfc-103d13c6fe2e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0005848 PMID:41385096 "[{""id"":""uuid:b9b0fd5d-30eb-4411-afe4-4a6bf8febe14"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:112443da-c338-48aa-a53c-88fcb941899a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:18b929ad-694e-4343-87d3-cc67e14ae2da biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0015927 PMID:41385096 "[{""id"":""uuid:90dff232-f286-46cf-af98-eeb0164a6a69"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:846a567c-9308-4af0-a7eb-a5a38a28ce44"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:de971741-d743-4ae5-880d-ce7d2143f273 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0019338 PMID:41385096 "[{""id"":""uuid:f1fd7c86-87ef-42f2-8f8a-1be035b28f06"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1023393c-bd66-4dba-9e57-ffbe8077f5b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:e49a0804-5d5d-4626-9913-7efb49039c15 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats UMLS:C0149896 PMID:41385096 "[{""id"":""uuid:1fdbe87f-fd84-4946-98f2-fbe0cfe639f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8d42e552-09f9-4aa4-98de-7c29a8474542"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:59e4cbde-a44e-4492-b8d5-ad457a884b3c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats UMLS:C5441648 PMID:41385096 "[{""id"":""uuid:af3e8596-afda-4f4d-acd3-07d98531c3c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c2c421eb-9c9f-46c0-8a3d-5188895ad69f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:7f9fe796-216e-4f4d-9412-57e276cba6ce biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0005306 PMID:41385096 "[{""id"":""uuid:fe5edcab-b711-4101-b388-cecf66fc0ec9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:977755f1-4b3d-4692-81c6-e7bc6ced73f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:9c8e8a7f-d301-4545-b5f7-a3eae4d10f9e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0011849 PMID:41385096 "[{""id"":""uuid:737a48f3-2c7c-43d4-b41b-0dbdd47c2423"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b8d603e6-bc02-4a0a-be0b-1a809d43c2b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:b3180f4d-6cb7-4311-b0b8-845f4cb49d90 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:89d9d1d0-1ded-499e-bb5a-4e29b368fc7d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2f261918-c4f5-4ba8-a95e-2243a33f92a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:596556c0-dae1-4d4a-aefb-cc41a5f9719f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0011429 PMID:41385096 "[{""id"":""uuid:5a8474f0-7085-4fc0-9733-2b2f9b5de7f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9d2cc176-bef4-4e35-9edc-9ccdaace919a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:07c48148-294b-4d42-a6f8-35ca4e6b7757 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0016367 PMID:41385096 "[{""id"":""uuid:e5b04b9f-3974-4c0a-a732-61fede60ff2b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:44ad86af-a2bc-4157-ae61-bb6fb1fb1ad7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:74212a49-3050-429f-9497-3f07dfb4a3a1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0019127 PMID:41385096 "[{""id"":""uuid:9dfab23c-b528-4c5f-823c-4867bba8758d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6f640693-ae41-4b80-a089-e13dd96aa126"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:df36aad6-117a-4eb0-bcb9-881b6e0cd09a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5134 biolink:treats MONDO:0004514 PMID:41385096 "[{""id"":""uuid:f461203e-b84a-4681-a9ab-192060b0cd1f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6a70dd17-995e-44de-b443-e637ea980833"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fluticasone propionate nasal spray, USP is indicated for the management of the nasal symptoms of perennial nonallergic rhinitis in adult and pediatric patients aged 4 years and older. uuid:bd22ef24-3722-4dc4-8383-3f826a4899b4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3561 biolink:treats MONDO:0005324 PMID:41385096 "[{""id"":""uuid:29de1138-9870-4da9-bbcd-170cecb46d80"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9ec1b1a1-254c-4f07-b836-eb63e18f2f53"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] temporarily relieves these symptoms due to hay fever or other upper respiratory allergies: runny nose sneezing itchy, watery eyes itching of the nose or throat uuid:aed4ff93-58b0-4f9b-99c1-e923a038a34c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3561 biolink:treats MONDO:0004867 PMID:41385096 "[{""id"":""uuid:28151674-1ef7-4ff1-8f87-e6f304624be3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:373a9b86-a491-4390-aa8a-1635ce26816d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] temporarily relieves these symptoms due to hay fever or other upper respiratory allergies: runny nose sneezing itchy, watery eyes itching of the nose or throat uuid:eed031d6-a72e-4a2d-8ad4-9d1a9c412151 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5855 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:7077d8e0-cb0f-43ff-ad08-5631a2d16b01"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:23bc022f-0347-4584-a0fd-c2e491b67dcf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oral prasterone (200mg per day) in female patients with active systemic lupus erythematosus (SLE) has in several blinded, placebo-controlled randomized clinical studies been associated with a reduced risk of auto-immune flare, §§ 6.2 , 14.1.1 , a reduced risk of breast cancer and a reduced risk of death from any cause, §§ 6.4 , 14.2 . Patients with SLE may have depressed serum levels of 5-dehydroepiandrosterone sulfate (5-DHEAS). Oral prasterone has been shown to restore SLE patients' serum 5-DHEAS levels. Prastera® oral softgels are intended for use in patients for whom medical evaluation shows a depressed serum level of DHEA and thus a distinctive need for exogenous DHEA. Prastera® oral prasterone softgels are intended to be used under medical supervision, for a patient receiving active and ongoing medical supervision, wherein the patient obtains medical care on a recurring basis for, among other things, instructions on the use of this product. Prastera® oral prasterone softgels are intended for the dietary management of SLE by meeting the distinctive nutritional requirement of women with mild-to-moderate active SLE. Prastera® oral prasterone softgels are intended for oral intake only. Prastera® does not cure, treat, mitigate or prevent SLE. To the contrary, patients taking Prastera® will continue to have SLE, and thus may continue to require other appropriate therapy . uuid:2734b202-8edd-4a59-8f73-fd8806f44f65 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8805 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:32e9ec49-8583-4097-ab2b-995785045e6d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ea8c6ce0-9a93-455b-b1bf-af3c2f1c5103"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:877b8402-40a3-41cc-8ad1-0fe531d649f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/repaglinide-krka""]},{""id"":""uuid:2bfeb248-c2a5-44cb-b4d0-f5a24a003c2e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PRANDIN is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.|[EMA] Repaglinide is indicated in patients with type-2 diabetes (non-insulin-dependent diabetes mellitus (NIDDM)) whose hyperglycaemia can no longer be controlled satisfactorily by diet, weight reduction and exercise.Treatment should be initiated as an adjunct to diet and exercise to lower the blood glucose in relation to meals.|[PMDA] Drugs with a new active ingredient indicated for the improvement of postprandial changes of blood glucose in type 2 diabetes mellitus (for use only in patients who have not responded sufficiently to either [1] diet and exercise therapies alone or [2] alpha-glucosidase inhibitors along with diet and exercise therapies). uuid:10f521f6-4cf6-4ca3-bc2e-d0bb01bd99b7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2955 biolink:treats UMLS:C0853854 PMID:41385096 "[{""id"":""uuid:d51942d8-f32c-4639-8d0c-2e98a129222d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2a58c52a-70cb-4a8d-986c-2ab55d68e85d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin tablets USP and other antibacterial drugs, azithromycin tablets USP should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Azithromycin tablets USP are a macrolide antibacterial drug indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. Recommended dosages and durations of therapy in adult and pediatric patient populations vary in these indications [see Dosage and Administration (2)]. 1.1 Adult Patients Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae. Acute bacterial sinusitis due to Haemophilus influenzae, Moraxella catarrhalis. or Streptococcus pneumoniae. Community-acquired pneumonia due to Chlamydophila pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae, or Streptococcus pneumoniae in patients appropriate for oral therapy. Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. Uncomplicated skin and skin structure infections due to Staphylococcus aureus, Streptococcus pyogenes, or Streptococcus agalactiae. Urethritis and cervicitis due to Chlamydia trachomatis or Neisseria gonorrhoeae. Genital ulcer disease in men due to Haemophilus ducreyi (chancroid). Due to the small number of women included in clinical trials, the efficacy of azithromycin in the treatment of chancroid in women has not been established. 1.2 Pediatric Patients [see Use in Specific Populations (8.4) and Clinical Studies (14.2)] Acute otitis media (> 6 months of age) caused by Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae Community-acquired pneumonia (> 6 months of age) due to Chlamydophila pneumoniae, Haemophilus influenzae, Mycoplasma pneumonia, or Streptococcus pneumoniae in patients appropriate for oral therapy. Pharyngitis/tonsillitis (> 2 years of age) caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. 1.3 Limitations of Use Azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomial infections, patients with known or suspected bacteremia, patients requiring hospitalization, elderly or debilitated patients, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). uuid:f13e0050-accd-40b0-80cb-e635d5f63a81 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2955 biolink:treats MONDO:0009061 PMID:41385096 "[{""id"":""uuid:a989165c-46b9-4170-a99a-7e2581746027"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4e5e2f95-5485-4e63-a593-61e833941967"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin tablets USP and other antibacterial drugs, azithromycin tablets USP should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Azithromycin tablets USP are a macrolide antibacterial drug indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. Recommended dosages and durations of therapy in adult and pediatric patient populations vary in these indications [see Dosage and Administration (2)]. 1.1 Adult Patients Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae. Acute bacterial sinusitis due to Haemophilus influenzae, Moraxella catarrhalis. or Streptococcus pneumoniae. Community-acquired pneumonia due to Chlamydophila pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae, or Streptococcus pneumoniae in patients appropriate for oral therapy. Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. Uncomplicated skin and skin structure infections due to Staphylococcus aureus, Streptococcus pyogenes, or Streptococcus agalactiae. Urethritis and cervicitis due to Chlamydia trachomatis or Neisseria gonorrhoeae. Genital ulcer disease in men due to Haemophilus ducreyi (chancroid). Due to the small number of women included in clinical trials, the efficacy of azithromycin in the treatment of chancroid in women has not been established. 1.2 Pediatric Patients [see Use in Specific Populations (8.4) and Clinical Studies (14.2)] Acute otitis media (> 6 months of age) caused by Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae Community-acquired pneumonia (> 6 months of age) due to Chlamydophila pneumoniae, Haemophilus influenzae, Mycoplasma pneumonia, or Streptococcus pneumoniae in patients appropriate for oral therapy. Pharyngitis/tonsillitis (> 2 years of age) caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. 1.3 Limitations of Use Azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomial infections, patients with known or suspected bacteremia, patients requiring hospitalization, elderly or debilitated patients, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). uuid:d9e9f4e7-a549-4002-8d26-4edea2bcae62 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2955 biolink:treats MONDO:0043544 PMID:41385096 "[{""id"":""uuid:0913341e-cf44-45a7-b382-e5db73438558"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6013b817-b44b-4b86-ae97-532732d7ef68"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin tablets USP and other antibacterial drugs, azithromycin tablets USP should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Azithromycin tablets USP are a macrolide antibacterial drug indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. Recommended dosages and durations of therapy in adult and pediatric patient populations vary in these indications [see Dosage and Administration (2)]. 1.1 Adult Patients Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae. Acute bacterial sinusitis due to Haemophilus influenzae, Moraxella catarrhalis. or Streptococcus pneumoniae. Community-acquired pneumonia due to Chlamydophila pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae, or Streptococcus pneumoniae in patients appropriate for oral therapy. Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. Uncomplicated skin and skin structure infections due to Staphylococcus aureus, Streptococcus pyogenes, or Streptococcus agalactiae. Urethritis and cervicitis due to Chlamydia trachomatis or Neisseria gonorrhoeae. Genital ulcer disease in men due to Haemophilus ducreyi (chancroid). Due to the small number of women included in clinical trials, the efficacy of azithromycin in the treatment of chancroid in women has not been established. 1.2 Pediatric Patients [see Use in Specific Populations (8.4) and Clinical Studies (14.2)] Acute otitis media (> 6 months of age) caused by Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae Community-acquired pneumonia (> 6 months of age) due to Chlamydophila pneumoniae, Haemophilus influenzae, Mycoplasma pneumonia, or Streptococcus pneumoniae in patients appropriate for oral therapy. Pharyngitis/tonsillitis (> 2 years of age) caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. 1.3 Limitations of Use Azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomial infections, patients with known or suspected bacteremia, patients requiring hospitalization, elderly or debilitated patients, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). uuid:3f2de7bd-f981-4c32-bac0-9d4eeb0c7a70 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2955 biolink:treats MONDO:0005229 PMID:41385096 "[{""id"":""uuid:73cfd2d0-b794-40d2-b131-73d8fcaefecb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:446975d4-40c0-402f-b9a9-c1f0582be886"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin tablets USP and other antibacterial drugs, azithromycin tablets USP should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Azithromycin tablets USP are a macrolide antibacterial drug indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. Recommended dosages and durations of therapy in adult and pediatric patient populations vary in these indications [see Dosage and Administration (2)]. 1.1 Adult Patients Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae. Acute bacterial sinusitis due to Haemophilus influenzae, Moraxella catarrhalis. or Streptococcus pneumoniae. Community-acquired pneumonia due to Chlamydophila pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae, or Streptococcus pneumoniae in patients appropriate for oral therapy. Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. Uncomplicated skin and skin structure infections due to Staphylococcus aureus, Streptococcus pyogenes, or Streptococcus agalactiae. Urethritis and cervicitis due to Chlamydia trachomatis or Neisseria gonorrhoeae. Genital ulcer disease in men due to Haemophilus ducreyi (chancroid). Due to the small number of women included in clinical trials, the efficacy of azithromycin in the treatment of chancroid in women has not been established. 1.2 Pediatric Patients [see Use in Specific Populations (8.4) and Clinical Studies (14.2)] Acute otitis media (> 6 months of age) caused by Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae Community-acquired pneumonia (> 6 months of age) due to Chlamydophila pneumoniae, Haemophilus influenzae, Mycoplasma pneumonia, or Streptococcus pneumoniae in patients appropriate for oral therapy. Pharyngitis/tonsillitis (> 2 years of age) caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. 1.3 Limitations of Use Azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomial infections, patients with known or suspected bacteremia, patients requiring hospitalization, elderly or debilitated patients, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). uuid:1cbe92c6-21ac-437d-b804-606fb3dda7bc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7852 biolink:treats NCIT:C27003 PMID:41385096 "[{""id"":""uuid:36643eb6-897f-4093-b08b-a5b7668967ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d431fd72-c2e1-4222-9269-b15265fbcd40"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxycodone hydrochloride oral solution USP, 100 mg per 5 mL (20 mg per mL) an opioid agonist is indicated for the relief of moderate to severe acute and chronic pain in opioid-tolerant patients. Oxycodone hydrochloride oral solution USP, 100 mg per 5 mL (20 mg per mL) may cause fatal respiratory depression when administered to patients not previously exposed to opioids. Patients considered to be opioid tolerant are those who are taking at least 30 mg of oral oxycodone per day, or at least 60 mg oral morphine per day, or at least 12 mg hydromorphone per day, or an equianalgesic dose of another opioid, for a week or longer. uuid:e734f022-3157-41e4-b82e-7eed52524d01 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7852 biolink:treats HP:0012532 PMID:41385096 "[{""id"":""uuid:1a9668d9-8782-4e54-b568-c259302932ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0efcbe48-c16c-455a-9726-8a55509109ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:59c38d53-07c8-4bfd-b5d4-69570283f2ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxycodone hydrochloride oral solution USP, 100 mg per 5 mL (20 mg per mL) an opioid agonist is indicated for the relief of moderate to severe acute and chronic pain in opioid-tolerant patients. Oxycodone hydrochloride oral solution USP, 100 mg per 5 mL (20 mg per mL) may cause fatal respiratory depression when administered to patients not previously exposed to opioids. Patients considered to be opioid tolerant are those who are taking at least 30 mg of oral oxycodone per day, or at least 60 mg oral morphine per day, or at least 12 mg hydromorphone per day, or an equianalgesic dose of another opioid, for a week or longer.|[PMDA] Drugs with a new indication and a new dosage for analgesia in moderate to severe chronic pain which cannot be managed by treatment with non-opioid analgesics or other opioid analgesics. uuid:41c95590-5c35-4494-b9ff-3780e40747f3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:82405 biolink:treats MONDO:0012865 PMID:41385096 "[{""id"":""uuid:68714fcf-3754-4b7a-91c0-ff032dad6313"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b2b9ab90-0064-44de-b297-4963bc9891df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ACNE AND SHAVING BUMPS. uuid:7e1b3e6c-a467-4608-9c53-ef7b94836780 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:7dbb5317-d304-439a-a0b2-a8b8d24cd8b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:61b1261a-7b45-41c8-b337-efdd06b3f963"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ECZEMA, SPECIFIC DRY SKIN, AND SPECIFIC SKIN IRRITATIONS. uuid:e461ff7d-f5a0-43c8-a8d8-2399478502a9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats HP:0000958 PMID:41385096 "[{""id"":""uuid:0f39903e-4db5-40a6-bdcc-e908eeb82635"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:390e0351-5b24-4e85-96ae-73d178d1c390"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ECZEMA, SPECIFIC DRY SKIN, AND SPECIFIC SKIN IRRITATIONS. uuid:068ab225-d610-45cf-82f0-588ee1844111 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15676 biolink:treats MONDO:0005093 PMID:41385096 "[{""id"":""uuid:fd03ceed-0038-4c4a-87be-0d13e5b24f89"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0f97ba99-eed6-4b01-bd88-903f47e77c9f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Uses - Scar Management - Temporarily protects minor cuts , scrapes and burns - Temporary relief of pain associated with minor cuts, scrapes and minor skin irritations uuid:bdf56b08-90b3-460c-8741-c0b545f15781 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2676 biolink:treats UMLS:C0877637 PMID:41385096 "[{""id"":""uuid:5b6e86bc-2405-4fbd-987e-3f17183856f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:86d3911f-bfe9-4c05-8c91-b81e55189902"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin tablets, USP and other antibacterial drugs, amoxicillin tablets, USP should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Amoxicillin tablets, USP are indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) isolates of the designated bacteria in the conditions listed below: 1.1 Infections of the Ear, Nose, and Throat Due to Streptococcus species (α- and β-hemolytic isolates only), Streptococcus pneumoniae, Staphylococcus spp., or Haemophilus influenzae. 1.2 Infections of the Genitourinary Tract Due to Escherichia coli, Proteus mirabilis, or Enterococcus faecalis. 1.3 Infections of the Skin and Skin Structure Due to Streptococcus spp. (α- and β-hemolytic isolates only), Staphylococcus spp., or E. coli. 1.4 Infections of the Lower Respiratory Tract Due to Streptococcus spp. (α- and β-hemolytic isolates only), S. pneumoniae, Staphylococcus spp., or H. influenzae. 1.5 Gonorrhea, Acute Uncomplicated (ano-genital and urethral infections) due to Neisseria gonorrhoeae. Because of high rates of amoxicillin resistance, amoxicillin tablets, USP are not recommended for empiric treatment of gonorrhea. Amoxicillin tablets, USP use should be limited to situations where N. gonorrhoeae isolates are known to be susceptible to amoxicillin. 1.6 Triple Therapy for Helicobacter pylori with Clarithromycin and Lansoprazole Amoxicillin tablets, USP, in combination with clarithromycin plus lansoprazole as triple therapy, are indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) to eradicate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. 1.7 Dual Therapy for H. pylori with Lansoprazole Amoxicillin tablets, USP, in combination with lansoprazole delayed-release capsules as dual therapy, are indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected. (See the clarithromycin package insert, MICROBIOLOGY.) Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. uuid:af563d90-6d8b-41d2-b12f-61f0cf69f268 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6367 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:7203c477-14a4-47aa-9640-2386ba670ae1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:460d8e48-5a18-4a6e-a1ac-1ec18e7309d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Epilepsy Adjunctive Therapy: Lamotrigine tablets are indicated as adjunctive therapy for the following seizure types in patients ≥ 2 years of age: partial seizures primary generalized tonic-clonic seizures generalized seizures of Lennox-Gastaut syndrome Monotherapy: Lamotrigine tablets are indicated for conversion to monotherapy in adults (≥16 years of age) with partial seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single antiepileptic drug (AED). Safety and effectiveness of lamotrigine tablets have not been established (1) as initial monotherapy; (2) for conversion to monotherapy from AEDs other than carbamazepine, phenytoin, phenobarbital, primidone, or valproate; or (3) for simultaneous conversion to monotherapy from 2 or more concomitant AEDs. 1.2 Bipolar Disorder Lamotrigine tablets are indicated for the maintenance treatment of Bipolar I Disorder to delay the time to occurrence of mood episodes (depression, mania, hypomania, mixed episodes) in adults (≥18 years of age) treated for acute mood episodes with standard therapy. The effectiveness of lamotrigine tablets in the acute treatment of mood episodes has not been established. The effectiveness of lamotrigine tablets as maintenance treatment was established in 2 placebo-controlled trials in patients with Bipolar I Disorder as defined by DSM-IV [see Clinical Studies (14.2)]. The physician who elects to prescribe lamotrigine tablets for periods extending beyond 16 weeks should periodically re-evaluate the long-term usefulness of the drug for the individual patient. uuid:5ce3a3b8-36d2-45bb-a915-fb93a9ff117f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6367 biolink:treats HP:0100754 PMID:41385096 "[{""id"":""uuid:6f4f7ee7-3348-458a-a0cc-ba2b37be7d67"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:21f2333d-e308-4ac9-85f8-43d9dd51440b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Epilepsy Adjunctive Therapy: Lamotrigine tablets are indicated as adjunctive therapy for the following seizure types in patients ≥ 2 years of age: partial seizures primary generalized tonic-clonic seizures generalized seizures of Lennox-Gastaut syndrome Monotherapy: Lamotrigine tablets are indicated for conversion to monotherapy in adults (≥16 years of age) with partial seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single antiepileptic drug (AED). Safety and effectiveness of lamotrigine tablets have not been established (1) as initial monotherapy; (2) for conversion to monotherapy from AEDs other than carbamazepine, phenytoin, phenobarbital, primidone, or valproate; or (3) for simultaneous conversion to monotherapy from 2 or more concomitant AEDs. 1.2 Bipolar Disorder Lamotrigine tablets are indicated for the maintenance treatment of Bipolar I Disorder to delay the time to occurrence of mood episodes (depression, mania, hypomania, mixed episodes) in adults (≥18 years of age) treated for acute mood episodes with standard therapy. The effectiveness of lamotrigine tablets in the acute treatment of mood episodes has not been established. The effectiveness of lamotrigine tablets as maintenance treatment was established in 2 placebo-controlled trials in patients with Bipolar I Disorder as defined by DSM-IV [see Clinical Studies (14.2)]. The physician who elects to prescribe lamotrigine tablets for periods extending beyond 16 weeks should periodically re-evaluate the long-term usefulness of the drug for the individual patient. uuid:afda2294-edf5-49b6-9dd1-abf5280000b4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6367 biolink:treats UMLS:C0865305 PMID:41385096 "[{""id"":""uuid:d6a2eb5e-afb8-47b0-a057-e9fbfc98eb48"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4eb1b667-8437-41ae-92ed-d7b4d7ce3e00"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Epilepsy Adjunctive Therapy: Lamotrigine tablets are indicated as adjunctive therapy for the following seizure types in patients ≥ 2 years of age: partial seizures primary generalized tonic-clonic seizures generalized seizures of Lennox-Gastaut syndrome Monotherapy: Lamotrigine tablets are indicated for conversion to monotherapy in adults (≥16 years of age) with partial seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single antiepileptic drug (AED). Safety and effectiveness of lamotrigine tablets have not been established (1) as initial monotherapy; (2) for conversion to monotherapy from AEDs other than carbamazepine, phenytoin, phenobarbital, primidone, or valproate; or (3) for simultaneous conversion to monotherapy from 2 or more concomitant AEDs. 1.2 Bipolar Disorder Lamotrigine tablets are indicated for the maintenance treatment of Bipolar I Disorder to delay the time to occurrence of mood episodes (depression, mania, hypomania, mixed episodes) in adults (≥18 years of age) treated for acute mood episodes with standard therapy. The effectiveness of lamotrigine tablets in the acute treatment of mood episodes has not been established. The effectiveness of lamotrigine tablets as maintenance treatment was established in 2 placebo-controlled trials in patients with Bipolar I Disorder as defined by DSM-IV [see Clinical Studies (14.2)]. The physician who elects to prescribe lamotrigine tablets for periods extending beyond 16 weeks should periodically re-evaluate the long-term usefulness of the drug for the individual patient. uuid:a4062912-11f8-4610-9ffa-e2422490fe2e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8707 biolink:treats MONDO:0001866 PMID:41385096 "[{""id"":""uuid:288a5c3e-ce6d-4f67-9c33-a1dd369ad22d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:95ecf00b-9be2-4898-8eaf-6eb1a77ae6ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Schizophrenia Quetiapine fumarate tablet is indicated for the treatment of schizophrenia. The efficacy of quetiapine fumarate tablets in schizophrenia was established in three 6-week trials in adults and one 6-week trial in adolescents (13 to 17 years). The effectiveness of quetiapine fumarate tablets for the maintenance treatment of schizophrenia has not been systematically evaluated in controlled clinical trials. [see Clinical Studies (14.1)] 1.2 Bipolar Disorder Quetiapine fumarate tablet is indicated for the acute treatment of manic episodes associated with bipolar I disorder, both as monotherapy and as an adjunct to lithium or divalproex. Efficacy was established in two 12-week monotherapy trials in adults, in one 3-week adjunctive trial in adults, and in one 3-week monotherapy trial in pediatric patients (10 to 17 years) [ see Clinical Studies (14.2)] . Quetiapine fumarate tablet is indicated as monotherapy for the acute treatment of depressive episodes associated with bipolar disorder. Efficacy was established in two 8-week monotherapy trials in adult patients with bipolar I and bipolar II disorder [ see Clinical Studies (14.2)] . Quetiapine fumarate tablet is indicated for the maintenance treatment of bipolar I disorder, as an adjunct to lithium or divalproex. Efficacy was established in two maintenance trials in adults. The effectiveness of quetiapine fumarate tablets as monotherapy for the maintenance treatment of bipolar disorder has not been systematically evaluated in controlled clinical trials. [ see Clinical Studies (14.2)] . 1.3 Special Considerations in Treating Pediatric Schizophrenia and Bipolar I Disorder Pediatric schizophrenia and bipolar I disorder are serious mental disorders, however, diagnosis can be challenging. For pediatric schizophrenia, symptom profiles can be variable, and for bipolar I disorder, patients may have variable patterns of periodicity of manic or mixed symptoms. It is recommended that medication therapy for pediatric schizophrenia and bipolar I disorder be initiated only after a thorough diagnostic evaluation has been performed and careful consideration given to the risks associated with medication treatment. Medication treatment for both pediatric schizophrenia and bipolar I disorder is indicated as part of a total treatment program that often includes psychological, educational and social interventions. uuid:07553f02-99c5-4f24-99b0-54de150b4617 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8707 biolink:treats MONDO:0024613 PMID:41385096 "[{""id"":""uuid:241fcfdf-8d4d-496d-a633-6c2f45df0394"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1cdf683a-32fa-4494-9202-f0bc6276c5aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Schizophrenia Quetiapine fumarate tablet is indicated for the treatment of schizophrenia. The efficacy of quetiapine fumarate tablets in schizophrenia was established in three 6-week trials in adults and one 6-week trial in adolescents (13 to 17 years). The effectiveness of quetiapine fumarate tablets for the maintenance treatment of schizophrenia has not been systematically evaluated in controlled clinical trials. [see Clinical Studies (14.1)] 1.2 Bipolar Disorder Quetiapine fumarate tablet is indicated for the acute treatment of manic episodes associated with bipolar I disorder, both as monotherapy and as an adjunct to lithium or divalproex. Efficacy was established in two 12-week monotherapy trials in adults, in one 3-week adjunctive trial in adults, and in one 3-week monotherapy trial in pediatric patients (10 to 17 years) [ see Clinical Studies (14.2)] . Quetiapine fumarate tablet is indicated as monotherapy for the acute treatment of depressive episodes associated with bipolar disorder. Efficacy was established in two 8-week monotherapy trials in adult patients with bipolar I and bipolar II disorder [ see Clinical Studies (14.2)] . Quetiapine fumarate tablet is indicated for the maintenance treatment of bipolar I disorder, as an adjunct to lithium or divalproex. Efficacy was established in two maintenance trials in adults. The effectiveness of quetiapine fumarate tablets as monotherapy for the maintenance treatment of bipolar disorder has not been systematically evaluated in controlled clinical trials. [ see Clinical Studies (14.2)] . 1.3 Special Considerations in Treating Pediatric Schizophrenia and Bipolar I Disorder Pediatric schizophrenia and bipolar I disorder are serious mental disorders, however, diagnosis can be challenging. For pediatric schizophrenia, symptom profiles can be variable, and for bipolar I disorder, patients may have variable patterns of periodicity of manic or mixed symptoms. It is recommended that medication therapy for pediatric schizophrenia and bipolar I disorder be initiated only after a thorough diagnostic evaluation has been performed and careful consideration given to the risks associated with medication treatment. Medication treatment for both pediatric schizophrenia and bipolar I disorder is indicated as part of a total treatment program that often includes psychological, educational and social interventions. uuid:971a1448-92f1-49e9-9ebe-778e7709f389 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8707 biolink:treats MONDO:0000693 PMID:41385096 "[{""id"":""uuid:a27c1b3b-9ea6-4f9f-ab98-8b11492255d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9250d0bb-6501-43f6-abdd-2d0d2b1a82af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Schizophrenia Quetiapine fumarate tablet is indicated for the treatment of schizophrenia. The efficacy of quetiapine fumarate tablets in schizophrenia was established in three 6-week trials in adults and one 6-week trial in adolescents (13 to 17 years). The effectiveness of quetiapine fumarate tablets for the maintenance treatment of schizophrenia has not been systematically evaluated in controlled clinical trials. [see Clinical Studies (14.1)] 1.2 Bipolar Disorder Quetiapine fumarate tablet is indicated for the acute treatment of manic episodes associated with bipolar I disorder, both as monotherapy and as an adjunct to lithium or divalproex. Efficacy was established in two 12-week monotherapy trials in adults, in one 3-week adjunctive trial in adults, and in one 3-week monotherapy trial in pediatric patients (10 to 17 years) [ see Clinical Studies (14.2)] . Quetiapine fumarate tablet is indicated as monotherapy for the acute treatment of depressive episodes associated with bipolar disorder. Efficacy was established in two 8-week monotherapy trials in adult patients with bipolar I and bipolar II disorder [ see Clinical Studies (14.2)] . Quetiapine fumarate tablet is indicated for the maintenance treatment of bipolar I disorder, as an adjunct to lithium or divalproex. Efficacy was established in two maintenance trials in adults. The effectiveness of quetiapine fumarate tablets as monotherapy for the maintenance treatment of bipolar disorder has not been systematically evaluated in controlled clinical trials. [ see Clinical Studies (14.2)] . 1.3 Special Considerations in Treating Pediatric Schizophrenia and Bipolar I Disorder Pediatric schizophrenia and bipolar I disorder are serious mental disorders, however, diagnosis can be challenging. For pediatric schizophrenia, symptom profiles can be variable, and for bipolar I disorder, patients may have variable patterns of periodicity of manic or mixed symptoms. It is recommended that medication therapy for pediatric schizophrenia and bipolar I disorder be initiated only after a thorough diagnostic evaluation has been performed and careful consideration given to the risks associated with medication treatment. Medication treatment for both pediatric schizophrenia and bipolar I disorder is indicated as part of a total treatment program that often includes psychological, educational and social interventions. uuid:9482e77f-7b37-4636-9119-a4d556dd8bca biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:94559 biolink:treats MONDO:0005324 PMID:41385096 "[{""id"":""uuid:e58a13a5-c7ee-4ab8-ba8e-92a9678e2bd0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1535880e-9226-4bad-9e9b-fdd40f80f72f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levocetirizine dihydrochloride tablets are a histamine H 1 -receptor antagonist indicated for: • The relief of symptoms associated with seasonal and perennial allergic rhinitis (1.1, 1.2) • The treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria (1.3) uuid:7d0f6609-95b8-4cc7-a04a-37156f9a4028 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:94559 biolink:treats MONDO:0024332 PMID:41385096 "[{""id"":""uuid:f4bea049-4a44-4d81-9ece-5fb69e4da99a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:79b003f6-308e-4917-af6f-cf94c437ed3b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levocetirizine dihydrochloride tablets are a histamine H 1 -receptor antagonist indicated for: • The relief of symptoms associated with seasonal and perennial allergic rhinitis (1.1, 1.2) • The treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria (1.3) uuid:0fdcf851-2c6b-467c-b5e1-bb3c582177e2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:25187 biolink:treats MONDO:0005578 PMID:41385096 "[{""id"":""uuid:7082ff5e-6f49-4b83-a204-4972fd5dd271"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:469cea26-3e29-4d11-937f-9080deebd267"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS For the temporary relief of minor pain of muscles and joints associated with: Arthritis Simple Backache Strains Sprains Bruises uuid:e88bf805-f14d-429c-8b51-2c275b86cef7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:25187 biolink:treats UMLS:C0038045 PMID:41385096 "[{""id"":""uuid:6da4c8e3-0194-4387-8397-c2b16dda95d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:caa814ba-1fd5-4153-bed4-11ad53c9f246"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS For the temporary relief of minor pain of muscles and joints associated with: Arthritis Simple Backache Strains Sprains Bruises uuid:3d9edfa4-c800-49a7-b3f7-9f99cfd17d55 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:25187 biolink:treats UMLS:C0009938 PMID:41385096 "[{""id"":""uuid:dfd1c910-c90a-4f06-bc95-62bf10b60738"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f0586575-b294-4e88-bce9-c2cc4fcbd286"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS For the temporary relief of minor pain of muscles and joints associated with: Arthritis Simple Backache Strains Sprains Bruises uuid:989483bf-9804-4d92-aa80-a06b2f07e7a9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16914 biolink:treats MONDO:0005578 PMID:41385096 "[{""id"":""uuid:aeaa9444-cb7f-4f44-b24d-cbb04ea476a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:38903b7b-3e00-4c3b-986d-aa27bb9f4ffa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS For the temporary relief of minor pain of muscles and joints associated with: Arthritis Simple Backache Strains Sprains Bruises DIRECTIONS Adults and children over 18 years: Apply generously to affected area Massage into painful area until thoroughly absorbed into skin Repeat as necessary, not more than 3-4 times daily. Wash hands with soap and water immediately after use. Children 18 years or younger: ask a doctor Store at 20°-25°C (68°-77 °F). Avoid direct sunlight. uuid:aa72cd18-3bfa-46a8-88a2-5aa2f85add7d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16914 biolink:treats UMLS:C0038045 PMID:41385096 "[{""id"":""uuid:e4e0863c-18ac-4b34-b0d8-2df65ce5b5ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:39c00939-e6d5-4fc1-84fd-b3f949db5650"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS For the temporary relief of minor pain of muscles and joints associated with: Arthritis Simple Backache Strains Sprains Bruises DIRECTIONS Adults and children over 18 years: Apply generously to affected area Massage into painful area until thoroughly absorbed into skin Repeat as necessary, not more than 3-4 times daily. Wash hands with soap and water immediately after use. Children 18 years or younger: ask a doctor Store at 20°-25°C (68°-77 °F). Avoid direct sunlight. uuid:45bdd1f1-2ff4-4fef-a929-76109ea2c3f7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16914 biolink:treats UMLS:C0009938 PMID:41385096 "[{""id"":""uuid:ba3589df-4f8b-4a0d-8389-656a93dc9639"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:017e4931-b8e7-4c3d-9528-6ac4563a963d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS For the temporary relief of minor pain of muscles and joints associated with: Arthritis Simple Backache Strains Sprains Bruises DIRECTIONS Adults and children over 18 years: Apply generously to affected area Massage into painful area until thoroughly absorbed into skin Repeat as necessary, not more than 3-4 times daily. Wash hands with soap and water immediately after use. Children 18 years or younger: ask a doctor Store at 20°-25°C (68°-77 °F). Avoid direct sunlight. uuid:c17b5d2a-905a-49bc-98c7-8f0e9f520788 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:375139 biolink:treats MONDO:0005578 PMID:41385096 "[{""id"":""uuid:f9628116-e1e9-4e6b-85e2-1aade49dcfa6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e4477222-e7a0-4b0c-a5f8-cbe759eeafa9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS For the temporary relief of pain of muscles and joints associated with: Arthritis Simple Backache Strains Sprains Bruises DIRECTIONS Adults and children over 12 years Apply generously to affected area Massage into painful area until thoroughly absorbed into skin, repeat as necessary, not more than 3-4 times daily Store at 20°-25°C (68°-77 °F). Avoid direct sunlight. uuid:19d9f7e8-117f-4f29-89ec-ad6936ea01c7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:375139 biolink:treats UMLS:C0038045 PMID:41385096 "[{""id"":""uuid:41fe78e6-3841-41e0-81e0-c65b73387839"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ecebecfc-8582-44b1-9429-99accfb698b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS For the temporary relief of pain of muscles and joints associated with: Arthritis Simple Backache Strains Sprains Bruises DIRECTIONS Adults and children over 12 years Apply generously to affected area Massage into painful area until thoroughly absorbed into skin, repeat as necessary, not more than 3-4 times daily Store at 20°-25°C (68°-77 °F). Avoid direct sunlight. uuid:28713315-139c-4138-8e17-b57e8a6d1e91 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:375139 biolink:treats UMLS:C0009938 PMID:41385096 "[{""id"":""uuid:9d65e9a7-656c-4bb5-9e08-a0429a9ca0db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:86796c0b-f918-4171-95c5-c79bb421c2a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS For the temporary relief of pain of muscles and joints associated with: Arthritis Simple Backache Strains Sprains Bruises DIRECTIONS Adults and children over 12 years Apply generously to affected area Massage into painful area until thoroughly absorbed into skin, repeat as necessary, not more than 3-4 times daily Store at 20°-25°C (68°-77 °F). Avoid direct sunlight. uuid:aeb597e9-9bbf-495e-96e3-1956db00f40d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17051 biolink:treats MONDO:0004059 PMID:41385096 "[{""id"":""uuid:3b4d4347-17f3-4377-a57b-68e34f08bbca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fc6458dd-8ebc-4dee-880d-04e25a04a506"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] This is a fluoride and potassium nitrate gel intended to aid in the prevention of dental decay and to help treat tooth sensitivity to cold, heat, sweets, acids, or contact. uuid:b21a9916-8b4c-47e9-bf3e-76baff33a8ab biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9241 biolink:treats HP:0000969 PMID:41385096 "[{""id"":""uuid:45165c0c-cdf0-4c16-808e-09a55037966f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:31407feb-0f2b-4818-9010-9273ab630c2a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Spironolactone tablets, USP are indicated in the management of: for: Primary Hyperaldosteronism Establishing the diagnosis of primary hyperaldosteronism by therapeutic trial. Short-term preoperative treatment of patients with primary hyperaldosteronism. Long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are judged to be poor operative risks or who decline surgery. Long-term maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). for Patients with: Edematous Conditions For the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures. Spironolactone tablets, USP are also indicated for patients with congestive heart failure taking digitalis when other therapies are considered inappropriate. Congestive Heart Failure: Spironolactone levels may be exceptionally high in this condition. Spironolactone tablets, USP are indicated for maintenance therapy together with bed rest and the restriction of fluid and sodium. Cirrhosis of the Liver Accompanied by Edema and/or Ascites: : For nephrotic patients when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics do not provide an adequate response. Nephrotic Syndrome uuid:96ac0806-e90e-4fd2-96ad-c55cd80d8f42 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9241 biolink:treats UMLS:C4722157 PMID:41385096 "[{""id"":""uuid:b9050935-96e5-4810-a279-7a5d3c8a5034"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a04774a5-0dcb-4d6c-aa1b-10c4b9e12717"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Spironolactone tablets, USP are indicated in the management of: for: Primary Hyperaldosteronism Establishing the diagnosis of primary hyperaldosteronism by therapeutic trial. Short-term preoperative treatment of patients with primary hyperaldosteronism. Long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are judged to be poor operative risks or who decline surgery. Long-term maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). for Patients with: Edematous Conditions For the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures. Spironolactone tablets, USP are also indicated for patients with congestive heart failure taking digitalis when other therapies are considered inappropriate. Congestive Heart Failure: Spironolactone levels may be exceptionally high in this condition. Spironolactone tablets, USP are indicated for maintenance therapy together with bed rest and the restriction of fluid and sodium. Cirrhosis of the Liver Accompanied by Edema and/or Ascites: : For nephrotic patients when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics do not provide an adequate response. Nephrotic Syndrome uuid:4a0e2df0-6f50-48a0-bedb-def09a00cb8d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2955 biolink:treats MONDO:0005002 PMID:41385096 "[{""id"":""uuid:68b82008-4ec4-4eb3-8b97-313fbfee46bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6e8b3470-e875-40f6-9bd2-c9a7538cbf2c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azithromycin for oral suspension USP is indicated for the treatment of patients with mild to moderate infections (pneumonia: see WARNINGS ) caused by susceptible strains of the designated microorganisms in the specific conditions listed below. As recommended dosages, durations of therapy and applicable patient populations vary among these infections, please see DOSAGE AND ADMINISTRATION for specific dosing recommendations. Adults Acute bacterial exacerbations of chronic obstructive pulmonary disease due to Haemophilus influenzae, Moraxella catarrhalis or Streptococcus pneumoniae. Acute bacterial sinusitis due to Haemophilus influenzae, Moraxella catarrhalis or Streptococcus pneumoniae. Community-acquired pneumonia due to Chlamydophila pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae or Streptococcus pneumoniae in patients appropriate for oral therapy. NOTE: Azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomially acquired infections, patients with known or suspected bacteremia, patients requiring hospitalization, elderly or debilitated patients, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. NOTE: Penicillin by the intramuscular route is the usual drug of choice in the treatment of Streptococcus pyogenes infection and the prophylaxis of rheumatic fever. Azithromycin for oral suspension USP is often effective in the eradication of susceptible strains of Streptococcus pyogenes from the nasopharynx. Because some strains are resistant to azithromycin for oral suspension USP, susceptibility tests should be performed when patients are treated with azithromycin for oral suspension USP. Data establishing efficacy of azithromycin in subsequent prevention of rheumatic fever are not available. Uncomplicated skin and skin structure infections due to Staphylococcus aureus, Streptococcus pyogenes, or Streptococcus agalactiae. Abscesses usually require surgical drainage. Urethritis and cervicitis due to Chlamydia trachomatis or Neisseria gonorrhoeae. Genital ulcer disease in men due to Haemophilus ducreyi (chancroid). Due to the small number of women included in clinical trials, the efficacy of azithromycin in the treatment of chancroid in women has not been established. Azithromycin for oral suspension USP, at the recommended dose, should not be relied upon to treat syphilis. Antimicrobial agents used in high doses for short periods of time to treat non-gonococcal urethritis may mask or delay the symptoms of incubating syphilis. All patients with sexually-transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate cultures for gonorrhea performed at the time of diagnosis. Appropriate antimicrobial therapy and follow-up tests for these diseases should be initiated if infection is confirmed. Appropriate culture and susceptibility tests should be performed before treatment to determine the causative organism and its susceptibility to azithromycin, USP. Therapy with azithromycin for oral suspension USP may be initiated before results of these tests are known; once the results become available, antimicrobial therapy should be adjusted accordingly. To reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin for oral suspension USP and other antibacterial drugs, azithromycin for oral suspension USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Pediatric Patients See PRECAUTIONS, Pediatric Use and CLINICAL STUDIES, Pediatric Patients. Acute otitis media caused by Haemophilus influenzae, Moraxella catarrhalis or Streptococcus pneumoniae. (For specific dosage recommendation, see DOSAGE AND ADMINISTRATION .) Community-acquired pneumonia due to Chlamydophila pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae or Streptococcus pneumoniae in patients appropriate for oral therapy. (For specific dosage recommendation, see DOSAGE AND ADMINISTRATION .) NOTE: Azithromycin should not be used in pediatric patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomially acquired infections, patients with known or suspected bacteremia, patients requiring hospitalization, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. (For specific dosage recommendation, see DOSAGE AND ADMINISTRATION .) NOTE: Penicillin by the intramuscular route is the usual drug of choice in the treatment of Streptococcus pyogenes infection and the prophylaxis of rheumatic fever. Azithromycin for oral suspension USP is often effective in the eradication of susceptible strains of Streptococcus pyogenes from the nasopharynx. Because some strains are resistant to azithromycin for oral suspension USP, susceptibility tests should be performed when patients are treated with azithromycin for oral suspension USP. Data establishing efficacy of azithromycin in subsequent prevention of rheumatic fever are not available. Appropriate culture and susceptibility tests should be performed before treatment to determine the causative organism and its susceptibility to azithromycin. Therapy with azithromycin for oral suspension USP may be initiated before results of these tests are known; once the results become available, antimicrobial therapy should be adjusted accordingly. uuid:031a37aa-5a1a-4363-9a08-0826f5aaab6a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2955 biolink:treats MONDO:0005976 PMID:41385096 "[{""id"":""uuid:3910f26c-93ed-43b0-b26e-a2fe510fea67"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:45e18e6a-703f-4df2-b50e-bcbd29b2f468"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azithromycin for oral suspension USP is indicated for the treatment of patients with mild to moderate infections (pneumonia: see WARNINGS ) caused by susceptible strains of the designated microorganisms in the specific conditions listed below. As recommended dosages, durations of therapy and applicable patient populations vary among these infections, please see DOSAGE AND ADMINISTRATION for specific dosing recommendations. Adults Acute bacterial exacerbations of chronic obstructive pulmonary disease due to Haemophilus influenzae, Moraxella catarrhalis or Streptococcus pneumoniae. Acute bacterial sinusitis due to Haemophilus influenzae, Moraxella catarrhalis or Streptococcus pneumoniae. Community-acquired pneumonia due to Chlamydophila pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae or Streptococcus pneumoniae in patients appropriate for oral therapy. NOTE: Azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomially acquired infections, patients with known or suspected bacteremia, patients requiring hospitalization, elderly or debilitated patients, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. NOTE: Penicillin by the intramuscular route is the usual drug of choice in the treatment of Streptococcus pyogenes infection and the prophylaxis of rheumatic fever. Azithromycin for oral suspension USP is often effective in the eradication of susceptible strains of Streptococcus pyogenes from the nasopharynx. Because some strains are resistant to azithromycin for oral suspension USP, susceptibility tests should be performed when patients are treated with azithromycin for oral suspension USP. Data establishing efficacy of azithromycin in subsequent prevention of rheumatic fever are not available. Uncomplicated skin and skin structure infections due to Staphylococcus aureus, Streptococcus pyogenes, or Streptococcus agalactiae. Abscesses usually require surgical drainage. Urethritis and cervicitis due to Chlamydia trachomatis or Neisseria gonorrhoeae. Genital ulcer disease in men due to Haemophilus ducreyi (chancroid). Due to the small number of women included in clinical trials, the efficacy of azithromycin in the treatment of chancroid in women has not been established. Azithromycin for oral suspension USP, at the recommended dose, should not be relied upon to treat syphilis. Antimicrobial agents used in high doses for short periods of time to treat non-gonococcal urethritis may mask or delay the symptoms of incubating syphilis. All patients with sexually-transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate cultures for gonorrhea performed at the time of diagnosis. Appropriate antimicrobial therapy and follow-up tests for these diseases should be initiated if infection is confirmed. Appropriate culture and susceptibility tests should be performed before treatment to determine the causative organism and its susceptibility to azithromycin, USP. Therapy with azithromycin for oral suspension USP may be initiated before results of these tests are known; once the results become available, antimicrobial therapy should be adjusted accordingly. To reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin for oral suspension USP and other antibacterial drugs, azithromycin for oral suspension USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Pediatric Patients See PRECAUTIONS, Pediatric Use and CLINICAL STUDIES, Pediatric Patients. Acute otitis media caused by Haemophilus influenzae, Moraxella catarrhalis or Streptococcus pneumoniae. (For specific dosage recommendation, see DOSAGE AND ADMINISTRATION .) Community-acquired pneumonia due to Chlamydophila pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae or Streptococcus pneumoniae in patients appropriate for oral therapy. (For specific dosage recommendation, see DOSAGE AND ADMINISTRATION .) NOTE: Azithromycin should not be used in pediatric patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomially acquired infections, patients with known or suspected bacteremia, patients requiring hospitalization, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. (For specific dosage recommendation, see DOSAGE AND ADMINISTRATION .) NOTE: Penicillin by the intramuscular route is the usual drug of choice in the treatment of Streptococcus pyogenes infection and the prophylaxis of rheumatic fever. Azithromycin for oral suspension USP is often effective in the eradication of susceptible strains of Streptococcus pyogenes from the nasopharynx. Because some strains are resistant to azithromycin for oral suspension USP, susceptibility tests should be performed when patients are treated with azithromycin for oral suspension USP. Data establishing efficacy of azithromycin in subsequent prevention of rheumatic fever are not available. Appropriate culture and susceptibility tests should be performed before treatment to determine the causative organism and its susceptibility to azithromycin. Therapy with azithromycin for oral suspension USP may be initiated before results of these tests are known; once the results become available, antimicrobial therapy should be adjusted accordingly. uuid:ba544bac-4036-4a03-930d-186c068ff2a0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:478164 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:d7b58742-8ee3-46ad-987e-e2227385ee35"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0b859840-9ad8-4a08-bf37-2f3a5bb06501"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefepime for injection, USP is indicated in the treatment of the following infections caused by susceptible strains of the designated microorganisms (see also PRECAUTIONS: Pediatric Use and DOSAGE AND ADMINISTRATION ): Pneumonia (moderate to severe) caused by Streptococcus pneumoniae , including cases associated with concurrent bacteremia, Pseudomonas aeruginosa , Klebsiella pneumoniae , or Enterobacter species. Empiric Therapy for Febrile Neutropenic Patients. Cefepime as monotherapy is indicated for empiric treatment of febrile neutropenic patients. In patients at high risk for severe infection (including patients with a history of recent bone marrow transplantation, with hypotension at presentation, with an underlying hematologic malignancy, or with severe or prolonged neutropenia), antimicrobial monotherapy may not be appropriate. Insufficient data exist to support the efficacy of cefepime monotherapy in such patients. (See CLINICAL STUDIES .) Uncomplicated and Complicated Urinary Tract Infections (including pyelonephritis) caused by Escherichia coli or Klebsiella pneumoniae , when the infection is severe, or caused by Escherichia coli, Klebsiella pneumoniae , or Proteus mirabilis , when the infection is mild to moderate, including cases associated with concurrent bacteremia with these microorganisms. Uncomplicated Skin and Skin Structure Infections caused by Staphylococcus aureus (methicillin-susceptible isolates only) or Streptococcus pyogenes . Complicated Intra-abdominal Infections (used in combination with metronidazole) caused by Escherichia coli , viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae , Enterobacter species, or Bacteroides fragilis . (See CLINICAL STUDIES .) To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefepime for injection, USP and other antibacterial drugs, cefepime for injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:63e1c589-e1cb-4e3b-8f37-ca9811dd5770 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:478164 biolink:treats UMLS:C0746883 PMID:41385096 "[{""id"":""uuid:09d69bc6-dd1a-4733-bdc3-324b8c004e14"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0ee11898-0142-42ef-bd07-5a9de82d985d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e8c02f77-d143-4436-b867-cfaa40884c9e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefepime for injection, USP is indicated in the treatment of the following infections caused by susceptible strains of the designated microorganisms (see also PRECAUTIONS: Pediatric Use and DOSAGE AND ADMINISTRATION ): Pneumonia (moderate to severe) caused by Streptococcus pneumoniae , including cases associated with concurrent bacteremia, Pseudomonas aeruginosa , Klebsiella pneumoniae , or Enterobacter species. Empiric Therapy for Febrile Neutropenic Patients. Cefepime as monotherapy is indicated for empiric treatment of febrile neutropenic patients. In patients at high risk for severe infection (including patients with a history of recent bone marrow transplantation, with hypotension at presentation, with an underlying hematologic malignancy, or with severe or prolonged neutropenia), antimicrobial monotherapy may not be appropriate. Insufficient data exist to support the efficacy of cefepime monotherapy in such patients. (See CLINICAL STUDIES .) Uncomplicated and Complicated Urinary Tract Infections (including pyelonephritis) caused by Escherichia coli or Klebsiella pneumoniae , when the infection is severe, or caused by Escherichia coli, Klebsiella pneumoniae , or Proteus mirabilis , when the infection is mild to moderate, including cases associated with concurrent bacteremia with these microorganisms. Uncomplicated Skin and Skin Structure Infections caused by Staphylococcus aureus (methicillin-susceptible isolates only) or Streptococcus pyogenes . Complicated Intra-abdominal Infections (used in combination with metronidazole) caused by Escherichia coli , viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae , Enterobacter species, or Bacteroides fragilis . (See CLINICAL STUDIES .) To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefepime for injection, USP and other antibacterial drugs, cefepime for injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.|[PMDA] Addition of indications on febrile neutropenia uuid:5decf649-2f1a-4067-abe5-8ed577ca7ecf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:478164 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:1c53506e-86d4-4625-b443-36b12237a64a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b5c6e1e6-a79b-408e-92fd-6126618cef8d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefepime for injection, USP is indicated in the treatment of the following infections caused by susceptible strains of the designated microorganisms (see also PRECAUTIONS: Pediatric Use and DOSAGE AND ADMINISTRATION ): Pneumonia (moderate to severe) caused by Streptococcus pneumoniae , including cases associated with concurrent bacteremia, Pseudomonas aeruginosa , Klebsiella pneumoniae , or Enterobacter species. Empiric Therapy for Febrile Neutropenic Patients. Cefepime as monotherapy is indicated for empiric treatment of febrile neutropenic patients. In patients at high risk for severe infection (including patients with a history of recent bone marrow transplantation, with hypotension at presentation, with an underlying hematologic malignancy, or with severe or prolonged neutropenia), antimicrobial monotherapy may not be appropriate. Insufficient data exist to support the efficacy of cefepime monotherapy in such patients. (See CLINICAL STUDIES .) Uncomplicated and Complicated Urinary Tract Infections (including pyelonephritis) caused by Escherichia coli or Klebsiella pneumoniae , when the infection is severe, or caused by Escherichia coli, Klebsiella pneumoniae , or Proteus mirabilis , when the infection is mild to moderate, including cases associated with concurrent bacteremia with these microorganisms. Uncomplicated Skin and Skin Structure Infections caused by Staphylococcus aureus (methicillin-susceptible isolates only) or Streptococcus pyogenes . Complicated Intra-abdominal Infections (used in combination with metronidazole) caused by Escherichia coli , viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae , Enterobacter species, or Bacteroides fragilis . (See CLINICAL STUDIES .) To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefepime for injection, USP and other antibacterial drugs, cefepime for injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:136f68d1-cdce-4a57-b814-74291db8e30c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:478164 biolink:treats MONDO:0006939 PMID:41385096 "[{""id"":""uuid:b6b301b9-64dd-4dd1-bae4-681aeffb2131"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7b4bf061-a8a5-4333-a128-709eb4348f15"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefepime for injection, USP is indicated in the treatment of the following infections caused by susceptible strains of the designated microorganisms (see also PRECAUTIONS: Pediatric Use and DOSAGE AND ADMINISTRATION ): Pneumonia (moderate to severe) caused by Streptococcus pneumoniae , including cases associated with concurrent bacteremia, Pseudomonas aeruginosa , Klebsiella pneumoniae , or Enterobacter species. Empiric Therapy for Febrile Neutropenic Patients. Cefepime as monotherapy is indicated for empiric treatment of febrile neutropenic patients. In patients at high risk for severe infection (including patients with a history of recent bone marrow transplantation, with hypotension at presentation, with an underlying hematologic malignancy, or with severe or prolonged neutropenia), antimicrobial monotherapy may not be appropriate. Insufficient data exist to support the efficacy of cefepime monotherapy in such patients. (See CLINICAL STUDIES .) Uncomplicated and Complicated Urinary Tract Infections (including pyelonephritis) caused by Escherichia coli or Klebsiella pneumoniae , when the infection is severe, or caused by Escherichia coli, Klebsiella pneumoniae , or Proteus mirabilis , when the infection is mild to moderate, including cases associated with concurrent bacteremia with these microorganisms. Uncomplicated Skin and Skin Structure Infections caused by Staphylococcus aureus (methicillin-susceptible isolates only) or Streptococcus pyogenes . Complicated Intra-abdominal Infections (used in combination with metronidazole) caused by Escherichia coli , viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae , Enterobacter species, or Bacteroides fragilis . (See CLINICAL STUDIES .) To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefepime for injection, USP and other antibacterial drugs, cefepime for injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:dfebb194-263b-4ba7-80e8-41f468751ac0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:478164 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:32710e87-940a-459c-923a-584647a69935"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2b767e25-f370-4d52-a14b-aab06c9f5917"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefepime for injection, USP is indicated in the treatment of the following infections caused by susceptible strains of the designated microorganisms (see also PRECAUTIONS: Pediatric Use and DOSAGE AND ADMINISTRATION ): Pneumonia (moderate to severe) caused by Streptococcus pneumoniae , including cases associated with concurrent bacteremia, Pseudomonas aeruginosa , Klebsiella pneumoniae , or Enterobacter species. Empiric Therapy for Febrile Neutropenic Patients. Cefepime as monotherapy is indicated for empiric treatment of febrile neutropenic patients. In patients at high risk for severe infection (including patients with a history of recent bone marrow transplantation, with hypotension at presentation, with an underlying hematologic malignancy, or with severe or prolonged neutropenia), antimicrobial monotherapy may not be appropriate. Insufficient data exist to support the efficacy of cefepime monotherapy in such patients. (See CLINICAL STUDIES .) Uncomplicated and Complicated Urinary Tract Infections (including pyelonephritis) caused by Escherichia coli or Klebsiella pneumoniae , when the infection is severe, or caused by Escherichia coli, Klebsiella pneumoniae , or Proteus mirabilis , when the infection is mild to moderate, including cases associated with concurrent bacteremia with these microorganisms. Uncomplicated Skin and Skin Structure Infections caused by Staphylococcus aureus (methicillin-susceptible isolates only) or Streptococcus pyogenes . Complicated Intra-abdominal Infections (used in combination with metronidazole) caused by Escherichia coli , viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae , Enterobacter species, or Bacteroides fragilis . (See CLINICAL STUDIES .) To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefepime for injection, USP and other antibacterial drugs, cefepime for injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:cc3f1b0f-fbfd-4eec-8f43-cb9bc20ca6fb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47381 biolink:treats MONDO:0005412 PMID:41385096 "[{""id"":""uuid:acec0b51-8588-4dd8-a636-69a86db5e525"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:301efaca-52da-4710-b4bb-aed7695c3234"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ranitidine is indicated in: Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks. Studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than 8 weeks. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. No placebo-controlled comparative studies have been carried out for periods of longer than 1 year. The treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome and systemic mastocytosis). Short-term treatment of active, benign gastric ulcer. Most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated. Studies available to date have not assessed the safety of ranitidine in uncomplicated, benign gastric ulcer for periods of more than 6 weeks. Maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers. Placebo-controlled studies have been carried out for 1 year. Treatment of GERD. Symptomatic relief commonly occurs within 24 hours after starting therapy with ranitidine 150 mg two times a day. Treatment of endoscopically diagnosed erosive esophagitis. Symptomatic relief of heartburn commonly occurs within 24 hours of therapy initiation with ranitidine 150 mg 4 times daily. Maintenance of healing of erosive esophagitis. Placebo-controlled trials have been carried out for 48 weeks. Concomitant antacids should be given as needed for pain relief to patients with active duodenal ulcer; active, benign gastric ulcer; hypersecretory states; GERD; and erosive esophagitis. uuid:1856f79c-6251-44b7-bd3e-7780b9f6f67b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47381 biolink:treats MONDO:0016586 PMID:41385096 "[{""id"":""uuid:fa3b6bcc-baee-4b65-a2e4-7db1f928d868"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6020e558-3880-4a07-a645-3fe1c917f20b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ranitidine is indicated in: Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks. Studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than 8 weeks. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. No placebo-controlled comparative studies have been carried out for periods of longer than 1 year. The treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome and systemic mastocytosis). Short-term treatment of active, benign gastric ulcer. Most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated. Studies available to date have not assessed the safety of ranitidine in uncomplicated, benign gastric ulcer for periods of more than 6 weeks. Maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers. Placebo-controlled studies have been carried out for 1 year. Treatment of GERD. Symptomatic relief commonly occurs within 24 hours after starting therapy with ranitidine 150 mg two times a day. Treatment of endoscopically diagnosed erosive esophagitis. Symptomatic relief of heartburn commonly occurs within 24 hours of therapy initiation with ranitidine 150 mg 4 times daily. Maintenance of healing of erosive esophagitis. Placebo-controlled trials have been carried out for 48 weeks. Concomitant antacids should be given as needed for pain relief to patients with active duodenal ulcer; active, benign gastric ulcer; hypersecretory states; GERD; and erosive esophagitis. uuid:b2f1b3d9-ddc2-4ef9-ab48-c6a7c2262f74 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47381 biolink:treats MONDO:0001126 PMID:41385096 "[{""id"":""uuid:606abe37-db84-43e3-95c4-37e80dc2802f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c971927c-9e46-4cb1-958e-507a964a9d69"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ranitidine is indicated in: Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks. Studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than 8 weeks. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. No placebo-controlled comparative studies have been carried out for periods of longer than 1 year. The treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome and systemic mastocytosis). Short-term treatment of active, benign gastric ulcer. Most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated. Studies available to date have not assessed the safety of ranitidine in uncomplicated, benign gastric ulcer for periods of more than 6 weeks. Maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers. Placebo-controlled studies have been carried out for 1 year. Treatment of GERD. Symptomatic relief commonly occurs within 24 hours after starting therapy with ranitidine 150 mg two times a day. Treatment of endoscopically diagnosed erosive esophagitis. Symptomatic relief of heartburn commonly occurs within 24 hours of therapy initiation with ranitidine 150 mg 4 times daily. Maintenance of healing of erosive esophagitis. Placebo-controlled trials have been carried out for 48 weeks. Concomitant antacids should be given as needed for pain relief to patients with active duodenal ulcer; active, benign gastric ulcer; hypersecretory states; GERD; and erosive esophagitis. uuid:7457a231-d989-4d88-aba6-216c3a768801 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47381 biolink:treats UMLS:C0267055 PMID:41385096 "[{""id"":""uuid:783f32de-d4a6-47ba-afe5-2e68afbaaf93"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1c28a0bf-7d41-4f96-b9c2-100a21d07ec0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ranitidine is indicated in: Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks. Studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than 8 weeks. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. No placebo-controlled comparative studies have been carried out for periods of longer than 1 year. The treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome and systemic mastocytosis). Short-term treatment of active, benign gastric ulcer. Most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated. Studies available to date have not assessed the safety of ranitidine in uncomplicated, benign gastric ulcer for periods of more than 6 weeks. Maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers. Placebo-controlled studies have been carried out for 1 year. Treatment of GERD. Symptomatic relief commonly occurs within 24 hours after starting therapy with ranitidine 150 mg two times a day. Treatment of endoscopically diagnosed erosive esophagitis. Symptomatic relief of heartburn commonly occurs within 24 hours of therapy initiation with ranitidine 150 mg 4 times daily. Maintenance of healing of erosive esophagitis. Placebo-controlled trials have been carried out for 48 weeks. Concomitant antacids should be given as needed for pain relief to patients with active duodenal ulcer; active, benign gastric ulcer; hypersecretory states; GERD; and erosive esophagitis. uuid:aee7cf98-06ca-4f1d-947a-7a8e3ca02722 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47381 biolink:treats MONDO:0007186 PMID:41385096 "[{""id"":""uuid:d1042182-a947-493e-80b5-6cc806df5628"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9cbf809f-a8f9-47c6-b10b-6a9bda0cae33"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ranitidine is indicated in: Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks. Studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than 8 weeks. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. No placebo-controlled comparative studies have been carried out for periods of longer than 1 year. The treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome and systemic mastocytosis). Short-term treatment of active, benign gastric ulcer. Most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated. Studies available to date have not assessed the safety of ranitidine in uncomplicated, benign gastric ulcer for periods of more than 6 weeks. Maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers. Placebo-controlled studies have been carried out for 1 year. Treatment of GERD. Symptomatic relief commonly occurs within 24 hours after starting therapy with ranitidine 150 mg two times a day. Treatment of endoscopically diagnosed erosive esophagitis. Symptomatic relief of heartburn commonly occurs within 24 hours of therapy initiation with ranitidine 150 mg 4 times daily. Maintenance of healing of erosive esophagitis. Placebo-controlled trials have been carried out for 48 weeks. Concomitant antacids should be given as needed for pain relief to patients with active duodenal ulcer; active, benign gastric ulcer; hypersecretory states; GERD; and erosive esophagitis. uuid:31c7fcbe-4865-4367-91bb-b1c9247026ec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:25681 biolink:treats MONDO:0005347 PMID:41385096 "[{""id"":""uuid:0855fb16-f162-4562-8eae-72ba4bfdd49a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:de501055-bc0a-4a8b-8258-a38c20423e78"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Omega-3-acid ethyl esters capsules, USP are indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia (HTG). Usage Considerations : Patients should be placed on an appropriate lipid-lowering diet before receiving omega-3-acid ethyl esters capsules, USP and should continue this diet during treatment with omega-3-acid ethyl esters capsules, USP. Laboratory studies should be done to ascertain that the lipid levels are consistently abnormal before instituting therapy with omega-3-acid ethyl esters. Every attempt should be made to control serum lipids with appropriate diet, exercise, weight loss in obese patients, and control of any medical problems such as diabetes mellitus and hypothyroidism that are contributing to the lipid abnormalities. Medications known to exacerbate hypertriglyceridemia (such as beta blockers, thiazides, estrogens) should be discontinued or changed if possible prior to consideration of triglyceride-lowering drug therapy. Limitations of Use: Sections or subsections omitted from the full prescribing information are not listed. The effect of omega-3-acid ethyl esters capsules, USP on the risk for pancreatitis has not been determined. The effect of omega-3-acid ethyl esters capsules, USP on cardiovascular mortality and morbidity has not been determined. uuid:9d147b26-8a57-484f-a157-62a3ff80d76e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:25681 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:f363978e-fd06-4989-97f8-b02441711c45"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3be5a03e-18c1-432c-b2d2-5f36f20d8773"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Omega-3-acid ethyl esters capsules, USP are indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia (HTG). Usage Considerations : Patients should be placed on an appropriate lipid-lowering diet before receiving omega-3-acid ethyl esters capsules, USP and should continue this diet during treatment with omega-3-acid ethyl esters capsules, USP. Laboratory studies should be done to ascertain that the lipid levels are consistently abnormal before instituting therapy with omega-3-acid ethyl esters. Every attempt should be made to control serum lipids with appropriate diet, exercise, weight loss in obese patients, and control of any medical problems such as diabetes mellitus and hypothyroidism that are contributing to the lipid abnormalities. Medications known to exacerbate hypertriglyceridemia (such as beta blockers, thiazides, estrogens) should be discontinued or changed if possible prior to consideration of triglyceride-lowering drug therapy. Limitations of Use: Sections or subsections omitted from the full prescribing information are not listed. The effect of omega-3-acid ethyl esters capsules, USP on the risk for pancreatitis has not been determined. The effect of omega-3-acid ethyl esters capsules, USP on cardiovascular mortality and morbidity has not been determined. uuid:e444e6c5-dd20-47bd-b128-d982aa71ba38 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:25681 biolink:treats MONDO:0005420 PMID:41385096 "[{""id"":""uuid:717890bb-8594-4da6-971a-5fadca73bf40"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:36e75876-2167-4f82-afc6-1757f22455eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Omega-3-acid ethyl esters capsules, USP are indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia (HTG). Usage Considerations : Patients should be placed on an appropriate lipid-lowering diet before receiving omega-3-acid ethyl esters capsules, USP and should continue this diet during treatment with omega-3-acid ethyl esters capsules, USP. Laboratory studies should be done to ascertain that the lipid levels are consistently abnormal before instituting therapy with omega-3-acid ethyl esters. Every attempt should be made to control serum lipids with appropriate diet, exercise, weight loss in obese patients, and control of any medical problems such as diabetes mellitus and hypothyroidism that are contributing to the lipid abnormalities. Medications known to exacerbate hypertriglyceridemia (such as beta blockers, thiazides, estrogens) should be discontinued or changed if possible prior to consideration of triglyceride-lowering drug therapy. Limitations of Use: Sections or subsections omitted from the full prescribing information are not listed. The effect of omega-3-acid ethyl esters capsules, USP on the risk for pancreatitis has not been determined. The effect of omega-3-acid ethyl esters capsules, USP on cardiovascular mortality and morbidity has not been determined. uuid:9269e243-41f1-4684-9a35-51a8970a10a9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4995 biolink:treats MONDO:0005027 PMID:41385096 "[{""id"":""uuid:b39a2f54-c1cd-41f3-8cd1-f0d5f8738833"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9eea5f02-aed7-449f-b793-fcf536812b58"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Felbamate tablets, USP are not indicated as a first line antiepileptic treatment (see Warnings ). Felbamate tablets, USP are recommended for use only in those patients who respond inadequately to alternative treatments and whose epilepsy is so severe that a substantial risk of aplastic anemia and/or liver failure is deemed acceptable in light of the benefits conferred by its use. If these criteria are met and the patient has been fully advised of the risk, and has provided written acknowledgment, felbamate tablets, USP can be considered for either monotherapy or adjunctive therapy in the treatment of partial seizures, with and without generalization, in adults with epilepsy and as adjunctive therapy in the treatment of partial and generalized seizures associated with Lennox-Gastaut syndrome in children. uuid:b19f0bf5-438a-44ff-99de-5cda972fadb3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4995 biolink:treats HP:0007359 PMID:41385096 "[{""id"":""uuid:e2d9478f-3984-47ce-b117-b142193c2225"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8af814bd-4bbd-4187-b707-423a7c6aedb4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Felbamate tablets, USP are not indicated as a first line antiepileptic treatment (see Warnings ). Felbamate tablets, USP are recommended for use only in those patients who respond inadequately to alternative treatments and whose epilepsy is so severe that a substantial risk of aplastic anemia and/or liver failure is deemed acceptable in light of the benefits conferred by its use. If these criteria are met and the patient has been fully advised of the risk, and has provided written acknowledgment, felbamate tablets, USP can be considered for either monotherapy or adjunctive therapy in the treatment of partial seizures, with and without generalization, in adults with epilepsy and as adjunctive therapy in the treatment of partial and generalized seizures associated with Lennox-Gastaut syndrome in children. uuid:45cb2582-88c8-4177-bca8-0cfdf7ff3a0e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4995 biolink:treats MONDO:0015909 PMID:41385096 "[{""id"":""uuid:da4f3ebc-350b-42cf-9b53-162440c7a158"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c2d21522-4e20-43a5-84e4-ea260e71ce51"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Felbamate tablets, USP are not indicated as a first line antiepileptic treatment (see Warnings ). Felbamate tablets, USP are recommended for use only in those patients who respond inadequately to alternative treatments and whose epilepsy is so severe that a substantial risk of aplastic anemia and/or liver failure is deemed acceptable in light of the benefits conferred by its use. If these criteria are met and the patient has been fully advised of the risk, and has provided written acknowledgment, felbamate tablets, USP can be considered for either monotherapy or adjunctive therapy in the treatment of partial seizures, with and without generalization, in adults with epilepsy and as adjunctive therapy in the treatment of partial and generalized seizures associated with Lennox-Gastaut syndrome in children. uuid:4213e965-82f3-4b30-8cbc-271d3f862d2b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4995 biolink:treats MONDO:0100192 PMID:41385096 "[{""id"":""uuid:2c8f6315-fca7-4771-a68f-2ff2b3e32086"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bc9f887d-7ce8-48a4-a725-d0fcc602fe75"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Felbamate tablets, USP are not indicated as a first line antiepileptic treatment (see Warnings ). Felbamate tablets, USP are recommended for use only in those patients who respond inadequately to alternative treatments and whose epilepsy is so severe that a substantial risk of aplastic anemia and/or liver failure is deemed acceptable in light of the benefits conferred by its use. If these criteria are met and the patient has been fully advised of the risk, and has provided written acknowledgment, felbamate tablets, USP can be considered for either monotherapy or adjunctive therapy in the treatment of partial seizures, with and without generalization, in adults with epilepsy and as adjunctive therapy in the treatment of partial and generalized seizures associated with Lennox-Gastaut syndrome in children. uuid:98c1c230-db2b-4b9b-8c6f-8f76054da483 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:453011 biolink:treats MONDO:0000879 PMID:41385096 "[{""id"":""uuid:4177bb86-ffa6-400e-8649-c357e9a0493c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:89fb8ebb-9898-4541-adab-96a457a494a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ciclopirox Topical Suspension USP, 0.77% (Lotion) is indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris, and tinea corporis due to Trichophyton rubrum , Trichophyton mentagrophytes , Epidermophyton floccosum , and Microsporum canis ; cutaneous candidiasis (moniliasis) due to Candida albicans ; and tinea (pityriasis) versicolor due to Malassezia furfur . uuid:bbb85f54-1f14-4f59-9131-c3e5abe4d0e1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1151145 biolink:treats UMLS:C0341178 PMID:41385096 "[{""id"":""uuid:2fe01a61-dcab-4b9c-a0db-58604c318d32"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:498af4f2-3f0f-4e29-a7f4-1fe063671612"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of diclofenac sodium and misoprostol delayed-release tablets and other treatment options before deciding to use diclofenac sodium and misoprostol delayed-release tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Diclofenac sodium and misoprostol delayed-release tablets are indicated for treatment of the signs and symptoms of osteoarthritis or rheumatoid arthritis in patients at high risk of developing NSAID-induced gastric and duodenal ulcers and their complications. See WARNINGS , Gastrointestinal Effects - Risk of Ulceration, Bleeding, and Perforation for a list of factors that may increase the risk of NSAID-induced gastric and duodenal ulcers and their complications. uuid:d6c490de-4c2f-459f-9da3-4c868f7ef43c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15365 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:c9c0af30-dbb4-48b2-a8ad-d5053259ec95"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:85d21f8b-5ecd-4f2d-b78f-d018c8f74091"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DURLAZA is indicated to: Reduce the risk of death and myocardial infarction (MI) in patients with chronic coronary artery disease, such as patients with a history of MI or unstable angina pectoris or with chronic stable angina Reduce the risk of death and recurrent stroke in patients who have had an ischemic stroke or transient ischemic attack Limitation of Use : Use immediate-release aspirin, not DURLAZA in situations where a rapid onset of action is required (such as acute treatment of myocardial infarction or before percutaneous coronary intervention). uuid:23b47b6c-2e96-4155-92ad-cc012f44e735 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15365 biolink:treats MONDO:0006805 PMID:41385096 "[{""id"":""uuid:365f0bef-dbd0-46da-afd8-da6ec246cd8e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8e2ec800-6ba4-4951-8c52-52e428f8cd09"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DURLAZA is indicated to: Reduce the risk of death and myocardial infarction (MI) in patients with chronic coronary artery disease, such as patients with a history of MI or unstable angina pectoris or with chronic stable angina Reduce the risk of death and recurrent stroke in patients who have had an ischemic stroke or transient ischemic attack Limitation of Use : Use immediate-release aspirin, not DURLAZA in situations where a rapid onset of action is required (such as acute treatment of myocardial infarction or before percutaneous coronary intervention). uuid:24bc6ba5-5128-4064-9a88-ce07c13bce5a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15365 biolink:treats HP:0002140 PMID:41385096 "[{""id"":""uuid:d56f8ace-0fa4-4956-93d4-63d53c8ba5f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7bc184f8-490f-4bd3-9c41-18b62239eb00"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DURLAZA is indicated to: Reduce the risk of death and myocardial infarction (MI) in patients with chronic coronary artery disease, such as patients with a history of MI or unstable angina pectoris or with chronic stable angina Reduce the risk of death and recurrent stroke in patients who have had an ischemic stroke or transient ischemic attack Limitation of Use : Use immediate-release aspirin, not DURLAZA in situations where a rapid onset of action is required (such as acute treatment of myocardial infarction or before percutaneous coronary intervention). uuid:d4915272-b03c-4bfa-9667-62fd43227e98 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15365 biolink:treats MONDO:0005264 PMID:41385096 "[{""id"":""uuid:2a75443d-255e-4cc8-8dee-97efea8c4230"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e9d4725f-1870-4e12-af3b-3445c0ae29fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DURLAZA is indicated to: Reduce the risk of death and myocardial infarction (MI) in patients with chronic coronary artery disease, such as patients with a history of MI or unstable angina pectoris or with chronic stable angina Reduce the risk of death and recurrent stroke in patients who have had an ischemic stroke or transient ischemic attack Limitation of Use : Use immediate-release aspirin, not DURLAZA in situations where a rapid onset of action is required (such as acute treatment of myocardial infarction or before percutaneous coronary intervention). uuid:efb427c1-aefe-420e-8222-fef33dd649d5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60648 biolink:treats MONDO:0019359 PMID:41385096 "[{""id"":""uuid:6a8d1cee-81dc-4f2e-aad6-97f26e5be0c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d05b0093-209f-4382-848c-4b85a36187db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent's infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:d9109bbe-a2cc-437e-bb50-cdc81c77edff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60648 biolink:treats MONDO:0001246 PMID:41385096 "[{""id"":""uuid:3c60f827-2866-456b-bdeb-976155bf74fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:082c8839-2035-4f2c-8adf-1c8a3401e02f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent's infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:96ccea4d-5d17-4182-9dc2-f56c6e204b30 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60648 biolink:treats MONDO:0019186 PMID:41385096 "[{""id"":""uuid:a3288591-1cf2-4f00-aaa8-c970df973e4b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f2538d27-681d-45b0-b13d-6e08f9b1b0bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent's infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:22f2d8ae-9e27-4725-866f-b332b1c0ca3b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60648 biolink:treats MONDO:0019360 PMID:41385096 "[{""id"":""uuid:277533d3-1d76-4aac-8ad0-8503a4cc2783"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:91b22aa1-970d-46ed-8d8a-945dc40327b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent's infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:5b020d15-cd91-4eef-b54e-799a45e8275c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60648 biolink:treats MONDO:0025294 PMID:41385096 "[{""id"":""uuid:f388dad2-21fb-48b5-a8d5-acd72c392ac8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:db275430-87ab-4c17-a1f7-fe3089d43639"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent's infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:6ee6f9f8-09a2-4443-8b3b-27c7a8ede418 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60648 biolink:treats MONDO:0024355 PMID:41385096 "[{""id"":""uuid:cd7193cc-da05-4030-bd04-cd982e3c641b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9281e3b1-c71d-44ef-9b2a-fbfc02fce0cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent's infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:12cbd5d4-1ed3-4b40-a7b8-a7cdfa5fd593 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60648 biolink:treats MONDO:0005834 PMID:41385096 "[{""id"":""uuid:4bbcb9cc-f074-4fe1-b260-f32dba02791e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cc192ccd-988c-4742-b9ce-6cf4d440638e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent's infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:56aa9ece-8172-4ca1-9696-74622ffb6471 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60648 biolink:treats MONDO:0005888 PMID:41385096 "[{""id"":""uuid:f1baf1da-ad33-4597-9c0a-0f95827f1d6d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0fec6e9f-4736-4fdb-be2e-426cc9a8b74e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent's infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:9e8bd2bd-da60-4149-a411-bd47b29edc25 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60648 biolink:treats MONDO:0001249 PMID:41385096 "[{""id"":""uuid:5575c979-387e-45b4-bc49-259423d2f4c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e62f81ed-4c2a-4cda-a2f5-a54b6f83a4ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent's infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:9135df04-3f58-48b7-9677-8150f30472fa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60648 biolink:treats MONDO:0005808 PMID:41385096 "[{""id"":""uuid:e63d8f0d-4ba6-4a96-b18e-7162d0eadaf8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5f9a6af8-53fa-433d-8299-ba9bbb792096"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent's infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:f5a75cdd-626a-4397-add6-d9fab0631ceb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60648 biolink:treats MONDO:0021697 PMID:41385096 "[{""id"":""uuid:3fdbee37-84ae-481f-9233-7525251557ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:20df1904-e7e5-4e8f-ab73-745dba5599f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent's infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:d22370c9-8500-4829-920b-2aa77ab49f59 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60648 biolink:treats MONDO:0005297 PMID:41385096 "[{""id"":""uuid:f08c3b25-0959-47fd-9feb-ecb9d355dde0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4d66224a-0494-4746-ac55-538044d33893"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent's infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:a3ef9eca-2a90-4fe1-9218-f6bf6d080954 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60648 biolink:treats MONDO:0019633 PMID:41385096 "[{""id"":""uuid:806490fb-5df4-4656-bb14-ba85a09c7a83"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e8693707-86c8-4b0e-82ff-dab3f48021e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent's infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:a235f49a-596d-473a-ae4b-797f1e574edd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60648 biolink:treats MONDO:0001797 PMID:41385096 "[{""id"":""uuid:c218a0db-10cc-4b77-906a-ba1939581764"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6946ef8f-719b-435f-9aa9-ee12e9b9fee6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent's infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:52edb274-efcc-4947-a0fa-a3a5f0e00245 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60648 biolink:treats MONDO:0019095 PMID:41385096 "[{""id"":""uuid:5f4a79a9-ac30-432d-8f16-9eaddea27a58"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1088ed79-5636-4afd-934c-fa7505753184"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent's infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:480f2534-ee73-4826-bca9-5bd747a75920 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60648 biolink:treats MONDO:0018077 PMID:41385096 "[{""id"":""uuid:67be0d45-a737-4f7c-9c5e-1a4268750e25"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0aae4dff-5e82-4752-bc83-27822a4b242a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent's infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:02ee7f80-ff76-4eac-ae66-401a5574267b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60648 biolink:treats MONDO:0015766 PMID:41385096 "[{""id"":""uuid:46eee08d-bfc9-4bb6-9408-8e19ac4f4ee5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b83731ba-5bdf-44e7-bfa2-16a8fc628be1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent's infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:938c2849-e3a2-4e0d-8364-8d9509d5ebd2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60648 biolink:treats MONDO:0040728 PMID:41385096 "[{""id"":""uuid:ad785ec2-c575-46ab-9793-1541caa74f79"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6a322c71-8739-46c0-be7b-f884a09c4ec9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent's infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:3a34fda5-31e9-4cbc-bfc2-71e121c72ca2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60648 biolink:treats MONDO:0005683 PMID:41385096 "[{""id"":""uuid:aa34f00e-7f4c-42d4-93ec-fb7d1ca06094"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a227f72f-5fda-4b71-9e17-a3d1a0f573a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent's infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:38c06eac-cdcd-4b74-953d-8c1a5d28bd67 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60648 biolink:treats MONDO:0005664 PMID:41385096 "[{""id"":""uuid:1aca66ec-5201-45bf-a63a-7e372f878de6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5b718bd9-244e-40dc-9cb6-ecf70a4faef2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent's infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:2c2c634f-6e3b-420e-ba1b-e922c9e47dbe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60648 biolink:treats MONDO:0005777 PMID:41385096 "[{""id"":""uuid:0b395f86-1447-4bcc-b90a-1285a42df7bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:43f118b8-0dcf-4baa-a9d1-b7ac1f2ece5b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent's infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:9bcdcc17-b425-41a3-bfe6-1f3a2ac9b987 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60648 biolink:treats MONDO:0020920 PMID:41385096 "[{""id"":""uuid:1fe078a6-4758-4cf8-be9c-fe107206b412"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:145ab465-20e4-4e96-bf31-63b3e4d4ddcc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent's infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:539a6540-1703-4566-a907-d006182878c1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60648 biolink:treats MONDO:0019345 PMID:41385096 "[{""id"":""uuid:cef0f0aa-9aab-47f8-be93-dca7df3a3afd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b08d6c03-ad6c-4c7f-b619-e5e97a0ef097"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent's infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:21ceece2-be17-4e42-aff4-c6c678649f99 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60648 biolink:treats MONDO:0006635 PMID:41385096 "[{""id"":""uuid:9b1be433-df37-4e51-8fa8-9b052e7f01e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:38be875c-008d-4d66-8f1c-9642f3326f34"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent's infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:a212a986-7c13-4913-b971-337861bf531e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60648 biolink:treats HP:0005376 PMID:41385096 "[{""id"":""uuid:db2824ba-5447-4520-b143-6c471814eced"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e511b0b7-9b7a-47c8-8cc6-b777275d1e16"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent's infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:7e22427d-6b15-4915-9d40-c1a86fb3867e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60648 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:ee602486-b860-46b7-9981-17a586ee695b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b13ddd2b-4aae-416a-9847-004bc2deee01"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent's infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:b20462a6-6b80-4586-9c79-bfae4dd7fc5e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60648 biolink:treats MONDO:0030603 PMID:41385096 "[{""id"":""uuid:6659a727-58ec-4f00-8c1b-a4210b539d48"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0e25992f-045f-4974-81e6-0a427c0eddaf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent's infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:6181753d-78b9-4eef-89aa-f53df0902c62 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60648 biolink:treats UMLS:C0041912 PMID:41385096 "[{""id"":""uuid:3036bb64-49d7-4b16-8d7a-821be2aefb23"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4b0b9560-fd75-4286-b2cd-8c3ee44b1caa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent's infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:c060e3ba-8309-4448-ae42-39d6d4fc7b8a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60648 biolink:treats MONDO:0005119 PMID:41385096 "[{""id"":""uuid:bf5258c2-1d82-4f4a-8fb9-f3c93f75d8c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6994b29a-1a34-4f21-83e2-a46907b3b559"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent's infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:b461586a-1945-4589-b00b-bbb7cf9e743b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60648 biolink:treats MONDO:0004277 PMID:41385096 "[{""id"":""uuid:62aa193e-b1fd-41b7-9b73-e85c85622451"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b137abbe-0ef4-4eb1-9a52-a9dffc2c26a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent's infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:6b8be7ab-cc28-4a53-b5b0-6f8a0f150371 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60648 biolink:treats MONDO:0005976 PMID:41385096 "[{""id"":""uuid:8b78248d-9945-4f1e-8c98-c8107edae8b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0f0ca66d-b660-4f6e-9078-f08805202178"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent's infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:a72f7982-6dd6-49fa-ac78-a9499baf1fd8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60648 biolink:treats MONDO:0006019 PMID:41385096 "[{""id"":""uuid:b8e9f3f6-32b8-4ee7-b5e4-36141cf67bd7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:81b993bf-d0dc-415f-9305-d282b8086ea9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent's infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:5b6faa12-9569-4c71-b50c-f850cb12f084 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60648 biolink:treats MONDO:0005828 PMID:41385096 "[{""id"":""uuid:e1ed2b8b-e625-44e6-8c83-1929bb06f23c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:77af66ed-a1de-407b-b50a-59c0a0b43748"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent's infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:e7d28856-8576-41ac-88fe-2d347877cb6b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60648 biolink:treats MONDO:0005631 PMID:41385096 "[{""id"":""uuid:905dd2b5-9c2d-4d36-a942-e55fa2962e8c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a6cbb168-6957-4803-916d-d2d40e233157"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent's infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:95b8fa4c-341a-4aab-a126-4c24300cadc4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60648 biolink:treats MONDO:0024388 PMID:41385096 "[{""id"":""uuid:3e909118-21d4-48c3-9fac-fee40403df1f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:34a96f33-a891-45f0-846e-512374198765"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent's infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:a8f09e9f-1470-4611-a258-9bfd7f4a585b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60648 biolink:treats MONDO:0005644 PMID:41385096 "[{""id"":""uuid:53285f3d-4d40-4d57-94e9-abd07aebb273"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:80f37a5d-fef9-4de0-b3f8-72572826d122"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent's infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:d71c5883-502e-4516-bfca-70b644373e27 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60648 biolink:treats MONDO:0011438 PMID:41385096 "[{""id"":""uuid:2e3aa16c-1ad8-4a39-8079-5f22c36d8b18"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4c1dbb16-d2f2-495a-9d80-10f6319b9d36"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent's infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:cdba62e5-e295-4023-86b5-60fb33628404 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50275 biolink:treats UMLS:C0267055 PMID:41385096 "[{""id"":""uuid:d3f0238e-aa5c-47af-bc9e-b2f7ed886831"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:36de4739-7c32-495b-a26a-479b59a991f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Treatment of Gastroesophageal Reflux Disease (GERD) Healing of Erosive Esophagitis Esomeprazole magnesium delayed-release capsules are indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed erosive esophagitis. For those patients who have not healed after 4 to 8 weeks of treatment, an additional 4 to 8 week course of esomeprazole magnesium delayed-release capsules may be considered. In infants 1 month to less than 1 year, esomeprazole magnesium delayed-release capsules are indicated for short-term treatment (up to 6 weeks) of erosive esophagitis due to acid-mediated GERD. Maintenance of Healing of Erosive Esophagitis Esomeprazole magnesium delayed-release capsules are indicated to maintain symptom resolution and healing of erosive esophagitis. Controlled studies do not extend beyond 6 months. Symptomatic Gastroesophageal Reflux Disease Esomeprazole magnesium delayed-release capsules are indicated for short-term treatment (4 to 8 weeks) of heartburn and other symptoms associated with GERD in adults and children 1 year or older. 1.2 Risk Reduction of NSAID-Associated Gastric Ulcer Esomeprazole magnesium delayed-release capsules are indicated for the reduction in the occurrence of gastric ulcers associated with continuous NSAID therapy in patients at risk for developing gastric ulcers. Patients are considered to be at risk due to their age (≥ 60) and/or documented history of gastric ulcers. Controlled studies do not extend beyond 6 months. 1.4 Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome Esomeprazole magnesium delayed-release capsule USP is indicated for the long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison Syndrome. uuid:cef5ec04-ca64-4013-8067-822228f4cde0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50275 biolink:treats UMLS:C0341178 PMID:41385096 "[{""id"":""uuid:92f4cdff-cdf8-4de0-8e3e-21415e2a168a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3d928b4c-86e9-47ba-8547-65a5ab58638f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Treatment of Gastroesophageal Reflux Disease (GERD) Healing of Erosive Esophagitis Esomeprazole magnesium delayed-release capsules are indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed erosive esophagitis. For those patients who have not healed after 4 to 8 weeks of treatment, an additional 4 to 8 week course of esomeprazole magnesium delayed-release capsules may be considered. In infants 1 month to less than 1 year, esomeprazole magnesium delayed-release capsules are indicated for short-term treatment (up to 6 weeks) of erosive esophagitis due to acid-mediated GERD. Maintenance of Healing of Erosive Esophagitis Esomeprazole magnesium delayed-release capsules are indicated to maintain symptom resolution and healing of erosive esophagitis. Controlled studies do not extend beyond 6 months. Symptomatic Gastroesophageal Reflux Disease Esomeprazole magnesium delayed-release capsules are indicated for short-term treatment (4 to 8 weeks) of heartburn and other symptoms associated with GERD in adults and children 1 year or older. 1.2 Risk Reduction of NSAID-Associated Gastric Ulcer Esomeprazole magnesium delayed-release capsules are indicated for the reduction in the occurrence of gastric ulcers associated with continuous NSAID therapy in patients at risk for developing gastric ulcers. Patients are considered to be at risk due to their age (≥ 60) and/or documented history of gastric ulcers. Controlled studies do not extend beyond 6 months. 1.4 Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome Esomeprazole magnesium delayed-release capsule USP is indicated for the long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison Syndrome. uuid:729d2efb-a883-4510-88f2-8817d16593ee biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41423 biolink:treats MONDO:0005178 PMID:41385096 "[{""id"":""uuid:67b58066-6df7-45b2-8966-fa78c84091a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:eee99cb6-6241-4e4e-9717-1775a07d5230"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:11555ad0-111a-48c8-87a4-6168b1f26ea1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of celecoxib and other treatment options before deciding to use celecoxib. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals [see Warnings and Precautions (5) ] 1.1 Osteoarthritis (OA) Celecoxib is indicated for relief of the signs and symptoms of OA [see Clinical Studies (14.1) ] 1.2 Rheumatoid Arthritis (RA) Celecoxib is indicated for relief of the signs and symptoms of RA [see Clinical Studies (14.2) ] 1.3 Juvenile Rheumatoid Arthritis (JRA) Celecoxib is indicated for relief of the signs and symptoms of JRA in patients 2 years and older [see Clinical Studies (14.3) ] 1.4 Ankylosing Spondylitis (AS) Celecoxib is indicated for the relief of signs and symptoms of AS [see Clinical Studies (14.4) ] 1.5 Acute Pain (AP) Celecoxib is indicated for the management of AP in adults [see Clinical Studies (14.5) ] 1.6 Primary Dysmenorrhea (PD) Celecoxib is indicated for the treatment of PD [see Clinical Studies (14.5) ]|[PMDA] Drugs with a new active ingredient indicated for relief of inflammation and pain associated with rheumatoid arthritis and osteoarthritis. uuid:802a4ac6-d4cc-43ae-a6f7-78e5e4f3fc1a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41423 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:20986679-a769-416c-bf94-8e654be14371"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:789f7623-14ec-4b37-8bd4-7c557995061f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e1c334f8-f954-49e3-8578-10fc65ecad78"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of celecoxib and other treatment options before deciding to use celecoxib. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals [see Warnings and Precautions (5) ] 1.1 Osteoarthritis (OA) Celecoxib is indicated for relief of the signs and symptoms of OA [see Clinical Studies (14.1) ] 1.2 Rheumatoid Arthritis (RA) Celecoxib is indicated for relief of the signs and symptoms of RA [see Clinical Studies (14.2) ] 1.3 Juvenile Rheumatoid Arthritis (JRA) Celecoxib is indicated for relief of the signs and symptoms of JRA in patients 2 years and older [see Clinical Studies (14.3) ] 1.4 Ankylosing Spondylitis (AS) Celecoxib is indicated for the relief of signs and symptoms of AS [see Clinical Studies (14.4) ] 1.5 Acute Pain (AP) Celecoxib is indicated for the management of AP in adults [see Clinical Studies (14.5) ] 1.6 Primary Dysmenorrhea (PD) Celecoxib is indicated for the treatment of PD [see Clinical Studies (14.5) ]|[PMDA] Drugs with a new active ingredient indicated for relief of inflammation and pain associated with rheumatoid arthritis and osteoarthritis. uuid:c08facf6-95d0-41d4-8a7c-121c26d4673d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41423 biolink:treats MONDO:0011429 PMID:41385096 "[{""id"":""uuid:41f03ff8-b649-4823-9f7e-a637e05b72b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f5a8e13d-76f4-4cb8-a37d-19c04bcdfcad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of celecoxib and other treatment options before deciding to use celecoxib. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals [see Warnings and Precautions (5) ] 1.1 Osteoarthritis (OA) Celecoxib is indicated for relief of the signs and symptoms of OA [see Clinical Studies (14.1) ] 1.2 Rheumatoid Arthritis (RA) Celecoxib is indicated for relief of the signs and symptoms of RA [see Clinical Studies (14.2) ] 1.3 Juvenile Rheumatoid Arthritis (JRA) Celecoxib is indicated for relief of the signs and symptoms of JRA in patients 2 years and older [see Clinical Studies (14.3) ] 1.4 Ankylosing Spondylitis (AS) Celecoxib is indicated for the relief of signs and symptoms of AS [see Clinical Studies (14.4) ] 1.5 Acute Pain (AP) Celecoxib is indicated for the management of AP in adults [see Clinical Studies (14.5) ] 1.6 Primary Dysmenorrhea (PD) Celecoxib is indicated for the treatment of PD [see Clinical Studies (14.5) ] uuid:daff2bd1-e220-45b1-87f5-81e6716e14bc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41423 biolink:treats MONDO:0005306 PMID:41385096 "[{""id"":""uuid:2ff83876-30ed-4f6a-ba50-d279ea3ac8a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3f46a365-3f75-48f1-85c4-53d8b378a52f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of celecoxib and other treatment options before deciding to use celecoxib. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals [see Warnings and Precautions (5) ] 1.1 Osteoarthritis (OA) Celecoxib is indicated for relief of the signs and symptoms of OA [see Clinical Studies (14.1) ] 1.2 Rheumatoid Arthritis (RA) Celecoxib is indicated for relief of the signs and symptoms of RA [see Clinical Studies (14.2) ] 1.3 Juvenile Rheumatoid Arthritis (JRA) Celecoxib is indicated for relief of the signs and symptoms of JRA in patients 2 years and older [see Clinical Studies (14.3) ] 1.4 Ankylosing Spondylitis (AS) Celecoxib is indicated for the relief of signs and symptoms of AS [see Clinical Studies (14.4) ] 1.5 Acute Pain (AP) Celecoxib is indicated for the management of AP in adults [see Clinical Studies (14.5) ] 1.6 Primary Dysmenorrhea (PD) Celecoxib is indicated for the treatment of PD [see Clinical Studies (14.5) ] uuid:3604f2b5-63fe-4323-b868-4afea5606436 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41423 biolink:treats NCIT:C27003 PMID:41385096 "[{""id"":""uuid:0de03960-7ff3-4619-97e6-ed66794b5adf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:24149aac-5607-4fc9-ad90-5af0330479d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of celecoxib and other treatment options before deciding to use celecoxib. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals [see Warnings and Precautions (5) ] 1.1 Osteoarthritis (OA) Celecoxib is indicated for relief of the signs and symptoms of OA [see Clinical Studies (14.1) ] 1.2 Rheumatoid Arthritis (RA) Celecoxib is indicated for relief of the signs and symptoms of RA [see Clinical Studies (14.2) ] 1.3 Juvenile Rheumatoid Arthritis (JRA) Celecoxib is indicated for relief of the signs and symptoms of JRA in patients 2 years and older [see Clinical Studies (14.3) ] 1.4 Ankylosing Spondylitis (AS) Celecoxib is indicated for the relief of signs and symptoms of AS [see Clinical Studies (14.4) ] 1.5 Acute Pain (AP) Celecoxib is indicated for the management of AP in adults [see Clinical Studies (14.5) ] 1.6 Primary Dysmenorrhea (PD) Celecoxib is indicated for the treatment of PD [see Clinical Studies (14.5) ] uuid:8851e9d6-658a-481f-8faa-4017f4bf2989 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41423 biolink:treats MONDO:1060206 PMID:41385096 "[{""id"":""uuid:e72f320a-82d6-4462-b608-91614e22f6be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:896393e7-f596-476a-b07b-5a1761f0fb70"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of celecoxib and other treatment options before deciding to use celecoxib. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals [see Warnings and Precautions (5) ] 1.1 Osteoarthritis (OA) Celecoxib is indicated for relief of the signs and symptoms of OA [see Clinical Studies (14.1) ] 1.2 Rheumatoid Arthritis (RA) Celecoxib is indicated for relief of the signs and symptoms of RA [see Clinical Studies (14.2) ] 1.3 Juvenile Rheumatoid Arthritis (JRA) Celecoxib is indicated for relief of the signs and symptoms of JRA in patients 2 years and older [see Clinical Studies (14.3) ] 1.4 Ankylosing Spondylitis (AS) Celecoxib is indicated for the relief of signs and symptoms of AS [see Clinical Studies (14.4) ] 1.5 Acute Pain (AP) Celecoxib is indicated for the management of AP in adults [see Clinical Studies (14.5) ] 1.6 Primary Dysmenorrhea (PD) Celecoxib is indicated for the treatment of PD [see Clinical Studies (14.5) ] UMLS:C0149875 uuid:5f535109-82ce-4b48-8f88-7a1f51b1e496 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0004646 PMID:41385096 "[{""id"":""uuid:58d2a5fe-e2ad-466e-8874-a15673317946"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c7760b9e-b319-401b-91fd-f1eeb84864a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Stage I - IV pressure ulcers Venous stasis ulcers Ulcerations caused by mixed vascular etiologies Diabetic skin ulcers First and second degree burns Post-surgical incisions, cuts and abrasions. uuid:9f4bf374-eae6-40aa-af41-35638e8447d4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats UMLS:C0042344 PMID:41385096 "[{""id"":""uuid:59be5c61-b924-43d3-891c-33165b1579f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3bec6000-7837-432b-8a68-4d6109d51e42"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Stage I - IV pressure ulcers Venous stasis ulcers Ulcerations caused by mixed vascular etiologies Diabetic skin ulcers First and second degree burns Post-surgical incisions, cuts and abrasions. uuid:63126a48-08cc-4fbd-93d1-b8bfb6caff76 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0004605 PMID:41385096 "[{""id"":""uuid:bf2d0871-2895-43ed-a1e5-67015874ed66"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:273190bd-8875-4bac-b297-a6af2e2384b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Stage I - IV pressure ulcers Venous stasis ulcers Ulcerations caused by mixed vascular etiologies Diabetic skin ulcers First and second degree burns Post-surgical incisions, cuts and abrasions. uuid:215b9a43-5d78-4c2d-af47-631bbe659070 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:92609 biolink:treats MONDO:0005147 PMID:41385096 "[{""id"":""uuid:b8b1c505-9847-453d-af31-405598688f75"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9af72ea0-7ff5-412a-8b85-ac9e5c6e2cd6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Glimepiride tablets USP are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus [see Clinical Studies (14.1) ]. 1.1 Important Limitations of Use Glimepiride tablets USP should not be used for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis, as it would not be effective in these settings. uuid:e15f877b-55dc-4e87-a24b-ee5a5bd12ccb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:92609 biolink:treats MONDO:0012819 PMID:41385096 "[{""id"":""uuid:693db770-5afe-47cc-a5eb-27fab41ac154"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:213fe97b-a36b-4c25-81e9-fc4457e21f35"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Glimepiride tablets USP are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus [see Clinical Studies (14.1) ]. 1.1 Important Limitations of Use Glimepiride tablets USP should not be used for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis, as it would not be effective in these settings. uuid:fa580dfb-6369-4752-bf69-badf2a8da285 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5001 biolink:treats MONDO:0005010 PMID:41385096 "[{""id"":""uuid:b2e6ed5b-02e9-4440-89e1-b92c09db5fc6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bc4c4c4c-7ae4-4e82-a433-d6b1dd7c5aef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Treatment of Hypercholesterolemia Fenofibrate tablets, USP are indicated as adjunctive therapy to diet to reduce elevated LDL-C, Total-C, Triglycerides and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb). Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and non-pharmacological interventions alone has been inadequate (See National Cholesterol Education Program [NCEP] Treatment Guidelines, below). Treatment of Hypertriglyceridemia Fenofibrate tablets, USP are also indicated as adjunctive therapy to diet for treatment of adult patients with hypertriglyceridemia (Fredrickson Types IV and V hyperlipidemia). Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually reduce fasting triglycerides and eliminate chylomicronemia thereby obviating the need for pharmacologic intervention. Markedly elevated levels of serum triglycerides (e.g. > 2,000 mg/dL) may increase the risk of developing pancreatitis. The effect of fenofibrate tablet, USP therapy on reducing this risk has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of very low density lipoprotein (VLDL). Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV and V hyperlipoproteinemia2. The initial treatment for dyslipidemia is dietary therapy specific for the type of lipoprotein abnormality. Excess body weight and excess alcoholic intake may be important factors in hypertriglyceridemia and should be addressed prior to any drug therapy. Physical exercise can be an important ancillary measure. Diseases contributory to hyperlipidemia, such as hypothyroidism or diabetes mellitus should be looked for and adequately treated. Estrogen therapy, thiazide diuretics and beta-blockers, are sometimes associated with massive rises in plasma triglycerides, especially in subjects with familial hypertriglyceridemia. In such cases, discontinuation of the specific etiologic agent may obviate the need for specific drug therapy of hypertriglyceridemia. The use of drugs should be considered only when reasonable attempts have been made to obtain satisfactory results with non-drug methods. If the decision is made to use drugs, the patient should be instructed that this does not reduce the importance of adhering to diet. (See WARNINGS and PRECAUTIONS). Fredrickson Classification of Hyperlipoproteinemias C = cholesterol TG = triglycerides LDL = low density lipoprotein VLDL = very low density lipoprotein IDL = intermediate density lipoprotein Lipid Elevation Type Lipoprotein Elevated Major Minor I (rare) chylomicrons TG ↑↔C IIa LDL C - IIb LDL, VLDL C TG III (rare) IDL C, TG - IV VLDL TG ↑↔C V (rare) chylomicrons, VLDL TG ↑↔ NCEP Treatment Guidelines: LDL-C Goals and Cutpoints for Therapeutic Lifestyle Changes and Drug Therapy in Different Risk Categories †CHD = coronary heart disease ††Some authorities recommend use of LDL-lowering drugs in this category if an LDL-C level of < 100 mg/dL cannot be achieved by therapeutic lifestyle changes. Others prefer use of drugs that primarily modify triglycerides and HDL-C, e.g., nicotinic acid or fibrate. Clinical judgment also may call for deferring drug therapy in this subcategory. †††Almost all people with 0 to 1 risk factor have 10-year risk < 10%; thus, 10-year risk assessment in people with 0 to 1 risk factor is not necessary. Risk Category LDL Goal (mg/dL) LDL Level at Which to Initiate Therapeutic Lifestyle Changes (mg/dL) LDL Level at Which to Consider Drug Therapy (mg/dL) CHD† or CHD risk equivalents (10-years risk > 20%) < 100 ≥ 100 ≥ 130 (100 to 129: drug optional)†† 2+ Risk Factors (10-year risk ≤ 20%) < 130 ≥ 130 10-year risk 10% to 20%: ≥ 130 10-year risk < 10%: ≥ 160 0 to 1 Risk Factor††† < 160 ≥ 160 ≥ 190 (160 to 189: LDL- lowering drug optional) After the LDL-C goal has been achieved, if the TG is still ≥ 200 mg/dL, non HDL-C (total-C minus HDL-C) becomes a secondary target of therapy. Non-HDL-C goals are set 30 mg/dL higher than LDL-C goals for each risk category. uuid:3e5102d5-8f03-46f2-a166-99dbd4a9fefa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49468 biolink:treats UMLS:C1141927 PMID:41385096 "[{""id"":""uuid:6569fde7-043f-47e2-b9d0-eedb802f7929"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a311777b-f496-4287-b856-7f0493003f5a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Silver sulfadiazine cream, USP 1% is a topical antimicrobial drug indicated as an adjunct for the prevention and treatment of wound sepsis in patients with second and third degree burns. uuid:6fb3f28d-3552-4ee4-9fc2-ee0945dfd7ea biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49468 biolink:treats UMLS:C0332687 PMID:41385096 "[{""id"":""uuid:46ad5619-a723-4300-8073-25a2de36e62f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:90cdcd5a-7b29-4ab0-b4be-ab812ddc7f61"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Silver sulfadiazine cream, USP 1% is a topical antimicrobial drug indicated as an adjunct for the prevention and treatment of wound sepsis in patients with second and third degree burns. uuid:49cc8e7f-8237-471a-b5d1-87e1976b0558 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49468 biolink:treats UMLS:C0433445 PMID:41385096 "[{""id"":""uuid:bd63a31e-31a6-4211-be95-709a25a4ff2f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6dec2184-df07-434a-b11a-fe9cdfd9d7c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Silver sulfadiazine cream, USP 1% is a topical antimicrobial drug indicated as an adjunct for the prevention and treatment of wound sepsis in patients with second and third degree burns. uuid:b40b54b6-c4b6-49ce-89b7-9a1b3609a349 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31498 biolink:treats MONDO:0005093 PMID:41385096 "[{""id"":""uuid:31f6bd4e-665e-426b-b98c-db07cf78f6b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1ead9632-2660-417e-993a-06afbeec9f8a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Triamcinolone acetonide cream is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. uuid:8751fedf-5c85-44af-9a09-ec02817cd0cd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6375 biolink:treats MONDO:0005412 PMID:41385096 "[{""id"":""uuid:0faa1e6e-d734-4eb4-b34d-eb42c151ef95"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b96ca066-8f46-4711-b77d-7f84bff50c2c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:58eb668d-8dde-4feb-9f85-165575a9f4ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Short-Term Treatment of Active Duodenal Ulcer Lansoprazole is indicated for short-term treatment (for 4 weeks) for healing and symptom relief of active duodenal ulcer [see CLINICAL STUDIES (14)]. 1.2 H. pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence Triple Therapy: Lansoprazole/amoxicillin/clarithromycin Lansoprazole in combination with amoxicillin plus clarithromycin as triple therapy is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or one year history of a duodenal ulcer) to eradicate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence [see CLINICAL STUDIES (14)]. Please refer to the full prescribing information for amoxicillin and clarithromycin. Dual Therapy: Lansoprazole/amoxicillin Lansoprazole in combination with amoxicillin as dual therapy is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or one year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected (see the clarithromycin package insert, MICROBIOLOGY section). Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence [see CLINICAL STUDIES (14)]. Please refer to the full prescribing information for amoxicillin. 1.3 Maintenance of Healed Duodenal Ulcers Lansoprazole is indicated to maintain healing of duodenal ulcers. Controlled studies do not extend beyond 12 months [see CLINICAL STUDIES (14)]. 1.4 Short-Term Treatment of Active Benign Gastric Ulcer Lansoprazole is indicated for short-term treatment (up to 8 weeks) for healing and symptom relief of active benign gastric ulcer [see CLINICAL STUDIES (14)]. 1.5 Healing of NSAID-Associated Gastric Ulcer Lansoprazole is indicated for the treatment of NSAID-associated gastric ulcer in patients who continue NSAID use. Controlled studies did not extend beyond 8 weeks [see CLINICAL STUDIES (14)]. 1.6 Risk Reduction of NSAID-Associated Gastric Ulcer Lansoprazole is indicated for reducing the risk of NSAID-associated gastric ulcers in patients with a history of a documented gastric ulcer who require the use of an NSAID. Controlled studies did not extend beyond 12 weeks [see CLINICAL STUDIES (14)]. 1.7 Gastroesophageal Reflux Disease (GERD) Short-Term Treatment of Symptomatic GERD Lansoprazole is indicated for the treatment of heartburn and other symptoms associated with GERD for up to 8 weeks [see CLINICAL STUDIES (14)]. Short-Term Treatment of Erosive Esophagitis Lansoprazole is indicated for short-term treatment (up to 8 weeks) for healing and symptom relief of all grades of erosive esophagitis. For patients who do not heal with Lansoprazole for 8 weeks (5 to 10%), it may be helpful to give an additional 8 weeks of treatment. If there is a recurrence of erosive esophagitis an additional 8 week course of Lansoprazole may be considered [see CLINICAL STUDIES (14)]. 1.8 Maintenance of Healing of Erosive Esophagitis (EE) Lansoprazole is indicated to maintain healing of erosive esophagitis. Controlled studies did not extend beyond 12 months [see CLINICAL STUDIES (14)]. 1.9 Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome(ZES) Lansoprazole is indicated for the long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome [see CLINICAL STUDIES (14)].|[PMDA] Drug with a new route of administration indicated for patients with gastric ulcer, duodenal ulcer, acute stress ulcer and acute gastric mucosal lesion with bleeding who are unable to take the oral formulations. uuid:13e61505-c0c8-4b56-8bce-0f488d680164 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6375 biolink:treats HP:0005202 PMID:41385096 "[{""id"":""uuid:c717e298-62f0-4e02-90f0-41b9b8ef2f45"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9d1f8ff9-40d9-4687-92d1-bdb2c18f0858"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c5b9cbdc-801d-4c5c-8375-d637c6169b0f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Short-Term Treatment of Active Duodenal Ulcer Lansoprazole is indicated for short-term treatment (for 4 weeks) for healing and symptom relief of active duodenal ulcer [see CLINICAL STUDIES (14)]. 1.2 H. pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence Triple Therapy: Lansoprazole/amoxicillin/clarithromycin Lansoprazole in combination with amoxicillin plus clarithromycin as triple therapy is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or one year history of a duodenal ulcer) to eradicate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence [see CLINICAL STUDIES (14)]. Please refer to the full prescribing information for amoxicillin and clarithromycin. Dual Therapy: Lansoprazole/amoxicillin Lansoprazole in combination with amoxicillin as dual therapy is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or one year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected (see the clarithromycin package insert, MICROBIOLOGY section). Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence [see CLINICAL STUDIES (14)]. Please refer to the full prescribing information for amoxicillin. 1.3 Maintenance of Healed Duodenal Ulcers Lansoprazole is indicated to maintain healing of duodenal ulcers. Controlled studies do not extend beyond 12 months [see CLINICAL STUDIES (14)]. 1.4 Short-Term Treatment of Active Benign Gastric Ulcer Lansoprazole is indicated for short-term treatment (up to 8 weeks) for healing and symptom relief of active benign gastric ulcer [see CLINICAL STUDIES (14)]. 1.5 Healing of NSAID-Associated Gastric Ulcer Lansoprazole is indicated for the treatment of NSAID-associated gastric ulcer in patients who continue NSAID use. Controlled studies did not extend beyond 8 weeks [see CLINICAL STUDIES (14)]. 1.6 Risk Reduction of NSAID-Associated Gastric Ulcer Lansoprazole is indicated for reducing the risk of NSAID-associated gastric ulcers in patients with a history of a documented gastric ulcer who require the use of an NSAID. Controlled studies did not extend beyond 12 weeks [see CLINICAL STUDIES (14)]. 1.7 Gastroesophageal Reflux Disease (GERD) Short-Term Treatment of Symptomatic GERD Lansoprazole is indicated for the treatment of heartburn and other symptoms associated with GERD for up to 8 weeks [see CLINICAL STUDIES (14)]. Short-Term Treatment of Erosive Esophagitis Lansoprazole is indicated for short-term treatment (up to 8 weeks) for healing and symptom relief of all grades of erosive esophagitis. For patients who do not heal with Lansoprazole for 8 weeks (5 to 10%), it may be helpful to give an additional 8 weeks of treatment. If there is a recurrence of erosive esophagitis an additional 8 week course of Lansoprazole may be considered [see CLINICAL STUDIES (14)]. 1.8 Maintenance of Healing of Erosive Esophagitis (EE) Lansoprazole is indicated to maintain healing of erosive esophagitis. Controlled studies did not extend beyond 12 months [see CLINICAL STUDIES (14)]. 1.9 Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome(ZES) Lansoprazole is indicated for the long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome [see CLINICAL STUDIES (14)].|[PMDA] Drugs with a new indication and dosage for use as a secondary eradication therapy for infection with Helicobacter pylori (3-drug combination therapy consisting of one-week dosing of a proton pump inhibitor (PPI), amoxicillin (AMPC), and metronidazole to patients in whom primary eradication therapy with PPI, AMPC, and clarithromycin was unsuccessful). uuid:e105f181-caf7-47a8-8961-e39ec9fc409b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6375 biolink:treats MONDO:0001126 PMID:41385096 "[{""id"":""uuid:23764bf8-cc5e-448a-89b0-3d47f0a1ea40"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4bc08e2f-7585-4fdd-8938-bad3408ca545"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:9e3f7bc7-a3c5-4fd3-a86f-61d2bab9220a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Short-Term Treatment of Active Duodenal Ulcer Lansoprazole is indicated for short-term treatment (for 4 weeks) for healing and symptom relief of active duodenal ulcer [see CLINICAL STUDIES (14)]. 1.2 H. pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence Triple Therapy: Lansoprazole/amoxicillin/clarithromycin Lansoprazole in combination with amoxicillin plus clarithromycin as triple therapy is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or one year history of a duodenal ulcer) to eradicate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence [see CLINICAL STUDIES (14)]. Please refer to the full prescribing information for amoxicillin and clarithromycin. Dual Therapy: Lansoprazole/amoxicillin Lansoprazole in combination with amoxicillin as dual therapy is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or one year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected (see the clarithromycin package insert, MICROBIOLOGY section). Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence [see CLINICAL STUDIES (14)]. Please refer to the full prescribing information for amoxicillin. 1.3 Maintenance of Healed Duodenal Ulcers Lansoprazole is indicated to maintain healing of duodenal ulcers. Controlled studies do not extend beyond 12 months [see CLINICAL STUDIES (14)]. 1.4 Short-Term Treatment of Active Benign Gastric Ulcer Lansoprazole is indicated for short-term treatment (up to 8 weeks) for healing and symptom relief of active benign gastric ulcer [see CLINICAL STUDIES (14)]. 1.5 Healing of NSAID-Associated Gastric Ulcer Lansoprazole is indicated for the treatment of NSAID-associated gastric ulcer in patients who continue NSAID use. Controlled studies did not extend beyond 8 weeks [see CLINICAL STUDIES (14)]. 1.6 Risk Reduction of NSAID-Associated Gastric Ulcer Lansoprazole is indicated for reducing the risk of NSAID-associated gastric ulcers in patients with a history of a documented gastric ulcer who require the use of an NSAID. Controlled studies did not extend beyond 12 weeks [see CLINICAL STUDIES (14)]. 1.7 Gastroesophageal Reflux Disease (GERD) Short-Term Treatment of Symptomatic GERD Lansoprazole is indicated for the treatment of heartburn and other symptoms associated with GERD for up to 8 weeks [see CLINICAL STUDIES (14)]. Short-Term Treatment of Erosive Esophagitis Lansoprazole is indicated for short-term treatment (up to 8 weeks) for healing and symptom relief of all grades of erosive esophagitis. For patients who do not heal with Lansoprazole for 8 weeks (5 to 10%), it may be helpful to give an additional 8 weeks of treatment. If there is a recurrence of erosive esophagitis an additional 8 week course of Lansoprazole may be considered [see CLINICAL STUDIES (14)]. 1.8 Maintenance of Healing of Erosive Esophagitis (EE) Lansoprazole is indicated to maintain healing of erosive esophagitis. Controlled studies did not extend beyond 12 months [see CLINICAL STUDIES (14)]. 1.9 Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome(ZES) Lansoprazole is indicated for the long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome [see CLINICAL STUDIES (14)].|[PMDA] Drug with a new route of administration indicated for patients with gastric ulcer, duodenal ulcer, acute stress ulcer and acute gastric mucosal lesion with bleeding who are unable to take the oral formulations. uuid:ee32a7de-0ecb-44a0-ad24-7520dbbbd52d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6375 biolink:treats MONDO:0007186 PMID:41385096 "[{""id"":""uuid:80d64d5b-b421-46ce-b9ea-a600a41cc327"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:69700c58-9beb-46dc-83ee-1ba51839ebfb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ed7b6778-d8ea-469c-871c-0db9612c09a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Short-Term Treatment of Active Duodenal Ulcer Lansoprazole is indicated for short-term treatment (for 4 weeks) for healing and symptom relief of active duodenal ulcer [see CLINICAL STUDIES (14)]. 1.2 H. pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence Triple Therapy: Lansoprazole/amoxicillin/clarithromycin Lansoprazole in combination with amoxicillin plus clarithromycin as triple therapy is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or one year history of a duodenal ulcer) to eradicate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence [see CLINICAL STUDIES (14)]. Please refer to the full prescribing information for amoxicillin and clarithromycin. Dual Therapy: Lansoprazole/amoxicillin Lansoprazole in combination with amoxicillin as dual therapy is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or one year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected (see the clarithromycin package insert, MICROBIOLOGY section). Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence [see CLINICAL STUDIES (14)]. Please refer to the full prescribing information for amoxicillin. 1.3 Maintenance of Healed Duodenal Ulcers Lansoprazole is indicated to maintain healing of duodenal ulcers. Controlled studies do not extend beyond 12 months [see CLINICAL STUDIES (14)]. 1.4 Short-Term Treatment of Active Benign Gastric Ulcer Lansoprazole is indicated for short-term treatment (up to 8 weeks) for healing and symptom relief of active benign gastric ulcer [see CLINICAL STUDIES (14)]. 1.5 Healing of NSAID-Associated Gastric Ulcer Lansoprazole is indicated for the treatment of NSAID-associated gastric ulcer in patients who continue NSAID use. Controlled studies did not extend beyond 8 weeks [see CLINICAL STUDIES (14)]. 1.6 Risk Reduction of NSAID-Associated Gastric Ulcer Lansoprazole is indicated for reducing the risk of NSAID-associated gastric ulcers in patients with a history of a documented gastric ulcer who require the use of an NSAID. Controlled studies did not extend beyond 12 weeks [see CLINICAL STUDIES (14)]. 1.7 Gastroesophageal Reflux Disease (GERD) Short-Term Treatment of Symptomatic GERD Lansoprazole is indicated for the treatment of heartburn and other symptoms associated with GERD for up to 8 weeks [see CLINICAL STUDIES (14)]. Short-Term Treatment of Erosive Esophagitis Lansoprazole is indicated for short-term treatment (up to 8 weeks) for healing and symptom relief of all grades of erosive esophagitis. For patients who do not heal with Lansoprazole for 8 weeks (5 to 10%), it may be helpful to give an additional 8 weeks of treatment. If there is a recurrence of erosive esophagitis an additional 8 week course of Lansoprazole may be considered [see CLINICAL STUDIES (14)]. 1.8 Maintenance of Healing of Erosive Esophagitis (EE) Lansoprazole is indicated to maintain healing of erosive esophagitis. Controlled studies did not extend beyond 12 months [see CLINICAL STUDIES (14)]. 1.9 Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome(ZES) Lansoprazole is indicated for the long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome [see CLINICAL STUDIES (14)].|[PMDA] Drugs with a new indication and dosage for treatment of non-erosive reflux disease. uuid:ffa985e3-4974-4220-b8a1-b8dbe825f4da biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6375 biolink:treats UMLS:C0267055 PMID:41385096 "[{""id"":""uuid:51cbcc6e-6815-4815-97a7-2c512529e9f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c7eba7ef-38c6-44fe-8858-8bf085cdac4e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Short-Term Treatment of Active Duodenal Ulcer Lansoprazole is indicated for short-term treatment (for 4 weeks) for healing and symptom relief of active duodenal ulcer [see CLINICAL STUDIES (14)]. 1.2 H. pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence Triple Therapy: Lansoprazole/amoxicillin/clarithromycin Lansoprazole in combination with amoxicillin plus clarithromycin as triple therapy is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or one year history of a duodenal ulcer) to eradicate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence [see CLINICAL STUDIES (14)]. Please refer to the full prescribing information for amoxicillin and clarithromycin. Dual Therapy: Lansoprazole/amoxicillin Lansoprazole in combination with amoxicillin as dual therapy is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or one year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected (see the clarithromycin package insert, MICROBIOLOGY section). Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence [see CLINICAL STUDIES (14)]. Please refer to the full prescribing information for amoxicillin. 1.3 Maintenance of Healed Duodenal Ulcers Lansoprazole is indicated to maintain healing of duodenal ulcers. Controlled studies do not extend beyond 12 months [see CLINICAL STUDIES (14)]. 1.4 Short-Term Treatment of Active Benign Gastric Ulcer Lansoprazole is indicated for short-term treatment (up to 8 weeks) for healing and symptom relief of active benign gastric ulcer [see CLINICAL STUDIES (14)]. 1.5 Healing of NSAID-Associated Gastric Ulcer Lansoprazole is indicated for the treatment of NSAID-associated gastric ulcer in patients who continue NSAID use. Controlled studies did not extend beyond 8 weeks [see CLINICAL STUDIES (14)]. 1.6 Risk Reduction of NSAID-Associated Gastric Ulcer Lansoprazole is indicated for reducing the risk of NSAID-associated gastric ulcers in patients with a history of a documented gastric ulcer who require the use of an NSAID. Controlled studies did not extend beyond 12 weeks [see CLINICAL STUDIES (14)]. 1.7 Gastroesophageal Reflux Disease (GERD) Short-Term Treatment of Symptomatic GERD Lansoprazole is indicated for the treatment of heartburn and other symptoms associated with GERD for up to 8 weeks [see CLINICAL STUDIES (14)]. Short-Term Treatment of Erosive Esophagitis Lansoprazole is indicated for short-term treatment (up to 8 weeks) for healing and symptom relief of all grades of erosive esophagitis. For patients who do not heal with Lansoprazole for 8 weeks (5 to 10%), it may be helpful to give an additional 8 weeks of treatment. If there is a recurrence of erosive esophagitis an additional 8 week course of Lansoprazole may be considered [see CLINICAL STUDIES (14)]. 1.8 Maintenance of Healing of Erosive Esophagitis (EE) Lansoprazole is indicated to maintain healing of erosive esophagitis. Controlled studies did not extend beyond 12 months [see CLINICAL STUDIES (14)]. 1.9 Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome(ZES) Lansoprazole is indicated for the long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome [see CLINICAL STUDIES (14)]. uuid:06f95cae-775f-4d63-9579-1608bac538c9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16469 biolink:treats UMLS:C0278488 PMID:41385096 "[{""id"":""uuid:9a29a16b-629b-4721-a861-47bf224b6e22"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9395c440-09b3-46d0-8494-7c9cb41301ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Estradiol Tablets USP are indicated in the: Treatment of moderate to severe vasomotor symptoms associated with the menopause. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. Treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. Treatment of breast cancer (for palliation only) in appropriately selected women and men with metastatic disease. Treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only). Prevention of osteoporosis. When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and for whom non-estrogen medications are not considered to be appropriate. (See CLINICAL PHARMACOLOGY, Clinical Studies.) The mainstays for decreasing the risk of postmenopausal osteoporosis are weight bearing exercise, adequate calcium and vitamin D intake, and when indicated, pharmacologic therapy. Postmenopausal women require an average of 500 mg/day of elemental calcium. Therefore, when not contraindicated, calcium supplementation may be helpful for women with suboptimal dietary intake. Vitamin D supplementation of 400-800 IU/day may also be required to ensure adequate daily intake in postmenopausal women. uuid:79a28d85-1fe9-42e5-a047-e16c117b18c2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:521033 biolink:treats MONDO:0008315 PMID:41385096 "[{""id"":""uuid:f84945dc-7303-44ad-856f-35f742627336"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5e386c3c-d359-42d2-809f-b20873889746"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dutasteride is a 5 alpha-reductase inhibitor indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to: ( 1.1 ) improve symptoms, reduce the risk of acute urinary retention, and reduce the risk of the need for BPH-related surgery. Dutasteride in combination with the alpha adrenergic antagonist, tamsulosin, is indicated for the treatment of symptomatic BPH in men with an enlarged prostate. ( 1.2 ) Limitations of Use: Dutasteride is not approved for the prevention of prostate cancer. ( 1.3 ) uuid:5b02be59-cc5d-440d-8f7a-fd75323a7a1f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31498 biolink:treats MONDO:0004592 PMID:41385096 "[{""id"":""uuid:819303e2-1745-46ca-9e4d-368564f5e5eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0ad29710-590f-4775-b253-1081e052f526"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mupirocin Ointment USP, 2% is indicated for the topical treatment of impetigo due to: S. aureus and S. pyogenes . uuid:2bb8eff2-3e1c-4620-8bf9-6bac749752f0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31498 biolink:treats MONDO:0005545 PMID:41385096 "[{""id"":""uuid:770a3931-40cd-459e-8e25-69b88fa9666d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2e6c2a7d-f9f0-48ee-a6be-01748d383774"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mupirocin Ointment USP, 2% is indicated for the topical treatment of impetigo due to: S. aureus and S. pyogenes . uuid:93886806-bca4-4f37-b750-d9d6da105f84 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3732 biolink:treats MONDO:0017767 PMID:41385096 "[{""id"":""uuid:2b716241-6437-4d9b-968e-d5f4a559e081"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dff15365-8710-400d-88c2-8db3006c5c96"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clarithromycin Tablets, USP are indicated for the treatment of mild to moderate infections caused by susceptible isolates of the designated bacteria in the conditions as listed below: Adults (Clarithromycin Tablets, USP) Pharyngitis/Tonsillitis due to Streptococcus pyogenes (The usual drug of choice in the treatment and prevention of streptococcal infections and the prophylaxis of rheumatic fever is penicillin administered by either the intramuscular or the oral route. Clarithromycin Tablets, USP are generally effective in the eradication of S. pyogenes from the nasopharynx; however, data establishing the efficacy of Clarithromycin Tablets, USP in the subsequent prevention of rheumatic fever are not available at present.) Acute maxillary sinusitis due to Haemophilus influenzae, Moraxella catarrhalis or Streptococcus pneumoniae. Acute bacterial exacerbation of chronic bronchitis due to Haemophilus influenzae,Haemophilus parainfluenzae, Moraxella catarrhalis , or Streptococcus pneumoniae. Community-Acquired Pneumonia due to Haemophilus influenzae, Mycoplasma pneumoniae, Streptococcus pneumoniae , or Chlamydophila pneumoniae (TWAR). Uncomplicated skin and skin structure infections due to Staphylococcus aureus , or Streptococcus pyogenes (Abscesses usually require surgical drainage). Disseminated mycobacterial infections due to Mycobacterium avium , or Mycobacterium intracellulare. Clarithromycin Tablets, USP in combination with amoxicillin and PREVACID (lansoprazole) or PRILOSEC (omeprazole) Delayed-Release Capsules, as triple therapy, are indicated for the treatment of patients with Helicobacter pylori infection and duodenal ulcer disease (active or five-year history of duodenal ulcer) to eradicate H. pylori . Clarithromycin Tablets, USP in combination with PRILOSEC (omeprazole) capsules or TIRTEC (ranitidine bismuth citrate) tablets are also indicated for the treatment of patients with an active duodenal ulcer associated with H. pylori infection. However, regimens which contain Clarithromycin Tablets, USP as the single antimicrobial agent are more likely to be associated with the development of clarithromycin resistance among patients who fail therapy. Clarithromycin-containing regimens should not be used in patients with known or suspected clarithromycin resistant isolates because the efficacy of treatment is reduced in this setting. In patients who fail therapy, susceptibility testing should be done if possible. If resistance to Clarithromycin Tablets, USP is demonstrated, a non-clarithromycin-containing therapy is recommended. (For information on development of resistance see MICROBIOLOGY section.) The eradication of H. pylori has been demonstrated to reduce the risk of duodenal ulcer recurrence. Children (Clarithromycin Tablets, USP) Pharyngitis/Tonsillitis due to Streptococcus pyogenes. Community-Acquired Pneumonia due to Mycoplasma pneumoniae, Streptococcus pneumoniae , or Chlamydophila pneumoniae (TWAR). Acute maxillary sinusitis due to Haemophilus influenzae, Moraxella catarrhalis , or Streptococcus pneumoniae. Acute otitis media due to Haemophilus influenzae, Moraxella catarrhalis , or Streptococcus pneumoniae. NOTE : For information on otitis media, see CLINICAL STUDIES – Otitis Media . Uncomplicated skin and skin structure infections due to Staphylococcus aureus , or Streptococcus pyogenes (Abscesses usually require surgical drainage). Disseminated mycobacterial infections due to Mycobacterium avium , or Mycobacterium intracellulare. Prophylaxis Clarithromycin Tablets, USP are indicated for the prevention of disseminated Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Clarithromycin Tablets, USP and other antibacterial drugs, Clarithromycin Tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:a50018f2-40d4-46b5-a2a4-4bd85ba88f7c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:57773 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:125ed99e-d299-4524-bf36-d8c5d5fd32f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2a3bb0f7-c143-469a-8b90-f272c5892347"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ampicillin and Sulbactam for Injection, USP is indicated for the treatment of infections due to susceptible strains of the designated microorganisms in the conditions listed below. Skin and Skin Structure Infections caused by beta-lactamase producing strains of Staphylococcus aureus, Escherichia coli, 2 Klebsiella spp. 2 (including K. pneumoniae 2 ), Proteus mirabilis, 2 Bacteroides fragilis, 2 Enterobacter spp., 2 and Acinetobacter calcoaceticus. 2 NOTE: For information on use in pediatric patients see PRECAUTIONS – Pediatric Use and CLINICAL STUDIES sections. Intra-Abdominal Infections caused by beta-lactamase producing strains of Escherichia coli, Klebsiella spp. (including K. pneumoniae 2 ), Bacteroides spp. (including B. fragilis ), and Enterobacter spp. 2 Gynecological Infections caused by beta-lactamase producing strains of Escherichia coli, 2 and Bacteroides spp. 2 (including B. fragilis 2 ). __________ 2 Efficacy for this microorganism in this organ system was studied in fewer than 10 infections. While Ampicillin and Sulbactam for Injection USP is indicated only for the conditions listed above, infections caused by ampicillin susceptible organisms are also amenable to treatment with Ampicillin and Sulbactam for Injection USP due to its ampicillin content. Therefore, mixed infections caused by ampicillin-susceptible organisms and beta-lactamase producing organisms susceptible to Ampicillin and Sulbactam for Injection USP should not require the addition of another antibacterial. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify the organisms causing infection and to determine their susceptibility to Ampicillin and Sulbactam. Therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies, when there is reason to believe the infection may involve any of the beta-lactamase producing organisms listed above in the indicated organ systems. Once the results are known, therapy should be adjusted if appropriate. To reduce the development of drug-resistant bacteria and maintain effectiveness of Ampicillin and Sulbactam and other antibacterial drugs, Ampicillin and Sulbactam for Injection USP should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:28c8276d-4062-4c31-ad1b-d00be26e13b7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:57773 biolink:treats UMLS:C1112209 PMID:41385096 "[{""id"":""uuid:b5c1f309-b2e2-4ef2-9b9f-50eb1e7eb9fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ed3b7a8b-7fed-491d-a287-28d9fb9fb8de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ampicillin and Sulbactam for Injection, USP is indicated for the treatment of infections due to susceptible strains of the designated microorganisms in the conditions listed below. Skin and Skin Structure Infections caused by beta-lactamase producing strains of Staphylococcus aureus, Escherichia coli, 2 Klebsiella spp. 2 (including K. pneumoniae 2 ), Proteus mirabilis, 2 Bacteroides fragilis, 2 Enterobacter spp., 2 and Acinetobacter calcoaceticus. 2 NOTE: For information on use in pediatric patients see PRECAUTIONS – Pediatric Use and CLINICAL STUDIES sections. Intra-Abdominal Infections caused by beta-lactamase producing strains of Escherichia coli, Klebsiella spp. (including K. pneumoniae 2 ), Bacteroides spp. (including B. fragilis ), and Enterobacter spp. 2 Gynecological Infections caused by beta-lactamase producing strains of Escherichia coli, 2 and Bacteroides spp. 2 (including B. fragilis 2 ). __________ 2 Efficacy for this microorganism in this organ system was studied in fewer than 10 infections. While Ampicillin and Sulbactam for Injection USP is indicated only for the conditions listed above, infections caused by ampicillin susceptible organisms are also amenable to treatment with Ampicillin and Sulbactam for Injection USP due to its ampicillin content. Therefore, mixed infections caused by ampicillin-susceptible organisms and beta-lactamase producing organisms susceptible to Ampicillin and Sulbactam for Injection USP should not require the addition of another antibacterial. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify the organisms causing infection and to determine their susceptibility to Ampicillin and Sulbactam. Therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies, when there is reason to believe the infection may involve any of the beta-lactamase producing organisms listed above in the indicated organ systems. Once the results are known, therapy should be adjusted if appropriate. To reduce the development of drug-resistant bacteria and maintain effectiveness of Ampicillin and Sulbactam and other antibacterial drugs, Ampicillin and Sulbactam for Injection USP should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:dafb6ce6-fbde-4d4b-a373-b42610d5a889 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:57773 biolink:treats UMLS:C1262234 PMID:41385096 "[{""id"":""uuid:18695040-4a19-4c9a-88df-7763980018d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:53661fd0-bf7b-4c9c-a09d-c7f3cf62bb41"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ampicillin and Sulbactam for Injection, USP is indicated for the treatment of infections due to susceptible strains of the designated microorganisms in the conditions listed below. Skin and Skin Structure Infections caused by beta-lactamase producing strains of Staphylococcus aureus, Escherichia coli, 2 Klebsiella spp. 2 (including K. pneumoniae 2 ), Proteus mirabilis, 2 Bacteroides fragilis, 2 Enterobacter spp., 2 and Acinetobacter calcoaceticus. 2 NOTE: For information on use in pediatric patients see PRECAUTIONS – Pediatric Use and CLINICAL STUDIES sections. Intra-Abdominal Infections caused by beta-lactamase producing strains of Escherichia coli, Klebsiella spp. (including K. pneumoniae 2 ), Bacteroides spp. (including B. fragilis ), and Enterobacter spp. 2 Gynecological Infections caused by beta-lactamase producing strains of Escherichia coli, 2 and Bacteroides spp. 2 (including B. fragilis 2 ). __________ 2 Efficacy for this microorganism in this organ system was studied in fewer than 10 infections. While Ampicillin and Sulbactam for Injection USP is indicated only for the conditions listed above, infections caused by ampicillin susceptible organisms are also amenable to treatment with Ampicillin and Sulbactam for Injection USP due to its ampicillin content. Therefore, mixed infections caused by ampicillin-susceptible organisms and beta-lactamase producing organisms susceptible to Ampicillin and Sulbactam for Injection USP should not require the addition of another antibacterial. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify the organisms causing infection and to determine their susceptibility to Ampicillin and Sulbactam. Therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies, when there is reason to believe the infection may involve any of the beta-lactamase producing organisms listed above in the indicated organ systems. Once the results are known, therapy should be adjusted if appropriate. To reduce the development of drug-resistant bacteria and maintain effectiveness of Ampicillin and Sulbactam and other antibacterial drugs, Ampicillin and Sulbactam for Injection USP should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:d4209e38-d416-411a-a9a7-3c108cef8563 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9907 biolink:treats MONDO:0005388 PMID:41385096 "[{""id"":""uuid:1a2d4c30-e5cd-4a7a-8aaa-6dcbc90416f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cc5c4200-1cbc-46b9-acdf-8c9ee9c516a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ursodiol tablets, USP are indicated for the treatment of patients with primary biliary cirrhosis (PBC). uuid:6e59dd9d-3c9e-4e19-8894-55d9b2ea675e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9907 biolink:treats MONDO:0007193 PMID:41385096 "[{""id"":""uuid:6a1a226a-9a2d-4cb6-b9e9-7c958367991b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a3e816cf-ad2c-486b-a963-d7caecfffb41"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ursodiol tablets, USP are indicated for the treatment of patients with primary biliary cirrhosis (PBC). uuid:162c2ff7-63ec-496a-b65f-d6a2f7d45b59 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4876 biolink:treats HP:0000969 PMID:41385096 "[{""id"":""uuid:8b265846-7dcc-4e53-8edc-df16b9ef60fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cd80547f-4a1d-4d59-a139-3cf2e88acd8f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EDECRIN is indicated for treatment of edema when an agent with greater diuretic potential than those commonly employed is required. 1. Treatment of the edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. 2. Short-term management of ascites due to malignancy, idiopathic edema, and lymphedema. 3. Short-term management of hospitalized pediatric patients, other than infants, with congenital heart disease or the nephrotic syndrome. 4. Intravenous SODIUM EDECRIN is indicated when a rapid onset of diuresis is desired, e.g., in acute pulmonary edema, or when gastrointestinal absorption is impaired or oral medication is not practicable. uuid:62383319-7077-4fb7-ae53-1fea05b4e411 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4876 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:6d15a680-a51a-4dcb-8602-befdacd60bcf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a964f30d-8d9a-46bb-8436-b84b3c6a8649"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EDECRIN is indicated for treatment of edema when an agent with greater diuretic potential than those commonly employed is required. 1. Treatment of the edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. 2. Short-term management of ascites due to malignancy, idiopathic edema, and lymphedema. 3. Short-term management of hospitalized pediatric patients, other than infants, with congenital heart disease or the nephrotic syndrome. 4. Intravenous SODIUM EDECRIN is indicated when a rapid onset of diuresis is desired, e.g., in acute pulmonary edema, or when gastrointestinal absorption is impaired or oral medication is not practicable. uuid:1fbab029-e9fa-46b9-817e-a6c5949e8aa4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4876 biolink:treats MONDO:0005155 PMID:41385096 "[{""id"":""uuid:47b96007-5a0c-46c9-8c9a-015b0f04df39"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4ae126d8-33db-4079-b2fc-94f29eaac4b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EDECRIN is indicated for treatment of edema when an agent with greater diuretic potential than those commonly employed is required. 1. Treatment of the edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. 2. Short-term management of ascites due to malignancy, idiopathic edema, and lymphedema. 3. Short-term management of hospitalized pediatric patients, other than infants, with congenital heart disease or the nephrotic syndrome. 4. Intravenous SODIUM EDECRIN is indicated when a rapid onset of diuresis is desired, e.g., in acute pulmonary edema, or when gastrointestinal absorption is impaired or oral medication is not practicable. uuid:5b260b7c-f250-4c64-8a2f-8e0505db0ec5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4876 biolink:treats MONDO:0005240 PMID:41385096 "[{""id"":""uuid:1b1bf80b-13b7-44d7-a0e6-97f78c41026c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dd51cd78-d0fa-40c6-8639-ee69a6f522d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EDECRIN is indicated for treatment of edema when an agent with greater diuretic potential than those commonly employed is required. 1. Treatment of the edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. 2. Short-term management of ascites due to malignancy, idiopathic edema, and lymphedema. 3. Short-term management of hospitalized pediatric patients, other than infants, with congenital heart disease or the nephrotic syndrome. 4. Intravenous SODIUM EDECRIN is indicated when a rapid onset of diuresis is desired, e.g., in acute pulmonary edema, or when gastrointestinal absorption is impaired or oral medication is not practicable. uuid:ce5e6a87-31e9-4c66-b19d-408846aa890f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4876 biolink:treats MONDO:0005377 PMID:41385096 "[{""id"":""uuid:c11728c1-1f68-4eb6-97f0-f3accc57d4d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ec07e8b1-3f06-4335-a7ca-7b3e914afab7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EDECRIN is indicated for treatment of edema when an agent with greater diuretic potential than those commonly employed is required. 1. Treatment of the edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. 2. Short-term management of ascites due to malignancy, idiopathic edema, and lymphedema. 3. Short-term management of hospitalized pediatric patients, other than infants, with congenital heart disease or the nephrotic syndrome. 4. Intravenous SODIUM EDECRIN is indicated when a rapid onset of diuresis is desired, e.g., in acute pulmonary edema, or when gastrointestinal absorption is impaired or oral medication is not practicable. uuid:833162f1-009a-4b85-b51c-b867a708ac08 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4876 biolink:treats UMLS:C0238094 PMID:41385096 "[{""id"":""uuid:c9f91df6-eac3-4ea7-bcfd-bba140a81d4b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d45192d0-d5c6-4506-adfe-2035f7693663"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EDECRIN is indicated for treatment of edema when an agent with greater diuretic potential than those commonly employed is required. 1. Treatment of the edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. 2. Short-term management of ascites due to malignancy, idiopathic edema, and lymphedema. 3. Short-term management of hospitalized pediatric patients, other than infants, with congenital heart disease or the nephrotic syndrome. 4. Intravenous SODIUM EDECRIN is indicated when a rapid onset of diuresis is desired, e.g., in acute pulmonary edema, or when gastrointestinal absorption is impaired or oral medication is not practicable. uuid:83d1c637-9bc0-4310-9c01-fa9923f15c22 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4876 biolink:treats MONDO:0019297 PMID:41385096 "[{""id"":""uuid:c208e7dd-80f9-4871-a2ec-15e5696f0d0f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:13a69546-4ef5-4704-b935-58ece14adb0c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EDECRIN is indicated for treatment of edema when an agent with greater diuretic potential than those commonly employed is required. 1. Treatment of the edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. 2. Short-term management of ascites due to malignancy, idiopathic edema, and lymphedema. 3. Short-term management of hospitalized pediatric patients, other than infants, with congenital heart disease or the nephrotic syndrome. 4. Intravenous SODIUM EDECRIN is indicated when a rapid onset of diuresis is desired, e.g., in acute pulmonary edema, or when gastrointestinal absorption is impaired or oral medication is not practicable. uuid:ab9788cf-c509-4f99-a49c-214646164b12 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4876 biolink:treats MONDO:0005453 PMID:41385096 "[{""id"":""uuid:685686c4-84ef-454b-b15d-13ae9ae38b2e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8fcfe5cc-625c-4fbc-a019-f035bcce9894"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EDECRIN is indicated for treatment of edema when an agent with greater diuretic potential than those commonly employed is required. 1. Treatment of the edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. 2. Short-term management of ascites due to malignancy, idiopathic edema, and lymphedema. 3. Short-term management of hospitalized pediatric patients, other than infants, with congenital heart disease or the nephrotic syndrome. 4. Intravenous SODIUM EDECRIN is indicated when a rapid onset of diuresis is desired, e.g., in acute pulmonary edema, or when gastrointestinal absorption is impaired or oral medication is not practicable. uuid:3822fe1b-68ef-46d9-b0f0-44a9835608c6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4876 biolink:treats UMLS:C0155919 PMID:41385096 "[{""id"":""uuid:53dff492-944c-4372-8758-12151053d237"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bb96b188-d590-4c48-bd6f-e86c84c51cb0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EDECRIN is indicated for treatment of edema when an agent with greater diuretic potential than those commonly employed is required. 1. Treatment of the edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. 2. Short-term management of ascites due to malignancy, idiopathic edema, and lymphedema. 3. Short-term management of hospitalized pediatric patients, other than infants, with congenital heart disease or the nephrotic syndrome. 4. Intravenous SODIUM EDECRIN is indicated when a rapid onset of diuresis is desired, e.g., in acute pulmonary edema, or when gastrointestinal absorption is impaired or oral medication is not practicable. uuid:58b16795-cce4-48c6-b5eb-e2f193069e14 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6909 biolink:treats UMLS:C1112209 PMID:41385096 "[{""id"":""uuid:2a37e655-a134-4ef2-a851-71fe9bc46d77"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d6ae4a6d-2c27-439f-bedc-cf99d6fe78bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Symptomatic Trichomoniasis. Metronidazole tablets are indicated for the treatment of T. vaginalis infection in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures). Asymptomatic Trichomoniasis. Metronidazole tablets are indicated in the treatment of asymptomatic T. vaginalis infection in females when the organism is associated with endocervicitis, cervicitis, or cervical erosion. Since there is evidence that presence of the trichomonad can interfere with accurate assessment of abnormal cytological smears, additional smears should be performed after eradication of the parasite. Treatment of Asymptomatic Sexual Partners. T. vaginalis infection is a venereal disease. Therefore, asymptomatic sexual partners of treated patients should be treated simultaneously if the organism has been found to be present, in order to prevent reinfection of the partner. The decision as to whether to treat an asymptomatic male partner who has a negative culture or one for whom no culture has been attempted is an individual one. In making this decision, it should be noted that there is evidence that a woman may become reinfected if her sexual partner is not treated. Also, since there can be considerable difficulty in isolating the organism from the asymptomatic male carrier, negative smears and cultures cannot be relied upon in this regard. In any event, the sexual partner should be treated with metronidazole tablets in cases of reinfection. Amebiasis. Metronidazole tablets are indicated in the treatment of acute intestinal amebiasis (amebic dysentery) and amebic liver abscess. In amebic liver abscess, metronidazole tablet therapy does not obviate the need for aspiration or drainage of pus. Anaerobic Bacterial Infections. Metronidazole tablets are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Indicated surgical procedures should be performed in conjunction with metronidazole tablet therapy. In a mixed aerobic and anaerobic infection, antimicrobials appropriate for the treatment of the aerobic infection should be used in addition to metronidazole tablets. INTRA-ABDOMINAL INFECTIONS, including peritonitis, intra-abdominal abscess, and liver abscess, caused by Bacteroides species including the B. fragilis group ( B. fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron, B. vulgatus ), Clostridium species, Eubacterium species, Peptococcus species, and Peptostreptococcus species. SKIN AND SKIN STRUCTURE INFECTIONS caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus species, Peptostreptococcus species, and Fusobacterium species. GYNECOLOGIC INFECTIONS, including endometritis, endomyometritis, tubo-ovarian abscess, and postsurgical vaginal cuff infection, caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus species, Peptostreptococcus species, and Fusobacterium species. BACTERIAL SEPTICEMIA caused by Bacteroides species including the B. fragilis group and Clostridium species. BONE AND JOINT INFECTIONS, (as adjunctive therapy), caused by Bacteroides species including the B. fragilis group. CENTRAL NERVOUS SYSTEM (CNS) INFECTIONS, including meningitis and brain abscess, caused by Bacteroides species including the B. fragilis group. LOWER RESPIRATORY TRACT INFECTIONS, including pneumonia, empyema, and lung abscess, caused by Bacteroides species including the B. fragilis group. ENDOCARDITIS caused by Bacteroides species including the B. fragilis group. To reduce the development of drug-resistant bacteria and maintain the effectiveness of metronidazole tablets and other antibacterial drugs, metronidazole tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:390c3561-1538-458f-980b-2eceed4f0ed9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6909 biolink:treats MONDO:0005113 PMID:41385096 "[{""id"":""uuid:6aece3c5-b5e8-4247-a4ba-4fab3f5d04ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a0c10c04-a5ca-41f5-a475-56c1f4c98be0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Symptomatic Trichomoniasis. Metronidazole tablets are indicated for the treatment of T. vaginalis infection in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures). Asymptomatic Trichomoniasis. Metronidazole tablets are indicated in the treatment of asymptomatic T. vaginalis infection in females when the organism is associated with endocervicitis, cervicitis, or cervical erosion. Since there is evidence that presence of the trichomonad can interfere with accurate assessment of abnormal cytological smears, additional smears should be performed after eradication of the parasite. Treatment of Asymptomatic Sexual Partners. T. vaginalis infection is a venereal disease. Therefore, asymptomatic sexual partners of treated patients should be treated simultaneously if the organism has been found to be present, in order to prevent reinfection of the partner. The decision as to whether to treat an asymptomatic male partner who has a negative culture or one for whom no culture has been attempted is an individual one. In making this decision, it should be noted that there is evidence that a woman may become reinfected if her sexual partner is not treated. Also, since there can be considerable difficulty in isolating the organism from the asymptomatic male carrier, negative smears and cultures cannot be relied upon in this regard. In any event, the sexual partner should be treated with metronidazole tablets in cases of reinfection. Amebiasis. Metronidazole tablets are indicated in the treatment of acute intestinal amebiasis (amebic dysentery) and amebic liver abscess. In amebic liver abscess, metronidazole tablet therapy does not obviate the need for aspiration or drainage of pus. Anaerobic Bacterial Infections. Metronidazole tablets are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Indicated surgical procedures should be performed in conjunction with metronidazole tablet therapy. In a mixed aerobic and anaerobic infection, antimicrobials appropriate for the treatment of the aerobic infection should be used in addition to metronidazole tablets. INTRA-ABDOMINAL INFECTIONS, including peritonitis, intra-abdominal abscess, and liver abscess, caused by Bacteroides species including the B. fragilis group ( B. fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron, B. vulgatus ), Clostridium species, Eubacterium species, Peptococcus species, and Peptostreptococcus species. SKIN AND SKIN STRUCTURE INFECTIONS caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus species, Peptostreptococcus species, and Fusobacterium species. GYNECOLOGIC INFECTIONS, including endometritis, endomyometritis, tubo-ovarian abscess, and postsurgical vaginal cuff infection, caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus species, Peptostreptococcus species, and Fusobacterium species. BACTERIAL SEPTICEMIA caused by Bacteroides species including the B. fragilis group and Clostridium species. BONE AND JOINT INFECTIONS, (as adjunctive therapy), caused by Bacteroides species including the B. fragilis group. CENTRAL NERVOUS SYSTEM (CNS) INFECTIONS, including meningitis and brain abscess, caused by Bacteroides species including the B. fragilis group. LOWER RESPIRATORY TRACT INFECTIONS, including pneumonia, empyema, and lung abscess, caused by Bacteroides species including the B. fragilis group. ENDOCARDITIS caused by Bacteroides species including the B. fragilis group. To reduce the development of drug-resistant bacteria and maintain the effectiveness of metronidazole tablets and other antibacterial drugs, metronidazole tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:51ed84e5-4de7-429d-8b3d-aa3d3700d204 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6909 biolink:treats MONDO:0024619 PMID:41385096 "[{""id"":""uuid:bc357488-554a-4f5b-9aaa-2a0c0c394f2b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2c90f258-70e9-4dc6-b5e4-557b7c3c9033"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Symptomatic Trichomoniasis. Metronidazole tablets are indicated for the treatment of T. vaginalis infection in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures). Asymptomatic Trichomoniasis. Metronidazole tablets are indicated in the treatment of asymptomatic T. vaginalis infection in females when the organism is associated with endocervicitis, cervicitis, or cervical erosion. Since there is evidence that presence of the trichomonad can interfere with accurate assessment of abnormal cytological smears, additional smears should be performed after eradication of the parasite. Treatment of Asymptomatic Sexual Partners. T. vaginalis infection is a venereal disease. Therefore, asymptomatic sexual partners of treated patients should be treated simultaneously if the organism has been found to be present, in order to prevent reinfection of the partner. The decision as to whether to treat an asymptomatic male partner who has a negative culture or one for whom no culture has been attempted is an individual one. In making this decision, it should be noted that there is evidence that a woman may become reinfected if her sexual partner is not treated. Also, since there can be considerable difficulty in isolating the organism from the asymptomatic male carrier, negative smears and cultures cannot be relied upon in this regard. In any event, the sexual partner should be treated with metronidazole tablets in cases of reinfection. Amebiasis. Metronidazole tablets are indicated in the treatment of acute intestinal amebiasis (amebic dysentery) and amebic liver abscess. In amebic liver abscess, metronidazole tablet therapy does not obviate the need for aspiration or drainage of pus. Anaerobic Bacterial Infections. Metronidazole tablets are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Indicated surgical procedures should be performed in conjunction with metronidazole tablet therapy. In a mixed aerobic and anaerobic infection, antimicrobials appropriate for the treatment of the aerobic infection should be used in addition to metronidazole tablets. INTRA-ABDOMINAL INFECTIONS, including peritonitis, intra-abdominal abscess, and liver abscess, caused by Bacteroides species including the B. fragilis group ( B. fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron, B. vulgatus ), Clostridium species, Eubacterium species, Peptococcus species, and Peptostreptococcus species. SKIN AND SKIN STRUCTURE INFECTIONS caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus species, Peptostreptococcus species, and Fusobacterium species. GYNECOLOGIC INFECTIONS, including endometritis, endomyometritis, tubo-ovarian abscess, and postsurgical vaginal cuff infection, caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus species, Peptostreptococcus species, and Fusobacterium species. BACTERIAL SEPTICEMIA caused by Bacteroides species including the B. fragilis group and Clostridium species. BONE AND JOINT INFECTIONS, (as adjunctive therapy), caused by Bacteroides species including the B. fragilis group. CENTRAL NERVOUS SYSTEM (CNS) INFECTIONS, including meningitis and brain abscess, caused by Bacteroides species including the B. fragilis group. LOWER RESPIRATORY TRACT INFECTIONS, including pneumonia, empyema, and lung abscess, caused by Bacteroides species including the B. fragilis group. ENDOCARDITIS caused by Bacteroides species including the B. fragilis group. To reduce the development of drug-resistant bacteria and maintain the effectiveness of metronidazole tablets and other antibacterial drugs, metronidazole tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:92578032-94a5-440f-a9d8-a964ee9cc722 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6909 biolink:treats MONDO:0024355 PMID:41385096 "[{""id"":""uuid:eb9ad048-ce46-49b7-9c6b-daf7a7719e5b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4dec4533-fc3b-4c3a-9242-08f9331b83f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Symptomatic Trichomoniasis. Metronidazole tablets are indicated for the treatment of T. vaginalis infection in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures). Asymptomatic Trichomoniasis. Metronidazole tablets are indicated in the treatment of asymptomatic T. vaginalis infection in females when the organism is associated with endocervicitis, cervicitis, or cervical erosion. Since there is evidence that presence of the trichomonad can interfere with accurate assessment of abnormal cytological smears, additional smears should be performed after eradication of the parasite. Treatment of Asymptomatic Sexual Partners. T. vaginalis infection is a venereal disease. Therefore, asymptomatic sexual partners of treated patients should be treated simultaneously if the organism has been found to be present, in order to prevent reinfection of the partner. The decision as to whether to treat an asymptomatic male partner who has a negative culture or one for whom no culture has been attempted is an individual one. In making this decision, it should be noted that there is evidence that a woman may become reinfected if her sexual partner is not treated. Also, since there can be considerable difficulty in isolating the organism from the asymptomatic male carrier, negative smears and cultures cannot be relied upon in this regard. In any event, the sexual partner should be treated with metronidazole tablets in cases of reinfection. Amebiasis. Metronidazole tablets are indicated in the treatment of acute intestinal amebiasis (amebic dysentery) and amebic liver abscess. In amebic liver abscess, metronidazole tablet therapy does not obviate the need for aspiration or drainage of pus. Anaerobic Bacterial Infections. Metronidazole tablets are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Indicated surgical procedures should be performed in conjunction with metronidazole tablet therapy. In a mixed aerobic and anaerobic infection, antimicrobials appropriate for the treatment of the aerobic infection should be used in addition to metronidazole tablets. INTRA-ABDOMINAL INFECTIONS, including peritonitis, intra-abdominal abscess, and liver abscess, caused by Bacteroides species including the B. fragilis group ( B. fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron, B. vulgatus ), Clostridium species, Eubacterium species, Peptococcus species, and Peptostreptococcus species. SKIN AND SKIN STRUCTURE INFECTIONS caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus species, Peptostreptococcus species, and Fusobacterium species. GYNECOLOGIC INFECTIONS, including endometritis, endomyometritis, tubo-ovarian abscess, and postsurgical vaginal cuff infection, caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus species, Peptostreptococcus species, and Fusobacterium species. BACTERIAL SEPTICEMIA caused by Bacteroides species including the B. fragilis group and Clostridium species. BONE AND JOINT INFECTIONS, (as adjunctive therapy), caused by Bacteroides species including the B. fragilis group. CENTRAL NERVOUS SYSTEM (CNS) INFECTIONS, including meningitis and brain abscess, caused by Bacteroides species including the B. fragilis group. LOWER RESPIRATORY TRACT INFECTIONS, including pneumonia, empyema, and lung abscess, caused by Bacteroides species including the B. fragilis group. ENDOCARDITIS caused by Bacteroides species including the B. fragilis group. To reduce the development of drug-resistant bacteria and maintain the effectiveness of metronidazole tablets and other antibacterial drugs, metronidazole tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:2bc03f7c-1ee7-4b74-8f8c-4ee8914a5ecf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28001 biolink:treats MONDO:0024313 PMID:41385096 "[{""id"":""uuid:0d1d6585-644c-48ef-bd88-8e424de70933"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d5261765-aa41-42d1-85cd-a91efddd97b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vancomycin is indicated for the treatment of serious or severe infections caused by susceptible strains of methicillin-resistant (beta-lactam-resistant) staphylococci. It is indicated for penicillin-allergic patients, for patients who cannot receive or who have failed to respond to other drugs, including the penicillins or cephalosporins, and for infections caused by vancomycin-susceptible organisms that are resistant to other antimicrobial drugs. Vancomycin is indicated for initial therapy when methicillin-resistant staphylococci are suspected, but after susceptibility data are available, therapy should be adjusted accordingly. Vancomycin is effective in the treatment of staphylococcal endocarditis. Its effectiveness has been documented in other infections due to staphylococci, including septicemia, bone infections, lower respiratory tract infections, skin and skin structure infections. When staphylococcal infections are localized and purulent, antibiotics are used as adjuncts to appropriate surgical measures. Vancomycin has been reported to be effective alone or in combination with an aminoglycoside for endocarditis caused by Streptococcus viridans or S. bovis . For endocarditis caused by enterococci ( e.g., E. faecalis ), vancomycin has been reported to be effective only in combination with an aminoglycoside. Vancomycin has been reported to be effective for the treatment of diphtheroid endocarditis. Vancomycin has been used successfully in combination with either rifampin, an aminoglycoside, or both in early-onset prosthetic valve endocarditis caused by S. epidermidis or diphtheroids. Specimens for bacteriologic cultures should be obtained in order to isolate and identify causative organisms and to determine their susceptibilities to vancomycin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of vancomycin and other antibacterial drugs, vancomycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection oftherapy. The parenteral form of Vancomycin Hydrochloride for Injection, USP may be administered orally for treatment of antibiotic-associated pseudomembranous colitis produced by C. difficile and for staphylococcal enterocolitis. Parenteral administration of vancomycin hydrochloride alone is of unproven benefit for these indications. Vancomycin is not effective by the oral route for other types of infection. uuid:3848f78d-b4d6-4566-9266-65c3d3f43c92 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77733 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:e8b18d52-31f5-4a23-9ddc-d8f9aa5d1a53"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ede9d3af-705a-4012-81a7-a135c5f53cb1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Verapamil hydrochloride sustained-release capsules are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. uuid:e677b8f7-d17a-486c-9506-0ba374b40f09 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77733 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:677f91ef-1900-49db-9d2e-7801cf85aa1d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e0d41042-5cb2-4e24-8b8c-6812c919fab1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Verapamil hydrochloride sustained-release capsules are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. uuid:e3b0d307-f770-45be-bb5f-a8fb57b3803e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2618 biolink:treats MONDO:0005812 PMID:41385096 "[{""id"":""uuid:51fbb425-9085-4a79-8bde-8a041402e87b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8fe9198c-c1fa-43de-a632-de00d50e835c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amantadine hydrochloride oral solution USP is indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus. Amantadine hydrochloride is also indicated in the treatment of parkinsonism and drug-induced extrapyramidal reactions. uuid:901e47fd-dfd8-4320-b703-64d31d37729a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:253342 biolink:treats MONDO:0005052 PMID:41385096 "[{""id"":""uuid:aecf8bfa-2bf0-4e1d-9cc4-3ed0fa4fe62c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:651806ed-4113-4a8c-b671-cfbf9fb2b609"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LOTRONEX is indicated only for women with severe diarrhea-predominant irritable bowel syndrome (IBS) who have: chronic IBS symptoms (generally lasting 6 months or longer), had anatomic or biochemical abnormalities of the gastrointestinal tract excluded, and not responded adequately to conventional therapy. Diarrhea-predominant IBS is severe if it includes diarrhea and one or more of the following: frequent and severe abdominal pain/discomfort, frequent bowel urgency or fecal incontinence, disability or restriction of daily activities due to IBS. Because of infrequent but serious gastrointestinal adverse reactions associated with LOTRONEX, the indication is restricted to those patients for whom the benefit-to-risk balance is most favorable. Clinical studies have not been performed to adequately confirm the benefits of LOTRONEX in men. uuid:5115c33a-9d76-4a61-8c28-5d98ab34f829 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:253342 biolink:treats HP:0002027 PMID:41385096 "[{""id"":""uuid:115d7b05-23a2-43c1-accb-5edee03d7973"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:03bf3207-e0f7-447e-87dd-f5061e1d39d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LOTRONEX is indicated only for women with severe diarrhea-predominant irritable bowel syndrome (IBS) who have: chronic IBS symptoms (generally lasting 6 months or longer), had anatomic or biochemical abnormalities of the gastrointestinal tract excluded, and not responded adequately to conventional therapy. Diarrhea-predominant IBS is severe if it includes diarrhea and one or more of the following: frequent and severe abdominal pain/discomfort, frequent bowel urgency or fecal incontinence, disability or restriction of daily activities due to IBS. Because of infrequent but serious gastrointestinal adverse reactions associated with LOTRONEX, the indication is restricted to those patients for whom the benefit-to-risk balance is most favorable. Clinical studies have not been performed to adequately confirm the benefits of LOTRONEX in men. uuid:8b52cdb6-059b-40b9-9874-3d4697f5d06d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:253342 biolink:treats HP:0012701 PMID:41385096 "[{""id"":""uuid:c21980ee-465c-41cc-9e43-cdf9f5567d86"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8d5e1cb0-a55d-4eda-b76a-98b806ed7570"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LOTRONEX is indicated only for women with severe diarrhea-predominant irritable bowel syndrome (IBS) who have: chronic IBS symptoms (generally lasting 6 months or longer), had anatomic or biochemical abnormalities of the gastrointestinal tract excluded, and not responded adequately to conventional therapy. Diarrhea-predominant IBS is severe if it includes diarrhea and one or more of the following: frequent and severe abdominal pain/discomfort, frequent bowel urgency or fecal incontinence, disability or restriction of daily activities due to IBS. Because of infrequent but serious gastrointestinal adverse reactions associated with LOTRONEX, the indication is restricted to those patients for whom the benefit-to-risk balance is most favorable. Clinical studies have not been performed to adequately confirm the benefits of LOTRONEX in men. uuid:ff3b4f3c-a577-4c48-82a8-40bb4fd780de biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:253342 biolink:treats HP:0002607 PMID:41385096 "[{""id"":""uuid:d3915a8b-3d36-4dcf-81c0-19c2f146c700"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a4ddbf80-abe3-409a-a556-a7b82d6a8264"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LOTRONEX is indicated only for women with severe diarrhea-predominant irritable bowel syndrome (IBS) who have: chronic IBS symptoms (generally lasting 6 months or longer), had anatomic or biochemical abnormalities of the gastrointestinal tract excluded, and not responded adequately to conventional therapy. Diarrhea-predominant IBS is severe if it includes diarrhea and one or more of the following: frequent and severe abdominal pain/discomfort, frequent bowel urgency or fecal incontinence, disability or restriction of daily activities due to IBS. Because of infrequent but serious gastrointestinal adverse reactions associated with LOTRONEX, the indication is restricted to those patients for whom the benefit-to-risk balance is most favorable. Clinical studies have not been performed to adequately confirm the benefits of LOTRONEX in men. uuid:be7af7d3-85e6-4b05-bbba-ca3d6ec8edbb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:1678OK0E08 biolink:treats MONDO:0005302 PMID:41385096 "[{""id"":""uuid:4ee2ba27-2dbb-4dc4-9a52-a8358985607b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:413edc47-253f-4171-b06c-1a103db6d093"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dexmethylphenidate hydrochloride extended-release capsules are indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients aged 6 years and older. The effectiveness of dexmethylphenidate hydrochloride extended-release capsules in the treatment of ADHD in patients aged 6 years and older was established in 2 placebo-controlled studies in patients meeting DSM-IV criteria for ADHD [ see Clinical Studies (14) ]. A diagnosis of Attention Deficit Hyperactivity Disorder (ADHD; DSM-IV) implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years. The symptoms must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and be present in 2 or more settings, e.g., school (or work) and at home. The symptoms must not be better accounted for by another mental disorder. For the Inattentive Type, at least 6 of the following symptoms must have persisted for at least 6 months: lack of attention to details/careless mistakes; lack of sustained attention; poor listener; failure to follow through on tasks; poor organization; avoids tasks requiring sustained mental effort; loses things; easily distracted; forgetful. For the Hyperactive-Impulsive Type, at least 6 of the following symptoms must have persisted for at least 6 months: fidgeting/squirming; leaving seat; inappropriate running/climbing; difficulty with quiet activities; “on the go”; excessive talking; blurting answers; can’t wait turn; intrusive. The Combined Types requires both inattentive and hyperactive-impulsive criteria to be met. Special Diagnostic Considerations Specific etiology of this syndrome is unknown, and there is no single diagnostic test. Adequate diagnosis requires the use not only of medical but of special psychological, educational, and social resources. Learning may or may not be impaired. The diagnosis must be based upon a complete history and evaluation of the child and not solely on the presence of the required number of DSM-IV characteristics. Need for Comprehensive Treatment Program Dexmethylphenidate hydrochloride extended-release capsules are indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational, social) for patients with this syndrome. Drug treatment may not be indicated for all children with this syndrome. Stimulants are not intended for use in the child who exhibits symptoms secondary to environmental factors and/or other primary psychiatric disorders, including psychosis. Appropriate educational placement is essential and psychosocial intervention is often helpful. When remedial measures alone are insufficient, the decision to prescribe stimulant medication will depend upon the physician’s assessment of the chronicity and severity of the child’s symptoms. Long-Term Use The effectiveness of dexmethylphenidate hydrochloride extended-release capsules for long-term use, i.e., for more than 7 weeks, has not been systematically evaluated in controlled trials. Therefore, the physician who elects to use dexmethylphenidate hydrochloride extended-release capsules for extended periods should periodically reevaluate the long-term usefulness of the drug for the individual patient [ see Dosage and Administration (2.3) ]. CHEMBL.COMPOUND:CHEMBL904 uuid:e57125ce-6dca-483e-8178-3161742fff9e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8310 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:5afa942a-8954-4e23-a3fa-e24f4a0f8fb7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9c20bef3-094d-4dd0-9e72-2d95d37191bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Acute Infections Caused by Susceptible Strains of Pseudomonas aeruginosa. Polymyxin B sulfate is a drug of choice in the treatment of infections of the urinary tract, meninges, and bloodstream caused by susceptible strains of Ps. aeruginosa . It may also be used topically and subconjunctivally in the treatment of infections of the eye caused by susceptible strains of Ps. aeruginosa . It may be indicated in serious infections caused by susceptible strains of the following organisms, when less potentially toxic drugs are ineffective or contraindicated: H influenzae , specifically meningeal infections. Escherichia coli , specifically urinary tract infections. Aerobacter aerogenes , specifically bacteremia. Klebsiella pneumoniae , specifically bacteremia. NOTE: IN MENINGEAL INFECTIONS, POLYMYXIN B SULFATE SHOULD BE ADMINISTERED ONLY BY THE INTRATHECAL ROUTE. To reduce the development of drug-resistant bacteria and maintain the effectiveness of polymyxin B and other antibacterial drugs, polymyxin B should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:059c9492-ef50-4ffe-90f6-74ef0baf8906 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8310 biolink:treats MONDO:0021108 PMID:41385096 "[{""id"":""uuid:6f7143be-16b7-4ed7-81c4-a4e552212595"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ce6f652a-3738-4920-bddd-f0aa9cb2a3f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Acute Infections Caused by Susceptible Strains of Pseudomonas aeruginosa. Polymyxin B sulfate is a drug of choice in the treatment of infections of the urinary tract, meninges, and bloodstream caused by susceptible strains of Ps. aeruginosa . It may also be used topically and subconjunctivally in the treatment of infections of the eye caused by susceptible strains of Ps. aeruginosa . It may be indicated in serious infections caused by susceptible strains of the following organisms, when less potentially toxic drugs are ineffective or contraindicated: H influenzae , specifically meningeal infections. Escherichia coli , specifically urinary tract infections. Aerobacter aerogenes , specifically bacteremia. Klebsiella pneumoniae , specifically bacteremia. NOTE: IN MENINGEAL INFECTIONS, POLYMYXIN B SULFATE SHOULD BE ADMINISTERED ONLY BY THE INTRATHECAL ROUTE. To reduce the development of drug-resistant bacteria and maintain the effectiveness of polymyxin B and other antibacterial drugs, polymyxin B should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:83da5685-c1da-4a0c-94be-4ab95b9435c3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8310 biolink:treats MONDO:0043885 PMID:41385096 "[{""id"":""uuid:67c0a57f-6252-4fb5-83fc-fa09fdc9c4ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f60c93bf-dc3f-4093-b9ff-38050fc78158"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Acute Infections Caused by Susceptible Strains of Pseudomonas aeruginosa. Polymyxin B sulfate is a drug of choice in the treatment of infections of the urinary tract, meninges, and bloodstream caused by susceptible strains of Ps. aeruginosa . It may also be used topically and subconjunctivally in the treatment of infections of the eye caused by susceptible strains of Ps. aeruginosa . It may be indicated in serious infections caused by susceptible strains of the following organisms, when less potentially toxic drugs are ineffective or contraindicated: H influenzae , specifically meningeal infections. Escherichia coli , specifically urinary tract infections. Aerobacter aerogenes , specifically bacteremia. Klebsiella pneumoniae , specifically bacteremia. NOTE: IN MENINGEAL INFECTIONS, POLYMYXIN B SULFATE SHOULD BE ADMINISTERED ONLY BY THE INTRATHECAL ROUTE. To reduce the development of drug-resistant bacteria and maintain the effectiveness of polymyxin B and other antibacterial drugs, polymyxin B should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:e17c63b6-e183-41db-88aa-4ae03ab7ba07 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8310 biolink:treats MONDO:0005229 PMID:41385096 "[{""id"":""uuid:1cb8a530-51c7-4da4-824c-6624ce3fae6b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f51d34a0-d822-497e-9a1c-739902c5caab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Acute Infections Caused by Susceptible Strains of Pseudomonas aeruginosa. Polymyxin B sulfate is a drug of choice in the treatment of infections of the urinary tract, meninges, and bloodstream caused by susceptible strains of Ps. aeruginosa . It may also be used topically and subconjunctivally in the treatment of infections of the eye caused by susceptible strains of Ps. aeruginosa . It may be indicated in serious infections caused by susceptible strains of the following organisms, when less potentially toxic drugs are ineffective or contraindicated: H influenzae , specifically meningeal infections. Escherichia coli , specifically urinary tract infections. Aerobacter aerogenes , specifically bacteremia. Klebsiella pneumoniae , specifically bacteremia. NOTE: IN MENINGEAL INFECTIONS, POLYMYXIN B SULFATE SHOULD BE ADMINISTERED ONLY BY THE INTRATHECAL ROUTE. To reduce the development of drug-resistant bacteria and maintain the effectiveness of polymyxin B and other antibacterial drugs, polymyxin B should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:809d7d99-8ea9-4786-bb4d-57418ced2730 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:25681 biolink:treats MONDO:0004982 PMID:41385096 "[{""id"":""uuid:4be14ab9-3e3d-4fb1-9603-484a76a5711f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2e8a9ef4-83ac-4415-b438-c30f9bc7c306"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Omega-3-acid ethyl esters capsules, USP are indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia (HTG). Patients should be placed on an appropriate lipid-lowering diet before receiving omega-3-acid ethyl esters capsules, USP and should continue this diet during treatment with omega-3-acid ethyl esters capsules, USP. Usage Considerations: Laboratory studies should be done to ascertain that the lipid levels are consistently abnormal before instituting therapy with omega-3-acid ethyl esters capsules, USP. Every attempt should be made to control serum lipids with appropriate diet, exercise, weight loss in obese patients, and control of any medical problems such as diabetes mellitus and hypothyroidism that are contributing to the lipid abnormalities. Medications known to exacerbate hypertriglyceridemia (such as beta blockers, thiazides, estrogens) should be discontinued or changed if possible prior to consideration of triglyceride-lowering drug therapy. Limitations of Use: The effect of omega-3-acid ethyl esters capsules, USP on the risk for pancreatitis has not been determined. The effect of omega-3-acid ethyl esters capsules, USP on cardiovascular mortality and morbidity has not been determined. uuid:0e602290-a316-4985-b0df-93ed49af754f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45285 biolink:treats MONDO:0100481 PMID:41385096 "[{""id"":""uuid:c70363be-7980-45b8-a882-24491fa047a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:50adc894-d141-42e5-bbca-b4cf3c4e92bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pyrazinamide is indicated for the initial treatment of active tuberculosis in adults and children when combined with other antituberculous agents. (The current recommendation of the CDC for drug-susceptible disease is to use a six-month regimen for initial treatment of active tuberculosis, consisting of isoniazid, rifampin and pyrazinamide given for 2 months, followed by isoniazid and rifampin for 4 months. *4 ) (Patients with drug-resistant disease should be treated with regimens individualized to their situation. Pyrazinamide frequently will be an important component of such therapy.) (In patients with concomitant HIV infection, the physician should be aware of current recommendation of CDC. It is possible these patients may require a longer course of treatment). It is also indicated after treatment failure with other primary drugs in any form of active tuberculosis. Pyrazinamide should only be used in conjunction with other effective antituberculous agents. *See recommendations of Center for Disease Control (CDC) and American Thoracic Society for complete regimen and dosage recommendations. 4 uuid:a6c4d67a-5a83-4e9d-8b95-5e07c7b14e54 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45285 biolink:treats MONDO:0005861 PMID:41385096 "[{""id"":""uuid:f368647c-5210-4645-a213-d4efb8c76a80"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7440002a-805f-4784-9397-dacc71169c32"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pyrazinamide is indicated for the initial treatment of active tuberculosis in adults and children when combined with other antituberculous agents. (The current recommendation of the CDC for drug-susceptible disease is to use a six-month regimen for initial treatment of active tuberculosis, consisting of isoniazid, rifampin and pyrazinamide given for 2 months, followed by isoniazid and rifampin for 4 months. *4 ) (Patients with drug-resistant disease should be treated with regimens individualized to their situation. Pyrazinamide frequently will be an important component of such therapy.) (In patients with concomitant HIV infection, the physician should be aware of current recommendation of CDC. It is possible these patients may require a longer course of treatment). It is also indicated after treatment failure with other primary drugs in any form of active tuberculosis. Pyrazinamide should only be used in conjunction with other effective antituberculous agents. *See recommendations of Center for Disease Control (CDC) and American Thoracic Society for complete regimen and dosage recommendations. 4 uuid:45017802-a5b2-4649-9d87-42cba589e9a4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6078 biolink:treats MONDO:0005974 PMID:41385096 "[{""id"":""uuid:5b673447-9b6c-4338-a7c8-f81ae322c81b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0eab850d-a80c-4f9d-825e-914b1999368d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] STROMECTOL is indicated for the treatment of the following infections: Strongyloidiasis of the intestinal tract . STROMECTOL is indicated for the treatment of intestinal (i.e., nondisseminated) strongyloidiasis due to the nematode parasite Strongyloides stercoralis . This indication is based on clinical studies of both comparative and open-label designs, in which 64-100% of infected patients were cured following a single 200-mcg/kg dose of ivermectin. (See CLINICAL PHARMACOLOGY, Clinical Studies .) Onchocerciasis . STROMECTOL is indicated for the treatment of onchocerciasis due to the nematode parasite Onchocerca volvulus . This indication is based on randomized, double-blind, placebo-controlled and comparative studies conducted in 1427 patients in onchocerciasis-endemic areas of West Africa. The comparative studies used diethylcarbamazine citrate (DEC-C). NOTE: STROMECTOL has no activity against adult Onchocerca volvulus parasites. The adult parasites reside in subcutaneous nodules which are infrequently palpable. Surgical excision of these nodules (nodulectomy) may be considered in the management of patients with onchocerciasis, since this procedure will eliminate the microfilariae-producing adult parasites. uuid:2c469869-0827-474a-abd2-786164c78e61 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6078 biolink:treats UMLS:C0348997 PMID:41385096 "[{""id"":""uuid:936fed39-1a7c-496d-b36b-d14bb32f2d5b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:de5e14e7-46ca-4a47-8001-b1f73ae18e03"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] STROMECTOL is indicated for the treatment of the following infections: Strongyloidiasis of the intestinal tract . STROMECTOL is indicated for the treatment of intestinal (i.e., nondisseminated) strongyloidiasis due to the nematode parasite Strongyloides stercoralis . This indication is based on clinical studies of both comparative and open-label designs, in which 64-100% of infected patients were cured following a single 200-mcg/kg dose of ivermectin. (See CLINICAL PHARMACOLOGY, Clinical Studies .) Onchocerciasis . STROMECTOL is indicated for the treatment of onchocerciasis due to the nematode parasite Onchocerca volvulus . This indication is based on randomized, double-blind, placebo-controlled and comparative studies conducted in 1427 patients in onchocerciasis-endemic areas of West Africa. The comparative studies used diethylcarbamazine citrate (DEC-C). NOTE: STROMECTOL has no activity against adult Onchocerca volvulus parasites. The adult parasites reside in subcutaneous nodules which are infrequently palpable. Surgical excision of these nodules (nodulectomy) may be considered in the management of patients with onchocerciasis, since this procedure will eliminate the microfilariae-producing adult parasites. uuid:e25afb2e-72f9-4b89-8c2d-f0fb0dd544e0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6078 biolink:treats MONDO:0017137 PMID:41385096 "[{""id"":""uuid:fc525a71-611c-4bf4-91a4-32d5ef57e6ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6ae6742b-e0af-471a-81d9-e7b128c13f41"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] STROMECTOL is indicated for the treatment of the following infections: Strongyloidiasis of the intestinal tract . STROMECTOL is indicated for the treatment of intestinal (i.e., nondisseminated) strongyloidiasis due to the nematode parasite Strongyloides stercoralis . This indication is based on clinical studies of both comparative and open-label designs, in which 64-100% of infected patients were cured following a single 200-mcg/kg dose of ivermectin. (See CLINICAL PHARMACOLOGY, Clinical Studies .) Onchocerciasis . STROMECTOL is indicated for the treatment of onchocerciasis due to the nematode parasite Onchocerca volvulus . This indication is based on randomized, double-blind, placebo-controlled and comparative studies conducted in 1427 patients in onchocerciasis-endemic areas of West Africa. The comparative studies used diethylcarbamazine citrate (DEC-C). NOTE: STROMECTOL has no activity against adult Onchocerca volvulus parasites. The adult parasites reside in subcutaneous nodules which are infrequently palpable. Surgical excision of these nodules (nodulectomy) may be considered in the management of patients with onchocerciasis, since this procedure will eliminate the microfilariae-producing adult parasites. uuid:c06ca657-7e29-4904-aef1-6ac844ec254d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:473990 biolink:treats MONDO:0005366 PMID:41385096 "[{""id"":""uuid:c4b6393b-6fde-4f4c-b1de-3bc2f349f2e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f0e8576c-aff3-4386-a095-b50a8262a4b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:716eb9e0-31d0-4894-860a-9a76eaff4628"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:63f1d9a3-8a5b-4382-b5e3-91a3e0661a43"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Entecavir tablets are indicated for the treatment of chronic hepatitis B virus infection in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease. The following points should be considered when initiating therapy with Entecavir tablets: In adult patients, this indication is based on clinical trial data in nucleoside-inhibitor-treatment-naïve and lamivudine-resistant subjects with HBeAg-positive and HBeAg-negative HBV infection and compensated liver disease and a more limited number of subjects with decompensated liver disease [see Clinical Studies (14.1) ]. Pediatric use information is approved for Bristol-Myers Squibb Company’s Baraclude (entecavir) tablets. However, due to Bristol-Myers Squibb Company’s marketing exclusivity rights, this drug product is not labeled with that information.|[EMA] Entecavir Mylan is indicated for the treatment of chronic hepatitis B virus (HBV) infection in adults with:compensated liver disease and evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active inflammation and/or fibrosis.decompensated liver disease.For both compensated and decompensated liver disease, this indication is based on clinical trial data in nucleoside naive patients with HBeAg positive and HBeAg negative HBV infection. With respect to patients with lamivudine-refractory hepatitis B.Entecavir Mylan is also indicated for the treatment of chronic HBV infection in nucleoside naive paediatric patients from 2 to|[PMDA] Drug containing a new active ingredient indicated for use to improve levels of viral marker, liver function, and the histology of the liver affected by chronic hepatitis B in patients with evidence of hepatitis B virus replication and associated abnormal liver function. [Priority Review] uuid:4d7d626d-725b-4785-a14b-76bc09b26455 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:473990 biolink:treats UMLS:C3839044 PMID:41385096 "[{""id"":""uuid:d6cf2576-de01-42a5-9f24-49b51959fcdd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:289b7eb5-858c-473f-aea3-d87aeff60f40"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Entecavir tablets are indicated for the treatment of chronic hepatitis B virus infection in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease. The following points should be considered when initiating therapy with Entecavir tablets: In adult patients, this indication is based on clinical trial data in nucleoside-inhibitor-treatment-naïve and lamivudine-resistant subjects with HBeAg-positive and HBeAg-negative HBV infection and compensated liver disease and a more limited number of subjects with decompensated liver disease [see Clinical Studies (14.1) ]. Pediatric use information is approved for Bristol-Myers Squibb Company’s Baraclude (entecavir) tablets. However, due to Bristol-Myers Squibb Company’s marketing exclusivity rights, this drug product is not labeled with that information. uuid:e79fe378-6cad-46b4-966d-863140949bc1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:473990 biolink:treats MONDO:0100192 PMID:41385096 "[{""id"":""uuid:3cb3fb96-cb28-4cbe-a5fb-30b0b04445fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:1184ef19-213d-496b-a430-f4fafcf13b37"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:a5f73f85-e831-4a62-ba76-aa703a58d7bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Entecavir tablets are indicated for the treatment of chronic hepatitis B virus infection in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease. The following points should be considered when initiating therapy with Entecavir tablets: In adult patients, this indication is based on clinical trial data in nucleoside-inhibitor-treatment-naïve and lamivudine-resistant subjects with HBeAg-positive and HBeAg-negative HBV infection and compensated liver disease and a more limited number of subjects with decompensated liver disease [see Clinical Studies (14.1) ]. Pediatric use information is approved for Bristol-Myers Squibb Company’s Baraclude (entecavir) tablets. However, due to Bristol-Myers Squibb Company’s marketing exclusivity rights, this drug product is not labeled with that information.|[EMA] Entecavir Mylan is indicated for the treatment of chronic hepatitis B virus (HBV) infection in adults with:compensated liver disease and evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active inflammation and/or fibrosis.decompensated liver disease.For both compensated and decompensated liver disease, this indication is based on clinical trial data in nucleoside naive patients with HBeAg positive and HBeAg negative HBV infection. With respect to patients with lamivudine-refractory hepatitis B.Entecavir Mylan is also indicated for the treatment of chronic HBV infection in nucleoside naive paediatric patients from 2 to uuid:311e660a-0c18-46ea-9ebc-b77b98c80729 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15940 biolink:treats MONDO:0004982 PMID:41385096 "[{""id"":""uuid:ebfe78a3-b8de-4396-9a0f-b9414492ce89"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2f2fb182-23c9-4852-99e8-8ca94002fc1b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hyperlipidemia. Niacin therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. Niacin extended-release tablets are indicated to reduce elevated TC, LDL-C, Apo B and TG levels, and to increase HDL-C in patients with primary hyperlipidemia and mixed dyslipidemia. In patients with a history of myocardial infarction and hyperlipidemia, niacin is indicated to reduce the risk of recurrent nonfatal myocardial infarction. In patients with a history of coronary artery disease (CAD) and hyperlipidemia, niacin, in combination with a bile acid binding resin, is indicated to slow progression or promote regression of atherosclerotic disease. Niacin extended-release tablets in combination with a bile acid binding resin is indicated to reduce elevated TC and LDL-C levels in adult patients with primary hyperlipidemia. Niacin is also indicated as adjunctive therapy for treatment of adult patients with severe hypertriglyceridemia who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Limitations of Use Addition of niacin extended-release tablets did not reduce cardiovascular morbidity or mortality among patients treated with simvastatin in a large, randomized controlled trial (AIM-HIGH) [see Warnings and Precautions (5.1) ] . uuid:e3af34f8-0536-4516-82aa-5af33f98834b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:72564 biolink:treats MONDO:0018177 PMID:41385096 "[{""id"":""uuid:86f3deb5-b3bd-4ea9-8a12-fae570eb078a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:15c25de6-cfa7-4388-810a-d3bf02bef583"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:d48e5ec7-74a5-418a-acaa-718c14ceca87"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/temozolomide-accord""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Temozolomide is an alkylating drug indicated for the treatment of adult patients with: Newly diagnosed glioblastoma multiforme (GBM) concomitantly with radiotherapy and then as maintenance treatment. ( 1.1 ) Refractory anaplastic astrocytoma patients who have experienced disease progression on a drug regimen containing nitrosourea and procarbazine. ( 1.2 )|[EMA] For the treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy (RT) and subsequently as monotherapy treatment.For the treatment of children from the age of three years, adolescents and adult patients with malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy. uuid:6cda5582-a3bb-40a4-90c2-7e13ba7c12ad biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:72564 biolink:treats MONDO:0016684 PMID:41385096 "[{""id"":""uuid:3157860c-92e1-44c8-ab53-a36ee2200d8f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:eaef0588-d4cb-42ba-8654-d2ba8765faf6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:60e844a3-f186-4977-84b0-180f1307c099"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/temozolomide-accord""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Temozolomide is an alkylating drug indicated for the treatment of adult patients with: Newly diagnosed glioblastoma multiforme (GBM) concomitantly with radiotherapy and then as maintenance treatment. ( 1.1 ) Refractory anaplastic astrocytoma patients who have experienced disease progression on a drug regimen containing nitrosourea and procarbazine. ( 1.2 )|[EMA] For the treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy (RT) and subsequently as monotherapy treatment.For the treatment of children from the age of three years, adolescents and adult patients with malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy. uuid:423992b2-a4ea-418f-ae7b-670785eae9af biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:24847800 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:66ed3f3b-d394-4f5c-aee0-9720cbd33b9c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:baa5298d-74a0-477d-be49-bb65366eb8b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nadolol and bendroflumethiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the classes to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with nadolol and bendroflumethiazide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Nadolol and bendroflumethiazide tablets are not indicated for initial therapy of hypertension. If the fixed combination represents the dose titrated to the individual patient's needs, it may be more convenient than the separate components. uuid:6a23e31d-3c61-4d94-8107-2966e94b04aa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:24847800 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:e8b3ec28-88e2-453a-bc67-1e2e8960eff1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0ad78d73-7b5b-4a4f-8f87-f4c77cbbeac3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nadolol and bendroflumethiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the classes to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with nadolol and bendroflumethiazide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Nadolol and bendroflumethiazide tablets are not indicated for initial therapy of hypertension. If the fixed combination represents the dose titrated to the individual patient's needs, it may be more convenient than the separate components. uuid:c820e438-bac4-4c06-8387-acb214f73e31 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:24847800 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:657c6281-9317-4069-ae90-1c27c45c0d63"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ebe4fdcf-e2ad-47a9-a2f4-13514b99ade8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nadolol and bendroflumethiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the classes to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with nadolol and bendroflumethiazide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Nadolol and bendroflumethiazide tablets are not indicated for initial therapy of hypertension. If the fixed combination represents the dose titrated to the individual patient's needs, it may be more convenient than the separate components. uuid:ca9f7e2a-b756-410f-943e-6d449f338fd9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:24847800 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:40cbb0c6-c452-43cf-af60-ad247a3eb4de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dd7f360d-c643-4d6f-b28b-6c69a524aae8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nadolol and bendroflumethiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the classes to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with nadolol and bendroflumethiazide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Nadolol and bendroflumethiazide tablets are not indicated for initial therapy of hypertension. If the fixed combination represents the dose titrated to the individual patient's needs, it may be more convenient than the separate components. uuid:d2f61aa9-a31e-4f53-97c7-35651f92cee2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:24847800 biolink:treats MONDO:0005016 PMID:41385096 "[{""id"":""uuid:75377ec8-2b2d-4052-bf98-9421d16d08e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:34c22619-7461-4aa5-ae8d-86bbfef96ccf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nadolol and bendroflumethiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the classes to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with nadolol and bendroflumethiazide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Nadolol and bendroflumethiazide tablets are not indicated for initial therapy of hypertension. If the fixed combination represents the dose titrated to the individual patient's needs, it may be more convenient than the separate components. uuid:d407463d-2e39-4398-ba58-1524181e4c34 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5127 biolink:treats MONDO:0005093 PMID:41385096 "[{""id"":""uuid:89fc58f3-0359-4f6a-b4e0-9487930666f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:04aa36b5-e9fd-417a-bf5e-aabe5e11c817"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Flurandrenolide Cream is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. uuid:4cd5eb21-ee4d-4c8b-9408-d1a73b15e448 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7934 biolink:treats MONDO:0005644 PMID:41385096 "[{""id"":""uuid:99b2d8cb-8918-4a4b-a61a-95dceded8276"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a5a17a8c-25ae-4cdb-a86a-8c9afddbf679"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Paromomycin sulfate is indicated for intestinal amebiasis–acute and chronic (NOTE-It is not effective in extraintestinal amebiasis); management of hepatic coma–as adjunctive therapy. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Paromomycin Sulfate Capsules and other antibacterial drugs, Paromomycin Sulfate Capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:5d2553c6-532e-4bbf-a0ee-6214ad8203e8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7934 biolink:treats MONDO:0001548 PMID:41385096 "[{""id"":""uuid:bed5ac85-05bc-4f39-9767-c66eac8d02f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5926332b-e1a3-474c-ae6e-6a6a8bd4beec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Paromomycin sulfate is indicated for intestinal amebiasis–acute and chronic (NOTE-It is not effective in extraintestinal amebiasis); management of hepatic coma–as adjunctive therapy. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Paromomycin Sulfate Capsules and other antibacterial drugs, Paromomycin Sulfate Capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:78294294-9f13-4352-aa1e-a7d4ec0c5a22 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:1D1822L42I biolink:treats HP:0002153 PMID:41385096 "[{""id"":""uuid:a99ff597-00f6-4608-96b3-7be0803879a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:24fabc10-e36a-46af-b51c-099d1f207d2c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Polystyrene Sulfonate, USP is indicated for the treatment of hyperkalemia. uuid:a085dc1d-3e54-4fa4-bed7-573ebd0a8148 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46081 biolink:treats MONDO:0005886 PMID:41385096 "[{""id"":""uuid:bb027e01-ff99-489e-8643-f0e08a6b5a8f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cadbd0fb-a00e-448e-a1e8-aa32a896b5c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fluconazole is indicated for the treatment of: Vaginal candidiasis (vaginal yeast infections due to ). Candida Oropharyngeal and esophageal candidiasis. In open noncomparative studies of relatively small numbers of patients, fluconazole was also effective for the treatment of urinary tract infections, peritonitis, and systemic infections including candidemia, disseminated candidiasis, and pneumonia. Candida Candida Cryptococcal meningitis. Before prescribing fluconazole for AIDS patients with cryptococcal meningitis, please see section. Studies comparing fluconazole to amphotericin B in non-HIV infected patients have not been conducted. CLINICAL STUDIES uuid:b3cbb6c4-df97-45f5-8d6f-acbd317fbbc9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46081 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:74e48e8d-f910-4754-9040-0d6b1e643e53"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:52284308-3216-44bb-be38-8899deede5da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fluconazole is indicated for the treatment of: Vaginal candidiasis (vaginal yeast infections due to ). Candida Oropharyngeal and esophageal candidiasis. In open noncomparative studies of relatively small numbers of patients, fluconazole was also effective for the treatment of urinary tract infections, peritonitis, and systemic infections including candidemia, disseminated candidiasis, and pneumonia. Candida Candida Cryptococcal meningitis. Before prescribing fluconazole for AIDS patients with cryptococcal meningitis, please see section. Studies comparing fluconazole to amphotericin B in non-HIV infected patients have not been conducted. CLINICAL STUDIES uuid:7a17cc9d-336d-4809-8cb2-3ad596dff952 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB11601 biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:1aa479b4-b752-408b-88d2-4562a99748a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:846a9015-5911-4549-88c5-eb8333bb151d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tuberculin PPD is indicated as an aid in the detection of infection with . The standard tuberculin test employs the intradermal (Mantoux) test using a 5 TU dose of tuberculin PPD. The 0.1 mL test dose of Aplisol (tuberculin PPD, diluted) is equivalent to the 5 TU dose which has been clinically utilized and standardized with PPD-S. Tuberculin skin testing is not contraindicated for persons who have been vaccinated with BCG and the skin-test results of such persons are used to support or exclude the diagnosis of infections. HIV infection is a strong risk factor for the development of TB disease in persons having TB infection. All HIV-infected persons should receive a PPD-tuberculin skin test. Mycobacterium tuberculosis 7 M. tuberculosis 4 3 uuid:7e3b8365-91ee-4a44-b244-da6cd2daa204 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0008109 PMID:41385096 "[{""id"":""uuid:48aed40e-cbca-4dcd-bfd3-027e84a16e72"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:034bfe37-16e1-4c86-bc4f-3497853dcf0a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of Methylprednisolone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:aa766f34-ecaa-4ebf-ab96-26fe9ff7b94b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7551 biolink:treats UMLS:C0577698 PMID:41385096 "[{""id"":""uuid:5c19e1d5-b543-4757-b37d-c61574f0f607"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0cad67f2-ec55-4e4a-9721-c0fbba455f88"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nicardipine hydrochloride capsules are indicated for the management of patients with chronic stable angina (effort-associated angina). They may be used alone or in combination with beta-blockers. uuid:ea455a3e-761b-45d1-9f59-be1cccdc1bbf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8768 biolink:treats MONDO:0006896 PMID:41385096 "[{""id"":""uuid:d2906789-3e23-45df-b9eb-cda4815367f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e516b743-d762-4856-a458-6af35c9c82a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:4cfc274f-1c61-42d3-b29c-1f7a16e5fe99"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ACIPHEX delayed-release tablets is a proton-pump inhibitor (PPI) indicated in adults for: Healing of Erosive or Ulcerative Gastroesophageal Reflux Disease (GERD) ( 1.1 ). Maintenance of Healing of Erosive or Ulcerative GERD ( 1.2 ). Treatment of Symptomatic GERD ( 1.3 ). Healing of Duodenal Ulcers ( 1.4 ). Helicobacter pylori Eradication to Reduce Risk of Duodenal Ulcer Recurrence ( 1.5 ). Treatment of Pathological Hypersecretory Conditions, Including Zollinger-Ellison Syndrome ( 1.6 ). In adolescent patients 12 years of age and older for: Short-term Treatment of Symptomatic GERD ( 1.7 ).|[PMDA] Drugs with a new dosage indicated for the treatment of reflux esophagitis. uuid:faec6268-91d2-4b80-a03c-5d492cb4bad6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8768 biolink:treats MONDO:0005412 PMID:41385096 "[{""id"":""uuid:f789f43c-7d71-4f1f-8337-15cc233189ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ae85450d-7be3-428b-b17a-e42e3161c858"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:b785ea0f-6f35-4885-9f36-22f3e1ff3239"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ACIPHEX delayed-release tablets is a proton-pump inhibitor (PPI) indicated in adults for: Healing of Erosive or Ulcerative Gastroesophageal Reflux Disease (GERD) ( 1.1 ). Maintenance of Healing of Erosive or Ulcerative GERD ( 1.2 ). Treatment of Symptomatic GERD ( 1.3 ). Healing of Duodenal Ulcers ( 1.4 ). Helicobacter pylori Eradication to Reduce Risk of Duodenal Ulcer Recurrence ( 1.5 ). Treatment of Pathological Hypersecretory Conditions, Including Zollinger-Ellison Syndrome ( 1.6 ). In adolescent patients 12 years of age and older for: Short-term Treatment of Symptomatic GERD ( 1.7 ).|[PMDA] A drug with a new additional indication and a new dosage in a newly-added dosage form, and a drug with a new additional indication and a new dosage for the prevention of recurrence of gastric ulcer or duodenal ulcer in patients treated with low-dose aspirin. uuid:6d0fda2d-8e98-424e-aa21-4c289092a2e9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:36795 biolink:treats UMLS:C0740447 PMID:41385096 "[{""id"":""uuid:f4787839-2c76-4df9-9db3-13f9b683a858"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:12c05316-6a60-490c-8bc9-9fa680feb4c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CYMBALTA ® is indicated for the treatment of: Major Depressive Disorder [see Clinical Studies ( 14.1 )] Generalized Anxiety Disorder [see Clinical Studies ( 14.2 )] Diabetic Peripheral Neuropathy [see Clinical Studies ( 14.3 )] Fibromyalgia [see Clinical Studies ( 14.4 )] Chronic Musculoskeletal Pain [see Clinical Studies ( 14.5 )] uuid:f96add5b-06df-4a0b-b802-7ca17485ca2f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0005301 PMID:41385096 "[{""id"":""uuid:78994744-957d-4fcf-a51f-82d507108f31"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c2bdb210-e61a-437c-9cc1-ca93861eb972"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydrocortisone tablets are indicated in the following conditions. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis Collagen Disease During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Nervous System Acute exacerbations of multiple sclerosis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:75f0355d-6db6-424a-9bb1-8b4f1678054e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:9YCX42I8IU biolink:treats MONDO:0000328 PMID:41385096 "[{""id"":""uuid:c6f8748a-08e7-4ff0-9c8d-f47c7d09b667"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:af2b6c81-9391-43d7-b790-7d6427fdefc3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Renvela ® (sevelamer carbonate) is indicated for the control of serum phosphorus in patients with chronic kidney disease (CKD) on dialysis. uuid:9c753630-d581-44a1-a5df-914e380bf000 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31236 biolink:treats MONDO:0007661 PMID:41385096 "[{""id"":""uuid:b4b41230-d9cc-4b13-9572-b0f21c59dc9d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b32880d5-6aed-45d1-96b7-3f24b4bf1c3d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ABILIFY Oral Tablets, Orally-Disintegrating Tablets, and Oral Solution are indicated for the treatment of: • Schizophrenia [see CLINICAL STUDIES (14.1) ] • Acute Treatment of Manic and Mixed Episodes associated with Bipolar I Disorder [see CLINICAL STUDIES (14.2) ] • Adjunctive Treatment of Major Depressive Disorder [see CLINICAL STUDIES (14.3) ] • Irritability Associated with Autistic Disorder [see CLINICAL STUDIES (14.4) ] • Treatment of Tourette’s Disorder [see CLINICAL STUDIES (14.5) ] ABILIFY Injection is indicated for the treatment of: • Agitation associated with schizophrenia or bipolar mania [see CLINICAL STUDIES (14.6) ] uuid:ac9e0e15-f6f7-4f2c-a868-a4517e4e1ced biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31236 biolink:treats HP:0100754 PMID:41385096 "[{""id"":""uuid:ce918822-6cbf-4d93-a436-ee37e6f8edf3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ff7d3292-2754-40f9-a1af-4f283bdc3114"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ABILIFY Oral Tablets, Orally-Disintegrating Tablets, and Oral Solution are indicated for the treatment of: • Schizophrenia [see CLINICAL STUDIES (14.1) ] • Acute Treatment of Manic and Mixed Episodes associated with Bipolar I Disorder [see CLINICAL STUDIES (14.2) ] • Adjunctive Treatment of Major Depressive Disorder [see CLINICAL STUDIES (14.3) ] • Irritability Associated with Autistic Disorder [see CLINICAL STUDIES (14.4) ] • Treatment of Tourette’s Disorder [see CLINICAL STUDIES (14.5) ] ABILIFY Injection is indicated for the treatment of: • Agitation associated with schizophrenia or bipolar mania [see CLINICAL STUDIES (14.6) ] uuid:f402f57d-8390-47c8-ab68-5133f817daf8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9588 biolink:treats UMLS:C0242129 PMID:41385096 "[{""id"":""uuid:df0cf3dc-44bf-43c3-9d74-9045faecfa5f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e31324ec-3d08-468f-8aaf-8446b256de46"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ticlopidine Hydrochloride Tablets USP are indicated: to reduce the risk of thrombotic stroke (fatal or nonfatal) in patients who have experienced stroke precursors, and in patients who have had a completed thrombotic stroke. Because ticlopidine is associated with a risk of life-threatening blood dyscrasias including thrombotic thrombocytopenic purpura (TTP), neutropenia/agranulocytosis and aplastic anemia (see and ), ticlopidine should be reserved for patients who are intolerant or allergic to aspirin therapy or who have failed aspirin therapy. BOXED WARNING WARNINGS as adjunctive therapy with aspirin to reduce the incidence of subacute stent thrombosis in patients undergoing successful coronary stent implantation (see ). CLINICAL TRIALS uuid:7a46ea53-9a8b-470b-bd05-b37d29f34475 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9588 biolink:treats MONDO:0018896 PMID:41385096 "[{""id"":""uuid:4bfec3f8-b102-414c-baf3-e23cc8fb6ef2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e68430cf-aad7-4643-8169-37873f6747f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ticlopidine Hydrochloride Tablets USP are indicated: to reduce the risk of thrombotic stroke (fatal or nonfatal) in patients who have experienced stroke precursors, and in patients who have had a completed thrombotic stroke. Because ticlopidine is associated with a risk of life-threatening blood dyscrasias including thrombotic thrombocytopenic purpura (TTP), neutropenia/agranulocytosis and aplastic anemia (see and ), ticlopidine should be reserved for patients who are intolerant or allergic to aspirin therapy or who have failed aspirin therapy. BOXED WARNING WARNINGS as adjunctive therapy with aspirin to reduce the incidence of subacute stent thrombosis in patients undergoing successful coronary stent implantation (see ). CLINICAL TRIALS uuid:7187f11e-e3e4-48de-8201-41ac8e8123d1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9588 biolink:treats MONDO:0015909 PMID:41385096 "[{""id"":""uuid:90b67dec-e8d2-44b0-a696-36b7e474f2f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5d168a95-06d9-4333-b3fd-912626096903"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ticlopidine Hydrochloride Tablets USP are indicated: to reduce the risk of thrombotic stroke (fatal or nonfatal) in patients who have experienced stroke precursors, and in patients who have had a completed thrombotic stroke. Because ticlopidine is associated with a risk of life-threatening blood dyscrasias including thrombotic thrombocytopenic purpura (TTP), neutropenia/agranulocytosis and aplastic anemia (see and ), ticlopidine should be reserved for patients who are intolerant or allergic to aspirin therapy or who have failed aspirin therapy. BOXED WARNING WARNINGS as adjunctive therapy with aspirin to reduce the incidence of subacute stent thrombosis in patients undergoing successful coronary stent implantation (see ). CLINICAL TRIALS uuid:0e545d7b-0ca2-4396-bf9f-326a1dd789a0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9588 biolink:treats NCIT:C123441 PMID:41385096 "[{""id"":""uuid:d9993187-1efc-4d7b-85f3-0a090803a1d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ea2459ec-7508-4596-9f75-7721dc2afb51"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ticlopidine Hydrochloride Tablets USP are indicated: to reduce the risk of thrombotic stroke (fatal or nonfatal) in patients who have experienced stroke precursors, and in patients who have had a completed thrombotic stroke. Because ticlopidine is associated with a risk of life-threatening blood dyscrasias including thrombotic thrombocytopenic purpura (TTP), neutropenia/agranulocytosis and aplastic anemia (see and ), ticlopidine should be reserved for patients who are intolerant or allergic to aspirin therapy or who have failed aspirin therapy. BOXED WARNING WARNINGS as adjunctive therapy with aspirin to reduce the incidence of subacute stent thrombosis in patients undergoing successful coronary stent implantation (see ). CLINICAL TRIALS uuid:26fdc3d0-4bc4-4050-81a8-e311a6b75e4a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8214 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:af446c04-8714-4376-bb9b-41a20403bb75"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:42c8bcdb-b29b-4d43-83a5-2cd1d8832b21"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pindolol tablets are indicated in the management of hypertension. It may be used alone or concomitantly with other antihypertensive agents, particularly with a thiazide-type diuretic. uuid:b440de7c-b4a4-48ad-a40e-83f72de3459b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3347 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:f9c4bded-4be7-4c0f-8a51-3c8fb71aa13b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4d60fd9c-2957-4b5c-bb06-df4e51697d9d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:a6a8af4d-983d-4866-8fcd-be10f223931b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Candesartan cilexetil tablets are an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension in adults and children 1 to <17 years of age, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions (1.1) . • Treatment of heart failure (NYHA class II-IV); candesartan cilexetil tablets reduce cardiovascular death and heart failure hospitalization (1.2) .|[PMDA] Drugs with a new additional pediatric dosage indicated for the treatment of hypertension. [Public knowledge-based application after preliminary assessment by the Pharmaceutical Affairs and Food Sanitation Council (PAFSC)] uuid:c4726045-6850-4720-9beb-06c1d9d90771 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3347 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:742d0cb4-e9db-442a-be76-3189e5f2bb31"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b516cb8f-6f5d-41c5-a9a4-e6b6306253e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Candesartan cilexetil tablets are an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension in adults and children 1 to <17 years of age, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions (1.1) . • Treatment of heart failure (NYHA class II-IV); candesartan cilexetil tablets reduce cardiovascular death and heart failure hospitalization (1.2) . uuid:00a6590c-aa8c-4992-96ca-1d2f2c7f5938 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6367 biolink:treats MONDO:0006710 PMID:41385096 "[{""id"":""uuid:42f0ba78-73b6-422d-8635-1cbf6f852905"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4ef951ed-d4b2-4fb0-8641-6585fb38d906"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lamotrigine tablets (chewable, dispersible) are indicated for: Epilepsy—adjunctive therapy in patients aged 2 years and older: • partial-onset seizures. • primary generalized tonic-clonic seizures. • generalized seizures of Lennox-Gastaut syndrome. ( 1.1 ) Epilepsy—monotherapy in patients aged 16 years and older: Conversion to monotherapy in patients with partial-onset seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single AED. ( 1.1 ) Bipolar disorder: Maintenance treatment of bipolar I disorder to delay the time to occurrence of mood episodes in patients treated for acute mood episodes with standard therapy. ( 1.2 ) Limitations of Use: Treatment of acute manic or mixed episodes is not recommended. Effectiveness of lamotrigine tablets (chewable, dispersible) in the acute treatment of mood episodes has not been established. uuid:9b475c95-9603-4eef-bc91-2f640dcb92d8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:46878853 biolink:treats UMLS:C0342879 PMID:41385096 "[{""id"":""uuid:e17af0b4-7887-44b8-9fa7-37772952b695"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:de5d0ce1-d76d-4b20-bbfc-642d95c74bfc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fenofibrate tablets for oral use are a peroxisome proliferator receptor alpha (PPARα) activator indicated as an adjunct to diet: To reduce elevated LDL-C, Total-C, TG and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia (1.1) . For treatment of adult patients with severe hypertriglyceridemia (1.2) . Important Limitations of Use: Fenofibrate was not shown to reduce coronary heart disease morbidity and mortality in patients with type 2 diabetes mellitus (5.1) . uuid:072e86d6-6b5e-4204-9082-dc93fc68b61e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3347 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:a4f575c5-fc04-44e3-bfde-6bd2e1284351"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:82e3dcf1-7e93-4d80-a49f-2b3dfeca6eaa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ATACAND is an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension in adults and children 1 to < 17 years of age, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions (1.1) . • Treatment of heart failure (NYHA class II-IV); ATACAND reduces cardiovascular death and heart failure hospitalization (1.2) . uuid:b9b42997-8faf-4d4e-aeb3-fe2efb4ac9a4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3347 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:1597ae33-3046-4c59-a9a3-d0d23bfd81b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8515553c-6c11-4718-bf8c-34f3c9384dc5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ATACAND is an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension in adults and children 1 to < 17 years of age, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions (1.1) . • Treatment of heart failure (NYHA class II-IV); ATACAND reduces cardiovascular death and heart failure hospitalization (1.2) . uuid:e176a749-a24a-4fa5-ab40-353bf1cec74a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:51041 biolink:treats MONDO:0007079 PMID:41385096 "[{""id"":""uuid:3a9e7d93-477f-4ad8-9aaa-f3e3b3c10ee2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4a57b1f2-a8bc-4aa2-8934-fa7ffce69094"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:85def959-6ecf-4e82-9b47-d63d2bc9c489"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Campral® is indicated for the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation. Treatment with Campral should be part of a comprehensive management program that includes psychosocial support. The efficacy of Campral in promoting abstinence has not been demonstrated in subjects who have not undergone detoxification and not achieved alcohol abstinence prior to beginning Campral treatment. The efficacy of Campral in promoting abstinence from alcohol in polysubstance abusers has not been adequately assessed.|[PMDA] A drug with a new active ingredient indicated for use as an aid for maintenance of abstinence in patients with alcohol dependence. uuid:5066b37a-5873-4db8-a7c0-59259b1b440f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:42797 biolink:treats MONDO:0005609 PMID:41385096 "[{""id"":""uuid:bf28c2e5-0ef5-4ee4-b82f-5e2df6332363"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:97ddfc78-512c-4fdc-8b31-090ed38858ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Gabapentin Tablets, USP Read the Medication Guide before you start taking gabapentin and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or treatment. What is the most important information I should know about gabapentin? Do not stop taking gabapentin without first talking to your healthcare provider. Stopping gabapentin suddenly can cause serious problems. Gabapentin can cause serious side effects including: 1. Like other antiepileptic drugs, gabapentin may cause suicidal thoughts or actions in a very small number of people, about 1 in 500. Call a healthcare provider right away if you have any of these symptoms, especially if they are new, worse, or worry you: thoughts about suicide or dying attempts to commit suicide new or worse depression new or worse anxiety feeling agitated or restless panic attacks trouble sleeping (insomnia) new or worse irritability acting aggressive, being angry, or violent acting on dangerous impulses an extreme increase in activity and talking (mania) other unusual changes in behavior or mood How can I watch for early symptoms of suicidal thoughts and actions? Pay attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or feelings. Keep all follow-up visits with your healthcare provider as scheduled. Call your healthcare provider between visits as needed, especially if you are worried about symptoms. Do not stop taking gabapentin without first talking to a healthcare provider. Stopping gabapentin suddenly can cause serious problems. Stopping a seizure medicine suddenly in a patient who has epilepsy can cause seizures that will not stop (status epilepticus). Suicidal thoughts or actions can be caused by things other than medicines. If you have suicidal thoughts or actions, your healthcare provider may check for other causes. 2. Changes in behavior and thinking - Using gabapentin in children 3 to 12 years of age can cause emotional changes, aggressive behavior, problems with concentration, restlessness, changes in school performance, and hyperactivity. What is gabapentin? Gabapentin is a prescription medicine used to treat: Pain from damaged nerves (postherpetic pain) that follows healing of shingles (a painful rash that comes after a herpes zoster infection) in adults. Partial seizures when taken together with other medicines in adults and children 3 years of age and older. Who should not take gabapentin? Do not take gabapentin if you are allergic to gabapentin or any of the other ingredients in gabapentin. See the end of this Medication Guide for a complete list of ingredients in gabapentin. What should I tell my healthcare provider before taking gabapentin? Before taking gabapentin, tell your healthcare provider if you: have or have had kidney problems or are on hemodialysis have or have had depression, mood problems, or suicidal thoughts or behavior are pregnant or plan to become pregnant. It is not known if gabapentin can harm your unborn baby. Tell your healthcare provider right away if you become pregnant while taking gabapentin. You and your healthcare provider will decide if you should take gabapentin while you are pregnant. If you become pregnant while taking gabapentin, talk to your healthcare provider about registering with the North American Antiepileptic Drug (NAAED) Pregnancy Registry. The purpose of this registry is to collect information about the safety of antiepileptic drugs during pregnancy. You can enroll in this registry by calling 1-888-233-2334. are breastfeeding or plan to breastfeed. Gabapentin can pass into breast milk. You and your healthcare provider should decide how you will feed your baby while you take gabapentin. Tell your healthcare provider about all the medicines you take , including prescription and non-prescription medicines, vitamins, and herbal supplements. Taking gabapentin with certain other medicines can cause side effects or affect how well they work. Do not start or stop other medicines without talking to your healthcare provider. Know the medicines you take. Keep a list of them and show it to your healthcare provider and pharmacist when you get a new medicine. How should I take gabapentin? Take gabapentin exactly as prescribed. Your healthcare provider will tell you how much gabapentin to take. Do not change your dose of gabapentin without talking to your healthcare provider. If you break a tablet in half the unused half of the tablet should be taken at your next scheduled dose. Half tablets not used within several days of breaking should be thrown away. Gabapentin can be taken with or without food. If you take an antacid containing aluminum and magnesium, such as Maalox®, Mylanta®, Gelusil®, Gaviscon®, or Di-Gel®, you should wait at least 2 hours before taking your next dose of gabapentin. If you take too much gabapentin, call your healthcare provider or your local Poison Control Center right away. What should I avoid while taking gabapentin? Do not drink alcohol or take other medicines that make you sleepy or dizzy while taking gabapentin without first talking with your healthcare provider. Taking gabapentin with alcohol or drugs that cause sleepiness or dizziness may make your sleepiness or dizziness worse. Do not drive, operate heavy machinery, or do other dangerous activities until you know how gabapentin affects you. Gabapentin can slow your thinking and motor skills. What are the possible side effects of gabapentin? See ""What is the most important information I should know about gabapentin?"" The most common side effects of gabapentin include: dizziness lack of coordination viral infection feeling drowsy feeling tired fever jerky movements difficulty with speaking temporary loss of memory (amnesia) tremor difficulty with coordination double vision unusual eye movement Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of gabapentin. For more information, ask your healthcare provider or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. How should I store gabapentin? Store gabapentin tablets at 20° to 25°C (68° to 77°F). [See USP controlled room temperature]. Keep gabapentin and all medicines out of the reach of children. General information about the safe and effective use of gabapentin Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use gabapentin for a condition for which it was not prescribed. Do not give gabapentin to other people, even if they have the same symptoms that you have. It may harm them. This Medication Guide summarizes the most important information about gabapentin. If you would like more information, talk with your healthcare provider. You can ask your healthcare provider or pharmacist for information about gabapentin that was written for healthcare professionals. For more information about gabapentin tablets, or to report side effects regarding gabapentin tablets, please call Exelan Pharmaceuticals Inc. at 1-855-295-7455. What are the ingredients in gabapentin Tablets? Active ingredient: Gabapentin, USP Inactive ingredients: Mannitol, Hydroxypropyl Cellulose, Crospovidone, Talc, Magnesium Stearate and Aquarius® BP18114 Cool Vanilla." uuid:f63207b8-3def-4345-a7c5-17991f11a593 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:42797 biolink:treats MONDO:0002125 PMID:41385096 "[{""id"":""uuid:a67bc68f-f5df-4a66-991e-39c92b30fc9a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:384325bf-57ae-4a8a-b880-d3d5e758efb6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Gabapentin Tablets, USP Read the Medication Guide before you start taking gabapentin and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or treatment. What is the most important information I should know about gabapentin? Do not stop taking gabapentin without first talking to your healthcare provider. Stopping gabapentin suddenly can cause serious problems. Gabapentin can cause serious side effects including: 1. Like other antiepileptic drugs, gabapentin may cause suicidal thoughts or actions in a very small number of people, about 1 in 500. Call a healthcare provider right away if you have any of these symptoms, especially if they are new, worse, or worry you: thoughts about suicide or dying attempts to commit suicide new or worse depression new or worse anxiety feeling agitated or restless panic attacks trouble sleeping (insomnia) new or worse irritability acting aggressive, being angry, or violent acting on dangerous impulses an extreme increase in activity and talking (mania) other unusual changes in behavior or mood How can I watch for early symptoms of suicidal thoughts and actions? Pay attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or feelings. Keep all follow-up visits with your healthcare provider as scheduled. Call your healthcare provider between visits as needed, especially if you are worried about symptoms. Do not stop taking gabapentin without first talking to a healthcare provider. Stopping gabapentin suddenly can cause serious problems. Stopping a seizure medicine suddenly in a patient who has epilepsy can cause seizures that will not stop (status epilepticus). Suicidal thoughts or actions can be caused by things other than medicines. If you have suicidal thoughts or actions, your healthcare provider may check for other causes. 2. Changes in behavior and thinking - Using gabapentin in children 3 to 12 years of age can cause emotional changes, aggressive behavior, problems with concentration, restlessness, changes in school performance, and hyperactivity. What is gabapentin? Gabapentin is a prescription medicine used to treat: Pain from damaged nerves (postherpetic pain) that follows healing of shingles (a painful rash that comes after a herpes zoster infection) in adults. Partial seizures when taken together with other medicines in adults and children 3 years of age and older. Who should not take gabapentin? Do not take gabapentin if you are allergic to gabapentin or any of the other ingredients in gabapentin. See the end of this Medication Guide for a complete list of ingredients in gabapentin. What should I tell my healthcare provider before taking gabapentin? Before taking gabapentin, tell your healthcare provider if you: have or have had kidney problems or are on hemodialysis have or have had depression, mood problems, or suicidal thoughts or behavior are pregnant or plan to become pregnant. It is not known if gabapentin can harm your unborn baby. Tell your healthcare provider right away if you become pregnant while taking gabapentin. You and your healthcare provider will decide if you should take gabapentin while you are pregnant. If you become pregnant while taking gabapentin, talk to your healthcare provider about registering with the North American Antiepileptic Drug (NAAED) Pregnancy Registry. The purpose of this registry is to collect information about the safety of antiepileptic drugs during pregnancy. You can enroll in this registry by calling 1-888-233-2334. are breastfeeding or plan to breastfeed. Gabapentin can pass into breast milk. You and your healthcare provider should decide how you will feed your baby while you take gabapentin. Tell your healthcare provider about all the medicines you take , including prescription and non-prescription medicines, vitamins, and herbal supplements. Taking gabapentin with certain other medicines can cause side effects or affect how well they work. Do not start or stop other medicines without talking to your healthcare provider. Know the medicines you take. Keep a list of them and show it to your healthcare provider and pharmacist when you get a new medicine. How should I take gabapentin? Take gabapentin exactly as prescribed. Your healthcare provider will tell you how much gabapentin to take. Do not change your dose of gabapentin without talking to your healthcare provider. If you break a tablet in half the unused half of the tablet should be taken at your next scheduled dose. Half tablets not used within several days of breaking should be thrown away. Gabapentin can be taken with or without food. If you take an antacid containing aluminum and magnesium, such as Maalox®, Mylanta®, Gelusil®, Gaviscon®, or Di-Gel®, you should wait at least 2 hours before taking your next dose of gabapentin. If you take too much gabapentin, call your healthcare provider or your local Poison Control Center right away. What should I avoid while taking gabapentin? Do not drink alcohol or take other medicines that make you sleepy or dizzy while taking gabapentin without first talking with your healthcare provider. Taking gabapentin with alcohol or drugs that cause sleepiness or dizziness may make your sleepiness or dizziness worse. Do not drive, operate heavy machinery, or do other dangerous activities until you know how gabapentin affects you. Gabapentin can slow your thinking and motor skills. What are the possible side effects of gabapentin? See ""What is the most important information I should know about gabapentin?"" The most common side effects of gabapentin include: dizziness lack of coordination viral infection feeling drowsy feeling tired fever jerky movements difficulty with speaking temporary loss of memory (amnesia) tremor difficulty with coordination double vision unusual eye movement Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of gabapentin. For more information, ask your healthcare provider or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. How should I store gabapentin? Store gabapentin tablets at 20° to 25°C (68° to 77°F). [See USP controlled room temperature]. Keep gabapentin and all medicines out of the reach of children. General information about the safe and effective use of gabapentin Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use gabapentin for a condition for which it was not prescribed. Do not give gabapentin to other people, even if they have the same symptoms that you have. It may harm them. This Medication Guide summarizes the most important information about gabapentin. If you would like more information, talk with your healthcare provider. You can ask your healthcare provider or pharmacist for information about gabapentin that was written for healthcare professionals. For more information about gabapentin tablets, or to report side effects regarding gabapentin tablets, please call Exelan Pharmaceuticals Inc. at 1-855-295-7455. What are the ingredients in gabapentin Tablets? Active ingredient: Gabapentin, USP Inactive ingredients: Mannitol, Hydroxypropyl Cellulose, Crospovidone, Talc, Magnesium Stearate and Aquarius® BP18114 Cool Vanilla." uuid:85aaa290-9390-40b2-91d8-9e41945f099a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:43968 biolink:treats UMLS:C1112209 PMID:41385096 "[{""id"":""uuid:9e782abb-a7cb-4db9-a4b9-04279d2096af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:906070fc-2c1e-4523-aec7-326c8d18aab2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Meropenem for Injection and other antibacterial drugs, Meropenem for Injection should only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Meropenem for Injection is useful as presumptive therapy in the indicated condition (e.g. intra-abdominal infections) prior to the identification of the causative organisms because of its broad spectrum of bactericidal activity. For information regarding use in pediatric patients see Indications and Usage (1.1) , (1.2) or (1.3) ; Dosage and Administration (2.3) , Adverse Reactions (6.1) , and Clinical Pharmacology (12.3) . uuid:f25d9d11-9374-4092-8902-38ba3ebbab4b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135927 biolink:treats MONDO:0001627 PMID:41385096 "[{""id"":""uuid:d478c684-b056-4cf5-bdc6-3db3df58a1a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f8917ccb-d0e8-4449-89c9-b566d3e4d20c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] A proportion of individuals over sixty who manifest signs and symptoms of an idiopathic decline in mental capacity (i.e., cognitive and interpersonal skills, mood, self-care, apparent motivation) can experience some symptomatic relief upon treatment with ergoloid mesylates preparations. The identity of the specific trait(s) or condition(s), if any, which would usefully predict a response to ergoloid mesylates therapy is not known. It appears, however, that those individuals who do respond come from groups of patients who would be considered clinically to suffer from some ill-defined process related to aging or to have some underlying dementing condition (i.e., primary progressive dementia, Alzheimer's dementia, senile onset, multi-infarct dementia). Before prescribing ergoloid mesylates, the physician should exclude the possibility that the patient's signs and symptoms arise from a potentially reversible and treatable condition. Particular care should be taken to exclude delirium and dementiform illness secondary to systemic disease, primary neurological disease, or primary disturbance of mood. Ergoloid mesylates preparations are not indicated in the treatment of acute or chronic psychosis, regardless of etiology (see CONTRAINDICATIONS ). The decision to use ergoloid mesylates in the treatment of an individual with a symptomatic decline in mental capacity of unknown etiology should be continually reviewed since the presenting clinical picture may subsequently evolve sufficiently to allow a specific diagnosis and a specific alternative treatment. In addition, continued clinical evaluation is required to determine whether any initial benefit conferred by ergoloid mesylates therapy persists with time. The efficacy of ergoloid mesylates was evaluated using a special rating scale known as the SCAG (Sandoz Clinical Assessment-Geriatric). The specific items on this scale on which modest but statistically significant changes were observed at the end of twelve weeks include: mental alertness, confusion, recent memory, orientation, emotional lability, self-care, depression, anxiety/fears, cooperation, sociability, appetite, dizziness, fatigue, bothersome(ness), and an overall impression of clinical status. uuid:75717ffd-c74d-4de7-b165-6a8547cd36b1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135927 biolink:treats MONDO:0004975 PMID:41385096 "[{""id"":""uuid:768bdfc3-c1b8-481d-bc91-011151376da8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b7ae81b5-4ed8-4599-9ba0-2d8d271c664e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] A proportion of individuals over sixty who manifest signs and symptoms of an idiopathic decline in mental capacity (i.e., cognitive and interpersonal skills, mood, self-care, apparent motivation) can experience some symptomatic relief upon treatment with ergoloid mesylates preparations. The identity of the specific trait(s) or condition(s), if any, which would usefully predict a response to ergoloid mesylates therapy is not known. It appears, however, that those individuals who do respond come from groups of patients who would be considered clinically to suffer from some ill-defined process related to aging or to have some underlying dementing condition (i.e., primary progressive dementia, Alzheimer's dementia, senile onset, multi-infarct dementia). Before prescribing ergoloid mesylates, the physician should exclude the possibility that the patient's signs and symptoms arise from a potentially reversible and treatable condition. Particular care should be taken to exclude delirium and dementiform illness secondary to systemic disease, primary neurological disease, or primary disturbance of mood. Ergoloid mesylates preparations are not indicated in the treatment of acute or chronic psychosis, regardless of etiology (see CONTRAINDICATIONS ). The decision to use ergoloid mesylates in the treatment of an individual with a symptomatic decline in mental capacity of unknown etiology should be continually reviewed since the presenting clinical picture may subsequently evolve sufficiently to allow a specific diagnosis and a specific alternative treatment. In addition, continued clinical evaluation is required to determine whether any initial benefit conferred by ergoloid mesylates therapy persists with time. The efficacy of ergoloid mesylates was evaluated using a special rating scale known as the SCAG (Sandoz Clinical Assessment-Geriatric). The specific items on this scale on which modest but statistically significant changes were observed at the end of twelve weeks include: mental alertness, confusion, recent memory, orientation, emotional lability, self-care, depression, anxiety/fears, cooperation, sociability, appetite, dizziness, fatigue, bothersome(ness), and an overall impression of clinical status. uuid:a9a6a3df-ea2f-4d27-82e5-40babb24f8a2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135927 biolink:treats MONDO:0043224 PMID:41385096 "[{""id"":""uuid:54057db1-763d-441d-b9c5-18e7e769bbc5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f6dec165-5cb6-4a49-bf6e-db06607229b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] A proportion of individuals over sixty who manifest signs and symptoms of an idiopathic decline in mental capacity (i.e., cognitive and interpersonal skills, mood, self-care, apparent motivation) can experience some symptomatic relief upon treatment with ergoloid mesylates preparations. The identity of the specific trait(s) or condition(s), if any, which would usefully predict a response to ergoloid mesylates therapy is not known. It appears, however, that those individuals who do respond come from groups of patients who would be considered clinically to suffer from some ill-defined process related to aging or to have some underlying dementing condition (i.e., primary progressive dementia, Alzheimer's dementia, senile onset, multi-infarct dementia). Before prescribing ergoloid mesylates, the physician should exclude the possibility that the patient's signs and symptoms arise from a potentially reversible and treatable condition. Particular care should be taken to exclude delirium and dementiform illness secondary to systemic disease, primary neurological disease, or primary disturbance of mood. Ergoloid mesylates preparations are not indicated in the treatment of acute or chronic psychosis, regardless of etiology (see CONTRAINDICATIONS ). The decision to use ergoloid mesylates in the treatment of an individual with a symptomatic decline in mental capacity of unknown etiology should be continually reviewed since the presenting clinical picture may subsequently evolve sufficiently to allow a specific diagnosis and a specific alternative treatment. In addition, continued clinical evaluation is required to determine whether any initial benefit conferred by ergoloid mesylates therapy persists with time. The efficacy of ergoloid mesylates was evaluated using a special rating scale known as the SCAG (Sandoz Clinical Assessment-Geriatric). The specific items on this scale on which modest but statistically significant changes were observed at the end of twelve weeks include: mental alertness, confusion, recent memory, orientation, emotional lability, self-care, depression, anxiety/fears, cooperation, sociability, appetite, dizziness, fatigue, bothersome(ness), and an overall impression of clinical status. uuid:a540cf4d-e232-4893-9ca5-f65db8310387 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135927 biolink:treats MONDO:0045057 PMID:41385096 "[{""id"":""uuid:ffe0da84-12ab-4e90-a168-295b63b6d8fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e783712c-29bc-4cee-95bb-98fd0b0f6941"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] A proportion of individuals over sixty who manifest signs and symptoms of an idiopathic decline in mental capacity (i.e., cognitive and interpersonal skills, mood, self-care, apparent motivation) can experience some symptomatic relief upon treatment with ergoloid mesylates preparations. The identity of the specific trait(s) or condition(s), if any, which would usefully predict a response to ergoloid mesylates therapy is not known. It appears, however, that those individuals who do respond come from groups of patients who would be considered clinically to suffer from some ill-defined process related to aging or to have some underlying dementing condition (i.e., primary progressive dementia, Alzheimer's dementia, senile onset, multi-infarct dementia). Before prescribing ergoloid mesylates, the physician should exclude the possibility that the patient's signs and symptoms arise from a potentially reversible and treatable condition. Particular care should be taken to exclude delirium and dementiform illness secondary to systemic disease, primary neurological disease, or primary disturbance of mood. Ergoloid mesylates preparations are not indicated in the treatment of acute or chronic psychosis, regardless of etiology (see CONTRAINDICATIONS ). The decision to use ergoloid mesylates in the treatment of an individual with a symptomatic decline in mental capacity of unknown etiology should be continually reviewed since the presenting clinical picture may subsequently evolve sufficiently to allow a specific diagnosis and a specific alternative treatment. In addition, continued clinical evaluation is required to determine whether any initial benefit conferred by ergoloid mesylates therapy persists with time. The efficacy of ergoloid mesylates was evaluated using a special rating scale known as the SCAG (Sandoz Clinical Assessment-Geriatric). The specific items on this scale on which modest but statistically significant changes were observed at the end of twelve weeks include: mental alertness, confusion, recent memory, orientation, emotional lability, self-care, depression, anxiety/fears, cooperation, sociability, appetite, dizziness, fatigue, bothersome(ness), and an overall impression of clinical status. uuid:66399968-bfb3-4b51-850b-4b846b73bbe7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135927 biolink:treats UMLS:C0281774 PMID:41385096 "[{""id"":""uuid:a435e0b5-44b1-4772-9e81-c5b4cf9c30b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:624268dd-4d14-4617-88a8-f417e4d64bc1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] A proportion of individuals over sixty who manifest signs and symptoms of an idiopathic decline in mental capacity (i.e., cognitive and interpersonal skills, mood, self-care, apparent motivation) can experience some symptomatic relief upon treatment with ergoloid mesylates preparations. The identity of the specific trait(s) or condition(s), if any, which would usefully predict a response to ergoloid mesylates therapy is not known. It appears, however, that those individuals who do respond come from groups of patients who would be considered clinically to suffer from some ill-defined process related to aging or to have some underlying dementing condition (i.e., primary progressive dementia, Alzheimer's dementia, senile onset, multi-infarct dementia). Before prescribing ergoloid mesylates, the physician should exclude the possibility that the patient's signs and symptoms arise from a potentially reversible and treatable condition. Particular care should be taken to exclude delirium and dementiform illness secondary to systemic disease, primary neurological disease, or primary disturbance of mood. Ergoloid mesylates preparations are not indicated in the treatment of acute or chronic psychosis, regardless of etiology (see CONTRAINDICATIONS ). The decision to use ergoloid mesylates in the treatment of an individual with a symptomatic decline in mental capacity of unknown etiology should be continually reviewed since the presenting clinical picture may subsequently evolve sufficiently to allow a specific diagnosis and a specific alternative treatment. In addition, continued clinical evaluation is required to determine whether any initial benefit conferred by ergoloid mesylates therapy persists with time. The efficacy of ergoloid mesylates was evaluated using a special rating scale known as the SCAG (Sandoz Clinical Assessment-Geriatric). The specific items on this scale on which modest but statistically significant changes were observed at the end of twelve weeks include: mental alertness, confusion, recent memory, orientation, emotional lability, self-care, depression, anxiety/fears, cooperation, sociability, appetite, dizziness, fatigue, bothersome(ness), and an overall impression of clinical status. uuid:122be767-708e-47c8-ab59-406cc97d3205 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135927 biolink:treats UMLS:C0221764 PMID:41385096 "[{""id"":""uuid:fb64a46d-0d7f-4bce-828a-224ffd7948d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f714865f-364b-497a-b9a2-7ad6a08612c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] A proportion of individuals over sixty who manifest signs and symptoms of an idiopathic decline in mental capacity (i.e., cognitive and interpersonal skills, mood, self-care, apparent motivation) can experience some symptomatic relief upon treatment with ergoloid mesylates preparations. The identity of the specific trait(s) or condition(s), if any, which would usefully predict a response to ergoloid mesylates therapy is not known. It appears, however, that those individuals who do respond come from groups of patients who would be considered clinically to suffer from some ill-defined process related to aging or to have some underlying dementing condition (i.e., primary progressive dementia, Alzheimer's dementia, senile onset, multi-infarct dementia). Before prescribing ergoloid mesylates, the physician should exclude the possibility that the patient's signs and symptoms arise from a potentially reversible and treatable condition. Particular care should be taken to exclude delirium and dementiform illness secondary to systemic disease, primary neurological disease, or primary disturbance of mood. Ergoloid mesylates preparations are not indicated in the treatment of acute or chronic psychosis, regardless of etiology (see CONTRAINDICATIONS ). The decision to use ergoloid mesylates in the treatment of an individual with a symptomatic decline in mental capacity of unknown etiology should be continually reviewed since the presenting clinical picture may subsequently evolve sufficiently to allow a specific diagnosis and a specific alternative treatment. In addition, continued clinical evaluation is required to determine whether any initial benefit conferred by ergoloid mesylates therapy persists with time. The efficacy of ergoloid mesylates was evaluated using a special rating scale known as the SCAG (Sandoz Clinical Assessment-Geriatric). The specific items on this scale on which modest but statistically significant changes were observed at the end of twelve weeks include: mental alertness, confusion, recent memory, orientation, emotional lability, self-care, depression, anxiety/fears, cooperation, sociability, appetite, dizziness, fatigue, bothersome(ness), and an overall impression of clinical status. uuid:8fbfd753-ab5c-461d-979a-b644aa443c6e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6076 biolink:treats MONDO:0005672 PMID:41385096 "[{""id"":""uuid:c412632e-6abb-4a5d-adbe-c14f9ce9a9bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ba83d09f-dd8a-44d5-b6df-2c710ed5f33b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c551e022-10a1-40e4-9a2d-cd23d381d746"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Itraconazole Capsules are indicated for the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: Blastomycosis, pulmonary and extrapulmonary Histoplasmosis, including chronic cavitary pulmonary disease and disseminated, non-meningeal histoplasmosis, and Aspergillosis, pulmonary and extrapulmonary, in patients who are intolerant of or who are refractory to amphotericin B therapy. Specimens for fungal cultures and other relevant laboratory studies (wet mount, histopathology, serology) should be obtained before therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, antiinfective therapy should be adjusted accordingly. Itraconazole Capsules are also indicated for the treatment of the following fungal infections in non-immunocompromised patients: Onychomycosis of the toenail, with or without fingernail involvement, due to dermatophytes (tinea unguium), and Onychomycosis of the fingernail due to dermatophytes (tinea unguium). Prior to initiating treatment, appropriate nail specimens for laboratory testing (KOH preparation, fungal culture, or nail biopsy) should be obtained to confirm the diagnosis of onychomycosis. (See CLINICAL PHARMACOLOGY: Special Populations , CONTRAINDICATIONS , WARNINGS , and ADVERSE REACTIONS: Post-marketing Experience for more information.)|[PMDA] Drug with a new route of administration indicated for treatment of fungemia, respiratory mycosis, gastrointestinal mycosis, urinary tract mycosis, fungal meningitis, esophageal candidiasis, blastomycosis, and histoplasmosis, caused by Aspergillus species, Candida species, Cryptococcus species, Blastomyces species or Histoplasma species and febrile neutropenia suspected of having fungal infections. uuid:da76ef69-8bcb-4f24-a4d5-8442d6929449 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6076 biolink:treats MONDO:0018312 PMID:41385096 "[{""id"":""uuid:28b82c9f-5685-47d5-8f43-8dd45e1415f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c1a53414-7f43-4552-b4ff-dfda1f5eaa94"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:0c6a53c4-d433-44a6-b301-cca1e1bbabfe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Itraconazole Capsules are indicated for the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: Blastomycosis, pulmonary and extrapulmonary Histoplasmosis, including chronic cavitary pulmonary disease and disseminated, non-meningeal histoplasmosis, and Aspergillosis, pulmonary and extrapulmonary, in patients who are intolerant of or who are refractory to amphotericin B therapy. Specimens for fungal cultures and other relevant laboratory studies (wet mount, histopathology, serology) should be obtained before therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, antiinfective therapy should be adjusted accordingly. Itraconazole Capsules are also indicated for the treatment of the following fungal infections in non-immunocompromised patients: Onychomycosis of the toenail, with or without fingernail involvement, due to dermatophytes (tinea unguium), and Onychomycosis of the fingernail due to dermatophytes (tinea unguium). Prior to initiating treatment, appropriate nail specimens for laboratory testing (KOH preparation, fungal culture, or nail biopsy) should be obtained to confirm the diagnosis of onychomycosis. (See CLINICAL PHARMACOLOGY: Special Populations , CONTRAINDICATIONS , WARNINGS , and ADVERSE REACTIONS: Post-marketing Experience for more information.)|[PMDA] Drug with a new route of administration indicated for treatment of fungemia, respiratory mycosis, gastrointestinal mycosis, urinary tract mycosis, fungal meningitis, esophageal candidiasis, blastomycosis, and histoplasmosis, caused by Aspergillus species, Candida species, Cryptococcus species, Blastomyces species or Histoplasma species and febrile neutropenia suspected of having fungal infections. uuid:f7a89182-956c-4a6b-8528-d19303448a51 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6076 biolink:treats MONDO:0005657 PMID:41385096 "[{""id"":""uuid:8f2b404a-5977-4aaf-9ff6-44fb7639d7a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:131ff064-02eb-45b1-bb4d-ae686ce536dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Itraconazole Capsules are indicated for the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: Blastomycosis, pulmonary and extrapulmonary Histoplasmosis, including chronic cavitary pulmonary disease and disseminated, non-meningeal histoplasmosis, and Aspergillosis, pulmonary and extrapulmonary, in patients who are intolerant of or who are refractory to amphotericin B therapy. Specimens for fungal cultures and other relevant laboratory studies (wet mount, histopathology, serology) should be obtained before therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, antiinfective therapy should be adjusted accordingly. Itraconazole Capsules are also indicated for the treatment of the following fungal infections in non-immunocompromised patients: Onychomycosis of the toenail, with or without fingernail involvement, due to dermatophytes (tinea unguium), and Onychomycosis of the fingernail due to dermatophytes (tinea unguium). Prior to initiating treatment, appropriate nail specimens for laboratory testing (KOH preparation, fungal culture, or nail biopsy) should be obtained to confirm the diagnosis of onychomycosis. (See CLINICAL PHARMACOLOGY: Special Populations , CONTRAINDICATIONS , WARNINGS , and ADVERSE REACTIONS: Post-marketing Experience for more information.) uuid:73568159-cebe-431d-996a-51dc36ed6619 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6076 biolink:treats MONDO:0001628 PMID:41385096 "[{""id"":""uuid:4f0feb75-0995-4af2-92d4-584d80a9dc9b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dd6c7156-7667-47f3-82ff-c2f699e0ddce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Itraconazole Capsules are indicated for the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: Blastomycosis, pulmonary and extrapulmonary Histoplasmosis, including chronic cavitary pulmonary disease and disseminated, non-meningeal histoplasmosis, and Aspergillosis, pulmonary and extrapulmonary, in patients who are intolerant of or who are refractory to amphotericin B therapy. Specimens for fungal cultures and other relevant laboratory studies (wet mount, histopathology, serology) should be obtained before therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, antiinfective therapy should be adjusted accordingly. Itraconazole Capsules are also indicated for the treatment of the following fungal infections in non-immunocompromised patients: Onychomycosis of the toenail, with or without fingernail involvement, due to dermatophytes (tinea unguium), and Onychomycosis of the fingernail due to dermatophytes (tinea unguium). Prior to initiating treatment, appropriate nail specimens for laboratory testing (KOH preparation, fungal culture, or nail biopsy) should be obtained to confirm the diagnosis of onychomycosis. (See CLINICAL PHARMACOLOGY: Special Populations , CONTRAINDICATIONS , WARNINGS , and ADVERSE REACTIONS: Post-marketing Experience for more information.) uuid:659cfebc-cf3b-41c5-934b-6be55452617f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:891521 biolink:treats MONDO:0005300 PMID:41385096 "[{""id"":""uuid:5dc093c0-f3d5-4465-81eb-b1539ab872da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6c201742-b92f-4ce1-a93c-f85b7bf8ceb3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mynephron capsule is indicated in the wasting syndrome of chronic renal failure, uremia and impaired metabolic functions of the kidney, and to maintain levels when the dietary intake of vitamins is inadequate or excretion (loss) is excessive. Mynephron is also highly effective as a stress vitamin. uuid:e3b42a02-df5e-47a4-ade0-889a133900b3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:891521 biolink:treats MONDO:0007008 PMID:41385096 "[{""id"":""uuid:487d1c52-28ba-44d2-9353-ddb116deb448"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5d25468b-589b-4362-9a32-948b481964c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mynephron capsule is indicated in the wasting syndrome of chronic renal failure, uremia and impaired metabolic functions of the kidney, and to maintain levels when the dietary intake of vitamins is inadequate or excretion (loss) is excessive. Mynephron is also highly effective as a stress vitamin. uuid:910abee9-a1a4-4410-b9a1-4ca5936c9a31 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:585948 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:7a6d41f1-d886-4315-8ce2-7b677ccc371e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1e489426-35ca-4da7-a59f-6f4c8ed87dc5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Felodipine extended-release tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including felodipine. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Felodipine extended-release tablets may be administered with other antihypertensive agents. uuid:0deb4a5d-9324-4cc7-b134-76fa460571f8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:585948 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:85862b39-c3a7-470c-a614-f846a42dcd78"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e89ddaee-1d55-4172-b9ee-a7d83c3a54de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Felodipine extended-release tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including felodipine. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Felodipine extended-release tablets may be administered with other antihypertensive agents. uuid:a92fcbe2-3cfc-47f3-9bee-b581811c065d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:585948 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:e05895cf-c821-43ba-8b72-9753483c2382"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c12a6bee-68a1-4c89-b8b3-ce763810f688"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Felodipine extended-release tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including felodipine. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Felodipine extended-release tablets may be administered with other antihypertensive agents. uuid:098f2675-3f3f-40f5-a374-065eb3220f59 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:585948 biolink:treats MONDO:0005016 PMID:41385096 "[{""id"":""uuid:c2076c0b-c985-4c99-9458-ea0e86059072"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4c68cbd9-4afd-4488-bf69-f512ea47ec3e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Felodipine extended-release tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including felodipine. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Felodipine extended-release tablets may be administered with other antihypertensive agents. uuid:0fe38915-3cda-449e-b184-8123894858d4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9086 biolink:treats MONDO:0005180 PMID:41385096 "[{""id"":""uuid:dfd2bf01-5663-429a-9f0e-5e7001db4d11"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:778b1e6b-905f-4689-97a3-fdc26c757595"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:76981751-ab5b-4109-82f7-963f51ccf1b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Selegiline is indicated as an adjunct in the management of Parkinsonian patients being treated with levodopa/carbidopa who exhibit deterioration in the quality of their response to this therapy. There is no evidence from controlled studies that selegiline has any beneficial effect in the absence of concurrent levodopa therapy. Evidence supporting this claim was obtained in randomized controlled clinical investigations that compared the effects of added selegiline or placebo in patients receiving levodopa/carbidopa. Selegiline was significantly superior to placebo on all three principal outcome measures employed: change from baseline in daily levodopa/carbidopa dose, the amount of ‘off’ time, and patient self-rating of treatment success. Beneficial effects were also observed on other measures of treatment success (e.g., measures of reduced end of dose akinesia, decreased tremor and sialorrhea, improved speech and dressing ability and improved overall disability as assessed by walking and comparison to previous state).|[PMDA] A drug with a revised indication and a new dosage for the treatment of Parkinson's disease (When used in combination with levodopa-containing products; patients are classified as Stage I to IV on the Hoehn and Yahr scale, and when not used in combination with levodopa-containing products; patients are classified as Stage I to III on the Hoehn and Yahr scale). uuid:98093b9a-8612-4751-921d-537927b3668c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9086 biolink:treats HP:0001337 PMID:41385096 "[{""id"":""uuid:6ad1b9ba-8146-4a1c-b5a8-4ae7d2fae0d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:88321107-f3df-433e-ac59-78d6b8a4afb2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Selegiline is indicated as an adjunct in the management of Parkinsonian patients being treated with levodopa/carbidopa who exhibit deterioration in the quality of their response to this therapy. There is no evidence from controlled studies that selegiline has any beneficial effect in the absence of concurrent levodopa therapy. Evidence supporting this claim was obtained in randomized controlled clinical investigations that compared the effects of added selegiline or placebo in patients receiving levodopa/carbidopa. Selegiline was significantly superior to placebo on all three principal outcome measures employed: change from baseline in daily levodopa/carbidopa dose, the amount of ‘off’ time, and patient self-rating of treatment success. Beneficial effects were also observed on other measures of treatment success (e.g., measures of reduced end of dose akinesia, decreased tremor and sialorrhea, improved speech and dressing ability and improved overall disability as assessed by walking and comparison to previous state). uuid:60b19368-2470-4e5a-9413-c1ef152054fa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9086 biolink:treats HP:0002307 PMID:41385096 "[{""id"":""uuid:ef72251b-c8bb-4bd0-8d61-621e407c76af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b81e2fad-87c5-42e0-aaaf-93c9d0885889"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Selegiline is indicated as an adjunct in the management of Parkinsonian patients being treated with levodopa/carbidopa who exhibit deterioration in the quality of their response to this therapy. There is no evidence from controlled studies that selegiline has any beneficial effect in the absence of concurrent levodopa therapy. Evidence supporting this claim was obtained in randomized controlled clinical investigations that compared the effects of added selegiline or placebo in patients receiving levodopa/carbidopa. Selegiline was significantly superior to placebo on all three principal outcome measures employed: change from baseline in daily levodopa/carbidopa dose, the amount of ‘off’ time, and patient self-rating of treatment success. Beneficial effects were also observed on other measures of treatment success (e.g., measures of reduced end of dose akinesia, decreased tremor and sialorrhea, improved speech and dressing ability and improved overall disability as assessed by walking and comparison to previous state). uuid:fa43a11d-376c-47ca-a56d-14fef06c6047 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:30769 biolink:treats MONDO:0008629 PMID:41385096 "[{""id"":""uuid:993e7b5c-fd15-4a3a-b631-42ad7daf7242"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0412493b-9665-41f9-8f63-ac0075b68fbe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CYTRA-K CRYSTALS is an effective alkalinizing agent useful in those conditions where long-term maintenance of an alkaline urine is desirable, such as in patients with uric acid and cystine calculi of the urinary tract, especially when the administration of sodium salts is undesirable or contraindicated. In addition, it is a valuable adjuvant when administered with uricosuric agents in gout therapy, since urates tend to crystallize out of an acid urine. It is also effective in correcting the acidosis of certain renal tubular disorders where the administration of potassium citrate may be preferable. CYTRA-K CRYSTALS is highly concentrated, and when administered after meals and before bedtime, allows one to maintain an alkaline urinary pH around the clock, usually without the necessity of a 2 A.M. dose. CYTRA-K CRYSTALS alkalinizes the urine without producing a systemic alkalosis in recommended dosage. It is highly palatable, pleasant tasting, and tolerable, even when administered for long periods. Potassium citrate does not neutralize the gastric juice or disturb digestion. uuid:b03c6881-2207-4f58-ad17-ed722c9d75aa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:30769 biolink:treats EFO:0010826 PMID:41385096 "[{""id"":""uuid:46d108ff-e544-41cb-8080-b805c91a3b0a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:159f235b-9bee-4f4f-9490-f288d170e2be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CYTRA-K CRYSTALS is an effective alkalinizing agent useful in those conditions where long-term maintenance of an alkaline urine is desirable, such as in patients with uric acid and cystine calculi of the urinary tract, especially when the administration of sodium salts is undesirable or contraindicated. In addition, it is a valuable adjuvant when administered with uricosuric agents in gout therapy, since urates tend to crystallize out of an acid urine. It is also effective in correcting the acidosis of certain renal tubular disorders where the administration of potassium citrate may be preferable. CYTRA-K CRYSTALS is highly concentrated, and when administered after meals and before bedtime, allows one to maintain an alkaline urinary pH around the clock, usually without the necessity of a 2 A.M. dose. CYTRA-K CRYSTALS alkalinizes the urine without producing a systemic alkalosis in recommended dosage. It is highly palatable, pleasant tasting, and tolerable, even when administered for long periods. Potassium citrate does not neutralize the gastric juice or disturb digestion. uuid:0667c46c-8627-4783-9f52-49d01106c324 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:30769 biolink:treats MONDO:0005393 PMID:41385096 "[{""id"":""uuid:9a0894d3-3056-490c-9937-e66e7b9af536"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:99ac2d89-3a27-4fd4-9159-25e0e525fbfa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CYTRA-K CRYSTALS is an effective alkalinizing agent useful in those conditions where long-term maintenance of an alkaline urine is desirable, such as in patients with uric acid and cystine calculi of the urinary tract, especially when the administration of sodium salts is undesirable or contraindicated. In addition, it is a valuable adjuvant when administered with uricosuric agents in gout therapy, since urates tend to crystallize out of an acid urine. It is also effective in correcting the acidosis of certain renal tubular disorders where the administration of potassium citrate may be preferable. CYTRA-K CRYSTALS is highly concentrated, and when administered after meals and before bedtime, allows one to maintain an alkaline urinary pH around the clock, usually without the necessity of a 2 A.M. dose. CYTRA-K CRYSTALS alkalinizes the urine without producing a systemic alkalosis in recommended dosage. It is highly palatable, pleasant tasting, and tolerable, even when administered for long periods. Potassium citrate does not neutralize the gastric juice or disturb digestion. uuid:64642870-4c40-4980-af87-4ca4e9cc1d15 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:30769 biolink:treats MONDO:0001909 PMID:41385096 "[{""id"":""uuid:c0c0f558-8cc3-4634-a70a-0072af0e2447"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:237f96ab-23df-4ef1-a4bf-0b668fa9ed99"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CYTRA-K CRYSTALS is an effective alkalinizing agent useful in those conditions where long-term maintenance of an alkaline urine is desirable, such as in patients with uric acid and cystine calculi of the urinary tract, especially when the administration of sodium salts is undesirable or contraindicated. In addition, it is a valuable adjuvant when administered with uricosuric agents in gout therapy, since urates tend to crystallize out of an acid urine. It is also effective in correcting the acidosis of certain renal tubular disorders where the administration of potassium citrate may be preferable. CYTRA-K CRYSTALS is highly concentrated, and when administered after meals and before bedtime, allows one to maintain an alkaline urinary pH around the clock, usually without the necessity of a 2 A.M. dose. CYTRA-K CRYSTALS alkalinizes the urine without producing a systemic alkalosis in recommended dosage. It is highly palatable, pleasant tasting, and tolerable, even when administered for long periods. Potassium citrate does not neutralize the gastric juice or disturb digestion. uuid:56c01c34-8866-4545-8f6f-e988b6cbe8c7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2453 biolink:treats MONDO:0004609 PMID:41385096 "[{""id"":""uuid:830d8d92-6011-4de6-9e71-2dad0e66829e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:616d60f0-dcff-43f1-bd10-d16095ff71d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:7d424c35-6d10-417c-b7ef-dd76d7b4a70f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Adult Patients Cold Sores (Herpes Labialis) Valacyclovir tablets, USP are indicated for treatment of cold sores (herpes labialis). The efficacy of valacyclovir tablets, USP initiated after the development of clinical signs of a cold sore (e.g., papule, vesicle, or ulcer) has not been established. Genital Herpes Initial Episode Valacyclovir tablets, USP are indicated for treatment of the initial episode of genital herpes in immunocompetent adults. The efficacy of treatment with valacyclovir tablets, USP when initiated more than 72 hours after the onset of signs and symptoms has not been established. Recurrent Episodes Valacyclovir tablets, USP are indicated for treatment of recurrent episodes of genital herpes in immunocompetent adults. The efficacy of treatment with valacyclovir tablets, USP when initiated more than 24 hours after the onset of signs and symptoms has not been established. Suppressive Therapy Valacyclovir tablets, USP are indicated for chronic suppressive therapy of recurrent episodes of genital herpes in immunocompetent and in HIV-infected adults. The efficacy and safety of valacyclovir tablets, USP for the suppression of genital herpes beyond 1 year in immunocompetent patients and beyond 6 months in HIV-infected patients have not been established. Reduction of Transmission Valacyclovir tablets, USP are indicated for the reduction of transmission of genital herpes in immunocompetent adults. The efficacy of valacyclovir tablets, USP for the reduction of transmission of genital herpes beyond 8 months in discordant couples has not been established. The efficacy of valacyclovir tablets, USP for the reduction of transmission of genital herpes in individuals with multiple partners and non-heterosexual couples has not been established. Safer sex practices should be used with suppressive therapy (see current Centers for Disease Control and Prevention [CDC] Sexually Transmitted Diseases Treatment Guidelines). Herpes Zoster Valacyclovir tablets, USP are indicated for the treatment of herpes zoster (shingles) in immunocompetent adults. The efficacy of valacyclovir tablets, USP when initiated more than 72 hours after the onset of rash and the efficacy and safety of valacyclovir tablets, USP for treatment of disseminated herpes zoster have not been established. 1.2 Pediatric Patients Cold Sores (Herpes Labialis) Valacyclovir tablets, USP are indicated for the treatment of cold sores (herpes labialis) in pediatric patients ≥12 years of age. The efficacy of valacyclovir tablets, USP initiated after the development of clinical signs of a cold sore (e.g., papule, vesicle, or ulcer) has not been established. Chickenpox Valacyclovir tablets, USP is indicated for the treatment of chickenpox in immunocompetent pediatric patients 2 to < 18 years of age. Based on efficacy data from clinical studies with oral acyclovir, treatment with valacyclovir tablets, USP should be initiated within 24 hours after the onset of rash [see Clinical Studies (14.4)] 1.3 Limitations of Use The efficacy and safety of valacyclovir tablets, USP have not been established in: Immunocompromised patients other than for the suppression of genital herpes in HIV-infected patients with a CD4+ cell count ≥100 cells/mm 3. Patients <12 years of age with cold sores (herpes labialis). Patients <2 years of age or ≥ 18 years of age with chickenpox. Patients <18 years of age with genital herpes. Patients <18 years of age with herpes zoster. Neonates and infants as suppressive therapy following neonatal herpes simplex virus (HSV) infection.|[PMDA] Drugs with new additional indications and a new additional dosage for herpes simplex, prevention of herpes simplex virus infection in hematopoietic stem cell transplantation, herpes zoster, and prevention of recurrence of genital herpes (oral dosage form), and neonatal herpes simplex virus infection (injectable dosage form) based on the discussion of the Investigational Committee on Pediatric Drug Therapies. uuid:193c4899-98c2-49f9-901e-92e786ad9750 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31355 biolink:treats UMLS:C5237199 PMID:41385096 "[{""id"":""uuid:9f5f7e4e-29cd-401d-8b4f-056e2ee39b1a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4471c200-6b1d-4964-bee4-97df74d8eea5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Initial Treatment of Advanced Ovarian Carcinoma Carboplatin injection is indicated for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents. One established combination regimen consists of carboplatin injection and cyclophosphamide. Two randomized controlled studies conducted by the NCIC and SWOG with carboplatin, USP vs. cisplatin, both in combination with cyclophosphamide, have demonstrated equivalent overall survival between the two groups (see CLINICAL STUDIES ). There is limited statistical power to demonstrate equivalence in overall pathologic complete response rates and long term survival (≥ 3 years) because of the small number of patients with these outcomes: the small number of patients with residual tumor < 2 cm after initial surgery also limits the statistical power to demonstrate equivalence in this subgroup. Secondary Treatment of Advanced Ovarian Carcinoma Carboplatin injection is indicated for the palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy, including patients who have been previously treated with cisplatin. Within the group of patients previously treated with cisplatin, those who have developed progressive disease while receiving cisplatin therapy may have a decreased response rate. uuid:7f17e896-39d7-4bcd-b16d-5e0d33d2cac0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31355 biolink:treats MONDO:0005140 PMID:41385096 "[{""id"":""uuid:61dab42d-edda-430b-a91f-6a396c63d5b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:497bb277-0992-41bf-a9e8-680725d7352a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Initial Treatment of Advanced Ovarian Carcinoma Carboplatin injection is indicated for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents. One established combination regimen consists of carboplatin injection and cyclophosphamide. Two randomized controlled studies conducted by the NCIC and SWOG with carboplatin, USP vs. cisplatin, both in combination with cyclophosphamide, have demonstrated equivalent overall survival between the two groups (see CLINICAL STUDIES ). There is limited statistical power to demonstrate equivalence in overall pathologic complete response rates and long term survival (≥ 3 years) because of the small number of patients with these outcomes: the small number of patients with residual tumor < 2 cm after initial surgery also limits the statistical power to demonstrate equivalence in this subgroup. Secondary Treatment of Advanced Ovarian Carcinoma Carboplatin injection is indicated for the palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy, including patients who have been previously treated with cisplatin. Within the group of patients previously treated with cisplatin, those who have developed progressive disease while receiving cisplatin therapy may have a decreased response rate. uuid:ec9751e3-0dd1-4f00-9b3b-eab0013c4ea5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45863 biolink:treats MONDO:0008170 PMID:41385096 "[{""id"":""uuid:95bdfeeb-c56f-4c29-89f0-8849b7354f65"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2a8652d5-50d9-4c94-aa28-fade79e3ebb9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:d22f50ef-f9f1-424f-ab5b-c8cdc7b91fbe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Paclitaxel Injection, USP is indicated as subsequent therapy for the treatment of advanced carcinoma of the ovary. As first-line therapy, paclitaxel is indicated in combination with cisplatin. Paclitaxel is indicated for the adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin-containing combination chemotherapy. In the clinical trial, there was an overall favorable effect on disease-free and overall survival in the total population of patients with receptor-positive and receptor-negative tumors, but the benefit has been specifically demonstrated by available data (median follow-up 30 months) only in the patients with estrogen and progesterone receptornegative tumors. (See CLINICAL STUDIES: Breast Carcinoma. ) Paclitaxel Injection, USP is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated. Paclitaxel, in combination with cisplatin, is indicated for the first-line treatment of nonsmall cell lung cancer in patients who are not candidates for potentially curative surgery and/or radiation therapy. Paclitaxel is indicated for the second-line treatment of AIDS-related Kaposi’s sarcoma.|[PMDA] Drugs with new additional indications and new dosages for the treatment of relapsed or metastatic head and neck cancer, relapsed or metastatic esophagus cancer, angiosarcoma, advanced or relapsed cervical cancer. A new dosage for once- weekly administration for ovarian cancer has also been added. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:9d8c7fc5-49c3-4c4c-99a8-859cba587c96 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45863 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:ea76304d-0d15-4a48-bca1-56806b8ecbdb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:47f6f4f5-9f6f-479a-b351-57ec99c9deac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:335531da-d76e-4f28-b4c4-a5e96bc44c5f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Paclitaxel Injection, USP is indicated as subsequent therapy for the treatment of advanced carcinoma of the ovary. As first-line therapy, paclitaxel is indicated in combination with cisplatin. Paclitaxel is indicated for the adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin-containing combination chemotherapy. In the clinical trial, there was an overall favorable effect on disease-free and overall survival in the total population of patients with receptor-positive and receptor-negative tumors, but the benefit has been specifically demonstrated by available data (median follow-up 30 months) only in the patients with estrogen and progesterone receptornegative tumors. (See CLINICAL STUDIES: Breast Carcinoma. ) Paclitaxel Injection, USP is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated. Paclitaxel, in combination with cisplatin, is indicated for the first-line treatment of nonsmall cell lung cancer in patients who are not candidates for potentially curative surgery and/or radiation therapy. Paclitaxel is indicated for the second-line treatment of AIDS-related Kaposi’s sarcoma.|[PMDA] A drug in a new dosage form and with a new dosage indicated for the treatment of breast cancer. uuid:9191dce1-fc8d-46ef-beb2-b1b5e2b25c78 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45863 biolink:treats MONDO:0024880 PMID:41385096 "[{""id"":""uuid:b0cfd6d1-d53c-471c-8fcf-9d47feabd1d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c1f786b0-8b8b-42ae-8f13-82541eb232d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Paclitaxel Injection, USP is indicated as subsequent therapy for the treatment of advanced carcinoma of the ovary. As first-line therapy, paclitaxel is indicated in combination with cisplatin. Paclitaxel is indicated for the adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin-containing combination chemotherapy. In the clinical trial, there was an overall favorable effect on disease-free and overall survival in the total population of patients with receptor-positive and receptor-negative tumors, but the benefit has been specifically demonstrated by available data (median follow-up 30 months) only in the patients with estrogen and progesterone receptornegative tumors. (See CLINICAL STUDIES: Breast Carcinoma. ) Paclitaxel Injection, USP is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated. Paclitaxel, in combination with cisplatin, is indicated for the first-line treatment of nonsmall cell lung cancer in patients who are not candidates for potentially curative surgery and/or radiation therapy. Paclitaxel is indicated for the second-line treatment of AIDS-related Kaposi’s sarcoma. uuid:04534014-32ba-450d-9618-12d26956dc7a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45863 biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:2a6c2853-0a4c-49dc-bf83-237545d1c5e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ce440c1e-f59e-439d-876a-4804875a6c98"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:15fd5eda-422a-4f7b-bd7b-593b9f69c924"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/apealea""]},{""id"":""uuid:433e4190-db3e-40eb-8b79-62a9a8d316a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Paclitaxel Injection, USP is indicated as subsequent therapy for the treatment of advanced carcinoma of the ovary. As first-line therapy, paclitaxel is indicated in combination with cisplatin. Paclitaxel is indicated for the adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin-containing combination chemotherapy. In the clinical trial, there was an overall favorable effect on disease-free and overall survival in the total population of patients with receptor-positive and receptor-negative tumors, but the benefit has been specifically demonstrated by available data (median follow-up 30 months) only in the patients with estrogen and progesterone receptornegative tumors. (See CLINICAL STUDIES: Breast Carcinoma. ) Paclitaxel Injection, USP is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated. Paclitaxel, in combination with cisplatin, is indicated for the first-line treatment of nonsmall cell lung cancer in patients who are not candidates for potentially curative surgery and/or radiation therapy. Paclitaxel is indicated for the second-line treatment of AIDS-related Kaposi’s sarcoma.|[EMA] Abraxane monotherapy is indicated for the treatment of metastatic breast cancer in adult patients who have failed first-line treatment for metastatic disease and for whom standard, anthracycline containing therapy is not indicated.Abraxane in combination with gemcitabine is indicated for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas.Abraxane in combination with carboplatin is indicated for the first-line treatment of non-small cell lung cancer in adult patients who are not candidates for potentially curative surgery and/or radiation therapy.|[PMDA] A drug with new additional indications and a new dosage for the treatment of gastric cancer and non-small cell lung cancer. uuid:d6789fb2-34e3-4dfb-98d0-67a2928de25a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45863 biolink:treats MONDO:0005055 PMID:41385096 "[{""id"":""uuid:dafa73a9-0314-4cc2-aa0b-f0c24d86c338"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5e25849e-71c6-4795-bd27-048879d6a3a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Paclitaxel Injection, USP is indicated as subsequent therapy for the treatment of advanced carcinoma of the ovary. As first-line therapy, paclitaxel is indicated in combination with cisplatin. Paclitaxel is indicated for the adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin-containing combination chemotherapy. In the clinical trial, there was an overall favorable effect on disease-free and overall survival in the total population of patients with receptor-positive and receptor-negative tumors, but the benefit has been specifically demonstrated by available data (median follow-up 30 months) only in the patients with estrogen and progesterone receptornegative tumors. (See CLINICAL STUDIES: Breast Carcinoma. ) Paclitaxel Injection, USP is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated. Paclitaxel, in combination with cisplatin, is indicated for the first-line treatment of nonsmall cell lung cancer in patients who are not candidates for potentially curative surgery and/or radiation therapy. Paclitaxel is indicated for the second-line treatment of AIDS-related Kaposi’s sarcoma. uuid:0bcfcbf1-bd42-4878-98d2-d0078c73f875 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4392 biolink:treats MONDO:0020920 PMID:41385096 "[{""id"":""uuid:462631df-337d-4534-9cc4-25d9b997a1c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:63e8ebbe-c8a4-4da8-acdf-aa14b1ca8b66"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Demeclocycline hydrochloride tablets USP is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by rickettsiae; Respiratory tract infections caused by Mycoplasma pneumoniae ; Lymphogranuloma venereum due to Chlamydia trachomatis ; Psittacosis (Ornithosis) due to Chlamydia psittaci ; Trachoma due to Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence; Inclusion conjunctivitis caused by Chlamydia trachomatis ; Nongonococcal urethritis in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis ; Relapsing fever due to Borrelia recurrentis ; Chancroid caused by Haemophilus ducreyi ; Plague due to Yersinia pestis ; Tularemia due to Francisella tularensis ; Cholera caused by Vibrio cholerae ; Campylobacter fetus infections caused by Campylobacter fetus ; Brucellosis due to Brucella species (in conjunction with streptomycin); Bartonellosis due to Bartonella bacilliformis ; Granuloma inguinale caused by Calymmatobacterium granulomatis ; Demeclocycline hydrochloride tablets USP is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli ; Enterobacter aerogenes ; Shigella species; Acinetobacter species; Respiratory tract infections caused by Haemophilus influenzae ; Respiratory tract and urinary tract infections caused by Klebsiella species. Demeclocycline hydrochloride tablets USP is indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae; Skin and skin structure infections caused by Staphylococcus aureus . (Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, tetracyclines, including demeclocycline hydrochloride, are alternative drugs in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae , and for the treatment of other uncomplicated gonococcal infections; Infections in women caused by Neisseria gonorrhoeae ; Syphilis caused by Treponema pallidum subspecies pallidum ; Yaws caused by Treponema pallidum subspecies pertenue ; Listeriosis due to Listeria monocytogenes ; Anthrax due to Bacillus anthracis ; Vincent’s infection caused by Fusobacterium fusiforme ; Actinomycosis caused by Actinomyces israelii ; Clostridial diseases caused by Clostridium species. In acute intestinal amebiasis, demeclocycline hydrochloride tablets USP may be a useful adjunct to amebicides. In severe acne, demeclocycline hydrochloride tablets USP may be a useful adjunctive therapy. To reduce the development of drug-resistant bacteria and maintain the effectiveness of demeclocycline hydrochloride tablets USP and other antibacterial drugs, demeclocycline hydrochloride tablets USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:99dfbaa8-a540-4cf7-a628-1568540eff66 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4392 biolink:treats MONDO:0019345 PMID:41385096 "[{""id"":""uuid:9eac1b8a-5802-4773-affe-7c8fe26f995c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b836c0a7-7c5f-49e9-ae99-66feb8102981"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Demeclocycline hydrochloride tablets USP is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by rickettsiae; Respiratory tract infections caused by Mycoplasma pneumoniae ; Lymphogranuloma venereum due to Chlamydia trachomatis ; Psittacosis (Ornithosis) due to Chlamydia psittaci ; Trachoma due to Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence; Inclusion conjunctivitis caused by Chlamydia trachomatis ; Nongonococcal urethritis in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis ; Relapsing fever due to Borrelia recurrentis ; Chancroid caused by Haemophilus ducreyi ; Plague due to Yersinia pestis ; Tularemia due to Francisella tularensis ; Cholera caused by Vibrio cholerae ; Campylobacter fetus infections caused by Campylobacter fetus ; Brucellosis due to Brucella species (in conjunction with streptomycin); Bartonellosis due to Bartonella bacilliformis ; Granuloma inguinale caused by Calymmatobacterium granulomatis ; Demeclocycline hydrochloride tablets USP is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli ; Enterobacter aerogenes ; Shigella species; Acinetobacter species; Respiratory tract infections caused by Haemophilus influenzae ; Respiratory tract and urinary tract infections caused by Klebsiella species. Demeclocycline hydrochloride tablets USP is indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae; Skin and skin structure infections caused by Staphylococcus aureus . (Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, tetracyclines, including demeclocycline hydrochloride, are alternative drugs in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae , and for the treatment of other uncomplicated gonococcal infections; Infections in women caused by Neisseria gonorrhoeae ; Syphilis caused by Treponema pallidum subspecies pallidum ; Yaws caused by Treponema pallidum subspecies pertenue ; Listeriosis due to Listeria monocytogenes ; Anthrax due to Bacillus anthracis ; Vincent’s infection caused by Fusobacterium fusiforme ; Actinomycosis caused by Actinomyces israelii ; Clostridial diseases caused by Clostridium species. In acute intestinal amebiasis, demeclocycline hydrochloride tablets USP may be a useful adjunct to amebicides. In severe acne, demeclocycline hydrochloride tablets USP may be a useful adjunctive therapy. To reduce the development of drug-resistant bacteria and maintain the effectiveness of demeclocycline hydrochloride tablets USP and other antibacterial drugs, demeclocycline hydrochloride tablets USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:1f6edc9f-c39f-4e8a-83a5-a6ec5b0f7de2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4392 biolink:treats MONDO:0006635 PMID:41385096 "[{""id"":""uuid:61942c6f-96fa-4773-86f0-0af2cc90700d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:add0e59f-5334-4a37-badd-59c116d8ae46"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Demeclocycline hydrochloride tablets USP is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by rickettsiae; Respiratory tract infections caused by Mycoplasma pneumoniae ; Lymphogranuloma venereum due to Chlamydia trachomatis ; Psittacosis (Ornithosis) due to Chlamydia psittaci ; Trachoma due to Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence; Inclusion conjunctivitis caused by Chlamydia trachomatis ; Nongonococcal urethritis in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis ; Relapsing fever due to Borrelia recurrentis ; Chancroid caused by Haemophilus ducreyi ; Plague due to Yersinia pestis ; Tularemia due to Francisella tularensis ; Cholera caused by Vibrio cholerae ; Campylobacter fetus infections caused by Campylobacter fetus ; Brucellosis due to Brucella species (in conjunction with streptomycin); Bartonellosis due to Bartonella bacilliformis ; Granuloma inguinale caused by Calymmatobacterium granulomatis ; Demeclocycline hydrochloride tablets USP is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli ; Enterobacter aerogenes ; Shigella species; Acinetobacter species; Respiratory tract infections caused by Haemophilus influenzae ; Respiratory tract and urinary tract infections caused by Klebsiella species. Demeclocycline hydrochloride tablets USP is indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae; Skin and skin structure infections caused by Staphylococcus aureus . (Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, tetracyclines, including demeclocycline hydrochloride, are alternative drugs in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae , and for the treatment of other uncomplicated gonococcal infections; Infections in women caused by Neisseria gonorrhoeae ; Syphilis caused by Treponema pallidum subspecies pallidum ; Yaws caused by Treponema pallidum subspecies pertenue ; Listeriosis due to Listeria monocytogenes ; Anthrax due to Bacillus anthracis ; Vincent’s infection caused by Fusobacterium fusiforme ; Actinomycosis caused by Actinomyces israelii ; Clostridial diseases caused by Clostridium species. In acute intestinal amebiasis, demeclocycline hydrochloride tablets USP may be a useful adjunct to amebicides. In severe acne, demeclocycline hydrochloride tablets USP may be a useful adjunctive therapy. To reduce the development of drug-resistant bacteria and maintain the effectiveness of demeclocycline hydrochloride tablets USP and other antibacterial drugs, demeclocycline hydrochloride tablets USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:b23b3ac0-d065-470e-8e49-4a64e8fc1112 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4392 biolink:treats HP:0005376 PMID:41385096 "[{""id"":""uuid:9c10fd28-e569-4786-a4da-f8b5522062c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f529365f-7cd2-4d02-903a-4eff1c3ff575"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Demeclocycline hydrochloride tablets USP is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by rickettsiae; Respiratory tract infections caused by Mycoplasma pneumoniae ; Lymphogranuloma venereum due to Chlamydia trachomatis ; Psittacosis (Ornithosis) due to Chlamydia psittaci ; Trachoma due to Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence; Inclusion conjunctivitis caused by Chlamydia trachomatis ; Nongonococcal urethritis in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis ; Relapsing fever due to Borrelia recurrentis ; Chancroid caused by Haemophilus ducreyi ; Plague due to Yersinia pestis ; Tularemia due to Francisella tularensis ; Cholera caused by Vibrio cholerae ; Campylobacter fetus infections caused by Campylobacter fetus ; Brucellosis due to Brucella species (in conjunction with streptomycin); Bartonellosis due to Bartonella bacilliformis ; Granuloma inguinale caused by Calymmatobacterium granulomatis ; Demeclocycline hydrochloride tablets USP is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli ; Enterobacter aerogenes ; Shigella species; Acinetobacter species; Respiratory tract infections caused by Haemophilus influenzae ; Respiratory tract and urinary tract infections caused by Klebsiella species. Demeclocycline hydrochloride tablets USP is indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae; Skin and skin structure infections caused by Staphylococcus aureus . (Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, tetracyclines, including demeclocycline hydrochloride, are alternative drugs in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae , and for the treatment of other uncomplicated gonococcal infections; Infections in women caused by Neisseria gonorrhoeae ; Syphilis caused by Treponema pallidum subspecies pallidum ; Yaws caused by Treponema pallidum subspecies pertenue ; Listeriosis due to Listeria monocytogenes ; Anthrax due to Bacillus anthracis ; Vincent’s infection caused by Fusobacterium fusiforme ; Actinomycosis caused by Actinomyces israelii ; Clostridial diseases caused by Clostridium species. In acute intestinal amebiasis, demeclocycline hydrochloride tablets USP may be a useful adjunct to amebicides. In severe acne, demeclocycline hydrochloride tablets USP may be a useful adjunctive therapy. To reduce the development of drug-resistant bacteria and maintain the effectiveness of demeclocycline hydrochloride tablets USP and other antibacterial drugs, demeclocycline hydrochloride tablets USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:77261d1a-3710-461b-996d-cb08ecdfb37b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4392 biolink:treats MONDO:0030603 PMID:41385096 "[{""id"":""uuid:214953b6-a824-468e-8103-349e105fe494"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:94be238e-f0dc-4025-9048-2ddcc8d9e4bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Demeclocycline hydrochloride tablets USP is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by rickettsiae; Respiratory tract infections caused by Mycoplasma pneumoniae ; Lymphogranuloma venereum due to Chlamydia trachomatis ; Psittacosis (Ornithosis) due to Chlamydia psittaci ; Trachoma due to Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence; Inclusion conjunctivitis caused by Chlamydia trachomatis ; Nongonococcal urethritis in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis ; Relapsing fever due to Borrelia recurrentis ; Chancroid caused by Haemophilus ducreyi ; Plague due to Yersinia pestis ; Tularemia due to Francisella tularensis ; Cholera caused by Vibrio cholerae ; Campylobacter fetus infections caused by Campylobacter fetus ; Brucellosis due to Brucella species (in conjunction with streptomycin); Bartonellosis due to Bartonella bacilliformis ; Granuloma inguinale caused by Calymmatobacterium granulomatis ; Demeclocycline hydrochloride tablets USP is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli ; Enterobacter aerogenes ; Shigella species; Acinetobacter species; Respiratory tract infections caused by Haemophilus influenzae ; Respiratory tract and urinary tract infections caused by Klebsiella species. Demeclocycline hydrochloride tablets USP is indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae; Skin and skin structure infections caused by Staphylococcus aureus . (Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, tetracyclines, including demeclocycline hydrochloride, are alternative drugs in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae , and for the treatment of other uncomplicated gonococcal infections; Infections in women caused by Neisseria gonorrhoeae ; Syphilis caused by Treponema pallidum subspecies pallidum ; Yaws caused by Treponema pallidum subspecies pertenue ; Listeriosis due to Listeria monocytogenes ; Anthrax due to Bacillus anthracis ; Vincent’s infection caused by Fusobacterium fusiforme ; Actinomycosis caused by Actinomyces israelii ; Clostridial diseases caused by Clostridium species. In acute intestinal amebiasis, demeclocycline hydrochloride tablets USP may be a useful adjunct to amebicides. In severe acne, demeclocycline hydrochloride tablets USP may be a useful adjunctive therapy. To reduce the development of drug-resistant bacteria and maintain the effectiveness of demeclocycline hydrochloride tablets USP and other antibacterial drugs, demeclocycline hydrochloride tablets USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:f5a7d840-14ce-4e26-8ac6-86981ca5ae71 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5959 biolink:treats MONDO:0005016 PMID:41385096 "[{""id"":""uuid:7cae827e-2c7f-447c-b321-dc6e1ff783e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:945ed703-c3a0-47f2-a1f5-0dc0b4636d98"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Irbesartan is an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) • Treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes, an elevated serum creatinine, and proteinuria. ( 1.2 ) uuid:848420f8-0dfb-4fdf-b3a7-8dec25062a87 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:187893 biolink:treats HP:0001257 PMID:41385096 "[{""id"":""uuid:ad1e31b3-59d7-439c-a409-a896bfdb5afa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b580a70e-b90d-4c68-a049-9caa182ef243"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f4c104ca-0033-40a9-bc4c-9de50850e049"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LIORESAL INTRATHECAL (baclofen injection) is indicated for use in the management of severe spasticity. Patients should first respond to a screening dose of intrathecal baclofen prior to consideration for long term infusion via an implantable pump. For spasticity of spinal cord origin, chronic infusion of LIORESAL INTRATHECAL via an implantable pump should be reserved for patients unresponsive to oral baclofen therapy, or those who experience intolerable CNS side effects at effective doses. Patients with spasticity due to traumatic brain injury should wait at least one year after the injury before consideration of long term intrathecal baclofen therapy. LIORESAL INTRATHECAL is intended for use by the intrathecal route in single bolus test doses (via spinal catheter or lumbar puncture) and, for chronic use, only in implantable pumps approved by the FDA specifically for the administration of LIORESAL INTRATHECAL into the intrathecal space. Spasticity of Spinal Cord Origin: Evidence supporting the efficacy of LIORESAL INTRATHECAL was obtained in randomized, controlled investigations that compared the effects of either a single intrathecal dose or a three day intrathecal infusion of LIORESAL INTRATHECAL to placebo in patients with severe spasticity and spasms due to either spinal cord trauma or multiple sclerosis. LIORESAL INTRATHECAL was superior to placebo on both principal outcome measures employed: change from baseline in the Ashworth rating of spasticity and the frequency of spasms. Spasticity of Cerebral Origin: The efficacy of LIORESAL INTRATHECAL was investigated in three controlled clinical trials; two enrolled patients with cerebral palsy and one enrolled patients with spasticity due to previous brain injury. The first study, a randomized controlled cross-over trial of 51 patients with cerebral palsy, provided strong, statistically significant results; LIORESAL INTRATHECAL was superior to placebo in reducing spasticity as measured by the Ashworth Scale. A second cross-over study was conducted in 11 patients with spasticity arising from brain injury. Despite the small sample size, the study yielded a nearly significant test statistic (p=0.066) and provided directionally favorable results. The last study, however, did not provide data that could be reliably analyzed. LIORESAL INTRATHECAL therapy may be considered an alternative to destructive neurosurgical procedures. Prior to implantation of a device for chronic intrathecal infusion of LIORESAL INTRATHECAL, patients must show a response to LIORESAL INTRATHECAL in a screening trial (see Dosage and Administration).|[PMDA] Drugs with a new route of intrathecal infusion indicated for the treatment of severe spasticity resulting from cerebrospinal diseases [Orphan drug] uuid:71cbfa24-3b9f-4406-a1d0-f24fa6cf82e2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:187893 biolink:treats MONDO:0043510 PMID:41385096 "[{""id"":""uuid:5b3907b9-ac62-4a5a-bab3-e3f984450ed8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1336f0ef-a02c-4a6f-ab58-67a702869c73"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LIORESAL INTRATHECAL (baclofen injection) is indicated for use in the management of severe spasticity. Patients should first respond to a screening dose of intrathecal baclofen prior to consideration for long term infusion via an implantable pump. For spasticity of spinal cord origin, chronic infusion of LIORESAL INTRATHECAL via an implantable pump should be reserved for patients unresponsive to oral baclofen therapy, or those who experience intolerable CNS side effects at effective doses. Patients with spasticity due to traumatic brain injury should wait at least one year after the injury before consideration of long term intrathecal baclofen therapy. LIORESAL INTRATHECAL is intended for use by the intrathecal route in single bolus test doses (via spinal catheter or lumbar puncture) and, for chronic use, only in implantable pumps approved by the FDA specifically for the administration of LIORESAL INTRATHECAL into the intrathecal space. Spasticity of Spinal Cord Origin: Evidence supporting the efficacy of LIORESAL INTRATHECAL was obtained in randomized, controlled investigations that compared the effects of either a single intrathecal dose or a three day intrathecal infusion of LIORESAL INTRATHECAL to placebo in patients with severe spasticity and spasms due to either spinal cord trauma or multiple sclerosis. LIORESAL INTRATHECAL was superior to placebo on both principal outcome measures employed: change from baseline in the Ashworth rating of spasticity and the frequency of spasms. Spasticity of Cerebral Origin: The efficacy of LIORESAL INTRATHECAL was investigated in three controlled clinical trials; two enrolled patients with cerebral palsy and one enrolled patients with spasticity due to previous brain injury. The first study, a randomized controlled cross-over trial of 51 patients with cerebral palsy, provided strong, statistically significant results; LIORESAL INTRATHECAL was superior to placebo in reducing spasticity as measured by the Ashworth Scale. A second cross-over study was conducted in 11 patients with spasticity arising from brain injury. Despite the small sample size, the study yielded a nearly significant test statistic (p=0.066) and provided directionally favorable results. The last study, however, did not provide data that could be reliably analyzed. LIORESAL INTRATHECAL therapy may be considered an alternative to destructive neurosurgical procedures. Prior to implantation of a device for chronic intrathecal infusion of LIORESAL INTRATHECAL, patients must show a response to LIORESAL INTRATHECAL in a screening trial (see Dosage and Administration). uuid:39b012e5-44f3-4271-9dc0-47aba33c6d38 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:100241 biolink:treats MONDO:0019095 PMID:41385096 "[{""id"":""uuid:0f4913cc-ea90-42c5-a62f-ed576999dcea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:669d4e6d-7019-422d-a032-35465eaad850"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ciprofloxacin is indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in the conditions and patient populations listed below. 1.1 Urinary Tract Infections Ciprofloxacin is indicated in adult patients for treatment of urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Serratia marcescens, Proteus mirabilis, Providencia rettgeri, Morganella morganii, Citrobacter koseri, Citrobacter freundii, Pseudomonas aeruginosa, methicillin-susceptible Staphylococcus epidermidis, Staphylococcus saprophyticus, or Enterococcus faecalis. 1.2 Acute Uncomplicated Cystitis Ciprofloxacin is indicated in adult female patients for treatment of acute uncomplicated cystitis caused by Escherichia coli or Staphylococcus saprophyticus. 1.3 Chronic Bacterial Prostatitis Ciprofloxacin is indicated in adult patients for treatment of chronic bacterial prostatitis caused by Escherichia coli or Proteus mirabilis. 1.4 Lower Respiratory Tract Infections Ciprofloxacin is indicated in adult patients for treatment of lower respiratory tract infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Pseudomonas aeruginosa, Haemophilus influenzae, Haemophilus parainfluenzae, or Streptococcus pneumoniae. Also, ciprofloxacin is indicated for the treatment of acute exacerbations of chronic bronchitis caused by Moraxella catarrhalis [see INDICATIONS AND USAGE (1.15)]. 1.5 Acute Sinusitis Ciprofloxacin is indicated in adult patients for treatment of acute sinusitis caused by Haemophilus influenzae, Streptococcus pneumoniae, or Moraxella catarrhalis. 1.6 Skin and Skin Structure Infections Ciprofloxacin is indicated in adult patients for treatment of skin and skin structure infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Proteus vulgaris, Providencia stuartii, Morganella morganii, Citrobacter freundii, Pseudomonas aeruginosa, methicillin-susceptible Staphylococcus aureus, methicillin-susceptible Staphylococcus epidermidis, or Streptococcus pyogenes. 1.7 Bone and Joint Infections Ciprofloxacin is indicated in adult patients for treatment of bone and joint infections caused by Enterobacter cloacae, Serratia marcescens, or Pseudomonas aeruginosa. 1.8 Complicated Intra-Abdominal Infections Ciprofloxacin is indicated in adult patients for treatment of complicated intra-abdominal infections (used in combination with metronidazole) caused by Escherichia coli, Pseudomonas aeruginosa, Proteus mirabilis, Klebsiella pneumoniae, or Bacteroides fragilis. 1.9 Infectious Diarrhea Ciprofloxacin is indicated in adult patients for treatment of infectious diarrhea caused by Escherichia coli (enterotoxigenic isolates), Campylobacter jejuni, Shigella boydii † , Shigella dysenteriae, Shigella flexneri or Shigella sonnei† when antibacterial therapy is indicated. †Although treatment of infections due to this organism in this organ system demonstrated a clinically significant outcome, efficacy was studied in fewer than 10 patients. 1.10 Typhoid Fever (Enteric Fever) Ciprofloxacin is indicated in adult patients for treatment of typhoid fever (enteric fever) caused by Salmonella typhi. The efficacy of ciprofloxacin in the eradication of the chronic typhoid carrier state has not been demonstrated. 1.11 Uncomplicated Cervical and Urethral Gonorrhea Ciprofloxacin is indicated in adult patients for treatment of uncomplicated cervical and urethral gonorrhea due to Neisseria gonorrhoeae [see WARNINGS AND PRECAUTIONS (5.16)]. 1.12 Complicated Urinary Tract Infections and Pyelonephritis Ciprofloxacin is indicated in pediatric patients one to 17 years of age for treatment of complicated urinary tract infections (cUTI) and pyelonephritis due to Escherichia coli [see INDICATIONS AND USAGE (1.15) and USE IN SPECIFIC POPULATIONS (8.4)]. 1.13 Inhalational Anthrax (post-exposure) Ciprofloxacin is indicated in adults and pediatric patients from birth to 17 years of age for inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. Ciprofloxacin serum concentrations achieved in humans served as a surrogate endpoint reasonably likely to predict clinical benefit and provided the initial basis for approval of this indication.1 Supportive clinical information for ciprofloxacin for anthrax post-exposure prophylaxis was obtained during the anthrax bioterror attacks of October 2001. [See CLINICAL STUDIES (14.2).] 1.14 Plague Ciprofloxacin is indicated for treatment of plague, including pneumonic and septicemic plague, due to Yersinia pestis (Y. pestis) and prophylaxis for plague in adults and pediatric patients from birth to 17 years of age. Efficacy studies of ciprofloxacin could not be conducted in humans with plague for feasibility reasons. Therefore this indication is based on an efficacy study conducted in animals only [see CLINICAL STUDIES (14.3) ]. 1.15 Limitation of Use Use in Pediatric Patients Although effective in clinical trials, ciprofloxacin is not a drug of first choice in the pediatric population due to an increased incidence of adverse events compared to controls, including events related to joints and/or surrounding tissues. Ciprofloxacin, like other fluoroquinolones, is associated with arthropathy and histopathological changes in weight-bearing joints of juvenile animals [see WARNINGS AND PRECAUTIONS (5.11), ADVERSE REACTIONS (6.1), USE IN SPECIFIC POPULATIONS (8.4) and NONCLINICAL TOXICOLOGY (13.2)]. Lower Respiratory Tract Infections Ciprofloxacin is not a drug of first choice in the treatment of presumed or confirmed pneumonia secondary to Streptococcus pneumoniae [see INDICATIONS AND USAGE (1.4)]. 1.16 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of ciprofloxacin and other antibacterial drugs ciprofloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. If anaerobic organisms are suspected of contributing to the infection, appropriate therapy should be administered. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to ciprofloxacin. Therapy with ciprofloxacin may be initiated before results of these tests are known; once results become available appropriate therapy should be continued. As with other drugs, some isolates of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with ciprofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information not only on the therapeutic effect of the antimicrobial agent but also on the possible emergence of bacterial resistance. uuid:19f7143b-c905-4530-bf57-2e832b190e0a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:100241 biolink:treats MONDO:0001024 PMID:41385096 "[{""id"":""uuid:5a749e84-1948-482f-9c70-3ca0dfa4c2b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ee9708d4-7d31-4dcc-b880-5670e3e36cd2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ciprofloxacin is indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in the conditions and patient populations listed below. 1.1 Urinary Tract Infections Ciprofloxacin is indicated in adult patients for treatment of urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Serratia marcescens, Proteus mirabilis, Providencia rettgeri, Morganella morganii, Citrobacter koseri, Citrobacter freundii, Pseudomonas aeruginosa, methicillin-susceptible Staphylococcus epidermidis, Staphylococcus saprophyticus, or Enterococcus faecalis. 1.2 Acute Uncomplicated Cystitis Ciprofloxacin is indicated in adult female patients for treatment of acute uncomplicated cystitis caused by Escherichia coli or Staphylococcus saprophyticus. 1.3 Chronic Bacterial Prostatitis Ciprofloxacin is indicated in adult patients for treatment of chronic bacterial prostatitis caused by Escherichia coli or Proteus mirabilis. 1.4 Lower Respiratory Tract Infections Ciprofloxacin is indicated in adult patients for treatment of lower respiratory tract infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Pseudomonas aeruginosa, Haemophilus influenzae, Haemophilus parainfluenzae, or Streptococcus pneumoniae. Also, ciprofloxacin is indicated for the treatment of acute exacerbations of chronic bronchitis caused by Moraxella catarrhalis [see INDICATIONS AND USAGE (1.15)]. 1.5 Acute Sinusitis Ciprofloxacin is indicated in adult patients for treatment of acute sinusitis caused by Haemophilus influenzae, Streptococcus pneumoniae, or Moraxella catarrhalis. 1.6 Skin and Skin Structure Infections Ciprofloxacin is indicated in adult patients for treatment of skin and skin structure infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Proteus vulgaris, Providencia stuartii, Morganella morganii, Citrobacter freundii, Pseudomonas aeruginosa, methicillin-susceptible Staphylococcus aureus, methicillin-susceptible Staphylococcus epidermidis, or Streptococcus pyogenes. 1.7 Bone and Joint Infections Ciprofloxacin is indicated in adult patients for treatment of bone and joint infections caused by Enterobacter cloacae, Serratia marcescens, or Pseudomonas aeruginosa. 1.8 Complicated Intra-Abdominal Infections Ciprofloxacin is indicated in adult patients for treatment of complicated intra-abdominal infections (used in combination with metronidazole) caused by Escherichia coli, Pseudomonas aeruginosa, Proteus mirabilis, Klebsiella pneumoniae, or Bacteroides fragilis. 1.9 Infectious Diarrhea Ciprofloxacin is indicated in adult patients for treatment of infectious diarrhea caused by Escherichia coli (enterotoxigenic isolates), Campylobacter jejuni, Shigella boydii † , Shigella dysenteriae, Shigella flexneri or Shigella sonnei† when antibacterial therapy is indicated. †Although treatment of infections due to this organism in this organ system demonstrated a clinically significant outcome, efficacy was studied in fewer than 10 patients. 1.10 Typhoid Fever (Enteric Fever) Ciprofloxacin is indicated in adult patients for treatment of typhoid fever (enteric fever) caused by Salmonella typhi. The efficacy of ciprofloxacin in the eradication of the chronic typhoid carrier state has not been demonstrated. 1.11 Uncomplicated Cervical and Urethral Gonorrhea Ciprofloxacin is indicated in adult patients for treatment of uncomplicated cervical and urethral gonorrhea due to Neisseria gonorrhoeae [see WARNINGS AND PRECAUTIONS (5.16)]. 1.12 Complicated Urinary Tract Infections and Pyelonephritis Ciprofloxacin is indicated in pediatric patients one to 17 years of age for treatment of complicated urinary tract infections (cUTI) and pyelonephritis due to Escherichia coli [see INDICATIONS AND USAGE (1.15) and USE IN SPECIFIC POPULATIONS (8.4)]. 1.13 Inhalational Anthrax (post-exposure) Ciprofloxacin is indicated in adults and pediatric patients from birth to 17 years of age for inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. Ciprofloxacin serum concentrations achieved in humans served as a surrogate endpoint reasonably likely to predict clinical benefit and provided the initial basis for approval of this indication.1 Supportive clinical information for ciprofloxacin for anthrax post-exposure prophylaxis was obtained during the anthrax bioterror attacks of October 2001. [See CLINICAL STUDIES (14.2).] 1.14 Plague Ciprofloxacin is indicated for treatment of plague, including pneumonic and septicemic plague, due to Yersinia pestis (Y. pestis) and prophylaxis for plague in adults and pediatric patients from birth to 17 years of age. Efficacy studies of ciprofloxacin could not be conducted in humans with plague for feasibility reasons. Therefore this indication is based on an efficacy study conducted in animals only [see CLINICAL STUDIES (14.3) ]. 1.15 Limitation of Use Use in Pediatric Patients Although effective in clinical trials, ciprofloxacin is not a drug of first choice in the pediatric population due to an increased incidence of adverse events compared to controls, including events related to joints and/or surrounding tissues. Ciprofloxacin, like other fluoroquinolones, is associated with arthropathy and histopathological changes in weight-bearing joints of juvenile animals [see WARNINGS AND PRECAUTIONS (5.11), ADVERSE REACTIONS (6.1), USE IN SPECIFIC POPULATIONS (8.4) and NONCLINICAL TOXICOLOGY (13.2)]. Lower Respiratory Tract Infections Ciprofloxacin is not a drug of first choice in the treatment of presumed or confirmed pneumonia secondary to Streptococcus pneumoniae [see INDICATIONS AND USAGE (1.4)]. 1.16 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of ciprofloxacin and other antibacterial drugs ciprofloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. If anaerobic organisms are suspected of contributing to the infection, appropriate therapy should be administered. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to ciprofloxacin. Therapy with ciprofloxacin may be initiated before results of these tests are known; once results become available appropriate therapy should be continued. As with other drugs, some isolates of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with ciprofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information not only on the therapeutic effect of the antimicrobial agent but also on the possible emergence of bacterial resistance. uuid:10c850f4-4cd1-4d28-b2da-089d4d40773e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:100241 biolink:treats MONDO:0005956 PMID:41385096 "[{""id"":""uuid:6b2516d4-4ea5-4118-b245-394b4f83e914"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:43acfff1-856b-44fd-86b2-6d4d4392a962"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ciprofloxacin is indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in the conditions and patient populations listed below. 1.1 Urinary Tract Infections Ciprofloxacin is indicated in adult patients for treatment of urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Serratia marcescens, Proteus mirabilis, Providencia rettgeri, Morganella morganii, Citrobacter koseri, Citrobacter freundii, Pseudomonas aeruginosa, methicillin-susceptible Staphylococcus epidermidis, Staphylococcus saprophyticus, or Enterococcus faecalis. 1.2 Acute Uncomplicated Cystitis Ciprofloxacin is indicated in adult female patients for treatment of acute uncomplicated cystitis caused by Escherichia coli or Staphylococcus saprophyticus. 1.3 Chronic Bacterial Prostatitis Ciprofloxacin is indicated in adult patients for treatment of chronic bacterial prostatitis caused by Escherichia coli or Proteus mirabilis. 1.4 Lower Respiratory Tract Infections Ciprofloxacin is indicated in adult patients for treatment of lower respiratory tract infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Pseudomonas aeruginosa, Haemophilus influenzae, Haemophilus parainfluenzae, or Streptococcus pneumoniae. Also, ciprofloxacin is indicated for the treatment of acute exacerbations of chronic bronchitis caused by Moraxella catarrhalis [see INDICATIONS AND USAGE (1.15)]. 1.5 Acute Sinusitis Ciprofloxacin is indicated in adult patients for treatment of acute sinusitis caused by Haemophilus influenzae, Streptococcus pneumoniae, or Moraxella catarrhalis. 1.6 Skin and Skin Structure Infections Ciprofloxacin is indicated in adult patients for treatment of skin and skin structure infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Proteus vulgaris, Providencia stuartii, Morganella morganii, Citrobacter freundii, Pseudomonas aeruginosa, methicillin-susceptible Staphylococcus aureus, methicillin-susceptible Staphylococcus epidermidis, or Streptococcus pyogenes. 1.7 Bone and Joint Infections Ciprofloxacin is indicated in adult patients for treatment of bone and joint infections caused by Enterobacter cloacae, Serratia marcescens, or Pseudomonas aeruginosa. 1.8 Complicated Intra-Abdominal Infections Ciprofloxacin is indicated in adult patients for treatment of complicated intra-abdominal infections (used in combination with metronidazole) caused by Escherichia coli, Pseudomonas aeruginosa, Proteus mirabilis, Klebsiella pneumoniae, or Bacteroides fragilis. 1.9 Infectious Diarrhea Ciprofloxacin is indicated in adult patients for treatment of infectious diarrhea caused by Escherichia coli (enterotoxigenic isolates), Campylobacter jejuni, Shigella boydii † , Shigella dysenteriae, Shigella flexneri or Shigella sonnei† when antibacterial therapy is indicated. †Although treatment of infections due to this organism in this organ system demonstrated a clinically significant outcome, efficacy was studied in fewer than 10 patients. 1.10 Typhoid Fever (Enteric Fever) Ciprofloxacin is indicated in adult patients for treatment of typhoid fever (enteric fever) caused by Salmonella typhi. The efficacy of ciprofloxacin in the eradication of the chronic typhoid carrier state has not been demonstrated. 1.11 Uncomplicated Cervical and Urethral Gonorrhea Ciprofloxacin is indicated in adult patients for treatment of uncomplicated cervical and urethral gonorrhea due to Neisseria gonorrhoeae [see WARNINGS AND PRECAUTIONS (5.16)]. 1.12 Complicated Urinary Tract Infections and Pyelonephritis Ciprofloxacin is indicated in pediatric patients one to 17 years of age for treatment of complicated urinary tract infections (cUTI) and pyelonephritis due to Escherichia coli [see INDICATIONS AND USAGE (1.15) and USE IN SPECIFIC POPULATIONS (8.4)]. 1.13 Inhalational Anthrax (post-exposure) Ciprofloxacin is indicated in adults and pediatric patients from birth to 17 years of age for inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. Ciprofloxacin serum concentrations achieved in humans served as a surrogate endpoint reasonably likely to predict clinical benefit and provided the initial basis for approval of this indication.1 Supportive clinical information for ciprofloxacin for anthrax post-exposure prophylaxis was obtained during the anthrax bioterror attacks of October 2001. [See CLINICAL STUDIES (14.2).] 1.14 Plague Ciprofloxacin is indicated for treatment of plague, including pneumonic and septicemic plague, due to Yersinia pestis (Y. pestis) and prophylaxis for plague in adults and pediatric patients from birth to 17 years of age. Efficacy studies of ciprofloxacin could not be conducted in humans with plague for feasibility reasons. Therefore this indication is based on an efficacy study conducted in animals only [see CLINICAL STUDIES (14.3) ]. 1.15 Limitation of Use Use in Pediatric Patients Although effective in clinical trials, ciprofloxacin is not a drug of first choice in the pediatric population due to an increased incidence of adverse events compared to controls, including events related to joints and/or surrounding tissues. Ciprofloxacin, like other fluoroquinolones, is associated with arthropathy and histopathological changes in weight-bearing joints of juvenile animals [see WARNINGS AND PRECAUTIONS (5.11), ADVERSE REACTIONS (6.1), USE IN SPECIFIC POPULATIONS (8.4) and NONCLINICAL TOXICOLOGY (13.2)]. Lower Respiratory Tract Infections Ciprofloxacin is not a drug of first choice in the treatment of presumed or confirmed pneumonia secondary to Streptococcus pneumoniae [see INDICATIONS AND USAGE (1.4)]. 1.16 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of ciprofloxacin and other antibacterial drugs ciprofloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. If anaerobic organisms are suspected of contributing to the infection, appropriate therapy should be administered. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to ciprofloxacin. Therapy with ciprofloxacin may be initiated before results of these tests are known; once results become available appropriate therapy should be continued. As with other drugs, some isolates of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with ciprofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information not only on the therapeutic effect of the antimicrobial agent but also on the possible emergence of bacterial resistance. uuid:efacb018-942c-47d9-9925-f50230335af1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:100241 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:192a0d60-03b6-4210-9d57-6e98152cbe35"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:42269208-9683-461d-a579-c2b3879b769f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c7446d83-3f68-432f-a247-d6a5a1a41bd2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ciprofloxacin is indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in the conditions and patient populations listed below. 1.1 Urinary Tract Infections Ciprofloxacin is indicated in adult patients for treatment of urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Serratia marcescens, Proteus mirabilis, Providencia rettgeri, Morganella morganii, Citrobacter koseri, Citrobacter freundii, Pseudomonas aeruginosa, methicillin-susceptible Staphylococcus epidermidis, Staphylococcus saprophyticus, or Enterococcus faecalis. 1.2 Acute Uncomplicated Cystitis Ciprofloxacin is indicated in adult female patients for treatment of acute uncomplicated cystitis caused by Escherichia coli or Staphylococcus saprophyticus. 1.3 Chronic Bacterial Prostatitis Ciprofloxacin is indicated in adult patients for treatment of chronic bacterial prostatitis caused by Escherichia coli or Proteus mirabilis. 1.4 Lower Respiratory Tract Infections Ciprofloxacin is indicated in adult patients for treatment of lower respiratory tract infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Pseudomonas aeruginosa, Haemophilus influenzae, Haemophilus parainfluenzae, or Streptococcus pneumoniae. Also, ciprofloxacin is indicated for the treatment of acute exacerbations of chronic bronchitis caused by Moraxella catarrhalis [see INDICATIONS AND USAGE (1.15)]. 1.5 Acute Sinusitis Ciprofloxacin is indicated in adult patients for treatment of acute sinusitis caused by Haemophilus influenzae, Streptococcus pneumoniae, or Moraxella catarrhalis. 1.6 Skin and Skin Structure Infections Ciprofloxacin is indicated in adult patients for treatment of skin and skin structure infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Proteus vulgaris, Providencia stuartii, Morganella morganii, Citrobacter freundii, Pseudomonas aeruginosa, methicillin-susceptible Staphylococcus aureus, methicillin-susceptible Staphylococcus epidermidis, or Streptococcus pyogenes. 1.7 Bone and Joint Infections Ciprofloxacin is indicated in adult patients for treatment of bone and joint infections caused by Enterobacter cloacae, Serratia marcescens, or Pseudomonas aeruginosa. 1.8 Complicated Intra-Abdominal Infections Ciprofloxacin is indicated in adult patients for treatment of complicated intra-abdominal infections (used in combination with metronidazole) caused by Escherichia coli, Pseudomonas aeruginosa, Proteus mirabilis, Klebsiella pneumoniae, or Bacteroides fragilis. 1.9 Infectious Diarrhea Ciprofloxacin is indicated in adult patients for treatment of infectious diarrhea caused by Escherichia coli (enterotoxigenic isolates), Campylobacter jejuni, Shigella boydii † , Shigella dysenteriae, Shigella flexneri or Shigella sonnei† when antibacterial therapy is indicated. †Although treatment of infections due to this organism in this organ system demonstrated a clinically significant outcome, efficacy was studied in fewer than 10 patients. 1.10 Typhoid Fever (Enteric Fever) Ciprofloxacin is indicated in adult patients for treatment of typhoid fever (enteric fever) caused by Salmonella typhi. The efficacy of ciprofloxacin in the eradication of the chronic typhoid carrier state has not been demonstrated. 1.11 Uncomplicated Cervical and Urethral Gonorrhea Ciprofloxacin is indicated in adult patients for treatment of uncomplicated cervical and urethral gonorrhea due to Neisseria gonorrhoeae [see WARNINGS AND PRECAUTIONS (5.16)]. 1.12 Complicated Urinary Tract Infections and Pyelonephritis Ciprofloxacin is indicated in pediatric patients one to 17 years of age for treatment of complicated urinary tract infections (cUTI) and pyelonephritis due to Escherichia coli [see INDICATIONS AND USAGE (1.15) and USE IN SPECIFIC POPULATIONS (8.4)]. 1.13 Inhalational Anthrax (post-exposure) Ciprofloxacin is indicated in adults and pediatric patients from birth to 17 years of age for inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. Ciprofloxacin serum concentrations achieved in humans served as a surrogate endpoint reasonably likely to predict clinical benefit and provided the initial basis for approval of this indication.1 Supportive clinical information for ciprofloxacin for anthrax post-exposure prophylaxis was obtained during the anthrax bioterror attacks of October 2001. [See CLINICAL STUDIES (14.2).] 1.14 Plague Ciprofloxacin is indicated for treatment of plague, including pneumonic and septicemic plague, due to Yersinia pestis (Y. pestis) and prophylaxis for plague in adults and pediatric patients from birth to 17 years of age. Efficacy studies of ciprofloxacin could not be conducted in humans with plague for feasibility reasons. Therefore this indication is based on an efficacy study conducted in animals only [see CLINICAL STUDIES (14.3) ]. 1.15 Limitation of Use Use in Pediatric Patients Although effective in clinical trials, ciprofloxacin is not a drug of first choice in the pediatric population due to an increased incidence of adverse events compared to controls, including events related to joints and/or surrounding tissues. Ciprofloxacin, like other fluoroquinolones, is associated with arthropathy and histopathological changes in weight-bearing joints of juvenile animals [see WARNINGS AND PRECAUTIONS (5.11), ADVERSE REACTIONS (6.1), USE IN SPECIFIC POPULATIONS (8.4) and NONCLINICAL TOXICOLOGY (13.2)]. Lower Respiratory Tract Infections Ciprofloxacin is not a drug of first choice in the treatment of presumed or confirmed pneumonia secondary to Streptococcus pneumoniae [see INDICATIONS AND USAGE (1.4)]. 1.16 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of ciprofloxacin and other antibacterial drugs ciprofloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. If anaerobic organisms are suspected of contributing to the infection, appropriate therapy should be administered. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to ciprofloxacin. Therapy with ciprofloxacin may be initiated before results of these tests are known; once results become available appropriate therapy should be continued. As with other drugs, some isolates of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with ciprofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information not only on the therapeutic effect of the antimicrobial agent but also on the possible emergence of bacterial resistance.|[PMDA] A drug with a new increased dose for adults indicated for the treatment of sepsis, pneumonia, etc., and also with new indications and new dosages for children for both the treatment of complicated cystitis, pyelonephritis and anthrax, and the improvement of symptoms associated with respiratory infection caused by Pseudomonas aeruginosa in cystic fibrosis. uuid:65011c53-09b1-482d-8712-80d81984de15 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8772 biolink:treats MONDO:0005298 PMID:41385096 "[{""id"":""uuid:03a32c51-95c2-43ef-8c91-d51c3d7d7c4a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:16b5ce52-6a90-48b0-856c-f0fc47457b46"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ee3a546b-6ca3-4e9a-869c-03463865f62f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Raloxifene hydrochloride tablet, USP is an estrogen agonist/antagonist indicated for: Treatment of osteoporosis in postmenopausal women. ( 1.1 )|[EMA] Optruma is indicated for the treatment and prevention of osteoporosis in post-menopausal women. A significant reduction in the incidence of vertebral, but not hip fractures has been demonstrated. When determining the choice of Optruma or other therapies, including oestrogens, for an individual postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefits (see section 5.1). uuid:9a1f4073-9505-4249-8862-d7571aa464b8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8772 biolink:treats MONDO:0008159 PMID:41385096 "[{""id"":""uuid:fb60a3b8-0748-47a5-a60a-21bc18f44d84"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:41b51a34-0c31-4276-8e0d-f115458c02bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Raloxifene hydrochloride tablet, USP is an estrogen agonist/antagonist indicated for: Treatment of osteoporosis in postmenopausal women. ( 1.1 ) uuid:c34732ce-d99d-4fcc-a849-8e1fe3ea4aa2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:36795 biolink:treats UMLS:C0457949 PMID:41385096 "[{""id"":""uuid:75cfae82-e4ef-49a0-8fca-354f6484ca21"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:420ea61f-6808-4001-8b2a-f40b79992056"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:7e099917-b77c-4578-8457-585088322c5b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Major Depressive Disorder Duloxetine Delayed-release Capsules are indicated for the treatment of major depressive disorder (MDD). The efficacy of Duloxetine Delayed-release Capsules was established in four short-term and one maintenance trial in adults [see Clinical Studies (14.1) ]. A major depressive episode (DSM-IV) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least 5 of the following 9 symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, or a suicide attempt or suicidal ideation. 1.2 Generalized Anxiety Disorder Duloxetine Delayed-release Capsules are indicated for the treatment of generalized anxiety disorder (GAD). The efficacy of Duloxetine Delayed-release Capsules was established in three short-term trials and one maintenance trial in adults [see Clinical Studies (14.2) ]. Generalized anxiety disorder is defined by the DSM-IV as excessive anxiety and worry, present more days than not, for at least 6 months. The excessive anxiety and worry must be difficult to control and must cause significant distress or impairment in normal functioning. It must be associated with at least 3 of the following 6 symptoms: restlessness or feeling keyed up or on edge, being easily fatigued, difficulty concentrating or mind going blank, irritability, muscle tension, and/or sleep disturbance. 1.3 Diabetic Peripheral Neuropathic Pain Duloxetine Delayed-release Capsules are indicated for the management of neuropathic pain (DPNP) associated with diabetic peripheral neuropathy [see Clinical Studies (14.3) ]. 1.5 Chronic Musculoskeletal Pain Duloxetine Delayed-release Capsules are indicated for the management of chronic musculoskeletal pain. This has been established in studies in patients with chronic low back pain (CLBP) and chronic pain due to osteoarthritis [see Clinical Studies (14.5) ].|[PMDA] Drugs with a new additional indication for the treatment of pain associated with chronic low back pain. uuid:b1d979d6-7555-4226-972d-433cf1b96884 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:36795 biolink:treats MONDO:0005178 PMID:41385096 "[{""id"":""uuid:bebec9c3-e5a2-4770-a93d-db908abaefce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:48c76a9e-4ef1-4e30-b2f4-70cbb5a74441"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Major Depressive Disorder Duloxetine Delayed-release Capsules are indicated for the treatment of major depressive disorder (MDD). The efficacy of Duloxetine Delayed-release Capsules was established in four short-term and one maintenance trial in adults [see Clinical Studies (14.1) ]. A major depressive episode (DSM-IV) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least 5 of the following 9 symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, or a suicide attempt or suicidal ideation. 1.2 Generalized Anxiety Disorder Duloxetine Delayed-release Capsules are indicated for the treatment of generalized anxiety disorder (GAD). The efficacy of Duloxetine Delayed-release Capsules was established in three short-term trials and one maintenance trial in adults [see Clinical Studies (14.2) ]. Generalized anxiety disorder is defined by the DSM-IV as excessive anxiety and worry, present more days than not, for at least 6 months. The excessive anxiety and worry must be difficult to control and must cause significant distress or impairment in normal functioning. It must be associated with at least 3 of the following 6 symptoms: restlessness or feeling keyed up or on edge, being easily fatigued, difficulty concentrating or mind going blank, irritability, muscle tension, and/or sleep disturbance. 1.3 Diabetic Peripheral Neuropathic Pain Duloxetine Delayed-release Capsules are indicated for the management of neuropathic pain (DPNP) associated with diabetic peripheral neuropathy [see Clinical Studies (14.3) ]. 1.5 Chronic Musculoskeletal Pain Duloxetine Delayed-release Capsules are indicated for the management of chronic musculoskeletal pain. This has been established in studies in patients with chronic low back pain (CLBP) and chronic pain due to osteoarthritis [see Clinical Studies (14.5) ]. uuid:6d09f2a9-3196-4183-993f-ada54ce28fef biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9123 biolink:treats MONDO:0003709 PMID:41385096 "[{""id"":""uuid:602a7d14-5bf3-446a-8799-e112fa4ff969"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a4a2a9f3-f06f-4082-ac08-64abf26bc2f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Major Depressive Disorder – Sertraline hydrochloride is indicated for the treatment of major depressive disorder in adults. The efficacy of Sertraline hydrochloride in the treatment of a major depressive episode was established in six to eight week controlled trials of adult outpatients whose diagnoses corresponded most closely to the DSM-III category of major depressive disorder (see Clinical Trials under CLINICAL PHARMACOLOGY). A major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks); it should include at least 4 of the following 8 symptoms: change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suicide attempt or suicidal ideation. The antidepressant action of sertraline hydrochloride in hospitalized depressed patients has not been adequately studied. The efficacy of sertraline hydrochloride in maintaining an antidepressant response for up to 44 weeks following 8 weeks of open-label acute treatment (52 weeks total) was demonstrated in a placebo-controlled trial. The usefulness of the drug in patients receiving sertraline hydrochloride for extended periods should be reevaluated periodically (see Clinical Trials under CLINICAL PHARMACOLOGY). Obsessive-Compulsive Disorder– Sertraline hydrochloride is indicated for the treatment of obsessions and compulsions in patients with obsessive-compulsive disorder (OCD), as defined in the DSM-III-R; i.e., the obsessions or compulsions cause marked distress, are time-consuming, or significantly interfere with social or occupational functioning. The efficacy of Sertraline hydrochloride was established in 12-week trials with obsessive-compulsive outpatients having diagnoses of obsessive-compulsive disorder as defined according to DSM-III or DSM-III-R criteria (see Clinical Trials under CLINICAL PHARMACOLOGY). Obsessive-compulsive disorder is characterized by recurrent and persistent ideas, thoughts, impulses, or images (obsessions) that are ego-dystonic and/or repetitive, purposeful, and intentional behaviors (compulsions) that are recognized by the person as excessive or unreasonable. The efficacy of Sertraline hydrochloride in maintaining a response, in patients with OCD who responded during a 52-week treatment phase while taking Sertraline hydrochloride and were then observed for relapse during a period of up to 28 weeks, was demonstrated in a placebo-controlled trial (see Clinical Trials under CLINICAL PHARMACOLOGY). Nevertheless, the physician who elects to use Sertraline hydrochloride for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION). Panic Disorder– Sertraline hydrochloride is indicated for the treatment of panic disorder in adults, with or without agoraphobia, as defined in DSM-IV. Panic disorder is characterized by the occurrence of unexpected panic attacks and associated concern about having additional attacks, worry about the implications or consequences of the attacks, and/or a significant change in behavior related to the attacks. The efficacy of Sertraline hydrochloride was established in three 10-12 week trials in adult panic disorder patients whose diagnoses corresponded to the DSM-III-R category of panic disorder (see Clinical Trials under CLINICAL PHARMACOLOGY). Panic disorder (DSM-IV) is characterized by recurrent unexpected panic attacks, i.e., a discrete period of intense fear or discomfort in which four (or more) of the following symptoms develop abruptly and reach a peak within 10 minutes: (1) palpitations, pounding heart, or accelerated heart rate; (2) sweating; (3) trembling or shaking; (4) sensations of shortness of breath or smothering; (5) feeling of choking; (6) chest pain or discomfort; (7) nausea or abdominal distress; (8) feeling dizzy, unsteady, lightheaded, or faint; (9) derealization (feelings of unreality) or depersonalization (being detached from oneself); (10) fear of losing control; (11) fear of dying; (12) paresthesias (numbness or tingling sensations); (13) chills or hot flushes. The efficacy of Sertraline hydrochloride in maintaining a response, in adult patients with panic disorder who responded during a 52-week treatment phase while taking Sertraline hydrochloride and were then observed for relapse during a period of up to 28 weeks, was demonstrated in a placebo-controlled trial (see Clinical Trials under CLINICAL PHARMACOLOGY). Nevertheless, the physician who elects to use Sertraline hydrochloride for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION). Posttraumatic Stress Disorder (PTSD) – Sertraline hydrochloride (sertraline hydrochloride) is indicated for the treatment of posttraumatic stress disorder in adults. The efficacy of Sertraline hydrochloride in the treatment of PTSD was established in two 12-week placebo-controlled trials of adult outpatients whose diagnosis met criteria for the DSM-III-R category of PTSD (see Clinical Trials under CLINICAL PHARMACOLOGY). PTSD, as defined by DSM-III-R/IV, requires exposure to a traumatic event that involved actual or threatened death or serious injury, or threat to the physical integrity of self or others, and a response which involves intense fear, helplessness, or horror. Symptoms that occur as a result of exposure to the traumatic event include reexperiencing of the event in the form of intrusive thoughts, flashbacks or dreams, and intense psychological distress and physiological reactivity on exposure to cues to the event; avoidance of situations reminiscent of the traumatic event, inability to recall details of the event, and/or numbing of general responsiveness manifested as diminished interest in significant activities, estrangement from others, restricted range of affect, or sense of foreshortened future; and symptoms of autonomic arousal including hypervigilance, exaggerated startle response, sleep disturbance, impaired concentration, and irritability or outbursts of anger. A PTSD diagnosis requires that the symptoms are present for at least a month and that they cause clinically significant distress or impairment in social, occupational, or other important areas of functioning. The efficacy of Sertraline hydrochloride in maintaining a response in adult patients with PTSD for up to 28 weeks following 24 weeks of open-label treatment was demonstrated in a placebo-controlled trial. Nevertheless, the physician who elects to use Sertraline hydrochloride for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION). Premenstrual Dysphoric Disorder (PMDD) – Sertraline hydrochloride is indicated for the treatment of premenstrual dysphoric disorder (PMDD) in adults. The efficacy of sertraline hydrochloride in the treatment of PMDD was established in 2 placebo-controlled trials of female adult outpatients treated for 3 menstrual cycles who met criteria for the DSM-IIIR/IV category of PMDD (see Clinical Trials under CLINICAL PHARMACOLOGY). The essential features of PMDD include markedly depressed mood, anxiety or tension, affective lability, and persistent anger or irritability. Other features include decreased interest in activities, difficulty concentrating, lack of energy, change in appetite or sleep, and feeling out of control. Physical symptoms associated with PMDD include breast tenderness, headache, joint and muscle pain, bloating and weight gain. These symptoms occur regularly during the luteal phase and remit within a few days following onset of menses; the disturbance markedly interferes with work or school or with usual social activities and relationships with others. In making the diagnosis, care should be taken to rule out other cyclical mood disorders that may be exacerbated by treatment with an antidepressant. The effectiveness of Sertraline hydrochloride in long-term use, that is, for more than 3 menstrual cycles, has not been systematically evaluated in controlled trials. Therefore, the physician who elects to use Sertraline hydrochloride for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION). Social Anxiety Disorder – Sertraline hydrochloride is indicated for the treatment of social anxiety disorder, also known as social phobia in adults. The efficacy of Sertraline hydrochloride in the treatment of social anxiety disorder was established in two placebo-controlled trials of adult outpatients with a diagnosis of social anxiety disorder as defined by DSM-IV criteria (see Clinical Trials under CLINICAL PHARMACOLOGY). Social anxiety disorder, as defined by DSM-IV, is characterized by marked and persistent fear of social or performance situations involving exposure to unfamiliar people or possible scrutiny by others and by fears of acting in a humiliating or embarrassing way. Exposure to the feared social situation almost always provokes anxiety and feared social or performance situations are avoided or else are endured with intense anxiety or distress. In addition, patients recognize that the fear is excessive or unreasonable and the avoidance and anticipatory anxiety of the feared situation is associated with functional impairment or marked distress. The efficacy of Sertraline hydrochloride in maintaining a response in adult patients with social anxiety disorder for up to 24 weeks following 20 weeks of Sertraline hydrochloride treatment was demonstrated in a placebo-controlled trial. Physicians who prescribe Sertraline hydrochloride for extended periods should periodically reevaluate the long-term usefulness of the drug for the individual patient (see Clinical Trials under CLINICAL PHARMACOLOGY). uuid:a08ed5e2-51a9-4320-a70e-988c4a11176f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6532 biolink:treats MONDO:0044751 PMID:41385096 "[{""id"":""uuid:92fa966b-12b6-4534-94fd-0c3594a1226c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c46e077e-d0d4-4b68-a6e8-69a993ae359a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Loperamide hydrochloride capsules are indicated for the control and symptomatic relief of acute nonspecific diarrhea in patients 2 years of age and older and of chronic diarrhea in adults associated with inflammatory bowel disease. Loperamide hydrochloride capsules are also indicated for reducing the volume of discharge from ileostomies. uuid:9e883ff1-7c2a-4831-8565-4f4dc9a2a748 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50275 biolink:treats HP:0005202 PMID:41385096 "[{""id"":""uuid:2538664e-22f4-420f-9a9d-8e3f9c7b533f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:08f59ceb-abff-49eb-84ff-4640323ae2d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Treatment of Gastroesophageal Reflux Disease (GERD) in Adults Healing of Erosive Esophagitis Esomeprazole strontium is indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed erosive esophagitis. For those patients who have not healed after 4 to 8 weeks of treatment, an additional 4 to 8 week course of esomeprazole strontium may be considered. Maintenance of Healing of Erosive Esophagitis Esomeprazole strontium is indicated to maintain symptom resolution and healing of erosive esophagitis. Controlled studies do not extend beyond 6 months. Symptomatic Gastroesophageal Reflux Disease Esomeprazole strontium is indicated for short-term treatment (4 to 8 weeks) of heartburn and other symptoms associated with GERD in adults. 1.2 Risk Reduction of NSAID-Associated Gastric Ulcer in Adults Esomeprazole strontium is indicated for the reduction in the occurrence of gastric ulcers associated with continuous NSAID therapy in patients at risk for developing gastric ulcers. Patients are considered to be at risk either due to their age (≥60) and/or documented history of gastric ulcers. Controlled studies do not extend beyond 6 months. 1.3 H. pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence in Adults Triple Therapy (esomeprazole strontium plus amoxicillin and clarithromycin): esomeprazole strontium, in combination with amoxicillin and clarithromycin, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or history of within the past 5 years) to eradicate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence [see Dosage and Administration (2) and Clinical Studies (14)]. In patients who fail therapy, susceptibility testing should be done. If resistance to clarithromycin is demonstrated or susceptibility testing is not possible, alternative antimicrobial therapy should be instituted [see Clinical Pharmacology (12.4) and the prescribing information for clarithromycin]. 1.4 Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome in Adults Esomeprazole strontium is indicated for the long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison Syndrome. uuid:bcdb2c28-cff4-4d73-aa57-5e2ef2c3977f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:577093 biolink:treats MONDO:0005147 PMID:41385096 "[{""id"":""uuid:0f1cf269-b79f-47ff-aa89-c770ea4d9507"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7ee5525a-e0f6-494a-b3e9-8d23fa6844c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pioglitazone and metformin hydrochloride tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both pioglitazone and metformin is appropriate [see CLINICAL STUDIES (14) ]. Important Limitations of Use Pioglitazone exerts its antihyperglycemic effect only in the presence of endogenous insulin. Pioglitazone and metformin hydrochloride tablets should not be used to treat type 1 diabetes or diabetic ketoacidosis, as it would not be effective in these settings. Use caution in patients with liver disease [see WARNINGS AND PRECAUTIONS (5.5) ]. uuid:06abe6c5-0e45-4d10-a8d2-580aca818682 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:577093 biolink:treats MONDO:0012819 PMID:41385096 "[{""id"":""uuid:45bced65-2e6f-4b05-8488-d75ca9341a1d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7f42a82f-dbb1-47d2-901b-21a703722705"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pioglitazone and metformin hydrochloride tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both pioglitazone and metformin is appropriate [see CLINICAL STUDIES (14) ]. Important Limitations of Use Pioglitazone exerts its antihyperglycemic effect only in the presence of endogenous insulin. Pioglitazone and metformin hydrochloride tablets should not be used to treat type 1 diabetes or diabetic ketoacidosis, as it would not be effective in these settings. Use caution in patients with liver disease [see WARNINGS AND PRECAUTIONS (5.5) ]. uuid:2cd122fa-347f-45f5-8388-5202582b03e6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8428 biolink:treats HP:0004308 PMID:41385096 "[{""id"":""uuid:2debc78d-96bb-48ea-a4c0-7b3d3ad22ed5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:059e0e8b-7666-4946-b250-53baa0594428"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Procainamide hydrochloride injection is indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgement of the physician, are life-threatening. Because of the proarrhythmic effects of procainamide, its use with lesser arrhythmias is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of procainamide treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias. Because procainamide has the potential to produce serious hematological disorders (0.5 percent) particularly leukopenia or agranulocytosis (sometimes fatal), its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment clearly outweigh the risks. (see WARNINGS and Boxed Warning.) uuid:d4c71d86-d59c-4c07-9f4f-6670434ef090 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8428 biolink:treats UMLS:C0750197 PMID:41385096 "[{""id"":""uuid:81ea7986-64e5-4c67-80eb-5f4fbd92a621"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e6f45318-7eca-4cf9-8659-c7933fa7087e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Procainamide hydrochloride injection is indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgement of the physician, are life-threatening. Because of the proarrhythmic effects of procainamide, its use with lesser arrhythmias is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of procainamide treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias. Because procainamide has the potential to produce serious hematological disorders (0.5 percent) particularly leukopenia or agranulocytosis (sometimes fatal), its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment clearly outweigh the risks. (see WARNINGS and Boxed Warning.) uuid:d085dc42-0109-4d79-af15-e6628788baef biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8428 biolink:treats HP:0006682 PMID:41385096 "[{""id"":""uuid:841fd084-1ad6-4a3d-b8df-e820e5d1dabe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2f6b16f1-a7b8-4c96-84cc-0d5d5cac548a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Procainamide hydrochloride injection is indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgement of the physician, are life-threatening. Because of the proarrhythmic effects of procainamide, its use with lesser arrhythmias is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of procainamide treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias. Because procainamide has the potential to produce serious hematological disorders (0.5 percent) particularly leukopenia or agranulocytosis (sometimes fatal), its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment clearly outweigh the risks. (see WARNINGS and Boxed Warning.) uuid:ffa1098d-8c58-43e4-b670-9e4a71142a89 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8428 biolink:treats MONDO:0003785 PMID:41385096 "[{""id"":""uuid:de9e23a3-b5e5-4a37-9cb0-5ca56b8d96ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b837697b-95c6-4b1b-a023-8ca9543d6887"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Procainamide hydrochloride injection is indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgement of the physician, are life-threatening. Because of the proarrhythmic effects of procainamide, its use with lesser arrhythmias is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of procainamide treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias. Because procainamide has the potential to produce serious hematological disorders (0.5 percent) particularly leukopenia or agranulocytosis (sometimes fatal), its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment clearly outweigh the risks. (see WARNINGS and Boxed Warning.) uuid:081bd917-dafa-46d4-a4a0-176d10bfdd08 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8428 biolink:treats MONDO:0001609 PMID:41385096 "[{""id"":""uuid:41d78549-afa1-49ee-a1fa-4a83b6718e53"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4711d62e-af16-4586-aff4-f1b230ed8e14"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Procainamide hydrochloride injection is indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgement of the physician, are life-threatening. Because of the proarrhythmic effects of procainamide, its use with lesser arrhythmias is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of procainamide treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias. Because procainamide has the potential to produce serious hematological disorders (0.5 percent) particularly leukopenia or agranulocytosis (sometimes fatal), its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment clearly outweigh the risks. (see WARNINGS and Boxed Warning.) uuid:980f9c35-af08-42d0-8927-cd24b19e1444 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2646319 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:0cdbcaa8-251c-4dd7-8756-ffb12aa0da2d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f8c2f44a-7d97-41b8-8639-50215fbce34a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hyophen ™ tablets are indicated for the treatment of symptoms of irritative voiding. Indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. Indicated for the relief of urinary tract symptoms caused by diagnostic procedures. uuid:5fac6ee2-2352-4165-8378-1874970c8698 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:25187 biolink:treats MONDO:0005277 PMID:41385096 "[{""id"":""uuid:e30cae29-02ef-4605-9d66-52e39893032d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b7381d86-b3b5-48cd-81f2-925be6985cce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sumatriptan tablets are indicated for the acute treatment of migraine attacks with or without aura in adults. Sumatriptan tablets are not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS ). Safety and effectiveness of sumatriptan tablets have not been established for cluster headache, which is present in an older, predominantly male population. uuid:64355d96-7f10-47f0-8ee1-3a6893ba8502 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:25187 biolink:treats MONDO:0018925 PMID:41385096 "[{""id"":""uuid:798561e9-d178-4704-8155-784581fff0de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f05d8291-0bb7-485d-83a4-afc0a34d51d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sumatriptan tablets are indicated for the acute treatment of migraine attacks with or without aura in adults. Sumatriptan tablets are not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS ). Safety and effectiveness of sumatriptan tablets have not been established for cluster headache, which is present in an older, predominantly male population. uuid:f1cc7882-6cf4-4e51-8745-3e36fec3f9f6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:25187 biolink:treats MONDO:0043219 PMID:41385096 "[{""id"":""uuid:afdabdd2-3e68-4091-8616-4d7d2ed3476e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d60f7305-ae68-4837-849a-7861ee20eeea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sumatriptan tablets are indicated for the acute treatment of migraine attacks with or without aura in adults. Sumatriptan tablets are not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS ). Safety and effectiveness of sumatriptan tablets have not been established for cluster headache, which is present in an older, predominantly male population. uuid:35361d5b-458c-4b7e-9be1-40cda38403a0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:25187 biolink:treats MONDO:0043537 PMID:41385096 "[{""id"":""uuid:11e9f212-68d8-46b4-9ac9-2a98313e48a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:234741df-2af9-4a34-983b-65c973a275f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sumatriptan tablets are indicated for the acute treatment of migraine attacks with or without aura in adults. Sumatriptan tablets are not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS ). Safety and effectiveness of sumatriptan tablets have not been established for cluster headache, which is present in an older, predominantly male population. uuid:6457341d-48fe-4bf3-bded-84a66812712b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4856 biolink:treats HP:0001649 PMID:41385096 "[{""id"":""uuid:71b1d7be-6f24-4e6d-b65c-512c0c27535a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d6a5d887-2e8e-413a-a4ed-68a7b46fc4a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Supraventricular Tachycardia Esmolol hydrochloride is indicated for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable. Esmolol hydrochloride is also indicated in noncompensatory sinus tachycardia where, in the physician’s judgment, the rapid heart rate requires specific intervention. Esmolol hydrochloride is not intended for use in chronic settings where transfer to another agent is anticipated. Intraoperative and Postoperative Tachycardia and/or Hypertension Esmolol hydrochloride is indicated for the treatment of tachycardia and hypertension that occur during induction and tracheal intubation, during surgery, on emergence from anesthesia, and in the postoperative period, when in the physician’s judgment such specific intervention is considered indicated. Use of esmolol hydrochloride to prevent such events is not recommended. uuid:71901263-16ac-48bc-94cd-7324d33fb2a9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4856 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:b0b3e78b-254f-425d-bd99-bb3723dcc353"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5aef8a1e-d98c-420d-aa7b-f250c9474bd0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Supraventricular Tachycardia Esmolol hydrochloride is indicated for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable. Esmolol hydrochloride is also indicated in noncompensatory sinus tachycardia where, in the physician’s judgment, the rapid heart rate requires specific intervention. Esmolol hydrochloride is not intended for use in chronic settings where transfer to another agent is anticipated. Intraoperative and Postoperative Tachycardia and/or Hypertension Esmolol hydrochloride is indicated for the treatment of tachycardia and hypertension that occur during induction and tracheal intubation, during surgery, on emergence from anesthesia, and in the postoperative period, when in the physician’s judgment such specific intervention is considered indicated. Use of esmolol hydrochloride to prevent such events is not recommended. uuid:518fd8c0-1e6a-4cfa-b8bf-344ae9a3a9ee biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18067 biolink:treats MONDO:0006784 PMID:41385096 "[{""id"":""uuid:c28c0b6c-b56e-4aee-b3de-591993511496"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6ef4b96f-5bd0-4e51-acc2-e22b7818765f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Phytonadione is indicated in the following coagulation disorders which are due to faulty formation of factors II, VII, IX and X when caused by vitamin K deficiency or interference with vitamin K activity. Phytonadione Injectable Emulsion, USP is indicated in: - anticoagulant-induced prothrombin deficiency caused by coumarin or indanedione derivatives; - prophylaxis and therapy of hemorrhagic disease of the newborn; - hypoprothrombinemia due to antibacterial therapy; - hypoprothrombinemia secondary to factors limiting absorption or synthesis of vitamin K, e.g., obstructive jaundice, biliary fistula, sprue, ulcerative colitis, celiac disease, intestinal resection, cystic fibrosis of the pancreas, and regional enteritis; - other drug-induced hypoprothombinemia where it is definately shown that the result is due to interference with vitamin K metabolism, e.g., salicylates. uuid:299b24d3-d9c3-4549-b71e-0c747c9c28b7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18067 biolink:treats UMLS:C0205707 PMID:41385096 "[{""id"":""uuid:6ce66494-dabd-4195-b4ed-b3de7c6d7af4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:831ecf8c-43f1-4672-988f-c1de3fa24429"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Phytonadione is indicated in the following coagulation disorders which are due to faulty formation of factors II, VII, IX and X when caused by vitamin K deficiency or interference with vitamin K activity. Phytonadione Injectable Emulsion, USP is indicated in: - anticoagulant-induced prothrombin deficiency caused by coumarin or indanedione derivatives; - prophylaxis and therapy of hemorrhagic disease of the newborn; - hypoprothrombinemia due to antibacterial therapy; - hypoprothrombinemia secondary to factors limiting absorption or synthesis of vitamin K, e.g., obstructive jaundice, biliary fistula, sprue, ulcerative colitis, celiac disease, intestinal resection, cystic fibrosis of the pancreas, and regional enteritis; - other drug-induced hypoprothombinemia where it is definately shown that the result is due to interference with vitamin K metabolism, e.g., salicylates. uuid:0e43ee4c-7d19-4219-8819-d9fc222cfb62 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18067 biolink:treats MONDO:0005101 PMID:41385096 "[{""id"":""uuid:4643b25d-132b-4951-b946-7d595a298f6e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fd66ecc9-2f7c-4105-a50f-e4ad7a0ad7ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Phytonadione is indicated in the following coagulation disorders which are due to faulty formation of factors II, VII, IX and X when caused by vitamin K deficiency or interference with vitamin K activity. Phytonadione Injectable Emulsion, USP is indicated in: - anticoagulant-induced prothrombin deficiency caused by coumarin or indanedione derivatives; - prophylaxis and therapy of hemorrhagic disease of the newborn; - hypoprothrombinemia due to antibacterial therapy; - hypoprothrombinemia secondary to factors limiting absorption or synthesis of vitamin K, e.g., obstructive jaundice, biliary fistula, sprue, ulcerative colitis, celiac disease, intestinal resection, cystic fibrosis of the pancreas, and regional enteritis; - other drug-induced hypoprothombinemia where it is definately shown that the result is due to interference with vitamin K metabolism, e.g., salicylates. uuid:6d56bdd8-d23a-4574-8361-82402ae4c86f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18067 biolink:treats MONDO:0005130 PMID:41385096 "[{""id"":""uuid:9576514c-dfff-4b94-80ca-991998d0b773"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2294ad97-b958-482d-9cea-ac79ee2a4c0d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Phytonadione is indicated in the following coagulation disorders which are due to faulty formation of factors II, VII, IX and X when caused by vitamin K deficiency or interference with vitamin K activity. Phytonadione Injectable Emulsion, USP is indicated in: - anticoagulant-induced prothrombin deficiency caused by coumarin or indanedione derivatives; - prophylaxis and therapy of hemorrhagic disease of the newborn; - hypoprothrombinemia due to antibacterial therapy; - hypoprothrombinemia secondary to factors limiting absorption or synthesis of vitamin K, e.g., obstructive jaundice, biliary fistula, sprue, ulcerative colitis, celiac disease, intestinal resection, cystic fibrosis of the pancreas, and regional enteritis; - other drug-induced hypoprothombinemia where it is definately shown that the result is due to interference with vitamin K metabolism, e.g., salicylates. uuid:c3ae2d86-6724-4442-97a9-22148ea12289 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18067 biolink:treats UMLS:C1527396 PMID:41385096 "[{""id"":""uuid:ef7b851d-809d-4e45-8ca8-bda60edc2e70"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e85c844a-ecab-422b-ae57-285f5023c5ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Phytonadione is indicated in the following coagulation disorders which are due to faulty formation of factors II, VII, IX and X when caused by vitamin K deficiency or interference with vitamin K activity. Phytonadione Injectable Emulsion, USP is indicated in: - anticoagulant-induced prothrombin deficiency caused by coumarin or indanedione derivatives; - prophylaxis and therapy of hemorrhagic disease of the newborn; - hypoprothrombinemia due to antibacterial therapy; - hypoprothrombinemia secondary to factors limiting absorption or synthesis of vitamin K, e.g., obstructive jaundice, biliary fistula, sprue, ulcerative colitis, celiac disease, intestinal resection, cystic fibrosis of the pancreas, and regional enteritis; - other drug-induced hypoprothombinemia where it is definately shown that the result is due to interference with vitamin K metabolism, e.g., salicylates. uuid:9eda0a4e-49f9-4cba-ac17-a7a2b35dbda8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18067 biolink:treats UMLS:C0678202 PMID:41385096 "[{""id"":""uuid:7ce0f7aa-9ddf-4c70-bfce-a3d01315fc09"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e9453fd6-bdb6-45bb-a6e1-3a3387cee462"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Phytonadione is indicated in the following coagulation disorders which are due to faulty formation of factors II, VII, IX and X when caused by vitamin K deficiency or interference with vitamin K activity. Phytonadione Injectable Emulsion, USP is indicated in: - anticoagulant-induced prothrombin deficiency caused by coumarin or indanedione derivatives; - prophylaxis and therapy of hemorrhagic disease of the newborn; - hypoprothrombinemia due to antibacterial therapy; - hypoprothrombinemia secondary to factors limiting absorption or synthesis of vitamin K, e.g., obstructive jaundice, biliary fistula, sprue, ulcerative colitis, celiac disease, intestinal resection, cystic fibrosis of the pancreas, and regional enteritis; - other drug-induced hypoprothombinemia where it is definately shown that the result is due to interference with vitamin K metabolism, e.g., salicylates. uuid:85778754-e809-44c5-a4ce-5d608273fb07 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18067 biolink:treats MONDO:0001531 PMID:41385096 "[{""id"":""uuid:c44098bd-8ec6-4d40-8fb9-1387ea259c43"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4a4e57dc-1b7f-4816-a4c9-5bf82f56c893"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Phytonadione is indicated in the following coagulation disorders which are due to faulty formation of factors II, VII, IX and X when caused by vitamin K deficiency or interference with vitamin K activity. Phytonadione Injectable Emulsion, USP is indicated in: anticoagulant-induced prothrombin deficiency caused by coumarin or indanedione derivatives; prophylaxis and therapy of hemorrhagic disease of the newborn; hypoprothrombinemia due to antibacterial therapy; hypoprothrombinemia secondary to factors limiting absorption or synthesis of vitamin K, e.g., obstructive jaundice, biliary fistula, sprue, ulcerative colitis, celiac disease, intestinal resection, cystic fibrosis of the pancreas, and regional enteritis; other drug-induced hypoprothrombinemia where it is definitely shown that the result is due to interference with vitamin K metabolism, e.g., salicylates. uuid:16acebc6-54ae-460e-9ec9-9934fbbbe616 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28304 biolink:treats MONDO:0004981 PMID:41385096 "[{""id"":""uuid:91fac1d6-f4bc-41ae-a59d-30b4f5b10fe2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d6d50a62-b6c9-4b26-b089-3f912698ba0e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Heparin Sodium Injection is indicated for: Anticoagulant therapy in prophylaxis and treatment of venous thrombosis and its extension; Low-dose regimen for prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdominothoracic surgery or who, for other reasons, are at risk of developing thromboembolic disease (see DOSAGE AND ADMINISTRATION) Prophylaxis and treatment of pulmonary embolism; Atrial fibrilation with embolization; Diagnosis and treatment of acute and chronic consumptive coagulopathies (disseminated intravascular coagulation); Prevention of clotting in arterial and cardiac surgery; Prophylaxis and treatment of peripheral arterial embolism. Heparin may also be employed as an anticoagulant in blood transfusions, extracorporeal circulation, and dialysis procedures and in blood samples for laboratory purposes. uuid:96ee6786-2221-4aa9-9cd9-1011e151d429 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:11979316 biolink:treats MONDO:0004782 PMID:41385096 "[{""id"":""uuid:2980bcea-f4f9-4301-b559-e2be9bcdd9f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:671b5738-a124-4acc-a3ae-4b7a126afa12"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vasopressin Injection, USP is indicated for prevention and treatment of postoperative abdominal distention, in abdominal roentgenography to dispel interfering gas shadows and in diabetes insipidus. uuid:2519f432-b587-4050-8a3c-bd8e33c11882 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77733 biolink:treats HP:0004755 PMID:41385096 "[{""id"":""uuid:726e285a-fae1-41c0-8740-62874e0c7d0c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d2dd6723-6a61-4ddf-9b1a-610a1334c006"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Verapamil is indicated for the treatment of supraventricular tachyarrhythmias, including: Rapid conversion to sinus rhythm of paroxysmal supraventricular tachycardias, including those associated with accessory bypass tracts (Wolff-Parkinson-White [WPW] and Lown-Ganong-Levine [LGL] syndromes). When clinically advisable, appropriate vagal maneuvers (e.g., Valsalva maneuver) should be attempted prior to Verapamil administration. Temporary control of rapid ventricular rate in atrial flutter or atrial fibrillation, except when the atrial flutter and/or atrial fibrillation are associated with accessory bypass tracts (Wolff-Parkinson-White [WPW] and Lown-Ganong-Levine [LGL] syndromes). In controlled studies in the U.S., about 60% of patients with supraventricular tachycardia converted to normal sinus rhythm within 10 minutes after intravenous Verapamil hydrochloride. Uncontrolled studies reported in the world literature describe a conversion rate of about 80%. About 70% of patients with atrial flutter and/or fibrillation with a fast ventricular rate respond with a decrease in heart rate of at least 20%. Conversion of atrial flutter or fibrillation to sinus rhythm is uncommon (about 10%) after Verapamil hydrochloride and may reflect the spontaneous conversion rate, since the conversion rate after placebo was similar. The effect of a single injection lasts for 30–60 minutes when conversion to sinus rhythm does not occur. Because a small fraction (<1.0%) of patients treated with Verapamil hydrochloride respond with life-threatening adverse responses (rapid ventricular rate in atrial flutter/fibrillation with an accessory bypass tract, marked hypotension, or extreme bradycardia/asystole- see Contraindications and Warnings ), the initial use of intravenous Verapamil hydrochloride should, if possible, be in a treatment setting with monitoring and resuscitation facilities, including DC-cardioversion capability (see Suggested Treatment of Acute Cardiovascular Adverse Reactions ) . As familiarity with the patient’s response is gained, an office setting may be acceptable. Cardioversion has been used safely and effectively after intravenous Verapamil. uuid:7cdabe85-3596-406e-88fa-3b6747a49860 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9150 biolink:treats UMLS:C0856526 PMID:41385096 "[{""id"":""uuid:a2a344e5-8d9c-4975-9fcc-c72fa814d4f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:42a000ab-c4a6-4dd6-9f9c-20e718f2b0fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Simvastatin is an HMG-CoA reductase inhibitor (statin) indicated as an adjunctive therapy to diet to: Reduce the risk of total mortality by reducing CHD deaths and reduce the risk of non-fatal myocardial infarction, stroke, and the need for revascularization procedures in patients at high risk of coronary events. ( 1.1 ) Reduce elevated total-C, LDL-C, Apo B, TG and increase HDL-C in patients with primary hyperlipidemia (heterozygous familial and nonfamilial) and mixed dyslipidemia. ( 1.2 ) Reduce elevated TG in patients with hypertriglyceridemia and reduce TG and VLDL-C in patients with primary dysbetalipoproteinemia. ( 1.2 ) Reduce total-C and LDL-C in adult patients with homozygous familial hypercholesterolemia. ( 1.2 ) Reduce elevated total-C, LDL-C, and Apo B in boys and postmenarchal girls, 10 to 17 years of age with heterozygous familial hypercholesterolemia after failing an adequate trial of diet therapy. ( 1.2 , 1.3 ) Limitations of Use Simvastatin has not been studied in Fredrickson Types I and V dyslipidemias. ( 1.4 ) uuid:628a1c03-8e1c-45de-8040-238a7a69ba58 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1153890 biolink:treats HP:0012735 PMID:41385096 "[{""id"":""uuid:2e109d35-5ff7-425e-a968-d3924787f1ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:896504a1-ed9f-470b-86b4-e960f548131d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CODEINE PHOSPHATE AND CHLORPHENIRAMINE MALEATE is indicated for the relief of cough and symptoms associated with upper respiratory allergies or a common cold in adults 18 years of age and older. Important Limitations of Use Not indicated for pediatric patients under 18 years of age [see Use in Special Population ( 8.4 )] uuid:17c0a87e-8e2e-4ab3-a7a3-cac04d2c12d0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1153890 biolink:treats MONDO:0004867 PMID:41385096 "[{""id"":""uuid:a770a997-d138-4d66-9acf-617e72a5863f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5d93cd2f-9607-44e7-9ced-f51628eb4f1d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CODEINE PHOSPHATE AND CHLORPHENIRAMINE MALEATE is indicated for the relief of cough and symptoms associated with upper respiratory allergies or a common cold in adults 18 years of age and older. Important Limitations of Use Not indicated for pediatric patients under 18 years of age [see Use in Special Population ( 8.4 )] uuid:95d32c8a-54f2-4584-81a8-5782f443ab9c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1153890 biolink:treats MONDO:0005709 PMID:41385096 "[{""id"":""uuid:65a89236-bed2-47ce-b23e-58981c5ee7cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:254ddc48-d7a9-48a4-b0b2-89b902e3c2b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CODEINE PHOSPHATE AND CHLORPHENIRAMINE MALEATE is indicated for the relief of cough and symptoms associated with upper respiratory allergies or a common cold in adults 18 years of age and older. Important Limitations of Use Not indicated for pediatric patients under 18 years of age [see Use in Special Population ( 8.4 )] uuid:1ed3b74a-8a28-4ce1-8ffa-1972006bc554 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5109 biolink:treats MONDO:0006604 PMID:41385096 "[{""id"":""uuid:48737db4-4717-46dd-93a5-736982ce8133"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8e087b3f-634b-4b3a-b0f0-59c301a914f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fluocinonide cream USP, 0.1% is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses in patients 12 years of age or older. ( 1 ) Limitation of Use: Treatment beyond 2 consecutive weeks is not recommended and the total dosage should not exceed 60 g per week because of the potential for the drug to suppress the hypothalamic-pituitary-adrenal (HPA) axis. ( 1 ) Avoid use on the face, groin, or axillae. ( 1.2 ) Avoid use in perioral dermatitis or rosacea. uuid:d7854886-3078-4fea-8b5b-95f3001adea4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47381 biolink:treats MONDO:0005173 PMID:41385096 "[{""id"":""uuid:ee798c32-3504-4e9a-8933-53f92a51314d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:abdb3fb6-1d9b-49a2-b573-dfda13c84427"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diclofenac Sodium Gel is indicated for the topical treatment of actinic keratoses (AK). Sun avoidance is indicated during therapy. uuid:220a7a6f-4e0e-452f-b63e-7710ee4fe804 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47381 biolink:treats UMLS:C0582412 PMID:41385096 "[{""id"":""uuid:21b8c95c-964e-43c7-89d8-fd9e92dc5696"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fc96cf26-5cb2-4fca-9115-836fe944cfbd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diclofenac Sodium Gel is indicated for the topical treatment of actinic keratoses (AK). Sun avoidance is indicated during therapy. uuid:27f3db01-2c8a-447b-a6da-d1bee71c08b9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63618 biolink:treats MONDO:0004781 PMID:41385096 "[{""id"":""uuid:7235862c-a6da-476f-a8b5-2fbe6780f8b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:08db39c7-9883-4660-aad1-3e02d3d9b5eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pravastatin sodium tablet, USP is an HMG-CoA reductase inhibitor (statin) indicated as an adjunctive therapy to diet to: Reduce the risk of MI, revascularization, and cardiovascular mortality in hypercholesterolemic patients without clinically evident CHD. ( 1.1 ) Reduce the risk of total mortality by reducing coronary death, MI, revascularization, stroke/TIA, and the progression of coronary atherosclerosis in patients with clinically evident CHD. ( 1.1 ) Reduce elevated Total-C, LDL-C, ApoB, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia and mixed dyslipidemia. ( 1.2 ) Reduce elevated serum TG levels in patients with hypertriglyceridemia. ( 1.2 ) Treat patients with primary dysbetalipoproteinemia who are not responding to diet. ( 1.2 ) Treat children and adolescent patients ages 8 years and older with heterozygous familial hypercholesterolemia after failing an adequate trial of diet therapy. ( 1.2 ) Limitations of use: Pravastatin sodium tablet, USP has not been studied in Fredrickson Types I and V dyslipidemias. ( 1.3 ) uuid:23342084-25a8-427b-a252-3346394c39f5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63618 biolink:treats MONDO:0021661 PMID:41385096 "[{""id"":""uuid:fc8e45f4-5018-45d2-b69d-70d24b2c39c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:81967392-8e46-4e38-8e39-3cd278786623"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pravastatin sodium tablet, USP is an HMG-CoA reductase inhibitor (statin) indicated as an adjunctive therapy to diet to: Reduce the risk of MI, revascularization, and cardiovascular mortality in hypercholesterolemic patients without clinically evident CHD. ( 1.1 ) Reduce the risk of total mortality by reducing coronary death, MI, revascularization, stroke/TIA, and the progression of coronary atherosclerosis in patients with clinically evident CHD. ( 1.1 ) Reduce elevated Total-C, LDL-C, ApoB, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia and mixed dyslipidemia. ( 1.2 ) Reduce elevated serum TG levels in patients with hypertriglyceridemia. ( 1.2 ) Treat patients with primary dysbetalipoproteinemia who are not responding to diet. ( 1.2 ) Treat children and adolescent patients ages 8 years and older with heterozygous familial hypercholesterolemia after failing an adequate trial of diet therapy. ( 1.2 ) Limitations of use: Pravastatin sodium tablet, USP has not been studied in Fredrickson Types I and V dyslipidemias. ( 1.3 ) uuid:eb0466a2-3eaa-4122-8683-1b01dace925c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46557 biolink:treats MONDO:0043455 PMID:41385096 "[{""id"":""uuid:b5842491-fb3b-43eb-acb3-fb288ef2ff0c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:ace54373-b2db-4e8c-bc50-208f14c3586b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c5e7d46f-d02e-4bcd-9467-9d0ac30bd561"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Zoledronic acid Injectionis a bisphosphonate indicated for the treatment of: • Hypercalcemia of malignancy. ( 1.1 ) • Patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. Prostate cancer should have progressed after treatment with at least one hormonal therapy. ( 1.2 ) Limitations of use : The safety and efficacy of Zoledronic acid Injection has not been established for use in hyperparathyroidism or non-tumor-related hypercalcemia.|[EMA] Prevention of skeletal-related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone.Treatment of adult patients with tumour-induced hypercalcaemia. uuid:42a5067f-823a-42ee-a126-3146a3e5156f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46557 biolink:treats MONDO:0009693 PMID:41385096 "[{""id"":""uuid:e02257ab-f552-49b4-bedd-b92ebeb5282e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:917c8285-5ff6-4fa8-b3af-08a54dc71ebe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:43d995f6-6d38-4f6e-8632-11a4683f71bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Zoledronic acid Injectionis a bisphosphonate indicated for the treatment of: • Hypercalcemia of malignancy. ( 1.1 ) • Patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. Prostate cancer should have progressed after treatment with at least one hormonal therapy. ( 1.2 ) Limitations of use : The safety and efficacy of Zoledronic acid Injection has not been established for use in hyperparathyroidism or non-tumor-related hypercalcemia.|[PMDA] Drug with a new indication and revised dosage indicated for bone lesions of multiple myeloma or bone metastasis from solid cancers. uuid:206af99a-8350-4ffc-b7a9-e0d2cc41f627 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46557 biolink:treats UMLS:C0153690 PMID:41385096 "[{""id"":""uuid:fba92a58-d915-4119-93cb-68bb1b2a2e56"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9fca2bfa-7c93-46db-b6f7-ffa01cf16d18"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:d0d11f42-e597-4e10-9d0e-1b06dc2bc8f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Zoledronic acid Injectionis a bisphosphonate indicated for the treatment of: • Hypercalcemia of malignancy. ( 1.1 ) • Patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. Prostate cancer should have progressed after treatment with at least one hormonal therapy. ( 1.2 ) Limitations of use : The safety and efficacy of Zoledronic acid Injection has not been established for use in hyperparathyroidism or non-tumor-related hypercalcemia.|[PMDA] Drug with a new indication and revised dosage indicated for bone lesions of multiple myeloma or bone metastasis from solid cancers. uuid:f445c1de-6e7b-4d05-80dd-27e274744242 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46557 biolink:treats MONDO:0008315 PMID:41385096 "[{""id"":""uuid:9d970822-9e47-4072-81d0-4436032e6328"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fe2c2b7c-5e4f-4bb6-9c3b-2a1899f1b014"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Zoledronic acid Injectionis a bisphosphonate indicated for the treatment of: • Hypercalcemia of malignancy. ( 1.1 ) • Patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. Prostate cancer should have progressed after treatment with at least one hormonal therapy. ( 1.2 ) Limitations of use : The safety and efficacy of Zoledronic acid Injection has not been established for use in hyperparathyroidism or non-tumor-related hypercalcemia. uuid:8cb84a82-bd19-4b78-af3d-2746daf85f5f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4681 biolink:treats MONDO:0004981 PMID:41385096 "[{""id"":""uuid:9772c8c5-5da2-4ebf-b05b-ae27354e286e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7b2acebe-6550-40bd-af7a-47630b6ed620"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TIKOSYN is indicated for the maintenance of normal sinus rhythm (delay in time to recurrence of atrial fibrillation/atrial flutter [AF/AFl]) in patients with atrial fibrillation/atrial flutter of greater than one week duration who have been converted to normal sinus rhythm. Because TIKOSYN can cause life threatening ventricular arrhythmias, it should be reserved for patients in whom atrial fibrillation/atrial flutter is highly symptomatic. In general, antiarrhythmic therapy for atrial fibrillation/atrial flutter aims to prolong the time in normal sinus rhythm. Recurrence is expected in some patients (see CLINICAL STUDIES ). uuid:4f891ac3-313f-4cd5-b80e-531519619a93 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4681 biolink:treats MONDO:0005310 PMID:41385096 "[{""id"":""uuid:2f04f7ea-2fa6-4653-b70e-9893c15ee158"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:286373e0-e0b8-4b4f-abfe-cb8fcc92bd4b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TIKOSYN is indicated for the maintenance of normal sinus rhythm (delay in time to recurrence of atrial fibrillation/atrial flutter [AF/AFl]) in patients with atrial fibrillation/atrial flutter of greater than one week duration who have been converted to normal sinus rhythm. Because TIKOSYN can cause life threatening ventricular arrhythmias, it should be reserved for patients in whom atrial fibrillation/atrial flutter is highly symptomatic. In general, antiarrhythmic therapy for atrial fibrillation/atrial flutter aims to prolong the time in normal sinus rhythm. Recurrence is expected in some patients (see CLINICAL STUDIES ). uuid:3e3d0259-dd7d-4272-b33b-5f65d8ac1dc5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:65173 biolink:treats MONDO:0005090 PMID:41385096 "[{""id"":""uuid:c682a469-ba01-4f7f-af15-80daeef7fed6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9531aa85-c1dc-467b-9c91-e80c4635541c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FANAPT ® tablets are indicated for the treatment of adults with schizophrenia. Efficacy was established in two short-term (4- and 6-week) placebo-and active-controlled studies of adult patients with schizophrenia [see Clinical Studies ( 14 )] . When deciding among the alternative treatments available for this condition, the prescriber should consider the finding that FANAPT is associated with prolongation of the QTc interval [see Warnings and Precautions ( 5.2 )] . Prolongation of the QTc interval is associated in some other drugs with the ability to cause torsade de pointes-type arrhythmia, a potentially fatal polymorphic ventricular tachycardia which can result in sudden death. In many cases this would lead to the conclusion that other drugs should be tried first. Whether FANAPT will cause torsade de pointes or increase the rate of sudden death is not yet known. Patients must be titrated to an effective dose of FANAPT. Thus, control of symptoms may be delayed during the first 1 to 2 weeks of treatment compared to some other antipsychotic drugs that do not require a similar titration. Prescribers should be mindful of this delay when selecting an antipsychotic drug for the treatment of schizophrenia [see Dosage and Administration ( 2.1 ) and Clinical Studies ( 14 )] . The effectiveness of FANAPT in long-term use, that is, for more than 6 weeks, has not been systematically evaluated in controlled trials. Therefore, the physician who elects to use FANAPT for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient [see Dosage and Administration ( 2.3 )] . uuid:f0075c97-e7df-4656-8374-9157b695c7a1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9599 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:df6982a2-4d60-4f05-b130-5289e4f352b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:62d29efb-b178-4c7e-8ac7-d53fde66bc81"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Timolol maleate tablets are indicated for the treatment of hypertension. They may be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. uuid:093836ec-bf14-43c3-beac-eff11d33a28e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6904 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:32a83d9d-456e-455a-8f77-f2e68f73288f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3859402c-0825-452d-8d0c-7a3f1f38ee6e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Hypertension Metoprolol succinate extended-release tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (eg, on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Metoprolol succinate extended-release tablets may be administered with other antihypertensive agents. 1.2 Angina Pectoris Metoprolol succinate extended-release tablets are indicated in the long-term treatment of angina pectoris, to reduce angina attacks and to improve exercise tolerance. 1.3 Heart Failure Metoprolol succinate extended-release tablets are indicated for the treatment of stable, symptomatic (NYHA Class II or III) heart failure of ischemic, hypertensive, or cardiomyopathic origin. It was studied in patients already receiving ACE inhibitors, diuretics, and, in the majority of cases, digitalis. In this population, metoprolol succinate extended-release tablets decreased the rate of mortality plus hospitalization, largely through a reduction in cardiovascular mortality and hospitalizations for heart failure. Please review the manufacturer's complete drug information available from the FDA at www.fda.gov Permanent Link: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=71c1d33e-be6f-6d59-b715-45075445891a uuid:d8870a94-a109-4184-aa9e-0458c3f8a7a6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6904 biolink:treats MONDO:0005016 PMID:41385096 "[{""id"":""uuid:d22c9bc6-64e9-491d-8ce9-19bdcf74bf06"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f23e227d-3b45-4d5d-9888-950d3d087561"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Hypertension Metoprolol succinate extended-release tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (eg, on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Metoprolol succinate extended-release tablets may be administered with other antihypertensive agents. 1.2 Angina Pectoris Metoprolol succinate extended-release tablets are indicated in the long-term treatment of angina pectoris, to reduce angina attacks and to improve exercise tolerance. 1.3 Heart Failure Metoprolol succinate extended-release tablets are indicated for the treatment of stable, symptomatic (NYHA Class II or III) heart failure of ischemic, hypertensive, or cardiomyopathic origin. It was studied in patients already receiving ACE inhibitors, diuretics, and, in the majority of cases, digitalis. In this population, metoprolol succinate extended-release tablets decreased the rate of mortality plus hospitalization, largely through a reduction in cardiovascular mortality and hospitalizations for heart failure. Please review the manufacturer's complete drug information available from the FDA at www.fda.gov Permanent Link: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=71c1d33e-be6f-6d59-b715-45075445891a uuid:a89e42dd-a09f-48eb-8b5c-ab248ea84a11 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5108 biolink:treats MONDO:0005093 PMID:41385096 "[{""id"":""uuid:781af7bf-3888-4257-9024-7e5ec155417a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2e01955d-62c4-48c1-893a-3e2e352a9da0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fluocinolone Acetonide Topical Solution is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. uuid:f7bb7c08-ef3c-4eb4-9e88-ce902d4e6207 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:73139 biolink:treats MONDO:0005812 PMID:41385096 "[{""id"":""uuid:cea88138-e6f7-4968-a4b0-2ce51c55665d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:73caf879-c603-4c5d-a2b9-f622719112c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oseltamivir phosphate is an influenza neuraminidase (NAI) inhibitor indicated for: Treatment of acute, uncomplicated influenza A and B in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours. ( 1.1 ) Prophylaxis of influenza A and B in patients 1 year and older. ( 1.2 ) Limitations of Use: Not a substitute for annual influenza vaccination. ( 1.3 ) Consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use. ( 1.3 ) Not recommended for patients with end-stage renal disease not undergoing dialysis. ( 1.3 ) uuid:b281d38a-c2b8-4d24-9a05-6bb72567fc9a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:73139 biolink:treats UMLS:C0276353 PMID:41385096 "[{""id"":""uuid:262f55fb-f7e2-4597-87d1-3b65cd41c731"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f549dbdd-63d1-42ef-8afc-a49a75b81afd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oseltamivir phosphate is an influenza neuraminidase (NAI) inhibitor indicated for: Treatment of acute, uncomplicated influenza A and B in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours. ( 1.1 ) Prophylaxis of influenza A and B in patients 1 year and older. ( 1.2 ) Limitations of Use: Not a substitute for annual influenza vaccination. ( 1.3 ) Consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use. ( 1.3 ) Not recommended for patients with end-stage renal disease not undergoing dialysis. ( 1.3 ) uuid:a51f2340-cd79-49a4-bf0c-c5cb3bc7b303 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:40303 biolink:treats MONDO:0007759 PMID:41385096 "[{""id"":""uuid:16d82c50-ea21-4078-a750-35af9841ae28"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:03d0c95d-289f-47d2-8013-03e66532a9df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lovastatin tablets USP should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin tablets USP should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C and below average HDL-C, lovastatin tablets USP are indicated to reduce the risk of: -Myocardial infarction -Unstable angina -Coronary revascularization procedures (See CLINICAL PHARMACOLOGY, Clinical Studies). Coronary Heart Disease Lovastatin tablets USP are indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Lovastatin tablets USP are indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb 2 ), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. 2 Classification of Hyperlipoproteinemias IDL = intermediate-density lipoprotein. Type Lipoproteins elevated Lipid Elevations major minor I chylomicrons TG ↑→C IIa LDL C — IIb LDL,VLDL C TG III (rare) IDL C/TG — IV VLDL TG ↑→C V (rare) chylomicrons,VLDL TG ↑→C Adolescent Patients with Heterozygous Familial Hypercholesterolemia Lovastatin tablets USP are indicated as an adjunct to diet to reduce total-C, LDL-C and apolipoprotein B levels in adolescent boys and girls who are at least one year post-menarche, 10 to 17 years of age, with heFH if after an adequate trial of diet therapy the following findings are present: 1. LDL-C remains >189 mg/dL or 2. LDL-C remains >160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the adolescent patient General Recommendations Prior to initiating therapy with lovastatin, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure total-C, HDL-C, and TG. For patients with TG less than 400 mg / dL (<4.5 mmol / L), LDL-C can be estimated using the following equation: LDL-C = total-C – [0.2 × (TG) + HDL-C] For TG levels >400 mg/dL (>4.5 mmol/L), this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated total-C. In such cases, lovastatin tablets USP are not indicated. The National Cholesterol Education Program (NCEP) Treatment Guidelines are summarized below: † CHD, coronary heart disease † † Some authorities recommend use of LDL-lowering drugs in this category if an LDL-C level of <100 mg/dL cannot be achieved by therapeutic lifestyle changes. Others prefer use of drugs that primarily modify triglycerides and HDL-C, e.g., nicotinic acid or fibrate. Clinical judgment also may call for deferring drug therapy in this subcategory. † † † Almost all people with 0 to 1 risk factor have a 10-year risk <10%; thus, 10-year risk assessment in people with 0 to 1 risk factor is not necessary. NCEP Treatment Guidelines : LDL - C Goals and Cutpoints for Therapeutic Lifestyle Changes and Drug Therapy in Different Risk Categories Risk Category LDL Goal ( mg / dL ) LDL Level at Which to Initiate Therapeutic Lifestyle Changes ( mg / dL ) LDL Level at Which to Consider Drug Therapy ( mg / dL ) CHD † or CHD risk equivalents (10-year risk >20%) <100 ≥100 ≥130 (100 to 129: drug optional) † † 2+ Risk factors (10-year risk ≤20%) <130 ≥130 10-year risk 10 to 20%: ≥130 10-year risk <10%: ≥160 0 to 1 Risk factor † † † <160 ≥160 ≥190 (160 to 189: LDL-lowering drug optional) After the LDL-C goal has been achieved, if the TG is still ≥200 mg/dL, non-HDL-C (total-C minus HDL-C) becomes a secondary target of therapy. Non-HDL-C goals are set 30 mg/dL higher than LDL-C goals for each risk category. At the time of hospitalization for an acute coronary event, consideration can be given to initiating drug therapy at discharge if the LDL-C is ≥130 mg/dL (see NCEP Guidelines above). Since the goal of treatment is to lower LDL-C, the NCEP recommends that LDL-C levels be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the total-C be used to monitor therapy. Although lovastatin tablets USP may be useful to reduce elevated LDL-C levels in patients with combined hypercholesterolemia and hypertriglyceridemia where hypercholesterolemia is the major abnormality (Type IIb hyperlipoproteinemia), it has not been studied in conditions where the major abnormality is elevation of chylomicrons, VLDL or IDL (i.e., hyperlipoproteinemia types I, III, IV, or V). 2 The NCEP classification of cholesterol levels in pediatric patients with a familial history of hypercholesterolemia or premature cardiovascular disease is summarized below: Category Total - C ( mg / dL ) LDL - C ( mg / dL ) Acceptable <170 <110 Borderline 170 to 199 110 to 129 High ≥200 ≥130 Children treated with lovastatin in adolescence should be re-evaluated in adulthood and appropriate changes made to their cholesterol-lowering regimen to achieve adult goals for LDL-C. uuid:8475d106-7b19-417d-ba4c-f57b99b68ca8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7931 biolink:treats MONDO:0001530 PMID:41385096 "[{""id"":""uuid:8ba41c5b-cc7f-40b2-bbec-6e72e6f28f4a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:09c9b508-0b96-420d-93fd-3de398f6a3c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Chronic Kidney Disease Stages 3 and 4 Paricalcitol Capsules are indicated in adults for the prevention and treatment of secondary hyperparathyroidism associated with Chronic Kidney Disease (CKD) Stages 3 and 4. Pediatric use information for patients 10 to 16 years of age is approved for AbbVie Inc.’s Zemplar (Paricalcitol) capsules. However, due to AbbVie Inc.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. 1.2 Chronic Kidney Disease Stage 5 Paricalcitol Capsules are indicated in adults for the prevention and treatment of secondary hyperparathyroidism associated with CKD Stage 5 in patients on hemodialysis (HD) or peritoneal dialysis (PD). Pediatric use information for patients 10 to 16 years of age is approved for AbbVie Inc.’s Zemplar (Paricalcitol) capsules. However, due to AbbVie Inc.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. uuid:03364337-0e7d-454a-99e2-cbeff823eac8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4YBM839JAC biolink:treats MONDO:0018048 PMID:41385096 "[{""id"":""uuid:93aa293b-6178-4aaf-af06-74b310b972ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1760a416-5180-4390-95e5-6663d166963c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Argatroban is a direct thrombin inhibitor indicated: For prophylaxis or treatment of thrombosis in adult patients with heparin-induced thrombocytopenia (HIT) (1.1) As an anticoagulant in adults patients with or at risk for HIT undergoing percutaneous coronary intervention (PCI) (1.2) uuid:99809f07-b748-44ab-bc2f-960733efe98e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4YBM839JAC biolink:treats MONDO:0000831 PMID:41385096 "[{""id"":""uuid:6324735a-acbc-4dfc-999a-4971f1bb3a1f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e4f15fe3-d4a1-4c2b-9057-31365c947e4f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Argatroban is a direct thrombin inhibitor indicated: For prophylaxis or treatment of thrombosis in adult patients with heparin-induced thrombocytopenia (HIT) (1.1) As an anticoagulant in adults patients with or at risk for HIT undergoing percutaneous coronary intervention (PCI) (1.2) uuid:1a2c6c9a-a387-481f-b1c4-bda62a2e8c84 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31941 biolink:treats MONDO:0021063 PMID:41385096 "[{""id"":""uuid:d2398b58-a838-4754-a4e7-7eafdc2415eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f9243bce-6e55-4f20-ab99-8000c99cf77a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:7742b749-cd1c-4023-a500-c8689a55ca09"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxaliplatin for injection USP, used in combination with infusional 5-fluorouracil/leucovorin, is indicated for: - adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor. - treatment of advanced colorectal cancer.|[PMDA] A drug containing a new active ingredient with indications for colonic and rectal cancers. uuid:6984015c-8485-4926-af0c-f890ca3a1315 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31941 biolink:treats MONDO:0005575 PMID:41385096 "[{""id"":""uuid:1b12213e-76be-41c6-ba2f-da1f5593df60"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:833e4d53-fceb-41fd-8039-72826105cf7d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:a01d4b0d-6470-4870-84c7-d5448c4f5942"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxaliplatin for injection USP, used in combination with infusional 5-fluorouracil/leucovorin, is indicated for: - adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor. - treatment of advanced colorectal cancer.|[PMDA] Drugs with a new additional indication and a new additional dosage and administration for combination therapy with other anticancer drugs (XELOX + BV regimen) for advanced or recurrent colorectal cancer not suited for curative resection. uuid:3e53e5cf-78b3-4a99-8c82-a529dc23e92b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8228 biolink:treats MONDO:0005154 PMID:41385096 "[{""id"":""uuid:e6a14eee-50e0-4347-987d-701ad8ccf2e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c3409478-a9f3-4be2-81c3-7e89c007d822"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Monotherapy and Combination Therapy Pioglitazone tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings [ see Clinical Studies (14) ]. Important Limitations of Use Pioglitazone tablets exert their antihyperglycemic effect only in the presence of endogenous insulin. Pioglitazone tablets should not be used to treat type 1 diabetes or diabetic ketoacidosis, as it would not be effective in these settings. Use caution in patients with liver disease [ see Warnings and Precautions (5.3) ]. uuid:4a176385-261f-4dce-b45b-5f49a2c22d58 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7565 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:8657eb78-c8e3-4618-af47-e717da229431"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8e10d6a8-ef92-4741-8efb-5424a9a0602b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] I. Vasospastic Angina Nifedipine Extended-release Tablet is indicated for the management of vasospastic angina confirmed by any of the following criteria: 1) classical pattern of angina at rest accompanied by ST segment elevation, 2) angina or coronary artery spasm provoked by ergonovine, or 3) angiographically demonstrated coronary artery spasm. In those patients who have had angiography, the presence of significant fixed obstructive disease is not incompatible with the diagnosis of vasospastic angina, provided that the above criteria are satisfied. Nifedipine Extended-release Tablet may also be used where the clinical presentation suggests a possible vasospastic component, but where vasospasm has not been confirmed, e.g., where pain has a variable threshold on exertion, or in unstable angina where electrocardiographic findings are compatible with intermittent vasospasm, or when angina is refractory to nitrates and/or adequate doses of beta-blockers. II. Chronic Stable Angina (Classical Effort-Associated Angina) Nifedipine Extended-release Tablet is indicated for the management of chronic stable angina (effort-associated angina) without evidence of vasospasm in patients who remain symptomatic despite adequate doses of beta-blockers and/or organic nitrates or who cannot tolerate those agents. In chronic stable angina (effort-associated angina), nifedipine has been effective in controlled trials of up to eight weeks duration in reducing angina frequency and increasing exercise tolerance, but confirmation of sustained effectiveness and evaluation of long-term safety in these patients is incomplete. Controlled studies in small numbers of patients suggest concomitant use of nifedipine and beta-blocking agents may be beneficial in patients with chronic stable angina, but available information is not sufficient to predict with confidence the effects of concurrent treatment, especially in patients with compromised left ventricular function or cardiac conduction abnormalities. When introducing such concomitant therapy, care must be taken to monitor blood pressure closely, since severe hypotension can occur from the combined effects of the drugs. (see WARNINGS.) III. Hypertension Nifedipine Extended-release Tablet is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including Nifedipine Extended-release Tablet. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Nifedipine Extended-release Tablet may be used alone or in combination with other antihypertensive agents. uuid:1d01b777-adb3-4ab2-a2f6-6b74a0299380 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7565 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:8297ccb5-50df-4b10-9fe5-8806968349e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ed10e22e-2f67-4a14-98f1-23c5b859563d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] I. Vasospastic Angina Nifedipine Extended-release Tablet is indicated for the management of vasospastic angina confirmed by any of the following criteria: 1) classical pattern of angina at rest accompanied by ST segment elevation, 2) angina or coronary artery spasm provoked by ergonovine, or 3) angiographically demonstrated coronary artery spasm. In those patients who have had angiography, the presence of significant fixed obstructive disease is not incompatible with the diagnosis of vasospastic angina, provided that the above criteria are satisfied. Nifedipine Extended-release Tablet may also be used where the clinical presentation suggests a possible vasospastic component, but where vasospasm has not been confirmed, e.g., where pain has a variable threshold on exertion, or in unstable angina where electrocardiographic findings are compatible with intermittent vasospasm, or when angina is refractory to nitrates and/or adequate doses of beta-blockers. II. Chronic Stable Angina (Classical Effort-Associated Angina) Nifedipine Extended-release Tablet is indicated for the management of chronic stable angina (effort-associated angina) without evidence of vasospasm in patients who remain symptomatic despite adequate doses of beta-blockers and/or organic nitrates or who cannot tolerate those agents. In chronic stable angina (effort-associated angina), nifedipine has been effective in controlled trials of up to eight weeks duration in reducing angina frequency and increasing exercise tolerance, but confirmation of sustained effectiveness and evaluation of long-term safety in these patients is incomplete. Controlled studies in small numbers of patients suggest concomitant use of nifedipine and beta-blocking agents may be beneficial in patients with chronic stable angina, but available information is not sufficient to predict with confidence the effects of concurrent treatment, especially in patients with compromised left ventricular function or cardiac conduction abnormalities. When introducing such concomitant therapy, care must be taken to monitor blood pressure closely, since severe hypotension can occur from the combined effects of the drugs. (see WARNINGS.) III. Hypertension Nifedipine Extended-release Tablet is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including Nifedipine Extended-release Tablet. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Nifedipine Extended-release Tablet may be used alone or in combination with other antihypertensive agents. uuid:1f1487a6-68fb-4b93-8560-12f82a645423 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7565 biolink:treats MONDO:0005016 PMID:41385096 "[{""id"":""uuid:c9494379-3edf-4f1f-8e1e-ae87a1fdc1cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0d33fd29-6165-447e-9ee1-514a829d3fa5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] I. Vasospastic Angina Nifedipine Extended-release Tablet is indicated for the management of vasospastic angina confirmed by any of the following criteria: 1) classical pattern of angina at rest accompanied by ST segment elevation, 2) angina or coronary artery spasm provoked by ergonovine, or 3) angiographically demonstrated coronary artery spasm. In those patients who have had angiography, the presence of significant fixed obstructive disease is not incompatible with the diagnosis of vasospastic angina, provided that the above criteria are satisfied. Nifedipine Extended-release Tablet may also be used where the clinical presentation suggests a possible vasospastic component, but where vasospasm has not been confirmed, e.g., where pain has a variable threshold on exertion, or in unstable angina where electrocardiographic findings are compatible with intermittent vasospasm, or when angina is refractory to nitrates and/or adequate doses of beta-blockers. II. Chronic Stable Angina (Classical Effort-Associated Angina) Nifedipine Extended-release Tablet is indicated for the management of chronic stable angina (effort-associated angina) without evidence of vasospasm in patients who remain symptomatic despite adequate doses of beta-blockers and/or organic nitrates or who cannot tolerate those agents. In chronic stable angina (effort-associated angina), nifedipine has been effective in controlled trials of up to eight weeks duration in reducing angina frequency and increasing exercise tolerance, but confirmation of sustained effectiveness and evaluation of long-term safety in these patients is incomplete. Controlled studies in small numbers of patients suggest concomitant use of nifedipine and beta-blocking agents may be beneficial in patients with chronic stable angina, but available information is not sufficient to predict with confidence the effects of concurrent treatment, especially in patients with compromised left ventricular function or cardiac conduction abnormalities. When introducing such concomitant therapy, care must be taken to monitor blood pressure closely, since severe hypotension can occur from the combined effects of the drugs. (see WARNINGS.) III. Hypertension Nifedipine Extended-release Tablet is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including Nifedipine Extended-release Tablet. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Nifedipine Extended-release Tablet may be used alone or in combination with other antihypertensive agents. uuid:b152825f-8531-48e1-96ad-e89b0a35dac1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6541 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:b3a7da61-0de7-4aed-b167-5b6b90b88d90"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:81773061-152f-4ae9-a0ae-b77973c7904a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Losartan potassium tablets are an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) • Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy. There is evidence that this benefit does not apply to Black patients. ( 1.2 ) • Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension. ( 1.3 ) uuid:de149a5f-32a8-4125-a25a-57477dc6e844 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6541 biolink:treats MONDO:0006652 PMID:41385096 "[{""id"":""uuid:32e57821-570e-4594-aa90-5076a8a57674"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:030afa71-2665-42ab-9759-884a46ef5696"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Losartan potassium tablets are an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) • Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy. There is evidence that this benefit does not apply to Black patients. ( 1.2 ) • Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension. ( 1.3 ) uuid:9f9b7509-b6cb-42f3-b01f-fc7ee9bfca3a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5100 biolink:treats MONDO:0700217 PMID:41385096 "[{""id"":""uuid:60229b44-fa3d-45a9-98d8-1c4be38e19b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8190c996-86e9-4a11-a044-f7b281688605"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Flucytosine Capsules are indicated only in the treatment of serious infections caused by susceptible strains of Candida and/or Cryptococcus . Candida: Septicemia, endocarditis and urinary system infections have been effectively treated with flucytosine. Limited trials in pulmonary infections justify the use of flucytosine. Cryptococcus: Meningitis and pulmonary infections have been treated effectively. Studies in septicemias and urinary tract infections are limited, but good responses have been reported. Flucytosine Capsules should be used in combination with amphotericin B for the treatment of systemic candidiasis and cryptococcosis because of the emergence of resistance to Flucytosine Capsules (see MICROBIOLOGY ). uuid:681ce5fa-ca04-47ca-a8ad-babd60d508a8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5100 biolink:treats MONDO:0005025 PMID:41385096 "[{""id"":""uuid:dfb5dcae-0297-459b-b231-ed95d68b4204"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:daed62d5-7e18-4331-b569-ef5a3ea1c6b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Flucytosine Capsules are indicated only in the treatment of serious infections caused by susceptible strains of Candida and/or Cryptococcus . Candida: Septicemia, endocarditis and urinary system infections have been effectively treated with flucytosine. Limited trials in pulmonary infections justify the use of flucytosine. Cryptococcus: Meningitis and pulmonary infections have been treated effectively. Studies in septicemias and urinary tract infections are limited, but good responses have been reported. Flucytosine Capsules should be used in combination with amphotericin B for the treatment of systemic candidiasis and cryptococcosis because of the emergence of resistance to Flucytosine Capsules (see MICROBIOLOGY ). uuid:8dca2d7d-9592-4927-b710-d5a46e2ee862 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5100 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:a12c08a8-6de6-4b38-88c2-f1783fda995d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a52b8d0e-9a69-4931-8e5d-2a015ee96eb9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Flucytosine Capsules are indicated only in the treatment of serious infections caused by susceptible strains of Candida and/or Cryptococcus . Candida: Septicemia, endocarditis and urinary system infections have been effectively treated with flucytosine. Limited trials in pulmonary infections justify the use of flucytosine. Cryptococcus: Meningitis and pulmonary infections have been treated effectively. Studies in septicemias and urinary tract infections are limited, but good responses have been reported. Flucytosine Capsules should be used in combination with amphotericin B for the treatment of systemic candidiasis and cryptococcosis because of the emergence of resistance to Flucytosine Capsules (see MICROBIOLOGY ). uuid:890db123-ec9a-49f2-adcf-c4cc7594764f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5100 biolink:treats MONDO:0021108 PMID:41385096 "[{""id"":""uuid:81f65622-604b-4425-a8f9-7411121d1995"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:39835cd5-e6d5-4e21-8030-0abe2d5253a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Flucytosine Capsules are indicated only in the treatment of serious infections caused by susceptible strains of Candida and/or Cryptococcus . Candida: Septicemia, endocarditis and urinary system infections have been effectively treated with flucytosine. Limited trials in pulmonary infections justify the use of flucytosine. Cryptococcus: Meningitis and pulmonary infections have been treated effectively. Studies in septicemias and urinary tract infections are limited, but good responses have been reported. Flucytosine Capsules should be used in combination with amphotericin B for the treatment of systemic candidiasis and cryptococcosis because of the emergence of resistance to Flucytosine Capsules (see MICROBIOLOGY ). uuid:9da3f512-3a2e-41ae-9877-ac710cefb9e2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5100 biolink:treats MONDO:0042233 PMID:41385096 "[{""id"":""uuid:ee0a7653-9664-469b-a70b-db84fd119ed9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d82caa0d-49af-451e-82d8-e85860067daf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Flucytosine Capsules are indicated only in the treatment of serious infections caused by susceptible strains of Candida and/or Cryptococcus . Candida: Septicemia, endocarditis and urinary system infections have been effectively treated with flucytosine. Limited trials in pulmonary infections justify the use of flucytosine. Cryptococcus: Meningitis and pulmonary infections have been treated effectively. Studies in septicemias and urinary tract infections are limited, but good responses have been reported. Flucytosine Capsules should be used in combination with amphotericin B for the treatment of systemic candidiasis and cryptococcosis because of the emergence of resistance to Flucytosine Capsules (see MICROBIOLOGY ). uuid:2f81f385-f6dc-4c89-9194-83a00b9e07a3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5100 biolink:treats MONDO:0005724 PMID:41385096 "[{""id"":""uuid:1b3eb7a8-c697-4cf2-b5cf-269233b4f32c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ce9b8c0c-04d4-46be-8a14-2cd343cd9791"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Flucytosine Capsules are indicated only in the treatment of serious infections caused by susceptible strains of Candida and/or Cryptococcus . Candida: Septicemia, endocarditis and urinary system infections have been effectively treated with flucytosine. Limited trials in pulmonary infections justify the use of flucytosine. Cryptococcus: Meningitis and pulmonary infections have been treated effectively. Studies in septicemias and urinary tract infections are limited, but good responses have been reported. Flucytosine Capsules should be used in combination with amphotericin B for the treatment of systemic candidiasis and cryptococcosis because of the emergence of resistance to Flucytosine Capsules (see MICROBIOLOGY ). uuid:dc2a4698-714e-4b63-a201-187815d4ddc4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6541 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:e4d708fc-40ff-454c-b5cc-997c13fabd1c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cf6630b0-c386-49d5-992c-08eb2134aa52"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Losartan potassium tablets are an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. (1.1) Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy. There is evidence that this benefit does not apply to Black patients. (1.2) Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension. (1.3) uuid:9db4675a-3f57-47a3-8d88-25be67fbdf6f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9671 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:1abdb6fb-d51c-467a-9dcd-82ab8b016538"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7dbd42ca-93ce-49cf-a65c-17677fcc736d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dyrenium (triamterene) is indicated in the treatment of edema associated with congestive heart failure, cirrhosis of the liver and the nephrotic syndrome; steroid-induced edema, idiopathic edema and edema due to secondary hyperaldosteronism. Dyrenium may be used alone or with other diuretics, either for its added diuretic effect or its potassium-sparing potential. It also promotes increased diuresis when patients prove resistant or only partially responsive to thiazides or other diuretics because of secondary hyperaldosteronism. Usage in Pregnancy . The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developed toxemia. Edema during pregnancy may arise from pathological causes or from the physiologic and mechanical consequences of pregnancy. Diuretics are indicated in pregnancy (however, see PRECAUTIONS below) when edema is due to pathologic causes, just as they are in the absence of pregnancy. Dependent edema in pregnancy, resulting from restriction of venous return by the expanded uterus, is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is illogical and unnecessary. There is hypervolemia during normal pregnancy which is harmful to neither the fetus nor the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema, in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances, this edema may cause extreme discomfort which is not relieved by rest. In these cases, a short course of diuretics may provide relief and may be appropriate. uuid:dab07447-d867-41c1-938b-7ca867cca38c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9671 biolink:treats MONDO:0005155 PMID:41385096 "[{""id"":""uuid:a9da1ee3-73ff-4364-bcce-f0c7e8a1c26f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ba066071-7a48-451e-a330-c3e2b4dab75d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dyrenium (triamterene) is indicated in the treatment of edema associated with congestive heart failure, cirrhosis of the liver and the nephrotic syndrome; steroid-induced edema, idiopathic edema and edema due to secondary hyperaldosteronism. Dyrenium may be used alone or with other diuretics, either for its added diuretic effect or its potassium-sparing potential. It also promotes increased diuresis when patients prove resistant or only partially responsive to thiazides or other diuretics because of secondary hyperaldosteronism. Usage in Pregnancy . The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developed toxemia. Edema during pregnancy may arise from pathological causes or from the physiologic and mechanical consequences of pregnancy. Diuretics are indicated in pregnancy (however, see PRECAUTIONS below) when edema is due to pathologic causes, just as they are in the absence of pregnancy. Dependent edema in pregnancy, resulting from restriction of venous return by the expanded uterus, is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is illogical and unnecessary. There is hypervolemia during normal pregnancy which is harmful to neither the fetus nor the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema, in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances, this edema may cause extreme discomfort which is not relieved by rest. In these cases, a short course of diuretics may provide relief and may be appropriate. uuid:877a2cb6-2819-485d-8ae8-69990fb77cc2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9671 biolink:treats MONDO:0005377 PMID:41385096 "[{""id"":""uuid:b293e713-d248-48d2-97f5-531815cd1d31"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c9346977-ba78-44d0-83ab-297e80667fad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dyrenium (triamterene) is indicated in the treatment of edema associated with congestive heart failure, cirrhosis of the liver and the nephrotic syndrome; steroid-induced edema, idiopathic edema and edema due to secondary hyperaldosteronism. Dyrenium may be used alone or with other diuretics, either for its added diuretic effect or its potassium-sparing potential. It also promotes increased diuresis when patients prove resistant or only partially responsive to thiazides or other diuretics because of secondary hyperaldosteronism. Usage in Pregnancy . The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developed toxemia. Edema during pregnancy may arise from pathological causes or from the physiologic and mechanical consequences of pregnancy. Diuretics are indicated in pregnancy (however, see PRECAUTIONS below) when edema is due to pathologic causes, just as they are in the absence of pregnancy. Dependent edema in pregnancy, resulting from restriction of venous return by the expanded uterus, is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is illogical and unnecessary. There is hypervolemia during normal pregnancy which is harmful to neither the fetus nor the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema, in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances, this edema may cause extreme discomfort which is not relieved by rest. In these cases, a short course of diuretics may provide relief and may be appropriate. uuid:125edc04-9906-4038-8a1a-80225bb2a5a7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9671 biolink:treats UMLS:C0238094 PMID:41385096 "[{""id"":""uuid:fd72496d-73dd-46f4-a5aa-5d87666aa598"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0bfefc5f-0041-4a86-8756-ce5c4d3d7178"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dyrenium (triamterene) is indicated in the treatment of edema associated with congestive heart failure, cirrhosis of the liver and the nephrotic syndrome; steroid-induced edema, idiopathic edema and edema due to secondary hyperaldosteronism. Dyrenium may be used alone or with other diuretics, either for its added diuretic effect or its potassium-sparing potential. It also promotes increased diuresis when patients prove resistant or only partially responsive to thiazides or other diuretics because of secondary hyperaldosteronism. Usage in Pregnancy . The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developed toxemia. Edema during pregnancy may arise from pathological causes or from the physiologic and mechanical consequences of pregnancy. Diuretics are indicated in pregnancy (however, see PRECAUTIONS below) when edema is due to pathologic causes, just as they are in the absence of pregnancy. Dependent edema in pregnancy, resulting from restriction of venous return by the expanded uterus, is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is illogical and unnecessary. There is hypervolemia during normal pregnancy which is harmful to neither the fetus nor the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema, in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances, this edema may cause extreme discomfort which is not relieved by rest. In these cases, a short course of diuretics may provide relief and may be appropriate. uuid:b470a909-dcd1-4823-948b-b4b55e77f5da biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9671 biolink:treats MONDO:0003009 PMID:41385096 "[{""id"":""uuid:53c3aa3f-84e3-48b6-9dcf-9b6ef99f6a8c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6464cd45-bc6c-4bfc-899e-f4a26b556dd6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dyrenium (triamterene) is indicated in the treatment of edema associated with congestive heart failure, cirrhosis of the liver and the nephrotic syndrome; steroid-induced edema, idiopathic edema and edema due to secondary hyperaldosteronism. Dyrenium may be used alone or with other diuretics, either for its added diuretic effect or its potassium-sparing potential. It also promotes increased diuresis when patients prove resistant or only partially responsive to thiazides or other diuretics because of secondary hyperaldosteronism. Usage in Pregnancy . The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developed toxemia. Edema during pregnancy may arise from pathological causes or from the physiologic and mechanical consequences of pregnancy. Diuretics are indicated in pregnancy (however, see PRECAUTIONS below) when edema is due to pathologic causes, just as they are in the absence of pregnancy. Dependent edema in pregnancy, resulting from restriction of venous return by the expanded uterus, is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is illogical and unnecessary. There is hypervolemia during normal pregnancy which is harmful to neither the fetus nor the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema, in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances, this edema may cause extreme discomfort which is not relieved by rest. In these cases, a short course of diuretics may provide relief and may be appropriate. uuid:b4b87874-d347-440e-ae0e-88119697b13b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9671 biolink:treats MONDO:0045048 PMID:41385096 "[{""id"":""uuid:3bc9b120-241d-4ace-a280-124ade1a4a12"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f598ad3f-170f-402c-aacd-42081ae5557c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dyrenium (triamterene) is indicated in the treatment of edema associated with congestive heart failure, cirrhosis of the liver and the nephrotic syndrome; steroid-induced edema, idiopathic edema and edema due to secondary hyperaldosteronism. Dyrenium may be used alone or with other diuretics, either for its added diuretic effect or its potassium-sparing potential. It also promotes increased diuresis when patients prove resistant or only partially responsive to thiazides or other diuretics because of secondary hyperaldosteronism. Usage in Pregnancy . The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developed toxemia. Edema during pregnancy may arise from pathological causes or from the physiologic and mechanical consequences of pregnancy. Diuretics are indicated in pregnancy (however, see PRECAUTIONS below) when edema is due to pathologic causes, just as they are in the absence of pregnancy. Dependent edema in pregnancy, resulting from restriction of venous return by the expanded uterus, is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is illogical and unnecessary. There is hypervolemia during normal pregnancy which is harmful to neither the fetus nor the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema, in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances, this edema may cause extreme discomfort which is not relieved by rest. In these cases, a short course of diuretics may provide relief and may be appropriate. uuid:c27248f7-7859-4336-b3f6-8a70f4d60476 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9671 biolink:treats MONDO:0005081 PMID:41385096 "[{""id"":""uuid:c0a1e9a0-340d-4366-9e92-0802f3f4463d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:efaf30f4-3f97-46e0-8b68-b1217943c70e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dyrenium (triamterene) is indicated in the treatment of edema associated with congestive heart failure, cirrhosis of the liver and the nephrotic syndrome; steroid-induced edema, idiopathic edema and edema due to secondary hyperaldosteronism. Dyrenium may be used alone or with other diuretics, either for its added diuretic effect or its potassium-sparing potential. It also promotes increased diuresis when patients prove resistant or only partially responsive to thiazides or other diuretics because of secondary hyperaldosteronism. Usage in Pregnancy . The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developed toxemia. Edema during pregnancy may arise from pathological causes or from the physiologic and mechanical consequences of pregnancy. Diuretics are indicated in pregnancy (however, see PRECAUTIONS below) when edema is due to pathologic causes, just as they are in the absence of pregnancy. Dependent edema in pregnancy, resulting from restriction of venous return by the expanded uterus, is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is illogical and unnecessary. There is hypervolemia during normal pregnancy which is harmful to neither the fetus nor the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema, in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances, this edema may cause extreme discomfort which is not relieved by rest. In these cases, a short course of diuretics may provide relief and may be appropriate. uuid:2fca799e-9d5b-4f11-a8b8-a6d9f59de77a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9671 biolink:treats UMLS:C0341960 PMID:41385096 "[{""id"":""uuid:91ac510c-0b78-40ed-a21d-0184c706e6b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d0d2eeb2-d36d-4f4c-8bdb-cb95678d07ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dyrenium (triamterene) is indicated in the treatment of edema associated with congestive heart failure, cirrhosis of the liver and the nephrotic syndrome; steroid-induced edema, idiopathic edema and edema due to secondary hyperaldosteronism. Dyrenium may be used alone or with other diuretics, either for its added diuretic effect or its potassium-sparing potential. It also promotes increased diuresis when patients prove resistant or only partially responsive to thiazides or other diuretics because of secondary hyperaldosteronism. Usage in Pregnancy . The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developed toxemia. Edema during pregnancy may arise from pathological causes or from the physiologic and mechanical consequences of pregnancy. Diuretics are indicated in pregnancy (however, see PRECAUTIONS below) when edema is due to pathologic causes, just as they are in the absence of pregnancy. Dependent edema in pregnancy, resulting from restriction of venous return by the expanded uterus, is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is illogical and unnecessary. There is hypervolemia during normal pregnancy which is harmful to neither the fetus nor the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema, in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances, this edema may cause extreme discomfort which is not relieved by rest. In these cases, a short course of diuretics may provide relief and may be appropriate. uuid:9123b01b-ad82-4758-8fb1-8204a37054dc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9671 biolink:treats HP:0007430 PMID:41385096 "[{""id"":""uuid:22d9d392-126e-4125-ae30-a9d1c5578460"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:50c4a5ba-1fdb-4ece-8885-df441163c30e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dyrenium (triamterene) is indicated in the treatment of edema associated with congestive heart failure, cirrhosis of the liver and the nephrotic syndrome; steroid-induced edema, idiopathic edema and edema due to secondary hyperaldosteronism. Dyrenium may be used alone or with other diuretics, either for its added diuretic effect or its potassium-sparing potential. It also promotes increased diuresis when patients prove resistant or only partially responsive to thiazides or other diuretics because of secondary hyperaldosteronism. Usage in Pregnancy . The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developed toxemia. Edema during pregnancy may arise from pathological causes or from the physiologic and mechanical consequences of pregnancy. Diuretics are indicated in pregnancy (however, see PRECAUTIONS below) when edema is due to pathologic causes, just as they are in the absence of pregnancy. Dependent edema in pregnancy, resulting from restriction of venous return by the expanded uterus, is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is illogical and unnecessary. There is hypervolemia during normal pregnancy which is harmful to neither the fetus nor the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema, in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances, this edema may cause extreme discomfort which is not relieved by rest. In these cases, a short course of diuretics may provide relief and may be appropriate. uuid:79b10531-98f1-4266-9c50-2d80996ab96f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29101 biolink:treats MONDO:0005412 PMID:41385096 "[{""id"":""uuid:0d2da68a-2b6c-4325-8cab-20da39f617ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0787fe09-56f6-4004-823f-9370b9d30801"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Omeprazole and sodium bicarbonate is a proton pump inhibitor indicated for: Short-term treatment of active duodenal ulcer ( 1.1 ) Short-term treatment of active benign gastric ulcer ( 1.2 ) Treatment of gastroesophageal reflux disease (GERD) ( 1.3 ) Maintenance of healing of erosive esophagitis (1.4) The safety and effectiveness of omeprazole and sodium bicarbonate capsules in pediatric patients (<18 years of age) have not been established. ( 8.4 ) uuid:f64163ec-d928-4a78-a3b5-3aebc7408606 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29101 biolink:treats MONDO:0001126 PMID:41385096 "[{""id"":""uuid:c06869ab-cc3b-4228-b3be-5ffb3158f945"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:df1c8aed-a423-4ffb-815c-9e6984c4560d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Omeprazole and sodium bicarbonate is a proton pump inhibitor indicated for: Short-term treatment of active duodenal ulcer ( 1.1 ) Short-term treatment of active benign gastric ulcer ( 1.2 ) Treatment of gastroesophageal reflux disease (GERD) ( 1.3 ) Maintenance of healing of erosive esophagitis (1.4) The safety and effectiveness of omeprazole and sodium bicarbonate capsules in pediatric patients (<18 years of age) have not been established. ( 8.4 ) uuid:36d84214-d04a-46ce-8708-6ed64f7fb1b5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29101 biolink:treats UMLS:C0267055 PMID:41385096 "[{""id"":""uuid:0794060c-a77c-4adf-9485-eef9d2961c62"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6bfcf5c6-68c2-4e70-ba22-616e9a967419"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Omeprazole and sodium bicarbonate is a proton pump inhibitor indicated for: Short-term treatment of active duodenal ulcer ( 1.1 ) Short-term treatment of active benign gastric ulcer ( 1.2 ) Treatment of gastroesophageal reflux disease (GERD) ( 1.3 ) Maintenance of healing of erosive esophagitis (1.4) The safety and effectiveness of omeprazole and sodium bicarbonate capsules in pediatric patients (<18 years of age) have not been established. ( 8.4 ) uuid:7e0078f0-837c-400d-b3e1-940fab4a0541 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0019801 PMID:41385096 "[{""id"":""uuid:ca87b39e-1602-4d06-92a8-afdcb727ca16"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b3650520-1c26-4380-b243-a8f484e263c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:9c14f68c-a41d-4589-a3e6-f7ef40e1f856 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0005178 PMID:41385096 "[{""id"":""uuid:47763387-0ea5-458d-8c24-a431a89f73cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:41ee22f7-eb9e-4c58-b004-0f2c66f51e4f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:c813e45c-98fe-48fc-a852-5270f19cb5df biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0040698 PMID:41385096 "[{""id"":""uuid:84970f1f-8490-48a6-9682-881c918768f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:97ca74c4-eb85-4518-bdc7-63417bb82dc7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:c86c0abc-f479-47cc-bd06-bec76163c3ff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0001875 PMID:41385096 "[{""id"":""uuid:c3373569-40a1-4da9-a2e5-b6ec92fd664e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a422ac5e-c067-46f5-8c27-64d38e35bae7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:67008511-f697-4b40-a31a-9ce3578c18ff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0004855 PMID:41385096 "[{""id"":""uuid:a4bdcf02-979c-4c3d-b88f-90af5527e580"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:051171c5-4b9a-4773-82a8-79ec4d384d7d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:4495e30d-ec94-4b09-bed3-f3934d9fa70e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0006545 PMID:41385096 "[{""id"":""uuid:fab15f32-b7b9-4b0a-bab5-e2a6794db25a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:707c9936-d831-4746-92f7-68c58a3e7066"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:4966094b-59ba-43fe-acf5-cb3f96de2e4a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0006608 PMID:41385096 "[{""id"":""uuid:32e9a94a-762e-43a4-9744-424f0d8c5a51"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:67f0ad9e-cc66-42ee-aac6-0636ab64bd1d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:1d6f4d91-3ec4-41d2-8170-eebb4740230a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0005083 PMID:41385096 "[{""id"":""uuid:88078a00-8b40-49e9-a02d-33ddf77f0e09"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2405cea6-988b-4713-8dc3-e85799788a8a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:9070a2df-d244-4487-b025-979992130f61 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0011786 PMID:41385096 "[{""id"":""uuid:41c3c984-04b1-4250-adb4-85ccc84e2501"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:69690f2b-9c49-4b1e-89cb-5d37ec69a885"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:c9ff89c9-ce8e-40b9-96e1-7439e79ad91d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats UMLS:C0274440 PMID:41385096 "[{""id"":""uuid:f9536dc6-3b42-4a68-a507-2b6d977513c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c868b93e-a314-4957-b758-e57bda4f3c5c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:794bb6a4-1279-41c9-8d37-2831871b2124 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0005883 PMID:41385096 "[{""id"":""uuid:aabfb8e0-7dd1-4a2b-8464-24bbc246cb9a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c8b23df1-cf32-49a1-bc6f-02fd51207397"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:26544b77-a275-43dd-b63d-47655f888759 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0004773 PMID:41385096 "[{""id"":""uuid:69be0b3b-1c34-4500-a9e0-73e0492e122d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c23a02f9-04d7-4073-8fde-fa9cc18d402c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:8ef68bf7-5f18-4493-a7fb-5cd188d79d36 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0004674 PMID:41385096 "[{""id"":""uuid:c3972812-42d7-4a65-a561-dd5d3a6eb553"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f294eb6a-0fe3-4d70-8f11-c8909055b03c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:0e547ebc-0f1e-44b3-865e-6faf60172338 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0005885 PMID:41385096 "[{""id"":""uuid:bbebd9f9-269d-48bb-a5ce-ffeb949028d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d741f4a9-553f-4b5d-8c7b-b40cfb123bf1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:e34abf05-42e3-48a2-a7fc-c0503dca95ab biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0006651 PMID:41385096 "[{""id"":""uuid:ee7ff9d8-cb5a-4f5d-b6e4-a6a4d44e6649"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0a578898-7489-47f2-9e2f-f375511e7eed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:a9566de2-18dd-4b09-a244-f32cd5cd3c22 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0003085 PMID:41385096 "[{""id"":""uuid:415a5d0a-91ca-4448-aa6b-59fd9ea7ddeb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2f6a383c-cdfb-489d-8eec-5a6f194dfe89"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:88ec79cf-b657-402a-9041-6159d93a25a4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0001034 PMID:41385096 "[{""id"":""uuid:9dae6210-09cd-4fca-8534-409bd3af3f74"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9431fd49-7c69-4203-abaf-d803d14a444b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:cd93571d-b494-4e08-b361-3ac32e2116fa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0005848 PMID:41385096 "[{""id"":""uuid:e872354b-aaca-453f-8802-eb47c463ad27"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f3974756-438c-412b-a66b-6b9606e4ad88"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:555348b7-e59f-42b5-b5e6-4fd2da4bb047 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0002572 PMID:41385096 "[{""id"":""uuid:4eaa4f00-0333-40f6-8821-ce0844564483"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5d713cae-59a0-4bf0-b501-fb931de26719"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:0f4fac93-1237-45a1-a69c-7b95f5c7ea42 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats UMLS:C0002879 PMID:41385096 "[{""id"":""uuid:c5abfe6c-011b-4b13-894e-d0d502262246"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f8af3b6e-d663-4413-91af-6aefa90fc81b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:9da27e06-ac51-4fee-8cfa-92f4e1eafde0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0002280 PMID:41385096 "[{""id"":""uuid:36a6c6dd-9586-4a68-ab0c-290dc0bb763f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0747916d-bc21-4c49-8330-8aa763befdf5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:eb8ab634-8491-4142-9ed3-fca8a9f47cf9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0015253 PMID:41385096 "[{""id"":""uuid:6daeb198-a76f-4512-bd36-09009fdafdd9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3e539d0e-1f82-4f04-ab03-4cd05bc4d1dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:cbf8742c-0e7b-46e5-9e8f-ed4a6a3eeed9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats HP:0001908 PMID:41385096 "[{""id"":""uuid:4eac32de-5592-40cc-9444-08b511fce97e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c3dc048b-0d95-404c-8501-17daada75dab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:f03aa970-0b25-4094-8bce-45a32ec4002f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0004355 PMID:41385096 "[{""id"":""uuid:fd89fe6d-6dd6-4fb7-b81e-893d445bfabe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0ff77b3c-7cad-4619-ae8a-7799fd823d56"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:b501c70d-2c53-4122-9b9f-c8ef47760588 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0005377 PMID:41385096 "[{""id"":""uuid:a84aeabd-69ca-4537-9bac-ac4ef2e45f50"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fe3bfade-feba-4ecd-9213-85f8d4d4d575"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:d2e6ce1f-c36f-4668-9716-d7603040f1b3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4450 biolink:treats HP:0001959 PMID:41385096 "[{""id"":""uuid:6f49878b-a3ee-41e9-9bd4-8a841468c70b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f2c93cf1-68a6-4800-93a4-c7465344648b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Desmopressin acetate tablets are indicated as antidiuretic replacement therapy in the management of central diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. Desmopressin acetate is ineffective for the treatment of nephrogenic diabetes insipidus. Patients were selected for therapy based on the diagnosis by means of the water deprivation test, the hypertonic saline infusion test, and/or response to antidiuretic hormone. Continued response to desmopressin acetate can be monitored by measuring urine volume and osmolality. uuid:2b50272c-d2fb-44db-9e55-f31cee5edc5f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3561 biolink:treats MONDO:0044212 PMID:41385096 "[{""id"":""uuid:9cf64b7d-4a36-4fda-b489-56e1599f0a6e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7254843a-ac86-4518-bfd2-96803056c8dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Perennial Allergic Rhinitis: Cetirizine hydrochloride is indicated for the relief of symptoms associated with perennial allergic rhinitis due to allergens such as dust mites, animal dander and molds in children 6 to 23 months of age. Symptoms treated effectively include sneezing, rhinorrhea, postnasal discharge, nasal pruritus, ocular pruritus, and tearing. Chronic Urticaria: Cetirizine hydrochloride is indicated for the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria in children 6 months to 5 years of age. It significantly reduces the occurrence, severity, and duration of hives and significantly reduces pruritus. uuid:a1356b9e-d27e-4199-b38a-8f9ad826afb2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:9938610 biolink:treats MONDO:0006805 PMID:41385096 "[{""id"":""uuid:826e44cd-b331-4b2d-a6cd-6b23689fac01"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e93080cb-00c6-484c-8576-f0d3fa7ad7a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clopidogrel bisulfate is a P2Y12 platelet inhibitor indicated for: • Acute coronary syndrome - For patients with non-ST-segment elevation ACS [unstable angina (UA)/non-ST-elevation myocardial infarction (NSTEMI)], clopidogrel bisulfate has been shown to reduce the rate of myocardial infarction (MI) and stroke. ( 1.1 ) - For patients with ST-elevation myocardial infarction (STEMI), clopidogrel bisulfate has been shown to reduce the rate of MI and stroke. ( 1.1 ) • Recent MI, recent stroke, or established peripheral arterial disease. Clopidogrel bisulfate has been shown to reduce the rate of MI and stroke. ( 1.2 ) uuid:7b0a0182-cb41-46e4-b18e-a212840fad6c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:9938610 biolink:treats MONDO:0000990 PMID:41385096 "[{""id"":""uuid:f7e43a0b-ac28-43a6-8f55-9520ec044589"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ddf86622-afbc-4b1d-8260-215795400067"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clopidogrel bisulfate is a P2Y12 platelet inhibitor indicated for: • Acute coronary syndrome - For patients with non-ST-segment elevation ACS [unstable angina (UA)/non-ST-elevation myocardial infarction (NSTEMI)], clopidogrel bisulfate has been shown to reduce the rate of myocardial infarction (MI) and stroke. ( 1.1 ) - For patients with ST-elevation myocardial infarction (STEMI), clopidogrel bisulfate has been shown to reduce the rate of MI and stroke. ( 1.1 ) • Recent MI, recent stroke, or established peripheral arterial disease. Clopidogrel bisulfate has been shown to reduce the rate of MI and stroke. ( 1.2 ) uuid:b5bcfd4a-89c3-438a-9375-5be67165fa3c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:9938610 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:69761c90-a142-4f38-ac77-6719d964b5eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3604596f-65ea-4b0d-bb30-abfb04cc49a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clopidogrel bisulfate is a P2Y12 platelet inhibitor indicated for: • Acute coronary syndrome - For patients with non-ST-segment elevation ACS [unstable angina (UA)/non-ST-elevation myocardial infarction (NSTEMI)], clopidogrel bisulfate has been shown to reduce the rate of myocardial infarction (MI) and stroke. ( 1.1 ) - For patients with ST-elevation myocardial infarction (STEMI), clopidogrel bisulfate has been shown to reduce the rate of MI and stroke. ( 1.1 ) • Recent MI, recent stroke, or established peripheral arterial disease. Clopidogrel bisulfate has been shown to reduce the rate of MI and stroke. ( 1.2 ) uuid:ccd93d6e-20b0-48d6-a72e-ebab7df0a92a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:9938610 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:1476f3df-d2ab-48a5-a8a7-c2c5380f4bde"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9868b869-a915-4e86-81d2-205edd652632"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clopidogrel bisulfate is a P2Y12 platelet inhibitor indicated for: • Acute coronary syndrome - For patients with non-ST-segment elevation ACS [unstable angina (UA)/non-ST-elevation myocardial infarction (NSTEMI)], clopidogrel bisulfate has been shown to reduce the rate of myocardial infarction (MI) and stroke. ( 1.1 ) - For patients with ST-elevation myocardial infarction (STEMI), clopidogrel bisulfate has been shown to reduce the rate of MI and stroke. ( 1.1 ) • Recent MI, recent stroke, or established peripheral arterial disease. Clopidogrel bisulfate has been shown to reduce the rate of MI and stroke. ( 1.2 ) uuid:7e853765-e10c-4986-98a6-9536b4746060 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:9938610 biolink:treats MONDO:0041656 PMID:41385096 "[{""id"":""uuid:45793c26-7f75-424d-ba88-6754ee53c968"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e6034821-436d-4cad-9de8-7789210931c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clopidogrel bisulfate is a P2Y12 platelet inhibitor indicated for: • Acute coronary syndrome - For patients with non-ST-segment elevation ACS [unstable angina (UA)/non-ST-elevation myocardial infarction (NSTEMI)], clopidogrel bisulfate has been shown to reduce the rate of myocardial infarction (MI) and stroke. ( 1.1 ) - For patients with ST-elevation myocardial infarction (STEMI), clopidogrel bisulfate has been shown to reduce the rate of MI and stroke. ( 1.1 ) • Recent MI, recent stroke, or established peripheral arterial disease. Clopidogrel bisulfate has been shown to reduce the rate of MI and stroke. ( 1.2 ) uuid:a00161d5-8d35-4339-b28c-5e5568bb9d4b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:9938610 biolink:treats MONDO:0005386 PMID:41385096 "[{""id"":""uuid:bda652db-d8e4-4807-8158-a25e724b9ccb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:286f18d1-6c7e-4d0c-8df8-d076753372e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clopidogrel bisulfate is a P2Y12 platelet inhibitor indicated for: • Acute coronary syndrome - For patients with non-ST-segment elevation ACS [unstable angina (UA)/non-ST-elevation myocardial infarction (NSTEMI)], clopidogrel bisulfate has been shown to reduce the rate of myocardial infarction (MI) and stroke. ( 1.1 ) - For patients with ST-elevation myocardial infarction (STEMI), clopidogrel bisulfate has been shown to reduce the rate of MI and stroke. ( 1.1 ) • Recent MI, recent stroke, or established peripheral arterial disease. Clopidogrel bisulfate has been shown to reduce the rate of MI and stroke. ( 1.2 ) uuid:08ffda01-794e-4199-88c5-5f9f5503b91f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10119 biolink:treats MONDO:0100511 PMID:41385096 "[{""id"":""uuid:01e63a4d-a201-4dfc-97e0-74029a85fdd4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9f5c1da0-db39-4cc0-bcee-3148feb96b1c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ziprasidone hydrochloride capsules are indicated for the treatment of schizophrenia. When deciding among the alternative treatments available for the condition needing treatment, the prescriber should consider the finding of ziprasidone’ s greater capacity to prolong the QT/QTc interval compared to several other antipsychotic drugs [ see Warnings and Precautions (5.2) ]. Prolongation of the QTc interval is associated in some other drugs with the ability to cause torsade de pointes-type arrhythmia, a potentially fatal polymorphic ventricular tachycardia, and sudden death. In many cases this would lead to the conclusion that other drugs should be tried first. Whether ziprasidone will cause torsade de pointes or increase the rate of sudden death is not yet known [ see Warnings and Precautions (5.2) ] uuid:4d535aa9-0ed2-4201-a26f-289b120620a6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:100241 biolink:treats UMLS:C0856695 PMID:41385096 "[{""id"":""uuid:1c5736ac-ed97-41e4-8bd6-51bfac8c9421"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d4f09aef-052f-4978-b8e9-b8807209536c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ciprofloxacin tablets are a fluoroquinolone antibacterial indicated in adults (greater than or equal to 18 years of age) with the following infections caused by designated, susceptible bacteria and in pediatric patients where indicated: Skin and Skin Structure Infections ( 1.1 ) Bone and Joint Infections ( 1.2 ) Complicated Intra-Abdominal Infections ( 1.3 ) Infectious Diarrhea ( 1.4 ) Typhoid Fever (Enteric Fever) ( 1.5 ) Uncomplicated Cervical and Urethral Gonorrhea ( 1.6 ) Inhalational Anthrax post-exposure in adult and pediatric patients ( 1.7 ) Plague in adult and pediatric patients ( 1.8 ) Chronic Bacterial Prostatitis ( 1.9 ) Lower Respiratory Tract Infections ( 1.10 ) ○ Acute Exacerbation of Chronic Bronchitis Urinary Tract Infections ( 1.11 ) ○ Urinary Tract Infections (UTI) ○ Acute Uncomplicated Cystitis ○ Complicated UTI and Pyelonephritis in Pediatric Patients Acute Sinusitis ( 1.12 ) Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of ciprofloxacin tablets and other antibacterial drugs, ciprofloxacin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.13 ) uuid:369e941e-740e-4b30-9582-1e884046c0d3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:100241 biolink:treats UMLS:C4524049 PMID:41385096 "[{""id"":""uuid:45eb2066-848b-4bb5-b0b4-f5a2df83d7de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5f266958-a7cc-46ce-b164-c3190da10bda"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ciprofloxacin tablets are a fluoroquinolone antibacterial indicated in adults (greater than or equal to 18 years of age) with the following infections caused by designated, susceptible bacteria and in pediatric patients where indicated: Skin and Skin Structure Infections ( 1.1 ) Bone and Joint Infections ( 1.2 ) Complicated Intra-Abdominal Infections ( 1.3 ) Infectious Diarrhea ( 1.4 ) Typhoid Fever (Enteric Fever) ( 1.5 ) Uncomplicated Cervical and Urethral Gonorrhea ( 1.6 ) Inhalational Anthrax post-exposure in adult and pediatric patients ( 1.7 ) Plague in adult and pediatric patients ( 1.8 ) Chronic Bacterial Prostatitis ( 1.9 ) Lower Respiratory Tract Infections ( 1.10 ) ○ Acute Exacerbation of Chronic Bronchitis Urinary Tract Infections ( 1.11 ) ○ Urinary Tract Infections (UTI) ○ Acute Uncomplicated Cystitis ○ Complicated UTI and Pyelonephritis in Pediatric Patients Acute Sinusitis ( 1.12 ) Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of ciprofloxacin tablets and other antibacterial drugs, ciprofloxacin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.13 ) uuid:afce5efb-d472-4ec2-b18f-129334080df9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28177 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:2111f7fe-2b33-4f3f-9bcc-3f7d582e3a24"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:57d6bf8b-dbbb-4beb-9ed7-fe64b1d7ee71"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Theophylline in 5% Dextrose Injection USP is indicated as an adjunct to inhaled beta-2 selective agonists and systemically administered corticosteroids for the treatment of acute exacerbations of the symptoms and reversible airflow obstruction associated with asthma and other chronic lung diseases, e.g., emphysema and chronic bronchitis. uuid:9a8cf5ff-0d0d-45d2-b9fd-604b8f61e8cf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7444 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:195ac450-05e4-4e1c-952a-26cdec6e1689"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a1a88318-4043-40fc-9ae6-ad2840043245"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Angina Pectoris Nadolol tablets, USP are indicated for the long-term management of patients with angina pectoris. Hypertension Nadolol is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Nadolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Nadolol may be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. uuid:ae0eb44f-078a-4e66-8798-9b44236ed8b3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7444 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:e122a5a0-bc75-4584-a020-3f654fac9773"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:46a73fca-ce74-4ecd-a11a-c95892e959da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Angina Pectoris Nadolol tablets, USP are indicated for the long-term management of patients with angina pectoris. Hypertension Nadolol is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Nadolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Nadolol may be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. uuid:467d234c-5f20-4126-908c-6dabd2a46d0f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7444 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:aa37efc1-4578-4ddd-8d51-b27ad5c31b51"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7fb44f34-e9de-4830-a7b2-feca33a16ddb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Angina Pectoris Nadolol tablets, USP are indicated for the long-term management of patients with angina pectoris. Hypertension Nadolol is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Nadolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Nadolol may be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. uuid:d5849221-738f-49e0-a221-97856e4bc59d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7444 biolink:treats MONDO:0005016 PMID:41385096 "[{""id"":""uuid:d433d3e6-e8b3-49fe-aac9-2822b4091951"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:44536ffc-0d5e-4367-a48f-b682c2557eb0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Angina Pectoris Nadolol tablets, USP are indicated for the long-term management of patients with angina pectoris. Hypertension Nadolol is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Nadolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Nadolol may be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. uuid:155b7d50-f620-4a05-8b18-bd84b7833455 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:91583 biolink:treats MONDO:0044345 PMID:41385096 "[{""id"":""uuid:9917d638-6426-4164-a824-1b3a532a46bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4fe398c1-6055-402a-a70a-933e4a1fedae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BILTRICIDE is indicated for the treatment of infections due to: all species of schistosoma (for example, Schistosoma mekongi, Schistosoma japonicum, Schistosoma mansoni and Schistosoma hematobium ), and infections due to the liver flukes, Clonorchis sinensis/Opisthorchis viverrini (approval of this indication was based on studies in which the two species were not differentiated). uuid:2522e871-7069-4dcb-a2b9-6adb637f67dd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:91583 biolink:treats MONDO:0006001 PMID:41385096 "[{""id"":""uuid:7a829eaa-3c0c-4925-8711-66d245b11222"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:51edd59a-47f0-45bd-b123-83a719039aed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BILTRICIDE is indicated for the treatment of infections due to: all species of schistosoma (for example, Schistosoma mekongi, Schistosoma japonicum, Schistosoma mansoni and Schistosoma hematobium ), and infections due to the liver flukes, Clonorchis sinensis/Opisthorchis viverrini (approval of this indication was based on studies in which the two species were not differentiated). uuid:9dca23c3-41b2-47d7-af79-b79870b74963 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:91583 biolink:treats MONDO:0005705 PMID:41385096 "[{""id"":""uuid:eef4081a-4a4c-425b-b503-7c77e0c9ee58"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:267b6ea8-7cce-4b38-9d91-a538c7a2a7c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BILTRICIDE is indicated for the treatment of infections due to: all species of schistosoma (for example, Schistosoma mekongi, Schistosoma japonicum, Schistosoma mansoni and Schistosoma hematobium ), and infections due to the liver flukes, Clonorchis sinensis/Opisthorchis viverrini (approval of this indication was based on studies in which the two species were not differentiated). uuid:dc6654ec-70a1-4a32-8a93-0c4abdefbd1f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:91583 biolink:treats MONDO:0005884 PMID:41385096 "[{""id"":""uuid:a7f324fa-6c34-4311-b278-f27df112d888"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e7c3f39f-3e98-4bbc-8af7-ef5bb8b3b2b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BILTRICIDE is indicated for the treatment of infections due to: all species of schistosoma (for example, Schistosoma mekongi, Schistosoma japonicum, Schistosoma mansoni and Schistosoma hematobium ), and infections due to the liver flukes, Clonorchis sinensis/Opisthorchis viverrini (approval of this indication was based on studies in which the two species were not differentiated). uuid:e8657e1f-0177-446c-aba2-63bcf60111ad biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:718834 biolink:treats MONDO:0005920 PMID:41385096 "[{""id"":""uuid:452ad15e-59cc-4bed-b960-aa31601996ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a4371835-82b5-41e7-994f-0a0d29c49f2b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Coartem (artemether/lumefantrine) Tablets are indicated for treatment of acute, uncomplicated malaria infections due to Plasmodium falciparum in patients of 5 kg bodyweight and above . Coartem Tablets have been shown to be effective in geographical regions where resistance to chloroquine has been reported [ see Clinical Studies (14.1) ]. Limitations of Use : Coartem Tablets are not approved for patients with severe or complicated P. falciparum malaria. Coartem Tablets are not approved for the prevention of malaria. uuid:3a03329a-d764-485f-bffb-3fe8373cee34 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8405 biolink:treats MONDO:0005921 PMID:41385096 "[{""id"":""uuid:bf21c0ff-6cbb-4368-9f69-236cc18a68e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4319c6b5-d3e6-4375-9b0b-1ef254a43ea2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:92158c71-b584-4c0c-a081-40e964a6fc11"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Primaquine phosphate is indicated for the radical cure (prevention of relapse) of vivax malaria.|[PMDA] A drug with a new active ingredient indicated for the treatment of malaria caused by Plasmodium vivax and Plasmodium oval . uuid:1f24cc97-2c5a-485e-a4d5-972f39da964b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16664 biolink:treats UMLS:C0338437 PMID:41385096 "[{""id"":""uuid:b760d5df-9259-4207-b760-1659c5a43e0a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:99425a56-13e6-4256-aacd-1c20219cb088"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ALBENZA is an anthelmintic drug indicated for: Treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, Taenia solium . ( 1.1 ) Treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, Echinococcus granulosus . ( 1.2 ) uuid:0052d5ac-8ecd-443c-8879-33136623705a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16664 biolink:treats MONDO:0018408 PMID:41385096 "[{""id"":""uuid:4aca5e0f-c94a-43d3-9817-2191b8c44be0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:03352810-5959-494c-af29-e813208b80aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ALBENZA is an anthelmintic drug indicated for: Treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, Taenia solium . ( 1.1 ) Treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, Echinococcus granulosus . ( 1.2 ) uuid:f5f2ab58-06c9-4b5e-bbca-ada211990054 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2955 biolink:treats MONDO:0020590 PMID:41385096 "[{""id"":""uuid:a4c2c2f8-c363-4890-887e-e798ae1f0f05"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ca8f7709-d250-4acd-a420-d6e83aa088d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azithromycin is a macrolide antibacterial indicated for mild to moderate infections caused by designated, susceptible bacteria: Mycobacterial Infections ( 1.2 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin tablets and other antibacterial drugs, azithromycin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. uuid:7cbd5e68-e4ae-45d2-b69e-e88a3ee220b2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17303 biolink:treats MONDO:0001673 PMID:41385096 "[{""id"":""uuid:5afe62fa-39b8-40eb-87b5-05dda4a5f71e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9e4b31b7-0550-4ffb-b8aa-15c3c9adcef0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Opium tincture is useful for the treatment of diarrhea. uuid:0b8576a2-3a43-4cc7-b68a-9ff13cbc15c1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9637 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:5a43f1d2-e73b-4cb1-b71a-eb18e5eb9cc2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1c335611-6ba4-4737-9342-d884a324014a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Torsemide is a loop diuretic indicated for: • the treatment of edema associated with heart failure, renal disease or hepatic disease. ( 1.1 ) • the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.2 ) uuid:754a278a-3350-4ebe-ae22-8e10fe9438ee biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9637 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:f8494ef7-7f9d-41ff-b078-e6c8001ff7c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f3c22748-61bc-4da8-9310-ed513188d74b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Torsemide is a loop diuretic indicated for: • the treatment of edema associated with heart failure, renal disease or hepatic disease. ( 1.1 ) • the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.2 ) uuid:ee4732a3-be2a-4b77-8d4e-b2a5d62b2d55 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9637 biolink:treats MONDO:0006652 PMID:41385096 "[{""id"":""uuid:50748d97-ba72-4746-82dc-db9b60e0679d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:68f60a2b-8a8c-4de8-bd59-ce9730bb820f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Torsemide is a loop diuretic indicated for: • the treatment of edema associated with heart failure, renal disease or hepatic disease. ( 1.1 ) • the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.2 ) uuid:2214d15f-cb6f-4fc4-a358-716ba8ab409d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32270 biolink:treats EFO:0006865 PMID:41385096 "[{""id"":""uuid:b2c9a8fa-b5b8-4818-af79-00d6b6ff5a8c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e92dcbd1-d4fc-4e9a-b11a-f14aaad43590"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Trospium chloride tablets USP are a muscarinic antagonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency. uuid:7706fc5a-2207-4adb-b3b6-f9abb8dc0db0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32270 biolink:treats HP:0100515 PMID:41385096 "[{""id"":""uuid:95282627-be6b-4717-914c-7a1ee18e3252"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:11d147a2-d244-49a1-97cb-afe14e0feb73"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Trospium chloride tablets USP are a muscarinic antagonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency. uuid:69814737-633b-4833-bd64-9ae79c55ee00 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:6473866 biolink:treats UMLS:C0400968 PMID:41385096 "[{""id"":""uuid:0686a339-215d-4187-9baf-5ad7b4158bb4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0e177b71-afa4-487d-9dbb-4eefcbd347b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tacrolimus capsules, USP are a calcineurin-inhibitor immunosuppressant indicated for: • Prophylaxis of organ rejection in patients receiving allogeneic liver, kidney or heart transplants ( 1.1 , 1.2 , 1.3 ) • Use concomitantly with adrenal corticosteroids; in kidney and heart transplant, use in conjunction with azathioprine or mycophenolate mofetil (MMF) ( 1.1 , 1.2 , 1.3 ) • Limitations of Use ( 1.4 ): • Do not use simultaneously with cyclosporine • Intravenous use reserved for patients who cannot tolerate capsules orally • Use with sirolimus is not recommended in liver and heart transplant; use with sirolimus in kidney transplant has not been established uuid:ee6cff27-6e27-47f9-b0d5-3f74adf90633 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:6473866 biolink:treats UMLS:C0238217 PMID:41385096 "[{""id"":""uuid:26cf5a54-0db2-489c-8060-e206abeac201"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a4c4b55e-2e4a-4428-8c19-ba3002ef6d50"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tacrolimus capsules, USP are a calcineurin-inhibitor immunosuppressant indicated for: • Prophylaxis of organ rejection in patients receiving allogeneic liver, kidney or heart transplants ( 1.1 , 1.2 , 1.3 ) • Use concomitantly with adrenal corticosteroids; in kidney and heart transplant, use in conjunction with azathioprine or mycophenolate mofetil (MMF) ( 1.1 , 1.2 , 1.3 ) • Limitations of Use ( 1.4 ): • Do not use simultaneously with cyclosporine • Intravenous use reserved for patients who cannot tolerate capsules orally • Use with sirolimus is not recommended in liver and heart transplant; use with sirolimus in kidney transplant has not been established uuid:b380e192-1a95-491b-8990-eee3629bce05 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:6473866 biolink:treats UMLS:C0340530 PMID:41385096 "[{""id"":""uuid:9920a009-836c-43d4-91e6-38e048498c78"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8d1b28c7-8716-47b2-a703-3bc2db88bfef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tacrolimus capsules, USP are a calcineurin-inhibitor immunosuppressant indicated for: • Prophylaxis of organ rejection in patients receiving allogeneic liver, kidney or heart transplants ( 1.1 , 1.2 , 1.3 ) • Use concomitantly with adrenal corticosteroids; in kidney and heart transplant, use in conjunction with azathioprine or mycophenolate mofetil (MMF) ( 1.1 , 1.2 , 1.3 ) • Limitations of Use ( 1.4 ): • Do not use simultaneously with cyclosporine • Intravenous use reserved for patients who cannot tolerate capsules orally • Use with sirolimus is not recommended in liver and heart transplant; use with sirolimus in kidney transplant has not been established uuid:60493943-e685-445d-8e69-c3aa459f174c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32184 biolink:treats HP:0100678 PMID:41385096 "[{""id"":""uuid:f7676537-3c10-4d6c-8826-fa5878799b5b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f148cc59-d3c6-437a-b30c-f4de29e08dbf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tazarotene cream, 0.1% is indicated as an adjunctive agent for use in the mitigation (palliation) of facial fine wrinkling, facial mottled hyper-and hypopigmentation, and benign facial lentigines in patients who use comprehensive skin care and sunlight avoidance programs. uuid:dd5d4235-c39a-46f2-9b10-d4e5d5b043a6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32184 biolink:treats MONDO:0019289 PMID:41385096 "[{""id"":""uuid:a066b5c4-5738-43d5-a140-62b3fc7270fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5e2f7be7-be38-4c64-8d96-23fc61033ce0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tazarotene cream, 0.1% is indicated as an adjunctive agent for use in the mitigation (palliation) of facial fine wrinkling, facial mottled hyper-and hypopigmentation, and benign facial lentigines in patients who use comprehensive skin care and sunlight avoidance programs. uuid:e2aa9d8e-fa4a-47d9-a8f7-1f1b84767521 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32184 biolink:treats MONDO:0019290 PMID:41385096 "[{""id"":""uuid:e7455bac-c4d6-4f91-b329-7e1cc5107d4a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:70544ab8-02cd-4254-a832-e07e84c4f57b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tazarotene cream, 0.1% is indicated as an adjunctive agent for use in the mitigation (palliation) of facial fine wrinkling, facial mottled hyper-and hypopigmentation, and benign facial lentigines in patients who use comprehensive skin care and sunlight avoidance programs. uuid:fc054f33-0566-4f84-9de7-a08f9a84d21a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32184 biolink:treats MONDO:0021582 PMID:41385096 "[{""id"":""uuid:ef3e17ad-d237-4950-a062-dd40d3686d5c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:340501ac-6b12-4999-a494-c4618f27203e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tazarotene cream, 0.1% is indicated as an adjunctive agent for use in the mitigation (palliation) of facial fine wrinkling, facial mottled hyper-and hypopigmentation, and benign facial lentigines in patients who use comprehensive skin care and sunlight avoidance programs. uuid:284e3e76-a641-4708-8002-baca2e32d93b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9566 biolink:treats MONDO:0005090 PMID:41385096 "[{""id"":""uuid:b5772dfd-e719-4876-8cc9-1e0b58d1943e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9099319d-befb-4f26-b6d9-99ef8acc8448"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Thioridazine hydrochloride tablets are indicated for the management of schizophrenic patients who fail to respond adequately to treatment with other antipsychotic drugs. Due to the risk of significant, potentially life threatening, proarrhythmic effects with thioridazine treatment, thioridazine hydrochloride tablets should be used only in patients who have failed to respond adequately to treatment with appropriate courses of other antipsychotic drugs, either because of insufficient effectiveness or the inability to achieve an effective dose due to intolerable adverse effects from those drugs. Consequently, before initiating treatment with thioridazine hydrochloride tablets, it is strongly recommended that a patient be given at least two trials, each with a different antipsychotic drug product, at an adequate dose, and for an adequate duration (see WARNINGS and CONTRAINDICATIONS ). However, the prescriber should be aware that thioridazine hydrochloride tablets have not been systematically evaluated in controlled trials in treatment refractory schizophrenic patients and its efficacy in such patients is unknown. uuid:2b894ca2-37f0-4321-b64b-2063b0fbef11 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9566 biolink:treats MONDO:0005414 PMID:41385096 "[{""id"":""uuid:9112c6c1-2290-4a35-8d7a-4b01c7e424b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:780f0625-e564-41cb-b5b9-35fbca831cce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Thioridazine hydrochloride tablets are indicated for the management of schizophrenic patients who fail to respond adequately to treatment with other antipsychotic drugs. Due to the risk of significant, potentially life threatening, proarrhythmic effects with thioridazine treatment, thioridazine hydrochloride tablets should be used only in patients who have failed to respond adequately to treatment with appropriate courses of other antipsychotic drugs, either because of insufficient effectiveness or the inability to achieve an effective dose due to intolerable adverse effects from those drugs. Consequently, before initiating treatment with thioridazine hydrochloride tablets, it is strongly recommended that a patient be given at least two trials, each with a different antipsychotic drug product, at an adequate dose, and for an adequate duration (see WARNINGS and CONTRAINDICATIONS ). However, the prescriber should be aware that thioridazine hydrochloride tablets have not been systematically evaluated in controlled trials in treatment refractory schizophrenic patients and its efficacy in such patients is unknown. uuid:5fbe5d5d-5d78-4144-842c-670351dd12ae biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16199 biolink:treats UMLS:C0406446 PMID:41385096 "[{""id"":""uuid:c857c988-bd1e-4a85-9ca5-6c72ab1c170f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:35a949b5-c30f-4c5a-a60c-60e0e6c7942d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For debridement and promotion of normal healing of hyperkeratotic surface lesions, particularly where healing is retarded by local infection, necrotic tissue, fibrinous or prurient debris or eschar. Urea is useful for the treatment of hyperkeratotic conditions such as dry, rough skin, dermatitis, psoriasis, xerosis, ichthyosis, eczema, keratosis, keratoderma, corns and calluses, as well as damaged, ingrown and devitalized nails. uuid:b68591de-cdc0-4a9e-be2f-ee8e6e8485b3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16199 biolink:treats MONDO:0002884 PMID:41385096 "[{""id"":""uuid:a93dcd74-9cee-4a5d-8ecd-9365e5b7e3a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:57137592-1c28-48c8-befa-6a4caaaaf63e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For debridement and promotion of normal healing of hyperkeratotic surface lesions, particularly where healing is retarded by local infection, necrotic tissue, fibrinous or prurient debris or eschar. Urea is useful for the treatment of hyperkeratotic conditions such as dry, rough skin, dermatitis, psoriasis, xerosis, ichthyosis, eczema, keratosis, keratoderma, corns and calluses, as well as damaged, ingrown and devitalized nails. uuid:29724957-016f-4b2d-bb0c-7abe40cd849b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5108 biolink:treats MONDO:0002406 PMID:41385096 "[{""id"":""uuid:5df8cb23-72af-4dfe-865c-84d6a128f2d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:89194422-0357-4cd5-a1dd-bdcbf35c21fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the management of hypertrophic tissues, keloid tissues, dermatitis and dermatoses. This statement has not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent disease. uuid:aad9f7e8-fa13-462c-934a-3553ee8b27ba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7983 biolink:treats MONDO:0013600 PMID:41385096 "[{""id"":""uuid:4c266889-305b-4af3-a553-4c19168681e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:65aa70f3-e3ce-4373-89c0-b768f126737b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Sedatives. Hypnotics, for the short-term treatment of insomnia, since they appear to lose their effectiveness for sleep induction and sleep maintenance after 2 weeks. (See "" Clinical Pharmacology "" section.) Preanesthetics. Anticonvulsant, in anesthetic doses, in the emergency control of certain acute convulsive episodes, e.g., those associated with status epilepticus, cholera, eclampsia, meningitis, tetanus, and toxic reactions to strychnine or local anesthetics." uuid:b6e0a8db-4bcf-4cf2-9662-4810088369bf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7983 biolink:treats MONDO:0002125 PMID:41385096 "[{""id"":""uuid:9d234e5f-e48b-4b25-b9ce-150d54b666d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3ee20d73-db06-4b3a-8342-b3285162082a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Sedatives. Hypnotics, for the short-term treatment of insomnia, since they appear to lose their effectiveness for sleep induction and sleep maintenance after 2 weeks. (See "" Clinical Pharmacology "" section.) Preanesthetics. Anticonvulsant, in anesthetic doses, in the emergency control of certain acute convulsive episodes, e.g., those associated with status epilepticus, cholera, eclampsia, meningitis, tetanus, and toxic reactions to strychnine or local anesthetics." uuid:1fdfd5ec-8c5e-4e9d-86dd-3b6bb7e684d1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7983 biolink:treats MONDO:0015766 PMID:41385096 "[{""id"":""uuid:2fe13952-03c6-45a3-ac46-e2f5fe829273"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:565d0887-cd27-48a6-9e02-93fde9715cdf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Sedatives. Hypnotics, for the short-term treatment of insomnia, since they appear to lose their effectiveness for sleep induction and sleep maintenance after 2 weeks. (See "" Clinical Pharmacology "" section.) Preanesthetics. Anticonvulsant, in anesthetic doses, in the emergency control of certain acute convulsive episodes, e.g., those associated with status epilepticus, cholera, eclampsia, meningitis, tetanus, and toxic reactions to strychnine or local anesthetics." uuid:c3a50daa-50f1-4f8c-8155-0efb83aa65bd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7983 biolink:treats MONDO:0001754 PMID:41385096 "[{""id"":""uuid:61ee6457-d4cd-4c4b-a98b-7674d4f17834"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3a567091-662b-448b-b193-1deb0d667708"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Sedatives. Hypnotics, for the short-term treatment of insomnia, since they appear to lose their effectiveness for sleep induction and sleep maintenance after 2 weeks. (See "" Clinical Pharmacology "" section.) Preanesthetics. Anticonvulsant, in anesthetic doses, in the emergency control of certain acute convulsive episodes, e.g., those associated with status epilepticus, cholera, eclampsia, meningitis, tetanus, and toxic reactions to strychnine or local anesthetics." uuid:743fc65b-2598-4b75-9b91-b243f5b951a7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7983 biolink:treats MONDO:0021108 PMID:41385096 "[{""id"":""uuid:b0687dd0-6137-4006-85ec-6b766ab338a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d8edd8c4-36db-4815-bcce-8fcab671c0fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Sedatives. Hypnotics, for the short-term treatment of insomnia, since they appear to lose their effectiveness for sleep induction and sleep maintenance after 2 weeks. (See "" Clinical Pharmacology "" section.) Preanesthetics. Anticonvulsant, in anesthetic doses, in the emergency control of certain acute convulsive episodes, e.g., those associated with status epilepticus, cholera, eclampsia, meningitis, tetanus, and toxic reactions to strychnine or local anesthetics." uuid:8cba05ad-32d7-4149-9273-9c09a000dec0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7983 biolink:treats MONDO:0005526 PMID:41385096 "[{""id"":""uuid:0b7bd91f-e600-4ef6-b2fb-b2e348688084"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:151f46f2-2cf4-41dd-8306-27a3c297de40"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Sedatives. Hypnotics, for the short-term treatment of insomnia, since they appear to lose their effectiveness for sleep induction and sleep maintenance after 2 weeks. (See "" Clinical Pharmacology "" section.) Preanesthetics. Anticonvulsant, in anesthetic doses, in the emergency control of certain acute convulsive episodes, e.g., those associated with status epilepticus, cholera, eclampsia, meningitis, tetanus, and toxic reactions to strychnine or local anesthetics." uuid:33b4cbe6-aab2-4bea-8f1e-7972536a8f6b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:370642 biolink:treats UMLS:C0278140 PMID:41385096 "[{""id"":""uuid:ad5cfd74-1df2-4af0-8517-c9b07606c21f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:52ebc86c-0988-4520-b7c1-f84815edf9a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydrocodone Bitartrate and Acetaminophen Tablets are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, and misuse, with opioids, even at recommended doses [see WARNINGS ], reserve Hydrocodone Bitartrate and Acetaminophen Tablets for use in patients for whom alternative treatment options (e.g., non-opioid analgesics): • have not been tolerated, or are not expected to be tolerated • have not provided adequate analgesia, or are not expected to provide adequate analgesia uuid:ffa9e907-b4b0-48e8-ae20-dd6c09473c49 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6904 biolink:treats MONDO:0006652 PMID:41385096 "[{""id"":""uuid:9690e9bf-6167-4ef3-bb56-08293e370547"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:90fd7bbe-5e51-4d04-8c37-d41069391e0e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Hypertension Metoprolol succinate extended-release tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (eg, on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Metoprolol succinate extended-release tablets may be administered with other antihypertensive agents. 1.2 Angina Pectoris Metoprolol succinate extended-release tablets are indicated in the long-term treatment of angina pectoris, to reduce angina attacks and to improve exercise tolerance. 1.3 Heart Failure Metoprolol succinate extended-release tablets are indicated for the treatment of stable, symptomatic (NYHA Class II or III) heart failure of ischemic, hypertensive, or cardiomyopathic origin. It was studied in patients already receiving ACE inhibitors, diuretics, and, in the majority of cases, digitalis. In this population, metoprolol succinate extended-release tablets decreased the rate of mortality plus hospitalization, largely through a reduction in cardiovascular mortality and hospitalizations for heart failure. uuid:cd1c628a-b8bb-46be-a72d-948b52421840 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6874 biolink:treats UMLS:C0426265 PMID:41385096 "[{""id"":""uuid:68d6330b-0586-43cd-bdae-22ef777dec3b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2652341c-6fec-4251-a172-d7b85b39b57f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Following delivery of placenta, for routine management of uterine atony, hemorrhage and subinvolution of the uterus. For control of uterine hemorrhage in the second stage of labor following delivery of the anterior shoulder. uuid:e983b791-f253-4c82-8214-6cbfe425ba24 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6874 biolink:treats UMLS:C0042134 PMID:41385096 "[{""id"":""uuid:7e7c1604-6cbb-4657-9e60-d2bcb61783c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:25c601fe-d3a6-4771-9036-72309cd478db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Following delivery of placenta, for routine management of uterine atony, hemorrhage and subinvolution of the uterus. For control of uterine hemorrhage in the second stage of labor following delivery of the anterior shoulder. uuid:548abe42-b7c2-415b-a355-c5dde3f5459f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18332 biolink:treats MONDO:0004425 PMID:41385096 "[{""id"":""uuid:7f531b6e-4ff3-4320-b805-b636bd095bd6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3ce1c622-8fcd-4e31-906d-26fd7010ea5a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypothyroidism SYNTHROID is indicated as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin (Thyroid‑Stimulating Hormone, TSH) Suppression SYNTHROID is indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer. Limitations of Use: SYNTHROID is not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients as there are no clinical benefits and overtreatment with SYNTHROID may induce hyperthyroidism [see Warnings and Precautions (5.4) ] . SYNTHROID is not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis. uuid:1e26cf56-1be0-47ea-9d5c-afa7b662cc80 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18332 biolink:treats MONDO:0006982 PMID:41385096 "[{""id"":""uuid:91a139c5-5d13-44c9-b886-f1692dea44a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:254a654e-ce93-4bf9-afe8-a6039f8ae6c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypothyroidism SYNTHROID is indicated as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin (Thyroid‑Stimulating Hormone, TSH) Suppression SYNTHROID is indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer. Limitations of Use: SYNTHROID is not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients as there are no clinical benefits and overtreatment with SYNTHROID may induce hyperthyroidism [see Warnings and Precautions (5.4) ] . SYNTHROID is not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis. uuid:ec599541-354f-4ab0-ae90-68d1e33c981f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:37941 biolink:treats MONDO:0004781 PMID:41385096 "[{""id"":""uuid:50e74871-0657-4d5e-81ef-6fa251add4f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:534119d4-79ab-4089-a944-bfe30c264160"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:45ac28b6-5063-415b-8092-5cc597db382b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Acute Coronary Syndrome (ACS) • Clopidogrel is indicated to reduce the rate of myocardial infarction (MI) and stroke in patients with non-ST-segment elevation ACS [unstable angina (UA)/non-ST-elevation myocardial infarction (NSTEMI)], including patients who are to be managed medically and those who are to be managed with coronary revascularization. Clopidogrel should be administered in conjunction with aspirin. • Clopidogrel is indicated to reduce the rate of myocardial infarction and stroke in patients with acute ST-elevation myocardial infarction (STEMI) who are to be managed medically. Clopidogrel should be administered in conjunction with aspirin. 1.2 Recent MI, Recent Stroke, or Established Peripheral Arterial Disease In patients with established peripheral arterial disease or with a history of recent myocardial infarction (MI) or recent stroke clopidogrel is indicated to reduce the rate of MI and stroke.|[PMDA] Drugs with a new indication and dosage for the treatment of acute coronary syndrome (unstable angina and non-ST-elevation myocardial infarction) in patients in whom percutaneous coronary intervention (PCI) is considered. [Priority review] uuid:33258d92-fdd1-4409-8baa-a0e2b8bd782c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:39585 biolink:treats MONDO:0005180 PMID:41385096 "[{""id"":""uuid:1f6e31e0-8d82-4163-b67d-e768e136cee7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cdeb756b-e77f-4753-b8bb-2addbdcf9c50"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Carbidopa tablets are indicated for use with carbidopa-levodopa or with levodopa in the treatment of the symptoms of idiopathic Parkinson's disease (paralysis agitans), postencephalitic parkinsonism, and symptomatic parkinsonism which may follow injury to the nervous system by carbon monoxide intoxication and/or manganese intoxication. Carbidopa is for use with carbidopa-levodopa in patients for whom the dosage of carbidopa-levodopa provides less than adequate daily dosage (usually 70 mg daily) of carbidopa. Carbidopa is for use with levodopa in the occasional patient whose dosage requirement of carbidopa and levodopa necessitates separate titration of each medication. Carbidopa is used with carbidopa-levodopa or with levodopa to permit the administration of lower doses of levodopa with reduced nausea and vomiting, more rapid dosage titration, and with a somewhat smoother response. However, patients with markedly irregular (""on-off"") responses to levodopa have not been shown to benefit from the addition of carbidopa. Since carbidopa prevents the reversal of levodopa effects caused by pyridoxine, supplemental pyridoxine (vitamin B 6 ), can be given to patients when they are receiving carbidopa and levodopa concomitantly or as carbidopa-levodopa. Although the administration of carbidopa permits control of parkinsonism and Parkinson's disease with much lower doses of levodopa, there is no conclusive evidence at present that this is beneficial other than in reducing nausea and vomiting, permitting more rapid titration, and providing a somewhat smoother response to levodopa. Certain patients who responded poorly to levodopa alone have improved when carbidopa and levodopa were given concurrently. This was most likely due to decreased peripheral decarboxylation of levodopa rather than to a primary effect of carbidopa on the peripheral nervous system. Carbidopa has not been shown to enhance the intrinsic efficacy of levodopa. In deciding whether to give carbidopa with carbidopa-levodopa or with levodopa to patients who have nausea and/or vomiting, the physician should be aware that, while many patients may be expected to improve, some may not. Since one cannot predict which patients are likely to improve, this can only be determined by a trial of therapy. It should be further noted that in controlled trials comparing carbidopa and levodopa with levodopa alone, about half the patients with nausea and/or vomiting on levodopa alone improved spontaneously despite being retained on the same dose of levodopa during the controlled portion of the trial." uuid:c8810e05-4ee2-4db8-ab71-8bf6e770d339 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:39585 biolink:treats MONDO:0001945 PMID:41385096 "[{""id"":""uuid:459c0c4a-abba-49e5-807b-b899b6391cf2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:13a1e12d-e5ab-4324-ba5f-8bac9712ef13"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Carbidopa tablets are indicated for use with carbidopa-levodopa or with levodopa in the treatment of the symptoms of idiopathic Parkinson's disease (paralysis agitans), postencephalitic parkinsonism, and symptomatic parkinsonism which may follow injury to the nervous system by carbon monoxide intoxication and/or manganese intoxication. Carbidopa is for use with carbidopa-levodopa in patients for whom the dosage of carbidopa-levodopa provides less than adequate daily dosage (usually 70 mg daily) of carbidopa. Carbidopa is for use with levodopa in the occasional patient whose dosage requirement of carbidopa and levodopa necessitates separate titration of each medication. Carbidopa is used with carbidopa-levodopa or with levodopa to permit the administration of lower doses of levodopa with reduced nausea and vomiting, more rapid dosage titration, and with a somewhat smoother response. However, patients with markedly irregular (""on-off"") responses to levodopa have not been shown to benefit from the addition of carbidopa. Since carbidopa prevents the reversal of levodopa effects caused by pyridoxine, supplemental pyridoxine (vitamin B 6 ), can be given to patients when they are receiving carbidopa and levodopa concomitantly or as carbidopa-levodopa. Although the administration of carbidopa permits control of parkinsonism and Parkinson's disease with much lower doses of levodopa, there is no conclusive evidence at present that this is beneficial other than in reducing nausea and vomiting, permitting more rapid titration, and providing a somewhat smoother response to levodopa. Certain patients who responded poorly to levodopa alone have improved when carbidopa and levodopa were given concurrently. This was most likely due to decreased peripheral decarboxylation of levodopa rather than to a primary effect of carbidopa on the peripheral nervous system. Carbidopa has not been shown to enhance the intrinsic efficacy of levodopa. In deciding whether to give carbidopa with carbidopa-levodopa or with levodopa to patients who have nausea and/or vomiting, the physician should be aware that, while many patients may be expected to improve, some may not. Since one cannot predict which patients are likely to improve, this can only be determined by a trial of therapy. It should be further noted that in controlled trials comparing carbidopa and levodopa with levodopa alone, about half the patients with nausea and/or vomiting on levodopa alone improved spontaneously despite being retained on the same dose of levodopa during the controlled portion of the trial." uuid:55e7a765-3a3e-4d93-9236-e921f596c304 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:39585 biolink:treats MONDO:0021095 PMID:41385096 "[{""id"":""uuid:ea9da557-34c8-4273-befe-bcf370dd1dad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:92aedc9d-f2f7-4560-81f0-86bdbad0dfb1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Carbidopa tablets are indicated for use with carbidopa-levodopa or with levodopa in the treatment of the symptoms of idiopathic Parkinson's disease (paralysis agitans), postencephalitic parkinsonism, and symptomatic parkinsonism which may follow injury to the nervous system by carbon monoxide intoxication and/or manganese intoxication. Carbidopa is for use with carbidopa-levodopa in patients for whom the dosage of carbidopa-levodopa provides less than adequate daily dosage (usually 70 mg daily) of carbidopa. Carbidopa is for use with levodopa in the occasional patient whose dosage requirement of carbidopa and levodopa necessitates separate titration of each medication. Carbidopa is used with carbidopa-levodopa or with levodopa to permit the administration of lower doses of levodopa with reduced nausea and vomiting, more rapid dosage titration, and with a somewhat smoother response. However, patients with markedly irregular (""on-off"") responses to levodopa have not been shown to benefit from the addition of carbidopa. Since carbidopa prevents the reversal of levodopa effects caused by pyridoxine, supplemental pyridoxine (vitamin B 6 ), can be given to patients when they are receiving carbidopa and levodopa concomitantly or as carbidopa-levodopa. Although the administration of carbidopa permits control of parkinsonism and Parkinson's disease with much lower doses of levodopa, there is no conclusive evidence at present that this is beneficial other than in reducing nausea and vomiting, permitting more rapid titration, and providing a somewhat smoother response to levodopa. Certain patients who responded poorly to levodopa alone have improved when carbidopa and levodopa were given concurrently. This was most likely due to decreased peripheral decarboxylation of levodopa rather than to a primary effect of carbidopa on the peripheral nervous system. Carbidopa has not been shown to enhance the intrinsic efficacy of levodopa. In deciding whether to give carbidopa with carbidopa-levodopa or with levodopa to patients who have nausea and/or vomiting, the physician should be aware that, while many patients may be expected to improve, some may not. Since one cannot predict which patients are likely to improve, this can only be determined by a trial of therapy. It should be further noted that in controlled trials comparing carbidopa and levodopa with levodopa alone, about half the patients with nausea and/or vomiting on levodopa alone improved spontaneously despite being retained on the same dose of levodopa during the controlled portion of the trial." uuid:0085a6a6-fd05-4b04-898b-7d458b9d3fc9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50690 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:539990e9-d6c3-4bfd-b2dc-4fcfebc3a514"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f691fcc0-5971-4789-b3d5-fe2b2de729b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin calcium tablets can be started simultaneously with diet. 1.1 Prevention of Cardiovascular Disease In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin calcium tablets is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, atorvastatin calcium tablets is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In patients with clinically evident coronary heart disease, atorvastatin calcium tablets is indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 1.2 Hyperlipidemia Atorvastatin calcium tablets is indicated: As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson Types IIa and IIb); As an adjunct to diet for the treatment of patients with elevated serum TG levels (Fredrickson Type IV); For the treatment of patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet; To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; As an adjunct to diet to reduce total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: a. LDL-C remains ≥ 190 mg/dL or b. LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient 1.3 Limitations of Use Atorvastatin calcium tablets has not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V). uuid:f890445d-cc30-4cdf-af25-1bd37df2b610 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50690 biolink:treats MONDO:0004995 PMID:41385096 "[{""id"":""uuid:d5047692-fe0d-48aa-b5af-f9f9859e7d0a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9f4786ef-5884-4683-8137-adc35e82caea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin calcium tablets can be started simultaneously with diet. 1.1 Prevention of Cardiovascular Disease In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin calcium tablets is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, atorvastatin calcium tablets is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In patients with clinically evident coronary heart disease, atorvastatin calcium tablets is indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 1.2 Hyperlipidemia Atorvastatin calcium tablets is indicated: As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson Types IIa and IIb); As an adjunct to diet for the treatment of patients with elevated serum TG levels (Fredrickson Type IV); For the treatment of patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet; To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; As an adjunct to diet to reduce total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: a. LDL-C remains ≥ 190 mg/dL or b. LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient 1.3 Limitations of Use Atorvastatin calcium tablets has not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V). uuid:81c026bf-b53c-4578-8d03-1e3a60cfa686 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:9887103 biolink:treats MONDO:0007263 PMID:41385096 "[{""id"":""uuid:b1dd4a38-a819-4a33-b525-19beb30ce215"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:20c809f9-8363-4dcd-9234-5221d6bae273"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ROBINUL Injection is indicated for use as a preoperative antimuscarinic to reduce salivary, tracheobronchial, and pharyngeal secretions; to reduce the volume and free acidity of gastric secretions; and to block cardiac vagal inhibitory reflexes during induction of anesthesia and intubation. When indicated, ROBINUL Injection may be used intraoperatively to counteract surgically or drug-induced or vagal reflexes associated arrhythmias. Glycopyrrolate protects against the peripheral muscarinic effects (e.g., bradycardia and excessive secretions) of cholinergic agents such as neostigmine and pyridostigmine given to reverse the neuromuscular blockade due to non-depolarizing muscle relaxants. uuid:31cb4737-8f14-4727-9eb8-c00a65629bf7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50690 biolink:treats HP:0001681 PMID:41385096 "[{""id"":""uuid:27a7c26f-eb82-49f6-b5df-22005b7aa77e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d337e1a4-2912-47a7-b37e-1d0da4e42db6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin calcium tablets can be started simultaneously with diet. 1.1 Prevention of Cardiovascular Disease in Adults In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In adult patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In adult patients with clinically evident coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 1.2 Hyperlipidemia Atorvastatin calcium tablets are indicated: As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in adult patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson Types IIa and IIb); As an adjunct to diet for the treatment of adult patients with elevated serum TG levels (Fredrickson Type IV); For the treatment of adult patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet; To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH) as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; As an adjunct to diet to reduce total-C, LDL-C, and apo B levels in pediatric patients, 10 years to 17 years of age, with heterozygous familial hypercholesterolemia (HeFH) if after an adequate trial of diet therapy the following findings are present: a. LDL-C remains ≥ 190 mg/dL or b. LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient 1.3 Limitations of Use Atorvastatin calcium tablets have not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V). uuid:f8505b2d-455f-478d-aebe-74e4e519e13f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50690 biolink:treats UMLS:C0860248 PMID:41385096 "[{""id"":""uuid:71afa1bd-81eb-4dd9-ae08-32a2c952cadf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:829ed214-43c9-4e30-9e75-9457ed2befb3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin calcium tablets can be started simultaneously with diet. 1.1 Prevention of Cardiovascular Disease in Adults In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In adult patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In adult patients with clinically evident coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 1.2 Hyperlipidemia Atorvastatin calcium tablets are indicated: As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in adult patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson Types IIa and IIb); As an adjunct to diet for the treatment of adult patients with elevated serum TG levels (Fredrickson Type IV); For the treatment of adult patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet; To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH) as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; As an adjunct to diet to reduce total-C, LDL-C, and apo B levels in pediatric patients, 10 years to 17 years of age, with heterozygous familial hypercholesterolemia (HeFH) if after an adequate trial of diet therapy the following findings are present: a. LDL-C remains ≥ 190 mg/dL or b. LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient 1.3 Limitations of Use Atorvastatin calcium tablets have not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V). uuid:4d985e7a-bc7f-4f4a-870a-efafd3339b98 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50690 biolink:treats UMLS:C0856526 PMID:41385096 "[{""id"":""uuid:e76fd93f-33d2-47af-bdb1-376c97ec6ba9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a1424b7c-d3a0-42bf-bd70-dc3a3942e2db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin calcium tablets can be started simultaneously with diet. 1.1 Prevention of Cardiovascular Disease in Adults In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In adult patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In adult patients with clinically evident coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 1.2 Hyperlipidemia Atorvastatin calcium tablets are indicated: As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in adult patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson Types IIa and IIb); As an adjunct to diet for the treatment of adult patients with elevated serum TG levels (Fredrickson Type IV); For the treatment of adult patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet; To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH) as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; As an adjunct to diet to reduce total-C, LDL-C, and apo B levels in pediatric patients, 10 years to 17 years of age, with heterozygous familial hypercholesterolemia (HeFH) if after an adequate trial of diet therapy the following findings are present: a. LDL-C remains ≥ 190 mg/dL or b. LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient 1.3 Limitations of Use Atorvastatin calcium tablets have not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V). uuid:b1883ccb-112f-47a4-b58a-8370dfb80914 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8412 biolink:treats MONDO:0005754 PMID:41385096 "[{""id"":""uuid:87c2a907-7f56-4d75-a77d-986b983707ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bb225567-7798-46a5-b2f8-7ef49c38bfa5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Primidone tablets, used alone or concomitantly with other anticonvulsants, are indicated in the control of grand mal, psychomotor, and focal epileptic seizures. It may control grand mal seizures refractory to other anticonvulsant therapy. uuid:a2ae35f0-c276-4ceb-9345-20eed521fd8f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8412 biolink:treats NCIT:C117194 PMID:41385096 "[{""id"":""uuid:3cea40c8-43b6-4d31-ac00-99fa6ebb27ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b07a13e8-d6d1-441a-8d35-7e18785fa668"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Primidone tablets, used alone or concomitantly with other anticonvulsants, are indicated in the control of grand mal, psychomotor, and focal epileptic seizures. It may control grand mal seizures refractory to other anticonvulsant therapy. uuid:22b6ade3-c3a4-4f2f-a479-7482bf4968ad biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0015129 PMID:41385096 "[{""id"":""uuid:542e7821-c493-44b1-8266-d5334d049318"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e1ef45f7-2b6f-4f41-85dd-c6beb4ace517"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:44d1a220-8e87-46fa-b176-2bee8574f9b0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0043370 PMID:41385096 "[{""id"":""uuid:ebce3c49-0e6d-4251-89c4-41beb95753b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:35d2e468-62bc-48da-ae4f-5cfc2f7cbc53"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:a983fa80-9c43-4588-9ec7-a4c40b98fa9e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0019801 PMID:41385096 "[{""id"":""uuid:73b90ade-48bd-4326-be03-f90e86c9da1b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0464ecea-4bb7-422f-baf3-089e38e4595d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:c78e4796-b8db-47fa-a6fe-f9b6543ac703 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0000004 PMID:41385096 "[{""id"":""uuid:9572ab32-24ba-483b-a653-689c8bd0015d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:16661efa-2334-4003-90f6-ac9caf94b602"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:7d367885-3c47-411c-9dee-6bc37ddb7b6e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0018479 PMID:41385096 "[{""id"":""uuid:e5be5540-80cd-4b6a-8336-47b53ebb0d04"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5183fade-cb15-425d-bd57-51fff85872f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:c7da3e76-2e37-4942-864b-7b26ad72985e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0006982 PMID:41385096 "[{""id"":""uuid:1da94df7-036f-426a-ac62-0d59cf5b3640"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e3bfeb1d-fc77-49a0-8223-c0edf5e99c3a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:b7e61f28-3c3a-416b-bcec-24c3eb501129 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0043455 PMID:41385096 "[{""id"":""uuid:04bf9e8a-7c5e-4fd7-8008-7f6bbb87b3f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a611049c-180c-4e83-9e53-d6b889824685"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:ce12d902-f989-4042-9b20-f1dc1423205a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0005178 PMID:41385096 "[{""id"":""uuid:37eed14c-d293-4bfe-b1f3-482ab2378e38"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:edd5e1c3-3116-4e7c-b746-e086949e5731"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:0bc67954-bc74-4591-b76a-bca52715b3af biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:59f84a5e-e3e9-4bdb-a5b0-b85c132264ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9ade3f1e-e566-4252-b8a1-39e3192014ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:b8f49598-8c04-433d-9766-0ae7f8173666 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0011429 PMID:41385096 "[{""id"":""uuid:afc3b66f-d75b-43ff-92d4-e952efb62c56"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8147258e-3316-4ee9-93bf-4ade107683d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:82e85258-876b-463f-b63c-38c0b463a8e9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats UMLS:C1290158 PMID:41385096 "[{""id"":""uuid:c157931a-98fd-4704-b071-5a435501f72c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:00d99ab3-c457-4b08-839e-0b118f1dae28"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:b134d4f0-f75e-4933-9ec8-d1b702c0ca14 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0040698 PMID:41385096 "[{""id"":""uuid:7e5c83f2-04f9-4ca7-9d98-56c1429a1e6d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:83818026-7f51-4e4f-86ea-76397b79b693"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:6369f17e-7e91-4b5c-8cab-63aa7f60a6e3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0001875 PMID:41385096 "[{""id"":""uuid:0202914f-34ac-4802-88f9-0a7e0166c883"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0ba0ac0d-3783-4d31-88f4-bd536dc028ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:2711af9f-d04a-46ec-9638-5a098ed896bc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0004855 PMID:41385096 "[{""id"":""uuid:b7864b49-fd2f-4447-8264-513798d58403"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:36a3aacc-e041-4867-9c91-6dad8a7cfc06"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:936cacf4-b2d7-430e-aca6-d89363d62b57 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats UMLS:C0149896 PMID:41385096 "[{""id"":""uuid:1cfe006d-a183-41ac-afa1-1c71ea4c50c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:896a1b88-f593-4f07-85a5-57c884ca6f02"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:68d239cc-7b97-49ca-b276-bca94216b78e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0011849 PMID:41385096 "[{""id"":""uuid:59df3a1a-51ac-414f-915d-a9e9ce2e5926"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d72b31d5-e89a-4538-838a-f7bf6ad86a72"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:964c1604-1df9-4074-95fd-b86782250a64 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0005306 PMID:41385096 "[{""id"":""uuid:2c2ec916-2d72-4f8c-8fbd-9889c9b32ba2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:45df1cae-54ac-44b1-b53f-08c319722ad0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:ac9ef166-7498-48d5-8aeb-973e26defb9c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats UMLS:C5441648 PMID:41385096 "[{""id"":""uuid:f7848227-6c47-4a65-8551-92932ba9b86f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c2cf9319-b5d0-427a-b733-d7618ff41111"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:f3601d18-4dd5-4e53-8350-0941c5d4d52c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0006594 PMID:41385096 "[{""id"":""uuid:a2446ef0-6560-4fcc-b935-220fc58d8c2a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:019e0180-56a4-47a2-b003-f6be22706d33"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:51f781ab-69e1-4886-a987-ae331ae8274b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0006545 PMID:41385096 "[{""id"":""uuid:6682caff-e2af-4f52-87fd-9e369bba8979"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e862fc2d-4eb6-4a8e-b5f6-ccab61c0fd32"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:575d50ae-df49-448e-8229-b9a141274af7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0018229 PMID:41385096 "[{""id"":""uuid:48477936-9aca-47b2-a204-1bac7a63e17d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:85cb1746-dedd-43ce-b902-d5c655b09db6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:06634346-d364-4947-a2b8-325f863fc5ac biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0043233 PMID:41385096 "[{""id"":""uuid:23d3e8c1-9e85-4dfd-8eea-ad86252194b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d9c924d5-7f0f-4a5f-853d-20804a95df66"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:2c13040c-0436-4ee4-a77f-bf0fc5f1e23f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0015614 PMID:41385096 "[{""id"":""uuid:9fdaab2f-8fbb-45c5-afc5-a4d102bfddb9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:331fe5ba-df41-4520-b968-716782ba57b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:1c404f7d-b1e7-46b8-9abc-504d21d35c47 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0006608 PMID:41385096 "[{""id"":""uuid:23d6447d-801f-47c2-868f-477005e844e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7c82452a-6cb5-4639-bb7f-716498515f2c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:daede8e0-c544-412d-8672-d98985db2c04 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0005083 PMID:41385096 "[{""id"":""uuid:5bd4759a-fd4f-4076-8c87-8025b6753ff9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c230cb3a-50a1-47d0-a4ae-a29301b33f3d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:54a494d6-0b90-497e-b03d-87b8731d2674 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0009691 PMID:41385096 "[{""id"":""uuid:a2e4234e-93d9-432b-8f29-3771c4602b21"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9ce747d9-fcc4-4b3a-b9af-ba499c0e487d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:5df55026-3996-4e23-bda7-9ed37112d1b8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:f74496c9-7a4b-4abf-8558-128bf1b48e1c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d4d40fcd-655a-4ec0-b7d9-159d91d44d02"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:9b8e0eec-5936-411a-a2e0-b2f9e1d202ca biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0005480 PMID:41385096 "[{""id"":""uuid:527de733-ca47-44c1-99f4-f662aa49f4e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:89374276-1b7a-41e0-8189-0ee1368f8372"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:67144a05-d775-4339-b88e-39e6b9aeaaf6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:0b6c50ec-2d3b-447c-ab4a-ade1f862d792"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:53b574a4-1e30-4706-85d9-564527aef0da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:ae4d179c-48dc-4179-b24c-ea2177f58356 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0043789 PMID:41385096 "[{""id"":""uuid:12b52f22-6260-4bb3-851e-cfbeaa8dfa1a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bf1383ad-c57a-487d-a0dd-0d110cfe02fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:db560a12-678e-4040-a741-38e794486f3f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0005324 PMID:41385096 "[{""id"":""uuid:b6e0b61d-c413-40c0-afdd-13ada4d9e4c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7913ade4-8d7b-4138-9a18-6708180bb443"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:39e1c7d1-3f9c-4e86-ab2d-f4a8881204d2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0024332 PMID:41385096 "[{""id"":""uuid:27944a10-3b68-4c5e-80bf-a66ea3b914a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:622a7d9c-465a-48e9-9739-59a4fc6c5a3b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:37c403aa-ee05-49c5-ac6a-ffb17b1d2f3a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0000775 PMID:41385096 "[{""id"":""uuid:1a93a20a-513b-4cb5-89aa-545f92d03527"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1e819787-4d76-40b3-91e1-c5467d234777"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:78188dd8-98ed-4714-afa7-37190917fcde biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats UMLS:C0274440 PMID:41385096 "[{""id"":""uuid:d5acef7a-dd5d-41ed-8449-bc2fc484639a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dbc938b2-c669-423f-b0cf-3a4660b7d6f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:29653c0c-1ae4-448d-ad99-861e4f667d00 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0005883 PMID:41385096 "[{""id"":""uuid:63339d05-facd-44b0-beb5-bf8a14df6e3e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1e4b80f4-4c50-47f0-bd22-b69f44e04c0f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:b1a0d911-dff8-4b17-bd6f-8297a0130944 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0006814 PMID:41385096 "[{""id"":""uuid:aa43f1dc-eb5b-4838-99a2-73dc1399a50a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cbd36e2b-db55-4280-8cf4-b7d6b0c81b37"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:ece9ccbe-7116-4ddc-b995-378231cb7164 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0004773 PMID:41385096 "[{""id"":""uuid:848b819a-7b71-47b2-9968-b887a3194d5d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cbc399fb-f391-406d-bf9b-28dc596fdcfe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:922217cd-ab5f-4bd9-b7d7-7c8a686a36ef biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0004674 PMID:41385096 "[{""id"":""uuid:2a825b93-21e5-4d80-a914-d8249bfe052d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c38b62e3-082f-4b04-9773-9dc2afa65d56"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:a541a018-39fe-4822-93f0-583d2b83ad22 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0006918 PMID:41385096 "[{""id"":""uuid:22319152-c342-47a3-9c48-83a98896193b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:23787678-da9d-4e3c-88c3-a5d65a5932c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:180c5a84-1c11-4347-ad8f-d7dfde699bd0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0001280 PMID:41385096 "[{""id"":""uuid:76c26b97-ab9c-45b6-87b8-ec9bc4ff26dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b521d1f6-4da0-4912-b3eb-7f51a1dcebbf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:05d2af8d-ef43-4f1e-9202-5b10be25255d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0005885 PMID:41385096 "[{""id"":""uuid:b0842f99-8c33-44f0-822c-f3369dc3ab5e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e5ef187c-08c0-45b1-b9e8-5dcd9a35c1bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:a7437c58-c3bb-47ce-8f7b-c6609465299d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0019198 PMID:41385096 "[{""id"":""uuid:04fbb1d4-bd3f-437c-92ce-b883c659b2c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fc5edd5e-c884-43b4-99f0-be3b107f203a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:242952c0-63bd-4dbd-a315-ea4fdfb629b3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0006651 PMID:41385096 "[{""id"":""uuid:18bfdc33-769e-4b26-a02a-c99debe4535d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:22dbfa3b-ecf2-43d4-af07-88aa0894b6cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:2d2553b0-64ab-4099-b2bf-e07772eea5d8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0003085 PMID:41385096 "[{""id"":""uuid:654295f0-3b20-40b5-b0bb-e89d0817cc29"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4113193c-67b9-4285-aaa9-9ae45bf58024"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:af6d9b95-2461-46db-aae1-a34ad965ee1c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0001034 PMID:41385096 "[{""id"":""uuid:39f8700c-acfa-471e-872e-8ee32fd5849d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:42cdf874-70fd-47da-8bc6-fe92dc7a9b62"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:af9f11f0-ffbc-4cba-ac05-a8968f67732b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0005101 PMID:41385096 "[{""id"":""uuid:a6b3cb82-f1d4-464d-9e5c-aee3bf2dcbee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2e857d5d-0d75-4403-ab46-34016270d370"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:b218b523-1f64-4399-beab-9c7d8e5776aa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats UMLS:C0678202 PMID:41385096 "[{""id"":""uuid:e46827f4-3e82-4872-8bef-2ed909fd1335"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8b14e422-4c6e-4aa7-80c2-7ceebf679dcd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:78d8930b-8bfb-4b97-ba93-3bb555830f79 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0019338 PMID:41385096 "[{""id"":""uuid:636b1384-433d-4c73-b8db-3218ecdd325b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a935e852-96c1-4a77-9093-8c08553d4eb3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:00d26799-e852-4575-bdbc-0fe966629959 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0015274 PMID:41385096 "[{""id"":""uuid:90cf44b4-090f-4042-9fde-d52c7d5b5867"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:364236e8-1b3b-498a-abd5-608ae07279e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:4985e3fc-2435-4a04-b898-16cf22affa7f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0006052 PMID:41385096 "[{""id"":""uuid:3ec5faf8-83fa-4784-9c5e-094ef613933f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8517a3ac-40af-4aed-86e9-b9ff77cf8edd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:cf930f96-321c-43a3-abc3-bee688d61877 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0005848 PMID:41385096 "[{""id"":""uuid:8e436425-8d76-42a7-b1a5-f42521ea0bba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b0de240a-9f46-4fce-8ec4-d7662c051313"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:d3e8c12c-288c-41b7-9f2d-c00f33b94c37 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0002572 PMID:41385096 "[{""id"":""uuid:b5ec13a5-a95e-4c47-b199-e925db8858e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7b99b1a1-b96d-445e-87c4-91d216d30d34"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:dbf4bdce-8f02-4e19-b0cc-0bd7045331aa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats UMLS:C0002879 PMID:41385096 "[{""id"":""uuid:854ddc89-0b61-4b00-8bbc-991813bfffa2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fefcab4d-02c6-4b99-8148-951ec2af3ec5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:551c6bed-4919-4d3b-a772-6714a0ed414f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0020108 PMID:41385096 "[{""id"":""uuid:13c2ae3b-c5fc-4637-9a8e-67df1b405845"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2a7bae93-09ee-4758-8bef-14c03534f7cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:1d244555-1171-4232-8919-04b78548cb56 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0019098 PMID:41385096 "[{""id"":""uuid:9046a59e-8bcd-479b-bff1-8f7bc87992b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c8aaff3c-2555-479b-915b-22ba28839f37"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:9b1d2c9a-1457-4742-a3b7-d14bd1cb78d2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0001198 PMID:41385096 "[{""id"":""uuid:13213ca2-1cff-45dd-98b2-61c8f5fb2a10"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:825eaa8e-e7c4-40ed-b456-fb5e9e53f6b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:83af8f11-81cd-41fd-9f11-02679a0dbab2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0002280 PMID:41385096 "[{""id"":""uuid:aed42f78-e8c5-46c8-9f60-115be0e05180"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:edb1a7c1-1e85-4a60-a46a-37966688d96c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:8fe5d4ea-6970-486b-aada-adfee1a403d1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0015253 PMID:41385096 "[{""id"":""uuid:f13ae1ac-9e54-44ce-8d8c-9fc30f78a5a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:99d7a900-00f6-4155-8c4f-77d0deced4cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:e9c147ff-d5b1-4690-a162-5116b3ec0b70 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats HP:0001908 PMID:41385096 "[{""id"":""uuid:2e8d4da3-d524-4400-934a-98e907455dcc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d876d9a5-7729-4bf1-819e-dd09b595423f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:f1906727-d35e-4200-a9f3-836cad8e22d8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0005059 PMID:41385096 "[{""id"":""uuid:1dd2b645-9492-4d78-87ac-43b0a367d8f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7064a739-767f-403a-ad5a-39c4d62bdce2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:20a27602-c2b2-4980-a523-ba7b5c237476 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0004095 PMID:41385096 "[{""id"":""uuid:716fc919-3970-417d-a846-4f1cbf50d238"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:909c52bb-d69e-40fe-a4bd-003acff7b6c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:0fa4af6b-759d-458c-a853-14dba196d71b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0004355 PMID:41385096 "[{""id"":""uuid:5c53a2bf-f853-43fc-bc3d-f4700cdd1d5c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:acce0966-b44b-4c34-8f2b-94d0ca78ffae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:81213146-880c-4428-92f0-432771b9a0a6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0005377 PMID:41385096 "[{""id"":""uuid:cb6d68a6-b586-4725-8e49-e519ed482201"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6657149a-96e5-4fd5-8f87-86b43be7544a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:d3ea27e4-eda3-48b1-a291-ad6189b76b41 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0006042 PMID:41385096 "[{""id"":""uuid:06161d7e-0133-417d-9580-24df350c4562"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fac636cb-e8ac-4404-8744-f459279d3261"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:6a18891e-32dd-4ec1-9509-50d21d9c9f6a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0019444 PMID:41385096 "[{""id"":""uuid:31f9a8d5-a1c5-4e45-86ac-5101e7c4dd9c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2b0cfe2b-e5b8-4d3b-8562-5df843c8dc00"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:fcef899a-4791-4a50-ac40-ee2f9bbe4f4e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0006684 PMID:41385096 "[{""id"":""uuid:18b7194b-cf9f-4aaa-afc4-2b8ae6d3ab67"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:966c2e96-8e21-4e51-a797-4a0112b5d3e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:8d8c30b0-cd38-4def-831c-c1c197e593ae biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0021211 PMID:41385096 "[{""id"":""uuid:f3ed3a4e-a709-427d-baa1-a3983a26ecf5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d2d1c358-6330-479d-ab36-1ba46da75b1e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:b8d80027-58e9-41b2-b697-1a48b9907cbb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64354 biolink:treats HP:0000969 PMID:41385096 "[{""id"":""uuid:ec30192c-197e-416c-acf5-61fb4b43eb7f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6e66b303-43ba-49e0-af06-0ffac95ab2dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Metolazone tablets are indicated for the treatment of salt and water retention including: • edema accompanying congestive heart failure; • edema accompanying renal diseases, including the nephrotic syndrome and states of diminished renal function. Metolazone tablets are also indicated for the treatment of hypertension, alone or in combination with other antihypertensive drugs of a different class. Mykrox ® tablets, a more rapidly available form of metolazone, are intended for the treatment of new patients with mild to moderate hypertension. A dose titration is necessary if Mykrox ® tablets are to be substituted for Zaroxolyn ® tablets and other formulations of metolazone that share its slow and incomplete bioavailability, in the treatment of hypertension. uuid:9942280c-bf54-46ee-8c08-98e8694c7227 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64354 biolink:treats UMLS:C0235415 PMID:41385096 "[{""id"":""uuid:3fc35423-22da-41e8-9a1b-9eefee87c535"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b53bb55a-2810-4a25-8f9c-ae08a6e9b99f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Metolazone tablets are indicated for the treatment of salt and water retention including: • edema accompanying congestive heart failure; • edema accompanying renal diseases, including the nephrotic syndrome and states of diminished renal function. Metolazone tablets are also indicated for the treatment of hypertension, alone or in combination with other antihypertensive drugs of a different class. Mykrox ® tablets, a more rapidly available form of metolazone, are intended for the treatment of new patients with mild to moderate hypertension. A dose titration is necessary if Mykrox ® tablets are to be substituted for Zaroxolyn ® tablets and other formulations of metolazone that share its slow and incomplete bioavailability, in the treatment of hypertension. uuid:fe6b0cd2-6618-422a-a9b4-3ad6b91c7cd0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3654 biolink:treats MONDO:0001644 PMID:41385096 "[{""id"":""uuid:fb0e5c58-a559-4bbd-b993-685a63ce47cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f007c10d-e285-4539-8977-27c5cd24df68"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diuretics such as chlorthalidone are indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertension. Chlorthalidone is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Chlorthalidone has also been found useful in edema due to various forms of renal dysfunction, such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. Usage in Pregnancy The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developed toxemia. Edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy. Chlorthalidone is indicated in pregnancy when edema is due to pathologic causes, just as it is in the absence of pregnancy (however, see PRECAUTIONS, below). Dependent edema in pregnancy, resulting from restriction of venous return by the expanded uterus, is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is illogical and unnecessary. There is hypervolemia during normal pregnancy that is harmful to neither the fetus nor the mother (in the absence of cardiovascular disease), but that is associated with edema, including generalized edema, in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances, this edema may cause extreme discomfort that is not relieved by rest. In these cases, a short course of diuretics may provide relief and be appropriate. uuid:3b8e938e-bab1-4bec-8155-2405b8623bd1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3654 biolink:treats HP:0007430 PMID:41385096 "[{""id"":""uuid:a4c884f2-443f-487f-a724-48a6b97fc358"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5919e504-1983-4275-b9fd-9bd324c24411"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diuretics such as chlorthalidone are indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertension. Chlorthalidone is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Chlorthalidone has also been found useful in edema due to various forms of renal dysfunction, such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. Usage in Pregnancy The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developed toxemia. Edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy. Chlorthalidone is indicated in pregnancy when edema is due to pathologic causes, just as it is in the absence of pregnancy (however, see PRECAUTIONS, below). Dependent edema in pregnancy, resulting from restriction of venous return by the expanded uterus, is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is illogical and unnecessary. There is hypervolemia during normal pregnancy that is harmful to neither the fetus nor the mother (in the absence of cardiovascular disease), but that is associated with edema, including generalized edema, in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances, this edema may cause extreme discomfort that is not relieved by rest. In these cases, a short course of diuretics may provide relief and be appropriate. uuid:266502e3-f40e-43ca-a9d5-cd7f2c446a30 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47519 biolink:treats MONDO:0001628 PMID:41385096 "[{""id"":""uuid:6dba8936-6724-48b2-8f4b-ad8df5857bb5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c009a0c5-817c-4b79-a5ad-47e37507fab7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ketoconazole tablets are not indicated for treatment of onychomycosis, cutaneous dermatophyte infections, or Candida infections. Ketoconazole tablets should be used only when other effective antifungal therapy is not available or tolerated and the potential benefits are considered to outweigh the potential risks. Ketoconazole tablets are indicated for the treatment of the following systemic fungal infections in patients who have failed or who are intolerant to other therapies: blastomycosis, coccidioidomycosis, histoplasmosis, chromomycosis, and paracoccidioidomycosis. Ketoconazole tablets should not be used for fungal meningitis because it penetrates poorly into the cerebrospinal fluid. uuid:1785c9f4-bbe4-4924-b937-d89b774287cf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47519 biolink:treats MONDO:0006764 PMID:41385096 "[{""id"":""uuid:494b62c5-ca3e-49a1-a59a-b6ab2fc74c45"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8a422f86-de15-4bcb-9470-440da903737c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ketoconazole tablets are not indicated for treatment of onychomycosis, cutaneous dermatophyte infections, or Candida infections. Ketoconazole tablets should be used only when other effective antifungal therapy is not available or tolerated and the potential benefits are considered to outweigh the potential risks. Ketoconazole tablets are indicated for the treatment of the following systemic fungal infections in patients who have failed or who are intolerant to other therapies: blastomycosis, coccidioidomycosis, histoplasmosis, chromomycosis, and paracoccidioidomycosis. Ketoconazole tablets should not be used for fungal meningitis because it penetrates poorly into the cerebrospinal fluid. uuid:3053d0d7-3367-42e8-8281-9174ea7689bc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:585948 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:5fac946e-5d1e-4f96-ae2f-3fa37311a427"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:92679c98-e562-41ec-b787-483e4bcdf1c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Felodipine tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including felodipine. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (eg, on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Felodipine tablets may be administered with other antihypertensive agents. uuid:a066c6ec-faa0-4353-affc-4ecc4489d011 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:585948 biolink:treats HP:0001681 PMID:41385096 "[{""id"":""uuid:cff95332-6bab-4bfc-8c7f-217ef9c8396b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c823c181-cb5b-4271-84ea-084c34b24738"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Felodipine tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including felodipine. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (eg, on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Felodipine tablets may be administered with other antihypertensive agents. uuid:fe9cdc15-1f01-44bd-aac2-1c2e25918f2c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:585948 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:6cb5b941-0cda-4ae9-97f1-a3c54307b8d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1c23ee5a-4149-452b-8b3f-d0a629ed8a08"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Felodipine tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including felodipine. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (eg, on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Felodipine tablets may be administered with other antihypertensive agents. uuid:00fd062a-fef8-4f29-9b00-3afe65ee26c4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8805 biolink:treats MONDO:0012819 PMID:41385096 "[{""id"":""uuid:a029ea93-50cc-4e3d-a898-c8b6cc56b029"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cad6bb6f-e05f-49fb-bd09-15606c3fe21f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PRANDIN is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitation of Use: PRANDIN should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. uuid:219f4fdb-f015-4fed-8317-9189db5d2b62 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8107 biolink:treats MONDO:0002125 PMID:41385096 "[{""id"":""uuid:967dc9e7-d4b8-4c03-93b7-e86de86f3840"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f14e79b5-2b35-4a20-87ff-8737a2bbb641"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fosphenytoin Sodium Injection, USP is indicated for the treatment of generalized tonic-clonic status epilepticus and prevention and treatment of seizures occurring during neurosurgery. Fosphenytoin Sodium Injection, USP can also be substituted, short-term, for oral phenytoin. Fosphenytoin Sodium Injection, USP should be used only when oral phenytoin administration is not possible [see Dosage and Administration (2.4) and Warnings and Precautions (5.2) ]. uuid:1e8a0f15-a447-4e72-b07e-873592882dd5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:30746 biolink:treats HP:0008281 PMID:41385096 "[{""id"":""uuid:6e42244b-f92f-4fa3-83d6-1647345bd066"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e815402e-b0af-4a76-b280-d48a515eddb6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AMMONUL is indicated as adjunctive therapy in pediatric and adult patients for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. During acute hyperammonemic episodes, arginine supplementation, caloric supplementation, dietary protein restriction, hemodialysis, and other ammonia lowering therapies should be considered [ see Warnings and Precautions (5) ]. uuid:58a44fed-ea02-4719-9bc2-9be814783ac1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64028 biolink:treats MONDO:0007739 PMID:41385096 "[{""id"":""uuid:cb65dcf9-a5bd-428d-b982-7943fb37a1c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:505d70f2-7db3-42fb-bbfb-24129d9b2850"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:96f3b91c-2d4d-42e4-bffb-6e836347a4cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tetrabenazine tablets are indicated for the treatment of chorea associated with Huntington's disease.|[PMDA] A drug with a new active ingredient indicated for the treatment of chorea associated with Huntington's disease. [Orphan drug] uuid:debf6dd9-00d7-4569-a668-57a85f9bbe46 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49662 biolink:treats NCIT:C27003 PMID:41385096 "[{""id"":""uuid:3cbc39e6-73e8-438a-9a75-a1adaf453486"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eff901ec-05fa-45ff-99ff-a0b4a9e566bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TIVORBEX is indicated for treatment of mild to moderate acute pain in adults. uuid:17b3626c-54a0-40ec-aa56-964b8eaf0c68 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3757 biolink:treats MONDO:0005302 PMID:41385096 "[{""id"":""uuid:91415e4f-e607-4ab9-a687-31d75070739a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:02f8c12e-6958-4b09-b2de-247c01d11e79"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clonidine hydrochloride extended-release tablets are indicated for the treatment of attention deficit hyperactivity disorder (ADHD) as monotherapy and as adjunctive therapy to stimulant medications [see Clinical Studies (14)]. uuid:155d9460-bd18-41a3-abb5-12691121b24e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats UMLS:C1290158 PMID:41385096 "[{""id"":""uuid:059cc554-18a1-4dcc-a2f7-0704c86f93a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cfc7a4dc-fffe-4d6a-8433-ecb9e15c81de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis Collagen Diseases: During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Dermatologic Diseases: Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases: Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Diseases: Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis Hematologic Disorders: Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Diseases: For palliative management of: Leukemia and lymphomas in adults Acute leukemia of childhood Edematous States: To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases: To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous: Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement Diagnostic testing of adrenocortical hyperfunction. uuid:50428996-80aa-46a7-9f87-69922a9faa39 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0006918 PMID:41385096 "[{""id"":""uuid:7e5b1af1-8403-40af-a8f3-e010f734e69f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c375af37-9398-41d8-94a6-072d96ea5053"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis Collagen Diseases: During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Dermatologic Diseases: Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases: Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Diseases: Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis Hematologic Disorders: Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Diseases: For palliative management of: Leukemia and lymphomas in adults Acute leukemia of childhood Edematous States: To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases: To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous: Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement Diagnostic testing of adrenocortical hyperfunction. uuid:1eca2fcc-2d79-4e89-9337-df31246e8115 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0001280 PMID:41385096 "[{""id"":""uuid:f63b489f-8bad-448c-9d37-5d57ec91b2ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8d02be3a-a97e-4d84-a138-518240fb24a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis Collagen Diseases: During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Dermatologic Diseases: Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases: Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Diseases: Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis Hematologic Disorders: Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Diseases: For palliative management of: Leukemia and lymphomas in adults Acute leukemia of childhood Edematous States: To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases: To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous: Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement Diagnostic testing of adrenocortical hyperfunction. uuid:b5010acb-ad65-4dd5-8624-5d0e20e7baf6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16684 biolink:treats MONDO:0001673 PMID:41385096 "[{""id"":""uuid:c01e4c24-cf79-484d-816d-21125e164fcb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:55c2ac31-84d5-42f5-99d2-54bf31ecaa52"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diphenoxylate Hydrochloride and Atropine Sulfate Tablets USP are indicated as adjunctive therapy in the management of diarrhea in patients 13 years of age and older. uuid:44fec664-6686-4447-a2c9-f4b18e7130b4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4356 biolink:treats UMLS:C1739382 PMID:41385096 "[{""id"":""uuid:4a0d2a73-2d27-49e2-a758-81c1919f979c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f2c4caff-87d3-4df9-a1a4-feb8c7552934"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Deferoxamine mesylate for injection, USP, is indicated for the treatment of acute iron intoxication and of chronic iron overload due to transfusion-dependent anemias. Acute Iron Intoxication Deferoxamine mesylate is an adjunct to, and not a substitute for, standard measures used in treating acute iron intoxication, which may include the following: induction of emesis with syrup of ipecac; gastric lavage; suction and maintenance of a clear airway; control of shock with intravenous fluids, blood, oxygen, and vasopressors; and correction of acidosis. Chronic Iron Overload Deferoxamine mesylate can promote iron excretion in patients with secondary iron overload from multiple transfusions (as may occur in the treatment of some chronic anemias, including thalassemia). Long-term therapy with deferoxamine mesylate slows accumulation of hepatic iron and retards or eliminates progression of hepatic fibrosis. Iron mobilization with deferoxamine mesylate is relatively poor in patients under the age of 3 years with relatively little iron overload. The drug should ordinarily not be given to such patients unless significant iron mobilization (e.g., 1 mg or more of iron per day) can be demonstrated. Deferoxamine mesylate is not indicated for the treatment of primary hemochromatosis, since phlebotomy is the method of choice for removing excess iron in this disorder. uuid:2d6df91c-1b2a-4cfc-b128-9edc4c2ed990 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4356 biolink:treats MONDO:0000984 PMID:41385096 "[{""id"":""uuid:4ecd05de-e6c1-494b-9403-e9d9a33f8e0f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5ace2aaa-870f-42fa-a26f-653048595c08"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Deferoxamine mesylate for injection, USP, is indicated for the treatment of acute iron intoxication and of chronic iron overload due to transfusion-dependent anemias. Acute Iron Intoxication Deferoxamine mesylate is an adjunct to, and not a substitute for, standard measures used in treating acute iron intoxication, which may include the following: induction of emesis with syrup of ipecac; gastric lavage; suction and maintenance of a clear airway; control of shock with intravenous fluids, blood, oxygen, and vasopressors; and correction of acidosis. Chronic Iron Overload Deferoxamine mesylate can promote iron excretion in patients with secondary iron overload from multiple transfusions (as may occur in the treatment of some chronic anemias, including thalassemia). Long-term therapy with deferoxamine mesylate slows accumulation of hepatic iron and retards or eliminates progression of hepatic fibrosis. Iron mobilization with deferoxamine mesylate is relatively poor in patients under the age of 3 years with relatively little iron overload. The drug should ordinarily not be given to such patients unless significant iron mobilization (e.g., 1 mg or more of iron per day) can be demonstrated. Deferoxamine mesylate is not indicated for the treatment of primary hemochromatosis, since phlebotomy is the method of choice for removing excess iron in this disorder. uuid:a1e2cb91-9083-456f-bb83-526104ebc3b6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4356 biolink:treats MONDO:0006507 PMID:41385096 "[{""id"":""uuid:f95852da-ee8c-4c3e-a79a-dce5ee534d35"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2506432f-3233-4185-8a45-2765e77c2e63"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Deferoxamine mesylate for injection, USP, is indicated for the treatment of acute iron intoxication and of chronic iron overload due to transfusion-dependent anemias. Acute Iron Intoxication Deferoxamine mesylate is an adjunct to, and not a substitute for, standard measures used in treating acute iron intoxication, which may include the following: induction of emesis with syrup of ipecac; gastric lavage; suction and maintenance of a clear airway; control of shock with intravenous fluids, blood, oxygen, and vasopressors; and correction of acidosis. Chronic Iron Overload Deferoxamine mesylate can promote iron excretion in patients with secondary iron overload from multiple transfusions (as may occur in the treatment of some chronic anemias, including thalassemia). Long-term therapy with deferoxamine mesylate slows accumulation of hepatic iron and retards or eliminates progression of hepatic fibrosis. Iron mobilization with deferoxamine mesylate is relatively poor in patients under the age of 3 years with relatively little iron overload. The drug should ordinarily not be given to such patients unless significant iron mobilization (e.g., 1 mg or more of iron per day) can be demonstrated. Deferoxamine mesylate is not indicated for the treatment of primary hemochromatosis, since phlebotomy is the method of choice for removing excess iron in this disorder. uuid:17632912-ea0e-49ce-8e4b-8ce06aa5770f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28918 biolink:treats MONDO:0000775 PMID:41385096 "[{""id"":""uuid:32a9fad1-e648-45c3-acec-66b9496a84a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:32615e8c-a082-4922-b926-fe013411ec49"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Epinephrine is used to relieve respiratory distress due to bronchospasm, to provide rapid relief of hypersensitivity reactions to drugs and other allergens, and to prolong the action of anesthetics. Its cardiac effects may be of use in restoring cardiac rhythm in cardiac arrest due to various causes, but it is not used in cardiac failure or in hemorrhagic, traumatic, or cardiogenic shock. Epinephrine is used as a hemostatic agent. It is also used in treating mucosal congestion of hay fever, rhinitis, and acute sinusitis; to relieve bronchial asthmatic paroxysms; in syncope due to complete heart block or carotid sinus hypersensitivity; for symptomatic relief of serum sickness, urticaria, angioneurotic edema; for resuscitation in cardiac arrest following anesthetic accidents; in simple (open angle) glaucoma; for relaxation of uterine musculature and to inhibit uterine contractions. Epinephrine Injection can be utilized to prolong the action of anesthetics used in local and regional anesthesia. uuid:5193de93-8e44-48ae-9fb5-cf92121996c2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28918 biolink:treats MONDO:0005271 PMID:41385096 "[{""id"":""uuid:57cdddce-8d34-4710-a6c9-6422db553a8c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cb6cebe2-407d-43bd-8199-624ebf15ae66"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Epinephrine is used to relieve respiratory distress due to bronchospasm, to provide rapid relief of hypersensitivity reactions to drugs and other allergens, and to prolong the action of anesthetics. Its cardiac effects may be of use in restoring cardiac rhythm in cardiac arrest due to various causes, but it is not used in cardiac failure or in hemorrhagic, traumatic, or cardiogenic shock. Epinephrine is used as a hemostatic agent. It is also used in treating mucosal congestion of hay fever, rhinitis, and acute sinusitis; to relieve bronchial asthmatic paroxysms; in syncope due to complete heart block or carotid sinus hypersensitivity; for symptomatic relief of serum sickness, urticaria, angioneurotic edema; for resuscitation in cardiac arrest following anesthetic accidents; in simple (open angle) glaucoma; for relaxation of uterine musculature and to inhibit uterine contractions. Epinephrine Injection can be utilized to prolong the action of anesthetics used in local and regional anesthesia. uuid:2c77e721-37a4-4c60-918f-846437b81070 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28918 biolink:treats MONDO:0000468 PMID:41385096 "[{""id"":""uuid:f827bbdf-9ecf-4786-93ea-24bd860457bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d2840690-c30b-40c5-8732-377bc8095ce8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Epinephrine is used to relieve respiratory distress due to bronchospasm, to provide rapid relief of hypersensitivity reactions to drugs and other allergens, and to prolong the action of anesthetics. Its cardiac effects may be of use in restoring cardiac rhythm in cardiac arrest due to various causes, but it is not used in cardiac failure or in hemorrhagic, traumatic, or cardiogenic shock. Epinephrine is used as a hemostatic agent. It is also used in treating mucosal congestion of hay fever, rhinitis, and acute sinusitis; to relieve bronchial asthmatic paroxysms; in syncope due to complete heart block or carotid sinus hypersensitivity; for symptomatic relief of serum sickness, urticaria, angioneurotic edema; for resuscitation in cardiac arrest following anesthetic accidents; in simple (open angle) glaucoma; for relaxation of uterine musculature and to inhibit uterine contractions. Epinephrine Injection can be utilized to prolong the action of anesthetics used in local and regional anesthesia. uuid:f4b304c1-302e-485b-98ca-88aa1c7cc0fa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28918 biolink:treats HP:0012669 PMID:41385096 "[{""id"":""uuid:a3b33c37-e956-493c-8b7b-de5e345d7a65"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:92004014-987c-4a8f-a214-2963b56e9e53"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Epinephrine is used to relieve respiratory distress due to bronchospasm, to provide rapid relief of hypersensitivity reactions to drugs and other allergens, and to prolong the action of anesthetics. Its cardiac effects may be of use in restoring cardiac rhythm in cardiac arrest due to various causes, but it is not used in cardiac failure or in hemorrhagic, traumatic, or cardiogenic shock. Epinephrine is used as a hemostatic agent. It is also used in treating mucosal congestion of hay fever, rhinitis, and acute sinusitis; to relieve bronchial asthmatic paroxysms; in syncope due to complete heart block or carotid sinus hypersensitivity; for symptomatic relief of serum sickness, urticaria, angioneurotic edema; for resuscitation in cardiac arrest following anesthetic accidents; in simple (open angle) glaucoma; for relaxation of uterine musculature and to inhibit uterine contractions. Epinephrine Injection can be utilized to prolong the action of anesthetics used in local and regional anesthesia. uuid:4ffaa2ad-bd92-4f31-898f-1be573fa3df5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28918 biolink:treats MONDO:0005338 PMID:41385096 "[{""id"":""uuid:1ac9ee9e-c0d1-4290-92d5-f3c1bf780011"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f44f5327-293c-4a60-9308-126dd0c54950"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Epinephrine is used to relieve respiratory distress due to bronchospasm, to provide rapid relief of hypersensitivity reactions to drugs and other allergens, and to prolong the action of anesthetics. Its cardiac effects may be of use in restoring cardiac rhythm in cardiac arrest due to various causes, but it is not used in cardiac failure or in hemorrhagic, traumatic, or cardiogenic shock. Epinephrine is used as a hemostatic agent. It is also used in treating mucosal congestion of hay fever, rhinitis, and acute sinusitis; to relieve bronchial asthmatic paroxysms; in syncope due to complete heart block or carotid sinus hypersensitivity; for symptomatic relief of serum sickness, urticaria, angioneurotic edema; for resuscitation in cardiac arrest following anesthetic accidents; in simple (open angle) glaucoma; for relaxation of uterine musculature and to inhibit uterine contractions. Epinephrine Injection can be utilized to prolong the action of anesthetics used in local and regional anesthesia. uuid:3e2e89b0-f0ed-49f8-84bd-e6ce1109e915 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64354 biolink:treats MONDO:0045048 PMID:41385096 "[{""id"":""uuid:39244006-e253-4019-bdcb-e1f759cd3328"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a75ffb12-5e35-4646-827c-b8fb0b4775b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Upstate's metolazone tablets, USP, are indicated for the treatment of salt and water retention including: edema accompanying congestive heart failure; edema accompanying renal diseases, including the nephrotic syndrome and states of diminished renal function. Metolazone tablets, USP, are also indicated for the treatment of hypertension, alone or in combination with other antihypertensive drugs of a different class. MYKROX Tablets, a more rapidly available form of metolazone, are intended for the treatment of new patients with mild to moderate hypertension. A dose titration is necessary if MYKROX Tablets are to be substituted for Upstate's metolazone tablets, USP, in the treatment of hypertension. See package circular for MYKROX Tablets (UCB). Usage In Pregnancy The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no evidence that they are useful in the treatment of developed toxemia. Edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy. Metolazone tablets, USP, are indicated in pregnancy when edema is due to pathologic causes, just as it is in the absence of pregnancy (see PRECAUTIONS). Dependent edema in pregnancy resulting from restriction of venous return by the expanded uterus is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is illogical and unnecessary. There is hypervolemia during normal pregnancy which is harmful to neither the fetus nor the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema, in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances, this edema may cause extreme discomfort which is not relieved by rest. In these cases, a short course of diuretics may be appropriate. uuid:f065cce1-9e88-4ce4-b0b8-85aa5d7fb30c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64354 biolink:treats MONDO:0005081 PMID:41385096 "[{""id"":""uuid:dbab5860-6f41-4580-8d9e-4dd3bd1c81d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:29b1778e-5a9a-4c91-af30-b0ec87fee532"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Upstate's metolazone tablets, USP, are indicated for the treatment of salt and water retention including: edema accompanying congestive heart failure; edema accompanying renal diseases, including the nephrotic syndrome and states of diminished renal function. Metolazone tablets, USP, are also indicated for the treatment of hypertension, alone or in combination with other antihypertensive drugs of a different class. MYKROX Tablets, a more rapidly available form of metolazone, are intended for the treatment of new patients with mild to moderate hypertension. A dose titration is necessary if MYKROX Tablets are to be substituted for Upstate's metolazone tablets, USP, in the treatment of hypertension. See package circular for MYKROX Tablets (UCB). Usage In Pregnancy The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no evidence that they are useful in the treatment of developed toxemia. Edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy. Metolazone tablets, USP, are indicated in pregnancy when edema is due to pathologic causes, just as it is in the absence of pregnancy (see PRECAUTIONS). Dependent edema in pregnancy resulting from restriction of venous return by the expanded uterus is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is illogical and unnecessary. There is hypervolemia during normal pregnancy which is harmful to neither the fetus nor the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema, in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances, this edema may cause extreme discomfort which is not relieved by rest. In these cases, a short course of diuretics may be appropriate. uuid:05b335bb-4819-4565-9966-7813bad73fa0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64354 biolink:treats HP:0007430 PMID:41385096 "[{""id"":""uuid:c01e9caa-4126-4ffb-9ac2-1e72f615bb83"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7352ef62-db9c-4a85-b9bf-bf28bf54607b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Upstate's metolazone tablets, USP, are indicated for the treatment of salt and water retention including: edema accompanying congestive heart failure; edema accompanying renal diseases, including the nephrotic syndrome and states of diminished renal function. Metolazone tablets, USP, are also indicated for the treatment of hypertension, alone or in combination with other antihypertensive drugs of a different class. MYKROX Tablets, a more rapidly available form of metolazone, are intended for the treatment of new patients with mild to moderate hypertension. A dose titration is necessary if MYKROX Tablets are to be substituted for Upstate's metolazone tablets, USP, in the treatment of hypertension. See package circular for MYKROX Tablets (UCB). Usage In Pregnancy The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no evidence that they are useful in the treatment of developed toxemia. Edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy. Metolazone tablets, USP, are indicated in pregnancy when edema is due to pathologic causes, just as it is in the absence of pregnancy (see PRECAUTIONS). Dependent edema in pregnancy resulting from restriction of venous return by the expanded uterus is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is illogical and unnecessary. There is hypervolemia during normal pregnancy which is harmful to neither the fetus nor the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema, in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances, this edema may cause extreme discomfort which is not relieved by rest. In these cases, a short course of diuretics may be appropriate. uuid:c66bed18-507b-4241-aec9-303506bc6f6b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:205919 biolink:treats MONDO:0006604 PMID:41385096 "[{""id"":""uuid:426e4d70-3a88-4638-941e-f4a3d1b815a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d0770c9f-4ef0-49b8-8843-5512c310e114"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clobetasol Propionate Topical Spray, 0.05% is a corticosteroid indicated for the topical treatment of moderate to severe plaque psoriasis affecting up to 20% body surface area (BSA) in patients 18 years of age or older. ( 1.1 ) Limitations of Use: Do not use on the face, axillae or groin. ( 1.2 ) Do not use if atrophy is present at the treatment site.( 1.2 ) Do not use for rosacea or perioral dermatitis. ( 1.2 ) uuid:42652d39-9208-441d-8f75-18e278157b69 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:499361 biolink:treats HP:0002018 PMID:41385096 "[{""id"":""uuid:f409d04b-a8b8-4d74-a70d-5176af5584cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e75f4069-05f6-462b-9578-68ed6b7ed532"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:600a999e-aa8e-4084-8668-9afc9280a97f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EMEND ® for injection, in combination with other antiemetic agents, is indicated in adults for the prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin. delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC).|[PMDA] Drugs with a new active ingredient indicated for the treatment of digestive symptoms (nausea and vomiting, including delayed phase) resulting from the administration of antineoplastic agents (cisplatin, etc.). uuid:7a1c515b-7f8e-4862-8a82-903ddd25a0a2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:499361 biolink:treats HP:0002013 PMID:41385096 "[{""id"":""uuid:098d8d07-67de-48b6-9568-da8fd6169f99"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:90ac5d23-9e87-4dbb-81fa-15bcd815b1be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:b086d7e0-13e3-4981-8c06-fe7a91431187"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EMEND ® for injection, in combination with other antiemetic agents, is indicated in adults for the prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin. delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC).|[PMDA] Drugs with a new active ingredient indicated for the treatment of digestive symptoms (nausea and vomiting, including delayed phase) resulting from the administration of antineoplastic agents (cisplatin, etc.). uuid:1d1e5dc0-c819-47c5-b4ba-44c9e6e52248 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0006640 PMID:41385096 "[{""id"":""uuid:ff82170a-676f-46f2-af27-2cb99101c1e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:98faff44-0d09-4526-8759-5e62b6140d49"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:345c6e52-f86a-4537-90ec-40d827ca5211 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1593740 biolink:treats MONDO:0001860 PMID:41385096 "[{""id"":""uuid:754cf427-91c3-4cd2-9c70-abf980354486"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:913ab742-35f6-4e5c-8119-4270e2268fe3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Noxifol-D is indicated for dietary management of patients with unique nutritional needs requiring increased folate levels, Vitamin D levels, or used in improving the nutritional status of patients with folic acid and vitamin D deficiency This statement has not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent disease. uuid:cfbe8819-0992-420e-8371-a3a4738ff874 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0001225 PMID:41385096 "[{""id"":""uuid:845c0372-7cc9-4738-b81e-683f79329208"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b77a8641-bf6f-4f32-9261-137bf011c885"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Treatment with naltrexone implants should be part of a comprehensive management program that includes psychological and psychosocial support. Naltrexone tablets were initially approved by the FDA in 1985 for the treatment of abuse and addiction of opioids. Naltrexone in oral and extended release injection forms have been approved by the FDA for the treatment and abuse of alcohol. Naltrexone implants may be useful for the treatment of alcohol or opioid dependence in patients who are able to abstain from opioid or alcohol in an outpatient setting prior to initiation of treatment. Patients should not be actively drinking or be on any opioids at the time of initial naltrexone implant administration. uuid:5c181ddc-3022-4515-8096-a25c6bfdce1d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0002046 PMID:41385096 "[{""id"":""uuid:7402d3ab-5760-426d-8a94-783193fd8a24"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:781054fc-57cc-4718-9418-b22344798401"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Treatment with naltrexone implants should be part of a comprehensive management program that includes psychological and psychosocial support. Naltrexone tablets were initially approved by the FDA in 1985 for the treatment of abuse and addiction of opioids. Naltrexone in oral and extended release injection forms have been approved by the FDA for the treatment and abuse of alcohol. Naltrexone implants may be useful for the treatment of alcohol or opioid dependence in patients who are able to abstain from opioid or alcohol in an outpatient setting prior to initiation of treatment. Patients should not be actively drinking or be on any opioids at the time of initial naltrexone implant administration. uuid:fb8e3cb1-42cf-4f79-8c5d-8a8c50456b87 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0007079 PMID:41385096 "[{""id"":""uuid:71111f0c-da7f-4c76-b59b-6ca3d2cc4385"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b6d3df44-be2d-45ba-942d-97d2adfb9c3a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Treatment with naltrexone implants should be part of a comprehensive management program that includes psychological and psychosocial support. Naltrexone tablets were initially approved by the FDA in 1985 for the treatment of abuse and addiction of opioids. Naltrexone in oral and extended release injection forms have been approved by the FDA for the treatment and abuse of alcohol. Naltrexone implants may be useful for the treatment of alcohol or opioid dependence in patients who are able to abstain from opioid or alcohol in an outpatient setting prior to initiation of treatment. Patients should not be actively drinking or be on any opioids at the time of initial naltrexone implant administration. uuid:eb117821-0af0-4081-a5f1-6908aaf7863c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0005530 PMID:41385096 "[{""id"":""uuid:3e341967-66a1-46fe-8979-f6dc89b58093"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:668fa364-0d88-4e3b-8102-8b9d25018df0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Treatment with naltrexone implants should be part of a comprehensive management program that includes psychological and psychosocial support. Naltrexone tablets were initially approved by the FDA in 1985 for the treatment of abuse and addiction of opioids. Naltrexone in oral and extended release injection forms have been approved by the FDA for the treatment and abuse of alcohol. Naltrexone implants may be useful for the treatment of alcohol or opioid dependence in patients who are able to abstain from opioid or alcohol in an outpatient setting prior to initiation of treatment. Patients should not be actively drinking or be on any opioids at the time of initial naltrexone implant administration. uuid:5e3d9f06-72d4-4ce5-b12c-cb2ab19fd461 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8772 biolink:treats MONDO:0006256 PMID:41385096 "[{""id"":""uuid:f995324e-7fd1-40a2-b846-3a0b9f54abe1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bb402e2b-761f-4578-873b-b540876024a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Raloxifene hydrochloride tablets, USP is an estrogen agonist/antagonist indicated for: Treatment and prevention of osteoporosis in postmenopausal women. ( 1.1 ) Reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis. ( 1.2 ) Reduction in risk of invasive breast cancer in postmenopausal women at high risk for invasive breast cancer. ( 1.3 ) Important Limitations: Raloxifene hydrochloride tablets, USP is not indicated for the treatment of invasive breast cancer, reduction of the risk of recurrence of breast cancer, or reduction of risk of noninvasive breast cancer. uuid:5b3e3fcc-a9cd-46c7-8b89-f04ea85c65ec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17347 biolink:treats HP:0008213 PMID:41385096 "[{""id"":""uuid:026f4cfa-8022-475f-a308-7a298ee0c67a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9b2da20b-f8f0-491c-859f-2e8911f664bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Testosterone gel is indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone: Primary Hypogonadism (congenital or acquired) - testicular failure due to conditions such as cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter’s syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone concentrations and gonadotropins (follicle stimulating hormone (FSH), luteinizing hormone (LH)) above the normal range. Hypogonadotropic hypogonadism (congenital or acquired) - gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation. These men have low testosterone serum concentrations but have gonadotropins in the normal or low range. Limitations of use: Safety and efficacy of testosterone gel in men with ""age-related hypogonadism"" (also referred to as ""late-onset hypogonadism"") have not been established. Safety and efficacy of testosterone gel in males less than 18 years old have not been established [ see Use in Specific Populations (8.4) ]. Topical testosterone products may have different doses, strengths, or application instructions that may result in different systemic exposure. (1, 12.3)" uuid:eb2bed82-5294-4682-bacb-cc5f33e5e78e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0009197 PMID:41385096 "[{""id"":""uuid:24603405-7cac-4cfb-a231-7f572a3d2518"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:da9e8f0d-e93e-4e35-bbe2-39e066ae4365"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Atopic dermatitis, Bronchial asthma, Contact dermatitis, Drug hypersensitivity reactions, Seasonal or perennial allergic rhinitis, and Serum sickness. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus, and Acute rheumatic carditis. Dermatologic Diseases Bullous dermatitis herpetiformis, Exfoliative dermatitis, Mycosis fungoides, Pemphigus, Severe erythema multiforme (Stevens-Johnson syndrome), Severe psoriasis, and Severe seborrheic dermatitis. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), Congenital adrenal hyperplasia, Hypercalcemia associated with cancer, and Nonsuppurative thyroiditis. Gastrointestinal diseases To tide the patient over a critical period of the disease in: Ulcerative colitis, and Regional enteritis. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults, Secondary thrombocytopenia in adults, Acquired (autoimmune) hemolytic anemia, Erythroblastopenia (RBC anemia), and Congenital (erythroid) hypoplastic anemia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy, and Trichinosis with neurologic or myocardial involvement. Neoplastic Diseases For palliative management of: Leukemia and lymphomas in adults, and Acute leukemia of childhood. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis, Keratitis, Allergic corneal marginal ulcers, Herpes zoster ophthalmicus, Iritis and iridocyclitis, Chorioretinitis, Anterior segment inflammation, Diffuse posterior uveitis and choroiditis, Optic neuritis, and Sympathetic ophthalmia. Respiratory Diseases Symptomatic sarcoidosis, Loeffler's syndrome not manageable by other means, Berylliosis, Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, and Aspiration pneumonitis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis, Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy), Ankylosing spondylitis, Acute and subacute bursitis, Acute nonspecific tenosynovitis, Acute gouty arthritis, Post-traumatic osteoarthritis, Synovitis of osteoarthritis, and Epicondylitis. uuid:2056c2a8-1449-4f92-bdd6-013e6186b3a7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:192254 biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:522f6ca7-6ff8-4547-8176-2131ce2df26b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a9a628c0-1733-4303-8c77-eeacf70cf48c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:1d32944b-65db-4625-a9c9-1b2ea0743fa1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/lamivudine-zidovudine-teva""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lamivudine and zidovudine tablets, a combination of 2 nucleoside analogues, is indicated in combination with other antiretrovirals for the treatment of human immunodeficiency virus type 1 (HIV‑1) infection.|[EMA] Combivir is indicated in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infection., uuid:6b100046-5d07-4a88-bf87-ac532adab23c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3752 biolink:treats MONDO:0021348 PMID:41385096 "[{""id"":""uuid:7bab42f8-5c56-4833-9438-ea8dac2ffadf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:917da0bc-dbc1-44d4-bd8a-aa268614fdf7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clomiphene citrate tablets USP is indicated for the treatment of ovulatory dysfunction in women desiring pregnancy. Impediments to achieving pregnancy must be excluded or adequately treated before beginning clomiphene citrate tablets USP therapy. Those patients most likely to achieve success with clomiphene therapy include patients with polycystic ovary syndrome (see WARNINGS: Ovarian Hyperstimulation Syndrome ), amenorrhea-galactorrhea syndrome, psychogenic amenorrhea, post-oral-contraceptive amenorrhea, and certain cases of secondary amenorrhea of undetermined etiology. Properly timed coitus in relationship to ovulation is important. A basal body temperature graph or other appropriate tests may help the patient and her physician determine if ovulation occurred. Once ovulation has been established, each course of clomiphene citrate tablets USP should be started on or about the 5th day of the cycle. Long-term cyclic therapy is not recommended beyond a total of about six cycles (including three ovulatory cycles). (See DOSAGE AND ADMINISTRATION and PRECAUTIONS .) Clomiphene citrate tablets USP is indicated only in patients with demonstrated ovulatory dysfunction who meet the conditions described below: 1. Patients who are not pregnant. 2. Patients without ovarian cysts. Clomiphene citrate tablets USP should not be used in patients with ovarian enlargement except those with polycystic ovary syndrome. Pelvic examination is necessary prior to the first and each subsequent course of clomiphene citrate tablets USP treatment. 3. Patients without abnormal vaginal bleeding. If abnormal vaginal bleeding is present, the patient should be carefully evaluated to ensure that neoplastic lesions are not present. 4. Patients with normal liver function. In addition, patients selected for clomiphene citrate tablets USP therapy should be evaluated in regard to the following: 1. Estrogen Levels. Patients should have adequate levels of endogenous estrogen (as estimated from vaginal smears, endometrial biopsy, assay of urinary estrogen, or from bleeding in response to progesterone). Reduced estrogen levels, while less favorable, do not preclude successful therapy. 2. Primary Pituitary or Ovarian Failure. Clomiphene citrate tablets USP therapy cannot be expected to substitute for specific treatment of other causes of ovulatory failure. 3. Endometriosis and Endometrial Carcinoma. The incidence of endometriosis and endometrial carcinoma increases with age as does the incidence of ovulatory disorders. Endometrial biopsy should always be performed prior to clomiphene citrate tablets USP therapy in this population. 4. Other Impediments to Pregnancy. Impediments to pregnancy can include thyroid disorders, adrenal disorders, hyperprolactinemia, and male factor infertility. 5. Uterine Fibroids. Caution should be exercised when using clomiphene citrate tablets USP in patients with uterine fibroids due to the potential for further enlargement of the fibroids. There are no adequate or well-controlled studies that demonstrate the effectiveness of clomiphene citrate tablets USP in the treatment of male infertility. In addition, testicular tumors and gynecomastia have been reported in males using clomiphene. The cause and effect relationship between reports of testicular tumors and the administration of clomiphene citrate tablets USP is not known. Although the medical literature suggests various methods, there is no universally accepted standard regimen for combined therapy (ie, clomiphene citrate tablets USP in conjunction with other ovulation-inducing drugs). Similarly, there is no standard clomiphene citrate tablets USP regimen for ovulation induction in in vitro fertilization programs to produce ova for fertilization and reintroduction. Therefore, clomiphene citrate tablets USP is not recommended for these uses. uuid:fb868f3f-e55e-4543-a774-d64566e6c9da biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0006956 PMID:41385096 "[{""id"":""uuid:022114f7-bd3d-47d7-9a1a-e45c4ab87d73"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4b31d82f-4926-4cf3-9e35-865957a8a686"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ACTICLATE ® and ACTICLATE ® CAP are tetracycline class drugs indicated for: Rickettsial infections ( 1.1 ) Sexually transmitted infections ( 1.2 ) Respiratory tract infections ( 1.3 ) Specific bacterial infections ( 1.4 ) Ophthalmic infections ( 1.5 ) Anthrax, including inhalational anthrax (post-exposure) ( 1.6 ) Alternative treatment for selected infections when penicillin is contraindicated ( 1.7 ) Adjunctive therapy for acute intestinal amebiasis and severe acne ( 1.8 ) Prophylaxis of malaria ( 1.9 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of ACTICLATE and ACTICLATE CAP and other antibacterial drugs, ACTICLATE and ACTICLATE CAP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.10 ) uuid:e5d49479-8fb5-47b8-8ed2-11f192910c83 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0021681 PMID:41385096 "[{""id"":""uuid:18c1c5b0-315b-4d31-b492-865de3eb8bc7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bc14b28e-976c-4b62-86cb-b9ce5d358264"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ACTICLATE ® and ACTICLATE ® CAP are tetracycline class drugs indicated for: Rickettsial infections ( 1.1 ) Sexually transmitted infections ( 1.2 ) Respiratory tract infections ( 1.3 ) Specific bacterial infections ( 1.4 ) Ophthalmic infections ( 1.5 ) Anthrax, including inhalational anthrax (post-exposure) ( 1.6 ) Alternative treatment for selected infections when penicillin is contraindicated ( 1.7 ) Adjunctive therapy for acute intestinal amebiasis and severe acne ( 1.8 ) Prophylaxis of malaria ( 1.9 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of ACTICLATE and ACTICLATE CAP and other antibacterial drugs, ACTICLATE and ACTICLATE CAP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.10 ) uuid:39215381-8069-4e77-91ac-8d048dc95b03 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0043885 PMID:41385096 "[{""id"":""uuid:6cd53a7d-7cac-4e13-aa50-fcb4173c06fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d061b8fc-130f-4482-add0-eaf979fe749f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ACTICLATE ® and ACTICLATE ® CAP are tetracycline class drugs indicated for: Rickettsial infections ( 1.1 ) Sexually transmitted infections ( 1.2 ) Respiratory tract infections ( 1.3 ) Specific bacterial infections ( 1.4 ) Ophthalmic infections ( 1.5 ) Anthrax, including inhalational anthrax (post-exposure) ( 1.6 ) Alternative treatment for selected infections when penicillin is contraindicated ( 1.7 ) Adjunctive therapy for acute intestinal amebiasis and severe acne ( 1.8 ) Prophylaxis of malaria ( 1.9 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of ACTICLATE and ACTICLATE CAP and other antibacterial drugs, ACTICLATE and ACTICLATE CAP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.10 ) uuid:8a3024fc-ce7c-453a-8834-75323d0478e8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63611 biolink:treats UMLS:C3840140 PMID:41385096 "[{""id"":""uuid:8a098eb0-df71-4f0d-b6ff-c82b4d312fd7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:699d428d-cc0a-44ca-b078-4fd9348a3a23"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Moxifloxacin ophthalmic solution is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Corynebacterium species* Micrococcus luteus* Staphylococcus aureus Staphylococcus epidermidis Staphylococcus haemolyticus Staphylococcus hominis Staphylococcus warneri* Streptococcus pneumoniae Streptococcus viridans group Acinetobacter lwoffii* Haemophilus influenza Haemophilus parainfluenzae* Chlamydia trachomatis *Efficacy for this organism was studied in fewer than 10 infections. uuid:d8d54fe6-9400-4474-b9a3-836bce69509f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63611 biolink:treats MONDO:0005545 PMID:41385096 "[{""id"":""uuid:50c93d6f-7899-46f5-acb3-e703b84f40ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:652f6006-d7b3-4f66-b7a1-1679074d9969"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Moxifloxacin ophthalmic solution is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Corynebacterium species* Micrococcus luteus* Staphylococcus aureus Staphylococcus epidermidis Staphylococcus haemolyticus Staphylococcus hominis Staphylococcus warneri* Streptococcus pneumoniae Streptococcus viridans group Acinetobacter lwoffii* Haemophilus influenza Haemophilus parainfluenzae* Chlamydia trachomatis *Efficacy for this organism was studied in fewer than 10 infections. uuid:76d564ef-5012-43f8-8ab1-f40675f7d510 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63611 biolink:treats UMLS:C5924387 PMID:41385096 "[{""id"":""uuid:b4fe0c7a-4618-4f1f-9dbb-141a0ebd23c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f0907f56-033f-4e6d-96d1-27837ab17350"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Moxifloxacin ophthalmic solution is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Corynebacterium species* Micrococcus luteus* Staphylococcus aureus Staphylococcus epidermidis Staphylococcus haemolyticus Staphylococcus hominis Staphylococcus warneri* Streptococcus pneumoniae Streptococcus viridans group Acinetobacter lwoffii* Haemophilus influenza Haemophilus parainfluenzae* Chlamydia trachomatis *Efficacy for this organism was studied in fewer than 10 infections. uuid:c834996e-fe35-4759-9143-5aecc82d467c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63611 biolink:treats MONDO:0005114 PMID:41385096 "[{""id"":""uuid:898cd041-2708-4f26-a081-ef322d861753"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:068ebaf3-2da3-48e8-baeb-358816ed4a02"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Moxifloxacin ophthalmic solution is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Corynebacterium species* Micrococcus luteus* Staphylococcus aureus Staphylococcus epidermidis Staphylococcus haemolyticus Staphylococcus hominis Staphylococcus warneri* Streptococcus pneumoniae Streptococcus viridans group Acinetobacter lwoffii* Haemophilus influenza Haemophilus parainfluenzae* Chlamydia trachomatis *Efficacy for this organism was studied in fewer than 10 infections. uuid:46953e18-6707-4b9c-ae21-94dc5ef08119 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63611 biolink:treats UMLS:C1096266 PMID:41385096 "[{""id"":""uuid:a30dfccf-c335-4c7a-9a20-a44c321576c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:72ced2ad-8635-41b2-92f6-e0c7526e7321"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Moxifloxacin ophthalmic solution is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Corynebacterium species* Micrococcus luteus* Staphylococcus aureus Staphylococcus epidermidis Staphylococcus haemolyticus Staphylococcus hominis Staphylococcus warneri* Streptococcus pneumoniae Streptococcus viridans group Acinetobacter lwoffii* Haemophilus influenza Haemophilus parainfluenzae* Chlamydia trachomatis *Efficacy for this organism was studied in fewer than 10 infections. uuid:caa6ab55-6a78-45b8-bdd4-8f6c16dce54d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63611 biolink:treats UMLS:C0348321 PMID:41385096 "[{""id"":""uuid:e413f392-e2e6-4d58-82fe-3569400df406"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d1c4bb99-661a-4c35-a956-3e6e8da1240d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Moxifloxacin ophthalmic solution is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Corynebacterium species* Micrococcus luteus* Staphylococcus aureus Staphylococcus epidermidis Staphylococcus haemolyticus Staphylococcus hominis Staphylococcus warneri* Streptococcus pneumoniae Streptococcus viridans group Acinetobacter lwoffii* Haemophilus influenza Haemophilus parainfluenzae* Chlamydia trachomatis *Efficacy for this organism was studied in fewer than 10 infections. uuid:4c94b868-86c6-40e5-a763-14227a88f991 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63611 biolink:treats MONDO:0005701 PMID:41385096 "[{""id"":""uuid:29993bf9-8a2b-4e69-a21c-4ecd9ff49b6b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7495d623-ea66-4589-814f-b2da50b15970"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Moxifloxacin ophthalmic solution is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Corynebacterium species* Micrococcus luteus* Staphylococcus aureus Staphylococcus epidermidis Staphylococcus haemolyticus Staphylococcus hominis Staphylococcus warneri* Streptococcus pneumoniae Streptococcus viridans group Acinetobacter lwoffii* Haemophilus influenza Haemophilus parainfluenzae* Chlamydia trachomatis *Efficacy for this organism was studied in fewer than 10 infections. uuid:1c1f0720-859b-407e-a7dd-79e4db5b9e96 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1811627 biolink:treats HP:0002140 PMID:41385096 "[{""id"":""uuid:8d8ce5ef-b4b2-454c-a084-23539f23a925"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1edc73db-2c9a-45c1-b0bc-ec02170bded8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] YOSPRALA, a combination of aspirin and omeprazole, is indicated for patients who require aspirin for secondary prevention of cardiovascular and cerebrovascular events and who are at risk of developing aspirin associated gastric ulcers. The aspirin component of YOSPRALA is indicated for: reducing the combined risk of death and nonfatal stroke in patients who have had ischemic stroke or transient ischemia of the brain due to fibrin platelet emboli, reducing the combined risk of death and nonfatal MI in patients with a previous MI or unstable angina pectoris, reducing the combined risk of MI and sudden death in patients with chronic stable angina pectoris, use in patients who have undergone revascularization procedures (Coronary Artery Bypass Graft [CABG] or Percutaneous Transluminal Coronary Angioplasty [PTCA]) when there is a pre-existing condition for which aspirin is already indicated. The omeprazole component of YOSPRALA is indicated for decreasing the risk of developing aspirin-associated gastric ulcers in patients at risk for developing aspirin-associated gastric ulcers due to age (≥ 55) or documented history of gastric ulcers. Limitations of Use : YOSPRALA contains a delayed-release formulation of aspirin and it is not for use as the initial dose of aspirin therapy during onset of acute coronary syndrome, acute myocardial infarction or before percutaneous coronary intervention (PCI), for which immediate-release aspirin therapy is appropriate. YOSPRALA has not been shown to reduce the risk of gastrointestinal bleeding due to aspirin. Do not substitute YOSPRALA with the single-ingredient products of aspirin and omeprazole. uuid:3e543ff6-de61-40b2-bf9f-77dc475c77e1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1811627 biolink:treats MONDO:0005299 PMID:41385096 "[{""id"":""uuid:2a8bc6c4-337a-4ba3-bcae-c6e735f44729"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:62dc4269-47bd-46da-88a2-de69ae216f70"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] YOSPRALA, a combination of aspirin and omeprazole, is indicated for patients who require aspirin for secondary prevention of cardiovascular and cerebrovascular events and who are at risk of developing aspirin associated gastric ulcers. The aspirin component of YOSPRALA is indicated for: reducing the combined risk of death and nonfatal stroke in patients who have had ischemic stroke or transient ischemia of the brain due to fibrin platelet emboli, reducing the combined risk of death and nonfatal MI in patients with a previous MI or unstable angina pectoris, reducing the combined risk of MI and sudden death in patients with chronic stable angina pectoris, use in patients who have undergone revascularization procedures (Coronary Artery Bypass Graft [CABG] or Percutaneous Transluminal Coronary Angioplasty [PTCA]) when there is a pre-existing condition for which aspirin is already indicated. The omeprazole component of YOSPRALA is indicated for decreasing the risk of developing aspirin-associated gastric ulcers in patients at risk for developing aspirin-associated gastric ulcers due to age (≥ 55) or documented history of gastric ulcers. Limitations of Use : YOSPRALA contains a delayed-release formulation of aspirin and it is not for use as the initial dose of aspirin therapy during onset of acute coronary syndrome, acute myocardial infarction or before percutaneous coronary intervention (PCI), for which immediate-release aspirin therapy is appropriate. YOSPRALA has not been shown to reduce the risk of gastrointestinal bleeding due to aspirin. Do not substitute YOSPRALA with the single-ingredient products of aspirin and omeprazole. uuid:c7f63deb-8e60-4560-a98f-7d00673dce42 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1811627 biolink:treats MONDO:0006805 PMID:41385096 "[{""id"":""uuid:0120296b-b2f8-4427-b386-12d91a2eecbe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bc134743-e8b0-45b9-ab59-a60f118ba156"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] YOSPRALA, a combination of aspirin and omeprazole, is indicated for patients who require aspirin for secondary prevention of cardiovascular and cerebrovascular events and who are at risk of developing aspirin associated gastric ulcers. The aspirin component of YOSPRALA is indicated for: reducing the combined risk of death and nonfatal stroke in patients who have had ischemic stroke or transient ischemia of the brain due to fibrin platelet emboli, reducing the combined risk of death and nonfatal MI in patients with a previous MI or unstable angina pectoris, reducing the combined risk of MI and sudden death in patients with chronic stable angina pectoris, use in patients who have undergone revascularization procedures (Coronary Artery Bypass Graft [CABG] or Percutaneous Transluminal Coronary Angioplasty [PTCA]) when there is a pre-existing condition for which aspirin is already indicated. The omeprazole component of YOSPRALA is indicated for decreasing the risk of developing aspirin-associated gastric ulcers in patients at risk for developing aspirin-associated gastric ulcers due to age (≥ 55) or documented history of gastric ulcers. Limitations of Use : YOSPRALA contains a delayed-release formulation of aspirin and it is not for use as the initial dose of aspirin therapy during onset of acute coronary syndrome, acute myocardial infarction or before percutaneous coronary intervention (PCI), for which immediate-release aspirin therapy is appropriate. YOSPRALA has not been shown to reduce the risk of gastrointestinal bleeding due to aspirin. Do not substitute YOSPRALA with the single-ingredient products of aspirin and omeprazole. uuid:aeaea120-dc94-41a3-8384-03122d0cbe1c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1811627 biolink:treats HP:0001681 PMID:41385096 "[{""id"":""uuid:33577079-c2d4-48ff-84d6-a658a878c5f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ef1c9a72-55d9-4605-8e05-07df49a3efba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] YOSPRALA, a combination of aspirin and omeprazole, is indicated for patients who require aspirin for secondary prevention of cardiovascular and cerebrovascular events and who are at risk of developing aspirin associated gastric ulcers. The aspirin component of YOSPRALA is indicated for: reducing the combined risk of death and nonfatal stroke in patients who have had ischemic stroke or transient ischemia of the brain due to fibrin platelet emboli, reducing the combined risk of death and nonfatal MI in patients with a previous MI or unstable angina pectoris, reducing the combined risk of MI and sudden death in patients with chronic stable angina pectoris, use in patients who have undergone revascularization procedures (Coronary Artery Bypass Graft [CABG] or Percutaneous Transluminal Coronary Angioplasty [PTCA]) when there is a pre-existing condition for which aspirin is already indicated. The omeprazole component of YOSPRALA is indicated for decreasing the risk of developing aspirin-associated gastric ulcers in patients at risk for developing aspirin-associated gastric ulcers due to age (≥ 55) or documented history of gastric ulcers. Limitations of Use : YOSPRALA contains a delayed-release formulation of aspirin and it is not for use as the initial dose of aspirin therapy during onset of acute coronary syndrome, acute myocardial infarction or before percutaneous coronary intervention (PCI), for which immediate-release aspirin therapy is appropriate. YOSPRALA has not been shown to reduce the risk of gastrointestinal bleeding due to aspirin. Do not substitute YOSPRALA with the single-ingredient products of aspirin and omeprazole. uuid:674a9aee-d926-46c4-9ee9-0e690b9bda7d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1811627 biolink:treats UMLS:C0341178 PMID:41385096 "[{""id"":""uuid:cb670ec9-ce40-4e30-b9dc-e00e9d6a3445"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fc6598f9-a87c-46fc-b60d-d35d425e312d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] YOSPRALA, a combination of aspirin and omeprazole, is indicated for patients who require aspirin for secondary prevention of cardiovascular and cerebrovascular events and who are at risk of developing aspirin associated gastric ulcers. The aspirin component of YOSPRALA is indicated for: reducing the combined risk of death and nonfatal stroke in patients who have had ischemic stroke or transient ischemia of the brain due to fibrin platelet emboli, reducing the combined risk of death and nonfatal MI in patients with a previous MI or unstable angina pectoris, reducing the combined risk of MI and sudden death in patients with chronic stable angina pectoris, use in patients who have undergone revascularization procedures (Coronary Artery Bypass Graft [CABG] or Percutaneous Transluminal Coronary Angioplasty [PTCA]) when there is a pre-existing condition for which aspirin is already indicated. The omeprazole component of YOSPRALA is indicated for decreasing the risk of developing aspirin-associated gastric ulcers in patients at risk for developing aspirin-associated gastric ulcers due to age (≥ 55) or documented history of gastric ulcers. Limitations of Use : YOSPRALA contains a delayed-release formulation of aspirin and it is not for use as the initial dose of aspirin therapy during onset of acute coronary syndrome, acute myocardial infarction or before percutaneous coronary intervention (PCI), for which immediate-release aspirin therapy is appropriate. YOSPRALA has not been shown to reduce the risk of gastrointestinal bleeding due to aspirin. Do not substitute YOSPRALA with the single-ingredient products of aspirin and omeprazole. uuid:b8e091e2-c53f-48a4-bcb8-a4f9cd04473a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1811627 biolink:treats MONDO:0005542 PMID:41385096 "[{""id"":""uuid:6c387f88-fe21-43d0-a7f6-bc45d6538fd1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b7322310-174a-469c-85e6-dec336fd4390"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] YOSPRALA, a combination of aspirin and omeprazole, is indicated for patients who require aspirin for secondary prevention of cardiovascular and cerebrovascular events and who are at risk of developing aspirin associated gastric ulcers. The aspirin component of YOSPRALA is indicated for: reducing the combined risk of death and nonfatal stroke in patients who have had ischemic stroke or transient ischemia of the brain due to fibrin platelet emboli, reducing the combined risk of death and nonfatal MI in patients with a previous MI or unstable angina pectoris, reducing the combined risk of MI and sudden death in patients with chronic stable angina pectoris, use in patients who have undergone revascularization procedures (Coronary Artery Bypass Graft [CABG] or Percutaneous Transluminal Coronary Angioplasty [PTCA]) when there is a pre-existing condition for which aspirin is already indicated. The omeprazole component of YOSPRALA is indicated for decreasing the risk of developing aspirin-associated gastric ulcers in patients at risk for developing aspirin-associated gastric ulcers due to age (≥ 55) or documented history of gastric ulcers. Limitations of Use : YOSPRALA contains a delayed-release formulation of aspirin and it is not for use as the initial dose of aspirin therapy during onset of acute coronary syndrome, acute myocardial infarction or before percutaneous coronary intervention (PCI), for which immediate-release aspirin therapy is appropriate. YOSPRALA has not been shown to reduce the risk of gastrointestinal bleeding due to aspirin. Do not substitute YOSPRALA with the single-ingredient products of aspirin and omeprazole. uuid:fb7d76f3-d47e-4464-8d23-904982b5ed9d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1811627 biolink:treats MONDO:0004781 PMID:41385096 "[{""id"":""uuid:d437f260-2636-4fc5-a567-b35d8a3cbb39"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6bd68f2e-8eb9-4e05-b974-8ff467f438aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] YOSPRALA, a combination of aspirin and omeprazole, is indicated for patients who require aspirin for secondary prevention of cardiovascular and cerebrovascular events and who are at risk of developing aspirin associated gastric ulcers. The aspirin component of YOSPRALA is indicated for: reducing the combined risk of death and nonfatal stroke in patients who have had ischemic stroke or transient ischemia of the brain due to fibrin platelet emboli, reducing the combined risk of death and nonfatal MI in patients with a previous MI or unstable angina pectoris, reducing the combined risk of MI and sudden death in patients with chronic stable angina pectoris, use in patients who have undergone revascularization procedures (Coronary Artery Bypass Graft [CABG] or Percutaneous Transluminal Coronary Angioplasty [PTCA]) when there is a pre-existing condition for which aspirin is already indicated. The omeprazole component of YOSPRALA is indicated for decreasing the risk of developing aspirin-associated gastric ulcers in patients at risk for developing aspirin-associated gastric ulcers due to age (≥ 55) or documented history of gastric ulcers. Limitations of Use : YOSPRALA contains a delayed-release formulation of aspirin and it is not for use as the initial dose of aspirin therapy during onset of acute coronary syndrome, acute myocardial infarction or before percutaneous coronary intervention (PCI), for which immediate-release aspirin therapy is appropriate. YOSPRALA has not been shown to reduce the risk of gastrointestinal bleeding due to aspirin. Do not substitute YOSPRALA with the single-ingredient products of aspirin and omeprazole. uuid:00241c48-4478-44f5-a757-1bb6a269bede biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:LYO9XZ250J biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:b04ef27c-997d-4c7f-adc0-6ffedc8a88b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ad792109-cc4d-44fe-b144-dcfdf0f9ccb3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZEMDRI is an aminoglycoside antibacterial indicated for the treatment of patients 18 years of age or older with Complicated Urinary Tract Infections (cUTI) including Pyelonephritis. ( 1.1 ) As only limited clinical safety and efficacy data are available, reserve ZEMDRI for use in patients who have limited or no alternative treatment options. ( 1.1 ) To reduce the development of drug-resistant bacteria and maintain effectiveness of ZEMDRI and other antibacterial drugs, ZEMDRI should be used only to treat infections that are proven or strongly suspected to be caused by susceptible microorganisms. ( 1.2 ) uuid:fd7f9ce4-3dd3-4904-8cfb-bb85b15a4a9a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:LYO9XZ250J biolink:treats MONDO:0006939 PMID:41385096 "[{""id"":""uuid:d3c036c3-570b-493d-99a6-9e957d6d3723"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8376f949-5bdf-47c5-8449-ed99c05b080e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZEMDRI is an aminoglycoside antibacterial indicated for the treatment of patients 18 years of age or older with Complicated Urinary Tract Infections (cUTI) including Pyelonephritis. ( 1.1 ) As only limited clinical safety and efficacy data are available, reserve ZEMDRI for use in patients who have limited or no alternative treatment options. ( 1.1 ) To reduce the development of drug-resistant bacteria and maintain effectiveness of ZEMDRI and other antibacterial drugs, ZEMDRI should be used only to treat infections that are proven or strongly suspected to be caused by susceptible microorganisms. ( 1.2 ) uuid:2ab2db33-5e6f-4f8b-a5f3-a9dcda736643 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75722 biolink:treats HP:0030858 PMID:41385096 "[{""id"":""uuid:2c8312b5-08d6-457e-9494-632b9338a2fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eea6ec2b-6741-4a0f-9a4e-94692e7a9e02"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tramadol hydrochloride tablets are indicated for the management of pain in adults that is severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses ( see WARNINGS ), reserve tramadol hydrochloride tablets for use in patients for whom alternative treatment options [e.g., non-opioid analgesics]: • Have not been tolerated, or are not expected to be tolerated. • Have not provided adequate analgesia, or are not expected to provide adequate analgesia. uuid:66eec8eb-32ce-4066-97dc-fb73e0e463e7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75722 biolink:treats MONDO:0002491 PMID:41385096 "[{""id"":""uuid:3bd1eb15-4e2a-4ff0-9b69-59e93c4156dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fd63c190-39b1-464f-a8fb-6050823c370c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tramadol hydrochloride tablets are indicated for the management of pain in adults that is severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses ( see WARNINGS ), reserve tramadol hydrochloride tablets for use in patients for whom alternative treatment options [e.g., non-opioid analgesics]: • Have not been tolerated, or are not expected to be tolerated. • Have not provided adequate analgesia, or are not expected to provide adequate analgesia. uuid:4ee1b56e-7a8f-4a92-8945-2350036a6b1a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75722 biolink:treats EFO:0011049 PMID:41385096 "[{""id"":""uuid:d6a50583-74fd-4345-8c7d-2825e0ae5dc5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:91762c2f-a9f4-46de-8911-0f770405b76c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tramadol hydrochloride tablets are indicated for the management of pain in adults that is severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses ( see WARNINGS ), reserve tramadol hydrochloride tablets for use in patients for whom alternative treatment options [e.g., non-opioid analgesics]: • Have not been tolerated, or are not expected to be tolerated. • Have not provided adequate analgesia, or are not expected to provide adequate analgesia. uuid:3109d617-bc7d-4eb5-930a-ef12257d1254 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5801 biolink:treats MONDO:0005920 PMID:41385096 "[{""id"":""uuid:0d2c1f80-185b-40bf-8a79-4c47b548e776"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2a254fc3-dbd4-41fd-8358-d0421c10a05e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydroxychloroquine sulfate tablets, USP are indicated for the treatment of uncomplicated malaria due to P. falciparum , P. malariae , P. ovale , and P. vivax . Hydroxychloroquine sulfate tablets, USP are indicated for the prophylaxis of malaria in geographic areas where chloroquine resistance is not reported. Limitations of Use in Malaria Hydroxychloroquine sulfate tablets, USP are not recommended for the treatment of complicated malaria. Hydroxychloroquine sulfate tablets, USP are not effective against chloroquine or hydroxychloroquine-resistant strains of Plasmodium species (see CLINICAL PHARMACOLOGY – Microbiology ) . Hydroxychloroquine sulfate tablets, USP are not recommended for the treatment of malaria acquired in geographic areas where chloroquine resistance occurs or when the Plasmodium species has not been identified. Hydroxychloroquine sulfate tablets, USP are not recommended for malaria prophylaxis in geographic areas where chloroquine resistance occurs. Hydroxychloroquine sulfate tablets, USP do not prevent relapses of P. vivax or P. ovale because it is not active against the hypnozoite forms of these parasites. For radical cure of P. vivax and P. ovale infections, concomitant therapy with an 8-aminoquinoline compound is necessary (see CLINICAL PHARMACOLOGY – Microbiology ). Prior to prescribing hydroxychloroquine sulfate tablets, USP for the treatment or prophylaxis of malaria, consult the Centers for Disease Control and Prevention (CDC) Malaria website (http://www.cdc.gov/malaria). uuid:9c42f637-bbc2-406d-a20f-af5bc4918dd7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5801 biolink:treats MONDO:0001943 PMID:41385096 "[{""id"":""uuid:6c3eb013-159d-41b1-8932-e267239e4f4a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b4796758-d978-4e23-b750-1a4ad6e747aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydroxychloroquine sulfate tablets, USP are indicated for the treatment of uncomplicated malaria due to P. falciparum , P. malariae , P. ovale , and P. vivax . Hydroxychloroquine sulfate tablets, USP are indicated for the prophylaxis of malaria in geographic areas where chloroquine resistance is not reported. Limitations of Use in Malaria Hydroxychloroquine sulfate tablets, USP are not recommended for the treatment of complicated malaria. Hydroxychloroquine sulfate tablets, USP are not effective against chloroquine or hydroxychloroquine-resistant strains of Plasmodium species (see CLINICAL PHARMACOLOGY – Microbiology ) . Hydroxychloroquine sulfate tablets, USP are not recommended for the treatment of malaria acquired in geographic areas where chloroquine resistance occurs or when the Plasmodium species has not been identified. Hydroxychloroquine sulfate tablets, USP are not recommended for malaria prophylaxis in geographic areas where chloroquine resistance occurs. Hydroxychloroquine sulfate tablets, USP do not prevent relapses of P. vivax or P. ovale because it is not active against the hypnozoite forms of these parasites. For radical cure of P. vivax and P. ovale infections, concomitant therapy with an 8-aminoquinoline compound is necessary (see CLINICAL PHARMACOLOGY – Microbiology ). Prior to prescribing hydroxychloroquine sulfate tablets, USP for the treatment or prophylaxis of malaria, consult the Centers for Disease Control and Prevention (CDC) Malaria website (http://www.cdc.gov/malaria). uuid:8f29b6de-7090-48f0-83a5-e60c4152ad9c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5801 biolink:treats MONDO:0001601 PMID:41385096 "[{""id"":""uuid:78774d89-0567-4adb-b6da-21798bf8d5bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5e5383c3-abb4-4e6f-aa69-306753019c3e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydroxychloroquine sulfate tablets, USP are indicated for the treatment of uncomplicated malaria due to P. falciparum , P. malariae , P. ovale , and P. vivax . Hydroxychloroquine sulfate tablets, USP are indicated for the prophylaxis of malaria in geographic areas where chloroquine resistance is not reported. Limitations of Use in Malaria Hydroxychloroquine sulfate tablets, USP are not recommended for the treatment of complicated malaria. Hydroxychloroquine sulfate tablets, USP are not effective against chloroquine or hydroxychloroquine-resistant strains of Plasmodium species (see CLINICAL PHARMACOLOGY – Microbiology ) . Hydroxychloroquine sulfate tablets, USP are not recommended for the treatment of malaria acquired in geographic areas where chloroquine resistance occurs or when the Plasmodium species has not been identified. Hydroxychloroquine sulfate tablets, USP are not recommended for malaria prophylaxis in geographic areas where chloroquine resistance occurs. Hydroxychloroquine sulfate tablets, USP do not prevent relapses of P. vivax or P. ovale because it is not active against the hypnozoite forms of these parasites. For radical cure of P. vivax and P. ovale infections, concomitant therapy with an 8-aminoquinoline compound is necessary (see CLINICAL PHARMACOLOGY – Microbiology ). Prior to prescribing hydroxychloroquine sulfate tablets, USP for the treatment or prophylaxis of malaria, consult the Centers for Disease Control and Prevention (CDC) Malaria website (http://www.cdc.gov/malaria). uuid:e40086fc-0967-475f-8508-705c2783ed3f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5801 biolink:treats MONDO:0005921 PMID:41385096 "[{""id"":""uuid:c05cfa9f-5e72-4f07-a5c6-22958768421b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e9838cc7-d074-4d2c-b4a6-f0c6ec88cf25"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydroxychloroquine sulfate tablets, USP are indicated for the treatment of uncomplicated malaria due to P. falciparum , P. malariae , P. ovale , and P. vivax . Hydroxychloroquine sulfate tablets, USP are indicated for the prophylaxis of malaria in geographic areas where chloroquine resistance is not reported. Limitations of Use in Malaria Hydroxychloroquine sulfate tablets, USP are not recommended for the treatment of complicated malaria. Hydroxychloroquine sulfate tablets, USP are not effective against chloroquine or hydroxychloroquine-resistant strains of Plasmodium species (see CLINICAL PHARMACOLOGY – Microbiology ) . Hydroxychloroquine sulfate tablets, USP are not recommended for the treatment of malaria acquired in geographic areas where chloroquine resistance occurs or when the Plasmodium species has not been identified. Hydroxychloroquine sulfate tablets, USP are not recommended for malaria prophylaxis in geographic areas where chloroquine resistance occurs. Hydroxychloroquine sulfate tablets, USP do not prevent relapses of P. vivax or P. ovale because it is not active against the hypnozoite forms of these parasites. For radical cure of P. vivax and P. ovale infections, concomitant therapy with an 8-aminoquinoline compound is necessary (see CLINICAL PHARMACOLOGY – Microbiology ). Prior to prescribing hydroxychloroquine sulfate tablets, USP for the treatment or prophylaxis of malaria, consult the Centers for Disease Control and Prevention (CDC) Malaria website (http://www.cdc.gov/malaria). uuid:269567c6-f41b-4f37-8e99-78de67f6fff1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5801 biolink:treats UMLS:C2747816 PMID:41385096 "[{""id"":""uuid:4e11032f-bd28-4d8d-b0cb-a2e44c4f97d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c15b7905-e79f-45f0-895c-9e4d15cdfafd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydroxychloroquine sulfate tablets, USP are indicated for the treatment of uncomplicated malaria due to P. falciparum , P. malariae , P. ovale , and P. vivax . Hydroxychloroquine sulfate tablets, USP are indicated for the prophylaxis of malaria in geographic areas where chloroquine resistance is not reported. Limitations of Use in Malaria Hydroxychloroquine sulfate tablets, USP are not recommended for the treatment of complicated malaria. Hydroxychloroquine sulfate tablets, USP are not effective against chloroquine or hydroxychloroquine-resistant strains of Plasmodium species (see CLINICAL PHARMACOLOGY – Microbiology ) . Hydroxychloroquine sulfate tablets, USP are not recommended for the treatment of malaria acquired in geographic areas where chloroquine resistance occurs or when the Plasmodium species has not been identified. Hydroxychloroquine sulfate tablets, USP are not recommended for malaria prophylaxis in geographic areas where chloroquine resistance occurs. Hydroxychloroquine sulfate tablets, USP do not prevent relapses of P. vivax or P. ovale because it is not active against the hypnozoite forms of these parasites. For radical cure of P. vivax and P. ovale infections, concomitant therapy with an 8-aminoquinoline compound is necessary (see CLINICAL PHARMACOLOGY – Microbiology ). Prior to prescribing hydroxychloroquine sulfate tablets, USP for the treatment or prophylaxis of malaria, consult the Centers for Disease Control and Prevention (CDC) Malaria website (http://www.cdc.gov/malaria). uuid:208e2cea-2c10-4404-97d2-a394ed504475 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5118 biolink:treats UMLS:C2063866 PMID:41385096 "[{""id"":""uuid:c12bf8c0-247c-4d43-ab33-d97e9906787d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:79cd83d7-de3a-49f8-9356-bb6862521643"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fluoxetine capsules are indicated for the treatment of: Acute and maintenance treatment of Major Depressive Disorder [see Clinical Studies (14.1) ] . Acute and maintenance treatment of obsessions and compulsions in patients with Obsessive Compulsive Disorder (OCD) [see Clinical Studies (14.2) ] . Acute and maintenance treatment of binge-eating and vomiting behaviors in patients with moderate to severe Bulimia Nervosa [see Clinical Studies (14.3) ] . Acute treatment of Panic Disorder, with or without agoraphobia [see Clinical Studies (14.4) ] . Fluoxetine capsules and Olanzapine in Combination are indicated for the treatment of: Acute treatment of depressive episodes associated with Bipolar I Disorder. Treatment resistant depression (Major Depressive Disorder in patients, who do not respond to 2 separate trials of different antidepressants of adequate dose and duration in the current episode). Fluoxetine capsules monotherapy is not indicated for the treatment of depressive episodes associated with Bipolar I Disorder or the treatment of treatment resistant depression. When using fluoxetine capsules and olanzapine in combination, also refer to the Clinical Studies section of the package insert for Symbyax ® . uuid:02af4333-956d-4010-8bfd-2bc99b620495 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7476 biolink:treats MONDO:0018456 PMID:41385096 "[{""id"":""uuid:e0bb0380-27a9-4613-b88b-4422720c73b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c5653272-c8ba-4936-bb68-719dfa295824"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Naproxen sodium tablets are indicated for: the relief of the signs and symptoms of: rheumatoid arthritis osteoarthritis ankylosing spondylitis Polyarticular Juvenile Idiopathic Arthritis Naproxen sodium tablets are also indicated for: the relief of signs and symptoms of: tendonitis bursitis acute gout the management of: pain primary dysmenorrhea uuid:b2f9fc59-8530-474d-944b-7ac11a50dc36 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:141474 biolink:treats MONDO:0003471 PMID:41385096 "[{""id"":""uuid:5c3447fc-7762-4b08-83fd-51a9d575eb51"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2b7fd096-c87c-4887-b39e-10d7fe459743"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OVIDE Lotion is indicated for patients infected with Pediculus humanus capitis (head lice and their ova) of the scalp hair. uuid:c1206aff-f09b-4b27-8840-79d87f873212 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8356 biolink:treats MONDO:0005391 PMID:41385096 "[{""id"":""uuid:b23caf8f-58ab-4227-8ce9-22ef7f62aa30"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:65fa7566-1640-4ba1-a3e7-122179c90555"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:9a1ac6c5-b2ab-45da-80ef-c043ab1291af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:4cfcc4ad-be76-4ac2-8f44-c4ba0953e0f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] PRAMIPEXOLE DIHYDROCHLORIDE tablets are a non-ergot dopamine agonist indicated for the treatment of: Parkinson’s disease (PD) ( 1.1 ) Moderate-to-severe primary Restless Legs Syndrome (RLS) ( 1.2 )|[EMA] Oprymea is indicated for treatment of the signs and symptoms of idiopathic Parkinson's disease, alone (without levodopa) or in combination with levodopa, i.e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end of dose or ""on off"" fluctuations).Oprymea is indicated in adults for symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome in doses up to 0.54 mg of base (0.75 mg of salt) (see section 4.2).|[PMDA] Drugs with a new additional indication and a new dosage for the treatment of moderate to severe idiopathic restless legs syndrome." uuid:541cbbad-a9c5-4638-b79e-525310201399 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9241 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:6c541cc0-6adf-468c-9942-0ec22646d59d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:99308fb1-2038-43e0-a038-b946c9747d2e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Spironolactone tablets are an aldosterone antagonist indicated for: The treatment of NYHA Class III-IV heart failure and reduced ejection fraction to increase survival, manage edema, and to reduce the need for hospitalization for heart failure ( 1.1 ). Use as an add-on therapy for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.2 ). The management of edema in adult patients who are cirrhotic when edema is not responsive to fluid and sodium restrictions and in the setting of nephrotic syndrome when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics produce an inadequate response ( 1.3 ). Treatment of primary hyperaldosternism for: ( 1.4 ) Short-term preoperative treatment Long-term maintenance for patients with discrete aldosterone-producing adrenal adenomas who are not candidates for surgery and patients with bilateral micro or macronodular adrenal hyperplasia uuid:95280d86-ed50-448b-a35e-821cf9c3c9f1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9241 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:c5338191-83e8-400e-8eb9-f69a3175af3e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1bd0aa55-1580-4f83-b66e-4ee434fe8278"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Spironolactone tablets are an aldosterone antagonist indicated for: The treatment of NYHA Class III-IV heart failure and reduced ejection fraction to increase survival, manage edema, and to reduce the need for hospitalization for heart failure ( 1.1 ). Use as an add-on therapy for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.2 ). The management of edema in adult patients who are cirrhotic when edema is not responsive to fluid and sodium restrictions and in the setting of nephrotic syndrome when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics produce an inadequate response ( 1.3 ). Treatment of primary hyperaldosternism for: ( 1.4 ) Short-term preoperative treatment Long-term maintenance for patients with discrete aldosterone-producing adrenal adenomas who are not candidates for surgery and patients with bilateral micro or macronodular adrenal hyperplasia uuid:779e1347-ac5a-43fd-a601-8092c35234fd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16586 biolink:treats HP:0004859 PMID:41385096 "[{""id"":""uuid:fde4b2e5-9b0e-4aab-a2a5-4167ce34265b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fd25f41d-feba-4bd8-9bc1-cc4e7678f413"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AMICAR is useful in enhancing hemostasis when fibrinolysis contributes to bleeding. In life-threatening situations, transfusion of appropriate blood products and other emergency measures may be required. Fibrinolytic bleeding may frequently be associated with surgical complications following heart surgery (with or without cardiac bypass procedures) and portacaval shunt; hematological disorders such as amegakaryocytic thrombocytopenia (accompanying aplastic anemia); acute and life-threatening abruptio placentae; hepatic cirrhosis; and neoplastic disease such as carcinoma of the prostate, lung, stomach, and cervix. Urinary fibrinolysis, usually a normal physiological phenomenon, may contribute to excessive urinary tract fibrinolytic bleeding associated with surgical hematuria (following prostatectomy and nephrectomy) or nonsurgical hematuria (accompanying polycystic or neoplastic diseases of the genitourinary system). (See WARNINGS .) uuid:b19f93d1-a70d-481b-b20f-aa2a77832be3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16586 biolink:treats MONDO:0015909 PMID:41385096 "[{""id"":""uuid:06c84572-e295-46b9-8e5f-d4450cd8cbd9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bd184105-9683-4754-bd54-e6e67d6aea35"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AMICAR is useful in enhancing hemostasis when fibrinolysis contributes to bleeding. In life-threatening situations, transfusion of appropriate blood products and other emergency measures may be required. Fibrinolytic bleeding may frequently be associated with surgical complications following heart surgery (with or without cardiac bypass procedures) and portacaval shunt; hematological disorders such as amegakaryocytic thrombocytopenia (accompanying aplastic anemia); acute and life-threatening abruptio placentae; hepatic cirrhosis; and neoplastic disease such as carcinoma of the prostate, lung, stomach, and cervix. Urinary fibrinolysis, usually a normal physiological phenomenon, may contribute to excessive urinary tract fibrinolytic bleeding associated with surgical hematuria (following prostatectomy and nephrectomy) or nonsurgical hematuria (accompanying polycystic or neoplastic diseases of the genitourinary system). (See WARNINGS .) uuid:1eb8a537-37e1-4198-98f3-845e65a90df4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16586 biolink:treats MONDO:0004846 PMID:41385096 "[{""id"":""uuid:8b831c47-5318-4a6f-9e48-70eb031ee93e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2489a039-368a-486c-903e-a5586aa8dc07"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AMICAR is useful in enhancing hemostasis when fibrinolysis contributes to bleeding. In life-threatening situations, transfusion of appropriate blood products and other emergency measures may be required. Fibrinolytic bleeding may frequently be associated with surgical complications following heart surgery (with or without cardiac bypass procedures) and portacaval shunt; hematological disorders such as amegakaryocytic thrombocytopenia (accompanying aplastic anemia); acute and life-threatening abruptio placentae; hepatic cirrhosis; and neoplastic disease such as carcinoma of the prostate, lung, stomach, and cervix. Urinary fibrinolysis, usually a normal physiological phenomenon, may contribute to excessive urinary tract fibrinolytic bleeding associated with surgical hematuria (following prostatectomy and nephrectomy) or nonsurgical hematuria (accompanying polycystic or neoplastic diseases of the genitourinary system). (See WARNINGS .) uuid:a697b184-c9ba-4dfb-be94-db0f125fac77 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16586 biolink:treats MONDO:0005155 PMID:41385096 "[{""id"":""uuid:fba7f4f7-684e-419f-b632-91246772b187"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a8fe1933-6e9b-4529-b21a-24dd8e1d5d55"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AMICAR is useful in enhancing hemostasis when fibrinolysis contributes to bleeding. In life-threatening situations, transfusion of appropriate blood products and other emergency measures may be required. Fibrinolytic bleeding may frequently be associated with surgical complications following heart surgery (with or without cardiac bypass procedures) and portacaval shunt; hematological disorders such as amegakaryocytic thrombocytopenia (accompanying aplastic anemia); acute and life-threatening abruptio placentae; hepatic cirrhosis; and neoplastic disease such as carcinoma of the prostate, lung, stomach, and cervix. Urinary fibrinolysis, usually a normal physiological phenomenon, may contribute to excessive urinary tract fibrinolytic bleeding associated with surgical hematuria (following prostatectomy and nephrectomy) or nonsurgical hematuria (accompanying polycystic or neoplastic diseases of the genitourinary system). (See WARNINGS .) uuid:a682d4fb-6166-47ff-a34d-84c9f998a07e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16586 biolink:treats MONDO:0005159 PMID:41385096 "[{""id"":""uuid:25c68ec6-11c7-4b56-88e4-6159ecba4b18"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:48e6d997-fa52-438e-90d8-e2022d5bc175"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AMICAR is useful in enhancing hemostasis when fibrinolysis contributes to bleeding. In life-threatening situations, transfusion of appropriate blood products and other emergency measures may be required. Fibrinolytic bleeding may frequently be associated with surgical complications following heart surgery (with or without cardiac bypass procedures) and portacaval shunt; hematological disorders such as amegakaryocytic thrombocytopenia (accompanying aplastic anemia); acute and life-threatening abruptio placentae; hepatic cirrhosis; and neoplastic disease such as carcinoma of the prostate, lung, stomach, and cervix. Urinary fibrinolysis, usually a normal physiological phenomenon, may contribute to excessive urinary tract fibrinolytic bleeding associated with surgical hematuria (following prostatectomy and nephrectomy) or nonsurgical hematuria (accompanying polycystic or neoplastic diseases of the genitourinary system). (See WARNINGS .) uuid:7d5b8b78-4fd8-4b0a-99b5-1c1fdc2431f9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16586 biolink:treats MONDO:0006279 PMID:41385096 "[{""id"":""uuid:3735f225-7362-43f5-b2f0-7b372321e1c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:46c39aec-7698-4107-8b71-390fb4b01174"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AMICAR is useful in enhancing hemostasis when fibrinolysis contributes to bleeding. In life-threatening situations, transfusion of appropriate blood products and other emergency measures may be required. Fibrinolytic bleeding may frequently be associated with surgical complications following heart surgery (with or without cardiac bypass procedures) and portacaval shunt; hematological disorders such as amegakaryocytic thrombocytopenia (accompanying aplastic anemia); acute and life-threatening abruptio placentae; hepatic cirrhosis; and neoplastic disease such as carcinoma of the prostate, lung, stomach, and cervix. Urinary fibrinolysis, usually a normal physiological phenomenon, may contribute to excessive urinary tract fibrinolytic bleeding associated with surgical hematuria (following prostatectomy and nephrectomy) or nonsurgical hematuria (accompanying polycystic or neoplastic diseases of the genitourinary system). (See WARNINGS .) uuid:5326e23a-eb24-49d0-b2ca-fca0bb96e005 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16586 biolink:treats MONDO:0004950 PMID:41385096 "[{""id"":""uuid:95ca04fb-4a2c-406e-b06b-314b789982a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c89c2c96-a092-4837-9936-2963563a7f66"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AMICAR is useful in enhancing hemostasis when fibrinolysis contributes to bleeding. In life-threatening situations, transfusion of appropriate blood products and other emergency measures may be required. Fibrinolytic bleeding may frequently be associated with surgical complications following heart surgery (with or without cardiac bypass procedures) and portacaval shunt; hematological disorders such as amegakaryocytic thrombocytopenia (accompanying aplastic anemia); acute and life-threatening abruptio placentae; hepatic cirrhosis; and neoplastic disease such as carcinoma of the prostate, lung, stomach, and cervix. Urinary fibrinolysis, usually a normal physiological phenomenon, may contribute to excessive urinary tract fibrinolytic bleeding associated with surgical hematuria (following prostatectomy and nephrectomy) or nonsurgical hematuria (accompanying polycystic or neoplastic diseases of the genitourinary system). (See WARNINGS .) uuid:17143c02-7246-481c-b9d6-3a1a465961ce biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16586 biolink:treats MONDO:0016276 PMID:41385096 "[{""id"":""uuid:9be2b476-4232-4f8c-9a6d-4cc8b2a1b26f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2cc17abe-c19e-4c8f-a846-fae4b2d9468c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AMICAR is useful in enhancing hemostasis when fibrinolysis contributes to bleeding. In life-threatening situations, transfusion of appropriate blood products and other emergency measures may be required. Fibrinolytic bleeding may frequently be associated with surgical complications following heart surgery (with or without cardiac bypass procedures) and portacaval shunt; hematological disorders such as amegakaryocytic thrombocytopenia (accompanying aplastic anemia); acute and life-threatening abruptio placentae; hepatic cirrhosis; and neoplastic disease such as carcinoma of the prostate, lung, stomach, and cervix. Urinary fibrinolysis, usually a normal physiological phenomenon, may contribute to excessive urinary tract fibrinolytic bleeding associated with surgical hematuria (following prostatectomy and nephrectomy) or nonsurgical hematuria (accompanying polycystic or neoplastic diseases of the genitourinary system). (See WARNINGS .) uuid:f8abd3ef-835f-4794-83b5-fa04229f0df6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16586 biolink:treats MONDO:0020642 PMID:41385096 "[{""id"":""uuid:2a350e9c-d50f-4fcb-a312-45ee5919a879"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2af6ddaa-f23a-4588-b83f-9c868c8f4a5e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AMICAR is useful in enhancing hemostasis when fibrinolysis contributes to bleeding. In life-threatening situations, transfusion of appropriate blood products and other emergency measures may be required. Fibrinolytic bleeding may frequently be associated with surgical complications following heart surgery (with or without cardiac bypass procedures) and portacaval shunt; hematological disorders such as amegakaryocytic thrombocytopenia (accompanying aplastic anemia); acute and life-threatening abruptio placentae; hepatic cirrhosis; and neoplastic disease such as carcinoma of the prostate, lung, stomach, and cervix. Urinary fibrinolysis, usually a normal physiological phenomenon, may contribute to excessive urinary tract fibrinolytic bleeding associated with surgical hematuria (following prostatectomy and nephrectomy) or nonsurgical hematuria (accompanying polycystic or neoplastic diseases of the genitourinary system). (See WARNINGS .) uuid:3726f84c-7872-4f00-804e-8bcb633afd90 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16586 biolink:treats MONDO:0002118 PMID:41385096 "[{""id"":""uuid:e49dc8c1-2612-4fdf-8db1-399c8190e906"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9268f9d3-678a-428b-89a2-db093501bd21"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AMICAR is useful in enhancing hemostasis when fibrinolysis contributes to bleeding. In life-threatening situations, transfusion of appropriate blood products and other emergency measures may be required. Fibrinolytic bleeding may frequently be associated with surgical complications following heart surgery (with or without cardiac bypass procedures) and portacaval shunt; hematological disorders such as amegakaryocytic thrombocytopenia (accompanying aplastic anemia); acute and life-threatening abruptio placentae; hepatic cirrhosis; and neoplastic disease such as carcinoma of the prostate, lung, stomach, and cervix. Urinary fibrinolysis, usually a normal physiological phenomenon, may contribute to excessive urinary tract fibrinolytic bleeding associated with surgical hematuria (following prostatectomy and nephrectomy) or nonsurgical hematuria (accompanying polycystic or neoplastic diseases of the genitourinary system). (See WARNINGS .) uuid:a81f9be1-25e0-4df0-b62c-3f006153ab74 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75722 biolink:treats EFO:0020911 PMID:41385096 "[{""id"":""uuid:e3eae649-04b6-442b-bdb5-5ddbfd2e1f96"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8195dfd3-7df4-475e-bf47-7878f356f97b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tramadol hydrochloride is an opioid agonist indicated for the management of pain severe enough to require daily around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. (1) Limitations of Use Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations, reserve tramadol hydrochloride extended-release tablets for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. (1) Tramadol hydrochloride extended-release tablets are not indicated as an as-needed (prn) analgesic. (1) uuid:bba0c328-f760-4589-bae8-8ebe54605839 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18420 biolink:treats MONDO:0005081 PMID:41385096 "[{""id"":""uuid:5b63e5b9-6ae8-41e8-b9b6-9ccde5fbe9e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:46e11542-d829-48dc-ae20-a136f82a7c13"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Magnesium Sulfate Injection, USP is suitable for replacement therapy in magnesium deficiency, especially in acute hypomagnesemia accompanied by signs of tetany similar to those observed in hypocalcemia. In such cases, the serum magnesium level is usually below the lower limit of normal (1.5 to 2.5 mEq/L) and the serum calcium level is normal (4.3 to 5.3 mEq/L) or elevated. In total parenteral nutrition (TPN), magnesium sulfate may be added to the nutrient admixture to correct or prevent hypomagnesemia which can arise during the course of therapy. Magnesium sulfate injection is also indicated for the prevention and control of seizures in pre-eclampsia and eclampsia, respectively. uuid:82d420a8-5ebd-4155-add3-d0d097a7e80b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4856 biolink:treats HP:0004755 PMID:41385096 "[{""id"":""uuid:fb5ec9c1-0c31-4923-b74d-0d2afa858b2e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3297b0e1-863b-428a-8a5c-60dd4efd6bb1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:9809c98d-aade-4b3e-9862-8ecc739f2dd4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Esmolol hydrochloride in sodium chloride injection is a beta adrenergic blocker indicated for the short-term treatment of: • Control of ventricular rate in supraventricular tachycardia including atrial fibrillation and atrial flutter and control of heart rate in noncompensatory sinus tachycardia ( 1.1 ) • Control of perioperative tachycardia and hypertension ( 1.2 )|[PMDA] A drug with a new dosage indicated for the emergency treatment of supraventricular tachyarrhythmia occurring during surgery. uuid:d766c6d2-8f3e-41c7-a720-62ad8291c0d3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2676 biolink:treats MONDO:0024623 PMID:41385096 "[{""id"":""uuid:f2b28280-742b-434d-b012-61822f470e5a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:16bc8672-feeb-4e28-8983-9eec14855bb4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Infections of the Ear, Nose, and Throat Amoxicillin capsules are indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) isolates of Streptococcus species. (α- and β-hemolytic isolates only),Streptococcus pneumoniae, Staphylococcus spp., or Haemophilus influenzae. 1.2 Infections of the Genitourinary Tract Amoxicillin capsules are indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) isolates of Escherichia coli, Proteus mirabilis, or Enterococcus faecalis. 1.3 Infections of the Skin and Skin Structure Amoxicillin capsules are indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) isolates of Streptococcus spp. (α- and β-hemolytic isolates only), Staphylococcusspp., or E. coli. 1.4 Infections of the Lower Respiratory Tract Amoxicillin capsules are indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) isolates of Streptococcus spp. (α- and β-hemolytic isolates only), S. pneumoniae, Staphylococcus spp., or H. influenzae. 1.5 Helicobacter pylori Infection Triple therapy for Helicobacter pylori with clarithromycin and lansoprazole: Amoxicillin capsules in combination with clarithromycin plus lansoprazole as triple therapy, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) to eradicate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. Dual therapy for H. pylori with lansoprazole: Amoxicillin capsules, in combination with lansoprazole delayed-release capsules as dual therapy, is indicated for the treatment of patients with H. pyloriinfection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected. (See the clarithromycin package insert, MICROBIOLOGY.) Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. 1.6 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin capsules and other antibacterial drugs, amoxicillin capsules should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:4b5abbf5-6924-4d50-9298-8a461e2a3673 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:48390 biolink:treats MONDO:0005300 PMID:41385096 "[{""id"":""uuid:25c8e682-f2a5-4344-80c2-c2ae5fd812f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d9f9b4b7-6878-4316-9d82-d990224db81f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cinacalcet is a calcium-sensing receptor agonist indicated for: Secondary Hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on dialysis. ( 1.1 ) Limitations of Use : Cinacalcet hydrochloride tablets are not indicated for use in patients with CKD who are not on dialysis. Hypercalcemia in adult patients with Parathyroid Carcinoma (PC). ( 1.2 ) Severe hypercalcemia in adult patients with primary HPT who are unable to undergo parathyroidectomy. ( 1.3 ) uuid:0816974a-ec13-4362-b0c0-891b1ab9c294 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3001 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:affe04bd-bbed-454b-ae9e-53f448f34207"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9939849c-89c2-4607-8a76-7840236d80a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] QVAR ® is indicated in the maintenance treatment of asthma as prophylactic therapy in patients 5 years of age and older. Important Limitations of Use: QVAR is NOT indicated for the relief of acute bronchospasm. uuid:19a15473-3a5d-4dda-ac19-859d3f684ea1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3001 biolink:treats UMLS:C0741804 PMID:41385096 "[{""id"":""uuid:28c6c1a0-81d4-4c6c-b191-184399cadb6e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c5aecfbb-3c8e-4b34-b26b-35a790da795d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] QVAR ® is indicated in the maintenance treatment of asthma as prophylactic therapy in patients 5 years of age and older. Important Limitations of Use: QVAR is NOT indicated for the relief of acute bronchospasm. uuid:9ff01ae4-3504-42a9-93d9-0c16703e4456 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18332 biolink:treats MONDO:0006107 PMID:41385096 "[{""id"":""uuid:9df27a81-91c8-47f4-8b27-b7d654863086"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7625ca7c-e2be-4724-b28d-102fcf5a7e0a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypothyroidism Levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression Levothyroxine sodium tablets are indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer. Limitations of Use: • Levothyroxine sodium tablets are not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients as there are no clinical benefits and overtreatment with levothyroxine sodium tablets may induce hyperthyroidism [see Warnings and Precautions (5.4)]. • Levothyroxine sodium tablets are not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis. uuid:91d94e91-468c-4a4f-8362-8fc6d4646d5e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18332 biolink:treats UMLS:C5779675 PMID:41385096 "[{""id"":""uuid:e5e17060-e82f-4ab5-a7d0-7df487ee5e27"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b1e436e9-0c43-49df-8c8b-cdcc8ec41de3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypothyroidism Levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression Levothyroxine sodium tablets are indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer. Limitations of Use: • Levothyroxine sodium tablets are not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients as there are no clinical benefits and overtreatment with levothyroxine sodium tablets may induce hyperthyroidism [see Warnings and Precautions (5.4)]. • Levothyroxine sodium tablets are not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis. uuid:d2214f54-0ea5-4b9f-9f97-29ab40e0fced biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64317 biolink:treats MONDO:0008848 PMID:41385096 "[{""id"":""uuid:ca081855-4a47-4dcc-9c8a-b6f638aece84"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4d21aee6-d0f1-4aa9-9072-c387f24e1c82"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Isoproterenol hydrochloride injection is indicated: For mild or transient episodes of heart block that do not require electric shock or pacemaker therapy. For serious episodes of heart block and Adams-Stokes attacks (except when caused by ventricular tachycardia or fibrillation). (See CONTRAINDICATIONS.) For use in cardiac arrest until electric shock or pacemaker therapy, the treatments of choice, is available. (See CONTRAINDICATIONS.) For bronchospasm occurring during anesthesia. As an adjunct to fluid and electrolyte replacement therapy and the use of other drugs and procedures in the treatment of hypovolemic and septic shock, low cardiac output (hypoperfusion) states, congestive heart failure, and cardiogenic shock. (See WARNINGS.) uuid:d4582d68-09bf-4c0b-b136-6cd3f42627ea biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64317 biolink:treats MONDO:0043475 PMID:41385096 "[{""id"":""uuid:1d0c90dd-332d-47d3-953c-f9ef9c4de54a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1f11928a-d4d8-4c5c-a4b4-7fea312ac0a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Isoproterenol hydrochloride injection is indicated: For mild or transient episodes of heart block that do not require electric shock or pacemaker therapy. For serious episodes of heart block and Adams-Stokes attacks (except when caused by ventricular tachycardia or fibrillation). (See CONTRAINDICATIONS.) For use in cardiac arrest until electric shock or pacemaker therapy, the treatments of choice, is available. (See CONTRAINDICATIONS.) For bronchospasm occurring during anesthesia. As an adjunct to fluid and electrolyte replacement therapy and the use of other drugs and procedures in the treatment of hypovolemic and septic shock, low cardiac output (hypoperfusion) states, congestive heart failure, and cardiogenic shock. (See WARNINGS.) uuid:a851b519-031c-47af-a402-f288746f477d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64317 biolink:treats MONDO:0000745 PMID:41385096 "[{""id"":""uuid:e162656d-e12e-4704-89bb-22898503beb1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9d94eb18-c88f-427a-903c-6ed24cd7a5d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Isoproterenol hydrochloride injection is indicated: For mild or transient episodes of heart block that do not require electric shock or pacemaker therapy. For serious episodes of heart block and Adams-Stokes attacks (except when caused by ventricular tachycardia or fibrillation). (See CONTRAINDICATIONS.) For use in cardiac arrest until electric shock or pacemaker therapy, the treatments of choice, is available. (See CONTRAINDICATIONS.) For bronchospasm occurring during anesthesia. As an adjunct to fluid and electrolyte replacement therapy and the use of other drugs and procedures in the treatment of hypovolemic and septic shock, low cardiac output (hypoperfusion) states, congestive heart failure, and cardiogenic shock. (See WARNINGS.) uuid:18751b51-1baf-4eff-81d8-6b5b516f049b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64317 biolink:treats MONDO:0001358 PMID:41385096 "[{""id"":""uuid:c1335adc-e03d-49e2-a87f-a5ce92fff71e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7968b5e9-8237-4a8f-9a44-7c78d9f819b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Isoproterenol hydrochloride injection is indicated: For mild or transient episodes of heart block that do not require electric shock or pacemaker therapy. For serious episodes of heart block and Adams-Stokes attacks (except when caused by ventricular tachycardia or fibrillation). (See CONTRAINDICATIONS.) For use in cardiac arrest until electric shock or pacemaker therapy, the treatments of choice, is available. (See CONTRAINDICATIONS.) For bronchospasm occurring during anesthesia. As an adjunct to fluid and electrolyte replacement therapy and the use of other drugs and procedures in the treatment of hypovolemic and septic shock, low cardiac output (hypoperfusion) states, congestive heart failure, and cardiogenic shock. (See WARNINGS.) uuid:c4dd99c7-ac0d-4a9e-b1f3-bf765769bf52 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64317 biolink:treats HP:0031274 PMID:41385096 "[{""id"":""uuid:88428ea0-2b89-40ac-809b-871ab03d872c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:af568e00-9dbe-4b25-a66e-f718ffa13100"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Isoproterenol hydrochloride injection is indicated: For mild or transient episodes of heart block that do not require electric shock or pacemaker therapy. For serious episodes of heart block and Adams-Stokes attacks (except when caused by ventricular tachycardia or fibrillation). (See CONTRAINDICATIONS.) For use in cardiac arrest until electric shock or pacemaker therapy, the treatments of choice, is available. (See CONTRAINDICATIONS.) For bronchospasm occurring during anesthesia. As an adjunct to fluid and electrolyte replacement therapy and the use of other drugs and procedures in the treatment of hypovolemic and septic shock, low cardiac output (hypoperfusion) states, congestive heart failure, and cardiogenic shock. (See WARNINGS.) uuid:fc286319-189e-4c7e-b1c6-777678a32a44 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64317 biolink:treats MONDO:0001881 PMID:41385096 "[{""id"":""uuid:443795c0-a41d-4f5b-b19d-27897d80b4bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f86f9758-d700-428c-95df-373c0e4dc759"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Isoproterenol hydrochloride injection is indicated: For mild or transient episodes of heart block that do not require electric shock or pacemaker therapy. For serious episodes of heart block and Adams-Stokes attacks (except when caused by ventricular tachycardia or fibrillation). (See CONTRAINDICATIONS.) For use in cardiac arrest until electric shock or pacemaker therapy, the treatments of choice, is available. (See CONTRAINDICATIONS.) For bronchospasm occurring during anesthesia. As an adjunct to fluid and electrolyte replacement therapy and the use of other drugs and procedures in the treatment of hypovolemic and septic shock, low cardiac output (hypoperfusion) states, congestive heart failure, and cardiogenic shock. (See WARNINGS.) uuid:4a5e884b-5dc2-4035-9732-90d82d68ab33 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64317 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:2d4d0592-7cd3-4f8a-8dc4-250864e09f46"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:244fb617-29d7-402d-8384-89ee4743d984"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Isoproterenol hydrochloride injection is indicated: For mild or transient episodes of heart block that do not require electric shock or pacemaker therapy. For serious episodes of heart block and Adams-Stokes attacks (except when caused by ventricular tachycardia or fibrillation). (See CONTRAINDICATIONS.) For use in cardiac arrest until electric shock or pacemaker therapy, the treatments of choice, is available. (See CONTRAINDICATIONS.) For bronchospasm occurring during anesthesia. As an adjunct to fluid and electrolyte replacement therapy and the use of other drugs and procedures in the treatment of hypovolemic and septic shock, low cardiac output (hypoperfusion) states, congestive heart failure, and cardiogenic shock. (See WARNINGS.) uuid:0dc59efa-f308-459f-98a4-3bb589743fe8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64317 biolink:treats MONDO:0800175 PMID:41385096 "[{""id"":""uuid:62f03158-f7de-4345-bcc4-94bd4f4fc5ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c52156ac-0579-4447-a364-84ac1053b914"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Isoproterenol hydrochloride injection is indicated: For mild or transient episodes of heart block that do not require electric shock or pacemaker therapy. For serious episodes of heart block and Adams-Stokes attacks (except when caused by ventricular tachycardia or fibrillation). (See CONTRAINDICATIONS.) For use in cardiac arrest until electric shock or pacemaker therapy, the treatments of choice, is available. (See CONTRAINDICATIONS.) For bronchospasm occurring during anesthesia. As an adjunct to fluid and electrolyte replacement therapy and the use of other drugs and procedures in the treatment of hypovolemic and septic shock, low cardiac output (hypoperfusion) states, congestive heart failure, and cardiogenic shock. (See WARNINGS.) uuid:7bab353f-5dc0-49dc-b7e7-b9e1b3eab852 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16914 biolink:treats MONDO:0002406 PMID:41385096 "[{""id"":""uuid:da80d2f3-7bd8-4306-915f-fb072bf04e04"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ecc24108-f698-4f6e-a9ad-83a04da9a541"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] An external treatment for the inflammation and irritation associated with many common forms of dermatitis, including certain eczematoid conditions. These conditions include complications associated with pyodermas. Indicated also in the treatment of insect bites, burns and fungal infections. uuid:31e9f184-a445-4481-af87-88c1d54cb202 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16914 biolink:treats MONDO:0002922 PMID:41385096 "[{""id"":""uuid:4e77435a-df51-4dcf-8005-236d6896ff7d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cadb9f35-e290-40b9-a319-0c2122c6c6c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] An external treatment for the inflammation and irritation associated with many common forms of dermatitis, including certain eczematoid conditions. These conditions include complications associated with pyodermas. Indicated also in the treatment of insect bites, burns and fungal infections. uuid:161f0517-3fcc-4a59-9af1-0e2c98d32b5c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16914 biolink:treats UMLS:C0021564 PMID:41385096 "[{""id"":""uuid:8586365c-fc6b-47bd-bcfd-c660bb3946e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6bcba3ae-76c5-44e2-86ea-5fea54a081e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] An external treatment for the inflammation and irritation associated with many common forms of dermatitis, including certain eczematoid conditions. These conditions include complications associated with pyodermas. Indicated also in the treatment of insect bites, burns and fungal infections. uuid:fc73629a-9b7b-450f-bdee-c726d586d26f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16914 biolink:treats MONDO:0002041 PMID:41385096 "[{""id"":""uuid:382fb89f-3849-40d2-810d-a9af65678d6c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f0839011-d95f-4253-8fe8-fb41e41eecd6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] An external treatment for the inflammation and irritation associated with many common forms of dermatitis, including certain eczematoid conditions. These conditions include complications associated with pyodermas. Indicated also in the treatment of insect bites, burns and fungal infections. uuid:759120a0-023c-4960-8d93-4dbba718ee0c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:UMD7G2653W biolink:treats MONDO:0008159 PMID:41385096 "[{""id"":""uuid:21bc119c-fe13-44e3-a39e-0b45c1469f76"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:648dee66-2e46-478e-9c08-7cf22b160274"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ibandronate sodium injection is a bisphosphonate indicated for the treatment of osteoporosis in postmenopausal women. ( 1.1 ) Limitations of Use Optimal duration of use has not been determined. For patients at low-risk for fracture, consider drug discontinuation after 3 to 5 years of use ( 1.2 ) uuid:3f24da81-00d8-4a1d-aff2-8d1244970470 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9139 biolink:treats MONDO:0017147 PMID:41385096 "[{""id"":""uuid:1da52be6-e703-45fc-bb3a-4d7cde336221"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ffe7071e-0fc1-47b4-be63-a643a43085c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sildenafil citrate is a phosphodiesterase-5 (PDE-5) inhibitor indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group I) in adults to improve exercise ability and delay clinical worsening. Studies establishing effectiveness were short-term (12 to 16 weeks), and included predominately patients with NYHA Functional Class II-III symptoms. Etiologies were idiopathic (71%) or associated with connective tissue disease (25%). (1) Limitation of Use : Adding sildenafil to bosentan therapy does not result in any beneficial effect on exercise capacity. (1, 14) uuid:4432753b-6a71-4f53-aa35-6d6f56aae8ff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9139 biolink:treats UMLS:C3697982 PMID:41385096 "[{""id"":""uuid:4049852a-bba6-453f-bda2-439a1b2da2ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2bad9691-343a-4c1c-b791-9b4eefeb6e3c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sildenafil citrate is a phosphodiesterase-5 (PDE-5) inhibitor indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group I) in adults to improve exercise ability and delay clinical worsening. Studies establishing effectiveness were short-term (12 to 16 weeks), and included predominately patients with NYHA Functional Class II-III symptoms. Etiologies were idiopathic (71%) or associated with connective tissue disease (25%). (1) Limitation of Use : Adding sildenafil to bosentan therapy does not result in any beneficial effect on exercise capacity. (1, 14) uuid:4da4800c-31bd-44b1-b9ee-4a7bfbf0f714 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31498 biolink:treats UMLS:C0011974 PMID:41385096 "[{""id"":""uuid:b4932db1-b236-420f-a0a6-5fe54d9cef61"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1c22766e-d428-4fdd-81a0-632c3bb39f3c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the treatment and/or prevention of diaper rash Temporarily protects and helps relieve chapped or cracked skin uuid:ecaa8eca-bbf1-4042-84cb-ea8900aad784 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31498 biolink:treats UMLS:C0549202 PMID:41385096 "[{""id"":""uuid:b4269f18-7061-4e75-930d-2ef7be3f9764"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7fecf627-4ece-4ae6-ae4a-70594e97c32a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the treatment and/or prevention of diaper rash Temporarily protects and helps relieve chapped or cracked skin uuid:b2c6624a-421b-4e7c-bfab-4c9ec300c321 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31498 biolink:treats HP:0031057 PMID:41385096 "[{""id"":""uuid:6c015854-052b-437e-8c20-370da5993286"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7d6b1609-39a5-4274-804d-91b8a5008495"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the treatment and/or prevention of diaper rash Temporarily protects and helps relieve chapped or cracked skin uuid:98a5cda5-ad5c-40f2-a897-886294af2d38 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2453 biolink:treats NCIT:C141249 PMID:41385096 "[{""id"":""uuid:f24d2fdc-4d7a-48a3-83c5-0fa187d1a476"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6853632a-0bdf-4999-8bd2-6b6f5810f280"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Acyclovir Sodium Injection is indicated for the treatment of initial and recurrent mucosal and cutaneous herpes simplex (HSV-1 and HSV-2) in immunocompromised patients. uuid:05440142-f0ad-4b08-95a6-730c056572c6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2453 biolink:treats NCIT:C188484 PMID:41385096 "[{""id"":""uuid:6175774d-ffa9-4f69-b3ad-fc08073259a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:878b0309-41e3-4fa6-85f5-ed2738d9e04d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Acyclovir Sodium Injection is indicated for the treatment of initial and recurrent mucosal and cutaneous herpes simplex (HSV-1 and HSV-2) in immunocompromised patients. uuid:0e96f6f7-50ff-4459-b03a-03e6b2be0f04 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4710 biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:4baf26ac-7f56-4843-886a-b506bec74615"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0860dd11-8c55-4cee-8607-62a397cf341b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PRUDOXIN ® Cream is indicated for the short-term (up to 8 days) management of moderate pruritus in adult patients with atopic dermatitis or lichen simplex chronicus. (See DOSAGE AND ADMINISTRATION .) uuid:c985f822-7233-4ef3-b063-df611194a758 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4710 biolink:treats UMLS:C0149922 PMID:41385096 "[{""id"":""uuid:714fa56b-5708-40f3-a581-a6334f883313"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:00c08606-1ed9-467f-9f16-199c91019749"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PRUDOXIN ® Cream is indicated for the short-term (up to 8 days) management of moderate pruritus in adult patients with atopic dermatitis or lichen simplex chronicus. (See DOSAGE AND ADMINISTRATION .) uuid:a11a0dd6-ae26-4593-8f02-51a1869bd51b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0007005 PMID:41385096 "[{""id"":""uuid:0c0d09d4-5a30-4f55-b541-cf81f80b71c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cf0fcc83-ad5e-4646-89d1-c6e60b45e850"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydrocortisone Rectal Suspension, USP is indicated as adjunctive therapy in the treatment of ulcerative colitis, especially distal forms, including ulcerative proctitis, ulcerative proctosigmoiditis, and left-sided ulcerative colitis. It has proved useful also in some cases involving the transverse and ascending colons. uuid:f2e20715-f995-47d6-8e86-191d9e876e86 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5132 biolink:treats MONDO:0004956 PMID:41385096 "[{""id"":""uuid:aea07229-6c28-4cdf-a91c-d289918df095"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bae8fd11-a680-4afd-87ca-c3705488c53e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Flutamide capsules are indicated for use in combination with LHRH agonists for the management of locally confined Stage B 2 -C and Stage D 2 metastatic carcinoma of the prostate. uuid:d58da43a-92c4-4fb9-a5fa-606985aef886 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5132 biolink:treats MONDO:0005159 PMID:41385096 "[{""id"":""uuid:8bc71177-255b-4030-8419-c2037303e3c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:49a635c5-0bab-46cb-8faa-e49eae66d3e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Flutamide capsules are indicated for use in combination with LHRH agonists for the management of locally confined Stage B 2 -C and Stage D 2 metastatic carcinoma of the prostate. uuid:d4cd060f-0a38-4aed-af39-f8ce27ce68f0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32588 biolink:treats MONDO:0003019 PMID:41385096 "[{""id"":""uuid:2995a496-37b7-4705-9905-7bdcaf7782ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:df470003-08bc-434f-9bc8-741c7bc6726f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Potassium Chloride is indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient. uuid:b9f030b9-a5e5-470b-940f-ac151165bce2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32588 biolink:treats HP:0200114 PMID:41385096 "[{""id"":""uuid:de547ed7-06fa-485e-ab61-d7ca710a56d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6f75e9b1-aa19-4c92-99a8-e22723232380"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Potassium Chloride is indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient. uuid:8b4f5f3e-1734-44f5-8ab6-4922039a7eb5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:187893 biolink:treats MONDO:0014115 PMID:41385096 "[{""id"":""uuid:3a195efa-bd82-4373-b256-d4f50e5ef630"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:87aba29f-7461-434c-8e7d-86b4e3f29d33"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Baclofen Injection (Intrathecal) is indicated for use in the management of severe spasticity. Patients should first respond to a screening dose of intrathecal baclofen prior to consideration for long term infusion via an implantable pump. For spasticity of spinal cord origin, chronic infusion of Baclofen Injection (Intrathecal) via an implantable pump should be reserved for patients unresponsive to oral baclofen therapy, or those who experience intolerable CNS side effects at effective doses. Patients with spasticity due to traumatic brain injury should wait at least one year after the injury before consideration of long term intrathecal baclofen therapy. Baclofen Injection (Intrathecal) is intended for use by the intrathecal route in single bolus test doses (via spinal catheter or lumbar puncture) and, for chronic use, only in implantable pumps approved by the FDA specifically for the administration of Baclofen Injection (Intrathecal) into the intrathecal space. uuid:ae300d1a-e380-483e-9c5e-17fb98db9d48 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8093 biolink:treats MONDO:0005468 PMID:41385096 "[{""id"":""uuid:91f10aff-f339-4ca4-aa40-425a006aad12"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c68fa0d7-90ce-4190-a888-09187885b608"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Phenylephrine hydrochloride is an alpha-1 adrenergic receptor agonist indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia. ( 1 ) uuid:ce6cd2b6-0bc3-4cf3-9a6d-7cb025b326b4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7596 biolink:treats HP:0100735 PMID:41385096 "[{""id"":""uuid:6483d36a-c142-4ab9-a4d4-6839489422c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d5cdd271-9eff-4edc-89ee-49be92d123ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium nitroprusside is indicated for the immediate reduction of blood pressure of adult and pediatric patients in hypertensive crises. Concomitant longer-acting antihypertensive medication should be administered so that the duration of treatment with sodium nitroprusside can be minimized. Sodium nitroprusside is also indicated for producing controlled hypotension in order to reduce bleeding during surgery. Sodium nitroprusside is also indicated for the treatment of acute congestive heart failure. uuid:54b65f0c-b0bc-4a8c-9e9a-06edcc2f4971 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7596 biolink:treats UMLS:C0264719 PMID:41385096 "[{""id"":""uuid:1028b32d-f3d5-44f1-a4fd-91129e41efdc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cf1cd480-9338-4cd2-9509-28e54f918803"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium nitroprusside is indicated for the immediate reduction of blood pressure of adult and pediatric patients in hypertensive crises. Concomitant longer-acting antihypertensive medication should be administered so that the duration of treatment with sodium nitroprusside can be minimized. Sodium nitroprusside is also indicated for producing controlled hypotension in order to reduce bleeding during surgery. Sodium nitroprusside is also indicated for the treatment of acute congestive heart failure. uuid:80fd740b-ba34-4ce7-84bd-b952ec9a44f7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:WA16A5Y52X biolink:treats MONDO:0002629 PMID:41385096 "[{""id"":""uuid:5004c992-3ab9-41dc-8d46-1c7539575df7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:59d4c4ee-4e72-48a5-88c3-493438263fa2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levoleucovorin injection is a folate analog. Levoleucovorin injection rescue is indicated after high-dose methotrexate therapy in osteosarcoma. Levoleucovorin injection is also indicated to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists. Levoleucovorin injection is indicated for use in combination chemotherapy with 5-fluorouracil in the palliative treatment of patients with advanced metastatic colorectal cancer. PUBCHEM.COMPOUND:135465090 uuid:f74bf35d-31a7-4da2-82d1-fa0c960b5c51 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:WA16A5Y52X biolink:treats MONDO:0005575 PMID:41385096 "[{""id"":""uuid:c80bc8ee-092a-4173-bd34-9ff7be39944e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0ce397ae-87b0-4710-ba80-7c36991b6a4d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levoleucovorin injection is a folate analog. Levoleucovorin injection rescue is indicated after high-dose methotrexate therapy in osteosarcoma. Levoleucovorin injection is also indicated to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists. Levoleucovorin injection is indicated for use in combination chemotherapy with 5-fluorouracil in the palliative treatment of patients with advanced metastatic colorectal cancer. PUBCHEM.COMPOUND:135465090 uuid:b9290126-1ab2-4d4c-a4bc-c9fc80b969d0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2038 biolink:treats MONDO:0005272 PMID:41385096 "[{""id"":""uuid:efcfe89d-e4d6-4091-8e55-a262bb718a12"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:49ae0b8a-84fb-489e-a72d-04942b831236"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azacitidine for injection is a nucleoside metabolic inhibitor indicated for the treatment of patients with the following FAB myelodysplastic syndrome (MDS) subtypes: Refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL). (1) uuid:787442b6-0cb4-4541-869f-c8083030bf58 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2038 biolink:treats MONDO:0019157 PMID:41385096 "[{""id"":""uuid:91673a7f-91c4-418c-97f0-d9300dbac10a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f354d2fa-5339-4a90-b531-cc9d4f9c9eea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azacitidine for injection is a nucleoside metabolic inhibitor indicated for the treatment of patients with the following FAB myelodysplastic syndrome (MDS) subtypes: Refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL). (1) uuid:e63c9667-598b-4086-969b-11dc9cbf14f8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2038 biolink:treats MONDO:0019454 PMID:41385096 "[{""id"":""uuid:e6467e8f-3b2f-4a43-a0fc-8184c87b165a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:63c9f59a-f3ec-4b54-aa02-894480e4d0c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ba124d3d-9621-4017-a617-7a9ca42f0873"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/azacitidine-mylan""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azacitidine for injection is a nucleoside metabolic inhibitor indicated for the treatment of patients with the following FAB myelodysplastic syndrome (MDS) subtypes: Refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL). (1)|[EMA] Vidaza is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (HSCT) with: intermediate 2 and high-risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System (IPSS),chronic myelomonocytic leukaemia (CMML) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (AML) with 20 30 % blasts and multi-lineage dysplasia, according to World Health Organisation (WHO) classification.Vidaza is indicated for the treatment of adult patients aged 65 years or older who are not eligible for HSCT with AML with >30% marrow blasts according to the WHO classification. uuid:033aaa45-40e1-435d-972e-dff319d16bc1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2038 biolink:treats MONDO:0015692 PMID:41385096 "[{""id"":""uuid:879d6fe7-f297-4ffc-9acd-a8b70e5fdcb0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f7a80408-4a10-446f-b38e-970f6d84049a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azacitidine for injection is a nucleoside metabolic inhibitor indicated for the treatment of patients with the following FAB myelodysplastic syndrome (MDS) subtypes: Refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL). (1) uuid:5fdb7a2d-541f-4dd5-845f-ace19995971c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2038 biolink:treats MONDO:0020311 PMID:41385096 "[{""id"":""uuid:cb2609cc-d062-4051-be5d-04983c2e2c67"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:953e7903-64c6-4761-890c-145b400500a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e793fa89-bf62-4511-83af-851d0e3db229"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/azacitidine-mylan""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azacitidine for injection is a nucleoside metabolic inhibitor indicated for the treatment of patients with the following FAB myelodysplastic syndrome (MDS) subtypes: Refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL). (1)|[EMA] Azacitidine Mylan is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (HSCT) with:intermediate 2 and high risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System (IPSS),chronic myelomonocytic leukaemia (CMML) with 10 29% marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (AML) with 20 30% blasts and multi lineage dysplasia, according to World Health Organisation (WHO) classification,AML with > 30% marrow blasts according to the WHO classification. uuid:4d4346f0-425c-4d3b-8b76-b14ccde3ae50 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4B33BGI082 biolink:treats HP:0003124 PMID:41385096 "[{""id"":""uuid:5d5c8380-5171-4e78-8eac-e49ac3a11bea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7fe713fc-4c39-4f5d-a49e-f4d1e62ccf47"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1) Cholestyramine for oral suspension USP light powder, is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet. Cholestyramine for oral suspension USP light powder may be useful to lower LDL cholesterol in patients who also have hypertriglyceridemia, but it is not indicated where hypertriglyceridemia is the abnormality of most concern. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Treatment should begin and continue with dietary therapy specific for the type of hyperlipoproteinemia determined prior to initiation of drug therapy. Excess body weight may be an important factor and caloric restriction for weight normalization should be addressed prior to drug therapy in the overweight. Prior to initiating therapy with cholestyramine for oral suspension USP light powder secondary causes of hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism), should be excluded, and a lipid profile performed to assess Total cholesterol, HDL-C, and triglycerides (TG). For individuals with TG less than 400 mg/dL (< 4.5 mmol/L), LDL-C can be estimated using the following equation:- LDL-C = Total cholesterol – [(TG/5) + HDL-C] For TG levels > 400 mg/dL, this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated Total-C. In such cases cholestyramine for oral suspension USP light powder may not be indicated. Serum cholesterol and triglyceride levels should be determined periodically based on NCEP guidelines to confirm initial and adequate long-term response. A favorable trend in cholesterol reduction should occur during the first month of cholestyramine for oral suspension USP light powder therapy. The therapy should be continued to sustain cholesterol reduction. If adequate cholesterol reduction is not attained, increasing the dosage of cholestyramine for oral suspension USP light powder or adding other lipid-lowering agents in combination with cholestyramine for oral suspension USP light powder should be considered. Since the goal of treatment is to lower LDL-C, the NCEP 4 recommends that LDL-C levels be used to initiate and assess treatment response. If LDL-C levels are not available then Total-C alone may be used to monitor long-term therapy. A lipoprotein analysis (including LDL-C determination) should be carried out once a year. The NCEP treatment guidelines are summarized below. * Coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease). * * Other risk factors for coronary heart disease (CHD) include: age (males ≥ 45 years; females ≥ 55 years or premature menopause without estrogen replacement therapy); family history of premature CHD; current cigarette smoking; hypertension; confirmed HDL-C < 35 mg/dL (< 0.91 mmol/L); and diabetes mellitus. Subtract one risk factor if HDL-C is ≥ 60 mg/dL (≥ 1.6 mmol/L). LDL - Cholesterol mg / dL ( mmol / L ) Definite Atherosclerotic Disease * Two or More Other Risk Factors ** Initiation Level Goal NO NO ≥ 190 (≥ 4.9) < 160 (< 4.1) NO YES ≥ 160 (≥ 4.1) < 130 (< 3.4) YES YES OR NO ≥ 130 (≥ 3.4) ≤ 100 ( ≤ 2.6) Cholestyramine for oral suspension USP light powder monotherapy has been demonstrated to retard the rate of progression 2,3 and increase the rate of regression 3 of coronary atherosclerosis. 2) Cholestyramine for oral suspension USP light powder is indicated for the relief of pruritus associated with partial biliary obstruction. Cholestyramine for oral suspension USP light powder has been shown to have a variable effect on serum cholesterol in these patients. Patients with primary biliary cirrhosis may exhibit an elevated cholesterol as part of their disease. uuid:c45d5296-8d16-4d0d-962d-6a043fa03cc8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4B33BGI082 biolink:treats MONDO:0021661 PMID:41385096 "[{""id"":""uuid:d2fb5165-ada2-4a6e-be44-15ced30ba5b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bda6ce74-9225-40c7-9165-351b984ef73d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1) Cholestyramine for oral suspension USP light powder, is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet. Cholestyramine for oral suspension USP light powder may be useful to lower LDL cholesterol in patients who also have hypertriglyceridemia, but it is not indicated where hypertriglyceridemia is the abnormality of most concern. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Treatment should begin and continue with dietary therapy specific for the type of hyperlipoproteinemia determined prior to initiation of drug therapy. Excess body weight may be an important factor and caloric restriction for weight normalization should be addressed prior to drug therapy in the overweight. Prior to initiating therapy with cholestyramine for oral suspension USP light powder secondary causes of hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism), should be excluded, and a lipid profile performed to assess Total cholesterol, HDL-C, and triglycerides (TG). For individuals with TG less than 400 mg/dL (< 4.5 mmol/L), LDL-C can be estimated using the following equation:- LDL-C = Total cholesterol – [(TG/5) + HDL-C] For TG levels > 400 mg/dL, this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated Total-C. In such cases cholestyramine for oral suspension USP light powder may not be indicated. Serum cholesterol and triglyceride levels should be determined periodically based on NCEP guidelines to confirm initial and adequate long-term response. A favorable trend in cholesterol reduction should occur during the first month of cholestyramine for oral suspension USP light powder therapy. The therapy should be continued to sustain cholesterol reduction. If adequate cholesterol reduction is not attained, increasing the dosage of cholestyramine for oral suspension USP light powder or adding other lipid-lowering agents in combination with cholestyramine for oral suspension USP light powder should be considered. Since the goal of treatment is to lower LDL-C, the NCEP 4 recommends that LDL-C levels be used to initiate and assess treatment response. If LDL-C levels are not available then Total-C alone may be used to monitor long-term therapy. A lipoprotein analysis (including LDL-C determination) should be carried out once a year. The NCEP treatment guidelines are summarized below. * Coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease). * * Other risk factors for coronary heart disease (CHD) include: age (males ≥ 45 years; females ≥ 55 years or premature menopause without estrogen replacement therapy); family history of premature CHD; current cigarette smoking; hypertension; confirmed HDL-C < 35 mg/dL (< 0.91 mmol/L); and diabetes mellitus. Subtract one risk factor if HDL-C is ≥ 60 mg/dL (≥ 1.6 mmol/L). LDL - Cholesterol mg / dL ( mmol / L ) Definite Atherosclerotic Disease * Two or More Other Risk Factors ** Initiation Level Goal NO NO ≥ 190 (≥ 4.9) < 160 (< 4.1) NO YES ≥ 160 (≥ 4.1) < 130 (< 3.4) YES YES OR NO ≥ 130 (≥ 3.4) ≤ 100 ( ≤ 2.6) Cholestyramine for oral suspension USP light powder monotherapy has been demonstrated to retard the rate of progression 2,3 and increase the rate of regression 3 of coronary atherosclerosis. 2) Cholestyramine for oral suspension USP light powder is indicated for the relief of pruritus associated with partial biliary obstruction. Cholestyramine for oral suspension USP light powder has been shown to have a variable effect on serum cholesterol in these patients. Patients with primary biliary cirrhosis may exhibit an elevated cholesterol as part of their disease. uuid:a3a45ae9-3ad2-4ab5-8962-d3e668e99d92 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:284544 biolink:treats HP:0040137 PMID:41385096 "[{""id"":""uuid:b4281ed5-0776-439c-a8fa-d55970a54cae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ce74cc67-8075-4fdb-980d-494a7b6feba3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clindamycin phosphate and benzoyl peroxide gel is a combination of clindamycin phosphate (a lincosamide antibacterial) and benzoyl peroxide indicated for the topical treatment of inflammatory acne vulgaris. ( 1.1 ) Limitation of Use: Clindamycin phosphate and benzoyl peroxide gel has not been demonstrated to have any additional benefit when compared with benzoyl peroxide alone in the same vehicle when used for the treatment of non-inflammatory acne. ( 1.2 ) uuid:d1f284ea-9205-4ca8-88ef-b2594687fbec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63632 biolink:treats MONDO:0008433 PMID:41385096 "[{""id"":""uuid:f08151a8-cf8f-4e1b-8870-4f06c34c3c52"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:e5f1c84b-18f3-4a30-a6ca-62815762bebb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:054e59a3-4944-40d4-b59f-07e3781643c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/hycamtin""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Topotecan hydrochloride for injection is indicated for the treatment of: Small cell lung cancer sensitive disease after failure of first-line chemotherapy. In clinical studies submitted to support approval, sensitive disease was defined as disease responding to chemotherapy but subsequently progressing at least 60 days (in the Phase 3 study) or at least 90 days (in the Phase 2 studies) after chemotherapy [see Clinical Studies (14 ) ]. Topotecan hydrochloride for injection in combination with cisplatin is indicated for the treatment of: stage IV-B, recurrent, or persistent carcinoma of the cervix which is not amenable to curative treatment with surgery and/or radiation therapy.|[EMA] Hycamtin capsules are indicated as monotherapy for the treatment of adult patients with relapsed small cell lung cancer (SCLC) for whom re-treatment with the first-line regimen is not considered appropriate.Topotecan is indicated for the treatment of patients with metastatic carcinoma of the ovary after failure of first-line or subsequent therapy.Hycamtin capsules are indicated as monotherapy for the treatment of adult patients with relapsed small cell lung cancer (SCLC) for whom re-treatment with the first-line regimen is not considered appropriate. uuid:d2c4cb6c-0fa8-46e8-8983-07795a47d724 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63632 biolink:treats MONDO:0016276 PMID:41385096 "[{""id"":""uuid:a0d323c0-5e5c-412d-9a04-248166ef6747"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8c61c201-de84-41f3-bb90-e7dd73a8e201"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Topotecan hydrochloride for injection is indicated for the treatment of: Small cell lung cancer sensitive disease after failure of first-line chemotherapy. In clinical studies submitted to support approval, sensitive disease was defined as disease responding to chemotherapy but subsequently progressing at least 60 days (in the Phase 3 study) or at least 90 days (in the Phase 2 studies) after chemotherapy [see Clinical Studies (14 ) ]. Topotecan hydrochloride for injection in combination with cisplatin is indicated for the treatment of: stage IV-B, recurrent, or persistent carcinoma of the cervix which is not amenable to curative treatment with surgery and/or radiation therapy. uuid:84893785-f743-4f1c-9426-919fa8aff68c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63618 biolink:treats UMLS:C0856526 PMID:41385096 "[{""id"":""uuid:4facdfb6-973f-45a3-a62b-bdfc3f9305f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0f58305a-4065-42c6-b324-6dfb73478e82"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pravastatin sodium tablets are an HMG-CoA reductase inhibitor (statin) indicated as an adjunctive therapy to diet to: Reduce the risk of MI, revascularization, and cardiovascular mortality in hypercholesterolemic patients without clinically evident CHD. ( 1.1 ) Reduce the risk of total mortality by reducing coronary death, MI, revascularization, stroke/TIA, and the progression of coronary atherosclerosis in patients with clinically evident CHD. ( 1.1 ) Reduce elevated Total-C, LDL-C, ApoB, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia and mixed dyslipidemia. ( 1.2 ) Reduce elevated serum TG levels in patients with hypertriglyceridemia.( 1.2 ) Treat patients with primary dysbetalipoproteinemia who are not responding to diet. ( 1.2 ) Treat children and adolescent patients ages 8 years and older with heterozygous familial hypercholesterolemia after failing an adequate trial of diet therapy. ( 1.2 ) Limitations of use: Pravastatin sodium tablets have not been studied in Fredrickson Types I and V dyslipidemias. ( 1.3 ) uuid:f61ee5f2-7056-4d2f-87ee-282cac5dc129 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63618 biolink:treats MONDO:0007762 PMID:41385096 "[{""id"":""uuid:70c56b84-22ce-470f-9a79-2ab5e08e518b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ede71df4-41fd-446e-8a60-b949feceff1d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pravastatin sodium tablets are an HMG-CoA reductase inhibitor (statin) indicated as an adjunctive therapy to diet to: Reduce the risk of MI, revascularization, and cardiovascular mortality in hypercholesterolemic patients without clinically evident CHD. ( 1.1 ) Reduce the risk of total mortality by reducing coronary death, MI, revascularization, stroke/TIA, and the progression of coronary atherosclerosis in patients with clinically evident CHD. ( 1.1 ) Reduce elevated Total-C, LDL-C, ApoB, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia and mixed dyslipidemia. ( 1.2 ) Reduce elevated serum TG levels in patients with hypertriglyceridemia.( 1.2 ) Treat patients with primary dysbetalipoproteinemia who are not responding to diet. ( 1.2 ) Treat children and adolescent patients ages 8 years and older with heterozygous familial hypercholesterolemia after failing an adequate trial of diet therapy. ( 1.2 ) Limitations of use: Pravastatin sodium tablets have not been studied in Fredrickson Types I and V dyslipidemias. ( 1.3 ) uuid:58958593-d92a-400f-b924-479e8c6fc999 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85157 biolink:treats HP:0002018 PMID:41385096 "[{""id"":""uuid:92f87c92-14d6-445c-a8d9-e610f9c967d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0cdf5c9d-71b2-493c-980e-3db400d006d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:3bbb6f71-8ca3-451d-9cea-8a45f1d22835"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:fa990299-6d24-426d-989c-acfff435b459"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Palonosetron Hydrochloride (HCl) Injection is a serotonin-3 (5-HT 3 ) receptor antagonist indicated in adults for: • Moderately emetogenic cancer chemotherapy – prevention of acute and delayed nausea and vomiting associated with initial and repeat courses ( 1.1 ) • Highly emetogenic cancer chemotherapy – prevention of acute nausea and vomiting associated with initial and repeat courses ( 1.1 )|[EMA] Aloxi is indicated in adults for:the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy,the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.Aloxi is indicated in paediatric patients 1 month of age and older for:the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy and prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.|[PMDA] A drug with a new active ingredient indicated for the treatment of digestive symptoms (nausea and vomiting, including delayed phase) resulting from the administration of antineoplastic agents (cisplatin, etc.). uuid:d312e03f-bd39-4421-bb97-c21d12531e9a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85157 biolink:treats HP:0002013 PMID:41385096 "[{""id"":""uuid:7f63d377-60d4-4d9b-b7f0-a93523cd3ab9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b8394920-c4bd-4169-8e74-c54e87e83e6d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:44f66afa-818e-4d0b-b0e6-b496711f3695"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:da69526c-ba1d-4a35-9976-ddf5aa784270"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Palonosetron Hydrochloride (HCl) Injection is a serotonin-3 (5-HT 3 ) receptor antagonist indicated in adults for: • Moderately emetogenic cancer chemotherapy – prevention of acute and delayed nausea and vomiting associated with initial and repeat courses ( 1.1 ) • Highly emetogenic cancer chemotherapy – prevention of acute nausea and vomiting associated with initial and repeat courses ( 1.1 )|[EMA] Aloxi is indicated in adults for:the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy,the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.Aloxi is indicated in paediatric patients 1 month of age and older for:the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy and prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.|[PMDA] A drug with a new active ingredient indicated for the treatment of digestive symptoms (nausea and vomiting, including delayed phase) resulting from the administration of antineoplastic agents (cisplatin, etc.). uuid:2ffbd42c-190d-4f7f-8054-ffb6fe75df01 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:218445 biolink:treats MONDO:0000257 PMID:41385096 "[{""id"":""uuid:0129ef7e-5d7c-4008-9b81-3ee7c522df51"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bd1badb7-7eee-4877-b201-074b11db9d37"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MOTOFEN® is indicated as adjunctive therapy in the management of acute nonspecific diarrhea and acute exacerbations of chronic functional diarrhea. uuid:75be2d9f-c119-487b-b442-78d237a9efa2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:218445 biolink:treats MONDO:0001272 PMID:41385096 "[{""id"":""uuid:3f569da9-4fc6-4197-8776-85fa732ef336"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:48c934a3-5415-481e-9f6a-4c08c6a09038"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MOTOFEN® is indicated as adjunctive therapy in the management of acute nonspecific diarrhea and acute exacerbations of chronic functional diarrhea. uuid:2e03cde4-2014-433d-a6e2-4ffe2166f399 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7773 biolink:treats HP:0002017 PMID:41385096 "[{""id"":""uuid:eb9d3065-df67-454e-b8af-ef0d10e202ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:73188715-4329-4e21-aed2-e9e9f23f1a79"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ondansetron Injection, USP is a 5-HT 3 receptor antagonist indicated for the prevention of: • nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy. ( 1.1 ) • postoperative nausea and/or vomiting. ( 1.2 ) uuid:0fdd9c23-f213-4c40-966b-f31e0c27e600 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7773 biolink:treats EFO:0004888 PMID:41385096 "[{""id"":""uuid:97043b09-6086-47cc-9204-13d344f9d959"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8e9a0156-a4eb-42d1-9740-bb31621068c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ondansetron Injection, USP is a 5-HT 3 receptor antagonist indicated for the prevention of: • nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy. ( 1.1 ) • postoperative nausea and/or vomiting. ( 1.2 ) uuid:f4356302-caa6-479a-8272-31677aed4541 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7575 biolink:treats MONDO:0005099 PMID:41385096 "[{""id"":""uuid:f992d448-4bf0-4d7c-a763-5e2ea0303b1d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ae34cd33-b60e-458b-94b8-0246c122f8c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nimodipine is indicated for the improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in patients with subarachnoid hemorrhage from ruptured intracranial berry aneurysms regardless of their post-ictus neurological condition (i.e., Hunt and Hess Grades I-V). uuid:85f62741-4632-4d62-beab-59e815bf96ee biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7575 biolink:treats MONDO:0005299 PMID:41385096 "[{""id"":""uuid:aabbf63a-c89d-4fff-a5e0-a858f5e67218"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b0a8ce97-cc01-4e8e-aa50-ec48af5e95bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nimodipine is indicated for the improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in patients with subarachnoid hemorrhage from ruptured intracranial berry aneurysms regardless of their post-ictus neurological condition (i.e., Hunt and Hess Grades I-V). uuid:5b0c59fe-1558-4559-8b6c-ea92ec0bbd88 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63613 biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:f7667cb1-493f-4e7b-a35a-3de12eaceb7b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d8c7327d-5fac-4afc-b508-7ee20b92c7f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nevirapine is an NNRTI indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV-1) infection in adults and pediatric patients 15 days and older. ( 1 ) Limitations of Use: Based on serious and life-threatening hepatotoxicity observed in controlled and uncontrolled trials, nevirapine is not recommended to be initiated, unless the benefit outweighs the risk, in: adult females with CD4 + cell counts greater than 250 cells/mm 3 adult males with CD4 + cell counts greater than 400 cells/mm 3 ( 1 , 5.1 ) uuid:2333b707-0259-4f53-b82e-651ad0b2fe23 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:114785 biolink:treats UMLS:C0278987 PMID:41385096 "[{""id"":""uuid:012a38d3-f0f9-49c5-8b25-ab2f86fef525"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ccc428bf-53bb-4c64-882b-29358752df37"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TARCEVA is a kinase inhibitor indicated for: • The treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test receiving first-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen. ( 1.1 ) • First-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer, in combination with gemcitabine. ( 1.2 ) Limitations of Use: • Safety and efficacy of TARCEVA have not been established in patients with NSCLC whose tumors have other EGFR mutations. ( 1.1 ) • TARCEVA is not recommended for use in combination with platinum-based chemotherapy. ( 1.1 ) uuid:3f16a6e1-b5b7-4989-abdc-0325bd0fe3e3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:114785 biolink:treats MONDO:0009831 PMID:41385096 "[{""id"":""uuid:5e52995c-87ba-4560-9cdf-70a204e8b6d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:5ff05735-e658-463a-9535-3769839bfbdf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:aeaece15-a74c-4f59-8d2b-6e63c1c25642"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/tarceva""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] TARCEVA is a kinase inhibitor indicated for: • The treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test receiving first-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen. ( 1.1 ) • First-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer, in combination with gemcitabine. ( 1.2 ) Limitations of Use: • Safety and efficacy of TARCEVA have not been established in patients with NSCLC whose tumors have other EGFR mutations. ( 1.1 ) • TARCEVA is not recommended for use in combination with platinum-based chemotherapy. ( 1.1 )|[EMA] Non-small cell lung cancer (NSCLC)Tarceva is also indicated for switch maintenance treatment in patients with locally advanced or metastatic non-small cell lung cancer with EGFR activating mutations and stable disease after first-line chemotherapy.Tarceva is also indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.In patients with tumours without EGFR activating mutations, Tarceva is indicated when other treatment options are not considered suitable.When prescribing Tarceva, factors associated with prolonged survival should be taken into account.No survival benefit or other clinically relevant effects of the treatment have been demonstrated in patients with Epidermal Growth Factor Receptor (EGFR)-IHC - negative tumours.Pancreatic cancerTarceva in combination with gemcitabine is indicated for the treatment of patients with metastatic pancreatic cancer.When prescribing Tarceva, factors associated with prolonged survival should be taken into account. uuid:6e7fc50c-e755-4647-a3e1-20434cd7d843 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1152286 biolink:treats MONDO:0006652 PMID:41385096 "[{""id"":""uuid:566d7172-287f-4ede-b675-b62902ec5c1a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b3a60e6a-7950-46ae-9a38-fe5651299048"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amlodipine and olmesartan medoxomil tablets are indicated for the treatment of hypertension, alone or with other antihypertensive agents, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with amlodipine and olmesartan medoxomil tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Amlodipine and olmesartan medoxomil tablets may also be used as initial therapy in patients who are likely to need multiple antihypertensive agents to achieve their blood pressure goals. Patients with moderate or severe hypertension are at relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. The decision to use a combination as initial therapy should be individualized and should be shaped by considerations such as baseline blood pressure, the target goal, and the incremental likelihood of achieving goal with a combination compared to monotherapy. Individual blood pressure goals may vary based upon the patient’s risk. Data from an 8-week, placebo-controlled, parallel-group factorial study [ see Clinical Studies ( 14.1 ) ] provide estimates of the probability of reaching a blood pressure goal with amlodipine and olmesartan medoxomil tablets compared to amlodipine or olmesartan medoxomil monotherapy. The figures below provide estimates of the likelihood of achieving the targeted systolic or diastolic blood pressure goals with amlodipine and olmesartan medoxomil tablets, 10 mg/40 mg compared with amlodipine or olmesartan medoxomil monotherapy, based upon baseline systolic or diastolic blood pressure. The curve of each treatment group was estimated by logistic regression modeling from all available data of that treatment group. The right tail of each curve is less reliable because of small numbers of subjects with high baseline blood pressures. The figures above provide an approximation of the likelihood of reaching a targeted blood pressure goal (e.g., Week 8 SBP < 140 mmHg or < 130 mmHg or a DBP < 90 mmHg or < 80 mmHg) for the high-dose treatment groups evaluated in the study. Amlodipine and olmesartan medoxomil tablets, 5 mg/20 mg, the lowest dose combination treatment group, increases the probability of reaching blood pressure goal compared with the highest dose monotherapies, amlodipine 10 mg and olmesartan medoxomil 40 mg. For example, a patient with a baseline blood pressure of 160/100 mmHg has about a 48% likelihood of achieving a goal of < 140 mmHg (systolic) and a 51% likelihood of achieving a goal of < 90 mmHg (diastolic) on monotherapy with olmesartan medoxomil 40 mg, and about a 46% likelihood of achieving a goal of < 140 mmHg (systolic) and a 60% likelihood of achieving a goal of < 90 mmHg (diastolic) on monotherapy with amlodipine 10 mg. The likelihood of achieving these same goals increases to 63% (systolic) and 71% (diastolic) on amlodipine and olmesartan medoxomil tablets, 5 mg/20 mg, and to 68% (systolic) and 85% (diastolic) on amlodipine and olmesartan medoxomil tablets, 10 mg/40 mg. uuid:8871b86b-5913-4b48-b040-d0e94b001c3e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0010643 PMID:41385096 "[{""id"":""uuid:b546ed3d-ed5d-4480-ae98-6c7f964abac6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:479cc69c-f61f-4dd8-a8fd-397f328881a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine Disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases: During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases: Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases: Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases: Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders: Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases: For palliative management of: Leukemia and lymphomas in adults Acute leukemia of childhood 10. Edematous States: To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases: To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous: Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement 13. Diagnostic testing of adrenocortical hyperfunction. uuid:2bd33c65-d309-4e3a-8094-d63af4e64bec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:722125 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:e6e88731-ae09-4e24-808a-7826323ae65c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e27f8b7d-9ec0-4e47-9f8c-d755196bd4b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amlodipine and valsartan tablet is the combination tablet of amlodipine, a dihydropyridine calcium channel blocker (DHP CCB), and valsartan, an angiotensin II receptor blocker (ARB). Amlodipine and valsartan tablets are indicated for the treatment of hypertension, to lower blood pressure: In patients not adequately controlled on monotherapy ( 1 ) As initial therapy in patients likely to need multiple drugs to achieve their blood pressure goals ( 1 ). Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. uuid:34f8940d-17fa-4edc-9693-a9473d97cc51 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:722125 biolink:treats MONDO:0006652 PMID:41385096 "[{""id"":""uuid:19c2d412-d0d1-4f1c-a65f-a8f7b605b345"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:95da2984-fa1d-442d-bd64-ee767a985e22"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amlodipine and valsartan tablet is the combination tablet of amlodipine, a dihydropyridine calcium channel blocker (DHP CCB), and valsartan, an angiotensin II receptor blocker (ARB). Amlodipine and valsartan tablets are indicated for the treatment of hypertension, to lower blood pressure: In patients not adequately controlled on monotherapy ( 1 ) As initial therapy in patients likely to need multiple drugs to achieve their blood pressure goals ( 1 ). Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. uuid:d1dfcefd-a69c-4c3a-ae9a-bfad647c154f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9434 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:7e6dd58e-edc4-44ee-8196-b87585542493"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3999e9d4-e2b8-4f34-8a76-bd4d9f108717"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Telmisartanis an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions(1.1) uuid:c7b47c1d-bf80-48b1-8768-cccd94d03e6a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9434 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:dd7d546d-008a-43c7-bcf9-6a8982e40127"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:6de3436a-a1f4-4766-998f-8652a107e73f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:54d0a92a-f568-4d6c-9f95-8912a8cb768f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/telmisartan-actavis""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Telmisartanis an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions(1.1)|[EMA] HypertensionTreatment of essential hypertension in adults.Cardiovascular preventionReduction of cardiovascular morbidity in patients with:manifest atherothrombotic cardiovascular disease (history of coronary heart disease, stroke, or peripheral arterial disease) or;type 2 diabetes mellitus with documented target organ damage. uuid:4743dc33-cdaa-463e-91e5-b8184478666a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9434 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:70b7bd1b-e851-4488-9fdf-554b7176e19a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ffaef813-4a3b-4cef-97b7-b1fbad680231"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Telmisartanis an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions(1.1) uuid:944e010a-83c5-4c1d-ae6a-1e7c779213b6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:RWM8CCW8GP biolink:treats MONDO:0019960 PMID:41385096 "[{""id"":""uuid:f3f6d668-96f1-40ff-a43d-602da85a94c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b5813850-89db-4f7c-8245-c8ca68a36bbc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Acromegaly Octreotide acetate injection is indicated to reduce blood levels of growth hormone and IGF-I (somatomedin C) in acromegaly patients who have had inadequate response to or cannot be treated with surgical resection, pituitary irradiation, and bromocriptine mesylate at maximally tolerated doses. The goal is to achieve normalization of growth hormone and IGF-I (somatomedin C) levels ( see DOSAGE AND ADMINISTRATION ). In patients with acromegaly, octreotide acetate injection reduces growth hormone to within normal ranges in 50% of patients and reduces IGF-I (somatomedin C) to within normal ranges in 50% to 60% of patients. Since the effects of pituitary irradiation may not become maximal for several years, adjunctive therapy with octreotide acetate injection to reduce blood levels of growth hormone and IGF-I (somatomedin C) offers potential benefit before the effects of irradiation are manifested. Improvement in clinical signs and symptoms or reduction in tumor size or rate of growth were not shown in clinical trials performed with octreotide acetate injection; these trials were not optimally designed to detect such effects. Carcinoid Tumors Octreotide acetate injection is indicated for the symptomatic treatment of patients with metastatic carcinoid tumors where it suppresses or inhibits the severe diarrhea and flushing episodes associated with the disease. Octreotide acetate injection studies were not designed to show an effect on the size, rate of growth or development of metastases. Vasoactive Intestinal Peptide Tumors (VIPomas) Octreotide acetate injection is indicated for the treatment of the profuse watery diarrhea associated with VIP-secreting tumors. Octreotide acetate injection studies were not designed to show an effect on the size, rate of growth or development of metastases. uuid:5203f8ba-876a-4a5d-9431-ea0b38bdd4c6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7915 biolink:treats MONDO:0006896 PMID:41385096 "[{""id"":""uuid:bdcf18ad-8dfa-4c9c-93b2-b65474f46bcf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:823ffeb0-853f-44b4-8851-e29dc3d34da0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pantoprazole sodium delayed-release tablets, USP are a proton pump inhibitor (PPI) indicated for the following: Short-Term Treatment of Erosive Esophagitis Associated with Gastroesophageal Reflux Disease (GERD) ( 1.1 ) Maintenance of Healing of Erosive Esophagitis ( 1.2 ) Pathological Hypersecretory Conditions Including Zollinger-Ellison (ZE) Syndrome ( 1.3 ) uuid:f06960a9-3157-4483-ad14-b9c1bfd699b8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6359 biolink:treats MONDO:0001711 PMID:41385096 "[{""id"":""uuid:4f47e45f-37e2-41da-9e3d-5b8f936d043c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:154b80a6-0ce5-4b67-ad41-adb3b190acc8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the prevention and treatment of portal-systemic encephalopathy, including the stages of hepatic pre-coma and coma. Controlled studies have shown that lactulose solution therapy reduces the blood ammonia levels by 25 to 50%; this is generally paralleled by an improvement in the patients' mental state and by an improvement in EEG patterns. The clinical response has been observed in about 75% of patients, which is at least as satisfactory as that resulting from neomycin therapy. An increase in patients' protein tolerance is also frequently observed with lactulose solution therapy. In the treatment of chronic portal-systemic encephalopathy, lactulose solution has been given for over 2 years in controlled studies. uuid:d533928a-c6a8-44be-a0bf-8c04e655ded7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6359 biolink:treats HP:0001259 PMID:41385096 "[{""id"":""uuid:28f99111-97a9-49a8-ad0c-d508fbc1806f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8eda6e86-a01b-49f5-990f-865ee79837de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the prevention and treatment of portal-systemic encephalopathy, including the stages of hepatic pre-coma and coma. Controlled studies have shown that lactulose solution therapy reduces the blood ammonia levels by 25 to 50%; this is generally paralleled by an improvement in the patients' mental state and by an improvement in EEG patterns. The clinical response has been observed in about 75% of patients, which is at least as satisfactory as that resulting from neomycin therapy. An increase in patients' protein tolerance is also frequently observed with lactulose solution therapy. In the treatment of chronic portal-systemic encephalopathy, lactulose solution has been given for over 2 years in controlled studies. uuid:ea95a4c7-3bb7-444e-81cf-a0d55f859222 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31663 biolink:treats MONDO:0005093 PMID:41385096 "[{""id"":""uuid:188563d5-d3bf-4b4c-a4f9-02c4aa88de46"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b0dc8985-1bd0-4070-8585-c216a5e5080d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] HALOG (Halcinonide Cream, USP) 0.1% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. uuid:1b6fffcc-bc42-4fce-8548-bcd1e2d9666e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5383 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:ae2a3d06-6381-4375-9715-4a96108b383a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e311ffb3-9b4b-4d97-9ebd-5a3723f59a5f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Glimepiride tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus [see Clinical Studies ( 14.1)]. 1.1 Important Limitations of Use Glimepiride tablets should not be used for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis, as it would not be effective in these settings. uuid:e70e411f-d039-479d-842b-b2307dfb5c6f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5383 biolink:treats MONDO:0005147 PMID:41385096 "[{""id"":""uuid:4d312322-8b91-40af-b927-0e55dcaf6e4d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3d356dcb-ffb6-4b40-a634-63809147f250"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Glimepiride tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus [see Clinical Studies ( 14.1)]. 1.1 Important Limitations of Use Glimepiride tablets should not be used for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis, as it would not be effective in these settings. uuid:49a990e6-beef-40e0-8a51-fd2fae99935d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5383 biolink:treats MONDO:0012819 PMID:41385096 "[{""id"":""uuid:2561dd68-551d-41d4-8ec9-c964a1652682"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a30c616a-bcac-44c7-9624-c1ba3f7facf7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Glimepiride tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus [see Clinical Studies ( 14.1)]. 1.1 Important Limitations of Use Glimepiride tablets should not be used for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis, as it would not be effective in these settings. uuid:82402658-4e91-429f-a97d-8e549bd76f4f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1119566 biolink:treats MONDO:0005347 PMID:41385096 "[{""id"":""uuid:5096332d-4c0c-42ca-935b-6698efbc4e08"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e3cad016-677f-4884-9a7a-909c3c7757fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Omega-3-acid ethyl esters capsules, USP are indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia (HTG). Usage Considerations : Patients should be placed on an appropriate lipid-lowering diet before receiving omega-3-acid ethyl esters capsules, USP and should continue this diet during treatment with omega-3-acid ethyl esters capsules, USP. Laboratory studies should be done to ascertain that the lipid levels are consistently abnormal before instituting therapy with omega-3-acid ethyl esters. Every attempt should be made to control serum lipids with appropriate diet, exercise, weight loss in obese patients, and control of any medical problems such as diabetes mellitus and hypothyroidism that are contributing to the lipid abnormalities. Medications known to exacerbate hypertriglyceridemia (such as beta blockers, thiazides, estrogens) should be discontinued or changed if possible prior to consideration of triglyceride-lowering drug therapy. Limitations of Use: Sections or subsections omitted from the full prescribing information are not listed. The effect of omega-3-acid ethyl esters capsules, USP on the risk for pancreatitis has not been determined. The effect of omega-3-acid ethyl esters capsules, USP on cardiovascular mortality and morbidity has not been determined. uuid:15d98ea9-8f77-49a5-b13b-5515fa44d784 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1119566 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:ef2f52a3-7951-4edc-9e36-2baf4f6e5150"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:56621e03-a451-4612-8db5-aaad53b215cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Omega-3-acid ethyl esters capsules, USP are indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia (HTG). Usage Considerations : Patients should be placed on an appropriate lipid-lowering diet before receiving omega-3-acid ethyl esters capsules, USP and should continue this diet during treatment with omega-3-acid ethyl esters capsules, USP. Laboratory studies should be done to ascertain that the lipid levels are consistently abnormal before instituting therapy with omega-3-acid ethyl esters. Every attempt should be made to control serum lipids with appropriate diet, exercise, weight loss in obese patients, and control of any medical problems such as diabetes mellitus and hypothyroidism that are contributing to the lipid abnormalities. Medications known to exacerbate hypertriglyceridemia (such as beta blockers, thiazides, estrogens) should be discontinued or changed if possible prior to consideration of triglyceride-lowering drug therapy. Limitations of Use: Sections or subsections omitted from the full prescribing information are not listed. The effect of omega-3-acid ethyl esters capsules, USP on the risk for pancreatitis has not been determined. The effect of omega-3-acid ethyl esters capsules, USP on cardiovascular mortality and morbidity has not been determined. uuid:f6111d24-9004-42ce-9c0b-eb8399f67c13 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1119566 biolink:treats MONDO:0005420 PMID:41385096 "[{""id"":""uuid:8368c9dd-01de-474e-bfd8-5150d073c076"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:79e0ab0f-d313-4138-8716-d6efa2c2e5ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Omega-3-acid ethyl esters capsules, USP are indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia (HTG). Usage Considerations : Patients should be placed on an appropriate lipid-lowering diet before receiving omega-3-acid ethyl esters capsules, USP and should continue this diet during treatment with omega-3-acid ethyl esters capsules, USP. Laboratory studies should be done to ascertain that the lipid levels are consistently abnormal before instituting therapy with omega-3-acid ethyl esters. Every attempt should be made to control serum lipids with appropriate diet, exercise, weight loss in obese patients, and control of any medical problems such as diabetes mellitus and hypothyroidism that are contributing to the lipid abnormalities. Medications known to exacerbate hypertriglyceridemia (such as beta blockers, thiazides, estrogens) should be discontinued or changed if possible prior to consideration of triglyceride-lowering drug therapy. Limitations of Use: Sections or subsections omitted from the full prescribing information are not listed. The effect of omega-3-acid ethyl esters capsules, USP on the risk for pancreatitis has not been determined. The effect of omega-3-acid ethyl esters capsules, USP on cardiovascular mortality and morbidity has not been determined. uuid:0a8a9b99-3eed-4016-b0d5-1ed817073f87 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:44476258 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:bebf336a-694c-45f9-94c3-f662461db99e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b993fa04-e1cd-4333-a7cf-20d970727404"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets are indicated for the treatment of hypertension, alone or with other antihypertensive agents, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Limitations of Use This fixed combination drug is not indicated for the initial therapy of hypertension. uuid:6ec05220-32bc-4829-ad26-4379a3c53bd6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:44476258 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:5ef8889f-8e17-4a69-bad6-dcea75692a19"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:077831d1-8995-42bc-9823-428169ff2a26"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets are indicated for the treatment of hypertension, alone or with other antihypertensive agents, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Limitations of Use This fixed combination drug is not indicated for the initial therapy of hypertension. uuid:b7b6eed1-ba80-4cc3-b76b-e712537b2e46 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:44476258 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:f115391e-6496-44d1-bc07-d3f116943409"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f75ee9e1-fd57-4c66-9ed7-d70d95916adf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets are indicated for the treatment of hypertension, alone or with other antihypertensive agents, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Limitations of Use This fixed combination drug is not indicated for the initial therapy of hypertension. uuid:38fdaeb7-65eb-484e-814c-6c4ad98a468f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:44476258 biolink:treats MONDO:0005016 PMID:41385096 "[{""id"":""uuid:55182465-3027-44a3-b7e6-be465e55d7e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6468edf5-949a-4b68-a8ba-c0b8b2e2d5e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets are indicated for the treatment of hypertension, alone or with other antihypertensive agents, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Limitations of Use This fixed combination drug is not indicated for the initial therapy of hypertension. uuid:15a8941c-e362-4c72-b751-86ea065c0265 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:137329 biolink:treats HP:0002140 PMID:41385096 "[{""id"":""uuid:f04100c4-d20a-4ef8-8cd6-21cdd9713c4d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:387a6ea2-6b32-440a-b2ab-81d2eb2a37ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Aspirin and extended-release dipyridamole capsules are indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis. uuid:d082b231-c2d0-4f7f-b483-df4dd6569c5e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45409 biolink:treats MONDO:0004951 PMID:41385096 "[{""id"":""uuid:1743e8ad-57db-476a-b2ad-2e80af0e2add"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1ba479fe-8a8f-4f44-8cc7-949b34c69afc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NORVIR tablets and oral solution are indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. NORVIR oral powder is indicated in combination with other antiretroviral agents for the treatment of pediatric patients with HIV-1 infection. uuid:af42e939-3fde-41a8-b0c8-1bc5df9cd07c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3441 biolink:treats MONDO:0010811 PMID:41385096 "[{""id"":""uuid:7eb70f6c-dfa3-4541-a627-c1c5dded0080"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:25fa5796-aa96-4905-b79e-c76553d969eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Monotherapy Finasteride tablets 5 mg are indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to: Improve symptoms Reduce the risk of the need for surgery including transurethral resection of the prostate (TURP) and prostatectomy. 1.2 Combination with Alpha-Blocker Finasteride tablets 5 mg administered in combination with the alpha-blocker doxazosin is indicated to reduce the risk of symptomatic progression of BPH (a confirmed ≥4 point increase in American Urological Association (AUA) symptom score). 1.3 Limitations of Use Finasteride is not approved for the prevention of prostate cancer. uuid:525c5547-d487-4701-9b1e-3df3bc9fd836 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3441 biolink:treats MONDO:0008315 PMID:41385096 "[{""id"":""uuid:07744f21-31d3-41ea-85f8-ed6a03c45a2b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4f32b365-2bbd-4adf-8011-ba0797ddf691"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Monotherapy Finasteride tablets 5 mg are indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to: Improve symptoms Reduce the risk of the need for surgery including transurethral resection of the prostate (TURP) and prostatectomy. 1.2 Combination with Alpha-Blocker Finasteride tablets 5 mg administered in combination with the alpha-blocker doxazosin is indicated to reduce the risk of symptomatic progression of BPH (a confirmed ≥4 point increase in American Urological Association (AUA) symptom score). 1.3 Limitations of Use Finasteride is not approved for the prevention of prostate cancer. uuid:a7ee2e86-6f0a-41d5-85de-428e08b006dc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:76010 biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:0011e5d3-230b-42d0-a011-b5bab1b0ea60"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ff8d8a04-d88e-42ec-a502-5f4d74fc4aae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e1d98294-5805-49bb-bd73-5b076b8dede3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/tivicay""]},{""id"":""uuid:2ccb0d21-a50e-40f7-987b-321838889aa3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TIVICAY is indicated in combination with: • other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and in pediatric patients weighing at least 30 kg [see Microbiology ( 12.4 )] . • rilpivirine as a complete regimen for the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least 6 months with no history of treatment failure or known substitutions associated with resistance to either antiretroviral agent.|[EMA] Tivicay is indicated in combination with other anti-retroviral medicinal products for the treatment of Human Immunodeficiency Virus (HIV) infected adults, adolescents and children of at least 6 years of age or older and weighing at least 14 kg.Tivicay is indicated in combination with other anti-retroviral medicinal products for the treatment of Human Immunodeficiency Virus (HIV) infected adults, adolescents and children of at least 4 weeks of age or older and weighing at least 3 kg.|[PMDA] A drug with a new active ingredient indicated for the treatment of HIV infection. [Orphan drug] uuid:bb2b3785-162c-4e6b-a503-4973ddb1f3ca biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:76010 biolink:treats MONDO:0004951 PMID:41385096 "[{""id"":""uuid:6d3a3737-b74e-47c8-9288-3724a672eda6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3cfcd6d0-a4f0-4ad2-b0df-2de2fa468ae4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TIVICAY is indicated in combination with: • other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and in pediatric patients weighing at least 30 kg [see Microbiology ( 12.4 )] . • rilpivirine as a complete regimen for the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least 6 months with no history of treatment failure or known substitutions associated with resistance to either antiretroviral agent. uuid:5043791c-785b-4410-92dc-640606663ab0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0008109 PMID:41385096 "[{""id"":""uuid:81f3bdc9-5885-4304-aae5-999d651d8ee6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:30940011-caee-4adb-959a-08288c5e387d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Prednisolone sodium phosphate oral solution is indicated in the following conditions: Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. Dermatologic Diseases: Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. Edematous States: To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. Endocrine Disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. Gastrointestinal Diseases: To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. Hematologic Disorders: Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. Neoplastic Diseases: For the treatment of acute leukemia and aggressive lymphomas in adults and children. Nervous System: Acute exacerbations of multiple sclerosis. Ophthalmic Diseases: Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. Respiratory Diseases: Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under "" Allergic States ""), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. Rheumatic Disorders: As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren's syndrome, relapsing polychrondritis, and certain cases of vasculitis. Miscellaneous: Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); Trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents)." uuid:2551284f-476f-45fd-bfe1-6ea147184c8c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5801 biolink:treats MONDO:0005136 PMID:41385096 "[{""id"":""uuid:c6ae08e3-00e1-43f6-a221-759ceba36fcb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8f9492d9-7512-4f95-b294-c73345d4acf1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Malaria Hydroxychloroquine sulfate tablets are indicated for the treatment of uncomplicated malaria due to P. falclparum, P. malariae, P. ovale, and P. vlvax. Hydroxychloroquine sulfate tablets are indicated for the prophylaxis of malaria in geographic areas where chloroquine resistance is not reported. Limitations of Use in Malaria • Hydroxychloroquine sulfate tablets are not recommended for the treatment of complicated malaria. • Hydroxychloroquine sulfate tablets are not effective against chloroquine or hydroxychloroquine-resistant strains of Plasmodium species ( see CLINICAL PHARMACOLOGY - Microbiology ). Hydroxychloroquine sulfate tablets are not recommended for the treatment of malaria acquired in geographic areas where chloroquine resistance occurs or when the Plasmodium species has not been identified. • Hydroxychloroquine sulfate tablets are not recommended for malaria prophylaxis in geographic areas where chloroquine resistance occurs. • Hydroxychloroquine sulfate tablets do not prevent relapses of P. vivaxor P. ovale because it is not active againstthe hypnozoite forms of these parasites. Forradical cure of P. vivaxand P. ovale infections, concomitant therapy with an 8-aminoquinoline compound is necessary (see CLINICAL PHARMACOLOGY - Microbiology ). Prior to prescribing hydroxychloroquine sulfate tablets for the treatment or prophylaxis of malaria, consult the Centers for Disease Control and Prevention (CDC) Malaria website ( http://www.cdc.gov/malaria ). Lupus Erythematosus Hydroxychloroquine sulfate tablets are indicated for the treatment of chronic discoid lupus erythematosus and systemic lupus erythematosus in adults. Rheumatoid Arthritis Hydroxychloroquine sulfate tablets are indicated for the treatment of acute and chronic rheumatoid arthritis in adults. uuid:1e3bdcf3-1209-4456-a631-942356e84eab biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5801 biolink:treats UMLS:C5554310 PMID:41385096 "[{""id"":""uuid:3874d0db-66c1-4479-ab98-e4b70a66b0eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:721437fd-73e5-4b1e-afa4-a2229c119f27"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Malaria Hydroxychloroquine sulfate tablets are indicated for the treatment of uncomplicated malaria due to P. falclparum, P. malariae, P. ovale, and P. vlvax. Hydroxychloroquine sulfate tablets are indicated for the prophylaxis of malaria in geographic areas where chloroquine resistance is not reported. Limitations of Use in Malaria • Hydroxychloroquine sulfate tablets are not recommended for the treatment of complicated malaria. • Hydroxychloroquine sulfate tablets are not effective against chloroquine or hydroxychloroquine-resistant strains of Plasmodium species ( see CLINICAL PHARMACOLOGY - Microbiology ). Hydroxychloroquine sulfate tablets are not recommended for the treatment of malaria acquired in geographic areas where chloroquine resistance occurs or when the Plasmodium species has not been identified. • Hydroxychloroquine sulfate tablets are not recommended for malaria prophylaxis in geographic areas where chloroquine resistance occurs. • Hydroxychloroquine sulfate tablets do not prevent relapses of P. vivaxor P. ovale because it is not active againstthe hypnozoite forms of these parasites. Forradical cure of P. vivaxand P. ovale infections, concomitant therapy with an 8-aminoquinoline compound is necessary (see CLINICAL PHARMACOLOGY - Microbiology ). Prior to prescribing hydroxychloroquine sulfate tablets for the treatment or prophylaxis of malaria, consult the Centers for Disease Control and Prevention (CDC) Malaria website ( http://www.cdc.gov/malaria ). Lupus Erythematosus Hydroxychloroquine sulfate tablets are indicated for the treatment of chronic discoid lupus erythematosus and systemic lupus erythematosus in adults. Rheumatoid Arthritis Hydroxychloroquine sulfate tablets are indicated for the treatment of acute and chronic rheumatoid arthritis in adults. uuid:b0ad7b61-f1e7-4c40-bd30-f25857906302 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5801 biolink:treats MONDO:0019558 PMID:41385096 "[{""id"":""uuid:7ccb3bd2-dee0-4e8c-9fa7-5afa3252b159"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:41666410-2f44-42af-af20-cf442cd65029"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Malaria Hydroxychloroquine sulfate tablets are indicated for the treatment of uncomplicated malaria due to P. falclparum, P. malariae, P. ovale, and P. vlvax. Hydroxychloroquine sulfate tablets are indicated for the prophylaxis of malaria in geographic areas where chloroquine resistance is not reported. Limitations of Use in Malaria • Hydroxychloroquine sulfate tablets are not recommended for the treatment of complicated malaria. • Hydroxychloroquine sulfate tablets are not effective against chloroquine or hydroxychloroquine-resistant strains of Plasmodium species ( see CLINICAL PHARMACOLOGY - Microbiology ). Hydroxychloroquine sulfate tablets are not recommended for the treatment of malaria acquired in geographic areas where chloroquine resistance occurs or when the Plasmodium species has not been identified. • Hydroxychloroquine sulfate tablets are not recommended for malaria prophylaxis in geographic areas where chloroquine resistance occurs. • Hydroxychloroquine sulfate tablets do not prevent relapses of P. vivaxor P. ovale because it is not active againstthe hypnozoite forms of these parasites. Forradical cure of P. vivaxand P. ovale infections, concomitant therapy with an 8-aminoquinoline compound is necessary (see CLINICAL PHARMACOLOGY - Microbiology ). Prior to prescribing hydroxychloroquine sulfate tablets for the treatment or prophylaxis of malaria, consult the Centers for Disease Control and Prevention (CDC) Malaria website ( http://www.cdc.gov/malaria ). Lupus Erythematosus Hydroxychloroquine sulfate tablets are indicated for the treatment of chronic discoid lupus erythematosus and systemic lupus erythematosus in adults. Rheumatoid Arthritis Hydroxychloroquine sulfate tablets are indicated for the treatment of acute and chronic rheumatoid arthritis in adults. uuid:50b2e620-5943-4279-ac57-fc96f77abb26 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5801 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:c28e7b08-5628-499c-b927-7eaf0f340783"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ff23eff2-1f74-4ef9-bef1-23c7de84fee6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Malaria Hydroxychloroquine sulfate tablets are indicated for the treatment of uncomplicated malaria due to P. falclparum, P. malariae, P. ovale, and P. vlvax. Hydroxychloroquine sulfate tablets are indicated for the prophylaxis of malaria in geographic areas where chloroquine resistance is not reported. Limitations of Use in Malaria • Hydroxychloroquine sulfate tablets are not recommended for the treatment of complicated malaria. • Hydroxychloroquine sulfate tablets are not effective against chloroquine or hydroxychloroquine-resistant strains of Plasmodium species ( see CLINICAL PHARMACOLOGY - Microbiology ). Hydroxychloroquine sulfate tablets are not recommended for the treatment of malaria acquired in geographic areas where chloroquine resistance occurs or when the Plasmodium species has not been identified. • Hydroxychloroquine sulfate tablets are not recommended for malaria prophylaxis in geographic areas where chloroquine resistance occurs. • Hydroxychloroquine sulfate tablets do not prevent relapses of P. vivaxor P. ovale because it is not active againstthe hypnozoite forms of these parasites. Forradical cure of P. vivaxand P. ovale infections, concomitant therapy with an 8-aminoquinoline compound is necessary (see CLINICAL PHARMACOLOGY - Microbiology ). Prior to prescribing hydroxychloroquine sulfate tablets for the treatment or prophylaxis of malaria, consult the Centers for Disease Control and Prevention (CDC) Malaria website ( http://www.cdc.gov/malaria ). Lupus Erythematosus Hydroxychloroquine sulfate tablets are indicated for the treatment of chronic discoid lupus erythematosus and systemic lupus erythematosus in adults. Rheumatoid Arthritis Hydroxychloroquine sulfate tablets are indicated for the treatment of acute and chronic rheumatoid arthritis in adults. uuid:5f22e196-ac27-45c1-abf0-4d4979232a9f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18332 biolink:treats MONDO:1010100 PMID:41385096 "[{""id"":""uuid:b88e6a64-04f7-4154-ab9b-bfb1a28e359f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a59c5da1-435c-4736-b94d-c9464d71dd3e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:a2c08e5c-ca3e-4aec-9582-18e363e7d5d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levothyroxine Sodium for Injection is indicated for the treatment of myxedema coma. Important Limitations of Use: The relative bioavailability between Levothyroxine Sodium for Injection and oral levothyroxine products has not been established. Caution should be used when switching patients from oral levothyroxine products to Levothyroxine Sodium for Injection as accurate dosing conversion has not been studied.|[PMDA] A drug with a new route of administration indicated for the treatment of myxedema coma and hypothyroidism (for hypothyroidism, only in patients ineligible for oral levothyroxine sodium therapy). UMLS:C0238298 uuid:386fb455-5260-402c-9ad3-e99a1a6d2bc9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32111 biolink:treats MONDO:0005276 PMID:41385096 "[{""id"":""uuid:efd3e808-82c7-4da0-8c68-6608456ebda9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:67f79109-5146-4009-bd7e-fa19c0608f24"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Aids in the prevention of dental cavities. This is an anti-cavity (preventive treatment gel, not a toothpaste. Read directions carefully before using. Clinical studies have shown that 1.1% sodium fluoride is safe and effective as an anti-cavity agent when used topically. This product should be applied with a toothbrush after brushing with a dentifrice toothpaste. It can be used in areas where drinking water is fluoridated since topical fluorides do not produce fluorosis when used as directed. Adults and children 6 years of age and older: Use once daily after brushing with a dentifrice toothpaste. Apply a thin ribbon of gel to toothbrush and brush teeth thoroughly. Allow the gel to reamin on your teeth for 1 minute and then spit out. Do not swallow gel. For best effectiveness, do not eat or drink for 30 minutes after brushing. Supervise children less than 12 years of age as necessary when using this product to minimize swallowing. Children under 6 years of age - consult a dentist or physician. uuid:b3483734-76bb-4e62-b18f-3612953c213e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:RWM8CCW8GP biolink:treats MONDO:0000249 PMID:41385096 "[{""id"":""uuid:be6bb868-505c-4899-a87e-c5d018fbf08f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:670443f1-a607-407e-8aa5-932ad459de09"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Acromegaly Octreotide acetate injection is indicated to reduce blood levels of growth hormone and IGF-I (somatomedin C) in acromegaly patients who have had inadequate response to or cannot be treated with surgical resection, pituitary irradiation, and bromocriptine mesylate at maximally tolerated doses. The goal is to achieve normalization of growth hormone and IGF-I (somatomedin C) levels (see DOSAGE AND ADMINISTRATION ). In patients with acromegaly, octreotide acetate injection reduces growth hormone to within normal ranges in 50% of patients and reduces IGF-I (somatomedin C) to within normal ranges in 50% to 60% of patients. Since the effects of pituitary irradiation may not become maximal for several years, adjunctive therapy with octreotide acetate injection to reduce blood levels of growth hormone and IGF-I (somatomedin C) offers potential benefit before the effects of irradiation are manifested. Improvement in clinical signs and symptoms or reduction in tumor size or rate of growth were not shown in clinical trials performed with octreotide acetate injection; these trials were not optimally designed to detect such effects. Carcinoid Tumors Octreotide acetate injection is indicated for the symptomatic treatment of patients with metastatic carcinoid tumors where it suppresses or inhibits the severe diarrhea and flushing episodes associated with the disease. Octreotide acetate injection studies were not designed to show an effect on the size, rate of growth or development of metastases. Vasoactive Intestinal Peptide Tumors (VIPomas) Octreotide acetate injection is indicated for the treatment of the profuse watery diarrhea associated with VIP-secreting tumors. Octreotide acetate injection studies were not designed to show an effect on the size, rate of growth or development of metastases. uuid:91701c38-e599-4156-bcbd-a2d01f25af02 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats NCIT:C50743 PMID:41385096 "[{""id"":""uuid:ccaced77-1e58-4810-acec-75b0d6494118"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:21b4f9a0-b641-4942-99dd-34599164645c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the temporary relief of pain and itching associated with minor burns, sunburn, minor cuts, scrapes, insect bites, and minor skin irritation. uuid:e51f2963-8792-4783-9512-bcded26d870f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16134 biolink:treats HP:0001279 PMID:41385096 "[{""id"":""uuid:5f4ab72d-bbc7-4904-a731-9461e80579ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f23cad5d-628e-465f-b655-c1def4858c7e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To prevent or treat fainting uuid:efa53dcb-154d-4680-affa-1becaf390d5f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29108 biolink:treats HP:0002901 PMID:41385096 "[{""id"":""uuid:7c729295-f1b9-4afe-82c6-9314cde8134b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5ab87d97-1353-4374-84b8-93f6d78dd57a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Calcium Gluconate Injection is indicated for pediatric and adult patients for the treatment of acute symptomatic hypocalcemia. Limitations of Use The safety of Calcium Gluconate Injection for long term use has not been established. uuid:5d586899-9cab-44cc-80a3-600fefbcdb42 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47381 biolink:treats MONDO:0006566 PMID:41385096 "[{""id"":""uuid:1d0cdeff-0f2d-4490-8461-74039363e9ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e2b0dbe6-d4af-4f7e-b656-b821015c178a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS: For the topical treatmentof active keratosis. uuid:02406576-9d8d-423b-9a3d-c7b576983e29 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16914 biolink:treats HP:0003326 PMID:41385096 "[{""id"":""uuid:d720dfef-9aed-4d72-9a67-3d11cdf913f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:93ead550-5a64-4847-9b0c-f63b9ce6caae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] USES: FOR THE TEMPORARY RELIEF OF MINOR ACHES AND PAINS OF MUSCLES AND JOINTS ASSOCIATED WITH ARTHRITIS, SIMPLE BACKACHE, STRAINS, SPRAINS, MUSCLE SORENESS AND STIFFNESS. uuid:7e382796-735f-4730-b3b4-d9a97171e1f2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16914 biolink:treats HP:0003552 PMID:41385096 "[{""id"":""uuid:622bfd28-d014-4372-b360-d4035f8e3f38"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:74474ad1-c00e-4a2a-b431-c8c112dca134"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] USES: FOR THE TEMPORARY RELIEF OF MINOR ACHES AND PAINS OF MUSCLES AND JOINTS ASSOCIATED WITH ARTHRITIS, SIMPLE BACKACHE, STRAINS, SPRAINS, MUSCLE SORENESS AND STIFFNESS. uuid:0cc6214c-adfc-4d81-9bad-bdeb311cc4b9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0005578 PMID:41385096 "[{""id"":""uuid:357f6408-1d5c-4a1b-bd6b-3b871a44ed55"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e65fc3ad-46f7-4e65-983c-8d3a67158ee5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] USES: For temporary relief of minor aches and muscle pains associated with arthritis, simple backache, strains, muscle soreness, and stiffness. uuid:1d4baecf-59b3-4c69-8e6b-717ac5ede99b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats HP:0003326 PMID:41385096 "[{""id"":""uuid:29504ee1-1295-4b95-b52e-aed75efb2eba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e2524c11-0ee5-47a9-8a9d-8671c6b587ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] USES: For temporary relief of minor aches and muscle pains associated with arthritis, simple backache, strains, muscle soreness, and stiffness. uuid:1a47979f-d221-4b63-9abc-812836eddced biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats UMLS:C0427008 PMID:41385096 "[{""id"":""uuid:59f29c15-2f9e-4e88-952d-b39aff6f49c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4e36032e-8d7e-4352-9cc5-4163674aea95"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] USES: For temporary relief of minor aches and muscle pains associated with arthritis, simple backache, strains, muscle soreness, and stiffness. uuid:e8b2f5f5-6a98-4a95-bc50-141f26e1eba6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2691 biolink:treats HP:0001681 PMID:41385096 "[{""id"":""uuid:bbf227e8-77f8-4e48-bc0e-28e2393f65bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e3666ea0-cd8e-4032-bfba-4b4dc35a018f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amyl nitrite is indicated for the rapid relief of angina pectoris. Its effect appears within 30 seconds and lasts for approximately 3 to 5 minutes. uuid:b67c1614-0040-4150-ae73-8bff9ded80bd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3441 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:d4dee879-34e2-4c9f-8c6b-57a4a80ad163"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5d595842-c294-4512-b738-443ce5d4a572"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Heart Failure Carvedilol tablets are indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in addition to diuretics, ACE inhibitors, and digitalis, to increase survival and, also, to reduce the risk of hospitalization [see Drug Interactions (7.4), Clinical Studies (14.1)]. 1.2 Left Ventricular Dysfunction following Myocardial Infarction Carvedilol tablets are indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of less than or equal to 40% (with or without symptomatic heart failure) [see Clinical Studies (14.2)]. 1.3 Hypertension Carvedilol tablets are indicated for the management of essential hypertension [see Clinical Studies (14.3, 14.4)]. It can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics [see Drug Interactions (7.2)]. uuid:39801c2d-70aa-45ab-9b4f-9d5acb1dd136 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45783 biolink:treats MONDO:0011996 PMID:41385096 "[{""id"":""uuid:8ebe9a63-ee06-4387-bc35-5c97935778e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:e7649199-3c36-4e61-a174-4727cd673392"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f76df42b-cb42-4366-be3c-9f785879e98b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/glivec""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Imatinib mesylate is a kinase inhibitor indicated for the treatment of: Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase ( 1.1 ) Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy ( 1.2 ) Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) ( 1.3 ) Adult patients with myelodysplastic/ myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements as determined with an FDA-approved test ( 1.5 ) Adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation as determined with an FDA-approved test or with c-Kit mutational status unknown ( 1.6 ) Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or FISH demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown ( 1.7) Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP) ( 1.8 )|[EMA] Glivec is indicated for the treatment of, , , adult and paediatric patients with newly diagnosed Philadelphia-chromosome (bcr-abl)-positive (Ph+) chronic myeloid leukaemia (CML) for whom bone-marrow transplantation is not considered as the first line of treatment;, adult and paediatric patients with Ph+ CML in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis;, adult and paediatric patients with newly diagnosed Philadelphia-chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy;, adult patients with relapsed or refractory Ph+ ALL as monotherapy;, adult patients with myelodysplastic / myeloproliferative diseases (MDS / MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements;, adult patients with advanced hypereosinophilic syndrome (HES) and / or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFRa rearrangement., , , The effect of Glivec on the outcome of bone-marrow transplantation has not been determined., , Glivec is indicated for:, , , the treatment of adult patients with Kit (CD 117)-positive unresectable and / or metastatic malignant gastrointestinal stromal tumours (GIST);, the adjuvant treatment of adult patients who are at significant risk of relapse following resection of Kit (CD117)-positive GIST. Patients who have a low or very low risk of recurrence should not receive adjuvant treatment;, the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and / or metastatic DFSP who are not eligible for surgery., , , In adult and paediatric patients, the effectiveness of Glivec is based on overall haematological and cytogenetic response rates and progression-free survival in CML, on haematological and cytogenetic response rates in Ph+ ALL, MDS / MPD, on haematological response rates in HES / CEL and on objective response rates in adult patients with unresectable and / or metastatic GIST and DFSP and on recurrence-free survival in adjuvant GIST. The experience with Glivec in patients with MDS / MPD associated with PDGFR gene re-arrangements is very limited (see section 5.1). Except in newly diagnosed chronic phase CML, there are no controlled trials demonstrating a clinical benefit or increased survival for these diseases., uuid:6f168b5b-ed9f-4b17-850d-de217acd6ac7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45783 biolink:treats HP:0004848 PMID:41385096 "[{""id"":""uuid:809b05dc-8fe4-4bd0-afc4-fbe8b4b4d4a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:25abb05e-661d-42bc-b2b0-dd765e72143d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Imatinib mesylate is a kinase inhibitor indicated for the treatment of: Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase ( 1.1 ) Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy ( 1.2 ) Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) ( 1.3 ) Adult patients with myelodysplastic/ myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements as determined with an FDA-approved test ( 1.5 ) Adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation as determined with an FDA-approved test or with c-Kit mutational status unknown ( 1.6 ) Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or FISH demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown ( 1.7) Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP) ( 1.8 ) uuid:89a88f50-de1d-49b8-8630-0cb718262aff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45783 biolink:treats MONDO:0006311 PMID:41385096 "[{""id"":""uuid:63155a81-eb4f-4a6c-b2bd-8e6c3c7de55d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fb67c16b-16d0-449b-bb7a-41e815d9bdf7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Imatinib mesylate is a kinase inhibitor indicated for the treatment of: Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase ( 1.1 ) Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy ( 1.2 ) Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) ( 1.3 ) Adult patients with myelodysplastic/ myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements as determined with an FDA-approved test ( 1.5 ) Adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation as determined with an FDA-approved test or with c-Kit mutational status unknown ( 1.6 ) Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or FISH demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown ( 1.7) Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP) ( 1.8 ) uuid:00364a2f-e4f6-4c58-8d07-ca84f34c6439 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45783 biolink:treats MONDO:0020333 PMID:41385096 "[{""id"":""uuid:d469dbf1-3b64-41cf-ad41-eb180b9b5e5b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6c706472-e8e1-4281-8d8a-a54344daa81e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Imatinib mesylate is a kinase inhibitor indicated for the treatment of: Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase ( 1.1 ) Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy ( 1.2 ) Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) ( 1.3 ) Adult patients with myelodysplastic/ myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements as determined with an FDA-approved test ( 1.5 ) Adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation as determined with an FDA-approved test or with c-Kit mutational status unknown ( 1.6 ) Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or FISH demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown ( 1.7) Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP) ( 1.8 ) uuid:cb2a49cc-33d7-4b5f-a10b-06f48208cac6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45783 biolink:treats MONDO:0011895 PMID:41385096 "[{""id"":""uuid:75060807-2b63-4c97-be1e-bcb8b159192c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e706ca83-3fd6-4c15-ad71-5eef5b21417f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Imatinib mesylate is a kinase inhibitor indicated for the treatment of: Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase ( 1.1 ) Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy ( 1.2 ) Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) ( 1.3 ) Adult patients with myelodysplastic/ myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements as determined with an FDA-approved test ( 1.5 ) Adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation as determined with an FDA-approved test or with c-Kit mutational status unknown ( 1.6 ) Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or FISH demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown ( 1.7) Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP) ( 1.8 ) uuid:f598f34d-9131-48fa-b407-0dbd0d170006 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45783 biolink:treats MONDO:0015687 PMID:41385096 "[{""id"":""uuid:2fb482f8-615b-43a8-ba74-14f92c8585d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7afe856e-2814-49f8-9e0f-5093eeb209e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:9f7dc37d-be06-4094-893a-ebbfb7bc1765"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/glivec""]},{""id"":""uuid:88c31776-2979-4660-b11c-81a5181f0f4d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Imatinib mesylate is a kinase inhibitor indicated for the treatment of: Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase ( 1.1 ) Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy ( 1.2 ) Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) ( 1.3 ) Adult patients with myelodysplastic/ myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements as determined with an FDA-approved test ( 1.5 ) Adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation as determined with an FDA-approved test or with c-Kit mutational status unknown ( 1.6 ) Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or FISH demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown ( 1.7) Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP) ( 1.8 )|[EMA] Glivec is indicated for the treatment of, , , adult and paediatric patients with newly diagnosed Philadelphia-chromosome (bcr-abl)-positive (Ph+) chronic myeloid leukaemia (CML) for whom bone-marrow transplantation is not considered as the first line of treatment;, adult and paediatric patients with Ph+ CML in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis;, adult and paediatric patients with newly diagnosed Philadelphia-chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy;, adult patients with relapsed or refractory Ph+ ALL as monotherapy;, adult patients with myelodysplastic / myeloproliferative diseases (MDS / MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements;, adult patients with advanced hypereosinophilic syndrome (HES) and / or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFRa rearrangement., , , The effect of Glivec on the outcome of bone-marrow transplantation has not been determined., , Glivec is indicated for:, , , the treatment of adult patients with Kit (CD 117)-positive unresectable and / or metastatic malignant gastrointestinal stromal tumours (GIST);, the adjuvant treatment of adult patients who are at significant risk of relapse following resection of Kit (CD117)-positive GIST. Patients who have a low or very low risk of recurrence should not receive adjuvant treatment;, the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and / or metastatic DFSP who are not eligible for surgery., , , In adult and paediatric patients, the effectiveness of Glivec is based on overall haematological and cytogenetic response rates and progression-free survival in CML, on haematological and cytogenetic response rates in Ph+ ALL, MDS / MPD, on haematological response rates in HES / CEL and on objective response rates in adult patients with unresectable and / or metastatic GIST and DFSP and on recurrence-free survival in adjuvant GIST. The experience with Glivec in patients with MDS / MPD associated with PDGFR gene re-arrangements is very limited (see section 5.1). Except in newly diagnosed chronic phase CML, there are no controlled trials demonstrating a clinical benefit or increased survival for these diseases.,|[PMDA] A drug with new additional indications and a new dosage for the treatment of FIP1L1-PDGFRα- positive hypereosinophilic syndrome or chronic eosinophilic leukemia. [Public knowledge-based application after PAFSC's preliminary assessment] [Orphan drug] uuid:081eba25-dc1d-43d3-91c4-d81384453fbb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45783 biolink:treats MONDO:0011934 PMID:41385096 "[{""id"":""uuid:563ca393-adf2-415d-8a47-91c8e20b8357"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:4c2fba7a-fd76-4c19-bc04-9e5dbe0d542f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:2a696ded-08ee-4f19-9b36-c4dea84d07b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/glivec""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Imatinib mesylate is a kinase inhibitor indicated for the treatment of: Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase ( 1.1 ) Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy ( 1.2 ) Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) ( 1.3 ) Adult patients with myelodysplastic/ myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements as determined with an FDA-approved test ( 1.5 ) Adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation as determined with an FDA-approved test or with c-Kit mutational status unknown ( 1.6 ) Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or FISH demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown ( 1.7) Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP) ( 1.8 )|[EMA] Glivec is indicated for the treatment of, , , adult and paediatric patients with newly diagnosed Philadelphia-chromosome (bcr-abl)-positive (Ph+) chronic myeloid leukaemia (CML) for whom bone-marrow transplantation is not considered as the first line of treatment;, adult and paediatric patients with Ph+ CML in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis;, adult and paediatric patients with newly diagnosed Philadelphia-chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy;, adult patients with relapsed or refractory Ph+ ALL as monotherapy;, adult patients with myelodysplastic / myeloproliferative diseases (MDS / MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements;, adult patients with advanced hypereosinophilic syndrome (HES) and / or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFRa rearrangement., , , The effect of Glivec on the outcome of bone-marrow transplantation has not been determined., , Glivec is indicated for:, , , the treatment of adult patients with Kit (CD 117)-positive unresectable and / or metastatic malignant gastrointestinal stromal tumours (GIST);, the adjuvant treatment of adult patients who are at significant risk of relapse following resection of Kit (CD117)-positive GIST. Patients who have a low or very low risk of recurrence should not receive adjuvant treatment;, the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and / or metastatic DFSP who are not eligible for surgery., , , In adult and paediatric patients, the effectiveness of Glivec is based on overall haematological and cytogenetic response rates and progression-free survival in CML, on haematological and cytogenetic response rates in Ph+ ALL, MDS / MPD, on haematological response rates in HES / CEL and on objective response rates in adult patients with unresectable and / or metastatic GIST and DFSP and on recurrence-free survival in adjuvant GIST. The experience with Glivec in patients with MDS / MPD associated with PDGFR gene re-arrangements is very limited (see section 5.1). Except in newly diagnosed chronic phase CML, there are no controlled trials demonstrating a clinical benefit or increased survival for these diseases., uuid:c169df52-0250-4e9f-b88a-aee5cb0c1ba7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:9831783 biolink:treats MONDO:0005180 PMID:41385096 "[{""id"":""uuid:e9c9d6b7-901a-4733-9ffa-f17c92a00b8d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4921a416-a71a-41ab-a7ee-55ece6932eb9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carbidopa, levodopa and entacapone tablets, a combination drug consisting of levodopa, carbidopa (dopa decarboxylase inhibitor), and entacapone (catechol-O-methyltransferase-COMT inhibitor) is indicated for the treatment of Parkinson’s disease. Carbidopa, levodopa and entacapone tablets can be used: To substitute (with equivalent strengths of each of the three components) carbidopa/levodopa and entacapone previously administered as individual products. To replace carbidopa/levodopa therapy (without entacapone) when patients experience the signs and symptoms of end-of-dose “wearing-off” and when they have been taking a total daily dose of levodopa of 600 mg or less and have not been experiencing dyskinesias. uuid:603be2c2-164e-470f-b0f9-02a54cb5ed29 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6367 biolink:treats MONDO:0005027 PMID:41385096 "[{""id"":""uuid:e1b45d54-2ccf-4067-930e-12af249852f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1e77caf8-d21e-4d3a-81c9-9ece5c946966"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:1a246f91-54a1-4a2b-82ae-a6c4819517a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Epilepsy Adjunctive Therapy Lamotrigine tablets, USP is indicated as adjunctive therapy for the following seizure types in patients aged 2 years and older: Monotherapy Lamotrigine tablets, USP is indicated for conversion to monotherapy in adults (aged 16 years and older) with partial-onset seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single antiepileptic drug (AED). Safety and effectiveness of lamotrigine tablets, USP have not been established (1) as initial monotherapy; (2) for conversion to monotherapy from AEDs other than carbamazepine, phenytoin, phenobarbital, primidone, or valproate; or (3) for simultaneous conversion to monotherapy from 2 or more concomitant AEDs. 1.2 Bipolar Disorder Lamotrigine tablets, USP is indicated for the maintenance treatment of Bipolar I disorder to delay the time to occurrence of mood episodes (depression, mania, hypomania, mixed episodes) in patients treated for acute mood episodes with standard therapy [SEE CLINICAL STUDIES (14.1)]. Limitations of Use Treatment of acute manic or mixed episodes is not recommended. Effectiveness of lamotrigine tablets, USP in the acute treatment of mood episodes has not been established.|[PMDA] Drugs with a new additional indication and a new dosage for use in the monotherapy for treatment of partial seizures (including secondary generalized seizure) and tonic-clonic seizures in patients with epilepsy. uuid:cf59a7be-6404-465d-895d-650b5394c170 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:9887103 biolink:treats HP:0001662 PMID:41385096 "[{""id"":""uuid:a3d2c754-a47d-4deb-bbae-911e085d4223"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0ae5915c-ca70-4f5b-a1ba-4f5fa6023a2a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In Anesthesia Glycopyrrolate injection is indicated for use as a preoperative antimuscarinic to reduce salivary, tracheobronchial, and pharyngeal secretions; to reduce the volume and free acidity of gastric secretions; and to block cardiac vagal inhibitory reflexes during induction of anesthesia and intubation. When indicated, glycopyrrolate injection may be used intraoperatively to counteract surgically or drug-induced or vagal reflexes associated arrhythmias. Glycopyrrolate protects against the peripheral muscarinic effects (e.g., bradycardia and excessive secretions) of cholinergic agents such as neostigmine and pyridostigmine given to reverse the neuromuscular blockade due to non-depolarizing muscle relaxants. In Peptic Ulcer For use in adults as adjunctive therapy for the treatment of peptic ulcer when rapid anticholinergic effect is desired or when oral medication is not tolerated. uuid:c530e800-1046-4d63-86ab-89cc285218b2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8665 biolink:treats MONDO:0009688 PMID:41385096 "[{""id"":""uuid:3a43d372-6625-4347-9950-b3c1f2690f98"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a5d078d5-3d42-4b9b-afab-daf1ac717ac9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pyridostigmine Bromide Oral Solution, USP is useful in the treatment of myasthenia gravis. uuid:e74eef77-60b1-4ee6-85d8-123f2f7ffc42 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63619 biolink:treats HP:0004754 PMID:41385096 "[{""id"":""uuid:3b661acb-6638-4ff4-9047-3b279765441e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2dbc263e-0f2b-4c15-8eb2-2c98eb23e55e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Propafenone hydrochloride is indicated to: prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms in patients without structural heart disease. prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms in patients without structural heart disease. treat documented ventricular arrhythmias, such as sustained ventricular tachycardia that, in the judgment of the physician, are life-threatening. Initiate treatment in the hospital. Usage Considerations: The use of propafenone hydrochloride tablets in patients with permanent atrial fibrillation (AF) or in patients exclusively with atrial flutter or PSVT has not been evaluated. Do not use propafenone hydrochloride tablets to control ventricular rate during AF. Some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. Concomitant treatment with drugs that increase the functional atrioventricular (AV) nodal refractory period is recommended. The use of propafenone hydrochloride tablets in patients with chronic atrial fibrillation has not been evaluated. Because of the proarrhythmic effects of propafenone hydrochloride, its use with lesser ventricular arrhythmias is not recommended, even if patients are symptomatic, and any use of the drug should be reserved for patients in whom, in the opinion of the physician, the potential benefits outweigh the risks. The effect of propafenone on mortality has not been determined [see Boxed Warning ]. uuid:1d7ff551-0c3c-40df-8d11-41790358f8f8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16240 biolink:treats MONDO:0008420 PMID:41385096 "[{""id"":""uuid:870c600d-8522-4693-a06f-cbc170a55f70"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4fd31409-fa9d-40bc-85f2-9e8a69e147ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ESKATA is indicated for the treatment of seborrheic keratoses that are raised. uuid:df35de75-189f-4020-afdd-34506224a1da biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB09422 biolink:treats UMLS:C0342919 PMID:41385096 "[{""id"":""uuid:fe379df1-cd32-41cc-97d8-560b3feb31c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:176d81dd-4fec-4bdf-8471-3ffb91d10297"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intralipid ® 20% Pharmacy Bulk Package is indicated for use in a pharmacy admixture program for the preparation of three-inone or total nutrition admixtures (TNAs) to provide a source of calories and essential fatty acids for patients requiring parenteral nutrition for extended periods of time (usually for more than 5 days) and a source of essential fatty acids for prevention of EFAD. uuid:accdfc90-d294-4745-9aa0-44076aea6fb7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0005096 PMID:41385096 "[{""id"":""uuid:0d21e41e-7887-4c35-b471-9a15ebfdd057"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7cee35c2-5ca7-4d37-b25e-8adcbc280831"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bleomycin for injection should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma: Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to bleomycin for injection is poorer in patients with previously irradiated head and neck cancer. Lymphomas: Hodgkin's disease, non-Hodgkin's lymphoma. Testicular Carcinoma: Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin for injection has also been shown to be useful in the management of: Malignant Pleural Effusion: Bleomycin for injection is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. uuid:6447ba42-e6fb-479c-a9b5-d80a1e20807e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0005627 PMID:41385096 "[{""id"":""uuid:99fb26e5-5e73-41f9-8298-a4cc31063d67"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8b0a1ad9-c35d-49a9-aae8-a8174a827475"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bleomycin for injection should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma: Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to bleomycin for injection is poorer in patients with previously irradiated head and neck cancer. Lymphomas: Hodgkin's disease, non-Hodgkin's lymphoma. Testicular Carcinoma: Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin for injection has also been shown to be useful in the management of: Malignant Pleural Effusion: Bleomycin for injection is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. uuid:6d2d2942-f3e1-4f96-a20c-4eb21fd03104 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0005515 PMID:41385096 "[{""id"":""uuid:6d8c56ec-2a84-4a3c-8b5b-1067f30b3a38"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:172dceb9-b1e0-4861-88e5-1110b6a4b6fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bleomycin for injection should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma: Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to bleomycin for injection is poorer in patients with previously irradiated head and neck cancer. Lymphomas: Hodgkin's disease, non-Hodgkin's lymphoma. Testicular Carcinoma: Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin for injection has also been shown to be useful in the management of: Malignant Pleural Effusion: Bleomycin for injection is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. uuid:cb8697d3-ee32-452e-a26a-da1e7d6dcf92 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0004631 PMID:41385096 "[{""id"":""uuid:52dad955-cd7a-46b9-a780-6a886d32cab9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ec576b4c-e3ec-4195-b8e9-35849beb8ff7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bleomycin for injection should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma: Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to bleomycin for injection is poorer in patients with previously irradiated head and neck cancer. Lymphomas: Hodgkin's disease, non-Hodgkin's lymphoma. Testicular Carcinoma: Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin for injection has also been shown to be useful in the management of: Malignant Pleural Effusion: Bleomycin for injection is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. uuid:dcdce0a4-d3c2-48b7-a18d-d69f8490e9a4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0006998 PMID:41385096 "[{""id"":""uuid:4a150e60-10be-458a-b1c0-eec555205c65"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2e23a62f-a4dd-4f59-9d05-aea3948c41b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bleomycin for injection should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma: Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to bleomycin for injection is poorer in patients with previously irradiated head and neck cancer. Lymphomas: Hodgkin's disease, non-Hodgkin's lymphoma. Testicular Carcinoma: Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin for injection has also been shown to be useful in the management of: Malignant Pleural Effusion: Bleomycin for injection is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. uuid:08271d2a-a466-4b38-bfee-09add0a9e1cd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0021315 PMID:41385096 "[{""id"":""uuid:9c710393-ae29-4c73-adc1-64e142912ed0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:63415d90-c3ce-4a48-9fb0-efa2eeea9018"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bleomycin for injection should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma: Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to bleomycin for injection is poorer in patients with previously irradiated head and neck cancer. Lymphomas: Hodgkin's disease, non-Hodgkin's lymphoma. Testicular Carcinoma: Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin for injection has also been shown to be useful in the management of: Malignant Pleural Effusion: Bleomycin for injection is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. uuid:0e1d6084-2078-49de-a6aa-1669bd6b115c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0004608 PMID:41385096 "[{""id"":""uuid:61054009-d2d7-4d7b-8b1b-b35a09dd9fc9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d7402d57-3762-4e05-9b7e-ace8275b0142"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bleomycin for injection should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma: Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to bleomycin for injection is poorer in patients with previously irradiated head and neck cancer. Lymphomas: Hodgkin's disease, non-Hodgkin's lymphoma. Testicular Carcinoma: Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin for injection has also been shown to be useful in the management of: Malignant Pleural Effusion: Bleomycin for injection is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. uuid:2ff19502-a067-4088-98f9-8717dc22763a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0020669 PMID:41385096 "[{""id"":""uuid:550b23b1-4618-435c-933e-9a260329b774"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7d5d67a0-48d2-4184-8978-0732e07690b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bleomycin for injection should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma: Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to bleomycin for injection is poorer in patients with previously irradiated head and neck cancer. Lymphomas: Hodgkin's disease, non-Hodgkin's lymphoma. Testicular Carcinoma: Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin for injection has also been shown to be useful in the management of: Malignant Pleural Effusion: Bleomycin for injection is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. uuid:ea063854-ba98-4cc0-96fb-2b0f0bb787a2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0006834 PMID:41385096 "[{""id"":""uuid:64229ab5-05a9-4bc8-8ff0-ea2928db80ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:317db3da-f97d-48e2-812c-3a126bd837d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bleomycin for injection should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma: Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to bleomycin for injection is poorer in patients with previously irradiated head and neck cancer. Lymphomas: Hodgkin's disease, non-Hodgkin's lymphoma. Testicular Carcinoma: Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin for injection has also been shown to be useful in the management of: Malignant Pleural Effusion: Bleomycin for injection is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. uuid:326fc03f-2c72-4276-8d0e-ed6c1115688f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0004645 PMID:41385096 "[{""id"":""uuid:2f959393-4331-4435-9f4b-907307437f4b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ca176879-9dc1-486d-9492-b4c61dbf3276"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bleomycin for injection should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma: Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to bleomycin for injection is poorer in patients with previously irradiated head and neck cancer. Lymphomas: Hodgkin's disease, non-Hodgkin's lymphoma. Testicular Carcinoma: Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin for injection has also been shown to be useful in the management of: Malignant Pleural Effusion: Bleomycin for injection is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. uuid:15e74268-61ca-4a19-a829-4e47b019e7cf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0004473 PMID:41385096 "[{""id"":""uuid:55f203e7-8151-4bb0-8b96-cb92140c1c04"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1736b701-707a-4ede-ab9b-0eb2b79cedca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bleomycin for injection should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma: Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to bleomycin for injection is poorer in patients with previously irradiated head and neck cancer. Lymphomas: Hodgkin's disease, non-Hodgkin's lymphoma. Testicular Carcinoma: Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin for injection has also been shown to be useful in the management of: Malignant Pleural Effusion: Bleomycin for injection is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. uuid:ecb3a7f6-72f0-4f4e-b8f4-4798a4cedc11 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0002898 PMID:41385096 "[{""id"":""uuid:61561ca9-7dee-4cae-9595-27aedf7e8df5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9bdd5b1f-6904-4b8a-ae29-917506f686dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bleomycin for injection should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma: Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to bleomycin for injection is poorer in patients with previously irradiated head and neck cancer. Lymphomas: Hodgkin's disease, non-Hodgkin's lymphoma. Testicular Carcinoma: Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin for injection has also been shown to be useful in the management of: Malignant Pleural Effusion: Bleomycin for injection is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. uuid:e4f00dae-b9bc-4394-ab9d-3d0732911a76 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0002352 PMID:41385096 "[{""id"":""uuid:dec18ca6-2efa-4d9f-a4aa-4f28b2a91fc3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:71a6de0a-e430-47d2-8b93-388a62e363b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bleomycin for injection should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma: Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to bleomycin for injection is poorer in patients with previously irradiated head and neck cancer. Lymphomas: Hodgkin's disease, non-Hodgkin's lymphoma. Testicular Carcinoma: Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin for injection has also been shown to be useful in the management of: Malignant Pleural Effusion: Bleomycin for injection is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. uuid:c5104664-efd1-43fc-b928-e6135297b0ed biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0001325 PMID:41385096 "[{""id"":""uuid:40ed4e15-c990-40ee-911e-4e8fffac1ffc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:24291fc5-05b8-40eb-a627-b1f011f67479"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bleomycin for injection should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma: Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to bleomycin for injection is poorer in patients with previously irradiated head and neck cancer. Lymphomas: Hodgkin's disease, non-Hodgkin's lymphoma. Testicular Carcinoma: Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin for injection has also been shown to be useful in the management of: Malignant Pleural Effusion: Bleomycin for injection is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. uuid:5120a684-f1dd-42c4-8110-f903137bbdcc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0005131 PMID:41385096 "[{""id"":""uuid:151db2b3-90bd-45b1-a243-4a58fd24c4b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f503ce88-e1d8-4369-8a16-8ecbd70ef7fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bleomycin for injection should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma: Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to bleomycin for injection is poorer in patients with previously irradiated head and neck cancer. Lymphomas: Hodgkin's disease, non-Hodgkin's lymphoma. Testicular Carcinoma: Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin for injection has also been shown to be useful in the management of: Malignant Pleural Effusion: Bleomycin for injection is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. uuid:6d5e6707-2ef6-463c-9ba4-5e39470c6409 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0001528 PMID:41385096 "[{""id"":""uuid:6640baee-1e9d-4447-8d4d-1e17300a49a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0b7b4903-6932-4068-90c2-7ca526cd786e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bleomycin for injection should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma: Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to bleomycin for injection is poorer in patients with previously irradiated head and neck cancer. Lymphomas: Hodgkin's disease, non-Hodgkin's lymphoma. Testicular Carcinoma: Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin for injection has also been shown to be useful in the management of: Malignant Pleural Effusion: Bleomycin for injection is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. uuid:58521b39-59ff-4134-8c48-d23bf0c94260 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0004095 PMID:41385096 "[{""id"":""uuid:7cfb0a39-6d0c-43c0-ac94-35c72e1607f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c664c609-f0c4-4de5-979b-ff86cd1a10bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bleomycin for injection should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma: Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to bleomycin for injection is poorer in patients with previously irradiated head and neck cancer. Lymphomas: Hodgkin's disease, non-Hodgkin's lymphoma. Testicular Carcinoma: Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin for injection has also been shown to be useful in the management of: Malignant Pleural Effusion: Bleomycin for injection is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. uuid:5b767b1d-01a4-40b1-8fb0-60e5eca91991 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0009348 PMID:41385096 "[{""id"":""uuid:c6c80e09-bf3b-449c-b42e-e81e3744cf8f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1abec24f-2c6c-4b9b-a5db-fd588671ca98"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bleomycin for injection should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma: Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to bleomycin for injection is poorer in patients with previously irradiated head and neck cancer. Lymphomas: Hodgkin's disease, non-Hodgkin's lymphoma. Testicular Carcinoma: Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin for injection has also been shown to be useful in the management of: Malignant Pleural Effusion: Bleomycin for injection is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. uuid:9404063b-ba36-4bc3-854a-b575f74b69d1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0018908 PMID:41385096 "[{""id"":""uuid:6595ae66-7955-4326-9f50-4987adc11a19"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fc85e577-6405-45bc-96d5-457717ffd4b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bleomycin for injection should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma: Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to bleomycin for injection is poorer in patients with previously irradiated head and neck cancer. Lymphomas: Hodgkin's disease, non-Hodgkin's lymphoma. Testicular Carcinoma: Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin for injection has also been shown to be useful in the management of: Malignant Pleural Effusion: Bleomycin for injection is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. uuid:653b9c34-d1e4-4cbe-8ab4-0b85462910eb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0005447 PMID:41385096 "[{""id"":""uuid:543f65b9-4f56-4621-81c3-154ed04bd987"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0c6696fa-f800-49f8-adbd-63b3fc87d130"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bleomycin for injection should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma: Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to bleomycin for injection is poorer in patients with previously irradiated head and neck cancer. Lymphomas: Hodgkin's disease, non-Hodgkin's lymphoma. Testicular Carcinoma: Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin for injection has also been shown to be useful in the management of: Malignant Pleural Effusion: Bleomycin for injection is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. uuid:323b03cf-f462-40f8-a737-115166f06a47 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0005440 PMID:41385096 "[{""id"":""uuid:42944527-2149-413b-bacc-ff91a6ddcbc7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d1dbab11-ac9e-44c3-a321-b6bb44f750ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bleomycin for injection should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma: Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to bleomycin for injection is poorer in patients with previously irradiated head and neck cancer. Lymphomas: Hodgkin's disease, non-Hodgkin's lymphoma. Testicular Carcinoma: Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin for injection has also been shown to be useful in the management of: Malignant Pleural Effusion: Bleomycin for injection is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. uuid:5a25df65-467d-4748-8f57-7f0b9cb781fd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0005207 PMID:41385096 "[{""id"":""uuid:f114d75a-64ad-417f-849b-4183916bc966"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ec38a481-9197-4be5-897d-8165014a0592"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bleomycin for injection should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma: Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to bleomycin for injection is poorer in patients with previously irradiated head and neck cancer. Lymphomas: Hodgkin's disease, non-Hodgkin's lymphoma. Testicular Carcinoma: Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin for injection has also been shown to be useful in the management of: Malignant Pleural Effusion: Bleomycin for injection is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. uuid:f93bb493-d88b-453e-9f99-06b908b28ddb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0002599 PMID:41385096 "[{""id"":""uuid:bebe0295-235a-4fc6-932b-d139e6472205"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e1d1bfab-033b-42d2-9edf-4f347d48c98e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bleomycin for injection should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma: Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to bleomycin for injection is poorer in patients with previously irradiated head and neck cancer. Lymphomas: Hodgkin's disease, non-Hodgkin's lymphoma. Testicular Carcinoma: Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin for injection has also been shown to be useful in the management of: Malignant Pleural Effusion: Bleomycin for injection is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. uuid:289f27e1-a76b-48e8-b91d-120d0e88de5b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats UMLS:C0080032 PMID:41385096 "[{""id"":""uuid:cc31fd5a-5143-49a5-92fe-bc64a12cc2b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8e3cfac2-e4b1-4e9a-94e9-4d9149c41c20"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bleomycin for injection should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma: Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to bleomycin for injection is poorer in patients with previously irradiated head and neck cancer. Lymphomas: Hodgkin's disease, non-Hodgkin's lymphoma. Testicular Carcinoma: Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin for injection has also been shown to be useful in the management of: Malignant Pleural Effusion: Bleomycin for injection is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. uuid:873e48dd-6916-4da3-af36-da154d198ef9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1151550 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:ab8f3ff2-b568-4979-8b64-58b6e7d3b69c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:863d52e8-9449-4792-bbb1-455206f7e46a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydrocodone bitartrate and acetaminophen tablets are indicated for the management of, pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, and misuse, with opioids, even at recommended doses [see WARNINGS], reserve hydrocodone bitartrate and acetaminophen tablets for use in patients for whom alternative treatment options [e.g., non-opioid analgesics] Have not been tolerated, or are not expected to be tolerated, Have not provided adequate analgesia, or are not expected to provide adequate analgesia uuid:c079b987-ecf0-4b65-a9ec-96a19e4ea1ed biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47381 biolink:treats NCIT:C27003 PMID:41385096 "[{""id"":""uuid:e640b264-7f28-48e8-b1fd-e04c739220c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c6c93c5f-e081-4a90-a72b-34ac149cdfe7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZORVOLEX is indicated for: Management of mild to moderate acute pain Management of osteoarthritis pain uuid:ccfb2036-43b9-4b7a-bc4f-40f74ccc661c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats MONDO:0004577 PMID:41385096 "[{""id"":""uuid:fdf7f5fc-4eed-4f54-96fc-838676a6f1ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3d6e7179-27b5-47d9-8d98-9168c13e9538"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:5390c397-7c1a-4d8e-84ff-188fbc8b22b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levofloxacin ophthalmic solution is indicated for the treatment of corneal ulcer caused by susceptible strains of the following bacteria: Gram-positive bacteria: Corynebacterium species Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumonia Viridans group streptococci* Gram-negative bacteria: Pseudomonas aeruginosa Serratia marcescens* * Efficacy for this organism was studied in fewer than 10 infections|[PMDA] A drug with a new dosage of the 1.5% formulation for the treatment of blepharitis, dacryocystitis, hordeolum, conjunctivitis, meibomianitis, and keratitis (including corneal ulcer) and sterilization during the ophthalmic perioperative period. uuid:ef63d17f-b648-4665-81d1-b6b89691ab2d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats MONDO:0005545 PMID:41385096 "[{""id"":""uuid:c60cdba1-0a74-4d48-a06e-bedfb5d272fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2f866e21-2c2c-43bb-b2df-faf05e61d238"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levofloxacin ophthalmic solution is indicated for the treatment of corneal ulcer caused by susceptible strains of the following bacteria: Gram-positive bacteria: Corynebacterium species Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumonia Viridans group streptococci* Gram-negative bacteria: Pseudomonas aeruginosa Serratia marcescens* * Efficacy for this organism was studied in fewer than 10 infections uuid:e4d74127-43d0-4e33-bf7b-75ea72117388 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats MONDO:0005972 PMID:41385096 "[{""id"":""uuid:1b8ed714-f0e9-4d16-8639-c7f808f8e207"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4f37a4bf-170f-49d8-b0ce-9a25b203c541"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levofloxacin ophthalmic solution is indicated for the treatment of corneal ulcer caused by susceptible strains of the following bacteria: Gram-positive bacteria: Corynebacterium species Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumonia Viridans group streptococci* Gram-negative bacteria: Pseudomonas aeruginosa Serratia marcescens* * Efficacy for this organism was studied in fewer than 10 infections uuid:c55f4858-32bd-4c04-aa8f-7f01666a419b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats MONDO:0040732 PMID:41385096 "[{""id"":""uuid:2bb1e18a-5b95-4ca1-b668-b26669842722"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:1b83bede-46ee-4c2c-9796-7bc0eaf9afa3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:34f69dc8-1f94-4d13-a630-db12084ab79e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/quinsair""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levofloxacin ophthalmic solution is indicated for the treatment of corneal ulcer caused by susceptible strains of the following bacteria: Gram-positive bacteria: Corynebacterium species Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumonia Viridans group streptococci* Gram-negative bacteria: Pseudomonas aeruginosa Serratia marcescens* * Efficacy for this organism was studied in fewer than 10 infections|[EMA] Quinsair is indicated for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.Consideration should be given to official guidance on the appropriate use of antibacterial agents. uuid:d2a6ab40-cf2c-4ca6-a3c8-424f95e0299b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:85783 biolink:treats MONDO:0004781 PMID:41385096 "[{""id"":""uuid:6effa865-6132-48df-b885-f7fd13fdb412"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d600e96e-ff15-4c00-b7b3-59a249c16cca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Hypertension Lisinopril is indicated for the treatment of hypertension in adult patients and pediatric patients 6 years of age and older to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Lisinopril may be administered alone or with other antihypertensive agents [see Clinical Studies (14.1)]. 1.2 Heart Failure Lisinopril is indicated to reduce signs and symptoms of systolic heart failure [see Clinical Studies (14.2)]. 1.3 Reduction of Mortality in Acute Myocardial Infarction Lisinopril is indicated for the reduction of mortality in treatment of hemodynamically stable patients within 24 hours of acute myocardial infarction. Patients should receive, as appropriate, the standard recommended treatments such as thrombolytics, aspirin and beta-blockers [see Clinical Studies (14.3)]. uuid:3319c509-c6b4-47c0-8362-4d445afd7a3f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3SY5LH9PMK biolink:treats MONDO:0005277 PMID:41385096 "[{""id"":""uuid:0bf236aa-1726-4ad8-b9fb-c7955b8cd186"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3b38b739-8cc5-46a8-a48a-021e767a56cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Rizatriptan benzoate tablets are indicated for the acute treatment of migraine with or without aura in adults and in pediatric patients 6 to 17 years old. Limitations of Use Rizatriptan benzoate tablets should only be used where a clear diagnosis of migraine has been established. If a patient has no response for the first migraine attack treated with rizatriptan benzoate tablets, the diagnosis of migraine should be reconsidered before rizatriptan benzoate tablets are administered to treat any subsequent attacks. Rizatriptan benzoate tablets are not indicated for use in the management of hemiplegic or basilar migraine [see Contraindications (4)]. Rizatriptan benzoate tablets are not indicated for the prevention of migraine attacks. Safety and effectiveness of rizatriptan benzoate tablets has not been established for cluster headache. uuid:618e9e0f-57b4-46d8-b587-bb383382f50e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3SY5LH9PMK biolink:treats MONDO:0018925 PMID:41385096 "[{""id"":""uuid:bd0c17a5-03ea-4599-b55f-8e4d6a345027"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ca652535-2d11-42cc-8616-e30f08731ba5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Rizatriptan benzoate tablets are indicated for the acute treatment of migraine with or without aura in adults and in pediatric patients 6 to 17 years old. Limitations of Use Rizatriptan benzoate tablets should only be used where a clear diagnosis of migraine has been established. If a patient has no response for the first migraine attack treated with rizatriptan benzoate tablets, the diagnosis of migraine should be reconsidered before rizatriptan benzoate tablets are administered to treat any subsequent attacks. Rizatriptan benzoate tablets are not indicated for use in the management of hemiplegic or basilar migraine [see Contraindications (4)]. Rizatriptan benzoate tablets are not indicated for the prevention of migraine attacks. Safety and effectiveness of rizatriptan benzoate tablets has not been established for cluster headache. uuid:4868b759-22c0-459f-aa6a-86e542ce98bd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3SY5LH9PMK biolink:treats MONDO:0043219 PMID:41385096 "[{""id"":""uuid:a6657d6f-451f-4c46-819a-32ce6fbfe5ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8e66cb61-9329-4e64-a46f-8f9f9e7d0851"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Rizatriptan benzoate tablets are indicated for the acute treatment of migraine with or without aura in adults and in pediatric patients 6 to 17 years old. Limitations of Use Rizatriptan benzoate tablets should only be used where a clear diagnosis of migraine has been established. If a patient has no response for the first migraine attack treated with rizatriptan benzoate tablets, the diagnosis of migraine should be reconsidered before rizatriptan benzoate tablets are administered to treat any subsequent attacks. Rizatriptan benzoate tablets are not indicated for use in the management of hemiplegic or basilar migraine [see Contraindications (4)]. Rizatriptan benzoate tablets are not indicated for the prevention of migraine attacks. Safety and effectiveness of rizatriptan benzoate tablets has not been established for cluster headache. uuid:087a1dcf-02d2-4b44-b976-51c4f0c87409 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3SY5LH9PMK biolink:treats MONDO:0043537 PMID:41385096 "[{""id"":""uuid:e36012d2-a3f7-4158-8862-f23420282443"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:05c9c0e7-1651-4279-9e5e-c195e6f45ce9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Rizatriptan benzoate tablets are indicated for the acute treatment of migraine with or without aura in adults and in pediatric patients 6 to 17 years old. Limitations of Use Rizatriptan benzoate tablets should only be used where a clear diagnosis of migraine has been established. If a patient has no response for the first migraine attack treated with rizatriptan benzoate tablets, the diagnosis of migraine should be reconsidered before rizatriptan benzoate tablets are administered to treat any subsequent attacks. Rizatriptan benzoate tablets are not indicated for use in the management of hemiplegic or basilar migraine [see Contraindications (4)]. Rizatriptan benzoate tablets are not indicated for the prevention of migraine attacks. Safety and effectiveness of rizatriptan benzoate tablets has not been established for cluster headache. uuid:69d4d27d-b3e5-40d0-aae0-671a454b79d0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:141521 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:622a9976-53d1-4903-8b4a-fdaf33af225f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5ac3a846-ccd5-43a7-9e7e-cdcb94bb64c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension Trandolapril tablets USP are indicated for the treatment of hypertension. They may be used alone or in combination with other antihypertensive medication such as hydrochlorothiazide. Heart Failure Post Myocardial Infarction or Left-Ventricular Dysfunction Post Myocardial Infarction Trandolapril tablets USP are indicated in stable patients who have evidence of left-ventricular systolic dysfunction (identified by wall motion abnormalities) or who are symptomatic from congestive heart failure within the first few days after sustaining acute myocardial infarction. Administration of trandolapril to Caucasian patients has been shown to decrease the risk of death (principally cardiovascular death) and to decrease the risk of heart failure-related hospitalization (see CLINICAL PHARMACOLOGY -Heart Failure or Left-Ventricular Dysfunction Post Myocardial Infarction for details of the survival trial). uuid:1cb8eb27-9059-4318-8f1d-a2319a166e63 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:141521 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:d4f2b2dd-044c-4075-a320-df74b2a2d2d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:411bbf7d-831a-41dc-a114-60ddef8eb82b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension Trandolapril tablets USP are indicated for the treatment of hypertension. They may be used alone or in combination with other antihypertensive medication such as hydrochlorothiazide. Heart Failure Post Myocardial Infarction or Left-Ventricular Dysfunction Post Myocardial Infarction Trandolapril tablets USP are indicated in stable patients who have evidence of left-ventricular systolic dysfunction (identified by wall motion abnormalities) or who are symptomatic from congestive heart failure within the first few days after sustaining acute myocardial infarction. Administration of trandolapril to Caucasian patients has been shown to decrease the risk of death (principally cardiovascular death) and to decrease the risk of heart failure-related hospitalization (see CLINICAL PHARMACOLOGY -Heart Failure or Left-Ventricular Dysfunction Post Myocardial Infarction for details of the survival trial). uuid:c11b9eb0-7dd6-49d4-bd63-7b8245ea5915 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:141521 biolink:treats MONDO:0004781 PMID:41385096 "[{""id"":""uuid:877547f0-8885-4459-9791-487d5dcbe0b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:797dea5d-4b29-4de9-baa7-675666740785"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension Trandolapril tablets USP are indicated for the treatment of hypertension. They may be used alone or in combination with other antihypertensive medication such as hydrochlorothiazide. Heart Failure Post Myocardial Infarction or Left-Ventricular Dysfunction Post Myocardial Infarction Trandolapril tablets USP are indicated in stable patients who have evidence of left-ventricular systolic dysfunction (identified by wall motion abnormalities) or who are symptomatic from congestive heart failure within the first few days after sustaining acute myocardial infarction. Administration of trandolapril to Caucasian patients has been shown to decrease the risk of death (principally cardiovascular death) and to decrease the risk of heart failure-related hospitalization (see CLINICAL PHARMACOLOGY -Heart Failure or Left-Ventricular Dysfunction Post Myocardial Infarction for details of the survival trial). uuid:62c92de6-6fdb-4431-a16f-129f2963148d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:38545 biolink:treats MONDO:0007788 PMID:41385096 "[{""id"":""uuid:69cd89aa-9159-4876-a754-9c5bab0df127"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b29a5a33-c6b8-4d89-9274-864d943bfcda"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Rosuvastatin tablets are an HMG Co-A reductase inhibitor indicated for: adult patients with hypertriglyceridemia as an adjunct to diet ( 1.3 ) adult patients with primary dysbetalipoproteinemia (Type III hyperlipoproteinemia) as an adjunct to diet ( 1.4 ) adult patients with homozygous familial hypercholesterolemia (HoFH) to reduce LDL-C, total-C, and ApoB ( 1.5 ) Limitations of use ( 1.8 ): Rosuvastatin tablets have not been studied in Fredrickson Type I and V dyslipidemias. uuid:bd0355b9-5e63-4b16-8aca-4ca515a84cbf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:38545 biolink:treats MONDO:0007762 PMID:41385096 "[{""id"":""uuid:73ee6f60-b97a-4d06-b2c9-4bc86500ac3a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:61aea699-bf7f-4ad6-a776-af26319c8a76"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Rosuvastatin tablets are an HMG Co-A reductase inhibitor indicated for: adult patients with hypertriglyceridemia as an adjunct to diet ( 1.3 ) adult patients with primary dysbetalipoproteinemia (Type III hyperlipoproteinemia) as an adjunct to diet ( 1.4 ) adult patients with homozygous familial hypercholesterolemia (HoFH) to reduce LDL-C, total-C, and ApoB ( 1.5 ) Limitations of use ( 1.8 ): Rosuvastatin tablets have not been studied in Fredrickson Type I and V dyslipidemias. uuid:9eb92dad-8099-4efe-9b71-cf1a77306aa3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5384 biolink:treats MONDO:0005147 PMID:41385096 "[{""id"":""uuid:c7905808-93a4-48f9-8981-011dbdb09249"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6b4b90f8-0bd5-4518-bfb3-c83eb3bfd73c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Glipizide extended-release tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. 1.1 Limitations of Use Glipizide extended-release tablets are not recommended for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis. uuid:db1b5d2f-05e1-4a99-965c-c676894478b7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5384 biolink:treats MONDO:0012819 PMID:41385096 "[{""id"":""uuid:ee89f972-97b5-4dba-87fc-6c04c9eebf55"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:359b10b0-3d21-4fa4-ab48-d59261f64aa4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Glipizide extended-release tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. 1.1 Limitations of Use Glipizide extended-release tablets are not recommended for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis. uuid:5bf0049e-001d-4791-85f1-e28f86c1f751 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PF9462I9HX biolink:treats UMLS:C0280100 PMID:41385096 "[{""id"":""uuid:fc579984-0ae2-4513-9095-d2b5cac48050"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:17e2b4ce-b156-4bb6-8324-8a1a1c35e69d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VITRAKVI is indicated for the treatment of adult and pediatric patients with solid tumors that: • have a neurotrophic receptor tyrosine kinase ( NTRK ) gene fusion without a known acquired resistance mutation, • are metastatic or where surgical resection is likely to result in severe morbidity, and • have no satisfactory alternative treatments or that have progressed following treatment. This indication is approved under accelerated approval based on overall response rate and duration of response [see Clinical Studies ( 14 )] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. uuid:aa6938d7-61d7-4550-bda3-961c997a4074 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63611 biolink:treats MONDO:0019095 PMID:41385096 "[{""id"":""uuid:b837896e-b8c3-47b4-802a-32473c626daf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1ba0e61a-428e-432f-8529-e18b608f6d1a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Moxifloxacin tablets are a fluoroquinolone antibacterial indicated for treating infections in adults 18 years of age and older caused by designated susceptible bacteria, in the conditions listed below: Community Acquired Pneumonia ( 1.1 ) Skin and Skin Structure Infections: Uncomplicated ( 1.2 ) and Complicated ( 1.3 ) Complicated Intra-Abdominal Infections ( 1.4 ) Plague ( 1.5 ) Acute Bacterial Sinusitis ( 1.6 ) Acute Bacterial Exacerbation of Chronic Bronchitis ( 1.7 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of moxifloxacin hydrochloride and other antibacterial drugs. Moxifloxacin hydrochloride should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. ( 1.8 ) uuid:6753e85d-0204-437d-991b-234b157c54b7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4325 biolink:treats MONDO:0011438 PMID:41385096 "[{""id"":""uuid:009c853f-d67b-45e4-828f-60931a308272"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d853f713-d980-4c0b-b299-8ec0ebe29e9b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dapsone Gel, 5%, is indicated for the topical treatment of acne vulgaris. uuid:4baa98ac-72e9-496e-a969-4f749dd58d49 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7447 biolink:treats MONDO:0005545 PMID:41385096 "[{""id"":""uuid:ef029fab-942d-4e09-85f4-d4f5464fc5a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:18e2dcbd-d623-44f2-add8-83c0d3927246"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nafcillin is indicated in the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug. Culture and susceptibility tests should be performed initially to determine the causative organism and its susceptibility to the drug (see CLINICAL PHARMACOLOGY , Susceptibility Testing ). Nafcillin should not be used in infections caused by organisms susceptible to penicillin G. If the susceptibility tests indicate that the infection is due to a methicillin-resistant Staphylococcus sp., therapy with Nafcillin for Injection should be discontinued and alternative therapy provided. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Nafcillin for Injection and other antibacterial drugs, Nafcillin for Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:4323f407-32d8-4a27-b92b-c004b0f65284 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7447 biolink:treats MONDO:0005113 PMID:41385096 "[{""id"":""uuid:1ccf96d4-cf7f-421c-b581-546b63cc2f69"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2d62b248-602d-4a96-b126-abf0c36447c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nafcillin is indicated in the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug. Culture and susceptibility tests should be performed initially to determine the causative organism and its susceptibility to the drug (see CLINICAL PHARMACOLOGY , Susceptibility Testing ). Nafcillin should not be used in infections caused by organisms susceptible to penicillin G. If the susceptibility tests indicate that the infection is due to a methicillin-resistant Staphylococcus sp., therapy with Nafcillin for Injection should be discontinued and alternative therapy provided. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Nafcillin for Injection and other antibacterial drugs, Nafcillin for Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:61845ecb-f6d6-4af2-86e7-4f7f464361d5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:18680304 biolink:treats MONDO:0004605 PMID:41385096 "[{""id"":""uuid:c1244508-80af-4202-8073-83a0aa8ce569"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cc2f33bb-2e14-4b43-af11-a5747acc5347"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Collagenase Santyl ◊ Ointment is indicated for debriding chronic dermal ulcers 2, 3, 4, 5, 6, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 and severely burned areas. 3, 4, 5, 7, 16, 19, 20, 21 uuid:98cf7902-f18c-4fe6-8b32-2dad977204d0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:18680304 biolink:treats UMLS:C0006434 PMID:41385096 "[{""id"":""uuid:21bf990f-4f5e-46ab-9f99-af629677761a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8b381ce2-aca1-4455-8648-aae59f3553a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Collagenase Santyl ◊ Ointment is indicated for debriding chronic dermal ulcers 2, 3, 4, 5, 6, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 and severely burned areas. 3, 4, 5, 7, 16, 19, 20, 21 uuid:5e45169c-af90-41ac-a269-0c033514ac41 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0301513 biolink:treats UMLS:C0936249 PMID:41385096 "[{""id"":""uuid:86c03bbf-290d-4963-ac85-41ce85b05465"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4c138075-97c0-4af2-bf64-79d7bccebb4e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VIGIV (vaccinia immune globulin intravenous, human) is indicated for the treatment and/or modification of the following conditions: • Eczema vaccinatum • Progressive vaccinia • Severe generalized vaccinia • Vaccinia infections in individuals who have skin conditions such as burns, impetigo, varicella-zoster, or poison ivy; or in individuals who have eczematous skin lesions because of either the activity or extensiveness of such lesions • Aberrant infections induced by vaccinia virus that include its accidental implantation in eyes (except in cases of isolated keratitis), mouth, or other areas where vaccinia infection would constitute a special hazard. VIGIV is not considered to be effective in the treatment of postvaccinial encephalitis. DRUGBANK:DB14112 uuid:0861437a-1a73-4bb3-b2a7-990dcb3cb388 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0301513 biolink:treats UMLS:C2721678 PMID:41385096 "[{""id"":""uuid:0eb74387-c299-4ec9-8f0a-569d2cfaf71f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3332f066-60cc-4ba4-9154-91d91b44e730"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VIGIV (vaccinia immune globulin intravenous, human) is indicated for the treatment and/or modification of the following conditions: • Eczema vaccinatum • Progressive vaccinia • Severe generalized vaccinia • Vaccinia infections in individuals who have skin conditions such as burns, impetigo, varicella-zoster, or poison ivy; or in individuals who have eczematous skin lesions because of either the activity or extensiveness of such lesions • Aberrant infections induced by vaccinia virus that include its accidental implantation in eyes (except in cases of isolated keratitis), mouth, or other areas where vaccinia infection would constitute a special hazard. VIGIV is not considered to be effective in the treatment of postvaccinial encephalitis. DRUGBANK:DB14112 uuid:a0bc9fc7-55c8-417b-a78d-fd99fff63672 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0301513 biolink:treats MONDO:0002595 PMID:41385096 "[{""id"":""uuid:ab23b49d-9323-4b1e-a83f-f99982f16119"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e8faa568-86b0-4b2f-bda6-069b5c3b20eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VIGIV (vaccinia immune globulin intravenous, human) is indicated for the treatment and/or modification of the following conditions: • Eczema vaccinatum • Progressive vaccinia • Severe generalized vaccinia • Vaccinia infections in individuals who have skin conditions such as burns, impetigo, varicella-zoster, or poison ivy; or in individuals who have eczematous skin lesions because of either the activity or extensiveness of such lesions • Aberrant infections induced by vaccinia virus that include its accidental implantation in eyes (except in cases of isolated keratitis), mouth, or other areas where vaccinia infection would constitute a special hazard. VIGIV is not considered to be effective in the treatment of postvaccinial encephalitis. DRUGBANK:DB14112 uuid:32f80385-1568-444e-ae3d-b81f092506b3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0301513 biolink:treats MONDO:0001773 PMID:41385096 "[{""id"":""uuid:4106a44e-2b3c-4bdc-90af-41b7aa752f99"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:125ca118-5dc0-4387-98d5-20b55c011e19"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VIGIV (vaccinia immune globulin intravenous, human) is indicated for the treatment and/or modification of the following conditions: • Eczema vaccinatum • Progressive vaccinia • Severe generalized vaccinia • Vaccinia infections in individuals who have skin conditions such as burns, impetigo, varicella-zoster, or poison ivy; or in individuals who have eczematous skin lesions because of either the activity or extensiveness of such lesions • Aberrant infections induced by vaccinia virus that include its accidental implantation in eyes (except in cases of isolated keratitis), mouth, or other areas where vaccinia infection would constitute a special hazard. VIGIV is not considered to be effective in the treatment of postvaccinial encephalitis. DRUGBANK:DB14112 uuid:be2e485f-71c0-4e34-a0a2-63a9a299b55e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31498 biolink:treats UMLS:C0406317 PMID:41385096 "[{""id"":""uuid:d4de129d-5c8d-47b7-9fc9-ffc2da9d2085"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fba3e911-5f4f-4ec4-9585-bc67b1cdfd25"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Calcipotriene Cream, 0.005%, is indicated for the treatment of plaque psoriasis. The safety and effectiveness of topical calcipotriene in dermatoses other than psoriasis have not been established. uuid:a0ad5611-ba15-446a-b985-0596eb51ab76 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9706 biolink:treats MONDO:0010200 PMID:41385096 "[{""id"":""uuid:5d9e71cd-c89b-419e-9d3e-003b1c804c3c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:022d97e6-e276-4d64-a5b7-d7283852a6f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:4aa3f87f-d178-4496-baab-50a14c7571c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Trientine hydrochloride capsules USP 250 mg is indicated in the treatment of patients with Wilson's disease who are intolerant of penicillamine. Clinical experience with trientine hydrochloride capsules USP 250 mg is limited and alternate dosing regimens have not been well-characterized; all endpoints in determining an individual patient's dose have not been well defined. Trientine hydrochloride capsules USP 250 mg and penicillamine cannot be considered interchangeable. Trientine hydrochloride capsules USP 250 mg should be used when continued treatment with penicillamine is no longer possible because of intolerable or life endangering side effects. Unlike penicillamine, trientine hydrochloride capsules USP 250 mg is not recommended in cystinuria or rheumatoid arthritis. The absence ofa sulfhydryl moiety renders it incapable of binding cystine and, therefore, it is of no use in cystinuria. In 15 patients with rheumatoid arthritis, trientine hydrochloride capsules USP 250 mg was reported not to be effective in improving any clinical or biochemical parameter after 12 weeks of treatment. Trientine hydrochloride capsules USP 250 mg is not indicated for treatment of biliary cirrhosis.|[EMA] Cuprior is indicated for the treatment of Wilson's disease in adults, adolescents and children ≥ 5 years intolerant to D-penicillamine therapy., uuid:90145cb3-74de-4055-91a5-9b43d0f9df30 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9706 biolink:treats MONDO:0009067 PMID:41385096 "[{""id"":""uuid:a226cbe4-57c7-46ff-8c63-f18ab02d92d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:99fd489d-8536-4a08-9dca-8024f2fac5ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Trientine hydrochloride capsules USP 250 mg is indicated in the treatment of patients with Wilson's disease who are intolerant of penicillamine. Clinical experience with trientine hydrochloride capsules USP 250 mg is limited and alternate dosing regimens have not been well-characterized; all endpoints in determining an individual patient's dose have not been well defined. Trientine hydrochloride capsules USP 250 mg and penicillamine cannot be considered interchangeable. Trientine hydrochloride capsules USP 250 mg should be used when continued treatment with penicillamine is no longer possible because of intolerable or life endangering side effects. Unlike penicillamine, trientine hydrochloride capsules USP 250 mg is not recommended in cystinuria or rheumatoid arthritis. The absence ofa sulfhydryl moiety renders it incapable of binding cystine and, therefore, it is of no use in cystinuria. In 15 patients with rheumatoid arthritis, trientine hydrochloride capsules USP 250 mg was reported not to be effective in improving any clinical or biochemical parameter after 12 weeks of treatment. Trientine hydrochloride capsules USP 250 mg is not indicated for treatment of biliary cirrhosis. uuid:0bf9bb6e-7fb8-4d2a-acd9-0b54f139e530 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9706 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:e84ad88f-abd5-449a-8fdb-92967dd8f5c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ec97459e-1882-4127-a417-c0397b9e0d13"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Trientine hydrochloride capsules USP 250 mg is indicated in the treatment of patients with Wilson's disease who are intolerant of penicillamine. Clinical experience with trientine hydrochloride capsules USP 250 mg is limited and alternate dosing regimens have not been well-characterized; all endpoints in determining an individual patient's dose have not been well defined. Trientine hydrochloride capsules USP 250 mg and penicillamine cannot be considered interchangeable. Trientine hydrochloride capsules USP 250 mg should be used when continued treatment with penicillamine is no longer possible because of intolerable or life endangering side effects. Unlike penicillamine, trientine hydrochloride capsules USP 250 mg is not recommended in cystinuria or rheumatoid arthritis. The absence ofa sulfhydryl moiety renders it incapable of binding cystine and, therefore, it is of no use in cystinuria. In 15 patients with rheumatoid arthritis, trientine hydrochloride capsules USP 250 mg was reported not to be effective in improving any clinical or biochemical parameter after 12 weeks of treatment. Trientine hydrochloride capsules USP 250 mg is not indicated for treatment of biliary cirrhosis. uuid:5ea81f22-0e8a-44f6-affe-b53035979e1c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9706 biolink:treats MONDO:0005388 PMID:41385096 "[{""id"":""uuid:624b221f-f8f6-4a0d-84f9-984df80240c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a31b75ea-f2ba-4d63-b4de-5ae809954899"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Trientine hydrochloride capsules USP 250 mg is indicated in the treatment of patients with Wilson's disease who are intolerant of penicillamine. Clinical experience with trientine hydrochloride capsules USP 250 mg is limited and alternate dosing regimens have not been well-characterized; all endpoints in determining an individual patient's dose have not been well defined. Trientine hydrochloride capsules USP 250 mg and penicillamine cannot be considered interchangeable. Trientine hydrochloride capsules USP 250 mg should be used when continued treatment with penicillamine is no longer possible because of intolerable or life endangering side effects. Unlike penicillamine, trientine hydrochloride capsules USP 250 mg is not recommended in cystinuria or rheumatoid arthritis. The absence ofa sulfhydryl moiety renders it incapable of binding cystine and, therefore, it is of no use in cystinuria. In 15 patients with rheumatoid arthritis, trientine hydrochloride capsules USP 250 mg was reported not to be effective in improving any clinical or biochemical parameter after 12 weeks of treatment. Trientine hydrochloride capsules USP 250 mg is not indicated for treatment of biliary cirrhosis. uuid:6c45e4c1-3183-49f2-93a0-ad587d19cf35 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75722 biolink:treats MONDO:0005530 PMID:41385096 "[{""id"":""uuid:61721768-b970-414b-885c-7a780b680609"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f3876d7c-3cb3-4877-a2f4-41cff12a13a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tramadol hydrochloride tablets are indicated in adults for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see Warnings and Precautions (5.1) ] , reserve tramadol hydrochloride tablets for use in patients for whom alternative treatment options [e.g., non-opioid analgesics]: Have not been tolerated or are not expected to be tolerated. Have not provided adequate analgesia or are not expected to provide adequate analgesia. uuid:19621e6d-c860-46a8-9cc3-c393c8beb3a6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63631 biolink:treats MONDO:0006710 PMID:41385096 "[{""id"":""uuid:8ebdc90c-7b85-4853-bffe-329a69bd6f85"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1e2ac326-30f1-4ebc-8b36-238011e5dcce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Monotherapy Epilepsy Topiramate tablets and topiramate capsules are indicated as initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 2 years of age and older. 1.2 Adjunctive Therapy Epilepsy Topiramate tablets and topiramate capsules are indicated as adjunctive therapy for for the treatment of partial-onset seizures, primary generalized tonic-clonic seizures, and seizures associated with Lennox-Gastaut syndrome in patients 2 years of age and older. 1.3 Migraine Topiramate tablets and topiramate capsules are indicated for the preventive treatment of migraine in patients 12 years of age and older. uuid:fa42a368-922d-40f0-8c52-5ee61fa40298 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:48669 biolink:treats MONDO:0018660 PMID:41385096 "[{""id"":""uuid:d10a8243-4ec9-4c9c-9008-008434f50556"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d0e09a9d-f002-4f8b-8919-8ff6ad36c84d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tranexamic Acid in Sodium Chloride Injection is indicated in patients with hemophilia for short-term use (two to eight days) to reduce the risk of hemorrhage during and following tooth extraction. uuid:f23e49eb-a6a1-4f0a-a04f-513cc8cdad8e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:48669 biolink:treats NCIT:C26791 PMID:41385096 "[{""id"":""uuid:308d912b-8b5b-4c7a-9a58-6acc862de33d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ca8ce71b-89fb-44a9-ac07-98a876085f15"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tranexamic Acid in Sodium Chloride Injection is indicated in patients with hemophilia for short-term use (two to eight days) to reduce the risk of hemorrhage during and following tooth extraction. uuid:3e24cb74-6480-441d-b058-8cb402759087 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:M89N0Q7EQR biolink:treats UMLS:C4721698 PMID:41385096 "[{""id"":""uuid:51572603-27dd-4e8f-8cbe-7af2c81ac91d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:37be91c5-e873-49cf-a192-8dd254be8ecb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Proleukin ® (aldesleukin) is indicated for the treatment of adults with metastatic renal cell carcinoma (metastatic RCC). Proleukin is indicated for the treatment of adults with metastatic melanoma. Careful patient selection is mandatory prior to the administration of Proleukin. See “ CONTRAINDICATIONS ”, “ WARNINGS ” and “ PRECAUTIONS ” sections regarding patient screening, including recommended cardiac and pulmonary function tests and laboratory tests. Evaluation of clinical studies to date reveals that patients with more favorable ECOG performance status (ECOG PS 0) at treatment initiation respond better to Proleukin, with a higher response rate and lower toxicity (See “ CLINICAL PHARMACOLOGY ” section, “ CLINICAL STUDIES ” section and “ ADVERSE REACTIONS ” section). Therefore, selection of patients for treatment should include assessment of performance status. Experience in patients with ECOG PS >1 is extremely limited. uuid:fc8e61ff-b597-4f2a-bd2b-d406511c28f0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:M89N0Q7EQR biolink:treats MONDO:0005191 PMID:41385096 "[{""id"":""uuid:8f74d9d2-0889-45c7-98eb-c254e9d881b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f6ee3e0f-4862-47f1-9a8b-cf83757e90f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Proleukin ® (aldesleukin) is indicated for the treatment of adults with metastatic renal cell carcinoma (metastatic RCC). Proleukin is indicated for the treatment of adults with metastatic melanoma. Careful patient selection is mandatory prior to the administration of Proleukin. See “ CONTRAINDICATIONS ”, “ WARNINGS ” and “ PRECAUTIONS ” sections regarding patient screening, including recommended cardiac and pulmonary function tests and laboratory tests. Evaluation of clinical studies to date reveals that patients with more favorable ECOG performance status (ECOG PS 0) at treatment initiation respond better to Proleukin, with a higher response rate and lower toxicity (See “ CLINICAL PHARMACOLOGY ” section, “ CLINICAL STUDIES ” section and “ ADVERSE REACTIONS ” section). Therefore, selection of patients for treatment should include assessment of performance status. Experience in patients with ECOG PS >1 is extremely limited. uuid:7d2973f4-5b7c-4001-bc63-ec9f90c991b4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7596 biolink:treats UMLS:C0264714 PMID:41385096 "[{""id"":""uuid:400cc48b-a9e8-4cfe-83b9-e158170141f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:80cebfcf-19c1-48f7-bdba-b17e1be7e78a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium nitroprusside is a direct acting vasodilator indicated for: • Immediate reduction of blood pressure ( 1.1 ) • Producing controlled hypotension to reduce bleeding during surgery. ( 1.2 ) • Treatment of acute heart failure to reduce left ventricular end-diastolic pressure, pulmonary capillary wedge pressure, peripheral vascular resistance and mean arterial blood pressure. ( 1.3 ) uuid:0e5e465d-9408-4040-8ae5-96f61d4bdf35 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1162777 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:a8f2394b-60ae-40fa-adfb-c5ebe4f75147"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0cd1cf9a-702b-4208-a09e-8330033fad5b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Olmesartan medoxomil and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Olmesartan medoxomil and hydrochlorothiazide tablets are not indicated for the initial therapy of hypertension [see Dosage and Administration (2) ] . Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with olmesartan medoxomil and hydrochlorothiazide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Olmesartan medoxomil and hydrochlorothiazide tablets may be used alone, or in combination with other antihypertensive drugs. uuid:98c21dfc-3458-47f4-a670-50a8c57b5ec8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1162777 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:b4ee8371-fa60-4106-906e-8eec746db04d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ee9d9d4f-e78c-44d7-a334-1804c53b27fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Olmesartan medoxomil and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Olmesartan medoxomil and hydrochlorothiazide tablets are not indicated for the initial therapy of hypertension [see Dosage and Administration (2) ] . Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with olmesartan medoxomil and hydrochlorothiazide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Olmesartan medoxomil and hydrochlorothiazide tablets may be used alone, or in combination with other antihypertensive drugs. uuid:82bb9cfb-cca9-458a-a6b7-7b47fb592a83 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1162777 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:0bb0deea-0178-4ee0-af7c-8d1b93c1d128"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c1df8aa4-a480-4d6e-8dc5-92da37aa9a1a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Olmesartan medoxomil and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Olmesartan medoxomil and hydrochlorothiazide tablets are not indicated for the initial therapy of hypertension [see Dosage and Administration (2) ] . Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with olmesartan medoxomil and hydrochlorothiazide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Olmesartan medoxomil and hydrochlorothiazide tablets may be used alone, or in combination with other antihypertensive drugs. uuid:a18fa7f9-1285-468a-9ba9-4b3f06c7b70d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1162777 biolink:treats MONDO:0005016 PMID:41385096 "[{""id"":""uuid:7d0a3f8b-a33a-4c3e-ae22-d9ecc576a64c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e25c8772-7aca-4aac-83fb-d31b392b05b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Olmesartan medoxomil and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Olmesartan medoxomil and hydrochlorothiazide tablets are not indicated for the initial therapy of hypertension [see Dosage and Administration (2) ] . Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with olmesartan medoxomil and hydrochlorothiazide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Olmesartan medoxomil and hydrochlorothiazide tablets may be used alone, or in combination with other antihypertensive drugs. uuid:fba516dd-27d6-4d48-ae69-899c0b4a1c50 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41423 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:91ae76e7-0cff-4f71-b58a-f817bd89c3a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f207ded2-4575-441b-9c2e-5934315aa811"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS Cardiovascular Thrombotic Events • Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction, and stroke, which can be fatal. This risk may occur early in the treatment and may increase with duration of use. [see Warnings and Precautions (5.1)] • Celecoxib capsules are contraindicated in the setting of coronary artery bypass graft (CABG) surgery. [see Contraindications (4) and Warnings and Precautions (5.1)] Gastrointestinal Bleeding, Ulceration, and Perforation • NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events. [see Warnings and Precautions (5.2)] uuid:fb01933b-ef6f-4078-a583-0d1eda58bb76 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41423 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:b9a843f8-15c1-454a-8387-35376bf6fa8e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:56237dcc-ed16-43c4-8422-ca1242e6615a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS Cardiovascular Thrombotic Events • Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction, and stroke, which can be fatal. This risk may occur early in the treatment and may increase with duration of use. [see Warnings and Precautions (5.1)] • Celecoxib capsules are contraindicated in the setting of coronary artery bypass graft (CABG) surgery. [see Contraindications (4) and Warnings and Precautions (5.1)] Gastrointestinal Bleeding, Ulceration, and Perforation • NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events. [see Warnings and Precautions (5.2)] uuid:f818b20e-009c-46d1-bd35-d93bd87c2e13 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41423 biolink:treats MONDO:0004247 PMID:41385096 "[{""id"":""uuid:4eed0f5a-268d-43a0-85f4-22835117f1d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4d1b5670-ea0b-4dd8-a78e-129e7cec0d9e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS Cardiovascular Thrombotic Events • Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction, and stroke, which can be fatal. This risk may occur early in the treatment and may increase with duration of use. [see Warnings and Precautions (5.1)] • Celecoxib capsules are contraindicated in the setting of coronary artery bypass graft (CABG) surgery. [see Contraindications (4) and Warnings and Precautions (5.1)] Gastrointestinal Bleeding, Ulceration, and Perforation • NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events. [see Warnings and Precautions (5.2)] uuid:b8c8e5eb-ec3c-4f91-a7e0-4f5fecedb9a5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41423 biolink:treats HP:0002239 PMID:41385096 "[{""id"":""uuid:c38cc523-834f-478b-b369-d19fa9321131"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d64bc5e7-34e9-4ca3-8b6d-38bb564b76cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS Cardiovascular Thrombotic Events • Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction, and stroke, which can be fatal. This risk may occur early in the treatment and may increase with duration of use. [see Warnings and Precautions (5.1)] • Celecoxib capsules are contraindicated in the setting of coronary artery bypass graft (CABG) surgery. [see Contraindications (4) and Warnings and Precautions (5.1)] Gastrointestinal Bleeding, Ulceration, and Perforation • NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events. [see Warnings and Precautions (5.2)] uuid:5c590652-b811-41fe-bd7a-17685d9d4230 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:34246 biolink:treats MONDO:0006668 PMID:41385096 "[{""id"":""uuid:002b4298-1424-446c-ba42-d885a1f4005b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a57dde25-91ef-4854-adc6-9c03b12e49ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Trimethoprim Sulfate and Polymyxin B Sulfate Ophthalmic Solution is indicated in the treatment of surface ocular bacterial infections, including acute bacterial conjunctivitis, and blepharoconjunctivitis, caused by susceptible strains of the following microorganisms: Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus viridans, Haemophilus influenza and Pseudomonas aeruginosa.* *Efficacy for this organism in this organ system was studied in fewer than 10 infections. uuid:cc27a949-74f4-49bf-b77d-c1154fd97c28 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:34246 biolink:treats MONDO:0002307 PMID:41385096 "[{""id"":""uuid:aa7a7d86-d6cb-461d-a47e-022eec552179"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2887bc3e-9242-4cae-aa48-b7d9583fbf5e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Trimethoprim Sulfate and Polymyxin B Sulfate Ophthalmic Solution is indicated in the treatment of surface ocular bacterial infections, including acute bacterial conjunctivitis, and blepharoconjunctivitis, caused by susceptible strains of the following microorganisms: Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus viridans, Haemophilus influenza and Pseudomonas aeruginosa.* *Efficacy for this organism in this organ system was studied in fewer than 10 infections. uuid:4a673d45-282a-4a22-9d28-b3ca69bb91c7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5134 biolink:treats UMLS:C0741804 PMID:41385096 "[{""id"":""uuid:67a46fca-9dcf-4301-b5a6-aa8a03d0c5a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6265b5b4-75ae-427d-be28-5749b97fda86"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Flovent DISKUS is indicated for the maintenance treatment of asthma as prophylactic therapy in patients aged 4 years and older. Important Limitation of Use FLOVENT DISKUS is NOT indicated for the relief of acute bronchospasm. uuid:42e23870-ff8a-46b6-8e23-989ec6b593a7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75722 biolink:treats MONDO:0001225 PMID:41385096 "[{""id"":""uuid:b71d5df9-25da-4681-b10e-27bf57db661f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cd761e0b-dfab-4e6d-9e35-d6430fb7742a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tramadol hydrochloride tablets are indicated in adults for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see Warnings and Precautions (5.1)], reserve tramadol hydrochloride tablets for use in patients for whom alternative treatment options [e.g., non-opioid analgesics]: Have not been tolerated or are not expected to be tolerated. Have not provided adequate analgesia or are not expected to provide adequate analgesia. uuid:2a2ece1c-c3d3-4284-8c57-4b0685b6253c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135939 biolink:treats MONDO:0006710 PMID:41385096 "[{""id"":""uuid:81f79d97-5ef2-40db-9043-73a22a78102f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e65400bd-04f6-48a0-9105-7d6c5ffc5d8e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VIMPAT is indicated for the treatment of partial-onset seizures in patients 4 years of age and older. As the safety of VIMPAT injection in pediatric patients has not been established, VIMPAT injection is indicated for the treatment of partial-onset seizures only in adult patients (17 years of age and older). uuid:7e5b13ad-e67d-4ea6-b3f8-30f65097e7d7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64356 biolink:treats MONDO:0006710 PMID:41385096 "[{""id"":""uuid:011fe346-a701-405f-9e97-f0ffdb62d0a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ebc8e618-fc04-4ec1-bf5b-64127f4540e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pregabalin capsules are indicated for: • Management of neuropathic pain associated with diabetic peripheral neuropathy • Management of postherpetic neuralgia • Adjunctive therapy for the treatment of partial-onset seizures in patients 17 years of age and older • Management of fibromyalgia • Management of neuropathic pain associated with spinal cord injury Pediatric use information is approved for Pfizer’s LYRICA (pregabalin) Capsules and Oral Solution products. However, due to Pfizer’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. uuid:e90f66a2-b169-4e2a-9e13-8198ec62f74b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:24783652 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:f9d95638-7709-41fb-a734-9680f05dc834"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a6900d2a-d659-4bcb-82a8-c10d0b00105d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Hypertension Losartan potassium and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan and hydrochlorothiazide. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in Black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. This fixed dose combination is not indicated for initial therapy of hypertension, except when the hypertension is severe enough that the value of achieving prompt blood pressure control exceeds the risk of initiating combination therapy in these patients [see CLINICAL STUDIES (14) and DOSAGE AND ADMINISTRATION (2.1)]. Losartan potassium and hydrochlorothiazide tablets may be administered with other antihypertensive agents. 1.2 Hypertensive Patients with Left Ventricular Hypertrophy Losartan potassium and hydrochlorothiazide tablets are indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to Black patients [see USE IN SPECIFIC POPULATIONS (8.6), CLINICAL PHARMACOLOGY (12.3), and DOSAGE AND ADMINISTRATION (2.2)]. uuid:6958032f-69b4-4a77-82b8-58c8d2029ca0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:24783652 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:a3d23c90-becd-464f-acf4-b1e6afe20983"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:05ed0b9a-a1a6-48ad-befe-eab6eeadc6ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Hypertension Losartan potassium and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan and hydrochlorothiazide. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in Black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. This fixed dose combination is not indicated for initial therapy of hypertension, except when the hypertension is severe enough that the value of achieving prompt blood pressure control exceeds the risk of initiating combination therapy in these patients [see CLINICAL STUDIES (14) and DOSAGE AND ADMINISTRATION (2.1)]. Losartan potassium and hydrochlorothiazide tablets may be administered with other antihypertensive agents. 1.2 Hypertensive Patients with Left Ventricular Hypertrophy Losartan potassium and hydrochlorothiazide tablets are indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to Black patients [see USE IN SPECIFIC POPULATIONS (8.6), CLINICAL PHARMACOLOGY (12.3), and DOSAGE AND ADMINISTRATION (2.2)]. uuid:733b4fed-4598-4091-a3a0-52c8981c7a88 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:24783652 biolink:treats HP:0001712 PMID:41385096 "[{""id"":""uuid:784b965e-7077-4644-af1d-19ec169f3d13"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:892965b1-03e7-4815-aed4-3648d7056947"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Hypertension Losartan potassium and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan and hydrochlorothiazide. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in Black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. This fixed dose combination is not indicated for initial therapy of hypertension, except when the hypertension is severe enough that the value of achieving prompt blood pressure control exceeds the risk of initiating combination therapy in these patients [see CLINICAL STUDIES (14) and DOSAGE AND ADMINISTRATION (2.1)]. Losartan potassium and hydrochlorothiazide tablets may be administered with other antihypertensive agents. 1.2 Hypertensive Patients with Left Ventricular Hypertrophy Losartan potassium and hydrochlorothiazide tablets are indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to Black patients [see USE IN SPECIFIC POPULATIONS (8.6), CLINICAL PHARMACOLOGY (12.3), and DOSAGE AND ADMINISTRATION (2.2)]. uuid:d19fdb85-93b3-4300-9e59-73b6f2d3988f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:24783652 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:7a981630-71a4-45dc-9635-26c4c1cb2ecd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:86b73500-1bf0-433f-a72f-b69d2c602db9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Hypertension Losartan potassium and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan and hydrochlorothiazide. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in Black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. This fixed dose combination is not indicated for initial therapy of hypertension, except when the hypertension is severe enough that the value of achieving prompt blood pressure control exceeds the risk of initiating combination therapy in these patients [see CLINICAL STUDIES (14) and DOSAGE AND ADMINISTRATION (2.1)]. Losartan potassium and hydrochlorothiazide tablets may be administered with other antihypertensive agents. 1.2 Hypertensive Patients with Left Ventricular Hypertrophy Losartan potassium and hydrochlorothiazide tablets are indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to Black patients [see USE IN SPECIFIC POPULATIONS (8.6), CLINICAL PHARMACOLOGY (12.3), and DOSAGE AND ADMINISTRATION (2.2)]. uuid:bf071b72-1789-4657-b6d4-46f182ec08b8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:24783652 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:9ceb31c5-7db3-46e0-8f5e-7fc706b340d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aaf16c7b-55b5-4db5-b949-4da7d643f4fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Hypertension Losartan potassium and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan and hydrochlorothiazide. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in Black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. This fixed dose combination is not indicated for initial therapy of hypertension, except when the hypertension is severe enough that the value of achieving prompt blood pressure control exceeds the risk of initiating combination therapy in these patients [see CLINICAL STUDIES (14) and DOSAGE AND ADMINISTRATION (2.1)]. Losartan potassium and hydrochlorothiazide tablets may be administered with other antihypertensive agents. 1.2 Hypertensive Patients with Left Ventricular Hypertrophy Losartan potassium and hydrochlorothiazide tablets are indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to Black patients [see USE IN SPECIFIC POPULATIONS (8.6), CLINICAL PHARMACOLOGY (12.3), and DOSAGE AND ADMINISTRATION (2.2)]. uuid:d13db0a1-e627-4b05-a550-e29b1e7ab937 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:24783652 biolink:treats HP:0001681 PMID:41385096 "[{""id"":""uuid:0cdd1781-8124-442e-84a1-083ef6bb0af2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d08db1cf-ef5c-4c16-8f0e-916ef932a50b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Hypertension Losartan potassium and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan and hydrochlorothiazide. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in Black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. This fixed dose combination is not indicated for initial therapy of hypertension, except when the hypertension is severe enough that the value of achieving prompt blood pressure control exceeds the risk of initiating combination therapy in these patients [see CLINICAL STUDIES (14) and DOSAGE AND ADMINISTRATION (2.1)]. Losartan potassium and hydrochlorothiazide tablets may be administered with other antihypertensive agents. 1.2 Hypertensive Patients with Left Ventricular Hypertrophy Losartan potassium and hydrochlorothiazide tablets are indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to Black patients [see USE IN SPECIFIC POPULATIONS (8.6), CLINICAL PHARMACOLOGY (12.3), and DOSAGE AND ADMINISTRATION (2.2)]. uuid:10b047c0-2132-478b-a366-07f109422e9b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:24783652 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:22617fef-3826-41a4-ad3f-45c076829fe1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:211acc23-4413-42a2-8070-9aac74b529a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Hypertension Losartan potassium and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan and hydrochlorothiazide. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in Black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. This fixed dose combination is not indicated for initial therapy of hypertension, except when the hypertension is severe enough that the value of achieving prompt blood pressure control exceeds the risk of initiating combination therapy in these patients [see CLINICAL STUDIES (14) and DOSAGE AND ADMINISTRATION (2.1)]. Losartan potassium and hydrochlorothiazide tablets may be administered with other antihypertensive agents. 1.2 Hypertensive Patients with Left Ventricular Hypertrophy Losartan potassium and hydrochlorothiazide tablets are indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to Black patients [see USE IN SPECIFIC POPULATIONS (8.6), CLINICAL PHARMACOLOGY (12.3), and DOSAGE AND ADMINISTRATION (2.2)]. uuid:6061d7e1-da69-433e-8f16-e7830ac2841b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:24783652 biolink:treats MONDO:0005016 PMID:41385096 "[{""id"":""uuid:5986ce3e-c579-4b0b-811c-e4c087828ae4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e12c111f-06d3-4ab2-8fca-b7a00918e901"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Hypertension Losartan potassium and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan and hydrochlorothiazide. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in Black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. This fixed dose combination is not indicated for initial therapy of hypertension, except when the hypertension is severe enough that the value of achieving prompt blood pressure control exceeds the risk of initiating combination therapy in these patients [see CLINICAL STUDIES (14) and DOSAGE AND ADMINISTRATION (2.1)]. Losartan potassium and hydrochlorothiazide tablets may be administered with other antihypertensive agents. 1.2 Hypertensive Patients with Left Ventricular Hypertrophy Losartan potassium and hydrochlorothiazide tablets are indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to Black patients [see USE IN SPECIFIC POPULATIONS (8.6), CLINICAL PHARMACOLOGY (12.3), and DOSAGE AND ADMINISTRATION (2.2)]. uuid:0419f6f3-c0c3-48c0-8a28-a29a5df36268 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17594 biolink:treats MONDO:0019289 PMID:41385096 "[{""id"":""uuid:d3352fb2-fb38-4bbd-93f9-01067e814587"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5fc20d94-6ce3-43bf-8a83-0339f860b5c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] HELPS LIGHTEN DARK PATCHES OF SKIN SUCH AS AGE SPOTS, MELASMA, FRECKLES AND HYPERPIGMENTATION THAT CAN OCCUR AS A RESULT OF PREGNANCY, USE OF ORAL CONTRACEPTIVES OR INJURY TO THE SKIN. RX ONLY. FOR EXTERNAL USE ONLY. uuid:76f28c7b-6c55-4256-a153-e9a6ea2ba1e1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6375 biolink:treats MONDO:0019610 PMID:41385096 "[{""id"":""uuid:9d9c7477-c3a9-4f03-b341-af9e6c8c0115"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c9839800-fd85-463a-b070-242bd49ef375"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lansoprazole delayed-release capsule is a proton pump inhibitor (PPIs) indicated for the: • Treatment of active duodenal ulcer in adults. ( 1.1 ) • Eradication of H. pylori to reduce the risk of duodenal ulcer recurrence in adults. ( 1.2 ) • Maintenance of healed duodenal ulcers in adults. ( 1.3 ) • Treatment of active benign gastric ulcer in adults. ( 1.4 ) • Healing of non-steroidal anti-inflammatory drugs (NSAID)-associated gastric ulcer in adults. ( 1.5 ) • Risk reduction of NSAID-associated gastric ulcer in adults. ( 1.6 ) • Treatment of symptomatic gastroesophageal reflux disease (GERD) in adults and pediatric patients 1 year of age and older.( 1.7 ) • Treatment of erosive esophagitis (EE) in adults and pediatric patients 1 year of age and older. ( 1.8 ) • Maintenance of healing of EE in adults. ( 1.9 ) • Pathological hypersecretory conditions, including Zollinger-Ellison syndrome (ZES) in adults. ( 1.10 ) uuid:b209a9b0-16b5-434b-a5b9-aa687ef2da12 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:87715 biolink:treats MONDO:0000990 PMID:41385096 "[{""id"":""uuid:e2745936-8717-4cf0-a536-226521bf2743"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:6a6f124f-09fd-4e99-a37f-65f8a2cbd01d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ee24ba54-0e4e-43db-97e4-e8a8573cda9f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/efient""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prasugrel tablets is a P2Y 12 platelet inhibitor indicated for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndrome who are to be managed with PCI as follows: • Patients with unstable angina or non-ST-elevation myocardial infarction (NSTEMI) ( 1.1 ). • Patients with ST-elevation myocardial infarction (STEMI) when managed with either primary or delayed PCI ( 1.1 ).|[EMA] Efient, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in patients with acute coronary syndrome (i.e. unstable angina, non-ST-segment-elevation myocardial infarction [UA / NSTEMI] or ST-segment-elevation myocardial infarction [STEMI]) undergoing primary or delayed percutaneous coronary intervention (PCI). uuid:e460793d-a456-4150-9e52-92f5add62988 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:87715 biolink:treats MONDO:0041656 PMID:41385096 "[{""id"":""uuid:8730c58f-f2db-432c-b3b0-7641a35543f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4cbcc257-a6c3-4252-9469-839869e6fd44"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:de42e5c4-8e28-4364-89ba-56bbef81c581"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/efient""]},{""id"":""uuid:1dcdddd3-4e36-41d8-8e48-786a541da120"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prasugrel tablets is a P2Y 12 platelet inhibitor indicated for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndrome who are to be managed with PCI as follows: • Patients with unstable angina or non-ST-elevation myocardial infarction (NSTEMI) ( 1.1 ). • Patients with ST-elevation myocardial infarction (STEMI) when managed with either primary or delayed PCI ( 1.1 ).|[EMA] Efient, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in patients with acute coronary syndrome (i.e. unstable angina, non-ST-segment-elevation myocardial infarction [UA / NSTEMI] or ST-segment-elevation myocardial infarction [STEMI]) undergoing primary or delayed percutaneous coronary intervention (PCI).|[PMDA] Drugs with a new active ingredient indicated for the treatment of the following ischemic heart diseases managed with percutaneous coronary intervention (PCI): acute coronary syndrome (unstable angina, non ST-segment elevation myocardial infarction, ST- segment elevation myocardial infarction), stable angina, old myocardial infarction. uuid:0649cc66-d68d-4c81-b1c5-b8922c588bf8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47426 biolink:treats UMLS:C0155919 PMID:41385096 "[{""id"":""uuid:d2fd5728-b9e0-4c76-b1c5-7ace871bb416"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:25ba3f8c-c796-46a2-99e2-9f97997d0d68"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Parenteral therapy should be reserved for patients unable to take oral medication or for patients in emergency clinical situations. Edema Furosemide is indicated in adults and pediatric patients for the treatment of edema associated with congestive heart failure, cirrhosis of the liver and renal disease, including the nephrotic syndrome. Furosemide is particularly useful when an agent with greater diuretic potential is desired. Furosemide is indicated as adjunctive therapy in acute pulmonary edema. The intravenous administration of furosemide is indicated when a rapid onset of diuresis is desired, e.g., in acute pulmonary edema. If gastrointestinal absorption is impaired or oral medication is not practical for any reason, furosemide is indicated by the intravenous or intramuscular route. Parenteral use should be replaced with oral furosemide as soon as practical. uuid:03dda0de-89c4-4275-98b3-64023723cd2a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63630 biolink:treats MONDO:0005180 PMID:41385096 "[{""id"":""uuid:3552461d-985f-4d5a-8916-2eb4862f179d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:375dcbcc-caad-4cea-add9-c5db310abd09"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:a67834cf-0266-4108-b3ec-f6c204e9380d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/tasmar""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tolcapone tablets, USP is indicated as an adjunct to levodopa and carbidopa for the treatment of the signs and symptoms of idiopathic Parkinson's disease. Because of the risk of potentially fatal, acute fulminant liver failure, tolcapone tablets, USP should ordinarily be used in patients with Parkinson's disease on l-dopa/carbidopa who are experiencing symptom fluctuations and are not responding satisfactorily to or are not appropriate candidates for other adjunctive therapies. Because of the risk of liver injury and because tolcapone tablets, USP, when it is effective, provides an observable symptomatic benefit, the patient who fails to show substantial clinical benefit within 3 weeks of initiation of treatment, should be withdrawn from tolcapone tablets, USP. The effectiveness of tolcapone tablets, USP was demonstrated in randomized controlled trials in patients receiving concomitant levodopa therapy with carbidopa or another aromatic amino acid decarboxylase inhibitor who experienced end of dose wearing-off phenomena as well as in patients who did not experience such phenomena (see CLINICAL PHARMACOLOGY : Clinical Studies ).|[EMA] Tasmar is indicated in combination with levodopa / benserazide or levodopa / carbidopa for use in patients with levodopa-responsive idiopathic Parkinson’s disease and motor fluctuations, who failed to respond to or are intolerant of other catechol-O-methyltransferase (COMT) inhibitors.Because of the risk of potentially fatal, acute liver injury, Tasmar should not be considered as a first-line adjunct therapy to levodopa / benserazide or levodopa / carbidopa.Since Tasmar should be used only in combination with levodopa / benserazide and levodopa / carbidopa, the prescribing information for these levodopa preparations is also applicable to their concomitant use with Tasmar. uuid:3ee2283f-2e68-453b-89d2-5aebc0bdbfc8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63630 biolink:treats MONDO:0019542 PMID:41385096 "[{""id"":""uuid:991eb27b-8c83-432f-b0c5-87a6dabedadc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7ccd253e-a92e-4ff6-8dd1-b1cf75575988"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tolcapone tablets, USP is indicated as an adjunct to levodopa and carbidopa for the treatment of the signs and symptoms of idiopathic Parkinson's disease. Because of the risk of potentially fatal, acute fulminant liver failure, tolcapone tablets, USP should ordinarily be used in patients with Parkinson's disease on l-dopa/carbidopa who are experiencing symptom fluctuations and are not responding satisfactorily to or are not appropriate candidates for other adjunctive therapies. Because of the risk of liver injury and because tolcapone tablets, USP, when it is effective, provides an observable symptomatic benefit, the patient who fails to show substantial clinical benefit within 3 weeks of initiation of treatment, should be withdrawn from tolcapone tablets, USP. The effectiveness of tolcapone tablets, USP was demonstrated in randomized controlled trials in patients receiving concomitant levodopa therapy with carbidopa or another aromatic amino acid decarboxylase inhibitor who experienced end of dose wearing-off phenomena as well as in patients who did not experience such phenomena (see CLINICAL PHARMACOLOGY : Clinical Studies ). uuid:7325b5ec-0de9-4d6c-a582-3c6b7f91c29b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3508 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:24097ea8-cc2b-4be0-a35a-de61fa85c699"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:86389938-bc76-40c3-bad6-676da97ac987"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FORTAZ is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: 1. Lower Respiratory Tract Infections, including pneumonia, caused by Pseudomonas aeruginosa and other Pseudomonas spp.; Haemophilus influenzae , including ampicillin-resistant strains; Klebsiella spp.; Enterobacter spp.; Proteus mirabilis ; Escherichia coli ; Serratia spp.; Citrobacter spp.; Streptococcus pneumoniae ; and Staphylococcus aureus (methicillin-susceptible strains). 2. Skin and Skin-Structure Infections caused by Pseudomonas aeruginosa ; Klebsiella spp.; Escherichia coli ; Proteus spp., including Proteus mirabilis and indole-positive Proteus ; Enterobacter spp.; Serratia spp.; Staphylococcus aureus (methicillin-susceptible strains); and Streptococcus pyogenes (group A beta-hemolytic streptococci). 3. Urinary Tract Infections, both complicated and uncomplicated, caused by Pseudomonas aeruginosa ; Enterobacter spp.; Proteus spp., including Proteus mirabilis and indole-positive Proteus ; Klebsiella spp.; and Escherichia coli . 4. Bacterial Septicemia caused by Pseudomonas aeruginosa , Klebsiella spp., Haemophilus influenzae, Escherichia coli , Serratia spp., Streptococcus pneumoniae, and Staphylococcus aureus (methicillin-susceptible strains). 5. Bone and Joint Infections caused by Pseudomonas aeruginosa, Klebsiella spp., Enterobacter spp., and Staphylococcus aureus (methicillin-susceptible strains). 6. Gynecologic Infections, including endometritis, pelvic cellulitis, and other infections of the female genital tract caused by Escherichia coli . 7. Intra-abdominal Infections, including peritonitis caused by Escherichia coli , Klebsiella spp., and Staphylococcus aureus (methicillin-susceptible strains) and polymicrobial infections caused by aerobic and anaerobic organisms and Bacteroides spp. (many strains of Bacteroides fragilis are resistant). 8. Central Nervous System Infections, including meningitis, caused by Haemophilus influenzae and Neisseria meningitidis . Ceftazidime has also been used successfully in a limited number of cases of meningitis due to Pseudomonas aeruginosa and Streptococcus pneumoniae. FORTAZ may be used alone in cases of confirmed or suspected sepsis. Ceftazidime has been used successfully in clinical trials as empiric therapy in cases where various concomitant therapies with other antibacterial drugs have been used. FORTAZ may also be used concomitantly with other antibacterial drugs, such as aminoglycosides, vancomycin, and clindamycin; in severe and life-threatening infections; and in the immunocompromised patient. When such concomitant treatment is appropriate, prescribing information in the labeling for the other antibacterial drugs should be followed. The dose depends on the severity of the infection and the patient's condition. To reduce the development of drug-resistant bacteria and maintain the effectiveness of FORTAZ and other antibacterial drugs, FORTAZ should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:72ad71ea-2c78-4210-9a37-f7480abeb8a4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3508 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:ef1186c4-e9ae-46c4-9f3e-d9f3172942fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bc6cb114-2990-4f1e-b184-4912f431644e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FORTAZ is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: 1. Lower Respiratory Tract Infections, including pneumonia, caused by Pseudomonas aeruginosa and other Pseudomonas spp.; Haemophilus influenzae , including ampicillin-resistant strains; Klebsiella spp.; Enterobacter spp.; Proteus mirabilis ; Escherichia coli ; Serratia spp.; Citrobacter spp.; Streptococcus pneumoniae ; and Staphylococcus aureus (methicillin-susceptible strains). 2. Skin and Skin-Structure Infections caused by Pseudomonas aeruginosa ; Klebsiella spp.; Escherichia coli ; Proteus spp., including Proteus mirabilis and indole-positive Proteus ; Enterobacter spp.; Serratia spp.; Staphylococcus aureus (methicillin-susceptible strains); and Streptococcus pyogenes (group A beta-hemolytic streptococci). 3. Urinary Tract Infections, both complicated and uncomplicated, caused by Pseudomonas aeruginosa ; Enterobacter spp.; Proteus spp., including Proteus mirabilis and indole-positive Proteus ; Klebsiella spp.; and Escherichia coli . 4. Bacterial Septicemia caused by Pseudomonas aeruginosa , Klebsiella spp., Haemophilus influenzae, Escherichia coli , Serratia spp., Streptococcus pneumoniae, and Staphylococcus aureus (methicillin-susceptible strains). 5. Bone and Joint Infections caused by Pseudomonas aeruginosa, Klebsiella spp., Enterobacter spp., and Staphylococcus aureus (methicillin-susceptible strains). 6. Gynecologic Infections, including endometritis, pelvic cellulitis, and other infections of the female genital tract caused by Escherichia coli . 7. Intra-abdominal Infections, including peritonitis caused by Escherichia coli , Klebsiella spp., and Staphylococcus aureus (methicillin-susceptible strains) and polymicrobial infections caused by aerobic and anaerobic organisms and Bacteroides spp. (many strains of Bacteroides fragilis are resistant). 8. Central Nervous System Infections, including meningitis, caused by Haemophilus influenzae and Neisseria meningitidis . Ceftazidime has also been used successfully in a limited number of cases of meningitis due to Pseudomonas aeruginosa and Streptococcus pneumoniae. FORTAZ may be used alone in cases of confirmed or suspected sepsis. Ceftazidime has been used successfully in clinical trials as empiric therapy in cases where various concomitant therapies with other antibacterial drugs have been used. FORTAZ may also be used concomitantly with other antibacterial drugs, such as aminoglycosides, vancomycin, and clindamycin; in severe and life-threatening infections; and in the immunocompromised patient. When such concomitant treatment is appropriate, prescribing information in the labeling for the other antibacterial drugs should be followed. The dose depends on the severity of the infection and the patient's condition. To reduce the development of drug-resistant bacteria and maintain the effectiveness of FORTAZ and other antibacterial drugs, FORTAZ should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:c98d459b-6706-49ec-9f1b-d8b040ed70fe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3508 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:f3596430-6f60-4fec-99ad-8eeb3f4bbd43"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bdaee3f5-da3e-4431-a137-d835a172df74"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FORTAZ is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: 1. Lower Respiratory Tract Infections, including pneumonia, caused by Pseudomonas aeruginosa and other Pseudomonas spp.; Haemophilus influenzae , including ampicillin-resistant strains; Klebsiella spp.; Enterobacter spp.; Proteus mirabilis ; Escherichia coli ; Serratia spp.; Citrobacter spp.; Streptococcus pneumoniae ; and Staphylococcus aureus (methicillin-susceptible strains). 2. Skin and Skin-Structure Infections caused by Pseudomonas aeruginosa ; Klebsiella spp.; Escherichia coli ; Proteus spp., including Proteus mirabilis and indole-positive Proteus ; Enterobacter spp.; Serratia spp.; Staphylococcus aureus (methicillin-susceptible strains); and Streptococcus pyogenes (group A beta-hemolytic streptococci). 3. Urinary Tract Infections, both complicated and uncomplicated, caused by Pseudomonas aeruginosa ; Enterobacter spp.; Proteus spp., including Proteus mirabilis and indole-positive Proteus ; Klebsiella spp.; and Escherichia coli . 4. Bacterial Septicemia caused by Pseudomonas aeruginosa , Klebsiella spp., Haemophilus influenzae, Escherichia coli , Serratia spp., Streptococcus pneumoniae, and Staphylococcus aureus (methicillin-susceptible strains). 5. Bone and Joint Infections caused by Pseudomonas aeruginosa, Klebsiella spp., Enterobacter spp., and Staphylococcus aureus (methicillin-susceptible strains). 6. Gynecologic Infections, including endometritis, pelvic cellulitis, and other infections of the female genital tract caused by Escherichia coli . 7. Intra-abdominal Infections, including peritonitis caused by Escherichia coli , Klebsiella spp., and Staphylococcus aureus (methicillin-susceptible strains) and polymicrobial infections caused by aerobic and anaerobic organisms and Bacteroides spp. (many strains of Bacteroides fragilis are resistant). 8. Central Nervous System Infections, including meningitis, caused by Haemophilus influenzae and Neisseria meningitidis . Ceftazidime has also been used successfully in a limited number of cases of meningitis due to Pseudomonas aeruginosa and Streptococcus pneumoniae. FORTAZ may be used alone in cases of confirmed or suspected sepsis. Ceftazidime has been used successfully in clinical trials as empiric therapy in cases where various concomitant therapies with other antibacterial drugs have been used. FORTAZ may also be used concomitantly with other antibacterial drugs, such as aminoglycosides, vancomycin, and clindamycin; in severe and life-threatening infections; and in the immunocompromised patient. When such concomitant treatment is appropriate, prescribing information in the labeling for the other antibacterial drugs should be followed. The dose depends on the severity of the infection and the patient's condition. To reduce the development of drug-resistant bacteria and maintain the effectiveness of FORTAZ and other antibacterial drugs, FORTAZ should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:27b0f1ae-7114-4d86-8e75-4e4036711560 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3508 biolink:treats UMLS:C0684256 PMID:41385096 "[{""id"":""uuid:e533e459-532a-4474-b7ce-6a95cef07e7b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c3590dda-6e77-4cc8-b69a-19269ad86fe9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FORTAZ is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: 1. Lower Respiratory Tract Infections, including pneumonia, caused by Pseudomonas aeruginosa and other Pseudomonas spp.; Haemophilus influenzae , including ampicillin-resistant strains; Klebsiella spp.; Enterobacter spp.; Proteus mirabilis ; Escherichia coli ; Serratia spp.; Citrobacter spp.; Streptococcus pneumoniae ; and Staphylococcus aureus (methicillin-susceptible strains). 2. Skin and Skin-Structure Infections caused by Pseudomonas aeruginosa ; Klebsiella spp.; Escherichia coli ; Proteus spp., including Proteus mirabilis and indole-positive Proteus ; Enterobacter spp.; Serratia spp.; Staphylococcus aureus (methicillin-susceptible strains); and Streptococcus pyogenes (group A beta-hemolytic streptococci). 3. Urinary Tract Infections, both complicated and uncomplicated, caused by Pseudomonas aeruginosa ; Enterobacter spp.; Proteus spp., including Proteus mirabilis and indole-positive Proteus ; Klebsiella spp.; and Escherichia coli . 4. Bacterial Septicemia caused by Pseudomonas aeruginosa , Klebsiella spp., Haemophilus influenzae, Escherichia coli , Serratia spp., Streptococcus pneumoniae, and Staphylococcus aureus (methicillin-susceptible strains). 5. Bone and Joint Infections caused by Pseudomonas aeruginosa, Klebsiella spp., Enterobacter spp., and Staphylococcus aureus (methicillin-susceptible strains). 6. Gynecologic Infections, including endometritis, pelvic cellulitis, and other infections of the female genital tract caused by Escherichia coli . 7. Intra-abdominal Infections, including peritonitis caused by Escherichia coli , Klebsiella spp., and Staphylococcus aureus (methicillin-susceptible strains) and polymicrobial infections caused by aerobic and anaerobic organisms and Bacteroides spp. (many strains of Bacteroides fragilis are resistant). 8. Central Nervous System Infections, including meningitis, caused by Haemophilus influenzae and Neisseria meningitidis . Ceftazidime has also been used successfully in a limited number of cases of meningitis due to Pseudomonas aeruginosa and Streptococcus pneumoniae. FORTAZ may be used alone in cases of confirmed or suspected sepsis. Ceftazidime has been used successfully in clinical trials as empiric therapy in cases where various concomitant therapies with other antibacterial drugs have been used. FORTAZ may also be used concomitantly with other antibacterial drugs, such as aminoglycosides, vancomycin, and clindamycin; in severe and life-threatening infections; and in the immunocompromised patient. When such concomitant treatment is appropriate, prescribing information in the labeling for the other antibacterial drugs should be followed. The dose depends on the severity of the infection and the patient's condition. To reduce the development of drug-resistant bacteria and maintain the effectiveness of FORTAZ and other antibacterial drugs, FORTAZ should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:2d98a20f-bc77-4fcc-862d-a96762e157fd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3508 biolink:treats UMLS:C0851989 PMID:41385096 "[{""id"":""uuid:745e7a5f-4a60-4ee6-9517-e3a5af047e00"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d5413475-e8ec-40a5-8a05-fda00b6ce29a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FORTAZ is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: 1. Lower Respiratory Tract Infections, including pneumonia, caused by Pseudomonas aeruginosa and other Pseudomonas spp.; Haemophilus influenzae , including ampicillin-resistant strains; Klebsiella spp.; Enterobacter spp.; Proteus mirabilis ; Escherichia coli ; Serratia spp.; Citrobacter spp.; Streptococcus pneumoniae ; and Staphylococcus aureus (methicillin-susceptible strains). 2. Skin and Skin-Structure Infections caused by Pseudomonas aeruginosa ; Klebsiella spp.; Escherichia coli ; Proteus spp., including Proteus mirabilis and indole-positive Proteus ; Enterobacter spp.; Serratia spp.; Staphylococcus aureus (methicillin-susceptible strains); and Streptococcus pyogenes (group A beta-hemolytic streptococci). 3. Urinary Tract Infections, both complicated and uncomplicated, caused by Pseudomonas aeruginosa ; Enterobacter spp.; Proteus spp., including Proteus mirabilis and indole-positive Proteus ; Klebsiella spp.; and Escherichia coli . 4. Bacterial Septicemia caused by Pseudomonas aeruginosa , Klebsiella spp., Haemophilus influenzae, Escherichia coli , Serratia spp., Streptococcus pneumoniae, and Staphylococcus aureus (methicillin-susceptible strains). 5. Bone and Joint Infections caused by Pseudomonas aeruginosa, Klebsiella spp., Enterobacter spp., and Staphylococcus aureus (methicillin-susceptible strains). 6. Gynecologic Infections, including endometritis, pelvic cellulitis, and other infections of the female genital tract caused by Escherichia coli . 7. Intra-abdominal Infections, including peritonitis caused by Escherichia coli , Klebsiella spp., and Staphylococcus aureus (methicillin-susceptible strains) and polymicrobial infections caused by aerobic and anaerobic organisms and Bacteroides spp. (many strains of Bacteroides fragilis are resistant). 8. Central Nervous System Infections, including meningitis, caused by Haemophilus influenzae and Neisseria meningitidis . Ceftazidime has also been used successfully in a limited number of cases of meningitis due to Pseudomonas aeruginosa and Streptococcus pneumoniae. FORTAZ may be used alone in cases of confirmed or suspected sepsis. Ceftazidime has been used successfully in clinical trials as empiric therapy in cases where various concomitant therapies with other antibacterial drugs have been used. FORTAZ may also be used concomitantly with other antibacterial drugs, such as aminoglycosides, vancomycin, and clindamycin; in severe and life-threatening infections; and in the immunocompromised patient. When such concomitant treatment is appropriate, prescribing information in the labeling for the other antibacterial drugs should be followed. The dose depends on the severity of the infection and the patient's condition. To reduce the development of drug-resistant bacteria and maintain the effectiveness of FORTAZ and other antibacterial drugs, FORTAZ should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:b56f5be2-0473-4343-a5b1-3ae42dae9125 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3508 biolink:treats MONDO:0000918 PMID:41385096 "[{""id"":""uuid:53994b60-1750-4bfe-a0d4-44fb831154b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7c048bdd-32cb-4085-920d-238e3c8bd297"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FORTAZ is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: 1. Lower Respiratory Tract Infections, including pneumonia, caused by Pseudomonas aeruginosa and other Pseudomonas spp.; Haemophilus influenzae , including ampicillin-resistant strains; Klebsiella spp.; Enterobacter spp.; Proteus mirabilis ; Escherichia coli ; Serratia spp.; Citrobacter spp.; Streptococcus pneumoniae ; and Staphylococcus aureus (methicillin-susceptible strains). 2. Skin and Skin-Structure Infections caused by Pseudomonas aeruginosa ; Klebsiella spp.; Escherichia coli ; Proteus spp., including Proteus mirabilis and indole-positive Proteus ; Enterobacter spp.; Serratia spp.; Staphylococcus aureus (methicillin-susceptible strains); and Streptococcus pyogenes (group A beta-hemolytic streptococci). 3. Urinary Tract Infections, both complicated and uncomplicated, caused by Pseudomonas aeruginosa ; Enterobacter spp.; Proteus spp., including Proteus mirabilis and indole-positive Proteus ; Klebsiella spp.; and Escherichia coli . 4. Bacterial Septicemia caused by Pseudomonas aeruginosa , Klebsiella spp., Haemophilus influenzae, Escherichia coli , Serratia spp., Streptococcus pneumoniae, and Staphylococcus aureus (methicillin-susceptible strains). 5. Bone and Joint Infections caused by Pseudomonas aeruginosa, Klebsiella spp., Enterobacter spp., and Staphylococcus aureus (methicillin-susceptible strains). 6. Gynecologic Infections, including endometritis, pelvic cellulitis, and other infections of the female genital tract caused by Escherichia coli . 7. Intra-abdominal Infections, including peritonitis caused by Escherichia coli , Klebsiella spp., and Staphylococcus aureus (methicillin-susceptible strains) and polymicrobial infections caused by aerobic and anaerobic organisms and Bacteroides spp. (many strains of Bacteroides fragilis are resistant). 8. Central Nervous System Infections, including meningitis, caused by Haemophilus influenzae and Neisseria meningitidis . Ceftazidime has also been used successfully in a limited number of cases of meningitis due to Pseudomonas aeruginosa and Streptococcus pneumoniae. FORTAZ may be used alone in cases of confirmed or suspected sepsis. Ceftazidime has been used successfully in clinical trials as empiric therapy in cases where various concomitant therapies with other antibacterial drugs have been used. FORTAZ may also be used concomitantly with other antibacterial drugs, such as aminoglycosides, vancomycin, and clindamycin; in severe and life-threatening infections; and in the immunocompromised patient. When such concomitant treatment is appropriate, prescribing information in the labeling for the other antibacterial drugs should be followed. The dose depends on the severity of the infection and the patient's condition. To reduce the development of drug-resistant bacteria and maintain the effectiveness of FORTAZ and other antibacterial drugs, FORTAZ should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:c6401873-9917-401b-a14f-28f5f32d190c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3508 biolink:treats MONDO:0006887 PMID:41385096 "[{""id"":""uuid:27493e4a-ae42-4ef9-bbcc-df0833dad952"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2f480d85-b3f2-4136-ad8a-8c213442db6f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FORTAZ is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: 1. Lower Respiratory Tract Infections, including pneumonia, caused by Pseudomonas aeruginosa and other Pseudomonas spp.; Haemophilus influenzae , including ampicillin-resistant strains; Klebsiella spp.; Enterobacter spp.; Proteus mirabilis ; Escherichia coli ; Serratia spp.; Citrobacter spp.; Streptococcus pneumoniae ; and Staphylococcus aureus (methicillin-susceptible strains). 2. Skin and Skin-Structure Infections caused by Pseudomonas aeruginosa ; Klebsiella spp.; Escherichia coli ; Proteus spp., including Proteus mirabilis and indole-positive Proteus ; Enterobacter spp.; Serratia spp.; Staphylococcus aureus (methicillin-susceptible strains); and Streptococcus pyogenes (group A beta-hemolytic streptococci). 3. Urinary Tract Infections, both complicated and uncomplicated, caused by Pseudomonas aeruginosa ; Enterobacter spp.; Proteus spp., including Proteus mirabilis and indole-positive Proteus ; Klebsiella spp.; and Escherichia coli . 4. Bacterial Septicemia caused by Pseudomonas aeruginosa , Klebsiella spp., Haemophilus influenzae, Escherichia coli , Serratia spp., Streptococcus pneumoniae, and Staphylococcus aureus (methicillin-susceptible strains). 5. Bone and Joint Infections caused by Pseudomonas aeruginosa, Klebsiella spp., Enterobacter spp., and Staphylococcus aureus (methicillin-susceptible strains). 6. Gynecologic Infections, including endometritis, pelvic cellulitis, and other infections of the female genital tract caused by Escherichia coli . 7. Intra-abdominal Infections, including peritonitis caused by Escherichia coli , Klebsiella spp., and Staphylococcus aureus (methicillin-susceptible strains) and polymicrobial infections caused by aerobic and anaerobic organisms and Bacteroides spp. (many strains of Bacteroides fragilis are resistant). 8. Central Nervous System Infections, including meningitis, caused by Haemophilus influenzae and Neisseria meningitidis . Ceftazidime has also been used successfully in a limited number of cases of meningitis due to Pseudomonas aeruginosa and Streptococcus pneumoniae. FORTAZ may be used alone in cases of confirmed or suspected sepsis. Ceftazidime has been used successfully in clinical trials as empiric therapy in cases where various concomitant therapies with other antibacterial drugs have been used. FORTAZ may also be used concomitantly with other antibacterial drugs, such as aminoglycosides, vancomycin, and clindamycin; in severe and life-threatening infections; and in the immunocompromised patient. When such concomitant treatment is appropriate, prescribing information in the labeling for the other antibacterial drugs should be followed. The dose depends on the severity of the infection and the patient's condition. To reduce the development of drug-resistant bacteria and maintain the effectiveness of FORTAZ and other antibacterial drugs, FORTAZ should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:5884a000-ec46-479f-af1f-4f9ffab7b430 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3508 biolink:treats UMLS:C1112209 PMID:41385096 "[{""id"":""uuid:3c96f779-0f48-4cc7-8b32-e85ea8ae23e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ff4ec2d0-6932-4d7e-80f3-e1ff217a5580"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FORTAZ is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: 1. Lower Respiratory Tract Infections, including pneumonia, caused by Pseudomonas aeruginosa and other Pseudomonas spp.; Haemophilus influenzae , including ampicillin-resistant strains; Klebsiella spp.; Enterobacter spp.; Proteus mirabilis ; Escherichia coli ; Serratia spp.; Citrobacter spp.; Streptococcus pneumoniae ; and Staphylococcus aureus (methicillin-susceptible strains). 2. Skin and Skin-Structure Infections caused by Pseudomonas aeruginosa ; Klebsiella spp.; Escherichia coli ; Proteus spp., including Proteus mirabilis and indole-positive Proteus ; Enterobacter spp.; Serratia spp.; Staphylococcus aureus (methicillin-susceptible strains); and Streptococcus pyogenes (group A beta-hemolytic streptococci). 3. Urinary Tract Infections, both complicated and uncomplicated, caused by Pseudomonas aeruginosa ; Enterobacter spp.; Proteus spp., including Proteus mirabilis and indole-positive Proteus ; Klebsiella spp.; and Escherichia coli . 4. Bacterial Septicemia caused by Pseudomonas aeruginosa , Klebsiella spp., Haemophilus influenzae, Escherichia coli , Serratia spp., Streptococcus pneumoniae, and Staphylococcus aureus (methicillin-susceptible strains). 5. Bone and Joint Infections caused by Pseudomonas aeruginosa, Klebsiella spp., Enterobacter spp., and Staphylococcus aureus (methicillin-susceptible strains). 6. Gynecologic Infections, including endometritis, pelvic cellulitis, and other infections of the female genital tract caused by Escherichia coli . 7. Intra-abdominal Infections, including peritonitis caused by Escherichia coli , Klebsiella spp., and Staphylococcus aureus (methicillin-susceptible strains) and polymicrobial infections caused by aerobic and anaerobic organisms and Bacteroides spp. (many strains of Bacteroides fragilis are resistant). 8. Central Nervous System Infections, including meningitis, caused by Haemophilus influenzae and Neisseria meningitidis . Ceftazidime has also been used successfully in a limited number of cases of meningitis due to Pseudomonas aeruginosa and Streptococcus pneumoniae. FORTAZ may be used alone in cases of confirmed or suspected sepsis. Ceftazidime has been used successfully in clinical trials as empiric therapy in cases where various concomitant therapies with other antibacterial drugs have been used. FORTAZ may also be used concomitantly with other antibacterial drugs, such as aminoglycosides, vancomycin, and clindamycin; in severe and life-threatening infections; and in the immunocompromised patient. When such concomitant treatment is appropriate, prescribing information in the labeling for the other antibacterial drugs should be followed. The dose depends on the severity of the infection and the patient's condition. To reduce the development of drug-resistant bacteria and maintain the effectiveness of FORTAZ and other antibacterial drugs, FORTAZ should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:73a506db-7ed4-4d4e-958c-78c327fdc07e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3508 biolink:treats MONDO:0004522 PMID:41385096 "[{""id"":""uuid:06925f31-d276-4783-88d4-3d556d6c1b8e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:60d56c94-a4ee-4fea-8608-6a0baf63e2ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FORTAZ is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: 1. Lower Respiratory Tract Infections, including pneumonia, caused by Pseudomonas aeruginosa and other Pseudomonas spp.; Haemophilus influenzae , including ampicillin-resistant strains; Klebsiella spp.; Enterobacter spp.; Proteus mirabilis ; Escherichia coli ; Serratia spp.; Citrobacter spp.; Streptococcus pneumoniae ; and Staphylococcus aureus (methicillin-susceptible strains). 2. Skin and Skin-Structure Infections caused by Pseudomonas aeruginosa ; Klebsiella spp.; Escherichia coli ; Proteus spp., including Proteus mirabilis and indole-positive Proteus ; Enterobacter spp.; Serratia spp.; Staphylococcus aureus (methicillin-susceptible strains); and Streptococcus pyogenes (group A beta-hemolytic streptococci). 3. Urinary Tract Infections, both complicated and uncomplicated, caused by Pseudomonas aeruginosa ; Enterobacter spp.; Proteus spp., including Proteus mirabilis and indole-positive Proteus ; Klebsiella spp.; and Escherichia coli . 4. Bacterial Septicemia caused by Pseudomonas aeruginosa , Klebsiella spp., Haemophilus influenzae, Escherichia coli , Serratia spp., Streptococcus pneumoniae, and Staphylococcus aureus (methicillin-susceptible strains). 5. Bone and Joint Infections caused by Pseudomonas aeruginosa, Klebsiella spp., Enterobacter spp., and Staphylococcus aureus (methicillin-susceptible strains). 6. Gynecologic Infections, including endometritis, pelvic cellulitis, and other infections of the female genital tract caused by Escherichia coli . 7. Intra-abdominal Infections, including peritonitis caused by Escherichia coli , Klebsiella spp., and Staphylococcus aureus (methicillin-susceptible strains) and polymicrobial infections caused by aerobic and anaerobic organisms and Bacteroides spp. (many strains of Bacteroides fragilis are resistant). 8. Central Nervous System Infections, including meningitis, caused by Haemophilus influenzae and Neisseria meningitidis . Ceftazidime has also been used successfully in a limited number of cases of meningitis due to Pseudomonas aeruginosa and Streptococcus pneumoniae. FORTAZ may be used alone in cases of confirmed or suspected sepsis. Ceftazidime has been used successfully in clinical trials as empiric therapy in cases where various concomitant therapies with other antibacterial drugs have been used. FORTAZ may also be used concomitantly with other antibacterial drugs, such as aminoglycosides, vancomycin, and clindamycin; in severe and life-threatening infections; and in the immunocompromised patient. When such concomitant treatment is appropriate, prescribing information in the labeling for the other antibacterial drugs should be followed. The dose depends on the severity of the infection and the patient's condition. To reduce the development of drug-resistant bacteria and maintain the effectiveness of FORTAZ and other antibacterial drugs, FORTAZ should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:49d5fd76-97f4-48c8-8ac7-45274ce2150d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3508 biolink:treats MONDO:0024619 PMID:41385096 "[{""id"":""uuid:5d6a1bcd-eec0-4d10-829b-df5d12534108"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:93fba6a2-1c7c-41df-97ee-120e58911999"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FORTAZ is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: 1. Lower Respiratory Tract Infections, including pneumonia, caused by Pseudomonas aeruginosa and other Pseudomonas spp.; Haemophilus influenzae , including ampicillin-resistant strains; Klebsiella spp.; Enterobacter spp.; Proteus mirabilis ; Escherichia coli ; Serratia spp.; Citrobacter spp.; Streptococcus pneumoniae ; and Staphylococcus aureus (methicillin-susceptible strains). 2. Skin and Skin-Structure Infections caused by Pseudomonas aeruginosa ; Klebsiella spp.; Escherichia coli ; Proteus spp., including Proteus mirabilis and indole-positive Proteus ; Enterobacter spp.; Serratia spp.; Staphylococcus aureus (methicillin-susceptible strains); and Streptococcus pyogenes (group A beta-hemolytic streptococci). 3. Urinary Tract Infections, both complicated and uncomplicated, caused by Pseudomonas aeruginosa ; Enterobacter spp.; Proteus spp., including Proteus mirabilis and indole-positive Proteus ; Klebsiella spp.; and Escherichia coli . 4. Bacterial Septicemia caused by Pseudomonas aeruginosa , Klebsiella spp., Haemophilus influenzae, Escherichia coli , Serratia spp., Streptococcus pneumoniae, and Staphylococcus aureus (methicillin-susceptible strains). 5. Bone and Joint Infections caused by Pseudomonas aeruginosa, Klebsiella spp., Enterobacter spp., and Staphylococcus aureus (methicillin-susceptible strains). 6. Gynecologic Infections, including endometritis, pelvic cellulitis, and other infections of the female genital tract caused by Escherichia coli . 7. Intra-abdominal Infections, including peritonitis caused by Escherichia coli , Klebsiella spp., and Staphylococcus aureus (methicillin-susceptible strains) and polymicrobial infections caused by aerobic and anaerobic organisms and Bacteroides spp. (many strains of Bacteroides fragilis are resistant). 8. Central Nervous System Infections, including meningitis, caused by Haemophilus influenzae and Neisseria meningitidis . Ceftazidime has also been used successfully in a limited number of cases of meningitis due to Pseudomonas aeruginosa and Streptococcus pneumoniae. FORTAZ may be used alone in cases of confirmed or suspected sepsis. Ceftazidime has been used successfully in clinical trials as empiric therapy in cases where various concomitant therapies with other antibacterial drugs have been used. FORTAZ may also be used concomitantly with other antibacterial drugs, such as aminoglycosides, vancomycin, and clindamycin; in severe and life-threatening infections; and in the immunocompromised patient. When such concomitant treatment is appropriate, prescribing information in the labeling for the other antibacterial drugs should be followed. The dose depends on the severity of the infection and the patient's condition. To reduce the development of drug-resistant bacteria and maintain the effectiveness of FORTAZ and other antibacterial drugs, FORTAZ should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:19af9e48-3335-4b52-8f72-ce935919cbcb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3508 biolink:treats MONDO:0021108 PMID:41385096 "[{""id"":""uuid:3dec547f-dcd7-4d2a-919f-9ea638a851a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8b598fe1-2626-4500-9f93-2b1706c8ba72"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FORTAZ is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: 1. Lower Respiratory Tract Infections, including pneumonia, caused by Pseudomonas aeruginosa and other Pseudomonas spp.; Haemophilus influenzae , including ampicillin-resistant strains; Klebsiella spp.; Enterobacter spp.; Proteus mirabilis ; Escherichia coli ; Serratia spp.; Citrobacter spp.; Streptococcus pneumoniae ; and Staphylococcus aureus (methicillin-susceptible strains). 2. Skin and Skin-Structure Infections caused by Pseudomonas aeruginosa ; Klebsiella spp.; Escherichia coli ; Proteus spp., including Proteus mirabilis and indole-positive Proteus ; Enterobacter spp.; Serratia spp.; Staphylococcus aureus (methicillin-susceptible strains); and Streptococcus pyogenes (group A beta-hemolytic streptococci). 3. Urinary Tract Infections, both complicated and uncomplicated, caused by Pseudomonas aeruginosa ; Enterobacter spp.; Proteus spp., including Proteus mirabilis and indole-positive Proteus ; Klebsiella spp.; and Escherichia coli . 4. Bacterial Septicemia caused by Pseudomonas aeruginosa , Klebsiella spp., Haemophilus influenzae, Escherichia coli , Serratia spp., Streptococcus pneumoniae, and Staphylococcus aureus (methicillin-susceptible strains). 5. Bone and Joint Infections caused by Pseudomonas aeruginosa, Klebsiella spp., Enterobacter spp., and Staphylococcus aureus (methicillin-susceptible strains). 6. Gynecologic Infections, including endometritis, pelvic cellulitis, and other infections of the female genital tract caused by Escherichia coli . 7. Intra-abdominal Infections, including peritonitis caused by Escherichia coli , Klebsiella spp., and Staphylococcus aureus (methicillin-susceptible strains) and polymicrobial infections caused by aerobic and anaerobic organisms and Bacteroides spp. (many strains of Bacteroides fragilis are resistant). 8. Central Nervous System Infections, including meningitis, caused by Haemophilus influenzae and Neisseria meningitidis . Ceftazidime has also been used successfully in a limited number of cases of meningitis due to Pseudomonas aeruginosa and Streptococcus pneumoniae. FORTAZ may be used alone in cases of confirmed or suspected sepsis. Ceftazidime has been used successfully in clinical trials as empiric therapy in cases where various concomitant therapies with other antibacterial drugs have been used. FORTAZ may also be used concomitantly with other antibacterial drugs, such as aminoglycosides, vancomycin, and clindamycin; in severe and life-threatening infections; and in the immunocompromised patient. When such concomitant treatment is appropriate, prescribing information in the labeling for the other antibacterial drugs should be followed. The dose depends on the severity of the infection and the patient's condition. To reduce the development of drug-resistant bacteria and maintain the effectiveness of FORTAZ and other antibacterial drugs, FORTAZ should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:3fb74b1f-262c-492f-9bfc-092d25fb9e50 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3508 biolink:treats HP:0100806 PMID:41385096 "[{""id"":""uuid:801fb606-1c7d-43ac-8818-44ed78c5306d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5bc21429-2ecc-41c0-bcb5-9e6407d4ca2b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FORTAZ is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: 1. Lower Respiratory Tract Infections, including pneumonia, caused by Pseudomonas aeruginosa and other Pseudomonas spp.; Haemophilus influenzae , including ampicillin-resistant strains; Klebsiella spp.; Enterobacter spp.; Proteus mirabilis ; Escherichia coli ; Serratia spp.; Citrobacter spp.; Streptococcus pneumoniae ; and Staphylococcus aureus (methicillin-susceptible strains). 2. Skin and Skin-Structure Infections caused by Pseudomonas aeruginosa ; Klebsiella spp.; Escherichia coli ; Proteus spp., including Proteus mirabilis and indole-positive Proteus ; Enterobacter spp.; Serratia spp.; Staphylococcus aureus (methicillin-susceptible strains); and Streptococcus pyogenes (group A beta-hemolytic streptococci). 3. Urinary Tract Infections, both complicated and uncomplicated, caused by Pseudomonas aeruginosa ; Enterobacter spp.; Proteus spp., including Proteus mirabilis and indole-positive Proteus ; Klebsiella spp.; and Escherichia coli . 4. Bacterial Septicemia caused by Pseudomonas aeruginosa , Klebsiella spp., Haemophilus influenzae, Escherichia coli , Serratia spp., Streptococcus pneumoniae, and Staphylococcus aureus (methicillin-susceptible strains). 5. Bone and Joint Infections caused by Pseudomonas aeruginosa, Klebsiella spp., Enterobacter spp., and Staphylococcus aureus (methicillin-susceptible strains). 6. Gynecologic Infections, including endometritis, pelvic cellulitis, and other infections of the female genital tract caused by Escherichia coli . 7. Intra-abdominal Infections, including peritonitis caused by Escherichia coli , Klebsiella spp., and Staphylococcus aureus (methicillin-susceptible strains) and polymicrobial infections caused by aerobic and anaerobic organisms and Bacteroides spp. (many strains of Bacteroides fragilis are resistant). 8. Central Nervous System Infections, including meningitis, caused by Haemophilus influenzae and Neisseria meningitidis . Ceftazidime has also been used successfully in a limited number of cases of meningitis due to Pseudomonas aeruginosa and Streptococcus pneumoniae. FORTAZ may be used alone in cases of confirmed or suspected sepsis. Ceftazidime has been used successfully in clinical trials as empiric therapy in cases where various concomitant therapies with other antibacterial drugs have been used. FORTAZ may also be used concomitantly with other antibacterial drugs, such as aminoglycosides, vancomycin, and clindamycin; in severe and life-threatening infections; and in the immunocompromised patient. When such concomitant treatment is appropriate, prescribing information in the labeling for the other antibacterial drugs should be followed. The dose depends on the severity of the infection and the patient's condition. To reduce the development of drug-resistant bacteria and maintain the effectiveness of FORTAZ and other antibacterial drugs, FORTAZ should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:5b25aa0b-622d-4eee-b066-d0240092e017 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3W5S57M958 biolink:treats UMLS:C0853854 PMID:41385096 "[{""id"":""uuid:34588930-69e2-45d4-b071-35a7d76af670"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b3ee48df-3dd8-423d-b207-a3595a881d1c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azithromycin tablets are a macrolide antibacterial drug indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. Recommended dosages and durations of therapy in adult and pediatric patient populations vary in these indications. [see DOSAGE AND ADMINISTRATION (2)] 1.1 Adult Patients Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae , Moraxella catarrhalis, or Streptococcus pneumoniae . Acute bacterial sinusitis due to Haemophilus influenzae , Moraxella catarrhalis or Streptococcus pneumoniae . Community-acquired pneumonia due to Chlamydophila pneumoniae , Haemophilus influenzae , Mycoplasma pneumoniae, or Streptococcus pneumoniae in patients appropriate for oral therapy. Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. Uncomplicated skin and skin structure infections due to Staphylococcus aureus , Streptococcus pyogenes , or Streptococcus agalactiae . Urethritis and cervicitis due to Chlamydia trachomatis or Neisseria gonorrhoeae . Genital ulcer disease in men due to Haemophilus ducreyi (chancroid). Due to the small number of women included in clinical trials, the efficacy of azithromycin in the treatment of chancroid in women has not been established. 1.2 Pediatric Patients [see USE IN SPECIFIC POPULATIONS (8.4) and CLINICAL STUDIES (14.2)] Acute otitis media (>6 months of age) caused by Haemophilus influenzae , Moraxella catarrhalis, or Streptococcus pneumoniae. Community-acquired pneumonia (>6 months ofage) due to Chlamydophila pneumoniae , Haemophilus influenzae , Mycoplasma pneumoniae , or Streptococcus pneumoniae in patients appropriate for oral therapy. Pharyngitis/tonsillitis (>2 years of age) caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. 1.3 Limitations of Use Azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomial infections, patients with known or suspected bacteremia, patients requiring hospitalization, elderly or debilitated patients, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). 1.4 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin and other antibacterial drugs, azithromycin should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. PUBCHEM.COMPOUND:16156 uuid:2b19c18a-4134-4a44-a0e9-06ffc70c7896 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3W5S57M958 biolink:treats UMLS:C0275556 PMID:41385096 "[{""id"":""uuid:6eba2359-ba3c-49a3-b6dc-6eb97ddb7568"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b1755096-a7b7-4a2d-b610-c96f9f484076"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azithromycin tablets are a macrolide antibacterial drug indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. Recommended dosages and durations of therapy in adult and pediatric patient populations vary in these indications. [see DOSAGE AND ADMINISTRATION (2)] 1.1 Adult Patients Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae , Moraxella catarrhalis, or Streptococcus pneumoniae . Acute bacterial sinusitis due to Haemophilus influenzae , Moraxella catarrhalis or Streptococcus pneumoniae . Community-acquired pneumonia due to Chlamydophila pneumoniae , Haemophilus influenzae , Mycoplasma pneumoniae, or Streptococcus pneumoniae in patients appropriate for oral therapy. Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. Uncomplicated skin and skin structure infections due to Staphylococcus aureus , Streptococcus pyogenes , or Streptococcus agalactiae . Urethritis and cervicitis due to Chlamydia trachomatis or Neisseria gonorrhoeae . Genital ulcer disease in men due to Haemophilus ducreyi (chancroid). Due to the small number of women included in clinical trials, the efficacy of azithromycin in the treatment of chancroid in women has not been established. 1.2 Pediatric Patients [see USE IN SPECIFIC POPULATIONS (8.4) and CLINICAL STUDIES (14.2)] Acute otitis media (>6 months of age) caused by Haemophilus influenzae , Moraxella catarrhalis, or Streptococcus pneumoniae. Community-acquired pneumonia (>6 months ofage) due to Chlamydophila pneumoniae , Haemophilus influenzae , Mycoplasma pneumoniae , or Streptococcus pneumoniae in patients appropriate for oral therapy. Pharyngitis/tonsillitis (>2 years of age) caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. 1.3 Limitations of Use Azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomial infections, patients with known or suspected bacteremia, patients requiring hospitalization, elderly or debilitated patients, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). 1.4 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin and other antibacterial drugs, azithromycin should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. PUBCHEM.COMPOUND:16156 uuid:3f073743-5470-4143-a9d4-35abdd6325e5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3W5S57M958 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:d9413af3-7051-46fc-9c54-9c114d58f1b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:06fc1b15-9cb8-4767-bc51-dd9a00c47a13"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azithromycin tablets are a macrolide antibacterial drug indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. Recommended dosages and durations of therapy in adult and pediatric patient populations vary in these indications. [see DOSAGE AND ADMINISTRATION (2)] 1.1 Adult Patients Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae , Moraxella catarrhalis, or Streptococcus pneumoniae . Acute bacterial sinusitis due to Haemophilus influenzae , Moraxella catarrhalis or Streptococcus pneumoniae . Community-acquired pneumonia due to Chlamydophila pneumoniae , Haemophilus influenzae , Mycoplasma pneumoniae, or Streptococcus pneumoniae in patients appropriate for oral therapy. Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. Uncomplicated skin and skin structure infections due to Staphylococcus aureus , Streptococcus pyogenes , or Streptococcus agalactiae . Urethritis and cervicitis due to Chlamydia trachomatis or Neisseria gonorrhoeae . Genital ulcer disease in men due to Haemophilus ducreyi (chancroid). Due to the small number of women included in clinical trials, the efficacy of azithromycin in the treatment of chancroid in women has not been established. 1.2 Pediatric Patients [see USE IN SPECIFIC POPULATIONS (8.4) and CLINICAL STUDIES (14.2)] Acute otitis media (>6 months of age) caused by Haemophilus influenzae , Moraxella catarrhalis, or Streptococcus pneumoniae. Community-acquired pneumonia (>6 months ofage) due to Chlamydophila pneumoniae , Haemophilus influenzae , Mycoplasma pneumoniae , or Streptococcus pneumoniae in patients appropriate for oral therapy. Pharyngitis/tonsillitis (>2 years of age) caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. 1.3 Limitations of Use Azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomial infections, patients with known or suspected bacteremia, patients requiring hospitalization, elderly or debilitated patients, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). 1.4 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin and other antibacterial drugs, azithromycin should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. PUBCHEM.COMPOUND:16156 uuid:0794f666-6d0b-470a-8ef2-4113fac4fb6b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3W5S57M958 biolink:treats MONDO:0002258 PMID:41385096 "[{""id"":""uuid:b9d9b5b4-4350-46bc-88d4-152e6e90b35a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e0df41bc-faff-4818-8c8a-d2d13a1872c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azithromycin tablets are a macrolide antibacterial drug indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. Recommended dosages and durations of therapy in adult and pediatric patient populations vary in these indications. [see DOSAGE AND ADMINISTRATION (2)] 1.1 Adult Patients Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae , Moraxella catarrhalis, or Streptococcus pneumoniae . Acute bacterial sinusitis due to Haemophilus influenzae , Moraxella catarrhalis or Streptococcus pneumoniae . Community-acquired pneumonia due to Chlamydophila pneumoniae , Haemophilus influenzae , Mycoplasma pneumoniae, or Streptococcus pneumoniae in patients appropriate for oral therapy. Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. Uncomplicated skin and skin structure infections due to Staphylococcus aureus , Streptococcus pyogenes , or Streptococcus agalactiae . Urethritis and cervicitis due to Chlamydia trachomatis or Neisseria gonorrhoeae . Genital ulcer disease in men due to Haemophilus ducreyi (chancroid). Due to the small number of women included in clinical trials, the efficacy of azithromycin in the treatment of chancroid in women has not been established. 1.2 Pediatric Patients [see USE IN SPECIFIC POPULATIONS (8.4) and CLINICAL STUDIES (14.2)] Acute otitis media (>6 months of age) caused by Haemophilus influenzae , Moraxella catarrhalis, or Streptococcus pneumoniae. Community-acquired pneumonia (>6 months ofage) due to Chlamydophila pneumoniae , Haemophilus influenzae , Mycoplasma pneumoniae , or Streptococcus pneumoniae in patients appropriate for oral therapy. Pharyngitis/tonsillitis (>2 years of age) caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. 1.3 Limitations of Use Azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomial infections, patients with known or suspected bacteremia, patients requiring hospitalization, elderly or debilitated patients, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). 1.4 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin and other antibacterial drugs, azithromycin should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. PUBCHEM.COMPOUND:16156 uuid:34e5578f-e0b3-4da7-ba4b-17c39dfbd45b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3W5S57M958 biolink:treats MONDO:0001039 PMID:41385096 "[{""id"":""uuid:80dd010d-3025-4089-874f-5ebbce51e2da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8bdc1d89-6685-411a-a5f8-f194c02b0861"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azithromycin tablets are a macrolide antibacterial drug indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. Recommended dosages and durations of therapy in adult and pediatric patient populations vary in these indications. [see DOSAGE AND ADMINISTRATION (2)] 1.1 Adult Patients Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae , Moraxella catarrhalis, or Streptococcus pneumoniae . Acute bacterial sinusitis due to Haemophilus influenzae , Moraxella catarrhalis or Streptococcus pneumoniae . Community-acquired pneumonia due to Chlamydophila pneumoniae , Haemophilus influenzae , Mycoplasma pneumoniae, or Streptococcus pneumoniae in patients appropriate for oral therapy. Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. Uncomplicated skin and skin structure infections due to Staphylococcus aureus , Streptococcus pyogenes , or Streptococcus agalactiae . Urethritis and cervicitis due to Chlamydia trachomatis or Neisseria gonorrhoeae . Genital ulcer disease in men due to Haemophilus ducreyi (chancroid). Due to the small number of women included in clinical trials, the efficacy of azithromycin in the treatment of chancroid in women has not been established. 1.2 Pediatric Patients [see USE IN SPECIFIC POPULATIONS (8.4) and CLINICAL STUDIES (14.2)] Acute otitis media (>6 months of age) caused by Haemophilus influenzae , Moraxella catarrhalis, or Streptococcus pneumoniae. Community-acquired pneumonia (>6 months ofage) due to Chlamydophila pneumoniae , Haemophilus influenzae , Mycoplasma pneumoniae , or Streptococcus pneumoniae in patients appropriate for oral therapy. Pharyngitis/tonsillitis (>2 years of age) caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. 1.3 Limitations of Use Azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomial infections, patients with known or suspected bacteremia, patients requiring hospitalization, elderly or debilitated patients, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). 1.4 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin and other antibacterial drugs, azithromycin should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. PUBCHEM.COMPOUND:16156 uuid:e0a39a0c-d32a-4d03-8be8-69c8a2c554df biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3W5S57M958 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:a7a79cf7-0d4a-4bea-a448-85a64a5262ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6cdea75e-e3a4-4730-ad6f-85e65fade5df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azithromycin tablets are a macrolide antibacterial drug indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. Recommended dosages and durations of therapy in adult and pediatric patient populations vary in these indications. [see DOSAGE AND ADMINISTRATION (2)] 1.1 Adult Patients Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae , Moraxella catarrhalis, or Streptococcus pneumoniae . Acute bacterial sinusitis due to Haemophilus influenzae , Moraxella catarrhalis or Streptococcus pneumoniae . Community-acquired pneumonia due to Chlamydophila pneumoniae , Haemophilus influenzae , Mycoplasma pneumoniae, or Streptococcus pneumoniae in patients appropriate for oral therapy. Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. Uncomplicated skin and skin structure infections due to Staphylococcus aureus , Streptococcus pyogenes , or Streptococcus agalactiae . Urethritis and cervicitis due to Chlamydia trachomatis or Neisseria gonorrhoeae . Genital ulcer disease in men due to Haemophilus ducreyi (chancroid). Due to the small number of women included in clinical trials, the efficacy of azithromycin in the treatment of chancroid in women has not been established. 1.2 Pediatric Patients [see USE IN SPECIFIC POPULATIONS (8.4) and CLINICAL STUDIES (14.2)] Acute otitis media (>6 months of age) caused by Haemophilus influenzae , Moraxella catarrhalis, or Streptococcus pneumoniae. Community-acquired pneumonia (>6 months ofage) due to Chlamydophila pneumoniae , Haemophilus influenzae , Mycoplasma pneumoniae , or Streptococcus pneumoniae in patients appropriate for oral therapy. Pharyngitis/tonsillitis (>2 years of age) caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. 1.3 Limitations of Use Azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomial infections, patients with known or suspected bacteremia, patients requiring hospitalization, elderly or debilitated patients, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). 1.4 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin and other antibacterial drugs, azithromycin should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. PUBCHEM.COMPOUND:16156 uuid:e3032492-d244-42c0-bf70-b3ed9e640eec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3W5S57M958 biolink:treats MONDO:0005297 PMID:41385096 "[{""id"":""uuid:4b7b878a-5511-4d1c-9576-0d1ce286050c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:81c1b0a6-2429-4d7e-8875-ddddcff6eea0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azithromycin tablets are a macrolide antibacterial drug indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. Recommended dosages and durations of therapy in adult and pediatric patient populations vary in these indications. [see DOSAGE AND ADMINISTRATION (2)] 1.1 Adult Patients Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae , Moraxella catarrhalis, or Streptococcus pneumoniae . Acute bacterial sinusitis due to Haemophilus influenzae , Moraxella catarrhalis or Streptococcus pneumoniae . Community-acquired pneumonia due to Chlamydophila pneumoniae , Haemophilus influenzae , Mycoplasma pneumoniae, or Streptococcus pneumoniae in patients appropriate for oral therapy. Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. Uncomplicated skin and skin structure infections due to Staphylococcus aureus , Streptococcus pyogenes , or Streptococcus agalactiae . Urethritis and cervicitis due to Chlamydia trachomatis or Neisseria gonorrhoeae . Genital ulcer disease in men due to Haemophilus ducreyi (chancroid). Due to the small number of women included in clinical trials, the efficacy of azithromycin in the treatment of chancroid in women has not been established. 1.2 Pediatric Patients [see USE IN SPECIFIC POPULATIONS (8.4) and CLINICAL STUDIES (14.2)] Acute otitis media (>6 months of age) caused by Haemophilus influenzae , Moraxella catarrhalis, or Streptococcus pneumoniae. Community-acquired pneumonia (>6 months ofage) due to Chlamydophila pneumoniae , Haemophilus influenzae , Mycoplasma pneumoniae , or Streptococcus pneumoniae in patients appropriate for oral therapy. Pharyngitis/tonsillitis (>2 years of age) caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. 1.3 Limitations of Use Azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomial infections, patients with known or suspected bacteremia, patients requiring hospitalization, elderly or debilitated patients, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). 1.4 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin and other antibacterial drugs, azithromycin should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. PUBCHEM.COMPOUND:16156 uuid:611d3c8b-6a25-4a3b-945b-9852047a94c2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3W5S57M958 biolink:treats MONDO:0002345 PMID:41385096 "[{""id"":""uuid:27ddccb6-5d6f-4410-95c9-a00bf957118d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:466e1fc5-6629-4e1e-bb28-b57702b17e3b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azithromycin tablets are a macrolide antibacterial drug indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. Recommended dosages and durations of therapy in adult and pediatric patient populations vary in these indications. [see DOSAGE AND ADMINISTRATION (2)] 1.1 Adult Patients Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae , Moraxella catarrhalis, or Streptococcus pneumoniae . Acute bacterial sinusitis due to Haemophilus influenzae , Moraxella catarrhalis or Streptococcus pneumoniae . Community-acquired pneumonia due to Chlamydophila pneumoniae , Haemophilus influenzae , Mycoplasma pneumoniae, or Streptococcus pneumoniae in patients appropriate for oral therapy. Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. Uncomplicated skin and skin structure infections due to Staphylococcus aureus , Streptococcus pyogenes , or Streptococcus agalactiae . Urethritis and cervicitis due to Chlamydia trachomatis or Neisseria gonorrhoeae . Genital ulcer disease in men due to Haemophilus ducreyi (chancroid). Due to the small number of women included in clinical trials, the efficacy of azithromycin in the treatment of chancroid in women has not been established. 1.2 Pediatric Patients [see USE IN SPECIFIC POPULATIONS (8.4) and CLINICAL STUDIES (14.2)] Acute otitis media (>6 months of age) caused by Haemophilus influenzae , Moraxella catarrhalis, or Streptococcus pneumoniae. Community-acquired pneumonia (>6 months ofage) due to Chlamydophila pneumoniae , Haemophilus influenzae , Mycoplasma pneumoniae , or Streptococcus pneumoniae in patients appropriate for oral therapy. Pharyngitis/tonsillitis (>2 years of age) caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. 1.3 Limitations of Use Azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomial infections, patients with known or suspected bacteremia, patients requiring hospitalization, elderly or debilitated patients, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). 1.4 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin and other antibacterial drugs, azithromycin should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. PUBCHEM.COMPOUND:16156 uuid:8153d968-bf92-4d16-81e2-ec0d9cd2edc4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3W5S57M958 biolink:treats MONDO:0001797 PMID:41385096 "[{""id"":""uuid:816a3c33-087a-405b-88ca-66fb8bb06c07"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4292786a-d08e-4b60-b5ed-852839da2fb1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azithromycin tablets are a macrolide antibacterial drug indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. Recommended dosages and durations of therapy in adult and pediatric patient populations vary in these indications. [see DOSAGE AND ADMINISTRATION (2)] 1.1 Adult Patients Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae , Moraxella catarrhalis, or Streptococcus pneumoniae . Acute bacterial sinusitis due to Haemophilus influenzae , Moraxella catarrhalis or Streptococcus pneumoniae . Community-acquired pneumonia due to Chlamydophila pneumoniae , Haemophilus influenzae , Mycoplasma pneumoniae, or Streptococcus pneumoniae in patients appropriate for oral therapy. Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. Uncomplicated skin and skin structure infections due to Staphylococcus aureus , Streptococcus pyogenes , or Streptococcus agalactiae . Urethritis and cervicitis due to Chlamydia trachomatis or Neisseria gonorrhoeae . Genital ulcer disease in men due to Haemophilus ducreyi (chancroid). Due to the small number of women included in clinical trials, the efficacy of azithromycin in the treatment of chancroid in women has not been established. 1.2 Pediatric Patients [see USE IN SPECIFIC POPULATIONS (8.4) and CLINICAL STUDIES (14.2)] Acute otitis media (>6 months of age) caused by Haemophilus influenzae , Moraxella catarrhalis, or Streptococcus pneumoniae. Community-acquired pneumonia (>6 months ofage) due to Chlamydophila pneumoniae , Haemophilus influenzae , Mycoplasma pneumoniae , or Streptococcus pneumoniae in patients appropriate for oral therapy. Pharyngitis/tonsillitis (>2 years of age) caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. 1.3 Limitations of Use Azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomial infections, patients with known or suspected bacteremia, patients requiring hospitalization, elderly or debilitated patients, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). 1.4 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin and other antibacterial drugs, azithromycin should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. PUBCHEM.COMPOUND:16156 uuid:ce70b56f-f67c-425e-a823-cb221346492d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3W5S57M958 biolink:treats HP:0000371 PMID:41385096 "[{""id"":""uuid:13be01d0-abcb-48dc-9d80-94ed342178a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5dc08270-b8f1-4a73-a360-8e85f292d2eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azithromycin tablets are a macrolide antibacterial drug indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. Recommended dosages and durations of therapy in adult and pediatric patient populations vary in these indications. [see DOSAGE AND ADMINISTRATION (2)] 1.1 Adult Patients Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae , Moraxella catarrhalis, or Streptococcus pneumoniae . Acute bacterial sinusitis due to Haemophilus influenzae , Moraxella catarrhalis or Streptococcus pneumoniae . Community-acquired pneumonia due to Chlamydophila pneumoniae , Haemophilus influenzae , Mycoplasma pneumoniae, or Streptococcus pneumoniae in patients appropriate for oral therapy. Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. Uncomplicated skin and skin structure infections due to Staphylococcus aureus , Streptococcus pyogenes , or Streptococcus agalactiae . Urethritis and cervicitis due to Chlamydia trachomatis or Neisseria gonorrhoeae . Genital ulcer disease in men due to Haemophilus ducreyi (chancroid). Due to the small number of women included in clinical trials, the efficacy of azithromycin in the treatment of chancroid in women has not been established. 1.2 Pediatric Patients [see USE IN SPECIFIC POPULATIONS (8.4) and CLINICAL STUDIES (14.2)] Acute otitis media (>6 months of age) caused by Haemophilus influenzae , Moraxella catarrhalis, or Streptococcus pneumoniae. Community-acquired pneumonia (>6 months ofage) due to Chlamydophila pneumoniae , Haemophilus influenzae , Mycoplasma pneumoniae , or Streptococcus pneumoniae in patients appropriate for oral therapy. Pharyngitis/tonsillitis (>2 years of age) caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. 1.3 Limitations of Use Azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomial infections, patients with known or suspected bacteremia, patients requiring hospitalization, elderly or debilitated patients, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). 1.4 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin and other antibacterial drugs, azithromycin should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. PUBCHEM.COMPOUND:16156 uuid:248bac1f-1b95-4d37-b94a-4f2bd152f88d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3W5S57M958 biolink:treats MONDO:0009061 PMID:41385096 "[{""id"":""uuid:210141f3-f17f-4982-a2ab-4e1d1f1607e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:46ac4e6f-0e89-42ba-9635-229820055327"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azithromycin tablets are a macrolide antibacterial drug indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. Recommended dosages and durations of therapy in adult and pediatric patient populations vary in these indications. [see DOSAGE AND ADMINISTRATION (2)] 1.1 Adult Patients Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae , Moraxella catarrhalis, or Streptococcus pneumoniae . Acute bacterial sinusitis due to Haemophilus influenzae , Moraxella catarrhalis or Streptococcus pneumoniae . Community-acquired pneumonia due to Chlamydophila pneumoniae , Haemophilus influenzae , Mycoplasma pneumoniae, or Streptococcus pneumoniae in patients appropriate for oral therapy. Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. Uncomplicated skin and skin structure infections due to Staphylococcus aureus , Streptococcus pyogenes , or Streptococcus agalactiae . Urethritis and cervicitis due to Chlamydia trachomatis or Neisseria gonorrhoeae . Genital ulcer disease in men due to Haemophilus ducreyi (chancroid). Due to the small number of women included in clinical trials, the efficacy of azithromycin in the treatment of chancroid in women has not been established. 1.2 Pediatric Patients [see USE IN SPECIFIC POPULATIONS (8.4) and CLINICAL STUDIES (14.2)] Acute otitis media (>6 months of age) caused by Haemophilus influenzae , Moraxella catarrhalis, or Streptococcus pneumoniae. Community-acquired pneumonia (>6 months ofage) due to Chlamydophila pneumoniae , Haemophilus influenzae , Mycoplasma pneumoniae , or Streptococcus pneumoniae in patients appropriate for oral therapy. Pharyngitis/tonsillitis (>2 years of age) caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. 1.3 Limitations of Use Azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomial infections, patients with known or suspected bacteremia, patients requiring hospitalization, elderly or debilitated patients, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). 1.4 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin and other antibacterial drugs, azithromycin should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. PUBCHEM.COMPOUND:16156 uuid:cde66c0b-acd3-46eb-adfc-dc5550f55b84 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3W5S57M958 biolink:treats MONDO:0043544 PMID:41385096 "[{""id"":""uuid:28e76a7a-4905-48d4-953d-1f8d4797350f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4629b140-5b3a-4925-9add-95fda3115d73"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azithromycin tablets are a macrolide antibacterial drug indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. Recommended dosages and durations of therapy in adult and pediatric patient populations vary in these indications. [see DOSAGE AND ADMINISTRATION (2)] 1.1 Adult Patients Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae , Moraxella catarrhalis, or Streptococcus pneumoniae . Acute bacterial sinusitis due to Haemophilus influenzae , Moraxella catarrhalis or Streptococcus pneumoniae . Community-acquired pneumonia due to Chlamydophila pneumoniae , Haemophilus influenzae , Mycoplasma pneumoniae, or Streptococcus pneumoniae in patients appropriate for oral therapy. Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. Uncomplicated skin and skin structure infections due to Staphylococcus aureus , Streptococcus pyogenes , or Streptococcus agalactiae . Urethritis and cervicitis due to Chlamydia trachomatis or Neisseria gonorrhoeae . Genital ulcer disease in men due to Haemophilus ducreyi (chancroid). Due to the small number of women included in clinical trials, the efficacy of azithromycin in the treatment of chancroid in women has not been established. 1.2 Pediatric Patients [see USE IN SPECIFIC POPULATIONS (8.4) and CLINICAL STUDIES (14.2)] Acute otitis media (>6 months of age) caused by Haemophilus influenzae , Moraxella catarrhalis, or Streptococcus pneumoniae. Community-acquired pneumonia (>6 months ofage) due to Chlamydophila pneumoniae , Haemophilus influenzae , Mycoplasma pneumoniae , or Streptococcus pneumoniae in patients appropriate for oral therapy. Pharyngitis/tonsillitis (>2 years of age) caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. 1.3 Limitations of Use Azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomial infections, patients with known or suspected bacteremia, patients requiring hospitalization, elderly or debilitated patients, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). 1.4 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin and other antibacterial drugs, azithromycin should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. PUBCHEM.COMPOUND:16156 uuid:2a3605f1-f2e2-4e52-b3b1-7cd81d36f574 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3W5S57M958 biolink:treats MONDO:0005229 PMID:41385096 "[{""id"":""uuid:4f6564c5-5627-4252-86de-a394e166a4ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:771823cb-2d62-4621-8773-3445c1795389"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azithromycin tablets are a macrolide antibacterial drug indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. Recommended dosages and durations of therapy in adult and pediatric patient populations vary in these indications. [see DOSAGE AND ADMINISTRATION (2)] 1.1 Adult Patients Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae , Moraxella catarrhalis, or Streptococcus pneumoniae . Acute bacterial sinusitis due to Haemophilus influenzae , Moraxella catarrhalis or Streptococcus pneumoniae . Community-acquired pneumonia due to Chlamydophila pneumoniae , Haemophilus influenzae , Mycoplasma pneumoniae, or Streptococcus pneumoniae in patients appropriate for oral therapy. Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. Uncomplicated skin and skin structure infections due to Staphylococcus aureus , Streptococcus pyogenes , or Streptococcus agalactiae . Urethritis and cervicitis due to Chlamydia trachomatis or Neisseria gonorrhoeae . Genital ulcer disease in men due to Haemophilus ducreyi (chancroid). Due to the small number of women included in clinical trials, the efficacy of azithromycin in the treatment of chancroid in women has not been established. 1.2 Pediatric Patients [see USE IN SPECIFIC POPULATIONS (8.4) and CLINICAL STUDIES (14.2)] Acute otitis media (>6 months of age) caused by Haemophilus influenzae , Moraxella catarrhalis, or Streptococcus pneumoniae. Community-acquired pneumonia (>6 months ofage) due to Chlamydophila pneumoniae , Haemophilus influenzae , Mycoplasma pneumoniae , or Streptococcus pneumoniae in patients appropriate for oral therapy. Pharyngitis/tonsillitis (>2 years of age) caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. 1.3 Limitations of Use Azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomial infections, patients with known or suspected bacteremia, patients requiring hospitalization, elderly or debilitated patients, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). 1.4 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin and other antibacterial drugs, azithromycin should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. PUBCHEM.COMPOUND:16156 uuid:aef33977-1c5d-4df8-b9aa-9ac5a9db889a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59173 biolink:treats MONDO:0018048 PMID:41385096 "[{""id"":""uuid:ae8548cd-2f12-4e7a-9b4a-e0339c598124"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e02b0ebf-9f73-414e-857b-235ae4e57c1d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bivalirudin for injection is indicated for use as an anticoagulant for use in patients undergoing percutaneous coronary intervention (PCI) including patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome. uuid:9c4fca19-1b16-47cf-b852-d0c649330adc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59173 biolink:treats UMLS:C0272275 PMID:41385096 "[{""id"":""uuid:14f872f8-fb4d-40fc-8c6a-d176ea3ae214"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:799b525b-16ce-48ea-9e68-a4383244a460"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bivalirudin for injection is indicated for use as an anticoagulant for use in patients undergoing percutaneous coronary intervention (PCI) including patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome. uuid:e014e251-1435-401e-93ac-5350c03eb223 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4875 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:0a72c326-0db7-4446-906d-4b72b20edb6d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b6d6ef6a-de33-465e-bb89-b49f85af452c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ad3dfe3f-afbc-48bc-ba84-2dd8ff77367c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/enbrel""]},{""id"":""uuid:c2bacd53-b78a-4a83-aa1b-875ff590836a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Enbrel is a tumor necrosis factor (TNF) blocker indicated for the treatment of: Rheumatoid Arthritis (RA) ( 1.1 ) Polyarticular Juvenile Idiopathic Arthritis (JIA) in patients aged 2 years or older ( 1.2 ) Psoriatic Arthritis (PsA) ( 1.3 ) Ankylosing Spondylitis (AS) ( 1.4 ) Plaque Psoriasis (PsO) in patients 4 years or older ( 1.5 )|[EMA] Rheumatoid arthritis, , Enbrel in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adults when the response to disease-modifying antirheumatic drugs, including methotrexate (unless contraindicated), has been inadequate., , Enbrel can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate., , Enbrel is also indicated in the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate., , Enbrel, alone or in combination with methotrexate, has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function., , Juvenile idiopathic arthritis, , Treatment of polyarthritis (rheumatoid-factor-positive or -negative) and extended oligoarthritis in children and adolescents from the age of two years who have had an inadequate response to, or who have proved intolerant of, methotrexate., , Treatment of psoriatic arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, methotrexate., , Treatment of enthesitis-related arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, conventional therapy., , Enbrel has not been studied in children aged less than two years., , Psoriatic arthritis, , Treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying antirheumatic drug therapy has been inadequate. Enbrel has been shown to improve physical function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease., , Axial spondyloarthritis, , Ankylosing spondylitis (AS), , Treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy., , Non-radiographic axial spondyloarthritis, , Treatment of adults with severe non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to nonsteroidal anti-inflammatory drugs (NSAIDs). , , Plaque psoriasis , , Treatment of adults with moderate to severe plaque psoriasis who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapy, including ciclosporin, methotrexate or psoralen and ultraviolet-A light (PUVA)., , Paediatric plaque psoriasis , , Treatment of chronic severe plaque psoriasis in children and adolescents from the age of six years who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.,|[PMDA] A drug containing a new active ingredient, humanized fusion protein having an inhibitory action on the binding of the tumor necrosis factor (TNF) to a TNF receptor that has indications for rheumatoid arthritis uuid:81c73cfe-5ddc-47f2-94cd-f3e84991e434 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4875 biolink:treats MONDO:0018456 PMID:41385096 "[{""id"":""uuid:4fe13238-b41b-4a36-b3ee-6e13e75c3d13"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ead26c85-b745-4ac8-a0d8-7789402dddc2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Enbrel is a tumor necrosis factor (TNF) blocker indicated for the treatment of: Rheumatoid Arthritis (RA) ( 1.1 ) Polyarticular Juvenile Idiopathic Arthritis (JIA) in patients aged 2 years or older ( 1.2 ) Psoriatic Arthritis (PsA) ( 1.3 ) Ankylosing Spondylitis (AS) ( 1.4 ) Plaque Psoriasis (PsO) in patients 4 years or older ( 1.5 ) uuid:f9d159b8-ea90-4053-a38b-ce1d6bf924c6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4875 biolink:treats MONDO:0011849 PMID:41385096 "[{""id"":""uuid:2c658c62-6104-4230-aa01-7dff95a55244"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:e72c9d88-f2ca-4011-9f45-51ff2ec0b710"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:09e0659f-e2db-4fb2-9c66-15b040658c0b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/enbrel""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Enbrel is a tumor necrosis factor (TNF) blocker indicated for the treatment of: Rheumatoid Arthritis (RA) ( 1.1 ) Polyarticular Juvenile Idiopathic Arthritis (JIA) in patients aged 2 years or older ( 1.2 ) Psoriatic Arthritis (PsA) ( 1.3 ) Ankylosing Spondylitis (AS) ( 1.4 ) Plaque Psoriasis (PsO) in patients 4 years or older ( 1.5 )|[EMA] Rheumatoid arthritis, , Enbrel in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adults when the response to disease-modifying antirheumatic drugs, including methotrexate (unless contraindicated), has been inadequate., , Enbrel can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate., , Enbrel is also indicated in the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate., , Enbrel, alone or in combination with methotrexate, has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function., , Juvenile idiopathic arthritis, , Treatment of polyarthritis (rheumatoid-factor-positive or -negative) and extended oligoarthritis in children and adolescents from the age of two years who have had an inadequate response to, or who have proved intolerant of, methotrexate., , Treatment of psoriatic arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, methotrexate., , Treatment of enthesitis-related arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, conventional therapy., , Enbrel has not been studied in children aged less than two years., , Psoriatic arthritis, , Treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying antirheumatic drug therapy has been inadequate. Enbrel has been shown to improve physical function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease., , Axial spondyloarthritis, , Ankylosing spondylitis (AS), , Treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy., , Non-radiographic axial spondyloarthritis, , Treatment of adults with severe non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to nonsteroidal anti-inflammatory drugs (NSAIDs). , , Plaque psoriasis , , Treatment of adults with moderate to severe plaque psoriasis who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapy, including ciclosporin, methotrexate or psoralen and ultraviolet-A light (PUVA)., , Paediatric plaque psoriasis , , Treatment of chronic severe plaque psoriasis in children and adolescents from the age of six years who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies., uuid:c7b29665-5a28-4a35-afc8-622aea7c6b04 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4875 biolink:treats MONDO:0005306 PMID:41385096 "[{""id"":""uuid:69da1e29-57c0-4890-8417-deb0471f6a18"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:44e11d68-84c1-4aea-835a-53261e8c9e9f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:0f6a6cdb-1ebc-48ef-be24-35f859fc43a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/enbrel""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Enbrel is a tumor necrosis factor (TNF) blocker indicated for the treatment of: Rheumatoid Arthritis (RA) ( 1.1 ) Polyarticular Juvenile Idiopathic Arthritis (JIA) in patients aged 2 years or older ( 1.2 ) Psoriatic Arthritis (PsA) ( 1.3 ) Ankylosing Spondylitis (AS) ( 1.4 ) Plaque Psoriasis (PsO) in patients 4 years or older ( 1.5 )|[EMA] Rheumatoid arthritis, , Enbrel in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adults when the response to disease-modifying antirheumatic drugs, including methotrexate (unless contraindicated), has been inadequate., , Enbrel can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate., , Enbrel is also indicated in the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate., , Enbrel, alone or in combination with methotrexate, has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function., , Juvenile idiopathic arthritis, , Treatment of polyarthritis (rheumatoid-factor-positive or -negative) and extended oligoarthritis in children and adolescents from the age of two years who have had an inadequate response to, or who have proved intolerant of, methotrexate., , Treatment of psoriatic arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, methotrexate., , Treatment of enthesitis-related arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, conventional therapy., , Enbrel has not been studied in children aged less than two years., , Psoriatic arthritis, , Treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying antirheumatic drug therapy has been inadequate. Enbrel has been shown to improve physical function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease., , Axial spondyloarthritis, , Ankylosing spondylitis (AS), , Treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy., , Non-radiographic axial spondyloarthritis, , Treatment of adults with severe non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to nonsteroidal anti-inflammatory drugs (NSAIDs). , , Plaque psoriasis , , Treatment of adults with moderate to severe plaque psoriasis who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapy, including ciclosporin, methotrexate or psoralen and ultraviolet-A light (PUVA)., , Paediatric plaque psoriasis , , Treatment of chronic severe plaque psoriasis in children and adolescents from the age of six years who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies., uuid:709f41f7-0163-4b86-b78e-afdccf7f9144 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4875 biolink:treats UMLS:C0406317 PMID:41385096 "[{""id"":""uuid:01c7b667-6fa7-4298-b97b-fc93d2e4a3b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3066e87d-1d77-4bef-9514-65c691290747"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Enbrel is a tumor necrosis factor (TNF) blocker indicated for the treatment of: Rheumatoid Arthritis (RA) ( 1.1 ) Polyarticular Juvenile Idiopathic Arthritis (JIA) in patients aged 2 years or older ( 1.2 ) Psoriatic Arthritis (PsA) ( 1.3 ) Ankylosing Spondylitis (AS) ( 1.4 ) Plaque Psoriasis (PsO) in patients 4 years or older ( 1.5 ) uuid:a2f699f3-fe44-4f7f-b55d-9624836750e4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27690 biolink:treats MONDO:0100574 PMID:41385096 "[{""id"":""uuid:de5d3c44-da7e-431e-8cd5-43f581ad0c57"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:09a77500-e17d-40a8-8a49-fd2268ab927e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For adjunctive treatment of: edema due to congestive heart failure; drug-induced edema; centrencephalic epilepsies (petit mal, unlocalized seizures); chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure. Acetazolamide Tablets are also indicated for the prevention or amelioration of symptoms associated with acute mountain sickness in climbers attempting rapid ascent and in those who are very susceptible to acute mountain sickness despite gradual ascent. uuid:c6582525-c756-4f21-a883-d65eb23da479 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats HP:0004308 PMID:41385096 "[{""id"":""uuid:055cc384-4e02-42fb-aeb4-28c98599859d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:776aa22e-2900-4255-ac53-1de87740a0b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lidocaine hydrochloride administered intravenously is specifically indicated in the acute management of (1) ventricular arrhythmias occurring during cardiac manipulations, such as cardiac surgery and (2) life-threatening arrhythmias which are ventricular in origin, such as occur during acute myocardial infarction. uuid:84787328-12f7-4cda-b7d0-06abcaaf22fe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0007263 PMID:41385096 "[{""id"":""uuid:7bf215c6-3e27-46d0-a22d-5f4c9c4eeab2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:30d20983-7342-4985-bafc-c8beae270bd4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lidocaine hydrochloride administered intravenously is specifically indicated in the acute management of (1) ventricular arrhythmias occurring during cardiac manipulations, such as cardiac surgery and (2) life-threatening arrhythmias which are ventricular in origin, such as occur during acute myocardial infarction. uuid:99f4f526-820a-4bb4-a3e7-f534a9917e45 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0004781 PMID:41385096 "[{""id"":""uuid:feffb656-de30-4477-809e-fd0f5af53b9f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1e986d6a-f10c-4635-9ab8-946b8612df7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lidocaine hydrochloride administered intravenously is specifically indicated in the acute management of (1) ventricular arrhythmias occurring during cardiac manipulations, such as cardiac surgery and (2) life-threatening arrhythmias which are ventricular in origin, such as occur during acute myocardial infarction. uuid:7b4fe494-6657-4c42-98c1-429c396b0a8e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:42355 biolink:treats MONDO:0003799 PMID:41385096 "[{""id"":""uuid:c927a5bd-d5c6-4de6-bdc4-578fe602465d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1e786302-edd9-43b2-b787-204aa37f7c3d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the treatment of superficial ocular infections involving the conjunctiva and/or cornea caused by organisms susceptible to erythromycin. For prophylaxis of ophthalmia neonatorum due to N. gonorrhoeae or C. trachomatis. The effectiveness of erythromycin in the prevention of ophthalmia caused by penicillinase-producing N. gonorrheae is not established. For infants born to mothers with clinically apparent gonorrhea, intravenous or intramuscular injections of aqueous crystalline penicillin G should be given; a single dose of 50,000 units for term infants or 20,000 units for infants of low birth weight. Topical prophylaxis alone is inadequate for these infants. uuid:5a85b251-6274-43b5-8fe1-4dc8005f27cd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:42355 biolink:treats MONDO:0023865 PMID:41385096 "[{""id"":""uuid:f666345a-315e-4eba-9436-09bbe65ff2e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9e6234c7-f5bd-4f8b-9d79-6ed17c02af96"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the treatment of superficial ocular infections involving the conjunctiva and/or cornea caused by organisms susceptible to erythromycin. For prophylaxis of ophthalmia neonatorum due to N. gonorrhoeae or C. trachomatis. The effectiveness of erythromycin in the prevention of ophthalmia caused by penicillinase-producing N. gonorrheae is not established. For infants born to mothers with clinically apparent gonorrhea, intravenous or intramuscular injections of aqueous crystalline penicillin G should be given; a single dose of 50,000 units for term infants or 20,000 units for infants of low birth weight. Topical prophylaxis alone is inadequate for these infants. uuid:5b549850-1548-46c4-9c6f-b8c14c8fd0e5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59773 biolink:treats MONDO:0019085 PMID:41385096 "[{""id"":""uuid:6ed6befc-7a95-4e5e-bb72-8ef57fff0edd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b229f1c1-d7d8-4e03-8423-bf766a5a4ec8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cromolyn Sodium Ophthalmic Solution USP, 4% is indicated in the treatment of vernal keratoconjunctivitis, vernal conjunctivitis, and vernal keratitis. uuid:f8f698b1-c2b7-433b-b46f-c77c5dddab3e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59773 biolink:treats MONDO:0002313 PMID:41385096 "[{""id"":""uuid:22dffb99-e3ab-48a8-a66a-888072c2ae8a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8e55fc95-91be-471f-91f7-434670365ac2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cromolyn Sodium Ophthalmic Solution USP, 4% is indicated in the treatment of vernal keratoconjunctivitis, vernal conjunctivitis, and vernal keratitis. uuid:949561f6-05ef-4b79-9130-d10f844171a9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2618 biolink:treats MONDO:0006012 PMID:41385096 "[{""id"":""uuid:e0fd7faa-395b-46a0-ad53-dbde2c4c98f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:73fcbfd9-4fa4-4ad1-bae7-e7a98d930e97"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amantadine hydrochloride capsules are indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus. Amantadine hydrochloride capsules are also indicated in the treatment of parkinsonism and drug-induced extrapyramidal reactions. Influenza A Prophylaxis Amantadine hydrochloride capsules are indicated for chemoprophylaxis against signs and symptoms of influenza A virus infection. Because amantadine does not completely prevent the host immune response to influenza A infection, individuals who take this drug may still develop immune responses to natural disease or vaccination and may be protected when later exposed to antigenically related viruses. Following vaccination during an influenza A outbreak, amantadine prophylaxis should be considered for the 2- to 4-week time period required to develop an antibody response. Influenza A Treatment Amantadine hydrochloride capsules are also indicated in the treatment of uncomplicated respiratory tract illness caused by influenza A virus strains especially when administered early in the course of illness. There are no well-controlled clinical studies demonstrating that treatment with amantadine hydrochloride capsules will avoid the development of influenza A virus pneumonitis or other complications in high risk patients. There is no clinical evidence indicating that amantadine hydrochloride capsules are effective in the prophylaxis or treatment of viral respiratory tract illnesses other than those caused by influenza A virus strains. The following points should be considered before initiating treatment or prophylaxis with amantadine hydrochloride capsules. • Amantadine hydrochloride capsules are not a substitute for early vaccination on an annual basis as recommended by the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices. • Influenza viruses change over time. Emergence of resistance mutations could decrease drug effectiveness. Other factors (for example, changes in viral virulence) might also diminish clinical benefit of antiviral drugs. Prescribers should consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use amantadine hydrochloride capsules. Parkinson’s Disease/Syndrome Amantadine hydrochloride capsules are indicated in the treatment of idiopathic Parkinson’s disease (Paralysis Agitans), postencephalitic parkinsonism and symptomatic parkinsonism which may follow injury to the nervous system by carbon monoxide intoxication. It is indicated in those elderly patients believed to develop parkinsonism in association with cerebral arteriosclerosis. In the treatment of Parkinson’s disease, amantadine is less effective than levodopa, (-)-3-(3,4-dihydroxyphenyl)-L-alanine, and its efficacy in comparison with the anticholinergic antiparkinson drugs has not yet been established. Drug-Induced Extrapyramidal Reactions Amantadine hydrochloride is indicated in the treatment of drug-induced extrapyramidal reactions. Although anticholinergic-type side effects have been noted with amantadine when used in patients with drug-induced extrapyramidal reactions, there is a lower incidence of these side effects than that observed with the anticholinergic antiparkinson drugs. uuid:81d235a5-463f-4d55-8dc0-a8fb43a3d27f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:24783652 biolink:treats MONDO:0001302 PMID:41385096 "[{""id"":""uuid:89ae5e56-35ef-4588-9095-3efe4d845cbb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f698a011-266e-4f42-89ab-30f3cf72aa71"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension Losartan Potassium and Hydrochlorothiazide Tablets are indicated for the treatment of hypertension. This fixed dose combination is not indicated for initial therapy of hypertension, except when the hypertension is severe enough that the value of achieving prompt blood pressure control exceeds the risk of initiating combination therapy in these patients (see CLINICAL PHARMACOLOGY, Pharmacodynamics and Clinical Effects, and DOSAGE AND ADMINISTRATION). Hypertensive Patients with Left Ventricular Hypertrophy Losartan Potassium and Hydrochlorothiazide Tablets are indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to Black patients. (See PRECAUTIONS, Race, CLINICAL PHARMACOLOGY, Pharmacodynamics and Clinical Effects, Losartan Potassium, Reduction in the Risk of Stroke, Race, and DOSAGE AND ADMINISTRATION.) uuid:fbadc3b3-6fc2-4e9e-b83c-154e6c2b5193 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49166 biolink:treats MONDO:0021095 PMID:41385096 "[{""id"":""uuid:2805c8f0-cd5b-4b59-a50e-a3382936339d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c8c10b42-f8ef-4cc7-8093-f9ffb62d9080"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fluorodopa F 18 Injection is indicated for use in positron emission tomography (PET) to visualize dopaminergic nerve terminals in the striatum for the evaluation of adult patients with suspected Parkinsonian syndromes (PS). Fluorodopa F 18 PET is an adjunct to other diagnostic evaluations. uuid:49fdeac8-b048-4cd4-9f58-4a762afa1e29 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:43968 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:fc75d17e-ba26-48e5-b312-8bfb39a2812d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ce6bff1c-eaad-4bf2-a790-d904216bc0fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Meropenem for injection (I.V.) is a penem antibacterial indicated for the treatment of: • Complicated skin and skin structure infections (adult patients and pediatric patients 3 months of age and older only). (1.1) • Complicated intra-abdominal infections (adult and pediatric patients). (1.2) • Bacterial meningitis (pediatric patients 3 months of age and older only). (1.3) To reduce the development of drug-resistant bacteria and maintain the effectiveness of meropenem for injection (I.V.) and other antibacterial drugs, meropenem for injection (I.V.) should only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. uuid:371dbb0e-9215-46fa-9dba-1fb36a49e713 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:43968 biolink:treats MONDO:0006670 PMID:41385096 "[{""id"":""uuid:dab0f2cb-4056-4587-88fd-39db845c784d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a48acb8b-eec5-40a8-bc4b-8704e2b4d0e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Meropenem for injection (I.V.) is a penem antibacterial indicated for the treatment of: • Complicated skin and skin structure infections (adult patients and pediatric patients 3 months of age and older only). (1.1) • Complicated intra-abdominal infections (adult and pediatric patients). (1.2) • Bacterial meningitis (pediatric patients 3 months of age and older only). (1.3) To reduce the development of drug-resistant bacteria and maintain the effectiveness of meropenem for injection (I.V.) and other antibacterial drugs, meropenem for injection (I.V.) should only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. uuid:c4f3ab55-e369-423d-b043-e933396d6b4f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6935 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:e80f6e08-44c7-48ab-977f-7c6b66ef9470"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:05437d20-ddf7-4116-bd2c-5a1ab5a15e5c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:969f2508-8c39-4445-9d46-0406c2e3c186"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Miglitol tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.|[PMDA] Drugs containing a new active ingredient, an -glucosidase inhibitor, indicated for improving postprandial hyperglycemia in patients with type 2 diabetes. uuid:3ae78cc5-c270-422b-9444-5dd84e4faa55 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:375139 biolink:treats UMLS:C0332686 PMID:41385096 "[{""id"":""uuid:1557b5c2-fbf5-401e-ad74-8999788c94ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b3867429-3423-4e78-b24e-d2c4cdda4b71"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lidocaine Ointment USP, 5% is indicated for production of anesthesia of accessible mucous membranes of the oropharynx. It is also useful as an anesthetic lubricant for intubation and for the temporary relief of pain associated with minor burns, including sunburn, abrasions of the skin, and insect bites. uuid:5963192c-c1d7-499d-b062-0c426ed4526c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:375139 biolink:treats MONDO:0005326 PMID:41385096 "[{""id"":""uuid:b0e49baf-fe4f-48c2-a9a3-b6e3e4b94b48"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9c3f0c19-3711-4ba7-928a-e1130d1733e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lidocaine Ointment USP, 5% is indicated for production of anesthesia of accessible mucous membranes of the oropharynx. It is also useful as an anesthetic lubricant for intubation and for the temporary relief of pain associated with minor burns, including sunburn, abrasions of the skin, and insect bites. uuid:03326c39-3ba5-4576-b9b1-b090375ce889 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:375139 biolink:treats UMLS:C0021564 PMID:41385096 "[{""id"":""uuid:9c1f022d-41e1-457c-bfb1-cb4f3182eef7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:49297555-fe0a-43b2-9834-2110143d4278"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lidocaine Ointment USP, 5% is indicated for production of anesthesia of accessible mucous membranes of the oropharynx. It is also useful as an anesthetic lubricant for intubation and for the temporary relief of pain associated with minor burns, including sunburn, abrasions of the skin, and insect bites. uuid:890ed6c6-7815-4d04-bd4d-531922b8b0cf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats UMLS:C0267055 PMID:41385096 "[{""id"":""uuid:590cbbad-aab9-492c-8187-1b7f97f4834b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3d9f4889-d693-42c4-8842-8fbab6f06bb3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pantoprazole sodium delayed-release tablets USP are indicated for: 1.1 Short-Term Treatment of Erosive Esophagitis Associated With Gastroesophageal Reflux Disease (GERD) Pantoprazole sodium delayed-release tablets USP are indicated in adults for the short-term treatment (up to 8 weeks) in the healing and symptomatic relief of erosive esophagitis. For those adult patients who have not healed after 8 weeks of treatment, an additional 8 week course of pantoprazole sodium delayed-release tablets USP may be considered. Safety of treatment beyond 8 weeks in pediatric patients has not been established. 1.2 Maintenance of Healing of Erosive Esophagitis Pantoprazole sodium delayed-release tablets USP are indicated for maintenance of healing of erosive esophagitis and reduction in relapse rates of daytime and nighttime heartburn symptoms in adult patients with GERD. Controlled studies did not extend beyond 12 months. 1.3 Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome Pantoprazole sodium delayed-release tablets USP are indicated for the long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome. uuid:002721d3-c42c-41ac-b7bc-a1595e7a4e61 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10124 biolink:treats MONDO:0100431 PMID:41385096 "[{""id"":""uuid:a4e82d02-82b5-4bc3-bb85-4acb89bd6928"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:943896f9-c8d0-4d3b-a294-e804fc27ae63"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Zolmitriptan is serotonin (5-HT) 1B/1D receptor agonist (triptan) indicated for the acute treatment of migraine with or without aura in adults ( 1 ) Limitations of Use : Use only after a clear diagnosis of migraine has been established ( 1 ) Not indicated for the prophylactic therapy of migraine ( 1 ) Not indicated for the treatment of cluster headache ( 1 ) uuid:321baf63-db04-42aa-b5b2-7c9597ca7612 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6030 biolink:treats MONDO:0004247 PMID:41385096 "[{""id"":""uuid:dce786e3-d232-4a0a-923a-9287adc19a83"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:572a22b4-1c44-48f9-9b43-1c8c079d235d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Isoniazid tablets are recommended for all forms of tuberculosis in which organisms are susceptible. However, active tuberculosis must be treated with multiple concomitant anti-tuberculosis medications to prevent the emergence of drug resistance. Single-drug treatment of active tuberculosis with isoniazid or any other medication, is inadequate therapy. Isoniazid tablets are recommended as preventive therapy for the following groups, regardless of age. (Note: the criterion for a positive reaction to a skin test (in millimeters of induration) for each group is given in parenthesis): 1. Persons with human immunodeficiency virus (HIV) infection (greater than or equal to 5 mm) and persons with risk factors for HIV infection whose HIV infection status is unknown but who are suspected of having HIV infection. Preventive therapy may be considered for HIV infected persons who are tuberculin-negative but belong to groups in which the prevalence of tuberculosis infection is high. Candidates for preventive therapy who have HIV infection should have a minimum of 12 months of therapy. 2. Close contacts of persons with newly diagnosed infectious tuberculosis (greater than or equal to 5 mm). In addition, tuberculin-negative (less than 5 mm) children and adolescents who have been close contacts of infectious persons within the past 3 months are candidates for preventive therapy until a repeat tuberculin skin test is done 12 weeks after contact with the infectious source. If the repeat skin test is positive (greater than 5 mm), therapy should be continued. 3. Recent converters, as indicated by a tuberculin skin test (greater than or equal to 10 mm increase within a 2-year period for those less than 35 years old; greater than or equal to 15 mm increase for those greater than or equal to 35 years of age). All infants and children younger than 4 years of age with a greater than 10 mm skin test are included in this category. 4. Persons with abnormal chest radiographs that show fibrotic lesions likely to represent old healed tuberculosis (greater than or equal to 5 mm). Candidates for preventive therapy who have fibrotic pulmonary lesions consistent with healed tuberculosis or who have pulmonary silicosis should have 12 months of isoniazid or 4 months of isoniazid and rifampin, concomitantly. 5. Intravenous drug users known to be HIV-seronegative (greater than 10 mm). 6. Persons with the following medical conditions that have been reported to increase the risk of tuberculosis (greater than or equal to 10 mm): silicosis; diabetes mellitus; prolonged therapy with adrenocorticosteroids; immunosuppressive therapy; some hematologic and reticuloendothelial diseases, such as leukemia or Hodgkin’s disease; end-stage renal disease; clinical situations associated with substantial rapid weight loss or chronic undernutrition (including: intestinal bypass surgery for obesity, the postgastrectomy state [with or without weight loss], chronic peptic ulcer disease, chronic malabsorption syndromes and carcinomas of the oropharynx and upper gastrointestinal tract that prevent adequate nutritional intake). Candidates for preventive therapy who have fibrotic pulmonary lesions consistent with healed tuberculosis or who have pulmonary silicosis should have 12 months of isoniazid or 4 months of isoniazid and rifampin, concomitantly. Additionally, in the absence of any of the above risk factors, persons under the age of 35 with a tuberculin skin test reaction of 10 mm or more are also appropriate candidates for preventive therapy if they are a member of any of the following high-incidence groups: 1. Foreign-born persons from high-prevalence countries who never received BCG vaccine. 2. Medically underserved low-income populations, including high-risk racial or ethnic minority populations, especially blacks, Hispanics and Native Americans. 3. Residents of facilities for long-term care (e.g., correctional institutions, nursing homes and mental institutions). Children who are less than 4 years old are candidates for isoniazid preventive therapy if they have greater than 10 mm induration from a PPD Mantoux tuberculin skin test. Finally, persons under the age of 35 who a) have none of the above risk factors (1 to 6); b) belong to none of the high-incidence groups; and c) have a tuberculin skin test reaction of 15 mm or more, are appropriate candidates for preventive therapy. The risk of hepatitis must be weighed against the risk of tuberculosis in positive tuberculin reactors over the age of 35. However, the use of isoniazid is recommended for those with the additional risk factors listed above (1 to 6) and on an individual basis in situations where there is likelihood of serious consequences to contacts who may become infected. uuid:39126009-9a1f-476b-aa5e-0304793c238e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6030 biolink:treats MONDO:0020598 PMID:41385096 "[{""id"":""uuid:62ee7c10-0f92-476b-a4c2-f45adf423d3b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e0ad9e80-73d7-444b-a71d-5b5d1d1a43c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Isoniazid tablets are recommended for all forms of tuberculosis in which organisms are susceptible. However, active tuberculosis must be treated with multiple concomitant anti-tuberculosis medications to prevent the emergence of drug resistance. Single-drug treatment of active tuberculosis with isoniazid or any other medication, is inadequate therapy. Isoniazid tablets are recommended as preventive therapy for the following groups, regardless of age. (Note: the criterion for a positive reaction to a skin test (in millimeters of induration) for each group is given in parenthesis): 1. Persons with human immunodeficiency virus (HIV) infection (greater than or equal to 5 mm) and persons with risk factors for HIV infection whose HIV infection status is unknown but who are suspected of having HIV infection. Preventive therapy may be considered for HIV infected persons who are tuberculin-negative but belong to groups in which the prevalence of tuberculosis infection is high. Candidates for preventive therapy who have HIV infection should have a minimum of 12 months of therapy. 2. Close contacts of persons with newly diagnosed infectious tuberculosis (greater than or equal to 5 mm). In addition, tuberculin-negative (less than 5 mm) children and adolescents who have been close contacts of infectious persons within the past 3 months are candidates for preventive therapy until a repeat tuberculin skin test is done 12 weeks after contact with the infectious source. If the repeat skin test is positive (greater than 5 mm), therapy should be continued. 3. Recent converters, as indicated by a tuberculin skin test (greater than or equal to 10 mm increase within a 2-year period for those less than 35 years old; greater than or equal to 15 mm increase for those greater than or equal to 35 years of age). All infants and children younger than 4 years of age with a greater than 10 mm skin test are included in this category. 4. Persons with abnormal chest radiographs that show fibrotic lesions likely to represent old healed tuberculosis (greater than or equal to 5 mm). Candidates for preventive therapy who have fibrotic pulmonary lesions consistent with healed tuberculosis or who have pulmonary silicosis should have 12 months of isoniazid or 4 months of isoniazid and rifampin, concomitantly. 5. Intravenous drug users known to be HIV-seronegative (greater than 10 mm). 6. Persons with the following medical conditions that have been reported to increase the risk of tuberculosis (greater than or equal to 10 mm): silicosis; diabetes mellitus; prolonged therapy with adrenocorticosteroids; immunosuppressive therapy; some hematologic and reticuloendothelial diseases, such as leukemia or Hodgkin’s disease; end-stage renal disease; clinical situations associated with substantial rapid weight loss or chronic undernutrition (including: intestinal bypass surgery for obesity, the postgastrectomy state [with or without weight loss], chronic peptic ulcer disease, chronic malabsorption syndromes and carcinomas of the oropharynx and upper gastrointestinal tract that prevent adequate nutritional intake). Candidates for preventive therapy who have fibrotic pulmonary lesions consistent with healed tuberculosis or who have pulmonary silicosis should have 12 months of isoniazid or 4 months of isoniazid and rifampin, concomitantly. Additionally, in the absence of any of the above risk factors, persons under the age of 35 with a tuberculin skin test reaction of 10 mm or more are also appropriate candidates for preventive therapy if they are a member of any of the following high-incidence groups: 1. Foreign-born persons from high-prevalence countries who never received BCG vaccine. 2. Medically underserved low-income populations, including high-risk racial or ethnic minority populations, especially blacks, Hispanics and Native Americans. 3. Residents of facilities for long-term care (e.g., correctional institutions, nursing homes and mental institutions). Children who are less than 4 years old are candidates for isoniazid preventive therapy if they have greater than 10 mm induration from a PPD Mantoux tuberculin skin test. Finally, persons under the age of 35 who a) have none of the above risk factors (1 to 6); b) belong to none of the high-incidence groups; and c) have a tuberculin skin test reaction of 15 mm or more, are appropriate candidates for preventive therapy. The risk of hepatitis must be weighed against the risk of tuberculosis in positive tuberculin reactors over the age of 35. However, the use of isoniazid is recommended for those with the additional risk factors listed above (1 to 6) and on an individual basis in situations where there is likelihood of serious consequences to contacts who may become infected. uuid:4dbaf407-7bff-4af1-9937-ef54b85c4ac4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:114785 biolink:treats MONDO:0021040 PMID:41385096 "[{""id"":""uuid:a115afef-4f8f-44bd-a4b2-bb9922394f5a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d0f237af-5bfa-43ca-89b4-4cfcbc3527fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Erlotinib tablets are kinase inhibitors indicated for: • The treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test receiving first-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen. (1.1) • First-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer, in combination with gemcitabine. (1.2) Limitations of Use : • Safety and efficacy of erlotinib tablets have not been established in patients with NSCLC whose tumors have other EGFR mutations. (1.1) • Erlotinib tablets are not recommended for use in combination with platinum-based chemotherapy. (1.1) uuid:14e00acd-7495-4487-9e38-3ffba56b82f1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1162127 biolink:treats MONDO:0006652 PMID:41385096 "[{""id"":""uuid:c4c9c816-7411-4d32-bb3a-2cbf5ccc9ea8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4d634e52-4717-4937-94f6-80f5262217d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Losartan potassium and hydrochlorothiazide tablets USP are a combination of losartan, an angiotensin II receptor blocker (ARB) and hydrochlorothiazide, a diuretic indicated for: · Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. (1.1) · Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy. There is evidence that this benefit does not apply to Black patients. (1.2) uuid:6716b8d6-0b50-4af5-8fae-ebb0d8c32b1a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:46878853 biolink:treats MONDO:0005420 PMID:41385096 "[{""id"":""uuid:a68bf25e-fe82-4406-9e77-08a5b797d69a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8b63b795-84a7-4031-8ea2-61b460cace34"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Treatment of Hypercholesterolemia Fenofibrate tablets, USP are indicated as adjunctive therapy to diet to reduce elevated LDL-C, Total-C, Triglycerides and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb). Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and non-pharmacological interventions alone has been inadequate (See National Cholesterol Education Program [NCEP] Treatment Guidelines, below). Treatment of Hypertriglyceridemia Fenofibrate tablets, USP are also indicated as adjunctive therapy to diet for treatment of adult patients with hypertriglyceridemia (Fredrickson Types IV and V hyperlipidemia). Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually reduce fasting triglycerides and eliminate chylomicronemia thereby obviating the need for pharmacologic intervention. Markedly elevated levels of serum triglycerides (e.g. > 2,000 mg/dL) may increase the risk of developing pancreatitis. The effect of fenofibrate tablet, USP therapy on reducing this risk has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of very low density lipoprotein (VLDL). Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV and V hyperlipoproteinemia 2 . The initial treatment for dyslipidemia is dietary therapy specific for the type of lipoprotein abnormality. Excess body weight and excess alcoholic intake may be important factors in hypertriglyceridemia and should be addressed prior to any drug therapy. Physical exercise can be an important ancillary measure. Diseases contributory to hyperlipidemia, such as hypothyroidism or diabetes mellitus should be looked for and adequately treated. Estrogen therapy, thiazide diuretics and beta-blockers, are sometimes associated with massive rises in plasma triglycerides, especially in subjects with familial hypertriglyceridemia. In such cases, discontinuation of the specific etiologic agent may obviate the need for specific drug therapy of hypertriglyceridemia. The use of drugs should be considered only when reasonable attempts have been made to obtain satisfactory results with non-drug methods. If the decision is made to use drugs, the patient should be instructed that this does not reduce the importance of adhering to diet. (See WARNINGS and PRECAUTIONS ). Fredrickson Classification of Hyperlipoproteinemias C = cholesterol TG = triglycerides LDL = low density lipoprotein VLDL = very low density lipoprotein IDL = intermediate density lipoprotein Lipid Elevation Type Lipoprotein Elevated Major Minor I (rare) chylomicrons TG ↑↔C IIa LDL C - IIb LDL, VLDL C TG III (rare) IDL C, TG - IV VLDL TG ↑↔C V (rare) chylomicrons, VLDL TG ↑↔ NCEP Treatment Guidelines: LDL-C Goals and Cutpoints for Therapeutic Lifestyle Changes and Drug Therapy in Different Risk Categories † CHD = coronary heart disease †† Some authorities recommend use of LDL-lowering drugs in this category if an LDL-C level of < 100 mg/dL cannot be achieved by therapeutic lifestyle changes. Others prefer use of drugs that primarily modify triglycerides and HDL-C, e.g., nicotinic acid or fibrate. Clinical judgment also may call for deferring drug therapy in this subcategory. ††† Almost all people with 0 to 1 risk factor have 10-year risk < 10%; thus, 10-year risk assessment in people with 0 to 1 risk factor is not necessary. Risk Category LDL Goal (mg/dL) LDL Level at Which to Initiate Therapeutic Lifestyle Changes (mg/dL) LDL Level at Which to Consider Drug Therapy (mg/dL) CHD † or CHD risk equivalents (10-years risk > 20%) < 100 ≥ 100 ≥ 130 (100 to 129: drug optional) †† 2+ Risk Factors (10-year risk ≤ 20%) < 130 ≥ 130 10-year risk 10% to 20%: ≥ 130 10-year risk < 10%: ≥ 160 0 to 1 Risk Factor ††† < 160 ≥ 160 ≥ 190 (160 to 189: LDL- lowering drug optional) After the LDL-C goal has been achieved, if the TG is still ≥ 200 mg/dL, non HDL-C (total-C minus HDL-C) becomes a secondary target of therapy. Non-HDL-C goals are set 30 mg/dL higher than LDL-C goals for each risk category. uuid:5e6bae71-283f-4a5b-89ec-3ef8eb33f939 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:46878853 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:51641f7c-318c-4042-8c43-ae7129545372"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e59841c3-cdd8-4dba-a60b-e48137a77048"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Treatment of Hypercholesterolemia Fenofibrate tablets, USP are indicated as adjunctive therapy to diet to reduce elevated LDL-C, Total-C, Triglycerides and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb). Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and non-pharmacological interventions alone has been inadequate (See National Cholesterol Education Program [NCEP] Treatment Guidelines, below). Treatment of Hypertriglyceridemia Fenofibrate tablets, USP are also indicated as adjunctive therapy to diet for treatment of adult patients with hypertriglyceridemia (Fredrickson Types IV and V hyperlipidemia). Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually reduce fasting triglycerides and eliminate chylomicronemia thereby obviating the need for pharmacologic intervention. Markedly elevated levels of serum triglycerides (e.g. > 2,000 mg/dL) may increase the risk of developing pancreatitis. The effect of fenofibrate tablet, USP therapy on reducing this risk has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of very low density lipoprotein (VLDL). Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV and V hyperlipoproteinemia 2 . The initial treatment for dyslipidemia is dietary therapy specific for the type of lipoprotein abnormality. Excess body weight and excess alcoholic intake may be important factors in hypertriglyceridemia and should be addressed prior to any drug therapy. Physical exercise can be an important ancillary measure. Diseases contributory to hyperlipidemia, such as hypothyroidism or diabetes mellitus should be looked for and adequately treated. Estrogen therapy, thiazide diuretics and beta-blockers, are sometimes associated with massive rises in plasma triglycerides, especially in subjects with familial hypertriglyceridemia. In such cases, discontinuation of the specific etiologic agent may obviate the need for specific drug therapy of hypertriglyceridemia. The use of drugs should be considered only when reasonable attempts have been made to obtain satisfactory results with non-drug methods. If the decision is made to use drugs, the patient should be instructed that this does not reduce the importance of adhering to diet. (See WARNINGS and PRECAUTIONS ). Fredrickson Classification of Hyperlipoproteinemias C = cholesterol TG = triglycerides LDL = low density lipoprotein VLDL = very low density lipoprotein IDL = intermediate density lipoprotein Lipid Elevation Type Lipoprotein Elevated Major Minor I (rare) chylomicrons TG ↑↔C IIa LDL C - IIb LDL, VLDL C TG III (rare) IDL C, TG - IV VLDL TG ↑↔C V (rare) chylomicrons, VLDL TG ↑↔ NCEP Treatment Guidelines: LDL-C Goals and Cutpoints for Therapeutic Lifestyle Changes and Drug Therapy in Different Risk Categories † CHD = coronary heart disease †† Some authorities recommend use of LDL-lowering drugs in this category if an LDL-C level of < 100 mg/dL cannot be achieved by therapeutic lifestyle changes. Others prefer use of drugs that primarily modify triglycerides and HDL-C, e.g., nicotinic acid or fibrate. Clinical judgment also may call for deferring drug therapy in this subcategory. ††† Almost all people with 0 to 1 risk factor have 10-year risk < 10%; thus, 10-year risk assessment in people with 0 to 1 risk factor is not necessary. Risk Category LDL Goal (mg/dL) LDL Level at Which to Initiate Therapeutic Lifestyle Changes (mg/dL) LDL Level at Which to Consider Drug Therapy (mg/dL) CHD † or CHD risk equivalents (10-years risk > 20%) < 100 ≥ 100 ≥ 130 (100 to 129: drug optional) †† 2+ Risk Factors (10-year risk ≤ 20%) < 130 ≥ 130 10-year risk 10% to 20%: ≥ 130 10-year risk < 10%: ≥ 160 0 to 1 Risk Factor ††† < 160 ≥ 160 ≥ 190 (160 to 189: LDL- lowering drug optional) After the LDL-C goal has been achieved, if the TG is still ≥ 200 mg/dL, non HDL-C (total-C minus HDL-C) becomes a secondary target of therapy. Non-HDL-C goals are set 30 mg/dL higher than LDL-C goals for each risk category. uuid:8d9f54d9-2360-474b-9004-3a8d3e5f79e9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4735 biolink:treats MONDO:0006604 PMID:41385096 "[{""id"":""uuid:05f4447b-57bf-43c9-986a-ab65fd3e51a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:20fce649-5b7b-42ea-8c91-65ebaafa3ec6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. uuid:9689a825-5656-4b75-8a89-94c9bf9f0150 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4735 biolink:treats MONDO:0033816 PMID:41385096 "[{""id"":""uuid:4f5f48ca-827c-4b46-8fba-954bfb6460d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:80be7b37-13d6-4bff-891b-1d116f09cedc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. uuid:097cfd0f-9693-4b6d-a866-c1a1463ec7f2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4735 biolink:treats UMLS:C1275687 PMID:41385096 "[{""id"":""uuid:6ab4cd47-68ff-45be-927f-e5da29cb318b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:723caf3d-c73a-4b87-9d64-60b41fb68f2d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. uuid:6695a9f5-ceb8-452a-a6e1-2c997addd494 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4735 biolink:treats MONDO:0006814 PMID:41385096 "[{""id"":""uuid:d53bff11-9b3c-45ab-b3fb-56351d1c759c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1a5a883c-ecb1-43e0-8831-6cb6bdf09d40"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. uuid:6bc0d327-d742-4395-9914-99dfe85380ee biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4735 biolink:treats UMLS:C0010543 PMID:41385096 "[{""id"":""uuid:814d74b4-b577-49f1-ac5a-b7ba7b6a53d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5db22759-4d37-4e73-b34e-a29881e4e7b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. uuid:865da561-6649-43d4-99a3-608636c286fe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4735 biolink:treats MONDO:0006668 PMID:41385096 "[{""id"":""uuid:3b94ac96-501a-42e1-823f-b969147e19cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3015a60e-7000-47c0-81b8-84eca51280bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. uuid:3d9eafee-ac75-40ac-b9e4-36b31f303a98 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4735 biolink:treats UMLS:C0339289 PMID:41385096 "[{""id"":""uuid:f73a166d-c311-4668-9e3b-a46f97006c3f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f26bf221-8779-4c32-bf37-46b767017457"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. uuid:2efb1f19-6b12-4575-8434-97c1db71f018 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16914 biolink:treats HP:0005202 PMID:41385096 "[{""id"":""uuid:2e4be9c1-293c-44df-9371-cb63a9e9049f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:52decc95-b158-4f83-befb-d3d541bd080c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The components of Bismuth Subsalicylate Chewable Tablets/ Metronidazole Tablets/Tetracycline Hydrochloride Capsules (bismuth subsalicylate, metronidazole, and tetracycline hydrochloride), in combination with an H 2 antagonist, are indicated for the eradication of H. pylori for treatment of patients with H. pylori infection and duodenal ulcer disease (active or a history of duodenal ulcer). The eradication of H. pylori has been demonstrated to reduce the risk of duodenal ulcer recurrence in patients with active duodenal ulcer disease (see CLINICAL STUDIES and DOSAGE AND ADMINISTRATION ). To reduce the development of drug-resistant bacteria and maintain the effectiveness of Bismuth Subsalicylate Chewable Tablets/Metronidazole Tablets/Tetracycline Hydrochloride Capsules and other antibacterial drugs, Bismuth Subsalicylate Chewable Tablets/Metronidazole Tablets/Tetracycline Hydrochloride Capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:6ec06bea-204a-4a94-9a47-557ac0fe298a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16914 biolink:treats MONDO:0005412 PMID:41385096 "[{""id"":""uuid:49d61b99-9dc4-4a67-acae-c7d20448d048"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4e38d535-617e-42dd-94fc-7094917ca426"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The components of Bismuth Subsalicylate Chewable Tablets/ Metronidazole Tablets/Tetracycline Hydrochloride Capsules (bismuth subsalicylate, metronidazole, and tetracycline hydrochloride), in combination with an H 2 antagonist, are indicated for the eradication of H. pylori for treatment of patients with H. pylori infection and duodenal ulcer disease (active or a history of duodenal ulcer). The eradication of H. pylori has been demonstrated to reduce the risk of duodenal ulcer recurrence in patients with active duodenal ulcer disease (see CLINICAL STUDIES and DOSAGE AND ADMINISTRATION ). To reduce the development of drug-resistant bacteria and maintain the effectiveness of Bismuth Subsalicylate Chewable Tablets/Metronidazole Tablets/Tetracycline Hydrochloride Capsules and other antibacterial drugs, Bismuth Subsalicylate Chewable Tablets/Metronidazole Tablets/Tetracycline Hydrochloride Capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:d28cc969-2c42-4c35-a8e1-e7cdef0e620b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats UMLS:C0033775 PMID:41385096 "[{""id"":""uuid:3f4b6cf8-04e4-49e6-887b-6cea689d7659"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:631b4637-fc3b-4a53-b201-c34416d579b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pruritus, pruritic eczemas, abrasions, minor burns, insect bites, pain, soreness and discomfort due to pruritus ani, pruritus vulvae, hemorrhoids, anal fissures, and similar conditions of the skin and mucous membranes. uuid:5d01b5b9-fc07-46c3-8b80-504342bf5e66 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7862 biolink:treats MONDO:0006604 PMID:41385096 "[{""id"":""uuid:e52f71c9-b314-4f41-8056-2b826d95723c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9db70d5b-8f94-4ca8-bfa8-4d0d5f237a67"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RHOFADE ® (oxymetazoline hydrochloride) cream, 1% is indicated for the topical treatment of persistent facial erythema associated with rosacea in adults. uuid:7d872edd-eb6c-4527-b497-c5bc1b1edb8e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1152781 biolink:treats MONDO:0011438 PMID:41385096 "[{""id"":""uuid:44a49650-f8ab-4f27-9828-edc05c1e9477"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7b94a8f9-48b7-42e6-a2da-be87effdb86c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZIANA Gel is indicated for the topical treatment of acne vulgaris in patients 12 years or older. uuid:f73cd3ee-2424-4f6d-b28a-300b3d8cde21 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:23742 biolink:treats MONDO:0045048 PMID:41385096 "[{""id"":""uuid:f95efc66-133c-4d61-8aec-951593703c7e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:32ea203f-914f-403e-ba95-80bd163d0690"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] This fixed combination drug is not indicated for the initial therapy of edema or hyper tension except in individuals in whom the developme nt of hypokalemia cannot be ris ked. Triamterene and hydrochlorothiazide capsules, USP are indicated for the treatment of hypertension or edema in patients who develop hypokalemia on hydrochlorothiazide alone. Triamterene and hydrochlorothiazide capsules, USP are also indicated for those patients who require a thiazide diuretic and in whom the development of hypokalemia cannot be risked. Triamterene and hydrochlorothiazide capsules, USP may be used alone or as an adjunct to other antihypertensive drugs, such as beta-blockers. Since triamterene and hydrochlorothiazide capsules, USP may enhance the action of these agents, dosage adjustments may be necessary. Us age in Pregnancy: The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developed toxemia. Edema during pregnancy may arise from pathological causes or from the physiologic and mechanical consequences of pregnancy. Diuretics are indicated in pregnancy when edema is due to pathologic causes, just as they are in the absence of pregnancy. Dependent edema in pregnancy resulting from restriction of venous return by the expanded uterus is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is illogical and unnecessary. There is hypervolemia during normal pregnancy which is harmful to neither the fetus nor the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances this edema may cause extreme discomfort which is not relieved by rest. In these cases a short course of diuretics may provide relief and may be appropriate. uuid:4c440a8b-23e7-4f62-bca8-0f91d7477c47 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:66964 biolink:treats MONDO:0005351 PMID:41385096 "[{""id"":""uuid:75f467e0-9a55-452c-983d-bb5819bb2763"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1229a14f-998d-48ea-b467-a1b783cae994"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SYNDROS is indicated in adults for the treatment of: anorexia associated with weight loss in patients with Acquired Immune Deficiency Syndrome (AIDS). nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. uuid:14109fc0-8ad8-41d8-ba40-dad079fd1d4d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:66964 biolink:treats MONDO:0012268 PMID:41385096 "[{""id"":""uuid:c839a937-853c-4e24-be56-f89a559619f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:993a0463-a611-4dcd-8892-059a1d2e7f19"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SYNDROS is indicated in adults for the treatment of: anorexia associated with weight loss in patients with Acquired Immune Deficiency Syndrome (AIDS). nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. uuid:844d2483-4ce4-4fa2-8ae0-a4a7d61cb05e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:66964 biolink:treats HP:0002018 PMID:41385096 "[{""id"":""uuid:85b2c581-f6fc-465a-8af5-05b71b91b2ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7c9c7898-c44f-4d5c-b39d-80783a0a35f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SYNDROS is indicated in adults for the treatment of: anorexia associated with weight loss in patients with Acquired Immune Deficiency Syndrome (AIDS). nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. uuid:6257ef58-c654-49b7-8956-b3cbabd50a1b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:66964 biolink:treats HP:0002013 PMID:41385096 "[{""id"":""uuid:11c1f0dc-50bd-404b-bd6b-a664ca05990a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0aa58751-761b-4a33-a36c-dd08822bef0b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SYNDROS is indicated in adults for the treatment of: anorexia associated with weight loss in patients with Acquired Immune Deficiency Syndrome (AIDS). nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. uuid:5d204161-cbb3-4975-aead-3b2c60cbbbac biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71940 biolink:treats MONDO:0015924 PMID:41385096 "[{""id"":""uuid:bddb6489-4b46-4f2b-a953-053e1817c53f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:bd1a46ee-f001-49d8-bece-5bd1ce7340b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:49d7933f-32c2-4fec-ae26-4674f3502690"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/cialis""]},{""id"":""uuid:9c58baf8-c74d-4158-879c-28f119e7bada"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ADCIRCA is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability. Studies establishing effectiveness included predominately patients with NYHA Functional Class II – III symptoms and etiologies of idiopathic or heritable PAH (61%) or PAH associated with connective tissue diseases (23%). ( 1.1 )|[EMA] Talmanco is indicated in adults for the treatment of pulmonary arterial hypertension (PAH) classified as WHO functional class II and III, to improve exercise capacity. Efficacy has been shown in idiopathic PAH (IPAH) and in PAH related to collagen vascular disease.|[PMDA] A drug with a new indication and a new dosage for the treatment of pulmonary arterial hypertension. uuid:78ef79d5-0210-4a88-94e4-06fc17c0878c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71940 biolink:treats MONDO:0017147 PMID:41385096 "[{""id"":""uuid:f2815f40-6335-4223-86a2-36ebf9d88015"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:b53d01b6-a367-4754-acb7-0df5a616dc88"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:64215908-8472-49ce-8384-e6ce9e99a85c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/cialis""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] ADCIRCA is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability. Studies establishing effectiveness included predominately patients with NYHA Functional Class II – III symptoms and etiologies of idiopathic or heritable PAH (61%) or PAH associated with connective tissue diseases (23%). ( 1.1 )|[EMA] Talmanco is indicated in adults for the treatment of pulmonary arterial hypertension (PAH) classified as WHO functional class II and III, to improve exercise capacity. Efficacy has been shown in idiopathic PAH (IPAH) and in PAH related to collagen vascular disease. uuid:dca5db25-6787-45e9-8e2e-1807bb843822 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71940 biolink:treats MONDO:0017148 PMID:41385096 "[{""id"":""uuid:ca5d6ff7-5f35-47e4-84b0-09fb532597aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:85502d93-6727-4c45-91d0-703110a5fb05"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ADCIRCA is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability. Studies establishing effectiveness included predominately patients with NYHA Functional Class II – III symptoms and etiologies of idiopathic or heritable PAH (61%) or PAH associated with connective tissue diseases (23%). ( 1.1 ) uuid:704c8a20-f7b2-49e2-a8d3-af63cd0f90b9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10023 biolink:treats MONDO:0000240 PMID:41385096 "[{""id"":""uuid:f62f9831-2ed0-47af-a19f-d8f9ee4c136e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:4546c89d-c4ad-4fee-9fcc-974973b3ac14"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ac4ecfd3-f173-4fbd-98bf-43fc86eb27f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/vfend""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Voriconazole is an azole antifungal drug indicated for use in the treatment of: Invasive aspergillosis ( 1.1 ) Candidemia (non-neutropenics) and disseminated candidiasis in skin, abdomen, kidney, bladder wall and wounds ( 1.2 ) Esophageal candidiasis ( 1.3 ) Serious infections caused by Scedosporium apiospermum and Fusarium species including Fusarium solani , in patients intolerant of, or refractory to, other therapy ( 1.4 )|[EMA] Voriconazole, is a broad spectrum, triazole antifungal agent and is indicated in adults and children aged 2 years and above as follows:treatment of invasive aspergillosis;treatment of in candidaemianon-neutropenic patients;treatment of fluconazole-resistant serious invasive Candida infections (including C. krusei);Treatment of serious fungal infections caused by Scedosporium spp. and Fusarium spp.Vfend should be administered primarily to patients with progressive, possibly life-threatening infections.Prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (HSCT) recipients. uuid:98e9da6c-8b79-452d-b875-29411981630d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10023 biolink:treats MONDO:0044070 PMID:41385096 "[{""id"":""uuid:b3443993-eb8d-4210-a1eb-925f1a96a176"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:3533a48b-81d0-45c3-9ce7-36d3c21f27f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:10c87557-c6a8-4bee-8166-d51970760f2e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/vfend""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Voriconazole is an azole antifungal drug indicated for use in the treatment of: Invasive aspergillosis ( 1.1 ) Candidemia (non-neutropenics) and disseminated candidiasis in skin, abdomen, kidney, bladder wall and wounds ( 1.2 ) Esophageal candidiasis ( 1.3 ) Serious infections caused by Scedosporium apiospermum and Fusarium species including Fusarium solani , in patients intolerant of, or refractory to, other therapy ( 1.4 )|[EMA] Voriconazole, is a broad spectrum, triazole antifungal agent and is indicated in adults and children aged 2 years and above as follows:treatment of invasive aspergillosis;treatment of in candidaemianon-neutropenic patients;treatment of fluconazole-resistant serious invasive Candida infections (including C. krusei);Treatment of serious fungal infections caused by Scedosporium spp. and Fusarium spp.Vfend should be administered primarily to patients with progressive, possibly life-threatening infections.Prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (HSCT) recipients. uuid:ad0565cb-3387-4f84-ac29-1a4563374fc5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10023 biolink:treats MONDO:0042233 PMID:41385096 "[{""id"":""uuid:0f1df27a-5877-4476-9916-637e1ccf1c68"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7661de98-f97f-4a3b-8a05-dd134de609de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Voriconazole is an azole antifungal drug indicated for use in the treatment of: Invasive aspergillosis ( 1.1 ) Candidemia (non-neutropenics) and disseminated candidiasis in skin, abdomen, kidney, bladder wall and wounds ( 1.2 ) Esophageal candidiasis ( 1.3 ) Serious infections caused by Scedosporium apiospermum and Fusarium species including Fusarium solani , in patients intolerant of, or refractory to, other therapy ( 1.4 ) uuid:296abaf7-9a69-454d-9386-d10f47180ef5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10023 biolink:treats MONDO:0001648 PMID:41385096 "[{""id"":""uuid:b2939fa3-c15e-4767-9694-c06ba0d01884"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:96bd5ef2-ff55-4915-8207-aa8fa01998b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Voriconazole is an azole antifungal drug indicated for use in the treatment of: Invasive aspergillosis ( 1.1 ) Candidemia (non-neutropenics) and disseminated candidiasis in skin, abdomen, kidney, bladder wall and wounds ( 1.2 ) Esophageal candidiasis ( 1.3 ) Serious infections caused by Scedosporium apiospermum and Fusarium species including Fusarium solani , in patients intolerant of, or refractory to, other therapy ( 1.4 ) uuid:851620b6-1720-4bac-81f5-fb92f071d219 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10023 biolink:treats MONDO:0001215 PMID:41385096 "[{""id"":""uuid:e913efc3-7cc2-41ae-9a82-d016ffdbc71f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fe33289e-2ead-4cc2-9e01-038aa3254d51"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Voriconazole is an azole antifungal drug indicated for use in the treatment of: Invasive aspergillosis ( 1.1 ) Candidemia (non-neutropenics) and disseminated candidiasis in skin, abdomen, kidney, bladder wall and wounds ( 1.2 ) Esophageal candidiasis ( 1.3 ) Serious infections caused by Scedosporium apiospermum and Fusarium species including Fusarium solani , in patients intolerant of, or refractory to, other therapy ( 1.4 ) UMLS:C0276706 uuid:6ad310a8-02e4-4d9c-9e2c-15437601c6b3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10023 biolink:treats MONDO:0016426 PMID:41385096 "[{""id"":""uuid:e988f940-5b27-4221-933f-0b2cece02e69"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:54cf0edd-3309-43a5-85e0-54284b4d220e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:6be4c9c4-f1c4-433b-a190-9e9af6b9e940"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/vfend""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Voriconazole is an azole antifungal drug indicated for use in the treatment of: Invasive aspergillosis ( 1.1 ) Candidemia (non-neutropenics) and disseminated candidiasis in skin, abdomen, kidney, bladder wall and wounds ( 1.2 ) Esophageal candidiasis ( 1.3 ) Serious infections caused by Scedosporium apiospermum and Fusarium species including Fusarium solani , in patients intolerant of, or refractory to, other therapy ( 1.4 )|[EMA] Voriconazole, is a broad spectrum, triazole antifungal agent and is indicated in adults and children aged 2 years and above as follows:treatment of invasive aspergillosis;treatment of in candidaemianon-neutropenic patients;treatment of fluconazole-resistant serious invasive Candida infections (including C. krusei);Treatment of serious fungal infections caused by Scedosporium spp. and Fusarium spp.Vfend should be administered primarily to patients with progressive, possibly life-threatening infections.Prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (HSCT) recipients. uuid:7e67447e-0f58-4258-bc2e-f258cee5cf16 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C3848548 biolink:treats MONDO:0006733 PMID:41385096 "[{""id"":""uuid:e48c8179-2730-4935-bb71-7ffc5cdf6277"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1bea1abb-d23b-40f4-809f-4040d3ff55cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Rose Bengal ophthalmic strips are used as a diagnostic agent in routine ocular examinations or when superficial conjunctiva or corneal tissue change is suspected. Rose Bengal ophthalmic strips can also serve as an effective aid in the diagnosis of keratoconjunctivitis sicca, keratitis, abrasions or corrosions as well as the detection of foreign bodies. uuid:7cf7f900-65ee-4053-adde-7ee2ebd21cf9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C3848548 biolink:treats MONDO:0003085 PMID:41385096 "[{""id"":""uuid:7b419fce-f211-4fbc-8480-2c24c728f305"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d36d6844-9a5d-465b-b3f9-8efcabb9ece8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Rose Bengal ophthalmic strips are used as a diagnostic agent in routine ocular examinations or when superficial conjunctiva or corneal tissue change is suspected. Rose Bengal ophthalmic strips can also serve as an effective aid in the diagnosis of keratoconjunctivitis sicca, keratitis, abrasions or corrosions as well as the detection of foreign bodies. uuid:141dba52-da9c-498e-a206-b980af0fe762 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17544 biolink:treats MONDO:0003019 PMID:41385096 "[{""id"":""uuid:21cd3ee6-eee0-4473-9716-e1dfa37dc436"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2ea41e33-aa56-465f-8f73-abad6bd5897e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For therapeutic use in patients with hypokalemia with or without metabolic alkalosis; in chronic digitalis intoxication; and in patients with hypokalemic familial periodic paralysis. For prevention of potassium depletion when the dietary intake of potassium ion is inadequate in the following conditions; patients receiving digitalis and diuretics for congestive heart failure; hepatic cirrhosis with ascites; states of aldosterone excess with normal renal function; potassiumlosing nephropathy, and certain diarrheal states; long-term corticosteroid therapy. The use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension or receiving certain antibiotics is often unnecessary when such patients have a normal dietary pattern. Serum potassium should be checked periodically, however, and, if hypokalemia occurs, dietary supplementation with potassium-containing foods may be adequate to control milder cases. In more severe cases supplementation with potassium salts may be indicated. uuid:24f81d2b-8789-44e2-9775-017f34a6f7ea biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17544 biolink:treats HP:0200114 PMID:41385096 "[{""id"":""uuid:3eb3337d-8e9f-4ca6-a726-d5d52ee9921b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:57cf568e-ad1d-49de-b020-6859ec4644cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For therapeutic use in patients with hypokalemia with or without metabolic alkalosis; in chronic digitalis intoxication; and in patients with hypokalemic familial periodic paralysis. For prevention of potassium depletion when the dietary intake of potassium ion is inadequate in the following conditions; patients receiving digitalis and diuretics for congestive heart failure; hepatic cirrhosis with ascites; states of aldosterone excess with normal renal function; potassiumlosing nephropathy, and certain diarrheal states; long-term corticosteroid therapy. The use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension or receiving certain antibiotics is often unnecessary when such patients have a normal dietary pattern. Serum potassium should be checked periodically, however, and, if hypokalemia occurs, dietary supplementation with potassium-containing foods may be adequate to control milder cases. In more severe cases supplementation with potassium salts may be indicated. uuid:8661afdd-46ff-4846-a83e-67eb5ab9cbb8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17544 biolink:treats MONDO:0008223 PMID:41385096 "[{""id"":""uuid:a9be773d-6761-4005-b25a-74de047bb19a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6ed46a8f-3d14-46ce-a498-7bbaaa0afe3b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For therapeutic use in patients with hypokalemia with or without metabolic alkalosis; in chronic digitalis intoxication; and in patients with hypokalemic familial periodic paralysis. For prevention of potassium depletion when the dietary intake of potassium ion is inadequate in the following conditions; patients receiving digitalis and diuretics for congestive heart failure; hepatic cirrhosis with ascites; states of aldosterone excess with normal renal function; potassiumlosing nephropathy, and certain diarrheal states; long-term corticosteroid therapy. The use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension or receiving certain antibiotics is often unnecessary when such patients have a normal dietary pattern. Serum potassium should be checked periodically, however, and, if hypokalemia occurs, dietary supplementation with potassium-containing foods may be adequate to control milder cases. In more severe cases supplementation with potassium salts may be indicated. uuid:6f1297fe-97df-4aff-a648-2a4d40758e4c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17544 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:46c794c2-3d44-45a6-811b-28a583d80b0d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:14071c58-2f19-4af1-b7e6-9b04775a7bbe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For therapeutic use in patients with hypokalemia with or without metabolic alkalosis; in chronic digitalis intoxication; and in patients with hypokalemic familial periodic paralysis. For prevention of potassium depletion when the dietary intake of potassium ion is inadequate in the following conditions; patients receiving digitalis and diuretics for congestive heart failure; hepatic cirrhosis with ascites; states of aldosterone excess with normal renal function; potassiumlosing nephropathy, and certain diarrheal states; long-term corticosteroid therapy. The use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension or receiving certain antibiotics is often unnecessary when such patients have a normal dietary pattern. Serum potassium should be checked periodically, however, and, if hypokalemia occurs, dietary supplementation with potassium-containing foods may be adequate to control milder cases. In more severe cases supplementation with potassium salts may be indicated. uuid:79c1ad10-8db1-4540-bb88-b25045ed9dd3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17544 biolink:treats MONDO:0005155 PMID:41385096 "[{""id"":""uuid:b8ff3ef5-cd17-4c59-a93e-6ae86ee557a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3e73ae36-7675-424d-8ba4-478b1ea4bd25"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For therapeutic use in patients with hypokalemia with or without metabolic alkalosis; in chronic digitalis intoxication; and in patients with hypokalemic familial periodic paralysis. For prevention of potassium depletion when the dietary intake of potassium ion is inadequate in the following conditions; patients receiving digitalis and diuretics for congestive heart failure; hepatic cirrhosis with ascites; states of aldosterone excess with normal renal function; potassiumlosing nephropathy, and certain diarrheal states; long-term corticosteroid therapy. The use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension or receiving certain antibiotics is often unnecessary when such patients have a normal dietary pattern. Serum potassium should be checked periodically, however, and, if hypokalemia occurs, dietary supplementation with potassium-containing foods may be adequate to control milder cases. In more severe cases supplementation with potassium salts may be indicated. uuid:a14c7f84-8624-43b7-8bf1-62d8254e972a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17544 biolink:treats MONDO:0001673 PMID:41385096 "[{""id"":""uuid:3a53134d-1572-4e78-8e77-c5bbcec3b9ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c746a71d-8167-4ca9-b3c7-82cfc24d3082"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For therapeutic use in patients with hypokalemia with or without metabolic alkalosis; in chronic digitalis intoxication; and in patients with hypokalemic familial periodic paralysis. For prevention of potassium depletion when the dietary intake of potassium ion is inadequate in the following conditions; patients receiving digitalis and diuretics for congestive heart failure; hepatic cirrhosis with ascites; states of aldosterone excess with normal renal function; potassiumlosing nephropathy, and certain diarrheal states; long-term corticosteroid therapy. The use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension or receiving certain antibiotics is often unnecessary when such patients have a normal dietary pattern. Serum potassium should be checked periodically, however, and, if hypokalemia occurs, dietary supplementation with potassium-containing foods may be adequate to control milder cases. In more severe cases supplementation with potassium salts may be indicated. uuid:e35c0597-dce0-4ba2-bfa4-dcfb15bf6020 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17544 biolink:treats MONDO:0001134 PMID:41385096 "[{""id"":""uuid:b568d223-cc1b-412b-b73c-8b2d8f88a69d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bf0b4a02-f8c3-41c7-be6d-1761f718589e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For therapeutic use in patients with hypokalemia with or without metabolic alkalosis; in chronic digitalis intoxication; and in patients with hypokalemic familial periodic paralysis. For prevention of potassium depletion when the dietary intake of potassium ion is inadequate in the following conditions; patients receiving digitalis and diuretics for congestive heart failure; hepatic cirrhosis with ascites; states of aldosterone excess with normal renal function; potassiumlosing nephropathy, and certain diarrheal states; long-term corticosteroid therapy. The use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension or receiving certain antibiotics is often unnecessary when such patients have a normal dietary pattern. Serum potassium should be checked periodically, however, and, if hypokalemia occurs, dietary supplementation with potassium-containing foods may be adequate to control milder cases. In more severe cases supplementation with potassium salts may be indicated. uuid:8f21648a-88c4-4994-9ab1-70780df4d155 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31624 biolink:treats UMLS:C0339289 PMID:41385096 "[{""id"":""uuid:efabf0b3-cda7-43f2-93bf-c2d7c7f25d7e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9be016b6-fb80-4c97-b473-1200632f9289"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For staining the anterior segment of the eye in disclosing corneal injury, in applanation tonometry and when fitting contact lenses. uuid:d2e6212a-0631-4fa8-9a72-51d735c06ff7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75275 biolink:treats MONDO:0008638 PMID:41385096 "[{""id"":""uuid:57c8557b-ea99-4d69-af06-c13c560b32bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ab62e291-9156-42ec-b28d-8841645fb495"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sotradecol (sodium tetradecyl sulfate injection) is indicated in the treatment of small uncomplicated varicose veins of the lower extremities that show simple dilation with competent valves. The benefit-to-risk ratio should be considered in selected patients who are great surgical risks. uuid:6cca6f6c-6876-47cb-bdf2-6901580500d3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:M4EN45951F biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:313d0913-94e5-4c66-a8d8-62a00feb62af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6881ba77-b7e0-4226-b21a-31742b5a9ac8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SUPRAX (cefixime) is a cephalosporin antibacterial drug indicated in the treatment of adults and pediatric patients six months and older with the following infections: Uncomplicated Urinary Tract Infections ( 1.1 ) Otitis Media ( 1.2 ) Pharyngitis and Tonsillitis ( 1.3 ) Acute Exacerbations of Chronic Bronchitis ( 1.4 ) Uncomplicated Gonorrhea (cervical/urethral) ( 1.5 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of SUPRAX and other antibacterial drugs, SUPRAX should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. ( 1.6 ) uuid:52ffaa71-61f4-496f-9bd1-2e6c96f2e048 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:M4EN45951F biolink:treats MONDO:0005441 PMID:41385096 "[{""id"":""uuid:9e6b8c30-e9e8-4cfe-a5b0-90b872ed197f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1b2e3f51-9feb-4687-9332-91add9cddf75"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SUPRAX (cefixime) is a cephalosporin antibacterial drug indicated in the treatment of adults and pediatric patients six months and older with the following infections: Uncomplicated Urinary Tract Infections ( 1.1 ) Otitis Media ( 1.2 ) Pharyngitis and Tonsillitis ( 1.3 ) Acute Exacerbations of Chronic Bronchitis ( 1.4 ) Uncomplicated Gonorrhea (cervical/urethral) ( 1.5 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of SUPRAX and other antibacterial drugs, SUPRAX should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. ( 1.6 ) uuid:5293061b-574c-422d-96d2-b57c7a9f14d6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:M4EN45951F biolink:treats MONDO:0002258 PMID:41385096 "[{""id"":""uuid:328ac0d3-7524-45d9-86d9-aca239a8463e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:94b301be-5f20-44b3-8404-0a69d8b41d96"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SUPRAX (cefixime) is a cephalosporin antibacterial drug indicated in the treatment of adults and pediatric patients six months and older with the following infections: Uncomplicated Urinary Tract Infections ( 1.1 ) Otitis Media ( 1.2 ) Pharyngitis and Tonsillitis ( 1.3 ) Acute Exacerbations of Chronic Bronchitis ( 1.4 ) Uncomplicated Gonorrhea (cervical/urethral) ( 1.5 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of SUPRAX and other antibacterial drugs, SUPRAX should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. ( 1.6 ) uuid:a396a7fc-663c-4fec-a689-8c7adb6033ec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:M4EN45951F biolink:treats MONDO:0001039 PMID:41385096 "[{""id"":""uuid:aa3700b1-8271-414d-8c76-1009d5a58f68"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e74ac54e-44b0-4924-b369-39761451af42"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SUPRAX (cefixime) is a cephalosporin antibacterial drug indicated in the treatment of adults and pediatric patients six months and older with the following infections: Uncomplicated Urinary Tract Infections ( 1.1 ) Otitis Media ( 1.2 ) Pharyngitis and Tonsillitis ( 1.3 ) Acute Exacerbations of Chronic Bronchitis ( 1.4 ) Uncomplicated Gonorrhea (cervical/urethral) ( 1.5 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of SUPRAX and other antibacterial drugs, SUPRAX should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. ( 1.6 ) uuid:9cdeed47-cb84-476b-9164-ade7bf7b2368 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:M4EN45951F biolink:treats UMLS:C0853854 PMID:41385096 "[{""id"":""uuid:796922e3-eeac-4add-8417-bd0f129f3620"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7d3eb95b-c285-4b4d-aff9-ee6785c0dfa4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SUPRAX (cefixime) is a cephalosporin antibacterial drug indicated in the treatment of adults and pediatric patients six months and older with the following infections: Uncomplicated Urinary Tract Infections ( 1.1 ) Otitis Media ( 1.2 ) Pharyngitis and Tonsillitis ( 1.3 ) Acute Exacerbations of Chronic Bronchitis ( 1.4 ) Uncomplicated Gonorrhea (cervical/urethral) ( 1.5 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of SUPRAX and other antibacterial drugs, SUPRAX should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. ( 1.6 ) uuid:c6347efa-00fc-4229-af05-46f18d9b63d8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:M4EN45951F biolink:treats MONDO:0004277 PMID:41385096 "[{""id"":""uuid:84049bee-7a8a-4995-9100-f5cc51389f79"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8555046e-d3fd-4fba-a23b-4f18607bdd69"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SUPRAX (cefixime) is a cephalosporin antibacterial drug indicated in the treatment of adults and pediatric patients six months and older with the following infections: Uncomplicated Urinary Tract Infections ( 1.1 ) Otitis Media ( 1.2 ) Pharyngitis and Tonsillitis ( 1.3 ) Acute Exacerbations of Chronic Bronchitis ( 1.4 ) Uncomplicated Gonorrhea (cervical/urethral) ( 1.5 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of SUPRAX and other antibacterial drugs, SUPRAX should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. ( 1.6 ) uuid:468f3e57-e0d8-4b45-9832-b7e31eb38f84 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16217 biolink:treats MONDO:0006678 PMID:41385096 "[{""id"":""uuid:20fbefd5-17b3-4474-b395-cad9674c8df2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:70e81c6b-4977-489e-9b93-a66204de5dc5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Renacidin is indicated for dissolution of bladder calculi of the struvite or apatite variety by local intermittent irrigation through a urethral catheter or cystostomy tube as an alternative or adjunct to surgical procedures. Renacidin is also indicated for use as an intermittent irrigating solution to prevent encrustations of indwelling urethral catheters and cystostomy tubes. uuid:a1950df2-823b-4297-8420-9e9ce768b4c1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29007 biolink:treats MONDO:0042485 PMID:41385096 "[{""id"":""uuid:6b189e5f-7d58-469c-b47b-e1ff5b64baa3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:be41d3a0-5df2-4cf8-8379-3416309e17d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Before instituting treatment with Ceftriaxone for Injection, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. Therapy may be instituted prior to obtaining results of susceptibility testing. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ceftriaxone for Injection and other antibacterial drugs, Ceftriaxone for Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ceftriaxone for Injection is indicated for the treatment of the following infections when caused by susceptible organisms: LOWER RESPIRATORY TRACT INFECTIONS caused by Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Escherichia coli, Enterobacter aerogenes, Proteus mirabilis or Serratia marcescens. ACUTE BACTERIAL OTITIS MEDIA caused by Streptococcus pneumoniae, Haemophilus influenzae (including beta-lactamase producing strains) or Moraxella catarrhalis (including beta-lactamase producing strains). NOTE : In one study lower clinical cure rates were observed with a single dose of Ceftriaxone for Injection compared to 10 days of oral therapy. In a second study comparable cure rates were observed between single dose Ceftriaxone for Injection and the comparator. The potentially lower clinical cure rate of Ceftriaxone for Injection should be balanced against the potential advantages of parenteral therapy (see CLINICAL STUDIES ). SKIN AND SKIN STRUCTURE INFECTIONS caused by Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Viridans group streptococci , Escherichia coli, Enterobacter cloacae, Klebsiella oxytoca, Klebsiella pneumoniae, Proteus mirabilis, Morganella morganii, * Pseudomonas aeruginosa, Serratia marcescens, Acinetobacter calcoaceticus, Bacteroides fragilis * or Peptostreptococcus species . URINARY TRACT INFECTIONS (complicated and uncomplicated) caused by Escherichia coli, Proteus mirabilis, Proteus vulgaris, Morganella morganii or Klebsiella pneumoniae. UNCOMPLICATED GONORRHEA (cervical/urethral and rectal) caused by Neisseria gonorrhoeae, including both penicillinase- and nonpenicillinase-producing strains, and pharyngeal gonorrhea caused by nonpenicillinase-producing strains of Neisseria gonorrhoeae. PELVIC INFLAMMATORY DISEASE caused by Neisseria gonorrhoeae. Ceftriaxone for Injection, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and Chlamydia trachomatis is one of the suspected pathogens, appropriate antichlamydial coverage should be added. BACTERIAL SEPTICEMIA caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae or Klebsiella pneumoniae. BONE AND JOINT INFECTIONS caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae or Enterobacter species. INTRA-ABDOMINAL INFECTIONS caused by Escherichia coli, Klebsiella pneumoniae, Bacteroides fragilis, Clostridium species (Note: most strains of Clostridium difficile are resistant) or Peptostreptococcus species. MENINGITIS caused by Haemophilus influenzae, Neisseria meningitidis or Streptococcus pneumoniae. Ceftriaxone for Injection has also been used successfully in a limited number of cases of meningitis and shunt infection caused by Staphylococcus epidermidis* and Escherichia coli*. * Efficacy for this organism in this organ system was studied in fewer than ten infections. SURGICAL PROPHYLAXIS: The preoperative administration of a single 1 g dose of Ceftriaxone for Injection may reduce the incidence of postoperative infections in patients undergoing surgical procedures classified as contaminated or potentially contaminated (e.g. , vaginal or abdominal hysterectomy or cholecystectomy for chronic calculous cholecystitis in high-risk patients, such as those over 70 years of age, with acute cholecystitis not requiring therapeutic antimicrobials, obstructive jaundice or common duct bile stones) and in surgical patients for whom infection at the operative site would present serious risk (e.g. , during coronary artery bypass surgery). Although Ceftriaxone for Injection has been shown to have been as effective as cefazolin in the prevention of infection following coronary artery bypass surgery, no placebo-controlled trials have been conducted to evaluate any cephalosporin antibiotic in the prevention of infection following coronary artery bypass surgery. When administered prior to surgical procedures for which it is indicated, a single 1 g dose of Ceftriaxone for Injection provides protection from most infections due to susceptible organisms throughout the course of the procedure. uuid:84533406-8949-49b7-b760-c982e78f13eb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29007 biolink:treats UMLS:C0392618 PMID:41385096 "[{""id"":""uuid:7362943e-e873-4de9-b83b-9eabdebc0c74"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:35da70de-b83e-4e92-a648-feb2376d0099"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Before instituting treatment with Ceftriaxone for Injection, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. Therapy may be instituted prior to obtaining results of susceptibility testing. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ceftriaxone for Injection and other antibacterial drugs, Ceftriaxone for Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ceftriaxone for Injection is indicated for the treatment of the following infections when caused by susceptible organisms: LOWER RESPIRATORY TRACT INFECTIONS caused by Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Escherichia coli, Enterobacter aerogenes, Proteus mirabilis or Serratia marcescens. ACUTE BACTERIAL OTITIS MEDIA caused by Streptococcus pneumoniae, Haemophilus influenzae (including beta-lactamase producing strains) or Moraxella catarrhalis (including beta-lactamase producing strains). NOTE : In one study lower clinical cure rates were observed with a single dose of Ceftriaxone for Injection compared to 10 days of oral therapy. In a second study comparable cure rates were observed between single dose Ceftriaxone for Injection and the comparator. The potentially lower clinical cure rate of Ceftriaxone for Injection should be balanced against the potential advantages of parenteral therapy (see CLINICAL STUDIES ). SKIN AND SKIN STRUCTURE INFECTIONS caused by Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Viridans group streptococci , Escherichia coli, Enterobacter cloacae, Klebsiella oxytoca, Klebsiella pneumoniae, Proteus mirabilis, Morganella morganii, * Pseudomonas aeruginosa, Serratia marcescens, Acinetobacter calcoaceticus, Bacteroides fragilis * or Peptostreptococcus species . URINARY TRACT INFECTIONS (complicated and uncomplicated) caused by Escherichia coli, Proteus mirabilis, Proteus vulgaris, Morganella morganii or Klebsiella pneumoniae. UNCOMPLICATED GONORRHEA (cervical/urethral and rectal) caused by Neisseria gonorrhoeae, including both penicillinase- and nonpenicillinase-producing strains, and pharyngeal gonorrhea caused by nonpenicillinase-producing strains of Neisseria gonorrhoeae. PELVIC INFLAMMATORY DISEASE caused by Neisseria gonorrhoeae. Ceftriaxone for Injection, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and Chlamydia trachomatis is one of the suspected pathogens, appropriate antichlamydial coverage should be added. BACTERIAL SEPTICEMIA caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae or Klebsiella pneumoniae. BONE AND JOINT INFECTIONS caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae or Enterobacter species. INTRA-ABDOMINAL INFECTIONS caused by Escherichia coli, Klebsiella pneumoniae, Bacteroides fragilis, Clostridium species (Note: most strains of Clostridium difficile are resistant) or Peptostreptococcus species. MENINGITIS caused by Haemophilus influenzae, Neisseria meningitidis or Streptococcus pneumoniae. Ceftriaxone for Injection has also been used successfully in a limited number of cases of meningitis and shunt infection caused by Staphylococcus epidermidis* and Escherichia coli*. * Efficacy for this organism in this organ system was studied in fewer than ten infections. SURGICAL PROPHYLAXIS: The preoperative administration of a single 1 g dose of Ceftriaxone for Injection may reduce the incidence of postoperative infections in patients undergoing surgical procedures classified as contaminated or potentially contaminated (e.g. , vaginal or abdominal hysterectomy or cholecystectomy for chronic calculous cholecystitis in high-risk patients, such as those over 70 years of age, with acute cholecystitis not requiring therapeutic antimicrobials, obstructive jaundice or common duct bile stones) and in surgical patients for whom infection at the operative site would present serious risk (e.g. , during coronary artery bypass surgery). Although Ceftriaxone for Injection has been shown to have been as effective as cefazolin in the prevention of infection following coronary artery bypass surgery, no placebo-controlled trials have been conducted to evaluate any cephalosporin antibiotic in the prevention of infection following coronary artery bypass surgery. When administered prior to surgical procedures for which it is indicated, a single 1 g dose of Ceftriaxone for Injection provides protection from most infections due to susceptible organisms throughout the course of the procedure. uuid:5f195503-2640-4a8e-a5dd-6e57ae78da82 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4712 biolink:treats MONDO:0006964 PMID:41385096 "[{""id"":""uuid:2ded0d40-aa45-4335-806a-468e1249228e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0c0bf0f9-35c8-423d-94d5-35b757109a67"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Doxercalciferol injection is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis. uuid:154cfe18-e7ad-4981-ba3f-fc295b33269e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4712 biolink:treats MONDO:0005300 PMID:41385096 "[{""id"":""uuid:ea8c69f4-0437-4f22-9f38-377d1ea5f767"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:72ea99aa-1bb6-4189-a4f1-b12abea10d7e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Doxercalciferol injection is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis. uuid:e44593b9-c826-4c71-aff1-a844e42b4ac2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31625 biolink:treats MONDO:0006170 PMID:41385096 "[{""id"":""uuid:386dcdce-6043-4d83-8f0a-0ecb6cfe3bf5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8d1b9dc9-9742-44cd-8b38-cbfef7a3cf79"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FLAREX (fluorometholone acetate ophthalmic suspension) is indicated for use in the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the eye. uuid:4d528d66-a707-40e0-b12e-c697ac6ee47a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31625 biolink:treats MONDO:0001718 PMID:41385096 "[{""id"":""uuid:566c6518-e9c5-4003-83ba-17c515a265c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2f53b359-b04d-4211-b771-86739430e61a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FLAREX (fluorometholone acetate ophthalmic suspension) is indicated for use in the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the eye. uuid:4c20cd2a-fc64-4306-985b-63015e4268ef biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:291902 biolink:treats MONDO:0005542 PMID:41385096 "[{""id"":""uuid:ba419e2f-ae52-43b2-840e-6aa3ea3bf364"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b7f2bf2c-d3aa-4c27-9bb9-99522d3c1a8f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Eptifibatide injection is a platelet aggregation inhibitor indicated for: Treatment of acute coronary syndrome (ACS) managed medically or with percutaneous coronary intervention (PCI) ( 1.1 ) Treatment of patients undergoing PCI (including intracoronary stenting) ( 1.2 ) uuid:a0c878ca-e563-43ef-b498-6d3d1127ed95 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:607 biolink:treats MONDO:0007743 PMID:41385096 "[{""id"":""uuid:8389f79b-d83a-438e-94bb-4c4b89669dfa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b36c62b0-7719-4904-97e8-5ee56773f315"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets are indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and Narcolepsy. MESH:C090411 uuid:1a1680b0-c4f4-4616-bbd3-ebc0e8f6afea biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63632 biolink:treats UMLS:C4721779 PMID:41385096 "[{""id"":""uuid:a9b9dc7d-b84c-4e05-a382-7198fa7fe5a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3c901376-5fc1-4415-8cf2-52e5f62c8072"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Topotecan Hydrochloride for Injection is a topoisomerase inhibitor indicated for treatment of: Patients with metastatic ovarian cancer after disease progression on or after initial or subsequent chemotherapy, as a single agent ( 1.1 ) Patients with small cell lung cancer (SCLC) platinum-sensitive disease who progressed at least 60 days after initiation of first-line chemotherapy, as a single agent ( 1.2 ) Patients with Stage IV-B, recurrent, or persistent cervical cancer which is not amenable to curative treatment, in combination with cisplatin ( 1.3 ) uuid:e7c2ade0-b23b-4acd-8054-806ced8176d3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63632 biolink:treats MONDO:0002974 PMID:41385096 "[{""id"":""uuid:e28c1b7c-a6b5-4da4-b66a-5f9c247ed196"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b63bafd0-401f-4147-8143-5a40d0019aaf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Topotecan Hydrochloride for Injection is a topoisomerase inhibitor indicated for treatment of: Patients with metastatic ovarian cancer after disease progression on or after initial or subsequent chemotherapy, as a single agent ( 1.1 ) Patients with small cell lung cancer (SCLC) platinum-sensitive disease who progressed at least 60 days after initiation of first-line chemotherapy, as a single agent ( 1.2 ) Patients with Stage IV-B, recurrent, or persistent cervical cancer which is not amenable to curative treatment, in combination with cisplatin ( 1.3 ) uuid:486d4b60-7027-43f3-9af0-35e9ce90d492 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:132233 biolink:treats MONDO:0021107 PMID:41385096 "[{""id"":""uuid:21789bb9-ccc2-4a3b-b115-3925a1d4d282"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6e466179-f87f-4359-9dbe-5db20cde3843"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amphetamine sulfate tablets are indicated for: Narcolepsy Attention Deficit Disorder with Hyperactivity as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. The diagnosis of the syndrome should not be made with finality when these symptoms are only of comparatively recent origin. Non-localizing (soft) neurological signs, learning disability, and abnormal EEG may or may not be present, and a diagnosis of central nervous system dysfunction may or not be warranted. Exogenous Obesity as a short-term (a few weeks) adjuncts in a regimen of weight reduction based on caloric restriction for patients refractory to alternative therapy, e.g., repeated diets, group programs, and other drugs. The limited usefulness of amphetamines (see CLINICAL PHARMACOLOGY ) should be weighed against possible risks inherent in the use of the drug, such as those described below. uuid:30cd77bc-7b21-4bc6-8e1f-e12a0db44636 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:132233 biolink:treats MONDO:0007743 PMID:41385096 "[{""id"":""uuid:8250fbd8-d349-49b5-a476-eef66b75c4aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:50d81d4f-4cc9-4bc7-965d-e34679ca6fc7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amphetamine sulfate tablets are indicated for: Narcolepsy Attention Deficit Disorder with Hyperactivity as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. The diagnosis of the syndrome should not be made with finality when these symptoms are only of comparatively recent origin. Non-localizing (soft) neurological signs, learning disability, and abnormal EEG may or may not be present, and a diagnosis of central nervous system dysfunction may or not be warranted. Exogenous Obesity as a short-term (a few weeks) adjuncts in a regimen of weight reduction based on caloric restriction for patients refractory to alternative therapy, e.g., repeated diets, group programs, and other drugs. The limited usefulness of amphetamines (see CLINICAL PHARMACOLOGY ) should be weighed against possible risks inherent in the use of the drug, such as those described below. uuid:a920e262-b167-4d14-865d-f35185a9cffa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:132233 biolink:treats NCIT:C120380 PMID:41385096 "[{""id"":""uuid:9a1c298d-6a96-47b1-935d-b6afe91dd71c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e7f33777-d3a7-4371-aebb-cd264f95c726"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amphetamine sulfate tablets are indicated for: Narcolepsy Attention Deficit Disorder with Hyperactivity as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. The diagnosis of the syndrome should not be made with finality when these symptoms are only of comparatively recent origin. Non-localizing (soft) neurological signs, learning disability, and abnormal EEG may or may not be present, and a diagnosis of central nervous system dysfunction may or not be warranted. Exogenous Obesity as a short-term (a few weeks) adjuncts in a regimen of weight reduction based on caloric restriction for patients refractory to alternative therapy, e.g., repeated diets, group programs, and other drugs. The limited usefulness of amphetamines (see CLINICAL PHARMACOLOGY ) should be weighed against possible risks inherent in the use of the drug, such as those described below. uuid:a1e00bfc-3cff-45cd-a798-350e16aabcee biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:175901 biolink:treats MONDO:0008170 PMID:41385096 "[{""id"":""uuid:2c176564-dfd4-45d6-ba84-a1c3df436d26"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0d0e84ae-2277-4fa0-beae-5ccb86ee255e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:282b78a6-c6e7-4755-85a3-b1966dd2cf73"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gemcitabine Injection is a nucleoside metabolic inhibitor indicated: in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. ( 1.1 ) in combination with paclitaxel, for first-line treatment of metastatic breast cancer after failure of prior anthracycline containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. ( 1.2 ) in combination with cisplatin for the treatment of non-small cell lung cancer. ( 1.3 ) as a single-agent for the treatment of pancreatic cancer. ( 1.4 )|[PMDA] Drugs with a new additional indication and a new dosage for the treatment of ovarian cancer which has progressed after cancer chemotherapy. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:4dcc89da-17ef-4742-bacd-6482b973ca03 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:175901 biolink:treats UMLS:C0278488 PMID:41385096 "[{""id"":""uuid:08c426cf-5eab-418d-9e68-c6b2817f5806"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a126e0e7-980a-4f51-b765-00dad1281a33"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gemcitabine Injection is a nucleoside metabolic inhibitor indicated: in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. ( 1.1 ) in combination with paclitaxel, for first-line treatment of metastatic breast cancer after failure of prior anthracycline containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. ( 1.2 ) in combination with cisplatin for the treatment of non-small cell lung cancer. ( 1.3 ) as a single-agent for the treatment of pancreatic cancer. ( 1.4 ) uuid:7856b1e8-eefe-4ecd-8c50-044707b7a687 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:175901 biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:e37e53b8-ec78-468a-9c2b-d950d925cd24"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ff2d7053-c9ac-4873-be9b-9ae69515b167"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c94ba6c1-5904-409d-813c-bf48c91eb8ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gemcitabine Injection is a nucleoside metabolic inhibitor indicated: in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. ( 1.1 ) in combination with paclitaxel, for first-line treatment of metastatic breast cancer after failure of prior anthracycline containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. ( 1.2 ) in combination with cisplatin for the treatment of non-small cell lung cancer. ( 1.3 ) as a single-agent for the treatment of pancreatic cancer. ( 1.4 )|[PMDA] Drugs with a new dosage indicated for the treatment of non-small cell lung cancer. uuid:efe06295-08b9-42ef-ac74-53a29c50ecc3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:175901 biolink:treats MONDO:0021040 PMID:41385096 "[{""id"":""uuid:3d08073f-f603-45de-9df4-04d3fd406e1d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:58f6bec4-1f3e-4245-b06e-20710125a4e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gemcitabine Injection is a nucleoside metabolic inhibitor indicated: in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. ( 1.1 ) in combination with paclitaxel, for first-line treatment of metastatic breast cancer after failure of prior anthracycline containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. ( 1.2 ) in combination with cisplatin for the treatment of non-small cell lung cancer. ( 1.3 ) as a single-agent for the treatment of pancreatic cancer. ( 1.4 ) uuid:6a6cab96-ff67-454f-8981-c0fd12a9915a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2668 biolink:treats HP:0001681 PMID:41385096 "[{""id"":""uuid:8ebefe91-f110-4d88-8fb1-d98992ac5dde"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:435b6f50-6b0d-4b74-b09c-d79fb709ba39"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:6b49787d-c220-4180-a73b-f5add67918b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Hypertension Amlodipine besylate tablets USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including amlodipine besylate tablets USP. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Amlodipine besylate tablets USP may be used alone or in combination with other antihypertensive agents. 1.2 Coronary Artery Disease (CAD) Chronic Stable Angina Amlodipine besylate tablets USP are indicated for the symptomatic treatment of chronic stable angina. Amlodipine besylate tablets USP may be used alone or in combination with other antianginal agents. Vasospastic Angina (Prinzmetal's or Variant Angina) Amlodipine besylate tablets USP are indicated for the treatment of confirmed or suspected vasospastic angina. Amlodipine besylate tablets USP may be used as monotherapy or in combination with other antianginal agents. Angiographically Documented CAD In patients with recently documented CAD by angiography and without heart failure or an ejection fraction <40%, amlodipine besylate tablets USP are indicated to reduce the risk of hospitalization for angina and to reduce the risk of a coronary revascularization procedure.|[PMDA] Drugs with a new dosage indicated for the treatment of hypertension and angina pectoris. uuid:c048b30b-443d-4e8f-9169-1695c27deda4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4672 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:feea6219-47ba-4e9b-98d2-ee1ed625de45"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ba04ea6b-6d4d-4f12-b85f-e731e28affa1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:bc563b75-b421-4e8a-8669-b76c2576cb3a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/docetaxel-kabi""]},{""id"":""uuid:9653dfcd-550c-4ae5-aa04-f2ffdcf057aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Docetaxel injection is a microtubule inhibitor indicated for: Breast Cancer (BC) : single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC ( 1.1 ) Non-small Cell Lung Cancer (NSCLC) : single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC ( 1.2 ) Castration-Resistant Prostate Cancer (CRPC) : with prednisone in metastatic castration-resistant prostate cancer ( 1.3 ) Gastric Adenocarcinoma (GC) : with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction ( 1.4 ) Squamous Cell Carcinoma of the Head and Neck (SCCHN) : with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN ( 1.5 )|[EMA] Breast cancerDocetaxel Kabi in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:operable node-positive breast cancer;operable node-negative breast cancer.For patients with operable node-negative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer.Docetaxel Kabi in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.Docetaxel Kabi monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent.Docetaxel Kabi in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress HER2 and who previously have not received chemotherapy for metastatic disease.Docetaxel Kabi in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline.Non-small-cell lung cancerDocetaxel Kabi is indicated for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer after failure of prior chemotherapy.Docetaxel Kabi in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small-cell lung cancer, in patients who have not previously received chemotherapy for this condition.Prostate cancerDocetaxel Kabi in combination with prednisone or prednisolone is indicated for the treatment of patients with castration-resistant metastatic prostate cancer.Docetaxel Kabi in combination with androgen-deprivation therapy (ADT), with or without prednisone or prednisolone, is indicated for the treatment of patients with metastatic hormone-sensitive prostate cancer.Gastric adenocarcinomaDocetaxel Kabi in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease.Head and neck cancerDocetaxel Kabi in combination with cisplatin and 5-fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.|[PMDA] Drugs with new dosages for the treatment of breast cancer, non-small cell lung cancer, gastric cancer, head and neck cancer and ovarian cancer. uuid:2e24ef4e-bde0-433e-92eb-0f07c132aad0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4672 biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:dba94d91-1fff-4055-af0c-4fb55f6d6f58"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:72c88e79-7480-4a19-acd6-f3d517931c32"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:56cab685-c44c-44b2-9696-59e878be1b70"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/docetaxel-kabi""]},{""id"":""uuid:f26feef0-2068-4664-a7d6-53447d19e724"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Docetaxel injection is a microtubule inhibitor indicated for: Breast Cancer (BC) : single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC ( 1.1 ) Non-small Cell Lung Cancer (NSCLC) : single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC ( 1.2 ) Castration-Resistant Prostate Cancer (CRPC) : with prednisone in metastatic castration-resistant prostate cancer ( 1.3 ) Gastric Adenocarcinoma (GC) : with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction ( 1.4 ) Squamous Cell Carcinoma of the Head and Neck (SCCHN) : with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN ( 1.5 )|[EMA] Breast cancerDocetaxel Kabi in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:operable node-positive breast cancer;operable node-negative breast cancer.For patients with operable node-negative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer.Docetaxel Kabi in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.Docetaxel Kabi monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent.Docetaxel Kabi in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress HER2 and who previously have not received chemotherapy for metastatic disease.Docetaxel Kabi in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline.Non-small-cell lung cancerDocetaxel Kabi is indicated for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer after failure of prior chemotherapy.Docetaxel Kabi in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small-cell lung cancer, in patients who have not previously received chemotherapy for this condition.Prostate cancerDocetaxel Kabi in combination with prednisone or prednisolone is indicated for the treatment of patients with castration-resistant metastatic prostate cancer.Docetaxel Kabi in combination with androgen-deprivation therapy (ADT), with or without prednisone or prednisolone, is indicated for the treatment of patients with metastatic hormone-sensitive prostate cancer.Gastric adenocarcinomaDocetaxel Kabi in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease.Head and neck cancerDocetaxel Kabi in combination with cisplatin and 5-fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.|[PMDA] Drugs with new dosages for the treatment of breast cancer, non-small cell lung cancer, gastric cancer, head and neck cancer and ovarian cancer. uuid:e144fc6e-b011-47ae-b766-83167d807626 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4672 biolink:treats MONDO:0005036 PMID:41385096 "[{""id"":""uuid:6d14ac93-a2e5-44a7-87f9-c1bd765a37e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:bd06445c-ae16-4afe-8ef7-bf8e4b3f5ad4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:0cdb984e-6740-4705-ba8a-aa25c2611384"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/docetaxel-kabi""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Docetaxel injection is a microtubule inhibitor indicated for: Breast Cancer (BC) : single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC ( 1.1 ) Non-small Cell Lung Cancer (NSCLC) : single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC ( 1.2 ) Castration-Resistant Prostate Cancer (CRPC) : with prednisone in metastatic castration-resistant prostate cancer ( 1.3 ) Gastric Adenocarcinoma (GC) : with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction ( 1.4 ) Squamous Cell Carcinoma of the Head and Neck (SCCHN) : with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN ( 1.5 )|[EMA] Breast cancerDocetaxel Kabi in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:operable node-positive breast cancer;operable node-negative breast cancer.For patients with operable node-negative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer.Docetaxel Kabi in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.Docetaxel Kabi monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent.Docetaxel Kabi in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress HER2 and who previously have not received chemotherapy for metastatic disease.Docetaxel Kabi in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline.Non-small-cell lung cancerDocetaxel Kabi is indicated for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer after failure of prior chemotherapy.Docetaxel Kabi in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small-cell lung cancer, in patients who have not previously received chemotherapy for this condition.Prostate cancerDocetaxel Kabi in combination with prednisone or prednisolone is indicated for the treatment of patients with castration-resistant metastatic prostate cancer.Docetaxel Kabi in combination with androgen-deprivation therapy (ADT), with or without prednisone or prednisolone, is indicated for the treatment of patients with metastatic hormone-sensitive prostate cancer.Gastric adenocarcinomaDocetaxel Kabi in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease.Head and neck cancerDocetaxel Kabi in combination with cisplatin and 5-fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck. uuid:ec5d0abb-397e-4e62-b906-18b8db728826 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4672 biolink:treats MONDO:0010150 PMID:41385096 "[{""id"":""uuid:79d1d136-cbd9-46f7-bfde-0fd8b1f18d70"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0600d90a-21c3-4f60-8828-eb40a4297be9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Docetaxel injection is a microtubule inhibitor indicated for: Breast Cancer (BC) : single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC ( 1.1 ) Non-small Cell Lung Cancer (NSCLC) : single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC ( 1.2 ) Castration-Resistant Prostate Cancer (CRPC) : with prednisone in metastatic castration-resistant prostate cancer ( 1.3 ) Gastric Adenocarcinoma (GC) : with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction ( 1.4 ) Squamous Cell Carcinoma of the Head and Neck (SCCHN) : with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN ( 1.5 ) uuid:e455cb8b-4c29-4313-a06a-3aafb4986775 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2663 biolink:treats HP:0001649 PMID:41385096 "[{""id"":""uuid:c4ec8f09-5e6f-491a-8c22-eaa184b695d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b6d01764-2284-41f1-8e41-e77a4d49f6c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amiodarone hydrochloride tablets are indicated for the treatment of documented, life-threatening recurrent ventricular fibrillation and life-threatening recurrent hemodynamically unstable tachycardia in adults who have not responded to adequate doses of other available antiarrhythmics or when alternative agents cannot be tolerated. uuid:536ef69d-89b5-4167-a4c8-29b16c80fa39 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:163203584 biolink:treats MONDO:0008228 PMID:41385096 "[{""id"":""uuid:66f56ce1-4056-4319-9f96-f56a4f4e8aab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3c8f6c39-37bb-4e78-832a-1ccb36d93323"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pernicious anemia, both uncomplicated and accompanied by nervous system involvement. Dietary deficiency of Vitamin B 12 , occurring in strict vegetarians and in their breast-fed infants. (Isolated vitamin B 12 deficiency is very rare). Malabsorption of vitamin B 12 , resulting from structural or functional damage to the stomach, where intrinsic factor is secreted or to the ileum, where intrinsic factor facilitates vitamin B 12 absorption. These conditions include tropical sprue, and nontropical sprue (idiopathic steatorrhea, gluten-induced enteropathy). Folate deficiency in these patients is usually more severe than vitamin B 12 deficiency. Inadequate secretion of intrinsic factor, resulting from lesions that destroy the gastric mucosa (ingestion of corrosives, extensive neoplasia), and a number of conditions associated with a variable degree of gastric atrophy (such as multiple sclerosis, certain endocrine disorders, iron deficiency, and subtotal gastrectomy). Total gastrectomy always produces vitamin B 12 deficiency. Structural lesions leading to vitamin B 12 deficiency include regional ileitis, ileal resections, malignancies, etc. Competition for Vitamin B 12 by intestinal parasites or bacteria. The fish tapeworm (Diphyllobothrium latum) absorbs huge quantities of vitamin B 12 and infested patients often have associated gastric atrophy. The blind-loop syndrome may produce deficiency of Vitamin B 12 or folate. Inadequate utilization of vitamin B 12 . This may occur if antimetabolites for the vitamin are employed in the treatment of neoplasia. For the Schilling Test. uuid:98169981-16d8-40a3-b067-927bcbb361eb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:163203584 biolink:treats MONDO:0020696 PMID:41385096 "[{""id"":""uuid:481283d4-adc2-4359-83b8-2d6e624d2c19"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9d6d8eed-afd8-4603-b392-d72a8fa6993b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pernicious anemia, both uncomplicated and accompanied by nervous system involvement. Dietary deficiency of Vitamin B 12 , occurring in strict vegetarians and in their breast-fed infants. (Isolated vitamin B 12 deficiency is very rare). Malabsorption of vitamin B 12 , resulting from structural or functional damage to the stomach, where intrinsic factor is secreted or to the ileum, where intrinsic factor facilitates vitamin B 12 absorption. These conditions include tropical sprue, and nontropical sprue (idiopathic steatorrhea, gluten-induced enteropathy). Folate deficiency in these patients is usually more severe than vitamin B 12 deficiency. Inadequate secretion of intrinsic factor, resulting from lesions that destroy the gastric mucosa (ingestion of corrosives, extensive neoplasia), and a number of conditions associated with a variable degree of gastric atrophy (such as multiple sclerosis, certain endocrine disorders, iron deficiency, and subtotal gastrectomy). Total gastrectomy always produces vitamin B 12 deficiency. Structural lesions leading to vitamin B 12 deficiency include regional ileitis, ileal resections, malignancies, etc. Competition for Vitamin B 12 by intestinal parasites or bacteria. The fish tapeworm (Diphyllobothrium latum) absorbs huge quantities of vitamin B 12 and infested patients often have associated gastric atrophy. The blind-loop syndrome may produce deficiency of Vitamin B 12 or folate. Inadequate utilization of vitamin B 12 . This may occur if antimetabolites for the vitamin are employed in the treatment of neoplasia. For the Schilling Test. uuid:98a3b754-f2cd-41bf-93dc-334ad75a0928 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:163203584 biolink:treats MONDO:0001078 PMID:41385096 "[{""id"":""uuid:d5e120fd-f0e4-4b6c-981b-79668149f23b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:283b1de8-c184-4e64-b089-296b71500792"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pernicious anemia, both uncomplicated and accompanied by nervous system involvement. Dietary deficiency of Vitamin B 12 , occurring in strict vegetarians and in their breast-fed infants. (Isolated vitamin B 12 deficiency is very rare). Malabsorption of vitamin B 12 , resulting from structural or functional damage to the stomach, where intrinsic factor is secreted or to the ileum, where intrinsic factor facilitates vitamin B 12 absorption. These conditions include tropical sprue, and nontropical sprue (idiopathic steatorrhea, gluten-induced enteropathy). Folate deficiency in these patients is usually more severe than vitamin B 12 deficiency. Inadequate secretion of intrinsic factor, resulting from lesions that destroy the gastric mucosa (ingestion of corrosives, extensive neoplasia), and a number of conditions associated with a variable degree of gastric atrophy (such as multiple sclerosis, certain endocrine disorders, iron deficiency, and subtotal gastrectomy). Total gastrectomy always produces vitamin B 12 deficiency. Structural lesions leading to vitamin B 12 deficiency include regional ileitis, ileal resections, malignancies, etc. Competition for Vitamin B 12 by intestinal parasites or bacteria. The fish tapeworm (Diphyllobothrium latum) absorbs huge quantities of vitamin B 12 and infested patients often have associated gastric atrophy. The blind-loop syndrome may produce deficiency of Vitamin B 12 or folate. Inadequate utilization of vitamin B 12 . This may occur if antimetabolites for the vitamin are employed in the treatment of neoplasia. For the Schilling Test. uuid:82e7b974-1716-48ea-831c-c71f6b590095 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:163203584 biolink:treats MONDO:0005130 PMID:41385096 "[{""id"":""uuid:185d44fb-4150-43ce-8534-4235bc25b201"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1d66fae3-de4d-4c7f-a623-69a1357c352c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pernicious anemia, both uncomplicated and accompanied by nervous system involvement. Dietary deficiency of Vitamin B 12 , occurring in strict vegetarians and in their breast-fed infants. (Isolated vitamin B 12 deficiency is very rare). Malabsorption of vitamin B 12 , resulting from structural or functional damage to the stomach, where intrinsic factor is secreted or to the ileum, where intrinsic factor facilitates vitamin B 12 absorption. These conditions include tropical sprue, and nontropical sprue (idiopathic steatorrhea, gluten-induced enteropathy). Folate deficiency in these patients is usually more severe than vitamin B 12 deficiency. Inadequate secretion of intrinsic factor, resulting from lesions that destroy the gastric mucosa (ingestion of corrosives, extensive neoplasia), and a number of conditions associated with a variable degree of gastric atrophy (such as multiple sclerosis, certain endocrine disorders, iron deficiency, and subtotal gastrectomy). Total gastrectomy always produces vitamin B 12 deficiency. Structural lesions leading to vitamin B 12 deficiency include regional ileitis, ileal resections, malignancies, etc. Competition for Vitamin B 12 by intestinal parasites or bacteria. The fish tapeworm (Diphyllobothrium latum) absorbs huge quantities of vitamin B 12 and infested patients often have associated gastric atrophy. The blind-loop syndrome may produce deficiency of Vitamin B 12 or folate. Inadequate utilization of vitamin B 12 . This may occur if antimetabolites for the vitamin are employed in the treatment of neoplasia. For the Schilling Test. uuid:1ed50a80-2f6c-4446-afe1-080418df01d5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:163203584 biolink:treats MONDO:0001075 PMID:41385096 "[{""id"":""uuid:b00aedcb-7438-468e-9819-d621ce7c74eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:380ff584-f2d2-46d6-b556-d813bf1d7874"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pernicious anemia, both uncomplicated and accompanied by nervous system involvement. Dietary deficiency of Vitamin B 12 , occurring in strict vegetarians and in their breast-fed infants. (Isolated vitamin B 12 deficiency is very rare). Malabsorption of vitamin B 12 , resulting from structural or functional damage to the stomach, where intrinsic factor is secreted or to the ileum, where intrinsic factor facilitates vitamin B 12 absorption. These conditions include tropical sprue, and nontropical sprue (idiopathic steatorrhea, gluten-induced enteropathy). Folate deficiency in these patients is usually more severe than vitamin B 12 deficiency. Inadequate secretion of intrinsic factor, resulting from lesions that destroy the gastric mucosa (ingestion of corrosives, extensive neoplasia), and a number of conditions associated with a variable degree of gastric atrophy (such as multiple sclerosis, certain endocrine disorders, iron deficiency, and subtotal gastrectomy). Total gastrectomy always produces vitamin B 12 deficiency. Structural lesions leading to vitamin B 12 deficiency include regional ileitis, ileal resections, malignancies, etc. Competition for Vitamin B 12 by intestinal parasites or bacteria. The fish tapeworm (Diphyllobothrium latum) absorbs huge quantities of vitamin B 12 and infested patients often have associated gastric atrophy. The blind-loop syndrome may produce deficiency of Vitamin B 12 or folate. Inadequate utilization of vitamin B 12 . This may occur if antimetabolites for the vitamin are employed in the treatment of neoplasia. For the Schilling Test. uuid:1b322086-27e7-4787-b268-de656aca6547 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:163203584 biolink:treats MONDO:0001860 PMID:41385096 "[{""id"":""uuid:551ab983-b117-4d9b-bbb2-e82469017080"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b9149888-ef78-47a8-a477-a2303ee970b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pernicious anemia, both uncomplicated and accompanied by nervous system involvement. Dietary deficiency of Vitamin B 12 , occurring in strict vegetarians and in their breast-fed infants. (Isolated vitamin B 12 deficiency is very rare). Malabsorption of vitamin B 12 , resulting from structural or functional damage to the stomach, where intrinsic factor is secreted or to the ileum, where intrinsic factor facilitates vitamin B 12 absorption. These conditions include tropical sprue, and nontropical sprue (idiopathic steatorrhea, gluten-induced enteropathy). Folate deficiency in these patients is usually more severe than vitamin B 12 deficiency. Inadequate secretion of intrinsic factor, resulting from lesions that destroy the gastric mucosa (ingestion of corrosives, extensive neoplasia), and a number of conditions associated with a variable degree of gastric atrophy (such as multiple sclerosis, certain endocrine disorders, iron deficiency, and subtotal gastrectomy). Total gastrectomy always produces vitamin B 12 deficiency. Structural lesions leading to vitamin B 12 deficiency include regional ileitis, ileal resections, malignancies, etc. Competition for Vitamin B 12 by intestinal parasites or bacteria. The fish tapeworm (Diphyllobothrium latum) absorbs huge quantities of vitamin B 12 and infested patients often have associated gastric atrophy. The blind-loop syndrome may produce deficiency of Vitamin B 12 or folate. Inadequate utilization of vitamin B 12 . This may occur if antimetabolites for the vitamin are employed in the treatment of neoplasia. For the Schilling Test. uuid:acd1638c-7964-405e-b3ee-9078debb81ee biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:163203584 biolink:treats MONDO:0005301 PMID:41385096 "[{""id"":""uuid:8d7f1526-5322-4c30-a35b-733e96179af5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:02380517-2df3-44cf-924d-6f09d3317178"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pernicious anemia, both uncomplicated and accompanied by nervous system involvement. Dietary deficiency of Vitamin B 12 , occurring in strict vegetarians and in their breast-fed infants. (Isolated vitamin B 12 deficiency is very rare). Malabsorption of vitamin B 12 , resulting from structural or functional damage to the stomach, where intrinsic factor is secreted or to the ileum, where intrinsic factor facilitates vitamin B 12 absorption. These conditions include tropical sprue, and nontropical sprue (idiopathic steatorrhea, gluten-induced enteropathy). Folate deficiency in these patients is usually more severe than vitamin B 12 deficiency. Inadequate secretion of intrinsic factor, resulting from lesions that destroy the gastric mucosa (ingestion of corrosives, extensive neoplasia), and a number of conditions associated with a variable degree of gastric atrophy (such as multiple sclerosis, certain endocrine disorders, iron deficiency, and subtotal gastrectomy). Total gastrectomy always produces vitamin B 12 deficiency. Structural lesions leading to vitamin B 12 deficiency include regional ileitis, ileal resections, malignancies, etc. Competition for Vitamin B 12 by intestinal parasites or bacteria. The fish tapeworm (Diphyllobothrium latum) absorbs huge quantities of vitamin B 12 and infested patients often have associated gastric atrophy. The blind-loop syndrome may produce deficiency of Vitamin B 12 or folate. Inadequate utilization of vitamin B 12 . This may occur if antimetabolites for the vitamin are employed in the treatment of neoplasia. For the Schilling Test. uuid:24d9d778-6a92-4189-9fd6-28b8480f6507 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:163203584 biolink:treats UMLS:C0240066 PMID:41385096 "[{""id"":""uuid:8429a234-bf39-4314-8e01-92a5600e029d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7e8c76a6-2ce8-4d66-add9-02308a6d5a26"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pernicious anemia, both uncomplicated and accompanied by nervous system involvement. Dietary deficiency of Vitamin B 12 , occurring in strict vegetarians and in their breast-fed infants. (Isolated vitamin B 12 deficiency is very rare). Malabsorption of vitamin B 12 , resulting from structural or functional damage to the stomach, where intrinsic factor is secreted or to the ileum, where intrinsic factor facilitates vitamin B 12 absorption. These conditions include tropical sprue, and nontropical sprue (idiopathic steatorrhea, gluten-induced enteropathy). Folate deficiency in these patients is usually more severe than vitamin B 12 deficiency. Inadequate secretion of intrinsic factor, resulting from lesions that destroy the gastric mucosa (ingestion of corrosives, extensive neoplasia), and a number of conditions associated with a variable degree of gastric atrophy (such as multiple sclerosis, certain endocrine disorders, iron deficiency, and subtotal gastrectomy). Total gastrectomy always produces vitamin B 12 deficiency. Structural lesions leading to vitamin B 12 deficiency include regional ileitis, ileal resections, malignancies, etc. Competition for Vitamin B 12 by intestinal parasites or bacteria. The fish tapeworm (Diphyllobothrium latum) absorbs huge quantities of vitamin B 12 and infested patients often have associated gastric atrophy. The blind-loop syndrome may produce deficiency of Vitamin B 12 or folate. Inadequate utilization of vitamin B 12 . This may occur if antimetabolites for the vitamin are employed in the treatment of neoplasia. For the Schilling Test. uuid:5f1aa61d-23ad-4851-a85b-93a66259ccfe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:163203584 biolink:treats MONDO:0000709 PMID:41385096 "[{""id"":""uuid:acd065ff-7172-4fec-b146-3d693b506d1f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aa6d9751-04ee-48bd-9f30-097d9ed60c5d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pernicious anemia, both uncomplicated and accompanied by nervous system involvement. Dietary deficiency of Vitamin B 12 , occurring in strict vegetarians and in their breast-fed infants. (Isolated vitamin B 12 deficiency is very rare). Malabsorption of vitamin B 12 , resulting from structural or functional damage to the stomach, where intrinsic factor is secreted or to the ileum, where intrinsic factor facilitates vitamin B 12 absorption. These conditions include tropical sprue, and nontropical sprue (idiopathic steatorrhea, gluten-induced enteropathy). Folate deficiency in these patients is usually more severe than vitamin B 12 deficiency. Inadequate secretion of intrinsic factor, resulting from lesions that destroy the gastric mucosa (ingestion of corrosives, extensive neoplasia), and a number of conditions associated with a variable degree of gastric atrophy (such as multiple sclerosis, certain endocrine disorders, iron deficiency, and subtotal gastrectomy). Total gastrectomy always produces vitamin B 12 deficiency. Structural lesions leading to vitamin B 12 deficiency include regional ileitis, ileal resections, malignancies, etc. Competition for Vitamin B 12 by intestinal parasites or bacteria. The fish tapeworm (Diphyllobothrium latum) absorbs huge quantities of vitamin B 12 and infested patients often have associated gastric atrophy. The blind-loop syndrome may produce deficiency of Vitamin B 12 or folate. Inadequate utilization of vitamin B 12 . This may occur if antimetabolites for the vitamin are employed in the treatment of neoplasia. For the Schilling Test. uuid:b110214b-787d-406f-8ed7-84bfe7114239 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:163203584 biolink:treats MONDO:0006665 PMID:41385096 "[{""id"":""uuid:6b6188de-a153-4a7f-957c-f965bf4bac76"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1ab46835-1ef4-4437-b25f-220d1cefdd70"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pernicious anemia, both uncomplicated and accompanied by nervous system involvement. Dietary deficiency of Vitamin B 12 , occurring in strict vegetarians and in their breast-fed infants. (Isolated vitamin B 12 deficiency is very rare). Malabsorption of vitamin B 12 , resulting from structural or functional damage to the stomach, where intrinsic factor is secreted or to the ileum, where intrinsic factor facilitates vitamin B 12 absorption. These conditions include tropical sprue, and nontropical sprue (idiopathic steatorrhea, gluten-induced enteropathy). Folate deficiency in these patients is usually more severe than vitamin B 12 deficiency. Inadequate secretion of intrinsic factor, resulting from lesions that destroy the gastric mucosa (ingestion of corrosives, extensive neoplasia), and a number of conditions associated with a variable degree of gastric atrophy (such as multiple sclerosis, certain endocrine disorders, iron deficiency, and subtotal gastrectomy). Total gastrectomy always produces vitamin B 12 deficiency. Structural lesions leading to vitamin B 12 deficiency include regional ileitis, ileal resections, malignancies, etc. Competition for Vitamin B 12 by intestinal parasites or bacteria. The fish tapeworm (Diphyllobothrium latum) absorbs huge quantities of vitamin B 12 and infested patients often have associated gastric atrophy. The blind-loop syndrome may produce deficiency of Vitamin B 12 or folate. Inadequate utilization of vitamin B 12 . This may occur if antimetabolites for the vitamin are employed in the treatment of neoplasia. For the Schilling Test. uuid:e1e8c393-1b03-4fe6-ba01-567c7e37dc9e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2955 biolink:treats MONDO:0021094 PMID:41385096 "[{""id"":""uuid:7546fd6e-bb88-4042-9eaa-14030a5d2edd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e6ff8aa9-0726-4f6e-ad0f-b3dfa0a49887"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae. • Acute bacterial sinusitis due to Haemophilus influenzae, Moraxella catarrhalis. or Streptococcus pneumoniae. • Community-acquired pneumonia due to Chlamydophila pneumoniae, Haemophilus influenzae,Mycoplasma pneumoniae, or Streptococcus pneumoniae in patients appropriate for oral therapy. • Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. • Uncomplicated skin and skin structure infections due to Staphylococcus aureus, Streptococcus pyogenes, or Streptococcus agalactiae. • Urethritis and cervicitis due to Chlamydia trachomatis or Neisseria gonorrhoeae. • Genital ulcer disease in men due to Haemophilus ducreyi (chancroid). Due to the small number of women included in clinical trials, the efficacy of azithromycin in the treatment of chancroid in women has not been established. 1.2 Pediatric Patients [see Use in Specific Populations (8.4) and Clinical Studies (14.2)] • Acute otitis media (> 6 months of age) caused by Haemophilus influenzae, Moraxella catarrhalis, orStreptococcus pneumoniae • Community-acquired pneumonia (> 6 months of age) due to Chlamydophila pneumoniae,Haemophilus influenzae, Mycoplasma pneumonia, or Streptococcus pneumoniae in patients appropriate for oral therapy. • Pharyngitis/tonsillitis (> 2 years of age) caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. 1.3 Limitations of Use Azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: • patients with cystic fibrosis, • patients with nosocomial infections, • patients with known or suspected bacteremia, • patients requiring hospitalization, • elderly or debilitated patients, or • patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). uuid:7b823c9d-33d3-4b5b-93af-69f1e42fa321 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2955 biolink:treats UMLS:C0272405 PMID:41385096 "[{""id"":""uuid:c0b42ca9-5036-441c-bece-a0ede34dde0e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4060d5ce-8b9b-4ccd-8214-d34681061ea5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae. • Acute bacterial sinusitis due to Haemophilus influenzae, Moraxella catarrhalis. or Streptococcus pneumoniae. • Community-acquired pneumonia due to Chlamydophila pneumoniae, Haemophilus influenzae,Mycoplasma pneumoniae, or Streptococcus pneumoniae in patients appropriate for oral therapy. • Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. • Uncomplicated skin and skin structure infections due to Staphylococcus aureus, Streptococcus pyogenes, or Streptococcus agalactiae. • Urethritis and cervicitis due to Chlamydia trachomatis or Neisseria gonorrhoeae. • Genital ulcer disease in men due to Haemophilus ducreyi (chancroid). Due to the small number of women included in clinical trials, the efficacy of azithromycin in the treatment of chancroid in women has not been established. 1.2 Pediatric Patients [see Use in Specific Populations (8.4) and Clinical Studies (14.2)] • Acute otitis media (> 6 months of age) caused by Haemophilus influenzae, Moraxella catarrhalis, orStreptococcus pneumoniae • Community-acquired pneumonia (> 6 months of age) due to Chlamydophila pneumoniae,Haemophilus influenzae, Mycoplasma pneumonia, or Streptococcus pneumoniae in patients appropriate for oral therapy. • Pharyngitis/tonsillitis (> 2 years of age) caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. 1.3 Limitations of Use Azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: • patients with cystic fibrosis, • patients with nosocomial infections, • patients with known or suspected bacteremia, • patients requiring hospitalization, • elderly or debilitated patients, or • patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). uuid:fc396e87-62bd-42a8-8d26-b39b63dcefb6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats UMLS:C0018674 PMID:41385096 "[{""id"":""uuid:c112cae3-8336-4c57-9788-d461c4f66a83"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ace62f45-3e9a-46cd-84c0-df16ebe7c66b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis and serum sickness. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus uuid:1837d7d1-dd33-4261-a2f4-76fc642865e0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:375581 biolink:treats UMLS:C0278140 PMID:41385096 "[{""id"":""uuid:e02dc036-429f-4572-9cdc-6f46cbeb385b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:948ed74f-60c6-44c0-b0ef-70ad396815ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxycodone Hydrochloride and Acetaminophen Tablets is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, and misuse, with opioids, even at recommended doses [see WARNINGS], reserve Oxycodone Hydrochloride and Acetaminophen Tablets for use in patients for whom alternative treatment options [e.g., non-opioid analgesics] Have not been tolerated, or are not expected to be tolerated, Have not provided adequate analgesia, or are not expected to provide adequate analgesia uuid:6b696875-3757-4b89-ad40-ec8a2079f4db biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:119915 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:0f4583fe-bdae-4e01-9c34-eebe13ef687d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:61635a48-0a7b-4343-8c17-2cb4cb133251"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fentanyl transdermal system is indicated for the management of pain in opioid-tolerant patients, severe enough to require daily, around-the-clock, long- term opioid treatment and for which alternative treatment options are inadequate. Patients considered opioid-tolerant are those who are taking, for one week or longer, at least 60 mg of morphine daily, or at least 30 mg of oral oxycodone daily, or at least 8 mg of oral hydromorphone daily, or an equianalgesic dose of another opioid. Limitations of Use Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations, reserve fentanyl transdermal system for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. uuid:ea4e93f9-79e2-4e57-9dc3-b9103598479f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3286 biolink:treats MONDO:0006373 PMID:41385096 "[{""id"":""uuid:ea30f2d2-0cb5-48b8-aaeb-faf599ca3daa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d6306631-83fd-4d6f-acdd-67f58c3c47f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cabergoline Tablets are indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas. uuid:8878c5df-51fd-4db6-a960-81dd5f02a471 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63611 biolink:treats MONDO:0001024 PMID:41385096 "[{""id"":""uuid:95fde061-cd5a-4450-aa62-6b15b09dcf2c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:875f5b8d-7048-4dd6-8d33-8d6152a85c6d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Community Acquired Pneumonia Moxifloxacin Hydrochloride is indicated in adult patients for the treatment of Community Acquired Pneumonia caused by susceptible isolates of Streptococcus pneumoniae (including multi-drug resistant Streptococcus pneumoniae [MDRSP]), Haemophilus influenzae, Moraxella catarrhalis, methicillin-susceptible Staphylococcus aureus, Klebsiella pneumoniae, Mycoplasma pneumoniae, or Chlamydophila pneumoniae [see Clinical Studies (14.3)]. MDRSP isolates are isolates resistant to two or more of the following antibacterial drugs: penicillin (minimum inhibitory concentrations [MIC] ≥ 2 mcg/mL), 2nd generation cephalosporins (for example, cefuroxime), macrolides, tetracyclines, and trimethoprim/sulfamethoxazole. 1.2 Uncomplicated Skin and Skin Structure Infections Moxifloxacin Hydrochloride is indicated in adult patients for the treatment of Uncomplicated Skin and Skin Structure Infections caused by susceptible isolates of methicillin-susceptible Staphylococcus aureus or Streptococcus pyogenes [see Clinical Studies (14.4)]. 1.3 Complicated Skin and Skin Structure Infections Moxifloxacin Hydrochloride is indicated in adult patients for the treatment of Complicated Skin and Skin Structure Infections caused by susceptible isolates of methicillin-susceptible Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, or Enterobacter cloacae[see Clinical Studies (14.5)]. 1.4 Complicated Intra-Abdominal Infections Moxifloxacin Hydrochloride is indicated in adult patients for the treatment of Complicated Intra-Abdominal Infections (cIAI) including polymicrobial infections such as abscess caused by susceptible isolates of Escherichia coli, Bacteroides fragilis, Streptococcus anginosus, Streptococcus constellatus, Enterococcus faecalis, Proteus mirabilis, Clostridium perfringens, Bacteroides thetaiotaomicron, or Peptostreptococcus species [see Clinical Studies (14.6)]. 1.5 Plague Moxifloxacin Hydrochloride is indicated in adult patients for the treatment of plague, including pneumonic and septicemic plague, due to susceptible isolates of Yersinia pestis and prophylaxis of plague in adult patients. Efficacy studies of moxifloxacin could not be conducted in humans with plague for feasibility reasons. Therefore this indication is based on an efficacy study conducted in animals only [see Clinical Studies (14.7)]. 1.6 Acute Bacterial Sinusitis Moxifloxacin Hydrochloride is indicated in adult patients (18 years of age and older) for the treatment of acute bacterial sinusitis (ABS) caused by susceptible isolates of Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis [see Clinical Studies (14.1)]. Because fluoroquinolones, including Moxifloxacin Hydrochloride, have been associated with serious adverse reactions [see Warnings and Precautions (5.1-5.13)] and for some patients ABS is self-limiting, reserve Moxifloxacin Hydrochloride for treatment of ABS in patients who have no alternative treatment options. 1.7 Acute Bacterial Exacerbation of Chronic Bronchitis Moxifloxacin Hydrochloride is indicated in adult patients for the treatment of Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB) caused by susceptible isolates of Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, methicillin-susceptible Staphylococcus aureus, or Moraxella catarrhalis [see Clinical Studies (14.2)]. Because fluoroquinolones, including Moxifloxacin Hydrochloride, have been associated with serious adverse reactions [see Warnings and Precautions (5.1-5.13)] and for some patients ABECB is self-limiting, reserve Moxifloxacin Hydrochloride for treatment of ABECB in patients who have no alternative treatment options. 1.8 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of Moxifloxacin Hydrochloride and other antibacterial drugs, Moxifloxacin Hydrochloride should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:ff2fe477-ea82-4c5a-b46c-1a60730c2a8d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63611 biolink:treats MONDO:0005956 PMID:41385096 "[{""id"":""uuid:5717a1dc-0f00-44e1-8d9b-5ce0800ee9ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:480e06c3-13af-43f2-8593-a1b812a8063e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Community Acquired Pneumonia Moxifloxacin Hydrochloride is indicated in adult patients for the treatment of Community Acquired Pneumonia caused by susceptible isolates of Streptococcus pneumoniae (including multi-drug resistant Streptococcus pneumoniae [MDRSP]), Haemophilus influenzae, Moraxella catarrhalis, methicillin-susceptible Staphylococcus aureus, Klebsiella pneumoniae, Mycoplasma pneumoniae, or Chlamydophila pneumoniae [see Clinical Studies (14.3)]. MDRSP isolates are isolates resistant to two or more of the following antibacterial drugs: penicillin (minimum inhibitory concentrations [MIC] ≥ 2 mcg/mL), 2nd generation cephalosporins (for example, cefuroxime), macrolides, tetracyclines, and trimethoprim/sulfamethoxazole. 1.2 Uncomplicated Skin and Skin Structure Infections Moxifloxacin Hydrochloride is indicated in adult patients for the treatment of Uncomplicated Skin and Skin Structure Infections caused by susceptible isolates of methicillin-susceptible Staphylococcus aureus or Streptococcus pyogenes [see Clinical Studies (14.4)]. 1.3 Complicated Skin and Skin Structure Infections Moxifloxacin Hydrochloride is indicated in adult patients for the treatment of Complicated Skin and Skin Structure Infections caused by susceptible isolates of methicillin-susceptible Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, or Enterobacter cloacae[see Clinical Studies (14.5)]. 1.4 Complicated Intra-Abdominal Infections Moxifloxacin Hydrochloride is indicated in adult patients for the treatment of Complicated Intra-Abdominal Infections (cIAI) including polymicrobial infections such as abscess caused by susceptible isolates of Escherichia coli, Bacteroides fragilis, Streptococcus anginosus, Streptococcus constellatus, Enterococcus faecalis, Proteus mirabilis, Clostridium perfringens, Bacteroides thetaiotaomicron, or Peptostreptococcus species [see Clinical Studies (14.6)]. 1.5 Plague Moxifloxacin Hydrochloride is indicated in adult patients for the treatment of plague, including pneumonic and septicemic plague, due to susceptible isolates of Yersinia pestis and prophylaxis of plague in adult patients. Efficacy studies of moxifloxacin could not be conducted in humans with plague for feasibility reasons. Therefore this indication is based on an efficacy study conducted in animals only [see Clinical Studies (14.7)]. 1.6 Acute Bacterial Sinusitis Moxifloxacin Hydrochloride is indicated in adult patients (18 years of age and older) for the treatment of acute bacterial sinusitis (ABS) caused by susceptible isolates of Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis [see Clinical Studies (14.1)]. Because fluoroquinolones, including Moxifloxacin Hydrochloride, have been associated with serious adverse reactions [see Warnings and Precautions (5.1-5.13)] and for some patients ABS is self-limiting, reserve Moxifloxacin Hydrochloride for treatment of ABS in patients who have no alternative treatment options. 1.7 Acute Bacterial Exacerbation of Chronic Bronchitis Moxifloxacin Hydrochloride is indicated in adult patients for the treatment of Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB) caused by susceptible isolates of Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, methicillin-susceptible Staphylococcus aureus, or Moraxella catarrhalis [see Clinical Studies (14.2)]. Because fluoroquinolones, including Moxifloxacin Hydrochloride, have been associated with serious adverse reactions [see Warnings and Precautions (5.1-5.13)] and for some patients ABECB is self-limiting, reserve Moxifloxacin Hydrochloride for treatment of ABECB in patients who have no alternative treatment options. 1.8 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of Moxifloxacin Hydrochloride and other antibacterial drugs, Moxifloxacin Hydrochloride should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:37cd44a4-52e3-4e8a-abd2-e263a4f90f4a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77363 biolink:treats MONDO:0005016 PMID:41385096 "[{""id"":""uuid:8df390ad-86cc-4967-9903-9d20b2746d6b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:364e14a2-4ab6-492a-a555-de296fe19fb9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Hypertension Ramipril capsules USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Ramipril capsules USP may be used alone or in combination with thiazide diuretics. 1.3 Heart Failure Post-Myocardial Infarction Ramipril capsules USP are indicated in stable patients who have demonstrated clinical signs of congestive heart failure within the first few days after sustaining acute myocardial infarction. Administration of ramipril capsule USP to such patients has been shown to decrease the risk of death (principally cardiovascular death) and to decrease the risks of failure-related hospitalization and progression to severe/resistant heart failure [see CLINICAL STUDIES ( 14.3 )]. uuid:c82b6e66-3fce-45c5-b414-d32e1d94db09 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71416 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:f9d8775b-21ed-433a-915c-2572c4675860"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dca643a4-295d-4e4c-b8de-bca0b59074d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Phenazopyridine HCl is indicated for the symptomatic relief of pain, burning, urgency, frequency, and other discomforts arising from irritation of the lower urinary tract mucosa caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters. The use of Phenazopyridine HCl for relief of symptoms should not delay definitive diagnosis and treatment of causative conditions. Because it provides only symptomatic relief, prompt appropriate treatment of the cause of pain must be instituted and Phenazopyridine HCl should be discontinued when symptoms are controlled. The analgesic action may reduce or eliminate the need for systemic analgesics or narcotics. It is, however, compatible with antibacterial therapy and can help to relieve pain and discomfort during the interval before antibacterial therapy controls the infection. Treatment of a urinary tract infection with Phenazopyridine HCl should not exceed 2 days because there is a lack of evidence that the combined administration of Phenazopyridine HCl and an antibacterial provides greater benefit than administration of the antibacterial alone after 2 days. (See DOSAGE AND ADMINISTRATION section). uuid:faa30221-45b5-4fbc-97bd-5cc886b77dfd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:73005609 biolink:treats MONDO:0011122 PMID:41385096 "[{""id"":""uuid:9c6a4b4e-ab05-4ef4-8241-ef3823f94091"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:05118572-6ea3-4763-b415-997df75711f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CONTRAVE is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of: 30 kg/m 2 or greater (obese) or 27 kg/m 2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia). Limitations of Use: The effect of CONTRAVE on cardiovascular morbidity and mortality has not been established. The safety and effectiveness of CONTRAVE in combination with other products intended for weight loss, including prescription drugs, over-the-counter drugs, and herbal preparations, have not been established. uuid:0c50d210-1b19-4672-852c-64b1687de1ff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:73005609 biolink:treats EFO:0005935 PMID:41385096 "[{""id"":""uuid:1e704f5f-51d0-4003-bac5-21c8bfc4afd1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c9d3b5be-61c9-4393-b2cd-0eb3b9f50aa7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CONTRAVE is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of: 30 kg/m 2 or greater (obese) or 27 kg/m 2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia). Limitations of Use: The effect of CONTRAVE on cardiovascular morbidity and mortality has not been established. The safety and effectiveness of CONTRAVE in combination with other products intended for weight loss, including prescription drugs, over-the-counter drugs, and herbal preparations, have not been established. uuid:4a282174-39f5-4257-940b-04608f180548 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:73005609 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:97b73332-726f-4d97-af94-6748957a99f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f593b996-5ca7-4182-8861-bfe2997d336e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CONTRAVE is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of: 30 kg/m 2 or greater (obese) or 27 kg/m 2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia). Limitations of Use: The effect of CONTRAVE on cardiovascular morbidity and mortality has not been established. The safety and effectiveness of CONTRAVE in combination with other products intended for weight loss, including prescription drugs, over-the-counter drugs, and herbal preparations, have not been established. uuid:9f8b0df3-f93b-44cc-b874-e9f667b5caf9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:73005609 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:49848e28-a89e-4b5b-8c14-31032081512c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e76507f7-c674-46e5-b2db-33838115ef33"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CONTRAVE is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of: 30 kg/m 2 or greater (obese) or 27 kg/m 2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia). Limitations of Use: The effect of CONTRAVE on cardiovascular morbidity and mortality has not been established. The safety and effectiveness of CONTRAVE in combination with other products intended for weight loss, including prescription drugs, over-the-counter drugs, and herbal preparations, have not been established. uuid:74a3f407-6cc7-4932-8db6-cdaae65238c5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:73005609 biolink:treats HP:0003119 PMID:41385096 "[{""id"":""uuid:4b09d472-a003-49d0-ba87-98bcf1a3a7d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ff6e4f1c-25ff-48d2-8a8c-c7296bf543d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CONTRAVE is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of: 30 kg/m 2 or greater (obese) or 27 kg/m 2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia). Limitations of Use: The effect of CONTRAVE on cardiovascular morbidity and mortality has not been established. The safety and effectiveness of CONTRAVE in combination with other products intended for weight loss, including prescription drugs, over-the-counter drugs, and herbal preparations, have not been established. uuid:0e2a7bd8-4042-4373-89e1-ef21f29374da biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10119 biolink:treats MONDO:0001866 PMID:41385096 "[{""id"":""uuid:38a81a52-f1da-4007-9a7a-7cf5540ee08a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:37e100b6-283e-417c-aeb2-7626d6ba48af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ziprasidone hydrochloride capsules are indicated for the treatment of schizophrenia. When deciding among the alternative treatments available for the condition needing treatment, the prescriber should consider the finding of ziprasidone’ s greater capacity to prolong the QT/QTc interval compared to several other antipsychotic drugs [ see Warnings and Precautions (5.3) ]. Prolongation of the QTc interval is associated in some other drugs with the ability to cause torsade de pointes-type arrhythmia, a potentially fatal polymorphic ventricular tachycardia, and sudden death. In many cases this would lead to the conclusion that other drugs should be tried first. Whether ziprasidone will cause torsade de pointes or increase the rate of sudden death is not yet known [ see Warnings and Precautions (5.3) ] Schizophrenia Ziprasidone hydrochloride capsules are indicated for the treatment of schizophrenia in adults [see Clinical Studies ( 14.1 )]. Bipolar I Disorder (Acute Mixed or Manic Episodes and Maintenance Treatment as an Adjunct to Lithium or Valproate) Ziprasidone hydrochloride capsules are indicated as monotherapy for the acute treatment of adults with manic or mixed episodes associated with bipolar I disorder [see Clinical Studies ( 14.2 )]. Ziprasidone hydrochloride capsules are indicated as an adjunct to lithium or valproate for the maintenance treatment of bipolar I disorder in adults [see Clinical Studies ( 14.2 )]. uuid:f5fc7ba9-3bef-4d5f-8c25-75390886b339 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49713 biolink:treats MONDO:0024612 PMID:41385096 "[{""id"":""uuid:1c5664f4-1720-47bb-ab9a-74b19fa45910"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4dd0922a-a404-49be-af98-1f5115956cd7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lithium is a mood-stabilizing agent indicated for the treatment of manic episodes and as maintenance treatment for Bipolar I Disorder. uuid:524d62a4-1048-4f7e-ba23-7c6fbab081a6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49713 biolink:treats MONDO:0001866 PMID:41385096 "[{""id"":""uuid:24862a3b-c0e8-4a3c-a970-cef120ef062e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1bf014bb-0b5e-4aac-ab0e-895592e75bc7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lithium is a mood-stabilizing agent indicated for the treatment of manic episodes and as maintenance treatment for Bipolar I Disorder. uuid:7d797e78-0a8c-4bca-81b2-64091ee796fc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29007 biolink:treats UMLS:C0275665 PMID:41385096 "[{""id"":""uuid:3b037f82-cc95-4f5d-bcbd-19011d34f355"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:35158e59-8cf9-4c8e-a3f1-9711c6619227"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f221b0d8-36a4-4fcb-9156-e563fc16e155"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Before instituting treatment with Ceftriaxone for Injection, USP, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. Therapy may be instituted prior to obtaining results of susceptibility testing. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ceftriaxone for Injection, USP and other antibacterial drugs, Ceftriaxone for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ceftriaxone for Injection, USP is indicated for the treatment of the following infections when caused by susceptible organisms: LOWER RESPIRATORY TRACT INFECTIONS caused by Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Escherichia coli, Enterobacter aerogenes, Proteus mirabilis or Serratia marcescens. ACUTE BACTERIAL OTITIS MEDIA caused by Streptococcus pneumoniae, Haemophilus influenzae (including beta‑lactamase producing strains) or Moraxella catarrhalis (including beta-lactamase producing strains). NOTE: In one study lower clinical cure rates were observed with a single dose of Ceftriaxone for Injection, USP compared to 10 days of oral therapy. In a second study comparable cure rates were observed between single dose of Ceftriaxone for Injection, USP and the comparator. The potentially lower clinical cure rate of Ceftriaxone for Injection, USP should be balanced against the potential advantages of parenteral therapy (see CLINICAL STUDIES ). SKIN AND SKIN STRUCTURE INFECTIONS caused by Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes , Viridans group streptococci, Escherichia coli, Enterobacter cloacae, Klebsiella oxytoca, Klebsiella pneumoniae, Proteus mirabilis, Morganella morganii 1 , Pseudomonas aeruginosa, Serratia marcescens, Acinetobacter calcoaceticus, Bacteroides fragilis 1 or Peptostreptococcus species. URINARY TRACT INFECTIONS (complicated and uncomplicated) caused by Escherichia coli, Proteus mirabilis, Proteus vulgaris, Morganella morganii or Klebsiella pneumoniae. UNCOMPLICATED GONORRHEA (cervical/urethral and rectal) caused by Neisseria gonorrhoeae, including both penicillinase- and nonpenicillinase-producing strains, and pharyngeal gonorrhea caused by nonpenicillinase‑producing strains of Neisseria gonorrhoeae. PELVIC INFLAMMATORY DISEASE caused by Neisseria gonorrhoeae. Ceftriaxone for Injection, USP, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and Chlamydia trachomatis is one of the suspected pathogens, appropriate antichlamydial coverage should be added. BACTERIAL SEPTICEMIA caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae or Klebsiella pneumoniae. BONE AND JOINT INFECTIONS caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae or Enterobacter species. INTRA-ABDOMINAL INFECTIONS caused by Escherichia coli, Klebsiella pneumoniae, Bacteroides fragilis, Clostridium species (Note: most strains of Clostridium difficile are resistant) or Peptostreptococcus species. MENINGITIS caused by Haemophilus influenzae, Neisseria meningitidis or Streptococcus pneumoniae. Ceftriaxone for Injection, USP has also been used successfully in a limited number of cases of meningitis and shunt infection caused by Staphylococcus epidermidis 1 and Escherichia coli. 1 1 Efficacy for this organism in this organ system was studied in fewer than ten infections.|[PMDA] Addition of indications for gonococcus and gonococcal pharyngitis, gonococcal urethritis, gonococcal uterine cervicitis, gonococcal pelvic inflammatory diseases, gonococcal epididymitis, gonococcal proctitis, and to dosage regimen. uuid:8142a233-f4ed-483a-9ad5-0900d1b138b8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4450 biolink:treats MONDO:0010602 PMID:41385096 "[{""id"":""uuid:c1d44059-e847-4d77-90d2-fdbba026e032"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8aa8adb8-41f2-4bf2-a385-11e663f71bbd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hemophilia A: Desmopressin Acetate Injection 4 mcg/mL is indicated for patients with hemophilia A with factor VIII coagulant activity levels greater than 5%. Desmopressin acetate injection will often maintain hemostasis in patients with hemophilia A during surgical procedures and postoperatively when administered 30 minutes prior to scheduled procedure. Desmopressin acetate injection will also stop bleeding in hemophilia A patients with episodes of spontaneous or trauma-induced injuries such as hemarthroses, intramuscular hematomas or mucosal bleeding. Desmopressin acetate injection is not indicated for the treatment of hemophilia A with factor VIII coagulant activity levels equal to or less than 5%, or for the treatment of hemophilia B, or in patients who have factor VIII antibodies. In certain clinical situations, it may be justified to try desmopressin acetate injection in patients with factor VIII levels between 2% to 5%; however, these patients should be carefully monitored. von Willebrand’s Disease (Type I): Desmopressin acetate injection 4 mcg/mL is indicated for patients with mild to moderate classic von Willebrand’s disease (Type I) with factor VIII levels greater than 5%. Desmopressin acetate injection will often maintain hemostasis in patients with mild to moderate von Willebrand’s disease during surgical procedures and postoperatively when administered 30 minutes prior to the scheduled procedure. Desmopressin acetate injection will usually stop bleeding in mild to moderate von Willebrand’s patients with episodes of spontaneous or trauma-induced injuries such as hemarthroses, intramuscular hematomas or mucosal bleeding. Those von Willebrand’s disease patients who are least likely to respond are those with severe homozygous von Willebrand’s disease with factor VIII coagulant activity and factor VIII von Willebrand factor antigen levels less than 1%. Other patients may respond in a variable fashion depending on the type of molecular defect they have. Bleeding time and factor VIII coagulant activity, ristocetin cofactor activity, and von Willebrand factor antigen should be checked during administration of desmopressin acetate injection to ensure that adequate levels are being achieved. Desmopressin acetate injection is not indicated for the treatment of severe classic von Willebrand’s disease (Type I) and when there is evidence of an abnormal molecular form of factor VIII antigen. ( See WARNINGS . ) Diabetes Insipidus: Desmopressin acetate injection 4 mcg/mL is indicated as antidiuretic replacement therapy in the management of central (cranial) diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. Desmopressin acetate injection is ineffective for the treatment of nephrogenic diabetes insipidus. Desmopressin acetate is also available as an intranasal preparation. However, this means of delivery can be compromised by a variety of factors that can make nasal insufflation ineffective or inappropriate. These include poor intranasal absorption, nasal congestion and blockage, nasal discharge, atrophy of nasal mucosa, and severe atrophic rhinitis. Intranasal delivery may be inappropriate where there is an impaired level of consciousness. In addition, cranial surgical procedures, such as transsphenoidal hypophysectomy, create situations where an alternative route of administration is needed as in cases of nasal packing or recovery from surgery. uuid:0aeafb33-3788-4399-a7a3-1a8e7d786e21 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4450 biolink:treats MONDO:0024574 PMID:41385096 "[{""id"":""uuid:64e5311d-713a-47a6-88bb-4f078539dec9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ca14a06f-903e-487b-ae49-7a20e537895e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hemophilia A: Desmopressin Acetate Injection 4 mcg/mL is indicated for patients with hemophilia A with factor VIII coagulant activity levels greater than 5%. Desmopressin acetate injection will often maintain hemostasis in patients with hemophilia A during surgical procedures and postoperatively when administered 30 minutes prior to scheduled procedure. Desmopressin acetate injection will also stop bleeding in hemophilia A patients with episodes of spontaneous or trauma-induced injuries such as hemarthroses, intramuscular hematomas or mucosal bleeding. Desmopressin acetate injection is not indicated for the treatment of hemophilia A with factor VIII coagulant activity levels equal to or less than 5%, or for the treatment of hemophilia B, or in patients who have factor VIII antibodies. In certain clinical situations, it may be justified to try desmopressin acetate injection in patients with factor VIII levels between 2% to 5%; however, these patients should be carefully monitored. von Willebrand’s Disease (Type I): Desmopressin acetate injection 4 mcg/mL is indicated for patients with mild to moderate classic von Willebrand’s disease (Type I) with factor VIII levels greater than 5%. Desmopressin acetate injection will often maintain hemostasis in patients with mild to moderate von Willebrand’s disease during surgical procedures and postoperatively when administered 30 minutes prior to the scheduled procedure. Desmopressin acetate injection will usually stop bleeding in mild to moderate von Willebrand’s patients with episodes of spontaneous or trauma-induced injuries such as hemarthroses, intramuscular hematomas or mucosal bleeding. Those von Willebrand’s disease patients who are least likely to respond are those with severe homozygous von Willebrand’s disease with factor VIII coagulant activity and factor VIII von Willebrand factor antigen levels less than 1%. Other patients may respond in a variable fashion depending on the type of molecular defect they have. Bleeding time and factor VIII coagulant activity, ristocetin cofactor activity, and von Willebrand factor antigen should be checked during administration of desmopressin acetate injection to ensure that adequate levels are being achieved. Desmopressin acetate injection is not indicated for the treatment of severe classic von Willebrand’s disease (Type I) and when there is evidence of an abnormal molecular form of factor VIII antigen. ( See WARNINGS . ) Diabetes Insipidus: Desmopressin acetate injection 4 mcg/mL is indicated as antidiuretic replacement therapy in the management of central (cranial) diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. Desmopressin acetate injection is ineffective for the treatment of nephrogenic diabetes insipidus. Desmopressin acetate is also available as an intranasal preparation. However, this means of delivery can be compromised by a variety of factors that can make nasal insufflation ineffective or inappropriate. These include poor intranasal absorption, nasal congestion and blockage, nasal discharge, atrophy of nasal mucosa, and severe atrophic rhinitis. Intranasal delivery may be inappropriate where there is an impaired level of consciousness. In addition, cranial surgical procedures, such as transsphenoidal hypophysectomy, create situations where an alternative route of administration is needed as in cases of nasal packing or recovery from surgery. uuid:7c0d4fb7-1f7c-4003-b4c8-7546d0babcca biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4450 biolink:treats MONDO:0004431 PMID:41385096 "[{""id"":""uuid:dacbc1df-7043-494e-bba3-4babc4e14688"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c5933e92-2df1-4a35-9ddb-804090d428bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hemophilia A: Desmopressin Acetate Injection 4 mcg/mL is indicated for patients with hemophilia A with factor VIII coagulant activity levels greater than 5%. Desmopressin acetate injection will often maintain hemostasis in patients with hemophilia A during surgical procedures and postoperatively when administered 30 minutes prior to scheduled procedure. Desmopressin acetate injection will also stop bleeding in hemophilia A patients with episodes of spontaneous or trauma-induced injuries such as hemarthroses, intramuscular hematomas or mucosal bleeding. Desmopressin acetate injection is not indicated for the treatment of hemophilia A with factor VIII coagulant activity levels equal to or less than 5%, or for the treatment of hemophilia B, or in patients who have factor VIII antibodies. In certain clinical situations, it may be justified to try desmopressin acetate injection in patients with factor VIII levels between 2% to 5%; however, these patients should be carefully monitored. von Willebrand’s Disease (Type I): Desmopressin acetate injection 4 mcg/mL is indicated for patients with mild to moderate classic von Willebrand’s disease (Type I) with factor VIII levels greater than 5%. Desmopressin acetate injection will often maintain hemostasis in patients with mild to moderate von Willebrand’s disease during surgical procedures and postoperatively when administered 30 minutes prior to the scheduled procedure. Desmopressin acetate injection will usually stop bleeding in mild to moderate von Willebrand’s patients with episodes of spontaneous or trauma-induced injuries such as hemarthroses, intramuscular hematomas or mucosal bleeding. Those von Willebrand’s disease patients who are least likely to respond are those with severe homozygous von Willebrand’s disease with factor VIII coagulant activity and factor VIII von Willebrand factor antigen levels less than 1%. Other patients may respond in a variable fashion depending on the type of molecular defect they have. Bleeding time and factor VIII coagulant activity, ristocetin cofactor activity, and von Willebrand factor antigen should be checked during administration of desmopressin acetate injection to ensure that adequate levels are being achieved. Desmopressin acetate injection is not indicated for the treatment of severe classic von Willebrand’s disease (Type I) and when there is evidence of an abnormal molecular form of factor VIII antigen. ( See WARNINGS . ) Diabetes Insipidus: Desmopressin acetate injection 4 mcg/mL is indicated as antidiuretic replacement therapy in the management of central (cranial) diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. Desmopressin acetate injection is ineffective for the treatment of nephrogenic diabetes insipidus. Desmopressin acetate is also available as an intranasal preparation. However, this means of delivery can be compromised by a variety of factors that can make nasal insufflation ineffective or inappropriate. These include poor intranasal absorption, nasal congestion and blockage, nasal discharge, atrophy of nasal mucosa, and severe atrophic rhinitis. Intranasal delivery may be inappropriate where there is an impaired level of consciousness. In addition, cranial surgical procedures, such as transsphenoidal hypophysectomy, create situations where an alternative route of administration is needed as in cases of nasal packing or recovery from surgery. uuid:3b3d5bf2-8813-4001-b868-ddca215d4382 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4450 biolink:treats HP:0012233 PMID:41385096 "[{""id"":""uuid:efda6963-cf6c-467d-9d70-c49593d6c296"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:69b2cca1-e3d4-4952-be5b-52d772266fba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hemophilia A: Desmopressin Acetate Injection 4 mcg/mL is indicated for patients with hemophilia A with factor VIII coagulant activity levels greater than 5%. Desmopressin acetate injection will often maintain hemostasis in patients with hemophilia A during surgical procedures and postoperatively when administered 30 minutes prior to scheduled procedure. Desmopressin acetate injection will also stop bleeding in hemophilia A patients with episodes of spontaneous or trauma-induced injuries such as hemarthroses, intramuscular hematomas or mucosal bleeding. Desmopressin acetate injection is not indicated for the treatment of hemophilia A with factor VIII coagulant activity levels equal to or less than 5%, or for the treatment of hemophilia B, or in patients who have factor VIII antibodies. In certain clinical situations, it may be justified to try desmopressin acetate injection in patients with factor VIII levels between 2% to 5%; however, these patients should be carefully monitored. von Willebrand’s Disease (Type I): Desmopressin acetate injection 4 mcg/mL is indicated for patients with mild to moderate classic von Willebrand’s disease (Type I) with factor VIII levels greater than 5%. Desmopressin acetate injection will often maintain hemostasis in patients with mild to moderate von Willebrand’s disease during surgical procedures and postoperatively when administered 30 minutes prior to the scheduled procedure. Desmopressin acetate injection will usually stop bleeding in mild to moderate von Willebrand’s patients with episodes of spontaneous or trauma-induced injuries such as hemarthroses, intramuscular hematomas or mucosal bleeding. Those von Willebrand’s disease patients who are least likely to respond are those with severe homozygous von Willebrand’s disease with factor VIII coagulant activity and factor VIII von Willebrand factor antigen levels less than 1%. Other patients may respond in a variable fashion depending on the type of molecular defect they have. Bleeding time and factor VIII coagulant activity, ristocetin cofactor activity, and von Willebrand factor antigen should be checked during administration of desmopressin acetate injection to ensure that adequate levels are being achieved. Desmopressin acetate injection is not indicated for the treatment of severe classic von Willebrand’s disease (Type I) and when there is evidence of an abnormal molecular form of factor VIII antigen. ( See WARNINGS . ) Diabetes Insipidus: Desmopressin acetate injection 4 mcg/mL is indicated as antidiuretic replacement therapy in the management of central (cranial) diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. Desmopressin acetate injection is ineffective for the treatment of nephrogenic diabetes insipidus. Desmopressin acetate is also available as an intranasal preparation. However, this means of delivery can be compromised by a variety of factors that can make nasal insufflation ineffective or inappropriate. These include poor intranasal absorption, nasal congestion and blockage, nasal discharge, atrophy of nasal mucosa, and severe atrophic rhinitis. Intranasal delivery may be inappropriate where there is an impaired level of consciousness. In addition, cranial surgical procedures, such as transsphenoidal hypophysectomy, create situations where an alternative route of administration is needed as in cases of nasal packing or recovery from surgery. uuid:a57bd2eb-510d-4f70-9658-72d3fa911932 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4450 biolink:treats UMLS:C2748540 PMID:41385096 "[{""id"":""uuid:25b29fd2-d6cf-4b0c-8d8c-285b367e5e32"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:47c5f3d4-a01b-4d36-8b47-2f022d07c3cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hemophilia A: Desmopressin Acetate Injection 4 mcg/mL is indicated for patients with hemophilia A with factor VIII coagulant activity levels greater than 5%. Desmopressin acetate injection will often maintain hemostasis in patients with hemophilia A during surgical procedures and postoperatively when administered 30 minutes prior to scheduled procedure. Desmopressin acetate injection will also stop bleeding in hemophilia A patients with episodes of spontaneous or trauma-induced injuries such as hemarthroses, intramuscular hematomas or mucosal bleeding. Desmopressin acetate injection is not indicated for the treatment of hemophilia A with factor VIII coagulant activity levels equal to or less than 5%, or for the treatment of hemophilia B, or in patients who have factor VIII antibodies. In certain clinical situations, it may be justified to try desmopressin acetate injection in patients with factor VIII levels between 2% to 5%; however, these patients should be carefully monitored. von Willebrand’s Disease (Type I): Desmopressin acetate injection 4 mcg/mL is indicated for patients with mild to moderate classic von Willebrand’s disease (Type I) with factor VIII levels greater than 5%. Desmopressin acetate injection will often maintain hemostasis in patients with mild to moderate von Willebrand’s disease during surgical procedures and postoperatively when administered 30 minutes prior to the scheduled procedure. Desmopressin acetate injection will usually stop bleeding in mild to moderate von Willebrand’s patients with episodes of spontaneous or trauma-induced injuries such as hemarthroses, intramuscular hematomas or mucosal bleeding. Those von Willebrand’s disease patients who are least likely to respond are those with severe homozygous von Willebrand’s disease with factor VIII coagulant activity and factor VIII von Willebrand factor antigen levels less than 1%. Other patients may respond in a variable fashion depending on the type of molecular defect they have. Bleeding time and factor VIII coagulant activity, ristocetin cofactor activity, and von Willebrand factor antigen should be checked during administration of desmopressin acetate injection to ensure that adequate levels are being achieved. Desmopressin acetate injection is not indicated for the treatment of severe classic von Willebrand’s disease (Type I) and when there is evidence of an abnormal molecular form of factor VIII antigen. ( See WARNINGS . ) Diabetes Insipidus: Desmopressin acetate injection 4 mcg/mL is indicated as antidiuretic replacement therapy in the management of central (cranial) diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. Desmopressin acetate injection is ineffective for the treatment of nephrogenic diabetes insipidus. Desmopressin acetate is also available as an intranasal preparation. However, this means of delivery can be compromised by a variety of factors that can make nasal insufflation ineffective or inappropriate. These include poor intranasal absorption, nasal congestion and blockage, nasal discharge, atrophy of nasal mucosa, and severe atrophic rhinitis. Intranasal delivery may be inappropriate where there is an impaired level of consciousness. In addition, cranial surgical procedures, such as transsphenoidal hypophysectomy, create situations where an alternative route of administration is needed as in cases of nasal packing or recovery from surgery. uuid:6ef8e486-96e4-432c-b740-90cbd6804148 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4450 biolink:treats MONDO:0004782 PMID:41385096 "[{""id"":""uuid:acc90ab2-45db-4310-8ce1-464120ab6847"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:956abfb6-cdd3-4561-9b92-2a8d4f2f1e1b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hemophilia A: Desmopressin Acetate Injection 4 mcg/mL is indicated for patients with hemophilia A with factor VIII coagulant activity levels greater than 5%. Desmopressin acetate injection will often maintain hemostasis in patients with hemophilia A during surgical procedures and postoperatively when administered 30 minutes prior to scheduled procedure. Desmopressin acetate injection will also stop bleeding in hemophilia A patients with episodes of spontaneous or trauma-induced injuries such as hemarthroses, intramuscular hematomas or mucosal bleeding. Desmopressin acetate injection is not indicated for the treatment of hemophilia A with factor VIII coagulant activity levels equal to or less than 5%, or for the treatment of hemophilia B, or in patients who have factor VIII antibodies. In certain clinical situations, it may be justified to try desmopressin acetate injection in patients with factor VIII levels between 2% to 5%; however, these patients should be carefully monitored. von Willebrand’s Disease (Type I): Desmopressin acetate injection 4 mcg/mL is indicated for patients with mild to moderate classic von Willebrand’s disease (Type I) with factor VIII levels greater than 5%. Desmopressin acetate injection will often maintain hemostasis in patients with mild to moderate von Willebrand’s disease during surgical procedures and postoperatively when administered 30 minutes prior to the scheduled procedure. Desmopressin acetate injection will usually stop bleeding in mild to moderate von Willebrand’s patients with episodes of spontaneous or trauma-induced injuries such as hemarthroses, intramuscular hematomas or mucosal bleeding. Those von Willebrand’s disease patients who are least likely to respond are those with severe homozygous von Willebrand’s disease with factor VIII coagulant activity and factor VIII von Willebrand factor antigen levels less than 1%. Other patients may respond in a variable fashion depending on the type of molecular defect they have. Bleeding time and factor VIII coagulant activity, ristocetin cofactor activity, and von Willebrand factor antigen should be checked during administration of desmopressin acetate injection to ensure that adequate levels are being achieved. Desmopressin acetate injection is not indicated for the treatment of severe classic von Willebrand’s disease (Type I) and when there is evidence of an abnormal molecular form of factor VIII antigen. ( See WARNINGS . ) Diabetes Insipidus: Desmopressin acetate injection 4 mcg/mL is indicated as antidiuretic replacement therapy in the management of central (cranial) diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. Desmopressin acetate injection is ineffective for the treatment of nephrogenic diabetes insipidus. Desmopressin acetate is also available as an intranasal preparation. However, this means of delivery can be compromised by a variety of factors that can make nasal insufflation ineffective or inappropriate. These include poor intranasal absorption, nasal congestion and blockage, nasal discharge, atrophy of nasal mucosa, and severe atrophic rhinitis. Intranasal delivery may be inappropriate where there is an impaired level of consciousness. In addition, cranial surgical procedures, such as transsphenoidal hypophysectomy, create situations where an alternative route of administration is needed as in cases of nasal packing or recovery from surgery. uuid:1b39e0aa-75a1-4b32-83a5-8c1124c9d0c5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3746 biolink:treats UMLS:C1262234 PMID:41385096 "[{""id"":""uuid:8e9a9b63-2a0e-402d-a79a-ec976a0c1807"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e7ed4352-c4fd-48ce-9e80-5b1953b6ef56"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the BOXED WARNING , before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibiotic therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae , other streptococci (except E. faecalis ), and Staphylococcus aureus . Skin and skin structure infections caused by Streptococcus pyogenes , Staphylococcus aureus , and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus , streptococci (except Enterococcus faecalis ), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin and other antibacterial drugs, clindamycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:70d289d9-c96a-409f-b4fe-ea54eb87bc41 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:204928 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:2de272ce-ac84-41e5-81be-bac2d769e1d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f00423b1-e2f4-41c6-b913-ce6d09176e13"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Treatment Cefotaxime for injection, USP is indicated for the treatment of patients with serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) Lower respiratory tract infections , including pneumonia, caused by Streptococcus pneumoniae (formerly Diplococcus pneumoniae ), Streptococcus pyogenes * (Group A streptococci) and other streptococci (excluding enterococci, e.g., Enterococcus faecalis ), Staphylococcus aureus (penicillinase and non-penicillinase producing), Escherichia coli , Klebsiella species, Haemophilus influenzae (including ampicillin resistant strains), Haemophilus parainfluenzae , Proteus mirabilis , Serratia marcescens *, Enterobacter species, indole positive Proteus and Pseudomonas species (including P. aeruginosa ). (2) Genitourinary infections . Urinary tract infections caused by Enterococcus species, Staphylococcus epidermidis , Staphylococcus aureus *, (penicillinase and non-penicillinase producing), Citrobacter species, Enterobacter species, Escherichia coli , Klebsiella species, Proteus mirabilis , Proteus vulgaris *, Providencia stuartii , Morganella morganii *, Providencia rettgeri *, Serratia marcescens and Pseudomonas species (including P. aeruginosa ). Also, uncomplicated gonorrhea (cervical/urethral and rectal) caused by Neisseria gonorrhoeae , including penicillinase producing strains. (3) Gynecologic infections , including pelvic inflammatory disease, endometritis and pelvic cellulitis caused by Staphylococcus epidermidis , Streptococcus species, Enterococcus species, Enterobacter species*, Klebsiella species*, Escherichia coli , Proteus mirabilis , Bacteroides species (including Bacteroides fragilis *), Clostridium species, and anaerobic cocci (including Peptostreptococcus species and Peptococcus species) and Fusobacterium species (including F. nucleatum *). Cefotaxime for injection, USP, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti-chlamydial coverage should be added. (4) Bacteremia/Septicemia caused by Escherichia coli , Klebsiella species, and Serratia marcescens , Staphylococcus aureus and Streptococcus species (including S. pneumonia ). (5) Skin and skin structure infections caused by Staphylococcus aureus (penicillinase and non-penicillinase producing), Staphylococcus epidermidis , Streptococcus pyogenes (Group A streptococci) and other streptococci, Enterococcus species, Acinetobacter species*, Escherichia coli , Citrobacter species (including C. freundii *), Enterobacter species, Klebsiella species, Proteus mirabilis , Proteus vulgaris *, Morganella morganii , Providencia rettgeri *, Pseudomonas species, Serratia marcescens , Bacteroides species, and anaerobic cocci (including Peptostreptococcus * species and Peptococcus species). (6) Intra-abdominal infections including peritonitis caused by Streptococcus species*, Escherichia coli , Klebsiella species, Bacteroides species, and anaerobic cocci (including Peptostreptococcus * species and Peptococcus * species) Proteus mirabilis *, and Clostridium species*. (7) Bone and/or joint infections caused by Staphylococcus aureus (penicillinase and non-penicillinase producing strains), Streptococcus species (including S. pyogenes *), Pseudomonas species (including P. aeruginosa *), and Proteus mirabilis *. (8) Central nervous system infections , e.g., meningitis and ventriculitis, caused by Neisseria meningitidis , Haemophilus influenzae , Streptococcus pneumoniae , Klebsiella pneumoniae * and Escherichia coli *. (*) Efficacy for this organism, in this organ system, has been studied in fewer than 10 infections. Although many strains of enterococci (e.g., S. faecalis ) and Pseudomonas species are resistant to cefotaxime sodium in vitro , cefotaxime for injection, USP has been used successfully in treating patients with infections caused by susceptible organisms. Specimens for bacteriologic culture should be obtained prior to therapy in order to isolate and identify causative organisms and to determine their susceptibilities to cefotaxime for injection, USP. Therapy may be instituted before results of susceptibility studies are known; however, once these results become available, the antibiotic treatment should be adjusted accordingly. In certain cases of confirmed or suspected gram-positive or gram-negative sepsis or in patients with other serious infections in which the causative organism has not been identified, cefotaxime for injection, USP may be used concomitantly with an aminoglycoside. The dosage recommended in the labeling of both antibiotics may be given and depends on the severity of the infection and the patient's condition. Renal function should be carefully monitored, especially if higher dosages of the aminoglycosides are to be administered or if therapy is prolonged, because of the potential nephrotoxicity and ototoxicity of aminoglycoside antibiotics. It is possible that nephrotoxicity may be potentiated if cefotaxime for injection, USP is used concomitantly with an aminoglycoside. uuid:8f6ff311-a913-480d-a1e8-d889a57b9801 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:204928 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:985fe152-3f7f-438f-9279-b70e3978a726"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ed9a4233-5679-441f-9b93-14955dabafb7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Treatment Cefotaxime for injection, USP is indicated for the treatment of patients with serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) Lower respiratory tract infections , including pneumonia, caused by Streptococcus pneumoniae (formerly Diplococcus pneumoniae ), Streptococcus pyogenes * (Group A streptococci) and other streptococci (excluding enterococci, e.g., Enterococcus faecalis ), Staphylococcus aureus (penicillinase and non-penicillinase producing), Escherichia coli , Klebsiella species, Haemophilus influenzae (including ampicillin resistant strains), Haemophilus parainfluenzae , Proteus mirabilis , Serratia marcescens *, Enterobacter species, indole positive Proteus and Pseudomonas species (including P. aeruginosa ). (2) Genitourinary infections . Urinary tract infections caused by Enterococcus species, Staphylococcus epidermidis , Staphylococcus aureus *, (penicillinase and non-penicillinase producing), Citrobacter species, Enterobacter species, Escherichia coli , Klebsiella species, Proteus mirabilis , Proteus vulgaris *, Providencia stuartii , Morganella morganii *, Providencia rettgeri *, Serratia marcescens and Pseudomonas species (including P. aeruginosa ). Also, uncomplicated gonorrhea (cervical/urethral and rectal) caused by Neisseria gonorrhoeae , including penicillinase producing strains. (3) Gynecologic infections , including pelvic inflammatory disease, endometritis and pelvic cellulitis caused by Staphylococcus epidermidis , Streptococcus species, Enterococcus species, Enterobacter species*, Klebsiella species*, Escherichia coli , Proteus mirabilis , Bacteroides species (including Bacteroides fragilis *), Clostridium species, and anaerobic cocci (including Peptostreptococcus species and Peptococcus species) and Fusobacterium species (including F. nucleatum *). Cefotaxime for injection, USP, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti-chlamydial coverage should be added. (4) Bacteremia/Septicemia caused by Escherichia coli , Klebsiella species, and Serratia marcescens , Staphylococcus aureus and Streptococcus species (including S. pneumonia ). (5) Skin and skin structure infections caused by Staphylococcus aureus (penicillinase and non-penicillinase producing), Staphylococcus epidermidis , Streptococcus pyogenes (Group A streptococci) and other streptococci, Enterococcus species, Acinetobacter species*, Escherichia coli , Citrobacter species (including C. freundii *), Enterobacter species, Klebsiella species, Proteus mirabilis , Proteus vulgaris *, Morganella morganii , Providencia rettgeri *, Pseudomonas species, Serratia marcescens , Bacteroides species, and anaerobic cocci (including Peptostreptococcus * species and Peptococcus species). (6) Intra-abdominal infections including peritonitis caused by Streptococcus species*, Escherichia coli , Klebsiella species, Bacteroides species, and anaerobic cocci (including Peptostreptococcus * species and Peptococcus * species) Proteus mirabilis *, and Clostridium species*. (7) Bone and/or joint infections caused by Staphylococcus aureus (penicillinase and non-penicillinase producing strains), Streptococcus species (including S. pyogenes *), Pseudomonas species (including P. aeruginosa *), and Proteus mirabilis *. (8) Central nervous system infections , e.g., meningitis and ventriculitis, caused by Neisseria meningitidis , Haemophilus influenzae , Streptococcus pneumoniae , Klebsiella pneumoniae * and Escherichia coli *. (*) Efficacy for this organism, in this organ system, has been studied in fewer than 10 infections. Although many strains of enterococci (e.g., S. faecalis ) and Pseudomonas species are resistant to cefotaxime sodium in vitro , cefotaxime for injection, USP has been used successfully in treating patients with infections caused by susceptible organisms. Specimens for bacteriologic culture should be obtained prior to therapy in order to isolate and identify causative organisms and to determine their susceptibilities to cefotaxime for injection, USP. Therapy may be instituted before results of susceptibility studies are known; however, once these results become available, the antibiotic treatment should be adjusted accordingly. In certain cases of confirmed or suspected gram-positive or gram-negative sepsis or in patients with other serious infections in which the causative organism has not been identified, cefotaxime for injection, USP may be used concomitantly with an aminoglycoside. The dosage recommended in the labeling of both antibiotics may be given and depends on the severity of the infection and the patient's condition. Renal function should be carefully monitored, especially if higher dosages of the aminoglycosides are to be administered or if therapy is prolonged, because of the potential nephrotoxicity and ototoxicity of aminoglycoside antibiotics. It is possible that nephrotoxicity may be potentiated if cefotaxime for injection, USP is used concomitantly with an aminoglycoside. uuid:a91c37f1-fdba-4279-bee6-cf3d20e312d5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:204928 biolink:treats MONDO:0004277 PMID:41385096 "[{""id"":""uuid:ec025b50-93dc-47d5-a17b-31dbbc1ae611"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fea08805-7038-4946-ae96-a064d254e8bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Treatment Cefotaxime for injection, USP is indicated for the treatment of patients with serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) Lower respiratory tract infections , including pneumonia, caused by Streptococcus pneumoniae (formerly Diplococcus pneumoniae ), Streptococcus pyogenes * (Group A streptococci) and other streptococci (excluding enterococci, e.g., Enterococcus faecalis ), Staphylococcus aureus (penicillinase and non-penicillinase producing), Escherichia coli , Klebsiella species, Haemophilus influenzae (including ampicillin resistant strains), Haemophilus parainfluenzae , Proteus mirabilis , Serratia marcescens *, Enterobacter species, indole positive Proteus and Pseudomonas species (including P. aeruginosa ). (2) Genitourinary infections . Urinary tract infections caused by Enterococcus species, Staphylococcus epidermidis , Staphylococcus aureus *, (penicillinase and non-penicillinase producing), Citrobacter species, Enterobacter species, Escherichia coli , Klebsiella species, Proteus mirabilis , Proteus vulgaris *, Providencia stuartii , Morganella morganii *, Providencia rettgeri *, Serratia marcescens and Pseudomonas species (including P. aeruginosa ). Also, uncomplicated gonorrhea (cervical/urethral and rectal) caused by Neisseria gonorrhoeae , including penicillinase producing strains. (3) Gynecologic infections , including pelvic inflammatory disease, endometritis and pelvic cellulitis caused by Staphylococcus epidermidis , Streptococcus species, Enterococcus species, Enterobacter species*, Klebsiella species*, Escherichia coli , Proteus mirabilis , Bacteroides species (including Bacteroides fragilis *), Clostridium species, and anaerobic cocci (including Peptostreptococcus species and Peptococcus species) and Fusobacterium species (including F. nucleatum *). Cefotaxime for injection, USP, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti-chlamydial coverage should be added. (4) Bacteremia/Septicemia caused by Escherichia coli , Klebsiella species, and Serratia marcescens , Staphylococcus aureus and Streptococcus species (including S. pneumonia ). (5) Skin and skin structure infections caused by Staphylococcus aureus (penicillinase and non-penicillinase producing), Staphylococcus epidermidis , Streptococcus pyogenes (Group A streptococci) and other streptococci, Enterococcus species, Acinetobacter species*, Escherichia coli , Citrobacter species (including C. freundii *), Enterobacter species, Klebsiella species, Proteus mirabilis , Proteus vulgaris *, Morganella morganii , Providencia rettgeri *, Pseudomonas species, Serratia marcescens , Bacteroides species, and anaerobic cocci (including Peptostreptococcus * species and Peptococcus species). (6) Intra-abdominal infections including peritonitis caused by Streptococcus species*, Escherichia coli , Klebsiella species, Bacteroides species, and anaerobic cocci (including Peptostreptococcus * species and Peptococcus * species) Proteus mirabilis *, and Clostridium species*. (7) Bone and/or joint infections caused by Staphylococcus aureus (penicillinase and non-penicillinase producing strains), Streptococcus species (including S. pyogenes *), Pseudomonas species (including P. aeruginosa *), and Proteus mirabilis *. (8) Central nervous system infections , e.g., meningitis and ventriculitis, caused by Neisseria meningitidis , Haemophilus influenzae , Streptococcus pneumoniae , Klebsiella pneumoniae * and Escherichia coli *. (*) Efficacy for this organism, in this organ system, has been studied in fewer than 10 infections. Although many strains of enterococci (e.g., S. faecalis ) and Pseudomonas species are resistant to cefotaxime sodium in vitro , cefotaxime for injection, USP has been used successfully in treating patients with infections caused by susceptible organisms. Specimens for bacteriologic culture should be obtained prior to therapy in order to isolate and identify causative organisms and to determine their susceptibilities to cefotaxime for injection, USP. Therapy may be instituted before results of susceptibility studies are known; however, once these results become available, the antibiotic treatment should be adjusted accordingly. In certain cases of confirmed or suspected gram-positive or gram-negative sepsis or in patients with other serious infections in which the causative organism has not been identified, cefotaxime for injection, USP may be used concomitantly with an aminoglycoside. The dosage recommended in the labeling of both antibiotics may be given and depends on the severity of the infection and the patient's condition. Renal function should be carefully monitored, especially if higher dosages of the aminoglycosides are to be administered or if therapy is prolonged, because of the potential nephrotoxicity and ototoxicity of aminoglycoside antibiotics. It is possible that nephrotoxicity may be potentiated if cefotaxime for injection, USP is used concomitantly with an aminoglycoside. uuid:5456b28b-ff0b-429c-8bea-7b9585dc4323 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:204928 biolink:treats MONDO:0000922 PMID:41385096 "[{""id"":""uuid:12961ad7-e13e-4838-bbb0-506be00449d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9462c742-0b9e-4b82-b7c2-4c27bce1ed34"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Treatment Cefotaxime for injection, USP is indicated for the treatment of patients with serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) Lower respiratory tract infections , including pneumonia, caused by Streptococcus pneumoniae (formerly Diplococcus pneumoniae ), Streptococcus pyogenes * (Group A streptococci) and other streptococci (excluding enterococci, e.g., Enterococcus faecalis ), Staphylococcus aureus (penicillinase and non-penicillinase producing), Escherichia coli , Klebsiella species, Haemophilus influenzae (including ampicillin resistant strains), Haemophilus parainfluenzae , Proteus mirabilis , Serratia marcescens *, Enterobacter species, indole positive Proteus and Pseudomonas species (including P. aeruginosa ). (2) Genitourinary infections . Urinary tract infections caused by Enterococcus species, Staphylococcus epidermidis , Staphylococcus aureus *, (penicillinase and non-penicillinase producing), Citrobacter species, Enterobacter species, Escherichia coli , Klebsiella species, Proteus mirabilis , Proteus vulgaris *, Providencia stuartii , Morganella morganii *, Providencia rettgeri *, Serratia marcescens and Pseudomonas species (including P. aeruginosa ). Also, uncomplicated gonorrhea (cervical/urethral and rectal) caused by Neisseria gonorrhoeae , including penicillinase producing strains. (3) Gynecologic infections , including pelvic inflammatory disease, endometritis and pelvic cellulitis caused by Staphylococcus epidermidis , Streptococcus species, Enterococcus species, Enterobacter species*, Klebsiella species*, Escherichia coli , Proteus mirabilis , Bacteroides species (including Bacteroides fragilis *), Clostridium species, and anaerobic cocci (including Peptostreptococcus species and Peptococcus species) and Fusobacterium species (including F. nucleatum *). Cefotaxime for injection, USP, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti-chlamydial coverage should be added. (4) Bacteremia/Septicemia caused by Escherichia coli , Klebsiella species, and Serratia marcescens , Staphylococcus aureus and Streptococcus species (including S. pneumonia ). (5) Skin and skin structure infections caused by Staphylococcus aureus (penicillinase and non-penicillinase producing), Staphylococcus epidermidis , Streptococcus pyogenes (Group A streptococci) and other streptococci, Enterococcus species, Acinetobacter species*, Escherichia coli , Citrobacter species (including C. freundii *), Enterobacter species, Klebsiella species, Proteus mirabilis , Proteus vulgaris *, Morganella morganii , Providencia rettgeri *, Pseudomonas species, Serratia marcescens , Bacteroides species, and anaerobic cocci (including Peptostreptococcus * species and Peptococcus species). (6) Intra-abdominal infections including peritonitis caused by Streptococcus species*, Escherichia coli , Klebsiella species, Bacteroides species, and anaerobic cocci (including Peptostreptococcus * species and Peptococcus * species) Proteus mirabilis *, and Clostridium species*. (7) Bone and/or joint infections caused by Staphylococcus aureus (penicillinase and non-penicillinase producing strains), Streptococcus species (including S. pyogenes *), Pseudomonas species (including P. aeruginosa *), and Proteus mirabilis *. (8) Central nervous system infections , e.g., meningitis and ventriculitis, caused by Neisseria meningitidis , Haemophilus influenzae , Streptococcus pneumoniae , Klebsiella pneumoniae * and Escherichia coli *. (*) Efficacy for this organism, in this organ system, has been studied in fewer than 10 infections. Although many strains of enterococci (e.g., S. faecalis ) and Pseudomonas species are resistant to cefotaxime sodium in vitro , cefotaxime for injection, USP has been used successfully in treating patients with infections caused by susceptible organisms. Specimens for bacteriologic culture should be obtained prior to therapy in order to isolate and identify causative organisms and to determine their susceptibilities to cefotaxime for injection, USP. Therapy may be instituted before results of susceptibility studies are known; however, once these results become available, the antibiotic treatment should be adjusted accordingly. In certain cases of confirmed or suspected gram-positive or gram-negative sepsis or in patients with other serious infections in which the causative organism has not been identified, cefotaxime for injection, USP may be used concomitantly with an aminoglycoside. The dosage recommended in the labeling of both antibiotics may be given and depends on the severity of the infection and the patient's condition. Renal function should be carefully monitored, especially if higher dosages of the aminoglycosides are to be administered or if therapy is prolonged, because of the potential nephrotoxicity and ototoxicity of aminoglycoside antibiotics. It is possible that nephrotoxicity may be potentiated if cefotaxime for injection, USP is used concomitantly with an aminoglycoside. uuid:cef50159-f47c-4ae8-a774-cb774598dafc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:204928 biolink:treats MONDO:0000918 PMID:41385096 "[{""id"":""uuid:a9f16bcc-a6c6-46d8-82c1-fef81724da26"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f2e3c02d-2758-4564-a13a-23b54a5d3bce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Treatment Cefotaxime for injection, USP is indicated for the treatment of patients with serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) Lower respiratory tract infections , including pneumonia, caused by Streptococcus pneumoniae (formerly Diplococcus pneumoniae ), Streptococcus pyogenes * (Group A streptococci) and other streptococci (excluding enterococci, e.g., Enterococcus faecalis ), Staphylococcus aureus (penicillinase and non-penicillinase producing), Escherichia coli , Klebsiella species, Haemophilus influenzae (including ampicillin resistant strains), Haemophilus parainfluenzae , Proteus mirabilis , Serratia marcescens *, Enterobacter species, indole positive Proteus and Pseudomonas species (including P. aeruginosa ). (2) Genitourinary infections . Urinary tract infections caused by Enterococcus species, Staphylococcus epidermidis , Staphylococcus aureus *, (penicillinase and non-penicillinase producing), Citrobacter species, Enterobacter species, Escherichia coli , Klebsiella species, Proteus mirabilis , Proteus vulgaris *, Providencia stuartii , Morganella morganii *, Providencia rettgeri *, Serratia marcescens and Pseudomonas species (including P. aeruginosa ). Also, uncomplicated gonorrhea (cervical/urethral and rectal) caused by Neisseria gonorrhoeae , including penicillinase producing strains. (3) Gynecologic infections , including pelvic inflammatory disease, endometritis and pelvic cellulitis caused by Staphylococcus epidermidis , Streptococcus species, Enterococcus species, Enterobacter species*, Klebsiella species*, Escherichia coli , Proteus mirabilis , Bacteroides species (including Bacteroides fragilis *), Clostridium species, and anaerobic cocci (including Peptostreptococcus species and Peptococcus species) and Fusobacterium species (including F. nucleatum *). Cefotaxime for injection, USP, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti-chlamydial coverage should be added. (4) Bacteremia/Septicemia caused by Escherichia coli , Klebsiella species, and Serratia marcescens , Staphylococcus aureus and Streptococcus species (including S. pneumonia ). (5) Skin and skin structure infections caused by Staphylococcus aureus (penicillinase and non-penicillinase producing), Staphylococcus epidermidis , Streptococcus pyogenes (Group A streptococci) and other streptococci, Enterococcus species, Acinetobacter species*, Escherichia coli , Citrobacter species (including C. freundii *), Enterobacter species, Klebsiella species, Proteus mirabilis , Proteus vulgaris *, Morganella morganii , Providencia rettgeri *, Pseudomonas species, Serratia marcescens , Bacteroides species, and anaerobic cocci (including Peptostreptococcus * species and Peptococcus species). (6) Intra-abdominal infections including peritonitis caused by Streptococcus species*, Escherichia coli , Klebsiella species, Bacteroides species, and anaerobic cocci (including Peptostreptococcus * species and Peptococcus * species) Proteus mirabilis *, and Clostridium species*. (7) Bone and/or joint infections caused by Staphylococcus aureus (penicillinase and non-penicillinase producing strains), Streptococcus species (including S. pyogenes *), Pseudomonas species (including P. aeruginosa *), and Proteus mirabilis *. (8) Central nervous system infections , e.g., meningitis and ventriculitis, caused by Neisseria meningitidis , Haemophilus influenzae , Streptococcus pneumoniae , Klebsiella pneumoniae * and Escherichia coli *. (*) Efficacy for this organism, in this organ system, has been studied in fewer than 10 infections. Although many strains of enterococci (e.g., S. faecalis ) and Pseudomonas species are resistant to cefotaxime sodium in vitro , cefotaxime for injection, USP has been used successfully in treating patients with infections caused by susceptible organisms. Specimens for bacteriologic culture should be obtained prior to therapy in order to isolate and identify causative organisms and to determine their susceptibilities to cefotaxime for injection, USP. Therapy may be instituted before results of susceptibility studies are known; however, once these results become available, the antibiotic treatment should be adjusted accordingly. In certain cases of confirmed or suspected gram-positive or gram-negative sepsis or in patients with other serious infections in which the causative organism has not been identified, cefotaxime for injection, USP may be used concomitantly with an aminoglycoside. The dosage recommended in the labeling of both antibiotics may be given and depends on the severity of the infection and the patient's condition. Renal function should be carefully monitored, especially if higher dosages of the aminoglycosides are to be administered or if therapy is prolonged, because of the potential nephrotoxicity and ototoxicity of aminoglycoside antibiotics. It is possible that nephrotoxicity may be potentiated if cefotaxime for injection, USP is used concomitantly with an aminoglycoside. uuid:499d8bcb-2d93-4f73-a80a-eb23cabc874b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:204928 biolink:treats MONDO:0006887 PMID:41385096 "[{""id"":""uuid:b4b69af0-e86f-4b65-8afa-1d67136677aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6798c838-8dbb-47e7-bccd-34d6089b2632"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Treatment Cefotaxime for injection, USP is indicated for the treatment of patients with serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) Lower respiratory tract infections , including pneumonia, caused by Streptococcus pneumoniae (formerly Diplococcus pneumoniae ), Streptococcus pyogenes * (Group A streptococci) and other streptococci (excluding enterococci, e.g., Enterococcus faecalis ), Staphylococcus aureus (penicillinase and non-penicillinase producing), Escherichia coli , Klebsiella species, Haemophilus influenzae (including ampicillin resistant strains), Haemophilus parainfluenzae , Proteus mirabilis , Serratia marcescens *, Enterobacter species, indole positive Proteus and Pseudomonas species (including P. aeruginosa ). (2) Genitourinary infections . Urinary tract infections caused by Enterococcus species, Staphylococcus epidermidis , Staphylococcus aureus *, (penicillinase and non-penicillinase producing), Citrobacter species, Enterobacter species, Escherichia coli , Klebsiella species, Proteus mirabilis , Proteus vulgaris *, Providencia stuartii , Morganella morganii *, Providencia rettgeri *, Serratia marcescens and Pseudomonas species (including P. aeruginosa ). Also, uncomplicated gonorrhea (cervical/urethral and rectal) caused by Neisseria gonorrhoeae , including penicillinase producing strains. (3) Gynecologic infections , including pelvic inflammatory disease, endometritis and pelvic cellulitis caused by Staphylococcus epidermidis , Streptococcus species, Enterococcus species, Enterobacter species*, Klebsiella species*, Escherichia coli , Proteus mirabilis , Bacteroides species (including Bacteroides fragilis *), Clostridium species, and anaerobic cocci (including Peptostreptococcus species and Peptococcus species) and Fusobacterium species (including F. nucleatum *). Cefotaxime for injection, USP, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti-chlamydial coverage should be added. (4) Bacteremia/Septicemia caused by Escherichia coli , Klebsiella species, and Serratia marcescens , Staphylococcus aureus and Streptococcus species (including S. pneumonia ). (5) Skin and skin structure infections caused by Staphylococcus aureus (penicillinase and non-penicillinase producing), Staphylococcus epidermidis , Streptococcus pyogenes (Group A streptococci) and other streptococci, Enterococcus species, Acinetobacter species*, Escherichia coli , Citrobacter species (including C. freundii *), Enterobacter species, Klebsiella species, Proteus mirabilis , Proteus vulgaris *, Morganella morganii , Providencia rettgeri *, Pseudomonas species, Serratia marcescens , Bacteroides species, and anaerobic cocci (including Peptostreptococcus * species and Peptococcus species). (6) Intra-abdominal infections including peritonitis caused by Streptococcus species*, Escherichia coli , Klebsiella species, Bacteroides species, and anaerobic cocci (including Peptostreptococcus * species and Peptococcus * species) Proteus mirabilis *, and Clostridium species*. (7) Bone and/or joint infections caused by Staphylococcus aureus (penicillinase and non-penicillinase producing strains), Streptococcus species (including S. pyogenes *), Pseudomonas species (including P. aeruginosa *), and Proteus mirabilis *. (8) Central nervous system infections , e.g., meningitis and ventriculitis, caused by Neisseria meningitidis , Haemophilus influenzae , Streptococcus pneumoniae , Klebsiella pneumoniae * and Escherichia coli *. (*) Efficacy for this organism, in this organ system, has been studied in fewer than 10 infections. Although many strains of enterococci (e.g., S. faecalis ) and Pseudomonas species are resistant to cefotaxime sodium in vitro , cefotaxime for injection, USP has been used successfully in treating patients with infections caused by susceptible organisms. Specimens for bacteriologic culture should be obtained prior to therapy in order to isolate and identify causative organisms and to determine their susceptibilities to cefotaxime for injection, USP. Therapy may be instituted before results of susceptibility studies are known; however, once these results become available, the antibiotic treatment should be adjusted accordingly. In certain cases of confirmed or suspected gram-positive or gram-negative sepsis or in patients with other serious infections in which the causative organism has not been identified, cefotaxime for injection, USP may be used concomitantly with an aminoglycoside. The dosage recommended in the labeling of both antibiotics may be given and depends on the severity of the infection and the patient's condition. Renal function should be carefully monitored, especially if higher dosages of the aminoglycosides are to be administered or if therapy is prolonged, because of the potential nephrotoxicity and ototoxicity of aminoglycoside antibiotics. It is possible that nephrotoxicity may be potentiated if cefotaxime for injection, USP is used concomitantly with an aminoglycoside. uuid:dffaa3ff-0482-4907-a03f-5f808fe39cc9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:204928 biolink:treats MONDO:0005229 PMID:41385096 "[{""id"":""uuid:db544f42-b586-4b67-8e7e-839627708a94"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:781c7ecc-e924-4c98-b87e-71b9bf20366c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Treatment Cefotaxime for injection, USP is indicated for the treatment of patients with serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) Lower respiratory tract infections , including pneumonia, caused by Streptococcus pneumoniae (formerly Diplococcus pneumoniae ), Streptococcus pyogenes * (Group A streptococci) and other streptococci (excluding enterococci, e.g., Enterococcus faecalis ), Staphylococcus aureus (penicillinase and non-penicillinase producing), Escherichia coli , Klebsiella species, Haemophilus influenzae (including ampicillin resistant strains), Haemophilus parainfluenzae , Proteus mirabilis , Serratia marcescens *, Enterobacter species, indole positive Proteus and Pseudomonas species (including P. aeruginosa ). (2) Genitourinary infections . Urinary tract infections caused by Enterococcus species, Staphylococcus epidermidis , Staphylococcus aureus *, (penicillinase and non-penicillinase producing), Citrobacter species, Enterobacter species, Escherichia coli , Klebsiella species, Proteus mirabilis , Proteus vulgaris *, Providencia stuartii , Morganella morganii *, Providencia rettgeri *, Serratia marcescens and Pseudomonas species (including P. aeruginosa ). Also, uncomplicated gonorrhea (cervical/urethral and rectal) caused by Neisseria gonorrhoeae , including penicillinase producing strains. (3) Gynecologic infections , including pelvic inflammatory disease, endometritis and pelvic cellulitis caused by Staphylococcus epidermidis , Streptococcus species, Enterococcus species, Enterobacter species*, Klebsiella species*, Escherichia coli , Proteus mirabilis , Bacteroides species (including Bacteroides fragilis *), Clostridium species, and anaerobic cocci (including Peptostreptococcus species and Peptococcus species) and Fusobacterium species (including F. nucleatum *). Cefotaxime for injection, USP, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti-chlamydial coverage should be added. (4) Bacteremia/Septicemia caused by Escherichia coli , Klebsiella species, and Serratia marcescens , Staphylococcus aureus and Streptococcus species (including S. pneumonia ). (5) Skin and skin structure infections caused by Staphylococcus aureus (penicillinase and non-penicillinase producing), Staphylococcus epidermidis , Streptococcus pyogenes (Group A streptococci) and other streptococci, Enterococcus species, Acinetobacter species*, Escherichia coli , Citrobacter species (including C. freundii *), Enterobacter species, Klebsiella species, Proteus mirabilis , Proteus vulgaris *, Morganella morganii , Providencia rettgeri *, Pseudomonas species, Serratia marcescens , Bacteroides species, and anaerobic cocci (including Peptostreptococcus * species and Peptococcus species). (6) Intra-abdominal infections including peritonitis caused by Streptococcus species*, Escherichia coli , Klebsiella species, Bacteroides species, and anaerobic cocci (including Peptostreptococcus * species and Peptococcus * species) Proteus mirabilis *, and Clostridium species*. (7) Bone and/or joint infections caused by Staphylococcus aureus (penicillinase and non-penicillinase producing strains), Streptococcus species (including S. pyogenes *), Pseudomonas species (including P. aeruginosa *), and Proteus mirabilis *. (8) Central nervous system infections , e.g., meningitis and ventriculitis, caused by Neisseria meningitidis , Haemophilus influenzae , Streptococcus pneumoniae , Klebsiella pneumoniae * and Escherichia coli *. (*) Efficacy for this organism, in this organ system, has been studied in fewer than 10 infections. Although many strains of enterococci (e.g., S. faecalis ) and Pseudomonas species are resistant to cefotaxime sodium in vitro , cefotaxime for injection, USP has been used successfully in treating patients with infections caused by susceptible organisms. Specimens for bacteriologic culture should be obtained prior to therapy in order to isolate and identify causative organisms and to determine their susceptibilities to cefotaxime for injection, USP. Therapy may be instituted before results of susceptibility studies are known; however, once these results become available, the antibiotic treatment should be adjusted accordingly. In certain cases of confirmed or suspected gram-positive or gram-negative sepsis or in patients with other serious infections in which the causative organism has not been identified, cefotaxime for injection, USP may be used concomitantly with an aminoglycoside. The dosage recommended in the labeling of both antibiotics may be given and depends on the severity of the infection and the patient's condition. Renal function should be carefully monitored, especially if higher dosages of the aminoglycosides are to be administered or if therapy is prolonged, because of the potential nephrotoxicity and ototoxicity of aminoglycoside antibiotics. It is possible that nephrotoxicity may be potentiated if cefotaxime for injection, USP is used concomitantly with an aminoglycoside. uuid:289c97ca-200c-4714-8c5f-eee5bbe41756 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:204928 biolink:treats MONDO:0700217 PMID:41385096 "[{""id"":""uuid:4cfe3c5f-7bb9-4815-a930-693ecc864db7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:26266e16-6fea-4eda-a7e7-c812800aa872"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Treatment Cefotaxime for injection, USP is indicated for the treatment of patients with serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) Lower respiratory tract infections , including pneumonia, caused by Streptococcus pneumoniae (formerly Diplococcus pneumoniae ), Streptococcus pyogenes * (Group A streptococci) and other streptococci (excluding enterococci, e.g., Enterococcus faecalis ), Staphylococcus aureus (penicillinase and non-penicillinase producing), Escherichia coli , Klebsiella species, Haemophilus influenzae (including ampicillin resistant strains), Haemophilus parainfluenzae , Proteus mirabilis , Serratia marcescens *, Enterobacter species, indole positive Proteus and Pseudomonas species (including P. aeruginosa ). (2) Genitourinary infections . Urinary tract infections caused by Enterococcus species, Staphylococcus epidermidis , Staphylococcus aureus *, (penicillinase and non-penicillinase producing), Citrobacter species, Enterobacter species, Escherichia coli , Klebsiella species, Proteus mirabilis , Proteus vulgaris *, Providencia stuartii , Morganella morganii *, Providencia rettgeri *, Serratia marcescens and Pseudomonas species (including P. aeruginosa ). Also, uncomplicated gonorrhea (cervical/urethral and rectal) caused by Neisseria gonorrhoeae , including penicillinase producing strains. (3) Gynecologic infections , including pelvic inflammatory disease, endometritis and pelvic cellulitis caused by Staphylococcus epidermidis , Streptococcus species, Enterococcus species, Enterobacter species*, Klebsiella species*, Escherichia coli , Proteus mirabilis , Bacteroides species (including Bacteroides fragilis *), Clostridium species, and anaerobic cocci (including Peptostreptococcus species and Peptococcus species) and Fusobacterium species (including F. nucleatum *). Cefotaxime for injection, USP, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti-chlamydial coverage should be added. (4) Bacteremia/Septicemia caused by Escherichia coli , Klebsiella species, and Serratia marcescens , Staphylococcus aureus and Streptococcus species (including S. pneumonia ). (5) Skin and skin structure infections caused by Staphylococcus aureus (penicillinase and non-penicillinase producing), Staphylococcus epidermidis , Streptococcus pyogenes (Group A streptococci) and other streptococci, Enterococcus species, Acinetobacter species*, Escherichia coli , Citrobacter species (including C. freundii *), Enterobacter species, Klebsiella species, Proteus mirabilis , Proteus vulgaris *, Morganella morganii , Providencia rettgeri *, Pseudomonas species, Serratia marcescens , Bacteroides species, and anaerobic cocci (including Peptostreptococcus * species and Peptococcus species). (6) Intra-abdominal infections including peritonitis caused by Streptococcus species*, Escherichia coli , Klebsiella species, Bacteroides species, and anaerobic cocci (including Peptostreptococcus * species and Peptococcus * species) Proteus mirabilis *, and Clostridium species*. (7) Bone and/or joint infections caused by Staphylococcus aureus (penicillinase and non-penicillinase producing strains), Streptococcus species (including S. pyogenes *), Pseudomonas species (including P. aeruginosa *), and Proteus mirabilis *. (8) Central nervous system infections , e.g., meningitis and ventriculitis, caused by Neisseria meningitidis , Haemophilus influenzae , Streptococcus pneumoniae , Klebsiella pneumoniae * and Escherichia coli *. (*) Efficacy for this organism, in this organ system, has been studied in fewer than 10 infections. Although many strains of enterococci (e.g., S. faecalis ) and Pseudomonas species are resistant to cefotaxime sodium in vitro , cefotaxime for injection, USP has been used successfully in treating patients with infections caused by susceptible organisms. Specimens for bacteriologic culture should be obtained prior to therapy in order to isolate and identify causative organisms and to determine their susceptibilities to cefotaxime for injection, USP. Therapy may be instituted before results of susceptibility studies are known; however, once these results become available, the antibiotic treatment should be adjusted accordingly. In certain cases of confirmed or suspected gram-positive or gram-negative sepsis or in patients with other serious infections in which the causative organism has not been identified, cefotaxime for injection, USP may be used concomitantly with an aminoglycoside. The dosage recommended in the labeling of both antibiotics may be given and depends on the severity of the infection and the patient's condition. Renal function should be carefully monitored, especially if higher dosages of the aminoglycosides are to be administered or if therapy is prolonged, because of the potential nephrotoxicity and ototoxicity of aminoglycoside antibiotics. It is possible that nephrotoxicity may be potentiated if cefotaxime for injection, USP is used concomitantly with an aminoglycoside. uuid:62dd181a-9e21-4321-ba84-32f56a4867df biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:204928 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:ee7eb623-1b7b-4e80-a5e1-9f981c6d1251"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:33152c23-8ab0-4a18-99a6-5f58c4c568b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Treatment Cefotaxime for injection, USP is indicated for the treatment of patients with serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) Lower respiratory tract infections , including pneumonia, caused by Streptococcus pneumoniae (formerly Diplococcus pneumoniae ), Streptococcus pyogenes * (Group A streptococci) and other streptococci (excluding enterococci, e.g., Enterococcus faecalis ), Staphylococcus aureus (penicillinase and non-penicillinase producing), Escherichia coli , Klebsiella species, Haemophilus influenzae (including ampicillin resistant strains), Haemophilus parainfluenzae , Proteus mirabilis , Serratia marcescens *, Enterobacter species, indole positive Proteus and Pseudomonas species (including P. aeruginosa ). (2) Genitourinary infections . Urinary tract infections caused by Enterococcus species, Staphylococcus epidermidis , Staphylococcus aureus *, (penicillinase and non-penicillinase producing), Citrobacter species, Enterobacter species, Escherichia coli , Klebsiella species, Proteus mirabilis , Proteus vulgaris *, Providencia stuartii , Morganella morganii *, Providencia rettgeri *, Serratia marcescens and Pseudomonas species (including P. aeruginosa ). Also, uncomplicated gonorrhea (cervical/urethral and rectal) caused by Neisseria gonorrhoeae , including penicillinase producing strains. (3) Gynecologic infections , including pelvic inflammatory disease, endometritis and pelvic cellulitis caused by Staphylococcus epidermidis , Streptococcus species, Enterococcus species, Enterobacter species*, Klebsiella species*, Escherichia coli , Proteus mirabilis , Bacteroides species (including Bacteroides fragilis *), Clostridium species, and anaerobic cocci (including Peptostreptococcus species and Peptococcus species) and Fusobacterium species (including F. nucleatum *). Cefotaxime for injection, USP, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti-chlamydial coverage should be added. (4) Bacteremia/Septicemia caused by Escherichia coli , Klebsiella species, and Serratia marcescens , Staphylococcus aureus and Streptococcus species (including S. pneumonia ). (5) Skin and skin structure infections caused by Staphylococcus aureus (penicillinase and non-penicillinase producing), Staphylococcus epidermidis , Streptococcus pyogenes (Group A streptococci) and other streptococci, Enterococcus species, Acinetobacter species*, Escherichia coli , Citrobacter species (including C. freundii *), Enterobacter species, Klebsiella species, Proteus mirabilis , Proteus vulgaris *, Morganella morganii , Providencia rettgeri *, Pseudomonas species, Serratia marcescens , Bacteroides species, and anaerobic cocci (including Peptostreptococcus * species and Peptococcus species). (6) Intra-abdominal infections including peritonitis caused by Streptococcus species*, Escherichia coli , Klebsiella species, Bacteroides species, and anaerobic cocci (including Peptostreptococcus * species and Peptococcus * species) Proteus mirabilis *, and Clostridium species*. (7) Bone and/or joint infections caused by Staphylococcus aureus (penicillinase and non-penicillinase producing strains), Streptococcus species (including S. pyogenes *), Pseudomonas species (including P. aeruginosa *), and Proteus mirabilis *. (8) Central nervous system infections , e.g., meningitis and ventriculitis, caused by Neisseria meningitidis , Haemophilus influenzae , Streptococcus pneumoniae , Klebsiella pneumoniae * and Escherichia coli *. (*) Efficacy for this organism, in this organ system, has been studied in fewer than 10 infections. Although many strains of enterococci (e.g., S. faecalis ) and Pseudomonas species are resistant to cefotaxime sodium in vitro , cefotaxime for injection, USP has been used successfully in treating patients with infections caused by susceptible organisms. Specimens for bacteriologic culture should be obtained prior to therapy in order to isolate and identify causative organisms and to determine their susceptibilities to cefotaxime for injection, USP. Therapy may be instituted before results of susceptibility studies are known; however, once these results become available, the antibiotic treatment should be adjusted accordingly. In certain cases of confirmed or suspected gram-positive or gram-negative sepsis or in patients with other serious infections in which the causative organism has not been identified, cefotaxime for injection, USP may be used concomitantly with an aminoglycoside. The dosage recommended in the labeling of both antibiotics may be given and depends on the severity of the infection and the patient's condition. Renal function should be carefully monitored, especially if higher dosages of the aminoglycosides are to be administered or if therapy is prolonged, because of the potential nephrotoxicity and ototoxicity of aminoglycoside antibiotics. It is possible that nephrotoxicity may be potentiated if cefotaxime for injection, USP is used concomitantly with an aminoglycoside. uuid:bfcc947e-1ff2-46e5-a0da-e63fda1a3015 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:204928 biolink:treats UMLS:C1112209 PMID:41385096 "[{""id"":""uuid:93a58f03-2ebf-4731-a64e-5525a1083976"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b20f1682-6bcc-4f50-ba77-2cc131e6fbd3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Treatment Cefotaxime for injection, USP is indicated for the treatment of patients with serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) Lower respiratory tract infections , including pneumonia, caused by Streptococcus pneumoniae (formerly Diplococcus pneumoniae ), Streptococcus pyogenes * (Group A streptococci) and other streptococci (excluding enterococci, e.g., Enterococcus faecalis ), Staphylococcus aureus (penicillinase and non-penicillinase producing), Escherichia coli , Klebsiella species, Haemophilus influenzae (including ampicillin resistant strains), Haemophilus parainfluenzae , Proteus mirabilis , Serratia marcescens *, Enterobacter species, indole positive Proteus and Pseudomonas species (including P. aeruginosa ). (2) Genitourinary infections . Urinary tract infections caused by Enterococcus species, Staphylococcus epidermidis , Staphylococcus aureus *, (penicillinase and non-penicillinase producing), Citrobacter species, Enterobacter species, Escherichia coli , Klebsiella species, Proteus mirabilis , Proteus vulgaris *, Providencia stuartii , Morganella morganii *, Providencia rettgeri *, Serratia marcescens and Pseudomonas species (including P. aeruginosa ). Also, uncomplicated gonorrhea (cervical/urethral and rectal) caused by Neisseria gonorrhoeae , including penicillinase producing strains. (3) Gynecologic infections , including pelvic inflammatory disease, endometritis and pelvic cellulitis caused by Staphylococcus epidermidis , Streptococcus species, Enterococcus species, Enterobacter species*, Klebsiella species*, Escherichia coli , Proteus mirabilis , Bacteroides species (including Bacteroides fragilis *), Clostridium species, and anaerobic cocci (including Peptostreptococcus species and Peptococcus species) and Fusobacterium species (including F. nucleatum *). Cefotaxime for injection, USP, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti-chlamydial coverage should be added. (4) Bacteremia/Septicemia caused by Escherichia coli , Klebsiella species, and Serratia marcescens , Staphylococcus aureus and Streptococcus species (including S. pneumonia ). (5) Skin and skin structure infections caused by Staphylococcus aureus (penicillinase and non-penicillinase producing), Staphylococcus epidermidis , Streptococcus pyogenes (Group A streptococci) and other streptococci, Enterococcus species, Acinetobacter species*, Escherichia coli , Citrobacter species (including C. freundii *), Enterobacter species, Klebsiella species, Proteus mirabilis , Proteus vulgaris *, Morganella morganii , Providencia rettgeri *, Pseudomonas species, Serratia marcescens , Bacteroides species, and anaerobic cocci (including Peptostreptococcus * species and Peptococcus species). (6) Intra-abdominal infections including peritonitis caused by Streptococcus species*, Escherichia coli , Klebsiella species, Bacteroides species, and anaerobic cocci (including Peptostreptococcus * species and Peptococcus * species) Proteus mirabilis *, and Clostridium species*. (7) Bone and/or joint infections caused by Staphylococcus aureus (penicillinase and non-penicillinase producing strains), Streptococcus species (including S. pyogenes *), Pseudomonas species (including P. aeruginosa *), and Proteus mirabilis *. (8) Central nervous system infections , e.g., meningitis and ventriculitis, caused by Neisseria meningitidis , Haemophilus influenzae , Streptococcus pneumoniae , Klebsiella pneumoniae * and Escherichia coli *. (*) Efficacy for this organism, in this organ system, has been studied in fewer than 10 infections. Although many strains of enterococci (e.g., S. faecalis ) and Pseudomonas species are resistant to cefotaxime sodium in vitro , cefotaxime for injection, USP has been used successfully in treating patients with infections caused by susceptible organisms. Specimens for bacteriologic culture should be obtained prior to therapy in order to isolate and identify causative organisms and to determine their susceptibilities to cefotaxime for injection, USP. Therapy may be instituted before results of susceptibility studies are known; however, once these results become available, the antibiotic treatment should be adjusted accordingly. In certain cases of confirmed or suspected gram-positive or gram-negative sepsis or in patients with other serious infections in which the causative organism has not been identified, cefotaxime for injection, USP may be used concomitantly with an aminoglycoside. The dosage recommended in the labeling of both antibiotics may be given and depends on the severity of the infection and the patient's condition. Renal function should be carefully monitored, especially if higher dosages of the aminoglycosides are to be administered or if therapy is prolonged, because of the potential nephrotoxicity and ototoxicity of aminoglycoside antibiotics. It is possible that nephrotoxicity may be potentiated if cefotaxime for injection, USP is used concomitantly with an aminoglycoside. uuid:57bd6b6e-3138-45ae-89df-0d5bea70edc5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:204928 biolink:treats MONDO:0004522 PMID:41385096 "[{""id"":""uuid:09cdf2d5-b8f7-49d9-a9e1-9b1181ede982"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a2a7e939-b3b7-48f7-84be-b3dedf7125dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Treatment Cefotaxime for injection, USP is indicated for the treatment of patients with serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) Lower respiratory tract infections , including pneumonia, caused by Streptococcus pneumoniae (formerly Diplococcus pneumoniae ), Streptococcus pyogenes * (Group A streptococci) and other streptococci (excluding enterococci, e.g., Enterococcus faecalis ), Staphylococcus aureus (penicillinase and non-penicillinase producing), Escherichia coli , Klebsiella species, Haemophilus influenzae (including ampicillin resistant strains), Haemophilus parainfluenzae , Proteus mirabilis , Serratia marcescens *, Enterobacter species, indole positive Proteus and Pseudomonas species (including P. aeruginosa ). (2) Genitourinary infections . Urinary tract infections caused by Enterococcus species, Staphylococcus epidermidis , Staphylococcus aureus *, (penicillinase and non-penicillinase producing), Citrobacter species, Enterobacter species, Escherichia coli , Klebsiella species, Proteus mirabilis , Proteus vulgaris *, Providencia stuartii , Morganella morganii *, Providencia rettgeri *, Serratia marcescens and Pseudomonas species (including P. aeruginosa ). Also, uncomplicated gonorrhea (cervical/urethral and rectal) caused by Neisseria gonorrhoeae , including penicillinase producing strains. (3) Gynecologic infections , including pelvic inflammatory disease, endometritis and pelvic cellulitis caused by Staphylococcus epidermidis , Streptococcus species, Enterococcus species, Enterobacter species*, Klebsiella species*, Escherichia coli , Proteus mirabilis , Bacteroides species (including Bacteroides fragilis *), Clostridium species, and anaerobic cocci (including Peptostreptococcus species and Peptococcus species) and Fusobacterium species (including F. nucleatum *). Cefotaxime for injection, USP, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti-chlamydial coverage should be added. (4) Bacteremia/Septicemia caused by Escherichia coli , Klebsiella species, and Serratia marcescens , Staphylococcus aureus and Streptococcus species (including S. pneumonia ). (5) Skin and skin structure infections caused by Staphylococcus aureus (penicillinase and non-penicillinase producing), Staphylococcus epidermidis , Streptococcus pyogenes (Group A streptococci) and other streptococci, Enterococcus species, Acinetobacter species*, Escherichia coli , Citrobacter species (including C. freundii *), Enterobacter species, Klebsiella species, Proteus mirabilis , Proteus vulgaris *, Morganella morganii , Providencia rettgeri *, Pseudomonas species, Serratia marcescens , Bacteroides species, and anaerobic cocci (including Peptostreptococcus * species and Peptococcus species). (6) Intra-abdominal infections including peritonitis caused by Streptococcus species*, Escherichia coli , Klebsiella species, Bacteroides species, and anaerobic cocci (including Peptostreptococcus * species and Peptococcus * species) Proteus mirabilis *, and Clostridium species*. (7) Bone and/or joint infections caused by Staphylococcus aureus (penicillinase and non-penicillinase producing strains), Streptococcus species (including S. pyogenes *), Pseudomonas species (including P. aeruginosa *), and Proteus mirabilis *. (8) Central nervous system infections , e.g., meningitis and ventriculitis, caused by Neisseria meningitidis , Haemophilus influenzae , Streptococcus pneumoniae , Klebsiella pneumoniae * and Escherichia coli *. (*) Efficacy for this organism, in this organ system, has been studied in fewer than 10 infections. Although many strains of enterococci (e.g., S. faecalis ) and Pseudomonas species are resistant to cefotaxime sodium in vitro , cefotaxime for injection, USP has been used successfully in treating patients with infections caused by susceptible organisms. Specimens for bacteriologic culture should be obtained prior to therapy in order to isolate and identify causative organisms and to determine their susceptibilities to cefotaxime for injection, USP. Therapy may be instituted before results of susceptibility studies are known; however, once these results become available, the antibiotic treatment should be adjusted accordingly. In certain cases of confirmed or suspected gram-positive or gram-negative sepsis or in patients with other serious infections in which the causative organism has not been identified, cefotaxime for injection, USP may be used concomitantly with an aminoglycoside. The dosage recommended in the labeling of both antibiotics may be given and depends on the severity of the infection and the patient's condition. Renal function should be carefully monitored, especially if higher dosages of the aminoglycosides are to be administered or if therapy is prolonged, because of the potential nephrotoxicity and ototoxicity of aminoglycoside antibiotics. It is possible that nephrotoxicity may be potentiated if cefotaxime for injection, USP is used concomitantly with an aminoglycoside. uuid:63a1f9c5-1a71-4905-8da4-46cf40d807de biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:204928 biolink:treats MONDO:0005246 PMID:41385096 "[{""id"":""uuid:21d128c6-481c-4f00-bdbc-6e5e1c72218e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:849c92ba-d420-4318-b9b9-90e2923a57fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Treatment Cefotaxime for injection, USP is indicated for the treatment of patients with serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) Lower respiratory tract infections , including pneumonia, caused by Streptococcus pneumoniae (formerly Diplococcus pneumoniae ), Streptococcus pyogenes * (Group A streptococci) and other streptococci (excluding enterococci, e.g., Enterococcus faecalis ), Staphylococcus aureus (penicillinase and non-penicillinase producing), Escherichia coli , Klebsiella species, Haemophilus influenzae (including ampicillin resistant strains), Haemophilus parainfluenzae , Proteus mirabilis , Serratia marcescens *, Enterobacter species, indole positive Proteus and Pseudomonas species (including P. aeruginosa ). (2) Genitourinary infections . Urinary tract infections caused by Enterococcus species, Staphylococcus epidermidis , Staphylococcus aureus *, (penicillinase and non-penicillinase producing), Citrobacter species, Enterobacter species, Escherichia coli , Klebsiella species, Proteus mirabilis , Proteus vulgaris *, Providencia stuartii , Morganella morganii *, Providencia rettgeri *, Serratia marcescens and Pseudomonas species (including P. aeruginosa ). Also, uncomplicated gonorrhea (cervical/urethral and rectal) caused by Neisseria gonorrhoeae , including penicillinase producing strains. (3) Gynecologic infections , including pelvic inflammatory disease, endometritis and pelvic cellulitis caused by Staphylococcus epidermidis , Streptococcus species, Enterococcus species, Enterobacter species*, Klebsiella species*, Escherichia coli , Proteus mirabilis , Bacteroides species (including Bacteroides fragilis *), Clostridium species, and anaerobic cocci (including Peptostreptococcus species and Peptococcus species) and Fusobacterium species (including F. nucleatum *). Cefotaxime for injection, USP, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti-chlamydial coverage should be added. (4) Bacteremia/Septicemia caused by Escherichia coli , Klebsiella species, and Serratia marcescens , Staphylococcus aureus and Streptococcus species (including S. pneumonia ). (5) Skin and skin structure infections caused by Staphylococcus aureus (penicillinase and non-penicillinase producing), Staphylococcus epidermidis , Streptococcus pyogenes (Group A streptococci) and other streptococci, Enterococcus species, Acinetobacter species*, Escherichia coli , Citrobacter species (including C. freundii *), Enterobacter species, Klebsiella species, Proteus mirabilis , Proteus vulgaris *, Morganella morganii , Providencia rettgeri *, Pseudomonas species, Serratia marcescens , Bacteroides species, and anaerobic cocci (including Peptostreptococcus * species and Peptococcus species). (6) Intra-abdominal infections including peritonitis caused by Streptococcus species*, Escherichia coli , Klebsiella species, Bacteroides species, and anaerobic cocci (including Peptostreptococcus * species and Peptococcus * species) Proteus mirabilis *, and Clostridium species*. (7) Bone and/or joint infections caused by Staphylococcus aureus (penicillinase and non-penicillinase producing strains), Streptococcus species (including S. pyogenes *), Pseudomonas species (including P. aeruginosa *), and Proteus mirabilis *. (8) Central nervous system infections , e.g., meningitis and ventriculitis, caused by Neisseria meningitidis , Haemophilus influenzae , Streptococcus pneumoniae , Klebsiella pneumoniae * and Escherichia coli *. (*) Efficacy for this organism, in this organ system, has been studied in fewer than 10 infections. Although many strains of enterococci (e.g., S. faecalis ) and Pseudomonas species are resistant to cefotaxime sodium in vitro , cefotaxime for injection, USP has been used successfully in treating patients with infections caused by susceptible organisms. Specimens for bacteriologic culture should be obtained prior to therapy in order to isolate and identify causative organisms and to determine their susceptibilities to cefotaxime for injection, USP. Therapy may be instituted before results of susceptibility studies are known; however, once these results become available, the antibiotic treatment should be adjusted accordingly. In certain cases of confirmed or suspected gram-positive or gram-negative sepsis or in patients with other serious infections in which the causative organism has not been identified, cefotaxime for injection, USP may be used concomitantly with an aminoglycoside. The dosage recommended in the labeling of both antibiotics may be given and depends on the severity of the infection and the patient's condition. Renal function should be carefully monitored, especially if higher dosages of the aminoglycosides are to be administered or if therapy is prolonged, because of the potential nephrotoxicity and ototoxicity of aminoglycoside antibiotics. It is possible that nephrotoxicity may be potentiated if cefotaxime for injection, USP is used concomitantly with an aminoglycoside. uuid:ef2b209b-cdc8-4aca-ac9c-4ab2086f3efe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:204928 biolink:treats MONDO:0021108 PMID:41385096 "[{""id"":""uuid:9cc09a7f-a38b-453f-9a5e-b61f7f7b2cdf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0cc637e1-79ec-4e0f-a2f7-0a3c01db39be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Treatment Cefotaxime for injection, USP is indicated for the treatment of patients with serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) Lower respiratory tract infections , including pneumonia, caused by Streptococcus pneumoniae (formerly Diplococcus pneumoniae ), Streptococcus pyogenes * (Group A streptococci) and other streptococci (excluding enterococci, e.g., Enterococcus faecalis ), Staphylococcus aureus (penicillinase and non-penicillinase producing), Escherichia coli , Klebsiella species, Haemophilus influenzae (including ampicillin resistant strains), Haemophilus parainfluenzae , Proteus mirabilis , Serratia marcescens *, Enterobacter species, indole positive Proteus and Pseudomonas species (including P. aeruginosa ). (2) Genitourinary infections . Urinary tract infections caused by Enterococcus species, Staphylococcus epidermidis , Staphylococcus aureus *, (penicillinase and non-penicillinase producing), Citrobacter species, Enterobacter species, Escherichia coli , Klebsiella species, Proteus mirabilis , Proteus vulgaris *, Providencia stuartii , Morganella morganii *, Providencia rettgeri *, Serratia marcescens and Pseudomonas species (including P. aeruginosa ). Also, uncomplicated gonorrhea (cervical/urethral and rectal) caused by Neisseria gonorrhoeae , including penicillinase producing strains. (3) Gynecologic infections , including pelvic inflammatory disease, endometritis and pelvic cellulitis caused by Staphylococcus epidermidis , Streptococcus species, Enterococcus species, Enterobacter species*, Klebsiella species*, Escherichia coli , Proteus mirabilis , Bacteroides species (including Bacteroides fragilis *), Clostridium species, and anaerobic cocci (including Peptostreptococcus species and Peptococcus species) and Fusobacterium species (including F. nucleatum *). Cefotaxime for injection, USP, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti-chlamydial coverage should be added. (4) Bacteremia/Septicemia caused by Escherichia coli , Klebsiella species, and Serratia marcescens , Staphylococcus aureus and Streptococcus species (including S. pneumonia ). (5) Skin and skin structure infections caused by Staphylococcus aureus (penicillinase and non-penicillinase producing), Staphylococcus epidermidis , Streptococcus pyogenes (Group A streptococci) and other streptococci, Enterococcus species, Acinetobacter species*, Escherichia coli , Citrobacter species (including C. freundii *), Enterobacter species, Klebsiella species, Proteus mirabilis , Proteus vulgaris *, Morganella morganii , Providencia rettgeri *, Pseudomonas species, Serratia marcescens , Bacteroides species, and anaerobic cocci (including Peptostreptococcus * species and Peptococcus species). (6) Intra-abdominal infections including peritonitis caused by Streptococcus species*, Escherichia coli , Klebsiella species, Bacteroides species, and anaerobic cocci (including Peptostreptococcus * species and Peptococcus * species) Proteus mirabilis *, and Clostridium species*. (7) Bone and/or joint infections caused by Staphylococcus aureus (penicillinase and non-penicillinase producing strains), Streptococcus species (including S. pyogenes *), Pseudomonas species (including P. aeruginosa *), and Proteus mirabilis *. (8) Central nervous system infections , e.g., meningitis and ventriculitis, caused by Neisseria meningitidis , Haemophilus influenzae , Streptococcus pneumoniae , Klebsiella pneumoniae * and Escherichia coli *. (*) Efficacy for this organism, in this organ system, has been studied in fewer than 10 infections. Although many strains of enterococci (e.g., S. faecalis ) and Pseudomonas species are resistant to cefotaxime sodium in vitro , cefotaxime for injection, USP has been used successfully in treating patients with infections caused by susceptible organisms. Specimens for bacteriologic culture should be obtained prior to therapy in order to isolate and identify causative organisms and to determine their susceptibilities to cefotaxime for injection, USP. Therapy may be instituted before results of susceptibility studies are known; however, once these results become available, the antibiotic treatment should be adjusted accordingly. In certain cases of confirmed or suspected gram-positive or gram-negative sepsis or in patients with other serious infections in which the causative organism has not been identified, cefotaxime for injection, USP may be used concomitantly with an aminoglycoside. The dosage recommended in the labeling of both antibiotics may be given and depends on the severity of the infection and the patient's condition. Renal function should be carefully monitored, especially if higher dosages of the aminoglycosides are to be administered or if therapy is prolonged, because of the potential nephrotoxicity and ototoxicity of aminoglycoside antibiotics. It is possible that nephrotoxicity may be potentiated if cefotaxime for injection, USP is used concomitantly with an aminoglycoside. uuid:ddc4f743-806e-445d-b392-44103ada351e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:204928 biolink:treats UMLS:C1455718 PMID:41385096 "[{""id"":""uuid:47547e17-2fb0-4749-8a79-ba5e5a32cbc9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d6631428-6096-4281-8c15-ed47d958c9a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Treatment Cefotaxime for injection, USP is indicated for the treatment of patients with serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) Lower respiratory tract infections , including pneumonia, caused by Streptococcus pneumoniae (formerly Diplococcus pneumoniae ), Streptococcus pyogenes * (Group A streptococci) and other streptococci (excluding enterococci, e.g., Enterococcus faecalis ), Staphylococcus aureus (penicillinase and non-penicillinase producing), Escherichia coli , Klebsiella species, Haemophilus influenzae (including ampicillin resistant strains), Haemophilus parainfluenzae , Proteus mirabilis , Serratia marcescens *, Enterobacter species, indole positive Proteus and Pseudomonas species (including P. aeruginosa ). (2) Genitourinary infections . Urinary tract infections caused by Enterococcus species, Staphylococcus epidermidis , Staphylococcus aureus *, (penicillinase and non-penicillinase producing), Citrobacter species, Enterobacter species, Escherichia coli , Klebsiella species, Proteus mirabilis , Proteus vulgaris *, Providencia stuartii , Morganella morganii *, Providencia rettgeri *, Serratia marcescens and Pseudomonas species (including P. aeruginosa ). Also, uncomplicated gonorrhea (cervical/urethral and rectal) caused by Neisseria gonorrhoeae , including penicillinase producing strains. (3) Gynecologic infections , including pelvic inflammatory disease, endometritis and pelvic cellulitis caused by Staphylococcus epidermidis , Streptococcus species, Enterococcus species, Enterobacter species*, Klebsiella species*, Escherichia coli , Proteus mirabilis , Bacteroides species (including Bacteroides fragilis *), Clostridium species, and anaerobic cocci (including Peptostreptococcus species and Peptococcus species) and Fusobacterium species (including F. nucleatum *). Cefotaxime for injection, USP, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti-chlamydial coverage should be added. (4) Bacteremia/Septicemia caused by Escherichia coli , Klebsiella species, and Serratia marcescens , Staphylococcus aureus and Streptococcus species (including S. pneumonia ). (5) Skin and skin structure infections caused by Staphylococcus aureus (penicillinase and non-penicillinase producing), Staphylococcus epidermidis , Streptococcus pyogenes (Group A streptococci) and other streptococci, Enterococcus species, Acinetobacter species*, Escherichia coli , Citrobacter species (including C. freundii *), Enterobacter species, Klebsiella species, Proteus mirabilis , Proteus vulgaris *, Morganella morganii , Providencia rettgeri *, Pseudomonas species, Serratia marcescens , Bacteroides species, and anaerobic cocci (including Peptostreptococcus * species and Peptococcus species). (6) Intra-abdominal infections including peritonitis caused by Streptococcus species*, Escherichia coli , Klebsiella species, Bacteroides species, and anaerobic cocci (including Peptostreptococcus * species and Peptococcus * species) Proteus mirabilis *, and Clostridium species*. (7) Bone and/or joint infections caused by Staphylococcus aureus (penicillinase and non-penicillinase producing strains), Streptococcus species (including S. pyogenes *), Pseudomonas species (including P. aeruginosa *), and Proteus mirabilis *. (8) Central nervous system infections , e.g., meningitis and ventriculitis, caused by Neisseria meningitidis , Haemophilus influenzae , Streptococcus pneumoniae , Klebsiella pneumoniae * and Escherichia coli *. (*) Efficacy for this organism, in this organ system, has been studied in fewer than 10 infections. Although many strains of enterococci (e.g., S. faecalis ) and Pseudomonas species are resistant to cefotaxime sodium in vitro , cefotaxime for injection, USP has been used successfully in treating patients with infections caused by susceptible organisms. Specimens for bacteriologic culture should be obtained prior to therapy in order to isolate and identify causative organisms and to determine their susceptibilities to cefotaxime for injection, USP. Therapy may be instituted before results of susceptibility studies are known; however, once these results become available, the antibiotic treatment should be adjusted accordingly. In certain cases of confirmed or suspected gram-positive or gram-negative sepsis or in patients with other serious infections in which the causative organism has not been identified, cefotaxime for injection, USP may be used concomitantly with an aminoglycoside. The dosage recommended in the labeling of both antibiotics may be given and depends on the severity of the infection and the patient's condition. Renal function should be carefully monitored, especially if higher dosages of the aminoglycosides are to be administered or if therapy is prolonged, because of the potential nephrotoxicity and ototoxicity of aminoglycoside antibiotics. It is possible that nephrotoxicity may be potentiated if cefotaxime for injection, USP is used concomitantly with an aminoglycoside. uuid:da9fb32e-721f-4989-b221-0761f158fae7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:61276 biolink:treats MONDO:0004247 PMID:41385096 "[{""id"":""uuid:e01913e5-7c36-4575-81bf-2c67abcb0977"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d6be18f6-b2f0-489d-b92c-d121fa2173ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Adjunctive therapy for the treatment of peptic ulcer. METHSCOPOLAMINE BROMIDE HAS NOT BEEN SHOWN TO BE EFFECTIVE IN CONTRIBUTING TO THE HEALING OF PEPTIC ULCER, DECREASING THE RATE OF RECURRENCE OR PREVENTING COMPLICATIONS. uuid:774a2d57-624c-45a4-88f5-b76dfac4346d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1811627 biolink:treats MONDO:0001126 PMID:41385096 "[{""id"":""uuid:56dc2b46-4fca-49b5-abf1-b808e7df3c9b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:37d03ca3-3a63-4303-8a81-5e749c2b3b3c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] YOSPRALA, a combination of aspirin and omeprazole, is indicated for patients who require aspirin for secondary prevention of cardiovascular and cerebrovascular events and who are at risk of developing aspirin associated gastric ulcers. The aspirin component of YOSPRALA is indicated for: reducing the combined risk of death and nonfatal stroke in patients who have had ischemic stroke or transient ischemia of the brain due to fibrin platelet emboli, reducing the combined risk of death and nonfatal MI in patients with a previous MI or unstable angina pectoris, reducing the combined risk of MI and sudden death in patients with chronic stable angina pectoris, use in patients who have undergone revascularization procedures (Coronary Artery Bypass Graft [CABG] or Percutaneous Transluminal Coronary Angioplasty [PTCA]) when there is a pre-existing condition for which aspirin is already indicated. The omeprazole component of YOSPRALA is indicated for decreasing the risk of developing aspirin-associated gastric ulcers in patients at risk for developing aspirin-associated gastric ulcers due to age (≥ 55) or documented history of gastric ulcers. uuid:008391bc-bf2b-4241-838d-aecc0c764b59 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0005093 PMID:41385096 "[{""id"":""uuid:dbc7e80b-518d-4ee0-8071-e024fb453aa4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:af4df8a9-91e3-4c62-8fd8-8f9511e12a72"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] U-cort ® , (Hydrocortisone Acetate Cream USP, 1%) is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. uuid:d9503626-ab5f-4e9d-923d-f458234cac0a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6923 biolink:treats UMLS:C0011974 PMID:41385096 "[{""id"":""uuid:90298ebd-b358-4ca8-9d29-3d0bf5e5f048"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:94657324-3219-4dd9-8b01-5971937f1078"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] • VUSION Ointment is indicated for adjunctive treatment of diaper dermatitis when complicated by documented candidiasis (microscopic evidence of pseudohyphae and /or budding yeast) in immunocompetent pediatric patients 4 weeks and older. ( 1.1 ) • VUSION Ointment should not be used as a substitute for frequent diaper changes. ( 1.1 ) • VUSION Ointment should not be used to prevent the occurrence of diaper dermatitis, since preventative use may result in the development of drug resistance. ( 1.2 ) uuid:ecbf6ea9-c54c-46cc-b41d-805718fdbaea biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats UMLS:C0274435 PMID:41385096 "[{""id"":""uuid:a44512e6-c931-45f9-82cc-d74dd3108e5c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:28f4db00-d9e4-4ba6-b302-8fc731b5ab21"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intramuscular Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection and Kenalog-80 Injection (triamcinolone acetonide injectable suspension, USP) are indicated for intramuscular use as follows: Allergic states : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases : Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases : To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders : Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases : For the palliative management of leukemias and lymphomas. Nervous system : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases : Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. Intra-Articular The intra-articular or soft tis sue administration of Kenalog-40 Injection and Kenalog-80 Injection are indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. uuid:e5b9a3e7-51f1-4f23-a4a7-901571a00513 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0001705 PMID:41385096 "[{""id"":""uuid:a5b9ef98-c567-4f7c-bc6c-4978d382c719"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:daa6b175-05a8-42e2-a69b-b88ec9e97fcc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intramuscular Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection and Kenalog-80 Injection (triamcinolone acetonide injectable suspension, USP) are indicated for intramuscular use as follows: Allergic states : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases : Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases : To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders : Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases : For the palliative management of leukemias and lymphomas. Nervous system : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases : Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. Intra-Articular The intra-articular or soft tis sue administration of Kenalog-40 Injection and Kenalog-80 Injection are indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. uuid:2f5c8df6-beaa-474f-b0c1-bad5ca554e5a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0005314 PMID:41385096 "[{""id"":""uuid:504ca817-9ae2-4a5b-bb7f-872733a805d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d56b8d0f-c0bb-4e39-8fdd-2852e0eb8941"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intramuscular Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection and Kenalog-80 Injection (triamcinolone acetonide injectable suspension, USP) are indicated for intramuscular use as follows: Allergic states : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases : Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases : To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders : Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases : For the palliative management of leukemias and lymphomas. Nervous system : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases : Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. Intra-Articular The intra-articular or soft tis sue administration of Kenalog-40 Injection and Kenalog-80 Injection are indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. uuid:62d99573-e9bd-4f20-9384-6e77c711eaf2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0008538 PMID:41385096 "[{""id"":""uuid:34330000-56d8-4e39-b129-bb4bbfd51b0a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ac758f88-683e-4353-8bb1-b4aff685ca23"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intramuscular Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection and Kenalog-80 Injection (triamcinolone acetonide injectable suspension, USP) are indicated for intramuscular use as follows: Allergic states : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases : Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases : To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders : Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases : For the palliative management of leukemias and lymphomas. Nervous system : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases : Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. Intra-Articular The intra-articular or soft tis sue administration of Kenalog-40 Injection and Kenalog-80 Injection are indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. uuid:8066a7b3-2a98-4e00-92e1-72705e5f4884 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0020283 PMID:41385096 "[{""id"":""uuid:aafd36ed-7433-4104-961a-49b9b97df678"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:13382bc5-6079-4af1-a3bc-f23268e07763"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intramuscular Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection and Kenalog-80 Injection (triamcinolone acetonide injectable suspension, USP) are indicated for intramuscular use as follows: Allergic states : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases : Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases : To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders : Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases : For the palliative management of leukemias and lymphomas. Nervous system : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases : Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. Intra-Articular The intra-articular or soft tis sue administration of Kenalog-40 Injection and Kenalog-80 Injection are indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. uuid:b5e0a938-f53d-4c15-bb78-28e8610f8d96 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0008109 PMID:41385096 "[{""id"":""uuid:681cc9d5-b9fe-497f-847f-7b27408c830f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0981d71e-60b8-4bde-87a1-b8275fbcdc3d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intramuscular Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection and Kenalog-80 Injection (triamcinolone acetonide injectable suspension, USP) are indicated for intramuscular use as follows: Allergic states : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases : Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases : To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders : Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases : For the palliative management of leukemias and lymphomas. Nervous system : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases : Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. Intra-Articular The intra-articular or soft tis sue administration of Kenalog-40 Injection and Kenalog-80 Injection are indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. uuid:da33fa2f-2fa4-4e92-aa47-1cdcdc3a1551 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0018170 PMID:41385096 "[{""id"":""uuid:1de8cc87-958e-49d7-8aac-bc77357bb125"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:df983892-2007-48f7-a9bc-122d7e70f4f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intramuscular Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection and Kenalog-80 Injection (triamcinolone acetonide injectable suspension, USP) are indicated for intramuscular use as follows: Allergic states : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases : Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases : To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders : Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases : For the palliative management of leukemias and lymphomas. Nervous system : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases : Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. Intra-Articular The intra-articular or soft tis sue administration of Kenalog-40 Injection and Kenalog-80 Injection are indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. uuid:2ae5462c-4b21-4b2b-a6a6-ea5dc446f398 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0005556 PMID:41385096 "[{""id"":""uuid:bf8d72bd-952b-4a87-953b-5ec337c62d9a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6daa8122-4bf7-47e7-9190-b86e8132d413"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intramuscular Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection and Kenalog-80 Injection (triamcinolone acetonide injectable suspension, USP) are indicated for intramuscular use as follows: Allergic states : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases : Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases : To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders : Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases : For the palliative management of leukemias and lymphomas. Nervous system : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases : Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. Intra-Articular The intra-articular or soft tis sue administration of Kenalog-40 Injection and Kenalog-80 Injection are indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. uuid:db58424c-711a-4090-875d-19057ed2ef4e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0015927 PMID:41385096 "[{""id"":""uuid:70a18a18-3301-43b8-bd04-2b61e67699df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:838f570b-f587-47a6-b73e-fb7d6f6f1610"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intramuscular Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection and Kenalog-80 Injection (triamcinolone acetonide injectable suspension, USP) are indicated for intramuscular use as follows: Allergic states : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases : Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases : To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders : Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases : For the palliative management of leukemias and lymphomas. Nervous system : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases : Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. Intra-Articular The intra-articular or soft tis sue administration of Kenalog-40 Injection and Kenalog-80 Injection are indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. uuid:66269f57-cf13-44ff-b01b-d9f82bc9a044 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0016367 PMID:41385096 "[{""id"":""uuid:9bbfe813-9fd1-475f-91d2-75e46875f507"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2d3e87a0-4e35-4dcc-aa0a-304d622c021d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intramuscular Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection and Kenalog-80 Injection (triamcinolone acetonide injectable suspension, USP) are indicated for intramuscular use as follows: Allergic states : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases : Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases : To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders : Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases : For the palliative management of leukemias and lymphomas. Nervous system : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases : Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. Intra-Articular The intra-articular or soft tis sue administration of Kenalog-40 Injection and Kenalog-80 Injection are indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. uuid:a990e2f2-3e46-4d05-add5-fa7c8d418465 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0019127 PMID:41385096 "[{""id"":""uuid:3496f9f0-4d89-4462-a890-10f1a9ffed8c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:83a735c0-fdae-4a78-af4c-61db1fbe9e84"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intramuscular Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection and Kenalog-80 Injection (triamcinolone acetonide injectable suspension, USP) are indicated for intramuscular use as follows: Allergic states : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases : Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases : To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders : Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases : For the palliative management of leukemias and lymphomas. Nervous system : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases : Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. Intra-Articular The intra-articular or soft tis sue administration of Kenalog-40 Injection and Kenalog-80 Injection are indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. uuid:57b605d5-951e-4dd1-b9a6-a727d462f8b0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0006982 PMID:41385096 "[{""id"":""uuid:332a0895-5cf6-4c5a-a1d5-7812cf84f50b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6ec6944b-a7eb-45af-8225-b21a923fec18"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intramuscular Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection and Kenalog-80 Injection (triamcinolone acetonide injectable suspension, USP) are indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. Intra-Articular The intra-articular or soft tis sue administration of Kenalog-40 Injection and Kenalog-80 Injection are indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. uuid:8a6f9881-40a9-439b-9268-b1b10f00ec3d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0008109 PMID:41385096 "[{""id"":""uuid:0c750a3a-eff4-4b0a-be09-765e2ef92840"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8dfb86ff-aa9f-494e-90d0-6d215d056206"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intramuscular Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection and Kenalog-80 Injection (triamcinolone acetonide injectable suspension, USP) are indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. Intra-Articular The intra-articular or soft tis sue administration of Kenalog-40 Injection and Kenalog-80 Injection are indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. uuid:73b895bb-e1e8-4e37-8ccb-8fe8ebb4f8a4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0040698 PMID:41385096 "[{""id"":""uuid:2a96972a-73b9-4c49-b64b-1e657d04a776"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4d667043-e087-4b29-a0c7-158738d792c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intramuscular Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection and Kenalog-80 Injection (triamcinolone acetonide injectable suspension, USP) are indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. Intra-Articular The intra-articular or soft tis sue administration of Kenalog-40 Injection and Kenalog-80 Injection are indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. uuid:dbc2eb7e-387a-43b9-a2f9-d0b62f20429e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0004855 PMID:41385096 "[{""id"":""uuid:ed0ccf8e-179c-41ff-b2f3-1713c78f0398"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ff80ba78-1741-498a-8d3b-3584bdb4b1e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intramuscular Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection and Kenalog-80 Injection (triamcinolone acetonide injectable suspension, USP) are indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. Intra-Articular The intra-articular or soft tis sue administration of Kenalog-40 Injection and Kenalog-80 Injection are indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. uuid:dec0c993-a46d-4b2b-999c-a130f52bfb54 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0001875 PMID:41385096 "[{""id"":""uuid:bd5b80d7-f633-4081-aef4-1599a5fd1501"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:21971f46-6d4d-44e8-9974-ce9220679612"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intramuscular Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection and Kenalog-80 Injection (triamcinolone acetonide injectable suspension, USP) are indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. Intra-Articular The intra-articular or soft tis sue administration of Kenalog-40 Injection and Kenalog-80 Injection are indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. uuid:ac1f7233-0d15-4f88-83ad-1c98cf0253c2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0005178 PMID:41385096 "[{""id"":""uuid:b6ae48ec-7cd1-4395-916f-4019ac1cfae0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5120b8fb-d393-4d2b-9ff0-e1f21cb3d819"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intramuscular Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection and Kenalog-80 Injection (triamcinolone acetonide injectable suspension, USP) are indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. Intra-Articular The intra-articular or soft tis sue administration of Kenalog-40 Injection and Kenalog-80 Injection are indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. uuid:b7dbcf3c-4bee-404c-a0b6-09599cf25151 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:40279 biolink:treats MONDO:0003652 PMID:41385096 "[{""id"":""uuid:ac434ef8-3bfd-488f-b1f0-ef3ca005f9de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1acb2371-89b0-4fe7-a733-abd26f2251b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] THIS IS NOT AN INNOCUOUS DRUG. IT IS NOT RECOMMENDED FOR THE TREATMENT OF ASYMPTOMATIC HYPERURICEMIA. Allopurinol tablets USP reduces serum and urinary uric acid concentrations. Its use should be individualized for each patient and requires an understanding of its mode of action and pharmacokinetics (see CLINICAL PHARMACOLOGY , CONTRAINDICATIONS , WARNINGS , and PRECAUTIONS ). Allopurinol tablet USP is indicated in: 1. the management of patients with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy). 2. the management of patients with leukemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. Treatment with allopurinol tablets USP should be discontinued when the potential for overproduction of uric acid is no longer present. 3. the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients. Therapy in such patients should be carefully assessed initially and reassessed periodically to determine in each case that treatment is beneficial and that the benefits outweigh the risks. uuid:d8ad1b97-79b1-4cca-84c5-5767fa7b15d2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4636 biolink:treats MONDO:0005271 PMID:41385096 "[{""id"":""uuid:00fd3277-9b9b-4acc-936f-354c2f72e831"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:70a38ea2-3877-4574-b3af-cf26b7f06288"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diphenhydramine hydrochloride in the injectable form is effective in adults and pediatric patients, other than premature infants and neonates, for the following conditions when diphenhydramine hydrochloride in the oral form is impractical. Antihistaminic: For amelioration of allergic reactions to blood or plasma, in anaphylaxis as an adjunct to epinephrine and other standard measures after the acute symptoms have been controlled, and for other uncomplicated allergic conditions of the immediate type when oral therapy is impossible or contraindicated. Motion sickness: For active treatment of motion sickness. Antiparkinsonism: For use in parkinsonism, when oral therapy is impossible or contraindicated, as follows: parkinsonism in the elderly who are unable to tolerate more potent agents; mild cases of parkinsonism in other age groups, and in other cases of parkinsonism in combination with centrally acting anticholinergic agents. uuid:5ecf6732-8fd1-43c4-887a-f306c515cff8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4636 biolink:treats MONDO:0100053 PMID:41385096 "[{""id"":""uuid:e2607993-6bab-4c14-86b9-b758927c6305"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f3cef6a6-c041-4b56-be3e-f06b51f56335"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diphenhydramine hydrochloride in the injectable form is effective in adults and pediatric patients, other than premature infants and neonates, for the following conditions when diphenhydramine hydrochloride in the oral form is impractical. Antihistaminic: For amelioration of allergic reactions to blood or plasma, in anaphylaxis as an adjunct to epinephrine and other standard measures after the acute symptoms have been controlled, and for other uncomplicated allergic conditions of the immediate type when oral therapy is impossible or contraindicated. Motion sickness: For active treatment of motion sickness. Antiparkinsonism: For use in parkinsonism, when oral therapy is impossible or contraindicated, as follows: parkinsonism in the elderly who are unable to tolerate more potent agents; mild cases of parkinsonism in other age groups, and in other cases of parkinsonism in combination with centrally acting anticholinergic agents. uuid:9d4788ce-7687-4caa-95f0-496366217408 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4636 biolink:treats UMLS:C0851444 PMID:41385096 "[{""id"":""uuid:0c1ea240-7ac6-40df-a0bf-67f190e4baac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:820bce73-32f2-4cd7-99c4-0d60f6eb6ec7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diphenhydramine hydrochloride in the injectable form is effective in adults and pediatric patients, other than premature infants and neonates, for the following conditions when diphenhydramine hydrochloride in the oral form is impractical. Antihistaminic: For amelioration of allergic reactions to blood or plasma, in anaphylaxis as an adjunct to epinephrine and other standard measures after the acute symptoms have been controlled, and for other uncomplicated allergic conditions of the immediate type when oral therapy is impossible or contraindicated. Motion sickness: For active treatment of motion sickness. Antiparkinsonism: For use in parkinsonism, when oral therapy is impossible or contraindicated, as follows: parkinsonism in the elderly who are unable to tolerate more potent agents; mild cases of parkinsonism in other age groups, and in other cases of parkinsonism in combination with centrally acting anticholinergic agents. uuid:98cdec9b-e358-4162-965d-d453bc2462a8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4636 biolink:treats MONDO:0008015 PMID:41385096 "[{""id"":""uuid:1e20afa0-83d3-4f36-a91f-406c2f281f4c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d531f1f3-c5f5-489e-b5f7-79586f67c040"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diphenhydramine hydrochloride in the injectable form is effective in adults and pediatric patients, other than premature infants and neonates, for the following conditions when diphenhydramine hydrochloride in the oral form is impractical. Antihistaminic: For amelioration of allergic reactions to blood or plasma, in anaphylaxis as an adjunct to epinephrine and other standard measures after the acute symptoms have been controlled, and for other uncomplicated allergic conditions of the immediate type when oral therapy is impossible or contraindicated. Motion sickness: For active treatment of motion sickness. Antiparkinsonism: For use in parkinsonism, when oral therapy is impossible or contraindicated, as follows: parkinsonism in the elderly who are unable to tolerate more potent agents; mild cases of parkinsonism in other age groups, and in other cases of parkinsonism in combination with centrally acting anticholinergic agents. uuid:20d32d88-054c-474c-941a-3bf678a703cd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4636 biolink:treats MONDO:0021095 PMID:41385096 "[{""id"":""uuid:f973a2e3-159c-4773-ba39-10083ba48ae9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aa05f62c-0923-4ea9-b59b-704038571f1a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diphenhydramine hydrochloride in the injectable form is effective in adults and pediatric patients, other than premature infants and neonates, for the following conditions when diphenhydramine hydrochloride in the oral form is impractical. Antihistaminic: For amelioration of allergic reactions to blood or plasma, in anaphylaxis as an adjunct to epinephrine and other standard measures after the acute symptoms have been controlled, and for other uncomplicated allergic conditions of the immediate type when oral therapy is impossible or contraindicated. Motion sickness: For active treatment of motion sickness. Antiparkinsonism: For use in parkinsonism, when oral therapy is impossible or contraindicated, as follows: parkinsonism in the elderly who are unable to tolerate more potent agents; mild cases of parkinsonism in other age groups, and in other cases of parkinsonism in combination with centrally acting anticholinergic agents. uuid:6e646525-9556-4938-97d8-2e8342e2b6e1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4735 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:16358082-ff28-45e2-847e-81bf603391cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:02a1ed7f-52b6-46db-9dc6-2a63c5c16c14"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Labetalol HCl injection is indicated for control of blood pressure in severe hypertension. uuid:8ce22a04-9d10-47d6-97a5-22d13b4e519c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1152251 biolink:treats HP:0012228 PMID:41385096 "[{""id"":""uuid:2abedec9-d47f-4e7a-8bed-19723ec2a1cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:45757363-8649-4a79-839b-b4d3583ae2d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules are indicated for the management of the symptom complex of tension (or muscle contraction) headache when non-opioid analgesic and alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, and misuse with opioids and butalbital, even at recommended doses [see Warnings and Precautions (5.1)], reserve Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules for use in patients for whom alternative treatment options [e.g., non-opioid, non-barbiturate analgesics]: • Have not been tolerated or are not expected to be tolerated, • Have not provided adequate analgesia or are not expected to provide adequate analgesia. uuid:f53f7dcd-0bd4-4fd6-83eb-96f17481241b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16684 biolink:treats MONDO:0001428 PMID:41385096 "[{""id"":""uuid:82ee2679-e756-449b-b33f-085fa0ef1507"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:579a2ede-8cf5-41ad-992b-eba2684a0c7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Atropine Sulfate Injection, USP, may be given parenterally as a pre-anesthetic medication in surgical patients to reduce salivation and bronchial secretions. It may also be used to suppress vagal activity associated with the use of halogenated hydrocarbons during inhalation anesthesia and reflex excitation arising from mechanical stimulation during surgery. The antispasmodic action of atropine is useful in pylorospasm and other spastic conditions of the gastrointestinal tract. For ureteral and biliary colic, atropine concomitantly with morphine may be indicated. Atropine relaxes the upper GI tract and colon during hypotonic radiography. In poisoning by the organic phosphate cholinesterase inhibitors found in certain insecticides and by chemical warfare nerve gases, large doses of atropine relieve the muscarine-like symptoms and some of the central nervous system manifestations. It is also used as an antidote for mushroom poisoning due to muscarine in certain species such as Amanita muscaria. uuid:dc3f4749-c0a8-4e08-b69d-26c43b913812 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16684 biolink:treats MONDO:0007009 PMID:41385096 "[{""id"":""uuid:122c0918-09ad-42f9-82ec-c0a199c32d56"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1b7daab5-b583-4145-9c6e-431abdff70e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Atropine Sulfate Injection, USP, may be given parenterally as a pre-anesthetic medication in surgical patients to reduce salivation and bronchial secretions. It may also be used to suppress vagal activity associated with the use of halogenated hydrocarbons during inhalation anesthesia and reflex excitation arising from mechanical stimulation during surgery. The antispasmodic action of atropine is useful in pylorospasm and other spastic conditions of the gastrointestinal tract. For ureteral and biliary colic, atropine concomitantly with morphine may be indicated. Atropine relaxes the upper GI tract and colon during hypotonic radiography. In poisoning by the organic phosphate cholinesterase inhibitors found in certain insecticides and by chemical warfare nerve gases, large doses of atropine relieve the muscarine-like symptoms and some of the central nervous system manifestations. It is also used as an antidote for mushroom poisoning due to muscarine in certain species such as Amanita muscaria. uuid:557432fa-c54f-4d43-af08-8c4a8c5d095c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16684 biolink:treats UMLS:C0151824 PMID:41385096 "[{""id"":""uuid:49834357-d065-4fe1-896e-83a815265766"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:269d5d96-5d5b-4637-833c-e7695a3cd358"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Atropine Sulfate Injection, USP, may be given parenterally as a pre-anesthetic medication in surgical patients to reduce salivation and bronchial secretions. It may also be used to suppress vagal activity associated with the use of halogenated hydrocarbons during inhalation anesthesia and reflex excitation arising from mechanical stimulation during surgery. The antispasmodic action of atropine is useful in pylorospasm and other spastic conditions of the gastrointestinal tract. For ureteral and biliary colic, atropine concomitantly with morphine may be indicated. Atropine relaxes the upper GI tract and colon during hypotonic radiography. In poisoning by the organic phosphate cholinesterase inhibitors found in certain insecticides and by chemical warfare nerve gases, large doses of atropine relieve the muscarine-like symptoms and some of the central nervous system manifestations. It is also used as an antidote for mushroom poisoning due to muscarine in certain species such as Amanita muscaria. uuid:989d6d24-c69a-4bb6-96d4-ce596c104574 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16684 biolink:treats EFO:0010581 PMID:41385096 "[{""id"":""uuid:c0d8669b-598b-4ddf-ba68-90ac8fc2ba4e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a4b50367-6bba-411b-9b4c-dad308bd1da2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Atropine Sulfate Injection, USP, may be given parenterally as a pre-anesthetic medication in surgical patients to reduce salivation and bronchial secretions. It may also be used to suppress vagal activity associated with the use of halogenated hydrocarbons during inhalation anesthesia and reflex excitation arising from mechanical stimulation during surgery. The antispasmodic action of atropine is useful in pylorospasm and other spastic conditions of the gastrointestinal tract. For ureteral and biliary colic, atropine concomitantly with morphine may be indicated. Atropine relaxes the upper GI tract and colon during hypotonic radiography. In poisoning by the organic phosphate cholinesterase inhibitors found in certain insecticides and by chemical warfare nerve gases, large doses of atropine relieve the muscarine-like symptoms and some of the central nervous system manifestations. It is also used as an antidote for mushroom poisoning due to muscarine in certain species such as Amanita muscaria. uuid:34099a4f-c665-4628-9566-b1d7217ce8c9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49544 biolink:treats UMLS:C0268093 PMID:41385096 "[{""id"":""uuid:28dae94b-6f9b-4fee-bda3-f72dc0f6a651"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5f274136-4b90-49b7-9f11-3e7f05ab12c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Chromium 4 mcg/mL (Chromic Chloride Injection, USP) is indicated for use as a supplement to intravenous solutions given for TPN. Administration helps to maintain chromium serum levels and to prevent depletion of endogenous stores and subsequent deficiency symptoms. uuid:35a47b66-cf76-4db7-98c0-bb363371a70b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0004126 PMID:41385096 "[{""id"":""uuid:1efb44a4-1ac9-45f2-b39b-3656a92cff75"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0d4700aa-f140-4865-a71f-ba48e36f5f92"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] A. For Intramuscular Administration When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of Methylprednisolone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of: leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. B. For Intra-articular Or Soft Tissue Administration (See WARNINGS .) Methylprednisolone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. C. For Intralesional Administration Methylprednisolone Acetate Injectable Suspension is indicated for intralesional use in alopecia areata, discoid lupus erythematosus; keloids, localized hypertrophic, infiltrated inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis) and psoriatic plaques; necrobiosis lipoidica diabeticorum. Methylprednisolone Acetate Injectable Suspension also may be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:abceb032-f1c0-4bf3-9b18-70a7b76ca92a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0005340 PMID:41385096 "[{""id"":""uuid:92d4b5a8-b290-490d-af37-7b290a89df0d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7ed3c43e-c9cc-4eed-9825-4a37a0135804"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] A. For Intramuscular Administration When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of Methylprednisolone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of: leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. B. For Intra-articular Or Soft Tissue Administration (See WARNINGS .) Methylprednisolone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. C. For Intralesional Administration Methylprednisolone Acetate Injectable Suspension is indicated for intralesional use in alopecia areata, discoid lupus erythematosus; keloids, localized hypertrophic, infiltrated inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis) and psoriatic plaques; necrobiosis lipoidica diabeticorum. Methylprednisolone Acetate Injectable Suspension also may be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:ba27179f-f0eb-400a-b534-cf64850af0a1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0019558 PMID:41385096 "[{""id"":""uuid:590ce5e2-eab8-4923-b20b-c7e121e67c63"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:72159a8f-45d7-4b54-b711-c967c8ebb2ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] A. For Intramuscular Administration When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of Methylprednisolone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of: leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. B. For Intra-articular Or Soft Tissue Administration (See WARNINGS .) Methylprednisolone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. C. For Intralesional Administration Methylprednisolone Acetate Injectable Suspension is indicated for intralesional use in alopecia areata, discoid lupus erythematosus; keloids, localized hypertrophic, infiltrated inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis) and psoriatic plaques; necrobiosis lipoidica diabeticorum. Methylprednisolone Acetate Injectable Suspension also may be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:d4072e61-5321-4ff2-a52e-080d7ffee337 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0005348 PMID:41385096 "[{""id"":""uuid:e811fcf3-9ae1-4712-ad92-8199fdb226c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7d39e56e-0b4b-4c5b-b5da-bf390e921463"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] A. For Intramuscular Administration When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of Methylprednisolone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of: leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. B. For Intra-articular Or Soft Tissue Administration (See WARNINGS .) Methylprednisolone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. C. For Intralesional Administration Methylprednisolone Acetate Injectable Suspension is indicated for intralesional use in alopecia areata, discoid lupus erythematosus; keloids, localized hypertrophic, infiltrated inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis) and psoriatic plaques; necrobiosis lipoidica diabeticorum. Methylprednisolone Acetate Injectable Suspension also may be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:ef95b65a-b6ef-4d29-a092-acfe1afb9faf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0006554 PMID:41385096 "[{""id"":""uuid:fba89786-8bf7-48a3-a477-b7674b0343e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:12d3654c-1252-44bc-a169-e8784b234337"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] A. For Intramuscular Administration When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of Methylprednisolone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of: leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. B. For Intra-articular Or Soft Tissue Administration (See WARNINGS .) Methylprednisolone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. C. For Intralesional Administration Methylprednisolone Acetate Injectable Suspension is indicated for intralesional use in alopecia areata, discoid lupus erythematosus; keloids, localized hypertrophic, infiltrated inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis) and psoriatic plaques; necrobiosis lipoidica diabeticorum. Methylprednisolone Acetate Injectable Suspension also may be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:4cadafe2-8771-4495-897e-8b9870060b68 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0006572 PMID:41385096 "[{""id"":""uuid:88ed8c5f-8bc3-4419-8da0-dac5fbc3171e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6d96ed91-f167-4af8-a399-77d267de22cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] A. For Intramuscular Administration When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of Methylprednisolone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of: leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. B. For Intra-articular Or Soft Tissue Administration (See WARNINGS .) Methylprednisolone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. C. For Intralesional Administration Methylprednisolone Acetate Injectable Suspension is indicated for intralesional use in alopecia areata, discoid lupus erythematosus; keloids, localized hypertrophic, infiltrated inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis) and psoriatic plaques; necrobiosis lipoidica diabeticorum. Methylprednisolone Acetate Injectable Suspension also may be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:319c8a1f-708c-4602-ab47-0c482b730f3e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0006585 PMID:41385096 "[{""id"":""uuid:02dedc45-5163-4df8-9232-24e407f94a6d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bc50a716-7646-4846-bc78-e53b02f27b52"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] A. For Intramuscular Administration When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of Methylprednisolone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of: leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. B. For Intra-articular Or Soft Tissue Administration (See WARNINGS .) Methylprednisolone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. C. For Intralesional Administration Methylprednisolone Acetate Injectable Suspension is indicated for intralesional use in alopecia areata, discoid lupus erythematosus; keloids, localized hypertrophic, infiltrated inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis) and psoriatic plaques; necrobiosis lipoidica diabeticorum. Methylprednisolone Acetate Injectable Suspension also may be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:70ec4294-66cc-4e60-837e-c6aaf77fcd86 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats UMLS:C0392445 PMID:41385096 "[{""id"":""uuid:47c11dc3-c6db-4409-b77a-84f73fa8cff5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7c8af884-5219-4361-b1b3-2e54ce435191"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] A. For Intramuscular Administration When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of Methylprednisolone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of: leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. B. For Intra-articular Or Soft Tissue Administration (See WARNINGS .) Methylprednisolone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. C. For Intralesional Administration Methylprednisolone Acetate Injectable Suspension is indicated for intralesional use in alopecia areata, discoid lupus erythematosus; keloids, localized hypertrophic, infiltrated inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis) and psoriatic plaques; necrobiosis lipoidica diabeticorum. Methylprednisolone Acetate Injectable Suspension also may be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:c4b6b3df-f208-4ba8-9275-8b80e611e248 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7459 biolink:treats UMLS:C0572061 PMID:41385096 "[{""id"":""uuid:44371fa3-2f1e-41e3-81a9-cd547a0455d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:492b4454-476d-4624-aeba-d2ac2e0ae931"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EVZIO is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression in adults and pediatric patients. EVZIO is intended for immediate administration as emergency therapy in settings where opioids may be present. EVZIO is not a substitute for emergency medical care. uuid:9d1d5df1-809b-4521-bff6-0a381dd1b3ce biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6129 biolink:treats NCIT:C34887 PMID:41385096 "[{""id"":""uuid:e1a5b13e-a0b2-4589-a45d-7767555a621c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:487caaa2-f475-4f72-b23c-ae217487b4c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks ketorolac tromethamine and other treatment options before deciding to use ketorolac. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS). Acute Pain in Adult Patients Ketorolac tromethamine is indicated for the short-term (≤5 days) management of moderately severe acute pain that requires analgesia at the opioid level, usually in a postoperative setting. Therapy should always be initiated with IV or IM dosing of ketorolac tromethamine and oral ketorolac tromethamine is to be used only as continuation treatment, if necessary. The total combined duration of use of ketorolac tromethamine injection and oral ketorolac tromethamine is not to exceed 5 days of use because of the potential of increasing the frequency and severity of adverse reactions associated with the recommended doses (see WARNINGS, PRECAUTIONS, DOSAGE AND ADMINISTRATION, and ADVERSE REACTIONS). Patients should be switched to alternative analgesics as soon as possible, but ketorolac tromethamine therapy is not to exceed 5 days. (see DOSAGE AND ADMINISTRATION -Pharmaceutical Information for Ketorolac Tromethamine Injection). uuid:83f364b5-6f79-4090-90c1-5305eaea69ff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68554 biolink:treats MONDO:0859316 PMID:41385096 "[{""id"":""uuid:fb22261d-ccf1-4ff6-965d-0db11ef2057c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:91da52b8-6c0d-4aff-a0c4-165283f24f58"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FERRIPROX ® is indicated for the treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate. Approval is based on a reduction in serum ferritin levels. There are no controlled trials demonstrating a direct treatment benefit, such as improvement in disease-related symptoms, functioning, or increased survival [see Clinical Studies (14) ] . Limitations of Use Safety and effectiveness have not been established for the treatment of transfusional iron overload in patients with other chronic anemias. uuid:890b3e7e-4c87-4166-a27a-cd6ab580c682 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9570 biolink:treats MONDO:0004988 PMID:41385096 "[{""id"":""uuid:5ae01e90-e54d-4478-924e-87f0ca8d42a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:21404f74-aebb-4d1d-95a7-88c6d25b2d70"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Thiotepa for injection is an alkylating drug indicated: For treatment of adenocarcinoma of the breast or ovary. ( 1.2 ) For controlling intracavitary effusions secondary to diffuse or localized neoplastic diseases of various serosal cavities. ( 1.3 ) For treatment of superficial papillary carcinoma of the urinary bladder. ( 1.4 ) uuid:79e16a06-fb33-4cfc-935b-9db2d3c64560 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9570 biolink:treats MONDO:0002752 PMID:41385096 "[{""id"":""uuid:b0d2ce45-b647-4dd6-a39e-71dd2b2e97e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b04796fd-9ece-469a-8e84-8a766a2cffdd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Thiotepa for injection is an alkylating drug indicated: For treatment of adenocarcinoma of the breast or ovary. ( 1.2 ) For controlling intracavitary effusions secondary to diffuse or localized neoplastic diseases of various serosal cavities. ( 1.3 ) For treatment of superficial papillary carcinoma of the urinary bladder. ( 1.4 ) uuid:cc13a343-5f99-484e-a5be-3cced0cbe550 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9570 biolink:treats MONDO:0004200 PMID:41385096 "[{""id"":""uuid:62c2c2fd-1e6d-4187-a4a3-38c52689e611"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2f0b5e41-a772-46d9-9b2b-0a2d35738256"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Thiotepa for injection is an alkylating drug indicated: For treatment of adenocarcinoma of the breast or ovary. ( 1.2 ) For controlling intracavitary effusions secondary to diffuse or localized neoplastic diseases of various serosal cavities. ( 1.3 ) For treatment of superficial papillary carcinoma of the urinary bladder. ( 1.4 ) uuid:70317a17-2c0d-49fc-93d3-ecfc942affb8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:140296 biolink:treats MONDO:0001609 PMID:41385096 "[{""id"":""uuid:723ee77a-033d-42e8-b156-bd88fe2d0c35"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:16b5ef4a-b960-4755-b1a4-128e1d75a9b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension Quinapril tablets, USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with quinapril tablets, USP. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Quinapril tablets, USP may be used alone or in combination with thiazide diuretics . Heart Failure Quinapril tablets, USP are indicated in the management of heart failure as adjunctive therapy when added to conventional therapy including diuretics and/or digitalis. In using quinapril tablets, USP consideration should be given to the fact that another ACE inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease. Available data are insufficient to show that quinapril tablets, USP do not have a similar risk (see WARNINGS ). Angioedema in Black Patients Black patients receiving ACE inhibitor monotherapy have been reported to have a higher incidence of angioedema compared to non-blacks. It should also be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. uuid:8dd5d2a7-7a64-462d-8239-dfc8832951a0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:140296 biolink:treats MONDO:0010481 PMID:41385096 "[{""id"":""uuid:876e9efe-635c-4f19-8f40-447a40c4f0fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4b74a1c2-4da1-41c6-9cb8-5b765707b50d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension Quinapril tablets, USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with quinapril tablets, USP. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Quinapril tablets, USP may be used alone or in combination with thiazide diuretics . Heart Failure Quinapril tablets, USP are indicated in the management of heart failure as adjunctive therapy when added to conventional therapy including diuretics and/or digitalis. In using quinapril tablets, USP consideration should be given to the fact that another ACE inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease. Available data are insufficient to show that quinapril tablets, USP do not have a similar risk (see WARNINGS ). Angioedema in Black Patients Black patients receiving ACE inhibitor monotherapy have been reported to have a higher incidence of angioedema compared to non-blacks. It should also be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. uuid:55566eca-55a0-4f98-b99d-e118bc3e92ea biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4450 biolink:treats MONDO:0010191 PMID:41385096 "[{""id"":""uuid:ee13e0be-2a26-4c6b-8591-e6b6c3cd77dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7720615d-2646-4f07-afac-b6981f0efb63"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hemophilia A: Desmopressin Acetate Injection 4 mcg/mL is indicated for patients with hemophilia A with factor VIII coagulant activity levels greater than 5%. Desmopressin Acetate Injection will often maintain hemostasis in patients with hemophilia A during surgical procedures and postoperatively when administered 30 minutes prior to scheduled procedure. Desmopressin Acetate Injection will also stop bleeding in hemophilia A patients with episodes of spontaneous or trauma-induced injuries such as hemarthroses, intramuscular hematomas or mucosal bleeding. Desmopressin Acetate Injection is not indicated for the treatment of hemophilia A with factor VIII coagulant activity levels equal to or less than 5%, or for the treatment of hemophilia B, or in patients who have factor VIII antibodies. In certain clinical situations, it may be justified to try Desmopressin Acetate Injection in patients with factor VIII levels between 2% to 5%; however, these patients should be carefully monitored. von Willebrands Disease (Type I): Desmopressin Acetate Injection 4 mcg/mL is indicated for patients with mild to moderate classic von Willebrands disease (Type I) with factor VIII levels greater than 5%. Desmopressin Acetate Injection will often maintain hemostasis in patients with mild to moderate von Willebrands disease during surgical procedures and postoperatively when administered 30 minutes prior to the scheduled procedure. Desmopressin Acetate Injection will usually stop bleeding in mild to moderate von Willebrands patients with episodes of spontaneous or trauma-induced injuries such as hemarthroses, intramuscular hematomas or mucosal bleeding. Those von Willebrands disease patients who are least likely to respond are those with severe homozygous von Willebrands disease with factor VIII coagulant activity and factor VIII von Willebrand factor antigen levels less than 1%. Other patients may respond in a variable fashion depending on the type of molecular defect they have. Bleeding time and factor VIII coagulant activity, ristocetin cofactor activity, and von Willebrand factor antigen should be checked during administration of Desmopressin Acetate Injection to ensure that adequate levels are being achieved. Desmopressin Acetate Injection is not indicated for the treatment of severe classic von Willebrands disease (Type I) and when there is evidence of an abnormal molecular form of factor VIII antigen. (See WARNINGS . ) Diabetes Insipidus: Desmopressin Acetate Injection 4 mcg/mL is indicated as antidiuretic replacement therapy in the management of central (cranial) diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. Desmopressin Acetate Injection is ineffective for the treatment of nephrogenic diabetes insipidus. Desmopressin Acetate Injection is also available as an intranasal preparation. However, this means of delivery can be compromised by a variety of factors that can make nasal insufflation ineffective or inappropriate. These include poor intranasal absorption, nasal congestion and blockage, nasal discharge, atrophy of nasal mucosa, and severe atrophic rhinitis. Intranasal delivery may be inappropriate where there is an impaired level of consciousness. In addition, cranial surgical procedures, such as transsphenoidal hypophysectomy, create situations where an alternative route of administration is needed as in cases of nasal packing or recovery from surgery. uuid:6fb2786e-4bad-44d0-a109-30d6485a4bc2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49470 biolink:treats HP:0000225 PMID:41385096 "[{""id"":""uuid:ccabb648-951d-4796-a993-eb8a5ee40ffe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fefcf501-9d8e-44b5-9e34-45ae4f37a4a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nephro-Stat is a topical astringent solution of Aluminum Chloride. Gingival retraction can be achieved using a plain gingival retraction cord moistened with Nephro-Stat. Stops gingival bleeding fast. If you should inadvertently damage the gingival margin during tooth preparation or while placing a strip, a band or a cervical matrix, moisten the area with Nephro-Stat which will control and stop bleeding quickly. Nephro-Stat contains no epinephrine. The use of vasoconstrictors for gingival retractions and bleeding is potentially dangerous and should be avoided. A plain gingival retraction cord can be dipped in Nephro-Stat solution and then placed into the gingival sulcus for its hemostatic action. uuid:6e4573cb-d307-4076-8af6-9d57bdb0df49 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4975 biolink:treats MONDO:0004247 PMID:41385096 "[{""id"":""uuid:749b00d1-fe5c-43dc-aa72-1ae452d98ba1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8567c534-7b7c-454d-ab34-8ed292b5e8ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Famotidine for oral suspension is indicated in adults for the treatment of: active duodenal ulcer (DU). active gastric ulcer (GU). symptomatic nonerosive gastroesophageal reflux disease (GERD). erosive esophagitis due to GERD, diagnosed by biopsy. treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). reduction of the risk of duodenal ulcer recurrence. Famotidine for oral suspension is indicated in pediatric patients 1 year of age and older for the treatment of: peptic ulcer disease. GERD with or without esophagitis and ulcerations. Famotidine for oral suspension is indicated in pediatric patients from birth to less than 1 year of age for the treatment of: GERD. uuid:6b289fd2-bc29-42d8-a075-ce3b7f00fe48 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:37943 biolink:treats MONDO:0005141 PMID:41385096 "[{""id"":""uuid:21214311-0278-47a6-a9c4-1a8274c312db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c4d101f5-3696-4abc-9bd9-69323c9aa16f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:b63ee3cf-e441-42d0-ba88-cbe39fafc2f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Colistimethate for Injection, USP is indicated for the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli. It is particularly indicated when the infection is caused by sensitive strains of Pseudomonas aeruginosa . This antibiotic is not indicated for infections due to Proteus or Neisseria . Colistimethate for Injection, USP has proven clinically effective in treatment of infections due to the following gram-negative organisms: Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa . Colistimethate for Injection, USP may be used to initiate therapy in serious infections that are suspected to be due to gram-negative organisms and in the treatment of infections due to susceptible gram-negative pathogenic bacilli. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Colistimethate for Injection, USP and other antibacterial drugs, Colistimethate for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.|[PMDA] A drug with a new route of administration indicated for the treatment of infections caused by colistin- sensitive Escherichia coli, Citrobacter, Klebsiella, Enterobacter, Pseudomonas aeruginosa, and Acinetobacter (limited to the strains resistant to other antimicrobial drugs). [Orphan drug] uuid:034fb932-c1b8-4cde-95c1-77f27f4e22d1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:37943 biolink:treats MONDO:0020920 PMID:41385096 "[{""id"":""uuid:875113c6-6e3b-4921-97d1-0bb1d7d2fdd4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:77d37fbb-1a22-4e83-ba42-09a943f3262f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:559eda0e-459a-4143-b259-78480fabec2b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Colistimethate for Injection, USP is indicated for the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli. It is particularly indicated when the infection is caused by sensitive strains of Pseudomonas aeruginosa . This antibiotic is not indicated for infections due to Proteus or Neisseria . Colistimethate for Injection, USP has proven clinically effective in treatment of infections due to the following gram-negative organisms: Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa . Colistimethate for Injection, USP may be used to initiate therapy in serious infections that are suspected to be due to gram-negative organisms and in the treatment of infections due to susceptible gram-negative pathogenic bacilli. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Colistimethate for Injection, USP and other antibacterial drugs, Colistimethate for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.|[PMDA] A drug with a new route of administration indicated for the treatment of infections caused by colistin- sensitive Escherichia coli, Citrobacter, Klebsiella, Enterobacter, Pseudomonas aeruginosa, and Acinetobacter (limited to the strains resistant to other antimicrobial drugs). [Orphan drug] uuid:20214888-a7af-4060-bcbe-bc22de6a2299 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:37943 biolink:treats MONDO:0030602 PMID:41385096 "[{""id"":""uuid:c27ad9c1-6583-4ea2-90bc-ca46e7178eb2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1f5d66c0-c7c8-4ea1-8dad-3f0c1d054f68"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Colistimethate for Injection, USP is indicated for the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli. It is particularly indicated when the infection is caused by sensitive strains of Pseudomonas aeruginosa . This antibiotic is not indicated for infections due to Proteus or Neisseria . Colistimethate for Injection, USP has proven clinically effective in treatment of infections due to the following gram-negative organisms: Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa . Colistimethate for Injection, USP may be used to initiate therapy in serious infections that are suspected to be due to gram-negative organisms and in the treatment of infections due to susceptible gram-negative pathogenic bacilli. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Colistimethate for Injection, USP and other antibacterial drugs, Colistimethate for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:44f16e71-c916-442d-9e92-593dfd451abe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63580 biolink:treats MONDO:0001577 PMID:41385096 "[{""id"":""uuid:fd5a6780-aea7-4510-bf0a-777f45316c17"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8760c17e-e63a-4447-b01e-8ecca982aea6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ribavirin for Inhalation Solution, USP is indicated for the treatment of hospitalized infants and young children with severe lower respiratory tract infections due to RSV. Treatment early in the course of severe lower respiratory tract infection may be necessary to achieve efficacy. Only severe RSV lower respiratory tract infection should be treated with Ribavirin for Inhalation Solution, USP. The vast majority of infants and children with RSV infection have disease that is mild, self-limited, and does not require hospitalization or antiviral treatment. Many children with mild lower respiratory tract involvement will require shorter hospitalization than would be required for a full course of Ribavirin for Inhalation Solution, USP aerosol (3 to 7 days) and should not be treated with the drug. Thus the decision to treat with Ribavirin for Inhalation Solution, USP should be based on the severity of the RSV infection. The presence of an underlying condition such as prematurity, immunosuppression or cardiopulmonary disease may increase the severity of clinical manifestations and complications of RSV infection. Use of aerosolized Ribavirin for Inhalation Solution, USP in patients requiring mechanical ventilator assistance should be undertaken only by physicians and support staff familiar with this mode of administration and the specific ventilator being used (see WARNINGS and DOSAGE AND ADMINISTRATION ). uuid:e8ad1082-7000-49c4-a431-60187b820198 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:310870 biolink:treats MONDO:0005480 PMID:41385096 "[{""id"":""uuid:09b9e0f2-3c35-48b9-a85e-c77495a99a60"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5d5ff7f8-1f96-4e59-a051-b01e7eb1bde7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] INDICATIONS AND USAGE Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; infantile eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis, bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); moniliasis, intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:4cf2f5fa-fa19-4b54-8464-0ad844c66f4f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:310870 biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:6c03414f-15bc-41e2-a892-19abac842c2a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2faf6235-940b-48b3-ac4e-e270412ed9fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] INDICATIONS AND USAGE Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; infantile eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis, bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); moniliasis, intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:c7a98c37-201d-4375-b546-859ebb33e623 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:310870 biolink:treats MONDO:0002406 PMID:41385096 "[{""id"":""uuid:d13f247e-ac16-4f3a-a382-239d634e6162"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:44d21909-b1eb-4185-a0e7-3443433eb7bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] INDICATIONS AND USAGE Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; infantile eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis, bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); moniliasis, intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:a0b47c1b-de34-4433-a193-e85c4c770572 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:310870 biolink:treats HP:0033120 PMID:41385096 "[{""id"":""uuid:f656c491-956c-4b60-af6b-982fe9969af0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c2a24da0-b21d-4912-8adf-84494dfc7e8e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] INDICATIONS AND USAGE Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; infantile eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis, bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); moniliasis, intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:3f8d5582-e1e6-4ce0-a22e-e7f81b7912ba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:310870 biolink:treats HP:0033564 PMID:41385096 "[{""id"":""uuid:e2fcb1fc-1840-4c1c-90fc-75c09c569606"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bb2ea0b8-4c0e-434b-b1b8-c03abbdf56f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] INDICATIONS AND USAGE Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; infantile eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis, bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); moniliasis, intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:f0925ce4-9d67-47c1-8e19-9055f2585c5f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:310870 biolink:treats MONDO:0002922 PMID:41385096 "[{""id"":""uuid:299b0b85-8102-40c8-a14b-e63c1d47d993"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c8dccb08-00c0-4156-882d-641b420b7745"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] INDICATIONS AND USAGE Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; infantile eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis, bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); moniliasis, intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:6091c3a1-24f1-4e48-bc1d-3119939eb5a5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:310870 biolink:treats MONDO:0004795 PMID:41385096 "[{""id"":""uuid:8c5a1ed9-8fe9-4491-966a-e6e44947147b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a8cb799d-3270-4545-961b-8a3ce2470d32"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] INDICATIONS AND USAGE Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; infantile eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis, bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); moniliasis, intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:8b3484c7-9f41-4792-8958-6c354564b802 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:310870 biolink:treats UMLS:C0406297 PMID:41385096 "[{""id"":""uuid:19b2cef1-6a62-44bb-8f0d-9fb4397c541f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5797add0-aa1e-407f-b9f9-ff2b3e444262"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] INDICATIONS AND USAGE Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; infantile eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis, bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); moniliasis, intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:ca416db8-cb20-4003-959b-76aad2b95d41 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:310870 biolink:treats MONDO:0006585 PMID:41385096 "[{""id"":""uuid:70bf8436-0b28-43c4-80db-2fcd307667a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:74f15a03-cdc6-4fb4-b356-8e5c85dc3513"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] INDICATIONS AND USAGE Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; infantile eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis, bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); moniliasis, intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:44f3c7a6-25ca-43bb-9058-e4bfddb22828 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:310870 biolink:treats UMLS:C0149922 PMID:41385096 "[{""id"":""uuid:3d17bc47-5ece-4430-b1e3-4382b3ad4171"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:78aab642-bf24-41a7-adcc-df97385cb5a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] INDICATIONS AND USAGE Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; infantile eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis, bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); moniliasis, intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:892405ee-1360-47f0-bdbd-2c768f0e774a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:310870 biolink:treats UMLS:C0003107 PMID:41385096 "[{""id"":""uuid:5bc5cd71-c592-460f-ba1c-523f10360cca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:489b684a-b243-4bf9-b600-4507828c704d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] INDICATIONS AND USAGE Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; infantile eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis, bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); moniliasis, intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:dea76dc6-9d0c-43e6-b26e-b35c79b2b017 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:310870 biolink:treats MONDO:0006552 PMID:41385096 "[{""id"":""uuid:d89188bb-0df4-4a7d-a661-68b5090cc28e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7387c0fc-8097-423a-965a-d5c5ce7c5943"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] INDICATIONS AND USAGE Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; infantile eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis, bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); moniliasis, intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:44280cfd-75c6-406d-b9bc-3056ac04172d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:310870 biolink:treats MONDO:0002967 PMID:41385096 "[{""id"":""uuid:2814194c-1bed-42a3-bf77-ad12f2f00959"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:539eb9bb-6284-4871-9eff-786601c01863"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] INDICATIONS AND USAGE Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; infantile eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis, bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); moniliasis, intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:83a46512-282f-481c-9e58-507c551453c6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:310870 biolink:treats MONDO:0001405 PMID:41385096 "[{""id"":""uuid:3ddecbc7-011f-4115-ae48-00b0c9cf0e88"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:400e189d-17e0-47b5-9f5d-c041dc92bfdf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] INDICATIONS AND USAGE Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; infantile eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis, bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); moniliasis, intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:9d9e7264-6dc0-4073-acf6-081df5a01fca biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:310870 biolink:treats MONDO:0001461 PMID:41385096 "[{""id"":""uuid:2c128112-7a00-4026-a8dc-36ce4f0d712a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:646d125c-c026-476c-bd83-e7f610695244"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] INDICATIONS AND USAGE Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; infantile eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis, bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); moniliasis, intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:d7c11465-b7b8-4f5b-bb11-6d32e2f6b85a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:310870 biolink:treats MONDO:0005984 PMID:41385096 "[{""id"":""uuid:f7431fd6-d982-439f-9aef-0cf1267c2e97"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:650e819e-65fb-4cc4-9be9-117ccdbe9f97"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] INDICATIONS AND USAGE Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; infantile eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis, bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); moniliasis, intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:c0fab1a7-06b2-4252-ad55-747ea14d9234 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:310870 biolink:treats UMLS:C0343886 PMID:41385096 "[{""id"":""uuid:a50095d2-2cec-4b68-bc45-b3080a3a9b3f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3a976c3f-f1c3-46c9-acfa-cc69959861bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] INDICATIONS AND USAGE Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; infantile eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis, bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); moniliasis, intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:7356f35f-fffb-4f25-8ba3-9d7dbc629c12 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:310870 biolink:treats MONDO:0021340 PMID:41385096 "[{""id"":""uuid:4aba4ced-3180-4af8-808f-473618a06efb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1dac2a16-2aba-48e3-9753-7c4a40756134"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] INDICATIONS AND USAGE Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; infantile eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis, bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); moniliasis, intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:ecac862a-26e6-4f41-8fc6-09703dedb2cc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1156610 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:3f8ab43d-b8c8-4aa7-939f-03b7ec371ec7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bc206dda-ea9f-43d4-a589-4ad1760b5e2d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ATACAND HCT is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with ATACAND HCT. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. This fixed dose combination is not indicated for initial therapy (see DOSAGE AND ADMINISTRATION ). uuid:32040296-293d-4f2a-bd16-18529f8cf1cd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1156610 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:d152cf5f-57fb-4470-947a-c191daa1f6d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5bec7820-486d-410c-9541-c4eed1104c7d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ATACAND HCT is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with ATACAND HCT. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. This fixed dose combination is not indicated for initial therapy (see DOSAGE AND ADMINISTRATION ). uuid:e8746add-6eb2-4412-8a69-55902c41fe13 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1156610 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:be012771-cd6c-4606-91f8-d3c493936648"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1355f93e-d097-4fb9-8dbd-98721a3a93e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ATACAND HCT is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with ATACAND HCT. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. This fixed dose combination is not indicated for initial therapy (see DOSAGE AND ADMINISTRATION ). uuid:f38a9f58-e42b-4ac7-b0db-2ddb89108976 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1156610 biolink:treats MONDO:0005016 PMID:41385096 "[{""id"":""uuid:74187d9f-9dd7-48ab-affb-8f7c1ac5265f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:90313f90-c3d5-4868-be97-52177fb12734"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ATACAND HCT is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with ATACAND HCT. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. This fixed dose combination is not indicated for initial therapy (see DOSAGE AND ADMINISTRATION ). uuid:8c6b6e94-3825-4e6f-9492-67acc1769165 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1156610 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:81d4011a-abec-41da-96c6-0431d63d7410"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cd6ca3b5-9ac5-442b-bb55-37ceb780930d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ATACAND HCT is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with ATACAND HCT. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. This fixed dose combination is not indicated for initial therapy (see DOSAGE AND ADMINISTRATION ). uuid:28ee4e8a-cd08-4530-b38d-9384af7b8d80 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1156610 biolink:treats HP:0001681 PMID:41385096 "[{""id"":""uuid:0605dc72-1de8-4652-ac93-00b27eb2809f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6edff068-a2ff-4609-af0a-4b450ba4ae9c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ATACAND HCT is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with ATACAND HCT. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. This fixed dose combination is not indicated for initial therapy (see DOSAGE AND ADMINISTRATION ). uuid:ec1118d2-426f-4689-a3e8-9a3a1cfbbd3f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1156610 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:df6a13fc-e40d-4d39-946c-5608b05c40ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ddd9a98e-cdda-4777-8e8b-cf5a9af7f8c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ATACAND HCT is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with ATACAND HCT. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. This fixed dose combination is not indicated for initial therapy (see DOSAGE AND ADMINISTRATION ). uuid:90fe11d6-8424-4477-b7aa-3de9bfcb1315 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15544 biolink:treats MONDO:0009931 PMID:41385096 "[{""id"":""uuid:33d1a410-d7f4-4cb9-841c-05f250f1780a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:533d7af4-04c1-4099-b745-696fd0d8cbc3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PROSTIN VR PEDIATRIC Sterile Solution is indicated for palliative, not definitive, therapy to temporarily maintain the patency of the ductus arteriosus until corrective or palliative surgery can be performed in neonates who have congenital heart defects and who depend upon the patent ductus for survival. Such congenital heart defects include pulmonary atresia, pulmonary stenosis, tricuspid atresia, tetralogy of Fallot, interruption of the aortic arch, coarctation of the aorta, or transposition of the great vessels with or without other defects. In infants with restricted pulmonary blood flow, the increase in blood oxygenation is inversely proportional to pretreatment pO 2 values; that is, patients with low pO 2 values respond best, and patients with pO 2 values of 40 torr or more usually have little response. PROSTIN VR PEDIATRIC should be administered only by trained personnel in facilities that provide pediatric intensive care. uuid:8c9135e2-1eac-4fba-8e33-db64406996e3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15544 biolink:treats MONDO:0009938 PMID:41385096 "[{""id"":""uuid:cee6f3e5-7481-4d06-8239-8a566260f50d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f9ef7409-63c7-40ca-af7c-9dd9a9e26e77"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PROSTIN VR PEDIATRIC Sterile Solution is indicated for palliative, not definitive, therapy to temporarily maintain the patency of the ductus arteriosus until corrective or palliative surgery can be performed in neonates who have congenital heart defects and who depend upon the patent ductus for survival. Such congenital heart defects include pulmonary atresia, pulmonary stenosis, tricuspid atresia, tetralogy of Fallot, interruption of the aortic arch, coarctation of the aorta, or transposition of the great vessels with or without other defects. In infants with restricted pulmonary blood flow, the increase in blood oxygenation is inversely proportional to pretreatment pO 2 values; that is, patients with low pO 2 values respond best, and patients with pO 2 values of 40 torr or more usually have little response. PROSTIN VR PEDIATRIC should be administered only by trained personnel in facilities that provide pediatric intensive care. uuid:484b832b-2046-4b86-a859-f64fbee13535 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15544 biolink:treats MONDO:0011514 PMID:41385096 "[{""id"":""uuid:dba83817-afc7-4353-a90c-134e4054abbd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:23c10568-0776-489c-8fb8-20a66cae8348"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PROSTIN VR PEDIATRIC Sterile Solution is indicated for palliative, not definitive, therapy to temporarily maintain the patency of the ductus arteriosus until corrective or palliative surgery can be performed in neonates who have congenital heart defects and who depend upon the patent ductus for survival. Such congenital heart defects include pulmonary atresia, pulmonary stenosis, tricuspid atresia, tetralogy of Fallot, interruption of the aortic arch, coarctation of the aorta, or transposition of the great vessels with or without other defects. In infants with restricted pulmonary blood flow, the increase in blood oxygenation is inversely proportional to pretreatment pO 2 values; that is, patients with low pO 2 values respond best, and patients with pO 2 values of 40 torr or more usually have little response. PROSTIN VR PEDIATRIC should be administered only by trained personnel in facilities that provide pediatric intensive care. uuid:22ca5038-a4d3-45b9-bd8d-5135e44c24b9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15544 biolink:treats MONDO:0008542 PMID:41385096 "[{""id"":""uuid:108c72ad-ec32-4b39-ae27-8c307904e155"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9d551e15-1a26-478a-afde-c58d8e809b98"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PROSTIN VR PEDIATRIC Sterile Solution is indicated for palliative, not definitive, therapy to temporarily maintain the patency of the ductus arteriosus until corrective or palliative surgery can be performed in neonates who have congenital heart defects and who depend upon the patent ductus for survival. Such congenital heart defects include pulmonary atresia, pulmonary stenosis, tricuspid atresia, tetralogy of Fallot, interruption of the aortic arch, coarctation of the aorta, or transposition of the great vessels with or without other defects. In infants with restricted pulmonary blood flow, the increase in blood oxygenation is inversely proportional to pretreatment pO 2 values; that is, patients with low pO 2 values respond best, and patients with pO 2 values of 40 torr or more usually have little response. PROSTIN VR PEDIATRIC should be administered only by trained personnel in facilities that provide pediatric intensive care. uuid:91f06259-9802-4cbc-b2e4-0ef4567ee561 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15544 biolink:treats MONDO:0009010 PMID:41385096 "[{""id"":""uuid:0d095af4-0252-4f28-8bf9-a105927c4307"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7bc96cf1-4876-46f5-918b-7829145baba4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PROSTIN VR PEDIATRIC Sterile Solution is indicated for palliative, not definitive, therapy to temporarily maintain the patency of the ductus arteriosus until corrective or palliative surgery can be performed in neonates who have congenital heart defects and who depend upon the patent ductus for survival. Such congenital heart defects include pulmonary atresia, pulmonary stenosis, tricuspid atresia, tetralogy of Fallot, interruption of the aortic arch, coarctation of the aorta, or transposition of the great vessels with or without other defects. In infants with restricted pulmonary blood flow, the increase in blood oxygenation is inversely proportional to pretreatment pO 2 values; that is, patients with low pO 2 values respond best, and patients with pO 2 values of 40 torr or more usually have little response. PROSTIN VR PEDIATRIC should be administered only by trained personnel in facilities that provide pediatric intensive care. uuid:90a5d0cd-7e2a-44bb-8ac6-76e9ca235b7e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15544 biolink:treats MONDO:0007345 PMID:41385096 "[{""id"":""uuid:9da12d39-3f76-4f18-8e31-df97d310ff77"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1867144b-a33b-455d-8f98-18a9421980f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PROSTIN VR PEDIATRIC Sterile Solution is indicated for palliative, not definitive, therapy to temporarily maintain the patency of the ductus arteriosus until corrective or palliative surgery can be performed in neonates who have congenital heart defects and who depend upon the patent ductus for survival. Such congenital heart defects include pulmonary atresia, pulmonary stenosis, tricuspid atresia, tetralogy of Fallot, interruption of the aortic arch, coarctation of the aorta, or transposition of the great vessels with or without other defects. In infants with restricted pulmonary blood flow, the increase in blood oxygenation is inversely proportional to pretreatment pO 2 values; that is, patients with low pO 2 values respond best, and patients with pO 2 values of 40 torr or more usually have little response. PROSTIN VR PEDIATRIC should be administered only by trained personnel in facilities that provide pediatric intensive care. uuid:5ea0bd17-3b7a-4fe1-aa43-f84e465e7d99 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15544 biolink:treats MONDO:0000153 PMID:41385096 "[{""id"":""uuid:3abba549-2ed1-4cf7-a613-34f02ba2b84b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a849b83a-ee47-4ff6-be6f-399b5af81ed2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PROSTIN VR PEDIATRIC Sterile Solution is indicated for palliative, not definitive, therapy to temporarily maintain the patency of the ductus arteriosus until corrective or palliative surgery can be performed in neonates who have congenital heart defects and who depend upon the patent ductus for survival. Such congenital heart defects include pulmonary atresia, pulmonary stenosis, tricuspid atresia, tetralogy of Fallot, interruption of the aortic arch, coarctation of the aorta, or transposition of the great vessels with or without other defects. In infants with restricted pulmonary blood flow, the increase in blood oxygenation is inversely proportional to pretreatment pO 2 values; that is, patients with low pO 2 values respond best, and patients with pO 2 values of 40 torr or more usually have little response. PROSTIN VR PEDIATRIC should be administered only by trained personnel in facilities that provide pediatric intensive care. uuid:b303a022-11a2-48de-adcc-4ee0defa8ff4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18385 biolink:treats UMLS:C0342936 PMID:41385096 "[{""id"":""uuid:1e19b509-0e2c-4e2f-9365-da2a20baacbe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:06aa9e58-20b8-416b-b114-99abe9d415bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Thiamine hydrochloride injection is effective for the treatment of thiamine deficiency or beriberi whether of the dry (major symptoms related to the nervous system) or wet (major symptoms related to the cardiovascular system) variety. Thiamine hydrochloride injection should be used where rapid restoration of thiamine is necessary, as in Wernicke’s encephalopathy, infantile beriberi with acute collapse, cardiovascular disease due to thiamine deficiency, or neuritis of pregnancy if vomiting is severe. It is also indicated when giving IV dextrose to individuals with marginal thiamine status to avoid precipitation of heart failure. Thiamine hydrochloride injection is also indicated in patients with established thiamine deficiency who cannot take thiamine orally due to coexisting severe anorexia, nausea, vomiting, or malabsorption. Thiamine hydrochloride injection is not usually indicated for conditions of decreased oral intake or decreased gastrointestinal absorption, because multiple vitamins should usually be given. uuid:d13b9d2c-2e34-49ac-ac6f-a374e26416a7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18385 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:92a75381-21f9-4607-bac3-ea46f3a4d372"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ce5aa882-23e0-4fe8-ae99-117be62fbb61"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Thiamine hydrochloride injection is effective for the treatment of thiamine deficiency or beriberi whether of the dry (major symptoms related to the nervous system) or wet (major symptoms related to the cardiovascular system) variety. Thiamine hydrochloride injection should be used where rapid restoration of thiamine is necessary, as in Wernicke’s encephalopathy, infantile beriberi with acute collapse, cardiovascular disease due to thiamine deficiency, or neuritis of pregnancy if vomiting is severe. It is also indicated when giving IV dextrose to individuals with marginal thiamine status to avoid precipitation of heart failure. Thiamine hydrochloride injection is also indicated in patients with established thiamine deficiency who cannot take thiamine orally due to coexisting severe anorexia, nausea, vomiting, or malabsorption. Thiamine hydrochloride injection is not usually indicated for conditions of decreased oral intake or decreased gastrointestinal absorption, because multiple vitamins should usually be given. uuid:24ad639f-c625-48cf-bf7f-8c976f44cc78 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17334 biolink:treats MONDO:0700217 PMID:41385096 "[{""id"":""uuid:28d8f299-b83d-47a1-9781-edc18194c49e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:734139d1-624d-4170-a222-49173a1651a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Penicillin G Sodium for Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Penicillin G Sodium for Injection, USP may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below, however, once these results become available, appropriate therapy should be continued. Clinical Indication Infecting Organism Septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis Streptococcus pyogenes (group A β-hemolytic streptococcus), other β-hemolytic streptococci including groups C, H, G, L and M, Streptococcus pneumoniae and Staphylococcus species (non- penicillinase producing strains) Anthrax Bacillus anthracis Actinomycosis (cervico- facial disease and thoracic and abdominal disease) Actinomyces Israelil Botulism (adjunctive therapy to antitoxin), gas gangrene, and tetanus (adjunctive therapy to human tetanus immune globulin) Clostridium species Diphtheria (adjunctive therapy to antitoxin and prevention of the carrier state) Corynebacterium diphtheriae Erysipelothrix endocarditis Erysipelothrix rhusiopthiae Fusospirochetosis (severe infections of the oropharynx [Vincent’s], lower respiratory tract and genital area) Fusobacterium species and spirochetes Listeria infections including meningitis and endocarditis Listeria monocytogenes Pasteurella infections including bacteremia and meningitis Pasteurella multocida Haverhill fever Streptobacillus moniliformis Rat-bite fever Spirillum minus or Streptobacillus moniliformis Disseminated gonococcal infections Neisseria gonorrhoeae (penicillin-susceptible) Syphilis (congenital and neurosyphilis) Treponema pallidum Meningococcal meningitis and/or septicemia Neisseria meningitidis Gram-negative bacillary infections (bacteremias) Escherichia coli, Enterobacter aerogenes, Alcaligenes faecalis, salmonella, shigella and Proteus mirabilis, Penicillin G is not the drug of choice in the treatment of gram-negative bacillary infections. To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin G sodium and other antibacterial drugs, penicillin G sodium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. CHEBI:18208 uuid:f88a1207-ebff-44e6-8509-e7eab3e64524 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17334 biolink:treats MONDO:0005242 PMID:41385096 "[{""id"":""uuid:afd5c1a6-e289-4643-b450-5e3680752b47"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:193735b0-d607-451f-bad8-5e7a27aba0aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Penicillin G Sodium for Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Penicillin G Sodium for Injection, USP may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below, however, once these results become available, appropriate therapy should be continued. Clinical Indication Infecting Organism Septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis Streptococcus pyogenes (group A β-hemolytic streptococcus), other β-hemolytic streptococci including groups C, H, G, L and M, Streptococcus pneumoniae and Staphylococcus species (non- penicillinase producing strains) Anthrax Bacillus anthracis Actinomycosis (cervico- facial disease and thoracic and abdominal disease) Actinomyces Israelil Botulism (adjunctive therapy to antitoxin), gas gangrene, and tetanus (adjunctive therapy to human tetanus immune globulin) Clostridium species Diphtheria (adjunctive therapy to antitoxin and prevention of the carrier state) Corynebacterium diphtheriae Erysipelothrix endocarditis Erysipelothrix rhusiopthiae Fusospirochetosis (severe infections of the oropharynx [Vincent’s], lower respiratory tract and genital area) Fusobacterium species and spirochetes Listeria infections including meningitis and endocarditis Listeria monocytogenes Pasteurella infections including bacteremia and meningitis Pasteurella multocida Haverhill fever Streptobacillus moniliformis Rat-bite fever Spirillum minus or Streptobacillus moniliformis Disseminated gonococcal infections Neisseria gonorrhoeae (penicillin-susceptible) Syphilis (congenital and neurosyphilis) Treponema pallidum Meningococcal meningitis and/or septicemia Neisseria meningitidis Gram-negative bacillary infections (bacteremias) Escherichia coli, Enterobacter aerogenes, Alcaligenes faecalis, salmonella, shigella and Proteus mirabilis, Penicillin G is not the drug of choice in the treatment of gram-negative bacillary infections. To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin G sodium and other antibacterial drugs, penicillin G sodium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. CHEBI:18208 uuid:31b3b2c8-7f9c-40ca-9216-97d961196d6c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17334 biolink:treats MONDO:0005904 PMID:41385096 "[{""id"":""uuid:b3a129e2-64a1-41aa-8f68-20094cf6ffde"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b3f0d684-9416-482d-971a-90f9135c8571"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Penicillin G Sodium for Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Penicillin G Sodium for Injection, USP may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below, however, once these results become available, appropriate therapy should be continued. Clinical Indication Infecting Organism Septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis Streptococcus pyogenes (group A β-hemolytic streptococcus), other β-hemolytic streptococci including groups C, H, G, L and M, Streptococcus pneumoniae and Staphylococcus species (non- penicillinase producing strains) Anthrax Bacillus anthracis Actinomycosis (cervico- facial disease and thoracic and abdominal disease) Actinomyces Israelil Botulism (adjunctive therapy to antitoxin), gas gangrene, and tetanus (adjunctive therapy to human tetanus immune globulin) Clostridium species Diphtheria (adjunctive therapy to antitoxin and prevention of the carrier state) Corynebacterium diphtheriae Erysipelothrix endocarditis Erysipelothrix rhusiopthiae Fusospirochetosis (severe infections of the oropharynx [Vincent’s], lower respiratory tract and genital area) Fusobacterium species and spirochetes Listeria infections including meningitis and endocarditis Listeria monocytogenes Pasteurella infections including bacteremia and meningitis Pasteurella multocida Haverhill fever Streptobacillus moniliformis Rat-bite fever Spirillum minus or Streptobacillus moniliformis Disseminated gonococcal infections Neisseria gonorrhoeae (penicillin-susceptible) Syphilis (congenital and neurosyphilis) Treponema pallidum Meningococcal meningitis and/or septicemia Neisseria meningitidis Gram-negative bacillary infections (bacteremias) Escherichia coli, Enterobacter aerogenes, Alcaligenes faecalis, salmonella, shigella and Proteus mirabilis, Penicillin G is not the drug of choice in the treatment of gram-negative bacillary infections. To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin G sodium and other antibacterial drugs, penicillin G sodium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. CHEBI:18208 uuid:2e5bd713-23b8-4b59-a273-2efd9ba4b8e7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17334 biolink:treats MONDO:0005025 PMID:41385096 "[{""id"":""uuid:62c999c2-22fb-4455-85e8-ed3f9bdd96ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fdc87a7a-4534-4079-8b7a-4657644eeec9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Penicillin G Sodium for Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Penicillin G Sodium for Injection, USP may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below, however, once these results become available, appropriate therapy should be continued. Clinical Indication Infecting Organism Septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis Streptococcus pyogenes (group A β-hemolytic streptococcus), other β-hemolytic streptococci including groups C, H, G, L and M, Streptococcus pneumoniae and Staphylococcus species (non- penicillinase producing strains) Anthrax Bacillus anthracis Actinomycosis (cervico- facial disease and thoracic and abdominal disease) Actinomyces Israelil Botulism (adjunctive therapy to antitoxin), gas gangrene, and tetanus (adjunctive therapy to human tetanus immune globulin) Clostridium species Diphtheria (adjunctive therapy to antitoxin and prevention of the carrier state) Corynebacterium diphtheriae Erysipelothrix endocarditis Erysipelothrix rhusiopthiae Fusospirochetosis (severe infections of the oropharynx [Vincent’s], lower respiratory tract and genital area) Fusobacterium species and spirochetes Listeria infections including meningitis and endocarditis Listeria monocytogenes Pasteurella infections including bacteremia and meningitis Pasteurella multocida Haverhill fever Streptobacillus moniliformis Rat-bite fever Spirillum minus or Streptobacillus moniliformis Disseminated gonococcal infections Neisseria gonorrhoeae (penicillin-susceptible) Syphilis (congenital and neurosyphilis) Treponema pallidum Meningococcal meningitis and/or septicemia Neisseria meningitidis Gram-negative bacillary infections (bacteremias) Escherichia coli, Enterobacter aerogenes, Alcaligenes faecalis, salmonella, shigella and Proteus mirabilis, Penicillin G is not the drug of choice in the treatment of gram-negative bacillary infections. To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin G sodium and other antibacterial drugs, penicillin G sodium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. CHEBI:18208 uuid:96ea3dc8-2fa5-4bcf-90d9-2b2c0335cb58 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17334 biolink:treats MONDO:0021108 PMID:41385096 "[{""id"":""uuid:f424e6d3-550f-42e3-90e3-e4f6c4b5fd18"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b5535d8d-aaa1-4891-9681-fe964ea605ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Penicillin G Sodium for Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Penicillin G Sodium for Injection, USP may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below, however, once these results become available, appropriate therapy should be continued. Clinical Indication Infecting Organism Septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis Streptococcus pyogenes (group A β-hemolytic streptococcus), other β-hemolytic streptococci including groups C, H, G, L and M, Streptococcus pneumoniae and Staphylococcus species (non- penicillinase producing strains) Anthrax Bacillus anthracis Actinomycosis (cervico- facial disease and thoracic and abdominal disease) Actinomyces Israelil Botulism (adjunctive therapy to antitoxin), gas gangrene, and tetanus (adjunctive therapy to human tetanus immune globulin) Clostridium species Diphtheria (adjunctive therapy to antitoxin and prevention of the carrier state) Corynebacterium diphtheriae Erysipelothrix endocarditis Erysipelothrix rhusiopthiae Fusospirochetosis (severe infections of the oropharynx [Vincent’s], lower respiratory tract and genital area) Fusobacterium species and spirochetes Listeria infections including meningitis and endocarditis Listeria monocytogenes Pasteurella infections including bacteremia and meningitis Pasteurella multocida Haverhill fever Streptobacillus moniliformis Rat-bite fever Spirillum minus or Streptobacillus moniliformis Disseminated gonococcal infections Neisseria gonorrhoeae (penicillin-susceptible) Syphilis (congenital and neurosyphilis) Treponema pallidum Meningococcal meningitis and/or septicemia Neisseria meningitidis Gram-negative bacillary infections (bacteremias) Escherichia coli, Enterobacter aerogenes, Alcaligenes faecalis, salmonella, shigella and Proteus mirabilis, Penicillin G is not the drug of choice in the treatment of gram-negative bacillary infections. To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin G sodium and other antibacterial drugs, penicillin G sodium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. CHEBI:18208 uuid:e9e29407-31b8-49af-94ac-df8646b040e3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17334 biolink:treats MONDO:0005119 PMID:41385096 "[{""id"":""uuid:5b83b55f-85d5-438c-8aa5-7b997d81b41f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6d38e9ee-475c-42cc-be41-49ec309043e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Penicillin G Sodium for Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Penicillin G Sodium for Injection, USP may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below, however, once these results become available, appropriate therapy should be continued. Clinical Indication Infecting Organism Septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis Streptococcus pyogenes (group A β-hemolytic streptococcus), other β-hemolytic streptococci including groups C, H, G, L and M, Streptococcus pneumoniae and Staphylococcus species (non- penicillinase producing strains) Anthrax Bacillus anthracis Actinomycosis (cervico- facial disease and thoracic and abdominal disease) Actinomyces Israelil Botulism (adjunctive therapy to antitoxin), gas gangrene, and tetanus (adjunctive therapy to human tetanus immune globulin) Clostridium species Diphtheria (adjunctive therapy to antitoxin and prevention of the carrier state) Corynebacterium diphtheriae Erysipelothrix endocarditis Erysipelothrix rhusiopthiae Fusospirochetosis (severe infections of the oropharynx [Vincent’s], lower respiratory tract and genital area) Fusobacterium species and spirochetes Listeria infections including meningitis and endocarditis Listeria monocytogenes Pasteurella infections including bacteremia and meningitis Pasteurella multocida Haverhill fever Streptobacillus moniliformis Rat-bite fever Spirillum minus or Streptobacillus moniliformis Disseminated gonococcal infections Neisseria gonorrhoeae (penicillin-susceptible) Syphilis (congenital and neurosyphilis) Treponema pallidum Meningococcal meningitis and/or septicemia Neisseria meningitidis Gram-negative bacillary infections (bacteremias) Escherichia coli, Enterobacter aerogenes, Alcaligenes faecalis, salmonella, shigella and Proteus mirabilis, Penicillin G is not the drug of choice in the treatment of gram-negative bacillary infections. To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin G sodium and other antibacterial drugs, penicillin G sodium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. CHEBI:18208 uuid:492b5fe4-314c-47a4-8c7c-1455a8c7ea29 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17334 biolink:treats MONDO:0005498 PMID:41385096 "[{""id"":""uuid:c341443f-2d71-40ee-b5d4-fd4e164716d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:426f3045-ddc8-4976-871a-cf188f3cd8c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Penicillin G Sodium for Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Penicillin G Sodium for Injection, USP may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below, however, once these results become available, appropriate therapy should be continued. Clinical Indication Infecting Organism Septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis Streptococcus pyogenes (group A β-hemolytic streptococcus), other β-hemolytic streptococci including groups C, H, G, L and M, Streptococcus pneumoniae and Staphylococcus species (non- penicillinase producing strains) Anthrax Bacillus anthracis Actinomycosis (cervico- facial disease and thoracic and abdominal disease) Actinomyces Israelil Botulism (adjunctive therapy to antitoxin), gas gangrene, and tetanus (adjunctive therapy to human tetanus immune globulin) Clostridium species Diphtheria (adjunctive therapy to antitoxin and prevention of the carrier state) Corynebacterium diphtheriae Erysipelothrix endocarditis Erysipelothrix rhusiopthiae Fusospirochetosis (severe infections of the oropharynx [Vincent’s], lower respiratory tract and genital area) Fusobacterium species and spirochetes Listeria infections including meningitis and endocarditis Listeria monocytogenes Pasteurella infections including bacteremia and meningitis Pasteurella multocida Haverhill fever Streptobacillus moniliformis Rat-bite fever Spirillum minus or Streptobacillus moniliformis Disseminated gonococcal infections Neisseria gonorrhoeae (penicillin-susceptible) Syphilis (congenital and neurosyphilis) Treponema pallidum Meningococcal meningitis and/or septicemia Neisseria meningitidis Gram-negative bacillary infections (bacteremias) Escherichia coli, Enterobacter aerogenes, Alcaligenes faecalis, salmonella, shigella and Proteus mirabilis, Penicillin G is not the drug of choice in the treatment of gram-negative bacillary infections. To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin G sodium and other antibacterial drugs, penicillin G sodium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. CHEBI:18208 uuid:359926b3-2f8d-4bd1-88de-5fa1f6b57f8d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17334 biolink:treats MONDO:0005767 PMID:41385096 "[{""id"":""uuid:9268caa4-0f45-43b0-821a-8b90b0f59b89"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:99002e1e-0846-4ba2-a3e8-dac5a537503a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Penicillin G Sodium for Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Penicillin G Sodium for Injection, USP may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below, however, once these results become available, appropriate therapy should be continued. Clinical Indication Infecting Organism Septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis Streptococcus pyogenes (group A β-hemolytic streptococcus), other β-hemolytic streptococci including groups C, H, G, L and M, Streptococcus pneumoniae and Staphylococcus species (non- penicillinase producing strains) Anthrax Bacillus anthracis Actinomycosis (cervico- facial disease and thoracic and abdominal disease) Actinomyces Israelil Botulism (adjunctive therapy to antitoxin), gas gangrene, and tetanus (adjunctive therapy to human tetanus immune globulin) Clostridium species Diphtheria (adjunctive therapy to antitoxin and prevention of the carrier state) Corynebacterium diphtheriae Erysipelothrix endocarditis Erysipelothrix rhusiopthiae Fusospirochetosis (severe infections of the oropharynx [Vincent’s], lower respiratory tract and genital area) Fusobacterium species and spirochetes Listeria infections including meningitis and endocarditis Listeria monocytogenes Pasteurella infections including bacteremia and meningitis Pasteurella multocida Haverhill fever Streptobacillus moniliformis Rat-bite fever Spirillum minus or Streptobacillus moniliformis Disseminated gonococcal infections Neisseria gonorrhoeae (penicillin-susceptible) Syphilis (congenital and neurosyphilis) Treponema pallidum Meningococcal meningitis and/or septicemia Neisseria meningitidis Gram-negative bacillary infections (bacteremias) Escherichia coli, Enterobacter aerogenes, Alcaligenes faecalis, salmonella, shigella and Proteus mirabilis, Penicillin G is not the drug of choice in the treatment of gram-negative bacillary infections. To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin G sodium and other antibacterial drugs, penicillin G sodium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. CHEBI:18208 uuid:ce9a0192-92f9-4160-a1b3-88d79dfe69a8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17334 biolink:treats MONDO:0005526 PMID:41385096 "[{""id"":""uuid:e5b9104d-88a3-42fd-9a30-5576a707207e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:414b1f52-f8f4-48cb-987b-16d7395e0812"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Penicillin G Sodium for Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Penicillin G Sodium for Injection, USP may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below, however, once these results become available, appropriate therapy should be continued. Clinical Indication Infecting Organism Septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis Streptococcus pyogenes (group A β-hemolytic streptococcus), other β-hemolytic streptococci including groups C, H, G, L and M, Streptococcus pneumoniae and Staphylococcus species (non- penicillinase producing strains) Anthrax Bacillus anthracis Actinomycosis (cervico- facial disease and thoracic and abdominal disease) Actinomyces Israelil Botulism (adjunctive therapy to antitoxin), gas gangrene, and tetanus (adjunctive therapy to human tetanus immune globulin) Clostridium species Diphtheria (adjunctive therapy to antitoxin and prevention of the carrier state) Corynebacterium diphtheriae Erysipelothrix endocarditis Erysipelothrix rhusiopthiae Fusospirochetosis (severe infections of the oropharynx [Vincent’s], lower respiratory tract and genital area) Fusobacterium species and spirochetes Listeria infections including meningitis and endocarditis Listeria monocytogenes Pasteurella infections including bacteremia and meningitis Pasteurella multocida Haverhill fever Streptobacillus moniliformis Rat-bite fever Spirillum minus or Streptobacillus moniliformis Disseminated gonococcal infections Neisseria gonorrhoeae (penicillin-susceptible) Syphilis (congenital and neurosyphilis) Treponema pallidum Meningococcal meningitis and/or septicemia Neisseria meningitidis Gram-negative bacillary infections (bacteremias) Escherichia coli, Enterobacter aerogenes, Alcaligenes faecalis, salmonella, shigella and Proteus mirabilis, Penicillin G is not the drug of choice in the treatment of gram-negative bacillary infections. To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin G sodium and other antibacterial drugs, penicillin G sodium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. CHEBI:18208 uuid:0b411686-37ee-4139-8c71-cbcb6e3f620c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17334 biolink:treats MONDO:0005504 PMID:41385096 "[{""id"":""uuid:8cb8910a-0e92-40b6-baaa-dc17b5d441ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b219f8c5-3911-4683-bf79-3b84cc3582ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Penicillin G Sodium for Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Penicillin G Sodium for Injection, USP may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below, however, once these results become available, appropriate therapy should be continued. Clinical Indication Infecting Organism Septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis Streptococcus pyogenes (group A β-hemolytic streptococcus), other β-hemolytic streptococci including groups C, H, G, L and M, Streptococcus pneumoniae and Staphylococcus species (non- penicillinase producing strains) Anthrax Bacillus anthracis Actinomycosis (cervico- facial disease and thoracic and abdominal disease) Actinomyces Israelil Botulism (adjunctive therapy to antitoxin), gas gangrene, and tetanus (adjunctive therapy to human tetanus immune globulin) Clostridium species Diphtheria (adjunctive therapy to antitoxin and prevention of the carrier state) Corynebacterium diphtheriae Erysipelothrix endocarditis Erysipelothrix rhusiopthiae Fusospirochetosis (severe infections of the oropharynx [Vincent’s], lower respiratory tract and genital area) Fusobacterium species and spirochetes Listeria infections including meningitis and endocarditis Listeria monocytogenes Pasteurella infections including bacteremia and meningitis Pasteurella multocida Haverhill fever Streptobacillus moniliformis Rat-bite fever Spirillum minus or Streptobacillus moniliformis Disseminated gonococcal infections Neisseria gonorrhoeae (penicillin-susceptible) Syphilis (congenital and neurosyphilis) Treponema pallidum Meningococcal meningitis and/or septicemia Neisseria meningitidis Gram-negative bacillary infections (bacteremias) Escherichia coli, Enterobacter aerogenes, Alcaligenes faecalis, salmonella, shigella and Proteus mirabilis, Penicillin G is not the drug of choice in the treatment of gram-negative bacillary infections. To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin G sodium and other antibacterial drugs, penicillin G sodium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. CHEBI:18208 uuid:14eea0fe-0da0-444b-9620-cff27e5b0767 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17334 biolink:treats MONDO:0006669 PMID:41385096 "[{""id"":""uuid:38878068-0557-4ebd-b768-3c7bede354f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d107d10c-c059-4d5a-a121-8ccf15ed3231"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Penicillin G Sodium for Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Penicillin G Sodium for Injection, USP may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below, however, once these results become available, appropriate therapy should be continued. Clinical Indication Infecting Organism Septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis Streptococcus pyogenes (group A β-hemolytic streptococcus), other β-hemolytic streptococci including groups C, H, G, L and M, Streptococcus pneumoniae and Staphylococcus species (non- penicillinase producing strains) Anthrax Bacillus anthracis Actinomycosis (cervico- facial disease and thoracic and abdominal disease) Actinomyces Israelil Botulism (adjunctive therapy to antitoxin), gas gangrene, and tetanus (adjunctive therapy to human tetanus immune globulin) Clostridium species Diphtheria (adjunctive therapy to antitoxin and prevention of the carrier state) Corynebacterium diphtheriae Erysipelothrix endocarditis Erysipelothrix rhusiopthiae Fusospirochetosis (severe infections of the oropharynx [Vincent’s], lower respiratory tract and genital area) Fusobacterium species and spirochetes Listeria infections including meningitis and endocarditis Listeria monocytogenes Pasteurella infections including bacteremia and meningitis Pasteurella multocida Haverhill fever Streptobacillus moniliformis Rat-bite fever Spirillum minus or Streptobacillus moniliformis Disseminated gonococcal infections Neisseria gonorrhoeae (penicillin-susceptible) Syphilis (congenital and neurosyphilis) Treponema pallidum Meningococcal meningitis and/or septicemia Neisseria meningitidis Gram-negative bacillary infections (bacteremias) Escherichia coli, Enterobacter aerogenes, Alcaligenes faecalis, salmonella, shigella and Proteus mirabilis, Penicillin G is not the drug of choice in the treatment of gram-negative bacillary infections. To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin G sodium and other antibacterial drugs, penicillin G sodium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. CHEBI:18208 uuid:b3ad6a2e-d560-45bb-815d-824db1acdb96 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17334 biolink:treats MONDO:0005828 PMID:41385096 "[{""id"":""uuid:1413574b-398c-40f1-ad24-4f6b31ba6881"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:18cb5181-d339-49c6-8a23-b3ed5c44876c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Penicillin G Sodium for Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Penicillin G Sodium for Injection, USP may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below, however, once these results become available, appropriate therapy should be continued. Clinical Indication Infecting Organism Septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis Streptococcus pyogenes (group A β-hemolytic streptococcus), other β-hemolytic streptococci including groups C, H, G, L and M, Streptococcus pneumoniae and Staphylococcus species (non- penicillinase producing strains) Anthrax Bacillus anthracis Actinomycosis (cervico- facial disease and thoracic and abdominal disease) Actinomyces Israelil Botulism (adjunctive therapy to antitoxin), gas gangrene, and tetanus (adjunctive therapy to human tetanus immune globulin) Clostridium species Diphtheria (adjunctive therapy to antitoxin and prevention of the carrier state) Corynebacterium diphtheriae Erysipelothrix endocarditis Erysipelothrix rhusiopthiae Fusospirochetosis (severe infections of the oropharynx [Vincent’s], lower respiratory tract and genital area) Fusobacterium species and spirochetes Listeria infections including meningitis and endocarditis Listeria monocytogenes Pasteurella infections including bacteremia and meningitis Pasteurella multocida Haverhill fever Streptobacillus moniliformis Rat-bite fever Spirillum minus or Streptobacillus moniliformis Disseminated gonococcal infections Neisseria gonorrhoeae (penicillin-susceptible) Syphilis (congenital and neurosyphilis) Treponema pallidum Meningococcal meningitis and/or septicemia Neisseria meningitidis Gram-negative bacillary infections (bacteremias) Escherichia coli, Enterobacter aerogenes, Alcaligenes faecalis, salmonella, shigella and Proteus mirabilis, Penicillin G is not the drug of choice in the treatment of gram-negative bacillary infections. To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin G sodium and other antibacterial drugs, penicillin G sodium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. CHEBI:18208 uuid:f7867c34-80d9-4f10-8213-e03dbb8c19bb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17334 biolink:treats MONDO:0005901 PMID:41385096 "[{""id"":""uuid:26fa6de6-3128-4c4d-86d7-60b8b68bdbc9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5e4f4c26-b3d4-4ba3-8c24-155a9beca9cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Penicillin G Sodium for Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Penicillin G Sodium for Injection, USP may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below, however, once these results become available, appropriate therapy should be continued. Clinical Indication Infecting Organism Septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis Streptococcus pyogenes (group A β-hemolytic streptococcus), other β-hemolytic streptococci including groups C, H, G, L and M, Streptococcus pneumoniae and Staphylococcus species (non- penicillinase producing strains) Anthrax Bacillus anthracis Actinomycosis (cervico- facial disease and thoracic and abdominal disease) Actinomyces Israelil Botulism (adjunctive therapy to antitoxin), gas gangrene, and tetanus (adjunctive therapy to human tetanus immune globulin) Clostridium species Diphtheria (adjunctive therapy to antitoxin and prevention of the carrier state) Corynebacterium diphtheriae Erysipelothrix endocarditis Erysipelothrix rhusiopthiae Fusospirochetosis (severe infections of the oropharynx [Vincent’s], lower respiratory tract and genital area) Fusobacterium species and spirochetes Listeria infections including meningitis and endocarditis Listeria monocytogenes Pasteurella infections including bacteremia and meningitis Pasteurella multocida Haverhill fever Streptobacillus moniliformis Rat-bite fever Spirillum minus or Streptobacillus moniliformis Disseminated gonococcal infections Neisseria gonorrhoeae (penicillin-susceptible) Syphilis (congenital and neurosyphilis) Treponema pallidum Meningococcal meningitis and/or septicemia Neisseria meningitidis Gram-negative bacillary infections (bacteremias) Escherichia coli, Enterobacter aerogenes, Alcaligenes faecalis, salmonella, shigella and Proteus mirabilis, Penicillin G is not the drug of choice in the treatment of gram-negative bacillary infections. To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin G sodium and other antibacterial drugs, penicillin G sodium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. CHEBI:18208 uuid:1fc19f53-a9ee-4da8-9891-2bbd0ebf84d0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17334 biolink:treats MONDO:0020533 PMID:41385096 "[{""id"":""uuid:72527540-5c9e-48e1-b316-115c63671430"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c69941ea-bfe5-4f36-9a22-3442b31fe74b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Penicillin G Sodium for Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Penicillin G Sodium for Injection, USP may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below, however, once these results become available, appropriate therapy should be continued. Clinical Indication Infecting Organism Septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis Streptococcus pyogenes (group A β-hemolytic streptococcus), other β-hemolytic streptococci including groups C, H, G, L and M, Streptococcus pneumoniae and Staphylococcus species (non- penicillinase producing strains) Anthrax Bacillus anthracis Actinomycosis (cervico- facial disease and thoracic and abdominal disease) Actinomyces Israelil Botulism (adjunctive therapy to antitoxin), gas gangrene, and tetanus (adjunctive therapy to human tetanus immune globulin) Clostridium species Diphtheria (adjunctive therapy to antitoxin and prevention of the carrier state) Corynebacterium diphtheriae Erysipelothrix endocarditis Erysipelothrix rhusiopthiae Fusospirochetosis (severe infections of the oropharynx [Vincent’s], lower respiratory tract and genital area) Fusobacterium species and spirochetes Listeria infections including meningitis and endocarditis Listeria monocytogenes Pasteurella infections including bacteremia and meningitis Pasteurella multocida Haverhill fever Streptobacillus moniliformis Rat-bite fever Spirillum minus or Streptobacillus moniliformis Disseminated gonococcal infections Neisseria gonorrhoeae (penicillin-susceptible) Syphilis (congenital and neurosyphilis) Treponema pallidum Meningococcal meningitis and/or septicemia Neisseria meningitidis Gram-negative bacillary infections (bacteremias) Escherichia coli, Enterobacter aerogenes, Alcaligenes faecalis, salmonella, shigella and Proteus mirabilis, Penicillin G is not the drug of choice in the treatment of gram-negative bacillary infections. To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin G sodium and other antibacterial drugs, penicillin G sodium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. CHEBI:18208 uuid:ff6b1763-473e-4ded-9bd0-d9820127bd2c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17334 biolink:treats MONDO:0006941 PMID:41385096 "[{""id"":""uuid:5b79f48c-106d-428c-b72a-e1fcd5c76cc3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ab3e838f-dfa1-4744-a48a-9b81ba9efb45"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Penicillin G Sodium for Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Penicillin G Sodium for Injection, USP may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below, however, once these results become available, appropriate therapy should be continued. Clinical Indication Infecting Organism Septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis Streptococcus pyogenes (group A β-hemolytic streptococcus), other β-hemolytic streptococci including groups C, H, G, L and M, Streptococcus pneumoniae and Staphylococcus species (non- penicillinase producing strains) Anthrax Bacillus anthracis Actinomycosis (cervico- facial disease and thoracic and abdominal disease) Actinomyces Israelil Botulism (adjunctive therapy to antitoxin), gas gangrene, and tetanus (adjunctive therapy to human tetanus immune globulin) Clostridium species Diphtheria (adjunctive therapy to antitoxin and prevention of the carrier state) Corynebacterium diphtheriae Erysipelothrix endocarditis Erysipelothrix rhusiopthiae Fusospirochetosis (severe infections of the oropharynx [Vincent’s], lower respiratory tract and genital area) Fusobacterium species and spirochetes Listeria infections including meningitis and endocarditis Listeria monocytogenes Pasteurella infections including bacteremia and meningitis Pasteurella multocida Haverhill fever Streptobacillus moniliformis Rat-bite fever Spirillum minus or Streptobacillus moniliformis Disseminated gonococcal infections Neisseria gonorrhoeae (penicillin-susceptible) Syphilis (congenital and neurosyphilis) Treponema pallidum Meningococcal meningitis and/or septicemia Neisseria meningitidis Gram-negative bacillary infections (bacteremias) Escherichia coli, Enterobacter aerogenes, Alcaligenes faecalis, salmonella, shigella and Proteus mirabilis, Penicillin G is not the drug of choice in the treatment of gram-negative bacillary infections. To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin G sodium and other antibacterial drugs, penicillin G sodium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. CHEBI:18208 uuid:06e9901d-0b9c-4095-8a53-1518a7d1439a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17334 biolink:treats MONDO:0018059 PMID:41385096 "[{""id"":""uuid:ef450fce-efd7-4e08-90c7-ef9418838492"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ee2fedef-c5b1-44a3-8c68-85be1f7c6c79"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Penicillin G Sodium for Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Penicillin G Sodium for Injection, USP may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below, however, once these results become available, appropriate therapy should be continued. Clinical Indication Infecting Organism Septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis Streptococcus pyogenes (group A β-hemolytic streptococcus), other β-hemolytic streptococci including groups C, H, G, L and M, Streptococcus pneumoniae and Staphylococcus species (non- penicillinase producing strains) Anthrax Bacillus anthracis Actinomycosis (cervico- facial disease and thoracic and abdominal disease) Actinomyces Israelil Botulism (adjunctive therapy to antitoxin), gas gangrene, and tetanus (adjunctive therapy to human tetanus immune globulin) Clostridium species Diphtheria (adjunctive therapy to antitoxin and prevention of the carrier state) Corynebacterium diphtheriae Erysipelothrix endocarditis Erysipelothrix rhusiopthiae Fusospirochetosis (severe infections of the oropharynx [Vincent’s], lower respiratory tract and genital area) Fusobacterium species and spirochetes Listeria infections including meningitis and endocarditis Listeria monocytogenes Pasteurella infections including bacteremia and meningitis Pasteurella multocida Haverhill fever Streptobacillus moniliformis Rat-bite fever Spirillum minus or Streptobacillus moniliformis Disseminated gonococcal infections Neisseria gonorrhoeae (penicillin-susceptible) Syphilis (congenital and neurosyphilis) Treponema pallidum Meningococcal meningitis and/or septicemia Neisseria meningitidis Gram-negative bacillary infections (bacteremias) Escherichia coli, Enterobacter aerogenes, Alcaligenes faecalis, salmonella, shigella and Proteus mirabilis, Penicillin G is not the drug of choice in the treatment of gram-negative bacillary infections. To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin G sodium and other antibacterial drugs, penicillin G sodium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. CHEBI:18208 uuid:cc559de2-db36-4ebe-8cee-970f5993d314 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17334 biolink:treats MONDO:0005229 PMID:41385096 "[{""id"":""uuid:97c29211-0d8e-4dbd-bade-6038e0596396"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9b64a2c1-1160-4adb-8929-1ac1dc0b9c1e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Penicillin G Sodium for Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Penicillin G Sodium for Injection, USP may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below, however, once these results become available, appropriate therapy should be continued. Clinical Indication Infecting Organism Septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis Streptococcus pyogenes (group A β-hemolytic streptococcus), other β-hemolytic streptococci including groups C, H, G, L and M, Streptococcus pneumoniae and Staphylococcus species (non- penicillinase producing strains) Anthrax Bacillus anthracis Actinomycosis (cervico- facial disease and thoracic and abdominal disease) Actinomyces Israelil Botulism (adjunctive therapy to antitoxin), gas gangrene, and tetanus (adjunctive therapy to human tetanus immune globulin) Clostridium species Diphtheria (adjunctive therapy to antitoxin and prevention of the carrier state) Corynebacterium diphtheriae Erysipelothrix endocarditis Erysipelothrix rhusiopthiae Fusospirochetosis (severe infections of the oropharynx [Vincent’s], lower respiratory tract and genital area) Fusobacterium species and spirochetes Listeria infections including meningitis and endocarditis Listeria monocytogenes Pasteurella infections including bacteremia and meningitis Pasteurella multocida Haverhill fever Streptobacillus moniliformis Rat-bite fever Spirillum minus or Streptobacillus moniliformis Disseminated gonococcal infections Neisseria gonorrhoeae (penicillin-susceptible) Syphilis (congenital and neurosyphilis) Treponema pallidum Meningococcal meningitis and/or septicemia Neisseria meningitidis Gram-negative bacillary infections (bacteremias) Escherichia coli, Enterobacter aerogenes, Alcaligenes faecalis, salmonella, shigella and Proteus mirabilis, Penicillin G is not the drug of choice in the treatment of gram-negative bacillary infections. To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin G sodium and other antibacterial drugs, penicillin G sodium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. CHEBI:18208 uuid:3b72dc42-052a-48c1-9cfe-38b4ef504fff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:5QS67N4551 biolink:treats MONDO:0019623 PMID:41385096 "[{""id"":""uuid:f5a4ffcd-0c7c-46db-8605-2add167a00e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d7a0b3c2-0464-4242-b24e-979853534a4e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:1a7862ed-43ee-4427-bc59-61ca907d9bf3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RUCONEST is a C1 esterase inhibitor [recombinant] indicated for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema (HAE). Limitation of Use: Effectiveness was not established in HAE patients with laryngeal attacks.|[EMA] Ruconest is indicated for treatment of acute angioedema attacks in adults with hereditary angioedema (HAE) due to C1-esterase-inhibitor deficiency. uuid:28f28f98-e890-4717-9813-bf3dcfc319b3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:5QS67N4551 biolink:treats MONDO:0012526 PMID:41385096 "[{""id"":""uuid:6763ba76-dbd5-4ce4-be80-5c8e9ffbfd84"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:59794d1f-4154-4dca-99c6-76e47444d88e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RUCONEST is a C1 esterase inhibitor [recombinant] indicated for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema (HAE). Limitation of Use: Effectiveness was not established in HAE patients with laryngeal attacks. uuid:639b41ad-2c68-439a-9643-1db54d448fd6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:51043 biolink:treats MONDO:0005052 PMID:41385096 "[{""id"":""uuid:3b731222-156e-415e-b8c6-f33cd159c37c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7ab2d0de-9503-4708-b85d-593d8a17e806"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZELNORM is indicated for the treatment of adult women less than 65 years of age with irritable bowel syndrome with constipation (IBS-C). Limitations of Use The safety and effectiveness of ZELNORM in men with IBS-C have not been established [see Clinical Studies ( 14 )] . uuid:e52e6033-5117-4ca0-9f19-75cecbbb09e6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:34825 biolink:treats MONDO:0005984 PMID:41385096 "[{""id"":""uuid:94fc6adf-7192-49db-a4f1-9023f5bf8144"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:625b18c2-e27a-4732-9a65-0e0588012a6e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Luliconazole Cream, 1% is indicated for the topical treatment of interdigital tinea pedis, tinea cruris, and tinea corporis caused by the organisms Trichophyton rubrum and Epidermophyton floccosum . uuid:4ef5857c-69a7-4f44-a417-3a0ac7d6abf9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:34825 biolink:treats MONDO:0001405 PMID:41385096 "[{""id"":""uuid:7f44b9dd-4028-4ec1-839b-bb6bf65d430d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e96e4c6e-743c-45f2-bf8f-b1ceb4807487"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Luliconazole Cream, 1% is indicated for the topical treatment of interdigital tinea pedis, tinea cruris, and tinea corporis caused by the organisms Trichophyton rubrum and Epidermophyton floccosum . uuid:34127263-0392-4da4-bcd4-154f4782403d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:34825 biolink:treats MONDO:0001461 PMID:41385096 "[{""id"":""uuid:d9308830-6a30-43a7-9c8d-d249f10f5853"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:abb9f81a-6535-4d64-993d-937616de797c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Luliconazole Cream, 1% is indicated for the topical treatment of interdigital tinea pedis, tinea cruris, and tinea corporis caused by the organisms Trichophyton rubrum and Epidermophyton floccosum . uuid:302410aa-e2ba-4f73-94f6-1395c5d03cd8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3640 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:74142edc-a28c-4f93-b605-9b107c137ed5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:866c8326-7e7e-4ca1-9477-8ab048130afd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Chlorothiazide sodium for injection, USP is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Chlorothiazide sodium for injection, USP has also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. uuid:78810e0e-fcbc-41d8-9a89-3e1cdb313527 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3640 biolink:treats MONDO:0005155 PMID:41385096 "[{""id"":""uuid:edc3ac8f-8359-4dd4-a26f-4adb1a4135f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4b544014-379e-45e9-8bab-65fe466d8224"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Chlorothiazide sodium for injection, USP is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Chlorothiazide sodium for injection, USP has also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. uuid:e11e2381-055d-4455-825e-bd2e7a518e13 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3640 biolink:treats MONDO:0005377 PMID:41385096 "[{""id"":""uuid:de61123e-744f-4385-9a20-45b7b2550d69"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:894f1aa1-6090-429f-8a4a-de43c95825e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Chlorothiazide sodium for injection, USP is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Chlorothiazide sodium for injection, USP has also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. uuid:a660e7d9-a7bd-4cd0-93e3-94b16f33837b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3640 biolink:treats UMLS:C0156221 PMID:41385096 "[{""id"":""uuid:38bb8a8f-f81b-451c-aa41-b17bf6607b54"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b34dc5df-e2f0-4845-84da-f6a3b832912e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Chlorothiazide sodium for injection, USP is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Chlorothiazide sodium for injection, USP has also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. uuid:0c7be8e8-8a56-4601-9cae-5284df31e11a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3640 biolink:treats MONDO:0005300 PMID:41385096 "[{""id"":""uuid:1eadfb22-22f6-48c0-9f69-30c4338cebdc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ed1ae2fd-fc19-48b4-b34a-26dc49591419"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Chlorothiazide sodium for injection, USP is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Chlorothiazide sodium for injection, USP has also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. uuid:0a41f805-f8d7-47dd-a5cc-2ccbd29acdff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0005867 PMID:41385096 "[{""id"":""uuid:1d5a88bb-6be0-485f-967f-91f9ba69f709"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:89ef525b-e96c-4b41-9f91-68a197063fad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Doxycycline for Injection, USP and other antibacterial drugs, Doxycycline for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline for Injection, USP is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever, and the typhus group, Q fever, rickettsial pox and tick fevers). Mycoplasma pneumoniae (PPLO, Eaton Agent). Agents of psittacosis and ornithosis. Agents of lymphogranuloma venereum and granuloma inguinale. The spirochetal agent of relapsing fever (Borrelia recurrentis) . The following gram-negative microorganisms: Haemophilus ducreyi (chancroid). Yersinia pestis (formerly Pasteurella pestis ) and Francisella tularensis (formerly Pasteurella tularensis ). Bartonella bacilliformis . Bacteroides species. Vibrio cholerae (formerly Vibrio comma ) and Campylobacter fetus (formerly Vibrio fetus ). Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli . Enterobacter aerogenes (formerly Aerobacter aerogenes ). Shigella species. Acinetobacter species (formerly Mima species and Herellea species). Haemophilus influenzae (respiratory infections). Klebsiella species (respiratory and urinary infections). Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Enterococcus faecalis (formerly Streptococcus faecalis ) have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Streptococcus pneumoniae (formerly Diplococcus pneumoniae ). Staphylococcus aureus , respiratory, skin and soft tissue infections. Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections. Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of infections due to: Neisseria gonorrhoeae and N. meningitidis . Treponema pallidum and Treponema pertenue (syphilis and yaws). Listeria monocytogenes . Clostridium species. Fusobacterium fusiforme (Vincent's infection). Actinomyces species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. Doxycycline is indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. uuid:a0f4d871-7359-4f42-bcf0-9d0d22f0030d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0006926 PMID:41385096 "[{""id"":""uuid:6b5ba632-5f72-438a-8a1c-2c81c21fc53f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e35d8787-5297-4a8f-b22f-92d0fda9b94a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Doxycycline for Injection, USP and other antibacterial drugs, Doxycycline for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline for Injection, USP is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever, and the typhus group, Q fever, rickettsial pox and tick fevers). Mycoplasma pneumoniae (PPLO, Eaton Agent). Agents of psittacosis and ornithosis. Agents of lymphogranuloma venereum and granuloma inguinale. The spirochetal agent of relapsing fever (Borrelia recurrentis) . The following gram-negative microorganisms: Haemophilus ducreyi (chancroid). Yersinia pestis (formerly Pasteurella pestis ) and Francisella tularensis (formerly Pasteurella tularensis ). Bartonella bacilliformis . Bacteroides species. Vibrio cholerae (formerly Vibrio comma ) and Campylobacter fetus (formerly Vibrio fetus ). Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli . Enterobacter aerogenes (formerly Aerobacter aerogenes ). Shigella species. Acinetobacter species (formerly Mima species and Herellea species). Haemophilus influenzae (respiratory infections). Klebsiella species (respiratory and urinary infections). Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Enterococcus faecalis (formerly Streptococcus faecalis ) have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Streptococcus pneumoniae (formerly Diplococcus pneumoniae ). Staphylococcus aureus , respiratory, skin and soft tissue infections. Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections. Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of infections due to: Neisseria gonorrhoeae and N. meningitidis . Treponema pallidum and Treponema pertenue (syphilis and yaws). Listeria monocytogenes . Clostridium species. Fusobacterium fusiforme (Vincent's infection). Actinomyces species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. Doxycycline is indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. uuid:4270e0a7-6ca3-4ce7-9aa5-632e3ef3004e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0021680 PMID:41385096 "[{""id"":""uuid:66f7826b-7a4a-4bfb-ada7-6f8dee1d4f19"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2674bab6-cdb4-405b-9810-a63352b8f0ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Doxycycline for Injection, USP and other antibacterial drugs, Doxycycline for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline for Injection, USP is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever, and the typhus group, Q fever, rickettsial pox and tick fevers). Mycoplasma pneumoniae (PPLO, Eaton Agent). Agents of psittacosis and ornithosis. Agents of lymphogranuloma venereum and granuloma inguinale. The spirochetal agent of relapsing fever (Borrelia recurrentis) . The following gram-negative microorganisms: Haemophilus ducreyi (chancroid). Yersinia pestis (formerly Pasteurella pestis ) and Francisella tularensis (formerly Pasteurella tularensis ). Bartonella bacilliformis . Bacteroides species. Vibrio cholerae (formerly Vibrio comma ) and Campylobacter fetus (formerly Vibrio fetus ). Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli . Enterobacter aerogenes (formerly Aerobacter aerogenes ). Shigella species. Acinetobacter species (formerly Mima species and Herellea species). Haemophilus influenzae (respiratory infections). Klebsiella species (respiratory and urinary infections). Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Enterococcus faecalis (formerly Streptococcus faecalis ) have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Streptococcus pneumoniae (formerly Diplococcus pneumoniae ). Staphylococcus aureus , respiratory, skin and soft tissue infections. Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections. Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of infections due to: Neisseria gonorrhoeae and N. meningitidis . Treponema pallidum and Treponema pertenue (syphilis and yaws). Listeria monocytogenes . Clostridium species. Fusobacterium fusiforme (Vincent's infection). Actinomyces species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. Doxycycline is indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. uuid:919f6a54-9920-446e-8ad3-051f4b059e53 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0005121 PMID:41385096 "[{""id"":""uuid:bc004aca-f07b-4439-98e8-78421e90f929"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a6291bd9-1505-40fa-b37b-a1869ddde5c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Doxycycline for Injection, USP and other antibacterial drugs, Doxycycline for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline for Injection, USP is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever, and the typhus group, Q fever, rickettsial pox and tick fevers). Mycoplasma pneumoniae (PPLO, Eaton Agent). Agents of psittacosis and ornithosis. Agents of lymphogranuloma venereum and granuloma inguinale. The spirochetal agent of relapsing fever (Borrelia recurrentis) . The following gram-negative microorganisms: Haemophilus ducreyi (chancroid). Yersinia pestis (formerly Pasteurella pestis ) and Francisella tularensis (formerly Pasteurella tularensis ). Bartonella bacilliformis . Bacteroides species. Vibrio cholerae (formerly Vibrio comma ) and Campylobacter fetus (formerly Vibrio fetus ). Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli . Enterobacter aerogenes (formerly Aerobacter aerogenes ). Shigella species. Acinetobacter species (formerly Mima species and Herellea species). Haemophilus influenzae (respiratory infections). Klebsiella species (respiratory and urinary infections). Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Enterococcus faecalis (formerly Streptococcus faecalis ) have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Streptococcus pneumoniae (formerly Diplococcus pneumoniae ). Staphylococcus aureus , respiratory, skin and soft tissue infections. Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections. Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of infections due to: Neisseria gonorrhoeae and N. meningitidis . Treponema pallidum and Treponema pertenue (syphilis and yaws). Listeria monocytogenes . Clostridium species. Fusobacterium fusiforme (Vincent's infection). Actinomyces species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. Doxycycline is indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. uuid:c16f32b2-705a-48b1-893b-bec87e8f088a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0005114 PMID:41385096 "[{""id"":""uuid:3265a1dc-db46-4253-9ccb-ba09481df7b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:50374e0b-11d6-4e3e-9710-b9e5e1cd9253"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Doxycycline for Injection, USP and other antibacterial drugs, Doxycycline for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline for Injection, USP is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever, and the typhus group, Q fever, rickettsial pox and tick fevers). Mycoplasma pneumoniae (PPLO, Eaton Agent). Agents of psittacosis and ornithosis. Agents of lymphogranuloma venereum and granuloma inguinale. The spirochetal agent of relapsing fever (Borrelia recurrentis) . The following gram-negative microorganisms: Haemophilus ducreyi (chancroid). Yersinia pestis (formerly Pasteurella pestis ) and Francisella tularensis (formerly Pasteurella tularensis ). Bartonella bacilliformis . Bacteroides species. Vibrio cholerae (formerly Vibrio comma ) and Campylobacter fetus (formerly Vibrio fetus ). Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli . Enterobacter aerogenes (formerly Aerobacter aerogenes ). Shigella species. Acinetobacter species (formerly Mima species and Herellea species). Haemophilus influenzae (respiratory infections). Klebsiella species (respiratory and urinary infections). Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Enterococcus faecalis (formerly Streptococcus faecalis ) have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Streptococcus pneumoniae (formerly Diplococcus pneumoniae ). Staphylococcus aureus , respiratory, skin and soft tissue infections. Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections. Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of infections due to: Neisseria gonorrhoeae and N. meningitidis . Treponema pallidum and Treponema pertenue (syphilis and yaws). Listeria monocytogenes . Clostridium species. Fusobacterium fusiforme (Vincent's infection). Actinomyces species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. Doxycycline is indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. uuid:4d9741f2-f9a5-4178-91fd-63f66f59770b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0005545 PMID:41385096 "[{""id"":""uuid:5ab36a32-401b-47d8-b0eb-891aef0839ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e0650119-a22d-40d5-8901-3bd12ed81302"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Doxycycline for Injection, USP and other antibacterial drugs, Doxycycline for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline for Injection, USP is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever, and the typhus group, Q fever, rickettsial pox and tick fevers). Mycoplasma pneumoniae (PPLO, Eaton Agent). Agents of psittacosis and ornithosis. Agents of lymphogranuloma venereum and granuloma inguinale. The spirochetal agent of relapsing fever (Borrelia recurrentis) . The following gram-negative microorganisms: Haemophilus ducreyi (chancroid). Yersinia pestis (formerly Pasteurella pestis ) and Francisella tularensis (formerly Pasteurella tularensis ). Bartonella bacilliformis . Bacteroides species. Vibrio cholerae (formerly Vibrio comma ) and Campylobacter fetus (formerly Vibrio fetus ). Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli . Enterobacter aerogenes (formerly Aerobacter aerogenes ). Shigella species. Acinetobacter species (formerly Mima species and Herellea species). Haemophilus influenzae (respiratory infections). Klebsiella species (respiratory and urinary infections). Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Enterococcus faecalis (formerly Streptococcus faecalis ) have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Streptococcus pneumoniae (formerly Diplococcus pneumoniae ). Staphylococcus aureus , respiratory, skin and soft tissue infections. Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections. Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of infections due to: Neisseria gonorrhoeae and N. meningitidis . Treponema pallidum and Treponema pertenue (syphilis and yaws). Listeria monocytogenes . Clostridium species. Fusobacterium fusiforme (Vincent's infection). Actinomyces species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. Doxycycline is indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. uuid:7da8acb9-c7a2-4ce7-86cf-485eb8092524 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0021108 PMID:41385096 "[{""id"":""uuid:0f390407-734c-4d4e-b4cf-3f2343d18db6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1557ed02-d43d-4547-9627-6b0192aac30b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Doxycycline for Injection, USP and other antibacterial drugs, Doxycycline for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline for Injection, USP is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever, and the typhus group, Q fever, rickettsial pox and tick fevers). Mycoplasma pneumoniae (PPLO, Eaton Agent). Agents of psittacosis and ornithosis. Agents of lymphogranuloma venereum and granuloma inguinale. The spirochetal agent of relapsing fever (Borrelia recurrentis) . The following gram-negative microorganisms: Haemophilus ducreyi (chancroid). Yersinia pestis (formerly Pasteurella pestis ) and Francisella tularensis (formerly Pasteurella tularensis ). Bartonella bacilliformis . Bacteroides species. Vibrio cholerae (formerly Vibrio comma ) and Campylobacter fetus (formerly Vibrio fetus ). Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli . Enterobacter aerogenes (formerly Aerobacter aerogenes ). Shigella species. Acinetobacter species (formerly Mima species and Herellea species). Haemophilus influenzae (respiratory infections). Klebsiella species (respiratory and urinary infections). Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Enterococcus faecalis (formerly Streptococcus faecalis ) have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Streptococcus pneumoniae (formerly Diplococcus pneumoniae ). Staphylococcus aureus , respiratory, skin and soft tissue infections. Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections. Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of infections due to: Neisseria gonorrhoeae and N. meningitidis . Treponema pallidum and Treponema pertenue (syphilis and yaws). Listeria monocytogenes . Clostridium species. Fusobacterium fusiforme (Vincent's infection). Actinomyces species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. Doxycycline is indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. uuid:128f92c4-912c-4ee3-b8bd-30708b083859 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0018984 PMID:41385096 "[{""id"":""uuid:0670fd20-4eb2-48d0-a0ed-f4ab1ea67ecb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b5580a89-f85e-4d29-b950-b4f1adafedbc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Doxycycline for Injection, USP and other antibacterial drugs, Doxycycline for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline for Injection, USP is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever, and the typhus group, Q fever, rickettsial pox and tick fevers). Mycoplasma pneumoniae (PPLO, Eaton Agent). Agents of psittacosis and ornithosis. Agents of lymphogranuloma venereum and granuloma inguinale. The spirochetal agent of relapsing fever (Borrelia recurrentis) . The following gram-negative microorganisms: Haemophilus ducreyi (chancroid). Yersinia pestis (formerly Pasteurella pestis ) and Francisella tularensis (formerly Pasteurella tularensis ). Bartonella bacilliformis . Bacteroides species. Vibrio cholerae (formerly Vibrio comma ) and Campylobacter fetus (formerly Vibrio fetus ). Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli . Enterobacter aerogenes (formerly Aerobacter aerogenes ). Shigella species. Acinetobacter species (formerly Mima species and Herellea species). Haemophilus influenzae (respiratory infections). Klebsiella species (respiratory and urinary infections). Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Enterococcus faecalis (formerly Streptococcus faecalis ) have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Streptococcus pneumoniae (formerly Diplococcus pneumoniae ). Staphylococcus aureus , respiratory, skin and soft tissue infections. Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections. Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of infections due to: Neisseria gonorrhoeae and N. meningitidis . Treponema pallidum and Treponema pertenue (syphilis and yaws). Listeria monocytogenes . Clostridium species. Fusobacterium fusiforme (Vincent's infection). Actinomyces species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. Doxycycline is indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. uuid:c261ff2b-344d-4da6-99cb-93c9207f64cb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0006671 PMID:41385096 "[{""id"":""uuid:d7128081-0a8f-4b90-a590-3be9116093ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d35a7c71-40d2-4d5d-a320-78a540a9fe6b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Doxycycline for Injection, USP and other antibacterial drugs, Doxycycline for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline for Injection, USP is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever, and the typhus group, Q fever, rickettsial pox and tick fevers). Mycoplasma pneumoniae (PPLO, Eaton Agent). Agents of psittacosis and ornithosis. Agents of lymphogranuloma venereum and granuloma inguinale. The spirochetal agent of relapsing fever (Borrelia recurrentis) . The following gram-negative microorganisms: Haemophilus ducreyi (chancroid). Yersinia pestis (formerly Pasteurella pestis ) and Francisella tularensis (formerly Pasteurella tularensis ). Bartonella bacilliformis . Bacteroides species. Vibrio cholerae (formerly Vibrio comma ) and Campylobacter fetus (formerly Vibrio fetus ). Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli . Enterobacter aerogenes (formerly Aerobacter aerogenes ). Shigella species. Acinetobacter species (formerly Mima species and Herellea species). Haemophilus influenzae (respiratory infections). Klebsiella species (respiratory and urinary infections). Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Enterococcus faecalis (formerly Streptococcus faecalis ) have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Streptococcus pneumoniae (formerly Diplococcus pneumoniae ). Staphylococcus aureus , respiratory, skin and soft tissue infections. Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections. Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of infections due to: Neisseria gonorrhoeae and N. meningitidis . Treponema pallidum and Treponema pertenue (syphilis and yaws). Listeria monocytogenes . Clostridium species. Fusobacterium fusiforme (Vincent's infection). Actinomyces species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. Doxycycline is indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. uuid:e306a2ff-93d6-4f3c-9a83-140a14fab0c4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:209807 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:640bb08d-e13f-4af6-8bd6-2f3913db83f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e788cee1-cdec-4539-b595-d1aa6a78570a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefoxitin for Injection, USP is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) Lower respiratory tract infections , including pneumonia and lung abscess, caused by Streptococcus pneumoniae , other streptococci (excluding enterococci, e.g., Enterococcus faecalis [formerly Streptococcus faecalis ]), Staphylococcus aureus (including penicillinase-producing strains), Escherichia coli , Klebsiella species, Haemophilus influenzae, and Bacteroides species. (2) Urinary tract infections caused by Escherichia coli , Klebsiella species, Proteus mirabilis , Morganella morganii , Proteus vulgaris and Providencia species (including P. rettgeri ). (3) Intra-abdominal infections, including peritonitis and intra-abdominal abscess, caused by Escherichia coli , Klebsiella species, Bacteroides species including Bacteroides fragilis , and Clostridium species. (4) Gynecological infections, including endometritis, pelvic cellulitis, and pelvic inflammatory disease caused by Escherichia coli , Neisseria gonorrhoeae (including penicillinase-producing strains), Bacteroides species including B. fragilis , Clostridium species, Peptococcus niger , Peptostreptococcus species, and Streptococcus agalactiae . Cefoxitin for Injection, USP, like cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when Cefoxitin for Injection, USP is used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti-chlamydial coverage should be added. (5) Septicemia caused by Streptococcus pneumoniae , Staphylococcus aureus (including penicillinase-producing strains), Escherichia coli , Klebsiella species, and Bacteroides species including B. fragilis. (6) Bone and joint infections caused by Staphylococcus aureus (including penicillinase-producing strains). (7) Skin and skin structure infections caused by Staphylococcus aureus (including penicillinase-producing strains), Staphylococcus epidermidis , Streptococcus pyogenes and other streptococci (excluding enterococci e.g., Enterococcus faecalis [formerly Streptococcus faecalis ]), Escherichia coli , Proteus mirabilis , Klebsiella species, Bacteroides species including B. fragilis , Clostridium species, Peptococcus niger , and Peptostreptococcus species. Appropriate culture and susceptibility studies should be performed to determine the susceptibility of the causative organisms to Cefoxitin for Injection, USP. Therapy may be started while awaiting the results of these studies. In randomized comparative studies, Cefoxitin for Injection, USP and cephalothin were comparably safe and effective in the management of infections caused by gram-positive cocci and gram-negative rods susceptible to the cephalosporins. Cefoxitin for Injection, USP has a high degree of stability in the presence of bacterial beta-lactamases, both penicillinases and cephalosporinases. Many infections caused by aerobic and anaerobic gram-negative bacteria resistant to some cephalosporins respond to Cefoxitin for Injection, USP. Similarly, many infections caused by aerobic and anaerobic bacteria resistant to some penicillin antibiotics (ampicillin, carbenicillin, penicillin G) respond to treatment with Cefoxitin for Injection, USP. Many infections caused by mixtures of susceptible aerobic and anaerobic bacteria respond to treatment with Cefoxitin for Injection, USP. uuid:0cf8b979-ab73-40c8-91fd-45a2a7ca4037 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:209807 biolink:treats MONDO:0000744 PMID:41385096 "[{""id"":""uuid:5933e9f9-1679-4843-86bc-2a69160e8130"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9b5cd534-11dc-4f14-a833-365450bac5fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefoxitin for Injection, USP is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) Lower respiratory tract infections , including pneumonia and lung abscess, caused by Streptococcus pneumoniae , other streptococci (excluding enterococci, e.g., Enterococcus faecalis [formerly Streptococcus faecalis ]), Staphylococcus aureus (including penicillinase-producing strains), Escherichia coli , Klebsiella species, Haemophilus influenzae, and Bacteroides species. (2) Urinary tract infections caused by Escherichia coli , Klebsiella species, Proteus mirabilis , Morganella morganii , Proteus vulgaris and Providencia species (including P. rettgeri ). (3) Intra-abdominal infections, including peritonitis and intra-abdominal abscess, caused by Escherichia coli , Klebsiella species, Bacteroides species including Bacteroides fragilis , and Clostridium species. (4) Gynecological infections, including endometritis, pelvic cellulitis, and pelvic inflammatory disease caused by Escherichia coli , Neisseria gonorrhoeae (including penicillinase-producing strains), Bacteroides species including B. fragilis , Clostridium species, Peptococcus niger , Peptostreptococcus species, and Streptococcus agalactiae . Cefoxitin for Injection, USP, like cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when Cefoxitin for Injection, USP is used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti-chlamydial coverage should be added. (5) Septicemia caused by Streptococcus pneumoniae , Staphylococcus aureus (including penicillinase-producing strains), Escherichia coli , Klebsiella species, and Bacteroides species including B. fragilis. (6) Bone and joint infections caused by Staphylococcus aureus (including penicillinase-producing strains). (7) Skin and skin structure infections caused by Staphylococcus aureus (including penicillinase-producing strains), Staphylococcus epidermidis , Streptococcus pyogenes and other streptococci (excluding enterococci e.g., Enterococcus faecalis [formerly Streptococcus faecalis ]), Escherichia coli , Proteus mirabilis , Klebsiella species, Bacteroides species including B. fragilis , Clostridium species, Peptococcus niger , and Peptostreptococcus species. Appropriate culture and susceptibility studies should be performed to determine the susceptibility of the causative organisms to Cefoxitin for Injection, USP. Therapy may be started while awaiting the results of these studies. In randomized comparative studies, Cefoxitin for Injection, USP and cephalothin were comparably safe and effective in the management of infections caused by gram-positive cocci and gram-negative rods susceptible to the cephalosporins. Cefoxitin for Injection, USP has a high degree of stability in the presence of bacterial beta-lactamases, both penicillinases and cephalosporinases. Many infections caused by aerobic and anaerobic gram-negative bacteria resistant to some cephalosporins respond to Cefoxitin for Injection, USP. Similarly, many infections caused by aerobic and anaerobic bacteria resistant to some penicillin antibiotics (ampicillin, carbenicillin, penicillin G) respond to treatment with Cefoxitin for Injection, USP. Many infections caused by mixtures of susceptible aerobic and anaerobic bacteria respond to treatment with Cefoxitin for Injection, USP. uuid:47932184-7c56-4576-ad82-f046145e8a0a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:209807 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:8837e9c9-96b7-4e7f-918a-4b528b21290f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e6030b66-7d82-4f6a-aa2d-4461f29341d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefoxitin for Injection, USP is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) Lower respiratory tract infections , including pneumonia and lung abscess, caused by Streptococcus pneumoniae , other streptococci (excluding enterococci, e.g., Enterococcus faecalis [formerly Streptococcus faecalis ]), Staphylococcus aureus (including penicillinase-producing strains), Escherichia coli , Klebsiella species, Haemophilus influenzae, and Bacteroides species. (2) Urinary tract infections caused by Escherichia coli , Klebsiella species, Proteus mirabilis , Morganella morganii , Proteus vulgaris and Providencia species (including P. rettgeri ). (3) Intra-abdominal infections, including peritonitis and intra-abdominal abscess, caused by Escherichia coli , Klebsiella species, Bacteroides species including Bacteroides fragilis , and Clostridium species. (4) Gynecological infections, including endometritis, pelvic cellulitis, and pelvic inflammatory disease caused by Escherichia coli , Neisseria gonorrhoeae (including penicillinase-producing strains), Bacteroides species including B. fragilis , Clostridium species, Peptococcus niger , Peptostreptococcus species, and Streptococcus agalactiae . Cefoxitin for Injection, USP, like cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when Cefoxitin for Injection, USP is used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti-chlamydial coverage should be added. (5) Septicemia caused by Streptococcus pneumoniae , Staphylococcus aureus (including penicillinase-producing strains), Escherichia coli , Klebsiella species, and Bacteroides species including B. fragilis. (6) Bone and joint infections caused by Staphylococcus aureus (including penicillinase-producing strains). (7) Skin and skin structure infections caused by Staphylococcus aureus (including penicillinase-producing strains), Staphylococcus epidermidis , Streptococcus pyogenes and other streptococci (excluding enterococci e.g., Enterococcus faecalis [formerly Streptococcus faecalis ]), Escherichia coli , Proteus mirabilis , Klebsiella species, Bacteroides species including B. fragilis , Clostridium species, Peptococcus niger , and Peptostreptococcus species. Appropriate culture and susceptibility studies should be performed to determine the susceptibility of the causative organisms to Cefoxitin for Injection, USP. Therapy may be started while awaiting the results of these studies. In randomized comparative studies, Cefoxitin for Injection, USP and cephalothin were comparably safe and effective in the management of infections caused by gram-positive cocci and gram-negative rods susceptible to the cephalosporins. Cefoxitin for Injection, USP has a high degree of stability in the presence of bacterial beta-lactamases, both penicillinases and cephalosporinases. Many infections caused by aerobic and anaerobic gram-negative bacteria resistant to some cephalosporins respond to Cefoxitin for Injection, USP. Similarly, many infections caused by aerobic and anaerobic bacteria resistant to some penicillin antibiotics (ampicillin, carbenicillin, penicillin G) respond to treatment with Cefoxitin for Injection, USP. Many infections caused by mixtures of susceptible aerobic and anaerobic bacteria respond to treatment with Cefoxitin for Injection, USP. uuid:864bb5d9-ec97-406d-8847-593e7bfcf1b6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:209807 biolink:treats MONDO:0004522 PMID:41385096 "[{""id"":""uuid:8eb8fc0d-42b9-4eb0-ab6d-bac767253f41"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a9a01e2b-d3b9-4bd4-a725-4093d0e8bb8d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefoxitin for Injection, USP is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) Lower respiratory tract infections , including pneumonia and lung abscess, caused by Streptococcus pneumoniae , other streptococci (excluding enterococci, e.g., Enterococcus faecalis [formerly Streptococcus faecalis ]), Staphylococcus aureus (including penicillinase-producing strains), Escherichia coli , Klebsiella species, Haemophilus influenzae, and Bacteroides species. (2) Urinary tract infections caused by Escherichia coli , Klebsiella species, Proteus mirabilis , Morganella morganii , Proteus vulgaris and Providencia species (including P. rettgeri ). (3) Intra-abdominal infections, including peritonitis and intra-abdominal abscess, caused by Escherichia coli , Klebsiella species, Bacteroides species including Bacteroides fragilis , and Clostridium species. (4) Gynecological infections, including endometritis, pelvic cellulitis, and pelvic inflammatory disease caused by Escherichia coli , Neisseria gonorrhoeae (including penicillinase-producing strains), Bacteroides species including B. fragilis , Clostridium species, Peptococcus niger , Peptostreptococcus species, and Streptococcus agalactiae . Cefoxitin for Injection, USP, like cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when Cefoxitin for Injection, USP is used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti-chlamydial coverage should be added. (5) Septicemia caused by Streptococcus pneumoniae , Staphylococcus aureus (including penicillinase-producing strains), Escherichia coli , Klebsiella species, and Bacteroides species including B. fragilis. (6) Bone and joint infections caused by Staphylococcus aureus (including penicillinase-producing strains). (7) Skin and skin structure infections caused by Staphylococcus aureus (including penicillinase-producing strains), Staphylococcus epidermidis , Streptococcus pyogenes and other streptococci (excluding enterococci e.g., Enterococcus faecalis [formerly Streptococcus faecalis ]), Escherichia coli , Proteus mirabilis , Klebsiella species, Bacteroides species including B. fragilis , Clostridium species, Peptococcus niger , and Peptostreptococcus species. Appropriate culture and susceptibility studies should be performed to determine the susceptibility of the causative organisms to Cefoxitin for Injection, USP. Therapy may be started while awaiting the results of these studies. In randomized comparative studies, Cefoxitin for Injection, USP and cephalothin were comparably safe and effective in the management of infections caused by gram-positive cocci and gram-negative rods susceptible to the cephalosporins. Cefoxitin for Injection, USP has a high degree of stability in the presence of bacterial beta-lactamases, both penicillinases and cephalosporinases. Many infections caused by aerobic and anaerobic gram-negative bacteria resistant to some cephalosporins respond to Cefoxitin for Injection, USP. Similarly, many infections caused by aerobic and anaerobic bacteria resistant to some penicillin antibiotics (ampicillin, carbenicillin, penicillin G) respond to treatment with Cefoxitin for Injection, USP. Many infections caused by mixtures of susceptible aerobic and anaerobic bacteria respond to treatment with Cefoxitin for Injection, USP. uuid:ef8ac618-3703-4bc6-a657-64b04d730901 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:209807 biolink:treats MONDO:0000918 PMID:41385096 "[{""id"":""uuid:bdeea7f6-28f3-43f2-b7af-0b2800e09717"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d5c443b1-e0e0-4454-9036-b1fce216cead"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefoxitin for Injection, USP is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) Lower respiratory tract infections , including pneumonia and lung abscess, caused by Streptococcus pneumoniae , other streptococci (excluding enterococci, e.g., Enterococcus faecalis [formerly Streptococcus faecalis ]), Staphylococcus aureus (including penicillinase-producing strains), Escherichia coli , Klebsiella species, Haemophilus influenzae, and Bacteroides species. (2) Urinary tract infections caused by Escherichia coli , Klebsiella species, Proteus mirabilis , Morganella morganii , Proteus vulgaris and Providencia species (including P. rettgeri ). (3) Intra-abdominal infections, including peritonitis and intra-abdominal abscess, caused by Escherichia coli , Klebsiella species, Bacteroides species including Bacteroides fragilis , and Clostridium species. (4) Gynecological infections, including endometritis, pelvic cellulitis, and pelvic inflammatory disease caused by Escherichia coli , Neisseria gonorrhoeae (including penicillinase-producing strains), Bacteroides species including B. fragilis , Clostridium species, Peptococcus niger , Peptostreptococcus species, and Streptococcus agalactiae . Cefoxitin for Injection, USP, like cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when Cefoxitin for Injection, USP is used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti-chlamydial coverage should be added. (5) Septicemia caused by Streptococcus pneumoniae , Staphylococcus aureus (including penicillinase-producing strains), Escherichia coli , Klebsiella species, and Bacteroides species including B. fragilis. (6) Bone and joint infections caused by Staphylococcus aureus (including penicillinase-producing strains). (7) Skin and skin structure infections caused by Staphylococcus aureus (including penicillinase-producing strains), Staphylococcus epidermidis , Streptococcus pyogenes and other streptococci (excluding enterococci e.g., Enterococcus faecalis [formerly Streptococcus faecalis ]), Escherichia coli , Proteus mirabilis , Klebsiella species, Bacteroides species including B. fragilis , Clostridium species, Peptococcus niger , and Peptostreptococcus species. Appropriate culture and susceptibility studies should be performed to determine the susceptibility of the causative organisms to Cefoxitin for Injection, USP. Therapy may be started while awaiting the results of these studies. In randomized comparative studies, Cefoxitin for Injection, USP and cephalothin were comparably safe and effective in the management of infections caused by gram-positive cocci and gram-negative rods susceptible to the cephalosporins. Cefoxitin for Injection, USP has a high degree of stability in the presence of bacterial beta-lactamases, both penicillinases and cephalosporinases. Many infections caused by aerobic and anaerobic gram-negative bacteria resistant to some cephalosporins respond to Cefoxitin for Injection, USP. Similarly, many infections caused by aerobic and anaerobic bacteria resistant to some penicillin antibiotics (ampicillin, carbenicillin, penicillin G) respond to treatment with Cefoxitin for Injection, USP. Many infections caused by mixtures of susceptible aerobic and anaerobic bacteria respond to treatment with Cefoxitin for Injection, USP. uuid:394b00da-1919-4bf1-924a-fff845eaf29c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:209807 biolink:treats MONDO:0006887 PMID:41385096 "[{""id"":""uuid:63ec08a2-dc80-4ffc-822f-979c8d0d5d97"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:19b32b10-a544-4da6-a4ee-16d0b3983d00"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefoxitin for Injection, USP is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) Lower respiratory tract infections , including pneumonia and lung abscess, caused by Streptococcus pneumoniae , other streptococci (excluding enterococci, e.g., Enterococcus faecalis [formerly Streptococcus faecalis ]), Staphylococcus aureus (including penicillinase-producing strains), Escherichia coli , Klebsiella species, Haemophilus influenzae, and Bacteroides species. (2) Urinary tract infections caused by Escherichia coli , Klebsiella species, Proteus mirabilis , Morganella morganii , Proteus vulgaris and Providencia species (including P. rettgeri ). (3) Intra-abdominal infections, including peritonitis and intra-abdominal abscess, caused by Escherichia coli , Klebsiella species, Bacteroides species including Bacteroides fragilis , and Clostridium species. (4) Gynecological infections, including endometritis, pelvic cellulitis, and pelvic inflammatory disease caused by Escherichia coli , Neisseria gonorrhoeae (including penicillinase-producing strains), Bacteroides species including B. fragilis , Clostridium species, Peptococcus niger , Peptostreptococcus species, and Streptococcus agalactiae . Cefoxitin for Injection, USP, like cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when Cefoxitin for Injection, USP is used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti-chlamydial coverage should be added. (5) Septicemia caused by Streptococcus pneumoniae , Staphylococcus aureus (including penicillinase-producing strains), Escherichia coli , Klebsiella species, and Bacteroides species including B. fragilis. (6) Bone and joint infections caused by Staphylococcus aureus (including penicillinase-producing strains). (7) Skin and skin structure infections caused by Staphylococcus aureus (including penicillinase-producing strains), Staphylococcus epidermidis , Streptococcus pyogenes and other streptococci (excluding enterococci e.g., Enterococcus faecalis [formerly Streptococcus faecalis ]), Escherichia coli , Proteus mirabilis , Klebsiella species, Bacteroides species including B. fragilis , Clostridium species, Peptococcus niger , and Peptostreptococcus species. Appropriate culture and susceptibility studies should be performed to determine the susceptibility of the causative organisms to Cefoxitin for Injection, USP. Therapy may be started while awaiting the results of these studies. In randomized comparative studies, Cefoxitin for Injection, USP and cephalothin were comparably safe and effective in the management of infections caused by gram-positive cocci and gram-negative rods susceptible to the cephalosporins. Cefoxitin for Injection, USP has a high degree of stability in the presence of bacterial beta-lactamases, both penicillinases and cephalosporinases. Many infections caused by aerobic and anaerobic gram-negative bacteria resistant to some cephalosporins respond to Cefoxitin for Injection, USP. Similarly, many infections caused by aerobic and anaerobic bacteria resistant to some penicillin antibiotics (ampicillin, carbenicillin, penicillin G) respond to treatment with Cefoxitin for Injection, USP. Many infections caused by mixtures of susceptible aerobic and anaerobic bacteria respond to treatment with Cefoxitin for Injection, USP. uuid:126f164d-9547-46b1-b89e-7fb7892f7879 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:209807 biolink:treats MONDO:0000922 PMID:41385096 "[{""id"":""uuid:9d30adbc-e3b3-4f1d-b9cb-3eaf14976b51"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:82241acb-8642-4079-87cb-c5ea99683553"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefoxitin for Injection, USP is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) Lower respiratory tract infections , including pneumonia and lung abscess, caused by Streptococcus pneumoniae , other streptococci (excluding enterococci, e.g., Enterococcus faecalis [formerly Streptococcus faecalis ]), Staphylococcus aureus (including penicillinase-producing strains), Escherichia coli , Klebsiella species, Haemophilus influenzae, and Bacteroides species. (2) Urinary tract infections caused by Escherichia coli , Klebsiella species, Proteus mirabilis , Morganella morganii , Proteus vulgaris and Providencia species (including P. rettgeri ). (3) Intra-abdominal infections, including peritonitis and intra-abdominal abscess, caused by Escherichia coli , Klebsiella species, Bacteroides species including Bacteroides fragilis , and Clostridium species. (4) Gynecological infections, including endometritis, pelvic cellulitis, and pelvic inflammatory disease caused by Escherichia coli , Neisseria gonorrhoeae (including penicillinase-producing strains), Bacteroides species including B. fragilis , Clostridium species, Peptococcus niger , Peptostreptococcus species, and Streptococcus agalactiae . Cefoxitin for Injection, USP, like cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when Cefoxitin for Injection, USP is used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti-chlamydial coverage should be added. (5) Septicemia caused by Streptococcus pneumoniae , Staphylococcus aureus (including penicillinase-producing strains), Escherichia coli , Klebsiella species, and Bacteroides species including B. fragilis. (6) Bone and joint infections caused by Staphylococcus aureus (including penicillinase-producing strains). (7) Skin and skin structure infections caused by Staphylococcus aureus (including penicillinase-producing strains), Staphylococcus epidermidis , Streptococcus pyogenes and other streptococci (excluding enterococci e.g., Enterococcus faecalis [formerly Streptococcus faecalis ]), Escherichia coli , Proteus mirabilis , Klebsiella species, Bacteroides species including B. fragilis , Clostridium species, Peptococcus niger , and Peptostreptococcus species. Appropriate culture and susceptibility studies should be performed to determine the susceptibility of the causative organisms to Cefoxitin for Injection, USP. Therapy may be started while awaiting the results of these studies. In randomized comparative studies, Cefoxitin for Injection, USP and cephalothin were comparably safe and effective in the management of infections caused by gram-positive cocci and gram-negative rods susceptible to the cephalosporins. Cefoxitin for Injection, USP has a high degree of stability in the presence of bacterial beta-lactamases, both penicillinases and cephalosporinases. Many infections caused by aerobic and anaerobic gram-negative bacteria resistant to some cephalosporins respond to Cefoxitin for Injection, USP. Similarly, many infections caused by aerobic and anaerobic bacteria resistant to some penicillin antibiotics (ampicillin, carbenicillin, penicillin G) respond to treatment with Cefoxitin for Injection, USP. Many infections caused by mixtures of susceptible aerobic and anaerobic bacteria respond to treatment with Cefoxitin for Injection, USP. uuid:9841fac4-62e6-49ce-bf06-c92888eabd4c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:209807 biolink:treats MONDO:0700217 PMID:41385096 "[{""id"":""uuid:8a6ea4b9-ff89-45cd-814c-015ce14760d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8b496933-7911-4e10-a4dc-6eefca6cd1ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefoxitin for Injection, USP is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) Lower respiratory tract infections , including pneumonia and lung abscess, caused by Streptococcus pneumoniae , other streptococci (excluding enterococci, e.g., Enterococcus faecalis [formerly Streptococcus faecalis ]), Staphylococcus aureus (including penicillinase-producing strains), Escherichia coli , Klebsiella species, Haemophilus influenzae, and Bacteroides species. (2) Urinary tract infections caused by Escherichia coli , Klebsiella species, Proteus mirabilis , Morganella morganii , Proteus vulgaris and Providencia species (including P. rettgeri ). (3) Intra-abdominal infections, including peritonitis and intra-abdominal abscess, caused by Escherichia coli , Klebsiella species, Bacteroides species including Bacteroides fragilis , and Clostridium species. (4) Gynecological infections, including endometritis, pelvic cellulitis, and pelvic inflammatory disease caused by Escherichia coli , Neisseria gonorrhoeae (including penicillinase-producing strains), Bacteroides species including B. fragilis , Clostridium species, Peptococcus niger , Peptostreptococcus species, and Streptococcus agalactiae . Cefoxitin for Injection, USP, like cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when Cefoxitin for Injection, USP is used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti-chlamydial coverage should be added. (5) Septicemia caused by Streptococcus pneumoniae , Staphylococcus aureus (including penicillinase-producing strains), Escherichia coli , Klebsiella species, and Bacteroides species including B. fragilis. (6) Bone and joint infections caused by Staphylococcus aureus (including penicillinase-producing strains). (7) Skin and skin structure infections caused by Staphylococcus aureus (including penicillinase-producing strains), Staphylococcus epidermidis , Streptococcus pyogenes and other streptococci (excluding enterococci e.g., Enterococcus faecalis [formerly Streptococcus faecalis ]), Escherichia coli , Proteus mirabilis , Klebsiella species, Bacteroides species including B. fragilis , Clostridium species, Peptococcus niger , and Peptostreptococcus species. Appropriate culture and susceptibility studies should be performed to determine the susceptibility of the causative organisms to Cefoxitin for Injection, USP. Therapy may be started while awaiting the results of these studies. In randomized comparative studies, Cefoxitin for Injection, USP and cephalothin were comparably safe and effective in the management of infections caused by gram-positive cocci and gram-negative rods susceptible to the cephalosporins. Cefoxitin for Injection, USP has a high degree of stability in the presence of bacterial beta-lactamases, both penicillinases and cephalosporinases. Many infections caused by aerobic and anaerobic gram-negative bacteria resistant to some cephalosporins respond to Cefoxitin for Injection, USP. Similarly, many infections caused by aerobic and anaerobic bacteria resistant to some penicillin antibiotics (ampicillin, carbenicillin, penicillin G) respond to treatment with Cefoxitin for Injection, USP. Many infections caused by mixtures of susceptible aerobic and anaerobic bacteria respond to treatment with Cefoxitin for Injection, USP. uuid:de600be5-eb19-497a-b8be-b8a5f920f150 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:209807 biolink:treats UMLS:C0851989 PMID:41385096 "[{""id"":""uuid:0f5e3a26-8efa-47e7-aa03-547f4eb22b16"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c7f8c874-e0ea-4ba1-86ea-6e1ce7d77890"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefoxitin for Injection, USP is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) Lower respiratory tract infections , including pneumonia and lung abscess, caused by Streptococcus pneumoniae , other streptococci (excluding enterococci, e.g., Enterococcus faecalis [formerly Streptococcus faecalis ]), Staphylococcus aureus (including penicillinase-producing strains), Escherichia coli , Klebsiella species, Haemophilus influenzae, and Bacteroides species. (2) Urinary tract infections caused by Escherichia coli , Klebsiella species, Proteus mirabilis , Morganella morganii , Proteus vulgaris and Providencia species (including P. rettgeri ). (3) Intra-abdominal infections, including peritonitis and intra-abdominal abscess, caused by Escherichia coli , Klebsiella species, Bacteroides species including Bacteroides fragilis , and Clostridium species. (4) Gynecological infections, including endometritis, pelvic cellulitis, and pelvic inflammatory disease caused by Escherichia coli , Neisseria gonorrhoeae (including penicillinase-producing strains), Bacteroides species including B. fragilis , Clostridium species, Peptococcus niger , Peptostreptococcus species, and Streptococcus agalactiae . Cefoxitin for Injection, USP, like cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when Cefoxitin for Injection, USP is used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti-chlamydial coverage should be added. (5) Septicemia caused by Streptococcus pneumoniae , Staphylococcus aureus (including penicillinase-producing strains), Escherichia coli , Klebsiella species, and Bacteroides species including B. fragilis. (6) Bone and joint infections caused by Staphylococcus aureus (including penicillinase-producing strains). (7) Skin and skin structure infections caused by Staphylococcus aureus (including penicillinase-producing strains), Staphylococcus epidermidis , Streptococcus pyogenes and other streptococci (excluding enterococci e.g., Enterococcus faecalis [formerly Streptococcus faecalis ]), Escherichia coli , Proteus mirabilis , Klebsiella species, Bacteroides species including B. fragilis , Clostridium species, Peptococcus niger , and Peptostreptococcus species. Appropriate culture and susceptibility studies should be performed to determine the susceptibility of the causative organisms to Cefoxitin for Injection, USP. Therapy may be started while awaiting the results of these studies. In randomized comparative studies, Cefoxitin for Injection, USP and cephalothin were comparably safe and effective in the management of infections caused by gram-positive cocci and gram-negative rods susceptible to the cephalosporins. Cefoxitin for Injection, USP has a high degree of stability in the presence of bacterial beta-lactamases, both penicillinases and cephalosporinases. Many infections caused by aerobic and anaerobic gram-negative bacteria resistant to some cephalosporins respond to Cefoxitin for Injection, USP. Similarly, many infections caused by aerobic and anaerobic bacteria resistant to some penicillin antibiotics (ampicillin, carbenicillin, penicillin G) respond to treatment with Cefoxitin for Injection, USP. Many infections caused by mixtures of susceptible aerobic and anaerobic bacteria respond to treatment with Cefoxitin for Injection, USP. uuid:0e2c2dc2-8e40-431a-8c5f-a56f9ec12d83 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:209807 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:c13104c1-0ed9-43b9-bd5a-8ae6f74798ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d2301381-b58a-4a6f-900f-87f3b7565337"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefoxitin for Injection, USP is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) Lower respiratory tract infections , including pneumonia and lung abscess, caused by Streptococcus pneumoniae , other streptococci (excluding enterococci, e.g., Enterococcus faecalis [formerly Streptococcus faecalis ]), Staphylococcus aureus (including penicillinase-producing strains), Escherichia coli , Klebsiella species, Haemophilus influenzae, and Bacteroides species. (2) Urinary tract infections caused by Escherichia coli , Klebsiella species, Proteus mirabilis , Morganella morganii , Proteus vulgaris and Providencia species (including P. rettgeri ). (3) Intra-abdominal infections, including peritonitis and intra-abdominal abscess, caused by Escherichia coli , Klebsiella species, Bacteroides species including Bacteroides fragilis , and Clostridium species. (4) Gynecological infections, including endometritis, pelvic cellulitis, and pelvic inflammatory disease caused by Escherichia coli , Neisseria gonorrhoeae (including penicillinase-producing strains), Bacteroides species including B. fragilis , Clostridium species, Peptococcus niger , Peptostreptococcus species, and Streptococcus agalactiae . Cefoxitin for Injection, USP, like cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when Cefoxitin for Injection, USP is used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti-chlamydial coverage should be added. (5) Septicemia caused by Streptococcus pneumoniae , Staphylococcus aureus (including penicillinase-producing strains), Escherichia coli , Klebsiella species, and Bacteroides species including B. fragilis. (6) Bone and joint infections caused by Staphylococcus aureus (including penicillinase-producing strains). (7) Skin and skin structure infections caused by Staphylococcus aureus (including penicillinase-producing strains), Staphylococcus epidermidis , Streptococcus pyogenes and other streptococci (excluding enterococci e.g., Enterococcus faecalis [formerly Streptococcus faecalis ]), Escherichia coli , Proteus mirabilis , Klebsiella species, Bacteroides species including B. fragilis , Clostridium species, Peptococcus niger , and Peptostreptococcus species. Appropriate culture and susceptibility studies should be performed to determine the susceptibility of the causative organisms to Cefoxitin for Injection, USP. Therapy may be started while awaiting the results of these studies. In randomized comparative studies, Cefoxitin for Injection, USP and cephalothin were comparably safe and effective in the management of infections caused by gram-positive cocci and gram-negative rods susceptible to the cephalosporins. Cefoxitin for Injection, USP has a high degree of stability in the presence of bacterial beta-lactamases, both penicillinases and cephalosporinases. Many infections caused by aerobic and anaerobic gram-negative bacteria resistant to some cephalosporins respond to Cefoxitin for Injection, USP. Similarly, many infections caused by aerobic and anaerobic bacteria resistant to some penicillin antibiotics (ampicillin, carbenicillin, penicillin G) respond to treatment with Cefoxitin for Injection, USP. Many infections caused by mixtures of susceptible aerobic and anaerobic bacteria respond to treatment with Cefoxitin for Injection, USP. uuid:45a2033e-8a51-4c9e-ae87-2adc695aebb1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50922 biolink:treats MONDO:0005277 PMID:41385096 "[{""id"":""uuid:d9e77fff-4d00-4193-b3f3-e6dfc40768a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:de59e84e-a03d-4b32-bd7f-8913313eed55"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Eletriptan hydrobromide tablets are indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use: • Use only if a clear diagnosis of migraine has been established. If a patient has no response to the first migraine attack treated with eletriptan hydrobromide tablets, reconsider the diagnosis of migraine before eletriptan hydrobromide tablets are administered to treat any subsequent attacks. • Eletriptan hydrobromide tablets are not intended for the prevention of migraine attacks. • Safety and effectiveness of eletriptan hydrobromide tablets have not been established for cluster headache. uuid:4856893c-11d9-4f78-abcb-349f88b9d40e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0005314 PMID:41385096 "[{""id"":""uuid:e87391d4-4564-4a6f-8d83-4123781b52af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:94a1fa00-fd82-4b33-a643-77994e8a4524"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis and serum sickness. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycisis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamon-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:d1bef059-d963-4115-b2d0-71160823fb47 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0021632 PMID:41385096 "[{""id"":""uuid:bd23dcd9-f3fc-4bce-841b-137e82d5af1b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:df6efdc4-5972-4928-8a36-17ddf972af4e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis and serum sickness. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycisis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamon-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:57ca459f-03a1-4c59-932c-b87bc4ddf21a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:1040026 PMID:41385096 "[{""id"":""uuid:3d888089-992a-487b-92f8-731983060553"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:49c3a87d-0c00-44c6-a98a-138e6b0d041e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis and serum sickness. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycisis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamon-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:233bf018-e2b4-43e9-bd91-a56e8fa858a4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0006640 PMID:41385096 "[{""id"":""uuid:66c5e3fd-9dd6-4965-aa67-335bf1c06b92"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ab31f07d-9619-4a2c-b305-1d5f1870be94"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:aa594033-9297-4976-bb03-bb276ca2a724 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68540 biolink:treats MONDO:0005301 PMID:41385096 "[{""id"":""uuid:d39f67e5-7ea1-42c8-b30d-b2dfe0493a81"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:faf02599-d689-48c8-a5ed-98005587de43"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:4c9193a2-c438-4115-ac6a-6edd626dabd0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/aubagio""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Teriflunomide tablets are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.|[EMA] AUBAGIO is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (MS) (please refer to section 5.1 for important information on the population for which efficacy has been established). uuid:e5863b02-6276-4fa2-8551-c006ed6db43e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68540 biolink:treats UMLS:C2921627 PMID:41385096 "[{""id"":""uuid:a91f73af-b50f-4939-9213-0f61eb9d6767"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dd07d040-6133-438b-9170-a8f599afd177"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Teriflunomide tablets are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. uuid:60776b71-5026-4eac-aac7-f18be3ea2006 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68540 biolink:treats MONDO:0000450 PMID:41385096 "[{""id"":""uuid:4f376ff7-bdbb-4f35-ac0d-603c6a1a4254"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a71edfb3-bf93-4a7e-82aa-188157092257"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Teriflunomide tablets are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. uuid:8c2df97d-f940-438f-8427-bad3f223dbdd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31498 biolink:treats UMLS:C0554628 PMID:41385096 "[{""id"":""uuid:dd777f58-8b44-462f-bf32-b48e7a6ce68f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fd4fc051-e8bf-4292-a4df-baf5b82986a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mupirocin ointment is indicated for the topical treatment of impetigo due to susceptible isolates of Staphylococcus aureus (S. aureus) and Streptococcus pyogenes (S. pyogenes) . uuid:933d1beb-79df-48a8-a110-9be6ff23e846 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6437 biolink:treats MONDO:0006710 PMID:41385096 "[{""id"":""uuid:11784306-0732-41f0-844e-656a20482c31"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:792d039b-075e-489c-96e0-27b8af722af3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:7967ead9-d834-40d2-a55f-d7bbb68086ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/levetiracetam-sun""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levetiracetam is indicated for the treatment of partial-onset seizures in patients 1 month of age and older (1.1) Levetiracetam is indicated for adjunctive therapy for the treatment of: • Myoclonic seizures in patients 12 years of age and older with juvenile myoclonic epilepsy (1.2) • Primary generalized tonic-clonic seizures in patients 6 years of age and older with idiopathic generalized epilepsy (1.3)|[EMA] Levetiracetam Hospira is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in adults and adolescents from 16 years of age with newly diagnosed epilepsy.Levetiracetam Hospira is indicated as adjunctive therapyin the treatment of partial onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with Idiopathic Generalised Epilepsy.Levetiracetam Hospira concentrate is an alternative for patients when oral administration is temporarily not feasible. uuid:07e4f65f-d113-4ff4-badb-e8498459e194 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64356 biolink:treats MONDO:0001583 PMID:41385096 "[{""id"":""uuid:7a94369a-c5fa-4987-9980-f000fe90aab1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2a3d6c0b-c9ea-402d-bf5e-b8f0f942be50"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pregabalin capsules are indicated for: Management of neuropathic pain associated with diabetic peripheral neuropathy Management of postherpetic neuralgia Adjunctive therapy for the treatment of partial-onset seizures in patients 17 years of age and older Management of fibromyalgia Management of neuropathic pain associated with spinal cord injury Pediatric use information is approved for Pfizer's LYRICA (pregabalin) Capsules and Oral Solution products. However, due to Pfizer's marketing exclusivity rights, this drug product is not labeled with that pediatric information. uuid:92fa7752-3821-4c61-810e-c375019734e8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:35A26E427H biolink:treats UMLS:C0581126 PMID:41385096 "[{""id"":""uuid:d77e68d0-315a-44c7-a0f7-d34488c88377"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:910215a5-68de-4ea5-a407-a5cb0a933150"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CINQAIR ® is indicated for the add-on maintenance treatment of patients with severe asthma aged 18 years and older with an eosinophilic phenotype [see Clinical Studies ( 14 )] . Limitation of Use: CINQAIR is not indicated for treatment of other eosinophilic conditions. CINQAIR is not indicated for the relief of acute bronchospasm or status asthmaticus [see Warnings and Precautions ( 5.2 )] . uuid:f944d336-c97c-40ff-9630-d94436e23b78 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats UMLS:C0406317 PMID:41385096 "[{""id"":""uuid:76ae3bda-15ce-4982-a924-5610cce17cc6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a0954d62-18b7-44c8-9eb9-3a6eff465239"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Betamethasone dipropionate spray is indicated for the treatment of mild to moderate plaque psoriasis in patients 18 years of age or older. uuid:6ba52dd7-4c76-478d-8d16-4f162c6c7837 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0005348 PMID:41385096 "[{""id"":""uuid:ce132ccc-8133-4db1-9289-79a62f706f6a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:023c86b3-20c2-42c4-9e33-3be7516afd29"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] A. By intravenous or intramuscular injection when oral therapy is not feasible: 1. Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia. Nonsuppurative thyroiditis. Hypercalcemia associated with cancer. 2. Rheumatic Disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis. Synovitis of osteoarthritis. Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis. Epicondylitis. Acute nonspecific tenosynovitis. Acute gouty arthritis. Psoriatic arthritis. Ankylosing spondylitis. 3. Collagen Diseases: During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus. Acute rheumatic carditis. 4. Dermatologic Diseases: Pemphigus. Severe erythema multiforme. (Stevens-Johnson Syndrome) Exfoliative dermatitis. Bullous dermatitis herpetiformis. Severe seborrheic dermatitis. Severe psoriasis. Mycosis fungoides. 5. Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma. Contact dermatitis. Atopic dermatitis. Serum sickness. Seasonal or perennial allergic rhinitis. Drug hypersensitivity reactions. Urticarial transfusion reactions. Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases: Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus. Iritis, iridocyclitis. Chorioretinitis. Diffuse posterior uveitis and choroiditis. Optic neuritis. Sympathetic ophthalmia. Anterior segment inflammation. Allergic conjunctivitis. Keratitis. Allergic corneal marginal ulcers. 7. Gastrointestinal Diseases: To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy). Regional enteritis (systemic therapy). 8. Respiratory Diseases: Symptomatic sarcoidosis. Berylliosis. Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler's syndrome not manageable by other means. Aspiration pneumonitis. 9. Hematologic Disorders: Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults. Erythroblastopenia (RBC anemia). Congenital (erythroid) hypoplastic anemia. 10. Neoplastic Diseases: For palliative management of: Leukemias and lymphomas in adults. Acute leukemia of childhood. 11. Edematous States: To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous: Tuberculosis meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. B. By intra-articular or soft tissue injection: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Synovitis of osteoarthritis. Rheumatoid arthritis. Acute and subacute bursitis. Acute gouty arthritis. Epicondylitis. Acute nonspecific tenosynovitis. Post-traumatic osteoarthritis. C. By intralesional injection: Keloids. Localized hypertrophic, infiltrated, inflammatory lesions of: lichen planus, psoriatic plaques, granuloma annulare, and lichen simplex chronicus (neurodermatitis). Discoid lupus erythematosus. Necrobiosis lipoidica diabeticorum. Alopecia areata. May also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:429f59ad-e99d-4376-8daa-fcc97e716c31 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0006572 PMID:41385096 "[{""id"":""uuid:68ab8e73-39ce-4a0b-98f6-96d2c6e2c6b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0d4b5bdd-7e04-4d19-8d69-83e39c10ec9e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] A. By intravenous or intramuscular injection when oral therapy is not feasible: 1. Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia. Nonsuppurative thyroiditis. Hypercalcemia associated with cancer. 2. Rheumatic Disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis. Synovitis of osteoarthritis. Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis. Epicondylitis. Acute nonspecific tenosynovitis. Acute gouty arthritis. Psoriatic arthritis. Ankylosing spondylitis. 3. Collagen Diseases: During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus. Acute rheumatic carditis. 4. Dermatologic Diseases: Pemphigus. Severe erythema multiforme. (Stevens-Johnson Syndrome) Exfoliative dermatitis. Bullous dermatitis herpetiformis. Severe seborrheic dermatitis. Severe psoriasis. Mycosis fungoides. 5. Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma. Contact dermatitis. Atopic dermatitis. Serum sickness. Seasonal or perennial allergic rhinitis. Drug hypersensitivity reactions. Urticarial transfusion reactions. Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases: Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus. Iritis, iridocyclitis. Chorioretinitis. Diffuse posterior uveitis and choroiditis. Optic neuritis. Sympathetic ophthalmia. Anterior segment inflammation. Allergic conjunctivitis. Keratitis. Allergic corneal marginal ulcers. 7. Gastrointestinal Diseases: To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy). Regional enteritis (systemic therapy). 8. Respiratory Diseases: Symptomatic sarcoidosis. Berylliosis. Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler's syndrome not manageable by other means. Aspiration pneumonitis. 9. Hematologic Disorders: Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults. Erythroblastopenia (RBC anemia). Congenital (erythroid) hypoplastic anemia. 10. Neoplastic Diseases: For palliative management of: Leukemias and lymphomas in adults. Acute leukemia of childhood. 11. Edematous States: To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous: Tuberculosis meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. B. By intra-articular or soft tissue injection: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Synovitis of osteoarthritis. Rheumatoid arthritis. Acute and subacute bursitis. Acute gouty arthritis. Epicondylitis. Acute nonspecific tenosynovitis. Post-traumatic osteoarthritis. C. By intralesional injection: Keloids. Localized hypertrophic, infiltrated, inflammatory lesions of: lichen planus, psoriatic plaques, granuloma annulare, and lichen simplex chronicus (neurodermatitis). Discoid lupus erythematosus. Necrobiosis lipoidica diabeticorum. Alopecia areata. May also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:13b73958-66aa-43ab-8d87-ce45398e859f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0006554 PMID:41385096 "[{""id"":""uuid:6b6eabb3-4418-4d45-a3e1-b2dd6180b24b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:83f72fe8-de37-4eb0-96f8-57f48489b31d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] A. By intravenous or intramuscular injection when oral therapy is not feasible: 1. Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia. Nonsuppurative thyroiditis. Hypercalcemia associated with cancer. 2. Rheumatic Disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis. Synovitis of osteoarthritis. Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis. Epicondylitis. Acute nonspecific tenosynovitis. Acute gouty arthritis. Psoriatic arthritis. Ankylosing spondylitis. 3. Collagen Diseases: During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus. Acute rheumatic carditis. 4. Dermatologic Diseases: Pemphigus. Severe erythema multiforme. (Stevens-Johnson Syndrome) Exfoliative dermatitis. Bullous dermatitis herpetiformis. Severe seborrheic dermatitis. Severe psoriasis. Mycosis fungoides. 5. Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma. Contact dermatitis. Atopic dermatitis. Serum sickness. Seasonal or perennial allergic rhinitis. Drug hypersensitivity reactions. Urticarial transfusion reactions. Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases: Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus. Iritis, iridocyclitis. Chorioretinitis. Diffuse posterior uveitis and choroiditis. Optic neuritis. Sympathetic ophthalmia. Anterior segment inflammation. Allergic conjunctivitis. Keratitis. Allergic corneal marginal ulcers. 7. Gastrointestinal Diseases: To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy). Regional enteritis (systemic therapy). 8. Respiratory Diseases: Symptomatic sarcoidosis. Berylliosis. Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler's syndrome not manageable by other means. Aspiration pneumonitis. 9. Hematologic Disorders: Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults. Erythroblastopenia (RBC anemia). Congenital (erythroid) hypoplastic anemia. 10. Neoplastic Diseases: For palliative management of: Leukemias and lymphomas in adults. Acute leukemia of childhood. 11. Edematous States: To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous: Tuberculosis meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. B. By intra-articular or soft tissue injection: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Synovitis of osteoarthritis. Rheumatoid arthritis. Acute and subacute bursitis. Acute gouty arthritis. Epicondylitis. Acute nonspecific tenosynovitis. Post-traumatic osteoarthritis. C. By intralesional injection: Keloids. Localized hypertrophic, infiltrated, inflammatory lesions of: lichen planus, psoriatic plaques, granuloma annulare, and lichen simplex chronicus (neurodermatitis). Discoid lupus erythematosus. Necrobiosis lipoidica diabeticorum. Alopecia areata. May also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:c5cd5522-43e6-4e31-a58a-7d461bd83eb1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats UMLS:C0149922 PMID:41385096 "[{""id"":""uuid:7fa40948-4343-4051-bfe1-abc17c442e47"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:176b3d7a-1f71-4793-a034-92052c8fecb5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] A. By intravenous or intramuscular injection when oral therapy is not feasible: 1. Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia. Nonsuppurative thyroiditis. Hypercalcemia associated with cancer. 2. Rheumatic Disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis. Synovitis of osteoarthritis. Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis. Epicondylitis. Acute nonspecific tenosynovitis. Acute gouty arthritis. Psoriatic arthritis. Ankylosing spondylitis. 3. Collagen Diseases: During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus. Acute rheumatic carditis. 4. Dermatologic Diseases: Pemphigus. Severe erythema multiforme. (Stevens-Johnson Syndrome) Exfoliative dermatitis. Bullous dermatitis herpetiformis. Severe seborrheic dermatitis. Severe psoriasis. Mycosis fungoides. 5. Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma. Contact dermatitis. Atopic dermatitis. Serum sickness. Seasonal or perennial allergic rhinitis. Drug hypersensitivity reactions. Urticarial transfusion reactions. Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases: Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus. Iritis, iridocyclitis. Chorioretinitis. Diffuse posterior uveitis and choroiditis. Optic neuritis. Sympathetic ophthalmia. Anterior segment inflammation. Allergic conjunctivitis. Keratitis. Allergic corneal marginal ulcers. 7. Gastrointestinal Diseases: To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy). Regional enteritis (systemic therapy). 8. Respiratory Diseases: Symptomatic sarcoidosis. Berylliosis. Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler's syndrome not manageable by other means. Aspiration pneumonitis. 9. Hematologic Disorders: Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults. Erythroblastopenia (RBC anemia). Congenital (erythroid) hypoplastic anemia. 10. Neoplastic Diseases: For palliative management of: Leukemias and lymphomas in adults. Acute leukemia of childhood. 11. Edematous States: To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous: Tuberculosis meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. B. By intra-articular or soft tissue injection: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Synovitis of osteoarthritis. Rheumatoid arthritis. Acute and subacute bursitis. Acute gouty arthritis. Epicondylitis. Acute nonspecific tenosynovitis. Post-traumatic osteoarthritis. C. By intralesional injection: Keloids. Localized hypertrophic, infiltrated, inflammatory lesions of: lichen planus, psoriatic plaques, granuloma annulare, and lichen simplex chronicus (neurodermatitis). Discoid lupus erythematosus. Necrobiosis lipoidica diabeticorum. Alopecia areata. May also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:0b8ad700-048b-46f2-bbdd-274b3e71ed45 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0006585 PMID:41385096 "[{""id"":""uuid:9a14bbeb-1807-4bca-80a5-c3518ce58be5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a8b4d019-e2de-4b7f-b610-375d251b4c7e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] A. By intravenous or intramuscular injection when oral therapy is not feasible: 1. Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia. Nonsuppurative thyroiditis. Hypercalcemia associated with cancer. 2. Rheumatic Disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis. Synovitis of osteoarthritis. Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis. Epicondylitis. Acute nonspecific tenosynovitis. Acute gouty arthritis. Psoriatic arthritis. Ankylosing spondylitis. 3. Collagen Diseases: During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus. Acute rheumatic carditis. 4. Dermatologic Diseases: Pemphigus. Severe erythema multiforme. (Stevens-Johnson Syndrome) Exfoliative dermatitis. Bullous dermatitis herpetiformis. Severe seborrheic dermatitis. Severe psoriasis. Mycosis fungoides. 5. Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma. Contact dermatitis. Atopic dermatitis. Serum sickness. Seasonal or perennial allergic rhinitis. Drug hypersensitivity reactions. Urticarial transfusion reactions. Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases: Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus. Iritis, iridocyclitis. Chorioretinitis. Diffuse posterior uveitis and choroiditis. Optic neuritis. Sympathetic ophthalmia. Anterior segment inflammation. Allergic conjunctivitis. Keratitis. Allergic corneal marginal ulcers. 7. Gastrointestinal Diseases: To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy). Regional enteritis (systemic therapy). 8. Respiratory Diseases: Symptomatic sarcoidosis. Berylliosis. Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler's syndrome not manageable by other means. Aspiration pneumonitis. 9. Hematologic Disorders: Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults. Erythroblastopenia (RBC anemia). Congenital (erythroid) hypoplastic anemia. 10. Neoplastic Diseases: For palliative management of: Leukemias and lymphomas in adults. Acute leukemia of childhood. 11. Edematous States: To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous: Tuberculosis meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. B. By intra-articular or soft tissue injection: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Synovitis of osteoarthritis. Rheumatoid arthritis. Acute and subacute bursitis. Acute gouty arthritis. Epicondylitis. Acute nonspecific tenosynovitis. Post-traumatic osteoarthritis. C. By intralesional injection: Keloids. Localized hypertrophic, infiltrated, inflammatory lesions of: lichen planus, psoriatic plaques, granuloma annulare, and lichen simplex chronicus (neurodermatitis). Discoid lupus erythematosus. Necrobiosis lipoidica diabeticorum. Alopecia areata. May also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:4d067a83-f292-4969-aff7-0c90955f5da0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0019558 PMID:41385096 "[{""id"":""uuid:74870c54-cc1a-46b2-9c1f-74855d0b6f98"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1558302c-bf33-4a3f-b356-55915f7183fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] A. By intravenous or intramuscular injection when oral therapy is not feasible: 1. Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia. Nonsuppurative thyroiditis. Hypercalcemia associated with cancer. 2. Rheumatic Disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis. Synovitis of osteoarthritis. Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis. Epicondylitis. Acute nonspecific tenosynovitis. Acute gouty arthritis. Psoriatic arthritis. Ankylosing spondylitis. 3. Collagen Diseases: During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus. Acute rheumatic carditis. 4. Dermatologic Diseases: Pemphigus. Severe erythema multiforme. (Stevens-Johnson Syndrome) Exfoliative dermatitis. Bullous dermatitis herpetiformis. Severe seborrheic dermatitis. Severe psoriasis. Mycosis fungoides. 5. Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma. Contact dermatitis. Atopic dermatitis. Serum sickness. Seasonal or perennial allergic rhinitis. Drug hypersensitivity reactions. Urticarial transfusion reactions. Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases: Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus. Iritis, iridocyclitis. Chorioretinitis. Diffuse posterior uveitis and choroiditis. Optic neuritis. Sympathetic ophthalmia. Anterior segment inflammation. Allergic conjunctivitis. Keratitis. Allergic corneal marginal ulcers. 7. Gastrointestinal Diseases: To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy). Regional enteritis (systemic therapy). 8. Respiratory Diseases: Symptomatic sarcoidosis. Berylliosis. Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler's syndrome not manageable by other means. Aspiration pneumonitis. 9. Hematologic Disorders: Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults. Erythroblastopenia (RBC anemia). Congenital (erythroid) hypoplastic anemia. 10. Neoplastic Diseases: For palliative management of: Leukemias and lymphomas in adults. Acute leukemia of childhood. 11. Edematous States: To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous: Tuberculosis meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. B. By intra-articular or soft tissue injection: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Synovitis of osteoarthritis. Rheumatoid arthritis. Acute and subacute bursitis. Acute gouty arthritis. Epicondylitis. Acute nonspecific tenosynovitis. Post-traumatic osteoarthritis. C. By intralesional injection: Keloids. Localized hypertrophic, infiltrated, inflammatory lesions of: lichen planus, psoriatic plaques, granuloma annulare, and lichen simplex chronicus (neurodermatitis). Discoid lupus erythematosus. Necrobiosis lipoidica diabeticorum. Alopecia areata. May also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:453989e8-ad57-4c30-abcd-65926a6da026 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats UMLS:C0392445 PMID:41385096 "[{""id"":""uuid:243f9248-b9c2-4b05-81a8-22f9fbb91e28"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:82c293df-45eb-42bb-af0d-f4b6839cebd9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] A. By intravenous or intramuscular injection when oral therapy is not feasible: 1. Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia. Nonsuppurative thyroiditis. Hypercalcemia associated with cancer. 2. Rheumatic Disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis. Synovitis of osteoarthritis. Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis. Epicondylitis. Acute nonspecific tenosynovitis. Acute gouty arthritis. Psoriatic arthritis. Ankylosing spondylitis. 3. Collagen Diseases: During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus. Acute rheumatic carditis. 4. Dermatologic Diseases: Pemphigus. Severe erythema multiforme. (Stevens-Johnson Syndrome) Exfoliative dermatitis. Bullous dermatitis herpetiformis. Severe seborrheic dermatitis. Severe psoriasis. Mycosis fungoides. 5. Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma. Contact dermatitis. Atopic dermatitis. Serum sickness. Seasonal or perennial allergic rhinitis. Drug hypersensitivity reactions. Urticarial transfusion reactions. Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases: Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus. Iritis, iridocyclitis. Chorioretinitis. Diffuse posterior uveitis and choroiditis. Optic neuritis. Sympathetic ophthalmia. Anterior segment inflammation. Allergic conjunctivitis. Keratitis. Allergic corneal marginal ulcers. 7. Gastrointestinal Diseases: To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy). Regional enteritis (systemic therapy). 8. Respiratory Diseases: Symptomatic sarcoidosis. Berylliosis. Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler's syndrome not manageable by other means. Aspiration pneumonitis. 9. Hematologic Disorders: Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults. Erythroblastopenia (RBC anemia). Congenital (erythroid) hypoplastic anemia. 10. Neoplastic Diseases: For palliative management of: Leukemias and lymphomas in adults. Acute leukemia of childhood. 11. Edematous States: To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous: Tuberculosis meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. B. By intra-articular or soft tissue injection: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Synovitis of osteoarthritis. Rheumatoid arthritis. Acute and subacute bursitis. Acute gouty arthritis. Epicondylitis. Acute nonspecific tenosynovitis. Post-traumatic osteoarthritis. C. By intralesional injection: Keloids. Localized hypertrophic, infiltrated, inflammatory lesions of: lichen planus, psoriatic plaques, granuloma annulare, and lichen simplex chronicus (neurodermatitis). Discoid lupus erythematosus. Necrobiosis lipoidica diabeticorum. Alopecia areata. May also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:76a4878e-4e40-447e-9676-0bb378563415 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0005340 PMID:41385096 "[{""id"":""uuid:59df11fa-27fa-485c-8711-6879acd92fd2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:081690e0-b8f0-4323-aaab-48ab6bdf86b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] A. By intravenous or intramuscular injection when oral therapy is not feasible: 1. Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia. Nonsuppurative thyroiditis. Hypercalcemia associated with cancer. 2. Rheumatic Disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis. Synovitis of osteoarthritis. Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis. Epicondylitis. Acute nonspecific tenosynovitis. Acute gouty arthritis. Psoriatic arthritis. Ankylosing spondylitis. 3. Collagen Diseases: During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus. Acute rheumatic carditis. 4. Dermatologic Diseases: Pemphigus. Severe erythema multiforme. (Stevens-Johnson Syndrome) Exfoliative dermatitis. Bullous dermatitis herpetiformis. Severe seborrheic dermatitis. Severe psoriasis. Mycosis fungoides. 5. Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma. Contact dermatitis. Atopic dermatitis. Serum sickness. Seasonal or perennial allergic rhinitis. Drug hypersensitivity reactions. Urticarial transfusion reactions. Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases: Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus. Iritis, iridocyclitis. Chorioretinitis. Diffuse posterior uveitis and choroiditis. Optic neuritis. Sympathetic ophthalmia. Anterior segment inflammation. Allergic conjunctivitis. Keratitis. Allergic corneal marginal ulcers. 7. Gastrointestinal Diseases: To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy). Regional enteritis (systemic therapy). 8. Respiratory Diseases: Symptomatic sarcoidosis. Berylliosis. Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler's syndrome not manageable by other means. Aspiration pneumonitis. 9. Hematologic Disorders: Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults. Erythroblastopenia (RBC anemia). Congenital (erythroid) hypoplastic anemia. 10. Neoplastic Diseases: For palliative management of: Leukemias and lymphomas in adults. Acute leukemia of childhood. 11. Edematous States: To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous: Tuberculosis meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. B. By intra-articular or soft tissue injection: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Synovitis of osteoarthritis. Rheumatoid arthritis. Acute and subacute bursitis. Acute gouty arthritis. Epicondylitis. Acute nonspecific tenosynovitis. Post-traumatic osteoarthritis. C. By intralesional injection: Keloids. Localized hypertrophic, infiltrated, inflammatory lesions of: lichen planus, psoriatic plaques, granuloma annulare, and lichen simplex chronicus (neurodermatitis). Discoid lupus erythematosus. Necrobiosis lipoidica diabeticorum. Alopecia areata. May also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:bd85c7bf-5285-4f8b-97ed-9fd0a803a8f6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:44185 biolink:treats MONDO:0004967 PMID:41385096 "[{""id"":""uuid:100dabda-f0e4-43e1-90d5-55db3a934e51"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:bc93f105-50bd-42ab-83ae-6b4cf4ba1b2e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:9ae39613-1bf0-46c4-a893-f494262dab7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/nordimet""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methotrexate tablets are a dihydrofolate reductase inhibitor indicated for the: Treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen ( 1.1 ) Treatment of adults with mycosis fungoides ( 1.1 ) Treatment of adults with relapsed or refractory non-Hodgkin lymphoma as part of a metronomic combination regimen ( 1.1 ) Treatment of adults with rheumatoid arthritis ( 1.2 ) Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA) ( 1.3 ) Treatment of adults with severe psoriasis ( 1.4 )|[EMA] In rheumatological and dermatological diseasesActive rheumatoid arthritis in adult patients.Polyarthritic forms of active, severe juvenile idiopathic arthritis (JIA) in adolescents and children aged 3 years and over when the response to non-steroidal anti-inflammatory drugs (NSAIDs) has been inadequate.Severe, treatment-refractory, disabling psoriasis which does not respond sufficiently to other forms of treatment such as phototherapy, psoralen and ultraviolet A radiation (PUVA) therapy and retinoids, and severe psoriatic arthritis in adult patients.In oncologyMaintenance treatment of acute lymphoblastic leukaemia (ALL) in adults, adolescents and children aged 3 years and over. uuid:060461f1-d3e5-4b17-920e-a0ca75703835 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:44185 biolink:treats MONDO:0009691 PMID:41385096 "[{""id"":""uuid:aeda305f-1910-4085-82db-cb275f544597"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6c8a7aa4-ddfa-4507-b892-70f271e23d44"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methotrexate tablets are a dihydrofolate reductase inhibitor indicated for the: Treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen ( 1.1 ) Treatment of adults with mycosis fungoides ( 1.1 ) Treatment of adults with relapsed or refractory non-Hodgkin lymphoma as part of a metronomic combination regimen ( 1.1 ) Treatment of adults with rheumatoid arthritis ( 1.2 ) Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA) ( 1.3 ) Treatment of adults with severe psoriasis ( 1.4 ) uuid:a72130dd-f533-4005-9767-cd8f0e2f56af biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:44185 biolink:treats MONDO:0018908 PMID:41385096 "[{""id"":""uuid:2a34f774-9c85-43bc-8152-d0d4cd9bdac7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ef1c8690-497b-4d52-b7e3-acf76f4124f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methotrexate tablets are a dihydrofolate reductase inhibitor indicated for the: Treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen ( 1.1 ) Treatment of adults with mycosis fungoides ( 1.1 ) Treatment of adults with relapsed or refractory non-Hodgkin lymphoma as part of a metronomic combination regimen ( 1.1 ) Treatment of adults with rheumatoid arthritis ( 1.2 ) Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA) ( 1.3 ) Treatment of adults with severe psoriasis ( 1.4 ) uuid:414b985a-052e-4f66-a3de-95487e0b1f5c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:44185 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:f9e06528-0867-400a-96ac-89af7c89924a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:27d3caf5-7a2f-4529-8c5c-6ca44dbc1f20"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:206b8386-3ade-4c79-98aa-4c47fff02427"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/nordimet""]},{""id"":""uuid:f5509e91-1c81-455b-8455-0b9add0edfb0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methotrexate tablets are a dihydrofolate reductase inhibitor indicated for the: Treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen ( 1.1 ) Treatment of adults with mycosis fungoides ( 1.1 ) Treatment of adults with relapsed or refractory non-Hodgkin lymphoma as part of a metronomic combination regimen ( 1.1 ) Treatment of adults with rheumatoid arthritis ( 1.2 ) Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA) ( 1.3 ) Treatment of adults with severe psoriasis ( 1.4 )|[EMA] Nordimet is indicated for the treatment of:active rheumatoid arthritis in adult patients,polyarthritic forms of severe, active juvenile idiopathic arthritis (JIA), when the response to nonsteroidal anti-inflammatory drugs (NSAIDs) has been inadequate,moderate to severe plaque psoriasis in adults who are candidates for systemic therapy, and severe psoriatic arthritis in adult patients, induction of remission in moderate steroid-dependent Crohn's disease in adult patients, in combination with corticosteroids and for maintenance of remission, as monotherapy, in patients who have responded to methotrexate.|[PMDA] Drugs with a new indication and a new dosage in an additional dosage form for the treatment of rheumatoid arthritis. uuid:1c866f5d-ebca-4d65-b9a3-7b57e357b10f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:44185 biolink:treats MONDO:0018456 PMID:41385096 "[{""id"":""uuid:571cf840-209d-4aeb-a035-437e1d76884f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:39162822-2346-4404-9bc6-cc8d16ff3d6d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methotrexate tablets are a dihydrofolate reductase inhibitor indicated for the: Treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen ( 1.1 ) Treatment of adults with mycosis fungoides ( 1.1 ) Treatment of adults with relapsed or refractory non-Hodgkin lymphoma as part of a metronomic combination regimen ( 1.1 ) Treatment of adults with rheumatoid arthritis ( 1.2 ) Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA) ( 1.3 ) Treatment of adults with severe psoriasis ( 1.4 ) uuid:cd7050bd-6000-4573-9d7b-fe7a6aefb308 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:44185 biolink:treats MONDO:0005083 PMID:41385096 "[{""id"":""uuid:96d49c81-43e7-4e8d-9b28-f9b53eb53a99"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:4b61e7f2-1a14-468d-b850-0dd7ffa848ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:4597da11-2be5-4fd0-b4d6-2798625a0a9b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/nordimet""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methotrexate tablets are a dihydrofolate reductase inhibitor indicated for the: Treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen ( 1.1 ) Treatment of adults with mycosis fungoides ( 1.1 ) Treatment of adults with relapsed or refractory non-Hodgkin lymphoma as part of a metronomic combination regimen ( 1.1 ) Treatment of adults with rheumatoid arthritis ( 1.2 ) Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA) ( 1.3 ) Treatment of adults with severe psoriasis ( 1.4 )|[EMA] Nordimet is indicated for the treatment of:active rheumatoid arthritis in adult patients,polyarthritic forms of severe, active juvenile idiopathic arthritis (JIA), when the response to nonsteroidal anti-inflammatory drugs (NSAIDs) has been inadequate,moderate to severe plaque psoriasis in adults who are candidates for systemic therapy, and severe psoriatic arthritis in adult patients, induction of remission in moderate steroid-dependent Crohn's disease in adult patients, in combination with corticosteroids and for maintenance of remission, as monotherapy, in patients who have responded to methotrexate. uuid:10f868c1-2227-435a-8ba0-3067102a3c5c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28680 biolink:treats MONDO:0018874 PMID:41385096 "[{""id"":""uuid:f96f3a4f-b92f-45b2-8aa3-16d05052b4ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:59b52ed6-5df5-4e22-b600-22abbe38cb0c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cytarabine Injection in combination with other approved anti-cancer drugs is indicated for remission induction in acute non-lymphocytic leukemia of adults and pediatric patients. It has also been found useful in the treatment of acute lymphocytic leukemia and the blast phase of chronic myelocytic leukemia. Intrathecal administration of Cytarabine Injection (preservative free preparations only) is indicated in the prophylaxis and treatment of meningeal leukemia. uuid:4bc98bc7-5a62-4569-acf4-ebbf9caf5ad7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28680 biolink:treats MONDO:0004967 PMID:41385096 "[{""id"":""uuid:341cc24e-1e34-4113-9e91-0b5a173eaa9f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a880b773-0837-4729-bfa6-ed06ff5228f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cytarabine Injection in combination with other approved anti-cancer drugs is indicated for remission induction in acute non-lymphocytic leukemia of adults and pediatric patients. It has also been found useful in the treatment of acute lymphocytic leukemia and the blast phase of chronic myelocytic leukemia. Intrathecal administration of Cytarabine Injection (preservative free preparations only) is indicated in the prophylaxis and treatment of meningeal leukemia. uuid:ba409429-83d3-4be4-9fba-b1b38ec6d824 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28680 biolink:treats MONDO:0006115 PMID:41385096 "[{""id"":""uuid:0c2edf7e-7b68-4362-ab50-041010a5ce15"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:696a9cbe-504d-432b-956f-d97eea820077"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:2e567571-8dba-45bb-83a5-1e2554974963"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cytarabine Injection in combination with other approved anti-cancer drugs is indicated for remission induction in acute non-lymphocytic leukemia of adults and pediatric patients. It has also been found useful in the treatment of acute lymphocytic leukemia and the blast phase of chronic myelocytic leukemia. Intrathecal administration of Cytarabine Injection (preservative free preparations only) is indicated in the prophylaxis and treatment of meningeal leukemia.|[PMDA] Drugs with a new dosage indicated for the treatment of acute leukemia (including erythroleukemia and blast crisis of chronic myeloid leukemia). [Public knowledge-based application] uuid:26b5fd1e-a7b3-43a1-beca-dec05c552339 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28680 biolink:treats UMLS:C0948840 PMID:41385096 "[{""id"":""uuid:f0cb071c-e101-4897-b925-d7d6b790eecf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a2d54ac0-f1af-4707-bc60-658623b466a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cytarabine Injection in combination with other approved anti-cancer drugs is indicated for remission induction in acute non-lymphocytic leukemia of adults and pediatric patients. It has also been found useful in the treatment of acute lymphocytic leukemia and the blast phase of chronic myelocytic leukemia. Intrathecal administration of Cytarabine Injection (preservative free preparations only) is indicated in the prophylaxis and treatment of meningeal leukemia. uuid:b2ea09f9-136f-4883-984e-7b1d9223831a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4B33BGI082 biolink:treats HP:0000989 PMID:41385096 "[{""id"":""uuid:09a0338b-646e-4990-9563-dffbcfc7a3f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:34dd2437-7f2f-49f4-a7d2-60761a4f4365"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1) Prevalite ® (cholestyramine for oral suspension, USP) powder is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet. Prevalite ® (cholestyramine for oral suspension, USP) powder may be useful to lower LDL cholesterol in patients who also have hypertriglyceridemia, but it is not indicated where hypertriglyceridemia is the abnormality of most concern. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Treatment should begin and continue with dietary therapy specific for the type of hyperlipoproteinemia determined prior to initiation of drug therapy. Excess body weight may be an important factor and caloric restriction for weight normalization should be addressed prior to drug therapy in the overweight. Prior to initiating therapy with cholestyramine resin, secondary causes of hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism), should be excluded and a lipid profile performed to assess Total Cholesterol, HDL-C and triglycerides (TG). For individuals with TG less than 400 mg/dL (<4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = Total Cholesterol - [(TG/5) + HDL-C] For TG levels > 400 mg/dL, this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated Total-C. In such cases cholestyramine resin may not be indicated. Serum cholesterol and triglyceride levels should be determined periodically based on NCEP guidelines to confirm initial and adequate long-term response. A favorable trend in cholesterol reduction should occur during the first month of cholestyramine resin therapy. The therapy should be continued to sustain cholesterol reduction. If adequate cholesterol reduction is not attained, increasing the dosage of cholestyramine resin or adding other lipid-lowering agents in combination with cholestyramine resin should be considered. Since the goal of treatment is to lower LDL-C, the NCEP 4 recommends that LDL-C levels be used to initiate and assess treatment response. If LDL-C levels are not available then Total-C alone may be used to monitor long-term therapy. A lipoprotein analysis (including LDL-C determination) should be carried out once a year. The NCEP treatment guidelines are summarized below. LDL-Cholesterol mg/dL (mmol/L) Definite Atherosclerotic Disease Coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease) Two or More Other Risk Factors Other risk factors for coronary heart disease (CHD) include: age (males ≥45 years; females: ≥55 years or premature menopause without estrogen replacement therapy); family history of premature CHD; current cigarette smoking; hypertension; confirmed HDL-C <35 mg/dL (<0.91 mmol/L); and diabetes mellitus. Subtract one risk factor if HDL-C is ≥60 mg/dL (≥1.6 mmol/L). Initiation Level Goal No No ≥190 (≥4.9) <160 (<4.1) No Yes ≥160 (≥4.1) <130 (<3.4) Yes Yes or No ≥130 (≥3.4) ≤100 (≤2.6) Cholestyramine resin monotherapy has been demonstrated to retard the rate of progression 2,3 and increase the rate of regression 3 of coronary atherosclerosis. 2) Prevalite ® (cholestyramine for oral suspension, USP) powder is indicated for the relief of pruritus associated with partial biliary obstruction. Cholestyramine resin has been shown to have a variable effect on serum cholesterol in these patients. Patients with primary biliary cirrhosis may exhibit an elevated cholesterol as part of their disease. uuid:bd9cad82-c5cd-42f7-b1c1-2d1f0f9ddb38 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4B33BGI082 biolink:treats MONDO:0005230 PMID:41385096 "[{""id"":""uuid:73e40093-96ae-448e-adae-405fe2f30d88"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bff81908-6bea-48ba-a8ef-5767a0d89469"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1) Prevalite ® (cholestyramine for oral suspension, USP) powder is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet. Prevalite ® (cholestyramine for oral suspension, USP) powder may be useful to lower LDL cholesterol in patients who also have hypertriglyceridemia, but it is not indicated where hypertriglyceridemia is the abnormality of most concern. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Treatment should begin and continue with dietary therapy specific for the type of hyperlipoproteinemia determined prior to initiation of drug therapy. Excess body weight may be an important factor and caloric restriction for weight normalization should be addressed prior to drug therapy in the overweight. Prior to initiating therapy with cholestyramine resin, secondary causes of hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism), should be excluded and a lipid profile performed to assess Total Cholesterol, HDL-C and triglycerides (TG). For individuals with TG less than 400 mg/dL (<4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = Total Cholesterol - [(TG/5) + HDL-C] For TG levels > 400 mg/dL, this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated Total-C. In such cases cholestyramine resin may not be indicated. Serum cholesterol and triglyceride levels should be determined periodically based on NCEP guidelines to confirm initial and adequate long-term response. A favorable trend in cholesterol reduction should occur during the first month of cholestyramine resin therapy. The therapy should be continued to sustain cholesterol reduction. If adequate cholesterol reduction is not attained, increasing the dosage of cholestyramine resin or adding other lipid-lowering agents in combination with cholestyramine resin should be considered. Since the goal of treatment is to lower LDL-C, the NCEP 4 recommends that LDL-C levels be used to initiate and assess treatment response. If LDL-C levels are not available then Total-C alone may be used to monitor long-term therapy. A lipoprotein analysis (including LDL-C determination) should be carried out once a year. The NCEP treatment guidelines are summarized below. LDL-Cholesterol mg/dL (mmol/L) Definite Atherosclerotic Disease Coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease) Two or More Other Risk Factors Other risk factors for coronary heart disease (CHD) include: age (males ≥45 years; females: ≥55 years or premature menopause without estrogen replacement therapy); family history of premature CHD; current cigarette smoking; hypertension; confirmed HDL-C <35 mg/dL (<0.91 mmol/L); and diabetes mellitus. Subtract one risk factor if HDL-C is ≥60 mg/dL (≥1.6 mmol/L). Initiation Level Goal No No ≥190 (≥4.9) <160 (<4.1) No Yes ≥160 (≥4.1) <130 (<3.4) Yes Yes or No ≥130 (≥3.4) ≤100 (≤2.6) Cholestyramine resin monotherapy has been demonstrated to retard the rate of progression 2,3 and increase the rate of regression 3 of coronary atherosclerosis. 2) Prevalite ® (cholestyramine for oral suspension, USP) powder is indicated for the relief of pruritus associated with partial biliary obstruction. Cholestyramine resin has been shown to have a variable effect on serum cholesterol in these patients. Patients with primary biliary cirrhosis may exhibit an elevated cholesterol as part of their disease. uuid:941527a0-ed2b-4e00-975e-344f1d85bd71 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:681569 biolink:treats MONDO:0004967 PMID:41385096 "[{""id"":""uuid:e07a23ac-86e0-4cdc-a5bc-f0c11ab0f60f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:af307b01-ecab-4cf9-b968-394a95d2055f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:74434a92-72e4-42b9-95a7-6577510f96fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/evoltra""]},{""id"":""uuid:e3d1674d-e48c-4d83-ac92-e4e3db017d65"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clofarabine Injection is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens. This indication is based upon response rate. There are no trials verifying an improvement in disease-related symptoms or increased survival with Clofarabine Injection.|[EMA] Treatment of acute lymphoblastic leukaemia (ALL) in paediatric patients who have relapsed or are refractory after receiving at least two prior regimens and where there is no other treatment option anticipated to result in a durable response. Safety and efficacy have been assessed in studies of patients ≤ 21 years old at initial diagnosis.|[PMDA] A drug with a new active ingredient for the treatment of recurrent or refractory acute lymphoblastic leukemia. [Orphan drug] uuid:34b91791-0e36-4612-9ea7-253760cbd02e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135949 biolink:treats MONDO:0015924 PMID:41385096 "[{""id"":""uuid:97ce3993-4ac5-400c-a4e3-08a13a454d97"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:46db2d73-ee9c-489b-a42c-903ff30ecfe1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:3d261823-a200-49c4-b967-95f98dfb6b21"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/volibris""]},{""id"":""uuid:d653de5e-8a16-4da2-96e7-b61e2bee11e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ambrisentan tablet is an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1): To improve exercise ability and delay clinical worsening. Studies establishing effectiveness included trials predominantly in patients with WHO Functional Class II–III symptoms and etiologies of idiopathic or heritable PAH (60%) or PAH associated with connective tissue diseases (34%) ( 1 ).|[EMA] Volibris is indicated for treatment of pulmonary arterial hypertension (PAH) in adult patients of WHO Functional Class (FC) II to III, including use in combination treatment (see section 5.1). Efficacy has been shown in idiopathic PAH (IPAH) and in PAH associated with connective tissue disease.Volibris is indicated for treatment of PAH in adolescents and children (aged 8 to less than 18 years) of WHO Functional Class (FC) II to III including use in combination treatment. Efficacy has been shown in IPAH, familial, corrected congenital and in PAH associated with connective tissue disease (see section 5.1).|[PMDA] A drug with a new active ingredient indicated for the treatment of pulmonary arterial hypertension. [Orphan drug] uuid:7aa275c3-005b-4638-8e65-228d2e1bf82d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135949 biolink:treats MONDO:0017147 PMID:41385096 "[{""id"":""uuid:cb74657b-aa91-4db2-a021-f2f69ac00885"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:344b0535-a825-44eb-9a0a-6177eb1057a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:5231c035-4981-476d-a2e1-264ac83deace"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/volibris""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ambrisentan tablet is an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1): To improve exercise ability and delay clinical worsening. Studies establishing effectiveness included trials predominantly in patients with WHO Functional Class II–III symptoms and etiologies of idiopathic or heritable PAH (60%) or PAH associated with connective tissue diseases (34%) ( 1 ).|[EMA] Volibris is indicated for treatment of pulmonary arterial hypertension (PAH) in adult patients of WHO Functional Class (FC) II to III, including use in combination treatment (see section 5.1). Efficacy has been shown in idiopathic PAH (IPAH) and in PAH associated with connective tissue disease.Volibris is indicated for treatment of PAH in adolescents and children (aged 8 to less than 18 years) of WHO Functional Class (FC) II to III including use in combination treatment. Efficacy has been shown in IPAH, familial, corrected congenital and in PAH associated with connective tissue disease (see section 5.1). uuid:5323f469-d2cb-4c0f-947a-5309fa9bf8fe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135949 biolink:treats MONDO:0017148 PMID:41385096 "[{""id"":""uuid:b7410c9e-a26c-4323-a048-079d97932605"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:323da0d7-4192-4196-b8d1-cb41bfc9f929"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ambrisentan tablet is an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1): To improve exercise ability and delay clinical worsening. Studies establishing effectiveness included trials predominantly in patients with WHO Functional Class II–III symptoms and etiologies of idiopathic or heritable PAH (60%) or PAH associated with connective tissue diseases (34%) ( 1 ). uuid:8c3da130-f90f-48b5-84c8-11fb7533ac61 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85157 biolink:treats EFO:0006911 PMID:41385096 "[{""id"":""uuid:f48d6a3e-4a8d-47b3-87e0-f8fd3b866c87"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:93c6c509-0fbc-4768-b914-ff1c65531655"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Palonosetron hydrochloride injection is indicated in adults for prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). acute nausea and vomiting associated with initial and repeat courses highly emetogenic cancer chemotherapy (HEC). postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. Efficacy beyond 24 hours has not been demonstrated. As with other antiemetics, routine prophylaxis is not recommended in patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. In patients where nausea and vomiting must be avoided during the postoperative period, palonosetron hydrochloride injection is recommended even where the incidence of postoperative nausea and/or vomiting is low. Palonosetron hydrochloride injection is indicated in pediatric patients 1 month to less than 17 years of age for prevention of: acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy. uuid:e2bccafa-ed3e-4021-b9db-0059636d7f4a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85157 biolink:treats EFO:0004888 PMID:41385096 "[{""id"":""uuid:36cab12e-d7dd-4395-8888-152fab89906e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9b3b85b3-bb3a-470e-8a04-c742bbdf3109"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Palonosetron hydrochloride injection is indicated in adults for prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). acute nausea and vomiting associated with initial and repeat courses highly emetogenic cancer chemotherapy (HEC). postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. Efficacy beyond 24 hours has not been demonstrated. As with other antiemetics, routine prophylaxis is not recommended in patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. In patients where nausea and vomiting must be avoided during the postoperative period, palonosetron hydrochloride injection is recommended even where the incidence of postoperative nausea and/or vomiting is low. Palonosetron hydrochloride injection is indicated in pediatric patients 1 month to less than 17 years of age for prevention of: acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy. uuid:731b5a3d-641a-42e8-97e2-0dea6ef85fff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50131 biolink:treats MONDO:0018881 PMID:41385096 "[{""id"":""uuid:4f740060-d1ae-41fb-8218-75f7468cacef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ab9b5759-b182-4173-86cb-cbb7f8ae41b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Decitabine for Injection is indicated for treatment of adult patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups. uuid:81370e9b-9193-41af-99ac-7a39a0020f7b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50131 biolink:treats MONDO:0005272 PMID:41385096 "[{""id"":""uuid:e433a1d1-5f94-4e7b-acde-d8a1399ef23b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4412253f-3f19-4173-8a4b-54adbcb7a052"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Decitabine for Injection is indicated for treatment of adult patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups. uuid:a2693056-290c-4bd6-855e-49ddb4e17720 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50131 biolink:treats MONDO:0019157 PMID:41385096 "[{""id"":""uuid:a2ab9df1-b3d0-4239-bdd5-451108a2b471"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3a8a09f1-e7f4-4a94-8cb1-b780e01b6a09"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Decitabine for Injection is indicated for treatment of adult patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups. uuid:54a215db-c930-4635-9ede-795262d6476d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50131 biolink:treats MONDO:0019454 PMID:41385096 "[{""id"":""uuid:fd135fb1-984c-4941-9caa-f08fa650784c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8f57256a-50b2-492d-aaa5-5cc89ed5a026"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Decitabine for Injection is indicated for treatment of adult patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups. uuid:bef69537-21de-4b0e-9ec0-14c672ff4e38 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50131 biolink:treats MONDO:0015692 PMID:41385096 "[{""id"":""uuid:0ae5f197-ea0d-4c78-9c3a-b8b5fa84a7ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9f6fb1f0-fa39-4779-94d9-9a1299c837e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Decitabine for Injection is indicated for treatment of adult patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups. uuid:1adb1f8d-fb6b-4fd3-9c6d-7532efc4976f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50131 biolink:treats MONDO:0020311 PMID:41385096 "[{""id"":""uuid:0e956714-9de8-4235-b972-2eb8e6c8fa67"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bcb53c52-49e9-446b-89b9-3048e609be24"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Decitabine for Injection is indicated for treatment of adult patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups. uuid:f8093ad0-2c34-4faf-be63-bdaf1a2198ac biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4975 biolink:treats MONDO:0019610 PMID:41385096 "[{""id"":""uuid:0059c267-eef4-4949-b0a9-b67ee7bfee79"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3c9e05a0-a354-47d8-a390-a0ad185c5aec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Famotidine tablets are indicated in adult and pediatric patients 40 kg and above for the treatment of: • active duodenal ulcer. • active gastric ulcer. • symptomatic non-erosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. Famotidine tablets are indicated in adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger- Ellison Syndrome, multiple endocrine neoplasias). • reduction of the risk of duodenal ulcer recurrence. uuid:10fb4948-a75d-4fe5-9bd7-9d34173ffc4b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1152239 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:5ce87ae6-76c6-4e98-8f14-14968d59b32f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f639f3df-1a5c-4c88-b4d7-f001e79cbda7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tramadol hydrochloride and acetaminophen tablets are indicated for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use Tramadol hydrochloride and acetaminophen tablets are indicated for short-term use of five days or less. Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see Warnings and Precautions ( 5.1 )] , reserve tramadol hydrochloride and acetaminophen tablets for use in patients for whom alternative treatment options [e.g., non-opioid analgesics]: Have not been tolerated, or are not expected to be tolerated, Have not provided adequate analgesia, or are not expected to provide adequate analgesia. uuid:c281c80c-9f5b-4912-8525-29117ee1f854 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135782 biolink:treats UMLS:C0406317 PMID:41385096 "[{""id"":""uuid:0dac705f-2cca-401f-8497-1db9f711897d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:56d3823c-9d92-4d5c-a5f9-76bf16fe0177"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BRYHALI ® (halobetasol propionate) lotion, 0.01% is indicated for the topical treatment of plaque psoriasis in adults. uuid:ba35b1c9-d270-466a-97d6-21a253a12f4c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46557 biolink:treats MONDO:0008159 PMID:41385096 "[{""id"":""uuid:408a0934-e132-409f-a8f6-0540e95cb309"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:28f3c9a0-143b-4aca-a201-e4c0243948ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Zoledronic acid injection is a bisphosphonate indicated for: •Treatment and prevention of postmenopausal osteoporosis ( 1.1 , 1.2 ) •Treatment to increase bone mass in men with osteoporosis ( 1.3 ) •Treatment and prevention of glucocorticoid-induced osteoporosis ( 1.4 ) •Treatment of Paget’s disease of bone in men and women ( 1.5 ) Limitations of Use Optimal duration of use has not been determined. For patients at low-risk for fracture, consider drug discontinuation after 3 to 5 years of use ( 1.6 ) uuid:eec671ac-6a84-4a94-a1e2-b71cfb108425 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46557 biolink:treats MONDO:0005298 PMID:41385096 "[{""id"":""uuid:2f281b03-f93e-45f9-9d87-cf03ebbf18df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:62c8563a-56c0-4832-9da0-87e07a90856c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:fd9e38f6-04c4-4c69-944c-e72e11b83b03"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:d324aba0-2e33-44e2-afb1-79e25a37aaef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Zoledronic acid injection is a bisphosphonate indicated for: •Treatment and prevention of postmenopausal osteoporosis ( 1.1 , 1.2 ) •Treatment to increase bone mass in men with osteoporosis ( 1.3 ) •Treatment and prevention of glucocorticoid-induced osteoporosis ( 1.4 ) •Treatment of Paget’s disease of bone in men and women ( 1.5 ) Limitations of Use Optimal duration of use has not been determined. For patients at low-risk for fracture, consider drug discontinuation after 3 to 5 years of use ( 1.6 )|[EMA] Treatment of osteoporosis:, , , in post-menopausal women;, in men;, , , at increased risk of fracture, including those with a recent low-trauma hip fracture., , Treatment of osteoporosis associated with long-term systemic glucocorticoid therapy in post-menopausal women and in men at increased risk of fracture., , Treatment of Paget's disease of the bone.,|[PMDA] A drug with a new indication and a new dosage in an additional dosage form indicated for the treatment of osteoporosis. uuid:fa73490b-d80e-42a9-a892-6bca42b7f0d3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46557 biolink:treats MONDO:0024651 PMID:41385096 "[{""id"":""uuid:0f4573c2-99ae-4cc6-9cb5-fcb17e53a37c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9be7fc5b-0fc0-4943-b262-6bc53eadc022"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Zoledronic acid injection is a bisphosphonate indicated for: •Treatment and prevention of postmenopausal osteoporosis ( 1.1 , 1.2 ) •Treatment to increase bone mass in men with osteoporosis ( 1.3 ) •Treatment and prevention of glucocorticoid-induced osteoporosis ( 1.4 ) •Treatment of Paget’s disease of bone in men and women ( 1.5 ) Limitations of Use Optimal duration of use has not been determined. For patients at low-risk for fracture, consider drug discontinuation after 3 to 5 years of use ( 1.6 ) uuid:7f36c812-c193-43c1-8746-1f071225e107 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46557 biolink:treats MONDO:0005382 PMID:41385096 "[{""id"":""uuid:af8ac6da-de93-4f86-8ed0-c1a0c85c7bfa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:e4dc4249-0a54-45eb-8cba-c8f94ac8e790"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:9dfa3504-e900-41c0-84f9-4480f6e9fc49"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Zoledronic acid injection is a bisphosphonate indicated for: •Treatment and prevention of postmenopausal osteoporosis ( 1.1 , 1.2 ) •Treatment to increase bone mass in men with osteoporosis ( 1.3 ) •Treatment and prevention of glucocorticoid-induced osteoporosis ( 1.4 ) •Treatment of Paget’s disease of bone in men and women ( 1.5 ) Limitations of Use Optimal duration of use has not been determined. For patients at low-risk for fracture, consider drug discontinuation after 3 to 5 years of use ( 1.6 )|[EMA] Treatment of osteoporosis:, , , in post-menopausal women;, in men;, , , at increased risk of fracture, including those with a recent low-trauma hip fracture., , Treatment of osteoporosis associated with long-term systemic glucocorticoid therapy in post-menopausal women and in men at increased risk of fracture., , Treatment of Paget's disease of the bone., uuid:f5c07083-49b9-4fe3-8236-ee7370b878ed biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10112 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:facc6f77-489d-4089-ab12-4de4eaf7f3ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6c85345e-4b6f-4482-acd5-24c5bcac5e7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Zileuton extended-release tabletis indicated for the prophylaxis and chronic treatment of asthma in adults and children 12 years of age and older. Zileuton extended-release tabletis not indicated for use in the reversal of bronchospasm in acute asthma attacks. Therapy with zileuton extended-release tablet can be continued during acute exacerbations of asthma. uuid:47b7c089-fbfd-4805-98e1-098ddb4605c7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10112 biolink:treats MONDO:0850283 PMID:41385096 "[{""id"":""uuid:9dfc2de8-692f-4ce2-a407-c4dbab3dd961"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ac0908de-071c-437a-9bc4-40710ff6099c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Zileuton extended-release tabletis indicated for the prophylaxis and chronic treatment of asthma in adults and children 12 years of age and older. Zileuton extended-release tabletis not indicated for use in the reversal of bronchospasm in acute asthma attacks. Therapy with zileuton extended-release tablet can be continued during acute exacerbations of asthma. uuid:72d60dd2-2bcd-434e-bd7c-35161a23752b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8863 biolink:treats MONDO:0004976 PMID:41385096 "[{""id"":""uuid:aff0c4db-9849-4b93-9cab-b5e9031d4b29"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:0ff71a88-b99b-469c-af89-bc0d77bd0769"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:21012540-e442-4276-84e5-88ad42002b92"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/rilutek""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Riluzole tablets, USP are indicated for the treatment of amyotrophic lateral sclerosis (ALS).|[EMA] Rilutek is indicated to extend life or the time to mechanical ventilation for patients with amyotrophic lateral sclerosis (ALS).Clinical trials have demonstrated that Rilutek extends survival for patients with ALS.Survival was defined as patients who were alive, not intubated for mechanical ventilation and tracheotomy-free.There is no evidence that Rilutek exerts a therapeutic effect on motor function, lung function, fasciculations, muscle strength and motor symptoms.Rilutek has not been shown to be effective in the late stages of ALS.Safety and efficacy of Rilutek has only been studied in ALS. Therefore, Rilutek should not be used in patients with any other form of motor-neurone disease. uuid:d366f10c-c460-4245-a827-e92a1579a11c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8863 biolink:treats MONDO:0008781 PMID:41385096 "[{""id"":""uuid:2a3ecd11-6118-4434-ae02-b98251906998"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a33ee053-afdb-4a08-b81e-7dc290f04e36"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Riluzole tablets, USP are indicated for the treatment of amyotrophic lateral sclerosis (ALS). uuid:8d303e6a-c5a7-41ee-bc4a-17268e130cd9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41774 biolink:treats MONDO:0005023 PMID:41385096 "[{""id"":""uuid:ef08a9f8-1516-4000-91b1-3257013e96bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a0f7e68a-cd13-4717-ab29-ced6b0b5b5f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Metastatic Breast Cancer: Tamoxifen citrate tablets are effective in the treatment of metastatic breast cancer in women and men. In premenopausal women with metastatic breast cancer, tamoxifen citrate tablets are an alternative to oophorectomy or ovarian irradiation. Available evidence indicates that patients whose tumors are estrogen receptor positive are more likely to benefit from tamoxifen citrate tablets therapy. Adjuvant Treatment of Breast Cancer: Tamoxifen citrate tablets are indicated for the treatment of node-positive breast cancer in women following total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation. In some tamoxifen citrate adjuvant studies, most of the benefit to date has been in the subgroup with four or more positive axillary nodes. Tamoxifen citrate tablets are indicated for the treatment of axillary node-negative breast cancer in women following total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation. The estrogen and progesterone receptor values may help to predict whether adjuvant tamoxifen citrate tablets therapy are likely to be beneficial. Tamoxifen citrate tablets reduces the occurrence of contralateral breast cancer in patients receiving adjuvant tamoxifen citrate tablets therapy for breast cancer. Ductal Carcinoma in Situ (DCIS): In women with DCIS, following breast surgery and radiation, tamoxifen citrate tablets are indicated to reduce the risk of invasive breast cancer (see BOXED WARNING at the beginning of the label). The decision regarding therapy with tamoxifen citrate tablets for the reduction in breast cancer incidence should be based upon an individual assessment of the benefits and risks of tamoxifen citrate tablets therapy. Current data from clinical trials support five years of adjuvant tamoxifen citrate tablets therapy for patients with breast cancer. Reduction in Breast Cancer Incidence in High Risk Women: Tamoxifen citrate tablets are indicated to reduce the incidence of breast cancer in women at high risk for breast cancer. This effect was shown in a study of 5 years planned duration with a median follow-up of 4.2 years. Twenty-five percent of the participants received drug for 5 years. The longer-term effects are not known. In this study, there was no impact of tamoxifen on overall or breast cancer-related mortality (see BOXED WARNING at the beginning of the label). Tamoxifen citrate tablets are indicated only for high-risk women. “High risk” is defined as women at least 35 years of age with a 5-year predicted risk of breast cancer ≥ 1.67%, as calculated by the Gail Model. Examples of combinations of factors predicting a 5-year risk ≥ 1.67% are: Age 35 or older and any of the following combination of factors: One first degree relative with a history of breast cancer, 2 or more benign biopsies, and a history of a breast biopsy showing atypical hyperplasia; or At least 2 first degree relatives with a history of breast cancer, and a personal history of at least one breast biopsy; or LCIS Age 40 or older and any of the following combination of factors: One first degree relative with a history of breast cancer, 2 or more benign biopsies, age at first live birth 25 or older, and age at menarche 11 or younger; or At least 2 first degree relatives with a history of breast cancer, and age at first live birth 19 or younger; or One first degree relative with a history of breast cancer, and a personal history of a breast biopsy showing atypical hyperplasia. Age 45 or older and any of the following combination of factors: At least 2 first degree relatives with a history of breast cancer and age at first live birth 24 or younger; or One first degree relative with a history of breast cancer with a personal history of a benign breast biopsy, age at menarche 11 or less and age at first live birth 20 or more. Age 50 or older and any of the following combination of factors: At least 2 first degree relatives with a history of breast cancer; or History of one breast biopsy showing atypical hyperplasia, and age at first live birth 30 or older and age at menarche 11 or less; or History of at least two breast biopsies with a history of atypical hyperplasia, and age at first live birth 30 or more. Age 55 or older and any of the following combination of factors: One first degree relative with a history of breast cancer with a personal history of a benign breast biopsy, and age at menarche 11 or less; or History of at least 2 breast biopsies with a history of atypical hyperplasia, and age at first live birth 20 or older. Age 60 or older and: 5-year predicted risk of breast cancer ≥ 1.67%, as calculated by the Gail Model. For women whose risk factors are not described in the above examples, the Gail Model is necessary to estimate absolute breast cancer risk. Health Care Professionals can obtain a Gail Model Risk Assessment Tool by dialing 1-866-850-2876. There are insufficient data available regarding the effect of tamoxifen citrate tablets on breast cancer incidence in women with inherited mutations (BRCA1, BRCA2) to be able to make specific recommendations on the effectiveness of tamoxifen citrate in these patients. After an assessment of the risk of developing breast cancer, the decision regarding therapy with tamoxifen citrate tablets for the reduction in breast cancer incidence should be based upon an individual assessment of the benefits and risks of tamoxifen citrate tablets therapy. In the NSABP P-1 trial, tamoxifen citrate tablets treatment lowered the risk of developing breast cancer during the follow-up period of the trial, but did not eliminate breast cancer risk (See Table 3 in CLINICAL PHARMACOLOGY ). uuid:a85c4645-30b0-49eb-ac68-61e95f1253f9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41774 biolink:treats MONDO:0006256 PMID:41385096 "[{""id"":""uuid:387690f2-1490-437a-9001-432eebf35a4b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:695280e1-e273-418c-ab6d-cfcf21759f6a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Metastatic Breast Cancer: Tamoxifen citrate tablets are effective in the treatment of metastatic breast cancer in women and men. In premenopausal women with metastatic breast cancer, tamoxifen citrate tablets are an alternative to oophorectomy or ovarian irradiation. Available evidence indicates that patients whose tumors are estrogen receptor positive are more likely to benefit from tamoxifen citrate tablets therapy. Adjuvant Treatment of Breast Cancer: Tamoxifen citrate tablets are indicated for the treatment of node-positive breast cancer in women following total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation. In some tamoxifen citrate adjuvant studies, most of the benefit to date has been in the subgroup with four or more positive axillary nodes. Tamoxifen citrate tablets are indicated for the treatment of axillary node-negative breast cancer in women following total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation. The estrogen and progesterone receptor values may help to predict whether adjuvant tamoxifen citrate tablets therapy are likely to be beneficial. Tamoxifen citrate tablets reduces the occurrence of contralateral breast cancer in patients receiving adjuvant tamoxifen citrate tablets therapy for breast cancer. Ductal Carcinoma in Situ (DCIS): In women with DCIS, following breast surgery and radiation, tamoxifen citrate tablets are indicated to reduce the risk of invasive breast cancer (see BOXED WARNING at the beginning of the label). The decision regarding therapy with tamoxifen citrate tablets for the reduction in breast cancer incidence should be based upon an individual assessment of the benefits and risks of tamoxifen citrate tablets therapy. Current data from clinical trials support five years of adjuvant tamoxifen citrate tablets therapy for patients with breast cancer. Reduction in Breast Cancer Incidence in High Risk Women: Tamoxifen citrate tablets are indicated to reduce the incidence of breast cancer in women at high risk for breast cancer. This effect was shown in a study of 5 years planned duration with a median follow-up of 4.2 years. Twenty-five percent of the participants received drug for 5 years. The longer-term effects are not known. In this study, there was no impact of tamoxifen on overall or breast cancer-related mortality (see BOXED WARNING at the beginning of the label). Tamoxifen citrate tablets are indicated only for high-risk women. “High risk” is defined as women at least 35 years of age with a 5-year predicted risk of breast cancer ≥ 1.67%, as calculated by the Gail Model. Examples of combinations of factors predicting a 5-year risk ≥ 1.67% are: Age 35 or older and any of the following combination of factors: One first degree relative with a history of breast cancer, 2 or more benign biopsies, and a history of a breast biopsy showing atypical hyperplasia; or At least 2 first degree relatives with a history of breast cancer, and a personal history of at least one breast biopsy; or LCIS Age 40 or older and any of the following combination of factors: One first degree relative with a history of breast cancer, 2 or more benign biopsies, age at first live birth 25 or older, and age at menarche 11 or younger; or At least 2 first degree relatives with a history of breast cancer, and age at first live birth 19 or younger; or One first degree relative with a history of breast cancer, and a personal history of a breast biopsy showing atypical hyperplasia. Age 45 or older and any of the following combination of factors: At least 2 first degree relatives with a history of breast cancer and age at first live birth 24 or younger; or One first degree relative with a history of breast cancer with a personal history of a benign breast biopsy, age at menarche 11 or less and age at first live birth 20 or more. Age 50 or older and any of the following combination of factors: At least 2 first degree relatives with a history of breast cancer; or History of one breast biopsy showing atypical hyperplasia, and age at first live birth 30 or older and age at menarche 11 or less; or History of at least two breast biopsies with a history of atypical hyperplasia, and age at first live birth 30 or more. Age 55 or older and any of the following combination of factors: One first degree relative with a history of breast cancer with a personal history of a benign breast biopsy, and age at menarche 11 or less; or History of at least 2 breast biopsies with a history of atypical hyperplasia, and age at first live birth 20 or older. Age 60 or older and: 5-year predicted risk of breast cancer ≥ 1.67%, as calculated by the Gail Model. For women whose risk factors are not described in the above examples, the Gail Model is necessary to estimate absolute breast cancer risk. Health Care Professionals can obtain a Gail Model Risk Assessment Tool by dialing 1-866-850-2876. There are insufficient data available regarding the effect of tamoxifen citrate tablets on breast cancer incidence in women with inherited mutations (BRCA1, BRCA2) to be able to make specific recommendations on the effectiveness of tamoxifen citrate in these patients. After an assessment of the risk of developing breast cancer, the decision regarding therapy with tamoxifen citrate tablets for the reduction in breast cancer incidence should be based upon an individual assessment of the benefits and risks of tamoxifen citrate tablets therapy. In the NSABP P-1 trial, tamoxifen citrate tablets treatment lowered the risk of developing breast cancer during the follow-up period of the trial, but did not eliminate breast cancer risk (See Table 3 in CLINICAL PHARMACOLOGY ). uuid:f13d9825-a987-468b-93d0-bd1ccadee329 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9635 biolink:treats UMLS:C0278488 PMID:41385096 "[{""id"":""uuid:6904f50a-02ee-4996-9f28-47ebc69c683e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cf79cbc7-2b70-44ed-8dca-4a46f3a467ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Toremifene citrate tablets are estrogen agonist/antagonist indicated for the treatment of metastatic breast cancer in postmenopausal women with estrogen-receptor positive or unknown tumors. uuid:6228ca0a-be74-4a2e-aa68-4a193a00b0f7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9635 biolink:treats MONDO:0006512 PMID:41385096 "[{""id"":""uuid:759a80a8-4801-4d27-b4a1-214e7b9347c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:82ca1786-2337-4ee7-88d0-44e861a4f7ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Toremifene citrate tablets are estrogen agonist/antagonist indicated for the treatment of metastatic breast cancer in postmenopausal women with estrogen-receptor positive or unknown tumors. uuid:90a46d4e-8785-4d2e-8d47-c13e829d64d6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:39585 biolink:treats MONDO:0008193 PMID:41385096 "[{""id"":""uuid:68cbfdbf-4579-4b17-b81f-af3d254b849c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2fea0e1c-5dec-4048-87bd-aadc149e9c94"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carbidopa tablets are indicated for use with carbidopa-levodopa or with levodopa in the treatment of the symptoms of idiopathic Parkinson’s disease (paralysis agitans), postencephalitic parkinsonism, and symptomatic parkinsonism, which may follow injury to the nervous system by carbon monoxide intoxication and/or manganese intoxication. Carbidopa is for use with carbidopa-levodopa in patients for whom the dosage of carbidopa-levodopa provides less than adequate daily dosage (usually 70 mg daily) of carbidopa. Carbidopa is for use with levodopa in the occasional patient whose dosage requirement of carbidopa and levodopa necessitates separate titration of each medication. Carbidopa is used with carbidopa-levodopa or with levodopa to permit the administration of lower doses of levodopa with reduced nausea and vomiting, more rapid dosage titration, and with a somewhat smoother response. However, patients with markedly irregular (“on-off”) responses to levodopa have not been shown to benefit from the addition of carbidopa. Since carbidopa prevents the reversal of levodopa effects caused by pyridoxine, supplemental pyridoxine (vitamin B 6 ), can be given to patients when they are receiving carbidopa and levodopa concomitantly or as carbidopa-levodopa. Although the administration of carbidopa permits control of parkinsonism and Parkinson’s disease with much lower doses of levodopa, there is no conclusive evidence at present that this is beneficial other than in reducing nausea and vomiting, permitting more rapid titration, and providing a somewhat smoother response to levodopa. Certain patients who responded poorly to levodopa alone have improved when carbidopa and levodopa were given concurrently. This was most likely due to decreased peripheral decarboxylation of levodopa rather than to a primary effect of carbidopa on the peripheral nervous system. Carbidopa has not been shown to enhance the intrinsic efficacy of levodopa. In deciding whether to give carbidopa with carbidopa-levodopa or with levodopa to patients who have nausea and/or vomiting, the physician should be aware that, while many patients may be expected to improve, some may not. Since one cannot predict which patients are likely to improve, this can only be determined by a trial of therapy. It should be further noted that in controlled trials comparing carbidopa and levodopa with levodopa alone, about half the patients with nausea and/or vomiting on levodopa alone improved spontaneously despite being retained on the same dose of levodopa during the controlled portion of the trial. uuid:3ce7ae86-900b-4ef9-b061-fcb8ade9bfa8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:520985 biolink:treats MONDO:0005475 PMID:41385096 "[{""id"":""uuid:3eaf9eca-d9bd-4630-8e44-dd3b916285a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:28c416d3-54d9-4339-8178-ee019be05908"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Almotriptan malate tablets are a 5HT 1B/1D receptor agonist (triptan) indicated for: Acute treatment of migraine attacks in adults with a history of migraine with or without aura ( 1.1 ) Acute treatment of migraine headache pain in adolescents age 12 to 17 years with a history of migraine with or without aura, and who have migraine attacks usually lasting 4 hours or more ( 1.1 ) Important limitations: Use only after a clear diagnosis of migraine has been established ( 1.2 ) In adolescents age 12 to 17 years, efficacy of almotriptan malate tablets on migraine-associated symptoms was not established ( 1.2 ) Not intended for the prophylactic therapy of migraine ( 1.2 ) Not indicated for the treatment of cluster headache ( 1.2 ) uuid:7698df44-8c84-4926-84b2-0776386f68f3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:520985 biolink:treats MONDO:0100431 PMID:41385096 "[{""id"":""uuid:fb58b9a6-7035-410e-93c0-c7a03bc6cec8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:26d3b29a-1966-45e1-88d6-d35a809ac7ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Almotriptan malate tablets are a 5HT 1B/1D receptor agonist (triptan) indicated for: Acute treatment of migraine attacks in adults with a history of migraine with or without aura ( 1.1 ) Acute treatment of migraine headache pain in adolescents age 12 to 17 years with a history of migraine with or without aura, and who have migraine attacks usually lasting 4 hours or more ( 1.1 ) Important limitations: Use only after a clear diagnosis of migraine has been established ( 1.2 ) In adolescents age 12 to 17 years, efficacy of almotriptan malate tablets on migraine-associated symptoms was not established ( 1.2 ) Not intended for the prophylactic therapy of migraine ( 1.2 ) Not indicated for the treatment of cluster headache ( 1.2 ) uuid:de5fd097-7428-4737-a289-094e1e78dcae biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:393355 biolink:treats MONDO:0005083 PMID:41385096 "[{""id"":""uuid:8653c646-0361-4eb1-9114-53ae62cc0287"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d7f84cf0-e45a-483d-8bbd-8aed533e12de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Calcipotriene and Betamethasone Dipropionate Topical Suspension is indicated for the topical treatment of plaque psoriasis of the scalp in patients 12 years and older and plaque psoriasis of the scalp and body in patients 18 years and older. Additional pediatric use information is approved for LEO Pharma A/S's Taclonex ® (calcipotriene and betamethasone dipropionate) Topical Suspension. However, due to LEO Pharma A/S's marketing exclusivity rights, this drug product is not labeled with that information. uuid:1946bdd5-bd3a-4372-bc6f-57f9e31a7992 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:998422 biolink:treats MONDO:0043653 PMID:41385096 "[{""id"":""uuid:9a570ac3-f8e5-4917-bf4e-d7a3ed4e8a06"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ded2ab86-554a-4d8a-bff6-0b05766c9cd5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XERESE, a combination of acyclovir, a herpes simplex virus deoxynucleoside analog DNA polymerase inhibitor, and hydrocortisone, a corticosteroid, is indicated for the early treatment of recurrent herpes labialis (cold sores) to reduce the likelihood of ulcerative cold sores and to shorten the lesion healing time in adults and children (6 years of age and older). uuid:5d184f45-9649-4ce4-a141-35f2b9a10d87 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:53426 biolink:treats MONDO:0018935 PMID:41385096 "[{""id"":""uuid:9bf8a6c3-47b1-4cf3-81b4-6cfe94c6d930"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:86671db2-5400-4e86-b67d-9215729bb6fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LUMOXITI is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who received at least two prior systemic therapies, including treatment with a purine nucleoside analog (PNA). uuid:344bf59e-8670-41c4-9a0b-eb8b52e0ee33 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:53426 biolink:treats MONDO:0004110 PMID:41385096 "[{""id"":""uuid:f614056a-ad3e-4e05-944f-ab586a538403"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:909bc30c-e610-49d2-bcbe-97cdde0bddc4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LUMOXITI is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who received at least two prior systemic therapies, including treatment with a purine nucleoside analog (PNA). uuid:416b978d-0bdc-49a1-ba69-a13e12c4935b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16684 biolink:treats UMLS:C0274707 PMID:41385096 "[{""id"":""uuid:4dab4961-b65d-4469-bd3b-8131d3bd28c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:78cda01f-e921-45f3-b81a-a47684ad680a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Atropine sulfate is given parenterally as a preanesthetic medication to decrease salivation and bronchial secretions. It is useful in pylorospasm and other spastic conditions of the gastrointestinal tract. For ureteral and biliary colic, atropine sulfate given with morphine may be indicated. Atropine sulfate is indicated for relaxation of the upper gastrointestinal tract and colon during hypotonic radiography. Atropine is used as an antidote for pilocarpine, physostigmine, isoflurophate, choline esters, certain species of aminata and in poisoning by the organic phosphate cholinesterase inhibitors found in certain insecticides and by chemical warfare “nerve gases”. Large doses relieve the muscarine-like symptoms and some of the central nervous system manifestations. uuid:042cf021-9d38-42d1-85de-d3a6a6ed56cf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16684 biolink:treats UMLS:C0274702 PMID:41385096 "[{""id"":""uuid:922d3801-7e3b-4bbd-9587-d871543c2173"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:70c2303b-02ee-46db-aab6-b87ce1a362a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Atropine sulfate is given parenterally as a preanesthetic medication to decrease salivation and bronchial secretions. It is useful in pylorospasm and other spastic conditions of the gastrointestinal tract. For ureteral and biliary colic, atropine sulfate given with morphine may be indicated. Atropine sulfate is indicated for relaxation of the upper gastrointestinal tract and colon during hypotonic radiography. Atropine is used as an antidote for pilocarpine, physostigmine, isoflurophate, choline esters, certain species of aminata and in poisoning by the organic phosphate cholinesterase inhibitors found in certain insecticides and by chemical warfare “nerve gases”. Large doses relieve the muscarine-like symptoms and some of the central nervous system manifestations. uuid:4649ece5-f4e6-41fb-b29c-2d94149b3835 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16684 biolink:treats MONDO:0042497 PMID:41385096 "[{""id"":""uuid:264f3ea3-3655-46e4-a4f3-1eda443b6eeb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4eb20afc-d9ff-4036-a92d-ad5bdbb2fdf6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Atropine sulfate is given parenterally as a preanesthetic medication to decrease salivation and bronchial secretions. It is useful in pylorospasm and other spastic conditions of the gastrointestinal tract. For ureteral and biliary colic, atropine sulfate given with morphine may be indicated. Atropine sulfate is indicated for relaxation of the upper gastrointestinal tract and colon during hypotonic radiography. Atropine is used as an antidote for pilocarpine, physostigmine, isoflurophate, choline esters, certain species of aminata and in poisoning by the organic phosphate cholinesterase inhibitors found in certain insecticides and by chemical warfare “nerve gases”. Large doses relieve the muscarine-like symptoms and some of the central nervous system manifestations. uuid:c09927f8-ce4b-42ec-9f4d-ea2c425877ac biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29034 biolink:treats MONDO:0004375 PMID:41385096 "[{""id"":""uuid:46d57719-6f69-49bd-b8b6-4998d6fe1cfb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:137788dc-a245-4e48-b290-28ca87f6b16e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Triferic is an iron replacement product indicated for the replacement of iron to maintain hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease (HDD-CKD). uuid:096098eb-2e28-4422-a62b-d0895677b455 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7573 biolink:treats MONDO:0004956 PMID:41385096 "[{""id"":""uuid:428da312-571f-4596-abf4-5a9c1f9684ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:85bb4ac2-70a1-4810-bba5-f029e39d13f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Metastatic Prostate Cancer Nilutamide Tablets are indicated for use in combination with surgical castration for the treatment of metastatic prostate cancer (Stage D 2 ). For maximum benefit, treatment with Nilutamide Tablets must begin on the same day as or on the day after surgical castration. uuid:af0f85e1-770c-4ced-a6c2-5e1f33cdd846 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:167574 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:822a0507-ea12-44b6-b73c-51cd5de5b65d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6fc67dd9-3ff0-4bc3-9bb7-5d4b786e5e16"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:5ebfab35-0908-4060-b30c-d72f6a546d4f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/wegovy""]},{""id"":""uuid:1ea012ca-baec-4f72-9b55-dc62ec551e81"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OZEMPIC is indicated: • as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus [see Clinical Studies ( 14.1 )] . • to reduce the risk of major adverse cardiovascular events ( cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease [see Clinical Studies ( 14.4 )]. Limitations of Use • OZEMPIC has not been studied in patients with a history of pancreatitis. Consider other antidiabetic therapies in patients with a history of pancreatitis [see Warnings and Precautions ( 5.2 )] . • OZEMPIC is not a substitute for insulin. OZEMPIC is not indicated for use in patients with type 1 diabetes mellitus or for the treatment of patients with diabetic ketoacidosis, as it would not be effective in these settings.|[EMA] Rybelsus is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance or contraindicationsin combination with other medicinal products for the treatment of diabetes.For study results with respect to combinations, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1.|[PMDA] A drug with a new active ingredient indicated for the treatment of type 2 diabetes mellitus. uuid:84b69139-80be-4a2d-adb7-181b18f5f13e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:167574 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:962c94bf-971e-45e8-ae71-620384f8bf97"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:984cebbf-d333-4bf4-8614-12b38f456d02"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OZEMPIC is indicated: • as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus [see Clinical Studies ( 14.1 )] . • to reduce the risk of major adverse cardiovascular events ( cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease [see Clinical Studies ( 14.4 )]. Limitations of Use • OZEMPIC has not been studied in patients with a history of pancreatitis. Consider other antidiabetic therapies in patients with a history of pancreatitis [see Warnings and Precautions ( 5.2 )] . • OZEMPIC is not a substitute for insulin. OZEMPIC is not indicated for use in patients with type 1 diabetes mellitus or for the treatment of patients with diabetic ketoacidosis, as it would not be effective in these settings. uuid:327bf248-005f-4836-8522-f52cd3501c2c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:167574 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:bf571578-45f1-48bf-a8d8-b167816de406"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9e9fd3d1-3971-4771-b38d-af1f6ab6ffe0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OZEMPIC is indicated: • as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus [see Clinical Studies ( 14.1 )] . • to reduce the risk of major adverse cardiovascular events ( cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease [see Clinical Studies ( 14.4 )]. Limitations of Use • OZEMPIC has not been studied in patients with a history of pancreatitis. Consider other antidiabetic therapies in patients with a history of pancreatitis [see Warnings and Precautions ( 5.2 )] . • OZEMPIC is not a substitute for insulin. OZEMPIC is not indicated for use in patients with type 1 diabetes mellitus or for the treatment of patients with diabetic ketoacidosis, as it would not be effective in these settings. uuid:c9a9ada4-9166-4a67-8d8c-02147bbc303e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:167574 biolink:treats MONDO:0005147 PMID:41385096 "[{""id"":""uuid:28006b43-17a5-4dcb-aae9-ee6d50d31799"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a5cfefdf-0c5a-40a0-931f-fe4ed5f52846"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OZEMPIC is indicated: • as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus [see Clinical Studies ( 14.1 )] . • to reduce the risk of major adverse cardiovascular events ( cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease [see Clinical Studies ( 14.4 )]. Limitations of Use • OZEMPIC has not been studied in patients with a history of pancreatitis. Consider other antidiabetic therapies in patients with a history of pancreatitis [see Warnings and Precautions ( 5.2 )] . • OZEMPIC is not a substitute for insulin. OZEMPIC is not indicated for use in patients with type 1 diabetes mellitus or for the treatment of patients with diabetic ketoacidosis, as it would not be effective in these settings. uuid:567cb075-e9aa-400e-8ad2-8e43bcb88860 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:167574 biolink:treats MONDO:0012819 PMID:41385096 "[{""id"":""uuid:7a168f91-66ed-4456-95da-419193c9e6ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b4c5e71b-5a4b-486f-a68c-a160e5601915"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OZEMPIC is indicated: • as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus [see Clinical Studies ( 14.1 )] . • to reduce the risk of major adverse cardiovascular events ( cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease [see Clinical Studies ( 14.4 )]. Limitations of Use • OZEMPIC has not been studied in patients with a history of pancreatitis. Consider other antidiabetic therapies in patients with a history of pancreatitis [see Warnings and Precautions ( 5.2 )] . • OZEMPIC is not a substitute for insulin. OZEMPIC is not indicated for use in patients with type 1 diabetes mellitus or for the treatment of patients with diabetic ketoacidosis, as it would not be effective in these settings. uuid:77c8f12c-700d-4e74-b311-8dfe7c6ef20c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1152251 biolink:treats UMLS:C0393736 PMID:41385096 "[{""id"":""uuid:954c51af-b920-4602-b60c-c71ff68068b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9e00108c-f3ea-4ce3-bb4e-fa9349f362f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules are indicated for the management of the symptom complex of tension (or muscle contraction) headache when non-opioid analgesic and alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, and misuse with opioids and butalbital, even at recommended doses [see Warnings and Precautions (5.1) ], reserve Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules for use in patients for whom alternative treatment options [e.g., non-opioid, non-barbiturate analgesics]: Have not been tolerated, or are not expected to be tolerated, Have not provided adequate analgesia, or are not expected to provide adequate analgesia. uuid:9e573bea-c4a7-478e-ba8d-a63fe72d3eda biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27470 biolink:treats UMLS:C0271930 PMID:41385096 "[{""id"":""uuid:3433bab2-4984-4987-b54f-52af88d78975"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a5a24b7f-3549-4612-afdb-7a08a5435550"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Folic acid is effective in the treatment of megaloblastic anemias due to a deficiency of folic acid (as may be seen in tropical or nontropical sprue) and in anemia of nutritional origin, pregnancy, infancy, or childhood. uuid:8f18670c-cab8-45bc-b36f-80b6b4b40c2e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27470 biolink:treats UMLS:C0475725 PMID:41385096 "[{""id"":""uuid:7cd7688e-daa6-428c-aa2f-017fe521c7d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:20f06e1d-392c-4d3f-997a-a316a8548a3f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Folic acid is effective in the treatment of megaloblastic anemias due to a deficiency of folic acid (as may be seen in tropical or nontropical sprue) and in anemia of nutritional origin, pregnancy, infancy, or childhood. uuid:1414cf4f-0bbc-40c7-9c33-fb3c15683c2e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27470 biolink:treats MONDO:0002280 PMID:41385096 "[{""id"":""uuid:1d2dafd0-a2dd-4480-9e80-899b48357f1c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2799305c-b248-46f9-b197-adaaedc54dbb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Folic acid is effective in the treatment of megaloblastic anemias due to a deficiency of folic acid (as may be seen in tropical or nontropical sprue) and in anemia of nutritional origin, pregnancy, infancy, or childhood. uuid:a6ee4b3c-23b0-4a8c-be70-e75357d0435b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50211 biolink:treats MONDO:0007016 PMID:41385096 "[{""id"":""uuid:a6e30822-7e84-4eb9-a39f-7e86618b2f5e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:972bdd56-2821-49cb-8842-4cb16e19d904"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Vitamin A injection is effective for the treatment of vitamin A deficiency. The parenteral administration is indicated when the oral administration is not feasible as in anorexia, nausea, vomiting, pre- and postoperative conditions, or it is not available as in the ""Malabsorption Syndrome"" with accompanying steatorrhea. Pediatric Use: Vitamin A treatment for deficiency states has been recognized as an especially effective and important therapy in the pediatric population. Vitamin A supplementation for deficiency states in this population has been addressed by the Committee on Clinical Practice Issues of the American Society for Clinical Nutrition, by the American Society for Parenteral and Enteral Nutrition, and by the World Health Organization." uuid:257e1374-db7c-48c8-9541-47d33165baa5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50211 biolink:treats MONDO:0005351 PMID:41385096 "[{""id"":""uuid:0b514566-7652-463c-9afe-50d31794396d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4b8c4e1b-e8c4-44f6-b98c-84cd786b750e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Vitamin A injection is effective for the treatment of vitamin A deficiency. The parenteral administration is indicated when the oral administration is not feasible as in anorexia, nausea, vomiting, pre- and postoperative conditions, or it is not available as in the ""Malabsorption Syndrome"" with accompanying steatorrhea. Pediatric Use: Vitamin A treatment for deficiency states has been recognized as an especially effective and important therapy in the pediatric population. Vitamin A supplementation for deficiency states in this population has been addressed by the Committee on Clinical Practice Issues of the American Society for Clinical Nutrition, by the American Society for Parenteral and Enteral Nutrition, and by the World Health Organization." uuid:742517a4-1934-47e6-b133-3919132d35a3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50211 biolink:treats HP:0002018 PMID:41385096 "[{""id"":""uuid:126eed7c-8009-4587-a1f1-44ca4d810cdb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0600ba96-cab9-4c30-ae90-f1ce7f66032e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Vitamin A injection is effective for the treatment of vitamin A deficiency. The parenteral administration is indicated when the oral administration is not feasible as in anorexia, nausea, vomiting, pre- and postoperative conditions, or it is not available as in the ""Malabsorption Syndrome"" with accompanying steatorrhea. Pediatric Use: Vitamin A treatment for deficiency states has been recognized as an especially effective and important therapy in the pediatric population. Vitamin A supplementation for deficiency states in this population has been addressed by the Committee on Clinical Practice Issues of the American Society for Clinical Nutrition, by the American Society for Parenteral and Enteral Nutrition, and by the World Health Organization." uuid:4d346d7d-9be9-4a5f-84df-a3cf9b7f60c9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50211 biolink:treats HP:0002013 PMID:41385096 "[{""id"":""uuid:dbe3342c-2579-4df0-8990-63546cfe9f3d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:70ab6c23-2977-4ddb-b285-e87a025c7e6b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Vitamin A injection is effective for the treatment of vitamin A deficiency. The parenteral administration is indicated when the oral administration is not feasible as in anorexia, nausea, vomiting, pre- and postoperative conditions, or it is not available as in the ""Malabsorption Syndrome"" with accompanying steatorrhea. Pediatric Use: Vitamin A treatment for deficiency states has been recognized as an especially effective and important therapy in the pediatric population. Vitamin A supplementation for deficiency states in this population has been addressed by the Committee on Clinical Practice Issues of the American Society for Clinical Nutrition, by the American Society for Parenteral and Enteral Nutrition, and by the World Health Organization." uuid:94b9771a-0dc9-4d69-beba-b81aa90dd8b3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50211 biolink:treats MONDO:0020598 PMID:41385096 "[{""id"":""uuid:de74da55-daa3-421e-8010-4e6b945faade"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:52a55c8e-854c-44d9-a218-b04c43bfc8bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Vitamin A injection is effective for the treatment of vitamin A deficiency. The parenteral administration is indicated when the oral administration is not feasible as in anorexia, nausea, vomiting, pre- and postoperative conditions, or it is not available as in the ""Malabsorption Syndrome"" with accompanying steatorrhea. Pediatric Use: Vitamin A treatment for deficiency states has been recognized as an especially effective and important therapy in the pediatric population. Vitamin A supplementation for deficiency states in this population has been addressed by the Committee on Clinical Practice Issues of the American Society for Clinical Nutrition, by the American Society for Parenteral and Enteral Nutrition, and by the World Health Organization." uuid:70ed2df3-552c-4e9f-a513-454bc8848ed4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50211 biolink:treats MONDO:0001075 PMID:41385096 "[{""id"":""uuid:80b78e52-4552-4064-b127-b4445cfa90c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:510047ce-b3bb-4045-903a-0d58d544986b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Vitamin A injection is effective for the treatment of vitamin A deficiency. The parenteral administration is indicated when the oral administration is not feasible as in anorexia, nausea, vomiting, pre- and postoperative conditions, or it is not available as in the ""Malabsorption Syndrome"" with accompanying steatorrhea. Pediatric Use: Vitamin A treatment for deficiency states has been recognized as an especially effective and important therapy in the pediatric population. Vitamin A supplementation for deficiency states in this population has been addressed by the Committee on Clinical Practice Issues of the American Society for Clinical Nutrition, by the American Society for Parenteral and Enteral Nutrition, and by the World Health Organization." uuid:4e9f3d59-6a01-4a99-b6d2-5e37578e69bd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41423 biolink:treats MONDO:0005475 PMID:41385096 "[{""id"":""uuid:702b1b37-7803-4ccd-85ef-eb199888903e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8d2f395a-6180-453f-a956-7c143e119de8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ELYXYB is indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use ELYXYB is not indicated for the preventive treatment of migraine. uuid:33b0fce7-9972-4a72-a8fd-f4efe60cf4e2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41423 biolink:treats MONDO:0100431 PMID:41385096 "[{""id"":""uuid:4c85188d-d06a-4408-bd9e-ca7ef08781fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e7c1b623-e2f5-486a-b9db-a28e199b444b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ELYXYB is indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use ELYXYB is not indicated for the preventive treatment of migraine. uuid:42b5be09-06b9-41e4-86c4-17d47b930d47 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71415 biolink:treats MONDO:0020920 PMID:41385096 "[{""id"":""uuid:df1c2c88-22c0-4b12-a790-542621a81c4f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0b46bcf4-d105-4cda-abca-77951f2fa122"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nitrofurantoin capsules (macrocrystals) are specifically indicated for the treatment of urinary tract infections when due to susceptible strains of Escherichia coli, enterococci , Staphylococcus aureus , and certain susceptible strains of Klebsiella and Enterobacter species. Nitrofurantoin is not indicated for the treatment of pyelonephritis or perinephric abscesses. To reduce the development of drug-resistant bacteria and maintain the effectiveness of nitrofurantoin capsules (macrocrystals) and other antibacterial drugs, nitrofurantoin capsules (macrocrystals) should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Nitrofurantoins lack the broader tissue distribution of other therapeutic agents approved for urinary tract infections. Consequently, many patients who are treated with nitrofurantoin capsules (macrocrystals) are predisposed to persistence or reappearance of bacteriuria. Urine specimens for culture and susceptibility testing should be obtained before and after completion of therapy. If persistence or reappearance of bacteriuria occurs after treatment with nitrofurantoin capsules (macrocrystals), other therapeutic agents with broader tissue distribution should be selected. In considering the use of nitrofurantoin capsules (macrocrystals), lower eradication rates should be balanced against the increased potential for systemic toxicity and for the development of antimicrobial resistance when agents with broader tissue distribution are utilized. uuid:9140c9e6-971d-4535-9d58-fecca5898ff1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71415 biolink:treats UMLS:C0851881 PMID:41385096 "[{""id"":""uuid:914915e2-9c1b-4b1a-a500-b2ac89e8e090"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:151c7579-f644-48dd-a1bd-b6726032f03f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nitrofurantoin capsules (macrocrystals) are specifically indicated for the treatment of urinary tract infections when due to susceptible strains of Escherichia coli, enterococci , Staphylococcus aureus , and certain susceptible strains of Klebsiella and Enterobacter species. Nitrofurantoin is not indicated for the treatment of pyelonephritis or perinephric abscesses. To reduce the development of drug-resistant bacteria and maintain the effectiveness of nitrofurantoin capsules (macrocrystals) and other antibacterial drugs, nitrofurantoin capsules (macrocrystals) should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Nitrofurantoins lack the broader tissue distribution of other therapeutic agents approved for urinary tract infections. Consequently, many patients who are treated with nitrofurantoin capsules (macrocrystals) are predisposed to persistence or reappearance of bacteriuria. Urine specimens for culture and susceptibility testing should be obtained before and after completion of therapy. If persistence or reappearance of bacteriuria occurs after treatment with nitrofurantoin capsules (macrocrystals), other therapeutic agents with broader tissue distribution should be selected. In considering the use of nitrofurantoin capsules (macrocrystals), lower eradication rates should be balanced against the increased potential for systemic toxicity and for the development of antimicrobial resistance when agents with broader tissue distribution are utilized. uuid:c7aa7425-893e-4179-8ed0-fc60601a6982 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71415 biolink:treats MONDO:0005545 PMID:41385096 "[{""id"":""uuid:d598cec6-6184-49da-a482-d20674e09861"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4506dae8-fa5d-4fea-b8e2-2cf967030b58"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nitrofurantoin capsules (macrocrystals) are specifically indicated for the treatment of urinary tract infections when due to susceptible strains of Escherichia coli, enterococci , Staphylococcus aureus , and certain susceptible strains of Klebsiella and Enterobacter species. Nitrofurantoin is not indicated for the treatment of pyelonephritis or perinephric abscesses. To reduce the development of drug-resistant bacteria and maintain the effectiveness of nitrofurantoin capsules (macrocrystals) and other antibacterial drugs, nitrofurantoin capsules (macrocrystals) should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Nitrofurantoins lack the broader tissue distribution of other therapeutic agents approved for urinary tract infections. Consequently, many patients who are treated with nitrofurantoin capsules (macrocrystals) are predisposed to persistence or reappearance of bacteriuria. Urine specimens for culture and susceptibility testing should be obtained before and after completion of therapy. If persistence or reappearance of bacteriuria occurs after treatment with nitrofurantoin capsules (macrocrystals), other therapeutic agents with broader tissue distribution should be selected. In considering the use of nitrofurantoin capsules (macrocrystals), lower eradication rates should be balanced against the increased potential for systemic toxicity and for the development of antimicrobial resistance when agents with broader tissue distribution are utilized. uuid:69fa38e8-ce35-407f-b12f-c19e3418ed0b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71415 biolink:treats MONDO:0030603 PMID:41385096 "[{""id"":""uuid:f92431d1-f714-484a-9bd7-5891bd8ba263"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:490c1fe3-7e21-4287-b9bd-c97d549c89cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nitrofurantoin capsules (macrocrystals) are specifically indicated for the treatment of urinary tract infections when due to susceptible strains of Escherichia coli, enterococci , Staphylococcus aureus , and certain susceptible strains of Klebsiella and Enterobacter species. Nitrofurantoin is not indicated for the treatment of pyelonephritis or perinephric abscesses. To reduce the development of drug-resistant bacteria and maintain the effectiveness of nitrofurantoin capsules (macrocrystals) and other antibacterial drugs, nitrofurantoin capsules (macrocrystals) should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Nitrofurantoins lack the broader tissue distribution of other therapeutic agents approved for urinary tract infections. Consequently, many patients who are treated with nitrofurantoin capsules (macrocrystals) are predisposed to persistence or reappearance of bacteriuria. Urine specimens for culture and susceptibility testing should be obtained before and after completion of therapy. If persistence or reappearance of bacteriuria occurs after treatment with nitrofurantoin capsules (macrocrystals), other therapeutic agents with broader tissue distribution should be selected. In considering the use of nitrofurantoin capsules (macrocrystals), lower eradication rates should be balanced against the increased potential for systemic toxicity and for the development of antimicrobial resistance when agents with broader tissue distribution are utilized. uuid:e02fcd57-f76a-455d-a371-ec5158584373 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71415 biolink:treats UMLS:C0948205 PMID:41385096 "[{""id"":""uuid:4653aec4-7f67-4b97-a052-af4175470f85"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2f0a3615-1ce4-492d-82cd-87485b39e967"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nitrofurantoin capsules (macrocrystals) are specifically indicated for the treatment of urinary tract infections when due to susceptible strains of Escherichia coli, enterococci , Staphylococcus aureus , and certain susceptible strains of Klebsiella and Enterobacter species. Nitrofurantoin is not indicated for the treatment of pyelonephritis or perinephric abscesses. To reduce the development of drug-resistant bacteria and maintain the effectiveness of nitrofurantoin capsules (macrocrystals) and other antibacterial drugs, nitrofurantoin capsules (macrocrystals) should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Nitrofurantoins lack the broader tissue distribution of other therapeutic agents approved for urinary tract infections. Consequently, many patients who are treated with nitrofurantoin capsules (macrocrystals) are predisposed to persistence or reappearance of bacteriuria. Urine specimens for culture and susceptibility testing should be obtained before and after completion of therapy. If persistence or reappearance of bacteriuria occurs after treatment with nitrofurantoin capsules (macrocrystals), other therapeutic agents with broader tissue distribution should be selected. In considering the use of nitrofurantoin capsules (macrocrystals), lower eradication rates should be balanced against the increased potential for systemic toxicity and for the development of antimicrobial resistance when agents with broader tissue distribution are utilized. uuid:3da397c5-5552-4a09-8089-5e4f7eb1368b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4W0459ZA4V biolink:treats UMLS:C1735365 PMID:41385096 "[{""id"":""uuid:e9df4fdb-2cea-48f8-8424-953eda741678"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9bd7cf83-4454-4d3b-a4f7-17d21a482816"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefprozil and other antibacterial drugs, cefprozil should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Cefprozil tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below: UPPER RESPIRATORY TRACT Pharyngitis/tonsillitis caused by Streptococcus pyogenes . NOTE: The usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. Cefprozil is generally effective in the eradication of Streptococcus pyogenes from the nasopharynx; however, substantial data establishing the efficacy of cefprozil in the subsequent prevention of rheumatic fever are not available at present. Otitis Media caused by Streptococcus pneumoniae , Haemophilus influenzae (including β-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including β-lactamase-producing strains). (See CLINICAL STUDIES .) NOTE: In the treatment of otitis media due to β-lactamase producing organisms, cefprozil had bacteriologic eradication rates somewhat lower than those observed with a product containing a specific β-lactamase inhibitor. In considering the use of cefprozil, lower overall eradication rates should be balanced against the susceptibility patterns of the common microbes in a given geographic area and the increased potential for toxicity with products containing β-lactamase inhibitors. Acute Sinusitis caused by Streptococcus pneumoniae , Haemophilus influenzae (including β-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including β-lactamase-producing strains). LOWER RESPIRATORY TRACT Acute Bacterial Exacerbation of Chronic Bronchitis caused by Streptococcus pneumoniae , Haemophilus influenzae (including β-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including β-lactamase-producing strains). SKIN AND SKIN STRUCTURE Uncomplicated Skin and Skin-Structure Infections caused by Staphylococcus aureus (including penicillinase-producing strains) and Streptococcus pyogenes . Abscesses usually require surgical drainage. uuid:5c42ebcc-04a8-4522-ae18-562e8b3eb513 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4W0459ZA4V biolink:treats MONDO:0005227 PMID:41385096 "[{""id"":""uuid:59dddbfb-1994-45b7-90bd-b8cc230a28f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f819c441-ab48-4606-8710-b4d2d05ff776"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefprozil and other antibacterial drugs, cefprozil should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Cefprozil tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below: UPPER RESPIRATORY TRACT Pharyngitis/tonsillitis caused by Streptococcus pyogenes . NOTE: The usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. Cefprozil is generally effective in the eradication of Streptococcus pyogenes from the nasopharynx; however, substantial data establishing the efficacy of cefprozil in the subsequent prevention of rheumatic fever are not available at present. Otitis Media caused by Streptococcus pneumoniae , Haemophilus influenzae (including β-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including β-lactamase-producing strains). (See CLINICAL STUDIES .) NOTE: In the treatment of otitis media due to β-lactamase producing organisms, cefprozil had bacteriologic eradication rates somewhat lower than those observed with a product containing a specific β-lactamase inhibitor. In considering the use of cefprozil, lower overall eradication rates should be balanced against the susceptibility patterns of the common microbes in a given geographic area and the increased potential for toxicity with products containing β-lactamase inhibitors. Acute Sinusitis caused by Streptococcus pneumoniae , Haemophilus influenzae (including β-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including β-lactamase-producing strains). LOWER RESPIRATORY TRACT Acute Bacterial Exacerbation of Chronic Bronchitis caused by Streptococcus pneumoniae , Haemophilus influenzae (including β-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including β-lactamase-producing strains). SKIN AND SKIN STRUCTURE Uncomplicated Skin and Skin-Structure Infections caused by Staphylococcus aureus (including penicillinase-producing strains) and Streptococcus pyogenes . Abscesses usually require surgical drainage. uuid:49c138b7-1d8a-461f-9b30-18d3504bd991 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:136051 biolink:treats MONDO:0002049 PMID:41385096 "[{""id"":""uuid:aafc191a-1082-4e73-8e85-1fcd628226b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:95ff59ec-93bc-4248-8794-93d859263ca2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:884de732-5dbd-43ca-b58a-0f459dc80cbb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/mulpleo""]},{""id"":""uuid:633c25fd-f21c-43af-8b99-3c6dcd9305e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MULPLETA is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.|[EMA] Mulpleo is indicated for the treatment of severe thrombocytopenia in adult patients with chronic liver disease undergoing invasive procedures|[PMDA] A drug with a new active ingredient indicated for the improvement of thrombocytopenia in patients with chronic liver disease for whom an elective invasive procedure is planned. uuid:0f21cdcc-2b33-454b-9cde-d4a50be89417 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:136051 biolink:treats UMLS:C0341439 PMID:41385096 "[{""id"":""uuid:e5ddf801-e180-40d4-854c-c67d8d70d279"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4c97f3e8-8f75-4da8-a559-a2d38c1619c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MULPLETA is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure. uuid:aeef14cd-0dde-4c5d-b1a6-9f2bab9e9ed7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5062 biolink:treats UMLS:C0341742 PMID:41385096 "[{""id"":""uuid:fe0ec44c-96ee-40cd-a71f-46faa2b2b156"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0c9daf6b-ae5c-41f5-b1a2-ace3fdf96e9c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Finasteride tablets is a 5α-reductase inhibitor, indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to (1.1) : Improve symptoms Reduce the risk of acute urinary retention Reduce the risk of the need for surgery including transurethral resection of the prostate (TURP) and prostatectomy. Finasteride tablets administered in combination with the alpha-blocker doxazosin is indicated to reduce the risk of symptomatic progression of BPH (a confirmed ≥4 point increase in American Urological Association (AUA) symptom score) (1.2) . Limitations of Use: Finasteride tablets is not approved for the prevention of prostate cancer (1.3) . uuid:e19fdf46-9160-4795-a334-2c1d5fed09a5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:232408 biolink:treats MONDO:0008233 PMID:41385096 "[{""id"":""uuid:dffdcb95-0349-4d8d-8dfa-3d9450858f3f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c2b0858d-0af6-4158-8976-50a1730b4dc5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Metyrosine capsules are indicated in the treatment of patients with pheochromocytoma for: 1. Preoperative preparation of patients for surgery. 2. Management of patients when surgery is contraindicated. 3. Chronic treatment of patients with malignant pheochromocytoma. Metyrosine capsules are not recommended for the control of essential hypertension. uuid:41920bd1-d04f-4316-b152-4dd3f398da07 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:232408 biolink:treats MONDO:0006288 PMID:41385096 "[{""id"":""uuid:42ca42e0-41e4-4c07-9134-b4f1a66c2ad2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ad36d3ae-dfb2-43b0-8ba0-0ef240228200"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Metyrosine capsules are indicated in the treatment of patients with pheochromocytoma for: 1. Preoperative preparation of patients for surgery. 2. Management of patients when surgery is contraindicated. 3. Chronic treatment of patients with malignant pheochromocytoma. Metyrosine capsules are not recommended for the control of essential hypertension. uuid:c0e71ee5-de6e-42ee-802c-08fb52166e79 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17334 biolink:treats MONDO:0005699 PMID:41385096 "[{""id"":""uuid:f15eec2b-7db8-4283-ae7f-b0a34239e1d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c7c03535-b5d0-4e4b-aab7-ba4339ba5039"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Buffered penicillin G potassium for injection is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Buffered penicillin G potassium for injection may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below, however, once these results become available, appropriate therapy should be continued. CLINICAL INDICATION INFECTING ORGANISM Septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis Streptococcus pyogenes (group A beta-hemolytic streptococcus ), other beta-hemolytic streptococci including groups C, H, G, L and M, Streptococcus pneumoniae and Staphylococcus species (non-penicillinase producing strains) Anthrax Bacillus anthracis Actinomycosis (cervicofacial disease and thoracic and abdominal disease) Actinomyces Israelil Botulism (adjunctive therapy to antitoxin), gas gangrene, and tetanus (adjunctive therapy to human tetanus immune globulin) Clostridium species Diphtheria (adjunctive therapy to antitoxin and prevention of the carrier state) Corynebacterium diphtheriae Erysipelothrix endocarditis Erysipelothrix rhusiopthiae Fusospirochetosis (severe infections of the oropharynx [Vincent’s], lower respiratory tract and genital area) Fusobacterium species and spirochetes Listeria infections including meningitis and endocarditis Listeria monocytogenes Pasteurella infections including bacteremia and meningitis Pasteurella multocida Haverhill fever Streptobacillus moniliformis Rat-bite fever Spirillum minus or Streptobacillus moniliformis Disseminated gonococcal infections Neisseria gonorrhoeae (penicillin-susceptible) Syphilis (congenital and neurosyphilis) Treponema pallidum Meningococcal meningitis and/or septicemia Neisseria meningitidis Gram-negative bacillary infections (bacteremias) Escherichia coli, Enterobacter aerogenes, Alcaligenes faecalis, salmonella, shigella and Proteus mirabilis, Penicillin G is not the drug of choice in the treatment of gram-negative bacillary infections. To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin G potassium and other antibacterial drugs, penicillin G potassium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. CHEBI:18208 uuid:d7c4a4c7-115f-401f-a071-a56e14dea2df biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1164043 biolink:treats MONDO:0004857 PMID:41385096 "[{""id"":""uuid:cba24ee8-c264-4550-9a23-48931dd9c9b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ff151c06-a4fc-4cad-af9a-ce6dfe7aa405"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lidothol is a formulation used to assist patients in the treatment of mild to moderate acute or chronic aches or pain. Muscle or joint pain can be due to muscle or ligament strains, simple backache, tendonitis, osteoarthritis, rheumatoid arthritis, peripheral neuropathies such as diabetic neuropathy or post herpetic neuralgia, and other complex regional pains. It can also be used to help with certain types of headaches, but use with caution when applying in order to avoid eye contact. Other uses may be considered if deemed clinically relevant. uuid:2fed1ddc-e24b-414a-b2c7-112ce89a1f85 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1164043 biolink:treats MONDO:0005178 PMID:41385096 "[{""id"":""uuid:51c852be-a5cf-473f-82fd-692fc311095f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eb1332ab-1214-4838-9c4c-7adec028eda6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lidothol is a formulation used to assist patients in the treatment of mild to moderate acute or chronic aches or pain. Muscle or joint pain can be due to muscle or ligament strains, simple backache, tendonitis, osteoarthritis, rheumatoid arthritis, peripheral neuropathies such as diabetic neuropathy or post herpetic neuralgia, and other complex regional pains. It can also be used to help with certain types of headaches, but use with caution when applying in order to avoid eye contact. Other uses may be considered if deemed clinically relevant. uuid:641f4941-0374-4d04-bdf2-8ee9e8270239 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1164043 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:7309af68-fbc9-439d-8226-500bf5843c79"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fe0764a7-50be-43ff-babc-f4c5597e524e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lidothol is a formulation used to assist patients in the treatment of mild to moderate acute or chronic aches or pain. Muscle or joint pain can be due to muscle or ligament strains, simple backache, tendonitis, osteoarthritis, rheumatoid arthritis, peripheral neuropathies such as diabetic neuropathy or post herpetic neuralgia, and other complex regional pains. It can also be used to help with certain types of headaches, but use with caution when applying in order to avoid eye contact. Other uses may be considered if deemed clinically relevant. uuid:d619ebca-33eb-4e9e-857f-2df3bc39479c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1164043 biolink:treats MONDO:0006626 PMID:41385096 "[{""id"":""uuid:f5ff13ba-a1d9-4b32-a970-380fed23b2c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:175ed5da-847b-43f8-b2a7-7214f2a82472"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lidothol is a formulation used to assist patients in the treatment of mild to moderate acute or chronic aches or pain. Muscle or joint pain can be due to muscle or ligament strains, simple backache, tendonitis, osteoarthritis, rheumatoid arthritis, peripheral neuropathies such as diabetic neuropathy or post herpetic neuralgia, and other complex regional pains. It can also be used to help with certain types of headaches, but use with caution when applying in order to avoid eye contact. Other uses may be considered if deemed clinically relevant. uuid:b51e854b-de3f-40be-9689-94eb5580f446 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1164043 biolink:treats MONDO:0041052 PMID:41385096 "[{""id"":""uuid:60456c43-f814-4829-8a7c-29cea11dec5c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:be88f342-67f1-415b-9e17-1ec3e94b5fd3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lidothol is a formulation used to assist patients in the treatment of mild to moderate acute or chronic aches or pain. Muscle or joint pain can be due to muscle or ligament strains, simple backache, tendonitis, osteoarthritis, rheumatoid arthritis, peripheral neuropathies such as diabetic neuropathy or post herpetic neuralgia, and other complex regional pains. It can also be used to help with certain types of headaches, but use with caution when applying in order to avoid eye contact. Other uses may be considered if deemed clinically relevant. uuid:d5523e0c-683a-4922-8b33-5f5fd1f43378 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1164043 biolink:treats MONDO:0021146 PMID:41385096 "[{""id"":""uuid:a2405667-9b62-4df6-adef-4fe150e4aeeb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:56f9a6de-37e3-4aad-8445-82618d2050aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lidothol is a formulation used to assist patients in the treatment of mild to moderate acute or chronic aches or pain. Muscle or joint pain can be due to muscle or ligament strains, simple backache, tendonitis, osteoarthritis, rheumatoid arthritis, peripheral neuropathies such as diabetic neuropathy or post herpetic neuralgia, and other complex regional pains. It can also be used to help with certain types of headaches, but use with caution when applying in order to avoid eye contact. Other uses may be considered if deemed clinically relevant. uuid:e1411805-5cd9-4c37-962d-37972dd33986 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28689 biolink:treats UMLS:C0423747 PMID:41385096 "[{""id"":""uuid:f5233950-3f3d-4199-ab7f-c5cb3a3a95b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6f0c8db7-b17c-488c-a38a-087ac19e3538"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INTRAROSA ® is a steroid indicated for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause. uuid:0bf68ea4-6955-4c00-aae3-f49f3e43569c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28689 biolink:treats MONDO:0001932 PMID:41385096 "[{""id"":""uuid:e3a51797-5388-48c9-bd19-57cde7a1c748"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f78114b5-db79-4af2-8928-34e6bc3e9f1e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:3d242b27-3f86-4dda-958f-1bcd2278c141"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/intrarosa""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] INTRAROSA ® is a steroid indicated for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause.|[EMA] Intrarosa is indicated for the treatment of vulvar and vaginal atrophy in postmenopausal women having moderate to severe symptoms., DOID:14275 uuid:3a91c715-3ac2-4486-a914-69ac0d460aad biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27666 biolink:treats MONDO:0006058 PMID:41385096 "[{""id"":""uuid:2bcbce5a-2800-41c9-b4a0-7ef846b67b05"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:210b28ec-0bd4-4e61-be36-df2389bd1618"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dactinomycin for Injection is an actinomycin indicated for the treatment of: adult and pediatric patients with Wilms tumor, as part of a multi-phase, combination chemotherapy regimen. ( 1.1 ) adult and pediatric patients with rhabdomyosarcoma, as part of a multi-phase, combination chemotherapy regimen. ( 1.2 ) adult and pediatric patients with Ewing sarcoma, as part of a multi-phase, combination chemotherapy regimen. ( 1.3 ) adult and pediatric patients with metastatic, nonseminomatous testicular cancer, as part of a multi-phase, combination chemotherapy regimen. ( 1.4 ) post-menarchal patients with gestational trophoblastic neoplasia, as a single agent or as part of a combination chemotherapy regimen. ( 1.5 ) adult patients with locally recurrent or locoregional solid malignancies, as a component of palliative or adjunctive regional perfusion. ( 1.6 ) uuid:48aa05f2-cb8d-4968-aa9a-aae108a61e82 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27666 biolink:treats MONDO:0005212 PMID:41385096 "[{""id"":""uuid:389a0b74-e5ac-4147-aa0e-92e5f17d1397"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:05040928-39f5-4aa8-a7a7-1fa9ef31890f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dactinomycin for Injection is an actinomycin indicated for the treatment of: adult and pediatric patients with Wilms tumor, as part of a multi-phase, combination chemotherapy regimen. ( 1.1 ) adult and pediatric patients with rhabdomyosarcoma, as part of a multi-phase, combination chemotherapy regimen. ( 1.2 ) adult and pediatric patients with Ewing sarcoma, as part of a multi-phase, combination chemotherapy regimen. ( 1.3 ) adult and pediatric patients with metastatic, nonseminomatous testicular cancer, as part of a multi-phase, combination chemotherapy regimen. ( 1.4 ) post-menarchal patients with gestational trophoblastic neoplasia, as a single agent or as part of a combination chemotherapy regimen. ( 1.5 ) adult patients with locally recurrent or locoregional solid malignancies, as a component of palliative or adjunctive regional perfusion. ( 1.6 ) uuid:266e583f-63cf-4bbe-8389-d0323ec94414 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27666 biolink:treats MONDO:0012817 PMID:41385096 "[{""id"":""uuid:9a05b850-5cc8-4666-8d98-57fcbf55bb47"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:87f100f2-2871-4500-a64e-3d60b3b50bd8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dactinomycin for Injection is an actinomycin indicated for the treatment of: adult and pediatric patients with Wilms tumor, as part of a multi-phase, combination chemotherapy regimen. ( 1.1 ) adult and pediatric patients with rhabdomyosarcoma, as part of a multi-phase, combination chemotherapy regimen. ( 1.2 ) adult and pediatric patients with Ewing sarcoma, as part of a multi-phase, combination chemotherapy regimen. ( 1.3 ) adult and pediatric patients with metastatic, nonseminomatous testicular cancer, as part of a multi-phase, combination chemotherapy regimen. ( 1.4 ) post-menarchal patients with gestational trophoblastic neoplasia, as a single agent or as part of a combination chemotherapy regimen. ( 1.5 ) adult patients with locally recurrent or locoregional solid malignancies, as a component of palliative or adjunctive regional perfusion. ( 1.6 ) uuid:4e9164eb-2fca-4542-9a59-0d0b87537210 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27666 biolink:treats MONDO:0018944 PMID:41385096 "[{""id"":""uuid:9506f6ca-9b74-4054-bb02-edf0f82a4d57"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1204ca55-01f9-4860-9792-0cddb0cc7e97"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dactinomycin for Injection is an actinomycin indicated for the treatment of: adult and pediatric patients with Wilms tumor, as part of a multi-phase, combination chemotherapy regimen. ( 1.1 ) adult and pediatric patients with rhabdomyosarcoma, as part of a multi-phase, combination chemotherapy regimen. ( 1.2 ) adult and pediatric patients with Ewing sarcoma, as part of a multi-phase, combination chemotherapy regimen. ( 1.3 ) adult and pediatric patients with metastatic, nonseminomatous testicular cancer, as part of a multi-phase, combination chemotherapy regimen. ( 1.4 ) post-menarchal patients with gestational trophoblastic neoplasia, as a single agent or as part of a combination chemotherapy regimen. ( 1.5 ) adult patients with locally recurrent or locoregional solid malignancies, as a component of palliative or adjunctive regional perfusion. ( 1.6 ) uuid:4064313d-1eb4-4f11-84ca-78f65f439869 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:79699 biolink:treats MONDO:0005086 PMID:41385096 "[{""id"":""uuid:e503625c-bba7-478c-8771-a284d2692fb8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:96a05958-bda3-41ad-bc7f-9ce1ce6edb3a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:cfe5b874-3ff2-4ec8-8c0c-d014908e3dd9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/torisel""]},{""id"":""uuid:32e910b8-7c2b-414b-ba5f-8d38891f6dca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Temsirolimus injection is indicated for the treatment of advanced renal cell carcinoma.|[EMA] Renal-cell carcinomaTorisel is indicated for the first-line treatment of adult patients with advanced renal-cell carcinoma (RCC) who have at least three of six prognostic risk factors.Mantle-cell lymphomaTorisel is indicated for the treatment of adult patients with relapsed and / or refractory mantle-cell lymphoma (MCL).|[PMDA] A drug with a new active ingredient indicated for the treatment of unresectable or metastatic renal cell carcinoma. uuid:205fcdbd-2d5f-4c60-89b0-4a18c9b38e26 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:WA16A5Y52X biolink:treats EFO:1001480 PMID:41385096 "[{""id"":""uuid:b7bcea54-fabc-4ecf-8006-7a3e0ea1e262"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:302b1ed2-5162-4d71-a53d-a085d012568e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levoleucovorin injection is indicated for: rescue after high-dose methotrexate therapy in adult and pediatric patients with osteosarcoma. diminishing the toxicity associated with overdosage of folic acid antagonists or impaired methotrexate elimination in adult and pediatric patients. the treatment of adults with metastatic colorectal cancer in combination with fluorouracil. Limitations of Use Levoleucovorin injection is not indicated for pernicious anemia and megaloblastic anemia secondary to the lack of vitamin B 12 , because of the risk of progression of neurologic manifestations despite hematologic remission. PUBCHEM.COMPOUND:135465090 uuid:a0ec828e-c36c-4385-94af-61cef7adc5ed biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:WA16A5Y52X biolink:treats MONDO:0008228 PMID:41385096 "[{""id"":""uuid:9944b8ae-8cbc-436c-82fe-92a658ff543b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7b3b20e5-5bd5-45d4-baac-a17bf8949b88"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levoleucovorin injection is indicated for: rescue after high-dose methotrexate therapy in adult and pediatric patients with osteosarcoma. diminishing the toxicity associated with overdosage of folic acid antagonists or impaired methotrexate elimination in adult and pediatric patients. the treatment of adults with metastatic colorectal cancer in combination with fluorouracil. Limitations of Use Levoleucovorin injection is not indicated for pernicious anemia and megaloblastic anemia secondary to the lack of vitamin B 12 , because of the risk of progression of neurologic manifestations despite hematologic remission. PUBCHEM.COMPOUND:135465090 uuid:c1120a9c-f51b-4e1a-ad7c-278901a8e4dc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:WA16A5Y52X biolink:treats UMLS:C0815316 PMID:41385096 "[{""id"":""uuid:26e72a35-4eab-4da0-b687-d4a11a81ab09"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2059a3f7-6912-47b7-87e6-ddeb533bcbc9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levoleucovorin injection is indicated for: rescue after high-dose methotrexate therapy in adult and pediatric patients with osteosarcoma. diminishing the toxicity associated with overdosage of folic acid antagonists or impaired methotrexate elimination in adult and pediatric patients. the treatment of adults with metastatic colorectal cancer in combination with fluorouracil. Limitations of Use Levoleucovorin injection is not indicated for pernicious anemia and megaloblastic anemia secondary to the lack of vitamin B 12 , because of the risk of progression of neurologic manifestations despite hematologic remission. PUBCHEM.COMPOUND:135465090 uuid:0fe057c8-003a-4cb2-aa82-96b334301dd8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15640 biolink:treats MONDO:0002629 PMID:41385096 "[{""id"":""uuid:4e6a3bcd-2d65-4d40-bf36-722f8c8bceb9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:13040951-d8fb-4b64-b6a4-331d10b41fc5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Leucovorin calcium rescue is indicated after high-dose methotrexate therapy in osteosarcoma. Leucovorin Calcium for Injection is also indicated to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists. Leucovorin Calcium for Injection is indicated in the treatment of megaloblastic anemias due to folic acid deficiency when oral therapy is not feasible. Leucovorin Calcium for Injection is also indicated for use in combination with 5-fluorouracil to prolong survival in the palliative treatment of patients with advanced colorectal cancer. Leucovorin Calcium for Injection should not be mixed in the same infusion as 5-fluorouracil because a precipitate may form. uuid:2e47257f-781f-48b5-81f0-39bdcb0f8f41 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15640 biolink:treats MONDO:0001860 PMID:41385096 "[{""id"":""uuid:2311c0b8-8c23-4428-b331-2ffc0c2c181f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4e111006-3d92-4dc4-a09b-11522ac92b3c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Leucovorin calcium rescue is indicated after high-dose methotrexate therapy in osteosarcoma. Leucovorin Calcium for Injection is also indicated to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists. Leucovorin Calcium for Injection is indicated in the treatment of megaloblastic anemias due to folic acid deficiency when oral therapy is not feasible. Leucovorin Calcium for Injection is also indicated for use in combination with 5-fluorouracil to prolong survival in the palliative treatment of patients with advanced colorectal cancer. Leucovorin Calcium for Injection should not be mixed in the same infusion as 5-fluorouracil because a precipitate may form. uuid:feefef10-09ae-4d13-b85f-e9652386c91c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15640 biolink:treats EFO:1001480 PMID:41385096 "[{""id"":""uuid:5ce9b2e8-d78b-4527-b163-7ebcbc1d4067"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5ab52249-ec64-47c9-8144-71f39bb568a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Leucovorin calcium rescue is indicated after high-dose methotrexate therapy in osteosarcoma. Leucovorin Calcium for Injection is also indicated to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists. Leucovorin Calcium for Injection is indicated in the treatment of megaloblastic anemias due to folic acid deficiency when oral therapy is not feasible. Leucovorin Calcium for Injection is also indicated for use in combination with 5-fluorouracil to prolong survival in the palliative treatment of patients with advanced colorectal cancer. Leucovorin Calcium for Injection should not be mixed in the same infusion as 5-fluorouracil because a precipitate may form. uuid:0739aaff-9a24-40c3-a8f9-68f13ee0550c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46195 biolink:treats HP:0001945 PMID:41385096 "[{""id"":""uuid:6e7428a9-b847-4130-97cf-e5b13f503958"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d0798e04-4ae3-43d1-ad4f-ff55a61ec096"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ad6a4859-0f4b-4144-97e9-f0c31701af17"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Acetaminophen injection is indicated for • the management of mild to moderate pain in adult and pediatric patients 2 years and older • the management of moderate to severe pain with adjunctive opioid analgesics in adult and pediatric patients 2 years and older • the reduction of fever in adult and pediatric patients.|[PMDA] A drug with a new route of administration indicated for the treatment of pain and pyrexia which cannnot be managed by oral preparations and suppositories. uuid:e8106120-82ea-4bb7-8e38-7060b71d9ad8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4562 biolink:treats MONDO:0005475 PMID:41385096 "[{""id"":""uuid:a10feafa-edd5-4f22-a956-086f06175422"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:208e6c4c-c767-4b55-8085-57a42169e170"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dihydroergotamine mesylate nasal spray is indicated for the acute treatment of migraine headaches with or without aura. Dihydroergotamine mesylate nasal spray is not intended for the prophylactic therapy of migraine or for the management of hemiplegic or basilar migraine. uuid:394ef239-2281-410c-89dc-27c7010e2f8e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4562 biolink:treats MONDO:0100431 PMID:41385096 "[{""id"":""uuid:57040607-18be-4101-af52-5e3057c66b32"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:61e18a94-a4f6-4269-b319-2015de268502"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dihydroergotamine mesylate nasal spray is indicated for the acute treatment of migraine headaches with or without aura. Dihydroergotamine mesylate nasal spray is not intended for the prophylactic therapy of migraine or for the management of hemiplegic or basilar migraine. uuid:ec4bd792-5f93-4ab0-9258-4ba03c327b53 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4562 biolink:treats MONDO:0018925 PMID:41385096 "[{""id"":""uuid:ee086b46-41bd-431c-a746-aca798b053a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7ccea9d3-722d-4afc-bf10-6d7620ce5481"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dihydroergotamine mesylate nasal spray is indicated for the acute treatment of migraine headaches with or without aura. Dihydroergotamine mesylate nasal spray is not intended for the prophylactic therapy of migraine or for the management of hemiplegic or basilar migraine. uuid:d1dcc3d9-b8a7-42b6-a6f6-4957ee9e3cf5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4562 biolink:treats MONDO:0043219 PMID:41385096 "[{""id"":""uuid:ddaab1fa-aca9-46fd-8bbd-c2f8f968b2d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f26af1cb-cc24-40d9-8e69-59fa21d4abf5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dihydroergotamine mesylate nasal spray is indicated for the acute treatment of migraine headaches with or without aura. Dihydroergotamine mesylate nasal spray is not intended for the prophylactic therapy of migraine or for the management of hemiplegic or basilar migraine. uuid:9a5d6d1c-b733-4658-bb28-035317432523 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18385 biolink:treats MONDO:0005351 PMID:41385096 "[{""id"":""uuid:0dfca7fe-dee1-402a-9c78-597b17b10c54"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e7456cbc-0657-4227-a1a2-433398ca707f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Thiamine hydrochloride injection is effective for the treatment of thiamine deficiency or beriberi whether of the dry (major symptoms related to the nervous system) or wet (major symptoms related to the cardiovascular system) variety. Thiamine hydrochloride injection should be used where rapid restoration of thiamine is necessary, as in Wernicke's encephalopathy, infantile beriberi with acute collapse, cardiovascular disease due to thiamine deficiency, or neuritis of pregnancy if vomiting is severe. It is also indicated when giving IV dextrose to individuals with marginal thiamine status to avoid precipitation of heart failure. Thiamine hydrochloride injection is also indicated in patients with established thiamine deficiency who cannot take thiamine orally due to coexisting severe anorexia, nausea, vomiting, or malabsorption. Thiamine hydrochloride injection is not usually indicated for conditions of decreased oral intake or decreased gastrointestinal absorption, because multiple vitamins should usually be given. uuid:823c048e-b60f-4eb9-bee6-4b97e533c37b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18385 biolink:treats HP:0002018 PMID:41385096 "[{""id"":""uuid:b2c510a7-6578-4091-b59d-3ad2637a0936"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:709d3919-5815-42c1-a6fc-7d69b71f05aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Thiamine hydrochloride injection is effective for the treatment of thiamine deficiency or beriberi whether of the dry (major symptoms related to the nervous system) or wet (major symptoms related to the cardiovascular system) variety. Thiamine hydrochloride injection should be used where rapid restoration of thiamine is necessary, as in Wernicke's encephalopathy, infantile beriberi with acute collapse, cardiovascular disease due to thiamine deficiency, or neuritis of pregnancy if vomiting is severe. It is also indicated when giving IV dextrose to individuals with marginal thiamine status to avoid precipitation of heart failure. Thiamine hydrochloride injection is also indicated in patients with established thiamine deficiency who cannot take thiamine orally due to coexisting severe anorexia, nausea, vomiting, or malabsorption. Thiamine hydrochloride injection is not usually indicated for conditions of decreased oral intake or decreased gastrointestinal absorption, because multiple vitamins should usually be given. uuid:ec68ec76-8335-410d-b17b-ae3105e3d510 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18385 biolink:treats HP:0002013 PMID:41385096 "[{""id"":""uuid:bcf437dc-ea23-4835-90bd-0f0df8343ecd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:57387241-6d61-4c23-9dea-1a52234f6e17"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Thiamine hydrochloride injection is effective for the treatment of thiamine deficiency or beriberi whether of the dry (major symptoms related to the nervous system) or wet (major symptoms related to the cardiovascular system) variety. Thiamine hydrochloride injection should be used where rapid restoration of thiamine is necessary, as in Wernicke's encephalopathy, infantile beriberi with acute collapse, cardiovascular disease due to thiamine deficiency, or neuritis of pregnancy if vomiting is severe. It is also indicated when giving IV dextrose to individuals with marginal thiamine status to avoid precipitation of heart failure. Thiamine hydrochloride injection is also indicated in patients with established thiamine deficiency who cannot take thiamine orally due to coexisting severe anorexia, nausea, vomiting, or malabsorption. Thiamine hydrochloride injection is not usually indicated for conditions of decreased oral intake or decreased gastrointestinal absorption, because multiple vitamins should usually be given. uuid:6beb5377-3c7f-4117-95b8-02cf9b5b1270 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18385 biolink:treats HP:0002024 PMID:41385096 "[{""id"":""uuid:4fa3581b-4867-42ec-9eab-56d7d8413b28"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e3d542bd-eeea-4a00-ab8c-b7d1c0a1a930"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Thiamine hydrochloride injection is effective for the treatment of thiamine deficiency or beriberi whether of the dry (major symptoms related to the nervous system) or wet (major symptoms related to the cardiovascular system) variety. Thiamine hydrochloride injection should be used where rapid restoration of thiamine is necessary, as in Wernicke's encephalopathy, infantile beriberi with acute collapse, cardiovascular disease due to thiamine deficiency, or neuritis of pregnancy if vomiting is severe. It is also indicated when giving IV dextrose to individuals with marginal thiamine status to avoid precipitation of heart failure. Thiamine hydrochloride injection is also indicated in patients with established thiamine deficiency who cannot take thiamine orally due to coexisting severe anorexia, nausea, vomiting, or malabsorption. Thiamine hydrochloride injection is not usually indicated for conditions of decreased oral intake or decreased gastrointestinal absorption, because multiple vitamins should usually be given. uuid:311cc6e6-519b-458b-974f-e5d7a3f8208e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63627 biolink:treats MONDO:0002154 PMID:41385096 "[{""id"":""uuid:39d69e44-c30b-4d86-909b-f5fc4b0a1d41"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4a99c974-2ccc-4d75-96f7-0e39b4250290"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tinidazole is a nitroimidazole antimicrobial indicated for: Trichomoniasis ( 1.1 ) Giardiasis: in patients age 3 and older ( 1.2 ) Amebiasis: in patients age 3 and older ( 1.3 ) Bacterial Vaginosis: in non-pregnant, adult women ( 1.4 , 8.1 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of tinidazole tablets and other antibacterial drugs, tinidazole tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. (1.5) uuid:c02c8616-d849-4208-9b7f-902346e9b51c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63627 biolink:treats MONDO:0001103 PMID:41385096 "[{""id"":""uuid:5bb45524-9c42-4468-a5f1-cb094becb819"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:889f16e7-11e9-4f01-b905-fc98dab874a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tinidazole is a nitroimidazole antimicrobial indicated for: Trichomoniasis ( 1.1 ) Giardiasis: in patients age 3 and older ( 1.2 ) Amebiasis: in patients age 3 and older ( 1.3 ) Bacterial Vaginosis: in non-pregnant, adult women ( 1.4 , 8.1 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of tinidazole tablets and other antibacterial drugs, tinidazole tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. (1.5) uuid:51cd3dfa-66bf-48fa-8f96-67c255ff4d8e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63627 biolink:treats MONDO:0005644 PMID:41385096 "[{""id"":""uuid:76798ba7-598c-45ad-9378-ce2ff83ab3a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ec4e30e0-acb6-4282-b309-1ff310b4a177"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tinidazole is a nitroimidazole antimicrobial indicated for: Trichomoniasis ( 1.1 ) Giardiasis: in patients age 3 and older ( 1.2 ) Amebiasis: in patients age 3 and older ( 1.3 ) Bacterial Vaginosis: in non-pregnant, adult women ( 1.4 , 8.1 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of tinidazole tablets and other antibacterial drugs, tinidazole tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. (1.5) uuid:804c9928-3422-4fb3-b78f-8672b2e02960 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63627 biolink:treats MONDO:0005316 PMID:41385096 "[{""id"":""uuid:38e4022b-b84b-4dae-9d75-00b9f0c8aee7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f55e216c-2e42-46fa-a853-385cb3cf6c0e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tinidazole is a nitroimidazole antimicrobial indicated for: Trichomoniasis ( 1.1 ) Giardiasis: in patients age 3 and older ( 1.2 ) Amebiasis: in patients age 3 and older ( 1.3 ) Bacterial Vaginosis: in non-pregnant, adult women ( 1.4 , 8.1 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of tinidazole tablets and other antibacterial drugs, tinidazole tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. (1.5) uuid:8cf65332-2f95-4a38-bde8-227d4e3842be biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85157 biolink:treats HP:0002017 PMID:41385096 "[{""id"":""uuid:aee990cb-4284-4897-bc56-6ebdc21e2491"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c8977bab-da85-48c0-9644-f83e9a816e81"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Palonosetron hydrochloride injection is a serotonin-3 (5-HT 3 ) receptor antagonist indicated in: Adults for prevention of : acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). ( 1 ) acute nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC). ( 1 ) postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. Efficacy beyond 24 hours has not been demonstrated ( 1 ) Pediatric patients aged 1 month to less than 17 years for prevention of : acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy (HEC). ( 1 ) uuid:c87c6754-fd1f-4f46-a4fc-576b94081d5a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85157 biolink:treats NCIT:C107517 PMID:41385096 "[{""id"":""uuid:9e316e9a-7f65-4aa2-9b11-94fd7418cab6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:93cab8d6-0df4-4e90-ac5e-c9aa594d3ee4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Palonosetron hydrochloride injection is a serotonin-3 (5-HT 3 ) receptor antagonist indicated in: Adults for prevention of : acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). ( 1 ) acute nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC). ( 1 ) postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. Efficacy beyond 24 hours has not been demonstrated ( 1 ) Pediatric patients aged 1 month to less than 17 years for prevention of : acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy (HEC). ( 1 ) uuid:eed91659-8a42-4fc5-acc2-ffe9535321b7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8077 biolink:treats MONDO:0008233 PMID:41385096 "[{""id"":""uuid:9dfbc4de-17f6-45d7-b770-d3e2968fbc7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:62c23dfb-95c3-49fb-b61b-2e2e30f2cedd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Phenoxybenzamine hydrochloride capsules are indicated in the treatment of pheochromocytoma, to control episodes of hypertension and sweating. If tachycardia is excessive, it may be necessary to use a beta -blocking agent concomitantly. uuid:1b36e7f6-4e73-48d4-9b0b-90928757d5ed biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8077 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:40898719-aab8-4a24-83d3-ea5d1700489f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8e88530f-2c74-430f-80f4-9e4b3d5c43d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Phenoxybenzamine hydrochloride capsules are indicated in the treatment of pheochromocytoma, to control episodes of hypertension and sweating. If tachycardia is excessive, it may be necessary to use a beta -blocking agent concomitantly. uuid:77b84359-7a4b-445c-822e-ef7c4f56a943 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85083 biolink:treats MONDO:0005354 PMID:41385096 "[{""id"":""uuid:3b44a3eb-ad98-47a0-8e98-171e2fedbef9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1449b3a4-51d0-4159-b858-510a129df5fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:788ed095-e37a-4700-9911-603bbfc1f6fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/sovaldi""]},{""id"":""uuid:9469881b-d8cf-4e47-9ddb-be4bba81edd0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SOVALDI is a hepatitis C virus (HCV) nucleotide analog NS5B polymerase inhibitor indicated for the treatment of: Adult patients with genotype 1, 2, 3 or 4 chronic hepatitis C virus (HCV) infection without cirrhosis or with compensated cirrhosis as a component of a combination antiviral treatment regimen. ( 1 ) Pediatric patients 12 years of age and older or weighing at least 35 kg with genotype 2 or 3 chronic HCV infection without cirrhosis or with compensated cirrhosis in combination with ribavirin. ( 1 )|[EMA] Sovaldi is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adult and paediatric patients aged 3 years and above (see sections 4.2, 4.4 and 5.1).For hepatitis C virus (HCV) genotype specific activity, see sections 4.4 and 5.1.Sovaldi is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adults and paediatric patients aged 3 years and above (see sections 4.2, 4.4 and 5.1).For hepatitis C virus (HCV) genotype specific activity, see sections 4.4 and 5.1.|[PMDA] A drug with a new active ingredient indicated for the improvement of viremia in patients with chronic hepatitis C or compensated cirrhosis type C in serogroup 2 (genotype 2) . [Priority review] uuid:f69bc349-122e-44af-8579-ffa004528404 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1156069 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:7bbeab1a-3a4c-4e64-97e7-03b2ca827fde"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0c13ec7d-3fda-4c88-a41f-99cdedbc3493"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE INHALATION AEROSOL is a combination product containing a corticosteroid and a long-acting beta 2 -adrenergic agonist indicated for: • Treatment of asthma in patients 6 years of age and older. ( 1.1 ) • Maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD) including chronic bronchitis and/or emphysema. ( 1.2 ) Important limitations: • Not indicated for the relief of acute bronchospasm. ( 1.1 , 1.2 ) uuid:28c6330e-d926-45a0-bbd6-b50723f34bfa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1156069 biolink:treats MONDO:0005002 PMID:41385096 "[{""id"":""uuid:55874309-45c9-4b1b-8f02-37657ab8856c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4a19b442-74e3-4cd7-a625-b7cadb8f29bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE INHALATION AEROSOL is a combination product containing a corticosteroid and a long-acting beta 2 -adrenergic agonist indicated for: • Treatment of asthma in patients 6 years of age and older. ( 1.1 ) • Maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD) including chronic bronchitis and/or emphysema. ( 1.2 ) Important limitations: • Not indicated for the relief of acute bronchospasm. ( 1.1 , 1.2 ) uuid:2ef1840a-66d0-4570-a43e-b405c3017bff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1156069 biolink:treats MONDO:0005607 PMID:41385096 "[{""id"":""uuid:2be0c60b-faa7-46cb-bb66-a75b65836dcd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:91bd6b90-5e5c-4609-8ef8-d7100dc8fec2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE INHALATION AEROSOL is a combination product containing a corticosteroid and a long-acting beta 2 -adrenergic agonist indicated for: • Treatment of asthma in patients 6 years of age and older. ( 1.1 ) • Maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD) including chronic bronchitis and/or emphysema. ( 1.2 ) Important limitations: • Not indicated for the relief of acute bronchospasm. ( 1.1 , 1.2 ) uuid:6ec9ad49-2b43-4370-acee-8b0cf887a6ed biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1156069 biolink:treats MONDO:0004849 PMID:41385096 "[{""id"":""uuid:e68b4b01-b58b-49e9-a84a-ddfa6cda2724"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8a2820c0-7161-4d94-85e1-cb324b95da26"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE INHALATION AEROSOL is a combination product containing a corticosteroid and a long-acting beta 2 -adrenergic agonist indicated for: • Treatment of asthma in patients 6 years of age and older. ( 1.1 ) • Maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD) including chronic bronchitis and/or emphysema. ( 1.2 ) Important limitations: • Not indicated for the relief of acute bronchospasm. ( 1.1 , 1.2 ) uuid:fd42dd0d-66a8-43be-9ebe-efa06bb52821 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59773 biolink:treats MONDO:0001673 PMID:41385096 "[{""id"":""uuid:621290aa-4ffb-4628-acd2-855a9548b023"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ff09073b-8591-4c30-a9d9-be1ce826e6fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cromolyn Sodium Oral Solution (Concentrate) is indicated in the management of patients with mastocytosis. Use of this product has been associated with improvement in diarrhea, flushing, headaches, vomiting, urticaria, abdominal pain, nausea, and itching in some patients. uuid:1c490e6d-83ec-4dd1-a676-c3ae8d9c7d1b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59773 biolink:treats MONDO:0007623 PMID:41385096 "[{""id"":""uuid:3782c67e-744f-4c11-91f9-c762e6723354"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:92c2660f-34a7-4f9a-b740-d39f23a530ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cromolyn Sodium Oral Solution (Concentrate) is indicated in the management of patients with mastocytosis. Use of this product has been associated with improvement in diarrhea, flushing, headaches, vomiting, urticaria, abdominal pain, nausea, and itching in some patients. uuid:3a369331-91ed-4576-b628-72369d47299f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59773 biolink:treats MONDO:0021146 PMID:41385096 "[{""id"":""uuid:b9f6c82a-900f-4f3b-9546-9fe6d1f6fc50"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f249cdcc-e5a6-40d5-90f7-24d8744c0ffa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cromolyn Sodium Oral Solution (Concentrate) is indicated in the management of patients with mastocytosis. Use of this product has been associated with improvement in diarrhea, flushing, headaches, vomiting, urticaria, abdominal pain, nausea, and itching in some patients. uuid:0f332a28-ba52-4b46-8b0b-1f4bc623d9a5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59773 biolink:treats HP:0002013 PMID:41385096 "[{""id"":""uuid:f596b4f3-2374-428a-ad45-a973d119c68d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3a58103d-70f4-439a-ad5b-af52ade7e933"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cromolyn Sodium Oral Solution (Concentrate) is indicated in the management of patients with mastocytosis. Use of this product has been associated with improvement in diarrhea, flushing, headaches, vomiting, urticaria, abdominal pain, nausea, and itching in some patients. uuid:e9482b01-644b-4115-80f7-8e810156b8ba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59773 biolink:treats MONDO:0005492 PMID:41385096 "[{""id"":""uuid:67988719-1045-469f-bc6c-6baa1481aedf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7823ec95-68f8-422b-be2a-50a17fd97809"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cromolyn Sodium Oral Solution (Concentrate) is indicated in the management of patients with mastocytosis. Use of this product has been associated with improvement in diarrhea, flushing, headaches, vomiting, urticaria, abdominal pain, nausea, and itching in some patients. uuid:6bc77ece-e95d-4f85-bed1-32d21dbc291f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59773 biolink:treats HP:0002027 PMID:41385096 "[{""id"":""uuid:5f4d87e6-8aed-4189-b68b-4cc632175102"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ebb0c5c1-3196-4c8b-a75f-d757cb861528"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cromolyn Sodium Oral Solution (Concentrate) is indicated in the management of patients with mastocytosis. Use of this product has been associated with improvement in diarrhea, flushing, headaches, vomiting, urticaria, abdominal pain, nausea, and itching in some patients. uuid:d4a0a9b3-213b-4257-98db-2c3be15252c2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59773 biolink:treats HP:0002018 PMID:41385096 "[{""id"":""uuid:d8899194-d4a8-4e1d-8f5b-78144365129c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1ff5f910-2860-484b-9afd-93077dd5826c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cromolyn Sodium Oral Solution (Concentrate) is indicated in the management of patients with mastocytosis. Use of this product has been associated with improvement in diarrhea, flushing, headaches, vomiting, urticaria, abdominal pain, nausea, and itching in some patients. uuid:4b6c9e6d-8ac1-49ab-b44e-a47b2ca8ce91 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59773 biolink:treats HP:0000989 PMID:41385096 "[{""id"":""uuid:1e9a915b-dc14-4a68-a18c-a85da601ca4f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:51c9575e-1a7b-4381-b4e1-a1ab72f87fba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cromolyn Sodium Oral Solution (Concentrate) is indicated in the management of patients with mastocytosis. Use of this product has been associated with improvement in diarrhea, flushing, headaches, vomiting, urticaria, abdominal pain, nausea, and itching in some patients. uuid:8d2e972f-29a3-4a4c-8a5d-625d05ee81d1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31547 biolink:treats UMLS:C3839346 PMID:41385096 "[{""id"":""uuid:e26a2b44-ca1f-4903-8abc-6a21e62374e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e5ab723b-4b08-4464-ad05-49b57ef3380b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Eplerenone tablets is an aldosterone antagonist indicated for: • Improving survival of stable patients with symptomatic heart failure with reduced ejection fraction (HFrEF) after an acute myocardial infarction. (1.1) • The treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. (1.2) uuid:b920de22-46c0-4070-9980-4a3d5a410786 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31547 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:aa24c1eb-cf74-4489-89a1-420e6d2fe286"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f8949cf0-c5b2-48d5-a8f9-5d00c51fb1b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Eplerenone tablets is an aldosterone antagonist indicated for: • Improving survival of stable patients with symptomatic heart failure with reduced ejection fraction (HFrEF) after an acute myocardial infarction. (1.1) • The treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. (1.2) uuid:9f79b52b-9f2e-4db1-95ff-c1fb36c92620 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31547 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:b4b329e5-8ab7-42e4-ab91-0f097c587f37"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bf0cd8f1-224c-456d-94cd-3bf4bd058c61"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Eplerenone tablets is an aldosterone antagonist indicated for: • Improving survival of stable patients with symptomatic heart failure with reduced ejection fraction (HFrEF) after an acute myocardial infarction. (1.1) • The treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. (1.2) uuid:91c5df66-a520-4d42-8675-cfb31e86d3ea biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49005 biolink:treats MONDO:0859316 PMID:41385096 "[{""id"":""uuid:a215ff11-a23b-469a-9799-d0c3d38fc2b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4f737829-1afa-4e24-99a3-5b13ec282161"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Deferasirox tablets are an iron chelator indicated for the treatment of chronic iron overload due to blood transfusions in patients 2 years of age and older. ( 1.1 ) Deferasirox tablets are indicated for the treatment of chronic iron overload in patients 10 years of age and older with non-transfusion-dependent thalassemia (NTDT) syndromes, and with a liver iron (Fe) concentration (LIC) of at least 5 mg Fe per gram of dry weight (Fe/g dw) and a serum ferritin greater than 300 mcg/L.( 1.2 ) Limitations of Use The safety and efficacy of deferasirox tablets when administered with other iron chelation therapy have not been established. ( 1.3 ) uuid:699dd553-d471-4918-ba06-aebe17d247d8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49005 biolink:treats MONDO:0008787 PMID:41385096 "[{""id"":""uuid:7a9fc0e1-ccd7-4065-ab3a-c8f9f7d284f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:316d0a3f-d2d9-4527-a004-3ea4e0f9f4b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Deferasirox tablets are an iron chelator indicated for the treatment of chronic iron overload due to blood transfusions in patients 2 years of age and older. ( 1.1 ) Deferasirox tablets are indicated for the treatment of chronic iron overload in patients 10 years of age and older with non-transfusion-dependent thalassemia (NTDT) syndromes, and with a liver iron (Fe) concentration (LIC) of at least 5 mg Fe per gram of dry weight (Fe/g dw) and a serum ferritin greater than 300 mcg/L.( 1.2 ) Limitations of Use The safety and efficacy of deferasirox tablets when administered with other iron chelation therapy have not been established. ( 1.3 ) uuid:dc6de10b-403c-412b-b109-c2009628c1fe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:600103 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:5e8b62a8-2f93-415a-823d-5f76bea07ec8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:751dbb5c-a1ed-4e45-83c5-1e084e1c3c6f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:13090053-d7f2-4eac-9c4a-3d2ad0241339"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/cubicin""]},{""id"":""uuid:692b46fb-0248-4dcc-94ce-e282257a8f97"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Daptomycin for injection is a lipopeptide antibacterial indicated for the treatment of: • Complicated skin and skin structure infections (cSSSI) in adult and pediatric patients (1 to 17 years of age) ( 1.1 ) and, • Staphylococcus aureus bloodstream infections (bacteremia), in adult patients including those with right-sided infective endocarditis, ( 1.2 ) • Staphylococcus aureus bloodstream infections (bacteremia) in pediatric patients (1 to 17 years of age). ( 1.3 ) Limitations of Use : • Daptomycin for injection is not indicated for the treatment of pneumonia. ( 1.4 ) • Daptomycin for injection is not indicated for the treatment of left-sided infective endocarditis due to S. aureus . ( 1.4 ) • Daptomycin for injection is not recommended in pediatric patients younger than one year of age due to the risk of potential effects on muscular, neuromuscular, and/or nervous systems (either peripheral and/or central) observed in neonatal dogs. ( 1.4 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of daptomycin for injection and other antibacterial drugs, daptomycin for injection should be used to treat infections that are proven or strongly suspected to be caused by bacteria. ( 1.5 )|[EMA] Cubicin is indicated for the treatment of the following infections.Adult and paediatric (1 to 17 years of age) patients with complicated skin and soft-tissue infections (cSSTI).Adult patients with right-sided infective endocarditis (RIE) due to Staphylococcus aureus.It is recommended that the decision to use daptomycin should take into account the antibacterial susceptibility of the organism and should be based on expert advice.Adult and paediatric (1 to 17 years of age) patients with Staphylococcus aureus bacteraemia (SAB). In adults, use in bacteraemia should be associated with RIE or with cSSTI, while in paediatric patients, use in bacteraemia should be associated with cSSTI.Daptomycin is active against Gram positive bacteria only. In mixed infections where Gram negative and/or certain types of anaerobic bacteria are suspected, Cubicin should be co-administered with appropriate antibacterial agent(s). Consideration should be given to official guidance on the appropriate use of antibacterial agents.|[PMDA] A drug with a new active ingredient indicated for the treatment of sepsis, infective endocarditis, deep skin infection, secondary infection of trauma, burn, and surgical wounds, and secondary infection of erosion and ulcer caused by daptomycin-sensitive methicillin-resistant Staphylococcus aureus (MRSA). uuid:0b5c54f5-d978-4e39-bd7e-9f12a3e6897c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:600103 biolink:treats MONDO:0005545 PMID:41385096 "[{""id"":""uuid:878b2023-9d62-43f6-be78-35cb14768ba4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:91df272f-56cc-42a0-a981-fc5303c3a25b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ca7c267d-3763-4214-8bcd-b78779fb657d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/cubicin""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Daptomycin for injection is a lipopeptide antibacterial indicated for the treatment of: • Complicated skin and skin structure infections (cSSSI) in adult and pediatric patients (1 to 17 years of age) ( 1.1 ) and, • Staphylococcus aureus bloodstream infections (bacteremia), in adult patients including those with right-sided infective endocarditis, ( 1.2 ) • Staphylococcus aureus bloodstream infections (bacteremia) in pediatric patients (1 to 17 years of age). ( 1.3 ) Limitations of Use : • Daptomycin for injection is not indicated for the treatment of pneumonia. ( 1.4 ) • Daptomycin for injection is not indicated for the treatment of left-sided infective endocarditis due to S. aureus . ( 1.4 ) • Daptomycin for injection is not recommended in pediatric patients younger than one year of age due to the risk of potential effects on muscular, neuromuscular, and/or nervous systems (either peripheral and/or central) observed in neonatal dogs. ( 1.4 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of daptomycin for injection and other antibacterial drugs, daptomycin for injection should be used to treat infections that are proven or strongly suspected to be caused by bacteria. ( 1.5 )|[EMA] Cubicin is indicated for the treatment of the following infections.Adult and paediatric (1 to 17 years of age) patients with complicated skin and soft-tissue infections (cSSTI).Adult patients with right-sided infective endocarditis (RIE) due to Staphylococcus aureus.It is recommended that the decision to use daptomycin should take into account the antibacterial susceptibility of the organism and should be based on expert advice.Adult and paediatric (1 to 17 years of age) patients with Staphylococcus aureus bacteraemia (SAB). In adults, use in bacteraemia should be associated with RIE or with cSSTI, while in paediatric patients, use in bacteraemia should be associated with cSSTI.Daptomycin is active against Gram positive bacteria only. In mixed infections where Gram negative and/or certain types of anaerobic bacteria are suspected, Cubicin should be co-administered with appropriate antibacterial agent(s). Consideration should be given to official guidance on the appropriate use of antibacterial agents. uuid:6745742b-2a27-4f09-80d5-c0fc6aceb1c9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:600103 biolink:treats MONDO:0005229 PMID:41385096 "[{""id"":""uuid:4f64d5f1-a3ad-4fc8-a8cf-61040b0dcc3d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3a1c2bcc-65fd-4485-a5bf-e2ac1f2653b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Daptomycin for injection is a lipopeptide antibacterial indicated for the treatment of: • Complicated skin and skin structure infections (cSSSI) in adult and pediatric patients (1 to 17 years of age) ( 1.1 ) and, • Staphylococcus aureus bloodstream infections (bacteremia), in adult patients including those with right-sided infective endocarditis, ( 1.2 ) • Staphylococcus aureus bloodstream infections (bacteremia) in pediatric patients (1 to 17 years of age). ( 1.3 ) Limitations of Use : • Daptomycin for injection is not indicated for the treatment of pneumonia. ( 1.4 ) • Daptomycin for injection is not indicated for the treatment of left-sided infective endocarditis due to S. aureus . ( 1.4 ) • Daptomycin for injection is not recommended in pediatric patients younger than one year of age due to the risk of potential effects on muscular, neuromuscular, and/or nervous systems (either peripheral and/or central) observed in neonatal dogs. ( 1.4 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of daptomycin for injection and other antibacterial drugs, daptomycin for injection should be used to treat infections that are proven or strongly suspected to be caused by bacteria. ( 1.5 ) uuid:f732d2f3-4da8-4493-b125-51ec2f0c4143 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:600103 biolink:treats MONDO:0000565 PMID:41385096 "[{""id"":""uuid:22a30a5e-2178-48f4-affb-adee0f7bf79a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8cf7db01-cc9d-424f-87fe-115a0571c221"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:84a57940-6295-486e-a76d-ff82258230c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/cubicin""]},{""id"":""uuid:618ca0c9-c6e4-4d71-9526-8155df04624b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Daptomycin for injection is a lipopeptide antibacterial indicated for the treatment of: • Complicated skin and skin structure infections (cSSSI) in adult and pediatric patients (1 to 17 years of age) ( 1.1 ) and, • Staphylococcus aureus bloodstream infections (bacteremia), in adult patients including those with right-sided infective endocarditis, ( 1.2 ) • Staphylococcus aureus bloodstream infections (bacteremia) in pediatric patients (1 to 17 years of age). ( 1.3 ) Limitations of Use : • Daptomycin for injection is not indicated for the treatment of pneumonia. ( 1.4 ) • Daptomycin for injection is not indicated for the treatment of left-sided infective endocarditis due to S. aureus . ( 1.4 ) • Daptomycin for injection is not recommended in pediatric patients younger than one year of age due to the risk of potential effects on muscular, neuromuscular, and/or nervous systems (either peripheral and/or central) observed in neonatal dogs. ( 1.4 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of daptomycin for injection and other antibacterial drugs, daptomycin for injection should be used to treat infections that are proven or strongly suspected to be caused by bacteria. ( 1.5 )|[EMA] Cubicin is indicated for the treatment of the following infections.Adult and paediatric (1 to 17 years of age) patients with complicated skin and soft-tissue infections (cSSTI).Adult patients with right-sided infective endocarditis (RIE) due to Staphylococcus aureus.It is recommended that the decision to use daptomycin should take into account the antibacterial susceptibility of the organism and should be based on expert advice.Adult and paediatric (1 to 17 years of age) patients with Staphylococcus aureus bacteraemia (SAB). In adults, use in bacteraemia should be associated with RIE or with cSSTI, while in paediatric patients, use in bacteraemia should be associated with cSSTI.Daptomycin is active against Gram positive bacteria only. In mixed infections where Gram negative and/or certain types of anaerobic bacteria are suspected, Cubicin should be co-administered with appropriate antibacterial agent(s). Consideration should be given to official guidance on the appropriate use of antibacterial agents.|[PMDA] A drug with a new active ingredient indicated for the treatment of sepsis, infective endocarditis, deep skin infection, secondary infection of trauma, burn, and surgical wounds, and secondary infection of erosion and ulcer caused by daptomycin-sensitive methicillin-resistant Staphylococcus aureus (MRSA). uuid:38a491c1-8260-429e-8ca8-cae11f399f22 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7565 biolink:treats MONDO:0005356 PMID:41385096 "[{""id"":""uuid:72950c60-9c93-4c12-a718-81e8389df004"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0e474487-cf11-4700-bcfa-41f2cb5d2ece"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] I. Vasospastic Angina Nifedipine Extended-Release Tablets, USP are indicated for the management of vasospastic angina confirmed by any of the following criteria: 1) classical pattern of angina at rest accompanied by ST segment elevation, 2) angina or coronary artery spasm provoked by ergonovine, or 3) angiographically demonstrated coronary artery spasm. In those patients who have had angiography, the presence of significant fixed obstructive disease is not incompatible with the diagnosis of vasospastic angina, provided that the above criteria are satisfied. Nifedipine Extended-Release Tablets, USP may also be used where the clinical presentation suggests a possible vasospastic component, but where vasospasm has not been confirmed, e.g., where pain has a variable threshold on exertion, or in unstable angina where electrocardiographic findings are compatible with intermittent vasospasm, or when angina is refractory to nitrates and/or adequate doses of beta blockers. II. Chronic Stable Angina (Classical Effort-Associated Angina) Nifedipine Extended-Release Tablets, USP are indicated for the management of chronic stable angina (effort-associated angina) without evidence of vasospasm in patients who remain symptomatic despite adequate doses of beta blockers and/or organic nitrates or who cannot tolerate those agents. In chronic stable angina (effort-associated angina), nifedipine has been effective in controlled trials of up to eight weeks duration in reducing angina frequency and increasing exercise tolerance, but confirmation of sustained effectiveness and evaluation of long-term safety in these patients is incomplete. Controlled studies in small numbers of patients suggest concomitant use of nifedipine and beta-blocking agents may be beneficial in patients with chronic stable angina, but available information is not sufficient to predict with confidence the effects of concurrent treatment, especially in patients with compromised left ventricular function or cardiac conduction abnormalities. When introducing such concomitant therapy, care must be taken to monitor blood pressure closely, since severe hypotension can occur from the combined effects of the drugs (see WARNINGS ). III. Hypertension Nifedipine Extended-Release Tablets, USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including Nifedipine Extended-Release Tablets, USP. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Nifedipine Extended-Release Tablets, USP may be used alone or in combination with other antihypertensive agents. uuid:2fcc5f81-3bcf-4da5-9aac-4eb2deafb25f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7959 biolink:treats MONDO:0010200 PMID:41385096 "[{""id"":""uuid:b46d1f92-7975-4d29-bc6b-aa0ab0f51f74"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e3d264fa-6960-43fe-9c30-5f1871a3bc50"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Penicillamine Capsules are indicated in the treatment of Wilson's disease, cystinuria, and in patients with severe, active rheumatoid arthritis who have failed to respond to an adequate trial of conventional therapy. Available evidence suggests that Penicillamine Capsules are not of value in ankylosing spondylitis. uuid:2ef1b008-f68b-4fbf-b1c8-c9ce0544505e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7959 biolink:treats MONDO:0009067 PMID:41385096 "[{""id"":""uuid:c25c3562-3eca-4ff6-83be-307f4722f510"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:72fd4ac4-6d46-48d0-8e78-19f838e23ccb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Penicillamine Capsules are indicated in the treatment of Wilson's disease, cystinuria, and in patients with severe, active rheumatoid arthritis who have failed to respond to an adequate trial of conventional therapy. Available evidence suggests that Penicillamine Capsules are not of value in ankylosing spondylitis. uuid:bd8ae622-117d-428e-a5bc-bf7c3cd79878 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7959 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:2b23518a-e4f2-4981-a0cc-9576224a4c20"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0c568ce1-5936-4579-bf39-99baf95e95f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Penicillamine Capsules are indicated in the treatment of Wilson's disease, cystinuria, and in patients with severe, active rheumatoid arthritis who have failed to respond to an adequate trial of conventional therapy. Available evidence suggests that Penicillamine Capsules are not of value in ankylosing spondylitis. uuid:1d27d94f-cb02-4228-93be-9d23ae1ced62 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1162127 biolink:treats HP:0001712 PMID:41385096 "[{""id"":""uuid:30cbec42-d3ae-4f31-94b6-089c0a7b6db5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4f35f2bc-cb56-4c80-964f-5cf59ee15c51"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Losartan potassium and hydrochlorothiazide is a combination of losartan, an angiotensin II receptor blocker (ARB) and hydrochlorothiazide, a diuretic indicated for: • Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) • Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy. There is evidence that this benefit does not apply to Black patients. ( 1.2 ) uuid:002f80db-104e-40f0-8540-27088256786c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3732 biolink:treats UMLS:C0348321 PMID:41385096 "[{""id"":""uuid:d9bdf53d-443b-4214-8a6b-96b72369e0f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0de7232f-37a9-47e3-be74-c1d343248927"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clarithromycin tablets are indicated in adults for the treatment of mild to moderate infections caused by susceptible isolates due to Haemophilus influenzae , Haemophilus parainfluenzae , Moraxella catarrhalis , or Streptococcus pneumoniae. uuid:092f73b5-0025-4644-9d71-5a4e9e593438 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3732 biolink:treats UMLS:C1096597 PMID:41385096 "[{""id"":""uuid:858819e7-bf21-4b54-9eaa-32720f3906a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7e053747-ee64-4807-8081-09e7183fe928"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clarithromycin tablets are indicated in adults for the treatment of mild to moderate infections caused by susceptible isolates due to Haemophilus influenzae , Haemophilus parainfluenzae , Moraxella catarrhalis , or Streptococcus pneumoniae. uuid:02a8fcc0-08d4-4a28-b3c7-27ab3036f637 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3732 biolink:treats UMLS:C1096746 PMID:41385096 "[{""id"":""uuid:bd0dba4b-5104-4442-8c1c-948b4adddd51"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:39074ec1-45ad-45d6-847f-1f1b6c1516dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clarithromycin tablets are indicated in adults for the treatment of mild to moderate infections caused by susceptible isolates due to Haemophilus influenzae , Haemophilus parainfluenzae , Moraxella catarrhalis , or Streptococcus pneumoniae. uuid:4849fbe0-9f46-4ffe-98e2-f14159377c1d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3732 biolink:treats MONDO:0005114 PMID:41385096 "[{""id"":""uuid:ae4fc18b-ac3f-4f90-b176-6604d721b0fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d03c6b25-2564-460d-b560-b2e9b0445409"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clarithromycin tablets are indicated in adults for the treatment of mild to moderate infections caused by susceptible isolates due to Haemophilus influenzae , Haemophilus parainfluenzae , Moraxella catarrhalis , or Streptococcus pneumoniae. uuid:ed120454-5633-454b-83d9-48c0256384b4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2676 biolink:treats MONDO:0021680 PMID:41385096 "[{""id"":""uuid:ca9ca0fb-ba69-4449-9aaa-c4210325d3c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:475a7e45-78f6-4519-9b92-74909c0c3786"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amoxicillin capsules are indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) isolates of Streptococcus species. (α- and β-hemolytic isolates only), Streptococcus pneumoniae , Staphylococcus spp., or Haemophilus influenzae . uuid:05cbe3a8-3024-4817-8c3d-e9f6e5c01e8a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2676 biolink:treats MONDO:0005114 PMID:41385096 "[{""id"":""uuid:88de964b-dfc9-4de1-8307-c4bb1865819c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fc7a2e16-3b5b-4248-95be-d86ad7261448"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amoxicillin capsules are indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) isolates of Streptococcus species. (α- and β-hemolytic isolates only), Streptococcus pneumoniae , Staphylococcus spp., or Haemophilus influenzae . uuid:c85a4e4a-f7f6-4268-ad69-25d854051540 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2676 biolink:treats MONDO:0024313 PMID:41385096 "[{""id"":""uuid:8c119f5e-0fb3-491b-8e00-6484985d7cc2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:088ffbd0-ad91-4989-87ea-976cbf641ff5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amoxicillin capsules are indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) isolates of Streptococcus species. (α- and β-hemolytic isolates only), Streptococcus pneumoniae , Staphylococcus spp., or Haemophilus influenzae . uuid:7b056189-aab5-4dc1-84d9-fde762ea672a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2676 biolink:treats HP:0005376 PMID:41385096 "[{""id"":""uuid:2729b4ae-b627-4788-a35d-70aee837b2fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9feb5327-8b34-48c5-8388-8b3279a7afab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amoxicillin capsules are indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) isolates of Streptococcus species. (α- and β-hemolytic isolates only), Streptococcus pneumoniae , Staphylococcus spp., or Haemophilus influenzae . uuid:6616bae4-468f-4638-bbda-a78eb062bf80 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77776 biolink:treats MONDO:0001405 PMID:41385096 "[{""id"":""uuid:b3a05618-c228-4d4c-8a05-d460e7cb248d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:187ac515-a5fa-4352-9d62-4d0364f20fce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SULCONAZOLE NITRATE topical solution 1.0% is a broad-spectrum antifungal agent indicated for the treatment of tinea cruris and tinea corporis caused by Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum, and Microsporum canis; and for the treatment of tinea versicolor. Effectiveness has not been proven in tinea pedis (athlete's foot). Symptomatic relief usually occurs within a few days after starting SULCONAZOLE NITRATE topical solution and clinical improvement usually occurs within one week. uuid:390457d3-e02a-4aa1-ac2a-679f435e3dda biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77776 biolink:treats MONDO:0001461 PMID:41385096 "[{""id"":""uuid:94c303a8-0e56-46f7-8097-bf6c665cbcae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:18e842a2-8585-48cf-a7fc-a79a68874ec7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SULCONAZOLE NITRATE topical solution 1.0% is a broad-spectrum antifungal agent indicated for the treatment of tinea cruris and tinea corporis caused by Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum, and Microsporum canis; and for the treatment of tinea versicolor. Effectiveness has not been proven in tinea pedis (athlete's foot). Symptomatic relief usually occurs within a few days after starting SULCONAZOLE NITRATE topical solution and clinical improvement usually occurs within one week. uuid:efa25caa-77d1-4081-82c5-56466eafa0e6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77776 biolink:treats MONDO:0005915 PMID:41385096 "[{""id"":""uuid:ca184e54-1a04-448b-892f-7a5ea4e8e166"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b1b95e99-b5ff-4981-aa6e-8a9b92b289aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SULCONAZOLE NITRATE topical solution 1.0% is a broad-spectrum antifungal agent indicated for the treatment of tinea cruris and tinea corporis caused by Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum, and Microsporum canis; and for the treatment of tinea versicolor. Effectiveness has not been proven in tinea pedis (athlete's foot). Symptomatic relief usually occurs within a few days after starting SULCONAZOLE NITRATE topical solution and clinical improvement usually occurs within one week. uuid:db8cf0c9-83f5-4c6f-b4ee-f0f8a0c2e547 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49468 biolink:treats MONDO:0001209 PMID:41385096 "[{""id"":""uuid:8b2ba8e6-aa3f-49c3-9412-59afe5bd6623"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7ccff449-2854-4578-adf6-490d760abe2d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Caustic applicators are useful for cauterization of skin or mucous membrane and for the removal of granulation tissue, warts and verrucae. uuid:a778c2f6-4453-4142-81cf-7100c2f0b946 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0003996 PMID:41385096 "[{""id"":""uuid:4d56e73f-2d15-4b5f-b455-177399288b8c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:feec3909-4a4c-4794-a570-1081a8c3acc9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or intramuscular administration. When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia. Nonsuppurative thyroiditis. Hypercalcemia associated with cancer. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis. Synovitis of osteoarthritis. Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis. Epicondylitis. Acute nonspecific tenosynovitis. Acute gouty arthritis. Psoriatic arthritis. Ankylosing spondylitis. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus. Acute rheumatic carditis. Dermatologic diseases. Pemphigus. Severe erythema multiforme (Stevens-Johnson Syndrome). Exfoliative dermatitis. Bullous dermatitis herpetiformis. Severe seborrheic dermatitis. Severe psoriasis. Mycosis fungoides. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma. Contact dermatitis. Atopic dermatitis. Serum sickness. Seasonal or perennial allergic rhinitis. Drug hypersensitivity reactions. Urticarial transfusion reactions. Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus. Iritis, iridocyclitis. Chorioretinitis. Diffuse posterior uveitis and choroiditis. Optic neuritis. Sympathetic ophthalmia. Anterior segment inflammation. Allergic conjunctivitis. Allergic corneal marginal ulcers. Keratitis. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy). Regional enteritis (systemic therapy). Respiratory diseases. Symptomatic Sarcoidosis. Berylliosis. Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate anti-tuberculosis chemotherapy. Loeffler's syndrome not manageable by other means. Aspiration pneumonitis. Hematologic disorders. Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (I.V. only; I.M. administration is contraindicated). Secondary thrombocytopenia in adults. Erythroblastopenia (RBC anemia). Congenital (erythroid) hypoplastic anemia. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults. Acute leukemia of childhood. Edematous states. To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. Nervous system. Acute exacerbations of multiple sclerosis. Miscellaneous. Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate anti-tuberculosis chemotherapy. Trichinosis with neurologic or myocardial involvement. Diagnostic testing of adrenocortical hyperfunction. Cerebral edema of diverse etiologies in conjunction with adequate neurological evaluation and management. Intra-articular or soft tissue administration. When the strength and dosage form of the drug lend the preparation to the treatment of the condition, those products labeled for intra-articular or soft tissue administration are indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Synovitis osteoarthritis. Rheumatoid arthritis. Acute and subacute bursitis. Acute gouty arthritis. Epicondylitis. Acute nonspecific tenosynovitis. Post-traumatic osteoarthritis. Intralesional administration. When the strength and dosage form of the drug lend the preparation to the treatment of the condition, those products labeled for intralesional administration are indicated for: Keloids. Localized hypertrophic, infiltrated, inflammatory lesions of: lichen planus, psoriatic plaques, granuloma annulare, and lichen simplex chronicus (neurodermatitis). Discoid lupus erythematosus. Necrobiosis lipoidica diabeticorum. Alopecia areata. They also may be useful in cystic tumors of an aponeurosis tendon (ganglia). uuid:35edd79c-88cf-43ba-be76-3de96a7f11f0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3614 biolink:treats MONDO:0005076 PMID:41385096 "[{""id"":""uuid:7653c82f-563f-4437-9402-6589870cc02c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3bdf2689-8cf5-463f-a136-0bb3590c5f85"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PerioGard® (Chlorhexidine Gluconate Oral Rinse USP, 0.12%) is indicated for use between dental visits as part of a professional program for the treatment of gingivitis as characterized by redness and swelling of the gingivae, including gingival bleeding upon probing. PerioGard® has not been tested among patients with acute necrotizing ulcerative gingivitis (ANUG). For patients having coexisting gingivitis and periodontitis, see PRECAUTIONS . uuid:9e378e29-93b2-4e39-9f31-20048699294d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:NS6Q291771 biolink:treats MONDO:0019297 PMID:41385096 "[{""id"":""uuid:cadabe70-7be6-42a4-abae-0649da4c6286"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:08e6c075-d59f-4f39-9d34-dc86f15f5ac0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Isosulfan blue injection 1% upon subcutaneous administration, delineates the lymphatic vessels draining the region of injection. It is an adjunct to lymphography in: primary and secondary lymphedema of the extremities; chyluria, chylous ascites or chylothorax; lymph node involvement by primary or secondary neoplasm; lymph node response to therapeutic modalities ( 1.1 ). PUBCHEM.COMPOUND:52946590 uuid:a4e17f32-e75a-4c85-b69a-0e46b68d0de9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:NS6Q291771 biolink:treats UMLS:C0159075 PMID:41385096 "[{""id"":""uuid:a73de2bd-501f-4245-9f96-3f5b2d69ae31"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b7074ddd-139a-4f98-af37-312f8678e895"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Isosulfan blue injection 1% upon subcutaneous administration, delineates the lymphatic vessels draining the region of injection. It is an adjunct to lymphography in: primary and secondary lymphedema of the extremities; chyluria, chylous ascites or chylothorax; lymph node involvement by primary or secondary neoplasm; lymph node response to therapeutic modalities ( 1.1 ). PUBCHEM.COMPOUND:52946590 uuid:e9736a75-37ea-4194-ace9-2b3af5e56978 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:NS6Q291771 biolink:treats MONDO:0008829 PMID:41385096 "[{""id"":""uuid:365ee2e0-1d4e-452b-a610-c772d07a49be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:826b2d17-96ce-44c8-bdb0-632e44e065f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Isosulfan blue injection 1% upon subcutaneous administration, delineates the lymphatic vessels draining the region of injection. It is an adjunct to lymphography in: primary and secondary lymphedema of the extremities; chyluria, chylous ascites or chylothorax; lymph node involvement by primary or secondary neoplasm; lymph node response to therapeutic modalities ( 1.1 ). PUBCHEM.COMPOUND:52946590 uuid:4c9267a5-759d-490a-88b1-d5888b869ea7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:NS6Q291771 biolink:treats HP:0010310 PMID:41385096 "[{""id"":""uuid:434968e4-10bc-4c6b-9b28-db5f07e32e93"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4961ceac-0f0d-4125-b911-7f505b064940"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Isosulfan blue injection 1% upon subcutaneous administration, delineates the lymphatic vessels draining the region of injection. It is an adjunct to lymphography in: primary and secondary lymphedema of the extremities; chyluria, chylous ascites or chylothorax; lymph node involvement by primary or secondary neoplasm; lymph node response to therapeutic modalities ( 1.1 ). PUBCHEM.COMPOUND:52946590 uuid:1b50a652-8bb4-4218-9a45-a754521bd45e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:NS6Q291771 biolink:treats MONDO:0005438 PMID:41385096 "[{""id"":""uuid:4b84d585-22ea-4209-a2fe-9eb5d8f238ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:742c7d1b-da46-441a-9bec-12cbe3803823"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Isosulfan blue injection 1% upon subcutaneous administration, delineates the lymphatic vessels draining the region of injection. It is an adjunct to lymphography in: primary and secondary lymphedema of the extremities; chyluria, chylous ascites or chylothorax; lymph node involvement by primary or secondary neoplasm; lymph node response to therapeutic modalities ( 1.1 ). PUBCHEM.COMPOUND:52946590 uuid:a118354c-5655-4196-80bf-92abf2bd171c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63632 biolink:treats UMLS:C5706270 PMID:41385096 "[{""id"":""uuid:4380ab57-86c3-41ac-9d4a-0f6602de9a7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3eaa43ff-9297-4ad6-aa8d-62e7022eebdb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Topotecan Injection is indicated for the treatment of patients with small cell lung cancer (SCLC) with platinum-sensitive disease who progressed at least 60 days after initiation of first-line chemotherapy. uuid:2d198aa3-25cb-4e4b-af4f-b6b05b9177d4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:70735 biolink:treats MONDO:0005090 PMID:41385096 "[{""id"":""uuid:6d514316-cec0-4000-92a9-b860de0680db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:13442e60-078c-4ec9-ab0e-8671444cf3af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:7f7a7ebf-c599-4152-bb36-9719f3551e6b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/latuda""]},{""id"":""uuid:337db5a0-4b41-4c64-aa0c-747747c76c58"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LATUDA is indicated for: Treatment of adult and adolescent patients (13 to 17 years) with schizophrenia [see Clinical Studies ( 14.1 )] . Monotherapy treatment of adult and pediatric patients (10 to 17 years) with major depressive episode associated with bipolar I disorder (bipolar depression) [see Clinical Studies ( 14.2 )] . Adjunctive treatment with lithium or valproate in adult patients with major depressive episode associated with bipolar I disorder (bipolar depression) [see Clinical Studies ( 14.2 )] .|[EMA] Treatment of schizophrenia in adults aged 18 years and over.|[PMDA] Drugs with a new active ingredient indicated for the treatment of schizophrenia and the improvement of depressive symptoms in patients with bipolar disorder. uuid:343643b7-0eac-484a-918e-4353c66a6d74 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:70735 biolink:treats MONDO:0024613 PMID:41385096 "[{""id"":""uuid:a0eb24e1-bddc-4944-b05d-154963379aa2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9f8a7e98-5e05-4e5e-b0d8-59b84a65c7da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LATUDA is indicated for: Treatment of adult and adolescent patients (13 to 17 years) with schizophrenia [see Clinical Studies ( 14.1 )] . Monotherapy treatment of adult and pediatric patients (10 to 17 years) with major depressive episode associated with bipolar I disorder (bipolar depression) [see Clinical Studies ( 14.2 )] . Adjunctive treatment with lithium or valproate in adult patients with major depressive episode associated with bipolar I disorder (bipolar depression) [see Clinical Studies ( 14.2 )] . uuid:ab8c1f34-3503-4520-a07f-1ec2bac16f72 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:48669 biolink:treats HP:0000132 PMID:41385096 "[{""id"":""uuid:13845caf-d641-4941-950d-ea51c170c361"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:597dfe12-0289-4f62-9a15-99a52f2b7359"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tranexamic acid tablets are indicated for the treatment of cyclic heavy menstrual bleeding in females of reproductive potential [see Clinical Studies ( 14 )] uuid:4c86f5e3-d466-408b-bee3-d25dffbeed32 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28918 biolink:treats MONDO:0000190 PMID:41385096 "[{""id"":""uuid:3311375f-9f4b-4c22-9cde-e38e4ff8874c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a6487eae-370f-40f0-8e3e-f0809d165ff6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EPINEPHRINE Epinephrine’s cardiac effects may be of use in the treatment and prophylaxis of cardiac arrest due to various causes in the absence of ventricular fibrillation and attacks of transitory atrioventricular (AV) heart block with syncopal seizures (Stokes-Adams syndrome), but it is not used in cardiac failure or in hemorrhagic, traumatic or in cardiogenic shock. Epinephrine may be used to stimulate the heart in syncope due to complete heart block or carotid sinus hypersensitivity. Epinephrine is also used for resuscitation in cardiac arrest following anesthetic accidents. In cardiopulmonary resuscitation, intracardiac puncture and intramyocardial injection of epinephrine may be effective when external cardiac compression and attempts to restore the circulation by electrical defibillation or use of a pacemaker fail. Epinephrine is seldom used as a vasopressor except in the treatment of anaphylactic shock and under certain conditions in insulin shock. uuid:c85247fa-b1d2-4719-a661-51fbd19d8d33 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28918 biolink:treats UMLS:C0741983 PMID:41385096 "[{""id"":""uuid:4e9a6c1b-bd25-4e8e-b4f3-b21e075f4a73"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2b6b0129-b64b-48d9-a756-a7dd40ede877"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EPINEPHRINE Epinephrine’s cardiac effects may be of use in the treatment and prophylaxis of cardiac arrest due to various causes in the absence of ventricular fibrillation and attacks of transitory atrioventricular (AV) heart block with syncopal seizures (Stokes-Adams syndrome), but it is not used in cardiac failure or in hemorrhagic, traumatic or in cardiogenic shock. Epinephrine may be used to stimulate the heart in syncope due to complete heart block or carotid sinus hypersensitivity. Epinephrine is also used for resuscitation in cardiac arrest following anesthetic accidents. In cardiopulmonary resuscitation, intracardiac puncture and intramyocardial injection of epinephrine may be effective when external cardiac compression and attempts to restore the circulation by electrical defibillation or use of a pacemaker fail. Epinephrine is seldom used as a vasopressor except in the treatment of anaphylactic shock and under certain conditions in insulin shock. uuid:314dce58-8255-4448-a6eb-d6005ea67de5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28918 biolink:treats UMLS:C1527401 PMID:41385096 "[{""id"":""uuid:f1da8806-6e73-4e0a-b8b3-6ef032b40900"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a7f229f4-35a2-48bf-87a3-0db6ffeec24e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EPINEPHRINE Epinephrine’s cardiac effects may be of use in the treatment and prophylaxis of cardiac arrest due to various causes in the absence of ventricular fibrillation and attacks of transitory atrioventricular (AV) heart block with syncopal seizures (Stokes-Adams syndrome), but it is not used in cardiac failure or in hemorrhagic, traumatic or in cardiogenic shock. Epinephrine may be used to stimulate the heart in syncope due to complete heart block or carotid sinus hypersensitivity. Epinephrine is also used for resuscitation in cardiac arrest following anesthetic accidents. In cardiopulmonary resuscitation, intracardiac puncture and intramyocardial injection of epinephrine may be effective when external cardiac compression and attempts to restore the circulation by electrical defibillation or use of a pacemaker fail. Epinephrine is seldom used as a vasopressor except in the treatment of anaphylactic shock and under certain conditions in insulin shock. uuid:accdaee7-0c78-495e-9485-48e61799c54d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:700516 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:b3361416-a484-4808-97f7-d3da575f617d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d51b4a9c-d004-492d-9c4c-bc260455881f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:68f78606-ba99-42a1-ade0-544ba3a6c192"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] JANUMET ® XR is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.|[PMDA] New combination drugs indicated for the treatment of type 2 diabetes mellitus (only when a concomitant use of anagliptin with metformin hydrochloride is deemed appropriate). uuid:85b4bbfd-61a2-40b5-a5b5-e8e998558649 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18357 biolink:treats MONDO:0017373 PMID:41385096 "[{""id"":""uuid:a375c298-2a94-43e9-a2ea-18bc23b84d5f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:29300ba1-13c0-491a-aa66-8c19e2b7b8eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For blood pressure control in certain acute hypotensive states (e.g., pheochromocytomectomy, sympathectomy, poliomyelitis, spinal anesthesia, myocardial infarction, septicemia, blood transfusion, and drug reactions). As an adjunct in the treatment of cardiac arrest and profound hypotension. uuid:e798039d-c147-4da2-8b8d-9e79c12ba892 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18357 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:7487204f-8240-4e0c-82dc-12767ac0e154"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:512d7001-9d95-438f-afae-cdc681fd35b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For blood pressure control in certain acute hypotensive states (e.g., pheochromocytomectomy, sympathectomy, poliomyelitis, spinal anesthesia, myocardial infarction, septicemia, blood transfusion, and drug reactions). As an adjunct in the treatment of cardiac arrest and profound hypotension. uuid:716c7d07-885b-46d5-84db-cb99d365f3e5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18357 biolink:treats MONDO:0700217 PMID:41385096 "[{""id"":""uuid:127b1602-a43f-4baf-ab32-88966ed26455"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9817b6a1-0824-43f1-b935-a39544679196"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For blood pressure control in certain acute hypotensive states (e.g., pheochromocytomectomy, sympathectomy, poliomyelitis, spinal anesthesia, myocardial infarction, septicemia, blood transfusion, and drug reactions). As an adjunct in the treatment of cardiac arrest and profound hypotension. uuid:55d6ab87-1e99-4f04-aa4b-431bbade9c0e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18357 biolink:treats MONDO:0000745 PMID:41385096 "[{""id"":""uuid:6ed60a4e-c0e6-4bd3-8f71-06cd9bfc55e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:47bf9de7-28ad-4de0-9f2b-ab6eec7ca858"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For blood pressure control in certain acute hypotensive states (e.g., pheochromocytomectomy, sympathectomy, poliomyelitis, spinal anesthesia, myocardial infarction, septicemia, blood transfusion, and drug reactions). As an adjunct in the treatment of cardiac arrest and profound hypotension. uuid:9e4a5f4a-18ef-409e-97e4-9bea674688c0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18357 biolink:treats MONDO:0005468 PMID:41385096 "[{""id"":""uuid:87c773eb-cf1a-4944-adee-26823cdce2cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0bd7f421-766b-40aa-b1b2-36ea447c74c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For blood pressure control in certain acute hypotensive states (e.g., pheochromocytomectomy, sympathectomy, poliomyelitis, spinal anesthesia, myocardial infarction, septicemia, blood transfusion, and drug reactions). As an adjunct in the treatment of cardiac arrest and profound hypotension. uuid:6fc72582-8d63-4b83-838b-8d9c7aef0707 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5391 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:baa0bc5a-2857-45d2-8854-a7678b1d5690"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:6d9c8477-d639-4d9b-b5d0-473a883857de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:9f494c78-f565-49e4-9015-21c70ad171b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ogluo""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the treatment of severe hypoglycemia: Glucagon is indicated as a treatment for severe hypoglycemia (low blood sugar) which may occur in patients with diabetes mellitus. Because patients with type 1 diabetes may have less of an increase in blood glucose levels compared with a stable type 2 patient, supplementary carbohydrate should be given as soon as possible, especially to a pediatric patient. For use as a diagnostic aid: Glucagon is indicated as a diagnostic aid in the radiologic examination of the stomach, duodenum, small bowel, and colon when diminished intestinal motility would be advantageous. Glucagon is as effective for this examination as are the anticholinergic drugs. However, as use of glucagon in combination with anticholinergic drugs may result in increased side effects, the use of glucagon in combination with anticholinergic drugs is not recommended.|[EMA] Ogluo is indicated for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. uuid:b2b4c1ba-4fed-4af0-89df-a0cc3c5acca1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45285 biolink:treats MONDO:0018076 PMID:41385096 "[{""id"":""uuid:8a21c327-1909-453a-938b-a1bd0277e130"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2446ceab-bff3-4f27-b0f0-4e11a975b3e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pyrazinamide is indicated for the initial treatment of active tuberculosis in adults and children when combined with other antituberculous agents. (The current recommendation of the CDC for drug-susceptible disease is to use a six-month regimen for initial treatment of active tuberculosis, consisting of isoniazid, rifampin and pyrazinamide given for 2 months, followed by isoniazid and rifampin for 4 months.* 4 ) (Patients with drug-resistant disease should be treated with regimens individualized to their situation. Pyrazinamide frequently will be an important component of such therapy.) (In patients with concomitant HIV infection, the physician should be aware of current recommendations of CDC. It is possible these patients may require a longer course of treatment.) It is also indicated after treatment failure with other primary drugs in any form of active tuberculosis. Pyrazinamide should only be used in conjunction with other effective antituberculous agents. *See recommendations of Center for Disease Control (CDC) and American Thoracic Society for complete regimen and dosage recommendations. 4 uuid:d9c9ae36-fa4f-4e53-bd00-2feac4fe552b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45285 biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:9bd09042-8e58-49cc-a3ea-b6e887bef0e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6f20eb25-380d-47d4-9c96-c132490c20ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pyrazinamide is indicated for the initial treatment of active tuberculosis in adults and children when combined with other antituberculous agents. (The current recommendation of the CDC for drug-susceptible disease is to use a six-month regimen for initial treatment of active tuberculosis, consisting of isoniazid, rifampin and pyrazinamide given for 2 months, followed by isoniazid and rifampin for 4 months.* 4 ) (Patients with drug-resistant disease should be treated with regimens individualized to their situation. Pyrazinamide frequently will be an important component of such therapy.) (In patients with concomitant HIV infection, the physician should be aware of current recommendations of CDC. It is possible these patients may require a longer course of treatment.) It is also indicated after treatment failure with other primary drugs in any form of active tuberculosis. Pyrazinamide should only be used in conjunction with other effective antituberculous agents. *See recommendations of Center for Disease Control (CDC) and American Thoracic Society for complete regimen and dosage recommendations. 4 uuid:0e06b8d6-6414-418b-ae87-f10ad08aa03c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31524 biolink:treats MONDO:0005180 PMID:41385096 "[{""id"":""uuid:a3288a74-9c5e-4d79-98fe-f291c5524056"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5efb25e5-81ea-4381-809b-32317d6f7092"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Droxidopa capsules are indicated for the treatment of orthostatic dizziness, lightheadedness, or the “feeling that you are about to black out” in adult patients with symptomatic neurogenic orthostatic hypotension (nOH) caused by primary autonomic failure (Parkinson's disease [PD], multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy. Effectiveness beyond 2 weeks of treatment has not been established. The continued effectiveness of Droxidopa should be assessed periodically. uuid:991dbbb6-e653-4d8c-bbf7-fca2aca4fc27 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31524 biolink:treats MONDO:0007803 PMID:41385096 "[{""id"":""uuid:da468c2c-aef5-4aa3-a618-b31250944847"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0788e633-c16d-4f88-9934-4f75a3e50c75"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Droxidopa capsules are indicated for the treatment of orthostatic dizziness, lightheadedness, or the “feeling that you are about to black out” in adult patients with symptomatic neurogenic orthostatic hypotension (nOH) caused by primary autonomic failure (Parkinson's disease [PD], multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy. Effectiveness beyond 2 weeks of treatment has not been established. The continued effectiveness of Droxidopa should be assessed periodically. uuid:a66265c2-47fe-4693-80a2-397239def163 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31524 biolink:treats MONDO:0018608 PMID:41385096 "[{""id"":""uuid:cda09661-bd20-4aae-8d98-ce7d943ec537"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:800c1362-556e-4916-bdec-5696c224da1c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Droxidopa capsules are indicated for the treatment of orthostatic dizziness, lightheadedness, or the “feeling that you are about to black out” in adult patients with symptomatic neurogenic orthostatic hypotension (nOH) caused by primary autonomic failure (Parkinson's disease [PD], multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy. Effectiveness beyond 2 weeks of treatment has not been established. The continued effectiveness of Droxidopa should be assessed periodically. uuid:099acccb-f7aa-47b8-99b6-261807a74905 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31524 biolink:treats MONDO:0001300 PMID:41385096 "[{""id"":""uuid:e8c0704d-b146-41f8-a9aa-715c20e333ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:49207ec3-9182-4eeb-905b-404695aa3b80"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Droxidopa capsules are indicated for the treatment of orthostatic dizziness, lightheadedness, or the “feeling that you are about to black out” in adult patients with symptomatic neurogenic orthostatic hypotension (nOH) caused by primary autonomic failure (Parkinson's disease [PD], multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy. Effectiveness beyond 2 weeks of treatment has not been established. The continued effectiveness of Droxidopa should be assessed periodically. uuid:f052a51e-9c62-4251-8530-7e520bd857ef biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31524 biolink:treats MONDO:0005469 PMID:41385096 "[{""id"":""uuid:8c9e77cb-cf1e-4147-8f0e-468b54aedd8d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:054d7e91-843e-4d2b-9024-72e665c8a911"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Droxidopa capsules are indicated for the treatment of orthostatic dizziness, lightheadedness, or the “feeling that you are about to black out” in adult patients with symptomatic neurogenic orthostatic hypotension (nOH) caused by primary autonomic failure (Parkinson's disease [PD], multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy. Effectiveness beyond 2 weeks of treatment has not been established. The continued effectiveness of Droxidopa should be assessed periodically. uuid:efb17d52-bd4a-45bf-9da6-cd5139b786e0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2618 biolink:treats MONDO:0024352 PMID:41385096 "[{""id"":""uuid:bdc1183d-4b7c-4c0f-9fb7-99f8b8a282b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aba6c9c8-1d30-4563-8020-d653a2145e24"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amantadine Hydrochloride is indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus. Amantadine Hydrochloride is also indicated in the treatment of parkinsonism and drug-induced extrapyramidal reactions. Influenza A Prophylaxis Amantadine Hydrochloride is indicated for chemoprophylaxis against signs and symptoms of influenza A virus infection. Because Amantadine Hydrochloride Tablets do not completely prevent the host immune response to influenza A infection, individuals who take this drug may still develop immune responses to natural disease or vaccination and may be protected when later exposed to antigenically related viruses. Following vaccination during an influenza A outbreak, Amantadine Hydrochloride Tablets prophylaxis should be considered for the 2- to 4- week time period required to develop an antibody response. Influenza A Treatment Amantadine Hydrochloride is also indicated in the treatment of uncomplicated respiratory tract illness caused by influenza A virus strains especially when administered early in the course of illness. There are no well-controlled clinical studies demonstrating that treatment with Amantadine Hydrochloride will avoid the development of influenza A virus pneumonitis or other complications in high risk patients. There is no clinical evidence indicating that Amantadine Hydrochloride Tablets and Capsules are effective in the prophylaxis or treatment of viral respiratory tract illnesses other than those caused by influenza A virus strains. The following points should be considered before initiating treatment or prophylaxis with Amantadine Hydrochloride: Amantadine Hydrochloride is not a substitute for early vaccination on an annual basis as recommended by the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices. Influenza viruses change over time. Emergence of resistance mutations could decrease drug effectiveness. Other factors (for example, changes in viral virulence) might also diminish clinical benefit of antiviral drugs. Prescribers should consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use Amantadine Hydrochloride. Parkinson's Disease / Syndrome Amantadine Hydrochloride is indicated in the treatment of idiopathic Parkinson's disease (Paralysis Agitans), postencephalitic parkinsonism, and symptomatic parkinsonism which may follow injury to the nervous system by carbon monoxide intoxication. It is indicated in those elderly patients believed to develop parkinsonism in association with cerebral arteriosclerosis. In the treatment of Parkinson's disease, Amantadine Hydrochloride is less effective than levodopa, (-)-3-(3,4-dihydroxyphenyl)-L-alanine, and its efficacy in comparison with the anticholinergic antiparkinson drugs has not yet been established. Drug-Induced Extrapyramidal Reactions Amantadine Hydrochloride is indicated in the treatment of drug-induced extrapyramidal reactions. Although anticholinergic-type side effects have been noted with Amantadine Hydrochloride Tablets when used in patients with drug-induced extrapyramidal reactions, there is a lower incidence of these side effects than that observed with the anticholinergic antiparkinson drugs. uuid:12630ea9-2d42-4d98-b91a-e897bfa9196a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7824 biolink:treats MONDO:0006710 PMID:41385096 "[{""id"":""uuid:0bb2a77f-092d-4bc3-a0bb-e310e7fa0734"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eaa3eab2-fc9a-42a2-89ba-34ca9c218e4c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxcarbazepine tablets are indicated for use as monotherapy or adjunctive therapy in the treatment of partial-onset seizures in adults and as monotherapy in the treatment of partial-onset seizures in pediatric patients aged 4 years and above, and as adjunctive therapy in pediatric patients aged 2 years and above with partial-onset seizures. uuid:d259c88a-1599-4425-92a5-63863830d7dc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28001 biolink:treats MONDO:0005545 PMID:41385096 "[{""id"":""uuid:e19e4aa9-9e22-40a8-962a-66fab54389f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8eca4f48-e0df-4e94-ae78-ddbc867434a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vancomycin Hydrochloride for Oral Solution is administered orally for treatment of enterocolitis caused by Staphylococcus aureus (including methicillin-resistant strains) and antibiotic-associated pseudomembranous colitis caused by C. difficile . Parenteral administration of vancomycin is not effective for the above indications; therefore, Vancomycin Hydrochloride for Oral Solution must be given orally for these infections. Orally administered Vancomycin Hydrochloride for Oral Solution is not effective for other types of infection. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Vancomycin Hydrochloride for Oral Solution and other antibacterial drugs, Vancomycin Hydrochloride for Oral Solution should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:902b86e2-a18a-48fc-a656-1a6bd47313ba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:375139 biolink:treats MONDO:0004857 PMID:41385096 "[{""id"":""uuid:f1f91755-a156-4ba0-9a8d-d9fed1f74714"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2ed26401-dd66-418b-ad10-068b316e9f77"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lidothol is a formulation used to assist patients in the treatment of mild to moderate acute or chronic aches or pain. Muscle or joint pain can be due to muscle or ligament strains, simple backache, tendonitis, osteoarthritis, rheumatoid arthritis, peripheral neuropathies such as diabetic neuropathy or post herpetic neuralgia, and other complex regional pains. It can also be used to help with certain types of headaches, but use with caution when applying in order to avoid eye contact. Other uses may be considered if deemed clinically relevant. uuid:eae87773-0b43-4343-95b8-5706c26c77c4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:375139 biolink:treats MONDO:0005178 PMID:41385096 "[{""id"":""uuid:9d22d93f-8b15-4425-9964-b62c3e6c4159"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9c438756-ce25-46a6-a7b9-b6509d019843"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lidothol is a formulation used to assist patients in the treatment of mild to moderate acute or chronic aches or pain. Muscle or joint pain can be due to muscle or ligament strains, simple backache, tendonitis, osteoarthritis, rheumatoid arthritis, peripheral neuropathies such as diabetic neuropathy or post herpetic neuralgia, and other complex regional pains. It can also be used to help with certain types of headaches, but use with caution when applying in order to avoid eye contact. Other uses may be considered if deemed clinically relevant. uuid:d31f53ff-efe4-4099-b341-f94ff532c170 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:375139 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:d3e35f48-decd-4dc9-a811-d9479fffa885"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0c4da896-1393-461b-b24c-f68eeb24fda6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lidothol is a formulation used to assist patients in the treatment of mild to moderate acute or chronic aches or pain. Muscle or joint pain can be due to muscle or ligament strains, simple backache, tendonitis, osteoarthritis, rheumatoid arthritis, peripheral neuropathies such as diabetic neuropathy or post herpetic neuralgia, and other complex regional pains. It can also be used to help with certain types of headaches, but use with caution when applying in order to avoid eye contact. Other uses may be considered if deemed clinically relevant. uuid:ca0cdac2-c517-4bb3-8790-8a5ba821f209 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:375139 biolink:treats MONDO:0006626 PMID:41385096 "[{""id"":""uuid:82b86959-6293-431f-af27-c88634b9f089"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:741cd0db-e925-4c96-92d8-944b708abac6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lidothol is a formulation used to assist patients in the treatment of mild to moderate acute or chronic aches or pain. Muscle or joint pain can be due to muscle or ligament strains, simple backache, tendonitis, osteoarthritis, rheumatoid arthritis, peripheral neuropathies such as diabetic neuropathy or post herpetic neuralgia, and other complex regional pains. It can also be used to help with certain types of headaches, but use with caution when applying in order to avoid eye contact. Other uses may be considered if deemed clinically relevant. uuid:ffd43317-49f6-42a8-a742-943bb5b0c695 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:375139 biolink:treats MONDO:0041052 PMID:41385096 "[{""id"":""uuid:9e668742-f13c-4764-ad8f-a80d29ec9187"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d69b3202-b001-4c25-9cad-adb37501c392"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lidothol is a formulation used to assist patients in the treatment of mild to moderate acute or chronic aches or pain. Muscle or joint pain can be due to muscle or ligament strains, simple backache, tendonitis, osteoarthritis, rheumatoid arthritis, peripheral neuropathies such as diabetic neuropathy or post herpetic neuralgia, and other complex regional pains. It can also be used to help with certain types of headaches, but use with caution when applying in order to avoid eye contact. Other uses may be considered if deemed clinically relevant. uuid:acdab28a-7af0-4158-b34a-feb6c52f8775 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:375139 biolink:treats MONDO:0021146 PMID:41385096 "[{""id"":""uuid:7c94b645-3f73-41c7-b98d-05ef5d8f5e76"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4e8e417d-dd8b-4b7e-96da-80d67aface1f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lidothol is a formulation used to assist patients in the treatment of mild to moderate acute or chronic aches or pain. Muscle or joint pain can be due to muscle or ligament strains, simple backache, tendonitis, osteoarthritis, rheumatoid arthritis, peripheral neuropathies such as diabetic neuropathy or post herpetic neuralgia, and other complex regional pains. It can also be used to help with certain types of headaches, but use with caution when applying in order to avoid eye contact. Other uses may be considered if deemed clinically relevant. uuid:e4b3047e-98c1-484b-9b1c-5111e7e8a1cf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1090966 biolink:treats MONDO:0007016 PMID:41385096 "[{""id"":""uuid:d35926a9-ee0c-4584-b457-02ee959705ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a62af74a-2488-4745-a342-1c20753da733"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Supplementation of the diet with ten essential vitamins. Supplementation of the diet with fluoride for caries prophylaxis. Multivitamin with 1.0 mg Fluoride Chewable Tablets provide 1.0 mg fluoride in tablet form for children 6-16 years of age in areas where the water fluoride level is less than 0.3 ppm. Multivitamin with 1.0 mg Fluoride Chewable Tablets supply significant amounts of Vitamins A, C, D, E, thiamine, riboflavin, niacin, vitamin B 6, vitamin B 12, and folate to supplement the diet, and to help assure that nutritional deficiencies of these vitamins will not develop. Thus, in a single easy-to-use preparation, children obtain ten essential vitamins and the important mineral, fluoride. The American Academy of Pediatrics recommends that children up to age 16, in areas where drinking water contains less than optimal levels of fluoride, receive daily fluoride supplements. Children using Multivitamin with 1.0 mg Fluoride Chewable Tablets regularly should receive semiannual dental examinations. The regular brushing of teeth and attention to good oral hygiene practices are also essential. Multivitamin with Fluoride Chewable Tablets is a prescription product for the clinical dietary management of the metabolic processes of caries prophylaxis and provides supplementation of the diet with ten essential vitamins. uuid:fbc83462-a4f4-4707-8c6b-04b8440fdd1b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1090966 biolink:treats MONDO:0009412 PMID:41385096 "[{""id"":""uuid:385027eb-73d2-47b5-864a-da6f7d80e958"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eb5be6e1-c5fa-4e56-900a-1c59af0af5ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Supplementation of the diet with ten essential vitamins. Supplementation of the diet with fluoride for caries prophylaxis. Multivitamin with 1.0 mg Fluoride Chewable Tablets provide 1.0 mg fluoride in tablet form for children 6-16 years of age in areas where the water fluoride level is less than 0.3 ppm. Multivitamin with 1.0 mg Fluoride Chewable Tablets supply significant amounts of Vitamins A, C, D, E, thiamine, riboflavin, niacin, vitamin B 6, vitamin B 12, and folate to supplement the diet, and to help assure that nutritional deficiencies of these vitamins will not develop. Thus, in a single easy-to-use preparation, children obtain ten essential vitamins and the important mineral, fluoride. The American Academy of Pediatrics recommends that children up to age 16, in areas where drinking water contains less than optimal levels of fluoride, receive daily fluoride supplements. Children using Multivitamin with 1.0 mg Fluoride Chewable Tablets regularly should receive semiannual dental examinations. The regular brushing of teeth and attention to good oral hygiene practices are also essential. Multivitamin with Fluoride Chewable Tablets is a prescription product for the clinical dietary management of the metabolic processes of caries prophylaxis and provides supplementation of the diet with ten essential vitamins. uuid:589d2c61-818a-4c5d-b757-81a1cb9a829b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1090966 biolink:treats MONDO:0100471 PMID:41385096 "[{""id"":""uuid:fed30dbb-6d0c-4b1a-a311-688f6b11e08d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:37b75cef-fb10-4350-9f73-3659009db1d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Supplementation of the diet with ten essential vitamins. Supplementation of the diet with fluoride for caries prophylaxis. Multivitamin with 1.0 mg Fluoride Chewable Tablets provide 1.0 mg fluoride in tablet form for children 6-16 years of age in areas where the water fluoride level is less than 0.3 ppm. Multivitamin with 1.0 mg Fluoride Chewable Tablets supply significant amounts of Vitamins A, C, D, E, thiamine, riboflavin, niacin, vitamin B 6, vitamin B 12, and folate to supplement the diet, and to help assure that nutritional deficiencies of these vitamins will not develop. Thus, in a single easy-to-use preparation, children obtain ten essential vitamins and the important mineral, fluoride. The American Academy of Pediatrics recommends that children up to age 16, in areas where drinking water contains less than optimal levels of fluoride, receive daily fluoride supplements. Children using Multivitamin with 1.0 mg Fluoride Chewable Tablets regularly should receive semiannual dental examinations. The regular brushing of teeth and attention to good oral hygiene practices are also essential. Multivitamin with Fluoride Chewable Tablets is a prescription product for the clinical dietary management of the metabolic processes of caries prophylaxis and provides supplementation of the diet with ten essential vitamins. uuid:db6930e1-42ef-4ae5-99c9-fb78ce3f8b72 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1090966 biolink:treats MONDO:0024298 PMID:41385096 "[{""id"":""uuid:28fd09ba-d6ad-4998-8b4e-d32500c3a8a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6e18064d-6574-4045-ac3b-5d5fb29bd68c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Supplementation of the diet with ten essential vitamins. Supplementation of the diet with fluoride for caries prophylaxis. Multivitamin with 1.0 mg Fluoride Chewable Tablets provide 1.0 mg fluoride in tablet form for children 6-16 years of age in areas where the water fluoride level is less than 0.3 ppm. Multivitamin with 1.0 mg Fluoride Chewable Tablets supply significant amounts of Vitamins A, C, D, E, thiamine, riboflavin, niacin, vitamin B 6, vitamin B 12, and folate to supplement the diet, and to help assure that nutritional deficiencies of these vitamins will not develop. Thus, in a single easy-to-use preparation, children obtain ten essential vitamins and the important mineral, fluoride. The American Academy of Pediatrics recommends that children up to age 16, in areas where drinking water contains less than optimal levels of fluoride, receive daily fluoride supplements. Children using Multivitamin with 1.0 mg Fluoride Chewable Tablets regularly should receive semiannual dental examinations. The regular brushing of teeth and attention to good oral hygiene practices are also essential. Multivitamin with Fluoride Chewable Tablets is a prescription product for the clinical dietary management of the metabolic processes of caries prophylaxis and provides supplementation of the diet with ten essential vitamins. uuid:805af120-7c45-4db0-abb5-660a34c074ff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1090966 biolink:treats MONDO:0042976 PMID:41385096 "[{""id"":""uuid:b70abbeb-d8cc-4148-b149-2bacc1bffdc5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bbfa282d-e052-4189-b6dc-c839999ad3f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Supplementation of the diet with ten essential vitamins. Supplementation of the diet with fluoride for caries prophylaxis. Multivitamin with 1.0 mg Fluoride Chewable Tablets provide 1.0 mg fluoride in tablet form for children 6-16 years of age in areas where the water fluoride level is less than 0.3 ppm. Multivitamin with 1.0 mg Fluoride Chewable Tablets supply significant amounts of Vitamins A, C, D, E, thiamine, riboflavin, niacin, vitamin B 6, vitamin B 12, and folate to supplement the diet, and to help assure that nutritional deficiencies of these vitamins will not develop. Thus, in a single easy-to-use preparation, children obtain ten essential vitamins and the important mineral, fluoride. The American Academy of Pediatrics recommends that children up to age 16, in areas where drinking water contains less than optimal levels of fluoride, receive daily fluoride supplements. Children using Multivitamin with 1.0 mg Fluoride Chewable Tablets regularly should receive semiannual dental examinations. The regular brushing of teeth and attention to good oral hygiene practices are also essential. Multivitamin with Fluoride Chewable Tablets is a prescription product for the clinical dietary management of the metabolic processes of caries prophylaxis and provides supplementation of the diet with ten essential vitamins. uuid:2ccb497b-c0e8-4261-9f5a-58e942950531 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1090966 biolink:treats MONDO:0004573 PMID:41385096 "[{""id"":""uuid:b0cf2aba-9f0a-40d1-a460-b6be50590c14"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:31430d75-d259-4421-80be-c641287bdaca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Supplementation of the diet with ten essential vitamins. Supplementation of the diet with fluoride for caries prophylaxis. Multivitamin with 1.0 mg Fluoride Chewable Tablets provide 1.0 mg fluoride in tablet form for children 6-16 years of age in areas where the water fluoride level is less than 0.3 ppm. Multivitamin with 1.0 mg Fluoride Chewable Tablets supply significant amounts of Vitamins A, C, D, E, thiamine, riboflavin, niacin, vitamin B 6, vitamin B 12, and folate to supplement the diet, and to help assure that nutritional deficiencies of these vitamins will not develop. Thus, in a single easy-to-use preparation, children obtain ten essential vitamins and the important mineral, fluoride. The American Academy of Pediatrics recommends that children up to age 16, in areas where drinking water contains less than optimal levels of fluoride, receive daily fluoride supplements. Children using Multivitamin with 1.0 mg Fluoride Chewable Tablets regularly should receive semiannual dental examinations. The regular brushing of teeth and attention to good oral hygiene practices are also essential. Multivitamin with Fluoride Chewable Tablets is a prescription product for the clinical dietary management of the metabolic processes of caries prophylaxis and provides supplementation of the diet with ten essential vitamins. uuid:791f03c3-9b2e-47a2-82ef-eba9ec972d79 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1090966 biolink:treats MONDO:0019975 PMID:41385096 "[{""id"":""uuid:7022e951-cc2b-4470-b49b-1c1f449f1e67"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:30229a56-9a48-47c4-981f-9802b38ea003"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Supplementation of the diet with ten essential vitamins. Supplementation of the diet with fluoride for caries prophylaxis. Multivitamin with 1.0 mg Fluoride Chewable Tablets provide 1.0 mg fluoride in tablet form for children 6-16 years of age in areas where the water fluoride level is less than 0.3 ppm. Multivitamin with 1.0 mg Fluoride Chewable Tablets supply significant amounts of Vitamins A, C, D, E, thiamine, riboflavin, niacin, vitamin B 6, vitamin B 12, and folate to supplement the diet, and to help assure that nutritional deficiencies of these vitamins will not develop. Thus, in a single easy-to-use preparation, children obtain ten essential vitamins and the important mineral, fluoride. The American Academy of Pediatrics recommends that children up to age 16, in areas where drinking water contains less than optimal levels of fluoride, receive daily fluoride supplements. Children using Multivitamin with 1.0 mg Fluoride Chewable Tablets regularly should receive semiannual dental examinations. The regular brushing of teeth and attention to good oral hygiene practices are also essential. Multivitamin with Fluoride Chewable Tablets is a prescription product for the clinical dietary management of the metabolic processes of caries prophylaxis and provides supplementation of the diet with ten essential vitamins. uuid:239612e8-8ce2-49ae-8cdb-52de4db32014 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1090966 biolink:treats MONDO:0004574 PMID:41385096 "[{""id"":""uuid:62bfa1d1-50e9-477c-b6ae-9bdaa98f63c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:884dbc2b-5d9d-42c5-8bc2-23d5390bd953"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Supplementation of the diet with ten essential vitamins. Supplementation of the diet with fluoride for caries prophylaxis. Multivitamin with 1.0 mg Fluoride Chewable Tablets provide 1.0 mg fluoride in tablet form for children 6-16 years of age in areas where the water fluoride level is less than 0.3 ppm. Multivitamin with 1.0 mg Fluoride Chewable Tablets supply significant amounts of Vitamins A, C, D, E, thiamine, riboflavin, niacin, vitamin B 6, vitamin B 12, and folate to supplement the diet, and to help assure that nutritional deficiencies of these vitamins will not develop. Thus, in a single easy-to-use preparation, children obtain ten essential vitamins and the important mineral, fluoride. The American Academy of Pediatrics recommends that children up to age 16, in areas where drinking water contains less than optimal levels of fluoride, receive daily fluoride supplements. Children using Multivitamin with 1.0 mg Fluoride Chewable Tablets regularly should receive semiannual dental examinations. The regular brushing of teeth and attention to good oral hygiene practices are also essential. Multivitamin with Fluoride Chewable Tablets is a prescription product for the clinical dietary management of the metabolic processes of caries prophylaxis and provides supplementation of the diet with ten essential vitamins. uuid:76b79384-2bd4-4262-a3ac-17b647592241 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1090966 biolink:treats MONDO:0020696 PMID:41385096 "[{""id"":""uuid:a6e2b4ca-d3e0-4cc0-b717-75d976ade2a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:abde83ce-7eb4-4d5d-ba23-cfaa7153dcd9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Supplementation of the diet with ten essential vitamins. Supplementation of the diet with fluoride for caries prophylaxis. Multivitamin with 1.0 mg Fluoride Chewable Tablets provide 1.0 mg fluoride in tablet form for children 6-16 years of age in areas where the water fluoride level is less than 0.3 ppm. Multivitamin with 1.0 mg Fluoride Chewable Tablets supply significant amounts of Vitamins A, C, D, E, thiamine, riboflavin, niacin, vitamin B 6, vitamin B 12, and folate to supplement the diet, and to help assure that nutritional deficiencies of these vitamins will not develop. Thus, in a single easy-to-use preparation, children obtain ten essential vitamins and the important mineral, fluoride. The American Academy of Pediatrics recommends that children up to age 16, in areas where drinking water contains less than optimal levels of fluoride, receive daily fluoride supplements. Children using Multivitamin with 1.0 mg Fluoride Chewable Tablets regularly should receive semiannual dental examinations. The regular brushing of teeth and attention to good oral hygiene practices are also essential. Multivitamin with Fluoride Chewable Tablets is a prescription product for the clinical dietary management of the metabolic processes of caries prophylaxis and provides supplementation of the diet with ten essential vitamins. uuid:31bd9c5f-d68d-400d-b74f-7871ac6aaf28 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1090966 biolink:treats MONDO:0001860 PMID:41385096 "[{""id"":""uuid:605a50fd-7903-48a1-9e8e-c810253e5329"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:678461ef-bbca-4a5f-a6ab-428ff7257ed7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Supplementation of the diet with ten essential vitamins. Supplementation of the diet with fluoride for caries prophylaxis. Multivitamin with 1.0 mg Fluoride Chewable Tablets provide 1.0 mg fluoride in tablet form for children 6-16 years of age in areas where the water fluoride level is less than 0.3 ppm. Multivitamin with 1.0 mg Fluoride Chewable Tablets supply significant amounts of Vitamins A, C, D, E, thiamine, riboflavin, niacin, vitamin B 6, vitamin B 12, and folate to supplement the diet, and to help assure that nutritional deficiencies of these vitamins will not develop. Thus, in a single easy-to-use preparation, children obtain ten essential vitamins and the important mineral, fluoride. The American Academy of Pediatrics recommends that children up to age 16, in areas where drinking water contains less than optimal levels of fluoride, receive daily fluoride supplements. Children using Multivitamin with 1.0 mg Fluoride Chewable Tablets regularly should receive semiannual dental examinations. The regular brushing of teeth and attention to good oral hygiene practices are also essential. Multivitamin with Fluoride Chewable Tablets is a prescription product for the clinical dietary management of the metabolic processes of caries prophylaxis and provides supplementation of the diet with ten essential vitamins. uuid:f495b696-2db2-409b-b64c-4e2667441650 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5801 biolink:treats MONDO:0005083 PMID:41385096 "[{""id"":""uuid:ef417932-7710-4738-9ef1-c71a11f22df7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d7b569a7-6372-4231-8565-85a5f1e8a1d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Malaria Hydroxychloroquine sulfate tablets are indicated for the treatment of uncomplicated malaria due to P. falciparum, P. malariae, P. ovale, and P. vivax. Hydroxychloroquine sulfate tablets are indicated for the prophylaxis of malaria in geographic areas where chloroquine resistance is not reported. Limitations of Use in Malaria • Hydroxychloroquine sulfate tablets are not recommended for the treatment of complicated malaria. • Hydroxychloroquine sulfate tablets are not effective against chloroquine or hydroxychloroquineresistant strains of Plasmodium species (see CLINICAL PHARMACOLOGY – Microbiology). Hydroxychloroquine sulfate tablets are not recommended for the treatment of malaria acquired in geographic areas where chloroquine resistance occurs or when the Plasmodium species has not been identified. • Hydroxychloroquine sulfate tablets are not recommended for malaria prophylaxis in geographic areas where chloroquine resistance occurs. • Hydroxychloroquine sulfate tablets do not prevent relapses of P. vivax or P. ovale because it is not active against the hypnozoite forms of these parasites. For radical cure of P. vivax and P. ovale infections, concomitant therapy with an 8-aminoquinoline compound is necessary (see CLINICAL PHARMACOLOGY – Microbiology). Prior to prescribing hydroxychloroquine sulfate tablets for the treatment or prophylaxis of malaria, consult the Centers for Disease Control and Prevention (CDC) Malaria website (http://www.cdc.gov/malaria). Lupus Erythematosus Hydroxychloroquine sulfate tablets are indicated for the treatment of chronic discoid lupus erythematosus and systemic lupus erythematosus in adults. Rheumatoid Arthritis Hydroxychloroquine sulfate tablets are indicated for the treatment of acute and chronic rheumatoid arthritis in adults. CONTRAINDICATIONS Use of hydroxychloroquine sulfate tablets are contraindicated in patients with known hypersensitivity to 4-aminoquinoline compounds. WARNINGS Resistant strains of malaria: hydroxychloroquine sulfate tablets are not effective against chloroquineresistant strains of P. falciparum (see CLINICAL PHARMACOLOGY – Microbiology). Ocular: Irreversible retinal damage has been observed in some patients who had received hydroxychloroquine sulfate. Significant risk factors for retinal damage include daily doses of hydroxychloroquine sulfate greater than 6.5 mg/kg (5 mg/kg base) of actual body weight, durations of use greater than five years, subnormal glomerular filtration, use of some concomitant drug products such as tamoxifen citrate and concurrent macular disease. A baseline ocular examination is recommended within the first year of starting hydroxychloroquine sulfate tablets. The baseline exam should include: best corrected distance visual acuity (BCVA), an automated threshold visual field (VF) of the central 10 degrees (with retesting if an abnormality is noted), and spectral domain ocular coherence tomography (SD‑OCT). For individuals with significant risk factors (daily dose of hydroxychloroquine sulfate greater than 5.0 mg/kg base of actual body weight, subnormal glomerular filtration, use of tamoxifen citrate or concurrent macular disease) monitoring should include annual examinations which include BCVA, VF and SD-OCT. For individuals without significant risk factors, annual exams can usually be deferred until five years of treatment. In individuals of Asian descent, retinal toxicity may first be noticed outside the macula. In patients of Asian descent, it is recommended that visual field testing be performed in the central 24 degrees instead of the central 10 degrees. It is recommended that hydroxychloroquine be discontinued if ocular toxicity is suspected and the patient should be closely observed given that retinal changes (and visual disturbances) may progress even after cessation of therapy. Cardiac Effects, including Cardiomyopathy and QT prolongation: Postmarketing cases of life-threatening and fatal cardiomyopathy have been reported with use of hydroxychloroquine sulfate tablets as well as with use of chloroquine. Patients may present with atrioventricular block, pulmonary hypertension, sick sinus syndrome or with cardiac complications. ECG findings may include atrioventricular, right or left bundle branch block. Signs or symptoms of cardiac compromise have appeared during acute and chronic treatment. Clinical monitoring for signs and symptoms of cardiomyopathy is advised, including use of appropriate diagnostic tools such as ECG to monitor patients for cardiomyopathy during Hydroxychloroquine Sulfate Tablets therapy. Chronic toxicity should be considered when conduction disorders (bundle branch block/atrio-ventricular heart block) or biventricular hypertrophy are diagnosed. If cardiotoxicity is suspected, prompt discontinuation of hydroxychloroquine sulfate tablets may prevent lifethreatening complications. Hydroxychloroquine sulfate tablets prolong the QT interval. Ventricular arrhythmias and torsades de pointes have been reported in patients taking Hydroxychloroquine Sulfate Tablets (see OVERDOSAGE). Therefore, hydroxychloroquine sulfate tablets should not be administered with other drugs that have the potential to prolong the QT interval (see DRUG INTERACTIONS). Worsening of psoriasis and porphyria: Use of hydroxychloroquine sulfate tablets in patients with psoriasis may precipitate a severe attack of psoriasis. When used in patients with porphyria the condition may be exacerbated. The preparation should not be used in these conditions unless in the judgment of the physician the benefit to the patient outweighs the possible hazard. Proximal Myopathy and Neuropathy: Skeletal muscle myopathy or neuropathy leading to progressive weakness and atrophy of proximal muscle groups, depressed tendon reflexes, and abnormal nerve conduction, have been reported. Muscle and nerve biopsies have been associated with curvilinear bodies and muscle fiber atrophy with vacuolar changes. Assess muscle strength and deep tendon reflexes periodically in patients on long-term therapy with hydroxychloroquine sulfate tablets. Neuropsychiatric events, including suicidality: Suicidal behavior has been rarely reported in patients treated with hydroxychloroquine sulfate tablets. Hypoglycemia: hydroxychloroquine sulfate tablets have been shown to cause severe hypoglycemia including loss of consciousness that could be life threatening in patients treated with or without antidiabetic medications (see DRUG INTERACTIONS and ADVERSE REACTIONS). Patients treated with hydroxychloroquine sulfate tablets should be warned about the risk of hypoglycemia and the associated clinical signs and symptoms. Patients presenting with clinical symptoms suggestive of hypoglycemia during treatment with hydroxychloroquine sulfate tablets should have their blood glucose checked and treatment reviewed as necessary. uuid:a2e55e67-46f0-4109-a2e7-79365aad908b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5801 biolink:treats MONDO:0019142 PMID:41385096 "[{""id"":""uuid:4f42ab86-7fef-4fcc-a31e-e92284b96fe9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:68c6f294-530b-49d7-9ec7-03a2bc05f4d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Malaria Hydroxychloroquine sulfate tablets are indicated for the treatment of uncomplicated malaria due to P. falciparum, P. malariae, P. ovale, and P. vivax. Hydroxychloroquine sulfate tablets are indicated for the prophylaxis of malaria in geographic areas where chloroquine resistance is not reported. Limitations of Use in Malaria • Hydroxychloroquine sulfate tablets are not recommended for the treatment of complicated malaria. • Hydroxychloroquine sulfate tablets are not effective against chloroquine or hydroxychloroquineresistant strains of Plasmodium species (see CLINICAL PHARMACOLOGY – Microbiology). Hydroxychloroquine sulfate tablets are not recommended for the treatment of malaria acquired in geographic areas where chloroquine resistance occurs or when the Plasmodium species has not been identified. • Hydroxychloroquine sulfate tablets are not recommended for malaria prophylaxis in geographic areas where chloroquine resistance occurs. • Hydroxychloroquine sulfate tablets do not prevent relapses of P. vivax or P. ovale because it is not active against the hypnozoite forms of these parasites. For radical cure of P. vivax and P. ovale infections, concomitant therapy with an 8-aminoquinoline compound is necessary (see CLINICAL PHARMACOLOGY – Microbiology). Prior to prescribing hydroxychloroquine sulfate tablets for the treatment or prophylaxis of malaria, consult the Centers for Disease Control and Prevention (CDC) Malaria website (http://www.cdc.gov/malaria). Lupus Erythematosus Hydroxychloroquine sulfate tablets are indicated for the treatment of chronic discoid lupus erythematosus and systemic lupus erythematosus in adults. Rheumatoid Arthritis Hydroxychloroquine sulfate tablets are indicated for the treatment of acute and chronic rheumatoid arthritis in adults. CONTRAINDICATIONS Use of hydroxychloroquine sulfate tablets are contraindicated in patients with known hypersensitivity to 4-aminoquinoline compounds. WARNINGS Resistant strains of malaria: hydroxychloroquine sulfate tablets are not effective against chloroquineresistant strains of P. falciparum (see CLINICAL PHARMACOLOGY – Microbiology). Ocular: Irreversible retinal damage has been observed in some patients who had received hydroxychloroquine sulfate. Significant risk factors for retinal damage include daily doses of hydroxychloroquine sulfate greater than 6.5 mg/kg (5 mg/kg base) of actual body weight, durations of use greater than five years, subnormal glomerular filtration, use of some concomitant drug products such as tamoxifen citrate and concurrent macular disease. A baseline ocular examination is recommended within the first year of starting hydroxychloroquine sulfate tablets. The baseline exam should include: best corrected distance visual acuity (BCVA), an automated threshold visual field (VF) of the central 10 degrees (with retesting if an abnormality is noted), and spectral domain ocular coherence tomography (SD‑OCT). For individuals with significant risk factors (daily dose of hydroxychloroquine sulfate greater than 5.0 mg/kg base of actual body weight, subnormal glomerular filtration, use of tamoxifen citrate or concurrent macular disease) monitoring should include annual examinations which include BCVA, VF and SD-OCT. For individuals without significant risk factors, annual exams can usually be deferred until five years of treatment. In individuals of Asian descent, retinal toxicity may first be noticed outside the macula. In patients of Asian descent, it is recommended that visual field testing be performed in the central 24 degrees instead of the central 10 degrees. It is recommended that hydroxychloroquine be discontinued if ocular toxicity is suspected and the patient should be closely observed given that retinal changes (and visual disturbances) may progress even after cessation of therapy. Cardiac Effects, including Cardiomyopathy and QT prolongation: Postmarketing cases of life-threatening and fatal cardiomyopathy have been reported with use of hydroxychloroquine sulfate tablets as well as with use of chloroquine. Patients may present with atrioventricular block, pulmonary hypertension, sick sinus syndrome or with cardiac complications. ECG findings may include atrioventricular, right or left bundle branch block. Signs or symptoms of cardiac compromise have appeared during acute and chronic treatment. Clinical monitoring for signs and symptoms of cardiomyopathy is advised, including use of appropriate diagnostic tools such as ECG to monitor patients for cardiomyopathy during Hydroxychloroquine Sulfate Tablets therapy. Chronic toxicity should be considered when conduction disorders (bundle branch block/atrio-ventricular heart block) or biventricular hypertrophy are diagnosed. If cardiotoxicity is suspected, prompt discontinuation of hydroxychloroquine sulfate tablets may prevent lifethreatening complications. Hydroxychloroquine sulfate tablets prolong the QT interval. Ventricular arrhythmias and torsades de pointes have been reported in patients taking Hydroxychloroquine Sulfate Tablets (see OVERDOSAGE). Therefore, hydroxychloroquine sulfate tablets should not be administered with other drugs that have the potential to prolong the QT interval (see DRUG INTERACTIONS). Worsening of psoriasis and porphyria: Use of hydroxychloroquine sulfate tablets in patients with psoriasis may precipitate a severe attack of psoriasis. When used in patients with porphyria the condition may be exacerbated. The preparation should not be used in these conditions unless in the judgment of the physician the benefit to the patient outweighs the possible hazard. Proximal Myopathy and Neuropathy: Skeletal muscle myopathy or neuropathy leading to progressive weakness and atrophy of proximal muscle groups, depressed tendon reflexes, and abnormal nerve conduction, have been reported. Muscle and nerve biopsies have been associated with curvilinear bodies and muscle fiber atrophy with vacuolar changes. Assess muscle strength and deep tendon reflexes periodically in patients on long-term therapy with hydroxychloroquine sulfate tablets. Neuropsychiatric events, including suicidality: Suicidal behavior has been rarely reported in patients treated with hydroxychloroquine sulfate tablets. Hypoglycemia: hydroxychloroquine sulfate tablets have been shown to cause severe hypoglycemia including loss of consciousness that could be life threatening in patients treated with or without antidiabetic medications (see DRUG INTERACTIONS and ADVERSE REACTIONS). Patients treated with hydroxychloroquine sulfate tablets should be warned about the risk of hypoglycemia and the associated clinical signs and symptoms. Patients presenting with clinical symptoms suggestive of hypoglycemia during treatment with hydroxychloroquine sulfate tablets should have their blood glucose checked and treatment reviewed as necessary. uuid:baa701d8-0925-4d5b-b612-21c147f01680 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4786 biolink:treats HP:0005162 PMID:41385096 "[{""id"":""uuid:bdda4ec8-1b3d-4633-96c6-c511c46e8e57"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6b9c6067-1d8a-411f-b99d-aa4619eba029"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension Enalapril Maleate Tablets are indicated for the treatment of hypertension. Enalapril Maleate Tablets are effective alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. The blood pressure lowering effects of Enalapril Maleate Tablets and thiazides are approximately additive. Heart Failure Enalapril Maleate Tablets are indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. In these patients Enalapril Maleate Tablets improve symptoms, increases survival, and decreases the frequency of hospitalization (see CLINICAL PHARMACOLOGY, Heart Failure, Mortality Trials for details and limitations of survival trials). Asymptomatic Left Ventricular Dysfunction In clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35 percent), Enalapril Maleate Tablets decrease the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure (see CLINICAL PHARMACOLOGY , Heart Failure , Mortality Trials for details and limitations of survival trials). In using Enalapril Maleate Tablets consideration should be given to the fact that another angiotensin- converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that Enalapril Maleate Tablets do not have a similar risk (see WARNINGS , Neutropenia/Agranulocytosis ). In considering use of Enalapril Maleate Tablets, it should be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, it should be noted that black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks (see WARNINGS , Head and Neck Angioedema ). uuid:a8017147-a675-4bde-9300-dcb82eba472f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2118728 biolink:treats NCIT:C27003 PMID:41385096 "[{""id"":""uuid:75dc7f1e-4558-42e5-85d2-0aedc6d29fff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b6ad1be1-f698-4f82-9bec-675a3b42b764"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] APADAZ is indicated for the short-term (no more than 14 days) management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [ see Warnings and Precautions (5.1) ], reserve APADAZ for use in patients for whom alternative treatment options [e.g., non-opioid analgesics]: Have not been tolerated, or are not expected to be tolerated, Have not provided adequate analgesia, or are not expected to provide adequate analgesia. uuid:280701cc-ae6c-48f8-8932-ddfab95ad060 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:42355 biolink:treats MONDO:0006669 PMID:41385096 "[{""id"":""uuid:403c3b7e-3e5e-427d-a5ee-12b38ba2a6f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d40499d8-32c1-430b-83ce-600679552b90"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Erythromycin lactobionate for injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below when oral administration is not possible or when the severity of the infection requires immediate high serum levels of erythromycin. Intravenous therapy should be replaced by oral administration at the appropriate time. Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes (Group A beta-hemolytic streptococci); Streptococcus pneumoniae (Diplococcus pneumoniae); Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.) Lower respiratory tract infections of mild to moderate severity caused by Streptococcus pyogenes (Group A beta-hemolytic streptococci); Streptococcus pneumoniae (Diplococcus pneumoniae). Respiratory tract infections due to Mycoplasma pneumoniae. Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes and Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: As an adjunct to antitoxin infections due to Corynebacterium diphtheriae to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma: In the treatment of infections due to Corynebacterium minutissimum . Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae : Erythromycin lactobionate for injection followed by erythromycin stearate or erythromycin base orally, as an alternative drug in treatment of acute pelvic inflammatory disease caused by N. gonorrhoeae in female patients with a history of sensitivity to penicillin. Before treatment of gonorrhea, patients who are suspected of also having syphilis should have a microscopic examination for T. pallidum (by immunofluorescence or darkfield) before receiving erythromycin and monthly serologic tests for a minimum of 4 months thereafter. Legionnaires' Disease caused by Legionella pneumophila. Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires' Disease. Prevention of Initial Attacks of Rheumatic Fever Penicillin is considered by the American Heart Association to be the drug of choice in the prevention of initial attacks of rheumatic fever (treatment of Group A beta-hemolytic streptococcal infections of the upper respiratory tract e.g., tonsillitis, or pharyngitis). 1 Erythromycin is indicated for the treatment of penicillin-allergic patients. The therapeutic dose should be administered for ten days. Prevention of Recurrent Attacks of Rheumatic Fever Penicillin or sulfonamides are considered by the American Heart Association to be the drugs of choice in the prevention of recurrent attacks of rheumatic fever. In patients who are allergic to penicillin and sulfonamides, oral erythromycin is recommended by the American Heart Association in the long-term prophylaxis of streptococcal pharyngitis (for the prevention of recurrent attacks of rheumatic fever). 1 Prevention of Bacterial Endocarditis Although no controlled clinical efficacy trials have been conducted, oral erythromycin has been recommended by the American Heart Association for prevention of bacterial endocarditis in penicillin- allergic patients with prosthetic cardiac valves, most congenital cardiac malformations, surgically constructed systemic pulmonary shunts, rheumatic or other acquired valvular dysfunction, idiopathic hypertrophic subaortic stenosis (IHSS), previous history of bacterial endocarditis and mitral valve prolapse with insufficiency when they undergo dental procedures and surgical procedures of the upper respiratory tract. 2 To reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin and other antibacterial drugs, erythromycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:9daef2ad-491f-41c5-b5ac-d76a4c7f189f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:44185 biolink:treats MONDO:0020550 PMID:41385096 "[{""id"":""uuid:8e25a5d6-59ab-4a05-80da-4bc4b160628a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b472e57e-5d50-406b-b32e-bf889e369286"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methotrexate is indicated in the treatment of gestational choriocarcinoma, chorioadenoma destruens and hydatidiform mole. In acute lymphocytic leukemia, methotrexate is indicated for use in maintenance therapy in combination with other chemotherapeutic agents. Methotrexate is used alone or in combination with other anticancer agents in the treatment of breast cancer, epidermoid cancers of the head and neck, advanced mycosis fungoides (cutaneous T cell lymphoma), and lung cancer, particularly squamous cell and small cell types. Methotrexate is also used in combination with other chemotherapeutic agents in the treatment of advanced stage non-Hodgkin’s lymphomas. Methotrexate in high doses followed by leucovorin rescue in combination with other chemotherapeutic agents is effective in prolonging relapse-free survival in patients with non-metastatic osteosarcoma who have undergone surgical resection or amputation for the primary tumor. uuid:a9c86f19-f0b1-4a59-8c44-124cfeaf9299 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:44185 biolink:treats MONDO:0020549 PMID:41385096 "[{""id"":""uuid:bdc9ad2b-a077-495e-beb7-9df8d3adf886"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:542379ad-cd17-4b13-b576-593e22fa1920"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methotrexate is indicated in the treatment of gestational choriocarcinoma, chorioadenoma destruens and hydatidiform mole. In acute lymphocytic leukemia, methotrexate is indicated for use in maintenance therapy in combination with other chemotherapeutic agents. Methotrexate is used alone or in combination with other anticancer agents in the treatment of breast cancer, epidermoid cancers of the head and neck, advanced mycosis fungoides (cutaneous T cell lymphoma), and lung cancer, particularly squamous cell and small cell types. Methotrexate is also used in combination with other chemotherapeutic agents in the treatment of advanced stage non-Hodgkin’s lymphomas. Methotrexate in high doses followed by leucovorin rescue in combination with other chemotherapeutic agents is effective in prolonging relapse-free survival in patients with non-metastatic osteosarcoma who have undergone surgical resection or amputation for the primary tumor. uuid:42f29330-fb2c-4721-a78c-254d6a7fc188 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:44185 biolink:treats MONDO:0006248 PMID:41385096 "[{""id"":""uuid:43e2eac0-66bf-46ad-8fdd-dfdb92be7f5a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5918b796-96cd-4d44-8ac7-e254217478dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methotrexate is indicated in the treatment of gestational choriocarcinoma, chorioadenoma destruens and hydatidiform mole. In acute lymphocytic leukemia, methotrexate is indicated for use in maintenance therapy in combination with other chemotherapeutic agents. Methotrexate is used alone or in combination with other anticancer agents in the treatment of breast cancer, epidermoid cancers of the head and neck, advanced mycosis fungoides (cutaneous T cell lymphoma), and lung cancer, particularly squamous cell and small cell types. Methotrexate is also used in combination with other chemotherapeutic agents in the treatment of advanced stage non-Hodgkin’s lymphomas. Methotrexate in high doses followed by leucovorin rescue in combination with other chemotherapeutic agents is effective in prolonging relapse-free survival in patients with non-metastatic osteosarcoma who have undergone surgical resection or amputation for the primary tumor. uuid:de23c8b5-1e69-4901-bd4d-7cda09bc877a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:44185 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:a0719467-dc3f-471c-92d4-8c7e3e79be5a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c80d4504-96ff-4d89-ba1f-c7e4271556b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methotrexate is indicated in the treatment of gestational choriocarcinoma, chorioadenoma destruens and hydatidiform mole. In acute lymphocytic leukemia, methotrexate is indicated for use in maintenance therapy in combination with other chemotherapeutic agents. Methotrexate is used alone or in combination with other anticancer agents in the treatment of breast cancer, epidermoid cancers of the head and neck, advanced mycosis fungoides (cutaneous T cell lymphoma), and lung cancer, particularly squamous cell and small cell types. Methotrexate is also used in combination with other chemotherapeutic agents in the treatment of advanced stage non-Hodgkin’s lymphomas. Methotrexate in high doses followed by leucovorin rescue in combination with other chemotherapeutic agents is effective in prolonging relapse-free survival in patients with non-metastatic osteosarcoma who have undergone surgical resection or amputation for the primary tumor. uuid:b24b0641-5277-438d-9c43-a0f7bd6ce940 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:44185 biolink:treats MONDO:0010150 PMID:41385096 "[{""id"":""uuid:fda1c5f6-ae77-4cc0-84b5-3b1095b12525"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:58eb1a59-04a7-488a-b73d-854d4ff96762"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methotrexate is indicated in the treatment of gestational choriocarcinoma, chorioadenoma destruens and hydatidiform mole. In acute lymphocytic leukemia, methotrexate is indicated for use in maintenance therapy in combination with other chemotherapeutic agents. Methotrexate is used alone or in combination with other anticancer agents in the treatment of breast cancer, epidermoid cancers of the head and neck, advanced mycosis fungoides (cutaneous T cell lymphoma), and lung cancer, particularly squamous cell and small cell types. Methotrexate is also used in combination with other chemotherapeutic agents in the treatment of advanced stage non-Hodgkin’s lymphomas. Methotrexate in high doses followed by leucovorin rescue in combination with other chemotherapeutic agents is effective in prolonging relapse-free survival in patients with non-metastatic osteosarcoma who have undergone surgical resection or amputation for the primary tumor. uuid:1feb6afa-53c4-4776-99ca-7a64a2cf631c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:44185 biolink:treats MONDO:0008903 PMID:41385096 "[{""id"":""uuid:e73b1395-878e-4cc9-b135-078e1d82c216"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6e467cd2-3c8a-4f24-935c-1cfb8e57078e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methotrexate is indicated in the treatment of gestational choriocarcinoma, chorioadenoma destruens and hydatidiform mole. In acute lymphocytic leukemia, methotrexate is indicated for use in maintenance therapy in combination with other chemotherapeutic agents. Methotrexate is used alone or in combination with other anticancer agents in the treatment of breast cancer, epidermoid cancers of the head and neck, advanced mycosis fungoides (cutaneous T cell lymphoma), and lung cancer, particularly squamous cell and small cell types. Methotrexate is also used in combination with other chemotherapeutic agents in the treatment of advanced stage non-Hodgkin’s lymphomas. Methotrexate in high doses followed by leucovorin rescue in combination with other chemotherapeutic agents is effective in prolonging relapse-free survival in patients with non-metastatic osteosarcoma who have undergone surgical resection or amputation for the primary tumor. uuid:52584d5d-9a10-446b-8dbf-460d340d33eb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:44185 biolink:treats MONDO:0005097 PMID:41385096 "[{""id"":""uuid:07aea283-507b-412c-b186-d32f226e6259"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6f9a9ff2-349a-4cde-8035-5c15a6d3c3f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methotrexate is indicated in the treatment of gestational choriocarcinoma, chorioadenoma destruens and hydatidiform mole. In acute lymphocytic leukemia, methotrexate is indicated for use in maintenance therapy in combination with other chemotherapeutic agents. Methotrexate is used alone or in combination with other anticancer agents in the treatment of breast cancer, epidermoid cancers of the head and neck, advanced mycosis fungoides (cutaneous T cell lymphoma), and lung cancer, particularly squamous cell and small cell types. Methotrexate is also used in combination with other chemotherapeutic agents in the treatment of advanced stage non-Hodgkin’s lymphomas. Methotrexate in high doses followed by leucovorin rescue in combination with other chemotherapeutic agents is effective in prolonging relapse-free survival in patients with non-metastatic osteosarcoma who have undergone surgical resection or amputation for the primary tumor. uuid:2435f32b-fd93-46b7-ac66-8c6ed800f5a6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:44185 biolink:treats MONDO:0008433 PMID:41385096 "[{""id"":""uuid:6f3cbc3f-b0d6-48b1-932e-2cd4c7607980"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c652f6b4-e9f6-41b7-8020-6195c8b7eefa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methotrexate is indicated in the treatment of gestational choriocarcinoma, chorioadenoma destruens and hydatidiform mole. In acute lymphocytic leukemia, methotrexate is indicated for use in maintenance therapy in combination with other chemotherapeutic agents. Methotrexate is used alone or in combination with other anticancer agents in the treatment of breast cancer, epidermoid cancers of the head and neck, advanced mycosis fungoides (cutaneous T cell lymphoma), and lung cancer, particularly squamous cell and small cell types. Methotrexate is also used in combination with other chemotherapeutic agents in the treatment of advanced stage non-Hodgkin’s lymphomas. Methotrexate in high doses followed by leucovorin rescue in combination with other chemotherapeutic agents is effective in prolonging relapse-free survival in patients with non-metastatic osteosarcoma who have undergone surgical resection or amputation for the primary tumor. uuid:3725d9e3-a3ce-4cf5-a435-9d617e63f91d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:44185 biolink:treats MONDO:0002629 PMID:41385096 "[{""id"":""uuid:1ce5b306-a8a6-4379-83f1-d3cc2ecb0c1a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3f7c78a6-5f2d-480a-a806-3bb40e3ad315"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methotrexate is indicated in the treatment of gestational choriocarcinoma, chorioadenoma destruens and hydatidiform mole. In acute lymphocytic leukemia, methotrexate is indicated for use in maintenance therapy in combination with other chemotherapeutic agents. Methotrexate is used alone or in combination with other anticancer agents in the treatment of breast cancer, epidermoid cancers of the head and neck, advanced mycosis fungoides (cutaneous T cell lymphoma), and lung cancer, particularly squamous cell and small cell types. Methotrexate is also used in combination with other chemotherapeutic agents in the treatment of advanced stage non-Hodgkin’s lymphomas. Methotrexate in high doses followed by leucovorin rescue in combination with other chemotherapeutic agents is effective in prolonging relapse-free survival in patients with non-metastatic osteosarcoma who have undergone surgical resection or amputation for the primary tumor. uuid:88349f17-6298-46f1-839e-3d3028a64f92 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:205919 biolink:treats UMLS:C0406326 PMID:41385096 "[{""id"":""uuid:2dda8070-ecfb-49fb-a479-fa37faec485a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4d57610a-d64c-4028-856d-7b8d80a75244"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clobetasol propionate shampoo, 0.05% is a corticosteroid indicated for the treatment of moderate to severe scalp psoriasis in subjects 18 years of age and older ( 1 ). Limitations of Use: Do not use on the face, axillae or groin. ( 1.2 ) Avoid any contact with the eyes and lips. ( 1.2 ) uuid:6f4b67da-0e0f-4eb9-bc77-02f220408f0e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:XII270YC6M biolink:treats MONDO:0005344 PMID:41385096 "[{""id"":""uuid:fd52e618-eceb-46c6-8f34-a96a055eac6c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:0242c84d-0718-4690-9295-c3ddd5362439"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:d2f3c962-bf7e-4f3d-969f-43c9dfac3b36"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/zutectra""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] HepaGam B [Hepatitis B immune globulin intravenous (Human)] is an intravenous immune globulin indicated for the following:|[EMA] Prevention of hepatitis B virus (HBV) re-infection in HBsAg and HBV-DNA negative adult patients at least one week after liver transplantation for hepatitis B induced liver failure. HBV-DNA negative status should be confirmed within the last 3 months prior to OLT. Patients should be HBsAg negative before treatment start., , The concomitant use of adequate virostatic agents should be considered as standard of hepatitis B re-infection prophylaxis., uuid:576e2143-f16f-4c8e-8bf9-14e5292bc346 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135934 biolink:treats UMLS:C0847631 PMID:41385096 "[{""id"":""uuid:ad8f517a-aa7c-4da7-866c-23caa0909aa0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e946afc7-e229-43d4-aa3b-0f6a69dd04d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Selenium Sulfide 2.3% Shampoo is a liquid antiseborrheic, antifungal preparation useful for the treatment of seborrheic dermatitis of the scalp, dandruff and tinea versicolor. Urea hydrates and is useful for conditions such as dry scalp. uuid:d56e46e0-d12a-490a-815d-c1c88c223744 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3504 biolink:treats HP:0000371 PMID:41385096 "[{""id"":""uuid:f32d85c2-2576-42ec-b8a5-78cc65ff0e34"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7a33b0b9-ae49-48be-860b-489eaf574335"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefpodoxime proxetil is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Recommended dosages, durations of therapy, and applicable patient populations vary among these infections. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute otitis media caused by Streptococcus pneumoniae (excluding penicillin-resistant strains), Streptococcus pyogenes, Haemophilus influenzae (including beta-lactamase-producing strains), or Moraxella (Branhamella) catarrhalis (including beta-lactamase-producing strains). Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes . NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefpodoxime proxetil is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefpodoxime proxetil for the prophylaxis of subsequent rheumatic fever are not available. Community-acquired pneumonia caused by S.pneumoniae or H.influenzae (including beta-lactamase-producing strains). Acute bacterial exacerbation of chronic bronchitis caused by S.pneumoniae, H.influenzae (non-beta-lactamase-producing strains only), or M.catarrhalis . Data are insufficient at this time to establish efficacy in patients with acute bacterial exacerbations of chronic bronchitis caused by beta-lactamase-producing strains of H.influenzae . Acute, uncomplicated urethral and cervical gonorrhea caused by Neisseria gonorrhoeae (including penicillinase-producing strains). Acute, uncomplicated ano-rectal infections in women due to Neisseria gonorrhoeae (including penicillinase-producing strains). NOTE: The efficacy of cefpodoxime in treating male patients with rectal infections caused by N.gonorrhoeae has not been established. Data do not support the use of cefpodoxime proxetil in the treatment of pharyngeal infections due to N.gonorrhoeae in men or women. Uncomplicated skin and skin structure infections caused by Staphylococcus aureus (including penicillinase-producing strains) or Streptococcus pyogenes . Abscesses should be surgically drained as clinically indicated. NOTE: In clinical trials, successful treatment of uncomplicated skin and skin structure infections was dose-related. The effective therapeutic dose for skin infections was higher than those used in other recommended indications (see DOSAGE AND ADMINISTRATION ). Acute maxillary sinusitis caused by Haemophilus influenzae (including beta-lactamase-producing strains), Streptococcus pneumoniae, and Moraxella catarrhalis . Uncomplicated urinary tract infections (cystitis) caused by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis , or Staphylococcus saprophyticus . NOTE: In considering the use of cefpodoxime proxetil in the treatment of cystitis, cefpodoxime proxetil’s lower bacterial eradication rates should be weighed against the increased eradication rates and different safety profiles of some other classes of approved agents (see CLINICAL STUDIES section). Appropriate specimens for bacteriological examination should be obtained in order to isolate and identify causative organisms and to determine their susceptibility to cefpodoxime. Therapy may be instituted while awaiting the results of these studies. Once these results become available, antimicrobial therapy should be adjusted accordingly. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefpodoxime proxetil tablets and other antibacterial drugs, Cefpodoxime proxetil tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:594e5efd-a898-4a53-ba02-bba687ae39f4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3504 biolink:treats MONDO:0002258 PMID:41385096 "[{""id"":""uuid:38a371b2-41fa-47da-8b48-84870a21772d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:83bf9394-40c4-4cf7-b816-1483c22717df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefpodoxime proxetil is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Recommended dosages, durations of therapy, and applicable patient populations vary among these infections. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute otitis media caused by Streptococcus pneumoniae (excluding penicillin-resistant strains), Streptococcus pyogenes, Haemophilus influenzae (including beta-lactamase-producing strains), or Moraxella (Branhamella) catarrhalis (including beta-lactamase-producing strains). Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes . NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefpodoxime proxetil is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefpodoxime proxetil for the prophylaxis of subsequent rheumatic fever are not available. Community-acquired pneumonia caused by S.pneumoniae or H.influenzae (including beta-lactamase-producing strains). Acute bacterial exacerbation of chronic bronchitis caused by S.pneumoniae, H.influenzae (non-beta-lactamase-producing strains only), or M.catarrhalis . Data are insufficient at this time to establish efficacy in patients with acute bacterial exacerbations of chronic bronchitis caused by beta-lactamase-producing strains of H.influenzae . Acute, uncomplicated urethral and cervical gonorrhea caused by Neisseria gonorrhoeae (including penicillinase-producing strains). Acute, uncomplicated ano-rectal infections in women due to Neisseria gonorrhoeae (including penicillinase-producing strains). NOTE: The efficacy of cefpodoxime in treating male patients with rectal infections caused by N.gonorrhoeae has not been established. Data do not support the use of cefpodoxime proxetil in the treatment of pharyngeal infections due to N.gonorrhoeae in men or women. Uncomplicated skin and skin structure infections caused by Staphylococcus aureus (including penicillinase-producing strains) or Streptococcus pyogenes . Abscesses should be surgically drained as clinically indicated. NOTE: In clinical trials, successful treatment of uncomplicated skin and skin structure infections was dose-related. The effective therapeutic dose for skin infections was higher than those used in other recommended indications (see DOSAGE AND ADMINISTRATION ). Acute maxillary sinusitis caused by Haemophilus influenzae (including beta-lactamase-producing strains), Streptococcus pneumoniae, and Moraxella catarrhalis . Uncomplicated urinary tract infections (cystitis) caused by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis , or Staphylococcus saprophyticus . NOTE: In considering the use of cefpodoxime proxetil in the treatment of cystitis, cefpodoxime proxetil’s lower bacterial eradication rates should be weighed against the increased eradication rates and different safety profiles of some other classes of approved agents (see CLINICAL STUDIES section). Appropriate specimens for bacteriological examination should be obtained in order to isolate and identify causative organisms and to determine their susceptibility to cefpodoxime. Therapy may be instituted while awaiting the results of these studies. Once these results become available, antimicrobial therapy should be adjusted accordingly. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefpodoxime proxetil tablets and other antibacterial drugs, Cefpodoxime proxetil tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:14a715fe-205a-4c79-baf0-6ac6b5eb3b7d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3504 biolink:treats MONDO:0001039 PMID:41385096 "[{""id"":""uuid:e7fa56f1-f981-416f-8f2d-4c9842363b93"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cd5dd6f4-c448-41ba-abf0-7922e9f2e009"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefpodoxime proxetil is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Recommended dosages, durations of therapy, and applicable patient populations vary among these infections. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute otitis media caused by Streptococcus pneumoniae (excluding penicillin-resistant strains), Streptococcus pyogenes, Haemophilus influenzae (including beta-lactamase-producing strains), or Moraxella (Branhamella) catarrhalis (including beta-lactamase-producing strains). Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes . NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefpodoxime proxetil is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefpodoxime proxetil for the prophylaxis of subsequent rheumatic fever are not available. Community-acquired pneumonia caused by S.pneumoniae or H.influenzae (including beta-lactamase-producing strains). Acute bacterial exacerbation of chronic bronchitis caused by S.pneumoniae, H.influenzae (non-beta-lactamase-producing strains only), or M.catarrhalis . Data are insufficient at this time to establish efficacy in patients with acute bacterial exacerbations of chronic bronchitis caused by beta-lactamase-producing strains of H.influenzae . Acute, uncomplicated urethral and cervical gonorrhea caused by Neisseria gonorrhoeae (including penicillinase-producing strains). Acute, uncomplicated ano-rectal infections in women due to Neisseria gonorrhoeae (including penicillinase-producing strains). NOTE: The efficacy of cefpodoxime in treating male patients with rectal infections caused by N.gonorrhoeae has not been established. Data do not support the use of cefpodoxime proxetil in the treatment of pharyngeal infections due to N.gonorrhoeae in men or women. Uncomplicated skin and skin structure infections caused by Staphylococcus aureus (including penicillinase-producing strains) or Streptococcus pyogenes . Abscesses should be surgically drained as clinically indicated. NOTE: In clinical trials, successful treatment of uncomplicated skin and skin structure infections was dose-related. The effective therapeutic dose for skin infections was higher than those used in other recommended indications (see DOSAGE AND ADMINISTRATION ). Acute maxillary sinusitis caused by Haemophilus influenzae (including beta-lactamase-producing strains), Streptococcus pneumoniae, and Moraxella catarrhalis . Uncomplicated urinary tract infections (cystitis) caused by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis , or Staphylococcus saprophyticus . NOTE: In considering the use of cefpodoxime proxetil in the treatment of cystitis, cefpodoxime proxetil’s lower bacterial eradication rates should be weighed against the increased eradication rates and different safety profiles of some other classes of approved agents (see CLINICAL STUDIES section). Appropriate specimens for bacteriological examination should be obtained in order to isolate and identify causative organisms and to determine their susceptibility to cefpodoxime. Therapy may be instituted while awaiting the results of these studies. Once these results become available, antimicrobial therapy should be adjusted accordingly. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefpodoxime proxetil tablets and other antibacterial drugs, Cefpodoxime proxetil tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:084a0f64-a81e-4a96-86b0-d9a031cd4ff0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3504 biolink:treats MONDO:0017767 PMID:41385096 "[{""id"":""uuid:eda5f7c8-68b7-4712-8829-11ce22da7c56"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fce40208-7945-48ff-80bd-f5db2cb0a728"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefpodoxime proxetil is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Recommended dosages, durations of therapy, and applicable patient populations vary among these infections. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute otitis media caused by Streptococcus pneumoniae (excluding penicillin-resistant strains), Streptococcus pyogenes, Haemophilus influenzae (including beta-lactamase-producing strains), or Moraxella (Branhamella) catarrhalis (including beta-lactamase-producing strains). Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes . NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefpodoxime proxetil is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefpodoxime proxetil for the prophylaxis of subsequent rheumatic fever are not available. Community-acquired pneumonia caused by S.pneumoniae or H.influenzae (including beta-lactamase-producing strains). Acute bacterial exacerbation of chronic bronchitis caused by S.pneumoniae, H.influenzae (non-beta-lactamase-producing strains only), or M.catarrhalis . Data are insufficient at this time to establish efficacy in patients with acute bacterial exacerbations of chronic bronchitis caused by beta-lactamase-producing strains of H.influenzae . Acute, uncomplicated urethral and cervical gonorrhea caused by Neisseria gonorrhoeae (including penicillinase-producing strains). Acute, uncomplicated ano-rectal infections in women due to Neisseria gonorrhoeae (including penicillinase-producing strains). NOTE: The efficacy of cefpodoxime in treating male patients with rectal infections caused by N.gonorrhoeae has not been established. Data do not support the use of cefpodoxime proxetil in the treatment of pharyngeal infections due to N.gonorrhoeae in men or women. Uncomplicated skin and skin structure infections caused by Staphylococcus aureus (including penicillinase-producing strains) or Streptococcus pyogenes . Abscesses should be surgically drained as clinically indicated. NOTE: In clinical trials, successful treatment of uncomplicated skin and skin structure infections was dose-related. The effective therapeutic dose for skin infections was higher than those used in other recommended indications (see DOSAGE AND ADMINISTRATION ). Acute maxillary sinusitis caused by Haemophilus influenzae (including beta-lactamase-producing strains), Streptococcus pneumoniae, and Moraxella catarrhalis . Uncomplicated urinary tract infections (cystitis) caused by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis , or Staphylococcus saprophyticus . NOTE: In considering the use of cefpodoxime proxetil in the treatment of cystitis, cefpodoxime proxetil’s lower bacterial eradication rates should be weighed against the increased eradication rates and different safety profiles of some other classes of approved agents (see CLINICAL STUDIES section). Appropriate specimens for bacteriological examination should be obtained in order to isolate and identify causative organisms and to determine their susceptibility to cefpodoxime. Therapy may be instituted while awaiting the results of these studies. Once these results become available, antimicrobial therapy should be adjusted accordingly. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefpodoxime proxetil tablets and other antibacterial drugs, Cefpodoxime proxetil tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:e937edc7-74c2-424f-a379-0cb9f4c5bf25 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3504 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:8604fa12-46e8-4026-96e7-9eb4b4d0c828"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:86157a0f-9b6e-4160-ab98-f41f14dbccd1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefpodoxime proxetil is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Recommended dosages, durations of therapy, and applicable patient populations vary among these infections. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute otitis media caused by Streptococcus pneumoniae (excluding penicillin-resistant strains), Streptococcus pyogenes, Haemophilus influenzae (including beta-lactamase-producing strains), or Moraxella (Branhamella) catarrhalis (including beta-lactamase-producing strains). Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes . NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefpodoxime proxetil is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefpodoxime proxetil for the prophylaxis of subsequent rheumatic fever are not available. Community-acquired pneumonia caused by S.pneumoniae or H.influenzae (including beta-lactamase-producing strains). Acute bacterial exacerbation of chronic bronchitis caused by S.pneumoniae, H.influenzae (non-beta-lactamase-producing strains only), or M.catarrhalis . Data are insufficient at this time to establish efficacy in patients with acute bacterial exacerbations of chronic bronchitis caused by beta-lactamase-producing strains of H.influenzae . Acute, uncomplicated urethral and cervical gonorrhea caused by Neisseria gonorrhoeae (including penicillinase-producing strains). Acute, uncomplicated ano-rectal infections in women due to Neisseria gonorrhoeae (including penicillinase-producing strains). NOTE: The efficacy of cefpodoxime in treating male patients with rectal infections caused by N.gonorrhoeae has not been established. Data do not support the use of cefpodoxime proxetil in the treatment of pharyngeal infections due to N.gonorrhoeae in men or women. Uncomplicated skin and skin structure infections caused by Staphylococcus aureus (including penicillinase-producing strains) or Streptococcus pyogenes . Abscesses should be surgically drained as clinically indicated. NOTE: In clinical trials, successful treatment of uncomplicated skin and skin structure infections was dose-related. The effective therapeutic dose for skin infections was higher than those used in other recommended indications (see DOSAGE AND ADMINISTRATION ). Acute maxillary sinusitis caused by Haemophilus influenzae (including beta-lactamase-producing strains), Streptococcus pneumoniae, and Moraxella catarrhalis . Uncomplicated urinary tract infections (cystitis) caused by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis , or Staphylococcus saprophyticus . NOTE: In considering the use of cefpodoxime proxetil in the treatment of cystitis, cefpodoxime proxetil’s lower bacterial eradication rates should be weighed against the increased eradication rates and different safety profiles of some other classes of approved agents (see CLINICAL STUDIES section). Appropriate specimens for bacteriological examination should be obtained in order to isolate and identify causative organisms and to determine their susceptibility to cefpodoxime. Therapy may be instituted while awaiting the results of these studies. Once these results become available, antimicrobial therapy should be adjusted accordingly. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefpodoxime proxetil tablets and other antibacterial drugs, Cefpodoxime proxetil tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:d2a13b7a-c4c4-4ba8-ab4a-d7d59a7685e8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3504 biolink:treats UMLS:C1735365 PMID:41385096 "[{""id"":""uuid:642f6ae1-95a8-4010-b6f2-cb0ef5d776a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7f11e6e4-5f8d-49e9-984d-a85312a8cdb6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefpodoxime proxetil is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Recommended dosages, durations of therapy, and applicable patient populations vary among these infections. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute otitis media caused by Streptococcus pneumoniae (excluding penicillin-resistant strains), Streptococcus pyogenes, Haemophilus influenzae (including beta-lactamase-producing strains), or Moraxella (Branhamella) catarrhalis (including beta-lactamase-producing strains). Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes . NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefpodoxime proxetil is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefpodoxime proxetil for the prophylaxis of subsequent rheumatic fever are not available. Community-acquired pneumonia caused by S.pneumoniae or H.influenzae (including beta-lactamase-producing strains). Acute bacterial exacerbation of chronic bronchitis caused by S.pneumoniae, H.influenzae (non-beta-lactamase-producing strains only), or M.catarrhalis . Data are insufficient at this time to establish efficacy in patients with acute bacterial exacerbations of chronic bronchitis caused by beta-lactamase-producing strains of H.influenzae . Acute, uncomplicated urethral and cervical gonorrhea caused by Neisseria gonorrhoeae (including penicillinase-producing strains). Acute, uncomplicated ano-rectal infections in women due to Neisseria gonorrhoeae (including penicillinase-producing strains). NOTE: The efficacy of cefpodoxime in treating male patients with rectal infections caused by N.gonorrhoeae has not been established. Data do not support the use of cefpodoxime proxetil in the treatment of pharyngeal infections due to N.gonorrhoeae in men or women. Uncomplicated skin and skin structure infections caused by Staphylococcus aureus (including penicillinase-producing strains) or Streptococcus pyogenes . Abscesses should be surgically drained as clinically indicated. NOTE: In clinical trials, successful treatment of uncomplicated skin and skin structure infections was dose-related. The effective therapeutic dose for skin infections was higher than those used in other recommended indications (see DOSAGE AND ADMINISTRATION ). Acute maxillary sinusitis caused by Haemophilus influenzae (including beta-lactamase-producing strains), Streptococcus pneumoniae, and Moraxella catarrhalis . Uncomplicated urinary tract infections (cystitis) caused by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis , or Staphylococcus saprophyticus . NOTE: In considering the use of cefpodoxime proxetil in the treatment of cystitis, cefpodoxime proxetil’s lower bacterial eradication rates should be weighed against the increased eradication rates and different safety profiles of some other classes of approved agents (see CLINICAL STUDIES section). Appropriate specimens for bacteriological examination should be obtained in order to isolate and identify causative organisms and to determine their susceptibility to cefpodoxime. Therapy may be instituted while awaiting the results of these studies. Once these results become available, antimicrobial therapy should be adjusted accordingly. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefpodoxime proxetil tablets and other antibacterial drugs, Cefpodoxime proxetil tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:eb376abf-aa01-46de-ba3c-c6af415bce0c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3504 biolink:treats MONDO:0004277 PMID:41385096 "[{""id"":""uuid:ec956def-2f1d-44d1-81bc-d03a0c5243ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:96391373-ad79-455c-8638-ba9552184fb9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefpodoxime proxetil is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Recommended dosages, durations of therapy, and applicable patient populations vary among these infections. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute otitis media caused by Streptococcus pneumoniae (excluding penicillin-resistant strains), Streptococcus pyogenes, Haemophilus influenzae (including beta-lactamase-producing strains), or Moraxella (Branhamella) catarrhalis (including beta-lactamase-producing strains). Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes . NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefpodoxime proxetil is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefpodoxime proxetil for the prophylaxis of subsequent rheumatic fever are not available. Community-acquired pneumonia caused by S.pneumoniae or H.influenzae (including beta-lactamase-producing strains). Acute bacterial exacerbation of chronic bronchitis caused by S.pneumoniae, H.influenzae (non-beta-lactamase-producing strains only), or M.catarrhalis . Data are insufficient at this time to establish efficacy in patients with acute bacterial exacerbations of chronic bronchitis caused by beta-lactamase-producing strains of H.influenzae . Acute, uncomplicated urethral and cervical gonorrhea caused by Neisseria gonorrhoeae (including penicillinase-producing strains). Acute, uncomplicated ano-rectal infections in women due to Neisseria gonorrhoeae (including penicillinase-producing strains). NOTE: The efficacy of cefpodoxime in treating male patients with rectal infections caused by N.gonorrhoeae has not been established. Data do not support the use of cefpodoxime proxetil in the treatment of pharyngeal infections due to N.gonorrhoeae in men or women. Uncomplicated skin and skin structure infections caused by Staphylococcus aureus (including penicillinase-producing strains) or Streptococcus pyogenes . Abscesses should be surgically drained as clinically indicated. NOTE: In clinical trials, successful treatment of uncomplicated skin and skin structure infections was dose-related. The effective therapeutic dose for skin infections was higher than those used in other recommended indications (see DOSAGE AND ADMINISTRATION ). Acute maxillary sinusitis caused by Haemophilus influenzae (including beta-lactamase-producing strains), Streptococcus pneumoniae, and Moraxella catarrhalis . Uncomplicated urinary tract infections (cystitis) caused by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis , or Staphylococcus saprophyticus . NOTE: In considering the use of cefpodoxime proxetil in the treatment of cystitis, cefpodoxime proxetil’s lower bacterial eradication rates should be weighed against the increased eradication rates and different safety profiles of some other classes of approved agents (see CLINICAL STUDIES section). Appropriate specimens for bacteriological examination should be obtained in order to isolate and identify causative organisms and to determine their susceptibility to cefpodoxime. Therapy may be instituted while awaiting the results of these studies. Once these results become available, antimicrobial therapy should be adjusted accordingly. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefpodoxime proxetil tablets and other antibacterial drugs, Cefpodoxime proxetil tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:c876a17c-68d3-409e-9cc6-fd104fe51957 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3504 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:1132daa7-766a-4930-a9ae-7a0f72fb3d80"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ca275f4e-4edb-4730-bf2a-650df7a28c7d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefpodoxime proxetil is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Recommended dosages, durations of therapy, and applicable patient populations vary among these infections. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute otitis media caused by Streptococcus pneumoniae (excluding penicillin-resistant strains), Streptococcus pyogenes, Haemophilus influenzae (including beta-lactamase-producing strains), or Moraxella (Branhamella) catarrhalis (including beta-lactamase-producing strains). Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes . NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefpodoxime proxetil is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefpodoxime proxetil for the prophylaxis of subsequent rheumatic fever are not available. Community-acquired pneumonia caused by S.pneumoniae or H.influenzae (including beta-lactamase-producing strains). Acute bacterial exacerbation of chronic bronchitis caused by S.pneumoniae, H.influenzae (non-beta-lactamase-producing strains only), or M.catarrhalis . Data are insufficient at this time to establish efficacy in patients with acute bacterial exacerbations of chronic bronchitis caused by beta-lactamase-producing strains of H.influenzae . Acute, uncomplicated urethral and cervical gonorrhea caused by Neisseria gonorrhoeae (including penicillinase-producing strains). Acute, uncomplicated ano-rectal infections in women due to Neisseria gonorrhoeae (including penicillinase-producing strains). NOTE: The efficacy of cefpodoxime in treating male patients with rectal infections caused by N.gonorrhoeae has not been established. Data do not support the use of cefpodoxime proxetil in the treatment of pharyngeal infections due to N.gonorrhoeae in men or women. Uncomplicated skin and skin structure infections caused by Staphylococcus aureus (including penicillinase-producing strains) or Streptococcus pyogenes . Abscesses should be surgically drained as clinically indicated. NOTE: In clinical trials, successful treatment of uncomplicated skin and skin structure infections was dose-related. The effective therapeutic dose for skin infections was higher than those used in other recommended indications (see DOSAGE AND ADMINISTRATION ). Acute maxillary sinusitis caused by Haemophilus influenzae (including beta-lactamase-producing strains), Streptococcus pneumoniae, and Moraxella catarrhalis . Uncomplicated urinary tract infections (cystitis) caused by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis , or Staphylococcus saprophyticus . NOTE: In considering the use of cefpodoxime proxetil in the treatment of cystitis, cefpodoxime proxetil’s lower bacterial eradication rates should be weighed against the increased eradication rates and different safety profiles of some other classes of approved agents (see CLINICAL STUDIES section). Appropriate specimens for bacteriological examination should be obtained in order to isolate and identify causative organisms and to determine their susceptibility to cefpodoxime. Therapy may be instituted while awaiting the results of these studies. Once these results become available, antimicrobial therapy should be adjusted accordingly. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefpodoxime proxetil tablets and other antibacterial drugs, Cefpodoxime proxetil tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:b5aef0a1-c792-4b59-9754-32b7ad2c5d33 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3504 biolink:treats MONDO:0002186 PMID:41385096 "[{""id"":""uuid:2e5a7f06-1172-4623-9fd3-7437544451eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:73014133-c964-4581-b03c-eadec4c4ee86"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefpodoxime proxetil is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Recommended dosages, durations of therapy, and applicable patient populations vary among these infections. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute otitis media caused by Streptococcus pneumoniae (excluding penicillin-resistant strains), Streptococcus pyogenes, Haemophilus influenzae (including beta-lactamase-producing strains), or Moraxella (Branhamella) catarrhalis (including beta-lactamase-producing strains). Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes . NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefpodoxime proxetil is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefpodoxime proxetil for the prophylaxis of subsequent rheumatic fever are not available. Community-acquired pneumonia caused by S.pneumoniae or H.influenzae (including beta-lactamase-producing strains). Acute bacterial exacerbation of chronic bronchitis caused by S.pneumoniae, H.influenzae (non-beta-lactamase-producing strains only), or M.catarrhalis . Data are insufficient at this time to establish efficacy in patients with acute bacterial exacerbations of chronic bronchitis caused by beta-lactamase-producing strains of H.influenzae . Acute, uncomplicated urethral and cervical gonorrhea caused by Neisseria gonorrhoeae (including penicillinase-producing strains). Acute, uncomplicated ano-rectal infections in women due to Neisseria gonorrhoeae (including penicillinase-producing strains). NOTE: The efficacy of cefpodoxime in treating male patients with rectal infections caused by N.gonorrhoeae has not been established. Data do not support the use of cefpodoxime proxetil in the treatment of pharyngeal infections due to N.gonorrhoeae in men or women. Uncomplicated skin and skin structure infections caused by Staphylococcus aureus (including penicillinase-producing strains) or Streptococcus pyogenes . Abscesses should be surgically drained as clinically indicated. NOTE: In clinical trials, successful treatment of uncomplicated skin and skin structure infections was dose-related. The effective therapeutic dose for skin infections was higher than those used in other recommended indications (see DOSAGE AND ADMINISTRATION ). Acute maxillary sinusitis caused by Haemophilus influenzae (including beta-lactamase-producing strains), Streptococcus pneumoniae, and Moraxella catarrhalis . Uncomplicated urinary tract infections (cystitis) caused by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis , or Staphylococcus saprophyticus . NOTE: In considering the use of cefpodoxime proxetil in the treatment of cystitis, cefpodoxime proxetil’s lower bacterial eradication rates should be weighed against the increased eradication rates and different safety profiles of some other classes of approved agents (see CLINICAL STUDIES section). Appropriate specimens for bacteriological examination should be obtained in order to isolate and identify causative organisms and to determine their susceptibility to cefpodoxime. Therapy may be instituted while awaiting the results of these studies. Once these results become available, antimicrobial therapy should be adjusted accordingly. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefpodoxime proxetil tablets and other antibacterial drugs, Cefpodoxime proxetil tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:46847fc1-f231-412d-a346-14bd92d5c6ba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3504 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:16ce0622-4dba-4ab9-885e-c8edc1c74cd4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5835a66c-7a60-4663-b6b9-b2baeb1d48ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefpodoxime proxetil is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Recommended dosages, durations of therapy, and applicable patient populations vary among these infections. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute otitis media caused by Streptococcus pneumoniae (excluding penicillin-resistant strains), Streptococcus pyogenes, Haemophilus influenzae (including beta-lactamase-producing strains), or Moraxella (Branhamella) catarrhalis (including beta-lactamase-producing strains). Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes . NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefpodoxime proxetil is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefpodoxime proxetil for the prophylaxis of subsequent rheumatic fever are not available. Community-acquired pneumonia caused by S.pneumoniae or H.influenzae (including beta-lactamase-producing strains). Acute bacterial exacerbation of chronic bronchitis caused by S.pneumoniae, H.influenzae (non-beta-lactamase-producing strains only), or M.catarrhalis . Data are insufficient at this time to establish efficacy in patients with acute bacterial exacerbations of chronic bronchitis caused by beta-lactamase-producing strains of H.influenzae . Acute, uncomplicated urethral and cervical gonorrhea caused by Neisseria gonorrhoeae (including penicillinase-producing strains). Acute, uncomplicated ano-rectal infections in women due to Neisseria gonorrhoeae (including penicillinase-producing strains). NOTE: The efficacy of cefpodoxime in treating male patients with rectal infections caused by N.gonorrhoeae has not been established. Data do not support the use of cefpodoxime proxetil in the treatment of pharyngeal infections due to N.gonorrhoeae in men or women. Uncomplicated skin and skin structure infections caused by Staphylococcus aureus (including penicillinase-producing strains) or Streptococcus pyogenes . Abscesses should be surgically drained as clinically indicated. NOTE: In clinical trials, successful treatment of uncomplicated skin and skin structure infections was dose-related. The effective therapeutic dose for skin infections was higher than those used in other recommended indications (see DOSAGE AND ADMINISTRATION ). Acute maxillary sinusitis caused by Haemophilus influenzae (including beta-lactamase-producing strains), Streptococcus pneumoniae, and Moraxella catarrhalis . Uncomplicated urinary tract infections (cystitis) caused by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis , or Staphylococcus saprophyticus . NOTE: In considering the use of cefpodoxime proxetil in the treatment of cystitis, cefpodoxime proxetil’s lower bacterial eradication rates should be weighed against the increased eradication rates and different safety profiles of some other classes of approved agents (see CLINICAL STUDIES section). Appropriate specimens for bacteriological examination should be obtained in order to isolate and identify causative organisms and to determine their susceptibility to cefpodoxime. Therapy may be instituted while awaiting the results of these studies. Once these results become available, antimicrobial therapy should be adjusted accordingly. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefpodoxime proxetil tablets and other antibacterial drugs, Cefpodoxime proxetil tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:cbd3f536-574f-45ce-a6bc-08e2e3e55596 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7956 biolink:treats MONDO:0005770 PMID:41385096 "[{""id"":""uuid:80af40f9-10a2-4c08-9df3-cb5551df96aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f7c568e4-7281-4cd6-be63-bab356686a0b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Famciclovir tablet, a prodrug of penciclovir, is a deoxynucleoside analog DNA polymerase inhibitor indicated for: Immunocompetent Adult Patients ( 1.1 ) • Herpes labialis (cold sores) o Treatment of recurrent episodes • Genital herpes o Treatment of recurrent episodes o Suppressive therapy of recurrent episodes • Herpes zoster (shingles) Human Immunodeficiency Virus (HIV)-Infected Adult Patients ( 1.2 ) • Treatment of recurrent episodes of orolabial or genital herpes Limitation of Use The efficacy and safety of famciclovir tablets have not been established for: • Patients with first episode of genital herpes • Patients with ophthalmic zoster • Immunocompromised patients other than for the treatment of recurrent episodes of orolabial or genital herpes in HIV-infected patients • Black and African American patients with recurrent genital herpes uuid:1ec9f82d-a5d0-4e05-bdf9-b367e1e416d0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7956 biolink:treats MONDO:0005609 PMID:41385096 "[{""id"":""uuid:fd2578aa-0a0c-45b8-9ed3-e52840b055f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:63e256b2-f158-4bd2-8941-86616f182b96"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Famciclovir tablet, a prodrug of penciclovir, is a deoxynucleoside analog DNA polymerase inhibitor indicated for: Immunocompetent Adult Patients ( 1.1 ) • Herpes labialis (cold sores) o Treatment of recurrent episodes • Genital herpes o Treatment of recurrent episodes o Suppressive therapy of recurrent episodes • Herpes zoster (shingles) Human Immunodeficiency Virus (HIV)-Infected Adult Patients ( 1.2 ) • Treatment of recurrent episodes of orolabial or genital herpes Limitation of Use The efficacy and safety of famciclovir tablets have not been established for: • Patients with first episode of genital herpes • Patients with ophthalmic zoster • Immunocompromised patients other than for the treatment of recurrent episodes of orolabial or genital herpes in HIV-infected patients • Black and African American patients with recurrent genital herpes uuid:d2b594fe-b604-4090-a573-9fde8e5a72ae biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:44185 biolink:treats UMLS:C0948840 PMID:41385096 "[{""id"":""uuid:fc4ceafa-cae0-4c11-a5d9-6187976d0853"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5474a281-730a-4e13-8941-10c2b4c56fc1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methotrexate is indicated in the treatment of gestational choriocarcinoma, chorioadenoma destruens and hydatidiform mole. In acute lymphocytic leukemia, methotrexate is indicated in the prophylaxis of meningeal leukemia and is used in maintenance therapy in combination with other chemotherapeutic agents. Methotrexate is also indicated in the treatment of meningeal leukemia. Methotrexate is used alone or in combination with other anticancer agents in the treatment of breast cancer, epidermoid cancers of the head and neck, advanced mycosis fungoides (cutaneous T cell lymphoma), and lung cancer, particularly squamous cell and small cell types. Methotrexate is also used in combination with other chemotherapeutic agents in the treatment of advanced stage non-Hodgkin’s lymphomas. Methotrexate in high doses followed by leucovorin rescue in combination with other chemotherapeutic agents is effective in prolonging relapse-free survival in patients with non-metastatic osteosarcoma who have undergone surgical resection or amputation for the primary tumor. uuid:5d20ebd8-d9fd-4b8e-b9c4-13a722812941 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15940 biolink:treats HP:0003124 PMID:41385096 "[{""id"":""uuid:878aca0a-bace-4268-a91f-2c3a59071f71"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:62ce4352-178f-4e94-8a29-41c8cad1e3d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] I. Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Nicotinic acid, alone or in combination with a bile-acid binding resin, is indicated as an adjunct to diet for the reduction of elevated total and LDL cholesterol levels in patients with primary hypercholesterolemia (Types IIa and IIb) † , when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate (see also the NCEP treatment guidelines 6 ). Prior to initiating therapy with nicotinic acid, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure total cholesterol, HDL cholesterol, and triglycerides. II. Nicotinic acid is also indicated as adjunctive therapy for the treatment of adult patients with very high serum triglyceride levels (Types IV and V hyperlipidemia)† who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Such patients typically have serum triglyceride levels over 2,000 mg/dL and have elevations of VLDL cholesterol as well as fasting chylomicrons (Type V hyperlipidemia) † . Subjects who consistently have total serum or plasma triglycerides below 1,000 mg/dL are unlikely to develop pancreatitis. Therapy with nicotinic acid may be considered for those subjects with triglyceride elevations between 1,000 and 2,000 mg/dL who have a history of pancreatitis or of recurrent abdominal pain typical of pancreatitis. Some Type IV patients with triglycerides under 1,000 mg/dL may, through dietary or alcoholic indiscretion, convert to a Type V pattern with massive triglyceride elevations accompanying fasting chylomicronemia, but the influence of nicotinic acid therapy on the risk of pancreatitis in such situations has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of VLDL. Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV, and V hyperlipoproteinemia 7 . † Classification of Hyperlipoproteinemias Lipoproteins Lipid Elevations Type Elevated Major Minor C = cholesterol, TG = triglycerides LDL = low-density lipoprotein VLDL = very low-density lipoprotein IDL = intermediate-density lipoprotein I (rare) Chylomicrons TG ↑→ C IIa LDL C ..... IIb LDL, VLDL C TG III (rare) IDL C/TG ..... IV VLDL TG ↑→ C V (rare) Chylomicrons, VLD TG ↑→ C uuid:707e34e2-f4d0-4896-8100-0ca7958b1ae0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15940 biolink:treats UMLS:C0342879 PMID:41385096 "[{""id"":""uuid:508dafb8-0b1a-425e-9625-81a11d9e01f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:27b4f1d3-cfde-4f7e-992b-b3465a1949a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] I. Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Nicotinic acid, alone or in combination with a bile-acid binding resin, is indicated as an adjunct to diet for the reduction of elevated total and LDL cholesterol levels in patients with primary hypercholesterolemia (Types IIa and IIb) † , when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate (see also the NCEP treatment guidelines 6 ). Prior to initiating therapy with nicotinic acid, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure total cholesterol, HDL cholesterol, and triglycerides. II. Nicotinic acid is also indicated as adjunctive therapy for the treatment of adult patients with very high serum triglyceride levels (Types IV and V hyperlipidemia)† who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Such patients typically have serum triglyceride levels over 2,000 mg/dL and have elevations of VLDL cholesterol as well as fasting chylomicrons (Type V hyperlipidemia) † . Subjects who consistently have total serum or plasma triglycerides below 1,000 mg/dL are unlikely to develop pancreatitis. Therapy with nicotinic acid may be considered for those subjects with triglyceride elevations between 1,000 and 2,000 mg/dL who have a history of pancreatitis or of recurrent abdominal pain typical of pancreatitis. Some Type IV patients with triglycerides under 1,000 mg/dL may, through dietary or alcoholic indiscretion, convert to a Type V pattern with massive triglyceride elevations accompanying fasting chylomicronemia, but the influence of nicotinic acid therapy on the risk of pancreatitis in such situations has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of VLDL. Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV, and V hyperlipoproteinemia 7 . † Classification of Hyperlipoproteinemias Lipoproteins Lipid Elevations Type Elevated Major Minor C = cholesterol, TG = triglycerides LDL = low-density lipoprotein VLDL = very low-density lipoprotein IDL = intermediate-density lipoprotein I (rare) Chylomicrons TG ↑→ C IIa LDL C ..... IIb LDL, VLDL C TG III (rare) IDL C/TG ..... IV VLDL TG ↑→ C V (rare) Chylomicrons, VLD TG ↑→ C uuid:170072e4-5251-45b4-9127-dd5f4ddcc2cb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15940 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:13feefe3-2cbc-4a38-920d-6f0f448cc9fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e601d243-f283-412e-b125-4492e455e229"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] I. Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Nicotinic acid, alone or in combination with a bile-acid binding resin, is indicated as an adjunct to diet for the reduction of elevated total and LDL cholesterol levels in patients with primary hypercholesterolemia (Types IIa and IIb) † , when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate (see also the NCEP treatment guidelines 6 ). Prior to initiating therapy with nicotinic acid, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure total cholesterol, HDL cholesterol, and triglycerides. II. Nicotinic acid is also indicated as adjunctive therapy for the treatment of adult patients with very high serum triglyceride levels (Types IV and V hyperlipidemia)† who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Such patients typically have serum triglyceride levels over 2,000 mg/dL and have elevations of VLDL cholesterol as well as fasting chylomicrons (Type V hyperlipidemia) † . Subjects who consistently have total serum or plasma triglycerides below 1,000 mg/dL are unlikely to develop pancreatitis. Therapy with nicotinic acid may be considered for those subjects with triglyceride elevations between 1,000 and 2,000 mg/dL who have a history of pancreatitis or of recurrent abdominal pain typical of pancreatitis. Some Type IV patients with triglycerides under 1,000 mg/dL may, through dietary or alcoholic indiscretion, convert to a Type V pattern with massive triglyceride elevations accompanying fasting chylomicronemia, but the influence of nicotinic acid therapy on the risk of pancreatitis in such situations has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of VLDL. Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV, and V hyperlipoproteinemia 7 . † Classification of Hyperlipoproteinemias Lipoproteins Lipid Elevations Type Elevated Major Minor C = cholesterol, TG = triglycerides LDL = low-density lipoprotein VLDL = very low-density lipoprotein IDL = intermediate-density lipoprotein I (rare) Chylomicrons TG ↑→ C IIa LDL C ..... IIb LDL, VLDL C TG III (rare) IDL C/TG ..... IV VLDL TG ↑→ C V (rare) Chylomicrons, VLD TG ↑→ C uuid:711c38cf-06e9-4180-922d-4e7b79d8fa78 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15940 biolink:treats MONDO:0005420 PMID:41385096 "[{""id"":""uuid:925b1900-cf82-4310-869d-7737b373f407"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a38248a8-c514-4b73-ab9c-1dc9eefc83c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] I. Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Nicotinic acid, alone or in combination with a bile-acid binding resin, is indicated as an adjunct to diet for the reduction of elevated total and LDL cholesterol levels in patients with primary hypercholesterolemia (Types IIa and IIb) † , when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate (see also the NCEP treatment guidelines 6 ). Prior to initiating therapy with nicotinic acid, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure total cholesterol, HDL cholesterol, and triglycerides. II. Nicotinic acid is also indicated as adjunctive therapy for the treatment of adult patients with very high serum triglyceride levels (Types IV and V hyperlipidemia)† who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Such patients typically have serum triglyceride levels over 2,000 mg/dL and have elevations of VLDL cholesterol as well as fasting chylomicrons (Type V hyperlipidemia) † . Subjects who consistently have total serum or plasma triglycerides below 1,000 mg/dL are unlikely to develop pancreatitis. Therapy with nicotinic acid may be considered for those subjects with triglyceride elevations between 1,000 and 2,000 mg/dL who have a history of pancreatitis or of recurrent abdominal pain typical of pancreatitis. Some Type IV patients with triglycerides under 1,000 mg/dL may, through dietary or alcoholic indiscretion, convert to a Type V pattern with massive triglyceride elevations accompanying fasting chylomicronemia, but the influence of nicotinic acid therapy on the risk of pancreatitis in such situations has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of VLDL. Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV, and V hyperlipoproteinemia 7 . † Classification of Hyperlipoproteinemias Lipoproteins Lipid Elevations Type Elevated Major Minor C = cholesterol, TG = triglycerides LDL = low-density lipoprotein VLDL = very low-density lipoprotein IDL = intermediate-density lipoprotein I (rare) Chylomicrons TG ↑→ C IIa LDL C ..... IIb LDL, VLDL C TG III (rare) IDL C/TG ..... IV VLDL TG ↑→ C V (rare) Chylomicrons, VLD TG ↑→ C uuid:ab6add5e-d350-42f7-9dfb-0a8a922b8c0d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15940 biolink:treats MONDO:0005377 PMID:41385096 "[{""id"":""uuid:1bda7d83-9a73-4fb5-b85b-79a2f83b27f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:486eb685-0ab8-474e-a6c8-bd62b2952bb8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] I. Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Nicotinic acid, alone or in combination with a bile-acid binding resin, is indicated as an adjunct to diet for the reduction of elevated total and LDL cholesterol levels in patients with primary hypercholesterolemia (Types IIa and IIb) † , when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate (see also the NCEP treatment guidelines 6 ). Prior to initiating therapy with nicotinic acid, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure total cholesterol, HDL cholesterol, and triglycerides. II. Nicotinic acid is also indicated as adjunctive therapy for the treatment of adult patients with very high serum triglyceride levels (Types IV and V hyperlipidemia)† who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Such patients typically have serum triglyceride levels over 2,000 mg/dL and have elevations of VLDL cholesterol as well as fasting chylomicrons (Type V hyperlipidemia) † . Subjects who consistently have total serum or plasma triglycerides below 1,000 mg/dL are unlikely to develop pancreatitis. Therapy with nicotinic acid may be considered for those subjects with triglyceride elevations between 1,000 and 2,000 mg/dL who have a history of pancreatitis or of recurrent abdominal pain typical of pancreatitis. Some Type IV patients with triglycerides under 1,000 mg/dL may, through dietary or alcoholic indiscretion, convert to a Type V pattern with massive triglyceride elevations accompanying fasting chylomicronemia, but the influence of nicotinic acid therapy on the risk of pancreatitis in such situations has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of VLDL. Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV, and V hyperlipoproteinemia 7 . † Classification of Hyperlipoproteinemias Lipoproteins Lipid Elevations Type Elevated Major Minor C = cholesterol, TG = triglycerides LDL = low-density lipoprotein VLDL = very low-density lipoprotein IDL = intermediate-density lipoprotein I (rare) Chylomicrons TG ↑→ C IIa LDL C ..... IIb LDL, VLDL C TG III (rare) IDL C/TG ..... IV VLDL TG ↑→ C V (rare) Chylomicrons, VLD TG ↑→ C uuid:d4150e68-cca1-4651-994f-b5e5170ed79e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15940 biolink:treats UMLS:C0259744 PMID:41385096 "[{""id"":""uuid:a8f0f0e8-ed53-4b11-afab-3654cd90d49f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a3470c9f-92cf-4acd-9ec9-d1b11b847a67"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] I. Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Nicotinic acid, alone or in combination with a bile-acid binding resin, is indicated as an adjunct to diet for the reduction of elevated total and LDL cholesterol levels in patients with primary hypercholesterolemia (Types IIa and IIb) † , when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate (see also the NCEP treatment guidelines 6 ). Prior to initiating therapy with nicotinic acid, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure total cholesterol, HDL cholesterol, and triglycerides. II. Nicotinic acid is also indicated as adjunctive therapy for the treatment of adult patients with very high serum triglyceride levels (Types IV and V hyperlipidemia)† who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Such patients typically have serum triglyceride levels over 2,000 mg/dL and have elevations of VLDL cholesterol as well as fasting chylomicrons (Type V hyperlipidemia) † . Subjects who consistently have total serum or plasma triglycerides below 1,000 mg/dL are unlikely to develop pancreatitis. Therapy with nicotinic acid may be considered for those subjects with triglyceride elevations between 1,000 and 2,000 mg/dL who have a history of pancreatitis or of recurrent abdominal pain typical of pancreatitis. Some Type IV patients with triglycerides under 1,000 mg/dL may, through dietary or alcoholic indiscretion, convert to a Type V pattern with massive triglyceride elevations accompanying fasting chylomicronemia, but the influence of nicotinic acid therapy on the risk of pancreatitis in such situations has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of VLDL. Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV, and V hyperlipoproteinemia 7 . † Classification of Hyperlipoproteinemias Lipoproteins Lipid Elevations Type Elevated Major Minor C = cholesterol, TG = triglycerides LDL = low-density lipoprotein VLDL = very low-density lipoprotein IDL = intermediate-density lipoprotein I (rare) Chylomicrons TG ↑→ C IIa LDL C ..... IIb LDL, VLDL C TG III (rare) IDL C/TG ..... IV VLDL TG ↑→ C V (rare) Chylomicrons, VLD TG ↑→ C uuid:b22d860e-9fbb-47d4-a569-09fb1e37a452 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15940 biolink:treats MONDO:0006874 PMID:41385096 "[{""id"":""uuid:0ee0324a-3c1f-467d-9bc3-2e57d63a3c3e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:afdb73e0-9089-4f4f-8676-4ae4b1a95294"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] I. Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Nicotinic acid, alone or in combination with a bile-acid binding resin, is indicated as an adjunct to diet for the reduction of elevated total and LDL cholesterol levels in patients with primary hypercholesterolemia (Types IIa and IIb) † , when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate (see also the NCEP treatment guidelines 6 ). Prior to initiating therapy with nicotinic acid, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure total cholesterol, HDL cholesterol, and triglycerides. II. Nicotinic acid is also indicated as adjunctive therapy for the treatment of adult patients with very high serum triglyceride levels (Types IV and V hyperlipidemia)† who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Such patients typically have serum triglyceride levels over 2,000 mg/dL and have elevations of VLDL cholesterol as well as fasting chylomicrons (Type V hyperlipidemia) † . Subjects who consistently have total serum or plasma triglycerides below 1,000 mg/dL are unlikely to develop pancreatitis. Therapy with nicotinic acid may be considered for those subjects with triglyceride elevations between 1,000 and 2,000 mg/dL who have a history of pancreatitis or of recurrent abdominal pain typical of pancreatitis. Some Type IV patients with triglycerides under 1,000 mg/dL may, through dietary or alcoholic indiscretion, convert to a Type V pattern with massive triglyceride elevations accompanying fasting chylomicronemia, but the influence of nicotinic acid therapy on the risk of pancreatitis in such situations has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of VLDL. Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV, and V hyperlipoproteinemia 7 . † Classification of Hyperlipoproteinemias Lipoproteins Lipid Elevations Type Elevated Major Minor C = cholesterol, TG = triglycerides LDL = low-density lipoprotein VLDL = very low-density lipoprotein IDL = intermediate-density lipoprotein I (rare) Chylomicrons TG ↑→ C IIa LDL C ..... IIb LDL, VLDL C TG III (rare) IDL C/TG ..... IV VLDL TG ↑→ C V (rare) Chylomicrons, VLD TG ↑→ C uuid:935c6608-515a-4a83-bd0e-343c781b05ed biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15940 biolink:treats MONDO:0009387 PMID:41385096 "[{""id"":""uuid:7f56802c-8960-4351-84f1-275715fdf35e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3bbf8f85-287d-410d-968b-5ed37323fdac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] I. Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Nicotinic acid, alone or in combination with a bile-acid binding resin, is indicated as an adjunct to diet for the reduction of elevated total and LDL cholesterol levels in patients with primary hypercholesterolemia (Types IIa and IIb) † , when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate (see also the NCEP treatment guidelines 6 ). Prior to initiating therapy with nicotinic acid, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure total cholesterol, HDL cholesterol, and triglycerides. II. Nicotinic acid is also indicated as adjunctive therapy for the treatment of adult patients with very high serum triglyceride levels (Types IV and V hyperlipidemia)† who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Such patients typically have serum triglyceride levels over 2,000 mg/dL and have elevations of VLDL cholesterol as well as fasting chylomicrons (Type V hyperlipidemia) † . Subjects who consistently have total serum or plasma triglycerides below 1,000 mg/dL are unlikely to develop pancreatitis. Therapy with nicotinic acid may be considered for those subjects with triglyceride elevations between 1,000 and 2,000 mg/dL who have a history of pancreatitis or of recurrent abdominal pain typical of pancreatitis. Some Type IV patients with triglycerides under 1,000 mg/dL may, through dietary or alcoholic indiscretion, convert to a Type V pattern with massive triglyceride elevations accompanying fasting chylomicronemia, but the influence of nicotinic acid therapy on the risk of pancreatitis in such situations has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of VLDL. Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV, and V hyperlipoproteinemia 7 . † Classification of Hyperlipoproteinemias Lipoproteins Lipid Elevations Type Elevated Major Minor C = cholesterol, TG = triglycerides LDL = low-density lipoprotein VLDL = very low-density lipoprotein IDL = intermediate-density lipoprotein I (rare) Chylomicrons TG ↑→ C IIa LDL C ..... IIb LDL, VLDL C TG III (rare) IDL C/TG ..... IV VLDL TG ↑→ C V (rare) Chylomicrons, VLD TG ↑→ C uuid:0c616201-4627-412d-b27a-edd01285619d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:82702 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:4941ba05-b25b-4160-84c3-8f0a1c78f1c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d55822f0-bb80-4c61-a823-d281c9f57bfb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZONTIVITY is a protease-activated receptor-1 (PAR-1) antagonist indicated for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD). ZONTIVITY has been shown to reduce the rate of a combined endpoint of cardiovascular death, MI, stroke, and urgent coronary revascularization. ( 1.1 ) uuid:47ee8eaa-0e82-406e-8cce-425e2cead8d5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:82702 biolink:treats MONDO:0005386 PMID:41385096 "[{""id"":""uuid:88f24db5-8184-4009-93fb-7ef4d803ffc5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:81800b8a-b6c5-49b8-8590-d2eceb6b6a0a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZONTIVITY is a protease-activated receptor-1 (PAR-1) antagonist indicated for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD). ZONTIVITY has been shown to reduce the rate of a combined endpoint of cardiovascular death, MI, stroke, and urgent coronary revascularization. ( 1.1 ) uuid:826d732e-8de9-4198-a203-5c4b7118c9fa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:82702 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:ea4d3f33-b713-4c89-8be2-ac6a53b6653c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7eaecddf-89a2-41f1-8475-bb2daf4b2135"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZONTIVITY is a protease-activated receptor-1 (PAR-1) antagonist indicated for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD). ZONTIVITY has been shown to reduce the rate of a combined endpoint of cardiovascular death, MI, stroke, and urgent coronary revascularization. ( 1.1 ) uuid:bafce86b-61bc-4a47-86dc-c337ae2f7b6b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32139 biolink:treats MONDO:0000440 PMID:41385096 "[{""id"":""uuid:dd211fff-4a88-4d59-ae34-4179bc518199"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ed725336-7d36-40fc-876c-38543894e9df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of hemoglobin and its breakdown products. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis – e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO 2 content is crucial – e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis. uuid:43da1287-5472-4113-b408-0f5c82c91ac2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32139 biolink:treats MONDO:0001106 PMID:41385096 "[{""id"":""uuid:569f31c5-e734-4d8f-96f1-d06e6ca3655b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b5d13240-e454-4096-b889-134871336126"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of hemoglobin and its breakdown products. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis – e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO 2 content is crucial – e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis. uuid:dd3074c1-4990-4876-984d-a85e3e72155b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32139 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:39e3cd16-d002-4720-9cdc-1f4b1445abe4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:46371d08-09e4-41ec-8a63-eec270318c3e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of hemoglobin and its breakdown products. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis – e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO 2 content is crucial – e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis. uuid:b22d8105-e62d-48af-a47f-aedb2455e258 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32139 biolink:treats HP:0031273 PMID:41385096 "[{""id"":""uuid:c848bba0-f94c-4c40-a01e-fe7e481fa0a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ea66c4ce-3f95-49aa-86d7-05964e225d8a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of hemoglobin and its breakdown products. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis – e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO 2 content is crucial – e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis. uuid:23a9f954-e6c8-4cc1-aafd-30e990147f52 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32139 biolink:treats UMLS:C3472181 PMID:41385096 "[{""id"":""uuid:734d9fd1-e3dd-4b9c-a701-94e2873c04cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1adc653d-29c8-4ad9-9296-5729621b0f4f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of hemoglobin and its breakdown products. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis – e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO 2 content is crucial – e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis. uuid:d9afcf3c-a0a2-455a-9f23-a235e40e2400 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32139 biolink:treats MONDO:0000745 PMID:41385096 "[{""id"":""uuid:6a04cb46-32c0-4758-a747-19d9f6aa35a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8cd29ca9-eed4-410b-8aac-453c8826258f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of hemoglobin and its breakdown products. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis – e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO 2 content is crucial – e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis. uuid:6f347533-bde1-4d0f-bd1e-10d38bee5fed biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32139 biolink:treats MONDO:0006040 PMID:41385096 "[{""id"":""uuid:05f67de5-e83b-44bc-9592-e9c69427be03"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:97b8138f-d8ef-4c7c-a239-12d44eaeb2b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of hemoglobin and its breakdown products. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis – e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO 2 content is crucial – e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis. uuid:5542baef-e2b8-405b-8afd-62b25507b820 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32139 biolink:treats EFO:0009574 PMID:41385096 "[{""id"":""uuid:75f94500-218e-483f-804f-37c623b113dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ef8bdb83-d1b9-4329-ac38-636679efb34f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of hemoglobin and its breakdown products. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis – e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO 2 content is crucial – e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis. uuid:905fddc7-5df7-46a5-9865-c370329a0d91 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32139 biolink:treats UMLS:C0161558 PMID:41385096 "[{""id"":""uuid:21fb7d07-179c-45de-a7df-ab3f587039bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:35a1a37a-b197-4e51-a6d9-4d8c7ea8a89a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of hemoglobin and its breakdown products. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis – e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO 2 content is crucial – e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis. uuid:f24f4257-42b8-47e1-af79-ae60957ac7b5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32139 biolink:treats UMLS:C0161544 PMID:41385096 "[{""id"":""uuid:258c5628-8dab-49bb-ae59-850f729379af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e61e2e0a-a120-4d31-8add-2e3f54461031"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of hemoglobin and its breakdown products. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis – e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO 2 content is crucial – e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis. uuid:fb7fa66a-5d84-48fe-8746-b9bfdbf7be07 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32139 biolink:treats UMLS:C0161680 PMID:41385096 "[{""id"":""uuid:53cb22be-5aff-4f02-a9e8-f065438562ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0987d46c-0a08-490a-8c59-243a8ea2c055"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of hemoglobin and its breakdown products. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis – e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO 2 content is crucial – e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis. uuid:af3e354f-6e4b-4cfb-b4be-9e9f73f3d448 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32139 biolink:treats UMLS:C0235575 PMID:41385096 "[{""id"":""uuid:7cdfbedb-0620-4e6c-8498-0962ca7022e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:96d59ef2-579b-448a-99c6-c6e8667c8b1c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of hemoglobin and its breakdown products. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis – e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO 2 content is crucial – e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis. uuid:cdad855a-01a0-47ba-bae8-d3b62fe604d8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32139 biolink:treats UMLS:C1443924 PMID:41385096 "[{""id"":""uuid:fd52becd-2661-4ddb-a56c-7cfbbe740666"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b6a3b7f0-53a8-45e4-a38c-afd9a6e8d333"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of hemoglobin and its breakdown products. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis – e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO 2 content is crucial – e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis. uuid:b586cd52-6e8c-4eb4-aa1b-063479f63013 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32139 biolink:treats MONDO:0012819 PMID:41385096 "[{""id"":""uuid:43fe4d24-ae56-46a4-a060-e076a9efbcff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5fafee6a-2574-470f-a66f-f98b8b07243b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of hemoglobin and its breakdown products. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis – e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO 2 content is crucial – e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis. uuid:5710e750-d657-4572-bb83-cebb25ed473a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50690 biolink:treats MONDO:0005347 PMID:41385096 "[{""id"":""uuid:4ece246c-a824-4a5f-813b-d643e74198b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:49b0ff55-80e3-4edd-824e-cb26dfb7f081"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Atorvastatin calcium tablets are an HMG-CoA reductase inhibitor indicated as an adjunct therapy to diet to: Reduce the risk of MI, stroke, revascularization procedures, and angina in adult patients without CHD, but with multiple risk factors ( 1.1 ). Reduce the risk of MI and stroke in adult patients with type 2 diabetes without CHD, but with multiple risk factors ( 1.1 ). Reduce the risk of non-fatal MI, fatal and non-fatal stroke, revascularization procedures, hospitalization for CHF, and angina in adult patients with CHD ( 1.1 ). Reduce elevated total-C, LDL-C, apo B, and TG levels and increase HDL-C in adult patients with primary hyperlipidemia (heterozygous familial and nonfamilial) and mixed dyslipidemia ( 1.2 ). Reduce elevated TG in adult patients with hypertriglyceridemia and primary dysbetalipoproteinemia ( 1.2 ). Reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH) ( 1.2 ). Reduce elevated total-C, LDL-C, and apo B levels in pediatric patients, 10 years to 17 years of age, with heterozygous familial hypercholesterolemia (HeFH) after failing an adequate trial of diet therapy ( 1.2 ). L i mitations of Use Atorvastatin calcium tablets have not been studied in Fredrickson Types I and V dyslipidemias ( 1.3 ). uuid:9694550a-3c26-43cc-b047-059a1e2bd57a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50690 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:5de3bb29-484d-4082-9340-00cfd1288306"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:01a4b341-73b5-43ef-9914-78db876ec018"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Atorvastatin calcium tablets are an HMG-CoA reductase inhibitor indicated as an adjunct therapy to diet to: Reduce the risk of MI, stroke, revascularization procedures, and angina in adult patients without CHD, but with multiple risk factors ( 1.1 ). Reduce the risk of MI and stroke in adult patients with type 2 diabetes without CHD, but with multiple risk factors ( 1.1 ). Reduce the risk of non-fatal MI, fatal and non-fatal stroke, revascularization procedures, hospitalization for CHF, and angina in adult patients with CHD ( 1.1 ). Reduce elevated total-C, LDL-C, apo B, and TG levels and increase HDL-C in adult patients with primary hyperlipidemia (heterozygous familial and nonfamilial) and mixed dyslipidemia ( 1.2 ). Reduce elevated TG in adult patients with hypertriglyceridemia and primary dysbetalipoproteinemia ( 1.2 ). Reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH) ( 1.2 ). Reduce elevated total-C, LDL-C, and apo B levels in pediatric patients, 10 years to 17 years of age, with heterozygous familial hypercholesterolemia (HeFH) after failing an adequate trial of diet therapy ( 1.2 ). L i mitations of Use Atorvastatin calcium tablets have not been studied in Fredrickson Types I and V dyslipidemias ( 1.3 ). uuid:41775639-26ff-4724-a894-b278188740bc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16684 biolink:treats MONDO:0021095 PMID:41385096 "[{""id"":""uuid:6e63d730-3d84-440b-bc1e-3dbbfebd1807"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:742afc55-f0a7-4e95-8f36-0f2fdfe4b7eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In the treatment of parkinsonism. Rigidity and tremor relieved by the apparently selective depressant action. In the gastrointestinal tract to relieve pylorospasm, hypertonicity of the small intestine and the hypermotility of the colon. To relieve hypertonicity of the uterine muscle. To relax the spasm of biliary and uretered colic and bronchial spasm. To diminish the tone of the detrusor muscle of the urinary bladder in the treatment of urinary tract disorders. To control the crying and laughing episodes in patients with brain lesions. In cases of closed head injuries which cause acetylcholine to be released or to be present in cerebrospinal fluid which in turn causes abnormal EEG patterns, stupor and neurological signs. In the management of peptic ulcer. In anesthesia to control excessive salivation and bronchial secretions. To control rhinorrhea of acute rhinitis or hay fever. As an antidote for pilocarpine, physostigmine, isoflurophate, choline esters, certain species of Aminata and in cases of anticholinesterase insecticide poisoning. In poisoning by the organic phosphate cholinesterase inhibitors found in certain insecticides and by chemical warfare “nerve gases”, large doses of atropine relieve the muscarine-like symptoms and some of the central-nervous-system manifestations. Adults suspected of contact with organic phosphorus insecticides of the parathion type should be given atropine sulfate, 0.8 mg, intramuscularly. If an atropine effect is not apparent within thirty minutes or if definite symptoms of the poisoning occur (nausea, vomiting, diarrhea, pupillary constriction, pulmonary edema, fasciculations of eyelids and tongue, jerky ocular movements, and excessive sweating, salivation, and bronchial secretion), atropine sulfate, 2 mg, should be given intramuscularly at hourly intervals until signs of atropinization are observed. Up to two or three times this dose (4 to 6 mg) may be required in severe cases. Removing contaminated clothing, washing the skin, and commencing artificial respiration and supportive therapy are also indicated. uuid:50e6cda8-cb97-4bdd-902f-83e3009674c5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16684 biolink:treats MONDO:0004247 PMID:41385096 "[{""id"":""uuid:0cea2308-55d7-41ee-a78f-c7612a98decf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f89c0afd-2598-47a5-9f4a-d6aae33a95d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In the treatment of parkinsonism. Rigidity and tremor relieved by the apparently selective depressant action. In the gastrointestinal tract to relieve pylorospasm, hypertonicity of the small intestine and the hypermotility of the colon. To relieve hypertonicity of the uterine muscle. To relax the spasm of biliary and uretered colic and bronchial spasm. To diminish the tone of the detrusor muscle of the urinary bladder in the treatment of urinary tract disorders. To control the crying and laughing episodes in patients with brain lesions. In cases of closed head injuries which cause acetylcholine to be released or to be present in cerebrospinal fluid which in turn causes abnormal EEG patterns, stupor and neurological signs. In the management of peptic ulcer. In anesthesia to control excessive salivation and bronchial secretions. To control rhinorrhea of acute rhinitis or hay fever. As an antidote for pilocarpine, physostigmine, isoflurophate, choline esters, certain species of Aminata and in cases of anticholinesterase insecticide poisoning. In poisoning by the organic phosphate cholinesterase inhibitors found in certain insecticides and by chemical warfare “nerve gases”, large doses of atropine relieve the muscarine-like symptoms and some of the central-nervous-system manifestations. Adults suspected of contact with organic phosphorus insecticides of the parathion type should be given atropine sulfate, 0.8 mg, intramuscularly. If an atropine effect is not apparent within thirty minutes or if definite symptoms of the poisoning occur (nausea, vomiting, diarrhea, pupillary constriction, pulmonary edema, fasciculations of eyelids and tongue, jerky ocular movements, and excessive sweating, salivation, and bronchial secretion), atropine sulfate, 2 mg, should be given intramuscularly at hourly intervals until signs of atropinization are observed. Up to two or three times this dose (4 to 6 mg) may be required in severe cases. Removing contaminated clothing, washing the skin, and commencing artificial respiration and supportive therapy are also indicated. uuid:5d588daa-86bc-4b9b-9ea3-f8b981c40c22 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16684 biolink:treats MONDO:0005709 PMID:41385096 "[{""id"":""uuid:6b920fbb-1e47-44ea-a6dc-2f77c33bece5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:334cb231-5a6e-4926-9322-19c476408eb3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In the treatment of parkinsonism. Rigidity and tremor relieved by the apparently selective depressant action. In the gastrointestinal tract to relieve pylorospasm, hypertonicity of the small intestine and the hypermotility of the colon. To relieve hypertonicity of the uterine muscle. To relax the spasm of biliary and uretered colic and bronchial spasm. To diminish the tone of the detrusor muscle of the urinary bladder in the treatment of urinary tract disorders. To control the crying and laughing episodes in patients with brain lesions. In cases of closed head injuries which cause acetylcholine to be released or to be present in cerebrospinal fluid which in turn causes abnormal EEG patterns, stupor and neurological signs. In the management of peptic ulcer. In anesthesia to control excessive salivation and bronchial secretions. To control rhinorrhea of acute rhinitis or hay fever. As an antidote for pilocarpine, physostigmine, isoflurophate, choline esters, certain species of Aminata and in cases of anticholinesterase insecticide poisoning. In poisoning by the organic phosphate cholinesterase inhibitors found in certain insecticides and by chemical warfare “nerve gases”, large doses of atropine relieve the muscarine-like symptoms and some of the central-nervous-system manifestations. Adults suspected of contact with organic phosphorus insecticides of the parathion type should be given atropine sulfate, 0.8 mg, intramuscularly. If an atropine effect is not apparent within thirty minutes or if definite symptoms of the poisoning occur (nausea, vomiting, diarrhea, pupillary constriction, pulmonary edema, fasciculations of eyelids and tongue, jerky ocular movements, and excessive sweating, salivation, and bronchial secretion), atropine sulfate, 2 mg, should be given intramuscularly at hourly intervals until signs of atropinization are observed. Up to two or three times this dose (4 to 6 mg) may be required in severe cases. Removing contaminated clothing, washing the skin, and commencing artificial respiration and supportive therapy are also indicated. uuid:21f94a9e-5d20-4a18-9ce8-dc98b7c1618b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16684 biolink:treats MONDO:0005324 PMID:41385096 "[{""id"":""uuid:da23d2dc-7e5a-499f-8eea-992a24a84b34"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:68b3a026-aead-4bcd-a03a-cb7e51e431cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In the treatment of parkinsonism. Rigidity and tremor relieved by the apparently selective depressant action. In the gastrointestinal tract to relieve pylorospasm, hypertonicity of the small intestine and the hypermotility of the colon. To relieve hypertonicity of the uterine muscle. To relax the spasm of biliary and uretered colic and bronchial spasm. To diminish the tone of the detrusor muscle of the urinary bladder in the treatment of urinary tract disorders. To control the crying and laughing episodes in patients with brain lesions. In cases of closed head injuries which cause acetylcholine to be released or to be present in cerebrospinal fluid which in turn causes abnormal EEG patterns, stupor and neurological signs. In the management of peptic ulcer. In anesthesia to control excessive salivation and bronchial secretions. To control rhinorrhea of acute rhinitis or hay fever. As an antidote for pilocarpine, physostigmine, isoflurophate, choline esters, certain species of Aminata and in cases of anticholinesterase insecticide poisoning. In poisoning by the organic phosphate cholinesterase inhibitors found in certain insecticides and by chemical warfare “nerve gases”, large doses of atropine relieve the muscarine-like symptoms and some of the central-nervous-system manifestations. Adults suspected of contact with organic phosphorus insecticides of the parathion type should be given atropine sulfate, 0.8 mg, intramuscularly. If an atropine effect is not apparent within thirty minutes or if definite symptoms of the poisoning occur (nausea, vomiting, diarrhea, pupillary constriction, pulmonary edema, fasciculations of eyelids and tongue, jerky ocular movements, and excessive sweating, salivation, and bronchial secretion), atropine sulfate, 2 mg, should be given intramuscularly at hourly intervals until signs of atropinization are observed. Up to two or three times this dose (4 to 6 mg) may be required in severe cases. Removing contaminated clothing, washing the skin, and commencing artificial respiration and supportive therapy are also indicated. uuid:9208be9b-d8ff-4f6a-a717-c50dfdfaa8cf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5523 biolink:treats MONDO:0005159 PMID:41385096 "[{""id"":""uuid:c4b55fb6-8fe5-4de2-af40-dcb2fee8278c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c6bfdb4f-12f7-4553-9dc8-c4479cc6295c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZOLADEX is a Gonadotropin Releasing Hormone (GnRH) agonist indicated for: Use in combination with flutamide for the management of locally confined carcinoma of the prostate ( 1.1 ) Palliative treatment of advanced carcinoma of the prostate ( 1.2 ) The management of endometriosis ( 1.3 ) Use as an endometrial-thinning agent prior to endometrial ablation for dysfunctional uterine bleeding ( 1.4 ) Use in the palliative treatment of advanced breast cancer in pre- and perimenopausal women ( 1.5 ) uuid:902da1a4-8a06-42d9-aa61-7dcb7ceb6644 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5523 biolink:treats MONDO:0005133 PMID:41385096 "[{""id"":""uuid:c3393656-fdbc-47b9-b086-986df5b2cdd8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a1c1b340-d0b9-4cad-b849-8df14148fc33"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZOLADEX is a Gonadotropin Releasing Hormone (GnRH) agonist indicated for: Use in combination with flutamide for the management of locally confined carcinoma of the prostate ( 1.1 ) Palliative treatment of advanced carcinoma of the prostate ( 1.2 ) The management of endometriosis ( 1.3 ) Use as an endometrial-thinning agent prior to endometrial ablation for dysfunctional uterine bleeding ( 1.4 ) Use in the palliative treatment of advanced breast cancer in pre- and perimenopausal women ( 1.5 ) uuid:aa1ad5a7-77aa-4315-9796-523f11cc9e71 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5523 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:e6a54a4d-9436-4e7a-b153-fa9235e6d1e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b515505a-39cc-4a18-972f-224a3dd7b070"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZOLADEX is a Gonadotropin Releasing Hormone (GnRH) agonist indicated for: Use in combination with flutamide for the management of locally confined carcinoma of the prostate ( 1.1 ) Palliative treatment of advanced carcinoma of the prostate ( 1.2 ) The management of endometriosis ( 1.3 ) Use as an endometrial-thinning agent prior to endometrial ablation for dysfunctional uterine bleeding ( 1.4 ) Use in the palliative treatment of advanced breast cancer in pre- and perimenopausal women ( 1.5 ) uuid:de597221-d9b6-44eb-bcf6-6fe4020f7856 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29007 biolink:treats MONDO:0005113 PMID:41385096 "[{""id"":""uuid:48d9e26f-feaf-4403-b252-dc0d69f01765"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:616cfe86-99e1-44df-bea1-72595d6d039e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Before instituting treatment with ceftriaxone, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. Therapy may be instituted prior to obtaining results of susceptibility testing. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftriaxone for injection, USP and other antibacterial drugs, ceftriaxone for injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ceftriaxone for injection, USP is indicated for the treatment of the following infections when caused by susceptible organisms: uuid:ba5e114a-3a90-4d0a-b394-7e07d0f9b74e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29034 biolink:treats MONDO:0001356 PMID:41385096 "[{""id"":""uuid:69447a99-f24b-474f-9c5f-4ba6a1bac7f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bbfb59bf-e4a5-4c5e-ab6f-771b71e9fe05"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Venofer is indicated for the treatment of iron deficiency anemia (IDA) in patients with chronic kidney disease (CKD). uuid:a0612d07-d886-4503-9c09-04c2a826a538 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29034 biolink:treats MONDO:0005300 PMID:41385096 "[{""id"":""uuid:c3539d2a-1c49-4c6d-a4f0-37d12311874c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:74e5a933-68e1-4de2-bdae-4f957dd52924"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Venofer is indicated for the treatment of iron deficiency anemia (IDA) in patients with chronic kidney disease (CKD). uuid:43e80585-958b-4592-aaba-94d3b8dc9301 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:505CXM6OHG biolink:treats MONDO:0005812 PMID:41385096 "[{""id"":""uuid:792577a0-13f5-49a0-bf3c-4efaec75774a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c164785c-6970-40a1-b1a4-172eb3b4b962"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:7df07b30-80c6-4b81-84df-038805b5c65a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/xofluza""]},{""id"":""uuid:ca4b293f-0cb6-4f41-9e1f-d667491cc056"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XOFLUZA is an influenza virus polymerase acidic (PA) endonuclease inhibitor indicated for: Treatment of acute uncomplicated influenza in patients 12 years of age and older who have been symptomatic for no more than 48 hours and who are: otherwise healthy, or at high risk of developing influenza-related complications. ( 1.1 ) Post-exposure prophylaxis of influenza in patients 12 years of age and older following contact with an individual who has influenza. ( 1.2 ) Limitations of Use Influenza viruses change over time, and factors such as the virus type or subtype, emergence of resistance, or changes in viral virulence could diminish the clinical benefit of antiviral drugs. Consider available information on drug susceptibility patterns for circulating influenza virus strains when deciding whether to use XOFLUZA. ( 1.3 )|[EMA] Treatment of influenzaXofluza is indicated for the treatment of uncomplicated influenza in patients aged 1 year and above.Post exposure prophylaxis of influenzaXofluza is indicated for post-exposure prophylaxis of influenza in individuals aged 1 year and above.Xofluza should be used in accordance with official recommendations.|[PMDA] Drugs with a new active ingredient indicated for the treatment of influenza A or B virus infections. [SAKIGAKE designation] uuid:a31f92ac-01ce-4a70-b673-30d216b39d99 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:127780 biolink:treats MONDO:0000878 PMID:41385096 "[{""id"":""uuid:b29863ee-cef6-4d6d-945c-feed0a6617f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1ad4329f-ae1f-4106-a7a5-399c49e74937"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CMV Retinitis Foscarnet sodium Injection is indicated for the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS). Combination therapy with foscarnet sodium Injection and ganciclovir is indicated for patients who have relapsed after monotherapy with either drug. SAFETY AND EFFICACY OF FOSCARNET SODIUM INJECTION HAVE NOT BEEN ESTABLISHED FOR TREATMENT OF OTHER CMV INFECTIONS (e.g., PNEUMONITIS, GASTROENTERITIS); CONGENITAL OR NEONATAL CMV DISEASE; OR NONIMMUNOCOMPROMISED INDIVIDUALS. Mucocutaneous Acyclovir Resistant HSV Infections Foscarnet sodium Injection is indicated for the treatment of acyclovir-resistant mucocutaneous HSV infections in immunocompromised patients. SAFETY AND EFFICACY OF FOSCARNET SODIUM INJECTION HAVE NOT BEEN ESTABLISHED FOR TREATMENT OF OTHER HSV INFECTIONS (e.g., RETINITIS, ENCEPHALITIS); CONGENITAL OR NEONATAL HSV DISEASE; OR HSV IN NONIMMUNOCOMPROMISED INDIVIDUALS. uuid:3c875b6d-4894-44ba-94e6-d3f44b7b6201 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:127780 biolink:treats MONDO:0012268 PMID:41385096 "[{""id"":""uuid:00353b9f-31e7-45d8-91ed-8a76cf4b4c2c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5a022450-fb84-493a-b5b4-2fb1334ba901"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CMV Retinitis Foscarnet sodium Injection is indicated for the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS). Combination therapy with foscarnet sodium Injection and ganciclovir is indicated for patients who have relapsed after monotherapy with either drug. SAFETY AND EFFICACY OF FOSCARNET SODIUM INJECTION HAVE NOT BEEN ESTABLISHED FOR TREATMENT OF OTHER CMV INFECTIONS (e.g., PNEUMONITIS, GASTROENTERITIS); CONGENITAL OR NEONATAL CMV DISEASE; OR NONIMMUNOCOMPROMISED INDIVIDUALS. Mucocutaneous Acyclovir Resistant HSV Infections Foscarnet sodium Injection is indicated for the treatment of acyclovir-resistant mucocutaneous HSV infections in immunocompromised patients. SAFETY AND EFFICACY OF FOSCARNET SODIUM INJECTION HAVE NOT BEEN ESTABLISHED FOR TREATMENT OF OTHER HSV INFECTIONS (e.g., RETINITIS, ENCEPHALITIS); CONGENITAL OR NEONATAL HSV DISEASE; OR HSV IN NONIMMUNOCOMPROMISED INDIVIDUALS. uuid:8f76d7f3-461d-4edc-a125-f246c742a534 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:36704 biolink:treats UMLS:C0343730 PMID:41385096 "[{""id"":""uuid:9650dc7c-6f8a-40e5-b66a-14af3a444438"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:510bdb0b-b215-455d-b4fa-c109a18eec8c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] • Imiquimod Cream, 3.75% is indicated for the topical treatment of clinically typical, visible or palpable actinic keratoses (AK) of the full face or balding scalp in immunocompetent adults. ( 1.1 ) • Imiquimod Cream, 3.75% is also indicated for the topical treatment of external genital and perianal warts/condyloma acuminata (EGW) in patients 12 years or older. ( 1.2 ) • Limitations of Use: Efficacy of imiquimod cream was not demonstrated for molluscum contagiosum in children 2 to 12 years of age. ( 1.3 , 8.4 ) uuid:27786c55-72fe-4c8b-bdb2-0d1c26bdadc2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0001713 PMID:41385096 "[{""id"":""uuid:82827783-de76-4913-b1a3-b3b82f62c1a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:abf41a57-6a93-4700-b830-157195452c06"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramuscular use of methylprednisolone sodium succinate for injection, USP is indicated as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administration is contraindicated), pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous System: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, temporal arteritis, polymyositis, and systemic lupus erythematosus. uuid:1f158e75-7ce6-4de8-b1ec-6176db33647f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0004670 PMID:41385096 "[{""id"":""uuid:5078dfde-b875-45ef-9dd0-d924340f4b09"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f6159438-d318-4591-94e4-c44a59c0b517"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramuscular use of methylprednisolone sodium succinate for injection, USP is indicated as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administration is contraindicated), pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous System: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, temporal arteritis, polymyositis, and systemic lupus erythematosus. uuid:fdd5421b-45d8-42b7-b7da-6e4a809202d7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:WA16A5Y52X biolink:treats MONDO:0034212 PMID:41385096 "[{""id"":""uuid:9bd0fd55-40ae-43fa-9034-4552d7ea6b54"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8b0732a7-a26e-4e45-a460-11520fdff029"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levoleucovorin for Injection is indicated for: rescue after high-dose methotrexate therapy in adult and pediatric patients with osteosarcoma. diminishing the toxicity associated with overdosage of folic acid antagonists or impaired methotrexate elimination in adult and pediatric patients. the treatment of adults with metastatic colorectal cancer in combination with fluorouracil. Limitations of Use Levoleucovorin for Injection is not indicated for pernicious anemia and megaloblastic anemia secondary to the lack of vitamin B12, because of the risk of progression of neurologic manifestations despite hematologic remission. PUBCHEM.COMPOUND:135465090 uuid:388f725f-c55b-41df-925c-a395515fb542 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3207 biolink:treats MONDO:0005101 PMID:41385096 "[{""id"":""uuid:2b9b3dbc-58d8-40e2-8f7a-e174d968edfd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2f29bdbf-3cc9-4a4a-94d5-7ef501cc5c3a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:6d625764-eb98-4168-ab8e-f6c042a5442f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] UCERIS rectal foam is indicated for the induction of remission in patients with active mild to moderate distal ulcerative colitis extending up to 40 cm from the anal verge.|[PMDA] A drug with a new route of administration indicated for the treatment of active ulcerative colitis (excluding severe cases). uuid:5d465f48-c5c1-49d7-a2a3-630220ccd4bb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28262 biolink:treats MONDO:0018301 PMID:41385096 "[{""id"":""uuid:fffaeaee-3077-4cca-a7a5-a120ef6bc5d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:12cbf6bd-97ea-43a6-9928-fe20b8a337eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:733b4244-268f-44f6-a6db-4d6a33b499aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RIMSO-50 ® (dimethyl sulfoxide) is indicated for the symptomatic relief of patients with interstitial cystitis. RIMSO-50 ® has not been approved as being safe and effective for any other indication. There is no clinical evidence of effectiveness of dimethyl sulfoxide in the treatment of bacterial infections of the urinary tract.|[PMDA] A drug with a new active ingredient indicated for the improvement of symptoms (chronic pelvic pain, pressure and discomfort perceived to be related to the urinary bladder; lower urinary tract symptoms such as persistent urge to void and urinary frequency) in patients with interstitial cystitis (Hunner type). [Orphan drug] uuid:a20535bd-893b-4ee5-a4c8-152aa877b912 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:26710 biolink:treats HP:0002902 PMID:41385096 "[{""id"":""uuid:d2a203e7-3c6f-4c2d-9f66-b504035baf88"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:903be142-a8c1-43bb-b051-235e061704a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 14.6% Sodium Chloride Injection, USP Additive Solution is indicated for parenteral restoration of sodium ion in patients with restricted oral intake. Sodium replacement is specifically indicated in patients with hyponatremia or low salt syndrome. 14.6% Sodium Chloride Additive Solution may also be added to compatible carbohydrate solutions such as dextrose in water to provide electrolytes. uuid:c7bc6de6-3d4d-4f7d-be41-2be491f1d5af biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:39211 biolink:treats MONDO:0003471 PMID:41385096 "[{""id"":""uuid:95157bf8-3870-4a0e-9047-d02e420e4b17"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2cf8471e-87cd-462d-9981-d565264b3b3b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NATROBA is a pediculicide indicated for the topical treatment of head lice infestations in adult and pediatric patients 6 months of age and older. ( 1.1 ) NATROBA is a scabicide indicated for the topical treatment of scabies infestations in adult and pediatric patients 4 years of age and older, ( 1.2 ) uuid:5cbaedf5-77df-44f9-8e71-312d02036105 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:39211 biolink:treats MONDO:0004525 PMID:41385096 "[{""id"":""uuid:77c3a11f-cfa4-4d1b-beda-c8792f149129"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:db6abf94-ac5c-4670-a38f-396ee002010f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NATROBA is a pediculicide indicated for the topical treatment of head lice infestations in adult and pediatric patients 6 months of age and older. ( 1.1 ) NATROBA is a scabicide indicated for the topical treatment of scabies infestations in adult and pediatric patients 4 years of age and older, ( 1.2 ) uuid:826dfecd-1b7d-46f5-a0b7-c55aa92c12f0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:26710 biolink:treats MONDO:0015129 PMID:41385096 "[{""id"":""uuid:90388f21-c497-4af7-ad61-6f12fb9deed5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0b87f104-b5ea-44ab-b2a3-83d88f6d304e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Chloride Injection, USP, 23.4%, is indicated as an additive in parenteral fluid therapy for use in patients who have special problems of sodium electrolyte intake or excretion. It is intended to meet the specific requirements of the patient with unusual fluid and electrolyte needs. After available clinical and laboratory information is considered and correlated, the appropriate number of milliequivalents of sodium chloride required can be withdrawn from Sodium Chloride Injection, USP, 23.4% and diluted for use. Sodium Chloride Injection is indicated for the treatment of sodium, chloride and water deficiencies that commonly occur in many diseases. Isotonic Sodium Chloride Injection should be limited to cases in which the chloride loss is greater than the sodium loss, as in vomiting from pyloric obstruction, or in which the loss is about equal, as in vomiting from duodenal, jejunal or ileal obstruction and in the replacement of aspirated gastrointestinal fluids. The toxic symptoms that follow various forms of intestinal obstruction are accompanied by a marked reduction of blood chloride and often sodium chloride has a lifesaving effect. Symptoms of sodium chloride deficiency are very similar to those of Addison’s disease and large doses of sodium chloride will produce temporary alleviation of the symptoms. Other disorders in which sodium chloride is therapeutically useful include extensive burns, failure of gastric secretion and postoperative intestinal paralysis. uuid:49584d94-9c76-4e48-9dbd-e7c8c510acf4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:26710 biolink:treats UMLS:C0856633 PMID:41385096 "[{""id"":""uuid:d4877884-265f-49d5-b3ef-d41d200a0e82"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:898e0007-270a-4e37-9110-68d35cdff354"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Chloride Injection, USP, 23.4%, is indicated as an additive in parenteral fluid therapy for use in patients who have special problems of sodium electrolyte intake or excretion. It is intended to meet the specific requirements of the patient with unusual fluid and electrolyte needs. After available clinical and laboratory information is considered and correlated, the appropriate number of milliequivalents of sodium chloride required can be withdrawn from Sodium Chloride Injection, USP, 23.4% and diluted for use. Sodium Chloride Injection is indicated for the treatment of sodium, chloride and water deficiencies that commonly occur in many diseases. Isotonic Sodium Chloride Injection should be limited to cases in which the chloride loss is greater than the sodium loss, as in vomiting from pyloric obstruction, or in which the loss is about equal, as in vomiting from duodenal, jejunal or ileal obstruction and in the replacement of aspirated gastrointestinal fluids. The toxic symptoms that follow various forms of intestinal obstruction are accompanied by a marked reduction of blood chloride and often sodium chloride has a lifesaving effect. Symptoms of sodium chloride deficiency are very similar to those of Addison’s disease and large doses of sodium chloride will produce temporary alleviation of the symptoms. Other disorders in which sodium chloride is therapeutically useful include extensive burns, failure of gastric secretion and postoperative intestinal paralysis. uuid:166a18d1-08ad-4543-b2da-e5693c3a8b8e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:26710 biolink:treats MONDO:0004565 PMID:41385096 "[{""id"":""uuid:353ee50f-40e8-4d8c-b411-6dbe39b6c070"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:731479fe-e1ba-4d50-a86b-d88ae366ea61"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Chloride Injection, USP, 23.4%, is indicated as an additive in parenteral fluid therapy for use in patients who have special problems of sodium electrolyte intake or excretion. It is intended to meet the specific requirements of the patient with unusual fluid and electrolyte needs. After available clinical and laboratory information is considered and correlated, the appropriate number of milliequivalents of sodium chloride required can be withdrawn from Sodium Chloride Injection, USP, 23.4% and diluted for use. Sodium Chloride Injection is indicated for the treatment of sodium, chloride and water deficiencies that commonly occur in many diseases. Isotonic Sodium Chloride Injection should be limited to cases in which the chloride loss is greater than the sodium loss, as in vomiting from pyloric obstruction, or in which the loss is about equal, as in vomiting from duodenal, jejunal or ileal obstruction and in the replacement of aspirated gastrointestinal fluids. The toxic symptoms that follow various forms of intestinal obstruction are accompanied by a marked reduction of blood chloride and often sodium chloride has a lifesaving effect. Symptoms of sodium chloride deficiency are very similar to those of Addison’s disease and large doses of sodium chloride will produce temporary alleviation of the symptoms. Other disorders in which sodium chloride is therapeutically useful include extensive burns, failure of gastric secretion and postoperative intestinal paralysis. uuid:3697c4f3-7c62-4bf2-a052-321d866705d3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:26710 biolink:treats MONDO:0004568 PMID:41385096 "[{""id"":""uuid:c4d1e51b-8a0e-4468-80ac-bded6dde9bfb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:21c56441-b5ea-4358-8610-94ff541bd3f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Chloride Injection, USP, 23.4%, is indicated as an additive in parenteral fluid therapy for use in patients who have special problems of sodium electrolyte intake or excretion. It is intended to meet the specific requirements of the patient with unusual fluid and electrolyte needs. After available clinical and laboratory information is considered and correlated, the appropriate number of milliequivalents of sodium chloride required can be withdrawn from Sodium Chloride Injection, USP, 23.4% and diluted for use. Sodium Chloride Injection is indicated for the treatment of sodium, chloride and water deficiencies that commonly occur in many diseases. Isotonic Sodium Chloride Injection should be limited to cases in which the chloride loss is greater than the sodium loss, as in vomiting from pyloric obstruction, or in which the loss is about equal, as in vomiting from duodenal, jejunal or ileal obstruction and in the replacement of aspirated gastrointestinal fluids. The toxic symptoms that follow various forms of intestinal obstruction are accompanied by a marked reduction of blood chloride and often sodium chloride has a lifesaving effect. Symptoms of sodium chloride deficiency are very similar to those of Addison’s disease and large doses of sodium chloride will produce temporary alleviation of the symptoms. Other disorders in which sodium chloride is therapeutically useful include extensive burns, failure of gastric secretion and postoperative intestinal paralysis. uuid:b60637bd-4ce6-4d2e-8cb6-6960bfc753ce biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:26710 biolink:treats UMLS:C1971019 PMID:41385096 "[{""id"":""uuid:119a3298-927c-4d26-8b51-0d5adb879aa8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:87e90e7b-e93c-4b3d-9268-14a1558d1bea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Chloride Injection, USP, 23.4%, is indicated as an additive in parenteral fluid therapy for use in patients who have special problems of sodium electrolyte intake or excretion. It is intended to meet the specific requirements of the patient with unusual fluid and electrolyte needs. After available clinical and laboratory information is considered and correlated, the appropriate number of milliequivalents of sodium chloride required can be withdrawn from Sodium Chloride Injection, USP, 23.4% and diluted for use. Sodium Chloride Injection is indicated for the treatment of sodium, chloride and water deficiencies that commonly occur in many diseases. Isotonic Sodium Chloride Injection should be limited to cases in which the chloride loss is greater than the sodium loss, as in vomiting from pyloric obstruction, or in which the loss is about equal, as in vomiting from duodenal, jejunal or ileal obstruction and in the replacement of aspirated gastrointestinal fluids. The toxic symptoms that follow various forms of intestinal obstruction are accompanied by a marked reduction of blood chloride and often sodium chloride has a lifesaving effect. Symptoms of sodium chloride deficiency are very similar to those of Addison’s disease and large doses of sodium chloride will produce temporary alleviation of the symptoms. Other disorders in which sodium chloride is therapeutically useful include extensive burns, failure of gastric secretion and postoperative intestinal paralysis. uuid:c2a30b39-8773-449f-b41d-b4575adfd3dd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:26710 biolink:treats UMLS:C0342921 PMID:41385096 "[{""id"":""uuid:dd568e8c-4a9e-4f94-aa7f-894d55a5bc23"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:85e1834c-758c-4dee-b140-3cf1aacd6418"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Chloride Injection, USP, 23.4%, is indicated as an additive in parenteral fluid therapy for use in patients who have special problems of sodium electrolyte intake or excretion. It is intended to meet the specific requirements of the patient with unusual fluid and electrolyte needs. After available clinical and laboratory information is considered and correlated, the appropriate number of milliequivalents of sodium chloride required can be withdrawn from Sodium Chloride Injection, USP, 23.4% and diluted for use. Sodium Chloride Injection is indicated for the treatment of sodium, chloride and water deficiencies that commonly occur in many diseases. Isotonic Sodium Chloride Injection should be limited to cases in which the chloride loss is greater than the sodium loss, as in vomiting from pyloric obstruction, or in which the loss is about equal, as in vomiting from duodenal, jejunal or ileal obstruction and in the replacement of aspirated gastrointestinal fluids. The toxic symptoms that follow various forms of intestinal obstruction are accompanied by a marked reduction of blood chloride and often sodium chloride has a lifesaving effect. Symptoms of sodium chloride deficiency are very similar to those of Addison’s disease and large doses of sodium chloride will produce temporary alleviation of the symptoms. Other disorders in which sodium chloride is therapeutically useful include extensive burns, failure of gastric secretion and postoperative intestinal paralysis. uuid:57b15acb-b74c-438f-9b4b-5831af50a3a2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77942 biolink:treats MONDO:0001628 PMID:41385096 "[{""id"":""uuid:8497bb84-6413-440c-9b39-c0991c61a0fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:719b7490-4e24-4fef-ac89-8d9c1178f226"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tavaborole topical solution, 5% is an oxaborole antifungal indicated for the treatment of onychomycosis of the toenails due to Trichophyton rubrum or Trichophyton mentagrophytes . uuid:6319d8aa-24b1-42e8-9f5c-af1d23bcb441 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77942 biolink:treats UMLS:C5192601 PMID:41385096 "[{""id"":""uuid:73ac8289-a194-47bf-9ba5-2c0483e6fd5d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3aebef4d-a3fb-4ec8-9608-46483b6a89a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tavaborole topical solution, 5% is an oxaborole antifungal indicated for the treatment of onychomycosis of the toenails due to Trichophyton rubrum or Trichophyton mentagrophytes . uuid:5d033e50-c9ef-423b-a7d2-dffefc5ef164 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3478 biolink:treats UMLS:C0853854 PMID:41385096 "[{""id"":""uuid:51f4bc6f-8f0b-4a32-803c-cdabb9f49652"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a2fc8e88-75a7-41a5-a529-3edca3030dd9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefaclor extended-release tablets USP and other antibacterial drugs, cefaclor extended-release tablets USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. The safety and effectiveness of cefaclor extended-release tablets in treating some of the indications and pathogens for which other formulations of cefaclor are approved have NOT been established. When administered at the recommended dosages and durations of therapy, cefaclor extended-release tablets are indicated for the treatment of patients with the following mild to moderate infections when caused by susceptible strains of the designated organisms. (See DOSAGE AND ADMINISTRATION and CLINICAL STUDIES sections.) Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae (excluding ß-lactamase-negative, ampicillin-resistant isolates), Moraxella catarrhalis, or Streptococcus pneumoniae . NOTE: In view of the insufficient numbers of isolates of ß-lactamase-producing isolates of Haemophilus influenzae that were obtained from clinical trials with cefaclor extended-release tablets for patients with acute bacterial exacerbations of chronic bronchitis, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for bronchitis known, suspected, or considered potentially to be caused by ß-lactamase-producing H. influenzae . Pharyngitis and tonsillitis due to Streptococcus pyogenes . NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefaclor extended-release tablets are generally effective in the eradication of S. pyogenes from the oropharynx; however, data establishing the efficacy of cefaclor extended-release tablets for the prophylaxis of subsequent rheumatic fever are not available. Uncomplicated skin and skin and structure infections due to Staphylococcus aureus (methicillin-susceptible only). NOTE: In view of the insufficient numbers of isolates of Streptococcus pyogenes that were obtained from clinical trials with cefaclor extended-release tablets for patients with uncomplicated skin and skin structure infections, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for skin infections known, suspected, or considered potentially to be caused by S. pyogenes . uuid:6a7fb507-5938-40d1-8256-197348322fe5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:149836 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:4db39167-8662-40c7-b76f-eea0637270fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:94ce6fa4-3511-4e13-8c4b-1ef3914dab3a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:73c17876-866d-4a86-b8cc-844846006edf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tigecycline for Injection is a tetracycline class antibacterial indicated in patients 18 years of age and older for: Complicated skin and skin structure infections ( 1.1 ) Complicated intra-abdominal infections ( 1.2 ) Community-acquired bacterial pneumonia ( 1.3 ) Limitations of Use : Tigecycline for Injection is not indicated for treatment of diabetic foot infection or hospital-acquired pneumonia, including ventilator-associated pneumonia. ( 1.4 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Tigecycline for Injection and other antibacterial drugs, Tigecycline for Injection should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. ( 1.5 )|[PMDA] A drug with a new active ingredient indicated for the treatment of deep skin infection, chronic pyoderma, secondary infection of trauma, burn, and surgical wounds, secondary infection of erosion and ulcer, peritonitis, intraperitoneal abscess, and cholecystitis. [Priority review] uuid:8636e05a-932a-4bcf-8e77-1d9a5fc4f986 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:149836 biolink:treats MONDO:0004652 PMID:41385096 "[{""id"":""uuid:0969e9e6-c287-4501-91fb-8b7503501a7d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fd63b661-b581-43a9-8780-59da7b0f70b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tigecycline for Injection is a tetracycline class antibacterial indicated in patients 18 years of age and older for: Complicated skin and skin structure infections ( 1.1 ) Complicated intra-abdominal infections ( 1.2 ) Community-acquired bacterial pneumonia ( 1.3 ) Limitations of Use : Tigecycline for Injection is not indicated for treatment of diabetic foot infection or hospital-acquired pneumonia, including ventilator-associated pneumonia. ( 1.4 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Tigecycline for Injection and other antibacterial drugs, Tigecycline for Injection should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. ( 1.5 ) uuid:81a55978-9ceb-4f95-8e6b-88e11ce6db51 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:149836 biolink:treats UMLS:C0744130 PMID:41385096 "[{""id"":""uuid:fd5d1829-6784-4eeb-b7b1-195ee8c8dd57"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4f624e84-5a28-4f0e-8852-873671abf2a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tigecycline for Injection is a tetracycline class antibacterial indicated in patients 18 years of age and older for: Complicated skin and skin structure infections ( 1.1 ) Complicated intra-abdominal infections ( 1.2 ) Community-acquired bacterial pneumonia ( 1.3 ) Limitations of Use : Tigecycline for Injection is not indicated for treatment of diabetic foot infection or hospital-acquired pneumonia, including ventilator-associated pneumonia. ( 1.4 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Tigecycline for Injection and other antibacterial drugs, Tigecycline for Injection should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. ( 1.5 ) uuid:d0c8d380-4fbc-4018-804f-926c26f1d989 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3757 biolink:treats EFO:0801084 PMID:41385096 "[{""id"":""uuid:7e96709d-dc48-476f-9843-2733a3f8ea58"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:19b34aa6-30d2-4264-9725-896f1a3a1b74"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Duraclon is indicated in combination with opiates for the treatment of severe pain in cancer patients that is not adequately relieved by opioid analgesics alone. Epidural clonidine is more likely to be effective in patients with neuropathic pain than somatic or visceral pain (see Clinical Trials ). The safety of this drug product has only been established in a highly selected group of cancer patients, and only after an adequate trial of opioid analgesia. Other use is of unproven safety and is not recommended. In a rare patient, the potential benefits may outweigh the known risks (see WARNINGS ). uuid:f4ea6653-1a5e-4a6f-a832-468771ae6a4f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9605 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:52666a8d-8e87-4b2a-9f52-8838d0056493"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:32d32915-87d1-47f8-ae36-f3e38a9c0d63"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tirofiban hydrochloride injection is indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS) . uuid:2c75bd17-4fc2-4a4c-981e-4f174fb88e04 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9605 biolink:treats UMLS:C1112767 PMID:41385096 "[{""id"":""uuid:ed9ee5e4-ab7b-44d3-99a0-53a9214a0384"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:450d5f9a-242a-4e97-aa99-953b67e9cc92"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tirofiban hydrochloride injection is indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS) . uuid:0276964d-176e-4da8-ba0e-e36b2d87d5f5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9605 biolink:treats MONDO:0005542 PMID:41385096 "[{""id"":""uuid:287067be-0da9-4bb4-966c-7461af5d8f00"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0d729605-8d37-4c2f-92ef-62ea59870fbe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tirofiban hydrochloride injection is indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS) . uuid:8dd5af2d-90a4-4a8f-9c38-74ee1341c390 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:74170 biolink:treats UMLS:C1112209 PMID:41385096 "[{""id"":""uuid:8b4f9293-5c76-4987-af16-d32d614ca3f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:51461adc-309d-44de-8e41-42f7c37a473a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Piperacillin and tazobactam for injection is a combination of piperacillin, a penicillin-class antibacterial and tazobactam, a beta-lactamase inhibitor, indicated for the treatment of: Intra-abdominal infections in adult and pediatric patients 2 months of age and older ( 1.1 ) Nosocomial pneumonia in adult and pediatric patients 2 months of age and older ( 1.2 ) Skin and skin structure infections in adults ( 1.3 ) Female pelvic infections in adults ( 1.4 ) Community-acquired pneumonia in adults ( 1.5 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of piperacillin and tazobactam for injection and other antibacterial drugs, piperacillin and tazobactam for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.6 ) uuid:0911aafd-042d-47a8-a319-e9b49fad934d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:74170 biolink:treats UMLS:C0949083 PMID:41385096 "[{""id"":""uuid:e5d119bc-5a0b-4708-9c52-255bc4d9a762"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4e02a2f7-1e8e-4671-9c02-4011bde66456"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Piperacillin and tazobactam for injection is a combination of piperacillin, a penicillin-class antibacterial and tazobactam, a beta-lactamase inhibitor, indicated for the treatment of: Intra-abdominal infections in adult and pediatric patients 2 months of age and older ( 1.1 ) Nosocomial pneumonia in adult and pediatric patients 2 months of age and older ( 1.2 ) Skin and skin structure infections in adults ( 1.3 ) Female pelvic infections in adults ( 1.4 ) Community-acquired pneumonia in adults ( 1.5 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of piperacillin and tazobactam for injection and other antibacterial drugs, piperacillin and tazobactam for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.6 ) uuid:ca79bdf5-c960-44fc-815a-8b2ceaa468a1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:74170 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:49765a73-0f5b-486e-9c6a-2fe3301853a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3a172409-41cf-46db-8a43-9d581dcc7ab7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f0197a35-820a-48c8-8cdf-7559286bf068"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Piperacillin and tazobactam for injection is a combination of piperacillin, a penicillin-class antibacterial and tazobactam, a beta-lactamase inhibitor, indicated for the treatment of: Intra-abdominal infections in adult and pediatric patients 2 months of age and older ( 1.1 ) Nosocomial pneumonia in adult and pediatric patients 2 months of age and older ( 1.2 ) Skin and skin structure infections in adults ( 1.3 ) Female pelvic infections in adults ( 1.4 ) Community-acquired pneumonia in adults ( 1.5 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of piperacillin and tazobactam for injection and other antibacterial drugs, piperacillin and tazobactam for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.6 )|[PMDA] Drugs with additional indications and new dosages for the treatment of ""bacterial skin infections mainly involving the dermis and/or subcutaneous tissues"" and ""secondary bacterial infections of pre-existing skin ulcers and/or erosion""." uuid:add2aae6-c0e0-4885-81c6-c44da4ec684c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:74170 biolink:treats MONDO:0000922 PMID:41385096 "[{""id"":""uuid:72cf7cae-b0e6-40f2-8dc3-9d9b1ef43e45"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f7d570cd-2c03-49e1-9c33-dd98c3b9d429"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Piperacillin and tazobactam for injection is a combination of piperacillin, a penicillin-class antibacterial and tazobactam, a beta-lactamase inhibitor, indicated for the treatment of: Intra-abdominal infections in adult and pediatric patients 2 months of age and older ( 1.1 ) Nosocomial pneumonia in adult and pediatric patients 2 months of age and older ( 1.2 ) Skin and skin structure infections in adults ( 1.3 ) Female pelvic infections in adults ( 1.4 ) Community-acquired pneumonia in adults ( 1.5 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of piperacillin and tazobactam for injection and other antibacterial drugs, piperacillin and tazobactam for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.6 ) uuid:7f98e9c1-f6ba-4032-b8c6-0587e276f769 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:74170 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:9b855f43-0aee-4978-9c67-d3a293e23589"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a73e9ae7-de0a-4732-99a3-17c28ec019ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Piperacillin and tazobactam for injection is a combination of piperacillin, a penicillin-class antibacterial and tazobactam, a beta-lactamase inhibitor, indicated for the treatment of: Intra-abdominal infections in adult and pediatric patients 2 months of age and older ( 1.1 ) Nosocomial pneumonia in adult and pediatric patients 2 months of age and older ( 1.2 ) Skin and skin structure infections in adults ( 1.3 ) Female pelvic infections in adults ( 1.4 ) Community-acquired pneumonia in adults ( 1.5 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of piperacillin and tazobactam for injection and other antibacterial drugs, piperacillin and tazobactam for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.6 ) uuid:6bedd6ef-cefa-463f-aeee-81c42446aece biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:575568 biolink:treats MONDO:0019121 PMID:41385096 "[{""id"":""uuid:cc4fc7f2-3bf7-4925-98ac-802fee9d9ee6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7b5c80f5-948a-49c8-b9c0-86d7094931b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:3df18f73-d1e3-42dc-a6c1-383a1cac4fd9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Atovaquone oral suspension is a quinone antimicrobial drug indicated for: Prevention of Pneumocystis jirovecii pneumonia (PCP) in adults and adolescents aged 13 years and older who cannot tolerate trimethoprim-sulfamethoxazole (TMP-SMX). ( 1.1 ) Treatment of mild-to-moderate PCP in adults and adolescents aged 13 years and older who cannot tolerate TMP-SMX. ( 1.2 ) Limitations of Use ( 1.3 ): Treatment of severe PCP (alveolar arterial oxygen diffusion gradient [(A-a)DO 2 ] >45 mm Hg) with atovaquone oral suspension has not been studied. The efficacy of atovaquone oral suspension in subjects who are failing therapy with TMP-SMX has also not been studied.|[PMDA] A drug with a new active ingredient indicated for the treatment and prevention of Pneumocystis pneumonia. [Priority review] uuid:fdbbe0c3-4f8a-4b76-a313-302080d0eec7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:616538 biolink:treats MONDO:0007186 PMID:41385096 "[{""id"":""uuid:8af18766-1757-40ea-9cad-976fda4f74f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7ea26195-c16e-4f30-8dbe-6e32df03d440"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Omeprazole and Sodium Bicarbonate capsules are indicated in adults for the: short-term treatment of active duodenal ulcer. Most patients heal within four weeks. Some patients may require an additional four weeks of therapy. short-term treatment (4 to 8 weeks) of active benign gastric ulcer. treatment of heartburn and other symptoms associated with GERD for up to 4 weeks. short-term treatment (4 to 8 weeks) of EE due to acid-mediated GERD which has been diagnosed by endoscopy in adults. The efficacy of Omeprazole and Sodium Bicarbonate capsules used for longer than 8 weeks in patient with EE has not been established. If a patient does not respond to 8 weeks of treatment, an additional 4 weeks of treatment may be given. If there is recurrence of EE or GERD symptoms (e.g., heartburn), additional 4 to 8-week courses of Omeprazole and Sodium Bicarbonate capsules may be considered. maintenance of healing of EE due to acid-mediated GERD. Controlled studies do not extend beyond 12 months uuid:f4af8c36-062f-4bfd-a2c7-ee86f6eb3aa0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:72296 biolink:treats MONDO:0004981 PMID:41385096 "[{""id"":""uuid:9495e05c-08a5-4803-a785-ae2d6700f6b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:41a339a3-5cdd-4702-8b2f-1c0b3f623c4a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Apixaban is a factor Xa inhibitor indicated: to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. ( 1.1 ) for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery. ( 1.2 ) for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE following initial therapy. ( 1.3 , 1.4 , 1.5 ) uuid:95aeb930-ae26-4801-85c4-3c525a1f951f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:72296 biolink:treats HP:0002625 PMID:41385096 "[{""id"":""uuid:44be84a0-35d3-4eff-bdc1-28d08aa7d45c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3161854a-bfc0-48cd-aae7-aad90b807602"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:3c2fa5f6-33b6-406e-96ec-d0e33506b7d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Apixaban is a factor Xa inhibitor indicated: to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. ( 1.1 ) for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery. ( 1.2 ) for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE following initial therapy. ( 1.3 , 1.4 , 1.5 )|[PMDA] Drugs with a new additional indication and a new dosage for the treatment and prevention of the recurrence of venous thromboembolism (deep vein thrombosis and pulmonary thromboembolism). uuid:ae35a04e-b24b-4d9b-ad40-5c2e95849828 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:72296 biolink:treats MONDO:0005279 PMID:41385096 "[{""id"":""uuid:7df659b9-19f7-4663-bf0f-e5a6d40b870a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:c9ee0347-eb83-47ce-8654-a146e7290d0b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c815c5e9-0e3d-4db4-9388-572b18649bb5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/eliquis""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Apixaban is a factor Xa inhibitor indicated: to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. ( 1.1 ) for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery. ( 1.2 ) for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE following initial therapy. ( 1.3 , 1.4 , 1.5 )|[EMA] For Eliquis 2.5 mg film-coated tablets:Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery.Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II).Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults (see section 4.4 for haemodynamically unstable PE patients).For Eliquis 5 mg film-coated tablets:Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II).Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults (see section 4.4 for haemodynamically unstable PE patients). uuid:8b135fec-5e42-4911-975c-62484dd4b028 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:72296 biolink:treats HP:0004850 PMID:41385096 "[{""id"":""uuid:c9c3eb32-e7aa-42fd-8851-532c3a986681"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1d787cac-fa82-49d2-9b78-33b9d8d0092f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Apixaban is a factor Xa inhibitor indicated: to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. ( 1.1 ) for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery. ( 1.2 ) for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE following initial therapy. ( 1.3 , 1.4 , 1.5 ) uuid:9c279aa2-a3b1-4d4f-8eb5-448d42b12de7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:72296 biolink:treats UMLS:C1735914 PMID:41385096 "[{""id"":""uuid:c199a18e-da68-46ef-a475-5b7bd5e04a99"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fa71b8f6-e5c9-474b-bf4a-fb2d2e462e39"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Apixaban is a factor Xa inhibitor indicated: to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. ( 1.1 ) for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery. ( 1.2 ) for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE following initial therapy. ( 1.3 , 1.4 , 1.5 ) uuid:5ba1d66f-9295-4042-9958-a74d1f45bc94 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50848 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:b4861704-f4f7-4715-8db5-de6b29d7072c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b6872f91-a63e-49e3-bff2-d462dc96dc55"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Loteprednol Etabonate Ophthalmic Gel is a corticosteroid indicated for the treatment of post-operative inflammation and pain following ocular surgery. uuid:2b11f15a-b5d9-4074-a2b6-84f4e1252aca biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7936 biolink:treats MONDO:0005146 PMID:41385096 "[{""id"":""uuid:d9beb6ba-3215-4dfa-9a2a-b8ae23cc0e3b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c4b0b678-cf15-4d18-952a-2490cd732bf3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:6edd9334-69c3-46c5-aa64-152ad680f80f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Major Depressive Disorder Paroxetine tablets, USP are indicated for the treatment of major depressive disorder. The efficacy of paroxetine in the treatment of a major depressive episode was established in 6-week controlled trials of outpatients whose diagnoses corresponded most closely to the DSM-III category of major depressive disorder (see CLINICAL PHARMACOLOGY: Clinical Trials ). A major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks); it should include at least 4 of the following 8 symptoms: Change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suicide attempt or suicidal ideation. The effects of paroxetine in hospitalized depressed patients have not been adequately studied. The efficacy of paroxetine in maintaining a response in major depressive disorder for up to 1 year was demonstrated in a placebo-controlled trial (see CLINICAL PHARMACOLOGY: Clinical Trials ). Nevertheless, the physician who elects to use paroxetine for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient. Obsessive Compulsive Disorder Paroxetine tablets, USP are indicated for the treatment of obsessions and compulsions in patients with obsessive compulsive disorder (OCD) as defined in the DSM-IV. The obsessions or compulsions cause marked distress, are time-consuming, or significantly interfere with social or occupational functioning. The efficacy of paroxetine was established in two 12-week trials with obsessive compulsive outpatients whose diagnoses corresponded most closely to the DSM-IIIR category of obsessive compulsive disorder (see CLINICAL PHARMACOLOGY: Clinical Trials ). Obsessive compulsive disorder is characterized by recurrent and persistent ideas, thoughts, impulses, or images (obsessions) that are ego-dystonic and/or repetitive, purposeful, and intentional behaviors (compulsions) that are recognized by the person as excessive or unreasonable. Long-term maintenance of efficacy was demonstrated in a 6-month relapse prevention trial. In this trial, patients assigned to paroxetine showed a lower relapse rate compared to patients on placebo (see CLINICAL PHARMACOLOGY: Clinical Trials ). Nevertheless, the physician who elects to use paroxetine for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION ). Panic Disorder Paroxetine tablets, USP are indicated for the treatment of panic disorder, with or without agoraphobia, as defined in DSM-IV. Panic disorder is characterized by the occurrence of unexpected panic attacks and associated concern about having additional attacks, worry about the implications or consequences of the attacks, and/or a significant change in behavior related to the attacks. The efficacy of paroxetine was established in three 10- to 12-week trials in panic disorder patients whose diagnoses corresponded to the DSM-IIIR category of panic disorder (see CLINICAL PHARMACOLOGY: Clinical Trials ). Panic disorder (DSM-IV) is characterized by recurrent unexpected panic attacks, i.e., a discrete period of intense fear or discomfort in which 4 (or more) of the following symptoms develop abruptly and reach a peak within 10 minutes: (1) palpitations, pounding heart, or accelerated heart rate; (2) sweating; (3) trembling or shaking; (4) sensations of shortness of breath or smothering; (5) feeling of choking; (6) chest pain or discomfort; (7) nausea or abdominal distress; (8) feeling dizzy, unsteady, lightheaded, or faint; (9) derealization (feelings of unreality) or depersonalization (being detached from oneself); (10) fear of losing control; (11) fear of dying; (12) paresthesias (numbness or tingling sensations); (13) chills or hot flushes. Long-term maintenance of efficacy was demonstrated in a 3-month relapse prevention trial. In this trial, patients with panic disorder assigned to paroxetine demonstrated a lower relapse rate compared to patients on placebo (see CLINICAL PHARMACOLOGY: Clinical Trials ). Nevertheless, the physician who prescribes paroxetine for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION ). Social Anxiety Disorder Paroxetine tablets are indicated for the treatment of social anxiety disorder, also known as social phobia, as defined in DSM-IV (300.23). Social anxiety disorder is characterized by a marked and persistent fear of 1 or more social or performance situations in which the person is exposed to unfamiliar people or to possible scrutiny by others. Exposure to the feared situation almost invariably provokes anxiety, which may approach the intensity of a panic attack. The feared situations are avoided or endured with intense anxiety or distress. The avoidance, anxious anticipation, or distress in the feared situation(s) interferes significantly with the person's normal routine, occupational or academic functioning, or social activities or relationships, or there is marked distress about having the phobias. Lesser degrees of performance anxiety or shyness generally do not require psychopharmacological treatment. The efficacy of paroxetine was established in three 12-week trials in adult patients with social anxiety disorder (DSM-IV). Paroxetine has not been studied in children or adolescents with social phobia (see CLINICAL PHARMACOLOGY: Clinical Trials ). The effectiveness of paroxetine in long-term treatment of social anxiety disorder, i.e., for more than 12 weeks, has not been systematically evaluated in adequate and well-controlled trials. Therefore, the physician who elects to prescribe paroxetine for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION ). Generalized Anxiety Disorder Paroxetine tablets, USP are indicated for the treatment of Generalized Anxiety Disorder (GAD), as defined in DSM-IV. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The efficacy of paroxetine in the treatment of GAD was established in two 8-week placebo-controlled trials in adults with GAD. Paroxetine has not been studied in children or adolescents with Generalized Anxiety Disorder (see CLINICAL PHARMACOLOGY: Clinical Trials ). Generalized Anxiety Disorder (DSM-IV) is characterized by excessive anxiety and worry (apprehensive expectation) that is persistent for at least 6 months and which the person finds difficult to control. It must be associated with at least 3 of the following 6 symptoms: Restlessness or feeling keyed up or on edge, being easily fatigued, difficulty concentrating or mind going blank, irritability, muscle tension, sleep disturbance. The efficacy of paroxetine in maintaining a response in patients with Generalized Anxiety Disorder, who responded during an 8-week acute treatment phase while taking paroxetine and were then observed for relapse during a period of up to 24 weeks, was demonstrated in a placebo-controlled trial (see CLINICAL PHARMACOLOGY: Clinical Trials ). Nevertheless, the physician who elects to use paroxetine for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION ). Posttraumatic Stress Disorder Paroxetine tablets are indicated for the treatment of Posttraumatic Stress Disorder (PTSD). The efficacy of paroxetine in the treatment of PTSD was established in two 12-week placebo-controlled trials in adults with PTSD (DSM-IV) (see CLINICAL PHARMACOLOGY: Clinical Trials ). PTSD, as defined by DSM-IV, requires exposure to a traumatic event that involved actual or threatened death or serious injury, or threat to the physical integrity of self or others, and a response that involves intense fear, helplessness, or horror. Symptoms that occur as a result of exposure to the traumatic event include reexperiencing of the event in the form of intrusive thoughts, flashbacks, or dreams, and intense psychological distress and physiological reactivity on exposure to cues to the event; avoidance of situations reminiscent of the traumatic event, inability to recall details of the event, and/or numbing of general responsiveness manifested as diminished interest in significant activities, estrangement from others, restricted range of affect, or sense of foreshortened future; and symptoms of autonomic arousal including hypervigilance, exaggerated startle response, sleep disturbance, impaired concentration, and irritability or outbursts of anger. A PTSD diagnosis requires that the symptoms are present for at least a month and that they cause clinically significant distress or impairment in social, occupational, or other important areas of functioning. The efficacy of paroxetine in longer-term treatment of PTSD, i.e., for more than 12 weeks, has not been systematically evaluated in placebo-controlled trials. Therefore, the physician who elects to prescribe paroxetine for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION ).|[PMDA] Drugs with a new additional indication and a new dosage for the treatment of posttraumatic stress disorder. uuid:042d0e5b-08ea-4623-95ad-5546147f3e4c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:70746 biolink:treats HP:0002625 PMID:41385096 "[{""id"":""uuid:e736f6dd-3131-4027-ba41-1380948696f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a5fb3933-c796-43d8-bdcc-345b9a967b1e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:72aa1e8c-adaa-4bd7-9c02-e660d52d5f7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PRADAXA is a direct thrombin inhibitor indicated: To reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation ( 1.1 ) For the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients who have been treated with a parenteral anticoagulant for 5-10 days ( 1.2 ) To reduce the risk of recurrence of DVT and PE in patients who have been previously treated ( 1.3 ) For the prophylaxis of DVT and PE in patients who have undergone hip replacement surgery ( 1.4 )|[EMA] Pradaxa 75 mgPrimary prevention of venous thromboembolic events in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery.Pradaxa 110 mgPrimary prevention of venous thromboembolic events in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery.Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischemic attack (TIA); age ≥ 75 years; heart failure (NYHA Class ≥ II); diabetes mellitus; hypertension.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.Pradaxa 150 mgPrevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischemic attack (TIA); age ≥ 75 years; heart failure (NYHA Class ≥ II); diabetes mellitus; hypertension.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. uuid:19d7f374-7f55-4e6e-978d-ab00f30c50ed biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:70746 biolink:treats MONDO:0005279 PMID:41385096 "[{""id"":""uuid:7c3edc2c-db29-4f55-aa96-eb07d25714ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:871fe2c7-6449-477b-ade2-654cf5fd815a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:5cf2f450-c941-4002-8ee2-86bbcf640b86"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PRADAXA is a direct thrombin inhibitor indicated: To reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation ( 1.1 ) For the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients who have been treated with a parenteral anticoagulant for 5-10 days ( 1.2 ) To reduce the risk of recurrence of DVT and PE in patients who have been previously treated ( 1.3 ) For the prophylaxis of DVT and PE in patients who have undergone hip replacement surgery ( 1.4 )|[EMA] Pradaxa 75 mgPrimary prevention of venous thromboembolic events in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery.Pradaxa 110 mgPrimary prevention of venous thromboembolic events in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery.Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischemic attack (TIA); age ≥ 75 years; heart failure (NYHA Class ≥ II); diabetes mellitus; hypertension.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.Pradaxa 150 mgPrevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischemic attack (TIA); age ≥ 75 years; heart failure (NYHA Class ≥ II); diabetes mellitus; hypertension.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. uuid:f39ab14e-1877-4ef9-88de-d37e22ca86e0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27504 biolink:treats MONDO:0005036 PMID:41385096 "[{""id"":""uuid:297a06be-2805-42f2-a1ff-a3fdbf127c79"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9a69fa04-fa92-4c5e-94a2-54531b9d9753"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mitomycin for Injection is not recommended as single-agent, primary therapy. It has been shown to be useful in the therapy of disseminated adenocarcinoma of the stomach or pancreas in proven combinations with other approved chemotherapeutic agents and as palliative treatment when other modalities have failed. Mitomycin is not recommended to replace appropriate surgery and/or radiotherapy. uuid:c0dd0162-28af-4d51-bc80-a1c70e3944a2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27504 biolink:treats MONDO:0006047 PMID:41385096 "[{""id"":""uuid:70a57510-c4b6-4add-9b48-551129688c07"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d83f0c3a-e5fb-4c39-a9d9-8c2c064a7051"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mitomycin for Injection is not recommended as single-agent, primary therapy. It has been shown to be useful in the therapy of disseminated adenocarcinoma of the stomach or pancreas in proven combinations with other approved chemotherapeutic agents and as palliative treatment when other modalities have failed. Mitomycin is not recommended to replace appropriate surgery and/or radiotherapy. uuid:7644adc4-073b-45a0-a62c-888588a940f4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3654 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:d11941a4-4a60-4664-b822-9000bdfe3f80"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:efc243df-2204-4e75-959f-9e025debc762"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] THALITONE is a thiazide-like diuretic indicated: • For the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions (1.1). • as adjunctive therapy in edema associated with heart failure, cirrhosis of the liver, and renal disease, including nephrotic syndrome (1.2). uuid:2a0d8865-9192-4940-beac-6ae073a9b3b5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3654 biolink:treats MONDO:0005240 PMID:41385096 "[{""id"":""uuid:688338b3-99de-476d-a7de-ea1973c5b15b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:819e1b25-ca81-4c58-b744-ec9da4091101"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] THALITONE is a thiazide-like diuretic indicated: • For the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions (1.1). • as adjunctive therapy in edema associated with heart failure, cirrhosis of the liver, and renal disease, including nephrotic syndrome (1.2). uuid:6d00a911-4565-4ab7-9261-7ba54e8c1cf8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7936 biolink:treats UMLS:C5442256 PMID:41385096 "[{""id"":""uuid:1c07cf37-2957-411c-b394-7c48b3e47600"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1e42856e-70d1-45c8-95a0-d81b6d1b130a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Paroxetine Capsules are indicated for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause. Limitation of Use : Paroxetine Capsules are not indicated for the treatment of any psychiatric condition. Paroxetine Capsules contain a lower dose of paroxetine than that used to treat depression, obsessive compulsive disorder, panic disorder, generalized anxiety disorder, social anxiety disorder, and post-traumatic stress disorder. The safety and efficacy of this lower dose of paroxetine in Paroxetine Capsules have not been established for any psychiatric condition. Patients who require paroxetine for treatment of a psychiatric condition should discontinue Paroxetine Capsules and initiate a paroxetine-containing medication that is indicated for such use. uuid:fea557e7-d5cf-433c-a575-9c1ef32c409f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:35828 biolink:treats MONDO:0012883 PMID:41385096 "[{""id"":""uuid:92ec7b1a-af66-44e5-a717-f732b4fd7fc1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a10df043-f60c-4c47-9824-0a64470a0db2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Arsenic Trioxide Injection is an arsenical indicated: For induction of remission and consolidation in patients with APL who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression. ( 1.2 ) uuid:1293b2c4-3e34-41b6-a6ab-17799b0cd250 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:131512 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:707557e7-061a-439c-b6f3-816b5d9e6d30"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:479baf89-f83d-4f34-a907-96ff11c29f44"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tranylcypromine tablets are indicated for the treatment of major depressive disorder (MDD) in adult patients who have not responded adequately to other antidepressants. Tranylcypromine tablets are not indicated for the initial treatment of MDD due to the potential for serious adverse reactions and drug interactions, and the need for dietary restrictions [see Contraindications (4), Warnings and Precautions (5), and Drug Interactions (7)] . uuid:9694c98d-1817-4d4d-abca-453cf46c2055 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:375719 biolink:treats HP:0012735 PMID:41385096 "[{""id"":""uuid:2a2feb73-3f56-487b-ab10-ec4fa3b6a387"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:001ac2fd-cd4e-43cb-ab77-5cf7796c0342"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Promethazine HCl and Codeine Phosphate Oral Solution is indicated for the temporary relief of coughs and upper respiratory symptoms associated with allergy or the common cold in patients 18 years of age and older. Important Limitations of Use Not indicated for pediatric patients under 18 years of age [see Use in Specific Populations (8.4) ]. Contraindicated in pediatric patients under 12 years of age [see Contraindications (4) , Use in Specific Populations (8.4) ]. Contraindicated in pediatric patients 12 to 18 years of age after tonsillectomy or adenoidectomy [see Contraindications (4) , Use in Specific Populations (8.4) ]. Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see Warnings and Precautions (5.1) ], reserve Promethazine HCl and Codeine Phosphate Oral Solution for use in adult patients for whom the benefits of cough suppression are expected to outweigh the risks, and in whom an adequate assessment of the etiology of the cough has been made. uuid:8c01c5ab-b86b-4292-b017-866600394b6e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:393355 biolink:treats UMLS:C0406317 PMID:41385096 "[{""id"":""uuid:ee7c7c11-ca7e-4093-807e-d456524add04"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bc3f8c68-a833-45e7-815c-ce5d24f07f04"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Taclonex ® Topical Suspension is indicated for the topical treatment of plaque psoriasis of the scalp and body in patients 12 years and older. uuid:5d54b9da-fbc7-4b8a-aa9d-6d30220307cd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17439 biolink:treats UMLS:C2959722 PMID:41385096 "[{""id"":""uuid:071e1274-ece4-4229-8ec8-985cdeed6073"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a4cd7c5e-c7e2-4be0-aa08-3463268382af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cyanocobalamin is indicated for Vitamin B 12 deficiencies due to malabsorption which may be associated with the following conditions: Addisonian (pernicious) anemia Gastrointestinal pathology, dysfunction, or surgery, including gluten enteropathy or sprue, small bowel bacterial overgrowth, total or partial gastrectomy Fish tapeworm infestation Malignancy of pancreas or bowel Folic acid deficiency It may be possible to treat the underlying disease by surgical correction of anatomic lesions leading to small bowel bacterial overgrowth, expulsion of fish tapeworm, discontinuation of drugs leading to vitamin malabsorption (see Drug/Laboratory Test Interactions ), use of a gluten-free diet in nontropical sprue, or administration of antibiotics in tropical sprue. Such measures remove the need for long-term administration of cyanocobalamin. Requirements of Vitamin B 12 in excess of normal (due to pregnancy, thyrotoxicosis, hemolytic anemia, hemorrhage, malignancy, hepatic and renal disease) can usually be met with oral supplementation. Cyanocobalamin injection is also suitable for the Vitamin B 12 absorption test (Schilling test). uuid:e7136441-6cb9-4222-9eb9-3de93336bf01 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:167450 biolink:treats MONDO:0005301 PMID:41385096 "[{""id"":""uuid:7488b8ce-b78b-41ce-ba93-fb5f78f70685"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1c3c1482-b9c2-4b5b-b60d-2f4a2d0d0279"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dimethyl fumarate delayed-release capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. uuid:5837da84-5e0c-4073-bf3b-ec665dff2335 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:167450 biolink:treats UMLS:C2921627 PMID:41385096 "[{""id"":""uuid:f456fec0-ce56-45f0-b94a-9fd6aa1536a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6896ded9-5078-4793-bba7-7a2bee370917"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dimethyl fumarate delayed-release capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. uuid:cdd15140-bb0b-4dd6-a806-80d9b4b5f308 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:167450 biolink:treats MONDO:0000450 PMID:41385096 "[{""id"":""uuid:26f5446c-d61f-4908-a47d-78425aad1cd3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5314f97b-7e34-44bd-a5dd-88a8d99874c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dimethyl fumarate delayed-release capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. uuid:1d1dfda8-a454-4d49-95fe-9758603c4f81 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:187893 biolink:treats MONDO:0011267 PMID:41385096 "[{""id"":""uuid:970b946b-33f1-4b4b-934d-58c54b53209c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6a9f462f-3626-47c8-9fc7-f25ff4afa3cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Baclofen injection (intrathecal) is indicated for use in the management of severe spasticity. Patients should first respond to a screening dose of intrathecal baclofen prior to consideration for long term infusion via an implantable pump. For spasticity of spinal cord origin, chronic infusion of baclofen injection (intrathecal) via an implantable pump should be reserved for patients unresponsive to oral baclofen therapy, or those who experience intolerable CNS side effects at effective doses. Patients with spasticity due to traumatic brain injury should wait at least one year after the injury before consideration of long term intrathecal baclofen therapy. Baclofen injection (intrathecal) is intended for use by the intrathecal route in single bolus test doses (via spinal catheter or lumbar puncture) and, for chronic use, only in implantable pumps approved by the FDA specifically for the administration of baclofen injection (intrathecal) into the intrathecal space. uuid:7d36f665-f246-4e41-a486-58ed04f69ab5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135929 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:6d862254-8c01-4bb2-af06-1be4b17af284"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e9711aec-dcca-41cf-bd2f-6278e00dd622"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Silodosin capsule, a selective alpha-1 adrenergic receptor antagonist, is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH) [see CLINICAL STUDIES (14)] . Silodosin capsule is not indicated for the treatment of hypertension. uuid:eca29bf4-b89c-438c-8558-65586457d7d6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28939 biolink:treats MONDO:0005359 PMID:41385096 "[{""id"":""uuid:707d448d-e0a1-44a8-820c-f7745cbd7c6e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bfa94fbb-1417-4e56-8f29-48d9d7a2a413"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Acetylcysteine injection is indicated to prevent or lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of acetaminophen in patients with acute ingestion or from repeated supratherapeutic ingestion (RSI). uuid:36b07dcd-b660-42e2-9965-08554f6f1fb6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5108 biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:0d0286d9-63e0-4090-969d-3684007be76c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f8bbfab5-3947-4a98-b132-040584cce0bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fluocinolone acetonide topical oil is a corticosteroid indicated for the topical treatment of atopic dermatitis in adult patients ( 1.1 ) topical treatment of moderate to severe atopic dermatitis in pediatric patients 3 months and older for up to 4 weeks ( 1.2 ) Limitations of Use: Apply the least amount to cover affected areas. Discontinue when disease is controlled. ( 1.3 ) Do not use in the diaper area. ( 1.3 ) Do not use on the face, axillae, or groin. ( 1.3 , 6.2 , 8.4 ) uuid:6b695c9c-143f-4320-9ad4-c8ab25c53e74 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28787 biolink:treats UMLS:C3661921 PMID:41385096 "[{""id"":""uuid:8d596b1b-b398-45aa-a688-d17b67c4386d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:20360350-e957-47f9-99a9-78134857884d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nitroglycerin Injection is indicated for treatment of peri-operative hypertension; for control of congestive heart failure in the setting of acute myocardial infarction; for treatment of angina pectoris in patients who have not responded to sublingual nitroglycerin and β -blockers; and for induction of intraoperative hypotension. uuid:e9084fa2-b3a6-49e6-b007-9856d0dcf82d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28787 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:cd4e4607-f04f-4c36-aa05-c98f64a1b528"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3c6991e1-5e30-4666-a910-7d392c055e0d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nitroglycerin Injection is indicated for treatment of peri-operative hypertension; for control of congestive heart failure in the setting of acute myocardial infarction; for treatment of angina pectoris in patients who have not responded to sublingual nitroglycerin and β -blockers; and for induction of intraoperative hypotension. uuid:1de6a313-c28f-44c9-af72-7c40d51caf14 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28787 biolink:treats MONDO:0004781 PMID:41385096 "[{""id"":""uuid:2e82d4b9-2f62-4e47-833b-e8b95ef90052"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fd578e9a-97e0-4616-9b9f-51cc3ec8239d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nitroglycerin Injection is indicated for treatment of peri-operative hypertension; for control of congestive heart failure in the setting of acute myocardial infarction; for treatment of angina pectoris in patients who have not responded to sublingual nitroglycerin and β -blockers; and for induction of intraoperative hypotension. uuid:2cb37ead-3243-4c11-b41a-014f94780403 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85990 biolink:treats MONDO:0009693 PMID:41385096 "[{""id"":""uuid:b2c5e9bc-a000-4a06-87ee-8774cacf063d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d47215e6-b74d-4a70-b0b6-3409be5fc0df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:63ef8d13-4dbf-43a3-9d6d-add51d50a72f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:868a2d37-6681-4320-bfab-152b51a3922e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FARYDAK, a histone deacetylase inhibitor, in combination with bortezomib and dexamethasone, is indicated for the treatment of patients with multiple myeloma who have received at least 2 prior regimens, including bortezomib and an immunomodulatory agent. This indication is approved under accelerated approval based on progression free survival [see Clinical Studies ( 14.1 )] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.|[EMA] Farydak, in combination with bortezomib and dexamethasone, is indicated for the treatment of adult patients with relapsed and/or refractory multiple myeloma who have received at least two prior regimens including bortezomib and an immunomodulatory agent.Farydak, in combination with bortezomib and dexamethasone, is indicated for the treatment of adult patients with relapsed and/or refractory multiple myeloma who have received at least two prior regimens including bortezomib and an immunomodulatory agent.|[PMDA] Drugs with a new active ingredient indicated for the treatment of relapsed or refractory multiple myeloma. [Orphan drug] uuid:2ffe19f2-955f-47bf-9caf-9f74b9cd2d77 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18367 biolink:treats MONDO:0000313 PMID:41385096 "[{""id"":""uuid:8b6155c1-600f-4ee4-a01a-072fed2bb600"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0d3fcc72-703e-4a69-ac0f-967aa7ff118f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Phosphates Injection, USP is indicated as a source of phosphate, for addition to large volume intravenous fluids, to prevent or correct hypophosphatemia in patients with restricted or no oral intake. It is also useful as an additive for preparing specific parenteral fluid formulas when the needs of the patient cannot be met by standard electrolyte or nutrient solutions. The concomitant amount of sodium (4 mEq/mL) must be calculated into total electrolyte dose of such prepared solutions. uuid:220b7860-d65f-40ac-a11a-8c817c4061be biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16684 biolink:treats UMLS:C0344132 PMID:41385096 "[{""id"":""uuid:de4efc61-b467-42fa-a402-30b0932fb0a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2b1e8e5d-0512-4b4b-bb9d-3f4bb0f302f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Atropine is indicated for temporary blockade of severe or life threatening muscarinic effects, e.g., as an antisialagogue, an antivagal agent, an antidote for organophosphorus, carbamate, or muscarinic mushroom poisoning, and to treat symptomatic bradycardia. uuid:6665a111-1de5-4743-b62a-a6148f2fd11b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16684 biolink:treats UMLS:C0026865 PMID:41385096 "[{""id"":""uuid:31e6d204-3132-4999-a7bf-191f8ee16e91"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f0302bad-856f-439c-9365-d471e55fbf1c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Atropine is indicated for temporary blockade of severe or life threatening muscarinic effects, e.g., as an antisialagogue, an antivagal agent, an antidote for organophosphorus, carbamate, or muscarinic mushroom poisoning, and to treat symptomatic bradycardia. uuid:ab19f923-dbfc-4ac4-8009-2ac258599c39 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2950 biolink:treats MONDO:0024332 PMID:41385096 "[{""id"":""uuid:682c1aaf-5ed7-48ac-944e-429b5b070455"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9c85cc3a-b9a4-42c7-9712-097922873d28"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azelastine hydrochloride nasal spray is an H 1 -receptor antagonist indicated for the relief of the symptoms of: Seasonal allergic rhinitis in patients 6 years of age and older. ( 1.1 ) Perennial allergic rhinitis in patients 6 years of age and older. ( 1.1 ) uuid:6c3aad55-c769-4b1e-8c2d-dc6a43ca9a4f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31485 biolink:treats MONDO:0006651 PMID:41385096 "[{""id"":""uuid:af44f973-8478-4950-bc0d-3f081732d98e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d830bb89-a575-4f8b-a510-2e574785fedf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Difluprednate ophthalmic emulsion is a topical corticosteroid that is indicated for: The treatment of inflammation and pain associated with ocular surgery ( 1.1 ) The treatment of endogenous anterior uveitis ( 1.2 ) uuid:29283880-024f-44db-9bfc-333371db837f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9570 biolink:treats MONDO:0004638 PMID:41385096 "[{""id"":""uuid:edc65b39-990a-4f5d-82c2-f224c8a352ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c11425b1-0d7e-4080-8624-bcc54f4090b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Thiotepa for Injection has been tried with varying results in the palliation of a wide variety of neoplastic diseases. However, the most consistent results have been seen in the following tumors: Adenocarcinoma of the breast. Adenocarcinoma of the ovary. For controlling intracavitary effusions secondary to diffuse or localized neoplastic diseases of various serosal cavities. For the treatment of superficial papillary carcinoma of the urinary bladder. While now largely superseded by other treatments, Thiotepa for Injection has been effective against other lymphomas, such as lymphosarcoma and Hodgkin's disease. uuid:4fe252d0-9906-4892-9e2c-1b0694aeeb7a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9570 biolink:treats MONDO:0009348 PMID:41385096 "[{""id"":""uuid:89964d4b-eb23-4af8-bdf6-e665880fc6b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4ed63f4f-1440-44cd-b785-81f0a1992003"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Thiotepa for Injection has been tried with varying results in the palliation of a wide variety of neoplastic diseases. However, the most consistent results have been seen in the following tumors: Adenocarcinoma of the breast. Adenocarcinoma of the ovary. For controlling intracavitary effusions secondary to diffuse or localized neoplastic diseases of various serosal cavities. For the treatment of superficial papillary carcinoma of the urinary bladder. While now largely superseded by other treatments, Thiotepa for Injection has been effective against other lymphomas, such as lymphosarcoma and Hodgkin's disease. uuid:a7c70d6b-a06d-47de-9801-8560c5d64674 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46345 biolink:treats MONDO:0005008 PMID:41385096 "[{""id"":""uuid:8300710f-38c3-44c6-b9b4-b7ddb5de5ed8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b7a9efc8-151e-46b2-ac87-567085e921aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fluorouracil is indicated for the treatment of patients with: 1.1 Adenocarcinoma of the Colon and Rectum 1.2 Adenocarcinoma of the Breast 1.3 Gastric Adenocarcinoma 1.4 Pancreatic Adenocarcinoma uuid:d5b43715-3279-4df4-8dc3-fbb7601b16dd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46345 biolink:treats MONDO:0004988 PMID:41385096 "[{""id"":""uuid:7ee42721-759a-462c-b9b2-53c395882e1d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:05cf7b61-a978-4ce8-ac06-ecef2d435812"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fluorouracil is indicated for the treatment of patients with: 1.1 Adenocarcinoma of the Colon and Rectum 1.2 Adenocarcinoma of the Breast 1.3 Gastric Adenocarcinoma 1.4 Pancreatic Adenocarcinoma uuid:d787d811-e965-4e68-9cbf-4aa801a4fef7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46345 biolink:treats MONDO:0005036 PMID:41385096 "[{""id"":""uuid:4550e976-88b9-4fcc-a7c3-092087224988"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:05ab2193-796b-4620-9886-5fc2d4755567"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fluorouracil is indicated for the treatment of patients with: 1.1 Adenocarcinoma of the Colon and Rectum 1.2 Adenocarcinoma of the Breast 1.3 Gastric Adenocarcinoma 1.4 Pancreatic Adenocarcinoma uuid:723ee3ed-c2ff-4724-b256-3eb5705cf9c4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46345 biolink:treats MONDO:0006047 PMID:41385096 "[{""id"":""uuid:379c84d8-7dd7-4c56-a325-9d5eb7954d87"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:45491557-7378-496b-a9f1-cd0b241aa2e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fluorouracil is indicated for the treatment of patients with: 1.1 Adenocarcinoma of the Colon and Rectum 1.2 Adenocarcinoma of the Breast 1.3 Gastric Adenocarcinoma 1.4 Pancreatic Adenocarcinoma uuid:0d8e5b0f-d52c-4401-b049-2f9c2679661a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27363 biolink:treats EFO:1000003 PMID:41385096 "[{""id"":""uuid:a5e390d1-a2f0-482d-9b6b-7d921aba5bd2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0b74497f-2055-441c-b392-e02c6f19bbf5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Zinc Chloride Injection, USP, 1 mg/mL is indicated for use as a supplement to intravenous solutions given for TPN. Administration helps to maintain zinc serum levels and to prevent depletion of endogenous stores, and subsequent deficiency symptoms. uuid:c2fb30e7-3c1e-4108-9734-e01ec0c1e6fd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3176 biolink:treats MONDO:0006875 PMID:41385096 "[{""id"":""uuid:959a95a4-01c3-4fa6-a993-123a279e7616"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:68dcd463-5c9e-47f5-99f3-b4a6fa6fa5c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:60de15df-87c9-46ef-b7b9-49cf7916fa94"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/azopt""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Brinzolamide ophthalmic suspension is a carbonic anhydrase inhibitor indicated in the treatment of elevated intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma.|[EMA] Azopt is indicated to decrease elevated intraocular pressure in:ocular hypertension;open-angle glaucomaas monotherapy in adult patients unresponsive to beta-blockers or in adult patients in whom beta-blockers are contraindicated, or as adjunctive therapy to beta-blockers or prostaglandin analogues. uuid:d27acce1-e5b1-4342-87a9-6d2b90f0c2f1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3176 biolink:treats MONDO:0005338 PMID:41385096 "[{""id"":""uuid:a7c3d224-b399-4880-8363-f1bfa45eb882"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:43f854c5-9f42-4c5f-afe1-0a1b92ce64c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:b9e1dbe9-09c6-4f96-95b9-17e8c185d289"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/azopt""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Brinzolamide ophthalmic suspension is a carbonic anhydrase inhibitor indicated in the treatment of elevated intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma.|[EMA] Azopt is indicated to decrease elevated intraocular pressure in:ocular hypertension;open-angle glaucomaas monotherapy in adult patients unresponsive to beta-blockers or in adult patients in whom beta-blockers are contraindicated, or as adjunctive therapy to beta-blockers or prostaglandin analogues. uuid:53b9493e-124a-40c2-8d64-5aec3f67cbd5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71253 biolink:treats MONDO:0024612 PMID:41385096 "[{""id"":""uuid:6996a789-6176-4ff4-b572-2097b258f4de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d351cb2f-83bf-40f8-9629-bf90ba690ee6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Asenapine sublingual tablets are indicated for: Schizophrenia in adults [see Clinical Studies (14.1) ] Bipolar I disorder [see Clinical Studies (14.2) ] Acute monotherapy of manic or mixed episodes, in adults and pediatric patients 10 to 17 years of age Adjunctive treatment to lithium or valproate in adults Maintenance monotherapy treatment in adults uuid:80aaccba-24fe-44bf-a057-f6d73b86318d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4450 biolink:treats MONDO:0003014 PMID:41385096 "[{""id"":""uuid:1590b35a-87b5-4563-9936-71b7b021d0aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ce729b52-c29d-4fee-90c1-bbc416fe3f1a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Desmopressin nasal spray solution is indicated as antidiuretic replacement therapy in the management of central diabetes insipidus in adults and pediatric patients 4 years of age and older. Limitations of Use: Desmopressin nasal spray solution is not indicated for: • Treatment of nephrogenic diabetes insipidus, • Treatment of primary nocturnal enuresis [ see Warnings and Precautions (5.1) ], • Use in patients with conditions that compromise the intranasal route of administration (e.g., severe nasal congestion and blockage, nasal mucosa atrophy, severe atrophic rhinitis, recent nasal surgery such as transsphenoidal hypophysectomy) [see Warnings and Precautions (5.2) ], • Use in patients with an impaired level of consciousness, • Use in patients requiring doses less than 10 mcg or doses that are not multiples of 10 mcg [see Dosage Forms and Strengths (3)]. uuid:9db8b789-1485-4c5a-bcb8-1c799c2689f8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4450 biolink:treats UMLS:C0919923 PMID:41385096 "[{""id"":""uuid:595b435e-094b-4755-9426-789d69a556fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ba5f6b24-a402-4af8-8e2b-0d3936baf4a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Desmopressin nasal spray solution is indicated as antidiuretic replacement therapy in the management of central diabetes insipidus in adults and pediatric patients 4 years of age and older. Limitations of Use: Desmopressin nasal spray solution is not indicated for: • Treatment of nephrogenic diabetes insipidus, • Treatment of primary nocturnal enuresis [ see Warnings and Precautions (5.1) ], • Use in patients with conditions that compromise the intranasal route of administration (e.g., severe nasal congestion and blockage, nasal mucosa atrophy, severe atrophic rhinitis, recent nasal surgery such as transsphenoidal hypophysectomy) [see Warnings and Precautions (5.2) ], • Use in patients with an impaired level of consciousness, • Use in patients requiring doses less than 10 mcg or doses that are not multiples of 10 mcg [see Dosage Forms and Strengths (3)]. uuid:1f22dd5d-7d6b-4dc5-b587-3006975a6725 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28918 biolink:treats MONDO:0001881 PMID:41385096 "[{""id"":""uuid:5a7c87d7-ccdb-4b37-a391-d19a09b2bd39"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8faceb8d-eb75-4906-90a6-757899f31336"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Epinephrine is a non-selective alpha and beta adrenergic agonist indicated: • To increase mean arterial blood pressure in adult patients with hypotension associated with septic shock. ( 1.1 ) • For emergency treatment of allergic reactions (Type 1), including anaphylaxis. ( 1.2 ) • For induction and maintenance of mydriasis during intraocular surgery. ( 1.3 ) uuid:03e63b60-c77c-463c-a7b5-d47ab9874310 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4031 biolink:treats UMLS:C0238217 PMID:41385096 "[{""id"":""uuid:4648318e-8c0c-435e-8b55-0b911b0a6497"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:80d44595-70cd-43f9-b27c-a4e21f271fdc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cyclosporine capsules, USP [MODIFIED] and cyclosporine oral solution, USP [MODIFIED] are indicated for the prophylaxis of organ rejection in kidney, liver, and heart allogeneic transplants. Cyclosporine capsules, USP [MODIFIED] and cyclosporine oral solution, USP [MODIFIED] have been used in combination with azathioprine and corticosteroids. uuid:4ecb18e7-3177-42bb-9130-4f3d23618f15 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4031 biolink:treats UMLS:C0340530 PMID:41385096 "[{""id"":""uuid:1c416f91-fb76-46a6-ab59-e58c0d90e365"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4431ae68-7a79-45c5-9a05-101ad61d142b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cyclosporine capsules, USP [MODIFIED] and cyclosporine oral solution, USP [MODIFIED] are indicated for the prophylaxis of organ rejection in kidney, liver, and heart allogeneic transplants. Cyclosporine capsules, USP [MODIFIED] and cyclosporine oral solution, USP [MODIFIED] have been used in combination with azathioprine and corticosteroids. uuid:4fc71dc3-cd96-4d91-a367-a87a31b70e08 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3SY5LH9PMK biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:6ac1e328-8178-4aef-8552-b71d5a7884be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:91524cc0-db4f-4f88-8730-bd0b65e22c1b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Benazepril hydrochloride tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. It may be used alone or in combination with thiazide diuretics. uuid:c22bfa27-36b0-4f7d-99a6-df2b8e227b04 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3SY5LH9PMK biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:69d8d095-6d04-425b-8466-337b754ede5d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c4463f65-5c88-41c7-8a9a-eb3046b2bfe8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Benazepril hydrochloride tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. It may be used alone or in combination with thiazide diuretics. uuid:9c62b436-6a00-4e2f-b08f-86693bb4e467 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3SY5LH9PMK biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:bbe80a0a-a242-4070-88a8-ab4c34478ab7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1dc015de-b1f1-45db-95de-ea3f206b0736"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Benazepril hydrochloride tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. It may be used alone or in combination with thiazide diuretics. uuid:a1a31757-7667-4f77-bd3d-fcb4fabd15c2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3SY5LH9PMK biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:2fc30d04-b626-43ed-8d67-90f20b119c4e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:756f0d02-f2fe-46b7-9b97-d162e5536581"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Benazepril hydrochloride tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. It may be used alone or in combination with thiazide diuretics. uuid:9cc69db4-6905-4925-9419-454c2f1d1b07 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3SY5LH9PMK biolink:treats MONDO:0005016 PMID:41385096 "[{""id"":""uuid:76b04110-2420-497d-bea0-0a02565569fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a79e33fd-ec7e-470e-883f-26ee0f6e558f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Benazepril hydrochloride tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. It may be used alone or in combination with thiazide diuretics. uuid:70d94483-07d8-4c6b-b25b-4aff55c166aa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:46878853 biolink:treats MONDO:0007788 PMID:41385096 "[{""id"":""uuid:3b3198ab-fb2b-4b34-8eeb-2097842a5421"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c3947135-67d5-491d-8a5e-6a7d8d0903ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Treatment of Hypercholesterolemia Fenofibrate capsules are indicated as adjunctive therapy to diet for the reduction of LDL-C, Total-C, Triglycerides and Apo B in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb). Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and non-pharmacological interventions alone has been inadequate (see National Cholesterol Education Program [NCEP] Treatment Guidelines, below). Treatment of Hypertriglyceridemia Fenofibrate capsules are also indicated as adjunctive therapy to diet for treatment of adult patients with hypertriglyceridemia (Fredrickson Types IV and V hyperlipidemia). Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually reduce fasting triglycerides and eliminate chylomicronemia thereby obviating the need for pharmacologic intervention. Markedly elevated levels of serum triglycerides (e.g. > 2,000 mg/dL) may increase the risk of developing pancreatitis. The effect of fenofibrate capsules therapy on reducing this risk has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of very low density lipoprotein (VLDL). Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV and V hyperlipoproteinemia 2 . The initial treatment for dyslipidemia is dietary therapy specific for the type of lipoprotein abnormality. Excess body weight and excess alcoholic intake may be important factors in hypertriglyceridemia and should be addressed prior to any drug therapy. Physical exercise can be an important ancillary measure. Diseases contributory to hyperlipidemia, such as hypothyroidism or diabetes mellitus should be looked for and adequately treated. Estrogen therapy, like thiazide diuretics and beta-blockers, is sometimes associated with massive rises in plasma triglycerides, especially in subjects with familial hypertriglyceridemia. In such cases, discontinuation of the specific etiologic agent may obviate the need for specific drug therapy of hypertriglyceridemia. The use of drugs should be considered only when reasonable attempts have been made to obtain satisfactory results with non-drug methods. If the decision is made to use drugs, the patient should be instructed that this does not reduce the importance of adhering to diet (See WARNINGS and PRECAUTIONS ). Fredrickson Classification of Hyperlipoproteinemias C = cholesterol TG = triglycerides LDL = low density lipoprotein VLDL = very low density lipoprotein IDL = intermediate density lipoprotein Lipid Elevation Type Lipoprotein Elevated Major Minor I (rare) chylomicrons TG ↑ ↔ C IIa LDL C — IIb LDL, VLDL C TG III (rare) IDL C, TG — IV VLDL TG ↑ ↔ C V (rare) chylomicrons, VLDL TG ↑ ↔ The NCEP Treatment Guidelines a) Coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease) b) Other risk factors for coronary heart disease (CHD) include age (males: ≥45 years females: ≥55 years or premature menopause without estrogen replacement therapy); family history of premature CHD, current cigarette smoking; hypertension; confirmed HDL-C is <35 mg/dL (< 0.91 mmol/L), and diabetes mellitus. Subtract 1 risk factor if HDL-C is >60 mg/dL (≥1.6 mmol/L) c) in CHD patients with LDL-C levels 100 to 129 mg/dL the physician should exercise clinical judgment in deciding whether to initiate drug treatment Definite Athlerosclerotic Disease a Two or More Other Risk Factors b LDL-Cholesterol mg/dL (mmol/L) Initiation Level Goal No No ≥ 190 (≥ 4.9) < 160 (< 4.1) No Yes ≥ 160 (≥ 4.1) < 130 (< 3.4) Yes Yes or No ≥ 130 c (≥ 3.4) < 100 (< 2.6) uuid:280495e6-73cf-4431-baae-a39ab8c8144f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:46878853 biolink:treats MONDO:0007762 PMID:41385096 "[{""id"":""uuid:fb669a7e-8ddd-4147-bd22-f1885f914043"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cf597378-ec51-4704-a706-3689def74d73"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Treatment of Hypercholesterolemia Fenofibrate capsules are indicated as adjunctive therapy to diet for the reduction of LDL-C, Total-C, Triglycerides and Apo B in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb). Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and non-pharmacological interventions alone has been inadequate (see National Cholesterol Education Program [NCEP] Treatment Guidelines, below). Treatment of Hypertriglyceridemia Fenofibrate capsules are also indicated as adjunctive therapy to diet for treatment of adult patients with hypertriglyceridemia (Fredrickson Types IV and V hyperlipidemia). Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually reduce fasting triglycerides and eliminate chylomicronemia thereby obviating the need for pharmacologic intervention. Markedly elevated levels of serum triglycerides (e.g. > 2,000 mg/dL) may increase the risk of developing pancreatitis. The effect of fenofibrate capsules therapy on reducing this risk has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of very low density lipoprotein (VLDL). Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV and V hyperlipoproteinemia 2 . The initial treatment for dyslipidemia is dietary therapy specific for the type of lipoprotein abnormality. Excess body weight and excess alcoholic intake may be important factors in hypertriglyceridemia and should be addressed prior to any drug therapy. Physical exercise can be an important ancillary measure. Diseases contributory to hyperlipidemia, such as hypothyroidism or diabetes mellitus should be looked for and adequately treated. Estrogen therapy, like thiazide diuretics and beta-blockers, is sometimes associated with massive rises in plasma triglycerides, especially in subjects with familial hypertriglyceridemia. In such cases, discontinuation of the specific etiologic agent may obviate the need for specific drug therapy of hypertriglyceridemia. The use of drugs should be considered only when reasonable attempts have been made to obtain satisfactory results with non-drug methods. If the decision is made to use drugs, the patient should be instructed that this does not reduce the importance of adhering to diet (See WARNINGS and PRECAUTIONS ). Fredrickson Classification of Hyperlipoproteinemias C = cholesterol TG = triglycerides LDL = low density lipoprotein VLDL = very low density lipoprotein IDL = intermediate density lipoprotein Lipid Elevation Type Lipoprotein Elevated Major Minor I (rare) chylomicrons TG ↑ ↔ C IIa LDL C — IIb LDL, VLDL C TG III (rare) IDL C, TG — IV VLDL TG ↑ ↔ C V (rare) chylomicrons, VLDL TG ↑ ↔ The NCEP Treatment Guidelines a) Coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease) b) Other risk factors for coronary heart disease (CHD) include age (males: ≥45 years females: ≥55 years or premature menopause without estrogen replacement therapy); family history of premature CHD, current cigarette smoking; hypertension; confirmed HDL-C is <35 mg/dL (< 0.91 mmol/L), and diabetes mellitus. Subtract 1 risk factor if HDL-C is >60 mg/dL (≥1.6 mmol/L) c) in CHD patients with LDL-C levels 100 to 129 mg/dL the physician should exercise clinical judgment in deciding whether to initiate drug treatment Definite Athlerosclerotic Disease a Two or More Other Risk Factors b LDL-Cholesterol mg/dL (mmol/L) Initiation Level Goal No No ≥ 190 (≥ 4.9) < 160 (< 4.1) No Yes ≥ 160 (≥ 4.1) < 130 (< 3.4) Yes Yes or No ≥ 130 c (≥ 3.4) < 100 (< 2.6) uuid:0e482477-8e7e-4d91-ab7d-bbb07fb678dd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:46878853 biolink:treats MONDO:0009387 PMID:41385096 "[{""id"":""uuid:b76af9ee-46ae-4c7a-bcf9-5d577054d3fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:750a58b8-4085-4d9c-a79b-c46609426d8c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Treatment of Hypercholesterolemia Fenofibrate capsules are indicated as adjunctive therapy to diet for the reduction of LDL-C, Total-C, Triglycerides and Apo B in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb). Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and non-pharmacological interventions alone has been inadequate (see National Cholesterol Education Program [NCEP] Treatment Guidelines, below). Treatment of Hypertriglyceridemia Fenofibrate capsules are also indicated as adjunctive therapy to diet for treatment of adult patients with hypertriglyceridemia (Fredrickson Types IV and V hyperlipidemia). Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually reduce fasting triglycerides and eliminate chylomicronemia thereby obviating the need for pharmacologic intervention. Markedly elevated levels of serum triglycerides (e.g. > 2,000 mg/dL) may increase the risk of developing pancreatitis. The effect of fenofibrate capsules therapy on reducing this risk has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of very low density lipoprotein (VLDL). Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV and V hyperlipoproteinemia 2 . The initial treatment for dyslipidemia is dietary therapy specific for the type of lipoprotein abnormality. Excess body weight and excess alcoholic intake may be important factors in hypertriglyceridemia and should be addressed prior to any drug therapy. Physical exercise can be an important ancillary measure. Diseases contributory to hyperlipidemia, such as hypothyroidism or diabetes mellitus should be looked for and adequately treated. Estrogen therapy, like thiazide diuretics and beta-blockers, is sometimes associated with massive rises in plasma triglycerides, especially in subjects with familial hypertriglyceridemia. In such cases, discontinuation of the specific etiologic agent may obviate the need for specific drug therapy of hypertriglyceridemia. The use of drugs should be considered only when reasonable attempts have been made to obtain satisfactory results with non-drug methods. If the decision is made to use drugs, the patient should be instructed that this does not reduce the importance of adhering to diet (See WARNINGS and PRECAUTIONS ). Fredrickson Classification of Hyperlipoproteinemias C = cholesterol TG = triglycerides LDL = low density lipoprotein VLDL = very low density lipoprotein IDL = intermediate density lipoprotein Lipid Elevation Type Lipoprotein Elevated Major Minor I (rare) chylomicrons TG ↑ ↔ C IIa LDL C — IIb LDL, VLDL C TG III (rare) IDL C, TG — IV VLDL TG ↑ ↔ C V (rare) chylomicrons, VLDL TG ↑ ↔ The NCEP Treatment Guidelines a) Coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease) b) Other risk factors for coronary heart disease (CHD) include age (males: ≥45 years females: ≥55 years or premature menopause without estrogen replacement therapy); family history of premature CHD, current cigarette smoking; hypertension; confirmed HDL-C is <35 mg/dL (< 0.91 mmol/L), and diabetes mellitus. Subtract 1 risk factor if HDL-C is >60 mg/dL (≥1.6 mmol/L) c) in CHD patients with LDL-C levels 100 to 129 mg/dL the physician should exercise clinical judgment in deciding whether to initiate drug treatment Definite Athlerosclerotic Disease a Two or More Other Risk Factors b LDL-Cholesterol mg/dL (mmol/L) Initiation Level Goal No No ≥ 190 (≥ 4.9) < 160 (< 4.1) No Yes ≥ 160 (≥ 4.1) < 130 (< 3.4) Yes Yes or No ≥ 130 c (≥ 3.4) < 100 (< 2.6) uuid:61c3da84-d4a9-48e5-bf4c-6e62ffe9c577 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:46878853 biolink:treats MONDO:0005294 PMID:41385096 "[{""id"":""uuid:bd2d5742-0af1-4896-bab7-e6c502843907"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9f170a30-6fa9-4085-88c0-5a3433ee4385"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Treatment of Hypercholesterolemia Fenofibrate capsules are indicated as adjunctive therapy to diet for the reduction of LDL-C, Total-C, Triglycerides and Apo B in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb). Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and non-pharmacological interventions alone has been inadequate (see National Cholesterol Education Program [NCEP] Treatment Guidelines, below). Treatment of Hypertriglyceridemia Fenofibrate capsules are also indicated as adjunctive therapy to diet for treatment of adult patients with hypertriglyceridemia (Fredrickson Types IV and V hyperlipidemia). Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually reduce fasting triglycerides and eliminate chylomicronemia thereby obviating the need for pharmacologic intervention. Markedly elevated levels of serum triglycerides (e.g. > 2,000 mg/dL) may increase the risk of developing pancreatitis. The effect of fenofibrate capsules therapy on reducing this risk has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of very low density lipoprotein (VLDL). Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV and V hyperlipoproteinemia 2 . The initial treatment for dyslipidemia is dietary therapy specific for the type of lipoprotein abnormality. Excess body weight and excess alcoholic intake may be important factors in hypertriglyceridemia and should be addressed prior to any drug therapy. Physical exercise can be an important ancillary measure. Diseases contributory to hyperlipidemia, such as hypothyroidism or diabetes mellitus should be looked for and adequately treated. Estrogen therapy, like thiazide diuretics and beta-blockers, is sometimes associated with massive rises in plasma triglycerides, especially in subjects with familial hypertriglyceridemia. In such cases, discontinuation of the specific etiologic agent may obviate the need for specific drug therapy of hypertriglyceridemia. The use of drugs should be considered only when reasonable attempts have been made to obtain satisfactory results with non-drug methods. If the decision is made to use drugs, the patient should be instructed that this does not reduce the importance of adhering to diet (See WARNINGS and PRECAUTIONS ). Fredrickson Classification of Hyperlipoproteinemias C = cholesterol TG = triglycerides LDL = low density lipoprotein VLDL = very low density lipoprotein IDL = intermediate density lipoprotein Lipid Elevation Type Lipoprotein Elevated Major Minor I (rare) chylomicrons TG ↑ ↔ C IIa LDL C — IIb LDL, VLDL C TG III (rare) IDL C, TG — IV VLDL TG ↑ ↔ C V (rare) chylomicrons, VLDL TG ↑ ↔ The NCEP Treatment Guidelines a) Coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease) b) Other risk factors for coronary heart disease (CHD) include age (males: ≥45 years females: ≥55 years or premature menopause without estrogen replacement therapy); family history of premature CHD, current cigarette smoking; hypertension; confirmed HDL-C is <35 mg/dL (< 0.91 mmol/L), and diabetes mellitus. Subtract 1 risk factor if HDL-C is >60 mg/dL (≥1.6 mmol/L) c) in CHD patients with LDL-C levels 100 to 129 mg/dL the physician should exercise clinical judgment in deciding whether to initiate drug treatment Definite Athlerosclerotic Disease a Two or More Other Risk Factors b LDL-Cholesterol mg/dL (mmol/L) Initiation Level Goal No No ≥ 190 (≥ 4.9) < 160 (< 4.1) No Yes ≥ 160 (≥ 4.1) < 130 (< 3.4) Yes Yes or No ≥ 130 c (≥ 3.4) < 100 (< 2.6) uuid:08f864fc-6136-4dee-8a8b-8611a9cdd1a4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:46878853 biolink:treats MONDO:0005269 PMID:41385096 "[{""id"":""uuid:4fef32c3-4a4b-43bb-a15f-65f2549a8dd3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:27435c06-de5a-4e75-8e54-4a01a86de2bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Treatment of Hypercholesterolemia Fenofibrate capsules are indicated as adjunctive therapy to diet for the reduction of LDL-C, Total-C, Triglycerides and Apo B in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb). Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and non-pharmacological interventions alone has been inadequate (see National Cholesterol Education Program [NCEP] Treatment Guidelines, below). Treatment of Hypertriglyceridemia Fenofibrate capsules are also indicated as adjunctive therapy to diet for treatment of adult patients with hypertriglyceridemia (Fredrickson Types IV and V hyperlipidemia). Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually reduce fasting triglycerides and eliminate chylomicronemia thereby obviating the need for pharmacologic intervention. Markedly elevated levels of serum triglycerides (e.g. > 2,000 mg/dL) may increase the risk of developing pancreatitis. The effect of fenofibrate capsules therapy on reducing this risk has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of very low density lipoprotein (VLDL). Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV and V hyperlipoproteinemia 2 . The initial treatment for dyslipidemia is dietary therapy specific for the type of lipoprotein abnormality. Excess body weight and excess alcoholic intake may be important factors in hypertriglyceridemia and should be addressed prior to any drug therapy. Physical exercise can be an important ancillary measure. Diseases contributory to hyperlipidemia, such as hypothyroidism or diabetes mellitus should be looked for and adequately treated. Estrogen therapy, like thiazide diuretics and beta-blockers, is sometimes associated with massive rises in plasma triglycerides, especially in subjects with familial hypertriglyceridemia. In such cases, discontinuation of the specific etiologic agent may obviate the need for specific drug therapy of hypertriglyceridemia. The use of drugs should be considered only when reasonable attempts have been made to obtain satisfactory results with non-drug methods. If the decision is made to use drugs, the patient should be instructed that this does not reduce the importance of adhering to diet (See WARNINGS and PRECAUTIONS ). Fredrickson Classification of Hyperlipoproteinemias C = cholesterol TG = triglycerides LDL = low density lipoprotein VLDL = very low density lipoprotein IDL = intermediate density lipoprotein Lipid Elevation Type Lipoprotein Elevated Major Minor I (rare) chylomicrons TG ↑ ↔ C IIa LDL C — IIb LDL, VLDL C TG III (rare) IDL C, TG — IV VLDL TG ↑ ↔ C V (rare) chylomicrons, VLDL TG ↑ ↔ The NCEP Treatment Guidelines a) Coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease) b) Other risk factors for coronary heart disease (CHD) include age (males: ≥45 years females: ≥55 years or premature menopause without estrogen replacement therapy); family history of premature CHD, current cigarette smoking; hypertension; confirmed HDL-C is <35 mg/dL (< 0.91 mmol/L), and diabetes mellitus. Subtract 1 risk factor if HDL-C is >60 mg/dL (≥1.6 mmol/L) c) in CHD patients with LDL-C levels 100 to 129 mg/dL the physician should exercise clinical judgment in deciding whether to initiate drug treatment Definite Athlerosclerotic Disease a Two or More Other Risk Factors b LDL-Cholesterol mg/dL (mmol/L) Initiation Level Goal No No ≥ 190 (≥ 4.9) < 160 (< 4.1) No Yes ≥ 160 (≥ 4.1) < 130 (< 3.4) Yes Yes or No ≥ 130 c (≥ 3.4) < 100 (< 2.6) uuid:bc69345b-5e10-49f1-9c61-bf07ddea6792 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:46878853 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:41ebc67d-3bda-4a43-92f1-4f7a84de8570"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c07b8bd9-ac30-45ce-b5e5-5285b95e87a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Treatment of Hypercholesterolemia Fenofibrate capsules are indicated as adjunctive therapy to diet for the reduction of LDL-C, Total-C, Triglycerides and Apo B in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb). Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and non-pharmacological interventions alone has been inadequate (see National Cholesterol Education Program [NCEP] Treatment Guidelines, below). Treatment of Hypertriglyceridemia Fenofibrate capsules are also indicated as adjunctive therapy to diet for treatment of adult patients with hypertriglyceridemia (Fredrickson Types IV and V hyperlipidemia). Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually reduce fasting triglycerides and eliminate chylomicronemia thereby obviating the need for pharmacologic intervention. Markedly elevated levels of serum triglycerides (e.g. > 2,000 mg/dL) may increase the risk of developing pancreatitis. The effect of fenofibrate capsules therapy on reducing this risk has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of very low density lipoprotein (VLDL). Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV and V hyperlipoproteinemia 2 . The initial treatment for dyslipidemia is dietary therapy specific for the type of lipoprotein abnormality. Excess body weight and excess alcoholic intake may be important factors in hypertriglyceridemia and should be addressed prior to any drug therapy. Physical exercise can be an important ancillary measure. Diseases contributory to hyperlipidemia, such as hypothyroidism or diabetes mellitus should be looked for and adequately treated. Estrogen therapy, like thiazide diuretics and beta-blockers, is sometimes associated with massive rises in plasma triglycerides, especially in subjects with familial hypertriglyceridemia. In such cases, discontinuation of the specific etiologic agent may obviate the need for specific drug therapy of hypertriglyceridemia. The use of drugs should be considered only when reasonable attempts have been made to obtain satisfactory results with non-drug methods. If the decision is made to use drugs, the patient should be instructed that this does not reduce the importance of adhering to diet (See WARNINGS and PRECAUTIONS ). Fredrickson Classification of Hyperlipoproteinemias C = cholesterol TG = triglycerides LDL = low density lipoprotein VLDL = very low density lipoprotein IDL = intermediate density lipoprotein Lipid Elevation Type Lipoprotein Elevated Major Minor I (rare) chylomicrons TG ↑ ↔ C IIa LDL C — IIb LDL, VLDL C TG III (rare) IDL C, TG — IV VLDL TG ↑ ↔ C V (rare) chylomicrons, VLDL TG ↑ ↔ The NCEP Treatment Guidelines a) Coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease) b) Other risk factors for coronary heart disease (CHD) include age (males: ≥45 years females: ≥55 years or premature menopause without estrogen replacement therapy); family history of premature CHD, current cigarette smoking; hypertension; confirmed HDL-C is <35 mg/dL (< 0.91 mmol/L), and diabetes mellitus. Subtract 1 risk factor if HDL-C is >60 mg/dL (≥1.6 mmol/L) c) in CHD patients with LDL-C levels 100 to 129 mg/dL the physician should exercise clinical judgment in deciding whether to initiate drug treatment Definite Athlerosclerotic Disease a Two or More Other Risk Factors b LDL-Cholesterol mg/dL (mmol/L) Initiation Level Goal No No ≥ 190 (≥ 4.9) < 160 (< 4.1) No Yes ≥ 160 (≥ 4.1) < 130 (< 3.4) Yes Yes or No ≥ 130 c (≥ 3.4) < 100 (< 2.6) uuid:62154e1e-bba3-4b51-9dc0-344a85b6ee79 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28364 biolink:treats MONDO:0005347 PMID:41385096 "[{""id"":""uuid:6e723767-1e7d-473e-bbdf-4fca22ca0f39"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d5bf1dfd-c2aa-4293-bc30-4be737b0a6c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Icosapent ethyl capsules are indicated: as an adjunct to diet to reduce TG levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia. Limitations of Use: The effect of icosapent ethyl capsules on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined. uuid:c6de56a9-e632-4091-9765-63bd29bd6ebb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28364 biolink:treats MONDO:0004982 PMID:41385096 "[{""id"":""uuid:97d70db4-a876-4a45-9eb9-31e8d7e6dff9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9a242eb4-4b85-41d4-83b5-a43cf1685a0b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Icosapent ethyl capsules are indicated: as an adjunct to diet to reduce TG levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia. Limitations of Use: The effect of icosapent ethyl capsules on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined. uuid:267e41e3-a249-4b7a-b954-621505eb8263 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27899 biolink:treats MONDO:0005447 PMID:41385096 "[{""id"":""uuid:761c5a73-e346-4424-a91c-8ec0968bbcc5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a2da9f76-418b-456a-bbe0-f37a4f039142"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cisplatin for injection is a platinum-based drug indicated for the treatment of: • Advanced testicular cancer ( 1.1 ) • Advanced ovarian cancer ( 1.2 ) • Advanced bladder cancer ( 1.3 ) uuid:76916d93-52d6-4f83-a0ba-fc62a7e5c7c5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27899 biolink:treats MONDO:0008170 PMID:41385096 "[{""id"":""uuid:2f667c36-3b40-43b1-9f46-d23ccb13f2d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a8987f0f-a415-4035-be1d-1e2add3bff43"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cisplatin for injection is a platinum-based drug indicated for the treatment of: • Advanced testicular cancer ( 1.1 ) • Advanced ovarian cancer ( 1.2 ) • Advanced bladder cancer ( 1.3 ) uuid:42131cba-e736-4e36-a49b-95caaba79c5e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27899 biolink:treats UMLS:C5554305 PMID:41385096 "[{""id"":""uuid:614542fa-4aad-4956-9f4e-ca9701f01922"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f74fe3ba-5eea-4daa-97c4-209bfd283b51"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cisplatin for injection is a platinum-based drug indicated for the treatment of: • Advanced testicular cancer ( 1.1 ) • Advanced ovarian cancer ( 1.2 ) • Advanced bladder cancer ( 1.3 ) uuid:440d6728-52ff-4c8a-9b8b-26507d422427 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3347 biolink:treats MONDO:0006652 PMID:41385096 "[{""id"":""uuid:35a1dc5f-983f-4fcc-9dee-bb286b29bd4a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bc539c98-20df-4dc4-8d0b-2117b75d886a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Candesartan cilexetil tablets are an angiotensin II receptor blocker (ARB) indicated for: · Treatment of hypertension in adults and children 1 to <17 years of age, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions (1.1). · Treatment of heart failure (NYHA class II-IV); candesartan cilexetil tablets reduces cardiovascular death and heart failure hospitalization (1.2). uuid:6ba440b8-b5f2-4303-ba48-950c32a959d2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:474053 biolink:treats MONDO:0021839 PMID:41385096 "[{""id"":""uuid:eb41f16f-95e0-4d77-9aba-26f96f2b5618"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5ef83f42-962b-4295-ae15-aebab364e6a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefazolin for Injection, USP is indicated for the treatment of the following serious infections due to susceptible organisms. Respiratory Tract Infections: Due to S. pneumoniae, Klebsiella species , H. influenzae, S. aureus (penicillin-sensitive and penicillin-resistant), and group A beta-hemolytic streptococci. Injectable benzathine penicillin is considered the drug of choice in treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cefazolin for Injection, USP is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of Cefazolin for Injection, USP in the subsequent prevention of rheumatic fever are not available at present. Urinary Tract Infections: Due to E. coli, P. mirabilis, Klebsiella species, and some strains of enterobacter and enterococci. Skin and Skin Structure Infections: Due to S. aureus (penicillin‑sensitive and penicillin-resistant), group A beta‑hemolytic streptococci, and other strains of streptococci. Biliary Tract Infections: Due to E. coli , various strains of streptococci, P. mirabilis , Klebsiella species, and S. aureus . Bone and Joint Infections: Due to S. aureus . Genital Infections: (i.e., prostatitis, epididymitis) due to E. coli , P. mirabilis , Klebsiella species, and some strains of enterococci. Septicemia: Due to S. pneumoniae , S. aureus (penicillin‑sensitive and penicillin‑resistant), P. mirabilis , E. coli , and Klebsiella species. Endocarditis: Due to S. aureus (penicillin‑sensitive and penicillin‑resistant) and group A beta‑hemolytic streptococci. Perioperative Prophylaxis: The prophylactic administration of Cefazolin for Injection, USP preoperatively, intraoperatively, and postoperatively may reduce the incidence of certain postoperative infections in patients undergoing surgical procedures which are classified as contaminated or potentially contaminated (e.g., vaginal hysterectomy, and cholecystectomy in high‑risk patients such as those older than 70 years, with acute cholecystitis, obstructive jaundice, or common duct bile stones). The perioperative use of Cefazolin for Injection, USP may also be effective in surgical patients in whom infection at the operative site would present a serious risk (e.g., during open‑heart surgery and prosthetic arthroplasty). The prophylactic administration of Cefazolin for Injection, USP should usually be discontinued within a 24‑hour period after the surgical procedure. In surgery where the occurrence of infection may be particularly devastating (e.g., open-heart surgery and prosthetic arthroplasty), the prophylactic administration of Cefazolin for Injection, USP may be continued for 3 to 5 days following the completion of surgery. If there are signs of infection, specimens for cultures should be obtained for the identification of the causative organism so that appropriate therapy may be instituted. (See DOSAGE AND ADMINISTRATION.) To reduce the development of drug‑resistant bacteria and maintain the effectiveness of Cefazolin for Injection, USP and other antibacterial drugs, Cefazolin for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:6fddc0c3-42ba-433e-81df-24ad3a9b05aa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:474180 biolink:treats MONDO:0002041 PMID:41385096 "[{""id"":""uuid:0630fd2f-d940-469f-b091-e62b41c9470c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1005b7af-6525-4ce6-9999-7e7e6653c54c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Caspofungin acetate for Injection is an echinocandin antifungal indicated in adults and pediatric patients (3 months of age and older) for: Empirical therapy for presumed fungal infections in febrile, neutropenic patients. ( 1 ) Treatment of candidemia and the following Candida infections: intra-abdominal abscesses, peritonitis and pleural space infections. ( 1 ) Treatment of esophageal candidiasis. ( 1 ) Treatment of invasive aspergillosis in patients who are refractory to or intolerant of other therapies. ( 1 ) uuid:94259532-12e4-4e46-8450-498eb8282e26 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:474180 biolink:treats MONDO:0044070 PMID:41385096 "[{""id"":""uuid:5d5a2675-4e8e-40e1-88fe-0c51ea8a7417"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:07482ccc-72df-46de-ab73-356c4723208d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Caspofungin acetate for Injection is an echinocandin antifungal indicated in adults and pediatric patients (3 months of age and older) for: Empirical therapy for presumed fungal infections in febrile, neutropenic patients. ( 1 ) Treatment of candidemia and the following Candida infections: intra-abdominal abscesses, peritonitis and pleural space infections. ( 1 ) Treatment of esophageal candidiasis. ( 1 ) Treatment of invasive aspergillosis in patients who are refractory to or intolerant of other therapies. ( 1 ) uuid:0ca295b9-7487-4068-9e3a-24446f186fbe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:474180 biolink:treats MONDO:0002026 PMID:41385096 "[{""id"":""uuid:c5980712-549a-4597-bcaa-2756523e763d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4e084271-a49d-4614-b236-6b107de57087"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Caspofungin acetate for Injection is an echinocandin antifungal indicated in adults and pediatric patients (3 months of age and older) for: Empirical therapy for presumed fungal infections in febrile, neutropenic patients. ( 1 ) Treatment of candidemia and the following Candida infections: intra-abdominal abscesses, peritonitis and pleural space infections. ( 1 ) Treatment of esophageal candidiasis. ( 1 ) Treatment of invasive aspergillosis in patients who are refractory to or intolerant of other therapies. ( 1 ) uuid:93491fe0-ba95-4055-9bca-5d5c8a276889 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:474180 biolink:treats EFO:1001753 PMID:41385096 "[{""id"":""uuid:a8594c42-7888-4642-a236-00b54a1775dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f7927d87-df3a-432a-a928-847514cdda45"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Caspofungin acetate for Injection is an echinocandin antifungal indicated in adults and pediatric patients (3 months of age and older) for: Empirical therapy for presumed fungal infections in febrile, neutropenic patients. ( 1 ) Treatment of candidemia and the following Candida infections: intra-abdominal abscesses, peritonitis and pleural space infections. ( 1 ) Treatment of esophageal candidiasis. ( 1 ) Treatment of invasive aspergillosis in patients who are refractory to or intolerant of other therapies. ( 1 ) uuid:63412af4-b3b1-49dd-be3f-19b0df61daa1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:474180 biolink:treats MONDO:0004522 PMID:41385096 "[{""id"":""uuid:4a3701f9-3750-4c87-a90f-db33df6b8bd1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:10c6c1c4-bbc2-4642-8972-1ffebdbf00c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Caspofungin acetate for Injection is an echinocandin antifungal indicated in adults and pediatric patients (3 months of age and older) for: Empirical therapy for presumed fungal infections in febrile, neutropenic patients. ( 1 ) Treatment of candidemia and the following Candida infections: intra-abdominal abscesses, peritonitis and pleural space infections. ( 1 ) Treatment of esophageal candidiasis. ( 1 ) Treatment of invasive aspergillosis in patients who are refractory to or intolerant of other therapies. ( 1 ) uuid:641a9cf0-df3f-48fe-a998-0aa81e4a6bd4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:474180 biolink:treats MONDO:0018667 PMID:41385096 "[{""id"":""uuid:074f2a0d-3fc5-4298-bf78-901d011b1a43"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f1d71125-a371-47b4-895c-e77fe8fb26bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Caspofungin acetate for Injection is an echinocandin antifungal indicated in adults and pediatric patients (3 months of age and older) for: Empirical therapy for presumed fungal infections in febrile, neutropenic patients. ( 1 ) Treatment of candidemia and the following Candida infections: intra-abdominal abscesses, peritonitis and pleural space infections. ( 1 ) Treatment of esophageal candidiasis. ( 1 ) Treatment of invasive aspergillosis in patients who are refractory to or intolerant of other therapies. ( 1 ) uuid:cdcf8a0a-4e4b-481c-a2ed-5b52d6c57f1a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:474180 biolink:treats MONDO:0001648 PMID:41385096 "[{""id"":""uuid:4f81014c-74d4-4a35-b185-b868fa1c7ede"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:48b0eb1f-88e0-427b-a9a1-361296ef9339"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:3fd53e57-0cb8-4894-bb17-4d073778c030"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Caspofungin acetate for Injection is an echinocandin antifungal indicated in adults and pediatric patients (3 months of age and older) for: Empirical therapy for presumed fungal infections in febrile, neutropenic patients. ( 1 ) Treatment of candidemia and the following Candida infections: intra-abdominal abscesses, peritonitis and pleural space infections. ( 1 ) Treatment of esophageal candidiasis. ( 1 ) Treatment of invasive aspergillosis in patients who are refractory to or intolerant of other therapies. ( 1 )|[PMDA] Drugs with a new active ingredient indicated for the treatment of febrile neutropenia suspected of a fungal infection and fungal infections due to Candida or Aspergillus (esophageal candidiasis, invasive candidiasis, aspergillosis). uuid:2e091682-6861-4608-b932-3cd051fb5830 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:474180 biolink:treats MONDO:0000240 PMID:41385096 "[{""id"":""uuid:25460822-bd94-4e51-9729-804fddf1554a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c272ca09-f374-42ec-adad-4917a0184446"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Caspofungin acetate for Injection is an echinocandin antifungal indicated in adults and pediatric patients (3 months of age and older) for: Empirical therapy for presumed fungal infections in febrile, neutropenic patients. ( 1 ) Treatment of candidemia and the following Candida infections: intra-abdominal abscesses, peritonitis and pleural space infections. ( 1 ) Treatment of esophageal candidiasis. ( 1 ) Treatment of invasive aspergillosis in patients who are refractory to or intolerant of other therapies. ( 1 ) uuid:9eb98e1d-cc47-47f4-bce5-969ddc189b72 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:691037 biolink:treats UMLS:C0406317 PMID:41385096 "[{""id"":""uuid:305ca4b2-87cd-4604-bf8d-9acce1fe6f48"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:08c47a7b-7b35-49e8-9cee-e49bae4d0c00"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Topicort ® Topical Spray is a corticosteroid indicated for the treatment of plaque psoriasis in patients 18 years of age or older. uuid:1d0e7c5f-15ad-433f-b395-6467e4ce73f6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17303 biolink:treats UMLS:C0278140 PMID:41385096 "[{""id"":""uuid:b144b679-25db-4643-9e31-052b140955b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1f579891-6fcf-4a58-9f1d-f2a2e3f76d8d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Morphine sulfate is indicated for the relief of severe pain. It is used preoperatively to sedate the patient and allay apprehension, facilitate anesthesia induction and reduce anesthetic dosage. It is likewise effective in the control of post-operative pain. The use of morphine for the relief of pain should be reserved for the more severe manifestations of pain, as in myocardial infarction, severe injuries, or in severe chronic pain associated with terminal cancer after all non-narcotic analgesics have failed. Effective analgesic therapy of severe chronic pain associated with terminal cancer continues to be a difficult problem. Intermittent administration of intramuscular morphine may be effective; however, the mode of therapy has significant limitations. Morphine has a short plasma half-life of 2.5 to 3.0 hours; therefore, frequent administration (every 1 to 2 hours) often becomes necessary to control severe pain associated with cancer. Tolerance develops to the analgesic effects and increasingly higher doses of morphine are required to produce analgesia. The higher morphine doses produce significant and often life-threatening side effects (see ADVERSE REACTIONS ) . The peak and trough effects produced by intermittent administration cause fluctuations in pain control. Repeated intramuscular injections are frequently unacceptable due to the lack of muscle mass in the debilitated patient, the tendency for bruising and bleeding at the injection site, and the anxiety and pain associated with the injection. Continuous intravenous infusion of morphine (see DOSAGE AND ADMINISTRATION ) has been employed as an alternative to traditional modes of administration. Lower doses of morphine produce uniform pain control because a steady morphine concentration is maintained. Titration of the dosage to the patient's needs is easily achieved by adjusting the infusion rate. The lag time between the patient's request for pain medication and administration of the dose and the amount of nursing time necessary for preparation and administration of frequent doses are reduced. The degree of respiratory depression and sedation may be decreased, and the anxiety experienced by the patient in anticipation of intramuscular administration is avoided. Some Investigators feel that tolerance to the analgesic effects may develop more slowly with continuous intravenous infusion. In addition to analgesia, the drug may relieve anxiety and reduce left ventricular work by reducing preload pressure. Morphine is also used in the therapy of dyspnea associated with acute left ventricular and pulmonary edema. Care must be taken to avoid inducing respiratory depression in such patients. For open-heart surgery, especially in high risk patients with cardiac disease, some anesthesiologists use morphine to produce anesthesia. uuid:84650505-bc16-4742-b497-3ed0bab6e683 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17303 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:4ef9bf64-ecd4-433f-87c3-3d787a50fe70"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:be97f0b8-21f2-4023-8d1a-4ccec43a3b41"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Morphine sulfate is indicated for the relief of severe pain. It is used preoperatively to sedate the patient and allay apprehension, facilitate anesthesia induction and reduce anesthetic dosage. It is likewise effective in the control of post-operative pain. The use of morphine for the relief of pain should be reserved for the more severe manifestations of pain, as in myocardial infarction, severe injuries, or in severe chronic pain associated with terminal cancer after all non-narcotic analgesics have failed. Effective analgesic therapy of severe chronic pain associated with terminal cancer continues to be a difficult problem. Intermittent administration of intramuscular morphine may be effective; however, the mode of therapy has significant limitations. Morphine has a short plasma half-life of 2.5 to 3.0 hours; therefore, frequent administration (every 1 to 2 hours) often becomes necessary to control severe pain associated with cancer. Tolerance develops to the analgesic effects and increasingly higher doses of morphine are required to produce analgesia. The higher morphine doses produce significant and often life-threatening side effects (see ADVERSE REACTIONS ) . The peak and trough effects produced by intermittent administration cause fluctuations in pain control. Repeated intramuscular injections are frequently unacceptable due to the lack of muscle mass in the debilitated patient, the tendency for bruising and bleeding at the injection site, and the anxiety and pain associated with the injection. Continuous intravenous infusion of morphine (see DOSAGE AND ADMINISTRATION ) has been employed as an alternative to traditional modes of administration. Lower doses of morphine produce uniform pain control because a steady morphine concentration is maintained. Titration of the dosage to the patient's needs is easily achieved by adjusting the infusion rate. The lag time between the patient's request for pain medication and administration of the dose and the amount of nursing time necessary for preparation and administration of frequent doses are reduced. The degree of respiratory depression and sedation may be decreased, and the anxiety experienced by the patient in anticipation of intramuscular administration is avoided. Some Investigators feel that tolerance to the analgesic effects may develop more slowly with continuous intravenous infusion. In addition to analgesia, the drug may relieve anxiety and reduce left ventricular work by reducing preload pressure. Morphine is also used in the therapy of dyspnea associated with acute left ventricular and pulmonary edema. Care must be taken to avoid inducing respiratory depression in such patients. For open-heart surgery, especially in high risk patients with cardiac disease, some anesthesiologists use morphine to produce anesthesia. uuid:0db8147d-6c0f-4cd9-994c-7ad378638daf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17303 biolink:treats EFO:0801084 PMID:41385096 "[{""id"":""uuid:a2ed7550-df1c-447f-81f8-b126ea125651"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:912f8555-c28c-4d19-a3d9-250e513cf8e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ae3fe4b0-d3e9-433c-a0b4-29e789665aae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Morphine sulfate is indicated for the relief of severe pain. It is used preoperatively to sedate the patient and allay apprehension, facilitate anesthesia induction and reduce anesthetic dosage. It is likewise effective in the control of post-operative pain. The use of morphine for the relief of pain should be reserved for the more severe manifestations of pain, as in myocardial infarction, severe injuries, or in severe chronic pain associated with terminal cancer after all non-narcotic analgesics have failed. Effective analgesic therapy of severe chronic pain associated with terminal cancer continues to be a difficult problem. Intermittent administration of intramuscular morphine may be effective; however, the mode of therapy has significant limitations. Morphine has a short plasma half-life of 2.5 to 3.0 hours; therefore, frequent administration (every 1 to 2 hours) often becomes necessary to control severe pain associated with cancer. Tolerance develops to the analgesic effects and increasingly higher doses of morphine are required to produce analgesia. The higher morphine doses produce significant and often life-threatening side effects (see ADVERSE REACTIONS ) . The peak and trough effects produced by intermittent administration cause fluctuations in pain control. Repeated intramuscular injections are frequently unacceptable due to the lack of muscle mass in the debilitated patient, the tendency for bruising and bleeding at the injection site, and the anxiety and pain associated with the injection. Continuous intravenous infusion of morphine (see DOSAGE AND ADMINISTRATION ) has been employed as an alternative to traditional modes of administration. Lower doses of morphine produce uniform pain control because a steady morphine concentration is maintained. Titration of the dosage to the patient's needs is easily achieved by adjusting the infusion rate. The lag time between the patient's request for pain medication and administration of the dose and the amount of nursing time necessary for preparation and administration of frequent doses are reduced. The degree of respiratory depression and sedation may be decreased, and the anxiety experienced by the patient in anticipation of intramuscular administration is avoided. Some Investigators feel that tolerance to the analgesic effects may develop more slowly with continuous intravenous infusion. In addition to analgesia, the drug may relieve anxiety and reduce left ventricular work by reducing preload pressure. Morphine is also used in the therapy of dyspnea associated with acute left ventricular and pulmonary edema. Care must be taken to avoid inducing respiratory depression in such patients. For open-heart surgery, especially in high risk patients with cardiac disease, some anesthesiologists use morphine to produce anesthesia.|[PMDA] A new formulation of opioid drug for daily administration with indications as analgesia for moderate to severe pain in various cancers. uuid:1dd22bac-34be-4860-867f-1744704f0ab5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17303 biolink:treats MONDO:0006932 PMID:41385096 "[{""id"":""uuid:dcfa3a5a-99e9-45f6-b8b8-4be84fda70da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:df1c3071-98c2-4d36-bd55-533b7fccb8c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Morphine sulfate is indicated for the relief of severe pain. It is used preoperatively to sedate the patient and allay apprehension, facilitate anesthesia induction and reduce anesthetic dosage. It is likewise effective in the control of post-operative pain. The use of morphine for the relief of pain should be reserved for the more severe manifestations of pain, as in myocardial infarction, severe injuries, or in severe chronic pain associated with terminal cancer after all non-narcotic analgesics have failed. Effective analgesic therapy of severe chronic pain associated with terminal cancer continues to be a difficult problem. Intermittent administration of intramuscular morphine may be effective; however, the mode of therapy has significant limitations. Morphine has a short plasma half-life of 2.5 to 3.0 hours; therefore, frequent administration (every 1 to 2 hours) often becomes necessary to control severe pain associated with cancer. Tolerance develops to the analgesic effects and increasingly higher doses of morphine are required to produce analgesia. The higher morphine doses produce significant and often life-threatening side effects (see ADVERSE REACTIONS ) . The peak and trough effects produced by intermittent administration cause fluctuations in pain control. Repeated intramuscular injections are frequently unacceptable due to the lack of muscle mass in the debilitated patient, the tendency for bruising and bleeding at the injection site, and the anxiety and pain associated with the injection. Continuous intravenous infusion of morphine (see DOSAGE AND ADMINISTRATION ) has been employed as an alternative to traditional modes of administration. Lower doses of morphine produce uniform pain control because a steady morphine concentration is maintained. Titration of the dosage to the patient's needs is easily achieved by adjusting the infusion rate. The lag time between the patient's request for pain medication and administration of the dose and the amount of nursing time necessary for preparation and administration of frequent doses are reduced. The degree of respiratory depression and sedation may be decreased, and the anxiety experienced by the patient in anticipation of intramuscular administration is avoided. Some Investigators feel that tolerance to the analgesic effects may develop more slowly with continuous intravenous infusion. In addition to analgesia, the drug may relieve anxiety and reduce left ventricular work by reducing preload pressure. Morphine is also used in the therapy of dyspnea associated with acute left ventricular and pulmonary edema. Care must be taken to avoid inducing respiratory depression in such patients. For open-heart surgery, especially in high risk patients with cardiac disease, some anesthesiologists use morphine to produce anesthesia. uuid:e182094f-c7f0-466a-9a7f-78b9064cd43e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17303 biolink:treats MONDO:0005267 PMID:41385096 "[{""id"":""uuid:33b07298-074c-4b3e-9ebf-8baa9f425d3c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ee630e6e-9e78-4a47-9447-4ef55ab1b634"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Morphine sulfate is indicated for the relief of severe pain. It is used preoperatively to sedate the patient and allay apprehension, facilitate anesthesia induction and reduce anesthetic dosage. It is likewise effective in the control of post-operative pain. The use of morphine for the relief of pain should be reserved for the more severe manifestations of pain, as in myocardial infarction, severe injuries, or in severe chronic pain associated with terminal cancer after all non-narcotic analgesics have failed. Effective analgesic therapy of severe chronic pain associated with terminal cancer continues to be a difficult problem. Intermittent administration of intramuscular morphine may be effective; however, the mode of therapy has significant limitations. Morphine has a short plasma half-life of 2.5 to 3.0 hours; therefore, frequent administration (every 1 to 2 hours) often becomes necessary to control severe pain associated with cancer. Tolerance develops to the analgesic effects and increasingly higher doses of morphine are required to produce analgesia. The higher morphine doses produce significant and often life-threatening side effects (see ADVERSE REACTIONS ) . The peak and trough effects produced by intermittent administration cause fluctuations in pain control. Repeated intramuscular injections are frequently unacceptable due to the lack of muscle mass in the debilitated patient, the tendency for bruising and bleeding at the injection site, and the anxiety and pain associated with the injection. Continuous intravenous infusion of morphine (see DOSAGE AND ADMINISTRATION ) has been employed as an alternative to traditional modes of administration. Lower doses of morphine produce uniform pain control because a steady morphine concentration is maintained. Titration of the dosage to the patient's needs is easily achieved by adjusting the infusion rate. The lag time between the patient's request for pain medication and administration of the dose and the amount of nursing time necessary for preparation and administration of frequent doses are reduced. The degree of respiratory depression and sedation may be decreased, and the anxiety experienced by the patient in anticipation of intramuscular administration is avoided. Some Investigators feel that tolerance to the analgesic effects may develop more slowly with continuous intravenous infusion. In addition to analgesia, the drug may relieve anxiety and reduce left ventricular work by reducing preload pressure. Morphine is also used in the therapy of dyspnea associated with acute left ventricular and pulmonary edema. Care must be taken to avoid inducing respiratory depression in such patients. For open-heart surgery, especially in high risk patients with cardiac disease, some anesthesiologists use morphine to produce anesthesia. uuid:0db7a324-819d-4dff-a588-aae63c3e67e7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:449763 biolink:treats MONDO:0005010 PMID:41385096 "[{""id"":""uuid:408c82fd-1ba4-4f6a-8a71-77f3620f2ed0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:50207aed-3ad5-4e5f-a05f-0d84c0dd19f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Myocardial Imaging: Kit for the preparation of Technetium Tc 99m Sestamibi Injection is a myocardial perfusion agent that is indicated for detecting coronary artery disease by localizing myocardial ischemia (reversible defects) and infarction (non-reversible defects), in evaluating myocardial function and developing information for use in patient management decisions. Technetium Tc 99m Sestamibi evaluation of myocardial ischemia can be accomplished with rest and cardiovascular stress techniques (e.g., exercise or pharmacologic stress in accordance with the pharmacologic stress agents labeling). It is usually not possible to determine the age of a myocardial infarction or to differentiate a recent myocardial infarction from ischemia. Breast Imaging: Kit for the preparation of Technetium Tc 99m Sestamibi Injection is indicated for planar imaging as a second line diagnostic drug after mammography to assist in the evaluation of breast lesions in patients with an abnormal mammogram or a palpable breast mass. Kit for the preparation of Technetium Tc 99m Sestamibi Injection is not indicated for breast cancer screening, to confirm the presence or absence of malignancy, and it is not an alternative to biopsy. uuid:194978cb-c055-45fe-a011-987ec41fa079 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:449763 biolink:treats MONDO:0024644 PMID:41385096 "[{""id"":""uuid:37d280a5-ef94-4d0f-b500-502452e68fb7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:37d7f8c0-eb9a-4302-90ec-2c9d9589db33"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Myocardial Imaging: Kit for the preparation of Technetium Tc 99m Sestamibi Injection is a myocardial perfusion agent that is indicated for detecting coronary artery disease by localizing myocardial ischemia (reversible defects) and infarction (non-reversible defects), in evaluating myocardial function and developing information for use in patient management decisions. Technetium Tc 99m Sestamibi evaluation of myocardial ischemia can be accomplished with rest and cardiovascular stress techniques (e.g., exercise or pharmacologic stress in accordance with the pharmacologic stress agents labeling). It is usually not possible to determine the age of a myocardial infarction or to differentiate a recent myocardial infarction from ischemia. Breast Imaging: Kit for the preparation of Technetium Tc 99m Sestamibi Injection is indicated for planar imaging as a second line diagnostic drug after mammography to assist in the evaluation of breast lesions in patients with an abnormal mammogram or a palpable breast mass. Kit for the preparation of Technetium Tc 99m Sestamibi Injection is not indicated for breast cancer screening, to confirm the presence or absence of malignancy, and it is not an alternative to biopsy. uuid:ffcf505d-dc7f-43bb-9717-655a2c960f53 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:449763 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:156f7ded-e167-4b3c-adce-72a5a540c334"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d7965eb0-d792-4420-85b0-da942942aae5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Myocardial Imaging: Kit for the preparation of Technetium Tc 99m Sestamibi Injection is a myocardial perfusion agent that is indicated for detecting coronary artery disease by localizing myocardial ischemia (reversible defects) and infarction (non-reversible defects), in evaluating myocardial function and developing information for use in patient management decisions. Technetium Tc 99m Sestamibi evaluation of myocardial ischemia can be accomplished with rest and cardiovascular stress techniques (e.g., exercise or pharmacologic stress in accordance with the pharmacologic stress agents labeling). It is usually not possible to determine the age of a myocardial infarction or to differentiate a recent myocardial infarction from ischemia. Breast Imaging: Kit for the preparation of Technetium Tc 99m Sestamibi Injection is indicated for planar imaging as a second line diagnostic drug after mammography to assist in the evaluation of breast lesions in patients with an abnormal mammogram or a palpable breast mass. Kit for the preparation of Technetium Tc 99m Sestamibi Injection is not indicated for breast cancer screening, to confirm the presence or absence of malignancy, and it is not an alternative to biopsy. uuid:96a42911-02ba-4dc0-b87e-5dd36703f234 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:449763 biolink:treats NCIT:C159594 PMID:41385096 "[{""id"":""uuid:b4620612-99ef-406a-9f7b-3418b8f25bdd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a2735b2a-33e2-4210-a679-7787213374ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Myocardial Imaging: Kit for the preparation of Technetium Tc 99m Sestamibi Injection is a myocardial perfusion agent that is indicated for detecting coronary artery disease by localizing myocardial ischemia (reversible defects) and infarction (non-reversible defects), in evaluating myocardial function and developing information for use in patient management decisions. Technetium Tc 99m Sestamibi evaluation of myocardial ischemia can be accomplished with rest and cardiovascular stress techniques (e.g., exercise or pharmacologic stress in accordance with the pharmacologic stress agents labeling). It is usually not possible to determine the age of a myocardial infarction or to differentiate a recent myocardial infarction from ischemia. Breast Imaging: Kit for the preparation of Technetium Tc 99m Sestamibi Injection is indicated for planar imaging as a second line diagnostic drug after mammography to assist in the evaluation of breast lesions in patients with an abnormal mammogram or a palpable breast mass. Kit for the preparation of Technetium Tc 99m Sestamibi Injection is not indicated for breast cancer screening, to confirm the presence or absence of malignancy, and it is not an alternative to biopsy. uuid:cfc7dddc-e31d-4156-9d07-6248dd9d3125 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:449763 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:96fecf81-f443-42f5-ba4a-712d751f5d9a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d54072a6-da36-4b64-bbff-7847a2f50d1e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Myocardial Imaging: Kit for the preparation of Technetium Tc 99m Sestamibi Injection is a myocardial perfusion agent that is indicated for detecting coronary artery disease by localizing myocardial ischemia (reversible defects) and infarction (non-reversible defects), in evaluating myocardial function and developing information for use in patient management decisions. Technetium Tc 99m Sestamibi evaluation of myocardial ischemia can be accomplished with rest and cardiovascular stress techniques (e.g., exercise or pharmacologic stress in accordance with the pharmacologic stress agents labeling). It is usually not possible to determine the age of a myocardial infarction or to differentiate a recent myocardial infarction from ischemia. Breast Imaging: Kit for the preparation of Technetium Tc 99m Sestamibi Injection is indicated for planar imaging as a second line diagnostic drug after mammography to assist in the evaluation of breast lesions in patients with an abnormal mammogram or a palpable breast mass. Kit for the preparation of Technetium Tc 99m Sestamibi Injection is not indicated for breast cancer screening, to confirm the presence or absence of malignancy, and it is not an alternative to biopsy. uuid:b75b3053-9af7-4b9d-9bc3-e59cc374de01 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:11979316 biolink:treats UMLS:C5400441 PMID:41385096 "[{""id"":""uuid:b473d013-1c3f-4323-a234-1834efb743a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f03ddea8-f36c-480d-be5a-858cb3f6ec58"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vasostrict® is indicated to increase blood pressure in adults with vasodilatory shock (e.g., post-cardiotomy or sepsis) who remain hypotensive despite fluids and catecholamines. uuid:871bb3cd-e7d2-4ee2-8509-164ea10bcf66 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:11979316 biolink:treats MONDO:0800175 PMID:41385096 "[{""id"":""uuid:a44a9512-6f40-477a-ac9f-f7efe7c73c50"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:102981dc-0de3-4cb7-8aa9-29212e4695cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vasostrict® is indicated to increase blood pressure in adults with vasodilatory shock (e.g., post-cardiotomy or sepsis) who remain hypotensive despite fluids and catecholamines. uuid:0540569e-64fe-4b3b-a11f-c445f14de0bc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:11979316 biolink:treats MONDO:0001881 PMID:41385096 "[{""id"":""uuid:0bf38514-87b4-4bbd-b0af-533f233a4549"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:df027884-8f43-46bc-be6b-39ae75316459"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vasostrict® is indicated to increase blood pressure in adults with vasodilatory shock (e.g., post-cardiotomy or sepsis) who remain hypotensive despite fluids and catecholamines. uuid:edeb04dc-2ad5-42c9-b414-23ab3f6d6db2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3508 biolink:treats MONDO:0024355 PMID:41385096 "[{""id"":""uuid:8bf0daf3-1868-486b-8163-c187a8450d5d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:414cea24-1430-47ff-ab79-53c25347efa6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tazicef (ceftazidime for injection, USP) is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: 1. Lower Respiratory Tract Infections, including pneumonia, caused by Pseudomonas aeruginosa and other Pseudomonas spp.; Haemophilus influenzae , including ampicillin-resistant strains; Klebsiella spp.; Enterobacter spp.; Proteus mirabilis ; Escherichia coli ; Serratia spp.; Citrobacter spp.; Streptococcus pneumoniae ; and Staphylococcus aureus (methicillin-susceptible strains). 2. Skin and Skin-Structure Infections caused by Pseudomonas aeruginosa ; Klebsiella spp.; Escherichia coli ; Proteus spp., including Proteus mirabilis and indole-positive Proteus ; Enterobacter spp.; Serratia spp.; Staphylococcus aureus (methicillin-susceptible strains); and Streptococcus pyogenes (group A beta-hemolytic streptococci). 3. Urinary Tract Infections, both complicated and uncomplicated, caused by Pseudomonas aeruginosa ; Enterobacter spp.; Proteus spp., including Proteus mirabilis and indole-positive Proteus ; Klebsiella spp.; and Escherichia coli . 4. Bacterial Septicemia caused by Pseudomonas aeruginosa , Klebsiella spp., Haemophilus influenzae , Escherichia coli , Serratia spp., Streptococcus pneumoniae , and Staphylococcus aureus (methicillin-susceptible strains). 5. Bone and Joint Infections caused by Pseudomonas aeruginosa, Klebsiella spp., Enterobacter spp., and Staphylococcus aureus (methicillin-susceptible strains). 6. Gynecologic Infections, including endometritis, pelvic cellulitis, and other infections of the female genital tract caused by Escherichia coli . 7. Intra-abdominal Infections, including peritonitis caused by Escherichia coli , Klebsiella spp., and Staphylococcus aureus (methicillin-susceptible strains) and polymicrobial infections caused by aerobic and anaerobic organisms and Bacteroides spp. (many strains of Bacteroides fragilis are resistant). 8. Central Nervous System Infections, including meningitis, caused by Haemophilus influenzae and Neisseria meningitidis . Ceftazidime has also been used successfully in a limited number of cases of meningitis due to Pseudomonas aeruginosa and Streptococcus pneumoniae . Tazicef (ceftazidime for injection, USP) may be used alone in cases of confirmed or suspected sepsis. Ceftazidime has been used successfully in clinical trials as empiric therapy in cases where various concomitant therapies with other antibacterial drugs have been used. Tazicef (ceftazidime for injection, USP) may also be used concomitantly with other antibacterial drugs, such as aminoglycosides, vancomycin, and clindamycin; in severe and life-threatening infections; and in the immunocompromised patient. When such concomitant treatment is appropriate, prescribing information in the labeling for the other antibacterial drugs should be followed. The dose depends on the severity of the infection and the patient's condition. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Tazicef (ceftazidime for injection, USP) and other antibacterial drugs, Tazicef (ceftazidime for injection, USP) should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:03cd3eb4-05a5-4fac-beb1-371d855826ff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4712 biolink:treats HP:0012625 PMID:41385096 "[{""id"":""uuid:ef7d7fd4-5bfa-4e91-8b5a-908eac490305"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:13f9540f-4ffa-4dfe-ada8-149d1932e4c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Doxercalciferol capsules are indicated for the treatment of secondary hyperparathyroidism in adult patients with Stage 3 or Stage 4 chronic kidney disease (CKD) and adult patients with CKD on dialysis. uuid:30e3e03a-7559-4c62-b2ef-258f52f20dc2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4712 biolink:treats HP:0012626 PMID:41385096 "[{""id"":""uuid:260afece-2432-4d54-9375-fcb84ae90b7b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6fa86810-72dc-4bcf-9d92-394ee1c3cd29"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Doxercalciferol capsules are indicated for the treatment of secondary hyperparathyroidism in adult patients with Stage 3 or Stage 4 chronic kidney disease (CKD) and adult patients with CKD on dialysis. uuid:2ddaa247-8b05-4ee8-a198-044d6715a925 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:122361353 biolink:treats MONDO:0015129 PMID:41385096 "[{""id"":""uuid:eb01fd5c-0d48-4df6-b41b-09e4539877d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f6ebeb56-a8f5-4297-9674-bbf4edc05498"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CORTROSYN™ (cosyntropin) for Injection is intended for use as a diagnostic agent in the screening of patients presumed to have adrenocortical insufficiency. Because of its rapid effect on the adrenal cortex it may be utilized to perform a 30-minute test of adrenal function (plasma cortisol response) as an office or outpatient procedure, using only 2 venipunctures (seeDOSAGE AND ADMINISTRATION section). Severe hypofunction of the pituitary - adrenal axis is usually associated with subnormal plasma cortisol values but a low basal level is not per se evidence of adrenal insufficiency and does not suffice to make the diagnosis. Many patients with proven insufficiency will have normal basal levels and will develop signs of insufficiency only when stressed. For this reason a criterion which should be used in establishing the diagnosis is the failure to respond to adequate corticotropin stimulation. When presumptive adrenal insufficiency is diagnosed by a subnormal CORTROSYN™ test, further studies are indicated to determine if it is primary or secondary. Primary adrenal insufficiency (Addison's disease) is the result of an intrinsic disease process, such as tuberculosis within the gland. The production of adrenocortical hormones is deficient despite high ACTH levels (feedback mechanism). Secondary or relative insufficiency arises as the result of defective production of ACTH leading in turn to disuse atrophy of the adrenal cortex. It is commonly seen, for example, as result of corticosteroid therapy, Sheehan's syndrome and pituitary tumors or ablation. The differentiation of both types is based on the premise that a primarily defective gland cannot be stimulated by ACTH whereas a secondarily defective gland is potentially functional and will respond to adequate stimulation with ACTH. Patients selected for further study as the result of a subnormal CORTROSYN™ test should be given a 3 or 4 day course of treatment with Repository Corticotropin Injection USP and then retested. Suggested doses are 40 USP units twice daily for 4 days or 60 USP units twice daily for 3 days. Under these conditions little or no increase in plasma cortisol levels will be seen in Addison's disease whereas higher or even normal levels will be seen in cases with secondary adrenal insufficiency. uuid:2a4e901a-c114-4663-adaf-d8eab41d9bae biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29101 biolink:treats HP:0001944 PMID:41385096 "[{""id"":""uuid:44efade5-83e2-499f-9c4e-155807fb72f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dcfca823-e2dd-46a7-9ef0-9095d9e69546"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] This solution is indicated for use in adults and pediatric patients as a source of electrolytes and water for hydration. uuid:e69aeb20-22d1-44b3-9398-309cf75ee565 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:53796 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:7187d2e4-bab1-4d8e-8e18-3c32e57a6786"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:15cc0a4a-58ad-4fff-938b-47af3fe43085"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LEVAMLODIPINE TABLETS is calcium channel blocker and may be used alone or in combination with other antihypertensive agents for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. uuid:4a8f794f-f92a-4252-a79b-d04f98bd5978 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:53796 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:2691eb78-2c02-490f-a304-8347482decc9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:abb9501a-ab8f-4ead-9cb8-be4ca35410ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LEVAMLODIPINE TABLETS is calcium channel blocker and may be used alone or in combination with other antihypertensive agents for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. uuid:f181eab1-8800-4d6b-bf86-5871f2d33150 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:53796 biolink:treats MONDO:0006652 PMID:41385096 "[{""id"":""uuid:64ba3462-ec59-4292-8704-f8354b90b29b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e343a00d-d651-44d6-8df1-19ecbc24ad3c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LEVAMLODIPINE TABLETS is calcium channel blocker and may be used alone or in combination with other antihypertensive agents for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. uuid:f9f8225a-28f9-4b82-8241-1fc0cc638da7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3996 biolink:treats MONDO:0002081 PMID:41385096 "[{""id"":""uuid:7b05aca1-2a81-4e89-998f-a693ef88959a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a05528f6-ee50-4235-92da-afb5a04cf74b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cyclobenzaprine hydrochloride tablets, USP is indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine hydrochloride, tablets should be used only for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride tablets has not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy. uuid:7fa993e6-490d-4ffe-a888-42faa5fe9ddf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:61080 biolink:treats MONDO:0015758 PMID:41385096 "[{""id"":""uuid:88127743-3fc9-4c21-bdf2-bb9fed40c721"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7571f1e9-2604-4d87-8ad5-95239976af5f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Romidepsin for injection is indicated for the treatment of cutaneous T-cell lymphoma (CTCL) in adult patients who have received at least one prior systemic therapy. uuid:45e187a5-8ad7-4800-8bd8-67fdd20345b7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:61080 biolink:treats MONDO:0009691 PMID:41385096 "[{""id"":""uuid:ec53da53-2866-41e5-9c2a-bd2b6cf195a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:02f4a742-fe1a-48fd-b215-bab986655153"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Romidepsin for injection is indicated for the treatment of cutaneous T-cell lymphoma (CTCL) in adult patients who have received at least one prior systemic therapy. uuid:e8a88eaa-7eff-45b3-a0b8-5289f98e536d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:101278 biolink:treats MONDO:0004981 PMID:41385096 "[{""id"":""uuid:8c7c810b-3b1f-4930-910f-f512a77d36e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c7eebabc-17f1-4f5d-b51d-1c41a366f66d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diltiazem Hydrochloride in Dextrose Injection is a non-dihydropyridine calcium-channel blocker indicated for the following: • Temporary control of rapid ventricular rate in atrial fibrillation or atrial flutter. ( 1.1) • Rapid conversion of paroxysmal supraventricular tachycardias (PSVT) to sinus rhythm. ( 1.2 ) uuid:d6a26056-e285-4be2-923f-dd96b35e30d5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:101278 biolink:treats MONDO:0005310 PMID:41385096 "[{""id"":""uuid:dc26c3a6-01bb-4f12-bf96-35c2a746ca62"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9d465dc6-369f-4b41-9fa7-37affdd60667"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diltiazem Hydrochloride in Dextrose Injection is a non-dihydropyridine calcium-channel blocker indicated for the following: • Temporary control of rapid ventricular rate in atrial fibrillation or atrial flutter. ( 1.1) • Rapid conversion of paroxysmal supraventricular tachycardias (PSVT) to sinus rhythm. ( 1.2 ) uuid:3af36494-497f-4079-b1b3-ad72ea0a798a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:101278 biolink:treats HP:0004763 PMID:41385096 "[{""id"":""uuid:de67acd4-f295-4f2a-b0d7-1e8a3fe69502"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3425026b-1f87-4c50-94e7-5fa4a13594dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diltiazem Hydrochloride in Dextrose Injection is a non-dihydropyridine calcium-channel blocker indicated for the following: • Temporary control of rapid ventricular rate in atrial fibrillation or atrial flutter. ( 1.1) • Rapid conversion of paroxysmal supraventricular tachycardias (PSVT) to sinus rhythm. ( 1.2 ) uuid:56f1f1e2-c726-4c74-85ec-2cc870798cb4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32354 biolink:treats MONDO:0005318 PMID:41385096 "[{""id"":""uuid:fad4cb7b-f15a-4137-8699-b5c7980a1da2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8337ccb7-12d4-4460-8809-afdbf719b7cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Debacterol is indicated in the topical treatment of ulcerating lesions of the oral cavity such as Recurrent Aphthous Stomatitis (Canker Sores). Debacterol provides relief from the pain and discomfort of oral mucosal ulcers. Debacterol is not intended for the treatment of vesicular lesions, such as Cold Sores or Fever Blisters . uuid:d5efb775-629d-4207-9e94-64911d9a0e39 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32354 biolink:treats HP:0000155 PMID:41385096 "[{""id"":""uuid:769f8b86-e024-428d-ab4c-29a4f37e364e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e2ffe9c9-09b1-40f1-afd5-fcfb654f5737"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Debacterol is indicated in the topical treatment of ulcerating lesions of the oral cavity such as Recurrent Aphthous Stomatitis (Canker Sores). Debacterol provides relief from the pain and discomfort of oral mucosal ulcers. Debacterol is not intended for the treatment of vesicular lesions, such as Cold Sores or Fever Blisters . uuid:f78fa314-5232-4942-aeb8-bc5b21c497c5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41774 biolink:treats MONDO:0006512 PMID:41385096 "[{""id"":""uuid:3d5229d9-808a-4fd7-94b3-a721f6ade027"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:92db9883-f2e3-407b-8586-f05fdfa584fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SOLTAMOX is an estrogen agonist/antagonist indicated: For treatment of adult patients with estrogen receptor-positive metastatic breast cancer ( 1.1 ) For adjuvant treatment of adult patients with early stage estrogen receptor- positive breast cancer ( 1.2 ) To reduce risk of invasive breast cancer following breast surgery and radiation in adult women with ductal carcinoma in situ (DCIS) ( 1.3 ) To reduce the incidence of breast cancer in adult women at high risk ( 1.4 ) uuid:0c424d24-78bf-483a-bc12-9c57af72409f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8673 biolink:treats MONDO:0005989 PMID:41385096 "[{""id"":""uuid:25ba4b73-2988-4481-885f-febb9b04c178"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:50b30ce3-fc7f-4aca-a615-ec07c671684e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Treatment of Toxoplasmosis: Pyrimethamine is indicated for the treatment of toxoplasmosis when used conjointly with a sulfonamide, since synergism exists with this combination. uuid:89cb5dab-f314-436b-883f-5586d77b4c24 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2453 biolink:treats MONDO:0012521 PMID:41385096 "[{""id"":""uuid:60bea6e2-4713-43ff-84de-73dd832a7569"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b8cc5346-f1d1-4f1d-a6a0-3b9ddce0f1cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Herpes Simplex Infections in Immunocompromised Patients Acyclovir Sodium Injection is indicated for the treatment of initial and recurrent mucosal and cutaneous herpes simplex (HSV-1 and HSV-2) in immunocompromised patients. Initial Episodes of Herpes Genitalis Acyclovir Sodium Injection is indicated for the treatment of severe initial clinical episodes of herpes genitalis in immunocompetent patients. Herpes Simplex Encephalitis Acyclovir Sodium Injection is indicated for the treatment of herpes simplex encephalitis. Neonatal Herpes Simplex Virus Infection Acyclovir Sodium Injection is indicated for the treatment of neonates and infants with herpes simplex infections. Varicella-Zoster Infections in Immunocompromised Patients Acyclovir Sodium Injection is indicated for the treatment of varicella-zoster (shingles) infections in immunocompromised patients. uuid:6755d2a5-5cc7-4f3c-959b-e3fbb5831503 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2453 biolink:treats MONDO:0005794 PMID:41385096 "[{""id"":""uuid:08935d41-6bea-463d-9697-1de6446f612d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:345d36cc-0bce-41c3-92aa-768f026ee8c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Herpes Simplex Infections in Immunocompromised Patients Acyclovir Sodium Injection is indicated for the treatment of initial and recurrent mucosal and cutaneous herpes simplex (HSV-1 and HSV-2) in immunocompromised patients. Initial Episodes of Herpes Genitalis Acyclovir Sodium Injection is indicated for the treatment of severe initial clinical episodes of herpes genitalis in immunocompetent patients. Herpes Simplex Encephalitis Acyclovir Sodium Injection is indicated for the treatment of herpes simplex encephalitis. Neonatal Herpes Simplex Virus Infection Acyclovir Sodium Injection is indicated for the treatment of neonates and infants with herpes simplex infections. Varicella-Zoster Infections in Immunocompromised Patients Acyclovir Sodium Injection is indicated for the treatment of varicella-zoster (shingles) infections in immunocompromised patients. uuid:55501ea8-e10a-428c-aa76-573b6190707c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7959 biolink:treats MONDO:0005306 PMID:41385096 "[{""id"":""uuid:02fa57d5-4843-409c-ab56-d4d5abf5d69b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:543ec6ae-f592-46fe-bdfc-dc5accca477a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Penicillamine capsules are indicated in the treatment of Wilson's disease, cystinuria, and in patients with severe, active rheumatoid arthritis who have failed to respond to an adequate trial of conventional therapy. Available evidence suggests that penicillamine capsules are not of value in ankylosing spondylitis. Wilson’s Disease — Wilson’s disease (hepatolenticular degeneration) occurs in individuals who have inherited an autosomal recessive defect that leads to an accumulation of copper far in excess of metabolic requirements. The excess copper is deposited in several organs and tissues, and eventually produces pathological effects primarily in the liver, where damage progresses to postnecrotic cirrhosis, and in the brain, where degeneration is widespread. Copper is also deposited as characteristic, asymptomatic, golden-brown Kayser-Fleischer rings in the corneas of all patients with cerebral symptomatology and some patients who are either asymptomatic or manifest only hepatic symptomatology. Two types of patients require treatment for Wilson's disease: (1) the symptomatic, and (2) the asymptomatic in whom it can be assumed the disease will develop in the future if the patient is not treated. The diagnosis, if suspected on the basis of family or individual history or physical examination, can be confirmed if the plasma copper-protein ceruloplasmin** is <20 mg/dL and either a quantitative determination in a liver biopsy specimen shows an abnormally high concentration of copper (>250 mcg/g dry weight) or Kayser-Fleischer rings are present. Treatment has two objectives: (1) to minimize dietary intake of copper; (2) to promote excretion and complex formation (i.e., detoxification) of excess tissue copper. The first objective is attained by a daily diet that contains no more than one or two milligrams of copper. Such a diet should exclude, most importantly, chocolate, nuts, shellfish, mushrooms, liver, molasses, broccoli, and cereals and dietary supplements enriched with copper, and be composed to as great an extent as possible of foods with a low copper content. Distilled or demineralized water should be used if the patient's drinking water contains more than 0.1 mg of copper per liter. For the second objective, a copper chelating agent is used. In symptomatic patients this treatment usually produces marked neurologic improvement, fading of Kayser-Fleischer rings, and gradual amelioration of hepatic dysfunction and psychic disturbances. Clinical experience to date suggests that life is prolonged with the above regimen. Noticeable improvement may not occur for one to three months. Occasionally, neurologic symptoms become worse during initiation of therapy with penicillamine capsules. Despite this, the drug should not be withdrawn. Temporary interruption carries an increased risk of developing a sensitivity reaction upon resumption of therapy, although it may result in clinical improvement of neurological symptoms (see WARNINGS ). If the neurological symptoms and signs continue to worsen for a month after the initiation of penicillamine capsules therapy, several short courses of treatment with 2,3 - dimercaprol (BAL) while continuing penicillamine capsules may be considered. Treatment of asymptomatic patients has been carried out for over thirty years. Symptoms and signs of the disease appear to be prevented indefinitely if daily treatment with penicillamine capsules is continued. Cystinuria — Cystinuria is characterized by excessive urinary excretion of the dibasic amino acids, arginine, lysine, ornithine, and cystine, and the mixed disulfide of cysteine and homocysteine. The metabolic defect that leads to cystinuria is inherited as an autosomal, recessive trait. Metabolism of the affected amino acids is influenced by at least two abnormal factors: (1) defective gastrointestinal absorption and (2) renal tubular dysfunction. Arginine, lysine, ornithine, and cysteine are soluble substances, readily excreted. There is no apparent pathology connected with their excretion in excessive quantities. Cystine, however, is so slightly soluble at the usual range of urinary pH that it is not excreted readily, and so crystallizes and forms stones in the urinary tract. Stone formation is the only known pathology in cystinuria. Normal daily output of cystine is 40 to 80 mg. In cystinuria, output is greatly increased and may exceed 1 g/day. At 500 to 600 mg/day, stone formation is almost certain. When it is more than 300 mg/day, treatment is indicated. Conventional treatment is directed at keeping urinary cystine diluted enough to prevent stone formation, keeping the urine alkaline enough to dissolve as much cystine as possible, and minimizing cystine production by a diet low in methionine (the major dietary precursor of cystine). Patients must drink enough fluid to keep urine specific gravity below 1.010, take enough alkali to keep urinary pH at 7.5 to 8, and maintain a diet low in methionine. This diet is not recommended in growing children and probably is contraindicated in pregnancy because of its low protein content (see PRECAUTIONS) . When these measures are inadequate to control recurrent stone formation, penicillamine capsules may be used as additional therapy, and when patients refuse to adhere to conventional treatment, penicillamine capsules may be a useful substitute. It is capable of keeping cystine excretion to near normal values, thereby hindering stone formation and the serious consequences of pyelonephritis and impaired renal function that develop in some patients. Bartter and colleagues depict the process by which penicillamine interacts with cystine to form penicillaminecysteine mixed disulfide as: CSSC = cystine CS ′ = deprotonated cysteine PSSP = penicillamine disulfide PS ′ = deprotonated penicillamine sulfhydryl CSSP = penicillamine-cysteine mixed disulfide In this process, it is assumed that the deprotonated form of penicillamine, PS', is the active factor in bringing about the disulfide interchange. Rheumatoid Arthritis — Because penicillamine capsules can cause severe adverse reactions, its use in rheumatoid arthritis should be restricted to patients who have severe, active disease and who have failed to respond to an adequate trial of conventional therapy. Even then, benefit-to-risk ratio should be carefully considered. Other measures, such as rest, physiotherapy, salicylates, and corticosteroids should be used, when indicated, in conjunction with penicillamine capsules (see PRECAUTIONS ). uuid:88ed94d9-2de1-4e07-a740-166f5e087ecc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7959 biolink:treats MONDO:0006939 PMID:41385096 "[{""id"":""uuid:86a397bd-4c36-493e-b1ad-1699dbd368f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6c5a0998-81bb-4d8e-903d-65977fb1c893"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Penicillamine capsules are indicated in the treatment of Wilson's disease, cystinuria, and in patients with severe, active rheumatoid arthritis who have failed to respond to an adequate trial of conventional therapy. Available evidence suggests that penicillamine capsules are not of value in ankylosing spondylitis. Wilson’s Disease — Wilson’s disease (hepatolenticular degeneration) occurs in individuals who have inherited an autosomal recessive defect that leads to an accumulation of copper far in excess of metabolic requirements. The excess copper is deposited in several organs and tissues, and eventually produces pathological effects primarily in the liver, where damage progresses to postnecrotic cirrhosis, and in the brain, where degeneration is widespread. Copper is also deposited as characteristic, asymptomatic, golden-brown Kayser-Fleischer rings in the corneas of all patients with cerebral symptomatology and some patients who are either asymptomatic or manifest only hepatic symptomatology. Two types of patients require treatment for Wilson's disease: (1) the symptomatic, and (2) the asymptomatic in whom it can be assumed the disease will develop in the future if the patient is not treated. The diagnosis, if suspected on the basis of family or individual history or physical examination, can be confirmed if the plasma copper-protein ceruloplasmin** is <20 mg/dL and either a quantitative determination in a liver biopsy specimen shows an abnormally high concentration of copper (>250 mcg/g dry weight) or Kayser-Fleischer rings are present. Treatment has two objectives: (1) to minimize dietary intake of copper; (2) to promote excretion and complex formation (i.e., detoxification) of excess tissue copper. The first objective is attained by a daily diet that contains no more than one or two milligrams of copper. Such a diet should exclude, most importantly, chocolate, nuts, shellfish, mushrooms, liver, molasses, broccoli, and cereals and dietary supplements enriched with copper, and be composed to as great an extent as possible of foods with a low copper content. Distilled or demineralized water should be used if the patient's drinking water contains more than 0.1 mg of copper per liter. For the second objective, a copper chelating agent is used. In symptomatic patients this treatment usually produces marked neurologic improvement, fading of Kayser-Fleischer rings, and gradual amelioration of hepatic dysfunction and psychic disturbances. Clinical experience to date suggests that life is prolonged with the above regimen. Noticeable improvement may not occur for one to three months. Occasionally, neurologic symptoms become worse during initiation of therapy with penicillamine capsules. Despite this, the drug should not be withdrawn. Temporary interruption carries an increased risk of developing a sensitivity reaction upon resumption of therapy, although it may result in clinical improvement of neurological symptoms (see WARNINGS ). If the neurological symptoms and signs continue to worsen for a month after the initiation of penicillamine capsules therapy, several short courses of treatment with 2,3 - dimercaprol (BAL) while continuing penicillamine capsules may be considered. Treatment of asymptomatic patients has been carried out for over thirty years. Symptoms and signs of the disease appear to be prevented indefinitely if daily treatment with penicillamine capsules is continued. Cystinuria — Cystinuria is characterized by excessive urinary excretion of the dibasic amino acids, arginine, lysine, ornithine, and cystine, and the mixed disulfide of cysteine and homocysteine. The metabolic defect that leads to cystinuria is inherited as an autosomal, recessive trait. Metabolism of the affected amino acids is influenced by at least two abnormal factors: (1) defective gastrointestinal absorption and (2) renal tubular dysfunction. Arginine, lysine, ornithine, and cysteine are soluble substances, readily excreted. There is no apparent pathology connected with their excretion in excessive quantities. Cystine, however, is so slightly soluble at the usual range of urinary pH that it is not excreted readily, and so crystallizes and forms stones in the urinary tract. Stone formation is the only known pathology in cystinuria. Normal daily output of cystine is 40 to 80 mg. In cystinuria, output is greatly increased and may exceed 1 g/day. At 500 to 600 mg/day, stone formation is almost certain. When it is more than 300 mg/day, treatment is indicated. Conventional treatment is directed at keeping urinary cystine diluted enough to prevent stone formation, keeping the urine alkaline enough to dissolve as much cystine as possible, and minimizing cystine production by a diet low in methionine (the major dietary precursor of cystine). Patients must drink enough fluid to keep urine specific gravity below 1.010, take enough alkali to keep urinary pH at 7.5 to 8, and maintain a diet low in methionine. This diet is not recommended in growing children and probably is contraindicated in pregnancy because of its low protein content (see PRECAUTIONS) . When these measures are inadequate to control recurrent stone formation, penicillamine capsules may be used as additional therapy, and when patients refuse to adhere to conventional treatment, penicillamine capsules may be a useful substitute. It is capable of keeping cystine excretion to near normal values, thereby hindering stone formation and the serious consequences of pyelonephritis and impaired renal function that develop in some patients. Bartter and colleagues depict the process by which penicillamine interacts with cystine to form penicillaminecysteine mixed disulfide as: CSSC = cystine CS ′ = deprotonated cysteine PSSP = penicillamine disulfide PS ′ = deprotonated penicillamine sulfhydryl CSSP = penicillamine-cysteine mixed disulfide In this process, it is assumed that the deprotonated form of penicillamine, PS', is the active factor in bringing about the disulfide interchange. Rheumatoid Arthritis — Because penicillamine capsules can cause severe adverse reactions, its use in rheumatoid arthritis should be restricted to patients who have severe, active disease and who have failed to respond to an adequate trial of conventional therapy. Even then, benefit-to-risk ratio should be carefully considered. Other measures, such as rest, physiotherapy, salicylates, and corticosteroids should be used, when indicated, in conjunction with penicillamine capsules (see PRECAUTIONS ). uuid:ccc0e865-6ec6-4e82-9c3e-c7601ff8334c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:65307 biolink:treats MONDO:0018912 PMID:41385096 "[{""id"":""uuid:782fc6c3-cc0b-4d06-8ba2-b3a750fc1e19"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c77d27d3-aa09-4cc0-9bc3-f19c5a8ea4ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ACTHREL® is indicated for use in differentiating pituitary and ectopic production of ACTH in patients with ACTH-dependent Cushing's syndrome. uuid:3ac5e652-0545-453d-9119-18f036bf74d2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31897 biolink:treats MONDO:0005147 PMID:41385096 "[{""id"":""uuid:e3464773-6570-4532-97ff-53a7bee4af46"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:340b5f24-eafd-450a-92f8-021e240bbeb5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nateglinide tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use : Nateglinide tablets should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. uuid:cb7e3e17-60c9-4063-958d-b83165eece29 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31897 biolink:treats MONDO:0012819 PMID:41385096 "[{""id"":""uuid:42bf9af8-0916-44b2-a2d6-7978c48ec6ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:191f1f37-ac2d-40bc-be4c-4dd41dd055a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nateglinide tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use : Nateglinide tablets should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. uuid:4e05594b-77bd-443c-8f6d-1de49b34cfec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16236 biolink:treats MONDO:0005045 PMID:41385096 "[{""id"":""uuid:d831e4a5-8d22-48af-a52a-c20c9f20b6ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ef605f8e-ebbb-4809-a229-28308c6dcc5e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ABLYSINOL ® is indicated to induce controlled cardiac septal infarction to improve exercise capacity in adults with symptomatic hypertrophic obstructive cardiomyopathy who are not candidates for surgical myectomy. uuid:4b24f244-b5ae-4560-b60a-f229a540d57a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:Y68179SY2L biolink:treats MONDO:0019496 PMID:41385096 "[{""id"":""uuid:f002742f-4992-474c-96e7-917ef46c80c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c54799e6-d1ef-4cd5-aca4-18129487b4f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ga 68 DOTATOC Injection is indicated for use with positron emission tomography (PET) for the localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult and pediatric patients. uuid:230eaf61-d240-4d83-a0cb-97c19aed63f1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6824 biolink:treats MONDO:0006939 PMID:41385096 "[{""id"":""uuid:5cc9ba57-8dde-474d-a293-f804728e467d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e1b3e97e-3fc9-4c80-a610-3313e7a947a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methenamine mandelate, USP is indicated for the suppression or elimination of bacteriuria associated with pyelonephritis, cystitis, and other chronic urinary tract infections; also for infected residual urine sometimes accompanying neurologic diseases. When used as recommended, methenamine mandelate, USP is particularly suitable for long-term therapy because of its safety and because resistance to the nonspecific bactericidal action of formaldehyde does not develop. Pathogens resistant to other antibacterial agents may respond to methenamine mandelate, USP because of the nonspecific effect of formaldehyde formed in an acid urine. Prophylactic Use Rationale: Urine is a good culture medium for many urinary pathogens. Inoculation by a few organisms (relapse or reinfection) may lead to bacteriuria in susceptible individuals. Thus, the rationale of management in recurring urinary tract infection (bacteriuria) is to change the urine from a growth-supporting to a growth-inhibiting medium. There is a growing body of evidence that long-term administration of methenamine mandelate, USP can prevent the recurrence of bacteriuria in patients with chronic pyelonephritis. Therapeutic Use Rationale: Methenamine mandelate, USP helps to sterilize the urine, and in some situations in which underlying pathologic conditions prevent sterilization by any means, it can help to suppress the bacteriuria. Methenamine mandelate, USP should not be used alone for acute infections with parenchymal involvement causing systemic symptoms such as chills and fever. A thorough diagnostic investigation as a part of the overall management of the urinary tract infection should accompany the use of methenamine mandelate, USP. uuid:e19dc681-1e64-486d-b4e4-010961a278b6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6824 biolink:treats MONDO:0006032 PMID:41385096 "[{""id"":""uuid:4c8d6d9e-ea76-4b67-a200-350184d4e1e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e3d6a07e-f61c-4f2b-9b1d-5c9993bea112"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methenamine mandelate, USP is indicated for the suppression or elimination of bacteriuria associated with pyelonephritis, cystitis, and other chronic urinary tract infections; also for infected residual urine sometimes accompanying neurologic diseases. When used as recommended, methenamine mandelate, USP is particularly suitable for long-term therapy because of its safety and because resistance to the nonspecific bactericidal action of formaldehyde does not develop. Pathogens resistant to other antibacterial agents may respond to methenamine mandelate, USP because of the nonspecific effect of formaldehyde formed in an acid urine. Prophylactic Use Rationale: Urine is a good culture medium for many urinary pathogens. Inoculation by a few organisms (relapse or reinfection) may lead to bacteriuria in susceptible individuals. Thus, the rationale of management in recurring urinary tract infection (bacteriuria) is to change the urine from a growth-supporting to a growth-inhibiting medium. There is a growing body of evidence that long-term administration of methenamine mandelate, USP can prevent the recurrence of bacteriuria in patients with chronic pyelonephritis. Therapeutic Use Rationale: Methenamine mandelate, USP helps to sterilize the urine, and in some situations in which underlying pathologic conditions prevent sterilization by any means, it can help to suppress the bacteriuria. Methenamine mandelate, USP should not be used alone for acute infections with parenchymal involvement causing systemic symptoms such as chills and fever. A thorough diagnostic investigation as a part of the overall management of the urinary tract infection should accompany the use of methenamine mandelate, USP. uuid:e964cfef-97e9-4d5e-b7fc-3b1fced5391e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6824 biolink:treats UMLS:C0262421 PMID:41385096 "[{""id"":""uuid:a96c049d-400e-4518-aa2d-aa6778453b4d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ae9664b1-b67c-4679-81f0-bac492b7ba5f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methenamine mandelate, USP is indicated for the suppression or elimination of bacteriuria associated with pyelonephritis, cystitis, and other chronic urinary tract infections; also for infected residual urine sometimes accompanying neurologic diseases. When used as recommended, methenamine mandelate, USP is particularly suitable for long-term therapy because of its safety and because resistance to the nonspecific bactericidal action of formaldehyde does not develop. Pathogens resistant to other antibacterial agents may respond to methenamine mandelate, USP because of the nonspecific effect of formaldehyde formed in an acid urine. Prophylactic Use Rationale: Urine is a good culture medium for many urinary pathogens. Inoculation by a few organisms (relapse or reinfection) may lead to bacteriuria in susceptible individuals. Thus, the rationale of management in recurring urinary tract infection (bacteriuria) is to change the urine from a growth-supporting to a growth-inhibiting medium. There is a growing body of evidence that long-term administration of methenamine mandelate, USP can prevent the recurrence of bacteriuria in patients with chronic pyelonephritis. Therapeutic Use Rationale: Methenamine mandelate, USP helps to sterilize the urine, and in some situations in which underlying pathologic conditions prevent sterilization by any means, it can help to suppress the bacteriuria. Methenamine mandelate, USP should not be used alone for acute infections with parenchymal involvement causing systemic symptoms such as chills and fever. A thorough diagnostic investigation as a part of the overall management of the urinary tract infection should accompany the use of methenamine mandelate, USP. uuid:f699791b-3b3e-4f19-8e47-d44323e0813a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6824 biolink:treats MONDO:0001882 PMID:41385096 "[{""id"":""uuid:c1d97972-9aba-4903-af78-f1f041e00a78"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:82d1a4de-b885-49b8-bab6-a2b103849633"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methenamine mandelate, USP is indicated for the suppression or elimination of bacteriuria associated with pyelonephritis, cystitis, and other chronic urinary tract infections; also for infected residual urine sometimes accompanying neurologic diseases. When used as recommended, methenamine mandelate, USP is particularly suitable for long-term therapy because of its safety and because resistance to the nonspecific bactericidal action of formaldehyde does not develop. Pathogens resistant to other antibacterial agents may respond to methenamine mandelate, USP because of the nonspecific effect of formaldehyde formed in an acid urine. Prophylactic Use Rationale: Urine is a good culture medium for many urinary pathogens. Inoculation by a few organisms (relapse or reinfection) may lead to bacteriuria in susceptible individuals. Thus, the rationale of management in recurring urinary tract infection (bacteriuria) is to change the urine from a growth-supporting to a growth-inhibiting medium. There is a growing body of evidence that long-term administration of methenamine mandelate, USP can prevent the recurrence of bacteriuria in patients with chronic pyelonephritis. Therapeutic Use Rationale: Methenamine mandelate, USP helps to sterilize the urine, and in some situations in which underlying pathologic conditions prevent sterilization by any means, it can help to suppress the bacteriuria. Methenamine mandelate, USP should not be used alone for acute infections with parenchymal involvement causing systemic symptoms such as chills and fever. A thorough diagnostic investigation as a part of the overall management of the urinary tract infection should accompany the use of methenamine mandelate, USP. uuid:69c3d809-0b9d-46ed-9cd4-f6d62dd1009b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4B33BGI082 biolink:treats MONDO:0037748 PMID:41385096 "[{""id"":""uuid:09a071f4-9fbd-4323-8c98-f0d275dd43dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e8b1584c-a212-4b0c-8a1e-d80a8345f7ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1) Cholestyramine for Oral Suspension, USP Light powder is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet. Cholestyramine for Oral Suspension, USP Light powder may be useful to lower LDL cholesterol in patients who also have hypertriglyceridemia, but it is not indicated where hypertriglyceridemia is the abnormality of most concern. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Treatment should begin and continue with dietary therapy specific for the type of hyperlipoproteinemia determined prior to initiation of drug therapy. Excess body weight may be an important factor and caloric restriction for weight normalization should be addressed prior to drug therapy in the overweight. Prior to initiating therapy with cholestyramine resin, secondary causes of hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism), should be excluded and a lipid profile performed to assess Total cholesterol, HDL-C and triglycerides (TG). For individuals with TG less than 400 mg/dL (<4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = Total cholesterol - [(TG/5) + HDL-C] For TG levels > 400 mg/dL, this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated Total-C. In such cases cholestyramine resin may not be indicated. Serum cholesterol and triglyceride levels should be determined periodically based on NCEP guidelines to confirm initial and adequate long-term response. A favorable trend in cholesterol reduction should occur during the first month of cholestyramine resin therapy. The therapy should be continued to sustain cholesterol reduction. If adequate cholesterol reduction is not attained, increasing the dosage of cholestyramine resin or adding other lipid-lowering agents in combination with cholestyramine resin should be considered. Since the goal of treatment is to lower LDL-C, the NCEP4 recommends that LDL-C levels be used to initiate and assess treatment response. If LDL-C levels are not available then Total-C alone may be used to monitor long-term therapy. A lipoprotein analysis (including LDL-C determination) should be carried out once a year. The NCEP treatment guidelines are summarized below. Definite Atherosclerotic Disease * Two or More Other Risk Factors † LDL-Cholesterol mg/dL (mmol/L) Initiation Level Goal No No ≥ 190 (4.9) ≥ 60 (4.1) No Yes ≥ 160 (4.1) ≥ 130 (3.4) Yes Yes or No ≥ 130 (3.4) ≥ 100 (‑2.6) * Coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease). † Other risk factors for coronary heart disease (CHD) include: age (males 45 years; females: 55 years or premature menopause without estrogen replacement therapy); family history of premature CHD; current cigarette smoking; hypertension; confirmed HDL-C <35 mg/dL (<0.91 mmol/L); and diabetes mellitus. Subtract one risk factor if HDL-C is 60 mg/dL (1.6 mmol/L). Cholestyramine resin monotherapy has been demonstrated to retard the rate of progression 2,3 and increase the rate of regression 3 of coronary atherosclerosis. 2) Cholestyramine for Oral Suspension, USP Light powder, is indicated for the relief of pruritus associated with partial biliary obstruction. Cholestyramine resin has been shown to have a variable effect on serum cholesterol in these patients. Patients with primary biliary cirrhosis may exhibit an elevated cholesterol as part of their disease. uuid:80253a9c-cbf9-4165-b43d-d70e14377fa8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4469 biolink:treats MONDO:0004681 PMID:41385096 "[{""id"":""uuid:54b36dfc-7548-48af-9da9-1eded25c6e74"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:03c5df24-fb52-4fe5-9dc4-a4743043effb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dextroamphetamine Sulfate Tablets USP are indicated for: Narcolepsy . Attention Deficit Disorder with Hyperactivity , as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in pediatric patients (ages 3 to 16 years) with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. The diagnosis of this syndrome should not be made with finality when these symptoms are only of comparatively recent origin. Nonlocalizing (soft) neurological signs, learning disability, and abnormal EEG may or may not be present, and a diagnosis of central nervous system dysfunction may or may not be warranted. uuid:fc4e5a25-1d0b-404b-9861-90cd492f3209 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4469 biolink:treats MONDO:0005302 PMID:41385096 "[{""id"":""uuid:47e82d3f-8dfd-473f-917d-6a2fe47aac51"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a012efee-5c4b-433c-bddc-1b78cee913b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Dextroamphetamine sulfate extended-release capsules are indicated in: Narcolepsy Attention Deficit Disorder with Hyperactivity As an integral part of a total treatment program that typically includes other measures (psychological, educational, social) for patients (ages 6 years to 16 years) with this syndrome. A diagnosis of Attention Deficit Hyperactivity Disorder (ADHD; DSM-IV) implies the presence of the hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years. The symptoms must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and be present in 2 or more settings, e.g., school (or work) and at home. The symptoms must not be better accounted for by another mental disorder. For the Inattentive Type, at least 6 of the following symptoms must have persisted for at least 6 months: lack of attention to details/careless mistakes; lack of sustained attention; poor listener; failure to follow through on tasks; poor organization; avoids tasks requiring sustained mental effort; loses things; easily distracted; forgetful. For the Hyperactive-Impulsive Type, at least 6 of the following symptoms must have persisted for at least 6 months: fidgeting/squirming; leaving seat; inappropriate running/climbing; difficulty with quiet activities; ""on the go""; excessive talking; blurting answers; can't wait turn; intrusive. The Combined Type requires both inattentive and hyperactive-impulsive criteria to be met. Special Diagnostic Considerations Specific etiology of this syndrome is unknown, and there is no single diagnostic test. Adequate diagnosis requires the use of medical and special psychological, educational, and social resources. Learning may or may not be impaired. The diagnosis must be based upon a complete history and evaluation of the patient and not solely on the presences of the required number of DSM-IV characteristics. Need for Comprehensive Treatment Program Dextroamphetamine sulfate extended-release capsules are indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational, social) for patients with this syndrome. Drug treatment may not be indicated for all patients with this syndrome. Stimulants are not intended for use in patients who exhibit symptoms secondary to environmental factors and/or other primary psychiatric disorders, including psychosis. Appropriate educational placement is essential and psychosocial intervention is often helpful. When remedial measures alone are insufficient, the decision to prescribe stimulant medication will depend upon the physician's assessment of the chronicity and severity of the patient's symptoms." uuid:504a89df-d125-4ac5-a406-42b30e4761df biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50859 biolink:treats MONDO:0015758 PMID:41385096 "[{""id"":""uuid:18f23791-13eb-47be-8f24-9ec0f3ba13be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:57002e8a-dc36-4141-8967-48f7514b73a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ac452b8c-9b14-4962-b84d-6a75eb1ca0e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/targretin""]},{""id"":""uuid:2e4b8888-a753-4abc-b3f4-b9d06edfdda8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bexarotene capsules are indicated for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy.|[EMA] Targretin capsules are indicated for the treatment of skin manifestations of advanced stage cutaneous T-cell lymphoma (CTCL) patients refractory to at least one systemic treatment.|[PMDA] A drug with a new active ingredient indicated for the treatment of cutaneous T-cell lymphoma. [Orphan drug] uuid:95e8da22-800c-4554-9b21-e727fa51058a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17303 biolink:treats HP:0030858 PMID:41385096 "[{""id"":""uuid:b77ebfad-0f07-40c2-a169-a04ad0ca73dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:58c050a9-191f-4d58-b94f-1b939418eb52"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Morphine sulfate extended-release tablets are an opioid agonist product indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. ( 1 ) Limitations of Use Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations, reserve morphine sulfate extended-release tablets for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. ( 1 ) Morphine sulfate extended-release tablets are not indicated as an as-needed (prn) analgesic. ( 1 ) uuid:2506a0f2-d44c-4105-bb9b-7349cfad92b6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17303 biolink:treats MONDO:0002491 PMID:41385096 "[{""id"":""uuid:5b03aa71-56c0-435d-8280-efea4f1efee2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5c41ca09-2ce2-484b-8188-84ffb5ad4806"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Morphine sulfate extended-release tablets are an opioid agonist product indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. ( 1 ) Limitations of Use Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations, reserve morphine sulfate extended-release tablets for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. ( 1 ) Morphine sulfate extended-release tablets are not indicated as an as-needed (prn) analgesic. ( 1 ) uuid:3a57e2f8-06f1-49a3-baf0-eb42412371a5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17303 biolink:treats EFO:0011049 PMID:41385096 "[{""id"":""uuid:3b87a562-8b95-40f6-a432-97cf9488e406"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4c3f9571-e13a-4bd9-84a7-069d82844671"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Morphine sulfate extended-release tablets are an opioid agonist product indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. ( 1 ) Limitations of Use Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations, reserve morphine sulfate extended-release tablets for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. ( 1 ) Morphine sulfate extended-release tablets are not indicated as an as-needed (prn) analgesic. ( 1 ) uuid:989e8fce-caa3-4038-b3db-029f839ecc02 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17303 biolink:treats EFO:0020911 PMID:41385096 "[{""id"":""uuid:a993f193-9909-4581-b0b6-a55cad5cfd91"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:29b745a9-d0f4-40c6-8766-9d47fc80809c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Morphine sulfate extended-release tablets are an opioid agonist product indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. ( 1 ) Limitations of Use Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations, reserve morphine sulfate extended-release tablets for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. ( 1 ) Morphine sulfate extended-release tablets are not indicated as an as-needed (prn) analgesic. ( 1 ) uuid:80b7a7e4-10c4-4d43-80d8-8e49ea66c228 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:647208 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:a33d7d3d-dba5-408f-b329-2a1c023ee05e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:2978bc1e-f396-479c-8900-155efd9940b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:63ca832f-d58b-4615-9d73-0eab337fbb57"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/tandemact""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pioglitazone and glimepiride tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who are already treated with a thiazolidinedione and sulfonylurea or who have inadequate glycemic control on a thiazolidinedione alone or a sulfonylurea alone [see Clinical Studies (14) ] .|[EMA] Tandemact is indicated for the treatment of patients with type-2 diabetes mellitus who show intolerance to metformin or for whom metformin is contraindicated and who are already treated with a combination of pioglitazone and glimepiride. uuid:d60ea554-a20d-4c5a-b946-474f67237dac biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15940 biolink:treats MONDO:0007788 PMID:41385096 "[{""id"":""uuid:00248a8b-f065-4050-a50b-28c3392bde15"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c5c25b45-fbc4-4642-8e12-c3e9d7278f50"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] I. Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Nicotinic acid, alone or in combination with a bile-acid binding resin, is indicated as an adjunct to diet for the reduction of elevated total and LDL cholesterol levels in patients with primary hypercholesterolemia (Types IIa and IIb) † , when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate (see also the NCEP treatment guidelines 6 ). Prior to initiating therapy with nicotinic acid, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure total cholesterol, HDL cholesterol, and triglycerides. II. Nicotinic acid is also indicated as adjunctive therapy for the treatment of adult patients with very high serum triglyceride levels (Types IV and V hyperlipidemia) † who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Such patients typically have serum triglyceride levels over 2,000 mg/dL and have elevations of VLDL cholesterol as well as fasting chylomicrons (Type V hyperlipidemia) † . Subjects who consistently have total serum or plasma triglycerides below 1,000 mg/dL are unlikely to develop pancreatitis. Therapy with nicotinic acid may be considered for those subjects with triglyceride elevations between 1,000 and 2,000 mg/dL who have a history of pancreatitis or of recurrent abdominal pain typical of pancreatitis. Some Type IV patients with triglycerides under 1,000 mg/dL may, through dietary or alcoholic indiscretion, convert to a Type V pattern with massive triglyceride elevations accompanying fasting chylomicronemia, but the influence of nicotinic acid therapy on the risk of pancreatitis in such situations has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of VLDL. Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV, and V hyperlipoproteinemia 7 . † Classification of Hyperlipoproteinemias Lipoproteins Lipid Elevations Type Elevated Major Minor C = cholesterol, TG = triglycerides LDL = low-density lipoprotein VLDL = very low-density lipoprotein IDL = intermediate-density lipoprotein I (rare) Chylomicrons TG ↑→ C IIa LDL C ..... IIb LDL, VLDL C TG III (rare) IDL C/TG ..... IV VLDL TG ↑→ C V (rare) Chylomicrons, VLDL TG ↑→ C uuid:791247ad-8f67-4d8a-8abe-eb07f168b2b3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15940 biolink:treats MONDO:0007762 PMID:41385096 "[{""id"":""uuid:c6d79e21-8da7-445f-92cf-07c8255a2ad2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fc89db04-d01c-49a5-a6a3-7a74211c2114"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] I. Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Nicotinic acid, alone or in combination with a bile-acid binding resin, is indicated as an adjunct to diet for the reduction of elevated total and LDL cholesterol levels in patients with primary hypercholesterolemia (Types IIa and IIb) † , when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate (see also the NCEP treatment guidelines 6 ). Prior to initiating therapy with nicotinic acid, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure total cholesterol, HDL cholesterol, and triglycerides. II. Nicotinic acid is also indicated as adjunctive therapy for the treatment of adult patients with very high serum triglyceride levels (Types IV and V hyperlipidemia) † who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Such patients typically have serum triglyceride levels over 2,000 mg/dL and have elevations of VLDL cholesterol as well as fasting chylomicrons (Type V hyperlipidemia) † . Subjects who consistently have total serum or plasma triglycerides below 1,000 mg/dL are unlikely to develop pancreatitis. Therapy with nicotinic acid may be considered for those subjects with triglyceride elevations between 1,000 and 2,000 mg/dL who have a history of pancreatitis or of recurrent abdominal pain typical of pancreatitis. Some Type IV patients with triglycerides under 1,000 mg/dL may, through dietary or alcoholic indiscretion, convert to a Type V pattern with massive triglyceride elevations accompanying fasting chylomicronemia, but the influence of nicotinic acid therapy on the risk of pancreatitis in such situations has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of VLDL. Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV, and V hyperlipoproteinemia 7 . † Classification of Hyperlipoproteinemias Lipoproteins Lipid Elevations Type Elevated Major Minor C = cholesterol, TG = triglycerides LDL = low-density lipoprotein VLDL = very low-density lipoprotein IDL = intermediate-density lipoprotein I (rare) Chylomicrons TG ↑→ C IIa LDL C ..... IIb LDL, VLDL C TG III (rare) IDL C/TG ..... IV VLDL TG ↑→ C V (rare) Chylomicrons, VLDL TG ↑→ C uuid:cd43c2fa-a9ba-4352-8365-61b36d0743ac biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63627 biolink:treats UMLS:C0023886 PMID:41385096 "[{""id"":""uuid:bc3455a6-5ade-4c6b-b6cb-1ec0462e78b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2c79a214-f364-45a4-8c52-9410fe014d5b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1 INDICATIONS AND USAGE 1.1 Trichomoniasis Tinidazole is indicated for the treatment of trichomoniasis caused by Trichomonas vaginalis. The organism should be identified by appropriate diagnostic procedures. Because trichomoniasis is a sexually transmitted disease with potentially serious sequelae, partners of infected patients should be treated simultaneously in order to prevent re-infection [see Clinical Studies (14.1)]. 1.2 Giardiasis Tinidazole is indicated for the treatment of giardiasis caused by Giardia duodenalis (also termed G. lamblia) in both adults and pediatric patients older than three years of age [see Clinical Studies (14.2)]. 1.3 Amebiasis Tinidazole is indicated for the treatment of intestinal amebiasis and amebic liver abscess caused by Entamoeba histolytica in both adults and pediatric patients older than three years of age. It is not indicated in the treatment of asymptomatic cyst passage [see Clinical Studies (14.3, 14.4)]. 1.4 Bacterial Vaginosis Tinidazole is indicated for the treatment of bacterial vaginosis (formerly referred to as Haemophilus vaginitis, Gardnerella vaginitis, nonspecific vaginitis, or anaerobic vaginosis) in adult women [see Use in Specific Populations (8.1) and Clinical Studies (14.5)]. Other pathogens commonly associated with vulvovaginitis such as Trichomonas vaginalis, Chlamydia trachomatis, Neisseria gonorrhoeae, Candida albicans and Herpes simplex virus should be ruled out. 1.5 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of Tindamax and other antibacterial drugs, Tindamax should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:97a46565-c201-454d-ad87-c1c76f0e932b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:131884828 biolink:treats MONDO:0008224 PMID:41385096 "[{""id"":""uuid:91fa7ec3-c72b-4380-87b7-f7305114ec3b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8b54ded8-7a89-4d57-950f-accf998babc2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KEVEYIS is indicated for the treatment of primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and related variants. uuid:ab07ce68-9291-4457-8dd6-cf35c8fe42ea biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:131884828 biolink:treats MONDO:0008223 PMID:41385096 "[{""id"":""uuid:8e805573-15ea-48bf-9107-4d84b6a73a6b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a6034688-d8e3-41f1-84d1-1b0d001daede"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KEVEYIS is indicated for the treatment of primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and related variants. uuid:f1e599a1-a4ce-4533-b390-a120d0af9c23 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28971 biolink:treats MONDO:0020920 PMID:41385096 "[{""id"":""uuid:3b2247b4-2666-45e9-b62d-a773d64972b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:766adf50-7445-425f-8de1-00a1c6457769"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of ampicillin capsules, ampicillin for oral suspension and other antibacterial drugs, ampicillin capsules and ampicillin for oral suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting of modifying antimicrobial therapy, in the absence of such data, local epidemiology and susceptibility patterns contribute to the empiric selection of therapy. Ampicillin capsules and ampicillin for oral suspension are indicated in the treatment of infections caused by susceptible strains of the designated organisms listed below: Infections of the genitourinary tract including gonorrhea: E. coli, P. mirabilis, enterococci , Shigella, S. typhosa and other Salmonella , and nonpenicillinase producing N. gonorrhoeae . Infections of the respiratory tract: Nonpenicillinase- producing H. influenzae and staphylococci, and streptococci including streptococcus pneumoniae . Infections of the gastrointestinal tract: Shigella, S. typhosa and other Salmonella, E. coli, P. mirabilis, and enterococci . Meningitis: N. Meningitides . Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to the results of susceptibility testing. uuid:c9b06a06-e50d-41e7-a726-699608065923 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28971 biolink:treats MONDO:0019345 PMID:41385096 "[{""id"":""uuid:6c45dba7-fc8c-47a6-8ea5-cf55fd03d84e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8a28f37c-3c75-4253-9524-5bd971b2bb6b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of ampicillin capsules, ampicillin for oral suspension and other antibacterial drugs, ampicillin capsules and ampicillin for oral suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting of modifying antimicrobial therapy, in the absence of such data, local epidemiology and susceptibility patterns contribute to the empiric selection of therapy. Ampicillin capsules and ampicillin for oral suspension are indicated in the treatment of infections caused by susceptible strains of the designated organisms listed below: Infections of the genitourinary tract including gonorrhea: E. coli, P. mirabilis, enterococci , Shigella, S. typhosa and other Salmonella , and nonpenicillinase producing N. gonorrhoeae . Infections of the respiratory tract: Nonpenicillinase- producing H. influenzae and staphylococci, and streptococci including streptococcus pneumoniae . Infections of the gastrointestinal tract: Shigella, S. typhosa and other Salmonella, E. coli, P. mirabilis, and enterococci . Meningitis: N. Meningitides . Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to the results of susceptibility testing. uuid:a6f37014-f9b5-486c-a907-2b0e9e0ea433 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28971 biolink:treats MONDO:0000827 PMID:41385096 "[{""id"":""uuid:7374a21b-d8d0-4e86-9e2b-16ac1dbe447b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b5632af1-d062-4d14-b25a-fe2c4d4f6254"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of ampicillin capsules, ampicillin for oral suspension and other antibacterial drugs, ampicillin capsules and ampicillin for oral suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting of modifying antimicrobial therapy, in the absence of such data, local epidemiology and susceptibility patterns contribute to the empiric selection of therapy. Ampicillin capsules and ampicillin for oral suspension are indicated in the treatment of infections caused by susceptible strains of the designated organisms listed below: Infections of the genitourinary tract including gonorrhea: E. coli, P. mirabilis, enterococci , Shigella, S. typhosa and other Salmonella , and nonpenicillinase producing N. gonorrhoeae . Infections of the respiratory tract: Nonpenicillinase- producing H. influenzae and staphylococci, and streptococci including streptococcus pneumoniae . Infections of the gastrointestinal tract: Shigella, S. typhosa and other Salmonella, E. coli, P. mirabilis, and enterococci . Meningitis: N. Meningitides . Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to the results of susceptibility testing. uuid:ba804722-84ea-4955-8ce6-d9bf23d2d2e0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28971 biolink:treats HP:0005376 PMID:41385096 "[{""id"":""uuid:7f247719-7250-4ed8-9df8-dfc815684b15"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:67e3f1c9-2a36-4da2-9856-a31246dfd613"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of ampicillin capsules, ampicillin for oral suspension and other antibacterial drugs, ampicillin capsules and ampicillin for oral suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting of modifying antimicrobial therapy, in the absence of such data, local epidemiology and susceptibility patterns contribute to the empiric selection of therapy. Ampicillin capsules and ampicillin for oral suspension are indicated in the treatment of infections caused by susceptible strains of the designated organisms listed below: Infections of the genitourinary tract including gonorrhea: E. coli, P. mirabilis, enterococci , Shigella, S. typhosa and other Salmonella , and nonpenicillinase producing N. gonorrhoeae . Infections of the respiratory tract: Nonpenicillinase- producing H. influenzae and staphylococci, and streptococci including streptococcus pneumoniae . Infections of the gastrointestinal tract: Shigella, S. typhosa and other Salmonella, E. coli, P. mirabilis, and enterococci . Meningitis: N. Meningitides . Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to the results of susceptibility testing. uuid:94b819be-5853-4e88-9e03-02cfa23f9665 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28971 biolink:treats MONDO:0024313 PMID:41385096 "[{""id"":""uuid:8363e86c-6389-4d6e-a37a-5fe6bbbf48fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c70f11c4-53d8-4089-bc66-493077e06689"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of ampicillin capsules, ampicillin for oral suspension and other antibacterial drugs, ampicillin capsules and ampicillin for oral suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting of modifying antimicrobial therapy, in the absence of such data, local epidemiology and susceptibility patterns contribute to the empiric selection of therapy. Ampicillin capsules and ampicillin for oral suspension are indicated in the treatment of infections caused by susceptible strains of the designated organisms listed below: Infections of the genitourinary tract including gonorrhea: E. coli, P. mirabilis, enterococci , Shigella, S. typhosa and other Salmonella , and nonpenicillinase producing N. gonorrhoeae . Infections of the respiratory tract: Nonpenicillinase- producing H. influenzae and staphylococci, and streptococci including streptococcus pneumoniae . Infections of the gastrointestinal tract: Shigella, S. typhosa and other Salmonella, E. coli, P. mirabilis, and enterococci . Meningitis: N. Meningitides . Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to the results of susceptibility testing. uuid:4f62e33d-7fce-4d23-bab7-aa66122cd458 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28971 biolink:treats MONDO:0021679 PMID:41385096 "[{""id"":""uuid:45a518a7-ea54-4f7a-afdf-98361fe5614b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b3f4fe1b-0202-49e1-ab3e-4b68a3b45286"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of ampicillin capsules, ampicillin for oral suspension and other antibacterial drugs, ampicillin capsules and ampicillin for oral suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting of modifying antimicrobial therapy, in the absence of such data, local epidemiology and susceptibility patterns contribute to the empiric selection of therapy. Ampicillin capsules and ampicillin for oral suspension are indicated in the treatment of infections caused by susceptible strains of the designated organisms listed below: Infections of the genitourinary tract including gonorrhea: E. coli, P. mirabilis, enterococci , Shigella, S. typhosa and other Salmonella , and nonpenicillinase producing N. gonorrhoeae . Infections of the respiratory tract: Nonpenicillinase- producing H. influenzae and staphylococci, and streptococci including streptococcus pneumoniae . Infections of the gastrointestinal tract: Shigella, S. typhosa and other Salmonella, E. coli, P. mirabilis, and enterococci . Meningitis: N. Meningitides . Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to the results of susceptibility testing. uuid:9d3941ad-cc94-448d-9e61-fed8bb6c2de3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28971 biolink:treats MONDO:0005114 PMID:41385096 "[{""id"":""uuid:73eff1c5-b14d-4a1b-a378-148e85fd2be2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:27732d9a-439e-477d-ab7c-a60cf0fea099"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of ampicillin capsules, ampicillin for oral suspension and other antibacterial drugs, ampicillin capsules and ampicillin for oral suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting of modifying antimicrobial therapy, in the absence of such data, local epidemiology and susceptibility patterns contribute to the empiric selection of therapy. Ampicillin capsules and ampicillin for oral suspension are indicated in the treatment of infections caused by susceptible strains of the designated organisms listed below: Infections of the genitourinary tract including gonorrhea: E. coli, P. mirabilis, enterococci , Shigella, S. typhosa and other Salmonella , and nonpenicillinase producing N. gonorrhoeae . Infections of the respiratory tract: Nonpenicillinase- producing H. influenzae and staphylococci, and streptococci including streptococcus pneumoniae . Infections of the gastrointestinal tract: Shigella, S. typhosa and other Salmonella, E. coli, P. mirabilis, and enterococci . Meningitis: N. Meningitides . Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to the results of susceptibility testing. uuid:d2531403-5a66-434f-b98b-777f8c8d0ce9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:72296 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:fa5aea64-2c98-4e51-b738-7436b01da94f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:53fc7b7c-9280-461a-a9e4-46a1a83f358a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:75a8dd89-5d9d-4243-acf1-f9f3b93c4a7c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/eliquis""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] ELIQUIS is a factor Xa inhibitor indicated: • to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. (1.1) • for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery. (1.2) • for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE following initial therapy. (1.3 , 1.4 , 1.5)|[EMA] For Eliquis 2.5 mg film-coated tablets:Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery.Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II).Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults (see section 4.4 for haemodynamically unstable PE patients).For Eliquis 5 mg film-coated tablets:Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II).Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults (see section 4.4 for haemodynamically unstable PE patients). uuid:61563301-efd7-4cba-99b7-8edd2ea23d6c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:72296 biolink:treats UMLS:C5400523 PMID:41385096 "[{""id"":""uuid:3f929536-9552-4e4a-b435-5d89fbf07018"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:57a01bd4-3ed0-47f1-97ec-bb98006767b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:b4ded867-e3dc-4795-ab53-830509261eca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ELIQUIS is a factor Xa inhibitor indicated: • to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. (1.1) • for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery. (1.2) • for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE following initial therapy. (1.3 , 1.4 , 1.5)|[PMDA] Drugs with a new active ingredient indicated for prevention of ischemic stroke and systemic embolism in patients with nonvalvular atrial fibrillation. uuid:c59c8b4f-cab2-4e03-abb3-b0f11b327406 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16914 biolink:treats MONDO:0019269 PMID:41385096 "[{""id"":""uuid:8985631c-ae1e-4a6c-9f8c-a1f76706a69f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:96f04e7c-d082-423c-ac1e-c5a065917daa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SALVAX is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders, including verrucae and the various ichthyoses, keratosis palmaris and plantaris, keratosis pilaris, pityriasis rubra pilaris, and psoriasis. uuid:eff9ce34-b9de-4c02-a2f3-6436686bf4f8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7459 biolink:treats UMLS:C0151559 PMID:41385096 "[{""id"":""uuid:c7d7aa04-fdc5-4f67-ba2a-b3f555644a3e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d656dbe6-e0fc-484c-bab6-83743a17561b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Naloxone HCl Nasal Spray is indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression. Naloxone HCl Nasal Spray is intended for immediate administration as emergency therapy in settings where opioids may be present. Naloxone HCl Nasal Spray is not a substitute for emergency medical care. uuid:eed27366-4c1c-4eae-954c-ba4431f6aee5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9570 biolink:treats MONDO:0002657 PMID:41385096 "[{""id"":""uuid:082cd2bf-6963-4245-9fee-5f3d05f5a9e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e4d11664-c3bc-4d39-93a5-e6c17d6d4f9a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Thiotepa for injection is an alkylating drug indicated: • For treatment of adenocarcinoma of the breast or ovary. ( 1.2 ) • For controlling intracavitary effusions secondary to diffuse or localized neoplastic diseases of various serosal cavities. ( 1.3 ) • For treatment of superficial papillary carcinoma of the urinary bladder. ( 1.4 ) uuid:7444c896-df67-4c0a-8fd3-5c408986a4ed biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:30769 biolink:treats MONDO:0957318 PMID:41385096 "[{""id"":""uuid:49178770-d6b8-447d-9189-358d8134e14d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fcd90816-c7ae-44c4-982d-b2249ddd35a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Potassium Citrate Extended-Release Tablets are a citrate salt of potassium indicated for the management of: • Renal tubular acidosis (RTA) with calcium stones ( 1.1 ) • Hypocitraturic calcium oxalate nephrolithiasis of any etiology ( 1.2 ) • Uric acid lithiasis with or without calcium stones ( 1.3 ) uuid:19b194ae-df39-4b2c-9056-6a6344ae90ea biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:30769 biolink:treats MONDO:0012692 PMID:41385096 "[{""id"":""uuid:b7752c6c-5024-472e-bb8d-34c58311f475"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:08dc13bc-8ca5-420b-94ce-3d1e20444288"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Potassium citrate extended-release tablets is a citrate salt of potassium indicated for the management of: Renal tubular acidosis (RTA) with calcium stones (1.1) Hypocitraturic calcium oxalate nephrolithiasis of any etiology (1.2) Uric acid lithiasis with or without calcium stones (1.3) uuid:8eb1bbdd-b897-41b4-8c2b-64b517885077 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:30769 biolink:treats MONDO:0024647 PMID:41385096 "[{""id"":""uuid:62b980e2-c247-494e-ae6e-850922ef9341"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8fa4138b-8d0b-46a0-90c4-d49c5a2285a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Potassium citrate extended-release tablets is a citrate salt of potassium indicated for the management of: Renal tubular acidosis (RTA) with calcium stones (1.1) Hypocitraturic calcium oxalate nephrolithiasis of any etiology (1.2) Uric acid lithiasis with or without calcium stones (1.3) uuid:0d283ee8-5d1d-4748-a42e-b5834f5618e5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:25939 biolink:treats UMLS:C0043255 PMID:41385096 "[{""id"":""uuid:998f927e-a555-4ca9-bced-807f2ad76ce7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:64c6f30c-5c94-4124-a3d1-2e42df9f6f4c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Astringent, Alkaline, for superficial and deep festering wounds. for 1st, 2nd and 3rd ulcers and burns. grade. Ideal for people with diabetes.Úpply directly without diluting, on the affected area or use an impregnated gauze. uuid:dc17c7d9-461e-472d-9a91-218684616ffc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:25939 biolink:treats MONDO:0043839 PMID:41385096 "[{""id"":""uuid:c22fe06c-a284-4742-8709-dd81379380f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:74f9bebe-8071-4c28-ac6d-90c7a0acad2a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Astringent, Alkaline, for superficial and deep festering wounds. for 1st, 2nd and 3rd ulcers and burns. grade. Ideal for people with diabetes.Úpply directly without diluting, on the affected area or use an impregnated gauze. uuid:9ea9b02d-7031-4e65-83de-81b4f4fe8f22 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:8c07c98a-a67a-47e2-ad11-df3c7ba6747d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fc430565-842d-4bc7-b73c-931efdeeb12c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Enterobacter aerogenes. Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus . (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal infections. Infections in women caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum subspecies pallidum . Yaws caused by Treponema pallidum subspecies pertenue . Listeriosis due to Listeria monocytogenes . Anthrax due to Bacillus anthracis . Vincent's infection caused by Fusobacterium fusiforme . � Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis , minocycline may be a useful adjunct to amebicides. In severe acne , minocycline may be useful adjunctive therapy. Oral minocycline is indicated in the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Oral minocycline is not indicated for the treatment of meningococcal infection . Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum . To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules, USP and other antibacterial drugs, minocycline hydrochloride capsules, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:7e248833-6638-40ff-ad85-1030b0201a5e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0005114 PMID:41385096 "[{""id"":""uuid:14fb5ebe-11e0-4a2b-8600-fbe6b6e81be5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:563203c5-a4ff-412c-9b15-300bbb24883a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Enterobacter aerogenes. Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus . (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal infections. Infections in women caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum subspecies pallidum . Yaws caused by Treponema pallidum subspecies pertenue . Listeriosis due to Listeria monocytogenes . Anthrax due to Bacillus anthracis . Vincent's infection caused by Fusobacterium fusiforme . � Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis , minocycline may be a useful adjunct to amebicides. In severe acne , minocycline may be useful adjunctive therapy. Oral minocycline is indicated in the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Oral minocycline is not indicated for the treatment of meningococcal infection . Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum . To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules, USP and other antibacterial drugs, minocycline hydrochloride capsules, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:3c2c8a95-41f1-4edb-9fbe-3f5fc3c0d99d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0005545 PMID:41385096 "[{""id"":""uuid:16d3fe55-626d-409b-a1f0-0501ace4033c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e9369e20-970c-40da-b5dc-3e5e26337821"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Enterobacter aerogenes. Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus . (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal infections. Infections in women caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum subspecies pallidum . Yaws caused by Treponema pallidum subspecies pertenue . Listeriosis due to Listeria monocytogenes . Anthrax due to Bacillus anthracis . Vincent's infection caused by Fusobacterium fusiforme . � Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis , minocycline may be a useful adjunct to amebicides. In severe acne , minocycline may be useful adjunctive therapy. Oral minocycline is indicated in the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Oral minocycline is not indicated for the treatment of meningococcal infection . Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum . To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules, USP and other antibacterial drugs, minocycline hydrochloride capsules, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:9ec805cf-0281-4bb5-a744-b25d8ff91730 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17347 biolink:treats HP:0012287 PMID:41385096 "[{""id"":""uuid:416a20b3-79d5-4189-a999-4baba5d9c5cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f27b7c8d-a7f2-4bbe-8ea5-80b922b6f799"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Testosterone gel, 1.62% is indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired): testicular failure due to conditions such as cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter's syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone concentrations and gonadotropins (follicle-stimulating hormone [FSH], luteinizing hormone [LH]) above the normal range. Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation. These men have low testosterone serum concentrations, but have gonadotropins in the normal or low range. Limitations of use: Safety and efficacy of testosterone gel, 1.62% in men with “age-related hypogonadism” (also referred to as “late-onset hypogonadism”) have not been established. Safety and efficacy of testosterone gel, 1.62% in males less than 18 years old have not been established [see Use in Specific Populations ( 8.4 )] . Topical testosterone products may have different doses, strengths, or application instructions that may result in different systemic exposure [see Indications and Usage ( 1 ), and Clinical Pharmacology ( 12.3 )]. uuid:483acf68-2ce9-4e6d-8651-d9a5b52df3bf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28748 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:d8e43197-7194-4b48-a944-2ff2bf3df480"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9060129f-5897-47d8-811a-9233cdb701b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:af878d93-c33c-40a7-a301-dd70e46a851e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:72e4eca9-c867-4de9-be41-86825e478f75"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Doxorubicin hydrochloride (HCl) is an anthracycline topoisomerase II inhibitor indicated: as a component of multiagent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer (1.1). for the treatment of: acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms’ tumor, metastatic neuroblastoma, metastatic soft tissue sarcoma, metastatic bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcinoma, metastatic bronchogenic carcinoma (1.2).|[EMA] Zolsketil pegylated liposomal is a medicine used to treat the following types of cancer in adults:• breast cancer that has spread to other parts of the body in patients at risk of heart problems. Zolsketil pegylated liposomal is used on its own for this disease;• advanced ovarian cancer in women whose previous treatment including a platinum-based cancer medicine has stopped working;• multiple myeloma (a cancer of the white blood cells in the bone marrow), in patients with progressive disease who have received at least one other treatment in the past and have already had, or are unsuitable for, a bone marrow transplantation. Zolsketil pegylated liposomal is used in combination with bortezomib (another cancer medicine);• Kaposi’s sarcoma in patients with AIDS who have a very damaged immune system. Kaposi’s sarcoma is a cancer that causes abnormal tissue to grow under the skin, on moist body surfaces or on internal organs.Zolsketil pegylated liposomal contains the active substance doxorubicin and is a ‘hybrid medicine’. This means that it is similar to a ‘reference medicine’ containing the same active substance called Adriamycin. However, in Zolsketil pegylated liposomal the active substance is enclosed in tiny fatty spheres called liposomes, whereas this is not the case for Adriamycin.|[PMDA] Drugs with a new dosage indicated for the treatment of breast cancer (preoperative or postoperative chemotherapy in patients with operable breast cancer). [Public knowledge-based application] uuid:dfa549e8-0948-4c2d-8fd1-f78d586a5cb1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28748 biolink:treats MONDO:0004967 PMID:41385096 "[{""id"":""uuid:2150f9d4-4797-45aa-b5c0-2947390369c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fe101d2d-841a-4f59-ab31-da3e39f639a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Doxorubicin hydrochloride (HCl) is an anthracycline topoisomerase II inhibitor indicated: as a component of multiagent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer (1.1). for the treatment of: acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms’ tumor, metastatic neuroblastoma, metastatic soft tissue sarcoma, metastatic bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcinoma, metastatic bronchogenic carcinoma (1.2). uuid:593e2070-88c0-4a7a-bf09-46f834281086 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28748 biolink:treats MONDO:0005224 PMID:41385096 "[{""id"":""uuid:31ca0a7f-321b-42ae-beca-ca6f2af61e73"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:da4f86ad-0357-431c-b639-65abc4c16eea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Doxorubicin hydrochloride (HCl) is an anthracycline topoisomerase II inhibitor indicated: as a component of multiagent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer (1.1). for the treatment of: acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms’ tumor, metastatic neuroblastoma, metastatic soft tissue sarcoma, metastatic bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcinoma, metastatic bronchogenic carcinoma (1.2). uuid:d810db2c-ee2b-404f-95e0-6db6a2e070b5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28748 biolink:treats MONDO:0009348 PMID:41385096 "[{""id"":""uuid:878d844c-793a-4784-b2b0-41096fa0edb3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9413487b-0300-4766-a662-e2d8a4f874f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Doxorubicin hydrochloride (HCl) is an anthracycline topoisomerase II inhibitor indicated: as a component of multiagent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer (1.1). for the treatment of: acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms’ tumor, metastatic neuroblastoma, metastatic soft tissue sarcoma, metastatic bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcinoma, metastatic bronchogenic carcinoma (1.2). uuid:26b628b9-a15d-49fd-a914-cf1688cfa568 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28748 biolink:treats MONDO:0018908 PMID:41385096 "[{""id"":""uuid:8eff119e-763a-4799-bd0d-0c51446a1008"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8d236861-5edd-4179-a66e-864fd7816990"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Doxorubicin hydrochloride (HCl) is an anthracycline topoisomerase II inhibitor indicated: as a component of multiagent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer (1.1). for the treatment of: acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms’ tumor, metastatic neuroblastoma, metastatic soft tissue sarcoma, metastatic bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcinoma, metastatic bronchogenic carcinoma (1.2). uuid:82c135b4-f8d6-4445-9f06-cf956db1e4dc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28748 biolink:treats UMLS:C0278488 PMID:41385096 "[{""id"":""uuid:e6d8002a-c719-4fac-976e-39c293cff569"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0e9999fc-ed0b-4ad4-9b3b-98d56ade87f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Doxorubicin hydrochloride (HCl) is an anthracycline topoisomerase II inhibitor indicated: as a component of multiagent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer (1.1). for the treatment of: acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms’ tumor, metastatic neuroblastoma, metastatic soft tissue sarcoma, metastatic bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcinoma, metastatic bronchogenic carcinoma (1.2). uuid:46cd57f3-50d2-421a-a56b-1e45c9b35b5a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28748 biolink:treats MONDO:0006058 PMID:41385096 "[{""id"":""uuid:86c67fbe-9b17-46c2-adeb-32a856dbd8c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2f004bc1-745d-42b3-9a7d-2a517816679b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Doxorubicin hydrochloride (HCl) is an anthracycline topoisomerase II inhibitor indicated: as a component of multiagent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer (1.1). for the treatment of: acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms’ tumor, metastatic neuroblastoma, metastatic soft tissue sarcoma, metastatic bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcinoma, metastatic bronchogenic carcinoma (1.2). uuid:53ba698b-940a-4362-a9ef-b6dda1102d66 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28748 biolink:treats MONDO:0005072 PMID:41385096 "[{""id"":""uuid:4b333149-9777-4112-a6eb-479c5ae13744"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:727bbaf0-d5a6-4f38-beba-40aa1e1552db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Doxorubicin hydrochloride (HCl) is an anthracycline topoisomerase II inhibitor indicated: as a component of multiagent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer (1.1). for the treatment of: acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms’ tumor, metastatic neuroblastoma, metastatic soft tissue sarcoma, metastatic bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcinoma, metastatic bronchogenic carcinoma (1.2). uuid:f0153d47-7936-477a-8d34-d51a7cdefea6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28748 biolink:treats MONDO:0018078 PMID:41385096 "[{""id"":""uuid:4384be45-1c3f-4c5e-b9fe-911065703bc5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:010d2548-89fe-4950-abcc-fbbf7252b488"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Doxorubicin hydrochloride (HCl) is an anthracycline topoisomerase II inhibitor indicated: as a component of multiagent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer (1.1). for the treatment of: acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms’ tumor, metastatic neuroblastoma, metastatic soft tissue sarcoma, metastatic bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcinoma, metastatic bronchogenic carcinoma (1.2). uuid:8582e478-51fb-4e9f-838c-b1f849a49fb8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28748 biolink:treats MONDO:0021054 PMID:41385096 "[{""id"":""uuid:e4847063-a5f9-4be1-8ce8-d91627875ac3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7ef3578d-d9c5-4e1e-a261-04192ad0191e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Doxorubicin hydrochloride (HCl) is an anthracycline topoisomerase II inhibitor indicated: as a component of multiagent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer (1.1). for the treatment of: acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms’ tumor, metastatic neuroblastoma, metastatic soft tissue sarcoma, metastatic bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcinoma, metastatic bronchogenic carcinoma (1.2). uuid:a2d4e3b4-36c9-4f93-ad53-1dd31db675fb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28748 biolink:treats MONDO:0005140 PMID:41385096 "[{""id"":""uuid:6f06498a-856e-47aa-971c-c7a3ec0ff5eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b21fe974-d1b3-4f61-b6a4-3cb9da0f5f53"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Doxorubicin hydrochloride (HCl) is an anthracycline topoisomerase II inhibitor indicated: as a component of multiagent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer (1.1). for the treatment of: acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms’ tumor, metastatic neuroblastoma, metastatic soft tissue sarcoma, metastatic bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcinoma, metastatic bronchogenic carcinoma (1.2). uuid:40dee35d-731e-480d-9004-ebd886a39698 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28748 biolink:treats MONDO:0005611 PMID:41385096 "[{""id"":""uuid:caaf91ca-89be-4aa6-96b7-3590b536b19c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:76b8efe8-fbd0-4067-b9b6-538b297724ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Doxorubicin hydrochloride (HCl) is an anthracycline topoisomerase II inhibitor indicated: as a component of multiagent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer (1.1). for the treatment of: acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms’ tumor, metastatic neuroblastoma, metastatic soft tissue sarcoma, metastatic bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcinoma, metastatic bronchogenic carcinoma (1.2). uuid:5912c0c2-78cf-4557-b7a1-06aa41a8b92a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28748 biolink:treats MONDO:0015075 PMID:41385096 "[{""id"":""uuid:436460bf-29c3-444f-8b75-a7851d9dd373"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7ce56fae-aab2-4c03-bbd7-f266b4fded25"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Doxorubicin hydrochloride (HCl) is an anthracycline topoisomerase II inhibitor indicated: as a component of multiagent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer (1.1). for the treatment of: acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms’ tumor, metastatic neuroblastoma, metastatic soft tissue sarcoma, metastatic bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcinoma, metastatic bronchogenic carcinoma (1.2). uuid:95add9d6-15f0-49ee-8188-fcff1b752607 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28748 biolink:treats MONDO:0004716 PMID:41385096 "[{""id"":""uuid:ec4fc5fb-8082-469f-86b2-668249269223"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:903e1ef6-2c46-4241-a9ce-d18316208d18"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Doxorubicin hydrochloride (HCl) is an anthracycline topoisomerase II inhibitor indicated: as a component of multiagent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer (1.1). for the treatment of: acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms’ tumor, metastatic neuroblastoma, metastatic soft tissue sarcoma, metastatic bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcinoma, metastatic bronchogenic carcinoma (1.2). uuid:b2355258-8691-44f2-bfcb-e75ec46d4d0e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28748 biolink:treats MONDO:0002806 PMID:41385096 "[{""id"":""uuid:1287718c-1194-416a-ae42-335c3feac060"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0a94bdaa-6add-4926-bd4b-0e36020ff38a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Doxorubicin hydrochloride (HCl) is an anthracycline topoisomerase II inhibitor indicated: as a component of multiagent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer (1.1). for the treatment of: acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms’ tumor, metastatic neuroblastoma, metastatic soft tissue sarcoma, metastatic bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcinoma, metastatic bronchogenic carcinoma (1.2). uuid:bde20fb7-926a-4c1b-b737-c291539a2385 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C3537689 biolink:treats MONDO:0005412 PMID:41385096 "[{""id"":""uuid:71e4ac49-0c8e-4d1c-b2e4-d62162700f18"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9f880b8b-d27d-4fc7-9d61-1d59cce7dbd2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Treatment of Active Duodenal Ulcer Omeprazole delayed-release capsules are indicated for short-term treatment of active duodenal ulcer in adults. Most patients heal within four weeks. Some patients may require an additional four weeks of therapy. 1.2 Helicobacter pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. Triple Therapy Omeprazole delayed-release capsules in combination with clarithromycin and amoxicillin, are indicated for treatment of patients with H. pylori infection and duodenal ulcer disease (active or up to 1-year history) to eradicate H. pylori in adults. Dual Therapy Omeprazole delayed-release capsules in combination with clarithromycin are indicated for treatment of patients with H. pylori infection and duodenal ulcer disease to eradicate H. pylori in adults. Among patients who fail therapy, omeprazole delayed-release capsules are with clarithromycin is more likely to be associated with the development of clarithromycin resistance as compared with triple therapy. In patients who fail therapy, susceptibility testing should be done. If resistance to clarithromycin is demonstrated or susceptibility testing is not possible, alternative antimicrobial therapy should be instituted [see Clinical Pharmacology (12.4) and the clarithromycin prescribing information, Microbiology section]. 1.3 Treatment of Active Benign Gastric Ulcer Omeprazole delayed-release capsules are indicated for short-term treatment (4 to 8 weeks) of active benign gastric ulcer in adults. 1.4 Treatment of Symptomatic Gastroesophageal Reflux Disease (GERD) Omeprazole delayed-release capsules are indicated for the treatment of heartburn and other symptoms associated with GERD for up to 4 weeks in patients 2 years of age and older. 1.5 Treatment of Erosive Esophagitis (EE) Due to Acid-Mediated GERD Pediatric Patients 2 Years of Age to Adults Omeprazole delayed-release capsules are indicated for the short-term treatment (4 to 8 weeks) of EE due to acid-mediated GERD that has been diagnosed by endoscopy in patients 2 years of age and older. The efficacy of omeprazole delayed-release capsules used for longer than 8 weeks in patients with EE has not been established. If a patient does not respond to 8 weeks of treatment, an additional 4 weeks of treatment may be given. If there is recurrence of EE or GERD symptoms (e.g., heartburn), additional 4 to 8 week courses of omeprazole delayed-release capsules may be considered. 1.6 Maintenance of Healing of EE Due to Acid-Mediated GERD Omeprazole delayed-release capsules are indicated for the maintenance healing of EE due to acid-mediated GERD in patients 2 years of age and older. Controlled studies do not extend beyond 12 months. 1.7 Pathological Hypersecretory Conditions Omeprazole delayed-release capsules are indicated for the long-term treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine adenomas and systemic mastocytosis) in adults. uuid:2ace4a19-5d3c-4534-ab8f-3fead295b1c2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C3537689 biolink:treats HP:0005202 PMID:41385096 "[{""id"":""uuid:3aba898a-53b4-4c58-962e-2c9f4a24032e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3dd9cefc-0ed0-4f38-a98e-c8a14e3f1d1e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Treatment of Active Duodenal Ulcer Omeprazole delayed-release capsules are indicated for short-term treatment of active duodenal ulcer in adults. Most patients heal within four weeks. Some patients may require an additional four weeks of therapy. 1.2 Helicobacter pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. Triple Therapy Omeprazole delayed-release capsules in combination with clarithromycin and amoxicillin, are indicated for treatment of patients with H. pylori infection and duodenal ulcer disease (active or up to 1-year history) to eradicate H. pylori in adults. Dual Therapy Omeprazole delayed-release capsules in combination with clarithromycin are indicated for treatment of patients with H. pylori infection and duodenal ulcer disease to eradicate H. pylori in adults. Among patients who fail therapy, omeprazole delayed-release capsules are with clarithromycin is more likely to be associated with the development of clarithromycin resistance as compared with triple therapy. In patients who fail therapy, susceptibility testing should be done. If resistance to clarithromycin is demonstrated or susceptibility testing is not possible, alternative antimicrobial therapy should be instituted [see Clinical Pharmacology (12.4) and the clarithromycin prescribing information, Microbiology section]. 1.3 Treatment of Active Benign Gastric Ulcer Omeprazole delayed-release capsules are indicated for short-term treatment (4 to 8 weeks) of active benign gastric ulcer in adults. 1.4 Treatment of Symptomatic Gastroesophageal Reflux Disease (GERD) Omeprazole delayed-release capsules are indicated for the treatment of heartburn and other symptoms associated with GERD for up to 4 weeks in patients 2 years of age and older. 1.5 Treatment of Erosive Esophagitis (EE) Due to Acid-Mediated GERD Pediatric Patients 2 Years of Age to Adults Omeprazole delayed-release capsules are indicated for the short-term treatment (4 to 8 weeks) of EE due to acid-mediated GERD that has been diagnosed by endoscopy in patients 2 years of age and older. The efficacy of omeprazole delayed-release capsules used for longer than 8 weeks in patients with EE has not been established. If a patient does not respond to 8 weeks of treatment, an additional 4 weeks of treatment may be given. If there is recurrence of EE or GERD symptoms (e.g., heartburn), additional 4 to 8 week courses of omeprazole delayed-release capsules may be considered. 1.6 Maintenance of Healing of EE Due to Acid-Mediated GERD Omeprazole delayed-release capsules are indicated for the maintenance healing of EE due to acid-mediated GERD in patients 2 years of age and older. Controlled studies do not extend beyond 12 months. 1.7 Pathological Hypersecretory Conditions Omeprazole delayed-release capsules are indicated for the long-term treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine adenomas and systemic mastocytosis) in adults. uuid:09e76fe8-7cec-415f-89d7-d0f27589ce3f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C3537689 biolink:treats MONDO:0001126 PMID:41385096 "[{""id"":""uuid:5d6ddef6-5391-4ce6-ab9c-83f0b255fadd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dffcec5b-1492-4245-ad7c-0e63a8bf2e67"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Treatment of Active Duodenal Ulcer Omeprazole delayed-release capsules are indicated for short-term treatment of active duodenal ulcer in adults. Most patients heal within four weeks. Some patients may require an additional four weeks of therapy. 1.2 Helicobacter pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. Triple Therapy Omeprazole delayed-release capsules in combination with clarithromycin and amoxicillin, are indicated for treatment of patients with H. pylori infection and duodenal ulcer disease (active or up to 1-year history) to eradicate H. pylori in adults. Dual Therapy Omeprazole delayed-release capsules in combination with clarithromycin are indicated for treatment of patients with H. pylori infection and duodenal ulcer disease to eradicate H. pylori in adults. Among patients who fail therapy, omeprazole delayed-release capsules are with clarithromycin is more likely to be associated with the development of clarithromycin resistance as compared with triple therapy. In patients who fail therapy, susceptibility testing should be done. If resistance to clarithromycin is demonstrated or susceptibility testing is not possible, alternative antimicrobial therapy should be instituted [see Clinical Pharmacology (12.4) and the clarithromycin prescribing information, Microbiology section]. 1.3 Treatment of Active Benign Gastric Ulcer Omeprazole delayed-release capsules are indicated for short-term treatment (4 to 8 weeks) of active benign gastric ulcer in adults. 1.4 Treatment of Symptomatic Gastroesophageal Reflux Disease (GERD) Omeprazole delayed-release capsules are indicated for the treatment of heartburn and other symptoms associated with GERD for up to 4 weeks in patients 2 years of age and older. 1.5 Treatment of Erosive Esophagitis (EE) Due to Acid-Mediated GERD Pediatric Patients 2 Years of Age to Adults Omeprazole delayed-release capsules are indicated for the short-term treatment (4 to 8 weeks) of EE due to acid-mediated GERD that has been diagnosed by endoscopy in patients 2 years of age and older. The efficacy of omeprazole delayed-release capsules used for longer than 8 weeks in patients with EE has not been established. If a patient does not respond to 8 weeks of treatment, an additional 4 weeks of treatment may be given. If there is recurrence of EE or GERD symptoms (e.g., heartburn), additional 4 to 8 week courses of omeprazole delayed-release capsules may be considered. 1.6 Maintenance of Healing of EE Due to Acid-Mediated GERD Omeprazole delayed-release capsules are indicated for the maintenance healing of EE due to acid-mediated GERD in patients 2 years of age and older. Controlled studies do not extend beyond 12 months. 1.7 Pathological Hypersecretory Conditions Omeprazole delayed-release capsules are indicated for the long-term treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine adenomas and systemic mastocytosis) in adults. uuid:547e33d6-cfc8-4eba-bd67-ec305676487e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C3537689 biolink:treats MONDO:0007186 PMID:41385096 "[{""id"":""uuid:84790386-04d0-433c-96cc-6eb401c36bcb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:90b4d32a-608d-42ca-855e-acf1c868734e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Treatment of Active Duodenal Ulcer Omeprazole delayed-release capsules are indicated for short-term treatment of active duodenal ulcer in adults. Most patients heal within four weeks. Some patients may require an additional four weeks of therapy. 1.2 Helicobacter pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. Triple Therapy Omeprazole delayed-release capsules in combination with clarithromycin and amoxicillin, are indicated for treatment of patients with H. pylori infection and duodenal ulcer disease (active or up to 1-year history) to eradicate H. pylori in adults. Dual Therapy Omeprazole delayed-release capsules in combination with clarithromycin are indicated for treatment of patients with H. pylori infection and duodenal ulcer disease to eradicate H. pylori in adults. Among patients who fail therapy, omeprazole delayed-release capsules are with clarithromycin is more likely to be associated with the development of clarithromycin resistance as compared with triple therapy. In patients who fail therapy, susceptibility testing should be done. If resistance to clarithromycin is demonstrated or susceptibility testing is not possible, alternative antimicrobial therapy should be instituted [see Clinical Pharmacology (12.4) and the clarithromycin prescribing information, Microbiology section]. 1.3 Treatment of Active Benign Gastric Ulcer Omeprazole delayed-release capsules are indicated for short-term treatment (4 to 8 weeks) of active benign gastric ulcer in adults. 1.4 Treatment of Symptomatic Gastroesophageal Reflux Disease (GERD) Omeprazole delayed-release capsules are indicated for the treatment of heartburn and other symptoms associated with GERD for up to 4 weeks in patients 2 years of age and older. 1.5 Treatment of Erosive Esophagitis (EE) Due to Acid-Mediated GERD Pediatric Patients 2 Years of Age to Adults Omeprazole delayed-release capsules are indicated for the short-term treatment (4 to 8 weeks) of EE due to acid-mediated GERD that has been diagnosed by endoscopy in patients 2 years of age and older. The efficacy of omeprazole delayed-release capsules used for longer than 8 weeks in patients with EE has not been established. If a patient does not respond to 8 weeks of treatment, an additional 4 weeks of treatment may be given. If there is recurrence of EE or GERD symptoms (e.g., heartburn), additional 4 to 8 week courses of omeprazole delayed-release capsules may be considered. 1.6 Maintenance of Healing of EE Due to Acid-Mediated GERD Omeprazole delayed-release capsules are indicated for the maintenance healing of EE due to acid-mediated GERD in patients 2 years of age and older. Controlled studies do not extend beyond 12 months. 1.7 Pathological Hypersecretory Conditions Omeprazole delayed-release capsules are indicated for the long-term treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine adenomas and systemic mastocytosis) in adults. uuid:06757b59-0a09-4391-b117-4d7cca8c2804 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C3537689 biolink:treats UMLS:C0267055 PMID:41385096 "[{""id"":""uuid:c0b3287f-5728-46d1-8dfb-9f891a97ae6d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7ef1f3a1-e16e-471b-a9c5-bef998132a67"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Treatment of Active Duodenal Ulcer Omeprazole delayed-release capsules are indicated for short-term treatment of active duodenal ulcer in adults. Most patients heal within four weeks. Some patients may require an additional four weeks of therapy. 1.2 Helicobacter pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. Triple Therapy Omeprazole delayed-release capsules in combination with clarithromycin and amoxicillin, are indicated for treatment of patients with H. pylori infection and duodenal ulcer disease (active or up to 1-year history) to eradicate H. pylori in adults. Dual Therapy Omeprazole delayed-release capsules in combination with clarithromycin are indicated for treatment of patients with H. pylori infection and duodenal ulcer disease to eradicate H. pylori in adults. Among patients who fail therapy, omeprazole delayed-release capsules are with clarithromycin is more likely to be associated with the development of clarithromycin resistance as compared with triple therapy. In patients who fail therapy, susceptibility testing should be done. If resistance to clarithromycin is demonstrated or susceptibility testing is not possible, alternative antimicrobial therapy should be instituted [see Clinical Pharmacology (12.4) and the clarithromycin prescribing information, Microbiology section]. 1.3 Treatment of Active Benign Gastric Ulcer Omeprazole delayed-release capsules are indicated for short-term treatment (4 to 8 weeks) of active benign gastric ulcer in adults. 1.4 Treatment of Symptomatic Gastroesophageal Reflux Disease (GERD) Omeprazole delayed-release capsules are indicated for the treatment of heartburn and other symptoms associated with GERD for up to 4 weeks in patients 2 years of age and older. 1.5 Treatment of Erosive Esophagitis (EE) Due to Acid-Mediated GERD Pediatric Patients 2 Years of Age to Adults Omeprazole delayed-release capsules are indicated for the short-term treatment (4 to 8 weeks) of EE due to acid-mediated GERD that has been diagnosed by endoscopy in patients 2 years of age and older. The efficacy of omeprazole delayed-release capsules used for longer than 8 weeks in patients with EE has not been established. If a patient does not respond to 8 weeks of treatment, an additional 4 weeks of treatment may be given. If there is recurrence of EE or GERD symptoms (e.g., heartburn), additional 4 to 8 week courses of omeprazole delayed-release capsules may be considered. 1.6 Maintenance of Healing of EE Due to Acid-Mediated GERD Omeprazole delayed-release capsules are indicated for the maintenance healing of EE due to acid-mediated GERD in patients 2 years of age and older. Controlled studies do not extend beyond 12 months. 1.7 Pathological Hypersecretory Conditions Omeprazole delayed-release capsules are indicated for the long-term treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine adenomas and systemic mastocytosis) in adults. uuid:b4ab326d-5bc7-4eb6-a3d6-c4136439e078 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C3537689 biolink:treats MONDO:0017169 PMID:41385096 "[{""id"":""uuid:32f310d7-fbf4-4d02-ab3b-e745d806cffe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b5b2ef5f-bae6-48f0-b9f2-056b35061e92"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Treatment of Active Duodenal Ulcer Omeprazole delayed-release capsules are indicated for short-term treatment of active duodenal ulcer in adults. Most patients heal within four weeks. Some patients may require an additional four weeks of therapy. 1.2 Helicobacter pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. Triple Therapy Omeprazole delayed-release capsules in combination with clarithromycin and amoxicillin, are indicated for treatment of patients with H. pylori infection and duodenal ulcer disease (active or up to 1-year history) to eradicate H. pylori in adults. Dual Therapy Omeprazole delayed-release capsules in combination with clarithromycin are indicated for treatment of patients with H. pylori infection and duodenal ulcer disease to eradicate H. pylori in adults. Among patients who fail therapy, omeprazole delayed-release capsules are with clarithromycin is more likely to be associated with the development of clarithromycin resistance as compared with triple therapy. In patients who fail therapy, susceptibility testing should be done. If resistance to clarithromycin is demonstrated or susceptibility testing is not possible, alternative antimicrobial therapy should be instituted [see Clinical Pharmacology (12.4) and the clarithromycin prescribing information, Microbiology section]. 1.3 Treatment of Active Benign Gastric Ulcer Omeprazole delayed-release capsules are indicated for short-term treatment (4 to 8 weeks) of active benign gastric ulcer in adults. 1.4 Treatment of Symptomatic Gastroesophageal Reflux Disease (GERD) Omeprazole delayed-release capsules are indicated for the treatment of heartburn and other symptoms associated with GERD for up to 4 weeks in patients 2 years of age and older. 1.5 Treatment of Erosive Esophagitis (EE) Due to Acid-Mediated GERD Pediatric Patients 2 Years of Age to Adults Omeprazole delayed-release capsules are indicated for the short-term treatment (4 to 8 weeks) of EE due to acid-mediated GERD that has been diagnosed by endoscopy in patients 2 years of age and older. The efficacy of omeprazole delayed-release capsules used for longer than 8 weeks in patients with EE has not been established. If a patient does not respond to 8 weeks of treatment, an additional 4 weeks of treatment may be given. If there is recurrence of EE or GERD symptoms (e.g., heartburn), additional 4 to 8 week courses of omeprazole delayed-release capsules may be considered. 1.6 Maintenance of Healing of EE Due to Acid-Mediated GERD Omeprazole delayed-release capsules are indicated for the maintenance healing of EE due to acid-mediated GERD in patients 2 years of age and older. Controlled studies do not extend beyond 12 months. 1.7 Pathological Hypersecretory Conditions Omeprazole delayed-release capsules are indicated for the long-term treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine adenomas and systemic mastocytosis) in adults. uuid:48ed752d-1915-4ac4-8958-0237f8f63af3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C3537689 biolink:treats MONDO:0016586 PMID:41385096 "[{""id"":""uuid:92b6c0f6-aabd-4a09-b30f-7d6c036d29c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5c038f6f-4c18-4fd6-a34e-27f24859c133"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Treatment of Active Duodenal Ulcer Omeprazole delayed-release capsules are indicated for short-term treatment of active duodenal ulcer in adults. Most patients heal within four weeks. Some patients may require an additional four weeks of therapy. 1.2 Helicobacter pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. Triple Therapy Omeprazole delayed-release capsules in combination with clarithromycin and amoxicillin, are indicated for treatment of patients with H. pylori infection and duodenal ulcer disease (active or up to 1-year history) to eradicate H. pylori in adults. Dual Therapy Omeprazole delayed-release capsules in combination with clarithromycin are indicated for treatment of patients with H. pylori infection and duodenal ulcer disease to eradicate H. pylori in adults. Among patients who fail therapy, omeprazole delayed-release capsules are with clarithromycin is more likely to be associated with the development of clarithromycin resistance as compared with triple therapy. In patients who fail therapy, susceptibility testing should be done. If resistance to clarithromycin is demonstrated or susceptibility testing is not possible, alternative antimicrobial therapy should be instituted [see Clinical Pharmacology (12.4) and the clarithromycin prescribing information, Microbiology section]. 1.3 Treatment of Active Benign Gastric Ulcer Omeprazole delayed-release capsules are indicated for short-term treatment (4 to 8 weeks) of active benign gastric ulcer in adults. 1.4 Treatment of Symptomatic Gastroesophageal Reflux Disease (GERD) Omeprazole delayed-release capsules are indicated for the treatment of heartburn and other symptoms associated with GERD for up to 4 weeks in patients 2 years of age and older. 1.5 Treatment of Erosive Esophagitis (EE) Due to Acid-Mediated GERD Pediatric Patients 2 Years of Age to Adults Omeprazole delayed-release capsules are indicated for the short-term treatment (4 to 8 weeks) of EE due to acid-mediated GERD that has been diagnosed by endoscopy in patients 2 years of age and older. The efficacy of omeprazole delayed-release capsules used for longer than 8 weeks in patients with EE has not been established. If a patient does not respond to 8 weeks of treatment, an additional 4 weeks of treatment may be given. If there is recurrence of EE or GERD symptoms (e.g., heartburn), additional 4 to 8 week courses of omeprazole delayed-release capsules may be considered. 1.6 Maintenance of Healing of EE Due to Acid-Mediated GERD Omeprazole delayed-release capsules are indicated for the maintenance healing of EE due to acid-mediated GERD in patients 2 years of age and older. Controlled studies do not extend beyond 12 months. 1.7 Pathological Hypersecretory Conditions Omeprazole delayed-release capsules are indicated for the long-term treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine adenomas and systemic mastocytosis) in adults. uuid:42871967-6caf-4be4-a4ed-1439b3d0b540 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9150 biolink:treats MONDO:0004995 PMID:41385096 "[{""id"":""uuid:8e2c89a3-0311-4a12-8ff0-14c7f56605c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9e389e5c-c7fe-4cd5-aebc-64bdfb111e5e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with coronary heart disease (CHD) or at high risk of CHD, simvastatin tablets can be started simultaneously with diet. 1.1 Reductions in Risk of CHD Mortality and Cardiovascular Events In patients at high risk of coronary events because of existing coronary heart disease, diabetes, peripheral vessel disease, history of stroke or other cerebrovascular disease, simvastatin tablets are indicated to: Reduce the risk of total mortality by reducing CHD deaths. Reduce the risk of non-fatal myocardial infarction and stroke. Reduce the need for coronary and non-coronary revascularization procedures. 1.2 Hyperlipidemia Simvastatin tablets are indicated to: Reduce elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), and triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary hyperlipidemia (Fredrickson type IIa, heterozygous familial and nonfamilial) or mixed dyslipidemia (Fredrickson type IIb). Reduce elevated TG in patients with hypertriglyceridemia (Fredrickson type lV hyperlipidemia). Reduce elevated TG and VLDL-C in patients with primary dysbetalipoproteinemia (Fredrickson type III hyperlipidemia). Reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH) as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable. 1.3 Adolescent Patients with Heterozygous Familial Hypercholesterolemia (HeFH) Simvastatin tablets are indicated as an adjunct to diet to reduce total-C, LDL-C, and Apo B levels in adolescent boys and girls who are at least one year post-menarche, 10 to 17 years of age, with HeFH, if after an adequate trial of diet therapy the following findings are present: LDL cholesterol remains ≥190 mg/dL; or LDL cholesterol remains ≥160 mg/dL and There is a positive family history of premature cardiovascular disease (CVD) or Two or more other CVD risk factors are present in the adolescent patient. The minimum goal of treatment in pediatric and adolescent patients is to achieve a mean LDL-C <130 mg/dL. The optimal age at which to initiate lipid-lowering therapy to decrease the risk of symptomatic adulthood CAD has not been determined. 1.4 Limitations of Use Simvastatin tablets have not been studied in conditions where the major abnormality is elevation of chylomicrons (i.e., hyperlipidemia Fredrickson types I and V). uuid:2bd655f0-a7b4-4645-b759-010e5599c80e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4710 biolink:treats MONDO:0013600 PMID:41385096 "[{""id"":""uuid:fce0d24a-6fcc-4be2-9696-46d8c616c4da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c4c45270-156d-402c-85fc-df42ad982416"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Doxepin HCl Tablets is indicated for the treatment of insomnia characterized by difficulty with sleep maintenance. The clinical trials performed in support of efficacy were up to 3 months in duration. uuid:35cbd127-c6fd-42d0-8e25-40fd2d228075 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3745 biolink:treats MONDO:0005242 PMID:41385096 "[{""id"":""uuid:797ef20c-97a1-4c2c-a65a-c39fe872524d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:67af166f-346b-4b97-af3c-ae05b533b4a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the BOXED WARNING, before selecting clindamycin, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin HCl and other antibacterial drugs, clindamycin HCl capsules, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:de6dc2ab-cb57-4de3-b874-a9a70c205f9f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3745 biolink:treats MONDO:0004649 PMID:41385096 "[{""id"":""uuid:0298f232-b904-4935-a19b-4bf36780417f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c79f478c-8f05-4bee-b9d5-b62ff5b19e3d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the BOXED WARNING, before selecting clindamycin, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin HCl and other antibacterial drugs, clindamycin HCl capsules, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:dc5e54b2-d328-49f4-9f3c-7b7885408477 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3745 biolink:treats MONDO:0000744 PMID:41385096 "[{""id"":""uuid:e899a5fd-d884-4436-9a57-7341a09ffb51"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9c71ed81-a74b-49a2-93f9-5d035533ae81"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the BOXED WARNING, before selecting clindamycin, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin HCl and other antibacterial drugs, clindamycin HCl capsules, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:41644647-d1d8-4a90-85d1-6eca70c20576 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3745 biolink:treats MONDO:0018602 PMID:41385096 "[{""id"":""uuid:55abcd3b-7ca8-418f-ba14-c41259af6d64"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eba98f90-aeac-4746-abc0-c3a943eded83"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the BOXED WARNING, before selecting clindamycin, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin HCl and other antibacterial drugs, clindamycin HCl capsules, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:3034d61b-6f5b-400c-8e75-d90a1892a8ac biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3745 biolink:treats MONDO:0700217 PMID:41385096 "[{""id"":""uuid:3f2167ad-6223-472d-8338-93f3bb708b7e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b251fb60-f57d-4824-bd69-3a4024cd706c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the BOXED WARNING, before selecting clindamycin, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin HCl and other antibacterial drugs, clindamycin HCl capsules, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:45cd2ea0-34e5-4db2-b7b8-a9f6af5f1ef4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3745 biolink:treats MONDO:0004522 PMID:41385096 "[{""id"":""uuid:e68f4f10-c0bf-48b9-8bf1-db9e7b7c0b9f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c15ba9d2-29fe-48f2-b3fa-40b92309a131"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the BOXED WARNING, before selecting clindamycin, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin HCl and other antibacterial drugs, clindamycin HCl capsules, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:91131c55-d21c-4834-ba36-4e5f9b16b7ee biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3745 biolink:treats MONDO:0000918 PMID:41385096 "[{""id"":""uuid:e6333317-bd5d-4cfc-acca-f47f3d7a9e0f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dc7c7596-5e22-4c3f-a823-200b121b3415"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the BOXED WARNING, before selecting clindamycin, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin HCl and other antibacterial drugs, clindamycin HCl capsules, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:acdacdfa-f754-4436-a6d5-ddeea7ea649c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3745 biolink:treats HP:0034493 PMID:41385096 "[{""id"":""uuid:72021447-c9f1-4cbf-a968-93ae30909e3b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:edd533b8-fe84-4ab3-ad93-9aabeface083"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the BOXED WARNING, before selecting clindamycin, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin HCl and other antibacterial drugs, clindamycin HCl capsules, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:f42d1c5d-fccd-48cf-88fc-3247ff0c25f8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3745 biolink:treats MONDO:0006887 PMID:41385096 "[{""id"":""uuid:ad4306de-4f22-4588-9cbb-5bb8829c58c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2cf6c7ea-4071-462c-94c6-8fc4b5f78b1b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the BOXED WARNING, before selecting clindamycin, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin HCl and other antibacterial drugs, clindamycin HCl capsules, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:78e0b1eb-cc2f-4a96-9648-b8b7aeb5e88b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3745 biolink:treats MONDO:0024355 PMID:41385096 "[{""id"":""uuid:3bd33e52-2864-47b4-83b9-dc7466d7c17f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:05da8592-b1bb-4c75-8b6e-97dc3d688d9c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the BOXED WARNING, before selecting clindamycin, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin HCl and other antibacterial drugs, clindamycin HCl capsules, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:fd8f1ee3-98ee-4005-a7f8-7ce22d380183 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2682 biolink:treats MONDO:0005657 PMID:41385096 "[{""id"":""uuid:d7c2493f-0bfe-4956-b781-a6fe15daed65"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a0ccfffb-9a02-471c-969c-78c37609fb91"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:05cc444e-b563-4451-af15-e99657140694"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amphotericin B for Injection USP should be administered primarily to patients with progressive, potentially life-threatening fungal infections. This potent drug should not be used to treat noninvasive fungal infections, such as oral thrush, vaginal candidiasis and esophageal candidiasis in patients with normal neutrophil counts. Amphotericin B for Injection USP is specifically intended to treat potentially life-threatening fungal infections: aspergillosis, cryptococcosis (torulosis), North American blastomycosis, systemic candidiasis, coccidioido-mycosis, histoplasmosis, zygomycosis including mucormycosis due to susceptible species of the genera Absidia , Mucor and Rhizopus , and infections due to related susceptible species of Conidiobolus and Basidiobolus , and sporotrichosis. Amphotericin B may be useful in the treatment of American mucocutaneous leishmaniasis, but it is not the drug of choice as primary therapy.|[PMDA] Various infections caused by Aspergillus species, Candida species or Cryptococcus species (drug with a new dosage and dosage form). uuid:31444225-9990-46c3-a065-8e9ddaaedb43 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2682 biolink:treats MONDO:0005724 PMID:41385096 "[{""id"":""uuid:8658ef7e-e3e4-4d9e-9d75-4e0a3b775367"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ba30f71c-1776-4fcb-9c04-4403476e102f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:efce6245-86b2-4787-8cc8-42bcbc5d6fd6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amphotericin B for Injection USP should be administered primarily to patients with progressive, potentially life-threatening fungal infections. This potent drug should not be used to treat noninvasive fungal infections, such as oral thrush, vaginal candidiasis and esophageal candidiasis in patients with normal neutrophil counts. Amphotericin B for Injection USP is specifically intended to treat potentially life-threatening fungal infections: aspergillosis, cryptococcosis (torulosis), North American blastomycosis, systemic candidiasis, coccidioido-mycosis, histoplasmosis, zygomycosis including mucormycosis due to susceptible species of the genera Absidia , Mucor and Rhizopus , and infections due to related susceptible species of Conidiobolus and Basidiobolus , and sporotrichosis. Amphotericin B may be useful in the treatment of American mucocutaneous leishmaniasis, but it is not the drug of choice as primary therapy.|[PMDA] Various infections caused by Aspergillus species, Candida species or Cryptococcus species (drug with a new dosage and dosage form). uuid:8fc3961c-ad07-4439-bf14-34124338337f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2682 biolink:treats MONDO:0005672 PMID:41385096 "[{""id"":""uuid:a49854bb-6e3e-46f4-903f-26230f8dfd22"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4f97cf54-ce13-4191-bfd4-03c7028cdd3f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:949939a9-f68a-46df-b19c-4760ce490a10"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amphotericin B for Injection USP should be administered primarily to patients with progressive, potentially life-threatening fungal infections. This potent drug should not be used to treat noninvasive fungal infections, such as oral thrush, vaginal candidiasis and esophageal candidiasis in patients with normal neutrophil counts. Amphotericin B for Injection USP is specifically intended to treat potentially life-threatening fungal infections: aspergillosis, cryptococcosis (torulosis), North American blastomycosis, systemic candidiasis, coccidioido-mycosis, histoplasmosis, zygomycosis including mucormycosis due to susceptible species of the genera Absidia , Mucor and Rhizopus , and infections due to related susceptible species of Conidiobolus and Basidiobolus , and sporotrichosis. Amphotericin B may be useful in the treatment of American mucocutaneous leishmaniasis, but it is not the drug of choice as primary therapy.|[PMDA] A drug with new additional indications and a new dosage for the treatment of fungal infections caused by Mucor species, Absidia species, Rhizopus species, Rhizomucor species, Cladosporium species, Cladophialophora species, Fonsecaea species, Phialophora species, Exophiala species, Coccidioides species, Histoplasma species, and Blastomyces species and visceral leishmaniasis. uuid:d7fb270d-2397-418a-a761-8eb42383b32f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2682 biolink:treats MONDO:0042233 PMID:41385096 "[{""id"":""uuid:1258a104-71a0-4a1c-ab74-4882ca68281c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aa24cf64-24ce-4e94-834d-1d52fa9ed7b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amphotericin B for Injection USP should be administered primarily to patients with progressive, potentially life-threatening fungal infections. This potent drug should not be used to treat noninvasive fungal infections, such as oral thrush, vaginal candidiasis and esophageal candidiasis in patients with normal neutrophil counts. Amphotericin B for Injection USP is specifically intended to treat potentially life-threatening fungal infections: aspergillosis, cryptococcosis (torulosis), North American blastomycosis, systemic candidiasis, coccidioido-mycosis, histoplasmosis, zygomycosis including mucormycosis due to susceptible species of the genera Absidia , Mucor and Rhizopus , and infections due to related susceptible species of Conidiobolus and Basidiobolus , and sporotrichosis. Amphotericin B may be useful in the treatment of American mucocutaneous leishmaniasis, but it is not the drug of choice as primary therapy. uuid:716a18b4-517a-475a-8764-11c7d25a3787 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2682 biolink:treats MONDO:0005706 PMID:41385096 "[{""id"":""uuid:fbb7412a-429f-4c35-928e-a4d8d997514b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:fc48c832-2145-41ee-8fc0-68c863479084"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:add9ed37-8e2b-4dc9-af3b-93011c05d3e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amphotericin B for Injection USP should be administered primarily to patients with progressive, potentially life-threatening fungal infections. This potent drug should not be used to treat noninvasive fungal infections, such as oral thrush, vaginal candidiasis and esophageal candidiasis in patients with normal neutrophil counts. Amphotericin B for Injection USP is specifically intended to treat potentially life-threatening fungal infections: aspergillosis, cryptococcosis (torulosis), North American blastomycosis, systemic candidiasis, coccidioido-mycosis, histoplasmosis, zygomycosis including mucormycosis due to susceptible species of the genera Absidia , Mucor and Rhizopus , and infections due to related susceptible species of Conidiobolus and Basidiobolus , and sporotrichosis. Amphotericin B may be useful in the treatment of American mucocutaneous leishmaniasis, but it is not the drug of choice as primary therapy.|[PMDA] A drug with new additional indications and a new dosage for the treatment of fungal infections caused by Mucor species, Absidia species, Rhizopus species, Rhizomucor species, Cladosporium species, Cladophialophora species, Fonsecaea species, Phialophora species, Exophiala species, Coccidioides species, Histoplasma species, and Blastomyces species and visceral leishmaniasis. uuid:ae6daa0c-7e1f-483d-a587-1a4483336231 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2682 biolink:treats MONDO:0018312 PMID:41385096 "[{""id"":""uuid:b9b51c09-01e1-4b5d-a4aa-bfbea453698e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:115b1d1b-7c1a-49ba-9da9-918949f5c6ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:40863bd2-6d77-447d-95cc-3cdc4c5050ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amphotericin B for Injection USP should be administered primarily to patients with progressive, potentially life-threatening fungal infections. This potent drug should not be used to treat noninvasive fungal infections, such as oral thrush, vaginal candidiasis and esophageal candidiasis in patients with normal neutrophil counts. Amphotericin B for Injection USP is specifically intended to treat potentially life-threatening fungal infections: aspergillosis, cryptococcosis (torulosis), North American blastomycosis, systemic candidiasis, coccidioido-mycosis, histoplasmosis, zygomycosis including mucormycosis due to susceptible species of the genera Absidia , Mucor and Rhizopus , and infections due to related susceptible species of Conidiobolus and Basidiobolus , and sporotrichosis. Amphotericin B may be useful in the treatment of American mucocutaneous leishmaniasis, but it is not the drug of choice as primary therapy.|[PMDA] A drug with new additional indications and a new dosage for the treatment of fungal infections caused by Mucor species, Absidia species, Rhizopus species, Rhizomucor species, Cladosporium species, Cladophialophora species, Fonsecaea species, Phialophora species, Exophiala species, Coccidioides species, Histoplasma species, and Blastomyces species and visceral leishmaniasis. uuid:26cfae74-fcbf-4360-984a-8dd0671db9fd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2682 biolink:treats MONDO:0019136 PMID:41385096 "[{""id"":""uuid:4ca28df9-9483-463a-8af3-31ffb6ff355a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e0bc1103-62b7-40b4-90f4-b39fb7d69958"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e4746b33-af43-4b6f-ada1-97bbee20fd76"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amphotericin B for Injection USP should be administered primarily to patients with progressive, potentially life-threatening fungal infections. This potent drug should not be used to treat noninvasive fungal infections, such as oral thrush, vaginal candidiasis and esophageal candidiasis in patients with normal neutrophil counts. Amphotericin B for Injection USP is specifically intended to treat potentially life-threatening fungal infections: aspergillosis, cryptococcosis (torulosis), North American blastomycosis, systemic candidiasis, coccidioido-mycosis, histoplasmosis, zygomycosis including mucormycosis due to susceptible species of the genera Absidia , Mucor and Rhizopus , and infections due to related susceptible species of Conidiobolus and Basidiobolus , and sporotrichosis. Amphotericin B may be useful in the treatment of American mucocutaneous leishmaniasis, but it is not the drug of choice as primary therapy.|[PMDA] A drug with new additional indications and a new dosage for the treatment of fungal infections caused by Mucor species, Absidia species, Rhizopus species, Rhizomucor species, Cladosporium species, Cladophialophora species, Fonsecaea species, Phialophora species, Exophiala species, Coccidioides species, Histoplasma species, and Blastomyces species and visceral leishmaniasis. uuid:e4e9779f-3413-492e-b110-b5f41f78a6b1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2682 biolink:treats MONDO:0005968 PMID:41385096 "[{""id"":""uuid:eaf6ac0d-4e85-4a62-9649-bd240010dcdc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0202e8ec-eba3-4eeb-9c12-fa8428d7af02"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amphotericin B for Injection USP should be administered primarily to patients with progressive, potentially life-threatening fungal infections. This potent drug should not be used to treat noninvasive fungal infections, such as oral thrush, vaginal candidiasis and esophageal candidiasis in patients with normal neutrophil counts. Amphotericin B for Injection USP is specifically intended to treat potentially life-threatening fungal infections: aspergillosis, cryptococcosis (torulosis), North American blastomycosis, systemic candidiasis, coccidioido-mycosis, histoplasmosis, zygomycosis including mucormycosis due to susceptible species of the genera Absidia , Mucor and Rhizopus , and infections due to related susceptible species of Conidiobolus and Basidiobolus , and sporotrichosis. Amphotericin B may be useful in the treatment of American mucocutaneous leishmaniasis, but it is not the drug of choice as primary therapy. uuid:b5eaedd4-1335-42f9-9665-c26102cdc7b6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2682 biolink:treats MONDO:0005859 PMID:41385096 "[{""id"":""uuid:54c0068e-7a68-4ea7-b86c-bc7d7b175c32"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4a39477c-c938-4e16-85ad-9945126d9a74"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amphotericin B for Injection USP should be administered primarily to patients with progressive, potentially life-threatening fungal infections. This potent drug should not be used to treat noninvasive fungal infections, such as oral thrush, vaginal candidiasis and esophageal candidiasis in patients with normal neutrophil counts. Amphotericin B for Injection USP is specifically intended to treat potentially life-threatening fungal infections: aspergillosis, cryptococcosis (torulosis), North American blastomycosis, systemic candidiasis, coccidioido-mycosis, histoplasmosis, zygomycosis including mucormycosis due to susceptible species of the genera Absidia , Mucor and Rhizopus , and infections due to related susceptible species of Conidiobolus and Basidiobolus , and sporotrichosis. Amphotericin B may be useful in the treatment of American mucocutaneous leishmaniasis, but it is not the drug of choice as primary therapy. uuid:2a63c05e-2da7-4e6d-b646-7be40044e722 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9241 biolink:treats HP:0007430 PMID:41385096 "[{""id"":""uuid:e7b56eb3-7747-48bd-906a-340a2ccff508"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2a8c8d68-565f-4b46-9e56-50e6bacb252f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Spironolactone tablets are indicated in the management of: Primary hyperaldosteronism for: Establishing the diagnosis of primary hyperaldosteronism by therapeutic trial. Short-term preoperative treatment of patients with primary hyperaldosteronism. Long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are judged to be poor operative risks or who decline surgery. Long-term maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). Edematous conditions for patients with: Congestive heart failure: For the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures. Spironolactone tablets are also indicated for patients with congestive heart failure taking digitalis when other therapies are considered inappropriate. Cirrhosis of the liver accompanied by edema and/or ascites: Aldosterone levels may be exceptionally high in this condition. Spironolactone tablets are indicated for maintenance therapy together with bed rest and the restriction of fluid and sodium. Nephrotic syndrome: For nephrotic patients when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics do not provide an adequate response. Essential hypertension Spironolactone tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Usually in combination with other drugs, spironolactone tablets are indicated for patients who cannot be treated adequately with other agents or for whom other agents are considered inappropriate. Hypokalemia For the treatment of patients with hypokalemia when other measures are considered inappropriate or inadequate. Spironolactone tablets are also indicated for the prophylaxis of hypokalemia in patients taking digitalis when other measures are considered inadequate or inappropriate. Severe heart failure (NYHA class III – IV) To increase survival, and to reduce the need for hospitalization for heart failure when used in addition to standard therapy. Usage in Pregnancy. The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developing toxemia. Edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy. Spironolactone tablets are indicated in pregnancy when edema is due to pathologic causes just as it is in the absence of pregnancy (however, see PRECAUTIONS: PREGNANCY). Dependent edema in pregnancy, resulting from restriction of venous return by the expanded uterus, is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is unsupported and unnecessary. There is hypervolemia during normal pregnancy which is not harmful to either the fetus or the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema, in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances, this edema may cause extreme discomfort that is not relieved by rest. In these cases, a short course of diuretics may provide relief and may be appropriate. uuid:55850f8c-b49e-4c18-b6d8-c90173be3426 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6GNT3Y5LMF biolink:treats UMLS:C0949083 PMID:41385096 "[{""id"":""uuid:4eb70ceb-446c-4d8e-b0af-9d69873dc331"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c348f32d-1f74-4444-aee8-5cfa7ba2ad9b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levofloxacin are indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. 1.1 Nosocomial Pneumonia Levofloxacin is indicated for the treatment of nosocomial pneumonia due to methicillin susceptible Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, or Streptococcus pneumoniae. Adjunctive therapy should be used as clinically indicated. Where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended [see Clinical Studies (14.1)]. 1.2 Community-Acquired Pneumonia: 7–14 day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae (including multi-drug-resistant Streptococcus pneumoniae [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae, Legionella pneumophila, or Mycoplasma pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.2)]. MDRSP isolates are strains resistant to two or more of the following antibacterials: penicillin (MIC ≥2 mcg/mL), 2nd generation cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole. 1.3 Community-Acquired Pneumonia: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to Streptococcus pneumoniae (excluding multi-drug-resistant isolates [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Mycoplasma pneumoniae, or Chlamydophila pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.3)] 1.4 Complicated Skin and Skin Structure Infections Levofloxacin s indicated for the treatment of complicated skin and skin structure infections due to methicillin-susceptible Staphylococcus aureus, Enterococcus faecalis, Streptococcus pyogenes, or Proteus mirabilis [see Clinical Studies (14.5)]. 1.5 Uncomplicated Skin and Skin Structure Infections Levofloxacin is indicated for the treatment of uncomplicated skin and skin structure infections (mild to moderate) including abscesses, cellulitis, furuncles, impetigo, pyoderma, wound infections, due to methicillin-susceptible Staphylococcus aureus, or Streptococcus pyogenes. 1.6 Chronic Bacterial Prostatitis Levofloxacin is indicated for the treatment of chronic bacterial prostatitis due to Escherichia coli, Enterococcus faecalis, or methicillin-susceptible Staphylococcus epidermidis [see Clinical Studies (14.6)]. 1.7 Inhalational Anthrax (Post-Exposure) Levofloxacin is indicated for inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. The effectiveness of levofloxacin is based on plasma concentrations achieved in humans, a surrogate endpoint reasonably likely to predict clinical benefit. Levofloxacin has not been tested in humans for the post-exposure prevention of inhalation anthrax. The safety of levofloxacin in adults for durations of therapy beyond 28 days or in pediatric patients for durations of therapy beyond 14 days has not been studied. Prolonged levofloxacin therapy should only be used when the benefit outweighs the risk [see Dosage and Administration (2.1, 2.2) and Clinical Studies (14.9)]. 1.8 Plague Levofloxacin is indicated for treatment of plague, including pneumonic and septicemic plague, due to Yersinia pestis (Y. pestis) and prophylaxis for plague in adults and pediatric patients, 6 months of age and older. Efficacy studies of levofloxacin could not be conducted in humans with plague for ethical and feasibility reasons. Therefore, approval of this indication was based on an efficacy study conducted in animals [see Dosage and Administration (2.1, 2.2) and Clinical Studies (14.10)]. 1.9 Complicated Urinary Tract Infections: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis [see Clinical Studies (14.7)]. 1.10 Complicated Urinary Tract Infections: 10-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections (mild to moderate) due to Enterococcus faecalis, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa [see Clinical Studies (14.8)]. 1.11 Acute Pyelonephritis: 5 or 10-day Treatment Regimen Levofloxacin s indicated for the treatment of acute pyelonephritis caused by Escherichia coli, including cases with concurrent bacteremia [see Clinical Studies (14.7, 14.8)]. 1.12 Uncomplicated Urinary Tract Infections Levofloxacin is indicated for the treatment of uncomplicated urinary tract infections (mild to moderate) due to Escherichia coli, Klebsiella pneumoniae, or Staphylococcus saprophyticus. Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1- 5.15)] and for some patients uncomplicated urinary tract infection is self-limiting, reserve levofloxacin for treatment of uncomplicated urinary tract infections in patients who have no alternative treatment options. 1.13 Acute Bacterial Exacerbation of Chronic Bronchitis Levofloxacin is indicated for the treatment of acute bacterial exacerbation of chronic bronchitis (ABECB) due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis. [see CLINICAL STUDIES (14.4)] Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1-5.15)] and for some patients ABECB is self-limiting, reserve levofloxacin for treatment of ABECB in patients who have no alternative treatment options. 1.14 Acute Bacterial Sinusitis: 5-day and 10–14 day Treatment Regimens Levofloxacin is indicated for the treatment of acute bacterial sinusitis due to Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis [see Clinical Studies (14.4)]. Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1-5.14)] and for some patients ABECB is self-limiting, reserve levofloxacin for treatment of ABECB in patients who have no alternative treatment options. 1.15 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin and other antibacterial drugs, levofloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Culture and susceptibility testing Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to levofloxacin [see Microbiology (12.4)]. Therapy with levofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be selected. As with other drugs in this class, some isolates of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with levofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information about the continued susceptibility of the pathogens to the antimicrobial agent and also the possible emergence of bacterial resistance. uuid:02a66211-e978-48bf-b324-33584489f989 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6GNT3Y5LMF biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:0bbf4759-98fc-42f2-85c0-8622ba3d8379"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:17609997-597c-4de8-99db-4f4713669ea4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levofloxacin are indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. 1.1 Nosocomial Pneumonia Levofloxacin is indicated for the treatment of nosocomial pneumonia due to methicillin susceptible Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, or Streptococcus pneumoniae. Adjunctive therapy should be used as clinically indicated. Where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended [see Clinical Studies (14.1)]. 1.2 Community-Acquired Pneumonia: 7–14 day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae (including multi-drug-resistant Streptococcus pneumoniae [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae, Legionella pneumophila, or Mycoplasma pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.2)]. MDRSP isolates are strains resistant to two or more of the following antibacterials: penicillin (MIC ≥2 mcg/mL), 2nd generation cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole. 1.3 Community-Acquired Pneumonia: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to Streptococcus pneumoniae (excluding multi-drug-resistant isolates [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Mycoplasma pneumoniae, or Chlamydophila pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.3)] 1.4 Complicated Skin and Skin Structure Infections Levofloxacin s indicated for the treatment of complicated skin and skin structure infections due to methicillin-susceptible Staphylococcus aureus, Enterococcus faecalis, Streptococcus pyogenes, or Proteus mirabilis [see Clinical Studies (14.5)]. 1.5 Uncomplicated Skin and Skin Structure Infections Levofloxacin is indicated for the treatment of uncomplicated skin and skin structure infections (mild to moderate) including abscesses, cellulitis, furuncles, impetigo, pyoderma, wound infections, due to methicillin-susceptible Staphylococcus aureus, or Streptococcus pyogenes. 1.6 Chronic Bacterial Prostatitis Levofloxacin is indicated for the treatment of chronic bacterial prostatitis due to Escherichia coli, Enterococcus faecalis, or methicillin-susceptible Staphylococcus epidermidis [see Clinical Studies (14.6)]. 1.7 Inhalational Anthrax (Post-Exposure) Levofloxacin is indicated for inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. The effectiveness of levofloxacin is based on plasma concentrations achieved in humans, a surrogate endpoint reasonably likely to predict clinical benefit. Levofloxacin has not been tested in humans for the post-exposure prevention of inhalation anthrax. The safety of levofloxacin in adults for durations of therapy beyond 28 days or in pediatric patients for durations of therapy beyond 14 days has not been studied. Prolonged levofloxacin therapy should only be used when the benefit outweighs the risk [see Dosage and Administration (2.1, 2.2) and Clinical Studies (14.9)]. 1.8 Plague Levofloxacin is indicated for treatment of plague, including pneumonic and septicemic plague, due to Yersinia pestis (Y. pestis) and prophylaxis for plague in adults and pediatric patients, 6 months of age and older. Efficacy studies of levofloxacin could not be conducted in humans with plague for ethical and feasibility reasons. Therefore, approval of this indication was based on an efficacy study conducted in animals [see Dosage and Administration (2.1, 2.2) and Clinical Studies (14.10)]. 1.9 Complicated Urinary Tract Infections: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis [see Clinical Studies (14.7)]. 1.10 Complicated Urinary Tract Infections: 10-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections (mild to moderate) due to Enterococcus faecalis, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa [see Clinical Studies (14.8)]. 1.11 Acute Pyelonephritis: 5 or 10-day Treatment Regimen Levofloxacin s indicated for the treatment of acute pyelonephritis caused by Escherichia coli, including cases with concurrent bacteremia [see Clinical Studies (14.7, 14.8)]. 1.12 Uncomplicated Urinary Tract Infections Levofloxacin is indicated for the treatment of uncomplicated urinary tract infections (mild to moderate) due to Escherichia coli, Klebsiella pneumoniae, or Staphylococcus saprophyticus. Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1- 5.15)] and for some patients uncomplicated urinary tract infection is self-limiting, reserve levofloxacin for treatment of uncomplicated urinary tract infections in patients who have no alternative treatment options. 1.13 Acute Bacterial Exacerbation of Chronic Bronchitis Levofloxacin is indicated for the treatment of acute bacterial exacerbation of chronic bronchitis (ABECB) due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis. [see CLINICAL STUDIES (14.4)] Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1-5.15)] and for some patients ABECB is self-limiting, reserve levofloxacin for treatment of ABECB in patients who have no alternative treatment options. 1.14 Acute Bacterial Sinusitis: 5-day and 10–14 day Treatment Regimens Levofloxacin is indicated for the treatment of acute bacterial sinusitis due to Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis [see Clinical Studies (14.4)]. Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1-5.14)] and for some patients ABECB is self-limiting, reserve levofloxacin for treatment of ABECB in patients who have no alternative treatment options. 1.15 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin and other antibacterial drugs, levofloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Culture and susceptibility testing Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to levofloxacin [see Microbiology (12.4)]. Therapy with levofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be selected. As with other drugs in this class, some isolates of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with levofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information about the continued susceptibility of the pathogens to the antimicrobial agent and also the possible emergence of bacterial resistance. uuid:0f7a36a9-f2a9-4e9d-bf15-0bc6c757715f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6GNT3Y5LMF biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:7aa8226f-719d-4f68-89ef-29845d5da469"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:566f780b-17d6-475e-a488-34753d7440fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levofloxacin are indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. 1.1 Nosocomial Pneumonia Levofloxacin is indicated for the treatment of nosocomial pneumonia due to methicillin susceptible Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, or Streptococcus pneumoniae. Adjunctive therapy should be used as clinically indicated. Where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended [see Clinical Studies (14.1)]. 1.2 Community-Acquired Pneumonia: 7–14 day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae (including multi-drug-resistant Streptococcus pneumoniae [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae, Legionella pneumophila, or Mycoplasma pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.2)]. MDRSP isolates are strains resistant to two or more of the following antibacterials: penicillin (MIC ≥2 mcg/mL), 2nd generation cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole. 1.3 Community-Acquired Pneumonia: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to Streptococcus pneumoniae (excluding multi-drug-resistant isolates [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Mycoplasma pneumoniae, or Chlamydophila pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.3)] 1.4 Complicated Skin and Skin Structure Infections Levofloxacin s indicated for the treatment of complicated skin and skin structure infections due to methicillin-susceptible Staphylococcus aureus, Enterococcus faecalis, Streptococcus pyogenes, or Proteus mirabilis [see Clinical Studies (14.5)]. 1.5 Uncomplicated Skin and Skin Structure Infections Levofloxacin is indicated for the treatment of uncomplicated skin and skin structure infections (mild to moderate) including abscesses, cellulitis, furuncles, impetigo, pyoderma, wound infections, due to methicillin-susceptible Staphylococcus aureus, or Streptococcus pyogenes. 1.6 Chronic Bacterial Prostatitis Levofloxacin is indicated for the treatment of chronic bacterial prostatitis due to Escherichia coli, Enterococcus faecalis, or methicillin-susceptible Staphylococcus epidermidis [see Clinical Studies (14.6)]. 1.7 Inhalational Anthrax (Post-Exposure) Levofloxacin is indicated for inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. The effectiveness of levofloxacin is based on plasma concentrations achieved in humans, a surrogate endpoint reasonably likely to predict clinical benefit. Levofloxacin has not been tested in humans for the post-exposure prevention of inhalation anthrax. The safety of levofloxacin in adults for durations of therapy beyond 28 days or in pediatric patients for durations of therapy beyond 14 days has not been studied. Prolonged levofloxacin therapy should only be used when the benefit outweighs the risk [see Dosage and Administration (2.1, 2.2) and Clinical Studies (14.9)]. 1.8 Plague Levofloxacin is indicated for treatment of plague, including pneumonic and septicemic plague, due to Yersinia pestis (Y. pestis) and prophylaxis for plague in adults and pediatric patients, 6 months of age and older. Efficacy studies of levofloxacin could not be conducted in humans with plague for ethical and feasibility reasons. Therefore, approval of this indication was based on an efficacy study conducted in animals [see Dosage and Administration (2.1, 2.2) and Clinical Studies (14.10)]. 1.9 Complicated Urinary Tract Infections: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis [see Clinical Studies (14.7)]. 1.10 Complicated Urinary Tract Infections: 10-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections (mild to moderate) due to Enterococcus faecalis, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa [see Clinical Studies (14.8)]. 1.11 Acute Pyelonephritis: 5 or 10-day Treatment Regimen Levofloxacin s indicated for the treatment of acute pyelonephritis caused by Escherichia coli, including cases with concurrent bacteremia [see Clinical Studies (14.7, 14.8)]. 1.12 Uncomplicated Urinary Tract Infections Levofloxacin is indicated for the treatment of uncomplicated urinary tract infections (mild to moderate) due to Escherichia coli, Klebsiella pneumoniae, or Staphylococcus saprophyticus. Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1- 5.15)] and for some patients uncomplicated urinary tract infection is self-limiting, reserve levofloxacin for treatment of uncomplicated urinary tract infections in patients who have no alternative treatment options. 1.13 Acute Bacterial Exacerbation of Chronic Bronchitis Levofloxacin is indicated for the treatment of acute bacterial exacerbation of chronic bronchitis (ABECB) due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis. [see CLINICAL STUDIES (14.4)] Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1-5.15)] and for some patients ABECB is self-limiting, reserve levofloxacin for treatment of ABECB in patients who have no alternative treatment options. 1.14 Acute Bacterial Sinusitis: 5-day and 10–14 day Treatment Regimens Levofloxacin is indicated for the treatment of acute bacterial sinusitis due to Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis [see Clinical Studies (14.4)]. Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1-5.14)] and for some patients ABECB is self-limiting, reserve levofloxacin for treatment of ABECB in patients who have no alternative treatment options. 1.15 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin and other antibacterial drugs, levofloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Culture and susceptibility testing Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to levofloxacin [see Microbiology (12.4)]. Therapy with levofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be selected. As with other drugs in this class, some isolates of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with levofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information about the continued susceptibility of the pathogens to the antimicrobial agent and also the possible emergence of bacterial resistance. uuid:62ba70b0-09e7-412d-89f6-8d8fa7c86930 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6GNT3Y5LMF biolink:treats MONDO:0005227 PMID:41385096 "[{""id"":""uuid:5da9f610-75ad-491e-9293-48ec4b08b21d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8ea7f172-3c6b-4530-9e87-4470a58ccb3d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levofloxacin are indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. 1.1 Nosocomial Pneumonia Levofloxacin is indicated for the treatment of nosocomial pneumonia due to methicillin susceptible Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, or Streptococcus pneumoniae. Adjunctive therapy should be used as clinically indicated. Where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended [see Clinical Studies (14.1)]. 1.2 Community-Acquired Pneumonia: 7–14 day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae (including multi-drug-resistant Streptococcus pneumoniae [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae, Legionella pneumophila, or Mycoplasma pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.2)]. MDRSP isolates are strains resistant to two or more of the following antibacterials: penicillin (MIC ≥2 mcg/mL), 2nd generation cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole. 1.3 Community-Acquired Pneumonia: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to Streptococcus pneumoniae (excluding multi-drug-resistant isolates [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Mycoplasma pneumoniae, or Chlamydophila pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.3)] 1.4 Complicated Skin and Skin Structure Infections Levofloxacin s indicated for the treatment of complicated skin and skin structure infections due to methicillin-susceptible Staphylococcus aureus, Enterococcus faecalis, Streptococcus pyogenes, or Proteus mirabilis [see Clinical Studies (14.5)]. 1.5 Uncomplicated Skin and Skin Structure Infections Levofloxacin is indicated for the treatment of uncomplicated skin and skin structure infections (mild to moderate) including abscesses, cellulitis, furuncles, impetigo, pyoderma, wound infections, due to methicillin-susceptible Staphylococcus aureus, or Streptococcus pyogenes. 1.6 Chronic Bacterial Prostatitis Levofloxacin is indicated for the treatment of chronic bacterial prostatitis due to Escherichia coli, Enterococcus faecalis, or methicillin-susceptible Staphylococcus epidermidis [see Clinical Studies (14.6)]. 1.7 Inhalational Anthrax (Post-Exposure) Levofloxacin is indicated for inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. The effectiveness of levofloxacin is based on plasma concentrations achieved in humans, a surrogate endpoint reasonably likely to predict clinical benefit. Levofloxacin has not been tested in humans for the post-exposure prevention of inhalation anthrax. The safety of levofloxacin in adults for durations of therapy beyond 28 days or in pediatric patients for durations of therapy beyond 14 days has not been studied. Prolonged levofloxacin therapy should only be used when the benefit outweighs the risk [see Dosage and Administration (2.1, 2.2) and Clinical Studies (14.9)]. 1.8 Plague Levofloxacin is indicated for treatment of plague, including pneumonic and septicemic plague, due to Yersinia pestis (Y. pestis) and prophylaxis for plague in adults and pediatric patients, 6 months of age and older. Efficacy studies of levofloxacin could not be conducted in humans with plague for ethical and feasibility reasons. Therefore, approval of this indication was based on an efficacy study conducted in animals [see Dosage and Administration (2.1, 2.2) and Clinical Studies (14.10)]. 1.9 Complicated Urinary Tract Infections: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis [see Clinical Studies (14.7)]. 1.10 Complicated Urinary Tract Infections: 10-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections (mild to moderate) due to Enterococcus faecalis, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa [see Clinical Studies (14.8)]. 1.11 Acute Pyelonephritis: 5 or 10-day Treatment Regimen Levofloxacin s indicated for the treatment of acute pyelonephritis caused by Escherichia coli, including cases with concurrent bacteremia [see Clinical Studies (14.7, 14.8)]. 1.12 Uncomplicated Urinary Tract Infections Levofloxacin is indicated for the treatment of uncomplicated urinary tract infections (mild to moderate) due to Escherichia coli, Klebsiella pneumoniae, or Staphylococcus saprophyticus. Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1- 5.15)] and for some patients uncomplicated urinary tract infection is self-limiting, reserve levofloxacin for treatment of uncomplicated urinary tract infections in patients who have no alternative treatment options. 1.13 Acute Bacterial Exacerbation of Chronic Bronchitis Levofloxacin is indicated for the treatment of acute bacterial exacerbation of chronic bronchitis (ABECB) due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis. [see CLINICAL STUDIES (14.4)] Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1-5.15)] and for some patients ABECB is self-limiting, reserve levofloxacin for treatment of ABECB in patients who have no alternative treatment options. 1.14 Acute Bacterial Sinusitis: 5-day and 10–14 day Treatment Regimens Levofloxacin is indicated for the treatment of acute bacterial sinusitis due to Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis [see Clinical Studies (14.4)]. Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1-5.14)] and for some patients ABECB is self-limiting, reserve levofloxacin for treatment of ABECB in patients who have no alternative treatment options. 1.15 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin and other antibacterial drugs, levofloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Culture and susceptibility testing Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to levofloxacin [see Microbiology (12.4)]. Therapy with levofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be selected. As with other drugs in this class, some isolates of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with levofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information about the continued susceptibility of the pathogens to the antimicrobial agent and also the possible emergence of bacterial resistance. uuid:96a6ab3f-e16f-4232-b289-f42ae05db547 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6GNT3Y5LMF biolink:treats MONDO:0005230 PMID:41385096 "[{""id"":""uuid:e42f70e6-e0b6-4cd4-a4b8-5106f3d1835e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1d171fd6-88cc-4328-bc71-a8099cc5f57e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levofloxacin are indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. 1.1 Nosocomial Pneumonia Levofloxacin is indicated for the treatment of nosocomial pneumonia due to methicillin susceptible Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, or Streptococcus pneumoniae. Adjunctive therapy should be used as clinically indicated. Where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended [see Clinical Studies (14.1)]. 1.2 Community-Acquired Pneumonia: 7–14 day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae (including multi-drug-resistant Streptococcus pneumoniae [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae, Legionella pneumophila, or Mycoplasma pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.2)]. MDRSP isolates are strains resistant to two or more of the following antibacterials: penicillin (MIC ≥2 mcg/mL), 2nd generation cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole. 1.3 Community-Acquired Pneumonia: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to Streptococcus pneumoniae (excluding multi-drug-resistant isolates [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Mycoplasma pneumoniae, or Chlamydophila pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.3)] 1.4 Complicated Skin and Skin Structure Infections Levofloxacin s indicated for the treatment of complicated skin and skin structure infections due to methicillin-susceptible Staphylococcus aureus, Enterococcus faecalis, Streptococcus pyogenes, or Proteus mirabilis [see Clinical Studies (14.5)]. 1.5 Uncomplicated Skin and Skin Structure Infections Levofloxacin is indicated for the treatment of uncomplicated skin and skin structure infections (mild to moderate) including abscesses, cellulitis, furuncles, impetigo, pyoderma, wound infections, due to methicillin-susceptible Staphylococcus aureus, or Streptococcus pyogenes. 1.6 Chronic Bacterial Prostatitis Levofloxacin is indicated for the treatment of chronic bacterial prostatitis due to Escherichia coli, Enterococcus faecalis, or methicillin-susceptible Staphylococcus epidermidis [see Clinical Studies (14.6)]. 1.7 Inhalational Anthrax (Post-Exposure) Levofloxacin is indicated for inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. The effectiveness of levofloxacin is based on plasma concentrations achieved in humans, a surrogate endpoint reasonably likely to predict clinical benefit. Levofloxacin has not been tested in humans for the post-exposure prevention of inhalation anthrax. The safety of levofloxacin in adults for durations of therapy beyond 28 days or in pediatric patients for durations of therapy beyond 14 days has not been studied. Prolonged levofloxacin therapy should only be used when the benefit outweighs the risk [see Dosage and Administration (2.1, 2.2) and Clinical Studies (14.9)]. 1.8 Plague Levofloxacin is indicated for treatment of plague, including pneumonic and septicemic plague, due to Yersinia pestis (Y. pestis) and prophylaxis for plague in adults and pediatric patients, 6 months of age and older. Efficacy studies of levofloxacin could not be conducted in humans with plague for ethical and feasibility reasons. Therefore, approval of this indication was based on an efficacy study conducted in animals [see Dosage and Administration (2.1, 2.2) and Clinical Studies (14.10)]. 1.9 Complicated Urinary Tract Infections: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis [see Clinical Studies (14.7)]. 1.10 Complicated Urinary Tract Infections: 10-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections (mild to moderate) due to Enterococcus faecalis, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa [see Clinical Studies (14.8)]. 1.11 Acute Pyelonephritis: 5 or 10-day Treatment Regimen Levofloxacin s indicated for the treatment of acute pyelonephritis caused by Escherichia coli, including cases with concurrent bacteremia [see Clinical Studies (14.7, 14.8)]. 1.12 Uncomplicated Urinary Tract Infections Levofloxacin is indicated for the treatment of uncomplicated urinary tract infections (mild to moderate) due to Escherichia coli, Klebsiella pneumoniae, or Staphylococcus saprophyticus. Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1- 5.15)] and for some patients uncomplicated urinary tract infection is self-limiting, reserve levofloxacin for treatment of uncomplicated urinary tract infections in patients who have no alternative treatment options. 1.13 Acute Bacterial Exacerbation of Chronic Bronchitis Levofloxacin is indicated for the treatment of acute bacterial exacerbation of chronic bronchitis (ABECB) due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis. [see CLINICAL STUDIES (14.4)] Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1-5.15)] and for some patients ABECB is self-limiting, reserve levofloxacin for treatment of ABECB in patients who have no alternative treatment options. 1.14 Acute Bacterial Sinusitis: 5-day and 10–14 day Treatment Regimens Levofloxacin is indicated for the treatment of acute bacterial sinusitis due to Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis [see Clinical Studies (14.4)]. Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1-5.14)] and for some patients ABECB is self-limiting, reserve levofloxacin for treatment of ABECB in patients who have no alternative treatment options. 1.15 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin and other antibacterial drugs, levofloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Culture and susceptibility testing Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to levofloxacin [see Microbiology (12.4)]. Therapy with levofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be selected. As with other drugs in this class, some isolates of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with levofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information about the continued susceptibility of the pathogens to the antimicrobial agent and also the possible emergence of bacterial resistance. uuid:ae675b10-6118-444f-b11c-ea56ef40a048 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6GNT3Y5LMF biolink:treats HP:0020083 PMID:41385096 "[{""id"":""uuid:de95cec8-a97f-4d58-aa15-3761f7a171d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c5e21890-503f-4d1d-b96c-c682b1335887"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levofloxacin are indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. 1.1 Nosocomial Pneumonia Levofloxacin is indicated for the treatment of nosocomial pneumonia due to methicillin susceptible Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, or Streptococcus pneumoniae. Adjunctive therapy should be used as clinically indicated. Where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended [see Clinical Studies (14.1)]. 1.2 Community-Acquired Pneumonia: 7–14 day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae (including multi-drug-resistant Streptococcus pneumoniae [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae, Legionella pneumophila, or Mycoplasma pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.2)]. MDRSP isolates are strains resistant to two or more of the following antibacterials: penicillin (MIC ≥2 mcg/mL), 2nd generation cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole. 1.3 Community-Acquired Pneumonia: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to Streptococcus pneumoniae (excluding multi-drug-resistant isolates [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Mycoplasma pneumoniae, or Chlamydophila pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.3)] 1.4 Complicated Skin and Skin Structure Infections Levofloxacin s indicated for the treatment of complicated skin and skin structure infections due to methicillin-susceptible Staphylococcus aureus, Enterococcus faecalis, Streptococcus pyogenes, or Proteus mirabilis [see Clinical Studies (14.5)]. 1.5 Uncomplicated Skin and Skin Structure Infections Levofloxacin is indicated for the treatment of uncomplicated skin and skin structure infections (mild to moderate) including abscesses, cellulitis, furuncles, impetigo, pyoderma, wound infections, due to methicillin-susceptible Staphylococcus aureus, or Streptococcus pyogenes. 1.6 Chronic Bacterial Prostatitis Levofloxacin is indicated for the treatment of chronic bacterial prostatitis due to Escherichia coli, Enterococcus faecalis, or methicillin-susceptible Staphylococcus epidermidis [see Clinical Studies (14.6)]. 1.7 Inhalational Anthrax (Post-Exposure) Levofloxacin is indicated for inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. The effectiveness of levofloxacin is based on plasma concentrations achieved in humans, a surrogate endpoint reasonably likely to predict clinical benefit. Levofloxacin has not been tested in humans for the post-exposure prevention of inhalation anthrax. The safety of levofloxacin in adults for durations of therapy beyond 28 days or in pediatric patients for durations of therapy beyond 14 days has not been studied. Prolonged levofloxacin therapy should only be used when the benefit outweighs the risk [see Dosage and Administration (2.1, 2.2) and Clinical Studies (14.9)]. 1.8 Plague Levofloxacin is indicated for treatment of plague, including pneumonic and septicemic plague, due to Yersinia pestis (Y. pestis) and prophylaxis for plague in adults and pediatric patients, 6 months of age and older. Efficacy studies of levofloxacin could not be conducted in humans with plague for ethical and feasibility reasons. Therefore, approval of this indication was based on an efficacy study conducted in animals [see Dosage and Administration (2.1, 2.2) and Clinical Studies (14.10)]. 1.9 Complicated Urinary Tract Infections: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis [see Clinical Studies (14.7)]. 1.10 Complicated Urinary Tract Infections: 10-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections (mild to moderate) due to Enterococcus faecalis, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa [see Clinical Studies (14.8)]. 1.11 Acute Pyelonephritis: 5 or 10-day Treatment Regimen Levofloxacin s indicated for the treatment of acute pyelonephritis caused by Escherichia coli, including cases with concurrent bacteremia [see Clinical Studies (14.7, 14.8)]. 1.12 Uncomplicated Urinary Tract Infections Levofloxacin is indicated for the treatment of uncomplicated urinary tract infections (mild to moderate) due to Escherichia coli, Klebsiella pneumoniae, or Staphylococcus saprophyticus. Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1- 5.15)] and for some patients uncomplicated urinary tract infection is self-limiting, reserve levofloxacin for treatment of uncomplicated urinary tract infections in patients who have no alternative treatment options. 1.13 Acute Bacterial Exacerbation of Chronic Bronchitis Levofloxacin is indicated for the treatment of acute bacterial exacerbation of chronic bronchitis (ABECB) due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis. [see CLINICAL STUDIES (14.4)] Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1-5.15)] and for some patients ABECB is self-limiting, reserve levofloxacin for treatment of ABECB in patients who have no alternative treatment options. 1.14 Acute Bacterial Sinusitis: 5-day and 10–14 day Treatment Regimens Levofloxacin is indicated for the treatment of acute bacterial sinusitis due to Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis [see Clinical Studies (14.4)]. Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1-5.14)] and for some patients ABECB is self-limiting, reserve levofloxacin for treatment of ABECB in patients who have no alternative treatment options. 1.15 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin and other antibacterial drugs, levofloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Culture and susceptibility testing Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to levofloxacin [see Microbiology (12.4)]. Therapy with levofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be selected. As with other drugs in this class, some isolates of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with levofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information about the continued susceptibility of the pathogens to the antimicrobial agent and also the possible emergence of bacterial resistance. uuid:c3647807-2036-43ee-bf17-c26dd739a245 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6GNT3Y5LMF biolink:treats MONDO:0004592 PMID:41385096 "[{""id"":""uuid:e8550576-6bb2-4070-9033-632914a034eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5a7d5413-e8c5-4352-a0ad-8ba286b24b5e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levofloxacin are indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. 1.1 Nosocomial Pneumonia Levofloxacin is indicated for the treatment of nosocomial pneumonia due to methicillin susceptible Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, or Streptococcus pneumoniae. Adjunctive therapy should be used as clinically indicated. Where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended [see Clinical Studies (14.1)]. 1.2 Community-Acquired Pneumonia: 7–14 day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae (including multi-drug-resistant Streptococcus pneumoniae [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae, Legionella pneumophila, or Mycoplasma pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.2)]. MDRSP isolates are strains resistant to two or more of the following antibacterials: penicillin (MIC ≥2 mcg/mL), 2nd generation cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole. 1.3 Community-Acquired Pneumonia: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to Streptococcus pneumoniae (excluding multi-drug-resistant isolates [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Mycoplasma pneumoniae, or Chlamydophila pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.3)] 1.4 Complicated Skin and Skin Structure Infections Levofloxacin s indicated for the treatment of complicated skin and skin structure infections due to methicillin-susceptible Staphylococcus aureus, Enterococcus faecalis, Streptococcus pyogenes, or Proteus mirabilis [see Clinical Studies (14.5)]. 1.5 Uncomplicated Skin and Skin Structure Infections Levofloxacin is indicated for the treatment of uncomplicated skin and skin structure infections (mild to moderate) including abscesses, cellulitis, furuncles, impetigo, pyoderma, wound infections, due to methicillin-susceptible Staphylococcus aureus, or Streptococcus pyogenes. 1.6 Chronic Bacterial Prostatitis Levofloxacin is indicated for the treatment of chronic bacterial prostatitis due to Escherichia coli, Enterococcus faecalis, or methicillin-susceptible Staphylococcus epidermidis [see Clinical Studies (14.6)]. 1.7 Inhalational Anthrax (Post-Exposure) Levofloxacin is indicated for inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. The effectiveness of levofloxacin is based on plasma concentrations achieved in humans, a surrogate endpoint reasonably likely to predict clinical benefit. Levofloxacin has not been tested in humans for the post-exposure prevention of inhalation anthrax. The safety of levofloxacin in adults for durations of therapy beyond 28 days or in pediatric patients for durations of therapy beyond 14 days has not been studied. Prolonged levofloxacin therapy should only be used when the benefit outweighs the risk [see Dosage and Administration (2.1, 2.2) and Clinical Studies (14.9)]. 1.8 Plague Levofloxacin is indicated for treatment of plague, including pneumonic and septicemic plague, due to Yersinia pestis (Y. pestis) and prophylaxis for plague in adults and pediatric patients, 6 months of age and older. Efficacy studies of levofloxacin could not be conducted in humans with plague for ethical and feasibility reasons. Therefore, approval of this indication was based on an efficacy study conducted in animals [see Dosage and Administration (2.1, 2.2) and Clinical Studies (14.10)]. 1.9 Complicated Urinary Tract Infections: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis [see Clinical Studies (14.7)]. 1.10 Complicated Urinary Tract Infections: 10-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections (mild to moderate) due to Enterococcus faecalis, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa [see Clinical Studies (14.8)]. 1.11 Acute Pyelonephritis: 5 or 10-day Treatment Regimen Levofloxacin s indicated for the treatment of acute pyelonephritis caused by Escherichia coli, including cases with concurrent bacteremia [see Clinical Studies (14.7, 14.8)]. 1.12 Uncomplicated Urinary Tract Infections Levofloxacin is indicated for the treatment of uncomplicated urinary tract infections (mild to moderate) due to Escherichia coli, Klebsiella pneumoniae, or Staphylococcus saprophyticus. Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1- 5.15)] and for some patients uncomplicated urinary tract infection is self-limiting, reserve levofloxacin for treatment of uncomplicated urinary tract infections in patients who have no alternative treatment options. 1.13 Acute Bacterial Exacerbation of Chronic Bronchitis Levofloxacin is indicated for the treatment of acute bacterial exacerbation of chronic bronchitis (ABECB) due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis. [see CLINICAL STUDIES (14.4)] Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1-5.15)] and for some patients ABECB is self-limiting, reserve levofloxacin for treatment of ABECB in patients who have no alternative treatment options. 1.14 Acute Bacterial Sinusitis: 5-day and 10–14 day Treatment Regimens Levofloxacin is indicated for the treatment of acute bacterial sinusitis due to Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis [see Clinical Studies (14.4)]. Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1-5.14)] and for some patients ABECB is self-limiting, reserve levofloxacin for treatment of ABECB in patients who have no alternative treatment options. 1.15 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin and other antibacterial drugs, levofloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Culture and susceptibility testing Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to levofloxacin [see Microbiology (12.4)]. Therapy with levofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be selected. As with other drugs in this class, some isolates of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with levofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information about the continued susceptibility of the pathogens to the antimicrobial agent and also the possible emergence of bacterial resistance. uuid:70316a34-64a5-4dc2-b2b8-f0387b8cc6d6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6GNT3Y5LMF biolink:treats MONDO:0002922 PMID:41385096 "[{""id"":""uuid:f0802181-6bc6-47cc-bc2f-add13e637d86"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6fc20a13-ef22-4493-9042-5bd01a2ae639"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levofloxacin are indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. 1.1 Nosocomial Pneumonia Levofloxacin is indicated for the treatment of nosocomial pneumonia due to methicillin susceptible Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, or Streptococcus pneumoniae. Adjunctive therapy should be used as clinically indicated. Where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended [see Clinical Studies (14.1)]. 1.2 Community-Acquired Pneumonia: 7–14 day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae (including multi-drug-resistant Streptococcus pneumoniae [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae, Legionella pneumophila, or Mycoplasma pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.2)]. MDRSP isolates are strains resistant to two or more of the following antibacterials: penicillin (MIC ≥2 mcg/mL), 2nd generation cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole. 1.3 Community-Acquired Pneumonia: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to Streptococcus pneumoniae (excluding multi-drug-resistant isolates [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Mycoplasma pneumoniae, or Chlamydophila pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.3)] 1.4 Complicated Skin and Skin Structure Infections Levofloxacin s indicated for the treatment of complicated skin and skin structure infections due to methicillin-susceptible Staphylococcus aureus, Enterococcus faecalis, Streptococcus pyogenes, or Proteus mirabilis [see Clinical Studies (14.5)]. 1.5 Uncomplicated Skin and Skin Structure Infections Levofloxacin is indicated for the treatment of uncomplicated skin and skin structure infections (mild to moderate) including abscesses, cellulitis, furuncles, impetigo, pyoderma, wound infections, due to methicillin-susceptible Staphylococcus aureus, or Streptococcus pyogenes. 1.6 Chronic Bacterial Prostatitis Levofloxacin is indicated for the treatment of chronic bacterial prostatitis due to Escherichia coli, Enterococcus faecalis, or methicillin-susceptible Staphylococcus epidermidis [see Clinical Studies (14.6)]. 1.7 Inhalational Anthrax (Post-Exposure) Levofloxacin is indicated for inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. The effectiveness of levofloxacin is based on plasma concentrations achieved in humans, a surrogate endpoint reasonably likely to predict clinical benefit. Levofloxacin has not been tested in humans for the post-exposure prevention of inhalation anthrax. The safety of levofloxacin in adults for durations of therapy beyond 28 days or in pediatric patients for durations of therapy beyond 14 days has not been studied. Prolonged levofloxacin therapy should only be used when the benefit outweighs the risk [see Dosage and Administration (2.1, 2.2) and Clinical Studies (14.9)]. 1.8 Plague Levofloxacin is indicated for treatment of plague, including pneumonic and septicemic plague, due to Yersinia pestis (Y. pestis) and prophylaxis for plague in adults and pediatric patients, 6 months of age and older. Efficacy studies of levofloxacin could not be conducted in humans with plague for ethical and feasibility reasons. Therefore, approval of this indication was based on an efficacy study conducted in animals [see Dosage and Administration (2.1, 2.2) and Clinical Studies (14.10)]. 1.9 Complicated Urinary Tract Infections: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis [see Clinical Studies (14.7)]. 1.10 Complicated Urinary Tract Infections: 10-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections (mild to moderate) due to Enterococcus faecalis, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa [see Clinical Studies (14.8)]. 1.11 Acute Pyelonephritis: 5 or 10-day Treatment Regimen Levofloxacin s indicated for the treatment of acute pyelonephritis caused by Escherichia coli, including cases with concurrent bacteremia [see Clinical Studies (14.7, 14.8)]. 1.12 Uncomplicated Urinary Tract Infections Levofloxacin is indicated for the treatment of uncomplicated urinary tract infections (mild to moderate) due to Escherichia coli, Klebsiella pneumoniae, or Staphylococcus saprophyticus. Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1- 5.15)] and for some patients uncomplicated urinary tract infection is self-limiting, reserve levofloxacin for treatment of uncomplicated urinary tract infections in patients who have no alternative treatment options. 1.13 Acute Bacterial Exacerbation of Chronic Bronchitis Levofloxacin is indicated for the treatment of acute bacterial exacerbation of chronic bronchitis (ABECB) due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis. [see CLINICAL STUDIES (14.4)] Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1-5.15)] and for some patients ABECB is self-limiting, reserve levofloxacin for treatment of ABECB in patients who have no alternative treatment options. 1.14 Acute Bacterial Sinusitis: 5-day and 10–14 day Treatment Regimens Levofloxacin is indicated for the treatment of acute bacterial sinusitis due to Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis [see Clinical Studies (14.4)]. Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1-5.14)] and for some patients ABECB is self-limiting, reserve levofloxacin for treatment of ABECB in patients who have no alternative treatment options. 1.15 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin and other antibacterial drugs, levofloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Culture and susceptibility testing Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to levofloxacin [see Microbiology (12.4)]. Therapy with levofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be selected. As with other drugs in this class, some isolates of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with levofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information about the continued susceptibility of the pathogens to the antimicrobial agent and also the possible emergence of bacterial resistance. uuid:ad2d8907-9a96-4483-8754-da43025350d7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6GNT3Y5LMF biolink:treats MONDO:0024313 PMID:41385096 "[{""id"":""uuid:7cef2672-cb5e-4928-a95f-40efa9a3459a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6f36c2a0-9247-46fe-bb17-7077903f6d4f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levofloxacin are indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. 1.1 Nosocomial Pneumonia Levofloxacin is indicated for the treatment of nosocomial pneumonia due to methicillin susceptible Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, or Streptococcus pneumoniae. Adjunctive therapy should be used as clinically indicated. Where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended [see Clinical Studies (14.1)]. 1.2 Community-Acquired Pneumonia: 7–14 day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae (including multi-drug-resistant Streptococcus pneumoniae [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae, Legionella pneumophila, or Mycoplasma pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.2)]. MDRSP isolates are strains resistant to two or more of the following antibacterials: penicillin (MIC ≥2 mcg/mL), 2nd generation cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole. 1.3 Community-Acquired Pneumonia: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to Streptococcus pneumoniae (excluding multi-drug-resistant isolates [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Mycoplasma pneumoniae, or Chlamydophila pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.3)] 1.4 Complicated Skin and Skin Structure Infections Levofloxacin s indicated for the treatment of complicated skin and skin structure infections due to methicillin-susceptible Staphylococcus aureus, Enterococcus faecalis, Streptococcus pyogenes, or Proteus mirabilis [see Clinical Studies (14.5)]. 1.5 Uncomplicated Skin and Skin Structure Infections Levofloxacin is indicated for the treatment of uncomplicated skin and skin structure infections (mild to moderate) including abscesses, cellulitis, furuncles, impetigo, pyoderma, wound infections, due to methicillin-susceptible Staphylococcus aureus, or Streptococcus pyogenes. 1.6 Chronic Bacterial Prostatitis Levofloxacin is indicated for the treatment of chronic bacterial prostatitis due to Escherichia coli, Enterococcus faecalis, or methicillin-susceptible Staphylococcus epidermidis [see Clinical Studies (14.6)]. 1.7 Inhalational Anthrax (Post-Exposure) Levofloxacin is indicated for inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. The effectiveness of levofloxacin is based on plasma concentrations achieved in humans, a surrogate endpoint reasonably likely to predict clinical benefit. Levofloxacin has not been tested in humans for the post-exposure prevention of inhalation anthrax. The safety of levofloxacin in adults for durations of therapy beyond 28 days or in pediatric patients for durations of therapy beyond 14 days has not been studied. Prolonged levofloxacin therapy should only be used when the benefit outweighs the risk [see Dosage and Administration (2.1, 2.2) and Clinical Studies (14.9)]. 1.8 Plague Levofloxacin is indicated for treatment of plague, including pneumonic and septicemic plague, due to Yersinia pestis (Y. pestis) and prophylaxis for plague in adults and pediatric patients, 6 months of age and older. Efficacy studies of levofloxacin could not be conducted in humans with plague for ethical and feasibility reasons. Therefore, approval of this indication was based on an efficacy study conducted in animals [see Dosage and Administration (2.1, 2.2) and Clinical Studies (14.10)]. 1.9 Complicated Urinary Tract Infections: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis [see Clinical Studies (14.7)]. 1.10 Complicated Urinary Tract Infections: 10-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections (mild to moderate) due to Enterococcus faecalis, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa [see Clinical Studies (14.8)]. 1.11 Acute Pyelonephritis: 5 or 10-day Treatment Regimen Levofloxacin s indicated for the treatment of acute pyelonephritis caused by Escherichia coli, including cases with concurrent bacteremia [see Clinical Studies (14.7, 14.8)]. 1.12 Uncomplicated Urinary Tract Infections Levofloxacin is indicated for the treatment of uncomplicated urinary tract infections (mild to moderate) due to Escherichia coli, Klebsiella pneumoniae, or Staphylococcus saprophyticus. Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1- 5.15)] and for some patients uncomplicated urinary tract infection is self-limiting, reserve levofloxacin for treatment of uncomplicated urinary tract infections in patients who have no alternative treatment options. 1.13 Acute Bacterial Exacerbation of Chronic Bronchitis Levofloxacin is indicated for the treatment of acute bacterial exacerbation of chronic bronchitis (ABECB) due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis. [see CLINICAL STUDIES (14.4)] Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1-5.15)] and for some patients ABECB is self-limiting, reserve levofloxacin for treatment of ABECB in patients who have no alternative treatment options. 1.14 Acute Bacterial Sinusitis: 5-day and 10–14 day Treatment Regimens Levofloxacin is indicated for the treatment of acute bacterial sinusitis due to Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis [see Clinical Studies (14.4)]. Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1-5.14)] and for some patients ABECB is self-limiting, reserve levofloxacin for treatment of ABECB in patients who have no alternative treatment options. 1.15 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin and other antibacterial drugs, levofloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Culture and susceptibility testing Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to levofloxacin [see Microbiology (12.4)]. Therapy with levofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be selected. As with other drugs in this class, some isolates of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with levofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information about the continued susceptibility of the pathogens to the antimicrobial agent and also the possible emergence of bacterial resistance. uuid:66667fa4-0271-495e-8969-f6b5c1694138 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6GNT3Y5LMF biolink:treats UMLS:C1720797 PMID:41385096 "[{""id"":""uuid:05324d97-2541-49c8-be5f-c581267ed076"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:60d59893-2a1c-4c68-8cf7-29dd0c45845a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levofloxacin are indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. 1.1 Nosocomial Pneumonia Levofloxacin is indicated for the treatment of nosocomial pneumonia due to methicillin susceptible Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, or Streptococcus pneumoniae. Adjunctive therapy should be used as clinically indicated. Where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended [see Clinical Studies (14.1)]. 1.2 Community-Acquired Pneumonia: 7–14 day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae (including multi-drug-resistant Streptococcus pneumoniae [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae, Legionella pneumophila, or Mycoplasma pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.2)]. MDRSP isolates are strains resistant to two or more of the following antibacterials: penicillin (MIC ≥2 mcg/mL), 2nd generation cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole. 1.3 Community-Acquired Pneumonia: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to Streptococcus pneumoniae (excluding multi-drug-resistant isolates [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Mycoplasma pneumoniae, or Chlamydophila pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.3)] 1.4 Complicated Skin and Skin Structure Infections Levofloxacin s indicated for the treatment of complicated skin and skin structure infections due to methicillin-susceptible Staphylococcus aureus, Enterococcus faecalis, Streptococcus pyogenes, or Proteus mirabilis [see Clinical Studies (14.5)]. 1.5 Uncomplicated Skin and Skin Structure Infections Levofloxacin is indicated for the treatment of uncomplicated skin and skin structure infections (mild to moderate) including abscesses, cellulitis, furuncles, impetigo, pyoderma, wound infections, due to methicillin-susceptible Staphylococcus aureus, or Streptococcus pyogenes. 1.6 Chronic Bacterial Prostatitis Levofloxacin is indicated for the treatment of chronic bacterial prostatitis due to Escherichia coli, Enterococcus faecalis, or methicillin-susceptible Staphylococcus epidermidis [see Clinical Studies (14.6)]. 1.7 Inhalational Anthrax (Post-Exposure) Levofloxacin is indicated for inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. The effectiveness of levofloxacin is based on plasma concentrations achieved in humans, a surrogate endpoint reasonably likely to predict clinical benefit. Levofloxacin has not been tested in humans for the post-exposure prevention of inhalation anthrax. The safety of levofloxacin in adults for durations of therapy beyond 28 days or in pediatric patients for durations of therapy beyond 14 days has not been studied. Prolonged levofloxacin therapy should only be used when the benefit outweighs the risk [see Dosage and Administration (2.1, 2.2) and Clinical Studies (14.9)]. 1.8 Plague Levofloxacin is indicated for treatment of plague, including pneumonic and septicemic plague, due to Yersinia pestis (Y. pestis) and prophylaxis for plague in adults and pediatric patients, 6 months of age and older. Efficacy studies of levofloxacin could not be conducted in humans with plague for ethical and feasibility reasons. Therefore, approval of this indication was based on an efficacy study conducted in animals [see Dosage and Administration (2.1, 2.2) and Clinical Studies (14.10)]. 1.9 Complicated Urinary Tract Infections: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis [see Clinical Studies (14.7)]. 1.10 Complicated Urinary Tract Infections: 10-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections (mild to moderate) due to Enterococcus faecalis, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa [see Clinical Studies (14.8)]. 1.11 Acute Pyelonephritis: 5 or 10-day Treatment Regimen Levofloxacin s indicated for the treatment of acute pyelonephritis caused by Escherichia coli, including cases with concurrent bacteremia [see Clinical Studies (14.7, 14.8)]. 1.12 Uncomplicated Urinary Tract Infections Levofloxacin is indicated for the treatment of uncomplicated urinary tract infections (mild to moderate) due to Escherichia coli, Klebsiella pneumoniae, or Staphylococcus saprophyticus. Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1- 5.15)] and for some patients uncomplicated urinary tract infection is self-limiting, reserve levofloxacin for treatment of uncomplicated urinary tract infections in patients who have no alternative treatment options. 1.13 Acute Bacterial Exacerbation of Chronic Bronchitis Levofloxacin is indicated for the treatment of acute bacterial exacerbation of chronic bronchitis (ABECB) due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis. [see CLINICAL STUDIES (14.4)] Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1-5.15)] and for some patients ABECB is self-limiting, reserve levofloxacin for treatment of ABECB in patients who have no alternative treatment options. 1.14 Acute Bacterial Sinusitis: 5-day and 10–14 day Treatment Regimens Levofloxacin is indicated for the treatment of acute bacterial sinusitis due to Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis [see Clinical Studies (14.4)]. Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1-5.14)] and for some patients ABECB is self-limiting, reserve levofloxacin for treatment of ABECB in patients who have no alternative treatment options. 1.15 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin and other antibacterial drugs, levofloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Culture and susceptibility testing Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to levofloxacin [see Microbiology (12.4)]. Therapy with levofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be selected. As with other drugs in this class, some isolates of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with levofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information about the continued susceptibility of the pathogens to the antimicrobial agent and also the possible emergence of bacterial resistance. uuid:8d9958f7-b588-497d-b1b3-b95c1e9d6824 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6GNT3Y5LMF biolink:treats MONDO:0016595 PMID:41385096 "[{""id"":""uuid:7f880b16-d5bf-4fd5-9ff9-e19f44a89edc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5473a9e7-55ba-4fe5-824d-2014d65a9c42"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levofloxacin are indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. 1.1 Nosocomial Pneumonia Levofloxacin is indicated for the treatment of nosocomial pneumonia due to methicillin susceptible Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, or Streptococcus pneumoniae. Adjunctive therapy should be used as clinically indicated. Where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended [see Clinical Studies (14.1)]. 1.2 Community-Acquired Pneumonia: 7–14 day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae (including multi-drug-resistant Streptococcus pneumoniae [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae, Legionella pneumophila, or Mycoplasma pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.2)]. MDRSP isolates are strains resistant to two or more of the following antibacterials: penicillin (MIC ≥2 mcg/mL), 2nd generation cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole. 1.3 Community-Acquired Pneumonia: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to Streptococcus pneumoniae (excluding multi-drug-resistant isolates [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Mycoplasma pneumoniae, or Chlamydophila pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.3)] 1.4 Complicated Skin and Skin Structure Infections Levofloxacin s indicated for the treatment of complicated skin and skin structure infections due to methicillin-susceptible Staphylococcus aureus, Enterococcus faecalis, Streptococcus pyogenes, or Proteus mirabilis [see Clinical Studies (14.5)]. 1.5 Uncomplicated Skin and Skin Structure Infections Levofloxacin is indicated for the treatment of uncomplicated skin and skin structure infections (mild to moderate) including abscesses, cellulitis, furuncles, impetigo, pyoderma, wound infections, due to methicillin-susceptible Staphylococcus aureus, or Streptococcus pyogenes. 1.6 Chronic Bacterial Prostatitis Levofloxacin is indicated for the treatment of chronic bacterial prostatitis due to Escherichia coli, Enterococcus faecalis, or methicillin-susceptible Staphylococcus epidermidis [see Clinical Studies (14.6)]. 1.7 Inhalational Anthrax (Post-Exposure) Levofloxacin is indicated for inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. The effectiveness of levofloxacin is based on plasma concentrations achieved in humans, a surrogate endpoint reasonably likely to predict clinical benefit. Levofloxacin has not been tested in humans for the post-exposure prevention of inhalation anthrax. The safety of levofloxacin in adults for durations of therapy beyond 28 days or in pediatric patients for durations of therapy beyond 14 days has not been studied. Prolonged levofloxacin therapy should only be used when the benefit outweighs the risk [see Dosage and Administration (2.1, 2.2) and Clinical Studies (14.9)]. 1.8 Plague Levofloxacin is indicated for treatment of plague, including pneumonic and septicemic plague, due to Yersinia pestis (Y. pestis) and prophylaxis for plague in adults and pediatric patients, 6 months of age and older. Efficacy studies of levofloxacin could not be conducted in humans with plague for ethical and feasibility reasons. Therefore, approval of this indication was based on an efficacy study conducted in animals [see Dosage and Administration (2.1, 2.2) and Clinical Studies (14.10)]. 1.9 Complicated Urinary Tract Infections: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis [see Clinical Studies (14.7)]. 1.10 Complicated Urinary Tract Infections: 10-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections (mild to moderate) due to Enterococcus faecalis, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa [see Clinical Studies (14.8)]. 1.11 Acute Pyelonephritis: 5 or 10-day Treatment Regimen Levofloxacin s indicated for the treatment of acute pyelonephritis caused by Escherichia coli, including cases with concurrent bacteremia [see Clinical Studies (14.7, 14.8)]. 1.12 Uncomplicated Urinary Tract Infections Levofloxacin is indicated for the treatment of uncomplicated urinary tract infections (mild to moderate) due to Escherichia coli, Klebsiella pneumoniae, or Staphylococcus saprophyticus. Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1- 5.15)] and for some patients uncomplicated urinary tract infection is self-limiting, reserve levofloxacin for treatment of uncomplicated urinary tract infections in patients who have no alternative treatment options. 1.13 Acute Bacterial Exacerbation of Chronic Bronchitis Levofloxacin is indicated for the treatment of acute bacterial exacerbation of chronic bronchitis (ABECB) due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis. [see CLINICAL STUDIES (14.4)] Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1-5.15)] and for some patients ABECB is self-limiting, reserve levofloxacin for treatment of ABECB in patients who have no alternative treatment options. 1.14 Acute Bacterial Sinusitis: 5-day and 10–14 day Treatment Regimens Levofloxacin is indicated for the treatment of acute bacterial sinusitis due to Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis [see Clinical Studies (14.4)]. Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1-5.14)] and for some patients ABECB is self-limiting, reserve levofloxacin for treatment of ABECB in patients who have no alternative treatment options. 1.15 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin and other antibacterial drugs, levofloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Culture and susceptibility testing Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to levofloxacin [see Microbiology (12.4)]. Therapy with levofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be selected. As with other drugs in this class, some isolates of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with levofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information about the continued susceptibility of the pathogens to the antimicrobial agent and also the possible emergence of bacterial resistance. uuid:91d28845-7a77-434b-baa3-dc5441cde50f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6GNT3Y5LMF biolink:treats MONDO:0019095 PMID:41385096 "[{""id"":""uuid:4d724867-6300-44d1-9ed7-58badf4d9fff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c007e53d-ac35-4c92-99b1-b58793a4b9c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levofloxacin are indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. 1.1 Nosocomial Pneumonia Levofloxacin is indicated for the treatment of nosocomial pneumonia due to methicillin susceptible Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, or Streptococcus pneumoniae. Adjunctive therapy should be used as clinically indicated. Where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended [see Clinical Studies (14.1)]. 1.2 Community-Acquired Pneumonia: 7–14 day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae (including multi-drug-resistant Streptococcus pneumoniae [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae, Legionella pneumophila, or Mycoplasma pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.2)]. MDRSP isolates are strains resistant to two or more of the following antibacterials: penicillin (MIC ≥2 mcg/mL), 2nd generation cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole. 1.3 Community-Acquired Pneumonia: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to Streptococcus pneumoniae (excluding multi-drug-resistant isolates [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Mycoplasma pneumoniae, or Chlamydophila pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.3)] 1.4 Complicated Skin and Skin Structure Infections Levofloxacin s indicated for the treatment of complicated skin and skin structure infections due to methicillin-susceptible Staphylococcus aureus, Enterococcus faecalis, Streptococcus pyogenes, or Proteus mirabilis [see Clinical Studies (14.5)]. 1.5 Uncomplicated Skin and Skin Structure Infections Levofloxacin is indicated for the treatment of uncomplicated skin and skin structure infections (mild to moderate) including abscesses, cellulitis, furuncles, impetigo, pyoderma, wound infections, due to methicillin-susceptible Staphylococcus aureus, or Streptococcus pyogenes. 1.6 Chronic Bacterial Prostatitis Levofloxacin is indicated for the treatment of chronic bacterial prostatitis due to Escherichia coli, Enterococcus faecalis, or methicillin-susceptible Staphylococcus epidermidis [see Clinical Studies (14.6)]. 1.7 Inhalational Anthrax (Post-Exposure) Levofloxacin is indicated for inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. The effectiveness of levofloxacin is based on plasma concentrations achieved in humans, a surrogate endpoint reasonably likely to predict clinical benefit. Levofloxacin has not been tested in humans for the post-exposure prevention of inhalation anthrax. The safety of levofloxacin in adults for durations of therapy beyond 28 days or in pediatric patients for durations of therapy beyond 14 days has not been studied. Prolonged levofloxacin therapy should only be used when the benefit outweighs the risk [see Dosage and Administration (2.1, 2.2) and Clinical Studies (14.9)]. 1.8 Plague Levofloxacin is indicated for treatment of plague, including pneumonic and septicemic plague, due to Yersinia pestis (Y. pestis) and prophylaxis for plague in adults and pediatric patients, 6 months of age and older. Efficacy studies of levofloxacin could not be conducted in humans with plague for ethical and feasibility reasons. Therefore, approval of this indication was based on an efficacy study conducted in animals [see Dosage and Administration (2.1, 2.2) and Clinical Studies (14.10)]. 1.9 Complicated Urinary Tract Infections: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis [see Clinical Studies (14.7)]. 1.10 Complicated Urinary Tract Infections: 10-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections (mild to moderate) due to Enterococcus faecalis, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa [see Clinical Studies (14.8)]. 1.11 Acute Pyelonephritis: 5 or 10-day Treatment Regimen Levofloxacin s indicated for the treatment of acute pyelonephritis caused by Escherichia coli, including cases with concurrent bacteremia [see Clinical Studies (14.7, 14.8)]. 1.12 Uncomplicated Urinary Tract Infections Levofloxacin is indicated for the treatment of uncomplicated urinary tract infections (mild to moderate) due to Escherichia coli, Klebsiella pneumoniae, or Staphylococcus saprophyticus. Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1- 5.15)] and for some patients uncomplicated urinary tract infection is self-limiting, reserve levofloxacin for treatment of uncomplicated urinary tract infections in patients who have no alternative treatment options. 1.13 Acute Bacterial Exacerbation of Chronic Bronchitis Levofloxacin is indicated for the treatment of acute bacterial exacerbation of chronic bronchitis (ABECB) due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis. [see CLINICAL STUDIES (14.4)] Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1-5.15)] and for some patients ABECB is self-limiting, reserve levofloxacin for treatment of ABECB in patients who have no alternative treatment options. 1.14 Acute Bacterial Sinusitis: 5-day and 10–14 day Treatment Regimens Levofloxacin is indicated for the treatment of acute bacterial sinusitis due to Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis [see Clinical Studies (14.4)]. Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1-5.14)] and for some patients ABECB is self-limiting, reserve levofloxacin for treatment of ABECB in patients who have no alternative treatment options. 1.15 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin and other antibacterial drugs, levofloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Culture and susceptibility testing Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to levofloxacin [see Microbiology (12.4)]. Therapy with levofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be selected. As with other drugs in this class, some isolates of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with levofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information about the continued susceptibility of the pathogens to the antimicrobial agent and also the possible emergence of bacterial resistance. uuid:cca059f2-0321-44bb-ae65-930b67d2b161 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6GNT3Y5LMF biolink:treats MONDO:0001024 PMID:41385096 "[{""id"":""uuid:93538b50-ee93-4539-987e-4b424f1b8a64"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:869dd02e-8ec0-40b6-9c0c-c274d868c46c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levofloxacin are indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. 1.1 Nosocomial Pneumonia Levofloxacin is indicated for the treatment of nosocomial pneumonia due to methicillin susceptible Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, or Streptococcus pneumoniae. Adjunctive therapy should be used as clinically indicated. Where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended [see Clinical Studies (14.1)]. 1.2 Community-Acquired Pneumonia: 7–14 day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae (including multi-drug-resistant Streptococcus pneumoniae [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae, Legionella pneumophila, or Mycoplasma pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.2)]. MDRSP isolates are strains resistant to two or more of the following antibacterials: penicillin (MIC ≥2 mcg/mL), 2nd generation cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole. 1.3 Community-Acquired Pneumonia: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to Streptococcus pneumoniae (excluding multi-drug-resistant isolates [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Mycoplasma pneumoniae, or Chlamydophila pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.3)] 1.4 Complicated Skin and Skin Structure Infections Levofloxacin s indicated for the treatment of complicated skin and skin structure infections due to methicillin-susceptible Staphylococcus aureus, Enterococcus faecalis, Streptococcus pyogenes, or Proteus mirabilis [see Clinical Studies (14.5)]. 1.5 Uncomplicated Skin and Skin Structure Infections Levofloxacin is indicated for the treatment of uncomplicated skin and skin structure infections (mild to moderate) including abscesses, cellulitis, furuncles, impetigo, pyoderma, wound infections, due to methicillin-susceptible Staphylococcus aureus, or Streptococcus pyogenes. 1.6 Chronic Bacterial Prostatitis Levofloxacin is indicated for the treatment of chronic bacterial prostatitis due to Escherichia coli, Enterococcus faecalis, or methicillin-susceptible Staphylococcus epidermidis [see Clinical Studies (14.6)]. 1.7 Inhalational Anthrax (Post-Exposure) Levofloxacin is indicated for inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. The effectiveness of levofloxacin is based on plasma concentrations achieved in humans, a surrogate endpoint reasonably likely to predict clinical benefit. Levofloxacin has not been tested in humans for the post-exposure prevention of inhalation anthrax. The safety of levofloxacin in adults for durations of therapy beyond 28 days or in pediatric patients for durations of therapy beyond 14 days has not been studied. Prolonged levofloxacin therapy should only be used when the benefit outweighs the risk [see Dosage and Administration (2.1, 2.2) and Clinical Studies (14.9)]. 1.8 Plague Levofloxacin is indicated for treatment of plague, including pneumonic and septicemic plague, due to Yersinia pestis (Y. pestis) and prophylaxis for plague in adults and pediatric patients, 6 months of age and older. Efficacy studies of levofloxacin could not be conducted in humans with plague for ethical and feasibility reasons. Therefore, approval of this indication was based on an efficacy study conducted in animals [see Dosage and Administration (2.1, 2.2) and Clinical Studies (14.10)]. 1.9 Complicated Urinary Tract Infections: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis [see Clinical Studies (14.7)]. 1.10 Complicated Urinary Tract Infections: 10-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections (mild to moderate) due to Enterococcus faecalis, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa [see Clinical Studies (14.8)]. 1.11 Acute Pyelonephritis: 5 or 10-day Treatment Regimen Levofloxacin s indicated for the treatment of acute pyelonephritis caused by Escherichia coli, including cases with concurrent bacteremia [see Clinical Studies (14.7, 14.8)]. 1.12 Uncomplicated Urinary Tract Infections Levofloxacin is indicated for the treatment of uncomplicated urinary tract infections (mild to moderate) due to Escherichia coli, Klebsiella pneumoniae, or Staphylococcus saprophyticus. Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1- 5.15)] and for some patients uncomplicated urinary tract infection is self-limiting, reserve levofloxacin for treatment of uncomplicated urinary tract infections in patients who have no alternative treatment options. 1.13 Acute Bacterial Exacerbation of Chronic Bronchitis Levofloxacin is indicated for the treatment of acute bacterial exacerbation of chronic bronchitis (ABECB) due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis. [see CLINICAL STUDIES (14.4)] Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1-5.15)] and for some patients ABECB is self-limiting, reserve levofloxacin for treatment of ABECB in patients who have no alternative treatment options. 1.14 Acute Bacterial Sinusitis: 5-day and 10–14 day Treatment Regimens Levofloxacin is indicated for the treatment of acute bacterial sinusitis due to Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis [see Clinical Studies (14.4)]. Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1-5.14)] and for some patients ABECB is self-limiting, reserve levofloxacin for treatment of ABECB in patients who have no alternative treatment options. 1.15 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin and other antibacterial drugs, levofloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Culture and susceptibility testing Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to levofloxacin [see Microbiology (12.4)]. Therapy with levofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be selected. As with other drugs in this class, some isolates of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with levofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information about the continued susceptibility of the pathogens to the antimicrobial agent and also the possible emergence of bacterial resistance. uuid:d54adf63-27b9-4b9e-9c03-887e2c8d704c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6GNT3Y5LMF biolink:treats MONDO:0005956 PMID:41385096 "[{""id"":""uuid:0a698251-b00e-4433-8109-d644bfd521ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:63e4f79c-0d6f-45d2-9b93-87a669d2a43b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levofloxacin are indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. 1.1 Nosocomial Pneumonia Levofloxacin is indicated for the treatment of nosocomial pneumonia due to methicillin susceptible Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, or Streptococcus pneumoniae. Adjunctive therapy should be used as clinically indicated. Where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended [see Clinical Studies (14.1)]. 1.2 Community-Acquired Pneumonia: 7–14 day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae (including multi-drug-resistant Streptococcus pneumoniae [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae, Legionella pneumophila, or Mycoplasma pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.2)]. MDRSP isolates are strains resistant to two or more of the following antibacterials: penicillin (MIC ≥2 mcg/mL), 2nd generation cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole. 1.3 Community-Acquired Pneumonia: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to Streptococcus pneumoniae (excluding multi-drug-resistant isolates [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Mycoplasma pneumoniae, or Chlamydophila pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.3)] 1.4 Complicated Skin and Skin Structure Infections Levofloxacin s indicated for the treatment of complicated skin and skin structure infections due to methicillin-susceptible Staphylococcus aureus, Enterococcus faecalis, Streptococcus pyogenes, or Proteus mirabilis [see Clinical Studies (14.5)]. 1.5 Uncomplicated Skin and Skin Structure Infections Levofloxacin is indicated for the treatment of uncomplicated skin and skin structure infections (mild to moderate) including abscesses, cellulitis, furuncles, impetigo, pyoderma, wound infections, due to methicillin-susceptible Staphylococcus aureus, or Streptococcus pyogenes. 1.6 Chronic Bacterial Prostatitis Levofloxacin is indicated for the treatment of chronic bacterial prostatitis due to Escherichia coli, Enterococcus faecalis, or methicillin-susceptible Staphylococcus epidermidis [see Clinical Studies (14.6)]. 1.7 Inhalational Anthrax (Post-Exposure) Levofloxacin is indicated for inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. The effectiveness of levofloxacin is based on plasma concentrations achieved in humans, a surrogate endpoint reasonably likely to predict clinical benefit. Levofloxacin has not been tested in humans for the post-exposure prevention of inhalation anthrax. The safety of levofloxacin in adults for durations of therapy beyond 28 days or in pediatric patients for durations of therapy beyond 14 days has not been studied. Prolonged levofloxacin therapy should only be used when the benefit outweighs the risk [see Dosage and Administration (2.1, 2.2) and Clinical Studies (14.9)]. 1.8 Plague Levofloxacin is indicated for treatment of plague, including pneumonic and septicemic plague, due to Yersinia pestis (Y. pestis) and prophylaxis for plague in adults and pediatric patients, 6 months of age and older. Efficacy studies of levofloxacin could not be conducted in humans with plague for ethical and feasibility reasons. Therefore, approval of this indication was based on an efficacy study conducted in animals [see Dosage and Administration (2.1, 2.2) and Clinical Studies (14.10)]. 1.9 Complicated Urinary Tract Infections: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis [see Clinical Studies (14.7)]. 1.10 Complicated Urinary Tract Infections: 10-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections (mild to moderate) due to Enterococcus faecalis, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa [see Clinical Studies (14.8)]. 1.11 Acute Pyelonephritis: 5 or 10-day Treatment Regimen Levofloxacin s indicated for the treatment of acute pyelonephritis caused by Escherichia coli, including cases with concurrent bacteremia [see Clinical Studies (14.7, 14.8)]. 1.12 Uncomplicated Urinary Tract Infections Levofloxacin is indicated for the treatment of uncomplicated urinary tract infections (mild to moderate) due to Escherichia coli, Klebsiella pneumoniae, or Staphylococcus saprophyticus. Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1- 5.15)] and for some patients uncomplicated urinary tract infection is self-limiting, reserve levofloxacin for treatment of uncomplicated urinary tract infections in patients who have no alternative treatment options. 1.13 Acute Bacterial Exacerbation of Chronic Bronchitis Levofloxacin is indicated for the treatment of acute bacterial exacerbation of chronic bronchitis (ABECB) due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis. [see CLINICAL STUDIES (14.4)] Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1-5.15)] and for some patients ABECB is self-limiting, reserve levofloxacin for treatment of ABECB in patients who have no alternative treatment options. 1.14 Acute Bacterial Sinusitis: 5-day and 10–14 day Treatment Regimens Levofloxacin is indicated for the treatment of acute bacterial sinusitis due to Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis [see Clinical Studies (14.4)]. Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1-5.14)] and for some patients ABECB is self-limiting, reserve levofloxacin for treatment of ABECB in patients who have no alternative treatment options. 1.15 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin and other antibacterial drugs, levofloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Culture and susceptibility testing Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to levofloxacin [see Microbiology (12.4)]. Therapy with levofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be selected. As with other drugs in this class, some isolates of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with levofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information about the continued susceptibility of the pathogens to the antimicrobial agent and also the possible emergence of bacterial resistance. uuid:d607d74b-424d-4ce4-aaf1-0c60d2165890 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6GNT3Y5LMF biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:e47c74df-a964-42b6-8858-c89c4406fc43"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c50aff4c-357f-43cf-9517-be7654a5466a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levofloxacin are indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. 1.1 Nosocomial Pneumonia Levofloxacin is indicated for the treatment of nosocomial pneumonia due to methicillin susceptible Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, or Streptococcus pneumoniae. Adjunctive therapy should be used as clinically indicated. Where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended [see Clinical Studies (14.1)]. 1.2 Community-Acquired Pneumonia: 7–14 day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae (including multi-drug-resistant Streptococcus pneumoniae [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae, Legionella pneumophila, or Mycoplasma pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.2)]. MDRSP isolates are strains resistant to two or more of the following antibacterials: penicillin (MIC ≥2 mcg/mL), 2nd generation cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole. 1.3 Community-Acquired Pneumonia: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to Streptococcus pneumoniae (excluding multi-drug-resistant isolates [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Mycoplasma pneumoniae, or Chlamydophila pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.3)] 1.4 Complicated Skin and Skin Structure Infections Levofloxacin s indicated for the treatment of complicated skin and skin structure infections due to methicillin-susceptible Staphylococcus aureus, Enterococcus faecalis, Streptococcus pyogenes, or Proteus mirabilis [see Clinical Studies (14.5)]. 1.5 Uncomplicated Skin and Skin Structure Infections Levofloxacin is indicated for the treatment of uncomplicated skin and skin structure infections (mild to moderate) including abscesses, cellulitis, furuncles, impetigo, pyoderma, wound infections, due to methicillin-susceptible Staphylococcus aureus, or Streptococcus pyogenes. 1.6 Chronic Bacterial Prostatitis Levofloxacin is indicated for the treatment of chronic bacterial prostatitis due to Escherichia coli, Enterococcus faecalis, or methicillin-susceptible Staphylococcus epidermidis [see Clinical Studies (14.6)]. 1.7 Inhalational Anthrax (Post-Exposure) Levofloxacin is indicated for inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. The effectiveness of levofloxacin is based on plasma concentrations achieved in humans, a surrogate endpoint reasonably likely to predict clinical benefit. Levofloxacin has not been tested in humans for the post-exposure prevention of inhalation anthrax. The safety of levofloxacin in adults for durations of therapy beyond 28 days or in pediatric patients for durations of therapy beyond 14 days has not been studied. Prolonged levofloxacin therapy should only be used when the benefit outweighs the risk [see Dosage and Administration (2.1, 2.2) and Clinical Studies (14.9)]. 1.8 Plague Levofloxacin is indicated for treatment of plague, including pneumonic and septicemic plague, due to Yersinia pestis (Y. pestis) and prophylaxis for plague in adults and pediatric patients, 6 months of age and older. Efficacy studies of levofloxacin could not be conducted in humans with plague for ethical and feasibility reasons. Therefore, approval of this indication was based on an efficacy study conducted in animals [see Dosage and Administration (2.1, 2.2) and Clinical Studies (14.10)]. 1.9 Complicated Urinary Tract Infections: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis [see Clinical Studies (14.7)]. 1.10 Complicated Urinary Tract Infections: 10-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections (mild to moderate) due to Enterococcus faecalis, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa [see Clinical Studies (14.8)]. 1.11 Acute Pyelonephritis: 5 or 10-day Treatment Regimen Levofloxacin s indicated for the treatment of acute pyelonephritis caused by Escherichia coli, including cases with concurrent bacteremia [see Clinical Studies (14.7, 14.8)]. 1.12 Uncomplicated Urinary Tract Infections Levofloxacin is indicated for the treatment of uncomplicated urinary tract infections (mild to moderate) due to Escherichia coli, Klebsiella pneumoniae, or Staphylococcus saprophyticus. Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1- 5.15)] and for some patients uncomplicated urinary tract infection is self-limiting, reserve levofloxacin for treatment of uncomplicated urinary tract infections in patients who have no alternative treatment options. 1.13 Acute Bacterial Exacerbation of Chronic Bronchitis Levofloxacin is indicated for the treatment of acute bacterial exacerbation of chronic bronchitis (ABECB) due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis. [see CLINICAL STUDIES (14.4)] Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1-5.15)] and for some patients ABECB is self-limiting, reserve levofloxacin for treatment of ABECB in patients who have no alternative treatment options. 1.14 Acute Bacterial Sinusitis: 5-day and 10–14 day Treatment Regimens Levofloxacin is indicated for the treatment of acute bacterial sinusitis due to Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis [see Clinical Studies (14.4)]. Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1-5.14)] and for some patients ABECB is self-limiting, reserve levofloxacin for treatment of ABECB in patients who have no alternative treatment options. 1.15 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin and other antibacterial drugs, levofloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Culture and susceptibility testing Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to levofloxacin [see Microbiology (12.4)]. Therapy with levofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be selected. As with other drugs in this class, some isolates of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with levofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information about the continued susceptibility of the pathogens to the antimicrobial agent and also the possible emergence of bacterial resistance. uuid:48c06a01-b982-45bb-8d74-5213540e0316 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6GNT3Y5LMF biolink:treats MONDO:0003529 PMID:41385096 "[{""id"":""uuid:556eaff8-de6d-4dae-a783-408c9bb57ae9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2997e4f5-4c73-477e-881d-5aea617f170b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levofloxacin are indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. 1.1 Nosocomial Pneumonia Levofloxacin is indicated for the treatment of nosocomial pneumonia due to methicillin susceptible Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, or Streptococcus pneumoniae. Adjunctive therapy should be used as clinically indicated. Where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended [see Clinical Studies (14.1)]. 1.2 Community-Acquired Pneumonia: 7–14 day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae (including multi-drug-resistant Streptococcus pneumoniae [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae, Legionella pneumophila, or Mycoplasma pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.2)]. MDRSP isolates are strains resistant to two or more of the following antibacterials: penicillin (MIC ≥2 mcg/mL), 2nd generation cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole. 1.3 Community-Acquired Pneumonia: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to Streptococcus pneumoniae (excluding multi-drug-resistant isolates [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Mycoplasma pneumoniae, or Chlamydophila pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.3)] 1.4 Complicated Skin and Skin Structure Infections Levofloxacin s indicated for the treatment of complicated skin and skin structure infections due to methicillin-susceptible Staphylococcus aureus, Enterococcus faecalis, Streptococcus pyogenes, or Proteus mirabilis [see Clinical Studies (14.5)]. 1.5 Uncomplicated Skin and Skin Structure Infections Levofloxacin is indicated for the treatment of uncomplicated skin and skin structure infections (mild to moderate) including abscesses, cellulitis, furuncles, impetigo, pyoderma, wound infections, due to methicillin-susceptible Staphylococcus aureus, or Streptococcus pyogenes. 1.6 Chronic Bacterial Prostatitis Levofloxacin is indicated for the treatment of chronic bacterial prostatitis due to Escherichia coli, Enterococcus faecalis, or methicillin-susceptible Staphylococcus epidermidis [see Clinical Studies (14.6)]. 1.7 Inhalational Anthrax (Post-Exposure) Levofloxacin is indicated for inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. The effectiveness of levofloxacin is based on plasma concentrations achieved in humans, a surrogate endpoint reasonably likely to predict clinical benefit. Levofloxacin has not been tested in humans for the post-exposure prevention of inhalation anthrax. The safety of levofloxacin in adults for durations of therapy beyond 28 days or in pediatric patients for durations of therapy beyond 14 days has not been studied. Prolonged levofloxacin therapy should only be used when the benefit outweighs the risk [see Dosage and Administration (2.1, 2.2) and Clinical Studies (14.9)]. 1.8 Plague Levofloxacin is indicated for treatment of plague, including pneumonic and septicemic plague, due to Yersinia pestis (Y. pestis) and prophylaxis for plague in adults and pediatric patients, 6 months of age and older. Efficacy studies of levofloxacin could not be conducted in humans with plague for ethical and feasibility reasons. Therefore, approval of this indication was based on an efficacy study conducted in animals [see Dosage and Administration (2.1, 2.2) and Clinical Studies (14.10)]. 1.9 Complicated Urinary Tract Infections: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis [see Clinical Studies (14.7)]. 1.10 Complicated Urinary Tract Infections: 10-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections (mild to moderate) due to Enterococcus faecalis, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa [see Clinical Studies (14.8)]. 1.11 Acute Pyelonephritis: 5 or 10-day Treatment Regimen Levofloxacin s indicated for the treatment of acute pyelonephritis caused by Escherichia coli, including cases with concurrent bacteremia [see Clinical Studies (14.7, 14.8)]. 1.12 Uncomplicated Urinary Tract Infections Levofloxacin is indicated for the treatment of uncomplicated urinary tract infections (mild to moderate) due to Escherichia coli, Klebsiella pneumoniae, or Staphylococcus saprophyticus. Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1- 5.15)] and for some patients uncomplicated urinary tract infection is self-limiting, reserve levofloxacin for treatment of uncomplicated urinary tract infections in patients who have no alternative treatment options. 1.13 Acute Bacterial Exacerbation of Chronic Bronchitis Levofloxacin is indicated for the treatment of acute bacterial exacerbation of chronic bronchitis (ABECB) due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis. [see CLINICAL STUDIES (14.4)] Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1-5.15)] and for some patients ABECB is self-limiting, reserve levofloxacin for treatment of ABECB in patients who have no alternative treatment options. 1.14 Acute Bacterial Sinusitis: 5-day and 10–14 day Treatment Regimens Levofloxacin is indicated for the treatment of acute bacterial sinusitis due to Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis [see Clinical Studies (14.4)]. Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1-5.14)] and for some patients ABECB is self-limiting, reserve levofloxacin for treatment of ABECB in patients who have no alternative treatment options. 1.15 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin and other antibacterial drugs, levofloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Culture and susceptibility testing Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to levofloxacin [see Microbiology (12.4)]. Therapy with levofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be selected. As with other drugs in this class, some isolates of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with levofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information about the continued susceptibility of the pathogens to the antimicrobial agent and also the possible emergence of bacterial resistance. uuid:9dd0870f-4004-43d3-b820-38a20f885e3d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6GNT3Y5LMF biolink:treats UMLS:C1735365 PMID:41385096 "[{""id"":""uuid:0583ad7e-3c79-4fa9-b5b0-48ea013eda97"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f4d9592b-031d-427a-8db9-235c4e52e6a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levofloxacin are indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. 1.1 Nosocomial Pneumonia Levofloxacin is indicated for the treatment of nosocomial pneumonia due to methicillin susceptible Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, or Streptococcus pneumoniae. Adjunctive therapy should be used as clinically indicated. Where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended [see Clinical Studies (14.1)]. 1.2 Community-Acquired Pneumonia: 7–14 day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae (including multi-drug-resistant Streptococcus pneumoniae [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae, Legionella pneumophila, or Mycoplasma pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.2)]. MDRSP isolates are strains resistant to two or more of the following antibacterials: penicillin (MIC ≥2 mcg/mL), 2nd generation cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole. 1.3 Community-Acquired Pneumonia: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to Streptococcus pneumoniae (excluding multi-drug-resistant isolates [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Mycoplasma pneumoniae, or Chlamydophila pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.3)] 1.4 Complicated Skin and Skin Structure Infections Levofloxacin s indicated for the treatment of complicated skin and skin structure infections due to methicillin-susceptible Staphylococcus aureus, Enterococcus faecalis, Streptococcus pyogenes, or Proteus mirabilis [see Clinical Studies (14.5)]. 1.5 Uncomplicated Skin and Skin Structure Infections Levofloxacin is indicated for the treatment of uncomplicated skin and skin structure infections (mild to moderate) including abscesses, cellulitis, furuncles, impetigo, pyoderma, wound infections, due to methicillin-susceptible Staphylococcus aureus, or Streptococcus pyogenes. 1.6 Chronic Bacterial Prostatitis Levofloxacin is indicated for the treatment of chronic bacterial prostatitis due to Escherichia coli, Enterococcus faecalis, or methicillin-susceptible Staphylococcus epidermidis [see Clinical Studies (14.6)]. 1.7 Inhalational Anthrax (Post-Exposure) Levofloxacin is indicated for inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. The effectiveness of levofloxacin is based on plasma concentrations achieved in humans, a surrogate endpoint reasonably likely to predict clinical benefit. Levofloxacin has not been tested in humans for the post-exposure prevention of inhalation anthrax. The safety of levofloxacin in adults for durations of therapy beyond 28 days or in pediatric patients for durations of therapy beyond 14 days has not been studied. Prolonged levofloxacin therapy should only be used when the benefit outweighs the risk [see Dosage and Administration (2.1, 2.2) and Clinical Studies (14.9)]. 1.8 Plague Levofloxacin is indicated for treatment of plague, including pneumonic and septicemic plague, due to Yersinia pestis (Y. pestis) and prophylaxis for plague in adults and pediatric patients, 6 months of age and older. Efficacy studies of levofloxacin could not be conducted in humans with plague for ethical and feasibility reasons. Therefore, approval of this indication was based on an efficacy study conducted in animals [see Dosage and Administration (2.1, 2.2) and Clinical Studies (14.10)]. 1.9 Complicated Urinary Tract Infections: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis [see Clinical Studies (14.7)]. 1.10 Complicated Urinary Tract Infections: 10-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections (mild to moderate) due to Enterococcus faecalis, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa [see Clinical Studies (14.8)]. 1.11 Acute Pyelonephritis: 5 or 10-day Treatment Regimen Levofloxacin s indicated for the treatment of acute pyelonephritis caused by Escherichia coli, including cases with concurrent bacteremia [see Clinical Studies (14.7, 14.8)]. 1.12 Uncomplicated Urinary Tract Infections Levofloxacin is indicated for the treatment of uncomplicated urinary tract infections (mild to moderate) due to Escherichia coli, Klebsiella pneumoniae, or Staphylococcus saprophyticus. Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1- 5.15)] and for some patients uncomplicated urinary tract infection is self-limiting, reserve levofloxacin for treatment of uncomplicated urinary tract infections in patients who have no alternative treatment options. 1.13 Acute Bacterial Exacerbation of Chronic Bronchitis Levofloxacin is indicated for the treatment of acute bacterial exacerbation of chronic bronchitis (ABECB) due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis. [see CLINICAL STUDIES (14.4)] Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1-5.15)] and for some patients ABECB is self-limiting, reserve levofloxacin for treatment of ABECB in patients who have no alternative treatment options. 1.14 Acute Bacterial Sinusitis: 5-day and 10–14 day Treatment Regimens Levofloxacin is indicated for the treatment of acute bacterial sinusitis due to Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis [see Clinical Studies (14.4)]. Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1-5.14)] and for some patients ABECB is self-limiting, reserve levofloxacin for treatment of ABECB in patients who have no alternative treatment options. 1.15 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin and other antibacterial drugs, levofloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Culture and susceptibility testing Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to levofloxacin [see Microbiology (12.4)]. Therapy with levofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be selected. As with other drugs in this class, some isolates of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with levofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information about the continued susceptibility of the pathogens to the antimicrobial agent and also the possible emergence of bacterial resistance. uuid:858c2b0d-43da-4e86-b7be-8a5bce4052e4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6GNT3Y5LMF biolink:treats UMLS:C0275556 PMID:41385096 "[{""id"":""uuid:b550e991-1d5b-41e6-a69d-5682f8d49d08"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:52007c7d-c539-4842-8791-e71a4b0d6957"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levofloxacin are indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. 1.1 Nosocomial Pneumonia Levofloxacin is indicated for the treatment of nosocomial pneumonia due to methicillin susceptible Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, or Streptococcus pneumoniae. Adjunctive therapy should be used as clinically indicated. Where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended [see Clinical Studies (14.1)]. 1.2 Community-Acquired Pneumonia: 7–14 day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae (including multi-drug-resistant Streptococcus pneumoniae [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae, Legionella pneumophila, or Mycoplasma pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.2)]. MDRSP isolates are strains resistant to two or more of the following antibacterials: penicillin (MIC ≥2 mcg/mL), 2nd generation cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole. 1.3 Community-Acquired Pneumonia: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to Streptococcus pneumoniae (excluding multi-drug-resistant isolates [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Mycoplasma pneumoniae, or Chlamydophila pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.3)] 1.4 Complicated Skin and Skin Structure Infections Levofloxacin s indicated for the treatment of complicated skin and skin structure infections due to methicillin-susceptible Staphylococcus aureus, Enterococcus faecalis, Streptococcus pyogenes, or Proteus mirabilis [see Clinical Studies (14.5)]. 1.5 Uncomplicated Skin and Skin Structure Infections Levofloxacin is indicated for the treatment of uncomplicated skin and skin structure infections (mild to moderate) including abscesses, cellulitis, furuncles, impetigo, pyoderma, wound infections, due to methicillin-susceptible Staphylococcus aureus, or Streptococcus pyogenes. 1.6 Chronic Bacterial Prostatitis Levofloxacin is indicated for the treatment of chronic bacterial prostatitis due to Escherichia coli, Enterococcus faecalis, or methicillin-susceptible Staphylococcus epidermidis [see Clinical Studies (14.6)]. 1.7 Inhalational Anthrax (Post-Exposure) Levofloxacin is indicated for inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. The effectiveness of levofloxacin is based on plasma concentrations achieved in humans, a surrogate endpoint reasonably likely to predict clinical benefit. Levofloxacin has not been tested in humans for the post-exposure prevention of inhalation anthrax. The safety of levofloxacin in adults for durations of therapy beyond 28 days or in pediatric patients for durations of therapy beyond 14 days has not been studied. Prolonged levofloxacin therapy should only be used when the benefit outweighs the risk [see Dosage and Administration (2.1, 2.2) and Clinical Studies (14.9)]. 1.8 Plague Levofloxacin is indicated for treatment of plague, including pneumonic and septicemic plague, due to Yersinia pestis (Y. pestis) and prophylaxis for plague in adults and pediatric patients, 6 months of age and older. Efficacy studies of levofloxacin could not be conducted in humans with plague for ethical and feasibility reasons. Therefore, approval of this indication was based on an efficacy study conducted in animals [see Dosage and Administration (2.1, 2.2) and Clinical Studies (14.10)]. 1.9 Complicated Urinary Tract Infections: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis [see Clinical Studies (14.7)]. 1.10 Complicated Urinary Tract Infections: 10-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections (mild to moderate) due to Enterococcus faecalis, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa [see Clinical Studies (14.8)]. 1.11 Acute Pyelonephritis: 5 or 10-day Treatment Regimen Levofloxacin s indicated for the treatment of acute pyelonephritis caused by Escherichia coli, including cases with concurrent bacteremia [see Clinical Studies (14.7, 14.8)]. 1.12 Uncomplicated Urinary Tract Infections Levofloxacin is indicated for the treatment of uncomplicated urinary tract infections (mild to moderate) due to Escherichia coli, Klebsiella pneumoniae, or Staphylococcus saprophyticus. Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1- 5.15)] and for some patients uncomplicated urinary tract infection is self-limiting, reserve levofloxacin for treatment of uncomplicated urinary tract infections in patients who have no alternative treatment options. 1.13 Acute Bacterial Exacerbation of Chronic Bronchitis Levofloxacin is indicated for the treatment of acute bacterial exacerbation of chronic bronchitis (ABECB) due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis. [see CLINICAL STUDIES (14.4)] Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1-5.15)] and for some patients ABECB is self-limiting, reserve levofloxacin for treatment of ABECB in patients who have no alternative treatment options. 1.14 Acute Bacterial Sinusitis: 5-day and 10–14 day Treatment Regimens Levofloxacin is indicated for the treatment of acute bacterial sinusitis due to Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis [see Clinical Studies (14.4)]. Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1-5.14)] and for some patients ABECB is self-limiting, reserve levofloxacin for treatment of ABECB in patients who have no alternative treatment options. 1.15 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin and other antibacterial drugs, levofloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Culture and susceptibility testing Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to levofloxacin [see Microbiology (12.4)]. Therapy with levofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be selected. As with other drugs in this class, some isolates of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with levofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information about the continued susceptibility of the pathogens to the antimicrobial agent and also the possible emergence of bacterial resistance. uuid:fb9e5f62-ffe3-4022-8712-e1be7f27b6bd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16914 biolink:treats UMLS:C3495878 PMID:41385096 "[{""id"":""uuid:bde803e7-dd1f-42f5-be12-b47cc6ddeda8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:00f5364a-c16d-4996-be65-b0cbfa2f1d5a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Salicylic Acid 6% (w/w) Cream is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders, including verrucae, and the various ichthyoses (vulgaris, sex-linked and lamellar), keratosis palmaris and plantaris, keratosis pilaris, pityriasis rubra pilaris, and psoriasis (including body, scalp, palms and soles). For Podiatric Use: Salicylic Acid 6% (w/w) Cream is a topical aid in the removal of excessive keratin on the dorsal and plantar hyperkeratotic lesions. Topical preparations of 6% salicylic acid have been reported to be useful adjunctive therapy for verrucae plantares. uuid:875d181c-d922-43ae-9936-a21f240d770e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats MONDO:0006668 PMID:41385096 "[{""id"":""uuid:48545be3-e378-4676-b104-44c52d9d7784"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d603df43-aee0-4647-9fe8-8aa146b1a73c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levofloxacin ophthalmic solution is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Gram-positive bacteria Corynebacterium species* Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumonia Streptococcus (Groups C/F) Streptococcus (Group G) Viridans group streptococci* Gram-negative bacteria Acinetobacter lwoffii* Haemophilus influenzae Serratia marcescens* * Efficacy for this organism was studied in fewer than 10 infections. uuid:9d662c74-584c-4c20-a278-59ab811c0bd7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28915 biolink:treats MONDO:0001650 PMID:41385096 "[{""id"":""uuid:fef625ef-5d89-49ac-be83-71296a6d6ba3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9880a45b-bc92-488c-8619-2d770da9cb84"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fosfomycin tromethamine granules for oral solution is indicated only for the treatment of uncomplicated urinary tract infections (acute cystitis) in women due to susceptible strains of Escherichia coli and Enterococcus faecalis . Fosfomycin tromethamine granules for oral solution is not indicated for the treatment of pyelonephritis or perinephric abscess. If persistence or reappearance of bacteriuria occurs after treatment with fosfomycin tromethamine granules for oral solution, other therapeutic agents should be selected. (See PRECAUTIONS and CLINICAL STUDIES sections.) uuid:00de91e6-ac0f-41ad-a425-c0549fae5402 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28915 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:712e3b67-ed8b-4df5-a653-c9b986f47a6b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8347a92f-192b-40c0-95e2-94a6aad47697"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fosfomycin tromethamine granules for oral solution is indicated only for the treatment of uncomplicated urinary tract infections (acute cystitis) in women due to susceptible strains of Escherichia coli and Enterococcus faecalis . Fosfomycin tromethamine granules for oral solution is not indicated for the treatment of pyelonephritis or perinephric abscess. If persistence or reappearance of bacteriuria occurs after treatment with fosfomycin tromethamine granules for oral solution, other therapeutic agents should be selected. (See PRECAUTIONS and CLINICAL STUDIES sections.) uuid:5c8490e6-56e3-4722-85c5-ccc22e73654e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28915 biolink:treats MONDO:0006939 PMID:41385096 "[{""id"":""uuid:2aacaf1e-449b-44cb-bb46-61c8667655f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:917c107d-c274-4a70-8a70-0c6bd3b84d77"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fosfomycin tromethamine granules for oral solution is indicated only for the treatment of uncomplicated urinary tract infections (acute cystitis) in women due to susceptible strains of Escherichia coli and Enterococcus faecalis . Fosfomycin tromethamine granules for oral solution is not indicated for the treatment of pyelonephritis or perinephric abscess. If persistence or reappearance of bacteriuria occurs after treatment with fosfomycin tromethamine granules for oral solution, other therapeutic agents should be selected. (See PRECAUTIONS and CLINICAL STUDIES sections.) uuid:9b1d8aec-940f-4b49-956c-6adaee72ea88 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28915 biolink:treats HP:0032619 PMID:41385096 "[{""id"":""uuid:c58c4a09-21ef-4666-9e69-3a209c9ca1ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5fad3b6a-3aed-451f-a032-25c4e869994d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fosfomycin tromethamine granules for oral solution is indicated only for the treatment of uncomplicated urinary tract infections (acute cystitis) in women due to susceptible strains of Escherichia coli and Enterococcus faecalis . Fosfomycin tromethamine granules for oral solution is not indicated for the treatment of pyelonephritis or perinephric abscess. If persistence or reappearance of bacteriuria occurs after treatment with fosfomycin tromethamine granules for oral solution, other therapeutic agents should be selected. (See PRECAUTIONS and CLINICAL STUDIES sections.) uuid:6e5dbaf7-1d8c-4cef-a07c-2090a3a8b070 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1164001 biolink:treats MONDO:0004872 PMID:41385096 "[{""id"":""uuid:8b72d56d-6d16-40b7-a659-a2639c057650"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:26fe4d37-335f-4661-9c2d-ed8a7b4e7d6b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydrocortisone acetate and pramoxine hydrochloride suppositories are indicated for use in inflamed hemorrhoids, post-irradiation (factitial) proctitis; as an adjunct in the treatment of chronic ulcerative colitis; cryptitis; and other inflammatory conditions of anorectum and pruritus ani. uuid:83fea6c2-7da9-484b-979f-50ae850b5bda biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1164001 biolink:treats MONDO:0019084 PMID:41385096 "[{""id"":""uuid:7c469498-ddf1-49b4-85cb-4a36c5a09138"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7c8a0ca4-e4b1-4a5e-94a1-c14d2fb8fbfa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydrocortisone acetate and pramoxine hydrochloride suppositories are indicated for use in inflamed hemorrhoids, post-irradiation (factitial) proctitis; as an adjunct in the treatment of chronic ulcerative colitis; cryptitis; and other inflammatory conditions of anorectum and pruritus ani. uuid:b61b28f3-1ada-4cc8-b3f8-52b0ca456aa3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1164001 biolink:treats UMLS:C2919828 PMID:41385096 "[{""id"":""uuid:e2470696-fecc-4741-8e96-d24ae27364b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c6cda84d-6b9c-4cdb-92c4-fee7c8732702"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydrocortisone acetate and pramoxine hydrochloride suppositories are indicated for use in inflamed hemorrhoids, post-irradiation (factitial) proctitis; as an adjunct in the treatment of chronic ulcerative colitis; cryptitis; and other inflammatory conditions of anorectum and pruritus ani. uuid:c6428a22-664c-4e90-82b2-c261c00941ee biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1164001 biolink:treats UMLS:C1394254 PMID:41385096 "[{""id"":""uuid:b1b56645-d507-459c-9034-2827b67cad35"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c13cb943-edbb-4131-9384-af4d491551c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydrocortisone acetate and pramoxine hydrochloride suppositories are indicated for use in inflamed hemorrhoids, post-irradiation (factitial) proctitis; as an adjunct in the treatment of chronic ulcerative colitis; cryptitis; and other inflammatory conditions of anorectum and pruritus ani. uuid:a6b0190b-0ffa-4974-8fe9-bed06872f4df biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1164001 biolink:treats UMLS:C0033775 PMID:41385096 "[{""id"":""uuid:f4aa0195-e137-4280-a896-9efce60f1ba1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:26838511-bc38-4a17-a6d1-8b764b95398d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydrocortisone acetate and pramoxine hydrochloride suppositories are indicated for use in inflamed hemorrhoids, post-irradiation (factitial) proctitis; as an adjunct in the treatment of chronic ulcerative colitis; cryptitis; and other inflammatory conditions of anorectum and pruritus ani. uuid:c0e0a8d2-d50a-45bf-984a-dfa665940874 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17051 biolink:treats MONDO:0002508 PMID:41385096 "[{""id"":""uuid:d1d3e41b-3024-4dc3-bb0f-e5fb7b609cdf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8a2041b7-9d2e-4b8c-903b-a14c44f9d553"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Aids in the prevention of dental decay. Helps prevent gingivitis. Helps control plaque bacteria. Increases protection against painful tooth sensitivity. This product mist be used under the supervision of a dentist. uuid:907cbaa7-6dcd-4bae-9481-08689a146a30 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:NQX9KB6PCL biolink:treats UMLS:C0043046 PMID:41385096 "[{""id"":""uuid:3a24fb3f-f73b-4e49-bc5f-d18660167f54"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7c12a1c8-2c2f-4f00-990d-22a0adc50ded"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SEROSTIM (somatropin) is indicated for the treatment of HIV patients with wasting or cachexia to increase lean body mass and body weight, and improve physical endurance. Concomitant antiretroviral therapy is necessary. uuid:8c3f1ff9-4f11-46ca-bce4-e5ef81e591f5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:NQX9KB6PCL biolink:treats MONDO:0005797 PMID:41385096 "[{""id"":""uuid:92a81144-f4e7-4d62-a603-e212e17acafb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b6e4085b-6142-49f7-882a-e2c96e72b632"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SEROSTIM (somatropin) is indicated for the treatment of HIV patients with wasting or cachexia to increase lean body mass and body weight, and improve physical endurance. Concomitant antiretroviral therapy is necessary. uuid:1023cd57-1aeb-494d-9098-c83326f3e043 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:86545 biolink:treats MONDO:0004739 PMID:41385096 "[{""id"":""uuid:41e6665c-06fd-4fae-af64-f91a8575177a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f3e032e7-68dc-4229-beba-fb1410dd7755"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Phenylbutyrate Powder is indicated as adjunctive therapy in the chronic management of patients with urea cycle disorders involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS). It is indicated in all patients with neonatal-onset deficiency (complete enzymatic deficiency, presenting within the first 28 days of life). It is also indicated in patients with late-onset disease (partial enzymatic deficiency, presenting after the first month of life) who have a history of hyperammonemic encephalopathy. It is important that the diagnosis be made early and treatment initiated immediately to improve survival. Any episode of acute hyperammonemia should be treated as a life-threatening emergency. Sodium Phenylbutyrate Powder must be combined with dietary protein restriction and, in some cases, essential amino acid supplementation. (See Nutritional Supplementation subsection of the DOSAGE AND ADMINISTRATION section.) Previously, neonatal-onset disease was almost universally fatal within the first year of life, even when treated with peritoneal dialysis and essential amino acids or their nitrogen-free analogs. However, with hemodialysis, use of alternative waste nitrogen excretion pathways (sodium phenylbutyrate, sodium benzoate, and sodium phenylacetate), dietary protein restriction, and, in some cases, essential amino acid supplementation, the survival rate in newborns diagnosed after birth but within the first month of life is almost 80%. Most deaths have occurred during an episode of acute hyperammonemic encephalopathy. Patients with neonatal-onset disease have a high incidence of mental retardation. Those who had IQ tests administered had an incidence of mental retardation as follows: ornithine transcarbamylase deficiency, 100% (14/14 patients tested); argininosuccinic acid synthetase deficiency, 88% (15/17 patients tested); and carbamylphosphate synthetase deficiency, 57% (4/7 patients tested). Retardation was severe in the majority of the retarded patients. In patients diagnosed during gestation and treated prior to any episode of hyperammonemic encephalopathy, survival is 100%, but even in these patients, most subsequently demonstrate cognitive impairment or other neurologic deficits. In late-onset deficiency patients, including females heterozygous for ornithine transcarbamylase deficiency, who recover from hyperammonemic encephalopathy and are then treated chronically with sodium phenylbutyrate and dietary protein restriction, the survival rate is 98%. The two deaths in this group of patients occurred during episodes of hyperammonemic encephalopathy. However, compliance with the therapeutic regimen has not been adequately documented to allow evaluation of the potential for Sodium Phenylbutyrate Powder and dietary protein restriction to prevent mental deterioration and recurrence of hyperammonemic encephalopathy if carefully adhered to. The majority of these patients tested (30/46 or 65%) have IQ's in the average to low average/borderline mentally retarded range. Reversal of pre-existing neurologic impairment is not likely to occur with treatment and neurologic deterioration may continue in some patients. Even on therapy, acute hyperammonemic encephalopathy recurred in the majority of patients for whom the drug is indicated. Sodium Phenylbutyrate Powder may be required life-long unless orthotopic liver transplantation is elected. (See CLINICAL PHARMACOLOGY , Pharmacodynamics subsection for the biochemical effects of Sodium Phenylbutyrate Powder). uuid:742bb171-4779-4f18-baa1-59edbab04d27 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:86545 biolink:treats MONDO:0009376 PMID:41385096 "[{""id"":""uuid:0bab48c3-9ec0-4e13-a4ba-bf543c6db3f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f862c350-cdf9-4b79-8435-68db4a22a63b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Phenylbutyrate Powder is indicated as adjunctive therapy in the chronic management of patients with urea cycle disorders involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS). It is indicated in all patients with neonatal-onset deficiency (complete enzymatic deficiency, presenting within the first 28 days of life). It is also indicated in patients with late-onset disease (partial enzymatic deficiency, presenting after the first month of life) who have a history of hyperammonemic encephalopathy. It is important that the diagnosis be made early and treatment initiated immediately to improve survival. Any episode of acute hyperammonemia should be treated as a life-threatening emergency. Sodium Phenylbutyrate Powder must be combined with dietary protein restriction and, in some cases, essential amino acid supplementation. (See Nutritional Supplementation subsection of the DOSAGE AND ADMINISTRATION section.) Previously, neonatal-onset disease was almost universally fatal within the first year of life, even when treated with peritoneal dialysis and essential amino acids or their nitrogen-free analogs. However, with hemodialysis, use of alternative waste nitrogen excretion pathways (sodium phenylbutyrate, sodium benzoate, and sodium phenylacetate), dietary protein restriction, and, in some cases, essential amino acid supplementation, the survival rate in newborns diagnosed after birth but within the first month of life is almost 80%. Most deaths have occurred during an episode of acute hyperammonemic encephalopathy. Patients with neonatal-onset disease have a high incidence of mental retardation. Those who had IQ tests administered had an incidence of mental retardation as follows: ornithine transcarbamylase deficiency, 100% (14/14 patients tested); argininosuccinic acid synthetase deficiency, 88% (15/17 patients tested); and carbamylphosphate synthetase deficiency, 57% (4/7 patients tested). Retardation was severe in the majority of the retarded patients. In patients diagnosed during gestation and treated prior to any episode of hyperammonemic encephalopathy, survival is 100%, but even in these patients, most subsequently demonstrate cognitive impairment or other neurologic deficits. In late-onset deficiency patients, including females heterozygous for ornithine transcarbamylase deficiency, who recover from hyperammonemic encephalopathy and are then treated chronically with sodium phenylbutyrate and dietary protein restriction, the survival rate is 98%. The two deaths in this group of patients occurred during episodes of hyperammonemic encephalopathy. However, compliance with the therapeutic regimen has not been adequately documented to allow evaluation of the potential for Sodium Phenylbutyrate Powder and dietary protein restriction to prevent mental deterioration and recurrence of hyperammonemic encephalopathy if carefully adhered to. The majority of these patients tested (30/46 or 65%) have IQ's in the average to low average/borderline mentally retarded range. Reversal of pre-existing neurologic impairment is not likely to occur with treatment and neurologic deterioration may continue in some patients. Even on therapy, acute hyperammonemic encephalopathy recurred in the majority of patients for whom the drug is indicated. Sodium Phenylbutyrate Powder may be required life-long unless orthotopic liver transplantation is elected. (See CLINICAL PHARMACOLOGY , Pharmacodynamics subsection for the biochemical effects of Sodium Phenylbutyrate Powder). uuid:91955406-25ba-4b9b-b68f-272e9c68b666 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:86545 biolink:treats MONDO:0010703 PMID:41385096 "[{""id"":""uuid:58e9691e-5911-4207-a24c-6e7a688b3e39"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:08d2c358-ddb6-4d79-accf-d99d1dd63df0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Phenylbutyrate Powder is indicated as adjunctive therapy in the chronic management of patients with urea cycle disorders involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS). It is indicated in all patients with neonatal-onset deficiency (complete enzymatic deficiency, presenting within the first 28 days of life). It is also indicated in patients with late-onset disease (partial enzymatic deficiency, presenting after the first month of life) who have a history of hyperammonemic encephalopathy. It is important that the diagnosis be made early and treatment initiated immediately to improve survival. Any episode of acute hyperammonemia should be treated as a life-threatening emergency. Sodium Phenylbutyrate Powder must be combined with dietary protein restriction and, in some cases, essential amino acid supplementation. (See Nutritional Supplementation subsection of the DOSAGE AND ADMINISTRATION section.) Previously, neonatal-onset disease was almost universally fatal within the first year of life, even when treated with peritoneal dialysis and essential amino acids or their nitrogen-free analogs. However, with hemodialysis, use of alternative waste nitrogen excretion pathways (sodium phenylbutyrate, sodium benzoate, and sodium phenylacetate), dietary protein restriction, and, in some cases, essential amino acid supplementation, the survival rate in newborns diagnosed after birth but within the first month of life is almost 80%. Most deaths have occurred during an episode of acute hyperammonemic encephalopathy. Patients with neonatal-onset disease have a high incidence of mental retardation. Those who had IQ tests administered had an incidence of mental retardation as follows: ornithine transcarbamylase deficiency, 100% (14/14 patients tested); argininosuccinic acid synthetase deficiency, 88% (15/17 patients tested); and carbamylphosphate synthetase deficiency, 57% (4/7 patients tested). Retardation was severe in the majority of the retarded patients. In patients diagnosed during gestation and treated prior to any episode of hyperammonemic encephalopathy, survival is 100%, but even in these patients, most subsequently demonstrate cognitive impairment or other neurologic deficits. In late-onset deficiency patients, including females heterozygous for ornithine transcarbamylase deficiency, who recover from hyperammonemic encephalopathy and are then treated chronically with sodium phenylbutyrate and dietary protein restriction, the survival rate is 98%. The two deaths in this group of patients occurred during episodes of hyperammonemic encephalopathy. However, compliance with the therapeutic regimen has not been adequately documented to allow evaluation of the potential for Sodium Phenylbutyrate Powder and dietary protein restriction to prevent mental deterioration and recurrence of hyperammonemic encephalopathy if carefully adhered to. The majority of these patients tested (30/46 or 65%) have IQ's in the average to low average/borderline mentally retarded range. Reversal of pre-existing neurologic impairment is not likely to occur with treatment and neurologic deterioration may continue in some patients. Even on therapy, acute hyperammonemic encephalopathy recurred in the majority of patients for whom the drug is indicated. Sodium Phenylbutyrate Powder may be required life-long unless orthotopic liver transplantation is elected. (See CLINICAL PHARMACOLOGY , Pharmacodynamics subsection for the biochemical effects of Sodium Phenylbutyrate Powder). uuid:1ec0512d-1d54-4ec8-81f2-7d6ef11a6705 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:86545 biolink:treats MONDO:0015991 PMID:41385096 "[{""id"":""uuid:0ef34c07-c082-49bc-bbb1-b1ca987ceb98"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0d85ac78-8b92-4729-8134-44384907cbaa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Phenylbutyrate Powder is indicated as adjunctive therapy in the chronic management of patients with urea cycle disorders involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS). It is indicated in all patients with neonatal-onset deficiency (complete enzymatic deficiency, presenting within the first 28 days of life). It is also indicated in patients with late-onset disease (partial enzymatic deficiency, presenting after the first month of life) who have a history of hyperammonemic encephalopathy. It is important that the diagnosis be made early and treatment initiated immediately to improve survival. Any episode of acute hyperammonemia should be treated as a life-threatening emergency. Sodium Phenylbutyrate Powder must be combined with dietary protein restriction and, in some cases, essential amino acid supplementation. (See Nutritional Supplementation subsection of the DOSAGE AND ADMINISTRATION section.) Previously, neonatal-onset disease was almost universally fatal within the first year of life, even when treated with peritoneal dialysis and essential amino acids or their nitrogen-free analogs. However, with hemodialysis, use of alternative waste nitrogen excretion pathways (sodium phenylbutyrate, sodium benzoate, and sodium phenylacetate), dietary protein restriction, and, in some cases, essential amino acid supplementation, the survival rate in newborns diagnosed after birth but within the first month of life is almost 80%. Most deaths have occurred during an episode of acute hyperammonemic encephalopathy. Patients with neonatal-onset disease have a high incidence of mental retardation. Those who had IQ tests administered had an incidence of mental retardation as follows: ornithine transcarbamylase deficiency, 100% (14/14 patients tested); argininosuccinic acid synthetase deficiency, 88% (15/17 patients tested); and carbamylphosphate synthetase deficiency, 57% (4/7 patients tested). Retardation was severe in the majority of the retarded patients. In patients diagnosed during gestation and treated prior to any episode of hyperammonemic encephalopathy, survival is 100%, but even in these patients, most subsequently demonstrate cognitive impairment or other neurologic deficits. In late-onset deficiency patients, including females heterozygous for ornithine transcarbamylase deficiency, who recover from hyperammonemic encephalopathy and are then treated chronically with sodium phenylbutyrate and dietary protein restriction, the survival rate is 98%. The two deaths in this group of patients occurred during episodes of hyperammonemic encephalopathy. However, compliance with the therapeutic regimen has not been adequately documented to allow evaluation of the potential for Sodium Phenylbutyrate Powder and dietary protein restriction to prevent mental deterioration and recurrence of hyperammonemic encephalopathy if carefully adhered to. The majority of these patients tested (30/46 or 65%) have IQ's in the average to low average/borderline mentally retarded range. Reversal of pre-existing neurologic impairment is not likely to occur with treatment and neurologic deterioration may continue in some patients. Even on therapy, acute hyperammonemic encephalopathy recurred in the majority of patients for whom the drug is indicated. Sodium Phenylbutyrate Powder may be required life-long unless orthotopic liver transplantation is elected. (See CLINICAL PHARMACOLOGY , Pharmacodynamics subsection for the biochemical effects of Sodium Phenylbutyrate Powder). uuid:8706f585-2c0b-494e-a77b-b4aaf069334d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:86545 biolink:treats UMLS:C1960448 PMID:41385096 "[{""id"":""uuid:149d7bf0-243a-41cf-862c-e1046c0befed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4fa83080-6df1-4c98-b501-9fb8578b6c20"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Phenylbutyrate Powder is indicated as adjunctive therapy in the chronic management of patients with urea cycle disorders involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS). It is indicated in all patients with neonatal-onset deficiency (complete enzymatic deficiency, presenting within the first 28 days of life). It is also indicated in patients with late-onset disease (partial enzymatic deficiency, presenting after the first month of life) who have a history of hyperammonemic encephalopathy. It is important that the diagnosis be made early and treatment initiated immediately to improve survival. Any episode of acute hyperammonemia should be treated as a life-threatening emergency. Sodium Phenylbutyrate Powder must be combined with dietary protein restriction and, in some cases, essential amino acid supplementation. (See Nutritional Supplementation subsection of the DOSAGE AND ADMINISTRATION section.) Previously, neonatal-onset disease was almost universally fatal within the first year of life, even when treated with peritoneal dialysis and essential amino acids or their nitrogen-free analogs. However, with hemodialysis, use of alternative waste nitrogen excretion pathways (sodium phenylbutyrate, sodium benzoate, and sodium phenylacetate), dietary protein restriction, and, in some cases, essential amino acid supplementation, the survival rate in newborns diagnosed after birth but within the first month of life is almost 80%. Most deaths have occurred during an episode of acute hyperammonemic encephalopathy. Patients with neonatal-onset disease have a high incidence of mental retardation. Those who had IQ tests administered had an incidence of mental retardation as follows: ornithine transcarbamylase deficiency, 100% (14/14 patients tested); argininosuccinic acid synthetase deficiency, 88% (15/17 patients tested); and carbamylphosphate synthetase deficiency, 57% (4/7 patients tested). Retardation was severe in the majority of the retarded patients. In patients diagnosed during gestation and treated prior to any episode of hyperammonemic encephalopathy, survival is 100%, but even in these patients, most subsequently demonstrate cognitive impairment or other neurologic deficits. In late-onset deficiency patients, including females heterozygous for ornithine transcarbamylase deficiency, who recover from hyperammonemic encephalopathy and are then treated chronically with sodium phenylbutyrate and dietary protein restriction, the survival rate is 98%. The two deaths in this group of patients occurred during episodes of hyperammonemic encephalopathy. However, compliance with the therapeutic regimen has not been adequately documented to allow evaluation of the potential for Sodium Phenylbutyrate Powder and dietary protein restriction to prevent mental deterioration and recurrence of hyperammonemic encephalopathy if carefully adhered to. The majority of these patients tested (30/46 or 65%) have IQ's in the average to low average/borderline mentally retarded range. Reversal of pre-existing neurologic impairment is not likely to occur with treatment and neurologic deterioration may continue in some patients. Even on therapy, acute hyperammonemic encephalopathy recurred in the majority of patients for whom the drug is indicated. Sodium Phenylbutyrate Powder may be required life-long unless orthotopic liver transplantation is elected. (See CLINICAL PHARMACOLOGY , Pharmacodynamics subsection for the biochemical effects of Sodium Phenylbutyrate Powder). uuid:30fc19ff-2250-4644-931e-b058ca32d321 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:86545 biolink:treats MONDO:0001071 PMID:41385096 "[{""id"":""uuid:bb2cc0d1-de82-4502-a7fa-80f26c7593a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a13f6673-8733-4b2e-b0ff-04988eee1008"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Phenylbutyrate Powder is indicated as adjunctive therapy in the chronic management of patients with urea cycle disorders involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS). It is indicated in all patients with neonatal-onset deficiency (complete enzymatic deficiency, presenting within the first 28 days of life). It is also indicated in patients with late-onset disease (partial enzymatic deficiency, presenting after the first month of life) who have a history of hyperammonemic encephalopathy. It is important that the diagnosis be made early and treatment initiated immediately to improve survival. Any episode of acute hyperammonemia should be treated as a life-threatening emergency. Sodium Phenylbutyrate Powder must be combined with dietary protein restriction and, in some cases, essential amino acid supplementation. (See Nutritional Supplementation subsection of the DOSAGE AND ADMINISTRATION section.) Previously, neonatal-onset disease was almost universally fatal within the first year of life, even when treated with peritoneal dialysis and essential amino acids or their nitrogen-free analogs. However, with hemodialysis, use of alternative waste nitrogen excretion pathways (sodium phenylbutyrate, sodium benzoate, and sodium phenylacetate), dietary protein restriction, and, in some cases, essential amino acid supplementation, the survival rate in newborns diagnosed after birth but within the first month of life is almost 80%. Most deaths have occurred during an episode of acute hyperammonemic encephalopathy. Patients with neonatal-onset disease have a high incidence of mental retardation. Those who had IQ tests administered had an incidence of mental retardation as follows: ornithine transcarbamylase deficiency, 100% (14/14 patients tested); argininosuccinic acid synthetase deficiency, 88% (15/17 patients tested); and carbamylphosphate synthetase deficiency, 57% (4/7 patients tested). Retardation was severe in the majority of the retarded patients. In patients diagnosed during gestation and treated prior to any episode of hyperammonemic encephalopathy, survival is 100%, but even in these patients, most subsequently demonstrate cognitive impairment or other neurologic deficits. In late-onset deficiency patients, including females heterozygous for ornithine transcarbamylase deficiency, who recover from hyperammonemic encephalopathy and are then treated chronically with sodium phenylbutyrate and dietary protein restriction, the survival rate is 98%. The two deaths in this group of patients occurred during episodes of hyperammonemic encephalopathy. However, compliance with the therapeutic regimen has not been adequately documented to allow evaluation of the potential for Sodium Phenylbutyrate Powder and dietary protein restriction to prevent mental deterioration and recurrence of hyperammonemic encephalopathy if carefully adhered to. The majority of these patients tested (30/46 or 65%) have IQ's in the average to low average/borderline mentally retarded range. Reversal of pre-existing neurologic impairment is not likely to occur with treatment and neurologic deterioration may continue in some patients. Even on therapy, acute hyperammonemic encephalopathy recurred in the majority of patients for whom the drug is indicated. Sodium Phenylbutyrate Powder may be required life-long unless orthotopic liver transplantation is elected. (See CLINICAL PHARMACOLOGY , Pharmacodynamics subsection for the biochemical effects of Sodium Phenylbutyrate Powder). uuid:34db6028-9938-4a3d-a249-a621fc48b2bc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:86545 biolink:treats HP:0100543 PMID:41385096 "[{""id"":""uuid:0bbc18be-8be8-4425-bf0c-3b3c8a2d2f0a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6e558ff3-3340-4812-8c4c-599b9e6d470d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Phenylbutyrate Powder is indicated as adjunctive therapy in the chronic management of patients with urea cycle disorders involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS). It is indicated in all patients with neonatal-onset deficiency (complete enzymatic deficiency, presenting within the first 28 days of life). It is also indicated in patients with late-onset disease (partial enzymatic deficiency, presenting after the first month of life) who have a history of hyperammonemic encephalopathy. It is important that the diagnosis be made early and treatment initiated immediately to improve survival. Any episode of acute hyperammonemia should be treated as a life-threatening emergency. Sodium Phenylbutyrate Powder must be combined with dietary protein restriction and, in some cases, essential amino acid supplementation. (See Nutritional Supplementation subsection of the DOSAGE AND ADMINISTRATION section.) Previously, neonatal-onset disease was almost universally fatal within the first year of life, even when treated with peritoneal dialysis and essential amino acids or their nitrogen-free analogs. However, with hemodialysis, use of alternative waste nitrogen excretion pathways (sodium phenylbutyrate, sodium benzoate, and sodium phenylacetate), dietary protein restriction, and, in some cases, essential amino acid supplementation, the survival rate in newborns diagnosed after birth but within the first month of life is almost 80%. Most deaths have occurred during an episode of acute hyperammonemic encephalopathy. Patients with neonatal-onset disease have a high incidence of mental retardation. Those who had IQ tests administered had an incidence of mental retardation as follows: ornithine transcarbamylase deficiency, 100% (14/14 patients tested); argininosuccinic acid synthetase deficiency, 88% (15/17 patients tested); and carbamylphosphate synthetase deficiency, 57% (4/7 patients tested). Retardation was severe in the majority of the retarded patients. In patients diagnosed during gestation and treated prior to any episode of hyperammonemic encephalopathy, survival is 100%, but even in these patients, most subsequently demonstrate cognitive impairment or other neurologic deficits. In late-onset deficiency patients, including females heterozygous for ornithine transcarbamylase deficiency, who recover from hyperammonemic encephalopathy and are then treated chronically with sodium phenylbutyrate and dietary protein restriction, the survival rate is 98%. The two deaths in this group of patients occurred during episodes of hyperammonemic encephalopathy. However, compliance with the therapeutic regimen has not been adequately documented to allow evaluation of the potential for Sodium Phenylbutyrate Powder and dietary protein restriction to prevent mental deterioration and recurrence of hyperammonemic encephalopathy if carefully adhered to. The majority of these patients tested (30/46 or 65%) have IQ's in the average to low average/borderline mentally retarded range. Reversal of pre-existing neurologic impairment is not likely to occur with treatment and neurologic deterioration may continue in some patients. Even on therapy, acute hyperammonemic encephalopathy recurred in the majority of patients for whom the drug is indicated. Sodium Phenylbutyrate Powder may be required life-long unless orthotopic liver transplantation is elected. (See CLINICAL PHARMACOLOGY , Pharmacodynamics subsection for the biochemical effects of Sodium Phenylbutyrate Powder). uuid:88e891f9-f895-4268-8ae3-31140d77069d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:86545 biolink:treats MONDO:0005071 PMID:41385096 "[{""id"":""uuid:3e6be329-9256-4889-81fc-74d3710789c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:649d06b3-a7cb-4d17-b253-2fae2cc3d132"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Phenylbutyrate Powder is indicated as adjunctive therapy in the chronic management of patients with urea cycle disorders involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS). It is indicated in all patients with neonatal-onset deficiency (complete enzymatic deficiency, presenting within the first 28 days of life). It is also indicated in patients with late-onset disease (partial enzymatic deficiency, presenting after the first month of life) who have a history of hyperammonemic encephalopathy. It is important that the diagnosis be made early and treatment initiated immediately to improve survival. Any episode of acute hyperammonemia should be treated as a life-threatening emergency. Sodium Phenylbutyrate Powder must be combined with dietary protein restriction and, in some cases, essential amino acid supplementation. (See Nutritional Supplementation subsection of the DOSAGE AND ADMINISTRATION section.) Previously, neonatal-onset disease was almost universally fatal within the first year of life, even when treated with peritoneal dialysis and essential amino acids or their nitrogen-free analogs. However, with hemodialysis, use of alternative waste nitrogen excretion pathways (sodium phenylbutyrate, sodium benzoate, and sodium phenylacetate), dietary protein restriction, and, in some cases, essential amino acid supplementation, the survival rate in newborns diagnosed after birth but within the first month of life is almost 80%. Most deaths have occurred during an episode of acute hyperammonemic encephalopathy. Patients with neonatal-onset disease have a high incidence of mental retardation. Those who had IQ tests administered had an incidence of mental retardation as follows: ornithine transcarbamylase deficiency, 100% (14/14 patients tested); argininosuccinic acid synthetase deficiency, 88% (15/17 patients tested); and carbamylphosphate synthetase deficiency, 57% (4/7 patients tested). Retardation was severe in the majority of the retarded patients. In patients diagnosed during gestation and treated prior to any episode of hyperammonemic encephalopathy, survival is 100%, but even in these patients, most subsequently demonstrate cognitive impairment or other neurologic deficits. In late-onset deficiency patients, including females heterozygous for ornithine transcarbamylase deficiency, who recover from hyperammonemic encephalopathy and are then treated chronically with sodium phenylbutyrate and dietary protein restriction, the survival rate is 98%. The two deaths in this group of patients occurred during episodes of hyperammonemic encephalopathy. However, compliance with the therapeutic regimen has not been adequately documented to allow evaluation of the potential for Sodium Phenylbutyrate Powder and dietary protein restriction to prevent mental deterioration and recurrence of hyperammonemic encephalopathy if carefully adhered to. The majority of these patients tested (30/46 or 65%) have IQ's in the average to low average/borderline mentally retarded range. Reversal of pre-existing neurologic impairment is not likely to occur with treatment and neurologic deterioration may continue in some patients. Even on therapy, acute hyperammonemic encephalopathy recurred in the majority of patients for whom the drug is indicated. Sodium Phenylbutyrate Powder may be required life-long unless orthotopic liver transplantation is elected. (See CLINICAL PHARMACOLOGY , Pharmacodynamics subsection for the biochemical effects of Sodium Phenylbutyrate Powder). uuid:3e7f9970-5fb2-4f42-98cf-bbe656013c5f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:21659 biolink:treats MONDO:0005545 PMID:41385096 "[{""id"":""uuid:9f26281c-3354-4cfb-9eeb-ef5a53ecd34b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:798969e8-b143-4038-a36a-d28a5801d6a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Neomycin and Polymyxin B Sulfates, Bacitracin Zinc, and Hydrocortisone Ophthalmic Ointment is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial infection exists. Ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe where the inherent risk of corticosteroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye (see CLINICAL PHARMACOLOGY: Microbiology ). The particular anti-infective drugs in this product are active against the following common bacterial eye pathogens: Staphylococcus aureus , streptococci, including Streptococcus pneumoniae , Escherichia coli , Haemophilus influenzae , Klebsiella/Enterobacter species , Neisseria species , and Pseudomonas aeruginosa . The product does not provide adequate coverage against Serratia marcescens . uuid:311d9171-73f3-4d76-87a1-a4cbfaa01697 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:21659 biolink:treats MONDO:0005114 PMID:41385096 "[{""id"":""uuid:e3dbc931-a957-4336-86ac-af44b636c53e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:155537c1-3767-443e-980d-c3a657d3c259"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Neomycin and Polymyxin B Sulfates, Bacitracin Zinc, and Hydrocortisone Ophthalmic Ointment is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial infection exists. Ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe where the inherent risk of corticosteroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye (see CLINICAL PHARMACOLOGY: Microbiology ). The particular anti-infective drugs in this product are active against the following common bacterial eye pathogens: Staphylococcus aureus , streptococci, including Streptococcus pneumoniae , Escherichia coli , Haemophilus influenzae , Klebsiella/Enterobacter species , Neisseria species , and Pseudomonas aeruginosa . The product does not provide adequate coverage against Serratia marcescens . uuid:89897321-ed89-406e-bc48-5939afff50d5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:21659 biolink:treats MONDO:0020920 PMID:41385096 "[{""id"":""uuid:645d3535-21ef-4e11-b302-91176363755f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:566f8077-f2e3-4d41-a399-d77f01cc08f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Neomycin and Polymyxin B Sulfates, Bacitracin Zinc, and Hydrocortisone Ophthalmic Ointment is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial infection exists. Ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe where the inherent risk of corticosteroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye (see CLINICAL PHARMACOLOGY: Microbiology ). The particular anti-infective drugs in this product are active against the following common bacterial eye pathogens: Staphylococcus aureus , streptococci, including Streptococcus pneumoniae , Escherichia coli , Haemophilus influenzae , Klebsiella/Enterobacter species , Neisseria species , and Pseudomonas aeruginosa . The product does not provide adequate coverage against Serratia marcescens . uuid:6548e695-b318-43e2-88e8-fb63779e73e1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:21659 biolink:treats UMLS:C0348321 PMID:41385096 "[{""id"":""uuid:e0a62459-1aae-4d9f-9969-2ecbdc4fa813"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eb94cbcd-4526-4720-9e33-1ca03a8690de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Neomycin and Polymyxin B Sulfates, Bacitracin Zinc, and Hydrocortisone Ophthalmic Ointment is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial infection exists. Ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe where the inherent risk of corticosteroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye (see CLINICAL PHARMACOLOGY: Microbiology ). The particular anti-infective drugs in this product are active against the following common bacterial eye pathogens: Staphylococcus aureus , streptococci, including Streptococcus pneumoniae , Escherichia coli , Haemophilus influenzae , Klebsiella/Enterobacter species , Neisseria species , and Pseudomonas aeruginosa . The product does not provide adequate coverage against Serratia marcescens . uuid:59842a0c-c6f6-426d-97d7-51a92992890a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:21659 biolink:treats UMLS:C0854135 PMID:41385096 "[{""id"":""uuid:976abe11-54a4-404a-b51f-a231381055cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:65fdb3da-3ae5-4745-8544-761fa93995a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Neomycin and Polymyxin B Sulfates, Bacitracin Zinc, and Hydrocortisone Ophthalmic Ointment is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial infection exists. Ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe where the inherent risk of corticosteroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye (see CLINICAL PHARMACOLOGY: Microbiology ). The particular anti-infective drugs in this product are active against the following common bacterial eye pathogens: Staphylococcus aureus , streptococci, including Streptococcus pneumoniae , Escherichia coli , Haemophilus influenzae , Klebsiella/Enterobacter species , Neisseria species , and Pseudomonas aeruginosa . The product does not provide adequate coverage against Serratia marcescens . uuid:76be3ccf-3b75-47a3-9bbb-b892d672de85 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63608 biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:a8bd0277-1fac-4091-91b4-419b3b42baad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2ed44687-ffa5-41fe-8658-24f6b4dc6d18"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Maraviroc tablets are indicated in combination with other antiretroviral agents for the treatment of only CCR5-tropic human immunodeficiency virus type 1 (HIV-1) infection in adult and pediatric patients 2 years of age and older weighing at least 10 kg. Limitations of Use: • Maraviroc tablets are not recommended in patients with dual/mixed- or CXCR4-tropic HIV-1 [ see Microbiology ( 12.4 ) ]. uuid:544fc4b1-8017-4eeb-9544-68ea7eb5a8ea biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:26710 biolink:treats HP:0200114 PMID:41385096 "[{""id"":""uuid:eeda8029-b216-4cc5-8ec9-cba442ebee68"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:32754311-acc3-488a-b508-f55631af3dcc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] These intravenous solutions are indicated for use in adults and pediatric patients as sources of electrolytes and water for hydration. 0.9% Sodium Chloride Injection USP is indicated for extracellular fluid replacement, treatment of metabolic alkalosis in the presence of fluid loss and mild sodium depletion. 0.9% Sodium Chloride Injection USP is also indicated for use as a priming solution in hemodialysis procedures and may be used to initiate and terminate blood transfusions without hemolyzing red blood cells. 0.45% Sodium Chloride Injection USP is primarily a hydrating solution and may be used to assess the status of the kidneys, since more water is provided than is required for excretion of salt. It may also be used in the treatment of hyperosmolar diabetes where the use of dextrose is inadvisable and there is a need for large amounts of fluid without an excess of sodium ions. Sodium Chloride Injections USP are also indicated as pharmaceutic aids and diluents for the infusion of compatible drug additives. Refer to prescribing information accompanying additive drugs. uuid:aeabe19f-e9d8-4911-b091-fe253e4af59b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:26710 biolink:treats UMLS:C0020457 PMID:41385096 "[{""id"":""uuid:bac953f5-7478-476f-8627-c6b833704d62"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:06cb1b4d-0166-4572-9d35-4db664394bbb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] These intravenous solutions are indicated for use in adults and pediatric patients as sources of electrolytes and water for hydration. 0.9% Sodium Chloride Injection USP is indicated for extracellular fluid replacement, treatment of metabolic alkalosis in the presence of fluid loss and mild sodium depletion. 0.9% Sodium Chloride Injection USP is also indicated for use as a priming solution in hemodialysis procedures and may be used to initiate and terminate blood transfusions without hemolyzing red blood cells. 0.45% Sodium Chloride Injection USP is primarily a hydrating solution and may be used to assess the status of the kidneys, since more water is provided than is required for excretion of salt. It may also be used in the treatment of hyperosmolar diabetes where the use of dextrose is inadvisable and there is a need for large amounts of fluid without an excess of sodium ions. Sodium Chloride Injections USP are also indicated as pharmaceutic aids and diluents for the infusion of compatible drug additives. Refer to prescribing information accompanying additive drugs. uuid:6b329cbe-3548-4e85-9e8f-f9d5ca6db095 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63451 biolink:treats MONDO:0019087 PMID:41385096 "[{""id"":""uuid:a8fed944-c29d-4613-8185-e5cffeec898e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:113b9535-a08a-4841-9409-17ed36396e69"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TRUSELTIQ is indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test [see Dosage and Administration ( 2.1 )] . This indication is approved under accelerated approval based on overall response rate and duration of response [see Clinical Studies ( 14.1 )] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). uuid:c29d7e41-8afb-4b02-ad31-4d13f673b512 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:194135 biolink:treats UMLS:C0853854 PMID:41385096 "[{""id"":""uuid:2e691dff-1583-48d2-93a6-0b4cb9e6dfb8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aaf81e05-e710-4a8a-87f3-276ffd8ca76d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of ofloxacin tablets, USP and other antibacterial drugs, ofloxacin tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ofloxacin tablets, USP are indicated for the treatment of adults with mild to moderate infections (unless otherwise indicated) caused by susceptible strains of the designated microorganisms in the infections listed below. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute Bacterial Exacerbations of Chronic Bronchitis (ABECB) due to Haemophilus influenzae or Streptococcus pneumoniae. Because fluoroquinolones, including ofloxacin, have been associated with serious adverse reactions (see Warnings ), -and for some patients ABECB is self-limiting, reserve ofloxacin for treatment of ABECB in patients who have no alternative treatment options. Community-Acquired Pneumonia due to Haemophilus influenzae or Streptococcus pneumoniae. Uncomplicated Skin and Skin Structure Infections due to methicillin-susceptible Staphylococcus aureus, Streptococcus pyogenes, or Proteus mirabilis. Acute, Uncomplicated Urethral and Cervical Gonorrhea due to Neisseria gonorrhoeae (see WARNINGS ). Nongonococcal Urethritis and Cervicitis due to Chlamydia trachomatis (see WARNINGS ). Mixed Infections of the Urethra and Cervix due to Chlamydia trachomatis and Neisseria gonorrhoeae (see WARNINGS ). Acute Pelvic Inflammatory Disease (including severe infection) due to Chlamydia trachomatis and/or Neisseria gonorrhoeae (see WARNINGS ). NOTE: If anaerobic microorganisms are suspected of contributing to the infection, appropriate therapy for anaerobic pathogens should be administered. Uncomplicated Cystitis due to Citrobacter diversus, Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa. Because fluoroquinolones, including ofloxacin, have been associated with serious adverse reactions (see WARNINGS ), and for some patients uncomplicated cystitis is self-limiting, reserve ofloxacin for treatment of uncomplicated cystitis in patients who have no alternative treatment options. Complicated Urinary Tract Infections due to Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Citrobacter diversus, Although treatment of infections due to this organism in this organ system demonstrated a clinically significant outcome, efficacy was studied in fewer than 10 patients. or Pseudomonas aeruginosa. Prostatitis due to Escherichia coli. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to ofloxacin, USP. Therapy with ofloxacin, USP may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. As with other drugs in this class, some strains of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with ofloxacin, USP. Culture and susceptibility testing performed periodically during therapy will provide information not only on the therapeutic effect of the antimicrobial agent but also on the possible emergence of bacterial resistance. uuid:ab9f0f57-c485-42c9-be11-b06a46b27c67 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:194135 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:5268ce72-1a36-48b7-8d86-498021d0e3fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:648bd3f5-5eff-48f7-ad7c-26de35069ad3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of ofloxacin tablets, USP and other antibacterial drugs, ofloxacin tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ofloxacin tablets, USP are indicated for the treatment of adults with mild to moderate infections (unless otherwise indicated) caused by susceptible strains of the designated microorganisms in the infections listed below. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute Bacterial Exacerbations of Chronic Bronchitis (ABECB) due to Haemophilus influenzae or Streptococcus pneumoniae. Because fluoroquinolones, including ofloxacin, have been associated with serious adverse reactions (see Warnings ), -and for some patients ABECB is self-limiting, reserve ofloxacin for treatment of ABECB in patients who have no alternative treatment options. Community-Acquired Pneumonia due to Haemophilus influenzae or Streptococcus pneumoniae. Uncomplicated Skin and Skin Structure Infections due to methicillin-susceptible Staphylococcus aureus, Streptococcus pyogenes, or Proteus mirabilis. Acute, Uncomplicated Urethral and Cervical Gonorrhea due to Neisseria gonorrhoeae (see WARNINGS ). Nongonococcal Urethritis and Cervicitis due to Chlamydia trachomatis (see WARNINGS ). Mixed Infections of the Urethra and Cervix due to Chlamydia trachomatis and Neisseria gonorrhoeae (see WARNINGS ). Acute Pelvic Inflammatory Disease (including severe infection) due to Chlamydia trachomatis and/or Neisseria gonorrhoeae (see WARNINGS ). NOTE: If anaerobic microorganisms are suspected of contributing to the infection, appropriate therapy for anaerobic pathogens should be administered. Uncomplicated Cystitis due to Citrobacter diversus, Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa. Because fluoroquinolones, including ofloxacin, have been associated with serious adverse reactions (see WARNINGS ), and for some patients uncomplicated cystitis is self-limiting, reserve ofloxacin for treatment of uncomplicated cystitis in patients who have no alternative treatment options. Complicated Urinary Tract Infections due to Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Citrobacter diversus, Although treatment of infections due to this organism in this organ system demonstrated a clinically significant outcome, efficacy was studied in fewer than 10 patients. or Pseudomonas aeruginosa. Prostatitis due to Escherichia coli. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to ofloxacin, USP. Therapy with ofloxacin, USP may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. As with other drugs in this class, some strains of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with ofloxacin, USP. Culture and susceptibility testing performed periodically during therapy will provide information not only on the therapeutic effect of the antimicrobial agent but also on the possible emergence of bacterial resistance. uuid:3ee69ed8-2744-412c-92cf-ea3ef925c6f4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:194135 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:f7fc53f8-11a8-4548-93f4-3eddbb2d0c7f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7d6ce75d-6a54-402c-bd56-743d5682d1aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of ofloxacin tablets, USP and other antibacterial drugs, ofloxacin tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ofloxacin tablets, USP are indicated for the treatment of adults with mild to moderate infections (unless otherwise indicated) caused by susceptible strains of the designated microorganisms in the infections listed below. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute Bacterial Exacerbations of Chronic Bronchitis (ABECB) due to Haemophilus influenzae or Streptococcus pneumoniae. Because fluoroquinolones, including ofloxacin, have been associated with serious adverse reactions (see Warnings ), -and for some patients ABECB is self-limiting, reserve ofloxacin for treatment of ABECB in patients who have no alternative treatment options. Community-Acquired Pneumonia due to Haemophilus influenzae or Streptococcus pneumoniae. Uncomplicated Skin and Skin Structure Infections due to methicillin-susceptible Staphylococcus aureus, Streptococcus pyogenes, or Proteus mirabilis. Acute, Uncomplicated Urethral and Cervical Gonorrhea due to Neisseria gonorrhoeae (see WARNINGS ). Nongonococcal Urethritis and Cervicitis due to Chlamydia trachomatis (see WARNINGS ). Mixed Infections of the Urethra and Cervix due to Chlamydia trachomatis and Neisseria gonorrhoeae (see WARNINGS ). Acute Pelvic Inflammatory Disease (including severe infection) due to Chlamydia trachomatis and/or Neisseria gonorrhoeae (see WARNINGS ). NOTE: If anaerobic microorganisms are suspected of contributing to the infection, appropriate therapy for anaerobic pathogens should be administered. Uncomplicated Cystitis due to Citrobacter diversus, Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa. Because fluoroquinolones, including ofloxacin, have been associated with serious adverse reactions (see WARNINGS ), and for some patients uncomplicated cystitis is self-limiting, reserve ofloxacin for treatment of uncomplicated cystitis in patients who have no alternative treatment options. Complicated Urinary Tract Infections due to Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Citrobacter diversus, Although treatment of infections due to this organism in this organ system demonstrated a clinically significant outcome, efficacy was studied in fewer than 10 patients. or Pseudomonas aeruginosa. Prostatitis due to Escherichia coli. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to ofloxacin, USP. Therapy with ofloxacin, USP may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. As with other drugs in this class, some strains of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with ofloxacin, USP. Culture and susceptibility testing performed periodically during therapy will provide information not only on the therapeutic effect of the antimicrobial agent but also on the possible emergence of bacterial resistance. uuid:1b4aebe9-4354-42af-b550-1c069bb8dd19 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:194135 biolink:treats MONDO:0004277 PMID:41385096 "[{""id"":""uuid:c4f1fe65-b932-4fa1-89c3-aadb09dc10ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5e51e63b-f43f-43a9-b2f0-0a4a7b751f12"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of ofloxacin tablets, USP and other antibacterial drugs, ofloxacin tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ofloxacin tablets, USP are indicated for the treatment of adults with mild to moderate infections (unless otherwise indicated) caused by susceptible strains of the designated microorganisms in the infections listed below. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute Bacterial Exacerbations of Chronic Bronchitis (ABECB) due to Haemophilus influenzae or Streptococcus pneumoniae. Because fluoroquinolones, including ofloxacin, have been associated with serious adverse reactions (see Warnings ), -and for some patients ABECB is self-limiting, reserve ofloxacin for treatment of ABECB in patients who have no alternative treatment options. Community-Acquired Pneumonia due to Haemophilus influenzae or Streptococcus pneumoniae. Uncomplicated Skin and Skin Structure Infections due to methicillin-susceptible Staphylococcus aureus, Streptococcus pyogenes, or Proteus mirabilis. Acute, Uncomplicated Urethral and Cervical Gonorrhea due to Neisseria gonorrhoeae (see WARNINGS ). Nongonococcal Urethritis and Cervicitis due to Chlamydia trachomatis (see WARNINGS ). Mixed Infections of the Urethra and Cervix due to Chlamydia trachomatis and Neisseria gonorrhoeae (see WARNINGS ). Acute Pelvic Inflammatory Disease (including severe infection) due to Chlamydia trachomatis and/or Neisseria gonorrhoeae (see WARNINGS ). NOTE: If anaerobic microorganisms are suspected of contributing to the infection, appropriate therapy for anaerobic pathogens should be administered. Uncomplicated Cystitis due to Citrobacter diversus, Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa. Because fluoroquinolones, including ofloxacin, have been associated with serious adverse reactions (see WARNINGS ), and for some patients uncomplicated cystitis is self-limiting, reserve ofloxacin for treatment of uncomplicated cystitis in patients who have no alternative treatment options. Complicated Urinary Tract Infections due to Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Citrobacter diversus, Although treatment of infections due to this organism in this organ system demonstrated a clinically significant outcome, efficacy was studied in fewer than 10 patients. or Pseudomonas aeruginosa. Prostatitis due to Escherichia coli. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to ofloxacin, USP. Therapy with ofloxacin, USP may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. As with other drugs in this class, some strains of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with ofloxacin, USP. Culture and susceptibility testing performed periodically during therapy will provide information not only on the therapeutic effect of the antimicrobial agent but also on the possible emergence of bacterial resistance. uuid:817c0377-a8a9-4531-a13f-273ff01c0f1a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:194135 biolink:treats MONDO:0005297 PMID:41385096 "[{""id"":""uuid:f40f13d9-b28d-45e7-af75-d680281122b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:114fdf96-cd1e-4444-91fa-225fede4163e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of ofloxacin tablets, USP and other antibacterial drugs, ofloxacin tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ofloxacin tablets, USP are indicated for the treatment of adults with mild to moderate infections (unless otherwise indicated) caused by susceptible strains of the designated microorganisms in the infections listed below. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute Bacterial Exacerbations of Chronic Bronchitis (ABECB) due to Haemophilus influenzae or Streptococcus pneumoniae. Because fluoroquinolones, including ofloxacin, have been associated with serious adverse reactions (see Warnings ), -and for some patients ABECB is self-limiting, reserve ofloxacin for treatment of ABECB in patients who have no alternative treatment options. Community-Acquired Pneumonia due to Haemophilus influenzae or Streptococcus pneumoniae. Uncomplicated Skin and Skin Structure Infections due to methicillin-susceptible Staphylococcus aureus, Streptococcus pyogenes, or Proteus mirabilis. Acute, Uncomplicated Urethral and Cervical Gonorrhea due to Neisseria gonorrhoeae (see WARNINGS ). Nongonococcal Urethritis and Cervicitis due to Chlamydia trachomatis (see WARNINGS ). Mixed Infections of the Urethra and Cervix due to Chlamydia trachomatis and Neisseria gonorrhoeae (see WARNINGS ). Acute Pelvic Inflammatory Disease (including severe infection) due to Chlamydia trachomatis and/or Neisseria gonorrhoeae (see WARNINGS ). NOTE: If anaerobic microorganisms are suspected of contributing to the infection, appropriate therapy for anaerobic pathogens should be administered. Uncomplicated Cystitis due to Citrobacter diversus, Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa. Because fluoroquinolones, including ofloxacin, have been associated with serious adverse reactions (see WARNINGS ), and for some patients uncomplicated cystitis is self-limiting, reserve ofloxacin for treatment of uncomplicated cystitis in patients who have no alternative treatment options. Complicated Urinary Tract Infections due to Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Citrobacter diversus, Although treatment of infections due to this organism in this organ system demonstrated a clinically significant outcome, efficacy was studied in fewer than 10 patients. or Pseudomonas aeruginosa. Prostatitis due to Escherichia coli. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to ofloxacin, USP. Therapy with ofloxacin, USP may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. As with other drugs in this class, some strains of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with ofloxacin, USP. Culture and susceptibility testing performed periodically during therapy will provide information not only on the therapeutic effect of the antimicrobial agent but also on the possible emergence of bacterial resistance. uuid:9b914f85-3f2e-4c5d-8fb9-a8cfd2b9bfcf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:194135 biolink:treats UMLS:C1960274 PMID:41385096 "[{""id"":""uuid:a0e5f421-4e9d-417e-a96a-72b3717e422e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7a39162c-4575-43a3-8fa5-64fa20721880"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of ofloxacin tablets, USP and other antibacterial drugs, ofloxacin tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ofloxacin tablets, USP are indicated for the treatment of adults with mild to moderate infections (unless otherwise indicated) caused by susceptible strains of the designated microorganisms in the infections listed below. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute Bacterial Exacerbations of Chronic Bronchitis (ABECB) due to Haemophilus influenzae or Streptococcus pneumoniae. Because fluoroquinolones, including ofloxacin, have been associated with serious adverse reactions (see Warnings ), -and for some patients ABECB is self-limiting, reserve ofloxacin for treatment of ABECB in patients who have no alternative treatment options. Community-Acquired Pneumonia due to Haemophilus influenzae or Streptococcus pneumoniae. Uncomplicated Skin and Skin Structure Infections due to methicillin-susceptible Staphylococcus aureus, Streptococcus pyogenes, or Proteus mirabilis. Acute, Uncomplicated Urethral and Cervical Gonorrhea due to Neisseria gonorrhoeae (see WARNINGS ). Nongonococcal Urethritis and Cervicitis due to Chlamydia trachomatis (see WARNINGS ). Mixed Infections of the Urethra and Cervix due to Chlamydia trachomatis and Neisseria gonorrhoeae (see WARNINGS ). Acute Pelvic Inflammatory Disease (including severe infection) due to Chlamydia trachomatis and/or Neisseria gonorrhoeae (see WARNINGS ). NOTE: If anaerobic microorganisms are suspected of contributing to the infection, appropriate therapy for anaerobic pathogens should be administered. Uncomplicated Cystitis due to Citrobacter diversus, Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa. Because fluoroquinolones, including ofloxacin, have been associated with serious adverse reactions (see WARNINGS ), and for some patients uncomplicated cystitis is self-limiting, reserve ofloxacin for treatment of uncomplicated cystitis in patients who have no alternative treatment options. Complicated Urinary Tract Infections due to Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Citrobacter diversus, Although treatment of infections due to this organism in this organ system demonstrated a clinically significant outcome, efficacy was studied in fewer than 10 patients. or Pseudomonas aeruginosa. Prostatitis due to Escherichia coli. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to ofloxacin, USP. Therapy with ofloxacin, USP may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. As with other drugs in this class, some strains of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with ofloxacin, USP. Culture and susceptibility testing performed periodically during therapy will provide information not only on the therapeutic effect of the antimicrobial agent but also on the possible emergence of bacterial resistance. uuid:5141042b-d439-46cb-b109-8e84860eebd8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:194135 biolink:treats MONDO:0100128 PMID:41385096 "[{""id"":""uuid:3b0a4748-6b94-4877-8492-823695ff1295"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3078d2d8-68e2-4f51-9a1d-d4e7b1501cb7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of ofloxacin tablets, USP and other antibacterial drugs, ofloxacin tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ofloxacin tablets, USP are indicated for the treatment of adults with mild to moderate infections (unless otherwise indicated) caused by susceptible strains of the designated microorganisms in the infections listed below. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute Bacterial Exacerbations of Chronic Bronchitis (ABECB) due to Haemophilus influenzae or Streptococcus pneumoniae. Because fluoroquinolones, including ofloxacin, have been associated with serious adverse reactions (see Warnings ), -and for some patients ABECB is self-limiting, reserve ofloxacin for treatment of ABECB in patients who have no alternative treatment options. Community-Acquired Pneumonia due to Haemophilus influenzae or Streptococcus pneumoniae. Uncomplicated Skin and Skin Structure Infections due to methicillin-susceptible Staphylococcus aureus, Streptococcus pyogenes, or Proteus mirabilis. Acute, Uncomplicated Urethral and Cervical Gonorrhea due to Neisseria gonorrhoeae (see WARNINGS ). Nongonococcal Urethritis and Cervicitis due to Chlamydia trachomatis (see WARNINGS ). Mixed Infections of the Urethra and Cervix due to Chlamydia trachomatis and Neisseria gonorrhoeae (see WARNINGS ). Acute Pelvic Inflammatory Disease (including severe infection) due to Chlamydia trachomatis and/or Neisseria gonorrhoeae (see WARNINGS ). NOTE: If anaerobic microorganisms are suspected of contributing to the infection, appropriate therapy for anaerobic pathogens should be administered. Uncomplicated Cystitis due to Citrobacter diversus, Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa. Because fluoroquinolones, including ofloxacin, have been associated with serious adverse reactions (see WARNINGS ), and for some patients uncomplicated cystitis is self-limiting, reserve ofloxacin for treatment of uncomplicated cystitis in patients who have no alternative treatment options. Complicated Urinary Tract Infections due to Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Citrobacter diversus, Although treatment of infections due to this organism in this organ system demonstrated a clinically significant outcome, efficacy was studied in fewer than 10 patients. or Pseudomonas aeruginosa. Prostatitis due to Escherichia coli. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to ofloxacin, USP. Therapy with ofloxacin, USP may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. As with other drugs in this class, some strains of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with ofloxacin, USP. Culture and susceptibility testing performed periodically during therapy will provide information not only on the therapeutic effect of the antimicrobial agent but also on the possible emergence of bacterial resistance. uuid:531a91cd-91c4-4e1e-841e-fc6b70b1bae6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:194135 biolink:treats UMLS:C0149959 PMID:41385096 "[{""id"":""uuid:5f6cf75e-6354-4e58-8d09-cd752bffe972"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1bebb72c-19e1-4154-8701-ff8ffd1ade64"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of ofloxacin tablets, USP and other antibacterial drugs, ofloxacin tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ofloxacin tablets, USP are indicated for the treatment of adults with mild to moderate infections (unless otherwise indicated) caused by susceptible strains of the designated microorganisms in the infections listed below. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute Bacterial Exacerbations of Chronic Bronchitis (ABECB) due to Haemophilus influenzae or Streptococcus pneumoniae. Because fluoroquinolones, including ofloxacin, have been associated with serious adverse reactions (see Warnings ), -and for some patients ABECB is self-limiting, reserve ofloxacin for treatment of ABECB in patients who have no alternative treatment options. Community-Acquired Pneumonia due to Haemophilus influenzae or Streptococcus pneumoniae. Uncomplicated Skin and Skin Structure Infections due to methicillin-susceptible Staphylococcus aureus, Streptococcus pyogenes, or Proteus mirabilis. Acute, Uncomplicated Urethral and Cervical Gonorrhea due to Neisseria gonorrhoeae (see WARNINGS ). Nongonococcal Urethritis and Cervicitis due to Chlamydia trachomatis (see WARNINGS ). Mixed Infections of the Urethra and Cervix due to Chlamydia trachomatis and Neisseria gonorrhoeae (see WARNINGS ). Acute Pelvic Inflammatory Disease (including severe infection) due to Chlamydia trachomatis and/or Neisseria gonorrhoeae (see WARNINGS ). NOTE: If anaerobic microorganisms are suspected of contributing to the infection, appropriate therapy for anaerobic pathogens should be administered. Uncomplicated Cystitis due to Citrobacter diversus, Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa. Because fluoroquinolones, including ofloxacin, have been associated with serious adverse reactions (see WARNINGS ), and for some patients uncomplicated cystitis is self-limiting, reserve ofloxacin for treatment of uncomplicated cystitis in patients who have no alternative treatment options. Complicated Urinary Tract Infections due to Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Citrobacter diversus, Although treatment of infections due to this organism in this organ system demonstrated a clinically significant outcome, efficacy was studied in fewer than 10 patients. or Pseudomonas aeruginosa. Prostatitis due to Escherichia coli. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to ofloxacin, USP. Therapy with ofloxacin, USP may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. As with other drugs in this class, some strains of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with ofloxacin, USP. Culture and susceptibility testing performed periodically during therapy will provide information not only on the therapeutic effect of the antimicrobial agent but also on the possible emergence of bacterial resistance. uuid:39872a63-d8fb-4770-ad72-3e1536110f99 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:194135 biolink:treats UMLS:C5769488 PMID:41385096 "[{""id"":""uuid:5c87a92f-affe-4420-b30d-b780e437400d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:03c4de6e-bcde-4685-b6b6-0772634c2951"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of ofloxacin tablets, USP and other antibacterial drugs, ofloxacin tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ofloxacin tablets, USP are indicated for the treatment of adults with mild to moderate infections (unless otherwise indicated) caused by susceptible strains of the designated microorganisms in the infections listed below. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute Bacterial Exacerbations of Chronic Bronchitis (ABECB) due to Haemophilus influenzae or Streptococcus pneumoniae. Because fluoroquinolones, including ofloxacin, have been associated with serious adverse reactions (see Warnings ), -and for some patients ABECB is self-limiting, reserve ofloxacin for treatment of ABECB in patients who have no alternative treatment options. Community-Acquired Pneumonia due to Haemophilus influenzae or Streptococcus pneumoniae. Uncomplicated Skin and Skin Structure Infections due to methicillin-susceptible Staphylococcus aureus, Streptococcus pyogenes, or Proteus mirabilis. Acute, Uncomplicated Urethral and Cervical Gonorrhea due to Neisseria gonorrhoeae (see WARNINGS ). Nongonococcal Urethritis and Cervicitis due to Chlamydia trachomatis (see WARNINGS ). Mixed Infections of the Urethra and Cervix due to Chlamydia trachomatis and Neisseria gonorrhoeae (see WARNINGS ). Acute Pelvic Inflammatory Disease (including severe infection) due to Chlamydia trachomatis and/or Neisseria gonorrhoeae (see WARNINGS ). NOTE: If anaerobic microorganisms are suspected of contributing to the infection, appropriate therapy for anaerobic pathogens should be administered. Uncomplicated Cystitis due to Citrobacter diversus, Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa. Because fluoroquinolones, including ofloxacin, have been associated with serious adverse reactions (see WARNINGS ), and for some patients uncomplicated cystitis is self-limiting, reserve ofloxacin for treatment of uncomplicated cystitis in patients who have no alternative treatment options. Complicated Urinary Tract Infections due to Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Citrobacter diversus, Although treatment of infections due to this organism in this organ system demonstrated a clinically significant outcome, efficacy was studied in fewer than 10 patients. or Pseudomonas aeruginosa. Prostatitis due to Escherichia coli. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to ofloxacin, USP. Therapy with ofloxacin, USP may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. As with other drugs in this class, some strains of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with ofloxacin, USP. Culture and susceptibility testing performed periodically during therapy will provide information not only on the therapeutic effect of the antimicrobial agent but also on the possible emergence of bacterial resistance. uuid:b604bd72-2ec5-4150-afc7-bb679b48665f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:194135 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:3f8287c0-9526-4d27-8376-4528a405178b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8a5adb8e-8516-4e19-bb32-f76ad94a37e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of ofloxacin tablets, USP and other antibacterial drugs, ofloxacin tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ofloxacin tablets, USP are indicated for the treatment of adults with mild to moderate infections (unless otherwise indicated) caused by susceptible strains of the designated microorganisms in the infections listed below. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute Bacterial Exacerbations of Chronic Bronchitis (ABECB) due to Haemophilus influenzae or Streptococcus pneumoniae. Because fluoroquinolones, including ofloxacin, have been associated with serious adverse reactions (see Warnings ), -and for some patients ABECB is self-limiting, reserve ofloxacin for treatment of ABECB in patients who have no alternative treatment options. Community-Acquired Pneumonia due to Haemophilus influenzae or Streptococcus pneumoniae. Uncomplicated Skin and Skin Structure Infections due to methicillin-susceptible Staphylococcus aureus, Streptococcus pyogenes, or Proteus mirabilis. Acute, Uncomplicated Urethral and Cervical Gonorrhea due to Neisseria gonorrhoeae (see WARNINGS ). Nongonococcal Urethritis and Cervicitis due to Chlamydia trachomatis (see WARNINGS ). Mixed Infections of the Urethra and Cervix due to Chlamydia trachomatis and Neisseria gonorrhoeae (see WARNINGS ). Acute Pelvic Inflammatory Disease (including severe infection) due to Chlamydia trachomatis and/or Neisseria gonorrhoeae (see WARNINGS ). NOTE: If anaerobic microorganisms are suspected of contributing to the infection, appropriate therapy for anaerobic pathogens should be administered. Uncomplicated Cystitis due to Citrobacter diversus, Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa. Because fluoroquinolones, including ofloxacin, have been associated with serious adverse reactions (see WARNINGS ), and for some patients uncomplicated cystitis is self-limiting, reserve ofloxacin for treatment of uncomplicated cystitis in patients who have no alternative treatment options. Complicated Urinary Tract Infections due to Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Citrobacter diversus, Although treatment of infections due to this organism in this organ system demonstrated a clinically significant outcome, efficacy was studied in fewer than 10 patients. or Pseudomonas aeruginosa. Prostatitis due to Escherichia coli. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to ofloxacin, USP. Therapy with ofloxacin, USP may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. As with other drugs in this class, some strains of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with ofloxacin, USP. Culture and susceptibility testing performed periodically during therapy will provide information not only on the therapeutic effect of the antimicrobial agent but also on the possible emergence of bacterial resistance. uuid:16868c80-dcf8-46e0-b32b-ca12e55e87cc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:194135 biolink:treats MONDO:0005280 PMID:41385096 "[{""id"":""uuid:40c172eb-fad5-4f87-9d26-be19c209f81c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9465395a-5fc4-4ca9-b936-a9b3e7aa440d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of ofloxacin tablets, USP and other antibacterial drugs, ofloxacin tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ofloxacin tablets, USP are indicated for the treatment of adults with mild to moderate infections (unless otherwise indicated) caused by susceptible strains of the designated microorganisms in the infections listed below. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute Bacterial Exacerbations of Chronic Bronchitis (ABECB) due to Haemophilus influenzae or Streptococcus pneumoniae. Because fluoroquinolones, including ofloxacin, have been associated with serious adverse reactions (see Warnings ), -and for some patients ABECB is self-limiting, reserve ofloxacin for treatment of ABECB in patients who have no alternative treatment options. Community-Acquired Pneumonia due to Haemophilus influenzae or Streptococcus pneumoniae. Uncomplicated Skin and Skin Structure Infections due to methicillin-susceptible Staphylococcus aureus, Streptococcus pyogenes, or Proteus mirabilis. Acute, Uncomplicated Urethral and Cervical Gonorrhea due to Neisseria gonorrhoeae (see WARNINGS ). Nongonococcal Urethritis and Cervicitis due to Chlamydia trachomatis (see WARNINGS ). Mixed Infections of the Urethra and Cervix due to Chlamydia trachomatis and Neisseria gonorrhoeae (see WARNINGS ). Acute Pelvic Inflammatory Disease (including severe infection) due to Chlamydia trachomatis and/or Neisseria gonorrhoeae (see WARNINGS ). NOTE: If anaerobic microorganisms are suspected of contributing to the infection, appropriate therapy for anaerobic pathogens should be administered. Uncomplicated Cystitis due to Citrobacter diversus, Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa. Because fluoroquinolones, including ofloxacin, have been associated with serious adverse reactions (see WARNINGS ), and for some patients uncomplicated cystitis is self-limiting, reserve ofloxacin for treatment of uncomplicated cystitis in patients who have no alternative treatment options. Complicated Urinary Tract Infections due to Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Citrobacter diversus, Although treatment of infections due to this organism in this organ system demonstrated a clinically significant outcome, efficacy was studied in fewer than 10 patients. or Pseudomonas aeruginosa. Prostatitis due to Escherichia coli. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to ofloxacin, USP. Therapy with ofloxacin, USP may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. As with other drugs in this class, some strains of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with ofloxacin, USP. Culture and susceptibility testing performed periodically during therapy will provide information not only on the therapeutic effect of the antimicrobial agent but also on the possible emergence of bacterial resistance. uuid:384b544b-e6fd-4d4a-99b6-336a82a5be91 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:131169 biolink:treats MONDO:0003864 PMID:41385096 "[{""id"":""uuid:2718f34d-832b-4418-a6d8-acece53dadc8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e88137bf-c0a0-4c31-816e-e6b9315049fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] COPIKTRA is a kinase inhibitor indicated for the treatment of adult patients with: Relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior therapies. ( 1.1 ). Relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. ( 1.2 ). This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. uuid:13bfdaeb-0e2c-4596-b44e-889adac75c5e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:131169 biolink:treats MONDO:0018906 PMID:41385096 "[{""id"":""uuid:496cd0af-fe71-473f-9b54-5e20402b6773"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:83d0a7e9-5811-41d9-8356-e1fbb0f0947b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:3451b460-5ca3-41b7-a1d9-c10a36050d0d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/copiktra""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] COPIKTRA is a kinase inhibitor indicated for the treatment of adult patients with: Relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior therapies. ( 1.1 ). Relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. ( 1.2 ). This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.|[EMA] Copiktra monotherapy is indicated for the treatment of adult patients with: Relapsed or refractory chronic lymphocytic leukaemia (CLL) after at least two prior therapies. Follicular lymphoma (FL) that is refractory to at least two prior systemic therapies. uuid:029b73be-9875-4bb7-aa35-f257f8f3fbd0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5280 biolink:treats MONDO:0005545 PMID:41385096 "[{""id"":""uuid:1dd3e051-9dd2-47b9-a7f6-e652734cf806"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:126d9239-c227-41c1-9b87-689b908b22cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gatifloxacin ophthalmic solution 0.5% is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: • Aerobic gram-positive bacteria Staphylococcus aureus Staphylococcus epidermidis Streptococcus mitis group * Streptococcus oralis * Streptococcus pneumoniae • Aerobic gram-negative bacteria Haemophilus influenzae * Efficacy for these organisms were studied in fewer than 10 infections. uuid:35edb485-5b48-4d09-a3e9-60da31c6ce60 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5280 biolink:treats UMLS:C3840159 PMID:41385096 "[{""id"":""uuid:3edbf9b1-1356-42d9-b0f4-78c2a22be14a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6f69c093-ddc0-4e20-a816-0b666c227c50"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gatifloxacin ophthalmic solution 0.5% is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: • Aerobic gram-positive bacteria Staphylococcus aureus Staphylococcus epidermidis Streptococcus mitis group * Streptococcus oralis * Streptococcus pneumoniae • Aerobic gram-negative bacteria Haemophilus influenzae * Efficacy for these organisms were studied in fewer than 10 infections. uuid:f62c189f-91f9-4bcc-9870-1b9285547e3d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5280 biolink:treats MONDO:0005114 PMID:41385096 "[{""id"":""uuid:9b9ed9cc-3758-44e0-8832-8deb7be65b84"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3a67f10d-5506-4582-8430-7485f2a8e87c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gatifloxacin ophthalmic solution 0.5% is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: • Aerobic gram-positive bacteria Staphylococcus aureus Staphylococcus epidermidis Streptococcus mitis group * Streptococcus oralis * Streptococcus pneumoniae • Aerobic gram-negative bacteria Haemophilus influenzae * Efficacy for these organisms were studied in fewer than 10 infections. uuid:be17ec5c-5439-4b12-ae90-a3326a23168e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27436 biolink:treats MONDO:0009420 PMID:41385096 "[{""id"":""uuid:0bcf8d47-f5a6-4a57-8d3b-ee8dfa87fb00"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8d86ce80-8879-4618-be5e-be5fe4707fa4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Males Androgens are indicated for replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired) — testicular failure due to cryptorchidism, bilateral torsions, orchitis, vanishing testis syndrome; or orchidectomy. Hypogonadotropic hypogonadism (congenital or acquired) — gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency, or pituitary hypothalamic injury from tumors, trauma, or radiation. (Appropriate adrenal cortical and thyroid hormone replacement therapy are still necessary, however, and are actually of primary importance.) If the above conditions occur prior to puberty, androgen replacement therapy will be needed during the adolescent years for development of secondary sexual characteristics. Prolonged androgen treatment will be required to maintain sexual characteristics in these and other males who develop testosterone deficiency after puberty. Safety and efficacy of methyltestosterone in men with “age-related hypogonadism” (also referred to as “late-onset hypogonadism”) have not been established. Androgens may be used to stimulate puberty in carefully selected males with clearly delayed puberty. These patients usually have a familial pattern of delayed puberty that is not secondary to a pathological disorder; puberty is expected to occur spontaneously at a relatively late date. Brief treatment with conservative doses may occasionally be justified in these patients if they do not respond to psychological support. The potential adverse effect on bone maturation should be discussed with the patient and parents prior to androgen administration. An X-ray of the hand and wrist to determine bone age should be obtained every 6 months to assess the effect of treatment on the epiphyseal centers (see WARNINGS ). 2. Females Androgens may be used secondarily in women with advancing inoperable metastatic (skeletal) mammary cancer who are 1 to 5 years postmenopausal. Primary goals of therapy in these women include ablation of the ovaries. Other methods of counteracting estrogen activity are adrenalectomy, hypophysectomy, and/or antiestrogen therapy. This treatment has also been used in premenopausal women with breast cancer who have benefitted from oophorectomy and are considered to have a hormone-responsive tumor. Judgment concerning androgen therapy should be made by an oncologist with expertise in this field. uuid:4fcb53b9-05d3-4ec4-a9c0-49749ece0866 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27436 biolink:treats MONDO:0023554 PMID:41385096 "[{""id"":""uuid:437818c1-f436-4bfe-b291-216e87c55378"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:76a8fe96-0cb7-4cfa-82a1-d513c4a5019c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Males Androgens are indicated for replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired) — testicular failure due to cryptorchidism, bilateral torsions, orchitis, vanishing testis syndrome; or orchidectomy. Hypogonadotropic hypogonadism (congenital or acquired) — gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency, or pituitary hypothalamic injury from tumors, trauma, or radiation. (Appropriate adrenal cortical and thyroid hormone replacement therapy are still necessary, however, and are actually of primary importance.) If the above conditions occur prior to puberty, androgen replacement therapy will be needed during the adolescent years for development of secondary sexual characteristics. Prolonged androgen treatment will be required to maintain sexual characteristics in these and other males who develop testosterone deficiency after puberty. Safety and efficacy of methyltestosterone in men with “age-related hypogonadism” (also referred to as “late-onset hypogonadism”) have not been established. Androgens may be used to stimulate puberty in carefully selected males with clearly delayed puberty. These patients usually have a familial pattern of delayed puberty that is not secondary to a pathological disorder; puberty is expected to occur spontaneously at a relatively late date. Brief treatment with conservative doses may occasionally be justified in these patients if they do not respond to psychological support. The potential adverse effect on bone maturation should be discussed with the patient and parents prior to androgen administration. An X-ray of the hand and wrist to determine bone age should be obtained every 6 months to assess the effect of treatment on the epiphyseal centers (see WARNINGS ). 2. Females Androgens may be used secondarily in women with advancing inoperable metastatic (skeletal) mammary cancer who are 1 to 5 years postmenopausal. Primary goals of therapy in these women include ablation of the ovaries. Other methods of counteracting estrogen activity are adrenalectomy, hypophysectomy, and/or antiestrogen therapy. This treatment has also been used in premenopausal women with breast cancer who have benefitted from oophorectomy and are considered to have a hormone-responsive tumor. Judgment concerning androgen therapy should be made by an oncologist with expertise in this field. uuid:fb8d6ce1-5bfe-45d9-9b56-3985fcde849f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27436 biolink:treats MONDO:0009047 PMID:41385096 "[{""id"":""uuid:18e4e89c-b92c-4f94-b3eb-68c8fe8c1ba6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ba59a22d-3a8d-4e03-92ac-6204c9aa022e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Males Androgens are indicated for replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired) — testicular failure due to cryptorchidism, bilateral torsions, orchitis, vanishing testis syndrome; or orchidectomy. Hypogonadotropic hypogonadism (congenital or acquired) — gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency, or pituitary hypothalamic injury from tumors, trauma, or radiation. (Appropriate adrenal cortical and thyroid hormone replacement therapy are still necessary, however, and are actually of primary importance.) If the above conditions occur prior to puberty, androgen replacement therapy will be needed during the adolescent years for development of secondary sexual characteristics. Prolonged androgen treatment will be required to maintain sexual characteristics in these and other males who develop testosterone deficiency after puberty. Safety and efficacy of methyltestosterone in men with “age-related hypogonadism” (also referred to as “late-onset hypogonadism”) have not been established. Androgens may be used to stimulate puberty in carefully selected males with clearly delayed puberty. These patients usually have a familial pattern of delayed puberty that is not secondary to a pathological disorder; puberty is expected to occur spontaneously at a relatively late date. Brief treatment with conservative doses may occasionally be justified in these patients if they do not respond to psychological support. The potential adverse effect on bone maturation should be discussed with the patient and parents prior to androgen administration. An X-ray of the hand and wrist to determine bone age should be obtained every 6 months to assess the effect of treatment on the epiphyseal centers (see WARNINGS ). 2. Females Androgens may be used secondarily in women with advancing inoperable metastatic (skeletal) mammary cancer who are 1 to 5 years postmenopausal. Primary goals of therapy in these women include ablation of the ovaries. Other methods of counteracting estrogen activity are adrenalectomy, hypophysectomy, and/or antiestrogen therapy. This treatment has also been used in premenopausal women with breast cancer who have benefitted from oophorectomy and are considered to have a hormone-responsive tumor. Judgment concerning androgen therapy should be made by an oncologist with expertise in this field. uuid:9a2a3304-f803-482c-990e-e4e8f9205218 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27436 biolink:treats MONDO:0006882 PMID:41385096 "[{""id"":""uuid:164178f2-c679-4206-8378-f1727396ff33"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:68054205-4ce8-440e-b350-54e7fffeeb0e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Males Androgens are indicated for replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired) — testicular failure due to cryptorchidism, bilateral torsions, orchitis, vanishing testis syndrome; or orchidectomy. Hypogonadotropic hypogonadism (congenital or acquired) — gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency, or pituitary hypothalamic injury from tumors, trauma, or radiation. (Appropriate adrenal cortical and thyroid hormone replacement therapy are still necessary, however, and are actually of primary importance.) If the above conditions occur prior to puberty, androgen replacement therapy will be needed during the adolescent years for development of secondary sexual characteristics. Prolonged androgen treatment will be required to maintain sexual characteristics in these and other males who develop testosterone deficiency after puberty. Safety and efficacy of methyltestosterone in men with “age-related hypogonadism” (also referred to as “late-onset hypogonadism”) have not been established. Androgens may be used to stimulate puberty in carefully selected males with clearly delayed puberty. These patients usually have a familial pattern of delayed puberty that is not secondary to a pathological disorder; puberty is expected to occur spontaneously at a relatively late date. Brief treatment with conservative doses may occasionally be justified in these patients if they do not respond to psychological support. The potential adverse effect on bone maturation should be discussed with the patient and parents prior to androgen administration. An X-ray of the hand and wrist to determine bone age should be obtained every 6 months to assess the effect of treatment on the epiphyseal centers (see WARNINGS ). 2. Females Androgens may be used secondarily in women with advancing inoperable metastatic (skeletal) mammary cancer who are 1 to 5 years postmenopausal. Primary goals of therapy in these women include ablation of the ovaries. Other methods of counteracting estrogen activity are adrenalectomy, hypophysectomy, and/or antiestrogen therapy. This treatment has also been used in premenopausal women with breast cancer who have benefitted from oophorectomy and are considered to have a hormone-responsive tumor. Judgment concerning androgen therapy should be made by an oncologist with expertise in this field. uuid:3f7ca56b-0abb-440d-a5f1-148f97f8bb2e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27436 biolink:treats MONDO:8000015 PMID:41385096 "[{""id"":""uuid:413dacda-5590-42cb-a582-2304d90c362e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c8ffc037-5b9c-45ab-ab49-990108760951"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Males Androgens are indicated for replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired) — testicular failure due to cryptorchidism, bilateral torsions, orchitis, vanishing testis syndrome; or orchidectomy. Hypogonadotropic hypogonadism (congenital or acquired) — gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency, or pituitary hypothalamic injury from tumors, trauma, or radiation. (Appropriate adrenal cortical and thyroid hormone replacement therapy are still necessary, however, and are actually of primary importance.) If the above conditions occur prior to puberty, androgen replacement therapy will be needed during the adolescent years for development of secondary sexual characteristics. Prolonged androgen treatment will be required to maintain sexual characteristics in these and other males who develop testosterone deficiency after puberty. Safety and efficacy of methyltestosterone in men with “age-related hypogonadism” (also referred to as “late-onset hypogonadism”) have not been established. Androgens may be used to stimulate puberty in carefully selected males with clearly delayed puberty. These patients usually have a familial pattern of delayed puberty that is not secondary to a pathological disorder; puberty is expected to occur spontaneously at a relatively late date. Brief treatment with conservative doses may occasionally be justified in these patients if they do not respond to psychological support. The potential adverse effect on bone maturation should be discussed with the patient and parents prior to androgen administration. An X-ray of the hand and wrist to determine bone age should be obtained every 6 months to assess the effect of treatment on the epiphyseal centers (see WARNINGS ). 2. Females Androgens may be used secondarily in women with advancing inoperable metastatic (skeletal) mammary cancer who are 1 to 5 years postmenopausal. Primary goals of therapy in these women include ablation of the ovaries. Other methods of counteracting estrogen activity are adrenalectomy, hypophysectomy, and/or antiestrogen therapy. This treatment has also been used in premenopausal women with breast cancer who have benefitted from oophorectomy and are considered to have a hormone-responsive tumor. Judgment concerning androgen therapy should be made by an oncologist with expertise in this field. uuid:4f5d34af-b073-4258-b9d5-3409da8f77ef biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27436 biolink:treats MONDO:0018555 PMID:41385096 "[{""id"":""uuid:9879e6e9-cb57-45c1-b82a-ecb34d034443"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:77c0f4b6-0176-4d70-a1d0-6972bcca7091"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Males Androgens are indicated for replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired) — testicular failure due to cryptorchidism, bilateral torsions, orchitis, vanishing testis syndrome; or orchidectomy. Hypogonadotropic hypogonadism (congenital or acquired) — gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency, or pituitary hypothalamic injury from tumors, trauma, or radiation. (Appropriate adrenal cortical and thyroid hormone replacement therapy are still necessary, however, and are actually of primary importance.) If the above conditions occur prior to puberty, androgen replacement therapy will be needed during the adolescent years for development of secondary sexual characteristics. Prolonged androgen treatment will be required to maintain sexual characteristics in these and other males who develop testosterone deficiency after puberty. Safety and efficacy of methyltestosterone in men with “age-related hypogonadism” (also referred to as “late-onset hypogonadism”) have not been established. Androgens may be used to stimulate puberty in carefully selected males with clearly delayed puberty. These patients usually have a familial pattern of delayed puberty that is not secondary to a pathological disorder; puberty is expected to occur spontaneously at a relatively late date. Brief treatment with conservative doses may occasionally be justified in these patients if they do not respond to psychological support. The potential adverse effect on bone maturation should be discussed with the patient and parents prior to androgen administration. An X-ray of the hand and wrist to determine bone age should be obtained every 6 months to assess the effect of treatment on the epiphyseal centers (see WARNINGS ). 2. Females Androgens may be used secondarily in women with advancing inoperable metastatic (skeletal) mammary cancer who are 1 to 5 years postmenopausal. Primary goals of therapy in these women include ablation of the ovaries. Other methods of counteracting estrogen activity are adrenalectomy, hypophysectomy, and/or antiestrogen therapy. This treatment has also been used in premenopausal women with breast cancer who have benefitted from oophorectomy and are considered to have a hormone-responsive tumor. Judgment concerning androgen therapy should be made by an oncologist with expertise in this field. uuid:8b47d6b4-0bcc-4eec-8c71-1edfde291d2a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27436 biolink:treats HP:0008213 PMID:41385096 "[{""id"":""uuid:cde44bb5-bb69-4775-8c2d-f0eaec9cf061"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:93d7b88e-8835-45e2-8196-888d7d55fe31"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Males Androgens are indicated for replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired) — testicular failure due to cryptorchidism, bilateral torsions, orchitis, vanishing testis syndrome; or orchidectomy. Hypogonadotropic hypogonadism (congenital or acquired) — gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency, or pituitary hypothalamic injury from tumors, trauma, or radiation. (Appropriate adrenal cortical and thyroid hormone replacement therapy are still necessary, however, and are actually of primary importance.) If the above conditions occur prior to puberty, androgen replacement therapy will be needed during the adolescent years for development of secondary sexual characteristics. Prolonged androgen treatment will be required to maintain sexual characteristics in these and other males who develop testosterone deficiency after puberty. Safety and efficacy of methyltestosterone in men with “age-related hypogonadism” (also referred to as “late-onset hypogonadism”) have not been established. Androgens may be used to stimulate puberty in carefully selected males with clearly delayed puberty. These patients usually have a familial pattern of delayed puberty that is not secondary to a pathological disorder; puberty is expected to occur spontaneously at a relatively late date. Brief treatment with conservative doses may occasionally be justified in these patients if they do not respond to psychological support. The potential adverse effect on bone maturation should be discussed with the patient and parents prior to androgen administration. An X-ray of the hand and wrist to determine bone age should be obtained every 6 months to assess the effect of treatment on the epiphyseal centers (see WARNINGS ). 2. Females Androgens may be used secondarily in women with advancing inoperable metastatic (skeletal) mammary cancer who are 1 to 5 years postmenopausal. Primary goals of therapy in these women include ablation of the ovaries. Other methods of counteracting estrogen activity are adrenalectomy, hypophysectomy, and/or antiestrogen therapy. This treatment has also been used in premenopausal women with breast cancer who have benefitted from oophorectomy and are considered to have a hormone-responsive tumor. Judgment concerning androgen therapy should be made by an oncologist with expertise in this field. uuid:dc073052-28a4-452c-8daf-f76fc482bd35 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27436 biolink:treats UMLS:C3714660 PMID:41385096 "[{""id"":""uuid:8562bfcf-0638-445a-b9aa-58d18fa6295d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cc8b303b-e3e0-4cc3-9a23-7857856c9262"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Males Androgens are indicated for replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired) — testicular failure due to cryptorchidism, bilateral torsions, orchitis, vanishing testis syndrome; or orchidectomy. Hypogonadotropic hypogonadism (congenital or acquired) — gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency, or pituitary hypothalamic injury from tumors, trauma, or radiation. (Appropriate adrenal cortical and thyroid hormone replacement therapy are still necessary, however, and are actually of primary importance.) If the above conditions occur prior to puberty, androgen replacement therapy will be needed during the adolescent years for development of secondary sexual characteristics. Prolonged androgen treatment will be required to maintain sexual characteristics in these and other males who develop testosterone deficiency after puberty. Safety and efficacy of methyltestosterone in men with “age-related hypogonadism” (also referred to as “late-onset hypogonadism”) have not been established. Androgens may be used to stimulate puberty in carefully selected males with clearly delayed puberty. These patients usually have a familial pattern of delayed puberty that is not secondary to a pathological disorder; puberty is expected to occur spontaneously at a relatively late date. Brief treatment with conservative doses may occasionally be justified in these patients if they do not respond to psychological support. The potential adverse effect on bone maturation should be discussed with the patient and parents prior to androgen administration. An X-ray of the hand and wrist to determine bone age should be obtained every 6 months to assess the effect of treatment on the epiphyseal centers (see WARNINGS ). 2. Females Androgens may be used secondarily in women with advancing inoperable metastatic (skeletal) mammary cancer who are 1 to 5 years postmenopausal. Primary goals of therapy in these women include ablation of the ovaries. Other methods of counteracting estrogen activity are adrenalectomy, hypophysectomy, and/or antiestrogen therapy. This treatment has also been used in premenopausal women with breast cancer who have benefitted from oophorectomy and are considered to have a hormone-responsive tumor. Judgment concerning androgen therapy should be made by an oncologist with expertise in this field. uuid:fe0bc934-f6ed-4fd2-a328-257ab7fe89a0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27436 biolink:treats MONDO:0043459 PMID:41385096 "[{""id"":""uuid:9df9faf3-9ec3-4d5f-90ee-2398d3c4cc9e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2e02d9d1-9d9a-4a74-94a0-df6f115efb8f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Males Androgens are indicated for replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired) — testicular failure due to cryptorchidism, bilateral torsions, orchitis, vanishing testis syndrome; or orchidectomy. Hypogonadotropic hypogonadism (congenital or acquired) — gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency, or pituitary hypothalamic injury from tumors, trauma, or radiation. (Appropriate adrenal cortical and thyroid hormone replacement therapy are still necessary, however, and are actually of primary importance.) If the above conditions occur prior to puberty, androgen replacement therapy will be needed during the adolescent years for development of secondary sexual characteristics. Prolonged androgen treatment will be required to maintain sexual characteristics in these and other males who develop testosterone deficiency after puberty. Safety and efficacy of methyltestosterone in men with “age-related hypogonadism” (also referred to as “late-onset hypogonadism”) have not been established. Androgens may be used to stimulate puberty in carefully selected males with clearly delayed puberty. These patients usually have a familial pattern of delayed puberty that is not secondary to a pathological disorder; puberty is expected to occur spontaneously at a relatively late date. Brief treatment with conservative doses may occasionally be justified in these patients if they do not respond to psychological support. The potential adverse effect on bone maturation should be discussed with the patient and parents prior to androgen administration. An X-ray of the hand and wrist to determine bone age should be obtained every 6 months to assess the effect of treatment on the epiphyseal centers (see WARNINGS ). 2. Females Androgens may be used secondarily in women with advancing inoperable metastatic (skeletal) mammary cancer who are 1 to 5 years postmenopausal. Primary goals of therapy in these women include ablation of the ovaries. Other methods of counteracting estrogen activity are adrenalectomy, hypophysectomy, and/or antiestrogen therapy. This treatment has also been used in premenopausal women with breast cancer who have benefitted from oophorectomy and are considered to have a hormone-responsive tumor. Judgment concerning androgen therapy should be made by an oncologist with expertise in this field. uuid:d8ecbc89-4e68-4b71-b88c-1ccd441205a5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27436 biolink:treats HP:0000823 PMID:41385096 "[{""id"":""uuid:bdc7a7d3-d34d-4caa-9e73-ea8384edabbf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:42d2ca2e-48ad-498f-8dfd-6ca3cdc75219"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Males Androgens are indicated for replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired) — testicular failure due to cryptorchidism, bilateral torsions, orchitis, vanishing testis syndrome; or orchidectomy. Hypogonadotropic hypogonadism (congenital or acquired) — gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency, or pituitary hypothalamic injury from tumors, trauma, or radiation. (Appropriate adrenal cortical and thyroid hormone replacement therapy are still necessary, however, and are actually of primary importance.) If the above conditions occur prior to puberty, androgen replacement therapy will be needed during the adolescent years for development of secondary sexual characteristics. Prolonged androgen treatment will be required to maintain sexual characteristics in these and other males who develop testosterone deficiency after puberty. Safety and efficacy of methyltestosterone in men with “age-related hypogonadism” (also referred to as “late-onset hypogonadism”) have not been established. Androgens may be used to stimulate puberty in carefully selected males with clearly delayed puberty. These patients usually have a familial pattern of delayed puberty that is not secondary to a pathological disorder; puberty is expected to occur spontaneously at a relatively late date. Brief treatment with conservative doses may occasionally be justified in these patients if they do not respond to psychological support. The potential adverse effect on bone maturation should be discussed with the patient and parents prior to androgen administration. An X-ray of the hand and wrist to determine bone age should be obtained every 6 months to assess the effect of treatment on the epiphyseal centers (see WARNINGS ). 2. Females Androgens may be used secondarily in women with advancing inoperable metastatic (skeletal) mammary cancer who are 1 to 5 years postmenopausal. Primary goals of therapy in these women include ablation of the ovaries. Other methods of counteracting estrogen activity are adrenalectomy, hypophysectomy, and/or antiestrogen therapy. This treatment has also been used in premenopausal women with breast cancer who have benefitted from oophorectomy and are considered to have a hormone-responsive tumor. Judgment concerning androgen therapy should be made by an oncologist with expertise in this field. uuid:617a1f33-a871-46cc-947d-6ba66eca76b4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27436 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:25b80676-3329-4b32-b32d-af878033a286"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d42a5cec-f932-46ba-9feb-6f978e94c221"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Males Androgens are indicated for replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired) — testicular failure due to cryptorchidism, bilateral torsions, orchitis, vanishing testis syndrome; or orchidectomy. Hypogonadotropic hypogonadism (congenital or acquired) — gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency, or pituitary hypothalamic injury from tumors, trauma, or radiation. (Appropriate adrenal cortical and thyroid hormone replacement therapy are still necessary, however, and are actually of primary importance.) If the above conditions occur prior to puberty, androgen replacement therapy will be needed during the adolescent years for development of secondary sexual characteristics. Prolonged androgen treatment will be required to maintain sexual characteristics in these and other males who develop testosterone deficiency after puberty. Safety and efficacy of methyltestosterone in men with “age-related hypogonadism” (also referred to as “late-onset hypogonadism”) have not been established. Androgens may be used to stimulate puberty in carefully selected males with clearly delayed puberty. These patients usually have a familial pattern of delayed puberty that is not secondary to a pathological disorder; puberty is expected to occur spontaneously at a relatively late date. Brief treatment with conservative doses may occasionally be justified in these patients if they do not respond to psychological support. The potential adverse effect on bone maturation should be discussed with the patient and parents prior to androgen administration. An X-ray of the hand and wrist to determine bone age should be obtained every 6 months to assess the effect of treatment on the epiphyseal centers (see WARNINGS ). 2. Females Androgens may be used secondarily in women with advancing inoperable metastatic (skeletal) mammary cancer who are 1 to 5 years postmenopausal. Primary goals of therapy in these women include ablation of the ovaries. Other methods of counteracting estrogen activity are adrenalectomy, hypophysectomy, and/or antiestrogen therapy. This treatment has also been used in premenopausal women with breast cancer who have benefitted from oophorectomy and are considered to have a hormone-responsive tumor. Judgment concerning androgen therapy should be made by an oncologist with expertise in this field. uuid:857d565c-3f89-4319-8cb3-88de04b687d8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46195 biolink:treats MONDO:0005578 PMID:41385096 "[{""id"":""uuid:bf75cc7f-3090-4255-9914-0019b687eea2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3f73db1a-ce34-4399-a542-7a5fbb5929bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] • temporarily relieves minor aches and pains due to: • minor pain of arthritis • muscular aches • backache • premenstrual and menstrual cramps • the common cold • headache • toothache • temporarily reduces fever uuid:1d428c48-e084-4968-8a99-3ef02528db90 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46195 biolink:treats HP:0003326 PMID:41385096 "[{""id"":""uuid:b2c7d60e-61b6-417f-95ec-4d416081c4ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ec457a11-ce77-4793-822f-da5791373ab9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] • temporarily relieves minor aches and pains due to: • minor pain of arthritis • muscular aches • backache • premenstrual and menstrual cramps • the common cold • headache • toothache • temporarily reduces fever uuid:6393db57-4b62-46ff-9a56-d5cbe3dc43b6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46195 biolink:treats HP:0003418 PMID:41385096 "[{""id"":""uuid:c9c06f8b-89ea-4ad3-8c98-c1a64b9b1b7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ad210c47-c8d6-4dd6-ac43-a151bfc7e663"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] • temporarily relieves minor aches and pains due to: • minor pain of arthritis • muscular aches • backache • premenstrual and menstrual cramps • the common cold • headache • toothache • temporarily reduces fever uuid:77460666-e993-41b6-b4f5-ab1cbd63f9e4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46195 biolink:treats UMLS:C1698508 PMID:41385096 "[{""id"":""uuid:822dc687-a20f-43e5-97c8-cce10c0f3ba8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:38fce4a2-29dd-49ff-acb9-46fa61dddc81"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] • temporarily relieves minor aches and pains due to: • minor pain of arthritis • muscular aches • backache • premenstrual and menstrual cramps • the common cold • headache • toothache • temporarily reduces fever uuid:bdc423d1-ad77-4f69-bacb-6abf2dbd9f47 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46195 biolink:treats HP:0100607 PMID:41385096 "[{""id"":""uuid:54ca6928-0e5a-4dae-8b9d-105ce1cfa172"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:51d284a0-7f84-46c3-85d4-83650d7f4ca8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] • temporarily relieves minor aches and pains due to: • minor pain of arthritis • muscular aches • backache • premenstrual and menstrual cramps • the common cold • headache • toothache • temporarily reduces fever uuid:11d546f8-6d14-4383-860c-8e1cd0e90513 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46195 biolink:treats MONDO:0005709 PMID:41385096 "[{""id"":""uuid:dd57711b-41d5-434b-9e86-7172c3a5e7e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7194f192-160f-4beb-9529-eae18f02f1ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] • temporarily relieves minor aches and pains due to: • minor pain of arthritis • muscular aches • backache • premenstrual and menstrual cramps • the common cold • headache • toothache • temporarily reduces fever uuid:f7e1fabc-b341-4443-8dff-065804443b2f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46195 biolink:treats HP:0002315 PMID:41385096 "[{""id"":""uuid:f9a80496-5da1-41d0-adf0-95f50c424681"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cfb1f9f7-32de-4bf8-99f5-bff195a69b3d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] • temporarily relieves minor aches and pains due to: • minor pain of arthritis • muscular aches • backache • premenstrual and menstrual cramps • the common cold • headache • toothache • temporarily reduces fever uuid:4e0b0391-b19f-457d-9b9c-22decf1183c1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46195 biolink:treats EFO:0010072 PMID:41385096 "[{""id"":""uuid:98646826-11f6-4ffc-9ba7-7410899ed5c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9fd76d7e-5b24-4d30-acd2-4d48f22c7fd0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] • temporarily relieves minor aches and pains due to: • minor pain of arthritis • muscular aches • backache • premenstrual and menstrual cramps • the common cold • headache • toothache • temporarily reduces fever uuid:338fc010-68e8-4387-a201-9fbc9eb9947a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:48538 biolink:treats MONDO:0005180 PMID:41385096 "[{""id"":""uuid:d2240cdb-a5e9-4a30-8ec9-fd1c255eafce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fb094352-86bf-4807-b0ef-9bb5d55c00a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Apomorphine hydrochloride injection is indicated for the acute, intermittent treatment of hypomobility, ""off"" episodes (""end-of-dose wearing off"" and unpredictable ""on/off"" episodes) in patients with advanced Parkinson's disease. Apomorphine hydrocloride inejction has been studied as an adjunct to other medications [see Clinical Studies (14) ] ." uuid:8bf2bd43-60dc-4e44-8f51-e344feb10949 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:48538 biolink:treats UMLS:C0391852 PMID:41385096 "[{""id"":""uuid:f10ee762-f9b0-4646-b074-f7a05d42a33d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:10920cb6-d81f-424c-9376-4278ab33039c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Apomorphine hydrochloride injection is indicated for the acute, intermittent treatment of hypomobility, ""off"" episodes (""end-of-dose wearing off"" and unpredictable ""on/off"" episodes) in patients with advanced Parkinson's disease. Apomorphine hydrocloride inejction has been studied as an adjunct to other medications [see Clinical Studies (14) ] ." uuid:f9fa9989-f69d-4f88-a0d3-e46b6118e946 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:48538 biolink:treats UMLS:C5681154 PMID:41385096 "[{""id"":""uuid:eacb6e58-cb55-40ab-b2e1-970b25456698"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ef5c9c4f-8e61-4653-a038-7651ea265d8c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Apomorphine hydrochloride injection is indicated for the acute, intermittent treatment of hypomobility, ""off"" episodes (""end-of-dose wearing off"" and unpredictable ""on/off"" episodes) in patients with advanced Parkinson's disease. Apomorphine hydrocloride inejction has been studied as an adjunct to other medications [see Clinical Studies (14) ] ." uuid:abc55d24-967f-4088-ab74-5f4d8b3e0bd3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:48538 biolink:treats UMLS:C1504539 PMID:41385096 "[{""id"":""uuid:5a6ef8d8-527b-4029-bdcb-8df43c6bfe15"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5b0504ae-d1c2-4b9a-b52f-5e9f0f524d85"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Apomorphine hydrochloride injection is indicated for the acute, intermittent treatment of hypomobility, ""off"" episodes (""end-of-dose wearing off"" and unpredictable ""on/off"" episodes) in patients with advanced Parkinson's disease. Apomorphine hydrocloride inejction has been studied as an adjunct to other medications [see Clinical Studies (14) ] ." uuid:cae7f87a-b9be-47e7-bf97-37c93b740ca9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4562 biolink:treats MONDO:0005277 PMID:41385096 "[{""id"":""uuid:7e4e4630-cccb-4e8b-95f2-c050696d47c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8a9f856f-5c6b-47cb-95fe-5b7c7b76c5aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dihydroergotamine Mesylate Injection, USP is indicated for the acute treatment of migraine headaches with or without aura and the acute treatment of cluster headache episodes. uuid:27c5d492-0bd7-4915-b059-ebfac0573b77 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4562 biolink:treats MONDO:0043537 PMID:41385096 "[{""id"":""uuid:b53e31be-0093-4dc3-91d2-79201e1dc419"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7ace457a-4f35-4045-9b85-325782b928bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dihydroergotamine Mesylate Injection, USP is indicated for the acute treatment of migraine headaches with or without aura and the acute treatment of cluster headache episodes. uuid:2eea7274-5a4a-408c-8e7d-7eb7fe44fa24 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0000004 PMID:41385096 "[{""id"":""uuid:758963f5-4c16-47a1-a6b0-63c4aacc9ecd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cdefe6b2-75a3-4990-9d96-27f8c8895180"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:ffb768d9-9310-49c2-b86c-f59e372c03be biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0019801 PMID:41385096 "[{""id"":""uuid:90a44efa-f303-47da-bc73-3883fc3ce150"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a46777e9-8d28-4c47-b766-4f6b01b4fbbc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:e3d78025-26c4-430e-a38b-4aaa0fb598c8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0018479 PMID:41385096 "[{""id"":""uuid:fc2986ee-0250-4713-ac6e-314fae49fb17"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7ab0cbcf-c622-49ff-95ad-d4b0892b7e04"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:5e6fc1af-358b-41e0-8aca-97473d287d2e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0043455 PMID:41385096 "[{""id"":""uuid:84392410-6bda-437a-950e-8e2c8a5b5b82"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4ef1f103-fd64-4293-aef3-ab1e81f54174"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:e3288e33-023b-4833-b2dc-7563cbf6899a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0005178 PMID:41385096 "[{""id"":""uuid:7353eb52-6f2c-46f2-9f0f-4d73f3a7d103"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8f9d8ecb-546b-4641-9f22-09424a77d385"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:5e5da985-5392-4636-8844-0b0af306624d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:813689a1-75af-417d-b5a1-d9fa4b71d081"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6bcc4c43-8e5e-4589-bb51-cba7bee7519f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:ce6dfaab-8849-4c3b-888a-538ddbb6d62a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0011429 PMID:41385096 "[{""id"":""uuid:5ff1ff1d-9cca-4107-8271-0aa1402f6ec2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c22e2f8b-24cd-4a7b-bd12-e316b80d9df3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:0ca9ee39-2c7c-409f-8c32-f53fc0e1e8cb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0040698 PMID:41385096 "[{""id"":""uuid:2344934f-86d6-4f29-936f-8d67c444c43f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aa3ff11e-9ff6-4e5c-81cd-5aa08d28eade"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:4085c8ad-7430-461d-ad8a-cb86fe3204d7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0001875 PMID:41385096 "[{""id"":""uuid:fd439be7-dc75-4bd0-9b7b-ae4bfaa23b3a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8f47b590-3ff1-4606-9da7-cc0ff542a63b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:ae7c9365-4e73-4365-a64b-f15e75f73d8f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0004855 PMID:41385096 "[{""id"":""uuid:598da9e7-650e-4760-93be-9dadcc24714b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:428724ec-dfb7-466e-baf1-412d48bd1b76"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:da2377cf-c28d-4dba-a246-5148cb397aae biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats UMLS:C0149896 PMID:41385096 "[{""id"":""uuid:e7a030ee-4b5b-402c-a950-98a951322fc3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:85214939-3f66-4ebd-b5a5-390c961d2ba5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:213a00f3-5865-4492-9cde-17e4cc3d048c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0011849 PMID:41385096 "[{""id"":""uuid:5c8e3ddd-cbe8-44ee-99d6-1e75a0a59ccf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:913f57e9-5c33-4531-8f79-a96c2fc58592"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:5c71d6e7-c80b-4684-9662-8a2907cd619c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0005306 PMID:41385096 "[{""id"":""uuid:12a1f0fb-490b-4079-aa58-085091533348"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:85bdb06e-0c0e-47d1-a372-4b942ed2ea83"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:028211d4-76d6-4126-acd1-994b3359059b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats UMLS:C5441648 PMID:41385096 "[{""id"":""uuid:8a5cf699-535c-4a22-ada4-0303352773f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e83783b1-d9ea-48db-919a-19cd8003ad5a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:f674ce7b-f38e-4931-805e-9cac18e26c72 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0006594 PMID:41385096 "[{""id"":""uuid:956f6eee-52f3-485a-91d8-8417ff6fa62f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1bb0f41e-eb65-407b-b084-0b667a271df7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:750dfd0d-4ea7-4251-aa46-5c7c990a944b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0006545 PMID:41385096 "[{""id"":""uuid:1469b940-2bdc-48e1-8354-6063016c01de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a53e1371-51af-4e95-9778-99e672961798"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:066614b6-97b9-4560-941e-44f848d97a02 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0018229 PMID:41385096 "[{""id"":""uuid:dc444bcd-aeca-47ad-87dd-a8d5d5a693aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:63200148-458f-47ba-8ec1-11590522cd5f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:9cafc286-988c-45d9-b068-3e39d8d1c39c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0043233 PMID:41385096 "[{""id"":""uuid:26f4dfb0-a7d4-44c6-9dc8-6d0ace67588e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2274ccc4-ef94-4620-a38d-ea621b48e4da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:7532311a-ca05-4a2a-9fae-3b291c51ef39 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0015614 PMID:41385096 "[{""id"":""uuid:ec007d37-dbbe-4346-bc25-3281563a3fe3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9f2aa419-f2da-4560-8933-3e487972ad2f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:1f1affc9-d672-4a1e-aa2d-e4b90bb18ef4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0006608 PMID:41385096 "[{""id"":""uuid:f27972d5-4823-4b4d-b86d-a9f8dc062f38"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:29f57c3f-2753-440d-9021-a3eddbcaa104"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:42d7f989-a24b-4365-9d23-ab73d185749f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0005083 PMID:41385096 "[{""id"":""uuid:cf631f58-4fe3-4449-987e-1e1ee205fd1f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:169cb754-947a-4eb6-bd80-e6a400786604"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:519afb0b-0f12-45a0-bb7d-bc62410dfc3a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0009691 PMID:41385096 "[{""id"":""uuid:5fc7c00a-7037-45a0-adc5-0e6e1aac9445"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a19ec5f2-6ff3-4461-a88c-1d083d1a74f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:a4fa03b1-6bc6-4cd5-901c-39c220c83115 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:2b5ff0a5-d7c7-4854-a88b-678abb67f0ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:34fd048b-7a32-4e42-b89a-5273025e4c68"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:0559ec20-0995-4fc2-bd16-8f58361d4f1e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0005480 PMID:41385096 "[{""id"":""uuid:10e5f63f-cdc1-4884-a710-8ff5f28e5ecb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:894d5ab6-09f9-40f2-9555-1770d25c111d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:16d3bbae-4bfb-4c87-a02a-c55aae42d970 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:8c3b4954-096b-4cff-baa0-02cc01f3d851"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:42868a52-2da6-4713-ae71-8051080ce18f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:98dc618a-f93a-4479-b9fe-345538625304 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0043789 PMID:41385096 "[{""id"":""uuid:51146c59-a7e8-4448-a4c2-abbe2adefcfc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:414b911c-fa50-40b4-9377-c77c4c7faac5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:cd0b58ef-e98c-4a0d-892a-2e22114e7662 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0011786 PMID:41385096 "[{""id"":""uuid:cccd64ba-d004-45d9-9696-ff2ef593f8e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6c24aa6b-2baf-463d-b646-61f2607460a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:d725a3b5-fd2f-48c6-afcc-9ab4db5266bc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0000775 PMID:41385096 "[{""id"":""uuid:31969e27-69f4-413e-81e8-74e1f110bc94"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7ce33912-eea4-4511-b181-0a1bd85fba25"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:e6d793a4-f957-494c-9cff-17f673672484 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats UMLS:C0274440 PMID:41385096 "[{""id"":""uuid:aa2fe2ce-b54d-492e-9377-1e868ed09a6c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:385d47c2-852d-4f1b-8214-28377ae94a24"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:85dbb645-4272-4d7a-be3c-cd8aeebbbcd5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0005883 PMID:41385096 "[{""id"":""uuid:a75bac30-145f-4340-b344-16daea320abc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:38e93815-921c-48e5-802a-4e08bb4c9db5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:c066a590-0d75-454a-8870-7e30e6c8b6d3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0006814 PMID:41385096 "[{""id"":""uuid:0d9af5e6-73e5-4a99-8887-6829e63da87d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fc92e969-1fd1-44cf-80dc-cf3ee2b13948"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:db19b2eb-8117-4938-b3c4-107beac79fed biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0004773 PMID:41385096 "[{""id"":""uuid:3e72bb6f-4eb4-4a9a-ba16-f67d6f1ad6ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:972241f1-b80b-4e6f-902c-d261303ca11f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:0b54865b-6d6e-463e-b01b-a0a5d2e830b0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0004674 PMID:41385096 "[{""id"":""uuid:d96a3e37-0816-4fba-bef5-6999a582afd8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b77ea4ab-3d4f-4652-a04d-8e522bdbd7c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:7ed26c4d-5841-49fb-a670-19222293fe93 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0005885 PMID:41385096 "[{""id"":""uuid:ac32161c-0333-498e-93c7-88cd9c453f09"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:52f93389-d16e-4978-a228-13b917ad4f6b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:511f4195-c23e-4016-a2ae-6fd8bdc9d050 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0019198 PMID:41385096 "[{""id"":""uuid:357b780b-5fc6-4a6d-9632-1441ab2b41d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6f344d90-b21a-4ce1-b748-9e47b0e524eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:922e8616-a461-4998-ae2b-56e25c715806 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0006651 PMID:41385096 "[{""id"":""uuid:9bf5892d-ce0a-490b-9762-0096e4c4d556"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4120df9b-d7d4-4844-abfa-21e1126584a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:16f3ec23-84b1-4685-9605-69161b15a322 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0003085 PMID:41385096 "[{""id"":""uuid:1bbde50e-642c-4b4f-8149-39eb4dd634df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5fcc58b4-cdf3-44f9-ba0c-9e111e755f88"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:1381c295-3607-4249-9e30-dd8e163329cc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0001034 PMID:41385096 "[{""id"":""uuid:61a10616-6107-4ab0-9214-6027735cf65c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:25b3fd19-4320-4dc7-927b-f8984ae4baf5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:99ef3c81-1de5-46eb-9754-08ea446a4420 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0005101 PMID:41385096 "[{""id"":""uuid:d6c08e12-57a0-4578-aac5-40bdfa1e6f9c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4502918a-a306-419e-b533-452d4b7d7f26"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:b833f591-bc45-4cdb-abc9-ff3a73e4ec84 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats UMLS:C0678202 PMID:41385096 "[{""id"":""uuid:3fe57682-16bf-4ea4-b526-192a6f87be3e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:af8d6890-e587-45a3-b5a9-d6db39172b54"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:6eb502c0-ec2c-417e-9a95-1f3d99d393be biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0019338 PMID:41385096 "[{""id"":""uuid:a35e0d01-d48f-46d8-8b27-0df7946cefe1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:adcde411-db35-4a74-bc04-d896d1315f21"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:190e64c7-4e87-470c-b096-21fe37f3b068 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0015274 PMID:41385096 "[{""id"":""uuid:89bea046-34fb-481c-ba60-639251286679"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e7953e7f-26b8-40c9-a250-a0fcc897054f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:cdc80322-e943-4646-a637-63138685cea7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0006052 PMID:41385096 "[{""id"":""uuid:7ec2bc65-f2eb-40d1-98eb-103a94846216"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a721cdc8-109d-4345-9524-0ddc6c6cc8db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:d0041abe-b186-47fa-825a-69f45d306d50 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0005848 PMID:41385096 "[{""id"":""uuid:dcecd759-d86c-45ba-9993-8cfe77f95bc0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f93cf68b-a5d7-4486-95de-537845f1e496"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:0c285ea5-de73-4333-9f8b-f2043d7515f5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0002572 PMID:41385096 "[{""id"":""uuid:b3fb03df-3c61-4051-b618-c900fff64c23"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5eb771e0-bcc0-4ddc-9088-6e08b411e409"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:e147ca03-adeb-4fe0-a10c-9b81f93f2522 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats UMLS:C0002879 PMID:41385096 "[{""id"":""uuid:2214bb27-e5c5-4aa8-bb1e-8b60ad87440c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:be44db21-f82c-4f4b-9bb6-ab5a4d4ff7bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:ba6cc195-e842-40ac-b075-17f5b5f3bbce biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0020108 PMID:41385096 "[{""id"":""uuid:aea5fb44-5cb6-4e9d-a18c-70ba3a0f3b91"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b362584c-f761-4c73-9813-7b134af5a2f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:c58dda69-0ed4-495d-a895-5cbf24e585cc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0019098 PMID:41385096 "[{""id"":""uuid:60848c73-fb59-4e20-b0dd-de8b318d1c57"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:266c0288-f71a-4e36-94b8-c12e32a92282"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:6067791b-32d2-40b2-81dd-9f1a898c67ad biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0001198 PMID:41385096 "[{""id"":""uuid:dfae5d78-8de9-4e2e-be27-865a8f01d796"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6daddec0-d5ed-4a82-8611-6841d136f59e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:0cc22fcc-35bc-4b3a-b67f-3ca703b67743 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0002280 PMID:41385096 "[{""id"":""uuid:7e5fa9c7-8986-466c-8d73-5a31bd90469b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:48e0b12c-ac69-4bbc-92eb-1cf357714f0b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:ce1a6b91-043a-4209-b37a-ed6ecb172030 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0015253 PMID:41385096 "[{""id"":""uuid:b90a0fd4-46be-4dda-8f53-e3a71eef6587"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:61f8ec50-6693-4ce8-9986-24eee87f1217"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:f3044614-4f5f-44c7-b39a-c945e25beda9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats HP:0001908 PMID:41385096 "[{""id"":""uuid:d121b779-5d4b-4f75-8b1b-40233cd5dafb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e06b98d4-2f7d-4e00-9957-710b2525f607"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:2da5d1c3-5e1b-4749-a33d-d7528be03919 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0005059 PMID:41385096 "[{""id"":""uuid:1f65b912-37bb-4d67-8b27-1dbfd61f68dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b67c9e83-2fa8-40f0-8106-42565a2b94d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:4593753d-9190-4d66-829b-f5b542f9168c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0004095 PMID:41385096 "[{""id"":""uuid:85afddf6-7e24-41f5-8e7d-72a137cca082"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b6dcc41a-3913-4f1e-b52b-2c0a1d30fedd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:3f9a1a8a-b3de-4101-ac8e-ee380399d509 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0004355 PMID:41385096 "[{""id"":""uuid:e873c701-bb52-406c-834e-b9c703e6ceff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3c9c7e0e-8c48-4af9-b93d-00ac32b8c0b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:4aaf53da-d582-4add-b4f9-c5c16e80d58e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0005377 PMID:41385096 "[{""id"":""uuid:6e7dcb5f-3f36-45c6-897f-42e31a76839f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7aae2ec6-2b26-4c5c-8a04-9832e15072ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:4aa3869b-91c5-4e98-9651-8ae4863edada biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0006042 PMID:41385096 "[{""id"":""uuid:918aead3-a0d9-4cf1-b454-439b36d8647a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9fa5c4fd-141a-4ac3-a9ad-3e3c345d28c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:0040fd78-8bff-4676-8cef-68e304e0331b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0019444 PMID:41385096 "[{""id"":""uuid:d1710a7e-8a64-4bfe-9e9d-de97c62f05a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:51096d4f-06a0-4989-874d-60630ac4e382"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:b590615f-e04c-4240-aeef-e41e57c5b837 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0006684 PMID:41385096 "[{""id"":""uuid:03281f8b-5cf9-42a4-9f75-3ef6f50bb960"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e7320b35-e6ce-4e58-aaa3-58fd44b5f6b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:f4a7429d-68f9-4583-a6dc-55cdafacd76a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1155345 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:29cd5b4e-4473-4802-a9bb-6fe8848cd2df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:30d64bca-a03e-4754-bed5-2991af076fcf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lidocaine HCI 2% Jelly is indicated for prevention and control of pain in procedures involving the male and female urethra, for topical treatment of painful urethritis, and as an anesthetic lubricant for endotracheal intubation (oral and nasal). uuid:575d428b-54be-405e-a412-4113c683ed11 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1155345 biolink:treats MONDO:0005297 PMID:41385096 "[{""id"":""uuid:5ea911f3-87ff-469a-8a8e-f0e2621f67c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:41c9a6c4-ca90-4ff8-94ba-13787b06501e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lidocaine HCI 2% Jelly is indicated for prevention and control of pain in procedures involving the male and female urethra, for topical treatment of painful urethritis, and as an anesthetic lubricant for endotracheal intubation (oral and nasal). uuid:3d495b0b-c6dc-43a3-a241-41c783ed5c85 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9241 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:743e7369-87fd-4c5b-9e06-b0b2e39efa45"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f78e1692-708e-413d-b6fa-dbd41d84f6ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Heart Failure Spironolactone tablets are indicated for treatment of NYHA Class III–IV heart failure and reduced ejection fraction to increase survival, manage edema, and reduce the need for hospitalization for heart failure. Spironolactone tablets are usually administered in conjunction with other heart failure therapies. 1.2 Hypertension Spironolactone tablets are indicated as add-on therapy for the treatment of hypertension, to lower blood pressure in patients who are not adequately controlled on other agents. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. 1.3 Edema Associated with Hepatic Cirrhosis or Nephrotic Syndrome Spironolactone tablets are indicated for the management of edema in the following settings: Cirrhosis of the liver when edema is not responsive to fluid and sodium restriction. Nephrotic syndrome when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics produce an inadequate response. Because it increases serum potassium, spironolactone tablets may be useful for treating edema when administration of other diuretics has caused hypokalemia. 1.4 Primary Hyperaldosteronism Spironolactone tablets are indicated in the following settings: Short-term preoperative treatment of patients with primary hyperaldosteronism. Long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are not candidates for surgery. Long-term maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). uuid:42f60b5d-8a5a-42e9-ab0e-6240f06c496e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9241 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:efbfecb3-b7a4-4361-b730-f2aa2bf5659c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5fedea78-4234-44e2-ad1b-a16ca640a1aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Heart Failure Spironolactone tablets are indicated for treatment of NYHA Class III–IV heart failure and reduced ejection fraction to increase survival, manage edema, and reduce the need for hospitalization for heart failure. Spironolactone tablets are usually administered in conjunction with other heart failure therapies. 1.2 Hypertension Spironolactone tablets are indicated as add-on therapy for the treatment of hypertension, to lower blood pressure in patients who are not adequately controlled on other agents. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. 1.3 Edema Associated with Hepatic Cirrhosis or Nephrotic Syndrome Spironolactone tablets are indicated for the management of edema in the following settings: Cirrhosis of the liver when edema is not responsive to fluid and sodium restriction. Nephrotic syndrome when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics produce an inadequate response. Because it increases serum potassium, spironolactone tablets may be useful for treating edema when administration of other diuretics has caused hypokalemia. 1.4 Primary Hyperaldosteronism Spironolactone tablets are indicated in the following settings: Short-term preoperative treatment of patients with primary hyperaldosteronism. Long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are not candidates for surgery. Long-term maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). uuid:8949ba5c-ca94-4d4a-9ce8-239205e38c15 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15407 biolink:treats MONDO:0005468 PMID:41385096 "[{""id"":""uuid:478acd14-3967-42b7-a4b4-a875a83b11c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ea4c03bb-78d4-41c7-95be-9f524efba5aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:bb909ee1-63e0-4426-98bc-fa98fe47e807"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ephedrine sulfate injection is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia.|[PMDA] Drugs with a new indication and route of administration, or the intravenous route for the treatment of hypotension occurring during anesthesia,G20 and without intramuscular injection administered for their approved indications. uuid:70365057-b858-4f01-ab82-8c9e59e80d8f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DQ448MW7KS biolink:treats MONDO:0000270 PMID:41385096 "[{""id"":""uuid:57191fe6-9cde-448e-9d1c-ced0faf4cb61"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cc85a549-f9e1-40c4-a106-5f4fa80e7e15"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Synagis is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients: with a history of premature birth (less than or equal to 35 weeks gestational age) and who are 6 months of age or younger at the beginning of RSV season, with bronchopulmonary dysplasia (BPD) that required medical treatment within the previous 6 months and who are 24 months of age or younger at the beginning of RSV season, with hemodynamically significant congenital heart disease (CHD) and who are 24 months of age or younger at the beginning of RSV season [see Clinical Studies ( 14 ) ]. uuid:d4578645-5cc8-44d9-bc65-7419e9126ce8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DQ448MW7KS biolink:treats MONDO:0019091 PMID:41385096 "[{""id"":""uuid:23503ef9-7436-4972-b845-e03e5fefad89"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:65354970-2435-4e94-95f3-7fe01be255a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:8e44f9dc-f075-4012-856b-343c3d8019f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/synagis""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Synagis is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients: with a history of premature birth (less than or equal to 35 weeks gestational age) and who are 6 months of age or younger at the beginning of RSV season, with bronchopulmonary dysplasia (BPD) that required medical treatment within the previous 6 months and who are 24 months of age or younger at the beginning of RSV season, with hemodynamically significant congenital heart disease (CHD) and who are 24 months of age or younger at the beginning of RSV season [see Clinical Studies ( 14 ) ].|[EMA] Synagis is indicated for the prevention of serious lower-respiratory-tract disease requiring hospitalisation caused by respiratory syncytial virus (RSV) in children at high risk for RSV disease:children born at 35 weeks of gestation or less and less than six months of age at the onset of the RSV season;children less than two years of age and requiring treatment for bronchopulmonary dysplasia within the last six months;children less than two years of age and with haemodynamically significant congenital heart disease. uuid:336c8e5f-3b6d-4b31-b3f4-b2a3db6ce543 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DQ448MW7KS biolink:treats MONDO:0005453 PMID:41385096 "[{""id"":""uuid:883e275f-b3b6-4c53-b36b-8fee7ab0fff2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8969bbdc-1576-4322-90b6-979d8ca7391e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:63c20eae-381b-4dbb-9619-c103710021dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/synagis""]},{""id"":""uuid:58173e28-a87d-42cc-8ed4-474831957806"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Synagis is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients: with a history of premature birth (less than or equal to 35 weeks gestational age) and who are 6 months of age or younger at the beginning of RSV season, with bronchopulmonary dysplasia (BPD) that required medical treatment within the previous 6 months and who are 24 months of age or younger at the beginning of RSV season, with hemodynamically significant congenital heart disease (CHD) and who are 24 months of age or younger at the beginning of RSV season [see Clinical Studies ( 14 ) ].|[EMA] Synagis is indicated for the prevention of serious lower-respiratory-tract disease requiring hospitalisation caused by respiratory syncytial virus (RSV) in children at high risk for RSV disease:children born at 35 weeks of gestation or less and less than six months of age at the onset of the RSV season;children less than two years of age and requiring treatment for bronchopulmonary dysplasia within the last six months;children less than two years of age and with haemodynamically significant congenital heart disease.|[PMDA] Drugs with a new indication for preventing serious lower respiratory tract disease caused by RS virus infections in newborns, infants and children under 24 months of age with haemodynamically significant congenital heart disease [Priority review drug] uuid:749f9304-32bc-4fee-8300-3b614182d884 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9599 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:d8f53763-a2b3-47fc-ba13-1e573aa05306"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6f856b83-694b-4978-90cb-e042f3b34074"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension Timolol maleate tablets are indicated for the treatment of hypertension. They may be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. Myocardial Infarction Timolol is indicated in patients who have survived the acute phase of myocardial infarction, and are clinically stable, to reduce cardiovascular mortality and the risk of reinfarction. Migraine Timolol is indicated for the prophylaxis of migraine headache. uuid:009c840f-8449-490e-96c2-4c81dd3013f2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9599 biolink:treats MONDO:0005277 PMID:41385096 "[{""id"":""uuid:9a70fc11-7371-48f1-bf2b-a6ddd6fe6f8b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a43d61f4-250b-4c08-923a-a4a0875b99f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension Timolol maleate tablets are indicated for the treatment of hypertension. They may be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. Myocardial Infarction Timolol is indicated in patients who have survived the acute phase of myocardial infarction, and are clinically stable, to reduce cardiovascular mortality and the risk of reinfarction. Migraine Timolol is indicated for the prophylaxis of migraine headache. uuid:d957bca5-aa41-4338-8337-9ee50a77835d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29101 biolink:treats MONDO:0000313 PMID:41385096 "[{""id"":""uuid:24c3869d-5c79-48da-a88c-3ea66a500382"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9564706c-78a3-4263-b02e-4e673cb3dcac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Phosphates Injection, USP, 3 mM P/mL is indicated as a source of phosphorus, for addition to large volume intravenous fluids, to prevent or correct hypophosphatemia in patients with restricted or no oral intake. It is also useful as an additive for preparing specific parenteral fluid formulas when the needs of the patient cannot be met by standard electrolyte or nutrient solutions. The concomitant amount of sodium (Na + 4 mEq/mL) must be calculated into total electrolyte dose of such prepared solutions. uuid:54c77712-2298-49da-bea7-1ba5b956f15c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0010643 PMID:41385096 "[{""id"":""uuid:5fe395aa-63a5-4725-9088-822e53f2ca09"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9e5311ce-c965-402b-9bee-26a5f22dfeb4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6 . Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7 . Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler's syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:74dcd9bb-c62d-4def-978f-87f837d07817 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:161680 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:57e94863-8a01-41bd-b7da-37521a4276ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4ec71205-bfaa-40fd-a190-cc66f026a6ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of aztreonam for injection, USP and other antibacterial drugs, aztreonam for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Aztreonam for Injection is indicated for the treatment of the following infections caused by susceptible Gram-negative microorganisms: Urinary Tract Infections (complicated and uncomplicated), including pyelonephritis and cystitis (initial and recurrent) caused by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Enterobacter cloacae, Klebsiella oxytoca *, Citrobacter species*, and Serratia marcescens *. Lower Respiratory Tract Infections , including pneumonia and bronchitis caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, and Serratia marcescens *. Septicemia caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Proteus mirabilis *, Serratia marcescens *, and Enterobacter species. Skin and Skin-Structure Infections , including those associated with postoperative wounds, ulcers, and burns, caused by Escherichia coli, Proteus mirabilis, Serratia marcescens, Enterobacter species, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Citrobacter species*. * Efficacy for this organism in this organ system was studied in fewer than 10 infections. Intra-abdominal Infections , including peritonitis caused by Escherichia coli, Klebsiella species including K. pneumoniae, Enterobacter species including E. cloacae *, Pseudomonas aeruginosa, Citrobacter species* including C. freundii *, and Serratia species* including S. marcescens *. Gynecologic Infections , including endometritis and pelvic cellulitis caused by Escherichia coli, Klebsiella pneumoniae *, Enterobacter species* including E. cloacae *, and Proteus mirabilis *. Aztreonam for injection is indicated for adjunctive therapy to surgery in the management of infections caused by susceptible organisms, including abscesses, infections complicating hollow viscus perforations, cutaneous infections, and infections of serous surfaces. Aztreonam for injection is effective against most of the commonly encountered Gram-negative aerobic pathogens seen in general surgery. uuid:c299c33d-6a56-4864-b7f5-28122e1df1e2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:161680 biolink:treats MONDO:0006939 PMID:41385096 "[{""id"":""uuid:dbd58436-f5e7-486f-b814-4d28184218ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b570260d-b88d-4f58-8e4e-a2e3b86929f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of aztreonam for injection, USP and other antibacterial drugs, aztreonam for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Aztreonam for Injection is indicated for the treatment of the following infections caused by susceptible Gram-negative microorganisms: Urinary Tract Infections (complicated and uncomplicated), including pyelonephritis and cystitis (initial and recurrent) caused by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Enterobacter cloacae, Klebsiella oxytoca *, Citrobacter species*, and Serratia marcescens *. Lower Respiratory Tract Infections , including pneumonia and bronchitis caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, and Serratia marcescens *. Septicemia caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Proteus mirabilis *, Serratia marcescens *, and Enterobacter species. Skin and Skin-Structure Infections , including those associated with postoperative wounds, ulcers, and burns, caused by Escherichia coli, Proteus mirabilis, Serratia marcescens, Enterobacter species, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Citrobacter species*. * Efficacy for this organism in this organ system was studied in fewer than 10 infections. Intra-abdominal Infections , including peritonitis caused by Escherichia coli, Klebsiella species including K. pneumoniae, Enterobacter species including E. cloacae *, Pseudomonas aeruginosa, Citrobacter species* including C. freundii *, and Serratia species* including S. marcescens *. Gynecologic Infections , including endometritis and pelvic cellulitis caused by Escherichia coli, Klebsiella pneumoniae *, Enterobacter species* including E. cloacae *, and Proteus mirabilis *. Aztreonam for injection is indicated for adjunctive therapy to surgery in the management of infections caused by susceptible organisms, including abscesses, infections complicating hollow viscus perforations, cutaneous infections, and infections of serous surfaces. Aztreonam for injection is effective against most of the commonly encountered Gram-negative aerobic pathogens seen in general surgery. uuid:d86d5892-8160-4ab7-8b09-0f7bc10db89d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:161680 biolink:treats MONDO:0006032 PMID:41385096 "[{""id"":""uuid:105f9795-bda9-4ad0-aa8b-a55a8ebfa9f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0ab0a983-e2f1-404d-acfb-fdd4fa7ffbdd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of aztreonam for injection, USP and other antibacterial drugs, aztreonam for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Aztreonam for Injection is indicated for the treatment of the following infections caused by susceptible Gram-negative microorganisms: Urinary Tract Infections (complicated and uncomplicated), including pyelonephritis and cystitis (initial and recurrent) caused by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Enterobacter cloacae, Klebsiella oxytoca *, Citrobacter species*, and Serratia marcescens *. Lower Respiratory Tract Infections , including pneumonia and bronchitis caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, and Serratia marcescens *. Septicemia caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Proteus mirabilis *, Serratia marcescens *, and Enterobacter species. Skin and Skin-Structure Infections , including those associated with postoperative wounds, ulcers, and burns, caused by Escherichia coli, Proteus mirabilis, Serratia marcescens, Enterobacter species, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Citrobacter species*. * Efficacy for this organism in this organ system was studied in fewer than 10 infections. Intra-abdominal Infections , including peritonitis caused by Escherichia coli, Klebsiella species including K. pneumoniae, Enterobacter species including E. cloacae *, Pseudomonas aeruginosa, Citrobacter species* including C. freundii *, and Serratia species* including S. marcescens *. Gynecologic Infections , including endometritis and pelvic cellulitis caused by Escherichia coli, Klebsiella pneumoniae *, Enterobacter species* including E. cloacae *, and Proteus mirabilis *. Aztreonam for injection is indicated for adjunctive therapy to surgery in the management of infections caused by susceptible organisms, including abscesses, infections complicating hollow viscus perforations, cutaneous infections, and infections of serous surfaces. Aztreonam for injection is effective against most of the commonly encountered Gram-negative aerobic pathogens seen in general surgery. uuid:7d28e311-22f4-487e-bdb7-d436218e0773 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:161680 biolink:treats MONDO:0024355 PMID:41385096 "[{""id"":""uuid:aa2acd5b-31eb-4e76-8c76-5192406e6236"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3012ae78-beb7-4a0b-9c9c-8ad3bd6ebcaf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of aztreonam for injection, USP and other antibacterial drugs, aztreonam for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Aztreonam for Injection is indicated for the treatment of the following infections caused by susceptible Gram-negative microorganisms: Urinary Tract Infections (complicated and uncomplicated), including pyelonephritis and cystitis (initial and recurrent) caused by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Enterobacter cloacae, Klebsiella oxytoca *, Citrobacter species*, and Serratia marcescens *. Lower Respiratory Tract Infections , including pneumonia and bronchitis caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, and Serratia marcescens *. Septicemia caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Proteus mirabilis *, Serratia marcescens *, and Enterobacter species. Skin and Skin-Structure Infections , including those associated with postoperative wounds, ulcers, and burns, caused by Escherichia coli, Proteus mirabilis, Serratia marcescens, Enterobacter species, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Citrobacter species*. * Efficacy for this organism in this organ system was studied in fewer than 10 infections. Intra-abdominal Infections , including peritonitis caused by Escherichia coli, Klebsiella species including K. pneumoniae, Enterobacter species including E. cloacae *, Pseudomonas aeruginosa, Citrobacter species* including C. freundii *, and Serratia species* including S. marcescens *. Gynecologic Infections , including endometritis and pelvic cellulitis caused by Escherichia coli, Klebsiella pneumoniae *, Enterobacter species* including E. cloacae *, and Proteus mirabilis *. Aztreonam for injection is indicated for adjunctive therapy to surgery in the management of infections caused by susceptible organisms, including abscesses, infections complicating hollow viscus perforations, cutaneous infections, and infections of serous surfaces. Aztreonam for injection is effective against most of the commonly encountered Gram-negative aerobic pathogens seen in general surgery. uuid:f0ee0993-2b6d-4191-8e28-7e351aa02607 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:161680 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:bd26b01f-59b2-477e-9c2b-6a305914d1eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:454567e0-13ac-466b-93f8-ceef51858fe1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of aztreonam for injection, USP and other antibacterial drugs, aztreonam for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Aztreonam for Injection is indicated for the treatment of the following infections caused by susceptible Gram-negative microorganisms: Urinary Tract Infections (complicated and uncomplicated), including pyelonephritis and cystitis (initial and recurrent) caused by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Enterobacter cloacae, Klebsiella oxytoca *, Citrobacter species*, and Serratia marcescens *. Lower Respiratory Tract Infections , including pneumonia and bronchitis caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, and Serratia marcescens *. Septicemia caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Proteus mirabilis *, Serratia marcescens *, and Enterobacter species. Skin and Skin-Structure Infections , including those associated with postoperative wounds, ulcers, and burns, caused by Escherichia coli, Proteus mirabilis, Serratia marcescens, Enterobacter species, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Citrobacter species*. * Efficacy for this organism in this organ system was studied in fewer than 10 infections. Intra-abdominal Infections , including peritonitis caused by Escherichia coli, Klebsiella species including K. pneumoniae, Enterobacter species including E. cloacae *, Pseudomonas aeruginosa, Citrobacter species* including C. freundii *, and Serratia species* including S. marcescens *. Gynecologic Infections , including endometritis and pelvic cellulitis caused by Escherichia coli, Klebsiella pneumoniae *, Enterobacter species* including E. cloacae *, and Proteus mirabilis *. Aztreonam for injection is indicated for adjunctive therapy to surgery in the management of infections caused by susceptible organisms, including abscesses, infections complicating hollow viscus perforations, cutaneous infections, and infections of serous surfaces. Aztreonam for injection is effective against most of the commonly encountered Gram-negative aerobic pathogens seen in general surgery. uuid:db8ccb04-e846-4f1e-939b-46ba04289923 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:161680 biolink:treats MONDO:0003781 PMID:41385096 "[{""id"":""uuid:5f093cb2-a262-4d4f-80b1-d06d029f8f24"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:be35c0f9-f25a-44fa-8eab-a1dd63c6ba15"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of aztreonam for injection, USP and other antibacterial drugs, aztreonam for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Aztreonam for Injection is indicated for the treatment of the following infections caused by susceptible Gram-negative microorganisms: Urinary Tract Infections (complicated and uncomplicated), including pyelonephritis and cystitis (initial and recurrent) caused by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Enterobacter cloacae, Klebsiella oxytoca *, Citrobacter species*, and Serratia marcescens *. Lower Respiratory Tract Infections , including pneumonia and bronchitis caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, and Serratia marcescens *. Septicemia caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Proteus mirabilis *, Serratia marcescens *, and Enterobacter species. Skin and Skin-Structure Infections , including those associated with postoperative wounds, ulcers, and burns, caused by Escherichia coli, Proteus mirabilis, Serratia marcescens, Enterobacter species, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Citrobacter species*. * Efficacy for this organism in this organ system was studied in fewer than 10 infections. Intra-abdominal Infections , including peritonitis caused by Escherichia coli, Klebsiella species including K. pneumoniae, Enterobacter species including E. cloacae *, Pseudomonas aeruginosa, Citrobacter species* including C. freundii *, and Serratia species* including S. marcescens *. Gynecologic Infections , including endometritis and pelvic cellulitis caused by Escherichia coli, Klebsiella pneumoniae *, Enterobacter species* including E. cloacae *, and Proteus mirabilis *. Aztreonam for injection is indicated for adjunctive therapy to surgery in the management of infections caused by susceptible organisms, including abscesses, infections complicating hollow viscus perforations, cutaneous infections, and infections of serous surfaces. Aztreonam for injection is effective against most of the commonly encountered Gram-negative aerobic pathogens seen in general surgery. uuid:e82c54ff-2360-41ae-9071-d2ff404b2f3a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:161680 biolink:treats MONDO:0700217 PMID:41385096 "[{""id"":""uuid:5337fb88-f2d0-4e40-b291-c0658bf177c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cd802076-e60c-467f-951c-725195b1b785"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of aztreonam for injection, USP and other antibacterial drugs, aztreonam for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Aztreonam for Injection is indicated for the treatment of the following infections caused by susceptible Gram-negative microorganisms: Urinary Tract Infections (complicated and uncomplicated), including pyelonephritis and cystitis (initial and recurrent) caused by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Enterobacter cloacae, Klebsiella oxytoca *, Citrobacter species*, and Serratia marcescens *. Lower Respiratory Tract Infections , including pneumonia and bronchitis caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, and Serratia marcescens *. Septicemia caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Proteus mirabilis *, Serratia marcescens *, and Enterobacter species. Skin and Skin-Structure Infections , including those associated with postoperative wounds, ulcers, and burns, caused by Escherichia coli, Proteus mirabilis, Serratia marcescens, Enterobacter species, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Citrobacter species*. * Efficacy for this organism in this organ system was studied in fewer than 10 infections. Intra-abdominal Infections , including peritonitis caused by Escherichia coli, Klebsiella species including K. pneumoniae, Enterobacter species including E. cloacae *, Pseudomonas aeruginosa, Citrobacter species* including C. freundii *, and Serratia species* including S. marcescens *. Gynecologic Infections , including endometritis and pelvic cellulitis caused by Escherichia coli, Klebsiella pneumoniae *, Enterobacter species* including E. cloacae *, and Proteus mirabilis *. Aztreonam for injection is indicated for adjunctive therapy to surgery in the management of infections caused by susceptible organisms, including abscesses, infections complicating hollow viscus perforations, cutaneous infections, and infections of serous surfaces. Aztreonam for injection is effective against most of the commonly encountered Gram-negative aerobic pathogens seen in general surgery. uuid:24fa70c0-a0a6-4a24-81e6-dba30108f07d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:161680 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:57826fb7-d387-4951-b41d-27a677ed9f24"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:830bc537-83ca-4d3c-9a9b-63e8a34f7dd2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of aztreonam for injection, USP and other antibacterial drugs, aztreonam for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Aztreonam for Injection is indicated for the treatment of the following infections caused by susceptible Gram-negative microorganisms: Urinary Tract Infections (complicated and uncomplicated), including pyelonephritis and cystitis (initial and recurrent) caused by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Enterobacter cloacae, Klebsiella oxytoca *, Citrobacter species*, and Serratia marcescens *. Lower Respiratory Tract Infections , including pneumonia and bronchitis caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, and Serratia marcescens *. Septicemia caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Proteus mirabilis *, Serratia marcescens *, and Enterobacter species. Skin and Skin-Structure Infections , including those associated with postoperative wounds, ulcers, and burns, caused by Escherichia coli, Proteus mirabilis, Serratia marcescens, Enterobacter species, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Citrobacter species*. * Efficacy for this organism in this organ system was studied in fewer than 10 infections. Intra-abdominal Infections , including peritonitis caused by Escherichia coli, Klebsiella species including K. pneumoniae, Enterobacter species including E. cloacae *, Pseudomonas aeruginosa, Citrobacter species* including C. freundii *, and Serratia species* including S. marcescens *. Gynecologic Infections , including endometritis and pelvic cellulitis caused by Escherichia coli, Klebsiella pneumoniae *, Enterobacter species* including E. cloacae *, and Proteus mirabilis *. Aztreonam for injection is indicated for adjunctive therapy to surgery in the management of infections caused by susceptible organisms, including abscesses, infections complicating hollow viscus perforations, cutaneous infections, and infections of serous surfaces. Aztreonam for injection is effective against most of the commonly encountered Gram-negative aerobic pathogens seen in general surgery. uuid:892934a0-6724-4ebe-9971-e75938433d52 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:161680 biolink:treats MONDO:0043839 PMID:41385096 "[{""id"":""uuid:706e231c-2562-48c3-8f7a-01e8bccc9199"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:14320c5a-f77b-4da9-9736-17968c555d25"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of aztreonam for injection, USP and other antibacterial drugs, aztreonam for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Aztreonam for Injection is indicated for the treatment of the following infections caused by susceptible Gram-negative microorganisms: Urinary Tract Infections (complicated and uncomplicated), including pyelonephritis and cystitis (initial and recurrent) caused by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Enterobacter cloacae, Klebsiella oxytoca *, Citrobacter species*, and Serratia marcescens *. Lower Respiratory Tract Infections , including pneumonia and bronchitis caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, and Serratia marcescens *. Septicemia caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Proteus mirabilis *, Serratia marcescens *, and Enterobacter species. Skin and Skin-Structure Infections , including those associated with postoperative wounds, ulcers, and burns, caused by Escherichia coli, Proteus mirabilis, Serratia marcescens, Enterobacter species, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Citrobacter species*. * Efficacy for this organism in this organ system was studied in fewer than 10 infections. Intra-abdominal Infections , including peritonitis caused by Escherichia coli, Klebsiella species including K. pneumoniae, Enterobacter species including E. cloacae *, Pseudomonas aeruginosa, Citrobacter species* including C. freundii *, and Serratia species* including S. marcescens *. Gynecologic Infections , including endometritis and pelvic cellulitis caused by Escherichia coli, Klebsiella pneumoniae *, Enterobacter species* including E. cloacae *, and Proteus mirabilis *. Aztreonam for injection is indicated for adjunctive therapy to surgery in the management of infections caused by susceptible organisms, including abscesses, infections complicating hollow viscus perforations, cutaneous infections, and infections of serous surfaces. Aztreonam for injection is effective against most of the commonly encountered Gram-negative aerobic pathogens seen in general surgery. uuid:c2c39e31-068c-42fd-b309-40c17d14c007 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:161680 biolink:treats UMLS:C1112209 PMID:41385096 "[{""id"":""uuid:6fbcaa34-7f01-4612-b19c-c93592e00232"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e411e02c-d09f-49b5-8c0e-e21c1d0d43bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of aztreonam for injection, USP and other antibacterial drugs, aztreonam for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Aztreonam for Injection is indicated for the treatment of the following infections caused by susceptible Gram-negative microorganisms: Urinary Tract Infections (complicated and uncomplicated), including pyelonephritis and cystitis (initial and recurrent) caused by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Enterobacter cloacae, Klebsiella oxytoca *, Citrobacter species*, and Serratia marcescens *. Lower Respiratory Tract Infections , including pneumonia and bronchitis caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, and Serratia marcescens *. Septicemia caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Proteus mirabilis *, Serratia marcescens *, and Enterobacter species. Skin and Skin-Structure Infections , including those associated with postoperative wounds, ulcers, and burns, caused by Escherichia coli, Proteus mirabilis, Serratia marcescens, Enterobacter species, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Citrobacter species*. * Efficacy for this organism in this organ system was studied in fewer than 10 infections. Intra-abdominal Infections , including peritonitis caused by Escherichia coli, Klebsiella species including K. pneumoniae, Enterobacter species including E. cloacae *, Pseudomonas aeruginosa, Citrobacter species* including C. freundii *, and Serratia species* including S. marcescens *. Gynecologic Infections , including endometritis and pelvic cellulitis caused by Escherichia coli, Klebsiella pneumoniae *, Enterobacter species* including E. cloacae *, and Proteus mirabilis *. Aztreonam for injection is indicated for adjunctive therapy to surgery in the management of infections caused by susceptible organisms, including abscesses, infections complicating hollow viscus perforations, cutaneous infections, and infections of serous surfaces. Aztreonam for injection is effective against most of the commonly encountered Gram-negative aerobic pathogens seen in general surgery. uuid:88a7da18-db3b-470f-9486-906cf536a511 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:161680 biolink:treats MONDO:0004522 PMID:41385096 "[{""id"":""uuid:e0759e76-f92e-4461-9daf-cafde71ee823"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eeba4611-bff4-444d-bc7f-908f0f57a6ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of aztreonam for injection, USP and other antibacterial drugs, aztreonam for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Aztreonam for Injection is indicated for the treatment of the following infections caused by susceptible Gram-negative microorganisms: Urinary Tract Infections (complicated and uncomplicated), including pyelonephritis and cystitis (initial and recurrent) caused by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Enterobacter cloacae, Klebsiella oxytoca *, Citrobacter species*, and Serratia marcescens *. Lower Respiratory Tract Infections , including pneumonia and bronchitis caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, and Serratia marcescens *. Septicemia caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Proteus mirabilis *, Serratia marcescens *, and Enterobacter species. Skin and Skin-Structure Infections , including those associated with postoperative wounds, ulcers, and burns, caused by Escherichia coli, Proteus mirabilis, Serratia marcescens, Enterobacter species, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Citrobacter species*. * Efficacy for this organism in this organ system was studied in fewer than 10 infections. Intra-abdominal Infections , including peritonitis caused by Escherichia coli, Klebsiella species including K. pneumoniae, Enterobacter species including E. cloacae *, Pseudomonas aeruginosa, Citrobacter species* including C. freundii *, and Serratia species* including S. marcescens *. Gynecologic Infections , including endometritis and pelvic cellulitis caused by Escherichia coli, Klebsiella pneumoniae *, Enterobacter species* including E. cloacae *, and Proteus mirabilis *. Aztreonam for injection is indicated for adjunctive therapy to surgery in the management of infections caused by susceptible organisms, including abscesses, infections complicating hollow viscus perforations, cutaneous infections, and infections of serous surfaces. Aztreonam for injection is effective against most of the commonly encountered Gram-negative aerobic pathogens seen in general surgery. uuid:e3aa6345-0d48-4aa6-a3cb-374f22e753e8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:161680 biolink:treats MONDO:0000918 PMID:41385096 "[{""id"":""uuid:ef1fae4a-6684-4540-ae07-4fff82d83033"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ca0f20fd-124b-462c-9b35-ad601d5b0d78"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of aztreonam for injection, USP and other antibacterial drugs, aztreonam for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Aztreonam for Injection is indicated for the treatment of the following infections caused by susceptible Gram-negative microorganisms: Urinary Tract Infections (complicated and uncomplicated), including pyelonephritis and cystitis (initial and recurrent) caused by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Enterobacter cloacae, Klebsiella oxytoca *, Citrobacter species*, and Serratia marcescens *. Lower Respiratory Tract Infections , including pneumonia and bronchitis caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, and Serratia marcescens *. Septicemia caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Proteus mirabilis *, Serratia marcescens *, and Enterobacter species. Skin and Skin-Structure Infections , including those associated with postoperative wounds, ulcers, and burns, caused by Escherichia coli, Proteus mirabilis, Serratia marcescens, Enterobacter species, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Citrobacter species*. * Efficacy for this organism in this organ system was studied in fewer than 10 infections. Intra-abdominal Infections , including peritonitis caused by Escherichia coli, Klebsiella species including K. pneumoniae, Enterobacter species including E. cloacae *, Pseudomonas aeruginosa, Citrobacter species* including C. freundii *, and Serratia species* including S. marcescens *. Gynecologic Infections , including endometritis and pelvic cellulitis caused by Escherichia coli, Klebsiella pneumoniae *, Enterobacter species* including E. cloacae *, and Proteus mirabilis *. Aztreonam for injection is indicated for adjunctive therapy to surgery in the management of infections caused by susceptible organisms, including abscesses, infections complicating hollow viscus perforations, cutaneous infections, and infections of serous surfaces. Aztreonam for injection is effective against most of the commonly encountered Gram-negative aerobic pathogens seen in general surgery. uuid:49493b34-fa2f-443a-bea3-b1594bec9927 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:161680 biolink:treats MONDO:0006887 PMID:41385096 "[{""id"":""uuid:8aaaae24-354d-4ffa-ab0d-f6690b373c81"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eda7c716-e0e9-430d-bf2b-c2a47d28fcb7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of aztreonam for injection, USP and other antibacterial drugs, aztreonam for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Aztreonam for Injection is indicated for the treatment of the following infections caused by susceptible Gram-negative microorganisms: Urinary Tract Infections (complicated and uncomplicated), including pyelonephritis and cystitis (initial and recurrent) caused by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Enterobacter cloacae, Klebsiella oxytoca *, Citrobacter species*, and Serratia marcescens *. Lower Respiratory Tract Infections , including pneumonia and bronchitis caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, and Serratia marcescens *. Septicemia caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Proteus mirabilis *, Serratia marcescens *, and Enterobacter species. Skin and Skin-Structure Infections , including those associated with postoperative wounds, ulcers, and burns, caused by Escherichia coli, Proteus mirabilis, Serratia marcescens, Enterobacter species, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Citrobacter species*. * Efficacy for this organism in this organ system was studied in fewer than 10 infections. Intra-abdominal Infections , including peritonitis caused by Escherichia coli, Klebsiella species including K. pneumoniae, Enterobacter species including E. cloacae *, Pseudomonas aeruginosa, Citrobacter species* including C. freundii *, and Serratia species* including S. marcescens *. Gynecologic Infections , including endometritis and pelvic cellulitis caused by Escherichia coli, Klebsiella pneumoniae *, Enterobacter species* including E. cloacae *, and Proteus mirabilis *. Aztreonam for injection is indicated for adjunctive therapy to surgery in the management of infections caused by susceptible organisms, including abscesses, infections complicating hollow viscus perforations, cutaneous infections, and infections of serous surfaces. Aztreonam for injection is effective against most of the commonly encountered Gram-negative aerobic pathogens seen in general surgery. uuid:3266f2a4-355b-4fd9-a19c-93b20f618013 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:161680 biolink:treats MONDO:0005227 PMID:41385096 "[{""id"":""uuid:6d4a6adb-c47f-401f-957e-0c07e05d4621"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1c8c2de5-1f92-4c15-816a-0b30eba50459"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of aztreonam for injection, USP and other antibacterial drugs, aztreonam for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Aztreonam for Injection is indicated for the treatment of the following infections caused by susceptible Gram-negative microorganisms: Urinary Tract Infections (complicated and uncomplicated), including pyelonephritis and cystitis (initial and recurrent) caused by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Enterobacter cloacae, Klebsiella oxytoca *, Citrobacter species*, and Serratia marcescens *. Lower Respiratory Tract Infections , including pneumonia and bronchitis caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, and Serratia marcescens *. Septicemia caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Proteus mirabilis *, Serratia marcescens *, and Enterobacter species. Skin and Skin-Structure Infections , including those associated with postoperative wounds, ulcers, and burns, caused by Escherichia coli, Proteus mirabilis, Serratia marcescens, Enterobacter species, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Citrobacter species*. * Efficacy for this organism in this organ system was studied in fewer than 10 infections. Intra-abdominal Infections , including peritonitis caused by Escherichia coli, Klebsiella species including K. pneumoniae, Enterobacter species including E. cloacae *, Pseudomonas aeruginosa, Citrobacter species* including C. freundii *, and Serratia species* including S. marcescens *. Gynecologic Infections , including endometritis and pelvic cellulitis caused by Escherichia coli, Klebsiella pneumoniae *, Enterobacter species* including E. cloacae *, and Proteus mirabilis *. Aztreonam for injection is indicated for adjunctive therapy to surgery in the management of infections caused by susceptible organisms, including abscesses, infections complicating hollow viscus perforations, cutaneous infections, and infections of serous surfaces. Aztreonam for injection is effective against most of the commonly encountered Gram-negative aerobic pathogens seen in general surgery. uuid:9ccf3258-f682-4a18-b8e3-3b63738199a5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:404903 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:0b759a14-d751-408b-951d-1da6ab6db298"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:711d8b3f-02b4-45b8-9529-d8f297ba0f0c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ertapenem for injection is a penem antibacterial indicated in adult patients and pediatric patients (3 months of age and older) for the treatment of the following moderate to severe infections caused by susceptible bacteria: • Complicated intra-abdominal infections. ( 1.1 ) • Complicated skin and skin structure infections, including diabetic foot infections without osteomyelitis. ( 1.2 ) • Community-acquired pneumonia. ( 1.3 ) • Complicated urinary tract infections including pyelonephritis. ( 1.4 ) • Acute pelvic infections including postpartum endomyometritis, septic abortion and post-surgical gynecologic infections. ( 1.5 ) Ertapenem for injection is indicated in adults for the prophylaxis of surgical site infection following elective colorectal surgery. ( 1.6 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ertapenem for injection and other antibacterial drugs, Ertapenem for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. ( 1.7 ) uuid:55c8f903-b1d2-4027-a1cc-7b4781f3ecbd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:404903 biolink:treats EFO:1001459 PMID:41385096 "[{""id"":""uuid:78482b86-0a09-455e-ab7b-b147512e753d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bb4fc1c6-1ac5-4e8a-a87e-05e12a0b9054"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ertapenem for injection is a penem antibacterial indicated in adult patients and pediatric patients (3 months of age and older) for the treatment of the following moderate to severe infections caused by susceptible bacteria: • Complicated intra-abdominal infections. ( 1.1 ) • Complicated skin and skin structure infections, including diabetic foot infections without osteomyelitis. ( 1.2 ) • Community-acquired pneumonia. ( 1.3 ) • Complicated urinary tract infections including pyelonephritis. ( 1.4 ) • Acute pelvic infections including postpartum endomyometritis, septic abortion and post-surgical gynecologic infections. ( 1.5 ) Ertapenem for injection is indicated in adults for the prophylaxis of surgical site infection following elective colorectal surgery. ( 1.6 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ertapenem for injection and other antibacterial drugs, Ertapenem for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. ( 1.7 ) uuid:b24b87f2-ec8e-44d9-a189-9aab6cc0c2de biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:404903 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:4a64e00a-0a71-46cd-bc90-6e0c98491bd9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d7a4e3b3-216a-4a31-ad72-a978e284bceb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ertapenem for injection is a penem antibacterial indicated in adult patients and pediatric patients (3 months of age and older) for the treatment of the following moderate to severe infections caused by susceptible bacteria: • Complicated intra-abdominal infections. ( 1.1 ) • Complicated skin and skin structure infections, including diabetic foot infections without osteomyelitis. ( 1.2 ) • Community-acquired pneumonia. ( 1.3 ) • Complicated urinary tract infections including pyelonephritis. ( 1.4 ) • Acute pelvic infections including postpartum endomyometritis, septic abortion and post-surgical gynecologic infections. ( 1.5 ) Ertapenem for injection is indicated in adults for the prophylaxis of surgical site infection following elective colorectal surgery. ( 1.6 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ertapenem for injection and other antibacterial drugs, Ertapenem for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. ( 1.7 ) uuid:48a3ebfc-be34-4407-812a-1493e03efbef biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:404903 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:9a3baa5c-1d11-4723-bfa3-c288a668b219"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:96d0f2fe-21dc-4d54-86a7-f70aa5f26b20"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ertapenem for injection is a penem antibacterial indicated in adult patients and pediatric patients (3 months of age and older) for the treatment of the following moderate to severe infections caused by susceptible bacteria: • Complicated intra-abdominal infections. ( 1.1 ) • Complicated skin and skin structure infections, including diabetic foot infections without osteomyelitis. ( 1.2 ) • Community-acquired pneumonia. ( 1.3 ) • Complicated urinary tract infections including pyelonephritis. ( 1.4 ) • Acute pelvic infections including postpartum endomyometritis, septic abortion and post-surgical gynecologic infections. ( 1.5 ) Ertapenem for injection is indicated in adults for the prophylaxis of surgical site infection following elective colorectal surgery. ( 1.6 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ertapenem for injection and other antibacterial drugs, Ertapenem for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. ( 1.7 ) uuid:7ac181a1-3055-44c6-9734-e1c4e6f664fe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:404903 biolink:treats MONDO:0006939 PMID:41385096 "[{""id"":""uuid:44b3560f-68b0-4ba1-acdc-65ab1f39f515"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:52cef663-7864-4d84-a73d-900f4e6971da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ertapenem for injection is a penem antibacterial indicated in adult patients and pediatric patients (3 months of age and older) for the treatment of the following moderate to severe infections caused by susceptible bacteria: • Complicated intra-abdominal infections. ( 1.1 ) • Complicated skin and skin structure infections, including diabetic foot infections without osteomyelitis. ( 1.2 ) • Community-acquired pneumonia. ( 1.3 ) • Complicated urinary tract infections including pyelonephritis. ( 1.4 ) • Acute pelvic infections including postpartum endomyometritis, septic abortion and post-surgical gynecologic infections. ( 1.5 ) Ertapenem for injection is indicated in adults for the prophylaxis of surgical site infection following elective colorectal surgery. ( 1.6 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ertapenem for injection and other antibacterial drugs, Ertapenem for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. ( 1.7 ) uuid:4f815ffd-430f-4a2d-89e0-9f8c4ce45e5f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:404903 biolink:treats MONDO:0000922 PMID:41385096 "[{""id"":""uuid:32a59147-4cae-4d4d-bfd6-3a742e8b4b93"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f2afafd9-f172-4e07-a2cb-fcac0e9f2b2b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ertapenem for injection is a penem antibacterial indicated in adult patients and pediatric patients (3 months of age and older) for the treatment of the following moderate to severe infections caused by susceptible bacteria: • Complicated intra-abdominal infections. ( 1.1 ) • Complicated skin and skin structure infections, including diabetic foot infections without osteomyelitis. ( 1.2 ) • Community-acquired pneumonia. ( 1.3 ) • Complicated urinary tract infections including pyelonephritis. ( 1.4 ) • Acute pelvic infections including postpartum endomyometritis, septic abortion and post-surgical gynecologic infections. ( 1.5 ) Ertapenem for injection is indicated in adults for the prophylaxis of surgical site infection following elective colorectal surgery. ( 1.6 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ertapenem for injection and other antibacterial drugs, Ertapenem for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. ( 1.7 ) uuid:4373cc70-d4ff-4b73-b20e-f4ec57bac795 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:404903 biolink:treats MONDO:0042451 PMID:41385096 "[{""id"":""uuid:187979a0-9af2-4bc1-8246-0ce9cf716238"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cdce8b20-1cc0-4795-be23-9d78cd1566ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ertapenem for injection is a penem antibacterial indicated in adult patients and pediatric patients (3 months of age and older) for the treatment of the following moderate to severe infections caused by susceptible bacteria: • Complicated intra-abdominal infections. ( 1.1 ) • Complicated skin and skin structure infections, including diabetic foot infections without osteomyelitis. ( 1.2 ) • Community-acquired pneumonia. ( 1.3 ) • Complicated urinary tract infections including pyelonephritis. ( 1.4 ) • Acute pelvic infections including postpartum endomyometritis, septic abortion and post-surgical gynecologic infections. ( 1.5 ) Ertapenem for injection is indicated in adults for the prophylaxis of surgical site infection following elective colorectal surgery. ( 1.6 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ertapenem for injection and other antibacterial drugs, Ertapenem for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. ( 1.7 ) uuid:58f55987-43ab-4e3d-8be7-f44bf0c5dff5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:404903 biolink:treats DOID:2910 PMID:41385096 "[{""id"":""uuid:ed7e9be2-6292-4c51-a591-bddf6aa326a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:40566f79-8fba-4ac0-8043-4a688c5a473c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ertapenem for injection is a penem antibacterial indicated in adult patients and pediatric patients (3 months of age and older) for the treatment of the following moderate to severe infections caused by susceptible bacteria: • Complicated intra-abdominal infections. ( 1.1 ) • Complicated skin and skin structure infections, including diabetic foot infections without osteomyelitis. ( 1.2 ) • Community-acquired pneumonia. ( 1.3 ) • Complicated urinary tract infections including pyelonephritis. ( 1.4 ) • Acute pelvic infections including postpartum endomyometritis, septic abortion and post-surgical gynecologic infections. ( 1.5 ) Ertapenem for injection is indicated in adults for the prophylaxis of surgical site infection following elective colorectal surgery. ( 1.6 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ertapenem for injection and other antibacterial drugs, Ertapenem for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. ( 1.7 ) uuid:5f703703-b40c-421d-9c5f-e894d7e2beab biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:404903 biolink:treats UMLS:C0038941 PMID:41385096 "[{""id"":""uuid:97d8f918-292d-4a9d-84d3-bdbcc0f0391e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e3731d80-43b4-4f90-b409-1a9634d78673"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ertapenem for injection is a penem antibacterial indicated in adult patients and pediatric patients (3 months of age and older) for the treatment of the following moderate to severe infections caused by susceptible bacteria: • Complicated intra-abdominal infections. ( 1.1 ) • Complicated skin and skin structure infections, including diabetic foot infections without osteomyelitis. ( 1.2 ) • Community-acquired pneumonia. ( 1.3 ) • Complicated urinary tract infections including pyelonephritis. ( 1.4 ) • Acute pelvic infections including postpartum endomyometritis, septic abortion and post-surgical gynecologic infections. ( 1.5 ) Ertapenem for injection is indicated in adults for the prophylaxis of surgical site infection following elective colorectal surgery. ( 1.6 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ertapenem for injection and other antibacterial drugs, Ertapenem for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. ( 1.7 ) uuid:888e334f-39d2-450f-bbdc-28c147b676be biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27568 biolink:treats UMLS:C0238421 PMID:41385096 "[{""id"":""uuid:5ec32ca3-9e5d-4e6a-8a38-aebae8aadf5f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:62e42cf4-4c86-4c4f-8eca-16d1f3f825ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Selenium Injection is indicated for use as a supplement to intravenous solutions given for total parenteral nutrition (TPN). Administration of selenium in TPN solutions helps to maintain plasma selenium levels and to prevent depletion of endogenous stores and subsequent deficiency symptoms. uuid:28c8ac2a-bd84-4ac4-8b56-ac5480e533ec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1161552 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:c370dbc2-0502-46ea-85c2-999ec4ad0e15"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d37e8db2-c1f2-41da-9ece-ac8d2f2fddf0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Isosorbide dinitrate and hydralazine hydrochloride tablets are a combination of isosorbide dinitrate, a nitrate vasodilator, and hydralazine hydrochloride, an arteriolar vasodilator, indicated for: the treatment of heart failure as an adjunct therapy to standard therapy in self-identified black patients to improve survival, prolong time to hospitalization for heart failure and to improve patient-reported functional status ( 1.1 ) Limitations of use: There is little experience in patients with NYHA class IV heart failure ( 1.2 ) uuid:dd5157e1-aeb0-4cda-9353-53d6e0b7fc06 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:231032 biolink:treats MONDO:0004651 PMID:41385096 "[{""id"":""uuid:a8a178be-2410-44ae-b991-a6c064329b65"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d125dee5-c8d3-451c-b05f-fc10de1f5166"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TEMBEXA is an orthopoxvirus nucleotide analog DNA polymerase inhibitor and is indicated for the treatment of human smallpox disease in adult and pediatric patients, including neonates. ( 1.1 ) Limitations of Use: • TEMBEXA is not indicated for the treatment of diseases other than human smallpox disease. ( 1.2 ) • The effectiveness of TEMBEXA for treatment of smallpox disease has not been determined in humans because adequate and well-controlled field trials have not been feasible, and inducing smallpox disease in humans to study the drug’s efficacy is not ethical. ( 1.2 ) • TEMBEXA efficacy may be reduced in immunocompromised patients based on studies in immune deficient animals. ( 1.2 ) uuid:4fa9eaba-a057-4fd5-9a2a-5ac86495c64a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64355 biolink:treats MONDO:0005657 PMID:41385096 "[{""id"":""uuid:cd8be740-756a-4f38-bc8a-8f389049a006"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:110998cc-753b-45c2-a37e-1ec51d799274"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Posaconazole is an azole antifungal indicated as follows: • Posaconazole is indicated for the prophylaxis of invasive Aspergillus and Candida infections in patients who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant (HSCT) recipients with graft versus-host disease (GVHD) or those with hematologic malignancies with prolonged neutropenia from chemotherapy as follows (1.2) ° Posaconazole delayed-release tablets: Adults and pediatric patients 13 years of age and older. uuid:a5c8d35b-139e-4949-ae08-2ddaf09af27b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64355 biolink:treats MONDO:0002026 PMID:41385096 "[{""id"":""uuid:6971acc1-ba7f-4042-bd11-aed06da2b365"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f02c4903-c6fc-4fed-9a85-c17bdc36ce3a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Posaconazole is an azole antifungal indicated as follows: • Posaconazole is indicated for the prophylaxis of invasive Aspergillus and Candida infections in patients who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant (HSCT) recipients with graft versus-host disease (GVHD) or those with hematologic malignancies with prolonged neutropenia from chemotherapy as follows (1.2) ° Posaconazole delayed-release tablets: Adults and pediatric patients 13 years of age and older. uuid:b4aa0d4e-d80c-4948-a4df-e37918dbac0e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64355 biolink:treats MONDO:0013730 PMID:41385096 "[{""id"":""uuid:3c88e964-8f82-48a6-9a2d-5c1d6f295e0f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:562af1e9-3043-46d0-b03a-d6c416d365a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:5fcbe292-78b4-414a-ab70-c8b613ba0918"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/posaconazole-ahcl""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Posaconazole is an azole antifungal indicated as follows: • Posaconazole is indicated for the prophylaxis of invasive Aspergillus and Candida infections in patients who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant (HSCT) recipients with graft versus-host disease (GVHD) or those with hematologic malignancies with prolonged neutropenia from chemotherapy as follows (1.2) ° Posaconazole delayed-release tablets: Adults and pediatric patients 13 years of age and older.|[EMA] Noxafil gastro-resistant tablets are indicated for use in the treatment of the following fungal infections in adults (see sections 4.2 and 5.1):- Invasive aspergillosisNoxafil gastro-resistant tablets are indicated for use in the treatment of the following fungal infections in paediatric patients from 2 years of age weighing more than 40 kg and adults (see sections 4.2 and 5.1):- Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products;- Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B;- Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products.Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.Noxafil gastro-resistant tablets are also indicated for prophylaxis of invasive fungal infections in the following paediatric patients from 2 years of age weighing more than 40 kg and adults (see sections 4.2 and 5.1):- Patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections.Please refer to the Summary of Product Characteristics of Noxafil oral suspension for use in oropharyngeal candidiasis. Noxafil concentrate for solution for infusion is indicated for use in the treatment of the following fungal infections in adults (see sections 4.2 and 5.1):- Invasive aspergillosisNoxafil concentrate for solution for infusion is indicated for use in the treatment of the following fungal infections in adult and paediatric patients from 2 years of age (see sections 4.2 and 5.1):- Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products;- Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B;- Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products.Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.Noxafil concentrate for solution for infusion is also indicated for prophylaxis of invasive fungal infections in the following adult and paediatric patients from 2 years of age (see sections 4.2 and 5.1):- Patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease (GVHD) and who are at high risk of developing invasive fungal infections.Please refer to the Summary of Product Characteristics of Noxafil oral suspension for use in oropharyngeal candidiasis. Noxafil gastro resistant powder and solvent for oral suspension is indicated for use in the treatment of the following fungal infections in paediatric patients from 2 years of age (see sections 4.2 and 5.1):- Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products;- Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B;- Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products.Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.Noxafil gastro-resistant powder and solvent for oral suspension is indicated for prophylaxis of invasive fungal infections in the following paediatric patients from 2 years of age:- Patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- Haematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections.Please refer to the Summary of Product Characteristics of Noxafil concentrate for solution for infusion and the gastro-resistant tablets for use in primary treatment of invasive aspergillosis.Please refer to the Summary of Product Characteristics of Noxafil oral suspension for use in oropharyngeal candidiasis. Noxafil oral suspension is indicated for use in the treatment of the following fungal infections in adults (see section 5.1):- Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products;- Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B;- Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products;- Oropharyngeal candidiasis: as first-line therapy in patients who have severe disease or are immunocompromised, in whom response to topical therapy is expected to be poor.Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.Noxafil oral suspension is also indicated for prophylaxis of invasive fungal infections in the following patients:- Patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections.Please refer to the Summary of Product Characteristics of Noxafil concentrate for solution for infusion and the gastro-resistant tablets for use in primary treatment of invasive aspergillosis. uuid:faeefb36-f5fe-4738-8506-7ed60aab7856 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64355 biolink:treats NCIT:C157387 PMID:41385096 "[{""id"":""uuid:02bb5364-9b26-4d2e-940c-77df8f9abfc4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c4da84f9-9b34-4a52-b6ed-3ccda9666b92"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Posaconazole is an azole antifungal indicated as follows: • Posaconazole is indicated for the prophylaxis of invasive Aspergillus and Candida infections in patients who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant (HSCT) recipients with graft versus-host disease (GVHD) or those with hematologic malignancies with prolonged neutropenia from chemotherapy as follows (1.2) ° Posaconazole delayed-release tablets: Adults and pediatric patients 13 years of age and older. uuid:b79cff43-0fdb-4cc3-baf6-7d2eaac2624b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2955 biolink:treats MONDO:0006668 PMID:41385096 "[{""id"":""uuid:0705493f-4a83-468c-8212-88ed29b0651a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:79595879-68c9-426b-88ef-3a3b49d417c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AzaSite ® is indicated for the treatment of bacterial conjunctivitis caused by susceptible isolates of the following microorganisms: CDC coryneform group G* Haemophilus influenzae Staphylococcus aureus Streptococcus mitis group Streptococcus pneumoniae * Efficacy for this organism was studied in fewer than 10 infections. uuid:5f32b2f6-6b71-44b1-a890-75f4867f3a01 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:52717 biolink:treats MONDO:0009693 PMID:41385096 "[{""id"":""uuid:101eda5a-f7ac-47fd-aab3-c35f7592e5ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8d89e608-cc9e-40eb-a789-ddefb76006d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:4e2e826e-f12e-4603-a614-b941b15b2fad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/bortezomib-hospira""]},{""id"":""uuid:a13f2127-41a3-431b-8521-ce917aab41bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bortezomib for injection is a proteasome inhibitor indicated for: treatment of adult patients with multiple myeloma ( 1.1 ) treatment of adult patients with mantle cell lymphoma ( 1.2 )|[EMA] Bortezomib Hospira as monotherapy or in combination with pegylated liposomal doxorubicin or dexamethasone is indicated for the treatment of adult patients with progressive multiple myeloma who have received at least 1 prior therapy and who have already undergone or are unsuitable for haematopoietic stem cell transplantation.Bortezomib Hospira in combination with melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.Bortezomib Hospira in combination with dexamethasone, or with dexamethasone and thalidomide, is indicated for the induction treatment of adult patients with previously untreated multiple myeloma who are eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.Bortezomib Hospira in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.|[PMDA] Drug containing a new active ingredient indicated for treatment of relapsed or refractory multiple myeloma. [Orphan Drug] uuid:a30e30b2-119c-45c4-8c4f-f69ee55bb090 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:52717 biolink:treats MONDO:0018876 PMID:41385096 "[{""id"":""uuid:db024863-01cb-4abf-b8cc-1c0b0a3e1574"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:baf26576-382c-4bc7-8850-eeec933e08ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:628713f7-b5c0-4f47-8588-57c3781fcb4e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/bortezomib-hospira""]},{""id"":""uuid:164c656f-e09d-4b25-a521-20eff2d2783a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bortezomib for injection is a proteasome inhibitor indicated for: treatment of adult patients with multiple myeloma ( 1.1 ) treatment of adult patients with mantle cell lymphoma ( 1.2 )|[EMA] Bortezomib Hospira as monotherapy or in combination with pegylated liposomal doxorubicin or dexamethasone is indicated for the treatment of adult patients with progressive multiple myeloma who have received at least 1 prior therapy and who have already undergone or are unsuitable for haematopoietic stem cell transplantation.Bortezomib Hospira in combination with melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.Bortezomib Hospira in combination with dexamethasone, or with dexamethasone and thalidomide, is indicated for the induction treatment of adult patients with previously untreated multiple myeloma who are eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.Bortezomib Hospira in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.|[PMDA] A drug with a new additional indication and a new dosage for the treatment of patients with mantle cell lymphoma. [Orphan drug] uuid:62f06754-041e-4934-88e0-44ec73eab7fd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:53796 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:8191c38e-655f-4571-b88b-e2d724664680"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:63082aea-8387-42f9-9218-1b3a4da99497"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CONJUPRI ® is calcium channel blocker and may be used alone or in combination with other antihypertensive agents for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. uuid:4a9cab97-f2a6-440b-bd00-c5de13330106 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:KE3U2023NP biolink:treats MONDO:0006502 PMID:41385096 "[{""id"":""uuid:1435145c-786d-49b4-ad50-ade1fbd31488"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:173e1a21-f553-4578-a206-abe083d82712"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CUROSURF ® (poractant alfa) Intratracheal Suspension is indicated for the rescue treatment of Respiratory Distress Syndrome (RDS) in premature infants. CUROSURF reduces mortality and pneumothoraces associated with RDS. uuid:c10a2b04-931f-4c82-95ef-246114622e86 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:KE3U2023NP biolink:treats HP:0006522 PMID:41385096 "[{""id"":""uuid:fd618d3d-a1e7-4708-b580-8a5ac35cdf06"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2a833ade-e727-4d71-b5bb-3ffd5bed5395"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CUROSURF ® (poractant alfa) Intratracheal Suspension is indicated for the rescue treatment of Respiratory Distress Syndrome (RDS) in premature infants. CUROSURF reduces mortality and pneumothoraces associated with RDS. uuid:066d4201-671a-42f2-bcba-0f71d92c2ffc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63638 biolink:treats MONDO:0006710 PMID:41385096 "[{""id"":""uuid:b382bb59-060b-48c2-85c9-97a72a757353"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b99c6b46-112b-4523-8b9f-437651037da1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vigabatrin for oral solution is indicated for the treatment of: Refractory Complex Partial Seizures as adjunctive therapy in patients 2 years of age and older who have responded inadequately to several alternative treatments; vigabatrin for oral solution is not indicated as a first line agent ( 1.1 ) Infantile Spasms - monotherapy in infants 1 month to 2 years of age for whom the potential benefits outweigh the potential risk of vision loss ( 1.2 ) uuid:d7235750-3de0-4b5c-8a43-0efdaada5538 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63638 biolink:treats MONDO:0018097 PMID:41385096 "[{""id"":""uuid:bc32efc2-55f8-4ccf-b4de-070973aca401"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:62ac0292-24f3-4873-bc87-8da482660f63"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:05c34664-561a-436f-9382-66c5920c9feb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/kigabeq""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vigabatrin for oral solution is indicated for the treatment of: Refractory Complex Partial Seizures as adjunctive therapy in patients 2 years of age and older who have responded inadequately to several alternative treatments; vigabatrin for oral solution is not indicated as a first line agent ( 1.1 ) Infantile Spasms - monotherapy in infants 1 month to 2 years of age for whom the potential benefits outweigh the potential risk of vision loss ( 1.2 )|[EMA] Kigabeq is indicated in infants and children from 1 month to less than 7 years of age for:Treatment in monotherapy of infantile spasms (West's syndrome).Treatment in combination with other antiepileptic medicinal products for patients with resistant partial epilepsy (focal onset seizures) with or without secondary generalisation, that is where all other appropriate medicinal product combinations have proved inadequate or have not been tolerated. uuid:7e853ea6-8889-4068-8b11-41a102a6b27d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3654 biolink:treats MONDO:0045048 PMID:41385096 "[{""id"":""uuid:6e249afa-de96-489c-a38f-613b6306fd48"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d8588cff-9d8f-49dd-b6cf-6e88928edd7e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diuretics such as chlorthalidone are indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertension. Chlorthalidone is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Chlorthalidone has also been found useful in edema due to various forms of renal dysfunction, such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure.Chlorthalidone has also been found useful in edema due to various forms of renal dysfunction, such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. Usage in Pregnancy The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developed toxemia. Edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy. Chlorthalidone is indicated in pregnancy when edema is due to pathologic causes, just as it is in the absence of pregnancy (however, see PRECAUTIONS , below). Dependent edema in pregnancy, resulting from restriction of venous return by the expanded uterus, is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is illogical and unnecessary. There is hypervolemia during normal pregnancy that is harmful to neither the fetus nor the mother (in the absence of cardiovascular disease), but that is associated with edema, including generalized edema, in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances, this edema may cause extreme discomfort that is not relieved by rest. In these cases, a short course of diuretics may provide relief and be appropriate. uuid:b3bf9b21-561f-4dff-9aa8-c062a1e33e90 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6824 biolink:treats MONDO:0005071 PMID:41385096 "[{""id"":""uuid:69345e21-e1e5-4635-a9cb-9e01a3f89a0c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bf2df93a-8de8-4e01-90d5-35b080b4c93f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methenamine mandelate is indicated for the suppression or elimination of bacteriuria associated with pyelonephritis, cystitis, and other chronic urinary tract infections; also those neurologic diseases leading to an infected residual urine. When used as recommended, methenamine mandelate is particularly suitable for long-term therapy because of its safety and because resistance to the nonspecific bactericidal action of formaldehyde does not develop. Pathogens resistant to other antibacterial agents may respond to methenamine mandelate because of the nonspecific effect of formaldehyde formed in an acid urine. Prophylactic Use Rationale: Urine is a good culture medium for many urinary pathogens. Inoculation by a few organisms (relapse or reinfection) may lead to bacteriuria in susceptible individuals. Thus, the rationale of management in recurring urinary tract infection (bacteriuria) is to change the urine from a growth-supporting to a growth-inhibiting medium. There is a growing body of evidence that long-term administration of methenamine mandelate can prevent the recurrence of bacteriuria in patients with chronic pyelonephritis. Therapeutic Use Rationale: Methenamine mandelate helps to sterilize the urine, and in some situations in which underlying pathologic conditions prevent sterilization by any means, it can help to suppress the bacteriuria. Methenamine mandelate should not be used alone for acute infections with parenchymal involvement causing systemic symptoms such as chills and fever. A thorough diagnostic investigation as a part of the overall management of the urinary tract infection should accompany the use of methenamine mandelate. uuid:bc2095d3-b21b-410b-a00d-68aafaafe462 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2N4O9L084N biolink:treats HP:0002018 PMID:41385096 "[{""id"":""uuid:668388f9-1f1e-44d1-b8d0-5c51640449c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e54ad370-f51d-41e4-ae1b-3c6f29478869"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cesamet capsules are indicated for the treatment of the nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. This restriction is required because a substantial proportion of any group of patients treated with Cesamet can be expected to experience disturbing psychotomimetic reactions not observed with other antiemetic agents. Because of its potential to alter the mental state, Cesamet is intended for use under circumstances that permit close supervision of the patient by a responsible individual particularly during initial use of Cesamet and during dose adjustments. Cesamet contains nabilone, which is controlled in Schedule II of the Controlled Substances Act. Schedule II substances have a high potential for abuse. Prescriptions for Cesamet should be limited to the amount necessary for a single cycle of chemotherapy (i.e., a few days). Cesamet capsules are not intended to be used on as needed basis or as a first antiemetic product prescribed for a patient. As with all controlled drugs, prescribers should monitor patients receiving nabilone for signs of excessive use, abuse and misuse. Patients who may be at increased risk for substance abuse include those with a personal or family history of substance abuse (including drug or alcohol abuse) or mental illness. uuid:909c5cfb-6f70-46e5-9037-58498c2d6b7e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2N4O9L084N biolink:treats HP:0002013 PMID:41385096 "[{""id"":""uuid:73fac712-1bf0-48c1-abeb-24fdbccc97b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:395ea840-06c8-4d27-af24-6834ed78f4a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cesamet capsules are indicated for the treatment of the nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. This restriction is required because a substantial proportion of any group of patients treated with Cesamet can be expected to experience disturbing psychotomimetic reactions not observed with other antiemetic agents. Because of its potential to alter the mental state, Cesamet is intended for use under circumstances that permit close supervision of the patient by a responsible individual particularly during initial use of Cesamet and during dose adjustments. Cesamet contains nabilone, which is controlled in Schedule II of the Controlled Substances Act. Schedule II substances have a high potential for abuse. Prescriptions for Cesamet should be limited to the amount necessary for a single cycle of chemotherapy (i.e., a few days). Cesamet capsules are not intended to be used on as needed basis or as a first antiemetic product prescribed for a patient. As with all controlled drugs, prescribers should monitor patients receiving nabilone for signs of excessive use, abuse and misuse. Patients who may be at increased risk for substance abuse include those with a personal or family history of substance abuse (including drug or alcohol abuse) or mental illness. uuid:b210040d-b72f-4229-bdab-cc74e99822b7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63616 biolink:treats MONDO:0005112 PMID:41385096 "[{""id"":""uuid:6ebe3dda-bc51-4ecc-81fc-73feed6f940a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:e7561d3d-f288-4be2-bbde-33e0c38665e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:d7a0cc7d-9196-4157-a3fa-2670ab89e2de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pemetrexed for injection, USP is a folate analog metabolic inhibitor indicated: in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous NSCLC, with no EGFR or ALK genomic tumor aberrations. ( 1.1 ) in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic, non-squamous, non-small cell lung cancer (NSCLC). ( 1.1 ) as a single agent for the maintenance treatment of patients with locally advanced or metastatic, non-squamous NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. ( 1.1 ) as a single agent for the treatment of patients with recurrent, metastatic non-squamous, NSCLC after prior chemotherapy. ( 1.1 ) Limitations of Use : Pemetrexed for injection, USP is not indicated for the treatment of patients with squamous cell, non-small cell lung cancer. ( 1.1 ) initial treatment, in combination with cisplatin, of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery. ( 1.2 )|[EMA] Malignant pleural mesotheliomaPemetrexed Accord in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma.Non-small cell lung cancerPemetrexed Accord in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.Pemetrexed Accord is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.Pemetrexed Accord is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. uuid:e14197ec-c96a-40f4-87a9-180c0981fecc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:N6OU7HJ70P biolink:treats MONDO:0005010 PMID:41385096 "[{""id"":""uuid:e615ad6c-29d5-475a-9cdf-5d75740bd864"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fa66a15c-438e-42a5-84ba-ff7362c0d436"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Myocardial Imaging: Kit for the Preparation of Technetium Tc99m Sestamibi Injection is a myocardial perfusion agent that is indicated for detecting coronary artery disease by localizing myocardial ischemia (reversible defects) and infarction (non-reversible defects), in evaluating myocardial function and developing information for use in patient management decisions. Technetium Tc99m Sestamibi evaluation of myocardial ischemia can be accomplished with rest and cardiovascular stress techniques (e.g., exercise or pharmacologic stress in accordance with the pharmacologic stress agent's labeling). It is usually not possible to determine the age of a myocardial infarction or to differentiate a recent myocardial infarction from ischemia. Breast Imaging: Kit for the Preparation of Technetium Tc99m Sestamibi Injection is indicated for planar imaging as a second line diagnostic drug after mammography to assist in the evaluation of breast lesions in patients with an abnormal mammogram or a palpable breast mass. Kit for the Preparation of Technetium Tc99m Sestamibi Injection is not indicated for breast cancer screening, to confirm the presence or absence of malignancy, and it is not an alternative to biopsy. uuid:03bd718d-81c2-4b8c-9b86-f9e5c5cc3060 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:N6OU7HJ70P biolink:treats MONDO:0024644 PMID:41385096 "[{""id"":""uuid:77b4548b-e428-4f0c-b4b7-7f0051ba5fe1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5dbddd8a-afd4-4da2-ac69-55fe7ba3322c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Myocardial Imaging: Kit for the Preparation of Technetium Tc99m Sestamibi Injection is a myocardial perfusion agent that is indicated for detecting coronary artery disease by localizing myocardial ischemia (reversible defects) and infarction (non-reversible defects), in evaluating myocardial function and developing information for use in patient management decisions. Technetium Tc99m Sestamibi evaluation of myocardial ischemia can be accomplished with rest and cardiovascular stress techniques (e.g., exercise or pharmacologic stress in accordance with the pharmacologic stress agent's labeling). It is usually not possible to determine the age of a myocardial infarction or to differentiate a recent myocardial infarction from ischemia. Breast Imaging: Kit for the Preparation of Technetium Tc99m Sestamibi Injection is indicated for planar imaging as a second line diagnostic drug after mammography to assist in the evaluation of breast lesions in patients with an abnormal mammogram or a palpable breast mass. Kit for the Preparation of Technetium Tc99m Sestamibi Injection is not indicated for breast cancer screening, to confirm the presence or absence of malignancy, and it is not an alternative to biopsy. uuid:02432642-6e69-479d-ad88-9264561e6ab1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:N6OU7HJ70P biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:5b10505a-05cf-40dd-a6ce-168eb349f8e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9fab847d-cf88-485c-b79d-87942b1d2898"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Myocardial Imaging: Kit for the Preparation of Technetium Tc99m Sestamibi Injection is a myocardial perfusion agent that is indicated for detecting coronary artery disease by localizing myocardial ischemia (reversible defects) and infarction (non-reversible defects), in evaluating myocardial function and developing information for use in patient management decisions. Technetium Tc99m Sestamibi evaluation of myocardial ischemia can be accomplished with rest and cardiovascular stress techniques (e.g., exercise or pharmacologic stress in accordance with the pharmacologic stress agent's labeling). It is usually not possible to determine the age of a myocardial infarction or to differentiate a recent myocardial infarction from ischemia. Breast Imaging: Kit for the Preparation of Technetium Tc99m Sestamibi Injection is indicated for planar imaging as a second line diagnostic drug after mammography to assist in the evaluation of breast lesions in patients with an abnormal mammogram or a palpable breast mass. Kit for the Preparation of Technetium Tc99m Sestamibi Injection is not indicated for breast cancer screening, to confirm the presence or absence of malignancy, and it is not an alternative to biopsy. uuid:12fa4b60-8a42-4586-8552-6157d7d79060 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:N6OU7HJ70P biolink:treats NCIT:C159594 PMID:41385096 "[{""id"":""uuid:7341f6db-7279-4acb-9203-a4fffe19bafe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5b6af37c-f98c-48d3-bb6b-b9b624197c81"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Myocardial Imaging: Kit for the Preparation of Technetium Tc99m Sestamibi Injection is a myocardial perfusion agent that is indicated for detecting coronary artery disease by localizing myocardial ischemia (reversible defects) and infarction (non-reversible defects), in evaluating myocardial function and developing information for use in patient management decisions. Technetium Tc99m Sestamibi evaluation of myocardial ischemia can be accomplished with rest and cardiovascular stress techniques (e.g., exercise or pharmacologic stress in accordance with the pharmacologic stress agent's labeling). It is usually not possible to determine the age of a myocardial infarction or to differentiate a recent myocardial infarction from ischemia. Breast Imaging: Kit for the Preparation of Technetium Tc99m Sestamibi Injection is indicated for planar imaging as a second line diagnostic drug after mammography to assist in the evaluation of breast lesions in patients with an abnormal mammogram or a palpable breast mass. Kit for the Preparation of Technetium Tc99m Sestamibi Injection is not indicated for breast cancer screening, to confirm the presence or absence of malignancy, and it is not an alternative to biopsy. uuid:b09e719e-cf8b-49df-8309-9fba245fb267 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:N6OU7HJ70P biolink:treats MONDO:0002657 PMID:41385096 "[{""id"":""uuid:203beb82-d497-485f-859d-5c59b7516e82"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5e073a18-1eee-4c9b-9d7e-78e04add781b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Myocardial Imaging: Kit for the Preparation of Technetium Tc99m Sestamibi Injection is a myocardial perfusion agent that is indicated for detecting coronary artery disease by localizing myocardial ischemia (reversible defects) and infarction (non-reversible defects), in evaluating myocardial function and developing information for use in patient management decisions. Technetium Tc99m Sestamibi evaluation of myocardial ischemia can be accomplished with rest and cardiovascular stress techniques (e.g., exercise or pharmacologic stress in accordance with the pharmacologic stress agent's labeling). It is usually not possible to determine the age of a myocardial infarction or to differentiate a recent myocardial infarction from ischemia. Breast Imaging: Kit for the Preparation of Technetium Tc99m Sestamibi Injection is indicated for planar imaging as a second line diagnostic drug after mammography to assist in the evaluation of breast lesions in patients with an abnormal mammogram or a palpable breast mass. Kit for the Preparation of Technetium Tc99m Sestamibi Injection is not indicated for breast cancer screening, to confirm the presence or absence of malignancy, and it is not an alternative to biopsy. uuid:6bbc0455-17f2-4554-8f9f-fc0ae611842d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:49821151 biolink:treats MONDO:0005002 PMID:41385096 "[{""id"":""uuid:2efcf969-44a9-479c-a1e1-5ed7bbc446c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f85c2330-9272-4320-b24a-fe1c5809cd0b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Arformoterol tartrate inhalation solution is a long-acting beta 2 -adrenergic agonist (beta 2 -agonist) indicated for: Long-term, twice daily (morning and evening) administration in the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. (1.1) Important limitations of use: Arformoterol tartrate inhalation solution is not indicated to treat acute deteriorations of chronic obstructive pulmonary disease. (1.2, 5.2) Arformoterol tartrate inhalation solution is not indicated to treat asthma. (1.2) uuid:58166c9d-1aac-4048-b47d-8aa479c18c0c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:49821151 biolink:treats MONDO:0005607 PMID:41385096 "[{""id"":""uuid:f9244043-a131-4f2c-b77c-83c392c9b94a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:06d220eb-bd50-4ea2-8295-544e2b109069"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Arformoterol tartrate inhalation solution is a long-acting beta 2 -adrenergic agonist (beta 2 -agonist) indicated for: Long-term, twice daily (morning and evening) administration in the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. (1.1) Important limitations of use: Arformoterol tartrate inhalation solution is not indicated to treat acute deteriorations of chronic obstructive pulmonary disease. (1.2, 5.2) Arformoterol tartrate inhalation solution is not indicated to treat asthma. (1.2) uuid:f97699a4-f4fc-4217-b95c-e0f5e62e0c4c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:49821151 biolink:treats MONDO:0004849 PMID:41385096 "[{""id"":""uuid:93695af1-3d6b-4f91-a7bf-b9771caabdf7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:76874a06-526f-4aad-b7d1-453d7c8700db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Arformoterol tartrate inhalation solution is a long-acting beta 2 -adrenergic agonist (beta 2 -agonist) indicated for: Long-term, twice daily (morning and evening) administration in the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. (1.1) Important limitations of use: Arformoterol tartrate inhalation solution is not indicated to treat acute deteriorations of chronic obstructive pulmonary disease. (1.2, 5.2) Arformoterol tartrate inhalation solution is not indicated to treat asthma. (1.2) uuid:b5dec189-07cb-4d40-85b8-68d11a541810 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:34385 biolink:treats MONDO:0005301 PMID:41385096 "[{""id"":""uuid:e812ee0e-d2d9-4c79-a8d1-16b277df5160"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:0cc7f1ba-e0a4-4323-9b2f-43f147408c86"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:2b2e2ec0-75dc-43cc-b1db-20770f152abf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/fampridine-accord""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dalfampridine extended-release tablets are indicated as a treatment to improve walking in adult patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed [see Clinical Studies (14) ].|[EMA] Fampridine Accord is indicated for the improvement of walking in adult patients with multiple sclerosis with walking disability (EDSS 4-7). uuid:8d2dff3a-931e-4aff-9b87-da5c5713181e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3504 biolink:treats MONDO:0005227 PMID:41385096 "[{""id"":""uuid:1c54d4fa-9be2-41f5-9cae-013f9898767d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5b83664b-a48f-47bc-b98e-ce47799dc01c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefpodoxime proxetil is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Recommended dosages, durations of therapy, and applicable patient populations vary among these infections. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute otitis media caused by Streptococcus pneumoniae (excluding penicillin-resistant strains), Streptococcus pyogenes , Haemophilus influenzae (including beta-lactamase-producing strains), or Moraxella (Branhamella) catarrhalis (including beta-lactamase-producing strains). Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes . NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefpodoxime proxetil is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefpodoxime proxetil for the prophylaxis of subsequent rheumatic fever are not available. Community-acquired pneumonia caused by S. pneumoniae or H. Influenzae (including beta-lactamase-producing strains). Acute bacterial exacerbation of chronic bronchitis caused by S. pneumoniae , H. influenzae (non-beta-lactamase-producing strains only), or M. catarrhalis . Data are insufficient at this time to establish efficacy in patients with acute bacterial exacerbations of chronic bronchitis caused by beta-lactamase-producing strains of H. influenzae . Acute, uncomplicated urethral and cervical gonorrhea caused by Neisseria gonorrhoeae (including penicillinase-producing strains). Acute, uncomplicated ano-rectal infections in women due to Neisseria gonorrhoeae (including penicillinase-producing strains). NOTE: The efficacy of cefpodoxime in treating male patients with rectal infections caused by N. gonorrhoeae has not been established. Data do not support the use of cefpodoxime proxetil in the treatment of pharyngeal infections due to N. gonorrhoeae in men or women. Uncomplicated skin and skin structure infections caused by Staphylococcus aureus (including penicillinase-producing strains) or Streptococcus pyogenes . Abscesses should be surgically drained as clinically indicated. NOTE: In clinical trials, successful treatment of uncomplicated skin and skin structure infections was dose-related. The effective therapeutic dose for skin infections was higher than those used in other recommended indications. (See DOSAGE AND ADMINISTRATION .) Acute maxillary sinusitis caused by Haemophilus influenzae (including beta-lactamase-producing strains), Streptococcus pneumoniae , and Moraxella catarrhalis . Uncomplicated urinary tract infections (cystitis) caused by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis , or Staphylococcus saprophyticus . NOTE: In considering the use of cefpodoxime proxetil in the treatment of cystitis, cefpodoxime proxetil’s lower bacterial eradication rates should be weighed against the increased eradication rates and different safety profiles of some other classes of approved agents. (See CLINICAL STUDIES section.) Appropriate specimens for bacteriological examination should be obtained in order to isolate and identify causative organisms and to determine their susceptibility to cefpodoxime. Therapy may be instituted while awaiting the results of these studies. Once these results become available, antimicrobial therapy should be adjusted accordingly. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefpodoxime proxetil and other antibacterial drugs, cefpodoxime proxetil should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:063ecef8-65ac-4c14-a003-b3cab3ca8fbc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0008109 PMID:41385096 "[{""id"":""uuid:2587b26b-37a0-4f04-9502-0109817cbe3a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9f93cefe-b50b-4928-b30d-d84afa37dff3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic states Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases For the palliative management of leukemias and lymphomas. Nervous system Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic diseases Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:728819eb-72b4-41a8-a868-1f28b73f18b6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17594 biolink:treats HP:0001003 PMID:41385096 "[{""id"":""uuid:a375c9b8-d205-4220-a770-daee033cd171"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ab87344b-4e82-4208-a7c4-80deccea0b35"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE 1.1Indication BLEMISH ERASER is a combination of hydrocortisone (a corticosteroid), hydroquinone (a melanin synthesis inhibitor), and a tretinoin (a retinoid) that is indicated for the gradual bleaching of hyperpigmented skin conditions age and liver spots, freckles, and other unwanted areas of melanin hyperpigmentation, in the presence of measures for sun avoidance, including the use of sunscreen. 1.2 Limitations of Use The safety and efficacy of BLEMISH ERASER in pregnant women and nursing mothers have not been established. uuid:f5835137-8fda-4e36-82d3-f195d915411d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16199 biolink:treats MONDO:0021036 PMID:41385096 "[{""id"":""uuid:24f444a4-985c-4d00-b4ff-6e9b53ce1291"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e2de3292-5775-4f34-b25e-0e738be5074f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For debridement and promotion of normal healing of hyperkeratotic surface lesions, particularly where healing is retarded by local infection, necrotic tissue, fibrinous or purulent debris or eshar. Urea is useful for the treatment of hyperkeratotic conditions such as dry, rough skin, dermatitis, psoriasis, xerosis, ichthyosis, eczema, keratosis pilaris, keratosis palmaris, keratoderma, corns and calluses, as well as damaged, ingrown and devitalized nails. uuid:96c37c3b-4cb8-4758-b715-ff77cbd952dc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16199 biolink:treats UMLS:C0856543 PMID:41385096 "[{""id"":""uuid:943101d1-009d-441a-83b2-1bd008daaf6a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9ce02047-6c14-442a-ae3d-3e73fb51958a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For debridement and promotion of normal healing of hyperkeratotic surface lesions, particularly where healing is retarded by local infection, necrotic tissue, fibrinous or purulent debris or eshar. Urea is useful for the treatment of hyperkeratotic conditions such as dry, rough skin, dermatitis, psoriasis, xerosis, ichthyosis, eczema, keratosis pilaris, keratosis palmaris, keratoderma, corns and calluses, as well as damaged, ingrown and devitalized nails. uuid:8921972b-8b66-4995-a015-d0361ac2ac2c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50378 biolink:treats MONDO:0004741 PMID:41385096 "[{""id"":""uuid:cf1f3180-5952-4d7a-ab83-15d479fa4bfb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4de5c32b-50aa-41e3-bcec-b458d533693c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ORFADIN ® is indicated for the treatment of adult and pediatric patients with hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine. uuid:5a4d5c89-f0f3-4709-b36a-2d915d3e89c9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:92511 biolink:treats MONDO:0001384 PMID:41385096 "[{""id"":""uuid:4b094b9c-57bc-4e16-875d-0a6138a0ff7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c26672ad-75c3-4139-9d63-aff73171faff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ACUVUE ® Theravision™ with Ketotifen is a daily wear, daily disposable etafilcon A drug-eluting contact lens for prevention ocular itch due to allergic conjunctivitis and correction of refractive ametropia (myopia and hyperopia) in aphakic and/or phakic patients who do not have red eye(s), are suitable for contact lens wear and do not have more than 1 D of astigmatism. The lens contains an H 1 histamine receptor antagonist for the prevention of ocular itch due to allergic conjunctivitis. The prevention of itch has been demonstrated to last through 12 hours in clinical trials; however, the lens may be worn for longer than 12 hours in a single day. uuid:fa649aa5-2ec3-48d2-97d0-e47ffe393fc3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:92511 biolink:treats MONDO:0004891 PMID:41385096 "[{""id"":""uuid:c2e7a738-ca7a-4ed0-8e30-5611cc90ea78"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:80bb7300-cef5-4513-ab2a-4a81fc3fbab3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ACUVUE ® Theravision™ with Ketotifen is a daily wear, daily disposable etafilcon A drug-eluting contact lens for prevention ocular itch due to allergic conjunctivitis and correction of refractive ametropia (myopia and hyperopia) in aphakic and/or phakic patients who do not have red eye(s), are suitable for contact lens wear and do not have more than 1 D of astigmatism. The lens contains an H 1 histamine receptor antagonist for the prevention of ocular itch due to allergic conjunctivitis. The prevention of itch has been demonstrated to last through 12 hours in clinical trials; however, the lens may be worn for longer than 12 hours in a single day. uuid:a332b681-3483-4b65-a6aa-24fdd8cce52f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59594 biolink:treats MONDO:0005147 PMID:41385096 "[{""id"":""uuid:f2084fc0-fab1-4e28-91d9-be1061cf5bc2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0c6b3038-d1e7-40ec-87f7-fe090004ef4c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] WELCHOL is a bile acid sequestrant indicated as an adjunct to diet and exercise to: reduce elevated low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia ( 1.1 ). reduce LDL-C levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia (HeFH), unable to reach LDL-C target levels despite an adequate trial of diet and lifestyle modification ( 1.1 ). improve glycemic control in adults with type 2 diabetes mellitus ( 1.2 ). Limitations of Use ( 1.3 ): Do not use for treatment of type 1 diabetes or for diabetic ketoacidosis. Not studied in Fredrickson Type I, III, IV, and V dyslipidemias uuid:534c0f72-083a-421c-bd0d-2ecfd63142b6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:308714 biolink:treats MONDO:0005982 PMID:41385096 "[{""id"":""uuid:75b17835-e02b-446e-b666-8d4b491e6e89"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:01fddd48-d74d-43d8-8500-53583630af33"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clotrimazole and Betamethasone Dipropionate Cream is indicated in patients 17 years and older for the topical treatment of symptomatic inflammatory tinea pedis, tinea cruris and tinea corporis due to Epidermophyton floccosum , Trichophyton mentagrophytes , and Trichophyton rubrum . Effective treatment without the risks associated with topical corticosteroid use may be obtained using a topical antifungal agent that does not contain a corticosteroid, especially for noninflammatory tinea infections. The efficacy of clotrimazole and betamethasone dipropionate cream for the treatment of infections caused by zoophilic dermatophytes (e.g., Microsporum canis ) has not been established. Several cases of treatment failure of clotrimazole and betamethasone dipropionate cream in the treatment of infections caused by Microsporum canis have been reported uuid:daff3477-dc2f-4f80-990b-4e00efdcc7a9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28939 biolink:treats MONDO:0018741 PMID:41385096 "[{""id"":""uuid:115e80d0-73f8-4fb8-8cbb-daccea14e7f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8bb6dbd3-23fa-4505-a483-79f5ef44a51e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Acetylcysteine Injection is indicated to prevent or lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of acetaminophen in patients with acute ingestion or from repeated supratherapeutic ingestion (RSI). uuid:fc73fdda-a4fd-4ceb-92ae-a43eb613902a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28939 biolink:treats UMLS:C0160390 PMID:41385096 "[{""id"":""uuid:397f130d-273f-4873-8af2-3c14f958b714"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ab4c1111-a6ac-4ff5-80ec-0d44fb8ee3c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Acetylcysteine Injection is indicated to prevent or lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of acetaminophen in patients with acute ingestion or from repeated supratherapeutic ingestion (RSI). uuid:8832d961-0c04-4702-a011-dc354bd66c8d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17252 biolink:treats MONDO:0006003 PMID:41385096 "[{""id"":""uuid:48272228-b367-460e-84e5-5623abb8bcdd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ea2e075d-c41c-43b7-85cd-1646866e6424"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydroxyprogesterone Caproate Injection, USP is indicated in non-pregnant women: for the treatment of advanced adenocarcinoma of the uterine corpus (Stage III or IV); in the management of amenorrhea (primary and secondary) and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer; as a test for endogenous estrogen production and for the production of secretory endometrium and desquamation. uuid:93a42830-2ab4-4c8c-9735-dbd113547b66 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17252 biolink:treats MONDO:0001836 PMID:41385096 "[{""id"":""uuid:5c810e03-d14b-4fc5-a3d3-12787ee7c52d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c8902e9f-9eef-485d-acff-e76b518fb583"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydroxyprogesterone Caproate Injection, USP is indicated in non-pregnant women: for the treatment of advanced adenocarcinoma of the uterine corpus (Stage III or IV); in the management of amenorrhea (primary and secondary) and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer; as a test for endogenous estrogen production and for the production of secretory endometrium and desquamation. uuid:daef9087-6992-4060-99b1-cd3392d7cd90 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17252 biolink:treats UMLS:C3650625 PMID:41385096 "[{""id"":""uuid:f9d57858-4681-47ca-a14c-ee48077c68e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9b9f1946-8baa-4b24-919f-8adfc3b8a3ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydroxyprogesterone Caproate Injection, USP is indicated in non-pregnant women: for the treatment of advanced adenocarcinoma of the uterine corpus (Stage III or IV); in the management of amenorrhea (primary and secondary) and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer; as a test for endogenous estrogen production and for the production of secretory endometrium and desquamation. uuid:6232b3c5-2596-4aa4-873f-9c2496680293 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17252 biolink:treats MONDO:0002715 PMID:41385096 "[{""id"":""uuid:b4feec59-ff48-464f-bbe6-5927f3aaf98f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fd693184-0738-42f1-8bce-0367ef7bc539"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydroxyprogesterone Caproate Injection, USP is indicated in non-pregnant women: for the treatment of advanced adenocarcinoma of the uterine corpus (Stage III or IV); in the management of amenorrhea (primary and secondary) and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer; as a test for endogenous estrogen production and for the production of secretory endometrium and desquamation. uuid:77a2c57b-32a9-4e2e-9d38-74a1bd4a9fea biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation MESH:C517983 biolink:treats EFO:0010581 PMID:41385096 "[{""id"":""uuid:24d88274-e854-490c-baaf-0081d825760f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5726d9b3-ede2-43a6-a967-aca09a9dc00c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DuoDote is indicated for the treatment of poisoning by organophosphorus nerve agents as well as organophosphorus insecticides in adults and pediatric patients weighing more than 41 kg (90 pounds). uuid:06a0f1b3-dc98-489e-ac95-42f0243ba827 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3757 biolink:treats UMLS:C0278140 PMID:41385096 "[{""id"":""uuid:9f6e4742-1b52-4ec9-acda-2eb7e0ce0564"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f4f066c4-754e-4d24-89a8-ca35789e92a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clonidine Hydrochloride Injection, USP is indicated in combination with opiates for the treatment of severe pain in cancer patients that is not adequately relieved by opioid analgesics alone. Epidural clonidine is more likely to be effective in patients with neuropathic pain than somatic or visceral pain (see CLINICAL PHARMACOLOGY: Clinical Trials ). The safety of this drug product has only been established in a highly selected group of cancer patients, and only after an adequate trial of opioid analgesia. Other use is of unproven safety and is not recommended. In a rare patient, the potential benefits may outweigh the known risks (see WARNINGS ). uuid:a8c43245-95b4-4cd8-a16b-29497f765535 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6472 biolink:treats MONDO:0005113 PMID:41385096 "[{""id"":""uuid:1b3774df-19a3-4c84-9582-ac35986158e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:34aa3fba-0910-4376-9682-9481b7547eb0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lincomycin injection is indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of CDAD, as described in the BOXED WARNING , before selecting lincomycin the physician should consider the nature of the infection and the suitability of other alternatives. Indicated surgical procedures should be performed in conjunction with antibacterial therapy. Lincomycin injection may be administered concomitantly with other antimicrobial agents when indicated. Lincomycin is not indicated in the treatment of minor bacterial infections or viral infections. To reduce the development of drug-resistant bacteria and maintain the effectiveness of lincomycin and other antibacterial drugs, lincomycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:4ddafd63-cbd2-4412-ab75-1bbe2f55a413 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6472 biolink:treats MONDO:0005108 PMID:41385096 "[{""id"":""uuid:7f5da0e1-ece5-4b3b-b30e-20d336f788c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cbcc3ee2-e5b2-4a1a-a9f0-8ec35d214dbf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lincomycin injection is indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of CDAD, as described in the BOXED WARNING , before selecting lincomycin the physician should consider the nature of the infection and the suitability of other alternatives. Indicated surgical procedures should be performed in conjunction with antibacterial therapy. Lincomycin injection may be administered concomitantly with other antimicrobial agents when indicated. Lincomycin is not indicated in the treatment of minor bacterial infections or viral infections. To reduce the development of drug-resistant bacteria and maintain the effectiveness of lincomycin and other antibacterial drugs, lincomycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:9243ca1c-5ed5-4f48-9c8b-0494a53ac649 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:9887103 biolink:treats MONDO:0006497 PMID:41385096 "[{""id"":""uuid:6ebdf685-82fe-4d5a-8121-385bbe32ae33"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:425da78d-c324-4ba9-bcc1-7479ac8cb679"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Glycopyrrolate oral solution is indicated to reduce chronic severe drooling in patients aged 3 to 16 years with neurologic conditions associated with problem drooling (e.g., cerebral palsy). uuid:cee19c25-9477-4e2c-ae60-7417efe29693 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:9887103 biolink:treats HP:0002307 PMID:41385096 "[{""id"":""uuid:1f69ca3c-2ebb-4dbc-b86b-a093a73383cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:23864f32-c0f3-490e-8a09-3a3831c0b82b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Glycopyrrolate oral solution is indicated to reduce chronic severe drooling in patients aged 3 to 16 years with neurologic conditions associated with problem drooling (e.g., cerebral palsy). uuid:6f82fb6e-ccc9-4401-93ab-55fb8c62bbca biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63616 biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:f2b26f41-6869-44d8-ac79-fa8033325990"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:231c330d-f5d0-492e-a77f-c6f9ba237985"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:780df1aa-a8dc-42d1-a445-98fbb1762e80"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:9f99538e-3b74-4509-8852-c0d44ace721c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pemetrexed Injection is a folate analog metabolic inhibitor indicated: In combination with cisplatin for the initial treatment of patients with locally advanced or metastatic, non-squamous, non-small cell lung cancer (NSCLC). ( 1.1 ) As a single agent for the maintenance treatment of patients with locally advanced or metastatic, non -squamous NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. ( 1.1 ) As a single agent for the treatment of patients with recurrent, metastatic non-squamous, NSCLC after prior chemotherapy. ( 1.1 ) Limitations of Use : Pemetrexed Injection is not indicated for the treatment of patients with squamous cell, non-small cell lung cancer. ( 1.1 ) Initial treatment, in combination with cisplatin, of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery. ( 1.2 )|[EMA] Malignant pleural mesotheliomaPemetrexed Accord in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma.Non-small cell lung cancerPemetrexed Accord in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.Pemetrexed Accord is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.Pemetrexed Accord is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.|[PMDA] Drugs with a new additional indication and a new dosage in an additional dosage form (Alimta Injection 100 mg) indicated for the treatment of unresectable advanced or recurrent non-small cell lung cancer. uuid:89e767a5-3576-4565-97ff-7cd3162b970c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77776 biolink:treats MONDO:0005984 PMID:41385096 "[{""id"":""uuid:5e4cad9b-914b-4456-96ec-0213a5a4f04a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e2dfe0e8-5c55-4cb5-87f1-0ddaad52f7ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EXELDERM (sulconazole nitrate, USP) CREAM, 1.0% is an antifungal agent indicated for the treatment of tinea pedis (athlete's foot), tinea cruris, and tinea corporis caused by Trichophyton rubrum, Trichophyton mentagro-phytes, Epidermophyton floccosum, and Microsporum canis,* and for the treatment of tinea versicolor. *Efficacy for this organism in the organ system was studied in fewer than ten infections. uuid:f72267aa-e859-464e-bec9-c008147ede1b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50223 biolink:treats UMLS:C0278488 PMID:41385096 "[{""id"":""uuid:b93b1b0b-d04f-4e79-9f6d-54aa86cac917"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5f5297c6-6846-4887-9f14-e0b9e3c7e001"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dexrazoxane for injection is indicated for reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose of 300 mg/m 2 and who will continue to receive doxorubicin therapy to maintain tumor control. Do not use with the initiation of doxorubicin therapy [see Warnings and Precautions (5.2) ] . uuid:c1db4aaa-65da-4955-81b4-2a58ca597eaf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50223 biolink:treats MONDO:0004994 PMID:41385096 "[{""id"":""uuid:95faab84-b384-4681-9388-590e440d9d9f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7944d7d1-a06d-4378-a75d-e5771e335bcc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dexrazoxane for injection is indicated for reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose of 300 mg/m 2 and who will continue to receive doxorubicin therapy to maintain tumor control. Do not use with the initiation of doxorubicin therapy [see Warnings and Precautions (5.2) ] . uuid:c6082568-1b25-489a-b172-cb4e1353012d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28001 biolink:treats UMLS:C0340359 PMID:41385096 "[{""id"":""uuid:9e0ef8f2-3194-4923-b0ee-daac25c670a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:330e01c9-96fd-43a2-a556-85e353f8564a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vancomycin hydrochloride for injection, USP is indicated for the treatment of serious or severe infections caused by susceptible strains of methicillin-resistant (β-lactam-resistant) staphylococci. It is indicated for penicillin-allergic patients, for patients who cannot receive or who have failed to respond to other drugs, including the penicillins or cephalosporins, and for infections caused by vancomycin-susceptible organisms that are resistant to other antimicrobial drugs. Vancomycin hydrochloride for injection, USP is indicated for initial therapy when methicillin-resistant staphylococci are suspected, but after susceptibility data are available, therapy should be adjusted accordingly. Vancomycin hydrochloride for injection, USP is effective in the treatment of staphylococcal endocarditis. Its effectiveness has been documented in other infections due to staphylococci, including septicemia, bone infections, lower respiratory tract infections, and skin and skin-structure infections. When staphylococcal infections are localized and purulent, antibiotics are used as adjuncts to appropriate surgical measures. Vancomycin hydrochloride for injection, USP has been reported to be effective alone or in combination with an aminoglycoside for endocarditis caused by S. viridans or S. bovis . For endocarditis caused by enterococci (e.g., E. faecalis ), vancomycin hydrochloride for injection, USP has been reported to be effective only in combination with an aminoglycoside. Vancomycin hydrochloride for injection, USP has been reported to be effective for the treatment of diphtheroid endocarditis. Vancomycin hydrochloride for injection, USP has been used successfully in combination with either rifampin, an aminoglycoside, or both in early-onset prosthetic valve endocarditis caused by S. epidermidis or diphtheroids. Specimens for bacteriologic cultures should be obtained in order to isolate and identify causative organisms and to determine their susceptibilities to vancomycin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of vancomycin hydrochloride for injection, USP and other antibacterial drugs, vancomycin hydrochloride for injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. The parenteral form of vancomycin hydrochloride may be administered orally for treatment of antibiotic-associated pseudomembranous colitis produced by C. difficile and for staphylococcal enterocolitis. Parenteral administration of vancomycin hydrochloride alone is of unproven benefit for these indications. Vancomycin is not effective by the oral route for other types of infections. uuid:79e963dd-3f67-457a-b0e3-52b84801734e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:216653 biolink:treats HP:0000505 PMID:41385096 "[{""id"":""uuid:9c4dad09-cbb5-46e1-9037-4c3019c4d7d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3a93ba61-0498-41f6-8a30-140d48bbfeca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Valsartan and hydrochlorothiazide tablets, USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including hydrochlorothiazide and the ARB class to which valsartan principally belongs. There are no controlled trials demonstrating risk reduction with valsartan and hydrochlorothiazide tablets, USP. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality have also been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Add-On Therapy Valsartan and hydrochlorothiazide tablets, USP may be used in patients whose blood pressure is not adequately controlled on monotherapy. Replacement Therapy Valsartan and hydrochlorothiazide tablets, USP may be substituted for the titrated components. Initial Therapy Valsartan and hydrochlorothiazide tablets, USP may be used as initial therapy in patients who are likely to need multiple drugs to achieve blood pressure goals. The choice of valsartan and hydrochlorothiazide tablets, USP as initial therapy for hypertension should be based on an assessment of potential benefits and risks. Patients with stage 2 hypertension are at a relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. The decision to use a combination as initial therapy should be individualized and should be shaped by considerations such as baseline blood pressure, the target goal and the incremental likelihood of achieving goal with a combination compared to monotherapy. Individual blood pressure goals may vary based upon the patient's risk. Data from the high dose multifactorial trial [see Clinical Studies ( 14.1)] provides estimates of the probability of reaching a target blood pressure with valsartan and hydrochlorothiazide tablets, USP compared to valsartan or hydrochlorothiazide monotherapy. The figures below provide estimates of the likelihood of achieving systolic or diastolic blood pressure control with valsartan and hydrochlorothiazide tablets, USP 320/25 mg, based upon baseline systolic or diastolic blood pressure. The curve of each treatment group was estimated by logistic regression modeling. The estimated likelihood at the right tail of each curve is less reliable due to small numbers of subjects with high baseline blood pressures. Figure 1: Probability of Achieving Systolic Blood Pressure <140 mmHg at Week 8 Figure 2: Probability of Achieving Diastolic Blood Pressure <90 mmHg at Week 8 Figure 3: Probability of Achieving Systolic Blood Pressure <130 mmHg at Week 8 Figure 4: Probability of Achieving Diastolic Blood Pressure <80 mmHg at Week 8 For example, a patient with a baseline blood pressure of 160/100 mmHg has about a 41% likelihood of achieving a goal of <140 mmHg (systolic) and 60% likelihood of achieving <90 mmHg (diastolic) on valsartan alone and the likelihood of achieving these goals on HCTZ alone is about 50% (systolic) or 57% (diastolic). The likelihood of achieving these goals on valsartan and hydrochlorothiazide tablets, USP rises to about 84% (systolic) or 80% (diastolic). The likelihood of achieving these goals on placebo is about 23% (systolic) or 36% (diastolic). uuid:c5653cfb-2ff2-4302-bbea-7958fec32085 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31638 biolink:treats UMLS:C3495917 PMID:41385096 "[{""id"":""uuid:96db4647-0741-42a7-8708-3eff4d54e6e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:96ccaad4-cc7c-4471-92ec-dfb36e5e7433"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Monotherapy Fulvestrant injection is indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy, or HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. Combination Therapy Fulvestrant injection is indicated for the treatment of: HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib as initial endocrine based therapy or following disease progression on endocrine therapy. HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. uuid:3eb75b3c-21e1-43c0-96e1-b2cfcddb9f39 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31638 biolink:treats UMLS:C0278488 PMID:41385096 "[{""id"":""uuid:64c3857c-15d1-4392-88c3-e6b830647145"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cb5a0276-b1bd-456a-a75c-07957fcb68db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Monotherapy Fulvestrant injection is indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy, or HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. Combination Therapy Fulvestrant injection is indicated for the treatment of: HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib as initial endocrine based therapy or following disease progression on endocrine therapy. HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. uuid:0f8361f0-bfd6-4a54-be62-778be9575ce6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:140628 biolink:treats MONDO:0005316 PMID:41385096 "[{""id"":""uuid:fd7fec05-5426-47e3-9c37-5491fc565dfa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:730f699d-5808-4bc1-8779-071307a611ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SOLOSEC ® is a nitroimidazole antimicrobial indicated for Treatment of bacterial vaginosis in female patients 12 years of age and older. ( 1.1 ) Treatment of trichomoniasis in patients 12 years of age and older. ( 1.2 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of SOLOSEC and other antibacterial drugs, SOLOSEC should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.3 ) uuid:10caa7d3-8f8c-4579-a3d4-afb002b1500d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:140628 biolink:treats MONDO:0002154 PMID:41385096 "[{""id"":""uuid:8a0455b1-159a-42f3-b5b5-191b7520fb21"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e57d311c-eba0-4784-8065-8a329fb089e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SOLOSEC ® is a nitroimidazole antimicrobial indicated for Treatment of bacterial vaginosis in female patients 12 years of age and older. ( 1.1 ) Treatment of trichomoniasis in patients 12 years of age and older. ( 1.2 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of SOLOSEC and other antibacterial drugs, SOLOSEC should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.3 ) uuid:b2bdd515-45e8-46eb-bd55-e6e56adaeb86 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:82718 biolink:treats MONDO:0001628 PMID:41385096 "[{""id"":""uuid:adaa20cc-e683-4259-81ef-a43509943add"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:932f0b91-8c98-45fc-ac8a-6b5e3639b1e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e0b4bcac-00c2-4f40-9152-2c9b20767bd5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] JUBLIA (efinaconazole) topical solution, 10% is an azole antifungal indicated for the topical treatment of onychomycosis of the toenail(s) due to Trichophyton rubrum and Trichophyton mentagrophytes .|[PMDA] A drug with a new active ingredient indicated for the treatment of tinea unguium caused by dermatophyte (trichophyton ). uuid:3462f915-197d-4efc-8340-d5cd399cd758 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:82718 biolink:treats UMLS:C5192601 PMID:41385096 "[{""id"":""uuid:574442c6-1660-4e5f-9926-9c3e423a0339"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6e93184f-75b4-4f94-8b76-b1fb97ceec0a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] JUBLIA (efinaconazole) topical solution, 10% is an azole antifungal indicated for the topical treatment of onychomycosis of the toenail(s) due to Trichophyton rubrum and Trichophyton mentagrophytes . uuid:bc111f31-89bc-4b43-97b1-82bbb54ad11f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:23742 biolink:treats MONDO:0004995 PMID:41385096 "[{""id"":""uuid:76049e14-8bab-44e8-b704-e9d90f5593a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0267299f-b7e8-464e-aca2-e9504325ae42"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] This fixed combination drug is not indicated for the initial therapy of edema or hypertension except in individuals in whom the development of hypokalemia cannot be risked. Triamterene and hydrochlorothiazide capsules, USP are indicated for the treatment of hypertension or edema in patients who develop hypokalemia on hydrochlorothiazide alone. Triamterene and hydrochlorothiazide capsules, USP are also indicated for those patients who require a thiazide diuretic and in whom the development of hypokalemia cannot be risked. Triamterene and hydrochlorothiazide capsules, USP may be used alone or as an adjunct to other antihypertensive drugs, such as beta-blockers. Since triamterene and hydrochlorothiazide capsules, USP may enhance the action of these agents, dosage adjustments may be necessary. Usage in Pregnancy: The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developed toxemia. Edema during pregnancy may arise from pathological causes or from the physiologic and mechanical consequences of pregnancy. Diuretics are indicated in pregnancy when edema is due to pathologic causes, just as they are in the absence of pregnancy. Dependent edema in pregnancy resulting from restriction of venous return by the expanded uterus is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is illogical and unnecessary. There is hypervolemia during normal pregnancy which is harmful to neither the fetus nor the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances this edema may cause extreme discomfort which is not relieved by rest. In these cases, a short course of diuretics may provide relief and may be appropriate. uuid:40895824-ebe2-4d20-b078-f0b663666978 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63916 biolink:treats MONDO:0015924 PMID:41385096 "[{""id"":""uuid:657e601e-fffb-418e-8d85-f99ffa464d23"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d9684d43-7bcb-4e78-9787-62d13234674e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:3c1bd400-0f26-48b3-bc58-c3d70bd22752"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VENTAVIS is a prostacyclin mimetic indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve a composite endpoint consisting of exercise tolerance, symptoms (NYHA Class), and lack of deterioration. Studies establishing effectiveness included predominately patients with NYHA Functional Class III-IV symptoms and etiologies of idiopathic or heritable PAH (65%) or PAH associated with connective tissue diseases (23%). ( 1.1 ).|[PMDA] A drug with a new active ingredient indicated for the treatment of pulmonary arterial hypertension. uuid:dc79a071-7db4-4f2f-893b-8054e319d7ed biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63916 biolink:treats MONDO:0017147 PMID:41385096 "[{""id"":""uuid:27dd26dd-1001-43bf-aeff-666a9ffc9857"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ce5a4738-3417-487d-aa78-944fb44a2392"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VENTAVIS is a prostacyclin mimetic indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve a composite endpoint consisting of exercise tolerance, symptoms (NYHA Class), and lack of deterioration. Studies establishing effectiveness included predominately patients with NYHA Functional Class III-IV symptoms and etiologies of idiopathic or heritable PAH (65%) or PAH associated with connective tissue diseases (23%). ( 1.1 ). uuid:fe856a4a-f51b-4df2-b949-e915576ea804 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63916 biolink:treats MONDO:0017148 PMID:41385096 "[{""id"":""uuid:0301b202-f34d-42af-9d35-5a97c0506377"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:489c66e4-cdcc-415e-b2d2-1fe5242be072"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VENTAVIS is a prostacyclin mimetic indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve a composite endpoint consisting of exercise tolerance, symptoms (NYHA Class), and lack of deterioration. Studies establishing effectiveness included predominately patients with NYHA Functional Class III-IV symptoms and etiologies of idiopathic or heritable PAH (65%) or PAH associated with connective tissue diseases (23%). ( 1.1 ). uuid:8bdee157-2b1a-46cd-ac99-89efe8525187 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47657 biolink:treats UMLS:C0853854 PMID:41385096 "[{""id"":""uuid:0e8f3ddb-69f1-4529-bc3b-07dca7dd3342"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8e147749-4fc1-4559-961c-54e63daa32fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Roflumilast is indicated as a treatment to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations. Limitations of Use Roflumilast is not a bronchodilator and is not indicated for the relief of acute bronchospasm. uuid:9602c2ae-5398-4db6-aae6-0e2772057a47 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47657 biolink:treats MONDO:0011751 PMID:41385096 "[{""id"":""uuid:1400b741-a93c-4ed1-9f54-f19666ea0c52"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6a956532-4f47-42ca-b1dc-78b37af246a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Roflumilast is indicated as a treatment to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations. Limitations of Use Roflumilast is not a bronchodilator and is not indicated for the relief of acute bronchospasm. uuid:44a9abf1-d9bd-4b75-9823-cd73cbf589a1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47657 biolink:treats MONDO:0005607 PMID:41385096 "[{""id"":""uuid:9d1f8e1a-e499-42d1-831d-8921e5592b45"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:5605d5d4-d522-4663-8cf2-7a93b58f0d78"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:8f6ff0dd-ab4d-408e-9f31-e50b26f59851"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/daxas""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Roflumilast is indicated as a treatment to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations. Limitations of Use Roflumilast is not a bronchodilator and is not indicated for the relief of acute bronchospasm.|[EMA] Daxas is indicated for maintenance treatment of severe chronic obstructive pulmonary disease (COPD) (FEV1 post-bronchodilator less than 50% predicted) associated with chronic bronchitis in adult patients with a history of frequent exacerbations as add-on to bronchodilator treatment., uuid:f57c71ad-7640-4884-973a-a170ba3dfacb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47657 biolink:treats UMLS:C0741804 PMID:41385096 "[{""id"":""uuid:5a24d4b7-ca1a-4643-ab77-a54b5aa7853c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ee7a2919-6d85-4f11-8674-d12a4e471fd3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Roflumilast is indicated as a treatment to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations. Limitations of Use Roflumilast is not a bronchodilator and is not indicated for the relief of acute bronchospasm. uuid:6632df4e-ca63-4284-be0e-748ab843e320 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59773 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:2d4b58d9-7680-46a8-9822-1664f1b3672a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:de4c2806-5367-4c18-8c34-28565b924f15"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cromolyn sodium inhalation solution USP is a prophylactic agent indicated in the management of patients with bronchial asthma. In patients whose symptoms are sufficiently frequent to require a continuous program of medication, cromolyn sodium inhalation solution USP is given by inhalation on a regular daily basis (see DOSAGE AND ADMINISTRATION ). The effect of cromolyn sodium is usually evident after several weeks of treatment, although some patients show an almost immediate response. In patients who develop acute bronchoconstriction in response to exposure to exercise, toluene diisocyanate, environmental pollutants, etc., cromolyn sodium should be given shortly before exposure to the precipitating factor (see DOSAGE AND ADMINISTRATION ). uuid:a55a89d9-9fac-4ca4-9025-dec17e1873e0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17439 biolink:treats UMLS:C0205707 PMID:41385096 "[{""id"":""uuid:0afb20a7-4ac8-4b46-88ea-daedfcaa61bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f483d98b-3f66-476f-838a-76a1e2bca595"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cyanocobalamin is indicated for vitamin B 12 deficiencies due to malabsorption which may be associated with the following conditions: • Addisonian (pernicious) anemia • Gastrointestinal pathology, dysfunction, or surgery, including gluten enteropathy or sprue, small bowel bacteria overgrowth, total or partial gastrectomy • Fish tapeworm infestation • Malignancy of pancreas or bowel • Folic acid deficiency It may be possible to treat the underlying disease by surgical correction of anatomic lesions leading to small bowel bacterial overgrowth, expulsion of fish tapeworm, discontinuation of drugs leading to vitamin malabsorption (see Drug Interactions ), use of a gluten-free diet in nontropical sprue, or administration of antibiotics in tropical sprue. Such measures remove the need for long-term administration of cyanocobalamin. Requirements of vitamin B 12 in excess of normal (due to pregnancy, thyrotoxicosis, hemolytic anemia, hemorrhage, malignancy, hepatic and renal disease) can usually be met with oral supplementation. Cyanocobalamin injection is also suitable for the vitamin B 12 absorption test (Schilling test). uuid:daa5078e-00f8-4251-98b1-862b561dc0c1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3515 biolink:treats UMLS:C0036685 PMID:41385096 "[{""id"":""uuid:8652ec96-e837-49a9-98b4-77908373846c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:61aa4946-0072-4453-8490-56d844a3e686"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefuroxime for Injection is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: Lower Respiratory Tract Infections , including pneumonia, caused by Streptococcus pneumoniae , Haemophilus influenzae (including ampicillin-resistant strains), Klebsiella spp., Staphylococcus aureus (penicillinase- and non–penicillinase-producing strains), Streptococcus pyogenes , and Escherichia coli . Urinary Tract Infections caused by Escherichia coli and Klebsiella spp. Skin and Skin­-Structure Infections caused by Staphylococcus aureus (penicillinase- and non–penicillinase-producing strains), Streptococcus pyogenes , Escherichia coli , Klebsiella spp., and Enterobacter spp. Septicemia caused by Staphylococcus aureus (penicillinase- and non–penicillinase-producing strains), Streptococcus pneumoniae , Escherichia coli , Haemophilus influenzae (including ampicillin-resistant strains), and Klebsiella spp. Meningitis caused by Streptococcus pneumoniae , Haemophilus influenzae (including ampicillin-resistant strains), Neisseria meningitidis , and Staphylococcus aureus (penicillinase- and non–penicillinase-producing strains). Gonorrhea: Uncomplicated and disseminated gonococcal infections due to Neisseria gonorrhoeae (penicillinase- and non–penicillinase-producing strains) in both males and females. Bone and Joint Infections caused by Staphylococcus aureus (penicillinase- and non–penicillinase-producing strains). Clinical microbiological studies in skin and skin­-structure infections frequently reveal the growth of susceptible strains of both aerobic and anaerobic organisms. Cefuroxime for Injection has been used successfully in these mixed infections in which several organisms have been isolated. In certain cases of confirmed or suspected gram-positive or gram-negative sepsis or in patients with other serious infections in which the causative organism has not been identified, Cefuroxime for Injection may be used concomitantly with an aminoglycoside (see PRECAUTIONS ). The recommended doses of both antibiotics may be given depending on the severity of the infection and the patient's condition. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefuroxime for Injection and other antibacterial drugs, Cefuroxime for Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:bf507e92-38e1-43f3-ab53-4242144d2d65 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29007 biolink:treats UMLS:C4552431 PMID:41385096 "[{""id"":""uuid:8922db83-3032-438e-a725-e94ef22559a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c6e14188-97dc-451a-81a3-37b151393fd5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Before instituting treatment with Ceftriaxone for Injection, USP, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. Therapy may be instituted prior to obtaining results of susceptibility testing. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ceftriaxone for Injection, USP and other antibacterial drugs, Ceftriaxone for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ceftriaxone for Injection, USP is indicated for the treatment of the following infections when caused by susceptible organisms: LOWER RESPIRATORY TRACT INFECTIONS caused by Streptococcus pneumoniae , Staphylococcus aureus, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Escherichia coli, Enterobacter aerogenes, Proteus mirabilis or Serratia marcescens . ACUTE BACTERIAL OTITIS MEDIA caused by Streptococcus pneumoniae, Haemophilus influenzae (including beta-lactamase producing strains) or Moraxella catarrhalis (including beta-lactamase producing strains). NOTE: In one study lower clinical cure rates were observed with a single dose of Ceftriaxone compared to 10 days of oral therapy. In a second study comparable cure rates were observed between single dose Ceftriaxone and the comparator. The potentially lower clinical cure rate of ceftriaxone should be balanced against the potential advantages of parenteral therapy (see CLINICAL STUDIES ). SKIN AND SKIN STRUCTURE INFECTIONS caused by Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes , Viridans group streptococci, Escherichia coli, Enterobacter cloacae, Klebsiella oxytoca, Klebsiella pneumoniae, Proteus mirabilis, Morganella morganii*, Pseudomonas aeruginosa, Serratia marcescens, Acinetobacter calcoaceticus, Bacteroides fragilis* or Peptostreptococcus species. * Efficacy for this organism in this organ system was studied in fewer than ten infections. URINARY TRACT INFECTIONS (complicated and uncomplicated) caused by Escherichia coli, Proteus mirabilis, Proteus vulgaris, Morganella morganii or Klebsiella pneumoniae . UNCOMPLICATED GONORRHEA (cervical/urethral and rectal) caused by Neisseria gonorrhoeae , including both penicillinase- and nonpenicillinase-producing strains, and pharyngeal gonorrhea caused by nonpenicillinase-producing strains of Neisseria gonorrhoeae . PELVIC INFLAMMATORY DISEASE caused by Neisseria gonorrhoeae . Ceftriaxone sodium, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and Chlamydia trachomatis is one of the suspected pathogens, appropriate antichlamydial coverage should be added. BACTERIAL SEPTICEMIA caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae or Klebsiella pneumoniae . BONE AND JOINT INFECTIONS caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae or Enterobacter species. INTRA-ABDOMINAL INFECTIONS caused by Escherichia coli, Klebsiella pneumoniae, Bacteroides fragilis, Clostridium species (Note: most strains of Clostridium difficile are resistant) or Peptostreptococcus species. MENINGITIS caused by Haemophilus influenzae, Neisseria meningitidis or Streptococcus pneumoniae . Ceftriaxone has also been used successfully in a limited number of cases of meningitis and shunt infection caused by Staphylococcus epidermidis* and Escherichia coli* . * Efficacy for this organism in this organ system was studied in fewer than ten infections. SURGICAL PROPHYLAXIS: The preoperative administration of a single 1 g dose of Ceftriaxone may reduce the incidence of postoperative infections in patients undergoing surgical procedures classified as contaminated or potentially contaminated (e.g., vaginal or abdominal hysterectomy or cholecystectomy for chronic calculous cholecystitis in high-risk patients, such as those over 70 years of age, with acute cholecystitis not requiring therapeutic antimicrobials, obstructive jaundice or common duct bile stones) and in surgical patients for whom infection at the operative site would present serious risk (e.g., during coronary artery bypass surgery). Although Ceftriaxone has been shown to have been as effective as cefazolin in the prevention of infection following coronary artery bypass surgery, no placebo-controlled trials have been conducted to evaluate any cephalosporin antibiotic in the prevention of infection following coronary artery bypass surgery. When administered prior to surgical procedures for which it is indicated, a single 1 g dose of Ceftriaxone provides protection from most infections due to susceptible organisms throughout the course of the procedure. uuid:63e0f576-5ecc-4d7d-9a52-4a992fb22a13 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:8230 biolink:treats UMLS:C5400441 PMID:41385096 "[{""id"":""uuid:7aead8f4-fbfa-4744-bc67-962eb9d583ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:303bc77a-eba4-46e1-8076-bcb1705f3ead"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vasopressin Injection, USP is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. uuid:a6d8cf4d-364d-48cd-a3a4-18dc33162fc4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:8230 biolink:treats MONDO:0005468 PMID:41385096 "[{""id"":""uuid:df2bc2a2-dc83-4de8-99f8-07980a6727f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eca7e607-2b46-4031-bd25-b2355d7ec04d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vasopressin Injection, USP is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. uuid:26472919-af7d-43d1-8d71-fd8c5c6cf351 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18067 biolink:treats MONDO:0024307 PMID:41385096 "[{""id"":""uuid:54b7c329-ea39-4139-9ef8-2d8440173f67"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d99ddc14-2556-4f3a-88bb-634c369b5bc5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Phytonadione injectable emulsion, USP is indicated in the following coagulation disorders which are due to faulty formation of factors II, VII, IX and X when caused by Vitamin K deficiency or interference with Vitamin K activity. Phytonadione injectable emulsion is indicated in­­ anticoagulant-induced prothrombin deficiency caused by coumarin or indanedione derivatives; ­­ prophylaxis and therapy of hemorrhagic disease of the newborn; ­­ hypoprothrombinemia due to antibacterial therapy; hypoprothrombinemia secondary to factors limiting absorption or synthesis of Vitamin K, e.g., obstructive jaundice, biliary fistula, sprue, ulcerative colitis, celiac disease, intestinal resection, cystic fibrosis of the pancreas, and regional enteritis; other drug-induced hypoprothrombinemia where it is definitely shown that the result is due to interference with phytonadione injectable emulsion metabolism, e.g., salicylates. uuid:e3f6249d-e72f-4be4-ad61-bd78db7f73c3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0010150 PMID:41385096 "[{""id"":""uuid:f5e78a7a-8073-4ea0-97c6-df223b44966e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2b702d34-fcd3-4979-ac34-0d6e837b561b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bleomycin for Injection should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to bleomycin is poorer in patients with previously irradiated head and neck cancer. Lymphomas Hodgkin's disease, non-Hodgkin's lymphoma. Testicular Carcinoma Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin has also been shown to be useful in the management of: Malignant Pleural Effusion Bleomycin is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. uuid:1f6d6c8f-93a2-4ada-bb01-ec2c8aae3ca2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0004958 PMID:41385096 "[{""id"":""uuid:4ab9d6c9-6b74-4672-ba1e-3bcae6401703"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:856e3c81-90f4-4a11-8237-b108c27c580e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bleomycin for Injection should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to bleomycin is poorer in patients with previously irradiated head and neck cancer. Lymphomas Hodgkin's disease, non-Hodgkin's lymphoma. Testicular Carcinoma Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin has also been shown to be useful in the management of: Malignant Pleural Effusion Bleomycin is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. uuid:667ce32c-bc8c-4972-9cc2-cc72f22d04d3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0000500 PMID:41385096 "[{""id"":""uuid:d3c658cb-d125-49c1-893f-0860a5911f08"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:82a5fbe3-bc24-4809-9fc5-b4bda62d6b9b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bleomycin for Injection should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to bleomycin is poorer in patients with previously irradiated head and neck cancer. Lymphomas Hodgkin's disease, non-Hodgkin's lymphoma. Testicular Carcinoma Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin has also been shown to be useful in the management of: Malignant Pleural Effusion Bleomycin is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. uuid:4de69100-e82a-47b7-b4a4-42300c1579df biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0006470 PMID:41385096 "[{""id"":""uuid:598d191c-add5-4020-a129-65cb36ed4c20"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:158737e4-8a36-4de2-87ad-d6680667d12e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bleomycin for Injection should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to bleomycin is poorer in patients with previously irradiated head and neck cancer. Lymphomas Hodgkin's disease, non-Hodgkin's lymphoma. Testicular Carcinoma Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin has also been shown to be useful in the management of: Malignant Pleural Effusion Bleomycin is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. uuid:ff71b43c-c7e3-49f9-aa56-e63571d5761a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0006060 PMID:41385096 "[{""id"":""uuid:62723182-2ea4-4005-a2b4-fcd3b733d53c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0a92a8ad-3068-4ed7-81de-e76598bc4754"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bleomycin for Injection should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to bleomycin is poorer in patients with previously irradiated head and neck cancer. Lymphomas Hodgkin's disease, non-Hodgkin's lymphoma. Testicular Carcinoma Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin has also been shown to be useful in the management of: Malignant Pleural Effusion Bleomycin is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. uuid:fc0b2b9c-f64c-4287-b67f-ca06a246aca5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0044704 PMID:41385096 "[{""id"":""uuid:2f9a23a8-c822-42e0-9421-0e86ddfbeaa3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:793b02b1-6ac0-4df1-97a0-3da547e0f755"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bleomycin for Injection should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to bleomycin is poorer in patients with previously irradiated head and neck cancer. Lymphomas Hodgkin's disease, non-Hodgkin's lymphoma. Testicular Carcinoma Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin has also been shown to be useful in the management of: Malignant Pleural Effusion Bleomycin is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. uuid:53a0dc68-c234-4701-b223-998ce792d68b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0044705 PMID:41385096 "[{""id"":""uuid:46b18b8d-0238-428f-8c7a-749c59c93dd6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4f70a425-8704-4de2-a767-c293f49735fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bleomycin for Injection should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to bleomycin is poorer in patients with previously irradiated head and neck cancer. Lymphomas Hodgkin's disease, non-Hodgkin's lymphoma. Testicular Carcinoma Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin has also been shown to be useful in the management of: Malignant Pleural Effusion Bleomycin is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. uuid:648cde04-e8c8-4120-a30e-e904883ac84a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0021427 PMID:41385096 "[{""id"":""uuid:4caf0045-6c22-44fa-b42c-78e292631f09"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b1f09b84-80e6-498b-bf0a-3947c98e47e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bleomycin for Injection should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to bleomycin is poorer in patients with previously irradiated head and neck cancer. Lymphomas Hodgkin's disease, non-Hodgkin's lymphoma. Testicular Carcinoma Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin has also been shown to be useful in the management of: Malignant Pleural Effusion Bleomycin is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. uuid:a8e03e49-2651-4036-83b2-c795482f8c46 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0021431 PMID:41385096 "[{""id"":""uuid:e01d6044-ffd2-4ef9-9f69-dbdaaa288a72"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:97a26c2c-1b23-4aa0-b7c7-e8b36077d2cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bleomycin for Injection should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to bleomycin is poorer in patients with previously irradiated head and neck cancer. Lymphomas Hodgkin's disease, non-Hodgkin's lymphoma. Testicular Carcinoma Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin has also been shown to be useful in the management of: Malignant Pleural Effusion Bleomycin is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. uuid:841e3a53-97fb-4850-b794-6553a3ed7ab6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0002529 PMID:41385096 "[{""id"":""uuid:8f895f8b-a9cb-4a3f-aae2-58ba8d6da686"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:352c305f-3174-4166-af16-fcea03a8e76b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bleomycin for Injection should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to bleomycin is poorer in patients with previously irradiated head and neck cancer. Lymphomas Hodgkin's disease, non-Hodgkin's lymphoma. Testicular Carcinoma Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin has also been shown to be useful in the management of: Malignant Pleural Effusion Bleomycin is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. uuid:61a5cf0e-8690-47bc-a163-9d3cd03aa431 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0005595 PMID:41385096 "[{""id"":""uuid:986a4c64-1a15-423d-b1a5-dce5448ea8c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e1cefa90-6c71-48ec-8421-37980c2efbe0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bleomycin for Injection should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to bleomycin is poorer in patients with previously irradiated head and neck cancer. Lymphomas Hodgkin's disease, non-Hodgkin's lymphoma. Testicular Carcinoma Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin has also been shown to be useful in the management of: Malignant Pleural Effusion Bleomycin is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. uuid:da5dac66-ddd4-449c-b300-65d9f1503b53 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0018352 PMID:41385096 "[{""id"":""uuid:6f782a34-eb7a-499e-b661-2ba633d90437"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5b2f656c-a4a3-432d-acae-38b87c9939d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bleomycin for Injection should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to bleomycin is poorer in patients with previously irradiated head and neck cancer. Lymphomas Hodgkin's disease, non-Hodgkin's lymphoma. Testicular Carcinoma Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin has also been shown to be useful in the management of: Malignant Pleural Effusion Bleomycin is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. uuid:04a5082b-70fc-4a5d-a240-cf3b3af68c2a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0006143 PMID:41385096 "[{""id"":""uuid:26f12d1f-6202-4e80-8fd5-c27615c7afed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:86872e55-326f-4c17-aa27-7cbb75c427b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bleomycin for Injection should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to bleomycin is poorer in patients with previously irradiated head and neck cancer. Lymphomas Hodgkin's disease, non-Hodgkin's lymphoma. Testicular Carcinoma Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin has also been shown to be useful in the management of: Malignant Pleural Effusion Bleomycin is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. uuid:c6947299-700e-49f5-a8da-c36ea4ff69c8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0024609 PMID:41385096 "[{""id"":""uuid:a62f46d9-fc3f-45d6-9df4-fac931f02238"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:125d0111-cbf4-4f47-9b36-9f34afe731c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bleomycin for Injection should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to bleomycin is poorer in patients with previously irradiated head and neck cancer. Lymphomas Hodgkin's disease, non-Hodgkin's lymphoma. Testicular Carcinoma Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin has also been shown to be useful in the management of: Malignant Pleural Effusion Bleomycin is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. uuid:1ffa5571-0f40-40bb-a674-654ccc191c60 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0007243 PMID:41385096 "[{""id"":""uuid:b06b801c-5a12-4eed-b79e-cf0b8f217f52"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6b04a5a3-5d83-4641-9c1c-41732059c180"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bleomycin for Injection should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to bleomycin is poorer in patients with previously irradiated head and neck cancer. Lymphomas Hodgkin's disease, non-Hodgkin's lymphoma. Testicular Carcinoma Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin has also been shown to be useful in the management of: Malignant Pleural Effusion Bleomycin is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. uuid:dc14794e-c542-4289-9d43-50cc7f1d674d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0006446 PMID:41385096 "[{""id"":""uuid:1f536188-9976-47c3-beba-8ac5712be36f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8664edca-dbd7-4c51-b0b2-6bfc33ea62d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bleomycin for Injection should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to bleomycin is poorer in patients with previously irradiated head and neck cancer. Lymphomas Hodgkin's disease, non-Hodgkin's lymphoma. Testicular Carcinoma Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin has also been shown to be useful in the management of: Malignant Pleural Effusion Bleomycin is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. uuid:4c9ed500-d4f7-418d-90c2-4fff8aca8c79 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0003508 PMID:41385096 "[{""id"":""uuid:31583c64-1371-4664-b717-40d35ca99cc3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ecdaf101-5fc6-4ffd-b9ed-14a77a743ca6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bleomycin for Injection should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to bleomycin is poorer in patients with previously irradiated head and neck cancer. Lymphomas Hodgkin's disease, non-Hodgkin's lymphoma. Testicular Carcinoma Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin has also been shown to be useful in the management of: Malignant Pleural Effusion Bleomycin is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. uuid:439a776c-6699-477a-8045-6bcffb5da297 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10119 biolink:treats MONDO:0020575 PMID:41385096 "[{""id"":""uuid:b798ec4e-cf6f-4502-bf52-620846415161"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f6e0c19e-d58a-420c-bc2a-3545624f1f1d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ziprasidone mesylate for injection intramuscular is indicated for acute agitation in schizophrenic patients. When deciding among the alternative treatments available for the condition needing treatment, the prescriber should consider the finding of ziprasidone’s greater capacity to prolong the QT/QTc interval compared to several other antipsychotic drugs [see Warnings and Precautions (5.3) ]. Prolongation of the QTc interval is associated in some other drugs with the ability to cause torsade de pointes-type arrhythmia, a potentially fatal polymorphic ventricular tachycardia, and sudden death. In many cases this would lead to the conclusion that other drugs should be tried first. Whether ziprasidone will cause torsade de pointes or increase the rate of sudden death is not yet known [see Warnings and Precautions (5.3) ] Acute Treatment of Agitation in Schizophrenia Ziprasidone mesylate for injection intramuscular is indicated for the treatment of acute agitation in schizophrenic adult patients for whom treatment with ziprasidone is appropriate and who need intramuscular antipsychotic medication for rapid control of agitation. Since there is no experience regarding the safety of administering ziprasidone intramuscular to schizophrenic patients already taking oral ziprasidone, the practice of co-administration is not recommended. uuid:1e0333c9-4583-4b2a-80ff-413bb31dc6a5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1100064 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:14eb069c-ed26-4673-934d-95ee31ebd268"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5a3611f9-e0f7-4d7e-b467-4d9b4e7c8864"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ibuprofen and famotidine tablet, a combination of the NSAID ibuprofen and the histamine H 2 -receptor antagonist famotidine, is indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis and to decrease the risk of developing upper gastrointestinal ulcers, which in the clinical trials was defined as a gastric and/or duodenal ulcer, in patients who are taking ibuprofen for those indications. The clinical trials primarily enrolled patients less than 65 years of age without a prior history of gastrointestinal ulcer. Controlled trials do not extend beyond 6 months [see Clinical Studies ( 14 ), Use in Specific Populations ( 8.5 )] . uuid:4a4c42ab-e42b-4fbf-ad58-e7b2b1fca88f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1100064 biolink:treats MONDO:0005178 PMID:41385096 "[{""id"":""uuid:027c4ce4-f4ec-4184-8816-96fd250117e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0600f356-02d7-48a1-baa9-2802b8b65bfa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ibuprofen and famotidine tablet, a combination of the NSAID ibuprofen and the histamine H 2 -receptor antagonist famotidine, is indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis and to decrease the risk of developing upper gastrointestinal ulcers, which in the clinical trials was defined as a gastric and/or duodenal ulcer, in patients who are taking ibuprofen for those indications. The clinical trials primarily enrolled patients less than 65 years of age without a prior history of gastrointestinal ulcer. Controlled trials do not extend beyond 6 months [see Clinical Studies ( 14 ), Use in Specific Populations ( 8.5 )] . uuid:b1264aaa-5439-41b6-b521-b3c5f65269ba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1100064 biolink:treats MONDO:0001126 PMID:41385096 "[{""id"":""uuid:6329465f-2564-4831-85c8-630b66b4e067"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6a98ff1e-d721-4d41-a76c-1594c4257127"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ibuprofen and famotidine tablet, a combination of the NSAID ibuprofen and the histamine H 2 -receptor antagonist famotidine, is indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis and to decrease the risk of developing upper gastrointestinal ulcers, which in the clinical trials was defined as a gastric and/or duodenal ulcer, in patients who are taking ibuprofen for those indications. The clinical trials primarily enrolled patients less than 65 years of age without a prior history of gastrointestinal ulcer. Controlled trials do not extend beyond 6 months [see Clinical Studies ( 14 ), Use in Specific Populations ( 8.5 )] . uuid:1d66111e-a111-4950-ae94-97f074be9a27 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1100064 biolink:treats MONDO:0005412 PMID:41385096 "[{""id"":""uuid:726bc544-e46c-47e5-88f1-a7aa64b33623"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:64cb0db7-c1a8-4c63-9d93-d6c92268b1a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ibuprofen and famotidine tablet, a combination of the NSAID ibuprofen and the histamine H 2 -receptor antagonist famotidine, is indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis and to decrease the risk of developing upper gastrointestinal ulcers, which in the clinical trials was defined as a gastric and/or duodenal ulcer, in patients who are taking ibuprofen for those indications. The clinical trials primarily enrolled patients less than 65 years of age without a prior history of gastrointestinal ulcer. Controlled trials do not extend beyond 6 months [see Clinical Studies ( 14 ), Use in Specific Populations ( 8.5 )] . uuid:e6c88ce5-2d70-4bd3-98e8-d4894a58288e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:9R3D3Y0UHS biolink:treats MONDO:0007064 PMID:41385096 "[{""id"":""uuid:c7b1560a-1746-43ef-9fa9-dfe93b4d0f40"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:595159e5-10a8-43df-b4fd-f0e14b261971"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:3fa54300-6298-48aa-9cdf-ac65cf88a9a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] REVCOVI is indicated for the treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID) in pediatric and adult patients.|[PMDA] A drug with a new active ingredient indicated for the treatment of adenosine deaminase deficiency. [Orphan drug] uuid:9615cf09-5f65-4bec-9e49-74cdf0c648b6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:231425 biolink:treats HP:0002902 PMID:41385096 "[{""id"":""uuid:d13106b0-873a-41c2-923a-c0a2e22d97cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:64e55f79-d74f-4a01-9996-c4d1c6ac140d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:343af71d-dade-4ac2-8f5e-683480ecabc1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/jinarc""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tolvaptan tablets are indicated for the treatment of clinically significant hypervolemic and euvolemic hyponatremia (serum sodium <125 mEq/L or less marked hyponatremia that is symptomatic and has resisted correction with fluid restriction), including patients with heart failure and Syndrome of Inappropriate Antidiuretic Hormone (SIADH). Limitations of Use: Patients requiring intervention to raise serum sodium urgently to prevent or to treat serious neurological symptoms should not be treated with tolvaptan tablets. It has not been established that raising serum sodium with tolvaptan tablets provide a symptomatic benefit to patients.|[EMA] Tolvaptan is indicated in adults for the treatment of hyponatremia secondary to the syndrome of inappropriate antidiuretic hormone secretion (SIADH). uuid:b42181df-a2ba-4c20-b783-aa7f33ba25a5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:231425 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:3389bf65-198f-4918-a140-038456640f70"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c3a17295-f21b-4a94-acac-689e37e441ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c0579dc2-5985-4628-9390-e30958461e5d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tolvaptan tablets are indicated for the treatment of clinically significant hypervolemic and euvolemic hyponatremia (serum sodium <125 mEq/L or less marked hyponatremia that is symptomatic and has resisted correction with fluid restriction), including patients with heart failure and Syndrome of Inappropriate Antidiuretic Hormone (SIADH). Limitations of Use: Patients requiring intervention to raise serum sodium urgently to prevent or to treat serious neurological symptoms should not be treated with tolvaptan tablets. It has not been established that raising serum sodium with tolvaptan tablets provide a symptomatic benefit to patients.|[PMDA] A drug with a new active ingredient indicated for the treatment of fluid retention in heart failure patients who have not responded sufficiently to other diuretics to such as loop diuretics. uuid:9ff89268-0c36-46e6-b71f-68d5a5a899d8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:231425 biolink:treats MONDO:0006802 PMID:41385096 "[{""id"":""uuid:6bcc78bf-cd61-4dd0-a26f-be99ecfc6cf0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c5aac9c4-7d66-4b09-8441-8071459874b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:bf0b29a4-b9f2-4222-9784-a04cbef07a80"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/jinarc""]},{""id"":""uuid:6fb97d61-e50c-4c30-8b11-d9dd9e39ab9f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tolvaptan tablets are indicated for the treatment of clinically significant hypervolemic and euvolemic hyponatremia (serum sodium <125 mEq/L or less marked hyponatremia that is symptomatic and has resisted correction with fluid restriction), including patients with heart failure and Syndrome of Inappropriate Antidiuretic Hormone (SIADH). Limitations of Use: Patients requiring intervention to raise serum sodium urgently to prevent or to treat serious neurological symptoms should not be treated with tolvaptan tablets. It has not been established that raising serum sodium with tolvaptan tablets provide a symptomatic benefit to patients.|[EMA] Tolvaptan is indicated in adults for the treatment of hyponatremia secondary to the syndrome of inappropriate antidiuretic hormone secretion (SIADH).|[PMDA] Drugs with a new indication and a new dosage for the improvement of hyponatraemia in patients with syndrome of inappropriate secretion of antidiuretic hormone (SIADH). [Orphan drug] uuid:bcdb9d0e-5243-4de0-9f1f-14796c008fc1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4786 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:edc3e274-e1d6-4260-9691-afce85cc2ac7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1487b5c4-5c46-4eee-8589-32dc22f03786"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Enalapril maleate is an angiotensin-converting enzyme inhibitor indicated for: treatment of hypertension in adults and children older than one month, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) treatment of symptomatic heart failure. ( 1.2 ) treatment of asymptomatic left ventricular dysfunction, to decrease the rate of development of overt heart failure and reduce hospitalization for heart failure. ( 1.3 ) uuid:0efe4104-33d5-476f-b821-bc63aab98e82 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4786 biolink:treats MONDO:0006652 PMID:41385096 "[{""id"":""uuid:204bacc6-9e08-4300-bcf0-6ced3622278a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:94eec03c-8952-47b2-bff2-b6926e38ea6f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Enalapril maleate is an angiotensin-converting enzyme inhibitor indicated for: treatment of hypertension in adults and children older than one month, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) treatment of symptomatic heart failure. ( 1.2 ) treatment of asymptomatic left ventricular dysfunction, to decrease the rate of development of overt heart failure and reduce hospitalization for heart failure. ( 1.3 ) uuid:d8fe4f92-3557-4b2d-aaa1-0b0e7e32e1fc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:375139 biolink:treats HP:0003418 PMID:41385096 "[{""id"":""uuid:329443cc-0061-429e-a550-1c9222513683"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:985bedad-69b3-43c2-b8ec-ade096fb84c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lidothol Gel is indicated for relief of pain associated with arthritis, backache, cramps, discomfort, neckache, soreness, sprains, strains. It should be applied only to intact skin. uuid:a3ebf702-4849-42c2-97f4-bd0cd43e5b58 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:375139 biolink:treats MONDO:0008022 PMID:41385096 "[{""id"":""uuid:4276f0f2-a449-4bc3-a581-b68b0bba92bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:02aa521e-112a-4c21-81ad-6aa207582c90"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lidothol Gel is indicated for relief of pain associated with arthritis, backache, cramps, discomfort, neckache, soreness, sprains, strains. It should be applied only to intact skin. uuid:39ed2b2e-0572-47ba-99a3-6b85bd42b4f2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:375139 biolink:treats HP:0030833 PMID:41385096 "[{""id"":""uuid:aafb3d73-2a92-4f77-a2c6-e023b36355fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2d47d5c6-5f5c-4d97-bf90-922c52e914d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lidothol Gel is indicated for relief of pain associated with arthritis, backache, cramps, discomfort, neckache, soreness, sprains, strains. It should be applied only to intact skin. uuid:3552326e-92a3-44ee-b1bd-730b9197e3d5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:375139 biolink:treats NCIT:C50748 PMID:41385096 "[{""id"":""uuid:6f674029-39b5-441c-80c1-0904946d42c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1a1c399d-5452-466b-b250-22870deb534e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lidothol Gel is indicated for relief of pain associated with arthritis, backache, cramps, discomfort, neckache, soreness, sprains, strains. It should be applied only to intact skin. uuid:77124f58-03fd-4da2-a07a-910125a761d0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16684 biolink:treats MONDO:0000745 PMID:41385096 "[{""id"":""uuid:83b9568a-1e42-4a5f-a63a-b0ff51de3d03"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:80ede6ae-3647-497a-b1cc-dced2c8b0b5e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Atropine Sulfate Injection, USP, is indicated for temporary blockade of severe or life threatening muscarinic effects, e.g., as an antisialagogue, an antivagal agent, an antidote for organophosphorus or muscarinic mushroom poisoning, and to treat bradyasystolic cardiac arrest. uuid:20093cd4-cb62-4b38-83d7-4d6ef6fc98dc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50173 biolink:treats MONDO:0005083 PMID:41385096 "[{""id"":""uuid:d779e5aa-ae07-43a6-addb-a70338b5ff6f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bdbcfbfe-41da-4d2e-ace9-e1ef88dc8463"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Acitretin Capsules are indicated for the treatment of severe psoriasis in adults. Because of significant adverse effects associated with its use, Acitretin Capsules should be prescribed only by those knowledgeable in the systemic use of retinoids. In females of reproductive potential, Acitretin Capsules should be reserved for non-pregnant patients who are unresponsive to other therapies or whose clinical condition contraindicates the use of other treatments (see boxed CONTRAINDICATIONS AND WARNINGS — Acitretin Capsules can cause severe birth defects). Most patients experience relapse of psoriasis after discontinuing therapy. Subsequent courses, when clinically indicated, have produced efficacy results similar to the initial course of therapy. uuid:3873f512-f673-451c-9762-0a2731b99708 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:101278 biolink:treats MONDO:0008685 PMID:41385096 "[{""id"":""uuid:98b2e277-bdbd-45e2-87e5-1e67d68a5f23"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:879f23f0-51fe-449d-a067-fcd25ad3d03c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diltiazem hydrochloride injection is indicated for the following: Atrial Fibrillation or Atrial Flutter. Temporary control of rapid ventricular rate in atrial fibrillation or atrial flutter. It should not be used in patients with atrial fibrillation or atrial flutter associated with an accessory bypass tract such as in Wolff-Parkinson-White (WPW) syndrome or short PR syndrome. Paroxysmal Supraventricular Tachycardia. Rapid conversion of paroxysmal supraventricular tachycardias (PSVT) to sinus rhythm. This includes AV nodal reentrant tachycardias and reciprocating tachycardias associated with an extranodal accessory pathway such as the WPW syndrome or short PR syndrome. Unless otherwise contraindicated, appropriate vagal maneuvers should be attempted prior to administration of diltiazem hydrochloride injection. The use of diltiazem hydrochloride injection for control of ventricular response in patients with atrial fibrillation or atrial flutter or conversion to sinus rhythm in patients with PSVT should be undertaken with caution when the patient is compromised hemodynamically or is taking other drugs that decrease any or all of the following: peripheral resistance, myocardial filling, myocardial contractility, or electrical impulse propagation in the myocardium. For either indication and particularly when employing continuous intravenous infusion, the setting should include continuous monitoring of the ECG and frequent measurement of blood pressure. A defibrillator and emergency equipment should be readily available. In domestic controlled trials in patients with atrial fibrillation or atrial flutter, bolus administration of diltiazem hydrochloride injection was effective in reducing heart rate by at least 20% in 95% of patients. Diltiazem hydrochloride injection rarely converts atrial fibrillation or atrial flutter to normal sinus rhythm. Following administration of one or two intravenous bolus doses of diltiazem hydrochloride injection, response usually occurs within 3 minutes and maximal heart rate reduction generally occurs in 2 to 7 minutes. Heart rate reduction may last from 1 to 3 hours. If hypotension occurs, it is generally short-lived, but may last from 1 to 3 hours. A 24-hour continuous infusion of diltiazem hydrochloride injection in the treatment of atrial fibrillation or atrial flutter maintained at least a 20% heart rate reduction during the infusion in 83% of patients. Upon discontinuation of infusion, heart rate reduction may last from 0.5 hours to more than 10 hours (median duration 7 hours). Hypotension, if it occurs, may be similarly persistent. In the controlled clinical trials, 3.2% of patients required some form of intervention (typically, use of intravenous fluids or the Trendelenburg position) for blood pressure support following diltiazem hydrochloride injection. In domestic controlled trials, bolus administration of diltiazem hydrochloride injection was effective in converting PSVT to normal sinus rhythm in 88% of patients within 3 minutes of the first or second bolus dose. Symptoms associated with the arrhythmia were improved in conjunction with decreased heart rate or conversion to normal sinus rhythm following administration of diltiazem hydrochloride injection. uuid:4eee0a49-f41e-4905-88b6-117e7333ca26 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:101278 biolink:treats MONDO:0007174 PMID:41385096 "[{""id"":""uuid:19bd8953-abab-4405-8fef-9da08853ead9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9ebc4c82-3590-43af-b606-d4f2c8c33735"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diltiazem hydrochloride injection is indicated for the following: Atrial Fibrillation or Atrial Flutter. Temporary control of rapid ventricular rate in atrial fibrillation or atrial flutter. It should not be used in patients with atrial fibrillation or atrial flutter associated with an accessory bypass tract such as in Wolff-Parkinson-White (WPW) syndrome or short PR syndrome. Paroxysmal Supraventricular Tachycardia. Rapid conversion of paroxysmal supraventricular tachycardias (PSVT) to sinus rhythm. This includes AV nodal reentrant tachycardias and reciprocating tachycardias associated with an extranodal accessory pathway such as the WPW syndrome or short PR syndrome. Unless otherwise contraindicated, appropriate vagal maneuvers should be attempted prior to administration of diltiazem hydrochloride injection. The use of diltiazem hydrochloride injection for control of ventricular response in patients with atrial fibrillation or atrial flutter or conversion to sinus rhythm in patients with PSVT should be undertaken with caution when the patient is compromised hemodynamically or is taking other drugs that decrease any or all of the following: peripheral resistance, myocardial filling, myocardial contractility, or electrical impulse propagation in the myocardium. For either indication and particularly when employing continuous intravenous infusion, the setting should include continuous monitoring of the ECG and frequent measurement of blood pressure. A defibrillator and emergency equipment should be readily available. In domestic controlled trials in patients with atrial fibrillation or atrial flutter, bolus administration of diltiazem hydrochloride injection was effective in reducing heart rate by at least 20% in 95% of patients. Diltiazem hydrochloride injection rarely converts atrial fibrillation or atrial flutter to normal sinus rhythm. Following administration of one or two intravenous bolus doses of diltiazem hydrochloride injection, response usually occurs within 3 minutes and maximal heart rate reduction generally occurs in 2 to 7 minutes. Heart rate reduction may last from 1 to 3 hours. If hypotension occurs, it is generally short-lived, but may last from 1 to 3 hours. A 24-hour continuous infusion of diltiazem hydrochloride injection in the treatment of atrial fibrillation or atrial flutter maintained at least a 20% heart rate reduction during the infusion in 83% of patients. Upon discontinuation of infusion, heart rate reduction may last from 0.5 hours to more than 10 hours (median duration 7 hours). Hypotension, if it occurs, may be similarly persistent. In the controlled clinical trials, 3.2% of patients required some form of intervention (typically, use of intravenous fluids or the Trendelenburg position) for blood pressure support following diltiazem hydrochloride injection. In domestic controlled trials, bolus administration of diltiazem hydrochloride injection was effective in converting PSVT to normal sinus rhythm in 88% of patients within 3 minutes of the first or second bolus dose. Symptoms associated with the arrhythmia were improved in conjunction with decreased heart rate or conversion to normal sinus rhythm following administration of diltiazem hydrochloride injection. uuid:866fc20c-b5d9-4d00-a540-3d97b94484b2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:101278 biolink:treats UMLS:C0039232 PMID:41385096 "[{""id"":""uuid:458d9cbc-4aa1-44a4-8f96-739921566143"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e3ff4ea5-2bf6-46ab-a779-a78a07b65e47"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diltiazem hydrochloride injection is indicated for the following: Atrial Fibrillation or Atrial Flutter. Temporary control of rapid ventricular rate in atrial fibrillation or atrial flutter. It should not be used in patients with atrial fibrillation or atrial flutter associated with an accessory bypass tract such as in Wolff-Parkinson-White (WPW) syndrome or short PR syndrome. Paroxysmal Supraventricular Tachycardia. Rapid conversion of paroxysmal supraventricular tachycardias (PSVT) to sinus rhythm. This includes AV nodal reentrant tachycardias and reciprocating tachycardias associated with an extranodal accessory pathway such as the WPW syndrome or short PR syndrome. Unless otherwise contraindicated, appropriate vagal maneuvers should be attempted prior to administration of diltiazem hydrochloride injection. The use of diltiazem hydrochloride injection for control of ventricular response in patients with atrial fibrillation or atrial flutter or conversion to sinus rhythm in patients with PSVT should be undertaken with caution when the patient is compromised hemodynamically or is taking other drugs that decrease any or all of the following: peripheral resistance, myocardial filling, myocardial contractility, or electrical impulse propagation in the myocardium. For either indication and particularly when employing continuous intravenous infusion, the setting should include continuous monitoring of the ECG and frequent measurement of blood pressure. A defibrillator and emergency equipment should be readily available. In domestic controlled trials in patients with atrial fibrillation or atrial flutter, bolus administration of diltiazem hydrochloride injection was effective in reducing heart rate by at least 20% in 95% of patients. Diltiazem hydrochloride injection rarely converts atrial fibrillation or atrial flutter to normal sinus rhythm. Following administration of one or two intravenous bolus doses of diltiazem hydrochloride injection, response usually occurs within 3 minutes and maximal heart rate reduction generally occurs in 2 to 7 minutes. Heart rate reduction may last from 1 to 3 hours. If hypotension occurs, it is generally short-lived, but may last from 1 to 3 hours. A 24-hour continuous infusion of diltiazem hydrochloride injection in the treatment of atrial fibrillation or atrial flutter maintained at least a 20% heart rate reduction during the infusion in 83% of patients. Upon discontinuation of infusion, heart rate reduction may last from 0.5 hours to more than 10 hours (median duration 7 hours). Hypotension, if it occurs, may be similarly persistent. In the controlled clinical trials, 3.2% of patients required some form of intervention (typically, use of intravenous fluids or the Trendelenburg position) for blood pressure support following diltiazem hydrochloride injection. In domestic controlled trials, bolus administration of diltiazem hydrochloride injection was effective in converting PSVT to normal sinus rhythm in 88% of patients within 3 minutes of the first or second bolus dose. Symptoms associated with the arrhythmia were improved in conjunction with decreased heart rate or conversion to normal sinus rhythm following administration of diltiazem hydrochloride injection. uuid:5ce8c6b4-f074-48c0-ade1-7eef5d721ec6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:101278 biolink:treats EFO:1001432 PMID:41385096 "[{""id"":""uuid:c1d40ea5-e9d7-492d-b7d1-c17e71766bba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1f311a84-6ab1-4401-b417-fc6b8f765e44"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diltiazem hydrochloride injection is indicated for the following: Atrial Fibrillation or Atrial Flutter. Temporary control of rapid ventricular rate in atrial fibrillation or atrial flutter. It should not be used in patients with atrial fibrillation or atrial flutter associated with an accessory bypass tract such as in Wolff-Parkinson-White (WPW) syndrome or short PR syndrome. Paroxysmal Supraventricular Tachycardia. Rapid conversion of paroxysmal supraventricular tachycardias (PSVT) to sinus rhythm. This includes AV nodal reentrant tachycardias and reciprocating tachycardias associated with an extranodal accessory pathway such as the WPW syndrome or short PR syndrome. Unless otherwise contraindicated, appropriate vagal maneuvers should be attempted prior to administration of diltiazem hydrochloride injection. The use of diltiazem hydrochloride injection for control of ventricular response in patients with atrial fibrillation or atrial flutter or conversion to sinus rhythm in patients with PSVT should be undertaken with caution when the patient is compromised hemodynamically or is taking other drugs that decrease any or all of the following: peripheral resistance, myocardial filling, myocardial contractility, or electrical impulse propagation in the myocardium. For either indication and particularly when employing continuous intravenous infusion, the setting should include continuous monitoring of the ECG and frequent measurement of blood pressure. A defibrillator and emergency equipment should be readily available. In domestic controlled trials in patients with atrial fibrillation or atrial flutter, bolus administration of diltiazem hydrochloride injection was effective in reducing heart rate by at least 20% in 95% of patients. Diltiazem hydrochloride injection rarely converts atrial fibrillation or atrial flutter to normal sinus rhythm. Following administration of one or two intravenous bolus doses of diltiazem hydrochloride injection, response usually occurs within 3 minutes and maximal heart rate reduction generally occurs in 2 to 7 minutes. Heart rate reduction may last from 1 to 3 hours. If hypotension occurs, it is generally short-lived, but may last from 1 to 3 hours. A 24-hour continuous infusion of diltiazem hydrochloride injection in the treatment of atrial fibrillation or atrial flutter maintained at least a 20% heart rate reduction during the infusion in 83% of patients. Upon discontinuation of infusion, heart rate reduction may last from 0.5 hours to more than 10 hours (median duration 7 hours). Hypotension, if it occurs, may be similarly persistent. In the controlled clinical trials, 3.2% of patients required some form of intervention (typically, use of intravenous fluids or the Trendelenburg position) for blood pressure support following diltiazem hydrochloride injection. In domestic controlled trials, bolus administration of diltiazem hydrochloride injection was effective in converting PSVT to normal sinus rhythm in 88% of patients within 3 minutes of the first or second bolus dose. Symptoms associated with the arrhythmia were improved in conjunction with decreased heart rate or conversion to normal sinus rhythm following administration of diltiazem hydrochloride injection. uuid:33915eae-8ae9-48c1-b1b8-bb7e3c2f07e5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:9811635 biolink:treats MONDO:0006604 PMID:41385096 "[{""id"":""uuid:14975286-c793-47b9-be4f-66a2119e01e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dbf1e2eb-aa37-4231-ae69-a66748e5a6c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZYLET ® (loteprednol etabonate and tobramycin ophthalmic suspension), 0.5%/0.3% is a topical anti-infective and corticosteroid combination for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, and where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product (tobramycin) is active against the following common bacterial eye pathogens: Staphylococci, including S. aureus and S. epidermidis (coagulase-positive and coagulase-negative), including penicillin-resistant strains. Streptococci, including some of the Group A-beta-hemolytic species, some nonhemolytic species, and some Streptococcus pneumoniae , Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, Proteus mirabilis, Morganella morganii , most Proteus vulgaris strains, Haemophilus influenzae , and H. aegyptius, Moraxella lacunata, Acinetobacter calcoaceticus and some Neisseria species. uuid:433bb549-bb17-4275-a96a-6e820e71f82d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:9811635 biolink:treats MONDO:0033816 PMID:41385096 "[{""id"":""uuid:2b7642c0-5ab9-4d27-a814-fb023a4e0fe2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a66c7b05-3a9e-4ebd-a675-e1caaed4e7a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZYLET ® (loteprednol etabonate and tobramycin ophthalmic suspension), 0.5%/0.3% is a topical anti-infective and corticosteroid combination for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, and where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product (tobramycin) is active against the following common bacterial eye pathogens: Staphylococci, including S. aureus and S. epidermidis (coagulase-positive and coagulase-negative), including penicillin-resistant strains. Streptococci, including some of the Group A-beta-hemolytic species, some nonhemolytic species, and some Streptococcus pneumoniae , Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, Proteus mirabilis, Morganella morganii , most Proteus vulgaris strains, Haemophilus influenzae , and H. aegyptius, Moraxella lacunata, Acinetobacter calcoaceticus and some Neisseria species. uuid:0df8524d-feb1-4914-b36c-3d8afd9b7cd4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:9811635 biolink:treats UMLS:C1275687 PMID:41385096 "[{""id"":""uuid:12cd52d7-81af-4cb6-8426-a2e0332b84fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0d15c0bc-6915-4ea3-a258-87a2ba469b72"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZYLET ® (loteprednol etabonate and tobramycin ophthalmic suspension), 0.5%/0.3% is a topical anti-infective and corticosteroid combination for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, and where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product (tobramycin) is active against the following common bacterial eye pathogens: Staphylococci, including S. aureus and S. epidermidis (coagulase-positive and coagulase-negative), including penicillin-resistant strains. Streptococci, including some of the Group A-beta-hemolytic species, some nonhemolytic species, and some Streptococcus pneumoniae , Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, Proteus mirabilis, Morganella morganii , most Proteus vulgaris strains, Haemophilus influenzae , and H. aegyptius, Moraxella lacunata, Acinetobacter calcoaceticus and some Neisseria species. uuid:d97972f9-b9c8-4737-b757-915f782d36c1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:9811635 biolink:treats MONDO:0006814 PMID:41385096 "[{""id"":""uuid:316adadc-8b21-4820-88c4-94236109f3b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:573d2f8f-5e7a-444f-96de-a2e77ec72d63"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZYLET ® (loteprednol etabonate and tobramycin ophthalmic suspension), 0.5%/0.3% is a topical anti-infective and corticosteroid combination for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, and where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product (tobramycin) is active against the following common bacterial eye pathogens: Staphylococci, including S. aureus and S. epidermidis (coagulase-positive and coagulase-negative), including penicillin-resistant strains. Streptococci, including some of the Group A-beta-hemolytic species, some nonhemolytic species, and some Streptococcus pneumoniae , Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, Proteus mirabilis, Morganella morganii , most Proteus vulgaris strains, Haemophilus influenzae , and H. aegyptius, Moraxella lacunata, Acinetobacter calcoaceticus and some Neisseria species. uuid:6d189093-c837-4242-b3b9-5d170388830a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:9811635 biolink:treats UMLS:C0010543 PMID:41385096 "[{""id"":""uuid:6f229212-c1a7-4512-84d6-0802abe1cb2e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6e8f0a6e-d4fc-42ca-88f1-19bceaa62026"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZYLET ® (loteprednol etabonate and tobramycin ophthalmic suspension), 0.5%/0.3% is a topical anti-infective and corticosteroid combination for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, and where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product (tobramycin) is active against the following common bacterial eye pathogens: Staphylococci, including S. aureus and S. epidermidis (coagulase-positive and coagulase-negative), including penicillin-resistant strains. Streptococci, including some of the Group A-beta-hemolytic species, some nonhemolytic species, and some Streptococcus pneumoniae , Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, Proteus mirabilis, Morganella morganii , most Proteus vulgaris strains, Haemophilus influenzae , and H. aegyptius, Moraxella lacunata, Acinetobacter calcoaceticus and some Neisseria species. uuid:36e99a16-64d6-445c-a305-cc03e2b20fdf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:9811635 biolink:treats UMLS:C0008690 PMID:41385096 "[{""id"":""uuid:af2b4555-108a-4fb0-916f-62a4e5d68654"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5b8c4c07-620c-476a-a923-26687bf34679"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZYLET ® (loteprednol etabonate and tobramycin ophthalmic suspension), 0.5%/0.3% is a topical anti-infective and corticosteroid combination for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, and where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product (tobramycin) is active against the following common bacterial eye pathogens: Staphylococci, including S. aureus and S. epidermidis (coagulase-positive and coagulase-negative), including penicillin-resistant strains. Streptococci, including some of the Group A-beta-hemolytic species, some nonhemolytic species, and some Streptococcus pneumoniae , Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, Proteus mirabilis, Morganella morganii , most Proteus vulgaris strains, Haemophilus influenzae , and H. aegyptius, Moraxella lacunata, Acinetobacter calcoaceticus and some Neisseria species. uuid:6597c583-4a89-468e-acb2-577078edffbf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:9811635 biolink:treats UMLS:C0339289 PMID:41385096 "[{""id"":""uuid:2aa20391-3be8-4a99-a2a0-9b2cf5575b22"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e9d25e3d-9ede-4f9c-ae73-d128a5580ada"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZYLET ® (loteprednol etabonate and tobramycin ophthalmic suspension), 0.5%/0.3% is a topical anti-infective and corticosteroid combination for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, and where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product (tobramycin) is active against the following common bacterial eye pathogens: Staphylococci, including S. aureus and S. epidermidis (coagulase-positive and coagulase-negative), including penicillin-resistant strains. Streptococci, including some of the Group A-beta-hemolytic species, some nonhemolytic species, and some Streptococcus pneumoniae , Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, Proteus mirabilis, Morganella morganii , most Proteus vulgaris strains, Haemophilus influenzae , and H. aegyptius, Moraxella lacunata, Acinetobacter calcoaceticus and some Neisseria species. uuid:b79eb92b-eadd-41c4-acb7-20e54d8959f8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45783 biolink:treats MONDO:0006159 PMID:41385096 "[{""id"":""uuid:1ca4e262-d118-49af-a727-1e10cd3c6928"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:594e17d4-2f4a-43ce-97ea-a898c28c42e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ab822c7d-775c-406f-a803-db78ace40d4d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/glivec""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Imatinib mesylate is a kinase inhibitor indicated for the treatment of: Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. ( 1.1 ) Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy. ( 1.2 ) Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL). ( 1.3 ) Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy. (1.4) Adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements. ( 1.5 ) Adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown. ( 1.6 ) Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or fluorescence in situ hybridization [FISH] demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1­-PDGFRα fusion kinase negative or unknown. ( 1.7 ) Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP). ( 1.8 ) Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST). (1.9) Adjuvant treatment of adult patients following resection of Kit (CD117) positive GIST. (1.10)|[EMA] Imatinib Teva is indicated for the treatment ofAdult and paediatric patients with newly diagnosed Philadelphia chromosome (bcr‑abl) positive (Ph+) chronic myeloid leukaemia (CML) for whom bone marrow transplantation is not considered as the first line of treatment.Adult and paediatric patients with Ph+ CML in chronic phase after failure of interferon‑alpha therapy, or in accelerated phase or blast crisis.Adult and paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy.Adult patients with relapsed or refractory Ph+ ALL as monotherapy.Adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.Adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFRα rearrangement.The effect of imatinib on the outcome of bone marrow transplantation has not been determined.Imatinib Teva is indicated forthe treatment of adult patients with Kit (CD 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST).the adjuvant treatment of adult patients who are at significant risk of relapse following resection of Kit (CD117)-positive GIST. Patients who have a low or very low risk of recurrence should not receive adjuvant treatment.The treatment of adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and/or metastatic DFSP who are not eligible for surgery.In adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in CML, on haematological and cytogenetic response rates in Ph+ ALL, MDS/MPD, on haematological response rates in HES/CEL and on objective response rates in adult patients with unresectable and/or metastatic GIST and DFSP and on recurrence-free survival in adjuvant GIST. The experience with imatinib in patients with MDS/MPD associated with PDGFR gene re-arrangements is very limited (see section 5.1). Except in newly diagnosed chronic phase CML, there are no controlled trials demonstrating a clinical benefit or increased survival for these diseases. uuid:0f9f8b09-1edb-4d72-841f-52ab1ab4b8ac biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0006604 PMID:41385096 "[{""id"":""uuid:9ef8ced0-dab6-4574-be77-997c40ec7f53"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5df33005-9e14-4208-af57-09cc7e09ca58"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZILXI is indicated for the treatment of inflammatory lesions of rosacea in adults [see Clinical Studies ( 14 )] . Limitations of Use This formulation of minocycline has not been evaluated in the treatment of infections. To reduce the development of drug-resistant bacteria as well as to maintain the effectiveness of other antibacterial drugs, ZILXI should be used only as indicated [see Warnings and Precautions ( 5.14 )] . uuid:b932d021-6734-40d8-8ea4-9bfdc4d1ccc0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16586 biolink:treats MONDO:0005039 PMID:41385096 "[{""id"":""uuid:3607fd6a-1fe8-4af4-88cc-76aabcb2bb49"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:12f3ed19-a141-4e21-b84f-ff7867466ab4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Aminocaproic acid tablets are useful in enhancing hemostasis when fibrinolysis contributes to bleeding. In life-threatening situations, transfusion of appropriate blood products and other emergency measures may be required. Fibrinolytic bleeding may frequently be associated with surgical complications following heart surgery (with or without cardiac bypass procedures) and portacaval shunt; hematological disorders such as amegakaryocytic thrombocytopenia (accompanying aplastic anemia); acute and life-threatening abruptio placentae; hepatic cirrhosis; and neoplastic disease such as carcinoma of the prostate, lung, stomach, and cervix. Urinary fibrinolysis, usually a normal physiological phenomenon, may contribute to excessive urinary tract fibrinolytic bleeding associated with surgical hematuria (following prostatectomy and nephrectomy) or nonsurgical hematuria (accompanying polycystic or neoplastic diseases of the genitourinary system). (See WARNINGS . ) uuid:170495cf-213a-4bf5-8d88-22dce9f5ae7f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28864 biolink:treats MONDO:0009061 PMID:41385096 "[{""id"":""uuid:61f3689f-2ecc-4716-9b1a-d8aab1c3defd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c5101135-4c11-44bb-8f90-bccffdeaff30"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:03db8f60-3d2b-4ef4-b4ff-3d95bfdc2424"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/vantobra-previously-tobramycin-pari""]},{""id"":""uuid:d295a5d3-9b39-463f-8ba1-e8692911296a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tobramycin inhalation solution is indicated for the management of cystic fibrosis in adults and pediatric patients 6 years of age and older with Pseudomonas aeruginosa . Safety and efficacy have not been demonstrated in patients under the age of 6 years, patients with forced expiratory volume in 1 second (FEV 1 ) <25% or >75% predicted, or patients colonized with Burkholderia cepacia [see Clinical Studies ( 14 )].|[EMA] Vantobra is indicated for the management of chronic pulmonary infection due to Pseudomonas aeruginosa in patients aged 6 years and older with cystic fibrosis (CF).Consideration should be given to official guidance on the appropriate use of antibacterial agents.|[PMDA] A drug with a new route of administration indicated for the improvement of symptoms associated with respiratory infection caused by Pseudomonas aeruginosa in cystic fibrosis patients. uuid:7cda769d-19c1-4717-9b52-a7cb42d693e7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28864 biolink:treats UMLS:C0854135 PMID:41385096 "[{""id"":""uuid:98bc3ad0-86c3-4a18-bf31-11ecdac2ffbf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:49e12c1b-a552-4c0e-ba8f-d096b76bddfb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:7021ca74-023d-4bb5-b1e7-25f55373dab7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tobramycin inhalation solution is indicated for the management of cystic fibrosis in adults and pediatric patients 6 years of age and older with Pseudomonas aeruginosa . Safety and efficacy have not been demonstrated in patients under the age of 6 years, patients with forced expiratory volume in 1 second (FEV 1 ) <25% or >75% predicted, or patients colonized with Burkholderia cepacia [see Clinical Studies ( 14 )].|[PMDA] A drug with a new route of administration indicated for the improvement of symptoms associated with respiratory infection caused by Pseudomonas aeruginosa in cystic fibrosis patients. uuid:091695b0-a54e-48d8-b438-8bd5eb1f9d58 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28864 biolink:treats UMLS:C1610617 PMID:41385096 "[{""id"":""uuid:5693050f-59a8-4d47-bc16-99d378d9a19b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:23ee92bc-f05d-4be0-b666-84fe557869d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tobramycin inhalation solution is indicated for the management of cystic fibrosis in adults and pediatric patients 6 years of age and older with Pseudomonas aeruginosa . Safety and efficacy have not been demonstrated in patients under the age of 6 years, patients with forced expiratory volume in 1 second (FEV 1 ) <25% or >75% predicted, or patients colonized with Burkholderia cepacia [see Clinical Studies ( 14 )]. uuid:b685341f-b8dd-4a86-8bad-a6d4c2e72b73 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45081 biolink:treats MONDO:0019121 PMID:41385096 "[{""id"":""uuid:b0d21759-f49c-4485-b093-d519865ba514"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:828059b2-c333-40d6-a5af-25ad3042a38a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pentam 300 (pentamidine isethionate for injection) is indicated for the treatment of pneumonia due to Pneumocystis carinii . uuid:228f44d8-25b4-4e37-8e0a-dfdacd96fced biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:N0A21N6RAU biolink:treats UMLS:C0406317 PMID:41385096 "[{""id"":""uuid:05c0fe85-12f2-42d0-8dab-b2699f5f47be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:509e0690-2ce4-4524-8ec4-3c51a86b012b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:486b2820-6f5d-4ef6-9ed3-ee30a9c52107"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SOTYKTU™ is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Limitations of Use : SOTYKTU is not recommended for use in combination with other potent immunosuppressants.|[PMDA] A drug with a new active ingredient indicated for the treatment of plaque psoriasis, pustular psoriasis, and erythrodermic psoriasis in patients who have not responded sufficiently to conventional therapies. uuid:2b384b3c-0738-44c5-94f2-8eee7cbd1e52 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2955 biolink:treats MONDO:0017767 PMID:41385096 "[{""id"":""uuid:ebfc4a2c-ceb3-4789-b475-c710e8c6e554"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a06dfce6-0e0f-4519-8a6c-c92f6661dad0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Acute bacterial exacerbations of chronic obstructive pulmonary disease due to Haemophilus influenzae, Moraxella catarrhalis or Streptococcus pneumoniae. Acute bacterial sinusitis due to Haemophilus influenzae, Moraxella catarrhalis or Streptococcus pneumoniae . Community-acquired pneumonia due to Chlamydophila pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae or Streptococcus pneumoniae in patients appropriate for oral therapy. NOTE: Azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomially acquired infections, patients with known or suspected bacteremia, patients requiring hospitalization, elderly or debilitated patients, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. NOTE: Penicillin by the intramuscular route is the usual drug of choice in the treatment of Streptococcus pyogenes infection and the prophylaxis of rheumatic fever. Azithromycin tablets USP are often effective in the eradication of susceptible strains of Streptococcus pyogenes from the nasopharynx. Because some strains are resistant to azithromycin tablets USP, susceptibility tests should be performed when patients are treated with azithromycin tablets USP. Data establishing efficacy of azithromycin in subsequent prevention of rheumatic fever are not available. Uncomplicated skin and skin structure infections due to Staphylococcus aureus, Streptococcus pyogenes, or Streptococcus agalactiae. Abscesses usually require surgical drainage. Urethritis and cervicitis due to Chlamydia trachomatis or Neisseria gonorrhoeae . Genital ulcer disease in men due to Haemophilus ducreyi (chancroid). Due to the small number of women included in clinical trials, the efficacy of azithromycin in the treatment of chancroid in women has not been established. Azithromycin tablets USP, at the recommended dose, should not be relied upon to treat syphilis. Antimicrobial agents used in high doses for short periods of time to treat non-gonococcal urethritis may mask or delay the symptoms of incubating syphilis. All patients with sexually-transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate cultures for gonorrhea performed at the time of diagnosis. Appropriate antimicrobial therapy and follow-up tests for these diseases should be initiated if infection is confirmed. Appropriate culture and susceptibility tests should be performed before treatment to determine the causative organism and its susceptibility to azithromycin, USP. Therapy with azithromycin tablets USP may be initiated before results of these tests are known; once the results become available, antimicrobial therapy should be adjusted accordingly. To reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin tablets USP and other antibacterial drugs, azithromycin tablets USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:869d5aab-f594-48f2-8793-c272d34aa30d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2955 biolink:treats MONDO:0005227 PMID:41385096 "[{""id"":""uuid:c7517abc-957c-43a2-9c6b-d5e364cba9ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:06a9cad7-3aa7-4568-b69a-b3f9ec2f0954"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Acute bacterial exacerbations of chronic obstructive pulmonary disease due to Haemophilus influenzae, Moraxella catarrhalis or Streptococcus pneumoniae. Acute bacterial sinusitis due to Haemophilus influenzae, Moraxella catarrhalis or Streptococcus pneumoniae . Community-acquired pneumonia due to Chlamydophila pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae or Streptococcus pneumoniae in patients appropriate for oral therapy. NOTE: Azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomially acquired infections, patients with known or suspected bacteremia, patients requiring hospitalization, elderly or debilitated patients, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. NOTE: Penicillin by the intramuscular route is the usual drug of choice in the treatment of Streptococcus pyogenes infection and the prophylaxis of rheumatic fever. Azithromycin tablets USP are often effective in the eradication of susceptible strains of Streptococcus pyogenes from the nasopharynx. Because some strains are resistant to azithromycin tablets USP, susceptibility tests should be performed when patients are treated with azithromycin tablets USP. Data establishing efficacy of azithromycin in subsequent prevention of rheumatic fever are not available. Uncomplicated skin and skin structure infections due to Staphylococcus aureus, Streptococcus pyogenes, or Streptococcus agalactiae. Abscesses usually require surgical drainage. Urethritis and cervicitis due to Chlamydia trachomatis or Neisseria gonorrhoeae . Genital ulcer disease in men due to Haemophilus ducreyi (chancroid). Due to the small number of women included in clinical trials, the efficacy of azithromycin in the treatment of chancroid in women has not been established. Azithromycin tablets USP, at the recommended dose, should not be relied upon to treat syphilis. Antimicrobial agents used in high doses for short periods of time to treat non-gonococcal urethritis may mask or delay the symptoms of incubating syphilis. All patients with sexually-transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate cultures for gonorrhea performed at the time of diagnosis. Appropriate antimicrobial therapy and follow-up tests for these diseases should be initiated if infection is confirmed. Appropriate culture and susceptibility tests should be performed before treatment to determine the causative organism and its susceptibility to azithromycin, USP. Therapy with azithromycin tablets USP may be initiated before results of these tests are known; once the results become available, antimicrobial therapy should be adjusted accordingly. To reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin tablets USP and other antibacterial drugs, azithromycin tablets USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:e7818a10-4cb1-4ea1-a238-cc79c3904a47 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135738 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:d52b5d46-17bc-44e7-ae6e-f832311f28aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:65e73450-f01d-40ef-a1b7-f8461da2e359"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cleviprex is indicated for the reduction of blood pressure when oral therapy is not feasible or not desirable. uuid:b06cfce7-ccf6-4eeb-8f66-cbd1730ca59d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28748 biolink:treats MONDO:0008170 PMID:41385096 "[{""id"":""uuid:43e95612-35da-4d90-a92b-545203b93ebd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4f16034e-3e28-4024-a93f-62b0c8046d1d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:62a045c2-4f2d-40e7-98cd-b312cca51e6f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:7079b78d-c136-4ea2-b507-8ea3907fb73a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Doxorubicin hydrochloride liposome injection is an anthracycline topoisomerase inhibitor indicated for: • Ovarian cancer After failure of platinum-based chemotherapy ( 1.1 ). • AIDS-related Kaposi’s Sarcoma After failure of prior systemic chemotherapy or intolerance to such therapy ( 1.2 ) . • Multiple Myeloma In combination with bortezomib in patients who have not previously received bortezomib and have received at least one prior therapy ( 1.3 ) .|[EMA] Zolsketil pegylated liposomal is a medicine used to treat the following types of cancer in adults:• breast cancer that has spread to other parts of the body in patients at risk of heart problems. Zolsketil pegylated liposomal is used on its own for this disease;• advanced ovarian cancer in women whose previous treatment including a platinum-based cancer medicine has stopped working;• multiple myeloma (a cancer of the white blood cells in the bone marrow), in patients with progressive disease who have received at least one other treatment in the past and have already had, or are unsuitable for, a bone marrow transplantation. Zolsketil pegylated liposomal is used in combination with bortezomib (another cancer medicine);• Kaposi’s sarcoma in patients with AIDS who have a very damaged immune system. Kaposi’s sarcoma is a cancer that causes abnormal tissue to grow under the skin, on moist body surfaces or on internal organs.Zolsketil pegylated liposomal contains the active substance doxorubicin and is a ‘hybrid medicine’. This means that it is similar to a ‘reference medicine’ containing the same active substance called Adriamycin. However, in Zolsketil pegylated liposomal the active substance is enclosed in tiny fatty spheres called liposomes, whereas this is not the case for Adriamycin.|[PMDA] A drug with a new indication and a new dosage for the treatment of ovarian cancer which has progressed after cancer chemotherapy. [Expedited review] uuid:111ea64a-51bc-441c-9173-fca647965837 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28748 biolink:treats MONDO:0005055 PMID:41385096 "[{""id"":""uuid:a204e210-52ac-449b-9fdf-c043351eb1b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e8f23788-ba6a-4b01-9d46-dd78ee80f192"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:96562e33-a302-4a57-83da-6d7b2aed8502"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:29006224-eea1-4788-a801-7f3a78d5776c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Doxorubicin hydrochloride liposome injection is an anthracycline topoisomerase inhibitor indicated for: • Ovarian cancer After failure of platinum-based chemotherapy ( 1.1 ). • AIDS-related Kaposi’s Sarcoma After failure of prior systemic chemotherapy or intolerance to such therapy ( 1.2 ) . • Multiple Myeloma In combination with bortezomib in patients who have not previously received bortezomib and have received at least one prior therapy ( 1.3 ) .|[EMA] Zolsketil pegylated liposomal is a medicine used to treat the following types of cancer in adults:• breast cancer that has spread to other parts of the body in patients at risk of heart problems. Zolsketil pegylated liposomal is used on its own for this disease;• advanced ovarian cancer in women whose previous treatment including a platinum-based cancer medicine has stopped working;• multiple myeloma (a cancer of the white blood cells in the bone marrow), in patients with progressive disease who have received at least one other treatment in the past and have already had, or are unsuitable for, a bone marrow transplantation. Zolsketil pegylated liposomal is used in combination with bortezomib (another cancer medicine);• Kaposi’s sarcoma in patients with AIDS who have a very damaged immune system. Kaposi’s sarcoma is a cancer that causes abnormal tissue to grow under the skin, on moist body surfaces or on internal organs.Zolsketil pegylated liposomal contains the active substance doxorubicin and is a ‘hybrid medicine’. This means that it is similar to a ‘reference medicine’ containing the same active substance called Adriamycin. However, in Zolsketil pegylated liposomal the active substance is enclosed in tiny fatty spheres called liposomes, whereas this is not the case for Adriamycin.|[PMDA] Drug with a new indication and dosage for treatment of AIDS-related Kaposi’s sarcoma. [Orphan Drug] uuid:eaac58c0-ba7f-4107-bc33-05cb0193bd24 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28748 biolink:treats MONDO:0009693 PMID:41385096 "[{""id"":""uuid:22e2336c-b7d8-4c8c-9db9-e46103ee271d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:18427f00-55ed-4cd4-bff7-7faf53c0f9ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:fc4b3fa6-a0e5-4f42-861e-fd1e77493efa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Doxorubicin hydrochloride liposome injection is an anthracycline topoisomerase inhibitor indicated for: • Ovarian cancer After failure of platinum-based chemotherapy ( 1.1 ). • AIDS-related Kaposi’s Sarcoma After failure of prior systemic chemotherapy or intolerance to such therapy ( 1.2 ) . • Multiple Myeloma In combination with bortezomib in patients who have not previously received bortezomib and have received at least one prior therapy ( 1.3 ) .|[EMA] Zolsketil pegylated liposomal is a medicine used to treat the following types of cancer in adults:• breast cancer that has spread to other parts of the body in patients at risk of heart problems. Zolsketil pegylated liposomal is used on its own for this disease;• advanced ovarian cancer in women whose previous treatment including a platinum-based cancer medicine has stopped working;• multiple myeloma (a cancer of the white blood cells in the bone marrow), in patients with progressive disease who have received at least one other treatment in the past and have already had, or are unsuitable for, a bone marrow transplantation. Zolsketil pegylated liposomal is used in combination with bortezomib (another cancer medicine);• Kaposi’s sarcoma in patients with AIDS who have a very damaged immune system. Kaposi’s sarcoma is a cancer that causes abnormal tissue to grow under the skin, on moist body surfaces or on internal organs.Zolsketil pegylated liposomal contains the active substance doxorubicin and is a ‘hybrid medicine’. This means that it is similar to a ‘reference medicine’ containing the same active substance called Adriamycin. However, in Zolsketil pegylated liposomal the active substance is enclosed in tiny fatty spheres called liposomes, whereas this is not the case for Adriamycin. uuid:a5959104-bd6c-407a-a4cb-d6d4a1367d77 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49040 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:d94ad3e0-0dd2-4ad9-a046-3b8253738c36"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:986b278d-33eb-49f1-8aa8-d63030c66601"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. 1.1 Primary Hyperlipidemia Monotherapy Ezetimibe Tablets, administered alone, is indicated as adjunctive therapy to diet for the reduction of elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), and non-high-density lipoprotein cholesterol (non-HDL-C) in patients with primary (heterozygous familial and non-familial) hyperlipidemia. Combination Therapy with HMG-CoA Reductase Inhibitors (Statins) Ezetimibe Tablets, administered in combination with a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor (statin), is indicated as adjunctive therapy to diet for the reduction of elevated total-C, LDL-C, Apo B, and non-HDL-C in patients with primary (heterozygous familial and non-familial) hyperlipidemia. Combination Therapy with Fenofibrate Ezetimibe Tablets, administered in combination with fenofibrate, is indicated as adjunctive therapy to diet for the reduction of elevated total-C, LDL-C, Apo B, and non-HDL-C in adult patients with mixed hyperlipidemia. 1.2 Homozygous Familial Hypercholesterolemia (HoFH) The combination of Ezetimibe Tablets and atorvastatin or simvastatin is indicated for the reduction of elevated total-C and LDL-C levels in patients with HoFH, as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable. 1.3 Homozygous Sitosterolemia Ezetimibe Tablet is indicated as adjunctive therapy to diet for the reduction of elevated sitosterol and campesterol levels in patients with homozygous familial sitosterolemia. 1.4 Limitations of Use The effect of Ezetimibe Tablets on cardiovascular morbidity and mortality has not been determined. Ezetimibe Tablets has not been studied in Fredrickson Type I, III, IV, and V dyslipidemias. uuid:5aa138dc-81ef-49e3-b0c6-6d981996c785 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4450 biolink:treats UMLS:C0018674 PMID:41385096 "[{""id"":""uuid:1182c893-3dd9-44f6-b9e0-b3961225f15d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c537f4b1-0c63-4425-b715-c5431e08dbe9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DDAVP Injection is a vasopressin analog used for: Central Diabetes Insipidus - as antidiuretic replacement therapy in the management of central (cranial) diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. ( 1.1 ) Hemophilia A- for patients with factor VIII coagulant activity levels greater than 5% to maintain hemostasis during surgical procedures and postoperatively or reduce bleeding with episodes of spontaneous or traumatic injuries such as hemarthroses, intramuscular hematomas, or mucosal bleeding. ( 1.2 ) von Willebrand's disease (Type I) - for patients with mild to moderate disease with factor VIII levels greater than 5% to maintain hemostasis during surgical procedures or traumatic injuries such as hemarthroses, intramuscular hematomas, or mucosal bleeding. ( 1.3 ) Limitations of Use DDAVP is ineffective and not indicated for the treatment of nephrogenic diabetes insipidus. ( 1.3 ) von Willebrand's disease (severe Type I) - not indicated for the treatment of patients with severe Type I von Willebrand's disease and when there is evidence of an abnormal molecular form of factor VIII antigen. ( 1.3 ) uuid:01ce748b-d2c7-44c6-ad99-aa26f51fd3d6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:66899 biolink:treats MONDO:0005338 PMID:41385096 "[{""id"":""uuid:bb08da83-cfdb-4c75-b110-57897b2d3a43"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f321c462-30e9-4fa1-a519-1f7d345d6b5c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZIOPTAN ® (tafluprost ophthalmic solution) 0.0015% is indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. uuid:3a94bbbc-f184-474f-a2a8-27bdf2a1b818 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:66899 biolink:treats MONDO:0006875 PMID:41385096 "[{""id"":""uuid:f27c44fd-584c-434f-a852-7f942dcdbb29"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5c579766-df9e-4e88-843e-65770a24d3fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZIOPTAN ® (tafluprost ophthalmic solution) 0.0015% is indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. uuid:57d3bd78-5ce0-4371-9f98-bad9345fc151 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:177736 biolink:treats UMLS:C4543399 PMID:41385096 "[{""id"":""uuid:23fc50e4-4fbf-41e3-b15e-cd392035dd7f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0eb35d94-2893-4a63-91cd-99131fe8afc5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Xermelo is indicated for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy. uuid:82c100da-5a21-4fd1-ba01-edad251d4bc9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0005244 PMID:41385096 "[{""id"":""uuid:451d4717-b27d-4af4-a8c3-b9b4090b7875"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:742cda98-f033-415e-a2b9-ae34a2910a17"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Anesthetic for relief of pain at site of injury; relief of musculoskeletal pain and soreness; pain from neuropathy; local medical procedures, injections and vaccines; relief of pruritis, pruritic eczema, abrasions, minor burns, insect bites, pain, soreness and discomfort due to pruritis ani, pruritis vulvae, hemorrhoids, anal fissures and similar conditions of the skin and mucous membranes. uuid:533e0c1a-0e93-4b24-97cb-f3282e4a729c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17026 biolink:treats MONDO:0001836 PMID:41385096 "[{""id"":""uuid:e80ffb39-65df-497d-a227-be180be1f5f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e97a2177-884e-4f83-a1ae-f6564d4a66bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] This drug is indicated in amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer. uuid:b0c4224e-6c16-4212-90fc-c75ea1fd03dd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17026 biolink:treats UMLS:C3650625 PMID:41385096 "[{""id"":""uuid:8a269ca9-7fe9-4a9e-b0a7-5e3385311456"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8a422997-1926-4c0d-8473-c44cf5441670"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] This drug is indicated in amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer. uuid:99556128-49d7-4a69-beec-50a95fa69e43 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17026 biolink:treats MONDO:0001664 PMID:41385096 "[{""id"":""uuid:f34b1161-40ef-42eb-8d70-eb58069ce3a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8227ee8a-75d3-4366-8fe6-cad6422d2141"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] This drug is indicated in amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer. uuid:b86fedc0-abad-490d-a27c-c25d446761b3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17026 biolink:treats MONDO:0002715 PMID:41385096 "[{""id"":""uuid:857f1d99-4168-4932-a41f-c15859870a6d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:af012642-f339-4008-bd2b-2c582d3b4ad2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] This drug is indicated in amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer. uuid:1e250c1e-aeb3-4142-a821-37074a903577 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17905 biolink:treats MONDO:0000496 PMID:41385096 "[{""id"":""uuid:ccb4ed1a-b491-40f0-a68c-9e41e44b49d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a2c82ffc-4ff8-4cc8-940c-8b92786efaf3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mesna Injection is indicated as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis. Limitation of Use : Mesna Injection is not indicated to reduce the risk of hematuria due to other pathological conditions such as thrombocytopenia. uuid:c8383c7a-15b7-4eb4-a748-c05860543237 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17905 biolink:treats MONDO:0002049 PMID:41385096 "[{""id"":""uuid:ca49a26d-13c7-488e-a02d-1bd77dfd4342"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cb905405-3130-44f5-9b4e-ae5e76423cf3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mesna Injection is indicated as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis. Limitation of Use : Mesna Injection is not indicated to reduce the risk of hematuria due to other pathological conditions such as thrombocytopenia. uuid:ed753c8a-fd8d-4712-842c-3accd0532128 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:183909 biolink:treats MONDO:0005393 PMID:41385096 "[{""id"":""uuid:5c5228a3-4d26-4ac3-ac50-4ca272193500"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6abf7199-5e77-47a8-95c1-935f8ee69079"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Colchicine tablets are an alkaloid indicated for: Prophylaxis and treatment of gout flares in adults ( 1.1 ). Familial Mediterranean fever (FMF) in adults and children 4 years or older ( 1.2 ). uuid:bddee830-d255-4144-aa60-f593bfbaec35 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:183909 biolink:treats MONDO:0018088 PMID:41385096 "[{""id"":""uuid:755e5bd9-07ed-44cd-84ee-76606811280c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:11f55797-e2a8-41d6-8245-7c7500aa59a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Colchicine tablets are an alkaloid indicated for: Prophylaxis and treatment of gout flares in adults ( 1.1 ). Familial Mediterranean fever (FMF) in adults and children 4 years or older ( 1.2 ). uuid:17304256-f67a-44ba-969d-3a40e8953167 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9241 biolink:treats UMLS:C0341960 PMID:41385096 "[{""id"":""uuid:982120f3-c6f6-4fa1-89f8-e2c4ea6b6cb4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dcb21003-cf2e-4865-9ecb-8831731ca1f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Spironolactone tablets are indicated in the management of: Primary hyperaldosteronism for: Establishing the diagnosis of primary hyperaldosteronism by therapeutic trial. Short-term preoperative treatment of patients with primary hyperaldosteronism. Long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are judged to be poor operative risks or who decline surgery. Long-term maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). Edematous conditions for patients with: Congestive heart failure: For the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures. Spironolactone tablets are also indicated for patients with congestive heart failure taking digitalis when other therapies are considered inappropriate. Cirrhosis of the liver accompanied by edema and/or ascites: Aldosterone levels may be exceptionally high in this condition. Spironolactone tablets are indicated for maintenance therapy together with bed rest and the restriction of fluid and sodium. Nephrotic syndrome: For nephrotic patients when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics do not provide an adequate response. Essential hypertension Spironolactone tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Usually in combination with other drugs, spironolactone tablets are indicated for patients who cannot be treated adequately with other agents or for whom other agents are considered inappropriate. Hypokalemia For the treatment of patients with hypokalemia when other measures are considered inappropriate or inadequate. Spironolactone tablets are also indicated for the prophylaxis of hypokalemia in patients taking digitalis when other measures are considered inadequate or inappropriate. Severe heart failure (NYHA class III – IV) To increase survival, and to reduce the need for hospitalization for heart failure when used in addition to standard therapy. Usage in Pregnancy: The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developing toxemia. Edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy. Spironolactone tablets are indicated in pregnancy when edema is due to pathologic causes just as it is in the absence of pregnancy (however, see Precautions: Pregnancy). Dependent edema in pregnancy, resulting from restriction of venous return by the expanded uterus, is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is unsupported and unnecessary. There is hypervolemia during normal pregnancy which is not harmful to either the fetus or the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema, in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances, this edema may cause extreme discomfort that is not relieved by rest. In these cases, a short course of diuretics may provide relief and may be appropriate. uuid:87a4fd1b-0660-4b97-bf65-7a17d9e1b2fd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:499361 biolink:treats HP:0002017 PMID:41385096 "[{""id"":""uuid:1859d812-0669-45ca-ac4d-4cae8151a9ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3959c4fe-7250-44a5-b802-eba69629dd5a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fosaprepitant for injection, in combination with other antiemetic agents, is indicated in adults and pediatric patients 6 months of age and older for the prevention of: • acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin. • delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). Limitations of Use • Fosaprepitant for injection has not been studied for the treatment of established nausea and vomiting. uuid:d3f32f1b-76e9-4c60-9784-fe97fa9c74dd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:499361 biolink:treats EFO:0006911 PMID:41385096 "[{""id"":""uuid:22561e2e-1e3f-4827-afa5-0102aab6ce0f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:9159fde7-c725-454e-a8eb-6ead9d71814e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:035924ba-83dd-4307-a7aa-10a436f93f30"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/emend""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fosaprepitant for injection, in combination with other antiemetic agents, is indicated in adults and pediatric patients 6 months of age and older for the prevention of: • acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin. • delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). Limitations of Use • Fosaprepitant for injection has not been studied for the treatment of established nausea and vomiting.|[EMA] Emend 40 mg hard capsules is indicated for the prevention of postoperative nausea and vomiting (PONV) in adults.Emend is also available as 80 mg and 125 mg hard capsules for the prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults and adolescents from the age of 12 (see separate Summary of Product Characteristics).Emend is also available as 165 mg hard capsules for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin based cancer chemotherapy in adults and the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy in adults.Emend is also available as powder for oral suspension for the prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in children, toddlers and infants from the age of 6 months to less than 12 years.Emend 80 mg, 125 mg, 165 mg hard capsules and Emend powder for oral suspension are given as part of combination therapy. uuid:f6cdd2ff-285f-4af8-8593-c240a4efb75d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:7758d916-32c0-4c7b-8be7-f6143f598c4c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bf53af6d-83e6-4426-bbbb-b17f979211ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:650c90f9-1020-4f47-9dcd-b85f60cdf352 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0005480 PMID:41385096 "[{""id"":""uuid:f174930e-ad41-4f72-a82f-a59d9955e28f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:37d3243e-9519-480a-b4c4-92921440f896"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:926a0686-dc48-4797-b4d2-9f6ca6664321 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0000775 PMID:41385096 "[{""id"":""uuid:4724ac57-9630-465a-b302-996bbe6ce3f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dd8e8706-3f9a-486f-a1ae-3db782ec9ff2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:31a707d4-118f-4f35-b3c2-af4a63cd42e1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0024332 PMID:41385096 "[{""id"":""uuid:917c6bf0-61ae-44a1-85b9-9e2c3f94f237"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:217a9eec-ab78-4b8f-a028-f7321bfa069a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:33723d79-8e20-4794-851e-c8e4cc80f07a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0005324 PMID:41385096 "[{""id"":""uuid:f287fbe7-7772-4ded-9592-a85eb8cc8cbd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1b6d977e-904e-4b04-95d8-3bbaf670abcd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:e8ae7a8f-a69d-4c1f-adfe-017e0e51ddef biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0043789 PMID:41385096 "[{""id"":""uuid:c76f1992-2a99-44d2-abb8-a5fb15bd873a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:00fa6508-d3e1-4eef-8e13-72dcfeb80643"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:7e94a4fd-a488-445a-afbb-234ad4681101 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats UMLS:C0274435 PMID:41385096 "[{""id"":""uuid:1b9e0dca-8924-4f76-a9df-ea43e181ec49"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:26434c64-67c7-440f-944b-b3d95619077e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:45a7468a-94cf-44ee-9e32-e47519ef43d2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0015614 PMID:41385096 "[{""id"":""uuid:b3021280-282d-4b13-9c37-0a9c8abdf18f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c3f59dc5-663c-4114-b99b-7a23aef8f106"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:01a998b3-aed0-428c-ba4a-501b4510db01 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0043233 PMID:41385096 "[{""id"":""uuid:a993bfa2-40fb-4358-ba0a-a3bd4553adec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:568a248e-770e-4a3f-8293-5141f05c0081"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:688a1965-8cb4-4fa6-aa0b-37d496b175f7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0009691 PMID:41385096 "[{""id"":""uuid:38bdad38-88af-43f1-97f0-c2c5066001a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cd3d60b6-ca35-4b84-8330-e0c04f8998d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:097fd50c-babf-4021-99dd-9c756fe41bb1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0006594 PMID:41385096 "[{""id"":""uuid:7e8cb0b8-e53b-4bdc-8fb8-6e6e7006e53c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bdc0b262-fecf-4d31-bfc9-e8a02c61441f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:8ebdf5eb-76c8-4ca3-86e3-34103aee07f4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0018229 PMID:41385096 "[{""id"":""uuid:83ec9695-686d-450c-b7c3-b0e8b9ee38a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8e4944b7-7500-4ff0-b436-f5a694b0353a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:53f63416-bcc5-41c9-bf74-cbb7ae81bfda biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0018479 PMID:41385096 "[{""id"":""uuid:17f63a6d-af4d-4215-8ca5-b4f6d10070a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e5530669-df0a-4586-a57c-2c51f7c3f12b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:7eb26acb-569f-4a97-a82a-3c904aff935e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0043455 PMID:41385096 "[{""id"":""uuid:bae5eae8-a5e4-49cd-a11e-b2f440f7d917"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b61b3f6a-8b82-4d50-9f40-aab63bbdfd48"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:8b1d5921-c29d-411b-9a1b-3be488d8979f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0006982 PMID:41385096 "[{""id"":""uuid:9f043eb8-2b6a-4658-a591-ec48bc687062"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a8158e03-507e-47bb-869c-1084602b68fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:5b05fc7e-8164-4c56-b094-639173564e8c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0000004 PMID:41385096 "[{""id"":""uuid:e280a70e-c94f-4eee-b5f6-428a652e3e64"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e360cdd5-1b7c-4aaa-b6a5-ff286523888c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:fdec9cab-d843-4a2e-b9de-4d373b8009c0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats UMLS:C0678202 PMID:41385096 "[{""id"":""uuid:3452bd05-cbeb-4eda-aec2-60ac22ae55cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:73bf87eb-6ef3-490e-a042-bc7c2dfe2a3e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:d86b34ff-2171-4260-a810-6ba7080a499b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0005101 PMID:41385096 "[{""id"":""uuid:9c3c87cb-05dd-4ee5-8657-eee6eebdf445"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1c2661b6-d6c5-4b30-ab96-42be7c5fb61e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:1b0853f7-b37a-4fa6-9927-a1cad8811ab9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0020108 PMID:41385096 "[{""id"":""uuid:23153138-2a06-4741-866d-246dadbfe38a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:deacb956-ee25-4ff8-8025-dd724520d23e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:d5d4933e-f55f-4a9b-97ad-7a2dbd4e8d06 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0015253 PMID:41385096 "[{""id"":""uuid:7c39640a-cf9b-4aa3-a312-2259eee64ccd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:53b92c35-1ae5-4076-8ab5-7958cab761ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:cb14e0f9-13f7-4c6d-9c11-9fbc3048f79e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0001705 PMID:41385096 "[{""id"":""uuid:c5035438-8abd-4190-8491-77560c281d19"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:039d74c5-a1f5-4a14-891a-204a2d5116fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:1fdb8802-4948-4008-a38d-1ef3651c8b64 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0001198 PMID:41385096 "[{""id"":""uuid:76822171-873c-4512-921f-29c2f150becd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3382c88b-09c5-4d41-9eda-fb3da4e959a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:e4df3c10-9fe5-45c2-a11d-4c481e50bba5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0019444 PMID:41385096 "[{""id"":""uuid:d1c7a9ca-6b18-41b4-9324-4329b82a93fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c13db0a8-d647-4224-9a93-3098efc3973e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:21590d2d-51c0-4d2f-b225-f86567b824e4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0006042 PMID:41385096 "[{""id"":""uuid:e4882ade-f308-4d72-9a60-c4ea088106a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5957b070-a22b-42a6-a0a0-f077ac248940"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:5ace0586-a6ff-4475-a6dc-09e234690c16 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0005059 PMID:41385096 "[{""id"":""uuid:f06a2da5-b1cf-4eca-9ed9-b72c7fcf6156"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a683912a-0c32-4e9b-a054-223efb2cf90c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:ff9e7693-862a-42c3-851d-0e2c02f56c41 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0004095 PMID:41385096 "[{""id"":""uuid:8b7f63b2-5776-49eb-9313-4dd6f5cf92ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eff7871b-da91-4cef-a491-17a586199dcc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:509da0de-7e3a-4f87-b574-41755f9a8bdf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0005301 PMID:41385096 "[{""id"":""uuid:2180a085-c556-416c-9edd-c2e540979758"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:34e087cc-47f9-4dcb-898e-7135cffa0390"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:e3a9c28b-2695-4530-b164-7985ece1c582 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0006684 PMID:41385096 "[{""id"":""uuid:da45304d-cf6c-4104-8ce2-c40c8ced1f77"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d9626369-3ea0-4fe2-baea-2775070a7687"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:e4951302-5627-41e9-902c-a2e0c3cb6ffb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0021632 PMID:41385096 "[{""id"":""uuid:11b23ab2-b5bc-4def-8287-fa4f0ef4c4f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f317ba52-f440-4925-bb0b-6c44faac81cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:95e80406-f325-4611-9833-7c54dcb9c97e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:1040026 PMID:41385096 "[{""id"":""uuid:eefe2821-3e25-47fc-be9f-283ae97004b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6d00260c-1ba0-4773-a2db-ac8c7d7f2c7f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:4d96117a-f3a2-4f7a-855e-31bc0e37dc19 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0019198 PMID:41385096 "[{""id"":""uuid:6d3d6cb4-6c1b-4a79-a52e-f7c451880d83"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9dbd7f41-04d6-4bdf-a376-0ada7dd1c7ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:5168031f-9ab4-431e-9c8e-9f9e41dbd73a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0008538 PMID:41385096 "[{""id"":""uuid:2c375cab-dd9f-45ef-90df-1d7633bd35a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:089746b6-9a67-4727-b5e3-cf3d3d0e610e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:ed988cca-d22a-49d8-9739-802de0668026 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0020283 PMID:41385096 "[{""id"":""uuid:07a74ff8-8a83-446e-baf0-942eaf3e1e71"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:df20246f-1535-444f-8dcf-6502207dcacd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:7ad3d8ba-5eed-4aee-a085-55997f488cba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0018170 PMID:41385096 "[{""id"":""uuid:f91f5337-c76c-4c85-83df-170dea2952e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a7551933-802f-4b9b-80ac-0ddf1aeeed3d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:00208a14-649e-460b-9213-54569449b680 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0004670 PMID:41385096 "[{""id"":""uuid:c7a3af3f-51c0-4adc-a7d2-242c6873f5b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f999e577-3c9d-4b77-b996-899d5a71523e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:2fd5635e-6042-457b-a0c1-45a9053ebf03 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0015274 PMID:41385096 "[{""id"":""uuid:7cf0d580-96cd-4b93-b877-6b2217c7aca9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fbea781e-6b35-4c35-9462-95544b14d9cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:a47698a3-92dc-4feb-9db0-cbc8e8e2991b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0006052 PMID:41385096 "[{""id"":""uuid:d6815d2d-fb67-4c7c-bd94-d39039f00fa3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5eb29397-adab-4bda-a275-2f60650d5420"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:e9cbe62d-ed4a-4b21-a622-216cbc704a37 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0005848 PMID:41385096 "[{""id"":""uuid:82b66de2-74dd-45dc-af65-bbfaf1db40ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3bd76983-547c-4211-9fd8-e518bc87dba1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:473f3d1b-579f-4c9a-bdb9-97bea85b6408 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0015927 PMID:41385096 "[{""id"":""uuid:426b5e98-4fcc-4cbe-b47b-8f3ae593e6d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9b1b7503-146d-441f-bde5-1879e71ba106"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:b5929bd9-d6f0-4447-9b04-3d080703badd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0019338 PMID:41385096 "[{""id"":""uuid:831c9e49-2243-4553-b8b7-d7c24b000d43"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c90353eb-f7f5-482d-88a6-d15a92e35e84"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:7b205b99-0ea4-4f65-9cdd-051ebcd662c5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats UMLS:C0149896 PMID:41385096 "[{""id"":""uuid:ae163f32-622f-4928-96be-d68045af194c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e7cdd632-79e5-481a-a089-b56c1bb217b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:510f494e-eb27-4a9d-a20a-95362aa66c98 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats UMLS:C5441648 PMID:41385096 "[{""id"":""uuid:32eb027a-d0b8-42ed-ab9d-2377fd9c4b7d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a496e539-f985-4ed8-a3b8-53343ecceebc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:241109b7-ad54-4ff6-8413-9697a6c1bdc4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0005306 PMID:41385096 "[{""id"":""uuid:bc160d8b-0d97-466e-a82b-339821cb9709"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:12f59150-f408-436a-95cc-da32adb2389a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:9fc384e6-44e1-4902-a49a-d2b2b98c975f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0011849 PMID:41385096 "[{""id"":""uuid:457c6218-0d1f-4cf3-89b4-217605be444e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ce566c2b-0496-41fe-aba7-d91206165c98"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:b5ca1b37-1e95-408f-b0fb-a2c8a484bddb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:d83f8eba-ff01-4aa9-9c84-72a1e5692d21"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:07966610-7eb1-45a0-9c31-3ae8a7d4ac3e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:1b8743ea-993e-4ca4-823e-7cfeb1731db8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0011429 PMID:41385096 "[{""id"":""uuid:c7fc964f-11c4-4d99-af09-4ad11ea28758"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c27a3e92-1b9f-4935-b447-2b8b5a239beb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:b7199381-0847-4241-a1f2-e4d1ae5925eb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0016367 PMID:41385096 "[{""id"":""uuid:208355b2-2fdb-4d35-84cc-46e065754f3d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:799cb887-d5c1-40b0-a074-91757861699e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:d5c6f202-7adc-4c4e-b690-532171909e22 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0019127 PMID:41385096 "[{""id"":""uuid:45efdfdd-6ebb-4a4e-b1f2-74433df3ba29"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:87921a70-0cc1-4c7e-94ba-5df31d4a6588"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:abe88432-39bd-4ec8-bdc9-7baaf4f7bdad biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0040698 PMID:41385096 "[{""id"":""uuid:1a8d8498-e29e-4264-82e8-b86f8225b3ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b04121e8-7815-4a40-ad76-4b2b7c5f74de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:1431853c-97d2-4378-9c9e-7fadc91d2673 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0004855 PMID:41385096 "[{""id"":""uuid:b3443dec-b98f-4a4f-9277-e2e25bbae77f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d9b657ef-4aaa-4305-800e-e39f5670f7d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:65550895-f721-46e3-a41f-90b550a668d4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0001875 PMID:41385096 "[{""id"":""uuid:545ec26c-f31a-4372-8890-a5959902c5cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:08f54b61-2003-4ddb-bc71-85b085bce27f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:a21de061-b033-41cd-ab14-3b7670f2933b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0005178 PMID:41385096 "[{""id"":""uuid:72e220f5-138b-4411-a4f1-36af3177f9db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d4148970-ad2c-432a-aaa8-f1b171b6a88c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:abbbe93b-b5ad-49af-b109-bc4b2b193771 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0005340 PMID:41385096 "[{""id"":""uuid:919bdb49-0365-4a60-919d-197721bb1aa2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ddecd1f4-6139-4b9e-876c-d70f45952dee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:bbd7ca59-a16f-45a0-9dd3-a6cd3f4a472e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0019558 PMID:41385096 "[{""id"":""uuid:3d477543-2ef0-4131-ac87-af38277d9d51"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:163eea25-03b1-4b8f-a987-3b4e7989da7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:0adb492f-9260-4b90-bf31-6218e43b0af0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0005348 PMID:41385096 "[{""id"":""uuid:8798a014-8c49-4fa7-802a-f3a727903cc9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1426c206-17f1-486f-beb5-91cef9dbf41a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:9ffcc310-e266-465d-b17d-e4de9b854164 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0006554 PMID:41385096 "[{""id"":""uuid:6318b5df-2c20-426e-80d3-aad364c67b24"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3e727882-7f9b-4cef-9f3f-6e86cfadf389"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:c9838c27-fff3-4795-acbe-a2aaee3d3c07 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0006572 PMID:41385096 "[{""id"":""uuid:f927fb22-6f2d-4353-a77a-70207fc243db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ef8db6ad-340d-42aa-bfd1-f3eb93c8f307"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:f9df6b38-1606-47ce-9907-4ba3a167ae5f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0006585 PMID:41385096 "[{""id"":""uuid:8c2d443e-1d29-4fad-a65e-0c4be62dd368"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4170191b-3e58-4a4b-8908-874f3d8eec27"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:235cb95b-2489-4e5a-aa22-ba95eaa183b5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats UMLS:C0392445 PMID:41385096 "[{""id"":""uuid:c35a6a23-a321-4770-a10f-ccd43f863286"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cad52e31-8553-488e-aed5-5288523bc46f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:d6c10243-3da6-4019-a2ee-50d82f7e4364 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0004874 PMID:41385096 "[{""id"":""uuid:670bd831-f916-465b-9b18-ab8d88a83f28"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f888ed3a-40f3-4eb5-905a-954a4f87c454"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:a0ecc783-b1fb-4fba-b31c-b74c27e56421 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:24847774 biolink:treats MONDO:0004795 PMID:41385096 "[{""id"":""uuid:af0387dd-a28e-4d4c-98b0-6c874c4874c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:60f2b136-d47c-4f01-9d14-9456188d2ba1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the treatment of superficial infections of the external auditory canal caused by organisms susceptible to the action of the antimicrobial, complicated by inflammation. uuid:8a234632-e61f-4dc8-a0eb-ee3914929de1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:24847774 biolink:treats NCIT:C3137 PMID:41385096 "[{""id"":""uuid:b2a71241-bc10-45ba-969f-9a9ed4822d6b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ebcc244a-bbad-4863-aa10-aae3d55bcc8b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the treatment of superficial infections of the external auditory canal caused by organisms susceptible to the action of the antimicrobial, complicated by inflammation. uuid:c3423c58-0a35-4331-a154-c94d8a3874f8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32588 biolink:treats UMLS:C0151595 PMID:41385096 "[{""id"":""uuid:e1a7b883-239b-4464-b075-d8bb61cf09e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bb4aa98d-b77b-4b94-a2a5-38c5e03379d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BECAUSE OF REPORTS OF INTESTINAL AND GASTRIC ULCERATION AND BLEEDING WITH CONTROLLED-RELEASE POTASSIUM CHLORIDE PREPARATIONS, THESE DRUGS SHOULD BE RESERVED FOR THOSE PATIENTS WHO CANNOT TOLERATE OR REFUSE TO TAKE LIQUID OR EFFERVESCENT POTASSIUM PREPARATIONS OR FOR PATIENTS IN WHOM THERE IS A PROBLEM OF COMPLIANCE WITH THESE PREPARATIONS. For the treatment of patients with hypokalemia with or without metabolic alkalosis, in digitalis intoxication, and in patients with hypokalemic familial periodic paralysis. If hypokalemia is the result of diuretic therapy, consideration should be given to the use of a lower dose of diuretic, which may be sufficient without leading to hypokalemia. For the prevention of hypokalemia in patients who would be at particular risk if hypokalemia were to develop, e.g., digitalized patients or patients with significant cardiac arrhythmias. The use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension is often unnecessary when such patients have a normal dietary pattern and when low doses of the diuretic are used. Serum potassium should be checked periodically, however, and if hypokalemia occurs, dietary supplementation with potassium-containing foods may be adequate to control milder cases. In more severe cases, and if dose adjustment of the diuretic is ineffective or unwarranted, supplementation with potassium salts may be indicated. uuid:a18d993f-9742-4e6c-842f-86e2820c53b6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32588 biolink:treats MONDO:0008223 PMID:41385096 "[{""id"":""uuid:aadd0569-7529-42f9-ba78-dd7fcfe30154"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6ca52543-717b-4f85-873e-1d4e5b90f603"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BECAUSE OF REPORTS OF INTESTINAL AND GASTRIC ULCERATION AND BLEEDING WITH CONTROLLED-RELEASE POTASSIUM CHLORIDE PREPARATIONS, THESE DRUGS SHOULD BE RESERVED FOR THOSE PATIENTS WHO CANNOT TOLERATE OR REFUSE TO TAKE LIQUID OR EFFERVESCENT POTASSIUM PREPARATIONS OR FOR PATIENTS IN WHOM THERE IS A PROBLEM OF COMPLIANCE WITH THESE PREPARATIONS. For the treatment of patients with hypokalemia with or without metabolic alkalosis, in digitalis intoxication, and in patients with hypokalemic familial periodic paralysis. If hypokalemia is the result of diuretic therapy, consideration should be given to the use of a lower dose of diuretic, which may be sufficient without leading to hypokalemia. For the prevention of hypokalemia in patients who would be at particular risk if hypokalemia were to develop, e.g., digitalized patients or patients with significant cardiac arrhythmias. The use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension is often unnecessary when such patients have a normal dietary pattern and when low doses of the diuretic are used. Serum potassium should be checked periodically, however, and if hypokalemia occurs, dietary supplementation with potassium-containing foods may be adequate to control milder cases. In more severe cases, and if dose adjustment of the diuretic is ineffective or unwarranted, supplementation with potassium salts may be indicated. uuid:9fce7459-368d-4e84-ab8e-ce0f2e6371b4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32588 biolink:treats MONDO:0007263 PMID:41385096 "[{""id"":""uuid:d15c9b1f-9b2d-4062-9137-69317d4d7edd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aeb73619-3c20-4f0d-8c60-c27e2f128ed6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BECAUSE OF REPORTS OF INTESTINAL AND GASTRIC ULCERATION AND BLEEDING WITH CONTROLLED-RELEASE POTASSIUM CHLORIDE PREPARATIONS, THESE DRUGS SHOULD BE RESERVED FOR THOSE PATIENTS WHO CANNOT TOLERATE OR REFUSE TO TAKE LIQUID OR EFFERVESCENT POTASSIUM PREPARATIONS OR FOR PATIENTS IN WHOM THERE IS A PROBLEM OF COMPLIANCE WITH THESE PREPARATIONS. For the treatment of patients with hypokalemia with or without metabolic alkalosis, in digitalis intoxication, and in patients with hypokalemic familial periodic paralysis. If hypokalemia is the result of diuretic therapy, consideration should be given to the use of a lower dose of diuretic, which may be sufficient without leading to hypokalemia. For the prevention of hypokalemia in patients who would be at particular risk if hypokalemia were to develop, e.g., digitalized patients or patients with significant cardiac arrhythmias. The use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension is often unnecessary when such patients have a normal dietary pattern and when low doses of the diuretic are used. Serum potassium should be checked periodically, however, and if hypokalemia occurs, dietary supplementation with potassium-containing foods may be adequate to control milder cases. In more severe cases, and if dose adjustment of the diuretic is ineffective or unwarranted, supplementation with potassium salts may be indicated. uuid:b344d0c2-2294-43d8-87bb-3be559093c98 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32588 biolink:treats MONDO:0001134 PMID:41385096 "[{""id"":""uuid:fada4e43-424c-4da4-af28-c3cc0c12d344"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2e3344af-ef2d-42d6-a991-0d7a6856f9dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BECAUSE OF REPORTS OF INTESTINAL AND GASTRIC ULCERATION AND BLEEDING WITH CONTROLLED-RELEASE POTASSIUM CHLORIDE PREPARATIONS, THESE DRUGS SHOULD BE RESERVED FOR THOSE PATIENTS WHO CANNOT TOLERATE OR REFUSE TO TAKE LIQUID OR EFFERVESCENT POTASSIUM PREPARATIONS OR FOR PATIENTS IN WHOM THERE IS A PROBLEM OF COMPLIANCE WITH THESE PREPARATIONS. For the treatment of patients with hypokalemia with or without metabolic alkalosis, in digitalis intoxication, and in patients with hypokalemic familial periodic paralysis. If hypokalemia is the result of diuretic therapy, consideration should be given to the use of a lower dose of diuretic, which may be sufficient without leading to hypokalemia. For the prevention of hypokalemia in patients who would be at particular risk if hypokalemia were to develop, e.g., digitalized patients or patients with significant cardiac arrhythmias. The use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension is often unnecessary when such patients have a normal dietary pattern and when low doses of the diuretic are used. Serum potassium should be checked periodically, however, and if hypokalemia occurs, dietary supplementation with potassium-containing foods may be adequate to control milder cases. In more severe cases, and if dose adjustment of the diuretic is ineffective or unwarranted, supplementation with potassium salts may be indicated. uuid:3f671727-487b-4756-8e89-3fc610ad5f36 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:72323 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:db0b87dc-7f85-4113-bd94-8ab4774ef48f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d438c0e0-579f-4ec8-8924-0aaa07fa1bf4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c9a328a1-7cfc-44fa-a50f-eb06c91831f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:919bd2ae-4727-4a0a-98e7-ec86dc9d3190"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Alogliptin tablets are a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1.1 , 14 ) Important Limitations of Use: Not for treatment of type 1 diabetes or diabetic ketoacidosis. ( 1.1 )|[EMA] Vipidia is indicated in adults aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control in combination with other glucose lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control (see sections 4.4, 4.5 and 5.1 for available data on different combinations).|[PMDA] Drugs with a new active ingredient indicated for the treatment of type 2 diabetes (for use only in patients with inadequate glycemic control by following treatments: Treatment by diet and exercise only In addition to treatment by diet and exercise, treatment by alpha-glucosidase inhibitor). uuid:eb67cb20-a9a7-45ad-acc0-fe69154e482b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:72323 biolink:treats MONDO:0005147 PMID:41385096 "[{""id"":""uuid:55f14b1f-c6eb-400b-a005-c5b6bb03809f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f7589edd-1baa-4150-a539-75677bb13885"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Alogliptin tablets are a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1.1 , 14 ) Important Limitations of Use: Not for treatment of type 1 diabetes or diabetic ketoacidosis. ( 1.1 ) uuid:30f13615-e2fc-4b81-8ade-1cc5c05cbfbe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:72323 biolink:treats MONDO:0012819 PMID:41385096 "[{""id"":""uuid:6bf1698b-d2c0-4908-a7df-643439a8b44b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1f85b0b2-4e20-4f65-b02a-69b15eeb42c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Alogliptin tablets are a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1.1 , 14 ) Important Limitations of Use: Not for treatment of type 1 diabetes or diabetic ketoacidosis. ( 1.1 ) uuid:fa4c012f-f2d6-4bab-9d17-90c7c994187f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5880 biolink:treats MONDO:0024355 PMID:41385096 "[{""id"":""uuid:5d3c506c-a0cc-4af4-b315-31941320f605"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:38c24451-e0b9-400c-894f-ddaeaf407b69"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Imipenem and Cilastatin for Injection, USP for intravenous use is a combination of imipenem, a penem antibacterial, and cilastatin, a renal dehydropeptidase inhibitor, indicated for the treatment of the following serious infections caused by designated susceptible bacteria: Lower respiratory tract infections. ( 1.1 ) Urinary tract infections. ( 1.2 ) Intra-abdominal infections. ( 1.3 ) Gynecologic infections. ( 1.4 ) Bacterial septicemia. ( 1.5 ) Bone and joint infections. ( 1.6 ) Skin and skin structure infections. ( 1.7 ) Endocarditis. ( 1.8 ) Limitations of Use : Imipenem and Cilastatin for Injection, USP (I.V.) is not indicated in patients with meningitis because safety and efficacy have not been established ( 1.9 ). Imipenem and Cilastatin for Injection, USP (I.V.) is not recommended in pediatric patients with CNS infections because of the risk of seizures ( 1.9 ). Imipenem and Cilastatin for Injection, USP (I.V.) is not recommended in pediatric patients weighing less than 30 kg with impaired renal function ( 1.9 ). Usage : To reduce the development of drug resistant bacteria and maintain the effectiveness of Imipenem and Cilastatin for Injection, USP (I.V.) and other antibacterial drugs, Imipenem and Cilastatin for Injection, USP (I.V.) should be used only to treat infections that are proven or strongly suspected to be caused by bacteria ( 1.10 ). PUBCHEM.COMPOUND:17756656 uuid:38d84265-dfcf-4074-b406-7971d65ce313 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5880 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:ef74a0fe-9aa7-4a11-bf3e-8a57d06e5564"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:19ec6191-368b-489a-b9ac-c215af9b011c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Imipenem and Cilastatin for Injection, USP for intravenous use is a combination of imipenem, a penem antibacterial, and cilastatin, a renal dehydropeptidase inhibitor, indicated for the treatment of the following serious infections caused by designated susceptible bacteria: Lower respiratory tract infections. ( 1.1 ) Urinary tract infections. ( 1.2 ) Intra-abdominal infections. ( 1.3 ) Gynecologic infections. ( 1.4 ) Bacterial septicemia. ( 1.5 ) Bone and joint infections. ( 1.6 ) Skin and skin structure infections. ( 1.7 ) Endocarditis. ( 1.8 ) Limitations of Use : Imipenem and Cilastatin for Injection, USP (I.V.) is not indicated in patients with meningitis because safety and efficacy have not been established ( 1.9 ). Imipenem and Cilastatin for Injection, USP (I.V.) is not recommended in pediatric patients with CNS infections because of the risk of seizures ( 1.9 ). Imipenem and Cilastatin for Injection, USP (I.V.) is not recommended in pediatric patients weighing less than 30 kg with impaired renal function ( 1.9 ). Usage : To reduce the development of drug resistant bacteria and maintain the effectiveness of Imipenem and Cilastatin for Injection, USP (I.V.) and other antibacterial drugs, Imipenem and Cilastatin for Injection, USP (I.V.) should be used only to treat infections that are proven or strongly suspected to be caused by bacteria ( 1.10 ). PUBCHEM.COMPOUND:17756656 uuid:c3e379ad-a0a9-47b3-93e0-38b55c3f611b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5880 biolink:treats UMLS:C1112209 PMID:41385096 "[{""id"":""uuid:46e0e901-6f4c-4974-b440-2c2a425b1779"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d894c054-8251-4ad6-b03e-49fc51389d52"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Imipenem and Cilastatin for Injection, USP for intravenous use is a combination of imipenem, a penem antibacterial, and cilastatin, a renal dehydropeptidase inhibitor, indicated for the treatment of the following serious infections caused by designated susceptible bacteria: Lower respiratory tract infections. ( 1.1 ) Urinary tract infections. ( 1.2 ) Intra-abdominal infections. ( 1.3 ) Gynecologic infections. ( 1.4 ) Bacterial septicemia. ( 1.5 ) Bone and joint infections. ( 1.6 ) Skin and skin structure infections. ( 1.7 ) Endocarditis. ( 1.8 ) Limitations of Use : Imipenem and Cilastatin for Injection, USP (I.V.) is not indicated in patients with meningitis because safety and efficacy have not been established ( 1.9 ). Imipenem and Cilastatin for Injection, USP (I.V.) is not recommended in pediatric patients with CNS infections because of the risk of seizures ( 1.9 ). Imipenem and Cilastatin for Injection, USP (I.V.) is not recommended in pediatric patients weighing less than 30 kg with impaired renal function ( 1.9 ). Usage : To reduce the development of drug resistant bacteria and maintain the effectiveness of Imipenem and Cilastatin for Injection, USP (I.V.) and other antibacterial drugs, Imipenem and Cilastatin for Injection, USP (I.V.) should be used only to treat infections that are proven or strongly suspected to be caused by bacteria ( 1.10 ). PUBCHEM.COMPOUND:17756656 uuid:9ad0a2b6-200e-4f7c-9e64-7a9148d2ef11 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5880 biolink:treats UMLS:C0684256 PMID:41385096 "[{""id"":""uuid:3b8a3f55-a8d6-4a11-bf30-288b6a011182"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8b9291c2-c626-40a4-93b6-df92aa78fd34"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Imipenem and Cilastatin for Injection, USP for intravenous use is a combination of imipenem, a penem antibacterial, and cilastatin, a renal dehydropeptidase inhibitor, indicated for the treatment of the following serious infections caused by designated susceptible bacteria: Lower respiratory tract infections. ( 1.1 ) Urinary tract infections. ( 1.2 ) Intra-abdominal infections. ( 1.3 ) Gynecologic infections. ( 1.4 ) Bacterial septicemia. ( 1.5 ) Bone and joint infections. ( 1.6 ) Skin and skin structure infections. ( 1.7 ) Endocarditis. ( 1.8 ) Limitations of Use : Imipenem and Cilastatin for Injection, USP (I.V.) is not indicated in patients with meningitis because safety and efficacy have not been established ( 1.9 ). Imipenem and Cilastatin for Injection, USP (I.V.) is not recommended in pediatric patients with CNS infections because of the risk of seizures ( 1.9 ). Imipenem and Cilastatin for Injection, USP (I.V.) is not recommended in pediatric patients weighing less than 30 kg with impaired renal function ( 1.9 ). Usage : To reduce the development of drug resistant bacteria and maintain the effectiveness of Imipenem and Cilastatin for Injection, USP (I.V.) and other antibacterial drugs, Imipenem and Cilastatin for Injection, USP (I.V.) should be used only to treat infections that are proven or strongly suspected to be caused by bacteria ( 1.10 ). PUBCHEM.COMPOUND:17756656 uuid:1aaeeb5d-aa09-4e35-ad27-b4f948dae7a0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5880 biolink:treats UMLS:C0851989 PMID:41385096 "[{""id"":""uuid:45bc2708-1377-40fe-ae49-2c4e302d0290"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ce28bf47-184f-4759-ab0a-bc3c3a4a547e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Imipenem and Cilastatin for Injection, USP for intravenous use is a combination of imipenem, a penem antibacterial, and cilastatin, a renal dehydropeptidase inhibitor, indicated for the treatment of the following serious infections caused by designated susceptible bacteria: Lower respiratory tract infections. ( 1.1 ) Urinary tract infections. ( 1.2 ) Intra-abdominal infections. ( 1.3 ) Gynecologic infections. ( 1.4 ) Bacterial septicemia. ( 1.5 ) Bone and joint infections. ( 1.6 ) Skin and skin structure infections. ( 1.7 ) Endocarditis. ( 1.8 ) Limitations of Use : Imipenem and Cilastatin for Injection, USP (I.V.) is not indicated in patients with meningitis because safety and efficacy have not been established ( 1.9 ). Imipenem and Cilastatin for Injection, USP (I.V.) is not recommended in pediatric patients with CNS infections because of the risk of seizures ( 1.9 ). Imipenem and Cilastatin for Injection, USP (I.V.) is not recommended in pediatric patients weighing less than 30 kg with impaired renal function ( 1.9 ). Usage : To reduce the development of drug resistant bacteria and maintain the effectiveness of Imipenem and Cilastatin for Injection, USP (I.V.) and other antibacterial drugs, Imipenem and Cilastatin for Injection, USP (I.V.) should be used only to treat infections that are proven or strongly suspected to be caused by bacteria ( 1.10 ). PUBCHEM.COMPOUND:17756656 uuid:91e0c851-1eea-468e-8a5e-402b59988e5c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5880 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:373e407a-9a29-4dec-af32-817f4522de44"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:226e0ea4-ca30-4f04-ad35-2b4416e1b659"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Imipenem and Cilastatin for Injection, USP for intravenous use is a combination of imipenem, a penem antibacterial, and cilastatin, a renal dehydropeptidase inhibitor, indicated for the treatment of the following serious infections caused by designated susceptible bacteria: Lower respiratory tract infections. ( 1.1 ) Urinary tract infections. ( 1.2 ) Intra-abdominal infections. ( 1.3 ) Gynecologic infections. ( 1.4 ) Bacterial septicemia. ( 1.5 ) Bone and joint infections. ( 1.6 ) Skin and skin structure infections. ( 1.7 ) Endocarditis. ( 1.8 ) Limitations of Use : Imipenem and Cilastatin for Injection, USP (I.V.) is not indicated in patients with meningitis because safety and efficacy have not been established ( 1.9 ). Imipenem and Cilastatin for Injection, USP (I.V.) is not recommended in pediatric patients with CNS infections because of the risk of seizures ( 1.9 ). Imipenem and Cilastatin for Injection, USP (I.V.) is not recommended in pediatric patients weighing less than 30 kg with impaired renal function ( 1.9 ). Usage : To reduce the development of drug resistant bacteria and maintain the effectiveness of Imipenem and Cilastatin for Injection, USP (I.V.) and other antibacterial drugs, Imipenem and Cilastatin for Injection, USP (I.V.) should be used only to treat infections that are proven or strongly suspected to be caused by bacteria ( 1.10 ). PUBCHEM.COMPOUND:17756656 uuid:49efba83-e41a-4b8e-b215-2289c0fbc468 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5880 biolink:treats MONDO:0005025 PMID:41385096 "[{""id"":""uuid:d70da553-3b0e-446a-a084-968d13c02127"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:24018b80-60fb-4568-8984-d3afb5e4622a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Imipenem and Cilastatin for Injection, USP for intravenous use is a combination of imipenem, a penem antibacterial, and cilastatin, a renal dehydropeptidase inhibitor, indicated for the treatment of the following serious infections caused by designated susceptible bacteria: Lower respiratory tract infections. ( 1.1 ) Urinary tract infections. ( 1.2 ) Intra-abdominal infections. ( 1.3 ) Gynecologic infections. ( 1.4 ) Bacterial septicemia. ( 1.5 ) Bone and joint infections. ( 1.6 ) Skin and skin structure infections. ( 1.7 ) Endocarditis. ( 1.8 ) Limitations of Use : Imipenem and Cilastatin for Injection, USP (I.V.) is not indicated in patients with meningitis because safety and efficacy have not been established ( 1.9 ). Imipenem and Cilastatin for Injection, USP (I.V.) is not recommended in pediatric patients with CNS infections because of the risk of seizures ( 1.9 ). Imipenem and Cilastatin for Injection, USP (I.V.) is not recommended in pediatric patients weighing less than 30 kg with impaired renal function ( 1.9 ). Usage : To reduce the development of drug resistant bacteria and maintain the effectiveness of Imipenem and Cilastatin for Injection, USP (I.V.) and other antibacterial drugs, Imipenem and Cilastatin for Injection, USP (I.V.) should be used only to treat infections that are proven or strongly suspected to be caused by bacteria ( 1.10 ). PUBCHEM.COMPOUND:17756656 uuid:812a4d32-6d8f-48eb-8eda-44e92049cf34 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7459 biolink:treats UMLS:C0029104 PMID:41385096 "[{""id"":""uuid:731f3b8e-1974-4a9d-958e-1dd61465af8c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c2e6bbc6-c2f4-49d8-865e-e0b85d3d4b0c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Naloxone HCl Nasal Spray is indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression. Naloxone HCl Nasal Spray is intended for immediate administration as emergency therapy in settings where opioids may be present. Naloxone HCl Nasal Spray is not a substitute for emergency medical care. Limitations of Use: Restrict prescription of naloxone hydrochloride nasal spray 2 mg to opioid-dependent patients expected to be at risk for severe opioid withdrawal in situations where there is a low risk for accidental or intentional opioid exposure by household contacts. uuid:fdbd2f66-cc6f-47ef-8c00-022fe7096ee6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5523 biolink:treats MONDO:0004956 PMID:41385096 "[{""id"":""uuid:8eb5edfd-3aa7-4bf0-9d5b-8a151d7ee831"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:64acce2a-1873-4c52-b7ac-c7fe8a015e12"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZOLADEX is a Gonadotropin Releasing Hormone (GnRH) agonist indicated for: Use in combination with flutamide for the management of locally confined carcinoma of the prostate ( 1.1 ) Use as palliative treatment of advanced carcinoma of the prostate ( 1.2 ) uuid:d74983e0-edd3-47f9-8f12-776c7ee04471 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3561 biolink:treats UMLS:C0234935 PMID:41385096 "[{""id"":""uuid:3177be0e-1359-4112-a846-69bebf372dee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a30aa385-02c5-472b-b57a-901ad003dce2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] QUZYTTIR™ is indicated for the treatment of acute urticaria in adults and children 6 months of age and older. uuid:993a985b-430c-431b-a3aa-713849720116 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135515 biolink:treats MONDO:0004948 PMID:41385096 "[{""id"":""uuid:54ac71e9-dc4d-4c8f-a58d-c30f2669301b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f0b4ed44-b432-4cee-b0e6-174b40fb788b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:5bafc964-334d-4067-b2df-ae0bbd70844a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TREANDA is an alkylating drug indicated for treatment of patients with: Chronic lymphocytic leukemia (CLL). Efficacy relative to first line therapies other than chlorambucil has not been established. ( 1.1 ) Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. ( 1.2 )|[PMDA] A drug with a new additional indication, dosage, and dosage form for the treatment of chronic lymphocytic leukemia. [Orphan drug] uuid:b37ef278-fb66-4b20-bb55-527687668094 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135515 biolink:treats MONDO:0017594 PMID:41385096 "[{""id"":""uuid:5d3cf0b8-bcc5-4c47-b922-55b457885b83"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9e0f74eb-da26-4400-a000-fe1147852ddc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:a0938add-087f-4f5d-a559-d650a345435f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TREANDA is an alkylating drug indicated for treatment of patients with: Chronic lymphocytic leukemia (CLL). Efficacy relative to first line therapies other than chlorambucil has not been established. ( 1.1 ) Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. ( 1.2 )|[PMDA] A drug with a new active ingredient indicated for the treatment of relapsed or refractory indolent B- cell non-Hodgkin’s lymphoma and mantle cell lymphoma. [Orphan drug] uuid:3fd2021e-8b84-4e8e-b1b5-88017c84efcd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:177836 biolink:treats MONDO:0005191 PMID:41385096 "[{""id"":""uuid:58fbfe4d-0d54-420e-9935-76191d91be31"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:27153610-f125-4951-98bf-54cefe7a8dc6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dacarbazine for Injection is indicated in the treatment of metastatic malignant melanoma. In addition, Dacarbazine for Injection is also indicated for Hodgkin’s disease as a second-line therapy when used in combination with other effective agents. uuid:9470a4c1-165d-4f22-b8d6-94f2875ff945 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:177836 biolink:treats MONDO:0009348 PMID:41385096 "[{""id"":""uuid:183e6716-e75e-4e88-b6e2-3635cddfaa22"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:59953102-5b98-4e82-a493-edda5e2ea5dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dacarbazine for Injection is indicated in the treatment of metastatic malignant melanoma. In addition, Dacarbazine for Injection is also indicated for Hodgkin’s disease as a second-line therapy when used in combination with other effective agents. uuid:44a67dc3-4dab-434a-8e8c-0efa5d5ee9bb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2038 biolink:treats MONDO:0018874 PMID:41385096 "[{""id"":""uuid:5bcf8dde-535c-44e2-9c98-190d34a5233b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:76568e12-5c83-48bf-823f-33cee7e5b80e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:d625ffb9-f3e7-4345-b292-40212e2a195a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/azacitidine-mylan""]},{""id"":""uuid:23a71fa0-0d46-4a38-bedc-880374ac1b14"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ONUREG is indicated for continued treatment of adult patients with acute myeloid leukemia who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and are not able to complete intensive curative therapy.|[EMA] Azacitidine Mylan is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (HSCT) with:intermediate 2 and high risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System (IPSS),chronic myelomonocytic leukaemia (CMML) with 10 29% marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (AML) with 20 30% blasts and multi lineage dysplasia, according to World Health Organisation (WHO) classification,AML with > 30% marrow blasts according to the WHO classification.|[PMDA] A drug with a new indication for the treatment of acute myeloid leukemia. [Expedited review] uuid:4dc382e2-a29d-4bf5-88fd-2ef4c4f7b202 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28939 biolink:treats UMLS:C0572025 PMID:41385096 "[{""id"":""uuid:5630081f-07f1-4e73-9ab1-a92be6e97cc6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c93b4fcd-b460-4fa1-8347-e70e0d713d8e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Acetylcysteine Injection is an antidote for acetaminophen overdose indicated to prevent or lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of acetaminophen. Overdose incidences are divided into two types; Acute Ingestion or Repeated Supratherapeutic Ingestion (RSI). [see Dosage and Administration ( 2 ) and Acetaminophen Assays – Interpretation and Methodology -(Acute or Repeated Supratherapeutic Ingestion) ( 1.1 , 1.2 )] . On admission for suspected acetaminophen overdose, a serum blood sample should be drawn at least 4 hours after ingestion to determine the acetaminophen level and will serve as a basis for determining the need for treatment with acetylcysteine. If the patient presents after 4 hours post-ingestion, the serum acetaminophen sample should be determined immediately. Acetylcysteine Injection should be administered within 8 hours from acetaminophen ingestion for maximal protection against hepatic injury for patients whose serum acetaminophen levels fall above the ""possible"" toxicity line on the Rumack-Matthew nomogram (line connecting 150 mcg/mL at 4 hours with 37.5 mcg/mL at 12 hours); [see Acetaminophen Assays – Interpretation and Methodology (1.1, 1.2 )] . If the time of ingestion is unknown, or the serum acetaminophen level is not available, cannot be interpreted, or is not available within the 8 hour time interval from acetaminophen ingestion, Acetylcysteine Injection should be administered immediately if 24 hours or less have elapsed from the reported time of ingestion of an overdose of acetaminophen, regardless of the quantity reported to have been ingested. The aspartate aminotransferase (AST, SGOT), alanine aminotranferase (ALT, SGPT), bilirubin, prothrombin time, creatinine, blood urea nitrogen (BUN), blood glucose, and electrolytes also should be determined in order to monitor hepatic and renal function and electrolyte and fluid balance. NOTE: The critical ingestion-treatment interval for maximal protection against severe hepatic injury is between 0 to 8 hours. Efficacy diminishes progressively after 8 hours and treatment initiation between 15 and 24 hours post-ingestion of acetaminophen yields limited efficacy. However, it does not appear to worsen the condition of patients and it should not be withheld, since the reported time of ingestion may not be correct." uuid:d05e170b-0f97-4bbf-ac55-7bfbd0087e14 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45924 biolink:treats MONDO:0006929 PMID:41385096 "[{""id"":""uuid:79e43e05-a55d-4f50-bdb3-f4ee0b97f9f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e539396b-cd1b-4a8d-93eb-553cca9cabfb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of trimethoprim tablets and other antibacterial drugs, trimethoprim tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. For the treatment of initial episodes of uncomplicated urinary tract infections due to susceptible strains of the following organisms: Escherichia coli , Proteus mirabilis , Klebsiella pneumoniae , Enterobacter species, and coagulase-negative Staphylococcus species, including S. saprophyticus . Cultures and susceptibility tests should be performed to determine the susceptibility of the bacteria to trimethoprim. Therapy may be initiated prior to obtaining the results of these tests. uuid:2fbe77e9-e74b-4e60-a121-9244cbe34fb4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45924 biolink:treats MONDO:0030602 PMID:41385096 "[{""id"":""uuid:8f68e1c2-ba46-4b4b-87c5-2969ccbbdd23"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4660795d-6a40-46f6-bed5-03b3a34e1e61"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of trimethoprim tablets and other antibacterial drugs, trimethoprim tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. For the treatment of initial episodes of uncomplicated urinary tract infections due to susceptible strains of the following organisms: Escherichia coli , Proteus mirabilis , Klebsiella pneumoniae , Enterobacter species, and coagulase-negative Staphylococcus species, including S. saprophyticus . Cultures and susceptibility tests should be performed to determine the susceptibility of the bacteria to trimethoprim. Therapy may be initiated prior to obtaining the results of these tests. uuid:0edeb0e6-6501-4e7d-9488-c6f0c42f150f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17750 biolink:treats MONDO:0009609 PMID:41385096 "[{""id"":""uuid:bd08f8df-cab7-4d66-a9c2-df4ccdf91e8b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:da1e988b-5291-4428-bfb6-41953178bd58"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Betaine Anhydrous for Oral Solution is indicated for the treatment of homocystinuria to decrease elevated homocysteine blood concentrations in pediatric and adult patients. Included within the category of homocystinuria are Cystathionine beta-synthase (CBS) deficiency 5,10-methylenetetrahydrofolate reductase (MTHFR) deficiency Cobalamin cofactor metabolism (cbl) defect uuid:1b369b1c-20a1-414a-9bd7-fc22cf7ec293 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135876 biolink:treats MONDO:0004703 PMID:41385096 "[{""id"":""uuid:5c9f721a-2c7b-497b-a60c-94a6a674f75f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:efee9583-6187-4e4a-8275-d0e6fab673bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Valrubicin intravesical solution is an anthracycline topoisomerase inhibitor indicated for intravesical therapy of BCG-refractory carcinoma in situ (CIS) of the urinary bladder in patients for whom immediate cystectomy would be associated with unacceptable morbidity or mortality. uuid:035a77a3-db64-468f-8ece-8d60fcccfc32 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2637 biolink:treats UMLS:C0684256 PMID:41385096 "[{""id"":""uuid:33acf0f9-f14c-45da-a379-c13039548d7e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:83bcc053-ec81-4031-90f5-ba98e69d5971"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amikacin Sulfate Injection, USP is indicated in the short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria, including Pseudomonas species, Escherichia coli , species of indole-positive and indole-negative Proteus , Providencia species, Klebsiella-Enterobacter-Serratia species, and Acinetobacter ( Mima-Herellea ) species. Clinical studies have shown Amikacin Sulfate Injection, USP to be effective in bacterial septicemia (including neonatal sepsis); in serious infections of the respiratory tract, bones and joints, central nervous system (including meningitis) and skin and soft tissue; intra-abdominal infections (including peritonitis); and in burns and postoperative infections (including post-vascular surgery). Clinical studies have shown amikacin also to be effective in serious complicated and recurrent urinary tract infections due to those organisms. Aminoglycosides, including Amikacin Sulfate Injection, USP are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics having less potential toxicity. Bacteriologic studies should be performed to identify causative organisms and their susceptibilities to amikacin. Amikacin may be considered as initial therapy in suspected Gram-negative infections and therapy may be instituted before obtaining the results of susceptibility testing. Clinical trials demonstrated that amikacin was effective in infections caused by gentamicin and/or tobramycin-resistant strains of Gram-negative organisms, particularly Proteus rettgeri , Providencia stuartii , Serratia marcescens , and Pseudomonas aeruginosa . The decision to continue therapy with the drug should be based on results of the susceptibility tests, the severity of the infection, the response of the patient and the important additional considerations contained in the WARNINGS box above. Amikacin has also been shown to be effective in staphylococci infections and may be considered as initial therapy under certain conditions in the treatment of known or suspected staphylococcal disease such as, severe infections where the causative organism may be either a Gram-negative bacterium or a staphylococcus, infections due to susceptible strains of staphylococci in patients allergic to other antibiotics, and in mixed staphylococci/Gram-negative infections. In certain severe infections such as neonatal sepsis, concomitant therapy with a penicillin-type drug may be indicated because of the possibility of infections due to Gram-positive organisms such as streptococci or pneumococci. To reduce the development of drug-resistant bacteria and maintain the effectiveness of amikacin and other antibacterial drugs, amikacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:46bfe59d-d779-464a-8dd9-8b90f58de023 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2637 biolink:treats MONDO:0700217 PMID:41385096 "[{""id"":""uuid:20bdd007-9707-4760-a4ee-38d1a2cf966c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:15542f24-9279-48da-abda-ab7d2ee610fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amikacin Sulfate Injection, USP is indicated in the short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria, including Pseudomonas species, Escherichia coli , species of indole-positive and indole-negative Proteus , Providencia species, Klebsiella-Enterobacter-Serratia species, and Acinetobacter ( Mima-Herellea ) species. Clinical studies have shown Amikacin Sulfate Injection, USP to be effective in bacterial septicemia (including neonatal sepsis); in serious infections of the respiratory tract, bones and joints, central nervous system (including meningitis) and skin and soft tissue; intra-abdominal infections (including peritonitis); and in burns and postoperative infections (including post-vascular surgery). Clinical studies have shown amikacin also to be effective in serious complicated and recurrent urinary tract infections due to those organisms. Aminoglycosides, including Amikacin Sulfate Injection, USP are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics having less potential toxicity. Bacteriologic studies should be performed to identify causative organisms and their susceptibilities to amikacin. Amikacin may be considered as initial therapy in suspected Gram-negative infections and therapy may be instituted before obtaining the results of susceptibility testing. Clinical trials demonstrated that amikacin was effective in infections caused by gentamicin and/or tobramycin-resistant strains of Gram-negative organisms, particularly Proteus rettgeri , Providencia stuartii , Serratia marcescens , and Pseudomonas aeruginosa . The decision to continue therapy with the drug should be based on results of the susceptibility tests, the severity of the infection, the response of the patient and the important additional considerations contained in the WARNINGS box above. Amikacin has also been shown to be effective in staphylococci infections and may be considered as initial therapy under certain conditions in the treatment of known or suspected staphylococcal disease such as, severe infections where the causative organism may be either a Gram-negative bacterium or a staphylococcus, infections due to susceptible strains of staphylococci in patients allergic to other antibiotics, and in mixed staphylococci/Gram-negative infections. In certain severe infections such as neonatal sepsis, concomitant therapy with a penicillin-type drug may be indicated because of the possibility of infections due to Gram-positive organisms such as streptococci or pneumococci. To reduce the development of drug-resistant bacteria and maintain the effectiveness of amikacin and other antibacterial drugs, amikacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:9a670a02-f91a-45bd-b389-5bbf0f02b09a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2637 biolink:treats MONDO:0024355 PMID:41385096 "[{""id"":""uuid:e03408aa-de89-4fd8-9a11-66f09f9fec0d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d15aceaa-37eb-42e7-9e08-3d68bf8c483c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amikacin Sulfate Injection, USP is indicated in the short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria, including Pseudomonas species, Escherichia coli , species of indole-positive and indole-negative Proteus , Providencia species, Klebsiella-Enterobacter-Serratia species, and Acinetobacter ( Mima-Herellea ) species. Clinical studies have shown Amikacin Sulfate Injection, USP to be effective in bacterial septicemia (including neonatal sepsis); in serious infections of the respiratory tract, bones and joints, central nervous system (including meningitis) and skin and soft tissue; intra-abdominal infections (including peritonitis); and in burns and postoperative infections (including post-vascular surgery). Clinical studies have shown amikacin also to be effective in serious complicated and recurrent urinary tract infections due to those organisms. Aminoglycosides, including Amikacin Sulfate Injection, USP are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics having less potential toxicity. Bacteriologic studies should be performed to identify causative organisms and their susceptibilities to amikacin. Amikacin may be considered as initial therapy in suspected Gram-negative infections and therapy may be instituted before obtaining the results of susceptibility testing. Clinical trials demonstrated that amikacin was effective in infections caused by gentamicin and/or tobramycin-resistant strains of Gram-negative organisms, particularly Proteus rettgeri , Providencia stuartii , Serratia marcescens , and Pseudomonas aeruginosa . The decision to continue therapy with the drug should be based on results of the susceptibility tests, the severity of the infection, the response of the patient and the important additional considerations contained in the WARNINGS box above. Amikacin has also been shown to be effective in staphylococci infections and may be considered as initial therapy under certain conditions in the treatment of known or suspected staphylococcal disease such as, severe infections where the causative organism may be either a Gram-negative bacterium or a staphylococcus, infections due to susceptible strains of staphylococci in patients allergic to other antibiotics, and in mixed staphylococci/Gram-negative infections. In certain severe infections such as neonatal sepsis, concomitant therapy with a penicillin-type drug may be indicated because of the possibility of infections due to Gram-positive organisms such as streptococci or pneumococci. To reduce the development of drug-resistant bacteria and maintain the effectiveness of amikacin and other antibacterial drugs, amikacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:164879ab-718d-45f9-9312-d60c4f9aced1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2637 biolink:treats MONDO:0005246 PMID:41385096 "[{""id"":""uuid:f5659d7c-fb1e-4133-bcdc-c7a9071d1c6d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c500a229-aed3-4237-be25-70e4031a7703"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amikacin Sulfate Injection, USP is indicated in the short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria, including Pseudomonas species, Escherichia coli , species of indole-positive and indole-negative Proteus , Providencia species, Klebsiella-Enterobacter-Serratia species, and Acinetobacter ( Mima-Herellea ) species. Clinical studies have shown Amikacin Sulfate Injection, USP to be effective in bacterial septicemia (including neonatal sepsis); in serious infections of the respiratory tract, bones and joints, central nervous system (including meningitis) and skin and soft tissue; intra-abdominal infections (including peritonitis); and in burns and postoperative infections (including post-vascular surgery). Clinical studies have shown amikacin also to be effective in serious complicated and recurrent urinary tract infections due to those organisms. Aminoglycosides, including Amikacin Sulfate Injection, USP are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics having less potential toxicity. Bacteriologic studies should be performed to identify causative organisms and their susceptibilities to amikacin. Amikacin may be considered as initial therapy in suspected Gram-negative infections and therapy may be instituted before obtaining the results of susceptibility testing. Clinical trials demonstrated that amikacin was effective in infections caused by gentamicin and/or tobramycin-resistant strains of Gram-negative organisms, particularly Proteus rettgeri , Providencia stuartii , Serratia marcescens , and Pseudomonas aeruginosa . The decision to continue therapy with the drug should be based on results of the susceptibility tests, the severity of the infection, the response of the patient and the important additional considerations contained in the WARNINGS box above. Amikacin has also been shown to be effective in staphylococci infections and may be considered as initial therapy under certain conditions in the treatment of known or suspected staphylococcal disease such as, severe infections where the causative organism may be either a Gram-negative bacterium or a staphylococcus, infections due to susceptible strains of staphylococci in patients allergic to other antibiotics, and in mixed staphylococci/Gram-negative infections. In certain severe infections such as neonatal sepsis, concomitant therapy with a penicillin-type drug may be indicated because of the possibility of infections due to Gram-positive organisms such as streptococci or pneumococci. To reduce the development of drug-resistant bacteria and maintain the effectiveness of amikacin and other antibacterial drugs, amikacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:97ad8d05-c8f5-4580-868c-a5b90ae51699 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2637 biolink:treats MONDO:0042485 PMID:41385096 "[{""id"":""uuid:1bd685de-5055-4b13-bb50-43b111c0456a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:887785bb-eb36-4708-87b8-13c7b26e05df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amikacin Sulfate Injection, USP is indicated in the short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria, including Pseudomonas species, Escherichia coli , species of indole-positive and indole-negative Proteus , Providencia species, Klebsiella-Enterobacter-Serratia species, and Acinetobacter ( Mima-Herellea ) species. Clinical studies have shown Amikacin Sulfate Injection, USP to be effective in bacterial septicemia (including neonatal sepsis); in serious infections of the respiratory tract, bones and joints, central nervous system (including meningitis) and skin and soft tissue; intra-abdominal infections (including peritonitis); and in burns and postoperative infections (including post-vascular surgery). Clinical studies have shown amikacin also to be effective in serious complicated and recurrent urinary tract infections due to those organisms. Aminoglycosides, including Amikacin Sulfate Injection, USP are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics having less potential toxicity. Bacteriologic studies should be performed to identify causative organisms and their susceptibilities to amikacin. Amikacin may be considered as initial therapy in suspected Gram-negative infections and therapy may be instituted before obtaining the results of susceptibility testing. Clinical trials demonstrated that amikacin was effective in infections caused by gentamicin and/or tobramycin-resistant strains of Gram-negative organisms, particularly Proteus rettgeri , Providencia stuartii , Serratia marcescens , and Pseudomonas aeruginosa . The decision to continue therapy with the drug should be based on results of the susceptibility tests, the severity of the infection, the response of the patient and the important additional considerations contained in the WARNINGS box above. Amikacin has also been shown to be effective in staphylococci infections and may be considered as initial therapy under certain conditions in the treatment of known or suspected staphylococcal disease such as, severe infections where the causative organism may be either a Gram-negative bacterium or a staphylococcus, infections due to susceptible strains of staphylococci in patients allergic to other antibiotics, and in mixed staphylococci/Gram-negative infections. In certain severe infections such as neonatal sepsis, concomitant therapy with a penicillin-type drug may be indicated because of the possibility of infections due to Gram-positive organisms such as streptococci or pneumococci. To reduce the development of drug-resistant bacteria and maintain the effectiveness of amikacin and other antibacterial drugs, amikacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:d8f3eb26-453d-4182-9636-0fb26e7e4b82 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2637 biolink:treats MONDO:0024619 PMID:41385096 "[{""id"":""uuid:066e0a13-ae93-4296-9d22-50f0820b6a33"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bb69cabb-6b36-4920-b09d-81929fed85a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amikacin Sulfate Injection, USP is indicated in the short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria, including Pseudomonas species, Escherichia coli , species of indole-positive and indole-negative Proteus , Providencia species, Klebsiella-Enterobacter-Serratia species, and Acinetobacter ( Mima-Herellea ) species. Clinical studies have shown Amikacin Sulfate Injection, USP to be effective in bacterial septicemia (including neonatal sepsis); in serious infections of the respiratory tract, bones and joints, central nervous system (including meningitis) and skin and soft tissue; intra-abdominal infections (including peritonitis); and in burns and postoperative infections (including post-vascular surgery). Clinical studies have shown amikacin also to be effective in serious complicated and recurrent urinary tract infections due to those organisms. Aminoglycosides, including Amikacin Sulfate Injection, USP are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics having less potential toxicity. Bacteriologic studies should be performed to identify causative organisms and their susceptibilities to amikacin. Amikacin may be considered as initial therapy in suspected Gram-negative infections and therapy may be instituted before obtaining the results of susceptibility testing. Clinical trials demonstrated that amikacin was effective in infections caused by gentamicin and/or tobramycin-resistant strains of Gram-negative organisms, particularly Proteus rettgeri , Providencia stuartii , Serratia marcescens , and Pseudomonas aeruginosa . The decision to continue therapy with the drug should be based on results of the susceptibility tests, the severity of the infection, the response of the patient and the important additional considerations contained in the WARNINGS box above. Amikacin has also been shown to be effective in staphylococci infections and may be considered as initial therapy under certain conditions in the treatment of known or suspected staphylococcal disease such as, severe infections where the causative organism may be either a Gram-negative bacterium or a staphylococcus, infections due to susceptible strains of staphylococci in patients allergic to other antibiotics, and in mixed staphylococci/Gram-negative infections. In certain severe infections such as neonatal sepsis, concomitant therapy with a penicillin-type drug may be indicated because of the possibility of infections due to Gram-positive organisms such as streptococci or pneumococci. To reduce the development of drug-resistant bacteria and maintain the effectiveness of amikacin and other antibacterial drugs, amikacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:f6ad24fa-6e25-4185-abfc-8dc8c1c05b8b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2637 biolink:treats MONDO:0021108 PMID:41385096 "[{""id"":""uuid:c7fdb1dd-9834-46e6-9d21-8017d69e9f3e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:25c583fe-5bc4-4eb0-92b8-1b0761a1f11f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amikacin Sulfate Injection, USP is indicated in the short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria, including Pseudomonas species, Escherichia coli , species of indole-positive and indole-negative Proteus , Providencia species, Klebsiella-Enterobacter-Serratia species, and Acinetobacter ( Mima-Herellea ) species. Clinical studies have shown Amikacin Sulfate Injection, USP to be effective in bacterial septicemia (including neonatal sepsis); in serious infections of the respiratory tract, bones and joints, central nervous system (including meningitis) and skin and soft tissue; intra-abdominal infections (including peritonitis); and in burns and postoperative infections (including post-vascular surgery). Clinical studies have shown amikacin also to be effective in serious complicated and recurrent urinary tract infections due to those organisms. Aminoglycosides, including Amikacin Sulfate Injection, USP are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics having less potential toxicity. Bacteriologic studies should be performed to identify causative organisms and their susceptibilities to amikacin. Amikacin may be considered as initial therapy in suspected Gram-negative infections and therapy may be instituted before obtaining the results of susceptibility testing. Clinical trials demonstrated that amikacin was effective in infections caused by gentamicin and/or tobramycin-resistant strains of Gram-negative organisms, particularly Proteus rettgeri , Providencia stuartii , Serratia marcescens , and Pseudomonas aeruginosa . The decision to continue therapy with the drug should be based on results of the susceptibility tests, the severity of the infection, the response of the patient and the important additional considerations contained in the WARNINGS box above. Amikacin has also been shown to be effective in staphylococci infections and may be considered as initial therapy under certain conditions in the treatment of known or suspected staphylococcal disease such as, severe infections where the causative organism may be either a Gram-negative bacterium or a staphylococcus, infections due to susceptible strains of staphylococci in patients allergic to other antibiotics, and in mixed staphylococci/Gram-negative infections. In certain severe infections such as neonatal sepsis, concomitant therapy with a penicillin-type drug may be indicated because of the possibility of infections due to Gram-positive organisms such as streptococci or pneumococci. To reduce the development of drug-resistant bacteria and maintain the effectiveness of amikacin and other antibacterial drugs, amikacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:59d5694b-e5a6-409c-910c-9d1d9a678bd1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2637 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:4cce7c88-070c-4619-bd35-7ef50577e64a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aae64541-66cb-456b-889c-61b5a03ec6bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amikacin Sulfate Injection, USP is indicated in the short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria, including Pseudomonas species, Escherichia coli , species of indole-positive and indole-negative Proteus , Providencia species, Klebsiella-Enterobacter-Serratia species, and Acinetobacter ( Mima-Herellea ) species. Clinical studies have shown Amikacin Sulfate Injection, USP to be effective in bacterial septicemia (including neonatal sepsis); in serious infections of the respiratory tract, bones and joints, central nervous system (including meningitis) and skin and soft tissue; intra-abdominal infections (including peritonitis); and in burns and postoperative infections (including post-vascular surgery). Clinical studies have shown amikacin also to be effective in serious complicated and recurrent urinary tract infections due to those organisms. Aminoglycosides, including Amikacin Sulfate Injection, USP are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics having less potential toxicity. Bacteriologic studies should be performed to identify causative organisms and their susceptibilities to amikacin. Amikacin may be considered as initial therapy in suspected Gram-negative infections and therapy may be instituted before obtaining the results of susceptibility testing. Clinical trials demonstrated that amikacin was effective in infections caused by gentamicin and/or tobramycin-resistant strains of Gram-negative organisms, particularly Proteus rettgeri , Providencia stuartii , Serratia marcescens , and Pseudomonas aeruginosa . The decision to continue therapy with the drug should be based on results of the susceptibility tests, the severity of the infection, the response of the patient and the important additional considerations contained in the WARNINGS box above. Amikacin has also been shown to be effective in staphylococci infections and may be considered as initial therapy under certain conditions in the treatment of known or suspected staphylococcal disease such as, severe infections where the causative organism may be either a Gram-negative bacterium or a staphylococcus, infections due to susceptible strains of staphylococci in patients allergic to other antibiotics, and in mixed staphylococci/Gram-negative infections. In certain severe infections such as neonatal sepsis, concomitant therapy with a penicillin-type drug may be indicated because of the possibility of infections due to Gram-positive organisms such as streptococci or pneumococci. To reduce the development of drug-resistant bacteria and maintain the effectiveness of amikacin and other antibacterial drugs, amikacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:24c9aefb-9cc7-4b83-982d-0f379326de7f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2637 biolink:treats UMLS:C0149778 PMID:41385096 "[{""id"":""uuid:56f71d13-c402-4dbf-8743-7fd279859ecf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a1091100-9c48-4888-9e0b-d532fadd8bb1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amikacin Sulfate Injection, USP is indicated in the short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria, including Pseudomonas species, Escherichia coli , species of indole-positive and indole-negative Proteus , Providencia species, Klebsiella-Enterobacter-Serratia species, and Acinetobacter ( Mima-Herellea ) species. Clinical studies have shown Amikacin Sulfate Injection, USP to be effective in bacterial septicemia (including neonatal sepsis); in serious infections of the respiratory tract, bones and joints, central nervous system (including meningitis) and skin and soft tissue; intra-abdominal infections (including peritonitis); and in burns and postoperative infections (including post-vascular surgery). Clinical studies have shown amikacin also to be effective in serious complicated and recurrent urinary tract infections due to those organisms. Aminoglycosides, including Amikacin Sulfate Injection, USP are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics having less potential toxicity. Bacteriologic studies should be performed to identify causative organisms and their susceptibilities to amikacin. Amikacin may be considered as initial therapy in suspected Gram-negative infections and therapy may be instituted before obtaining the results of susceptibility testing. Clinical trials demonstrated that amikacin was effective in infections caused by gentamicin and/or tobramycin-resistant strains of Gram-negative organisms, particularly Proteus rettgeri , Providencia stuartii , Serratia marcescens , and Pseudomonas aeruginosa . The decision to continue therapy with the drug should be based on results of the susceptibility tests, the severity of the infection, the response of the patient and the important additional considerations contained in the WARNINGS box above. Amikacin has also been shown to be effective in staphylococci infections and may be considered as initial therapy under certain conditions in the treatment of known or suspected staphylococcal disease such as, severe infections where the causative organism may be either a Gram-negative bacterium or a staphylococcus, infections due to susceptible strains of staphylococci in patients allergic to other antibiotics, and in mixed staphylococci/Gram-negative infections. In certain severe infections such as neonatal sepsis, concomitant therapy with a penicillin-type drug may be indicated because of the possibility of infections due to Gram-positive organisms such as streptococci or pneumococci. To reduce the development of drug-resistant bacteria and maintain the effectiveness of amikacin and other antibacterial drugs, amikacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:0882f8aa-e837-4c26-940c-c29e2ad84ed4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2637 biolink:treats UMLS:C1112209 PMID:41385096 "[{""id"":""uuid:4d8e3477-b068-43fe-b7a3-c5a9d49bbf58"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:33cbb535-4141-4076-844b-3ffadacac7c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amikacin Sulfate Injection, USP is indicated in the short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria, including Pseudomonas species, Escherichia coli , species of indole-positive and indole-negative Proteus , Providencia species, Klebsiella-Enterobacter-Serratia species, and Acinetobacter ( Mima-Herellea ) species. Clinical studies have shown Amikacin Sulfate Injection, USP to be effective in bacterial septicemia (including neonatal sepsis); in serious infections of the respiratory tract, bones and joints, central nervous system (including meningitis) and skin and soft tissue; intra-abdominal infections (including peritonitis); and in burns and postoperative infections (including post-vascular surgery). Clinical studies have shown amikacin also to be effective in serious complicated and recurrent urinary tract infections due to those organisms. Aminoglycosides, including Amikacin Sulfate Injection, USP are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics having less potential toxicity. Bacteriologic studies should be performed to identify causative organisms and their susceptibilities to amikacin. Amikacin may be considered as initial therapy in suspected Gram-negative infections and therapy may be instituted before obtaining the results of susceptibility testing. Clinical trials demonstrated that amikacin was effective in infections caused by gentamicin and/or tobramycin-resistant strains of Gram-negative organisms, particularly Proteus rettgeri , Providencia stuartii , Serratia marcescens , and Pseudomonas aeruginosa . The decision to continue therapy with the drug should be based on results of the susceptibility tests, the severity of the infection, the response of the patient and the important additional considerations contained in the WARNINGS box above. Amikacin has also been shown to be effective in staphylococci infections and may be considered as initial therapy under certain conditions in the treatment of known or suspected staphylococcal disease such as, severe infections where the causative organism may be either a Gram-negative bacterium or a staphylococcus, infections due to susceptible strains of staphylococci in patients allergic to other antibiotics, and in mixed staphylococci/Gram-negative infections. In certain severe infections such as neonatal sepsis, concomitant therapy with a penicillin-type drug may be indicated because of the possibility of infections due to Gram-positive organisms such as streptococci or pneumococci. To reduce the development of drug-resistant bacteria and maintain the effectiveness of amikacin and other antibacterial drugs, amikacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:a2ef2b12-5315-4eb5-ac8b-d2efa99105b2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2637 biolink:treats MONDO:0004522 PMID:41385096 "[{""id"":""uuid:c791a97f-96e2-45be-9fef-5666b3a253cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2d3ec556-f885-4d51-9b90-e0a348518724"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amikacin Sulfate Injection, USP is indicated in the short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria, including Pseudomonas species, Escherichia coli , species of indole-positive and indole-negative Proteus , Providencia species, Klebsiella-Enterobacter-Serratia species, and Acinetobacter ( Mima-Herellea ) species. Clinical studies have shown Amikacin Sulfate Injection, USP to be effective in bacterial septicemia (including neonatal sepsis); in serious infections of the respiratory tract, bones and joints, central nervous system (including meningitis) and skin and soft tissue; intra-abdominal infections (including peritonitis); and in burns and postoperative infections (including post-vascular surgery). Clinical studies have shown amikacin also to be effective in serious complicated and recurrent urinary tract infections due to those organisms. Aminoglycosides, including Amikacin Sulfate Injection, USP are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics having less potential toxicity. Bacteriologic studies should be performed to identify causative organisms and their susceptibilities to amikacin. Amikacin may be considered as initial therapy in suspected Gram-negative infections and therapy may be instituted before obtaining the results of susceptibility testing. Clinical trials demonstrated that amikacin was effective in infections caused by gentamicin and/or tobramycin-resistant strains of Gram-negative organisms, particularly Proteus rettgeri , Providencia stuartii , Serratia marcescens , and Pseudomonas aeruginosa . The decision to continue therapy with the drug should be based on results of the susceptibility tests, the severity of the infection, the response of the patient and the important additional considerations contained in the WARNINGS box above. Amikacin has also been shown to be effective in staphylococci infections and may be considered as initial therapy under certain conditions in the treatment of known or suspected staphylococcal disease such as, severe infections where the causative organism may be either a Gram-negative bacterium or a staphylococcus, infections due to susceptible strains of staphylococci in patients allergic to other antibiotics, and in mixed staphylococci/Gram-negative infections. In certain severe infections such as neonatal sepsis, concomitant therapy with a penicillin-type drug may be indicated because of the possibility of infections due to Gram-positive organisms such as streptococci or pneumococci. To reduce the development of drug-resistant bacteria and maintain the effectiveness of amikacin and other antibacterial drugs, amikacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:4e267f68-9fc7-410f-b0d1-b3ed97efc406 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2637 biolink:treats UMLS:C0548923 PMID:41385096 "[{""id"":""uuid:de3f5091-c5ec-4b91-a1de-a68b4815f821"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1396d701-166a-4341-a23d-4d8bce123f22"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amikacin Sulfate Injection, USP is indicated in the short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria, including Pseudomonas species, Escherichia coli , species of indole-positive and indole-negative Proteus , Providencia species, Klebsiella-Enterobacter-Serratia species, and Acinetobacter ( Mima-Herellea ) species. Clinical studies have shown Amikacin Sulfate Injection, USP to be effective in bacterial septicemia (including neonatal sepsis); in serious infections of the respiratory tract, bones and joints, central nervous system (including meningitis) and skin and soft tissue; intra-abdominal infections (including peritonitis); and in burns and postoperative infections (including post-vascular surgery). Clinical studies have shown amikacin also to be effective in serious complicated and recurrent urinary tract infections due to those organisms. Aminoglycosides, including Amikacin Sulfate Injection, USP are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics having less potential toxicity. Bacteriologic studies should be performed to identify causative organisms and their susceptibilities to amikacin. Amikacin may be considered as initial therapy in suspected Gram-negative infections and therapy may be instituted before obtaining the results of susceptibility testing. Clinical trials demonstrated that amikacin was effective in infections caused by gentamicin and/or tobramycin-resistant strains of Gram-negative organisms, particularly Proteus rettgeri , Providencia stuartii , Serratia marcescens , and Pseudomonas aeruginosa . The decision to continue therapy with the drug should be based on results of the susceptibility tests, the severity of the infection, the response of the patient and the important additional considerations contained in the WARNINGS box above. Amikacin has also been shown to be effective in staphylococci infections and may be considered as initial therapy under certain conditions in the treatment of known or suspected staphylococcal disease such as, severe infections where the causative organism may be either a Gram-negative bacterium or a staphylococcus, infections due to susceptible strains of staphylococci in patients allergic to other antibiotics, and in mixed staphylococci/Gram-negative infections. In certain severe infections such as neonatal sepsis, concomitant therapy with a penicillin-type drug may be indicated because of the possibility of infections due to Gram-positive organisms such as streptococci or pneumococci. To reduce the development of drug-resistant bacteria and maintain the effectiveness of amikacin and other antibacterial drugs, amikacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:1d621250-8fac-4d4d-9223-ee62fb8cca39 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2637 biolink:treats MONDO:0021839 PMID:41385096 "[{""id"":""uuid:06fdddbc-4e3f-499b-bee3-c30c64f55e34"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ec110f8b-ee7a-430a-9406-6f6f11bf114f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amikacin Sulfate Injection, USP is indicated in the short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria, including Pseudomonas species, Escherichia coli , species of indole-positive and indole-negative Proteus , Providencia species, Klebsiella-Enterobacter-Serratia species, and Acinetobacter ( Mima-Herellea ) species. Clinical studies have shown Amikacin Sulfate Injection, USP to be effective in bacterial septicemia (including neonatal sepsis); in serious infections of the respiratory tract, bones and joints, central nervous system (including meningitis) and skin and soft tissue; intra-abdominal infections (including peritonitis); and in burns and postoperative infections (including post-vascular surgery). Clinical studies have shown amikacin also to be effective in serious complicated and recurrent urinary tract infections due to those organisms. Aminoglycosides, including Amikacin Sulfate Injection, USP are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics having less potential toxicity. Bacteriologic studies should be performed to identify causative organisms and their susceptibilities to amikacin. Amikacin may be considered as initial therapy in suspected Gram-negative infections and therapy may be instituted before obtaining the results of susceptibility testing. Clinical trials demonstrated that amikacin was effective in infections caused by gentamicin and/or tobramycin-resistant strains of Gram-negative organisms, particularly Proteus rettgeri , Providencia stuartii , Serratia marcescens , and Pseudomonas aeruginosa . The decision to continue therapy with the drug should be based on results of the susceptibility tests, the severity of the infection, the response of the patient and the important additional considerations contained in the WARNINGS box above. Amikacin has also been shown to be effective in staphylococci infections and may be considered as initial therapy under certain conditions in the treatment of known or suspected staphylococcal disease such as, severe infections where the causative organism may be either a Gram-negative bacterium or a staphylococcus, infections due to susceptible strains of staphylococci in patients allergic to other antibiotics, and in mixed staphylococci/Gram-negative infections. In certain severe infections such as neonatal sepsis, concomitant therapy with a penicillin-type drug may be indicated because of the possibility of infections due to Gram-positive organisms such as streptococci or pneumococci. To reduce the development of drug-resistant bacteria and maintain the effectiveness of amikacin and other antibacterial drugs, amikacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:5e015016-2214-48d5-a3f7-688da921944a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2637 biolink:treats MONDO:0043544 PMID:41385096 "[{""id"":""uuid:4d992331-e5bf-4aaa-9cc5-40e6ab3fb936"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:823599d5-7ee7-48a4-8985-9ebfa8560e69"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amikacin Sulfate Injection, USP is indicated in the short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria, including Pseudomonas species, Escherichia coli , species of indole-positive and indole-negative Proteus , Providencia species, Klebsiella-Enterobacter-Serratia species, and Acinetobacter ( Mima-Herellea ) species. Clinical studies have shown Amikacin Sulfate Injection, USP to be effective in bacterial septicemia (including neonatal sepsis); in serious infections of the respiratory tract, bones and joints, central nervous system (including meningitis) and skin and soft tissue; intra-abdominal infections (including peritonitis); and in burns and postoperative infections (including post-vascular surgery). Clinical studies have shown amikacin also to be effective in serious complicated and recurrent urinary tract infections due to those organisms. Aminoglycosides, including Amikacin Sulfate Injection, USP are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics having less potential toxicity. Bacteriologic studies should be performed to identify causative organisms and their susceptibilities to amikacin. Amikacin may be considered as initial therapy in suspected Gram-negative infections and therapy may be instituted before obtaining the results of susceptibility testing. Clinical trials demonstrated that amikacin was effective in infections caused by gentamicin and/or tobramycin-resistant strains of Gram-negative organisms, particularly Proteus rettgeri , Providencia stuartii , Serratia marcescens , and Pseudomonas aeruginosa . The decision to continue therapy with the drug should be based on results of the susceptibility tests, the severity of the infection, the response of the patient and the important additional considerations contained in the WARNINGS box above. Amikacin has also been shown to be effective in staphylococci infections and may be considered as initial therapy under certain conditions in the treatment of known or suspected staphylococcal disease such as, severe infections where the causative organism may be either a Gram-negative bacterium or a staphylococcus, infections due to susceptible strains of staphylococci in patients allergic to other antibiotics, and in mixed staphylococci/Gram-negative infections. In certain severe infections such as neonatal sepsis, concomitant therapy with a penicillin-type drug may be indicated because of the possibility of infections due to Gram-positive organisms such as streptococci or pneumococci. To reduce the development of drug-resistant bacteria and maintain the effectiveness of amikacin and other antibacterial drugs, amikacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:59e841b6-c875-4bcd-ab03-51a1e6204800 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2637 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:714a1a40-511f-40d8-a1f1-d75ac2c09b49"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b1624092-25af-48e9-8d38-178333ea3759"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amikacin Sulfate Injection, USP is indicated in the short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria, including Pseudomonas species, Escherichia coli , species of indole-positive and indole-negative Proteus , Providencia species, Klebsiella-Enterobacter-Serratia species, and Acinetobacter ( Mima-Herellea ) species. Clinical studies have shown Amikacin Sulfate Injection, USP to be effective in bacterial septicemia (including neonatal sepsis); in serious infections of the respiratory tract, bones and joints, central nervous system (including meningitis) and skin and soft tissue; intra-abdominal infections (including peritonitis); and in burns and postoperative infections (including post-vascular surgery). Clinical studies have shown amikacin also to be effective in serious complicated and recurrent urinary tract infections due to those organisms. Aminoglycosides, including Amikacin Sulfate Injection, USP are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics having less potential toxicity. Bacteriologic studies should be performed to identify causative organisms and their susceptibilities to amikacin. Amikacin may be considered as initial therapy in suspected Gram-negative infections and therapy may be instituted before obtaining the results of susceptibility testing. Clinical trials demonstrated that amikacin was effective in infections caused by gentamicin and/or tobramycin-resistant strains of Gram-negative organisms, particularly Proteus rettgeri , Providencia stuartii , Serratia marcescens , and Pseudomonas aeruginosa . The decision to continue therapy with the drug should be based on results of the susceptibility tests, the severity of the infection, the response of the patient and the important additional considerations contained in the WARNINGS box above. Amikacin has also been shown to be effective in staphylococci infections and may be considered as initial therapy under certain conditions in the treatment of known or suspected staphylococcal disease such as, severe infections where the causative organism may be either a Gram-negative bacterium or a staphylococcus, infections due to susceptible strains of staphylococci in patients allergic to other antibiotics, and in mixed staphylococci/Gram-negative infections. In certain severe infections such as neonatal sepsis, concomitant therapy with a penicillin-type drug may be indicated because of the possibility of infections due to Gram-positive organisms such as streptococci or pneumococci. To reduce the development of drug-resistant bacteria and maintain the effectiveness of amikacin and other antibacterial drugs, amikacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:618fbc33-430c-44c0-b836-e873282bbb65 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2637 biolink:treats MONDO:0024313 PMID:41385096 "[{""id"":""uuid:61d0ada5-98c3-40c9-8e5a-07000f7f2d01"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5683c64a-7dde-4908-9ea2-3075e2f33e63"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amikacin Sulfate Injection, USP is indicated in the short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria, including Pseudomonas species, Escherichia coli , species of indole-positive and indole-negative Proteus , Providencia species, Klebsiella-Enterobacter-Serratia species, and Acinetobacter ( Mima-Herellea ) species. Clinical studies have shown Amikacin Sulfate Injection, USP to be effective in bacterial septicemia (including neonatal sepsis); in serious infections of the respiratory tract, bones and joints, central nervous system (including meningitis) and skin and soft tissue; intra-abdominal infections (including peritonitis); and in burns and postoperative infections (including post-vascular surgery). Clinical studies have shown amikacin also to be effective in serious complicated and recurrent urinary tract infections due to those organisms. Aminoglycosides, including Amikacin Sulfate Injection, USP are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics having less potential toxicity. Bacteriologic studies should be performed to identify causative organisms and their susceptibilities to amikacin. Amikacin may be considered as initial therapy in suspected Gram-negative infections and therapy may be instituted before obtaining the results of susceptibility testing. Clinical trials demonstrated that amikacin was effective in infections caused by gentamicin and/or tobramycin-resistant strains of Gram-negative organisms, particularly Proteus rettgeri , Providencia stuartii , Serratia marcescens , and Pseudomonas aeruginosa . The decision to continue therapy with the drug should be based on results of the susceptibility tests, the severity of the infection, the response of the patient and the important additional considerations contained in the WARNINGS box above. Amikacin has also been shown to be effective in staphylococci infections and may be considered as initial therapy under certain conditions in the treatment of known or suspected staphylococcal disease such as, severe infections where the causative organism may be either a Gram-negative bacterium or a staphylococcus, infections due to susceptible strains of staphylococci in patients allergic to other antibiotics, and in mixed staphylococci/Gram-negative infections. In certain severe infections such as neonatal sepsis, concomitant therapy with a penicillin-type drug may be indicated because of the possibility of infections due to Gram-positive organisms such as streptococci or pneumococci. To reduce the development of drug-resistant bacteria and maintain the effectiveness of amikacin and other antibacterial drugs, amikacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:702a0c0d-5424-41c7-8db2-07091d9ba3e4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2637 biolink:treats MONDO:0100128 PMID:41385096 "[{""id"":""uuid:cdba00b4-670d-4a88-9e8b-06feda70030b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7e788b3b-4851-45ad-ab83-821ef601619b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amikacin Sulfate Injection, USP is indicated in the short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria, including Pseudomonas species, Escherichia coli , species of indole-positive and indole-negative Proteus , Providencia species, Klebsiella-Enterobacter-Serratia species, and Acinetobacter ( Mima-Herellea ) species. Clinical studies have shown Amikacin Sulfate Injection, USP to be effective in bacterial septicemia (including neonatal sepsis); in serious infections of the respiratory tract, bones and joints, central nervous system (including meningitis) and skin and soft tissue; intra-abdominal infections (including peritonitis); and in burns and postoperative infections (including post-vascular surgery). Clinical studies have shown amikacin also to be effective in serious complicated and recurrent urinary tract infections due to those organisms. Aminoglycosides, including Amikacin Sulfate Injection, USP are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics having less potential toxicity. Bacteriologic studies should be performed to identify causative organisms and their susceptibilities to amikacin. Amikacin may be considered as initial therapy in suspected Gram-negative infections and therapy may be instituted before obtaining the results of susceptibility testing. Clinical trials demonstrated that amikacin was effective in infections caused by gentamicin and/or tobramycin-resistant strains of Gram-negative organisms, particularly Proteus rettgeri , Providencia stuartii , Serratia marcescens , and Pseudomonas aeruginosa . The decision to continue therapy with the drug should be based on results of the susceptibility tests, the severity of the infection, the response of the patient and the important additional considerations contained in the WARNINGS box above. Amikacin has also been shown to be effective in staphylococci infections and may be considered as initial therapy under certain conditions in the treatment of known or suspected staphylococcal disease such as, severe infections where the causative organism may be either a Gram-negative bacterium or a staphylococcus, infections due to susceptible strains of staphylococci in patients allergic to other antibiotics, and in mixed staphylococci/Gram-negative infections. In certain severe infections such as neonatal sepsis, concomitant therapy with a penicillin-type drug may be indicated because of the possibility of infections due to Gram-positive organisms such as streptococci or pneumococci. To reduce the development of drug-resistant bacteria and maintain the effectiveness of amikacin and other antibacterial drugs, amikacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:2e6e0b2f-81ae-4978-a13f-132a38ccee61 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16347 biolink:treats MONDO:0008919 PMID:41385096 "[{""id"":""uuid:b23b9672-6d2d-41f4-9ac5-09cf1f14ed79"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:13aacc1a-68d7-4360-88ba-fbc463852eb6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e2071445-b302-438c-95b0-44d85f42a310"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levocarnitine is indicated in the treatment of primary systemic carnitine deficiency. In the reported cases, the clinical presentation consisted of recurrent episodes of Reye-like encephalopathy, hypoketotic hypoglycemia, and/or cardiomyopathy. Associated symptoms included hypotonia, muscle weakness and failure to thrive. A diagnosis of primary carnitine deficiency requires that serum, red cell and/or tissue carnitine levels be low and that the patient does not have a primary defect in fatty acid or organic acid oxidation (see CLINICAL PHARMACOLOGY ). In some patients, particularly those presenting with cardiomyopathy, carnitine supplementation rapidly alleviated signs and symptoms. Treatment should include, in addition to carnitine, supportive and other therapy as indicated by the condition of the patient. Levocarnitine is also indicated for acute and chronic treatment of patients with an inborn error of metabolism which results in a secondary carnitine deficiency.|[PMDA] Drugs with a new active ingredient indicated for the treatment of carnitine deficiency. uuid:8cb628be-d36f-489b-9f57-67da8c925c1b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16347 biolink:treats HP:0001985 PMID:41385096 "[{""id"":""uuid:be227737-4756-4138-9166-bec476770d4b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5ef4227b-7fb3-4324-8111-bcc373e58376"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levocarnitine is indicated in the treatment of primary systemic carnitine deficiency. In the reported cases, the clinical presentation consisted of recurrent episodes of Reye-like encephalopathy, hypoketotic hypoglycemia, and/or cardiomyopathy. Associated symptoms included hypotonia, muscle weakness and failure to thrive. A diagnosis of primary carnitine deficiency requires that serum, red cell and/or tissue carnitine levels be low and that the patient does not have a primary defect in fatty acid or organic acid oxidation (see CLINICAL PHARMACOLOGY ). In some patients, particularly those presenting with cardiomyopathy, carnitine supplementation rapidly alleviated signs and symptoms. Treatment should include, in addition to carnitine, supportive and other therapy as indicated by the condition of the patient. Levocarnitine is also indicated for acute and chronic treatment of patients with an inborn error of metabolism which results in a secondary carnitine deficiency. uuid:ffe72ebe-3108-4924-8457-5dac37760025 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16347 biolink:treats MONDO:0004994 PMID:41385096 "[{""id"":""uuid:f5208fa3-fa11-4047-adac-04afca8d83e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9e5b5d14-1ab8-47f4-b198-8631cbaf2238"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levocarnitine is indicated in the treatment of primary systemic carnitine deficiency. In the reported cases, the clinical presentation consisted of recurrent episodes of Reye-like encephalopathy, hypoketotic hypoglycemia, and/or cardiomyopathy. Associated symptoms included hypotonia, muscle weakness and failure to thrive. A diagnosis of primary carnitine deficiency requires that serum, red cell and/or tissue carnitine levels be low and that the patient does not have a primary defect in fatty acid or organic acid oxidation (see CLINICAL PHARMACOLOGY ). In some patients, particularly those presenting with cardiomyopathy, carnitine supplementation rapidly alleviated signs and symptoms. Treatment should include, in addition to carnitine, supportive and other therapy as indicated by the condition of the patient. Levocarnitine is also indicated for acute and chronic treatment of patients with an inborn error of metabolism which results in a secondary carnitine deficiency. uuid:612d7da1-7cb1-461e-9412-2dfa0e8d4f15 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0015129 PMID:41385096 "[{""id"":""uuid:ed3a1a27-bc37-454d-89e6-1012a00274ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2ed4834c-5c9e-4b20-99fd-cf9613c22f54"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute non-specific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia. 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate anti-tuberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:ef5df007-6d0f-4228-bf7b-4c87a209e3d2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0043370 PMID:41385096 "[{""id"":""uuid:9e2d25f8-4f3f-438d-824d-40b86d5a3121"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6e33fea0-2853-4b79-9f06-05d43ca97859"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute non-specific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia. 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate anti-tuberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:e28f1de7-b6f6-4bed-b2cc-0db4d5be2bb7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0009197 PMID:41385096 "[{""id"":""uuid:8aa359f7-f1dd-4e0c-b9f1-e799bfa9ad48"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9106dedf-69f3-4885-a6c8-51cb5653241c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute non-specific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia. 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate anti-tuberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:6ae26a15-9966-4192-90a7-0835278fb0ac biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1992683 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:a42461b1-cbce-43eb-93d9-2f0c6bac8bbd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:6ca69d56-03ca-4880-af1e-3e028f07a70e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f1a5617d-8ab1-4967-a6d4-2902ac22f606"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/segluromet""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] SEGLUROMET ® is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.|[EMA] Segluromet is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:in patients not adequately controlled on their maximally tolerated dose of metformin alonein patients on their maximally tolerated doses of metformin in addition to other medicinal products for the treatment of diabetesin patients already being treated with the combination of ertugliflozin and metformin as separate tablets. uuid:036e1f15-7dd6-446b-b915-f51c5f83625b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64317 biolink:treats HP:0031275 PMID:41385096 "[{""id"":""uuid:da2f1534-83d7-4a40-bf7c-a8be14e141e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:203596be-e7ee-4cdd-b9a0-c4cc2596875f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Isoproterenol hydrochloride injection is indicated: To improve hemodynamic status in patients in distributive shock and shock due to reduced cardiac output For bronchospasm occurring during anesthesia uuid:eddf64dc-bdd5-4c29-b77f-10e9be8fa36a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:T432289GYZ biolink:treats MONDO:0005647 PMID:41385096 "[{""id"":""uuid:0e253de5-80ca-4efc-ba59-2d5396c09d61"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a398fcb0-01f3-447e-91dd-0573c8ee1b2f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Veregen is a topical ointment indicated for the treatment of external genital and perianal warts (Condylomata acuminata) in immunocompetent patients 18 years and older (1.1) . Limitations of Use Safety and effectiveness of Veregen have not been established in immunosuppressed patients, in treatment of external genital and perianal warts beyond 16-weeks, or for multiple treatment courses (1.2) . uuid:b20dfd6b-f364-48c4-8b95-9b0bd5f8bef7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:56841573 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:82f3641f-9e1f-4d02-a052-c9b8734f91d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:15987cf6-b135-4357-bbaf-4d4fa0eb1b4b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tekturna HCT is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including hydrochlorothiazide (HCTZ). There are no controlled trials demonstrating risk reduction with Tekturna HCT. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality have also been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (e.g., patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. uuid:4c99d240-c793-4f32-8402-7b2dfcff4aec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:56841573 biolink:treats MONDO:0005016 PMID:41385096 "[{""id"":""uuid:f0f9c9d7-b731-4513-a52a-0921c825b13e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c0a355df-8533-4549-878e-bf41293e55f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tekturna HCT is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including hydrochlorothiazide (HCTZ). There are no controlled trials demonstrating risk reduction with Tekturna HCT. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality have also been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (e.g., patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. uuid:d2df0631-1dd1-466b-9d47-8eecb8e8fa39 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:56841573 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:50cb511f-5d12-47b8-9786-47b47f7b0e42"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2b3429da-10d4-4913-b489-aea8ba36f7f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tekturna HCT is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including hydrochlorothiazide (HCTZ). There are no controlled trials demonstrating risk reduction with Tekturna HCT. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality have also been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (e.g., patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. uuid:32a09cc7-1b1f-4d6b-b377-bc92998acaa2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:56841573 biolink:treats HP:0001681 PMID:41385096 "[{""id"":""uuid:7993c60a-1c65-4be0-b6e0-b7453470d391"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cd5f82a9-619b-40bf-aace-0288c9ebab26"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tekturna HCT is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including hydrochlorothiazide (HCTZ). There are no controlled trials demonstrating risk reduction with Tekturna HCT. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality have also been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (e.g., patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. uuid:42bb09ad-83e3-4712-9109-454303932392 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:24783652 biolink:treats MONDO:0006652 PMID:41385096 "[{""id"":""uuid:90f2412e-4690-4ece-9f82-b1f54b4a3db2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ec81312a-3f3a-42d1-b77c-80fab2c4d808"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Losartan potassium and hydrochlorothiazide tablet is a combination of losartan, an angiotensin II receptor blocker (ARB) and hydrochlorothiazide, a diuretic indicated for: Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1) Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy. There is evidence that this benefit does not apply to Black patients. ( 1.2 ) uuid:cc0ea869-c82b-45a9-89c2-94e72116f1cc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:608828 biolink:treats MONDO:0004951 PMID:41385096 "[{""id"":""uuid:25491eb5-0664-4ed8-83a5-203d38fd8109"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2f2e2e41-5ca1-4b4b-a989-01edd0be869f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FUZEON ® in combination with other antiretroviral agents is indicated for the treatment of HIV-1 infection in treatment-experienced patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy. uuid:00082834-be70-479a-89b6-517083edc0c4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB13883 biolink:treats MONDO:0018669 PMID:41385096 "[{""id"":""uuid:8f0d16d6-54df-47b3-b408-49e0b5dcdf71"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:35ad17a0-28e7-42b3-95f8-76554582d17d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] North American Coral Snake Antivenin (Equine) is indicated only for the treatment of envenomation caused by bites of North American coral snakes - Micrurus (including the eastern and Texas varieties). uuid:930c7d71-4d39-4e97-80c4-59643db98f41 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2682 biolink:treats MONDO:0002041 PMID:41385096 "[{""id"":""uuid:92853094-6b9f-4c1b-806d-43681d933a22"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ce0acd23-db82-403c-9dab-725fc3d409ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amphotericin B liposome for injection is indicated for the following: Empirical therapy for presumed fungal infection in febrile, neutropenic patients. Treatment of Cryptococcal Meningitis in HIV-infected patients (see DESCRIPTION OF CLINICAL STUDIES ). Treatment of patients with Aspergillus species, Candida species and/or Cryptococcus species infections (see above for the treatment of Cryptococcal Meningitis) refractory to amphotericin B deoxycholate, or in patients where renal impairment or unacceptable toxicity precludes the use of amphotericin B deoxycholate. Treatment of visceral leishmaniasis. In immunocompromised patients with visceral leishmaniasis treated with amphotericin B liposome for injection, relapse rates were high following initial clearance of parasites (see DESCRIPTION OF CLINICAL STUDIES ). See DOSAGE AND ADMINISTRATION for recommended doses by indication. uuid:9cc77814-d139-4b8e-8d7c-483a6c820490 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2682 biolink:treats MONDO:0005723 PMID:41385096 "[{""id"":""uuid:d5b9365d-dd0f-4df1-b91a-504928e8ee3c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:be511d97-e2d2-4fc8-948f-0b9b7070749d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amphotericin B liposome for injection is indicated for the following: Empirical therapy for presumed fungal infection in febrile, neutropenic patients. Treatment of Cryptococcal Meningitis in HIV-infected patients (see DESCRIPTION OF CLINICAL STUDIES ). Treatment of patients with Aspergillus species, Candida species and/or Cryptococcus species infections (see above for the treatment of Cryptococcal Meningitis) refractory to amphotericin B deoxycholate, or in patients where renal impairment or unacceptable toxicity precludes the use of amphotericin B deoxycholate. Treatment of visceral leishmaniasis. In immunocompromised patients with visceral leishmaniasis treated with amphotericin B liposome for injection, relapse rates were high following initial clearance of parasites (see DESCRIPTION OF CLINICAL STUDIES ). See DOSAGE AND ADMINISTRATION for recommended doses by indication. uuid:70b3329c-a88f-4460-a4e6-f33d07ae6f82 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2682 biolink:treats MONDO:0002026 PMID:41385096 "[{""id"":""uuid:9c7aaa91-2880-42d1-8772-0ec6a09ad7be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:fe31e0ac-dd0c-4f1a-a5b8-45afcaba6015"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:0112a31b-056b-405d-814a-e21cf524e2a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amphotericin B liposome for injection is indicated for the following: Empirical therapy for presumed fungal infection in febrile, neutropenic patients. Treatment of Cryptococcal Meningitis in HIV-infected patients (see DESCRIPTION OF CLINICAL STUDIES ). Treatment of patients with Aspergillus species, Candida species and/or Cryptococcus species infections (see above for the treatment of Cryptococcal Meningitis) refractory to amphotericin B deoxycholate, or in patients where renal impairment or unacceptable toxicity precludes the use of amphotericin B deoxycholate. Treatment of visceral leishmaniasis. In immunocompromised patients with visceral leishmaniasis treated with amphotericin B liposome for injection, relapse rates were high following initial clearance of parasites (see DESCRIPTION OF CLINICAL STUDIES ). See DOSAGE AND ADMINISTRATION for recommended doses by indication.|[PMDA] Various infections caused by Aspergillus species, Candida species or Cryptococcus species (drug with a new dosage and dosage form). uuid:4f0fab97-e4ad-4943-80f9-873af9fe3310 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2682 biolink:treats MONDO:0005445 PMID:41385096 "[{""id"":""uuid:60034c4c-bd60-44e9-8663-f0c48435946d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:fc26334d-c066-4b96-865c-1f7c1e135d07"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:5c7be226-40cd-4ed5-8d0e-7fbfc581cbb7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amphotericin B liposome for injection is indicated for the following: Empirical therapy for presumed fungal infection in febrile, neutropenic patients. Treatment of Cryptococcal Meningitis in HIV-infected patients (see DESCRIPTION OF CLINICAL STUDIES ). Treatment of patients with Aspergillus species, Candida species and/or Cryptococcus species infections (see above for the treatment of Cryptococcal Meningitis) refractory to amphotericin B deoxycholate, or in patients where renal impairment or unacceptable toxicity precludes the use of amphotericin B deoxycholate. Treatment of visceral leishmaniasis. In immunocompromised patients with visceral leishmaniasis treated with amphotericin B liposome for injection, relapse rates were high following initial clearance of parasites (see DESCRIPTION OF CLINICAL STUDIES ). See DOSAGE AND ADMINISTRATION for recommended doses by indication.|[PMDA] A drug with new additional indications and a new dosage for the treatment of fungal infections caused by Mucor species, Absidia species, Rhizopus species, Rhizomucor species, Cladosporium species, Cladophialophora species, Fonsecaea species, Phialophora species, Exophiala species, Coccidioides species, Histoplasma species, and Blastomyces species and visceral leishmaniasis. uuid:d4ab353f-0ad9-40b7-a173-217ebd7535ce biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7565 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:69f3833d-5887-4b52-a936-43cf474798d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d02cab62-94f2-46d8-acc3-c46ee3d6511a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] I. Vasospastic Angina Nifedipine extended-release tablets are indicated for the management of vasospastic angina confirmed by any of the following criteria: 1) classical pattern of angina at rest accompanied by ST segment elevation, 2) angina or coronary artery spasm provoked by ergonovine, or 3) angiographically demonstrated coronary artery spasm. In those patients who have had angiography, the presence of significant fixed obstructive disease is not incompatible with the diagnosis of vasospastic angina, provided that the above criteria are satisfied. Nifedipine extended-release tablets may also be used where the clinical presentation suggests a possible vasospastic component, but where vasospasm has not been confirmed, e.g., where pain has a variable threshold on exertion, or in unstable angina where electrocardiographic findings are compatible with intermittent vasospasm, or when angina is refractory to nitrates and/or adequate doses of beta blockers. II. Chronic Stable Angina (Classical Effort-Associated Angina) Nifedipine extended-release tablets are indicated for the management of chronic stable angina (effort-associated angina) without evidence of vasospasm in patients who remain symptomatic despite adequate doses of beta blockers and/or organic nitrates or who cannot tolerate those agents. In chronic stable angina (effort-associated angina), nifedipine has been effective in controlled trials of up to eight weeks duration in reducing angina frequency and increasing exercise tolerance, but confirmation of sustained effectiveness and evaluation of long-term safety in these patients is incomplete. Controlled studies in small numbers of patients suggest concomitant use of nifedipine and beta-blocking agents may be beneficial in patients with chronic stable angina, but available information is not sufficient to predict with confidence the effects of concurrent treatment, especially in patients with compromised left ventricular function or cardiac conduction abnormalities. When introducing such concomitant therapy, care must be taken to monitor blood pressure closely, since severe hypotension can occur from the combined effects of the drugs (see WARNINGS). III. Hypertension Nifedipine extended-release tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including nifedipine extended-release tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Nifedipine extended-release tablets may be used alone or in combination with other antihypertensive agents. uuid:45b4b6d1-affa-42d2-b6ea-a215ffae5770 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7565 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:839519b2-6e28-4016-af52-1f748c5e7d13"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:034c0568-884c-4cb8-b857-816f32776a3b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] I. Vasospastic Angina Nifedipine extended-release tablets are indicated for the management of vasospastic angina confirmed by any of the following criteria: 1) classical pattern of angina at rest accompanied by ST segment elevation, 2) angina or coronary artery spasm provoked by ergonovine, or 3) angiographically demonstrated coronary artery spasm. In those patients who have had angiography, the presence of significant fixed obstructive disease is not incompatible with the diagnosis of vasospastic angina, provided that the above criteria are satisfied. Nifedipine extended-release tablets may also be used where the clinical presentation suggests a possible vasospastic component, but where vasospasm has not been confirmed, e.g., where pain has a variable threshold on exertion, or in unstable angina where electrocardiographic findings are compatible with intermittent vasospasm, or when angina is refractory to nitrates and/or adequate doses of beta blockers. II. Chronic Stable Angina (Classical Effort-Associated Angina) Nifedipine extended-release tablets are indicated for the management of chronic stable angina (effort-associated angina) without evidence of vasospasm in patients who remain symptomatic despite adequate doses of beta blockers and/or organic nitrates or who cannot tolerate those agents. In chronic stable angina (effort-associated angina), nifedipine has been effective in controlled trials of up to eight weeks duration in reducing angina frequency and increasing exercise tolerance, but confirmation of sustained effectiveness and evaluation of long-term safety in these patients is incomplete. Controlled studies in small numbers of patients suggest concomitant use of nifedipine and beta-blocking agents may be beneficial in patients with chronic stable angina, but available information is not sufficient to predict with confidence the effects of concurrent treatment, especially in patients with compromised left ventricular function or cardiac conduction abnormalities. When introducing such concomitant therapy, care must be taken to monitor blood pressure closely, since severe hypotension can occur from the combined effects of the drugs (see WARNINGS). III. Hypertension Nifedipine extended-release tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including nifedipine extended-release tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Nifedipine extended-release tablets may be used alone or in combination with other antihypertensive agents. uuid:90d0e3d5-f70a-49aa-b971-0fa203009d09 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1304557 biolink:treats MONDO:0024298 PMID:41385096 "[{""id"":""uuid:75f0748c-ec7d-4032-aae7-cfb33fbb9922"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:31ea47c9-61aa-4a49-b450-1efd110257ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INFUVITE PEDIATRIC is a combination of vitamins indicated for the prevention of vitamin deficiency in pediatric patients up to 11 years of age receiving parenteral nutrition. The physician should not await the development of clinical signs of vitamin deficiency before initiating vitamin therapy. uuid:399c76aa-af39-476c-817b-dceffa7ccaea biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:B005P07V07 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:65aa6502-7496-404a-ad1c-b25aa14ed9bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dc84090c-3739-4dbd-96b3-a95a81f32a2e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Neurolite single photon emission computerized tomography (SPECT) is indicated as an adjunct to conventional CT or MRI imaging in the localization of stroke in patients in whom stroke has already been diagnosed. Neurolite is not indicated for assessment of functional viability of brain tissue. Also, Neurolite is not indicated for distinguishing between stroke and other brain lesions. uuid:e59ae570-0a14-45cd-bc7b-e9a5d1d90767 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32184 biolink:treats UMLS:C0406317 PMID:41385096 "[{""id"":""uuid:66b410ae-544e-4118-a6c2-3b04e8284b68"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4a85a429-623a-4eb1-91ba-6235ac5cf06c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tazarotene cream 0.1% is a retinoid indicated for the topical treatment of plaque psoriasis. ( 1.1 ) Tazarotene cream 0.1% is indicated for the topical treatment of acne vulgaris. ( 1.2 ) uuid:b2945040-8b42-458a-839c-395de10c5708 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:478164 biolink:treats UMLS:C4552431 PMID:41385096 "[{""id"":""uuid:a4929fea-e11d-4b25-95f3-8964c725539f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cdc589b3-ab63-4c94-88f2-8782354ff1a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefepime for Injection is a cephalosporin antibacterial indicated for the treatment of the following infections caused by susceptible strains of the designated microorganisms: Pneumonia. ( 1.1 ) Empiric therapy for febrile neutropenic patients. ( 1.2 ) Uncomplicated and complicated urinary tract infections (including pyelonephritis). ( 1.3 ) Uncomplicated skin and skin structure infections. ( 1.4 ) Complicated intra-abdominal infections (used in combination with metronidazole) in adults. ( 1.5 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefepime for Injection and other antibacterial drugs, Cefepime for Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.6 ) uuid:cb9627ef-723c-4b8f-a97d-c31c41256f1f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15552 biolink:treats MONDO:0015924 PMID:41385096 "[{""id"":""uuid:f1498a02-9415-47e6-902b-a77746c90579"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e95e22ba-b9ec-43de-bb55-8ccabf39ec9f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:1f2a6095-bb60-471a-bafb-ef07304223e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VELETRI is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise capacity. Studies establishing effectiveness included predominantly patients with NYHA Functional Class III–IV symptoms and etiologies of idiopathic or heritable PAH or PAH associated with connective tissue diseases.|[PMDA] Drugs with a new additional pediatric dosage indicated for the treatment of pulmonary arterial hypertension. uuid:c1df94ba-f327-4134-a13f-dad05dfc382b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15552 biolink:treats MONDO:0017147 PMID:41385096 "[{""id"":""uuid:89cc21ca-6151-4cfe-b216-6ce6f814b697"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:551a65ff-134e-4d44-875b-6576176ff14b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VELETRI is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise capacity. Studies establishing effectiveness included predominantly patients with NYHA Functional Class III–IV symptoms and etiologies of idiopathic or heritable PAH or PAH associated with connective tissue diseases. uuid:0bd5ce1a-c5dc-475f-a85d-b50678c8b259 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15552 biolink:treats MONDO:0017148 PMID:41385096 "[{""id"":""uuid:78e34d74-bfe5-4cd2-a293-120e71b68fc0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5b841f45-0e2c-4031-889c-8869234a25e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VELETRI is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise capacity. Studies establishing effectiveness included predominantly patients with NYHA Functional Class III–IV symptoms and etiologies of idiopathic or heritable PAH or PAH associated with connective tissue diseases. uuid:e6d6867b-a7d2-4f96-a3c6-53cbffabb3e5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3654 biolink:treats HP:0000969 PMID:41385096 "[{""id"":""uuid:2f89b99f-32a6-4185-a0b1-e30943e5b047"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b7cbb637-073d-47ce-ae27-b4dbff5410cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diuretics such as chlorthalidone are indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertension. Chlorthalidone is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Chlorthalidone has also been found useful in edema due to various forms of renal dysfunction, such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. Usage in Pregnancy: The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developed toxemia. Edema during pregnancy may arise from pathological causes or from the physiologic and mechanical consequences of pregnancy. Chlorthalidone is indicated in pregnancy when edema is due to pathologic causes, just as it is in the absence of pregnancy (however, see PRECAUTIONS , below). Dependent edema in pregnancy, resulting from restriction of venous return by the expanded uterus, is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is illogical and unnecessary. There is hypervolemia during normal pregnancy that is harmful to neither the fetus nor the mother (in the absence of cardiovascular disease), but that is associated with edema, including generalized edema, in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances, this edema may cause extreme discomfort that is not relieved by rest. In these cases, a short course of diuretics may provide relief and be appropriate. uuid:cc7f94f9-642f-4cb5-90ee-762bd479eb81 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16899 biolink:treats MONDO:0006684 PMID:41385096 "[{""id"":""uuid:d3e5cb01-a79e-45e8-9473-1c5a140c0384"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:96b1509e-e5bb-44ff-8f5c-8d9ec4d47709"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mannitol Injection is indicated for the reduction of: intracranial pressure and treatment of cerebral edema; elevated intraocular pressure. uuid:f3c3cfe1-7992-4ba7-9602-baeb4c42e9ab biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16899 biolink:treats HP:0007906 PMID:41385096 "[{""id"":""uuid:ac94e54b-fa08-4f12-8e4c-30419de2fe5f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e73f7667-605a-42ae-9bb2-155251e25d4d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mannitol Injection is indicated for the reduction of: intracranial pressure and treatment of cerebral edema; elevated intraocular pressure. uuid:7d2cf58a-96cc-46e9-a055-97eead970bbb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:46878853 biolink:treats MONDO:0004982 PMID:41385096 "[{""id"":""uuid:b0a8f279-a9d0-4d82-b1d4-279eab104566"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:01558d9f-bd2e-4922-801b-691d7baae322"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Treatment of Hypercholesterolemia Fenofibrate capsules are indicated as adjunctive therapy to diet for the reduction of LDL-C, Total-C, Triglycerides and Apo B in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb). Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and non-pharmacological interventions alone has been inadequate (see National Cholesterol Education Program [NCEP] Treatment Guidelines, below). Treatment of Hypertriglyceridemia Fenofibrate capsules are also indicated as adjunctive therapy to diet for treatment of adult patients with hypertriglyceridemia (Fredrickson Types IV and V hyperlipidemia). Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually reduce fasting triglycerides and eliminate chylomicronemia thereby obviating the need for pharmacologic intervention. Markedly elevated levels of serum triglycerides (e.g., > 2,000 mg/dL) may increase the risk of developing pancreatitis. The effect of fenofibrate therapy on reducing this risk has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of very low density lipoprotein (VLDL). Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV and V hyperlipoproteinemia 2 . The initial treatment for dyslipidemia is dietary therapy specific for the type of lipoprotein abnormality. Excess body weight and excess alcoholic intake may be important factors in hypertriglyceridemia and should be addressed prior to any drug therapy. Physical exercise can be an important ancillary measure. Diseases contributory to hyperlipidemia, such as hypothyroidism or diabetes mellitus should be looked for and adequately treated. Estrogen therapy, like thiazide diuretics and beta-blockers, is sometimes associated with massive rises in plasma triglycerides, especially in subjects with familial hypertriglyceridemia. In such cases, discontinuation of the specific etiologic agent may obviate the need for specific drug therapy of hypertriglyceridemia. The use of drugs should be considered only when reasonable attempts have been made to obtain satisfactory results with non-drug methods. If the decision is made to use drugs, the patient should be instructed that this does not reduce the importance of adhering to diet (see WARNINGS and PRECAUTIONS ). Fredrickson Classification of Hyperlipoproteinemias Type Lipoprotein Elevated Lipid Elevation Major Minor I (rare) Chylomicrons TG ↑↔C IIa LDL C — IIb LDL, VLDL C TG III (rare) IDL C, TG — IV VLDL TG ↑↔C V (rare) Chylomicrons, VLDL TG ↑↔ C = cholesterol TG = triglycerides LDL = low density lipoprotein VLDL = very low density lipoprotein IDL = intermediate density lipoprotein The NCEP Treatment Guidelines Definite Athlerosclerotic Disease a Two or More Other Risk Factors b LDL-Cholesterol mg/dL (mmol/L) Initiation Level Goal No No ≥ 190 (≥ 4.9) < 160 (< 4.1) No Yes ≥ 160 (≥ 4.1) < 130 (< 3.4) Yes Yes or No ≥ 130 c (≥ 3.4) < 100 (< 2.6) a Coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease). b Other risk factors for coronary heart disease (CHD) include: age (males: ≥ 45 years; females: ≥ 55 years or premature menopause without estrogen replacement therapy); family history of premature CHD; current cigarette smoking; hypertension; confirmed HDL-C < 35 mg/dL (< 0.91mmol/L); and diabetes mellitus. Subtract 1 risk factor if HDL-C is ≥ 60 mg/dL (≥ 1.6 mmol/L) c In CHD patients with LDL-C levels 100 to 129 mg/dL, the physician should exercise clinical judgment in deciding whether to initiate drug treatment. uuid:361d362c-5a74-42dc-ab9d-2efd1bda1b1a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17234 biolink:treats MONDO:0004946 PMID:41385096 "[{""id"":""uuid:a3ea1dee-8a95-4007-997d-f08e5cd396b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f193c68d-fa26-4a05-bdd3-728fb8d27ff2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 25% Dextrose Injection is indicated in the treatment of acute symptomatic episodes of hypoglycemia in the neonate or older infant to restore depressed blood glucose levels and control symptoms. Other drugs, such as epinephrine and glucagon, should be considered in patients unresponsive or intolerant to dextrose (glucose). Oral feeding of dextrose may be necessary in infants with frequently recurring hypoglycemic episodes or to prevent recurrences due to hyperinsulinemia. 25% Dextrose Injection also provides a minimal source of carbohydrate calories. uuid:d07a1900-6353-4879-a0de-47d4c72bba4d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28787 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:8d28c02c-50ab-419b-9c93-d75efb768640"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2da43dc2-2dc7-40e0-a453-8ef091f32162"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nitroglycerin in 5% Dextrose Injection is indicated for treatment of peri-operative hypertension; for control of heart failure in the setting of acute myocardial infarction; for treatment of angina pectoris in patients who have not responded to sublingual nitroglycerin and ß-blockers; and for induction of intraoperative hypotension. uuid:2000d592-69de-431e-8cfb-bd6f76d10398 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:107736 biolink:treats HP:0002018 PMID:41385096 "[{""id"":""uuid:5b8f9924-145f-4559-b243-8591f2204d05"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8e567ba2-43ab-41dc-9100-bd24bb10648c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diabetic Gastroparesis (Diabetic Gastric Stasis) Metoclopramide Injection (metoclopramide hydrochloride, USP) is indicated for the relief of symptoms associated with acute and recurrent diabetic gastric stasis. The Prevention of Nausea and Vomiting Associated with Emetogenic Cancer Chemotherapy Metoclopramide Injection is indicated for the prophylaxis of vomiting associated with emetogenic cancer chemotherapy. The Prevention of Postoperative Nausea and Vomiting Metoclopramide Injection is indicated for the prophylaxis of postoperative nausea and vomiting in those circumstances where nasogastric suction is undesirable. Small Bowel Intubation Metoclopramide Injection may be used to facilitate small bowel intubation in adults and pediatric patients in whom the tube does not pass the pylorus with conventional maneuvers. Radiological Examination Metoclopramide Injection may be used to stimulate gastric emptying and intestinal transit of barium in cases where delayed emptying interferes with radiological examination of the stomach and/or small intestine. uuid:c8862c58-adfc-471f-a1a4-4eb9967e86b0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:107736 biolink:treats HP:0002013 PMID:41385096 "[{""id"":""uuid:9bfda4b1-50fd-4fc8-9936-34e9856b1636"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ffa13780-cb2d-45ee-bc1f-e5d872c53b0a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diabetic Gastroparesis (Diabetic Gastric Stasis) Metoclopramide Injection (metoclopramide hydrochloride, USP) is indicated for the relief of symptoms associated with acute and recurrent diabetic gastric stasis. The Prevention of Nausea and Vomiting Associated with Emetogenic Cancer Chemotherapy Metoclopramide Injection is indicated for the prophylaxis of vomiting associated with emetogenic cancer chemotherapy. The Prevention of Postoperative Nausea and Vomiting Metoclopramide Injection is indicated for the prophylaxis of postoperative nausea and vomiting in those circumstances where nasogastric suction is undesirable. Small Bowel Intubation Metoclopramide Injection may be used to facilitate small bowel intubation in adults and pediatric patients in whom the tube does not pass the pylorus with conventional maneuvers. Radiological Examination Metoclopramide Injection may be used to stimulate gastric emptying and intestinal transit of barium in cases where delayed emptying interferes with radiological examination of the stomach and/or small intestine. uuid:cd81f014-748c-44d0-8e3e-025ab513c8d9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7773 biolink:treats EFO:0006911 PMID:41385096 "[{""id"":""uuid:04c857a2-4707-402e-a5bf-c92282db0ecb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4c5691bc-9b4d-4277-8af0-d154059e6703"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Prevention of Nausea and Vomiting Associated with Initial and Repeat Courses of Emetogenic Cancer Chemotherapy Ondansetron injection is indicated for the prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including high-dose cisplatin [see CLINICAL STUDIES (14.1)]. Ondansetron is approved for patients aged 6 months and older. 1.2 Prevention of Postoperative Nausea and/or Vomiting Ondansetron injection is indicated for the prevention of postoperative nausea and/or vomiting. As with other antiemetics, routine prophylaxis is not recommended for patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. In patients in whom nausea and/or vomiting must be avoided postoperatively, ondansetron injection is recommended even when the incidence of postoperative nausea and/or vomiting is low. For patients who do not receive prophylactic ondansetron injection and experience nausea and/or vomiting postoperatively, ondansetron injection may be given to prevent further episodes [see CLINICAL STUDIES (14.3)]. Ondansetron is approved for patients aged 1 month and older. uuid:cd45d75c-60aa-4163-8ab2-c8cfe04c1a08 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27953 biolink:treats UMLS:C0151500 PMID:41385096 "[{""id"":""uuid:0405909e-9360-448a-b8b4-e62c7402be14"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bc72cfc5-5866-4116-a583-7f845481a949"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reverse the effect upon the central nervous system, caused by clinical or toxic dosages of drugs capable of producing the anticholinergic syndrome. uuid:46bd3c29-315f-4a5d-8716-e489dffd7a24 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:Q46947FE7K biolink:treats MONDO:0005354 PMID:41385096 "[{""id"":""uuid:87cacad1-5ce3-41bd-a390-b02c0153388b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:625288c1-d349-40f2-b745-6b16201e9e88"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ddf1e759-5700-4c11-8dbd-85f681e2c580"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/pegasys""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] PEGASYS is an inducer of the innate immune response indicated for the treatment of Chronic Hepatitis C (CHC) ( 1.1 ) Adult Patients: In combination therapy with other hepatitis C virus drugs for adults with compensated liver disease. PEGASYS monotherapy is indicated only if patient has contraindication or significant intolerance to other HCV drugs. Pediatric Patients: In combination with ribavirin for pediatric patients 5 years of age and older with compensated liver disease Chronic Hepatitis B (CHB) ( 1.2 ) Adult Patients: Treatment of adults with HBeAg-positive and HBeAg-negative chronic hepatitis B (CHB) infection who have compensated liver disease and evidence of viral replication and liver inflammation Pediatric Patients: Treatment of non-cirrhotic pediatric patients 3 years of age and older with HBeAg-positive CHB and evidence of viral replication and elevations in serum alanine aminotransferase (ALT)|[EMA] Chronic hepatitis B, , Adult patients, , Pegasys is indicated for the treatment of hepatitis B envelope antigen (HBeAg)-positive or HBeAg-negative chronic hepatitis B (CHB) in adult patients with compensated liver disease and evidence of viral replication, increased alanine aminotransferase (ALT) and histologically verified liver inflammation and/or fibrosis (see sections 4.4 and 5.1)., , Paediatric patients 3 years of age and older, , Pegasys is indicated for the treatment of HBeAg-positive CHB in non-cirrhotic children and adolescents 3 years of age and older with evidence of viral replication and persistently elevated serum ALT levels. With respect to the decision to initiate treatment in paediatric patients see sections 4.2, 4.4 and 5.1., , Chronic hepatitis C, , Adult patients, , Pegasys is indicated in combination with other medicinal products, for the treatment of chronic hepatitis C (CHC) in patients with compensated liver disease (see sections 4.2, 4.4 and 5.1)., , For hepatitis C virus (HCV) genotype specific activity, see sections 4.2 and 5.1., , Paediatric patients 5 years of age and older, , Pegasys in combination with ribavirin is indicated for the treatment of CHC in treatment-naïve children and adolescents 5 years of age and older who are positive for serum HCV-RNA., , When deciding to initiate treatment in childhood, it is important to consider growth inhibition induced by combination therapy. The reversibility of growth inhibition is uncertain. The decision to treat should be made on a case by case basis (see section 4.4)., uuid:0f81c08a-427c-42ef-8838-2494de0d83f1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:Q46947FE7K biolink:treats MONDO:0005366 PMID:41385096 "[{""id"":""uuid:6c85aac0-c308-4a38-921f-ef8ec2c499f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:86447be1-2e1a-4067-9b7a-1845e2120681"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c8c21062-fcd1-4eb1-9a8c-12737855c2e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/pegasys""]},{""id"":""uuid:7fd7b6c0-87ce-42fa-803f-0f867f2cf50a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PEGASYS is an inducer of the innate immune response indicated for the treatment of Chronic Hepatitis C (CHC) ( 1.1 ) Adult Patients: In combination therapy with other hepatitis C virus drugs for adults with compensated liver disease. PEGASYS monotherapy is indicated only if patient has contraindication or significant intolerance to other HCV drugs. Pediatric Patients: In combination with ribavirin for pediatric patients 5 years of age and older with compensated liver disease Chronic Hepatitis B (CHB) ( 1.2 ) Adult Patients: Treatment of adults with HBeAg-positive and HBeAg-negative chronic hepatitis B (CHB) infection who have compensated liver disease and evidence of viral replication and liver inflammation Pediatric Patients: Treatment of non-cirrhotic pediatric patients 3 years of age and older with HBeAg-positive CHB and evidence of viral replication and elevations in serum alanine aminotransferase (ALT)|[EMA] Chronic hepatitis B, , Adult patients, , Pegasys is indicated for the treatment of hepatitis B envelope antigen (HBeAg)-positive or HBeAg-negative chronic hepatitis B (CHB) in adult patients with compensated liver disease and evidence of viral replication, increased alanine aminotransferase (ALT) and histologically verified liver inflammation and/or fibrosis (see sections 4.4 and 5.1)., , Paediatric patients 3 years of age and older, , Pegasys is indicated for the treatment of HBeAg-positive CHB in non-cirrhotic children and adolescents 3 years of age and older with evidence of viral replication and persistently elevated serum ALT levels. With respect to the decision to initiate treatment in paediatric patients see sections 4.2, 4.4 and 5.1., , Chronic hepatitis C, , Adult patients, , Pegasys is indicated in combination with other medicinal products, for the treatment of chronic hepatitis C (CHC) in patients with compensated liver disease (see sections 4.2, 4.4 and 5.1)., , For hepatitis C virus (HCV) genotype specific activity, see sections 4.2 and 5.1., , Paediatric patients 5 years of age and older, , Pegasys in combination with ribavirin is indicated for the treatment of CHC in treatment-naïve children and adolescents 5 years of age and older who are positive for serum HCV-RNA., , When deciding to initiate treatment in childhood, it is important to consider growth inhibition induced by combination therapy. The reversibility of growth inhibition is uncertain. The decision to treat should be made on a case by case basis (see section 4.4).,|[PMDA] Drugs with a new additional indication and a new dosage for the improvement of viremia in patients with chronic active hepatitis B. [Priority review] uuid:04837f93-aaac-4956-8d00-cca4c5b63496 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1540231 biolink:treats HP:0000616 PMID:41385096 "[{""id"":""uuid:b0e4fb9a-79fb-45d8-93a1-ec55740f0804"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f886dd7f-fd6e-44bc-b88f-0c4e478d9ae4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Omidria ® is added to an ocular irrigating solution used during cataract surgery or intraocular lens replacement and is indicated for maintaining pupil size by preventing intraoperative miosis and reducing postoperative ocular pain. uuid:db236e20-a8c1-4eb4-843a-33d6706a2fd2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:438HCF2X0M biolink:treats MONDO:0009338 PMID:41385096 "[{""id"":""uuid:78785f35-20d1-476b-a98c-a689977365e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4d299d60-2e7d-4d69-8c03-dfe0c1508709"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DEFITELIO is indicated for the treatment of adult and pediatric patients with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation (HSCT). uuid:9acbcff8-0517-4d30-a5e3-f0b9bddf3d1c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:438HCF2X0M biolink:treats MONDO:0019514 PMID:41385096 "[{""id"":""uuid:b0a7f09c-3155-4c1e-bcd4-c6c3dd02f617"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7ed3f11c-c11a-475e-8db7-608c8fdecf65"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:3f211d84-7ff8-4dc9-bc73-760074dd75ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/defitelio""]},{""id"":""uuid:55fca012-0b6f-4a9a-af02-7eba666396b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DEFITELIO is indicated for the treatment of adult and pediatric patients with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation (HSCT).|[EMA] Defitelio is indicated for the treatment of severe hepatic veno-occlusive disease (VOD) also known as sinusoidal obstructive syndrome (SOS) in haematopoietic stem-cell transplantation (HSCT) therapy.It is indicated in adults and in adolescents, children and infants over 1 month of age.|[PMDA] A drug with a new active ingredient indicated for the treatment of sinusoidal obstruction syndrome (SOS) /hepatic veno-occlusive disease (VOD). [Orphan drug] uuid:1411a78f-674b-411e-9a40-d1e8c5ae0576 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68642 biolink:treats MONDO:0004956 PMID:41385096 "[{""id"":""uuid:b1569ec7-c1cb-40f5-93ba-f4008a8bbaa2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0e56397e-a258-4a68-a285-a55ceb7b1751"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Abiraterone acetate tablets are indicated in combination with prednisone for the treatment of patients with • Metastatic castration-resistant prostate cancer (CRPC) • Metastatic high-risk castration-sensitive prostate cancer (CSPC) uuid:d52c6120-0274-4c85-8dd9-cc70f14e1810 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4466 biolink:treats MONDO:0001866 PMID:41385096 "[{""id"":""uuid:44819cfd-d28f-4e84-bff8-1153bbf8e83f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cfdfd3aa-0999-4baa-bec7-e403f6d9d2bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] IGALMI is indicated for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. uuid:d1fe728f-829f-4880-92b3-9398ad01d812 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4466 biolink:treats MONDO:0000693 PMID:41385096 "[{""id"":""uuid:09d1d148-af9a-4645-9292-a2e2db85edf5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:efe070e5-8700-4d26-9cb1-8e9cebe860b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] IGALMI is indicated for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. uuid:05161a93-9534-4a65-be02-31cd55bd1f01 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6717 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:812f0215-de8c-43b8-b11b-a2389cdb8ec1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4bedffde-30bd-4f57-8163-f24c70291ba2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of mefenamic acid and other treatment options before deciding to use mefenamic acid. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals ( see WARNINGS ). Mefenamic acid is indicated: For relief of mild to moderate pain in patients ≥14 years of age, when therapy will not exceed one week (7 days). For treatment of primary dysmenorrhea. uuid:3335a4bb-efcd-4a67-8c0f-14de152ff394 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6717 biolink:treats MONDO:1060206 PMID:41385096 "[{""id"":""uuid:caacbc34-06ca-4af2-b4ac-c8a9d0c335ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:69617786-af8f-44b2-913d-3153add8218d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of mefenamic acid and other treatment options before deciding to use mefenamic acid. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals ( see WARNINGS ). Mefenamic acid is indicated: For relief of mild to moderate pain in patients ≥14 years of age, when therapy will not exceed one week (7 days). For treatment of primary dysmenorrhea. UMLS:C0149875 uuid:3f3253a9-f8d7-4171-9d0c-3627328aa1b5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28001 biolink:treats UMLS:C0235952 PMID:41385096 "[{""id"":""uuid:729019c8-712e-4744-bf38-a946fd340140"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d275dfd0-ed6f-4923-bf3c-8d0ce44d9ad3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vancomycin hydrochloride capsule is indicated for the treatment of Clostridioides difficile -associated diarrhea. Vancomycin hydrochloride capsule is also used for the treatment of enterocolitis caused by Staphylococcus aureus (including methicillin-resistant strains) in adult and pediatric patients less than 18 years of age. uuid:b2358dcc-bcff-4a04-9578-cf85b3981d81 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28001 biolink:treats MONDO:0009172 PMID:41385096 "[{""id"":""uuid:bd18e2cb-e933-4faa-be8d-4c515db02e05"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c22b3874-2722-49d9-8a5b-11eb06821855"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vancomycin hydrochloride capsule is indicated for the treatment of Clostridioides difficile -associated diarrhea. Vancomycin hydrochloride capsule is also used for the treatment of enterocolitis caused by Staphylococcus aureus (including methicillin-resistant strains) in adult and pediatric patients less than 18 years of age. uuid:55bc85e6-62db-4beb-a592-f364dcfe9f7a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32588 biolink:treats MONDO:0006919 PMID:41385096 "[{""id"":""uuid:96aa881c-fb6d-48a1-9702-e6319489a53e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dc042eaa-ccc2-4173-beac-a8d327ba8680"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Potassium Chloride for Injection Concentrate USP is indicated in the treatment of potassium deficiency states when oral replacement is not feasible. This is a concentrated solution which is intended for use in a pharmacy admixture service and is restricted to the preparation of admixtures for intravenous infusion. uuid:a904d8b0-6afd-47a4-be50-1129c237910f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:74T7185BMM biolink:treats MONDO:0035663 PMID:41385096 "[{""id"":""uuid:0fda3bf9-e8e7-4638-8c7c-35015b434616"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:61af26eb-3916-4128-9283-b5392b32a3dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c107f9de-3873-44e8-8d1d-9a10d748e423"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/uplizna""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] UPLIZNA is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.|[EMA] Uplizna is indicated as monotherapy for the treatment of adult patients with neuromyelitis optica spectrum disorders (NMOSD) who are anti-aquaporin 4 immunoglobulin G (AQP4-IgG) seropositive (see section 5.1). uuid:e3143c70-e311-45e3-84b1-544f2f669a0e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:74T7185BMM biolink:treats MONDO:0019100 PMID:41385096 "[{""id"":""uuid:52d4ccf6-c67f-4df7-8cbd-ca0c8a7bfca3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:585d30e2-82cb-44d0-b2e7-bfdbb1a4773e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:16fbbc06-82a4-4d32-8582-a766677eef50"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] UPLIZNA is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.|[PMDA] A drug with a new active ingredient indicated for the prevention of relapse of neuromyelitis optica spectrum disorder (including neuromyelitis optica). [Orphan drug] uuid:0c9acd46-7f4a-4aa7-8184-f3f1f9bcde4f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5537 biolink:treats UMLS:C0520904 PMID:41385096 "[{""id"":""uuid:c29a3d47-a790-44ce-9a1d-62aea1dd6005"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cd68f6a2-37d2-4efb-be7e-c749f0000fed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Granisetron Hydrochloride Injection, USP is a serotonin-3 (5-HT 3 ) receptor antagonist indicated for: The prevention of nausea and/or vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin. The prevention and treatment of postoperative nausea and vomiting in adults. As with other antiemetics, routine prophylaxis is not recommended in patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. In patients where nausea and/or vomiting must be avoided during the postoperative period, granisetron hydrochloride injection, USP is recommended even where the incidence of postoperative nausea and/or vomiting is low. uuid:82698d53-2292-4abf-a9b4-90bff8dbf9ec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5537 biolink:treats UMLS:C0520905 PMID:41385096 "[{""id"":""uuid:20a4d20f-5f90-4151-8d28-6b0e2f4cb275"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f2e1e274-e588-4d9a-9374-86bdc279b54d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Granisetron Hydrochloride Injection, USP is a serotonin-3 (5-HT 3 ) receptor antagonist indicated for: The prevention of nausea and/or vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin. The prevention and treatment of postoperative nausea and vomiting in adults. As with other antiemetics, routine prophylaxis is not recommended in patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. In patients where nausea and/or vomiting must be avoided during the postoperative period, granisetron hydrochloride injection, USP is recommended even where the incidence of postoperative nausea and/or vomiting is low. uuid:56c1442c-03a9-4a06-94c1-3d011e04a381 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:230846 biolink:treats MONDO:0009861 PMID:41385096 "[{""id"":""uuid:cd901fe1-c5cd-42d4-adb3-15bc14f24ed0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:747eff5b-3174-4c02-96d5-3a786530f284"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:567e8a4d-b731-43cd-8e39-4ff38fcfbf92"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/palynziq""]},{""id"":""uuid:769fc56d-0dd2-4f30-95e8-c71c68aa7d85"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Palynziq is indicated to reduce blood phenylalanine concentrations in adult patients with phenylketonuria (PKU) who have uncontrolled blood phenylalanine concentrations greater than 600 micromol/L on existing management.|[EMA] Palynziq is indicated for the treatment of patients with phenylketonuria (PKU) aged 16 years and older who have inadequate blood phenylalanine control (blood phenylalanine levels greater than 600 micromol/l) despite prior management with available treatment options.|[PMDA] Drugs with a new active ingredient indicated for the treatment of phenylketonuria. [Orphan drug] uuid:59f30c6c-66ea-430b-80c1-861b81ab77d8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32151 biolink:treats UMLS:C0341736 PMID:41385096 "[{""id"":""uuid:300e1882-6655-47b9-a2a5-2ee90b6eb661"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:262e8728-8dcd-419f-8d9f-221867f7efcd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VESIcare LS ® is indicated for the treatment of neurogenic detrusor overactivity (NDO) in pediatric patients aged 2 years and older. uuid:30e9c5c5-be36-47c6-bb9d-41b915d36289 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:V1N8F1RVVO biolink:treats MONDO:0100187 PMID:41385096 "[{""id"":""uuid:9d44d8d9-93b3-4b33-9c12-008a7e744da5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f52d766a-1446-42f2-95f3-14c41a2cdcce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SYMPROIC is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation. uuid:687677e5-72b4-464b-868f-387ba905f226 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:V1N8F1RVVO biolink:treats HP:0012532 PMID:41385096 "[{""id"":""uuid:cc36cb2e-6629-44a4-93c3-93be47721f77"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cd7a0c75-ecde-4c3b-a139-be84b5fcaf48"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SYMPROIC is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation. uuid:3b55eff5-2ba7-422e-9284-6049573a8608 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:V1N8F1RVVO biolink:treats EFO:0801084 PMID:41385096 "[{""id"":""uuid:5a7c1b3f-894a-42d3-b317-c66bd7e053f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ebb9bad0-17df-46e8-bc36-ed9f94acc398"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SYMPROIC is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation. uuid:1fdb1e14-cf92-4d3c-a6ff-c22201283e20 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27732 biolink:treats MONDO:0043775 PMID:41385096 "[{""id"":""uuid:20c504fb-b29e-4bb2-9521-d992401de746"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:13e3ae5d-b2d7-4976-82bf-f38d2654f2da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Caffeine and Sodium Benzoate Injection has been used in conjunction with supportive measure to treat respiratory depression associated with overdosage with CNS depressant drugs (e.g., narcotic analgesics, alcohol). However, because of questionable benefit and transient action, most authorities believe caffeine and other analeptics should not be used in these conditions and recommend other supportive therapy. uuid:bc7c1302-55d3-4201-904b-0f589a842c3d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68855 biolink:treats MONDO:0021095 PMID:41385096 "[{""id"":""uuid:cfff55ce-0d36-494d-a4ac-008d2db65211"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:b4acf780-f1bb-4d6c-9f27-5f9da3f51771"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:53b8450b-1777-4548-8850-37260d950437"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ioflupane I 123 Injection is indicated as an adjunct to other diagnostic evaluations for striatal dopamine transporter visualization using single photon emission computed tomography (SPECT) brain imaging in adult patients with: ● suspected Parkinsonian syndromes (PS) or ● suspected dementia with Lewy bodies (DLB).|[EMA] This medicinal product is for diagnostic use only.Striascan is indicated for detecting loss of functional dopaminergic neuron terminals in the striatum:In adult patients with clinically uncertain parkinsonian syndromes, for example those with early symptoms, in order to help differentiate essential tremor from parkinsonian syndromes related to idiopathic Parkinson’s disease, multiple system atrophy and progressive supranuclear palsy. Striascan is unable to discriminate between Parkinson's disease, multiple system atrophy and progressive supranuclear palsy.In adult patients, to help differentiate probable dementia with Lewy bodies from Alzheimer’s disease. Striascan is unable to discriminate between dementia with Lewy bodies and Parkinson’s disease dementia. uuid:d3016139-e595-41ab-ba1f-9727fcfe1348 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6427 biolink:treats MONDO:0008315 PMID:41385096 "[{""id"":""uuid:87a02c7a-5c16-4761-8c5e-87019f2899e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d394c7a7-3a02-4f61-b2f9-5f3953b1a5a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CAMCEVI is indicated for the treatment of adult patients with advanced prostate cancer. uuid:06eaac06-f1e0-4747-a299-2b426b225775 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28830 biolink:treats MONDO:0004948 PMID:41385096 "[{""id"":""uuid:8c4648ea-d5b6-4c9f-b6cd-5202b07317e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:207334c8-6f56-40bc-8616-8fc58947de03"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LEUKERAN (chlorambucil) is indicated in the treatment of chronic lymphatic (lymphocytic) leukemia, malignant lymphomas including lymphosarcoma, giant follicular lymphoma, and Hodgkin’s disease. It is not curative in any of these disorders but may produce clinically useful palliation. uuid:bf7b51e7-4b30-467d-8630-85441795aa11 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28830 biolink:treats MONDO:0004638 PMID:41385096 "[{""id"":""uuid:278be460-7c5b-4e70-bf85-fe8eb86520f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6126073c-9353-4d95-bc01-f9b41f703887"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LEUKERAN (chlorambucil) is indicated in the treatment of chronic lymphatic (lymphocytic) leukemia, malignant lymphomas including lymphosarcoma, giant follicular lymphoma, and Hodgkin’s disease. It is not curative in any of these disorders but may produce clinically useful palliation. uuid:873e0b73-df5d-4be0-afc3-8f3d83540fcc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28830 biolink:treats MONDO:0018906 PMID:41385096 "[{""id"":""uuid:27a59cd6-9a56-4965-b72a-dcf6759f1ee1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8631f7fc-6da3-4796-a663-48de4cb7f0ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LEUKERAN (chlorambucil) is indicated in the treatment of chronic lymphatic (lymphocytic) leukemia, malignant lymphomas including lymphosarcoma, giant follicular lymphoma, and Hodgkin’s disease. It is not curative in any of these disorders but may produce clinically useful palliation. uuid:ca721aa0-d7c8-4d05-aa26-8f0446861362 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28830 biolink:treats MONDO:0009348 PMID:41385096 "[{""id"":""uuid:3bb89502-cce8-4fcf-9dfc-df025f922312"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c46e8aae-a4fc-42d9-854f-7a2915f0dade"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LEUKERAN (chlorambucil) is indicated in the treatment of chronic lymphatic (lymphocytic) leukemia, malignant lymphomas including lymphosarcoma, giant follicular lymphoma, and Hodgkin’s disease. It is not curative in any of these disorders but may produce clinically useful palliation. uuid:db645afd-4fa5-46bd-b01b-56c888464c99 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50275 biolink:treats MONDO:0007186 PMID:41385096 "[{""id"":""uuid:758cd70a-fb49-41ad-9a61-9b668b31436d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:cfa8d358-b2ad-40c7-b24c-f22cec8cccf8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:39ff38bd-4360-4945-8a55-27b9f5b42e1f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Esomeprazole magnesium delayed-release capsules is a proton pump inhibitor (PPI). Esomeprazole magnesium delayed-release capsules is indicated for the: • Short-term treatment in the healing of erosive esophagitis (EE) in adults and pediatric patients 12 years to 17 years of age. ( 1.1 ) • Maintenance of healing of EE in adults. ( 1.2 ) • Short-term treatment of heartburn and other symptoms associated GERD in adults and pediatric patients 12 years to 17 years of age. ( 1.3 ) • Risk reduction of nonsteroidal anti-inflammatory drugs (NSAID)-associated gastric ulcer in adults at risk for developing gastric ulcers due to age (60 years and older) and/or documented history of gastric ulcers. ( 1.4 ) • Helicobacter pylori eradication in adult patients to reduce the risk of duodenal ulcer recurrence in combination with amoxicillin and clarithromycin. ( 1.5 ) • Long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome in adults. ( 1.6 )|[PMDA] A drug with a new active ingredient indicated for the treatment of gastric ulcer, duodenal ulcer, anastomotic ulcer, reflux esophagitis, non-erosive reflux disease and Zollinger-Ellison syndrome, prevention of recurrence of gastric ulcer or duodenal ulcer in patients treated with nonsteroidal antiinflammatory drugs, and aid to eradication of Helicobacter pylori in patients with gastric ulcer, duodenal ulcer, gastric MALT lymphoma, idiopathic thrombocytopenic purpura, and stomach after endoscopic treatment for early gastric cancer. uuid:f5a5ba7a-ab9e-4341-9abe-cc731bb9f161 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50275 biolink:treats MONDO:0006781 PMID:41385096 "[{""id"":""uuid:c1928fe8-0ac7-402b-ac7e-b591522acbda"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2f377fd1-dd9c-4e4e-a846-c8054bd34538"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Esomeprazole magnesium delayed-release capsules is a proton pump inhibitor (PPI). Esomeprazole magnesium delayed-release capsules is indicated for the: • Short-term treatment in the healing of erosive esophagitis (EE) in adults and pediatric patients 12 years to 17 years of age. ( 1.1 ) • Maintenance of healing of EE in adults. ( 1.2 ) • Short-term treatment of heartburn and other symptoms associated GERD in adults and pediatric patients 12 years to 17 years of age. ( 1.3 ) • Risk reduction of nonsteroidal anti-inflammatory drugs (NSAID)-associated gastric ulcer in adults at risk for developing gastric ulcers due to age (60 years and older) and/or documented history of gastric ulcers. ( 1.4 ) • Helicobacter pylori eradication in adult patients to reduce the risk of duodenal ulcer recurrence in combination with amoxicillin and clarithromycin. ( 1.5 ) • Long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome in adults. ( 1.6 ) uuid:9d0664f5-1693-42ad-8386-5a84fbd06fe7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3175 biolink:treats MONDO:0006604 PMID:41385096 "[{""id"":""uuid:fc7a4470-51f1-4e17-9a9c-5bc63921517d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:669648e0-494d-4440-8eb4-8220f52e52bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:6b5f24c4-3bac-488a-9b83-1b08b697d330"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Brimonidine topical gel, 0.33% is an alpha adrenergic agonist indicated for the topical treatment of persistent (nontransient) erythema of rosacea in adults 18 years of age or older.|[EMA] Mirvaso is indicated for the symptomatic treatment of facial erythema of rosacea in adult patients. uuid:5e0c0714-7895-4cf9-b2f5-f826b717d213 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:51230 biolink:treats MONDO:0001335 PMID:41385096 "[{""id"":""uuid:e482d1e1-816e-49b4-8f14-66cf8980cbc0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5ead88fc-0a3c-440b-ae11-2af2d231d84c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bimatoprost ophthalmic solution 0.03% is indicated to treat hypotrichosis of the eyelashes by increasing their growth including length, thickness and darkness. uuid:80364e61-d378-4cb6-8b30-37d0a1eb3fff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9738 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:a9c1e832-3a50-4a81-80e8-4bb473574a9f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:494971a9-2dc3-41c6-b5dd-f8a293850d62"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Trimipramine Maleate Capsules are indicated for the relief of symptoms of depression. Endogenous depression is more likely to be alleviated than other depressive states. In studies with neurotic outpatients, the drug appeared to be equivalent to amitriptyline in the less-depressed patients but somewhat less effective than amitriptyline in the more severely depressed patients. In hospitalized depressed patients, trimipramine and imipramine were equally effective in relieving depression. uuid:9574eb79-6afb-4bd2-9245-b7b8c3cd8702 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9738 biolink:treats MONDO:0012048 PMID:41385096 "[{""id"":""uuid:82b69c84-df09-4fa3-bf13-211cace595ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:940afcf6-61a6-49c7-9e71-dbca30787788"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Trimipramine Maleate Capsules are indicated for the relief of symptoms of depression. Endogenous depression is more likely to be alleviated than other depressive states. In studies with neurotic outpatients, the drug appeared to be equivalent to amitriptyline in the less-depressed patients but somewhat less effective than amitriptyline in the more severely depressed patients. In hospitalized depressed patients, trimipramine and imipramine were equally effective in relieving depression. uuid:34c53004-b6da-4177-89a8-1e8d30370bfb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8597 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:6cc375f6-92ba-4095-be28-57403934e530"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bf23e3af-12f0-4f34-93eb-e175e3bfab49"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Protriptyline hydrochloride tablets are indicated for the treatment of symptoms of mental depression in patients who are under close medical supervision. Its activating properties make it particularly suitable for withdrawn and anergic patients. uuid:bac3afc6-8f60-4036-a7ac-247c4383537c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22652 biolink:treats MONDO:0001356 PMID:41385096 "[{""id"":""uuid:1db7c653-3cab-4dd5-8d96-72004f032fb3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:82d203c1-5cba-4cf2-9d28-0ad42361bcd3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PureVit DualFe Plus is indicated for the treatment of iron deficiency anemia and folate deficiency as in extended convalescence, menorrhagia, pregnancy, puberty, excessive blood loss and advanced age. Also for treatment of condition in which iron deficiency and vitamin C deficiency occur together, along with a deficient intake or increased need for B-Complex vitamins in chronic and acute illness, as well as cases of metabolic stress, and in convalescence. uuid:c5d3c985-d5ea-402b-a5c7-77ece5ab53fd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22652 biolink:treats MONDO:0001860 PMID:41385096 "[{""id"":""uuid:cee3ca74-14b1-447b-ab0d-af44e40505a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8d2a814e-3523-495a-b8fd-ae824bb1a303"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PureVit DualFe Plus is indicated for the treatment of iron deficiency anemia and folate deficiency as in extended convalescence, menorrhagia, pregnancy, puberty, excessive blood loss and advanced age. Also for treatment of condition in which iron deficiency and vitamin C deficiency occur together, along with a deficient intake or increased need for B-Complex vitamins in chronic and acute illness, as well as cases of metabolic stress, and in convalescence. uuid:13f5e471-6d0d-43b7-9a4c-7210d65520da biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22652 biolink:treats MONDO:0009412 PMID:41385096 "[{""id"":""uuid:df72a466-d66e-4c9d-a468-9ef391e56fe8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c1915feb-1f85-48de-916e-c9aa0fb02b84"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PureVit DualFe Plus is indicated for the treatment of iron deficiency anemia and folate deficiency as in extended convalescence, menorrhagia, pregnancy, puberty, excessive blood loss and advanced age. Also for treatment of condition in which iron deficiency and vitamin C deficiency occur together, along with a deficient intake or increased need for B-Complex vitamins in chronic and acute illness, as well as cases of metabolic stress, and in convalescence. uuid:77c892a9-80fd-441f-93eb-94eb81ffbc13 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49544 biolink:treats MONDO:0001700 PMID:41385096 "[{""id"":""uuid:4a8e986d-ae7b-49d3-a855-30203bf7d97f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e916df05-c62d-44f5-994e-58f6e321b81b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vitrexyl™ is indicated to provide vitamin supplement to men and women. Folic acid is effective in the treatment of megaloblastic anemias due to a deficiency of folic acid (as may be seen in tropical or nontropical sprue) and in anemias of nutritional origin, pregnancy, infancy, or childhood. uuid:b3e6e027-7ba6-4bf2-a1f1-f39da1735e8b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49544 biolink:treats MONDO:0001078 PMID:41385096 "[{""id"":""uuid:c16c7d1b-d7b0-468c-b161-d4afa0d9d367"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:00f2d187-d7c6-48a3-8558-f2c93f61357a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vitrexyl™ is indicated to provide vitamin supplement to men and women. Folic acid is effective in the treatment of megaloblastic anemias due to a deficiency of folic acid (as may be seen in tropical or nontropical sprue) and in anemias of nutritional origin, pregnancy, infancy, or childhood. uuid:5f1e8fa1-fdd5-422e-8729-6e65f014ff54 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49544 biolink:treats MONDO:0005130 PMID:41385096 "[{""id"":""uuid:f0641197-2075-4056-b29d-1b91c5dc8869"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8bed6260-e46c-4382-8dcf-500e2487b54e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vitrexyl™ is indicated to provide vitamin supplement to men and women. Folic acid is effective in the treatment of megaloblastic anemias due to a deficiency of folic acid (as may be seen in tropical or nontropical sprue) and in anemias of nutritional origin, pregnancy, infancy, or childhood. uuid:e67aaa0d-2149-4c39-9d04-cdb7ee21cc61 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49544 biolink:treats UMLS:C0271903 PMID:41385096 "[{""id"":""uuid:fc7157ca-bd26-48c3-a116-3b737cd28aad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5f894596-143d-4fd0-bdcd-57c7966127ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vitrexyl™ is indicated to provide vitamin supplement to men and women. Folic acid is effective in the treatment of megaloblastic anemias due to a deficiency of folic acid (as may be seen in tropical or nontropical sprue) and in anemias of nutritional origin, pregnancy, infancy, or childhood. uuid:b97d9f43-ff4e-4c2b-8847-1dd65f932407 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49544 biolink:treats MONDO:0009197 PMID:41385096 "[{""id"":""uuid:219a3ddc-342d-4554-8d83-180939f53d81"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6a95695a-06e4-4a46-9fe9-5a3a2874aa7b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vitrexyl™ is indicated to provide vitamin supplement to men and women. Folic acid is effective in the treatment of megaloblastic anemias due to a deficiency of folic acid (as may be seen in tropical or nontropical sprue) and in anemias of nutritional origin, pregnancy, infancy, or childhood. uuid:f1ba7e52-9c0d-4627-8d00-3f6b8237109e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1163417 biolink:treats MONDO:0002406 PMID:41385096 "[{""id"":""uuid:517fa07e-823b-4a95-8cca-91b12e610be7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bb6bb123-6bdf-4812-b01e-d36005673a96"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The product is used for the anti-inflammatory and anesthetic relief of redness, pain, itching, and discoloration due to inflammation and skin burns. For the relief of redness, pain, itching, discoloration, inflammation and mild skin burns associated with radiation. For use after radiation treatment, cosmetic procedures, sun exposure, and for inflammatory skin conditions. uuid:6a39d418-bde3-4941-acfc-622d7d7bfb61 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6078 biolink:treats MONDO:0006604 PMID:41385096 "[{""id"":""uuid:cd414dc4-ab9f-4858-ba26-2298b4b545f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0dab0354-fe2b-428a-9523-fb3268e8dd4d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ivermectin cream, 1% is indicated for the treatment of inflammatory lesions of rosacea. uuid:9d1b24eb-24b2-40d0-877f-86da0d470d06 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2587738 biolink:treats MONDO:0010811 PMID:41385096 "[{""id"":""uuid:51864e9c-1525-4e05-8c8c-a079835636dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f90bd2d8-1f90-4c06-bda3-dce232e6ae67"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ENTADFI is indicated to initiate treatment of the signs and symptoms of benign prostatic hyperplasia (BPH) in men with an enlarged prostate for up to 26 weeks. Limitations of Use ENTADFI is not recommended for more than 26 weeks because the incremental benefit of tadalafil decreases from 4 weeks until 26 weeks, and the incremental benefit beyond 26 weeks is unknown [see Clinical Studies ( 14 )] . uuid:502a30a7-9cbb-4f2f-afbe-5e128d1895c8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:119486 biolink:treats MONDO:0004951 PMID:41385096 "[{""id"":""uuid:0c577ca8-188c-4028-9bb8-7be2d191efbe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0f0e78dc-77b0-4718-89a5-bf8969c16e30"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Efavirenz tablets in combination with other antiretroviral agents are indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and in pediatric patients at least 3 months old and weighing at least 3.5 kg. uuid:1cbdcf76-8288-458d-9e47-a039a45d2a86 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3387 biolink:treats MONDO:0001866 PMID:41385096 "[{""id"":""uuid:7e271cae-4a1a-49cb-9a3f-d8eb6ef44d28"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:89094c18-c108-4504-8cc6-97a90df48110"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EQUETRO is: A mood stabilizer indicated for the treatment of acute manic or mixed episodes associated with bipolar I disorder ( 1.1 ) Indicated for the treatment of the pain associated with trigeminal neuralgia ( 1.2 ) An anti-epileptic drug (AED) indicated for the treatment of partial seizures with complex symptomatology, generalized tonic-clonic seizures, and mixed seizures ( 1.3 ) uuid:09283e06-b849-48a5-982b-4425f9933786 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6909 biolink:treats MONDO:0005246 PMID:41385096 "[{""id"":""uuid:bbdd6fb3-6b14-40c9-af9d-bba27e0466e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:42cb1a24-a5e0-49e3-a4b0-925266c43002"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Symptomatic Trichomoniasis Metronidazole tablets USP are indicated for the treatment of T. vaginalis infection in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures). Asymptomatic Trichomoniasis Metronidazole tablets USP are indicated in the treatment of asymptomatic T. vaginalis infection in females when the organism is associated with endocervicitis, cervicitis, or cervical erosion. Since there is evidence that presence of the trichomonad can interfere with accurate assessment of abnormal cytological smears, additional smears should be performed after eradication of the parasite. Treatment of Asymptomatic Sexual Partners T. vaginalis infection is a venereal disease. Therefore, asymptomatic sexual partners of treated patients should be treated simultaneously if the organism has been found to be present, in order to prevent reinfection of the partner. The decision as to whether to treat an asymptomatic male partner who has a negative culture or one for whom no culture has been attempted is an individual one. In making this decision, it should be noted that there is evidence that a woman may become reinfected if her sexual partner is not treated. Also, since there can be considerable difficulty in isolating the organism from the asymptomatic male carrier, negative smears and cultures cannot be relied upon in this regard. In any event, the sexual partner should be treated with metronidazole tablets USP in cases of reinfection. Amebiasis Metronidazole tablets USP are indicated in the treatment of acute intestinal amebiasis (amebic dysentery) and amebic liver abscess. In amebic liver abscess, metronidazole tablet therapy does not obviate the need for aspiration or drainage of pus. Anaerobic Bacterial Infections Metronidazole tablets USP are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Indicated surgical procedures should be performed in conjunction with metronidazole tablet therapy. In a mixed aerobic and anaerobic infection, antimicrobials appropriate for the treatment of the aerobic infection should be used in addition to metronidazole tablets USP. INTRA-ABDOMINAL INFECTIONS, including peritonitis, intra-abdominal abscess, and liver abscess, caused by Bacteroides species including the B. fragilis group (B. fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron, B. vulgatus), Clostridium species, Eubacterium species, Peptococcus species, and Peptostreptococcus species. SKIN AND SKIN STRUCTURE INFECTIONS caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus species, Peptostreptococcus species, and Fusobacterium species. GYNECOLOGIC INFECTIONS, including endometritis, endomyometritis, tubo-ovarian abscess, and postsurgical vaginal cuff infection, caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus species, Peptostreptococcus species, and Fusobacterium species. BACTERIAL SEPTICEMIA caused by Bacteroides species including the B. fragilis group and Clostridium species. BONE AND JOINT INFECTIONS, (as adjunctive therapy), caused by Bacteroides species including the B. fragilis group. CENTRAL NERVOUS SYSTEM (CNS) INFECTIONS, including meningitis and brain abscess, caused by Bacteroides species including the B. fragilis group. LOWER RESPIRATORY TRACT INFECTIONS, including pneumonia, empyema, and lung abscess, caused by Bacteroides species including the B. fragilis group. ENDOCARDITIS caused by Bacteroides species including the B. fragilis group. To reduce the development of drug-resistant bacteria and maintain the effectiveness of metronidazole tablets USP and other antibacterial drugs, metronidazole tablets USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:e21e5330-b148-4b0c-927f-6da2d677431d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6909 biolink:treats MONDO:0042485 PMID:41385096 "[{""id"":""uuid:d450892b-78a5-4762-8e54-285f4b9c701d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cd92acb6-cc66-4598-a18b-8600245c4524"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Symptomatic Trichomoniasis Metronidazole tablets USP are indicated for the treatment of T. vaginalis infection in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures). Asymptomatic Trichomoniasis Metronidazole tablets USP are indicated in the treatment of asymptomatic T. vaginalis infection in females when the organism is associated with endocervicitis, cervicitis, or cervical erosion. Since there is evidence that presence of the trichomonad can interfere with accurate assessment of abnormal cytological smears, additional smears should be performed after eradication of the parasite. Treatment of Asymptomatic Sexual Partners T. vaginalis infection is a venereal disease. Therefore, asymptomatic sexual partners of treated patients should be treated simultaneously if the organism has been found to be present, in order to prevent reinfection of the partner. The decision as to whether to treat an asymptomatic male partner who has a negative culture or one for whom no culture has been attempted is an individual one. In making this decision, it should be noted that there is evidence that a woman may become reinfected if her sexual partner is not treated. Also, since there can be considerable difficulty in isolating the organism from the asymptomatic male carrier, negative smears and cultures cannot be relied upon in this regard. In any event, the sexual partner should be treated with metronidazole tablets USP in cases of reinfection. Amebiasis Metronidazole tablets USP are indicated in the treatment of acute intestinal amebiasis (amebic dysentery) and amebic liver abscess. In amebic liver abscess, metronidazole tablet therapy does not obviate the need for aspiration or drainage of pus. Anaerobic Bacterial Infections Metronidazole tablets USP are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Indicated surgical procedures should be performed in conjunction with metronidazole tablet therapy. In a mixed aerobic and anaerobic infection, antimicrobials appropriate for the treatment of the aerobic infection should be used in addition to metronidazole tablets USP. INTRA-ABDOMINAL INFECTIONS, including peritonitis, intra-abdominal abscess, and liver abscess, caused by Bacteroides species including the B. fragilis group (B. fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron, B. vulgatus), Clostridium species, Eubacterium species, Peptococcus species, and Peptostreptococcus species. SKIN AND SKIN STRUCTURE INFECTIONS caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus species, Peptostreptococcus species, and Fusobacterium species. GYNECOLOGIC INFECTIONS, including endometritis, endomyometritis, tubo-ovarian abscess, and postsurgical vaginal cuff infection, caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus species, Peptostreptococcus species, and Fusobacterium species. BACTERIAL SEPTICEMIA caused by Bacteroides species including the B. fragilis group and Clostridium species. BONE AND JOINT INFECTIONS, (as adjunctive therapy), caused by Bacteroides species including the B. fragilis group. CENTRAL NERVOUS SYSTEM (CNS) INFECTIONS, including meningitis and brain abscess, caused by Bacteroides species including the B. fragilis group. LOWER RESPIRATORY TRACT INFECTIONS, including pneumonia, empyema, and lung abscess, caused by Bacteroides species including the B. fragilis group. ENDOCARDITIS caused by Bacteroides species including the B. fragilis group. To reduce the development of drug-resistant bacteria and maintain the effectiveness of metronidazole tablets USP and other antibacterial drugs, metronidazole tablets USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:60bb63eb-6206-41cf-8d70-4dd996e6e733 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31932 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:36738fce-0e68-4c0a-a2a7-87a3b67d2ad0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e1ec7fc5-1ae6-47e9-8eb8-b34acfec7180"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Olmesartan medoxomil is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with olmesartan medoxomil. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. It may be used alone or in combination with other antihypertensive agents. uuid:cde07477-9fdd-459e-adbd-d8ed256b8e1c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31932 biolink:treats HP:0001681 PMID:41385096 "[{""id"":""uuid:de13c2e4-0670-4714-a4cd-1fdd1bf34997"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a88896ed-b20f-4288-aaf6-60d972ced646"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Olmesartan medoxomil is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with olmesartan medoxomil. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. It may be used alone or in combination with other antihypertensive agents. uuid:ec1253aa-087a-4b7c-9c65-b55227eb266a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:40009 biolink:treats MONDO:0018076 PMID:41385096 "[{""id"":""uuid:abf256f6-22d4-45ee-90d9-5613fb748b8c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c76a6b12-8847-4f48-92a3-cb55276f0afe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cycloserine is indicated in the treatment of active pulmonary and extrapulmonary tuberculosis (including renal disease) when the causative organisms are susceptible to this drug and when treatment with the primary medications (streptomycin, isoniazid, rifampin, and ethambutol) has proved inadequate. Like all antituberculosis drugs, cycloserine should be administered in conjunction with other effective chemotherapy and not as the sole therapeutic agent. Cycloserine may be effective in the treatment of acute urinary tract infections caused by susceptible strains of gram–positive and gram–negative bacteria, especially Enterobacter spp. and Escherichia coli. It is generally no more and is usually less effective than other antimicrobial agents in the treatment of urinary tract infections caused by bacteria other than mycobacteria. Use of cycloserine in these infections should be considered only when more conventional therapy has failed and when the organism has been demonstrated to be susceptible to the drug. uuid:e74db502-f931-44da-a0d7-78678368c45f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:40009 biolink:treats MONDO:0005240 PMID:41385096 "[{""id"":""uuid:3b1d3125-9457-4adf-80be-cc4b82ac5b7f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9da0b851-18e3-4722-9266-902cca4261de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cycloserine is indicated in the treatment of active pulmonary and extrapulmonary tuberculosis (including renal disease) when the causative organisms are susceptible to this drug and when treatment with the primary medications (streptomycin, isoniazid, rifampin, and ethambutol) has proved inadequate. Like all antituberculosis drugs, cycloserine should be administered in conjunction with other effective chemotherapy and not as the sole therapeutic agent. Cycloserine may be effective in the treatment of acute urinary tract infections caused by susceptible strains of gram–positive and gram–negative bacteria, especially Enterobacter spp. and Escherichia coli. It is generally no more and is usually less effective than other antimicrobial agents in the treatment of urinary tract infections caused by bacteria other than mycobacteria. Use of cycloserine in these infections should be considered only when more conventional therapy has failed and when the organism has been demonstrated to be susceptible to the drug. uuid:15a7bf8c-2009-40a8-91eb-bde5d0fedbb9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:40009 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:8dd1ecc8-ba8e-49c9-b8cf-ebe4b2f5de8c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0a581d03-a452-4363-bc41-ef74e21bb249"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cycloserine is indicated in the treatment of active pulmonary and extrapulmonary tuberculosis (including renal disease) when the causative organisms are susceptible to this drug and when treatment with the primary medications (streptomycin, isoniazid, rifampin, and ethambutol) has proved inadequate. Like all antituberculosis drugs, cycloserine should be administered in conjunction with other effective chemotherapy and not as the sole therapeutic agent. Cycloserine may be effective in the treatment of acute urinary tract infections caused by susceptible strains of gram–positive and gram–negative bacteria, especially Enterobacter spp. and Escherichia coli. It is generally no more and is usually less effective than other antimicrobial agents in the treatment of urinary tract infections caused by bacteria other than mycobacteria. Use of cycloserine in these infections should be considered only when more conventional therapy has failed and when the organism has been demonstrated to be susceptible to the drug. uuid:cf840fd2-560a-4ec3-99a5-29fbd88af6f4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:46878853 biolink:treats MONDO:0037748 PMID:41385096 "[{""id"":""uuid:16c0f64b-e773-40ee-bc60-b20e25a1a03a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:af23390f-9985-4158-8423-d9797a589618"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Treatment of Hypercholesterolemia Fenofibrate capsules, USP are indicated as adjunctive therapy to diet for the reduction of LDLC, total-C, Triglycerides and apo B in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb). Lipid altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and non-pharmacological interventions alone has been inadequate (see National Cholesterol Education Program [NCEP] Treatment Guidelines , below). Treatment of Hypertriglyceridemia Fenofibrate capsules, USP are also indicated as adjunctive therapy to diet for treatment of adult patients with hypertriglyceridemia (Fredrickson Types IV and V hyperlipidemia). Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually reduce fasting triglycerides and eliminate chylomicronemia thereby obviating the need for pharmacologic intervention. Markedly elevated levels of serum triglycerides (e.g. > 2,000 mg/dL) may increase the risk of developing pancreatitis. The effect of fenofibrate therapy on reducing this risk has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of very low density lipoprotein (VLDL). Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV and V hyperlipoproteinemia 2 . The initial treatment for dyslipidemia is dietary therapy specific for the type of lipoprotein abnormality. Excess body weight and excess alcoholic intake may be important factors in hypertriglyceridemia and should be addressed prior to any drug therapy. Physical exercise can be an important ancillary measure. Diseases contributory to hyperlipidemia, such as hypothyroidism or diabetes mellitus should be looked for and adequately treated. Estrogen therapy, like thiazide diuretics and beta-blockers, is sometimes associated with massive rises in plasma triglycerides, especially in subjects with familial hypertriglyceridemia. In such cases, discontinuation of the specific etiologic agent may obviate the need for specific drug therapy of hypertriglyceridemia. The use of drugs should be considered only when reasonable attempts have been made to obtain satisfactory results with non-drug methods. If the decision is made to use drugs, the patient should be instructed that this does not reduce the importance of adhering to diet (See WARNINGS and PRECAUTIONS ). Fredrickson Classification of Hyperlipoproteinemias C = cholesterol TG = triglycerides LDL = low density lipoprotein VLDL = very lot density lipoprotein IDL = intermediate density lipoprotein Lipid Elevation Type Lipoprotein Elevated Major Minor I (rare) IIa IIb III (rare) IV V (rare) Chylomicrons LDL LDL, VLDL IDL VLDL Chylomicrons, VLDL TG C C C, TG TG TG ↑ ↔ C - TG - ↑ ↔ C ↑ ↔ The NCEP Treatment Guidelines Definite Atherosclerotic Two or More Other LDL-Cholesterol mg/dL (mmol/L) Disease Coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease). Risk Factors Other risk factors for coronary heart disease (CHD) include: age (males: ≥ 45 years; females: ≥ 55 years or premature menopause without estrogen replacement therapy); family history of premature CHD; current cigarette smoking; hypertension; confirmed HDL-C < 35 mg/dL (< 0.91 mmol/L); and diabetes mellitus. Subtract I risk favor if HDL-C is ≥ 60 mg/dL (≥ 1.6 mmol/L) Initiation Level Goal No No Yes No Yes Yes or No ≥ 190 (≥ 4.9) ≥ 160 (≥ 4.1) ≥ 130 In CHD patients with LDL-C levels 100 to 129 mg/dL, the physician should exercise clinical judgment in deciding whether to initiate drug treatment. (≥ 3.4) < 160 (< 4.1) < 130 (< 3.4) < 100 (< 2.6) uuid:9c33e03a-602e-498f-96ca-c322e9489407 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:46878853 biolink:treats MONDO:0005311 PMID:41385096 "[{""id"":""uuid:a6da8c4c-40cb-4bb4-88c6-a509a64baeb7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6f7276df-4b13-4b3f-9fab-2a0893546836"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Treatment of Hypercholesterolemia Fenofibrate capsules, USP are indicated as adjunctive therapy to diet for the reduction of LDLC, total-C, Triglycerides and apo B in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb). Lipid altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and non-pharmacological interventions alone has been inadequate (see National Cholesterol Education Program [NCEP] Treatment Guidelines , below). Treatment of Hypertriglyceridemia Fenofibrate capsules, USP are also indicated as adjunctive therapy to diet for treatment of adult patients with hypertriglyceridemia (Fredrickson Types IV and V hyperlipidemia). Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually reduce fasting triglycerides and eliminate chylomicronemia thereby obviating the need for pharmacologic intervention. Markedly elevated levels of serum triglycerides (e.g. > 2,000 mg/dL) may increase the risk of developing pancreatitis. The effect of fenofibrate therapy on reducing this risk has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of very low density lipoprotein (VLDL). Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV and V hyperlipoproteinemia 2 . The initial treatment for dyslipidemia is dietary therapy specific for the type of lipoprotein abnormality. Excess body weight and excess alcoholic intake may be important factors in hypertriglyceridemia and should be addressed prior to any drug therapy. Physical exercise can be an important ancillary measure. Diseases contributory to hyperlipidemia, such as hypothyroidism or diabetes mellitus should be looked for and adequately treated. Estrogen therapy, like thiazide diuretics and beta-blockers, is sometimes associated with massive rises in plasma triglycerides, especially in subjects with familial hypertriglyceridemia. In such cases, discontinuation of the specific etiologic agent may obviate the need for specific drug therapy of hypertriglyceridemia. The use of drugs should be considered only when reasonable attempts have been made to obtain satisfactory results with non-drug methods. If the decision is made to use drugs, the patient should be instructed that this does not reduce the importance of adhering to diet (See WARNINGS and PRECAUTIONS ). Fredrickson Classification of Hyperlipoproteinemias C = cholesterol TG = triglycerides LDL = low density lipoprotein VLDL = very lot density lipoprotein IDL = intermediate density lipoprotein Lipid Elevation Type Lipoprotein Elevated Major Minor I (rare) IIa IIb III (rare) IV V (rare) Chylomicrons LDL LDL, VLDL IDL VLDL Chylomicrons, VLDL TG C C C, TG TG TG ↑ ↔ C - TG - ↑ ↔ C ↑ ↔ The NCEP Treatment Guidelines Definite Atherosclerotic Two or More Other LDL-Cholesterol mg/dL (mmol/L) Disease Coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease). Risk Factors Other risk factors for coronary heart disease (CHD) include: age (males: ≥ 45 years; females: ≥ 55 years or premature menopause without estrogen replacement therapy); family history of premature CHD; current cigarette smoking; hypertension; confirmed HDL-C < 35 mg/dL (< 0.91 mmol/L); and diabetes mellitus. Subtract I risk favor if HDL-C is ≥ 60 mg/dL (≥ 1.6 mmol/L) Initiation Level Goal No No Yes No Yes Yes or No ≥ 190 (≥ 4.9) ≥ 160 (≥ 4.1) ≥ 130 In CHD patients with LDL-C levels 100 to 129 mg/dL, the physician should exercise clinical judgment in deciding whether to initiate drug treatment. (≥ 3.4) < 160 (< 4.1) < 130 (< 3.4) < 100 (< 2.6) uuid:94647352-be3b-4b31-ac29-28d820acbec1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:E3B2GI648A biolink:treats UMLS:C0345468 PMID:41385096 "[{""id"":""uuid:05cbf959-db28-4f78-98b3-8423af864c48"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c2c07f02-18b4-4192-bf4b-e0ee0c483a91"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] • NULOJIX is a selective T cell costimulation blocker indicated for prophylaxis of organ rejection in adult patients receiving a kidney transplant. (1.1) • Use in combination with basiliximab induction, mycophenolate mofetil, and corticosteroids. (1.1) Limitations of Use : • Use only in patients who are EBV seropositive. (1.2 , 4 , 5.1) • Use has not been established for the prophylaxis of organ rejection in transplanted organs other than the kidney. (1.2 , 5.6) uuid:e4fb0f10-402f-4428-8ae3-77adff598884 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7447 biolink:treats MONDO:0005644 PMID:41385096 "[{""id"":""uuid:f42bc11e-fbc3-45d9-8e4e-8f8a8f8c5ea5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a57fe406-ca41-45a8-b46b-67ac98ed55e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nafcillin is indicated in the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug. Culture and susceptibility tests should be performed initially to determine the causative organism and its susceptibility to the drug (see CLINICAL PHARMACOLOGY- Susceptibility Test Methods ). Nafcillin should not be used in infections caused by organisms susceptible to penicillin G. If the susceptibility tests indicate that the infection is due to methicillin-resistant Staphylococcus sp., therapy with Nafcillin for Injection, USP should be discontinued and alternative therapy provided. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Nafcillin for Injection, USP and other antibacterial drugs, Nafcillin for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:7bb2c570-dcbb-43cd-869d-f4204a0ecaa8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9241 biolink:treats MONDO:0017871 PMID:41385096 "[{""id"":""uuid:a9c7e7ba-3076-4a6e-8362-de9f7ccd6f21"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:76d6038f-6217-454c-ac75-09c4a6b869b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Spironolactone tablets are an aldosterone antagonist indicated for: • The treatment of NYHA Class III-IV heart failure and reduced ejection fraction to increase survival, manage edema, and to reduce the need for hospitalization for heart failure ( 1.1 ). • Use as an add-on therapy for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.2 ). • The management of edema in adult patients who are cirrhotic when edema is not responsive to fluid and sodium restrictions and in the setting of nephrotic syndrome when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics produce an inadequate response ( 1.3 ). • Treatment of primary hyperaldosternism for: ( 1.4 ). • Short-term preoperative treatment • Long-term maintenance for patients with discrete aldosterone-producing adrenal adenomas who are not candidates for surgery and patients with bilateral micro or macronodular adrenal hyperplasia uuid:019e121f-1001-494d-b953-d11e72f83511 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:50FKX8CB2Y biolink:treats MONDO:0007100 PMID:41385096 "[{""id"":""uuid:b21210f7-9310-4346-bb7a-2427048e2b49"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2d9fc822-406f-4454-92ab-0af9ecdbe388"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c2957d0e-8b5b-4194-8cde-bddcab82b22c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f5f173ca-df1b-4f4e-aa80-de1059835b30"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ONPATTRO is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.|[EMA] Onpattro is indicated for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy.|[PMDA] A drug with a new active ingredient indicated for the treatment of transthyretin familial amyloid polyneuropathy. [Orphan drug] uuid:752517b1-c220-4f9e-bf11-44ad67c964de biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6970 biolink:treats EFO:1002029 PMID:41385096 "[{""id"":""uuid:8637541f-f194-4002-a77a-7dc55dbee63d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b88b00b3-baeb-4d86-b454-12baa2a31147"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SINUVA Sinus Implant is indicated for the treatment of chronic rhinosinusitis with nasal polyps in adult patients ≥18 years of age who have had ethmoid sinus surgery. uuid:78a603d9-7e10-42b3-bfd1-190517cdfd61 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:997b3595-5a38-4ebd-bf7e-ef0b08dad609"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b1ec7b70-18cc-4914-b340-5484f33a1fa3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Duloxetine delayed-release capsule is a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the treatment of the following conditions: Major depressive disorder (MDD) in adults ( 1 ) Generalized anxiety disorder (GAD) in adults and pediatric patients 7 years of age and older ( 1 ) Diabetic peripheral neuropathic Pain (DPNP) in adults ( 1 ) Fibromyalgia (FM) in adults ( 1 ) Chronic musculoskeletal pain in adults ( 1 ) uuid:0884c700-89c8-4363-8725-9f71b7441453 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0001942 PMID:41385096 "[{""id"":""uuid:b0a8d643-6237-45b7-8197-e92a2fb93eaa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4acbf3b7-32c9-4984-92a4-1f2fc63ad17f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Duloxetine delayed-release capsule is a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the treatment of the following conditions: Major depressive disorder (MDD) in adults ( 1 ) Generalized anxiety disorder (GAD) in adults and pediatric patients 7 years of age and older ( 1 ) Diabetic peripheral neuropathic Pain (DPNP) in adults ( 1 ) Fibromyalgia (FM) in adults ( 1 ) Chronic musculoskeletal pain in adults ( 1 ) uuid:2ffacab6-fe0c-4df3-b766-7f1f25e8dc8c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats UMLS:C1963916 PMID:41385096 "[{""id"":""uuid:14cb6df2-8f52-4326-a4b5-3969753b969b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1b391a59-f9b2-485b-8db0-6148ad50e44a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Duloxetine delayed-release capsule is a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the treatment of the following conditions: Major depressive disorder (MDD) in adults ( 1 ) Generalized anxiety disorder (GAD) in adults and pediatric patients 7 years of age and older ( 1 ) Diabetic peripheral neuropathic Pain (DPNP) in adults ( 1 ) Fibromyalgia (FM) in adults ( 1 ) Chronic musculoskeletal pain in adults ( 1 ) uuid:38b8bb7e-278c-4af6-a86e-5a84b7aa3e2b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0005546 PMID:41385096 "[{""id"":""uuid:6628cfea-221f-4a08-956a-f014412ace71"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:25900fe7-ecec-43a6-bf0a-2d07e6b403c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Duloxetine delayed-release capsule is a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the treatment of the following conditions: Major depressive disorder (MDD) in adults ( 1 ) Generalized anxiety disorder (GAD) in adults and pediatric patients 7 years of age and older ( 1 ) Diabetic peripheral neuropathic Pain (DPNP) in adults ( 1 ) Fibromyalgia (FM) in adults ( 1 ) Chronic musculoskeletal pain in adults ( 1 ) uuid:466c4301-791d-4218-b270-8f0fb64b7236 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats UMLS:C0746683 PMID:41385096 "[{""id"":""uuid:b13b744d-211f-4d5c-94ad-ed9613ca4a68"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cd9c926e-c585-4722-8192-c2c2bf6d6f06"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Duloxetine delayed-release capsule is a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the treatment of the following conditions: Major depressive disorder (MDD) in adults ( 1 ) Generalized anxiety disorder (GAD) in adults and pediatric patients 7 years of age and older ( 1 ) Diabetic peripheral neuropathic Pain (DPNP) in adults ( 1 ) Fibromyalgia (FM) in adults ( 1 ) Chronic musculoskeletal pain in adults ( 1 ) uuid:92adaff4-c074-436e-9bcc-89ad88b2bf5d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6931 biolink:treats MONDO:0002125 PMID:41385096 "[{""id"":""uuid:6b3fac3e-eb15-4162-9271-96bd9df67bdd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7fd94f74-088d-4194-bdee-4ea392ac2223"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c91fc702-94d9-4878-8bec-afc3889a8ffe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SEIZALAM is indicated for the treatment of status epilepticus in adults.|[PMDA] A drug with a new additional indication and a new dosage in an additional dosage form indicated for the treatment of status epilepticus. uuid:fa74e096-f6ed-4459-b677-bc709ae181b9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6931 biolink:treats MONDO:0005027 PMID:41385096 "[{""id"":""uuid:c2fdac53-2531-435a-b960-8d60207032f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:e825f421-26ab-4ae4-8724-a7e3ee7092c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:a0e57684-c8b3-4881-a6c2-a014fb587467"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/buccolam""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] NAYZILAM is indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern in patients with epilepsy 12 years of age and older.|[EMA] Treatment of prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents (from three months to less than 18 years).Buccolam must only be used by parents / carers where the patient has been diagnosed to have epilepsy.For infants between three and six months of age, treatment should be in a hospital setting where monitoring is possible and resuscitation equipment is available. uuid:9b40ca7c-caf2-42a6-a6e3-cad815f828a8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6931 biolink:treats UMLS:C3203523 PMID:41385096 "[{""id"":""uuid:f4f93e6d-e54d-4818-afc5-c6986a8bbf3f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dd50f833-e6f1-4532-ab16-e8328e350bc6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NAYZILAM is indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern in patients with epilepsy 12 years of age and older. uuid:dc961a7a-e5a6-4217-8389-e744dd29ec52 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6472 biolink:treats MONDO:0021680 PMID:41385096 "[{""id"":""uuid:2691fdeb-4892-4620-902c-fa91e668f32f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:16162add-7199-42e4-a1e5-500397ea00b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lincomycin Injection sterile solution is indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of CDAD, as described in the BOXED WARNING , before selecting lincomycin the physician should consider the nature of the infection and the suitability of other alternatives. Indicated surgical procedures should be performed in conjunction with antibacterial therapy. Lincomycin Injection may be administered concomitantly with other antimicrobial agents when indicated. Lincomycin Injection is not indicated in the treatment of minor bacterial infections or viral infections. To reduce the development of drug-resistant bacteria and maintain the effectiveness of lincomycin injection and other antibacterial drugs, lincomycin injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:ce410932-c1ed-473b-a1fd-e25cab6a012b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6472 biolink:treats MONDO:0005114 PMID:41385096 "[{""id"":""uuid:6e86a280-fdec-498c-b73b-ff3d86d46a73"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a91e92eb-5067-4b58-a25e-f3d3317b9325"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lincomycin Injection sterile solution is indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of CDAD, as described in the BOXED WARNING , before selecting lincomycin the physician should consider the nature of the infection and the suitability of other alternatives. Indicated surgical procedures should be performed in conjunction with antibacterial therapy. Lincomycin Injection may be administered concomitantly with other antimicrobial agents when indicated. Lincomycin Injection is not indicated in the treatment of minor bacterial infections or viral infections. To reduce the development of drug-resistant bacteria and maintain the effectiveness of lincomycin injection and other antibacterial drugs, lincomycin injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:7fde0190-270c-42e2-b5d3-dd3b9efa3051 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6472 biolink:treats MONDO:0024313 PMID:41385096 "[{""id"":""uuid:d79bdda7-7824-46ca-b7b7-7a0768fa173d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9790afb0-219b-43f4-ad36-19eff4598a05"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lincomycin Injection sterile solution is indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of CDAD, as described in the BOXED WARNING , before selecting lincomycin the physician should consider the nature of the infection and the suitability of other alternatives. Indicated surgical procedures should be performed in conjunction with antibacterial therapy. Lincomycin Injection may be administered concomitantly with other antimicrobial agents when indicated. Lincomycin Injection is not indicated in the treatment of minor bacterial infections or viral infections. To reduce the development of drug-resistant bacteria and maintain the effectiveness of lincomycin injection and other antibacterial drugs, lincomycin injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:ae3aa3df-9d8b-48c0-9fe8-ef57d2b0bf65 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:70707 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:77f16228-9a63-4dbc-a05d-3cfae2d7279f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3f4223b1-ee05-4086-918e-288f1e3765b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vilazodone hydrochloride tablets are indicated for the treatment of major depressive disorder (MDD) in adults [see Clinical Studies (14)]. uuid:35280e30-f6a9-43aa-bb35-3e1c6e126d95 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:11672431 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:711df8d2-7353-42fe-b01c-fece746aa612"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f48772c5-89a9-4ea0-b8c3-f64cce94b484"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Telmisartan and amlodipine tablets are indicated for the treatment of hypertension, alone or with other antihypertensive agents to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including angiotensin II receptor blockers and dihydropyridine calcium channel blockers. There are no controlled trials demonstrating risk reduction with telmisartan and amlodipine tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Telmisartan and amlodipine tablets may also be used as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals. Base the choice of telmisartan and amlodipine tablets as initial therapy for hypertension on an assessment of potential benefits and risks including whether the patient is likely to tolerate the starting dose of telmisartan and amlodipine tablets. Patients with moderate or severe hypertension are at relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. Consider the patient’s baseline blood pressure, the target goal, and the incremental likelihood of achieving goal with a combination compared with monotherapy when deciding whether to use telmisartan and amlodipine tablets as initial therapy. Individual blood pressure goals may vary based upon the patient’s risk. Data from an 8-week, placebo-controlled, multidose, factorial trial provide estimates of the probability of reaching a blood pressure goal with telmisartan and amlodipine tablets compared to telmisartan or amlodipine monotherapy and placebo [see Clinical Studies (14.1)] . The figures below provide estimates of the likelihood of achieving systolic and diastolic blood pressure control with telmisartan and amlodipine 80/10 mg tablets, based upon baseline systolic or diastolic blood pressure. The curve of each treatment group was estimated by logistic regression modeling. The estimated likelihood at the right tail of each curve is less reliable due to small numbers of subjects with high baseline blood pressures. The figures above provide an approximation of the likelihood of reaching a targeted blood pressure goal at 8 weeks. For example, a patient with a baseline blood pressure of 160/110 mmHg has about a 16% likelihood of achieving a goal of <140 mmHg (systolic) and 16% likelihood of achieving <90 mmHg (diastolic) on placebo. The likelihood of achieving these same goals on telmisartan is about 46% (systolic) and 26% (diastolic). The likelihood of achieving these same goals on amlodipine is about 69% (systolic) and 22% (diastolic). These likelihoods rise to 79% for systolic and 55% for diastolic with telmisartan and amlodipine tablets. uuid:5decc5be-c1ab-49d8-9975-099df86efe5e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:11672431 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:8a7d1da2-44dc-40d3-9d81-cd919318c697"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eb3ea4e2-8120-4cb6-8257-e4f2b633b3f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Telmisartan and amlodipine tablets are indicated for the treatment of hypertension, alone or with other antihypertensive agents to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including angiotensin II receptor blockers and dihydropyridine calcium channel blockers. There are no controlled trials demonstrating risk reduction with telmisartan and amlodipine tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Telmisartan and amlodipine tablets may also be used as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals. Base the choice of telmisartan and amlodipine tablets as initial therapy for hypertension on an assessment of potential benefits and risks including whether the patient is likely to tolerate the starting dose of telmisartan and amlodipine tablets. Patients with moderate or severe hypertension are at relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. Consider the patient’s baseline blood pressure, the target goal, and the incremental likelihood of achieving goal with a combination compared with monotherapy when deciding whether to use telmisartan and amlodipine tablets as initial therapy. Individual blood pressure goals may vary based upon the patient’s risk. Data from an 8-week, placebo-controlled, multidose, factorial trial provide estimates of the probability of reaching a blood pressure goal with telmisartan and amlodipine tablets compared to telmisartan or amlodipine monotherapy and placebo [see Clinical Studies (14.1)] . The figures below provide estimates of the likelihood of achieving systolic and diastolic blood pressure control with telmisartan and amlodipine 80/10 mg tablets, based upon baseline systolic or diastolic blood pressure. The curve of each treatment group was estimated by logistic regression modeling. The estimated likelihood at the right tail of each curve is less reliable due to small numbers of subjects with high baseline blood pressures. The figures above provide an approximation of the likelihood of reaching a targeted blood pressure goal at 8 weeks. For example, a patient with a baseline blood pressure of 160/110 mmHg has about a 16% likelihood of achieving a goal of <140 mmHg (systolic) and 16% likelihood of achieving <90 mmHg (diastolic) on placebo. The likelihood of achieving these same goals on telmisartan is about 46% (systolic) and 26% (diastolic). The likelihood of achieving these same goals on amlodipine is about 69% (systolic) and 22% (diastolic). These likelihoods rise to 79% for systolic and 55% for diastolic with telmisartan and amlodipine tablets. uuid:d9462366-2deb-408f-be15-4c9714615c48 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:11672431 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:0693dd5e-38c9-41da-9e71-ca91a6109eed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:50d1c0ce-ee00-4124-8716-c1d1bbcd2d08"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Telmisartan and amlodipine tablets are indicated for the treatment of hypertension, alone or with other antihypertensive agents to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including angiotensin II receptor blockers and dihydropyridine calcium channel blockers. There are no controlled trials demonstrating risk reduction with telmisartan and amlodipine tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Telmisartan and amlodipine tablets may also be used as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals. Base the choice of telmisartan and amlodipine tablets as initial therapy for hypertension on an assessment of potential benefits and risks including whether the patient is likely to tolerate the starting dose of telmisartan and amlodipine tablets. Patients with moderate or severe hypertension are at relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. Consider the patient’s baseline blood pressure, the target goal, and the incremental likelihood of achieving goal with a combination compared with monotherapy when deciding whether to use telmisartan and amlodipine tablets as initial therapy. Individual blood pressure goals may vary based upon the patient’s risk. Data from an 8-week, placebo-controlled, multidose, factorial trial provide estimates of the probability of reaching a blood pressure goal with telmisartan and amlodipine tablets compared to telmisartan or amlodipine monotherapy and placebo [see Clinical Studies (14.1)] . The figures below provide estimates of the likelihood of achieving systolic and diastolic blood pressure control with telmisartan and amlodipine 80/10 mg tablets, based upon baseline systolic or diastolic blood pressure. The curve of each treatment group was estimated by logistic regression modeling. The estimated likelihood at the right tail of each curve is less reliable due to small numbers of subjects with high baseline blood pressures. The figures above provide an approximation of the likelihood of reaching a targeted blood pressure goal at 8 weeks. For example, a patient with a baseline blood pressure of 160/110 mmHg has about a 16% likelihood of achieving a goal of <140 mmHg (systolic) and 16% likelihood of achieving <90 mmHg (diastolic) on placebo. The likelihood of achieving these same goals on telmisartan is about 46% (systolic) and 26% (diastolic). The likelihood of achieving these same goals on amlodipine is about 69% (systolic) and 22% (diastolic). These likelihoods rise to 79% for systolic and 55% for diastolic with telmisartan and amlodipine tablets. uuid:3da35d4e-047a-46fb-b2bf-513e7fe294f3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:11672431 biolink:treats HP:0001681 PMID:41385096 "[{""id"":""uuid:8c815295-9e4c-4548-bafe-d231c8cfd004"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:212f3001-b153-4b88-b0a0-85e886dcb166"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Telmisartan and amlodipine tablets are indicated for the treatment of hypertension, alone or with other antihypertensive agents to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including angiotensin II receptor blockers and dihydropyridine calcium channel blockers. There are no controlled trials demonstrating risk reduction with telmisartan and amlodipine tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Telmisartan and amlodipine tablets may also be used as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals. Base the choice of telmisartan and amlodipine tablets as initial therapy for hypertension on an assessment of potential benefits and risks including whether the patient is likely to tolerate the starting dose of telmisartan and amlodipine tablets. Patients with moderate or severe hypertension are at relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. Consider the patient’s baseline blood pressure, the target goal, and the incremental likelihood of achieving goal with a combination compared with monotherapy when deciding whether to use telmisartan and amlodipine tablets as initial therapy. Individual blood pressure goals may vary based upon the patient’s risk. Data from an 8-week, placebo-controlled, multidose, factorial trial provide estimates of the probability of reaching a blood pressure goal with telmisartan and amlodipine tablets compared to telmisartan or amlodipine monotherapy and placebo [see Clinical Studies (14.1)] . The figures below provide estimates of the likelihood of achieving systolic and diastolic blood pressure control with telmisartan and amlodipine 80/10 mg tablets, based upon baseline systolic or diastolic blood pressure. The curve of each treatment group was estimated by logistic regression modeling. The estimated likelihood at the right tail of each curve is less reliable due to small numbers of subjects with high baseline blood pressures. The figures above provide an approximation of the likelihood of reaching a targeted blood pressure goal at 8 weeks. For example, a patient with a baseline blood pressure of 160/110 mmHg has about a 16% likelihood of achieving a goal of <140 mmHg (systolic) and 16% likelihood of achieving <90 mmHg (diastolic) on placebo. The likelihood of achieving these same goals on telmisartan is about 46% (systolic) and 26% (diastolic). The likelihood of achieving these same goals on amlodipine is about 69% (systolic) and 22% (diastolic). These likelihoods rise to 79% for systolic and 55% for diastolic with telmisartan and amlodipine tablets. uuid:5df5bcb6-db89-47a5-b279-242b099a9fd5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:11672431 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:99cc5bee-621c-4e2d-9ac3-ae60d28d49d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a3c74d46-0186-4a5b-99d1-07ee8a3b3106"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Telmisartan and amlodipine tablets are indicated for the treatment of hypertension, alone or with other antihypertensive agents to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including angiotensin II receptor blockers and dihydropyridine calcium channel blockers. There are no controlled trials demonstrating risk reduction with telmisartan and amlodipine tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Telmisartan and amlodipine tablets may also be used as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals. Base the choice of telmisartan and amlodipine tablets as initial therapy for hypertension on an assessment of potential benefits and risks including whether the patient is likely to tolerate the starting dose of telmisartan and amlodipine tablets. Patients with moderate or severe hypertension are at relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. Consider the patient’s baseline blood pressure, the target goal, and the incremental likelihood of achieving goal with a combination compared with monotherapy when deciding whether to use telmisartan and amlodipine tablets as initial therapy. Individual blood pressure goals may vary based upon the patient’s risk. Data from an 8-week, placebo-controlled, multidose, factorial trial provide estimates of the probability of reaching a blood pressure goal with telmisartan and amlodipine tablets compared to telmisartan or amlodipine monotherapy and placebo [see Clinical Studies (14.1)] . The figures below provide estimates of the likelihood of achieving systolic and diastolic blood pressure control with telmisartan and amlodipine 80/10 mg tablets, based upon baseline systolic or diastolic blood pressure. The curve of each treatment group was estimated by logistic regression modeling. The estimated likelihood at the right tail of each curve is less reliable due to small numbers of subjects with high baseline blood pressures. The figures above provide an approximation of the likelihood of reaching a targeted blood pressure goal at 8 weeks. For example, a patient with a baseline blood pressure of 160/110 mmHg has about a 16% likelihood of achieving a goal of <140 mmHg (systolic) and 16% likelihood of achieving <90 mmHg (diastolic) on placebo. The likelihood of achieving these same goals on telmisartan is about 46% (systolic) and 26% (diastolic). The likelihood of achieving these same goals on amlodipine is about 69% (systolic) and 22% (diastolic). These likelihoods rise to 79% for systolic and 55% for diastolic with telmisartan and amlodipine tablets. uuid:db09c640-9e8f-4dbb-9b33-85b021b17ed8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:11672431 biolink:treats MONDO:0005016 PMID:41385096 "[{""id"":""uuid:1ae67de1-1649-4d65-a3b4-f133a4b27f5c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7f7cd68e-6b62-42e5-98eb-c80d2e0fde77"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Telmisartan and amlodipine tablets are indicated for the treatment of hypertension, alone or with other antihypertensive agents to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including angiotensin II receptor blockers and dihydropyridine calcium channel blockers. There are no controlled trials demonstrating risk reduction with telmisartan and amlodipine tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Telmisartan and amlodipine tablets may also be used as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals. Base the choice of telmisartan and amlodipine tablets as initial therapy for hypertension on an assessment of potential benefits and risks including whether the patient is likely to tolerate the starting dose of telmisartan and amlodipine tablets. Patients with moderate or severe hypertension are at relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. Consider the patient’s baseline blood pressure, the target goal, and the incremental likelihood of achieving goal with a combination compared with monotherapy when deciding whether to use telmisartan and amlodipine tablets as initial therapy. Individual blood pressure goals may vary based upon the patient’s risk. Data from an 8-week, placebo-controlled, multidose, factorial trial provide estimates of the probability of reaching a blood pressure goal with telmisartan and amlodipine tablets compared to telmisartan or amlodipine monotherapy and placebo [see Clinical Studies (14.1)] . The figures below provide estimates of the likelihood of achieving systolic and diastolic blood pressure control with telmisartan and amlodipine 80/10 mg tablets, based upon baseline systolic or diastolic blood pressure. The curve of each treatment group was estimated by logistic regression modeling. The estimated likelihood at the right tail of each curve is less reliable due to small numbers of subjects with high baseline blood pressures. The figures above provide an approximation of the likelihood of reaching a targeted blood pressure goal at 8 weeks. For example, a patient with a baseline blood pressure of 160/110 mmHg has about a 16% likelihood of achieving a goal of <140 mmHg (systolic) and 16% likelihood of achieving <90 mmHg (diastolic) on placebo. The likelihood of achieving these same goals on telmisartan is about 46% (systolic) and 26% (diastolic). The likelihood of achieving these same goals on amlodipine is about 69% (systolic) and 22% (diastolic). These likelihoods rise to 79% for systolic and 55% for diastolic with telmisartan and amlodipine tablets. uuid:7e37f7a5-5c0a-4b09-af44-cc31dd975984 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:11672431 biolink:treats MONDO:0001106 PMID:41385096 "[{""id"":""uuid:1c447e29-3e07-43d5-a4d7-478bf9889778"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:90352caf-49a1-47e3-865c-9c626b4edf92"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Telmisartan and amlodipine tablets are indicated for the treatment of hypertension, alone or with other antihypertensive agents to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including angiotensin II receptor blockers and dihydropyridine calcium channel blockers. There are no controlled trials demonstrating risk reduction with telmisartan and amlodipine tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Telmisartan and amlodipine tablets may also be used as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals. Base the choice of telmisartan and amlodipine tablets as initial therapy for hypertension on an assessment of potential benefits and risks including whether the patient is likely to tolerate the starting dose of telmisartan and amlodipine tablets. Patients with moderate or severe hypertension are at relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. Consider the patient’s baseline blood pressure, the target goal, and the incremental likelihood of achieving goal with a combination compared with monotherapy when deciding whether to use telmisartan and amlodipine tablets as initial therapy. Individual blood pressure goals may vary based upon the patient’s risk. Data from an 8-week, placebo-controlled, multidose, factorial trial provide estimates of the probability of reaching a blood pressure goal with telmisartan and amlodipine tablets compared to telmisartan or amlodipine monotherapy and placebo [see Clinical Studies (14.1)] . The figures below provide estimates of the likelihood of achieving systolic and diastolic blood pressure control with telmisartan and amlodipine 80/10 mg tablets, based upon baseline systolic or diastolic blood pressure. The curve of each treatment group was estimated by logistic regression modeling. The estimated likelihood at the right tail of each curve is less reliable due to small numbers of subjects with high baseline blood pressures. The figures above provide an approximation of the likelihood of reaching a targeted blood pressure goal at 8 weeks. For example, a patient with a baseline blood pressure of 160/110 mmHg has about a 16% likelihood of achieving a goal of <140 mmHg (systolic) and 16% likelihood of achieving <90 mmHg (diastolic) on placebo. The likelihood of achieving these same goals on telmisartan is about 46% (systolic) and 26% (diastolic). The likelihood of achieving these same goals on amlodipine is about 69% (systolic) and 22% (diastolic). These likelihoods rise to 79% for systolic and 55% for diastolic with telmisartan and amlodipine tablets. uuid:ae66b995-420e-41b0-81f4-108a856ff465 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63607 biolink:treats DOID:50360 PMID:41385096 "[{""id"":""uuid:8b4b089c-643f-49dd-8ecd-a7fd102f3c2d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b913d3c6-5e92-4a0e-8d39-65de6b44f96d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Linezolid tablets are indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. Linezolid tablets are not indicated for the treatment of Gram-negative infections. It is critical that specific Gram-negative therapy be initiated immediately if a concomitant Gram-negative pathogen is documented or suspected [ see Warnings and Precautions (5.4) ]. uuid:514a8935-1c1a-4f29-879d-4acf6b56ab97 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9168 biolink:treats UMLS:C0345468 PMID:41385096 "[{""id"":""uuid:182cb09f-5972-4616-bf33-bfbdcb9dfad8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:fbb0627f-8665-4eeb-8987-f88a155106cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:bbc880f6-7812-465a-b773-6ef54d1c3c6e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/hyftor""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] • Sirolimus tablet is an mTOR inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in patients aged ≥13 years receiving renal transplants: o Patients at low-to moderate-immunologic risk: Use initially with cyclosporine (CsA) and corticosteroids. CsA withdrawal is recommended 2-4 months after transplantation ( 1.1 ). o Patients at high-immunologic risk: Use in combination with CsA and corticosteroids for the first 12 months following transplantation ( 1.1 ). Safety and efficacy of CsA withdrawal has not been established in high risk patients ( 1.1 , 1.2 , 14.3 ). • Sirolimus tablet is an mTOR inhibitor indicated for the treatment of patients with lymphangioleiomyomatosis ( 1.3 ).|[EMA] Rapamune is indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving a renal transplant. It is recommended that Rapamune be used initially in combination with ciclosporin microemulsion and corticosteroids for 2 to 3 months. Rapamune may be continued as maintenance therapy with corticosteroids only if ciclosporin microemulsion can be progressively discontinued., , Rapamune is indicated for the treatment of patients with sporadic lymphangioleiomyomatosis with moderate lung disease or declining lung function., uuid:6b96d8cf-58c0-4489-93fd-5c6f98b8ac47 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9168 biolink:treats MONDO:0011705 PMID:41385096 "[{""id"":""uuid:36f9f7b0-3368-456c-aafb-16dc3560eaa8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:093598b7-2ddb-4a14-ab4a-d0c73169bcff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:7ae30da1-1009-4196-b49f-f6121d73fdd7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/hyftor""]},{""id"":""uuid:4b214abb-7f2f-4190-9b5d-85102bd7591e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] • Sirolimus tablet is an mTOR inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in patients aged ≥13 years receiving renal transplants: o Patients at low-to moderate-immunologic risk: Use initially with cyclosporine (CsA) and corticosteroids. CsA withdrawal is recommended 2-4 months after transplantation ( 1.1 ). o Patients at high-immunologic risk: Use in combination with CsA and corticosteroids for the first 12 months following transplantation ( 1.1 ). Safety and efficacy of CsA withdrawal has not been established in high risk patients ( 1.1 , 1.2 , 14.3 ). • Sirolimus tablet is an mTOR inhibitor indicated for the treatment of patients with lymphangioleiomyomatosis ( 1.3 ).|[EMA] Rapamune is indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving a renal transplant. It is recommended that Rapamune be used initially in combination with ciclosporin microemulsion and corticosteroids for 2 to 3 months. Rapamune may be continued as maintenance therapy with corticosteroids only if ciclosporin microemulsion can be progressively discontinued., , Rapamune is indicated for the treatment of patients with sporadic lymphangioleiomyomatosis with moderate lung disease or declining lung function.,|[PMDA] A drug with a new active ingredient indicated for the treatment of lymphangioleiomyomatosis. [Orphan drug] uuid:83d90c89-b6fc-4b15-aa6a-1fad3740fbb6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49005 biolink:treats UMLS:C1739382 PMID:41385096 "[{""id"":""uuid:21cd4db1-6770-4916-8649-c0b3384b469a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:08089bee-50fe-4a5c-99c5-5d015e881576"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:169d5b0a-7112-4d16-8371-2a4676f49c4b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Deferasirox tablets are an iron chelator indicated for the treatment of chronic iron overload due to blood transfusions in patients 2 years of age and older. Limitations of Use: The safety and efficacy of deferasirox tablets when administered with other iron chelation therapy have not been established. (1.3)|[PMDA] Drugs in a new dosage form indicated for the treatment of chronic iron overload due to blood transfusions (in patients for whom injection of iron chelating agents is inappropriate). uuid:2430fd99-340d-4009-9b7e-d9e045229b14 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49005 biolink:treats UMLS:C0282193 PMID:41385096 "[{""id"":""uuid:1cd82381-16af-47c2-a91a-7319793a4a68"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e21ebb11-3bb1-4acc-ac87-4d249426065d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Deferasirox tablets are an iron chelator indicated for the treatment of chronic iron overload due to blood transfusions in patients 2 years of age and older. Limitations of Use: The safety and efficacy of deferasirox tablets when administered with other iron chelation therapy have not been established. (1.3) uuid:b3a3c94a-fe41-42ee-ba27-85683980d47b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:40009 biolink:treats MONDO:0006052 PMID:41385096 "[{""id"":""uuid:5dae9a34-59bb-4f7f-9f77-fcbb3b7877a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:24208e17-d3be-4676-b4fb-814df31f4831"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cycloserine is indicated in the treatment of active pulmonary and extrapulmonary tuberculosis (including renal disease) when the causative organisms are susceptible to this drug and when treatment with the primary medications (streptomycin, isoniazid, rifampin, and ethambutol) has proved inadequate. Like all antituberculosis drugs, cycloserine should be administered in conjunction with other effective chemotherapy and not as the sole therapeutic agent. Cycloserine may be effective in the treatment of acute urinary tract infections caused by susceptible strains of gram-positive and gram- negative bacteria. Use of cycloserine in these infections should be considered only when more conventional therapy has failed and when the organism has been demonstrated to be susceptible to the drug uuid:0bfc66ba-1e58-48c6-bf02-cc1311df5315 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:40009 biolink:treats MONDO:0000368 PMID:41385096 "[{""id"":""uuid:55687948-aa31-484a-99cc-9d73faa70bf8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b08fef7d-df92-4d5d-852d-d8c8ca7f5d18"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cycloserine is indicated in the treatment of active pulmonary and extrapulmonary tuberculosis (including renal disease) when the causative organisms are susceptible to this drug and when treatment with the primary medications (streptomycin, isoniazid, rifampin, and ethambutol) has proved inadequate. Like all antituberculosis drugs, cycloserine should be administered in conjunction with other effective chemotherapy and not as the sole therapeutic agent. Cycloserine may be effective in the treatment of acute urinary tract infections caused by susceptible strains of gram-positive and gram- negative bacteria. Use of cycloserine in these infections should be considered only when more conventional therapy has failed and when the organism has been demonstrated to be susceptible to the drug uuid:c779518d-94ef-48f1-9aac-97c6e9819e1b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:B72HH48FLU biolink:treats MONDO:0005011 PMID:41385096 "[{""id"":""uuid:d8782085-0a1c-4e9f-a709-e7b5394a87dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:1b514de4-5444-4238-843a-38b6207b8b96"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:bcdfee22-82d9-439d-8bed-25a14ae7c18b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/zessly""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] RENFLEXIS is a tumor necrosis factor (TNF) blocker indicated for: Crohn's Disease: • reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. ( 1.1 ) • reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing disease. ( 1.1 ) Pediatric Crohn's Disease: • reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients with moderately to severely active disease who have had an inadequate response to conventional therapy. ( 1.2 ) Ulcerative Colitis: • reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. ( 1.3 ) Pediatric Ulcerative Colitis: • reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients with moderately to severely active disease who have had an inadequate response to conventional therapy. ( 1.4 ) Rheumatoid Arthritis in combination with methotrexate: • reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active disease. ( 1.5 ) Ankylosing Spondylitis: • reducing signs and symptoms in patients with active disease. ( 1.6 ) Psoriatic Arthritis: • reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function. ( 1.7 ) Plaque Psoriasis: • treatment of adult patients with chronic severe (i.e., extensive and/or disabling) plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate. ( 1.8 )|[EMA] Treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and psoriasis. uuid:3e84d866-667f-454b-b96b-40d5d99e41d1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:B72HH48FLU biolink:treats MONDO:0005101 PMID:41385096 "[{""id"":""uuid:e9ce3c8d-d028-4fce-ab9c-f6d2a8c74528"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a0185f63-fde6-4d5a-9ce7-e4a284b85557"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c9ade73b-c35b-4343-94c3-b5ab2cf26c69"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/zessly""]},{""id"":""uuid:dc7a1de4-6297-41c5-b5c8-c99a2be34cd7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RENFLEXIS is a tumor necrosis factor (TNF) blocker indicated for: Crohn's Disease: • reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. ( 1.1 ) • reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing disease. ( 1.1 ) Pediatric Crohn's Disease: • reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients with moderately to severely active disease who have had an inadequate response to conventional therapy. ( 1.2 ) Ulcerative Colitis: • reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. ( 1.3 ) Pediatric Ulcerative Colitis: • reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients with moderately to severely active disease who have had an inadequate response to conventional therapy. ( 1.4 ) Rheumatoid Arthritis in combination with methotrexate: • reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active disease. ( 1.5 ) Ankylosing Spondylitis: • reducing signs and symptoms in patients with active disease. ( 1.6 ) Psoriatic Arthritis: • reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function. ( 1.7 ) Plaque Psoriasis: • treatment of adult patients with chronic severe (i.e., extensive and/or disabling) plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate. ( 1.8 )|[EMA] Treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and psoriasis.|[PMDA] Follow-on biologics indicated for the treatment of rheumatoid arthritis, psoriasis, Crohn’s disease, and ulcerative colitis. uuid:4443ff4e-c3f6-4300-aa56-5acbdc543bd3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:B72HH48FLU biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:b89bc610-e303-4819-9d19-993ddd4fb3aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9491128d-5234-4d80-ac68-045dfbace20b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:520e46e0-216d-4d5c-b7d0-785b6892393c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/zessly""]},{""id"":""uuid:6beb42eb-aa04-44f1-a118-4975bc4aa55e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RENFLEXIS is a tumor necrosis factor (TNF) blocker indicated for: Crohn's Disease: • reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. ( 1.1 ) • reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing disease. ( 1.1 ) Pediatric Crohn's Disease: • reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients with moderately to severely active disease who have had an inadequate response to conventional therapy. ( 1.2 ) Ulcerative Colitis: • reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. ( 1.3 ) Pediatric Ulcerative Colitis: • reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients with moderately to severely active disease who have had an inadequate response to conventional therapy. ( 1.4 ) Rheumatoid Arthritis in combination with methotrexate: • reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active disease. ( 1.5 ) Ankylosing Spondylitis: • reducing signs and symptoms in patients with active disease. ( 1.6 ) Psoriatic Arthritis: • reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function. ( 1.7 ) Plaque Psoriasis: • treatment of adult patients with chronic severe (i.e., extensive and/or disabling) plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate. ( 1.8 )|[EMA] Treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and psoriasis.|[PMDA] Follow-on biologics indicated for the treatment of rheumatoid arthritis, psoriasis, Crohn’s disease, and ulcerative colitis. uuid:45d795e2-5f1a-4ace-87f7-32a845d7188f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:B72HH48FLU biolink:treats MONDO:0005306 PMID:41385096 "[{""id"":""uuid:e7a7a309-974f-4748-a37e-0e7d9f015049"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e6d991b9-c657-4cb9-bc2e-44db44f1fbaf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:0893414d-4dd8-4f77-8ac8-dbf629ea39f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/zessly""]},{""id"":""uuid:dfb7636f-fa06-4e49-bdaf-6435a226b89f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RENFLEXIS is a tumor necrosis factor (TNF) blocker indicated for: Crohn's Disease: • reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. ( 1.1 ) • reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing disease. ( 1.1 ) Pediatric Crohn's Disease: • reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients with moderately to severely active disease who have had an inadequate response to conventional therapy. ( 1.2 ) Ulcerative Colitis: • reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. ( 1.3 ) Pediatric Ulcerative Colitis: • reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients with moderately to severely active disease who have had an inadequate response to conventional therapy. ( 1.4 ) Rheumatoid Arthritis in combination with methotrexate: • reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active disease. ( 1.5 ) Ankylosing Spondylitis: • reducing signs and symptoms in patients with active disease. ( 1.6 ) Psoriatic Arthritis: • reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function. ( 1.7 ) Plaque Psoriasis: • treatment of adult patients with chronic severe (i.e., extensive and/or disabling) plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate. ( 1.8 )|[EMA] Treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and psoriasis.|[PMDA] A drug with a new additional indication and a new dosage for the treatment of ankylosing spondylitis in patients who have not responded sufficiently to conventional treatments. [Orphan drug] uuid:8ee3e7f8-8037-4cb0-b378-bbd6a6fe14aa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:B72HH48FLU biolink:treats MONDO:0011849 PMID:41385096 "[{""id"":""uuid:cb7d9530-bb2e-414b-ae91-063749ec19c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ffe58f5a-e4aa-4d92-8244-2acbf9e377e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:8897c8ef-bae6-4ac4-a2de-035e138d80b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/zessly""]},{""id"":""uuid:df73f088-199a-4e5b-b582-1a1f4e33adbf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RENFLEXIS is a tumor necrosis factor (TNF) blocker indicated for: Crohn's Disease: • reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. ( 1.1 ) • reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing disease. ( 1.1 ) Pediatric Crohn's Disease: • reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients with moderately to severely active disease who have had an inadequate response to conventional therapy. ( 1.2 ) Ulcerative Colitis: • reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. ( 1.3 ) Pediatric Ulcerative Colitis: • reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients with moderately to severely active disease who have had an inadequate response to conventional therapy. ( 1.4 ) Rheumatoid Arthritis in combination with methotrexate: • reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active disease. ( 1.5 ) Ankylosing Spondylitis: • reducing signs and symptoms in patients with active disease. ( 1.6 ) Psoriatic Arthritis: • reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function. ( 1.7 ) Plaque Psoriasis: • treatment of adult patients with chronic severe (i.e., extensive and/or disabling) plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate. ( 1.8 )|[EMA] Treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and psoriasis.|[PMDA] A drug with a new dosage indicated for plaque psoriasis, psoriatic arthritis, pustular psoriasis, and erythrodermic psoriasis in patients who have not responded sufficiently to conventional treatments. uuid:c1afa829-6118-41c9-adbd-a08fdb8af502 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:B72HH48FLU biolink:treats UMLS:C0406317 PMID:41385096 "[{""id"":""uuid:5b4984f5-ca05-45c7-a3af-28964a11b4ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:bd15ce33-7bca-41f9-a504-44ca686da9da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c8f59837-a662-4e60-9cd9-49bc0f5bbdaa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RENFLEXIS is a tumor necrosis factor (TNF) blocker indicated for: Crohn's Disease: • reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. ( 1.1 ) • reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing disease. ( 1.1 ) Pediatric Crohn's Disease: • reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients with moderately to severely active disease who have had an inadequate response to conventional therapy. ( 1.2 ) Ulcerative Colitis: • reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. ( 1.3 ) Pediatric Ulcerative Colitis: • reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients with moderately to severely active disease who have had an inadequate response to conventional therapy. ( 1.4 ) Rheumatoid Arthritis in combination with methotrexate: • reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active disease. ( 1.5 ) Ankylosing Spondylitis: • reducing signs and symptoms in patients with active disease. ( 1.6 ) Psoriatic Arthritis: • reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function. ( 1.7 ) Plaque Psoriasis: • treatment of adult patients with chronic severe (i.e., extensive and/or disabling) plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate. ( 1.8 )|[PMDA] A drug with a new dosage indicated for plaque psoriasis, psoriatic arthritis, pustular psoriasis, and erythrodermic psoriasis in patients who have not responded sufficiently to conventional treatments. uuid:47883629-d95b-4b67-9361-df36417aabf6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71193 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:b005fdb6-cee4-4f72-ba2a-c406b7ec289e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:16d95f32-f0a8-42a6-9816-32a546cb5a48"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:60fa4933-eb62-45e3-8982-6f51a64a0d94"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/saxenda""]},{""id"":""uuid:5c3d8f47-24a1-4121-8ba2-720b143e6051"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VICTOZA is indicated: • as an adjunct to diet and exercise to improve glycemic control in patients 10 years and older with type 2 diabetes mellitus, • to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease [see Clinical Studies ( 14.3 )] . Limitations of Use : VICTOZA should not be used in patients with type 1 diabetes mellitus. VICTOZA contains liraglutide and should not be coadministered with other liraglutide-containing products.|[EMA] Saxenda is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial Body Mass Index (BMI) of• ≥ 30 kg/m² (obese), or• ≥ 27 kg/m² to < 30 kg/m² (overweight) in the presence of at least one weight-related comorbidity such as dysglycaemia (pre-diabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia or obstructive sleep apnoea.Treatment with Saxenda should be discontinued after 12 weeks on the 3.0 mg/day dose if patients have not lost at least 5% of their initial body weight.|[PMDA] A drug with a new active ingredient indicated for the treatment of type 2 diabetes mellitus (for use only in patients who have not responded sufficiently to either [1] diet and exercise therapies alone or [2] sulfonylurea along with diet and exercise therapies). uuid:32a91fe9-e1b7-4099-8a13-c8c669cf45e5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71193 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:f7f21864-d0f6-46c3-8a0b-8d97df1724ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4fd62266-f73c-424b-9709-a102a3398d33"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VICTOZA is indicated: • as an adjunct to diet and exercise to improve glycemic control in patients 10 years and older with type 2 diabetes mellitus, • to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease [see Clinical Studies ( 14.3 )] . Limitations of Use : VICTOZA should not be used in patients with type 1 diabetes mellitus. VICTOZA contains liraglutide and should not be coadministered with other liraglutide-containing products. uuid:bc99fb30-2793-42fd-ada0-41fe0e4e1baf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71193 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:21d3d807-fa5e-456a-897e-fbeb996b9816"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:684ac0f1-b9fe-4cd0-aacd-d21473e8db38"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VICTOZA is indicated: • as an adjunct to diet and exercise to improve glycemic control in patients 10 years and older with type 2 diabetes mellitus, • to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease [see Clinical Studies ( 14.3 )] . Limitations of Use : VICTOZA should not be used in patients with type 1 diabetes mellitus. VICTOZA contains liraglutide and should not be coadministered with other liraglutide-containing products. uuid:4ed512aa-df93-4fc5-8cdb-b35fc59d1861 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71193 biolink:treats MONDO:0005147 PMID:41385096 "[{""id"":""uuid:9f31dce2-21df-4218-908c-446121dcffd2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c5fcbd57-b94c-4e38-b429-c60568c160bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VICTOZA is indicated: • as an adjunct to diet and exercise to improve glycemic control in patients 10 years and older with type 2 diabetes mellitus, • to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease [see Clinical Studies ( 14.3 )] . Limitations of Use : VICTOZA should not be used in patients with type 1 diabetes mellitus. VICTOZA contains liraglutide and should not be coadministered with other liraglutide-containing products. uuid:be2e6da0-4068-465a-9641-d9b8408c78ac biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3207 biolink:treats UMLS:C0741804 PMID:41385096 "[{""id"":""uuid:473a3630-d22c-4378-9a22-9cdfcd4ba843"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f330d61e-8c55-467f-bc4a-5d4fd060d560"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PULMICORT FLEXHALER is a corticosteroid indicated for: • Maintenance treatment of asthma as prophylactic therapy in adult and pediatric patients six years of age or older ( 1 ) Limitations of Use: Not indicated for the relief of acute bronchospasm ( 1 ) uuid:e7a19bac-1519-45c8-ab72-8d69017d4768 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50690 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:44b27653-362a-48bd-a1ee-bf04978d7a1b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8a28d699-e5e5-4671-9de0-4c0d4df0ea28"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Atorvastatin calcium is indicated: To reduce the risk of. Myocardial infarction (MI), stroke, revascularization procedures, and angina in adults with multiple risk factors for coronary heart disease (CHD) but without clinically evident CHD. MI and stroke in adults with type 2 diabetes mellitus with multiple risk factors for CHD but without clinically evident CHD. Non-fatal MI, fatal and non-fatal stroke, revascularization procedures, hospitalization for congestive heart failure, and angina in adults with clinically evident CHD. As an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in: Adults with primary hyperlipidemia. Adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to other LDL-C-lowering therapies, or alone if such treatments are unavailable, to reduce LDL-C in adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia (HoFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia. uuid:d20b6bf0-be36-43e7-92ae-1b7ff98eef9e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50690 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:a301da45-2f58-4550-a284-9a373e90588d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8b134a26-6d67-401c-831a-de609873da56"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Atorvastatin calcium is indicated: To reduce the risk of. Myocardial infarction (MI), stroke, revascularization procedures, and angina in adults with multiple risk factors for coronary heart disease (CHD) but without clinically evident CHD. MI and stroke in adults with type 2 diabetes mellitus with multiple risk factors for CHD but without clinically evident CHD. Non-fatal MI, fatal and non-fatal stroke, revascularization procedures, hospitalization for congestive heart failure, and angina in adults with clinically evident CHD. As an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in: Adults with primary hyperlipidemia. Adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to other LDL-C-lowering therapies, or alone if such treatments are unavailable, to reduce LDL-C in adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia (HoFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia. uuid:8a01f6fb-cfc4-4870-96ec-87d457c45c01 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C4277251 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:6bd25be9-f89e-4a12-9bbf-28f0fef09922"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:37e92015-e649-4e57-a837-b5760879e573"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LANTUS is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. MESH:C000606659 uuid:c71fc3f0-aea1-4a69-affa-373d61034d52 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68540 biolink:treats MONDO:0005314 PMID:41385096 "[{""id"":""uuid:d1e77245-2dc1-42b4-8cb4-1fe41ec58129"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:82b43c47-f869-487c-99e8-6649cfa6e97d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:5a7351b0-ab35-4278-b577-8b7534863ef8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/aubagio""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Teriflunomide tablets are indicated for the treatment of patients with relapsing forms of multiple sclerosis.|[EMA] AUBAGIO is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (MS) (please refer to section 5.1 for important information on the population for which efficacy has been established). uuid:38a2d91a-c61f-4ec6-a5e3-efa9e34bd6b0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3640 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:a5669a15-3b33-4cde-8fb5-885cb7bfc2e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eef37906-968c-4e8c-8b24-0c5eec586e9a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DIURIL is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. DIURIL has also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. DIURIL is indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension. Use in Pregnancy - Routine use of diuretics during normal pregnancy is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy and there is no satisfactory evidence that they are useful in the treatment of toxemia. Edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy. Thiazides are indicated in pregnancy when edema is due to pathologic causes, just as they are in the absence of pregnancy (see PRECAUTIONS, Pregnancy ). Dependent edema in pregnancy, resulting from restriction of venous return by the gravid uterus, is properly treated through elevation of the lower extremities and use of support stockings. Use of diuretics to lower intravascular volume in this instance is illogical and unnecessary. During normal pregnancy there is hypervolemia which is not harmful to the fetus or the mother in the absence of cardiovascular disease. However, it may be associated with edema, rarely generalized edema. If such edema causes discomfort, increased recumbency will often provide relief. Rarely this edema may cause extreme discomfort which is not relieved by rest. In these instances, a short course of diuretic therapy may provide relief and be appropriate. uuid:d93bac1f-07a2-4909-a1a6-b810afea5277 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3640 biolink:treats MONDO:0045048 PMID:41385096 "[{""id"":""uuid:5ac06a37-544a-4269-974a-4c69fe99a6e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d9178b17-b070-4e7e-bc72-cdf637344100"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DIURIL is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. DIURIL has also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. DIURIL is indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension. Use in Pregnancy - Routine use of diuretics during normal pregnancy is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy and there is no satisfactory evidence that they are useful in the treatment of toxemia. Edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy. Thiazides are indicated in pregnancy when edema is due to pathologic causes, just as they are in the absence of pregnancy (see PRECAUTIONS, Pregnancy ). Dependent edema in pregnancy, resulting from restriction of venous return by the gravid uterus, is properly treated through elevation of the lower extremities and use of support stockings. Use of diuretics to lower intravascular volume in this instance is illogical and unnecessary. During normal pregnancy there is hypervolemia which is not harmful to the fetus or the mother in the absence of cardiovascular disease. However, it may be associated with edema, rarely generalized edema. If such edema causes discomfort, increased recumbency will often provide relief. Rarely this edema may cause extreme discomfort which is not relieved by rest. In these instances, a short course of diuretic therapy may provide relief and be appropriate. uuid:219426eb-351e-4e1a-8ae8-0d93566bc14f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3640 biolink:treats HP:0000969 PMID:41385096 "[{""id"":""uuid:590a6b8a-0428-4a35-b5aa-c4255736e2cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1b7bc99d-e9e7-48d7-845d-2b2b065d41dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DIURIL is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. DIURIL has also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. DIURIL is indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension. Use in Pregnancy - Routine use of diuretics during normal pregnancy is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy and there is no satisfactory evidence that they are useful in the treatment of toxemia. Edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy. Thiazides are indicated in pregnancy when edema is due to pathologic causes, just as they are in the absence of pregnancy (see PRECAUTIONS, Pregnancy ). Dependent edema in pregnancy, resulting from restriction of venous return by the gravid uterus, is properly treated through elevation of the lower extremities and use of support stockings. Use of diuretics to lower intravascular volume in this instance is illogical and unnecessary. During normal pregnancy there is hypervolemia which is not harmful to the fetus or the mother in the absence of cardiovascular disease. However, it may be associated with edema, rarely generalized edema. If such edema causes discomfort, increased recumbency will often provide relief. Rarely this edema may cause extreme discomfort which is not relieved by rest. In these instances, a short course of diuretic therapy may provide relief and be appropriate. uuid:9b61a506-b8f6-4281-bf9e-dde3f367011a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41977 biolink:treats MONDO:0018874 PMID:41385096 "[{""id"":""uuid:a778a6b2-f906-4163-8c40-8c6ebe38a1f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c463bc6a-a5b3-465f-82e5-f729f7d06b27"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Daunorubicin hydrochloride injection in combination with other approved anticancer drugs is indicated for remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults. uuid:dc67a583-d466-4947-9a97-b3f479b5625e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41977 biolink:treats MONDO:0004643 PMID:41385096 "[{""id"":""uuid:f91e2818-2d38-41a1-a168-b3ec2cef3d82"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:087bc0fd-4446-4d48-ab52-007c807c223a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Daunorubicin hydrochloride injection in combination with other approved anticancer drugs is indicated for remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults. uuid:77fae9d9-929d-44a4-87cd-1fbc20dac033 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41977 biolink:treats MONDO:0004600 PMID:41385096 "[{""id"":""uuid:87ae1737-42e9-42a8-8b9f-6279d9dd2c2e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:efaf6623-ab20-4398-a993-c21cf427ec40"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Daunorubicin hydrochloride injection in combination with other approved anticancer drugs is indicated for remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults. uuid:0bfe5870-9e47-4923-b1e1-23d6689b08b7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41977 biolink:treats MONDO:0017858 PMID:41385096 "[{""id"":""uuid:8f263df7-c002-4df3-9899-06d6f56c44a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2f17b5f5-203b-494c-8896-5ba77b1842d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Daunorubicin hydrochloride injection in combination with other approved anticancer drugs is indicated for remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults. uuid:99d52f76-6497-4e75-a18b-916408bb85a3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41977 biolink:treats MONDO:0004967 PMID:41385096 "[{""id"":""uuid:039eda7a-d031-4f76-886d-0658596db883"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c201eecb-ec2f-4956-ac8b-76dd61bb6f20"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Daunorubicin hydrochloride injection in combination with other approved anticancer drugs is indicated for remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults. uuid:0811d07a-9321-427d-a785-e540099212be biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68579 biolink:treats MONDO:0004981 PMID:41385096 "[{""id"":""uuid:8fe9cfdb-ab74-4ddf-93c6-bb311de1d455"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:2ca3724c-04db-4507-bf55-8f0cd7008678"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:9d3eb6c2-8347-4b0a-923e-2a9bdc5eaecd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/rivaroxaban-accord""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] XARELTO is a factor Xa inhibitor indicated: to reduce risk of stroke and systemic embolism in nonvalvular atrial fibrillation ( 1.1 ) for treatment of deep vein thrombosis (DVT) ( 1.2 ) for treatment of pulmonary embolism (PE) ( 1.3 ) for reduction in the risk of recurrence of DVT or PE ( 1.4 ) for the prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery ( 1.5 ) for prophylaxis of venous thromboembolism (VTE) in acutely ill medical patients ( 1.6 ) to reduce the risk of major cardiovascular events in patients with coronary artery disease (CAD) ( 1.7 ) to reduce the risk of major thrombotic vascular events in patients with peripheral artery disease (PAD), including patients after recent lower extremity revascularization due to symptomatic PAD ( 1.8 ) for treatment of VTE and reduction in the risk of recurrent VTE in pediatric patients from birth to less than 18 years ( 1.9 ) for thromboprophylaxis in pediatric patients 2 years and older with congenital heart disease after the Fontan procedure ( 1.10 )|[EMA] Xarelto, co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers.Xarelto, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischaemic events.Prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.AdultsPrevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack.Paediatric population Treatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment.Paediatric population Treatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment. uuid:0e177de2-67dc-46e9-aa9b-08551033cd0a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68579 biolink:treats HP:0002625 PMID:41385096 "[{""id"":""uuid:33400e10-20d2-43d3-9261-8516095a4091"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3cc1775c-b165-4d3b-85da-f4cf9b5bfd3b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:8c5d6f21-8bbf-4dc3-885a-099b6468e9c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/rivaroxaban-accord""]},{""id"":""uuid:f4f9c77b-dcdd-44f7-9bd3-498cfc9fa072"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XARELTO is a factor Xa inhibitor indicated: to reduce risk of stroke and systemic embolism in nonvalvular atrial fibrillation ( 1.1 ) for treatment of deep vein thrombosis (DVT) ( 1.2 ) for treatment of pulmonary embolism (PE) ( 1.3 ) for reduction in the risk of recurrence of DVT or PE ( 1.4 ) for the prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery ( 1.5 ) for prophylaxis of venous thromboembolism (VTE) in acutely ill medical patients ( 1.6 ) to reduce the risk of major cardiovascular events in patients with coronary artery disease (CAD) ( 1.7 ) to reduce the risk of major thrombotic vascular events in patients with peripheral artery disease (PAD), including patients after recent lower extremity revascularization due to symptomatic PAD ( 1.8 ) for treatment of VTE and reduction in the risk of recurrent VTE in pediatric patients from birth to less than 18 years ( 1.9 ) for thromboprophylaxis in pediatric patients 2 years and older with congenital heart disease after the Fontan procedure ( 1.10 )|[EMA] Xarelto, co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers.Xarelto, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischaemic events.Prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.AdultsPrevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack.Paediatric population Treatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment.Paediatric population Treatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.|[PMDA] Drugs with a new additional indication and a new dosage for the treatment and prevention of recurrence of deep vein thrombosis and pulmonary thromboembolism. uuid:90d59200-3895-42e8-934b-ed97d3e98c32 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68579 biolink:treats MONDO:0005279 PMID:41385096 "[{""id"":""uuid:34fcadb2-b6bb-455d-bd29-d27639c902f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:19d16622-664a-432a-b289-06f61fcf7e6f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:cafb8ac8-c519-4cbb-92a1-78f779b84c2a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/rivaroxaban-accord""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] XARELTO is a factor Xa inhibitor indicated: to reduce risk of stroke and systemic embolism in nonvalvular atrial fibrillation ( 1.1 ) for treatment of deep vein thrombosis (DVT) ( 1.2 ) for treatment of pulmonary embolism (PE) ( 1.3 ) for reduction in the risk of recurrence of DVT or PE ( 1.4 ) for the prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery ( 1.5 ) for prophylaxis of venous thromboembolism (VTE) in acutely ill medical patients ( 1.6 ) to reduce the risk of major cardiovascular events in patients with coronary artery disease (CAD) ( 1.7 ) to reduce the risk of major thrombotic vascular events in patients with peripheral artery disease (PAD), including patients after recent lower extremity revascularization due to symptomatic PAD ( 1.8 ) for treatment of VTE and reduction in the risk of recurrent VTE in pediatric patients from birth to less than 18 years ( 1.9 ) for thromboprophylaxis in pediatric patients 2 years and older with congenital heart disease after the Fontan procedure ( 1.10 )|[EMA] Prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for haemodynamically unstable PE patients.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for haemodynamically unstable PE patients).AdultsPrevention of stroke and systemic embolism in adult patients with non valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for haemodynamically unstable PE patients.)Paediatric populationTreatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment.Rivaroxaban Accord, co administered with acetylsalicylic acid (ASA) alone or with ASA plus ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers (see sections 4.3, 4.4 and 5.1).Rivaroxaban Accord, co administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischaemic events.AdultsPrevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for haemodynamically unstable PE patients.)Paediatric populationTreatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment. uuid:2917e071-1650-496c-8ab7-6dda95d73dae biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68579 biolink:treats MONDO:0005010 PMID:41385096 "[{""id"":""uuid:f9880f23-5d67-4b68-b9c5-a243db241b79"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:15228f89-b291-48ff-9aa0-8c8c01da4dfa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:02040346-1f80-40b4-a576-2ea4bae19245"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/rivaroxaban-accord""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] XARELTO is a factor Xa inhibitor indicated: to reduce risk of stroke and systemic embolism in nonvalvular atrial fibrillation ( 1.1 ) for treatment of deep vein thrombosis (DVT) ( 1.2 ) for treatment of pulmonary embolism (PE) ( 1.3 ) for reduction in the risk of recurrence of DVT or PE ( 1.4 ) for the prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery ( 1.5 ) for prophylaxis of venous thromboembolism (VTE) in acutely ill medical patients ( 1.6 ) to reduce the risk of major cardiovascular events in patients with coronary artery disease (CAD) ( 1.7 ) to reduce the risk of major thrombotic vascular events in patients with peripheral artery disease (PAD), including patients after recent lower extremity revascularization due to symptomatic PAD ( 1.8 ) for treatment of VTE and reduction in the risk of recurrent VTE in pediatric patients from birth to less than 18 years ( 1.9 ) for thromboprophylaxis in pediatric patients 2 years and older with congenital heart disease after the Fontan procedure ( 1.10 )|[EMA] Prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for haemodynamically unstable PE patients.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for haemodynamically unstable PE patients).AdultsPrevention of stroke and systemic embolism in adult patients with non valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for haemodynamically unstable PE patients.)Paediatric populationTreatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment.Rivaroxaban Accord, co administered with acetylsalicylic acid (ASA) alone or with ASA plus ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers (see sections 4.3, 4.4 and 5.1).Rivaroxaban Accord, co administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischaemic events.AdultsPrevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for haemodynamically unstable PE patients.)Paediatric populationTreatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment. uuid:df6a208e-76b1-4aeb-b374-8ff6dc9804a3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68579 biolink:treats MONDO:0005386 PMID:41385096 "[{""id"":""uuid:66c43069-bda4-4189-bb4e-8253fed0e426"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f8c3b38e-b7db-4286-873a-d1ae5e72c1dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:968c56c5-3c00-4107-93c1-e03aafc899eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/rivaroxaban-accord""]},{""id"":""uuid:4596010f-cf81-4e5b-afbb-6244c1b089c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XARELTO is a factor Xa inhibitor indicated: to reduce risk of stroke and systemic embolism in nonvalvular atrial fibrillation ( 1.1 ) for treatment of deep vein thrombosis (DVT) ( 1.2 ) for treatment of pulmonary embolism (PE) ( 1.3 ) for reduction in the risk of recurrence of DVT or PE ( 1.4 ) for the prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery ( 1.5 ) for prophylaxis of venous thromboembolism (VTE) in acutely ill medical patients ( 1.6 ) to reduce the risk of major cardiovascular events in patients with coronary artery disease (CAD) ( 1.7 ) to reduce the risk of major thrombotic vascular events in patients with peripheral artery disease (PAD), including patients after recent lower extremity revascularization due to symptomatic PAD ( 1.8 ) for treatment of VTE and reduction in the risk of recurrent VTE in pediatric patients from birth to less than 18 years ( 1.9 ) for thromboprophylaxis in pediatric patients 2 years and older with congenital heart disease after the Fontan procedure ( 1.10 )|[EMA] Prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for haemodynamically unstable PE patients.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for haemodynamically unstable PE patients).AdultsPrevention of stroke and systemic embolism in adult patients with non valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for haemodynamically unstable PE patients.)Paediatric populationTreatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment.Rivaroxaban Accord, co administered with acetylsalicylic acid (ASA) alone or with ASA plus ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers (see sections 4.3, 4.4 and 5.1).Rivaroxaban Accord, co administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischaemic events.AdultsPrevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for haemodynamically unstable PE patients.)Paediatric populationTreatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.|[PMDA] A drug with a new indication and a new dosage in an additional dosage form for the inhibition of thrombus/embolization formation in patients with peripheral arterial disease after lower extremity revascularization. uuid:bafc7745-dfba-445c-8163-ce3446d12a83 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68579 biolink:treats MONDO:0005399 PMID:41385096 "[{""id"":""uuid:e0931c37-3a01-44d4-8d1b-77b8838c82f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:3c0e405d-ca7d-4c04-874e-669bf146cbd6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:d28e9df1-dd21-4ef2-abd3-8c7826e14ad7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/rivaroxaban-accord""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] XARELTO is a factor Xa inhibitor indicated: to reduce risk of stroke and systemic embolism in nonvalvular atrial fibrillation ( 1.1 ) for treatment of deep vein thrombosis (DVT) ( 1.2 ) for treatment of pulmonary embolism (PE) ( 1.3 ) for reduction in the risk of recurrence of DVT or PE ( 1.4 ) for the prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery ( 1.5 ) for prophylaxis of venous thromboembolism (VTE) in acutely ill medical patients ( 1.6 ) to reduce the risk of major cardiovascular events in patients with coronary artery disease (CAD) ( 1.7 ) to reduce the risk of major thrombotic vascular events in patients with peripheral artery disease (PAD), including patients after recent lower extremity revascularization due to symptomatic PAD ( 1.8 ) for treatment of VTE and reduction in the risk of recurrent VTE in pediatric patients from birth to less than 18 years ( 1.9 ) for thromboprophylaxis in pediatric patients 2 years and older with congenital heart disease after the Fontan procedure ( 1.10 )|[EMA] Prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for haemodynamically unstable PE patients.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for haemodynamically unstable PE patients).AdultsPrevention of stroke and systemic embolism in adult patients with non valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for haemodynamically unstable PE patients.)Paediatric populationTreatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment.Rivaroxaban Accord, co administered with acetylsalicylic acid (ASA) alone or with ASA plus ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers (see sections 4.3, 4.4 and 5.1).Rivaroxaban Accord, co administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischaemic events.AdultsPrevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for haemodynamically unstable PE patients.)Paediatric populationTreatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment. uuid:b2bbd19b-e9a0-4c6b-941b-1b7e29391a8f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68579 biolink:treats MONDO:0005453 PMID:41385096 "[{""id"":""uuid:b67d3bfb-6f24-4ef7-8e44-385f0cbfc968"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:49f576e3-9dbe-4c6b-8804-e1cd39173fd8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XARELTO is a factor Xa inhibitor indicated: to reduce risk of stroke and systemic embolism in nonvalvular atrial fibrillation ( 1.1 ) for treatment of deep vein thrombosis (DVT) ( 1.2 ) for treatment of pulmonary embolism (PE) ( 1.3 ) for reduction in the risk of recurrence of DVT or PE ( 1.4 ) for the prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery ( 1.5 ) for prophylaxis of venous thromboembolism (VTE) in acutely ill medical patients ( 1.6 ) to reduce the risk of major cardiovascular events in patients with coronary artery disease (CAD) ( 1.7 ) to reduce the risk of major thrombotic vascular events in patients with peripheral artery disease (PAD), including patients after recent lower extremity revascularization due to symptomatic PAD ( 1.8 ) for treatment of VTE and reduction in the risk of recurrent VTE in pediatric patients from birth to less than 18 years ( 1.9 ) for thromboprophylaxis in pediatric patients 2 years and older with congenital heart disease after the Fontan procedure ( 1.10 ) uuid:6a134166-d340-4748-8106-d1422c891ef3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9434 biolink:treats MONDO:0006652 PMID:41385096 "[{""id"":""uuid:7ca9ce0f-9274-4678-ac8f-035f5db92d1d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5c63f146-40b0-4aa4-ab4f-465a31be20b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Telmisartanis an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. (1.1) • Cardiovascular (CV) risk reduction in patients unable to take ACE inhibitors (1.2) uuid:2a100160-3c97-4359-96b9-6d19c04b916a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134716 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:52a4da25-eb02-464f-9bb8-d18ac85bfa9e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0c197a86-aee0-42c5-b40c-a6765c51df5f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Brexpiprazole tablets are indicated for: Adjunctive treatment of major depressive disorder (MDD) in adults. Treatment of schizophrenia in adults. uuid:2e3f0e95-e51b-4479-aaf7-d5e008235a72 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134716 biolink:treats MONDO:0005090 PMID:41385096 "[{""id"":""uuid:9d62a2bc-ea50-4265-9f54-bb70852aacd5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9cc120fe-eb39-4a58-9ccd-3a8f61a4897b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:2a681cb3-2306-4ba0-b6fc-9a5ee5f44fd8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/rxulti""]},{""id"":""uuid:9b7e4891-6a95-4aed-ace2-1254557b61f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Brexpiprazole tablets are indicated for: Adjunctive treatment of major depressive disorder (MDD) in adults. Treatment of schizophrenia in adults.|[EMA] Treatment of schizophrenia.|[PMDA] Drugs with a new active ingredient indicated for the treatment of schizophrenia. uuid:32f8f62b-5831-4514-8f0a-c36245a145da biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49668 biolink:treats UMLS:C0278987 PMID:41385096 "[{""id"":""uuid:45284f7b-627a-4ce4-b87e-3c205921f541"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:48658d4b-6753-4a45-b570-7eab44c30d17"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gefitinib tablets are indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test [ see Clinical Studies (14) ]. Limitation of Use: Safety and efficacy of gefitinib tablets have not been established in patients with metastatic NSCLC whose tumors have EGFR mutations other than exon 19 deletions or exon 21 (L858R) substitution mutations [ see Clinical Studies (14) ]. uuid:924c249c-9589-49b1-ace0-5193f687704d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49668 biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:ae3e6eec-8362-4f14-aebd-ea61f6a5cd13"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:70777e27-4a45-4630-a629-04adc864bb14"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:71cf7795-8c32-4389-a368-f4a1ad229900"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/gefitinib-mylan""]},{""id"":""uuid:ee0402ab-85b4-459e-9999-e7dbe52e697f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gefitinib tablets are indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test [ see Clinical Studies (14) ]. Limitation of Use: Safety and efficacy of gefitinib tablets have not been established in patients with metastatic NSCLC whose tumors have EGFR mutations other than exon 19 deletions or exon 21 (L858R) substitution mutations [ see Clinical Studies (14) ].|[EMA] Gefitinib Mylan is indicated as monotherapy for the treatment of adult patients with locally advanced or metastatic non‑small cell lung cancer (NSCLC) with activating mutations of EGFR‑TK.|[PMDA] A drug with a revised indication for the treatment of unresectable advanced or recurrent non-small cell lung cancer in patients with EGFR gene mutation. uuid:fa50798f-5a7e-4ef7-a1af-7b2641fc26a4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28864 biolink:treats MONDO:0040732 PMID:41385096 "[{""id"":""uuid:d4d3c405-71b9-4b31-aa12-52b88ac6da14"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:20f755f7-ad8a-431b-a203-06aaac6d1512"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:860ae4fa-4fa6-484a-ba33-82c18d173ced"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/vantobra-previously-tobramycin-pari""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] BETHKIS is indicated for the management of cystic fibrosis patients with Pseudomonas aeruginosa . Safety and efficacy have not been demonstrated in patients under the age of six years, patients with FEV 1 less than 40% or greater than 80% predicted, or patients colonized with Burkholderia cepacia [see Clinical Studies ( 14 )] .|[EMA] Vantobra is indicated for the management of chronic pulmonary infection due to Pseudomonas aeruginosa in patients aged 6 years and older with cystic fibrosis (CF).Consideration should be given to official guidance on the appropriate use of antibacterial agents. uuid:a4358639-d78d-44ff-8de6-1fc8fbaedf43 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16382 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:2b0a984a-16f4-4591-a853-08ca8040d6a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1252569b-9a84-46f4-bd02-bd2ed88e6c89"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Potassium iodide oral solution, USP is for use as an expectorant in the symptomatic treatment of chronic pulmonary diseases where tenacious mucus complicates the problem, including bronchial asthma, bronchitis and pulmonary emphysema. uuid:72d817d0-79b5-45a3-9d88-37a21460469b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16382 biolink:treats MONDO:0003781 PMID:41385096 "[{""id"":""uuid:71b01d91-7b77-451e-b906-3fb4811182bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9ddac8ee-6db1-4de6-af20-1c1aa1b738f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Potassium iodide oral solution, USP is for use as an expectorant in the symptomatic treatment of chronic pulmonary diseases where tenacious mucus complicates the problem, including bronchial asthma, bronchitis and pulmonary emphysema. uuid:27178494-cdbf-42de-97d4-77edf90aa6e1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16382 biolink:treats MONDO:0004849 PMID:41385096 "[{""id"":""uuid:6428d5c1-5b7b-4997-8899-f30c2666e079"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:962d9621-03a9-4171-9b43-20521c2807f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Potassium iodide oral solution, USP is for use as an expectorant in the symptomatic treatment of chronic pulmonary diseases where tenacious mucus complicates the problem, including bronchial asthma, bronchitis and pulmonary emphysema. uuid:f87c3920-2468-407d-94dd-1c4106486b5e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31348 biolink:treats MONDO:0005575 PMID:41385096 "[{""id"":""uuid:5a867c2a-6923-4d1a-ac85-8bfe3af53190"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3b09f5a4-3577-44f8-a7f0-7cb869520e5b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:0e1ac56e-07d2-4f5a-8f94-4d0ee9774925"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ecansya""]},{""id"":""uuid:0f34b5c9-ca15-457b-a79a-e2db4a741e90"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Capecitabine is a nucleoside metabolic inhibitor indicated for: Colorectal Cancer • adjuvant treatment of patients with Stage III colon cancer as a single agent or as a component of a combination chemotherapy regimen. (1.1) • perioperative treatment of adults with locally advanced rectal cancer as a component of chemoradiotherapy. (1.1) • treatment of patients with unresectable or metastatic colorectal cancer as a single agent or as a component of a combination chemotherapy regimen. (1.1) Breast Cancer • treatment of patients with advanced or metastatic breast cancer as a single agent if an anthracycline-or taxane-containing chemotherapy is not indicated. (1.2) • treatment of patients with advanced or metastatic breast cancer in combination with docetaxel after disease progression on prior anthracycline-containing chemotherapy. (1.2) Gastric, Esophageal, or Gastroesophageal Junction Cancer • treatment of adults with unresectable or metastatic gastric, esophageal, or gastroesophageal junction cancer as a component of a combination chemotherapy regimen. (1.3) • treatment of adults with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease as a component of a combination regimen. (1.3) Pancreatic Cancer • adjuvant treatment of adults with pancreatic adenocarcinoma as a component of a combination chemotherapy regimen. (1.4)|[EMA] Capecitabine Medac is indicated for the adjuvant treatment of patients following surgery of stage-III (Dukes’ stage-C) colon cancer.Capecitabine Medac is indicated for the treatment of metastatic colorectal cancer.Capecitabine Medac is indicated for first-line treatment of advanced gastric cancer in combination with a platinum-based regimen.Capecitabine Medac in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline.Capecitabine Medac is also indicated as monotherapy for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline-containing chemotherapy regimen or for whom further anthracycline therapy is not indicated.|[PMDA] A drug with a new dosage indicated for the treatment of unresectable or recurrent breast cancer and colorectal cancer. [Public knowledge-based application] uuid:81765a2d-382f-44fa-b673-975806c96018 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31348 biolink:treats MONDO:0006519 PMID:41385096 "[{""id"":""uuid:c4aaeb03-4a97-44ae-bd95-229ad53a19a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:fe359700-c479-4f18-91b0-e3c7bb6ca37d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:67376f01-0eca-407e-b500-e6a676fe58ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Capecitabine is a nucleoside metabolic inhibitor indicated for: Colorectal Cancer • adjuvant treatment of patients with Stage III colon cancer as a single agent or as a component of a combination chemotherapy regimen. (1.1) • perioperative treatment of adults with locally advanced rectal cancer as a component of chemoradiotherapy. (1.1) • treatment of patients with unresectable or metastatic colorectal cancer as a single agent or as a component of a combination chemotherapy regimen. (1.1) Breast Cancer • treatment of patients with advanced or metastatic breast cancer as a single agent if an anthracycline-or taxane-containing chemotherapy is not indicated. (1.2) • treatment of patients with advanced or metastatic breast cancer in combination with docetaxel after disease progression on prior anthracycline-containing chemotherapy. (1.2) Gastric, Esophageal, or Gastroesophageal Junction Cancer • treatment of adults with unresectable or metastatic gastric, esophageal, or gastroesophageal junction cancer as a component of a combination chemotherapy regimen. (1.3) • treatment of adults with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease as a component of a combination regimen. (1.3) Pancreatic Cancer • adjuvant treatment of adults with pancreatic adenocarcinoma as a component of a combination chemotherapy regimen. (1.4)|[PMDA] A drug with a new additional indication and a new dosage for adjuvant chemotherapy for rectal cancer. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:99fa9a3a-b3bd-4add-9a9b-9235f9c8edef biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31348 biolink:treats UMLS:C3495917 PMID:41385096 "[{""id"":""uuid:6092dc95-287f-4e64-8a6b-53acfcac99c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5793a2f9-ac3c-45b7-a115-bbe3c697d9ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Capecitabine is a nucleoside metabolic inhibitor indicated for: Colorectal Cancer • adjuvant treatment of patients with Stage III colon cancer as a single agent or as a component of a combination chemotherapy regimen. (1.1) • perioperative treatment of adults with locally advanced rectal cancer as a component of chemoradiotherapy. (1.1) • treatment of patients with unresectable or metastatic colorectal cancer as a single agent or as a component of a combination chemotherapy regimen. (1.1) Breast Cancer • treatment of patients with advanced or metastatic breast cancer as a single agent if an anthracycline-or taxane-containing chemotherapy is not indicated. (1.2) • treatment of patients with advanced or metastatic breast cancer in combination with docetaxel after disease progression on prior anthracycline-containing chemotherapy. (1.2) Gastric, Esophageal, or Gastroesophageal Junction Cancer • treatment of adults with unresectable or metastatic gastric, esophageal, or gastroesophageal junction cancer as a component of a combination chemotherapy regimen. (1.3) • treatment of adults with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease as a component of a combination regimen. (1.3) Pancreatic Cancer • adjuvant treatment of adults with pancreatic adenocarcinoma as a component of a combination chemotherapy regimen. (1.4) uuid:3552dbe4-e78b-4a35-909d-a68e8a1a8fe8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31348 biolink:treats MONDO:0001056 PMID:41385096 "[{""id"":""uuid:c73b7293-02b5-4112-8ce0-4786295d3cd9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:15a8f1b4-c8c7-4d90-bf58-88b2a61eb831"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ff2f07d5-ce1c-4700-afec-58929c28fe98"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ecansya""]},{""id"":""uuid:07f1009d-95ad-416a-8313-d0c08aab7b04"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Capecitabine is a nucleoside metabolic inhibitor indicated for: Colorectal Cancer • adjuvant treatment of patients with Stage III colon cancer as a single agent or as a component of a combination chemotherapy regimen. (1.1) • perioperative treatment of adults with locally advanced rectal cancer as a component of chemoradiotherapy. (1.1) • treatment of patients with unresectable or metastatic colorectal cancer as a single agent or as a component of a combination chemotherapy regimen. (1.1) Breast Cancer • treatment of patients with advanced or metastatic breast cancer as a single agent if an anthracycline-or taxane-containing chemotherapy is not indicated. (1.2) • treatment of patients with advanced or metastatic breast cancer in combination with docetaxel after disease progression on prior anthracycline-containing chemotherapy. (1.2) Gastric, Esophageal, or Gastroesophageal Junction Cancer • treatment of adults with unresectable or metastatic gastric, esophageal, or gastroesophageal junction cancer as a component of a combination chemotherapy regimen. (1.3) • treatment of adults with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease as a component of a combination regimen. (1.3) Pancreatic Cancer • adjuvant treatment of adults with pancreatic adenocarcinoma as a component of a combination chemotherapy regimen. (1.4)|[EMA] Ecansya is indicated for the adjuvant treatment of patients following surgery of stage-III (Dukes’ stage-C) colon cancer.Ecansya is indicated for the treatment of metastatic colorectal cancer.Ecansya is indicated for first-line treatment of advanced gastric cancer in combination with a platinum-based regimen.Ecansya in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline. Ecansya is also indicated as monotherapy for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline containing chemotherapy regimen or for whom further anthracycline therapy is not indicated.|[PMDA] A drug with a new additional indication and a new dosage for the treatment of unresectable advanced or recurrent gastric cancer. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:9fe91661-6c1e-4ae4-a59a-399836285e8c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31348 biolink:treats UMLS:C0278498 PMID:41385096 "[{""id"":""uuid:6bec5f62-5e13-4344-b00b-c3ac2b3ff311"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:271fdffc-da2b-4743-b69d-5a68e0546e27"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Capecitabine is a nucleoside metabolic inhibitor indicated for: Colorectal Cancer • adjuvant treatment of patients with Stage III colon cancer as a single agent or as a component of a combination chemotherapy regimen. (1.1) • perioperative treatment of adults with locally advanced rectal cancer as a component of chemoradiotherapy. (1.1) • treatment of patients with unresectable or metastatic colorectal cancer as a single agent or as a component of a combination chemotherapy regimen. (1.1) Breast Cancer • treatment of patients with advanced or metastatic breast cancer as a single agent if an anthracycline-or taxane-containing chemotherapy is not indicated. (1.2) • treatment of patients with advanced or metastatic breast cancer in combination with docetaxel after disease progression on prior anthracycline-containing chemotherapy. (1.2) Gastric, Esophageal, or Gastroesophageal Junction Cancer • treatment of adults with unresectable or metastatic gastric, esophageal, or gastroesophageal junction cancer as a component of a combination chemotherapy regimen. (1.3) • treatment of adults with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease as a component of a combination regimen. (1.3) Pancreatic Cancer • adjuvant treatment of adults with pancreatic adenocarcinoma as a component of a combination chemotherapy regimen. (1.4) uuid:4072c9be-a62d-4ebd-8d19-6628296d5b58 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31348 biolink:treats MONDO:0007576 PMID:41385096 "[{""id"":""uuid:66d73af3-265e-4fb5-ae9e-e6bcb1595980"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8be723ea-b3c7-461c-a888-45ef4eb69594"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Capecitabine is a nucleoside metabolic inhibitor indicated for: Colorectal Cancer • adjuvant treatment of patients with Stage III colon cancer as a single agent or as a component of a combination chemotherapy regimen. (1.1) • perioperative treatment of adults with locally advanced rectal cancer as a component of chemoradiotherapy. (1.1) • treatment of patients with unresectable or metastatic colorectal cancer as a single agent or as a component of a combination chemotherapy regimen. (1.1) Breast Cancer • treatment of patients with advanced or metastatic breast cancer as a single agent if an anthracycline-or taxane-containing chemotherapy is not indicated. (1.2) • treatment of patients with advanced or metastatic breast cancer in combination with docetaxel after disease progression on prior anthracycline-containing chemotherapy. (1.2) Gastric, Esophageal, or Gastroesophageal Junction Cancer • treatment of adults with unresectable or metastatic gastric, esophageal, or gastroesophageal junction cancer as a component of a combination chemotherapy regimen. (1.3) • treatment of adults with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease as a component of a combination regimen. (1.3) Pancreatic Cancer • adjuvant treatment of adults with pancreatic adenocarcinoma as a component of a combination chemotherapy regimen. (1.4) uuid:9a1ae9f2-ff9b-4282-97d6-01327adc05d1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31348 biolink:treats UMLS:C5400195 PMID:41385096 "[{""id"":""uuid:071fddf3-e1ef-4ae4-915b-2e2d409b4c25"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5df2b5e5-b665-4ee1-8854-affd56859536"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Capecitabine is a nucleoside metabolic inhibitor indicated for: Colorectal Cancer • adjuvant treatment of patients with Stage III colon cancer as a single agent or as a component of a combination chemotherapy regimen. (1.1) • perioperative treatment of adults with locally advanced rectal cancer as a component of chemoradiotherapy. (1.1) • treatment of patients with unresectable or metastatic colorectal cancer as a single agent or as a component of a combination chemotherapy regimen. (1.1) Breast Cancer • treatment of patients with advanced or metastatic breast cancer as a single agent if an anthracycline-or taxane-containing chemotherapy is not indicated. (1.2) • treatment of patients with advanced or metastatic breast cancer in combination with docetaxel after disease progression on prior anthracycline-containing chemotherapy. (1.2) Gastric, Esophageal, or Gastroesophageal Junction Cancer • treatment of adults with unresectable or metastatic gastric, esophageal, or gastroesophageal junction cancer as a component of a combination chemotherapy regimen. (1.3) • treatment of adults with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease as a component of a combination regimen. (1.3) Pancreatic Cancer • adjuvant treatment of adults with pancreatic adenocarcinoma as a component of a combination chemotherapy regimen. (1.4) uuid:afbbdb5b-1874-4f2a-959d-d2842d011f89 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31348 biolink:treats MONDO:0003219 PMID:41385096 "[{""id"":""uuid:e6a82245-c9aa-447d-a28d-599578fcfed3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b62d95e1-6671-4b53-8f8b-c961e77c3158"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Capecitabine is a nucleoside metabolic inhibitor indicated for: Colorectal Cancer • adjuvant treatment of patients with Stage III colon cancer as a single agent or as a component of a combination chemotherapy regimen. (1.1) • perioperative treatment of adults with locally advanced rectal cancer as a component of chemoradiotherapy. (1.1) • treatment of patients with unresectable or metastatic colorectal cancer as a single agent or as a component of a combination chemotherapy regimen. (1.1) Breast Cancer • treatment of patients with advanced or metastatic breast cancer as a single agent if an anthracycline-or taxane-containing chemotherapy is not indicated. (1.2) • treatment of patients with advanced or metastatic breast cancer in combination with docetaxel after disease progression on prior anthracycline-containing chemotherapy. (1.2) Gastric, Esophageal, or Gastroesophageal Junction Cancer • treatment of adults with unresectable or metastatic gastric, esophageal, or gastroesophageal junction cancer as a component of a combination chemotherapy regimen. (1.3) • treatment of adults with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease as a component of a combination regimen. (1.3) Pancreatic Cancer • adjuvant treatment of adults with pancreatic adenocarcinoma as a component of a combination chemotherapy regimen. (1.4) uuid:72f4a176-70ca-435d-9da3-6bbf43f87aef biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31348 biolink:treats MONDO:0006047 PMID:41385096 "[{""id"":""uuid:f42ccaa9-323e-48b6-9f3a-8d1f92919d0b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1bbc1be7-2908-4d83-85a0-3b6a2d0f0513"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Capecitabine is a nucleoside metabolic inhibitor indicated for: Colorectal Cancer • adjuvant treatment of patients with Stage III colon cancer as a single agent or as a component of a combination chemotherapy regimen. (1.1) • perioperative treatment of adults with locally advanced rectal cancer as a component of chemoradiotherapy. (1.1) • treatment of patients with unresectable or metastatic colorectal cancer as a single agent or as a component of a combination chemotherapy regimen. (1.1) Breast Cancer • treatment of patients with advanced or metastatic breast cancer as a single agent if an anthracycline-or taxane-containing chemotherapy is not indicated. (1.2) • treatment of patients with advanced or metastatic breast cancer in combination with docetaxel after disease progression on prior anthracycline-containing chemotherapy. (1.2) Gastric, Esophageal, or Gastroesophageal Junction Cancer • treatment of adults with unresectable or metastatic gastric, esophageal, or gastroesophageal junction cancer as a component of a combination chemotherapy regimen. (1.3) • treatment of adults with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease as a component of a combination regimen. (1.3) Pancreatic Cancer • adjuvant treatment of adults with pancreatic adenocarcinoma as a component of a combination chemotherapy regimen. (1.4) uuid:8223e9a9-811f-411b-a67f-538dd31f077b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5108 biolink:treats MONDO:0004795 PMID:41385096 "[{""id"":""uuid:832223ba-8275-488e-ac77-c14f4a84d185"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:60e8f44a-baf9-474a-823f-6b6ea6e90f7c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fluocinolone acetonide oil, 0.01% is a low to medium potency corticosteroid indicated for the treatment of chronic eczematous external otitis in adults and pediatric patients 2 years and older. uuid:b563b74e-370f-4e1e-9803-2946b87c015a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6933 biolink:treats MONDO:0006875 PMID:41385096 "[{""id"":""uuid:7a63e3a2-747d-4f25-9036-795ccdc739a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5bbd1340-d4b7-4595-9120-0c4100cbc4a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Midodrine hydrochloride tablets, USP are indicated for the treatment of symptomatic orthostatic hypotension (OH). Because midodrine hydrochloride tablets, USP can cause marked elevation of supine blood pressure (BP > 200 mmHg systolic), it should be used in patients whose lives are considerably impaired despite standard clinical care, including non-pharmacologic treatment (such as support stockings), fluid expansion, and lifestyle alterations. The indication is based on midodrine hydrochloride tablets, USP effect on increases in 1-minute standing systolic blood pressure, a surrogate marker considered likely to correspond to a clinical benefit. At present, however, clinical benefits of midodrine hydrochloride tablets, USP principally improved ability to perform life activities, have not been established. Further clinical trials are underway to verify and describe the clinical benefits of midodrine hydrochloride tablets, USP. After initiation of treatment, midodrine hydrochloride tablets, USP should be continued only for patients who report significant symptomatic improvement. uuid:276c6342-ae3c-4b4b-8c6c-74c270daf9bf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7445 biolink:treats MONDO:0019165 PMID:41385096 "[{""id"":""uuid:b391f93c-6c70-452f-b82f-2b960bd00dac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4c316db3-13a2-4983-9bc0-50d236eea6fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] (For Endometriosis, See Reverse Side ) SYNAREL is indicated for treatment of central precocious puberty (CPP) (gonadotropin-dependent precocious puberty) in children of both sexes. The diagnosis of central precocious puberty (CPP) is suspected when premature development of secondary sexual characteristics occurs at or before the age of 8 years in girls and 9 years in boys, and is accompanied by significant advancement of bone age and/or a poor adult height prediction. The diagnosis should be confirmed by pubertal gonadal sex steroid levels and a pubertal LH response to stimulation by native GnRH. Pelvic ultrasound assessment in girls usually reveals enlarged uterus and ovaries, the latter often with multiple cystic formations. Magnetic resonance imaging or CT-scanning of the brain is recommended to detect hypothalamic or pituitary tumors, or anatomical changes associated with increased intracranial pressure. Other causes of sexual precocity, such as congenital adrenal hyperplasia, testotoxicosis, testicular tumors and/or other autonomous feminizing or masculinizing disorders must be excluded by proper clinical hormonal and diagnostic imaging examinations. uuid:00e20a4d-6efe-4e60-9587-558b718972f0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7445 biolink:treats MONDO:0018479 PMID:41385096 "[{""id"":""uuid:1372564d-b4f1-4743-8def-3a82baf4b046"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f3b2b3b8-6ab9-47d5-8f40-cafd8ea4ed87"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] (For Endometriosis, See Reverse Side ) SYNAREL is indicated for treatment of central precocious puberty (CPP) (gonadotropin-dependent precocious puberty) in children of both sexes. The diagnosis of central precocious puberty (CPP) is suspected when premature development of secondary sexual characteristics occurs at or before the age of 8 years in girls and 9 years in boys, and is accompanied by significant advancement of bone age and/or a poor adult height prediction. The diagnosis should be confirmed by pubertal gonadal sex steroid levels and a pubertal LH response to stimulation by native GnRH. Pelvic ultrasound assessment in girls usually reveals enlarged uterus and ovaries, the latter often with multiple cystic formations. Magnetic resonance imaging or CT-scanning of the brain is recommended to detect hypothalamic or pituitary tumors, or anatomical changes associated with increased intracranial pressure. Other causes of sexual precocity, such as congenital adrenal hyperplasia, testotoxicosis, testicular tumors and/or other autonomous feminizing or masculinizing disorders must be excluded by proper clinical hormonal and diagnostic imaging examinations. uuid:b8940376-c554-475d-a29e-e890a3522ed8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7445 biolink:treats MONDO:0008303 PMID:41385096 "[{""id"":""uuid:a516e4cf-cdb4-494c-a65e-f4918e318d8d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:be88bcf6-3028-4345-83fe-1ee6fb63faf8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] (For Endometriosis, See Reverse Side ) SYNAREL is indicated for treatment of central precocious puberty (CPP) (gonadotropin-dependent precocious puberty) in children of both sexes. The diagnosis of central precocious puberty (CPP) is suspected when premature development of secondary sexual characteristics occurs at or before the age of 8 years in girls and 9 years in boys, and is accompanied by significant advancement of bone age and/or a poor adult height prediction. The diagnosis should be confirmed by pubertal gonadal sex steroid levels and a pubertal LH response to stimulation by native GnRH. Pelvic ultrasound assessment in girls usually reveals enlarged uterus and ovaries, the latter often with multiple cystic formations. Magnetic resonance imaging or CT-scanning of the brain is recommended to detect hypothalamic or pituitary tumors, or anatomical changes associated with increased intracranial pressure. Other causes of sexual precocity, such as congenital adrenal hyperplasia, testotoxicosis, testicular tumors and/or other autonomous feminizing or masculinizing disorders must be excluded by proper clinical hormonal and diagnostic imaging examinations. uuid:0e29335f-e95e-4702-b7be-94460a46698e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17823 biolink:treats UMLS:C0406317 PMID:41385096 "[{""id"":""uuid:9e484b2f-14c0-4932-9894-f44e295a9d11"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d16b1f38-c15f-4c7b-befa-efe7a7da72bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Calcitriol Ointment is a vitamin D analog indicated for the topical treatment of mild to moderate plaque psoriasis in adults and pediatric patients 2 years and older ( 1.1 ) Limitations of Use The safety and effectiveness of Calcitriol Ointment in patients with known or suspected disorders of calcium metabolism have not been evaluated. ( 1.2 ) uuid:cd35341a-d56d-49ab-8118-eb9b37e9b580 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63791 biolink:treats MONDO:0009693 PMID:41385096 "[{""id"":""uuid:bcaf6c95-30a1-42ae-8e9e-633d6b0283f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:05fdfac3-c769-4fb1-bdf5-d75e225c9c3c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:d3ad9150-d785-4e2c-99a8-9ed7cc6a12a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/revlimid""]},{""id"":""uuid:0ca4e9ad-4ce9-4d81-bd1c-63aee1527951"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lenalidomide is a thalidomide analogue indicated for the treatment of adult patients with: Multiple myeloma (MM), in combination with dexamethasone ( 1.1 ). MM, as maintenance following autologous hematopoietic stem cell transplantation (auto-HSCT) ( 1.1 ). Transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities ( 1.2 ). Mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib ( 1.3 ). Previously treated follicular lymphoma (FL), in combination with a rituximab product ( 1.4 ). Previously treated marginal zone lymphoma (MZL), in combination with a rituximab product ( 1.5 ). Limitations of Use: Lenalidomide capsules are not indicated and are not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials.( 1.4 ).|[EMA] Multiple myelomaRevlimid as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation.Revlimid as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4.2) is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant.Revlimid in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy.Myelodysplastic syndromesRevlimid as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.Mantle cell lymphomaRevlimid as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma.Follicular lymphomaRevlimid in combination with rituximab (anti-CD20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (Grade 1 – 3a).|[PMDA] A drug with a new active ingredient indicated for the treatment of relapsed or refractory multiple myeloma. [Orphan drug] uuid:a08f5e6a-db31-43f0-9f8b-280135ec72bc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63791 biolink:treats MONDO:0007925 PMID:41385096 "[{""id"":""uuid:7ee86d08-7336-42ad-b46e-ba97b36a2b7f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:62f2298c-8ed7-4e1d-b89a-ae675ad9d32c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:2907f3d2-1ef3-4c18-9075-727a3808a008"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lenalidomide is a thalidomide analogue indicated for the treatment of adult patients with: Multiple myeloma (MM), in combination with dexamethasone ( 1.1 ). MM, as maintenance following autologous hematopoietic stem cell transplantation (auto-HSCT) ( 1.1 ). Transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities ( 1.2 ). Mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib ( 1.3 ). Previously treated follicular lymphoma (FL), in combination with a rituximab product ( 1.4 ). Previously treated marginal zone lymphoma (MZL), in combination with a rituximab product ( 1.5 ). Limitations of Use: Lenalidomide capsules are not indicated and are not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials.( 1.4 ).|[PMDA] A drug with a new additional indication and a new dosage for the treatment of myelodysplastic syndrome associated with a deletion 5q cytogenetic abnormality. [Orphan drug] uuid:17ea621e-5934-4362-bbf9-196da1b602a9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63791 biolink:treats MONDO:0018876 PMID:41385096 "[{""id"":""uuid:228479a9-7aec-4df8-8f99-be9624ec4888"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:5f38ca03-ca45-465a-b4a3-75f9ad0da9ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:8645d6d6-ad3c-47cc-a850-91ec6b6ca68b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/revlimid""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lenalidomide is a thalidomide analogue indicated for the treatment of adult patients with: Multiple myeloma (MM), in combination with dexamethasone ( 1.1 ). MM, as maintenance following autologous hematopoietic stem cell transplantation (auto-HSCT) ( 1.1 ). Transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities ( 1.2 ). Mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib ( 1.3 ). Previously treated follicular lymphoma (FL), in combination with a rituximab product ( 1.4 ). Previously treated marginal zone lymphoma (MZL), in combination with a rituximab product ( 1.5 ). Limitations of Use: Lenalidomide capsules are not indicated and are not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials.( 1.4 ).|[EMA] Multiple myelomaRevlimid as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation.Revlimid as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4.2) is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant.Revlimid in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy.Myelodysplastic syndromesRevlimid as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.Mantle cell lymphomaRevlimid as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma.Follicular lymphomaRevlimid in combination with rituximab (anti-CD20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (Grade 1 – 3a). uuid:29337390-adb0-4c03-955e-bfd81846f3e5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63791 biolink:treats MONDO:0018906 PMID:41385096 "[{""id"":""uuid:fafc8965-2b81-4f6b-a55b-10d6fd28f154"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:eba04668-a96d-42fb-9123-a12ec34cd9fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:2622d6aa-ba97-4a78-b956-02f07aceb520"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/revlimid""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lenalidomide is a thalidomide analogue indicated for the treatment of adult patients with: Multiple myeloma (MM), in combination with dexamethasone ( 1.1 ). MM, as maintenance following autologous hematopoietic stem cell transplantation (auto-HSCT) ( 1.1 ). Transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities ( 1.2 ). Mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib ( 1.3 ). Previously treated follicular lymphoma (FL), in combination with a rituximab product ( 1.4 ). Previously treated marginal zone lymphoma (MZL), in combination with a rituximab product ( 1.5 ). Limitations of Use: Lenalidomide capsules are not indicated and are not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials.( 1.4 ).|[EMA] Multiple myelomaRevlimid as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation.Revlimid as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4.2) is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant.Revlimid in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy.Myelodysplastic syndromesRevlimid as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.Mantle cell lymphomaRevlimid as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma.Follicular lymphomaRevlimid in combination with rituximab (anti-CD20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (Grade 1 – 3a). uuid:18075dd5-f85a-4690-8c08-304cb7246072 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63791 biolink:treats MONDO:0017604 PMID:41385096 "[{""id"":""uuid:41358e48-4fee-492e-8744-ca4df2af7771"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:70bc1513-e468-41f7-94ca-3379b225dcbd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:8e4f4a76-fdff-4b24-832b-30ad26241d7d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lenalidomide is a thalidomide analogue indicated for the treatment of adult patients with: Multiple myeloma (MM), in combination with dexamethasone ( 1.1 ). MM, as maintenance following autologous hematopoietic stem cell transplantation (auto-HSCT) ( 1.1 ). Transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities ( 1.2 ). Mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib ( 1.3 ). Previously treated follicular lymphoma (FL), in combination with a rituximab product ( 1.4 ). Previously treated marginal zone lymphoma (MZL), in combination with a rituximab product ( 1.5 ). Limitations of Use: Lenalidomide capsules are not indicated and are not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials.( 1.4 ).|[PMDA] Drugs with new indications and a new dosage for the treatment of relapsed or refractory follicular lymphoma and marginal zone lymphoma. uuid:17990caf-bf02-48ca-b4bf-4280a067be6c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17347 biolink:treats UMLS:C3714660 PMID:41385096 "[{""id"":""uuid:a21702c9-e2a0-4bed-9aa1-ecafe97fd788"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1e1c6dad-aba4-4445-a102-d7cf688837f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Testosterone Topical Solution is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone. • Primary hypogonadism (congenital or acquired): testicular failure due to conditions such as cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter’s syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone concentrations and gonadotropins (FSH, LH) above the normal range. • Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation. These men have low testosterone serum concentrations but have gonadotropins in the normal or low range. Limitations of use: • Safety and efficacy of Testosterone Topical Solution in men with “age-related hypogonadism” (also referred to as “late-onset hypogonadism”) have not been established. • Safety and efficacy of Testosterone Topical Solution in males <18 years old have not been established [ see Use in Specific Populations (8.4) ]. uuid:91708f70-4273-4883-8d1f-91196f3b75a4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB10553 biolink:treats MONDO:0005902 PMID:41385096 "[{""id"":""uuid:1d306ade-8d21-486b-8f38-8161785b5872"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:26af54ae-7220-47de-bc55-ea2007ac4976"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:75de0768-6b88-41a2-ba45-1827f8ead25d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/palforzia""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] PALFORZIA is an oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanut. PALFORZIA is approved for use in patients with a confirmed diagnosis of peanut allergy. Initial Dose Escalation may be administered to patients aged 4 through 17 years. Up-Dosing and Maintenance may be continued in patients 4 years of age and older [see Dosage and Administration (2.4) ] . PALFORZIA is to be used in conjunction with a peanut-avoidant diet.|[EMA] Palforzia is indicated for the treatment of patients aged 4 to 17 years with a confirmed diagnosis of peanut allergy. Palforzia may be continued in patients 18 years of age and older.Palforzia should be used in conjunction with a peanut-avoidant diet. DOID:4378 uuid:e209cfbb-1f1d-46aa-8524-fcf044a7340b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB10553 biolink:treats MONDO:0100053 PMID:41385096 "[{""id"":""uuid:49aed787-1c6e-495b-9973-fdaf3878276d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:62a0c8af-1f41-4561-a3d1-01a52e9b9d77"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PALFORZIA is an oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanut. PALFORZIA is approved for use in patients with a confirmed diagnosis of peanut allergy. Initial Dose Escalation may be administered to patients aged 4 through 17 years. Up-Dosing and Maintenance may be continued in patients 4 years of age and older [see Dosage and Administration (2.4) ] . PALFORZIA is to be used in conjunction with a peanut-avoidant diet. uuid:8c6b4bdb-81a3-420d-8941-bc7615e70263 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0004126 PMID:41385096 "[{""id"":""uuid:76d19eed-7207-4dd8-b9dc-7bca6101a639"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:51e47a46-1854-47b2-bea4-1b400025d9ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydrocortisone tablets are indicated in the following conditions. 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Non suppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:3481e4e8-0ffe-4e59-8b84-4c2f913979f4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16899 biolink:treats MONDO:0002492 PMID:41385096 "[{""id"":""uuid:61c72469-5768-4c0a-b7b1-a6ba58867bce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5e3676db-fd2a-44ac-a240-95de8ea548aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mannitol Injection, USP is indicated for the following therapeutic uses: • The promotion of diuresis, in the prevention and/or treatment of the oliguric phase of acute renal failure before irreversible renal failure becomes established. • The reduction of intracranial pressure and treatment of cerebral edema by reducing brain mass. • The reduction of elevated intraocular pressure when it cannot be lowered by other means. • The promotion of urinary excretion of toxic substances. uuid:5c0e7f6e-b707-45b8-93aa-2fc857c0fd40 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9241 biolink:treats MONDO:0003924 PMID:41385096 "[{""id"":""uuid:303b098d-f943-4dbb-bf58-fd05565c294f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e98ff6dc-b2fe-43d8-9975-ffe8214c613d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Spironolactone tablets are an aldosterone antagonist indicated for: • The treatment of NYHA Class III-IV heart failure and reduced ejection fraction to increase survival, manage edema, and to reduce the need for hospitalization for heart failure ( 1.1 ). • Use as an add-on therapy for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.2 ). • The management of edema in adult patients who are cirrhotic when edema is not responsive to fluid and sodium restrictions and in the setting of nephrotic syndrome when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics produce an inadequate response ( 1.3 ). • Treatment of primary hyperaldosternism for: ( 1.4 ). o Short-term preoperative treatment o Long-term maintenance for patients with discrete aldosterone-producing adrenal adenomas who are not candidates for surgery and patients with bilateral micro or macronodular adrenal hyperplasia uuid:8c86fbd8-709b-4a8d-be49-d1b29d6074b1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31524 biolink:treats UMLS:C1400301 PMID:41385096 "[{""id"":""uuid:738fdaf9-6492-447c-a6ca-0fea16cb51bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b850015b-7398-4248-8121-1b52e3e11b42"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Droxidopa capsules indicated for the treatment of orthostatic dizziness, lightheadedness, or the “feeling that you are about to black out” in adult patients with symptomatic neurogenic orthostatic hypotension (nOH) caused by primary autonomic failure (Parkinson's disease [PD], multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy. Effectiveness beyond 2 weeks of treatment has not been established. The continued effectiveness of droxidopa capsules should be assessed periodically. uuid:100fb65d-fc0e-4fa6-9b1a-8f31042e5ac6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C1372952 biolink:treats MONDO:0005700 PMID:41385096 "[{""id"":""uuid:c378ca45-12a3-4836-8f06-7f40ee42b6d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e0405c87-26ed-44cc-8982-94d4f043b156"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VARIZIG ® [Varicella Zoster Immune Globulin (Human)] is indicated for post-exposure prophylaxis of varicella in high risk individuals. High risk groups include: immunocompromised children and adults, newborns of mothers with varicella shortly before or after delivery, premature infants, neonates and infants less than one year of age, adults without evidence of immunity, pregnant women. VARIZIG administration is intended to reduce the severity of varicella. Administer VARIZIG as soon as possible following varicella zoster virus (VZV) exposure, ideally within 96 hours for greatest effectiveness. There is no convincing evidence that VARIZIG reduces the incidence of chickenpox infection after exposure to VZV. There is no convincing evidence that established infections with VZV can be modified by VARIZIG administration. There is no indication for the prophylactic use of VARIZIG in immunodeficient children or adults when there is a past history of varicella, unless the patient is undergoing bone marrow transplantation. DRUGBANK:DB11621 uuid:583e4764-2b25-46dc-85be-c93249df11f4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16914 biolink:treats HP:0000958 PMID:41385096 "[{""id"":""uuid:5d4489ca-bf81-4fee-82e0-dba7faf5f60d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d8ab3e3f-d3b0-4a10-bc03-15d66cdfea18"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For debridement and promotion of normal healing of hyperkeratotic surface lesions, particularly where healing is retarded by local infection, necrotic tissue, fibrinous or purulent debris or eshar. Urea is useful for the treatment of hyperkeratotic conditions such as dermatitis, psoriasis, soothes rough and dry skin, xerosis, ichthyosis, eczema, keratosis pilaris, keratosis palmaris, keratoderma, corns and calluses, as well as damaged, ingrown and devitalized nails. uuid:5cef4ea0-7b3e-4324-bcd1-14f8a6fdeb93 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16914 biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:52194720-09d7-411b-b659-1ec6c42c226c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:85890b5a-ef63-4d35-873e-56e1029bc5b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For debridement and promotion of normal healing of hyperkeratotic surface lesions, particularly where healing is retarded by local infection, necrotic tissue, fibrinous or purulent debris or eshar. Urea is useful for the treatment of hyperkeratotic conditions such as dermatitis, psoriasis, soothes rough and dry skin, xerosis, ichthyosis, eczema, keratosis pilaris, keratosis palmaris, keratoderma, corns and calluses, as well as damaged, ingrown and devitalized nails. uuid:d4cb5f51-6773-4f6f-b583-6c3b60ac2f36 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16914 biolink:treats MONDO:0019272 PMID:41385096 "[{""id"":""uuid:85228213-91ab-40a8-9378-c45cf22ec795"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0d156641-8807-4d7a-b40b-fdf687982ce3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For debridement and promotion of normal healing of hyperkeratotic surface lesions, particularly where healing is retarded by local infection, necrotic tissue, fibrinous or purulent debris or eshar. Urea is useful for the treatment of hyperkeratotic conditions such as dermatitis, psoriasis, soothes rough and dry skin, xerosis, ichthyosis, eczema, keratosis pilaris, keratosis palmaris, keratoderma, corns and calluses, as well as damaged, ingrown and devitalized nails. uuid:b747a2c5-a66e-476f-8bc9-81c54b0723ad biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16914 biolink:treats HP:6000789 PMID:41385096 "[{""id"":""uuid:535dd2b8-60c1-48b1-bc95-3ac4033df445"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6d7bce0c-ad9b-4148-ba76-9e53a48af59d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For debridement and promotion of normal healing of hyperkeratotic surface lesions, particularly where healing is retarded by local infection, necrotic tissue, fibrinous or purulent debris or eshar. Urea is useful for the treatment of hyperkeratotic conditions such as dermatitis, psoriasis, soothes rough and dry skin, xerosis, ichthyosis, eczema, keratosis pilaris, keratosis palmaris, keratoderma, corns and calluses, as well as damaged, ingrown and devitalized nails. uuid:8aff9554-dca7-4049-968a-2cb485e3e467 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16914 biolink:treats MONDO:0007758 PMID:41385096 "[{""id"":""uuid:a48a3906-2091-4783-96d3-115e084a833d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e9b6b5d6-f550-40ea-9122-65da07a3309d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For debridement and promotion of normal healing of hyperkeratotic surface lesions, particularly where healing is retarded by local infection, necrotic tissue, fibrinous or purulent debris or eshar. Urea is useful for the treatment of hyperkeratotic conditions such as dermatitis, psoriasis, soothes rough and dry skin, xerosis, ichthyosis, eczema, keratosis pilaris, keratosis palmaris, keratoderma, corns and calluses, as well as damaged, ingrown and devitalized nails. uuid:c4066b93-0e37-470a-9c12-715990a898c3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16914 biolink:treats UMLS:C0406446 PMID:41385096 "[{""id"":""uuid:ed4c020d-f490-4db1-b456-ec1c87d62cb0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7bfdb311-2f1e-4222-9b90-0b2cff138517"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For debridement and promotion of normal healing of hyperkeratotic surface lesions, particularly where healing is retarded by local infection, necrotic tissue, fibrinous or purulent debris or eshar. Urea is useful for the treatment of hyperkeratotic conditions such as dermatitis, psoriasis, soothes rough and dry skin, xerosis, ichthyosis, eczema, keratosis pilaris, keratosis palmaris, keratoderma, corns and calluses, as well as damaged, ingrown and devitalized nails. uuid:b4e4f0a1-02f6-4a67-b09c-ec0d89fbb4c7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16914 biolink:treats HP:0012710 PMID:41385096 "[{""id"":""uuid:892b2684-9957-462a-8815-c183708f9495"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:93b2d4f9-a325-4146-9558-57ba3f445289"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For debridement and promotion of normal healing of hyperkeratotic surface lesions, particularly where healing is retarded by local infection, necrotic tissue, fibrinous or purulent debris or eshar. Urea is useful for the treatment of hyperkeratotic conditions such as dermatitis, psoriasis, soothes rough and dry skin, xerosis, ichthyosis, eczema, keratosis pilaris, keratosis palmaris, keratoderma, corns and calluses, as well as damaged, ingrown and devitalized nails. uuid:f323bb5b-9a9c-41d7-be91-8f738d3c26d7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16914 biolink:treats MONDO:0002884 PMID:41385096 "[{""id"":""uuid:1949609c-9ff4-4402-92ec-a21704936b07"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:99210238-2515-4a13-8858-4678045ab5c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For debridement and promotion of normal healing of hyperkeratotic surface lesions, particularly where healing is retarded by local infection, necrotic tissue, fibrinous or purulent debris or eshar. Urea is useful for the treatment of hyperkeratotic conditions such as dermatitis, psoriasis, soothes rough and dry skin, xerosis, ichthyosis, eczema, keratosis pilaris, keratosis palmaris, keratoderma, corns and calluses, as well as damaged, ingrown and devitalized nails. uuid:e152b711-b557-4ca0-84c0-eb92d27987c4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7451 biolink:treats UMLS:C5192601 PMID:41385096 "[{""id"":""uuid:c242ffdd-3582-4a64-b93a-29a542224591"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e10ee0a9-0bc9-4a3e-ad0a-8e1d19dab0b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Naftifine hydrochloride gel USP, 2% is indicated for the treatment of interdigital tinea pedis caused by the organisms Trichophyton rubrum , Trichophyton mentagrophytes , and Epidermophyton floccosum . uuid:52975a35-31b6-4e0c-884b-c3e1a4e44a90 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8207 biolink:treats MONDO:0001330 PMID:41385096 "[{""id"":""uuid:a469a9c8-f39b-4085-9429-ffe1986fe240"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6bec942c-4538-4711-93c7-fe02a82fa3c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VUITY ® is indicated for the treatment of presbyopia in adults. uuid:2ed80602-6136-419c-892e-6dacf3129ad4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16359 biolink:treats MONDO:0019218 PMID:41385096 "[{""id"":""uuid:478b5397-b866-4451-903f-8ca8dd140893"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9e7af80c-4cf1-4e82-8e2f-d9c3730f0149"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:1ccedad5-5849-4f68-93ab-f7db4fbe9d75"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CHOLBAM is a bile acid indicated for: Treatment of bile acid synthesis disorders due to single enzyme defects (SEDs). ( 1.1 ) Adjunctive treatment of peroxisomal disorders (PDs) including Zellweger spectrum disorders in patients who exhibit manifestations of liver disease, steatorrhea or complications from decreased fat-soluble vitamin absorption. ( 1.2 ) Limitations of use: The safety and effectiveness of CHOLBAM on extrahepatic manifestations of bile acid synthesis disorders due to SEDs or PDs including Zellweger spectrum disorders have not been established. ( 1.3 ).|[PMDA] A drug with a new active ingredient indicated for the treatment of inborn errors of bile acid metabolism. [Orphan drug] uuid:ec52764e-cabe-4e4a-b3e0-de451104774d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16359 biolink:treats MONDO:0019053 PMID:41385096 "[{""id"":""uuid:e549eb4f-2e05-42cb-a9c6-4d7b6a396d30"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a942f150-fb53-41ff-9316-ce76d247db1e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CHOLBAM is a bile acid indicated for: Treatment of bile acid synthesis disorders due to single enzyme defects (SEDs). ( 1.1 ) Adjunctive treatment of peroxisomal disorders (PDs) including Zellweger spectrum disorders in patients who exhibit manifestations of liver disease, steatorrhea or complications from decreased fat-soluble vitamin absorption. ( 1.2 ) Limitations of use: The safety and effectiveness of CHOLBAM on extrahepatic manifestations of bile acid synthesis disorders due to SEDs or PDs including Zellweger spectrum disorders have not been established. ( 1.3 ). uuid:095983c7-d7c3-4c37-8d3c-b5ebb5e0455e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16359 biolink:treats MONDO:0019609 PMID:41385096 "[{""id"":""uuid:50c79b6d-992f-480e-96e1-e77509235fe7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e5c04d29-71bb-43f9-90a9-787d8b025597"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CHOLBAM is a bile acid indicated for: Treatment of bile acid synthesis disorders due to single enzyme defects (SEDs). ( 1.1 ) Adjunctive treatment of peroxisomal disorders (PDs) including Zellweger spectrum disorders in patients who exhibit manifestations of liver disease, steatorrhea or complications from decreased fat-soluble vitamin absorption. ( 1.2 ) Limitations of use: The safety and effectiveness of CHOLBAM on extrahepatic manifestations of bile acid synthesis disorders due to SEDs or PDs including Zellweger spectrum disorders have not been established. ( 1.3 ). uuid:c41053eb-ca7f-4fd1-bbda-a0afbf46c00b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8805 biolink:treats MONDO:0005147 PMID:41385096 "[{""id"":""uuid:75c6e4bd-d8a8-472c-a2e6-f118ba820821"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1ae8e2b7-d151-4b79-8b8a-5929ad1622d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Repaglinide tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitation of Use: Repaglinide tablets should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. uuid:7662dead-f733-459b-9b4a-aaefe9cacd08 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:74947 biolink:treats MONDO:0009693 PMID:41385096 "[{""id"":""uuid:808fcbe4-4da5-4bc4-a9b2-c4ef235b318c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e496063c-01a4-45e4-83a5-8d37d0b5134b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:67761e74-7cf9-406e-a005-1a3aff15e1f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/thalidomide-celgene""]},{""id"":""uuid:1c52dcd0-cfd1-473e-9c93-d9338c79386e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] • THALOMID in combination with dexamethasone is indicated for the treatment of patients with newly diagnosed multiple myeloma (MM). ( 1.1 ) • THALOMID is indicated for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL). THALOMID is not indicated as monotherapy for such ENL treatment in the presence of moderate to severe neuritis. THALOMID is also indicated as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence. ( 1.2 )|[EMA] Thalidomide BMS in combination with melphalan and prednisone as first line treatment of patients with untreated multiple myeloma, aged >/= 65 years or ineligible for high dose chemotherapy.Thalidomide BMS is prescribed and dispensed according to the Thalidomide Celgene Pregnancy Prevention Programme (see section 4.4).|[PMDA] A drug containing a new active ingredient indicated for the treatment of relapsed or refractory multiple myeloma. [Orphan drug] uuid:955701c4-f843-4297-b991-3d35b77be2e3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:74947 biolink:treats UMLS:C0343467 PMID:41385096 "[{""id"":""uuid:e8e13b92-5b46-4b2d-a3a5-cd8f6fae92e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a5c1d5b2-156e-4074-a80e-f6d50448a165"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e7b5daf1-5f4b-451d-897b-25eb0f712c96"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] • THALOMID in combination with dexamethasone is indicated for the treatment of patients with newly diagnosed multiple myeloma (MM). ( 1.1 ) • THALOMID is indicated for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL). THALOMID is not indicated as monotherapy for such ENL treatment in the presence of moderate to severe neuritis. THALOMID is also indicated as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence. ( 1.2 )|[PMDA] Drugs with a new additional indication and a new dosage for the treatment of erythema nodosum leprosum. [Orphan drug] uuid:63a5c494-0611-4be2-a7e0-8ef37a15fe83 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60210 biolink:treats MONDO:0009643 PMID:41385096 "[{""id"":""uuid:a0007657-a2ba-47f5-855c-da553c6e3467"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:5aa6d765-0c4c-4e20-b561-5f649b86223a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:db47eab7-e5a3-491a-b958-b40c55239155"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NULIBRY is indicated to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A.|[EMA] NULIBRY is indicated for the treatment of patients with molybdenum cofactor deficiency (MoCD) Type A. uuid:2712c600-871a-4858-a1da-2a01b54e1246 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8768 biolink:treats HP:0005202 PMID:41385096 "[{""id"":""uuid:8c6a5ae4-2a9a-4037-8368-29bf59260b29"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5d07dbb2-ee51-47fc-b845-025a10809ca2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Healing of Erosive or Ulcerative GERD in Adults Rabeprazole sodium delayed-release tablets are indicated for short-term (4 to 8 weeks) treatment in the healing and symptomatic relief of erosive or ulcerative gastroesophageal reflux disease (GERD). For those patients who have not healed after 8 weeks of treatment, an additional 8-week course of rabeprazole sodium delayed-release tablets may be considered. 1.2 Maintenance of Healing of Erosive or Ulcerative GERD in Adults Rabeprazole sodium delayed-release tablets are indicated for maintaining healing and reduction in relapse rates of heartburn symptoms in patients with erosive or ulcerative gastroesophageal reflux disease (GERD Maintenance). Controlled studies do not extend beyond 12 months. 1.3 Treatment of Symptomatic GERD in Adults Rabeprazole sodium delayed-release tablets are indicated for the treatment of daytime and nighttime heartburn and other symptoms associated with GERD in adults for up to 4 weeks. 1.4 Healing of Duodenal Ulcers in Adults Rabeprazole sodium delayed-release tablets are indicated for short-term (up to four weeks) treatment in the healing and symptomatic relief of duodenal ulcers. Most patients heal within four weeks. 1.5 Helicobacter pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence in Adults Rabeprazole sodium delayed-release tablets, in combination with amoxicillin and clarithromycin as a three drug regimen, are indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or history within the past 5 years) to eradicate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. In patients who fail therapy, susceptibility testing should be done. If resistance to clarithromycin is demonstrated or susceptibility testing is not possible, alternative antimicrobial therapy should be instituted [see Clinical Pharmacology (12.2) and the full prescribing information for clarithromycin]. 1.6 Treatment of Pathological Hypersecretory Conditions, Including Zollinger-Ellison Syndrome in Adults Rabeprazole sodium delayed-release tablets are indicated for the long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome. 1.7 Treatment of Symptomatic GERD in Adolescent Patients 12 Years of Age and Older Rabeprazole sodium delayed-release tablets are indicated for the treatment of symptomatic GERD in adolescents 12 years of age and above for up to 8 weeks. uuid:550571a9-5821-4c35-9a04-ef7ddd679d80 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9943 biolink:treats MONDO:0003709 PMID:41385096 "[{""id"":""uuid:ece224f6-a099-454a-8913-26cbd3cbf685"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:83b1e0e6-27d5-47d3-a965-ac1ee92a638c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Major Depressive Disorder Venlafaxine hydrochloride extended-release capsules, USP are indicated for the treatment of major depressive disorder (MDD). Efficacy was established in three short-term (4, 8, and 12 weeks) and two long-term, maintenance trials. 1.3 Social Anxiety Disorder Venlafaxine hydrochloride extended-release capsules, USP are indicated for the treatment of Social Anxiety Disorder (SAD), also known as social phobia. Efficacy was established in four 12-week and one 26-week, placebo-controlled trials. 1.4 Panic Disorder Venlafaxine hydrochloride extended-release capsules, USP are indicated for the treatment of Panic Disorder (PD), with or without agoraphobia. Efficacy was established in two 12-week placebo-controlled trials. uuid:abd65116-f2f5-4c7d-b58c-a4a8d2d1cd68 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:567361 biolink:treats MONDO:0018935 PMID:41385096 "[{""id"":""uuid:2b62d4c4-4cce-4666-aea7-199103339b01"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:0415a47d-32e2-453b-b9a8-10a22f43d460"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:36624c42-3c74-4682-984d-5bb89e703e0d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/mavenclad""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cladribine Injection, USP is indicated for the treatment of active Hairy Cell Leukemia as defined by clinically significant anemia, neutropenia, thrombocytopenia or disease-related symptoms.|[EMA] Litak is indicated for the treatment of hairy-cell leukaemia. uuid:7576ddda-3565-444f-9f4d-21e6e7fa91e4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:42068 biolink:treats MONDO:0018874 PMID:41385096 "[{""id"":""uuid:68fa1842-2cd8-4399-ae18-e5dfbb66005a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1aed727f-b5e0-4e22-99ab-8242fbe16a3c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Idarubicin Hydrochloride injection, USP in combination with other approved antileukemic drugs is indicated for the treatment of acute myeloid leukemia (AML) in adults. This includes French-American-British (FAB) classifications M1 through M7. uuid:9c7bfb81-bc9f-496e-b16c-c9193dfb0ee8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50381 biolink:treats MONDO:0018150 PMID:41385096 "[{""id"":""uuid:d4e34033-b8c9-405b-820e-f856704b1ad4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:56d18540-4262-42a4-913b-09d1f52864a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:92ff9ca0-d188-4ab6-a8f5-07c621fa658c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/opfolda""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZAVESCA is a glucosylceramide synthase inhibitor indicated as monotherapy for treatment of adult patients with mild/moderate type 1 Gaucher disease for whom enzyme replacement therapy is not a therapeutic option ( 1.1 ).|[EMA] Miglustat Dipharma is indicated for the oral treatment of adult patients with mild to moderate type 1 Gaucher disease.Miglustat Dipharma may be used only in the treatment of patients for whom enzyme replacement therapy is unsuitable.Miglustat Dipharma is indicated for the treatment of progressive neurological manifestations in adult patients and paediatric patients with Niemann-Pick type C disease. uuid:9e840174-0124-4cb2-97ff-22a7f203bc14 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50381 biolink:treats MONDO:0009265 PMID:41385096 "[{""id"":""uuid:6525e8d8-d7e9-4906-bd85-774e75bad624"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ff87061a-ee97-46ca-828d-f5996167befe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZAVESCA is a glucosylceramide synthase inhibitor indicated as monotherapy for treatment of adult patients with mild/moderate type 1 Gaucher disease for whom enzyme replacement therapy is not a therapeutic option ( 1.1 ). uuid:eb23de64-35e0-4345-8f6b-ae33fe644069 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15367 biolink:treats MONDO:0012883 PMID:41385096 "[{""id"":""uuid:b3800eac-a7de-4f5b-a69b-1b36596d4e2e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5f537cea-d481-4f02-9a1b-6573bac69a4e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tretinoin capsules are indicated for the induction of remission in adults and pediatric patients 1 year of age and older with acute promyelocytic leukemia (APL) characterized by the presence of the t(15;17) translocation or PML/RARα gene expression, and who are refractory to or who have relapsed from anthracycline chemotherapy or for whom anthracycline-based chemotherapy is contraindicated. uuid:01c21052-7b38-4827-8cb2-20aacb9a426e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2166086 biolink:treats UMLS:C0406317 PMID:41385096 "[{""id"":""uuid:a12fdcc6-fcd4-49b7-bb69-8dc62893bad2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b07f147f-9f2a-42ec-b0c6-a51e076ea5f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DUOBRII ® (halobetasol propionate and tazarotene) Lotion, 0.01%/0.045% is indicated for the topical treatment of plaque psoriasis in adults. uuid:55e961ea-bd57-4fb6-af8e-59258a41f929 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4Q52C550XK biolink:treats MONDO:0018906 PMID:41385096 "[{""id"":""uuid:2b280704-6e99-499a-bba4-b9e5d9ecf302"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:3caf35a6-ea9c-4875-80c2-a75c5d5b898f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:21fe82ce-e9d4-4bc1-967d-1b7078e053f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/zevalin""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Zevalin is a CD20-directed radiotherapeutic antibody administered as part of the Zevalin therapeutic regimen indicated for the treatment of adult patients with: relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's lymphoma (NHL) ( 1.1 ). previously untreated follicular NHL who achieve a partial or complete response to first-line chemotherapy ( 1.2 ).|[EMA] Zevalin is indicated in adults.[90Y]-radiolabelled Zevalin is indicated as consolidation therapy after remission induction in previously untreated patients with follicular lymphoma. The benefit of Zevalin following rituximab in combination with chemotherapy has not been established.[90Y]-radiolabelled Zevalin is indicated for the treatment of adult patients with rituximab relapsedorrefractory CD20+ follicular B-cell non-Hodgkin's lymphoma (NHL). uuid:f91f8fe5-e500-4079-81c3-27d49803456d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28364 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:7853f28c-fd18-4500-bc4a-2f03bf716a75"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b175d8c6-e0a2-4a93-bc8c-0c223ed48ad1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VASCEPA ® (icosapent ethyl) is indicated: as an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization, and unstable angina requiring hospitalization in adult patients with elevated triglyceride (TG) levels (≥ 150 mg/dL) and established cardiovascular disease or diabetes mellitus and 2 or more additional risk factors for cardiovascular disease. as an adjunct to diet to reduce TG levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia. Limitations of Use: The effect of VASCEPA on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined. uuid:30ddc3d2-5759-4aa6-a3ce-c0226abbc661 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28364 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:2c8597d1-8905-44f2-a97c-da8336bfc745"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c7b1f9e5-5a52-4d90-885b-e1815dae7a06"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VASCEPA ® (icosapent ethyl) is indicated: as an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization, and unstable angina requiring hospitalization in adult patients with elevated triglyceride (TG) levels (≥ 150 mg/dL) and established cardiovascular disease or diabetes mellitus and 2 or more additional risk factors for cardiovascular disease. as an adjunct to diet to reduce TG levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia. Limitations of Use: The effect of VASCEPA on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined. uuid:49dc3894-7250-42a1-9c26-aee891cfddc9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28364 biolink:treats MONDO:0006805 PMID:41385096 "[{""id"":""uuid:2f76be43-098f-4b0e-af6a-bee3b35366dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:393b48db-03a6-42da-aae5-514eb3f5b007"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VASCEPA ® (icosapent ethyl) is indicated: as an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization, and unstable angina requiring hospitalization in adult patients with elevated triglyceride (TG) levels (≥ 150 mg/dL) and established cardiovascular disease or diabetes mellitus and 2 or more additional risk factors for cardiovascular disease. as an adjunct to diet to reduce TG levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia. Limitations of Use: The effect of VASCEPA on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined. uuid:79f44ca2-1171-473e-919f-9ad97e740188 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:581255 biolink:treats MONDO:0004567 PMID:41385096 "[{""id"":""uuid:9e70dd50-98a4-40d4-9ae1-b2fe34c04f82"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:630fcd5c-7a97-4088-9d68-2901a01fc254"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Plenamine™ 15% is indicated as an amino acid (nitrogen) source in parenteral nutrition regimens. This use is appropriate when the enteral route is inadvisable, inadequate or not possible, as when: — Gastrointestinal absorption is impaired by obstruction, inflammatory disease or its complications, or antineoplastic therapy; — Bowel rest is needed because of gastrointestinal surgery or its complications such as ileus, fistulae or anastomotic leaks; — Tube feeding methods alone cannot provide adequate nutrition. uuid:bb9d1de0-72f2-461f-828d-8edb2b01c180 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:581255 biolink:treats UMLS:C0919691 PMID:41385096 "[{""id"":""uuid:90c61929-27f2-4f47-925e-d27fce008172"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:92ef34e6-ee06-4056-8c67-3535d21f96ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Plenamine™ 15% is indicated as an amino acid (nitrogen) source in parenteral nutrition regimens. This use is appropriate when the enteral route is inadvisable, inadequate or not possible, as when: — Gastrointestinal absorption is impaired by obstruction, inflammatory disease or its complications, or antineoplastic therapy; — Bowel rest is needed because of gastrointestinal surgery or its complications such as ileus, fistulae or anastomotic leaks; — Tube feeding methods alone cannot provide adequate nutrition. uuid:f6034ced-7bca-46d0-96b5-3a856fa11780 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2379 biolink:treats HP:0004308 PMID:41385096 "[{""id"":""uuid:6a7140d5-5bcd-4beb-a278-e5208d10bf8a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7a2bc2bd-f41d-404b-8667-5d3683b9cebc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension Acebutolol HCl capsules are indicated for the management of hypertension in adults. It may be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. Ventricular Arrhythmias Acebutolol HCl capsules are indicated in the management of ventricular premature beats; it reduces the total number of premature beats, as well as the number of paired and multiform ventricular ectopic beats, and R-on-T beats. uuid:846ad0e5-b3fa-4771-8bd9-bd38c9c8305b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:82720 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:92a059d3-348d-4cec-9b06-2f636a893e13"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:11d6b22f-52d9-4489-a2cc-4c1de0d01b88"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:3316a055-86ff-4bf0-b325-6ea0080ed167"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/jardiance""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] JARDIANCE is indicated: to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure. to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease. as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.|[EMA] Type 2 diabetes mellitusJardiance is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered in addition to other medicinal products for the treatment of diabetesFor study results with respect to combinations of therapies, effects on glycaemic control, and cardiovascular and renal events, and the populations studied, see sections 4.4, 4.5 and 5.1. of the annex.Heart failureJardiance is indicated in adults for the treatment of symptomatic chronic heart failure. Chronic kidney diseaseJardiance is indicated in adults for the treatment of chronic kidney disease. uuid:f2cbe036-1e1f-4dc1-aa9e-53e59a9dce78 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:82720 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:9aa744de-facc-42a6-90fe-088224f7ea98"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4abd4bd3-7d7d-499f-bc36-6a2acd1179f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f6088e2c-89c9-4dff-b58e-d5026d244f2f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/jardiance""]},{""id"":""uuid:53c49d2d-913a-46fc-81f3-810e28f37b7b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] JARDIANCE is indicated: to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure. to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease. as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.|[EMA] Type 2 diabetes mellitusJardiance is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered in addition to other medicinal products for the treatment of diabetesFor study results with respect to combinations of therapies, effects on glycaemic control, and cardiovascular and renal events, and the populations studied, see sections 4.4, 4.5 and 5.1. of the annex.Heart failureJardiance is indicated in adults for the treatment of symptomatic chronic heart failure. Chronic kidney diseaseJardiance is indicated in adults for the treatment of chronic kidney disease.|[PMDA] Drugs with a new active ingredient indicated for the treatment of type 2 diabetes mellitus. uuid:f57d0cee-73c7-42d0-ac27-871cd62ef525 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6846 biolink:treats MONDO:0010826 PMID:41385096 "[{""id"":""uuid:75532c5e-315c-4075-9f83-a5dee84c0cbc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a41fd9d7-33e5-4011-9165-5b55a97fb459"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methsuximide is indicated for the control of absence (petit mal) seizures that are refractory to other drugs. uuid:b770192a-3c77-4f21-b483-1a265050c4be biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:WTT295HSY5 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:e999798a-7921-485f-ad55-37adf8b47b2d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5ad5ec7c-dcc4-42a2-b288-6def785e421a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ed51f04d-1dc9-4ae9-92f5-2380223827b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/trulicity""]},{""id"":""uuid:414cbd76-84ce-4fe2-b2ed-2231d58761eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TRULICITY ® is indicated: As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. To reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors.|[EMA] Trulicity is indicated for the treatment of patients 10 years and above with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance or contraindicationsin addition to other medicinal products for the treatment of diabetes.For study results with respect to combinations, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1.|[PMDA] A drug with a new active ingredient indicated for the treatment of type 2 diabetes mellitus. uuid:7ab07a07-085a-45e6-866d-ebdfc48a2ccb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:WTT295HSY5 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:d8f9f80b-b18c-4fe7-93c1-3d6ba47c022a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:50194a1e-7301-46a3-8eed-406cf2473134"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TRULICITY ® is indicated: As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. To reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors. uuid:80fb1884-f033-4a66-aed4-d95bae3724d7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:WTT295HSY5 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:ef3a66ff-3254-41f4-bb89-63e10975185d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:17619463-f501-4608-81e5-e7a07f54d84b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TRULICITY ® is indicated: As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. To reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors. uuid:61acfa7c-6fda-4293-9b48-327b62a194ff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats MONDO:0700217 PMID:41385096 "[{""id"":""uuid:539e2590-3891-49f6-bbf5-82766f0f1851"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:831262b7-f328-4295-81c9-5ff992d6b5c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of gentamicin and other antibacterial drugs, gentamicin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Gentamicin Sulfate Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: Pseudomonas aeruginosa , Proteus species (indole-positive and indole-negative), Escherichia coli , Klebsiella-Enterobacter-Serratia species, Citrobacter species, and Staphylococcus species (coagulase-positive and coagulase-negative). Clinical studies have shown Gentamicin Sulfate Injection, USP to be effective in bacterial neonatal sepsis; bacterial septicemia; and serious bacterial infections of the central nervous system (meningitis), urinary tract, respiratory tract, gastrointestinal tract (including peritonitis), skin, bone and soft tissue (including burns). Aminoglycosides, including gentamicin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are susceptible to these antibiotics and are not susceptible to antibiotics having less potential for toxicity. Specimens for bacterial culture should be obtained to isolate and identify causative organisms and to determine their susceptibility to gentamicin. Gentamicin sulfate may be considered as initial therapy in suspected or confirmed gram-negative infections, and therapy may be instituted before obtaining results of susceptibility testing. The decision to continue therapy with this drug should be based on the results of susceptibility tests, the severity of the infection, and the important additional concepts contained in the WARNINGS box. If the causative organisms are resistant to gentamicin, other appropriate therapy should be instituted. In serious infections when the causative organisms are unknown, gentamicin sulfate may be administered as initial therapy in conjunction with a penicillin-type or cephalosporin-type drug before obtaining results of susceptibility testing. If anaerobic organisms are suspected as etiologic agents, consideration should be given to using other suitable antimicrobial therapy in conjunction with gentamicin. Following identification of the organism and its susceptibility, appropriate antibiotic therapy should then be continued. Gentamicin sulfate has been used effectively in combination with carbenicillin for the treatment of life-threatening infections caused by Pseudomonas aeruginosa . It has also been found effective when used in conjunction with a penicillin-type drug for the treatment of endocarditis caused by group D streptococci. Gentamicin Sulfate Injection, USP has also been shown to be effective in the treatment of serious staphylococcal infections. While not the antibiotic of first choice, gentamicin may be considered when penicillins or other less potentially toxic drugs are contraindicated and bacterial susceptibility tests and clinical judgment indicate its use. It may also be considered in mixed infections caused by susceptible strains of staphylococci and gram-negative organisms. In the neonate with suspected bacterial sepsis or staphylococcal pneumonia, a penicillin-type drug is also usually indicated as concomitant therapy with gentamicin. uuid:ccb5b652-aff7-462f-86d4-8830644e5e40 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats UMLS:C0684256 PMID:41385096 "[{""id"":""uuid:0e2fc4f9-f039-46cb-b134-1a8e47b2adc7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6743d0b3-d6cb-4a11-9253-724cd08936be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of gentamicin and other antibacterial drugs, gentamicin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Gentamicin Sulfate Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: Pseudomonas aeruginosa , Proteus species (indole-positive and indole-negative), Escherichia coli , Klebsiella-Enterobacter-Serratia species, Citrobacter species, and Staphylococcus species (coagulase-positive and coagulase-negative). Clinical studies have shown Gentamicin Sulfate Injection, USP to be effective in bacterial neonatal sepsis; bacterial septicemia; and serious bacterial infections of the central nervous system (meningitis), urinary tract, respiratory tract, gastrointestinal tract (including peritonitis), skin, bone and soft tissue (including burns). Aminoglycosides, including gentamicin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are susceptible to these antibiotics and are not susceptible to antibiotics having less potential for toxicity. Specimens for bacterial culture should be obtained to isolate and identify causative organisms and to determine their susceptibility to gentamicin. Gentamicin sulfate may be considered as initial therapy in suspected or confirmed gram-negative infections, and therapy may be instituted before obtaining results of susceptibility testing. The decision to continue therapy with this drug should be based on the results of susceptibility tests, the severity of the infection, and the important additional concepts contained in the WARNINGS box. If the causative organisms are resistant to gentamicin, other appropriate therapy should be instituted. In serious infections when the causative organisms are unknown, gentamicin sulfate may be administered as initial therapy in conjunction with a penicillin-type or cephalosporin-type drug before obtaining results of susceptibility testing. If anaerobic organisms are suspected as etiologic agents, consideration should be given to using other suitable antimicrobial therapy in conjunction with gentamicin. Following identification of the organism and its susceptibility, appropriate antibiotic therapy should then be continued. Gentamicin sulfate has been used effectively in combination with carbenicillin for the treatment of life-threatening infections caused by Pseudomonas aeruginosa . It has also been found effective when used in conjunction with a penicillin-type drug for the treatment of endocarditis caused by group D streptococci. Gentamicin Sulfate Injection, USP has also been shown to be effective in the treatment of serious staphylococcal infections. While not the antibiotic of first choice, gentamicin may be considered when penicillins or other less potentially toxic drugs are contraindicated and bacterial susceptibility tests and clinical judgment indicate its use. It may also be considered in mixed infections caused by susceptible strains of staphylococci and gram-negative organisms. In the neonate with suspected bacterial sepsis or staphylococcal pneumonia, a penicillin-type drug is also usually indicated as concomitant therapy with gentamicin. uuid:ee587517-3102-448a-9ffa-8c6b9ce39941 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats MONDO:0021108 PMID:41385096 "[{""id"":""uuid:f7456580-f3ec-4ec1-9c77-8a58bcac11f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f2699646-467e-40e9-a6b5-7b78f65216f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of gentamicin and other antibacterial drugs, gentamicin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Gentamicin Sulfate Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: Pseudomonas aeruginosa , Proteus species (indole-positive and indole-negative), Escherichia coli , Klebsiella-Enterobacter-Serratia species, Citrobacter species, and Staphylococcus species (coagulase-positive and coagulase-negative). Clinical studies have shown Gentamicin Sulfate Injection, USP to be effective in bacterial neonatal sepsis; bacterial septicemia; and serious bacterial infections of the central nervous system (meningitis), urinary tract, respiratory tract, gastrointestinal tract (including peritonitis), skin, bone and soft tissue (including burns). Aminoglycosides, including gentamicin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are susceptible to these antibiotics and are not susceptible to antibiotics having less potential for toxicity. Specimens for bacterial culture should be obtained to isolate and identify causative organisms and to determine their susceptibility to gentamicin. Gentamicin sulfate may be considered as initial therapy in suspected or confirmed gram-negative infections, and therapy may be instituted before obtaining results of susceptibility testing. The decision to continue therapy with this drug should be based on the results of susceptibility tests, the severity of the infection, and the important additional concepts contained in the WARNINGS box. If the causative organisms are resistant to gentamicin, other appropriate therapy should be instituted. In serious infections when the causative organisms are unknown, gentamicin sulfate may be administered as initial therapy in conjunction with a penicillin-type or cephalosporin-type drug before obtaining results of susceptibility testing. If anaerobic organisms are suspected as etiologic agents, consideration should be given to using other suitable antimicrobial therapy in conjunction with gentamicin. Following identification of the organism and its susceptibility, appropriate antibiotic therapy should then be continued. Gentamicin sulfate has been used effectively in combination with carbenicillin for the treatment of life-threatening infections caused by Pseudomonas aeruginosa . It has also been found effective when used in conjunction with a penicillin-type drug for the treatment of endocarditis caused by group D streptococci. Gentamicin Sulfate Injection, USP has also been shown to be effective in the treatment of serious staphylococcal infections. While not the antibiotic of first choice, gentamicin may be considered when penicillins or other less potentially toxic drugs are contraindicated and bacterial susceptibility tests and clinical judgment indicate its use. It may also be considered in mixed infections caused by susceptible strains of staphylococci and gram-negative organisms. In the neonate with suspected bacterial sepsis or staphylococcal pneumonia, a penicillin-type drug is also usually indicated as concomitant therapy with gentamicin. uuid:970ae9e5-9d09-4106-9ba2-1b40fded18a1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:6e2f6c6a-4a0f-4263-9965-23993afec8a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d6c6e3ad-33ae-452e-90e2-cc1a64bfdb46"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of gentamicin and other antibacterial drugs, gentamicin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Gentamicin Sulfate Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: Pseudomonas aeruginosa , Proteus species (indole-positive and indole-negative), Escherichia coli , Klebsiella-Enterobacter-Serratia species, Citrobacter species, and Staphylococcus species (coagulase-positive and coagulase-negative). Clinical studies have shown Gentamicin Sulfate Injection, USP to be effective in bacterial neonatal sepsis; bacterial septicemia; and serious bacterial infections of the central nervous system (meningitis), urinary tract, respiratory tract, gastrointestinal tract (including peritonitis), skin, bone and soft tissue (including burns). Aminoglycosides, including gentamicin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are susceptible to these antibiotics and are not susceptible to antibiotics having less potential for toxicity. Specimens for bacterial culture should be obtained to isolate and identify causative organisms and to determine their susceptibility to gentamicin. Gentamicin sulfate may be considered as initial therapy in suspected or confirmed gram-negative infections, and therapy may be instituted before obtaining results of susceptibility testing. The decision to continue therapy with this drug should be based on the results of susceptibility tests, the severity of the infection, and the important additional concepts contained in the WARNINGS box. If the causative organisms are resistant to gentamicin, other appropriate therapy should be instituted. In serious infections when the causative organisms are unknown, gentamicin sulfate may be administered as initial therapy in conjunction with a penicillin-type or cephalosporin-type drug before obtaining results of susceptibility testing. If anaerobic organisms are suspected as etiologic agents, consideration should be given to using other suitable antimicrobial therapy in conjunction with gentamicin. Following identification of the organism and its susceptibility, appropriate antibiotic therapy should then be continued. Gentamicin sulfate has been used effectively in combination with carbenicillin for the treatment of life-threatening infections caused by Pseudomonas aeruginosa . It has also been found effective when used in conjunction with a penicillin-type drug for the treatment of endocarditis caused by group D streptococci. Gentamicin Sulfate Injection, USP has also been shown to be effective in the treatment of serious staphylococcal infections. While not the antibiotic of first choice, gentamicin may be considered when penicillins or other less potentially toxic drugs are contraindicated and bacterial susceptibility tests and clinical judgment indicate its use. It may also be considered in mixed infections caused by susceptible strains of staphylococci and gram-negative organisms. In the neonate with suspected bacterial sepsis or staphylococcal pneumonia, a penicillin-type drug is also usually indicated as concomitant therapy with gentamicin. uuid:5abf29c5-e183-4eb9-ba42-a93d71b8af51 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats MONDO:0024355 PMID:41385096 "[{""id"":""uuid:4bdda170-5f2c-4c44-95fd-0cb2026e5407"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:58c38bb8-8ada-4b60-8fb3-11729cebc8ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of gentamicin and other antibacterial drugs, gentamicin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Gentamicin Sulfate Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: Pseudomonas aeruginosa , Proteus species (indole-positive and indole-negative), Escherichia coli , Klebsiella-Enterobacter-Serratia species, Citrobacter species, and Staphylococcus species (coagulase-positive and coagulase-negative). Clinical studies have shown Gentamicin Sulfate Injection, USP to be effective in bacterial neonatal sepsis; bacterial septicemia; and serious bacterial infections of the central nervous system (meningitis), urinary tract, respiratory tract, gastrointestinal tract (including peritonitis), skin, bone and soft tissue (including burns). Aminoglycosides, including gentamicin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are susceptible to these antibiotics and are not susceptible to antibiotics having less potential for toxicity. Specimens for bacterial culture should be obtained to isolate and identify causative organisms and to determine their susceptibility to gentamicin. Gentamicin sulfate may be considered as initial therapy in suspected or confirmed gram-negative infections, and therapy may be instituted before obtaining results of susceptibility testing. The decision to continue therapy with this drug should be based on the results of susceptibility tests, the severity of the infection, and the important additional concepts contained in the WARNINGS box. If the causative organisms are resistant to gentamicin, other appropriate therapy should be instituted. In serious infections when the causative organisms are unknown, gentamicin sulfate may be administered as initial therapy in conjunction with a penicillin-type or cephalosporin-type drug before obtaining results of susceptibility testing. If anaerobic organisms are suspected as etiologic agents, consideration should be given to using other suitable antimicrobial therapy in conjunction with gentamicin. Following identification of the organism and its susceptibility, appropriate antibiotic therapy should then be continued. Gentamicin sulfate has been used effectively in combination with carbenicillin for the treatment of life-threatening infections caused by Pseudomonas aeruginosa . It has also been found effective when used in conjunction with a penicillin-type drug for the treatment of endocarditis caused by group D streptococci. Gentamicin Sulfate Injection, USP has also been shown to be effective in the treatment of serious staphylococcal infections. While not the antibiotic of first choice, gentamicin may be considered when penicillins or other less potentially toxic drugs are contraindicated and bacterial susceptibility tests and clinical judgment indicate its use. It may also be considered in mixed infections caused by susceptible strains of staphylococci and gram-negative organisms. In the neonate with suspected bacterial sepsis or staphylococcal pneumonia, a penicillin-type drug is also usually indicated as concomitant therapy with gentamicin. uuid:399e77fc-8f67-4f42-901e-442414c8aace biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats MONDO:0043424 PMID:41385096 "[{""id"":""uuid:606c9b47-e606-4236-b7c6-6eedde96361e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ed563d6f-1d18-40dc-8b1b-2f96ea73b770"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of gentamicin and other antibacterial drugs, gentamicin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Gentamicin Sulfate Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: Pseudomonas aeruginosa , Proteus species (indole-positive and indole-negative), Escherichia coli , Klebsiella-Enterobacter-Serratia species, Citrobacter species, and Staphylococcus species (coagulase-positive and coagulase-negative). Clinical studies have shown Gentamicin Sulfate Injection, USP to be effective in bacterial neonatal sepsis; bacterial septicemia; and serious bacterial infections of the central nervous system (meningitis), urinary tract, respiratory tract, gastrointestinal tract (including peritonitis), skin, bone and soft tissue (including burns). Aminoglycosides, including gentamicin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are susceptible to these antibiotics and are not susceptible to antibiotics having less potential for toxicity. Specimens for bacterial culture should be obtained to isolate and identify causative organisms and to determine their susceptibility to gentamicin. Gentamicin sulfate may be considered as initial therapy in suspected or confirmed gram-negative infections, and therapy may be instituted before obtaining results of susceptibility testing. The decision to continue therapy with this drug should be based on the results of susceptibility tests, the severity of the infection, and the important additional concepts contained in the WARNINGS box. If the causative organisms are resistant to gentamicin, other appropriate therapy should be instituted. In serious infections when the causative organisms are unknown, gentamicin sulfate may be administered as initial therapy in conjunction with a penicillin-type or cephalosporin-type drug before obtaining results of susceptibility testing. If anaerobic organisms are suspected as etiologic agents, consideration should be given to using other suitable antimicrobial therapy in conjunction with gentamicin. Following identification of the organism and its susceptibility, appropriate antibiotic therapy should then be continued. Gentamicin sulfate has been used effectively in combination with carbenicillin for the treatment of life-threatening infections caused by Pseudomonas aeruginosa . It has also been found effective when used in conjunction with a penicillin-type drug for the treatment of endocarditis caused by group D streptococci. Gentamicin Sulfate Injection, USP has also been shown to be effective in the treatment of serious staphylococcal infections. While not the antibiotic of first choice, gentamicin may be considered when penicillins or other less potentially toxic drugs are contraindicated and bacterial susceptibility tests and clinical judgment indicate its use. It may also be considered in mixed infections caused by susceptible strains of staphylococci and gram-negative organisms. In the neonate with suspected bacterial sepsis or staphylococcal pneumonia, a penicillin-type drug is also usually indicated as concomitant therapy with gentamicin. uuid:bf2cda85-fc45-4035-bf9f-85fa48f57a1d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats MONDO:0004522 PMID:41385096 "[{""id"":""uuid:0d35c132-5866-4937-a089-a182de557dff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:60812e7a-4ecb-47e1-aaef-473d4b23c64a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:93dc7c33-92b8-4772-9ccd-d73cf319dc44"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of gentamicin and other antibacterial drugs, gentamicin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Gentamicin Sulfate Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: Pseudomonas aeruginosa , Proteus species (indole-positive and indole-negative), Escherichia coli , Klebsiella-Enterobacter-Serratia species, Citrobacter species, and Staphylococcus species (coagulase-positive and coagulase-negative). Clinical studies have shown Gentamicin Sulfate Injection, USP to be effective in bacterial neonatal sepsis; bacterial septicemia; and serious bacterial infections of the central nervous system (meningitis), urinary tract, respiratory tract, gastrointestinal tract (including peritonitis), skin, bone and soft tissue (including burns). Aminoglycosides, including gentamicin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are susceptible to these antibiotics and are not susceptible to antibiotics having less potential for toxicity. Specimens for bacterial culture should be obtained to isolate and identify causative organisms and to determine their susceptibility to gentamicin. Gentamicin sulfate may be considered as initial therapy in suspected or confirmed gram-negative infections, and therapy may be instituted before obtaining results of susceptibility testing. The decision to continue therapy with this drug should be based on the results of susceptibility tests, the severity of the infection, and the important additional concepts contained in the WARNINGS box. If the causative organisms are resistant to gentamicin, other appropriate therapy should be instituted. In serious infections when the causative organisms are unknown, gentamicin sulfate may be administered as initial therapy in conjunction with a penicillin-type or cephalosporin-type drug before obtaining results of susceptibility testing. If anaerobic organisms are suspected as etiologic agents, consideration should be given to using other suitable antimicrobial therapy in conjunction with gentamicin. Following identification of the organism and its susceptibility, appropriate antibiotic therapy should then be continued. Gentamicin sulfate has been used effectively in combination with carbenicillin for the treatment of life-threatening infections caused by Pseudomonas aeruginosa . It has also been found effective when used in conjunction with a penicillin-type drug for the treatment of endocarditis caused by group D streptococci. Gentamicin Sulfate Injection, USP has also been shown to be effective in the treatment of serious staphylococcal infections. While not the antibiotic of first choice, gentamicin may be considered when penicillins or other less potentially toxic drugs are contraindicated and bacterial susceptibility tests and clinical judgment indicate its use. It may also be considered in mixed infections caused by susceptible strains of staphylococci and gram-negative organisms. In the neonate with suspected bacterial sepsis or staphylococcal pneumonia, a penicillin-type drug is also usually indicated as concomitant therapy with gentamicin.|[PMDA] Drugs with a new dosage indicated for the treatment of sepsis, secondary infection of trauma, burn, and surgical wound, pneumonia, cystitis, pyelonephritis, peritonitis, otitis media caused by following applicable microorganisms: Gentamicin-sensitive Staphylococcus, Escherichia coli, Klebsiella, Enterobacter, Serratia, Proteus, Morganella morganii, Providencia, Pseudomonas aeruginosa uuid:6d1a8c77-e409-4416-b078-0ca02bce3e9b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats MONDO:0005246 PMID:41385096 "[{""id"":""uuid:ddde21ac-a942-4c02-8f65-d010f2c78092"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ea30306b-a8fe-4a05-b267-e3f8cd076cc4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of gentamicin and other antibacterial drugs, gentamicin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Gentamicin Sulfate Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: Pseudomonas aeruginosa , Proteus species (indole-positive and indole-negative), Escherichia coli , Klebsiella-Enterobacter-Serratia species, Citrobacter species, and Staphylococcus species (coagulase-positive and coagulase-negative). Clinical studies have shown Gentamicin Sulfate Injection, USP to be effective in bacterial neonatal sepsis; bacterial septicemia; and serious bacterial infections of the central nervous system (meningitis), urinary tract, respiratory tract, gastrointestinal tract (including peritonitis), skin, bone and soft tissue (including burns). Aminoglycosides, including gentamicin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are susceptible to these antibiotics and are not susceptible to antibiotics having less potential for toxicity. Specimens for bacterial culture should be obtained to isolate and identify causative organisms and to determine their susceptibility to gentamicin. Gentamicin sulfate may be considered as initial therapy in suspected or confirmed gram-negative infections, and therapy may be instituted before obtaining results of susceptibility testing. The decision to continue therapy with this drug should be based on the results of susceptibility tests, the severity of the infection, and the important additional concepts contained in the WARNINGS box. If the causative organisms are resistant to gentamicin, other appropriate therapy should be instituted. In serious infections when the causative organisms are unknown, gentamicin sulfate may be administered as initial therapy in conjunction with a penicillin-type or cephalosporin-type drug before obtaining results of susceptibility testing. If anaerobic organisms are suspected as etiologic agents, consideration should be given to using other suitable antimicrobial therapy in conjunction with gentamicin. Following identification of the organism and its susceptibility, appropriate antibiotic therapy should then be continued. Gentamicin sulfate has been used effectively in combination with carbenicillin for the treatment of life-threatening infections caused by Pseudomonas aeruginosa . It has also been found effective when used in conjunction with a penicillin-type drug for the treatment of endocarditis caused by group D streptococci. Gentamicin Sulfate Injection, USP has also been shown to be effective in the treatment of serious staphylococcal infections. While not the antibiotic of first choice, gentamicin may be considered when penicillins or other less potentially toxic drugs are contraindicated and bacterial susceptibility tests and clinical judgment indicate its use. It may also be considered in mixed infections caused by susceptible strains of staphylococci and gram-negative organisms. In the neonate with suspected bacterial sepsis or staphylococcal pneumonia, a penicillin-type drug is also usually indicated as concomitant therapy with gentamicin. uuid:23d29711-e7bd-45ce-bc71-9a27e47a4341 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats UMLS:C0149778 PMID:41385096 "[{""id"":""uuid:385e30ec-9042-41f9-b2df-859d25c58a93"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6e3bc0f9-76ec-402e-91f7-3ea9e2f3482a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of gentamicin and other antibacterial drugs, gentamicin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Gentamicin Sulfate Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: Pseudomonas aeruginosa , Proteus species (indole-positive and indole-negative), Escherichia coli , Klebsiella-Enterobacter-Serratia species, Citrobacter species, and Staphylococcus species (coagulase-positive and coagulase-negative). Clinical studies have shown Gentamicin Sulfate Injection, USP to be effective in bacterial neonatal sepsis; bacterial septicemia; and serious bacterial infections of the central nervous system (meningitis), urinary tract, respiratory tract, gastrointestinal tract (including peritonitis), skin, bone and soft tissue (including burns). Aminoglycosides, including gentamicin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are susceptible to these antibiotics and are not susceptible to antibiotics having less potential for toxicity. Specimens for bacterial culture should be obtained to isolate and identify causative organisms and to determine their susceptibility to gentamicin. Gentamicin sulfate may be considered as initial therapy in suspected or confirmed gram-negative infections, and therapy may be instituted before obtaining results of susceptibility testing. The decision to continue therapy with this drug should be based on the results of susceptibility tests, the severity of the infection, and the important additional concepts contained in the WARNINGS box. If the causative organisms are resistant to gentamicin, other appropriate therapy should be instituted. In serious infections when the causative organisms are unknown, gentamicin sulfate may be administered as initial therapy in conjunction with a penicillin-type or cephalosporin-type drug before obtaining results of susceptibility testing. If anaerobic organisms are suspected as etiologic agents, consideration should be given to using other suitable antimicrobial therapy in conjunction with gentamicin. Following identification of the organism and its susceptibility, appropriate antibiotic therapy should then be continued. Gentamicin sulfate has been used effectively in combination with carbenicillin for the treatment of life-threatening infections caused by Pseudomonas aeruginosa . It has also been found effective when used in conjunction with a penicillin-type drug for the treatment of endocarditis caused by group D streptococci. Gentamicin Sulfate Injection, USP has also been shown to be effective in the treatment of serious staphylococcal infections. While not the antibiotic of first choice, gentamicin may be considered when penicillins or other less potentially toxic drugs are contraindicated and bacterial susceptibility tests and clinical judgment indicate its use. It may also be considered in mixed infections caused by susceptible strains of staphylococci and gram-negative organisms. In the neonate with suspected bacterial sepsis or staphylococcal pneumonia, a penicillin-type drug is also usually indicated as concomitant therapy with gentamicin. uuid:d4491a47-8eea-40ab-bf1d-d14f2f1be9c8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats MONDO:0005025 PMID:41385096 "[{""id"":""uuid:1e82b1b7-8939-4bd8-9160-52045cd97961"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:39191fe4-107c-460a-af1e-ebda8a38c7f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of gentamicin and other antibacterial drugs, gentamicin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Gentamicin Sulfate Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: Pseudomonas aeruginosa , Proteus species (indole-positive and indole-negative), Escherichia coli , Klebsiella-Enterobacter-Serratia species, Citrobacter species, and Staphylococcus species (coagulase-positive and coagulase-negative). Clinical studies have shown Gentamicin Sulfate Injection, USP to be effective in bacterial neonatal sepsis; bacterial septicemia; and serious bacterial infections of the central nervous system (meningitis), urinary tract, respiratory tract, gastrointestinal tract (including peritonitis), skin, bone and soft tissue (including burns). Aminoglycosides, including gentamicin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are susceptible to these antibiotics and are not susceptible to antibiotics having less potential for toxicity. Specimens for bacterial culture should be obtained to isolate and identify causative organisms and to determine their susceptibility to gentamicin. Gentamicin sulfate may be considered as initial therapy in suspected or confirmed gram-negative infections, and therapy may be instituted before obtaining results of susceptibility testing. The decision to continue therapy with this drug should be based on the results of susceptibility tests, the severity of the infection, and the important additional concepts contained in the WARNINGS box. If the causative organisms are resistant to gentamicin, other appropriate therapy should be instituted. In serious infections when the causative organisms are unknown, gentamicin sulfate may be administered as initial therapy in conjunction with a penicillin-type or cephalosporin-type drug before obtaining results of susceptibility testing. If anaerobic organisms are suspected as etiologic agents, consideration should be given to using other suitable antimicrobial therapy in conjunction with gentamicin. Following identification of the organism and its susceptibility, appropriate antibiotic therapy should then be continued. Gentamicin sulfate has been used effectively in combination with carbenicillin for the treatment of life-threatening infections caused by Pseudomonas aeruginosa . It has also been found effective when used in conjunction with a penicillin-type drug for the treatment of endocarditis caused by group D streptococci. Gentamicin Sulfate Injection, USP has also been shown to be effective in the treatment of serious staphylococcal infections. While not the antibiotic of first choice, gentamicin may be considered when penicillins or other less potentially toxic drugs are contraindicated and bacterial susceptibility tests and clinical judgment indicate its use. It may also be considered in mixed infections caused by susceptible strains of staphylococci and gram-negative organisms. In the neonate with suspected bacterial sepsis or staphylococcal pneumonia, a penicillin-type drug is also usually indicated as concomitant therapy with gentamicin. uuid:d86f7db7-1a92-480a-ba66-4db1f6d66bbb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats MONDO:0005970 PMID:41385096 "[{""id"":""uuid:19cae8e7-cc53-44bf-b269-676e6749cdd2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:68789954-ab68-4dda-ab49-61e6b038eef5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of gentamicin and other antibacterial drugs, gentamicin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Gentamicin Sulfate Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: Pseudomonas aeruginosa , Proteus species (indole-positive and indole-negative), Escherichia coli , Klebsiella-Enterobacter-Serratia species, Citrobacter species, and Staphylococcus species (coagulase-positive and coagulase-negative). Clinical studies have shown Gentamicin Sulfate Injection, USP to be effective in bacterial neonatal sepsis; bacterial septicemia; and serious bacterial infections of the central nervous system (meningitis), urinary tract, respiratory tract, gastrointestinal tract (including peritonitis), skin, bone and soft tissue (including burns). Aminoglycosides, including gentamicin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are susceptible to these antibiotics and are not susceptible to antibiotics having less potential for toxicity. Specimens for bacterial culture should be obtained to isolate and identify causative organisms and to determine their susceptibility to gentamicin. Gentamicin sulfate may be considered as initial therapy in suspected or confirmed gram-negative infections, and therapy may be instituted before obtaining results of susceptibility testing. The decision to continue therapy with this drug should be based on the results of susceptibility tests, the severity of the infection, and the important additional concepts contained in the WARNINGS box. If the causative organisms are resistant to gentamicin, other appropriate therapy should be instituted. In serious infections when the causative organisms are unknown, gentamicin sulfate may be administered as initial therapy in conjunction with a penicillin-type or cephalosporin-type drug before obtaining results of susceptibility testing. If anaerobic organisms are suspected as etiologic agents, consideration should be given to using other suitable antimicrobial therapy in conjunction with gentamicin. Following identification of the organism and its susceptibility, appropriate antibiotic therapy should then be continued. Gentamicin sulfate has been used effectively in combination with carbenicillin for the treatment of life-threatening infections caused by Pseudomonas aeruginosa . It has also been found effective when used in conjunction with a penicillin-type drug for the treatment of endocarditis caused by group D streptococci. Gentamicin Sulfate Injection, USP has also been shown to be effective in the treatment of serious staphylococcal infections. While not the antibiotic of first choice, gentamicin may be considered when penicillins or other less potentially toxic drugs are contraindicated and bacterial susceptibility tests and clinical judgment indicate its use. It may also be considered in mixed infections caused by susceptible strains of staphylococci and gram-negative organisms. In the neonate with suspected bacterial sepsis or staphylococcal pneumonia, a penicillin-type drug is also usually indicated as concomitant therapy with gentamicin. uuid:3aaa79a4-4882-4c1e-88bd-ab28d560ee8c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8093 biolink:treats MONDO:0001881 PMID:41385096 "[{""id"":""uuid:5e8d2de0-bf51-4e17-bf13-72dcfa28dd18"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3d83e577-22f1-4beb-92d7-d3fa283eaa85"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Phenylephrine hydrochloride injection is an alpha-1 adrenergic receptor agonist indicated for increasing blood pressure in adults with clinically important hypotension resulting primarily from vasodilation, in such settings as septic shock or anesthesia. uuid:71f9bf82-b860-4c01-b41c-0c20408aea79 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:163203584 biolink:treats MONDO:0018754 PMID:41385096 "[{""id"":""uuid:fa7d7823-53f4-4353-838f-2906065e00fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5a4fcf6e-419a-4272-8a4c-cf71bfce36d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CYANOKIT is indicated for the treatment of known or suspected cyanide poisoning. uuid:324d7208-c9c4-4191-bab7-e6eda5adb0bb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:6473866 biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:512a7a90-6728-4263-b85e-04d985a9cc63"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:150e6834-ad44-4e5e-8b89-c16cc8e5c083"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tacrolimus Ointment, both 0.03% and 0.1% for adults, and only 0.03% for children aged 2 to 15 years, is indicated as second-line therapy for the short-term and non-continuous chronic treatment of moderate to severe atopic dermatitis in non-immunocompromised adults and children who have failed to respond adequately to other topical prescription treatments for atopic dermatitis, or when those treatments are not advisable. Tacrolimus Ointment is not indicated for children younger than 2 years of age (see boxed WARNING , WARNINGS and PRECAUTIONS: Pediatric Use ). uuid:358ae86f-c26c-4ae2-8cd0-08f06b62f3a2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5147 biolink:treats MONDO:0005002 PMID:41385096 "[{""id"":""uuid:99deb555-7e39-44c2-b716-24a029866e81"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:937a8542-50c4-4f52-aa8d-43aa83aab4d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PERFOROMIST Inhalation Solution is a long-acting beta 2 -adrenergic agonist (beta 2 -agonist) indicated for: • Long-term, twice daily (morning and evening) administration in the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. ( 1.1 ) Important limitations of use: • PERFOROMIST Inhalation Solution is not indicated to treat acute deteriorations of chronic obstructive pulmonary disease. ( 1.2 , 5.2 ) • PERFOROMIST Inhalation Solution is not indicated to treat asthma. ( 1.2 ) uuid:198b029c-199a-469b-ad6d-1fbe2381b3c2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5147 biolink:treats MONDO:0005607 PMID:41385096 "[{""id"":""uuid:4fc21df1-54dd-41dd-b694-f6f4b786fefe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:68deaeec-ba6d-4c26-b5af-e0e2588bf259"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:3f092ebb-1839-420e-8627-e9998192b31f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PERFOROMIST Inhalation Solution is a long-acting beta 2 -adrenergic agonist (beta 2 -agonist) indicated for: • Long-term, twice daily (morning and evening) administration in the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. ( 1.1 ) Important limitations of use: • PERFOROMIST Inhalation Solution is not indicated to treat acute deteriorations of chronic obstructive pulmonary disease. ( 1.2 , 5.2 ) • PERFOROMIST Inhalation Solution is not indicated to treat asthma. ( 1.2 )|[PMDA] Drugs with a new indication and a new dosage for the alleviation of various symptoms due to airway obstructive impairment in chronic obstructive pulmonary diseases (chronic bronchitis and emphysema). uuid:e97bf34b-f66d-4a13-961f-096b86d2ac91 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5147 biolink:treats MONDO:0004849 PMID:41385096 "[{""id"":""uuid:4d30abcc-b3a5-4d52-9b7d-4bd14bfdfa73"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:21843ca4-1d52-4d75-baad-d9d17a192dc3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:08163dcf-1426-4adb-bff5-3893dffca85f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PERFOROMIST Inhalation Solution is a long-acting beta 2 -adrenergic agonist (beta 2 -agonist) indicated for: • Long-term, twice daily (morning and evening) administration in the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. ( 1.1 ) Important limitations of use: • PERFOROMIST Inhalation Solution is not indicated to treat acute deteriorations of chronic obstructive pulmonary disease. ( 1.2 , 5.2 ) • PERFOROMIST Inhalation Solution is not indicated to treat asthma. ( 1.2 )|[PMDA] Drugs with a new indication and a new dosage for the alleviation of various symptoms due to airway obstructive impairment in chronic obstructive pulmonary diseases (chronic bronchitis and emphysema). uuid:ffa384ac-8b47-43f0-a134-212280366708 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28748 biolink:treats UMLS:C0278714 PMID:41385096 "[{""id"":""uuid:6dc56cbc-c751-4cb1-8356-3b36aa4e12f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d4751cab-2e0c-4a53-b46f-7acd2eb7f7dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Doxorubicin Hydrochloride Injection is an anthracycline topoisomerase inhibitor indicated: • as a component of multiagent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer ( 1.1 ). • for the treatment of: acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms' tumor, metastatic neuroblastoma, metastatic soft tissue sarcoma, metastatic bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcinoma, metastatic bronchogenic carcinoma ( 1.2 ). uuid:7bef30ec-c13a-4bdb-81ef-a14ce86c5c6a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28748 biolink:treats UMLS:C4722306 PMID:41385096 "[{""id"":""uuid:2edcf581-fef1-492b-92b6-20c8270d3132"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:54053045-d67d-4985-980e-ee706adfb247"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Doxorubicin Hydrochloride Injection is an anthracycline topoisomerase inhibitor indicated: • as a component of multiagent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer ( 1.1 ). • for the treatment of: acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms' tumor, metastatic neuroblastoma, metastatic soft tissue sarcoma, metastatic bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcinoma, metastatic bronchogenic carcinoma ( 1.2 ). uuid:3cb02e72-0d2d-4273-a9b4-963534222916 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28748 biolink:treats UMLS:C4724394 PMID:41385096 "[{""id"":""uuid:bc84b182-3e34-4d16-baa6-5daceb370529"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:99fb00d3-e6d6-44fb-96d4-faf378f3fc5d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Doxorubicin Hydrochloride Injection is an anthracycline topoisomerase inhibitor indicated: • as a component of multiagent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer ( 1.1 ). • for the treatment of: acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms' tumor, metastatic neuroblastoma, metastatic soft tissue sarcoma, metastatic bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcinoma, metastatic bronchogenic carcinoma ( 1.2 ). uuid:796bd4ad-6b6c-44aa-9420-61921c4f1730 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28748 biolink:treats UMLS:C0278688 PMID:41385096 "[{""id"":""uuid:3329ef7f-91a4-4629-9b36-df60ac4d4a8a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9a259dc2-9979-4722-98e0-dd21e8281477"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Doxorubicin Hydrochloride Injection is an anthracycline topoisomerase inhibitor indicated: • as a component of multiagent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer ( 1.1 ). • for the treatment of: acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms' tumor, metastatic neuroblastoma, metastatic soft tissue sarcoma, metastatic bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcinoma, metastatic bronchogenic carcinoma ( 1.2 ). uuid:b0278c67-ae32-4368-bead-0d488e7a1f9e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28748 biolink:treats UMLS:C4727169 PMID:41385096 "[{""id"":""uuid:314f1daa-d58b-4f13-a127-dc81ad0443f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0b0ed8bd-7cf5-4b19-9e95-d2289b9a5349"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Doxorubicin Hydrochloride Injection is an anthracycline topoisomerase inhibitor indicated: • as a component of multiagent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer ( 1.1 ). • for the treatment of: acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms' tumor, metastatic neuroblastoma, metastatic soft tissue sarcoma, metastatic bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcinoma, metastatic bronchogenic carcinoma ( 1.2 ). uuid:c9da0daa-ff5f-4864-8c72-f46a7d701831 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4027 biolink:treats MONDO:0005059 PMID:41385096 "[{""id"":""uuid:8d40ae56-437c-4aae-9f39-851d08502c28"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ea659700-ac5f-4dc2-9f0e-6174febbe0cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cyclophosphamide is an alkylating drug indicated for treatment of: Malignant Diseases: malignant lymphomas: Hodgkin's disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt's lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma. ( 1.1 ) uuid:b05268dc-6c54-431e-a66c-926e93bf95fc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:17276 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:24a879a7-67a4-401c-9f74-72d33bd3e3e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1fd631d8-6ce3-438b-aa32-450c77a9d2fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Spironolactone, an ingredient of spironolactone and hydrochlorothiazide tablets, has been shown to be a tumorigen in chronic toxicity studies in rats (see PRECAUTIONS section). Spironolactone and hydrochlorothiazide tablets should be used only in those conditions described below. Unnecessary use of this drug should be avoided. Spironolactone and hydrochlorothiazide tablets are indicated for: Edematous conditions for patients with: Congestive heart failure: • For the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures; • The treatment of diuretic-induced hypokalemia in patients with congestive heart failure when other measures are considered inappropriate; • The treatment of patients with congestive heart failure taking digitalis when other therapies are considered inadequate or inappropriate. Cirrhosis of the liver accompanied by edema and/or ascites: • Aldosterone levels may be exceptionally high in this condition. Spironolactone and hydrochlorothiazide tablets are indicated for maintenance therapy together with bed rest and the restriction of fluid and sodium. The nephrotic syndrome: • For nephrotic patients when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics do not provide an adequate response. Essential hypertension: • For patients with essential hypertension in whom other measures are considered inadequate or inappropriate; • In hypertensive patients for the treatment of a diuretic-induced hypokalemia when other measures are considered inappropriate; • Spironolactone and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the classes to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with spironolactone and hydrochlorothiazide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. uuid:4c36058d-b363-4bbc-bbf4-8d2c07fb15ec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:17276 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:bac9ea62-a883-4810-8a30-0ce85361b6c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:37f1df0b-16f4-404a-94fe-e6beacd7f287"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Spironolactone, an ingredient of spironolactone and hydrochlorothiazide tablets, has been shown to be a tumorigen in chronic toxicity studies in rats (see PRECAUTIONS section). Spironolactone and hydrochlorothiazide tablets should be used only in those conditions described below. Unnecessary use of this drug should be avoided. Spironolactone and hydrochlorothiazide tablets are indicated for: Edematous conditions for patients with: Congestive heart failure: • For the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures; • The treatment of diuretic-induced hypokalemia in patients with congestive heart failure when other measures are considered inappropriate; • The treatment of patients with congestive heart failure taking digitalis when other therapies are considered inadequate or inappropriate. Cirrhosis of the liver accompanied by edema and/or ascites: • Aldosterone levels may be exceptionally high in this condition. Spironolactone and hydrochlorothiazide tablets are indicated for maintenance therapy together with bed rest and the restriction of fluid and sodium. The nephrotic syndrome: • For nephrotic patients when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics do not provide an adequate response. Essential hypertension: • For patients with essential hypertension in whom other measures are considered inadequate or inappropriate; • In hypertensive patients for the treatment of a diuretic-induced hypokalemia when other measures are considered inappropriate; • Spironolactone and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the classes to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with spironolactone and hydrochlorothiazide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. uuid:1b2eca32-d273-4447-bd70-fa7d07fd7c0b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:17276 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:83ac6bc3-b7b1-483e-a62b-da7a3ed5bd5c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1fac464a-3548-4231-a204-726577a22e2d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Spironolactone, an ingredient of spironolactone and hydrochlorothiazide tablets, has been shown to be a tumorigen in chronic toxicity studies in rats (see PRECAUTIONS section). Spironolactone and hydrochlorothiazide tablets should be used only in those conditions described below. Unnecessary use of this drug should be avoided. Spironolactone and hydrochlorothiazide tablets are indicated for: Edematous conditions for patients with: Congestive heart failure: • For the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures; • The treatment of diuretic-induced hypokalemia in patients with congestive heart failure when other measures are considered inappropriate; • The treatment of patients with congestive heart failure taking digitalis when other therapies are considered inadequate or inappropriate. Cirrhosis of the liver accompanied by edema and/or ascites: • Aldosterone levels may be exceptionally high in this condition. Spironolactone and hydrochlorothiazide tablets are indicated for maintenance therapy together with bed rest and the restriction of fluid and sodium. The nephrotic syndrome: • For nephrotic patients when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics do not provide an adequate response. Essential hypertension: • For patients with essential hypertension in whom other measures are considered inadequate or inappropriate; • In hypertensive patients for the treatment of a diuretic-induced hypokalemia when other measures are considered inappropriate; • Spironolactone and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the classes to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with spironolactone and hydrochlorothiazide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. uuid:459f2b18-8af4-4f5e-a468-aa5cd9214b5b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:17276 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:034c12b0-b942-40a2-bbb7-24b893c0281e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a3ae878b-91fb-478f-8903-6fa2ab70cc75"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Spironolactone, an ingredient of spironolactone and hydrochlorothiazide tablets, has been shown to be a tumorigen in chronic toxicity studies in rats (see PRECAUTIONS section). Spironolactone and hydrochlorothiazide tablets should be used only in those conditions described below. Unnecessary use of this drug should be avoided. Spironolactone and hydrochlorothiazide tablets are indicated for: Edematous conditions for patients with: Congestive heart failure: • For the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures; • The treatment of diuretic-induced hypokalemia in patients with congestive heart failure when other measures are considered inappropriate; • The treatment of patients with congestive heart failure taking digitalis when other therapies are considered inadequate or inappropriate. Cirrhosis of the liver accompanied by edema and/or ascites: • Aldosterone levels may be exceptionally high in this condition. Spironolactone and hydrochlorothiazide tablets are indicated for maintenance therapy together with bed rest and the restriction of fluid and sodium. The nephrotic syndrome: • For nephrotic patients when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics do not provide an adequate response. Essential hypertension: • For patients with essential hypertension in whom other measures are considered inadequate or inappropriate; • In hypertensive patients for the treatment of a diuretic-induced hypokalemia when other measures are considered inappropriate; • Spironolactone and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the classes to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with spironolactone and hydrochlorothiazide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. uuid:e37425a7-d6b7-4aa2-8ef6-6280c0097f83 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:17276 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:8494fa75-40db-43d0-8c31-887f9f699dc1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fcc4abf4-dd4d-4de2-ad82-64dd7b83f45b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Spironolactone, an ingredient of spironolactone and hydrochlorothiazide tablets, has been shown to be a tumorigen in chronic toxicity studies in rats (see PRECAUTIONS section). Spironolactone and hydrochlorothiazide tablets should be used only in those conditions described below. Unnecessary use of this drug should be avoided. Spironolactone and hydrochlorothiazide tablets are indicated for: Edematous conditions for patients with: Congestive heart failure: • For the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures; • The treatment of diuretic-induced hypokalemia in patients with congestive heart failure when other measures are considered inappropriate; • The treatment of patients with congestive heart failure taking digitalis when other therapies are considered inadequate or inappropriate. Cirrhosis of the liver accompanied by edema and/or ascites: • Aldosterone levels may be exceptionally high in this condition. Spironolactone and hydrochlorothiazide tablets are indicated for maintenance therapy together with bed rest and the restriction of fluid and sodium. The nephrotic syndrome: • For nephrotic patients when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics do not provide an adequate response. Essential hypertension: • For patients with essential hypertension in whom other measures are considered inadequate or inappropriate; • In hypertensive patients for the treatment of a diuretic-induced hypokalemia when other measures are considered inappropriate; • Spironolactone and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the classes to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with spironolactone and hydrochlorothiazide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. uuid:20e53bb5-299e-475c-aaa2-6f808aa90de3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:17276 biolink:treats HP:0001681 PMID:41385096 "[{""id"":""uuid:8b2dfe50-8f50-47b3-90da-c60fa05e8a45"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1139668c-3add-420e-bd88-42477ba21dcb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Spironolactone, an ingredient of spironolactone and hydrochlorothiazide tablets, has been shown to be a tumorigen in chronic toxicity studies in rats (see PRECAUTIONS section). Spironolactone and hydrochlorothiazide tablets should be used only in those conditions described below. Unnecessary use of this drug should be avoided. Spironolactone and hydrochlorothiazide tablets are indicated for: Edematous conditions for patients with: Congestive heart failure: • For the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures; • The treatment of diuretic-induced hypokalemia in patients with congestive heart failure when other measures are considered inappropriate; • The treatment of patients with congestive heart failure taking digitalis when other therapies are considered inadequate or inappropriate. Cirrhosis of the liver accompanied by edema and/or ascites: • Aldosterone levels may be exceptionally high in this condition. Spironolactone and hydrochlorothiazide tablets are indicated for maintenance therapy together with bed rest and the restriction of fluid and sodium. The nephrotic syndrome: • For nephrotic patients when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics do not provide an adequate response. Essential hypertension: • For patients with essential hypertension in whom other measures are considered inadequate or inappropriate; • In hypertensive patients for the treatment of a diuretic-induced hypokalemia when other measures are considered inappropriate; • Spironolactone and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the classes to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with spironolactone and hydrochlorothiazide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. uuid:5ad7998d-db90-4fce-92da-51b2311ca73e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:17276 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:cc13ebf4-f491-4202-9665-9e610f61f286"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2701191f-b86a-494e-baa9-d8c71d583a36"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Spironolactone, an ingredient of spironolactone and hydrochlorothiazide tablets, has been shown to be a tumorigen in chronic toxicity studies in rats (see PRECAUTIONS section). Spironolactone and hydrochlorothiazide tablets should be used only in those conditions described below. Unnecessary use of this drug should be avoided. Spironolactone and hydrochlorothiazide tablets are indicated for: Edematous conditions for patients with: Congestive heart failure: • For the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures; • The treatment of diuretic-induced hypokalemia in patients with congestive heart failure when other measures are considered inappropriate; • The treatment of patients with congestive heart failure taking digitalis when other therapies are considered inadequate or inappropriate. Cirrhosis of the liver accompanied by edema and/or ascites: • Aldosterone levels may be exceptionally high in this condition. Spironolactone and hydrochlorothiazide tablets are indicated for maintenance therapy together with bed rest and the restriction of fluid and sodium. The nephrotic syndrome: • For nephrotic patients when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics do not provide an adequate response. Essential hypertension: • For patients with essential hypertension in whom other measures are considered inadequate or inappropriate; • In hypertensive patients for the treatment of a diuretic-induced hypokalemia when other measures are considered inappropriate; • Spironolactone and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the classes to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with spironolactone and hydrochlorothiazide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. uuid:34fe4ed0-69f8-4d3b-8c90-33f44a1e19db biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:17276 biolink:treats MONDO:0005016 PMID:41385096 "[{""id"":""uuid:b841a17c-ef89-4cba-9357-0f94cd82541a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6b5452c4-03f5-4aec-8744-ed806658d71b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Spironolactone, an ingredient of spironolactone and hydrochlorothiazide tablets, has been shown to be a tumorigen in chronic toxicity studies in rats (see PRECAUTIONS section). Spironolactone and hydrochlorothiazide tablets should be used only in those conditions described below. Unnecessary use of this drug should be avoided. Spironolactone and hydrochlorothiazide tablets are indicated for: Edematous conditions for patients with: Congestive heart failure: • For the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures; • The treatment of diuretic-induced hypokalemia in patients with congestive heart failure when other measures are considered inappropriate; • The treatment of patients with congestive heart failure taking digitalis when other therapies are considered inadequate or inappropriate. Cirrhosis of the liver accompanied by edema and/or ascites: • Aldosterone levels may be exceptionally high in this condition. Spironolactone and hydrochlorothiazide tablets are indicated for maintenance therapy together with bed rest and the restriction of fluid and sodium. The nephrotic syndrome: • For nephrotic patients when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics do not provide an adequate response. Essential hypertension: • For patients with essential hypertension in whom other measures are considered inadequate or inappropriate; • In hypertensive patients for the treatment of a diuretic-induced hypokalemia when other measures are considered inappropriate; • Spironolactone and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the classes to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with spironolactone and hydrochlorothiazide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. uuid:c3815468-e812-4d4a-ba46-0fd3e6d60ee2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31711 biolink:treats MONDO:0021042 PMID:41385096 "[{""id"":""uuid:e64a02cb-1d88-4652-8593-9c7f0b306757"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:edfc9b4e-1264-45a4-8288-28f11f636ae0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ISOVUE (Iopamidol Injection) is indicated for angiography throughout the cardiovascular system in adults, including cerebral and peripheral arteriography, coronary arteriography and ventriculography, selective visceral arteriography and aortography, peripheral venography (phlebography), and in pediatric patients for angiocardiography; or for intravenous use in adult and pediatric for computed tomographic (CT) imaging of the head and body (see below). CT Head Imaging ISOVUE may be used to refine diagnostic precision in areas of the brain which may not otherwise have been satisfactorily visualized. Tumors ISOVUE may be useful to investigate the presence and extent of certain malignancies such as: gliomas including malignant gliomas, glioblastomas, astrocytomas, oligodendrogliomas and gangliomas, ependymomas, medulloblastomas, meningiomas, neuromas, pinealomas, pituitary adenomas, craniopharyngiomas, germinomas, and metastatic lesions. The usefulness of contrast enhancement for the investigation of the retrobulbar space and in cases of low grade or infiltrative glioma has not been demonstrated. In calcified lesions, there is less likelihood of enhancement. Following therapy, tumors may show decreased or no enhancement. The opacification of the inferior vermis following contrast media administration has resulted in false-positive diagnosis in a number of otherwise normal studies. Nonneoplastic Conditions ISOVUE may be beneficial in the image enhancement of nonneoplastic lesions. Cerebral infarctions of recent onset may be better visualized with contrast enhancement, while some infarctions are obscured if contrast media are used. The use of iodinated contrast media results in contrast enhancement in about 60 percent of cerebral infarctions studied from one to four weeks from the onset of symptoms. Sites of active infection may also be enhanced following contrast media administration. Arteriovenous malformations and aneurysms will show contrast enhancement. For these vascular lesions, the enhancement is probably dependent on the iodine content of the circulating blood pool. Hematomas and intraparenchymal bleeders seldom demonstrate any contrast enhancement. However, in cases of intraparenchymal clot, for which there is no obvious clinical explanation, contrast media administration may be helpful in ruling out the possibility of associated arteriovenous malformation. CT Body Imaging ISOVUE (Iopamidol Injection) may be used for enhancement of computed tomographic images for detection and evaluation of lesions in the liver, pancreas, kidneys, aorta, mediastinum, abdominal cavity, pelvis and retroperitoneal space. Enhancement of computed tomography with ISOVUE may be of benefit in establishing diagnoses of certain lesions in these sites with greater assurance than is possible with CT alone, and in supplying additional features of the lesions (e.g., hepatic abscess delineation prior to percutaneous drainage). In other cases, the contrast agent may allow visualization of lesions not seen with CT alone (e.g. tumor extension), or may help to define suspicious lesions seen with unenhanced CT (e.g., pancreatic cyst). Contrast enhancement appears to be greatest within 60 to 90 seconds after bolus administration of contrast agent. Therefore, utilization of a continuous scanning technique (“dynamic CT scanning”) may improve enhancement and diagnostic assessment of tumor and other lesions such as an abscess, occasionally revealing unsuspected or more extensive disease. For example, a cyst may be distinguished from a vascularized solid lesion when precontrast and enhanced scans are compared; the nonperfused mass shows unchanged x-ray absorption (CT number). A vascularized lesion is characterized by an increase in CT number in the few minutes after a bolus of intravascular contrast agent; it may be malignant, benign, or normal tissue, but would probably not be a cyst, hematoma, or other nonvascular lesion. Because unenhanced scanning may provide adequate diagnostic information in the individual patient, the decision to employ contrast enhancement, which may be associated with risk and increased radiation exposure, should be based upon a careful evaluation of clinical, other radiological, and unenhanced CT findings. uuid:5ed12047-58be-4a90-a564-c204c97f103e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31711 biolink:treats MONDO:0100342 PMID:41385096 "[{""id"":""uuid:4caa4b90-9693-417c-8452-dcbd803596ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:39928456-372b-4e9c-b3a4-c2ce3c06360b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ISOVUE (Iopamidol Injection) is indicated for angiography throughout the cardiovascular system in adults, including cerebral and peripheral arteriography, coronary arteriography and ventriculography, selective visceral arteriography and aortography, peripheral venography (phlebography), and in pediatric patients for angiocardiography; or for intravenous use in adult and pediatric for computed tomographic (CT) imaging of the head and body (see below). CT Head Imaging ISOVUE may be used to refine diagnostic precision in areas of the brain which may not otherwise have been satisfactorily visualized. Tumors ISOVUE may be useful to investigate the presence and extent of certain malignancies such as: gliomas including malignant gliomas, glioblastomas, astrocytomas, oligodendrogliomas and gangliomas, ependymomas, medulloblastomas, meningiomas, neuromas, pinealomas, pituitary adenomas, craniopharyngiomas, germinomas, and metastatic lesions. The usefulness of contrast enhancement for the investigation of the retrobulbar space and in cases of low grade or infiltrative glioma has not been demonstrated. In calcified lesions, there is less likelihood of enhancement. Following therapy, tumors may show decreased or no enhancement. The opacification of the inferior vermis following contrast media administration has resulted in false-positive diagnosis in a number of otherwise normal studies. Nonneoplastic Conditions ISOVUE may be beneficial in the image enhancement of nonneoplastic lesions. Cerebral infarctions of recent onset may be better visualized with contrast enhancement, while some infarctions are obscured if contrast media are used. The use of iodinated contrast media results in contrast enhancement in about 60 percent of cerebral infarctions studied from one to four weeks from the onset of symptoms. Sites of active infection may also be enhanced following contrast media administration. Arteriovenous malformations and aneurysms will show contrast enhancement. For these vascular lesions, the enhancement is probably dependent on the iodine content of the circulating blood pool. Hematomas and intraparenchymal bleeders seldom demonstrate any contrast enhancement. However, in cases of intraparenchymal clot, for which there is no obvious clinical explanation, contrast media administration may be helpful in ruling out the possibility of associated arteriovenous malformation. CT Body Imaging ISOVUE (Iopamidol Injection) may be used for enhancement of computed tomographic images for detection and evaluation of lesions in the liver, pancreas, kidneys, aorta, mediastinum, abdominal cavity, pelvis and retroperitoneal space. Enhancement of computed tomography with ISOVUE may be of benefit in establishing diagnoses of certain lesions in these sites with greater assurance than is possible with CT alone, and in supplying additional features of the lesions (e.g., hepatic abscess delineation prior to percutaneous drainage). In other cases, the contrast agent may allow visualization of lesions not seen with CT alone (e.g. tumor extension), or may help to define suspicious lesions seen with unenhanced CT (e.g., pancreatic cyst). Contrast enhancement appears to be greatest within 60 to 90 seconds after bolus administration of contrast agent. Therefore, utilization of a continuous scanning technique (“dynamic CT scanning”) may improve enhancement and diagnostic assessment of tumor and other lesions such as an abscess, occasionally revealing unsuspected or more extensive disease. For example, a cyst may be distinguished from a vascularized solid lesion when precontrast and enhanced scans are compared; the nonperfused mass shows unchanged x-ray absorption (CT number). A vascularized lesion is characterized by an increase in CT number in the few minutes after a bolus of intravascular contrast agent; it may be malignant, benign, or normal tissue, but would probably not be a cyst, hematoma, or other nonvascular lesion. Because unenhanced scanning may provide adequate diagnostic information in the individual patient, the decision to employ contrast enhancement, which may be associated with risk and increased radiation exposure, should be based upon a careful evaluation of clinical, other radiological, and unenhanced CT findings. uuid:50d2f804-0263-4d95-8043-c4c6d246ee5e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31711 biolink:treats MONDO:0016682 PMID:41385096 "[{""id"":""uuid:5bc37609-7b58-478d-89ec-5ab042e2a8cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ff917234-ca35-4254-bf8d-e4642e79d881"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ISOVUE (Iopamidol Injection) is indicated for angiography throughout the cardiovascular system in adults, including cerebral and peripheral arteriography, coronary arteriography and ventriculography, selective visceral arteriography and aortography, peripheral venography (phlebography), and in pediatric patients for angiocardiography; or for intravenous use in adult and pediatric for computed tomographic (CT) imaging of the head and body (see below). CT Head Imaging ISOVUE may be used to refine diagnostic precision in areas of the brain which may not otherwise have been satisfactorily visualized. Tumors ISOVUE may be useful to investigate the presence and extent of certain malignancies such as: gliomas including malignant gliomas, glioblastomas, astrocytomas, oligodendrogliomas and gangliomas, ependymomas, medulloblastomas, meningiomas, neuromas, pinealomas, pituitary adenomas, craniopharyngiomas, germinomas, and metastatic lesions. The usefulness of contrast enhancement for the investigation of the retrobulbar space and in cases of low grade or infiltrative glioma has not been demonstrated. In calcified lesions, there is less likelihood of enhancement. Following therapy, tumors may show decreased or no enhancement. The opacification of the inferior vermis following contrast media administration has resulted in false-positive diagnosis in a number of otherwise normal studies. Nonneoplastic Conditions ISOVUE may be beneficial in the image enhancement of nonneoplastic lesions. Cerebral infarctions of recent onset may be better visualized with contrast enhancement, while some infarctions are obscured if contrast media are used. The use of iodinated contrast media results in contrast enhancement in about 60 percent of cerebral infarctions studied from one to four weeks from the onset of symptoms. Sites of active infection may also be enhanced following contrast media administration. Arteriovenous malformations and aneurysms will show contrast enhancement. For these vascular lesions, the enhancement is probably dependent on the iodine content of the circulating blood pool. Hematomas and intraparenchymal bleeders seldom demonstrate any contrast enhancement. However, in cases of intraparenchymal clot, for which there is no obvious clinical explanation, contrast media administration may be helpful in ruling out the possibility of associated arteriovenous malformation. CT Body Imaging ISOVUE (Iopamidol Injection) may be used for enhancement of computed tomographic images for detection and evaluation of lesions in the liver, pancreas, kidneys, aorta, mediastinum, abdominal cavity, pelvis and retroperitoneal space. Enhancement of computed tomography with ISOVUE may be of benefit in establishing diagnoses of certain lesions in these sites with greater assurance than is possible with CT alone, and in supplying additional features of the lesions (e.g., hepatic abscess delineation prior to percutaneous drainage). In other cases, the contrast agent may allow visualization of lesions not seen with CT alone (e.g. tumor extension), or may help to define suspicious lesions seen with unenhanced CT (e.g., pancreatic cyst). Contrast enhancement appears to be greatest within 60 to 90 seconds after bolus administration of contrast agent. Therefore, utilization of a continuous scanning technique (“dynamic CT scanning”) may improve enhancement and diagnostic assessment of tumor and other lesions such as an abscess, occasionally revealing unsuspected or more extensive disease. For example, a cyst may be distinguished from a vascularized solid lesion when precontrast and enhanced scans are compared; the nonperfused mass shows unchanged x-ray absorption (CT number). A vascularized lesion is characterized by an increase in CT number in the few minutes after a bolus of intravascular contrast agent; it may be malignant, benign, or normal tissue, but would probably not be a cyst, hematoma, or other nonvascular lesion. Because unenhanced scanning may provide adequate diagnostic information in the individual patient, the decision to employ contrast enhancement, which may be associated with risk and increased radiation exposure, should be based upon a careful evaluation of clinical, other radiological, and unenhanced CT findings. uuid:ae89f480-4bc2-4d63-a56d-e2479fe1a636 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31711 biolink:treats MONDO:0003169 PMID:41385096 "[{""id"":""uuid:90729a55-e995-4d79-9aca-327f12cec9b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0f9a3ef5-c190-46b2-8bbd-7f50a20da4b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ISOVUE (Iopamidol Injection) is indicated for angiography throughout the cardiovascular system in adults, including cerebral and peripheral arteriography, coronary arteriography and ventriculography, selective visceral arteriography and aortography, peripheral venography (phlebography), and in pediatric patients for angiocardiography; or for intravenous use in adult and pediatric for computed tomographic (CT) imaging of the head and body (see below). CT Head Imaging ISOVUE may be used to refine diagnostic precision in areas of the brain which may not otherwise have been satisfactorily visualized. Tumors ISOVUE may be useful to investigate the presence and extent of certain malignancies such as: gliomas including malignant gliomas, glioblastomas, astrocytomas, oligodendrogliomas and gangliomas, ependymomas, medulloblastomas, meningiomas, neuromas, pinealomas, pituitary adenomas, craniopharyngiomas, germinomas, and metastatic lesions. The usefulness of contrast enhancement for the investigation of the retrobulbar space and in cases of low grade or infiltrative glioma has not been demonstrated. In calcified lesions, there is less likelihood of enhancement. Following therapy, tumors may show decreased or no enhancement. The opacification of the inferior vermis following contrast media administration has resulted in false-positive diagnosis in a number of otherwise normal studies. Nonneoplastic Conditions ISOVUE may be beneficial in the image enhancement of nonneoplastic lesions. Cerebral infarctions of recent onset may be better visualized with contrast enhancement, while some infarctions are obscured if contrast media are used. The use of iodinated contrast media results in contrast enhancement in about 60 percent of cerebral infarctions studied from one to four weeks from the onset of symptoms. Sites of active infection may also be enhanced following contrast media administration. Arteriovenous malformations and aneurysms will show contrast enhancement. For these vascular lesions, the enhancement is probably dependent on the iodine content of the circulating blood pool. Hematomas and intraparenchymal bleeders seldom demonstrate any contrast enhancement. However, in cases of intraparenchymal clot, for which there is no obvious clinical explanation, contrast media administration may be helpful in ruling out the possibility of associated arteriovenous malformation. CT Body Imaging ISOVUE (Iopamidol Injection) may be used for enhancement of computed tomographic images for detection and evaluation of lesions in the liver, pancreas, kidneys, aorta, mediastinum, abdominal cavity, pelvis and retroperitoneal space. Enhancement of computed tomography with ISOVUE may be of benefit in establishing diagnoses of certain lesions in these sites with greater assurance than is possible with CT alone, and in supplying additional features of the lesions (e.g., hepatic abscess delineation prior to percutaneous drainage). In other cases, the contrast agent may allow visualization of lesions not seen with CT alone (e.g. tumor extension), or may help to define suspicious lesions seen with unenhanced CT (e.g., pancreatic cyst). Contrast enhancement appears to be greatest within 60 to 90 seconds after bolus administration of contrast agent. Therefore, utilization of a continuous scanning technique (“dynamic CT scanning”) may improve enhancement and diagnostic assessment of tumor and other lesions such as an abscess, occasionally revealing unsuspected or more extensive disease. For example, a cyst may be distinguished from a vascularized solid lesion when precontrast and enhanced scans are compared; the nonperfused mass shows unchanged x-ray absorption (CT number). A vascularized lesion is characterized by an increase in CT number in the few minutes after a bolus of intravascular contrast agent; it may be malignant, benign, or normal tissue, but would probably not be a cyst, hematoma, or other nonvascular lesion. Because unenhanced scanning may provide adequate diagnostic information in the individual patient, the decision to employ contrast enhancement, which may be associated with risk and increased radiation exposure, should be based upon a careful evaluation of clinical, other radiological, and unenhanced CT findings. uuid:538b4e51-8c2b-4fbe-a3da-3e15a9dc9de3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31711 biolink:treats MONDO:0016695 PMID:41385096 "[{""id"":""uuid:099a2559-7fad-4208-94b2-bdb7398a18a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d47ad1b0-b15b-441f-8b32-9663d07cface"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ISOVUE (Iopamidol Injection) is indicated for angiography throughout the cardiovascular system in adults, including cerebral and peripheral arteriography, coronary arteriography and ventriculography, selective visceral arteriography and aortography, peripheral venography (phlebography), and in pediatric patients for angiocardiography; or for intravenous use in adult and pediatric for computed tomographic (CT) imaging of the head and body (see below). CT Head Imaging ISOVUE may be used to refine diagnostic precision in areas of the brain which may not otherwise have been satisfactorily visualized. Tumors ISOVUE may be useful to investigate the presence and extent of certain malignancies such as: gliomas including malignant gliomas, glioblastomas, astrocytomas, oligodendrogliomas and gangliomas, ependymomas, medulloblastomas, meningiomas, neuromas, pinealomas, pituitary adenomas, craniopharyngiomas, germinomas, and metastatic lesions. The usefulness of contrast enhancement for the investigation of the retrobulbar space and in cases of low grade or infiltrative glioma has not been demonstrated. In calcified lesions, there is less likelihood of enhancement. Following therapy, tumors may show decreased or no enhancement. The opacification of the inferior vermis following contrast media administration has resulted in false-positive diagnosis in a number of otherwise normal studies. Nonneoplastic Conditions ISOVUE may be beneficial in the image enhancement of nonneoplastic lesions. Cerebral infarctions of recent onset may be better visualized with contrast enhancement, while some infarctions are obscured if contrast media are used. The use of iodinated contrast media results in contrast enhancement in about 60 percent of cerebral infarctions studied from one to four weeks from the onset of symptoms. Sites of active infection may also be enhanced following contrast media administration. Arteriovenous malformations and aneurysms will show contrast enhancement. For these vascular lesions, the enhancement is probably dependent on the iodine content of the circulating blood pool. Hematomas and intraparenchymal bleeders seldom demonstrate any contrast enhancement. However, in cases of intraparenchymal clot, for which there is no obvious clinical explanation, contrast media administration may be helpful in ruling out the possibility of associated arteriovenous malformation. CT Body Imaging ISOVUE (Iopamidol Injection) may be used for enhancement of computed tomographic images for detection and evaluation of lesions in the liver, pancreas, kidneys, aorta, mediastinum, abdominal cavity, pelvis and retroperitoneal space. Enhancement of computed tomography with ISOVUE may be of benefit in establishing diagnoses of certain lesions in these sites with greater assurance than is possible with CT alone, and in supplying additional features of the lesions (e.g., hepatic abscess delineation prior to percutaneous drainage). In other cases, the contrast agent may allow visualization of lesions not seen with CT alone (e.g. tumor extension), or may help to define suspicious lesions seen with unenhanced CT (e.g., pancreatic cyst). Contrast enhancement appears to be greatest within 60 to 90 seconds after bolus administration of contrast agent. Therefore, utilization of a continuous scanning technique (“dynamic CT scanning”) may improve enhancement and diagnostic assessment of tumor and other lesions such as an abscess, occasionally revealing unsuspected or more extensive disease. For example, a cyst may be distinguished from a vascularized solid lesion when precontrast and enhanced scans are compared; the nonperfused mass shows unchanged x-ray absorption (CT number). A vascularized lesion is characterized by an increase in CT number in the few minutes after a bolus of intravascular contrast agent; it may be malignant, benign, or normal tissue, but would probably not be a cyst, hematoma, or other nonvascular lesion. Because unenhanced scanning may provide adequate diagnostic information in the individual patient, the decision to employ contrast enhancement, which may be associated with risk and increased radiation exposure, should be based upon a careful evaluation of clinical, other radiological, and unenhanced CT findings. uuid:96343a26-f754-4daa-b3b7-140140571bbc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31711 biolink:treats MONDO:0016698 PMID:41385096 "[{""id"":""uuid:699acf51-2ffe-4983-88a5-c04639cddf5d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b6491bab-5cc6-4a1c-952a-b9e75e96a51b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ISOVUE (Iopamidol Injection) is indicated for angiography throughout the cardiovascular system in adults, including cerebral and peripheral arteriography, coronary arteriography and ventriculography, selective visceral arteriography and aortography, peripheral venography (phlebography), and in pediatric patients for angiocardiography; or for intravenous use in adult and pediatric for computed tomographic (CT) imaging of the head and body (see below). CT Head Imaging ISOVUE may be used to refine diagnostic precision in areas of the brain which may not otherwise have been satisfactorily visualized. Tumors ISOVUE may be useful to investigate the presence and extent of certain malignancies such as: gliomas including malignant gliomas, glioblastomas, astrocytomas, oligodendrogliomas and gangliomas, ependymomas, medulloblastomas, meningiomas, neuromas, pinealomas, pituitary adenomas, craniopharyngiomas, germinomas, and metastatic lesions. The usefulness of contrast enhancement for the investigation of the retrobulbar space and in cases of low grade or infiltrative glioma has not been demonstrated. In calcified lesions, there is less likelihood of enhancement. Following therapy, tumors may show decreased or no enhancement. The opacification of the inferior vermis following contrast media administration has resulted in false-positive diagnosis in a number of otherwise normal studies. Nonneoplastic Conditions ISOVUE may be beneficial in the image enhancement of nonneoplastic lesions. Cerebral infarctions of recent onset may be better visualized with contrast enhancement, while some infarctions are obscured if contrast media are used. The use of iodinated contrast media results in contrast enhancement in about 60 percent of cerebral infarctions studied from one to four weeks from the onset of symptoms. Sites of active infection may also be enhanced following contrast media administration. Arteriovenous malformations and aneurysms will show contrast enhancement. For these vascular lesions, the enhancement is probably dependent on the iodine content of the circulating blood pool. Hematomas and intraparenchymal bleeders seldom demonstrate any contrast enhancement. However, in cases of intraparenchymal clot, for which there is no obvious clinical explanation, contrast media administration may be helpful in ruling out the possibility of associated arteriovenous malformation. CT Body Imaging ISOVUE (Iopamidol Injection) may be used for enhancement of computed tomographic images for detection and evaluation of lesions in the liver, pancreas, kidneys, aorta, mediastinum, abdominal cavity, pelvis and retroperitoneal space. Enhancement of computed tomography with ISOVUE may be of benefit in establishing diagnoses of certain lesions in these sites with greater assurance than is possible with CT alone, and in supplying additional features of the lesions (e.g., hepatic abscess delineation prior to percutaneous drainage). In other cases, the contrast agent may allow visualization of lesions not seen with CT alone (e.g. tumor extension), or may help to define suspicious lesions seen with unenhanced CT (e.g., pancreatic cyst). Contrast enhancement appears to be greatest within 60 to 90 seconds after bolus administration of contrast agent. Therefore, utilization of a continuous scanning technique (“dynamic CT scanning”) may improve enhancement and diagnostic assessment of tumor and other lesions such as an abscess, occasionally revealing unsuspected or more extensive disease. For example, a cyst may be distinguished from a vascularized solid lesion when precontrast and enhanced scans are compared; the nonperfused mass shows unchanged x-ray absorption (CT number). A vascularized lesion is characterized by an increase in CT number in the few minutes after a bolus of intravascular contrast agent; it may be malignant, benign, or normal tissue, but would probably not be a cyst, hematoma, or other nonvascular lesion. Because unenhanced scanning may provide adequate diagnostic information in the individual patient, the decision to employ contrast enhancement, which may be associated with risk and increased radiation exposure, should be based upon a careful evaluation of clinical, other radiological, and unenhanced CT findings. uuid:388fb2f8-39de-4f45-9b0d-6cbacc7ccceb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31711 biolink:treats MONDO:0007959 PMID:41385096 "[{""id"":""uuid:2180d314-7896-410f-88d4-a9fe3f870815"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:614546cf-b68d-46dc-ba26-d33ccc2c1b75"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ISOVUE (Iopamidol Injection) is indicated for angiography throughout the cardiovascular system in adults, including cerebral and peripheral arteriography, coronary arteriography and ventriculography, selective visceral arteriography and aortography, peripheral venography (phlebography), and in pediatric patients for angiocardiography; or for intravenous use in adult and pediatric for computed tomographic (CT) imaging of the head and body (see below). CT Head Imaging ISOVUE may be used to refine diagnostic precision in areas of the brain which may not otherwise have been satisfactorily visualized. Tumors ISOVUE may be useful to investigate the presence and extent of certain malignancies such as: gliomas including malignant gliomas, glioblastomas, astrocytomas, oligodendrogliomas and gangliomas, ependymomas, medulloblastomas, meningiomas, neuromas, pinealomas, pituitary adenomas, craniopharyngiomas, germinomas, and metastatic lesions. The usefulness of contrast enhancement for the investigation of the retrobulbar space and in cases of low grade or infiltrative glioma has not been demonstrated. In calcified lesions, there is less likelihood of enhancement. Following therapy, tumors may show decreased or no enhancement. The opacification of the inferior vermis following contrast media administration has resulted in false-positive diagnosis in a number of otherwise normal studies. Nonneoplastic Conditions ISOVUE may be beneficial in the image enhancement of nonneoplastic lesions. Cerebral infarctions of recent onset may be better visualized with contrast enhancement, while some infarctions are obscured if contrast media are used. The use of iodinated contrast media results in contrast enhancement in about 60 percent of cerebral infarctions studied from one to four weeks from the onset of symptoms. Sites of active infection may also be enhanced following contrast media administration. Arteriovenous malformations and aneurysms will show contrast enhancement. For these vascular lesions, the enhancement is probably dependent on the iodine content of the circulating blood pool. Hematomas and intraparenchymal bleeders seldom demonstrate any contrast enhancement. However, in cases of intraparenchymal clot, for which there is no obvious clinical explanation, contrast media administration may be helpful in ruling out the possibility of associated arteriovenous malformation. CT Body Imaging ISOVUE (Iopamidol Injection) may be used for enhancement of computed tomographic images for detection and evaluation of lesions in the liver, pancreas, kidneys, aorta, mediastinum, abdominal cavity, pelvis and retroperitoneal space. Enhancement of computed tomography with ISOVUE may be of benefit in establishing diagnoses of certain lesions in these sites with greater assurance than is possible with CT alone, and in supplying additional features of the lesions (e.g., hepatic abscess delineation prior to percutaneous drainage). In other cases, the contrast agent may allow visualization of lesions not seen with CT alone (e.g. tumor extension), or may help to define suspicious lesions seen with unenhanced CT (e.g., pancreatic cyst). Contrast enhancement appears to be greatest within 60 to 90 seconds after bolus administration of contrast agent. Therefore, utilization of a continuous scanning technique (“dynamic CT scanning”) may improve enhancement and diagnostic assessment of tumor and other lesions such as an abscess, occasionally revealing unsuspected or more extensive disease. For example, a cyst may be distinguished from a vascularized solid lesion when precontrast and enhanced scans are compared; the nonperfused mass shows unchanged x-ray absorption (CT number). A vascularized lesion is characterized by an increase in CT number in the few minutes after a bolus of intravascular contrast agent; it may be malignant, benign, or normal tissue, but would probably not be a cyst, hematoma, or other nonvascular lesion. Because unenhanced scanning may provide adequate diagnostic information in the individual patient, the decision to employ contrast enhancement, which may be associated with risk and increased radiation exposure, should be based upon a careful evaluation of clinical, other radiological, and unenhanced CT findings. uuid:4934a058-e3ca-4cfb-ac44-fd3a5c412629 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31711 biolink:treats MONDO:0016642 PMID:41385096 "[{""id"":""uuid:1d8978d3-bac6-4374-aa56-f098123982c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cc20e44c-6495-4fe2-95b4-896f1037d393"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ISOVUE (Iopamidol Injection) is indicated for angiography throughout the cardiovascular system in adults, including cerebral and peripheral arteriography, coronary arteriography and ventriculography, selective visceral arteriography and aortography, peripheral venography (phlebography), and in pediatric patients for angiocardiography; or for intravenous use in adult and pediatric for computed tomographic (CT) imaging of the head and body (see below). CT Head Imaging ISOVUE may be used to refine diagnostic precision in areas of the brain which may not otherwise have been satisfactorily visualized. Tumors ISOVUE may be useful to investigate the presence and extent of certain malignancies such as: gliomas including malignant gliomas, glioblastomas, astrocytomas, oligodendrogliomas and gangliomas, ependymomas, medulloblastomas, meningiomas, neuromas, pinealomas, pituitary adenomas, craniopharyngiomas, germinomas, and metastatic lesions. The usefulness of contrast enhancement for the investigation of the retrobulbar space and in cases of low grade or infiltrative glioma has not been demonstrated. In calcified lesions, there is less likelihood of enhancement. Following therapy, tumors may show decreased or no enhancement. The opacification of the inferior vermis following contrast media administration has resulted in false-positive diagnosis in a number of otherwise normal studies. Nonneoplastic Conditions ISOVUE may be beneficial in the image enhancement of nonneoplastic lesions. Cerebral infarctions of recent onset may be better visualized with contrast enhancement, while some infarctions are obscured if contrast media are used. The use of iodinated contrast media results in contrast enhancement in about 60 percent of cerebral infarctions studied from one to four weeks from the onset of symptoms. Sites of active infection may also be enhanced following contrast media administration. Arteriovenous malformations and aneurysms will show contrast enhancement. For these vascular lesions, the enhancement is probably dependent on the iodine content of the circulating blood pool. Hematomas and intraparenchymal bleeders seldom demonstrate any contrast enhancement. However, in cases of intraparenchymal clot, for which there is no obvious clinical explanation, contrast media administration may be helpful in ruling out the possibility of associated arteriovenous malformation. CT Body Imaging ISOVUE (Iopamidol Injection) may be used for enhancement of computed tomographic images for detection and evaluation of lesions in the liver, pancreas, kidneys, aorta, mediastinum, abdominal cavity, pelvis and retroperitoneal space. Enhancement of computed tomography with ISOVUE may be of benefit in establishing diagnoses of certain lesions in these sites with greater assurance than is possible with CT alone, and in supplying additional features of the lesions (e.g., hepatic abscess delineation prior to percutaneous drainage). In other cases, the contrast agent may allow visualization of lesions not seen with CT alone (e.g. tumor extension), or may help to define suspicious lesions seen with unenhanced CT (e.g., pancreatic cyst). Contrast enhancement appears to be greatest within 60 to 90 seconds after bolus administration of contrast agent. Therefore, utilization of a continuous scanning technique (“dynamic CT scanning”) may improve enhancement and diagnostic assessment of tumor and other lesions such as an abscess, occasionally revealing unsuspected or more extensive disease. For example, a cyst may be distinguished from a vascularized solid lesion when precontrast and enhanced scans are compared; the nonperfused mass shows unchanged x-ray absorption (CT number). A vascularized lesion is characterized by an increase in CT number in the few minutes after a bolus of intravascular contrast agent; it may be malignant, benign, or normal tissue, but would probably not be a cyst, hematoma, or other nonvascular lesion. Because unenhanced scanning may provide adequate diagnostic information in the individual patient, the decision to employ contrast enhancement, which may be associated with risk and increased radiation exposure, should be based upon a careful evaluation of clinical, other radiological, and unenhanced CT findings. uuid:bc0f7964-cc96-4947-b0c2-d11b4726bd05 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31711 biolink:treats MONDO:0002173 PMID:41385096 "[{""id"":""uuid:4b528691-a5c5-4230-8c36-bdd2a0ab8fba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7336ee12-0f37-4cdf-af7d-f939df3e1e72"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ISOVUE (Iopamidol Injection) is indicated for angiography throughout the cardiovascular system in adults, including cerebral and peripheral arteriography, coronary arteriography and ventriculography, selective visceral arteriography and aortography, peripheral venography (phlebography), and in pediatric patients for angiocardiography; or for intravenous use in adult and pediatric for computed tomographic (CT) imaging of the head and body (see below). CT Head Imaging ISOVUE may be used to refine diagnostic precision in areas of the brain which may not otherwise have been satisfactorily visualized. Tumors ISOVUE may be useful to investigate the presence and extent of certain malignancies such as: gliomas including malignant gliomas, glioblastomas, astrocytomas, oligodendrogliomas and gangliomas, ependymomas, medulloblastomas, meningiomas, neuromas, pinealomas, pituitary adenomas, craniopharyngiomas, germinomas, and metastatic lesions. The usefulness of contrast enhancement for the investigation of the retrobulbar space and in cases of low grade or infiltrative glioma has not been demonstrated. In calcified lesions, there is less likelihood of enhancement. Following therapy, tumors may show decreased or no enhancement. The opacification of the inferior vermis following contrast media administration has resulted in false-positive diagnosis in a number of otherwise normal studies. Nonneoplastic Conditions ISOVUE may be beneficial in the image enhancement of nonneoplastic lesions. Cerebral infarctions of recent onset may be better visualized with contrast enhancement, while some infarctions are obscured if contrast media are used. The use of iodinated contrast media results in contrast enhancement in about 60 percent of cerebral infarctions studied from one to four weeks from the onset of symptoms. Sites of active infection may also be enhanced following contrast media administration. Arteriovenous malformations and aneurysms will show contrast enhancement. For these vascular lesions, the enhancement is probably dependent on the iodine content of the circulating blood pool. Hematomas and intraparenchymal bleeders seldom demonstrate any contrast enhancement. However, in cases of intraparenchymal clot, for which there is no obvious clinical explanation, contrast media administration may be helpful in ruling out the possibility of associated arteriovenous malformation. CT Body Imaging ISOVUE (Iopamidol Injection) may be used for enhancement of computed tomographic images for detection and evaluation of lesions in the liver, pancreas, kidneys, aorta, mediastinum, abdominal cavity, pelvis and retroperitoneal space. Enhancement of computed tomography with ISOVUE may be of benefit in establishing diagnoses of certain lesions in these sites with greater assurance than is possible with CT alone, and in supplying additional features of the lesions (e.g., hepatic abscess delineation prior to percutaneous drainage). In other cases, the contrast agent may allow visualization of lesions not seen with CT alone (e.g. tumor extension), or may help to define suspicious lesions seen with unenhanced CT (e.g., pancreatic cyst). Contrast enhancement appears to be greatest within 60 to 90 seconds after bolus administration of contrast agent. Therefore, utilization of a continuous scanning technique (“dynamic CT scanning”) may improve enhancement and diagnostic assessment of tumor and other lesions such as an abscess, occasionally revealing unsuspected or more extensive disease. For example, a cyst may be distinguished from a vascularized solid lesion when precontrast and enhanced scans are compared; the nonperfused mass shows unchanged x-ray absorption (CT number). A vascularized lesion is characterized by an increase in CT number in the few minutes after a bolus of intravascular contrast agent; it may be malignant, benign, or normal tissue, but would probably not be a cyst, hematoma, or other nonvascular lesion. Because unenhanced scanning may provide adequate diagnostic information in the individual patient, the decision to employ contrast enhancement, which may be associated with risk and increased radiation exposure, should be based upon a careful evaluation of clinical, other radiological, and unenhanced CT findings. uuid:544d5cba-facb-4455-a25d-ed244dbc5922 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31711 biolink:treats MONDO:0024890 PMID:41385096 "[{""id"":""uuid:323f230f-5313-4a1f-84f7-8ff510f5f26d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cb5ba9b3-9184-40ba-bf94-37060a79c459"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ISOVUE (Iopamidol Injection) is indicated for angiography throughout the cardiovascular system in adults, including cerebral and peripheral arteriography, coronary arteriography and ventriculography, selective visceral arteriography and aortography, peripheral venography (phlebography), and in pediatric patients for angiocardiography; or for intravenous use in adult and pediatric for computed tomographic (CT) imaging of the head and body (see below). CT Head Imaging ISOVUE may be used to refine diagnostic precision in areas of the brain which may not otherwise have been satisfactorily visualized. Tumors ISOVUE may be useful to investigate the presence and extent of certain malignancies such as: gliomas including malignant gliomas, glioblastomas, astrocytomas, oligodendrogliomas and gangliomas, ependymomas, medulloblastomas, meningiomas, neuromas, pinealomas, pituitary adenomas, craniopharyngiomas, germinomas, and metastatic lesions. The usefulness of contrast enhancement for the investigation of the retrobulbar space and in cases of low grade or infiltrative glioma has not been demonstrated. In calcified lesions, there is less likelihood of enhancement. Following therapy, tumors may show decreased or no enhancement. The opacification of the inferior vermis following contrast media administration has resulted in false-positive diagnosis in a number of otherwise normal studies. Nonneoplastic Conditions ISOVUE may be beneficial in the image enhancement of nonneoplastic lesions. Cerebral infarctions of recent onset may be better visualized with contrast enhancement, while some infarctions are obscured if contrast media are used. The use of iodinated contrast media results in contrast enhancement in about 60 percent of cerebral infarctions studied from one to four weeks from the onset of symptoms. Sites of active infection may also be enhanced following contrast media administration. Arteriovenous malformations and aneurysms will show contrast enhancement. For these vascular lesions, the enhancement is probably dependent on the iodine content of the circulating blood pool. Hematomas and intraparenchymal bleeders seldom demonstrate any contrast enhancement. However, in cases of intraparenchymal clot, for which there is no obvious clinical explanation, contrast media administration may be helpful in ruling out the possibility of associated arteriovenous malformation. CT Body Imaging ISOVUE (Iopamidol Injection) may be used for enhancement of computed tomographic images for detection and evaluation of lesions in the liver, pancreas, kidneys, aorta, mediastinum, abdominal cavity, pelvis and retroperitoneal space. Enhancement of computed tomography with ISOVUE may be of benefit in establishing diagnoses of certain lesions in these sites with greater assurance than is possible with CT alone, and in supplying additional features of the lesions (e.g., hepatic abscess delineation prior to percutaneous drainage). In other cases, the contrast agent may allow visualization of lesions not seen with CT alone (e.g. tumor extension), or may help to define suspicious lesions seen with unenhanced CT (e.g., pancreatic cyst). Contrast enhancement appears to be greatest within 60 to 90 seconds after bolus administration of contrast agent. Therefore, utilization of a continuous scanning technique (“dynamic CT scanning”) may improve enhancement and diagnostic assessment of tumor and other lesions such as an abscess, occasionally revealing unsuspected or more extensive disease. For example, a cyst may be distinguished from a vascularized solid lesion when precontrast and enhanced scans are compared; the nonperfused mass shows unchanged x-ray absorption (CT number). A vascularized lesion is characterized by an increase in CT number in the few minutes after a bolus of intravascular contrast agent; it may be malignant, benign, or normal tissue, but would probably not be a cyst, hematoma, or other nonvascular lesion. Because unenhanced scanning may provide adequate diagnostic information in the individual patient, the decision to employ contrast enhancement, which may be associated with risk and increased radiation exposure, should be based upon a careful evaluation of clinical, other radiological, and unenhanced CT findings. uuid:4511cebf-0656-435f-a919-29b869e8b731 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31711 biolink:treats MONDO:0006373 PMID:41385096 "[{""id"":""uuid:7058473d-784d-4bbd-b80e-4f69516e34d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aaa6ce83-86e4-4567-8107-347566ff8f0d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ISOVUE (Iopamidol Injection) is indicated for angiography throughout the cardiovascular system in adults, including cerebral and peripheral arteriography, coronary arteriography and ventriculography, selective visceral arteriography and aortography, peripheral venography (phlebography), and in pediatric patients for angiocardiography; or for intravenous use in adult and pediatric for computed tomographic (CT) imaging of the head and body (see below). CT Head Imaging ISOVUE may be used to refine diagnostic precision in areas of the brain which may not otherwise have been satisfactorily visualized. Tumors ISOVUE may be useful to investigate the presence and extent of certain malignancies such as: gliomas including malignant gliomas, glioblastomas, astrocytomas, oligodendrogliomas and gangliomas, ependymomas, medulloblastomas, meningiomas, neuromas, pinealomas, pituitary adenomas, craniopharyngiomas, germinomas, and metastatic lesions. The usefulness of contrast enhancement for the investigation of the retrobulbar space and in cases of low grade or infiltrative glioma has not been demonstrated. In calcified lesions, there is less likelihood of enhancement. Following therapy, tumors may show decreased or no enhancement. The opacification of the inferior vermis following contrast media administration has resulted in false-positive diagnosis in a number of otherwise normal studies. Nonneoplastic Conditions ISOVUE may be beneficial in the image enhancement of nonneoplastic lesions. Cerebral infarctions of recent onset may be better visualized with contrast enhancement, while some infarctions are obscured if contrast media are used. The use of iodinated contrast media results in contrast enhancement in about 60 percent of cerebral infarctions studied from one to four weeks from the onset of symptoms. Sites of active infection may also be enhanced following contrast media administration. Arteriovenous malformations and aneurysms will show contrast enhancement. For these vascular lesions, the enhancement is probably dependent on the iodine content of the circulating blood pool. Hematomas and intraparenchymal bleeders seldom demonstrate any contrast enhancement. However, in cases of intraparenchymal clot, for which there is no obvious clinical explanation, contrast media administration may be helpful in ruling out the possibility of associated arteriovenous malformation. CT Body Imaging ISOVUE (Iopamidol Injection) may be used for enhancement of computed tomographic images for detection and evaluation of lesions in the liver, pancreas, kidneys, aorta, mediastinum, abdominal cavity, pelvis and retroperitoneal space. Enhancement of computed tomography with ISOVUE may be of benefit in establishing diagnoses of certain lesions in these sites with greater assurance than is possible with CT alone, and in supplying additional features of the lesions (e.g., hepatic abscess delineation prior to percutaneous drainage). In other cases, the contrast agent may allow visualization of lesions not seen with CT alone (e.g. tumor extension), or may help to define suspicious lesions seen with unenhanced CT (e.g., pancreatic cyst). Contrast enhancement appears to be greatest within 60 to 90 seconds after bolus administration of contrast agent. Therefore, utilization of a continuous scanning technique (“dynamic CT scanning”) may improve enhancement and diagnostic assessment of tumor and other lesions such as an abscess, occasionally revealing unsuspected or more extensive disease. For example, a cyst may be distinguished from a vascularized solid lesion when precontrast and enhanced scans are compared; the nonperfused mass shows unchanged x-ray absorption (CT number). A vascularized lesion is characterized by an increase in CT number in the few minutes after a bolus of intravascular contrast agent; it may be malignant, benign, or normal tissue, but would probably not be a cyst, hematoma, or other nonvascular lesion. Because unenhanced scanning may provide adequate diagnostic information in the individual patient, the decision to employ contrast enhancement, which may be associated with risk and increased radiation exposure, should be based upon a careful evaluation of clinical, other radiological, and unenhanced CT findings. uuid:31a5b759-b518-442a-a3fc-24d7b15bafd6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31711 biolink:treats MONDO:0002787 PMID:41385096 "[{""id"":""uuid:8bbd594a-949c-4cf7-8fc2-59997f16dc32"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:94453084-173e-4a38-8884-9d9751c96c8a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ISOVUE (Iopamidol Injection) is indicated for angiography throughout the cardiovascular system in adults, including cerebral and peripheral arteriography, coronary arteriography and ventriculography, selective visceral arteriography and aortography, peripheral venography (phlebography), and in pediatric patients for angiocardiography; or for intravenous use in adult and pediatric for computed tomographic (CT) imaging of the head and body (see below). CT Head Imaging ISOVUE may be used to refine diagnostic precision in areas of the brain which may not otherwise have been satisfactorily visualized. Tumors ISOVUE may be useful to investigate the presence and extent of certain malignancies such as: gliomas including malignant gliomas, glioblastomas, astrocytomas, oligodendrogliomas and gangliomas, ependymomas, medulloblastomas, meningiomas, neuromas, pinealomas, pituitary adenomas, craniopharyngiomas, germinomas, and metastatic lesions. The usefulness of contrast enhancement for the investigation of the retrobulbar space and in cases of low grade or infiltrative glioma has not been demonstrated. In calcified lesions, there is less likelihood of enhancement. Following therapy, tumors may show decreased or no enhancement. The opacification of the inferior vermis following contrast media administration has resulted in false-positive diagnosis in a number of otherwise normal studies. Nonneoplastic Conditions ISOVUE may be beneficial in the image enhancement of nonneoplastic lesions. Cerebral infarctions of recent onset may be better visualized with contrast enhancement, while some infarctions are obscured if contrast media are used. The use of iodinated contrast media results in contrast enhancement in about 60 percent of cerebral infarctions studied from one to four weeks from the onset of symptoms. Sites of active infection may also be enhanced following contrast media administration. Arteriovenous malformations and aneurysms will show contrast enhancement. For these vascular lesions, the enhancement is probably dependent on the iodine content of the circulating blood pool. Hematomas and intraparenchymal bleeders seldom demonstrate any contrast enhancement. However, in cases of intraparenchymal clot, for which there is no obvious clinical explanation, contrast media administration may be helpful in ruling out the possibility of associated arteriovenous malformation. CT Body Imaging ISOVUE (Iopamidol Injection) may be used for enhancement of computed tomographic images for detection and evaluation of lesions in the liver, pancreas, kidneys, aorta, mediastinum, abdominal cavity, pelvis and retroperitoneal space. Enhancement of computed tomography with ISOVUE may be of benefit in establishing diagnoses of certain lesions in these sites with greater assurance than is possible with CT alone, and in supplying additional features of the lesions (e.g., hepatic abscess delineation prior to percutaneous drainage). In other cases, the contrast agent may allow visualization of lesions not seen with CT alone (e.g. tumor extension), or may help to define suspicious lesions seen with unenhanced CT (e.g., pancreatic cyst). Contrast enhancement appears to be greatest within 60 to 90 seconds after bolus administration of contrast agent. Therefore, utilization of a continuous scanning technique (“dynamic CT scanning”) may improve enhancement and diagnostic assessment of tumor and other lesions such as an abscess, occasionally revealing unsuspected or more extensive disease. For example, a cyst may be distinguished from a vascularized solid lesion when precontrast and enhanced scans are compared; the nonperfused mass shows unchanged x-ray absorption (CT number). A vascularized lesion is characterized by an increase in CT number in the few minutes after a bolus of intravascular contrast agent; it may be malignant, benign, or normal tissue, but would probably not be a cyst, hematoma, or other nonvascular lesion. Because unenhanced scanning may provide adequate diagnostic information in the individual patient, the decision to employ contrast enhancement, which may be associated with risk and increased radiation exposure, should be based upon a careful evaluation of clinical, other radiological, and unenhanced CT findings. uuid:58bc7f05-ac89-418c-aa73-78f09d99e39b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31711 biolink:treats MONDO:0002598 PMID:41385096 "[{""id"":""uuid:8f14dd46-d1f5-4ddf-a203-4018c31006f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ae23cef5-9802-4a93-8534-a885a930fe54"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ISOVUE (Iopamidol Injection) is indicated for angiography throughout the cardiovascular system in adults, including cerebral and peripheral arteriography, coronary arteriography and ventriculography, selective visceral arteriography and aortography, peripheral venography (phlebography), and in pediatric patients for angiocardiography; or for intravenous use in adult and pediatric for computed tomographic (CT) imaging of the head and body (see below). CT Head Imaging ISOVUE may be used to refine diagnostic precision in areas of the brain which may not otherwise have been satisfactorily visualized. Tumors ISOVUE may be useful to investigate the presence and extent of certain malignancies such as: gliomas including malignant gliomas, glioblastomas, astrocytomas, oligodendrogliomas and gangliomas, ependymomas, medulloblastomas, meningiomas, neuromas, pinealomas, pituitary adenomas, craniopharyngiomas, germinomas, and metastatic lesions. The usefulness of contrast enhancement for the investigation of the retrobulbar space and in cases of low grade or infiltrative glioma has not been demonstrated. In calcified lesions, there is less likelihood of enhancement. Following therapy, tumors may show decreased or no enhancement. The opacification of the inferior vermis following contrast media administration has resulted in false-positive diagnosis in a number of otherwise normal studies. Nonneoplastic Conditions ISOVUE may be beneficial in the image enhancement of nonneoplastic lesions. Cerebral infarctions of recent onset may be better visualized with contrast enhancement, while some infarctions are obscured if contrast media are used. The use of iodinated contrast media results in contrast enhancement in about 60 percent of cerebral infarctions studied from one to four weeks from the onset of symptoms. Sites of active infection may also be enhanced following contrast media administration. Arteriovenous malformations and aneurysms will show contrast enhancement. For these vascular lesions, the enhancement is probably dependent on the iodine content of the circulating blood pool. Hematomas and intraparenchymal bleeders seldom demonstrate any contrast enhancement. However, in cases of intraparenchymal clot, for which there is no obvious clinical explanation, contrast media administration may be helpful in ruling out the possibility of associated arteriovenous malformation. CT Body Imaging ISOVUE (Iopamidol Injection) may be used for enhancement of computed tomographic images for detection and evaluation of lesions in the liver, pancreas, kidneys, aorta, mediastinum, abdominal cavity, pelvis and retroperitoneal space. Enhancement of computed tomography with ISOVUE may be of benefit in establishing diagnoses of certain lesions in these sites with greater assurance than is possible with CT alone, and in supplying additional features of the lesions (e.g., hepatic abscess delineation prior to percutaneous drainage). In other cases, the contrast agent may allow visualization of lesions not seen with CT alone (e.g. tumor extension), or may help to define suspicious lesions seen with unenhanced CT (e.g., pancreatic cyst). Contrast enhancement appears to be greatest within 60 to 90 seconds after bolus administration of contrast agent. Therefore, utilization of a continuous scanning technique (“dynamic CT scanning”) may improve enhancement and diagnostic assessment of tumor and other lesions such as an abscess, occasionally revealing unsuspected or more extensive disease. For example, a cyst may be distinguished from a vascularized solid lesion when precontrast and enhanced scans are compared; the nonperfused mass shows unchanged x-ray absorption (CT number). A vascularized lesion is characterized by an increase in CT number in the few minutes after a bolus of intravascular contrast agent; it may be malignant, benign, or normal tissue, but would probably not be a cyst, hematoma, or other nonvascular lesion. Because unenhanced scanning may provide adequate diagnostic information in the individual patient, the decision to employ contrast enhancement, which may be associated with risk and increased radiation exposure, should be based upon a careful evaluation of clinical, other radiological, and unenhanced CT findings. uuid:1ed42a08-ef03-4551-8a1a-c205ac62207c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31711 biolink:treats MONDO:0024879 PMID:41385096 "[{""id"":""uuid:0955b368-d1a5-4de8-baae-990bb59cc1ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:385ef3d8-a860-471b-b26f-d407071780f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ISOVUE (Iopamidol Injection) is indicated for angiography throughout the cardiovascular system in adults, including cerebral and peripheral arteriography, coronary arteriography and ventriculography, selective visceral arteriography and aortography, peripheral venography (phlebography), and in pediatric patients for angiocardiography; or for intravenous use in adult and pediatric for computed tomographic (CT) imaging of the head and body (see below). CT Head Imaging ISOVUE may be used to refine diagnostic precision in areas of the brain which may not otherwise have been satisfactorily visualized. Tumors ISOVUE may be useful to investigate the presence and extent of certain malignancies such as: gliomas including malignant gliomas, glioblastomas, astrocytomas, oligodendrogliomas and gangliomas, ependymomas, medulloblastomas, meningiomas, neuromas, pinealomas, pituitary adenomas, craniopharyngiomas, germinomas, and metastatic lesions. The usefulness of contrast enhancement for the investigation of the retrobulbar space and in cases of low grade or infiltrative glioma has not been demonstrated. In calcified lesions, there is less likelihood of enhancement. Following therapy, tumors may show decreased or no enhancement. The opacification of the inferior vermis following contrast media administration has resulted in false-positive diagnosis in a number of otherwise normal studies. Nonneoplastic Conditions ISOVUE may be beneficial in the image enhancement of nonneoplastic lesions. Cerebral infarctions of recent onset may be better visualized with contrast enhancement, while some infarctions are obscured if contrast media are used. The use of iodinated contrast media results in contrast enhancement in about 60 percent of cerebral infarctions studied from one to four weeks from the onset of symptoms. Sites of active infection may also be enhanced following contrast media administration. Arteriovenous malformations and aneurysms will show contrast enhancement. For these vascular lesions, the enhancement is probably dependent on the iodine content of the circulating blood pool. Hematomas and intraparenchymal bleeders seldom demonstrate any contrast enhancement. However, in cases of intraparenchymal clot, for which there is no obvious clinical explanation, contrast media administration may be helpful in ruling out the possibility of associated arteriovenous malformation. CT Body Imaging ISOVUE (Iopamidol Injection) may be used for enhancement of computed tomographic images for detection and evaluation of lesions in the liver, pancreas, kidneys, aorta, mediastinum, abdominal cavity, pelvis and retroperitoneal space. Enhancement of computed tomography with ISOVUE may be of benefit in establishing diagnoses of certain lesions in these sites with greater assurance than is possible with CT alone, and in supplying additional features of the lesions (e.g., hepatic abscess delineation prior to percutaneous drainage). In other cases, the contrast agent may allow visualization of lesions not seen with CT alone (e.g. tumor extension), or may help to define suspicious lesions seen with unenhanced CT (e.g., pancreatic cyst). Contrast enhancement appears to be greatest within 60 to 90 seconds after bolus administration of contrast agent. Therefore, utilization of a continuous scanning technique (“dynamic CT scanning”) may improve enhancement and diagnostic assessment of tumor and other lesions such as an abscess, occasionally revealing unsuspected or more extensive disease. For example, a cyst may be distinguished from a vascularized solid lesion when precontrast and enhanced scans are compared; the nonperfused mass shows unchanged x-ray absorption (CT number). A vascularized lesion is characterized by an increase in CT number in the few minutes after a bolus of intravascular contrast agent; it may be malignant, benign, or normal tissue, but would probably not be a cyst, hematoma, or other nonvascular lesion. Because unenhanced scanning may provide adequate diagnostic information in the individual patient, the decision to employ contrast enhancement, which may be associated with risk and increased radiation exposure, should be based upon a careful evaluation of clinical, other radiological, and unenhanced CT findings. uuid:c94e91b3-2776-477c-a83f-7dd1894967f8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31711 biolink:treats MONDO:0002679 PMID:41385096 "[{""id"":""uuid:98a481f2-d195-4736-88d4-8ed6e273ea64"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4d304d6e-fa5c-431c-9506-ddc3016545e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ISOVUE (Iopamidol Injection) is indicated for angiography throughout the cardiovascular system in adults, including cerebral and peripheral arteriography, coronary arteriography and ventriculography, selective visceral arteriography and aortography, peripheral venography (phlebography), and in pediatric patients for angiocardiography; or for intravenous use in adult and pediatric for computed tomographic (CT) imaging of the head and body (see below). CT Head Imaging ISOVUE may be used to refine diagnostic precision in areas of the brain which may not otherwise have been satisfactorily visualized. Tumors ISOVUE may be useful to investigate the presence and extent of certain malignancies such as: gliomas including malignant gliomas, glioblastomas, astrocytomas, oligodendrogliomas and gangliomas, ependymomas, medulloblastomas, meningiomas, neuromas, pinealomas, pituitary adenomas, craniopharyngiomas, germinomas, and metastatic lesions. The usefulness of contrast enhancement for the investigation of the retrobulbar space and in cases of low grade or infiltrative glioma has not been demonstrated. In calcified lesions, there is less likelihood of enhancement. Following therapy, tumors may show decreased or no enhancement. The opacification of the inferior vermis following contrast media administration has resulted in false-positive diagnosis in a number of otherwise normal studies. Nonneoplastic Conditions ISOVUE may be beneficial in the image enhancement of nonneoplastic lesions. Cerebral infarctions of recent onset may be better visualized with contrast enhancement, while some infarctions are obscured if contrast media are used. The use of iodinated contrast media results in contrast enhancement in about 60 percent of cerebral infarctions studied from one to four weeks from the onset of symptoms. Sites of active infection may also be enhanced following contrast media administration. Arteriovenous malformations and aneurysms will show contrast enhancement. For these vascular lesions, the enhancement is probably dependent on the iodine content of the circulating blood pool. Hematomas and intraparenchymal bleeders seldom demonstrate any contrast enhancement. However, in cases of intraparenchymal clot, for which there is no obvious clinical explanation, contrast media administration may be helpful in ruling out the possibility of associated arteriovenous malformation. CT Body Imaging ISOVUE (Iopamidol Injection) may be used for enhancement of computed tomographic images for detection and evaluation of lesions in the liver, pancreas, kidneys, aorta, mediastinum, abdominal cavity, pelvis and retroperitoneal space. Enhancement of computed tomography with ISOVUE may be of benefit in establishing diagnoses of certain lesions in these sites with greater assurance than is possible with CT alone, and in supplying additional features of the lesions (e.g., hepatic abscess delineation prior to percutaneous drainage). In other cases, the contrast agent may allow visualization of lesions not seen with CT alone (e.g. tumor extension), or may help to define suspicious lesions seen with unenhanced CT (e.g., pancreatic cyst). Contrast enhancement appears to be greatest within 60 to 90 seconds after bolus administration of contrast agent. Therefore, utilization of a continuous scanning technique (“dynamic CT scanning”) may improve enhancement and diagnostic assessment of tumor and other lesions such as an abscess, occasionally revealing unsuspected or more extensive disease. For example, a cyst may be distinguished from a vascularized solid lesion when precontrast and enhanced scans are compared; the nonperfused mass shows unchanged x-ray absorption (CT number). A vascularized lesion is characterized by an increase in CT number in the few minutes after a bolus of intravascular contrast agent; it may be malignant, benign, or normal tissue, but would probably not be a cyst, hematoma, or other nonvascular lesion. Because unenhanced scanning may provide adequate diagnostic information in the individual patient, the decision to employ contrast enhancement, which may be associated with risk and increased radiation exposure, should be based upon a careful evaluation of clinical, other radiological, and unenhanced CT findings. uuid:cfab8faa-04e6-41f5-ad95-d48731c6a048 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31711 biolink:treats MONDO:0001256 PMID:41385096 "[{""id"":""uuid:d0bd17db-a286-4d46-ab56-4b892ebfc454"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a3e69952-4119-462c-8703-512016de9de8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ISOVUE (Iopamidol Injection) is indicated for angiography throughout the cardiovascular system in adults, including cerebral and peripheral arteriography, coronary arteriography and ventriculography, selective visceral arteriography and aortography, peripheral venography (phlebography), and in pediatric patients for angiocardiography; or for intravenous use in adult and pediatric for computed tomographic (CT) imaging of the head and body (see below). CT Head Imaging ISOVUE may be used to refine diagnostic precision in areas of the brain which may not otherwise have been satisfactorily visualized. Tumors ISOVUE may be useful to investigate the presence and extent of certain malignancies such as: gliomas including malignant gliomas, glioblastomas, astrocytomas, oligodendrogliomas and gangliomas, ependymomas, medulloblastomas, meningiomas, neuromas, pinealomas, pituitary adenomas, craniopharyngiomas, germinomas, and metastatic lesions. The usefulness of contrast enhancement for the investigation of the retrobulbar space and in cases of low grade or infiltrative glioma has not been demonstrated. In calcified lesions, there is less likelihood of enhancement. Following therapy, tumors may show decreased or no enhancement. The opacification of the inferior vermis following contrast media administration has resulted in false-positive diagnosis in a number of otherwise normal studies. Nonneoplastic Conditions ISOVUE may be beneficial in the image enhancement of nonneoplastic lesions. Cerebral infarctions of recent onset may be better visualized with contrast enhancement, while some infarctions are obscured if contrast media are used. The use of iodinated contrast media results in contrast enhancement in about 60 percent of cerebral infarctions studied from one to four weeks from the onset of symptoms. Sites of active infection may also be enhanced following contrast media administration. Arteriovenous malformations and aneurysms will show contrast enhancement. For these vascular lesions, the enhancement is probably dependent on the iodine content of the circulating blood pool. Hematomas and intraparenchymal bleeders seldom demonstrate any contrast enhancement. However, in cases of intraparenchymal clot, for which there is no obvious clinical explanation, contrast media administration may be helpful in ruling out the possibility of associated arteriovenous malformation. CT Body Imaging ISOVUE (Iopamidol Injection) may be used for enhancement of computed tomographic images for detection and evaluation of lesions in the liver, pancreas, kidneys, aorta, mediastinum, abdominal cavity, pelvis and retroperitoneal space. Enhancement of computed tomography with ISOVUE may be of benefit in establishing diagnoses of certain lesions in these sites with greater assurance than is possible with CT alone, and in supplying additional features of the lesions (e.g., hepatic abscess delineation prior to percutaneous drainage). In other cases, the contrast agent may allow visualization of lesions not seen with CT alone (e.g. tumor extension), or may help to define suspicious lesions seen with unenhanced CT (e.g., pancreatic cyst). Contrast enhancement appears to be greatest within 60 to 90 seconds after bolus administration of contrast agent. Therefore, utilization of a continuous scanning technique (“dynamic CT scanning”) may improve enhancement and diagnostic assessment of tumor and other lesions such as an abscess, occasionally revealing unsuspected or more extensive disease. For example, a cyst may be distinguished from a vascularized solid lesion when precontrast and enhanced scans are compared; the nonperfused mass shows unchanged x-ray absorption (CT number). A vascularized lesion is characterized by an increase in CT number in the few minutes after a bolus of intravascular contrast agent; it may be malignant, benign, or normal tissue, but would probably not be a cyst, hematoma, or other nonvascular lesion. Because unenhanced scanning may provide adequate diagnostic information in the individual patient, the decision to employ contrast enhancement, which may be associated with risk and increased radiation exposure, should be based upon a careful evaluation of clinical, other radiological, and unenhanced CT findings. uuid:d488ca3a-b52d-4a01-9562-742bcabc07bf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31711 biolink:treats MONDO:0005385 PMID:41385096 "[{""id"":""uuid:b2c70346-cf09-4b86-9b1e-2d52cccae88c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eece5d7b-dad7-4957-b21e-5453f6fbbc73"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ISOVUE (Iopamidol Injection) is indicated for angiography throughout the cardiovascular system in adults, including cerebral and peripheral arteriography, coronary arteriography and ventriculography, selective visceral arteriography and aortography, peripheral venography (phlebography), and in pediatric patients for angiocardiography; or for intravenous use in adult and pediatric for computed tomographic (CT) imaging of the head and body (see below). CT Head Imaging ISOVUE may be used to refine diagnostic precision in areas of the brain which may not otherwise have been satisfactorily visualized. Tumors ISOVUE may be useful to investigate the presence and extent of certain malignancies such as: gliomas including malignant gliomas, glioblastomas, astrocytomas, oligodendrogliomas and gangliomas, ependymomas, medulloblastomas, meningiomas, neuromas, pinealomas, pituitary adenomas, craniopharyngiomas, germinomas, and metastatic lesions. The usefulness of contrast enhancement for the investigation of the retrobulbar space and in cases of low grade or infiltrative glioma has not been demonstrated. In calcified lesions, there is less likelihood of enhancement. Following therapy, tumors may show decreased or no enhancement. The opacification of the inferior vermis following contrast media administration has resulted in false-positive diagnosis in a number of otherwise normal studies. Nonneoplastic Conditions ISOVUE may be beneficial in the image enhancement of nonneoplastic lesions. Cerebral infarctions of recent onset may be better visualized with contrast enhancement, while some infarctions are obscured if contrast media are used. The use of iodinated contrast media results in contrast enhancement in about 60 percent of cerebral infarctions studied from one to four weeks from the onset of symptoms. Sites of active infection may also be enhanced following contrast media administration. Arteriovenous malformations and aneurysms will show contrast enhancement. For these vascular lesions, the enhancement is probably dependent on the iodine content of the circulating blood pool. Hematomas and intraparenchymal bleeders seldom demonstrate any contrast enhancement. However, in cases of intraparenchymal clot, for which there is no obvious clinical explanation, contrast media administration may be helpful in ruling out the possibility of associated arteriovenous malformation. CT Body Imaging ISOVUE (Iopamidol Injection) may be used for enhancement of computed tomographic images for detection and evaluation of lesions in the liver, pancreas, kidneys, aorta, mediastinum, abdominal cavity, pelvis and retroperitoneal space. Enhancement of computed tomography with ISOVUE may be of benefit in establishing diagnoses of certain lesions in these sites with greater assurance than is possible with CT alone, and in supplying additional features of the lesions (e.g., hepatic abscess delineation prior to percutaneous drainage). In other cases, the contrast agent may allow visualization of lesions not seen with CT alone (e.g. tumor extension), or may help to define suspicious lesions seen with unenhanced CT (e.g., pancreatic cyst). Contrast enhancement appears to be greatest within 60 to 90 seconds after bolus administration of contrast agent. Therefore, utilization of a continuous scanning technique (“dynamic CT scanning”) may improve enhancement and diagnostic assessment of tumor and other lesions such as an abscess, occasionally revealing unsuspected or more extensive disease. For example, a cyst may be distinguished from a vascularized solid lesion when precontrast and enhanced scans are compared; the nonperfused mass shows unchanged x-ray absorption (CT number). A vascularized lesion is characterized by an increase in CT number in the few minutes after a bolus of intravascular contrast agent; it may be malignant, benign, or normal tissue, but would probably not be a cyst, hematoma, or other nonvascular lesion. Because unenhanced scanning may provide adequate diagnostic information in the individual patient, the decision to employ contrast enhancement, which may be associated with risk and increased radiation exposure, should be based upon a careful evaluation of clinical, other radiological, and unenhanced CT findings. uuid:f94aefb1-27d8-4026-8fc5-e7c8ee3d1f26 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31711 biolink:treats EFO:0010680 PMID:41385096 "[{""id"":""uuid:c4e6ec9d-c46e-4f27-9f58-3e50a5c0328f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:38bbf39e-f860-4413-836d-1824877e4c4c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ISOVUE (Iopamidol Injection) is indicated for angiography throughout the cardiovascular system in adults, including cerebral and peripheral arteriography, coronary arteriography and ventriculography, selective visceral arteriography and aortography, peripheral venography (phlebography), and in pediatric patients for angiocardiography; or for intravenous use in adult and pediatric for computed tomographic (CT) imaging of the head and body (see below). CT Head Imaging ISOVUE may be used to refine diagnostic precision in areas of the brain which may not otherwise have been satisfactorily visualized. Tumors ISOVUE may be useful to investigate the presence and extent of certain malignancies such as: gliomas including malignant gliomas, glioblastomas, astrocytomas, oligodendrogliomas and gangliomas, ependymomas, medulloblastomas, meningiomas, neuromas, pinealomas, pituitary adenomas, craniopharyngiomas, germinomas, and metastatic lesions. The usefulness of contrast enhancement for the investigation of the retrobulbar space and in cases of low grade or infiltrative glioma has not been demonstrated. In calcified lesions, there is less likelihood of enhancement. Following therapy, tumors may show decreased or no enhancement. The opacification of the inferior vermis following contrast media administration has resulted in false-positive diagnosis in a number of otherwise normal studies. Nonneoplastic Conditions ISOVUE may be beneficial in the image enhancement of nonneoplastic lesions. Cerebral infarctions of recent onset may be better visualized with contrast enhancement, while some infarctions are obscured if contrast media are used. The use of iodinated contrast media results in contrast enhancement in about 60 percent of cerebral infarctions studied from one to four weeks from the onset of symptoms. Sites of active infection may also be enhanced following contrast media administration. Arteriovenous malformations and aneurysms will show contrast enhancement. For these vascular lesions, the enhancement is probably dependent on the iodine content of the circulating blood pool. Hematomas and intraparenchymal bleeders seldom demonstrate any contrast enhancement. However, in cases of intraparenchymal clot, for which there is no obvious clinical explanation, contrast media administration may be helpful in ruling out the possibility of associated arteriovenous malformation. CT Body Imaging ISOVUE (Iopamidol Injection) may be used for enhancement of computed tomographic images for detection and evaluation of lesions in the liver, pancreas, kidneys, aorta, mediastinum, abdominal cavity, pelvis and retroperitoneal space. Enhancement of computed tomography with ISOVUE may be of benefit in establishing diagnoses of certain lesions in these sites with greater assurance than is possible with CT alone, and in supplying additional features of the lesions (e.g., hepatic abscess delineation prior to percutaneous drainage). In other cases, the contrast agent may allow visualization of lesions not seen with CT alone (e.g. tumor extension), or may help to define suspicious lesions seen with unenhanced CT (e.g., pancreatic cyst). Contrast enhancement appears to be greatest within 60 to 90 seconds after bolus administration of contrast agent. Therefore, utilization of a continuous scanning technique (“dynamic CT scanning”) may improve enhancement and diagnostic assessment of tumor and other lesions such as an abscess, occasionally revealing unsuspected or more extensive disease. For example, a cyst may be distinguished from a vascularized solid lesion when precontrast and enhanced scans are compared; the nonperfused mass shows unchanged x-ray absorption (CT number). A vascularized lesion is characterized by an increase in CT number in the few minutes after a bolus of intravascular contrast agent; it may be malignant, benign, or normal tissue, but would probably not be a cyst, hematoma, or other nonvascular lesion. Because unenhanced scanning may provide adequate diagnostic information in the individual patient, the decision to employ contrast enhancement, which may be associated with risk and increased radiation exposure, should be based upon a careful evaluation of clinical, other radiological, and unenhanced CT findings. uuid:7ef371a4-0ef0-4dc1-be41-2a6cd695d2bf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31711 biolink:treats MONDO:0700051 PMID:41385096 "[{""id"":""uuid:ea344463-ee4e-4788-8e38-2446515a03c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d42f48cc-f4ae-4cfc-b169-c55bfa5a3b25"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ISOVUE (Iopamidol Injection) is indicated for angiography throughout the cardiovascular system in adults, including cerebral and peripheral arteriography, coronary arteriography and ventriculography, selective visceral arteriography and aortography, peripheral venography (phlebography), and in pediatric patients for angiocardiography; or for intravenous use in adult and pediatric for computed tomographic (CT) imaging of the head and body (see below). CT Head Imaging ISOVUE may be used to refine diagnostic precision in areas of the brain which may not otherwise have been satisfactorily visualized. Tumors ISOVUE may be useful to investigate the presence and extent of certain malignancies such as: gliomas including malignant gliomas, glioblastomas, astrocytomas, oligodendrogliomas and gangliomas, ependymomas, medulloblastomas, meningiomas, neuromas, pinealomas, pituitary adenomas, craniopharyngiomas, germinomas, and metastatic lesions. The usefulness of contrast enhancement for the investigation of the retrobulbar space and in cases of low grade or infiltrative glioma has not been demonstrated. In calcified lesions, there is less likelihood of enhancement. Following therapy, tumors may show decreased or no enhancement. The opacification of the inferior vermis following contrast media administration has resulted in false-positive diagnosis in a number of otherwise normal studies. Nonneoplastic Conditions ISOVUE may be beneficial in the image enhancement of nonneoplastic lesions. Cerebral infarctions of recent onset may be better visualized with contrast enhancement, while some infarctions are obscured if contrast media are used. The use of iodinated contrast media results in contrast enhancement in about 60 percent of cerebral infarctions studied from one to four weeks from the onset of symptoms. Sites of active infection may also be enhanced following contrast media administration. Arteriovenous malformations and aneurysms will show contrast enhancement. For these vascular lesions, the enhancement is probably dependent on the iodine content of the circulating blood pool. Hematomas and intraparenchymal bleeders seldom demonstrate any contrast enhancement. However, in cases of intraparenchymal clot, for which there is no obvious clinical explanation, contrast media administration may be helpful in ruling out the possibility of associated arteriovenous malformation. CT Body Imaging ISOVUE (Iopamidol Injection) may be used for enhancement of computed tomographic images for detection and evaluation of lesions in the liver, pancreas, kidneys, aorta, mediastinum, abdominal cavity, pelvis and retroperitoneal space. Enhancement of computed tomography with ISOVUE may be of benefit in establishing diagnoses of certain lesions in these sites with greater assurance than is possible with CT alone, and in supplying additional features of the lesions (e.g., hepatic abscess delineation prior to percutaneous drainage). In other cases, the contrast agent may allow visualization of lesions not seen with CT alone (e.g. tumor extension), or may help to define suspicious lesions seen with unenhanced CT (e.g., pancreatic cyst). Contrast enhancement appears to be greatest within 60 to 90 seconds after bolus administration of contrast agent. Therefore, utilization of a continuous scanning technique (“dynamic CT scanning”) may improve enhancement and diagnostic assessment of tumor and other lesions such as an abscess, occasionally revealing unsuspected or more extensive disease. For example, a cyst may be distinguished from a vascularized solid lesion when precontrast and enhanced scans are compared; the nonperfused mass shows unchanged x-ray absorption (CT number). A vascularized lesion is characterized by an increase in CT number in the few minutes after a bolus of intravascular contrast agent; it may be malignant, benign, or normal tissue, but would probably not be a cyst, hematoma, or other nonvascular lesion. Because unenhanced scanning may provide adequate diagnostic information in the individual patient, the decision to employ contrast enhancement, which may be associated with risk and increased radiation exposure, should be based upon a careful evaluation of clinical, other radiological, and unenhanced CT findings. uuid:19301526-128f-400b-bd8d-9e52d6a1b8f3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:133082145 biolink:treats HP:0003124 PMID:41385096 "[{""id"":""uuid:5d34cbad-4199-44be-8e6d-95fb9222fc42"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:deb482ef-1033-4ba0-9c8b-f5f88c8235c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin calcium tablets can be started simultaneously with diet. 1.1 Prevention of Cardiovascular Disease in Adults In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In adult patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In adult patients with clinically evident coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 1.2 Hyperlipidemia Atorvastatin calcium tablets are indicated: As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in adult patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson Types IIa and IIb); As an adjunct to diet for the treatment of adult patients with elevated serum TG levels (Fredrickson Type IV); For the treatment of adult patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet; To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH) as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; As an adjunct to diet to reduce total-C, LDL-C, and apo B levels in pediatric patients, 10 years to 17 years of age, with heterozygous familial hypercholesterolemia (HeFH) if after an adequate trial of diet therapy the following findings are present: a. LDL-C remains ≥ 190 mg/dL or b. LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient 1.3 Limitations of Use Atorvastatin calcium tablets have not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V). uuid:fc12c13b-c176-4567-b236-a6249c97322c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:133082145 biolink:treats MONDO:0005010 PMID:41385096 "[{""id"":""uuid:72114f6f-157b-407c-a46e-7a7c29ad7f54"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:78a5cc45-2f13-46cc-a2c3-da426aaed852"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin calcium tablets can be started simultaneously with diet. 1.1 Prevention of Cardiovascular Disease in Adults In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In adult patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In adult patients with clinically evident coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 1.2 Hyperlipidemia Atorvastatin calcium tablets are indicated: As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in adult patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson Types IIa and IIb); As an adjunct to diet for the treatment of adult patients with elevated serum TG levels (Fredrickson Type IV); For the treatment of adult patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet; To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH) as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; As an adjunct to diet to reduce total-C, LDL-C, and apo B levels in pediatric patients, 10 years to 17 years of age, with heterozygous familial hypercholesterolemia (HeFH) if after an adequate trial of diet therapy the following findings are present: a. LDL-C remains ≥ 190 mg/dL or b. LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient 1.3 Limitations of Use Atorvastatin calcium tablets have not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V). uuid:3eef3606-3002-4019-a1de-ad06ec528a17 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:133082145 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:3264ee22-a636-48f9-80af-2b3668d9f98c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fcfc4044-2c75-473a-b484-c99f72979aad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin calcium tablets can be started simultaneously with diet. 1.1 Prevention of Cardiovascular Disease in Adults In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In adult patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In adult patients with clinically evident coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 1.2 Hyperlipidemia Atorvastatin calcium tablets are indicated: As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in adult patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson Types IIa and IIb); As an adjunct to diet for the treatment of adult patients with elevated serum TG levels (Fredrickson Type IV); For the treatment of adult patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet; To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH) as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; As an adjunct to diet to reduce total-C, LDL-C, and apo B levels in pediatric patients, 10 years to 17 years of age, with heterozygous familial hypercholesterolemia (HeFH) if after an adequate trial of diet therapy the following findings are present: a. LDL-C remains ≥ 190 mg/dL or b. LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient 1.3 Limitations of Use Atorvastatin calcium tablets have not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V). uuid:fe59c8a8-8cdb-432e-a9fa-a8bd5babbbe4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:133082145 biolink:treats HP:0001681 PMID:41385096 "[{""id"":""uuid:c6b99962-dd3a-4010-bc00-88a63513142d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d79c6bf8-fc6d-457a-b11f-7545c1df3e68"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin calcium tablets can be started simultaneously with diet. 1.1 Prevention of Cardiovascular Disease in Adults In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In adult patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In adult patients with clinically evident coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 1.2 Hyperlipidemia Atorvastatin calcium tablets are indicated: As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in adult patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson Types IIa and IIb); As an adjunct to diet for the treatment of adult patients with elevated serum TG levels (Fredrickson Type IV); For the treatment of adult patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet; To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH) as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; As an adjunct to diet to reduce total-C, LDL-C, and apo B levels in pediatric patients, 10 years to 17 years of age, with heterozygous familial hypercholesterolemia (HeFH) if after an adequate trial of diet therapy the following findings are present: a. LDL-C remains ≥ 190 mg/dL or b. LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient 1.3 Limitations of Use Atorvastatin calcium tablets have not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V). uuid:e3155f49-c731-41a8-9e37-23594b96b138 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:133082145 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:190f4ad6-3c81-4fb9-b459-9b91e1e9777f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cfa4da84-d36d-4ea0-86d3-4761e2b6a778"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin calcium tablets can be started simultaneously with diet. 1.1 Prevention of Cardiovascular Disease in Adults In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In adult patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In adult patients with clinically evident coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 1.2 Hyperlipidemia Atorvastatin calcium tablets are indicated: As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in adult patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson Types IIa and IIb); As an adjunct to diet for the treatment of adult patients with elevated serum TG levels (Fredrickson Type IV); For the treatment of adult patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet; To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH) as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; As an adjunct to diet to reduce total-C, LDL-C, and apo B levels in pediatric patients, 10 years to 17 years of age, with heterozygous familial hypercholesterolemia (HeFH) if after an adequate trial of diet therapy the following findings are present: a. LDL-C remains ≥ 190 mg/dL or b. LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient 1.3 Limitations of Use Atorvastatin calcium tablets have not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V). uuid:a96a6759-169c-443e-af9f-08aaec7e6ae7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:133082145 biolink:treats UMLS:C0342879 PMID:41385096 "[{""id"":""uuid:e526a840-4c1a-454d-8b9e-0c157e7e7515"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2a1209de-48e0-4281-90fc-0fd1e478d635"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin calcium tablets can be started simultaneously with diet. 1.1 Prevention of Cardiovascular Disease in Adults In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In adult patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In adult patients with clinically evident coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 1.2 Hyperlipidemia Atorvastatin calcium tablets are indicated: As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in adult patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson Types IIa and IIb); As an adjunct to diet for the treatment of adult patients with elevated serum TG levels (Fredrickson Type IV); For the treatment of adult patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet; To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH) as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; As an adjunct to diet to reduce total-C, LDL-C, and apo B levels in pediatric patients, 10 years to 17 years of age, with heterozygous familial hypercholesterolemia (HeFH) if after an adequate trial of diet therapy the following findings are present: a. LDL-C remains ≥ 190 mg/dL or b. LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient 1.3 Limitations of Use Atorvastatin calcium tablets have not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V). uuid:a6b51e47-a2d0-4b23-a3f8-aecfb9270e68 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:133082145 biolink:treats UMLS:C0342882 PMID:41385096 "[{""id"":""uuid:5267cbb9-68a1-4444-a3b2-385bf48ba46a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:497b8136-a4a2-45bd-a5c8-f9cb4183b070"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin calcium tablets can be started simultaneously with diet. 1.1 Prevention of Cardiovascular Disease in Adults In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In adult patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In adult patients with clinically evident coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 1.2 Hyperlipidemia Atorvastatin calcium tablets are indicated: As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in adult patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson Types IIa and IIb); As an adjunct to diet for the treatment of adult patients with elevated serum TG levels (Fredrickson Type IV); For the treatment of adult patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet; To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH) as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; As an adjunct to diet to reduce total-C, LDL-C, and apo B levels in pediatric patients, 10 years to 17 years of age, with heterozygous familial hypercholesterolemia (HeFH) if after an adequate trial of diet therapy the following findings are present: a. LDL-C remains ≥ 190 mg/dL or b. LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient 1.3 Limitations of Use Atorvastatin calcium tablets have not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V). uuid:fa6e5321-654b-4845-bc7e-b24299893619 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:133082145 biolink:treats HP:0003119 PMID:41385096 "[{""id"":""uuid:3cf0d6f6-43fc-4715-a1b3-84a7d58bb02c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ce54ccae-e4af-49ba-975f-d715bac6e3e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin calcium tablets can be started simultaneously with diet. 1.1 Prevention of Cardiovascular Disease in Adults In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In adult patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In adult patients with clinically evident coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 1.2 Hyperlipidemia Atorvastatin calcium tablets are indicated: As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in adult patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson Types IIa and IIb); As an adjunct to diet for the treatment of adult patients with elevated serum TG levels (Fredrickson Type IV); For the treatment of adult patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet; To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH) as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; As an adjunct to diet to reduce total-C, LDL-C, and apo B levels in pediatric patients, 10 years to 17 years of age, with heterozygous familial hypercholesterolemia (HeFH) if after an adequate trial of diet therapy the following findings are present: a. LDL-C remains ≥ 190 mg/dL or b. LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient 1.3 Limitations of Use Atorvastatin calcium tablets have not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V). uuid:3cc15503-f867-4f02-b331-95102eab9c16 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:133082145 biolink:treats MONDO:0007750 PMID:41385096 "[{""id"":""uuid:4f3e46dc-5c0c-4e2e-9c4a-262228fb9647"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:af563cf6-225c-48bc-8cf0-038dfd9fdb2b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin calcium tablets can be started simultaneously with diet. 1.1 Prevention of Cardiovascular Disease in Adults In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In adult patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In adult patients with clinically evident coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 1.2 Hyperlipidemia Atorvastatin calcium tablets are indicated: As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in adult patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson Types IIa and IIb); As an adjunct to diet for the treatment of adult patients with elevated serum TG levels (Fredrickson Type IV); For the treatment of adult patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet; To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH) as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; As an adjunct to diet to reduce total-C, LDL-C, and apo B levels in pediatric patients, 10 years to 17 years of age, with heterozygous familial hypercholesterolemia (HeFH) if after an adequate trial of diet therapy the following findings are present: a. LDL-C remains ≥ 190 mg/dL or b. LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient 1.3 Limitations of Use Atorvastatin calcium tablets have not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V). uuid:6475849b-c289-44f8-b1e0-b153d2643c13 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:133082145 biolink:treats MONDO:0007759 PMID:41385096 "[{""id"":""uuid:85cfe4cb-fa68-4021-9a70-12b1708a76c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a17349d9-02fd-40c4-88f0-3621c4218cdb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin calcium tablets can be started simultaneously with diet. 1.1 Prevention of Cardiovascular Disease in Adults In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In adult patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In adult patients with clinically evident coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 1.2 Hyperlipidemia Atorvastatin calcium tablets are indicated: As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in adult patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson Types IIa and IIb); As an adjunct to diet for the treatment of adult patients with elevated serum TG levels (Fredrickson Type IV); For the treatment of adult patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet; To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH) as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; As an adjunct to diet to reduce total-C, LDL-C, and apo B levels in pediatric patients, 10 years to 17 years of age, with heterozygous familial hypercholesterolemia (HeFH) if after an adequate trial of diet therapy the following findings are present: a. LDL-C remains ≥ 190 mg/dL or b. LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient 1.3 Limitations of Use Atorvastatin calcium tablets have not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V). uuid:3f8419ca-fc6f-4a91-b729-3fb0a574aaae biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:133082145 biolink:treats MONDO:0007788 PMID:41385096 "[{""id"":""uuid:c2f0b084-50ab-477f-83ca-552c718d8296"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a90d979c-236e-42b6-aa13-dc5ca4e16ba6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin calcium tablets can be started simultaneously with diet. 1.1 Prevention of Cardiovascular Disease in Adults In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In adult patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In adult patients with clinically evident coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 1.2 Hyperlipidemia Atorvastatin calcium tablets are indicated: As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in adult patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson Types IIa and IIb); As an adjunct to diet for the treatment of adult patients with elevated serum TG levels (Fredrickson Type IV); For the treatment of adult patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet; To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH) as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; As an adjunct to diet to reduce total-C, LDL-C, and apo B levels in pediatric patients, 10 years to 17 years of age, with heterozygous familial hypercholesterolemia (HeFH) if after an adequate trial of diet therapy the following findings are present: a. LDL-C remains ≥ 190 mg/dL or b. LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient 1.3 Limitations of Use Atorvastatin calcium tablets have not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V). uuid:37ea847f-6c96-4550-ae33-48b7bca6a0b1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:133082145 biolink:treats MONDO:0018473 PMID:41385096 "[{""id"":""uuid:8b56cc99-cba7-4ce0-9af2-d55546ee38f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d707d77f-c7bb-4fad-be32-618a5cadccc5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin calcium tablets can be started simultaneously with diet. 1.1 Prevention of Cardiovascular Disease in Adults In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In adult patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In adult patients with clinically evident coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 1.2 Hyperlipidemia Atorvastatin calcium tablets are indicated: As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in adult patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson Types IIa and IIb); As an adjunct to diet for the treatment of adult patients with elevated serum TG levels (Fredrickson Type IV); For the treatment of adult patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet; To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH) as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; As an adjunct to diet to reduce total-C, LDL-C, and apo B levels in pediatric patients, 10 years to 17 years of age, with heterozygous familial hypercholesterolemia (HeFH) if after an adequate trial of diet therapy the following findings are present: a. LDL-C remains ≥ 190 mg/dL or b. LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient 1.3 Limitations of Use Atorvastatin calcium tablets have not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V). uuid:f88bfef9-c0cd-487a-a218-a38adfbe51e3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:133082145 biolink:treats UMLS:C0860248 PMID:41385096 "[{""id"":""uuid:79b9ee7e-aafd-4ba8-8b88-44721a2003ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:de77e3bd-9a6a-4ffc-ac99-b4e20831aefa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin calcium tablets can be started simultaneously with diet. 1.1 Prevention of Cardiovascular Disease in Adults In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In adult patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In adult patients with clinically evident coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 1.2 Hyperlipidemia Atorvastatin calcium tablets are indicated: As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in adult patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson Types IIa and IIb); As an adjunct to diet for the treatment of adult patients with elevated serum TG levels (Fredrickson Type IV); For the treatment of adult patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet; To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH) as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; As an adjunct to diet to reduce total-C, LDL-C, and apo B levels in pediatric patients, 10 years to 17 years of age, with heterozygous familial hypercholesterolemia (HeFH) if after an adequate trial of diet therapy the following findings are present: a. LDL-C remains ≥ 190 mg/dL or b. LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient 1.3 Limitations of Use Atorvastatin calcium tablets have not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V). uuid:0293d1a7-0d33-4350-8de0-dca1aaded8b5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:133082145 biolink:treats MONDO:0018328 PMID:41385096 "[{""id"":""uuid:d73ed723-8d07-4007-8ae3-144be2e1796d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f33b2c53-f9f2-4dca-8af5-cb663654bdf5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin calcium tablets can be started simultaneously with diet. 1.1 Prevention of Cardiovascular Disease in Adults In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In adult patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In adult patients with clinically evident coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 1.2 Hyperlipidemia Atorvastatin calcium tablets are indicated: As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in adult patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson Types IIa and IIb); As an adjunct to diet for the treatment of adult patients with elevated serum TG levels (Fredrickson Type IV); For the treatment of adult patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet; To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH) as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; As an adjunct to diet to reduce total-C, LDL-C, and apo B levels in pediatric patients, 10 years to 17 years of age, with heterozygous familial hypercholesterolemia (HeFH) if after an adequate trial of diet therapy the following findings are present: a. LDL-C remains ≥ 190 mg/dL or b. LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient 1.3 Limitations of Use Atorvastatin calcium tablets have not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V). uuid:033fa521-f99a-4d48-92ff-ea863f49f987 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:133082145 biolink:treats UMLS:C0856526 PMID:41385096 "[{""id"":""uuid:f2cf2344-5bf6-46eb-bb31-e10b23c0addd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:876af417-1381-4c9f-a4c3-958d68f0d00a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin calcium tablets can be started simultaneously with diet. 1.1 Prevention of Cardiovascular Disease in Adults In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In adult patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In adult patients with clinically evident coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 1.2 Hyperlipidemia Atorvastatin calcium tablets are indicated: As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in adult patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson Types IIa and IIb); As an adjunct to diet for the treatment of adult patients with elevated serum TG levels (Fredrickson Type IV); For the treatment of adult patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet; To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH) as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; As an adjunct to diet to reduce total-C, LDL-C, and apo B levels in pediatric patients, 10 years to 17 years of age, with heterozygous familial hypercholesterolemia (HeFH) if after an adequate trial of diet therapy the following findings are present: a. LDL-C remains ≥ 190 mg/dL or b. LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient 1.3 Limitations of Use Atorvastatin calcium tablets have not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V). uuid:fa6c9f0f-97e5-4f97-9049-70af8e7b0bef biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:133082145 biolink:treats MONDO:0007762 PMID:41385096 "[{""id"":""uuid:d70691be-4e23-4f7b-9cf4-4785d259a153"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:159a338c-05ca-4f3e-9c8e-d7cec15ed382"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin calcium tablets can be started simultaneously with diet. 1.1 Prevention of Cardiovascular Disease in Adults In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In adult patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In adult patients with clinically evident coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 1.2 Hyperlipidemia Atorvastatin calcium tablets are indicated: As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in adult patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson Types IIa and IIb); As an adjunct to diet for the treatment of adult patients with elevated serum TG levels (Fredrickson Type IV); For the treatment of adult patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet; To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH) as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; As an adjunct to diet to reduce total-C, LDL-C, and apo B levels in pediatric patients, 10 years to 17 years of age, with heterozygous familial hypercholesterolemia (HeFH) if after an adequate trial of diet therapy the following findings are present: a. LDL-C remains ≥ 190 mg/dL or b. LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient 1.3 Limitations of Use Atorvastatin calcium tablets have not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V). uuid:d5a58b8b-4c2a-4a4c-bd55-fbb12830a22c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:40303 biolink:treats MONDO:0018473 PMID:41385096 "[{""id"":""uuid:d6641751-77b8-4f8a-9f90-94122acdeb18"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7e421f3c-19eb-4e6f-91cd-b42390130864"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lovastatin should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C, and below average HDL-C, lovastatin is indicated to reduce the risk of: Myocardial infarction Unstable angina Coronary revascularization procedures (See CLINICAL PHARMACOLOGY, Clinical Studies.) Coronary Heart Disease Lovastatin is indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for artherosclerotic vascular disease due to hypercholesterolemia. Lovastatin is indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb 2), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. Adolescent Patients with Heterozygous Familial Hypercholesterolemia Lovastatin is indicated as an adjunct to diet to reduce total-C, LDL-C and apolipoprotein B levels in adolescent boys and girls who are at least one year post-menarche, 10 to 17 years of age, with heFH if after an adequate trial of diet therapy the following findings are present: LDL-C remains >189 mg/dL or LDL-C remains >160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the adolescent patient General Recommendations Prior to initiating therapy with lovastatin, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure total-C, HDL-C, and TG. For patients with TG less than 400 mg/dL (<4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = total-C - [0.2 × (TG) + HDL-C] For TG levels >400 mg/dL (>4.5 mmol/L), this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated total-C. In such cases, lovastatin is not indicated. The National Cholesterol Education Program (NCEP) Treatment Guidelines are summarized below: † CHD, coronary heart disease †† Some authorities recommend use of LDL-lowering drugs in this category if an LDL-C level of <100 mg/dL cannot be achieved by therapeutic lifestyle changes. Others prefer use of drugs that primarily modify triglycerides and HDL-C, e.g., nicotinic acid or fibrate. Clinical judgment also may call for deferring drug therapy in this subcategory. ††† Almost all people with 0-1 risk factor have a 10-year risk <10%; thus, 10-year risk assessment in people with 0-1 risk factor is not necessary. NCEP Treatment Guidelines: LDL-C Goals and Cutpoints for Therapeutic Lifestyle Changes and Drug Therapy in Different Risk Categories Risk Category LDL Goal (mg/dL) LDL Level at Which to Initiate Therapeutic Lifestyle Changes (mg/dL) LDL Level at Which to Consider Drug Therapy (mg/dL) CHD † or CHD risk equivalents (10-year risk >20%) <100 ≥100 ≥130 (100-129: drug optional) †† 2+ Risk factors (10 year risk ≤20%) <130 ≥130 10-year risk 10-20%: ≥130 10-year risk <10%: ≥160 0-1 Risk factor ††† <160 ≥160 ≥190 (160-189: LDL-lowering drug optional) 2 Classification of Hyperlipoproteinemias Lipid Elevations Type Lipoproteins elevated major minor I chylomicrons TG ↑→C IIa LDL C -- IIb LDL, VLDL C TG III (rare) IDL C/TG -- IV VLDL TG ↑→C V (rare) chylomicrons, VLDL TG ↑→C IDL = intermediate-density lipoprotein. After the LDL-C goal has been achieved, if the TG is still ≥200 mg/dL, non-HDL-C (total-C minus HDL-C) becomes a secondary target of therapy. Non-HDL-C goals are set 30 mg/dL higher than LDL-C goals for each risk category. At the time of hospitalization for an acute coronary event, consideration can be given to initiating drug therapy at discharge if the LDL-C is ≥130 mg/dL (see NCEP Guidelines above). Since the goal of treatment is to lower LDL-C, the NCEP recommends that LDL-C levels be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the total-C be used to monitor therapy. Although lovastatin may be useful to reduce elevated LDL-C levels in patients with combined hypercholesterolemia and hypertriglyceridemia where hypercholesterolemia is the major abnormality (Type IIb hyperlipoproteinemia), it has not been studied in conditions where the major abnormality is elevation of chylomicrons, VLDL or IDL (i.e., hyperlipoproteinemia types I, III, IV, or V). *** The NCEP classification of cholesterol levels in pediatric patients with a familial history of hypercholesterolemia or premature cardiovascular disease is summarized below: Category Total-C (mg/dL) LDL-C (mg/dL) Acceptable <170 <110 Borderline 170-199 110-129 High ≥200 ≥130 Children treated with lovastatin in adolescence should be re-evaluated in adulthood and appropriate changes made to their cholesterol-lowering regimen to achieve adult goals for LDL-C. uuid:0fda4e2a-68c5-48e3-be81-15178ee41719 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:40303 biolink:treats MONDO:0007762 PMID:41385096 "[{""id"":""uuid:ea82c082-c922-42d0-a626-3da8889b8014"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9ed2e05e-959b-4ee2-a4f0-083fdcfc831c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lovastatin should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C, and below average HDL-C, lovastatin is indicated to reduce the risk of: Myocardial infarction Unstable angina Coronary revascularization procedures (See CLINICAL PHARMACOLOGY, Clinical Studies.) Coronary Heart Disease Lovastatin is indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for artherosclerotic vascular disease due to hypercholesterolemia. Lovastatin is indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb 2), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. Adolescent Patients with Heterozygous Familial Hypercholesterolemia Lovastatin is indicated as an adjunct to diet to reduce total-C, LDL-C and apolipoprotein B levels in adolescent boys and girls who are at least one year post-menarche, 10 to 17 years of age, with heFH if after an adequate trial of diet therapy the following findings are present: LDL-C remains >189 mg/dL or LDL-C remains >160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the adolescent patient General Recommendations Prior to initiating therapy with lovastatin, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure total-C, HDL-C, and TG. For patients with TG less than 400 mg/dL (<4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = total-C - [0.2 × (TG) + HDL-C] For TG levels >400 mg/dL (>4.5 mmol/L), this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated total-C. In such cases, lovastatin is not indicated. The National Cholesterol Education Program (NCEP) Treatment Guidelines are summarized below: † CHD, coronary heart disease †† Some authorities recommend use of LDL-lowering drugs in this category if an LDL-C level of <100 mg/dL cannot be achieved by therapeutic lifestyle changes. Others prefer use of drugs that primarily modify triglycerides and HDL-C, e.g., nicotinic acid or fibrate. Clinical judgment also may call for deferring drug therapy in this subcategory. ††† Almost all people with 0-1 risk factor have a 10-year risk <10%; thus, 10-year risk assessment in people with 0-1 risk factor is not necessary. NCEP Treatment Guidelines: LDL-C Goals and Cutpoints for Therapeutic Lifestyle Changes and Drug Therapy in Different Risk Categories Risk Category LDL Goal (mg/dL) LDL Level at Which to Initiate Therapeutic Lifestyle Changes (mg/dL) LDL Level at Which to Consider Drug Therapy (mg/dL) CHD † or CHD risk equivalents (10-year risk >20%) <100 ≥100 ≥130 (100-129: drug optional) †† 2+ Risk factors (10 year risk ≤20%) <130 ≥130 10-year risk 10-20%: ≥130 10-year risk <10%: ≥160 0-1 Risk factor ††† <160 ≥160 ≥190 (160-189: LDL-lowering drug optional) 2 Classification of Hyperlipoproteinemias Lipid Elevations Type Lipoproteins elevated major minor I chylomicrons TG ↑→C IIa LDL C -- IIb LDL, VLDL C TG III (rare) IDL C/TG -- IV VLDL TG ↑→C V (rare) chylomicrons, VLDL TG ↑→C IDL = intermediate-density lipoprotein. After the LDL-C goal has been achieved, if the TG is still ≥200 mg/dL, non-HDL-C (total-C minus HDL-C) becomes a secondary target of therapy. Non-HDL-C goals are set 30 mg/dL higher than LDL-C goals for each risk category. At the time of hospitalization for an acute coronary event, consideration can be given to initiating drug therapy at discharge if the LDL-C is ≥130 mg/dL (see NCEP Guidelines above). Since the goal of treatment is to lower LDL-C, the NCEP recommends that LDL-C levels be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the total-C be used to monitor therapy. Although lovastatin may be useful to reduce elevated LDL-C levels in patients with combined hypercholesterolemia and hypertriglyceridemia where hypercholesterolemia is the major abnormality (Type IIb hyperlipoproteinemia), it has not been studied in conditions where the major abnormality is elevation of chylomicrons, VLDL or IDL (i.e., hyperlipoproteinemia types I, III, IV, or V). *** The NCEP classification of cholesterol levels in pediatric patients with a familial history of hypercholesterolemia or premature cardiovascular disease is summarized below: Category Total-C (mg/dL) LDL-C (mg/dL) Acceptable <170 <110 Borderline 170-199 110-129 High ≥200 ≥130 Children treated with lovastatin in adolescence should be re-evaluated in adulthood and appropriate changes made to their cholesterol-lowering regimen to achieve adult goals for LDL-C. uuid:d66c483f-09ba-4f48-853d-3153327f0603 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3312 biolink:treats HP:0002901 PMID:41385096 "[{""id"":""uuid:eba169b7-0abd-4243-b8c3-7d1875fa080e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:18bd7afc-00b9-42c3-b9a7-46f899e9acea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 10% Calcium Chloride Injection, USP is indicated for the treatment of hypocalcemia in those conditions requiring a prompt increase in plasma calcium levels. uuid:344506b8-e56b-4890-8c15-e4e9a064ef5e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46726 biolink:treats MONDO:0001356 PMID:41385096 "[{""id"":""uuid:f8524c69-1d8a-4069-aa3d-c81b9fa14895"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7b554a5a-9e7c-44fc-bdc4-5f5f4d4682e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Feraheme is indicated for the treatment of iron deficiency anemia (IDA) in adult patients: • who have intolerance to oral iron or have had unsatisfactory response to oral iron or • who have chronic kidney disease (CKD). uuid:364375f5-1ce1-430b-80ff-8a2ecc79a8d7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46726 biolink:treats MONDO:0005300 PMID:41385096 "[{""id"":""uuid:9e733102-b562-4eab-9f1a-1e5db61a6756"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a5be7b71-f4e7-4be2-8d96-6b53e926d542"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Feraheme is indicated for the treatment of iron deficiency anemia (IDA) in adult patients: • who have intolerance to oral iron or have had unsatisfactory response to oral iron or • who have chronic kidney disease (CKD). uuid:3fc4d9f7-515c-4a84-af52-0de2d749f381 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63578 biolink:treats MONDO:0005070 PMID:41385096 "[{""id"":""uuid:6d997552-9893-42c5-b578-3ed476b62842"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4927db4c-10d3-4415-beb3-76e4a4650714"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ULTRAVIST ® injection is an iodinated contrast agent indicated In Adults • For Computed Tomography (CT) of the head and body (intrathoracic, intra-abdominal and retroperitoneal regions) for the evaluation of neoplastic and non-neoplastic lesions in adults. • The usefulness of contrast enhancement for the investigation of the retrobulbar space and of low grade or infiltrative glioma has not been demonstrated. Pediatric Patients • For Computed Tomography (CT) of the head and body For use only with an automated contrast injection system, contrast management system, or contrast media transfer set approved or cleared for use with this contrast agent in this Imaging Bulk Package. uuid:63be11b3-6923-4597-aa35-3d05811d3a76 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63578 biolink:treats MONDO:0021637 PMID:41385096 "[{""id"":""uuid:0e5d8e7f-2996-4851-a5d9-7936b69f5e36"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c4314b64-f0a6-49c2-8692-961b1a9b4759"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ULTRAVIST ® injection is an iodinated contrast agent indicated In Adults • For Computed Tomography (CT) of the head and body (intrathoracic, intra-abdominal and retroperitoneal regions) for the evaluation of neoplastic and non-neoplastic lesions in adults. • The usefulness of contrast enhancement for the investigation of the retrobulbar space and of low grade or infiltrative glioma has not been demonstrated. Pediatric Patients • For Computed Tomography (CT) of the head and body For use only with an automated contrast injection system, contrast management system, or contrast media transfer set approved or cleared for use with this contrast agent in this Imaging Bulk Package. uuid:87a18450-8072-4588-85bc-7ba8b7f05a7b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63578 biolink:treats MONDO:0021042 PMID:41385096 "[{""id"":""uuid:0be68172-b24d-40d1-b295-da33e4994062"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9542373c-3207-416c-979e-fe9ab5af1dfc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ULTRAVIST ® injection is an iodinated contrast agent indicated In Adults • For Computed Tomography (CT) of the head and body (intrathoracic, intra-abdominal and retroperitoneal regions) for the evaluation of neoplastic and non-neoplastic lesions in adults. • The usefulness of contrast enhancement for the investigation of the retrobulbar space and of low grade or infiltrative glioma has not been demonstrated. Pediatric Patients • For Computed Tomography (CT) of the head and body For use only with an automated contrast injection system, contrast management system, or contrast media transfer set approved or cleared for use with this contrast agent in this Imaging Bulk Package. uuid:37151ad4-0a09-4962-8566-e403cc94a047 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB16791 biolink:treats MONDO:0010604 PMID:41385096 "[{""id"":""uuid:c6d745c7-f3ee-4e78-b9e0-10d64345a6d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:107f7edd-5138-4f4f-b13a-70399ccebe47"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e06bd296-e2b8-49be-8be4-82c351f568ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/hemgenix""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] HEMGENIX is an adeno-associated virus vector-based gene therapy indicated for treatment of adults with Hemophilia B (congenital Factor IX deficiency) who: Currently use Factor IX prophylaxis therapy, or Have current or historical life-threatening hemorrhage, or Have repeated, serious spontaneous bleeding episodes.|[EMA] Treatment of severe and moderately severe Haemophilia B (congenital Factor IX deficiency) in adult patients without a history of Factor IX inhibitors. uuid:9c5808bb-f9a7-4010-8b7c-3a59b42fc5b3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB16791 biolink:treats NCIT:C26791 PMID:41385096 "[{""id"":""uuid:9eee3e9c-96dd-48e6-a3b5-aa28c4fcec00"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b3f0d878-57e6-41ed-8baf-7a40c9b2d7c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] HEMGENIX is an adeno-associated virus vector-based gene therapy indicated for treatment of adults with Hemophilia B (congenital Factor IX deficiency) who: Currently use Factor IX prophylaxis therapy, or Have current or historical life-threatening hemorrhage, or Have repeated, serious spontaneous bleeding episodes. uuid:98cb57b2-4d9d-468d-8fcc-78c475b0dd9c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7454 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:14b2a1dc-505f-4f22-b756-423e24e70d5e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:75d614a0-33b2-44c6-b393-ae22cabb932c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nalbuphine Hydrochloride Injection is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Nalbuphine Hydrochloride Injection can also be used as a supplement to balanced anesthesia, for preoperative and postoperative analgesia, and for obstetrical analgesia during labor and delivery. uuid:820a53a1-7631-4104-96c1-b98c90d2f0d4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7454 biolink:treats NCIT:C92821 PMID:41385096 "[{""id"":""uuid:4b485db6-1e92-461f-90e9-dcee6374ea5f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:29cd57f6-fbc7-43b6-a882-ccb5f726af00"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nalbuphine Hydrochloride Injection is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Nalbuphine Hydrochloride Injection can also be used as a supplement to balanced anesthesia, for preoperative and postoperative analgesia, and for obstetrical analgesia during labor and delivery. uuid:9786f340-2987-439f-ab0f-b41920be64a2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:107736 biolink:treats EFO:0004888 PMID:41385096 "[{""id"":""uuid:ea9570e5-6f8e-4c71-bea7-3b978f56f67c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:36404b75-3136-40d9-ac45-f95bf3c1cff8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diabetic Gastroparesis (Diabetic Gastric Stasis) Metoclopramide is indicated for the relief of symptoms associated with acute and recurrent diabetic gastric stasis. The Prevention of Nausea and Vomiting Associated with Emetogenic Cancer Chemotherapy Metoclopramide Injection, USP is indicated for the prophylaxis of vomiting associated with emetogenic cancer chemotherapy. The Prevention of Postoperative Nausea and Vomiting Metoclopramide Injection, USP is indicated for the prophylaxis of postoperative nausea and vomiting in those circumstances where nasogastric suction is undesirable. Small Bowel Intubation Metoclopramide Injection, USP may be used to facilitate small bowel intubation in adults and pediatric patients in whom the tube does not pass the pylorus with conventional maneuvers. Radiological Examination Metoclopramide Injection, USP may be used to stimulate gastric emptying and intestinal transit of barium in cases where delayed emptying interferes with radiological examination of the stomach and/or small intestine. uuid:9356ce30-8d38-4a5d-ac42-72b1f4466e42 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:187893 biolink:treats MONDO:0033613 PMID:41385096 "[{""id"":""uuid:36b73186-4d48-41ca-901f-0bdc346fb127"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:49a60173-0022-49cf-ae18-be3e32860a43"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Baclofen Injection is indicated for use in the management of severe spasticity. Patients should first respond to a screening dose of intrathecal baclofen prior to consideration for long term infusion via an implantable pump. For spasticity of spinal cord origin, chronic infusion of Baclofen Injection via an implantable pump should be reserved for patients unresponsive to oral baclofen therapy, or those who experience intolerable CNS side effects at effective doses. Patients with spasticity due to traumatic brain injury should wait at least one year after the injury before consideration of long term intrathecal baclofen therapy. Baclofen Injection is intended for use by the intrathecal route in single bolus test doses (via spinal catheter or lumbar puncture) and, for chronic use, only in implantable pumps approved by the FDA specifically for the administration of Baclofen Injection into the intrathecal space. Spasticity of Spinal Cord Origin: Evidence supporting the efficacy of Baclofen Injection was obtained in randomized, controlled investigations that compared the effects of either a single intrathecal dose or a three day intrathecal infusion of Baclofen Injection to placebo in patients with severe spasticity and spasms due to either spinal cord trauma or multiple sclerosis. Baclofen Injection was superior to placebo on both principal outcome measures employed: change from baseline in the Ashworth rating of spasticity and the frequency of spasms. Spasticity of Cerebral Origin: The efficacy of Baclofen Injection was investigated in three controlled clinical trials; two enrolled patients with cerebral palsy and one enrolled patients with spasticity due to previous brain injury. The first study, a randomized controlled cross-over trial of 51 patients with cerebral palsy, provided strong, statistically significant results; Baclofen Injection was superior to placebo in reducing spasticity as measured by the Ashworth Scale. A second cross-over study was conducted in 11 patients with spasticity arising from brain injury. Despite the small sample size, the study yielded a nearly significant test statistic (p= 0.066) and provided directionally favorable results. The last study, however, did not provide data that could be reliably analyzed. Baclofen Injection therapy may be considered an alternative to destructive neurosurgical procedures. Prior to implantation of a device for chronic intrathecal infusion of Baclofen Injection, patients must show a response to Baclofen Injection in a screening trial (see Dosage and Administration). uuid:6ccdc6b7-231a-48eb-b12d-5ebc40d1f95b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63611 biolink:treats MONDO:0002885 PMID:41385096 "[{""id"":""uuid:47e72df2-b898-4e4f-9c5b-60503d92ff8a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ae73b5bd-3d6a-460f-90a1-6bd683c55011"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Moxifloxacin ophthalmic solution is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Corynebacterium species Efficacy for this organism was studied in fewer than 10 infections. Micrococcus luteus Staphylococcus aureus Staphylococcus epidermidis Staphylococcus haemolyticus Staphylococcus hominis Staphylococcus warneri Streptococcus pneumoniae Streptococcus viridans group Acinetobacter lwoffii Haemophilus influenza Haemophilus parainfluenzae Chlamydia trachomatis uuid:99433cd3-5929-41ff-9a98-e74787c7122c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63611 biolink:treats MONDO:0021679 PMID:41385096 "[{""id"":""uuid:d917282d-be92-4a7c-b3bc-0c1a9c915503"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9f17c702-c2bb-4ed1-bc42-be52d2c4bb2f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Moxifloxacin ophthalmic solution is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Corynebacterium species Efficacy for this organism was studied in fewer than 10 infections. Micrococcus luteus Staphylococcus aureus Staphylococcus epidermidis Staphylococcus haemolyticus Staphylococcus hominis Staphylococcus warneri Streptococcus pneumoniae Streptococcus viridans group Acinetobacter lwoffii Haemophilus influenza Haemophilus parainfluenzae Chlamydia trachomatis uuid:25b22d4e-5a14-44f6-b1f4-fa75d73c467e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63611 biolink:treats MONDO:0024313 PMID:41385096 "[{""id"":""uuid:6b1e685e-dd7e-4ac8-843e-0feb0c1b152a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d698cffa-a83c-40e2-a1b5-a51e582d88f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Moxifloxacin ophthalmic solution is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Corynebacterium species Efficacy for this organism was studied in fewer than 10 infections. Micrococcus luteus Staphylococcus aureus Staphylococcus epidermidis Staphylococcus haemolyticus Staphylococcus hominis Staphylococcus warneri Streptococcus pneumoniae Streptococcus viridans group Acinetobacter lwoffii Haemophilus influenza Haemophilus parainfluenzae Chlamydia trachomatis uuid:4ad16e82-18b4-46ef-bdc6-5886c41deec9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63611 biolink:treats MONDO:0021680 PMID:41385096 "[{""id"":""uuid:f01382de-258d-4cb7-8244-52ea8f0df9e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fdb9885b-e9e7-43c2-b701-34b3df4d9ebf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Moxifloxacin ophthalmic solution is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Corynebacterium species Efficacy for this organism was studied in fewer than 10 infections. Micrococcus luteus Staphylococcus aureus Staphylococcus epidermidis Staphylococcus haemolyticus Staphylococcus hominis Staphylococcus warneri Streptococcus pneumoniae Streptococcus viridans group Acinetobacter lwoffii Haemophilus influenza Haemophilus parainfluenzae Chlamydia trachomatis uuid:f6042dd7-894c-4269-8c52-fd9671c7bade biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63611 biolink:treats MONDO:0006635 PMID:41385096 "[{""id"":""uuid:c885d018-4dff-428f-a5f2-6b43e827c242"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:36d8d90d-4af1-481c-bf0f-0a4e5d978fc5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Moxifloxacin ophthalmic solution is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Corynebacterium species Efficacy for this organism was studied in fewer than 10 infections. Micrococcus luteus Staphylococcus aureus Staphylococcus epidermidis Staphylococcus haemolyticus Staphylococcus hominis Staphylococcus warneri Streptococcus pneumoniae Streptococcus viridans group Acinetobacter lwoffii Haemophilus influenza Haemophilus parainfluenzae Chlamydia trachomatis uuid:d75b585e-1b65-4d4b-9fbe-cc927408750a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63611 biolink:treats MONDO:0006926 PMID:41385096 "[{""id"":""uuid:544e1e6f-5f94-4bdd-abe3-4309f9794d06"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5d9ce7d4-b7d6-4c6c-9fa2-3d96f75e6ee1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Moxifloxacin ophthalmic solution is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Corynebacterium species Efficacy for this organism was studied in fewer than 10 infections. Micrococcus luteus Staphylococcus aureus Staphylococcus epidermidis Staphylococcus haemolyticus Staphylococcus hominis Staphylococcus warneri Streptococcus pneumoniae Streptococcus viridans group Acinetobacter lwoffii Haemophilus influenza Haemophilus parainfluenzae Chlamydia trachomatis uuid:478a3df6-2c4d-45a6-83fa-6375f3f88640 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63611 biolink:treats MONDO:0021697 PMID:41385096 "[{""id"":""uuid:19aceca2-812e-417a-8fbf-4d21b873252b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f4484579-f8d9-418d-83f6-9b80d3c70f57"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Moxifloxacin ophthalmic solution is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Corynebacterium species Efficacy for this organism was studied in fewer than 10 infections. Micrococcus luteus Staphylococcus aureus Staphylococcus epidermidis Staphylococcus haemolyticus Staphylococcus hominis Staphylococcus warneri Streptococcus pneumoniae Streptococcus viridans group Acinetobacter lwoffii Haemophilus influenza Haemophilus parainfluenzae Chlamydia trachomatis uuid:a1fb6930-b7d5-49a5-8aac-336b92f4533a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29108 biolink:treats UMLS:C0270224 PMID:41385096 "[{""id"":""uuid:7eeee233-95fa-450f-9452-c8afb5262777"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:88903955-ec52-4991-978b-d3dc83a15ebb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Calcium Chloride Injection, USP, 10% is indicated: In the treatment of hypocalcemia in conditions requiring a prompt increase in plasma calcium levels (e.g., neonatal tetany and tetany due to parathyroid deficiency, vitamin D deficiency and alkalosis) and for prevention of hypocalcemia during exchange transfusions. As adjunctive therapy in the management of acute symptoms in lead colic. In the treatment of magnesium intoxication due to overdosage of magnesium sulfate. In severe hyperkalemia, to combat deleterious effects on electrocardiographic (ECG) function, pending correction of the potassium level in the extracellular fluid. In cardiac resuscitation, particularly after open heart surgery, when epinephrine fails to improve weak or ineffective myocardial contractions. uuid:7010419c-b00c-444d-a5aa-795226865e03 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29108 biolink:treats MONDO:0001220 PMID:41385096 "[{""id"":""uuid:6489cbcf-8516-4a1f-92b1-70b68ab30469"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6666b0c0-ad6b-4ac2-a2c8-cb0eeba3bb08"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Calcium Chloride Injection, USP, 10% is indicated: In the treatment of hypocalcemia in conditions requiring a prompt increase in plasma calcium levels (e.g., neonatal tetany and tetany due to parathyroid deficiency, vitamin D deficiency and alkalosis) and for prevention of hypocalcemia during exchange transfusions. As adjunctive therapy in the management of acute symptoms in lead colic. In the treatment of magnesium intoxication due to overdosage of magnesium sulfate. In severe hyperkalemia, to combat deleterious effects on electrocardiographic (ECG) function, pending correction of the potassium level in the extracellular fluid. In cardiac resuscitation, particularly after open heart surgery, when epinephrine fails to improve weak or ineffective myocardial contractions. uuid:ec7a0b7e-5b1f-43a9-a389-4dc6c62ad2c1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29108 biolink:treats MONDO:0100471 PMID:41385096 "[{""id"":""uuid:9916f1c2-d5b0-448d-86a2-7930dcb738ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:273e2127-199b-4e6b-86db-b9d51e51660b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Calcium Chloride Injection, USP, 10% is indicated: In the treatment of hypocalcemia in conditions requiring a prompt increase in plasma calcium levels (e.g., neonatal tetany and tetany due to parathyroid deficiency, vitamin D deficiency and alkalosis) and for prevention of hypocalcemia during exchange transfusions. As adjunctive therapy in the management of acute symptoms in lead colic. In the treatment of magnesium intoxication due to overdosage of magnesium sulfate. In severe hyperkalemia, to combat deleterious effects on electrocardiographic (ECG) function, pending correction of the potassium level in the extracellular fluid. In cardiac resuscitation, particularly after open heart surgery, when epinephrine fails to improve weak or ineffective myocardial contractions. uuid:9f578130-0fda-4be3-8f66-76ec4c39e060 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29108 biolink:treats HP:0001948 PMID:41385096 "[{""id"":""uuid:d0148937-c3e7-4ca0-b412-d4d707179614"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:02e1bb80-c07a-4b47-933d-c38761fe41bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Calcium Chloride Injection, USP, 10% is indicated: In the treatment of hypocalcemia in conditions requiring a prompt increase in plasma calcium levels (e.g., neonatal tetany and tetany due to parathyroid deficiency, vitamin D deficiency and alkalosis) and for prevention of hypocalcemia during exchange transfusions. As adjunctive therapy in the management of acute symptoms in lead colic. In the treatment of magnesium intoxication due to overdosage of magnesium sulfate. In severe hyperkalemia, to combat deleterious effects on electrocardiographic (ECG) function, pending correction of the potassium level in the extracellular fluid. In cardiac resuscitation, particularly after open heart surgery, when epinephrine fails to improve weak or ineffective myocardial contractions. uuid:56f35d66-0b1c-4c97-9aa3-87fddebfa023 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29108 biolink:treats MONDO:0018019 PMID:41385096 "[{""id"":""uuid:c13b9078-6b1a-4733-b867-ca51400a105b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7f224cd9-e4e1-461b-95bf-d6ed6b4349f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Calcium Chloride Injection, USP, 10% is indicated: In the treatment of hypocalcemia in conditions requiring a prompt increase in plasma calcium levels (e.g., neonatal tetany and tetany due to parathyroid deficiency, vitamin D deficiency and alkalosis) and for prevention of hypocalcemia during exchange transfusions. As adjunctive therapy in the management of acute symptoms in lead colic. In the treatment of magnesium intoxication due to overdosage of magnesium sulfate. In severe hyperkalemia, to combat deleterious effects on electrocardiographic (ECG) function, pending correction of the potassium level in the extracellular fluid. In cardiac resuscitation, particularly after open heart surgery, when epinephrine fails to improve weak or ineffective myocardial contractions. uuid:a5da0478-0817-45bb-a22b-8c3e079498c1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29108 biolink:treats HP:0002153 PMID:41385096 "[{""id"":""uuid:62784255-66c9-44c0-a8a3-a20b57ac1c38"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7929470b-513c-4522-ab9b-312dfe36c119"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Calcium Chloride Injection, USP, 10% is indicated: In the treatment of hypocalcemia in conditions requiring a prompt increase in plasma calcium levels (e.g., neonatal tetany and tetany due to parathyroid deficiency, vitamin D deficiency and alkalosis) and for prevention of hypocalcemia during exchange transfusions. As adjunctive therapy in the management of acute symptoms in lead colic. In the treatment of magnesium intoxication due to overdosage of magnesium sulfate. In severe hyperkalemia, to combat deleterious effects on electrocardiographic (ECG) function, pending correction of the potassium level in the extracellular fluid. In cardiac resuscitation, particularly after open heart surgery, when epinephrine fails to improve weak or ineffective myocardial contractions. uuid:a0922594-2733-4084-9c6c-405411fb8ed9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18243 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:742b7a8d-bc5b-4656-bf8d-60b53bbfb62b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bea2bf79-6397-46d3-aeed-17b222c48cd8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dopamine HCl is indicated for the correction of hemodynamic imbalances present in the shock syndrome due to myocardial infarction, trauma, endotoxic septicemia, open-heart surgery, renal failure, and chronic cardiac decompensation as in congestive failure. Patients most likely to respond adequately to dopamine HCl are those in whom physiological parameters, such as urine flow, myocardial function, and blood pressure, have not undergone profound deterioration. Multiclinic trials indicate that the shorter the time interval between onset of signs and symptoms and initiation of therapy with blood volume correction and dopamine HCl, the better the prognosis. Where appropriate, blood volume restoration with a suitable plasma expander or whole blood should be accomplished prior to administration of dopamine HCl. Poor Perfusion of Vital Organs – Urine flow appears to be one of the better diagnostic signs by which adequacy of vital organ perfusion can be monitored. Nevertheless, the physician should also observe the patient for signs of reversal of confusion or reversal of comatose condition. Loss of pallor, increase in toe temperature, and/or adequacy of nail bed capillary filling may also be used as indices of adequate dosage. Clinical studies have shown that when dopamine HCl is administered before urine flow has diminished to levels of approximately 0.3 mL/minute, prognosis is more favorable. Nevertheless, in a number of oliguric or anuric patients, administration of dopamine HCl has resulted in an increase in urine flow, which in some cases reached normal levels. Dopamine HCl may also increase urine flow in patients whose output is within normal limits and thus may be of value in reducing the degree of pre-existing fluid accumulation. It should be noted that at doses above those optimal for the individual patient, urine flow may decrease, necessitating reduction of dosage. Low Cardiac Output – Increased cardiac output is related to dopamine's direct inotropic effect on the myocardium. Increased cardiac output at low or moderate doses appears to be related to a favorable prognosis. Increase in cardiac output has been associated with either static or decreased systemic vascular resistance (SVR). Static or decreased SVR associated with low or moderate movements in cardiac output is believed to be a reflection of differential effects on specific vascular beds with increased resistance in peripheral beds (e.g., femoral) and concomitant decreases in mesenteric and renal vascular beds. Redistribution of blood flow parallels these changes so that an increase in cardiac output is accompanied by an increase in mesenteric and renal blood flow. In many instances the renal fraction of the total cardiac output has been found to increase. Increase in cardiac output produced by dopamine is not associated with substantial decreases in systemic vascular resistance as may occur with isoproterenol. Hypotension – Hypotension due to inadequate cardiac output can be managed by administration of low to moderate doses of dopamine HCl which have little effect on SVR. At high therapeutic doses, dopamine's alpha-adrenergic activity becomes more prominent and thus may correct hypotension due to diminished SVR. As in the case of other circulatory decompensation states, prognosis is better in patients whose blood pressure and urine flow have not undergone profound deterioration. Therefore, it is suggested that the physician administer dopamine HCl as soon as a definite trend toward decreased systolic and diastolic pressure becomes evident. uuid:31d1cdf7-0163-46b4-93fd-38771f2fd5e1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18243 biolink:treats MONDO:0006893 PMID:41385096 "[{""id"":""uuid:12deca75-34c5-4ca2-8eea-08f636f03e3e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6684bd06-d5b9-4d56-8851-e55d8fe953d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dopamine HCl is indicated for the correction of hemodynamic imbalances present in the shock syndrome due to myocardial infarction, trauma, endotoxic septicemia, open-heart surgery, renal failure, and chronic cardiac decompensation as in congestive failure. Patients most likely to respond adequately to dopamine HCl are those in whom physiological parameters, such as urine flow, myocardial function, and blood pressure, have not undergone profound deterioration. Multiclinic trials indicate that the shorter the time interval between onset of signs and symptoms and initiation of therapy with blood volume correction and dopamine HCl, the better the prognosis. Where appropriate, blood volume restoration with a suitable plasma expander or whole blood should be accomplished prior to administration of dopamine HCl. Poor Perfusion of Vital Organs – Urine flow appears to be one of the better diagnostic signs by which adequacy of vital organ perfusion can be monitored. Nevertheless, the physician should also observe the patient for signs of reversal of confusion or reversal of comatose condition. Loss of pallor, increase in toe temperature, and/or adequacy of nail bed capillary filling may also be used as indices of adequate dosage. Clinical studies have shown that when dopamine HCl is administered before urine flow has diminished to levels of approximately 0.3 mL/minute, prognosis is more favorable. Nevertheless, in a number of oliguric or anuric patients, administration of dopamine HCl has resulted in an increase in urine flow, which in some cases reached normal levels. Dopamine HCl may also increase urine flow in patients whose output is within normal limits and thus may be of value in reducing the degree of pre-existing fluid accumulation. It should be noted that at doses above those optimal for the individual patient, urine flow may decrease, necessitating reduction of dosage. Low Cardiac Output – Increased cardiac output is related to dopamine's direct inotropic effect on the myocardium. Increased cardiac output at low or moderate doses appears to be related to a favorable prognosis. Increase in cardiac output has been associated with either static or decreased systemic vascular resistance (SVR). Static or decreased SVR associated with low or moderate movements in cardiac output is believed to be a reflection of differential effects on specific vascular beds with increased resistance in peripheral beds (e.g., femoral) and concomitant decreases in mesenteric and renal vascular beds. Redistribution of blood flow parallels these changes so that an increase in cardiac output is accompanied by an increase in mesenteric and renal blood flow. In many instances the renal fraction of the total cardiac output has been found to increase. Increase in cardiac output produced by dopamine is not associated with substantial decreases in systemic vascular resistance as may occur with isoproterenol. Hypotension – Hypotension due to inadequate cardiac output can be managed by administration of low to moderate doses of dopamine HCl which have little effect on SVR. At high therapeutic doses, dopamine's alpha-adrenergic activity becomes more prominent and thus may correct hypotension due to diminished SVR. As in the case of other circulatory decompensation states, prognosis is better in patients whose blood pressure and urine flow have not undergone profound deterioration. Therefore, it is suggested that the physician administer dopamine HCl as soon as a definite trend toward decreased systolic and diastolic pressure becomes evident. uuid:86fb06b1-f60c-41d7-9fe9-f37fddd7194a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18243 biolink:treats MONDO:0001106 PMID:41385096 "[{""id"":""uuid:dde6a267-207f-4218-a5ef-e847597190aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bc11908d-34de-4c91-bfff-36cec01e1382"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dopamine HCl is indicated for the correction of hemodynamic imbalances present in the shock syndrome due to myocardial infarction, trauma, endotoxic septicemia, open-heart surgery, renal failure, and chronic cardiac decompensation as in congestive failure. Patients most likely to respond adequately to dopamine HCl are those in whom physiological parameters, such as urine flow, myocardial function, and blood pressure, have not undergone profound deterioration. Multiclinic trials indicate that the shorter the time interval between onset of signs and symptoms and initiation of therapy with blood volume correction and dopamine HCl, the better the prognosis. Where appropriate, blood volume restoration with a suitable plasma expander or whole blood should be accomplished prior to administration of dopamine HCl. Poor Perfusion of Vital Organs – Urine flow appears to be one of the better diagnostic signs by which adequacy of vital organ perfusion can be monitored. Nevertheless, the physician should also observe the patient for signs of reversal of confusion or reversal of comatose condition. Loss of pallor, increase in toe temperature, and/or adequacy of nail bed capillary filling may also be used as indices of adequate dosage. Clinical studies have shown that when dopamine HCl is administered before urine flow has diminished to levels of approximately 0.3 mL/minute, prognosis is more favorable. Nevertheless, in a number of oliguric or anuric patients, administration of dopamine HCl has resulted in an increase in urine flow, which in some cases reached normal levels. Dopamine HCl may also increase urine flow in patients whose output is within normal limits and thus may be of value in reducing the degree of pre-existing fluid accumulation. It should be noted that at doses above those optimal for the individual patient, urine flow may decrease, necessitating reduction of dosage. Low Cardiac Output – Increased cardiac output is related to dopamine's direct inotropic effect on the myocardium. Increased cardiac output at low or moderate doses appears to be related to a favorable prognosis. Increase in cardiac output has been associated with either static or decreased systemic vascular resistance (SVR). Static or decreased SVR associated with low or moderate movements in cardiac output is believed to be a reflection of differential effects on specific vascular beds with increased resistance in peripheral beds (e.g., femoral) and concomitant decreases in mesenteric and renal vascular beds. Redistribution of blood flow parallels these changes so that an increase in cardiac output is accompanied by an increase in mesenteric and renal blood flow. In many instances the renal fraction of the total cardiac output has been found to increase. Increase in cardiac output produced by dopamine is not associated with substantial decreases in systemic vascular resistance as may occur with isoproterenol. Hypotension – Hypotension due to inadequate cardiac output can be managed by administration of low to moderate doses of dopamine HCl which have little effect on SVR. At high therapeutic doses, dopamine's alpha-adrenergic activity becomes more prominent and thus may correct hypotension due to diminished SVR. As in the case of other circulatory decompensation states, prognosis is better in patients whose blood pressure and urine flow have not undergone profound deterioration. Therefore, it is suggested that the physician administer dopamine HCl as soon as a definite trend toward decreased systolic and diastolic pressure becomes evident. uuid:cc0a8a0a-2508-4439-8a62-e988b2c65ab4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18243 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:a840ed3c-f041-4a67-a8c1-5d929a88c5e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:69f2e9b3-098f-44c8-ac8e-7c1c98cbf752"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dopamine HCl is indicated for the correction of hemodynamic imbalances present in the shock syndrome due to myocardial infarction, trauma, endotoxic septicemia, open-heart surgery, renal failure, and chronic cardiac decompensation as in congestive failure. Patients most likely to respond adequately to dopamine HCl are those in whom physiological parameters, such as urine flow, myocardial function, and blood pressure, have not undergone profound deterioration. Multiclinic trials indicate that the shorter the time interval between onset of signs and symptoms and initiation of therapy with blood volume correction and dopamine HCl, the better the prognosis. Where appropriate, blood volume restoration with a suitable plasma expander or whole blood should be accomplished prior to administration of dopamine HCl. Poor Perfusion of Vital Organs – Urine flow appears to be one of the better diagnostic signs by which adequacy of vital organ perfusion can be monitored. Nevertheless, the physician should also observe the patient for signs of reversal of confusion or reversal of comatose condition. Loss of pallor, increase in toe temperature, and/or adequacy of nail bed capillary filling may also be used as indices of adequate dosage. Clinical studies have shown that when dopamine HCl is administered before urine flow has diminished to levels of approximately 0.3 mL/minute, prognosis is more favorable. Nevertheless, in a number of oliguric or anuric patients, administration of dopamine HCl has resulted in an increase in urine flow, which in some cases reached normal levels. Dopamine HCl may also increase urine flow in patients whose output is within normal limits and thus may be of value in reducing the degree of pre-existing fluid accumulation. It should be noted that at doses above those optimal for the individual patient, urine flow may decrease, necessitating reduction of dosage. Low Cardiac Output – Increased cardiac output is related to dopamine's direct inotropic effect on the myocardium. Increased cardiac output at low or moderate doses appears to be related to a favorable prognosis. Increase in cardiac output has been associated with either static or decreased systemic vascular resistance (SVR). Static or decreased SVR associated with low or moderate movements in cardiac output is believed to be a reflection of differential effects on specific vascular beds with increased resistance in peripheral beds (e.g., femoral) and concomitant decreases in mesenteric and renal vascular beds. Redistribution of blood flow parallels these changes so that an increase in cardiac output is accompanied by an increase in mesenteric and renal blood flow. In many instances the renal fraction of the total cardiac output has been found to increase. Increase in cardiac output produced by dopamine is not associated with substantial decreases in systemic vascular resistance as may occur with isoproterenol. Hypotension – Hypotension due to inadequate cardiac output can be managed by administration of low to moderate doses of dopamine HCl which have little effect on SVR. At high therapeutic doses, dopamine's alpha-adrenergic activity becomes more prominent and thus may correct hypotension due to diminished SVR. As in the case of other circulatory decompensation states, prognosis is better in patients whose blood pressure and urine flow have not undergone profound deterioration. Therefore, it is suggested that the physician administer dopamine HCl as soon as a definite trend toward decreased systolic and diastolic pressure becomes evident. uuid:ac35189f-63ff-4e45-8a08-ab5ed35f6b7c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18243 biolink:treats HP:0100520 PMID:41385096 "[{""id"":""uuid:2c0603f1-cbe8-4c3b-b708-039a70c97a80"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2ca67a12-07d8-40d6-be5d-9443b50410e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dopamine HCl is indicated for the correction of hemodynamic imbalances present in the shock syndrome due to myocardial infarction, trauma, endotoxic septicemia, open-heart surgery, renal failure, and chronic cardiac decompensation as in congestive failure. Patients most likely to respond adequately to dopamine HCl are those in whom physiological parameters, such as urine flow, myocardial function, and blood pressure, have not undergone profound deterioration. Multiclinic trials indicate that the shorter the time interval between onset of signs and symptoms and initiation of therapy with blood volume correction and dopamine HCl, the better the prognosis. Where appropriate, blood volume restoration with a suitable plasma expander or whole blood should be accomplished prior to administration of dopamine HCl. Poor Perfusion of Vital Organs – Urine flow appears to be one of the better diagnostic signs by which adequacy of vital organ perfusion can be monitored. Nevertheless, the physician should also observe the patient for signs of reversal of confusion or reversal of comatose condition. Loss of pallor, increase in toe temperature, and/or adequacy of nail bed capillary filling may also be used as indices of adequate dosage. Clinical studies have shown that when dopamine HCl is administered before urine flow has diminished to levels of approximately 0.3 mL/minute, prognosis is more favorable. Nevertheless, in a number of oliguric or anuric patients, administration of dopamine HCl has resulted in an increase in urine flow, which in some cases reached normal levels. Dopamine HCl may also increase urine flow in patients whose output is within normal limits and thus may be of value in reducing the degree of pre-existing fluid accumulation. It should be noted that at doses above those optimal for the individual patient, urine flow may decrease, necessitating reduction of dosage. Low Cardiac Output – Increased cardiac output is related to dopamine's direct inotropic effect on the myocardium. Increased cardiac output at low or moderate doses appears to be related to a favorable prognosis. Increase in cardiac output has been associated with either static or decreased systemic vascular resistance (SVR). Static or decreased SVR associated with low or moderate movements in cardiac output is believed to be a reflection of differential effects on specific vascular beds with increased resistance in peripheral beds (e.g., femoral) and concomitant decreases in mesenteric and renal vascular beds. Redistribution of blood flow parallels these changes so that an increase in cardiac output is accompanied by an increase in mesenteric and renal blood flow. In many instances the renal fraction of the total cardiac output has been found to increase. Increase in cardiac output produced by dopamine is not associated with substantial decreases in systemic vascular resistance as may occur with isoproterenol. Hypotension – Hypotension due to inadequate cardiac output can be managed by administration of low to moderate doses of dopamine HCl which have little effect on SVR. At high therapeutic doses, dopamine's alpha-adrenergic activity becomes more prominent and thus may correct hypotension due to diminished SVR. As in the case of other circulatory decompensation states, prognosis is better in patients whose blood pressure and urine flow have not undergone profound deterioration. Therefore, it is suggested that the physician administer dopamine HCl as soon as a definite trend toward decreased systolic and diastolic pressure becomes evident. uuid:36b2c9a7-4cf2-4ebe-ab60-559b4997a27b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18243 biolink:treats MONDO:0002476 PMID:41385096 "[{""id"":""uuid:068fbbfb-e8e7-434c-a8c8-8d2253436383"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:144f88c1-353d-45e2-96f3-10faa62ec533"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dopamine HCl is indicated for the correction of hemodynamic imbalances present in the shock syndrome due to myocardial infarction, trauma, endotoxic septicemia, open-heart surgery, renal failure, and chronic cardiac decompensation as in congestive failure. Patients most likely to respond adequately to dopamine HCl are those in whom physiological parameters, such as urine flow, myocardial function, and blood pressure, have not undergone profound deterioration. Multiclinic trials indicate that the shorter the time interval between onset of signs and symptoms and initiation of therapy with blood volume correction and dopamine HCl, the better the prognosis. Where appropriate, blood volume restoration with a suitable plasma expander or whole blood should be accomplished prior to administration of dopamine HCl. Poor Perfusion of Vital Organs – Urine flow appears to be one of the better diagnostic signs by which adequacy of vital organ perfusion can be monitored. Nevertheless, the physician should also observe the patient for signs of reversal of confusion or reversal of comatose condition. Loss of pallor, increase in toe temperature, and/or adequacy of nail bed capillary filling may also be used as indices of adequate dosage. Clinical studies have shown that when dopamine HCl is administered before urine flow has diminished to levels of approximately 0.3 mL/minute, prognosis is more favorable. Nevertheless, in a number of oliguric or anuric patients, administration of dopamine HCl has resulted in an increase in urine flow, which in some cases reached normal levels. Dopamine HCl may also increase urine flow in patients whose output is within normal limits and thus may be of value in reducing the degree of pre-existing fluid accumulation. It should be noted that at doses above those optimal for the individual patient, urine flow may decrease, necessitating reduction of dosage. Low Cardiac Output – Increased cardiac output is related to dopamine's direct inotropic effect on the myocardium. Increased cardiac output at low or moderate doses appears to be related to a favorable prognosis. Increase in cardiac output has been associated with either static or decreased systemic vascular resistance (SVR). Static or decreased SVR associated with low or moderate movements in cardiac output is believed to be a reflection of differential effects on specific vascular beds with increased resistance in peripheral beds (e.g., femoral) and concomitant decreases in mesenteric and renal vascular beds. Redistribution of blood flow parallels these changes so that an increase in cardiac output is accompanied by an increase in mesenteric and renal blood flow. In many instances the renal fraction of the total cardiac output has been found to increase. Increase in cardiac output produced by dopamine is not associated with substantial decreases in systemic vascular resistance as may occur with isoproterenol. Hypotension – Hypotension due to inadequate cardiac output can be managed by administration of low to moderate doses of dopamine HCl which have little effect on SVR. At high therapeutic doses, dopamine's alpha-adrenergic activity becomes more prominent and thus may correct hypotension due to diminished SVR. As in the case of other circulatory decompensation states, prognosis is better in patients whose blood pressure and urine flow have not undergone profound deterioration. Therefore, it is suggested that the physician administer dopamine HCl as soon as a definite trend toward decreased systolic and diastolic pressure becomes evident. uuid:345d6044-2f53-41e6-bc75-5603745e8f74 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18243 biolink:treats MONDO:0005468 PMID:41385096 "[{""id"":""uuid:ace6d5b2-d0c3-4e8c-a6c2-9cd57ef1e390"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9a8469a1-ba5d-4906-ad3b-d818b63077eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dopamine HCl is indicated for the correction of hemodynamic imbalances present in the shock syndrome due to myocardial infarction, trauma, endotoxic septicemia, open-heart surgery, renal failure, and chronic cardiac decompensation as in congestive failure. Patients most likely to respond adequately to dopamine HCl are those in whom physiological parameters, such as urine flow, myocardial function, and blood pressure, have not undergone profound deterioration. Multiclinic trials indicate that the shorter the time interval between onset of signs and symptoms and initiation of therapy with blood volume correction and dopamine HCl, the better the prognosis. Where appropriate, blood volume restoration with a suitable plasma expander or whole blood should be accomplished prior to administration of dopamine HCl. Poor Perfusion of Vital Organs – Urine flow appears to be one of the better diagnostic signs by which adequacy of vital organ perfusion can be monitored. Nevertheless, the physician should also observe the patient for signs of reversal of confusion or reversal of comatose condition. Loss of pallor, increase in toe temperature, and/or adequacy of nail bed capillary filling may also be used as indices of adequate dosage. Clinical studies have shown that when dopamine HCl is administered before urine flow has diminished to levels of approximately 0.3 mL/minute, prognosis is more favorable. Nevertheless, in a number of oliguric or anuric patients, administration of dopamine HCl has resulted in an increase in urine flow, which in some cases reached normal levels. Dopamine HCl may also increase urine flow in patients whose output is within normal limits and thus may be of value in reducing the degree of pre-existing fluid accumulation. It should be noted that at doses above those optimal for the individual patient, urine flow may decrease, necessitating reduction of dosage. Low Cardiac Output – Increased cardiac output is related to dopamine's direct inotropic effect on the myocardium. Increased cardiac output at low or moderate doses appears to be related to a favorable prognosis. Increase in cardiac output has been associated with either static or decreased systemic vascular resistance (SVR). Static or decreased SVR associated with low or moderate movements in cardiac output is believed to be a reflection of differential effects on specific vascular beds with increased resistance in peripheral beds (e.g., femoral) and concomitant decreases in mesenteric and renal vascular beds. Redistribution of blood flow parallels these changes so that an increase in cardiac output is accompanied by an increase in mesenteric and renal blood flow. In many instances the renal fraction of the total cardiac output has been found to increase. Increase in cardiac output produced by dopamine is not associated with substantial decreases in systemic vascular resistance as may occur with isoproterenol. Hypotension – Hypotension due to inadequate cardiac output can be managed by administration of low to moderate doses of dopamine HCl which have little effect on SVR. At high therapeutic doses, dopamine's alpha-adrenergic activity becomes more prominent and thus may correct hypotension due to diminished SVR. As in the case of other circulatory decompensation states, prognosis is better in patients whose blood pressure and urine flow have not undergone profound deterioration. Therefore, it is suggested that the physician administer dopamine HCl as soon as a definite trend toward decreased systolic and diastolic pressure becomes evident. uuid:0081484e-0a89-4505-a253-8adbeb923e33 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:134694335 biolink:treats HP:0002153 PMID:41385096 "[{""id"":""uuid:192bab58-b3d8-4961-9636-13de6da30334"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:937bf6d7-eb02-40c3-bbf8-33974535b917"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LOKELMA is indicated for the treatment of hyperkalemia in adults. Limitation of Use LOKELMA should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action [see Clinical Pharmacology (12.2) and Clinical Studies (14) ] . uuid:35e9b2fd-300f-4405-8496-5cd4998709bb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:WA16A5Y52X biolink:treats MONDO:0001700 PMID:41385096 "[{""id"":""uuid:d1655290-dff2-418d-b3c7-a0976fecb808"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f4bfdfd1-772b-43a9-9395-347c07e2f9a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levoleucovorin injection is indicated for: rescue after high-dose methotrexate therapy in adult and pediatric patients with osteosarcoma. diminishing the toxicity associated with overdosage of folic acid antagonists or impaired methotrexate elimination in adult and pediatric patients. the treatment of adults with metastatic colorectal cancer in combination with fluorouracil. Limitations of Use: Levoleucovorin injection is not indicated for pernicious anemia and megaloblastic anemia secondary to the lack of vitamin B 12 , because of the risk of progression of neurologic manifestations despite hematologic remission. PUBCHEM.COMPOUND:135465090 uuid:f8769bdf-8ec1-4914-8952-e15d27e81857 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16347 biolink:treats MONDO:0019052 PMID:41385096 "[{""id"":""uuid:5af6b797-8857-49c1-b7d5-213cc65c521d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:00cf7631-d5e9-49de-9ae5-121b3bb6121a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the acute and chronic treatment of patients with an inborn error of metabolism which results in secondary carnitine deficiency. For the prevention and treatment of carnitine deficiency in patients with end stage renal disease who are undergoing dialysis. uuid:a90fd6f6-f7c5-47b8-8de9-faffc754ad51 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16347 biolink:treats MONDO:0004375 PMID:41385096 "[{""id"":""uuid:d21c838d-0f83-4e48-9856-bac3a95c3549"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ade772e8-9f18-45c4-93bb-02facc96f4f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the acute and chronic treatment of patients with an inborn error of metabolism which results in secondary carnitine deficiency. For the prevention and treatment of carnitine deficiency in patients with end stage renal disease who are undergoing dialysis. uuid:1abae82c-25e3-43f4-bbdd-e446b4a84c90 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:499361 biolink:treats NCIT:C107517 PMID:41385096 "[{""id"":""uuid:8c93223a-9e66-4f34-bfd0-e15d5e5ba33c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c8f26646-5b14-40dd-a598-578ff484f005"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fosaprepitant for Injection, in combination with other antiemetic agents, is indicated in adults for the prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin. delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). Limitations of Use Fosaprepitant for Injection has not been studied for the treatment of established nausea and vomiting. uuid:8585f75d-586c-417d-8082-094ab1af8867 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3240 biolink:treats MONDO:0006014 PMID:41385096 "[{""id"":""uuid:6e4bcf0f-bacc-48f8-83c0-aeb2126448f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3438c385-ff0e-4817-878c-ed0b0f604399"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] GYNAZOLE • 1 ® Butoconazole Nitrate Vaginal Cream USP, 2% is indicated for the local treatment of vulvovaginal candidiasis (infections caused by Candida ). The diagnosis should be confirmed by KOH smears and/or cultures (see CLINICAL STUDIES ). Note: GYNAZOLE • 1 ® Butoconazole Nitrate Vaginal Cream USP, 2% is safe and effective in non-pregnant women; however, the safety and effectiveness of this product in pregnant women has not been established (see PRECAUTIONS - Pregnancy ). uuid:d0088816-eeaa-4f0c-8a76-63b164e6e124 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:11979316 biolink:treats HP:0100806 PMID:41385096 "[{""id"":""uuid:e73e1bae-07d9-478f-9d40-5ee992e23fdb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:de753ea6-b462-4156-bbb8-ec1e1bbc091a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vasostrict ® is indicated to increase blood pressure in adults with vasodilatory shock (e.g., post-cardiotomy or sepsis) who remain hypotensive despite fluids and catecholamines. uuid:f49c51a7-3147-4a48-9263-437ee85cd134 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49662 biolink:treats MONDO:0011827 PMID:41385096 "[{""id"":""uuid:a24e756b-ff89-4b3a-8d1c-0c131073d3fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ac4e0e41-b050-447f-8d4f-4596382e6659"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Indomethacin for Injection is indicated to close a hemodynamically significant patent ductus arteriosus in premature infants weighing between 500 and 1,750 g when 48 hours usual medical management (e.g., fluid restriction, diuretics, digitalis, respiratory support, etc.) is ineffective. Clear-cut clinical evidence of a hemodynamically significant patent ductus arteriosus should be present, such as respiratory distress, a continuous murmur, a hyperactive precordium, cardiomegaly, or pulmonary plethora on chest x-ray. uuid:cdf14320-e974-4cb3-be40-c1f76c37fad4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49662 biolink:treats HP:0002098 PMID:41385096 "[{""id"":""uuid:0ee23690-a5c2-4a13-a746-36b9ddcd8d5c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:76de6d27-a10c-4b08-9e94-79a9661b22ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Indomethacin for Injection is indicated to close a hemodynamically significant patent ductus arteriosus in premature infants weighing between 500 and 1,750 g when 48 hours usual medical management (e.g., fluid restriction, diuretics, digitalis, respiratory support, etc.) is ineffective. Clear-cut clinical evidence of a hemodynamically significant patent ductus arteriosus should be present, such as respiratory distress, a continuous murmur, a hyperactive precordium, cardiomegaly, or pulmonary plethora on chest x-ray. uuid:2c19be95-a133-40de-b3d0-61818313cfbf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49662 biolink:treats HP:0001640 PMID:41385096 "[{""id"":""uuid:73946fcd-00fa-44c2-bc9d-63612cbf3977"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ca40ad11-f5fb-4b32-9fce-7a61398d57aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Indomethacin for Injection is indicated to close a hemodynamically significant patent ductus arteriosus in premature infants weighing between 500 and 1,750 g when 48 hours usual medical management (e.g., fluid restriction, diuretics, digitalis, respiratory support, etc.) is ineffective. Clear-cut clinical evidence of a hemodynamically significant patent ductus arteriosus should be present, such as respiratory distress, a continuous murmur, a hyperactive precordium, cardiomegaly, or pulmonary plethora on chest x-ray. uuid:69e7444a-e018-412e-9b79-c91629fc4964 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45304 biolink:treats MONDO:0006052 PMID:41385096 "[{""id"":""uuid:ab985739-ef60-4fa7-b895-b753b8254a4f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c3a25a04-b5f8-4604-bde4-6eef107c8d42"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PRIFTIN is a rifamycin antimycobacterial drug indicated in patients 12 years of age and older for the treatment of active pulmonary tuberculosis (TB) caused by Mycobacterium tuberculosis in combination with one or more antituberculosis (anti-TB) drugs to which the isolate is susceptible. ( 1.1 ) PRIFTIN is indicated for the treatment of latent tuberculosis infection (LTBI) caused by M. tuberculosis in combination with isoniazid in patients 2 years of age and older at high risk of progression to TB disease. ( 1.2 ) See Full Prescribing Information for Limitations of Use. ( 1.1 , 1.2 ) uuid:b57a6d2d-1a15-4cb4-b964-24e3b7dbc26e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45304 biolink:treats MONDO:0040753 PMID:41385096 "[{""id"":""uuid:7f4dadf0-8a5d-413a-a32f-102c8755a8e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:03511fa0-9bee-4cbc-8522-6d2be48945ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PRIFTIN is a rifamycin antimycobacterial drug indicated in patients 12 years of age and older for the treatment of active pulmonary tuberculosis (TB) caused by Mycobacterium tuberculosis in combination with one or more antituberculosis (anti-TB) drugs to which the isolate is susceptible. ( 1.1 ) PRIFTIN is indicated for the treatment of latent tuberculosis infection (LTBI) caused by M. tuberculosis in combination with isoniazid in patients 2 years of age and older at high risk of progression to TB disease. ( 1.2 ) See Full Prescribing Information for Limitations of Use. ( 1.1 , 1.2 ) uuid:751787d3-a96b-4e29-93cb-7c13d5bba2c4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8871 biolink:treats MONDO:0004985 PMID:41385096 "[{""id"":""uuid:661b23cc-8bcd-4fb2-8f74-372f8f723b65"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:279074fc-31db-418e-a6ba-0452441e17b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Risperidone is an atypical antipsychotic indicated for: Treatment of schizophrenia ( 1.1 ) As monotherapy or adjunctive therapy with lithium or valproate, for the treatment of acute manic or mixed episodes associated with Bipolar Disorder ( 1.2 ) Treatment of irritability associated with autistic disorder ( 1.3 ) uuid:af551700-11b1-48fa-998d-f22dde5fb604 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68478 biolink:treats MONDO:0005086 PMID:41385096 "[{""id"":""uuid:464920be-d8b4-4aaf-ad91-da569822a4e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:81257e58-cff6-4f95-a794-8be8de50c43c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:13d8e171-2636-4155-b351-e71828c740c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/votubia""]},{""id"":""uuid:f08df0ee-a8f4-4b77-833d-34a1b4577e3a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Everolimus tablets are a kinase inhibitor indicated for the treatment of: Adults with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib. ( 1.3 ) Adults with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery. ( 1.4 ) Everolimus tablets are kinase inhibitors indicated for the treatment of adult and pediatric patients aged 1 year and older with TSC who have subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected. ( 1.5 )|[EMA] Hormone-receptor-positive advanced breast cancerAfinitor is indicated for the treatment of hormone-receptor-positive, HER2/neu-negative advanced breast cancer, in combination with exemestane, in post-menopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor.Neuroendocrine tumours of pancreatic originAfinitor is indicated for the treatment of unresectable or metastatic, well or moderately differentiated neuroendocrine tumours of pancreatic origin in adults with progressive disease.Neuroendocrine tumours of gastrointestinal or lung originAfinitor is indicated for the treatment of unresectable or metastatic, well-differentiated (Grade 1 or Grade 2) non-functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease.Renal-cell carcinomaAfinitor is indicated for the treatment of patients with advanced renal-cell carcinoma, whose disease has progressed on or after treatment with VEGF-targeted therapy.|[PMDA] A drug with a new additional indication and a new dosage for the treatment of unresectable or metastatic renal cell carcinoma. [Priority review] uuid:635ee223-7484-4bb4-b34d-e06c41576ec7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68478 biolink:treats MONDO:0002603 PMID:41385096 "[{""id"":""uuid:472a5388-9f03-46c8-aa12-3441ff2e6e72"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:56580682-97c6-4258-bd56-9644aa2acca0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:fa7235a4-4695-4c91-9492-e8ffffc50b79"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Everolimus tablets are a kinase inhibitor indicated for the treatment of: Adults with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib. ( 1.3 ) Adults with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery. ( 1.4 ) Everolimus tablets are kinase inhibitors indicated for the treatment of adult and pediatric patients aged 1 year and older with TSC who have subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected. ( 1.5 )|[PMDA] Drugs with new additional indications and a new dosage for the treatment of renal angiomyolipoma associated with tuberous sclerosis complex and subependymal giant cell astrocytoma associated with tuberous sclerosis complex. [Orphan drug] uuid:97d95913-0294-4457-85ee-7f1341ebd3d3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68478 biolink:treats MONDO:0016693 PMID:41385096 "[{""id"":""uuid:f48f0965-92de-4e31-8c0f-a4771d533f84"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:92e24f41-f302-4327-943c-85e940017571"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:9b2bd9a2-30ca-4429-ac14-2095050d6758"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/votubia""]},{""id"":""uuid:246ffa58-7757-4b97-91a5-ef90c02548f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Everolimus tablets are a kinase inhibitor indicated for the treatment of: Adults with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib. ( 1.3 ) Adults with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery. ( 1.4 ) Everolimus tablets are kinase inhibitors indicated for the treatment of adult and pediatric patients aged 1 year and older with TSC who have subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected. ( 1.5 )|[EMA] Renal angiomyolipoma associated with tuberous sclerosis complex (TSC)Votubia is indicated for the treatment of adult patients with renal angiomyolipoma associated with tuberous sclerosis complex (TSC) who are at risk of complications (based on factors such as tumour size or presence of aneurysm, or presence of multiple or bilateral tumours) but who do not require immediate surgery.The evidence is based on analysis of change in sum of angiomyolipoma volume.Subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC)Votubia is indicated for the treatment of patients with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC) who require therapeutic intervention but are not amenable to surgery.The evidence is based on analysis of change in SEGA volume. Further clinical benefit, such as improvement in disease‑related symptoms, has not been demonstrated.|[PMDA] Drugs with a new additional indication and a new dosage in an additional dosage form for the treatment of subependymal giant cell astrocytoma associated with tuberous sclerosis complex (currently in the reexamination period). [Orphan drug] uuid:a969c1ff-fbf9-460e-8f85-fcce1d23f727 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:480999 biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:a28d5c0f-cf61-4c4a-ac2e-7827f2c14f40"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b02e7bd4-79cd-4694-81e9-043545c9155a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vinorelbine injection is indicated: In combination with cisplatin for first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) As a single agent for the treatment of patients with metastatic NSCLC uuid:e23cb053-0bdd-4143-bad3-c43f6aad2cca biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:480999 biolink:treats UMLS:C0278987 PMID:41385096 "[{""id"":""uuid:a815c9b2-eaf3-4d34-8032-a3e44b3de53e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:822aa82e-d3af-495b-9ea4-1be40cc4f29c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vinorelbine injection is indicated: In combination with cisplatin for first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) As a single agent for the treatment of patients with metastatic NSCLC uuid:537ba8bc-11af-4c11-b3b2-3af0e1c34aef biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85966 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:6b840780-1399-44ca-aeb5-ef3a8cae578d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:3c1d7b55-04a7-4f61-8132-0534b7810be0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:9b05858e-069e-4344-ba91-691af3969aba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Corlanor (ivabradine) is a hyperpolarization-activated cyclic nucleotide-gated channel blocker indicated: To reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with reduced left ventricular ejection fraction. ( 1.1 ) For the treatment of stable symptomatic heart failure due to dilated cardiomyopathy in pediatric patients ages 6 months and older. ( 1.2 )|[EMA] Symptomatic treatment of chronic stable angina pectoris Ivabradine is indicated for the symptomatic treatment of chronic stable angina pectoris in coronary artery disease adults with normal sinus rhythm and heart rate ≥ 70 bpm. Ivabradine is indicated:in adults unable to tolerate or with a contra-indication to the use of beta-blockersorin combination with beta-blockers in patients inadequately controlled with an optimal beta-blocker dose. Treatment of chronic heart failure Ivabradine is indicated in chronic heart failure NYHA II to IV class with systolic dysfunction, in patients in sinus rhythm and whose heart rate is ≥ 75 bpm, in combination with standard therapy including beta-blocker therapy or when beta-blocker therapy is contraindicated or not tolerated. uuid:9bc49e32-acb3-458f-bf91-8866444205a3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85966 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:f3289fe4-fae5-43a1-b0f7-e38a9ca139d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:23b9e367-56b7-4168-9260-df8d0a2df982"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:b33d4486-d7be-42d9-b6cb-3f840cdc5af9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Corlanor (ivabradine) is a hyperpolarization-activated cyclic nucleotide-gated channel blocker indicated: To reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with reduced left ventricular ejection fraction. ( 1.1 ) For the treatment of stable symptomatic heart failure due to dilated cardiomyopathy in pediatric patients ages 6 months and older. ( 1.2 )|[PMDA] Drugs with a new active ingredient indicated for the treatment of chronic heart failure with sinus rhythm and a resting heart rate of 75 bpm or greater at baseline ( for use only in patients receiving standard treatment of chronic heart failure, including β-blocker). uuid:60c670e6-386c-4ef9-9012-7525a4171aba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85966 biolink:treats MONDO:0005021 PMID:41385096 "[{""id"":""uuid:ea47dff7-3f57-41e6-af9e-c134dfa51319"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b21a164a-f49b-4d2a-8a56-305e64c5894c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Corlanor (ivabradine) is a hyperpolarization-activated cyclic nucleotide-gated channel blocker indicated: To reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with reduced left ventricular ejection fraction. ( 1.1 ) For the treatment of stable symptomatic heart failure due to dilated cardiomyopathy in pediatric patients ages 6 months and older. ( 1.2 ) uuid:2868f616-550d-4744-8e70-5524fa9e30f9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10127 biolink:treats MONDO:0006710 PMID:41385096 "[{""id"":""uuid:4a60b624-92de-4dc1-bbec-44fac468c37f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:854b4437-dc27-41c0-bb91-fbaa1d371f2c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZONISADE is indicated as adjunctive therapy for the treatment of partial-onset seizures in adults and pediatric patients 16 years and older. uuid:9f2c6ec4-1532-4322-9dd7-926f3727242c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31696 biolink:treats MONDO:0002974 PMID:41385096 "[{""id"":""uuid:8a96e9e1-f797-4b5a-a64e-951ddd30f7c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:09ca2131-8916-4c94-aef4-79f9e7c783ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SPY AGENT GREEN is an optical imaging agent indicated for use with a fluorescence imaging device for: Visualization of vessels (micro and macro vasculature), blood flow and tissue perfusion before, during, and after vascular, gastrointestinal, organ transplant, plastic, micro- and reconstructive surgeries including general minimally invasive surgical procedures in adults and pediatric patients one month of age and older. ( 1.1 ) Visualization of extrahepatic biliary ducts in adults and pediatric patients aged 12 years and older. ( 1.2 ) Visualization of lymph nodes and lymphatic vessels during lymphatic mapping in adults with cervical and uterine cancer. ( 1.3 ) Visualization of lymph nodes and lymphatic vessels during lymphatic mapping in adults with breast cancer. ( 1.4 ) uuid:24850de5-84e4-4385-9a34-c0bb8f0a64aa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31696 biolink:treats MONDO:0002715 PMID:41385096 "[{""id"":""uuid:2848f937-5879-4403-9a45-1a5c8884f184"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:63003c73-cc0b-49c5-a92d-56e133760afa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SPY AGENT GREEN is an optical imaging agent indicated for use with a fluorescence imaging device for: Visualization of vessels (micro and macro vasculature), blood flow and tissue perfusion before, during, and after vascular, gastrointestinal, organ transplant, plastic, micro- and reconstructive surgeries including general minimally invasive surgical procedures in adults and pediatric patients one month of age and older. ( 1.1 ) Visualization of extrahepatic biliary ducts in adults and pediatric patients aged 12 years and older. ( 1.2 ) Visualization of lymph nodes and lymphatic vessels during lymphatic mapping in adults with cervical and uterine cancer. ( 1.3 ) Visualization of lymph nodes and lymphatic vessels during lymphatic mapping in adults with breast cancer. ( 1.4 ) uuid:e64ae440-2e26-445f-b2e3-95bad8e7113c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31696 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:fde0c69f-7c9f-4a88-8ff4-01cf82b4fa81"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d60e2ec1-1b56-4f61-bbeb-b2205e81cae8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:42fcdd97-5c37-4cf9-b407-eb2402123555"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SPY AGENT GREEN is an optical imaging agent indicated for use with a fluorescence imaging device for: Visualization of vessels (micro and macro vasculature), blood flow and tissue perfusion before, during, and after vascular, gastrointestinal, organ transplant, plastic, micro- and reconstructive surgeries including general minimally invasive surgical procedures in adults and pediatric patients one month of age and older. ( 1.1 ) Visualization of extrahepatic biliary ducts in adults and pediatric patients aged 12 years and older. ( 1.2 ) Visualization of lymph nodes and lymphatic vessels during lymphatic mapping in adults with cervical and uterine cancer. ( 1.3 ) Visualization of lymph nodes and lymphatic vessels during lymphatic mapping in adults with breast cancer. ( 1.4 )|[PMDA] A drug with a new route of administration, a new indication, and a new dosage for sentinel lymph node mapping in breast cancer and malignant melanoma. [Expedited review] uuid:40274e3a-78bc-484c-8a08-83a0cd0def1f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15355 biolink:treats MONDO:0005129 PMID:41385096 "[{""id"":""uuid:7f93def5-bc86-4806-9a85-d72aa182e90e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1762a5d1-1253-4ad3-bc95-5d0089f18fcf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To obtain miosis of the iris in seconds after delivery of the lens in cataract surgery, in penetrating keratoplasty, iridectomy, and other anterior segment surgery where rapid miosis may be required. uuid:e38f8f97-bdfa-49d5-810b-730cd76b3b75 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:AD4J2O47FQ biolink:treats UMLS:C4728082 PMID:41385096 "[{""id"":""uuid:c53028a7-0f25-4e8f-b906-6f997b89fdb8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8c8afa99-13c1-45c4-895f-34943ce10770"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZEGALOGUE ® is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 6 years and above. uuid:c4500df8-27ca-4095-b3e2-e3c0792f766d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5893 biolink:treats HP:0000969 PMID:41385096 "[{""id"":""uuid:dd4848a7-d12c-4acb-95b6-f6b471dfa3da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d725bc49-1641-4b9f-b424-2f32174cd72d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Indapamide tablets are indicated for the treatment of hypertension, alone or in combination with other antihypertensive drugs. Indapamide tablets are also indicated for the treatment of salt and fluid retention associated with congestive heart failure. Usage in Pregnancy : The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard (see PRECAUTIONS below). Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developed toxemia. Edema during pregnancy may arise from pathological causes or from the physiologic and mechanical consequences of pregnancy. Indapamide is indicated in pregnancy when edema is due to pathologic causes, just as it is in the absence of pregnancy (however, see PRECAUTIONS below). Dependent edema in pregnancy, resulting from restriction of venous return by the expanded uterus, is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is illogical and unnecessary. There is hypervolemia during normal pregnancy which is not harmful to either the fetus or the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances, this edema may cause extreme discomfort which is not relieved by rest. In these cases, a short course of diuretics may provide relief and may be appropriate. uuid:b626c9d3-55ad-468f-918d-3d2faf4c915d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45863 biolink:treats UMLS:C0278488 PMID:41385096 "[{""id"":""uuid:1f40a9b5-928d-4453-99da-104a37a54ef5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:61928018-9a51-494e-aa35-3227d2b0fed0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ABRAXANE is a microtubule inhibitor indicated for the treatment of: • Metastatic breast cancer, after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated. ( 1.1 ) • Locally advanced or metastatic non-small cell lung cancer (NSCLC), as first-line treatment in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy. ( 1.2 ) • Metastatic adenocarcinoma of the pancreas as first-line treatment, in combination with gemcitabine. ( 1.3 ) uuid:50ba223a-c910-4cf3-b203-8f9ba1e81f35 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45863 biolink:treats UMLS:C0278987 PMID:41385096 "[{""id"":""uuid:f3a5bc5b-fa3c-4e7d-87be-4d713bbdbbc4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f2c22ec2-cfdb-4d16-8b59-3310d84ca692"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ABRAXANE is a microtubule inhibitor indicated for the treatment of: • Metastatic breast cancer, after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated. ( 1.1 ) • Locally advanced or metastatic non-small cell lung cancer (NSCLC), as first-line treatment in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy. ( 1.2 ) • Metastatic adenocarcinoma of the pancreas as first-line treatment, in combination with gemcitabine. ( 1.3 ) uuid:89296737-483d-48f5-9579-bd1db71ce8cf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45863 biolink:treats MONDO:0006047 PMID:41385096 "[{""id"":""uuid:881cbef9-9bba-4bb4-9aff-1fe317dd844a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:14789442-9ef0-460d-8774-6aa6ef491306"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:3a535a50-093c-4446-822b-c04db4f7d764"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/apealea""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] ABRAXANE is a microtubule inhibitor indicated for the treatment of: • Metastatic breast cancer, after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated. ( 1.1 ) • Locally advanced or metastatic non-small cell lung cancer (NSCLC), as first-line treatment in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy. ( 1.2 ) • Metastatic adenocarcinoma of the pancreas as first-line treatment, in combination with gemcitabine. ( 1.3 )|[EMA] Abraxane monotherapy is indicated for the treatment of metastatic breast cancer in adult patients who have failed first-line treatment for metastatic disease and for whom standard, anthracycline containing therapy is not indicated.Abraxane in combination with gemcitabine is indicated for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas.Abraxane in combination with carboplatin is indicated for the first-line treatment of non-small cell lung cancer in adult patients who are not candidates for potentially curative surgery and/or radiation therapy. uuid:3e7fcb3f-34be-4ea0-ae87-2e698d098f8a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:100241 biolink:treats MONDO:0006668 PMID:41385096 "[{""id"":""uuid:5b92025a-de4f-4752-8bbe-aaa2c9d35b16"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:773bd255-77b1-459b-bbbc-8ccd222d6c5c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CILOXAN ® (ciprofloxacin ophthalmic ointment) 0.3% is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the microorganisms listed below: Gram-Positive: Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae Streptococcus Viridans Group Gram-Negative: Haemophilus influenzae uuid:6697825e-51b9-4cfa-b517-e1d3575e05a5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:100241 biolink:treats MONDO:0005545 PMID:41385096 "[{""id"":""uuid:d9b848e3-17be-479e-a7f9-ffbcd8b04c14"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:daa9bf38-d442-41e9-a28f-cde5d711408a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CILOXAN ® (ciprofloxacin ophthalmic ointment) 0.3% is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the microorganisms listed below: Gram-Positive: Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae Streptococcus Viridans Group Gram-Negative: Haemophilus influenzae uuid:7e4c9b84-cd63-4ac9-a748-54b861335ef9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:100241 biolink:treats MONDO:0005114 PMID:41385096 "[{""id"":""uuid:8d8824c4-db2a-499e-861a-4faabd54d91f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:199cd12a-7d41-4179-8136-c21fb4c7678e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CILOXAN ® (ciprofloxacin ophthalmic ointment) 0.3% is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the microorganisms listed below: Gram-Positive: Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae Streptococcus Viridans Group Gram-Negative: Haemophilus influenzae uuid:99db0c18-8f80-4951-ba12-4114979c26b7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:100241 biolink:treats UMLS:C1096266 PMID:41385096 "[{""id"":""uuid:8ac31d8e-14c8-459a-b897-d5bab393ae1b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c59734a9-0983-4d2e-b95d-6b7243396b4f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CILOXAN ® (ciprofloxacin ophthalmic ointment) 0.3% is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the microorganisms listed below: Gram-Positive: Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae Streptococcus Viridans Group Gram-Negative: Haemophilus influenzae uuid:3931013c-c699-401a-8ca5-991897f035b3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29108 biolink:treats HP:0001944 PMID:41385096 "[{""id"":""uuid:aa754fb0-8479-4105-a5f8-34de11601d31"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cb2abe0e-3c5a-4af3-8d21-1c2fae75c55d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] This solution is indicated for use in adults and pediatric patients as a source of electrolytes and water for hydration. uuid:14e8e2e1-0835-4ba9-b775-c9abd6accae6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3A58010674 biolink:treats UMLS:C0746883 PMID:41385096 "[{""id"":""uuid:7bbe8c9e-fccb-4ac7-a892-d9cce01f9293"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4550ef70-feab-4086-a698-ee6997da9665"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:7a1aef2f-5192-41e3-ada9-e7b76b145ba4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NYVEPRIA is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia [see Clinical Studies (14) ] .|[PMDA] A drug with a new active ingredient indicated for decreasing the incidence of cancer chemotherapy- induced febrile neutropenia. uuid:5cf915be-5313-4e90-a9a9-f3b53537b643 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3A58010674 biolink:treats UMLS:C3714514 PMID:41385096 "[{""id"":""uuid:f57336fd-6ae7-43f1-a630-232f559c9b20"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:abb07318-5612-4408-829e-fc2f3c9f9b20"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NYVEPRIA is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia [see Clinical Studies (14) ] . uuid:61a9b9a1-91da-4edd-9025-77898dbd6d37 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63791 biolink:treats MONDO:0004948 PMID:41385096 "[{""id"":""uuid:2e15639c-c491-459d-9757-c76c6b2edb8b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8aa7f46a-f3c5-43bf-9ecb-bffec380af8e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lenalidomide is a thalidomide analogue indicated for the treatment of adult patients with: Multiple myeloma (MM), in combination with dexamethasone ( 1.1 ). MM, as maintenance following autologous hematopoietic stem cell transplantation (auto-HSCT) ( 1.1 ). Transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities ( 1.2 ). Limitations of Use: Lenalidomide capsules are not indicated and are not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials ( 1.6 ). uuid:cd3ba6ce-d5f9-4264-80ab-deb825f74201 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18258 biolink:treats MONDO:0002108 PMID:41385096 "[{""id"":""uuid:b91a2ec0-a96a-442c-81c1-284f163a3313"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d88225b2-1b17-4824-a6f3-a501abe09136"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Liothyronine sodium tablets are an L-triiodothyronine (T3) indicated for: Hypothyroidism: As replacement in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism ( 1.1 ) Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression: As an adjunct to surgery and radioiodine therapy in the management of well-differentiated thyroid cancer ( 1.2 ) Thyroid Suppression Test: As a diagnostic agent in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy ( 1.3 ) Limitations of Use : - Not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients. ( 1 ) - Not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis. ( 1 ) uuid:d7cca248-e09b-463a-aab9-d4dce5788542 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:30746 biolink:treats MONDO:0004739 PMID:41385096 "[{""id"":""uuid:607bcb98-186c-4337-9464-c8a01c108ceb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:497db6e2-34f3-4a01-ac84-9e9247dc50f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium phenylacetate and sodium benzoate injection is indicated as adjunctive therapy in pediatric and adult patients for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. During acute hyperammonemic episodes, arginine supplementation, caloric supplementation, dietary protein restriction, hemodialysis, and other ammonia lowering therapies should be considered [ see Warnings and Precautions (5) ]. uuid:4a0f3c4e-abdc-46fc-8ce6-6b66ed278452 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2637 biolink:treats MONDO:0005113 PMID:41385096 "[{""id"":""uuid:5d22b7a3-a4ac-485b-99ee-f07c57865351"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eed377c4-9dc8-4c01-ad53-754fe409d4f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amikacin sulfate injection, USP is indicated in the short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria, including Pseudomonas species, Escherichia coli , species of indole-positive and indole-negative Proteus , Providencia species, Klebsiella species, Enterobacter species, Serratia species, and Acinetobacter species. To reduce the development of drug-resistant bacteria and maintain the effectiveness of amikacin and other antibacterial drugs, amikacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:f26be292-90ce-45e6-9f04-2d45eb682da0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:939U7C91AI biolink:treats MONDO:0021107 PMID:41385096 "[{""id"":""uuid:ccfc170e-b367-4c55-b07a-98620d51dac1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:7ca02897-9146-4871-9edc-0b22ce3f6bfb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:7c70014c-8a2f-4ac6-9179-474e636eccb1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SUNOSI is indicated to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (OSA) [see Clinical Studies ( 14 )] . Limitations of Use SUNOSI is not indicated to treat the underlying airway obstruction in OSA. Ensure that the underlying airway obstruction is treated (e.g., with continuous positive airway pressure (CPAP)) for at least one month prior to initiating SUNOSI for excessive daytime sleepiness. Modalities to treat the underlying airway obstruction should be continued during treatment with SUNOSI. SUNOSI is not a substitute for these modalities.|[EMA] Sunosi is indicated to improve wakefulness and reduce excessive daytime sleepiness in adult patients with narcolepsy (with or without cataplexy).Sunosi is indicated to improve wakefulness and reduce excessive daytime sleepiness (EDS) in adult patients with obstructive sleep apnoea (OSA) whose EDS has not been satisfactorily treated by primary OSA therapy, such as continuous positive airway pressure (CPAP). uuid:a1b92aa5-dc49-44fb-bbd3-4b99aba99195 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:939U7C91AI biolink:treats MONDO:0007147 PMID:41385096 "[{""id"":""uuid:35ffe4f4-a407-4412-a690-fc34e2bafaaa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:26805a41-ce71-4610-a477-2916ded09c7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:dd1941a9-a9e7-4773-a6c7-e29fa0fd3d79"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SUNOSI is indicated to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (OSA) [see Clinical Studies ( 14 )] . Limitations of Use SUNOSI is not indicated to treat the underlying airway obstruction in OSA. Ensure that the underlying airway obstruction is treated (e.g., with continuous positive airway pressure (CPAP)) for at least one month prior to initiating SUNOSI for excessive daytime sleepiness. Modalities to treat the underlying airway obstruction should be continued during treatment with SUNOSI. SUNOSI is not a substitute for these modalities.|[EMA] Sunosi is indicated to improve wakefulness and reduce excessive daytime sleepiness in adult patients with narcolepsy (with or without cataplexy).Sunosi is indicated to improve wakefulness and reduce excessive daytime sleepiness (EDS) in adult patients with obstructive sleep apnoea (OSA) whose EDS has not been satisfactorily treated by primary OSA therapy, such as continuous positive airway pressure (CPAP). uuid:6c794049-6eb9-4b5e-936c-bff6755f29d6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:44476258 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:427df181-43fc-4123-a384-ca8ab50925dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1fd4c74a-1c66-427f-a496-b4b16f6f577f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tribenzor is indicated for the treatment of hypertension, alone or with other antihypertensive agents, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular (CV) events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Tribenzor. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Limitations of Use This fixed combination drug is not indicated for the initial therapy of hypertension . uuid:8136f378-6798-431a-96fd-2ce86b2c9a9e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1162777 biolink:treats MONDO:0006652 PMID:41385096 "[{""id"":""uuid:82fffdd0-553a-40be-87a7-8fdc7ddeafe7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6de4f27a-903e-4690-ab89-46d2d3b59c14"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BENICAR HCT (olmesartan medoxomil and hydrochlorothiazide) is indicated for the treatment of hypertension, to lower blood pressure. BENICAR HCT is not indicated for the initial therapy of hypertension [see Dosage and Administration (2) ] . Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with BENICAR HCT. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. BENICAR HCT may be used alone, or in combination with other antihypertensive drugs. uuid:31099afa-c645-47b7-bad1-2c66c70efac9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1162777 biolink:treats HP:0001681 PMID:41385096 "[{""id"":""uuid:0edeacdd-1fa1-48e9-8c6d-22240e93ba93"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:986de045-e59d-44e3-829a-58f343bee5f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BENICAR HCT (olmesartan medoxomil and hydrochlorothiazide) is indicated for the treatment of hypertension, to lower blood pressure. BENICAR HCT is not indicated for the initial therapy of hypertension [see Dosage and Administration (2) ] . Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with BENICAR HCT. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. BENICAR HCT may be used alone, or in combination with other antihypertensive drugs. uuid:65b9e5c7-9b52-4a95-9a68-66861bd9ec2b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1162777 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:c3b48f9b-1626-46e3-8337-9ceb9ff92958"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:25b6d9f9-155e-4dc6-89a9-bc4fb9c1d4ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BENICAR HCT (olmesartan medoxomil and hydrochlorothiazide) is indicated for the treatment of hypertension, to lower blood pressure. BENICAR HCT is not indicated for the initial therapy of hypertension [see Dosage and Administration (2) ] . Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with BENICAR HCT. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. BENICAR HCT may be used alone, or in combination with other antihypertensive drugs. uuid:79f24225-4b06-47a8-89b5-57c0b361660d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:189563 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:6b164ef7-998e-45b1-9639-f16d02ec5b3a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7cca1e01-cb9d-42e8-8ae1-5235ad6ce5bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nebivolol tablets are a beta-adrenergic blocking agent indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) uuid:596f7242-113f-4f81-aba7-1ef59f26ae2f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2S713A4VP3 biolink:treats MONDO:0005647 PMID:41385096 "[{""id"":""uuid:d25f83bc-7e78-42ad-a392-ca2aa8f79f10"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5925fb2c-a4a1-43fc-af3a-838e3b61ac66"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Podocon-25® (25% podophyllin in benzoin tincture) is indicated for the removal of soft genital (venereal) warts (condylomata acuminata) (4) . uuid:82d860a7-480b-43dc-a965-58289414621d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:93635 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:27c69d90-1993-48ed-86c5-a82d3b3e1499"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ab58468c-d37d-42b4-adf0-f594350213ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Marplan is indicated for the treatment of depression. Because of its potentially serious side effects, Marplan is not an antidepressant of first choice in the treatment of newly diagnosed depressed patients. The efficacy of Marplan in the treatment of depression was established in 6-week controlled trials of depressed outpatients. These patients had symptoms that corresponded to the DSM-IV category of major depressive disorder; however, they often also had signs and symptoms of anxiety (anxious mood, panic, and/or phobic symptoms) ( see CLINICAL PHARMACOLOGY ). A major depressive episode (DSM-IV) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least five of the following nine symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suicide attempt or suicidal ideation. The antidepressant effectiveness of Marplan in hospitalized depressed patients, or in endogenomorphically retarded and delusionally depressed patients, has not been adequately studied. The effectiveness of Marplan in long-term use, that is, for more than 6 weeks, has not been systematically evaluated in controlled trials. Therefore, the physician who elects to use Marplan for extended periods should periodically evaluate the long-term usefulness of the drug for the individual patient. uuid:581a546e-3939-4c5d-b6e6-c2ef8be3949e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats MONDO:0005688 PMID:41385096 "[{""id"":""uuid:b7b7c843-76d2-47b7-a62a-a891a7ff8414"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b94d1a5a-f537-4bdb-b6fa-8d7978b70c1b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes, Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes, Streptococcus pneumoniae, Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp . ) Skin and soft tissue infections caused by Streptococcus pyogenes, Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci. Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli, Klebsiella, etc. Other infections caused by susceptible gram-negative organisms such as E. coli, Enterobacter aerogenes, Shigella sp ., Acinetobacter sp ., Klebsiella sp. , and Bacteroides sp. In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: Syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent's infection caused by Fusobacterium fusiforme , Infections caused by Neisseria gonorrhoeae , Anthrax caused by Bacillus anthracis , Infections due to Listeria monocytogenes , Actinomycosis caused by Actinomyces species, Infections due to Clostridium species. uuid:d44f63ac-a703-4498-9eac-b9002d363985 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats MONDO:0005828 PMID:41385096 "[{""id"":""uuid:c7f83bf6-992d-429a-80f0-5aeb43571b66"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a0b811b9-8826-4142-93a8-3443b9c5591a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes, Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes, Streptococcus pneumoniae, Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp . ) Skin and soft tissue infections caused by Streptococcus pyogenes, Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci. Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli, Klebsiella, etc. Other infections caused by susceptible gram-negative organisms such as E. coli, Enterobacter aerogenes, Shigella sp ., Acinetobacter sp ., Klebsiella sp. , and Bacteroides sp. In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: Syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent's infection caused by Fusobacterium fusiforme , Infections caused by Neisseria gonorrhoeae , Anthrax caused by Bacillus anthracis , Infections due to Listeria monocytogenes , Actinomycosis caused by Actinomyces species, Infections due to Clostridium species. uuid:fed80c78-f3e5-43da-89dc-96895bd342ab biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats MONDO:0024388 PMID:41385096 "[{""id"":""uuid:46768732-bb85-4c13-bb6c-37305f43fa36"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0c478329-7782-4c8f-84ec-318cd7ca66f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes, Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes, Streptococcus pneumoniae, Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp . ) Skin and soft tissue infections caused by Streptococcus pyogenes, Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci. Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli, Klebsiella, etc. Other infections caused by susceptible gram-negative organisms such as E. coli, Enterobacter aerogenes, Shigella sp ., Acinetobacter sp ., Klebsiella sp. , and Bacteroides sp. In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: Syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent's infection caused by Fusobacterium fusiforme , Infections caused by Neisseria gonorrhoeae , Anthrax caused by Bacillus anthracis , Infections due to Listeria monocytogenes , Actinomycosis caused by Actinomyces species, Infections due to Clostridium species. uuid:c086e38a-3e6c-4829-91ec-43809a80b9a8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats MONDO:0021680 PMID:41385096 "[{""id"":""uuid:66231aa6-ad0c-49dc-a919-fddc523bfea1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:59c5d29a-6f5b-4cd3-9efd-09756436d3bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes, Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes, Streptococcus pneumoniae, Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp . ) Skin and soft tissue infections caused by Streptococcus pyogenes, Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci. Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli, Klebsiella, etc. Other infections caused by susceptible gram-negative organisms such as E. coli, Enterobacter aerogenes, Shigella sp ., Acinetobacter sp ., Klebsiella sp. , and Bacteroides sp. In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: Syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent's infection caused by Fusobacterium fusiforme , Infections caused by Neisseria gonorrhoeae , Anthrax caused by Bacillus anthracis , Infections due to Listeria monocytogenes , Actinomycosis caused by Actinomyces species, Infections due to Clostridium species. uuid:5c9438d7-7db5-4398-a395-804f86280784 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16794 biolink:treats EFO:0004888 PMID:41385096 "[{""id"":""uuid:a2f872bb-2155-43bb-a7ac-4a78465e7e20"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:68ac9f42-60c9-45b4-b3d2-82177c230094"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Scopolamine transdermal system is indicated in adults for the prevention of: • nausea and vomiting associated with motion sickness. • post-operative nausea and vomiting (PONV) associated with recovery from anesthesia and/or opiate analgesia and surgery. uuid:204154e4-3548-49a5-84b5-b7e26b8672db biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:700516 biolink:treats MONDO:0005147 PMID:41385096 "[{""id"":""uuid:3641e696-3eac-4931-b9d3-81de4b22b7e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5126ec02-b3f3-46f0-b804-666b675827bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] JANUMET is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use JANUMET should not be used in patients with type 1 diabetes mellitus. JANUMET has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using JANUMET. [See Warnings and Precautions (5.2) .] uuid:541da823-ec0a-4bc7-8acf-6076d99bb04c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:700516 biolink:treats MONDO:0004982 PMID:41385096 "[{""id"":""uuid:f46e51d3-30c2-492f-91c4-263a1f67704f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:db75342d-cb26-4b0e-b292-9cdc2d9d04c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] JANUMET is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use JANUMET should not be used in patients with type 1 diabetes mellitus. JANUMET has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using JANUMET. [See Warnings and Precautions (5.2) .] uuid:86a083c3-5345-4fd6-9fe7-dedd778b6a54 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7478 biolink:treats MONDO:0005475 PMID:41385096 "[{""id"":""uuid:b00ca48c-9ad9-4bb7-ac4a-ceab582bc8a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:77158bb8-2e38-450d-b644-029ce668f139"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Naratriptan is indicated for the acute treatment of migraine attacks with or without aura in adults. Limitations of Use: • Use only if a clear diagnosis of migraine has been established. If a patient has no response to the first migraine attack treated with naratriptan, reconsider the diagnosis of migraine before naratriptan is administered to treat any subsequent attacks. • Naratriptan is not indicated for the prevention of migraine attacks. • Safety and effectiveness of naratriptan have not been established for cluster headache. uuid:6ebb32b0-c60b-453e-840d-c1019e62d61c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7478 biolink:treats MONDO:0100431 PMID:41385096 "[{""id"":""uuid:2f19b37c-7bb9-4841-ac0a-f3025b3a7eac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:74a0cf57-9489-4a3c-8cf1-e4ec0794e80d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Naratriptan is indicated for the acute treatment of migraine attacks with or without aura in adults. Limitations of Use: • Use only if a clear diagnosis of migraine has been established. If a patient has no response to the first migraine attack treated with naratriptan, reconsider the diagnosis of migraine before naratriptan is administered to treat any subsequent attacks. • Naratriptan is not indicated for the prevention of migraine attacks. • Safety and effectiveness of naratriptan have not been established for cluster headache. uuid:7b40b1c6-20db-4153-8a40-f192d1a4182d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7478 biolink:treats MONDO:0005277 PMID:41385096 "[{""id"":""uuid:0a54d824-78ea-4970-b463-ae66699bf9da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:af8cd488-7f2f-4f88-86b0-33842ea1b1c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:0014f8af-a230-4f81-8592-4d190bcc3682"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Naratriptan is indicated for the acute treatment of migraine attacks with or without aura in adults. Limitations of Use: • Use only if a clear diagnosis of migraine has been established. If a patient has no response to the first migraine attack treated with naratriptan, reconsider the diagnosis of migraine before naratriptan is administered to treat any subsequent attacks. • Naratriptan is not indicated for the prevention of migraine attacks. • Safety and effectiveness of naratriptan have not been established for cluster headache.|[PMDA] A drug containing a new active ingredient indicated for the treatment of migraine. uuid:d9159d81-d220-41b2-92bf-aa78d504eb15 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:194135 biolink:treats MONDO:0002345 PMID:41385096 "[{""id"":""uuid:402955e8-84a4-4797-af35-60057615ae20"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:12d05b63-bdde-4e1e-827c-e2d71d80ea41"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of ofloxacin tablets, USP and other antibacterial drugs, ofloxacin tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ofloxacin tablets, USP are indicated for the treatment of adults with mild to moderate infections (unless otherwise indicated) caused by susceptible strains of the designated microorganisms in the infections listed below. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute Bacterial Exacerbations of Chronic Bronchitis (ABECB) due to Haemophilus influenzae or Streptococcus pneumoniae . Because fluoroquinolones, including ofloxacin, have been associated with serious adverse reactions (see Warnings ), - and for some patients ABECB is self-limiting, reserve ofloxacin for treatment of ABECB in patients who have no alternative treatment options . Community-Acquired Pneumonia due to Haemophilus influenzae or Streptococcus pneumoniae . Uncomplicated Skin and Skin Structure Infections due to methicillin-susceptible Staphylococcus aureus, Streptococcus pyogenes, or Proteus mirabilis. Acute, Uncomplicated Urethral and Cervical Gonorrhea due to Neisseria gonorrhoeae (see WARNINGS ). Nongonococcal Urethritis and Cervicitis due to Chlamydia trachomatis (see WARNINGS ). Mixed Infections of the Urethra and Cervix due to Chlamydia trachomatis and Neisseria gonorrhoeae (see WARNINGS ). Acute Pelvic Inflammatory Disease (including severe infection) due to Chlamydia trachomatis and/or Neisseria gonorrhoeae (see WARNINGS ). NOTE: If anaerobic microorganisms are suspected of contributing to the infection, appropriate therapy for anaerobic pathogens should be administered. Uncomplicated Cystitis due to Citrobacter diversus, Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa. Because fluoroquinolones, including ofloxacin, have been associated with serious adverse reactions (see WARNINGS ), and for some patients uncomplicated cystitis is self-limiting, reserve ofloxacin for treatment of uncomplicated cystitis in patients who have no alternative treatment options. Complicated Urinary Tract Infections due to Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Citrobacter diversus, = Although treatment of infections due to this organism in this organ system demonstrated a clinically significant outcome, efficacy was studied in fewer than 10 patients. or Pseudomonas aeruginosa. Prostatitis due to Escherichia coli. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to ofloxacin, USP. Therapy with ofloxacin, USP may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. As with other drugs in this class, some strains of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with ofloxacin, USP. Culture and susceptibility testing performed periodically during therapy will provide information not only on the therapeutic effect of the antimicrobial agent but also on the possible emergence of bacterial resistance. uuid:71dd8ec7-59bb-4f71-a2b1-232073f8bf98 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:616538 biolink:treats MONDO:0800501 PMID:41385096 "[{""id"":""uuid:045fa8cd-67e5-45ab-99a1-09349ccbc44d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5bb84bf2-3203-4cd2-aa02-64f731449546"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZEGERID for oral suspension and ZEGERID capsules are indicated in adults for the : • short-term treatment of active duodenal ulcer. Most patients heal within four weeks. Some patients may require an additional four weeks of therapy. • short-term treatment (4 to 8 weeks) of active benign gastric ulcer. • treatment of heartburn and other symptoms associated with GERD for up to 4 weeks. • short-term treatment (4 to 8 weeks) of EE due to acid-mediated GERD which has been diagnosed by endoscopy in adults. • The efficacy of ZEGERID used for longer than 8 weeks in patients with EE has not been established. If a patient does not respond to 8 weeks of treatment, an additional 4 weeks of treatment may be given. If there is recurrence of EE or GERD symptoms (e.g., heartburn), additional 4 to 8-week courses of ZEGERID may be considered. • maintenance of healing of EE due to acid-mediated GERD. Controlled studies do not extend beyond 12 months. ZEGERID for oral suspension is indicated in adults for the : • reduction of risk of upper GI bleeding in critically ill adult patients. uuid:7d2b0b21-c3bd-4cf9-9252-ce869dad4f07 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6633 biolink:treats UMLS:C0332687 PMID:41385096 "[{""id"":""uuid:947390b7-db85-4dc5-9cb8-e33a5186681e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c77bbcec-a294-4a4f-ae29-98c092665c20"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SULFAMYLON Cream is a topical agent indicated for adjunctive therapy of patients with second- and third-degree burns. uuid:37373265-590c-423c-8240-f041f99deca8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6633 biolink:treats UMLS:C0433445 PMID:41385096 "[{""id"":""uuid:d41e1804-60d1-4663-a372-fe12aa92c142"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5c02cba8-5149-4ab5-bbd6-184aad06518d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SULFAMYLON Cream is a topical agent indicated for adjunctive therapy of patients with second- and third-degree burns. uuid:d6eafbe9-73a1-4842-8b2d-a72d73b81c99 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:SXA7YP6EKX biolink:treats MONDO:0010679 PMID:41385096 "[{""id"":""uuid:fd00a59c-f215-4c6d-993f-95f9b0673b8f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:87374177-5bd4-4223-92fa-3058ff71d913"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e5e6f664-16b0-4728-a9ef-1671c731b9c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VILTEPSO is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with VILTEPSO [see Clinical Studies ( 14 )]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.|[PMDA] A drug with a new active ingredient indicated for the treatment of Duchenne muscular dystrophy (DMD) with a confirmed deficiency of the dystrophin gene amenable to exon 53 skipping therapy. [SAKIGAKE designation] [Conditional early approval] [Orphan drug] uuid:ead1f9ab-82fa-41c7-a0b6-effc684b8457 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133023 biolink:treats MONDO:0006733 PMID:41385096 "[{""id"":""uuid:ad96cbdf-931b-43c8-8917-933388b73ac1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:17d79fad-c9f4-4109-b7b3-d40ed3db252a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Xiidra ® (lifitegrast ophthalmic solution) 5% is indicated for the treatment of the signs and symptoms of dry eye disease (DED). uuid:9c480019-33b3-49a1-9097-412ecaaeb633 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:11979316 biolink:treats MONDO:0005468 PMID:41385096 "[{""id"":""uuid:9c3eac53-c910-40ef-b9f7-3afa2ffff8e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d4d0e6a0-cecb-49b2-b3e3-d0eae253f8f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vasopressin injection is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. uuid:5ad44e46-4872-4bca-9d0b-e86808849c4e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71272 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:84d1a0a2-6761-4833-9799-e4769f976772"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b8b55ff6-dc20-41c6-b684-04d92892d395"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:0cd58360-d8e9-41dc-ba7f-76d1a6e05ca5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Saxagliptin tablets are a dipeptidyl peptidase-4 (DPP4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1.1 , 14 ) Limitation of use: • Not used for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis. ( 1.2 )|[PMDA] Drugs with a new active ingredient indicated for the treatment of type 2 diabetes mellitus. uuid:1db86cb0-4ee0-4acb-a4e4-dccff6ddd431 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71272 biolink:treats MONDO:0005147 PMID:41385096 "[{""id"":""uuid:16534bed-305f-48d0-b1ff-c2d3c4728f4f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:be40dd04-e49a-4782-a9d7-c6cf6dfc3e96"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Saxagliptin tablets are a dipeptidyl peptidase-4 (DPP4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1.1 , 14 ) Limitation of use: • Not used for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis. ( 1.2 ) uuid:8435a393-6b20-4af8-9d93-effba61eb7df biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71272 biolink:treats MONDO:0012819 PMID:41385096 "[{""id"":""uuid:f0797250-85c4-4c81-a617-28df63cd1e23"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a53cdb9e-c957-4879-9d43-4a40b8b3cb22"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Saxagliptin tablets are a dipeptidyl peptidase-4 (DPP4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1.1 , 14 ) Limitation of use: • Not used for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis. ( 1.2 ) uuid:f50a9f61-6849-4eab-8247-e0297e960866 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29036 biolink:treats HP:0011967 PMID:41385096 "[{""id"":""uuid:e25f5133-dbcf-4683-9c93-bcf691fd06b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d39a52cd-ce9f-47a7-a258-34973a626214"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cupric Chloride Injection, USP 0.4 mg/mL is indicated for use as a supplement to intravenous solutions given for total parenteral nutrition (TPN). Administration helps to maintain copper serum levels and to prevent depletion of endogenous stores and subsequent deficiency symptoms. uuid:035c8b90-e015-438e-b85d-697e7be77652 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18067 biolink:treats MONDO:0001244 PMID:41385096 "[{""id"":""uuid:ef72393c-63f6-4e27-97ee-0a9824b4551c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7809360d-b1aa-43e1-81c5-0e85fdb6d862"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Phytonadione is indicated for the treatment of adults with the following coagulation disorders which are due to faulty formation of factors II, VII, IX and X when caused by vitamin K deficiency or interference with vitamin K activity. • anticoagulant-induced hypoprothrombinemia caused by coumarin or indanedione derivatives; • hypoprothrombinemia secondary to antibacterial therapy; • hypoprothrombinemia secondary to factors limiting absorpsion or synthesis of vitamin K, e.g., obstructive jaundice, biliary fistula, sprue, ulcerative colitis, celiac disease, intestinal resection, cystic fibrosis of the pancrease, and regional enteritis; • Other drug-induced hypoprothrombinemia where it is definitely shown that the result is due to interference with vitamin K metabolism, e.g., salicylates. uuid:f1874782-15d2-4a2f-bf9b-4572fe043461 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18067 biolink:treats MONDO:0009061 PMID:41385096 "[{""id"":""uuid:b3c9c935-dc7c-4a9d-b585-d7914a9939d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f97b8966-65be-4a3b-921a-fea4803ea5fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Phytonadione is indicated for the treatment of adults with the following coagulation disorders which are due to faulty formation of factors II, VII, IX and X when caused by vitamin K deficiency or interference with vitamin K activity. • anticoagulant-induced hypoprothrombinemia caused by coumarin or indanedione derivatives; • hypoprothrombinemia secondary to antibacterial therapy; • hypoprothrombinemia secondary to factors limiting absorpsion or synthesis of vitamin K, e.g., obstructive jaundice, biliary fistula, sprue, ulcerative colitis, celiac disease, intestinal resection, cystic fibrosis of the pancrease, and regional enteritis; • Other drug-induced hypoprothrombinemia where it is definitely shown that the result is due to interference with vitamin K metabolism, e.g., salicylates. uuid:5d832ebe-4727-4f6c-9bbd-2dfb056b1e30 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:L0HR9A577V biolink:treats UMLS:C5577628 PMID:41385096 "[{""id"":""uuid:13408376-0a78-4f1f-9ab7-6400990af293"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:335ae59f-515e-4c58-94b2-27d015a0c31d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ELREXFIO is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. This indication is approved under accelerated approval based on response rate and durability of response [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s). uuid:9f98fad8-072e-466c-868b-3f734b35c1c6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:L0HR9A577V biolink:treats UMLS:C4551538 PMID:41385096 "[{""id"":""uuid:193f2082-f8fa-4fb6-a486-8bb128a0aaad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5fba2d58-d18f-4530-9a6d-86f3faa0ad06"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ELREXFIO is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. This indication is approved under accelerated approval based on response rate and durability of response [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s). uuid:09255f97-bf8c-43c6-9eb2-5dfdd12d5063 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32229 biolink:treats EFO:0010826 PMID:41385096 "[{""id"":""uuid:9bdbbd0b-aef0-4d59-8e33-15f8eb4128b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b7d721a8-b713-488d-87a2-8aab9818279b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tiopronin delayed-release tablets are indicated, in combination with high fluid intake, alkali, and diet modification, for the prevention of cystine stone formation in adults and pediatric patients 9 years of age and older with severe homozygous cystinuria, who are not responsive to these measures alone. Additional pediatric use information is approved for Mission Pharmacal Company’s THIOLA EC (tiopronin) delayed-release tablets. However, due to Mission Pharmacal Company’s marketing exclusivity rights, this drug product is not labeled with that information. uuid:8bb54a83-efa3-4b64-a211-9ecef74e3870 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32229 biolink:treats MONDO:0009067 PMID:41385096 "[{""id"":""uuid:7432ee86-84fb-4324-bbf1-b0fe55c720d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:09706b4c-4bc4-4ace-8592-889bc329d9bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tiopronin delayed-release tablets are indicated, in combination with high fluid intake, alkali, and diet modification, for the prevention of cystine stone formation in adults and pediatric patients 9 years of age and older with severe homozygous cystinuria, who are not responsive to these measures alone. Additional pediatric use information is approved for Mission Pharmacal Company’s THIOLA EC (tiopronin) delayed-release tablets. However, due to Mission Pharmacal Company’s marketing exclusivity rights, this drug product is not labeled with that information. uuid:6bd1f353-295e-4118-880f-9aa5db3cbccc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB09422 biolink:treats UMLS:C0854100 PMID:41385096 "[{""id"":""uuid:0b226a03-ead4-49e3-b7a3-a0cc045fd886"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:30197ef4-f26d-4cb3-acd8-576b246a00a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KABIVEN is indicated as a source of calories, protein, electrolytes and essential fatty acids for adult patients requiring parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. KABIVEN may be used to prevent essential fatty acid deficiency or treat negative nitrogen balance in adult patients. Limitations of Use: KABIVEN is not recommended for use in pediatric patients under the age of 2 years, including preterm infants because the fixed content of the formulation does not meet the nutritional requirements of this age group [see Warnings and Precautions ( 5.1 ) and Use in Specific Populations ( 8.4 )] . uuid:4175d774-6cd0-434f-9b34-81f775e2a541 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17076 biolink:treats MONDO:0018076 PMID:41385096 "[{""id"":""uuid:9ff43d70-d0ee-49d0-a7a8-410aaeeab108"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3bcd740d-a1f4-411d-9887-8b88b26189ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Streptomycin is indicated for the treatment of individuals with moderate to severe infections caused by susceptibile strains of microorganisms in the specific conditions listed below: Mycobacterium tuberculosis: The Advisory Council for the Elimination of Tuberculosis, the American Thoracic Society, and the Center for Disease Control recommend that either streptomycin or ethambutol be added as a fourth drug in a regimen containing isoniazid (INH), rifampin and pyrazinamide for initial treatment of tuberculosis unless the likelihood of INH or rifampin resistance is very low. The need for a fourth drug should be reassessed when the results of susceptibility testing are known. In the past when the national rate of primary drug resistance to isoniazid was known to be less than 4% and was either stable or declining, therapy with two and three drug regimens was considered adequate. If community rates of INH resistance are currently less than 4%, an initial treatment regimen with less than four drugs may be considered. Streptomycin is also indicated for therapy of tuberculosis when one or more of the above drugs is contraindicated because of toxicity or intolerance. The management of tuberculosis has become more complex as a consequence of increasing rates of drug resistance and concomitant HIV infection. Additional consultation from experts in the treatment of tuberculosis may be desirable in those settings. Non-tuberculosis infections: The use of streptomycin should be limited to the treatment of infections caused by bacteria which have been shown to be susceptible to the antibacterial effects of streptomycin and which are not amenable to therapy with less potentially toxic agents. Yersinia pestis (plague), Francisella tularensis (tularemia), Brucella , Calymmatobacterium granulomatis (donovanosis, granuloma inguinale), H. ducreyi (chancroid), H. influenzae (in respiratory, endocardial, and meningeal infections-concomitantly with another antibacterial agent), K. pneumoniae pneumonia (concomitantly with another antibacterial agent), E.coli, Proteus, A. aerogenes, K. pneumoniae, and Enterococcus faecalis in urinary tract infections, Streptococcus viridans , Enterococcus faecalis (in endocardial infections - concomitantly with penicillin), Gram-negative bacillary bacteremia (concomitantly with another antibacterial agent). To reduce the development of drug-resistant bacteria and maintain the effectiveness of streptomycin and other antibacterial drugs, streptomycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:aa1c1440-344a-4194-826c-9efb7cf1d72f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17076 biolink:treats MONDO:0019095 PMID:41385096 "[{""id"":""uuid:71137963-aa5e-431b-9acc-3c483eb72f77"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d453bf97-a358-491d-ac3c-e79e2d725cf1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Streptomycin is indicated for the treatment of individuals with moderate to severe infections caused by susceptibile strains of microorganisms in the specific conditions listed below: Mycobacterium tuberculosis: The Advisory Council for the Elimination of Tuberculosis, the American Thoracic Society, and the Center for Disease Control recommend that either streptomycin or ethambutol be added as a fourth drug in a regimen containing isoniazid (INH), rifampin and pyrazinamide for initial treatment of tuberculosis unless the likelihood of INH or rifampin resistance is very low. The need for a fourth drug should be reassessed when the results of susceptibility testing are known. In the past when the national rate of primary drug resistance to isoniazid was known to be less than 4% and was either stable or declining, therapy with two and three drug regimens was considered adequate. If community rates of INH resistance are currently less than 4%, an initial treatment regimen with less than four drugs may be considered. Streptomycin is also indicated for therapy of tuberculosis when one or more of the above drugs is contraindicated because of toxicity or intolerance. The management of tuberculosis has become more complex as a consequence of increasing rates of drug resistance and concomitant HIV infection. Additional consultation from experts in the treatment of tuberculosis may be desirable in those settings. Non-tuberculosis infections: The use of streptomycin should be limited to the treatment of infections caused by bacteria which have been shown to be susceptible to the antibacterial effects of streptomycin and which are not amenable to therapy with less potentially toxic agents. Yersinia pestis (plague), Francisella tularensis (tularemia), Brucella , Calymmatobacterium granulomatis (donovanosis, granuloma inguinale), H. ducreyi (chancroid), H. influenzae (in respiratory, endocardial, and meningeal infections-concomitantly with another antibacterial agent), K. pneumoniae pneumonia (concomitantly with another antibacterial agent), E.coli, Proteus, A. aerogenes, K. pneumoniae, and Enterococcus faecalis in urinary tract infections, Streptococcus viridans , Enterococcus faecalis (in endocardial infections - concomitantly with penicillin), Gram-negative bacillary bacteremia (concomitantly with another antibacterial agent). To reduce the development of drug-resistant bacteria and maintain the effectiveness of streptomycin and other antibacterial drugs, streptomycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:255d0421-9d48-48bd-9634-1cf6d7aa781f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17076 biolink:treats MONDO:0018077 PMID:41385096 "[{""id"":""uuid:b641af57-13c2-4c9f-8acc-0e716d928427"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e9edbc10-4006-436e-a1e9-7d061c21799b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Streptomycin is indicated for the treatment of individuals with moderate to severe infections caused by susceptibile strains of microorganisms in the specific conditions listed below: Mycobacterium tuberculosis: The Advisory Council for the Elimination of Tuberculosis, the American Thoracic Society, and the Center for Disease Control recommend that either streptomycin or ethambutol be added as a fourth drug in a regimen containing isoniazid (INH), rifampin and pyrazinamide for initial treatment of tuberculosis unless the likelihood of INH or rifampin resistance is very low. The need for a fourth drug should be reassessed when the results of susceptibility testing are known. In the past when the national rate of primary drug resistance to isoniazid was known to be less than 4% and was either stable or declining, therapy with two and three drug regimens was considered adequate. If community rates of INH resistance are currently less than 4%, an initial treatment regimen with less than four drugs may be considered. Streptomycin is also indicated for therapy of tuberculosis when one or more of the above drugs is contraindicated because of toxicity or intolerance. The management of tuberculosis has become more complex as a consequence of increasing rates of drug resistance and concomitant HIV infection. Additional consultation from experts in the treatment of tuberculosis may be desirable in those settings. Non-tuberculosis infections: The use of streptomycin should be limited to the treatment of infections caused by bacteria which have been shown to be susceptible to the antibacterial effects of streptomycin and which are not amenable to therapy with less potentially toxic agents. Yersinia pestis (plague), Francisella tularensis (tularemia), Brucella , Calymmatobacterium granulomatis (donovanosis, granuloma inguinale), H. ducreyi (chancroid), H. influenzae (in respiratory, endocardial, and meningeal infections-concomitantly with another antibacterial agent), K. pneumoniae pneumonia (concomitantly with another antibacterial agent), E.coli, Proteus, A. aerogenes, K. pneumoniae, and Enterococcus faecalis in urinary tract infections, Streptococcus viridans , Enterococcus faecalis (in endocardial infections - concomitantly with penicillin), Gram-negative bacillary bacteremia (concomitantly with another antibacterial agent). To reduce the development of drug-resistant bacteria and maintain the effectiveness of streptomycin and other antibacterial drugs, streptomycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:35e5f9f6-a38c-4950-9c8e-83dc3753d3a0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17076 biolink:treats MONDO:0005683 PMID:41385096 "[{""id"":""uuid:2678d107-00b9-4c3c-b451-10fded5d829a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:da1cba2a-4a00-463a-980a-2b55a21cf8ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Streptomycin is indicated for the treatment of individuals with moderate to severe infections caused by susceptibile strains of microorganisms in the specific conditions listed below: Mycobacterium tuberculosis: The Advisory Council for the Elimination of Tuberculosis, the American Thoracic Society, and the Center for Disease Control recommend that either streptomycin or ethambutol be added as a fourth drug in a regimen containing isoniazid (INH), rifampin and pyrazinamide for initial treatment of tuberculosis unless the likelihood of INH or rifampin resistance is very low. The need for a fourth drug should be reassessed when the results of susceptibility testing are known. In the past when the national rate of primary drug resistance to isoniazid was known to be less than 4% and was either stable or declining, therapy with two and three drug regimens was considered adequate. If community rates of INH resistance are currently less than 4%, an initial treatment regimen with less than four drugs may be considered. Streptomycin is also indicated for therapy of tuberculosis when one or more of the above drugs is contraindicated because of toxicity or intolerance. The management of tuberculosis has become more complex as a consequence of increasing rates of drug resistance and concomitant HIV infection. Additional consultation from experts in the treatment of tuberculosis may be desirable in those settings. Non-tuberculosis infections: The use of streptomycin should be limited to the treatment of infections caused by bacteria which have been shown to be susceptible to the antibacterial effects of streptomycin and which are not amenable to therapy with less potentially toxic agents. Yersinia pestis (plague), Francisella tularensis (tularemia), Brucella , Calymmatobacterium granulomatis (donovanosis, granuloma inguinale), H. ducreyi (chancroid), H. influenzae (in respiratory, endocardial, and meningeal infections-concomitantly with another antibacterial agent), K. pneumoniae pneumonia (concomitantly with another antibacterial agent), E.coli, Proteus, A. aerogenes, K. pneumoniae, and Enterococcus faecalis in urinary tract infections, Streptococcus viridans , Enterococcus faecalis (in endocardial infections - concomitantly with penicillin), Gram-negative bacillary bacteremia (concomitantly with another antibacterial agent). To reduce the development of drug-resistant bacteria and maintain the effectiveness of streptomycin and other antibacterial drugs, streptomycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:3e4e00bc-7513-4846-b33a-6961d092907f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17076 biolink:treats MONDO:0005777 PMID:41385096 "[{""id"":""uuid:c0e96a0b-3e9a-4b63-974f-8f74112cfdde"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bc0c1d85-ecd0-493f-9b46-64b3acd73dde"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Streptomycin is indicated for the treatment of individuals with moderate to severe infections caused by susceptibile strains of microorganisms in the specific conditions listed below: Mycobacterium tuberculosis: The Advisory Council for the Elimination of Tuberculosis, the American Thoracic Society, and the Center for Disease Control recommend that either streptomycin or ethambutol be added as a fourth drug in a regimen containing isoniazid (INH), rifampin and pyrazinamide for initial treatment of tuberculosis unless the likelihood of INH or rifampin resistance is very low. The need for a fourth drug should be reassessed when the results of susceptibility testing are known. In the past when the national rate of primary drug resistance to isoniazid was known to be less than 4% and was either stable or declining, therapy with two and three drug regimens was considered adequate. If community rates of INH resistance are currently less than 4%, an initial treatment regimen with less than four drugs may be considered. Streptomycin is also indicated for therapy of tuberculosis when one or more of the above drugs is contraindicated because of toxicity or intolerance. The management of tuberculosis has become more complex as a consequence of increasing rates of drug resistance and concomitant HIV infection. Additional consultation from experts in the treatment of tuberculosis may be desirable in those settings. Non-tuberculosis infections: The use of streptomycin should be limited to the treatment of infections caused by bacteria which have been shown to be susceptible to the antibacterial effects of streptomycin and which are not amenable to therapy with less potentially toxic agents. Yersinia pestis (plague), Francisella tularensis (tularemia), Brucella , Calymmatobacterium granulomatis (donovanosis, granuloma inguinale), H. ducreyi (chancroid), H. influenzae (in respiratory, endocardial, and meningeal infections-concomitantly with another antibacterial agent), K. pneumoniae pneumonia (concomitantly with another antibacterial agent), E.coli, Proteus, A. aerogenes, K. pneumoniae, and Enterococcus faecalis in urinary tract infections, Streptococcus viridans , Enterococcus faecalis (in endocardial infections - concomitantly with penicillin), Gram-negative bacillary bacteremia (concomitantly with another antibacterial agent). To reduce the development of drug-resistant bacteria and maintain the effectiveness of streptomycin and other antibacterial drugs, streptomycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:73c013af-bce8-49aa-accd-8ce2e16ba4f6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17076 biolink:treats MONDO:0001797 PMID:41385096 "[{""id"":""uuid:171d8034-66fc-4c8b-983b-fff69f221013"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e6f9ff09-3cdf-4526-807d-abe0de0d2da2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Streptomycin is indicated for the treatment of individuals with moderate to severe infections caused by susceptibile strains of microorganisms in the specific conditions listed below: Mycobacterium tuberculosis: The Advisory Council for the Elimination of Tuberculosis, the American Thoracic Society, and the Center for Disease Control recommend that either streptomycin or ethambutol be added as a fourth drug in a regimen containing isoniazid (INH), rifampin and pyrazinamide for initial treatment of tuberculosis unless the likelihood of INH or rifampin resistance is very low. The need for a fourth drug should be reassessed when the results of susceptibility testing are known. In the past when the national rate of primary drug resistance to isoniazid was known to be less than 4% and was either stable or declining, therapy with two and three drug regimens was considered adequate. If community rates of INH resistance are currently less than 4%, an initial treatment regimen with less than four drugs may be considered. Streptomycin is also indicated for therapy of tuberculosis when one or more of the above drugs is contraindicated because of toxicity or intolerance. The management of tuberculosis has become more complex as a consequence of increasing rates of drug resistance and concomitant HIV infection. Additional consultation from experts in the treatment of tuberculosis may be desirable in those settings. Non-tuberculosis infections: The use of streptomycin should be limited to the treatment of infections caused by bacteria which have been shown to be susceptible to the antibacterial effects of streptomycin and which are not amenable to therapy with less potentially toxic agents. Yersinia pestis (plague), Francisella tularensis (tularemia), Brucella , Calymmatobacterium granulomatis (donovanosis, granuloma inguinale), H. ducreyi (chancroid), H. influenzae (in respiratory, endocardial, and meningeal infections-concomitantly with another antibacterial agent), K. pneumoniae pneumonia (concomitantly with another antibacterial agent), E.coli, Proteus, A. aerogenes, K. pneumoniae, and Enterococcus faecalis in urinary tract infections, Streptococcus viridans , Enterococcus faecalis (in endocardial infections - concomitantly with penicillin), Gram-negative bacillary bacteremia (concomitantly with another antibacterial agent). To reduce the development of drug-resistant bacteria and maintain the effectiveness of streptomycin and other antibacterial drugs, streptomycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:c193d609-dceb-4ddb-bdd2-52b6d1fd7945 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17076 biolink:treats HP:0005376 PMID:41385096 "[{""id"":""uuid:b123ed9b-09f7-4ba9-94f2-d0913044304c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0531007d-e6c1-4fad-9702-0f3b44529790"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Streptomycin is indicated for the treatment of individuals with moderate to severe infections caused by susceptibile strains of microorganisms in the specific conditions listed below: Mycobacterium tuberculosis: The Advisory Council for the Elimination of Tuberculosis, the American Thoracic Society, and the Center for Disease Control recommend that either streptomycin or ethambutol be added as a fourth drug in a regimen containing isoniazid (INH), rifampin and pyrazinamide for initial treatment of tuberculosis unless the likelihood of INH or rifampin resistance is very low. The need for a fourth drug should be reassessed when the results of susceptibility testing are known. In the past when the national rate of primary drug resistance to isoniazid was known to be less than 4% and was either stable or declining, therapy with two and three drug regimens was considered adequate. If community rates of INH resistance are currently less than 4%, an initial treatment regimen with less than four drugs may be considered. Streptomycin is also indicated for therapy of tuberculosis when one or more of the above drugs is contraindicated because of toxicity or intolerance. The management of tuberculosis has become more complex as a consequence of increasing rates of drug resistance and concomitant HIV infection. Additional consultation from experts in the treatment of tuberculosis may be desirable in those settings. Non-tuberculosis infections: The use of streptomycin should be limited to the treatment of infections caused by bacteria which have been shown to be susceptible to the antibacterial effects of streptomycin and which are not amenable to therapy with less potentially toxic agents. Yersinia pestis (plague), Francisella tularensis (tularemia), Brucella , Calymmatobacterium granulomatis (donovanosis, granuloma inguinale), H. ducreyi (chancroid), H. influenzae (in respiratory, endocardial, and meningeal infections-concomitantly with another antibacterial agent), K. pneumoniae pneumonia (concomitantly with another antibacterial agent), E.coli, Proteus, A. aerogenes, K. pneumoniae, and Enterococcus faecalis in urinary tract infections, Streptococcus viridans , Enterococcus faecalis (in endocardial infections - concomitantly with penicillin), Gram-negative bacillary bacteremia (concomitantly with another antibacterial agent). To reduce the development of drug-resistant bacteria and maintain the effectiveness of streptomycin and other antibacterial drugs, streptomycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:6c6c3e6f-1d77-427a-89ef-ffdbec8401f0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17076 biolink:treats MONDO:0030602 PMID:41385096 "[{""id"":""uuid:28012b08-194a-49b1-9c71-7410ce85ce86"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6984a019-48ed-4e00-b5d5-0126f6fe86e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Streptomycin is indicated for the treatment of individuals with moderate to severe infections caused by susceptibile strains of microorganisms in the specific conditions listed below: Mycobacterium tuberculosis: The Advisory Council for the Elimination of Tuberculosis, the American Thoracic Society, and the Center for Disease Control recommend that either streptomycin or ethambutol be added as a fourth drug in a regimen containing isoniazid (INH), rifampin and pyrazinamide for initial treatment of tuberculosis unless the likelihood of INH or rifampin resistance is very low. The need for a fourth drug should be reassessed when the results of susceptibility testing are known. In the past when the national rate of primary drug resistance to isoniazid was known to be less than 4% and was either stable or declining, therapy with two and three drug regimens was considered adequate. If community rates of INH resistance are currently less than 4%, an initial treatment regimen with less than four drugs may be considered. Streptomycin is also indicated for therapy of tuberculosis when one or more of the above drugs is contraindicated because of toxicity or intolerance. The management of tuberculosis has become more complex as a consequence of increasing rates of drug resistance and concomitant HIV infection. Additional consultation from experts in the treatment of tuberculosis may be desirable in those settings. Non-tuberculosis infections: The use of streptomycin should be limited to the treatment of infections caused by bacteria which have been shown to be susceptible to the antibacterial effects of streptomycin and which are not amenable to therapy with less potentially toxic agents. Yersinia pestis (plague), Francisella tularensis (tularemia), Brucella , Calymmatobacterium granulomatis (donovanosis, granuloma inguinale), H. ducreyi (chancroid), H. influenzae (in respiratory, endocardial, and meningeal infections-concomitantly with another antibacterial agent), K. pneumoniae pneumonia (concomitantly with another antibacterial agent), E.coli, Proteus, A. aerogenes, K. pneumoniae, and Enterococcus faecalis in urinary tract infections, Streptococcus viridans , Enterococcus faecalis (in endocardial infections - concomitantly with penicillin), Gram-negative bacillary bacteremia (concomitantly with another antibacterial agent). To reduce the development of drug-resistant bacteria and maintain the effectiveness of streptomycin and other antibacterial drugs, streptomycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:320277b2-2cb5-4677-8198-8c34c6757a6f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17076 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:a862114d-72f9-4bde-8b55-e7feb118fc51"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a4b85e82-4561-476f-9dc3-d07ff958cbed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Streptomycin is indicated for the treatment of individuals with moderate to severe infections caused by susceptibile strains of microorganisms in the specific conditions listed below: Mycobacterium tuberculosis: The Advisory Council for the Elimination of Tuberculosis, the American Thoracic Society, and the Center for Disease Control recommend that either streptomycin or ethambutol be added as a fourth drug in a regimen containing isoniazid (INH), rifampin and pyrazinamide for initial treatment of tuberculosis unless the likelihood of INH or rifampin resistance is very low. The need for a fourth drug should be reassessed when the results of susceptibility testing are known. In the past when the national rate of primary drug resistance to isoniazid was known to be less than 4% and was either stable or declining, therapy with two and three drug regimens was considered adequate. If community rates of INH resistance are currently less than 4%, an initial treatment regimen with less than four drugs may be considered. Streptomycin is also indicated for therapy of tuberculosis when one or more of the above drugs is contraindicated because of toxicity or intolerance. The management of tuberculosis has become more complex as a consequence of increasing rates of drug resistance and concomitant HIV infection. Additional consultation from experts in the treatment of tuberculosis may be desirable in those settings. Non-tuberculosis infections: The use of streptomycin should be limited to the treatment of infections caused by bacteria which have been shown to be susceptible to the antibacterial effects of streptomycin and which are not amenable to therapy with less potentially toxic agents. Yersinia pestis (plague), Francisella tularensis (tularemia), Brucella , Calymmatobacterium granulomatis (donovanosis, granuloma inguinale), H. ducreyi (chancroid), H. influenzae (in respiratory, endocardial, and meningeal infections-concomitantly with another antibacterial agent), K. pneumoniae pneumonia (concomitantly with another antibacterial agent), E.coli, Proteus, A. aerogenes, K. pneumoniae, and Enterococcus faecalis in urinary tract infections, Streptococcus viridans , Enterococcus faecalis (in endocardial infections - concomitantly with penicillin), Gram-negative bacillary bacteremia (concomitantly with another antibacterial agent). To reduce the development of drug-resistant bacteria and maintain the effectiveness of streptomycin and other antibacterial drugs, streptomycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:c65f8f0c-d5af-4f63-9389-e9459c17f345 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17076 biolink:treats UMLS:C0744471 PMID:41385096 "[{""id"":""uuid:f897bb31-7038-4449-b708-9602be0a685c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3c3e79fc-fd09-4137-ad6e-0bcea2e7a33c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Streptomycin is indicated for the treatment of individuals with moderate to severe infections caused by susceptibile strains of microorganisms in the specific conditions listed below: Mycobacterium tuberculosis: The Advisory Council for the Elimination of Tuberculosis, the American Thoracic Society, and the Center for Disease Control recommend that either streptomycin or ethambutol be added as a fourth drug in a regimen containing isoniazid (INH), rifampin and pyrazinamide for initial treatment of tuberculosis unless the likelihood of INH or rifampin resistance is very low. The need for a fourth drug should be reassessed when the results of susceptibility testing are known. In the past when the national rate of primary drug resistance to isoniazid was known to be less than 4% and was either stable or declining, therapy with two and three drug regimens was considered adequate. If community rates of INH resistance are currently less than 4%, an initial treatment regimen with less than four drugs may be considered. Streptomycin is also indicated for therapy of tuberculosis when one or more of the above drugs is contraindicated because of toxicity or intolerance. The management of tuberculosis has become more complex as a consequence of increasing rates of drug resistance and concomitant HIV infection. Additional consultation from experts in the treatment of tuberculosis may be desirable in those settings. Non-tuberculosis infections: The use of streptomycin should be limited to the treatment of infections caused by bacteria which have been shown to be susceptible to the antibacterial effects of streptomycin and which are not amenable to therapy with less potentially toxic agents. Yersinia pestis (plague), Francisella tularensis (tularemia), Brucella , Calymmatobacterium granulomatis (donovanosis, granuloma inguinale), H. ducreyi (chancroid), H. influenzae (in respiratory, endocardial, and meningeal infections-concomitantly with another antibacterial agent), K. pneumoniae pneumonia (concomitantly with another antibacterial agent), E.coli, Proteus, A. aerogenes, K. pneumoniae, and Enterococcus faecalis in urinary tract infections, Streptococcus viridans , Enterococcus faecalis (in endocardial infections - concomitantly with penicillin), Gram-negative bacillary bacteremia (concomitantly with another antibacterial agent). To reduce the development of drug-resistant bacteria and maintain the effectiveness of streptomycin and other antibacterial drugs, streptomycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:461e3c0d-b263-4a0e-9d41-f988c59231b4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:O43472U9X8 biolink:treats MONDO:0004948 PMID:41385096 "[{""id"":""uuid:8bfa8f91-d376-44f4-a9b6-9a322526179a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1a4a132d-3806-4af1-b856-ce5aee0d02ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:86a0d9b7-5473-4e35-ab28-2dde14b7a184"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/gazyvaro""]},{""id"":""uuid:e6c85f1f-f0d6-4917-b573-b2f4149b2500"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] GAZYVA is a CD20-directed cytolytic antibody indicated: in combination with chlorambucil, for the treatment of patients with previously untreated chronic lymphocytic leukemia. ( 1 , 14 ) in combination with bendamustine followed by GAZYVA monotherapy, for the treatment of patients with follicular lymphoma who relapsed after, or are refractory to, a rituximab-containing regimen. ( 1 , 14 ) in combination with chemotherapy followed by GAZYVA monotherapy in patients achieving at least a partial remission, for the treatment of adult patients with previously untreated stage II bulky, III or IV follicular lymphoma. ( 1 , 14 )|[EMA] Chronic Lymphocytic Leukaemia (CLL)Gazyvaro in combination with chlorambucil is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) and with comorbidities making them unsuitable for full-dose fludarabine based therapy (see section 5.1).Follicular Lymphoma (FL)Gazyvaro in combination with chemotherapy, followed by Gazyvaro maintenance therapy in patients achieving a response, is indicated for the treatment of patients with previously untreated advanced follicular lymphoma.Gazyvaro in combination with bendamustine followed by Gazyvaro maintenance is indicated for the treatment of patients with follicular lymphoma (FL) who did not respond or who progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen.|[PMDA] A drug with a new indication and a new dosage for the treatment of CD20-positive chronic lymphocytic leukemia (including small lymphocytic lymphoma). uuid:91331436-e0d1-449c-843e-c913fa8d54a2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:O43472U9X8 biolink:treats MONDO:0018906 PMID:41385096 "[{""id"":""uuid:9d82ed9b-c7b2-4143-b427-6e4b24a7d7d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a17d5ba4-df19-41a9-b3dd-3272155bc958"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:31b0ba5d-c85a-41ba-8f22-236ca923f4ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/gazyvaro""]},{""id"":""uuid:9ff0baeb-2da0-46d4-b16a-8b07a383b024"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] GAZYVA is a CD20-directed cytolytic antibody indicated: in combination with chlorambucil, for the treatment of patients with previously untreated chronic lymphocytic leukemia. ( 1 , 14 ) in combination with bendamustine followed by GAZYVA monotherapy, for the treatment of patients with follicular lymphoma who relapsed after, or are refractory to, a rituximab-containing regimen. ( 1 , 14 ) in combination with chemotherapy followed by GAZYVA monotherapy in patients achieving at least a partial remission, for the treatment of adult patients with previously untreated stage II bulky, III or IV follicular lymphoma. ( 1 , 14 )|[EMA] Chronic Lymphocytic Leukaemia (CLL)Gazyvaro in combination with chlorambucil is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) and with comorbidities making them unsuitable for full-dose fludarabine based therapy (see section 5.1).Follicular Lymphoma (FL)Gazyvaro in combination with chemotherapy, followed by Gazyvaro maintenance therapy in patients achieving a response, is indicated for the treatment of patients with previously untreated advanced follicular lymphoma.Gazyvaro in combination with bendamustine followed by Gazyvaro maintenance is indicated for the treatment of patients with follicular lymphoma (FL) who did not respond or who progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen.|[PMDA] A drug with a new active ingredient indicated for the treatment of CD20-positive follicular lymphoma. uuid:2623b83b-ec96-42f4-bc65-97628f6f73fb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7478 biolink:treats MONDO:0043537 PMID:41385096 "[{""id"":""uuid:183059b8-b2d1-4603-bacb-e99d94e4dd11"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a2b508c9-88f2-48c7-81b7-d4c77ab2f527"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Naratriptan tablets are indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use: Use only if a clear diagnosis of migraine has been established. If a patient has no response to the first migraine attack treated with naratriptan tablets reconsider the diagnosis of migraine before naratriptan tablets are administered to treat any subsequent attacks. Naratriptan tablets are not indicated for the prevention of migraine attacks. Safety and effectiveness of naratriptan tablets have not been established for cluster headache. uuid:b5478beb-0ca8-4874-80b6-149874ad1028 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9241 biolink:treats MONDO:0006652 PMID:41385096 "[{""id"":""uuid:af6ef075-b297-4881-a47b-828f9ada5c4e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:91dd5a5b-6d5c-490b-bd76-d9f2b1519c94"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Spironolactone is an aldosterone antagonist indicated for: The treatment of NYHA Class III-IV heart failure and reduced ejection fraction to increase survival, manage edema, and to reduce the need for hospitalization for heart failure (1.1) . Use as an add-on therapy for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions (1.2) . The management of edema in adult patients who are cirrhotic when edema is not responsive to fluid and sodium restrictions and in the setting of nephrotic syndrome when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics produce an inadequate response (1.3) . Treatment of primary hyperaldosternism for: (1.4) Short-term preoperative treatment Long-term maintenance for patients with discrete aldosterone-producing adrenal adenomas who are not candidates for surgery and patients with bilateral micro or macronodular adrenal hyperplasia uuid:93b5ea1a-fe05-46e0-99d7-ef889e68b95d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135925 biolink:treats MONDO:0007743 PMID:41385096 "[{""id"":""uuid:cc1b90bc-9013-40b6-a9c6-d13424cc2917"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c67ed027-814a-40f3-bc5e-73277344e76e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lisdexamfetamine dimesylate capsules are indicated for the treatment of: Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older [see Clinical Studies (14.1)] Moderate to severe binge eating disorder (BED) in adults [see Clinical Studies (14.2)]. Limitations of Use: Pediatric patients with ADHD younger than 6 years of age experienced more long-term weight loss than patients 6 years and older [see Use in Specific Populations (8.4)]. Lisdexamfetamine dimesylate capsules are not indicated or recommended for weight loss. Use of other sympathomimetic drugs for weight loss has been associated with serious cardiovascular adverse events. The safety and effectiveness of lisdexamfetamine dimesylate capsules for the treatment of obesity have not been established [see Warnings and Precautions (5.2)]. uuid:abb0e692-096e-47a5-8286-65dc6faf8166 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135925 biolink:treats MONDO:0005582 PMID:41385096 "[{""id"":""uuid:73ea6f68-cc29-4e19-8e47-3217149f0af7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:add606e1-d259-46b5-95cc-06308e2e0a76"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lisdexamfetamine dimesylate capsules are indicated for the treatment of: Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older [see Clinical Studies (14.1)] Moderate to severe binge eating disorder (BED) in adults [see Clinical Studies (14.2)]. Limitations of Use: Pediatric patients with ADHD younger than 6 years of age experienced more long-term weight loss than patients 6 years and older [see Use in Specific Populations (8.4)]. Lisdexamfetamine dimesylate capsules are not indicated or recommended for weight loss. Use of other sympathomimetic drugs for weight loss has been associated with serious cardiovascular adverse events. The safety and effectiveness of lisdexamfetamine dimesylate capsules for the treatment of obesity have not been established [see Warnings and Precautions (5.2)]. uuid:72c9715c-4c7d-4132-b7df-28ff22fdd405 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1375946 biolink:treats MONDO:0006791 PMID:41385096 "[{""id"":""uuid:2143cf97-c292-47e9-845d-ea3f73a752ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eb24f526-b10b-4146-a367-18b4889f288a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Doxylamine succinate and pyridoxine hydrochloride delayed-release tablets are indicated for the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management. Limitations of Use Doxylamine succinate and pyridoxine hydrochloride delayed-release tablet has not been studied in women with hyperemesis gravidarum. uuid:b55cd25c-1c1c-4320-bd8f-34377a8c175d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135925 biolink:treats MONDO:0005302 PMID:41385096 "[{""id"":""uuid:954b7b54-c362-4326-9bfd-ef2f75c80dfa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5d22f1b6-86ec-4b3b-af9b-489e0055ff3c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:53a12a52-7be1-4d1d-ab07-38cc04eabbc5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lisdexamfetamine dimesylate chewable tablets are indicated for the treatment of: Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older [see Clinical Studies (14.1)] Moderate to severe binge eating disorder (BED) in adults [see Clinical Studies (14.2)]. Limitations of Use: Pediatric patients with ADHD younger than 6 years of age experienced more long-term weight loss than patients 6 years and older [see Use in Specific Populations (8.4)]. Lisdexamfetamine dimesylate are not indicated or recommended for weight loss. Use of other sympathomimetic drugs for weight loss has been associated with serious cardiovascular adverse events. The safety and effectiveness of lisdexamfetamine dimesylate for the treatment of obesity have not been established [see Warnings and Precautions (5.2)]|[PMDA] Drugs with a new active ingredient indicated for the treatment of pediatric attention deficit/hyperactivity disorder (AD/HD). uuid:a34915b5-d56d-4da1-b7df-0d4dd9caacef biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6942 biolink:treats MONDO:0006846 PMID:41385096 "[{""id"":""uuid:5b20f456-c6b7-4a6b-8387-5b0888371cd7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:51cb3046-c9fd-4918-a796-817a3fe49a01"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Because of the potential for serious adverse effects, minoxidil tablets are indicated only in the treatment of hypertension that is symptomatic or associated with target organ damage and is not manageable with maximum therapeutic doses of a diuretic plus two other antihypertensive drugs. At the present time use in milder degrees of hypertension is not recommended because the benefit-risk relationship in such patients has not been defined. Minoxidil reduced supine diastolic blood pressure by 20 mmHg or to 90 mmHg or less in approximately 75% of patients, most of who had hypertension that could not be controlled by other drugs. uuid:c43c5101-4918-4d00-a628-ced1cdedfc75 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17996 biolink:treats MONDO:0003019 PMID:41385096 "[{""id"":""uuid:1c544ff9-64a0-4787-84e7-5510617e8b09"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:605256da-caaa-4f62-9162-4c21c2d13e57"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Potassium Chloride is indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient. uuid:fac10857-c46a-482f-9123-deec902c372b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17996 biolink:treats HP:0200114 PMID:41385096 "[{""id"":""uuid:92ce759f-8015-4969-b165-de051199303e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6c24041d-f005-4a93-8e76-04e190ba7422"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Potassium Chloride is indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient. uuid:fc233066-d0ef-4233-8aa5-fc7fe876cac3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:38545 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:13908549-6b90-43ad-8c18-bbe25d12078c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:76bd1c60-5f45-496b-8355-33b0a2527665"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Rosuvastatin tablets are indicated: To reduce the risk of stroke, myocardial infarction, and arterial revascularization procedures in adults without established coronary heart disease who are at increased risk of cardiovascular (CV) disease based on age, hsCRP ≥2 mg/L, and at least one additional CV risk factor. As an adjunct to diet to: o Reduce LDL-C in adults with primary hyperlipidemia. o Reduce low-density lipoprotein cholesterol (LDL-C) and slow the progression of atherosclerosis in adults. o Reduce LDL-C in adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to other LDL-C-lowering therapies, or alone if such treatments are unavailable, to reduce LDL-C in adults and pediatric patients aged 7 years and older with homozygous familial hypercholesterolemia (HoFH). As an adjunct to diet for the treatment of adults with: o Primary dysbetalipoproteinemia. o Hypertriglyceridemia. uuid:52223922-fd86-4a62-999f-c43146f78718 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:38545 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:5b1e0987-6ef5-4621-acaf-4a7b7d511533"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8231c056-5088-4cf5-b936-4e94cfc94882"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Rosuvastatin tablets are indicated: To reduce the risk of stroke, myocardial infarction, and arterial revascularization procedures in adults without established coronary heart disease who are at increased risk of cardiovascular (CV) disease based on age, hsCRP ≥2 mg/L, and at least one additional CV risk factor. As an adjunct to diet to: o Reduce LDL-C in adults with primary hyperlipidemia. o Reduce low-density lipoprotein cholesterol (LDL-C) and slow the progression of atherosclerosis in adults. o Reduce LDL-C in adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to other LDL-C-lowering therapies, or alone if such treatments are unavailable, to reduce LDL-C in adults and pediatric patients aged 7 years and older with homozygous familial hypercholesterolemia (HoFH). As an adjunct to diet for the treatment of adults with: o Primary dysbetalipoproteinemia. o Hypertriglyceridemia. uuid:1d66a03a-cd46-40fd-820e-e3a3b4ae56d5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6076 biolink:treats UMLS:C0919659 PMID:41385096 "[{""id"":""uuid:745ac5d1-22d3-450d-a46b-34ac13832100"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0e05cee9-4bde-468f-8437-be803445fced"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:8bce19b1-28de-45cf-876f-2fe5eb0541f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Itraconazole oral solution is indicated for the treatment of oropharyngeal and esophageal candidiasis. (See CLINICAL PHARMACOLOGY: Special Populations , WARNINGS , and ADVERSE REACTIONS: Post-marketing Experience for more information .)|[PMDA] Addition of a new dosage form and dosage for treatment of oropharyngeal candidiasis and oesophageal candidiasis. uuid:3f177cf2-30bd-4376-b28f-1725fac79f4e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6076 biolink:treats MONDO:0001648 PMID:41385096 "[{""id"":""uuid:711d5941-c299-4753-a84a-b0cf16f020c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1fce25e0-4ea3-40e9-8dcf-3d8fe3425631"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:a6717c82-886d-48f2-98e5-eb4f5ad26aef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Itraconazole oral solution is indicated for the treatment of oropharyngeal and esophageal candidiasis. (See CLINICAL PHARMACOLOGY: Special Populations , WARNINGS , and ADVERSE REACTIONS: Post-marketing Experience for more information .)|[PMDA] Addition of a new dosage form and dosage for treatment of oropharyngeal candidiasis and oesophageal candidiasis. uuid:ed5dd72d-3e8f-42cb-aa07-12774ea1c3e0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats MONDO:0024313 PMID:41385096 "[{""id"":""uuid:fe702e41-7187-4f1b-8c02-eebc0041b755"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9a990928-b546-4c75-a609-3518d02c6b5f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of gentamicin injection and other antibacterial drugs, gentamicin injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Gentamicin injection is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: Pseudomonas aeruginosa, Proteus species (indole-positive and indole-negative), Escherichia coli, Klebsiella-Enterobacter- Serratia species, Citrobacter species and Staphylococcus species (coagulase-positive and coagulase-negative). Clinical studies have shown gentamicin injection to be effective in bacterial neonatal sepsis; bacterial septicemia and serious bacterial infections of the central nervous system (meningitis), urinary tract, respiratory tract, gastrointestinal tract (including peritonitis), skin, bone and soft tissue (including burns). Aminoglycosides, including gentamicin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are susceptible to these antibiotics and are not susceptible to antibiotics having less potential for toxicity. Specimens for bacterial culture should be obtained to isolate and identify causative organisms and to determine their susceptibility to gentamicin. Gentamicin injection may be considered as initial therapy in suspected or confirmed gram-negative infections, and therapy may be instituted before obtaining results of susceptibility testing. The decision to continue therapy with this drug should be based on the results of susceptibility tests, the severity of the infection and the important additional concepts contained in the BOXED WARNINGS . If the causative organisms are resistant to gentamicin, other appropriate therapy should be instituted. In serious infections when the causative organisms are unknown, gentamicin injection may be administered as initial therapy in conjunction with a penicillin-type or cephalosporin-type drug before obtaining results of susceptibility testing. If anaerobic organisms are suspected as etiologic agents, consideration should be given to using other suitable antimicrobial therapy in conjunction with gentamicin. Following identification of the organism and its susceptibility, appropriate antibiotic therapy should then be continued. Gentamicin injection has been used effectively in combination with carbenicillin for the treatment of life-threatening infections caused by Pseudomonas aeruginosa. It has also been found effective when used in conjunction with a penicillin-type drug for treatment of endocarditis caused by group D streptococci. Gentamicin injection has also been shown to be effective in the treatment of serious staphylococcal infections. While not the antibiotic of first choice, gentamicin injection may be considered when penicillins or other less potentially toxic drugs are contraindicated and bacterial susceptibility tests and clinical judgment indicate its use. It may also be considered in mixed infections caused by susceptible strains of staphylococci and gram-negative organisms. In the neonate with suspected bacterial sepsis or staphylococcal pneumonia, a penicillin- type drug is also usually indicated as concomitant therapy with gentamicin. uuid:4a1d8328-22cb-4fa5-bf4f-f2f19e7e4871 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats DOID:50360 PMID:41385096 "[{""id"":""uuid:f8e09214-f72c-46f6-a71e-a851a2dec24f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c847091a-64db-4276-91b7-299707878b39"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of gentamicin injection and other antibacterial drugs, gentamicin injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Gentamicin injection is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: Pseudomonas aeruginosa, Proteus species (indole-positive and indole-negative), Escherichia coli, Klebsiella-Enterobacter- Serratia species, Citrobacter species and Staphylococcus species (coagulase-positive and coagulase-negative). Clinical studies have shown gentamicin injection to be effective in bacterial neonatal sepsis; bacterial septicemia and serious bacterial infections of the central nervous system (meningitis), urinary tract, respiratory tract, gastrointestinal tract (including peritonitis), skin, bone and soft tissue (including burns). Aminoglycosides, including gentamicin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are susceptible to these antibiotics and are not susceptible to antibiotics having less potential for toxicity. Specimens for bacterial culture should be obtained to isolate and identify causative organisms and to determine their susceptibility to gentamicin. Gentamicin injection may be considered as initial therapy in suspected or confirmed gram-negative infections, and therapy may be instituted before obtaining results of susceptibility testing. The decision to continue therapy with this drug should be based on the results of susceptibility tests, the severity of the infection and the important additional concepts contained in the BOXED WARNINGS . If the causative organisms are resistant to gentamicin, other appropriate therapy should be instituted. In serious infections when the causative organisms are unknown, gentamicin injection may be administered as initial therapy in conjunction with a penicillin-type or cephalosporin-type drug before obtaining results of susceptibility testing. If anaerobic organisms are suspected as etiologic agents, consideration should be given to using other suitable antimicrobial therapy in conjunction with gentamicin. Following identification of the organism and its susceptibility, appropriate antibiotic therapy should then be continued. Gentamicin injection has been used effectively in combination with carbenicillin for the treatment of life-threatening infections caused by Pseudomonas aeruginosa. It has also been found effective when used in conjunction with a penicillin-type drug for treatment of endocarditis caused by group D streptococci. Gentamicin injection has also been shown to be effective in the treatment of serious staphylococcal infections. While not the antibiotic of first choice, gentamicin injection may be considered when penicillins or other less potentially toxic drugs are contraindicated and bacterial susceptibility tests and clinical judgment indicate its use. It may also be considered in mixed infections caused by susceptible strains of staphylococci and gram-negative organisms. In the neonate with suspected bacterial sepsis or staphylococcal pneumonia, a penicillin- type drug is also usually indicated as concomitant therapy with gentamicin. uuid:e6f79a8e-25de-43ad-9d78-3882fec29a47 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60311 biolink:treats MONDO:0006982 PMID:41385096 "[{""id"":""uuid:c45baabb-8f6e-47bc-931d-c45afd233170"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ce46bcc7-7aee-41f6-af84-74b728c82fd9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Armour® Thyroid tablets are indicated: 1. As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (See WARNINGS ). 2. As pituitary TSH suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto’s), multinodular goiter, and in the management of thyroid cancer. CONTRAINDICATIONS Thyroid hormone preparations are generally contraindicated in patients with diagnosed but as yet uncorrected adrenal cortical insufficiency, untreated thyrotoxicosis, and apparent hypersensitivity to any of their active or extraneous constituents. There is no well-documented evidence from the literature, however, of true allergic or idiosyncratic reactions to thyroid hormone. PUBCHEM.COMPOUND:53462828 uuid:0dd3a51d-3c6f-435e-846c-7cb204d4ca50 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60311 biolink:treats MONDO:0000004 PMID:41385096 "[{""id"":""uuid:cdf960e0-2b58-4660-8ed8-dffb2f4f21a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:86d84a7b-87e0-4b24-8caa-b076a66e3da6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Armour® Thyroid tablets are indicated: 1. As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (See WARNINGS ). 2. As pituitary TSH suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto’s), multinodular goiter, and in the management of thyroid cancer. CONTRAINDICATIONS Thyroid hormone preparations are generally contraindicated in patients with diagnosed but as yet uncorrected adrenal cortical insufficiency, untreated thyrotoxicosis, and apparent hypersensitivity to any of their active or extraneous constituents. There is no well-documented evidence from the literature, however, of true allergic or idiosyncratic reactions to thyroid hormone. PUBCHEM.COMPOUND:53462828 uuid:3c2c307b-6ade-4bb6-abdc-71d8bae79838 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60311 biolink:treats MONDO:0010138 PMID:41385096 "[{""id"":""uuid:17e2ad96-742a-49a4-804d-2b55ffe00e76"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e98287ee-d81c-4083-af19-598ab65bcb86"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Armour® Thyroid tablets are indicated: 1. As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (See WARNINGS ). 2. As pituitary TSH suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto’s), multinodular goiter, and in the management of thyroid cancer. CONTRAINDICATIONS Thyroid hormone preparations are generally contraindicated in patients with diagnosed but as yet uncorrected adrenal cortical insufficiency, untreated thyrotoxicosis, and apparent hypersensitivity to any of their active or extraneous constituents. There is no well-documented evidence from the literature, however, of true allergic or idiosyncratic reactions to thyroid hormone. PUBCHEM.COMPOUND:53462828 uuid:ba7c34a0-f432-4481-bae8-9f5fe513a93c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50861 biolink:treats MONDO:0015924 PMID:41385096 "[{""id"":""uuid:ca5b9a47-8958-4cd2-99aa-32629a666102"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ae2c4856-06d4-464e-81ea-78af0335445e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:5f2da3b3-6fef-497b-b62c-0175a352cdf1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Treprostinil injection is a prostacyclin mimetic indicated for: • Treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to diminish symptoms associated with exercise. Studies establishing effectiveness included patients with NYHA Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (58%), PAH associated with congenital systemic-to-pulmonary shunts (23%), or PAH associated with connective tissue diseases (19%). ( 1.1 ) • Patients who require transition from epoprostenol, to reduce the rate of clinical deterioration. The risks and benefits of each drug should be carefully considered prior to transition. ( 1.2 )|[PMDA] A drug with a new route of administration indicated for the treatment of pulmonary arterial hypertension. uuid:cc7b0a5c-331e-4736-a75d-becb6b180194 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50861 biolink:treats MONDO:0017147 PMID:41385096 "[{""id"":""uuid:15842de7-e38f-4bba-b6a8-f3a181652ae5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a9826839-256e-48cb-8524-b4a67abc1118"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Treprostinil injection is a prostacyclin mimetic indicated for: • Treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to diminish symptoms associated with exercise. Studies establishing effectiveness included patients with NYHA Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (58%), PAH associated with congenital systemic-to-pulmonary shunts (23%), or PAH associated with connective tissue diseases (19%). ( 1.1 ) • Patients who require transition from epoprostenol, to reduce the rate of clinical deterioration. The risks and benefits of each drug should be carefully considered prior to transition. ( 1.2 ) uuid:81dc841b-be39-416b-9a8f-b49c2088957f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50861 biolink:treats MONDO:0017148 PMID:41385096 "[{""id"":""uuid:914038d9-d52f-4139-9772-17e92a787b56"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d21a2ef2-b57b-487d-a46f-936c4fe2c962"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Treprostinil injection is a prostacyclin mimetic indicated for: • Treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to diminish symptoms associated with exercise. Studies establishing effectiveness included patients with NYHA Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (58%), PAH associated with congenital systemic-to-pulmonary shunts (23%), or PAH associated with connective tissue diseases (19%). ( 1.1 ) • Patients who require transition from epoprostenol, to reduce the rate of clinical deterioration. The risks and benefits of each drug should be carefully considered prior to transition. ( 1.2 ) uuid:ebf2070a-a91a-48f4-907b-a0f2a707efae biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3181 biolink:treats MONDO:0019933 PMID:41385096 "[{""id"":""uuid:11675811-7336-4183-8048-70104c133d13"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:df6e68b6-6699-480c-99c5-242de25e273c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Hyperprolactinemia-Associated Dysfunctions Bromocriptine mesylate capsules are indicated for the treatment of dysfunctions associated with hyperprolactinemia including amenorrhea with or without galactorrhea, infertility or hypogonadism. Bromocriptine treatment is indicated in patients with prolactin-secreting adenomas, which may be the basic underlying endocrinopathy contributing to the above clinical presentations. Reduction in tumor size has been demonstrated in both male and female patients with macroadenomas. In cases where adenectomy is elected, a course of bromocriptine mesylate capsule therapy may be used to reduce the tumor mass prior to surgery. Acromegaly Bromocriptine mesylate capsule therapy is indicated in the treatment of acromegaly. Bromocriptine mesylate capsule therapy, alone or as adjunctive therapy with pituitary irradiation or surgery, reduces serum growth hormone by 50% or more in approximately ½ of patients treated, although not usually to normal levels. Since the effects of external pituitary radiation may not become maximal for several years, adjunctive therapy with bromocriptine mesylate capsule offers potential benefit before the effects of irradiation are manifested. Parkinson's Disease Bromocriptine mesylate capsules are indicated in the treatment of the signs and symptoms of idiopathic or postencephalitic Parkinson's disease. As adjunctive treatment to levodopa (alone or with a peripheral decarboxylase inhibitor), bromocriptine mesylate capsule therapy may provide additional therapeutic benefits in those patients who are currently maintained on optimal dosages of levodopa, those who are beginning to deteriorate (develop tolerance) to levodopa therapy, and those who are experiencing ""end of dose failure"" on levodopa therapy. Bromocriptine mesylate capsule therapy may permit a reduction of the maintenance dose of levodopa and, thus may ameliorate the occurrence and/or severity of adverse reactions associated with long-term levodopa therapy such as abnormal involuntary movements (e.g., dyskinesias) and the marked swings in motor function (""on-off"" phenomenon). Continued efficacy of bromocriptine mesylate capsule therapy during treatment of more than 2 years has not been established. Data are insufficient to evaluate potential benefit from treating newly diagnosed Parkinson's disease with bromocriptine mesylate capsules. Studies have shown, however, significantly more adverse reactions (notably nausea, hallucinations, confusion and hypotension) in bromocriptine-treated patients than in levodopa/carbidopa-treated patients. Patients unresponsive to levodopa are poor candidates for bromocriptine mesylate capsule therapy." uuid:e5106cd6-602f-474c-bd6e-1dfbb0158b8f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3181 biolink:treats MONDO:0005180 PMID:41385096 "[{""id"":""uuid:267c71a3-71e2-4e22-8438-ea4af5e2c2fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f9207635-45b2-47a9-9027-9e6830ac7ff8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Hyperprolactinemia-Associated Dysfunctions Bromocriptine mesylate capsules are indicated for the treatment of dysfunctions associated with hyperprolactinemia including amenorrhea with or without galactorrhea, infertility or hypogonadism. Bromocriptine treatment is indicated in patients with prolactin-secreting adenomas, which may be the basic underlying endocrinopathy contributing to the above clinical presentations. Reduction in tumor size has been demonstrated in both male and female patients with macroadenomas. In cases where adenectomy is elected, a course of bromocriptine mesylate capsule therapy may be used to reduce the tumor mass prior to surgery. Acromegaly Bromocriptine mesylate capsule therapy is indicated in the treatment of acromegaly. Bromocriptine mesylate capsule therapy, alone or as adjunctive therapy with pituitary irradiation or surgery, reduces serum growth hormone by 50% or more in approximately ½ of patients treated, although not usually to normal levels. Since the effects of external pituitary radiation may not become maximal for several years, adjunctive therapy with bromocriptine mesylate capsule offers potential benefit before the effects of irradiation are manifested. Parkinson's Disease Bromocriptine mesylate capsules are indicated in the treatment of the signs and symptoms of idiopathic or postencephalitic Parkinson's disease. As adjunctive treatment to levodopa (alone or with a peripheral decarboxylase inhibitor), bromocriptine mesylate capsule therapy may provide additional therapeutic benefits in those patients who are currently maintained on optimal dosages of levodopa, those who are beginning to deteriorate (develop tolerance) to levodopa therapy, and those who are experiencing ""end of dose failure"" on levodopa therapy. Bromocriptine mesylate capsule therapy may permit a reduction of the maintenance dose of levodopa and, thus may ameliorate the occurrence and/or severity of adverse reactions associated with long-term levodopa therapy such as abnormal involuntary movements (e.g., dyskinesias) and the marked swings in motor function (""on-off"" phenomenon). Continued efficacy of bromocriptine mesylate capsule therapy during treatment of more than 2 years has not been established. Data are insufficient to evaluate potential benefit from treating newly diagnosed Parkinson's disease with bromocriptine mesylate capsules. Studies have shown, however, significantly more adverse reactions (notably nausea, hallucinations, confusion and hypotension) in bromocriptine-treated patients than in levodopa/carbidopa-treated patients. Patients unresponsive to levodopa are poor candidates for bromocriptine mesylate capsule therapy." uuid:79588129-ab11-45a5-a2a6-b7a29219da32 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:284780 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:182a6ec8-ed06-4905-9e82-e23e488094fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d9345765-80d3-4205-93a7-d3a1ba9c21cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Telmisartan and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the classes to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with telmisartan and hydrochlorothiazide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy [see Clinical Studies (14)]. Telmisartan and hydrochlorothiazide tablets are not indicated for initial therapy for the treatment of hypertension [see Dosage and Administration (2.1)]. Telmisartan and hydrochlorothiazide tablets may be used alone or in combination with other antihypertensive agents. uuid:35c0dcd4-999c-4d95-9a7c-192056791222 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:284780 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:48bdf017-60a1-404a-8512-508c03e73f44"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ac6865cc-9160-43fe-9ec1-28334f1b7e07"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Telmisartan and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the classes to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with telmisartan and hydrochlorothiazide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy [see Clinical Studies (14)]. Telmisartan and hydrochlorothiazide tablets are not indicated for initial therapy for the treatment of hypertension [see Dosage and Administration (2.1)]. Telmisartan and hydrochlorothiazide tablets may be used alone or in combination with other antihypertensive agents. uuid:7b9ad397-b5b4-4ef5-a5e0-590bbe10108e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:284780 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:c93d4038-61c4-4b7d-a722-6ef211f8d87b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d2e3e964-f372-410a-9306-4dee1f8ed212"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Telmisartan and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the classes to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with telmisartan and hydrochlorothiazide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy [see Clinical Studies (14)]. Telmisartan and hydrochlorothiazide tablets are not indicated for initial therapy for the treatment of hypertension [see Dosage and Administration (2.1)]. Telmisartan and hydrochlorothiazide tablets may be used alone or in combination with other antihypertensive agents. uuid:a8f51cf2-2069-419c-8428-e2f5a27941f7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:284780 biolink:treats MONDO:0005016 PMID:41385096 "[{""id"":""uuid:5c17efd2-51fc-448c-94ab-9984479cea1f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:012506cf-04c1-45c6-8f79-f864faa420ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Telmisartan and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the classes to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with telmisartan and hydrochlorothiazide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy [see Clinical Studies (14)]. Telmisartan and hydrochlorothiazide tablets are not indicated for initial therapy for the treatment of hypertension [see Dosage and Administration (2.1)]. Telmisartan and hydrochlorothiazide tablets may be used alone or in combination with other antihypertensive agents. uuid:0a069363-8b8f-4955-b849-5a683c3aa9c9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16094 biolink:treats MONDO:0011438 PMID:41385096 "[{""id"":""uuid:26b00094-32ef-4337-96a6-ed2d90bb9793"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:53bd7afa-58a0-4662-9d19-b3e3b8d7a7e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] This product is indicated for use in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis. uuid:ba90e62c-e4cc-421a-a21c-9a5a30cf4b63 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16094 biolink:treats MONDO:0006604 PMID:41385096 "[{""id"":""uuid:3fa2529f-11a2-4a6c-b43d-7bd7f9c9c831"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2c12b2e6-d7fa-46c0-a7ee-946533d68016"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] This product is indicated for use in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis. uuid:1b369a32-384b-449c-9482-b4f0613eba02 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16094 biolink:treats MONDO:0006608 PMID:41385096 "[{""id"":""uuid:a06f558a-b272-405c-955d-e5dd92fe5ffd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ee46130c-9a92-4f39-88aa-5c31a2f3e783"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] This product is indicated for use in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis. uuid:37ede0ff-4abb-4af3-be4d-be5c267ac149 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0006050 biolink:treats UMLS:C1996997 PMID:41385096 "[{""id"":""uuid:c00987cd-929e-4aed-b39b-f831c74e0b75"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3fbf5eb9-5b47-41d7-94a9-25d9ce4d16b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DYSPORT is an acetylcholine release inhibitor and a neuromuscular blocking agent indicated for: The treatment of cervical dystonia in adults ( 1.1 ) The temporary improvement in the appearance of moderate to severe glabellar lines associated with procerus and corrugator muscle activity in adults < 65 years of age ( 1.2 ) The treatment of spasticity in patients 2 years of age and older ( 1.3 ) DRUGBANK:DB00083 uuid:e9b60d0e-cc45-4218-b0e8-25da3ad36962 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0006050 biolink:treats HP:0001257 PMID:41385096 "[{""id"":""uuid:f61131fb-b5a7-4bfd-afd8-f497374660b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e59a4b7c-e332-47d1-a31c-e59f8d026efd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:6ad9c902-2171-4d4d-9dd6-204fc8f4d0ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DYSPORT is an acetylcholine release inhibitor and a neuromuscular blocking agent indicated for: The treatment of cervical dystonia in adults ( 1.1 ) The temporary improvement in the appearance of moderate to severe glabellar lines associated with procerus and corrugator muscle activity in adults < 65 years of age ( 1.2 ) The treatment of spasticity in patients 2 years of age and older ( 1.3 )|[PMDA] Drugs with new additional indications and new dosages for the treatment of upper and lower limb spasticity. DRUGBANK:DB00083 uuid:5234125a-2b31-4e00-b072-3a4af88dd996 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:FYS6T7F842 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:3d3f6ba3-f318-4085-8aba-1fda5726b007"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f47a08bb-06fe-45f8-9949-65f8c5abf0de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:3df3210a-7979-4b2e-8bff-a75dfdbfd76c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/hulio""]},{""id"":""uuid:34e0bc4e-dedd-4a20-a799-dc2ba6a74c47"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] HADLIMA is a tumor necrosis factor (TNF) blocker indicated for • Rheumatoid Arthritis (RA) ( 1.1 ): reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active RA. • Juvenile Idiopathic Arthritis (JIA) ( 1.2 ): reducing signs and symptoms of moderately to severely active polyarticular JIA in patients 2 years of age and older. • Psoriatic Arthritis (PsA) ( 1.3 ) : reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active PsA. • Ankylosing Spondylitis (AS) ( 1.4 ): reducing signs and symptoms in adult patients with active AS. • Crohn’s Disease (CD) ( 1.5 ): treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older. • Ulcerative Colitis (UC) ( 1.6 ): treatment of moderately to severely active ulcerative colitis in adult patients. Limitations of Use : Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers. • Plaque Psoriasis (Ps) ( 1.7 ): treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. • Hidradenitis Suppurativa (HS) ( 1.8 ): treatment of moderate to severe hidradenitis suppurativa in adult patients. • Uveitis (UV) ( 1.9 ): treatment of non-infectious intermediate, posterior, and panuveitis in adult patients.|[EMA] Rheumatoid arthritisYuflyma in combination with methotrexate, is indicated for:- the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate.- the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.Yuflyma can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.Adalimumab has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate.Juvenile idiopathic arthritisPolyarticular juvenile idiopathic arthritisYuflyma in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). Yuflyma can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate (for the efficacy in monotherapy see section 5.1). Adalimumab has not been studied in patients aged less than 2 years.Enthesitis-related arthritisYuflyma is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy (see section 5.1).Axial spondyloarthritisAnkylosing spondylitis (AS)Yuflyma is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy.Axial spondyloarthritis without radiographic evidence of ASYuflyma is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of AS but with objective signs of inflammation by elevated CRP and/or MRI, who have had an inadequate response to, or are intolerant to non-steroidal anti-inflammatory drugs (NSAIDs).Psoriatic arthritisYuflyma is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate.Adalimumab has been shown to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease (see section 5.1) and to improve physical function.PsoriasisYuflyma is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy.Paediatric plaque psoriasisYuflyma is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies.Hidradenitis suppurativa (HS)Yuflyma is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults and adolescents from 12 years of age with an inadequate response to conventional systemic HS therapy (see sections 5.1 and 5.2).Crohn’s diseaseYuflyma is indicated for treatment of moderately to severely active Crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies.Paediatric Crohn's diseaseYuflyma is indicated for the treatment of moderately to severely active Crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or have contraindications for such therapies.Ulcerative colitisYuflyma is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.Paediatric ulcerative colitisYuflyma is indicated for the treatment of moderately to severely active ulcerative colitis in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including corticosteroids and/or 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.UveitisYuflyma is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid- sparing, or in whom corticosteroid treatment is inappropriate.Paediatric uveitisYuflyma is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.|[PMDA] A drug containing a new active ingredient indicated for the treatment of rheumatoid arthritis (for use only when conventional therapies are not sufficiently effective). uuid:3c739b90-7d92-49d9-a91c-7d3b97fa5e9a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:FYS6T7F842 biolink:treats MONDO:0011429 PMID:41385096 "[{""id"":""uuid:2bc3aece-48b3-47e9-8724-f3209f0f69db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ef51d952-e2c6-4dbd-9780-5ff4fe4f5f46"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:b98cec80-97e0-4a6e-a25a-27644f30ee39"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/hulio""]},{""id"":""uuid:e5a7967d-2071-43fb-8fa1-afe943efb16c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] HADLIMA is a tumor necrosis factor (TNF) blocker indicated for • Rheumatoid Arthritis (RA) ( 1.1 ): reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active RA. • Juvenile Idiopathic Arthritis (JIA) ( 1.2 ): reducing signs and symptoms of moderately to severely active polyarticular JIA in patients 2 years of age and older. • Psoriatic Arthritis (PsA) ( 1.3 ) : reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active PsA. • Ankylosing Spondylitis (AS) ( 1.4 ): reducing signs and symptoms in adult patients with active AS. • Crohn’s Disease (CD) ( 1.5 ): treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older. • Ulcerative Colitis (UC) ( 1.6 ): treatment of moderately to severely active ulcerative colitis in adult patients. Limitations of Use : Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers. • Plaque Psoriasis (Ps) ( 1.7 ): treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. • Hidradenitis Suppurativa (HS) ( 1.8 ): treatment of moderate to severe hidradenitis suppurativa in adult patients. • Uveitis (UV) ( 1.9 ): treatment of non-infectious intermediate, posterior, and panuveitis in adult patients.|[EMA] Rheumatoid arthritisYuflyma in combination with methotrexate, is indicated for:- the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate.- the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.Yuflyma can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.Adalimumab has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate.Juvenile idiopathic arthritisPolyarticular juvenile idiopathic arthritisYuflyma in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). Yuflyma can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate (for the efficacy in monotherapy see section 5.1). Adalimumab has not been studied in patients aged less than 2 years.Enthesitis-related arthritisYuflyma is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy (see section 5.1).Axial spondyloarthritisAnkylosing spondylitis (AS)Yuflyma is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy.Axial spondyloarthritis without radiographic evidence of ASYuflyma is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of AS but with objective signs of inflammation by elevated CRP and/or MRI, who have had an inadequate response to, or are intolerant to non-steroidal anti-inflammatory drugs (NSAIDs).Psoriatic arthritisYuflyma is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate.Adalimumab has been shown to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease (see section 5.1) and to improve physical function.PsoriasisYuflyma is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy.Paediatric plaque psoriasisYuflyma is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies.Hidradenitis suppurativa (HS)Yuflyma is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults and adolescents from 12 years of age with an inadequate response to conventional systemic HS therapy (see sections 5.1 and 5.2).Crohn’s diseaseYuflyma is indicated for treatment of moderately to severely active Crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies.Paediatric Crohn's diseaseYuflyma is indicated for the treatment of moderately to severely active Crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or have contraindications for such therapies.Ulcerative colitisYuflyma is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.Paediatric ulcerative colitisYuflyma is indicated for the treatment of moderately to severely active ulcerative colitis in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including corticosteroids and/or 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.UveitisYuflyma is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid- sparing, or in whom corticosteroid treatment is inappropriate.Paediatric uveitisYuflyma is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.|[PMDA] Drugs with a new additional indication, a new dosage, and an additional dosage form for the treatment of polyarticular-course juvenile idiopathic arthritis (for use only in patients who have not sufficiently responded to conventional treatments). uuid:7a69a2d2-c1a2-4612-99d5-d16b524e87d1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:FYS6T7F842 biolink:treats MONDO:0011849 PMID:41385096 "[{""id"":""uuid:84e0b601-04d9-4e18-9490-e82b1d05bdf8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3f68eb8f-e34f-4d3d-be05-b47d8e7e30f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:5694949e-e343-4319-af0f-f253f36aefdc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/hulio""]},{""id"":""uuid:d8fc2d21-bb2f-4379-ab32-1bb6d169ee75"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] HADLIMA is a tumor necrosis factor (TNF) blocker indicated for • Rheumatoid Arthritis (RA) ( 1.1 ): reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active RA. • Juvenile Idiopathic Arthritis (JIA) ( 1.2 ): reducing signs and symptoms of moderately to severely active polyarticular JIA in patients 2 years of age and older. • Psoriatic Arthritis (PsA) ( 1.3 ) : reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active PsA. • Ankylosing Spondylitis (AS) ( 1.4 ): reducing signs and symptoms in adult patients with active AS. • Crohn’s Disease (CD) ( 1.5 ): treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older. • Ulcerative Colitis (UC) ( 1.6 ): treatment of moderately to severely active ulcerative colitis in adult patients. Limitations of Use : Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers. • Plaque Psoriasis (Ps) ( 1.7 ): treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. • Hidradenitis Suppurativa (HS) ( 1.8 ): treatment of moderate to severe hidradenitis suppurativa in adult patients. • Uveitis (UV) ( 1.9 ): treatment of non-infectious intermediate, posterior, and panuveitis in adult patients.|[EMA] Rheumatoid arthritisYuflyma in combination with methotrexate, is indicated for:- the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate.- the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.Yuflyma can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.Adalimumab has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate.Juvenile idiopathic arthritisPolyarticular juvenile idiopathic arthritisYuflyma in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). Yuflyma can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate (for the efficacy in monotherapy see section 5.1). Adalimumab has not been studied in patients aged less than 2 years.Enthesitis-related arthritisYuflyma is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy (see section 5.1).Axial spondyloarthritisAnkylosing spondylitis (AS)Yuflyma is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy.Axial spondyloarthritis without radiographic evidence of ASYuflyma is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of AS but with objective signs of inflammation by elevated CRP and/or MRI, who have had an inadequate response to, or are intolerant to non-steroidal anti-inflammatory drugs (NSAIDs).Psoriatic arthritisYuflyma is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate.Adalimumab has been shown to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease (see section 5.1) and to improve physical function.PsoriasisYuflyma is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy.Paediatric plaque psoriasisYuflyma is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies.Hidradenitis suppurativa (HS)Yuflyma is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults and adolescents from 12 years of age with an inadequate response to conventional systemic HS therapy (see sections 5.1 and 5.2).Crohn’s diseaseYuflyma is indicated for treatment of moderately to severely active Crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies.Paediatric Crohn's diseaseYuflyma is indicated for the treatment of moderately to severely active Crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or have contraindications for such therapies.Ulcerative colitisYuflyma is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.Paediatric ulcerative colitisYuflyma is indicated for the treatment of moderately to severely active ulcerative colitis in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including corticosteroids and/or 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.UveitisYuflyma is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid- sparing, or in whom corticosteroid treatment is inappropriate.Paediatric uveitisYuflyma is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.|[PMDA] Follow-on biologics indicated for the treatment of rheumatoid arthritis (including the prevention of structural joint damage), and the treatment of the following diseases in patients who have not responded sufficiently to conventional treatments; polyarticular- course juvenile idiopathic arthritis, plaque psoriasis, psoriatic arthritis, pustular psoriasis, ankylosing spondylitis and intestinal Behcet’s disease; and the remission induction therapy and maintenance therapy for moderate to severe active Crohn's disease (for use only in patients who have not sufficiently responded to conventional therapies). uuid:aa15c71d-ec9f-4bb4-96cb-738b11e4e452 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:FYS6T7F842 biolink:treats MONDO:0005306 PMID:41385096 "[{""id"":""uuid:55ad8674-2d4f-42f3-973b-969c67cf90f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0e7de877-adc0-46e3-bbf7-b50b038b7561"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:86024a52-d676-4f66-a6ea-f45350e72f90"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/hulio""]},{""id"":""uuid:cf15304c-4cbd-4cf5-90c7-75f69910b5fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] HADLIMA is a tumor necrosis factor (TNF) blocker indicated for • Rheumatoid Arthritis (RA) ( 1.1 ): reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active RA. • Juvenile Idiopathic Arthritis (JIA) ( 1.2 ): reducing signs and symptoms of moderately to severely active polyarticular JIA in patients 2 years of age and older. • Psoriatic Arthritis (PsA) ( 1.3 ) : reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active PsA. • Ankylosing Spondylitis (AS) ( 1.4 ): reducing signs and symptoms in adult patients with active AS. • Crohn’s Disease (CD) ( 1.5 ): treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older. • Ulcerative Colitis (UC) ( 1.6 ): treatment of moderately to severely active ulcerative colitis in adult patients. Limitations of Use : Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers. • Plaque Psoriasis (Ps) ( 1.7 ): treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. • Hidradenitis Suppurativa (HS) ( 1.8 ): treatment of moderate to severe hidradenitis suppurativa in adult patients. • Uveitis (UV) ( 1.9 ): treatment of non-infectious intermediate, posterior, and panuveitis in adult patients.|[EMA] Rheumatoid arthritisYuflyma in combination with methotrexate, is indicated for:- the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate.- the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.Yuflyma can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.Adalimumab has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate.Juvenile idiopathic arthritisPolyarticular juvenile idiopathic arthritisYuflyma in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). Yuflyma can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate (for the efficacy in monotherapy see section 5.1). Adalimumab has not been studied in patients aged less than 2 years.Enthesitis-related arthritisYuflyma is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy (see section 5.1).Axial spondyloarthritisAnkylosing spondylitis (AS)Yuflyma is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy.Axial spondyloarthritis without radiographic evidence of ASYuflyma is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of AS but with objective signs of inflammation by elevated CRP and/or MRI, who have had an inadequate response to, or are intolerant to non-steroidal anti-inflammatory drugs (NSAIDs).Psoriatic arthritisYuflyma is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate.Adalimumab has been shown to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease (see section 5.1) and to improve physical function.PsoriasisYuflyma is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy.Paediatric plaque psoriasisYuflyma is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies.Hidradenitis suppurativa (HS)Yuflyma is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults and adolescents from 12 years of age with an inadequate response to conventional systemic HS therapy (see sections 5.1 and 5.2).Crohn’s diseaseYuflyma is indicated for treatment of moderately to severely active Crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies.Paediatric Crohn's diseaseYuflyma is indicated for the treatment of moderately to severely active Crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or have contraindications for such therapies.Ulcerative colitisYuflyma is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.Paediatric ulcerative colitisYuflyma is indicated for the treatment of moderately to severely active ulcerative colitis in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including corticosteroids and/or 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.UveitisYuflyma is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid- sparing, or in whom corticosteroid treatment is inappropriate.Paediatric uveitisYuflyma is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.|[PMDA] Follow-on biologics indicated for the treatment of rheumatoid arthritis (including the prevention of structural joint damage), and the treatment of the following diseases in patients who have not responded sufficiently to conventional treatments; polyarticular- course juvenile idiopathic arthritis, plaque psoriasis, psoriatic arthritis, pustular psoriasis, ankylosing spondylitis and intestinal Behcet’s disease; and the remission induction therapy and maintenance therapy for moderate to severe active Crohn's disease (for use only in patients who have not sufficiently responded to conventional therapies). uuid:5d7b4a2f-e0e9-44d1-a814-62d80facf67a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:FYS6T7F842 biolink:treats MONDO:0005011 PMID:41385096 "[{""id"":""uuid:7f9d8304-43d6-44ed-bef3-929253422317"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a0b9287c-cfe1-4623-a0c5-dd539a3af18c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:1d22b8fb-40eb-43bb-958a-d0348bde5bd4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/hulio""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] HADLIMA is a tumor necrosis factor (TNF) blocker indicated for • Rheumatoid Arthritis (RA) ( 1.1 ): reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active RA. • Juvenile Idiopathic Arthritis (JIA) ( 1.2 ): reducing signs and symptoms of moderately to severely active polyarticular JIA in patients 2 years of age and older. • Psoriatic Arthritis (PsA) ( 1.3 ) : reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active PsA. • Ankylosing Spondylitis (AS) ( 1.4 ): reducing signs and symptoms in adult patients with active AS. • Crohn’s Disease (CD) ( 1.5 ): treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older. • Ulcerative Colitis (UC) ( 1.6 ): treatment of moderately to severely active ulcerative colitis in adult patients. Limitations of Use : Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers. • Plaque Psoriasis (Ps) ( 1.7 ): treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. • Hidradenitis Suppurativa (HS) ( 1.8 ): treatment of moderate to severe hidradenitis suppurativa in adult patients. • Uveitis (UV) ( 1.9 ): treatment of non-infectious intermediate, posterior, and panuveitis in adult patients.|[EMA] Rheumatoid arthritisYuflyma in combination with methotrexate, is indicated for:- the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate.- the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.Yuflyma can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.Adalimumab has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate.Juvenile idiopathic arthritisPolyarticular juvenile idiopathic arthritisYuflyma in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). Yuflyma can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate (for the efficacy in monotherapy see section 5.1). Adalimumab has not been studied in patients aged less than 2 years.Enthesitis-related arthritisYuflyma is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy (see section 5.1).Axial spondyloarthritisAnkylosing spondylitis (AS)Yuflyma is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy.Axial spondyloarthritis without radiographic evidence of ASYuflyma is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of AS but with objective signs of inflammation by elevated CRP and/or MRI, who have had an inadequate response to, or are intolerant to non-steroidal anti-inflammatory drugs (NSAIDs).Psoriatic arthritisYuflyma is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate.Adalimumab has been shown to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease (see section 5.1) and to improve physical function.PsoriasisYuflyma is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy.Paediatric plaque psoriasisYuflyma is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies.Hidradenitis suppurativa (HS)Yuflyma is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults and adolescents from 12 years of age with an inadequate response to conventional systemic HS therapy (see sections 5.1 and 5.2).Crohn’s diseaseYuflyma is indicated for treatment of moderately to severely active Crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies.Paediatric Crohn's diseaseYuflyma is indicated for the treatment of moderately to severely active Crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or have contraindications for such therapies.Ulcerative colitisYuflyma is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.Paediatric ulcerative colitisYuflyma is indicated for the treatment of moderately to severely active ulcerative colitis in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including corticosteroids and/or 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.UveitisYuflyma is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid- sparing, or in whom corticosteroid treatment is inappropriate.Paediatric uveitisYuflyma is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate. uuid:f0d180cb-4a50-47f4-88e5-1458cab06033 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:FYS6T7F842 biolink:treats MONDO:0005101 PMID:41385096 "[{""id"":""uuid:006fa8f4-cf9d-422f-a781-1ea8e350d0be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:827ded13-b99d-4bb3-9315-64cfacfd659d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f48a2fef-b5b3-4ddc-8246-1561bbdc7263"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/hulio""]},{""id"":""uuid:b26a0db3-d8c2-4c90-b99c-7e025c948155"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] HADLIMA is a tumor necrosis factor (TNF) blocker indicated for • Rheumatoid Arthritis (RA) ( 1.1 ): reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active RA. • Juvenile Idiopathic Arthritis (JIA) ( 1.2 ): reducing signs and symptoms of moderately to severely active polyarticular JIA in patients 2 years of age and older. • Psoriatic Arthritis (PsA) ( 1.3 ) : reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active PsA. • Ankylosing Spondylitis (AS) ( 1.4 ): reducing signs and symptoms in adult patients with active AS. • Crohn’s Disease (CD) ( 1.5 ): treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older. • Ulcerative Colitis (UC) ( 1.6 ): treatment of moderately to severely active ulcerative colitis in adult patients. Limitations of Use : Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers. • Plaque Psoriasis (Ps) ( 1.7 ): treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. • Hidradenitis Suppurativa (HS) ( 1.8 ): treatment of moderate to severe hidradenitis suppurativa in adult patients. • Uveitis (UV) ( 1.9 ): treatment of non-infectious intermediate, posterior, and panuveitis in adult patients.|[EMA] Rheumatoid arthritisYuflyma in combination with methotrexate, is indicated for:- the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate.- the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.Yuflyma can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.Adalimumab has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate.Juvenile idiopathic arthritisPolyarticular juvenile idiopathic arthritisYuflyma in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). Yuflyma can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate (for the efficacy in monotherapy see section 5.1). Adalimumab has not been studied in patients aged less than 2 years.Enthesitis-related arthritisYuflyma is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy (see section 5.1).Axial spondyloarthritisAnkylosing spondylitis (AS)Yuflyma is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy.Axial spondyloarthritis without radiographic evidence of ASYuflyma is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of AS but with objective signs of inflammation by elevated CRP and/or MRI, who have had an inadequate response to, or are intolerant to non-steroidal anti-inflammatory drugs (NSAIDs).Psoriatic arthritisYuflyma is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate.Adalimumab has been shown to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease (see section 5.1) and to improve physical function.PsoriasisYuflyma is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy.Paediatric plaque psoriasisYuflyma is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies.Hidradenitis suppurativa (HS)Yuflyma is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults and adolescents from 12 years of age with an inadequate response to conventional systemic HS therapy (see sections 5.1 and 5.2).Crohn’s diseaseYuflyma is indicated for treatment of moderately to severely active Crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies.Paediatric Crohn's diseaseYuflyma is indicated for the treatment of moderately to severely active Crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or have contraindications for such therapies.Ulcerative colitisYuflyma is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.Paediatric ulcerative colitisYuflyma is indicated for the treatment of moderately to severely active ulcerative colitis in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including corticosteroids and/or 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.UveitisYuflyma is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid- sparing, or in whom corticosteroid treatment is inappropriate.Paediatric uveitisYuflyma is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.|[PMDA] Follow-on biologics indicated for the treatment of rheumatoid arthritis (including the prevention of structural joint damage), and the treatment of the following diseases in patients who have not responded sufficiently to conventional treatments; polyarticular- course juvenile idiopathic arthritis, plaque psoriasis, psoriatic arthritis, pustular psoriasis, ankylosing spondylitis and intestinal Behçet's disease; the remission induction therapy and maintenance therapy for moderate to severe active Crohn's disease, and treatment of moderate to severe ulcerative colitis. uuid:919c4866-de49-436b-928b-693d4a178163 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:FYS6T7F842 biolink:treats UMLS:C0406317 PMID:41385096 "[{""id"":""uuid:beb0a221-1112-45eb-a13b-962b8add95b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7ad2ae3b-1679-4765-9219-23442ae5eebf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:4b1a9bc0-9d2b-4c0e-932a-6a62e8a751aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] HADLIMA is a tumor necrosis factor (TNF) blocker indicated for • Rheumatoid Arthritis (RA) ( 1.1 ): reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active RA. • Juvenile Idiopathic Arthritis (JIA) ( 1.2 ): reducing signs and symptoms of moderately to severely active polyarticular JIA in patients 2 years of age and older. • Psoriatic Arthritis (PsA) ( 1.3 ) : reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active PsA. • Ankylosing Spondylitis (AS) ( 1.4 ): reducing signs and symptoms in adult patients with active AS. • Crohn’s Disease (CD) ( 1.5 ): treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older. • Ulcerative Colitis (UC) ( 1.6 ): treatment of moderately to severely active ulcerative colitis in adult patients. Limitations of Use : Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers. • Plaque Psoriasis (Ps) ( 1.7 ): treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. • Hidradenitis Suppurativa (HS) ( 1.8 ): treatment of moderate to severe hidradenitis suppurativa in adult patients. • Uveitis (UV) ( 1.9 ): treatment of non-infectious intermediate, posterior, and panuveitis in adult patients.|[PMDA] Follow-on biologics indicated for the treatment of rheumatoid arthritis (including the prevention of structural joint damage), and the treatment of the following diseases in patients who have not responded sufficiently to conventional treatments; polyarticular- course juvenile idiopathic arthritis, plaque psoriasis, psoriatic arthritis, pustular psoriasis, ankylosing spondylitis and intestinal Behcet’s disease; and the remission induction therapy and maintenance therapy for moderate to severe active Crohn's disease (for use only in patients who have not sufficiently responded to conventional therapies). uuid:e06064d2-6d8a-45c0-8c47-289f01c155b4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:FYS6T7F842 biolink:treats MONDO:0006559 PMID:41385096 "[{""id"":""uuid:cff1d821-686c-4ee9-ba0f-9c3c7150cb78"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:065cdc9b-3617-49bc-9eec-7f13c5e66a80"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:1eec62a0-2d62-4bce-8345-c6bec7fdb4d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/hulio""]},{""id"":""uuid:a6d55ed6-bb5b-47cf-a73e-7e0a795c215f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] HADLIMA is a tumor necrosis factor (TNF) blocker indicated for • Rheumatoid Arthritis (RA) ( 1.1 ): reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active RA. • Juvenile Idiopathic Arthritis (JIA) ( 1.2 ): reducing signs and symptoms of moderately to severely active polyarticular JIA in patients 2 years of age and older. • Psoriatic Arthritis (PsA) ( 1.3 ) : reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active PsA. • Ankylosing Spondylitis (AS) ( 1.4 ): reducing signs and symptoms in adult patients with active AS. • Crohn’s Disease (CD) ( 1.5 ): treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older. • Ulcerative Colitis (UC) ( 1.6 ): treatment of moderately to severely active ulcerative colitis in adult patients. Limitations of Use : Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers. • Plaque Psoriasis (Ps) ( 1.7 ): treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. • Hidradenitis Suppurativa (HS) ( 1.8 ): treatment of moderate to severe hidradenitis suppurativa in adult patients. • Uveitis (UV) ( 1.9 ): treatment of non-infectious intermediate, posterior, and panuveitis in adult patients.|[EMA] Rheumatoid arthritisYuflyma in combination with methotrexate, is indicated for:- the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate.- the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.Yuflyma can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.Adalimumab has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate.Juvenile idiopathic arthritisPolyarticular juvenile idiopathic arthritisYuflyma in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). Yuflyma can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate (for the efficacy in monotherapy see section 5.1). Adalimumab has not been studied in patients aged less than 2 years.Enthesitis-related arthritisYuflyma is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy (see section 5.1).Axial spondyloarthritisAnkylosing spondylitis (AS)Yuflyma is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy.Axial spondyloarthritis without radiographic evidence of ASYuflyma is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of AS but with objective signs of inflammation by elevated CRP and/or MRI, who have had an inadequate response to, or are intolerant to non-steroidal anti-inflammatory drugs (NSAIDs).Psoriatic arthritisYuflyma is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate.Adalimumab has been shown to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease (see section 5.1) and to improve physical function.PsoriasisYuflyma is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy.Paediatric plaque psoriasisYuflyma is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies.Hidradenitis suppurativa (HS)Yuflyma is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults and adolescents from 12 years of age with an inadequate response to conventional systemic HS therapy (see sections 5.1 and 5.2).Crohn’s diseaseYuflyma is indicated for treatment of moderately to severely active Crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies.Paediatric Crohn's diseaseYuflyma is indicated for the treatment of moderately to severely active Crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or have contraindications for such therapies.Ulcerative colitisYuflyma is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.Paediatric ulcerative colitisYuflyma is indicated for the treatment of moderately to severely active ulcerative colitis in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including corticosteroids and/or 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.UveitisYuflyma is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid- sparing, or in whom corticosteroid treatment is inappropriate.Paediatric uveitisYuflyma is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.|[PMDA] Drugs with a new dosage indicated for the treatment of hidradenitis suppurativa. [Orphan drug] uuid:5db2fce1-3bc7-4698-9be8-c9669f4f6c61 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:FYS6T7F842 biolink:treats MONDO:0020283 PMID:41385096 "[{""id"":""uuid:a9b32bb8-2ff9-44e6-b35e-b5196b1a6015"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:ba5521c2-4144-4672-9113-22356f5034b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:732bb134-cc95-4558-b659-edd825645ddc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/hulio""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] HADLIMA is a tumor necrosis factor (TNF) blocker indicated for • Rheumatoid Arthritis (RA) ( 1.1 ): reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active RA. • Juvenile Idiopathic Arthritis (JIA) ( 1.2 ): reducing signs and symptoms of moderately to severely active polyarticular JIA in patients 2 years of age and older. • Psoriatic Arthritis (PsA) ( 1.3 ) : reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active PsA. • Ankylosing Spondylitis (AS) ( 1.4 ): reducing signs and symptoms in adult patients with active AS. • Crohn’s Disease (CD) ( 1.5 ): treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older. • Ulcerative Colitis (UC) ( 1.6 ): treatment of moderately to severely active ulcerative colitis in adult patients. Limitations of Use : Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers. • Plaque Psoriasis (Ps) ( 1.7 ): treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. • Hidradenitis Suppurativa (HS) ( 1.8 ): treatment of moderate to severe hidradenitis suppurativa in adult patients. • Uveitis (UV) ( 1.9 ): treatment of non-infectious intermediate, posterior, and panuveitis in adult patients.|[EMA] Rheumatoid arthritisYuflyma in combination with methotrexate, is indicated for:- the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate.- the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.Yuflyma can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.Adalimumab has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate.Juvenile idiopathic arthritisPolyarticular juvenile idiopathic arthritisYuflyma in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). Yuflyma can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate (for the efficacy in monotherapy see section 5.1). Adalimumab has not been studied in patients aged less than 2 years.Enthesitis-related arthritisYuflyma is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy (see section 5.1).Axial spondyloarthritisAnkylosing spondylitis (AS)Yuflyma is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy.Axial spondyloarthritis without radiographic evidence of ASYuflyma is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of AS but with objective signs of inflammation by elevated CRP and/or MRI, who have had an inadequate response to, or are intolerant to non-steroidal anti-inflammatory drugs (NSAIDs).Psoriatic arthritisYuflyma is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate.Adalimumab has been shown to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease (see section 5.1) and to improve physical function.PsoriasisYuflyma is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy.Paediatric plaque psoriasisYuflyma is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies.Hidradenitis suppurativa (HS)Yuflyma is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults and adolescents from 12 years of age with an inadequate response to conventional systemic HS therapy (see sections 5.1 and 5.2).Crohn’s diseaseYuflyma is indicated for treatment of moderately to severely active Crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies.Paediatric Crohn's diseaseYuflyma is indicated for the treatment of moderately to severely active Crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or have contraindications for such therapies.Ulcerative colitisYuflyma is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.Paediatric ulcerative colitisYuflyma is indicated for the treatment of moderately to severely active ulcerative colitis in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including corticosteroids and/or 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.UveitisYuflyma is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid- sparing, or in whom corticosteroid treatment is inappropriate.Paediatric uveitisYuflyma is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate. uuid:6754f13e-edca-41a6-ae98-5109dff1d1bc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:125354 biolink:treats MONDO:0018908 PMID:41385096 "[{""id"":""uuid:e44dcd7a-b445-47c1-88b8-68d4799d983d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:79fe2356-ba61-42c5-b1f6-c506e04d1889"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mozobil is indicated in combination with filgrastim to mobilize hematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma (NHL) or multiple myeloma (MM). uuid:df5aa3f8-0d41-4fef-8516-599c4b8e8528 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:125354 biolink:treats MONDO:0009693 PMID:41385096 "[{""id"":""uuid:4558ad8e-427e-444b-baf0-0bbbbb7f7c5e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:e7b65c48-7c6c-4258-8d1d-610e2f4d2698"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:cbbd6921-c96d-452a-9ba3-70df6102bb8c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/mozobil""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mozobil is indicated in combination with filgrastim to mobilize hematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma (NHL) or multiple myeloma (MM).|[EMA] Mozobil is indicated in combination with granulocyte-colony-stimulating factor to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with lymphoma and multiple myeloma whose cells mobilise poorly., uuid:1a40dffa-1a20-412e-b590-ce471cb91b17 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:G0G0H52U6K biolink:treats MONDO:0005338 PMID:41385096 "[{""id"":""uuid:b6833c53-eb19-43a9-8619-4c7047389d76"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f74d3f55-0191-40d3-bd24-76865bbe52c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Omlonti (omidenepag isopropyl ophthalmic solution) 0.002%, is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. uuid:bbcd510b-2a2e-4087-8f15-57cd82d1f10b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:G0G0H52U6K biolink:treats MONDO:0006875 PMID:41385096 "[{""id"":""uuid:39f8f479-f3f5-4efd-b5f5-991410d2b740"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d97b33fd-5791-4195-9556-489f6f260943"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Omlonti (omidenepag isopropyl ophthalmic solution) 0.002%, is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. uuid:5b38a3ee-c9d4-4c0b-b68e-08377b14bf5f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4735 biolink:treats UMLS:C0572061 PMID:41385096 "[{""id"":""uuid:95b55eb1-5fbd-4023-9843-c7d637b5a56c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f444b946-25f9-45ee-b44d-0e5b4d2b8a38"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NARCAN Nasal Spray is indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression. NARCAN Nasal Spray is intended for immediate administration as emergency therapy in settings where opioids may be present. NARCAN Nasal Spray is not a substitute for emergency medical care. Limitations of Use: Restrict prescription of NARCAN Nasal Spray 2 mg to opioid-dependent patients expected to be at risk for severe opioid withdrawal in situations where there is a low risk for accidental or intentional opioid exposure by household contacts. uuid:ae5a40bf-6c61-4ed8-8098-09be65dd6c5d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4735 biolink:treats UMLS:C0029104 PMID:41385096 "[{""id"":""uuid:e188a7f7-d3a7-45e3-a6ff-bf48a5f7318d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8b4cec07-42ec-47c9-a969-349b4548cd71"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NARCAN Nasal Spray is indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression. NARCAN Nasal Spray is intended for immediate administration as emergency therapy in settings where opioids may be present. NARCAN Nasal Spray is not a substitute for emergency medical care. Limitations of Use: Restrict prescription of NARCAN Nasal Spray 2 mg to opioid-dependent patients expected to be at risk for severe opioid withdrawal in situations where there is a low risk for accidental or intentional opioid exposure by household contacts. uuid:e2f26fe0-cdb1-4341-abea-f94fafad83fa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:72564 biolink:treats UMLS:C5239366 PMID:41385096 "[{""id"":""uuid:3f86e451-dd03-4c44-91a1-9285fe5e8c90"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:55c2333b-7829-4722-a3f0-01ab5eb3840e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Temozolomide is an alkylating drug indicated for the treatment of adults with: • Newly diagnosed glioblastoma concomitantly with radiotherapy and then as maintenance treatment. (1.1) • Anaplastic astrocytoma. (1.2) o Adjuvant treatment of adults with newly diagnosed anaplastic astrocytoma. (1.2) o Treatment of adults with refractory anaplastic astrocytoma. (1.2) uuid:e48554da-990c-45be-b3af-8110d515c665 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9620 biolink:treats MONDO:0005984 PMID:41385096 "[{""id"":""uuid:d640492e-53a5-4972-919e-b7a03d0b3edb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1fda952d-9e27-49ed-b93b-70f9660e85a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mycozyl AL™ is effective in the treatment of most skin infections such as athlete's foot (tinea pedis) and ringworm (tinea corporis). Mycozyl AL™ has been designed to reach skin areas around and under the nails while it relives burning, cracking, scaling and discomfort which accompany these conditions. Mycozyl AL™ is an antifungal that works by preventing and eliminating the growth of fungus on fingers, toes and around the nails. It eliminates and helps stop the spread of fungal infections on cuticles around nail edges and under the nail tips where reachable with applicator brush. Mycozyl AL™ cures and prevents fungal infections from coming back with daily use. uuid:908b4722-8ced-4883-9ba9-f04fee74d854 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9620 biolink:treats MONDO:0001461 PMID:41385096 "[{""id"":""uuid:ef2cab95-c75d-48df-a51d-09fa52d5663a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9783cb56-3451-46af-b92f-09033051ea35"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mycozyl AL™ is effective in the treatment of most skin infections such as athlete's foot (tinea pedis) and ringworm (tinea corporis). Mycozyl AL™ has been designed to reach skin areas around and under the nails while it relives burning, cracking, scaling and discomfort which accompany these conditions. Mycozyl AL™ is an antifungal that works by preventing and eliminating the growth of fungus on fingers, toes and around the nails. It eliminates and helps stop the spread of fungal infections on cuticles around nail edges and under the nail tips where reachable with applicator brush. Mycozyl AL™ cures and prevents fungal infections from coming back with daily use. uuid:c6089ba3-22ff-46b4-8afc-6dd6cc587c99 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9620 biolink:treats MONDO:0002041 PMID:41385096 "[{""id"":""uuid:dd5c6ba6-24f0-4edc-a12e-c7d32ce0bce1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2bae1793-fc24-4f9a-b812-4906a772faec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mycozyl AL™ is effective in the treatment of most skin infections such as athlete's foot (tinea pedis) and ringworm (tinea corporis). Mycozyl AL™ has been designed to reach skin areas around and under the nails while it relives burning, cracking, scaling and discomfort which accompany these conditions. Mycozyl AL™ is an antifungal that works by preventing and eliminating the growth of fungus on fingers, toes and around the nails. It eliminates and helps stop the spread of fungal infections on cuticles around nail edges and under the nail tips where reachable with applicator brush. Mycozyl AL™ cures and prevents fungal infections from coming back with daily use. uuid:d47c0091-f23d-4bb2-b0ce-c1509ef6f9c1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27899 biolink:treats MONDO:0004829 PMID:41385096 "[{""id"":""uuid:6ff9c193-79a1-441b-92e0-96a7e347c436"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3f21b03e-ecd1-4f17-a220-a3e5765e9343"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cisplatin Injection is indicated as therapy to be employed as follows: Metastatic Testicular Tumors In established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radiotherapeutic procedures. Metastatic Ovarian Tumors In established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. An established combination consists of cisplatin and cyclophosphamide. Cisplatin Injection, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received Cisplatin Injection therapy. Advanced Bladder Cancer Cisplatin Injection is indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy. uuid:fc2ea11e-9501-465c-9868-a04e17869df2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27899 biolink:treats MONDO:0005611 PMID:41385096 "[{""id"":""uuid:d5c4e7f0-9311-42e3-a9e7-df703dc36cc0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e8393be9-9356-4d2b-a844-e2cefb6a138a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cisplatin Injection is indicated as therapy to be employed as follows: Metastatic Testicular Tumors In established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radiotherapeutic procedures. Metastatic Ovarian Tumors In established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. An established combination consists of cisplatin and cyclophosphamide. Cisplatin Injection, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received Cisplatin Injection therapy. Advanced Bladder Cancer Cisplatin Injection is indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy. uuid:c299b29d-e043-4e71-8c56-ef4110dfa73b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:73274 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:7221fd61-716f-42ef-888b-87300da654cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:415a1e43-8ce8-4791-a2e2-8a7c787df68d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:12e41b60-1d15-477f-83c0-19f5a83e0664"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/invokana""]},{""id"":""uuid:963c9a47-1eab-438a-b615-dd05f6101f9c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INVOKANA (canagliflozin) is indicated: as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. to reduce the risk of major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction and nonfatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease (CVD). to reduce the risk of end-stage kidney disease (ESKD), doubling of serum creatinine, cardiovascular (CV) death, and hospitalization for heart failure in adults with type 2 diabetes mellitus and diabetic nephropathy with albuminuria greater than 300 mg/day.|[EMA] Invokana is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:as monotherapy when metformin is considered inappropriate due to intolerance or contraindicationsin addition to other medicinal products for the treatment of diabetes.For study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4.4, 4.5 and 5.1.|[PMDA] A drug with a new active ingredient indicated for the treatment of type 2 diabetes mellitus. uuid:73bc62c9-f65a-49d7-84f2-4576e060e09b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:73274 biolink:treats MONDO:0004995 PMID:41385096 "[{""id"":""uuid:66222108-eb2c-4aab-a88e-b940ae33a7de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0c198f24-bfa5-41b4-a2e7-aa27fb44211b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INVOKANA (canagliflozin) is indicated: as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. to reduce the risk of major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction and nonfatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease (CVD). to reduce the risk of end-stage kidney disease (ESKD), doubling of serum creatinine, cardiovascular (CV) death, and hospitalization for heart failure in adults with type 2 diabetes mellitus and diabetic nephropathy with albuminuria greater than 300 mg/day. uuid:7b4ead7e-0cd2-41b5-9c53-f0fdf8451206 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:73274 biolink:treats MONDO:0005016 PMID:41385096 "[{""id"":""uuid:57d4f1c9-584f-4c3d-92a7-2ecb8b5f1eb7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fe22e95c-6523-443c-8956-05ad2cfac93e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INVOKANA (canagliflozin) is indicated: as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. to reduce the risk of major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction and nonfatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease (CVD). to reduce the risk of end-stage kidney disease (ESKD), doubling of serum creatinine, cardiovascular (CV) death, and hospitalization for heart failure in adults with type 2 diabetes mellitus and diabetic nephropathy with albuminuria greater than 300 mg/day. uuid:09b98e5d-03a1-4da5-874d-2bec5119b699 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:73274 biolink:treats MONDO:0004375 PMID:41385096 "[{""id"":""uuid:befb59f9-fdbf-4ccc-a546-6950374ef15b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f7b4c5a4-625f-4811-8d5d-c5af7c7c408b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INVOKANA (canagliflozin) is indicated: as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. to reduce the risk of major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction and nonfatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease (CVD). to reduce the risk of end-stage kidney disease (ESKD), doubling of serum creatinine, cardiovascular (CV) death, and hospitalization for heart failure in adults with type 2 diabetes mellitus and diabetic nephropathy with albuminuria greater than 300 mg/day. uuid:f33a99c2-2dff-4989-b2ab-4a0298958db5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:73274 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:cb8eda65-b99f-4d4b-8402-a5e635aff39b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:838cc033-17db-4acb-b2b9-619f9b597447"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INVOKANA (canagliflozin) is indicated: as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. to reduce the risk of major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction and nonfatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease (CVD). to reduce the risk of end-stage kidney disease (ESKD), doubling of serum creatinine, cardiovascular (CV) death, and hospitalization for heart failure in adults with type 2 diabetes mellitus and diabetic nephropathy with albuminuria greater than 300 mg/day. uuid:f4052603-7250-46d1-bd57-7da0ad7420ed biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17334 biolink:treats MONDO:0017767 PMID:41385096 "[{""id"":""uuid:84bb0203-ff60-4fd9-bfec-6e0b7c7b9355"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a6ce80c3-ef70-47d5-af91-be1f6f0628e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Bicillin L-A and other antibacterial drugs, Bicillin L-A should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Intramuscular penicillin G benzathine is indicated in the treatment of infections due to penicillin-G-sensitive microorganisms that are susceptible to the low and very prolonged serum levels common to this particular dosage form. Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response. The following infections will usually respond to adequate dosage of intramuscular penicillin G benzathine: Mild-to-moderate infections of the upper-respiratory tract due to susceptible streptococci. Venereal infections —Syphilis, yaws, bejel, and pinta. Medical Conditions in which Penicillin G Benzathine Therapy is indicated as Prophylaxis: Rheumatic fever and/or chorea —Prophylaxis with penicillin G benzathine has proven effective in preventing recurrence of these conditions. It has also been used as follow-up prophylactic therapy for rheumatic heart disease and acute glomerulonephritis. CHEBI:18208 uuid:760c4237-1bde-4831-88be-d38588d56b0e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17334 biolink:treats MONDO:0001595 PMID:41385096 "[{""id"":""uuid:f2f0cb64-fa72-40b1-b31b-156a78bb3187"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e13fcd8a-7b9e-431a-ae8e-11720ae87d2f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Bicillin L-A and other antibacterial drugs, Bicillin L-A should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Intramuscular penicillin G benzathine is indicated in the treatment of infections due to penicillin-G-sensitive microorganisms that are susceptible to the low and very prolonged serum levels common to this particular dosage form. Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response. The following infections will usually respond to adequate dosage of intramuscular penicillin G benzathine: Mild-to-moderate infections of the upper-respiratory tract due to susceptible streptococci. Venereal infections —Syphilis, yaws, bejel, and pinta. Medical Conditions in which Penicillin G Benzathine Therapy is indicated as Prophylaxis: Rheumatic fever and/or chorea —Prophylaxis with penicillin G benzathine has proven effective in preventing recurrence of these conditions. It has also been used as follow-up prophylactic therapy for rheumatic heart disease and acute glomerulonephritis. CHEBI:18208 uuid:07658225-52fa-40e5-8e59-dbf7fcf2c77a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17334 biolink:treats MONDO:0006955 PMID:41385096 "[{""id"":""uuid:a311aaf7-05d1-4010-98eb-6089672cb236"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f68d200e-2d7a-4136-8f52-d5c72f54b85f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Bicillin L-A and other antibacterial drugs, Bicillin L-A should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Intramuscular penicillin G benzathine is indicated in the treatment of infections due to penicillin-G-sensitive microorganisms that are susceptible to the low and very prolonged serum levels common to this particular dosage form. Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response. The following infections will usually respond to adequate dosage of intramuscular penicillin G benzathine: Mild-to-moderate infections of the upper-respiratory tract due to susceptible streptococci. Venereal infections —Syphilis, yaws, bejel, and pinta. Medical Conditions in which Penicillin G Benzathine Therapy is indicated as Prophylaxis: Rheumatic fever and/or chorea —Prophylaxis with penicillin G benzathine has proven effective in preventing recurrence of these conditions. It has also been used as follow-up prophylactic therapy for rheumatic heart disease and acute glomerulonephritis. CHEBI:18208 uuid:0e81e918-b439-45bd-9b0e-bee960273f47 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17334 biolink:treats UMLS:C0156221 PMID:41385096 "[{""id"":""uuid:472bcde2-e4c1-460d-829c-c21907529faa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a9d55486-64a3-4611-a360-20259495f0fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Bicillin L-A and other antibacterial drugs, Bicillin L-A should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Intramuscular penicillin G benzathine is indicated in the treatment of infections due to penicillin-G-sensitive microorganisms that are susceptible to the low and very prolonged serum levels common to this particular dosage form. Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response. The following infections will usually respond to adequate dosage of intramuscular penicillin G benzathine: Mild-to-moderate infections of the upper-respiratory tract due to susceptible streptococci. Venereal infections —Syphilis, yaws, bejel, and pinta. Medical Conditions in which Penicillin G Benzathine Therapy is indicated as Prophylaxis: Rheumatic fever and/or chorea —Prophylaxis with penicillin G benzathine has proven effective in preventing recurrence of these conditions. It has also been used as follow-up prophylactic therapy for rheumatic heart disease and acute glomerulonephritis. CHEBI:18208 uuid:1f2c8621-7680-4384-9f4a-c4500e844810 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3696 biolink:treats MONDO:0043424 PMID:41385096 "[{""id"":""uuid:eefcdede-00bb-4b40-a269-c8df20744490"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dfcb2fa0-bc9a-488a-91ac-5857dda224c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cidofovir injection is indicated for the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS). THE SAFETY AND EFFICACY OF CIDOFOVIR INJECTION HAVE NOT BEEN ESTABLISHED FOR TREATMENT OF OTHER CMV INFECTIONS (SUCH AS PNEUMONITIS OR GASTROENTERITIS), CONGENITAL OR NEONATAL CMV DISEASE, OR CMV DISEASE IN NON-HIV-INFECTED INDIVIDUALS. DESCRIPTION OF CLINICAL TRIALS Three phase II/III controlled trials of cidofovir injection have been conducted in HIV-infected patients with CMV retinitis. Delayed Versus Immediate Therapy (Study 105) In stage 1 of this open-label trial, conducted by the Studies of the Ocular Complications of AIDS (SOCA) Clinical Research Group, 29 previously untreated patients with peripheral CMV retinitis were randomized to either immediate treatment with cidofovir injection (5 mg/kg once a week for 2 weeks, then 3 mg/kg every other week) or to have cidofovir injection delayed until progression of CMV retinitis 13 . In stage 2 of this trial, an additional 35 previously untreated patients with peripheral CMV retinitis were randomized to either immediate treatment with cidofovir injection (5 mg/kg once a week for 2 weeks, then 5 mg/kg every other week), immediate treatment with cidofovir injection (5 mg/kg once a week for 2 weeks, then 3 mg/kg every other week), or to have cidofovir injection delayed until progression of CMV retinitis. Of the 64 patients in this study, 12 were randomized to 5 mg/kg maintenance therapy, 26 to 3 mg/kg maintenance therapy, and 26 to delayed therapy. Of the 12 patients enrolled in the 5 mg/kg maintenance group, 5 patients progressed, 5 patients discontinued therapy and 2 patients had no progression at study completion. Based on masked readings of retinal photographs, the median [95% confidence interval (CI)] time to retinitis progression was not reached (25, not reached) for the 5 mg/kg maintenance group. Median (95% CI) time to the alternative endpoint of retinitis progression or study drug discontinuation was 44 days (24, 207) for the 5 mg/kg maintenance group. Patients receiving 5 mg/kg maintenance had delayed time to retinitis progression compared to patients receiving 3 mg/kg maintenance or deferred therapy. Delayed Versus Immediate Therapy (Study 106) In an open-label trial, 48 previously untreated patients with peripheral CMV retinitis were randomized to either immediate treatment with cidofovir injection (5 mg/kg once a week for 2 weeks, then 5 mg/kg every other week), or to have cidofovir injection delayed until progression of CMV retinitis 14 . Patient baseline characteristics and disposition are shown in Table 3. Of 25 and 23 patients in the immediate and delayed groups respectively, 23 and 21 were evaluable for retinitis progression as determined by retinal photography. Based on masked readings of retinal photographs, the median [95% confidence interval (CI)] times to retinitis progression were 120 days (40, 134) and 22 days (10, 27) for the immediate and delayed therapy groups, respectively. This difference was statistically significant. However, because of the limited number of patients remaining on treatment over time (3 of 25 patients received cidofovir injection for 120 days or longer), the median time to progression for the immediate therapy group was difficult to precisely estimate. Median (95% CI) times to the alternative endpoint of retinitis progression or study drug discontinuation (including adverse events, withdrawn consent, and systemic CMV disease) were 52 days (37, 85) and 22 days (13, 27) for the immediate and delayed therapy groups, respectively. This difference was statistically significant. Time to progression estimates from this study may not be directly comparable to estimates reported for other therapies. Table 3. Patient Characteristics and Disposition (Study 106) * One patient died 2 weeks after withdrawing consent. † Two patients on immediate therapy were diagnosed with CMV disease and discontinued from study. One patient on delayed therapy was diagnosed with CMV gastrointestinal disease. ‡ CMV retinitis progression not confirmed by retinal photography. Immediate Therapy (n = 25) Delayed Therapy (n = 23) Baseline Characteristics Age (years) 38 38 Sex (M/F) 24/1 22/1 Median CD4 Cell Count 6 9 Endpoints CMV Retinitis Progression 10 18 Discontinued Due to Adverse Event 6 0 Withdrew Consent 3 * 1 Discontinued Due to Intercurrent Illness 2 † 1 † Discontinued Based on Ophthalmological Examination 1 ‡ 1 ‡ No Progression at Study Completion 1 0 Not Evaluable at Baseline 2 2 Dose-response study of cidofovir injection (Study 107) In an open-label trial, 100 patients with relapsing CMV retinitis were randomized to receive 5 mg/kg once a week for 2 weeks and then either 5 mg/kg (n = 49) or 3 mg/kg (n = 51) every other week. Enrolled patients had been diagnosed with CMV retinitis an average of 390 days prior to randomization and had received a median of 3.8 prior courses of systemic CMV therapy. Eighty four of the 100 patients were considered evaluable for progression by serial retinal photographs (43 randomized to 5 mg/kg and 41 randomized to 3 mg/kg). Twenty-six and 21 patients discontinued therapy due to either an adverse event, intercurrent illness, excluded medication, or withdrawn consent in the 5 mg/kg and 3 mg/kg groups, respectively. Thirty-eight of the 100 randomized patients had progressed according to masked assessment of serial retinal photographs (13 randomized to 5 mg/kg and 25 randomized to 3 mg/kg). Using retinal photographs, the median (95% CI) times to retinitis progression for the 5 mg/kg and 3 mg/kg groups were 115 days (70, not reached) and 49 days (35, 52), respectively. This difference was statistically significant. Similar to Study 106, the median time to retinitis progression for the 5 mg/kg group was difficult to precisely estimate due to the limited number of patients remaining on treatment over time (4 of the 49 patients in the 5 mg/kg group were treated for 115 days or longer). Median (95% CI) times to the alternative endpoint of retinitis progression or study drug discontinuation were 49 days (38, 63) and 35 days (27, 39) for the 5 mg/kg and 3 mg/kg groups, respectively. This difference was statistically significant. uuid:aaabd1f5-ee06-4715-9302-8759b6aba6ba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3696 biolink:treats MONDO:0005132 PMID:41385096 "[{""id"":""uuid:e87a0b17-e7f3-4f98-99c9-3d1849b74f7d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c43dd47a-c019-4ec8-90b5-1b7b1471aec9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cidofovir injection is indicated for the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS). THE SAFETY AND EFFICACY OF CIDOFOVIR INJECTION HAVE NOT BEEN ESTABLISHED FOR TREATMENT OF OTHER CMV INFECTIONS (SUCH AS PNEUMONITIS OR GASTROENTERITIS), CONGENITAL OR NEONATAL CMV DISEASE, OR CMV DISEASE IN NON-HIV-INFECTED INDIVIDUALS. DESCRIPTION OF CLINICAL TRIALS Three phase II/III controlled trials of cidofovir injection have been conducted in HIV-infected patients with CMV retinitis. Delayed Versus Immediate Therapy (Study 105) In stage 1 of this open-label trial, conducted by the Studies of the Ocular Complications of AIDS (SOCA) Clinical Research Group, 29 previously untreated patients with peripheral CMV retinitis were randomized to either immediate treatment with cidofovir injection (5 mg/kg once a week for 2 weeks, then 3 mg/kg every other week) or to have cidofovir injection delayed until progression of CMV retinitis 13 . In stage 2 of this trial, an additional 35 previously untreated patients with peripheral CMV retinitis were randomized to either immediate treatment with cidofovir injection (5 mg/kg once a week for 2 weeks, then 5 mg/kg every other week), immediate treatment with cidofovir injection (5 mg/kg once a week for 2 weeks, then 3 mg/kg every other week), or to have cidofovir injection delayed until progression of CMV retinitis. Of the 64 patients in this study, 12 were randomized to 5 mg/kg maintenance therapy, 26 to 3 mg/kg maintenance therapy, and 26 to delayed therapy. Of the 12 patients enrolled in the 5 mg/kg maintenance group, 5 patients progressed, 5 patients discontinued therapy and 2 patients had no progression at study completion. Based on masked readings of retinal photographs, the median [95% confidence interval (CI)] time to retinitis progression was not reached (25, not reached) for the 5 mg/kg maintenance group. Median (95% CI) time to the alternative endpoint of retinitis progression or study drug discontinuation was 44 days (24, 207) for the 5 mg/kg maintenance group. Patients receiving 5 mg/kg maintenance had delayed time to retinitis progression compared to patients receiving 3 mg/kg maintenance or deferred therapy. Delayed Versus Immediate Therapy (Study 106) In an open-label trial, 48 previously untreated patients with peripheral CMV retinitis were randomized to either immediate treatment with cidofovir injection (5 mg/kg once a week for 2 weeks, then 5 mg/kg every other week), or to have cidofovir injection delayed until progression of CMV retinitis 14 . Patient baseline characteristics and disposition are shown in Table 3. Of 25 and 23 patients in the immediate and delayed groups respectively, 23 and 21 were evaluable for retinitis progression as determined by retinal photography. Based on masked readings of retinal photographs, the median [95% confidence interval (CI)] times to retinitis progression were 120 days (40, 134) and 22 days (10, 27) for the immediate and delayed therapy groups, respectively. This difference was statistically significant. However, because of the limited number of patients remaining on treatment over time (3 of 25 patients received cidofovir injection for 120 days or longer), the median time to progression for the immediate therapy group was difficult to precisely estimate. Median (95% CI) times to the alternative endpoint of retinitis progression or study drug discontinuation (including adverse events, withdrawn consent, and systemic CMV disease) were 52 days (37, 85) and 22 days (13, 27) for the immediate and delayed therapy groups, respectively. This difference was statistically significant. Time to progression estimates from this study may not be directly comparable to estimates reported for other therapies. Table 3. Patient Characteristics and Disposition (Study 106) * One patient died 2 weeks after withdrawing consent. † Two patients on immediate therapy were diagnosed with CMV disease and discontinued from study. One patient on delayed therapy was diagnosed with CMV gastrointestinal disease. ‡ CMV retinitis progression not confirmed by retinal photography. Immediate Therapy (n = 25) Delayed Therapy (n = 23) Baseline Characteristics Age (years) 38 38 Sex (M/F) 24/1 22/1 Median CD4 Cell Count 6 9 Endpoints CMV Retinitis Progression 10 18 Discontinued Due to Adverse Event 6 0 Withdrew Consent 3 * 1 Discontinued Due to Intercurrent Illness 2 † 1 † Discontinued Based on Ophthalmological Examination 1 ‡ 1 ‡ No Progression at Study Completion 1 0 Not Evaluable at Baseline 2 2 Dose-response study of cidofovir injection (Study 107) In an open-label trial, 100 patients with relapsing CMV retinitis were randomized to receive 5 mg/kg once a week for 2 weeks and then either 5 mg/kg (n = 49) or 3 mg/kg (n = 51) every other week. Enrolled patients had been diagnosed with CMV retinitis an average of 390 days prior to randomization and had received a median of 3.8 prior courses of systemic CMV therapy. Eighty four of the 100 patients were considered evaluable for progression by serial retinal photographs (43 randomized to 5 mg/kg and 41 randomized to 3 mg/kg). Twenty-six and 21 patients discontinued therapy due to either an adverse event, intercurrent illness, excluded medication, or withdrawn consent in the 5 mg/kg and 3 mg/kg groups, respectively. Thirty-eight of the 100 randomized patients had progressed according to masked assessment of serial retinal photographs (13 randomized to 5 mg/kg and 25 randomized to 3 mg/kg). Using retinal photographs, the median (95% CI) times to retinitis progression for the 5 mg/kg and 3 mg/kg groups were 115 days (70, not reached) and 49 days (35, 52), respectively. This difference was statistically significant. Similar to Study 106, the median time to retinitis progression for the 5 mg/kg group was difficult to precisely estimate due to the limited number of patients remaining on treatment over time (4 of the 49 patients in the 5 mg/kg group were treated for 115 days or longer). Median (95% CI) times to the alternative endpoint of retinitis progression or study drug discontinuation were 49 days (38, 63) and 35 days (27, 39) for the 5 mg/kg and 3 mg/kg groups, respectively. This difference was statistically significant. uuid:c21245e5-22de-4b51-93f5-64343d8dfbe8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3A58010674 biolink:treats UMLS:C4509926 PMID:41385096 "[{""id"":""uuid:d64d15af-1045-4940-b3f1-bfacd7432d78"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:016bb788-c7ae-45ce-ad0d-693098db864c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Stimufend is a leukocyte growth factor indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. ( 1.1 ) Increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome). ( 1.2 ) Limitations of Use Stimufend is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation. uuid:928ae2e8-9dd4-4b80-869f-783d20af222a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4469 biolink:treats MONDO:0005485 PMID:41385096 "[{""id"":""uuid:551192e6-65f9-48af-9aa7-41b916266f59"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6fff5a11-ae31-4e2b-b54c-76b637e071fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DEXEDRINE is indicated in: Narcolepsy Attention Deficit Disorder with Hyperactivity As an integral part of a total treatment program that typically includes other measures (psychological, educational, social) for patients (ages 6 years to 16 years) with this syndrome. A diagnosis of Attention Deficit Hyperactivity Disorder (ADHD; DSM-IV) implies the presence of the hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years. The symptoms must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and be present in 2 or more settings, e.g., school (or work) and at home. The symptoms must not be better accounted for by another mental disorder. For the Inattentive Type, at least 6 of the following symptoms must have persisted for at least 6 months: lack of attention to details/careless mistakes; lack of sustained attention; poor listener; failure to follow through on tasks; poor organization; avoids tasks requiring sustained mental effort; loses things; easily distracted; forgetful. For the Hyperactive-Impulsive Type, at least 6 of the following symptoms must have persisted for at least 6 months: fidgeting/squirming; leaving seat; inappropriate running/climbing; difficulty with quiet activities; “on the go”; excessive talking; blurting answers; can't wait turn; intrusive. The Combined Type requires both inattentive and hyperactive-impulsive criteria to be met. Special Diagnostic Considerations Specific etiology of this syndrome is unknown, and there is no single diagnostic test. Adequate diagnosis requires the use of medical and special psychological, educational, and social resources. Learning may or may not be impaired. The diagnosis must be based upon a complete history and evaluation of the patient and not solely on the presences of the required number of DSM-IV characteristics. Need for Comprehensive Treatment Program DEXEDRINE is indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational, social) for patients with this syndrome. Drug treatment may not be indicated for all patients with this syndrome. Stimulants are not intended for use in patients who exhibit symptoms secondary to environmental factors and/or other primary psychiatric disorders, including psychosis. Appropriate educational placement is essential and psychosocial intervention is often helpful. When remedial measures alone are insufficient, the decision to prescribe stimulant medication will depend upon the physician’s assessment of the chronicity and severity of the patient’s symptoms. uuid:f4324599-8a0f-4549-a357-021dcbcc6513 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17347 biolink:treats UMLS:C0432476 PMID:41385096 "[{""id"":""uuid:999cdb68-2f96-4a18-ba1b-fc1d3f30e358"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4d04db82-590e-484f-88d2-194fd2e567af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KYZATREX™ is indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired): testicular failure due to conditions such as cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone concentrations and gonadotropins (folliclestimulating hormone (FSH), luteinizing hormone (LH)) above the normal range. Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency, pituitary-hypothalamic injury from tumors, trauma, or radiation. These men have low serum testosterone concentrations but have gonadotropins in the normal or low range. uuid:0bb5d9a4-723e-4390-90c6-ea53a1932951 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:30746 biolink:treats HP:0001987 PMID:41385096 "[{""id"":""uuid:1255dae0-8b47-4a11-a8d5-d0b32191be42"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b0437ecd-63f7-4912-8251-7cea6392d1df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Phenylacetate and Sodium Benzoate Injection is a nitrogen binding agent indicated as adjunctive therapy for the treatment of acute hyperammonemia and associated encephalopathy in paediatric and adult patients with deficiencies in enzymes of the urea cycle. ( 1 ) uuid:06004aca-ab2e-482a-946c-04d662b4d9b1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1368383 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:d276ad01-cca1-4e14-95cc-e330b452ec18"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c57c5e43-10a4-42e6-8e9b-726424276145"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:bd97f219-c5c7-4349-9016-744c8f439735"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Alogliptin and metformin HCl tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.|[PMDA] A new combination drug indicated for the treatment of type 2 diabetes mellitus (only when a concomitant use of alogliptin benzoate with metformin hydrochloride is deemed appropriate). uuid:c363c29b-f2db-4097-9dfb-7723a4e09086 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:122361353 biolink:treats MONDO:0018076 PMID:41385096 "[{""id"":""uuid:f4e01b99-9fda-4076-8017-076af553c2d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:913bfc46-2307-47b5-b4e2-86996bd45d22"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cosyntropin for Injection is intended for use as a diagnostic agent in the screening of patients presumed to have adrenocortical insufficiency. Because of its rapid effect on the adrenal cortex it may be utilized to perform a 30-minute test of adrenal function (plasma cortisol response) as an office or outpatient procedure, using only 2 venipunctures (see DOSAGE AND ADMINISTRATION section). Severe hypofunction of the pituitary - adrenal axis is usually associated with subnormal plasma cortisol values but a low basal level is not per se evidence of adrenal insufficiency and does not suffice to make the diagnosis. Many patients with proven insufficiency will have normal basal levels and will develop signs of insufficiency only when stressed. For this reason a criterion which should be used in establishing the diagnosis is the failure to respond to adequate corticotropin stimulation. When presumptive adrenal insufficiency is diagnosed by a subnormal Cosyntropin for Injection test, further studies are indicated to determine if it is primary or secondary. Primary adrenal insufficiency (Addison's disease) is the result of an intrinsic disease process, such as tuberculosis within the gland. The production of adrenocortical hormones is deficient despite high ACTH levels (feedback mechanism). Secondary or relative insufficiency arises as the result of defective production of ACTH leading in turn to disuse atrophy of the adrenal cortex. It is commonly seen, for example, as result of corticosteroid therapy, Sheehan's syndrome and pituitary tumors or ablation. The differentiation of both types is based on the premise that a primarily defective gland cannot be stimulated by ACTH whereas a secondarily defective gland is potentially functional and will respond to adequate stimulation with ACTH. Patients selected for further study as the result of a subnormal Cosyntropin for Injection test should be given a 3 or 4 day course of treatment with Repository Corticotropin Injection USP and then retested. Suggested doses are 40 USP units twice daily for 4 days or 60 USP units twice daily for 3 days. Under these conditions little or no increase in plasma cortisol levels will be seen in Addison's disease whereas higher or even normal levels will be seen in cases with secondary adrenal insufficiency. uuid:eb8766c5-8e91-4281-962f-ae5d8874af74 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:122361353 biolink:treats MONDO:0019618 PMID:41385096 "[{""id"":""uuid:604b0bc5-f93e-4c20-a1ab-1806e7f41922"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9b6ceac2-eac8-4e15-9cc2-cfed83601bd7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cosyntropin for Injection is intended for use as a diagnostic agent in the screening of patients presumed to have adrenocortical insufficiency. Because of its rapid effect on the adrenal cortex it may be utilized to perform a 30-minute test of adrenal function (plasma cortisol response) as an office or outpatient procedure, using only 2 venipunctures (see DOSAGE AND ADMINISTRATION section). Severe hypofunction of the pituitary - adrenal axis is usually associated with subnormal plasma cortisol values but a low basal level is not per se evidence of adrenal insufficiency and does not suffice to make the diagnosis. Many patients with proven insufficiency will have normal basal levels and will develop signs of insufficiency only when stressed. For this reason a criterion which should be used in establishing the diagnosis is the failure to respond to adequate corticotropin stimulation. When presumptive adrenal insufficiency is diagnosed by a subnormal Cosyntropin for Injection test, further studies are indicated to determine if it is primary or secondary. Primary adrenal insufficiency (Addison's disease) is the result of an intrinsic disease process, such as tuberculosis within the gland. The production of adrenocortical hormones is deficient despite high ACTH levels (feedback mechanism). Secondary or relative insufficiency arises as the result of defective production of ACTH leading in turn to disuse atrophy of the adrenal cortex. It is commonly seen, for example, as result of corticosteroid therapy, Sheehan's syndrome and pituitary tumors or ablation. The differentiation of both types is based on the premise that a primarily defective gland cannot be stimulated by ACTH whereas a secondarily defective gland is potentially functional and will respond to adequate stimulation with ACTH. Patients selected for further study as the result of a subnormal Cosyntropin for Injection test should be given a 3 or 4 day course of treatment with Repository Corticotropin Injection USP and then retested. Suggested doses are 40 USP units twice daily for 4 days or 60 USP units twice daily for 3 days. Under these conditions little or no increase in plasma cortisol levels will be seen in Addison's disease whereas higher or even normal levels will be seen in cases with secondary adrenal insufficiency. uuid:931e3dc5-60cd-4bb6-9e13-1cd64156b633 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:122361353 biolink:treats MONDO:0017611 PMID:41385096 "[{""id"":""uuid:e22bd2a6-0e2a-4f4f-941e-70d3d80c2560"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a8f6805f-c96d-4c5f-92e1-87689774bac5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cosyntropin for Injection is intended for use as a diagnostic agent in the screening of patients presumed to have adrenocortical insufficiency. Because of its rapid effect on the adrenal cortex it may be utilized to perform a 30-minute test of adrenal function (plasma cortisol response) as an office or outpatient procedure, using only 2 venipunctures (see DOSAGE AND ADMINISTRATION section). Severe hypofunction of the pituitary - adrenal axis is usually associated with subnormal plasma cortisol values but a low basal level is not per se evidence of adrenal insufficiency and does not suffice to make the diagnosis. Many patients with proven insufficiency will have normal basal levels and will develop signs of insufficiency only when stressed. For this reason a criterion which should be used in establishing the diagnosis is the failure to respond to adequate corticotropin stimulation. When presumptive adrenal insufficiency is diagnosed by a subnormal Cosyntropin for Injection test, further studies are indicated to determine if it is primary or secondary. Primary adrenal insufficiency (Addison's disease) is the result of an intrinsic disease process, such as tuberculosis within the gland. The production of adrenocortical hormones is deficient despite high ACTH levels (feedback mechanism). Secondary or relative insufficiency arises as the result of defective production of ACTH leading in turn to disuse atrophy of the adrenal cortex. It is commonly seen, for example, as result of corticosteroid therapy, Sheehan's syndrome and pituitary tumors or ablation. The differentiation of both types is based on the premise that a primarily defective gland cannot be stimulated by ACTH whereas a secondarily defective gland is potentially functional and will respond to adequate stimulation with ACTH. Patients selected for further study as the result of a subnormal Cosyntropin for Injection test should be given a 3 or 4 day course of treatment with Repository Corticotropin Injection USP and then retested. Suggested doses are 40 USP units twice daily for 4 days or 60 USP units twice daily for 3 days. Under these conditions little or no increase in plasma cortisol levels will be seen in Addison's disease whereas higher or even normal levels will be seen in cases with secondary adrenal insufficiency. uuid:d4ddf8fb-f45b-4cf8-867a-524440c52fb8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3423 biolink:treats MONDO:0018177 PMID:41385096 "[{""id"":""uuid:1c01b406-16f1-4de0-bd40-82d74bb5e471"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:fdbaf881-1c3f-49c4-a2f0-8404fac80913"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:081fe208-a3a1-42ee-b5e9-7d1ac8ed8858"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/carmustine-medac-previously-carmustine-obvius""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carmustine for injection is indicated as palliative therapy as a single agent or in established combination therapy in the following: - Brain tumors glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma, and metastatic brain tumors. - Multiple myeloma in combination with prednisone. - Relapsed or refractory Hodgkin's lymphoma in combination with other approved drugs. - Relapsed or refractory Non-Hodgkin's lymphomas in combination with other approved drugs.|[EMA] Carmustine is indicated n adults in the following malignant neoplasms as a single agent or in combination with other antineoplastic agents and/or other therapeutic measures (radiotherapy, surgery):, , , Brain tumours (glioblastoma, brain-stem gliomas, medulloblastoma, astrocytoma and ependymoma), brain metastases, Secondary therapy in non-Hodgkin’s lymphoma and Hodgkin’s disease, as conditioning treatment prior to autologous haematopoietic progenitor cell transplantation (HPCT) in malignant haematological diseases (Hodgkin’s disease / Non-hodgkin’s lymphoma)., , uuid:43a6e4f5-030f-4f09-be7a-99749378309b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3423 biolink:treats MONDO:0003153 PMID:41385096 "[{""id"":""uuid:699819ed-4949-446a-8a0b-593c08d88c92"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5e9b247d-c1d6-47c8-814b-17ee82d623a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carmustine for injection is indicated as palliative therapy as a single agent or in established combination therapy in the following: - Brain tumors glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma, and metastatic brain tumors. - Multiple myeloma in combination with prednisone. - Relapsed or refractory Hodgkin's lymphoma in combination with other approved drugs. - Relapsed or refractory Non-Hodgkin's lymphomas in combination with other approved drugs. uuid:7bff1609-c1b6-4435-9652-b5bb0ee2ee7a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3423 biolink:treats MONDO:0007959 PMID:41385096 "[{""id"":""uuid:77755e06-f0aa-4eb6-b206-25d3646f095a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:acb2c27f-ca47-48ab-9fd0-8dbda817cd81"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:d816d8e5-7d2c-41b3-89ba-bf7fc1e63a08"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/carmustine-medac-previously-carmustine-obvius""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carmustine for injection is indicated as palliative therapy as a single agent or in established combination therapy in the following: - Brain tumors glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma, and metastatic brain tumors. - Multiple myeloma in combination with prednisone. - Relapsed or refractory Hodgkin's lymphoma in combination with other approved drugs. - Relapsed or refractory Non-Hodgkin's lymphomas in combination with other approved drugs.|[EMA] Carmustine is indicated n adults in the following malignant neoplasms as a single agent or in combination with other antineoplastic agents and/or other therapeutic measures (radiotherapy, surgery):, , , Brain tumours (glioblastoma, brain-stem gliomas, medulloblastoma, astrocytoma and ependymoma), brain metastases, Secondary therapy in non-Hodgkin’s lymphoma and Hodgkin’s disease, as conditioning treatment prior to autologous haematopoietic progenitor cell transplantation (HPCT) in malignant haematological diseases (Hodgkin’s disease / Non-hodgkin’s lymphoma)., , uuid:5648666f-aa41-4dbb-bd59-e53ededa1550 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3423 biolink:treats MONDO:0019781 PMID:41385096 "[{""id"":""uuid:121ba5d0-96a6-4ed5-b71a-75c9262bed66"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:9e06e9cf-3abb-4790-965a-710ca99b2625"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e56fe8ec-9cbe-43d6-8e8a-821e8a7aeecc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/carmustine-medac-previously-carmustine-obvius""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carmustine for injection is indicated as palliative therapy as a single agent or in established combination therapy in the following: - Brain tumors glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma, and metastatic brain tumors. - Multiple myeloma in combination with prednisone. - Relapsed or refractory Hodgkin's lymphoma in combination with other approved drugs. - Relapsed or refractory Non-Hodgkin's lymphomas in combination with other approved drugs.|[EMA] Carmustine is indicated n adults in the following malignant neoplasms as a single agent or in combination with other antineoplastic agents and/or other therapeutic measures (radiotherapy, surgery):, , , Brain tumours (glioblastoma, brain-stem gliomas, medulloblastoma, astrocytoma and ependymoma), brain metastases, Secondary therapy in non-Hodgkin’s lymphoma and Hodgkin’s disease, as conditioning treatment prior to autologous haematopoietic progenitor cell transplantation (HPCT) in malignant haematological diseases (Hodgkin’s disease / Non-hodgkin’s lymphoma)., , uuid:30199c12-e4fb-41af-9873-9192f62047cb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3423 biolink:treats MONDO:0016698 PMID:41385096 "[{""id"":""uuid:a1e1c321-1fa3-4ec8-9172-de111c70789c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:ba46e566-1290-44d7-a628-ecd09ee431bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:0546add5-76b6-448f-ba72-2ed137cf50e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/carmustine-medac-previously-carmustine-obvius""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carmustine for injection is indicated as palliative therapy as a single agent or in established combination therapy in the following: - Brain tumors glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma, and metastatic brain tumors. - Multiple myeloma in combination with prednisone. - Relapsed or refractory Hodgkin's lymphoma in combination with other approved drugs. - Relapsed or refractory Non-Hodgkin's lymphomas in combination with other approved drugs.|[EMA] Carmustine is indicated n adults in the following malignant neoplasms as a single agent or in combination with other antineoplastic agents and/or other therapeutic measures (radiotherapy, surgery):, , , Brain tumours (glioblastoma, brain-stem gliomas, medulloblastoma, astrocytoma and ependymoma), brain metastases, Secondary therapy in non-Hodgkin’s lymphoma and Hodgkin’s disease, as conditioning treatment prior to autologous haematopoietic progenitor cell transplantation (HPCT) in malignant haematological diseases (Hodgkin’s disease / Non-hodgkin’s lymphoma)., , uuid:a7019ef1-8b72-45d6-8b73-fd06361f0bb7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3423 biolink:treats MONDO:1040026 PMID:41385096 "[{""id"":""uuid:6b227142-baa7-4f3a-8512-be5b52487a3e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:bece6057-46f6-4c60-bc07-ff3f17501cc9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:8ca8d773-dc6d-4217-95d0-be0f3b00db16"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/carmustine-medac-previously-carmustine-obvius""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carmustine for injection is indicated as palliative therapy as a single agent or in established combination therapy in the following: - Brain tumors glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma, and metastatic brain tumors. - Multiple myeloma in combination with prednisone. - Relapsed or refractory Hodgkin's lymphoma in combination with other approved drugs. - Relapsed or refractory Non-Hodgkin's lymphomas in combination with other approved drugs.|[EMA] Carmustine is indicated n adults in the following malignant neoplasms as a single agent or in combination with other antineoplastic agents and/or other therapeutic measures (radiotherapy, surgery):, , , Brain tumours (glioblastoma, brain-stem gliomas, medulloblastoma, astrocytoma and ependymoma), brain metastases, Secondary therapy in non-Hodgkin’s lymphoma and Hodgkin’s disease, as conditioning treatment prior to autologous haematopoietic progenitor cell transplantation (HPCT) in malignant haematological diseases (Hodgkin’s disease / Non-hodgkin’s lymphoma)., , uuid:65da4fc9-3c60-4906-a126-fa8a85d55772 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3423 biolink:treats MONDO:0009693 PMID:41385096 "[{""id"":""uuid:8daaab49-59fe-4dfd-b926-3bc69f65da2c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b24c34db-1389-48a6-a885-c57520514adb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carmustine for injection is indicated as palliative therapy as a single agent or in established combination therapy in the following: - Brain tumors glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma, and metastatic brain tumors. - Multiple myeloma in combination with prednisone. - Relapsed or refractory Hodgkin's lymphoma in combination with other approved drugs. - Relapsed or refractory Non-Hodgkin's lymphomas in combination with other approved drugs. uuid:ca8bb654-af7b-4e7e-b97b-899491e29069 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3423 biolink:treats MONDO:0009348 PMID:41385096 "[{""id"":""uuid:083e144a-099f-4410-82d5-c5faae6cf4d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e1d4748a-c69a-461a-8dc4-b664359231aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carmustine for injection is indicated as palliative therapy as a single agent or in established combination therapy in the following: - Brain tumors glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma, and metastatic brain tumors. - Multiple myeloma in combination with prednisone. - Relapsed or refractory Hodgkin's lymphoma in combination with other approved drugs. - Relapsed or refractory Non-Hodgkin's lymphomas in combination with other approved drugs. uuid:3a15d29c-7225-4626-bea0-514eb4236ee3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32954 biolink:treats HP:0002902 PMID:41385096 "[{""id"":""uuid:67c41d5b-f80a-41d8-a4b9-0205af3327e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:39f13e87-60b7-4326-b09b-435fa93e664f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Acetate Injection, USP is indicated as a source of sodium for addition to large volume intravenous fluids to prevent or correct hyponatremia in patients with restricted or no oral intake. It is also useful as an additive for preparing specific intravenous fluid formulas when the needs of the patient cannot be met by standard electrolyte or nutrient solutions. uuid:b9c73668-bd15-4a89-af2b-e288ff3d9a98 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:44149770 biolink:treats MONDO:0005393 PMID:41385096 "[{""id"":""uuid:b6df7aba-41f3-40d6-a3d7-da581e32c8da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ed9a9d5f-9468-4c8e-8f9a-83067c479a98"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the treatment of chronic gouty arthritis when complicated by frequent, recurrent acute attacks of gout. uuid:440a55cc-e583-4f1e-9a23-3a53cda95c62 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18258 biolink:treats MONDO:1010100 PMID:41385096 "[{""id"":""uuid:127268fb-ccfb-4a49-946e-22692b175b3f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dbd6e77b-2e30-4c27-b35d-c5d0951847a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Liothyronine sodium injection (T 3 ) is indicated in the treatment of myxedema coma/precoma. Liothyronine sodium injection (T 3 ) can be used in patients allergic to desiccated thyroid or thyroid extract derived from pork or beef. UMLS:C0238298 uuid:7e581ac6-7df0-4d06-ac49-4d856f6b35ec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75984 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:77d5168a-1f0d-4b02-99cb-a1bc5438878f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dfe3efd9-fc36-4350-8436-f49f434f5d54"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In patients without structural heart disease, flecainide is indicated for the prevention of - paroxysmal supraventricular tachycardias (PSVT), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms - paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms. Flecainide is also indicated for the prevention of - documented ventricular arrhythmias, such as sustained ventricular tachycardia ( sustained VT), that in the judgment of the physician, are life-threatening. Use of flecainide for the treatment of sustained VT, like other antiarrhythmics, should be initiated in the hospital. The use of flecainide is not recommended in patients with less severe ventricular arrhythmias even if the patients are symptomatic. Because of the proarrhythmic effects of flecainide, its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment outweigh the risks. Flecainide should not be used in patients with recent myocardial infarction (see Boxed WARNINGS ). Use of flecainide in chronic atrial fibrillation has not been adequately studied and is not recommended (see Boxed WARNINGS ). As is the case for other antiarrhythmic agents, there is no evidence from controlled trials that the use of flecainide favorably affects survival or the incidence of sudden death. uuid:69ff0e3b-1ec3-408d-a1f5-175ffe1d27d4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75984 biolink:treats HP:0004754 PMID:41385096 "[{""id"":""uuid:112999fe-628c-479b-a2c9-f46a1073d6d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:da81d78d-e911-4c53-adf5-5df78ee523fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In patients without structural heart disease, flecainide is indicated for the prevention of - paroxysmal supraventricular tachycardias (PSVT), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms - paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms. Flecainide is also indicated for the prevention of - documented ventricular arrhythmias, such as sustained ventricular tachycardia ( sustained VT), that in the judgment of the physician, are life-threatening. Use of flecainide for the treatment of sustained VT, like other antiarrhythmics, should be initiated in the hospital. The use of flecainide is not recommended in patients with less severe ventricular arrhythmias even if the patients are symptomatic. Because of the proarrhythmic effects of flecainide, its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment outweigh the risks. Flecainide should not be used in patients with recent myocardial infarction (see Boxed WARNINGS ). Use of flecainide in chronic atrial fibrillation has not been adequately studied and is not recommended (see Boxed WARNINGS ). As is the case for other antiarrhythmic agents, there is no evidence from controlled trials that the use of flecainide favorably affects survival or the incidence of sudden death. uuid:c5172df7-f409-431e-b3b2-282974b323a8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135935 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:402107a4-54ff-4a1a-88a1-61fd4dc7cf95"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:85f013b1-3e8b-4249-825d-c92aa0052616"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NUCYNTA ER (tapentadol) is indicated for the management of: pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate neuropathic pain associated with diabetic peripheral neuropathy (DPN) severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. uuid:976caf4b-1fad-49e6-b166-8ed72c062b90 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135935 biolink:treats MONDO:0001583 PMID:41385096 "[{""id"":""uuid:0ba5a29c-bb63-42d9-97a9-3a0778d90830"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:18b945b8-1afe-4ee0-8b61-fe1da3e5692d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NUCYNTA ER (tapentadol) is indicated for the management of: pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate neuropathic pain associated with diabetic peripheral neuropathy (DPN) severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. uuid:bf2cfe09-c092-4715-8f90-d73be1163342 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135935 biolink:treats UMLS:C0278140 PMID:41385096 "[{""id"":""uuid:e5db2dc6-343b-4032-ac95-740087c54365"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:abb476b7-900f-4a82-89d5-949204f80a9f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NUCYNTA (tapentadol) tablets are indicated for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate in adults. uuid:993fee61-b39b-4d53-af62-2e91d0b4901e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:722125 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:57451bdc-3e58-4115-b1d4-708e2cc3cc34"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f20459ba-b5c4-4fb7-9375-00e4db77157c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amlodipine and valsartan tablets are a combination tablet of amlodipine, a dihydropyridine calcium channel blocker (DHP CCB), and valsartan, an angiotensin II receptor blocker (ARB). Amlodipine and valsartan tablets are indicated for the treatment of hypertension, to lower blood pressure: In patients not adequately controlled on monotherapy ( 1 ) As initial therapy in patients likely to need multiple drugs to achieve their blood pressure goals ( 1 ) Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. uuid:a5416cf2-75a7-493f-92a1-8a16e61714f1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2566414 biolink:treats MONDO:0005114 PMID:41385096 "[{""id"":""uuid:7f3aabf9-ad9d-4d24-9dbc-15540c0a367d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8b9adc80-09e4-4208-9743-1b56361b2631"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:24a14fb4-4358-4b72-b2e0-d8999b00124b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In children 6 weeks through 5 years of age (prior to the 6 th birthday), Prevnar 13 is indicated for: active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F. ( 1.1 ) active immunization for the prevention of otitis media caused by S. pneumoniae serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F. No otitis media efficacy data are available for serotypes 1, 3, 5, 6A, 7F, and 19A. ( 1.1 ) In children 6 years through 17 years of age (prior to the 18 th birthday), Prevnar 13 is indicated for: active immunization for the prevention of invasive disease caused by S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F. ( 1.2 ) In adults 18 years of age and older, Prevnar 13 is indicated for: active immunization for the prevention of pneumonia and invasive disease caused by S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F. ( 1.3 ) Limitations of Prevnar 13 Use and Effectiveness Prevnar 13 does not protect against disease caused by S. pneumoniae serotypes that are not in the vaccine. ( 1.4 )|[PMDA] A drug with a new active ingredient indicated for the prophylaxis of pneumococcal disease (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F) in the elderly or in adults who are considered to be at a high risk of pneumococcal disease. uuid:871823f1-02da-423e-a8fc-70e17973ce5d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2566414 biolink:treats MONDO:0005441 PMID:41385096 "[{""id"":""uuid:24d6c10b-6c18-4e61-9c60-8e2831216fa3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2cb7e673-6a56-4cf7-85b1-c52397975709"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In children 6 weeks through 5 years of age (prior to the 6 th birthday), Prevnar 13 is indicated for: active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F. ( 1.1 ) active immunization for the prevention of otitis media caused by S. pneumoniae serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F. No otitis media efficacy data are available for serotypes 1, 3, 5, 6A, 7F, and 19A. ( 1.1 ) In children 6 years through 17 years of age (prior to the 18 th birthday), Prevnar 13 is indicated for: active immunization for the prevention of invasive disease caused by S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F. ( 1.2 ) In adults 18 years of age and older, Prevnar 13 is indicated for: active immunization for the prevention of pneumonia and invasive disease caused by S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F. ( 1.3 ) Limitations of Prevnar 13 Use and Effectiveness Prevnar 13 does not protect against disease caused by S. pneumoniae serotypes that are not in the vaccine. ( 1.4 ) uuid:3c9dbf25-0e62-46dc-b019-0d8017c44372 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2566414 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:77d50fbb-ab95-4d9c-a9ff-4f82c8c58d4e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fa30a9d8-3412-4107-9135-23a3b554f537"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In children 6 weeks through 5 years of age (prior to the 6 th birthday), Prevnar 13 is indicated for: active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F. ( 1.1 ) active immunization for the prevention of otitis media caused by S. pneumoniae serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F. No otitis media efficacy data are available for serotypes 1, 3, 5, 6A, 7F, and 19A. ( 1.1 ) In children 6 years through 17 years of age (prior to the 18 th birthday), Prevnar 13 is indicated for: active immunization for the prevention of invasive disease caused by S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F. ( 1.2 ) In adults 18 years of age and older, Prevnar 13 is indicated for: active immunization for the prevention of pneumonia and invasive disease caused by S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F. ( 1.3 ) Limitations of Prevnar 13 Use and Effectiveness Prevnar 13 does not protect against disease caused by S. pneumoniae serotypes that are not in the vaccine. ( 1.4 ) uuid:4bf5c153-b783-47d4-9a9e-151f5e7e3cb5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:11679580 biolink:treats UMLS:C0426732 PMID:41385096 "[{""id"":""uuid:07167788-2e4a-4278-8074-4619b5ea244a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c05a3bc1-0d50-43f5-999e-db754907f01d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dutasteride and tamsulosin hydrochloride capsules are a combination of dutasteride, a 5-alpha-reductase inhibitor, and tamsulosin, an alpha-adrenergic antagonist, indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate. ( 1.1 ) Limitations of Use: Dutasteride-containing products, including dutasteride and tamsulosin hydrochloride capsules, are not approved for the prevention of prostate cancer. ( 1.2 ) uuid:583fcbf1-367a-4518-ae58-427554e483cf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3638 biolink:treats UMLS:C5554310 PMID:41385096 "[{""id"":""uuid:b9651282-7bb7-4913-a612-61cb7da4a5e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c5ea40bd-11c6-4624-b6d4-3d072b03edf0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Chloroquine phosphate tablets are indicated for the: Treatment of uncomplicated malaria due to susceptible strains of P. falciparum, P.malariae, P. ovale , and P.vivax. Prophylaxis of malaria in geographic areas where resistance to chloroquine is not present. Treatment of extraintestinal amebiasis. Chloroquine phosphate tablets do not prevent relapses in patients with vivax or ovale malaria because it is not effective against exoerythrocytic forms of the parasites. Limitations of Use in Malaria: Do not use chloroquine phosphate tablets for the treatment of complicated malaria (high-grade parasitemia and/or complications e.g., cerebral malaria or acute renal failure). Do not use chloroquine phosphate tablets for malaria prophylaxis in areas where chloroquine resistance occurs, Resistance to chloroquine phosphate tablets are widespread in P. falciparum, and is reported in P.vivax (see WARNINGS ). Concomitant therapy with an 8-aminoquinoline drug is necessary for treatment of the hypnozoite liver stage forms of P.vivax and P.ovale (see DOSAGE AND ADMINISTRATION ). uuid:2f98e244-0e5e-45b4-a94e-f16f4a0c6caf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3638 biolink:treats MONDO:0005644 PMID:41385096 "[{""id"":""uuid:c59372e3-82a0-4e3f-9d72-53be3a7e3f36"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1f6fcdec-cc63-463c-9bf1-c9b3d085765f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Chloroquine phosphate tablets are indicated for the: Treatment of uncomplicated malaria due to susceptible strains of P. falciparum, P.malariae, P. ovale , and P.vivax. Prophylaxis of malaria in geographic areas where resistance to chloroquine is not present. Treatment of extraintestinal amebiasis. Chloroquine phosphate tablets do not prevent relapses in patients with vivax or ovale malaria because it is not effective against exoerythrocytic forms of the parasites. Limitations of Use in Malaria: Do not use chloroquine phosphate tablets for the treatment of complicated malaria (high-grade parasitemia and/or complications e.g., cerebral malaria or acute renal failure). Do not use chloroquine phosphate tablets for malaria prophylaxis in areas where chloroquine resistance occurs, Resistance to chloroquine phosphate tablets are widespread in P. falciparum, and is reported in P.vivax (see WARNINGS ). Concomitant therapy with an 8-aminoquinoline drug is necessary for treatment of the hypnozoite liver stage forms of P.vivax and P.ovale (see DOSAGE AND ADMINISTRATION ). uuid:8f3f7a41-8ab5-4797-bc8a-419344f036a4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3638 biolink:treats MONDO:0005921 PMID:41385096 "[{""id"":""uuid:71872a14-9d09-4443-bb9c-07190d6cf1ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2acaf7fb-4df1-4a81-a93d-a65ea27b29ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Chloroquine phosphate tablets are indicated for the: Treatment of uncomplicated malaria due to susceptible strains of P. falciparum, P.malariae, P. ovale , and P.vivax. Prophylaxis of malaria in geographic areas where resistance to chloroquine is not present. Treatment of extraintestinal amebiasis. Chloroquine phosphate tablets do not prevent relapses in patients with vivax or ovale malaria because it is not effective against exoerythrocytic forms of the parasites. Limitations of Use in Malaria: Do not use chloroquine phosphate tablets for the treatment of complicated malaria (high-grade parasitemia and/or complications e.g., cerebral malaria or acute renal failure). Do not use chloroquine phosphate tablets for malaria prophylaxis in areas where chloroquine resistance occurs, Resistance to chloroquine phosphate tablets are widespread in P. falciparum, and is reported in P.vivax (see WARNINGS ). Concomitant therapy with an 8-aminoquinoline drug is necessary for treatment of the hypnozoite liver stage forms of P.vivax and P.ovale (see DOSAGE AND ADMINISTRATION ). uuid:64daecf4-eff2-449f-8062-170438fd4812 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3638 biolink:treats MONDO:0001601 PMID:41385096 "[{""id"":""uuid:ccb1084a-fb9f-40b5-9975-b3d7718a6650"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cbaee083-1724-4d1a-8b61-a729662572a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Chloroquine phosphate tablets are indicated for the: Treatment of uncomplicated malaria due to susceptible strains of P. falciparum, P.malariae, P. ovale , and P.vivax. Prophylaxis of malaria in geographic areas where resistance to chloroquine is not present. Treatment of extraintestinal amebiasis. Chloroquine phosphate tablets do not prevent relapses in patients with vivax or ovale malaria because it is not effective against exoerythrocytic forms of the parasites. Limitations of Use in Malaria: Do not use chloroquine phosphate tablets for the treatment of complicated malaria (high-grade parasitemia and/or complications e.g., cerebral malaria or acute renal failure). Do not use chloroquine phosphate tablets for malaria prophylaxis in areas where chloroquine resistance occurs, Resistance to chloroquine phosphate tablets are widespread in P. falciparum, and is reported in P.vivax (see WARNINGS ). Concomitant therapy with an 8-aminoquinoline drug is necessary for treatment of the hypnozoite liver stage forms of P.vivax and P.ovale (see DOSAGE AND ADMINISTRATION ). uuid:4bf87f68-a292-4394-8792-529089ee8a5d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3638 biolink:treats UMLS:C2747816 PMID:41385096 "[{""id"":""uuid:4907d68f-b7d4-4976-818c-2cc38c5ca709"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d1f46efa-6bf2-47da-a978-c9da464da61c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Chloroquine phosphate tablets are indicated for the: Treatment of uncomplicated malaria due to susceptible strains of P. falciparum, P.malariae, P. ovale , and P.vivax. Prophylaxis of malaria in geographic areas where resistance to chloroquine is not present. Treatment of extraintestinal amebiasis. Chloroquine phosphate tablets do not prevent relapses in patients with vivax or ovale malaria because it is not effective against exoerythrocytic forms of the parasites. Limitations of Use in Malaria: Do not use chloroquine phosphate tablets for the treatment of complicated malaria (high-grade parasitemia and/or complications e.g., cerebral malaria or acute renal failure). Do not use chloroquine phosphate tablets for malaria prophylaxis in areas where chloroquine resistance occurs, Resistance to chloroquine phosphate tablets are widespread in P. falciparum, and is reported in P.vivax (see WARNINGS ). Concomitant therapy with an 8-aminoquinoline drug is necessary for treatment of the hypnozoite liver stage forms of P.vivax and P.ovale (see DOSAGE AND ADMINISTRATION ). uuid:cf5802b4-c853-4678-829a-562beaac928e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3638 biolink:treats MONDO:0005625 PMID:41385096 "[{""id"":""uuid:86c70654-fe80-49c7-8cd6-e3876cf859c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:55dbc594-b6a6-44bb-964f-3f25933f87e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Chloroquine phosphate tablets are indicated for the: Treatment of uncomplicated malaria due to susceptible strains of P. falciparum, P.malariae, P. ovale , and P.vivax. Prophylaxis of malaria in geographic areas where resistance to chloroquine is not present. Treatment of extraintestinal amebiasis. Chloroquine phosphate tablets do not prevent relapses in patients with vivax or ovale malaria because it is not effective against exoerythrocytic forms of the parasites. Limitations of Use in Malaria: Do not use chloroquine phosphate tablets for the treatment of complicated malaria (high-grade parasitemia and/or complications e.g., cerebral malaria or acute renal failure). Do not use chloroquine phosphate tablets for malaria prophylaxis in areas where chloroquine resistance occurs, Resistance to chloroquine phosphate tablets are widespread in P. falciparum, and is reported in P.vivax (see WARNINGS ). Concomitant therapy with an 8-aminoquinoline drug is necessary for treatment of the hypnozoite liver stage forms of P.vivax and P.ovale (see DOSAGE AND ADMINISTRATION ). uuid:28f67585-35c7-49eb-a3ad-54a811949e1c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3638 biolink:treats MONDO:0002492 PMID:41385096 "[{""id"":""uuid:8a762835-a0a2-4799-9ba0-a79ca0960d69"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:31dffdb7-234e-45e6-8089-6c70f7ed587e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Chloroquine phosphate tablets are indicated for the: Treatment of uncomplicated malaria due to susceptible strains of P. falciparum, P.malariae, P. ovale , and P.vivax. Prophylaxis of malaria in geographic areas where resistance to chloroquine is not present. Treatment of extraintestinal amebiasis. Chloroquine phosphate tablets do not prevent relapses in patients with vivax or ovale malaria because it is not effective against exoerythrocytic forms of the parasites. Limitations of Use in Malaria: Do not use chloroquine phosphate tablets for the treatment of complicated malaria (high-grade parasitemia and/or complications e.g., cerebral malaria or acute renal failure). Do not use chloroquine phosphate tablets for malaria prophylaxis in areas where chloroquine resistance occurs, Resistance to chloroquine phosphate tablets are widespread in P. falciparum, and is reported in P.vivax (see WARNINGS ). Concomitant therapy with an 8-aminoquinoline drug is necessary for treatment of the hypnozoite liver stage forms of P.vivax and P.ovale (see DOSAGE AND ADMINISTRATION ). uuid:cb659f93-0d54-4ff2-a1e3-bd0f62e4c02b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:91820600 biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:53941109-3b52-4643-baa8-310e22c785a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b7df33e2-f8b4-45e5-baa0-c8bc7c8cf09e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Efavirenz, lamivudine and tenofovir disoproxil fumarate tablets are indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adult and pediatric patients weighing at least 40 kg. uuid:d816eb40-bcc0-4abc-9efb-edd876bf798e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28241 biolink:treats MONDO:0004781 PMID:41385096 "[{""id"":""uuid:db07f362-94c6-4471-a7f7-34335bda1427"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:429f23c5-12a1-4a06-b75d-75e7e823c0b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Papaverine is recommended in various conditions accompanied by spasm of smooth muscle, such as vascular spasm associated with acute myocardial infarction (coronary occlusion), angina pectoris, peripheral and pulmonary embolism, peripheral vascular disease in which there is a vasospastic element, or certain cerebral angiospastic states; and visceral spasm, as in ureteral, biliary, or gastrointestinal colic. uuid:b759254c-8f49-4347-b533-63b1f1fdaac9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28241 biolink:treats HP:0001681 PMID:41385096 "[{""id"":""uuid:ecdf252f-9d80-4838-8981-403d3af19f1f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8d81a357-d6fd-4915-a6c1-44a7678faa54"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Papaverine is recommended in various conditions accompanied by spasm of smooth muscle, such as vascular spasm associated with acute myocardial infarction (coronary occlusion), angina pectoris, peripheral and pulmonary embolism, peripheral vascular disease in which there is a vasospastic element, or certain cerebral angiospastic states; and visceral spasm, as in ureteral, biliary, or gastrointestinal colic. uuid:c5379762-1066-4e45-922e-8c98d8abf86e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28241 biolink:treats UMLS:C0856049 PMID:41385096 "[{""id"":""uuid:faea0df9-3ea7-40b3-8ffa-98993e60394b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4a0fca5e-aa66-49f0-a678-dfac7f1a0522"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Papaverine is recommended in various conditions accompanied by spasm of smooth muscle, such as vascular spasm associated with acute myocardial infarction (coronary occlusion), angina pectoris, peripheral and pulmonary embolism, peripheral vascular disease in which there is a vasospastic element, or certain cerebral angiospastic states; and visceral spasm, as in ureteral, biliary, or gastrointestinal colic. uuid:3f8b3aaa-eb92-4395-acce-8389fdf62094 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28241 biolink:treats MONDO:0005279 PMID:41385096 "[{""id"":""uuid:0ba79204-c1fa-4e14-a3af-17084c7c4895"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5a687132-ad26-428f-bb85-d796bdc68200"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Papaverine is recommended in various conditions accompanied by spasm of smooth muscle, such as vascular spasm associated with acute myocardial infarction (coronary occlusion), angina pectoris, peripheral and pulmonary embolism, peripheral vascular disease in which there is a vasospastic element, or certain cerebral angiospastic states; and visceral spasm, as in ureteral, biliary, or gastrointestinal colic. uuid:a04221a6-d3ed-423c-a51c-35f83f442c8a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28241 biolink:treats MONDO:0005294 PMID:41385096 "[{""id"":""uuid:d2314fb6-3ea1-47cd-a5ba-f29015b5af9d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a527de15-e113-4359-8b9d-fc9af1a2de4b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Papaverine is recommended in various conditions accompanied by spasm of smooth muscle, such as vascular spasm associated with acute myocardial infarction (coronary occlusion), angina pectoris, peripheral and pulmonary embolism, peripheral vascular disease in which there is a vasospastic element, or certain cerebral angiospastic states; and visceral spasm, as in ureteral, biliary, or gastrointestinal colic. uuid:bdd703b9-e261-4faf-ad5c-03760a289b4f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28241 biolink:treats UMLS:C0265110 PMID:41385096 "[{""id"":""uuid:09b16d09-1405-43f3-8625-6d0ab02e172d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aa246137-105c-40d5-bf4c-98c0c276d725"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Papaverine is recommended in various conditions accompanied by spasm of smooth muscle, such as vascular spasm associated with acute myocardial infarction (coronary occlusion), angina pectoris, peripheral and pulmonary embolism, peripheral vascular disease in which there is a vasospastic element, or certain cerebral angiospastic states; and visceral spasm, as in ureteral, biliary, or gastrointestinal colic. uuid:d1fe45cb-aed7-4673-95f6-c26b2ee9a8cc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28241 biolink:treats MONDO:0007009 PMID:41385096 "[{""id"":""uuid:649ed146-8e2d-4348-a957-0608fb7ba4ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6b0b7617-86b2-4a10-a688-2c8a86b02005"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Papaverine is recommended in various conditions accompanied by spasm of smooth muscle, such as vascular spasm associated with acute myocardial infarction (coronary occlusion), angina pectoris, peripheral and pulmonary embolism, peripheral vascular disease in which there is a vasospastic element, or certain cerebral angiospastic states; and visceral spasm, as in ureteral, biliary, or gastrointestinal colic. uuid:a6e98f35-ed0c-4ae5-b570-c189cbb004f1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28241 biolink:treats UMLS:C0151824 PMID:41385096 "[{""id"":""uuid:eee86beb-274c-4afa-9879-03cacfd78e0c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2036ae2b-4a76-45c0-b06d-f6f294f7d49a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Papaverine is recommended in various conditions accompanied by spasm of smooth muscle, such as vascular spasm associated with acute myocardial infarction (coronary occlusion), angina pectoris, peripheral and pulmonary embolism, peripheral vascular disease in which there is a vasospastic element, or certain cerebral angiospastic states; and visceral spasm, as in ureteral, biliary, or gastrointestinal colic. uuid:789fbbe4-df13-41d4-91db-579e6c82c943 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28241 biolink:treats HP:0011848 PMID:41385096 "[{""id"":""uuid:058a2947-a740-414c-8fe8-e1ef4c7f9cac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3752d991-e297-4c2a-b429-6840d06ecaac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Papaverine is recommended in various conditions accompanied by spasm of smooth muscle, such as vascular spasm associated with acute myocardial infarction (coronary occlusion), angina pectoris, peripheral and pulmonary embolism, peripheral vascular disease in which there is a vasospastic element, or certain cerebral angiospastic states; and visceral spasm, as in ureteral, biliary, or gastrointestinal colic. uuid:bb9e25b1-cd55-48a6-8c8d-4554755c74d6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:167574 biolink:treats MONDO:0004995 PMID:41385096 "[{""id"":""uuid:66d09894-6f67-4f30-a005-0f29941847dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b0eafe94-5bc4-4148-a951-074f16ad5701"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OZEMPIC is indicated: • as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. • to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease. Limitations of Use • OZEMPIC has not been studied in patients with a history of pancreatitis. Consider other antidiabetic therapies in patients with a history of pancreatitis [see Warnings and Precautions ( 5.2 )] . • OZEMPIC is not indicated for use in patients with type 1 diabetes mellitus. uuid:6d1174d9-edcf-4705-a3b4-2dea659db02e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:167574 biolink:treats MONDO:0004982 PMID:41385096 "[{""id"":""uuid:ddbb4f67-4d16-4d52-9bf1-97b599c4ef5a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:27621b6c-04e9-461f-9ed4-ee232ca664e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OZEMPIC is indicated: • as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. • to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease. Limitations of Use • OZEMPIC has not been studied in patients with a history of pancreatitis. Consider other antidiabetic therapies in patients with a history of pancreatitis [see Warnings and Precautions ( 5.2 )] . • OZEMPIC is not indicated for use in patients with type 1 diabetes mellitus. uuid:a5c5d164-f528-4b4f-bef4-348e253f80b5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:404930 biolink:treats MONDO:0005545 PMID:41385096 "[{""id"":""uuid:304b4c20-730e-4619-8231-332b6e2c0584"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e1158b6c-3932-4d33-8408-8198803b02bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension USP is indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in the specific conditions listed below: Acute Otitis Externa (AOE) in pediatric (age 6 months and older), adult and elderly patients due to Staphylococcus aureus and Pseudomonas aeruginosa . uuid:4980daf6-1616-493c-9d3c-3aa78519b4ca biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:404930 biolink:treats UMLS:C0854135 PMID:41385096 "[{""id"":""uuid:68d11216-babe-47d8-8722-1c360cbe8b58"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cc5602e3-3142-4e09-afdb-10659a1467cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension USP is indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in the specific conditions listed below: Acute Otitis Externa (AOE) in pediatric (age 6 months and older), adult and elderly patients due to Staphylococcus aureus and Pseudomonas aeruginosa . uuid:d4abec19-d279-45ec-b2b0-f7356ae69721 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3082 biolink:treats MONDO:0100470 PMID:41385096 "[{""id"":""uuid:10e923bb-7638-4fc8-aa28-de1749cb4ad8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:14c0e1c0-bf22-467d-ba15-759b91925c29"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Betaxolol Hydrochloride Ophthalmic Solution has been shown to be effective in lowering intraocular pressure and is indicated in the treatment of ocular hypertension and chronic open-angle glaucoma. It may be used alone or in combination with other anti-glaucoma drugs. In clinical studies, Betaxolol Hydrochloride Ophthalmic Solution was safely used to lower intraocular pressure in 47 patients with both glaucoma and reactive airway disease who were followed for a mean period of 15 months. However, caution should be used in treating patients with severe reactive airway disease or a history of asthma. uuid:81c655c6-271f-41bc-ae7d-d12ff66a54ec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2682 biolink:treats MONDO:0016426 PMID:41385096 "[{""id"":""uuid:95f82720-29a4-4fba-83af-8ececb21d407"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c7576256-26aa-40db-a077-7735459dd8cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ABELCET ® is indicated for the treatment of invasive fungal infections in patients who are refractory to or intolerant of conventional amphotericin B therapy. This is based on open-label treatment of patients judged by their physicians to be intolerant to or failing conventional amphotericin B therapy (See DESCRIPTION OF CLINICAL STUDIES). DESCRIPTION OF CLINICAL STUDIES Fungal Infections Data from 473 patients were pooled from three open-label studies in which ABELCET ® was provided for the treatment of patients with invasive fungal infections who were judged by their physicians to be refractory to or intolerant of conventional amphotericin B, or who had preexisting nephrotoxicity. Results of these studies demonstrated effectiveness of ABELCET ® in the treatment of invasive fungal infections as a second line therapy. Patients were defined by their individual physician as being refractory to or failing conventional amphotericin B therapy based on overall clinical judgement after receiving a minimum total dose of 500 mg of amphotericin B. Nephrotoxicity was defined as a serum creatinine that had increased to >2.5 mg/dL in adults and >1.5 mg/dL in pediatric patients, or a creatinine clearance of <25 mL/min while receiving conventional amphotericin B therapy. Of the 473 patients, four were enrolled more than once; each enrollment contributed separately to the denominator. The median age was 39 years (range of <1 to 93 years); 307 patients were male and 166 female. Patients were Caucasian (381, 81%), African-American (41, 9%), Hispanic (27, 6%), Asian (10, 2%), and various other races (14, 3%). The median baseline neutrophil count was 4,000 PMN/mm3; of these, 101 (21%) had a baseline neutrophil count <500/mm 3 . Two-hundred eighty-two patients of the 473 patients were considered evaluable for response to therapy; the other 191 patients were excluded on the basis of unconfirmed diagnosis, confounding factors, concomitant systemic antifungal therapy, or receiving 4 doses or less of ABELCET ® . For evaluable patients, the following fungal infections were treated (n=282): aspergillosis (n=111), candidiasis (n=87), zygomycosis (n=25), cryptococcosis (n=16), and fusariosis (n=11). There were fewer than 10 evaluable patients for each of several other fungal species treated. For each type of fungal infection listed above there were some patients successfully treated. However, in the absence of controlled studies it is unknown how response would have compared to either continuing conventional amphotericin B therapy or the use of alternative antifungal agents. Renal Function: Patients with aspergillosis who initiated treatment with ABELCET ® when serum creatinine was above 2.5 mg/dL experienced a decline in serum creatinine during treatment (Figure 1). Serum creatinine levels were also lower during treatment with ABELCET ® when compared to the serum creatinine levels of patients treated with conventional amphotericin B in a retrospective historical control study. Meaningful statistical testing of the differences between these two groups is precluded since these data were obtained from two separate studies. [ ]= Number of patients at each time point. Note: These curves do not represent the clinical course of a given patient, but that of an open-label cohort of patients. [ ]= Number of patients at each time point. Note: These curves do not represent the clinical course of a given patient, but that of an open-label cohort of patients. In a randomized study of ABELCET ® for the treatment of invasive candidiasis in patients with normal baseline renal function, the incidence of nephrotoxicity was significantly less for ABELCET ® at a dose of 5 mg/kg/day than for conventional amphotericin B at a dose of 0.7 mg/kg/day. Despite generally less nephrotoxicity of ABELCET ® observed at a dose of 5 mg/kg/day compared with conventional amphotericin B therapy at a dose range of 0.6-1 mg/kg/day, dose-limiting renal toxicity may still be observed with ABELCET ® . Renal toxicity of doses greater than 5 mg/kg/day of ABELCET ® has not been formally studied. uuid:aba41c1b-48a4-4f0d-a53c-c8d837def72d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2682 biolink:treats HP:0020101 PMID:41385096 "[{""id"":""uuid:26ccca71-f251-4224-a851-84cf92ec28b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:29f3b684-9303-4404-ba63-792254474e42"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ABELCET ® is indicated for the treatment of invasive fungal infections in patients who are refractory to or intolerant of conventional amphotericin B therapy. This is based on open-label treatment of patients judged by their physicians to be intolerant to or failing conventional amphotericin B therapy (See DESCRIPTION OF CLINICAL STUDIES). DESCRIPTION OF CLINICAL STUDIES Fungal Infections Data from 473 patients were pooled from three open-label studies in which ABELCET ® was provided for the treatment of patients with invasive fungal infections who were judged by their physicians to be refractory to or intolerant of conventional amphotericin B, or who had preexisting nephrotoxicity. Results of these studies demonstrated effectiveness of ABELCET ® in the treatment of invasive fungal infections as a second line therapy. Patients were defined by their individual physician as being refractory to or failing conventional amphotericin B therapy based on overall clinical judgement after receiving a minimum total dose of 500 mg of amphotericin B. Nephrotoxicity was defined as a serum creatinine that had increased to >2.5 mg/dL in adults and >1.5 mg/dL in pediatric patients, or a creatinine clearance of <25 mL/min while receiving conventional amphotericin B therapy. Of the 473 patients, four were enrolled more than once; each enrollment contributed separately to the denominator. The median age was 39 years (range of <1 to 93 years); 307 patients were male and 166 female. Patients were Caucasian (381, 81%), African-American (41, 9%), Hispanic (27, 6%), Asian (10, 2%), and various other races (14, 3%). The median baseline neutrophil count was 4,000 PMN/mm3; of these, 101 (21%) had a baseline neutrophil count <500/mm 3 . Two-hundred eighty-two patients of the 473 patients were considered evaluable for response to therapy; the other 191 patients were excluded on the basis of unconfirmed diagnosis, confounding factors, concomitant systemic antifungal therapy, or receiving 4 doses or less of ABELCET ® . For evaluable patients, the following fungal infections were treated (n=282): aspergillosis (n=111), candidiasis (n=87), zygomycosis (n=25), cryptococcosis (n=16), and fusariosis (n=11). There were fewer than 10 evaluable patients for each of several other fungal species treated. For each type of fungal infection listed above there were some patients successfully treated. However, in the absence of controlled studies it is unknown how response would have compared to either continuing conventional amphotericin B therapy or the use of alternative antifungal agents. Renal Function: Patients with aspergillosis who initiated treatment with ABELCET ® when serum creatinine was above 2.5 mg/dL experienced a decline in serum creatinine during treatment (Figure 1). Serum creatinine levels were also lower during treatment with ABELCET ® when compared to the serum creatinine levels of patients treated with conventional amphotericin B in a retrospective historical control study. Meaningful statistical testing of the differences between these two groups is precluded since these data were obtained from two separate studies. [ ]= Number of patients at each time point. Note: These curves do not represent the clinical course of a given patient, but that of an open-label cohort of patients. [ ]= Number of patients at each time point. Note: These curves do not represent the clinical course of a given patient, but that of an open-label cohort of patients. In a randomized study of ABELCET ® for the treatment of invasive candidiasis in patients with normal baseline renal function, the incidence of nephrotoxicity was significantly less for ABELCET ® at a dose of 5 mg/kg/day than for conventional amphotericin B at a dose of 0.7 mg/kg/day. Despite generally less nephrotoxicity of ABELCET ® observed at a dose of 5 mg/kg/day compared with conventional amphotericin B therapy at a dose range of 0.6-1 mg/kg/day, dose-limiting renal toxicity may still be observed with ABELCET ® . Renal toxicity of doses greater than 5 mg/kg/day of ABELCET ® has not been formally studied. uuid:2b0d76ee-7ac1-4597-b742-842197d0ee1a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27796 biolink:treats MONDO:0005942 PMID:41385096 "[{""id"":""uuid:c6b22106-91b9-4b22-9ba4-90aada62071b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d99ff5b4-aa27-42d4-90df-66fdcc364b13"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Trimethobenzamide hydrochloride capsules are indicated in adults for the treatment of postoperative nausea and vomiting and for nausea associated with gastroenteritis. Limitation of Use: Trimethobenzamide hydrochloride capsules are not recommended for use in pediatric patients due to the risk of extrapyramidal signs and symptoms and other serious central nervous system (CNS) effects, and the risk of exacerbation of the underlying disease in pediatric patients with Reye’s syndrome or other hepatic impairment. uuid:51c9450f-9609-4735-b1da-cf3eaced797a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1157355 biolink:treats MONDO:0005298 PMID:41385096 "[{""id"":""uuid:aa487313-efa7-48b3-bcd1-bec5d28a1b9a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e424d2ab-1f3f-48c3-9a60-e9aeb1eaab51"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Norethindrone acetate and Ethinyl estradiol tablets are an estrogen plus progestin indicated in a woman with a uterus for: Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause ( 1.1 ) Prevention of Postmenopausal Osteoporosis ( 1.2 ) uuid:d275bfc0-d076-4ec4-9026-aa84c064405a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71013 biolink:treats MONDO:0005027 PMID:41385096 "[{""id"":""uuid:d42bd16d-7675-4887-8254-7a07409112ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:79d19155-5721-4a17-96fb-26cdfbc5e00d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:d99a4d97-0b4c-401d-9649-b8796dd70827"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FYCOMPA, a non-competitive AMPA glutamate receptor antagonist, is indicated for: Treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy 4 years of age and older ( 1.1 ) Adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients with epilepsy 12 years of age and older ( 1.2 )|[PMDA] Drugs with a new active ingredient indicated for use as an adjunctive therapy with other antiepileptic drugs to treat partial seizures (including secondary generalized seizures) and tonic-clonic seizures in patients with epilepsy who have not responded sufficiently to other antiepileptic drugs. uuid:4862b36c-2f22-4b22-8717-42ddeb81c163 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71013 biolink:treats MONDO:0006710 PMID:41385096 "[{""id"":""uuid:09cad425-9b38-4ddc-acb3-c8186b07187a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e5d70cec-c283-418c-9a84-27db19d0dae0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FYCOMPA, a non-competitive AMPA glutamate receptor antagonist, is indicated for: Treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy 4 years of age and older ( 1.1 ) Adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients with epilepsy 12 years of age and older ( 1.2 ) uuid:591b1d10-7f2f-4866-ad60-31ed387a3cef biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71013 biolink:treats MONDO:0005754 PMID:41385096 "[{""id"":""uuid:454ee6c7-83ba-40a6-82a1-63181d3c26a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:30a4a20a-371e-4837-9e80-61820d4f229f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:57770325-2bed-4006-a480-fc4fc3ccb866"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/fycompa""]},{""id"":""uuid:5a8af404-4a03-42ba-a871-edfbae64f3c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FYCOMPA, a non-competitive AMPA glutamate receptor antagonist, is indicated for: Treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy 4 years of age and older ( 1.1 ) Adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients with epilepsy 12 years of age and older ( 1.2 )|[EMA] Fycompa is indicated for the adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in adult and adolescent patients from 12 years of age with epilepsy.Fycompa is indicated for the adjunctive treatment of primary generalised tonic-clonic seizures in adult and adolescent patients from 12 years of age with idiopathic generalised epilepsy.|[PMDA] Drugs with a new active ingredient indicated for use as an adjunctive therapy with other antiepileptic drugs to treat partial seizures (including secondary generalized seizures) and tonic-clonic seizures in patients with epilepsy who have not responded sufficiently to other antiepileptic drugs. uuid:57e7d90a-6343-43ce-a5bc-bb2e97b4962b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:70746 biolink:treats HP:0001907 PMID:41385096 "[{""id"":""uuid:934f3d5e-0d38-424e-8234-3350f46aebb9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ce49005e-5510-47d0-a191-56d474867e9f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PRADAXA Oral Pellets are a direct thrombin inhibitor indicated: For the treatment of venous thromboembolic events (VTE) in pediatric patients aged 3 months to less than 12 years of age who have been treated with a parenteral anticoagulant for at least 5 days ( 1.1 ) To reduce the risk of recurrence of VTE in pediatric patients aged 3 months to less than 12 years of age who have been previously treated ( 1.2 ) uuid:245a1a40-6a8d-4cb5-83e7-8100cc2cd952 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31941 biolink:treats UMLS:C0278480 PMID:41385096 "[{""id"":""uuid:899f3172-f08d-4494-8413-f3350279792c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:854289d1-ff34-405e-8ea1-f8fe330e21c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxaliplatin injection is a platinum-based drug used in combination with infusional fluorouracil/leucovorin, which is indicated for: adjuvant treatment of Stage III colon cancer in patients who have undergone complete resection of the primary tumor. ( 1 ) treatment of advanced colorectal cancer. ( 1 ) uuid:5857f76e-858e-4b9e-9038-835ee5be7046 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31941 biolink:treats EFO:1001480 PMID:41385096 "[{""id"":""uuid:bc677df5-e724-437a-b5e1-bdd6b2ca3c13"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:708d1699-dc1e-43f0-8da5-3f5e4da4c8f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxaliplatin injection is a platinum-based drug used in combination with infusional fluorouracil/leucovorin, which is indicated for: adjuvant treatment of Stage III colon cancer in patients who have undergone complete resection of the primary tumor. ( 1 ) treatment of advanced colorectal cancer. ( 1 ) uuid:fc57a46a-7347-4913-9415-adef4f62f90c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:600520 biolink:treats MONDO:0044070 PMID:41385096 "[{""id"":""uuid:a6b5bec7-1137-4fc9-9a89-d0a2750c239d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:73c9d5f7-6070-4e46-b58e-d5cf19484547"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Micafungin for Injection is indicated for: Treatment of Candidemia, Acute Disseminated Candidiasis, Candida Peritonitis and Abscesses in adult and pediatric patients 4 months of age and older [see Clinical Studies (14.1) and Use in Specific Populations (8.4) ]. Treatment of Esophageal Candidiasis in adult and pediatric patients 4 months of age and older [see Clinical Studies (14.2) ]. Prophylaxis of Candida Infections in adult and pediatric patients 4 months of age and older undergoing hematopoietic stem cell transplantation [see Clinical Studies (14.3) ]. uuid:1896d64d-7e92-4cb1-ae5e-65eb3f818442 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:600520 biolink:treats UMLS:C0343884 PMID:41385096 "[{""id"":""uuid:72acdda5-f1f0-45e6-8e2f-da77a6f6a2a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:25469536-6866-4599-8e1a-7c29de4dce6f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Micafungin for Injection is indicated for: Treatment of Candidemia, Acute Disseminated Candidiasis, Candida Peritonitis and Abscesses in adult and pediatric patients 4 months of age and older [see Clinical Studies (14.1) and Use in Specific Populations (8.4) ]. Treatment of Esophageal Candidiasis in adult and pediatric patients 4 months of age and older [see Clinical Studies (14.2) ]. Prophylaxis of Candida Infections in adult and pediatric patients 4 months of age and older undergoing hematopoietic stem cell transplantation [see Clinical Studies (14.3) ]. uuid:97cf3036-b25a-4e9d-8d8a-18d7c63a12dc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:600520 biolink:treats MONDO:0005227 PMID:41385096 "[{""id"":""uuid:a475929d-a1a5-4dd1-bdd5-dc6bcdadc062"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:10ea9001-534d-4eb5-bd42-357ac49f1fb5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Micafungin for Injection is indicated for: Treatment of Candidemia, Acute Disseminated Candidiasis, Candida Peritonitis and Abscesses in adult and pediatric patients 4 months of age and older [see Clinical Studies (14.1) and Use in Specific Populations (8.4) ]. Treatment of Esophageal Candidiasis in adult and pediatric patients 4 months of age and older [see Clinical Studies (14.2) ]. Prophylaxis of Candida Infections in adult and pediatric patients 4 months of age and older undergoing hematopoietic stem cell transplantation [see Clinical Studies (14.3) ]. uuid:40c49d27-2edc-4a63-9442-a030f39486e9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:600520 biolink:treats MONDO:0001648 PMID:41385096 "[{""id"":""uuid:13ac422a-db10-4458-8b9a-21d534324359"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:9db2d3f6-c8a7-45ac-8db2-891af88c7d4f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:339984e1-db46-420c-8383-ce739b769e55"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/mycamine""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Micafungin for Injection is indicated for: Treatment of Candidemia, Acute Disseminated Candidiasis, Candida Peritonitis and Abscesses in adult and pediatric patients 4 months of age and older [see Clinical Studies (14.1) and Use in Specific Populations (8.4) ]. Treatment of Esophageal Candidiasis in adult and pediatric patients 4 months of age and older [see Clinical Studies (14.2) ]. Prophylaxis of Candida Infections in adult and pediatric patients 4 months of age and older undergoing hematopoietic stem cell transplantation [see Clinical Studies (14.3) ].|[EMA] Mycamine is indicated for:Adults, adolescents ≥ 16 years of age and elderlytreatment of invasive candidiasis;treatment of oesophageal candidiasis in patients for whom intravenous therapy is appropriate;prophylaxis of Candida infection in patients undergoing allogeneic haematopoietic stem-cell transplantation or patients who are expected to have neutropenia (absolute neutrophil count < 500 cells/µl) for 10 or more days.Children (including neonates) and adolescents < 16 years of agetreatment of invasive candidiasis.prophylaxis of Candida infection in patients undergoing allogeneic haematopoietic stem-cell transplantation or patients who are expected to have neutropenia (absolute neutrophil count < 500 cells/µl) for 10 or more days.The decision to use Mycamine should take into account a potential risk for the development of liver tumours. Mycamine should therefore only be used if other antifungals are not appropriate. uuid:cf694d9a-9cc5-42c5-aa09-617b310f66cc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:600520 biolink:treats MONDO:0002026 PMID:41385096 "[{""id"":""uuid:12014138-2f9b-4cea-845f-b6a9e1599bd7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4700d4b1-32c8-4dc7-bcaa-921b7991766e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:58e677f1-ebec-47c6-acf3-d1f8a5835185"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/mycamine""]},{""id"":""uuid:f96f6c2c-5695-4664-ae10-310b955ad7db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Micafungin for Injection is indicated for: Treatment of Candidemia, Acute Disseminated Candidiasis, Candida Peritonitis and Abscesses in adult and pediatric patients 4 months of age and older [see Clinical Studies (14.1) and Use in Specific Populations (8.4) ]. Treatment of Esophageal Candidiasis in adult and pediatric patients 4 months of age and older [see Clinical Studies (14.2) ]. Prophylaxis of Candida Infections in adult and pediatric patients 4 months of age and older undergoing hematopoietic stem cell transplantation [see Clinical Studies (14.3) ].|[EMA] Mycamine is indicated for:Adults, adolescents ≥ 16 years of age and elderlytreatment of invasive candidiasis;treatment of oesophageal candidiasis in patients for whom intravenous therapy is appropriate;prophylaxis of Candida infection in patients undergoing allogeneic haematopoietic stem-cell transplantation or patients who are expected to have neutropenia (absolute neutrophil count < 500 cells/µl) for 10 or more days.Children (including neonates) and adolescents < 16 years of agetreatment of invasive candidiasis.prophylaxis of Candida infection in patients undergoing allogeneic haematopoietic stem-cell transplantation or patients who are expected to have neutropenia (absolute neutrophil count < 500 cells/µl) for 10 or more days.The decision to use Mycamine should take into account a potential risk for the development of liver tumours. Mycamine should therefore only be used if other antifungals are not appropriate.|[PMDA] Drugs with a new indication and dosage for prophylaxis of aspergillosis and candidiasis in hematopoietic stem cell transplant patients. uuid:3a8b8f26-0e8c-41dd-9c15-9cd672eed6d7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:142406 biolink:treats HP:0012532 PMID:41385096 "[{""id"":""uuid:549698e6-3b74-421a-a03d-ab5b648789a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4b608f2a-9463-40da-8e3f-5002b72a96e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PRIALT (ziconotide) solution, intrathecal infusion is indicated for the management of severe chronic pain in adult patients for whom intrathecal therapy is warranted, and who are intolerant of or refractory to other treatment, such as systemic analgesics, adjunctive therapies, or intrathecal morphine. uuid:518d85b2-825e-48dc-8c18-82ba54ca0c22 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135939 biolink:treats MONDO:0005754 PMID:41385096 "[{""id"":""uuid:36b542af-85ed-4407-b07e-40a888306378"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:bb04ea56-f890-4385-967f-5fb43bf344fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:6066915c-b50c-40f8-93c6-05f12e77ffda"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/vimpat""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lacosamide tablets are indicated for: • Treatment of partial-onset seizures in patients 4 years of age and older (1.1) • Adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients 4 years of age and older (1.2)|[EMA] Lacosamide Adroiq is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy.Lacosamide Adroiq is indicated as adjunctive therapyin the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy.in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy. uuid:3c389786-87db-43af-af73-805b8b6a4e63 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:87016 biolink:treats MONDO:0006710 PMID:41385096 "[{""id"":""uuid:8983ca85-1032-4472-9d12-fc3b8f4e43b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eace868e-4d1d-4516-9b02-329762850787"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] APTIOM is indicated for the treatment of partial-onset seizures in patients 4 years of age and older. uuid:70f44e57-b0d3-4b2c-a09a-776914346d26 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71229 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:7346e1e6-cb21-4f5f-8617-de061fe154c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a7e56e76-84a3-44dc-88ae-782e20f08b44"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VIBATIV is a lipoglycopeptide antibacterial drug indicated for the treatment of the following infections in adult patients caused by designated susceptible bacteria: Complicated skin and skin structure infections (cSSSI) ( 1.1 ) Hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates of Staphylococcus aureus . VIBATIV should be reserved for use when alternative treatments are not suitable. ( 1.2 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of VIBATIV and other antibacterial drugs VIBATIV should only be used to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. uuid:e2747263-a357-4ac2-8906-03534c8873c0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71229 biolink:treats MONDO:0004652 PMID:41385096 "[{""id"":""uuid:f55ea404-2c22-4483-8cb4-f8c9b3b8dc45"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:16259ba6-bbce-4fe7-96da-22ea9e87184a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VIBATIV is a lipoglycopeptide antibacterial drug indicated for the treatment of the following infections in adult patients caused by designated susceptible bacteria: Complicated skin and skin structure infections (cSSSI) ( 1.1 ) Hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates of Staphylococcus aureus . VIBATIV should be reserved for use when alternative treatments are not suitable. ( 1.2 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of VIBATIV and other antibacterial drugs VIBATIV should only be used to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. uuid:432ec534-0843-4776-b187-42b0119aac99 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1552339 biolink:treats HP:0002018 PMID:41385096 "[{""id"":""uuid:19926d11-dbd9-40bb-bd86-fa5341bd27f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:050d1b44-2899-42bf-b8a1-643eda52644b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AKYNZEO capsules is indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. AKYNZEO capsules is a combination of palonosetron and netupitant: palonosetron prevents nausea and vomiting during the acute phase and netupitant prevents nausea and vomiting during both the acute and delayed phase after cancer chemotherapy. AKYNZEO for injection and AKYNZEO injection are indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. AKYNZEO for injection is a combination of palonosetron and fosnetupitant, a prodrug of netupitant: palonosetron prevents nausea and vomiting during the acute phase and fosnetupitant prevents nausea and vomiting during both the acute and delayed phase after cancer chemotherapy. Limitations of Use AKYNZEO for injection and AKYNZEO injection have not been studied for the prevention of nausea and vomiting associated with anthracycline plus cyclophosphamide chemotherapy. uuid:693365fa-1698-4ef6-85a8-a2e8e55c8868 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1552339 biolink:treats HP:0002013 PMID:41385096 "[{""id"":""uuid:1854cbb9-3351-4d03-8ef9-0e14730543c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6ece6cac-a9ea-4eec-83c8-663c528a1d5b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AKYNZEO capsules is indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. AKYNZEO capsules is a combination of palonosetron and netupitant: palonosetron prevents nausea and vomiting during the acute phase and netupitant prevents nausea and vomiting during both the acute and delayed phase after cancer chemotherapy. AKYNZEO for injection and AKYNZEO injection are indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. AKYNZEO for injection is a combination of palonosetron and fosnetupitant, a prodrug of netupitant: palonosetron prevents nausea and vomiting during the acute phase and fosnetupitant prevents nausea and vomiting during both the acute and delayed phase after cancer chemotherapy. Limitations of Use AKYNZEO for injection and AKYNZEO injection have not been studied for the prevention of nausea and vomiting associated with anthracycline plus cyclophosphamide chemotherapy. uuid:37a6964e-b529-4d6e-8196-acb47f465aa2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7507 biolink:treats MONDO:0001548 PMID:41385096 "[{""id"":""uuid:bf130ea8-a457-4555-ade9-dabaa4dbbb8b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6a612860-deba-4099-88e7-e635017a347b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of neomycin sulfate tablets and other antibacterial drugs, neomycin sulfate tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Suppression of Intestinal Bacteria Neomycin sulfate tablets are indicated as adjunctive therapy as part of a regimen for the suppression of the normal bacterial flora of the bowel, e.g., preoperative preparation of the bowel. It is given concomitantly with erythromycin enteric-coated base (see DOSAGE AND ADMINISTRATION ). Hepatic Coma (Portal-Systemic Encephalopathy) Neomycin sulfate has been shown to be effective adjunctive therapy in hepatic coma by reduction of the ammonia-forming bacteria in the intestinal tract. The subsequent reduction in blood ammonia has resulted in neurologic improvement. uuid:15cd94de-a632-41c8-8e83-73ea40eb2dcb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7507 biolink:treats MONDO:0001711 PMID:41385096 "[{""id"":""uuid:0f463dab-bc5f-46d3-b2a9-edd7e0a56276"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a9ce10b5-a155-44d7-b217-df1f53a738c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of neomycin sulfate tablets and other antibacterial drugs, neomycin sulfate tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Suppression of Intestinal Bacteria Neomycin sulfate tablets are indicated as adjunctive therapy as part of a regimen for the suppression of the normal bacterial flora of the bowel, e.g., preoperative preparation of the bowel. It is given concomitantly with erythromycin enteric-coated base (see DOSAGE AND ADMINISTRATION ). Hepatic Coma (Portal-Systemic Encephalopathy) Neomycin sulfate has been shown to be effective adjunctive therapy in hepatic coma by reduction of the ammonia-forming bacteria in the intestinal tract. The subsequent reduction in blood ammonia has resulted in neurologic improvement. uuid:7c021e57-b9da-4efc-ada9-c5f00b2904c6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6427 biolink:treats MONDO:0019165 PMID:41385096 "[{""id"":""uuid:49d1e288-7e6e-4adf-9473-c4d81e5b08bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1939394b-9bf0-4a88-86b4-c96ccd58c92a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FENSOLVI is indicated for the treatment of pediatric patients 2 years of age and older with central precocious puberty (CPP). uuid:ef28c98d-19e6-48a2-b77f-62576540991e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7627 biolink:treats HP:0000869 PMID:41385096 "[{""id"":""uuid:94d0b99d-b85e-4cbe-b8e4-da38f34b9979"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a2d1c78f-cc5d-4d9f-b75b-b2f91ba89dfc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Norethindrone acetate tablets are indicated for the treatment of secondary amenorrhea, endometriosis, and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer. Norethindrone acetate tablets are not intended, recommended or approved to be used with concomitant estrogen therapy in postmenopausal women for endometrial protection. uuid:5963a8f0-685a-4822-b6e2-fd7adfbc36d5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7627 biolink:treats MONDO:0005133 PMID:41385096 "[{""id"":""uuid:1c378ad9-f196-4b83-87a9-0f215fc94c63"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:08c53146-cbf4-4f60-9262-6d151dda4ab9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Norethindrone acetate tablets are indicated for the treatment of secondary amenorrhea, endometriosis, and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer. Norethindrone acetate tablets are not intended, recommended or approved to be used with concomitant estrogen therapy in postmenopausal women for endometrial protection. uuid:3368e877-44d8-4c9a-8aa2-3ca5f360503d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7627 biolink:treats UMLS:C3650625 PMID:41385096 "[{""id"":""uuid:8fe19354-1ae9-4805-80d1-4bab579b8023"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0b7cc2c2-718f-4c94-9edb-42e93e7cdf4f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Norethindrone acetate tablets are indicated for the treatment of secondary amenorrhea, endometriosis, and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer. Norethindrone acetate tablets are not intended, recommended or approved to be used with concomitant estrogen therapy in postmenopausal women for endometrial protection. uuid:52e7e163-b872-4529-91e7-16265a1a6775 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7627 biolink:treats MONDO:0002715 PMID:41385096 "[{""id"":""uuid:4e936b26-3cac-4538-921a-0ee0da2179a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c1e77a0b-ad11-41ed-b577-5809ab90933b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Norethindrone acetate tablets are indicated for the treatment of secondary amenorrhea, endometriosis, and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer. Norethindrone acetate tablets are not intended, recommended or approved to be used with concomitant estrogen therapy in postmenopausal women for endometrial protection. uuid:7d2f2831-62fc-4599-b49c-d08f4cc327c5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29034 biolink:treats UMLS:C0240066 PMID:41385096 "[{""id"":""uuid:8e9663bc-33d2-4d83-ab83-f9c3374de21f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0457297d-13f4-4c90-81b0-83c8cdc35c9b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ACCRUFER is indicated for the treatment of iron deficiency in adults. uuid:af719104-5b1d-45d8-b312-4acf1941f4b0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2205092 biolink:treats MONDO:0005002 PMID:41385096 "[{""id"":""uuid:313dcc20-d54f-445a-adbb-36191b3312e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:8e940e46-a1d2-4cea-bd12-2c3247033238"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:1f3c4960-cc6e-4357-9158-6f46bd281007"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/brimica-genuair""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] DUAKLIR PRESSAIR is a combination of aclidinium bromide (an anticholinergic) and formoterol fumarate (a LABA) indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Limitations of Use: DUAKLIR PRESSAIR is not indicated for the relief of acute bronchospasm or for the treatment of asthma [see Warnings and Precautions ( 5.1 , 5.4 )] .|[EMA] Brimica Genuair is indicated as a maintenance bronchodilator treatment for airflow obstruction and relief of symptoms in adult patients with chronic obstructive pulmonary disease (COPD). uuid:3a980eff-9b0a-4233-8ff3-5eb967a20379 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2205092 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:4af811fc-420c-485e-8d88-e29324a87a63"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:17a93413-c822-4895-86a2-ba431be63bff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DUAKLIR PRESSAIR is a combination of aclidinium bromide (an anticholinergic) and formoterol fumarate (a LABA) indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Limitations of Use: DUAKLIR PRESSAIR is not indicated for the relief of acute bronchospasm or for the treatment of asthma [see Warnings and Precautions ( 5.1 , 5.4 )] . uuid:81a4a206-3f19-40b9-a261-a54fc24589f7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1040052 biolink:treats HP:0002193 PMID:41385096 "[{""id"":""uuid:b5e1e943-2f98-438a-804b-35936aa0d618"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:449a5c6a-5466-48e7-bbc8-64367530df86"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NUEDEXTA is indicated for the treatment of pseudobulbar affect (PBA). PBA occurs secondary to a variety of otherwise unrelated neurologic conditions, and is characterized by involuntary, sudden, and frequent episodes of laughing and/or crying. PBA episodes typically occur out of proportion or incongruent to the underlying emotional state. PBA is a specific condition, distinct from other types of emotional lability that may occur in patients with neurological disease or injury. uuid:8a3e433c-8e85-42f1-9942-793576130a05 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:65346 biolink:treats MONDO:0005002 PMID:41385096 "[{""id"":""uuid:57fd1b65-75a6-4832-88b9-0cd415532d4b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:6c049b0a-cf90-4f30-9266-1c827e55baef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:df72b897-c144-42f3-a558-2c2302af80be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/eklira-genuair""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] TUDORZA® PRESSAIR® (aclidinium bromide inhalation powder) is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).|[EMA] Eklira Genuair is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). uuid:08c76bc5-3739-4fd5-9376-6fb429ac5172 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:65346 biolink:treats MONDO:0011751 PMID:41385096 "[{""id"":""uuid:29da898a-db1c-4400-90fc-8187aa1c8935"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:563b88d1-0c01-4344-a581-8f6c64cba7af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TUDORZA® PRESSAIR® (aclidinium bromide inhalation powder) is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). uuid:f874fe14-a488-4c0d-ad7e-f99b16ea2f0c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:30769 biolink:treats MONDO:0000440 PMID:41385096 "[{""id"":""uuid:a8fb68c6-024e-4cfb-b341-280b78731649"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:17fe5909-0866-493c-9758-e520a762384b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ORACIT ® is indicated for the treatment of metabolic acidosis. This solution is also useful in conditions where long term maintenance of alkaline urine is needed (e.g. uric acid and cystine calculi of the urinary tract). ORACIT ® is also effective in treatment for acidosis of certain renal tubular disorders. uuid:cf0f51d9-ad1b-4773-bb0e-87ba77c0bb47 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PVI5M0M1GW biolink:treats UMLS:C0746883 PMID:41385096 "[{""id"":""uuid:93ec629a-d679-4ce5-98a4-31b1e5807f88"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9cd6afc1-8a0e-4d78-9662-40251a73120e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] GRANIX is indicated to reduce the duration of severe neutropenia in adult and pediatric patients 1 month and older with non-myeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia. uuid:120064cf-5110-4e19-ab81-c2bddfd02d44 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2671296 biolink:treats MONDO:0002040 PMID:41385096 "[{""id"":""uuid:cc5b5b9e-cc30-4798-887a-8942d8e724b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:15206774-19de-4d6e-8c6e-2b7adc45c7b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mycozyl HC ™ is indicated for treatment of fungal infection of the skin, skin around the nail, and for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. uuid:6a920f77-565b-4faf-aa1e-ce5b67f7cf63 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:1B56C968OA biolink:treats MONDO:0004601 PMID:41385096 "[{""id"":""uuid:5a80c245-6b95-41da-94f5-bf5d0ea1c60d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:627206f7-9a28-4808-884e-53388736b123"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] REGRANEX is indicated for the treatment of lower extremity diabetic neuropathic ulcers that extend into the subcutaneous tissue or beyond and have an adequate blood supply, when used as an adjunct to, and not a substitute for, good ulcer care practices including initial sharp debridement, pressure relief and infection control. Limitations of Use : The efficacy of REGRANEX has not been established for the treatment of pressure ulcers and venous stasis ulcers [ see Clinical Studies (14.2) ] and has not been evaluated for the treatment of diabetic neuropathic ulcers that do not extend through the dermis into subcutaneous tissue [Stage I or II, International Association of Enterostomal Therapy (IAET) staging classification] or ischemic diabetic ulcers. The effects of becaplermin on exposed joints, tendons, ligaments, and bone have not been established in humans [ see Nonclinical Toxicology (13.2) ] . REGRANEX is not intended to be used in wounds that close by primary intention. uuid:b74aa7fa-104f-4d5d-9ab1-d38c5a2c1df9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:1B56C968OA biolink:treats MONDO:0004646 PMID:41385096 "[{""id"":""uuid:9cd35ad4-33e5-4d48-8607-2f7c25b29151"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0ac1ea68-fcc4-401a-b831-6419c9b9354f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] REGRANEX is indicated for the treatment of lower extremity diabetic neuropathic ulcers that extend into the subcutaneous tissue or beyond and have an adequate blood supply, when used as an adjunct to, and not a substitute for, good ulcer care practices including initial sharp debridement, pressure relief and infection control. Limitations of Use : The efficacy of REGRANEX has not been established for the treatment of pressure ulcers and venous stasis ulcers [ see Clinical Studies (14.2) ] and has not been evaluated for the treatment of diabetic neuropathic ulcers that do not extend through the dermis into subcutaneous tissue [Stage I or II, International Association of Enterostomal Therapy (IAET) staging classification] or ischemic diabetic ulcers. The effects of becaplermin on exposed joints, tendons, ligaments, and bone have not been established in humans [ see Nonclinical Toxicology (13.2) ] . REGRANEX is not intended to be used in wounds that close by primary intention. uuid:9f705a4b-77ca-4ffb-b53e-babcb8866168 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:1B56C968OA biolink:treats UMLS:C0042344 PMID:41385096 "[{""id"":""uuid:06bf7a92-e8d1-4bb2-a06a-2391e78a4933"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4640f828-2b36-4e7e-aece-32b81d4b5bff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] REGRANEX is indicated for the treatment of lower extremity diabetic neuropathic ulcers that extend into the subcutaneous tissue or beyond and have an adequate blood supply, when used as an adjunct to, and not a substitute for, good ulcer care practices including initial sharp debridement, pressure relief and infection control. Limitations of Use : The efficacy of REGRANEX has not been established for the treatment of pressure ulcers and venous stasis ulcers [ see Clinical Studies (14.2) ] and has not been evaluated for the treatment of diabetic neuropathic ulcers that do not extend through the dermis into subcutaneous tissue [Stage I or II, International Association of Enterostomal Therapy (IAET) staging classification] or ischemic diabetic ulcers. The effects of becaplermin on exposed joints, tendons, ligaments, and bone have not been established in humans [ see Nonclinical Toxicology (13.2) ] . REGRANEX is not intended to be used in wounds that close by primary intention. uuid:2a76e31e-62eb-41f3-ae7a-4fb38784bab3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85078 biolink:treats MONDO:0005300 PMID:41385096 "[{""id"":""uuid:8d05cba8-f363-4d92-9a03-33e84f88b7cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7343f279-39aa-4f6b-b9d0-5f269651af1f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f565a3ca-9342-417e-8c83-4e123cf3d50b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:0c0e608a-c957-46d9-b541-f4e4107c2315"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FARXIGA (dapagliflozin) is indicated: • To reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease at risk of progression. • To reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure. • To reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and either established cardiovascular disease or multiple cardiovascular risk factors. • As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use • FARXIGA is not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus [see Warnings and Precautions (5.1) ] . • FARXIGA is not recommended for use to improve glycemic control in adults with type 2 diabetes mellitus with an eGFR less than 45 mL/min/1.73 m 2 . FARXIGA is likely to be ineffective in this setting based upon its mechanism of action. • FARXIGA is not recommended for the treatment of chronic kidney disease in patients with polycystic kidney disease or patients requiring or with a recent history of immunosuppressive therapy for kidney disease. FARXIGA is not expected to be effective in these populations.|[EMA] Type 2 diabetes mellitusForxiga is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance.in addition to other medicinal products for the treatment of type 2 diabetes.For study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4.4, 4.5 and 5.1.Heart failureForxiga is indicated in adults for the treatment of symptomatic chronic heart failure.Chronic kidney diseaseForxiga is indicated in adults for the treatment of chronic kidney disease.|[PMDA] Drugs with a new indication for the treatment of chronic kidney disease. [Priority review] uuid:bbf166ea-23ad-4168-a788-95fd3b534e7b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85078 biolink:treats MONDO:0004375 PMID:41385096 "[{""id"":""uuid:3711001d-a8c3-4f44-8a05-2d7028495950"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:586450a8-bd36-4e74-81f8-c7c380f30585"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FARXIGA (dapagliflozin) is indicated: • To reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease at risk of progression. • To reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure. • To reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and either established cardiovascular disease or multiple cardiovascular risk factors. • As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use • FARXIGA is not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus [see Warnings and Precautions (5.1) ] . • FARXIGA is not recommended for use to improve glycemic control in adults with type 2 diabetes mellitus with an eGFR less than 45 mL/min/1.73 m 2 . FARXIGA is likely to be ineffective in this setting based upon its mechanism of action. • FARXIGA is not recommended for the treatment of chronic kidney disease in patients with polycystic kidney disease or patients requiring or with a recent history of immunosuppressive therapy for kidney disease. FARXIGA is not expected to be effective in these populations. uuid:738fe6f9-515a-4f37-8e88-89445819aebf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85078 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:cfe2ecb4-8c17-498f-b4cb-a1eae82180f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f23b37a4-76b5-4fde-88f7-0891ec84ea6b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:297a28dd-70ec-4a97-87d6-e0fc4fb90a49"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FARXIGA (dapagliflozin) is indicated: • To reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease at risk of progression. • To reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure. • To reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and either established cardiovascular disease or multiple cardiovascular risk factors. • As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use • FARXIGA is not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus [see Warnings and Precautions (5.1) ] . • FARXIGA is not recommended for use to improve glycemic control in adults with type 2 diabetes mellitus with an eGFR less than 45 mL/min/1.73 m 2 . FARXIGA is likely to be ineffective in this setting based upon its mechanism of action. • FARXIGA is not recommended for the treatment of chronic kidney disease in patients with polycystic kidney disease or patients requiring or with a recent history of immunosuppressive therapy for kidney disease. FARXIGA is not expected to be effective in these populations.|[EMA] Type 2 diabetes mellitusForxiga is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance.in addition to other medicinal products for the treatment of type 2 diabetes.For study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4.4, 4.5 and 5.1.Heart failureForxiga is indicated in adults for the treatment of symptomatic chronic heart failure.Chronic kidney diseaseForxiga is indicated in adults for the treatment of chronic kidney disease. uuid:ad206553-d51c-4da8-acbf-66bb0caafbd4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85078 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:74213148-cdad-417a-a461-1910893bff55"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f83010ef-42be-4a04-975d-4975b7d77846"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:36eedb99-79c2-4bfe-a92f-6745dbf8f0d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c0a6a56c-d668-4762-b7b0-a24b6d453b1c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FARXIGA (dapagliflozin) is indicated: • To reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease at risk of progression. • To reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure. • To reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and either established cardiovascular disease or multiple cardiovascular risk factors. • As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use • FARXIGA is not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus [see Warnings and Precautions (5.1) ] . • FARXIGA is not recommended for use to improve glycemic control in adults with type 2 diabetes mellitus with an eGFR less than 45 mL/min/1.73 m 2 . FARXIGA is likely to be ineffective in this setting based upon its mechanism of action. • FARXIGA is not recommended for the treatment of chronic kidney disease in patients with polycystic kidney disease or patients requiring or with a recent history of immunosuppressive therapy for kidney disease. FARXIGA is not expected to be effective in these populations.|[EMA] Type 2 diabetes mellitusForxiga is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance.in addition to other medicinal products for the treatment of type 2 diabetes.For study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4.4, 4.5 and 5.1.Heart failureForxiga is indicated in adults for the treatment of symptomatic chronic heart failure.Chronic kidney diseaseForxiga is indicated in adults for the treatment of chronic kidney disease.|[PMDA] Drugs with a new active ingredient indicated for the treatment of type 2 diabetes mellitus. uuid:26ad85a8-c14b-475b-b978-7ce7eb66288b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85078 biolink:treats MONDO:0005147 PMID:41385096 "[{""id"":""uuid:8824c613-debf-4213-bd02-d12c8bd8de6b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:dc5d4ccd-aa39-45fb-bba9-baa62ce5e0ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:7fa78f99-48b3-4d9a-91b2-75c1a1a7e503"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FARXIGA (dapagliflozin) is indicated: • To reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease at risk of progression. • To reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure. • To reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and either established cardiovascular disease or multiple cardiovascular risk factors. • As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use • FARXIGA is not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus [see Warnings and Precautions (5.1) ] . • FARXIGA is not recommended for use to improve glycemic control in adults with type 2 diabetes mellitus with an eGFR less than 45 mL/min/1.73 m 2 . FARXIGA is likely to be ineffective in this setting based upon its mechanism of action. • FARXIGA is not recommended for the treatment of chronic kidney disease in patients with polycystic kidney disease or patients requiring or with a recent history of immunosuppressive therapy for kidney disease. FARXIGA is not expected to be effective in these populations.|[PMDA] Drugs with a new additional indication and a new dosage for the treatment of type 1 diabetes mellitus. uuid:fb91ed44-78be-438f-bc1f-30f9796db820 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85078 biolink:treats MONDO:0020642 PMID:41385096 "[{""id"":""uuid:a41ec1b4-b4bc-423a-842b-20a551c6e732"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7bb1c91f-4051-487f-a9e8-a8a6f79618cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FARXIGA (dapagliflozin) is indicated: • To reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease at risk of progression. • To reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure. • To reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and either established cardiovascular disease or multiple cardiovascular risk factors. • As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use • FARXIGA is not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus [see Warnings and Precautions (5.1) ] . • FARXIGA is not recommended for use to improve glycemic control in adults with type 2 diabetes mellitus with an eGFR less than 45 mL/min/1.73 m 2 . FARXIGA is likely to be ineffective in this setting based upon its mechanism of action. • FARXIGA is not recommended for the treatment of chronic kidney disease in patients with polycystic kidney disease or patients requiring or with a recent history of immunosuppressive therapy for kidney disease. FARXIGA is not expected to be effective in these populations. uuid:a5e45596-8a07-473a-99f4-a2be54db922d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50305 biolink:treats UMLS:C0343730 PMID:41385096 "[{""id"":""uuid:847c01ee-2715-4aee-9bcf-5466ec18fa00"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1fe903a4-d16f-462b-a7f3-a21aaf06c8a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Podofilox gel is indicated for the topical treatment of anogenital warts (external genital warts and perianal warts). This product is not indicated in the treatment of mucous membrane warts (see PRECAUTIONS ). Diagnosis Although anogenital warts have a characteristic appearance, histopathologic confirmation should be obtained if there is any doubt of the diagnosis. Differentiating warts from squamous cell carcinoma and ""Bowenoid papulosis"" is of particular concern. Squamous cell carcinoma may also be associated with human papillomavirus which should not be treated with podofilox gel." uuid:52d48449-b1a3-4654-aeb9-7cddd984427f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50305 biolink:treats MONDO:0005096 PMID:41385096 "[{""id"":""uuid:3e3de5de-a2f7-4ba4-99f8-69924762989a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4a5004ab-88b7-45d2-957c-e6eff1be84bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Podofilox gel is indicated for the topical treatment of anogenital warts (external genital warts and perianal warts). This product is not indicated in the treatment of mucous membrane warts (see PRECAUTIONS ). Diagnosis Although anogenital warts have a characteristic appearance, histopathologic confirmation should be obtained if there is any doubt of the diagnosis. Differentiating warts from squamous cell carcinoma and ""Bowenoid papulosis"" is of particular concern. Squamous cell carcinoma may also be associated with human papillomavirus which should not be treated with podofilox gel." uuid:412987fb-ff56-4f32-8708-02b307e31078 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50305 biolink:treats MONDO:0022022 PMID:41385096 "[{""id"":""uuid:7a009cbd-9310-4681-b53c-85b5b87056b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:601edf15-ab25-4324-9975-df3377b4243f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Podofilox gel is indicated for the topical treatment of anogenital warts (external genital warts and perianal warts). This product is not indicated in the treatment of mucous membrane warts (see PRECAUTIONS ). Diagnosis Although anogenital warts have a characteristic appearance, histopathologic confirmation should be obtained if there is any doubt of the diagnosis. Differentiating warts from squamous cell carcinoma and ""Bowenoid papulosis"" is of particular concern. Squamous cell carcinoma may also be associated with human papillomavirus which should not be treated with podofilox gel." uuid:b4ab73cc-c5d2-463d-8fa9-1a27115df5e3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1155433 biolink:treats MONDO:0005578 PMID:41385096 "[{""id"":""uuid:3c20361b-ac74-4510-a1f2-9f1385445019"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:163fec05-11fc-4244-b630-5c31804fa92a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Trubrexa TM Transdermal Patch is indicated in adults over the age of 12 years old for the treatment of acute and chronic pain in muscles and joints associated with muscle soreness, strains, sprains, arthritis, simple backache, muscle stiffness, and more. uuid:7100be9d-0dec-4134-b1ee-019d9067022b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4682 biolink:treats HP:0002018 PMID:41385096 "[{""id"":""uuid:c36f9711-7cf3-44f0-8508-19ddd6f18e9b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f1c7702b-b916-4b32-b9e7-20721de1d179"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ANZEMET Tablets are indicated for the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy, including initial and repeat courses in adults and children 2 years and older. uuid:4e575628-6994-4e72-9a2a-2429fc064014 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4682 biolink:treats HP:0002013 PMID:41385096 "[{""id"":""uuid:bb852a8d-f196-4103-b09b-547ecdcb5fb1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e7f66ad9-f87a-4fcf-a9ae-4fbc5b509f25"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ANZEMET Tablets are indicated for the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy, including initial and repeat courses in adults and children 2 years and older. uuid:32bba310-6804-4895-b8a2-7e5a60ed8eff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:848151 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:3bebe9fc-f182-487a-89fb-34844a40a8a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b5a737a9-ad73-41f7-ae00-dba79e5f0a1b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amlodipine, valsartan and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including amlodipine, hydrochlorothiazide, and the ARB class to which valsartan principally belongs. There are no controlled trials demonstrating risk reduction with amlodipine, valsartan and hydrochlorothiazide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (e.g., patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Limitation of Use Amlodipine, valsartan and hydrochlorothiazide tablets are not indicated for the initial therapy of hypertension [ see Dosage and Administration ( 2 ) ]. uuid:7cf70933-a4d9-42f6-a22b-37c8b1cf598c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:848151 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:c3501d69-ff8b-47e1-b286-05a6076d99d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a1b53994-8db3-4ad0-aef5-1736f5d8c223"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amlodipine, valsartan and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including amlodipine, hydrochlorothiazide, and the ARB class to which valsartan principally belongs. There are no controlled trials demonstrating risk reduction with amlodipine, valsartan and hydrochlorothiazide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (e.g., patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Limitation of Use Amlodipine, valsartan and hydrochlorothiazide tablets are not indicated for the initial therapy of hypertension [ see Dosage and Administration ( 2 ) ]. uuid:1a8134e4-a418-43c7-874e-ee18acf47b65 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:848151 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:9a1e0925-bf8e-4a92-b2f0-2b2291b959a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f152f094-18c5-4bda-b6a8-d47c2e237acb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amlodipine, valsartan and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including amlodipine, hydrochlorothiazide, and the ARB class to which valsartan principally belongs. There are no controlled trials demonstrating risk reduction with amlodipine, valsartan and hydrochlorothiazide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (e.g., patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Limitation of Use Amlodipine, valsartan and hydrochlorothiazide tablets are not indicated for the initial therapy of hypertension [ see Dosage and Administration ( 2 ) ]. uuid:2ee0c35a-8e6e-40b2-8713-46986a315f55 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:848151 biolink:treats MONDO:0005016 PMID:41385096 "[{""id"":""uuid:539a9e5a-b561-4f7e-b8f9-a37abc0d16b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e233e549-91ae-42c3-ab6b-9e24e09ab076"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amlodipine, valsartan and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including amlodipine, hydrochlorothiazide, and the ARB class to which valsartan principally belongs. There are no controlled trials demonstrating risk reduction with amlodipine, valsartan and hydrochlorothiazide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (e.g., patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Limitation of Use Amlodipine, valsartan and hydrochlorothiazide tablets are not indicated for the initial therapy of hypertension [ see Dosage and Administration ( 2 ) ]. uuid:8f7991b3-da28-40d7-bf8f-01a38bdafdda biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2BT4C47RUI biolink:treats MONDO:0056806 PMID:41385096 "[{""id"":""uuid:127e96a6-53ef-4540-9dee-6d4f8e6eafe6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:00b12971-3608-411e-8832-5b1260b98a7e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PORTRAZZA™ is an epidermal growth factor receptor (EGFR) antagonist indicated, in combination with gemcitabine and cisplatin, for first-line treatment of patients with metastatic squamous non-small cell lung cancer. ( 1.1 ) Limitation of Use: PORTRAZZA is not indicated for treatment of non-squamous non-small cell lung cancer. ( 1.2 , 5.6 , 14.2 ) uuid:da41cc71-b3dc-4d0c-a3e7-4342e2f92b65 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:11672431 biolink:treats MONDO:0006652 PMID:41385096 "[{""id"":""uuid:d53dadf4-9edc-4b90-9e9f-fe385c53a5ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dda9a20f-cd1b-455b-a941-f9aa772e2f38"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Telmisartan and amlodipine tablet is an angiotensin II receptor blocker (ARB) and a dihydropyridine calcium channel blocker (DHP-CCB) combination product indicated for the treatment of hypertension alone or with other antihypertensive agents to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1 ) Telmisartan and amlodipine tablets are indicated as initial therapy in patients likely to need multiple antihypertensive agents to achieve their blood pressure goals ( 1 ) uuid:28bb2280-dbc8-4172-8b91-86ca4185829f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49575 biolink:treats MONDO:0005027 PMID:41385096 "[{""id"":""uuid:02d4fb18-b89b-48b0-8f17-1e95d9b9d3f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7a928ba5-e956-48bd-810c-4a268a0927c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diazepam rectal gel is intended for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern in patients with epilepsy 2 years of age and older. uuid:3bc61ae4-14d0-4873-aa9c-44826432b749 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49575 biolink:treats UMLS:C3203523 PMID:41385096 "[{""id"":""uuid:89a3afee-4d6c-4da1-bee6-364ba309cd6a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aec04781-0e1b-4387-b941-05a686b8f199"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diazepam rectal gel is intended for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern in patients with epilepsy 2 years of age and older. uuid:6a8f6219-8463-497c-8901-b96e00e0aa79 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6965 biolink:treats MONDO:0005090 PMID:41385096 "[{""id"":""uuid:86576f21-1884-4b88-a069-7a053ee1877a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cd07a14a-a420-4692-8625-d8b199732c67"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Molindone Hydrochloride Tablets, USP are indicated for the management of schizophrenia. The efficacy of Molindone Hydrochloride Tablets, USP in schizophrenia was established in clinical studies which enrolled newly hospitalized and chronically hospitalized, acutely ill, schizophrenic patients as subjects. uuid:95f4216a-b2b3-42f2-9ce7-e149c02945b4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9328 biolink:treats MONDO:0001797 PMID:41385096 "[{""id"":""uuid:42398f4e-1c8d-4d1a-9857-7302d8eea1ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d2efd4d0-523b-4a44-8eb2-0be9fc14db39"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] sulfADIAZINE Tablets, USP are indicated in the following conditions: Chancroid Trachoma Inclusion conjunctivitis Nocardiosis Urinary tract infections (primarily pyelonephritis, pyelitis and cystitis) in the absence of obstructive uropathy or foreign bodies, when these infections are caused by susceptible strains of the following organisms: Esch erichia coli, Klebsiella species, Enterobacter species, Staphylococcus aureus, Proteus mirabilis and P. vulgaris . Sulfadiazine should be used for urinary tract infections only after use of more soluble sulfonamides has been unsuccessful. Toxoplasmosis encephalitis in patients with and without acquired immunodeficiency syndrome, as adjunctive therapy with pyrimethamine. Malaria due to chloroquine-resistant strains of Plasmodium falciparum , when used as adjunctive therapy. Prophylaxis of meningococcal meningitis when sulfonamide-sensitive group A strains are known to prevail in family groups or larger closed populations (the prophylactic usefulness of sulfonamides when group B or C infections are prevalent is not proved and may be harmful in closed population groups). Meningococcal meningitis, when the organism has been demonstrated to be susceptible. Acute otitis media due to Haemophilus influenzae, when used concomitantly with adequate doses of penicilin. Prophylaxis against recurrences of rheumatic fever, as an alternative to penicillin. H. influenzae meningitis, as adjunctive therapy with parental streptomycin. IMPORTANT NOTES In vitro sulfonamide susceptibility tests are not always reliable. The test must be carefully coordinated with bacteriologic and clinical response. When the patient is already taking sulfonamides, follow-up cultures should have aminobenzoic acid added to the culture media. Currently, the increasing frequency of resistant organisms limits the usefulness of antibacterial agents, including the sulfonamides, especially in the treatment of recurrent and complicated urinary tract infections. Wide variation in blood levels may result with identical doses. Blood levels should be measured in patients receiving sulfonamides for serious infections. Free sulfonamide blood levels of 5 mg to 15 mg per 100 mL may be considered therapeutically effective for most infections and blood levels of 12 mg to 15 mg per 100 mL may be considered optimal for serious infections. Twenty mg per 100 mL should be the maximum total sulfonamide level, since adverse reactions occur more frequently above this level. uuid:efa46456-54fc-490b-a507-10f63ded5b11 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9328 biolink:treats MONDO:0001249 PMID:41385096 "[{""id"":""uuid:75361a08-ba8c-4724-9316-c01532beba92"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:973479da-b357-4782-8195-f58bd9b57696"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] sulfADIAZINE Tablets, USP are indicated in the following conditions: Chancroid Trachoma Inclusion conjunctivitis Nocardiosis Urinary tract infections (primarily pyelonephritis, pyelitis and cystitis) in the absence of obstructive uropathy or foreign bodies, when these infections are caused by susceptible strains of the following organisms: Esch erichia coli, Klebsiella species, Enterobacter species, Staphylococcus aureus, Proteus mirabilis and P. vulgaris . Sulfadiazine should be used for urinary tract infections only after use of more soluble sulfonamides has been unsuccessful. Toxoplasmosis encephalitis in patients with and without acquired immunodeficiency syndrome, as adjunctive therapy with pyrimethamine. Malaria due to chloroquine-resistant strains of Plasmodium falciparum , when used as adjunctive therapy. Prophylaxis of meningococcal meningitis when sulfonamide-sensitive group A strains are known to prevail in family groups or larger closed populations (the prophylactic usefulness of sulfonamides when group B or C infections are prevalent is not proved and may be harmful in closed population groups). Meningococcal meningitis, when the organism has been demonstrated to be susceptible. Acute otitis media due to Haemophilus influenzae, when used concomitantly with adequate doses of penicilin. Prophylaxis against recurrences of rheumatic fever, as an alternative to penicillin. H. influenzae meningitis, as adjunctive therapy with parental streptomycin. IMPORTANT NOTES In vitro sulfonamide susceptibility tests are not always reliable. The test must be carefully coordinated with bacteriologic and clinical response. When the patient is already taking sulfonamides, follow-up cultures should have aminobenzoic acid added to the culture media. Currently, the increasing frequency of resistant organisms limits the usefulness of antibacterial agents, including the sulfonamides, especially in the treatment of recurrent and complicated urinary tract infections. Wide variation in blood levels may result with identical doses. Blood levels should be measured in patients receiving sulfonamides for serious infections. Free sulfonamide blood levels of 5 mg to 15 mg per 100 mL may be considered therapeutically effective for most infections and blood levels of 12 mg to 15 mg per 100 mL may be considered optimal for serious infections. Twenty mg per 100 mL should be the maximum total sulfonamide level, since adverse reactions occur more frequently above this level. uuid:6a3df24b-1840-4122-878c-513a16570bb3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9328 biolink:treats MONDO:0005808 PMID:41385096 "[{""id"":""uuid:371f89ea-9605-4607-b13a-119e39da9869"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:db3bc138-cdf5-4786-9d5c-4219bcb09ee2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] sulfADIAZINE Tablets, USP are indicated in the following conditions: Chancroid Trachoma Inclusion conjunctivitis Nocardiosis Urinary tract infections (primarily pyelonephritis, pyelitis and cystitis) in the absence of obstructive uropathy or foreign bodies, when these infections are caused by susceptible strains of the following organisms: Esch erichia coli, Klebsiella species, Enterobacter species, Staphylococcus aureus, Proteus mirabilis and P. vulgaris . Sulfadiazine should be used for urinary tract infections only after use of more soluble sulfonamides has been unsuccessful. Toxoplasmosis encephalitis in patients with and without acquired immunodeficiency syndrome, as adjunctive therapy with pyrimethamine. Malaria due to chloroquine-resistant strains of Plasmodium falciparum , when used as adjunctive therapy. Prophylaxis of meningococcal meningitis when sulfonamide-sensitive group A strains are known to prevail in family groups or larger closed populations (the prophylactic usefulness of sulfonamides when group B or C infections are prevalent is not proved and may be harmful in closed population groups). Meningococcal meningitis, when the organism has been demonstrated to be susceptible. Acute otitis media due to Haemophilus influenzae, when used concomitantly with adequate doses of penicilin. Prophylaxis against recurrences of rheumatic fever, as an alternative to penicillin. H. influenzae meningitis, as adjunctive therapy with parental streptomycin. IMPORTANT NOTES In vitro sulfonamide susceptibility tests are not always reliable. The test must be carefully coordinated with bacteriologic and clinical response. When the patient is already taking sulfonamides, follow-up cultures should have aminobenzoic acid added to the culture media. Currently, the increasing frequency of resistant organisms limits the usefulness of antibacterial agents, including the sulfonamides, especially in the treatment of recurrent and complicated urinary tract infections. Wide variation in blood levels may result with identical doses. Blood levels should be measured in patients receiving sulfonamides for serious infections. Free sulfonamide blood levels of 5 mg to 15 mg per 100 mL may be considered therapeutically effective for most infections and blood levels of 12 mg to 15 mg per 100 mL may be considered optimal for serious infections. Twenty mg per 100 mL should be the maximum total sulfonamide level, since adverse reactions occur more frequently above this level. uuid:dbeef281-c8b8-43c3-9172-0682378dde67 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9328 biolink:treats MONDO:0017776 PMID:41385096 "[{""id"":""uuid:74d7d0cb-a364-4b3d-a446-db3a3e8ded91"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ccd93c27-0b22-4718-8573-1b65c13f11b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] sulfADIAZINE Tablets, USP are indicated in the following conditions: Chancroid Trachoma Inclusion conjunctivitis Nocardiosis Urinary tract infections (primarily pyelonephritis, pyelitis and cystitis) in the absence of obstructive uropathy or foreign bodies, when these infections are caused by susceptible strains of the following organisms: Esch erichia coli, Klebsiella species, Enterobacter species, Staphylococcus aureus, Proteus mirabilis and P. vulgaris . Sulfadiazine should be used for urinary tract infections only after use of more soluble sulfonamides has been unsuccessful. Toxoplasmosis encephalitis in patients with and without acquired immunodeficiency syndrome, as adjunctive therapy with pyrimethamine. Malaria due to chloroquine-resistant strains of Plasmodium falciparum , when used as adjunctive therapy. Prophylaxis of meningococcal meningitis when sulfonamide-sensitive group A strains are known to prevail in family groups or larger closed populations (the prophylactic usefulness of sulfonamides when group B or C infections are prevalent is not proved and may be harmful in closed population groups). Meningococcal meningitis, when the organism has been demonstrated to be susceptible. Acute otitis media due to Haemophilus influenzae, when used concomitantly with adequate doses of penicilin. Prophylaxis against recurrences of rheumatic fever, as an alternative to penicillin. H. influenzae meningitis, as adjunctive therapy with parental streptomycin. IMPORTANT NOTES In vitro sulfonamide susceptibility tests are not always reliable. The test must be carefully coordinated with bacteriologic and clinical response. When the patient is already taking sulfonamides, follow-up cultures should have aminobenzoic acid added to the culture media. Currently, the increasing frequency of resistant organisms limits the usefulness of antibacterial agents, including the sulfonamides, especially in the treatment of recurrent and complicated urinary tract infections. Wide variation in blood levels may result with identical doses. Blood levels should be measured in patients receiving sulfonamides for serious infections. Free sulfonamide blood levels of 5 mg to 15 mg per 100 mL may be considered therapeutically effective for most infections and blood levels of 12 mg to 15 mg per 100 mL may be considered optimal for serious infections. Twenty mg per 100 mL should be the maximum total sulfonamide level, since adverse reactions occur more frequently above this level. uuid:6351e214-36fd-487d-bc44-bdbba5359ce2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9328 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:fe20fd0d-eeaf-4a5f-95e3-4ad7d4c45b13"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9a858f03-2336-442f-8f6a-f988f4e7da1e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] sulfADIAZINE Tablets, USP are indicated in the following conditions: Chancroid Trachoma Inclusion conjunctivitis Nocardiosis Urinary tract infections (primarily pyelonephritis, pyelitis and cystitis) in the absence of obstructive uropathy or foreign bodies, when these infections are caused by susceptible strains of the following organisms: Esch erichia coli, Klebsiella species, Enterobacter species, Staphylococcus aureus, Proteus mirabilis and P. vulgaris . Sulfadiazine should be used for urinary tract infections only after use of more soluble sulfonamides has been unsuccessful. Toxoplasmosis encephalitis in patients with and without acquired immunodeficiency syndrome, as adjunctive therapy with pyrimethamine. Malaria due to chloroquine-resistant strains of Plasmodium falciparum , when used as adjunctive therapy. Prophylaxis of meningococcal meningitis when sulfonamide-sensitive group A strains are known to prevail in family groups or larger closed populations (the prophylactic usefulness of sulfonamides when group B or C infections are prevalent is not proved and may be harmful in closed population groups). Meningococcal meningitis, when the organism has been demonstrated to be susceptible. Acute otitis media due to Haemophilus influenzae, when used concomitantly with adequate doses of penicilin. Prophylaxis against recurrences of rheumatic fever, as an alternative to penicillin. H. influenzae meningitis, as adjunctive therapy with parental streptomycin. IMPORTANT NOTES In vitro sulfonamide susceptibility tests are not always reliable. The test must be carefully coordinated with bacteriologic and clinical response. When the patient is already taking sulfonamides, follow-up cultures should have aminobenzoic acid added to the culture media. Currently, the increasing frequency of resistant organisms limits the usefulness of antibacterial agents, including the sulfonamides, especially in the treatment of recurrent and complicated urinary tract infections. Wide variation in blood levels may result with identical doses. Blood levels should be measured in patients receiving sulfonamides for serious infections. Free sulfonamide blood levels of 5 mg to 15 mg per 100 mL may be considered therapeutically effective for most infections and blood levels of 12 mg to 15 mg per 100 mL may be considered optimal for serious infections. Twenty mg per 100 mL should be the maximum total sulfonamide level, since adverse reactions occur more frequently above this level. uuid:c2575eb1-1521-4b37-bbd3-98562bca82f4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9328 biolink:treats MONDO:0006939 PMID:41385096 "[{""id"":""uuid:df412f3e-09bf-45c3-b92d-be016f97e596"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ea9ce993-6646-436e-8048-555da61e9207"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] sulfADIAZINE Tablets, USP are indicated in the following conditions: Chancroid Trachoma Inclusion conjunctivitis Nocardiosis Urinary tract infections (primarily pyelonephritis, pyelitis and cystitis) in the absence of obstructive uropathy or foreign bodies, when these infections are caused by susceptible strains of the following organisms: Esch erichia coli, Klebsiella species, Enterobacter species, Staphylococcus aureus, Proteus mirabilis and P. vulgaris . Sulfadiazine should be used for urinary tract infections only after use of more soluble sulfonamides has been unsuccessful. Toxoplasmosis encephalitis in patients with and without acquired immunodeficiency syndrome, as adjunctive therapy with pyrimethamine. Malaria due to chloroquine-resistant strains of Plasmodium falciparum , when used as adjunctive therapy. Prophylaxis of meningococcal meningitis when sulfonamide-sensitive group A strains are known to prevail in family groups or larger closed populations (the prophylactic usefulness of sulfonamides when group B or C infections are prevalent is not proved and may be harmful in closed population groups). Meningococcal meningitis, when the organism has been demonstrated to be susceptible. Acute otitis media due to Haemophilus influenzae, when used concomitantly with adequate doses of penicilin. Prophylaxis against recurrences of rheumatic fever, as an alternative to penicillin. H. influenzae meningitis, as adjunctive therapy with parental streptomycin. IMPORTANT NOTES In vitro sulfonamide susceptibility tests are not always reliable. The test must be carefully coordinated with bacteriologic and clinical response. When the patient is already taking sulfonamides, follow-up cultures should have aminobenzoic acid added to the culture media. Currently, the increasing frequency of resistant organisms limits the usefulness of antibacterial agents, including the sulfonamides, especially in the treatment of recurrent and complicated urinary tract infections. Wide variation in blood levels may result with identical doses. Blood levels should be measured in patients receiving sulfonamides for serious infections. Free sulfonamide blood levels of 5 mg to 15 mg per 100 mL may be considered therapeutically effective for most infections and blood levels of 12 mg to 15 mg per 100 mL may be considered optimal for serious infections. Twenty mg per 100 mL should be the maximum total sulfonamide level, since adverse reactions occur more frequently above this level. uuid:83c8dab7-19fe-44b1-a6b9-78dbe9e733e5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9328 biolink:treats MONDO:0006938 PMID:41385096 "[{""id"":""uuid:4dc09125-ce7f-49a4-b495-421b0859a071"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0e3ec84b-c3f2-4ef2-965d-fce1542148eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] sulfADIAZINE Tablets, USP are indicated in the following conditions: Chancroid Trachoma Inclusion conjunctivitis Nocardiosis Urinary tract infections (primarily pyelonephritis, pyelitis and cystitis) in the absence of obstructive uropathy or foreign bodies, when these infections are caused by susceptible strains of the following organisms: Esch erichia coli, Klebsiella species, Enterobacter species, Staphylococcus aureus, Proteus mirabilis and P. vulgaris . Sulfadiazine should be used for urinary tract infections only after use of more soluble sulfonamides has been unsuccessful. Toxoplasmosis encephalitis in patients with and without acquired immunodeficiency syndrome, as adjunctive therapy with pyrimethamine. Malaria due to chloroquine-resistant strains of Plasmodium falciparum , when used as adjunctive therapy. Prophylaxis of meningococcal meningitis when sulfonamide-sensitive group A strains are known to prevail in family groups or larger closed populations (the prophylactic usefulness of sulfonamides when group B or C infections are prevalent is not proved and may be harmful in closed population groups). Meningococcal meningitis, when the organism has been demonstrated to be susceptible. Acute otitis media due to Haemophilus influenzae, when used concomitantly with adequate doses of penicilin. Prophylaxis against recurrences of rheumatic fever, as an alternative to penicillin. H. influenzae meningitis, as adjunctive therapy with parental streptomycin. IMPORTANT NOTES In vitro sulfonamide susceptibility tests are not always reliable. The test must be carefully coordinated with bacteriologic and clinical response. When the patient is already taking sulfonamides, follow-up cultures should have aminobenzoic acid added to the culture media. Currently, the increasing frequency of resistant organisms limits the usefulness of antibacterial agents, including the sulfonamides, especially in the treatment of recurrent and complicated urinary tract infections. Wide variation in blood levels may result with identical doses. Blood levels should be measured in patients receiving sulfonamides for serious infections. Free sulfonamide blood levels of 5 mg to 15 mg per 100 mL may be considered therapeutically effective for most infections and blood levels of 12 mg to 15 mg per 100 mL may be considered optimal for serious infections. Twenty mg per 100 mL should be the maximum total sulfonamide level, since adverse reactions occur more frequently above this level. uuid:1453f1b7-b737-45a0-897e-98f53d4a3e95 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9328 biolink:treats MONDO:0006032 PMID:41385096 "[{""id"":""uuid:339818e7-a2cc-4dda-a9bd-edb9d392f55f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:93d2f4a0-e1d3-4408-8655-c32589452591"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] sulfADIAZINE Tablets, USP are indicated in the following conditions: Chancroid Trachoma Inclusion conjunctivitis Nocardiosis Urinary tract infections (primarily pyelonephritis, pyelitis and cystitis) in the absence of obstructive uropathy or foreign bodies, when these infections are caused by susceptible strains of the following organisms: Esch erichia coli, Klebsiella species, Enterobacter species, Staphylococcus aureus, Proteus mirabilis and P. vulgaris . Sulfadiazine should be used for urinary tract infections only after use of more soluble sulfonamides has been unsuccessful. Toxoplasmosis encephalitis in patients with and without acquired immunodeficiency syndrome, as adjunctive therapy with pyrimethamine. Malaria due to chloroquine-resistant strains of Plasmodium falciparum , when used as adjunctive therapy. Prophylaxis of meningococcal meningitis when sulfonamide-sensitive group A strains are known to prevail in family groups or larger closed populations (the prophylactic usefulness of sulfonamides when group B or C infections are prevalent is not proved and may be harmful in closed population groups). Meningococcal meningitis, when the organism has been demonstrated to be susceptible. Acute otitis media due to Haemophilus influenzae, when used concomitantly with adequate doses of penicilin. Prophylaxis against recurrences of rheumatic fever, as an alternative to penicillin. H. influenzae meningitis, as adjunctive therapy with parental streptomycin. IMPORTANT NOTES In vitro sulfonamide susceptibility tests are not always reliable. The test must be carefully coordinated with bacteriologic and clinical response. When the patient is already taking sulfonamides, follow-up cultures should have aminobenzoic acid added to the culture media. Currently, the increasing frequency of resistant organisms limits the usefulness of antibacterial agents, including the sulfonamides, especially in the treatment of recurrent and complicated urinary tract infections. Wide variation in blood levels may result with identical doses. Blood levels should be measured in patients receiving sulfonamides for serious infections. Free sulfonamide blood levels of 5 mg to 15 mg per 100 mL may be considered therapeutically effective for most infections and blood levels of 12 mg to 15 mg per 100 mL may be considered optimal for serious infections. Twenty mg per 100 mL should be the maximum total sulfonamide level, since adverse reactions occur more frequently above this level. uuid:21a28a2d-0660-4283-8ee3-f75d57d0103a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9328 biolink:treats MONDO:0005697 PMID:41385096 "[{""id"":""uuid:6369992d-e1cf-4978-a855-0a22161dfb1e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d4a20a66-c12e-4976-8e87-331c73fd1b27"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] sulfADIAZINE Tablets, USP are indicated in the following conditions: Chancroid Trachoma Inclusion conjunctivitis Nocardiosis Urinary tract infections (primarily pyelonephritis, pyelitis and cystitis) in the absence of obstructive uropathy or foreign bodies, when these infections are caused by susceptible strains of the following organisms: Esch erichia coli, Klebsiella species, Enterobacter species, Staphylococcus aureus, Proteus mirabilis and P. vulgaris . Sulfadiazine should be used for urinary tract infections only after use of more soluble sulfonamides has been unsuccessful. Toxoplasmosis encephalitis in patients with and without acquired immunodeficiency syndrome, as adjunctive therapy with pyrimethamine. Malaria due to chloroquine-resistant strains of Plasmodium falciparum , when used as adjunctive therapy. Prophylaxis of meningococcal meningitis when sulfonamide-sensitive group A strains are known to prevail in family groups or larger closed populations (the prophylactic usefulness of sulfonamides when group B or C infections are prevalent is not proved and may be harmful in closed population groups). Meningococcal meningitis, when the organism has been demonstrated to be susceptible. Acute otitis media due to Haemophilus influenzae, when used concomitantly with adequate doses of penicilin. Prophylaxis against recurrences of rheumatic fever, as an alternative to penicillin. H. influenzae meningitis, as adjunctive therapy with parental streptomycin. IMPORTANT NOTES In vitro sulfonamide susceptibility tests are not always reliable. The test must be carefully coordinated with bacteriologic and clinical response. When the patient is already taking sulfonamides, follow-up cultures should have aminobenzoic acid added to the culture media. Currently, the increasing frequency of resistant organisms limits the usefulness of antibacterial agents, including the sulfonamides, especially in the treatment of recurrent and complicated urinary tract infections. Wide variation in blood levels may result with identical doses. Blood levels should be measured in patients receiving sulfonamides for serious infections. Free sulfonamide blood levels of 5 mg to 15 mg per 100 mL may be considered therapeutically effective for most infections and blood levels of 12 mg to 15 mg per 100 mL may be considered optimal for serious infections. Twenty mg per 100 mL should be the maximum total sulfonamide level, since adverse reactions occur more frequently above this level. uuid:87db7c7e-e418-4f06-9384-1a97f192b161 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9328 biolink:treats MONDO:0012268 PMID:41385096 "[{""id"":""uuid:ef0d8756-3543-4754-99f2-66f3499b9ac5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f63615c9-d424-4a33-b397-46848aa7fc81"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] sulfADIAZINE Tablets, USP are indicated in the following conditions: Chancroid Trachoma Inclusion conjunctivitis Nocardiosis Urinary tract infections (primarily pyelonephritis, pyelitis and cystitis) in the absence of obstructive uropathy or foreign bodies, when these infections are caused by susceptible strains of the following organisms: Esch erichia coli, Klebsiella species, Enterobacter species, Staphylococcus aureus, Proteus mirabilis and P. vulgaris . Sulfadiazine should be used for urinary tract infections only after use of more soluble sulfonamides has been unsuccessful. Toxoplasmosis encephalitis in patients with and without acquired immunodeficiency syndrome, as adjunctive therapy with pyrimethamine. Malaria due to chloroquine-resistant strains of Plasmodium falciparum , when used as adjunctive therapy. Prophylaxis of meningococcal meningitis when sulfonamide-sensitive group A strains are known to prevail in family groups or larger closed populations (the prophylactic usefulness of sulfonamides when group B or C infections are prevalent is not proved and may be harmful in closed population groups). Meningococcal meningitis, when the organism has been demonstrated to be susceptible. Acute otitis media due to Haemophilus influenzae, when used concomitantly with adequate doses of penicilin. Prophylaxis against recurrences of rheumatic fever, as an alternative to penicillin. H. influenzae meningitis, as adjunctive therapy with parental streptomycin. IMPORTANT NOTES In vitro sulfonamide susceptibility tests are not always reliable. The test must be carefully coordinated with bacteriologic and clinical response. When the patient is already taking sulfonamides, follow-up cultures should have aminobenzoic acid added to the culture media. Currently, the increasing frequency of resistant organisms limits the usefulness of antibacterial agents, including the sulfonamides, especially in the treatment of recurrent and complicated urinary tract infections. Wide variation in blood levels may result with identical doses. Blood levels should be measured in patients receiving sulfonamides for serious infections. Free sulfonamide blood levels of 5 mg to 15 mg per 100 mL may be considered therapeutically effective for most infections and blood levels of 12 mg to 15 mg per 100 mL may be considered optimal for serious infections. Twenty mg per 100 mL should be the maximum total sulfonamide level, since adverse reactions occur more frequently above this level. uuid:3a384729-3359-4acb-9723-2d9f4b84bcc4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9328 biolink:treats MONDO:0005136 PMID:41385096 "[{""id"":""uuid:eec06702-4894-404e-8113-f1fa6f00c3c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d5062972-f6bf-4628-8603-26b50a3ff24b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] sulfADIAZINE Tablets, USP are indicated in the following conditions: Chancroid Trachoma Inclusion conjunctivitis Nocardiosis Urinary tract infections (primarily pyelonephritis, pyelitis and cystitis) in the absence of obstructive uropathy or foreign bodies, when these infections are caused by susceptible strains of the following organisms: Esch erichia coli, Klebsiella species, Enterobacter species, Staphylococcus aureus, Proteus mirabilis and P. vulgaris . Sulfadiazine should be used for urinary tract infections only after use of more soluble sulfonamides has been unsuccessful. Toxoplasmosis encephalitis in patients with and without acquired immunodeficiency syndrome, as adjunctive therapy with pyrimethamine. Malaria due to chloroquine-resistant strains of Plasmodium falciparum , when used as adjunctive therapy. Prophylaxis of meningococcal meningitis when sulfonamide-sensitive group A strains are known to prevail in family groups or larger closed populations (the prophylactic usefulness of sulfonamides when group B or C infections are prevalent is not proved and may be harmful in closed population groups). Meningococcal meningitis, when the organism has been demonstrated to be susceptible. Acute otitis media due to Haemophilus influenzae, when used concomitantly with adequate doses of penicilin. Prophylaxis against recurrences of rheumatic fever, as an alternative to penicillin. H. influenzae meningitis, as adjunctive therapy with parental streptomycin. IMPORTANT NOTES In vitro sulfonamide susceptibility tests are not always reliable. The test must be carefully coordinated with bacteriologic and clinical response. When the patient is already taking sulfonamides, follow-up cultures should have aminobenzoic acid added to the culture media. Currently, the increasing frequency of resistant organisms limits the usefulness of antibacterial agents, including the sulfonamides, especially in the treatment of recurrent and complicated urinary tract infections. Wide variation in blood levels may result with identical doses. Blood levels should be measured in patients receiving sulfonamides for serious infections. Free sulfonamide blood levels of 5 mg to 15 mg per 100 mL may be considered therapeutically effective for most infections and blood levels of 12 mg to 15 mg per 100 mL may be considered optimal for serious infections. Twenty mg per 100 mL should be the maximum total sulfonamide level, since adverse reactions occur more frequently above this level. uuid:0198bf92-5d13-49a0-bbfa-c77bd5aab43b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9328 biolink:treats MONDO:0018059 PMID:41385096 "[{""id"":""uuid:33681c78-450e-4eee-b2f0-5084a272d347"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7cf60771-142b-4163-bffa-a6e43547d877"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] sulfADIAZINE Tablets, USP are indicated in the following conditions: Chancroid Trachoma Inclusion conjunctivitis Nocardiosis Urinary tract infections (primarily pyelonephritis, pyelitis and cystitis) in the absence of obstructive uropathy or foreign bodies, when these infections are caused by susceptible strains of the following organisms: Esch erichia coli, Klebsiella species, Enterobacter species, Staphylococcus aureus, Proteus mirabilis and P. vulgaris . Sulfadiazine should be used for urinary tract infections only after use of more soluble sulfonamides has been unsuccessful. Toxoplasmosis encephalitis in patients with and without acquired immunodeficiency syndrome, as adjunctive therapy with pyrimethamine. Malaria due to chloroquine-resistant strains of Plasmodium falciparum , when used as adjunctive therapy. Prophylaxis of meningococcal meningitis when sulfonamide-sensitive group A strains are known to prevail in family groups or larger closed populations (the prophylactic usefulness of sulfonamides when group B or C infections are prevalent is not proved and may be harmful in closed population groups). Meningococcal meningitis, when the organism has been demonstrated to be susceptible. Acute otitis media due to Haemophilus influenzae, when used concomitantly with adequate doses of penicilin. Prophylaxis against recurrences of rheumatic fever, as an alternative to penicillin. H. influenzae meningitis, as adjunctive therapy with parental streptomycin. IMPORTANT NOTES In vitro sulfonamide susceptibility tests are not always reliable. The test must be carefully coordinated with bacteriologic and clinical response. When the patient is already taking sulfonamides, follow-up cultures should have aminobenzoic acid added to the culture media. Currently, the increasing frequency of resistant organisms limits the usefulness of antibacterial agents, including the sulfonamides, especially in the treatment of recurrent and complicated urinary tract infections. Wide variation in blood levels may result with identical doses. Blood levels should be measured in patients receiving sulfonamides for serious infections. Free sulfonamide blood levels of 5 mg to 15 mg per 100 mL may be considered therapeutically effective for most infections and blood levels of 12 mg to 15 mg per 100 mL may be considered optimal for serious infections. Twenty mg per 100 mL should be the maximum total sulfonamide level, since adverse reactions occur more frequently above this level. uuid:0f94dd04-53e1-4165-97f3-cf0426025205 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9328 biolink:treats HP:0000371 PMID:41385096 "[{""id"":""uuid:ab2aa1a1-6bb0-4637-b3ca-553d0cb49085"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4bd94b2a-6751-4700-979c-b91cd911ef80"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] sulfADIAZINE Tablets, USP are indicated in the following conditions: Chancroid Trachoma Inclusion conjunctivitis Nocardiosis Urinary tract infections (primarily pyelonephritis, pyelitis and cystitis) in the absence of obstructive uropathy or foreign bodies, when these infections are caused by susceptible strains of the following organisms: Esch erichia coli, Klebsiella species, Enterobacter species, Staphylococcus aureus, Proteus mirabilis and P. vulgaris . Sulfadiazine should be used for urinary tract infections only after use of more soluble sulfonamides has been unsuccessful. Toxoplasmosis encephalitis in patients with and without acquired immunodeficiency syndrome, as adjunctive therapy with pyrimethamine. Malaria due to chloroquine-resistant strains of Plasmodium falciparum , when used as adjunctive therapy. Prophylaxis of meningococcal meningitis when sulfonamide-sensitive group A strains are known to prevail in family groups or larger closed populations (the prophylactic usefulness of sulfonamides when group B or C infections are prevalent is not proved and may be harmful in closed population groups). Meningococcal meningitis, when the organism has been demonstrated to be susceptible. Acute otitis media due to Haemophilus influenzae, when used concomitantly with adequate doses of penicilin. Prophylaxis against recurrences of rheumatic fever, as an alternative to penicillin. H. influenzae meningitis, as adjunctive therapy with parental streptomycin. IMPORTANT NOTES In vitro sulfonamide susceptibility tests are not always reliable. The test must be carefully coordinated with bacteriologic and clinical response. When the patient is already taking sulfonamides, follow-up cultures should have aminobenzoic acid added to the culture media. Currently, the increasing frequency of resistant organisms limits the usefulness of antibacterial agents, including the sulfonamides, especially in the treatment of recurrent and complicated urinary tract infections. Wide variation in blood levels may result with identical doses. Blood levels should be measured in patients receiving sulfonamides for serious infections. Free sulfonamide blood levels of 5 mg to 15 mg per 100 mL may be considered therapeutically effective for most infections and blood levels of 12 mg to 15 mg per 100 mL may be considered optimal for serious infections. Twenty mg per 100 mL should be the maximum total sulfonamide level, since adverse reactions occur more frequently above this level. uuid:a73213bb-ce19-4c06-8817-47fd3d4a9aa7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9328 biolink:treats MONDO:0017767 PMID:41385096 "[{""id"":""uuid:8ca3ca4f-375c-4e71-a09f-63b13ea24699"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1bd6d9e0-0594-4eeb-9afe-087e50724196"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] sulfADIAZINE Tablets, USP are indicated in the following conditions: Chancroid Trachoma Inclusion conjunctivitis Nocardiosis Urinary tract infections (primarily pyelonephritis, pyelitis and cystitis) in the absence of obstructive uropathy or foreign bodies, when these infections are caused by susceptible strains of the following organisms: Esch erichia coli, Klebsiella species, Enterobacter species, Staphylococcus aureus, Proteus mirabilis and P. vulgaris . Sulfadiazine should be used for urinary tract infections only after use of more soluble sulfonamides has been unsuccessful. Toxoplasmosis encephalitis in patients with and without acquired immunodeficiency syndrome, as adjunctive therapy with pyrimethamine. Malaria due to chloroquine-resistant strains of Plasmodium falciparum , when used as adjunctive therapy. Prophylaxis of meningococcal meningitis when sulfonamide-sensitive group A strains are known to prevail in family groups or larger closed populations (the prophylactic usefulness of sulfonamides when group B or C infections are prevalent is not proved and may be harmful in closed population groups). Meningococcal meningitis, when the organism has been demonstrated to be susceptible. Acute otitis media due to Haemophilus influenzae, when used concomitantly with adequate doses of penicilin. Prophylaxis against recurrences of rheumatic fever, as an alternative to penicillin. H. influenzae meningitis, as adjunctive therapy with parental streptomycin. IMPORTANT NOTES In vitro sulfonamide susceptibility tests are not always reliable. The test must be carefully coordinated with bacteriologic and clinical response. When the patient is already taking sulfonamides, follow-up cultures should have aminobenzoic acid added to the culture media. Currently, the increasing frequency of resistant organisms limits the usefulness of antibacterial agents, including the sulfonamides, especially in the treatment of recurrent and complicated urinary tract infections. Wide variation in blood levels may result with identical doses. Blood levels should be measured in patients receiving sulfonamides for serious infections. Free sulfonamide blood levels of 5 mg to 15 mg per 100 mL may be considered therapeutically effective for most infections and blood levels of 12 mg to 15 mg per 100 mL may be considered optimal for serious infections. Twenty mg per 100 mL should be the maximum total sulfonamide level, since adverse reactions occur more frequently above this level. uuid:0d3a6268-9294-4891-8ecf-21073c0d2815 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9328 biolink:treats MONDO:0000889 PMID:41385096 "[{""id"":""uuid:76eb8292-1c22-40a4-95ae-5f7b983b66bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8a257e84-005c-484b-bfb5-803105464a94"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] sulfADIAZINE Tablets, USP are indicated in the following conditions: Chancroid Trachoma Inclusion conjunctivitis Nocardiosis Urinary tract infections (primarily pyelonephritis, pyelitis and cystitis) in the absence of obstructive uropathy or foreign bodies, when these infections are caused by susceptible strains of the following organisms: Esch erichia coli, Klebsiella species, Enterobacter species, Staphylococcus aureus, Proteus mirabilis and P. vulgaris . Sulfadiazine should be used for urinary tract infections only after use of more soluble sulfonamides has been unsuccessful. Toxoplasmosis encephalitis in patients with and without acquired immunodeficiency syndrome, as adjunctive therapy with pyrimethamine. Malaria due to chloroquine-resistant strains of Plasmodium falciparum , when used as adjunctive therapy. Prophylaxis of meningococcal meningitis when sulfonamide-sensitive group A strains are known to prevail in family groups or larger closed populations (the prophylactic usefulness of sulfonamides when group B or C infections are prevalent is not proved and may be harmful in closed population groups). Meningococcal meningitis, when the organism has been demonstrated to be susceptible. Acute otitis media due to Haemophilus influenzae, when used concomitantly with adequate doses of penicilin. Prophylaxis against recurrences of rheumatic fever, as an alternative to penicillin. H. influenzae meningitis, as adjunctive therapy with parental streptomycin. IMPORTANT NOTES In vitro sulfonamide susceptibility tests are not always reliable. The test must be carefully coordinated with bacteriologic and clinical response. When the patient is already taking sulfonamides, follow-up cultures should have aminobenzoic acid added to the culture media. Currently, the increasing frequency of resistant organisms limits the usefulness of antibacterial agents, including the sulfonamides, especially in the treatment of recurrent and complicated urinary tract infections. Wide variation in blood levels may result with identical doses. Blood levels should be measured in patients receiving sulfonamides for serious infections. Free sulfonamide blood levels of 5 mg to 15 mg per 100 mL may be considered therapeutically effective for most infections and blood levels of 12 mg to 15 mg per 100 mL may be considered optimal for serious infections. Twenty mg per 100 mL should be the maximum total sulfonamide level, since adverse reactions occur more frequently above this level. uuid:a9c3654f-d469-499a-bcde-05751fb2574a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9316 biolink:treats NCIT:C27003 PMID:41385096 "[{""id"":""uuid:54067bde-d270-4c29-b29c-e0f04df5ad76"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:5a25fe6c-7004-454e-9bca-c887491bd5fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:4717bd3b-9b13-4d94-a1b8-afa6999c6897"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DSUVIA is indicated for use in adults in a certified medically supervised healthcare setting, such as hospitals, surgical centers, and emergency departments, for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use: Not for home use or for use in children. Discontinue treatment with DSUVIA before patients leave the certified medically supervised healthcare setting. Not for use for more than 72 hours. The use of DSUVIA beyond 72 hours has not been studied. Only to be administered by a healthcare provider. Because of the risks of addiction, abuse, and misuse with opioids, which can occur at any dosage or duration [see Warnings and Precautions ( 5.3 )] , reserve DSUVIA for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or opioid combination products): - Have not been tolerated, or are not expected to be tolerated, - Have not provided adequate analgesia, or are not expected to provide adequate analgesia.|[EMA] Dzuveo is indicated for the management of acute moderate to severe pain in adult patients. uuid:1dbc35e9-b7cb-4c25-9bd2-285178109ed9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:5Q6TZN2HNM biolink:treats MONDO:0019623 PMID:41385096 "[{""id"":""uuid:f2f89c4e-1234-4f67-b65f-50630a614a45"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5d065147-974b-4a33-a393-bd83114607ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KALBITOR ® (ecallantide) is indicated for treatment of acute attacks of hereditary angioedema (HAE) in patients 12 years of age and older. uuid:f069f31d-0037-49e9-8a49-ad7358b6fcb3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:5Q6TZN2HNM biolink:treats MONDO:0012526 PMID:41385096 "[{""id"":""uuid:d5a02fd9-8451-42e2-b753-3da0838b8fac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7d41a1de-6cd7-48e6-9336-94522bdd9569"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KALBITOR ® (ecallantide) is indicated for treatment of acute attacks of hereditary angioedema (HAE) in patients 12 years of age and older. uuid:52676449-584f-4fe2-b4df-01051b8b96e5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135935 biolink:treats MONDO:0018362 PMID:41385096 "[{""id"":""uuid:65d8aa82-92b9-488b-ae40-5ada1fe231eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4b28f11f-e931-4f99-867a-3e3f5bd3c5a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NUCYNTA ER (tapentadol) is indicated for the management of: Severe and persistent pain in adults that requires an extended treatment period with a daily opioid analgesic and for which alternative treatment options are inadequate. Severe and persistent neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults that requires an extended treatment period with a daily opioid analgesic and for which alternative treatment options are inadequate. uuid:2becdf6f-8c21-4070-80fa-4343e176c285 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0005580 PMID:41385096 "[{""id"":""uuid:5e706ded-6ca1-4410-9f73-a1c5bbb05b04"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fe8008d4-a33c-45bb-89eb-2d74141d86cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Palliation and treatment adjutant to surgery and radiation therapy of the following neoplasms: Squamous cell carcinoma of the skin, head and neck, and esophagus (primary indication). Squamous cell carcinoma of the larynx, penis and uterine cervix. Squamous cell carcinoma of the bronchus (response infrequent). Ch0riocarcinoma and embryonal cell carcinoma of the testis. Advanced Hodgkin’s disease and Other lymphomas. Mycosis fungoides. Note . Use of bleomycin after radiation therapy is less successful than use before radiation therapy. Bleomycin is bone marrow sparing and may be used when other cytotoxic agents are contraindicated. uuid:a5589423-cab9-4bdd-be18-f6d81c49bd13 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0004430 PMID:41385096 "[{""id"":""uuid:1b9d047c-77de-4468-9d83-2f24159d3504"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:45a8170b-6f36-42e3-bba5-78c561b06bc1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Palliation and treatment adjutant to surgery and radiation therapy of the following neoplasms: Squamous cell carcinoma of the skin, head and neck, and esophagus (primary indication). Squamous cell carcinoma of the larynx, penis and uterine cervix. Squamous cell carcinoma of the bronchus (response infrequent). Ch0riocarcinoma and embryonal cell carcinoma of the testis. Advanced Hodgkin’s disease and Other lymphomas. Mycosis fungoides. Note . Use of bleomycin after radiation therapy is less successful than use before radiation therapy. Bleomycin is bone marrow sparing and may be used when other cytotoxic agents are contraindicated. uuid:6f896d2f-cff1-4b5f-808f-bb927b9d524f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0005097 PMID:41385096 "[{""id"":""uuid:dba2a199-4c53-4067-b738-d229a28811dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b22f3b53-1b06-4577-a6d8-0e49bcb3fa3a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Palliation and treatment adjutant to surgery and radiation therapy of the following neoplasms: Squamous cell carcinoma of the skin, head and neck, and esophagus (primary indication). Squamous cell carcinoma of the larynx, penis and uterine cervix. Squamous cell carcinoma of the bronchus (response infrequent). Ch0riocarcinoma and embryonal cell carcinoma of the testis. Advanced Hodgkin’s disease and Other lymphomas. Mycosis fungoides. Note . Use of bleomycin after radiation therapy is less successful than use before radiation therapy. Bleomycin is bone marrow sparing and may be used when other cytotoxic agents are contraindicated. uuid:dfc35c87-7b62-4b6b-b3c4-52f7d02cd2a1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0005062 PMID:41385096 "[{""id"":""uuid:96e8fa22-6d3f-4ee6-b4ee-e9f09b6f8cd1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a4815cbb-160d-4609-b435-dc919f75e7b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Palliation and treatment adjutant to surgery and radiation therapy of the following neoplasms: Squamous cell carcinoma of the skin, head and neck, and esophagus (primary indication). Squamous cell carcinoma of the larynx, penis and uterine cervix. Squamous cell carcinoma of the bronchus (response infrequent). Ch0riocarcinoma and embryonal cell carcinoma of the testis. Advanced Hodgkin’s disease and Other lymphomas. Mycosis fungoides. Note . Use of bleomycin after radiation therapy is less successful than use before radiation therapy. Bleomycin is bone marrow sparing and may be used when other cytotoxic agents are contraindicated. uuid:9c321e24-64a7-4e82-821c-c4d76b1f62e5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0009691 PMID:41385096 "[{""id"":""uuid:23d4fb62-e4a9-4525-98c7-9b18979892f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8ce2fe6a-ffe9-47fd-8def-4a5667c64a7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Palliation and treatment adjutant to surgery and radiation therapy of the following neoplasms: Squamous cell carcinoma of the skin, head and neck, and esophagus (primary indication). Squamous cell carcinoma of the larynx, penis and uterine cervix. Squamous cell carcinoma of the bronchus (response infrequent). Ch0riocarcinoma and embryonal cell carcinoma of the testis. Advanced Hodgkin’s disease and Other lymphomas. Mycosis fungoides. Note . Use of bleomycin after radiation therapy is less successful than use before radiation therapy. Bleomycin is bone marrow sparing and may be used when other cytotoxic agents are contraindicated. uuid:dd1723c1-6f86-49e1-9a70-453d9a7b287c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:42355 biolink:treats MONDO:0021697 PMID:41385096 "[{""id"":""uuid:63471813-04f5-4193-ad31-660fc90829c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6279329a-13f0-4635-83a5-40af767e9737"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin tablets and other antibacterial drugs, erythromycin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Erythromycin tablets are indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes ; Streptococcus pneumoniae ; Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.) Lower respiratory tract infections of mild to moderate severity caused by Streptococcus pyogenes or Streptococcus pneumoniae . Listeriosis caused by Listeria monocytogenes . Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals, rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Diphtheria: Infections due to Corynebacterium diphtheriae , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma: In the treatment of infections due to Corynebacterium minutissimum . Intestinal amebiasis caused by Entamoeba histolytica (oral erythromycins only). Extraenteric amebiasis requires treatment with other agents. Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae : Erythrocin™ Lactobionate-I.V. (erythromycin lactobionate for injection, USP) followed by erythromycin base orally, as an alternative drug in treatment of acute pelvic inflammatory disease caused by N. gonorrhoeae in female patients with a history of sensitivity to penicillin. Patients should have a serologic test for syphilis before receiving erythromycin as treatment of gonorrhea and a follow-up serologic test for syphilis after 3 months. Erythromycins are indicated for treatment of the following infections caused by Chlamydia trachomatis : conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections during pregnancy. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to Chlamydia trachomatis. 3 When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of nongonococcal urethritis caused by Ureaplasma urealyticum. 3 Primary syphilis caused by Treponema pallidum . Erythromycin (oral forms only) is an alternative choice of treatment for primary syphilis in patients allergic to the penicillins. In treatment of primary syphilis, spinal fluid should be examined before treatment and as part of the follow-up after therapy. Legionnaires' Disease caused by Legionella pneumophila . Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires' Disease. Prophylaxis Prevention of Initial Attacks of Rheumatic Fever Penicillin is considered by the American Heart Association to be the drug of choice in the prevention of initial attacks of rheumatic fever (treatment of Streptococcus pyogenes infections of the upper respiratory tract e.g., tonsillitis, or pharyngitis). 1 Erythromycin is indicated for the treatment of penicillin-allergic patients. The therapeutic dose should be administered for ten days. Prevention of Recurrent Attacks of Rheumatic Fever Penicillin or sulfonamides are considered by the American Heart Association to be the drugs of choice in the prevention of recurrent attacks of rheumatic fever. In patients who are allergic to penicillin and sulfonamides, oral erythromycin is recommended by the American Heart Association in the long-term prophylaxis of streptococcal pharyngitis (for the prevention of recurrent attacks of rheumatic fever). 1 uuid:b8f2ef3e-807c-4538-898e-d6bc99018376 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3ZO554A4Q8 biolink:treats MONDO:0011382 PMID:41385096 "[{""id"":""uuid:1077a15d-dbc9-4ac7-a9e1-527838b39a1c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:6c13f5d8-6ce7-4171-b523-67e68fadcacc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:19d6ab20-8c0e-4b71-8937-76821f211f7c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/oxbryta""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] OXBRYTA is indicated for the treatment of sickle cell disease (SCD) in adults and pediatric patients 4 years of age and older. This indication is approved under accelerated approval based on increase in hemoglobin (Hb) [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).|[EMA] Oxbryta is indicated for the treatment of haemolytic anaemia due to sickle cell disease (SCD) in adults and paediatric patients 12 years of age and older as monotherapy or in combination with hydroxycarbamide. uuid:c87a3d76-4044-4fd2-99f8-3757e37acbec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5296 biolink:treats MONDO:0015629 PMID:41385096 "[{""id"":""uuid:6e1cb983-866a-42e0-9c28-bc3dcb4cd78a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7e836aad-ce79-475d-9828-0b27ceb33526"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gemfibrozil tablets, USP are indicated as adjunctive therapy to diet for: 1. Treatment of adult patients with very high elevations of serum triglyceride levels (Types IV and V hyperlipidemia) who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Patients who present such risk typically have serum triglycerides over 2000 mg/dL and have elevations of VLDL-cholesterol as well as fasting chylomicrons (Type V hyperlipidemia). Subjects who consistently have total serum or plasma triglycerides below 1000 mg/dL are unlikely to present a risk of pancreatitis. Gemfibrozil therapy may be considered for those subjects with triglyceride elevations between 1000 and 2000 mg/dL who have a history of pancreatitis or of recurrent abdominal pain typical of pancreatitis. It is recognized that some Type IV patients with triglycerides under 1000 mg/dL may, through dietary or alcoholic indiscretion, convert to a Type V pattern with massive triglyceride elevations accompanying fasting chylomicronemia, but the influence of gemfibrozil therapy on the risk of pancreatitis in such situations has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of very low density lipoprotein (VLDL). Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV, and V hyperlipoproteinemia. 2. Reducing the risk of developing coronary heart disease only in Type IIb patients without history of or symptoms of existing coronary heart disease who have had an inadequate response to weight loss, dietary therapy, exercise, and other pharmacologic agents (such as bile acid sequestrants and nicotinic acid, known to reduce LDL- and raise HDL-cholesterol) and who have the following triad of lipid abnormalities: low HDL-cholesterol levels in addition to elevated LDL-cholesterol and elevated triglycerides (see WARNINGS , PRECAUTIONS , and CLINICAL PHARMACOLOGY ). The National Cholesterol Education Program has defined a serum HDL-cholesterol value that is consistently below 35 mg/dL as constituting an independent risk factor for coronary heart disease. Patients with significantly elevated triglycerides should be closely observed when treated with gemfibrozil. In some patients with high triglyceride levels, treatment with gemfibrozil is associated with a significant increase in LDL-cholesterol. BECAUSE OF POTENTIAL TOXICITY SUCH AS MALIGNANCY, GALLBLADDER DISEASE, ABDOMINAL PAIN LEADING TO APPENDECTOMY AND OTHER ABDOMINAL SURGERIES, AN INCREASED INCIDENCE IN NON-CORONARY MORTALITY, AND THE 44% RELATIVE INCREASE DURING THE TRIAL PERIOD IN AGE-ADJUSTED ALL-CAUSE MORTALITY SEEN WITH THE CHEMICALLY AND PHARMACOLOGICALLY RELATED DRUG, CLOFIBRATE, THE POTENTIAL BENEFIT OF GEMFIBROZIL IN TREATING TYPE IIA PATIENTS WITH ELEVATIONS OF LDL-CHOLESTEROL ONLY IS NOT LIKELY TO OUTWEIGH THE RISKS. GEMFIBROZIL IS ALSO NOT INDICATED FOR THE TREATMENT OF PATIENTS WITH LOW HDL-CHOLESTEROL AS THEIR ONLY LIPID ABNORMALITY. In a subgroup analysis of patients in the Helsinki Heart Study with above-median HDL-cholesterol values at baseline (greater than 46.4 mg/dL), the incidence of serious coronary events was similar for gemfibrozil and placebo subgroups (see Table I). The initial treatment for dyslipidemia is dietary therapy specific for the type of lipoprotein abnormality. Excess body weight and excess alcohol intake may be important factors in hypertriglyceridemia and should be managed prior to any drug therapy. Physical exercise can be an important ancillary measure, and has been associated with rises in HDL-cholesterol. Diseases contributory to hyperlipidemia such as hypothyroidism or diabetes mellitus should be looked for and adequately treated. Estrogen therapy is sometimes associated with massive rises in plasma triglycerides, especially in subjects with familial hypertriglyceridemia. In such cases, discontinuation of estrogen therapy may obviate the need for specific drug therapy of hypertriglyceridemia. The use of drugs should be considered only when reasonable attempts have been made to obtain satisfactory results with nondrug methods. If the decision is made to use drugs, the patient should be instructed that this does not reduce the importance of adhering to diet. uuid:178a4d79-8ec2-42ae-b2d8-decfa79d156f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:91495 biolink:treats MONDO:0024332 PMID:41385096 "[{""id"":""uuid:fb9a6b9c-7f9c-4b4b-99f0-b952fdc20b64"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f7466667-8f7f-4b39-8b50-167dfca8f20c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ipratropium Bromide Nasal Solution 0.03% is indicated for the symptomatic relief of rhinorrhea associated with allergic and nonallergic perennial rhinitis in adults and children age 6 years and older. Ipratropium Bromide Nasal Solution 0.03% does not relieve nasal congestion, sneezing, or postnasal drip associated with allergic or nonallergic perennial rhinitis. uuid:95c034b7-6af0-4f19-bfbe-bcca0981a58d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:91495 biolink:treats MONDO:0004514 PMID:41385096 "[{""id"":""uuid:2c6673f7-4d94-4988-a550-802c53264fc6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:94074474-d153-49a0-8e8b-65d87edf5920"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ipratropium Bromide Nasal Solution 0.03% is indicated for the symptomatic relief of rhinorrhea associated with allergic and nonallergic perennial rhinitis in adults and children age 6 years and older. Ipratropium Bromide Nasal Solution 0.03% does not relieve nasal congestion, sneezing, or postnasal drip associated with allergic or nonallergic perennial rhinitis. uuid:d5f2a491-d59a-4fcb-b8e5-2c0332c90b1f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7852 biolink:treats MONDO:0005530 PMID:41385096 "[{""id"":""uuid:060d2005-c4da-4025-82ee-fe90b9156a2e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f163b54d-63e8-407c-9579-5652e37ab954"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OXYCODONE HCl EXTENDED-RELEASE TABLETS are indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate in: Adults; and Opioid-tolerant pediatric patients 11 years of age and older who are already receiving and tolerate a minimum daily opioid dose of at least 20 mg oxycodone orally or its equivalent. Limitations of Use Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations [see Warnings and Precautions (5.1) ] , reserve OXYCODONE HCl EXTENDED-RELEASE TABLETS for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. OXYCODONE HCl EXTENDED-RELEASE TABLETS are not indicated as an as-needed (prn) analgesic. uuid:99f22ae6-9233-416c-af3a-b81ff9a40c49 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7852 biolink:treats MONDO:0001225 PMID:41385096 "[{""id"":""uuid:64adf850-e95f-4261-9e47-a266caa7d8d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:65cb41e9-2f0c-4aa5-96d1-2b899d3f09d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OXYCODONE HCl EXTENDED-RELEASE TABLETS are indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate in: Adults; and Opioid-tolerant pediatric patients 11 years of age and older who are already receiving and tolerate a minimum daily opioid dose of at least 20 mg oxycodone orally or its equivalent. Limitations of Use Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations [see Warnings and Precautions (5.1) ] , reserve OXYCODONE HCl EXTENDED-RELEASE TABLETS for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. OXYCODONE HCl EXTENDED-RELEASE TABLETS are not indicated as an as-needed (prn) analgesic. uuid:61ca8f2b-4c11-44a2-b51d-5df99570ed64 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7852 biolink:treats UMLS:C0572061 PMID:41385096 "[{""id"":""uuid:75e977cd-e8a8-45da-9db4-f009d58b7ff6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:40d73bae-0498-42ea-b618-0c8ad3f8011d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OXYCODONE HCl EXTENDED-RELEASE TABLETS are indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate in: Adults; and Opioid-tolerant pediatric patients 11 years of age and older who are already receiving and tolerate a minimum daily opioid dose of at least 20 mg oxycodone orally or its equivalent. Limitations of Use Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations [see Warnings and Precautions (5.1) ] , reserve OXYCODONE HCl EXTENDED-RELEASE TABLETS for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. OXYCODONE HCl EXTENDED-RELEASE TABLETS are not indicated as an as-needed (prn) analgesic. uuid:46a013cc-9640-4f29-a5c4-e707aedb5e81 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4027 biolink:treats MONDO:0018874 PMID:41385096 "[{""id"":""uuid:641c1a0a-c855-4cb6-8182-3dd97f5e1954"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:df79a725-3be1-4f25-91cc-78573f4d430c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Malignant Diseases Cyclophosphamide Injection is indicated for the treatment of adult and pediatric patients with: malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin's disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma, Burkitt's lymphoma multiple myeloma leukemias: chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia (cyclophosphamide given during remission is effective in prolonging its duration) mycosis fungoides (advanced disease) neuroblastoma (disseminated disease) adenocarcinoma of the ovary retinoblastoma carcinoma of the breast Cyclophosphamide, although effective alone in susceptible malignancies, is more frequently used concurrently or sequentially with other antineoplastic drugs. uuid:08f431f5-ca10-4cb9-af43-0a48ee9823b2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4027 biolink:treats MONDO:0004600 PMID:41385096 "[{""id"":""uuid:582431eb-80fe-4aa1-a7b3-5db0a95fe1fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1dd70d85-ce5b-4934-a316-647ed79711c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Malignant Diseases Cyclophosphamide Injection is indicated for the treatment of adult and pediatric patients with: malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin's disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma, Burkitt's lymphoma multiple myeloma leukemias: chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia (cyclophosphamide given during remission is effective in prolonging its duration) mycosis fungoides (advanced disease) neuroblastoma (disseminated disease) adenocarcinoma of the ovary retinoblastoma carcinoma of the breast Cyclophosphamide, although effective alone in susceptible malignancies, is more frequently used concurrently or sequentially with other antineoplastic drugs. uuid:f28e9b11-12af-4679-a027-8b8cb8b93795 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:76511460 biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:d411ca50-9821-4db6-aca2-3ad4e3be63c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:931775bc-ac28-4acc-8836-83ca254fc3d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PREZCOBIX is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV-1) infection in treatment-naïve and treatment-experienced adults and pediatric patients weighing at least 40 kg with no darunavir resistance-associated substitutions (V11I, V32I, L33F, I47V, I50V, I54L, I54M, T74P, L76V, I84V, L89V). uuid:6bc3e025-65db-4a10-a5d2-03a5c23886d6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63612 biolink:treats MONDO:0003537 PMID:41385096 "[{""id"":""uuid:deedaf98-c1ea-4cd1-ae4e-c46369486901"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:615b5bac-e0ee-41de-9614-6aac44321e07"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:79533cb5-fbf2-4e2f-9d2c-23b6e43e98c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/atriance""]},{""id"":""uuid:d4754637-7337-4a6c-817a-aefd1442ed3f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nelarabine Injection is indicated for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following treatment with at least 2 chemotherapy regimens.|[EMA] Nelarabine is indicated for the treatment of patients with T-cell acute lymphoblastic leukaemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens., , Due to the small patient populations in these disease settings, the information to support these indications is based on limited data.,|[PMDA] A drug containing a new active ingredient indicated for the treatment of relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. [Orphan drug] uuid:b702262a-6005-4f09-aa61-dfef93a6c59f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:913P6LK81M biolink:treats MONDO:0004951 PMID:41385096 "[{""id"":""uuid:cd31a70f-869f-4199-9e46-05dafbf13e3c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:09e9dba8-f1a5-4ca1-99d0-04c7b9357b2d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PIFELTRO ® is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg: with no prior antiretroviral treatment history; OR to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no history of treatment failure and no known substitutions associated with resistance to doravirine [see Clinical Studies (14) ] . uuid:9b887d0d-2222-4d04-b279-f9c85f57ef2e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134991 biolink:treats MONDO:0005277 PMID:41385096 "[{""id"":""uuid:e1a919ee-747f-462c-9dd6-cd7f27c34db6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6e48cd57-69cd-40c5-a3b3-3547a85cdad3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Frovatriptan succinate tablets are indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use • Use only if a clear diagnosis of migraine has been established. If a patient has no response for the first migraine attack treated with frovatriptan succinate tablets, reconsider the diagnosis of migraine before frovatriptan succinate tablets are administered to treat any subsequent attacks. • Frovatriptan succinate tablets are not indicated for the prevention of migraine attacks. • Safety and effectiveness of frovatriptan succinate tablets have not been established for cluster headache. uuid:5dd4a21d-9ef5-45b2-a7db-b7d19b331d66 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5134 biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:ee909088-28af-46b4-ae48-320a8532a2b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:db41efe9-a6dd-4cdc-a821-4b22435b23ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fluticasone propionate lotion is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of atopic dermatitis in patients 3 months of age or older. uuid:3c989c74-36aa-4857-a9db-eebc48b5602d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64355 biolink:treats MONDO:0000240 PMID:41385096 "[{""id"":""uuid:a3a34dbc-fb1f-4a40-97e8-b9986c109771"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c7fb9de2-1842-4a21-859f-998fee927368"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:88c1d87c-6af4-4c2c-83aa-71d44aa17de5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/posaconazole-ahcl""]},{""id"":""uuid:2b36d52b-538b-4c4b-bad4-ee38c37680fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Posaconazole is an azole antifungal indicated as follows: Posaconazole injection is indicated for the treatment of invasive aspergillosis in adults and pediatric patients 13 years of age and older. ( 1.1 ) Posaconazole is indicated for the prophylaxis of invasive Aspergillus and Candida infections in patients who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD) or those with hematologic malignancies with prolonged neutropenia from chemotherapy as follows: ( 1.2 ) Posaconazole injection: adults and pediatric patients 2 years of age and older|[EMA] Posaconazole AHCL oral suspension is indicated for use in the treatment of the following fungal infections in adults:Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products;Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B;Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products.Oropharyngeal candidiasis: as first-line therapy in patients who have severe disease or are immunocompromised, in whom response to topical therapy is expected to be poor.Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.Posaconazole AHCL oral suspension is also indicated for prophylaxis of invasive fungal infections in the following patients:Patients receiving remission-induction chemotherapy for acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections.|[PMDA] Drugs with a new indication for the treatment of invasive aspergillosis. uuid:1426d115-8e28-4fc9-9940-27a0e9a413e2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3216 biolink:treats MONDO:0018362 PMID:41385096 "[{""id"":""uuid:bb5a9cf1-873a-49f3-91b3-985467794abc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:964ff873-a8cf-43e8-a14a-d553be57bce2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BELBUCA is indicated for the management of severe and persistent pain that requires an extended treatment period with a daily opioid analgesic and for which alternative treatment options are inadequate. uuid:5f37e7a0-3d1a-45cb-8bf1-7490e5664a06 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29103 biolink:treats MONDO:0005020 PMID:41385096 "[{""id"":""uuid:bb689448-ba56-4ccb-a7b1-f7ef01415255"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5fb45d5b-5dbb-469a-9e0a-7d7f95d15f99"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BECAUSE OF REPORTS OF INTESTINAL AND GASTRIC ULCERATION AND BLEEDING WITH CONTROLLED-RELEASE POTASSIUM CHLORIDE PREPARATIONS, THESE DRUGS SHOULD BE RESERVED FOR THOSE PATIENTS WHO CANNOT TOLERATE OR REFUSE TO TAKE LIQUID OR EFFERVESCENT POTASSIUM PREPARATIONS OR FOR PATIENTS IN WHOM THERE IS A PROBLEM OF COMPLIANCE WITH THESE PREPARATIONS. 1. For the treatment of patients with hypokalemia with or without metabolic alkalosis, in digitalis intoxication, and in patients with hypokalemic familial periodic paralysis. If hypokalemia is the result of diuretic therapy, consideration should be given to the use of a lower dose of diuretic, which may be sufficient without leading to hypokalemia. 2. For the prevention of hypokalemia in patients who would be at particular risk if hypokalemia were to develop, e.g., digitalized patients or patients with significant cardiac arrhythmias. The use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension is often unnecessary when such patients have a normal dietary pattern and when low doses of the diuretic are used. Serum potassium should be checked periodically, however, and if hypokalemia occurs, dietary supplementation with potassium-containing foods may be adequate to control milder cases. In more severe cases, and if dose adjustment of the diuretic is ineffective or unwarranted, supplementation with potassium salts may be indicated. uuid:6b41d94f-0422-4bf3-b355-d766c553c3e9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29103 biolink:treats MONDO:0001126 PMID:41385096 "[{""id"":""uuid:da756c59-b9a0-495e-af88-82158061d349"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bd2f463c-0ccb-46ae-830d-b39395a02496"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BECAUSE OF REPORTS OF INTESTINAL AND GASTRIC ULCERATION AND BLEEDING WITH CONTROLLED-RELEASE POTASSIUM CHLORIDE PREPARATIONS, THESE DRUGS SHOULD BE RESERVED FOR THOSE PATIENTS WHO CANNOT TOLERATE OR REFUSE TO TAKE LIQUID OR EFFERVESCENT POTASSIUM PREPARATIONS OR FOR PATIENTS IN WHOM THERE IS A PROBLEM OF COMPLIANCE WITH THESE PREPARATIONS. 1. For the treatment of patients with hypokalemia with or without metabolic alkalosis, in digitalis intoxication, and in patients with hypokalemic familial periodic paralysis. If hypokalemia is the result of diuretic therapy, consideration should be given to the use of a lower dose of diuretic, which may be sufficient without leading to hypokalemia. 2. For the prevention of hypokalemia in patients who would be at particular risk if hypokalemia were to develop, e.g., digitalized patients or patients with significant cardiac arrhythmias. The use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension is often unnecessary when such patients have a normal dietary pattern and when low doses of the diuretic are used. Serum potassium should be checked periodically, however, and if hypokalemia occurs, dietary supplementation with potassium-containing foods may be adequate to control milder cases. In more severe cases, and if dose adjustment of the diuretic is ineffective or unwarranted, supplementation with potassium salts may be indicated. uuid:a0953ee7-dad0-4f8a-9a87-4fe27ec73719 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31348 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:85949b72-abd1-4b8c-bfee-39d698dc7e7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2d14d336-1b98-4838-b1d2-b898174c58a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:b751bd96-901d-435b-bdab-83ed032b1c43"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ecansya""]},{""id"":""uuid:1d67b166-80df-466e-9408-ad11a4b102d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Capecitabine is a nucleoside metabolic inhibitor indicated for: Colorectal Cancer adjuvant treatment of patients with Stage III colon cancer as a single agent or as a component of a combination chemotherapy regimen. ( 1.1 ) perioperative treatment of adults with locally advanced rectal cancer as a component of chemoradiotherapy. ( 1.1 ) treatment of patients with unresectable or metastatic colorectal cancer as a single agent or as a component of a combination chemotherapy regimen. ( 1.1 ) Breast Cancer treatment of patients with advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated. ( 1.2 ) treatment of patients with advanced or metastatic breast cancer in combination with docetaxel after disease progression on prior anthracycline-containing chemotherapy.( 1.2 ) Gastric, Esophageal, or Gastroesophageal Junction Cancer treatment of adults with unresectable or metastatic gastric, esophageal, or gastroesophageal junction cancer as a component of a combination chemotherapy regimen. ( 1.3 ) treatment of adults with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease as a component of a combination regimen. ( 1.3 ) Pancreatic Cancer adjuvant treatment of adults with pancreatic adenocarcinoma as a component of a combination chemotherapy regimen. ( 1.4 )|[EMA] Capecitabine Medac is indicated for the adjuvant treatment of patients following surgery of stage-III (Dukes’ stage-C) colon cancer.Capecitabine Medac is indicated for the treatment of metastatic colorectal cancer.Capecitabine Medac is indicated for first-line treatment of advanced gastric cancer in combination with a platinum-based regimen.Capecitabine Medac in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline.Capecitabine Medac is also indicated as monotherapy for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline-containing chemotherapy regimen or for whom further anthracycline therapy is not indicated.|[PMDA] A drug with a new dosage indicated for the treatment of unresectable or recurrent breast cancer and colorectal cancer. [Public knowledge-based application] uuid:60b8a938-db5d-46b7-9760-3436bd82f348 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31348 biolink:treats MONDO:0850129 PMID:41385096 "[{""id"":""uuid:7a2f50b6-3da6-43de-961d-d094df20ff9f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:04c3c21e-4a7f-43c9-a843-193517723f9d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Capecitabine is a nucleoside metabolic inhibitor indicated for: Colorectal Cancer adjuvant treatment of patients with Stage III colon cancer as a single agent or as a component of a combination chemotherapy regimen. ( 1.1 ) perioperative treatment of adults with locally advanced rectal cancer as a component of chemoradiotherapy. ( 1.1 ) treatment of patients with unresectable or metastatic colorectal cancer as a single agent or as a component of a combination chemotherapy regimen. ( 1.1 ) Breast Cancer treatment of patients with advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated. ( 1.2 ) treatment of patients with advanced or metastatic breast cancer in combination with docetaxel after disease progression on prior anthracycline-containing chemotherapy.( 1.2 ) Gastric, Esophageal, or Gastroesophageal Junction Cancer treatment of adults with unresectable or metastatic gastric, esophageal, or gastroesophageal junction cancer as a component of a combination chemotherapy regimen. ( 1.3 ) treatment of adults with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease as a component of a combination regimen. ( 1.3 ) Pancreatic Cancer adjuvant treatment of adults with pancreatic adenocarcinoma as a component of a combination chemotherapy regimen. ( 1.4 ) uuid:cefaf332-443b-48cb-b932-5b539e5cc8b3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31348 biolink:treats MONDO:0021040 PMID:41385096 "[{""id"":""uuid:fafa231b-80cf-42a5-8849-f4289025dbef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:729c7aed-7bd1-4f95-bfd3-11baea281429"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Capecitabine is a nucleoside metabolic inhibitor indicated for: Colorectal Cancer adjuvant treatment of patients with Stage III colon cancer as a single agent or as a component of a combination chemotherapy regimen. ( 1.1 ) perioperative treatment of adults with locally advanced rectal cancer as a component of chemoradiotherapy. ( 1.1 ) treatment of patients with unresectable or metastatic colorectal cancer as a single agent or as a component of a combination chemotherapy regimen. ( 1.1 ) Breast Cancer treatment of patients with advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated. ( 1.2 ) treatment of patients with advanced or metastatic breast cancer in combination with docetaxel after disease progression on prior anthracycline-containing chemotherapy.( 1.2 ) Gastric, Esophageal, or Gastroesophageal Junction Cancer treatment of adults with unresectable or metastatic gastric, esophageal, or gastroesophageal junction cancer as a component of a combination chemotherapy regimen. ( 1.3 ) treatment of adults with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease as a component of a combination regimen. ( 1.3 ) Pancreatic Cancer adjuvant treatment of adults with pancreatic adenocarcinoma as a component of a combination chemotherapy regimen. ( 1.4 ) uuid:1f173832-d958-42d9-9236-322d5f4edf33 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:209807 biolink:treats UMLS:C1112209 PMID:41385096 "[{""id"":""uuid:baa379e7-20a7-4b79-8952-be2785e885c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ff8ce4bb-f826-4e77-85ee-1a9f0f94fb8c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefoxitin for Injection, USP is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) Lower respiratory tract infections, including pneumonia and lung abscess, caused by Streptococcus pneumoniae , other streptococci (excluding enterococci, e.g., Enterococcus faecalis [formerly Streptococcus faecalis ]), Staphylococcus aureus (including penicillinase-producing strains), Escherichia coli , Klebsiella species, Haemophilus influenzae, and Bacteroides species. (2) Urinary tract infections caused by Escherichia coli , Klebsiella species, Proteus mirabilis , Morganella morganii , Proteus vulgaris and Providencia species (including P. rettgeri ). (3) Intra-abdominal infections, including peritonitis and intra-abdominal abscess, caused by Escherichia coli , Klebsiella species, Bacteroides species including Bacteroides fragilis , and Clostridium species. (4) Gynecological infections, including endometritis, pelvic cellulitis, and pelvic inflammatory disease caused by Escherichia coli , Neisseria gonorrhoeae (including penicillinase-producing strains), Bacteroides species including B. fragilis , Clostridium species, Peptococcus niger , Peptostreptococcus species, and Streptococcus agalactiae . Cefoxitin for Injection, USP, like cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when Cefoxitin for Injection, USP is used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti-chlamydial coverage should be added. (5) Septicemia caused by Streptococcus pneumoniae , Staphylococcus aureus (including penicillinase-producing strains), Escherichia coli , Klebsiella species, and Bacteroides species including B. fragilis. (6) Bone and joint infections caused by Staphylococcus aureus (including Penicillinase-producing strains). (7) Skin and skin structure infections caused by Staphylococcus aureus (including penicillinase-producing strains), Staphylococcus epidermidis , Streptococcus pyogenes and other streptococci (excluding enterococci e.g., Enterococcus faecalis [formerly Streptococcus faecalis ]), Escherichia coli , Proteus mirabilis , Klebsiella species, Bacteroides species including B. fragilis , Clostridium species, Peptococcus niger , and Peptostreptococcus species. Appropriate culture and susceptibility studies should be performed to determine the susceptibility of the causative organisms to Cefoxitin for Injection, USP. Therapy may be started while awaiting the results of these studies. In randomized comparative studies, Cefoxitin for Injection, USP and cephalothin were comparably safe and effective in the management of infections caused by gram-positive cocci and gram-negative rods susceptible to the cephalosporins. Cefoxitin for Injection, USP has a high degree of stability in the presence of bacterial beta-lactamases, both penicillinases and cephalosporinases. Many infections caused by aerobic and anaerobic gram-negative bacteria resistant to some cephalosporins respond to Cefoxitin for Injection, USP. Similarly, many infections caused by aerobic and anaerobic bacteria resistant to some penicillin antibiotics (ampicillin, carbenicillin, penicillin G) respond to treatment with Cefoxitin for Injection, USP. Many infections caused by mixtures of susceptible aerobic and anaerobic bacteria respond to treatment with Cefoxitin for Injection, USP. uuid:4d7267d0-2909-41c4-aa13-60afc0ed86cf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:209807 biolink:treats UMLS:C1262234 PMID:41385096 "[{""id"":""uuid:d75ac36d-e337-4ff7-8f75-023e47f66844"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:751c6aec-086f-45ae-a474-f0957c820a54"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefoxitin for Injection, USP is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) Lower respiratory tract infections, including pneumonia and lung abscess, caused by Streptococcus pneumoniae , other streptococci (excluding enterococci, e.g., Enterococcus faecalis [formerly Streptococcus faecalis ]), Staphylococcus aureus (including penicillinase-producing strains), Escherichia coli , Klebsiella species, Haemophilus influenzae, and Bacteroides species. (2) Urinary tract infections caused by Escherichia coli , Klebsiella species, Proteus mirabilis , Morganella morganii , Proteus vulgaris and Providencia species (including P. rettgeri ). (3) Intra-abdominal infections, including peritonitis and intra-abdominal abscess, caused by Escherichia coli , Klebsiella species, Bacteroides species including Bacteroides fragilis , and Clostridium species. (4) Gynecological infections, including endometritis, pelvic cellulitis, and pelvic inflammatory disease caused by Escherichia coli , Neisseria gonorrhoeae (including penicillinase-producing strains), Bacteroides species including B. fragilis , Clostridium species, Peptococcus niger , Peptostreptococcus species, and Streptococcus agalactiae . Cefoxitin for Injection, USP, like cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when Cefoxitin for Injection, USP is used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti-chlamydial coverage should be added. (5) Septicemia caused by Streptococcus pneumoniae , Staphylococcus aureus (including penicillinase-producing strains), Escherichia coli , Klebsiella species, and Bacteroides species including B. fragilis. (6) Bone and joint infections caused by Staphylococcus aureus (including Penicillinase-producing strains). (7) Skin and skin structure infections caused by Staphylococcus aureus (including penicillinase-producing strains), Staphylococcus epidermidis , Streptococcus pyogenes and other streptococci (excluding enterococci e.g., Enterococcus faecalis [formerly Streptococcus faecalis ]), Escherichia coli , Proteus mirabilis , Klebsiella species, Bacteroides species including B. fragilis , Clostridium species, Peptococcus niger , and Peptostreptococcus species. Appropriate culture and susceptibility studies should be performed to determine the susceptibility of the causative organisms to Cefoxitin for Injection, USP. Therapy may be started while awaiting the results of these studies. In randomized comparative studies, Cefoxitin for Injection, USP and cephalothin were comparably safe and effective in the management of infections caused by gram-positive cocci and gram-negative rods susceptible to the cephalosporins. Cefoxitin for Injection, USP has a high degree of stability in the presence of bacterial beta-lactamases, both penicillinases and cephalosporinases. Many infections caused by aerobic and anaerobic gram-negative bacteria resistant to some cephalosporins respond to Cefoxitin for Injection, USP. Similarly, many infections caused by aerobic and anaerobic bacteria resistant to some penicillin antibiotics (ampicillin, carbenicillin, penicillin G) respond to treatment with Cefoxitin for Injection, USP. Many infections caused by mixtures of susceptible aerobic and anaerobic bacteria respond to treatment with Cefoxitin for Injection, USP. uuid:c5361db8-3922-4c31-9f55-4d3ed07d9650 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5855 biolink:treats MONDO:0011827 PMID:41385096 "[{""id"":""uuid:3c373478-10dc-43cd-ba7f-8b3ea5adb952"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f79a5a2c-468b-48f6-9f3b-44d794974410"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:b46e7d67-c682-4f14-acf5-b51695a8cd72"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/pedea""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ibuprofen Lysine is indicated to close a clinically significant patent ductus arteriosus (PDA) in premature infants weighing between 500 and 1500 g, who are no more than 32 weeks gestational age when usual medical management (e.g., fluid restriction, diuretics, respiratory support, etc.) is ineffective. The clinical trial was conducted among infants with an asymptomatic PDA. However, the consequences beyond 8 weeks after treatment have not been evaluated; therefore, treatment should be reserved for infants with clear evidence of a clinically significant PDA.|[EMA] Treatment of a haemodynamically significant patent ductus arteriosus in preterm newborn infants less than 34 weeks of gestational age. uuid:f51c5273-b03c-44cf-a53d-3d032fbe1f67 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68556 biolink:treats MONDO:0019623 PMID:41385096 "[{""id"":""uuid:d929849b-77a2-4096-a48b-621bb78e8d64"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4755fa05-a0e9-4e5b-b0e9-4c011e1556c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:d7402bb5-d006-402a-8f8e-925b6fdf8769"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/firazyr""]},{""id"":""uuid:fd6958ec-6396-4134-a309-6cd0ea00c885"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Icatibant injection is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older.|[EMA] Firazyr is indicated for symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults (with C1-esterase-inhibitor deficiency).|[PMDA] A drug with a new active ingredient indicated for the treatment of acute attacks of hereditary angioedema. [Orphan drug] uuid:f6426bdb-3441-4594-8347-ed724306ea34 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68556 biolink:treats MONDO:0012526 PMID:41385096 "[{""id"":""uuid:783c56a2-366a-42df-b4cf-7b3861f29824"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:17446d09-c41d-480a-a8d6-e840162ae7b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Icatibant injection is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older. uuid:1d29bf92-1311-4d95-b1ea-9af7e6186065 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4464 biolink:treats MONDO:0024332 PMID:41385096 "[{""id"":""uuid:e1903bc4-18f0-4bb9-b26a-63ba7e9af0b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b8230bfa-a153-47c1-9948-8e003bed6ddf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Perennial and seasonal allergic rhinitis Vasomotor rhinitis Allergic conjunctivitis due to inhalant allergens and foods Mild, uncomplicated allergic skin manifestations of urticaria and angioedema Amelioration of allergic reactions to blood or plasma Dermographism As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled. uuid:7b4b0691-7071-407a-ab61-e7cc07c90fc5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4464 biolink:treats MONDO:0005324 PMID:41385096 "[{""id"":""uuid:456ff626-e333-4446-a14c-b586f3495229"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:25ab0282-7d66-4d16-8686-b3ca151e3c7c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Perennial and seasonal allergic rhinitis Vasomotor rhinitis Allergic conjunctivitis due to inhalant allergens and foods Mild, uncomplicated allergic skin manifestations of urticaria and angioedema Amelioration of allergic reactions to blood or plasma Dermographism As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled. uuid:6e91ac79-51b3-42c5-92b2-3edfbbd4a181 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4464 biolink:treats MONDO:0006004 PMID:41385096 "[{""id"":""uuid:c277b2d5-a8db-497d-a914-b62479208c30"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ad7ae178-817a-4c3e-bb3a-6a74b8ce1083"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Perennial and seasonal allergic rhinitis Vasomotor rhinitis Allergic conjunctivitis due to inhalant allergens and foods Mild, uncomplicated allergic skin manifestations of urticaria and angioedema Amelioration of allergic reactions to blood or plasma Dermographism As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled. uuid:52bee94b-9656-4877-891d-99ea1fb350e8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4464 biolink:treats MONDO:0005492 PMID:41385096 "[{""id"":""uuid:bb9ba5f6-f638-428b-a8e3-6e860cf0fce3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b64076dd-e298-48da-b321-9b24bc5a9147"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Perennial and seasonal allergic rhinitis Vasomotor rhinitis Allergic conjunctivitis due to inhalant allergens and foods Mild, uncomplicated allergic skin manifestations of urticaria and angioedema Amelioration of allergic reactions to blood or plasma Dermographism As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled. uuid:9e3baf27-c8e6-4002-8287-8e92a118ab3a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4464 biolink:treats MONDO:0010481 PMID:41385096 "[{""id"":""uuid:7f18886e-8574-4f1f-9823-ba945fd2aea7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:53adb2ff-2165-46d9-a196-0685fb7824d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Perennial and seasonal allergic rhinitis Vasomotor rhinitis Allergic conjunctivitis due to inhalant allergens and foods Mild, uncomplicated allergic skin manifestations of urticaria and angioedema Amelioration of allergic reactions to blood or plasma Dermographism As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled. uuid:6c3cf9b9-9379-4aa5-8648-5a53db05a44c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4464 biolink:treats MONDO:0100053 PMID:41385096 "[{""id"":""uuid:b9dd4322-741c-499d-9b8d-772f71e33019"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:98e4ffde-e5ab-4efd-9be0-774f131e7f8a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Perennial and seasonal allergic rhinitis Vasomotor rhinitis Allergic conjunctivitis due to inhalant allergens and foods Mild, uncomplicated allergic skin manifestations of urticaria and angioedema Amelioration of allergic reactions to blood or plasma Dermographism As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled. uuid:391366db-a41c-42fc-900d-17e2be549d04 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4464 biolink:treats MONDO:0007448 PMID:41385096 "[{""id"":""uuid:42c7253f-4945-4599-ad24-7a12fff6fbb8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c1b71305-b662-40ef-a817-29cbe36520e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Perennial and seasonal allergic rhinitis Vasomotor rhinitis Allergic conjunctivitis due to inhalant allergens and foods Mild, uncomplicated allergic skin manifestations of urticaria and angioedema Amelioration of allergic reactions to blood or plasma Dermographism As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled. uuid:b0d5b4f4-ca98-4b88-bea9-c796fbb4f205 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:WA16A5Y52X biolink:treats UMLS:C0573830 PMID:41385096 "[{""id"":""uuid:c9df6226-b88d-41d8-a662-825558fa54e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6f7658a8-bda5-474a-878d-9b413d8ab034"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levoleucovorin Injection is indicated for: rescue after high-dose methotrexate therapy in adult and pediatric patients with osteosarcoma. diminishing the toxicity associated with overdosage of folic acid antagonists or impaired methotrexate elimination in adult and pediatric patients. the treatment of adults with metastatic colorectal cancer in combination with fluorouracil. Limitations of Use Levoleucovorin Injection is not indicated for pernicious anemia and megaloblastic anemia secondary to the lack of vitamin B 12 , because of the risk of progression of neurologic manifestations despite hematologic remission. PUBCHEM.COMPOUND:135465090 uuid:1675d2c9-97d9-4362-86c7-42497a85cd98 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16469 biolink:treats UMLS:C3671918 PMID:41385096 "[{""id"":""uuid:465ceba0-051e-4cca-88e8-0e014f1b5a56"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9a9bea7b-abaf-4bf6-9a35-ac5f464517ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c136e276-a781-4689-802f-619c09e5d525"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Estradiol tablets are indicated in the: Treatment of moderate to severe vasomotor symptoms associated with the menopause. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. Treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. Treatment of breast cancer (for palliation only) in appropriately selected women and men with metastatic disease. Treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only). Prevention of osteoporosis. When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and for whom non-estrogen medications are not considered to be appropriate. (See CLINICAL PHARMACOLOGY , Clinical Studies. ) The mainstays for decreasing the risk of postmenopausal osteoporosis are weight bearing exercise, adequate calcium and vitamin D intake, and when indicated, pharmacologic therapy. Postmenopausal women require an average of 1500 mg/day of elemental calcium. Therefore, when not contraindicated, calcium supplementation may be helpful for women with suboptimal dietary intake. Vitamin D supplementation of 400 to 800 IU/day may also be required to ensure adequate daily intake in postmenopausal women.|[PMDA] A drug with a new additional indication and new dosages for the treatment of hypoestrogenism caused by hypogonadism, gonadectomy or primary ovarian insufficiency. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:21b31876-0d9d-4551-88d2-4d5213148ab4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16469 biolink:treats MONDO:0002146 PMID:41385096 "[{""id"":""uuid:8f680559-85d3-4425-a744-16b653f82cc0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c4a3ae3a-c4ec-456a-800d-1fc12d644c88"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:24881685-0189-47ff-9e41-a2f64e755e21"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Estradiol tablets are indicated in the: Treatment of moderate to severe vasomotor symptoms associated with the menopause. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. Treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. Treatment of breast cancer (for palliation only) in appropriately selected women and men with metastatic disease. Treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only). Prevention of osteoporosis. When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and for whom non-estrogen medications are not considered to be appropriate. (See CLINICAL PHARMACOLOGY , Clinical Studies. ) The mainstays for decreasing the risk of postmenopausal osteoporosis are weight bearing exercise, adequate calcium and vitamin D intake, and when indicated, pharmacologic therapy. Postmenopausal women require an average of 1500 mg/day of elemental calcium. Therefore, when not contraindicated, calcium supplementation may be helpful for women with suboptimal dietary intake. Vitamin D supplementation of 400 to 800 IU/day may also be required to ensure adequate daily intake in postmenopausal women.|[PMDA] A drug with a new additional indication and new dosages for the treatment of hypoestrogenism caused by hypogonadism, gonadectomy or primary ovarian insufficiency. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:a1447a86-e558-4868-8b23-0de03dfd56e2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3398 biolink:treats MONDO:0005324 PMID:41385096 "[{""id"":""uuid:28b3fe33-716b-4d13-ba28-29a2c523081d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5aa0c93d-64d9-4940-a2c8-73ef010342b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carbinoxamine maleate is effective for the symptomatic treatment of: Seasonal and perennial allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Dermatographism. As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled. Amelioration of the severity of allergic reactions to blood or plasma. uuid:af47b9ff-ab79-46c3-a68c-83073d1321b7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3398 biolink:treats MONDO:0024332 PMID:41385096 "[{""id"":""uuid:2e8a2e3d-49b3-46f2-a2d5-6c960f36da73"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6a79d594-aa58-434f-93ff-84ae16d63937"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carbinoxamine maleate is effective for the symptomatic treatment of: Seasonal and perennial allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Dermatographism. As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled. Amelioration of the severity of allergic reactions to blood or plasma. uuid:f027ecaf-f15b-44b4-a570-9bd02900cb63 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3398 biolink:treats MONDO:0006004 PMID:41385096 "[{""id"":""uuid:82dc23d4-9988-4435-a89f-55d79ea8b14e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:42696f73-5418-4191-b08c-dba9b0b588d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carbinoxamine maleate is effective for the symptomatic treatment of: Seasonal and perennial allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Dermatographism. As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled. Amelioration of the severity of allergic reactions to blood or plasma. uuid:eb730e1b-e7a3-4e55-a3e4-337e9b611040 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3398 biolink:treats MONDO:0005492 PMID:41385096 "[{""id"":""uuid:abaeedd5-c0d4-4f2a-87a4-c38028d209be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1a19c605-f7f0-4571-babd-d9baf8684215"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carbinoxamine maleate is effective for the symptomatic treatment of: Seasonal and perennial allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Dermatographism. As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled. Amelioration of the severity of allergic reactions to blood or plasma. uuid:a2cd4e19-511c-4d9b-98d9-63e75a80457b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3398 biolink:treats MONDO:0010481 PMID:41385096 "[{""id"":""uuid:0ff38a53-04aa-4094-9457-0584d0b1ae17"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:68abc80e-7346-4ce3-8a28-df6eec48d056"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carbinoxamine maleate is effective for the symptomatic treatment of: Seasonal and perennial allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Dermatographism. As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled. Amelioration of the severity of allergic reactions to blood or plasma. uuid:a1e2865f-6b47-4894-b307-2402a53c344e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3398 biolink:treats MONDO:0007448 PMID:41385096 "[{""id"":""uuid:c1c5bbb3-72cd-4b11-9b67-46d47e69043c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2a6df3b3-cdf5-41bf-b719-1d2451b77e27"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carbinoxamine maleate is effective for the symptomatic treatment of: Seasonal and perennial allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Dermatographism. As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled. Amelioration of the severity of allergic reactions to blood or plasma. uuid:71caef53-6224-43be-9da5-a1b3230baf53 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3398 biolink:treats MONDO:0100053 PMID:41385096 "[{""id"":""uuid:37217d96-e031-482b-897b-a55c92225e1b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:77353e15-6fbc-4eae-850a-50b904feb0b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carbinoxamine maleate is effective for the symptomatic treatment of: Seasonal and perennial allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Dermatographism. As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled. Amelioration of the severity of allergic reactions to blood or plasma. uuid:d33806c8-afd2-493d-be84-acbbdb745d42 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:91583 biolink:treats MONDO:0015254 PMID:41385096 "[{""id"":""uuid:b3cb09cf-79e0-41d6-a117-abb3dc089650"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9553a107-a54c-4cab-bd7f-cc53976531c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Biltricide is indicated in patients aged 1 year and older for the treatment of the following infections: • Schistosomiasis due to all species of schistosoma (for example, Schistosoma mekongi, Schistosoma japonicum, Schistosoma mansoni and Schistosoma hematobium ), and • Clonorchiasis and Opisthorchiasis due to the liver flukes, Clonorchis sinensis/Opisthorchis viverrini (approval of this indication was based on studies in which the two species were not differentiated) uuid:4fec4941-e9e6-4c87-8d52-fe46f6d5c636 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3A58010674 biolink:treats MONDO:0004992 PMID:41385096 "[{""id"":""uuid:5a400cf9-ee54-4898-bf99-5ade5c723374"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b962770a-fe68-4514-9ca4-903ab36c9c89"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fulphila is a leukocyte growth factor indicated to • Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. ( 1.1 ) Limitations of Use Fulphila is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation. uuid:4139db45-583d-4046-bb74-68203d230a08 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32229 biolink:treats MONDO:0024647 PMID:41385096 "[{""id"":""uuid:482a71d7-fb19-4f95-be44-db8d93275cee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:581c798c-8446-486f-bd90-175d156868d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] THIOLA ® is indicated for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria with urinary cystine greater than 500 mg/day, who are resistant to treatment with conservative measures of high fluid intake, alkali and diet modification, or who have adverse reactions to d-penicillamine. Cystine stones typically occur in approximately 10,000 persons in the United States who are homozygous for cystinuria. These persons excrete abnormal amounts of cystine in urine of over 250 mg/g creatinine, as well as excessive amounts of other dibasic amino acids (lysine, arginine and ornithine). In addition, they show varying intestinal transport defects for these same amino acids. The stone formation is the result of poor aqueous solubility of cystine. Since there are no known inhibitors of the crystallization of cystine, the stone formation is determined primarily by the urinary supersaturation of cystine. Thus, cystine stones could theoretically form whenever urinary cystine concentration exceeds the solubility limit. Cystine solubility in urine is pH-dependent, and ranges from 170-300 mg/liter at pH 5, 190-400 mg/liter at pH 7 and 220-500 mg/liter at pH 7.5. The goal of therapy is to reduce urinary cystine concentration below its solubility limit. It may be accomplished by dietary means aimed at reducing cystine synthesis and by a high fluid intake in order to increase urine volume and thereby lower cystine concentration. Unfortunately, the above conservative measures alone may be ineffective in controlling cystine stone formation in some homozygous patients with severe cystinuria (urinary cystine exceeding 500 mg/day). In such patients, d-penicillamine has been used as an additional therapy. Like THIOLA ™ , dpenicillamine undergoes thiol-disulfide exchange with cystine, thereby lowering the amount of sparingly soluble cystine in urine. However, d-penicillamine treatment is frequently accompanied by adverse reactions, such as dermatologic complications, hypersensitivity reactions, hematologic abnormalities and renal disturbances. THIOLA ® may have a particular therapeutic role in such patients. uuid:75ce357f-5f43-4e09-8172-f4fd78424ab1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27777 biolink:treats MONDO:0006030 PMID:41385096 "[{""id"":""uuid:40ee7041-49a0-471d-ac31-ee178c1260ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9e3041b0-4181-44c4-966a-ff87ca50d15b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Acetohydroxamic acid is indicated as adjunctive therapy in patients with chronic urea-splitting urinary infection. AHA is intended to decrease urinary ammonia and alkalinity, but it should not be used in lieu of curative surgical treatment (for patients with stones) or antimicrobial treatment. Long-term treatment with AHA may be warranted to maintain urease inhibition as long as urea-splitting infection is present. Experience with AHA does not go beyond 7 years. A patient package insert should be distributed to each patient who receives AHA. uuid:8092ecec-60a2-4552-9c6f-63fa5230155f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68642 biolink:treats MONDO:0850353 PMID:41385096 "[{""id"":""uuid:a029773c-68a2-4b8d-9a7c-20813b4604dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ba246957-f10c-4217-b124-fb25361ff6be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Abiraterone acetate tablets are indicated in combination with prednisone for the treatment of patients with Metastatic castration-resistant prostate cancer (CRPC) uuid:0f0785f5-6b42-4cbf-8b46-eeb13dfb540a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:51066 biolink:treats MONDO:0005338 PMID:41385096 "[{""id"":""uuid:a0054a57-fa98-498f-a8e1-c10dfaf5c832"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:320cd25c-7b85-4d94-a768-f232247c9b50"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dapiprazole hydrochloride ophthalmic solution is indicated in the treatment of iatrogenically induced mydriasis produced by adrenergic (phenylephrine) or parasympatholytic (tropicamide) agents. Dapiprazole hydrochloride ophthalmic solution is not indicated for the reduction of intraocular pressure or in the treatment of open angle glaucoma. uuid:3948226f-686c-458c-afe3-6e0e7b207862 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:42944 biolink:treats MONDO:0001627 PMID:41385096 "[{""id"":""uuid:6120ff06-c8fc-4170-93af-e3341098da2c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b8c9419f-c31f-4f11-89dd-3713c915bbb4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Galantamine is indicated for the treatment of mild to moderate dementia of the Alzheimer’s type. uuid:b0332df3-c480-4740-b6fc-3c5eee192c05 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6923 biolink:treats UMLS:C0919659 PMID:41385096 "[{""id"":""uuid:03a523e8-633d-4c48-bed2-c605186f7cb1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a9a53c81-aefa-45ae-8af7-79215ec345ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f216e4ae-97c0-474b-98f7-db7c63a35b0f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ORAVIG is indicated for the local treatment of oropharyngeal candidiasis (OPC) in adults.|[PMDA] A drug in a new dosage form indicated for the treatment of oropharyngeal candidiasis caused by Candida . uuid:af114c61-5ace-4875-9365-0085ae011fcf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6923 biolink:treats MONDO:0009769 PMID:41385096 "[{""id"":""uuid:f5db39bc-45e1-46c5-b0e4-e71e420d9e11"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fe57b3e8-c84d-4824-9ae3-effa1cd9af37"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ORAVIG is indicated for the local treatment of oropharyngeal candidiasis (OPC) in adults. uuid:2e5cf70f-012b-4631-a3c9-c900331284ec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:135659058 biolink:treats MONDO:0024613 PMID:41385096 "[{""id"":""uuid:794e19f3-f626-4e43-bb1d-56dc5148e211"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6572751e-4368-42b6-b541-3e7e1316f95f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Olanzapine and fluoxetine capsules are indicated for the treatment of: Acute depressive episodes in Bipolar I Disorder [see Clinical Studies (14.1) ]. Treatment resistant depression (Major Depressive Disorder in patient who do not respond to 2 separate trials of different antidepressants of adequate dose and duration in the current episode) [see Clinical Studies (14.2) ]. uuid:5935d3e1-327d-4bb5-b04b-6808e57a371a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:135659058 biolink:treats UMLS:C2063866 PMID:41385096 "[{""id"":""uuid:06801343-461e-4b10-8567-5e08f589679d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:31366f61-e6de-4c3d-b6e1-7246c35cc38a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Olanzapine and fluoxetine capsules are indicated for the treatment of: Acute depressive episodes in Bipolar I Disorder [see Clinical Studies (14.1) ]. Treatment resistant depression (Major Depressive Disorder in patient who do not respond to 2 separate trials of different antidepressants of adequate dose and duration in the current episode) [see Clinical Studies (14.2) ]. uuid:0ebc1583-a0e2-4e24-a0b7-71e153010b36 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:135659058 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:32227ff8-f98e-4bce-8309-544f4287860d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d02425b6-c811-4732-9233-7c910650a95f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Olanzapine and fluoxetine capsules are indicated for the treatment of: Acute depressive episodes in Bipolar I Disorder [see Clinical Studies (14.1) ]. Treatment resistant depression (Major Depressive Disorder in patient who do not respond to 2 separate trials of different antidepressants of adequate dose and duration in the current episode) [see Clinical Studies (14.2) ]. uuid:6bded65c-4b11-4ddd-a888-55d9c943fc52 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135598 biolink:treats MONDO:0005010 PMID:41385096 "[{""id"":""uuid:f2dec220-2e3f-4cbe-9a1d-473c2431a7ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:990fc4c9-d1d5-4c10-bb49-75f2fa08fe0f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MYOVIEW is a kit for the preparation of technetium Tc99m tetrofosmin for injection. Technetium Tc99m tetrofosmin injection is a radioactive diagnostic agent indicated for the following: Myocardial perfusion imaging under rest and/or exercise or pharmacologic stress conditions to delineate regions of reversible myocardial ischemia or infarcted myocardium in patients with known or suspected coronary artery disease ( 1.1 ) Assessment of left ventricular function (left ventricular ejection fraction and wall motion) in patients with known or suspected heart disease ( 1.2 ) uuid:f8e489e9-07b5-4809-8622-e97a7d7f5e84 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135598 biolink:treats MONDO:0005267 PMID:41385096 "[{""id"":""uuid:6bd20dc5-6c73-4bba-b029-1e2f4fa4c51f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0a5febd6-639b-4db5-ac7d-59a7b43a94aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MYOVIEW is a kit for the preparation of technetium Tc99m tetrofosmin for injection. Technetium Tc99m tetrofosmin injection is a radioactive diagnostic agent indicated for the following: Myocardial perfusion imaging under rest and/or exercise or pharmacologic stress conditions to delineate regions of reversible myocardial ischemia or infarcted myocardium in patients with known or suspected coronary artery disease ( 1.1 ) Assessment of left ventricular function (left ventricular ejection fraction and wall motion) in patients with known or suspected heart disease ( 1.2 ) uuid:14601c6f-b69f-4533-b692-397392555db9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:105013 biolink:treats MONDO:0005227 PMID:41385096 "[{""id"":""uuid:c8e1cd86-36b5-4a13-b2e1-abf378bf02f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f5ff1bbb-70fa-4ffe-8dd3-ef7bbe5ac01b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Indium In 111 Oxyquinoline Solution is indicated for radiolabeling autologous leukocytes. Indium In 111 oxyquinoline labeled leukocytes may be used as an adjunct in the detection of inflammatory processes to which leukocytes migrate, such as those associated with abscesses or other infection, following reinjection and detection by appropriate imaging procedures. The degree of accuracy may vary with labeling techniques and with the size, location and nature of the inflammatory process. Indium In 111 oxyquinoline labeled leukocyte imaging is not the preferred technique for the initial evaluation of patients with a high clinical probability of an abscess in a known location. Ultrasound or computed tomography may provide a better anatomical delineation of the infectious process and information may be obtained more quickly than with labeled leukocytes. If localization by these techniques is successful, labeled leukocytes should not be used as a confirmatory procedure. If localization or diagnosis by these methods fails or is ambiguous, indium In 111 oxyquinoline labeled leukocyte imaging may be appropriate. uuid:c715d6b5-a25b-4189-9594-aa4f4382a7db biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:105013 biolink:treats UMLS:C3714514 PMID:41385096 "[{""id"":""uuid:83ee3bf4-a1f7-48bd-9ee6-04dd0a1b6e05"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b1156230-82d5-43cc-8848-f8d21875ab7f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Indium In 111 Oxyquinoline Solution is indicated for radiolabeling autologous leukocytes. Indium In 111 oxyquinoline labeled leukocytes may be used as an adjunct in the detection of inflammatory processes to which leukocytes migrate, such as those associated with abscesses or other infection, following reinjection and detection by appropriate imaging procedures. The degree of accuracy may vary with labeling techniques and with the size, location and nature of the inflammatory process. Indium In 111 oxyquinoline labeled leukocyte imaging is not the preferred technique for the initial evaluation of patients with a high clinical probability of an abscess in a known location. Ultrasound or computed tomography may provide a better anatomical delineation of the infectious process and information may be obtained more quickly than with labeled leukocytes. If localization by these techniques is successful, labeled leukocytes should not be used as a confirmatory procedure. If localization or diagnosis by these methods fails or is ambiguous, indium In 111 oxyquinoline labeled leukocyte imaging may be appropriate. uuid:fab46967-eea7-4aa2-b90a-11e241cd9c59 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4027 biolink:treats MONDO:0006835 PMID:41385096 "[{""id"":""uuid:c292f4a4-8b0d-4441-8bee-56d9ade1131e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4d6c0ca9-cbc1-4cce-b2ac-30ff33293174"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cyclophosphamide is an alkylating drug indicated for treatment of: Malignant Diseases : malignant lymphomas: Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma ( 1.1 ) Minimal Change Nephrotic Syndrome in Pediatric Patients : biopsy proven minimal change nephrotic syndrome in pediatric patients who failed to adequately respond to or are unable to tolerate adrenocorticosteroid therapy ( 1.2 ) Limitations of Use: The safety and effectiveness for the treatment of nephrotic syndrome in adults or other renal disease has not been established. uuid:32df2c12-9595-4b03-9270-9cb8176d5d36 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1043298 biolink:treats MONDO:0006873 PMID:41385096 "[{""id"":""uuid:405760e6-c65c-4760-aab6-42f4a9513dfc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:abb5b175-a5b5-4d85-bc42-3c61c88de973"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS: PNV-DHA is a multivitamin/multimineral nutritional supplement indicated for use in the dietary management of patients with nutritional deficiencies or are in need of nutritional supplementation. uuid:d27c834f-f4f4-497b-a6f3-083f679e711d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71260 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:c23a9068-1d88-4991-9c7c-aa129205d13b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bdf12780-dfed-415f-864e-6e60ac6260cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pitavastatin tablets are indicated as an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in: Adult with primary hyperlipidemia. Adults with heterozygous familial hypercholesterolemia (HeFH). Pediatric use information is approved for Kowa Co Ltd’s LIVALO (pitavastatin) tablets. However, due to Kowa Co Ltd’s marketing exclusivity rights, this drug product is not labeled with that information. uuid:65d700fb-cf58-42dd-b379-348c21576b77 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71260 biolink:treats UMLS:C0342882 PMID:41385096 "[{""id"":""uuid:6a513efe-9561-4a9b-b48d-0ccafcb5f1b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2735e3e2-4fb9-4578-99e2-eb3c8191561b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pitavastatin tablets are indicated as an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in: Adult with primary hyperlipidemia. Adults with heterozygous familial hypercholesterolemia (HeFH). Pediatric use information is approved for Kowa Co Ltd’s LIVALO (pitavastatin) tablets. However, due to Kowa Co Ltd’s marketing exclusivity rights, this drug product is not labeled with that information. uuid:5d16733c-d6bd-4aad-80a3-9993a0a9058f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3242 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:12ebc544-ee34-44cb-b660-1a080d368c92"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:661ed1ea-cee7-4e26-9334-4e16827439d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Butorphanol tartrate nasal spray is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use : Because of the risks of addiction, abuse, and misuse, with opioids, which can occur at any dosage or duration [see WARNINGS ] reserve butorphanol tartrate nasal spray for use in patients for whom alternative treatment options (e.g., non-opioid analgesics): Have not been tolerated or are not expected to be tolerated, Have not provided adequate analgesia or are not expected to provide adequate analgesia Butorphanol tartrate nasal spray should not be used for an extended period of time unless the pain remains severe enough to require an opioid analgesic and for which alternative treatment options continue to be inadequate. uuid:6a1806db-5bff-4134-ac9e-c57006b6c256 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1153890 biolink:treats MONDO:0005271 PMID:41385096 "[{""id"":""uuid:495d247f-e443-41aa-87be-2a40ef7e16ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:000e38af-82a3-4303-b73a-4971f496b0b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TUXARIN ER is indicated for the temporary relief of cough and upper respiratory symptoms associated with allergy or the common cold in patients 18 years of age and older. uuid:81fbdf67-9a80-4811-9fb5-1a8a6b768590 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50692 biolink:treats MONDO:0018912 PMID:41385096 "[{""id"":""uuid:1e7a6de5-3785-4155-bb20-53626c7d8e31"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b8dd7874-b033-4798-8485-a621c3a7201a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mifepristone is a cortisol receptor blocker indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. LIMITATIONS OF USE: Mifepristone tablets should not be used in the treatment of patients with type 2 diabetes unless it is secondary to Cushing’s syndrome. uuid:f1dbab2f-65e0-4511-ae29-9da4192c6d70 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50692 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:f2219c2d-9ff3-4b01-b7a1-eba17043c4b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c4a913e0-d768-4564-bece-0b338c91b85d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mifepristone is a cortisol receptor blocker indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. LIMITATIONS OF USE: Mifepristone tablets should not be used in the treatment of patients with type 2 diabetes unless it is secondary to Cushing’s syndrome. uuid:5f0f7233-8290-4837-81e4-adb59c13206f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50692 biolink:treats MONDO:0001076 PMID:41385096 "[{""id"":""uuid:040dba95-6e06-432f-af2d-cdce4a4073c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:29239cd4-ac64-4d87-957d-3dd88718d074"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mifepristone is a cortisol receptor blocker indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. LIMITATIONS OF USE: Mifepristone tablets should not be used in the treatment of patients with type 2 diabetes unless it is secondary to Cushing’s syndrome. uuid:31ed795e-817c-41f3-9a84-d77c036d182a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1164653 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:164ff37a-419e-44b3-80c3-fd20c9f47d78"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:15827bbf-fb2a-4eff-bed4-2b1210c1b8d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] UrNeva Capsules is indicated for the treatment of symptoms of irritative voiding. Indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. Indicated for the relief of urinary tract symptoms caused by diagnostic procedures. uuid:c33f4cba-0e4c-4ee7-afd3-1fb396addaa6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:284780 biolink:treats MONDO:0006652 PMID:41385096 "[{""id"":""uuid:bbe48fee-c600-41be-b397-73344b1186e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c61267b2-2a22-4b07-8f76-772de0809dd4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Telmisartan and hydrochlorothiazide tablets are combination of an angiotensin II receptor blocker (ARB) and a thiazide diuretic indicated for the treatment of hypertension, alone or with other antihypertensive agents, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1 ) Telmisartan and hydrochlorothiazide tablets are not indicated for initial therapy ( 1 ) uuid:1e03122b-bee1-40ba-994c-700de862b80c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6717 biolink:treats HP:0100607 PMID:41385096 "[{""id"":""uuid:f8ca7391-c1a0-421d-8f32-f265592ede3b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9e7db464-9e26-437a-b127-4fbaae53a011"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of mefenamic acid capsules and other treatment options before deciding to use mefenamic acid capsules. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ; Gastrointestinal Bleeding, Ulceration, and Perforation ). Mefenamic acid capsules are indicated: For relief of mild to moderate pain in patients ≥14 years of age, when therapy will not exceed one week (7 days). For treatment of primary dysmenorrhea. uuid:ae7f503c-7693-46f9-a005-b111f4f40d3e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:372890 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:1658c031-d290-44f6-8238-46fb190326a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b965b586-4790-4c2e-9ef8-aa19acb24bc2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Metoprolol tartrate and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Metoprolol tartrate and hydrochlorothiazide tablets may be administered with other antihypertensive agents. Limitation of Use Metoprolol tartrate and hydrochlorothiazide tablets are not indicated for initial therapy of hypertension. If the fixed combination represents the dose titrated to the individual patient’s needs, therapy with the fixed combination may be more convenient than with the separate components. uuid:39c2ae0e-fbca-422e-a975-413571e3fcaa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:372890 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:585b8aa9-4993-4057-b465-8ac612f01f5b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cb980227-f3f3-4423-b334-7679f0abd53b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Metoprolol tartrate and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Metoprolol tartrate and hydrochlorothiazide tablets may be administered with other antihypertensive agents. Limitation of Use Metoprolol tartrate and hydrochlorothiazide tablets are not indicated for initial therapy of hypertension. If the fixed combination represents the dose titrated to the individual patient’s needs, therapy with the fixed combination may be more convenient than with the separate components. uuid:acc478e1-9306-4531-a5ba-d9be0d8acd63 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:372890 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:e0617ed8-f277-4351-a61f-3ffe80543781"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3415466a-6df6-4950-850d-b69d4882495e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Metoprolol tartrate and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Metoprolol tartrate and hydrochlorothiazide tablets may be administered with other antihypertensive agents. Limitation of Use Metoprolol tartrate and hydrochlorothiazide tablets are not indicated for initial therapy of hypertension. If the fixed combination represents the dose titrated to the individual patient’s needs, therapy with the fixed combination may be more convenient than with the separate components. uuid:380dd29c-72be-4ba3-9236-1025a927e884 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:372890 biolink:treats MONDO:0005016 PMID:41385096 "[{""id"":""uuid:73cdf80f-6310-4941-8628-f9c8037d1feb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:59409d8d-9565-4db0-98fc-e2ba88ca77fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Metoprolol tartrate and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Metoprolol tartrate and hydrochlorothiazide tablets may be administered with other antihypertensive agents. Limitation of Use Metoprolol tartrate and hydrochlorothiazide tablets are not indicated for initial therapy of hypertension. If the fixed combination represents the dose titrated to the individual patient’s needs, therapy with the fixed combination may be more convenient than with the separate components. uuid:3be4e4ea-8803-4daf-81f4-a49d670c833f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:372890 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:0ea53d9c-79b3-4157-951f-106a03395e89"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:10fde54a-4f4b-438d-8c25-81e019dcb7c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Metoprolol tartrate and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Metoprolol tartrate and hydrochlorothiazide tablets may be administered with other antihypertensive agents. Limitation of Use Metoprolol tartrate and hydrochlorothiazide tablets are not indicated for initial therapy of hypertension. If the fixed combination represents the dose titrated to the individual patient’s needs, therapy with the fixed combination may be more convenient than with the separate components. uuid:abc17345-9ebf-4b56-83ee-daf7ee2298cf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:372890 biolink:treats HP:0001681 PMID:41385096 "[{""id"":""uuid:6f4a605e-d0cd-4042-aa14-da91ab17b509"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:73b717f9-7ccc-4d75-804b-aa484e3fb93f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Metoprolol tartrate and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Metoprolol tartrate and hydrochlorothiazide tablets may be administered with other antihypertensive agents. Limitation of Use Metoprolol tartrate and hydrochlorothiazide tablets are not indicated for initial therapy of hypertension. If the fixed combination represents the dose titrated to the individual patient’s needs, therapy with the fixed combination may be more convenient than with the separate components. uuid:b99c8f18-49e6-43b2-93b0-056c99804c07 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:372890 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:da73c91a-b68e-4720-881b-c3cd87b8e121"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:34d9d900-8783-4651-8693-f6afc0424232"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Metoprolol tartrate and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Metoprolol tartrate and hydrochlorothiazide tablets may be administered with other antihypertensive agents. Limitation of Use Metoprolol tartrate and hydrochlorothiazide tablets are not indicated for initial therapy of hypertension. If the fixed combination represents the dose titrated to the individual patient’s needs, therapy with the fixed combination may be more convenient than with the separate components. uuid:8e8b3799-e1b7-46ed-a263-b920a2e656e8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16899 biolink:treats MONDO:0009061 PMID:41385096 "[{""id"":""uuid:a1a4d072-0977-4352-8805-c2d725b14b10"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:2953d569-fe34-447d-98d9-1b748be19545"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:37a7d1c8-2160-4548-ab5b-2141df941438"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/bronchitol""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] BRONCHITOL is indicated as add-on maintenance therapy to improve pulmonary function in adult patients 18 years and older with Cystic Fibrosis. Use BRONCHITOL only for adults who have passed the BRONCHITOL Tolerance Test [see Dosage and Administration ( 2.1 )].|[EMA] Bronchitol is indicated for the treatment of cystic fibrosis (CF) in adults aged 18 years and above as an add-on therapy to best standard of care. uuid:34a77f7b-d47f-4316-a1e8-feda892ee8df biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:0DE9724IHC biolink:treats UMLS:C0573789 PMID:41385096 "[{""id"":""uuid:3bdb9e07-27c0-408c-94fb-ca12b7a5378d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:48c45a31-2e1f-4b8c-b8cd-448fa95d0e58"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Protamine Sulfate Injection, USP is indicated in the treatment of heparin overdosage. uuid:deef647b-062e-45c8-aeff-b2e3aa793e24 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68610 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:9abec093-af03-4fd7-a1ea-98a710d7f1bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:77668776-14bb-487d-9070-ee1bcdfe7056"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:601091b8-0574-44c1-ac33-320802a27d39"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/trajenta""]},{""id"":""uuid:22c40d6d-3370-4023-b1b9-89b7375cb399"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TRADJENTA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus .|[EMA] Trajenta is indicated in the treatment of type 2 diabetes mellitus to improve glycaemic control in adults:as monotherapyin patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to intolerance, or contraindicated due to renal impairment.as combination therapyin combination with metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control.in combination with a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.in combination with insulin with or without metformin, when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.|[PMDA] A drug with a new active ingredient indicated for the treatment of type 2 diabetes mellitus (for use only in patients who have not responded sufficiently to diet and exercise therapies alone). uuid:f37a6814-f1b0-4048-bb20-0d5071f91ca1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135686 biolink:treats UMLS:C0400877 PMID:41385096 "[{""id"":""uuid:6a0a9b15-a02b-49e0-800c-b8516bdd8557"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2b5bc372-8648-43bd-b9f2-f782e1a701e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Alvimopan capsules are indicated to accelerate the time to upper and lower gastrointestinal recovery following surgeries that include partial bowel resection with primary anastomosis. uuid:9f632350-56e1-4a8c-8fa2-6f47162bfa28 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5856 biolink:treats MONDO:0004981 PMID:41385096 "[{""id"":""uuid:e92b07d3-f9e0-44a0-afca-c5f803bd2c0e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:142b7cf7-acbd-46e9-9209-27c2bd84dfa0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CORVERT Injection is indicated for the rapid conversion of atrial fibrillation or atrial flutter of recent onset to sinus rhythm. Patients with atrial arrhythmias of longer duration are less likely to respond to CORVERT. The effectiveness of ibutilide has not been determined in patients with arrhythmias of more than 90 days in duration. uuid:a503df9d-1452-4fb5-9ad3-18e1819c50a3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5856 biolink:treats MONDO:0005310 PMID:41385096 "[{""id"":""uuid:815036ac-b8f2-4541-aaaa-bf05c6c5878c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d7eaa7c6-7e4f-43f7-87ff-ed7cc17f42ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CORVERT Injection is indicated for the rapid conversion of atrial fibrillation or atrial flutter of recent onset to sinus rhythm. Patients with atrial arrhythmias of longer duration are less likely to respond to CORVERT. The effectiveness of ibutilide has not been determined in patients with arrhythmias of more than 90 days in duration. uuid:3ae2090d-ddb3-4f4d-a058-5ca3e1807de5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:0IEO0F56LV biolink:treats MONDO:0007100 PMID:41385096 "[{""id"":""uuid:eb08e1a7-6d39-4d65-8915-5f3c7004bb61"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a3f0b329-d711-4a8e-a78c-067c0f5a4f60"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:b6b01b39-9d81-4970-86c9-eed7d7cc345c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TEGSEDI is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.|[EMA] Treatment of stage 1 or Stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis (hATTR). uuid:d82aeba2-1800-43e3-a90e-c78c0303ff04 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18243 biolink:treats HP:0031273 PMID:41385096 "[{""id"":""uuid:3f2d5a46-cd49-43e4-b4f6-150b2981cc63"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9b76f4cd-2772-4f60-9697-dec08c57f46e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dopamine Hydrochloride in 5% Dextrose Injection, USP is indicated for the correction of hemodynamic imbalances present in shock due to myocardial infarction, trauma, endotoxic septicemia, open heart surgery, renal failure and chronic cardiac decompensation as in refractory congestive failure. When indicated, restoration of circulatory volume should be instituted or completed with a suitable plasma expander or whole blood, prior to administration of dopamine hydrochloride. Patients most likely to respond to dopamine are those whose physiological parameters (such as urine flow, myocardial function and blood pressure) have not undergone extreme deterioration. Reports indicate that the shorter the time between onset of signs and symptoms and initiation of therapy with volume restoration and dopamine, the better the prognosis. Poor Perfusion of Vital Organs: Although urine flow is apparently one of the better diagnostic signs for monitoring vital organ perfusion, the physician also should observe the patient for signs of reversal of mental confusion or coma. Loss of pallor, increase in toe temperature or adequacy of nail bed capillary filling also may be observed as indices of adequate dosage. Reported studies indicate that when dopamine is administered before urine flow has decreased to approximately 0.3 mL/minute prognosis is more favorable. However, it has been observed that in some oliguric or anuric patients, administration of the drug has produced an increase in urine flow which may reach normal levels. The drug also may increase urine flow in patients whose output is within normal limits and thus may help in reducing the degree of pre-existing fluid accumulation. Conversely, at higher than optimal doses for a given patient, urinary flow may decrease, requiring a reduction of dosage. Concomitant administration of dopamine and diuretic agents may produce an additive or potentiating effect. Low Cardiac Output: Dopamine's direct inotropic effect on the myocardium which increases cardiac output at low or moderate doses is related to a favorable prognosis. Increased output has been associated with unchanged or decreased systemic vascular resistance (SVR). The association of static or decreased SVR with low or moderate increases in cardiac output is regarded as a reflection of differential effects on specific vascular beds, with increased resistance in peripheral beds (e.g., femoral), and concurrent decreases in mesenteric and renal vascular beds. Redistribution of blood flow parallels these changes so that an increase in cardiac output is accompanied by an increase in mesenteric and renal blood flow. In many instances the renal fraction of the total cardiac output has been found to increase. Increase in cardiac output produced by dopamine is not associated with substantial decreases in systemic vascular resistance as may occur with isoproterenol. Hypotension: Low to moderate doses of dopamine, which have little effect on SVR, can be used to manage hypotension due to inadequate cardiac output. At high therapeutic doses, dopamine's α-adrenergic action becomes more prominent and thus may correct hypotension due to diminished SVR. As in other circulatory decompensation states, prognosis is better in patients whose blood pressure and urine flow have not undergone extreme deterioration. Therefore, it is suggested the physician administer dopamine as soon as a definite trend toward decreased systolic and diastolic pressure becomes apparent. uuid:611cafab-9966-46a5-a585-d2a52be7315f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18243 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:519efc34-bf82-4bce-bdb5-7eb87c7f9a61"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5f2063b7-13f2-49e6-a7aa-df8122db4fde"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dopamine Hydrochloride in 5% Dextrose Injection, USP is indicated for the correction of hemodynamic imbalances present in shock due to myocardial infarction, trauma, endotoxic septicemia, open heart surgery, renal failure and chronic cardiac decompensation as in refractory congestive failure. When indicated, restoration of circulatory volume should be instituted or completed with a suitable plasma expander or whole blood, prior to administration of dopamine hydrochloride. Patients most likely to respond to dopamine are those whose physiological parameters (such as urine flow, myocardial function and blood pressure) have not undergone extreme deterioration. Reports indicate that the shorter the time between onset of signs and symptoms and initiation of therapy with volume restoration and dopamine, the better the prognosis. Poor Perfusion of Vital Organs: Although urine flow is apparently one of the better diagnostic signs for monitoring vital organ perfusion, the physician also should observe the patient for signs of reversal of mental confusion or coma. Loss of pallor, increase in toe temperature or adequacy of nail bed capillary filling also may be observed as indices of adequate dosage. Reported studies indicate that when dopamine is administered before urine flow has decreased to approximately 0.3 mL/minute prognosis is more favorable. However, it has been observed that in some oliguric or anuric patients, administration of the drug has produced an increase in urine flow which may reach normal levels. The drug also may increase urine flow in patients whose output is within normal limits and thus may help in reducing the degree of pre-existing fluid accumulation. Conversely, at higher than optimal doses for a given patient, urinary flow may decrease, requiring a reduction of dosage. Concomitant administration of dopamine and diuretic agents may produce an additive or potentiating effect. Low Cardiac Output: Dopamine's direct inotropic effect on the myocardium which increases cardiac output at low or moderate doses is related to a favorable prognosis. Increased output has been associated with unchanged or decreased systemic vascular resistance (SVR). The association of static or decreased SVR with low or moderate increases in cardiac output is regarded as a reflection of differential effects on specific vascular beds, with increased resistance in peripheral beds (e.g., femoral), and concurrent decreases in mesenteric and renal vascular beds. Redistribution of blood flow parallels these changes so that an increase in cardiac output is accompanied by an increase in mesenteric and renal blood flow. In many instances the renal fraction of the total cardiac output has been found to increase. Increase in cardiac output produced by dopamine is not associated with substantial decreases in systemic vascular resistance as may occur with isoproterenol. Hypotension: Low to moderate doses of dopamine, which have little effect on SVR, can be used to manage hypotension due to inadequate cardiac output. At high therapeutic doses, dopamine's α-adrenergic action becomes more prominent and thus may correct hypotension due to diminished SVR. As in other circulatory decompensation states, prognosis is better in patients whose blood pressure and urine flow have not undergone extreme deterioration. Therefore, it is suggested the physician administer dopamine as soon as a definite trend toward decreased systolic and diastolic pressure becomes apparent. uuid:e35e7af4-aedd-40f7-ae98-693709059150 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18243 biolink:treats HP:0001259 PMID:41385096 "[{""id"":""uuid:86732904-bc39-4c2b-b5da-5a065ec694a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9c08fde7-ff4e-407f-9cb8-dc5b472a2bb6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dopamine Hydrochloride in 5% Dextrose Injection, USP is indicated for the correction of hemodynamic imbalances present in shock due to myocardial infarction, trauma, endotoxic septicemia, open heart surgery, renal failure and chronic cardiac decompensation as in refractory congestive failure. When indicated, restoration of circulatory volume should be instituted or completed with a suitable plasma expander or whole blood, prior to administration of dopamine hydrochloride. Patients most likely to respond to dopamine are those whose physiological parameters (such as urine flow, myocardial function and blood pressure) have not undergone extreme deterioration. Reports indicate that the shorter the time between onset of signs and symptoms and initiation of therapy with volume restoration and dopamine, the better the prognosis. Poor Perfusion of Vital Organs: Although urine flow is apparently one of the better diagnostic signs for monitoring vital organ perfusion, the physician also should observe the patient for signs of reversal of mental confusion or coma. Loss of pallor, increase in toe temperature or adequacy of nail bed capillary filling also may be observed as indices of adequate dosage. Reported studies indicate that when dopamine is administered before urine flow has decreased to approximately 0.3 mL/minute prognosis is more favorable. However, it has been observed that in some oliguric or anuric patients, administration of the drug has produced an increase in urine flow which may reach normal levels. The drug also may increase urine flow in patients whose output is within normal limits and thus may help in reducing the degree of pre-existing fluid accumulation. Conversely, at higher than optimal doses for a given patient, urinary flow may decrease, requiring a reduction of dosage. Concomitant administration of dopamine and diuretic agents may produce an additive or potentiating effect. Low Cardiac Output: Dopamine's direct inotropic effect on the myocardium which increases cardiac output at low or moderate doses is related to a favorable prognosis. Increased output has been associated with unchanged or decreased systemic vascular resistance (SVR). The association of static or decreased SVR with low or moderate increases in cardiac output is regarded as a reflection of differential effects on specific vascular beds, with increased resistance in peripheral beds (e.g., femoral), and concurrent decreases in mesenteric and renal vascular beds. Redistribution of blood flow parallels these changes so that an increase in cardiac output is accompanied by an increase in mesenteric and renal blood flow. In many instances the renal fraction of the total cardiac output has been found to increase. Increase in cardiac output produced by dopamine is not associated with substantial decreases in systemic vascular resistance as may occur with isoproterenol. Hypotension: Low to moderate doses of dopamine, which have little effect on SVR, can be used to manage hypotension due to inadequate cardiac output. At high therapeutic doses, dopamine's α-adrenergic action becomes more prominent and thus may correct hypotension due to diminished SVR. As in other circulatory decompensation states, prognosis is better in patients whose blood pressure and urine flow have not undergone extreme deterioration. Therefore, it is suggested the physician administer dopamine as soon as a definite trend toward decreased systolic and diastolic pressure becomes apparent. uuid:670c16bf-f657-48ac-82ae-00ac371348f4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28304 biolink:treats MONDO:0005399 PMID:41385096 "[{""id"":""uuid:4cb7c572-e4d2-4bce-9be4-290c6faa2cf2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a399e2c0-1f09-4797-acc4-55cdb395cd8c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Heparin sodium is indicated for: Prophylaxis and treatment of venous thromboembolism and pulmonary embolism; Atrial fibrillation with embolization; Treatment of acute and chronic consumptive coagulopathies (disseminated intravascular coagulation); Prevention of clotting in arterial and cardiac surgery; Prophylaxis and treatment of peripheral arterial embolism; Anticoagulant use in blood transfusions, extracorporeal circulation, and dialysis procedures. uuid:5d715a8d-77dd-46ae-be3e-1c2ce976eae2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16709 biolink:treats MONDO:0004574 PMID:41385096 "[{""id"":""uuid:4c83616c-4710-479d-91ce-c829bea0a94d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c704b498-3fab-47e7-9a84-9e5e2fd6e78a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pyridoxine Hydrochloride Injection is effective for the treatment of pyridoxine deficiency as seen in the following: Inadequate dietary intake. Drug-induced deficiency, as from isoniazid (INH) or oral contraceptives. Inborn errors of metabolism, e.g., vitamin B6 dependent convulsions or vitamin B6 responsive anemia. The parenteral route is indicated when oral administration is not feasible as in anorexia, nausea and vomiting, and preoperative and postoperative conditions. It is also indicated when gastrointestinal absorption is impaired. uuid:9235facd-2bd7-48e3-8fbd-43d28260a35b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16709 biolink:treats MONDO:0015005 PMID:41385096 "[{""id"":""uuid:3590e2ca-cabe-4b07-ad65-76dd34c530fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:29c6ede1-74c7-4351-9aa2-758cb78018b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pyridoxine Hydrochloride Injection is effective for the treatment of pyridoxine deficiency as seen in the following: Inadequate dietary intake. Drug-induced deficiency, as from isoniazid (INH) or oral contraceptives. Inborn errors of metabolism, e.g., vitamin B6 dependent convulsions or vitamin B6 responsive anemia. The parenteral route is indicated when oral administration is not feasible as in anorexia, nausea and vomiting, and preoperative and postoperative conditions. It is also indicated when gastrointestinal absorption is impaired. uuid:7945d9ac-e754-40b3-a3e2-d0a50d2cb3c7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16709 biolink:treats MONDO:0005351 PMID:41385096 "[{""id"":""uuid:f63fb488-c0dc-442a-86a6-267635a9dc55"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:340de55a-e009-47fd-aec7-27f5b32177e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pyridoxine Hydrochloride Injection is effective for the treatment of pyridoxine deficiency as seen in the following: Inadequate dietary intake. Drug-induced deficiency, as from isoniazid (INH) or oral contraceptives. Inborn errors of metabolism, e.g., vitamin B6 dependent convulsions or vitamin B6 responsive anemia. The parenteral route is indicated when oral administration is not feasible as in anorexia, nausea and vomiting, and preoperative and postoperative conditions. It is also indicated when gastrointestinal absorption is impaired. uuid:e96cc78e-0702-47ad-85be-3f71f42ebbb7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16709 biolink:treats HP:0002017 PMID:41385096 "[{""id"":""uuid:a0881c4c-6acd-435e-9c2f-fea0817b750c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8be54584-e427-4d88-af84-e20d554b4f18"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pyridoxine Hydrochloride Injection is effective for the treatment of pyridoxine deficiency as seen in the following: Inadequate dietary intake. Drug-induced deficiency, as from isoniazid (INH) or oral contraceptives. Inborn errors of metabolism, e.g., vitamin B6 dependent convulsions or vitamin B6 responsive anemia. The parenteral route is indicated when oral administration is not feasible as in anorexia, nausea and vomiting, and preoperative and postoperative conditions. It is also indicated when gastrointestinal absorption is impaired. uuid:3d47813d-9769-4b43-aee2-548f73b78e7d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5134 biolink:treats MONDO:0005093 PMID:41385096 "[{""id"":""uuid:7917e23a-f979-444a-934a-3773e499aadf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0995ff74-d031-4591-97aa-548d05032305"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fluticasone propionate ointment is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in adult patients. uuid:c8d463b1-1828-46d0-a375-54657d700b30 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:229226 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:9b7766a6-a501-492f-83ce-9cefa1104161"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6afbbb50-6aa1-4e4e-857a-ee63565c9349"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INPEFA is indicated to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with: heart failure or type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors uuid:35b62848-455d-4bf5-8443-3105b3aea9d9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:229226 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:0d6ab838-c1aa-4401-a7ee-d25fc980c8c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e21b2631-dde0-4443-bb62-2e547ce5bdf5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INPEFA is indicated to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with: heart failure or type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors uuid:c129293f-6a7a-46d6-b237-535962fe8432 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:229226 biolink:treats MONDO:0005300 PMID:41385096 "[{""id"":""uuid:b49f3647-8db1-46af-9243-9784a7b493c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3f1d66ef-e6a0-46f0-9bf8-5e67fcd0c57c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INPEFA is indicated to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with: heart failure or type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors uuid:4c1d1e1c-21cb-465f-a83f-303e1521c490 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2038 biolink:treats MONDO:0011908 PMID:41385096 "[{""id"":""uuid:d081ab7f-9890-40cb-8ed5-ac114510a46f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0f63106d-89c8-408b-a388-05e7d7403acb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VIDAZA is a nucleoside metabolic inhibitor indicated for the treatment of: • Adult patients with the following FAB myelodysplastic syndrome (MDS) subtypes: Refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL). ( 1.1 ) • Pediatric patients aged 1 month and older with newly diagnosed Juvenile Myelomonocytic Leukemia (JMML). ( 1.2 ) uuid:60770384-99a2-426c-8009-6a19e92fedaa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71028 biolink:treats MONDO:0009377 PMID:41385096 "[{""id"":""uuid:534d19b0-f576-4936-bebe-011cf4587309"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f5853d23-a6eb-4327-8c93-760ef097c893"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c2a80a07-b016-4c05-89ba-b7478b18165a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/carbaglu""]},{""id"":""uuid:354f3962-0b2f-4372-a134-80c041f56ff5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CARBAGLU is a carbamoyl phosphate synthetase 1 (CPS 1) activator indicated in pediatric and adult patients as: Adjunctive therapy to standard of care for the treatment of acute hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. ( 1.1 ) Maintenance therapy for the treatment of chronic hyperammonemia due to NAGS deficiency. ( 1.1 ) Adjunctive therapy to standard of care for the treatment of acute hyperammonemia due to propionic acidemia (PA) or methylmalonic acidemia (MMA). ( 1.2 )|[EMA] Carbaglu is indicated in treatment of:hyperammonaemia due to N-acetylglutamate-synthase primary deficiency;hyperammonaemia due to isovaleric acidaemia;hyperammonaemia due to methymalonic acidaemia;hyperammonaemia due to propionic acidaemia.|[PMDA] A drug with a new active ingredient indicated for the treatment of hyperammonemia due to N- acetylglutamate synthetase deficiency, isovaleric acidemia, methylmalonic acidemia, and propionic acidemia. [Orphan drug] uuid:4aa2a716-6169-49dc-af2f-a667a34d9b72 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71028 biolink:treats HP:0001987 PMID:41385096 "[{""id"":""uuid:219bc263-02e3-4c76-888f-893b8a5c3161"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b236290b-72e3-4de4-b531-7de053e4809d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CARBAGLU is a carbamoyl phosphate synthetase 1 (CPS 1) activator indicated in pediatric and adult patients as: Adjunctive therapy to standard of care for the treatment of acute hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. ( 1.1 ) Maintenance therapy for the treatment of chronic hyperammonemia due to NAGS deficiency. ( 1.1 ) Adjunctive therapy to standard of care for the treatment of acute hyperammonemia due to propionic acidemia (PA) or methylmalonic acidemia (MMA). ( 1.2 ) uuid:f3ba11c7-4b77-44be-9cdb-fcf26dd1bf3a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71028 biolink:treats MONDO:0011628 PMID:41385096 "[{""id"":""uuid:125f1f1a-7adb-4c3b-b87b-0141400478d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5ba270aa-49b1-4187-aa57-e4f2348a3f5a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f650f458-2c57-4f2a-9003-ab549c3f8a9b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CARBAGLU is a carbamoyl phosphate synthetase 1 (CPS 1) activator indicated in pediatric and adult patients as: Adjunctive therapy to standard of care for the treatment of acute hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. ( 1.1 ) Maintenance therapy for the treatment of chronic hyperammonemia due to NAGS deficiency. ( 1.1 ) Adjunctive therapy to standard of care for the treatment of acute hyperammonemia due to propionic acidemia (PA) or methylmalonic acidemia (MMA). ( 1.2 )|[PMDA] A drug with a new active ingredient indicated for the treatment of hyperammonemia due to N- acetylglutamate synthetase deficiency, isovaleric acidemia, methylmalonic acidemia, and propionic acidemia. [Orphan drug] uuid:64654cb5-8e54-48e3-9498-d80ff687ade7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71028 biolink:treats MONDO:0002012 PMID:41385096 "[{""id"":""uuid:85bfc683-a815-4577-a4fc-a68568c6b130"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5eb31b9d-604c-4dd5-bdaf-17ca24ec62b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:277f50c2-cf4c-4440-8582-3e1b0f4dc27c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CARBAGLU is a carbamoyl phosphate synthetase 1 (CPS 1) activator indicated in pediatric and adult patients as: Adjunctive therapy to standard of care for the treatment of acute hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. ( 1.1 ) Maintenance therapy for the treatment of chronic hyperammonemia due to NAGS deficiency. ( 1.1 ) Adjunctive therapy to standard of care for the treatment of acute hyperammonemia due to propionic acidemia (PA) or methylmalonic acidemia (MMA). ( 1.2 )|[PMDA] A drug with a new active ingredient indicated for the treatment of hyperammonemia due to N- acetylglutamate synthetase deficiency, isovaleric acidemia, methylmalonic acidemia, and propionic acidemia. [Orphan drug] uuid:bedd587a-65f9-416b-a2ef-14d647b6e5aa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68845 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:56cad6aa-fe50-4180-a5be-ce10d1434a3c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1038d091-60f1-405e-89d2-316fe596d276"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Edarbi is indicated for the treatment of hypertension in adults, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Edarbi. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Edarbi may be used alone or in combination with other antihypertensive agents. uuid:1b9a186b-65b5-49a6-984f-c05a1ca11476 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68845 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:a50183f7-2702-40a3-9dca-779d7c5a3cde"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a40b7ef4-e4f0-499f-ac2a-628f27634c13"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Edarbi is indicated for the treatment of hypertension in adults, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Edarbi. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Edarbi may be used alone or in combination with other antihypertensive agents. uuid:97be7aeb-2953-4cdc-a4ae-f52be328d64f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68845 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:e6c26e83-4a7a-4ad0-b5d9-9ad05ae2ad6f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:68adf8fc-09cb-4319-a9ca-d7be26b33b52"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Edarbi is indicated for the treatment of hypertension in adults, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Edarbi. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Edarbi may be used alone or in combination with other antihypertensive agents. uuid:441ac77b-d35c-4749-b6e4-b5e63e4ce1fb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68845 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:06d2fcbb-ca73-4443-bdbf-e73e70a7241d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a1105286-4f91-481a-98e7-a67ba42ff2e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Edarbi is indicated for the treatment of hypertension in adults, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Edarbi. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Edarbi may be used alone or in combination with other antihypertensive agents. uuid:6ae60261-bfda-48ef-a024-82114414cf54 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68845 biolink:treats MONDO:0005016 PMID:41385096 "[{""id"":""uuid:77716a7a-0572-4eeb-a8d0-844b4be91f24"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1b607589-92aa-42da-8058-00282aceacde"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Edarbi is indicated for the treatment of hypertension in adults, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Edarbi. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Edarbi may be used alone or in combination with other antihypertensive agents. uuid:5bb133d0-1ca0-42a8-b569-3601855cc04f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68845 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:b9d8e13f-be39-4c5f-b114-6cfa08a5a762"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:db7b9a65-1b58-4075-ae2d-cfe5a90f7ef9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Edarbi is indicated for the treatment of hypertension in adults, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Edarbi. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Edarbi may be used alone or in combination with other antihypertensive agents. uuid:dda38dc8-ad03-4cb9-b036-1048adce2c10 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68845 biolink:treats HP:0001681 PMID:41385096 "[{""id"":""uuid:58b49685-d076-4004-ada0-a1b398010dcd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:22681980-4b0c-4e80-88e5-f665680174fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Edarbi is indicated for the treatment of hypertension in adults, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Edarbi. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Edarbi may be used alone or in combination with other antihypertensive agents. uuid:09bd3f0d-9b24-496e-ac81-4abeeff21c0b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68845 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:cbf13b08-6d76-4761-89c6-20ff599c7658"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:87426e6c-9a36-4663-9a87-e82ff582e678"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Edarbi is indicated for the treatment of hypertension in adults, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Edarbi. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Edarbi may be used alone or in combination with other antihypertensive agents. uuid:e6efa9ed-8e86-4779-9b1a-4b23e11813f9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1163417 biolink:treats MONDO:0004872 PMID:41385096 "[{""id"":""uuid:8ffa13ea-f61e-4bda-aeb3-5ac9d61f1858"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d3e94cf5-33fa-479e-813b-9b454baf1d40"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Product is used for the anti-inflammatory and anesthetic relief of itching, pain, soreness and discomfort due to hemorrhoids, anal fissures, pruritus ani and similar conditions of the anal area. uuid:ffc186f7-bba1-4a68-9849-2695f54278da biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1163417 biolink:treats HP:0012390 PMID:41385096 "[{""id"":""uuid:9df2ade0-2d12-4bb1-a17c-b3ef5e50ebce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:387a3705-02ee-48c0-991a-891c8e8d0bf4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Product is used for the anti-inflammatory and anesthetic relief of itching, pain, soreness and discomfort due to hemorrhoids, anal fissures, pruritus ani and similar conditions of the anal area. uuid:844d2ca2-7685-4a9e-ad85-fc7c1360f612 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1163417 biolink:treats UMLS:C0033775 PMID:41385096 "[{""id"":""uuid:3f68b974-dac2-4a38-8547-9c4aec649a12"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:73b1c36d-1653-42ec-ab1f-a84d311dcc3e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Product is used for the anti-inflammatory and anesthetic relief of itching, pain, soreness and discomfort due to hemorrhoids, anal fissures, pruritus ani and similar conditions of the anal area. uuid:8d677728-06d9-4626-9840-7b1206a80177 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3312 biolink:treats HP:0002153 PMID:41385096 "[{""id"":""uuid:08f1e4cc-22f4-4a66-97fb-5f6e89ea3059"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ec8b59e4-9673-45dc-b734-3f2b7829b1a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 10% Calcium Chloride Injection, USP is indicated (1) for the treatment of hypocalcemia in those conditions requiring a prompt increase in blood plasma calcium levels, (2) in the treatment of magnesium intoxication due to overdosage of magnesium sulfate and (3) to combat the deleterious effects of hyperkalemia as measured by electrocardiographic (ECG), pending correction of the increased potassium level in the extracellular fluid. 10% Calcium Chloride Injection, USP also may be used in cardiac resuscitation when weak or inadequate contractions return following defibrillation or when epinephrine injection has failed to strengthen myocardial contractions. uuid:6680e44d-0ea4-48f3-9ee4-dfa7480dd67b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1154831 biolink:treats MONDO:0005271 PMID:41385096 "[{""id"":""uuid:287faab7-f7cc-4dd7-bb0c-025bac4506a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6902b410-1016-4ba5-99f5-17b2c3e815dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Promethazine VC with Codeine Oral Solution is indicated for the temporary relief of coughs and upper respiratory symptoms, including nasal congestion, associated with allergy or the common cold in patients 18 years of age and older. Important Limitations of Use • Not indicated for pediatric patients under 18 years of age [see Use in Specific Populations (8.4)]. • Contraindicated in pediatric patients under 12 years of age [see Contraindications (4) and Use in Specific Populations (8.4)]. • Contraindicated in pediatric patients 12 to 18 years of age after tonsillectomy or adenoidectomy [see Contraindications (4) and Use in Specific Populations (8.4)]. • Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see Warnings and Precautions (5.1)], reserve Promethazine VC with Codeine Oral Solution for use in adult patients for whom the benefits of cough suppression are expected to outweigh the risks,and in whom an adequate assessment of the etiology of the cough has been made. uuid:c27f8975-abd3-49ea-915b-04c8b6ffa776 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1154831 biolink:treats MONDO:0005709 PMID:41385096 "[{""id"":""uuid:58ff4bdf-8849-4521-8d71-2841b89176cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3bed413f-3b55-44c7-8e7b-e0264fe361cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Promethazine VC with Codeine Oral Solution is indicated for the temporary relief of coughs and upper respiratory symptoms, including nasal congestion, associated with allergy or the common cold in patients 18 years of age and older. Important Limitations of Use • Not indicated for pediatric patients under 18 years of age [see Use in Specific Populations (8.4)]. • Contraindicated in pediatric patients under 12 years of age [see Contraindications (4) and Use in Specific Populations (8.4)]. • Contraindicated in pediatric patients 12 to 18 years of age after tonsillectomy or adenoidectomy [see Contraindications (4) and Use in Specific Populations (8.4)]. • Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see Warnings and Precautions (5.1)], reserve Promethazine VC with Codeine Oral Solution for use in adult patients for whom the benefits of cough suppression are expected to outweigh the risks,and in whom an adequate assessment of the etiology of the cough has been made. uuid:25756b23-da33-406f-b42a-db8afcf36717 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1163417 biolink:treats HP:0000989 PMID:41385096 "[{""id"":""uuid:bb251c21-018f-4844-b795-5c2de82830b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4be011ee-d444-4904-a801-de2eb470b821"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Product is used for the anti-inflammatory and anesthetic relief of pruritus, pruritic eczemas, abrasions, minor burns, insect bites, pain, soreness and discomfort due to pruritus ani, pruritus vulvae, hemorrhoids, anal fissures and similar conditions of the skin and mucous membranes. uuid:aaeb5d76-81fb-4a30-8053-a34d0471fb1c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1163417 biolink:treats UMLS:C0332686 PMID:41385096 "[{""id"":""uuid:537dded0-1bfd-4374-9579-44f8f726fe61"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:10548c95-c8a2-4bce-8270-9f040df08ea2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Product is used for the anti-inflammatory and anesthetic relief of pruritus, pruritic eczemas, abrasions, minor burns, insect bites, pain, soreness and discomfort due to pruritus ani, pruritus vulvae, hemorrhoids, anal fissures and similar conditions of the skin and mucous membranes. uuid:7260d608-70e8-4301-bf73-8f54806d54f0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1163417 biolink:treats UMLS:C0021564 PMID:41385096 "[{""id"":""uuid:78052307-3346-4ce0-8d4f-46f96023cfb8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:caf9a0ab-ac4d-4c09-870b-10e6150f51b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Product is used for the anti-inflammatory and anesthetic relief of pruritus, pruritic eczemas, abrasions, minor burns, insect bites, pain, soreness and discomfort due to pruritus ani, pruritus vulvae, hemorrhoids, anal fissures and similar conditions of the skin and mucous membranes. uuid:de4f367f-e3c4-4d85-b3b5-60f73a2911cf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1163417 biolink:treats HP:0032004 PMID:41385096 "[{""id"":""uuid:7b64cbe8-637d-4c52-b7d8-1d45a9552c80"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f5573685-3f0c-4cdc-b78d-2cf27188f2c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Product is used for the anti-inflammatory and anesthetic relief of pruritus, pruritic eczemas, abrasions, minor burns, insect bites, pain, soreness and discomfort due to pruritus ani, pruritus vulvae, hemorrhoids, anal fissures and similar conditions of the skin and mucous membranes. uuid:eeccfb7f-f7e9-4c13-b10a-8c3a48157f8f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71193 biolink:treats MONDO:0011122 PMID:41385096 "[{""id"":""uuid:458dbbbb-bd65-40ac-b28d-e4235d303aa0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:9d195bc0-4abd-46ec-a232-cfead10fcf2e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:092161f5-7d81-4c3c-bd62-288572edc31a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/saxenda""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] SAXENDA is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in: • Adult patients with an initial body mass index (BMI) of [see Dosage and Administration ( 2.1 )] : ▪ 30 kg/m 2 or greater (obese), or ▪ 27 kg/m 2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia) • Pediatric patients aged 12 years and older with: ▪ body weight above 60 kg and ▪ an initial BMI corresponding to 30 kg/m 2 or greater for adults (obese) by international cut-offs (Cole Criteria, Table 2) [see Dosage and Administration ( 2.1 )] Limitations of Use ▪ SAXENDA contains liraglutide and should not be coadministered with other liraglutide-containing products or with any other GLP-1 receptor agonist. ▪ The safety and effectiveness of SAXENDA in pediatric patients with type 2 diabetes have not been established. ▪ The safety and effectiveness of SAXENDA in combination with other products intended for weight loss, including prescription drugs, over-the-counter drugs, and herbal preparations, have not been established.|[EMA] Saxenda is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial Body Mass Index (BMI) of• ≥ 30 kg/m² (obese), or• ≥ 27 kg/m² to < 30 kg/m² (overweight) in the presence of at least one weight-related comorbidity such as dysglycaemia (pre-diabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia or obstructive sleep apnoea.Treatment with Saxenda should be discontinued after 12 weeks on the 3.0 mg/day dose if patients have not lost at least 5% of their initial body weight. uuid:e7860911-9870-4f34-95a9-3a0a8df0e11f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71193 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:ded66d96-9a8d-43f2-9d0f-040d76633439"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e5980e91-7197-4e4a-bf34-3728bacc17ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SAXENDA is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in: • Adult patients with an initial body mass index (BMI) of [see Dosage and Administration ( 2.1 )] : ▪ 30 kg/m 2 or greater (obese), or ▪ 27 kg/m 2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia) • Pediatric patients aged 12 years and older with: ▪ body weight above 60 kg and ▪ an initial BMI corresponding to 30 kg/m 2 or greater for adults (obese) by international cut-offs (Cole Criteria, Table 2) [see Dosage and Administration ( 2.1 )] Limitations of Use ▪ SAXENDA contains liraglutide and should not be coadministered with other liraglutide-containing products or with any other GLP-1 receptor agonist. ▪ The safety and effectiveness of SAXENDA in pediatric patients with type 2 diabetes have not been established. ▪ The safety and effectiveness of SAXENDA in combination with other products intended for weight loss, including prescription drugs, over-the-counter drugs, and herbal preparations, have not been established. uuid:58f25e9a-09c2-42a5-b3b9-e57e6c943bc0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71193 biolink:treats HP:0003119 PMID:41385096 "[{""id"":""uuid:e9f352eb-af43-41a5-9795-2ffd82abb900"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:ca0e712d-9feb-403e-9a5b-f6e2f79015e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:3f7ee0e7-1c63-431d-a17b-1506971cc31b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/saxenda""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] SAXENDA is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in: • Adult patients with an initial body mass index (BMI) of [see Dosage and Administration ( 2.1 )] : ▪ 30 kg/m 2 or greater (obese), or ▪ 27 kg/m 2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia) • Pediatric patients aged 12 years and older with: ▪ body weight above 60 kg and ▪ an initial BMI corresponding to 30 kg/m 2 or greater for adults (obese) by international cut-offs (Cole Criteria, Table 2) [see Dosage and Administration ( 2.1 )] Limitations of Use ▪ SAXENDA contains liraglutide and should not be coadministered with other liraglutide-containing products or with any other GLP-1 receptor agonist. ▪ The safety and effectiveness of SAXENDA in pediatric patients with type 2 diabetes have not been established. ▪ The safety and effectiveness of SAXENDA in combination with other products intended for weight loss, including prescription drugs, over-the-counter drugs, and herbal preparations, have not been established.|[EMA] Saxenda is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial Body Mass Index (BMI) of• ≥ 30 kg/m² (obese), or• ≥ 27 kg/m² to < 30 kg/m² (overweight) in the presence of at least one weight-related comorbidity such as dysglycaemia (pre-diabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia or obstructive sleep apnoea.Treatment with Saxenda should be discontinued after 12 weeks on the 3.0 mg/day dose if patients have not lost at least 5% of their initial body weight. uuid:97253012-7b5f-44e2-8c08-1ef0a8840d56 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB09106 biolink:treats HP:0011106 PMID:41385096 "[{""id"":""uuid:51bdf178-2b5a-4083-b4b0-3e8889444c53"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8b967b12-27e9-471a-953a-9025e2c4f91e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 6% Hetastarch in 0.9% Sodium Chloride Injection is indicated in the treatment of hypovolemia when plasma volume expansion is desired. It is not a substitute for blood or plasma. The adjunctive use of 6% Hetastarch in 0.9% Sodium Chloride Injection in leukapheresis has also been shown to be safe and efficacious in improving the harvesting and increasing the yield of granulocytes by centrifugal means. uuid:c899e488-2a70-4505-9276-155bbf0ae34f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63635 biolink:treats MONDO:0000878 PMID:41385096 "[{""id"":""uuid:1e56e1bc-0730-4c86-af7b-58fb8d2981fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fc67f6cf-aaeb-43b9-b291-9431643b987a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Valganciclovir hydrochloride is a deoxynucleoside analogue cytomegalovirus (CMV) DNA polymerase inhibitor indicated for: Adult Patients (1.1) • Treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS). • Prevention of CMV disease in kidney, heart, and kidney-pancreas transplant patients at high risk. Pediatric Patients (1.2) • Prevention of CMV disease in kidney and heart transplant patients at high risk. uuid:1581453c-960c-4cb0-b574-416aab3259bb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63635 biolink:treats MONDO:0012268 PMID:41385096 "[{""id"":""uuid:11827f5e-e82a-422b-8fad-e359d58a700b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3c22a87a-cc21-4463-8c83-5e757ee04218"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:deecd07f-7926-4c33-a679-409d465f7c49"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Valganciclovir hydrochloride is a deoxynucleoside analogue cytomegalovirus (CMV) DNA polymerase inhibitor indicated for: Adult Patients (1.1) • Treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS). • Prevention of CMV disease in kidney, heart, and kidney-pancreas transplant patients at high risk. Pediatric Patients (1.2) • Prevention of CMV disease in kidney and heart transplant patients at high risk.|[PMDA] A drug containing a new active ingredient, L- valine ester of ganciclovir, with indications for treatment of retinitis caused by cytomegalovirus in patients with acquired immune deficiency syndrome (AIDS) and dosage regimen. uuid:160c4e5f-ccc2-4bc4-9dc1-5729d6c4fad3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63635 biolink:treats MONDO:0005132 PMID:41385096 "[{""id"":""uuid:6aaa23d8-4058-452f-9088-3440d5942bfb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:504f6518-4926-4133-83c0-9c2786cd4d19"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:75a6f412-935d-4b8b-a8fb-642051218a0e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Valganciclovir hydrochloride is a deoxynucleoside analogue cytomegalovirus (CMV) DNA polymerase inhibitor indicated for: Adult Patients (1.1) • Treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS). • Prevention of CMV disease in kidney, heart, and kidney-pancreas transplant patients at high risk. Pediatric Patients (1.2) • Prevention of CMV disease in kidney and heart transplant patients at high risk.|[PMDA] A drug with a new additional indication and a new dosage for the prevention of cytomegalovirus disease in organ transplant patients (excluding hematopoietic stem cell transplantation). [Public knowledge-based application after PAFSC's preliminary assessment] uuid:c3f27920-4383-4d6c-bf64-a28ce34e5bb4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1422082 biolink:treats HP:0003124 PMID:41385096 "[{""id"":""uuid:763a67b3-733a-458c-a8eb-e60f39ce03cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:22004993-704d-4818-86f1-96a3266571c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c8762249-539c-4fd6-bebb-0df2fb153c08"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate.|[PMDA] New combination drugs indicated for the treatment of hypercholesterolemia and familial hypercholesterolemia. uuid:43201586-b079-4b88-8560-ec9d6224bf19 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1422082 biolink:treats MONDO:0005311 PMID:41385096 "[{""id"":""uuid:45e25d5c-714e-48ee-8809-a9c2580c05f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c0641bf1-b8ee-4f9a-bcd2-bbd51e238096"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. uuid:b1fdf351-4b83-4bc7-ad7d-45fede5a3a30 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0017767 PMID:41385096 "[{""id"":""uuid:06f0151e-adea-4805-9d75-5ca0b38f394b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bc2b0329-eb06-47ad-b2f0-8c35e9306a5e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Doxycycline for Injection, USP and other antibacterial drugs, Doxycycline for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline for Injection, USP is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever, and the typhus group, Q fever, rickettsial pox and tick fevers). Mycoplasma pneumoniae (PPLO, Eaton Agent). Agents of psittacosis and ornithosis. Agents of lymphogranuloma venereum and granuloma inguinale. The spirochetal agent of relapsing fever (Borrelia recurrentis). The following gram-negative microorganisms: Haemophilus ducreyi (chancroid). Yersinia pestis (formerly Pasteurella pestis) and Francisella tularensis (formerly Pasteurella tularensis). Bartonella bacilliformis. Bacteroides species. Vibrio cholerae (formerly Vibrio comma) and Campylobacter fetus (formerly Vibrio fetus). Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Enterobacter aerogenes (formerly Aerobacter aerogenes). Shigella species. Acinetobacter species (formerly Mima species and Herellea species). Haemophilus influenzae (respiratory infections). Klebsiella species (respiratory and urinary infections). Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Enterococcus faecalis (formerly Streptococcus faecalis) have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Streptococcus pneumoniae (formerly Diplococcus pneumoniae). Staphylococcus aureus, respiratory, skin and soft tissue infections. Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections. Anthrax due to Bacillus anthracis, including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of infections due to: Neisseria gonorrhoeae and N. meningitidis. Treponema pallidum and Treponema pertenue (syphilis and yaws). Listeria monocytogenes. Clostridium species. Fusobacterium fusiforme (Vincent's infection). Actinomyces species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. Doxycycline is indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. uuid:44ccfa17-fe5d-4685-bc0f-128fdf26e967 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135961 biolink:treats MONDO:0008315 PMID:41385096 "[{""id"":""uuid:17d1188c-b3b7-4991-b4f2-7ac65228556f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:cfe6d47d-acdd-4617-bd52-465cae68ec45"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c76d87a6-cacc-4ea1-a76c-276b9ba65eee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:45a9687b-fb40-4006-b0d5-889aaeaf9530"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FIRMAGON ® is indicated for treatment of patients with advanced prostate cancer.|[EMA] Degarelix Accord is a gonadotrophin releasing hormone (GnRH) antagonist indicated:for treatment of adult male patients with advanced hormone-dependent prostate cancer.for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy.as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.|[PMDA] Drugs with a new active ingredient indicated for the treatment of prostate cancer. uuid:4d75af1f-4f9f-4eb8-8224-63499e9c5fbb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1235141 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:e7693ea5-c884-4a8e-898e-10f9917e15f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:35a7b0c5-3d17-42fb-8d16-6c34e172252f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Edarbyclor is indicated for the treatment of hypertension, to lower blood pressure. Edarbyclor may be used in patients whose blood pressure is not adequately controlled on monotherapy. Edarbyclor may be used as initial therapy if a patient is likely to need multiple drugs to achieve blood pressure goals. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including thiazide-like diuretics such as chlorthalidone and ARBs such as azilsartan medoxomil. There are no controlled trials demonstrating risk reduction with Edarbyclor. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management of high blood pressure, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients; however, the blood pressure effect of Edarbyclor in blacks is similar to that in non-blacks. Many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. The choice of Edarbyclor as initial therapy for hypertension should be based on an assessment of potential benefits and risks including whether the patient is likely to tolerate the starting dose of Edarbyclor. Patients with moderate-to-severe hypertension are at a relatively high risk of cardiovascular events (e.g., stroke, heart attack, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. Consider the patient's baseline blood pressure, target goal and the incremental likelihood of achieving the goal with a combination product, such as Edarbyclor, versus a monotherapy product when deciding upon initial therapy. Individual blood pressure goals may vary based on the patient's risk. Data from an 8-week, active-controlled, factorial trial provide estimates of the probability of reaching a target blood pressure with Edarbyclor compared with azilsartan medoxomil or chlorthalidone monotherapy [see Clinical Studies (14) ] . Figures 1.a-1.d provide estimates of the likelihood of achieving target clinic systolic and diastolic blood pressure control with Edarbyclor 40/25 mg tablets after 8 weeks, based on baseline systolic or diastolic blood pressure. The curve for each treatment group was estimated by logistic regression modeling and is more variable at the tails. Figure 1.a Probability of Achieving Systolic Blood Pressure <140 mmHg at Week 8 Figure 1.b Probability of Achieving Systolic Blood Pressure <130 mmHg at Week 8 Figure 1.c Probability of Achieving Diastolic Blood Pressure <90 mmHg at Week 8 Figure 1.d Probability of Achieving Diastolic Blood Pressure <80 mmHg at Week 8 For example, a patient with a baseline blood pressure of 170/105 mm Hg has approximately a 48% likelihood of achieving a goal of <140 mm Hg (systolic) and 48% likelihood of achieving <90 mm Hg (diastolic) on azilsartan medoxomil 80 mg. The likelihood of achieving these same goals on chlorthalidone 25 mg is approximately 51% (systolic) and 40% (diastolic). These likelihoods rise to 85% (systolic) and 85% (diastolic) with Edarbyclor 40/25 mg. uuid:b30c1545-68f8-4efa-87d5-14f2f0550166 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1235141 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:6890d66b-8075-4d64-9e03-42e9d9560c38"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:297d9fe5-b94a-4424-9c34-7aedb232d2f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Edarbyclor is indicated for the treatment of hypertension, to lower blood pressure. Edarbyclor may be used in patients whose blood pressure is not adequately controlled on monotherapy. Edarbyclor may be used as initial therapy if a patient is likely to need multiple drugs to achieve blood pressure goals. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including thiazide-like diuretics such as chlorthalidone and ARBs such as azilsartan medoxomil. There are no controlled trials demonstrating risk reduction with Edarbyclor. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management of high blood pressure, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients; however, the blood pressure effect of Edarbyclor in blacks is similar to that in non-blacks. Many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. The choice of Edarbyclor as initial therapy for hypertension should be based on an assessment of potential benefits and risks including whether the patient is likely to tolerate the starting dose of Edarbyclor. Patients with moderate-to-severe hypertension are at a relatively high risk of cardiovascular events (e.g., stroke, heart attack, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. Consider the patient's baseline blood pressure, target goal and the incremental likelihood of achieving the goal with a combination product, such as Edarbyclor, versus a monotherapy product when deciding upon initial therapy. Individual blood pressure goals may vary based on the patient's risk. Data from an 8-week, active-controlled, factorial trial provide estimates of the probability of reaching a target blood pressure with Edarbyclor compared with azilsartan medoxomil or chlorthalidone monotherapy [see Clinical Studies (14) ] . Figures 1.a-1.d provide estimates of the likelihood of achieving target clinic systolic and diastolic blood pressure control with Edarbyclor 40/25 mg tablets after 8 weeks, based on baseline systolic or diastolic blood pressure. The curve for each treatment group was estimated by logistic regression modeling and is more variable at the tails. Figure 1.a Probability of Achieving Systolic Blood Pressure <140 mmHg at Week 8 Figure 1.b Probability of Achieving Systolic Blood Pressure <130 mmHg at Week 8 Figure 1.c Probability of Achieving Diastolic Blood Pressure <90 mmHg at Week 8 Figure 1.d Probability of Achieving Diastolic Blood Pressure <80 mmHg at Week 8 For example, a patient with a baseline blood pressure of 170/105 mm Hg has approximately a 48% likelihood of achieving a goal of <140 mm Hg (systolic) and 48% likelihood of achieving <90 mm Hg (diastolic) on azilsartan medoxomil 80 mg. The likelihood of achieving these same goals on chlorthalidone 25 mg is approximately 51% (systolic) and 40% (diastolic). These likelihoods rise to 85% (systolic) and 85% (diastolic) with Edarbyclor 40/25 mg. uuid:27fc4d90-227b-4c8c-8a8a-e310cc79c8de biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1235141 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:aa82414d-77fd-42af-b045-ec7f0cfbec0d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f3dd35a9-2416-4171-a2fb-7eed6040a781"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Edarbyclor is indicated for the treatment of hypertension, to lower blood pressure. Edarbyclor may be used in patients whose blood pressure is not adequately controlled on monotherapy. Edarbyclor may be used as initial therapy if a patient is likely to need multiple drugs to achieve blood pressure goals. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including thiazide-like diuretics such as chlorthalidone and ARBs such as azilsartan medoxomil. There are no controlled trials demonstrating risk reduction with Edarbyclor. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management of high blood pressure, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients; however, the blood pressure effect of Edarbyclor in blacks is similar to that in non-blacks. Many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. The choice of Edarbyclor as initial therapy for hypertension should be based on an assessment of potential benefits and risks including whether the patient is likely to tolerate the starting dose of Edarbyclor. Patients with moderate-to-severe hypertension are at a relatively high risk of cardiovascular events (e.g., stroke, heart attack, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. Consider the patient's baseline blood pressure, target goal and the incremental likelihood of achieving the goal with a combination product, such as Edarbyclor, versus a monotherapy product when deciding upon initial therapy. Individual blood pressure goals may vary based on the patient's risk. Data from an 8-week, active-controlled, factorial trial provide estimates of the probability of reaching a target blood pressure with Edarbyclor compared with azilsartan medoxomil or chlorthalidone monotherapy [see Clinical Studies (14) ] . Figures 1.a-1.d provide estimates of the likelihood of achieving target clinic systolic and diastolic blood pressure control with Edarbyclor 40/25 mg tablets after 8 weeks, based on baseline systolic or diastolic blood pressure. The curve for each treatment group was estimated by logistic regression modeling and is more variable at the tails. Figure 1.a Probability of Achieving Systolic Blood Pressure <140 mmHg at Week 8 Figure 1.b Probability of Achieving Systolic Blood Pressure <130 mmHg at Week 8 Figure 1.c Probability of Achieving Diastolic Blood Pressure <90 mmHg at Week 8 Figure 1.d Probability of Achieving Diastolic Blood Pressure <80 mmHg at Week 8 For example, a patient with a baseline blood pressure of 170/105 mm Hg has approximately a 48% likelihood of achieving a goal of <140 mm Hg (systolic) and 48% likelihood of achieving <90 mm Hg (diastolic) on azilsartan medoxomil 80 mg. The likelihood of achieving these same goals on chlorthalidone 25 mg is approximately 51% (systolic) and 40% (diastolic). These likelihoods rise to 85% (systolic) and 85% (diastolic) with Edarbyclor 40/25 mg. uuid:a23a230f-79f8-489b-80b2-2a1de77f1048 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1235141 biolink:treats HP:0001681 PMID:41385096 "[{""id"":""uuid:cf3f2626-043b-4207-a6ab-178fd0fa3e7e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:33be8b0d-b10b-48d8-9bc1-46814f9c1b27"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Edarbyclor is indicated for the treatment of hypertension, to lower blood pressure. Edarbyclor may be used in patients whose blood pressure is not adequately controlled on monotherapy. Edarbyclor may be used as initial therapy if a patient is likely to need multiple drugs to achieve blood pressure goals. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including thiazide-like diuretics such as chlorthalidone and ARBs such as azilsartan medoxomil. There are no controlled trials demonstrating risk reduction with Edarbyclor. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management of high blood pressure, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients; however, the blood pressure effect of Edarbyclor in blacks is similar to that in non-blacks. Many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. The choice of Edarbyclor as initial therapy for hypertension should be based on an assessment of potential benefits and risks including whether the patient is likely to tolerate the starting dose of Edarbyclor. Patients with moderate-to-severe hypertension are at a relatively high risk of cardiovascular events (e.g., stroke, heart attack, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. Consider the patient's baseline blood pressure, target goal and the incremental likelihood of achieving the goal with a combination product, such as Edarbyclor, versus a monotherapy product when deciding upon initial therapy. Individual blood pressure goals may vary based on the patient's risk. Data from an 8-week, active-controlled, factorial trial provide estimates of the probability of reaching a target blood pressure with Edarbyclor compared with azilsartan medoxomil or chlorthalidone monotherapy [see Clinical Studies (14) ] . Figures 1.a-1.d provide estimates of the likelihood of achieving target clinic systolic and diastolic blood pressure control with Edarbyclor 40/25 mg tablets after 8 weeks, based on baseline systolic or diastolic blood pressure. The curve for each treatment group was estimated by logistic regression modeling and is more variable at the tails. Figure 1.a Probability of Achieving Systolic Blood Pressure <140 mmHg at Week 8 Figure 1.b Probability of Achieving Systolic Blood Pressure <130 mmHg at Week 8 Figure 1.c Probability of Achieving Diastolic Blood Pressure <90 mmHg at Week 8 Figure 1.d Probability of Achieving Diastolic Blood Pressure <80 mmHg at Week 8 For example, a patient with a baseline blood pressure of 170/105 mm Hg has approximately a 48% likelihood of achieving a goal of <140 mm Hg (systolic) and 48% likelihood of achieving <90 mm Hg (diastolic) on azilsartan medoxomil 80 mg. The likelihood of achieving these same goals on chlorthalidone 25 mg is approximately 51% (systolic) and 40% (diastolic). These likelihoods rise to 85% (systolic) and 85% (diastolic) with Edarbyclor 40/25 mg. uuid:3f24a703-a4dc-4ad3-836e-ebba2a824336 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1235141 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:9171b194-d6b0-43c1-acb5-2748428415a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:493a90a6-f7f4-4f0f-a5b1-f57cee72a567"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Edarbyclor is indicated for the treatment of hypertension, to lower blood pressure. Edarbyclor may be used in patients whose blood pressure is not adequately controlled on monotherapy. Edarbyclor may be used as initial therapy if a patient is likely to need multiple drugs to achieve blood pressure goals. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including thiazide-like diuretics such as chlorthalidone and ARBs such as azilsartan medoxomil. There are no controlled trials demonstrating risk reduction with Edarbyclor. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management of high blood pressure, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients; however, the blood pressure effect of Edarbyclor in blacks is similar to that in non-blacks. Many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. The choice of Edarbyclor as initial therapy for hypertension should be based on an assessment of potential benefits and risks including whether the patient is likely to tolerate the starting dose of Edarbyclor. Patients with moderate-to-severe hypertension are at a relatively high risk of cardiovascular events (e.g., stroke, heart attack, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. Consider the patient's baseline blood pressure, target goal and the incremental likelihood of achieving the goal with a combination product, such as Edarbyclor, versus a monotherapy product when deciding upon initial therapy. Individual blood pressure goals may vary based on the patient's risk. Data from an 8-week, active-controlled, factorial trial provide estimates of the probability of reaching a target blood pressure with Edarbyclor compared with azilsartan medoxomil or chlorthalidone monotherapy [see Clinical Studies (14) ] . Figures 1.a-1.d provide estimates of the likelihood of achieving target clinic systolic and diastolic blood pressure control with Edarbyclor 40/25 mg tablets after 8 weeks, based on baseline systolic or diastolic blood pressure. The curve for each treatment group was estimated by logistic regression modeling and is more variable at the tails. Figure 1.a Probability of Achieving Systolic Blood Pressure <140 mmHg at Week 8 Figure 1.b Probability of Achieving Systolic Blood Pressure <130 mmHg at Week 8 Figure 1.c Probability of Achieving Diastolic Blood Pressure <90 mmHg at Week 8 Figure 1.d Probability of Achieving Diastolic Blood Pressure <80 mmHg at Week 8 For example, a patient with a baseline blood pressure of 170/105 mm Hg has approximately a 48% likelihood of achieving a goal of <140 mm Hg (systolic) and 48% likelihood of achieving <90 mm Hg (diastolic) on azilsartan medoxomil 80 mg. The likelihood of achieving these same goals on chlorthalidone 25 mg is approximately 51% (systolic) and 40% (diastolic). These likelihoods rise to 85% (systolic) and 85% (diastolic) with Edarbyclor 40/25 mg. uuid:d9153239-eda8-473d-aa19-21a4a9534f99 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1235141 biolink:treats MONDO:0005016 PMID:41385096 "[{""id"":""uuid:0b0edb5d-1fba-48db-9249-a29cb74b9750"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b42a1670-12da-432c-b7cf-3c534558a251"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Edarbyclor is indicated for the treatment of hypertension, to lower blood pressure. Edarbyclor may be used in patients whose blood pressure is not adequately controlled on monotherapy. Edarbyclor may be used as initial therapy if a patient is likely to need multiple drugs to achieve blood pressure goals. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including thiazide-like diuretics such as chlorthalidone and ARBs such as azilsartan medoxomil. There are no controlled trials demonstrating risk reduction with Edarbyclor. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management of high blood pressure, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients; however, the blood pressure effect of Edarbyclor in blacks is similar to that in non-blacks. Many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. The choice of Edarbyclor as initial therapy for hypertension should be based on an assessment of potential benefits and risks including whether the patient is likely to tolerate the starting dose of Edarbyclor. Patients with moderate-to-severe hypertension are at a relatively high risk of cardiovascular events (e.g., stroke, heart attack, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. Consider the patient's baseline blood pressure, target goal and the incremental likelihood of achieving the goal with a combination product, such as Edarbyclor, versus a monotherapy product when deciding upon initial therapy. Individual blood pressure goals may vary based on the patient's risk. Data from an 8-week, active-controlled, factorial trial provide estimates of the probability of reaching a target blood pressure with Edarbyclor compared with azilsartan medoxomil or chlorthalidone monotherapy [see Clinical Studies (14) ] . Figures 1.a-1.d provide estimates of the likelihood of achieving target clinic systolic and diastolic blood pressure control with Edarbyclor 40/25 mg tablets after 8 weeks, based on baseline systolic or diastolic blood pressure. The curve for each treatment group was estimated by logistic regression modeling and is more variable at the tails. Figure 1.a Probability of Achieving Systolic Blood Pressure <140 mmHg at Week 8 Figure 1.b Probability of Achieving Systolic Blood Pressure <130 mmHg at Week 8 Figure 1.c Probability of Achieving Diastolic Blood Pressure <90 mmHg at Week 8 Figure 1.d Probability of Achieving Diastolic Blood Pressure <80 mmHg at Week 8 For example, a patient with a baseline blood pressure of 170/105 mm Hg has approximately a 48% likelihood of achieving a goal of <140 mm Hg (systolic) and 48% likelihood of achieving <90 mm Hg (diastolic) on azilsartan medoxomil 80 mg. The likelihood of achieving these same goals on chlorthalidone 25 mg is approximately 51% (systolic) and 40% (diastolic). These likelihoods rise to 85% (systolic) and 85% (diastolic) with Edarbyclor 40/25 mg. uuid:59193bf1-8081-45df-868a-3df78b0807cf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1235141 biolink:treats MONDO:0001106 PMID:41385096 "[{""id"":""uuid:d66763ed-4f52-41b8-a013-72d991872437"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7633d99b-52fa-42e3-b298-a62b9e3f2838"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Edarbyclor is indicated for the treatment of hypertension, to lower blood pressure. Edarbyclor may be used in patients whose blood pressure is not adequately controlled on monotherapy. Edarbyclor may be used as initial therapy if a patient is likely to need multiple drugs to achieve blood pressure goals. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including thiazide-like diuretics such as chlorthalidone and ARBs such as azilsartan medoxomil. There are no controlled trials demonstrating risk reduction with Edarbyclor. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management of high blood pressure, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients; however, the blood pressure effect of Edarbyclor in blacks is similar to that in non-blacks. Many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. The choice of Edarbyclor as initial therapy for hypertension should be based on an assessment of potential benefits and risks including whether the patient is likely to tolerate the starting dose of Edarbyclor. Patients with moderate-to-severe hypertension are at a relatively high risk of cardiovascular events (e.g., stroke, heart attack, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. Consider the patient's baseline blood pressure, target goal and the incremental likelihood of achieving the goal with a combination product, such as Edarbyclor, versus a monotherapy product when deciding upon initial therapy. Individual blood pressure goals may vary based on the patient's risk. Data from an 8-week, active-controlled, factorial trial provide estimates of the probability of reaching a target blood pressure with Edarbyclor compared with azilsartan medoxomil or chlorthalidone monotherapy [see Clinical Studies (14) ] . Figures 1.a-1.d provide estimates of the likelihood of achieving target clinic systolic and diastolic blood pressure control with Edarbyclor 40/25 mg tablets after 8 weeks, based on baseline systolic or diastolic blood pressure. The curve for each treatment group was estimated by logistic regression modeling and is more variable at the tails. Figure 1.a Probability of Achieving Systolic Blood Pressure <140 mmHg at Week 8 Figure 1.b Probability of Achieving Systolic Blood Pressure <130 mmHg at Week 8 Figure 1.c Probability of Achieving Diastolic Blood Pressure <90 mmHg at Week 8 Figure 1.d Probability of Achieving Diastolic Blood Pressure <80 mmHg at Week 8 For example, a patient with a baseline blood pressure of 170/105 mm Hg has approximately a 48% likelihood of achieving a goal of <140 mm Hg (systolic) and 48% likelihood of achieving <90 mm Hg (diastolic) on azilsartan medoxomil 80 mg. The likelihood of achieving these same goals on chlorthalidone 25 mg is approximately 51% (systolic) and 40% (diastolic). These likelihoods rise to 85% (systolic) and 85% (diastolic) with Edarbyclor 40/25 mg. uuid:fb63ed8d-b00e-43f2-ab9b-6f1e3a1755e9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22652 biolink:treats MONDO:0002280 PMID:41385096 "[{""id"":""uuid:f0ef6763-7f19-4031-bde8-5735069abad8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:424265bc-65b4-4113-bdcf-93353eec7714"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the treatment of anemia due to lack of iron and low folate as in menorrhagia, pregnancy, puberty, excessive blood loss, and advanced age. Also for treatment of conditions where iron and vitamin C deficiency occur together, along with a poor intake or increased need for B-complex vitamins in chronic and acute illness, as well as cases of metabolic stress, and in periods of extended recovery. uuid:aed1d173-6770-4f7b-8b63-fdb8a0be233c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17561 biolink:treats UMLS:C5707743 PMID:41385096 "[{""id"":""uuid:f675e203-3ad7-4652-b137-154037b745d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b287a633-0df8-4865-b5b4-891569ab2d7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ELCYS ® is indicated for use as an additive to amino acid solutions to meet the nutritional requirements of newborn infants requiring total parenteral nutrition (TPN); and of adult and pediatric patients with severe liver disease who may have impaired enzymatic processes and require TPN. It can also be added to amino acid solutions to provide a more complete profile of amino acids for protein synthesis. uuid:38a78745-b0a9-4fcf-b874-42f73a0fd18c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6444 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:01d5fef3-99f4-4f36-8663-80cb35167a32"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:57636ea2-f461-4c9d-9d0a-83f51648a9c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levorphanol tartrate tablets are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, and misuse, with opioids, which can occur at any dosage or duration [see WARNINGS ] , reserve levorphanol tartrate tablets for use in patients for whom alternative treatment options [e.g., non-opioid analgesics]: • Have not been tolerated or are not expected to be tolerated, • Have not provided adequate analgesia or are not expected to provide adequate analgesia Levorphanol tartrate tablets should not be used for an extended period of time unless the pain remains severe enough to require an opioid analgesic and for which alternative treatment options continue to be inadequate. uuid:e966c9be-7efa-47af-af54-4791cab7a2f7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17439 biolink:treats MONDO:0011786 PMID:41385096 "[{""id"":""uuid:8677861f-78b5-4c34-bc35-00e8bfafbe09"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9abf2a83-78cc-42bb-acc1-abb1746caadb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cyanocobalamin Nasal Spray is indicated for: Vitamin B12 maintenance therapy in adult patients with pernicious anemia who are in remission following intramuscular vitamin B12 therapy and who have no nervous system involvement Treatment of adult patients with dietary, drug-induced, or malabsorption-related vitamin B12 deficiency not due to pernicious anemia Prevention of vitamin B12 deficiency in adult patients with vitamin B12 requirements in excess of normal Limitations of Use: Cyanocobalamin Nasal Spray should not be used for the vitamin B12 absorption test (Schilling test). In patients with correctible or temporary causes of vitamin B12 deficiency, the benefit of continued long term use of Cyanocobalamin Nasal Spray following adequate correction of vitamin B12 deficiency and underlying disease has not been established. The effectiveness of Cyanocobalamin Nasal Spray in patients with active symptoms of nasal congestion, allergic rhinitis or upper respiratory infection has not been determined. Treatment with Cyanocobalamin Nasal Spray should be deferred until symptoms have subsided. uuid:c8b64c09-c3b9-4206-b1e1-be1ea4bc0ebd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17439 biolink:treats UMLS:C0041912 PMID:41385096 "[{""id"":""uuid:7e25de04-512b-42b4-be81-467990e91c77"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5cfa09d1-cbad-44b7-8f57-842570a68b9c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cyanocobalamin Nasal Spray is indicated for: Vitamin B12 maintenance therapy in adult patients with pernicious anemia who are in remission following intramuscular vitamin B12 therapy and who have no nervous system involvement Treatment of adult patients with dietary, drug-induced, or malabsorption-related vitamin B12 deficiency not due to pernicious anemia Prevention of vitamin B12 deficiency in adult patients with vitamin B12 requirements in excess of normal Limitations of Use: Cyanocobalamin Nasal Spray should not be used for the vitamin B12 absorption test (Schilling test). In patients with correctible or temporary causes of vitamin B12 deficiency, the benefit of continued long term use of Cyanocobalamin Nasal Spray following adequate correction of vitamin B12 deficiency and underlying disease has not been established. The effectiveness of Cyanocobalamin Nasal Spray in patients with active symptoms of nasal congestion, allergic rhinitis or upper respiratory infection has not been determined. Treatment with Cyanocobalamin Nasal Spray should be deferred until symptoms have subsided. uuid:2dae0ea1-876d-4175-9319-0ab48d1c7ff8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0015129 PMID:41385096 "[{""id"":""uuid:a323aa36-06ae-4ba6-ab05-da81c2df521b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fb376e7c-822d-4299-8b60-9d9c09e0ec5b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PEDIAPRED ​® is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under “Allergic States”), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren’s syndrome, relapsing polychondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents). uuid:410fe138-30ef-42a5-bb93-2c8272b89baa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0043370 PMID:41385096 "[{""id"":""uuid:b1c0b4e3-0e5c-4cbc-ae99-b1baef928f2f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3bcbe876-2339-4fde-a281-c0e1980e2830"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PEDIAPRED ​® is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under “Allergic States”), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren’s syndrome, relapsing polychondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents). uuid:2d9d9414-0858-4985-b2e2-e113cd8d897e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8389 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:24ed5bbd-73bf-415b-8f43-1ec977cb1153"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:70e3c5a7-515b-4221-aca2-fc2828e61022"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PREMARIN is a mixture of estrogens indicated for: • Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause ( 1.1 ) • Treatment of Moderate to Severe Vulvar and Vaginal Atrophy due to Menopause ( 1.2 ) • Treatment of Hypoestrogenism due to Hypogonadism, Castration or Primary Ovarian Failure ( 1.3 ) • Treatment of Breast Cancer (for Palliation Only) in Appropriately Selected Women and Men with Metastatic Disease ( 1.4 ) • Treatment of Advanced Androgen-Dependent Carcinoma of the Prostate (for Palliation Only) ( 1.5 ) • Prevention of Postmenopausal Osteoporosis ( 1.6 ) uuid:122732e0-044e-425d-bb34-6b5f80cf7d71 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49040 biolink:treats UMLS:C0342882 PMID:41385096 "[{""id"":""uuid:3579bd88-32bb-4f3d-b359-827bc2892cf3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c9ca0f29-53c5-42af-952c-891e6b64c98a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ezetimibe tablets are indicated: • In combination with a statin, or alone when additional low-density lipoprotein cholesterol (LDL-C) lowering therapy is not possible, as an adjunct to diet to reduce elevated LDL-C in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH). • In combination with a statin as an adjunct to diet to reduce elevated LDL-C in pediatric patients 10 years of age and older with HeFH. • In combination with fenofibrate as an adjunct to diet to reduce elevated LDL-C in adults with mixed hyperlipidemia. • In combination with a statin, and other LDL-C lowering therapies, to reduce elevated LDL-C levels in adults and in pediatric patients 10 years of age and older with homozygous familial hypercholesterolemia (HoFH). • As an adjunct to diet for the reduction of elevated sitosterol and campesterol levels in adults and in pediatric patients 9 years of age and older with homozygous familial sitosterolemia. When ezetimibe tablets are used in combination with a statin, fenofibrate, or other LDL-C lowering therapies, refer to the Prescribing Information of these products for information on the safe and effective use. uuid:6bd36c1b-ce69-47c9-9400-adcb5d55418a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63580 biolink:treats MONDO:0012143 PMID:41385096 "[{""id"":""uuid:3f6cfb92-6004-4ba3-b3da-960859650681"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bc9a5863-c0dd-4e57-8467-eb3ed0ab2247"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ribavirin capsules are a nucleoside analogue indicated in combination with interferon alfa-2b (pegylated and nonpegylated) for the treatment of Chronic Hepatitis C (CHC) in patients 3 years of age or older with compensated liver disease. ( 1.1 ) Patients with the following characteristics are less likely to benefit from re-treatment after failing a course of therapy: previous nonresponse, previous pegylated interferon treatment, significant bridging fibrosis or cirrhosis, and genotype 1 infection. uuid:2d5975c2-0430-4401-a4de-3d67801bcd98 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1165654 biolink:treats MONDO:0001358 PMID:41385096 "[{""id"":""uuid:6cd06763-fdcd-4a4d-9c60-311dbd513019"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3f7f136c-b26e-46c9-9383-bdbb5c1f4c37"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AIRDUO ® RESPICLICK ® is indicated for the treatment of asthma in adult and pediatric patients aged 12 years and older. AIRDUO RESPICLICK should be used for patients not adequately controlled on a long term asthma control medication such as an inhaled corticosteroid or whose disease warrants initiation of treatment with both an inhaled corticosteroid and long acting beta 2 -adrenergic agonist (LABA). Limitations of Use : AIRDUO RESPICLICK is not indicated for the relief of acute bronchospasm. uuid:0cdc12f7-53cb-4413-8198-a8c1f0aa1a05 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63580 biolink:treats MONDO:0043479 PMID:41385096 "[{""id"":""uuid:22aa32d7-a35f-4c0b-a6b1-3e2b6edba9f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:292bad3e-741d-4930-bc5b-d5155e310603"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ribavirin tablets in combination with PEGASYS ® (peginterferon alfa-2a) are indicated for the treatment of patients 5 years of age and older with chronic hepatitis C (CHC) virus infection who have compensated liver disease and have not been previously treated with interferon alpha. The following points should be considered when initiating ribavirin tablets combination therapy with PEGASYS ® : This indication is based on clinical trials of combination therapy in patients with CHC and compensated liver disease, some of whom had histological evidence of cirrhosis (Child-Pugh class A), and in adult patients with clinically stable HIV disease and CD4 count greater than 100 cells/mm 3 . This indication is based on achieving undetectable HCV RNA after treatment for 24 or 48 weeks, based on HCV genotype, and maintaining a Sustained Virologic Response (SVR) 24 weeks after the last dose. Safety and efficacy data are not available for treatment longer than 48 weeks. The safety and efficacy of ribavirin tablets and PEGASYS ® therapy have not been established in liver or other organ transplant recipients, patients with decompensated liver disease, or previous non-responders to interferon therapy. The safety and efficacy of ribavirin tablets therapy for the treatment of adenovirus, RSV, parainfluenza or influenza infections have not been established. Ribavirin tablets should not be used for these indications. Ribavirin for inhalation has a separate package insert, which should be consulted if ribavirin inhalation therapy is being considered. uuid:5bb847a9-3aea-4ce5-b496-f0cb70327030 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63580 biolink:treats UMLS:C0302507 PMID:41385096 "[{""id"":""uuid:f0581281-668f-4bb2-9b39-8e7150b252e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b55cb1d1-9505-4180-85a1-9d3d3612b453"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ribavirin tablets in combination with PEGASYS ® (peginterferon alfa-2a) are indicated for the treatment of patients 5 years of age and older with chronic hepatitis C (CHC) virus infection who have compensated liver disease and have not been previously treated with interferon alpha. The following points should be considered when initiating ribavirin tablets combination therapy with PEGASYS ® : This indication is based on clinical trials of combination therapy in patients with CHC and compensated liver disease, some of whom had histological evidence of cirrhosis (Child-Pugh class A), and in adult patients with clinically stable HIV disease and CD4 count greater than 100 cells/mm 3 . This indication is based on achieving undetectable HCV RNA after treatment for 24 or 48 weeks, based on HCV genotype, and maintaining a Sustained Virologic Response (SVR) 24 weeks after the last dose. Safety and efficacy data are not available for treatment longer than 48 weeks. The safety and efficacy of ribavirin tablets and PEGASYS ® therapy have not been established in liver or other organ transplant recipients, patients with decompensated liver disease, or previous non-responders to interferon therapy. The safety and efficacy of ribavirin tablets therapy for the treatment of adenovirus, RSV, parainfluenza or influenza infections have not been established. Ribavirin tablets should not be used for these indications. Ribavirin for inhalation has a separate package insert, which should be consulted if ribavirin inhalation therapy is being considered. uuid:56a89fa0-05cb-4a60-87fe-8f9e67088acb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63580 biolink:treats MONDO:0005812 PMID:41385096 "[{""id"":""uuid:e9f8a5a0-7c52-4d4b-b2cf-25ab296a79f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4c987178-f8c6-4f73-8746-0a398aad29c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ribavirin tablets in combination with PEGASYS ® (peginterferon alfa-2a) are indicated for the treatment of patients 5 years of age and older with chronic hepatitis C (CHC) virus infection who have compensated liver disease and have not been previously treated with interferon alpha. The following points should be considered when initiating ribavirin tablets combination therapy with PEGASYS ® : This indication is based on clinical trials of combination therapy in patients with CHC and compensated liver disease, some of whom had histological evidence of cirrhosis (Child-Pugh class A), and in adult patients with clinically stable HIV disease and CD4 count greater than 100 cells/mm 3 . This indication is based on achieving undetectable HCV RNA after treatment for 24 or 48 weeks, based on HCV genotype, and maintaining a Sustained Virologic Response (SVR) 24 weeks after the last dose. Safety and efficacy data are not available for treatment longer than 48 weeks. The safety and efficacy of ribavirin tablets and PEGASYS ® therapy have not been established in liver or other organ transplant recipients, patients with decompensated liver disease, or previous non-responders to interferon therapy. The safety and efficacy of ribavirin tablets therapy for the treatment of adenovirus, RSV, parainfluenza or influenza infections have not been established. Ribavirin tablets should not be used for these indications. Ribavirin for inhalation has a separate package insert, which should be consulted if ribavirin inhalation therapy is being considered. uuid:3ec37c25-4675-4b35-984c-0a5580cf6e51 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:229661 biolink:treats MONDO:0100339 PMID:41385096 "[{""id"":""uuid:9a60e2ec-331b-41e3-a845-1be80187de59"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0274aa0b-faef-49d8-8fa2-43479cefd008"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SKYCLARYS is indicated for the treatment of Friedreich's ataxia in adults and adolescents aged 16 years and older. uuid:817abd0b-2c1a-496f-a097-a167ee32d33f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PY79D6C8RX biolink:treats MONDO:0001673 PMID:41385096 "[{""id"":""uuid:9aeff82b-f0cd-4839-9a2c-17fc0b2999bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:afd19bd2-0a79-4780-ab23-99d23d611313"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MYTESI is indicated for symptomatic relief of non-infectious diarrhea in adult patients with HIV/AIDS on anti-retroviral therapy. uuid:89cfb746-9bd3-44bc-a873-69c3f4a4aeed biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1165654 biolink:treats UMLS:C0741804 PMID:41385096 "[{""id"":""uuid:80fd2e9b-8e48-4f9e-aebe-118be253b4e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1b767ea3-21bb-4c70-be3b-b79b477f1903"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler (FS MDPI) is indicated for the treatment of asthma in adult and pediatric patients aged 12 years and older. Fluticasone Propionate/Salmeterol MDPI should be used for patients not adequately controlled on a long term asthma control medication such as an inhaled corticosteroid or whose disease warrants initiation of treatment with both an inhaled corticosteroid and long acting beta 2 -adrenergic agonist (LABA). Limitations of Use : Fluticasone Propionate/Salmeterol MDPI is not indicated for the relief of acute bronchospasm. uuid:1c61e331-e43c-4b14-bcf5-3c0836f69dfd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71028 biolink:treats HP:0008281 PMID:41385096 "[{""id"":""uuid:5c3789f4-5f3a-4322-9c64-fe588b203ee4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:797c805a-7d90-40b8-83ea-0434b15ad6dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carglumic acid tablets for oral suspension is a carbamoyl phosphate synthetase 1 (CPS 1) activator indicated in pediatric and adult patients as: Adjunctive therapy to standard of care for the treatment of acute hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. (1.1) Maintenance therapy for the treatment of chronic hyperammonemia due to NAGS deficiency. (1.1) uuid:f2aeb996-e448-4492-8af5-a06a54450b00 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1090966 biolink:treats MONDO:0006873 PMID:41385096 "[{""id"":""uuid:12c9457e-0d2e-4e40-8553-eb0b4a7a8ac9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:56e8487d-d9a2-4b5c-936f-c2e4819bd603"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Supplementation of the diet with fluoride and ten essential vitamins. Multivitamin with 1.0 mg Fluoride Chewable Tablets provide fluoride in tablet form for children 6-16 years of age in areas where the water fluoride level is less than 0.3 ppm. Multivitamin with 0.5 mg Fluoride Chewable Tablet s provide fluoride in tablet form for children 4-6 years of age where the water fluoride level is less than 0.3 ppm, and for children 6 years of age and above where the drinking water contains 0.3 through 0.6 ppm of fluoride. Multivitamin with 0.25 mg Fluoride Chewable Tablets provide fluoride in tablet form for children 4-6 years of age where the drinking water contains 0.3 through 0.6 ppm of fluoride. Multivitamin with Fluoride Chewable Tablets supply significant amounts of vitamins A, C, D, E, thiamine, riboflavin, niacin, vitamin B6, vitamin B12, and folate to supplement the diet, and to help assure that nutritional deficiencies of these vitamins will not develop. Thus, in a single easy-to-use preparation, children obtain ten essential vitamins and the important mineral, fluoride. Supplementation of the diet with fluoride for caries prophylaxis. The American Academy of Pediatrics recommends that children up to age 16, in areas where drinking water contains less than optimal levels of fluoride, receive daily fluoride supplementation. Children using Multivitamin with Fluoride Chewable Tablets regularly should receive semiannual dental examinations. The regular brushing of teeth and attention to good oral hygiene practices are also essential. Multivitamin with Fluoride Chewable tablets are prescription product for the clinical dietary management of metabolic processes of caries prophylaxis and provides supplementation of the diet with ten essential vitamins. uuid:1e1464e5-9185-4783-bb37-e4ecbafebcc8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135990 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:0ce461f3-1396-44a8-beb9-5a00ebc4aecd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2202f7c9-9a97-4851-881a-9ce1ea31fbae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EXXUA is indicated for the treatment of major depressive disorder (MDD) in adults. uuid:d3ee340a-8b5b-4d35-945b-c576da6bfb92 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63115 biolink:treats MONDO:0005301 PMID:41385096 "[{""id"":""uuid:5fe36641-8e72-468a-b27e-351250f06f4b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:255232b3-a355-4241-821b-52bf30d4a194"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c13c67df-0c06-4fa9-a7ad-c47eb54fe7b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fingolimod capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in patients 10 years of age and older.|[PMDA] Drugs with a new active ingredient indicated for the prevention of relapse and for delaying the accumulation of physical disability in multiple sclerosis. [Orphan drug] uuid:4de048d9-c2c9-4ab1-a679-5cd7fff244ef biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63115 biolink:treats UMLS:C2921627 PMID:41385096 "[{""id"":""uuid:256a9dd4-9f88-4246-8473-63758f1c2e35"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dda5cb2d-e6bf-4bab-9c09-4f6bb0fbd440"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fingolimod capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in patients 10 years of age and older. uuid:6de7af08-f10e-490a-8206-ab22f4803747 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63115 biolink:treats MONDO:0000450 PMID:41385096 "[{""id"":""uuid:e1195735-ad8b-4e58-88c1-e232dcca86d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bbcdbb44-b97d-4d25-a3c4-f8cb6138cb24"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fingolimod capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in patients 10 years of age and older. uuid:f77bab1b-23c2-4685-b397-9b85ef3fd9de biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6775 biolink:treats MONDO:0021736 PMID:41385096 "[{""id"":""uuid:ff9b868b-fe40-4b57-b16a-2675ea36accb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b432801c-8889-4ccf-8c15-ee47d02672da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mesalamine Rectal Suspension Enema is indicated for the treatment of active mild to moderate distal ulcerative colitis, proctosigmoiditis or proctitis in adults. uuid:e23be106-f1d3-4be4-a1d3-96d0f29acbcf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6775 biolink:treats MONDO:0005538 PMID:41385096 "[{""id"":""uuid:4648ef56-2d01-4b19-a5f3-27d6b8f40e88"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:55d560c5-5a18-4319-a7d6-fb9148dba9ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mesalamine Rectal Suspension Enema is indicated for the treatment of active mild to moderate distal ulcerative colitis, proctosigmoiditis or proctitis in adults. uuid:9979c524-6976-4d36-8a58-a0af153792d6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:55346 biolink:treats MONDO:0044070 PMID:41385096 "[{""id"":""uuid:fa4c8166-4b86-40b7-96cd-9bb5beea6c9e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f6e82722-4c66-4077-8670-224a36344ba3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ERAXIS is an echinocandin antifungal indicated for the treatment of the following infections: • Candidemia and other forms of Candida infections (intra-abdominal abscess and peritonitis) in adults and pediatric patients (1 month of age and older) ( 1.1 ) • Esophageal candidiasis in adults ( 1.2 ) Limitations of use • ERAXIS has not been studied in adult and pediatric patients with endocarditis, osteomyelitis, and meningitis due to Candida or in sufficient numbers of neutropenic patients. The dosage of ERAXIS for the treatment of Candida dissemination into the CNS and the eye has not been established. ( 1.3 , 5.3 , 8.4 ) • ERAXIS is associated with high relapse rates in esophageal candidiasis. ( 1.3 , 14.2 ) uuid:11e7a9f9-ef06-4165-9b3f-eca02d49f4af biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:55346 biolink:treats MONDO:0002026 PMID:41385096 "[{""id"":""uuid:1de55abb-8e62-4b1f-83a0-e9f1906b63a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c6408080-c8b1-4355-9ee1-3361c0529d9e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ERAXIS is an echinocandin antifungal indicated for the treatment of the following infections: • Candidemia and other forms of Candida infections (intra-abdominal abscess and peritonitis) in adults and pediatric patients (1 month of age and older) ( 1.1 ) • Esophageal candidiasis in adults ( 1.2 ) Limitations of use • ERAXIS has not been studied in adult and pediatric patients with endocarditis, osteomyelitis, and meningitis due to Candida or in sufficient numbers of neutropenic patients. The dosage of ERAXIS for the treatment of Candida dissemination into the CNS and the eye has not been established. ( 1.3 , 5.3 , 8.4 ) • ERAXIS is associated with high relapse rates in esophageal candidiasis. ( 1.3 , 14.2 ) uuid:dbdea29d-9624-4217-8bd7-8b9c41e42a1b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:55346 biolink:treats MONDO:0001648 PMID:41385096 "[{""id"":""uuid:28c62aab-8bdd-491d-84ee-9acf2aff917b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c44904a3-6bcb-4a2e-8c6f-b864e91065c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ERAXIS is an echinocandin antifungal indicated for the treatment of the following infections: • Candidemia and other forms of Candida infections (intra-abdominal abscess and peritonitis) in adults and pediatric patients (1 month of age and older) ( 1.1 ) • Esophageal candidiasis in adults ( 1.2 ) Limitations of use • ERAXIS has not been studied in adult and pediatric patients with endocarditis, osteomyelitis, and meningitis due to Candida or in sufficient numbers of neutropenic patients. The dosage of ERAXIS for the treatment of Candida dissemination into the CNS and the eye has not been established. ( 1.3 , 5.3 , 8.4 ) • ERAXIS is associated with high relapse rates in esophageal candidiasis. ( 1.3 , 14.2 ) uuid:e77b56e5-2e69-4e24-a5e8-ad0cdee92bac biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71219 biolink:treats MONDO:0005086 PMID:41385096 "[{""id"":""uuid:cb11846b-850c-4ffa-9043-536678460a0e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ee19c6b7-c912-4c12-80ca-41b2ab1668f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:7fa99bbc-98cb-4c84-95de-50efcc107fc7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/votrient""]},{""id"":""uuid:413b90e1-d95e-4540-95a6-7c1622e72274"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pazopanib tablets are kinase inhibitor indicated for the treatment of adults with: • advanced renal cell carcinoma (RCC). (1.1) • advanced soft tissue sarcoma (STS) who have received prior chemotherapy. (1.2) Limitations of Use : The efficacy of pazopanib tablets for the treatment of patients with adipocytic soft tissue sarcoma or gastrointestinal stromal tumors has not been demonstrated.|[EMA] Renal-cell carcinoma (RCC)Votrient is indicated in adults for the first-line treatment of advanced renal-cell carcinoma (RCC) and for patients who have received prior cytokine therapy for advanced disease.Soft-tissue sarcoma (STS)Votrient is indicated for the treatment of adult patients with selective subtypes of advanced soft-tissue sarcoma (STS) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo)adjuvant therapy.Efficacy and safety have only been established in certain STS histological tumour subtypes.|[PMDA] A drug with a new additional indication for the treatment of unresectable or metastatic renal cell carcinoma. uuid:dc134048-3209-49c5-9ef2-52bb119c9ee2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71219 biolink:treats MONDO:0018078 PMID:41385096 "[{""id"":""uuid:d3f3a2f5-875e-4188-857d-69a0a3aaca49"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8b6e1177-ac4c-4a02-a29c-582a30f0d86b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:7c3e2175-7b17-4f17-a921-65c2ba09e316"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/votrient""]},{""id"":""uuid:729636e0-8d42-473c-adb4-774a0c335980"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pazopanib tablets are kinase inhibitor indicated for the treatment of adults with: • advanced renal cell carcinoma (RCC). (1.1) • advanced soft tissue sarcoma (STS) who have received prior chemotherapy. (1.2) Limitations of Use : The efficacy of pazopanib tablets for the treatment of patients with adipocytic soft tissue sarcoma or gastrointestinal stromal tumors has not been demonstrated.|[EMA] Renal-cell carcinoma (RCC)Votrient is indicated in adults for the first-line treatment of advanced renal-cell carcinoma (RCC) and for patients who have received prior cytokine therapy for advanced disease.Soft-tissue sarcoma (STS)Votrient is indicated for the treatment of adult patients with selective subtypes of advanced soft-tissue sarcoma (STS) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo)adjuvant therapy.Efficacy and safety have only been established in certain STS histological tumour subtypes.|[PMDA] A drug with a new active ingredient indicated for the treatment of soft tissue sarcoma. [Orphan drug] uuid:18366464-728c-42aa-8f22-fd309a26f9c4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6754 biolink:treats NCIT:C27003 PMID:41385096 "[{""id"":""uuid:401d4472-4523-47fe-871a-e10c936eb4a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3e7c7f30-f2d5-46b3-b1b0-b7ec590d083a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Meperidine hydrochloride tablets are indicated for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. uuid:0bd254e6-3b1e-477c-8149-c214a20c1cbc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6754 biolink:treats UMLS:C0278140 PMID:41385096 "[{""id"":""uuid:d9f7bc96-d7a1-4570-ad72-c40eb40f6d78"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:999bbcd2-5313-4dd0-8dfe-b56dfb73a92b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Meperidine hydrochloride tablets are indicated for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. uuid:ca32a71a-a2aa-48dd-8593-5287ecfb1767 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134689 biolink:treats MONDO:0008170 PMID:41385096 "[{""id"":""uuid:c0144e9c-01fd-4db6-a9d9-307d302d57bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:43191cb4-3900-49f7-aa70-4d7f4bde8641"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:3f38b969-b51d-46b0-9117-fc21502365ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RUBRACA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated: Ovarian cancer for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)- associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. ( 1.1 ) Prostate cancer for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for RUBRACA. ( 1.2 , 2.1 ) This indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. ( 1.2 )|[EMA] Rubraca is indicated as monotherapy for the maintenance treatment of adult patients with advanced (FIGO Stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.Rubraca is indicated as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy. uuid:3cf0002a-e2cc-481f-ac25-5ff6923e0a3d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134689 biolink:treats MONDO:0002158 PMID:41385096 "[{""id"":""uuid:5a0c2384-0617-48a0-b625-6b8e8f3d0b80"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:5fd337d5-cfd6-47dd-bd1c-c61db0461350"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:88e340db-1162-4681-bbd3-03c73bdd08e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RUBRACA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated: Ovarian cancer for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)- associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. ( 1.1 ) Prostate cancer for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for RUBRACA. ( 1.2 , 2.1 ) This indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. ( 1.2 )|[EMA] Rubraca is indicated as monotherapy for the maintenance treatment of adult patients with advanced (FIGO Stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.Rubraca is indicated as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy. uuid:8a203653-9cb3-4ea6-a852-65d8992d8836 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134689 biolink:treats MONDO:0015686 PMID:41385096 "[{""id"":""uuid:4b6ae5da-bcc9-48c3-baf5-1af2cc610aae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:5a5aaf74-df8f-4cdb-aa93-35a083e5fc77"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:8089d507-ae2a-4406-9663-b7d5425276b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RUBRACA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated: Ovarian cancer for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)- associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. ( 1.1 ) Prostate cancer for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for RUBRACA. ( 1.2 , 2.1 ) This indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. ( 1.2 )|[EMA] Rubraca is indicated as monotherapy for the maintenance treatment of adult patients with advanced (FIGO Stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.Rubraca is indicated as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy. uuid:1f1c9c10-6d56-4d08-bb57-3f9f822cff6d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134689 biolink:treats MONDO:0004956 PMID:41385096 "[{""id"":""uuid:0d2c2596-8170-48a2-945f-0a3eae6b9c41"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6d81f599-71da-409a-99c3-fdacbbfab631"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RUBRACA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated: Ovarian cancer for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)- associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. ( 1.1 ) Prostate cancer for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for RUBRACA. ( 1.2 , 2.1 ) This indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. ( 1.2 ) uuid:6d1c1054-4f34-4cae-af63-f5ddba9c73f3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:30769 biolink:treats MONDO:0004828 PMID:41385096 "[{""id"":""uuid:24ba7dff-c0e3-4f4b-8204-c65c22e03507"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:39c35c2c-ab9c-454c-9cec-226e52a196fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oral Citrate Solution is indicated for the treatment of metabolic acidosis. This solution is also useful in conditions where long-term maintenance of alkaline urine is needed (e.g. uric acid and cystine calculi of the urinary tract). Oral Citrate Solution is also effective in treatment for acidosis of certain renal tubular disorders. uuid:f3e07bd4-9d2c-42e5-891e-d0251b74f565 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats UMLS:C0274435 PMID:41385096 "[{""id"":""uuid:a6d11b82-22ee-409d-8ae8-f892958daea7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eae1647e-8509-44af-be05-4a515e857fee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramusculat use of SOLU-CORTEF Sterile Powder is indicated as follows: Allergic states Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administration is contraindicated), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic diseases Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, temporal arteritis, polymyositis, and systemic lupus erythematosus. uuid:55a0a21b-a3fa-4a7b-85b7-47e4c9dc71ce biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0015129 PMID:41385096 "[{""id"":""uuid:9d3f0984-5c3a-43c6-a0bf-3101b7c62fa4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d245e837-b07b-4568-a7d6-7a0ec19bfd8d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramusculat use of SOLU-CORTEF Sterile Powder is indicated as follows: Allergic states Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administration is contraindicated), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic diseases Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, temporal arteritis, polymyositis, and systemic lupus erythematosus. uuid:365f14ce-a17c-49c0-ad67-5e54688be734 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0043370 PMID:41385096 "[{""id"":""uuid:3429db2b-74e6-408e-9d68-4cf71915b93c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d41c3294-0bce-4b90-9e89-d75fb8e01888"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramusculat use of SOLU-CORTEF Sterile Powder is indicated as follows: Allergic states Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administration is contraindicated), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic diseases Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, temporal arteritis, polymyositis, and systemic lupus erythematosus. uuid:6a9dc00f-41bb-41fb-81da-ca9e42abbe44 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0001705 PMID:41385096 "[{""id"":""uuid:14ad02e7-2966-4de3-a02f-c7c9fd1ed454"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:46f4428a-9c62-4005-a62b-1048d187899b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramusculat use of SOLU-CORTEF Sterile Powder is indicated as follows: Allergic states Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administration is contraindicated), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic diseases Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, temporal arteritis, polymyositis, and systemic lupus erythematosus. uuid:56b44ea8-85a7-4b27-98dc-c750d2fda2df biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0006684 PMID:41385096 "[{""id"":""uuid:6703bf33-e9dc-4f0f-a318-1f9c3853456d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:435b9ecb-c025-4ae0-9af8-736646e61192"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramusculat use of SOLU-CORTEF Sterile Powder is indicated as follows: Allergic states Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administration is contraindicated), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic diseases Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, temporal arteritis, polymyositis, and systemic lupus erythematosus. uuid:c4443324-6023-4ab4-a469-2da82be2df06 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0020283 PMID:41385096 "[{""id"":""uuid:4a083a91-ed96-424d-a354-31418af4465a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:63ebb5df-e1ce-4126-b5d8-49dc95f6d55b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramusculat use of SOLU-CORTEF Sterile Powder is indicated as follows: Allergic states Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administration is contraindicated), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic diseases Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, temporal arteritis, polymyositis, and systemic lupus erythematosus. uuid:6219a070-a562-4c51-b067-36e654564531 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0008109 PMID:41385096 "[{""id"":""uuid:ad304753-b712-435c-a39f-7b8dcac56f4d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:581eee97-d32d-4a35-ab14-d3d7e0c6c62f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramusculat use of SOLU-CORTEF Sterile Powder is indicated as follows: Allergic states Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administration is contraindicated), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic diseases Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, temporal arteritis, polymyositis, and systemic lupus erythematosus. uuid:986efd8d-bc93-4bbb-a57d-ab0bd8767e5b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0018170 PMID:41385096 "[{""id"":""uuid:5d1a66e6-08f2-48eb-ac67-29577db108a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b3cf3f37-37d5-4f73-bec9-de0d71114794"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramusculat use of SOLU-CORTEF Sterile Powder is indicated as follows: Allergic states Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administration is contraindicated), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic diseases Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, temporal arteritis, polymyositis, and systemic lupus erythematosus. uuid:8bc7cfbd-bf52-4a00-b252-507833450c5b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0005556 PMID:41385096 "[{""id"":""uuid:816a2ae8-6efd-4a22-b974-0e751197fbbf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:227632d4-2c3d-44b3-99c9-0ce47038ae71"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramusculat use of SOLU-CORTEF Sterile Powder is indicated as follows: Allergic states Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administration is contraindicated), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic diseases Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, temporal arteritis, polymyositis, and systemic lupus erythematosus. uuid:b287af55-a8b2-41e5-92af-c1539ba6e575 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0015927 PMID:41385096 "[{""id"":""uuid:f48158b4-981f-4b9d-a025-ecc8658ee8c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ba096446-aba3-4a11-a0c5-8d6ea6aaa25d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramusculat use of SOLU-CORTEF Sterile Powder is indicated as follows: Allergic states Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administration is contraindicated), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic diseases Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, temporal arteritis, polymyositis, and systemic lupus erythematosus. uuid:b956c258-a2a3-4278-a565-82d272c7912b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0008538 PMID:41385096 "[{""id"":""uuid:f8d40773-7245-404f-85fb-cbf7896a64f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7212e0d2-3ccd-425a-b623-5a92290ec820"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramusculat use of SOLU-CORTEF Sterile Powder is indicated as follows: Allergic states Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administration is contraindicated), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic diseases Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, temporal arteritis, polymyositis, and systemic lupus erythematosus. uuid:549bfa71-f2dd-47e9-b463-2be85509ed05 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1165173 biolink:treats MONDO:0018555 PMID:41385096 "[{""id"":""uuid:bb103a6d-bc0d-44da-958d-d8241e1169a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a8b526cf-170b-4f97-b984-5609390284f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CombiPatch is indicated in a woman with a uterus for: Treatment of moderate to severe vasomotor symptoms due to menopause. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. Treatment of hypoestrogenism due to hypogonadism, castration, or primary ovarian failure. uuid:1458d8ce-eaf6-4ed8-b68a-c0ab872a60f7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1165173 biolink:treats MONDO:0005387 PMID:41385096 "[{""id"":""uuid:6c9273a0-3e1d-47b5-abdc-759383067879"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:76594921-1af9-4ac2-9153-4046990dc923"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CombiPatch is indicated in a woman with a uterus for: Treatment of moderate to severe vasomotor symptoms due to menopause. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. Treatment of hypoestrogenism due to hypogonadism, castration, or primary ovarian failure. uuid:09f65326-2f5a-41ee-84e6-91048e8ae6d5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28787 biolink:treats UMLS:C0349071 PMID:41385096 "[{""id"":""uuid:308e6174-fd90-43b7-a61a-6398c8826e55"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c954aebe-4f2c-4bc4-aaa1-17ed8a37a46f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nitroglycerin ointment 0.4% is indicated for the treatment of moderate to severe pain associated with chronic anal fissure. uuid:16f2525f-f2a0-432b-b1f6-8c0cec64dec4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2675584 biolink:treats MONDO:0006543 PMID:41385096 "[{""id"":""uuid:dfa08453-ba51-4fb3-a64b-4d38521ee7ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a5b7b0f3-f265-4fb2-83fc-3af334619321"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FILSUVEZ is indicated for the treatment of wounds associated with dystrophic and junctional epidermolysis bullosa (EB) in adult and pediatric patients 6 months of age and older. uuid:a812f9e4-bb29-40c5-9182-860c3c9f0aea biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2675584 biolink:treats MONDO:0017612 PMID:41385096 "[{""id"":""uuid:b3681cac-7188-4481-88fc-d0c24dd9a637"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8416dcc9-1dd8-40aa-b7d3-804b1a9cfcfe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FILSUVEZ is indicated for the treatment of wounds associated with dystrophic and junctional epidermolysis bullosa (EB) in adult and pediatric patients 6 months of age and older. uuid:78c8ce66-5624-493f-bb6f-6be9d59dab42 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB09381 biolink:treats UMLS:C5442256 PMID:41385096 "[{""id"":""uuid:f511648c-3706-4fb2-8230-b883ce946bfb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0bb2c30e-57eb-490e-a88e-85fd5adfb5a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Menest is indicated in the: 1. Treatment of moderate to severe vasomotor symptoms associated with the menopause. 2. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. 3. Female hypogonadism. 4. Female castration. 5. Primary ovarian failure. 6. Breast cancer (for palliation only) in appropriately selected women and men with metastatic disease. 7. Prostatic carcinoma - palliative therapy of advanced disease. uuid:72a95afb-0709-422b-9e6d-78c3c139683a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB09381 biolink:treats MONDO:0001932 PMID:41385096 "[{""id"":""uuid:07530031-818b-4a5b-a584-04573602fa45"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:39678bad-2b02-4df9-a7a9-92de587fbf7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Menest is indicated in the: 1. Treatment of moderate to severe vasomotor symptoms associated with the menopause. 2. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. 3. Female hypogonadism. 4. Female castration. 5. Primary ovarian failure. 6. Breast cancer (for palliation only) in appropriately selected women and men with metastatic disease. 7. Prostatic carcinoma - palliative therapy of advanced disease. DOID:14275 uuid:0147aedb-8997-4443-adfc-07f19bb783c4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:53394049 biolink:treats MONDO:0005338 PMID:41385096 "[{""id"":""uuid:77db592f-d99f-49dc-bfb0-c9671f3a0427"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:71d70948-e357-48bd-81ff-5df87c6fc597"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VYZULTA ® (latanoprostene bunod ophthalmic solution) 0.024% is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. uuid:1c5ad569-93e0-4227-96f3-089c805d890e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:53394049 biolink:treats MONDO:0006875 PMID:41385096 "[{""id"":""uuid:f1db7304-64e8-483d-bed2-702ffaf198b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e77c51ea-66c8-416a-ab51-8ca470eaf9ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VYZULTA ® (latanoprostene bunod ophthalmic solution) 0.024% is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. uuid:779ff586-0f95-4e40-b779-33d271d7a1fe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:51450 biolink:treats MONDO:0015924 PMID:41385096 "[{""id"":""uuid:4e55c126-d393-448d-978e-b9d32e8a9836"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3ad67016-ec2a-4741-9d21-f52b92e3bc19"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c60a0476-aab4-418a-9da7-035b9c5b7da7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:8ba22126-e9e6-421b-8a77-c8635c35b9d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bosentan tablets are indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1): in adults to improve exercise ability and to decrease clinical worsening. Studies establishing effectiveness included predominantly patients with WHO Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (60%), PAH associated with connective tissue diseases (21%), and PAH associated with congenital heart disease with left-to-right shunts (18%) [see Clinical Studies ( 14.1 )] .|[EMA] Treatment of pulmonary arterial hypertension (PAH) to improve exercise capacity and symptoms in patients with WHO functional class III.Efficacy has been shown in:, , , Primary (idiopathic and familial) PAH;, PAH secondary to scleroderma without significant interstitial pulmonary disease;, PAH associated with congenital systemic-to-pulmonary shunts and Eisenmenger's physiology., , , Some improvements have also been shown in patients with PAH WHO functional class II., , Tracleer is also indicated to reduce the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcer disease.,|[PMDA] A drug with a new indication and a new dosage in a new additional dosage form indicated for the treatment of pulmonary arterial hypertension. [Orphan drug] uuid:888dba6c-ee96-4a6c-803d-c4ffbc0ba856 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:51450 biolink:treats MONDO:0017147 PMID:41385096 "[{""id"":""uuid:9adcf216-9dfa-4cbf-b83b-63339bd4ee63"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5d47d7d5-8784-4a31-86d7-3859fb4864a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bosentan tablets are indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1): in adults to improve exercise ability and to decrease clinical worsening. Studies establishing effectiveness included predominantly patients with WHO Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (60%), PAH associated with connective tissue diseases (21%), and PAH associated with congenital heart disease with left-to-right shunts (18%) [see Clinical Studies ( 14.1 )] . uuid:da59dd9b-9ab1-48f6-9798-bb135ec34805 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:51450 biolink:treats MONDO:0017148 PMID:41385096 "[{""id"":""uuid:9287fac8-c9ab-4816-89da-1aac9fa74e74"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:161efc58-2adf-408e-aa68-39045f048658"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bosentan tablets are indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1): in adults to improve exercise ability and to decrease clinical worsening. Studies establishing effectiveness included predominantly patients with WHO Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (60%), PAH associated with connective tissue diseases (21%), and PAH associated with congenital heart disease with left-to-right shunts (18%) [see Clinical Studies ( 14.1 )] . uuid:7fbfb14e-867c-4e42-8b98-d33d09ba06e1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:465284 biolink:treats MONDO:0015288 PMID:41385096 "[{""id"":""uuid:55543077-442a-4f5a-8d67-979381aa411f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fce77967-a014-4e17-9f4a-288739f8d7a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZIRGAN ® (ganciclovir ophthalmic gel) 0.15% is indicated for the treatment of acute herpetic keratitis (dendritic ulcers). uuid:b2f1f86f-f5e4-4a26-9a39-28ccdcbfed38 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:465284 biolink:treats UMLS:C0333303 PMID:41385096 "[{""id"":""uuid:f1c0d28b-174d-460d-8c01-9fc7c3a507ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ce386d7d-9555-40f3-93cf-8a6ddee5406f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZIRGAN ® (ganciclovir ophthalmic gel) 0.15% is indicated for the treatment of acute herpetic keratitis (dendritic ulcers). uuid:3dcf26c3-1285-4256-aacb-9d7ddfc99d74 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15544 biolink:treats NCIT:C55615 PMID:41385096 "[{""id"":""uuid:79389741-a582-4d8c-8800-3dd7e1ac78a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:46b5aad5-2151-4e74-bae2-f77bd2254dae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CAVERJECT IMPULSE is a prostaglandin E1 agonist indicated • For the treatment of erectile dysfunction ( 1.1 ) • As an adjunct to other diagnostic tests in the diagnosis of erectile dysfunction ( 1.2 ). uuid:793a8d3c-9302-403f-8f8b-e3e2efc950e6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:S866O45PIG biolink:treats MONDO:0006502 PMID:41385096 "[{""id"":""uuid:1840e23e-2fb1-4cb9-bf4e-4310d2d08c6b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fe3ddfdb-33a7-4358-87b1-29b92223f038"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SURVANTA is indicated for prevention and treatment (“rescue”) of Respiratory Distress Syndrome (RDS) (hyaline membrane disease) in premature infants. uuid:e7ec2bb3-b475-4e7f-9c2a-d5eba53cdb4d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:S866O45PIG biolink:treats MONDO:0700081 PMID:41385096 "[{""id"":""uuid:8c95fc5f-e1e5-4fab-9e6f-cbdf194c2aa4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a0e33115-1179-436b-aa7d-9ba9fffae66b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SURVANTA is indicated for prevention and treatment (“rescue”) of Respiratory Distress Syndrome (RDS) (hyaline membrane disease) in premature infants. uuid:7e15bda8-4f08-49d5-90d1-864fcd0bb621 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1945037 biolink:treats MONDO:0005002 PMID:41385096 "[{""id"":""uuid:96c729d5-da2b-4051-badb-fd848be1394b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:af8da7f1-8e6f-4b0c-a8da-5dcfbd79541d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:4ee28021-64e2-40f5-96d8-4d9f4faef900"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/trelegy-ellipta""]},{""id"":""uuid:f0170a39-67d6-4c2d-ae69-5b27750ace45"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TRELEGY ELLIPTA is a combination of fluticasone furoate, an inhaled corticosteroid (ICS); umeclidinium, an anticholinergic; and vilanterol, a long-acting beta 2 -adrenergic agonist (LABA), indicated for: • the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). ( 1.1 ) • the maintenance treatment of asthma in patients aged 18 years and older. ( 1.2 ) Limitations of Use: Not indicated for relief of acute bronchospasm. ( 1.3 , 5.2 )|[EMA] Trelegy Ellipta is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting β2-agonist.|[PMDA] New combination drugs indicated for the relief of symptoms in patients with chronic obstructive pulmonary disease (chronic bronchitis, emphysema) (who require a combination therapy with an inhaled corticosteroid, a long-acting inhaled anticholinergic agent and a long-acting beta-2 agonist). uuid:d59cb5eb-88cf-4831-bc17-d360cd8d3062 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1945037 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:de855d21-da90-41bd-a669-1800b32f0d69"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d33b9944-8428-4258-9828-6634a82c1d18"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TRELEGY ELLIPTA is a combination of fluticasone furoate, an inhaled corticosteroid (ICS); umeclidinium, an anticholinergic; and vilanterol, a long-acting beta 2 -adrenergic agonist (LABA), indicated for: • the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). ( 1.1 ) • the maintenance treatment of asthma in patients aged 18 years and older. ( 1.2 ) Limitations of Use: Not indicated for relief of acute bronchospasm. ( 1.3 , 5.2 ) uuid:4c2c0795-6b6c-4084-a591-d9a0511e363b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6520 biolink:treats MONDO:0021211 PMID:41385096 "[{""id"":""uuid:ee67e787-b349-4cce-ba0d-f8c384a65f68"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f9d66c71-e947-4b93-b339-73da1243f329"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gleostine is an alkylating drug indicated for the treatment of patients with: Brain tumors, primary and metastatic, following appropriate surgical and/or radiotherapeutic procedures. ( 1 ) Hodgkin's lymphoma in combination with other chemotherapies, following disease progression with initial chemotherapy. ( 1 ) uuid:edc63baa-f3a7-4bee-a056-6f0b9f080250 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6520 biolink:treats MONDO:0009348 PMID:41385096 "[{""id"":""uuid:a2fd15b1-4908-49a8-8dc2-ff5649f7d0cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b19c7f86-dee7-4e49-a76f-f9cf02952efb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gleostine is an alkylating drug indicated for the treatment of patients with: Brain tumors, primary and metastatic, following appropriate surgical and/or radiotherapeutic procedures. ( 1 ) Hodgkin's lymphoma in combination with other chemotherapies, following disease progression with initial chemotherapy. ( 1 ) uuid:653c6890-de15-4f78-b8b8-03e9ac77c418 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0005556 PMID:41385096 "[{""id"":""uuid:a3493950-a1cb-42eb-af6b-49bf992d88e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3e3a7a20-64a7-483d-862f-a0cad59628cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low- dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:b6c9e387-bf30-4245-a040-86c26bc220da biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:681K1JDI8M biolink:treats MONDO:0010602 PMID:41385096 "[{""id"":""uuid:65d3d8e2-263e-4082-91c6-e924c7f11222"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:5c2b45a3-91b6-4de8-a6d6-3c34e280d9e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:bb388f46-bcbc-40ea-ba2c-33bddc9bf9aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/roctavian-0""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] ROCTAVIAN is an adeno-associated virus vector-based gene therapy indicated for the treatment of adults with severe hemophilia A (congenital factor VIII deficiency with factor VIII activity < 1 IU/dL) without antibodies to adeno-associated virus serotype 5 (AAV5) detected by an FDA-approved test.|[EMA] Treatment of severe haemophilia A (congenital factor VIII deficiency) in adult patients without a history of factor VIII inhibitors and without detectable antibodies to adeno-associated virus serotype 5 (AAV5). uuid:116b34e7-b28c-467c-83f0-29b18cad0f26 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2596777 biolink:treats MONDO:0005105 PMID:41385096 "[{""id"":""uuid:c388df90-01ee-4000-ae34-545d34585cd3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:4fe60625-d3d7-4800-98e2-bda1381e74ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c2b07cea-e889-46f9-8c5a-6bfd42452043"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OPDUALAG™ is indicated for the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma.|[EMA] Opdualag is indicated for the first line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older with tumour cell PD L1 expression < 1%. uuid:b90c6c96-769c-49bf-bd8e-ad5937736523 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31638 biolink:treats MONDO:0000618 PMID:41385096 "[{""id"":""uuid:06798327-68db-4e42-92c8-c1782e62b75e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:32a68f09-5ac7-4f71-8f06-f3b698a6cc1d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fulvestrant Injection is an estrogen receptor antagonist indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy. ( 1 ) HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. ( 1 ) HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib, as initial endocrine based therapy or following disease progression on endocrine therapy. ( 1 ) HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. ( 1 ) uuid:05b885ec-b54e-4a78-9a17-5ccfb5ec5fc1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31638 biolink:treats MONDO:0006512 PMID:41385096 "[{""id"":""uuid:162528a7-effc-4e81-b16f-5ab9c4cc0913"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5d4d2d31-1c68-4ff5-9aa3-7b2096bcce52"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fulvestrant Injection is an estrogen receptor antagonist indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy. ( 1 ) HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. ( 1 ) HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib, as initial endocrine based therapy or following disease progression on endocrine therapy. ( 1 ) HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. ( 1 ) uuid:5b35b57b-1a04-4d08-85c2-0fe8bfcba7d6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:82752 biolink:treats MONDO:0009265 PMID:41385096 "[{""id"":""uuid:dca21537-4a0c-421b-91c5-cc30983ec2ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:0ba1c598-b162-4c35-8adc-e1a8c596dcba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:6e697ad1-8e95-4aca-8311-3102957308b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/cerdelga""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] CERDELGA is indicated for the long-term treatment of adult patients with Gaucher disease type 1 (GD1) who are CYP2D6 extensive metabolizers (EMs), intermediate metabolizers (IMs), or poor metabolizers (PMs) as detected by an FDA-cleared test [see Dosage and Administration (2.1) ] .|[EMA] Cerdelga is indicated for the long-term treatment of adult patients with Gaucher disease type 1 (GD1), who are CYP2D6 poor metabolisers (PMs), intermediate metabolisers (IMs) or extensive metabolisers (EMs). uuid:9ee81106-c29a-4579-b48e-613fcadec403 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47426 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:4e367303-c610-4bdd-ac9d-4ab9a5394da0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2871a40b-d202-46e0-af90-33ae97f39ac3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Furosemide Injection is a loop diuretic indicated for: The treatment of edema associated with heart failure, cirrhosis of the liver, and renal disease ( 1.1 ) Acute pulmonary edema as adjunctive therapy ( 1.2 ) uuid:594913b1-1c18-4563-b5fd-72856b8d0bf8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:601027 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:d930a285-2999-4042-adcb-f997bf86f804"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:da3aa806-332c-472f-9756-15fa00fd9816"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tekturna is a renin inhibitor (RI) indicated for the treatment of hypertension in adults and in pediatric patients weighing 50 kg or greater who are at least 6 years of age, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) uuid:00b27133-c20a-42db-8ce4-2e136d9fc794 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:601027 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:49df13fb-2daa-4dbb-8f8b-4524f25e9810"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:feaeba09-207a-4143-9b59-3a2c5d689286"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tekturna is a renin inhibitor (RI) indicated for the treatment of hypertension in adults and in pediatric patients weighing 50 kg or greater who are at least 6 years of age, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) uuid:2fc032cb-29bd-4b8e-9d2a-f9561591a753 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17234 biolink:treats HP:0001944 PMID:41385096 "[{""id"":""uuid:00120100-4171-4480-93b5-8a846eccbd39"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:51a699d5-4fe7-4305-8320-3374416284ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] These intravenous solutions are indicated for use in adults and pediatric patients as sources of calories and water for hydration. uuid:68c74e12-2b65-4739-9a44-1ba54192cdd6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1939325 biolink:treats MONDO:0005354 PMID:41385096 "[{""id"":""uuid:05d12ee4-8f3e-44dc-85eb-842edbf3c608"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:df78634d-d270-4193-9abd-a50361cb1333"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VOSEVI is indicated for the treatment of adult patients with chronic hepatitis C virus (HCV) infection without cirrhosis or with compensated cirrhosis (Child-Pugh A) who have [see Dosage and Administration (2.2) and Clinical Studies (14) ]: genotype 1, 2, 3, 4, 5, or 6 infection and have previously been treated with an HCV regimen containing an NS5A inhibitor. genotype 1a or 3 infection and have previously been treated with an HCV regimen containing sofosbuvir without an NS5A inhibitor. Additional benefit of VOSEVI over sofosbuvir/velpatasvir was not shown in adults with genotype 1b, 2, 4, 5, or 6 infection previously treated with sofosbuvir without an NS5A inhibitor. uuid:48dfc5ce-e4c9-47b5-a82f-9621eb2ca2b9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0003634 PMID:41385096 "[{""id"":""uuid:ba79ec4f-57ce-4938-987f-24e8b3a4c53f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8262db59-b0c2-4fff-826c-847b3d6b3061"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prednisolone Oral Solution USP is indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice: synthetic analogs may be used in conjunction with mineralocorticoids where applicable: in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and Iridocyclitis 7. Respiratory Disorders Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. In addition to the above indications, Prednisolone Oral Solution USP is indicated for systemic dermatomyositis (polymyositis). uuid:393d517b-6605-4c3e-93a8-971e63c73f82 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:UT99UG9QJX biolink:treats UMLS:C0746883 PMID:41385096 "[{""id"":""uuid:d7bc8f3f-a149-4311-a0f1-f3ced12d222b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7ceceb87-a5b0-48eb-9c3f-8b31a586c255"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Rolvedon is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia. Limitations of Use Rolvedon is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation. uuid:87490819-2bd3-4f7a-8e4d-c01bfc8c16e8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:UT99UG9QJX biolink:treats UMLS:C3714514 PMID:41385096 "[{""id"":""uuid:73487c89-3fad-499b-95d7-772efd91da36"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7285179e-6d99-46aa-a29d-fd0d09b7b9c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Rolvedon is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia. Limitations of Use Rolvedon is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation. uuid:d22b0c1f-070b-4009-9b8b-a45044173d25 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0004874 PMID:41385096 "[{""id"":""uuid:8939d4d6-91e9-4e3b-a4f8-1a6a21fcc055"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:526fdc5e-90ec-4139-82df-fa712b28b47c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] A. FOR INTRAMUSCULAR ADMINISTRATION When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of Methylprednisolone acetate Sterile Aqueous Suspension is indicated as follows: Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions. Dermatologic Diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders: Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases: For palliative management of leukemias and lymphomas. Nervous System: Cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases: Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. B. FOR INTRA-ARTICULAR OR SOFT TISSUE ADMINISTRATION (See WARNINGS ) Methylprednisolone acetate injectable suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. C. FOR INTRALESIONAL ADMINISTRATION Methylprednisolone acetate injectable suspension is indicated for intralesional use in alopecia areata, discoid lupus erythematosus, keloids, localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques, necrobiosis lipoidica diabeticorum. Methylprednisolone acetate injectable suspension also may be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:c435696e-9390-4a6a-8164-d5669c890391 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8081 biolink:treats MONDO:0008233 PMID:41385096 "[{""id"":""uuid:7edbf206-1d8c-4d5f-ac54-399a21c30873"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ccf3ee74-abb9-43c0-bbb6-bf62abecedc8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Phentolamine Mesylate for Injection is indicated for the prevention or control of hypertensive episodes that may occur in a patient with pheochromocytoma as a result of stress or manipulation during preoperative preparation and surgical excision. Phentolamine Mesylate for Injection is indicated for the prevention or treatment of dermal necrosis and sloughing following intravenous administration or extravasation of norepinephrine. Phentolamine Mesylate for Injection is also indicated for the diagnosis of pheochromocytoma by the phentolamine blocking test. uuid:1ad2db9c-e4bf-45fe-8be2-12d0b9233ac7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17051 biolink:treats MONDO:0006873 PMID:41385096 "[{""id"":""uuid:13c24bb7-cb60-46bf-8d1a-425fa3607eff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7ce6218c-cfc0-43aa-82c3-f8e7dc3cd81c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Supplementation of the diet with ten essential vitamins. Supplementation of the diet with fluoride for caries prophylaxis. Contraindications : This product is contraindicated in patients with a known hypersensitivity to any of the ingredients. The American Academy of Pediatrics recommends that children up to the age 16, in areas where drinking water contains less than optimal levels of fluoride, receive daily fluoride supplementation. Davimet™ with Flouride 0.75 mg Chewable Multivitamin provide 0.75 mg fluoride in tablet form for children 6-16 years of age in areas where the drinking water fluoride level is less than 0.3 ppm. Davimet™ with Flouride 0.75 mg Chewable Multivitamin supply significant amounts of Vitamins A, C, D, E, thiamine, riboflavin, niacin, vitamin B6, vitamin B12, and folate to supplement the diet, and to help assure that nutritional deficiencies of these vitamins will not develop. Thus, in a single easy-to-use preparation, children obtain ten essential vitamins and the important mineral, fluoride. Children using Davimet™ with Flouride 0.75 mg Chewable Multivitamin regularly should receive semiannual dental examinations. The regular brushing of teeth and attention to good oral hygiene practices are also essential. Davimet™ with Flouride 0.75 mg Chewable Multivitamin is a prescription product for the clinical dietary management of the metabolic processes of caries prophylaxis and provides supplementation of the diet with ten essential vitamins. uuid:9f5c3ef4-0864-4027-a974-450f0903f5ad biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:132041 biolink:treats MONDO:0021661 PMID:41385096 "[{""id"":""uuid:bd230a4f-6208-4a2c-bf34-362664d4685f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c9bb2eba-4aab-4ce0-ae26-99530bc01c31"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Perindopril erbumine tablets are indicated for the treatment of patients with essential hypertension. (1.1) Perindopril erbumine tablets are indicated for treatment of patients with stable coronary artery disease to reduce the risk of cardiovascular mortality or nonfatal myocardial infarction. (1.2) uuid:c8d0873b-8bc5-4fb0-b835-461698f19dd0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:499361 biolink:treats EFO:0004888 PMID:41385096 "[{""id"":""uuid:d65c1d41-f99c-4204-9e9f-8dfc0e49930b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b30bf01a-8741-42d0-ad87-8bed810d0592"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] APONVIE is indicated for the prevention of postoperative nausea and vomiting (PONV) in adults. uuid:e33a615d-b9a3-4982-962b-152cdee5b89e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45081 biolink:treats MONDO:0005055 PMID:41385096 "[{""id"":""uuid:aab119e2-cf60-469a-87c3-a1a867535d15"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bacc3067-0369-4568-94a7-0b7faa57aa34"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pentamidine Isethionate is indicated for the prevention of Pneumocystis jiroveci pneumonia (PJP) in high-risk, HIV-infected patients defined by one or both of the following criteria: i. a history of one or more episodes of PJP ii. a peripheral CD4+ (T4 helper/inducer) lymphocyte count less than or equal to 200/mm 3 . These indications are based on the results of an 18-month randomized, dose-response trial in high risk HIV-infected patients and on existing epidemiological data from natural history studies. The patient population of the controlled trial consisted of 408 patients, 237 of whom had a history of one or more episodes of PJP. The remaining patients without a history of PJP included 55 patients with Kaposi’s sarcoma and 116 patients with other AIDS diagnoses, ARC or asymptomatic HIV infection. Patients were randomly assigned to receive Pentamidine isethionate via the Respirgard ® II nebulizer at one of the following three doses: 30 mg every two weeks (n=135), 150 mg every two weeks (n=134) or 300 mg every four weeks (n=139). The results of the trial demonstrated a significant protective effect (p<0.01) against PJP with the 300 mg every four week dosage regimen compared to the 30 mg every two week dosage regimen. The 300 mg dose regimen reduced the risk of developing PJP by 50 to 70% compared to the 30 mg regimen. A total of 293 patients (72% of all patients) also received zidovudine at sometime during the trial. The analysis of the data demonstrated the efficacy of the 300 mg dose even after adjusting for the effect of zidovudine. The results of the trial further demonstrate that the dose and frequency of dosing are important to the efficacy of Pentamidine Isethionate prophylaxis in that multiple analyses consistently demonstrated a trend toward greater efficacy with 300 mg every four weeks as compared to 150 mg every two weeks. No dose-response was observed for reduction in overall mortality; however, mortality from PJP was low in all three dosage groups. uuid:84450a68-a1e5-487c-bf70-91d3d29c339c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:80343 biolink:treats NCIT:C118469 PMID:41385096 "[{""id"":""uuid:e485bd99-73c1-4883-a5a1-c2d51cca5fb5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:24b2ef15-4dda-45ca-b89e-a8e11ab303fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:20ba5e2a-98d0-41b3-a738-02fca6f12a45"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/increlex""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] INCRELEX (mecasermin) injection is indicated for the treatment of growth failure in pediatric patients 2 years of age and older with severe primary IGF-1 deficiency or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH. ( 1 ) Limitations of use: INCRELEX is not a substitute to GH for approved GH indications.|[EMA] For the long-term treatment of growth failure in children and adolescents with severe primary insulin-like-growth-factor-1 deficiency (primary IGFD).Severe primary IGFD is defined by:height standard deviation score ≤ -3.0 and;basal insulin-like growth factor-1 (IGF-1) levels below the 2.5th percentile for age and gender and;growth hormone (GH) sufficiency;exclusion of secondary forms of IGF-1 deficiency, such as malnutrition, hypothyroidism, or chronic treatment with pharmacologic doses of anti-inflammatory steroids.Severe primary IGFD includes patients with mutations in the GH receptor (GHR), post-GHR signalling pathway, and IGF-1 gene defects; they are not GH deficient, and therefore, they cannot be expected to respond adequately to exogenous GH treatment. It is recommended to confirm the diagnosis by conducting an IGF-1 generation test. uuid:53b44d0f-a2d7-40a1-9aee-392faa3db7ec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:0JJ21K6L2I biolink:treats MONDO:0032586 PMID:41385096 "[{""id"":""uuid:1a0b19f7-6354-4a69-a689-5a0813358309"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:adff8b66-9ef8-4791-9bd9-300654441a1b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VEOPOZ is indicated for the treatment of adult and pediatric patients 1 year of age and older with CD55-deficient protein-losing enteropathy (PLE), also known as CHAPLE disease. uuid:24be339b-5ecd-4e52-bfb9-65707027b4fd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8499 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:27bf430a-d5fd-4bec-89b3-dc42e28e8b83"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:764e1f56-0eee-427b-b3df-ad3cc3ba4fdf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDERAL XL is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including beta-blockers. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mm Hg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. uuid:f87d91a6-87a4-4385-bd70-aab75bccc3fe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8499 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:0259b863-4edf-41b3-9690-f385817b9bad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:acefa244-2d2a-4aa8-a1ad-74b25f8feac1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDERAL XL is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including beta-blockers. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mm Hg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. uuid:deca3957-4bb5-4422-8e2a-139afff4d4b5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8499 biolink:treats MONDO:0005016 PMID:41385096 "[{""id"":""uuid:6e7d44c7-7a0c-4f5d-a317-8f1219c20104"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ea077cce-b038-4a68-be45-7be8f3e71947"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDERAL XL is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including beta-blockers. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mm Hg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. uuid:5158fb74-3ba4-4e2a-b6be-1f7e19f62c85 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8499 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:b0e0cb65-230e-4d5f-b966-74600302f305"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:365fca1d-2035-44de-a776-6b146430f6a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDERAL XL is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including beta-blockers. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mm Hg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. uuid:8e2ccaef-4570-4703-a587-1e5f1907e51e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8499 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:ac878741-0593-4a52-a2d6-684e8320c92d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a2deeca8-46cf-4497-9a1f-2934eb56ce64"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDERAL XL is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including beta-blockers. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mm Hg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. uuid:7d027209-639a-40db-b1dd-1d766fabe4a8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:94807 biolink:treats MONDO:0001103 PMID:41385096 "[{""id"":""uuid:e1a38545-e207-41b2-8f3e-31b94e064eb8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cd8dcee6-3e51-4831-a982-be6dccadc1b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diarrhea caused by Giardia lamblia or Cryptosporidium parvum: ALINIA for Oral Suspension (patients 1 year of age and older) and ALINIA Tablets (patients 12 years and older) are indicated for the treatment of diarrhea caused by Giardia lamblia or Cryptosporidium parvum . Limitations of Use ALINIA for Oral Suspension and ALINIA Tablets have not been shown to be effective for the treatment of diarrhea caused by Cryptosporidium parvum in HIV-infected or immunodeficient patients [ see Clinical Studies (14.2) ] uuid:ac5361cf-5f06-4e95-b51a-c5cbe855d9ce biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:94807 biolink:treats MONDO:0015474 PMID:41385096 "[{""id"":""uuid:04026361-cf72-4b7e-98c9-45c1a89bcc07"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:96615901-4f07-4b6c-973a-17a7542b9445"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diarrhea caused by Giardia lamblia or Cryptosporidium parvum: ALINIA for Oral Suspension (patients 1 year of age and older) and ALINIA Tablets (patients 12 years and older) are indicated for the treatment of diarrhea caused by Giardia lamblia or Cryptosporidium parvum . Limitations of Use ALINIA for Oral Suspension and ALINIA Tablets have not been shown to be effective for the treatment of diarrhea caused by Cryptosporidium parvum in HIV-infected or immunodeficient patients [ see Clinical Studies (14.2) ] uuid:aa5b3c58-9c62-4c0e-b88e-34169b7c69f1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2637 biolink:treats MONDO:0018602 PMID:41385096 "[{""id"":""uuid:664ec602-ca43-4249-af82-9b98c51d9306"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b787c9ee-04dd-4a12-ade6-4dce3dfe23cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amikacin Sulfate Injection is indicated in the short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria, including Pseudomonas species, Escherichia coli , species of indole-positive and indole-negative Proteus , Providencia species, Klebsiella-Enterobacter-Serratia species, and Acinetobacter ( Mima-Herellea ) species. Clinical studies have shown Amikacin Sulfate Injection to be effective in bacterial septicemia (including neonatal sepsis); in serious infections of the respiratory tract, bones and joints, central nervous system (including meningitis) and skin and soft tissue; intra-abdominal infections (including peritonitis); and in burns and post-operative infections (including post-vascular surgery). Clinical studies have shown amikacin also to be effective in serious complicated and recurrent urinary tract infections due to these organisms. Aminoglycosides, including Amikacin Sulfate Injection are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics having less potential toxicity. Bacteriologic studies should be performed to identify causative organisms and their susceptibilities to amikacin. Amikacin may be considered as initial therapy in suspected Gram-negative infections and therapy may be instituted before obtaining the results of susceptibility testing. Clinical trials demonstrated that amikacin was effective in infections caused by gentamicin and/or tobramycin-resistant strains of Gram-negative organisms, particularly Proteus rettgeri , Providencia stuartii , Serratia marcescens , and Pseudomonas aeruginosa . The decision to continue therapy with the drug should be based on results of the susceptibility tests, the severity of the infection, the response of the patient and the important additional considerations contained in the WARNINGS box above. Amikacin has also been shown to be effective in staphylococcal infections and may be considered as initial therapy under certain conditions in the treatment of known or suspected staphylococcal disease such as, severe infections where the causative organism may be either a Gram-negative bacterium or a staphylococcus, infections due to susceptible strains of staphylococci in patients allergic to other antibiotics, and in mixed staphylococci/Gram-negative infections. In certain severe infections such as neonatal sepsis, concomitant therapy with a penicillin-type drug may be indicated because of the possibility of infections due to Gram-positive organisms such as streptococci or pneumococci. To reduce the development of drug-resistant bacteria and maintain the effectiveness of amikacin and other antibacterial drugs, amikacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:d9b7a561-1f4b-45e6-ac7d-70db29bc3ad9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2637 biolink:treats HP:0000010 PMID:41385096 "[{""id"":""uuid:56efcea1-b97f-43c1-936f-68f73d900fb4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cff6a0e7-c534-4e29-b45f-8b79d56fc60c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amikacin Sulfate Injection is indicated in the short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria, including Pseudomonas species, Escherichia coli , species of indole-positive and indole-negative Proteus , Providencia species, Klebsiella-Enterobacter-Serratia species, and Acinetobacter ( Mima-Herellea ) species. Clinical studies have shown Amikacin Sulfate Injection to be effective in bacterial septicemia (including neonatal sepsis); in serious infections of the respiratory tract, bones and joints, central nervous system (including meningitis) and skin and soft tissue; intra-abdominal infections (including peritonitis); and in burns and post-operative infections (including post-vascular surgery). Clinical studies have shown amikacin also to be effective in serious complicated and recurrent urinary tract infections due to these organisms. Aminoglycosides, including Amikacin Sulfate Injection are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics having less potential toxicity. Bacteriologic studies should be performed to identify causative organisms and their susceptibilities to amikacin. Amikacin may be considered as initial therapy in suspected Gram-negative infections and therapy may be instituted before obtaining the results of susceptibility testing. Clinical trials demonstrated that amikacin was effective in infections caused by gentamicin and/or tobramycin-resistant strains of Gram-negative organisms, particularly Proteus rettgeri , Providencia stuartii , Serratia marcescens , and Pseudomonas aeruginosa . The decision to continue therapy with the drug should be based on results of the susceptibility tests, the severity of the infection, the response of the patient and the important additional considerations contained in the WARNINGS box above. Amikacin has also been shown to be effective in staphylococcal infections and may be considered as initial therapy under certain conditions in the treatment of known or suspected staphylococcal disease such as, severe infections where the causative organism may be either a Gram-negative bacterium or a staphylococcus, infections due to susceptible strains of staphylococci in patients allergic to other antibiotics, and in mixed staphylococci/Gram-negative infections. In certain severe infections such as neonatal sepsis, concomitant therapy with a penicillin-type drug may be indicated because of the possibility of infections due to Gram-positive organisms such as streptococci or pneumococci. To reduce the development of drug-resistant bacteria and maintain the effectiveness of amikacin and other antibacterial drugs, amikacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:109f8d54-92d1-4b0d-a446-dca1f84a07f0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1153736 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:439a87e3-9385-4386-a449-9abad9e24552"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bae4b9bf-28f9-47ee-b6c1-c8e738f772ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydrocodone Bitartrate and Aspirin Tablets are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, and misuse, with opioids, which can occur at any dosage or duration, reserve Hydrocodone Bitartrate and Aspirin Tablets for use in patients for whom alternative treatment options (e.g., non-opioid analgesics): have not been tolerated or are not expected to be tolerated. have not provided adequate analgesia or are not expected to provide adequate analgesia. Hydrocodone Bitartrate and Aspirin Tablets should not be used for extended period of time unless the pain remains severe enough to require an opioid analgesic and for which alternative treatment options continue to be inadequate. uuid:f98d38c7-ab81-4635-84fc-97b52cc3c816 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6909 biolink:treats MONDO:0024388 PMID:41385096 "[{""id"":""uuid:8fc8a3c6-5646-4ead-82eb-3423c8397ae1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2e2618c6-780f-4c2c-8bed-663425562087"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Metronidazole Injection and other antibacterial drugs, Metronidazole Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment of Anaerobic Infections Metronidazole Injection is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Indicated surgical procedures should be performed in conjunction with Metronidazole Injection therapy. In a mixed aerobic and anaerobic infection, antibiotics appropriate for the treatment of the aerobic infection should be used in addition to Metronidazole Injection. Metronidazole Injection is effective in Bacteroides fragilis infections resistant to clindamycin, chloramphenicol, and penicillin. Intra-Abdominal Infections, including peritonitis, intra-abdominal abscess, and liver abscess, caused by Bacteroides species including the B. fragilis group (B. fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron, B. vulgatus), Clostridium species, Eubacterium species, Peptococcus species, and Peptostreptococcus species. Skin and Skin Structure Infections caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus species, Peptostreptococcus species, and Fusobacterium species. Gynecologic Infections, including endometritis, endomyometritis, tubo-ovarian abscess, and post-surgical vaginal cuff infection, caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus species, and Peptostreptococcus species. Bacterial Septicemia caused by Bacteroides species including the B. fragilis group and Clostridium species. Bone and Joint Infections, as adjunctive therapy, caused by Bacteroides species including the B. fragilis group. Central Nervous System (CNS) Infections, including meningitis and brain abscess, caused by Bacteroides species including the B. fragilis group. Lower Respiratory Tract Infections, including pneumonia, empyema, and lung abscess, caused by Bacteroides species including the B. fragilis group. Endocarditis caused by Bacteroides species including the B. fragilis group. Prophylaxis The prophylactic administration of Metronidazole Injection preoperatively, intraoperatively, and postoperatively may reduce the incidence of postoperative infection in patients undergoing elective colorectal surgery which is classified as contaminated or potentially contaminated. Prophylactic use of Metronidazole Injection should be discontinued within 12 hours after surgery. If there are signs of infection, specimens for cultures should be obtained for the identification of the causative organism(s) so that appropriate therapy may be given (see DOSAGE AND ADMINISTRATION). To reduce the development of drug-resistant bacteria and maintain the effectiveness of metronidazole and other antibacterial drugs, metronidazole should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antimicrobial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:7e4816d6-5c20-458f-933a-ffaebbd59ea7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6909 biolink:treats MONDO:0006671 PMID:41385096 "[{""id"":""uuid:b1aa4640-de61-4160-8cb0-5253cc02ba94"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5e84bab2-af3f-4dd1-90f3-123e248b4212"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Metronidazole Injection and other antibacterial drugs, Metronidazole Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment of Anaerobic Infections Metronidazole Injection is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Indicated surgical procedures should be performed in conjunction with Metronidazole Injection therapy. In a mixed aerobic and anaerobic infection, antibiotics appropriate for the treatment of the aerobic infection should be used in addition to Metronidazole Injection. Metronidazole Injection is effective in Bacteroides fragilis infections resistant to clindamycin, chloramphenicol, and penicillin. Intra-Abdominal Infections, including peritonitis, intra-abdominal abscess, and liver abscess, caused by Bacteroides species including the B. fragilis group (B. fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron, B. vulgatus), Clostridium species, Eubacterium species, Peptococcus species, and Peptostreptococcus species. Skin and Skin Structure Infections caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus species, Peptostreptococcus species, and Fusobacterium species. Gynecologic Infections, including endometritis, endomyometritis, tubo-ovarian abscess, and post-surgical vaginal cuff infection, caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus species, and Peptostreptococcus species. Bacterial Septicemia caused by Bacteroides species including the B. fragilis group and Clostridium species. Bone and Joint Infections, as adjunctive therapy, caused by Bacteroides species including the B. fragilis group. Central Nervous System (CNS) Infections, including meningitis and brain abscess, caused by Bacteroides species including the B. fragilis group. Lower Respiratory Tract Infections, including pneumonia, empyema, and lung abscess, caused by Bacteroides species including the B. fragilis group. Endocarditis caused by Bacteroides species including the B. fragilis group. Prophylaxis The prophylactic administration of Metronidazole Injection preoperatively, intraoperatively, and postoperatively may reduce the incidence of postoperative infection in patients undergoing elective colorectal surgery which is classified as contaminated or potentially contaminated. Prophylactic use of Metronidazole Injection should be discontinued within 12 hours after surgery. If there are signs of infection, specimens for cultures should be obtained for the identification of the causative organism(s) so that appropriate therapy may be given (see DOSAGE AND ADMINISTRATION). To reduce the development of drug-resistant bacteria and maintain the effectiveness of metronidazole and other antibacterial drugs, metronidazole should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antimicrobial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:786fe992-cb8c-4233-a53c-92058343d0b8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6909 biolink:treats UMLS:C0392618 PMID:41385096 "[{""id"":""uuid:aed55225-43e0-4e07-b9d6-8a425131fa32"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:04217e0e-c389-4604-8e93-e03284b56d29"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Metronidazole Injection and other antibacterial drugs, Metronidazole Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment of Anaerobic Infections Metronidazole Injection is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Indicated surgical procedures should be performed in conjunction with Metronidazole Injection therapy. In a mixed aerobic and anaerobic infection, antibiotics appropriate for the treatment of the aerobic infection should be used in addition to Metronidazole Injection. Metronidazole Injection is effective in Bacteroides fragilis infections resistant to clindamycin, chloramphenicol, and penicillin. Intra-Abdominal Infections, including peritonitis, intra-abdominal abscess, and liver abscess, caused by Bacteroides species including the B. fragilis group (B. fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron, B. vulgatus), Clostridium species, Eubacterium species, Peptococcus species, and Peptostreptococcus species. Skin and Skin Structure Infections caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus species, Peptostreptococcus species, and Fusobacterium species. Gynecologic Infections, including endometritis, endomyometritis, tubo-ovarian abscess, and post-surgical vaginal cuff infection, caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus species, and Peptostreptococcus species. Bacterial Septicemia caused by Bacteroides species including the B. fragilis group and Clostridium species. Bone and Joint Infections, as adjunctive therapy, caused by Bacteroides species including the B. fragilis group. Central Nervous System (CNS) Infections, including meningitis and brain abscess, caused by Bacteroides species including the B. fragilis group. Lower Respiratory Tract Infections, including pneumonia, empyema, and lung abscess, caused by Bacteroides species including the B. fragilis group. Endocarditis caused by Bacteroides species including the B. fragilis group. Prophylaxis The prophylactic administration of Metronidazole Injection preoperatively, intraoperatively, and postoperatively may reduce the incidence of postoperative infection in patients undergoing elective colorectal surgery which is classified as contaminated or potentially contaminated. Prophylactic use of Metronidazole Injection should be discontinued within 12 hours after surgery. If there are signs of infection, specimens for cultures should be obtained for the identification of the causative organism(s) so that appropriate therapy may be given (see DOSAGE AND ADMINISTRATION). To reduce the development of drug-resistant bacteria and maintain the effectiveness of metronidazole and other antibacterial drugs, metronidazole should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antimicrobial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:724255cc-79f8-4e30-918b-784814c55e3e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31547 biolink:treats MONDO:0006652 PMID:41385096 "[{""id"":""uuid:0504d58d-e6b3-41bb-b9cc-907e402538a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a072c5a3-f935-4973-81e6-e1ffe4dfe072"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Eplerenone Tablets are an aldosterone antagonist indicated for: the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.2 ). uuid:b8813985-1151-42a1-be8c-672c3f8e6854 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68478 biolink:treats UMLS:C0345468 PMID:41385096 "[{""id"":""uuid:f6f643ad-9298-40b7-ac70-c1074ce64102"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:08fdc224-c24e-4174-be35-137058c689ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ccefce76-9ab6-4c77-83bd-7fe21fe86e0d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Everolimus is an mTOR inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in adult patients: Kidney Transplant : at low-moderate immunologic risk. Use in combination with basiliximab, cyclosporine (reduced doses) and corticosteroids. ( 1.1 ) Liver Transplant : Administer no earlier than 30 days post transplant. Use in combination with tacrolimus (reduced doses) and corticosteroids. ( 1.2 , 5.5 ) Limitations of Use ( 1.3 ) Safety and efficacy have not been established in the following: Kidney transplant patients at high immunologic risk ( 1.3 ) Recipients of transplanted organs other than kidney or liver ( 1.3 , 5.7 ) Pediatric patients (less than 18 years) ( 1.3 )|[PMDA] Drugs containing a new active ingredient indicated for the prophylaxis of organ rejection in cardiac transplant. [Priority Review] uuid:b126d305-2831-43dc-9c1f-5c221d1ef35a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:24755620 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:75adcc69-3b22-4b58-b874-e4849a62740b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:29e30d26-71a7-4ac4-90e1-6ddcc4cbd5ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ENTRESTO is indicated: to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal. ( 1.1 ) for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. ENTRESTO reduces NT-proBNP and is expected to improve cardiovascular outcomes. ( 1.2 ) uuid:52ae4912-7420-4ad4-afff-535173aab169 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:24755620 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:0ab871a3-f229-42c9-bab9-e1506096f15e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:25d7c76a-f815-4347-a04b-4737374ac4d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ENTRESTO is indicated: to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal. ( 1.1 ) for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. ENTRESTO reduces NT-proBNP and is expected to improve cardiovascular outcomes. ( 1.2 ) uuid:7fe8efd9-b1bc-4221-bd14-1c0d5c62a378 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:24755620 biolink:treats MONDO:0005254 PMID:41385096 "[{""id"":""uuid:67c3ee0e-61c8-49c3-b6d6-8b822f35d5b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d11a5379-b792-46c1-a8f7-185d73c411f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ENTRESTO is indicated: to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal. ( 1.1 ) for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. ENTRESTO reduces NT-proBNP and is expected to improve cardiovascular outcomes. ( 1.2 ) uuid:bba45dbf-7a9f-4d46-8801-3ad0f57f8495 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5856 biolink:treats MONDO:0020575 PMID:41385096 "[{""id"":""uuid:f2c27d05-bc09-4dc8-925f-c9f016a7eea6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c17e455a-60e7-4e0c-bffc-02f1c21ccd5f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ibutilide fumarate injection is indicated for the rapid conversion of atrial fibrillation or atrial flutter of recent onset to sinus rhythm. Patients with atrial arrhythmias of longer duration are less likely to respond to ibutilide fumarate. The effectiveness of ibutilide has not been determined in patients with arrhythmias of more than 90 days in duration. LIFE-THREATENING ARRHYTHMIAS—APPROPRIATE TREATMENT ENVIRONMENT Ibutilide fumarate can cause potentially fatal arrhythmias, particularly sustained polymorphic ventricular tachycardia, usually in association with QT prolongation (torsades de pointes), but sometimes without documented QT prolongation. In registration studies, these arrhythmias, which require cardioversion, occurred in 1.7% of treated patients during, or within a number of hours of, use of Ibutilide fumarate. These arrhythmias can be reversed if treated promptly (see WARNINGS, Proarrhythmia ). It is essential that Ibutilide fumarate be administered in a setting of continuous ECG monitoring and by personnel trained in identification and treatment of acute ventricular arrhythmias, particularly polymorphic ventricular tachycardia. Patients with atrial fibrillation of more than 2 to 3 days’ duration must be adequately anticoagulated, generally for at least 2 weeks. CHOICE OF PATIENTS Patients with chronic atrial fibrillation have a strong tendency to revert after conversion to sinus rhythm (see CLINICAL STUDIES ) and treatments to maintain sinus rhythm carry risks. Patients to be treated with Ibutilide fumarate , therefore, should be carefully selected such that the expected benefits of maintaining sinus rhythm outweigh the immediate risks of Ibutilide fumarate , and the risks of maintenance therapy, and are likely to offer an advantage compared with alternative management. uuid:199448fe-b268-4541-b97a-e9d5d4f84006 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16467 biolink:treats MONDO:0019591 PMID:41385096 "[{""id"":""uuid:4a806d16-5bf0-4673-9eb1-5c7f6fe5cd45"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:78b46d11-4dd5-4beb-adae-bd3fce36cfcb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] R-Gene ® 10 is indicated as an intravenous stimulant to the pituitary for the release of human growth hormone in patients where the measurement of pituitary reserve for HGH can be of diagnostic usefulness. It can be used as a diagnostic aid in such conditions as panhypopituitarism, pituitary dwarfism, chromophobe adenoma, postsurgical craniopharyngioma, hypophysectomy, pituitary trauma, acromegaly, gigantism and problems of growth and stature. If the insulin hypoglycemia test has indicated a deficiency of pituitary reserve for HGH, a test with R-Gene ® 10 is advisable to confirm the negative response. This can be done after a waiting period of one day. As patients may not respond to R-Gene ® 10 (Arginine Hydrochloride Injection, USP) during the first test, the unresponsive patient should be tested again to confirm the negative result. A second test can be performed after a waiting period of one day. Some patients who respond to R-Gene ® 10 do not respond to insulin and vice versa. The rate of false positive responses for R-Gene ® 10 is approximately 32%, and the rate of false negatives is approximately 27%. uuid:c70d2619-3c35-4131-aa5a-05e47e2ceb77 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16467 biolink:treats MONDO:0008250 PMID:41385096 "[{""id"":""uuid:b01d64c7-d0d0-4235-96be-c4d8c05e509b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9522cccd-416b-438e-878f-4d3274d09ca0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] R-Gene ® 10 is indicated as an intravenous stimulant to the pituitary for the release of human growth hormone in patients where the measurement of pituitary reserve for HGH can be of diagnostic usefulness. It can be used as a diagnostic aid in such conditions as panhypopituitarism, pituitary dwarfism, chromophobe adenoma, postsurgical craniopharyngioma, hypophysectomy, pituitary trauma, acromegaly, gigantism and problems of growth and stature. If the insulin hypoglycemia test has indicated a deficiency of pituitary reserve for HGH, a test with R-Gene ® 10 is advisable to confirm the negative response. This can be done after a waiting period of one day. As patients may not respond to R-Gene ® 10 (Arginine Hydrochloride Injection, USP) during the first test, the unresponsive patient should be tested again to confirm the negative result. A second test can be performed after a waiting period of one day. Some patients who respond to R-Gene ® 10 do not respond to insulin and vice versa. The rate of false positive responses for R-Gene ® 10 is approximately 32%, and the rate of false negatives is approximately 27%. uuid:8adbf4c6-b9cd-4b9f-8e7a-584852371d45 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16467 biolink:treats MONDO:0006701 PMID:41385096 "[{""id"":""uuid:c2671b56-6c39-4bcb-82e1-2d77dc400b8d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f8ecec67-5292-4cf6-84df-6d7989a32a57"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] R-Gene ® 10 is indicated as an intravenous stimulant to the pituitary for the release of human growth hormone in patients where the measurement of pituitary reserve for HGH can be of diagnostic usefulness. It can be used as a diagnostic aid in such conditions as panhypopituitarism, pituitary dwarfism, chromophobe adenoma, postsurgical craniopharyngioma, hypophysectomy, pituitary trauma, acromegaly, gigantism and problems of growth and stature. If the insulin hypoglycemia test has indicated a deficiency of pituitary reserve for HGH, a test with R-Gene ® 10 is advisable to confirm the negative response. This can be done after a waiting period of one day. As patients may not respond to R-Gene ® 10 (Arginine Hydrochloride Injection, USP) during the first test, the unresponsive patient should be tested again to confirm the negative result. A second test can be performed after a waiting period of one day. Some patients who respond to R-Gene ® 10 do not respond to insulin and vice versa. The rate of false positive responses for R-Gene ® 10 is approximately 32%, and the rate of false negatives is approximately 27%. uuid:a8b389ac-947c-4f72-afd5-9fd44c252f5e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16467 biolink:treats MONDO:0019933 PMID:41385096 "[{""id"":""uuid:a4eb21f0-5a1c-45b4-95a5-b0ce384b291e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3beb2178-590e-48f1-aed2-e83aaa51cf74"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] R-Gene ® 10 is indicated as an intravenous stimulant to the pituitary for the release of human growth hormone in patients where the measurement of pituitary reserve for HGH can be of diagnostic usefulness. It can be used as a diagnostic aid in such conditions as panhypopituitarism, pituitary dwarfism, chromophobe adenoma, postsurgical craniopharyngioma, hypophysectomy, pituitary trauma, acromegaly, gigantism and problems of growth and stature. If the insulin hypoglycemia test has indicated a deficiency of pituitary reserve for HGH, a test with R-Gene ® 10 is advisable to confirm the negative response. This can be done after a waiting period of one day. As patients may not respond to R-Gene ® 10 (Arginine Hydrochloride Injection, USP) during the first test, the unresponsive patient should be tested again to confirm the negative result. A second test can be performed after a waiting period of one day. Some patients who respond to R-Gene ® 10 do not respond to insulin and vice versa. The rate of false positive responses for R-Gene ® 10 is approximately 32%, and the rate of false negatives is approximately 27%. uuid:7089a10e-ad45-4206-962e-c227c285eb72 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16467 biolink:treats MONDO:0020479 PMID:41385096 "[{""id"":""uuid:2da6197b-ba03-4299-a3fc-408e35c641b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c44cdef6-6bda-4a67-8c15-8109d5555e90"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] R-Gene ® 10 is indicated as an intravenous stimulant to the pituitary for the release of human growth hormone in patients where the measurement of pituitary reserve for HGH can be of diagnostic usefulness. It can be used as a diagnostic aid in such conditions as panhypopituitarism, pituitary dwarfism, chromophobe adenoma, postsurgical craniopharyngioma, hypophysectomy, pituitary trauma, acromegaly, gigantism and problems of growth and stature. If the insulin hypoglycemia test has indicated a deficiency of pituitary reserve for HGH, a test with R-Gene ® 10 is advisable to confirm the negative response. This can be done after a waiting period of one day. As patients may not respond to R-Gene ® 10 (Arginine Hydrochloride Injection, USP) during the first test, the unresponsive patient should be tested again to confirm the negative result. A second test can be performed after a waiting period of one day. Some patients who respond to R-Gene ® 10 do not respond to insulin and vice versa. The rate of false positive responses for R-Gene ® 10 is approximately 32%, and the rate of false negatives is approximately 27%. uuid:f3d5717a-3d10-4920-8287-3fc012c3d94a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:94187 biolink:treats MONDO:0010679 PMID:41385096 "[{""id"":""uuid:0a5147ac-6650-4fb6-820d-b466482dba70"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5739d466-772c-4f64-9349-df447b49627f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DUVYZAT is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 6 years of age and older. uuid:18fc1ed1-c93a-4bce-aa11-ccda45932657 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PP0SHH6V16 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:564e8c80-ed1c-49a3-ba22-fa2d3715edaf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9cb5563f-8fd1-46e1-adf4-bd052d8140c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PRALUENT ® is indicated: To reduce the risk of myocardial infarction, stroke, and unstable angina requiring hospitalization in adults with established cardiovascular disease . As an adjunct to diet, alone or in combination with other low density lipoprotein cholesterol (LDL-C)-lowering therapies, in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), to reduce LDL-C. As an adjunct to other LDL-C-lowering therapies in adult patients with homozygous familial hypercholesterolemia (HoFH) to reduce LDL-C. As an adjunct to diet and other LDL-C-lowering therapies in pediatric patients aged 8 years and older with HeFH to reduce LDL-C. uuid:72a5a5b6-fd17-418a-9277-df78a13c78cd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PP0SHH6V16 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:0188786c-085e-4125-8c9e-40b601bd6bab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fe20b8b4-373d-4996-843d-1b8977234e11"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PRALUENT ® is indicated: To reduce the risk of myocardial infarction, stroke, and unstable angina requiring hospitalization in adults with established cardiovascular disease . As an adjunct to diet, alone or in combination with other low density lipoprotein cholesterol (LDL-C)-lowering therapies, in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), to reduce LDL-C. As an adjunct to other LDL-C-lowering therapies in adult patients with homozygous familial hypercholesterolemia (HoFH) to reduce LDL-C. As an adjunct to diet and other LDL-C-lowering therapies in pediatric patients aged 8 years and older with HeFH to reduce LDL-C. uuid:1da28401-c5dc-4eeb-a9ba-1186f5bd3708 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PP0SHH6V16 biolink:treats MONDO:0006805 PMID:41385096 "[{""id"":""uuid:4e70109b-8e5b-4c63-aed4-f483ee85430a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7e4687e6-850d-4d4b-baf9-9313102d29a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PRALUENT ® is indicated: To reduce the risk of myocardial infarction, stroke, and unstable angina requiring hospitalization in adults with established cardiovascular disease . As an adjunct to diet, alone or in combination with other low density lipoprotein cholesterol (LDL-C)-lowering therapies, in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), to reduce LDL-C. As an adjunct to other LDL-C-lowering therapies in adult patients with homozygous familial hypercholesterolemia (HoFH) to reduce LDL-C. As an adjunct to diet and other LDL-C-lowering therapies in pediatric patients aged 8 years and older with HeFH to reduce LDL-C. uuid:cbd38f51-1fc2-4b20-b59d-efa1ee481ab6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PP0SHH6V16 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:78fc283c-d053-4386-9dc0-ce3219b5b6c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6b33d74a-f4ba-4e8f-a43b-acf198706af9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PRALUENT ® is indicated: To reduce the risk of myocardial infarction, stroke, and unstable angina requiring hospitalization in adults with established cardiovascular disease . As an adjunct to diet, alone or in combination with other low density lipoprotein cholesterol (LDL-C)-lowering therapies, in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), to reduce LDL-C. As an adjunct to other LDL-C-lowering therapies in adult patients with homozygous familial hypercholesterolemia (HoFH) to reduce LDL-C. As an adjunct to diet and other LDL-C-lowering therapies in pediatric patients aged 8 years and older with HeFH to reduce LDL-C. uuid:2c5a0216-b508-4798-9235-dc35265a0b7b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PP0SHH6V16 biolink:treats UMLS:C0342882 PMID:41385096 "[{""id"":""uuid:42b2e330-41fb-4141-aede-976d3d5ccc47"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4ce01d5a-8974-4eee-bbb8-34f48e1af6e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PRALUENT ® is indicated: To reduce the risk of myocardial infarction, stroke, and unstable angina requiring hospitalization in adults with established cardiovascular disease . As an adjunct to diet, alone or in combination with other low density lipoprotein cholesterol (LDL-C)-lowering therapies, in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), to reduce LDL-C. As an adjunct to other LDL-C-lowering therapies in adult patients with homozygous familial hypercholesterolemia (HoFH) to reduce LDL-C. As an adjunct to diet and other LDL-C-lowering therapies in pediatric patients aged 8 years and older with HeFH to reduce LDL-C. uuid:4efdfdb5-aacf-4164-884e-01e475108c5e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PP0SHH6V16 biolink:treats MONDO:0018328 PMID:41385096 "[{""id"":""uuid:791f36f3-ed02-4031-a2c7-1f607a7f7143"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:55425de5-53d6-4066-bb10-d3067b334bbb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PRALUENT ® is indicated: To reduce the risk of myocardial infarction, stroke, and unstable angina requiring hospitalization in adults with established cardiovascular disease . As an adjunct to diet, alone or in combination with other low density lipoprotein cholesterol (LDL-C)-lowering therapies, in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), to reduce LDL-C. As an adjunct to other LDL-C-lowering therapies in adult patients with homozygous familial hypercholesterolemia (HoFH) to reduce LDL-C. As an adjunct to diet and other LDL-C-lowering therapies in pediatric patients aged 8 years and older with HeFH to reduce LDL-C. uuid:1e2c9399-3bf9-41e9-8ef0-8ffd9febd852 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47097 biolink:treats MONDO:0008310 PMID:41385096 "[{""id"":""uuid:0b0a76f0-6710-4d4d-85df-261989ed0c36"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4e0e5a7c-754b-4508-a6e7-76d146bbf4df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:cc477621-65de-4d65-aae0-aeef63eeec36"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/zokinvy""]},{""id"":""uuid:cc4d7f83-cda0-4fa0-a2d0-f91a51902305"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZOKINVY is indicated in patients 12 months of age and older with a body surface area (BSA) of 0.39 m 2 and above: To reduce the risk of mortality in Hutchinson-Gilford Progeria Syndrome (HGPS) For the treatment of processing-deficient Progeroid Laminopathies with either: Heterozygous LMNA mutation with progerin-like protein accumulation Homozygous or compound heterozygous ZMPSTE24 mutations Limitations of Use ZOKINVY is not indicated for other Progeroid Syndromes or processing-proficient Progeroid Laminopathies. Based upon its mechanism of action, ZOKINVY would not be expected to be effective in these populations.|[EMA] Zokinvy is indicated for the treatment of patients 12 months of age and older with a genetically confirmed diagnosis of Hutchinson-Gilford progeria syndrome or a processing-deficient progeroid laminopathy associated with either a heterozygous LMNA mutation with progerin-like protein accumulation or a homozygous or compound heterozygous ZMPSTE24 mutation.|[PMDA] Drugs with a new active ingredient indicated for the treatment of Hutchinson-Gilford Progeria syndrome and processing-deficient progeroid laminopathies. [Orphan drug] uuid:b44e3cb8-eb7e-4b46-a35b-5ad4f309ea6f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47097 biolink:treats MONDO:0021106 PMID:41385096 "[{""id"":""uuid:5b142647-36b9-4b65-9094-54f9f560a142"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:da5c9ed4-28bb-4e61-822e-551ae528ac13"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c4a87b04-cdb6-4acf-8075-bf5a9552c5be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/zokinvy""]},{""id"":""uuid:33992ab9-7c3b-4a2b-b01e-edff214fd128"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZOKINVY is indicated in patients 12 months of age and older with a body surface area (BSA) of 0.39 m 2 and above: To reduce the risk of mortality in Hutchinson-Gilford Progeria Syndrome (HGPS) For the treatment of processing-deficient Progeroid Laminopathies with either: Heterozygous LMNA mutation with progerin-like protein accumulation Homozygous or compound heterozygous ZMPSTE24 mutations Limitations of Use ZOKINVY is not indicated for other Progeroid Syndromes or processing-proficient Progeroid Laminopathies. Based upon its mechanism of action, ZOKINVY would not be expected to be effective in these populations.|[EMA] Zokinvy is indicated for the treatment of patients 12 months of age and older with a genetically confirmed diagnosis of Hutchinson-Gilford progeria syndrome or a processing-deficient progeroid laminopathy associated with either a heterozygous LMNA mutation with progerin-like protein accumulation or a homozygous or compound heterozygous ZMPSTE24 mutation.|[PMDA] Drugs with a new active ingredient indicated for the treatment of Hutchinson-Gilford Progeria syndrome and processing-deficient progeroid laminopathies. [Orphan drug] uuid:233c7916-63e8-414e-b492-cadbeaa8aa76 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7IK8Z952OK biolink:treats UMLS:C0267509 PMID:41385096 "[{""id"":""uuid:ffcbf051-f44b-4a4b-86f0-29041a377e8c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9fd42093-d2a6-4261-a9b7-5289088942bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TRULANCE is indicated in adults for the treatment of: chronic idiopathic constipation (CIC). irritable bowel syndrome with constipation (IBS-C). uuid:c1e50af9-ae93-4960-99c5-bdadb25c7804 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7IK8Z952OK biolink:treats MONDO:0005052 PMID:41385096 "[{""id"":""uuid:ded811fe-f04f-4ed6-9b05-e6e638fbbc5a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e94aa3e5-6cf0-4780-9e54-736972b1e4e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TRULANCE is indicated in adults for the treatment of: chronic idiopathic constipation (CIC). irritable bowel syndrome with constipation (IBS-C). uuid:895eee3a-f492-4c34-a865-489e06285146 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68558 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:74ec44c1-bc42-4f9d-ae5d-fc436a55a947"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:02b9dc46-5544-4b90-97af-35eef03d47b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:93b790ca-b4fc-401e-81e7-d85b836c34d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/brilique""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] BRILINTA is a P2Y 12 platelet inhibitor indicated to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of MI. For at least the first 12 months following ACS, it is superior to clopidogrel. BRILINTA also reduces the risk of stent thrombosis in patients who have been stented for treatment of ACS. (1.1) to reduce the risk of a first MI or stroke in patients with coronary artery disease (CAD) at high risk for such events. While use is not limited to this setting, the efficacy of BRILINTA was established in a population with type 2 diabetes mellitus (T2DM). (1.2) to reduce the risk of stroke in patients with acute ischemic stroke (NIH Stroke Scale score ≤5) or high-risk transient ischemic attack (TIA). (1.3)|[EMA] Brilique, co administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients withacute coronary syndromes (ACS) ora history of myocardial infarction (MI) and a high risk of developing an atherothrombotic eventBrilique, co-administered with acetyl salicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with a history of myocardial infarction (MI occurred at least one year ago) and a high risk of developing an atherothrombotic event. uuid:c288d8a4-0d1e-4722-8e4e-d706a2fbd9fb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68558 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:4ac51142-7c22-4a09-a45c-6721a4c4d258"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:417592c3-5b91-447d-94ae-95601c84bac3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BRILINTA is a P2Y 12 platelet inhibitor indicated to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of MI. For at least the first 12 months following ACS, it is superior to clopidogrel. BRILINTA also reduces the risk of stent thrombosis in patients who have been stented for treatment of ACS. (1.1) to reduce the risk of a first MI or stroke in patients with coronary artery disease (CAD) at high risk for such events. While use is not limited to this setting, the efficacy of BRILINTA was established in a population with type 2 diabetes mellitus (T2DM). (1.2) to reduce the risk of stroke in patients with acute ischemic stroke (NIH Stroke Scale score ≤5) or high-risk transient ischemic attack (TIA). (1.3) uuid:ce2494f4-4215-4fb2-baaa-230ccdfa47ff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68558 biolink:treats MONDO:0005542 PMID:41385096 "[{""id"":""uuid:e46ad554-947e-4a24-a21f-f259086a3875"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f449e161-7547-47be-9e27-c0afae81f4ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:56fe67e9-1a5b-4902-88d2-0120fc07b9eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/brilique""]},{""id"":""uuid:a82e61bc-0497-4d53-9619-5ee83f1b7625"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BRILINTA is a P2Y 12 platelet inhibitor indicated to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of MI. For at least the first 12 months following ACS, it is superior to clopidogrel. BRILINTA also reduces the risk of stent thrombosis in patients who have been stented for treatment of ACS. (1.1) to reduce the risk of a first MI or stroke in patients with coronary artery disease (CAD) at high risk for such events. While use is not limited to this setting, the efficacy of BRILINTA was established in a population with type 2 diabetes mellitus (T2DM). (1.2) to reduce the risk of stroke in patients with acute ischemic stroke (NIH Stroke Scale score ≤5) or high-risk transient ischemic attack (TIA). (1.3)|[EMA] Brilique, co administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients withacute coronary syndromes (ACS) ora history of myocardial infarction (MI) and a high risk of developing an atherothrombotic eventBrilique, co-administered with acetyl salicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with a history of myocardial infarction (MI occurred at least one year ago) and a high risk of developing an atherothrombotic event.|[PMDA] Drugs with a new active ingredient indicated for the treatment of: Old myocardial infarction at especially high risk of developing atherothrombosis with at least one of the following risk factors: age of 65 years or older, with diabetes mellitus requiring drug therapy, history of two or more episodes of myocardial infarction, angiography- confirmed multivessel coronary artery disease, or non-end-stage chronic renal dysfunction. Acute coronary syndrome (unstable angina, non-ST-segment elevation myocardial infarction, and ST-segment elevation myocardial infarction) for which percutaneous coronary intervention (PCI) is indicated. (provided that dual antiplatelet therapy including aspirin is appropriate but the administration of other antiplatelet drugs in combination with aspirin is not suitable for the patient.) uuid:44de8792-6d00-473c-9f12-24b837df02a6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68558 biolink:treats UMLS:C3897493 PMID:41385096 "[{""id"":""uuid:bb698460-fab3-499b-857e-9ac346899f55"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9a33ec51-cfd9-4b54-8673-7c0ee577a192"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BRILINTA is a P2Y 12 platelet inhibitor indicated to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of MI. For at least the first 12 months following ACS, it is superior to clopidogrel. BRILINTA also reduces the risk of stent thrombosis in patients who have been stented for treatment of ACS. (1.1) to reduce the risk of a first MI or stroke in patients with coronary artery disease (CAD) at high risk for such events. While use is not limited to this setting, the efficacy of BRILINTA was established in a population with type 2 diabetes mellitus (T2DM). (1.2) to reduce the risk of stroke in patients with acute ischemic stroke (NIH Stroke Scale score ≤5) or high-risk transient ischemic attack (TIA). (1.3) uuid:e5b9d364-1ca3-4481-a9f4-ca8d76493c99 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68558 biolink:treats MONDO:0005010 PMID:41385096 "[{""id"":""uuid:0c2a08a9-49a0-404e-84a2-767784dab62a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:51090fd4-b318-43bb-ba00-494eafe2563e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BRILINTA is a P2Y 12 platelet inhibitor indicated to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of MI. For at least the first 12 months following ACS, it is superior to clopidogrel. BRILINTA also reduces the risk of stent thrombosis in patients who have been stented for treatment of ACS. (1.1) to reduce the risk of a first MI or stroke in patients with coronary artery disease (CAD) at high risk for such events. While use is not limited to this setting, the efficacy of BRILINTA was established in a population with type 2 diabetes mellitus (T2DM). (1.2) to reduce the risk of stroke in patients with acute ischemic stroke (NIH Stroke Scale score ≤5) or high-risk transient ischemic attack (TIA). (1.3) uuid:471d5982-09fb-4320-a647-a072faec0532 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68558 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:c5f422fb-bc6c-44db-aabd-72b332e66794"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9dd85720-8dca-40ae-ad9b-f6e2f22a993b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BRILINTA is a P2Y 12 platelet inhibitor indicated to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of MI. For at least the first 12 months following ACS, it is superior to clopidogrel. BRILINTA also reduces the risk of stent thrombosis in patients who have been stented for treatment of ACS. (1.1) to reduce the risk of a first MI or stroke in patients with coronary artery disease (CAD) at high risk for such events. While use is not limited to this setting, the efficacy of BRILINTA was established in a population with type 2 diabetes mellitus (T2DM). (1.2) to reduce the risk of stroke in patients with acute ischemic stroke (NIH Stroke Scale score ≤5) or high-risk transient ischemic attack (TIA). (1.3) uuid:15179c3f-cebb-43ee-84ce-02fdca1e9c41 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68558 biolink:treats HP:0002140 PMID:41385096 "[{""id"":""uuid:5843694d-16c8-406a-8891-849060e17314"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ec658729-32d4-4b03-b2d9-d51ad1d524d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BRILINTA is a P2Y 12 platelet inhibitor indicated to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of MI. For at least the first 12 months following ACS, it is superior to clopidogrel. BRILINTA also reduces the risk of stent thrombosis in patients who have been stented for treatment of ACS. (1.1) to reduce the risk of a first MI or stroke in patients with coronary artery disease (CAD) at high risk for such events. While use is not limited to this setting, the efficacy of BRILINTA was established in a population with type 2 diabetes mellitus (T2DM). (1.2) to reduce the risk of stroke in patients with acute ischemic stroke (NIH Stroke Scale score ≤5) or high-risk transient ischemic attack (TIA). (1.3) uuid:2602638e-2fb6-4aec-a286-c9ed54dcff01 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68558 biolink:treats MONDO:0005264 PMID:41385096 "[{""id"":""uuid:2c6c370d-25b2-4954-80cc-c2012c9111f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5620313e-27c6-409a-82a9-4b220749fcb1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BRILINTA is a P2Y 12 platelet inhibitor indicated to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of MI. For at least the first 12 months following ACS, it is superior to clopidogrel. BRILINTA also reduces the risk of stent thrombosis in patients who have been stented for treatment of ACS. (1.1) to reduce the risk of a first MI or stroke in patients with coronary artery disease (CAD) at high risk for such events. While use is not limited to this setting, the efficacy of BRILINTA was established in a population with type 2 diabetes mellitus (T2DM). (1.2) to reduce the risk of stroke in patients with acute ischemic stroke (NIH Stroke Scale score ≤5) or high-risk transient ischemic attack (TIA). (1.3) uuid:c9c6b592-dfb4-40b5-bad8-86219fd5b2e5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6344 biolink:treats MONDO:0006846 PMID:41385096 "[{""id"":""uuid:a5014f6c-c756-402c-b78a-dc3e54a5fb9d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3232a7b2-c22d-468c-b624-c067c86eaafa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Labetalol HCl Injection is indicated in severe hypertension, to lower blood pressure. uuid:a593a766-7928-44c1-bb6f-7af8aa79f746 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4514 biolink:treats MONDO:0004880 PMID:41385096 "[{""id"":""uuid:cb1b0b8a-7349-4f2f-b710-265976f315bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c20df547-8d69-4353-b776-2876c7733fb4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dicyclomine Hydrochloride Injection, USP is indicated for the treatment of patients with functional bowel/irritable bowel syndrome. uuid:5efb0e73-58df-4ca8-9fd9-83dfb4b182a5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5790 biolink:treats MONDO:0004992 PMID:41385096 "[{""id"":""uuid:215de520-109b-4972-8092-20b1fe02cc7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bdd5545d-bea3-43ff-ae79-affa4ec6188f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydromorphone Hydrochloride Injection is indicated for the relief of moderate to severe pain such as that due to: surgery, cancer, trauma (soft tissue and bone), biliary colic, myocardial infarction, burns, renal colic. uuid:86736621-42c9-4614-bcfd-13f814955d79 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5790 biolink:treats UMLS:C0151824 PMID:41385096 "[{""id"":""uuid:768a05db-a077-4399-b4f4-8591827eb4e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e75c06d4-b9bf-478b-802f-16bebc4b6c3c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydromorphone Hydrochloride Injection is indicated for the relief of moderate to severe pain such as that due to: surgery, cancer, trauma (soft tissue and bone), biliary colic, myocardial infarction, burns, renal colic. uuid:8c9411c6-6337-41b0-99a0-c1cac61c81d6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5790 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:00e282f4-963e-448e-a1b7-9a3adef44339"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cf27956e-6854-4c32-a2b1-17d814e99e07"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydromorphone Hydrochloride Injection is indicated for the relief of moderate to severe pain such as that due to: surgery, cancer, trauma (soft tissue and bone), biliary colic, myocardial infarction, burns, renal colic. uuid:b7eb7f0e-a6a3-4759-931e-209b0fd2e727 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5790 biolink:treats EFO:1001412 PMID:41385096 "[{""id"":""uuid:1dd1598f-df67-44d3-9638-3e8ea301557b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9aa4283d-5583-43d5-8e48-b537a504dceb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydromorphone Hydrochloride Injection is indicated for the relief of moderate to severe pain such as that due to: surgery, cancer, trauma (soft tissue and bone), biliary colic, myocardial infarction, burns, renal colic. uuid:c6fb4149-3744-4005-9a10-7f16d130f8e6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:681848 biolink:treats MONDO:0043775 PMID:41385096 "[{""id"":""uuid:5659ffdf-186e-48b5-9e51-693667c708bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6b702c4b-e3b8-42e3-997d-59eee15fc7ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When the possibility of airway obstruction and/or hypoxia have been eliminated, doxapram may be used to stimulate respiration in patients with drug-induced postanesthesia respiratory depression or apnea other than that due to muscle relaxant drugs. To pharmacologically stimulate deep breathing in the postoperative patient. (A quantitative method of assessing oxygenation, such as pulse oximetry, is recommended.) uuid:ca22f4c7-f5ba-49bd-a07b-771a962d926f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:681848 biolink:treats HP:0002104 PMID:41385096 "[{""id"":""uuid:1ab8014e-6e7e-40ec-b3c7-0e4bad2d66e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:93961e48-31e5-4359-bcc0-aecff496ae09"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When the possibility of airway obstruction and/or hypoxia have been eliminated, doxapram may be used to stimulate respiration in patients with drug-induced postanesthesia respiratory depression or apnea other than that due to muscle relaxant drugs. To pharmacologically stimulate deep breathing in the postoperative patient. (A quantitative method of assessing oxygenation, such as pulse oximetry, is recommended.) uuid:7229a0e8-1693-4345-b96b-0171723d5f13 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17303 biolink:treats MONDO:0024317 PMID:41385096 "[{""id"":""uuid:f081a2df-2513-4250-bafa-b5a1c5632880"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:49995a28-38db-4d8f-998e-21e4fdb8d3ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INFUMORPH is for use in continuous microinfusion devices and indicated only for intrathecal or epidural infusion in the management of intractable chronic pain severe enough to require an opioid analgesic and for which less invasive means of controlling pain are inadequate. Limitations of Use Not for single-dose intravenous, intramuscular, or subcutaneous administration due to the risk of overdose. Not for single-dose neuraxial injection because INFUMORPH is too concentrated for accurate delivery of the smaller doses used in this setting. INFUMORPH should not be used for an extended period of time unless the pain remains severe enough to require an opioid analgesic and for which alternative treatment options continue to be inadequate. uuid:e443f324-e10f-4dee-9c13-b701c3fc235c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63625 biolink:treats MONDO:0005344 PMID:41385096 "[{""id"":""uuid:d89ecb7e-2236-477a-9c46-f187a4679c60"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9e4ec945-47b5-4a24-8221-8bdf34ccaa31"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VEMLIDY is indicated for the treatment of chronic hepatitis B virus (HBV) infection in adults and pediatric patients 6 years of age and older and weighing at least 25 kg with compensated liver disease [see Clinical Studies (14) ] . uuid:d341470f-883b-438d-8fd2-3683281bc02a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8069 biolink:treats UMLS:C0700613 PMID:41385096 "[{""id"":""uuid:cf71a616-028d-4966-86a0-154f66e0e03d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:30226f3e-9e23-444c-9d30-157b4fafce32"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sedative. Sedation is obtainable within an hour, and in adequate dosage, the duration of action is more than six hours. Included in the more common conditions in which the sedative action of this class of drugs is desired are anxiety-tension states, hyperthyroidism, essential hypertension, nausea and vomiting of functional origin, motion sickness, acute labyrinthitis, pylorospasm in infants, chorea and cardiac failure. Phenobarbital is also a useful adjunct in treatment of hemorrhage from the respiratory or gastrointestinal tract. Phenobarbital controls anxiety, decreases muscular activity and lessens nervous excitability in hyperthyroid patients. However, thyrotoxic individuals occasionally react poorly to barbiturates. Hypnotic, for the short-term treatment of insomnia, since it appears to lose its effectiveness for sleep induction and sleep maintenance after 2 weeks (see CLINICAL PHARMACOLOGY ). Preanesthetic. Long-term anticonvulsant, (phenobarbital, mephobarbital and metharbital) for the treatment of generalized tonic-clonic and cortical focal seizures. And, in the emergency control of certain acute convulsive episodes, e.g., those associated with status epilepticus, cholera, eclampsia, cerebral hemorrhage, meningitis, tetanus, and toxic reactions to strychnine or local anesthetics. Phenobarbital sodium may be administered intramuscularly or intravenously as an anticonvulsant for emergency use. When administered intravenously, it may require 15 or more minutes before reaching peak concentrations in the brain. Therefore, injecting phenobarbital sodium until the convulsions stop may cause the brain level to exceed that required to control the convulsions and lead to severe barbiturate-induced depression. Phenobarbital is indicated in pediatric patients as an anticonvulsant and as a sedative, including its preoperative and postoperative use. uuid:784f2b2d-6b4e-48aa-be68-fc29d47d1485 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8069 biolink:treats MONDO:0004425 PMID:41385096 "[{""id"":""uuid:59ddf1b5-8f22-4786-a483-3c87750367ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1ee616fa-75e0-4fae-94dc-dfdc51349acf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sedative. Sedation is obtainable within an hour, and in adequate dosage, the duration of action is more than six hours. Included in the more common conditions in which the sedative action of this class of drugs is desired are anxiety-tension states, hyperthyroidism, essential hypertension, nausea and vomiting of functional origin, motion sickness, acute labyrinthitis, pylorospasm in infants, chorea and cardiac failure. Phenobarbital is also a useful adjunct in treatment of hemorrhage from the respiratory or gastrointestinal tract. Phenobarbital controls anxiety, decreases muscular activity and lessens nervous excitability in hyperthyroid patients. However, thyrotoxic individuals occasionally react poorly to barbiturates. Hypnotic, for the short-term treatment of insomnia, since it appears to lose its effectiveness for sleep induction and sleep maintenance after 2 weeks (see CLINICAL PHARMACOLOGY ). Preanesthetic. Long-term anticonvulsant, (phenobarbital, mephobarbital and metharbital) for the treatment of generalized tonic-clonic and cortical focal seizures. And, in the emergency control of certain acute convulsive episodes, e.g., those associated with status epilepticus, cholera, eclampsia, cerebral hemorrhage, meningitis, tetanus, and toxic reactions to strychnine or local anesthetics. Phenobarbital sodium may be administered intramuscularly or intravenously as an anticonvulsant for emergency use. When administered intravenously, it may require 15 or more minutes before reaching peak concentrations in the brain. Therefore, injecting phenobarbital sodium until the convulsions stop may cause the brain level to exceed that required to control the convulsions and lead to severe barbiturate-induced depression. Phenobarbital is indicated in pediatric patients as an anticonvulsant and as a sedative, including its preoperative and postoperative use. uuid:90ce62af-5fa3-4802-9c22-9d52ad70141d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8069 biolink:treats MONDO:0001134 PMID:41385096 "[{""id"":""uuid:d4927989-b89b-4b91-9930-8a79aa7c2565"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:54ff1911-9bc1-42d8-afe6-bab5a6cf3000"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sedative. Sedation is obtainable within an hour, and in adequate dosage, the duration of action is more than six hours. Included in the more common conditions in which the sedative action of this class of drugs is desired are anxiety-tension states, hyperthyroidism, essential hypertension, nausea and vomiting of functional origin, motion sickness, acute labyrinthitis, pylorospasm in infants, chorea and cardiac failure. Phenobarbital is also a useful adjunct in treatment of hemorrhage from the respiratory or gastrointestinal tract. Phenobarbital controls anxiety, decreases muscular activity and lessens nervous excitability in hyperthyroid patients. However, thyrotoxic individuals occasionally react poorly to barbiturates. Hypnotic, for the short-term treatment of insomnia, since it appears to lose its effectiveness for sleep induction and sleep maintenance after 2 weeks (see CLINICAL PHARMACOLOGY ). Preanesthetic. Long-term anticonvulsant, (phenobarbital, mephobarbital and metharbital) for the treatment of generalized tonic-clonic and cortical focal seizures. And, in the emergency control of certain acute convulsive episodes, e.g., those associated with status epilepticus, cholera, eclampsia, cerebral hemorrhage, meningitis, tetanus, and toxic reactions to strychnine or local anesthetics. Phenobarbital sodium may be administered intramuscularly or intravenously as an anticonvulsant for emergency use. When administered intravenously, it may require 15 or more minutes before reaching peak concentrations in the brain. Therefore, injecting phenobarbital sodium until the convulsions stop may cause the brain level to exceed that required to control the convulsions and lead to severe barbiturate-induced depression. Phenobarbital is indicated in pediatric patients as an anticonvulsant and as a sedative, including its preoperative and postoperative use. uuid:841f0681-fc4f-4506-9cb8-13799533e4e2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8069 biolink:treats MONDO:0001318 PMID:41385096 "[{""id"":""uuid:5da6cec6-1cf6-41fe-8f23-a847c7c737ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d89b0ece-9515-40b9-9ef0-43be7af3262a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sedative. Sedation is obtainable within an hour, and in adequate dosage, the duration of action is more than six hours. Included in the more common conditions in which the sedative action of this class of drugs is desired are anxiety-tension states, hyperthyroidism, essential hypertension, nausea and vomiting of functional origin, motion sickness, acute labyrinthitis, pylorospasm in infants, chorea and cardiac failure. Phenobarbital is also a useful adjunct in treatment of hemorrhage from the respiratory or gastrointestinal tract. Phenobarbital controls anxiety, decreases muscular activity and lessens nervous excitability in hyperthyroid patients. However, thyrotoxic individuals occasionally react poorly to barbiturates. Hypnotic, for the short-term treatment of insomnia, since it appears to lose its effectiveness for sleep induction and sleep maintenance after 2 weeks (see CLINICAL PHARMACOLOGY ). Preanesthetic. Long-term anticonvulsant, (phenobarbital, mephobarbital and metharbital) for the treatment of generalized tonic-clonic and cortical focal seizures. And, in the emergency control of certain acute convulsive episodes, e.g., those associated with status epilepticus, cholera, eclampsia, cerebral hemorrhage, meningitis, tetanus, and toxic reactions to strychnine or local anesthetics. Phenobarbital sodium may be administered intramuscularly or intravenously as an anticonvulsant for emergency use. When administered intravenously, it may require 15 or more minutes before reaching peak concentrations in the brain. Therefore, injecting phenobarbital sodium until the convulsions stop may cause the brain level to exceed that required to control the convulsions and lead to severe barbiturate-induced depression. Phenobarbital is indicated in pediatric patients as an anticonvulsant and as a sedative, including its preoperative and postoperative use. uuid:8c7f836c-91c8-4fb4-93b5-e540035efa90 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8069 biolink:treats MONDO:0008015 PMID:41385096 "[{""id"":""uuid:0ee60290-1e88-4d32-b605-751c50bf64e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b223247b-4673-4bac-95e8-fdb77b4a6d6f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sedative. Sedation is obtainable within an hour, and in adequate dosage, the duration of action is more than six hours. Included in the more common conditions in which the sedative action of this class of drugs is desired are anxiety-tension states, hyperthyroidism, essential hypertension, nausea and vomiting of functional origin, motion sickness, acute labyrinthitis, pylorospasm in infants, chorea and cardiac failure. Phenobarbital is also a useful adjunct in treatment of hemorrhage from the respiratory or gastrointestinal tract. Phenobarbital controls anxiety, decreases muscular activity and lessens nervous excitability in hyperthyroid patients. However, thyrotoxic individuals occasionally react poorly to barbiturates. Hypnotic, for the short-term treatment of insomnia, since it appears to lose its effectiveness for sleep induction and sleep maintenance after 2 weeks (see CLINICAL PHARMACOLOGY ). Preanesthetic. Long-term anticonvulsant, (phenobarbital, mephobarbital and metharbital) for the treatment of generalized tonic-clonic and cortical focal seizures. And, in the emergency control of certain acute convulsive episodes, e.g., those associated with status epilepticus, cholera, eclampsia, cerebral hemorrhage, meningitis, tetanus, and toxic reactions to strychnine or local anesthetics. Phenobarbital sodium may be administered intramuscularly or intravenously as an anticonvulsant for emergency use. When administered intravenously, it may require 15 or more minutes before reaching peak concentrations in the brain. Therefore, injecting phenobarbital sodium until the convulsions stop may cause the brain level to exceed that required to control the convulsions and lead to severe barbiturate-induced depression. Phenobarbital is indicated in pediatric patients as an anticonvulsant and as a sedative, including its preoperative and postoperative use. uuid:bb2451ff-2566-4ac3-a4b9-9309e3f0cf8f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8069 biolink:treats UMLS:C3536631 PMID:41385096 "[{""id"":""uuid:00622aef-bff3-4019-aebd-cca2ebaabb70"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:85bab6b3-c23f-4273-8ddb-fef15682d202"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sedative. Sedation is obtainable within an hour, and in adequate dosage, the duration of action is more than six hours. Included in the more common conditions in which the sedative action of this class of drugs is desired are anxiety-tension states, hyperthyroidism, essential hypertension, nausea and vomiting of functional origin, motion sickness, acute labyrinthitis, pylorospasm in infants, chorea and cardiac failure. Phenobarbital is also a useful adjunct in treatment of hemorrhage from the respiratory or gastrointestinal tract. Phenobarbital controls anxiety, decreases muscular activity and lessens nervous excitability in hyperthyroid patients. However, thyrotoxic individuals occasionally react poorly to barbiturates. Hypnotic, for the short-term treatment of insomnia, since it appears to lose its effectiveness for sleep induction and sleep maintenance after 2 weeks (see CLINICAL PHARMACOLOGY ). Preanesthetic. Long-term anticonvulsant, (phenobarbital, mephobarbital and metharbital) for the treatment of generalized tonic-clonic and cortical focal seizures. And, in the emergency control of certain acute convulsive episodes, e.g., those associated with status epilepticus, cholera, eclampsia, cerebral hemorrhage, meningitis, tetanus, and toxic reactions to strychnine or local anesthetics. Phenobarbital sodium may be administered intramuscularly or intravenously as an anticonvulsant for emergency use. When administered intravenously, it may require 15 or more minutes before reaching peak concentrations in the brain. Therefore, injecting phenobarbital sodium until the convulsions stop may cause the brain level to exceed that required to control the convulsions and lead to severe barbiturate-induced depression. Phenobarbital is indicated in pediatric patients as an anticonvulsant and as a sedative, including its preoperative and postoperative use. uuid:23f83eb0-d30f-40a0-8dfe-2c089406f7b4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8069 biolink:treats MONDO:0001428 PMID:41385096 "[{""id"":""uuid:0cca4dd0-243b-4a49-a7f7-b701bdb891ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6ebe5b12-5a5f-4f90-a242-d071b5cefed7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sedative. Sedation is obtainable within an hour, and in adequate dosage, the duration of action is more than six hours. Included in the more common conditions in which the sedative action of this class of drugs is desired are anxiety-tension states, hyperthyroidism, essential hypertension, nausea and vomiting of functional origin, motion sickness, acute labyrinthitis, pylorospasm in infants, chorea and cardiac failure. Phenobarbital is also a useful adjunct in treatment of hemorrhage from the respiratory or gastrointestinal tract. Phenobarbital controls anxiety, decreases muscular activity and lessens nervous excitability in hyperthyroid patients. However, thyrotoxic individuals occasionally react poorly to barbiturates. Hypnotic, for the short-term treatment of insomnia, since it appears to lose its effectiveness for sleep induction and sleep maintenance after 2 weeks (see CLINICAL PHARMACOLOGY ). Preanesthetic. Long-term anticonvulsant, (phenobarbital, mephobarbital and metharbital) for the treatment of generalized tonic-clonic and cortical focal seizures. And, in the emergency control of certain acute convulsive episodes, e.g., those associated with status epilepticus, cholera, eclampsia, cerebral hemorrhage, meningitis, tetanus, and toxic reactions to strychnine or local anesthetics. Phenobarbital sodium may be administered intramuscularly or intravenously as an anticonvulsant for emergency use. When administered intravenously, it may require 15 or more minutes before reaching peak concentrations in the brain. Therefore, injecting phenobarbital sodium until the convulsions stop may cause the brain level to exceed that required to control the convulsions and lead to severe barbiturate-induced depression. Phenobarbital is indicated in pediatric patients as an anticonvulsant and as a sedative, including its preoperative and postoperative use. uuid:0afefab0-e2b8-4d7a-a343-0488e50084f1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8069 biolink:treats MONDO:0001595 PMID:41385096 "[{""id"":""uuid:f818f7d3-2da8-4d44-bb51-540b98a891d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8d07d641-7112-4863-9d27-74ab1094cef8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sedative. Sedation is obtainable within an hour, and in adequate dosage, the duration of action is more than six hours. Included in the more common conditions in which the sedative action of this class of drugs is desired are anxiety-tension states, hyperthyroidism, essential hypertension, nausea and vomiting of functional origin, motion sickness, acute labyrinthitis, pylorospasm in infants, chorea and cardiac failure. Phenobarbital is also a useful adjunct in treatment of hemorrhage from the respiratory or gastrointestinal tract. Phenobarbital controls anxiety, decreases muscular activity and lessens nervous excitability in hyperthyroid patients. However, thyrotoxic individuals occasionally react poorly to barbiturates. Hypnotic, for the short-term treatment of insomnia, since it appears to lose its effectiveness for sleep induction and sleep maintenance after 2 weeks (see CLINICAL PHARMACOLOGY ). Preanesthetic. Long-term anticonvulsant, (phenobarbital, mephobarbital and metharbital) for the treatment of generalized tonic-clonic and cortical focal seizures. And, in the emergency control of certain acute convulsive episodes, e.g., those associated with status epilepticus, cholera, eclampsia, cerebral hemorrhage, meningitis, tetanus, and toxic reactions to strychnine or local anesthetics. Phenobarbital sodium may be administered intramuscularly or intravenously as an anticonvulsant for emergency use. When administered intravenously, it may require 15 or more minutes before reaching peak concentrations in the brain. Therefore, injecting phenobarbital sodium until the convulsions stop may cause the brain level to exceed that required to control the convulsions and lead to severe barbiturate-induced depression. Phenobarbital is indicated in pediatric patients as an anticonvulsant and as a sedative, including its preoperative and postoperative use. uuid:00eaeab8-d0a5-4f2f-815b-0224af35a873 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8069 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:1dd5aed7-e8b4-40a5-ae1a-4a6d3a354617"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ea0a4edd-263c-4310-8722-d10802c180ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sedative. Sedation is obtainable within an hour, and in adequate dosage, the duration of action is more than six hours. Included in the more common conditions in which the sedative action of this class of drugs is desired are anxiety-tension states, hyperthyroidism, essential hypertension, nausea and vomiting of functional origin, motion sickness, acute labyrinthitis, pylorospasm in infants, chorea and cardiac failure. Phenobarbital is also a useful adjunct in treatment of hemorrhage from the respiratory or gastrointestinal tract. Phenobarbital controls anxiety, decreases muscular activity and lessens nervous excitability in hyperthyroid patients. However, thyrotoxic individuals occasionally react poorly to barbiturates. Hypnotic, for the short-term treatment of insomnia, since it appears to lose its effectiveness for sleep induction and sleep maintenance after 2 weeks (see CLINICAL PHARMACOLOGY ). Preanesthetic. Long-term anticonvulsant, (phenobarbital, mephobarbital and metharbital) for the treatment of generalized tonic-clonic and cortical focal seizures. And, in the emergency control of certain acute convulsive episodes, e.g., those associated with status epilepticus, cholera, eclampsia, cerebral hemorrhage, meningitis, tetanus, and toxic reactions to strychnine or local anesthetics. Phenobarbital sodium may be administered intramuscularly or intravenously as an anticonvulsant for emergency use. When administered intravenously, it may require 15 or more minutes before reaching peak concentrations in the brain. Therefore, injecting phenobarbital sodium until the convulsions stop may cause the brain level to exceed that required to control the convulsions and lead to severe barbiturate-induced depression. Phenobarbital is indicated in pediatric patients as an anticonvulsant and as a sedative, including its preoperative and postoperative use. uuid:3ef4191e-9a9c-4c00-99b0-30f6d318e641 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8069 biolink:treats MONDO:0013600 PMID:41385096 "[{""id"":""uuid:9ab6e1f5-e080-4160-b82a-546ec2101ee8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:276760b0-785a-4281-80af-82fcdf8958d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sedative. Sedation is obtainable within an hour, and in adequate dosage, the duration of action is more than six hours. Included in the more common conditions in which the sedative action of this class of drugs is desired are anxiety-tension states, hyperthyroidism, essential hypertension, nausea and vomiting of functional origin, motion sickness, acute labyrinthitis, pylorospasm in infants, chorea and cardiac failure. Phenobarbital is also a useful adjunct in treatment of hemorrhage from the respiratory or gastrointestinal tract. Phenobarbital controls anxiety, decreases muscular activity and lessens nervous excitability in hyperthyroid patients. However, thyrotoxic individuals occasionally react poorly to barbiturates. Hypnotic, for the short-term treatment of insomnia, since it appears to lose its effectiveness for sleep induction and sleep maintenance after 2 weeks (see CLINICAL PHARMACOLOGY ). Preanesthetic. Long-term anticonvulsant, (phenobarbital, mephobarbital and metharbital) for the treatment of generalized tonic-clonic and cortical focal seizures. And, in the emergency control of certain acute convulsive episodes, e.g., those associated with status epilepticus, cholera, eclampsia, cerebral hemorrhage, meningitis, tetanus, and toxic reactions to strychnine or local anesthetics. Phenobarbital sodium may be administered intramuscularly or intravenously as an anticonvulsant for emergency use. When administered intravenously, it may require 15 or more minutes before reaching peak concentrations in the brain. Therefore, injecting phenobarbital sodium until the convulsions stop may cause the brain level to exceed that required to control the convulsions and lead to severe barbiturate-induced depression. Phenobarbital is indicated in pediatric patients as an anticonvulsant and as a sedative, including its preoperative and postoperative use. uuid:348fea14-d620-4d1d-998e-0bc8470c070b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8069 biolink:treats MONDO:0002125 PMID:41385096 "[{""id"":""uuid:efc39cdb-3d29-4ff6-8ffe-284b2fd13ea1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:37d43aba-b02d-41f7-ac2d-81df540b1dad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sedative. Sedation is obtainable within an hour, and in adequate dosage, the duration of action is more than six hours. Included in the more common conditions in which the sedative action of this class of drugs is desired are anxiety-tension states, hyperthyroidism, essential hypertension, nausea and vomiting of functional origin, motion sickness, acute labyrinthitis, pylorospasm in infants, chorea and cardiac failure. Phenobarbital is also a useful adjunct in treatment of hemorrhage from the respiratory or gastrointestinal tract. Phenobarbital controls anxiety, decreases muscular activity and lessens nervous excitability in hyperthyroid patients. However, thyrotoxic individuals occasionally react poorly to barbiturates. Hypnotic, for the short-term treatment of insomnia, since it appears to lose its effectiveness for sleep induction and sleep maintenance after 2 weeks (see CLINICAL PHARMACOLOGY ). Preanesthetic. Long-term anticonvulsant, (phenobarbital, mephobarbital and metharbital) for the treatment of generalized tonic-clonic and cortical focal seizures. And, in the emergency control of certain acute convulsive episodes, e.g., those associated with status epilepticus, cholera, eclampsia, cerebral hemorrhage, meningitis, tetanus, and toxic reactions to strychnine or local anesthetics. Phenobarbital sodium may be administered intramuscularly or intravenously as an anticonvulsant for emergency use. When administered intravenously, it may require 15 or more minutes before reaching peak concentrations in the brain. Therefore, injecting phenobarbital sodium until the convulsions stop may cause the brain level to exceed that required to control the convulsions and lead to severe barbiturate-induced depression. Phenobarbital is indicated in pediatric patients as an anticonvulsant and as a sedative, including its preoperative and postoperative use. uuid:4af1827c-6b6c-4611-9d2e-fa78842af7e3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8069 biolink:treats MONDO:0015766 PMID:41385096 "[{""id"":""uuid:2675d84d-0a29-4f5c-9e57-2e986223faca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fc92444a-b31d-43f8-9ec7-6636fe3f8d31"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sedative. Sedation is obtainable within an hour, and in adequate dosage, the duration of action is more than six hours. Included in the more common conditions in which the sedative action of this class of drugs is desired are anxiety-tension states, hyperthyroidism, essential hypertension, nausea and vomiting of functional origin, motion sickness, acute labyrinthitis, pylorospasm in infants, chorea and cardiac failure. Phenobarbital is also a useful adjunct in treatment of hemorrhage from the respiratory or gastrointestinal tract. Phenobarbital controls anxiety, decreases muscular activity and lessens nervous excitability in hyperthyroid patients. However, thyrotoxic individuals occasionally react poorly to barbiturates. Hypnotic, for the short-term treatment of insomnia, since it appears to lose its effectiveness for sleep induction and sleep maintenance after 2 weeks (see CLINICAL PHARMACOLOGY ). Preanesthetic. Long-term anticonvulsant, (phenobarbital, mephobarbital and metharbital) for the treatment of generalized tonic-clonic and cortical focal seizures. And, in the emergency control of certain acute convulsive episodes, e.g., those associated with status epilepticus, cholera, eclampsia, cerebral hemorrhage, meningitis, tetanus, and toxic reactions to strychnine or local anesthetics. Phenobarbital sodium may be administered intramuscularly or intravenously as an anticonvulsant for emergency use. When administered intravenously, it may require 15 or more minutes before reaching peak concentrations in the brain. Therefore, injecting phenobarbital sodium until the convulsions stop may cause the brain level to exceed that required to control the convulsions and lead to severe barbiturate-induced depression. Phenobarbital is indicated in pediatric patients as an anticonvulsant and as a sedative, including its preoperative and postoperative use. uuid:9e79513c-cc79-4606-bbda-6d4431a3dd03 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8069 biolink:treats MONDO:0001754 PMID:41385096 "[{""id"":""uuid:1b577089-3583-4c04-a0fc-d708a8bf3735"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4263b6ea-3ff2-4a6a-af05-9c44af2bdc35"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sedative. Sedation is obtainable within an hour, and in adequate dosage, the duration of action is more than six hours. Included in the more common conditions in which the sedative action of this class of drugs is desired are anxiety-tension states, hyperthyroidism, essential hypertension, nausea and vomiting of functional origin, motion sickness, acute labyrinthitis, pylorospasm in infants, chorea and cardiac failure. Phenobarbital is also a useful adjunct in treatment of hemorrhage from the respiratory or gastrointestinal tract. Phenobarbital controls anxiety, decreases muscular activity and lessens nervous excitability in hyperthyroid patients. However, thyrotoxic individuals occasionally react poorly to barbiturates. Hypnotic, for the short-term treatment of insomnia, since it appears to lose its effectiveness for sleep induction and sleep maintenance after 2 weeks (see CLINICAL PHARMACOLOGY ). Preanesthetic. Long-term anticonvulsant, (phenobarbital, mephobarbital and metharbital) for the treatment of generalized tonic-clonic and cortical focal seizures. And, in the emergency control of certain acute convulsive episodes, e.g., those associated with status epilepticus, cholera, eclampsia, cerebral hemorrhage, meningitis, tetanus, and toxic reactions to strychnine or local anesthetics. Phenobarbital sodium may be administered intramuscularly or intravenously as an anticonvulsant for emergency use. When administered intravenously, it may require 15 or more minutes before reaching peak concentrations in the brain. Therefore, injecting phenobarbital sodium until the convulsions stop may cause the brain level to exceed that required to control the convulsions and lead to severe barbiturate-induced depression. Phenobarbital is indicated in pediatric patients as an anticonvulsant and as a sedative, including its preoperative and postoperative use. uuid:c50835a1-4970-484e-89e7-2d282062376b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8069 biolink:treats MONDO:0013792 PMID:41385096 "[{""id"":""uuid:da74af61-9c46-43e4-8b3e-acc5dad2f141"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dd686551-4e44-4537-932f-8b9714e5c17c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sedative. Sedation is obtainable within an hour, and in adequate dosage, the duration of action is more than six hours. Included in the more common conditions in which the sedative action of this class of drugs is desired are anxiety-tension states, hyperthyroidism, essential hypertension, nausea and vomiting of functional origin, motion sickness, acute labyrinthitis, pylorospasm in infants, chorea and cardiac failure. Phenobarbital is also a useful adjunct in treatment of hemorrhage from the respiratory or gastrointestinal tract. Phenobarbital controls anxiety, decreases muscular activity and lessens nervous excitability in hyperthyroid patients. However, thyrotoxic individuals occasionally react poorly to barbiturates. Hypnotic, for the short-term treatment of insomnia, since it appears to lose its effectiveness for sleep induction and sleep maintenance after 2 weeks (see CLINICAL PHARMACOLOGY ). Preanesthetic. Long-term anticonvulsant, (phenobarbital, mephobarbital and metharbital) for the treatment of generalized tonic-clonic and cortical focal seizures. And, in the emergency control of certain acute convulsive episodes, e.g., those associated with status epilepticus, cholera, eclampsia, cerebral hemorrhage, meningitis, tetanus, and toxic reactions to strychnine or local anesthetics. Phenobarbital sodium may be administered intramuscularly or intravenously as an anticonvulsant for emergency use. When administered intravenously, it may require 15 or more minutes before reaching peak concentrations in the brain. Therefore, injecting phenobarbital sodium until the convulsions stop may cause the brain level to exceed that required to control the convulsions and lead to severe barbiturate-induced depression. Phenobarbital is indicated in pediatric patients as an anticonvulsant and as a sedative, including its preoperative and postoperative use. uuid:738cd293-addc-42fd-bfe8-8614d4d6db43 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8069 biolink:treats MONDO:0021108 PMID:41385096 "[{""id"":""uuid:de79040a-5718-487c-934a-f456606f65a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5f05164b-f774-4a4b-87ee-fe56210598cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sedative. Sedation is obtainable within an hour, and in adequate dosage, the duration of action is more than six hours. Included in the more common conditions in which the sedative action of this class of drugs is desired are anxiety-tension states, hyperthyroidism, essential hypertension, nausea and vomiting of functional origin, motion sickness, acute labyrinthitis, pylorospasm in infants, chorea and cardiac failure. Phenobarbital is also a useful adjunct in treatment of hemorrhage from the respiratory or gastrointestinal tract. Phenobarbital controls anxiety, decreases muscular activity and lessens nervous excitability in hyperthyroid patients. However, thyrotoxic individuals occasionally react poorly to barbiturates. Hypnotic, for the short-term treatment of insomnia, since it appears to lose its effectiveness for sleep induction and sleep maintenance after 2 weeks (see CLINICAL PHARMACOLOGY ). Preanesthetic. Long-term anticonvulsant, (phenobarbital, mephobarbital and metharbital) for the treatment of generalized tonic-clonic and cortical focal seizures. And, in the emergency control of certain acute convulsive episodes, e.g., those associated with status epilepticus, cholera, eclampsia, cerebral hemorrhage, meningitis, tetanus, and toxic reactions to strychnine or local anesthetics. Phenobarbital sodium may be administered intramuscularly or intravenously as an anticonvulsant for emergency use. When administered intravenously, it may require 15 or more minutes before reaching peak concentrations in the brain. Therefore, injecting phenobarbital sodium until the convulsions stop may cause the brain level to exceed that required to control the convulsions and lead to severe barbiturate-induced depression. Phenobarbital is indicated in pediatric patients as an anticonvulsant and as a sedative, including its preoperative and postoperative use. uuid:9bce36ad-1f20-440f-b6d1-c9928d3043d8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8069 biolink:treats MONDO:0005526 PMID:41385096 "[{""id"":""uuid:cf5df6a4-53ba-43bd-9873-77bce6d0ae8f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:48512d7b-6984-402b-923e-2e32a8747ecc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sedative. Sedation is obtainable within an hour, and in adequate dosage, the duration of action is more than six hours. Included in the more common conditions in which the sedative action of this class of drugs is desired are anxiety-tension states, hyperthyroidism, essential hypertension, nausea and vomiting of functional origin, motion sickness, acute labyrinthitis, pylorospasm in infants, chorea and cardiac failure. Phenobarbital is also a useful adjunct in treatment of hemorrhage from the respiratory or gastrointestinal tract. Phenobarbital controls anxiety, decreases muscular activity and lessens nervous excitability in hyperthyroid patients. However, thyrotoxic individuals occasionally react poorly to barbiturates. Hypnotic, for the short-term treatment of insomnia, since it appears to lose its effectiveness for sleep induction and sleep maintenance after 2 weeks (see CLINICAL PHARMACOLOGY ). Preanesthetic. Long-term anticonvulsant, (phenobarbital, mephobarbital and metharbital) for the treatment of generalized tonic-clonic and cortical focal seizures. And, in the emergency control of certain acute convulsive episodes, e.g., those associated with status epilepticus, cholera, eclampsia, cerebral hemorrhage, meningitis, tetanus, and toxic reactions to strychnine or local anesthetics. Phenobarbital sodium may be administered intramuscularly or intravenously as an anticonvulsant for emergency use. When administered intravenously, it may require 15 or more minutes before reaching peak concentrations in the brain. Therefore, injecting phenobarbital sodium until the convulsions stop may cause the brain level to exceed that required to control the convulsions and lead to severe barbiturate-induced depression. Phenobarbital is indicated in pediatric patients as an anticonvulsant and as a sedative, including its preoperative and postoperative use. uuid:f72b4ccb-ac46-4952-be6a-16737e476787 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135515 biolink:treats MONDO:0018908 PMID:41385096 "[{""id"":""uuid:9463459c-0c17-4cfc-85ce-825ca2b68c55"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5146f741-e581-43ed-afa9-aafdc636445d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:40a92cd0-76a2-4751-83a4-d36002c3ca32"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Non-Hodgkin Lymphoma (NHL) Bendamustine hydrochloride injection is indicated for the treatment of adult patients with indolent B-cell non-Hodgkin lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.|[PMDA] A drug with a new dosage indicated for the treatment of low-grade B-cell non-Hodgkin’s lymphoma, mantle cell lymphoma, chronic lymphocytic leukemia, and relapsed or refractory diffuse large B-cell lymphoma. uuid:05b1d620-fa36-4e22-9a7d-cd5221f4edcb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:N824AOU5XV biolink:treats MONDO:0019933 PMID:41385096 "[{""id"":""uuid:3edcdcaa-3364-41d2-bf51-05d07e77fbaf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:508dbf90-57c4-4762-a094-b737cf03264a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:75667c12-59e0-4016-bf6a-d6d91fa20f05"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/somavert""]},{""id"":""uuid:d90cfbf4-55a6-402b-9235-a2c2e7474fc5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SOMAVERT is indicated for the treatment of acromegaly in patients who have had an inadequate response to surgery or radiation therapy, or for whom these therapies are not appropriate. The goal of treatment is to normalize serum insulin-like growth factor-1 (IGF-1) levels.|[EMA] Treatment of adult patients with acromegaly who have had an inadequate response to surgery and/or radiation therapy and in whom an appropriate medical treatment with somatostatin analogues did not normalize IGF-I concentrations or was not tolerated.Treatment of adult patients with acromegaly who have had an inadequate response to surgery and/or radiation therapy and in whom an appropriate medical treatment with somatostatin analogues did not normalize IGF -I concentrations or was not tolerated.|[PMDA] Drugs with a new active ingredient used to treat excessive secretion of IGF-I (somatomedin C) and other related symptoms in patients with acromegaly (used in cases where other surgical and pharmaceutical therapies are not sufficiently effective or practicable.) [Orphan Drug] uuid:1db51f4b-68bb-4ec2-8571-4aadd8314754 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28748 biolink:treats MONDO:0024643 PMID:41385096 "[{""id"":""uuid:6efba24e-073d-4828-8a81-eb827d15d89d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ca32bedc-5143-4da1-aa70-22eb73d9e721"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cardiomyopathy: Myocardial damage, including acute left ventricular failure can occur with doxorubicin. The risk of cardiomyopathy is proportional to the cumulative exposure with incidences from 1% to 20% for cumulative doses from 300 mg/m 2 to 500 mg/m 2 when doxorubicin is administered every 3 weeks. The risk of cardiomyopathy is further increased with concomitant cardiotoxic therapy. Assess LVEF before and regularly during and after treatment with doxorubicin [see Warnings and Precautions ( 5.1 )]. Secondary Malignancies: Secondary acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) occur at a higher incidence in patients treated with anthracyclines, including doxorubicin [see Warnings and Precautions ( 5.2 )]. Extravasation and Tissue Necrosis: Extravasation of doxorubicin can result in severe local tissue injury and necrosis requiring wide excision of the affected area and skin grafting.Immediately terminate the drug, and apply ice to the affected area [see Warnings and Precautions ( 5.3 )]. Severe myelosuppression resulting in serious infection, septic shock, requirement for transfusions, hospitalization, and death may occur [see Warnings and Precautions ( 5.4 )]. uuid:f329ec16-d70c-4fe7-ad96-9e9013b0ddeb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28748 biolink:treats UMLS:C1306063 PMID:41385096 "[{""id"":""uuid:5d57eede-f464-4197-ac5d-0c86b629b577"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9b6954d9-d985-496e-baf5-c97cdc870b9b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cardiomyopathy: Myocardial damage, including acute left ventricular failure can occur with doxorubicin. The risk of cardiomyopathy is proportional to the cumulative exposure with incidences from 1% to 20% for cumulative doses from 300 mg/m 2 to 500 mg/m 2 when doxorubicin is administered every 3 weeks. The risk of cardiomyopathy is further increased with concomitant cardiotoxic therapy. Assess LVEF before and regularly during and after treatment with doxorubicin [see Warnings and Precautions ( 5.1 )]. Secondary Malignancies: Secondary acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) occur at a higher incidence in patients treated with anthracyclines, including doxorubicin [see Warnings and Precautions ( 5.2 )]. Extravasation and Tissue Necrosis: Extravasation of doxorubicin can result in severe local tissue injury and necrosis requiring wide excision of the affected area and skin grafting.Immediately terminate the drug, and apply ice to the affected area [see Warnings and Precautions ( 5.3 )]. Severe myelosuppression resulting in serious infection, septic shock, requirement for transfusions, hospitalization, and death may occur [see Warnings and Precautions ( 5.4 )]. uuid:19798ad6-88cb-47a5-bdc1-5da0d0c4cb6f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28748 biolink:treats MONDO:0019457 PMID:41385096 "[{""id"":""uuid:673ee854-e7b1-4ab4-8e64-4f19aa4e9be2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4ff2c2f0-5d92-4a4f-9503-e3b36eb38d38"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cardiomyopathy: Myocardial damage, including acute left ventricular failure can occur with doxorubicin. The risk of cardiomyopathy is proportional to the cumulative exposure with incidences from 1% to 20% for cumulative doses from 300 mg/m 2 to 500 mg/m 2 when doxorubicin is administered every 3 weeks. The risk of cardiomyopathy is further increased with concomitant cardiotoxic therapy. Assess LVEF before and regularly during and after treatment with doxorubicin [see Warnings and Precautions ( 5.1 )]. Secondary Malignancies: Secondary acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) occur at a higher incidence in patients treated with anthracyclines, including doxorubicin [see Warnings and Precautions ( 5.2 )]. Extravasation and Tissue Necrosis: Extravasation of doxorubicin can result in severe local tissue injury and necrosis requiring wide excision of the affected area and skin grafting.Immediately terminate the drug, and apply ice to the affected area [see Warnings and Precautions ( 5.3 )]. Severe myelosuppression resulting in serious infection, septic shock, requirement for transfusions, hospitalization, and death may occur [see Warnings and Precautions ( 5.4 )]. uuid:a8d95214-09fd-49f1-9967-ee829f598772 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28748 biolink:treats MONDO:0018881 PMID:41385096 "[{""id"":""uuid:99c464c8-629a-44ae-b0e6-d81538d57389"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8ebea157-d117-487a-a07c-9a414585af80"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cardiomyopathy: Myocardial damage, including acute left ventricular failure can occur with doxorubicin. The risk of cardiomyopathy is proportional to the cumulative exposure with incidences from 1% to 20% for cumulative doses from 300 mg/m 2 to 500 mg/m 2 when doxorubicin is administered every 3 weeks. The risk of cardiomyopathy is further increased with concomitant cardiotoxic therapy. Assess LVEF before and regularly during and after treatment with doxorubicin [see Warnings and Precautions ( 5.1 )]. Secondary Malignancies: Secondary acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) occur at a higher incidence in patients treated with anthracyclines, including doxorubicin [see Warnings and Precautions ( 5.2 )]. Extravasation and Tissue Necrosis: Extravasation of doxorubicin can result in severe local tissue injury and necrosis requiring wide excision of the affected area and skin grafting.Immediately terminate the drug, and apply ice to the affected area [see Warnings and Precautions ( 5.3 )]. Severe myelosuppression resulting in serious infection, septic shock, requirement for transfusions, hospitalization, and death may occur [see Warnings and Precautions ( 5.4 )]. uuid:29fd5f23-f925-4ec7-9d73-1ef3d91c0674 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28748 biolink:treats EFO:0009426 PMID:41385096 "[{""id"":""uuid:652b3593-f2a1-4789-8cde-9c7ea5a95c18"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:71c9eeca-f342-43f6-8eac-14606426677c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cardiomyopathy: Myocardial damage, including acute left ventricular failure can occur with doxorubicin. The risk of cardiomyopathy is proportional to the cumulative exposure with incidences from 1% to 20% for cumulative doses from 300 mg/m 2 to 500 mg/m 2 when doxorubicin is administered every 3 weeks. The risk of cardiomyopathy is further increased with concomitant cardiotoxic therapy. Assess LVEF before and regularly during and after treatment with doxorubicin [see Warnings and Precautions ( 5.1 )]. Secondary Malignancies: Secondary acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) occur at a higher incidence in patients treated with anthracyclines, including doxorubicin [see Warnings and Precautions ( 5.2 )]. Extravasation and Tissue Necrosis: Extravasation of doxorubicin can result in severe local tissue injury and necrosis requiring wide excision of the affected area and skin grafting.Immediately terminate the drug, and apply ice to the affected area [see Warnings and Precautions ( 5.3 )]. Severe myelosuppression resulting in serious infection, septic shock, requirement for transfusions, hospitalization, and death may occur [see Warnings and Precautions ( 5.4 )]. uuid:28c160dc-26d8-4d90-9aa8-0a5de5aaa185 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28748 biolink:treats MONDO:0001881 PMID:41385096 "[{""id"":""uuid:cf5c8779-0c18-435f-9a50-3429b845dea2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d9b006fe-a8ef-4f2e-99d4-778cd07b50e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cardiomyopathy: Myocardial damage, including acute left ventricular failure can occur with doxorubicin. The risk of cardiomyopathy is proportional to the cumulative exposure with incidences from 1% to 20% for cumulative doses from 300 mg/m 2 to 500 mg/m 2 when doxorubicin is administered every 3 weeks. The risk of cardiomyopathy is further increased with concomitant cardiotoxic therapy. Assess LVEF before and regularly during and after treatment with doxorubicin [see Warnings and Precautions ( 5.1 )]. Secondary Malignancies: Secondary acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) occur at a higher incidence in patients treated with anthracyclines, including doxorubicin [see Warnings and Precautions ( 5.2 )]. Extravasation and Tissue Necrosis: Extravasation of doxorubicin can result in severe local tissue injury and necrosis requiring wide excision of the affected area and skin grafting.Immediately terminate the drug, and apply ice to the affected area [see Warnings and Precautions ( 5.3 )]. Severe myelosuppression resulting in serious infection, septic shock, requirement for transfusions, hospitalization, and death may occur [see Warnings and Precautions ( 5.4 )]. uuid:083ae46d-cf76-4842-abd2-cc84ae331f52 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3242 biolink:treats NCIT:C92821 PMID:41385096 "[{""id"":""uuid:8aa6fea0-efea-4a1a-b89d-af8141f7e300"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8b4e2240-a21b-420c-b88c-bfaebb75a3ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Butorphanol Tartrate Injection is indicated: as a preoperative or pre-anesthetic medication as a supplement to balanced anesthesia for the relief of pain during labor, and for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, and misuse, with opioids, even at recommended doses [see WARNINGS ], reserve Butorphanol Tartrate Injection for use in patients for whom alternative treatment options [e.g. non-opioid analgesics] Have not been tolerated, or are not expected to be tolerated Have not provided adequate analgesia, or are not expected to provide adequate analgesia uuid:8c454829-af2a-48b8-934c-a8790da10a83 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:204928 biolink:treats MONDO:0024355 PMID:41385096 "[{""id"":""uuid:de4b6da7-99af-43f6-8340-bab530937967"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:57152140-e029-42ad-be3f-58c636ac8d15"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefotaxime for Injection, USP is indicated for the treatment of patients with serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) Lower respiratory tract infections, including pneumonia, caused by Streptococcus pneumoniae (formerly Diplococcus pneumoniae ), Streptococcus pyogenes* (Group A streptococci) and other streptococci (excluding enterococci, e.g., Enterococcus faecalis ), Staphylococcus aureus (penicillinase and non-penicillinase producing), Escherichia coli , Klebsiella species, Haemophilus influenzae (including ampicillin resistant strains), Haemophilus parainfluenzae , Proteus mirabilis , Serratia marcescens* , Enterobacter species, indole positive Proteus and Pseudomonas species (including P. aeruginosa ). (2) Genitourinary infections . Urinary tract infections caused by Enterococcus species, Staphylococcus epidermidis , Staphylococcus aureus* , (penicillinase and non-penicillinase producing), Citrobacter species, Enterobacter species, Escherichia coli , Klebsiella species, Proteus mirabilis , Proteus vulgaris* , Providencia stuartii , Morganella morganii* , Providencia rettgeri* , Serratia marcescens and Pseudomonas species (including P. aeruginosa ). Also, uncomplicated gonorrhea (cervical/urethral and rectal) caused by Neisseria gonorrhoeae , including penicillinase producing strains. (3) Gynecologic infections, including pelvic inflammatory disease, endometritis and pelvic cellulitis caused by Staphylococcus epidermidis , Streptococcus species, Enterococcus species, Enterobacter species*, Klebsiella species*, Escherichia coli , Proteus mirabilis , Bacteroides species (including Bacteroides fragilis* ), Clostridium species, and anaerobic cocci (including Peptostreptococcus species and Peptococcus species) and Fusobacterium species (including F. nucleatum* ). Cefotaxime for Injection, USP, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti-chlamydial coverage should be added. (4) Bacteremia/Septicemia caused by Escherichia coli , Klebsiella species, and Serratia marcescens , Staphylococcus aureus and Streptococcus species (including S. pneumoniae ). (5) Skin and skin structure infections caused by Staphylococcus aureus (penicillinase and non-penicillinase producing), Staphylococcus epidermidis , Streptococcus pyogenes (Group A streptococci) and other streptococci, Enterococcus species, Acinetobacter species*, Escherichia coli , Citrobacter species (including C. freundii* ), Enterobacter species, Klebsiella species, Proteus mirabilis , Proteus vulgaris* , Morganella morganii , Providencia rettgeri* , Pseudomonas species, Serratia marcescens , Bacteroides species, and anaerobic cocci (including Peptostreptococcus* species and Peptococcus species). (6) Intra-abdominal infections including peritonitis caused by Streptococcus species*, Escherichia coli , Klebsiella species, Bacteroides species, and anaerobic cocci (including Peptostreptococcus* species and Peptococcus* species) Proteus mirabilis* , and Clostridium species*. (7) Bone and/or joint infections caused by Staphylococcus aureus (penicillinase and non-penicillinase producing strains), Streptococcus species (including S. pyogenes* ), Pseudomonas species (including P. aeruginosa* ), and Proteus mirabilis* . (8) Central nervous system infections, e.g., meningitis and ventriculitis, caused by Neisseria meningitidis , Haemophilus influenzae , Streptococcus pneumoniae , Klebsiella pneumoniae* and Escherichia coli* . (*) Efficacy for this organism, in this organ system, has been studied in fewer than 10 infections. Although many strains of enterococci (e.g., S. faecalis ) and Pseudomonas species are resistant to cefotaxime sodium in vitro , Cefotaxime for Injection, USP has been used successfully in treating patients with infections caused by susceptible organisms. Specimens for bacteriologic culture should be obtained prior to therapy in order to isolate and identify causative organisms and to determine their susceptibilities to cefotaxime. Therapy may be instituted before results of susceptibility studies are known; however, once these results become available, the antibiotic treatment should be adjusted accordingly. In certain cases of confirmed or suspected gram-positive or gram-negative sepsis or in patients with other serious infections in which the causative organism has not been identified, Cefotaxime for Injection, USP may be used concomitantly with an aminoglycoside. The dosage recommended in the labeling of both antibiotics may be given and depends on the severity of the infection and the patient's condition. Renal function should be carefully monitored, especially if higher dosages of the aminoglycosides are to be administered or if therapy is prolonged, because of the potential nephrotoxicity and ototoxicity of aminoglycoside antibiotics. It is possible that nephrotoxicity may be potentiated if Cefotaxime for Injection, USP is used concomitantly with an aminoglycoside. uuid:917098db-23bb-48dc-a771-00cada0c3e86 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63587 biolink:treats UMLS:C0278488 PMID:41385096 "[{""id"":""uuid:5c2dd6e1-6b29-482b-9df8-b855112f8dbf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5db81238-3b1e-4c55-a1c0-a02311c27e25"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Eribulin mesylate injection is a microtubule inhibitor indicated for the treatment of patients with: Metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting. ( 1.1 ) Unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen. ( 1.2 ) uuid:e89af2d0-2b65-4d66-b873-293297fb5a12 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63587 biolink:treats UMLS:C4331476 PMID:41385096 "[{""id"":""uuid:cd185a5f-b5cd-4fc5-ad2d-ebdc2a54c7e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7d60c8c7-be61-44a8-8363-0f4a0dedb942"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Eribulin mesylate injection is a microtubule inhibitor indicated for the treatment of patients with: Metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting. ( 1.1 ) Unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen. ( 1.2 ) uuid:8e49c553-632e-4bd6-b9b2-fbd1b193f27c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63587 biolink:treats UMLS:C0855059 PMID:41385096 "[{""id"":""uuid:07f3b818-4fa7-43da-a535-92c122fced19"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e857ee25-c324-4476-b6c0-daebbb0a4295"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Eribulin mesylate injection is a microtubule inhibitor indicated for the treatment of patients with: Metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting. ( 1.1 ) Unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen. ( 1.2 ) uuid:3a51ded5-e5b5-44f9-a91e-24a30e9272fd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59297 biolink:treats MONDO:0000775 PMID:41385096 "[{""id"":""uuid:bc6fe6c1-bc57-4338-9dd1-79149ec7c3c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2be5b108-0e83-47ab-a89a-0af1dd690633"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PRE-PEN is indicated for the assessment of sensitization to penicillin (benzylpenicillin or penicillin G) in patients suspected to have clinical penicillin hypersensitivity. A negative skin test to PRE-PEN is associated with an incidence of immediate allergic reactions of less than 5% after the administration of therapeutic penicillin, whereas the incidence may be more than 50% in a history-positive patient with a positive skin test to PRE-PEN. These allergic reactions are predominantly dermatologic. Whether a negative skin test to PRE-PEN predicts a lower risk of anaphylaxis is not established. Similarly, when deciding the risk of proposed penicillin treatment, there are not enough data at present to permit relative weighing in individual cases of a history of clinical penicillin hypersensitivity as compared to positive skin tests to PRE-PEN and/or minor penicillin determinants. uuid:22226aa3-c57c-4790-8e9d-2b8ec19d69d2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59297 biolink:treats MONDO:0005271 PMID:41385096 "[{""id"":""uuid:8a1e7525-478c-4ae7-912b-fb52e12c81d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8a3eef9c-82fb-4ae9-9cde-1f7258c712c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PRE-PEN is indicated for the assessment of sensitization to penicillin (benzylpenicillin or penicillin G) in patients suspected to have clinical penicillin hypersensitivity. A negative skin test to PRE-PEN is associated with an incidence of immediate allergic reactions of less than 5% after the administration of therapeutic penicillin, whereas the incidence may be more than 50% in a history-positive patient with a positive skin test to PRE-PEN. These allergic reactions are predominantly dermatologic. Whether a negative skin test to PRE-PEN predicts a lower risk of anaphylaxis is not established. Similarly, when deciding the risk of proposed penicillin treatment, there are not enough data at present to permit relative weighing in individual cases of a history of clinical penicillin hypersensitivity as compared to positive skin tests to PRE-PEN and/or minor penicillin determinants. uuid:8e07bc9a-6ca7-4d4c-8219-3f1a588e9081 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59297 biolink:treats MONDO:0100053 PMID:41385096 "[{""id"":""uuid:135135ee-e6a6-499c-83b8-e60a4f6d3fd1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a5bd0537-3d02-420a-9621-e489e85274eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PRE-PEN is indicated for the assessment of sensitization to penicillin (benzylpenicillin or penicillin G) in patients suspected to have clinical penicillin hypersensitivity. A negative skin test to PRE-PEN is associated with an incidence of immediate allergic reactions of less than 5% after the administration of therapeutic penicillin, whereas the incidence may be more than 50% in a history-positive patient with a positive skin test to PRE-PEN. These allergic reactions are predominantly dermatologic. Whether a negative skin test to PRE-PEN predicts a lower risk of anaphylaxis is not established. Similarly, when deciding the risk of proposed penicillin treatment, there are not enough data at present to permit relative weighing in individual cases of a history of clinical penicillin hypersensitivity as compared to positive skin tests to PRE-PEN and/or minor penicillin determinants. uuid:767487f2-d367-4c68-b162-726d2026f952 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:167309 biolink:treats MONDO:0018362 PMID:41385096 "[{""id"":""uuid:76af2947-6c7c-4119-a98f-fb038e3568da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ce0f5a35-0df2-4106-a63b-8683ab00e584"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methadone hydrochloride tablets are indicated for the: 1. Management of severe and persistent pain that requires an extended treatment period with a daily opioid analgesic and for which alternative treatment options are inadequate. Limitations of Use Because of the risks of addiction, abuse, and misuse with opioids, which can occur at any dosage or duration [see Warnings and Precautions (5.1)] , reserve methadone hydrochloride tablets for use in patients for whom alternative analgesic treatment options (e.g., non-opioid analgesics or opioid combination products) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. Methadone hydrochloride tablets are not indicated as an as-needed (prn) analgesic. 2. Detoxification treatment of opioid addiction (heroin or other morphine-like drugs). 3. Maintenance treatment of opioid addiction (heroin or other morphine-like drugs), in conjunction with appropriate social and medical services. Limitations of Use Methadone products used for the treatment of opioid addiction in detoxification or maintenance programs are subject to the conditions for distribution and use required under 42 CFR 8.12 [see Dosage and Administration (2.1)]. uuid:4655bd11-1fe2-450a-bef4-7135b827d488 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63577 biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:cee6532c-f209-41d1-bcc6-b38ec8315322"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:e1abeee5-147e-4b75-803a-a9e2d1050afe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:863651dc-b2eb-4644-94ca-1138be5a9c52"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/lamivudine-teva-pharma-bv""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lamivudine oral solution is a nucleoside analogue indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. Limitations of Use: The dosage of this product is for HIV-1 and not for HBV.|[EMA] Lamivudine Teva Pharma B.V. is indicated as part of antiretroviral combination therapy for the treatment of human-immunodeficiency-virus (HIV)-infected adults and children. uuid:4476d0bf-ab5b-486a-8ff1-9ae538053d5a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135905 biolink:treats MONDO:0001382 PMID:41385096 "[{""id"":""uuid:c804b2a0-e79b-4f63-9a86-80fa62cfd0e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ef177b92-9ec4-48d7-b758-afea25c8f641"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TERLIVAZ is indicated to improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function. uuid:b545f361-0bd9-42b1-94b5-61b45c19c16d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31439 biolink:treats MONDO:0004525 PMID:41385096 "[{""id"":""uuid:a7bce531-fff2-4c08-82b9-90a4c335d2f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:750e5130-6aed-45d1-87ce-61e0e7ac4bea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CROTAN ™ (crotamiton USP 10%) is a scabicidal and antipruritic agent as a lotion for topical use only. Crotamiton is a colorless to slightly yellowish oil, having a faint amine-like odor. It is miscible with alcohol and with methanol. Crotamiton is a mixture of the cis and trans isomers. Its molecular weight is 203. 28. Crotamiton is N-ethyl-N(o-methyl-phenyl) 2-butenamide and its structural formula is: CROTAN lotion contains crotamiton USP 10% (100mg/ml) in a creamy lotion base containing purified water, light mineral oil, propylene glycol, cetearyl alcohol (and) cetearth-20, cetyl alcohol, lanolin, benzyl alcohol, carbomer 971P, sodium hydroxide with citric acid (for pH adjustment). uuid:1961fb3b-e7ae-44ed-8595-8e321c355682 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31439 biolink:treats HP:0000989 PMID:41385096 "[{""id"":""uuid:190ef601-24c1-4c51-8723-d7efb5df4ac7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1babf5a1-c7ad-47d2-8d5a-24d7e1e6d508"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CROTAN ™ (crotamiton USP 10%) is a scabicidal and antipruritic agent as a lotion for topical use only. Crotamiton is a colorless to slightly yellowish oil, having a faint amine-like odor. It is miscible with alcohol and with methanol. Crotamiton is a mixture of the cis and trans isomers. Its molecular weight is 203. 28. Crotamiton is N-ethyl-N(o-methyl-phenyl) 2-butenamide and its structural formula is: CROTAN lotion contains crotamiton USP 10% (100mg/ml) in a creamy lotion base containing purified water, light mineral oil, propylene glycol, cetearyl alcohol (and) cetearth-20, cetyl alcohol, lanolin, benzyl alcohol, carbomer 971P, sodium hydroxide with citric acid (for pH adjustment). uuid:eccf17af-e2a0-4177-92eb-5c41c48a1587 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2665904 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:0bcfb353-356d-4e61-854a-66fa9c472ac3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:821dec1a-f582-4afa-a1da-b41d83db5b69"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AIRSUPRA is indicated for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in patients with asthma 18 years of age and older. uuid:9b753634-d387-4c99-908a-ddff6264d3f7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2665904 biolink:treats HP:4000007 PMID:41385096 "[{""id"":""uuid:6a9b1f22-aabf-4e96-b195-a30075f4bdcd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cf36886d-9739-41a4-a64e-22deae726ed3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AIRSUPRA is indicated for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in patients with asthma 18 years of age and older. uuid:43b2ab35-f12d-45ff-ae8b-441c39de6f89 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:51450 biolink:treats UMLS:C3697119 PMID:41385096 "[{""id"":""uuid:69f6aa5d-ba69-4fcf-afbc-1dab93f70da4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:89244eb2-641e-43ef-8d27-7c800d217bd3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bosentan tablets are indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1): in adults to improve exercise ability and to decrease clinical worsening. Studies establishing effectiveness included predominantly patients with WHO Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (60%), PAH associated with connective tissue diseases (21%), and PAH associated with congenital heart disease with left-to-right shunts (18%) [see Clinical Studies (14.1) ] . in pediatric patients aged 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance (PVR), which is expected to result in an improvement in exercise ability. uuid:2b3bdbf3-275b-4e2b-bbef-56d9bffd75d3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:5Z9SP3X666 biolink:treats MONDO:0001516 PMID:41385096 "[{""id"":""uuid:1660b34a-7cd1-4485-af42-e7dcd5bbd978"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:15c012fc-1942-46fe-9256-172e5d51d8c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c1a717ae-9d02-45ee-8c59-0cf90a060206"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SPINRAZA is indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.|[PMDA] A drug with a new indication for the treatment of spinal muscular atrophy without any clinical manifestations that is predicted to develop with genetic test. [Orphan drug] uuid:d21a685f-589e-457c-8b13-98e5d24511cb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:5Z9SP3X666 biolink:treats MONDO:0019079 PMID:41385096 "[{""id"":""uuid:7d3bd334-5cb6-44bb-9715-3c6331c5f699"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:77354c95-797a-4724-8716-de0141b96315"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:79e6de8e-1244-4385-ba8f-167efea95a55"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SPINRAZA is indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.|[EMA] Spinraza is indicated for the treatment of 5q Spinal Muscular Atrophy. uuid:37308a54-169f-42cf-b9b3-c81df71792c6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5739 biolink:treats MONDO:0019165 PMID:41385096 "[{""id"":""uuid:3866099b-21a7-41e7-bf3c-f123d1b3c3c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:81725eeb-33ce-4f50-a82e-c59e5865db24"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SUPPRELIN LA (histrelin acetate) subcutaneous implant is indicated for the treatment of children with central precocious puberty (CPP). Children with CPP (neurogenic or idiopathic) have an early onset of secondary sexual characteristics (earlier than 8 years of age in females and 9 years of age in males). They also show a significantly advanced bone age that can result in diminished adult height attainment. Prior to initiation of treatment a clinical diagnosis of CPP should be confirmed by measurement of blood concentrations of total sex steroids, luteinizing hormone (LH) and follicle stimulating hormone (FSH) following stimulation with a GnRH analog, and assessment of bone age versus chronological age. Baseline evaluations should include height and weight measurements, diagnostic imaging of the brain (to rule out intracranial tumor), pelvic/testicular/adrenal ultrasound (to rule out steroid secreting tumors), human chorionic gonadotropin levels (to rule out a chorionic gonadotropin secreting tumor), and adrenal steroids to exclude congenital adrenal hyperplasia. uuid:e36cacd1-6713-4ee1-9bf1-5613572a2061 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5739 biolink:treats MONDO:0015713 PMID:41385096 "[{""id"":""uuid:0530e6d1-e4d1-43a8-971c-33899f0c3f30"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fcf444ea-a59f-40d3-9909-6e23d6c1d56b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SUPPRELIN LA (histrelin acetate) subcutaneous implant is indicated for the treatment of children with central precocious puberty (CPP). Children with CPP (neurogenic or idiopathic) have an early onset of secondary sexual characteristics (earlier than 8 years of age in females and 9 years of age in males). They also show a significantly advanced bone age that can result in diminished adult height attainment. Prior to initiation of treatment a clinical diagnosis of CPP should be confirmed by measurement of blood concentrations of total sex steroids, luteinizing hormone (LH) and follicle stimulating hormone (FSH) following stimulation with a GnRH analog, and assessment of bone age versus chronological age. Baseline evaluations should include height and weight measurements, diagnostic imaging of the brain (to rule out intracranial tumor), pelvic/testicular/adrenal ultrasound (to rule out steroid secreting tumors), human chorionic gonadotropin levels (to rule out a chorionic gonadotropin secreting tumor), and adrenal steroids to exclude congenital adrenal hyperplasia. uuid:042bed04-2dfc-4720-b6b5-448af8b159d2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5739 biolink:treats MONDO:0021211 PMID:41385096 "[{""id"":""uuid:d8d2fdfd-aa60-4fc0-ba3f-d1eceb3d8385"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0f86a3a3-72fe-429b-a78e-25a816574c1e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SUPPRELIN LA (histrelin acetate) subcutaneous implant is indicated for the treatment of children with central precocious puberty (CPP). Children with CPP (neurogenic or idiopathic) have an early onset of secondary sexual characteristics (earlier than 8 years of age in females and 9 years of age in males). They also show a significantly advanced bone age that can result in diminished adult height attainment. Prior to initiation of treatment a clinical diagnosis of CPP should be confirmed by measurement of blood concentrations of total sex steroids, luteinizing hormone (LH) and follicle stimulating hormone (FSH) following stimulation with a GnRH analog, and assessment of bone age versus chronological age. Baseline evaluations should include height and weight measurements, diagnostic imaging of the brain (to rule out intracranial tumor), pelvic/testicular/adrenal ultrasound (to rule out steroid secreting tumors), human chorionic gonadotropin levels (to rule out a chorionic gonadotropin secreting tumor), and adrenal steroids to exclude congenital adrenal hyperplasia. uuid:87a6d78a-f268-4c26-9139-c15d4069a2dd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5739 biolink:treats MONDO:0018479 PMID:41385096 "[{""id"":""uuid:2210fc1e-c7c1-4e4b-a860-12838006c5b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:da8072f3-62ef-48e5-ad82-3672d61ca42c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SUPPRELIN LA (histrelin acetate) subcutaneous implant is indicated for the treatment of children with central precocious puberty (CPP). Children with CPP (neurogenic or idiopathic) have an early onset of secondary sexual characteristics (earlier than 8 years of age in females and 9 years of age in males). They also show a significantly advanced bone age that can result in diminished adult height attainment. Prior to initiation of treatment a clinical diagnosis of CPP should be confirmed by measurement of blood concentrations of total sex steroids, luteinizing hormone (LH) and follicle stimulating hormone (FSH) following stimulation with a GnRH analog, and assessment of bone age versus chronological age. Baseline evaluations should include height and weight measurements, diagnostic imaging of the brain (to rule out intracranial tumor), pelvic/testicular/adrenal ultrasound (to rule out steroid secreting tumors), human chorionic gonadotropin levels (to rule out a chorionic gonadotropin secreting tumor), and adrenal steroids to exclude congenital adrenal hyperplasia. uuid:0344c27b-bf71-43d8-b824-4073ddd51c31 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:167574 biolink:treats MONDO:0011122 PMID:41385096 "[{""id"":""uuid:5717d95a-7be7-4a73-a7c7-d5e0e317ae91"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:72f1f5c1-cd0a-408a-856b-46bd2f28959c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:78ce5770-5eee-44a3-8400-aae7b14bf875"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/wegovy""]},{""id"":""uuid:31d6941f-ae3c-40d8-9625-28377f150e1f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] WEGOVY is indicated in combination with a reduced calorie diet and increased physical activity: • to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight. • to reduce excess body weight and maintain weight reduction long term in: o Adults and pediatric patients aged 12 years and older with obesity o Adults with overweight in the presence of at least one weight-related comorbid condition. Limitations of Use • WEGOVY contains semaglutide. Coadministration with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended.|[EMA] Wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of- ≥30 kg/m² (obesity), or- ≥27 kg/m² to|[PMDA] Drugs with a new indication, a new dosage and other characteristics for the treatment of obesity. Drugs with a new indication and a new dosage in an additional dosage form for the treatment of obesity. For use only in patients with any of hypertension, hyperlipidemia or type 2 diabetes mellitus who have not responded sufficiently to diet therapy and exercise therapy, and meet the following conditions: BMI of 27 kg/m2 or greater in the presence of at least two obesity-related comorbidities or BMI of 35 kg/m2 or greater uuid:5052597d-69d8-43dd-983c-0fe9e797705d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:167574 biolink:treats EFO:0005935 PMID:41385096 "[{""id"":""uuid:516903b4-a9f6-4cce-a0a3-5e9caca280bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6eee36e2-a3b5-48af-94dc-bbe6a5f722ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] WEGOVY is indicated in combination with a reduced calorie diet and increased physical activity: • to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight. • to reduce excess body weight and maintain weight reduction long term in: o Adults and pediatric patients aged 12 years and older with obesity o Adults with overweight in the presence of at least one weight-related comorbid condition. Limitations of Use • WEGOVY contains semaglutide. Coadministration with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended. uuid:e6055ad3-892b-46fc-80a8-ae42fe10be2b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1999667 biolink:treats MONDO:0004951 PMID:41385096 "[{""id"":""uuid:ff7bb4d5-d8cc-4f74-931b-7d9d49bc603a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:371f1d0d-ce11-49b1-9b9c-69378d82a4ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BIKTARVY is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and pediatric patients weighing at least 14 kg: who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no known or suspected substitutions associated with resistance to bictegravir or tenofovir. uuid:13780e43-9aa1-4910-837a-63fe52450157 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4B93MGE4AL biolink:treats MONDO:0003210 PMID:41385096 "[{""id"":""uuid:48cfa7ed-1b2b-40a1-86b3-f17d87e6f768"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:05229ad5-3db9-49d7-8082-986be9f786e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LYTGOBI is indicated for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements [see Dosage and Administration (2.1) ] . This indication is approved under accelerated approval based on overall response rate and duration of response [see Clinical Studies (14.1) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). uuid:cd4e589f-b928-40a7-af40-bbd5deeb3123 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:476348 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:506ff146-e12b-4d95-af29-da1944344f18"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9dcb4f7e-6e23-41d6-abbf-7c4da4580fe7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ezetimibe and Simvastatin Tablets Ezetimibe and Simvastatin Tablets are a combination of simvastatin and ezetimibe indicated: • As an adjunct to diet to reduce elevated low density lipoprotein cholesterol (LDL-C): o In adults with primary hyperlipidemia. o In adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH). • As an adjunct to other LDL-C-lowering therapies to reduce elevated LDL-C in adults with homozygous familial hypercholesterolemia (HoFH). Simvastatin Simvastatin, when used as a component of ezetimibe and simvastatin tablets, is indicated to reduce the risk of total mortality by reducing risk of coronary heart disease death, non-fatal myocardial infarction and stroke, and the need for coronary and non-coronary revascularization procedures in adults with established coronary heart disease, cerebrovascular disease, peripheral vascular disease, and/or diabetes, who are at high risk of coronary heart disease events. uuid:cab7dff8-d206-4a97-ae8d-e95661c4c01a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:476348 biolink:treats UMLS:C0342882 PMID:41385096 "[{""id"":""uuid:48bafcad-a2de-49a8-b9c8-de84f1c58cac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:19fa0074-196d-4b8c-b9f7-c5fa1643a207"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ezetimibe and Simvastatin Tablets Ezetimibe and Simvastatin Tablets are a combination of simvastatin and ezetimibe indicated: • As an adjunct to diet to reduce elevated low density lipoprotein cholesterol (LDL-C): o In adults with primary hyperlipidemia. o In adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH). • As an adjunct to other LDL-C-lowering therapies to reduce elevated LDL-C in adults with homozygous familial hypercholesterolemia (HoFH). Simvastatin Simvastatin, when used as a component of ezetimibe and simvastatin tablets, is indicated to reduce the risk of total mortality by reducing risk of coronary heart disease death, non-fatal myocardial infarction and stroke, and the need for coronary and non-coronary revascularization procedures in adults with established coronary heart disease, cerebrovascular disease, peripheral vascular disease, and/or diabetes, who are at high risk of coronary heart disease events. uuid:18d549c0-dc27-4df5-9487-cab9325812d0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:476348 biolink:treats MONDO:0018328 PMID:41385096 "[{""id"":""uuid:68afe950-4794-4b3b-b516-cbbfade0dda1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bb047cca-066d-474f-a222-2f67a5994874"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ezetimibe and Simvastatin Tablets Ezetimibe and Simvastatin Tablets are a combination of simvastatin and ezetimibe indicated: • As an adjunct to diet to reduce elevated low density lipoprotein cholesterol (LDL-C): o In adults with primary hyperlipidemia. o In adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH). • As an adjunct to other LDL-C-lowering therapies to reduce elevated LDL-C in adults with homozygous familial hypercholesterolemia (HoFH). Simvastatin Simvastatin, when used as a component of ezetimibe and simvastatin tablets, is indicated to reduce the risk of total mortality by reducing risk of coronary heart disease death, non-fatal myocardial infarction and stroke, and the need for coronary and non-coronary revascularization procedures in adults with established coronary heart disease, cerebrovascular disease, peripheral vascular disease, and/or diabetes, who are at high risk of coronary heart disease events. uuid:72571695-5c13-4559-bb57-637fbb0cb932 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:476348 biolink:treats MONDO:0005010 PMID:41385096 "[{""id"":""uuid:0ff7d1c4-d674-467d-a04d-9aff77dd3faf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d7f53758-ea16-48a5-913e-919f00c11b56"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ezetimibe and Simvastatin Tablets Ezetimibe and Simvastatin Tablets are a combination of simvastatin and ezetimibe indicated: • As an adjunct to diet to reduce elevated low density lipoprotein cholesterol (LDL-C): o In adults with primary hyperlipidemia. o In adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH). • As an adjunct to other LDL-C-lowering therapies to reduce elevated LDL-C in adults with homozygous familial hypercholesterolemia (HoFH). Simvastatin Simvastatin, when used as a component of ezetimibe and simvastatin tablets, is indicated to reduce the risk of total mortality by reducing risk of coronary heart disease death, non-fatal myocardial infarction and stroke, and the need for coronary and non-coronary revascularization procedures in adults with established coronary heart disease, cerebrovascular disease, peripheral vascular disease, and/or diabetes, who are at high risk of coronary heart disease events. uuid:a3ad1f05-78de-4ce0-96cc-87ad891c6b24 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:476348 biolink:treats MONDO:0011057 PMID:41385096 "[{""id"":""uuid:5da4b60c-e472-400f-a3ff-3541fe754180"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:70e7d97d-7c4f-417c-8478-60eba1928ab6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ezetimibe and Simvastatin Tablets Ezetimibe and Simvastatin Tablets are a combination of simvastatin and ezetimibe indicated: • As an adjunct to diet to reduce elevated low density lipoprotein cholesterol (LDL-C): o In adults with primary hyperlipidemia. o In adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH). • As an adjunct to other LDL-C-lowering therapies to reduce elevated LDL-C in adults with homozygous familial hypercholesterolemia (HoFH). Simvastatin Simvastatin, when used as a component of ezetimibe and simvastatin tablets, is indicated to reduce the risk of total mortality by reducing risk of coronary heart disease death, non-fatal myocardial infarction and stroke, and the need for coronary and non-coronary revascularization procedures in adults with established coronary heart disease, cerebrovascular disease, peripheral vascular disease, and/or diabetes, who are at high risk of coronary heart disease events. uuid:f5b9c70f-095e-49e6-8762-8cf23f9c59b3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:476348 biolink:treats MONDO:0005294 PMID:41385096 "[{""id"":""uuid:8fb2a160-dd30-4fb8-a31a-f36ee7d16a49"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ae5d2952-db6a-4d1d-a650-ec30c4b9453d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ezetimibe and Simvastatin Tablets Ezetimibe and Simvastatin Tablets are a combination of simvastatin and ezetimibe indicated: • As an adjunct to diet to reduce elevated low density lipoprotein cholesterol (LDL-C): o In adults with primary hyperlipidemia. o In adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH). • As an adjunct to other LDL-C-lowering therapies to reduce elevated LDL-C in adults with homozygous familial hypercholesterolemia (HoFH). Simvastatin Simvastatin, when used as a component of ezetimibe and simvastatin tablets, is indicated to reduce the risk of total mortality by reducing risk of coronary heart disease death, non-fatal myocardial infarction and stroke, and the need for coronary and non-coronary revascularization procedures in adults with established coronary heart disease, cerebrovascular disease, peripheral vascular disease, and/or diabetes, who are at high risk of coronary heart disease events. uuid:b60df293-e132-40c3-8e72-0bab407afb09 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:476348 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:9db46e3f-d8ca-4681-af30-90f619eef099"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:96d2fc45-11d2-4383-bbd1-7187618e3e9f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ezetimibe and Simvastatin Tablets Ezetimibe and Simvastatin Tablets are a combination of simvastatin and ezetimibe indicated: • As an adjunct to diet to reduce elevated low density lipoprotein cholesterol (LDL-C): o In adults with primary hyperlipidemia. o In adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH). • As an adjunct to other LDL-C-lowering therapies to reduce elevated LDL-C in adults with homozygous familial hypercholesterolemia (HoFH). Simvastatin Simvastatin, when used as a component of ezetimibe and simvastatin tablets, is indicated to reduce the risk of total mortality by reducing risk of coronary heart disease death, non-fatal myocardial infarction and stroke, and the need for coronary and non-coronary revascularization procedures in adults with established coronary heart disease, cerebrovascular disease, peripheral vascular disease, and/or diabetes, who are at high risk of coronary heart disease events. uuid:49856040-63c8-46fd-928d-8844e04fd71b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28445 biolink:treats MONDO:0010643 PMID:41385096 "[{""id"":""uuid:cd4f9a72-0cd3-4aa3-bc1f-62fe9d22f529"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5b1368e9-edf0-46eb-ba68-7b2fc01843b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vincristine Sulfate Injection is indicated in acute leukemia. Vincristine Sulfate Injection has also been shown to be useful in combination with other oncolytic agents in Hodgkin's disease, non–Hodgkin's malignant lymphomas, rhabdomyosarcoma, neuroblastoma, and Wilms' tumor. uuid:f714f16b-b4c8-4041-9bca-2c8f7d524641 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28445 biolink:treats MONDO:0009348 PMID:41385096 "[{""id"":""uuid:89dfc4ad-cd20-42ca-abc2-05c147a45854"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4b3da8e6-1c7d-4b2c-bb06-7fc382af03e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vincristine Sulfate Injection is indicated in acute leukemia. Vincristine Sulfate Injection has also been shown to be useful in combination with other oncolytic agents in Hodgkin's disease, non–Hodgkin's malignant lymphomas, rhabdomyosarcoma, neuroblastoma, and Wilms' tumor. uuid:9e8de1cf-1ee6-4c12-acab-72178ea84eac biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28445 biolink:treats MONDO:0005062 PMID:41385096 "[{""id"":""uuid:259a89e9-a180-455c-b95d-163b52eed0b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:43e91a0c-ffb4-40e8-8a78-645ffaa0fe44"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vincristine Sulfate Injection is indicated in acute leukemia. Vincristine Sulfate Injection has also been shown to be useful in combination with other oncolytic agents in Hodgkin's disease, non–Hodgkin's malignant lymphomas, rhabdomyosarcoma, neuroblastoma, and Wilms' tumor. uuid:db9ddaaa-3ae3-4541-a135-6fa1d65fa66c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28445 biolink:treats MONDO:0005212 PMID:41385096 "[{""id"":""uuid:a445acca-34a7-4399-8252-92d21056707d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a9f24e20-be60-4deb-864f-9399f0809808"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vincristine Sulfate Injection is indicated in acute leukemia. Vincristine Sulfate Injection has also been shown to be useful in combination with other oncolytic agents in Hodgkin's disease, non–Hodgkin's malignant lymphomas, rhabdomyosarcoma, neuroblastoma, and Wilms' tumor. uuid:6aa41d4d-115d-47f5-b4cd-38ddd5272c1b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28445 biolink:treats MONDO:0005072 PMID:41385096 "[{""id"":""uuid:af2271cf-0c96-4bdb-9ce8-402cc798ed40"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fc34d940-fd01-49ed-a9f3-8eb70f0939b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vincristine Sulfate Injection is indicated in acute leukemia. Vincristine Sulfate Injection has also been shown to be useful in combination with other oncolytic agents in Hodgkin's disease, non–Hodgkin's malignant lymphomas, rhabdomyosarcoma, neuroblastoma, and Wilms' tumor. uuid:fc3a2802-720d-40db-b94b-b450f4f73ea4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28445 biolink:treats MONDO:0006058 PMID:41385096 "[{""id"":""uuid:5c554e80-5795-4fbc-9642-4d738dddf9a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5ed22a24-fe93-4de5-b172-ec8fc803ecac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vincristine Sulfate Injection is indicated in acute leukemia. Vincristine Sulfate Injection has also been shown to be useful in combination with other oncolytic agents in Hodgkin's disease, non–Hodgkin's malignant lymphomas, rhabdomyosarcoma, neuroblastoma, and Wilms' tumor. uuid:a6cfd14f-57b1-4608-b9f0-5a4dc972a575 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:151539 biolink:treats MONDO:0005002 PMID:41385096 "[{""id"":""uuid:7312da53-bfdf-45c6-be1e-074c634fd976"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2840f359-e6aa-4183-8157-02097c8265d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] COMBIVENT RESPIMAT is a combination of ipratropium bromide (an anticholinergic agent) and albuterol sulfate (a beta 2 -adrenergic agonist) indicated for use in patients with chronic obstructive pulmonary disease (COPD) on a regular aerosol bronchodilator who continue to have evidence of bronchospasm and who require a second bronchodilator. uuid:6c91b929-e948-47a9-b488-d9671e837ef1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:136040 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:4ad38079-5f3b-45c4-a48b-9179bbe406db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:148fb4fb-2a45-4e28-a8df-d513592af404"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FETZIMA ® is indicated for the treatment of major depressive disorder (MDD) in adults [see Clinical Studies ( 14 )]. Limitation of Use: FETZIMA is not approved for the management of fibromyalgia. The efficacy and safety of FETZIMA for the management of fibromyalgia have not been established. uuid:9c63ad0e-d93a-4c34-bbec-aa0a4994f5fa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:136040 biolink:treats MONDO:0005546 PMID:41385096 "[{""id"":""uuid:69522ba7-f08f-4708-94a2-ffe66581f9ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eeb1d84e-6834-4a7f-bb6e-de727261f44a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FETZIMA ® is indicated for the treatment of major depressive disorder (MDD) in adults [see Clinical Studies ( 14 )]. Limitation of Use: FETZIMA is not approved for the management of fibromyalgia. The efficacy and safety of FETZIMA for the management of fibromyalgia have not been established. uuid:abe068f9-70cd-4010-b363-88dd0d36e36f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7496 biolink:treats MONDO:0004951 PMID:41385096 "[{""id"":""uuid:22be5d53-b59c-4555-a4d6-581a63ebc3b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:da5769fc-9748-4959-a27c-760f64c3278a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VIRACEPT in combination with other antiretroviral agents is indicated for the treatment of HIV-1 infection. uuid:154a7ca1-b8f3-4961-b59d-f3161eecc1a0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5864 biolink:treats MONDO:0003120 PMID:41385096 "[{""id"":""uuid:7096b59d-5c69-4917-982f-0e1924550156"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9161a89c-9511-4922-b177-950594431717"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ifosfamide Injection is indicated for use in combination with certain other approved antineoplastic agentsfor third-line chemotherapy of germ cell testicular cancer. It should be used in combination with mesna for prophylaxis of hemorrhagic cystitis. uuid:90bfc61a-4409-4bca-9626-615352c77a3e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5864 biolink:treats MONDO:0000496 PMID:41385096 "[{""id"":""uuid:fe307f90-85fb-4a10-bcd2-5b814aa8215d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a3fc736a-9e59-4674-9202-433f8dcb67cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ifosfamide Injection is indicated for use in combination with certain other approved antineoplastic agentsfor third-line chemotherapy of germ cell testicular cancer. It should be used in combination with mesna for prophylaxis of hemorrhagic cystitis. uuid:ea85c12c-022c-4b88-afd4-0f2fae4fb53c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17549 biolink:treats MONDO:0021042 PMID:41385096 "[{""id"":""uuid:fc39a5d2-14a7-4117-8ee7-ecb439b006e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1e385a4b-4de6-43b0-80f5-22d02b507583"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gleolan is indicated in patients with glioma [suspected World Health Organization (WHO) Grades III or IV on preoperative imaging] as an adjunct for the visualization of malignant tissue during surgery. uuid:bf63590d-bb2d-4deb-827e-3df3c6745a9c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB09100 biolink:treats MONDO:0006982 PMID:41385096 "[{""id"":""uuid:104f3e1d-182c-45b1-bd27-6b14c8940b91"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ccffea74-4c71-4178-a58f-d621f8f0d99c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Armour Thyroid (thyroid tablets, USP) are indicated: 1. As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (See WARNINGS ). 2. As pituitary TSH suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto’s), multinodular goiter, and in the management of thyroid cancer. uuid:6b3bfb35-7bfc-4a92-98e6-faf2d6466ffb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:NQX9KB6PCL biolink:treats MONDO:0008250 PMID:41385096 "[{""id"":""uuid:1c081427-e595-4540-ac06-fa8e6900dd15"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:ec1f4a08-1339-42c5-927f-1247e43e75c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:5bf069a8-e6c7-4ab9-a9a8-db54efcbe733"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/omnitrope""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZOMACTON is a recombinant human growth hormone indicated for: Pediatric: Treatment of pediatric patients with growth failure due to inadequate secretion of endogenous growth hormone (GH), short stature associated with Turner syndrome, idiopathic short stature (ISS), short stature or growth failure in short stature homeobox-containing gene (SHOX) deficiency, and short stature born small for gestational age (SGA) with no catch-up growth by 2 years to 4 years. ( 1.1 ) Adult: Replacement of endogenous GH in adults with GH deficiency ( 1.2 )|[EMA] Infants, children and adolescentsGrowth disturbance due to insufficient secretion of growth hormone (GH).Growth disturbance associated with Turner syndrome.Growth disturbance associated with chronic renal insufficiency.Growth disturbance (current height standard-deviation score (SDS) < -2.5 and parental adjusted SDS < -1) in short children / adolescents born small for gestational age (SGA), with a birth weight and / or length below -2 standard deviations (SDs), who failed to show catch-up growth (height velocity (HV) SDS < 0 during the last year) by four years of age or later.Prader-Willi syndrome (PWS), for improvement of growth and body composition. The diagnosis of PWS should be confirmed by appropriate genetic testing.AdultsReplacement therapy in adults with pronounced growth hormone deficiency. Patients with severe growth hormone deficiency in adulthood are defined as patients with known hypothalamic pituitary pathology and at least one known deficiency of a pituitary hormone not being prolactin. These patients should undergo a single dynamic test in order to diagnose or exclude a growth hormone deficiency. In patients with childhood-onset isolated GH deficiency (no evidence of hypothalamic-pituitary disease or cranial irradiation), two dynamic tests should be recommended, except for those having low insulin-like-growth-factor-I (IGF-I) concentrations (SDS < -2) who may be considered for one test. The cut-off point of the dynamic test should be strict. uuid:f3752984-33e2-44de-9ad0-d05a04e26cea biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:NQX9KB6PCL biolink:treats UMLS:C1740819 PMID:41385096 "[{""id"":""uuid:11713db3-a9eb-494b-834e-ede5ae02fb5e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:74cf36f1-e569-459b-9fa2-d4ae0ee9eccc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZOMACTON is a recombinant human growth hormone indicated for: Pediatric: Treatment of pediatric patients with growth failure due to inadequate secretion of endogenous growth hormone (GH), short stature associated with Turner syndrome, idiopathic short stature (ISS), short stature or growth failure in short stature homeobox-containing gene (SHOX) deficiency, and short stature born small for gestational age (SGA) with no catch-up growth by 2 years to 4 years. ( 1.1 ) Adult: Replacement of endogenous GH in adults with GH deficiency ( 1.2 ) uuid:943f5c48-b687-4b39-976c-ea1b14cc130f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:NQX9KB6PCL biolink:treats MONDO:0010367 PMID:41385096 "[{""id"":""uuid:47c1f49c-a61c-4289-9dde-4517da0f63d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:9bc225b8-bab4-46d2-988f-cc71becd29d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:5df8899e-6b29-4bfe-bc6f-34d2c472270a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/omnitrope""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZOMACTON is a recombinant human growth hormone indicated for: Pediatric: Treatment of pediatric patients with growth failure due to inadequate secretion of endogenous growth hormone (GH), short stature associated with Turner syndrome, idiopathic short stature (ISS), short stature or growth failure in short stature homeobox-containing gene (SHOX) deficiency, and short stature born small for gestational age (SGA) with no catch-up growth by 2 years to 4 years. ( 1.1 ) Adult: Replacement of endogenous GH in adults with GH deficiency ( 1.2 )|[EMA] Infants, children and adolescentsGrowth disturbance due to insufficient secretion of growth hormone (GH).Growth disturbance associated with Turner syndrome.Growth disturbance associated with chronic renal insufficiency.Growth disturbance (current height standard-deviation score (SDS) < -2.5 and parental adjusted SDS < -1) in short children / adolescents born small for gestational age (SGA), with a birth weight and / or length below -2 standard deviations (SDs), who failed to show catch-up growth (height velocity (HV) SDS < 0 during the last year) by four years of age or later.Prader-Willi syndrome (PWS), for improvement of growth and body composition. The diagnosis of PWS should be confirmed by appropriate genetic testing.AdultsReplacement therapy in adults with pronounced growth hormone deficiency. Patients with severe growth hormone deficiency in adulthood are defined as patients with known hypothalamic pituitary pathology and at least one known deficiency of a pituitary hormone not being prolactin. These patients should undergo a single dynamic test in order to diagnose or exclude a growth hormone deficiency. In patients with childhood-onset isolated GH deficiency (no evidence of hypothalamic-pituitary disease or cranial irradiation), two dynamic tests should be recommended, except for those having low insulin-like-growth-factor-I (IGF-I) concentrations (SDS < -2) who may be considered for one test. The cut-off point of the dynamic test should be strict. uuid:5cc78522-e26f-45cc-9c88-fa5440e36021 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:38940 biolink:treats MONDO:0005086 PMID:41385096 "[{""id"":""uuid:afa8cb5b-0e27-408e-8f30-f0426fc5bf29"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e4eb5dc2-b954-48ee-99ba-f58281091ab0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c0869279-e7ca-4653-ae96-b1535a074431"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/sunitinib-accord""]},{""id"":""uuid:f5a2d718-db34-4fdc-bef4-b81153b13f72"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sunitinib malate capsules are a kinase inhibitor indicated for: • treatment of adult patients with gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate. ( 1.1 ) • treatment of adult patients with advanced renal cell carcinoma (RCC). ( 1.2 ) • adjuvant treatment of adult patients at high risk of recurrent RCC following nephrectomy. ( 1.3 ) • treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in adult patients with unresectable locally advanced or metastatic disease. ( 1.4 )|[EMA] Gastrointestinal stromal tumour (GIST)Sunitinib Accord is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST) in adults after failure of imatinib treatment due to resistance or intolerance.Metastatic renal cell carcinoma (MRCC)Sunitinib Accord is indicated for the treatment of advanced/metastatic renal cell carcinoma (MRCC) in adults.Pancreatic neuroendocrine tumours (pNET)Sunitinib Accord is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pNET) with disease progression in adults.|[PMDA] A drug containing a new active ingredient indicated for the treatment of imatinib-resistant gastrointestinal stromal tumors, and unresectable or metastatic renal cell carcinomas. [Priority review] uuid:2d8bc577-ab59-4c80-a16f-fb5938f4e44a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:38940 biolink:treats MONDO:0005815 PMID:41385096 "[{""id"":""uuid:9e583b35-900b-4ee8-bb48-b438bebf80e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:82a757c1-5ad8-4bbb-80ce-35cae4411806"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:3345734b-f903-4ac6-8c82-cf772373fa63"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/sunitinib-accord""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sunitinib malate capsules are a kinase inhibitor indicated for: • treatment of adult patients with gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate. ( 1.1 ) • treatment of adult patients with advanced renal cell carcinoma (RCC). ( 1.2 ) • adjuvant treatment of adult patients at high risk of recurrent RCC following nephrectomy. ( 1.3 ) • treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in adult patients with unresectable locally advanced or metastatic disease. ( 1.4 )|[EMA] Gastrointestinal stromal tumour (GIST)Sunitinib Accord is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST) in adults after failure of imatinib treatment due to resistance or intolerance.Metastatic renal cell carcinoma (MRCC)Sunitinib Accord is indicated for the treatment of advanced/metastatic renal cell carcinoma (MRCC) in adults.Pancreatic neuroendocrine tumours (pNET)Sunitinib Accord is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pNET) with disease progression in adults. uuid:2a2a1cc2-0af1-4fda-a002-f35333aa32f3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31530 biolink:treats MONDO:0004976 PMID:41385096 "[{""id"":""uuid:117519de-62d9-4adf-9b02-cb3dea2a4372"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b95f7264-fd86-4679-bb4d-e49201986298"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:7236b0c1-7570-4097-a5c4-5b058f22b657"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Edaravone injection is indicated for the treatment of amyotrophic lateral sclerosis (ALS).|[PMDA] A drug with a new route of administration indicated for delaying the functional disorder in patients with amyotrophic lateral sclerosis (ALS). uuid:b3560ab6-d993-4c31-a5e2-d95469854b68 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31530 biolink:treats MONDO:0008781 PMID:41385096 "[{""id"":""uuid:9475c979-7f1c-480b-9daf-058c546fdc7f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ae238791-43c2-4c79-a5f6-13a2621c57a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Edaravone injection is indicated for the treatment of amyotrophic lateral sclerosis (ALS). uuid:27e50635-b5d2-4ed9-850e-fbcd992e5938 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4FI88BTT8M biolink:treats MONDO:0009348 PMID:41385096 "[{""id"":""uuid:d1137231-d729-445f-8c22-38cf22e18001"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:abb5f6fb-1ab3-461c-bd30-88d34812e0f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gallium Citrate Ga 67 Injection may be useful to demonstrate the presence and extent of Hodgkin's disease, lymphoma, and bronchogenic carcinoma. Positive gallium Ga-67 uptake in the absence of prior symptoms warrants follow-up as an indication of a potential disease state. Gallium Citrate Ga 67 Injection may be useful as an aid in detecting some acute inflammatory lesions. uuid:80b31665-d6ee-4eb4-bcaf-43ebd1205142 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4FI88BTT8M biolink:treats MONDO:0005062 PMID:41385096 "[{""id"":""uuid:ad828082-f4f8-499b-a26d-be144aef0288"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:678c1d59-393e-4d71-a585-7e00f5c0bf8a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gallium Citrate Ga 67 Injection may be useful to demonstrate the presence and extent of Hodgkin's disease, lymphoma, and bronchogenic carcinoma. Positive gallium Ga-67 uptake in the absence of prior symptoms warrants follow-up as an indication of a potential disease state. Gallium Citrate Ga 67 Injection may be useful as an aid in detecting some acute inflammatory lesions. uuid:166212b9-a978-4d4d-9b4b-03ba204c9c2e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4FI88BTT8M biolink:treats MONDO:0002806 PMID:41385096 "[{""id"":""uuid:e657057f-42d2-442c-b131-74e1add6ad3f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:80101c86-c09a-4ff6-96c9-7e7e124f9fa0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gallium Citrate Ga 67 Injection may be useful to demonstrate the presence and extent of Hodgkin's disease, lymphoma, and bronchogenic carcinoma. Positive gallium Ga-67 uptake in the absence of prior symptoms warrants follow-up as an indication of a potential disease state. Gallium Citrate Ga 67 Injection may be useful as an aid in detecting some acute inflammatory lesions. uuid:b28cdd71-aa18-4ce1-a7e7-e41d2c682e30 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:26710 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:56099cb7-9162-44a0-9032-357d66f55a74"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f94d3d3c-2b94-4686-a67f-c1b223ec3184"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] These intravenous solutions are indicated for use in adults and pediatric patients as sources of electrolytes and water for hydration. 3% and 5% Sodium Chloride Injections USP are of particular value in severe salt depletion when rapid electrolyte restoration is of paramount importance. The low salt syndrome may occur in the presence of heart failure, renal impairment, during surgery, and postoperatively. In these conditions, chloride loss frequently exceeds sodium loss. These hypertonic sodium chloride solutions are also indicated for the following clinical conditions. Hyponatremia and hypochloremia due to electrolyte and fluid loss replaced with sodium-free fluids. Drastic dilution of extracellular body fluid following excessive water intake sometimes resulting from multiple enemas or perfusion of irrigating fluids into open venous sinuses during transurethral prostatic resections. Emergency treatment of severe salt depletion due to excess sweating, vomiting, diarrhea and other conditions. uuid:aab1f1e9-631d-433a-9ed0-5b6b86d4c054 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:26710 biolink:treats MONDO:0001343 PMID:41385096 "[{""id"":""uuid:0ecebd0c-3b34-429b-9fdc-f980b143ed4a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b54c1684-97a4-4d0b-beec-7155721ca9e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] These intravenous solutions are indicated for use in adults and pediatric patients as sources of electrolytes and water for hydration. 3% and 5% Sodium Chloride Injections USP are of particular value in severe salt depletion when rapid electrolyte restoration is of paramount importance. The low salt syndrome may occur in the presence of heart failure, renal impairment, during surgery, and postoperatively. In these conditions, chloride loss frequently exceeds sodium loss. These hypertonic sodium chloride solutions are also indicated for the following clinical conditions. Hyponatremia and hypochloremia due to electrolyte and fluid loss replaced with sodium-free fluids. Drastic dilution of extracellular body fluid following excessive water intake sometimes resulting from multiple enemas or perfusion of irrigating fluids into open venous sinuses during transurethral prostatic resections. Emergency treatment of severe salt depletion due to excess sweating, vomiting, diarrhea and other conditions. uuid:7cf42a25-6cd0-4d2f-b445-3f042342bf6b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:26710 biolink:treats HP:0003113 PMID:41385096 "[{""id"":""uuid:72dc8356-d9e2-4a2c-abf9-6415b761a912"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d136f1a1-241e-4793-9ff7-d1a7e30431d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] These intravenous solutions are indicated for use in adults and pediatric patients as sources of electrolytes and water for hydration. 3% and 5% Sodium Chloride Injections USP are of particular value in severe salt depletion when rapid electrolyte restoration is of paramount importance. The low salt syndrome may occur in the presence of heart failure, renal impairment, during surgery, and postoperatively. In these conditions, chloride loss frequently exceeds sodium loss. These hypertonic sodium chloride solutions are also indicated for the following clinical conditions. Hyponatremia and hypochloremia due to electrolyte and fluid loss replaced with sodium-free fluids. Drastic dilution of extracellular body fluid following excessive water intake sometimes resulting from multiple enemas or perfusion of irrigating fluids into open venous sinuses during transurethral prostatic resections. Emergency treatment of severe salt depletion due to excess sweating, vomiting, diarrhea and other conditions. uuid:9bbbcd20-1a65-44af-8d13-85a7027666fe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:78540 biolink:treats MONDO:0011849 PMID:41385096 "[{""id"":""uuid:5b27abce-ea5f-42e9-afb7-8aabf3bd970c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:dd2bec30-d4b4-4c9d-a5e0-aa6bbc2df7e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:fd1f07f2-9e54-43d0-af5d-29c2dd0876c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/otezla""]},{""id"":""uuid:269b7c26-675f-487a-b885-746bbb974505"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OTEZLA, an inhibitor of phosphodiesterase 4 (PDE4), is indicated for the treatment of: Adult patients with active psoriatic arthritis ( 1.1 ) Adult patients with plaque psoriasis who are candidates for phototherapy or systemic therapy ( 1.2 ) Pediatric patients 6 years of age and older and weighing at least 20 kg with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy ( 1.2 ) Adult patients with oral ulcers associated with Behçet's Disease ( 1.3 )|[EMA] Psoriatic arthritisOtezla, alone or in combination with Disease Modifying Antirheumatic Drugs (DMARDs), is indicated for the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or who have been intolerant to a prior DMARD therapy.PsoriasisOtezla is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who failed to respond to or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or psoralen and ultraviolet-A light (PUVA).|[PMDA] Drugs with a new active ingredient indicated for the treatment of plaque psoriasis in patients who have not responded sufficiently to topical therapy or psoriatic arthritis. uuid:e51fa45a-1b3b-4aaf-ac84-ecb661bd973a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:78540 biolink:treats UMLS:C0406317 PMID:41385096 "[{""id"":""uuid:d5793a81-c344-4ec0-bbc5-6ddfef05318b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4dc797a7-4aca-4b96-9df4-68245026eabd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:9e04030e-c36c-4215-93f2-267c365c8176"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OTEZLA, an inhibitor of phosphodiesterase 4 (PDE4), is indicated for the treatment of: Adult patients with active psoriatic arthritis ( 1.1 ) Adult patients with plaque psoriasis who are candidates for phototherapy or systemic therapy ( 1.2 ) Pediatric patients 6 years of age and older and weighing at least 20 kg with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy ( 1.2 ) Adult patients with oral ulcers associated with Behçet's Disease ( 1.3 )|[PMDA] Drugs with a new active ingredient indicated for the treatment of plaque psoriasis in patients who have not responded sufficiently to topical therapy or psoriatic arthritis. uuid:052c802d-7191-4ce2-a97c-3bc35eed2eb3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:78540 biolink:treats MONDO:0007191 PMID:41385096 "[{""id"":""uuid:7f2c0ba8-c82a-46f1-b03a-05eb6ce9a1b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7a28bcfc-dd97-44f4-86fd-1f26385dabd1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:84acf107-8667-4139-9234-665349ca7573"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OTEZLA, an inhibitor of phosphodiesterase 4 (PDE4), is indicated for the treatment of: Adult patients with active psoriatic arthritis ( 1.1 ) Adult patients with plaque psoriasis who are candidates for phototherapy or systemic therapy ( 1.2 ) Pediatric patients 6 years of age and older and weighing at least 20 kg with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy ( 1.2 ) Adult patients with oral ulcers associated with Behçet's Disease ( 1.3 )|[PMDA] Drugs with a new indication for the treatment of oral ulcer associated with Behcet’s disease in patients who have not responded sufficiently to local treatment. uuid:3d492249-9c80-490c-a07d-91d3ac13d92c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64355 biolink:treats MONDO:0020546 PMID:41385096 "[{""id"":""uuid:9d4e74fe-bbf6-4307-a717-7db882c67c0c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:091c6d33-fd0f-4688-95cc-b8e60fe7605a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Posaconazole delayed-release tablets is an azole antifungal agent indicated for: prophylaxis of invasive Aspergillus and Candida infections in patients who are at high risk of developing these infections due to being severely immunocompromised, such as HSCT recipients with GVHD or those with hematologic malignancies with prolonged neutropenia from chemotherapy. (1.1) uuid:8806fdd2-fa4b-477d-a32d-646f5f5ae10c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:ROV204583W biolink:treats MONDO:0002520 PMID:41385096 "[{""id"":""uuid:f390c7f5-0573-4a9b-afe1-343d83a2a4e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:326652fe-dcf3-40bf-8fc7-fc92db9772dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:a2bd429c-d34c-47f1-80d0-65a259028abc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/givlaari""]},{""id"":""uuid:a7e254b0-9d39-46c9-8cca-7e46833da2e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] GIVLAARI is indicated for the treatment of adults with acute hepatic porphyria (AHP).|[EMA] Treatment of acute hepatic porphyria (AHP) in adults and adolescents aged 12 years and older.|[PMDA] A drug with a new active ingredient indicated for the treatment of acute hepatic porphyria. [Orphan drug] uuid:072ed72d-03d0-484e-9ef8-e34f74ffd76a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:ROV204583W biolink:treats MONDO:0013564 PMID:41385096 "[{""id"":""uuid:8108825d-f4a3-4f6a-b179-2ffb8b310f89"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8acbd955-da79-4a3a-ac44-e44d1d440c84"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] GIVLAARI is indicated for the treatment of adults with acute hepatic porphyria (AHP). uuid:9e3c3697-67b5-48e3-911d-40416582ac77 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:GNWE7KJ995 biolink:treats MONDO:0018922 PMID:41385096 "[{""id"":""uuid:6417322a-fec8-4d33-b46b-275f157c02be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:52c60f33-38eb-4d1b-a654-1693dd3b5ad8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c43a52c2-f799-46e4-9369-24fa599154f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/enjaymo""]},{""id"":""uuid:970a8fd1-189f-44ad-9017-106aec151176"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ENJAYMO is a classical complement inhibitor indicated for the treatment of hemolysis in adults with cold agglutinin disease (CAD). ( 1 )|[EMA] Enjaymo is indicated for the treatment of haemolytic anaemia in adult patients with cold agglutinin disease (CAD).|[PMDA] A drug with a new active ingredient indicated for the treatment of cold agglutinin disease. [Orphan drug] uuid:e7ac43a1-1aa9-4003-b108-105bef768e9e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:GNWE7KJ995 biolink:treats UMLS:C0019054 PMID:41385096 "[{""id"":""uuid:99880ef8-1c7d-4160-b19e-af0450cab756"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3188b7bd-6900-40d0-b2be-d84fa6ba0620"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ENJAYMO is a classical complement inhibitor indicated for the treatment of hemolysis in adults with cold agglutinin disease (CAD). ( 1 ) uuid:66c430df-f90b-450e-9600-cc19af318d81 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63633 biolink:treats MONDO:0019165 PMID:41385096 "[{""id"":""uuid:263aacb3-c7a7-4773-82b5-be0a57dcc03a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0e5300f1-51b6-41a7-8fe6-94853d2c5681"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TRIPTODUR is indicated for the treatment of pediatric patients 2 years of age and older with central precocious puberty (CPP). uuid:5cbb4df1-7dfa-4307-ace4-1a4f1d49db84 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18145 biolink:treats MONDO:0005276 PMID:41385096 "[{""id"":""uuid:411e4279-5789-412a-99db-84f7d04a3535"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a300b9a2-d9d5-4a38-b0cd-1d44c640540d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Supplementation of the diet with ten essential vitamins. Supplementation of the diet with fluoride for caries prophylaxis. Multivitamin with Fluoride 1.0 mg Chewable Tablets provide 1.0 mg fluoride in tablet form for children 6-16 years of age in areas where the water fluoride level is less than 0.3 ppm. Multivitamin with Fluoride 1.0 mg Chewable Tablets supply significant amounts of Vitamins A, C, D, E, thiamine, riboflavin, niacin, vitamin B6, vitamin B12, and folate to supplement the diet, and to help assure that nutritional deficiencies of these vitamins will not develop. Thus, in a single easy-to-use preparation, children obtain ten essential vitamins and the important mineral, fluoride. The American Academy of Pediatrics recommends that children up to age 16, in areas where drinking water contains less than optimal levels of fluoride, receive daily fluoride supplements. Children using Multivitamin with Fluoride 1.0 mg Chewable Tablets regularly should receive semiannual dental examinations. The regular brushing of teeth and attention to good oral hygiene practices are also essential. Multivitamin with Fluoride Chewable Tablets is a prescription product for the clinical dietary management of the metabolic processes of caries prophylaxis and provides supplementation of the diet with ten essential vitamins. uuid:4d1e316c-80fc-4f56-b128-7d297b69e640 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17051 biolink:treats MONDO:0007016 PMID:41385096 "[{""id"":""uuid:3abd21b9-d254-476d-97e9-520e4d5a8986"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7b48b8ad-f8d9-409a-ab25-aa1a09cbccb5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Supplementation of the diet with vitamins A, C and D. Tri-Vite Drops with Fluoride 0.5 mg also provides fluoride for caries prophylaxis. The American Academy of Pediatrics recommend that infants and young children 6 months to 3 years of age, in areas where the drinking water contains less than 0.3 ppm of fluoride, and children 3-6 years of age, in areas where the drinking water contains 0.3 through 0.6 ppm of fluoride, receive 0.5 mg of supplemental fluoride daily which is provided in a dose of 1 mL of Tri-Vite Drops with Fluoride 0.5 mg (See Dosage and Administration ). Tri-Vite Drops with Fluoride 0.5 mg supply significant amounts of vitamins A, C and D to supplement the diet, and to help assure that nutritional deficiencies of these vitamins will not develop. Thus, in a single easy-to-use preparation, children obtain essential vitamins and fluoride. uuid:cf4cf04e-b662-4312-b72b-e87a67d57935 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17051 biolink:treats MONDO:0009412 PMID:41385096 "[{""id"":""uuid:e401fab5-0ec2-4bd6-bd18-91b36c29fc3d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5694cde7-e721-4b38-84b9-fd4b6598016d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Supplementation of the diet with vitamins A, C and D. Tri-Vite Drops with Fluoride 0.5 mg also provides fluoride for caries prophylaxis. The American Academy of Pediatrics recommend that infants and young children 6 months to 3 years of age, in areas where the drinking water contains less than 0.3 ppm of fluoride, and children 3-6 years of age, in areas where the drinking water contains 0.3 through 0.6 ppm of fluoride, receive 0.5 mg of supplemental fluoride daily which is provided in a dose of 1 mL of Tri-Vite Drops with Fluoride 0.5 mg (See Dosage and Administration ). Tri-Vite Drops with Fluoride 0.5 mg supply significant amounts of vitamins A, C and D to supplement the diet, and to help assure that nutritional deficiencies of these vitamins will not develop. Thus, in a single easy-to-use preparation, children obtain essential vitamins and fluoride. uuid:a2b82d1d-cc51-48a7-8252-25415541fd9e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17051 biolink:treats MONDO:0100471 PMID:41385096 "[{""id"":""uuid:2bff4937-a064-4454-bb61-61b09cc70f17"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:857bbbba-ee4c-4742-bb85-a6a8592adcaa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Supplementation of the diet with vitamins A, C and D. Tri-Vite Drops with Fluoride 0.5 mg also provides fluoride for caries prophylaxis. The American Academy of Pediatrics recommend that infants and young children 6 months to 3 years of age, in areas where the drinking water contains less than 0.3 ppm of fluoride, and children 3-6 years of age, in areas where the drinking water contains 0.3 through 0.6 ppm of fluoride, receive 0.5 mg of supplemental fluoride daily which is provided in a dose of 1 mL of Tri-Vite Drops with Fluoride 0.5 mg (See Dosage and Administration ). Tri-Vite Drops with Fluoride 0.5 mg supply significant amounts of vitamins A, C and D to supplement the diet, and to help assure that nutritional deficiencies of these vitamins will not develop. Thus, in a single easy-to-use preparation, children obtain essential vitamins and fluoride. uuid:5093e2d7-e108-4a74-b939-139cc7c182f9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17996 biolink:treats MONDO:0015129 PMID:41385096 "[{""id"":""uuid:4425fe11-a672-4211-abee-1f9b3b74ff92"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0c80296e-dd36-4ada-94e2-bf780970ef97"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Chloride Injection, USP, 23.4%, is indicated as an additive in parenteral fluid therapy for use in patients who have special problems of sodium electrolyte intake or excretion. It is intended to meet the specific requirements of the patient with unusual fluid and electrolyte needs. After available clinical and laboratory information is considered and correlated, the appropriate number of milliequivalents of sodium chloride required can be withdrawn from Sodium Chloride Injection, USP, 23.4% and diluted for use. Sodium Chloride Injection is indicated for the treatment of sodium, chloride and water deficiencies that commonly occur in many diseases. Isotonic Sodium Chloride Injection should be limited to cases in which the chloride loss is greater than the sodium loss, as in vomiting from pyloric obstruction, or in which the loss is about equal, as in vomiting from duodenal, jejunal or ileal obstruction and in the replacement of aspirated gastrointestinal fluids. The toxic symptoms that follow various forms of intestinal obstruction are accompanied by a marked reduction of blood chloride and often sodium chloride has a lifesaving effect. Symptoms of sodium chloride deficiency are very similar to those of Addison’s disease and large doses of sodium chloride will produce temporary alleviation of the symptoms. Other disorders in which sodium chloride is therapeutically useful include extensive burns, failure of gastric secretion and postoperative intestinal paralysis. uuid:e8f6904f-c193-43b1-84a4-751c8ac932d8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17996 biolink:treats UMLS:C0856633 PMID:41385096 "[{""id"":""uuid:06437909-1e15-47bc-88f0-7dd405bdf503"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e8107149-e172-4c11-8938-f9021c934669"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Chloride Injection, USP, 23.4%, is indicated as an additive in parenteral fluid therapy for use in patients who have special problems of sodium electrolyte intake or excretion. It is intended to meet the specific requirements of the patient with unusual fluid and electrolyte needs. After available clinical and laboratory information is considered and correlated, the appropriate number of milliequivalents of sodium chloride required can be withdrawn from Sodium Chloride Injection, USP, 23.4% and diluted for use. Sodium Chloride Injection is indicated for the treatment of sodium, chloride and water deficiencies that commonly occur in many diseases. Isotonic Sodium Chloride Injection should be limited to cases in which the chloride loss is greater than the sodium loss, as in vomiting from pyloric obstruction, or in which the loss is about equal, as in vomiting from duodenal, jejunal or ileal obstruction and in the replacement of aspirated gastrointestinal fluids. The toxic symptoms that follow various forms of intestinal obstruction are accompanied by a marked reduction of blood chloride and often sodium chloride has a lifesaving effect. Symptoms of sodium chloride deficiency are very similar to those of Addison’s disease and large doses of sodium chloride will produce temporary alleviation of the symptoms. Other disorders in which sodium chloride is therapeutically useful include extensive burns, failure of gastric secretion and postoperative intestinal paralysis. uuid:9d0dcb87-fc5b-4144-a11c-50d54453f9b2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17996 biolink:treats MONDO:0004565 PMID:41385096 "[{""id"":""uuid:4205ef2e-dd16-40c9-a9cb-5ee2883d62b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dc4000fd-df36-41b7-89a7-2b3e1ca2a064"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Chloride Injection, USP, 23.4%, is indicated as an additive in parenteral fluid therapy for use in patients who have special problems of sodium electrolyte intake or excretion. It is intended to meet the specific requirements of the patient with unusual fluid and electrolyte needs. After available clinical and laboratory information is considered and correlated, the appropriate number of milliequivalents of sodium chloride required can be withdrawn from Sodium Chloride Injection, USP, 23.4% and diluted for use. Sodium Chloride Injection is indicated for the treatment of sodium, chloride and water deficiencies that commonly occur in many diseases. Isotonic Sodium Chloride Injection should be limited to cases in which the chloride loss is greater than the sodium loss, as in vomiting from pyloric obstruction, or in which the loss is about equal, as in vomiting from duodenal, jejunal or ileal obstruction and in the replacement of aspirated gastrointestinal fluids. The toxic symptoms that follow various forms of intestinal obstruction are accompanied by a marked reduction of blood chloride and often sodium chloride has a lifesaving effect. Symptoms of sodium chloride deficiency are very similar to those of Addison’s disease and large doses of sodium chloride will produce temporary alleviation of the symptoms. Other disorders in which sodium chloride is therapeutically useful include extensive burns, failure of gastric secretion and postoperative intestinal paralysis. uuid:d4505cb8-2d3a-4879-ac17-3445828ddeba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17996 biolink:treats MONDO:0004568 PMID:41385096 "[{""id"":""uuid:91a1b874-5341-4c7b-9671-809a0372408f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1603b788-394e-42f9-8387-d5e2ee40716f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Chloride Injection, USP, 23.4%, is indicated as an additive in parenteral fluid therapy for use in patients who have special problems of sodium electrolyte intake or excretion. It is intended to meet the specific requirements of the patient with unusual fluid and electrolyte needs. After available clinical and laboratory information is considered and correlated, the appropriate number of milliequivalents of sodium chloride required can be withdrawn from Sodium Chloride Injection, USP, 23.4% and diluted for use. Sodium Chloride Injection is indicated for the treatment of sodium, chloride and water deficiencies that commonly occur in many diseases. Isotonic Sodium Chloride Injection should be limited to cases in which the chloride loss is greater than the sodium loss, as in vomiting from pyloric obstruction, or in which the loss is about equal, as in vomiting from duodenal, jejunal or ileal obstruction and in the replacement of aspirated gastrointestinal fluids. The toxic symptoms that follow various forms of intestinal obstruction are accompanied by a marked reduction of blood chloride and often sodium chloride has a lifesaving effect. Symptoms of sodium chloride deficiency are very similar to those of Addison’s disease and large doses of sodium chloride will produce temporary alleviation of the symptoms. Other disorders in which sodium chloride is therapeutically useful include extensive burns, failure of gastric secretion and postoperative intestinal paralysis. uuid:b62b3784-b8fe-4d9e-a5eb-213b15adbdff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17996 biolink:treats UMLS:C1971019 PMID:41385096 "[{""id"":""uuid:c6cc0218-ed07-4ae5-87ed-ae0c13efc8cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2f8a554d-8723-4944-bafb-8b504ac91d1f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Chloride Injection, USP, 23.4%, is indicated as an additive in parenteral fluid therapy for use in patients who have special problems of sodium electrolyte intake or excretion. It is intended to meet the specific requirements of the patient with unusual fluid and electrolyte needs. After available clinical and laboratory information is considered and correlated, the appropriate number of milliequivalents of sodium chloride required can be withdrawn from Sodium Chloride Injection, USP, 23.4% and diluted for use. Sodium Chloride Injection is indicated for the treatment of sodium, chloride and water deficiencies that commonly occur in many diseases. Isotonic Sodium Chloride Injection should be limited to cases in which the chloride loss is greater than the sodium loss, as in vomiting from pyloric obstruction, or in which the loss is about equal, as in vomiting from duodenal, jejunal or ileal obstruction and in the replacement of aspirated gastrointestinal fluids. The toxic symptoms that follow various forms of intestinal obstruction are accompanied by a marked reduction of blood chloride and often sodium chloride has a lifesaving effect. Symptoms of sodium chloride deficiency are very similar to those of Addison’s disease and large doses of sodium chloride will produce temporary alleviation of the symptoms. Other disorders in which sodium chloride is therapeutically useful include extensive burns, failure of gastric secretion and postoperative intestinal paralysis. uuid:a17f776b-3b9e-471b-bbe6-72a84471c912 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17996 biolink:treats UMLS:C0342921 PMID:41385096 "[{""id"":""uuid:2bfc9502-a5f3-435f-8dc5-f0fbe1ddb59e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bdd4189d-b64f-450a-9a26-64614cbc40c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Chloride Injection, USP, 23.4%, is indicated as an additive in parenteral fluid therapy for use in patients who have special problems of sodium electrolyte intake or excretion. It is intended to meet the specific requirements of the patient with unusual fluid and electrolyte needs. After available clinical and laboratory information is considered and correlated, the appropriate number of milliequivalents of sodium chloride required can be withdrawn from Sodium Chloride Injection, USP, 23.4% and diluted for use. Sodium Chloride Injection is indicated for the treatment of sodium, chloride and water deficiencies that commonly occur in many diseases. Isotonic Sodium Chloride Injection should be limited to cases in which the chloride loss is greater than the sodium loss, as in vomiting from pyloric obstruction, or in which the loss is about equal, as in vomiting from duodenal, jejunal or ileal obstruction and in the replacement of aspirated gastrointestinal fluids. The toxic symptoms that follow various forms of intestinal obstruction are accompanied by a marked reduction of blood chloride and often sodium chloride has a lifesaving effect. Symptoms of sodium chloride deficiency are very similar to those of Addison’s disease and large doses of sodium chloride will produce temporary alleviation of the symptoms. Other disorders in which sodium chloride is therapeutically useful include extensive burns, failure of gastric secretion and postoperative intestinal paralysis. uuid:8cd3ebff-1598-4099-87e0-d1e93a26509a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2591804 biolink:treats MONDO:0005324 PMID:41385096 "[{""id"":""uuid:858865a7-8e4d-4b8e-9b58-fc414b38bf86"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c13cad90-1a2f-49e1-852e-8a69ff5c11ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RYALTRIS is indicated for the treatment of symptoms of seasonal allergic rhinitis in adult and pediatric patients 12 years of age and older. uuid:dd7fff60-2ad1-4353-8cf5-4e507b4eb93d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18145 biolink:treats MONDO:0007016 PMID:41385096 "[{""id"":""uuid:78b26958-bb5b-404a-be6d-69c44ee66f64"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:085972da-0b46-4842-a90d-c9073e4d75b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Supplementation of the diet with ten essential vitamins. Supplementation of the diet with fluoride for caries prophylaxis. M ultivitamin with Fluoride 0.5 mg Chewable Tablets provide 0.5 mg fluoride in tablet form for children 4-6 years of age in areas where the drinking water fluoride level is less than 0.3 ppm, and for children 6 years of age and above where the drinking water contains 0.3 through 0.6 ppm of fluoride. Multivitamin with Fluoride 0.5 mg Chewable Tablets supply significant amounts of Vitamins A, C, D, E, thiamine, riboflavin, niacin, vitamin B6, vitamin B12, and folate to supplement the diet, and to help assure that nutritional deficiencies of these vitamins will not develop. Thus, in a single easy-to-use preparation, children obtain ten essential vitamins and the important mineral, fluoride. The American Academy of Pediatrics recommends that children up to age 16, in areas where drinking water contains less than optimal levels of fluoride, receive daily fluoride supplements. Children using Multivitamin with Fluoride 0 . 5 mg Chewable Tablets regularly should receive semiannual dental examinations. The regular brushing of teeth and attention to good oral hygiene practices are also essential. Multivitamin with Fluoride Chewable Tablets is a prescription product for the clinical dietary management of the metabolic processes of caries prophylaxis and provides supplementation of the diet with ten essential vitamins. uuid:91489be1-8ddd-487a-9b82-b8469a0aecc5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18145 biolink:treats MONDO:0009412 PMID:41385096 "[{""id"":""uuid:7ed30769-dfe4-443a-b0b4-c5abc35c53ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:943f1da1-ee24-4947-b5aa-0c5e81f9e64d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Supplementation of the diet with ten essential vitamins. Supplementation of the diet with fluoride for caries prophylaxis. M ultivitamin with Fluoride 0.5 mg Chewable Tablets provide 0.5 mg fluoride in tablet form for children 4-6 years of age in areas where the drinking water fluoride level is less than 0.3 ppm, and for children 6 years of age and above where the drinking water contains 0.3 through 0.6 ppm of fluoride. Multivitamin with Fluoride 0.5 mg Chewable Tablets supply significant amounts of Vitamins A, C, D, E, thiamine, riboflavin, niacin, vitamin B6, vitamin B12, and folate to supplement the diet, and to help assure that nutritional deficiencies of these vitamins will not develop. Thus, in a single easy-to-use preparation, children obtain ten essential vitamins and the important mineral, fluoride. The American Academy of Pediatrics recommends that children up to age 16, in areas where drinking water contains less than optimal levels of fluoride, receive daily fluoride supplements. Children using Multivitamin with Fluoride 0 . 5 mg Chewable Tablets regularly should receive semiannual dental examinations. The regular brushing of teeth and attention to good oral hygiene practices are also essential. Multivitamin with Fluoride Chewable Tablets is a prescription product for the clinical dietary management of the metabolic processes of caries prophylaxis and provides supplementation of the diet with ten essential vitamins. uuid:e8f6acfe-87ff-4b60-97ef-7a706f172f6e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18145 biolink:treats MONDO:0100471 PMID:41385096 "[{""id"":""uuid:db4d74ef-badc-4dc7-aa10-3edb31c9d2de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:89ff7028-e9a8-4748-8852-0ff6f298299b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Supplementation of the diet with ten essential vitamins. Supplementation of the diet with fluoride for caries prophylaxis. M ultivitamin with Fluoride 0.5 mg Chewable Tablets provide 0.5 mg fluoride in tablet form for children 4-6 years of age in areas where the drinking water fluoride level is less than 0.3 ppm, and for children 6 years of age and above where the drinking water contains 0.3 through 0.6 ppm of fluoride. Multivitamin with Fluoride 0.5 mg Chewable Tablets supply significant amounts of Vitamins A, C, D, E, thiamine, riboflavin, niacin, vitamin B6, vitamin B12, and folate to supplement the diet, and to help assure that nutritional deficiencies of these vitamins will not develop. Thus, in a single easy-to-use preparation, children obtain ten essential vitamins and the important mineral, fluoride. The American Academy of Pediatrics recommends that children up to age 16, in areas where drinking water contains less than optimal levels of fluoride, receive daily fluoride supplements. Children using Multivitamin with Fluoride 0 . 5 mg Chewable Tablets regularly should receive semiannual dental examinations. The regular brushing of teeth and attention to good oral hygiene practices are also essential. Multivitamin with Fluoride Chewable Tablets is a prescription product for the clinical dietary management of the metabolic processes of caries prophylaxis and provides supplementation of the diet with ten essential vitamins. uuid:0d554ec9-844b-442f-88d1-78647ca9357f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18145 biolink:treats MONDO:0042976 PMID:41385096 "[{""id"":""uuid:18d3c88e-0031-461a-ae5b-5ed4a349dea9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:367b2057-0fff-49f4-9db4-100b0a755df4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Supplementation of the diet with ten essential vitamins. Supplementation of the diet with fluoride for caries prophylaxis. M ultivitamin with Fluoride 0.5 mg Chewable Tablets provide 0.5 mg fluoride in tablet form for children 4-6 years of age in areas where the drinking water fluoride level is less than 0.3 ppm, and for children 6 years of age and above where the drinking water contains 0.3 through 0.6 ppm of fluoride. Multivitamin with Fluoride 0.5 mg Chewable Tablets supply significant amounts of Vitamins A, C, D, E, thiamine, riboflavin, niacin, vitamin B6, vitamin B12, and folate to supplement the diet, and to help assure that nutritional deficiencies of these vitamins will not develop. Thus, in a single easy-to-use preparation, children obtain ten essential vitamins and the important mineral, fluoride. The American Academy of Pediatrics recommends that children up to age 16, in areas where drinking water contains less than optimal levels of fluoride, receive daily fluoride supplements. Children using Multivitamin with Fluoride 0 . 5 mg Chewable Tablets regularly should receive semiannual dental examinations. The regular brushing of teeth and attention to good oral hygiene practices are also essential. Multivitamin with Fluoride Chewable Tablets is a prescription product for the clinical dietary management of the metabolic processes of caries prophylaxis and provides supplementation of the diet with ten essential vitamins. uuid:8c503bb9-3c51-44a5-b012-a720fe63fd87 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18145 biolink:treats MONDO:0004573 PMID:41385096 "[{""id"":""uuid:11db8593-b5f3-443e-9764-3b014c13781b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f642d13a-70fe-4e4a-a824-49b19f2877ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Supplementation of the diet with ten essential vitamins. Supplementation of the diet with fluoride for caries prophylaxis. M ultivitamin with Fluoride 0.5 mg Chewable Tablets provide 0.5 mg fluoride in tablet form for children 4-6 years of age in areas where the drinking water fluoride level is less than 0.3 ppm, and for children 6 years of age and above where the drinking water contains 0.3 through 0.6 ppm of fluoride. Multivitamin with Fluoride 0.5 mg Chewable Tablets supply significant amounts of Vitamins A, C, D, E, thiamine, riboflavin, niacin, vitamin B6, vitamin B12, and folate to supplement the diet, and to help assure that nutritional deficiencies of these vitamins will not develop. Thus, in a single easy-to-use preparation, children obtain ten essential vitamins and the important mineral, fluoride. The American Academy of Pediatrics recommends that children up to age 16, in areas where drinking water contains less than optimal levels of fluoride, receive daily fluoride supplements. Children using Multivitamin with Fluoride 0 . 5 mg Chewable Tablets regularly should receive semiannual dental examinations. The regular brushing of teeth and attention to good oral hygiene practices are also essential. Multivitamin with Fluoride Chewable Tablets is a prescription product for the clinical dietary management of the metabolic processes of caries prophylaxis and provides supplementation of the diet with ten essential vitamins. uuid:391b3628-29ab-4264-8599-d1a8db8f7c8a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18145 biolink:treats MONDO:0019975 PMID:41385096 "[{""id"":""uuid:b3c9937a-9cba-4b25-a51d-0674ddf5d883"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:86e10235-a662-41c4-bc9a-7a76f0c0bd8a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Supplementation of the diet with ten essential vitamins. Supplementation of the diet with fluoride for caries prophylaxis. M ultivitamin with Fluoride 0.5 mg Chewable Tablets provide 0.5 mg fluoride in tablet form for children 4-6 years of age in areas where the drinking water fluoride level is less than 0.3 ppm, and for children 6 years of age and above where the drinking water contains 0.3 through 0.6 ppm of fluoride. Multivitamin with Fluoride 0.5 mg Chewable Tablets supply significant amounts of Vitamins A, C, D, E, thiamine, riboflavin, niacin, vitamin B6, vitamin B12, and folate to supplement the diet, and to help assure that nutritional deficiencies of these vitamins will not develop. Thus, in a single easy-to-use preparation, children obtain ten essential vitamins and the important mineral, fluoride. The American Academy of Pediatrics recommends that children up to age 16, in areas where drinking water contains less than optimal levels of fluoride, receive daily fluoride supplements. Children using Multivitamin with Fluoride 0 . 5 mg Chewable Tablets regularly should receive semiannual dental examinations. The regular brushing of teeth and attention to good oral hygiene practices are also essential. Multivitamin with Fluoride Chewable Tablets is a prescription product for the clinical dietary management of the metabolic processes of caries prophylaxis and provides supplementation of the diet with ten essential vitamins. uuid:fd154549-f475-4d81-b44f-950cc6f4546c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18145 biolink:treats MONDO:0004574 PMID:41385096 "[{""id"":""uuid:24e7873e-80ae-45f0-b7ee-dd9526a7da35"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9e6be37e-2959-4fa4-89a3-fa40f6b7cd42"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Supplementation of the diet with ten essential vitamins. Supplementation of the diet with fluoride for caries prophylaxis. M ultivitamin with Fluoride 0.5 mg Chewable Tablets provide 0.5 mg fluoride in tablet form for children 4-6 years of age in areas where the drinking water fluoride level is less than 0.3 ppm, and for children 6 years of age and above where the drinking water contains 0.3 through 0.6 ppm of fluoride. Multivitamin with Fluoride 0.5 mg Chewable Tablets supply significant amounts of Vitamins A, C, D, E, thiamine, riboflavin, niacin, vitamin B6, vitamin B12, and folate to supplement the diet, and to help assure that nutritional deficiencies of these vitamins will not develop. Thus, in a single easy-to-use preparation, children obtain ten essential vitamins and the important mineral, fluoride. The American Academy of Pediatrics recommends that children up to age 16, in areas where drinking water contains less than optimal levels of fluoride, receive daily fluoride supplements. Children using Multivitamin with Fluoride 0 . 5 mg Chewable Tablets regularly should receive semiannual dental examinations. The regular brushing of teeth and attention to good oral hygiene practices are also essential. Multivitamin with Fluoride Chewable Tablets is a prescription product for the clinical dietary management of the metabolic processes of caries prophylaxis and provides supplementation of the diet with ten essential vitamins. uuid:716fbcc2-063a-4df7-a2e6-0bbcb334a048 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18145 biolink:treats MONDO:0020696 PMID:41385096 "[{""id"":""uuid:8832ac10-de54-41c2-9b95-e75e64f5dc93"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:140ca568-3653-4a1b-bb08-48f31e5f13de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Supplementation of the diet with ten essential vitamins. Supplementation of the diet with fluoride for caries prophylaxis. M ultivitamin with Fluoride 0.5 mg Chewable Tablets provide 0.5 mg fluoride in tablet form for children 4-6 years of age in areas where the drinking water fluoride level is less than 0.3 ppm, and for children 6 years of age and above where the drinking water contains 0.3 through 0.6 ppm of fluoride. Multivitamin with Fluoride 0.5 mg Chewable Tablets supply significant amounts of Vitamins A, C, D, E, thiamine, riboflavin, niacin, vitamin B6, vitamin B12, and folate to supplement the diet, and to help assure that nutritional deficiencies of these vitamins will not develop. Thus, in a single easy-to-use preparation, children obtain ten essential vitamins and the important mineral, fluoride. The American Academy of Pediatrics recommends that children up to age 16, in areas where drinking water contains less than optimal levels of fluoride, receive daily fluoride supplements. Children using Multivitamin with Fluoride 0 . 5 mg Chewable Tablets regularly should receive semiannual dental examinations. The regular brushing of teeth and attention to good oral hygiene practices are also essential. Multivitamin with Fluoride Chewable Tablets is a prescription product for the clinical dietary management of the metabolic processes of caries prophylaxis and provides supplementation of the diet with ten essential vitamins. uuid:bd9d03a7-42b0-4da0-bb7a-9b2c0bb680f2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18145 biolink:treats MONDO:0001860 PMID:41385096 "[{""id"":""uuid:98cb5fa5-c27d-4bd5-a0e8-b901767e1f85"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4744644a-4069-4f6b-ade4-c55bf0ed515d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Supplementation of the diet with ten essential vitamins. Supplementation of the diet with fluoride for caries prophylaxis. M ultivitamin with Fluoride 0.5 mg Chewable Tablets provide 0.5 mg fluoride in tablet form for children 4-6 years of age in areas where the drinking water fluoride level is less than 0.3 ppm, and for children 6 years of age and above where the drinking water contains 0.3 through 0.6 ppm of fluoride. Multivitamin with Fluoride 0.5 mg Chewable Tablets supply significant amounts of Vitamins A, C, D, E, thiamine, riboflavin, niacin, vitamin B6, vitamin B12, and folate to supplement the diet, and to help assure that nutritional deficiencies of these vitamins will not develop. Thus, in a single easy-to-use preparation, children obtain ten essential vitamins and the important mineral, fluoride. The American Academy of Pediatrics recommends that children up to age 16, in areas where drinking water contains less than optimal levels of fluoride, receive daily fluoride supplements. Children using Multivitamin with Fluoride 0 . 5 mg Chewable Tablets regularly should receive semiannual dental examinations. The regular brushing of teeth and attention to good oral hygiene practices are also essential. Multivitamin with Fluoride Chewable Tablets is a prescription product for the clinical dietary management of the metabolic processes of caries prophylaxis and provides supplementation of the diet with ten essential vitamins. uuid:844aa01c-f35f-434c-8540-087ba4467d98 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:RWM8CCW8GP biolink:treats MONDO:0005369 PMID:41385096 "[{""id"":""uuid:e2236959-14e6-46b4-a91c-a13d44ec0d81"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7ce7ee44-ae22-4723-951f-a45ee2d028ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Octreotide Acetate Injection is a somatostatin analogue indicated: Acromegaly : To reduce blood levels of growth hormone (GH) and insulin growth factor-1 (IGF-1; somatomedin C) in acromegaly patients who have had inadequate response to or cannot be treated with surgical resection, pituitary irradiation, and bromocriptine mesylate at maximally tolerated doses. ( 1.1 ) Carcinoid Tumors : For the symptomatic treatment of patients with metastatic carcinoid tumors where it suppresses or inhibits the severe diarrhea and flushing episodes associated with the disease. ( 1.2 ) Vasoactive Intestinal Peptide Tumors (VIPomas) : For the treatment of profuse watery diarrhea associated with VIP-secreting tumors. ( 1.3 ) Limitations of Use Improvement in clinical signs and symptoms, or reduction in tumor size or rate of growth, were not shown in clinical trials performed with Octreotide Acetate Injection; these trials were not optimally designed to detect such effects. ( 1.4 ) uuid:ddd40872-045f-4052-b2db-aa5a4849a65c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4885 biolink:treats MONDO:0018076 PMID:41385096 "[{""id"":""uuid:6b35f344-74f0-4134-8909-49e27c867b5f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:263c7f3a-1ab9-46f1-9d2e-b48e44a5968b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Trecator is primarily indicated for the treatment of active tuberculosis in patients with M. tuberculosis resistant to isoniazid or rifampin, or when there is intolerance on the part of the patient to other drugs. Its use alone in the treatment of tuberculosis results in the rapid development of resistance. It is essential, therefore, to give a suitable companion drug or drugs, the choice being based on the results of susceptibility tests. If the susceptibility tests indicate that the patient's organism is resistant to one of the first-line anti-tuberculosis drugs (i.e., isoniazid or rifampin) yet susceptible to ethionamide, ethionamide should be accompanied by at least one drug to which the M. tuberculosis isolate is known to be susceptible. 3 If the tuberculosis is resistant to both isoniazid and rifampin, yet susceptible to ethionamide, ethionamide should be accompanied by at least two other drugs to which the M. tuberculosis isolate is known to be susceptible. 3 To reduce the development of drug-resistant bacteria and maintain the effectiveness of Trecator and other antibacterial drugs, Trecator should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Patient nonadherence to prescribed treatment can result in treatment failure and in the development of drug-resistant tuberculosis, which can be life-threatening and lead to other serious health risks. It is, therefore, essential that patients adhere to the drug regimen for the full duration of treatment. Directly observed therapy is recommended for all patients receiving treatment for tuberculosis. Patients in whom drug-resistant M. tuberculosis organisms are isolated should be managed in consultation with an expert in the treatment of drug-resistant tuberculosis. uuid:ac50127a-310a-4a56-908d-890c103c40bb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4885 biolink:treats MONDO:0005861 PMID:41385096 "[{""id"":""uuid:519a4e29-56e5-4dd6-8349-4a6732a46bfc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8cf37fe1-14ad-4e24-9f76-4eb293dd9201"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Trecator is primarily indicated for the treatment of active tuberculosis in patients with M. tuberculosis resistant to isoniazid or rifampin, or when there is intolerance on the part of the patient to other drugs. Its use alone in the treatment of tuberculosis results in the rapid development of resistance. It is essential, therefore, to give a suitable companion drug or drugs, the choice being based on the results of susceptibility tests. If the susceptibility tests indicate that the patient's organism is resistant to one of the first-line anti-tuberculosis drugs (i.e., isoniazid or rifampin) yet susceptible to ethionamide, ethionamide should be accompanied by at least one drug to which the M. tuberculosis isolate is known to be susceptible. 3 If the tuberculosis is resistant to both isoniazid and rifampin, yet susceptible to ethionamide, ethionamide should be accompanied by at least two other drugs to which the M. tuberculosis isolate is known to be susceptible. 3 To reduce the development of drug-resistant bacteria and maintain the effectiveness of Trecator and other antibacterial drugs, Trecator should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Patient nonadherence to prescribed treatment can result in treatment failure and in the development of drug-resistant tuberculosis, which can be life-threatening and lead to other serious health risks. It is, therefore, essential that patients adhere to the drug regimen for the full duration of treatment. Directly observed therapy is recommended for all patients receiving treatment for tuberculosis. Patients in whom drug-resistant M. tuberculosis organisms are isolated should be managed in consultation with an expert in the treatment of drug-resistant tuberculosis. uuid:5dbd7de9-8ede-468a-a655-96370f0eaacb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3A189DH42V biolink:treats MONDO:0005301 PMID:41385096 "[{""id"":""uuid:edf498f3-31b0-4b0c-abc8-4cb307f46a79"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ce8a81cc-9f80-49a7-9db0-28ee5b2accf3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LEMTRADA is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults. Because of its safety profile, the use of LEMTRADA should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS [see Warnings and Precautions (5) ] . uuid:d2b34540-e290-4712-95f8-f13505459f89 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3A189DH42V biolink:treats MONDO:0000450 PMID:41385096 "[{""id"":""uuid:8a409060-58a6-48ec-8867-88b519c899a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4a88fb98-256f-4e55-b0ff-d11f6d914f69"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LEMTRADA is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults. Because of its safety profile, the use of LEMTRADA should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS [see Warnings and Precautions (5) ] . uuid:1df90dae-117a-4776-aa89-1401f44eecb9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:18680304 biolink:treats MONDO:0007476 PMID:41385096 "[{""id"":""uuid:6f9d160b-1405-41ed-9655-2aca3a69e312"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:11b7750e-87d4-4967-9321-f021f4e5b66c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XIAFLEX is indicated for the treatment of adult patients with Dupuytren’s contracture with a palpable cord. XIAFLEX is indicated for the treatment of adult men with Peyronie’s disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy. uuid:c508cc1d-66c3-4578-8c23-8afb05d219a1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:18680304 biolink:treats MONDO:0008231 PMID:41385096 "[{""id"":""uuid:f274060e-a352-413a-9333-15265b60c0dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2675654f-b632-4cb5-bbf8-fa8693d68778"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XIAFLEX is indicated for the treatment of adult patients with Dupuytren’s contracture with a palpable cord. XIAFLEX is indicated for the treatment of adult men with Peyronie’s disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy. uuid:dc68482e-0d7a-4b2c-bd8a-c7d109eff1e1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:567361 biolink:treats MONDO:0005314 PMID:41385096 "[{""id"":""uuid:b52f6b7a-3e25-47bc-9549-5a46cb5ce977"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:de0d429b-9f0d-4402-b961-b4ce24f938ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MAVENCLAD is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults. Because of its safety profile, use of MAVENCLAD is generally recommended for patients who have had an inadequate response to, or are unable to tolerate, an alternate drug indicated for the treatment of MS [see Warnings and Precautions (5) ]. uuid:676bc119-3aa9-4bbc-b8af-28f3d468dff6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:567361 biolink:treats MONDO:0000450 PMID:41385096 "[{""id"":""uuid:ab2772e0-7443-46c9-9a31-031619de2d94"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:68aa1a6a-8b91-4c5b-9684-8eea6fed6c6f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MAVENCLAD is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults. Because of its safety profile, use of MAVENCLAD is generally recommended for patients who have had an inadequate response to, or are unable to tolerate, an alternate drug indicated for the treatment of MS [see Warnings and Precautions (5) ]. uuid:522a8874-9669-486a-a034-45950194f517 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats MONDO:0100128 PMID:41385096 "[{""id"":""uuid:4e3d3acc-949d-4497-ae64-e68966397004"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:55014c97-b9e9-4c2f-a5f7-f3107404fe0c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of gentamicin and other antibacterial drugs, gentamicin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Gentamicin Sulfate Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: Pseudomonas aeruginosa, Proteus species (indole-positive and indole-negative), Escherichia coli, Klebsiella-Enterobacter-Serratia species, Citrobacter species, and Staphylococcus species (coagulase-positive and coagulase-negative). Clinical studies have shown Gentamicin Sulfate Injection, USP to be effective in bacterial neonatal sepsis; bacterial septicemia; and serious bacterial infections of the central nervous system (meningitis), urinary tract, respiratory tract, gastrointestinal tract (including peritonitis), skin, bone and soft tissue (including burns). Aminoglycosides, including gentamicin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are susceptible to these antibiotics and are not susceptible to antibiotics having less potential for toxicity. Specimens for bacterial culture should be obtained to isolate and identify causative organisms and to determine their susceptibility to gentamicin. Gentamicin sulfate may be considered as initial therapy in suspected or confirmed gram-negative infections, and therapy may be instituted before obtaining results of susceptibility testing. The decision to continue therapy with this drug should be based on the results of susceptibility tests, the severity of the infection, and the important additional concepts contained in the WARNINGS BOX. If the causative organisms are resistant to gentamicin, other appropriate therapy should be instituted. In serious infections when the causative organisms are unknown, gentamicin sulfate may be administered as initial therapy in conjunction with a penicillin-type or cephalosporin-type drug before obtaining results of susceptibility testing. If anaerobic organisms are suspected as etiologic agents, consideration should be given to using other suitable antimicrobial therapy in conjunction with gentamicin. Following identification of the organism and its susceptibility, appropriate antibiotic therapy should then be continued. Gentamicin sulfate has been used effectively in combination with carbenicillin for the treatment of life-threatening infections caused by Pseudomonas aeruginosa. It has also been found effective when used in conjunction with a penicillin-type drug for the treatment of endocarditis caused by group D streptococci. Gentamicin Sulfate Injection, USP has also been shown to be effective in the treatment of serious staphylococcal infections. While not the antibiotic of first choice, gentamicin may be considered when penicillins or other less potentially toxic drugs are contraindicated and bacterial susceptibility tests and clinical judgment indicate its use. It may also be considered in mixed infections caused by susceptible strains of staphylococci and gram-negative organisms. In the neonate with suspected bacterial sepsis or staphylococcal pneumonia, a penicillin-type drug is also usually indicated as concomitant therapy with gentamicin. uuid:23c441b1-e53d-4a4c-b343-1fb456c35b1e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5818 biolink:treats HP:0000713 PMID:41385096 "[{""id"":""uuid:88b627ab-728d-4ae0-b0b2-e4a223bfd09c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c455aa6b-b8e1-4e52-905d-3ffdfc11fc48"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The total management of anxiety, tension, and psychomotor agitation in conditions of emotional stress requires in most instances a combined approach of psychotherapy and chemotherapy. Hydroxyzine has been found to be particularly useful for this latter phase of therapy in its ability to render the disturbed patient more amenable to psychotherapy in long term treatment of the psychoneurotic and psychotic, although it should not be used as the sole treatment of psychosis or of clearly demonstrated cases of depression. Hydroxyzine is also useful in alleviating the manifestations of anxiety and tension as in the preparation for dental procedures and in acute emotional problems. It has also been recommended for the management of anxiety associated with organic disturbances and as adjunctive therapy in alcoholism and allergic conditions with strong emotional overlay, such as in asthma, chronic urticaria, and pruritus. Hydroxyzine hydrochloride intramuscular solution is useful in treating the following types of patients when intramuscular administration is indicated: 1. The acutely disturbed or hysterical patient. 2. The acute or chronic alcoholic with anxiety withdrawal symptoms or delirium tremens. 3. As pre-and postoperative and pre- and postpartum adjunctive medication to permit reduction in narcotic dosage, allay anxiety and control emesis. Hydroxyzine hydrochloride has also demonstrated effectiveness in controlling nausea and vomiting, excluding nausea and vomiting of pregnancy. (See CONTRAINDICATIONS). In prepartum states, the reduction in narcotic requirement effected by hydroxyzine is of particular benefit to both mother and neonate. Hydroxyzine benefits the cardiac patient by its ability to allay the associated anxiety and apprehension attendant to certain types of heart disease. Hydroxyzine is not known to interfere with the action of digitalis in any way and may be used concurrently with this agent. The effectiveness of hydroxyzine in long term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should reassess periodically the usefulness of the drug for the individual patient. uuid:da683489-1c0a-40e6-be25-08f6719e5ad3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5818 biolink:treats UMLS:C0086209 PMID:41385096 "[{""id"":""uuid:b5aec1d8-357f-4b13-88eb-5ec2439af350"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:629505c6-c55d-49b7-b9b8-24aaf540f344"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The total management of anxiety, tension, and psychomotor agitation in conditions of emotional stress requires in most instances a combined approach of psychotherapy and chemotherapy. Hydroxyzine has been found to be particularly useful for this latter phase of therapy in its ability to render the disturbed patient more amenable to psychotherapy in long term treatment of the psychoneurotic and psychotic, although it should not be used as the sole treatment of psychosis or of clearly demonstrated cases of depression. Hydroxyzine is also useful in alleviating the manifestations of anxiety and tension as in the preparation for dental procedures and in acute emotional problems. It has also been recommended for the management of anxiety associated with organic disturbances and as adjunctive therapy in alcoholism and allergic conditions with strong emotional overlay, such as in asthma, chronic urticaria, and pruritus. Hydroxyzine hydrochloride intramuscular solution is useful in treating the following types of patients when intramuscular administration is indicated: 1. The acutely disturbed or hysterical patient. 2. The acute or chronic alcoholic with anxiety withdrawal symptoms or delirium tremens. 3. As pre-and postoperative and pre- and postpartum adjunctive medication to permit reduction in narcotic dosage, allay anxiety and control emesis. Hydroxyzine hydrochloride has also demonstrated effectiveness in controlling nausea and vomiting, excluding nausea and vomiting of pregnancy. (See CONTRAINDICATIONS). In prepartum states, the reduction in narcotic requirement effected by hydroxyzine is of particular benefit to both mother and neonate. Hydroxyzine benefits the cardiac patient by its ability to allay the associated anxiety and apprehension attendant to certain types of heart disease. Hydroxyzine is not known to interfere with the action of digitalis in any way and may be used concurrently with this agent. The effectiveness of hydroxyzine in long term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should reassess periodically the usefulness of the drug for the individual patient. uuid:80191953-daa8-4589-bc55-803cd3b17342 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5818 biolink:treats MONDO:0005379 PMID:41385096 "[{""id"":""uuid:5a724b62-fa88-4a65-afd9-908ea246a8d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:14ca38ab-5b39-4829-bf99-75e208eba068"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The total management of anxiety, tension, and psychomotor agitation in conditions of emotional stress requires in most instances a combined approach of psychotherapy and chemotherapy. Hydroxyzine has been found to be particularly useful for this latter phase of therapy in its ability to render the disturbed patient more amenable to psychotherapy in long term treatment of the psychoneurotic and psychotic, although it should not be used as the sole treatment of psychosis or of clearly demonstrated cases of depression. Hydroxyzine is also useful in alleviating the manifestations of anxiety and tension as in the preparation for dental procedures and in acute emotional problems. It has also been recommended for the management of anxiety associated with organic disturbances and as adjunctive therapy in alcoholism and allergic conditions with strong emotional overlay, such as in asthma, chronic urticaria, and pruritus. Hydroxyzine hydrochloride intramuscular solution is useful in treating the following types of patients when intramuscular administration is indicated: 1. The acutely disturbed or hysterical patient. 2. The acute or chronic alcoholic with anxiety withdrawal symptoms or delirium tremens. 3. As pre-and postoperative and pre- and postpartum adjunctive medication to permit reduction in narcotic dosage, allay anxiety and control emesis. Hydroxyzine hydrochloride has also demonstrated effectiveness in controlling nausea and vomiting, excluding nausea and vomiting of pregnancy. (See CONTRAINDICATIONS). In prepartum states, the reduction in narcotic requirement effected by hydroxyzine is of particular benefit to both mother and neonate. Hydroxyzine benefits the cardiac patient by its ability to allay the associated anxiety and apprehension attendant to certain types of heart disease. Hydroxyzine is not known to interfere with the action of digitalis in any way and may be used concurrently with this agent. The effectiveness of hydroxyzine in long term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should reassess periodically the usefulness of the drug for the individual patient. uuid:c0a8bab5-ce3c-4043-96c0-9c0470aa42a1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5818 biolink:treats MONDO:0005485 PMID:41385096 "[{""id"":""uuid:d16e8d38-2f38-4cbc-912a-261474f70a63"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d6a5eaf3-6ade-4a94-80ec-78e7f5749887"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The total management of anxiety, tension, and psychomotor agitation in conditions of emotional stress requires in most instances a combined approach of psychotherapy and chemotherapy. Hydroxyzine has been found to be particularly useful for this latter phase of therapy in its ability to render the disturbed patient more amenable to psychotherapy in long term treatment of the psychoneurotic and psychotic, although it should not be used as the sole treatment of psychosis or of clearly demonstrated cases of depression. Hydroxyzine is also useful in alleviating the manifestations of anxiety and tension as in the preparation for dental procedures and in acute emotional problems. It has also been recommended for the management of anxiety associated with organic disturbances and as adjunctive therapy in alcoholism and allergic conditions with strong emotional overlay, such as in asthma, chronic urticaria, and pruritus. Hydroxyzine hydrochloride intramuscular solution is useful in treating the following types of patients when intramuscular administration is indicated: 1. The acutely disturbed or hysterical patient. 2. The acute or chronic alcoholic with anxiety withdrawal symptoms or delirium tremens. 3. As pre-and postoperative and pre- and postpartum adjunctive medication to permit reduction in narcotic dosage, allay anxiety and control emesis. Hydroxyzine hydrochloride has also demonstrated effectiveness in controlling nausea and vomiting, excluding nausea and vomiting of pregnancy. (See CONTRAINDICATIONS). In prepartum states, the reduction in narcotic requirement effected by hydroxyzine is of particular benefit to both mother and neonate. Hydroxyzine benefits the cardiac patient by its ability to allay the associated anxiety and apprehension attendant to certain types of heart disease. Hydroxyzine is not known to interfere with the action of digitalis in any way and may be used concurrently with this agent. The effectiveness of hydroxyzine in long term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should reassess periodically the usefulness of the drug for the individual patient. uuid:58c46bd6-7393-499c-9fa0-0ddadc845ea5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5818 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:e006a10f-20a2-4f42-b4c8-d228e57f53ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fc7e07d2-ff5a-4318-82ac-8c22e92dc488"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The total management of anxiety, tension, and psychomotor agitation in conditions of emotional stress requires in most instances a combined approach of psychotherapy and chemotherapy. Hydroxyzine has been found to be particularly useful for this latter phase of therapy in its ability to render the disturbed patient more amenable to psychotherapy in long term treatment of the psychoneurotic and psychotic, although it should not be used as the sole treatment of psychosis or of clearly demonstrated cases of depression. Hydroxyzine is also useful in alleviating the manifestations of anxiety and tension as in the preparation for dental procedures and in acute emotional problems. It has also been recommended for the management of anxiety associated with organic disturbances and as adjunctive therapy in alcoholism and allergic conditions with strong emotional overlay, such as in asthma, chronic urticaria, and pruritus. Hydroxyzine hydrochloride intramuscular solution is useful in treating the following types of patients when intramuscular administration is indicated: 1. The acutely disturbed or hysterical patient. 2. The acute or chronic alcoholic with anxiety withdrawal symptoms or delirium tremens. 3. As pre-and postoperative and pre- and postpartum adjunctive medication to permit reduction in narcotic dosage, allay anxiety and control emesis. Hydroxyzine hydrochloride has also demonstrated effectiveness in controlling nausea and vomiting, excluding nausea and vomiting of pregnancy. (See CONTRAINDICATIONS). In prepartum states, the reduction in narcotic requirement effected by hydroxyzine is of particular benefit to both mother and neonate. Hydroxyzine benefits the cardiac patient by its ability to allay the associated anxiety and apprehension attendant to certain types of heart disease. Hydroxyzine is not known to interfere with the action of digitalis in any way and may be used concurrently with this agent. The effectiveness of hydroxyzine in long term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should reassess periodically the usefulness of the drug for the individual patient. uuid:74554e74-7bde-44a3-bbb2-96741b0b9eb0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5818 biolink:treats UMLS:C0236748 PMID:41385096 "[{""id"":""uuid:9075a2e7-6ab6-48a4-a3d3-6d2d11d9de5a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f5112740-37b6-4606-81b6-ab849ccdd561"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The total management of anxiety, tension, and psychomotor agitation in conditions of emotional stress requires in most instances a combined approach of psychotherapy and chemotherapy. Hydroxyzine has been found to be particularly useful for this latter phase of therapy in its ability to render the disturbed patient more amenable to psychotherapy in long term treatment of the psychoneurotic and psychotic, although it should not be used as the sole treatment of psychosis or of clearly demonstrated cases of depression. Hydroxyzine is also useful in alleviating the manifestations of anxiety and tension as in the preparation for dental procedures and in acute emotional problems. It has also been recommended for the management of anxiety associated with organic disturbances and as adjunctive therapy in alcoholism and allergic conditions with strong emotional overlay, such as in asthma, chronic urticaria, and pruritus. Hydroxyzine hydrochloride intramuscular solution is useful in treating the following types of patients when intramuscular administration is indicated: 1. The acutely disturbed or hysterical patient. 2. The acute or chronic alcoholic with anxiety withdrawal symptoms or delirium tremens. 3. As pre-and postoperative and pre- and postpartum adjunctive medication to permit reduction in narcotic dosage, allay anxiety and control emesis. Hydroxyzine hydrochloride has also demonstrated effectiveness in controlling nausea and vomiting, excluding nausea and vomiting of pregnancy. (See CONTRAINDICATIONS). In prepartum states, the reduction in narcotic requirement effected by hydroxyzine is of particular benefit to both mother and neonate. Hydroxyzine benefits the cardiac patient by its ability to allay the associated anxiety and apprehension attendant to certain types of heart disease. Hydroxyzine is not known to interfere with the action of digitalis in any way and may be used concurrently with this agent. The effectiveness of hydroxyzine in long term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should reassess periodically the usefulness of the drug for the individual patient. uuid:0f11355d-93b5-4654-adf9-bd682646e3ec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5818 biolink:treats MONDO:0007079 PMID:41385096 "[{""id"":""uuid:b185099f-cfe3-46c8-b407-60c458d40af0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1a1689eb-05df-4939-b51b-0d316a8a07ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The total management of anxiety, tension, and psychomotor agitation in conditions of emotional stress requires in most instances a combined approach of psychotherapy and chemotherapy. Hydroxyzine has been found to be particularly useful for this latter phase of therapy in its ability to render the disturbed patient more amenable to psychotherapy in long term treatment of the psychoneurotic and psychotic, although it should not be used as the sole treatment of psychosis or of clearly demonstrated cases of depression. Hydroxyzine is also useful in alleviating the manifestations of anxiety and tension as in the preparation for dental procedures and in acute emotional problems. It has also been recommended for the management of anxiety associated with organic disturbances and as adjunctive therapy in alcoholism and allergic conditions with strong emotional overlay, such as in asthma, chronic urticaria, and pruritus. Hydroxyzine hydrochloride intramuscular solution is useful in treating the following types of patients when intramuscular administration is indicated: 1. The acutely disturbed or hysterical patient. 2. The acute or chronic alcoholic with anxiety withdrawal symptoms or delirium tremens. 3. As pre-and postoperative and pre- and postpartum adjunctive medication to permit reduction in narcotic dosage, allay anxiety and control emesis. Hydroxyzine hydrochloride has also demonstrated effectiveness in controlling nausea and vomiting, excluding nausea and vomiting of pregnancy. (See CONTRAINDICATIONS). In prepartum states, the reduction in narcotic requirement effected by hydroxyzine is of particular benefit to both mother and neonate. Hydroxyzine benefits the cardiac patient by its ability to allay the associated anxiety and apprehension attendant to certain types of heart disease. Hydroxyzine is not known to interfere with the action of digitalis in any way and may be used concurrently with this agent. The effectiveness of hydroxyzine in long term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should reassess periodically the usefulness of the drug for the individual patient. uuid:1338a567-e79d-4ca5-9db6-5289b4f79d81 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5818 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:6da7f965-48a9-404b-92eb-a98a5dba45b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:327b7cdf-ae1d-4550-838f-1dae15de3642"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The total management of anxiety, tension, and psychomotor agitation in conditions of emotional stress requires in most instances a combined approach of psychotherapy and chemotherapy. Hydroxyzine has been found to be particularly useful for this latter phase of therapy in its ability to render the disturbed patient more amenable to psychotherapy in long term treatment of the psychoneurotic and psychotic, although it should not be used as the sole treatment of psychosis or of clearly demonstrated cases of depression. Hydroxyzine is also useful in alleviating the manifestations of anxiety and tension as in the preparation for dental procedures and in acute emotional problems. It has also been recommended for the management of anxiety associated with organic disturbances and as adjunctive therapy in alcoholism and allergic conditions with strong emotional overlay, such as in asthma, chronic urticaria, and pruritus. Hydroxyzine hydrochloride intramuscular solution is useful in treating the following types of patients when intramuscular administration is indicated: 1. The acutely disturbed or hysterical patient. 2. The acute or chronic alcoholic with anxiety withdrawal symptoms or delirium tremens. 3. As pre-and postoperative and pre- and postpartum adjunctive medication to permit reduction in narcotic dosage, allay anxiety and control emesis. Hydroxyzine hydrochloride has also demonstrated effectiveness in controlling nausea and vomiting, excluding nausea and vomiting of pregnancy. (See CONTRAINDICATIONS). In prepartum states, the reduction in narcotic requirement effected by hydroxyzine is of particular benefit to both mother and neonate. Hydroxyzine benefits the cardiac patient by its ability to allay the associated anxiety and apprehension attendant to certain types of heart disease. Hydroxyzine is not known to interfere with the action of digitalis in any way and may be used concurrently with this agent. The effectiveness of hydroxyzine in long term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should reassess periodically the usefulness of the drug for the individual patient. uuid:65d43c11-e7a3-4888-93e5-ba12a2c226d9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5818 biolink:treats UMLS:C0020701 PMID:41385096 "[{""id"":""uuid:1f545754-e69f-425a-b303-b3a902de56d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7e198069-fa0d-41f2-b296-18aedb9447dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The total management of anxiety, tension, and psychomotor agitation in conditions of emotional stress requires in most instances a combined approach of psychotherapy and chemotherapy. Hydroxyzine has been found to be particularly useful for this latter phase of therapy in its ability to render the disturbed patient more amenable to psychotherapy in long term treatment of the psychoneurotic and psychotic, although it should not be used as the sole treatment of psychosis or of clearly demonstrated cases of depression. Hydroxyzine is also useful in alleviating the manifestations of anxiety and tension as in the preparation for dental procedures and in acute emotional problems. It has also been recommended for the management of anxiety associated with organic disturbances and as adjunctive therapy in alcoholism and allergic conditions with strong emotional overlay, such as in asthma, chronic urticaria, and pruritus. Hydroxyzine hydrochloride intramuscular solution is useful in treating the following types of patients when intramuscular administration is indicated: 1. The acutely disturbed or hysterical patient. 2. The acute or chronic alcoholic with anxiety withdrawal symptoms or delirium tremens. 3. As pre-and postoperative and pre- and postpartum adjunctive medication to permit reduction in narcotic dosage, allay anxiety and control emesis. Hydroxyzine hydrochloride has also demonstrated effectiveness in controlling nausea and vomiting, excluding nausea and vomiting of pregnancy. (See CONTRAINDICATIONS). In prepartum states, the reduction in narcotic requirement effected by hydroxyzine is of particular benefit to both mother and neonate. Hydroxyzine benefits the cardiac patient by its ability to allay the associated anxiety and apprehension attendant to certain types of heart disease. Hydroxyzine is not known to interfere with the action of digitalis in any way and may be used concurrently with this agent. The effectiveness of hydroxyzine in long term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should reassess periodically the usefulness of the drug for the individual patient. uuid:fa3a6acd-83cb-4bf6-9882-eca7a1a972d3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5818 biolink:treats MONDO:0005567 PMID:41385096 "[{""id"":""uuid:95b62640-69d8-4a0f-ad3a-2bcc6fa08e03"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dc620b55-0809-49fe-a07f-45806e773861"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The total management of anxiety, tension, and psychomotor agitation in conditions of emotional stress requires in most instances a combined approach of psychotherapy and chemotherapy. Hydroxyzine has been found to be particularly useful for this latter phase of therapy in its ability to render the disturbed patient more amenable to psychotherapy in long term treatment of the psychoneurotic and psychotic, although it should not be used as the sole treatment of psychosis or of clearly demonstrated cases of depression. Hydroxyzine is also useful in alleviating the manifestations of anxiety and tension as in the preparation for dental procedures and in acute emotional problems. It has also been recommended for the management of anxiety associated with organic disturbances and as adjunctive therapy in alcoholism and allergic conditions with strong emotional overlay, such as in asthma, chronic urticaria, and pruritus. Hydroxyzine hydrochloride intramuscular solution is useful in treating the following types of patients when intramuscular administration is indicated: 1. The acutely disturbed or hysterical patient. 2. The acute or chronic alcoholic with anxiety withdrawal symptoms or delirium tremens. 3. As pre-and postoperative and pre- and postpartum adjunctive medication to permit reduction in narcotic dosage, allay anxiety and control emesis. Hydroxyzine hydrochloride has also demonstrated effectiveness in controlling nausea and vomiting, excluding nausea and vomiting of pregnancy. (See CONTRAINDICATIONS). In prepartum states, the reduction in narcotic requirement effected by hydroxyzine is of particular benefit to both mother and neonate. Hydroxyzine benefits the cardiac patient by its ability to allay the associated anxiety and apprehension attendant to certain types of heart disease. Hydroxyzine is not known to interfere with the action of digitalis in any way and may be used concurrently with this agent. The effectiveness of hydroxyzine in long term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should reassess periodically the usefulness of the drug for the individual patient. uuid:2f74a555-40d9-4d20-b336-9cb44204ffbd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5818 biolink:treats MONDO:0006642 PMID:41385096 "[{""id"":""uuid:5d7a7c6d-1220-44ed-be8f-e57bc356bad3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a3cabf91-eb96-486c-9f82-25faa1f0263d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The total management of anxiety, tension, and psychomotor agitation in conditions of emotional stress requires in most instances a combined approach of psychotherapy and chemotherapy. Hydroxyzine has been found to be particularly useful for this latter phase of therapy in its ability to render the disturbed patient more amenable to psychotherapy in long term treatment of the psychoneurotic and psychotic, although it should not be used as the sole treatment of psychosis or of clearly demonstrated cases of depression. Hydroxyzine is also useful in alleviating the manifestations of anxiety and tension as in the preparation for dental procedures and in acute emotional problems. It has also been recommended for the management of anxiety associated with organic disturbances and as adjunctive therapy in alcoholism and allergic conditions with strong emotional overlay, such as in asthma, chronic urticaria, and pruritus. Hydroxyzine hydrochloride intramuscular solution is useful in treating the following types of patients when intramuscular administration is indicated: 1. The acutely disturbed or hysterical patient. 2. The acute or chronic alcoholic with anxiety withdrawal symptoms or delirium tremens. 3. As pre-and postoperative and pre- and postpartum adjunctive medication to permit reduction in narcotic dosage, allay anxiety and control emesis. Hydroxyzine hydrochloride has also demonstrated effectiveness in controlling nausea and vomiting, excluding nausea and vomiting of pregnancy. (See CONTRAINDICATIONS). In prepartum states, the reduction in narcotic requirement effected by hydroxyzine is of particular benefit to both mother and neonate. Hydroxyzine benefits the cardiac patient by its ability to allay the associated anxiety and apprehension attendant to certain types of heart disease. Hydroxyzine is not known to interfere with the action of digitalis in any way and may be used concurrently with this agent. The effectiveness of hydroxyzine in long term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should reassess periodically the usefulness of the drug for the individual patient. uuid:f44c8fe4-8beb-4402-870a-374233833dea biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5818 biolink:treats HP:0002018 PMID:41385096 "[{""id"":""uuid:90956846-f064-4e6b-aa13-09abcc59863d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:93b8aa8c-561b-481f-bb4c-083a9c544074"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The total management of anxiety, tension, and psychomotor agitation in conditions of emotional stress requires in most instances a combined approach of psychotherapy and chemotherapy. Hydroxyzine has been found to be particularly useful for this latter phase of therapy in its ability to render the disturbed patient more amenable to psychotherapy in long term treatment of the psychoneurotic and psychotic, although it should not be used as the sole treatment of psychosis or of clearly demonstrated cases of depression. Hydroxyzine is also useful in alleviating the manifestations of anxiety and tension as in the preparation for dental procedures and in acute emotional problems. It has also been recommended for the management of anxiety associated with organic disturbances and as adjunctive therapy in alcoholism and allergic conditions with strong emotional overlay, such as in asthma, chronic urticaria, and pruritus. Hydroxyzine hydrochloride intramuscular solution is useful in treating the following types of patients when intramuscular administration is indicated: 1. The acutely disturbed or hysterical patient. 2. The acute or chronic alcoholic with anxiety withdrawal symptoms or delirium tremens. 3. As pre-and postoperative and pre- and postpartum adjunctive medication to permit reduction in narcotic dosage, allay anxiety and control emesis. Hydroxyzine hydrochloride has also demonstrated effectiveness in controlling nausea and vomiting, excluding nausea and vomiting of pregnancy. (See CONTRAINDICATIONS). In prepartum states, the reduction in narcotic requirement effected by hydroxyzine is of particular benefit to both mother and neonate. Hydroxyzine benefits the cardiac patient by its ability to allay the associated anxiety and apprehension attendant to certain types of heart disease. Hydroxyzine is not known to interfere with the action of digitalis in any way and may be used concurrently with this agent. The effectiveness of hydroxyzine in long term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should reassess periodically the usefulness of the drug for the individual patient. uuid:61bdc4e7-a56e-46b1-b7f7-cb2314aaea67 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5818 biolink:treats HP:0002013 PMID:41385096 "[{""id"":""uuid:99d1a3ef-ee79-44c7-9fbb-1dd60c54d7bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:56e5460a-5a92-43da-af6d-fae0182f4b27"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The total management of anxiety, tension, and psychomotor agitation in conditions of emotional stress requires in most instances a combined approach of psychotherapy and chemotherapy. Hydroxyzine has been found to be particularly useful for this latter phase of therapy in its ability to render the disturbed patient more amenable to psychotherapy in long term treatment of the psychoneurotic and psychotic, although it should not be used as the sole treatment of psychosis or of clearly demonstrated cases of depression. Hydroxyzine is also useful in alleviating the manifestations of anxiety and tension as in the preparation for dental procedures and in acute emotional problems. It has also been recommended for the management of anxiety associated with organic disturbances and as adjunctive therapy in alcoholism and allergic conditions with strong emotional overlay, such as in asthma, chronic urticaria, and pruritus. Hydroxyzine hydrochloride intramuscular solution is useful in treating the following types of patients when intramuscular administration is indicated: 1. The acutely disturbed or hysterical patient. 2. The acute or chronic alcoholic with anxiety withdrawal symptoms or delirium tremens. 3. As pre-and postoperative and pre- and postpartum adjunctive medication to permit reduction in narcotic dosage, allay anxiety and control emesis. Hydroxyzine hydrochloride has also demonstrated effectiveness in controlling nausea and vomiting, excluding nausea and vomiting of pregnancy. (See CONTRAINDICATIONS). In prepartum states, the reduction in narcotic requirement effected by hydroxyzine is of particular benefit to both mother and neonate. Hydroxyzine benefits the cardiac patient by its ability to allay the associated anxiety and apprehension attendant to certain types of heart disease. Hydroxyzine is not known to interfere with the action of digitalis in any way and may be used concurrently with this agent. The effectiveness of hydroxyzine in long term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should reassess periodically the usefulness of the drug for the individual patient. uuid:070964d5-ecd7-4e1e-a0ca-fd812b630cc5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5818 biolink:treats MONDO:0005267 PMID:41385096 "[{""id"":""uuid:091d500d-2c88-476b-9fea-96bff8770614"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:54ffc5b9-4fe3-4172-bcb6-8c4b5cd1d530"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The total management of anxiety, tension, and psychomotor agitation in conditions of emotional stress requires in most instances a combined approach of psychotherapy and chemotherapy. Hydroxyzine has been found to be particularly useful for this latter phase of therapy in its ability to render the disturbed patient more amenable to psychotherapy in long term treatment of the psychoneurotic and psychotic, although it should not be used as the sole treatment of psychosis or of clearly demonstrated cases of depression. Hydroxyzine is also useful in alleviating the manifestations of anxiety and tension as in the preparation for dental procedures and in acute emotional problems. It has also been recommended for the management of anxiety associated with organic disturbances and as adjunctive therapy in alcoholism and allergic conditions with strong emotional overlay, such as in asthma, chronic urticaria, and pruritus. Hydroxyzine hydrochloride intramuscular solution is useful in treating the following types of patients when intramuscular administration is indicated: 1. The acutely disturbed or hysterical patient. 2. The acute or chronic alcoholic with anxiety withdrawal symptoms or delirium tremens. 3. As pre-and postoperative and pre- and postpartum adjunctive medication to permit reduction in narcotic dosage, allay anxiety and control emesis. Hydroxyzine hydrochloride has also demonstrated effectiveness in controlling nausea and vomiting, excluding nausea and vomiting of pregnancy. (See CONTRAINDICATIONS). In prepartum states, the reduction in narcotic requirement effected by hydroxyzine is of particular benefit to both mother and neonate. Hydroxyzine benefits the cardiac patient by its ability to allay the associated anxiety and apprehension attendant to certain types of heart disease. Hydroxyzine is not known to interfere with the action of digitalis in any way and may be used concurrently with this agent. The effectiveness of hydroxyzine in long term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should reassess periodically the usefulness of the drug for the individual patient. uuid:dacb0d33-4592-4338-894b-c5288fb546e7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5103 biolink:treats MONDO:0002125 PMID:41385096 "[{""id"":""uuid:c7dbb221-302e-407d-8f93-0cb4914784e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2e763371-63dc-4e7a-b88b-d7f3b902a1b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Adult Patients: Flumazenil injection is indicated for the complete or partial reversal of the sedative effects of benzodiazepines in cases where general anesthesia has been induced and/or maintained with benzodiazepines, where sedation has been produced with benzodiazepines for diagnostic and therapeutic procedures, and for the management of benzodiazepine overdose. Pediatric Patients (aged 1 to 17): Flumazenil injection is indicated for the reversal of conscious sedation induced with benzodiazepines (see PRECAUTIONS: PEDIATRIC USE). CLOSE CONTRAINDICATIONS Flumazenil injection is contraindicated: •in patients with a known hypersensitivity to flumazenil or benzodiazepines. •in patients who have been given a benzodiazepine for control of a potentially life-threatening condition (e.g., control of intracranial pressure or status epilepticus). •in patients who are showing signs of serious cyclic antidepressant overdose (see WARNINGS). uuid:0b64c944-0618-47fe-891a-7ace525f6e1d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:9843669 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:d9a48688-1a6a-4aa2-87c6-0dc49c8db90c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:532e5ab2-09d7-4f65-adf2-4be61437e4c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Isosorbide dinitrate and hydralazine hydrochloride tablets are a combination of isosorbide dinitrate, a nitrate vasodilator, and hydralazine hydrochloride, an arteriolar vasodilator, indicated for: the treatment of heart failure as an adjunct therapy to standard therapy in self-identified black patients to improve survival, prolong time to hospitalization for heart failure and to improve patient-reported functional status ( 1.1 ) Limitations of use: There is little experience in patients with NYHA class IV heart failure ( 1.2 ) uuid:f837161c-4e61-4aab-83e9-be21a5490ad5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:AQK7UBA1LS biolink:treats MONDO:0016486 PMID:41385096 "[{""id"":""uuid:4ecfc54b-109c-44bf-b468-3d492a2dcf4f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bba4a737-fbea-45b6-bf1a-1bb31e3092ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] REBLOZYL is an erythroid maturation agent indicated for the treatment of: • Anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions ( 1.1 ). • Anemia without previous erythropoiesis stimulating agent use (ESA-naïve) in adult patients with very low- to intermediate-risk myelodysplastic syndromes (MDS) who may require regular red blood cell (RBC) transfusions ( 1.2 ). • Anemia failing an erythropoiesis stimulating agent and requiring 2 or more RBC units over 8 weeks in adult patients with very low- to intermediate-risk myelodysplastic syndromes with ring sideroblasts (MDS-RS) or with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) ( 1.3 ). • Limitations of Use: REBLOZYL is not indicated for use as a substitute for RBC transfusions in patients who require immediate correction of anemia ( 1.4 ). uuid:b7b8b3ef-efd3-4715-bfd5-7e83237c4862 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:AQK7UBA1LS biolink:treats MONDO:0019157 PMID:41385096 "[{""id"":""uuid:2db1cff8-ca16-495c-adb2-642dfdedc2b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:bd7bc029-e519-4a29-8411-bdcae161c5e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:5571d0d6-ec4e-425a-86d4-65cd8dc2a380"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/reblozyl""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] REBLOZYL is an erythroid maturation agent indicated for the treatment of: • Anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions ( 1.1 ). • Anemia without previous erythropoiesis stimulating agent use (ESA-naïve) in adult patients with very low- to intermediate-risk myelodysplastic syndromes (MDS) who may require regular red blood cell (RBC) transfusions ( 1.2 ). • Anemia failing an erythropoiesis stimulating agent and requiring 2 or more RBC units over 8 weeks in adult patients with very low- to intermediate-risk myelodysplastic syndromes with ring sideroblasts (MDS-RS) or with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) ( 1.3 ). • Limitations of Use: REBLOZYL is not indicated for use as a substitute for RBC transfusions in patients who require immediate correction of anemia ( 1.4 ).|[EMA] Reblozyl is indicated for the treatment of adult patients with transfusion-dependent anaemia due to very low, low and intermediate-risk myelodysplastic syndromes (MDS) with ring sideroblasts, who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy (see section 5.1).Reblozyl is indicated in adults for the treatment of anaemia associated with transfusion dependent and non transfusion dependent beta thalassaemia (see section 5.1). uuid:2d181d6b-a7eb-4371-80cc-cf4ce6c84fa7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:122361353 biolink:treats MONDO:0000004 PMID:41385096 "[{""id"":""uuid:32e611fa-409b-493a-93d2-7ef0c264e823"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e8aaa939-b26e-4e20-ae9e-cfac9f36d447"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cosyntropin for injection is indicated, in combination with other diagnostic tests, for use as a diagnostic agent in the screening of adrenocortical insufficiency in adults and pediatric patients. uuid:381eedff-4b53-4b91-8aab-bf588de16b97 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6367 biolink:treats MONDO:0004985 PMID:41385096 "[{""id"":""uuid:82fba141-b828-4bd0-b8da-33ce2fe8404e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c1a1fa67-8ab8-4c75-9907-fe4f004c9bf0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e23acee4-34f6-48f5-9afd-ec2cd77f634b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lamotrigine tablet is indicated for: Epilepsy—adjunctive therapy in patients aged 2 years and older: partial-onset seizures. primary generalized tonic-clonic seizures. generalized seizures of Lennox-Gastaut syndrome. ( 1.1 ) Epilepsy—monotherapy in patients aged 16 years and older: Conversion to monotherapy in patients with partial-onset seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single antiepileptic drug. ( 1.1 ) Bipolar disorder : Maintenance treatment of bipolar I disorder to delay the time to occurrence of mood episodes in patients treated for acute mood episodes with standard therapy. ( 1.2 ) Limitations of Use: Treatment of acute manic or mixed episodes is not recommended. Effectiveness of lamotrigine tablets in the acute treatment of mood episodes has not been established.|[PMDA] Drugs with a new additional indication and a new dosage for the prevention of recurrence/relapse of mood episodes in patients with bipolar disorder. uuid:7441eafa-61e3-4cd8-9afd-a4bccea4dead biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90227 biolink:treats MONDO:0003304 PMID:41385096 "[{""id"":""uuid:d4f6145d-e008-4490-91ab-4f45210efe1e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:091f0987-de56-471e-b547-f16125b344ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:9c8f9bc6-be3e-4f1d-a642-b70addedaed5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:be55b633-0a6e-48c5-b05b-719e88005486"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KOSELUGO is indicated for the treatment of pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN).|[EMA] Koselugo as monotherapy is indicated for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in paediatric patients with neurofibromatosis type 1 (NF1) aged 3 years and above|[PMDA] Drugs with a new active ingredient indicated for the treatment of plexiform neurofibroma in patients with neurofibromatosis type 1. [Orphan drug] uuid:9fc51f75-0c13-4a58-b4dd-ae67c09b8655 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:30769 biolink:treats HP:0001996 PMID:41385096 "[{""id"":""uuid:1ed8bda9-72e5-421b-98d0-048f3be2eef5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7aee367c-3986-4093-890e-33b2f6081c21"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium citrate and citric acid oral solution, is an effective alkalinizing agent. It is useful in those conditions where long-term maintenance of an alkaline urine is desirable, and is of value in the alleviation of chronic metabolic acidosis, such as results from chronic renal insufficiency or the syndrome of renal tubular acidosis, especially when the administration of potassium salts is undesirable or contraindicated. This product is also useful for buffering and neutralizing gastric hydrochloric acid quickly and effectively. Sodium citrate and citric acid oral solution is concentrated, and when administered after meals and before bedtime, allows one to maintain an alkaline urinary pH around the clock, usually without the necessity of a 2 A.M. dose. This product alkalinizes the urine without producing a systemic alkalosis in the recommended dosage. This product is highly palatable, pleasant tasting, and tolerable, even when administered for long periods. uuid:a5df6334-303d-4f72-9997-0b84b6485705 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:30769 biolink:treats MONDO:0005300 PMID:41385096 "[{""id"":""uuid:95858e39-71c4-4b0e-8af4-8d0a73c744dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4dabf4a8-c5bc-48ce-8d80-af6d34f6752c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium citrate and citric acid oral solution, is an effective alkalinizing agent. It is useful in those conditions where long-term maintenance of an alkaline urine is desirable, and is of value in the alleviation of chronic metabolic acidosis, such as results from chronic renal insufficiency or the syndrome of renal tubular acidosis, especially when the administration of potassium salts is undesirable or contraindicated. This product is also useful for buffering and neutralizing gastric hydrochloric acid quickly and effectively. Sodium citrate and citric acid oral solution is concentrated, and when administered after meals and before bedtime, allows one to maintain an alkaline urinary pH around the clock, usually without the necessity of a 2 A.M. dose. This product alkalinizes the urine without producing a systemic alkalosis in the recommended dosage. This product is highly palatable, pleasant tasting, and tolerable, even when administered for long periods. uuid:d0d3317d-9939-4890-a275-ce5343f92a0d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1163417 biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:4bd9676e-8668-46e1-91bb-64e39fb56844"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ac557d5f-ab41-4274-90c2-2ffb1f8d6e6f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the temporary relief of pain and itching associated with minor burns, sunburns or minor skin irritations or hemorrhoids and itching associated with inflammation, and rashes due to eczema. uuid:44881df2-cc54-4e4a-8948-f868979c9089 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1163417 biolink:treats MONDO:0005326 PMID:41385096 "[{""id"":""uuid:464c5576-4264-474a-8226-aa794c490ab8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:03963654-7d36-43aa-826a-fe7fdb27a8cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the temporary relief of pain and itching associated with minor burns, sunburns or minor skin irritations or hemorrhoids and itching associated with inflammation, and rashes due to eczema. uuid:3e2cc086-7b58-43a9-a130-1f55108b8ad0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:AL3L5D17Y7 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:8b574c70-b344-439f-a6e9-5fea7f12ea31"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:74ec8660-234d-447e-8725-df1e9a0391b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LUMISIGHT is indicated for fluorescence imaging in adults with breast cancer as an adjunct for the intraoperative detection of cancerous tissue within the resection cavity following removal of the primary specimen during lumpectomy surgery. uuid:8506c9bf-10d9-4e0e-8765-fad53e27268f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3398 biolink:treats MONDO:0100177 PMID:41385096 "[{""id"":""uuid:6f4b12e0-96eb-4ef6-9fbe-d5c7feab0b15"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cf0164f5-146f-43c4-ab94-d0fbb0484ef6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carbinoxamine Maleate extended-release oral suspension is indicated for adults and pediatric patients 2 years of age and older for the symptomatic treatment of: Seasonal and perennial allergic rhinitis Vasomotor rhinitis Allergic conjunctivitis due to inhalant allergens and foods Mild, uncomplicated allergic skin manifestations of urticaria and angioedema Dermatographism As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled Amelioration of the severity of allergic reactions to blood or plasma uuid:15e55680-0130-4769-a12c-4b0e0e947dff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0009693 PMID:41385096 "[{""id"":""uuid:abbcbadb-37d9-4bbd-afa4-e09e4a30eae4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:255c0041-08a8-4d03-bfc5-3332812a579d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:324d34e8-6ddb-4e35-a37d-f897dfab8241"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] HEMADY is indicated in combination with other anti-myeloma products for the treatment of adults with multiple myeloma (MM).|[PMDA] A drug with a new additional indication and a new dosage for the treatment of multiple myeloma. [Expedited review] uuid:2f9d38cd-9ce3-4daf-9baf-4826fd329caa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0009685 PMID:41385096 "[{""id"":""uuid:2c00e0cb-4c4a-4383-87cc-50aa1dd031e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f51acc2a-babf-422c-8c2a-8e2b775984a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] HEMADY is indicated in combination with other anti-myeloma products for the treatment of adults with multiple myeloma (MM). uuid:1f4804f5-6083-4343-aa60-f5cca466cfdf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6427 biolink:treats UMLS:C5553997 PMID:41385096 "[{""id"":""uuid:8ee9bd99-8c77-4a19-87f1-69b1d7cd3553"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1a1b827a-508b-4e87-84f6-b0023ff262a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LUPRON DEPOT 7.5 mg for 1-month administration, 22.5 mg for 3-month administration, 30 mg for 4-month administration, and 45 mg for 6-month administration (leuprolide acetate) are indicated for the treatment of advanced prostate cancer. uuid:5f992c25-7dd4-4e14-a9cc-d883fa164be5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6QVL057INT biolink:treats UMLS:C4087141 PMID:41385096 "[{""id"":""uuid:5ed89a3f-2040-4457-a220-76c841ee275d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3d7f2b8d-b5a1-4e27-b131-9020a27edd15"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LIBTAYO is a programmed death receptor-1 (PD-1) blocking antibody indicated: Cutaneous Squamous Cell Carcinoma (CSCC) for the treatment of patients with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation. ( 1.1 ) Basal Cell Carcinoma (BCC) for the treatment of patients with locally advanced or metastatic BCC (laBCC or mBCC) who have been previously treated with a hedgehog pathway inhibitor or for whom a hedgehog pathway inhibitor is not appropriate. ( 1.2 ) Non-Small Cell Lung Cancer (NSCLC) in combination with platinum-based chemotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) with no EGFR, ALK or ROS1 aberrations and is: locally advanced where patients are not candidates for surgical resection or definitive chemoradiation or metastatic. ( 1.3 ) as single agent for the first-line treatment of adult patients with NSCLC whose tumors have high PD-L1 expression [Tumor Proportion Score (TPS) ≥ 50%] as determined by an FDA-approved test, with no EGFR, ALK or ROS1 aberrations, and is: locally advanced where patients are not candidates for surgical resection or definitive chemoradiation or metastatic. ( 1.3 , 2.1 ) uuid:1cacc958-d55a-4b07-90ca-a4edffb2820c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6QVL057INT biolink:treats UMLS:C5556695 PMID:41385096 "[{""id"":""uuid:9a823e4c-4d0e-4037-a942-b9be34c7b9ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2a3ffeea-c13c-4831-8e28-dde86769c93b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LIBTAYO is a programmed death receptor-1 (PD-1) blocking antibody indicated: Cutaneous Squamous Cell Carcinoma (CSCC) for the treatment of patients with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation. ( 1.1 ) Basal Cell Carcinoma (BCC) for the treatment of patients with locally advanced or metastatic BCC (laBCC or mBCC) who have been previously treated with a hedgehog pathway inhibitor or for whom a hedgehog pathway inhibitor is not appropriate. ( 1.2 ) Non-Small Cell Lung Cancer (NSCLC) in combination with platinum-based chemotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) with no EGFR, ALK or ROS1 aberrations and is: locally advanced where patients are not candidates for surgical resection or definitive chemoradiation or metastatic. ( 1.3 ) as single agent for the first-line treatment of adult patients with NSCLC whose tumors have high PD-L1 expression [Tumor Proportion Score (TPS) ≥ 50%] as determined by an FDA-approved test, with no EGFR, ALK or ROS1 aberrations, and is: locally advanced where patients are not candidates for surgical resection or definitive chemoradiation or metastatic. ( 1.3 , 2.1 ) uuid:0500edd4-b7ba-4fb6-95c4-70cf680200b3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6QVL057INT biolink:treats MONDO:0020804 PMID:41385096 "[{""id"":""uuid:b6dc6f9f-25e4-4a37-ae23-312f22c909b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:2b3eecd0-3270-488a-9f20-56d18b68493b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:a45ea201-40c0-4a77-a75f-d16e1aaad15d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/libtayo""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] LIBTAYO is a programmed death receptor-1 (PD-1) blocking antibody indicated: Cutaneous Squamous Cell Carcinoma (CSCC) for the treatment of patients with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation. ( 1.1 ) Basal Cell Carcinoma (BCC) for the treatment of patients with locally advanced or metastatic BCC (laBCC or mBCC) who have been previously treated with a hedgehog pathway inhibitor or for whom a hedgehog pathway inhibitor is not appropriate. ( 1.2 ) Non-Small Cell Lung Cancer (NSCLC) in combination with platinum-based chemotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) with no EGFR, ALK or ROS1 aberrations and is: locally advanced where patients are not candidates for surgical resection or definitive chemoradiation or metastatic. ( 1.3 ) as single agent for the first-line treatment of adult patients with NSCLC whose tumors have high PD-L1 expression [Tumor Proportion Score (TPS) ≥ 50%] as determined by an FDA-approved test, with no EGFR, ALK or ROS1 aberrations, and is: locally advanced where patients are not candidates for surgical resection or definitive chemoradiation or metastatic. ( 1.3 , 2.1 )|[EMA] Cutaneous Squamous Cell CarcinomaLibtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mCSCC or laCSCC) who are not candidates for curative surgery or curative radiation.Basal Cell CarcinomaLibtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (laBCC or mBCC) who have progressed on or are intolerant to a hedgehog pathway inhibitor (HHI).Non-Small Cell Lung CancerLibtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) expressing PD-L1 (in ≥ 50% tumour cells), with no EGFR, ALK or ROS1 aberrations, who have:locally advanced NSCLC who are not candidates for definitive chemoradiation, ormetastatic NSCLC.Libtayo in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with NSCLC expressing PD-L1 (in ≥ 1% of tumour cells), with no EGFR, ALK or ROS1 aberrations, who have:locally advanced NSCLC who are not candidates for definitive chemoradiation, ormetastatic NSCLC.Cervical CancerLibtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy. uuid:86ad791b-04eb-45a1-92ba-7b86c51b1321 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6QVL057INT biolink:treats UMLS:C4745056 PMID:41385096 "[{""id"":""uuid:ac0dc08a-1ff1-4e18-b143-22fe6b07e299"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0f33773e-e304-4d4b-a78b-6dba79120337"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LIBTAYO is a programmed death receptor-1 (PD-1) blocking antibody indicated: Cutaneous Squamous Cell Carcinoma (CSCC) for the treatment of patients with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation. ( 1.1 ) Basal Cell Carcinoma (BCC) for the treatment of patients with locally advanced or metastatic BCC (laBCC or mBCC) who have been previously treated with a hedgehog pathway inhibitor or for whom a hedgehog pathway inhibitor is not appropriate. ( 1.2 ) Non-Small Cell Lung Cancer (NSCLC) in combination with platinum-based chemotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) with no EGFR, ALK or ROS1 aberrations and is: locally advanced where patients are not candidates for surgical resection or definitive chemoradiation or metastatic. ( 1.3 ) as single agent for the first-line treatment of adult patients with NSCLC whose tumors have high PD-L1 expression [Tumor Proportion Score (TPS) ≥ 50%] as determined by an FDA-approved test, with no EGFR, ALK or ROS1 aberrations, and is: locally advanced where patients are not candidates for surgical resection or definitive chemoradiation or metastatic. ( 1.3 , 2.1 ) uuid:73fb32b0-c5c6-4662-bc74-b17bb041f418 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6QVL057INT biolink:treats UMLS:C1304306 PMID:41385096 "[{""id"":""uuid:dce26195-099b-495b-8232-3b7475737d73"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9a7c25a9-cd46-46bf-a2fe-31d663ea4491"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LIBTAYO is a programmed death receptor-1 (PD-1) blocking antibody indicated: Cutaneous Squamous Cell Carcinoma (CSCC) for the treatment of patients with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation. ( 1.1 ) Basal Cell Carcinoma (BCC) for the treatment of patients with locally advanced or metastatic BCC (laBCC or mBCC) who have been previously treated with a hedgehog pathway inhibitor or for whom a hedgehog pathway inhibitor is not appropriate. ( 1.2 ) Non-Small Cell Lung Cancer (NSCLC) in combination with platinum-based chemotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) with no EGFR, ALK or ROS1 aberrations and is: locally advanced where patients are not candidates for surgical resection or definitive chemoradiation or metastatic. ( 1.3 ) as single agent for the first-line treatment of adult patients with NSCLC whose tumors have high PD-L1 expression [Tumor Proportion Score (TPS) ≥ 50%] as determined by an FDA-approved test, with no EGFR, ALK or ROS1 aberrations, and is: locally advanced where patients are not candidates for surgical resection or definitive chemoradiation or metastatic. ( 1.3 , 2.1 ) uuid:280fc0c9-e161-4412-bd66-09e3997b7c77 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6QVL057INT biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:2cc26f41-cc6d-4ea4-a5c9-d764bb1ae442"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:15d5549d-d562-468a-aa4b-2dbeb0e4fd61"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:a2affc75-aeb4-4ac0-a2ed-e9df01a7ffa6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/libtayo""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] LIBTAYO is a programmed death receptor-1 (PD-1) blocking antibody indicated: Cutaneous Squamous Cell Carcinoma (CSCC) for the treatment of patients with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation. ( 1.1 ) Basal Cell Carcinoma (BCC) for the treatment of patients with locally advanced or metastatic BCC (laBCC or mBCC) who have been previously treated with a hedgehog pathway inhibitor or for whom a hedgehog pathway inhibitor is not appropriate. ( 1.2 ) Non-Small Cell Lung Cancer (NSCLC) in combination with platinum-based chemotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) with no EGFR, ALK or ROS1 aberrations and is: locally advanced where patients are not candidates for surgical resection or definitive chemoradiation or metastatic. ( 1.3 ) as single agent for the first-line treatment of adult patients with NSCLC whose tumors have high PD-L1 expression [Tumor Proportion Score (TPS) ≥ 50%] as determined by an FDA-approved test, with no EGFR, ALK or ROS1 aberrations, and is: locally advanced where patients are not candidates for surgical resection or definitive chemoradiation or metastatic. ( 1.3 , 2.1 )|[EMA] Cutaneous Squamous Cell CarcinomaLibtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mCSCC or laCSCC) who are not candidates for curative surgery or curative radiation.Basal Cell CarcinomaLibtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (laBCC or mBCC) who have progressed on or are intolerant to a hedgehog pathway inhibitor (HHI).Non-Small Cell Lung CancerLibtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) expressing PD-L1 (in ≥ 50% tumour cells), with no EGFR, ALK or ROS1 aberrations, who have:locally advanced NSCLC who are not candidates for definitive chemoradiation, ormetastatic NSCLC.Libtayo in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with NSCLC expressing PD-L1 (in ≥ 1% of tumour cells), with no EGFR, ALK or ROS1 aberrations, who have:locally advanced NSCLC who are not candidates for definitive chemoradiation, ormetastatic NSCLC.Cervical CancerLibtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy. uuid:954f015b-2f6b-4565-bb64-6e8ba50ea107 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:94435 biolink:treats MONDO:0100135 PMID:41385096 "[{""id"":""uuid:5e4aee2b-9c68-450a-bcb7-9339cc4199a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:b112b663-f769-4346-b07d-0d9693bccccd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:195501b2-32ac-42ae-81c9-324a10689535"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/diacomit""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] DIACOMIT is indicated for the treatment of seizures associated with Dravet syndrome (DS) in patients taking clobazam who are 6 months of age and older and weighing 7 kg or more. There are no clinical data to support the use of DIACOMIT as monotherapy in Dravet syndrome.|[EMA] Diacomit is indicated for use in conjunction with clobazam and valproate as adjunctive therapy of refractory generalized tonic-clonic seizures in patients with severe myoclonic epilepsy in infancy (SMEI, Dravet's syndrome) whose seizures are not adequately controlled with clobazam and valproate. uuid:356161bf-b6bf-405f-9fb7-30ae1b8a369a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:9RV78Q2002 biolink:treats MONDO:0005101 PMID:41385096 "[{""id"":""uuid:c16069b8-d298-4af0-b81d-4a1225a20599"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1e860e11-cb9b-4d99-9579-4f79278e01fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f93c03fe-722c-4f46-8b10-4bbc4a8aadf2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/entyvio""]},{""id"":""uuid:6ef3d3bc-059c-4939-b17a-18de11acfeae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ENTYVIO is indicated in adults for the treatment of: moderately to severely active ulcerative colitis (UC). moderately to severely active Crohn's disease (CD).|[EMA] Ulcerative colitisEntyvio is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor alpha (TNFα) antagonist.Crohn’s diseaseEntyvio is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor alpha (TNFα) antagonist.PouchitisEntyvio is indicated for the treatment of adult patients with moderately to severely active chronic pouchitis, who have undergone proctocolectomy and ileal pouch anal anastomosis for ulcerative colitis, and have had an inadequate response with or lost response to antibiotic therapy.|[PMDA] A drug with a new active ingredient indicated for the treatment and maintenance therapy of moderate to severe ulcerative colitis (for use only in patients who have not sufficiently responded to conventional treatments). uuid:ba5d48ad-31f5-43fc-84bb-8aea81c846b8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:9RV78Q2002 biolink:treats MONDO:0005011 PMID:41385096 "[{""id"":""uuid:cf931c1f-cf3b-4a39-a325-131fee044706"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:83a6d0d7-454c-46cd-8c86-6f035aa554cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:4c3b91f1-bf1d-4c9b-b929-5e712ae88526"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/entyvio""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] ENTYVIO is indicated in adults for the treatment of: moderately to severely active ulcerative colitis (UC). moderately to severely active Crohn's disease (CD).|[EMA] Ulcerative colitisEntyvio is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor alpha (TNFα) antagonist.Crohn’s diseaseEntyvio is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor alpha (TNFα) antagonist.PouchitisEntyvio is indicated for the treatment of adult patients with moderately to severely active chronic pouchitis, who have undergone proctocolectomy and ileal pouch anal anastomosis for ulcerative colitis, and have had an inadequate response with or lost response to antibiotic therapy. uuid:e71abb19-4a0a-4fc0-adbe-11627dbef67f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60311 biolink:treats MONDO:0005397 PMID:41385096 "[{""id"":""uuid:73e7cdae-95c8-4809-83ec-41ed61e86de4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4d1b82d7-3fdb-469a-8f52-31e9fd5e6ea9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Thyroid Tablets are indicated: 1. As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (see WARNINGS ). 2. As pituitary TSH suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto’s), multinodular goiter, and in the management of thyroid cancer. PUBCHEM.COMPOUND:53462828 uuid:b9cfcdf8-1286-4537-bd1c-e1b472a5ef09 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:36161 biolink:treats MONDO:0008294 PMID:41385096 "[{""id"":""uuid:1856d6c8-7e81-460b-8373-d528452b21a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:289b79be-3e19-4518-9e67-d213cf03ad93"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:b4e2f5f4-93b9-4e7b-bfcf-b62e7710add1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PANHEMATIN is a hemin for injection indicated for the amelioration of recurrent attacks of acute intermittent porphyria temporally related to the menstrual cycle in susceptible women, after initial carbohydrate therapy is known or suspected to be inadequate. Limitations of Use • Before administering PANHEMATIN, consider an appropriate period of carbohydrate loading (i.e., 400 g glucose/day for 1 to 2 days) [See Dosage and Administration ( 2.1 )] . • Attacks of porphyria may progress to a point where irreversible neuronal damage has occurred. PANHEMATIN therapy is intended to prevent an attack from reaching the critical stage of neuronal degeneration. PANHEMATIN is not effective in repairing neuronal damage.|[PMDA] A drug with a new active ingredient indicated for the improvement of symptoms of acute attack in patients with acute porphyria. [Orphan drug] uuid:bfeba128-49fb-4049-9e9b-e9cf2db9396d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2J3H5C81A5 biolink:treats MONDO:0005388 PMID:41385096 "[{""id"":""uuid:918553c5-0e76-435f-96ce-05057548f8d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1c363905-57ff-4cfd-84bb-d1e19cd55542"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] IQIRVO is indicated for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have had an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA. This indication is approved under accelerated approval based on reduction of alkaline phosphatase (ALP) [see Clinical Studies (14) ] . Improvement in survival or prevention of liver decompensation events have not been demonstrated. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). uuid:5bc022d2-02cf-4626-bf5d-270da66fe431 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2J3H5C81A5 biolink:treats MONDO:0007193 PMID:41385096 "[{""id"":""uuid:15815e62-0ee5-4710-8f3f-ea24d5ac958c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b5a3c259-060e-4f6f-b183-193443c2c667"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] IQIRVO is indicated for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have had an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA. This indication is approved under accelerated approval based on reduction of alkaline phosphatase (ALP) [see Clinical Studies (14) ] . Improvement in survival or prevention of liver decompensation events have not been demonstrated. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). uuid:c32963c1-01ba-401e-9dd7-d56c4325b8aa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17334 biolink:treats UMLS:C0554628 PMID:41385096 "[{""id"":""uuid:9468b321-e04f-4c60-836b-d6522d6a7f2d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fb31cec8-c86c-4a0c-8cc4-4d74e74c2446"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lentocilin S is indicated for the treatment of the following infections in adults and children: - Upper respiratory tract infections, namely group A streptococcal infections - Primary and secondary syphilis - Latent syphilis - Tertiary syphilis (in adults) - Congenital syphilis (in children) - Yaws - Bejel - Pinta Lentocilin S is also indicated prophylactically in the following situations: - Rheumatic fever - Diphtheria (including elimination of the asymptomatic carrier state) Consideration should be given to official guidelines for appropriate use of antimicrobial agents. CHEBI:18208 uuid:b57c3408-411d-45f2-8e67-8e35235226d7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17334 biolink:treats MONDO:0002896 PMID:41385096 "[{""id"":""uuid:dc50fa8c-5b0d-4f6d-921a-b0374eacdeba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:35708312-80b1-4709-b026-1bc21c62b41f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lentocilin S is indicated for the treatment of the following infections in adults and children: - Upper respiratory tract infections, namely group A streptococcal infections - Primary and secondary syphilis - Latent syphilis - Tertiary syphilis (in adults) - Congenital syphilis (in children) - Yaws - Bejel - Pinta Lentocilin S is also indicated prophylactically in the following situations: - Rheumatic fever - Diphtheria (including elimination of the asymptomatic carrier state) Consideration should be given to official guidelines for appropriate use of antimicrobial agents. CHEBI:18208 uuid:7466fa1e-4502-485a-9daf-0fad111db74b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17334 biolink:treats MONDO:0002897 PMID:41385096 "[{""id"":""uuid:25f63687-08ba-4b01-aede-e334d32eb4a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1dfb80ff-731e-4107-93ba-9ec98b52cd39"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lentocilin S is indicated for the treatment of the following infections in adults and children: - Upper respiratory tract infections, namely group A streptococcal infections - Primary and secondary syphilis - Latent syphilis - Tertiary syphilis (in adults) - Congenital syphilis (in children) - Yaws - Bejel - Pinta Lentocilin S is also indicated prophylactically in the following situations: - Rheumatic fever - Diphtheria (including elimination of the asymptomatic carrier state) Consideration should be given to official guidelines for appropriate use of antimicrobial agents. CHEBI:18208 uuid:851a8136-25d4-41cf-a6c0-c5b87da137ca biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17334 biolink:treats MONDO:0005822 PMID:41385096 "[{""id"":""uuid:ad4d7844-d6f0-4d11-b649-bc17d6e28a27"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7b049487-c6bf-4166-bf0e-105ea8c21fbd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lentocilin S is indicated for the treatment of the following infections in adults and children: - Upper respiratory tract infections, namely group A streptococcal infections - Primary and secondary syphilis - Latent syphilis - Tertiary syphilis (in adults) - Congenital syphilis (in children) - Yaws - Bejel - Pinta Lentocilin S is also indicated prophylactically in the following situations: - Rheumatic fever - Diphtheria (including elimination of the asymptomatic carrier state) Consideration should be given to official guidelines for appropriate use of antimicrobial agents. CHEBI:18208 uuid:f65307c6-e1e3-4e8a-843c-73d6a7391b72 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17334 biolink:treats MONDO:0004497 PMID:41385096 "[{""id"":""uuid:d058532b-b588-45fd-9cc4-f874cd2b5c2f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a2029f03-a7ae-4e9e-a403-cb53bbe9c863"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lentocilin S is indicated for the treatment of the following infections in adults and children: - Upper respiratory tract infections, namely group A streptococcal infections - Primary and secondary syphilis - Latent syphilis - Tertiary syphilis (in adults) - Congenital syphilis (in children) - Yaws - Bejel - Pinta Lentocilin S is also indicated prophylactically in the following situations: - Rheumatic fever - Diphtheria (including elimination of the asymptomatic carrier state) Consideration should be given to official guidelines for appropriate use of antimicrobial agents. CHEBI:18208 uuid:36755b0b-df98-4096-9de8-44c1b03594fd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17334 biolink:treats MONDO:0005714 PMID:41385096 "[{""id"":""uuid:d63317cb-9a5e-4974-8d4b-47b847818469"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7177ffc9-fc7f-47d6-9896-fa5c028f1354"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lentocilin S is indicated for the treatment of the following infections in adults and children: - Upper respiratory tract infections, namely group A streptococcal infections - Primary and secondary syphilis - Latent syphilis - Tertiary syphilis (in adults) - Congenital syphilis (in children) - Yaws - Bejel - Pinta Lentocilin S is also indicated prophylactically in the following situations: - Rheumatic fever - Diphtheria (including elimination of the asymptomatic carrier state) Consideration should be given to official guidelines for appropriate use of antimicrobial agents. CHEBI:18208 uuid:b6b5216b-aa7d-49e2-a3a8-7300f8a79a39 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:LR3UXN0193 biolink:treats MONDO:0020725 PMID:41385096 "[{""id"":""uuid:056a5a5e-9168-4777-a7ec-1b13beb6e3f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:2e0c4d96-8195-4a46-8187-bedaec3b26ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ee7f75fd-0f1d-4bda-b624-a3a6e9fc5062"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/mircera""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mircera is an erythropoiesis-stimulating agent (ESA) indicated for the treatment of anemia associated with chronic kidney disease (CKD) in: • adult patients on dialysis and adult patients not on dialysis ( 1.1 ). • pediatric patients 3 months to 17 years of age on dialysis or not on dialysis who are converting from another ESA after their hemoglobin level was stabilized with an ESA ( 1.1 ). Limitations of Use Mircera is not indicated and is not recommended for use: • In the treatment of anemia due to cancer chemotherapy ( 5.2 ). • As a substitute for RBC transfusions in patients who require immediate correction of anemia ( 12.2 ). Mircera has not been shown to improve quality of life, fatigue, or patient well-being.|[EMA] Treatment of symptomatic anaemia associated with chronic kidney disease (CKD) in adult patients (see section 5.1).Treatment of symptomatic anaemia associated with chronic kidney disease (CKD) in paediatric patients from 3 months to less than 18 years of age who are converting from another erythropoiesis stimulating agent (ESA) after their haemoglobin level was stabilised with the previous ESA (see section 5.1). uuid:0995c2fb-b61e-43de-8bd0-40bde04f1095 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:F60NE4XB53 biolink:treats MONDO:0018881 PMID:41385096 "[{""id"":""uuid:ff9d19d5-21a0-4c63-bae7-8d214b414ba1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7ffc0acc-c1ba-4831-b68d-2babd4735bce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RYTELO is indicated for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring 4 or more red blood cell units over 8 weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESA). uuid:1b0a8d30-a176-449c-9769-2333d0397ad1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18243 biolink:treats HP:0031275 PMID:41385096 "[{""id"":""uuid:6c36fa76-f6b4-4edc-865b-a13411ee8004"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:91e3d1f7-fef0-465e-b816-05e778caa916"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dopamine HCl Injection is indicated to improve hemodynamic status in patients in distributive shock or shock due to reduced cardiac output. uuid:3b0b8e52-ec24-4887-853e-40a40f5c8acd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0021632 PMID:41385096 "[{""id"":""uuid:6788bda2-77c8-4b46-acd6-ecec36b59636"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:43221ecf-2aed-42a5-b00c-95f8da499f2c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, and the strength, dosage form and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramuscular use of methylprednisolone sodium succinate for injection, USP is indicated as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions. Dermatologic diseases : Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administration is contraindicated), pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic diseases : For the palliative management of leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic diseases : Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, temporal arteritis, polymyositis, and systemic lupus erythematosus. uuid:983d95d7-1eeb-4979-bf84-d96e6bd9f899 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:1040026 PMID:41385096 "[{""id"":""uuid:990b7ad8-fdd5-4a71-9595-e67443c3972d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:96c9fad5-47b7-406f-ace5-4d9c7239e216"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, and the strength, dosage form and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramuscular use of methylprednisolone sodium succinate for injection, USP is indicated as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions. Dermatologic diseases : Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administration is contraindicated), pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic diseases : For the palliative management of leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic diseases : Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, temporal arteritis, polymyositis, and systemic lupus erythematosus. uuid:4fbb1cd2-f37c-4aff-a003-30c1b068863f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3207 biolink:treats MONDO:0005342 PMID:41385096 "[{""id"":""uuid:e97cb8f6-7ebb-4bf3-9128-f5d7b2945c4a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:2b175ee9-4f31-4403-9db9-f407f7659097"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:fddca6f0-923c-430b-ab39-35a533e180b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TARPEYO is indicated to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression.|[EMA] Kinpeygo is indicated for the treatment of primary immunoglobulin A (IgA) nephropathy (IgAN) in adults at risk of rapid disease progression with a urine protein-to-creatinine ratio (UPCR) ≥1.5 g/gram. uuid:8f33e208-cdde-4abe-b161-cc7415313592 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3207 biolink:treats MONDO:0008072 PMID:41385096 "[{""id"":""uuid:cac2188b-3882-4aaa-b05b-e6151c1a9d4d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:64783695-7176-4225-a48b-bc4eb19c1037"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TARPEYO is indicated to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression. uuid:4cb12005-379e-45db-8b8e-12ced3745a67 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:54681908 biolink:treats MONDO:0011438 PMID:41385096 "[{""id"":""uuid:49dc81ba-bb82-41fe-a688-84fb559eb104"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e22b1289-30c8-4071-9838-3d311ebdc57f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SEYSARA ® (sarecycline) tablet, is indicated for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 9 years of age and older. Limitations of Use Efficacy of SEYSARA beyond 12 weeks and safety beyond 12 months have not been established. SEYSARA has not been evaluated in the treatment of infections [see Clinical Studies ( 14 )] . To reduce the development of drug-resistant bacteria as well as to maintain the effectiveness of other antibacterial drugs, SEYSARA should be used only as indicated [see Warnings and Precautions ( 5.6 )] . uuid:e508d086-0fb3-43e9-802e-968f88325967 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:17276 biolink:treats MONDO:0003019 PMID:41385096 "[{""id"":""uuid:cd7b51e0-c641-4617-a1f8-e8da8b8fb63c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:def7e5e2-92b7-4a0c-9482-e8d099beac47"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Spironolactone, an ingredient of spironolactone and hydrochlorothiazide tablets, has been shown to be a tumorigen in chronic toxicity studies in rats (see PRECAUTIONS section). Spironolactone and hydrochlorothiazide tablets should be used only in those conditions described below. Unnecessary use of this drug should be avoided. Spironolactone and hydrochlorothiazide tablets are indicated for: Edematous conditions for patients with: Congestive heart failure: For the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures; The treatment of diuretic-induced hypokalemia in patients with congestive heart failure when other measures are considered inappropriate; The treatment of patients with congestive heart failure taking digitalis when other therapies are considered inadequate or inappropriate. Cirrhosis of the liver accompanied by edema and/or ascites: Aldosterone levels may be exceptionally high in this condition. Spironolactone and hydrochlorothiazide tablets are indicated for maintenance therapy together with bed rest and the restriction of fluid and sodium. The nephrotic syndrome: For nephrotic patients when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics do not provide an adequate response. Essential hypertension: For patients with essential hypertension in whom other measures are considered inadequate or inappropriate; In hypertensive patients for the treatment of a diuretic-induced hypokalemia when other measures are considered inappropriate; Spironolactone and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the classes to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with spironolactone and hydrochlorothiazide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. uuid:0bc28660-2fa1-491e-b6db-fe444dddd042 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3219 biolink:treats MONDO:0008575 PMID:41385096 "[{""id"":""uuid:84ea59fb-0b58-4561-8094-8be32f4c2f64"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c31ae155-04b0-403b-aaf0-6056ef59e67b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bupropion Hydrochloride Extended-Release Tablets (SR) are indicated as an aid to smoking cessation treatment. uuid:832c8bd2-1e90-4e7e-97ac-1d1819d7b14c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18145 biolink:treats MONDO:0024298 PMID:41385096 "[{""id"":""uuid:6c618236-982f-4ac3-a9ae-aefa25524b2b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:50177f64-e937-4c6f-844a-d1b49e75cd7c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Supplementation of the diet with ten essential vitamins. Supplementation of the diet with fluoride for caries prophylaxis. Multivitamin with Fluoride 0.25 mg Chewable Tablets provide 0.25 mg fluoride in tablet form for children 4-6years of age in areas where the drinking water contains 0.3 through 0.6 ppm of fluoride. Multivitamin with Fluoride 0.25 mg Chewable Tablets supply significant amounts of Vitamins A, C, D, E, thiamine, riboflavin, niacin, vitamin B6, vitamin B12, and folate to supplement the diet, and to help assure that nutritional deficiencies of these vitamins will not develop. Thus, in a single easy-to-use preparation, children obtain ten essential vitamins and the important mineral, fluoride. The American Academy of Pediatrics recommends that children up to age 16, in areas where drinking water contains less than optimal levels of fluoride, receive daily fluoride supplements. Children using Multivitamin with Fluoride 0 . 25 mg Chewable Tablets regularly should receive semiannual dental examinations. The regular brushing of teeth and attention to good oral hygiene practices are also essential. Multivitamin with Fluoride Chewable Tablets is a prescription product for the clinical dietary management of the metabolic processes of caries prophylaxis and provides supplementation of the diet with ten essential vitamins. uuid:a06a073c-a10d-4df7-91c3-6cdeb0c75e2e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:229230 biolink:treats MONDO:0005101 PMID:41385096 "[{""id"":""uuid:6cf96123-5fa3-4147-bb39-97cb66fd3f41"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:14189df2-dca4-4f93-8e04-ea1bc7c69bee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VELSIPITY is indicated for the treatment of moderately to severely active ulcerative colitis (UC) in adults. uuid:0a71b30f-d7ab-4d77-b1e4-3fc7ad7821c0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:129073603 biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:92ba0958-6f51-4020-982e-ddeead664ef2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:1c7fc2e5-9404-4b2e-bb84-041b90830018"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ebde61c8-4268-4689-9789-7ec4409544c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/gavreto""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] GAVRETO is a kinase inhibitor indicated for treatment of: Adult patients with metastatic rearranged during transfection (RET ) fusion-positive non-small cell lung cancer as detected by an FDA approved test (NSCLC). ( 1.1 ) Adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate). This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). ( 1.2 )|[EMA] Gavreto is indicated as monotherapy for the treatment of adult patients with rearranged during transfection (RET) fusion-positive advanced non-small cell lung cancer (NSCLC) not previously treated with a RET inhibitor. uuid:a05ebaa8-c972-4057-87d1-eef44e851d3a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:129073603 biolink:treats MONDO:0002108 PMID:41385096 "[{""id"":""uuid:274a942d-27b4-4c9b-8545-f081e7877fec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2a0ae71f-c90b-40bf-bc84-3c398c809abe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] GAVRETO is a kinase inhibitor indicated for treatment of: Adult patients with metastatic rearranged during transfection (RET ) fusion-positive non-small cell lung cancer as detected by an FDA approved test (NSCLC). ( 1.1 ) Adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate). This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). ( 1.2 ) uuid:a473538f-f1b8-4adb-93d1-755d31313571 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71193 biolink:treats MONDO:0004995 PMID:41385096 "[{""id"":""uuid:71e081f6-3cf0-4260-b759-3fb053fc2776"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d9403999-463a-460a-823d-7670c979b165"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Liraglutide is indicated: • as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus, • to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease. Limitations of Use : Liraglutide should not be used in patients with type 1 diabetes mellitus. Liraglutide contains liraglutide and should not be coadministered with other liraglutide-containing products. uuid:f3ce780e-bc2a-4813-bc75-dcd39c841878 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135720 biolink:treats MONDO:0010679 PMID:41385096 "[{""id"":""uuid:c2ebb7e3-e45f-4d03-96e3-d284de29786e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bacc5436-3f98-440b-93eb-60d5c5911737"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Deflazacort tablets are indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older. Additional pediatric use information is approved for PTC Therapeutics, Inc.'s Emflaza TM (deflazacort) tablets. However, due to PTC Therapeutics, Inc.'s marketing exclusivity rights, this drug product is not labeled with that information . uuid:8a736631-4a9f-4a73-950b-29f21989baf5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135948 biolink:treats MONDO:0018556 PMID:41385096 "[{""id"":""uuid:f0e86a58-795c-42ac-a225-35532dc80e8a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:44c57794-098a-4406-bcfa-34e1a45a5a31"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:53c9746a-03e6-4b52-bd47-240f1eaf699f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/firdapse""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] FIRDAPSE ® is indicated for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults and pediatric patients 6 years of age and older.|[EMA] Symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. uuid:e882846c-61a1-4195-b79c-06f1d52acabf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2359277 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:ca0d8833-7e14-4230-a77b-92453fe3405b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c01ca047-9268-45b5-886a-133e10f5bebb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TRIJARDY XR is a combination of empagliflozin, linagliptin, and metformin hydrochloride (HCl) indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus . Empagliflozin is indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease [see Clinical Studies (14.2) ] . uuid:a7ad1f8c-9e3b-473e-a494-4ae1894bd825 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2359277 biolink:treats MONDO:0004995 PMID:41385096 "[{""id"":""uuid:f2393c95-9bf5-4510-af4a-2ef027821dd2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d0ca74e4-417e-4720-9af9-435a3b2c7a35"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TRIJARDY XR is a combination of empagliflozin, linagliptin, and metformin hydrochloride (HCl) indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus . Empagliflozin is indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease [see Clinical Studies (14.2) ] . uuid:ad9a32d9-82ec-4663-8485-88ee9bcc1ec9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:1351PE5UGS biolink:treats MONDO:0009693 PMID:41385096 "[{""id"":""uuid:1488dd35-2d1c-4580-ba21-cf5e53a59670"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b7621925-bad0-4554-a08a-0d2e2d599dd3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:893139f0-10f6-41aa-8c4c-1a7478c2b77d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/empliciti""]},{""id"":""uuid:0ade50f3-3ebc-4784-af78-d11762222ea8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] • EMPLICITI is indicated in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one to three prior therapies. • EMPLICITI is indicated in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.|[EMA] Empliciti is indicated in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma in adult patients who have received at least one prior therapy (see sections 4.2 and 5.1).|[PMDA] Drugs with a new active ingredient indicated for the treatment of relapsed or refractory multiple myeloma. [Orphan drug] uuid:aa04384e-69ac-4f1e-8e4d-763e77f16d55 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C4534619 biolink:treats MONDO:0005326 PMID:41385096 "[{""id"":""uuid:2dc7a6ca-6a38-4ccc-82c7-5d50d9100541"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:befe6264-3fd8-41bd-b238-0071ac58a4ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] helps prevent sunburn if used as directed with other sun protection measures (see Directions ), decreases the risk of skin cancer and early skin aging caused by the sun uuid:9ea42586-ffef-4890-b11e-7ac57f44c8a4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17334 biolink:treats MONDO:0005631 PMID:41385096 "[{""id"":""uuid:c03cfafc-f028-414e-9b0b-5e6e478cbe54"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4c238646-5c9f-4b14-b25c-156f50a2e251"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy Penicillin G Potassium for Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Penicillin G Potassium for Injection, USP may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below; however, once these results become available, appropriate therapy should be continued. Clinical Indication Infecting Organism Septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis Streptococcus pyogenes (group A β-hemolytic streptococcus), other β-hemolytic streptococci including groups C,H,G,L and M, Streptococcus pneumoniae and Staphylococcus species (non-penicillinase producing strains) Anthrax Bacillus anthracis Actinomycosis (cervico-facial disease and thoracic and abdominal disease) Actinomyces israelii Botulism (adjunctive therapy to antitoxin), gas gangrene, and tetanus (adjunctive therapy to human tetanus immune globulin) Clostridium species Diphtheria (adjunctive therapy to antitoxin and prevention of the carrier state) Corynebacterium diphtheriae Erysipelothrix endocarditis Erysipelothrix rhusiopathiae Fusospirochetosis (severe infections of the oropharynx [Vincent’s], lower respiratory tract and genital area) Fusobacterium species and spirochetes Listeria infections including meningitis and endocarditis Listeria monocytogenes Pasteurella infections including bacteremia and meningitis Pasteurella multocida Haverhill fever Streptobacillus moniliformis Rat bite fever Spirillum minus or Streptobacillus moniliformis Disseminated gonococcal infections Neisseria gonorrhoeae (penicillin-susceptible) Syphilis (congenital and neurosyphilis) Treponema pallidum Meningococcal meningitis and / or septicemia Neisseria meningitidis Gram-negative bacillary infections (bacteremias) Penicillin G is not the drug of choice in the treatment of gram-negative bacillary infections . Gram -negative bacillary organisms (i.e. Enterobacteriaceae) To reduce the development of drug-resistant bacteria and maintain effectiveness of Penicillin G Potassium for Injection, USP and other antibacterial drugs, Penicillin G Potassium for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. CHEBI:18208 uuid:d76f6c6c-6442-4762-aca5-30e79deb2756 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17334 biolink:treats UMLS:C0039978 PMID:41385096 "[{""id"":""uuid:57089198-b2f8-4d99-ad49-c805c38a5d5b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:742de745-6e45-4824-983d-05d39a45a750"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy Penicillin G Potassium for Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Penicillin G Potassium for Injection, USP may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below; however, once these results become available, appropriate therapy should be continued. Clinical Indication Infecting Organism Septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis Streptococcus pyogenes (group A β-hemolytic streptococcus), other β-hemolytic streptococci including groups C,H,G,L and M, Streptococcus pneumoniae and Staphylococcus species (non-penicillinase producing strains) Anthrax Bacillus anthracis Actinomycosis (cervico-facial disease and thoracic and abdominal disease) Actinomyces israelii Botulism (adjunctive therapy to antitoxin), gas gangrene, and tetanus (adjunctive therapy to human tetanus immune globulin) Clostridium species Diphtheria (adjunctive therapy to antitoxin and prevention of the carrier state) Corynebacterium diphtheriae Erysipelothrix endocarditis Erysipelothrix rhusiopathiae Fusospirochetosis (severe infections of the oropharynx [Vincent’s], lower respiratory tract and genital area) Fusobacterium species and spirochetes Listeria infections including meningitis and endocarditis Listeria monocytogenes Pasteurella infections including bacteremia and meningitis Pasteurella multocida Haverhill fever Streptobacillus moniliformis Rat bite fever Spirillum minus or Streptobacillus moniliformis Disseminated gonococcal infections Neisseria gonorrhoeae (penicillin-susceptible) Syphilis (congenital and neurosyphilis) Treponema pallidum Meningococcal meningitis and / or septicemia Neisseria meningitidis Gram-negative bacillary infections (bacteremias) Penicillin G is not the drug of choice in the treatment of gram-negative bacillary infections . Gram -negative bacillary organisms (i.e. Enterobacteriaceae) To reduce the development of drug-resistant bacteria and maintain effectiveness of Penicillin G Potassium for Injection, USP and other antibacterial drugs, Penicillin G Potassium for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. CHEBI:18208 uuid:1e597293-b86e-42e8-b540-b0b07879bebd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17334 biolink:treats MONDO:0006865 PMID:41385096 "[{""id"":""uuid:f1943b19-349c-452c-ba04-fe34565c87a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:02bbc350-4686-4f52-b62a-9a823f4c3747"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy Penicillin G Potassium for Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Penicillin G Potassium for Injection, USP may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below; however, once these results become available, appropriate therapy should be continued. Clinical Indication Infecting Organism Septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis Streptococcus pyogenes (group A β-hemolytic streptococcus), other β-hemolytic streptococci including groups C,H,G,L and M, Streptococcus pneumoniae and Staphylococcus species (non-penicillinase producing strains) Anthrax Bacillus anthracis Actinomycosis (cervico-facial disease and thoracic and abdominal disease) Actinomyces israelii Botulism (adjunctive therapy to antitoxin), gas gangrene, and tetanus (adjunctive therapy to human tetanus immune globulin) Clostridium species Diphtheria (adjunctive therapy to antitoxin and prevention of the carrier state) Corynebacterium diphtheriae Erysipelothrix endocarditis Erysipelothrix rhusiopathiae Fusospirochetosis (severe infections of the oropharynx [Vincent’s], lower respiratory tract and genital area) Fusobacterium species and spirochetes Listeria infections including meningitis and endocarditis Listeria monocytogenes Pasteurella infections including bacteremia and meningitis Pasteurella multocida Haverhill fever Streptobacillus moniliformis Rat bite fever Spirillum minus or Streptobacillus moniliformis Disseminated gonococcal infections Neisseria gonorrhoeae (penicillin-susceptible) Syphilis (congenital and neurosyphilis) Treponema pallidum Meningococcal meningitis and / or septicemia Neisseria meningitidis Gram-negative bacillary infections (bacteremias) Penicillin G is not the drug of choice in the treatment of gram-negative bacillary infections . Gram -negative bacillary organisms (i.e. Enterobacteriaceae) To reduce the development of drug-resistant bacteria and maintain effectiveness of Penicillin G Potassium for Injection, USP and other antibacterial drugs, Penicillin G Potassium for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. CHEBI:18208 uuid:99f31d2a-bfd9-448e-a3bd-da5cec799886 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17334 biolink:treats MONDO:0004944 PMID:41385096 "[{""id"":""uuid:7b76ceca-3953-485f-a220-14d8b3bd7419"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d0cc3a6b-bb92-404d-a8d6-9a15a2528070"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy Penicillin G Potassium for Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Penicillin G Potassium for Injection, USP may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below; however, once these results become available, appropriate therapy should be continued. Clinical Indication Infecting Organism Septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis Streptococcus pyogenes (group A β-hemolytic streptococcus), other β-hemolytic streptococci including groups C,H,G,L and M, Streptococcus pneumoniae and Staphylococcus species (non-penicillinase producing strains) Anthrax Bacillus anthracis Actinomycosis (cervico-facial disease and thoracic and abdominal disease) Actinomyces israelii Botulism (adjunctive therapy to antitoxin), gas gangrene, and tetanus (adjunctive therapy to human tetanus immune globulin) Clostridium species Diphtheria (adjunctive therapy to antitoxin and prevention of the carrier state) Corynebacterium diphtheriae Erysipelothrix endocarditis Erysipelothrix rhusiopathiae Fusospirochetosis (severe infections of the oropharynx [Vincent’s], lower respiratory tract and genital area) Fusobacterium species and spirochetes Listeria infections including meningitis and endocarditis Listeria monocytogenes Pasteurella infections including bacteremia and meningitis Pasteurella multocida Haverhill fever Streptobacillus moniliformis Rat bite fever Spirillum minus or Streptobacillus moniliformis Disseminated gonococcal infections Neisseria gonorrhoeae (penicillin-susceptible) Syphilis (congenital and neurosyphilis) Treponema pallidum Meningococcal meningitis and / or septicemia Neisseria meningitidis Gram-negative bacillary infections (bacteremias) Penicillin G is not the drug of choice in the treatment of gram-negative bacillary infections . Gram -negative bacillary organisms (i.e. Enterobacteriaceae) To reduce the development of drug-resistant bacteria and maintain effectiveness of Penicillin G Potassium for Injection, USP and other antibacterial drugs, Penicillin G Potassium for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. CHEBI:18208 uuid:9fcf896c-27a0-4890-b52c-febe973528cc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:GK1LYB375A biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:b565fed3-708c-4539-8f70-0b53478bba66"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f0dc91af-f84a-420f-93c1-7ad7fbd57e63"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:d53db933-4c39-4170-94cf-eb74e1c6ac26"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/adtralza""]},{""id"":""uuid:f4578c5e-8ef1-41b9-ab95-a3e64c63f260"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ADBRY is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and pediatric patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. ADBRY can be used with or without topical corticosteroids.|[EMA] Adtralza is indicated for the treatment of moderate to severe atopic dermatitis in adult and adolescent patients 12 years and older who are candidates for systemic therapy.|[PMDA] A drug with a new active ingredient indicated for the treatment of atopic dermatitis in patients who have not responded sufficiently to conventional treatments. uuid:cd6f2ebe-51e9-4a15-bab4-2a890d2c20d1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1158330 biolink:treats HP:0000132 PMID:41385096 "[{""id"":""uuid:dedc84d2-12fa-4fe1-89a8-5dac138b4be0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a89c130e-ef80-4962-b10d-cd8cdfe0c776"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] • Natazia is a combination of dienogest , a progestin, and estradiol valerate, an estrogen, indicated for use by females of reproductive potential to prevent pregnancy. ( 1 ) • The efficacy of Natazia in females of reproductive potential with a body mass index (BMI) of >30 kg/m 2 has not been evaluated. ( 1 , 8.8 ) • Treatment of heavy menstrual bleeding in females of reproductive potential without organic pathology who choose to use an oral contraceptive as their method of contraception. ( 1.2 ) uuid:248c7032-b8aa-40d0-a444-31ec5685890a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C5418336 biolink:treats MONDO:0100244 PMID:41385096 "[{""id"":""uuid:18ba37ba-53b4-477a-bae3-2d1c950ccca4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:37b4a8e7-fd83-4ed1-af35-7bdbf16ba047"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:802c0f79-e4c0-440d-8d83-1ee8ba48f387"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PIASKY is indicated for the treatment of adult and pediatric patients 13 years and older with paroxysmal nocturnal hemoglobinuria (PNH) and body weight of at least 40 kg.|[PMDA] A drug with a new active ingredient indicated for the treatment of paroxysmal nocturnal haemoglobinuria. DRUGBANK:DB16128 uuid:f2a5c993-1b20-424e-a38a-26823070672c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:9H414A99MD biolink:treats UMLS:C5444038 PMID:41385096 "[{""id"":""uuid:a35f8b4e-1822-479e-bff6-cf33327f59fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f67021a2-1a69-4331-958e-19be061de167"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Xofigo is indicated for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease. uuid:712da4e0-0d6e-4689-a4e0-61d54557535d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:188153 biolink:treats HP:0012204 PMID:41385096 "[{""id"":""uuid:06619e56-85d2-4579-9d10-63c11198eaad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6ea1c5f7-0b36-48a7-a803-e212011e7945"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VIVJOA ® is an azole antifungal indicated to reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in females with a history of RVVC who are NOT of reproductive potential. ( 1 ) uuid:7a322e23-04a8-46a7-a983-3b68f3f0a827 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135752 biolink:treats MONDO:0005921 PMID:41385096 "[{""id"":""uuid:d785ee30-9a6a-40a9-b52d-ef6e2bacee64"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:65a11384-dbbd-49ef-8732-6f51297cd918"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KRINTAFEL is indicated for the radical cure (prevention of relapse) of Plasmodium vivax malaria in patients aged 16 years and older who are receiving chloroquine therapy for acute P. vivax infection [see Dosage and Administration ( 2.2 )] . Limitations of Use • KRINTAFEL is NOT indicated for the treatment of acute P. vivax malaria. • Concomitant use of KRINTAFEL with antimalarials other than chloroquine is not recommended because of the risk of recurrence of P. vivax malaria [see Warnings and Precautions ( 5.6 )] . uuid:8e40804e-8db2-4f36-a9a7-e7341a99f0bd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4W3KFI3TN3 biolink:treats MONDO:0009693 PMID:41385096 "[{""id"":""uuid:93853b3d-8b25-4774-b423-a4a3b4fbb123"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:5b3e147c-2483-47dd-83ad-c3bd2d2e1bd1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:b900287b-0a34-4217-9a1b-808c884fa773"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/talvey""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] TALVEY is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody. This indication is approved under accelerated approval based on response rate and durability of response [see Clinical Studies (14) ]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).|[EMA] Talvey is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti CD38 antibody and have demonstrated disease progression on the last therapy., uuid:5c5044a9-7593-40cc-8162-8635f831cc42 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90217 biolink:treats MONDO:0018874 PMID:41385096 "[{""id"":""uuid:879e9941-3c22-4978-b638-d781362fc649"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9181605f-b1af-4f0f-9f61-addc531757e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:bb4e1ece-20ef-4d25-82f7-c14923292cce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:178205f7-ba46-44c5-a979-ffe26df91ccc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VANFLYTA is indicated in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 internal tandem duplication (ITD)-positive as detected by an FDA-approved test [see Dosage and Administration (2.1) and Clinical Studies (14) ] .|[EMA] Vanflyta is indicated in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by Vanflyta single-agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukaemia (AML) that is FLT3-ITD positive.|[PMDA] Drugs with a new indication and a new dosage for the treatment of newly diagnosed FLT3-ITD mutation-positive acute myeloid leukemia. [Orphan drug] uuid:3bf51948-7c4b-4701-9500-bac1e5011155 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:94686 biolink:treats MONDO:0011122 PMID:41385096 "[{""id"":""uuid:1ed68d37-c940-42d2-911a-27146929671b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:dc34ab4f-5e88-407a-b8ea-73b14578b1e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:cd06c2c7-3e7d-4d41-945e-c6325975465d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/alli""]}]" infores:medic knowledge_assertion text_mining_agent "[FDA] XENICAL is indicated for obesity management including weight loss and weight maintenance when used in conjunction with a reduced-calorie diet. XENICAL is also indicated to reduce the risk for weight regain after prior weight loss. XENICAL is indicated for obese patients with an initial body mass index (BMI) ≥30 kg/m 2 or ≥27 kg/m 2 in the presence of other risk factors (e.g., hypertension, diabetes, dyslipidemia). Table 1 illustrates body mass index (BMI) according to a variety of weights and heights. The BMI is calculated by dividing weight in kilograms by height in meters squared. For example, a person who weighs 180 lbs and is 5 ' 5 "" would have a BMI of 30. Table 1 Body Mass Index (BMI), kg/m 2 Conversion Factors: Weight in lbs ÷ 2.2 = weight in kilograms (kg) Height in inches × 0.0254 = height in meters (m) 1 foot = 12 inches|[EMA] Alli is indicated for weight loss in adults who are overweight (body mass index, BMI, ≥ 28 kg/m2) and should be taken in conjunction with a mildly hypocaloric, lower-fat diet." uuid:a6f7f541-17d1-4305-a148-01d07cd48789 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:94686 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:2c3e6ac5-bdd0-469a-b1d2-0c4916998681"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0ce2a87b-736c-47c0-abc9-2a2cb290261b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] XENICAL is indicated for obesity management including weight loss and weight maintenance when used in conjunction with a reduced-calorie diet. XENICAL is also indicated to reduce the risk for weight regain after prior weight loss. XENICAL is indicated for obese patients with an initial body mass index (BMI) ≥30 kg/m 2 or ≥27 kg/m 2 in the presence of other risk factors (e.g., hypertension, diabetes, dyslipidemia). Table 1 illustrates body mass index (BMI) according to a variety of weights and heights. The BMI is calculated by dividing weight in kilograms by height in meters squared. For example, a person who weighs 180 lbs and is 5 ' 5 "" would have a BMI of 30. Table 1 Body Mass Index (BMI), kg/m 2 Conversion Factors: Weight in lbs ÷ 2.2 = weight in kilograms (kg) Height in inches × 0.0254 = height in meters (m) 1 foot = 12 inches" uuid:c9f4cc2f-bf9b-4fae-b11a-cb5baa9add75 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:94686 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:f89fb3f7-5f5e-4b2e-8f04-ee1cf5cd18a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5ac1462a-49ef-4fcd-9743-5f2a67429872"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] XENICAL is indicated for obesity management including weight loss and weight maintenance when used in conjunction with a reduced-calorie diet. XENICAL is also indicated to reduce the risk for weight regain after prior weight loss. XENICAL is indicated for obese patients with an initial body mass index (BMI) ≥30 kg/m 2 or ≥27 kg/m 2 in the presence of other risk factors (e.g., hypertension, diabetes, dyslipidemia). Table 1 illustrates body mass index (BMI) according to a variety of weights and heights. The BMI is calculated by dividing weight in kilograms by height in meters squared. For example, a person who weighs 180 lbs and is 5 ' 5 "" would have a BMI of 30. Table 1 Body Mass Index (BMI), kg/m 2 Conversion Factors: Weight in lbs ÷ 2.2 = weight in kilograms (kg) Height in inches × 0.0254 = height in meters (m) 1 foot = 12 inches" uuid:d97a119d-4b89-4c5c-9765-6b0d8f3f9364 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:94686 biolink:treats HP:0003119 PMID:41385096 "[{""id"":""uuid:3a4ae569-f221-4f1e-b7eb-49941f390b55"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e6f399b5-5c14-48d4-a9b8-fbd3615b5904"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] XENICAL is indicated for obesity management including weight loss and weight maintenance when used in conjunction with a reduced-calorie diet. XENICAL is also indicated to reduce the risk for weight regain after prior weight loss. XENICAL is indicated for obese patients with an initial body mass index (BMI) ≥30 kg/m 2 or ≥27 kg/m 2 in the presence of other risk factors (e.g., hypertension, diabetes, dyslipidemia). Table 1 illustrates body mass index (BMI) according to a variety of weights and heights. The BMI is calculated by dividing weight in kilograms by height in meters squared. For example, a person who weighs 180 lbs and is 5 ' 5 "" would have a BMI of 30. Table 1 Body Mass Index (BMI), kg/m 2 Conversion Factors: Weight in lbs ÷ 2.2 = weight in kilograms (kg) Height in inches × 0.0254 = height in meters (m) 1 foot = 12 inches" uuid:c5749b1a-c9e3-4649-9e7f-0c37cde71f25 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:8M7V7Q6537 biolink:treats MONDO:0010526 PMID:41385096 "[{""id"":""uuid:c1c9f56d-49ec-4b38-a732-f4a39c7f1490"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:63ad05cf-f315-4b4b-b49a-0f5e4453bf9e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:1a14ae0d-3054-49a6-b478-ffa0ac2142cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/elfabrio""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] ELFABRIO is indicated for the treatment of adults with confirmed Fabry disease.|[EMA] Elfabrio is indicated for long-term enzyme replacement therapy in adult patients with a confirmed diagnosis of Fabry disease (deficiency of alpha-galactosidase). uuid:72b27710-c6ee-471c-9d3f-7b0d05cd9b7d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90844 biolink:treats MONDO:0015924 PMID:41385096 "[{""id"":""uuid:d27d51f4-5df0-4a0e-9477-8a98801c6895"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:92ee6308-83c3-435b-ac35-21e612b7224c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:a2be1c4a-f4e8-474e-8c1a-d82bc1f1a6cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/uptravi""]},{""id"":""uuid:a1ee5afc-7c29-4ee6-8d7d-7701f902f601"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] UPTRAVI is a prostacyclin receptor agonist indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression and reduce the risk of hospitalization for PAH. ( 1.1 )|[EMA] Uptravi is indicated for the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients with WHO functional class (FC) II–III, either as combination therapy in patients insufficiently controlled with an endothelin receptor antagonist (ERA) and/or a phosphodiesterase type 5 (PDE-5) inhibitor, or as monotherapy in patients who are not candidates for these therapies., , Efficacy has been shown in a PAH population including idiopathic and heritable PAH, PAH associated with connective tissue disorders, and PAH associated with corrected simple congenital heart disease.,|[PMDA] Drugs with a new active ingredient indicated for the treatment of pulmonary arterial hypertension. [Orphan drug] uuid:a21df51e-55a1-4f7d-a74d-169c8b634d28 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:9934746 biolink:treats MONDO:0005002 PMID:41385096 "[{""id"":""uuid:7f1a5d19-6098-4f6b-8e38-76db090f5193"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ccc71765-6ea1-497c-a939-7773eb502dbb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OHTUVAYRE is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients. uuid:6a029928-a642-41b0-8ef9-fd87c442b80f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:9934746 biolink:treats MONDO:0011751 PMID:41385096 "[{""id"":""uuid:220754ad-eb80-48b9-b49b-1c458b470d10"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9fa7efe7-ef6d-4593-8e05-2ef95af7fda1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OHTUVAYRE is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients. uuid:5fe7932f-3442-444c-a5b6-c84296d3c168 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59560 biolink:treats MONDO:0016543 PMID:41385096 "[{""id"":""uuid:c877f352-8070-4bac-b02b-fa1a0cad1252"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:22ff913f-adac-4fae-a9bc-4552a0549b7f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sapropterin dihydrochloride powder for oral solution is indicated to reduce blood phenylalanine (Phe) levels in adult and pediatric patients one month of age and older with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin-(BH4-) responsive Phenylketonuria (PKU). Sapropterin dihydrochloride powder for oral solution is to be used in conjunction with a Phe-restricted diet. uuid:ff360e77-4c83-46b3-ab2c-ce4f106ab13d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59560 biolink:treats MONDO:0009861 PMID:41385096 "[{""id"":""uuid:f710150b-434a-4fa6-933e-3b8b8970198f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cb215736-f1ef-4a41-afd9-81caf729006e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sapropterin dihydrochloride powder for oral solution is indicated to reduce blood phenylalanine (Phe) levels in adult and pediatric patients one month of age and older with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin-(BH4-) responsive Phenylketonuria (PKU). Sapropterin dihydrochloride powder for oral solution is to be used in conjunction with a Phe-restricted diet. uuid:41f21e00-c754-45c7-813e-8f45e0d9d611 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68551 biolink:treats MONDO:0005052 PMID:41385096 "[{""id"":""uuid:cd4041ac-267b-43a0-b0fc-991da26f16bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:87582e00-cafd-494b-a6f1-eb7f49ef51a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LINZESS is indicated for the treatment of: • irritable bowel syndrome with constipation (IBS-C) in adults • chronic idiopathic constipation (CIC) in adults • functional constipation (FC) in pediatric patients 6 to 17 years of age uuid:cede033c-0917-451c-94e4-a1497de33795 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68551 biolink:treats UMLS:C0267509 PMID:41385096 "[{""id"":""uuid:d40253ae-0021-478c-a55c-9ee5793a8e8f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ba49d0f6-918d-41e7-abf9-67a930e53a34"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LINZESS is indicated for the treatment of: • irritable bowel syndrome with constipation (IBS-C) in adults • chronic idiopathic constipation (CIC) in adults • functional constipation (FC) in pediatric patients 6 to 17 years of age uuid:2607cad8-94dc-4080-88d4-4fbeb6417efe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68551 biolink:treats UMLS:C0401146 PMID:41385096 "[{""id"":""uuid:3c1dc73e-2d6c-4b4c-b4f7-9a61f6a647a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:62bb6607-79c1-4ace-9719-368b7064ebce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LINZESS is indicated for the treatment of: • irritable bowel syndrome with constipation (IBS-C) in adults • chronic idiopathic constipation (CIC) in adults • functional constipation (FC) in pediatric patients 6 to 17 years of age uuid:e0577c67-8675-44fc-8fdd-caf4578a5e8e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1546884 biolink:treats MONDO:0004951 PMID:41385096 "[{""id"":""uuid:fe98f6ae-0292-4aa4-938a-7743314d864f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ce22a41b-d162-4aa7-ab4f-4a91ce3e532d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TRIUMEQ and TRIUMEQ PD are indicated for the treatment of HIV-1 infection in adults and in pediatric patients aged at least 3 months and weighing at least 6 kg. Limitations of Use: TRIUMEQ and TRIUMEQ PD alone are not recommended in patients with resistance‑associated integrase substitutions or clinically suspected integrase strand transfer inhibitor (INSTI) resistance because the dose of dolutegravir in TRIUMEQ and TRIUMEQ PD is insufficient in these subpopulations. See full prescribing information for TIVICAY (dolutegravir). uuid:ad4be942-8d57-491e-bedc-a5110e2dc683 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63036 biolink:treats MONDO:0000313 PMID:41385096 "[{""id"":""uuid:3d38c999-aa2b-4aa9-ade2-9699928e90c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6ea19f5d-3e03-4870-9d2c-bb08349076a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Potassium phosphates injection is indicated as a source of phosphorus: in intravenous fluids to correct hypophosphatemia in adults and pediatric patients when oral or enteral replacement is not possible, insufficient or contraindicated. for parenteral nutrition in adults and pediatric patients when oral or enteral nutrition is not possible, insufficient or contraindicated. uuid:7d755269-acc4-41e9-a488-ce897ba2b2b1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18050 biolink:treats MONDO:0011382 PMID:41385096 "[{""id"":""uuid:99ee2da8-0e2e-40c8-8458-e5bddc9fe0ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f94ae513-77e2-4e85-9742-38f0d2e7734e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] L-glutamine is indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years of age and older. uuid:b96e3c5b-ff86-4122-b399-8663944587d3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50663 biolink:treats UMLS:C0276353 PMID:41385096 "[{""id"":""uuid:c31a0fe4-1ead-4428-b715-d3dbf25008a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:372efd8b-1226-4926-ab08-fe4b48d0d108"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RELENZA, an influenza virus neuraminidase inhibitor (NAI), is indicated for: Treatment of acute, uncomplicated influenza type A and B infections in patients aged 7 years and older who have been symptomatic for no more than 2 days. ( 1.1 ) Prophylaxis of influenza in patients aged 5 years and older. ( 1.2 ) Important Limitations of Use: Not recommended for treatment or prophylaxis of influenza in: • Individuals with underlying airways disease. ( 5.1 ) Not proven effective for: • Treatment in individuals with underlying airways disease. ( 1.3 ) • Prophylaxis in nursing home residents. ( 1.3 ) Not a substitute for annual influenza vaccination. ( 1.3 ) Consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use RELENZA. ( 1.3 ) uuid:d5cbbc46-afe0-4a37-a8b4-c6f38761fd37 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1734632 biolink:treats MONDO:0005354 PMID:41385096 "[{""id"":""uuid:b5077186-e12d-4102-8fdd-4aa1b554578d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:bc5b09b6-9e8e-464e-8bf2-925b6b072216"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:b48f8c17-4153-4f89-95c4-c40878bf5eee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/zepatier""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZEPATIER ® is indicated for the treatment of chronic hepatitis C virus (HCV) genotype 1 or 4 infection in adult and pediatric patients 12 years of age and older or weighing at least 30 kg. ZEPATIER is indicated for use with ribavirin in certain patient populations [see Dosage and Administration (2.2) ] .|[EMA] ZEPATIER is indicated for the treatment of chronic hepatitis C (CHC) in adult and paediatric patients 12 years of age and older who weigh at least 30 kg (see sections 4.2, 4.4 and 5.1).For hepatitis C virus (HCV) genotype-specific activity see sections 4.4 and 5.1. uuid:53f421e4-58df-4776-8af2-2c6a7574e0f7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C5237999 biolink:treats MONDO:0004975 PMID:41385096 "[{""id"":""uuid:14b242ae-1fa3-4006-bff3-ed0c66ecdd07"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2aae838c-07c8-4bd0-855c-c4b5b7e57613"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KISUNLA TM is indicated for the treatment of Alzheimer's disease. Treatment with KISUNLA should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in the clinical trials. DRUGBANK:DB16647 uuid:d0e70b7b-e40a-400e-aa75-36b09acc8448 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C5237999 biolink:treats EFO:0007982 PMID:41385096 "[{""id"":""uuid:2ca46200-73ac-48b4-bb47-1cb4f6ba4667"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:768fe301-ff2a-48e0-9552-5b24e07fb56a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KISUNLA TM is indicated for the treatment of Alzheimer's disease. Treatment with KISUNLA should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in the clinical trials. DRUGBANK:DB16647 uuid:a0156bfa-6d86-4a31-99dc-281c94e6327f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C5237999 biolink:treats UMLS:C3494623 PMID:41385096 "[{""id"":""uuid:9b6f4662-061f-4067-a606-0c9deaa1c2de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b6b64334-0c9f-4c1e-ae90-756f0ce9df87"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KISUNLA TM is indicated for the treatment of Alzheimer's disease. Treatment with KISUNLA should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in the clinical trials. DRUGBANK:DB16647 uuid:68ecdd49-1bba-451e-a219-35fca908fdea biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1602106 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:38913481-9484-4833-ab17-859a2d6e0e7c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5b378911-331e-4e3c-bb41-d8c2928bee07"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:86833429-529d-4f3d-8385-2aa6c889d05a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/glyxambi""]},{""id"":""uuid:43a9d9f3-2d8b-409e-bd35-a7668bd84ed3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] GLYXAMBI is a combination of empagliflozin and linagliptin indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus . Empagliflozin is indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease [see Clinical Studies (14.2) ] .|[EMA] Glyxambi, fixed dose combination of empagliflozin and linagliptin, is indicated in adults aged 18 years and older with type 2 diabetes mellitus:to improve glycaemic control when metformin and/or sulphonylurea (SU) and one of the monocomponents of Glyxambi do not provide adequate glycaemic control;when already being treated with the free combination of empagliflozin and linagliptin.|[PMDA] New combination drugs indicated for the treatment of type 2 diabetes mellitus (only when a concomitant use of empagliflozin with linagliptin is deemed appropriate). uuid:cfca342e-dd7f-45e4-b618-858c8e6f4d68 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1602106 biolink:treats MONDO:0004995 PMID:41385096 "[{""id"":""uuid:0ba66c33-4793-4b98-a8e8-951129299dc2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:03d393d6-242d-4259-af8d-eaa93ff9d5b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] GLYXAMBI is a combination of empagliflozin and linagliptin indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus . Empagliflozin is indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease [see Clinical Studies (14.2) ] . uuid:3bef495f-bd34-436d-b88f-645aad56b99a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DE2O63YV8R biolink:treats MONDO:0005300 PMID:41385096 "[{""id"":""uuid:e065c4f6-caaf-44c6-bd8f-35e32ed2c764"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:1a909edc-8041-4fba-950e-3cd240c41560"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:0b876b39-e2bf-472b-bbb0-ee90e7c0db8d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/kerendia""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Kerendia is indicated to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D).|[EMA] Kerendia is indicated for the treatment of chronic kidney disease (stage 3 and 4 with albuminuria) associated with type 2 diabetes in adults. uuid:e3d4a647-221c-4bfe-af8c-02f0a7d2d9cc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DE2O63YV8R biolink:treats MONDO:0004375 PMID:41385096 "[{""id"":""uuid:33438f42-44bb-4900-a600-e0be0e41176a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:964180bf-a692-4a17-9623-fc6d6bebe803"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Kerendia is indicated to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D). uuid:10eb0595-84b7-4124-82af-5be62f116547 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DE2O63YV8R biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:aa6568f2-8f43-4630-bf81-18f5cdf87b7c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:3f048af3-b7f3-4306-9830-5773dedf5682"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:99b59a59-2ad6-4764-9498-11e9f7ddd588"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/kerendia""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Kerendia is indicated to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D).|[EMA] Kerendia is indicated for the treatment of chronic kidney disease (stage 3 and 4 with albuminuria) associated with type 2 diabetes in adults. uuid:232567d9-960e-4dbe-bc87-1a046f212581 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DE2O63YV8R biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:4db6a2eb-b111-4ca1-b8ba-8d5ad6aed5a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a921f115-a27f-412f-a931-d48146bcd518"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Kerendia is indicated to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D). uuid:199b7384-7fcd-43b5-bd84-7c2f21249445 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DE2O63YV8R biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:11c340e4-1626-408d-bc28-5c2d7aea4e7c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:96f9df88-cfc2-4a4f-a874-c6be208c978e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Kerendia is indicated to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D). uuid:85b7a749-bc15-40b8-9c74-61fad72044af biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27470 biolink:treats MONDO:0008228 PMID:41385096 "[{""id"":""uuid:0dc82f3b-5186-43b1-9797-ab87b2fcd116"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fe38f205-f84e-4dcf-981d-1ee9c8136051"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Biopar TM delta -FORTE is specifically indicated as a primary and adjunctive treatment in pernicious anemia patients having idiosyncrasy or sensitivity to parenteral administration - or when parental therapy is refused; uuid:d5b7f0cc-3a51-49dc-a26a-030104eb206f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C4687660 biolink:treats MONDO:0008433 PMID:41385096 "[{""id"":""uuid:87b5fa50-7f63-4c22-8f2b-4413a362b474"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1f8e2bb1-c81c-488d-a915-64a1a993acba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] IMDELLTRA is indicated for the treatment of adult patients with extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy. This indication is approved under accelerated approval based on overall response rate and duration of response [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). DRUGBANK:DB17256 uuid:36478d97-dc43-465d-b078-e543845d0028 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3766 biolink:treats MONDO:0005414 PMID:41385096 "[{""id"":""uuid:971ce8d1-1c35-4adb-aba7-edb5c364d3e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c58887e3-5569-4676-bb18-944c1c311c4d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clozapine is an atypical antipsychotic indicated for: Treatment-resistant schizophrenia. Efficacy was established in an active-controlled study. ( 1.1 , 14.1 ) Reducing suicidal behavior in patients with schizophrenia or schizoaffective disorder. Efficacy was established in an active-controlled study. ( 1.2 , 14.2 ) uuid:cf789c92-0ab4-4c3e-a705-e176fc3b0332 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:83353 biolink:treats MONDO:0010526 PMID:41385096 "[{""id"":""uuid:4aab18b9-b241-400c-8983-161c75d9b5a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e1e6e381-cce3-4b75-858a-29698f6fc26f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:0e93ccb4-c854-4cfa-a0b4-62fbceec5519"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/fabrazyme""]},{""id"":""uuid:ade86890-0a61-4ca9-800c-6123061f0573"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FABRAZYME ® is indicated for the treatment of adult and pediatric patients 2 years of age and older with confirmed Fabry disease.|[EMA] Fabrazyme is indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease (α-galactosidase-A deficiency).|[PMDA] Follow-on biologics indicated for the treatment of Fabry disease. uuid:15dbfe6b-e5e8-4b54-b6df-32b9759cac64 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133021 biolink:treats MONDO:0004948 PMID:41385096 "[{""id"":""uuid:ab85ecc8-5441-4a49-83fb-78c71b25e9d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:db033af7-562a-4a87-8c71-e2948aa48e92"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:4a76ea0d-17f2-4665-abc9-9544df90ff86"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/venclyxto""]},{""id"":""uuid:235af65b-1021-44fd-9a72-84d797123e01"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VENCLEXTA is a BCL-2 inhibitor indicated: For the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). ( 1.1 ) In combination with azacitidine, or decitabine, or low-dose cytarabine for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. ( 1.2 )|[EMA] Venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) (see section 5.1).Venclyxto in combination with rituximab is indicated for the treatment of adult patients with CLL who have received at least one prior therapy.Venclyxto monotherapy is indicated for the treatment of CLL:- in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B cell receptor pathway inhibitor, or- in the absence of 17p deletion or TP53 mutation in adult patients who have failed both chemoimmunotherapy and a B-cell receptor pathway inhibitor.Venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy.|[PMDA] Drugs with a new active ingredient indicated for the treatment of relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. uuid:caae08b6-9c63-44ed-bffe-2c43fb841681 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133021 biolink:treats MONDO:0003864 PMID:41385096 "[{""id"":""uuid:b8a58967-84c1-42c2-a486-b4e7ecf159ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e0cfca8d-7d2f-4770-bb9d-ebe8c2024c96"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:1050b899-1bfe-432b-9c51-5cde1564e881"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VENCLEXTA is a BCL-2 inhibitor indicated: For the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). ( 1.1 ) In combination with azacitidine, or decitabine, or low-dose cytarabine for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. ( 1.2 )|[PMDA] Drugs with a new active ingredient indicated for the treatment of relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. uuid:c4fad5d7-c0e1-4bd8-85ad-5ec4c0243488 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133021 biolink:treats MONDO:0018874 PMID:41385096 "[{""id"":""uuid:4d18d104-80e6-4be0-9130-0a40d37da893"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:36947be6-6061-4bc1-bf7f-909ac09b1ed4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:9da68e58-6510-4cb5-b627-c3d5646419fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/venclyxto""]},{""id"":""uuid:499928e7-3f04-40df-ae19-d536d4120631"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VENCLEXTA is a BCL-2 inhibitor indicated: For the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). ( 1.1 ) In combination with azacitidine, or decitabine, or low-dose cytarabine for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. ( 1.2 )|[EMA] Venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) (see section 5.1).Venclyxto in combination with rituximab is indicated for the treatment of adult patients with CLL who have received at least one prior therapy.Venclyxto monotherapy is indicated for the treatment of CLL:- in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B cell receptor pathway inhibitor, or- in the absence of 17p deletion or TP53 mutation in adult patients who have failed both chemoimmunotherapy and a B-cell receptor pathway inhibitor.Venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy.|[PMDA] Drugs with a new indication and a new dosage for the treatment of acute myeloid leukemia. [Orphan drug] uuid:0320ef12-5a36-4361-a9ee-d7056565109d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:F925RR824R biolink:treats MONDO:0004651 PMID:41385096 "[{""id"":""uuid:aa454d19-52a8-43b8-9155-b14f8018241b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3e3f9162-3676-47c1-a5d1-0fb806bf4dd9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TPOXX is an inhibitor of the orthopoxvirus VP37 envelope wrapping protein and is indicated for the treatment of human smallpox disease in adults and pediatric patients weighing at least 3 kg. ( 1.1 ) Limitations of Use: The effectiveness of TPOXX for treatment of smallpox disease has not been determined in humans because adequate and well-controlled field trials have not been feasible, and inducing smallpox disease in humans to study the drug’s efficacy is not ethical. ( 1.2 ) TPOXX efficacy may be reduced in immunocompromised patients based on studies demonstrating reduced efficacy in immunocompromised animal models. ( 1.2 ) uuid:a1093ea5-f373-44b5-90d4-1db01a32f18d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:Z633861EIM biolink:treats MONDO:0018570 PMID:41385096 "[{""id"":""uuid:953f6e48-7d63-4367-91c1-8fc2768d92f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:bf382197-6021-46a4-a9df-78830898cb96"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:8be66984-95e5-4bae-9e49-7b20d777123f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/strensiq""]},{""id"":""uuid:1e85b75e-36cf-456c-9eaf-93f295c74cf7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] STRENSIQ ® is indicated for the treatment of patients with perinatal/infantile- and juvenile-onset hypophosphatasia (HPP).|[EMA] Strensiq is indicated for long-term enzyme replacement therapy in patients with paediatric-onset hypophosphatasia to treat the bone manifestations of the disease.|[PMDA] Drugs with a new active ingredient indicated for the treatment of hypophosphatasia. [Orphan drug] uuid:6e3766c1-7d00-4025-9fdd-b491e237d826 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:Z633861EIM biolink:treats MONDO:0016605 PMID:41385096 "[{""id"":""uuid:7da5bf24-4d94-4626-90ec-a56a56ff931b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f53a3532-b7bf-4895-9173-4b3efa59c73a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] STRENSIQ ® is indicated for the treatment of patients with perinatal/infantile- and juvenile-onset hypophosphatasia (HPP). uuid:c860f84e-55a4-4cbb-be3e-a42529730a72 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:229658 biolink:treats MONDO:0006733 PMID:41385096 "[{""id"":""uuid:e12cc20c-043a-4eca-a80a-b8836dc9db91"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:82f0b36c-437e-40aa-833c-20f8d1a69e17"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MIEBO ® (perfluorohexyloctane ophthalmic solution) is indicated for the treatment of the signs and symptoms of dry eye disease (DED). uuid:25d0c6ff-44ca-4783-85d0-58b775af84aa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:K4YTU42T8G biolink:treats MONDO:0800449 PMID:41385096 "[{""id"":""uuid:89e0dced-1eb8-4d77-ab0f-dd4b4a6a54d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3d0eb2fc-0404-44eb-b25a-34f89c81da02"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:454da6ee-55d1-4e3b-91f9-2f3038e54197"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/kanuma""]},{""id"":""uuid:37893f10-34df-4046-939c-fc5dcf61c581"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KANUMA ® is indicated for the treatment of patients with a diagnosis of Lysosomal Acid Lipase (LAL) deficiency.|[EMA] Kanuma is indicated for long-term enzyme replacement therapy (ERT) in patients of all ages with lysosomal acid lipase (LAL) deficiency.|[PMDA] A drug with a new active ingredient indicated for the treatment of lysosomal acid lipase deficiency. [Orphan drug] uuid:ff2e22b8-0092-49af-9845-ac9d08e48aa4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:72312 biolink:treats MONDO:0019933 PMID:41385096 "[{""id"":""uuid:9c4f6fae-5407-47f8-8561-9a32cf8c7572"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:fb9f67b3-42cb-4f01-aadb-fd1adf1f12c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c2f33408-dce0-4de5-b364-b5282aa25f15"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/signifor""]},{""id"":""uuid:dafc1bed-99ed-4bba-acef-323fad1bb648"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SIGNIFOR LAR is a somatostatin analog indicated for the treatment of: Patients with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. ( 1.1 ) Patients with Cushing's disease for whom pituitary surgery is not an option or has not been curative. ( 1.2 )|[EMA] Signifor is indicated for the treatment of adult patients with Cushing’s disease for whom surgery is not an option or for whom surgery has failed.Signifor is indicated for the treatment of adult patients with acromegaly for whom surgery is not an option or has not been curative and who are inadequately controlled on treatment with another somatostatin analogue.|[PMDA] Drugs with a new active ingredient indicated for the improvement of hypersecretion of growth hormone and IGF-I (somatomedin-C) and related symptoms in acromegaly and pituitary gigantism (when surgical therapies are not sufficiently effective or are difficult to perform). uuid:4dfacb49-a6d5-4718-914f-4d929817057f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:72312 biolink:treats MONDO:0009050 PMID:41385096 "[{""id"":""uuid:f13b331b-456c-40a2-a4b3-893ca0396b78"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:99e852ef-b2b2-4419-9e91-d55dae4b472e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:200f1ff9-7d0d-4742-a6f6-a6ec4e9d012f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/signifor""]},{""id"":""uuid:a7753996-c092-4c74-b235-4a3c77c9edd9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SIGNIFOR LAR is a somatostatin analog indicated for the treatment of: Patients with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. ( 1.1 ) Patients with Cushing's disease for whom pituitary surgery is not an option or has not been curative. ( 1.2 )|[EMA] Signifor is indicated for the treatment of adult patients with Cushing’s disease for whom surgery is not an option or for whom surgery has failed.Signifor is indicated for the treatment of adult patients with acromegaly for whom surgery is not an option or has not been curative and who are inadequately controlled on treatment with another somatostatin analogue.|[PMDA] Drugs with a new additional indication and a new dosage and in additional dosage forms indicated for the treatment of Cushing’s disease (when surgical therapies are not sufficiently effective or are difficult to perform). [Orphan drug] uuid:1201e205-1ae4-4916-a452-768491e06cbb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63616 biolink:treats UMLS:C0278987 PMID:41385096 "[{""id"":""uuid:e4af43d7-2cc1-4606-970c-e65020618273"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5eaa7fa2-ef82-4c3b-86ed-aa495af97b92"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pemetrexed for injection is a folate analog metabolic inhibitor indicated: in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations. ( 1.1 ) in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic, non-squamous NSCLC. ( 1.1 ) as a single agent for the maintenance treatment of patients with locally advanced or metastatic, non-squamous NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. ( 1.1 ) as a single agent for the treatment of patients with recurrent, metastatic non-squamous, NSCLC after prior chemotherapy. ( 1.1 ) Limitations of Use: Pemetrexed for injection is not indicated for the treatment of patients with squamous cell, non-small cell lung cancer. ( 1.1 ) initial treatment, in combination with cisplatin, of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery. ( 1.2 ) uuid:fbacbb12-fb4b-4330-944f-91524bc78e11 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4495 biolink:treats MONDO:0004946 PMID:41385096 "[{""id"":""uuid:1a873448-6727-4e44-aca4-8994f9fc88bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bccfe19d-e925-4c38-96d4-3b428090620b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PROGLYCEM is indicated for the management of hypoglycemia due to hyperinsulinism associated with the following conditions: Adults: Inoperable islet cell adenoma or carcinoma, or extrapancreatic malignancy. Infants and children: Leucine sensitivity, islet cell hyperplasia, nesidioblastosis, extrapancreatic malignancy, islet cell adenoma, or adenomatosis. PROGLYCEM may be used preoperatively as a temporary measure, and postoperatively, if hypoglycemia persists. PROGLYCEM should be used only after a diagnosis of hypoglycemia due to one of the above conditions has been definitely established. When other specific medical therapy or surgical management either has been unsuccessful or is not feasible, treatment with PROGLYCEM should be considered. uuid:05fe5132-065c-4387-bcd8-2ae283285599 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4495 biolink:treats MONDO:0002177 PMID:41385096 "[{""id"":""uuid:09a93a6d-e2e9-4748-8052-a268fc679ad3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cb6c7451-8fb4-4534-86da-c41cf3939eb4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PROGLYCEM is indicated for the management of hypoglycemia due to hyperinsulinism associated with the following conditions: Adults: Inoperable islet cell adenoma or carcinoma, or extrapancreatic malignancy. Infants and children: Leucine sensitivity, islet cell hyperplasia, nesidioblastosis, extrapancreatic malignancy, islet cell adenoma, or adenomatosis. PROGLYCEM may be used preoperatively as a temporary measure, and postoperatively, if hypoglycemia persists. PROGLYCEM should be used only after a diagnosis of hypoglycemia due to one of the above conditions has been definitely established. When other specific medical therapy or surgical management either has been unsuccessful or is not feasible, treatment with PROGLYCEM should be considered. uuid:afe1ad91-fc8b-4a1c-b27a-2ed7c0e7a6b4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4495 biolink:treats MONDO:0005815 PMID:41385096 "[{""id"":""uuid:e75c0120-9ab2-4f07-9366-1d2e12c797ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:68b7c049-8549-4caa-b9d9-380cac6cc221"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PROGLYCEM is indicated for the management of hypoglycemia due to hyperinsulinism associated with the following conditions: Adults: Inoperable islet cell adenoma or carcinoma, or extrapancreatic malignancy. Infants and children: Leucine sensitivity, islet cell hyperplasia, nesidioblastosis, extrapancreatic malignancy, islet cell adenoma, or adenomatosis. PROGLYCEM may be used preoperatively as a temporary measure, and postoperatively, if hypoglycemia persists. PROGLYCEM should be used only after a diagnosis of hypoglycemia due to one of the above conditions has been definitely established. When other specific medical therapy or surgical management either has been unsuccessful or is not feasible, treatment with PROGLYCEM should be considered. uuid:40438e08-83cf-4905-9bc4-08a495f2d9eb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4495 biolink:treats MONDO:0004993 PMID:41385096 "[{""id"":""uuid:57f0a70e-fb05-4692-9035-eb6c14fe4bfe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cc3ab96e-2c33-44af-9806-42b31321d43e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PROGLYCEM is indicated for the management of hypoglycemia due to hyperinsulinism associated with the following conditions: Adults: Inoperable islet cell adenoma or carcinoma, or extrapancreatic malignancy. Infants and children: Leucine sensitivity, islet cell hyperplasia, nesidioblastosis, extrapancreatic malignancy, islet cell adenoma, or adenomatosis. PROGLYCEM may be used preoperatively as a temporary measure, and postoperatively, if hypoglycemia persists. PROGLYCEM should be used only after a diagnosis of hypoglycemia due to one of the above conditions has been definitely established. When other specific medical therapy or surgical management either has been unsuccessful or is not feasible, treatment with PROGLYCEM should be considered. uuid:af65ffc2-3023-4c9c-a520-9fbf73a05e5d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4495 biolink:treats HP:0004510 PMID:41385096 "[{""id"":""uuid:0c6baba4-bedd-4971-baa7-aaf79b4847c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:18058a3e-39e2-4311-a898-2ef2d68f8db2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PROGLYCEM is indicated for the management of hypoglycemia due to hyperinsulinism associated with the following conditions: Adults: Inoperable islet cell adenoma or carcinoma, or extrapancreatic malignancy. Infants and children: Leucine sensitivity, islet cell hyperplasia, nesidioblastosis, extrapancreatic malignancy, islet cell adenoma, or adenomatosis. PROGLYCEM may be used preoperatively as a temporary measure, and postoperatively, if hypoglycemia persists. PROGLYCEM should be used only after a diagnosis of hypoglycemia due to one of the above conditions has been definitely established. When other specific medical therapy or surgical management either has been unsuccessful or is not feasible, treatment with PROGLYCEM should be considered. uuid:702621c4-0863-4c3d-979a-4c8e0d8d4fa3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4495 biolink:treats MONDO:0019010 PMID:41385096 "[{""id"":""uuid:61ef40eb-f68a-43d6-81c0-d091f95dcb24"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1e64c069-e793-43d2-847e-b7f7a890641a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PROGLYCEM is indicated for the management of hypoglycemia due to hyperinsulinism associated with the following conditions: Adults: Inoperable islet cell adenoma or carcinoma, or extrapancreatic malignancy. Infants and children: Leucine sensitivity, islet cell hyperplasia, nesidioblastosis, extrapancreatic malignancy, islet cell adenoma, or adenomatosis. PROGLYCEM may be used preoperatively as a temporary measure, and postoperatively, if hypoglycemia persists. PROGLYCEM should be used only after a diagnosis of hypoglycemia due to one of the above conditions has been definitely established. When other specific medical therapy or surgical management either has been unsuccessful or is not feasible, treatment with PROGLYCEM should be considered. uuid:ed462d96-9a24-4e0a-a6e9-2acbc27d640c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation MESH:C000632565 biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:1e7d4812-34f6-4f2f-b9f2-52af64f27bb6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1130823b-abaa-40bd-bb35-d0103dbab5c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SYMTUZA is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and pediatric patients weighing at least 40 kg: who have no prior antiretroviral treatment history or who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least 6 months and have no known substitutions associated with resistance to darunavir or tenofovir. uuid:45ff12c1-d2f4-4a09-addb-b711cfa4ff9f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6443 biolink:treats HP:0000132 PMID:41385096 "[{""id"":""uuid:2d778b58-7406-4427-a6bb-7d6ba5dcddba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c5bd9f82-0042-42ae-bf3f-a0eb9f53ea0e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:1523db6f-14a7-4e4a-a5d6-7dd5a4024560"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mirena is a progestin-containing intrauterine system (IUS) indicated for: • Prevention of pregnancy for up to 8 years ( 1.1 ) • Treatment of heavy menstrual bleeding for women who choose to use intrauterine contraception as their method of contraception for up to 5 years. ( 1.2 )|[PMDA] A drug with a new additional indication for the treatment of hypermenorrhea. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:b85c3ab6-9c42-4826-a854-62c58fd11bdb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:66876 biolink:treats NCIT:C55615 PMID:41385096 "[{""id"":""uuid:a8c1f5a6-3a7d-4475-a91d-344bd02b1f7c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ce8998df-51de-4799-935c-a949e4e289a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] STENDRA is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction in adult males. uuid:8ea4f7e7-3888-4b50-870e-41239988b716 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2556795 biolink:treats MONDO:0007886 PMID:41385096 "[{""id"":""uuid:6d6c2fa1-6e13-4cb3-98e6-c66fa9cf5440"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:69ff1688-4b71-4660-909e-1229a5577ba2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MYFEMBREE is a combination of relugolix, a gonadotropin-releasing hormone (GnRH) receptor antagonist, estradiol, an estrogen, and norethindrone acetate, a progestin, indicated in premenopausal women for the: management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids). ( 1.1 , 14.1 ) management of moderate to severe pain associated with endometriosis. ( 1.2 , 14.2 ) Limitations of Use Use of MYFEMBREE should be limited to 24 months due to the risk of continued bone loss which may not be reversible. ( 1.3 , 5.2 , 6 ) uuid:be937142-b8bc-48a2-92c9-18f7f1770053 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2556795 biolink:treats MONDO:0005133 PMID:41385096 "[{""id"":""uuid:31c3761e-22e6-4f0f-986e-492ea832f317"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:82a30dfb-716a-4917-9d7e-015c6fd31503"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MYFEMBREE is a combination of relugolix, a gonadotropin-releasing hormone (GnRH) receptor antagonist, estradiol, an estrogen, and norethindrone acetate, a progestin, indicated in premenopausal women for the: management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids). ( 1.1 , 14.1 ) management of moderate to severe pain associated with endometriosis. ( 1.2 , 14.2 ) Limitations of Use Use of MYFEMBREE should be limited to 24 months due to the risk of continued bone loss which may not be reversible. ( 1.3 , 5.2 , 6 ) uuid:a3d7660d-d162-4bda-95bd-c7ecfef35a6f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2668 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:4c5e102e-a7d1-41d6-a9c2-5d500a29afb1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d4311027-547e-499d-ab35-77b8d674fcbf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amlodipine besylate tablets is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including Amlodipine besylate tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Amlodipine besylate tablets may be used alone or in combination with other antihypertensive agents. uuid:7f1bde9f-c350-4cca-8da3-afdf76793eb9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2668 biolink:treats MONDO:0005016 PMID:41385096 "[{""id"":""uuid:b54f127b-28af-491e-9543-ec731c8b6ede"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:941345a6-f1be-4add-b86c-533d6c1a7d6c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amlodipine besylate tablets is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including Amlodipine besylate tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Amlodipine besylate tablets may be used alone or in combination with other antihypertensive agents. uuid:e14ee75e-af1a-4fd1-874e-933b9feeddaa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:705860 biolink:treats HP:0005202 PMID:41385096 "[{""id"":""uuid:b8f13c32-4539-45d4-ac18-6d7c279ce3d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6ef7507a-c308-4b8f-a42f-2efadf63c045"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bismuth Subcitrate Potassium, Metronidazole and Tetracycline Hydrochloride Capsules is a combination of metronidazole, a nitroimidazole antimicrobial, tetracycline,- a tetracycline class antimicrobial and bismuth subcitrate potassium, indicated for use, in combination with omeprazole, for the treatment of patients with Helicobacter pylori infection and duodenal ulcer disease (active or history of within the past 5 years) to eradicate H. pylori. ( 1.1 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Bismuth Subcitrate Potassium, Metronidazole and Tetracycline Hydrochloride Capsules and other antibacterial drugs, Bismuth Subcitrate Potassium, Metronidazole and Tetracycline Hydrochloride Capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.2 ) uuid:269a276b-4c73-44bf-be19-a67d12972a4a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:705860 biolink:treats MONDO:0005412 PMID:41385096 "[{""id"":""uuid:e8e1f902-3e8a-4bcc-bb8d-7885e9e49bbd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f683347b-4047-42f0-9ead-55066fc645d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bismuth Subcitrate Potassium, Metronidazole and Tetracycline Hydrochloride Capsules is a combination of metronidazole, a nitroimidazole antimicrobial, tetracycline,- a tetracycline class antimicrobial and bismuth subcitrate potassium, indicated for use, in combination with omeprazole, for the treatment of patients with Helicobacter pylori infection and duodenal ulcer disease (active or history of within the past 5 years) to eradicate H. pylori. ( 1.1 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Bismuth Subcitrate Potassium, Metronidazole and Tetracycline Hydrochloride Capsules and other antibacterial drugs, Bismuth Subcitrate Potassium, Metronidazole and Tetracycline Hydrochloride Capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.2 ) uuid:3aaa2b77-13a3-4e28-b45c-adbe1170f7c3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:9XZ8H6N6OH biolink:treats MONDO:0006733 PMID:41385096 "[{""id"":""uuid:1f38e9a1-56fc-4564-9e96-5286bfb53a0d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f47bdd1d-2e1f-4b96-ade1-53c89d870ce0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LACRISERT is indicated in patients with moderate to severe dry eye syndromes, including keratoconjunctivitis sicca. LACRISERT is indicated especially in patients who remain symptomatic after an adequate trial of therapy with artificial tear solutions. LACRISERT is also indicated for patients with: Exposure keratitis Decreased corneal sensitivity Recurrent corneal erosions uuid:363d1a9a-cc88-4da2-8705-f05c0a4522a6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:9XZ8H6N6OH biolink:treats MONDO:0004794 PMID:41385096 "[{""id"":""uuid:b4917a51-11ee-4c4f-85cb-d19b1450c53d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:944feab8-0b60-4b8f-8248-07706f0d57da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LACRISERT is indicated in patients with moderate to severe dry eye syndromes, including keratoconjunctivitis sicca. LACRISERT is indicated especially in patients who remain symptomatic after an adequate trial of therapy with artificial tear solutions. LACRISERT is also indicated for patients with: Exposure keratitis Decreased corneal sensitivity Recurrent corneal erosions uuid:5373c6b4-c13f-40c7-98fb-52cde4028b20 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:9XZ8H6N6OH biolink:treats HP:0012155 PMID:41385096 "[{""id"":""uuid:48df4034-339e-480e-b50a-5d3bdf9ee1b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0e92923e-ce8c-4d90-b1b9-4a14ac37c234"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LACRISERT is indicated in patients with moderate to severe dry eye syndromes, including keratoconjunctivitis sicca. LACRISERT is indicated especially in patients who remain symptomatic after an adequate trial of therapy with artificial tear solutions. LACRISERT is also indicated for patients with: Exposure keratitis Decreased corneal sensitivity Recurrent corneal erosions uuid:19f54d17-f8a9-48c4-bc6a-d8dfff793168 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:9XZ8H6N6OH biolink:treats HP:0000495 PMID:41385096 "[{""id"":""uuid:a13d03f3-b857-470f-aaa3-0847a6ab4267"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d9eaf2eb-554f-45ce-98d5-c427bcf614fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LACRISERT is indicated in patients with moderate to severe dry eye syndromes, including keratoconjunctivitis sicca. LACRISERT is indicated especially in patients who remain symptomatic after an adequate trial of therapy with artificial tear solutions. LACRISERT is also indicated for patients with: Exposure keratitis Decreased corneal sensitivity Recurrent corneal erosions uuid:d70781fa-bcd7-4b7e-95c2-5ae7f920083e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6754 biolink:treats HP:0012532 PMID:41385096 "[{""id"":""uuid:3e3fc077-b09e-4672-98fc-1cc854e4b534"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c2470a91-d816-4c89-9078-131c185c199c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Meperidine Hydrochloride Tablets and Oral Solution are indicated for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, and misuse with opioids, which can occur at any dosage or duration [see Warnings and Precautions ( 5.2 )] , reserve Meperidine Hydrochloride Tablets and Oral Solution for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products] : • Have not been tolerated or are not expected to be tolerated, • Have not provided adequate analgesia or are not expected to provide adequate analgesia. Meperidine Hydrochloride Tablets or Oral Solution should not be used for an extended period of time unless the pain remains severe enough to require an opioid analgesic and for which alternative treatment options continue to be inadequate. Meperidine Hydrochloride Tablets or Oral Solution should not be used for the treatment of chronic pain. Use of Meperidine Hydrochloride Tablets or Oral Solution for an extended period of time may increase the risk of toxicity (e.g. seizures) from the accumulation of the meperidine metabolite, normeperidine . uuid:12d87cbd-75ac-4e44-b7ac-81fb0bbfaf81 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PQX0D8J21J biolink:treats MONDO:0005627 PMID:41385096 "[{""id"":""uuid:87bf5fe5-80cb-4f35-b72b-4922446948c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f175db41-9714-47ca-9a6d-0c5d3d356b9c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:54aab6b0-f82a-4508-a46e-61765565b23f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ERBITUX ® is an epidermal growth factor receptor (EGFR) antagonist indicated for treatment of: Head and Neck Cancer Locally or regionally advanced squamous cell carcinoma of the head and neck in combination with radiation therapy. ( 1.1 , 14.1 ) Recurrent locoregional disease or metastatic squamous cell carcinoma of the head and neck in combination with platinum-based therapy with fluorouracil. ( 1.1 , 14.1 ) Recurrent or metastatic squamous cell carcinoma of the head and neck progressing after platinum-based therapy. ( 1.1 , 14.1 ) Colorectal Cancer K-Ras wild-type, EGFR-expressing, metastatic colorectal cancer as determined by an FDA-approved test in combination with FOLFIRI for first-line treatment, in combination with irinotecan in patients who are refractory to irinotecan-based chemotherapy, as a single-agent in patients who have failed oxaliplatin- and irinotecan-based chemotherapy or who are intolerant to irinotecan. ( 1.2 , 5.7 , 12.1 , 14.2 ) Limitations of Use: ERBITUX is not indicated for treatment of Ras-mutant colorectal cancer or when the results of the Ras mutation tests are unknown. ( 5.7 ) BRAF V600E Mutation-Positive Metastatic Colorectal Cancer (CRC) in combination with encorafenib, for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy. ( 1.3 )|[PMDA] A drug with a new additional dosage indicated for the treatment of unresectable, advanced or recurrent colon or rectal cancer with wild-type RAS and head and neck cancer. [Public knowledge-based application] uuid:c2ab8e37-482a-4626-a043-475db335b84e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PQX0D8J21J biolink:treats MONDO:0010150 PMID:41385096 "[{""id"":""uuid:2cdbc7bd-f6ef-4f65-b791-cca5b0622583"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:4b480eab-b5ce-4e83-9950-06bc8a63195f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:6807ee2c-bbb7-4a66-8ae0-cd16aa163b4b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/erbitux""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] ERBITUX ® is an epidermal growth factor receptor (EGFR) antagonist indicated for treatment of: Head and Neck Cancer Locally or regionally advanced squamous cell carcinoma of the head and neck in combination with radiation therapy. ( 1.1 , 14.1 ) Recurrent locoregional disease or metastatic squamous cell carcinoma of the head and neck in combination with platinum-based therapy with fluorouracil. ( 1.1 , 14.1 ) Recurrent or metastatic squamous cell carcinoma of the head and neck progressing after platinum-based therapy. ( 1.1 , 14.1 ) Colorectal Cancer K-Ras wild-type, EGFR-expressing, metastatic colorectal cancer as determined by an FDA-approved test in combination with FOLFIRI for first-line treatment, in combination with irinotecan in patients who are refractory to irinotecan-based chemotherapy, as a single-agent in patients who have failed oxaliplatin- and irinotecan-based chemotherapy or who are intolerant to irinotecan. ( 1.2 , 5.7 , 12.1 , 14.2 ) Limitations of Use: ERBITUX is not indicated for treatment of Ras-mutant colorectal cancer or when the results of the Ras mutation tests are unknown. ( 5.7 ) BRAF V600E Mutation-Positive Metastatic Colorectal Cancer (CRC) in combination with encorafenib, for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy. ( 1.3 )|[EMA] Erbitux is indicated for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer:in combination with irinotecan-based chemotherapy;in first-line in combination with FOLFOX;as a single agent in patients who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecan.For details, see section 5.1.Erbitux is indicated for the treatment of patients with squamous cell cancer of the head and neck:in combination with radiation therapy for locally advanced disease;in combination with platinum-based chemotherapy for recurrent and/or metastatic disease. uuid:72fddb64-3efc-4900-a2ea-059fdc7671c7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PQX0D8J21J biolink:treats MONDO:0005575 PMID:41385096 "[{""id"":""uuid:12c034a8-4ea0-411a-8d66-b506ff126894"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ce02ed61-a7ef-4064-864f-31f9b9fd67c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ERBITUX ® is an epidermal growth factor receptor (EGFR) antagonist indicated for treatment of: Head and Neck Cancer Locally or regionally advanced squamous cell carcinoma of the head and neck in combination with radiation therapy. ( 1.1 , 14.1 ) Recurrent locoregional disease or metastatic squamous cell carcinoma of the head and neck in combination with platinum-based therapy with fluorouracil. ( 1.1 , 14.1 ) Recurrent or metastatic squamous cell carcinoma of the head and neck progressing after platinum-based therapy. ( 1.1 , 14.1 ) Colorectal Cancer K-Ras wild-type, EGFR-expressing, metastatic colorectal cancer as determined by an FDA-approved test in combination with FOLFIRI for first-line treatment, in combination with irinotecan in patients who are refractory to irinotecan-based chemotherapy, as a single-agent in patients who have failed oxaliplatin- and irinotecan-based chemotherapy or who are intolerant to irinotecan. ( 1.2 , 5.7 , 12.1 , 14.2 ) Limitations of Use: ERBITUX is not indicated for treatment of Ras-mutant colorectal cancer or when the results of the Ras mutation tests are unknown. ( 5.7 ) BRAF V600E Mutation-Positive Metastatic Colorectal Cancer (CRC) in combination with encorafenib, for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy. ( 1.3 ) uuid:6c42e392-0de9-4d0a-b450-59d8c46805d1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PQX0D8J21J biolink:treats EFO:1001480 PMID:41385096 "[{""id"":""uuid:12cc02d9-24af-4024-a133-6c65be25f7d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e8fd5673-3434-4371-b5a8-7d2768356d09"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ERBITUX ® is an epidermal growth factor receptor (EGFR) antagonist indicated for treatment of: Head and Neck Cancer Locally or regionally advanced squamous cell carcinoma of the head and neck in combination with radiation therapy. ( 1.1 , 14.1 ) Recurrent locoregional disease or metastatic squamous cell carcinoma of the head and neck in combination with platinum-based therapy with fluorouracil. ( 1.1 , 14.1 ) Recurrent or metastatic squamous cell carcinoma of the head and neck progressing after platinum-based therapy. ( 1.1 , 14.1 ) Colorectal Cancer K-Ras wild-type, EGFR-expressing, metastatic colorectal cancer as determined by an FDA-approved test in combination with FOLFIRI for first-line treatment, in combination with irinotecan in patients who are refractory to irinotecan-based chemotherapy, as a single-agent in patients who have failed oxaliplatin- and irinotecan-based chemotherapy or who are intolerant to irinotecan. ( 1.2 , 5.7 , 12.1 , 14.2 ) Limitations of Use: ERBITUX is not indicated for treatment of Ras-mutant colorectal cancer or when the results of the Ras mutation tests are unknown. ( 5.7 ) BRAF V600E Mutation-Positive Metastatic Colorectal Cancer (CRC) in combination with encorafenib, for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy. ( 1.3 ) uuid:b0a293a1-5540-4c43-8742-acac6d166207 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2955 biolink:treats MONDO:0005545 PMID:41385096 "[{""id"":""uuid:777de8af-6238-4573-aa47-b009147db3f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6cf5f824-54c7-483b-8f88-fc1cfc8ec7a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AzaSite ® is indicated for the treatment of bacterial conjunctivitis caused by susceptible isolates of the following microorganisms: CDC coryneform group G Efficacy for this organism was studied in fewer than 10 infections. Haemophilus influenzae Staphylococcus aureus Streptococcus mitis group Streptococcus pneumoniae uuid:c96d868b-07aa-46eb-b998-789cb310c3a1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2955 biolink:treats MONDO:0005114 PMID:41385096 "[{""id"":""uuid:7d2e8a18-5452-4b35-9dce-9b9876b50f35"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5bbbcdae-bc1d-4706-a901-ecfd5fc80c40"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AzaSite ® is indicated for the treatment of bacterial conjunctivitis caused by susceptible isolates of the following microorganisms: CDC coryneform group G Efficacy for this organism was studied in fewer than 10 infections. Haemophilus influenzae Staphylococcus aureus Streptococcus mitis group Streptococcus pneumoniae uuid:4785d8f5-8e4c-4cd1-a9dd-4a5462314ee4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:136048 biolink:treats UMLS:C0267055 PMID:41385096 "[{""id"":""uuid:5062127f-ffa9-4a09-9d47-bcfb9a107b1b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8dceb4d9-41af-4847-b4d8-0a92ab8aaa21"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VOQUEZNA is indicated: for healing of all grades of erosive esophagitis and relief of heartburn associated with erosive esophagitis in adults. to maintain healing of all grades of erosive esophagitis and relief of heartburn associated with erosive esophagitis in adults. for the relief of heartburn associated with non-erosive gastroesophageal reflux disease in adults. in combination with amoxicillin and clarithromycin for the treatment of Helicobacter pylori ( H. pylori ) infection in adults. in combination with amoxicillin for the treatment of H. pylori infection in adults. uuid:7bb3e97a-1743-4592-8afa-4617f245d94f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:136048 biolink:treats HP:0005202 PMID:41385096 "[{""id"":""uuid:b5d8435c-fd3d-4235-bc04-668735b371c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f8250e6b-25ae-4492-89eb-6cb48d94240c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VOQUEZNA is indicated: for healing of all grades of erosive esophagitis and relief of heartburn associated with erosive esophagitis in adults. to maintain healing of all grades of erosive esophagitis and relief of heartburn associated with erosive esophagitis in adults. for the relief of heartburn associated with non-erosive gastroesophageal reflux disease in adults. in combination with amoxicillin and clarithromycin for the treatment of Helicobacter pylori ( H. pylori ) infection in adults. in combination with amoxicillin for the treatment of H. pylori infection in adults. uuid:8be0df14-6ed4-46bf-9419-42ad5a02fa30 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6129 biolink:treats NCIT:C3137 PMID:41385096 "[{""id"":""uuid:803c63c9-e6d3-4e84-9d85-84281af77521"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5507331a-5161-4ff2-ad3c-536cdb796119"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ACUVAIL ® is indicated for the treatment of pain and inflammation following cataract surgery. uuid:8839256f-5c79-4ddb-b4c4-21d467146a8d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:GDW7M2P1IS biolink:treats MONDO:0002049 PMID:41385096 "[{""id"":""uuid:dcd094cf-615c-4df5-8cbd-57ab94dd0457"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a3360f46-7cb8-46a8-912c-943e135510bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:8b9d4bdf-9a01-4a98-bd54-283019ebcef9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DOPTELET is a thrombopoietin receptor agonist indicated for the treatment of: Thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure. ( 1.1 ) Thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. ( 1.2 )|[PMDA] A drug with a new active ingredient indicated for the improvement of thrombocytopenia in patients with chronic liver disease for whom an elective invasive procedure is planned. uuid:34e7a0f3-6732-4891-b643-6bea895d1591 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:GDW7M2P1IS biolink:treats MONDO:0019098 PMID:41385096 "[{""id"":""uuid:cfd80b56-7879-4e26-b106-4a35bca8242e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:586a18fb-9278-4185-a24d-ca077221c843"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DOPTELET is a thrombopoietin receptor agonist indicated for the treatment of: Thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure. ( 1.1 ) Thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. ( 1.2 ) uuid:bbe1d42c-e7db-4065-ba0a-25cfa4e3e244 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:192617 biolink:treats MONDO:0003471 PMID:41385096 "[{""id"":""uuid:60cca20c-0600-46b0-94e3-af8de10596bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:36c05f25-d33d-49f5-a0c3-134b19f2ddeb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XEGLYZE is indicated for the topical treatment of head lice infestation in patients 6 months of age and older. XEGLYZE should be used in the context of an overall lice management program: Wash (with hot water) or dry-clean all recently worn clothing, hats, used bedding and towels Wash personal care items such as combs, brushes, and hair clips in hot water Use a fine-tooth comb or special nit comb to remove dead lice and nits uuid:fd2eb1af-646b-4c1f-bc39-47b1e1883341 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:ZJ0EKR6M10 biolink:treats MONDO:0019496 PMID:41385096 "[{""id"":""uuid:34b8adab-737a-40ab-b8e0-a7e367632650"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:48449856-40e2-43b2-a974-ce9ad299351c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NETSPOT, after radiolabeling with gallium-68, is indicated for use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult and pediatric patients. uuid:0152ab35-0146-47db-8c50-783beb8cd8eb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:0P70AR5BYB biolink:treats MONDO:0005300 PMID:41385096 "[{""id"":""uuid:4ad605fd-49a2-44ae-9cdc-81b11c2ba1b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:c27a9c9b-4c91-4bfd-b2a2-9da46b0a30db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:6434c0e6-f357-467d-87eb-efaef4303382"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/kapruvia""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] KORSUVA is indicated for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis (HD). Limitation of Use Korsuva has not been studied in patients on peritoneal dialysis and is not recommended for use in this population.|[EMA] Kapruvia is indicated for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult patients on haemodialysis (see section 5.1). uuid:061a73ed-8163-448b-b3d2-b8c2d9034e98 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:72292 biolink:treats MONDO:0006052 PMID:41385096 "[{""id"":""uuid:6b93e203-3dce-42f2-8956-a4908b2502ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4c1ff01a-a5ad-455f-8aef-e6becfa62a49"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SIRTURO is a diarylquinoline antimycobacterial drug indicated as part of combination therapy in the treatment of adult and pediatric patients (5 years and older and weighing at least 15 kg) with pulmonary tuberculosis (TB) due to Mycobacterium tuberculosis resistant to at least rifampin and isoniazid. uuid:d4972084-0c00-4da9-af23-794f073c7191 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5118 biolink:treats MONDO:0024613 PMID:41385096 "[{""id"":""uuid:8bb7d154-7867-406b-aac0-1c8ec6af7b83"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b92f874b-d4be-4cdf-b630-e0879f0c6311"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fluoxetine is a selective serotonin reuptake inhibitor indicated for: Acute and maintenance treatment of Major Depressive Disorder (MDD) ( 1 ) Acute and maintenance treatment of Obsessive Compulsive Disorder (OCD) ( 1 ) Acute and maintenance treatment of Bulimia Nervosa ( 1 ) Acute treatment of Panic Disorder, with or without agoraphobia ( 1 ) Fluoxetine capsules and olanzapine in combination for treatment of: Acute Depressive Episodes Associated with Bipolar I Disorder ( 1 ) Treatment Resistant Depression ( 1 ) uuid:9362373a-cf38-468c-ac86-2d5f8115cb40 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:QEN1X95CIX biolink:treats UMLS:C1112459 PMID:41385096 "[{""id"":""uuid:92d1a9d2-7ae8-4267-986c-3ccd4d9e7998"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8698252c-bec4-4518-8aa5-2aa089aad70b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] IMJUDO is a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) blocking antibody indicated: • in combination with durvalumab, for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC). ( 1.1 ) • in combination with durvalumab and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) genomic tumor aberrations. ( 1.2 ) uuid:bfaa797d-0d99-4416-a253-b4bb7fffcd12 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:QEN1X95CIX biolink:treats UMLS:C0278987 PMID:41385096 "[{""id"":""uuid:7bb3ec5d-d3b0-4d8a-91ff-99ae60a09cfe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:44c39832-b4b7-47c8-8b90-f3b3f11849fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] IMJUDO is a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) blocking antibody indicated: • in combination with durvalumab, for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC). ( 1.1 ) • in combination with durvalumab and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) genomic tumor aberrations. ( 1.2 ) uuid:f9550a54-e630-429a-86b7-633a95ca39aa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:1864 biolink:treats MONDO:0005062 PMID:41385096 "[{""id"":""uuid:a8fc25cc-f89e-4b06-b587-c17acc8f1d40"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7aabe411-8873-42af-a558-a7da27e8fdb5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Malignant Diseases Cyclophosphamide Injection is indicated for the treatment of adult and pediatric patients with: malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin's disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma Burkitt's lymphoma multiple myeloma leukemias: chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia (cyclophosphamide given during remission is effective in prolonging its duration) mycosis fungoides (advanced disease) neuroblastoma (disseminated disease) adenocarcinoma of the ovary retinoblastoma carcinoma of the breast Cyclophosphamide Injection, although effective alone in susceptible malignancies, is more frequently used concurrently or sequentially with other antineoplastic drugs. uuid:38239f1e-809c-4cd3-9947-107bef4bc3bc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:1864 biolink:treats MONDO:0009348 PMID:41385096 "[{""id"":""uuid:a2e02c0f-d2de-4048-a3b3-d50390fed8de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:225c2499-4005-4529-87a5-4bbe1a559436"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Malignant Diseases Cyclophosphamide Injection is indicated for the treatment of adult and pediatric patients with: malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin's disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma Burkitt's lymphoma multiple myeloma leukemias: chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia (cyclophosphamide given during remission is effective in prolonging its duration) mycosis fungoides (advanced disease) neuroblastoma (disseminated disease) adenocarcinoma of the ovary retinoblastoma carcinoma of the breast Cyclophosphamide Injection, although effective alone in susceptible malignancies, is more frequently used concurrently or sequentially with other antineoplastic drugs. uuid:b62553e9-c464-4e0d-9cd2-57eb21728a20 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:1864 biolink:treats MONDO:0003864 PMID:41385096 "[{""id"":""uuid:70c748f7-6b2a-49ab-922c-fb96fe22491a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cfcc443a-8863-4f12-beb8-4dce43ff8a94"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Malignant Diseases Cyclophosphamide Injection is indicated for the treatment of adult and pediatric patients with: malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin's disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma Burkitt's lymphoma multiple myeloma leukemias: chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia (cyclophosphamide given during remission is effective in prolonging its duration) mycosis fungoides (advanced disease) neuroblastoma (disseminated disease) adenocarcinoma of the ovary retinoblastoma carcinoma of the breast Cyclophosphamide Injection, although effective alone in susceptible malignancies, is more frequently used concurrently or sequentially with other antineoplastic drugs. uuid:16ab4a91-d0f5-413d-b902-620d45da142c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:1864 biolink:treats MONDO:0004633 PMID:41385096 "[{""id"":""uuid:3f7dc5bf-62b4-4eee-b682-3317862b0bfd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f47cad76-702c-4462-aa67-bd4280bb1b98"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Malignant Diseases Cyclophosphamide Injection is indicated for the treatment of adult and pediatric patients with: malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin's disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma Burkitt's lymphoma multiple myeloma leukemias: chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia (cyclophosphamide given during remission is effective in prolonging its duration) mycosis fungoides (advanced disease) neuroblastoma (disseminated disease) adenocarcinoma of the ovary retinoblastoma carcinoma of the breast Cyclophosphamide Injection, although effective alone in susceptible malignancies, is more frequently used concurrently or sequentially with other antineoplastic drugs. uuid:6ee8feac-4e93-47f1-b833-71d3fc41a595 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:1864 biolink:treats MONDO:0004604 PMID:41385096 "[{""id"":""uuid:6a12f16b-cf1d-44c8-9979-f60f49c004c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e4e70a60-3dc2-4337-a78c-7c5807213e9f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Malignant Diseases Cyclophosphamide Injection is indicated for the treatment of adult and pediatric patients with: malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin's disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma Burkitt's lymphoma multiple myeloma leukemias: chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia (cyclophosphamide given during remission is effective in prolonging its duration) mycosis fungoides (advanced disease) neuroblastoma (disseminated disease) adenocarcinoma of the ovary retinoblastoma carcinoma of the breast Cyclophosphamide Injection, although effective alone in susceptible malignancies, is more frequently used concurrently or sequentially with other antineoplastic drugs. uuid:6face188-f5ac-47d6-98b0-b9f9e9002db0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:1864 biolink:treats MONDO:0006150 PMID:41385096 "[{""id"":""uuid:bb6f7c2a-1fa3-4cc9-8132-f9398569ce7b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:388fa68b-cde4-4813-bd9b-e426032fab61"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Malignant Diseases Cyclophosphamide Injection is indicated for the treatment of adult and pediatric patients with: malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin's disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma Burkitt's lymphoma multiple myeloma leukemias: chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia (cyclophosphamide given during remission is effective in prolonging its duration) mycosis fungoides (advanced disease) neuroblastoma (disseminated disease) adenocarcinoma of the ovary retinoblastoma carcinoma of the breast Cyclophosphamide Injection, although effective alone in susceptible malignancies, is more frequently used concurrently or sequentially with other antineoplastic drugs. uuid:cb26fca2-6d36-4cfe-b894-6072bdb603fb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:1864 biolink:treats MONDO:0009693 PMID:41385096 "[{""id"":""uuid:e1fbbbce-653d-4f2b-b678-71b144394aca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1a4b791c-07ca-45fc-b2d3-c306c93bd035"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Malignant Diseases Cyclophosphamide Injection is indicated for the treatment of adult and pediatric patients with: malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin's disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma Burkitt's lymphoma multiple myeloma leukemias: chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia (cyclophosphamide given during remission is effective in prolonging its duration) mycosis fungoides (advanced disease) neuroblastoma (disseminated disease) adenocarcinoma of the ovary retinoblastoma carcinoma of the breast Cyclophosphamide Injection, although effective alone in susceptible malignancies, is more frequently used concurrently or sequentially with other antineoplastic drugs. uuid:dd2cc082-2505-404c-905f-a5dffaed6e80 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:1864 biolink:treats MONDO:0004948 PMID:41385096 "[{""id"":""uuid:6518b71d-ade3-4a33-ab94-0a0e8e82e123"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6f74d811-87d2-4c9f-80b2-3a95daf87b74"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Malignant Diseases Cyclophosphamide Injection is indicated for the treatment of adult and pediatric patients with: malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin's disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma Burkitt's lymphoma multiple myeloma leukemias: chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia (cyclophosphamide given during remission is effective in prolonging its duration) mycosis fungoides (advanced disease) neuroblastoma (disseminated disease) adenocarcinoma of the ovary retinoblastoma carcinoma of the breast Cyclophosphamide Injection, although effective alone in susceptible malignancies, is more frequently used concurrently or sequentially with other antineoplastic drugs. uuid:9b7c4325-b34a-473e-9258-aa5187077760 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:1864 biolink:treats MONDO:0011996 PMID:41385096 "[{""id"":""uuid:e87aea38-6b34-4a33-aebc-5ce6c9d5c176"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f19bddd6-95dd-4c1b-b79e-c27b94d4ea7b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Malignant Diseases Cyclophosphamide Injection is indicated for the treatment of adult and pediatric patients with: malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin's disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma Burkitt's lymphoma multiple myeloma leukemias: chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia (cyclophosphamide given during remission is effective in prolonging its duration) mycosis fungoides (advanced disease) neuroblastoma (disseminated disease) adenocarcinoma of the ovary retinoblastoma carcinoma of the breast Cyclophosphamide Injection, although effective alone in susceptible malignancies, is more frequently used concurrently or sequentially with other antineoplastic drugs. uuid:98273050-7c15-4e58-b08f-38628cbdb044 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:1864 biolink:treats MONDO:0018871 PMID:41385096 "[{""id"":""uuid:a9c734cb-7e46-4343-9b8c-7ca983eae9e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b793cb43-5ff5-4e03-a69d-d972ed9fff60"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Malignant Diseases Cyclophosphamide Injection is indicated for the treatment of adult and pediatric patients with: malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin's disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma Burkitt's lymphoma multiple myeloma leukemias: chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia (cyclophosphamide given during remission is effective in prolonging its duration) mycosis fungoides (advanced disease) neuroblastoma (disseminated disease) adenocarcinoma of the ovary retinoblastoma carcinoma of the breast Cyclophosphamide Injection, although effective alone in susceptible malignancies, is more frequently used concurrently or sequentially with other antineoplastic drugs. uuid:cc85f90b-61e5-438c-b30a-1950c48d4158 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:1864 biolink:treats MONDO:0004967 PMID:41385096 "[{""id"":""uuid:e80f6129-5927-4a89-9bba-af67465c8773"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9c0ffb14-c602-44f1-97e3-ee19c9a4c8e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Malignant Diseases Cyclophosphamide Injection is indicated for the treatment of adult and pediatric patients with: malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin's disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma Burkitt's lymphoma multiple myeloma leukemias: chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia (cyclophosphamide given during remission is effective in prolonging its duration) mycosis fungoides (advanced disease) neuroblastoma (disseminated disease) adenocarcinoma of the ovary retinoblastoma carcinoma of the breast Cyclophosphamide Injection, although effective alone in susceptible malignancies, is more frequently used concurrently or sequentially with other antineoplastic drugs. uuid:e29784c0-b914-4d29-ae07-0433982c492e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:1864 biolink:treats MONDO:0009691 PMID:41385096 "[{""id"":""uuid:bbf3b3a3-2dc2-446f-8c54-0f34dd7cb584"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f881cfa2-421d-4f60-bf65-b13caa6e6088"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Malignant Diseases Cyclophosphamide Injection is indicated for the treatment of adult and pediatric patients with: malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin's disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma Burkitt's lymphoma multiple myeloma leukemias: chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia (cyclophosphamide given during remission is effective in prolonging its duration) mycosis fungoides (advanced disease) neuroblastoma (disseminated disease) adenocarcinoma of the ovary retinoblastoma carcinoma of the breast Cyclophosphamide Injection, although effective alone in susceptible malignancies, is more frequently used concurrently or sequentially with other antineoplastic drugs. uuid:f3c328d2-7dcd-4ada-bec3-4f870aa87ff9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:1864 biolink:treats MONDO:0005072 PMID:41385096 "[{""id"":""uuid:15c783ed-096f-49b7-a72a-93cb32b48c82"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e02d5343-a301-4ef3-a1da-ad60dfcaf5b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Malignant Diseases Cyclophosphamide Injection is indicated for the treatment of adult and pediatric patients with: malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin's disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma Burkitt's lymphoma multiple myeloma leukemias: chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia (cyclophosphamide given during remission is effective in prolonging its duration) mycosis fungoides (advanced disease) neuroblastoma (disseminated disease) adenocarcinoma of the ovary retinoblastoma carcinoma of the breast Cyclophosphamide Injection, although effective alone in susceptible malignancies, is more frequently used concurrently or sequentially with other antineoplastic drugs. uuid:a49d6652-1fa5-469c-89ec-f6de69b1b124 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:1864 biolink:treats MONDO:0002752 PMID:41385096 "[{""id"":""uuid:c4fd6b4c-6712-49ff-b8b1-c74948105f1e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:34b97fe4-062a-4ff4-b7f4-67e350625fc7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Malignant Diseases Cyclophosphamide Injection is indicated for the treatment of adult and pediatric patients with: malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin's disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma Burkitt's lymphoma multiple myeloma leukemias: chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia (cyclophosphamide given during remission is effective in prolonging its duration) mycosis fungoides (advanced disease) neuroblastoma (disseminated disease) adenocarcinoma of the ovary retinoblastoma carcinoma of the breast Cyclophosphamide Injection, although effective alone in susceptible malignancies, is more frequently used concurrently or sequentially with other antineoplastic drugs. uuid:07b88f53-07ee-4cf1-90f8-3986b4a03aa0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:1864 biolink:treats MONDO:0008380 PMID:41385096 "[{""id"":""uuid:0ee0c5df-1414-4997-8de7-bac40356a8ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f6dac4ef-e606-413f-b160-9a9002115270"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Malignant Diseases Cyclophosphamide Injection is indicated for the treatment of adult and pediatric patients with: malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin's disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma Burkitt's lymphoma multiple myeloma leukemias: chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia (cyclophosphamide given during remission is effective in prolonging its duration) mycosis fungoides (advanced disease) neuroblastoma (disseminated disease) adenocarcinoma of the ovary retinoblastoma carcinoma of the breast Cyclophosphamide Injection, although effective alone in susceptible malignancies, is more frequently used concurrently or sequentially with other antineoplastic drugs. uuid:93cf4fa9-3b76-4c03-b61c-aef7822b90c6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:1864 biolink:treats MONDO:0004989 PMID:41385096 "[{""id"":""uuid:91d0f058-ee4b-4c66-a945-9502b33a9fa0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:484cbe31-1073-435c-9039-6d3bb8be3926"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Malignant Diseases Cyclophosphamide Injection is indicated for the treatment of adult and pediatric patients with: malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin's disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma Burkitt's lymphoma multiple myeloma leukemias: chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia (cyclophosphamide given during remission is effective in prolonging its duration) mycosis fungoides (advanced disease) neuroblastoma (disseminated disease) adenocarcinoma of the ovary retinoblastoma carcinoma of the breast Cyclophosphamide Injection, although effective alone in susceptible malignancies, is more frequently used concurrently or sequentially with other antineoplastic drugs. uuid:ca8c095f-d27b-476d-96b7-96b61d771f49 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71260 biolink:treats HP:0003119 PMID:41385096 "[{""id"":""uuid:5f357ed7-efc5-4cc8-9c98-b30b9fa9cfb8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2ef8616a-3ed8-4f38-838c-4efcdf99340d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pitavastatin is indicated as an adjunctive therapy to diet in: Adult patients with primary hyperlipidemia or mixed dyslipidemia to reduce elevated total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C). Limitations of Use The effect of pitavastatin on cardiovascular morbidity and mortality has not been determined. Pediatric use information is approved for Kowa Co Ltd's LIVALO (pitavastatin) tablets. However, due to Kowa Co Ltd's marketing exclusivity rights, this drug product is not labeled with that information. uuid:3a7df543-e75e-4a9e-8fb1-fac733d4b478 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:229213 biolink:treats UMLS:C0278488 PMID:41385096 "[{""id"":""uuid:0122abc0-7ebd-45d9-9a27-dd61dc3dbaf4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fceaa362-8610-4601-b48c-1f6d662c19d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ORSERDU is indicated for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)‑negative, ESR1 -mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy. uuid:4d413817-0761-4a44-8c0c-42a5b9ecc5e7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:36791 biolink:treats MONDO:0002050 PMID:41385096 "[{""id"":""uuid:0b7f2a2d-d11f-4330-bd35-3bdb728875aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6c70d239-f5cf-49cb-9436-929140ab4eae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:949a8404-c18d-4f39-bb0e-7e4267dbd64f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Escitalopram tablet, is indicated for the acute and maintenance treatment of major depressive disorder in adults and in adolescents 12 to 17 years of age [ see Clinical Studies ( 14.1 ) ]. A major depressive episode (DSM-IV) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least five of the following nine symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation.|[PMDA] A drug with a new active ingredient indicated for the treatment of depression. uuid:3ee790d1-f130-4327-bb29-2f4963fa522c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:36791 biolink:treats MONDO:0013600 PMID:41385096 "[{""id"":""uuid:09788d7f-71fa-4277-91ce-b862c0bcd542"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:af7a9723-8074-4a75-8569-2d1247ddb491"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Escitalopram tablet, is indicated for the acute and maintenance treatment of major depressive disorder in adults and in adolescents 12 to 17 years of age [ see Clinical Studies ( 14.1 ) ]. A major depressive episode (DSM-IV) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least five of the following nine symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. uuid:8254356a-fcb6-4632-b246-8d0a8128ceb0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:36791 biolink:treats MONDO:0005466 PMID:41385096 "[{""id"":""uuid:6dec6e27-37e6-4935-b936-cf3e8b4bbc78"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9f541409-b3bb-457b-b373-8a57447c76ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Escitalopram tablet, is indicated for the acute and maintenance treatment of major depressive disorder in adults and in adolescents 12 to 17 years of age [ see Clinical Studies ( 14.1 ) ]. A major depressive episode (DSM-IV) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least five of the following nine symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. uuid:57712933-2e5f-439c-8c18-fd5a3a7bd6f2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:36791 biolink:treats NCIT:C143864 PMID:41385096 "[{""id"":""uuid:32ecc3a3-cebf-404f-9565-0aa7b9224e4f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0aabd8fe-9660-4cab-8892-081b0c8fa995"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Escitalopram tablet, is indicated for the acute and maintenance treatment of major depressive disorder in adults and in adolescents 12 to 17 years of age [ see Clinical Studies ( 14.1 ) ]. A major depressive episode (DSM-IV) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least five of the following nine symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. uuid:28fc2f85-cee3-4444-af05-6abfc0672d7a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:131169 biolink:treats MONDO:0004948 PMID:41385096 "[{""id"":""uuid:8c5e1485-9a86-425b-aaf4-7af51ce9fee1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:480f28a2-ebb0-4dcf-8f3a-30fc4fa4c635"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ddb2d785-4586-4203-928d-a4a3cf79947e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/copiktra""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] COPIKTRA is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL) after at least two prior therapies. Limitations of Use : COPIKTRA is not indicated or recommended for the treatment of any patients with CLL or SLL as initial or second line treatment due to an increased risk of treatment-related mortality.|[EMA] Copiktra monotherapy is indicated for the treatment of adult patients with: Relapsed or refractory chronic lymphocytic leukaemia (CLL) after at least two prior therapies. Follicular lymphoma (FL) that is refractory to at least two prior systemic therapies. uuid:eb424c18-69ec-492b-b926-dae2a1972f70 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10023 biolink:treats MONDO:0002026 PMID:41385096 "[{""id"":""uuid:ca884563-b1da-46f5-b9b7-ac47ad48df82"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fd2c101d-1d2e-4935-9d8b-50ab3d6fdb59"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Voriconazole tablets are an azole antifungal indicated for the treatment of adults and pediatric patients aged 12 to 14 years weighing greater than or equal to 50 kg and those aged 15 years and older regardless of body weight with: • Invasive aspergillosis ( 1.1 ) • Candidemia in non-neutropenics and other deep tissue Candida infections ( 1.2 ) • Esophageal candidiasis ( 1.3 ) • Serious fungal infections caused by Scedosporium apiospermum and Fusarium species including Fusarium solani , in patients intolerant of, or refractory to, other therapy ( 1.4 ) uuid:be5a9c34-f6ea-48da-86ec-226376f5961a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:X8R2D92QP1 biolink:treats MONDO:0008769 PMID:41385096 "[{""id"":""uuid:1438df67-bab5-4f90-ae1d-93c4ff1d8fc1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1befe914-ddba-4d66-a0c3-568faf477317"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:d35f9eed-9d77-4e74-8ebd-4d61ce468438"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/brineura""]},{""id"":""uuid:416c921d-92f5-413d-95c5-d7fe57bc262e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BRINEURA is indicated to slow the loss of ambulation in pediatric patients with neuronal ceroid lipofuscinosis type 2 (CLN2 disease), also known as tripeptidyl peptidase 1 (TPP1) deficiency.|[EMA] Brineura is indicated for the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2) disease, also known as tripeptidyl peptidase 1 (TPP1) deficiency,|[PMDA] A drug with a new active ingredient indicated for the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2). [Orphan drug] uuid:e9db61af-dbd6-460d-9a96-193895ee6b6f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:600520 biolink:treats MONDO:0005025 PMID:41385096 "[{""id"":""uuid:841c0747-a04c-4481-a13d-e54651c2b7a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7c14cce5-ff95-48d1-afe5-07e68edd7983"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Micafungin for Injection, USP is indicated for: Treatment of Candidemia, Acute Disseminated Candidiasis, Candida Peritonitis and Abscesses in adult and pediatric patients 4 months of age and older [see Clinical Studies (14.1) and Use in Specific Populations (8.4 )]. Treatment of Candidemia, Acute Disseminated Candidiasis, Candida Peritonitis and Abscesses without meningoencephalitis and/or ocular dissemination in pediatric patients younger than 4 months of age [see Use in Specific Populations (8.4) ]. Treatment of Esophageal Candidiasis in adult and pediatric patients 4 months of age and older [see Clinical Studies (14.2 )]. Prophylaxis of Candida Infections in adult and pediatric patients 4 months of age and older undergoing hematopoietic stem cell transplantation [see Clinical Studies (14.3 )]. Limitations of Use The safety and effectiveness of Micafungin for Injection, USP have not been established for the treatment of candidemia with meningoencephalitis and/or ocular dissemination in pediatric patients younger than 4 months of age as a higher dose may be needed [see Use in Specific Populations (8.4) ] Micafungin for Injection, USP has not been adequately studied in patients with endocarditis, osteomyelitis and meningoencephalitis due to Candida. The efficacy of Micafungin for Injection, USP against infections caused by fungi other than Candida has not been established. uuid:60d93e5a-f36b-4914-affe-b1cca79279cf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:600520 biolink:treats MONDO:0005246 PMID:41385096 "[{""id"":""uuid:63eba2e3-e0c4-471f-b2fc-f55f5ad6534b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:007b0294-467c-4e3d-bb17-34d8b33784e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Micafungin for Injection, USP is indicated for: Treatment of Candidemia, Acute Disseminated Candidiasis, Candida Peritonitis and Abscesses in adult and pediatric patients 4 months of age and older [see Clinical Studies (14.1) and Use in Specific Populations (8.4 )]. Treatment of Candidemia, Acute Disseminated Candidiasis, Candida Peritonitis and Abscesses without meningoencephalitis and/or ocular dissemination in pediatric patients younger than 4 months of age [see Use in Specific Populations (8.4) ]. Treatment of Esophageal Candidiasis in adult and pediatric patients 4 months of age and older [see Clinical Studies (14.2 )]. Prophylaxis of Candida Infections in adult and pediatric patients 4 months of age and older undergoing hematopoietic stem cell transplantation [see Clinical Studies (14.3 )]. Limitations of Use The safety and effectiveness of Micafungin for Injection, USP have not been established for the treatment of candidemia with meningoencephalitis and/or ocular dissemination in pediatric patients younger than 4 months of age as a higher dose may be needed [see Use in Specific Populations (8.4) ] Micafungin for Injection, USP has not been adequately studied in patients with endocarditis, osteomyelitis and meningoencephalitis due to Candida. The efficacy of Micafungin for Injection, USP against infections caused by fungi other than Candida has not been established. uuid:7f42d755-5fa5-4780-81f6-2ab59a2e7ddd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:600520 biolink:treats MONDO:0005845 PMID:41385096 "[{""id"":""uuid:a45cd2f7-ba5c-4e46-be27-daf370dd719e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:07f7f653-f36f-4afb-bc0d-d52ef2c70bba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Micafungin for Injection, USP is indicated for: Treatment of Candidemia, Acute Disseminated Candidiasis, Candida Peritonitis and Abscesses in adult and pediatric patients 4 months of age and older [see Clinical Studies (14.1) and Use in Specific Populations (8.4 )]. Treatment of Candidemia, Acute Disseminated Candidiasis, Candida Peritonitis and Abscesses without meningoencephalitis and/or ocular dissemination in pediatric patients younger than 4 months of age [see Use in Specific Populations (8.4) ]. Treatment of Esophageal Candidiasis in adult and pediatric patients 4 months of age and older [see Clinical Studies (14.2 )]. Prophylaxis of Candida Infections in adult and pediatric patients 4 months of age and older undergoing hematopoietic stem cell transplantation [see Clinical Studies (14.3 )]. Limitations of Use The safety and effectiveness of Micafungin for Injection, USP have not been established for the treatment of candidemia with meningoencephalitis and/or ocular dissemination in pediatric patients younger than 4 months of age as a higher dose may be needed [see Use in Specific Populations (8.4) ] Micafungin for Injection, USP has not been adequately studied in patients with endocarditis, osteomyelitis and meningoencephalitis due to Candida. The efficacy of Micafungin for Injection, USP against infections caused by fungi other than Candida has not been established. uuid:bf80d65a-24f6-48d5-918e-d68895dd6424 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2375135 biolink:treats MONDO:0009693 PMID:41385096 "[{""id"":""uuid:d2a35436-6c76-413d-b507-9c75b5883fb1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:af91805a-1ab4-4062-8313-d8a148eda997"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DARZALEX FASPRO is a combination of daratumumab, a CD38-directed cytolytic antibody, and hyaluronidase, an endoglycosidase, indicated for the treatment of adult patients with: multiple myeloma in combination with bortezomib, lenalidomide, and dexamethasone for induction and consolidation in newly diagnosed patients who are eligible for autologous stem cell transplant multiple myeloma in combination with bortezomib, melphalan and prednisone in newly diagnosed patients who are ineligible for autologous stem cell transplant multiple myeloma in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy multiple myeloma in combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for autologous stem cell transplant multiple myeloma in combination with bortezomib and dexamethasone in patients who have received at least one prior therapy multiple myeloma in combination with pomalidomide and dexamethasone in patients who have received at least one prior line of therapy including lenalidomide and a proteasome inhibitor multiple myeloma in combination with carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy multiple myeloma as monotherapy, in patients who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent light chain (AL) amyloidosis in combination with bortezomib, cyclophosphamide and dexamethasone in newly diagnosed patients. This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s) ( 1.2 ) Limitations of Use: DARZALEX FASPRO is not indicated and is not recommended for the treatment of patients with light chain (AL) amyloidosis who have NYHA Class IIIB or Class IV cardiac disease or Mayo Stage IIIB outside of controlled clinical trials ( 1.2 ) uuid:7bc17dd9-5fe0-46bb-afb3-a730f2777319 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2375135 biolink:treats MONDO:0019438 PMID:41385096 "[{""id"":""uuid:86b0afca-edac-455f-ab00-2c5a05042020"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e9605253-11b3-4a52-9445-a8ae266b7bd4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DARZALEX FASPRO is a combination of daratumumab, a CD38-directed cytolytic antibody, and hyaluronidase, an endoglycosidase, indicated for the treatment of adult patients with: multiple myeloma in combination with bortezomib, lenalidomide, and dexamethasone for induction and consolidation in newly diagnosed patients who are eligible for autologous stem cell transplant multiple myeloma in combination with bortezomib, melphalan and prednisone in newly diagnosed patients who are ineligible for autologous stem cell transplant multiple myeloma in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy multiple myeloma in combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for autologous stem cell transplant multiple myeloma in combination with bortezomib and dexamethasone in patients who have received at least one prior therapy multiple myeloma in combination with pomalidomide and dexamethasone in patients who have received at least one prior line of therapy including lenalidomide and a proteasome inhibitor multiple myeloma in combination with carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy multiple myeloma as monotherapy, in patients who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent light chain (AL) amyloidosis in combination with bortezomib, cyclophosphamide and dexamethasone in newly diagnosed patients. This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s) ( 1.2 ) Limitations of Use: DARZALEX FASPRO is not indicated and is not recommended for the treatment of patients with light chain (AL) amyloidosis who have NYHA Class IIIB or Class IV cardiac disease or Mayo Stage IIIB outside of controlled clinical trials ( 1.2 ) uuid:2485326b-588f-4be6-bbad-cdd3d6b68c08 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:D6OMY2L0WA biolink:treats MONDO:0018905 PMID:41385096 "[{""id"":""uuid:8baa62da-1508-47b6-92b3-d53b384719d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c6e1c08f-4b27-421f-8db5-74e195ffa772"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:4038b0ec-d2af-4326-90db-7031d149a6fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/tepkinly""]},{""id"":""uuid:b2fcde53-7b81-4af8-bf0a-0069127e1bd0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EPKINLY is a bispecific CD20-directed CD3 T-cell engager indicated for the treatment of: Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy. ( 1.1 ) Follicular Lymphoma adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. ( 1.2 ) These indications are approved under accelerated approval based on response rate and durability of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).|[EMA] Tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.|[PMDA] Drugs with a new active ingredient indicated for the treatment of relapsed or refractory large B-cell lymphoma (diffuse large B-cell lymphoma, high- grade B-cell lymphoma, and primary mediastinal large B-cell lymphoma) or relapsed or refractory follicular lymphoma. uuid:94d8b434-2771-4cc4-8ad5-e8745d712955 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:D6OMY2L0WA biolink:treats MONDO:0000901 PMID:41385096 "[{""id"":""uuid:96c6f449-62c0-4317-ad7b-98f485f12205"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:02848fc7-6643-43c5-ada7-eb45be1c71a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:acab1a4d-7d75-4d56-8690-15c5b8319404"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EPKINLY is a bispecific CD20-directed CD3 T-cell engager indicated for the treatment of: Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy. ( 1.1 ) Follicular Lymphoma adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. ( 1.2 ) These indications are approved under accelerated approval based on response rate and durability of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).|[PMDA] Drugs with a new active ingredient indicated for the treatment of relapsed or refractory large B-cell lymphoma (diffuse large B-cell lymphoma, high- grade B-cell lymphoma, and primary mediastinal large B-cell lymphoma) or relapsed or refractory follicular lymphoma. uuid:e11cc950-74ff-4a9b-9e38-bccdfb58afea biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:D6OMY2L0WA biolink:treats MONDO:0018906 PMID:41385096 "[{""id"":""uuid:1837d1f6-0ae5-462e-8d4f-8f4ff1211e4e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:fbb15cd1-8e61-4129-b3ea-7937d8c7a651"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:7d66edc2-0a9b-4d48-bd1e-340a29f30c39"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EPKINLY is a bispecific CD20-directed CD3 T-cell engager indicated for the treatment of: Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy. ( 1.1 ) Follicular Lymphoma adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. ( 1.2 ) These indications are approved under accelerated approval based on response rate and durability of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).|[PMDA] Drugs with a new active ingredient indicated for the treatment of relapsed or refractory large B-cell lymphoma (diffuse large B-cell lymphoma, high- grade B-cell lymphoma, and primary mediastinal large B-cell lymphoma) or relapsed or refractory follicular lymphoma. uuid:46b6c5de-7df3-49fa-852f-733b17a8937c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:370642 biolink:treats HP:0030858 PMID:41385096 "[{""id"":""uuid:b8381744-efeb-4cb5-a1be-8a582a8b44cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7520330d-d2c4-45eb-a744-28107184f5ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydrocodone Bitartrate and Acetaminophen Oral Solution is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, and misuse, with opioids, even at recommended doses [see WARNINGS ], reserve Hydrocodone Bitartrate and Acetaminophen Oral Solution for use in patients for whom alternative treatment options (e.g., non-opioid analgesics): have not been tolerated, or are not expected to be tolerated have not provided adequate analgesia, or are not expected to provide adequate analgesia uuid:41366d2b-40d0-4db4-8dd8-644f237a1537 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:370642 biolink:treats MONDO:0002491 PMID:41385096 "[{""id"":""uuid:5e6bad8e-7f71-457c-9632-6b678a6c8251"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a034b1f2-ba77-4d6c-9c56-72ea645458fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydrocodone Bitartrate and Acetaminophen Oral Solution is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, and misuse, with opioids, even at recommended doses [see WARNINGS ], reserve Hydrocodone Bitartrate and Acetaminophen Oral Solution for use in patients for whom alternative treatment options (e.g., non-opioid analgesics): have not been tolerated, or are not expected to be tolerated have not provided adequate analgesia, or are not expected to provide adequate analgesia uuid:4fbc51ae-60c7-4c97-83ce-1ddd21099497 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:370642 biolink:treats EFO:0011049 PMID:41385096 "[{""id"":""uuid:7b3a0945-b9b9-4aab-96f8-866d76d707b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:89a3c970-a3d5-449b-bb6a-aceff67f547e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydrocodone Bitartrate and Acetaminophen Oral Solution is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, and misuse, with opioids, even at recommended doses [see WARNINGS ], reserve Hydrocodone Bitartrate and Acetaminophen Oral Solution for use in patients for whom alternative treatment options (e.g., non-opioid analgesics): have not been tolerated, or are not expected to be tolerated have not provided adequate analgesia, or are not expected to provide adequate analgesia uuid:c2ed148f-5ff5-450a-928a-1b8d11a07730 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3374 biolink:treats MONDO:0041052 PMID:41385096 "[{""id"":""uuid:1b8b409f-cac9-44b3-8d32-48b8da400747"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:09c43bbe-1ad0-42b1-b7f9-c65ce1cac1bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] QUTENZA is indicated in adults for the treatment of neuropathic pain associated with postherpetic neuralgia (PHN) and for neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet. uuid:0d35826f-23ca-460e-9684-799e7df5644d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3374 biolink:treats UMLS:C0740447 PMID:41385096 "[{""id"":""uuid:3a0ff256-7aca-474c-90ac-85f97b5ccbe7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1b237e0e-b2ed-4cf0-8a82-fea6a8b1aaeb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] QUTENZA is indicated in adults for the treatment of neuropathic pain associated with postherpetic neuralgia (PHN) and for neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet. uuid:78167056-c23d-4805-962e-e5ff93e2c605 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:229657 biolink:treats UMLS:C5780078 PMID:41385096 "[{""id"":""uuid:648e2a2b-1ca3-4040-81cc-211451d99b1e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eeced388-c649-4e58-a316-88bbbaa21c76"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XDEMVY is indicated for the treatment of Demodex blepharitis. uuid:8b3b00aa-36a2-43b4-bb89-44a56df43685 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47657 biolink:treats UMLS:C0406317 PMID:41385096 "[{""id"":""uuid:44733ea4-0e29-4c99-96d7-92c555b9d8a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:98cde9ec-4b81-47e0-adaf-5f24fbd5de1c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZORYVE cream is a phosphodiesterase 4 inhibitor: ZORYVE cream, 0.3%, is indicated for the topical treatment of plaque psoriasis, including intertriginous areas, in adult and pediatric patients 6 years of age and older. ( 1.1 ) ZORYVE cream, 0.15%, is indicated for the topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients 6 years of age and older. ( 1.2 ) uuid:091da4ae-8283-441b-a397-b4a333ee7d04 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47657 biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:691fce8f-6dfd-43a5-9496-5ed7358db3b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:05079061-12ac-4f6e-ac4b-9459590f6350"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZORYVE cream is a phosphodiesterase 4 inhibitor: ZORYVE cream, 0.3%, is indicated for the topical treatment of plaque psoriasis, including intertriginous areas, in adult and pediatric patients 6 years of age and older. ( 1.1 ) ZORYVE cream, 0.15%, is indicated for the topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients 6 years of age and older. ( 1.2 ) uuid:0d241c2f-df53-4b54-9c39-a78bf8699d0b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0009850 PMID:41385096 "[{""id"":""uuid:3e829a20-e754-48a3-9f29-587ea551e5c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7dbc507d-ad45-425a-8ccf-67a405b15236"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ARESTIN is indicated as an adjunct to scaling and root planing procedures for reduction of pocket depth in patients with adult periodontitis. ARESTIN may be used as part of a periodontal maintenance program which includes good oral hygiene and scaling and root planing. uuid:04db67e3-f1c5-4676-94ea-09ace8dde7fd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:11476297 biolink:treats MONDO:0005388 PMID:41385096 "[{""id"":""uuid:3dbc48a9-305c-4460-a1e6-4c7beaacf0eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1fde147b-f98f-411b-90ff-944010abd5d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LIVDELZI is indicated for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have had an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA. This indication is approved under accelerated approval based on a reduction of alkaline phosphatase (ALP) [see Clinical Studies (14) ] . Improvement in survival or prevention of liver decompensation events have not been demonstrated. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). uuid:93257a89-18cf-43fe-bf2a-8e4a6c327587 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:11476297 biolink:treats MONDO:0007193 PMID:41385096 "[{""id"":""uuid:d418a965-aeba-4fb2-a0e4-785e1a192357"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8e88ada4-6994-4e29-96a9-0811f766cd1f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LIVDELZI is indicated for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have had an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA. This indication is approved under accelerated approval based on a reduction of alkaline phosphatase (ALP) [see Clinical Studies (14) ] . Improvement in survival or prevention of liver decompensation events have not been demonstrated. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). uuid:41ada97f-9ca4-4a3c-8c5a-807aca9458c4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:136034 biolink:treats MONDO:0001676 PMID:41385096 "[{""id"":""uuid:0b9baf4d-b31d-4c13-ab61-24003159ff39"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:1d7337ba-9d67-408f-9457-4ecf46c5f734"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:3018241b-bc19-47d0-b2ab-0733a2bea163"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/scenesse""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] SCENESSE ® is indicated to increase pain free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (EPP).|[EMA] Prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). uuid:58489eb6-91c6-4226-8f99-a1b2b38c0f6c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:8A7F670F2Y biolink:treats MONDO:0009114 PMID:41385096 "[{""id"":""uuid:9f105460-ae0e-4ead-9200-4d9d841534b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3210541a-0016-45d7-8247-c365cfbd3765"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sucraid ® (sacrosidase) Oral Solution is indicated for the treatment of sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency (CSID), in adult and pediatric patients 5 months of age and older. uuid:7b9a1b4c-47da-45f2-ad79-e31464e1d1d6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16724 biolink:treats HP:0001262 PMID:41385096 "[{""id"":""uuid:f028da8d-d0be-4462-a10a-21304f9aa8f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:af31eafd-d95f-421b-931a-f27be42443da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Xyrem is indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy. uuid:6ce454d2-56ef-43d6-ba6f-cc4030cebc0d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16724 biolink:treats MONDO:0021107 PMID:41385096 "[{""id"":""uuid:5e59b2c9-1432-44d4-8396-9a8f56002be4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:860f600a-2e35-413e-b679-086842d483f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Xyrem is indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy. uuid:90c5bf13-a6e7-456d-bd54-6c7ad0de9e76 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:44423 biolink:treats MONDO:0011382 PMID:41385096 "[{""id"":""uuid:c65dafef-d3b5-4722-9000-829ac6fec393"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:482e8359-4098-4006-b6bd-e8cafef3ee2b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:8bd432e0-21bc-4aff-b7ce-e3a472ade7de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/siklos""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] DROXIA is indicated to reduce the frequency of painful crises and to reduce the need for blood transfusions in patients with sickle cell anemia with recurrent moderate to severe painful crises.|[EMA] Prevention of vaso-occlusive complications of sickle cell disease in patients over 2 years of age uuid:bf2516bf-a694-49e5-8970-084568a33294 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:44423 biolink:treats MONDO:0018820 PMID:41385096 "[{""id"":""uuid:c486d638-d4c0-46c5-8e22-524bf39d5051"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:967eed5c-a5ca-4fc2-b539-c46faae8fbbf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DROXIA is indicated to reduce the frequency of painful crises and to reduce the need for blood transfusions in patients with sickle cell anemia with recurrent moderate to severe painful crises. uuid:848087f8-b284-4be5-8514-893a3a369f2a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135922 biolink:treats MONDO:0005147 PMID:41385096 "[{""id"":""uuid:62b5e055-adba-48f2-ade9-82d79358f13e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0ce41d96-8862-40a2-a008-3a2c48d9a586"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SYMLIN is indicated as an adjunctive treatment in patients with type 1 or type 2 diabetes who use mealtime insulin therapy and who have failed to achieve desired glucose control despite optimal insulin therapy. uuid:5a8b496e-b6ee-4b27-8beb-ec65389763c2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135922 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:b0275a6c-91c4-4c36-8dd3-d45dc6cf7015"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:78372232-7fe1-48f4-91a9-775d18c6c131"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SYMLIN is indicated as an adjunctive treatment in patients with type 1 or type 2 diabetes who use mealtime insulin therapy and who have failed to achieve desired glucose control despite optimal insulin therapy. uuid:1d928d3b-6399-4ff4-bf14-653d2280a270 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:231598 biolink:treats MONDO:0017387 PMID:41385096 "[{""id"":""uuid:649240cd-5707-4e78-b935-5a3ac39d5b71"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9d6fecfc-6fe4-4b17-a976-278b9bc086f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TAZVERIK is a methyltransferase inhibitor indicated for the treatment of: Adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. ( 1.1 ) Adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies. ( 1.2 ) Adult patients with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options. ( 1.2 ) These indications are approved under accelerated approval based on overall response rate and duration of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). uuid:c5eb1d71-3a90-4381-bb13-511260ebdb17 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:231598 biolink:treats MONDO:0018906 PMID:41385096 "[{""id"":""uuid:765c0717-74ee-4a02-b79e-cf6326f8c9db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:167bf2ca-c8c5-4ff9-be21-7bf12a031bc1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:5178dce9-cc26-4396-b38c-4e5c44e16fd2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TAZVERIK is a methyltransferase inhibitor indicated for the treatment of: Adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. ( 1.1 ) Adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies. ( 1.2 ) Adult patients with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options. ( 1.2 ) These indications are approved under accelerated approval based on overall response rate and duration of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).|[PMDA] A drug with a new active ingredient indicated for the treatment of relapsed or refractory EZH 2 gene mutation-positive follicular lymphoma (for use only if refractory or intolerant to standard therapies). uuid:b8f6212e-e073-4940-bcf9-b6c5695c769e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2645243 biolink:treats MONDO:0004956 PMID:41385096 "[{""id"":""uuid:b9d3da79-e765-445b-a62c-f22fdb247c95"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3b9ac9ec-b2ab-4a21-8343-38943b27697b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AKEEGA with prednisone is indicated for the treatment of adult patients with deleterious or suspected deleterious BRCA -mutated ( BRCA m) metastatic castration-resistant prostate cancer (mCRPC). Select patients for therapy based on an FDA-approved test for AKEEGA [see Dosage and Administration (2.1) ] . uuid:ffd7aea2-787a-40b7-8d2a-e862c9f664dd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:65349 biolink:treats EFO:0006865 PMID:41385096 "[{""id"":""uuid:09553a7e-b3de-4ca0-919e-9e6729b7c2c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:fb0a4a3e-c010-413b-8bdc-553109232d1c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:bcfec9ba-f952-4a2c-8f5c-d3e19e630464"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MYRBETRIQ is a beta-3 adrenergic agonist indicated for the treatment of: • Overactive bladder (OAB) in adult patients with symptoms of urge urinary incontinence, urgency, and urinary frequency, either alone or in combination with the muscarinic antagonist solifenacin succinate. ( 1.1 ) • Neurogenic detrusor overactivity (NDO) in pediatric patients aged 3 years and older and weighing 35 kg or more. ( 1.2 ) MYRBETRIQ Granules is a beta-3 adrenergic agonist indicated for the treatment of NDO in pediatric patients aged 3 years and older. ( 1.2 )|[PMDA] Drugs with a new active ingredient indicated for the treatment of urinary urgency, urinary frequency, and urge urinary incontinence associated with overactive bladder. uuid:53540a22-5315-4a6e-85c2-ea74f279e2c3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:65349 biolink:treats UMLS:C0341736 PMID:41385096 "[{""id"":""uuid:26fe2034-dfec-4a08-8605-e8f4fa5cd2b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:71379112-a83f-4173-bf6e-35019712d2aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MYRBETRIQ is a beta-3 adrenergic agonist indicated for the treatment of: • Overactive bladder (OAB) in adult patients with symptoms of urge urinary incontinence, urgency, and urinary frequency, either alone or in combination with the muscarinic antagonist solifenacin succinate. ( 1.1 ) • Neurogenic detrusor overactivity (NDO) in pediatric patients aged 3 years and older and weighing 35 kg or more. ( 1.2 ) MYRBETRIQ Granules is a beta-3 adrenergic agonist indicated for the treatment of NDO in pediatric patients aged 3 years and older. ( 1.2 ) uuid:f1cd89f9-f565-4db8-8a34-df1378836d2a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3D089V7L0K biolink:treats MONDO:0006698 PMID:41385096 "[{""id"":""uuid:53afc822-64db-4c80-b941-dda23e670d92"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9fea006b-6d44-4f1e-9342-0ce389111596"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ursodiol Capsules are indicated for patients with radiolucent, noncalcified gallbladder stones < 20 mm in greatest diameter in whom elective cholecystectomy would be undertaken except for the presence of increased surgical risk due to systemic disease, advanced age, idiosyncratic reaction to general anesthesia, or for those patients who refuse surgery. Safety of use of ursodiol capsules beyond 24 months is not established. Ursodiol capsules are indicated for the prevention of gallstone formation in obese patients experiencing rapid weight loss. uuid:10a1602b-2559-4bde-be8a-c333a52773de biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3D089V7L0K biolink:treats MONDO:0012672 PMID:41385096 "[{""id"":""uuid:0e00a30f-e660-46d6-bb54-9f352b71508c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f262394e-6ab9-4505-8816-44a153cc3a19"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ursodiol Capsules are indicated for patients with radiolucent, noncalcified gallbladder stones < 20 mm in greatest diameter in whom elective cholecystectomy would be undertaken except for the presence of increased surgical risk due to systemic disease, advanced age, idiosyncratic reaction to general anesthesia, or for those patients who refuse surgery. Safety of use of ursodiol capsules beyond 24 months is not established. Ursodiol capsules are indicated for the prevention of gallstone formation in obese patients experiencing rapid weight loss. uuid:9ab50c02-6aaf-4ec8-8c0d-943e00c15304 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5938 biolink:treats MONDO:0005301 PMID:41385096 "[{""id"":""uuid:4518e743-5695-400f-9cae-fd1d325d9d93"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f0adf36b-ea26-4f4d-aa53-f7e92dec64ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:4e1b351e-7b61-46f2-b671-7b17bb16283c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/betaferon""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] BETASERON is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.|[EMA] Betaferon is indicated for the treatment ofpatients with a single demyelinating event with an active inflammatory process, if it is severe enough to warrant treatment with intravenous corticosteroids, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite multiple sclerosis;patients with relapsing-remitting multiple sclerosis and two or more relapses within the last two years;patients with secondary progressive multiple sclerosis with active disease, evidenced by relapses. uuid:d55a2576-48ab-4d39-9864-593e8326a0bc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5938 biolink:treats UMLS:C2921627 PMID:41385096 "[{""id"":""uuid:023d1515-ad78-4cb3-9e24-d9372fb26279"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fa4a974e-9cdf-44f8-9a3d-5a9c590e53cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BETASERON is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. uuid:31cd847f-6450-4aac-a837-756284ccbb36 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5938 biolink:treats MONDO:0000450 PMID:41385096 "[{""id"":""uuid:25e2b6ca-f6f5-4801-9279-0b36bda216b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:52b33085-87e0-4131-ab4e-1aa9ab7f2fae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:081b5beb-a009-4d58-afb1-20c637cf305a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/betaferon""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] BETASERON is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.|[EMA] Betaferon is indicated for the treatment ofpatients with a single demyelinating event with an active inflammatory process, if it is severe enough to warrant treatment with intravenous corticosteroids, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite multiple sclerosis;patients with relapsing-remitting multiple sclerosis and two or more relapses within the last two years;patients with secondary progressive multiple sclerosis with active disease, evidenced by relapses. uuid:7579d382-350f-4b5c-a10b-98d3c070a5d5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75722 biolink:treats MONDO:0018362 PMID:41385096 "[{""id"":""uuid:81bc9630-3172-4ad0-b1d6-a3dfab4e115b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ce0db58d-841b-47fc-8882-7589b06d8f23"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tramadol hydrochloride extended-release tablet is indicated for the management of severe and persistent pain that requires an extended treatment period with a daily opioid analgesic and for which alternative treatment options are inadequate. Limitations of Use • Because of the risks of addiction, abuse, and misuse with opioids, which can occur at any dosages or duration, and because of the greater risks of overdose and death with extended-release opioid formulations [see Warnings and Precautions ( 5.1 )] , reserve tramadol hydrochloride extended-release tablets for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. • Tramadol hydrochloride extended-release tablet is not indicated as an as-needed (prn) analgesic. uuid:a176bc6e-968d-45e2-82f7-a2df7ffbc920 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:51368 biolink:treats MONDO:0005567 PMID:41385096 "[{""id"":""uuid:ac248c48-a92a-4660-8128-2d3911a11020"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:77b2294e-16e7-4a50-8cfc-8b72df7a355d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lofexidine tablets are indicated for mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults. uuid:ecabf277-c9d8-455e-ad2e-7b24ee5f7282 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:38RL9AE51Q biolink:treats MONDO:0005556 PMID:41385096 "[{""id"":""uuid:b3a4ec18-6635-4eae-99b4-0f039dd2409b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:88f7d718-6b7c-4002-b959-74b30842ec79"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SAPHNELO (anifrolumab-fnia) is indicated for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE), who are receiving standard therapy [see Clinical Studies (14) ] . Limitations of Use The efficacy of SAPHNELO has not been evaluated in patients with severe active lupus nephritis or severe active central nervous system lupus. Use of SAPHNELO is not recommended in these situations. uuid:e43e2707-8f15-41a4-b2a7-398aa43223f7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:38RL9AE51Q biolink:treats MONDO:0043985 PMID:41385096 "[{""id"":""uuid:7082befc-388c-48b0-9c50-e48582b6ca7c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:61aa0947-2011-443d-9997-195765a62d69"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SAPHNELO (anifrolumab-fnia) is indicated for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE), who are receiving standard therapy [see Clinical Studies (14) ] . Limitations of Use The efficacy of SAPHNELO has not been evaluated in patients with severe active lupus nephritis or severe active central nervous system lupus. Use of SAPHNELO is not recommended in these situations. uuid:48a9cfd8-36b1-4470-a649-5b4b69fb9e40 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0005062 PMID:41385096 "[{""id"":""uuid:da237941-285d-4827-9476-eb6b0e761d10"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2c80175e-5d2e-46ac-aaac-f5d80e2db345"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PredniSONE Tablets are indicated in the following conditions: Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer ​Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Aspiration pneumonitis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:b4dda332-537a-4aff-a19c-e7b9c9c134b4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27882 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:502ad033-03e6-4810-b7ad-517e63e9c8aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aece5ac0-6d49-442a-903c-d0ad557efc10"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LODOCO is indicated to reduce the risk of myocardial infarction (MI), stroke, coronary revascularization, and cardiovascular death in adult patients with established atherosclerotic disease or with multiple risk factors for cardiovascular disease. uuid:f15771e1-5821-4be9-a4e3-678ef6bc6e5e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27882 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:556f7ec9-5311-4dd7-888d-82b8ee9665d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:69ff35a9-30c5-4824-8b72-99d9b10d4ba3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LODOCO is indicated to reduce the risk of myocardial infarction (MI), stroke, coronary revascularization, and cardiovascular death in adult patients with established atherosclerotic disease or with multiple risk factors for cardiovascular disease. uuid:0e28592b-ef42-4ef7-8c97-48a0b3244731 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27882 biolink:treats MONDO:0005311 PMID:41385096 "[{""id"":""uuid:bdd37c11-a7e5-4417-beeb-7d10e92a2570"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bbf5508f-a1ed-4aae-a231-b77defd8c876"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LODOCO is indicated to reduce the risk of myocardial infarction (MI), stroke, coronary revascularization, and cardiovascular death in adult patients with established atherosclerotic disease or with multiple risk factors for cardiovascular disease. uuid:0cd21429-f739-425c-9c17-ae60e09ff541 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:44185 biolink:treats MONDO:0018944 PMID:41385096 "[{""id"":""uuid:08d29138-757f-4657-a0f0-4dbbfdadeee6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d2a0e6ef-5cea-4e0a-9a54-326ce7289e87"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methotrexate Injection is a folate analog metabolic inhibitor indicated for: • The following neoplastic diseases for the: o Treatment of adult and pediatric patients with acute lymphoblastic leukemia as part of a combination chemotherapy regimen ( 1.1 ) o Prophylaxis and treatment of adult and pediatric patients with meningeal leukemia ( 1.2 ) o Treatment of adult and pediatric patients with non-Hodgkin lymphoma ( 1.3 ) o Treatment of adult and pediatric patients with osteosarcoma as part of a combination chemotherapy regimen ( 1.4 ) o Treatment of adults with breast cancer as part of a combination chemotherapy regimen ( 1.5 ) o Treatment of adults with squamous cell carcinoma of the head and neck as single-agent ( 1.6 ) o Treatment of adults with gestational trophoblastic neoplasia as part of a combination chemotherapy regimen ( 1.7 ) • Treatment of adults with rheumatoid arthritis (RA). ( 1.8 ) • Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA). ( 1.9 ) • Treatment of adults with severe psoriasis. ( 1.10 ) uuid:9e807fd9-6b9e-4320-9d00-61b4f10dfffe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50275 biolink:treats UMLS:C0341164 PMID:41385096 "[{""id"":""uuid:677decb7-9cda-4fd7-861b-71f63109bd6d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0daabaf5-a752-491c-8e3f-be76cc6e1bfe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Esomeprazole sodium for injection is a proton pump inhibitor (PPI) indicated for the: Short-term treatment of Gastroesophageal Reflux Disease (GERD) with erosive esophagitis (EE) in adults and pediatric patients 1 month to 17 years of age, as an alternative to oral therapy when oral esomeprazole is not possible or appropriate. ( 1.1 ) Risk reduction of rebleeding of gastric or duodenal ulcers following therapeutic endoscopy for acute bleeding gastric or duodenal ulcers in adults. ( 1.2 ) uuid:6a049094-55e3-4ffe-9fb5-fc4042771ad1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50275 biolink:treats UMLS:C0155992 PMID:41385096 "[{""id"":""uuid:0a7fee8e-78d2-47fd-b518-b0dbf8f83f2e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:210e5c3a-7d34-4182-ba8b-1e4302549d6a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Esomeprazole sodium for injection is a proton pump inhibitor (PPI) indicated for the: Short-term treatment of Gastroesophageal Reflux Disease (GERD) with erosive esophagitis (EE) in adults and pediatric patients 1 month to 17 years of age, as an alternative to oral therapy when oral esomeprazole is not possible or appropriate. ( 1.1 ) Risk reduction of rebleeding of gastric or duodenal ulcers following therapeutic endoscopy for acute bleeding gastric or duodenal ulcers in adults. ( 1.2 ) uuid:778beb06-fb5f-48dd-a24d-14098db62699 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:T4H8FMA7IM biolink:treats MONDO:0019754 PMID:41385096 "[{""id"":""uuid:33d0b5b4-b071-4583-8ab4-bdf19ed907cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d10ee14b-c555-4087-82d7-14236ccbfa46"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:643cd29a-0004-4fc6-a424-221762b7eae9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/sylvant""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] SYLVANT is indicated for the treatment of patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.|[EMA] Sylvant is indicated for the treatment of adult patients with multicentric Castleman’s disease (MCD who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative., uuid:2f0cc013-2bd3-4113-adbf-e05e006676ee biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:T4H8FMA7IM biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:6f9c1900-855a-4856-902a-f0ab21e84b76"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3bd5019c-9edc-45c1-985a-ddb8ed451097"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SYLVANT is indicated for the treatment of patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative. uuid:8553e921-8358-4263-9dc1-0bc25794d1d4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:T4H8FMA7IM biolink:treats MONDO:0005187 PMID:41385096 "[{""id"":""uuid:e7a7227b-8f19-48e9-86e8-ff6eaf7cfdd2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:551b5777-cd1b-48a8-936b-9943e94aff07"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SYLVANT is indicated for the treatment of patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative. uuid:12dda17e-2a2b-4cdb-9dcb-ee2782e026d8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64355 biolink:treats UMLS:C0919659 PMID:41385096 "[{""id"":""uuid:be539f59-7c4c-4c09-8895-a18b601a9986"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c025d39f-c9a6-4709-a565-360755eb0059"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Posaconazole is an azole antifungal indicated as follows: Posaconazole delayed-release tablets are indicated for the treatment of invasive aspergillosis in adults and pediatric patients 13 years of age and older. ( 1.1 ) Posaconazole is indicated for the prophylaxis of invasive Aspergillus and Candida infections in patients who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD) or those with hematologic malignancies with prolonged neutropenia from chemotherapy as follows: ( 1.2 ) Posaconazole delayed-release tablets: adults and pediatric patients 2 years of age and older who weigh greater than 40 kg Posaconazole oral suspension: adults and pediatric patients 13 years of age and older Posaconazole oral suspension is indicated for the treatment of oropharyngeal candidiasis (OPC), including OPC refractory (rOPC) to itraconazole and/or fluconazole in adult and pediatric patients aged 13 years and older. ( 1.3 ) uuid:b40a1b9f-1fa4-41db-af66-7fe42cbb28e4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:SQ8A3S5101 biolink:treats MONDO:0002049 PMID:41385096 "[{""id"":""uuid:c0574424-c14f-4cac-8e1d-450777451d53"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:32113a1d-da8d-47e2-aaea-a943ec903db9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TAVALISSE is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. uuid:e084b26b-12b0-402d-a7e7-642081b2f5a2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:SQ8A3S5101 biolink:treats MONDO:0019098 PMID:41385096 "[{""id"":""uuid:56552d54-4e1f-403e-9c73-8905d2d51b62"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5baae57c-218d-412d-b90a-58e155891072"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:12527f5c-60aa-496b-b18d-9b29288f8d8e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:b886daa1-19aa-46dc-aaac-1af21f0dabb7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TAVALISSE is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.|[EMA] Tavlesse is indicated for the treatment of chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments.|[PMDA] Drugs with a new active ingredient indicated for the treatment of chronic idiopathic thrombocytopenic purpura. [Orphan drug] uuid:c17fb97f-cc2a-43fd-99e2-a42abf2d3344 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:B72HH48FLU biolink:treats UMLS:C2931173 PMID:41385096 "[{""id"":""uuid:27c0a4c6-f099-42c7-8d33-34907394f4da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d731436b-08ca-454c-9a44-19cab67da3dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INFLECTRA is a tumor necrosis factor (TNF) blocker indicated for: Crohn's Disease ( 1.1 ): • reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. • reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing disease. Pediatric Crohn's Disease ( 1.2 ): • reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active disease who have had an inadequate response to conventional therapy. Ulcerative Colitis ( 1.3 ): • reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. Pediatric Ulcerative Colitis ( 1.4 ): • reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active disease who have had an inadequate response to conventional therapy. Rheumatoid Arthritis ( 1.5 ) in combination with methotrexate: • reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active disease. Ankylosing Spondylitis ( 1.6 ): • reducing signs and symptoms in adult patients with active disease. Psoriatic Arthritis ( 1.7 ): • reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function in adult patients. Plaque Psoriasis ( 1.8 ): • treatment of adult patients with chronic severe (i.e., extensive and/or disabling) plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate. uuid:1fdcb009-f15e-4f01-a62a-dd4e636b1b77 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:404914 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:87740afc-5a18-4711-a5ed-e2bfbe13ecc0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5551d782-c9da-4360-84f2-d69b1732625b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amlodipine and atorvastatin tablets are indicated in patients for whom treatment with both amlodipine and atorvastatin is appropriate. Amlodipine Hypertension Amlodipine is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including amlodipine. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Amlodipine may be used alone or in combination with other antihypertensive agents. Coronary Artery Disease (CAD) Chronic Stable Angina Amlodipine is indicated for the symptomatic treatment of chronic stable angina. Amlodipine may be used alone or in combination with other antianginal agents. Vasospastic Angina (Prinzmetal’s or Variant Angina) Amlodipine is indicated for the treatment of confirmed or suspected vasospastic angina. Amlodipine may be used as monotherapy or in combination with other antianginal agents. Angiographically Documented CAD In patients with recently documented CAD by angiography and without heart failure or an ejection fraction < 40%, amlodipine is indicated to reduce the risk of hospitalization for angina and to reduce the risk of a coronary revascularization procedure. Atorvastatin Atorvastatin is indicated: To reduce the risk of: Myocardial infarction (MI), stroke, revascularization procedures, and angina in adults with multiple risk factors for coronary heart disease (CHD) but without clinically evident CHD MI and stroke in adults with type 2 diabetes mellitus with multiple risk factors for CHD but without clinically evident CHD Non-fatal MI, fatal and non-fatal stroke, revascularization procedures, hospitalization for congestive heart failure, and angina in adults with clinically evident CHD As an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in:Adults with primary hyperlipidemia.Adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH).As an adjunct to other LDL-C lowering therapies, or alone if such treatments are unavailable, to reduce LDL-C in adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia (HoFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia Hypertriglyceridemia uuid:73047d89-44c0-478d-ae7b-d7080b37874c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:404914 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:06806d36-7c8b-4a02-ba5a-7a55f830f734"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1de8d7eb-aad7-4074-aa43-e758a34c3f4e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amlodipine and atorvastatin tablets are indicated in patients for whom treatment with both amlodipine and atorvastatin is appropriate. Amlodipine Hypertension Amlodipine is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including amlodipine. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Amlodipine may be used alone or in combination with other antihypertensive agents. Coronary Artery Disease (CAD) Chronic Stable Angina Amlodipine is indicated for the symptomatic treatment of chronic stable angina. Amlodipine may be used alone or in combination with other antianginal agents. Vasospastic Angina (Prinzmetal’s or Variant Angina) Amlodipine is indicated for the treatment of confirmed or suspected vasospastic angina. Amlodipine may be used as monotherapy or in combination with other antianginal agents. Angiographically Documented CAD In patients with recently documented CAD by angiography and without heart failure or an ejection fraction < 40%, amlodipine is indicated to reduce the risk of hospitalization for angina and to reduce the risk of a coronary revascularization procedure. Atorvastatin Atorvastatin is indicated: To reduce the risk of: Myocardial infarction (MI), stroke, revascularization procedures, and angina in adults with multiple risk factors for coronary heart disease (CHD) but without clinically evident CHD MI and stroke in adults with type 2 diabetes mellitus with multiple risk factors for CHD but without clinically evident CHD Non-fatal MI, fatal and non-fatal stroke, revascularization procedures, hospitalization for congestive heart failure, and angina in adults with clinically evident CHD As an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in:Adults with primary hyperlipidemia.Adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH).As an adjunct to other LDL-C lowering therapies, or alone if such treatments are unavailable, to reduce LDL-C in adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia (HoFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia Hypertriglyceridemia uuid:66ec919d-b01b-4fe0-8e08-9dce173a3d17 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:404914 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:6f92a0e2-8928-4ab0-955b-d85b6285cd50"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d0fee3cc-3230-4c65-958b-b4aa79a367ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amlodipine and atorvastatin tablets are indicated in patients for whom treatment with both amlodipine and atorvastatin is appropriate. Amlodipine Hypertension Amlodipine is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including amlodipine. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Amlodipine may be used alone or in combination with other antihypertensive agents. Coronary Artery Disease (CAD) Chronic Stable Angina Amlodipine is indicated for the symptomatic treatment of chronic stable angina. Amlodipine may be used alone or in combination with other antianginal agents. Vasospastic Angina (Prinzmetal’s or Variant Angina) Amlodipine is indicated for the treatment of confirmed or suspected vasospastic angina. Amlodipine may be used as monotherapy or in combination with other antianginal agents. Angiographically Documented CAD In patients with recently documented CAD by angiography and without heart failure or an ejection fraction < 40%, amlodipine is indicated to reduce the risk of hospitalization for angina and to reduce the risk of a coronary revascularization procedure. Atorvastatin Atorvastatin is indicated: To reduce the risk of: Myocardial infarction (MI), stroke, revascularization procedures, and angina in adults with multiple risk factors for coronary heart disease (CHD) but without clinically evident CHD MI and stroke in adults with type 2 diabetes mellitus with multiple risk factors for CHD but without clinically evident CHD Non-fatal MI, fatal and non-fatal stroke, revascularization procedures, hospitalization for congestive heart failure, and angina in adults with clinically evident CHD As an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in:Adults with primary hyperlipidemia.Adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH).As an adjunct to other LDL-C lowering therapies, or alone if such treatments are unavailable, to reduce LDL-C in adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia (HoFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia Hypertriglyceridemia uuid:d2a3ee1e-7213-427c-a78b-903e6c8a7893 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:404914 biolink:treats UMLS:C0342882 PMID:41385096 "[{""id"":""uuid:ffefa0c8-3d5e-4529-8b80-3000f7bbeff9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4f23a9d1-822e-4fef-b859-4f1fd23969dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amlodipine and atorvastatin tablets are indicated in patients for whom treatment with both amlodipine and atorvastatin is appropriate. Amlodipine Hypertension Amlodipine is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including amlodipine. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Amlodipine may be used alone or in combination with other antihypertensive agents. Coronary Artery Disease (CAD) Chronic Stable Angina Amlodipine is indicated for the symptomatic treatment of chronic stable angina. Amlodipine may be used alone or in combination with other antianginal agents. Vasospastic Angina (Prinzmetal’s or Variant Angina) Amlodipine is indicated for the treatment of confirmed or suspected vasospastic angina. Amlodipine may be used as monotherapy or in combination with other antianginal agents. Angiographically Documented CAD In patients with recently documented CAD by angiography and without heart failure or an ejection fraction < 40%, amlodipine is indicated to reduce the risk of hospitalization for angina and to reduce the risk of a coronary revascularization procedure. Atorvastatin Atorvastatin is indicated: To reduce the risk of: Myocardial infarction (MI), stroke, revascularization procedures, and angina in adults with multiple risk factors for coronary heart disease (CHD) but without clinically evident CHD MI and stroke in adults with type 2 diabetes mellitus with multiple risk factors for CHD but without clinically evident CHD Non-fatal MI, fatal and non-fatal stroke, revascularization procedures, hospitalization for congestive heart failure, and angina in adults with clinically evident CHD As an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in:Adults with primary hyperlipidemia.Adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH).As an adjunct to other LDL-C lowering therapies, or alone if such treatments are unavailable, to reduce LDL-C in adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia (HoFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia Hypertriglyceridemia uuid:4179619d-10c9-4d7f-8b35-cdd7cbe1fbda biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:37943 biolink:treats UMLS:C0275518 PMID:41385096 "[{""id"":""uuid:100e9ca8-6059-498c-9ced-122b3609e4a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:87eb3631-9d07-48a1-82c0-c4b4e9c7a632"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Colistimethate for Injection, USP is indicated for the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli. It is particularly indicated when the infection is caused by sensitive strains of Pseudomonas aeruginosa . This antibiotic is not indicated for infections due to Proteus or Neisseria . Colistimethate for Injection, USP has proven clinically effective in treatment of infections due to the following gram-negative organisms: Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa. Colistimethate for Injection, USP may be used to initiate therapy in serious infections that are suspected to be due to gram-negative organisms and in the treatment of infections due to susceptible gram-negative pathogenic bacilli. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Colistimethate for Injection, USP and other antibacterial drugs, Colistimethate for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:b54526c7-043b-4217-863b-4e138f4bc1bb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C4547518 biolink:treats MONDO:0010122 PMID:41385096 "[{""id"":""uuid:6f036fa0-d6b2-4981-af58-162ec32708b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:81050067-e1bc-4ce2-a401-1af1946fc9fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:4454338f-dc2a-4a67-9254-9aa7ee5530a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ADZYNMA (ADAMTS13, recombinant-krhn) is a human recombinant “A disintegrin and metalloproteinase with thrombospondin motifs 13” (rADAMTS13) indicated for prophylactic or on demand enzyme replacement therapy (ERT) in adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP) [see Use in Specific Populations (8.4) , Clinical Studies (14) ].|[PMDA] A drug with a new active ingredient indicated for the treatment of congenital thrombotic thrombocytopenic purpura. [Orphan drug] DRUGBANK:DB15164 uuid:3eea8c3e-7393-404b-b87b-f215b4099e1b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:65349 biolink:treats HP:0100515 PMID:41385096 "[{""id"":""uuid:ee887a71-1775-44ef-b23e-086e235cb3cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2c0d90cd-3d45-4510-8814-e08ea03c2af5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:4b45ee85-9250-4bcd-9cf6-22495af435e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mirabegron extended-release tablets are beta-3 adrenergic agonist indicated for the treatment of: Overactive bladder (OAB) in adult patients with symptoms of urge urinary incontinence, urgency, and urinary frequency. ( 1.1 )|[PMDA] Drugs with a new active ingredient indicated for the treatment of urinary urgency, urinary frequency, and urge urinary incontinence associated with overactive bladder. uuid:c0c33b0b-a19a-4a50-b564-0138bffdf67f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB16802 biolink:treats MONDO:0010679 PMID:41385096 "[{""id"":""uuid:30cbbca6-9379-43a7-9c5c-8e45db577fe4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d3710bda-b7c3-4e76-b959-e4df593d13cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ELEVIDYS is indicated for the treatment of Duchenne muscular dystrophy (DMD) in individuals at least 4 years of age: For patients who are ambulatory and have a confirmed mutation in the DMD gene [see Clinical Pharmacology ( 12.2 ), Clinical Studies ( 14 ) ] For patients who are non-ambulatory and have a confirmed mutation in the DMD gene. The DMD indication in non-ambulatory patients is approved under accelerated approval based on expression of ELEVIDYS micro-dystrophin (noted hereafter as “micro-dystrophin”) in skeletal muscle. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). [see Clinical Pharmacology ( 12.2 )]. uuid:ab8166c7-9d57-4029-89b3-524a9a679084 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB11597 biolink:treats MONDO:0008558 PMID:41385096 "[{""id"":""uuid:dd6a7c7a-363e-4879-bc73-31f1f7f85a86"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9107aeba-27c6-46e0-8b4e-58fcd6db3606"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] WinRho ® SDF is a Rh o (D) Immune Globulin Intravenous (Human) (anti-D) product that is indicated for the treatment of ITP in Rh o (D)-positive patients and for the suppression of Rh isoimmunization in non-sensitized Rh o (D)-negative patients. uuid:c402fa0c-f29e-4fa7-9b18-93ba9e755437 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB11597 biolink:treats MONDO:0006953 PMID:41385096 "[{""id"":""uuid:33e5e8aa-5628-400c-bd6f-f78fd8670adf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dd7ce3bb-a8f8-4522-974f-b1c26f794f35"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] WinRho ® SDF is a Rh o (D) Immune Globulin Intravenous (Human) (anti-D) product that is indicated for the treatment of ITP in Rh o (D)-positive patients and for the suppression of Rh isoimmunization in non-sensitized Rh o (D)-negative patients. uuid:ca737d16-3c5c-4ad3-92ed-7187ab2b31eb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats MONDO:0040732 PMID:41385096 "[{""id"":""uuid:0de56ad7-3992-4ea0-9a40-d3aef45249c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:096bfae2-3c2e-4c3a-a844-40e108fc38f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of gentamicin and other antibacterial drugs, gentamicin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Gentamicin Sulfate Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: Pseudomonas aeruginosa , Proteus species (indole-positive and indole-negative), Escherichia coli , Klebsiella-Enterobacter-Serratia species, Citrobacter species, and Staphylococcus species (coagulase-positive and coagulase-negative). Clinical studies have shown Gentamicin Sulfate Injection, USP to be effective in bacterial neonatal sepsis; bacterial septicemia; and serious bacterial infections of the central nervous system (meningitis), urinary tract, respiratory tract, gastrointestinal tract (including peritonitis), skin, bone and soft tissue (including burns). Aminoglycosides, including gentamicin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are susceptible to these antibiotics and are not susceptible to antibiotics having less potential for toxicity. Specimens for bacterial culture should be obtained to isolate and identify causative organisms and to determine their susceptibility to gentamicin. Gentamicin sulfate may be considered as initial therapy in suspected or confirmed gram-negative infections, and therapy may be instituted before obtaining results of susceptibility testing. The decision to continue therapy with this drug should be based on the results of susceptibility tests, the severity of the infection, and the important additional concepts contained in the WARNINGS box . If the causative organisms are resistant to gentamicin, other appropriate therapy should be instituted. In serious infections when the causative organisms are unknown, gentamicin sulfate may be administered as initial therapy in conjunction with a penicillin-type or cephalosporin-type drug before obtaining results of susceptibility testing. If anaerobic organisms are suspected as etiologic agents, consideration should be given to using other suitable antimicrobial therapy in conjunction with gentamicin. Following identification of the organism and its susceptibility, appropriate antibiotic therapy should then be continued. Gentamicin sulfate has been used effectively in combination with carbenicillin for the treatment of life-threatening infections caused by Pseudomonas aeruginosa . It has also been found effective when used in conjunction with a penicillin-type drug for the treatment of endocarditis caused by group D streptococci. Gentamicin Sulfate Injection, USP has also been shown to be effective in the treatment of serious staphylococcal infections. While not the antibiotic of first choice, gentamicin may be considered when penicillins or other less potentially toxic drugs are contraindicated and bacterial susceptibility tests and clinical judgment indicate its use. It may also be considered in mixed infections caused by susceptible strains of staphylococci and gram-negative organisms. In the neonate with suspected bacterial sepsis or staphylococcal pneumonia, a penicillin-type drug is also usually indicated as concomitant therapy with gentamicin. uuid:7c62bfb9-e354-4c78-b671-8d9a03de173d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats MONDO:0006929 PMID:41385096 "[{""id"":""uuid:a60e76f3-68e0-4748-9de0-0cdb2a3c790c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:09268b8f-7f2d-43d9-87cd-fdb2ac6e5656"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of gentamicin and other antibacterial drugs, gentamicin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Gentamicin Sulfate Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: Pseudomonas aeruginosa , Proteus species (indole-positive and indole-negative), Escherichia coli , Klebsiella-Enterobacter-Serratia species, Citrobacter species, and Staphylococcus species (coagulase-positive and coagulase-negative). Clinical studies have shown Gentamicin Sulfate Injection, USP to be effective in bacterial neonatal sepsis; bacterial septicemia; and serious bacterial infections of the central nervous system (meningitis), urinary tract, respiratory tract, gastrointestinal tract (including peritonitis), skin, bone and soft tissue (including burns). Aminoglycosides, including gentamicin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are susceptible to these antibiotics and are not susceptible to antibiotics having less potential for toxicity. Specimens for bacterial culture should be obtained to isolate and identify causative organisms and to determine their susceptibility to gentamicin. Gentamicin sulfate may be considered as initial therapy in suspected or confirmed gram-negative infections, and therapy may be instituted before obtaining results of susceptibility testing. The decision to continue therapy with this drug should be based on the results of susceptibility tests, the severity of the infection, and the important additional concepts contained in the WARNINGS box . If the causative organisms are resistant to gentamicin, other appropriate therapy should be instituted. In serious infections when the causative organisms are unknown, gentamicin sulfate may be administered as initial therapy in conjunction with a penicillin-type or cephalosporin-type drug before obtaining results of susceptibility testing. If anaerobic organisms are suspected as etiologic agents, consideration should be given to using other suitable antimicrobial therapy in conjunction with gentamicin. Following identification of the organism and its susceptibility, appropriate antibiotic therapy should then be continued. Gentamicin sulfate has been used effectively in combination with carbenicillin for the treatment of life-threatening infections caused by Pseudomonas aeruginosa . It has also been found effective when used in conjunction with a penicillin-type drug for the treatment of endocarditis caused by group D streptococci. Gentamicin Sulfate Injection, USP has also been shown to be effective in the treatment of serious staphylococcal infections. While not the antibiotic of first choice, gentamicin may be considered when penicillins or other less potentially toxic drugs are contraindicated and bacterial susceptibility tests and clinical judgment indicate its use. It may also be considered in mixed infections caused by susceptible strains of staphylococci and gram-negative organisms. In the neonate with suspected bacterial sepsis or staphylococcal pneumonia, a penicillin-type drug is also usually indicated as concomitant therapy with gentamicin. uuid:84740457-9344-4f55-898d-ccd4a5643e9c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats MONDO:0020920 PMID:41385096 "[{""id"":""uuid:265629ce-b63e-4892-85df-f96b080eea4e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f3fd37f5-3b35-49e5-8e8a-91624bad47b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of gentamicin and other antibacterial drugs, gentamicin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Gentamicin Sulfate Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: Pseudomonas aeruginosa , Proteus species (indole-positive and indole-negative), Escherichia coli , Klebsiella-Enterobacter-Serratia species, Citrobacter species, and Staphylococcus species (coagulase-positive and coagulase-negative). Clinical studies have shown Gentamicin Sulfate Injection, USP to be effective in bacterial neonatal sepsis; bacterial septicemia; and serious bacterial infections of the central nervous system (meningitis), urinary tract, respiratory tract, gastrointestinal tract (including peritonitis), skin, bone and soft tissue (including burns). Aminoglycosides, including gentamicin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are susceptible to these antibiotics and are not susceptible to antibiotics having less potential for toxicity. Specimens for bacterial culture should be obtained to isolate and identify causative organisms and to determine their susceptibility to gentamicin. Gentamicin sulfate may be considered as initial therapy in suspected or confirmed gram-negative infections, and therapy may be instituted before obtaining results of susceptibility testing. The decision to continue therapy with this drug should be based on the results of susceptibility tests, the severity of the infection, and the important additional concepts contained in the WARNINGS box . If the causative organisms are resistant to gentamicin, other appropriate therapy should be instituted. In serious infections when the causative organisms are unknown, gentamicin sulfate may be administered as initial therapy in conjunction with a penicillin-type or cephalosporin-type drug before obtaining results of susceptibility testing. If anaerobic organisms are suspected as etiologic agents, consideration should be given to using other suitable antimicrobial therapy in conjunction with gentamicin. Following identification of the organism and its susceptibility, appropriate antibiotic therapy should then be continued. Gentamicin sulfate has been used effectively in combination with carbenicillin for the treatment of life-threatening infections caused by Pseudomonas aeruginosa . It has also been found effective when used in conjunction with a penicillin-type drug for the treatment of endocarditis caused by group D streptococci. Gentamicin Sulfate Injection, USP has also been shown to be effective in the treatment of serious staphylococcal infections. While not the antibiotic of first choice, gentamicin may be considered when penicillins or other less potentially toxic drugs are contraindicated and bacterial susceptibility tests and clinical judgment indicate its use. It may also be considered in mixed infections caused by susceptible strains of staphylococci and gram-negative organisms. In the neonate with suspected bacterial sepsis or staphylococcal pneumonia, a penicillin-type drug is also usually indicated as concomitant therapy with gentamicin. uuid:31d696cc-2360-4d36-b2d3-46cc48e9bf62 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats MONDO:0030603 PMID:41385096 "[{""id"":""uuid:cb77adeb-1a21-49ba-b9c7-49ab10ce7412"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:00c505fb-130a-43eb-88bb-f948e3242066"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of gentamicin and other antibacterial drugs, gentamicin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Gentamicin Sulfate Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: Pseudomonas aeruginosa , Proteus species (indole-positive and indole-negative), Escherichia coli , Klebsiella-Enterobacter-Serratia species, Citrobacter species, and Staphylococcus species (coagulase-positive and coagulase-negative). Clinical studies have shown Gentamicin Sulfate Injection, USP to be effective in bacterial neonatal sepsis; bacterial septicemia; and serious bacterial infections of the central nervous system (meningitis), urinary tract, respiratory tract, gastrointestinal tract (including peritonitis), skin, bone and soft tissue (including burns). Aminoglycosides, including gentamicin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are susceptible to these antibiotics and are not susceptible to antibiotics having less potential for toxicity. Specimens for bacterial culture should be obtained to isolate and identify causative organisms and to determine their susceptibility to gentamicin. Gentamicin sulfate may be considered as initial therapy in suspected or confirmed gram-negative infections, and therapy may be instituted before obtaining results of susceptibility testing. The decision to continue therapy with this drug should be based on the results of susceptibility tests, the severity of the infection, and the important additional concepts contained in the WARNINGS box . If the causative organisms are resistant to gentamicin, other appropriate therapy should be instituted. In serious infections when the causative organisms are unknown, gentamicin sulfate may be administered as initial therapy in conjunction with a penicillin-type or cephalosporin-type drug before obtaining results of susceptibility testing. If anaerobic organisms are suspected as etiologic agents, consideration should be given to using other suitable antimicrobial therapy in conjunction with gentamicin. Following identification of the organism and its susceptibility, appropriate antibiotic therapy should then be continued. Gentamicin sulfate has been used effectively in combination with carbenicillin for the treatment of life-threatening infections caused by Pseudomonas aeruginosa . It has also been found effective when used in conjunction with a penicillin-type drug for the treatment of endocarditis caused by group D streptococci. Gentamicin Sulfate Injection, USP has also been shown to be effective in the treatment of serious staphylococcal infections. While not the antibiotic of first choice, gentamicin may be considered when penicillins or other less potentially toxic drugs are contraindicated and bacterial susceptibility tests and clinical judgment indicate its use. It may also be considered in mixed infections caused by susceptible strains of staphylococci and gram-negative organisms. In the neonate with suspected bacterial sepsis or staphylococcal pneumonia, a penicillin-type drug is also usually indicated as concomitant therapy with gentamicin. uuid:9f0bdcd2-0282-4e56-9cee-214343a43de8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats MONDO:0005545 PMID:41385096 "[{""id"":""uuid:b23027d2-a6f9-4b69-a6bc-bece43d83b2d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9aaae467-a503-4fc9-bf11-40b5a66375e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of gentamicin and other antibacterial drugs, gentamicin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Gentamicin Sulfate Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: Pseudomonas aeruginosa , Proteus species (indole-positive and indole-negative), Escherichia coli , Klebsiella-Enterobacter-Serratia species, Citrobacter species, and Staphylococcus species (coagulase-positive and coagulase-negative). Clinical studies have shown Gentamicin Sulfate Injection, USP to be effective in bacterial neonatal sepsis; bacterial septicemia; and serious bacterial infections of the central nervous system (meningitis), urinary tract, respiratory tract, gastrointestinal tract (including peritonitis), skin, bone and soft tissue (including burns). Aminoglycosides, including gentamicin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are susceptible to these antibiotics and are not susceptible to antibiotics having less potential for toxicity. Specimens for bacterial culture should be obtained to isolate and identify causative organisms and to determine their susceptibility to gentamicin. Gentamicin sulfate may be considered as initial therapy in suspected or confirmed gram-negative infections, and therapy may be instituted before obtaining results of susceptibility testing. The decision to continue therapy with this drug should be based on the results of susceptibility tests, the severity of the infection, and the important additional concepts contained in the WARNINGS box . If the causative organisms are resistant to gentamicin, other appropriate therapy should be instituted. In serious infections when the causative organisms are unknown, gentamicin sulfate may be administered as initial therapy in conjunction with a penicillin-type or cephalosporin-type drug before obtaining results of susceptibility testing. If anaerobic organisms are suspected as etiologic agents, consideration should be given to using other suitable antimicrobial therapy in conjunction with gentamicin. Following identification of the organism and its susceptibility, appropriate antibiotic therapy should then be continued. Gentamicin sulfate has been used effectively in combination with carbenicillin for the treatment of life-threatening infections caused by Pseudomonas aeruginosa . It has also been found effective when used in conjunction with a penicillin-type drug for the treatment of endocarditis caused by group D streptococci. Gentamicin Sulfate Injection, USP has also been shown to be effective in the treatment of serious staphylococcal infections. While not the antibiotic of first choice, gentamicin may be considered when penicillins or other less potentially toxic drugs are contraindicated and bacterial susceptibility tests and clinical judgment indicate its use. It may also be considered in mixed infections caused by susceptible strains of staphylococci and gram-negative organisms. In the neonate with suspected bacterial sepsis or staphylococcal pneumonia, a penicillin-type drug is also usually indicated as concomitant therapy with gentamicin. uuid:37c7f2d1-4942-4600-8478-bd2aed64e889 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:Z80293URPV biolink:treats MONDO:0005314 PMID:41385096 "[{""id"":""uuid:c449be26-f0f5-47a7-8931-3be1d59dd59d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f607e88d-4566-4b07-b7cf-80fc813c5a53"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZEPOSIA is indicated for the treatment of: • relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. • moderately to severely active ulcerative colitis (UC) in adults. uuid:107404b6-818d-4438-af27-62ae520667c4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:Z80293URPV biolink:treats UMLS:C2921627 PMID:41385096 "[{""id"":""uuid:35d41b50-8e3d-45f5-bf75-b6d0c29b684f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0bdf55a2-3203-4602-8d7f-856f1d1a7c27"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZEPOSIA is indicated for the treatment of: • relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. • moderately to severely active ulcerative colitis (UC) in adults. uuid:2c784e65-d0df-47d2-8eff-e031677f65b1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:Z80293URPV biolink:treats MONDO:0000450 PMID:41385096 "[{""id"":""uuid:22e86fda-76c9-40ec-bcd9-15be6e7e1ec1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3ddd5d8d-75f6-49db-9d05-13f8583c2f79"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZEPOSIA is indicated for the treatment of: • relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. • moderately to severely active ulcerative colitis (UC) in adults. uuid:4134296a-f3b4-40fd-9d5e-1d8439bc639e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:Z80293URPV biolink:treats MONDO:0005101 PMID:41385096 "[{""id"":""uuid:9ac303d7-13e4-4933-aa7e-3e465e599af3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:93430103-8a80-4b77-a0ab-2618051f5e52"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZEPOSIA is indicated for the treatment of: • relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. • moderately to severely active ulcerative colitis (UC) in adults. uuid:da9f96b6-36f4-4950-ba74-10150dea5dd4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:129011819 biolink:treats MONDO:0005382 PMID:41385096 "[{""id"":""uuid:ae345e30-5602-4d7b-b1e0-589312cf338f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4b22d6b3-557a-4917-a363-4dad9522e46a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Miacalcin synthetic injection is a calcitonin, indicated for the following conditions: • Treatment of symptomatic Paget’s disease of bone when alternative treatments are not suitable ( 1.1 ) • Treatment of hypercalcemia ( 1.2 ) • Treatment of postmenopausal osteoporosis when alternative treatments are not suitable. Fracture reduction efficacy has not been demonstrated ( 1.3 ) Limitations of Use: • Due to the possible association between malignancy and calcitonin salmon use, the need for continued therapy should be re-evaluated on a periodic basis ( 1.4 , 5.3 ) uuid:00291ac9-3246-4b6a-9ffd-b1635510dcdb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:129011819 biolink:treats MONDO:0001566 PMID:41385096 "[{""id"":""uuid:542fe63e-83ba-4fd2-a790-fddadb6e5f09"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:742ea0e8-7302-440b-8430-025278c50e36"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Miacalcin synthetic injection is a calcitonin, indicated for the following conditions: • Treatment of symptomatic Paget’s disease of bone when alternative treatments are not suitable ( 1.1 ) • Treatment of hypercalcemia ( 1.2 ) • Treatment of postmenopausal osteoporosis when alternative treatments are not suitable. Fracture reduction efficacy has not been demonstrated ( 1.3 ) Limitations of Use: • Due to the possible association between malignancy and calcitonin salmon use, the need for continued therapy should be re-evaluated on a periodic basis ( 1.4 , 5.3 ) uuid:8302efe6-056a-4076-9e18-1ab40df56ab5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4753 biolink:treats HP:0007906 PMID:41385096 "[{""id"":""uuid:4a1b2786-41af-42fe-856a-3f051dea5117"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b2e5047c-878d-4c12-999b-bff505cfb860"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Echothiophate iodide for ophthalmic solution is indicated for the reduction of elevated IOP. uuid:c4c4ba74-db53-4052-a8c9-54a881634ebb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4495 biolink:treats MONDO:0005893 PMID:41385096 "[{""id"":""uuid:e3723eb5-c02a-400c-b136-656c862f41f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8f011956-9299-4522-afec-9c44463dc8a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diazoxide oral suspension is indicated for the management of hypoglycemia due to hyperinsulinism associated with the following conditions: Adults: Inoperable islet cell adenoma or carcinoma, or extrapancreatic malignancy. Infants and children: Leucine sensitivity, islet cell hyperplasia, nesidioblastosis, extrapancreatic malignancy, islet cell adenoma, or adenomatosis. Diazoxide oral suspension may be used preoperatively as a temporary measure, and postoperatively, if hypoglycemia persists. Diazoxide oral suspension should be used only after a diagnosis of hypoglycemia due to one of the above conditions has been definitely established. When other specific medical therapy or surgical management either has been unsuccessful or is not feasible, treatment with diazoxide oral suspension should be considered. uuid:2447115e-587e-48fe-a3c5-4e2f7a65a096 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49701 biolink:treats MONDO:0004375 PMID:41385096 "[{""id"":""uuid:41902b60-4399-4173-8e7c-6fe784765e46"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:52a9287b-afd4-458c-a4ec-d1f4ff325c09"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LANTHANUM CARBONATE is a phosphate binder indicated to reduce serum phosphate in patients with end-stage renal disease (ESRD). Management of elevated serum phosphorus levels in patients with ESRD usually includes all of the following: reduction in dietary intake of phosphate, removal of phosphate by dialysis, and reduction of intestinal phosphate absorption with phosphate binders. uuid:1a9f3367-58ef-4be0-8b1b-bde3b4d9ed67 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49701 biolink:treats MONDO:0000328 PMID:41385096 "[{""id"":""uuid:748eee2e-0cc5-49f4-a7b2-ed24fb2603fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:93a135d0-2895-4aec-975f-cabf0c2a0e8d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LANTHANUM CARBONATE is a phosphate binder indicated to reduce serum phosphate in patients with end-stage renal disease (ESRD). Management of elevated serum phosphorus levels in patients with ESRD usually includes all of the following: reduction in dietary intake of phosphate, removal of phosphate by dialysis, and reduction of intestinal phosphate absorption with phosphate binders. uuid:1e36abcd-1f2c-4aab-b529-80ed6d448529 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1368399 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:d2d7a557-6901-4878-93a7-38bc66d6ad04"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c6b738b2-2e1f-4438-8974-0e9215bdf487"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:be7f470f-d565-467e-b7bb-11476daa7ebf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/incresync""]},{""id"":""uuid:8ce1b3d1-0b7f-4079-85c3-e21a30f2977d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Alogliptin and pioglitazone tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus .|[EMA] Incresync is indicated as a second- or third-line treatment in adult patients aged 18 years and older with type-2 diabetes mellitus:, , , as an adjunct to diet and exercise to improve glycaemic control in adult patients (particularly overweight patients) inadequately controlled on pioglitazone alone, and for whom metformin is inappropriate due to contraindications or intolerance;, in combination with metformin (i.e. triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in adult patients (particularly overweight patients) inadequately controlled on their maximal tolerated dose of metformin and pioglitazone., , , In addition, Incresync can be used to replace separate tablets of alogliptin and pioglitazone in those adult patients aged 18 years and older with type-2 diabetes mellitus already being treated with this combination., , After initiation of therapy with Incresync, patients should be reviewed after three to six months to assess adequacy of response to treatment (e.g. reduction in HbA1c). In patients who fail to show an adequate response, Incresync should be discontinued. In light of potential risks with prolonged pioglitazone therapy, prescribers should confirm at subsequent routine reviews that the benefit of Incresync is maintained (see section 4.4).,|[PMDA] New combination drugs indicated for the treatment of type 2 diabetes mellitus. uuid:e0b17715-7b76-451f-86a7-12206321934d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7852 biolink:treats UMLS:C0278140 PMID:41385096 "[{""id"":""uuid:21bacd4e-b01a-4db3-b038-7f928368468e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:27ac370d-517e-4711-a569-3519f0b736bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ROXYBOND is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. uuid:93d32c8e-cf23-4c94-8aaa-d38780b35180 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22652 biolink:treats MONDO:0001700 PMID:41385096 "[{""id"":""uuid:695819b4-5818-49d4-a8e2-2b64f855530a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9c9d4c52-df58-41ce-9a71-0f387fc99de1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dexatran™ is indicated to provide dietary management for men and women. Folic acid is effective in the treatment of megaloblastic anemias due to a deficiency of folic acid (as may be seen in tropical or nontropical sprue) and in anemias of nutritional origin, pregnancy, infancy, or childhood. uuid:e5971da2-9b51-4754-8dae-bd2c520d76bd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22652 biolink:treats UMLS:C0271903 PMID:41385096 "[{""id"":""uuid:76bf5763-f6ec-4c50-b5a8-a862c3c821fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:913386de-a7e2-4777-a8ce-5b1f1140b4ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dexatran™ is indicated to provide dietary management for men and women. Folic acid is effective in the treatment of megaloblastic anemias due to a deficiency of folic acid (as may be seen in tropical or nontropical sprue) and in anemias of nutritional origin, pregnancy, infancy, or childhood. uuid:728ddb73-b59d-407c-88cc-b2b29df27055 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:0J8RN2W0HK biolink:treats MONDO:0011438 PMID:41385096 "[{""id"":""uuid:9fd1b801-7227-4080-8b7c-89bce76a6f76"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4d62f668-e9b8-4a32-9e9a-b99998a0bdf9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AKLIEF Cream is a retinoid indicated for the topical treatment of acne vulgaris in patients 9 years of age and older. uuid:f9392ef5-0a98-4c01-9cf5-035b189f8e74 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C4753601 biolink:treats MONDO:0020511 PMID:41385096 "[{""id"":""uuid:c9a62991-29fa-49ef-aafc-8181dc189fb6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:9e9430bd-5a44-4f04-8618-a8800e5d706d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:91d33af1-c34f-42ee-9937-c3854d2d7e65"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/besponsa""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] BESPONSA is indicated for the treatment of relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients 1 year and older .|[EMA] Besponsa is indicated as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B cell precursor acute lymphoblastic leukaemia (ALL). Adult patients with Philadelphia chromosome positive (Ph+) relapsed or refractory B cell precursor ALL should have failed treatment with at least 1 tyrosine kinase inhibitor (TKI). uuid:7ccdf91c-bf96-480f-8527-578996729d9a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C4753601 biolink:treats MONDO:0004967 PMID:41385096 "[{""id"":""uuid:c24f7454-06de-4644-aded-9bf6dc57d398"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2d895bda-c277-42b2-8a5c-e20e09c081ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BESPONSA is indicated for the treatment of relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients 1 year and older . uuid:466a33b2-5fbb-442a-a9fe-0c328a359dad biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:AHU547PI9H biolink:treats MONDO:0001356 PMID:41385096 "[{""id"":""uuid:9ede152a-9b76-45cd-9204-20f1c6ac2217"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:19c4f598-bed3-46c5-8e2a-2029816f6d9f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Monoferric is indicated for the treatment of iron deficiency anemia (IDA) in adult patients: who have intolerance to oral iron or have had unsatisfactory response to oral iron who have non-hemodialysis dependent chronic kidney disease (NDD-CKD) uuid:f4bfca74-44f1-49c8-b0ad-f923e5c8f3f0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:AHU547PI9H biolink:treats MONDO:0005300 PMID:41385096 "[{""id"":""uuid:498a8216-ed04-4e1a-a7f1-3239af8fdb31"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:346b483a-c5eb-4444-8c9d-c0a07e944267"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Monoferric is indicated for the treatment of iron deficiency anemia (IDA) in adult patients: who have intolerance to oral iron or have had unsatisfactory response to oral iron who have non-hemodialysis dependent chronic kidney disease (NDD-CKD) uuid:494f1d82-f76d-4550-b857-a777609b1f1f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2611258 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:1f129673-68e0-45fb-a252-b71fa1febee2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0e3cee2e-fa8d-42a0-aa09-71b93e6d892a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AUVELITY is indicated for the treatment of major depressive disorder (MDD) in adults. uuid:26bc66f8-029b-4758-971f-7232412e17fd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:145430 biolink:treats MONDO:0018874 PMID:41385096 "[{""id"":""uuid:5ac42c0c-8816-424b-b781-ab73ed30c3e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d39c2add-b112-420a-ac54-2ecd8d2783fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:6bc9c80e-6060-4ee2-a49d-52081402dc36"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/tibsovo-0""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] TIBSOVO is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for patients with a susceptible IDH1 mutation as detected by an FDA-approved test with: Newly Diagnosed Acute Myeloid Leukemia (AML) In combination with azacitidine or as monotherapy for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy ( 1.1 ). Relapsed or refractory AML For the treatment of adult patients with relapsed or refractory AML ( 1.2 ). Relapsed or refractory Myelodysplastic Syndromes (MDS) For the treatment of adult patients with relapsed or refractory myelodysplastic syndromes ( 1.3 ). Locally Advanced or Metastatic Cholangiocarcinoma For the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma who have been previously treated ( 1.4 ).|[EMA] Tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive standard induction chemotherapy (see section 5.1).Tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation who were previously treated by at least one prior line of systemic therapy. uuid:66fa2d96-e96a-40c9-89c7-746f0c78033c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:145430 biolink:treats MONDO:0018881 PMID:41385096 "[{""id"":""uuid:fdcdb865-8aba-4ad4-b949-bb6beb98b1ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:89ecc76b-56ab-466b-b7e3-8aabfe1a12e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TIBSOVO is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for patients with a susceptible IDH1 mutation as detected by an FDA-approved test with: Newly Diagnosed Acute Myeloid Leukemia (AML) In combination with azacitidine or as monotherapy for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy ( 1.1 ). Relapsed or refractory AML For the treatment of adult patients with relapsed or refractory AML ( 1.2 ). Relapsed or refractory Myelodysplastic Syndromes (MDS) For the treatment of adult patients with relapsed or refractory myelodysplastic syndromes ( 1.3 ). Locally Advanced or Metastatic Cholangiocarcinoma For the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma who have been previously treated ( 1.4 ). uuid:05eead15-21c7-4f6c-b2d4-66e23148bb83 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:145430 biolink:treats MONDO:0019087 PMID:41385096 "[{""id"":""uuid:72db3952-3b52-4998-9218-50b5e3d504aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:8e0452d6-f82d-43a5-9779-aa61b2e47004"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:700057b0-ab34-4b6b-b565-1e66bc4dddac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/tibsovo-0""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] TIBSOVO is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for patients with a susceptible IDH1 mutation as detected by an FDA-approved test with: Newly Diagnosed Acute Myeloid Leukemia (AML) In combination with azacitidine or as monotherapy for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy ( 1.1 ). Relapsed or refractory AML For the treatment of adult patients with relapsed or refractory AML ( 1.2 ). Relapsed or refractory Myelodysplastic Syndromes (MDS) For the treatment of adult patients with relapsed or refractory myelodysplastic syndromes ( 1.3 ). Locally Advanced or Metastatic Cholangiocarcinoma For the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma who have been previously treated ( 1.4 ).|[EMA] Tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive standard induction chemotherapy (see section 5.1).Tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation who were previously treated by at least one prior line of systemic therapy. uuid:f00e8d01-80ef-4e5e-87e3-d79690439e61 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:54736666 biolink:treats MONDO:0004951 PMID:41385096 "[{""id"":""uuid:5cdb7ac3-46d9-44a7-b35f-1d6d3553ce7d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c2988c11-55d2-4104-8041-f88a39c5ae14"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DOVATO is indicated as a complete regimen for the treatment of HIV-1 infection in adults and adolescents 12 years of age and older and weighing at least 25 kg with no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies/mL) on a stable antiretroviral regimen with no history of treatment failure and no known substitutions associated with resistance to the individual components of DOVATO. uuid:aa3c6030-1828-4f77-b776-af54d08fedcc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:46878853 biolink:treats MONDO:0018637 PMID:41385096 "[{""id"":""uuid:68264832-1a8f-49c1-a887-19c7d394a6b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fe951ce6-6f54-4d6d-b538-e1aa2f2bcb0b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Treatment of Hypercholesterolemia Fenofibrate capsules are indicated as adjunctive therapy to diet for the reduction of LDL-C, Total-C, Triglycerides and apo B in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb). Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and non-pharmacological interventions alone has been inadequate (see National Cholesterol Education Program [NCEP] Treatment Guidelines, below). Treatment of Hypertriglyceridemia Fenofibrate capsules are also indicated as adjunctive therapy to diet for treatment of adult patients with hypertriglyceridemia (Fredrickson Types IV and V hyperlipidemia). Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually reduce fasting triglycerides and eliminate chylomicronemia thereby obviating the need for pharmacologic intervention. Markedly elevated levels of serum triglycerides (e.g. > 2,000 mg/dL) may increase the risk of developing pancreatitis. The effect of fenofibrate therapy on reducing this risk has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of very low density lipoprotein (VLDL). Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV and V hyperlipoproteinemia 2 . The initial treatment for dyslipidemia is dietary therapy specific for the type of lipoprotein abnormality. Excess body weight and excess alcoholic intake may be important factors in hypertriglyceridemia and should be addressed prior to any drug therapy. Physical exercise can be an important ancillary measure. Diseases contributory to hyperlipidemia, such as hypothyroidism or diabetes mellitus should be looked for and adequately treated. Estrogen therapy, like thiazide diuretics and beta-blockers, is sometimes associated with massive rises in plasma triglycerides, especially in subjects with familial hypertriglyceridemia. In such cases, discontinuation of the specific etiologic agent may obviate the need for specific drug therapy of hypertriglyceridemia. The use of drugs should be considered only when reasonable attempts have been made to obtain satisfactory results with non-drug methods. If the decision is made to use drugs, the patient should be instructed that this does not reduce the importance of adhering to diet (see WARNINGS and PRECAUTIONS ). Fredrickson Classification of Hyperlipoproteinemias Lipid Elevation Type Lipoprotein Elevated Major Minor I (rare) Chylomicrons TG ↑↔C IIa LDL C — IIb LDL, VLDL C TG III (rare) IDL C, TG — IV VLDL TG ↑↔C V (rare) Chylomicrons, VLDL TG ↑↔ C = cholesterol TG = triglycerides LDL = low density lipoprotein VLDL = very low density lipoprotein IDL = intermediate density lipoprotein The NCEP Treatment Guidelines Definite Athlerosclerotic Disease a Two or More Other Risk Factors b LDL-Cholesterol mg/dL (mmol/L) Initiation Level Goal No No ≥ 190 (≥ 4.9) < 160 (< 4.1) No Yes ≥ 160 (≥ 4.1) < 130 (< 3.4) Yes Yes or No ≥ 130 c (≥ 3.4) < 100 (< 2.6) a Coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease). b Other risk factors for coronary heart disease (CHD) include: age (males: ≥ 4 5 years; females: ≥ 55 years or premature menopause without estrogen replacement therapy); family history of premature CHD; current cigarette smoking; hypertension; confirmed HDL- C <35 mg/dL (<0.91mmol/L); and diabetes mellitus. Subtract 1 risk factor if HDL-C is ≥ 60 mg/dL (≥1.6 mmol/L) c In CHD patients with LDL-C levels 100 to 129 mg/dL, the physician should exercise clinical judgment in deciding whether to initiate drug treatment. uuid:16f99c85-0f78-42eb-8855-2d4090752bfd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135901 biolink:treats MONDO:0019933 PMID:41385096 "[{""id"":""uuid:28d3caf7-aaaa-4bc2-a28b-c1f64126baf5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0958e228-5e3e-49ca-a1b4-85e6cc79ae61"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:a1f4cfae-2919-4bb8-84cf-730fd2d54499"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lanreotide Injection is a somatostatin analog indicated for: the long-term treatment of acromegalic patients who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy. ( 1.1 ) the treatment of adult patients with unresectable, well- or moderately- differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to improve progression-free survival. ( 1.2 ) the treatment of adults with carcinoid syndrome; when used, it reduces the frequency of short-acting somatostatin analog rescue therapy. ( 1.3 )|[PMDA] Drugs with a new active ingredient for the improvement of hypersecretion of growth hormone and IGF-I (somatomedin-C) and related symptoms in acromegaly and pituitary gigantism (when surgical therapies are not sufficiently effective or are difficult to perform). uuid:8bae6a46-e75c-486d-8dce-f4e028162fd9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135901 biolink:treats MONDO:0024503 PMID:41385096 "[{""id"":""uuid:8ec3fdcc-5eb3-4c98-b43e-d8ef6e5922d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8f31c3e8-36fa-49f6-b825-5cf3b3310ba6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:fad3d234-3fbe-4617-b612-4199e74ba96a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lanreotide Injection is a somatostatin analog indicated for: the long-term treatment of acromegalic patients who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy. ( 1.1 ) the treatment of adult patients with unresectable, well- or moderately- differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to improve progression-free survival. ( 1.2 ) the treatment of adults with carcinoid syndrome; when used, it reduces the frequency of short-acting somatostatin analog rescue therapy. ( 1.3 )|[PMDA] A drug with a new additional indication and a new dosage indicated for the treatment of neuroendocrine tumors of the pancreas and gastrointestinal tract. uuid:7e56b1cb-0e9e-47da-a458-a3bde83988d8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135901 biolink:treats MONDO:0100347 PMID:41385096 "[{""id"":""uuid:b9d40935-c70c-44d4-a0f4-05a86aa4b810"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:96fa9732-775d-49c0-a169-07e1116882b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lanreotide Injection is a somatostatin analog indicated for: the long-term treatment of acromegalic patients who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy. ( 1.1 ) the treatment of adult patients with unresectable, well- or moderately- differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to improve progression-free survival. ( 1.2 ) the treatment of adults with carcinoid syndrome; when used, it reduces the frequency of short-acting somatostatin analog rescue therapy. ( 1.3 ) uuid:68ead794-174d-478f-9e05-a2fade71998b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71417 biolink:treats MONDO:0009348 PMID:41385096 "[{""id"":""uuid:84a89a4e-6b6b-40e8-892a-ce7605e4776f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9a8f820e-45f4-4f66-a625-d6fbb8d3d1b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Matulane is indicated for use in combination with other anticancer drugs for the treatment of Stage III and IV Hodgkin's disease. Matulane is used as part of the MOPP (nitrogen mustard, vincristine, procarbazine, prednisone) regimen. uuid:644a440c-5e3d-4c9c-9a6b-15ece173da40 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17347 biolink:treats MONDO:0002146 PMID:41385096 "[{""id"":""uuid:ede63c2d-2305-460f-8f85-5fadcfedaa11"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2377a7ac-c0da-4293-9eb9-0125953ec7e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Testosterone implants are pellets containing 100mg of the active ingredient testosterone. These implants are used in hormone replacement therapy in men. Testosterone is a natural male hormone, known as an androgen, which controls normal sexual development in men. Testosterone implants are used in testosterone replacement therapy in men with low or no natural testosterone (a condition known as hypogonadism). uuid:f4c4d903-a074-4fe1-98b8-885d06ce2a5e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4031 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:586403f9-908e-4a95-a657-fb3ddefbb0d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6863f1f2-4f64-48e3-b274-f7fb06bedb8e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Kidney, Liver, and Heart Transplantation Cyclosporine capsules (modified) is indicated for the prophylaxis of organ rejection in kidney, liver, and heart allogeneic transplants. Cyclosporine capsules (modified) has been used in combination with azathioprine and corticosteroids. Rheumatoid Arthritis Cyclosporine capsules (modified) is indicated for the treatment of patients with severe active, rheumatoid arthritis where the disease has not adequately responded to methotrexate. Cyclosporine capsules (modified) can be used in combination with methotrexate in rheumatoid arthritis patients who do not respond adequately to methotrexate alone. Psoriasis Cyclosporine capsules (modified) is indicated for the treatment of adult, nonimmunocompromised patients with severe (i.e., extensive and/or disabling), recalcitrant, plaque psoriasis who have failed to respond to at least one systemic therapy (e.g., PUVA, retinoids, or methotrexate) or in patients for whom other systemic therapies are contraindicated or cannot be tolerated. While rebound rarely occurs, most patients will experience relapse with cyclosporine capsules (modified) as with other therapies upon cessation of treatment. uuid:2dc81316-369a-41de-8e8c-731dcee7481b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4031 biolink:treats UMLS:C0406317 PMID:41385096 "[{""id"":""uuid:f677156c-f9ef-48a5-87dc-249953c2d90e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0bc928b7-6a77-4db4-9b47-8bdca851f226"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Kidney, Liver, and Heart Transplantation Cyclosporine capsules (modified) is indicated for the prophylaxis of organ rejection in kidney, liver, and heart allogeneic transplants. Cyclosporine capsules (modified) has been used in combination with azathioprine and corticosteroids. Rheumatoid Arthritis Cyclosporine capsules (modified) is indicated for the treatment of patients with severe active, rheumatoid arthritis where the disease has not adequately responded to methotrexate. Cyclosporine capsules (modified) can be used in combination with methotrexate in rheumatoid arthritis patients who do not respond adequately to methotrexate alone. Psoriasis Cyclosporine capsules (modified) is indicated for the treatment of adult, nonimmunocompromised patients with severe (i.e., extensive and/or disabling), recalcitrant, plaque psoriasis who have failed to respond to at least one systemic therapy (e.g., PUVA, retinoids, or methotrexate) or in patients for whom other systemic therapies are contraindicated or cannot be tolerated. While rebound rarely occurs, most patients will experience relapse with cyclosporine capsules (modified) as with other therapies upon cessation of treatment. uuid:2df6cfe6-5173-49f0-bcea-069845bd9824 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0005002 PMID:41385096 "[{""id"":""uuid:cf17a580-da24-4191-92fe-ffb684d772d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6283392a-040a-461f-8b35-a9b6b444004e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prednisolone Sodium Phosphate Oral Solution is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under “Allergic States”), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti- PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren’s syndrome, relapsing polychondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); Trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents). uuid:abf8beb9-7731-42cc-ba2b-4eccf55c94bf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0018076 PMID:41385096 "[{""id"":""uuid:d326bcd9-60c6-43e6-8077-5ba45724c5eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:78339512-3d13-4560-8cc4-35886a505225"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prednisolone Sodium Phosphate Oral Solution is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under “Allergic States”), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti- PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren’s syndrome, relapsing polychondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); Trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents). uuid:61d06bed-ff16-4ef7-ac18-56eafb3108a0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8212 biolink:treats MONDO:0007661 PMID:41385096 "[{""id"":""uuid:abbb701c-05ad-40d1-bd8c-793209d924de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8f904c8e-7706-4c66-9320-3afa7b047cbe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pimozide tablets, USP are indicated for the suppression of motor and phonic tics in patients with Tourette’s Disorder who have failed to respond satisfactorily to standard treatment. Pimozide Tablets, USP are not intended as a treatment of first choice nor is it intended for the treatment of tics that are merely annoying or cosmetically troublesome. Pimozide Tablets, USP should be reserved for use in Tourette’s Disorder patients whose development and/or daily life function is severely compromised by the presence of motor and phonic tics. Evidence supporting approval of pimozide tablets, USP for use in Tourette’s Disorder was obtained in two controlled clinical investigations which enrolled patients between the ages of 8 and 53 years. Most subjects in the two trials were 12 or older. uuid:76bc99f0-c9e1-4237-8b7e-d723634f107d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:VL756B1K0U biolink:treats MONDO:0005338 PMID:41385096 "[{""id"":""uuid:03b42632-b772-4319-a5f5-494021a44b9d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:18010837-1edc-46c5-9694-a4c25155eaf3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RHOPRESSA is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. uuid:11aee8bd-042e-4764-8a41-4b22053e6ffc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:VL756B1K0U biolink:treats MONDO:0006875 PMID:41385096 "[{""id"":""uuid:a870820d-9baa-48db-9772-eaeb3a729b50"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1cf975ae-ee16-4723-a9bf-44261768227c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RHOPRESSA is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. uuid:5208d22e-5cc1-434b-9fb9-338907409012 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4356 biolink:treats MONDO:0859316 PMID:41385096 "[{""id"":""uuid:2342d4d9-4579-4b0d-8c54-f7bbe177d9a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:59fe7b8f-7c9b-46b2-b192-155122839efa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Deferoxamine mesylate for injection is an iron-chelating agent indicated: Limitations of Use Deferoxamine mesylate for injection is not indicated for the treatment of primary hemochromatosis (since phlebotomy is the method of choice for removing excess iron in this disorder). As an adjunct to standard measures for the treatment of acute iron intoxication. ( 1.1 ) For the treatment of transfusional iron overload in patients with chronic anemia. ( 1.2 ) Limitations of Use Deferoxamine mesylate for injection is not indicated for the treatment of primary hemochromatosis (since phlebotomy is the method of choice for removing excess iron in this disorder). uuid:556b6334-61f6-4a4d-8dfd-739b8a186d45 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4356 biolink:treats UMLS:C0581384 PMID:41385096 "[{""id"":""uuid:7a995aa1-256c-4c10-9937-b01e5dacdb9b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b07e5881-ddb8-44d9-abc0-f99ee4173fe1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Deferoxamine mesylate for injection is an iron-chelating agent indicated: Limitations of Use Deferoxamine mesylate for injection is not indicated for the treatment of primary hemochromatosis (since phlebotomy is the method of choice for removing excess iron in this disorder). As an adjunct to standard measures for the treatment of acute iron intoxication. ( 1.1 ) For the treatment of transfusional iron overload in patients with chronic anemia. ( 1.2 ) Limitations of Use Deferoxamine mesylate for injection is not indicated for the treatment of primary hemochromatosis (since phlebotomy is the method of choice for removing excess iron in this disorder). uuid:4f59c821-8d10-4299-9a8e-628ccd1fa061 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63623 biolink:treats MONDO:0018019 PMID:41385096 "[{""id"":""uuid:2b1ed072-3bc3-41a7-b465-fe645ab3061f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:57d64c85-246e-4c88-9a7d-7df156177dcc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CHEMET is indicated for the treatment of lead poisoning in pediatric patients aged 1 year and older with blood lead levels above 45 mcg/dL. uuid:9001531d-a03e-48d5-85fa-14d30610e1ef biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27834 biolink:treats MONDO:0018935 PMID:41385096 "[{""id"":""uuid:5385c76e-9a9f-4e33-9c4e-9e3363937a2c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9c2b78b2-b4a0-4438-ac0b-e3718588ef92"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NIPENT is indicated as single-agent treatment for both untreated and alpha-interferon-refractory hairy cell leukemia patients with active disease as defined by clinically significant anemia, neutropenia, thrombocytopenia, or disease-related symptoms. uuid:a60877b0-3bf1-4ce7-bf5c-e2d02e81adf7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27834 biolink:treats MONDO:0002280 PMID:41385096 "[{""id"":""uuid:f58c1dd8-c7e2-46da-a0e2-040bb120ca6d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:64242454-6631-4685-a172-845fb0bc9ed2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NIPENT is indicated as single-agent treatment for both untreated and alpha-interferon-refractory hairy cell leukemia patients with active disease as defined by clinically significant anemia, neutropenia, thrombocytopenia, or disease-related symptoms. uuid:e0fd653e-587f-4e2f-a862-1eff0d0cd2e0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27834 biolink:treats MONDO:0001475 PMID:41385096 "[{""id"":""uuid:dbdd3a23-1ede-4821-a717-e1fba82be2a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e2d93b47-4041-4551-bb97-e17c9068910f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NIPENT is indicated as single-agent treatment for both untreated and alpha-interferon-refractory hairy cell leukemia patients with active disease as defined by clinically significant anemia, neutropenia, thrombocytopenia, or disease-related symptoms. uuid:007b2983-eaa0-4ea3-b947-ab7ab864dc79 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27834 biolink:treats MONDO:0002049 PMID:41385096 "[{""id"":""uuid:9404283e-ea34-4d67-b4a4-898948e7e30b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:17707311-21fd-4e50-a9ab-650a96ad0c5b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NIPENT is indicated as single-agent treatment for both untreated and alpha-interferon-refractory hairy cell leukemia patients with active disease as defined by clinically significant anemia, neutropenia, thrombocytopenia, or disease-related symptoms. uuid:e36d3a0a-d14e-415f-a06d-800de8572048 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8069 biolink:treats MONDO:0016027 PMID:41385096 "[{""id"":""uuid:ed8b79a9-17a4-466f-9fa8-7f3e8e68e904"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e8f69dda-fa4a-4c08-9aaf-b9e5d89202d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SEZABY is indicated for the treatment of neonatal seizures in term and preterm infants. uuid:3f013f84-db37-4688-be5e-4d5294d25382 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:52CMI0WC3Y biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:20ed47df-9a69-4ac5-915d-642b0aa669a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:cc5813d1-be11-4921-8005-8af683ab3032"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c0f45782-8480-4731-accb-d4e185e451be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/tecentriq""]},{""id"":""uuid:8aafc9e0-5e7f-4e1e-851f-527dcdbb4d1a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TECENTRIQ HYBREZA is a combination of atezolizumab, a programmed death-ligand 1 (PD-L1) blocking antibody, and hyaluronidase, an endoglycosidase indicated: Non-Small Cell Lung Cancer (NSCLC) as adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage II to IIIA NSCLC whose tumors have PD-L1 expression on ≥ 1% of tumor cells, as determined by an FDA-approved test. ( 1.2 , 2.1 ) for the first-line treatment of adult patients with metastatic NSCLC whose tumors have high PD-L1 expression (PD-L1 stained ≥ 50% of tumor cells [TC ≥ 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering ≥ 10% of the tumor area [IC ≥ 10%]), as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations. ( 1.2 , 2.1 ) in combination with bevacizumab, paclitaxel, and carboplatin, for the first-line treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations. ( 1.2 ) in combination with paclitaxel protein-bound and carboplatin for the first-line treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations. ( 1.2 ) for the treatment of adult patients with metastatic NSCLC who have disease progression during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for NSCLC harboring these aberrations prior to receiving TECENTRIQ HYBREZA. ( 1.2 ) Small Cell Lung Cancer (SCLC) ( 1.3 ) in combination with carboplatin and etoposide, for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC). ( 1.3 ) Hepatocellular Carcinoma (HCC) ( 1.4 ) in combination with bevacizumab for the treatment of adult patients with unresectable or metastatic HCC who have not received prior systemic therapy. ( 1.4 ) Melanoma ( 1.5 ) in combination with cobimetinib and vemurafenib for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma as determined by an FDA-approved test. ( 1.5 , 2.1 ) Alveolar Soft Part Sarcoma (ASPS) (1.6) for the treatment of adult patients with unresectable or metastatic ASPS. (1.6)|[EMA] Urothelial carcinomaTecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC):- after prior platinum containing chemotherapy, or - who are considered cisplatin ineligible, and whose tumours have a PD-L1 expression ≥ 5% (see section 5.1).Non-small cell lung cancer Tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non small cell lung cancer (NSCLC). In patients with EGFR mutant or ALK-positive NSCLC, Tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies (see section 5.1).Tecentriq, in combination with nab paclitaxel and carboplatin, is indicated for the first line treatment of adult patients with metastatic non-squamous NSCLC who do not have EGFR mutant or ALK positive NSCLC (see section 5.1).Tecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have a PD-L1 expression ≥ 50% tumour cells (TC) or ≥ 10% tumour-infiltrating immune cells (IC) and who do not have EGFR mutant or ALK-positive NSCLC (see section 5.1).Tecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC after prior chemotherapy. Patients with EGFR mutant or ALK positive NSCLC should also have received targeted therapies before receiving Tecentriq (see section 5.1).Small cell lung cancerTecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) (see section 5.1).Hepatocellular carcinomaTecentriq, in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy (see section 5.1).Urothelial carcinomaTecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC):- after prior platinum containing chemotherapy, or- who are considered cisplatin ineligible, and whose tumours have a PD-L1 expression ≥ 5% (see section 5.1).Non-small cell lung cancerTecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have a PD-L1 expression ≥ 50% tumour cells (TC) or ≥ 10% tumour-infiltrating immune cells (IC) and who do not have EGFR mutant or ALK-positive NSCLC (see section 5.1).Tecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC after prior chemotherapy. Patients with EGFR mutant or ALK positive NSCLC should also have received targeted therapies before receiving Tecentriq (see section 5.1).Triple-negative breast cancerTecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumours have PD-L1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.|[PMDA] A drug with a new active ingredient indicated for the treatment of unresectable advanced or recurrent non-small-cell lung cancer. uuid:15a9ea1d-dcdb-4d4c-9909-6f2c43212788 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:52CMI0WC3Y biolink:treats MONDO:0008433 PMID:41385096 "[{""id"":""uuid:aa034221-d1d6-46ae-862d-6e4801518be5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:767e7844-3205-46b8-95ba-4ec34d1c345a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c6485b14-7615-4d1a-b043-3a79d87f4997"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/tecentriq""]},{""id"":""uuid:1e86f162-558a-49f0-9e64-5ffd4fd441ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TECENTRIQ HYBREZA is a combination of atezolizumab, a programmed death-ligand 1 (PD-L1) blocking antibody, and hyaluronidase, an endoglycosidase indicated: Non-Small Cell Lung Cancer (NSCLC) as adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage II to IIIA NSCLC whose tumors have PD-L1 expression on ≥ 1% of tumor cells, as determined by an FDA-approved test. ( 1.2 , 2.1 ) for the first-line treatment of adult patients with metastatic NSCLC whose tumors have high PD-L1 expression (PD-L1 stained ≥ 50% of tumor cells [TC ≥ 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering ≥ 10% of the tumor area [IC ≥ 10%]), as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations. ( 1.2 , 2.1 ) in combination with bevacizumab, paclitaxel, and carboplatin, for the first-line treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations. ( 1.2 ) in combination with paclitaxel protein-bound and carboplatin for the first-line treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations. ( 1.2 ) for the treatment of adult patients with metastatic NSCLC who have disease progression during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for NSCLC harboring these aberrations prior to receiving TECENTRIQ HYBREZA. ( 1.2 ) Small Cell Lung Cancer (SCLC) ( 1.3 ) in combination with carboplatin and etoposide, for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC). ( 1.3 ) Hepatocellular Carcinoma (HCC) ( 1.4 ) in combination with bevacizumab for the treatment of adult patients with unresectable or metastatic HCC who have not received prior systemic therapy. ( 1.4 ) Melanoma ( 1.5 ) in combination with cobimetinib and vemurafenib for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma as determined by an FDA-approved test. ( 1.5 , 2.1 ) Alveolar Soft Part Sarcoma (ASPS) (1.6) for the treatment of adult patients with unresectable or metastatic ASPS. (1.6)|[EMA] Urothelial carcinomaTecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC):- after prior platinum containing chemotherapy, or - who are considered cisplatin ineligible, and whose tumours have a PD-L1 expression ≥ 5% (see section 5.1).Non-small cell lung cancer Tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non small cell lung cancer (NSCLC). In patients with EGFR mutant or ALK-positive NSCLC, Tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies (see section 5.1).Tecentriq, in combination with nab paclitaxel and carboplatin, is indicated for the first line treatment of adult patients with metastatic non-squamous NSCLC who do not have EGFR mutant or ALK positive NSCLC (see section 5.1).Tecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have a PD-L1 expression ≥ 50% tumour cells (TC) or ≥ 10% tumour-infiltrating immune cells (IC) and who do not have EGFR mutant or ALK-positive NSCLC (see section 5.1).Tecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC after prior chemotherapy. Patients with EGFR mutant or ALK positive NSCLC should also have received targeted therapies before receiving Tecentriq (see section 5.1).Small cell lung cancerTecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) (see section 5.1).Hepatocellular carcinomaTecentriq, in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy (see section 5.1).Urothelial carcinomaTecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC):- after prior platinum containing chemotherapy, or- who are considered cisplatin ineligible, and whose tumours have a PD-L1 expression ≥ 5% (see section 5.1).Non-small cell lung cancerTecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have a PD-L1 expression ≥ 50% tumour cells (TC) or ≥ 10% tumour-infiltrating immune cells (IC) and who do not have EGFR mutant or ALK-positive NSCLC (see section 5.1).Tecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC after prior chemotherapy. Patients with EGFR mutant or ALK positive NSCLC should also have received targeted therapies before receiving Tecentriq (see section 5.1).Triple-negative breast cancerTecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumours have PD-L1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.|[PMDA] A drug with a new indication and a new dosage for the treatment of extensive-stage small-cell lung cancer. [Orphan drug] uuid:b54fbfc1-9d81-4774-b340-5c539fecceca biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:52CMI0WC3Y biolink:treats MONDO:0007256 PMID:41385096 "[{""id"":""uuid:2e83b62e-f6e3-4017-9328-df5038f3e49c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:e2b99104-69da-40e2-881f-e2f50148f60c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:bbf40a13-b8d7-4cd1-848c-803a159e72df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/tecentriq""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] TECENTRIQ HYBREZA is a combination of atezolizumab, a programmed death-ligand 1 (PD-L1) blocking antibody, and hyaluronidase, an endoglycosidase indicated: Non-Small Cell Lung Cancer (NSCLC) as adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage II to IIIA NSCLC whose tumors have PD-L1 expression on ≥ 1% of tumor cells, as determined by an FDA-approved test. ( 1.2 , 2.1 ) for the first-line treatment of adult patients with metastatic NSCLC whose tumors have high PD-L1 expression (PD-L1 stained ≥ 50% of tumor cells [TC ≥ 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering ≥ 10% of the tumor area [IC ≥ 10%]), as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations. ( 1.2 , 2.1 ) in combination with bevacizumab, paclitaxel, and carboplatin, for the first-line treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations. ( 1.2 ) in combination with paclitaxel protein-bound and carboplatin for the first-line treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations. ( 1.2 ) for the treatment of adult patients with metastatic NSCLC who have disease progression during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for NSCLC harboring these aberrations prior to receiving TECENTRIQ HYBREZA. ( 1.2 ) Small Cell Lung Cancer (SCLC) ( 1.3 ) in combination with carboplatin and etoposide, for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC). ( 1.3 ) Hepatocellular Carcinoma (HCC) ( 1.4 ) in combination with bevacizumab for the treatment of adult patients with unresectable or metastatic HCC who have not received prior systemic therapy. ( 1.4 ) Melanoma ( 1.5 ) in combination with cobimetinib and vemurafenib for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma as determined by an FDA-approved test. ( 1.5 , 2.1 ) Alveolar Soft Part Sarcoma (ASPS) (1.6) for the treatment of adult patients with unresectable or metastatic ASPS. (1.6)|[EMA] Urothelial carcinomaTecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC):- after prior platinum containing chemotherapy, or - who are considered cisplatin ineligible, and whose tumours have a PD-L1 expression ≥ 5% (see section 5.1).Non-small cell lung cancer Tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non small cell lung cancer (NSCLC). In patients with EGFR mutant or ALK-positive NSCLC, Tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies (see section 5.1).Tecentriq, in combination with nab paclitaxel and carboplatin, is indicated for the first line treatment of adult patients with metastatic non-squamous NSCLC who do not have EGFR mutant or ALK positive NSCLC (see section 5.1).Tecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have a PD-L1 expression ≥ 50% tumour cells (TC) or ≥ 10% tumour-infiltrating immune cells (IC) and who do not have EGFR mutant or ALK-positive NSCLC (see section 5.1).Tecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC after prior chemotherapy. Patients with EGFR mutant or ALK positive NSCLC should also have received targeted therapies before receiving Tecentriq (see section 5.1).Small cell lung cancerTecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) (see section 5.1).Hepatocellular carcinomaTecentriq, in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy (see section 5.1).Urothelial carcinomaTecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC):- after prior platinum containing chemotherapy, or- who are considered cisplatin ineligible, and whose tumours have a PD-L1 expression ≥ 5% (see section 5.1).Non-small cell lung cancerTecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have a PD-L1 expression ≥ 50% tumour cells (TC) or ≥ 10% tumour-infiltrating immune cells (IC) and who do not have EGFR mutant or ALK-positive NSCLC (see section 5.1).Tecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC after prior chemotherapy. Patients with EGFR mutant or ALK positive NSCLC should also have received targeted therapies before receiving Tecentriq (see section 5.1).Triple-negative breast cancerTecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumours have PD-L1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease. uuid:8bf1e4a2-b724-4eb0-aa31-466f1a4fa2de biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:52CMI0WC3Y biolink:treats MONDO:0005105 PMID:41385096 "[{""id"":""uuid:d662fb70-a945-4aff-8f04-03570c6eb0b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:725f9dc7-831b-4d0b-b253-3d6e931d75c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TECENTRIQ HYBREZA is a combination of atezolizumab, a programmed death-ligand 1 (PD-L1) blocking antibody, and hyaluronidase, an endoglycosidase indicated: Non-Small Cell Lung Cancer (NSCLC) as adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage II to IIIA NSCLC whose tumors have PD-L1 expression on ≥ 1% of tumor cells, as determined by an FDA-approved test. ( 1.2 , 2.1 ) for the first-line treatment of adult patients with metastatic NSCLC whose tumors have high PD-L1 expression (PD-L1 stained ≥ 50% of tumor cells [TC ≥ 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering ≥ 10% of the tumor area [IC ≥ 10%]), as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations. ( 1.2 , 2.1 ) in combination with bevacizumab, paclitaxel, and carboplatin, for the first-line treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations. ( 1.2 ) in combination with paclitaxel protein-bound and carboplatin for the first-line treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations. ( 1.2 ) for the treatment of adult patients with metastatic NSCLC who have disease progression during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for NSCLC harboring these aberrations prior to receiving TECENTRIQ HYBREZA. ( 1.2 ) Small Cell Lung Cancer (SCLC) ( 1.3 ) in combination with carboplatin and etoposide, for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC). ( 1.3 ) Hepatocellular Carcinoma (HCC) ( 1.4 ) in combination with bevacizumab for the treatment of adult patients with unresectable or metastatic HCC who have not received prior systemic therapy. ( 1.4 ) Melanoma ( 1.5 ) in combination with cobimetinib and vemurafenib for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma as determined by an FDA-approved test. ( 1.5 , 2.1 ) Alveolar Soft Part Sarcoma (ASPS) (1.6) for the treatment of adult patients with unresectable or metastatic ASPS. (1.6) uuid:a4e37793-718b-4982-9584-bd4b19c9e4fe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:52CMI0WC3Y biolink:treats MONDO:0005191 PMID:41385096 "[{""id"":""uuid:c2203b4a-35e0-4c0b-8c99-30bb2469d728"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:182475c8-d37a-4081-8c3f-1fad775d4b49"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TECENTRIQ HYBREZA is a combination of atezolizumab, a programmed death-ligand 1 (PD-L1) blocking antibody, and hyaluronidase, an endoglycosidase indicated: Non-Small Cell Lung Cancer (NSCLC) as adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage II to IIIA NSCLC whose tumors have PD-L1 expression on ≥ 1% of tumor cells, as determined by an FDA-approved test. ( 1.2 , 2.1 ) for the first-line treatment of adult patients with metastatic NSCLC whose tumors have high PD-L1 expression (PD-L1 stained ≥ 50% of tumor cells [TC ≥ 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering ≥ 10% of the tumor area [IC ≥ 10%]), as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations. ( 1.2 , 2.1 ) in combination with bevacizumab, paclitaxel, and carboplatin, for the first-line treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations. ( 1.2 ) in combination with paclitaxel protein-bound and carboplatin for the first-line treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations. ( 1.2 ) for the treatment of adult patients with metastatic NSCLC who have disease progression during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for NSCLC harboring these aberrations prior to receiving TECENTRIQ HYBREZA. ( 1.2 ) Small Cell Lung Cancer (SCLC) ( 1.3 ) in combination with carboplatin and etoposide, for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC). ( 1.3 ) Hepatocellular Carcinoma (HCC) ( 1.4 ) in combination with bevacizumab for the treatment of adult patients with unresectable or metastatic HCC who have not received prior systemic therapy. ( 1.4 ) Melanoma ( 1.5 ) in combination with cobimetinib and vemurafenib for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma as determined by an FDA-approved test. ( 1.5 , 2.1 ) Alveolar Soft Part Sarcoma (ASPS) (1.6) for the treatment of adult patients with unresectable or metastatic ASPS. (1.6) uuid:fbd2e5e0-c387-4f4b-a71a-410d654f6541 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:52CMI0WC3Y biolink:treats MONDO:0011655 PMID:41385096 "[{""id"":""uuid:0c7ef568-0aee-407d-b4bd-78b464cabe71"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:decae53f-73ba-4c9b-8426-2be54a9606b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TECENTRIQ HYBREZA is a combination of atezolizumab, a programmed death-ligand 1 (PD-L1) blocking antibody, and hyaluronidase, an endoglycosidase indicated: Non-Small Cell Lung Cancer (NSCLC) as adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage II to IIIA NSCLC whose tumors have PD-L1 expression on ≥ 1% of tumor cells, as determined by an FDA-approved test. ( 1.2 , 2.1 ) for the first-line treatment of adult patients with metastatic NSCLC whose tumors have high PD-L1 expression (PD-L1 stained ≥ 50% of tumor cells [TC ≥ 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering ≥ 10% of the tumor area [IC ≥ 10%]), as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations. ( 1.2 , 2.1 ) in combination with bevacizumab, paclitaxel, and carboplatin, for the first-line treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations. ( 1.2 ) in combination with paclitaxel protein-bound and carboplatin for the first-line treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations. ( 1.2 ) for the treatment of adult patients with metastatic NSCLC who have disease progression during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for NSCLC harboring these aberrations prior to receiving TECENTRIQ HYBREZA. ( 1.2 ) Small Cell Lung Cancer (SCLC) ( 1.3 ) in combination with carboplatin and etoposide, for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC). ( 1.3 ) Hepatocellular Carcinoma (HCC) ( 1.4 ) in combination with bevacizumab for the treatment of adult patients with unresectable or metastatic HCC who have not received prior systemic therapy. ( 1.4 ) Melanoma ( 1.5 ) in combination with cobimetinib and vemurafenib for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma as determined by an FDA-approved test. ( 1.5 , 2.1 ) Alveolar Soft Part Sarcoma (ASPS) (1.6) for the treatment of adult patients with unresectable or metastatic ASPS. (1.6) uuid:7c8f23f2-ef11-4c90-bdfc-92feae3d6ef3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:C3VX249T6L biolink:treats MONDO:0100244 PMID:41385096 "[{""id"":""uuid:5d79f29e-a424-433a-a6c4-a1e1dfc10252"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4a4f391c-0204-4896-be13-12ea4a0e4a39"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:b5deb827-acd5-4dcd-8b56-e40d229e3110"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ultomiris""]},{""id"":""uuid:199874aa-8b2d-4d3c-be99-176ca696b98e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ULTOMIRIS is a complement inhibitor indicated for: the treatment of adult and pediatric patients one month of age and older with paroxysmal nocturnal hemoglobinuria (PNH). ( 1.1 ) the treatment of adult and pediatric patients one month of age and older with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA). ( 1.2 ) Limitations of Use: ULTOMIRIS is not indicated for the treatment of patients with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS). the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive. ( 1.3 ) the treatment of adult patients with neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin-4 (AQP4) antibody-positive. ( 1.4 )|[EMA] Paroxysmal nocturnal haemoglobinuria (PNH)Ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with PNH:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity.- in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5.1).Atypical haemolytic uremic syndrome (aHUS)Ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with aHUS who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5.1).Generalized myasthenia gravis (gMG)Ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gMG who are anti-acetylcholine receptor (AChR) antibody-positive.Neuromyelitis Optica Spectrum Disorder (NMOSD)Ultomiris is indicated in the treatment of adult patients with NMOSD who are anti-aquaporin 4 (AQP4) antibody-positive (see section 5.1).Ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity.- in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months.Ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (aHUS) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.|[PMDA] A drug with a new active ingredient indicated for the treatment of paroxysmal nocturnal hemoglobinuria. [Orphan drug] uuid:66be80e6-00f1-4dbf-ba95-4336e47c29e7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:C3VX249T6L biolink:treats MONDO:0016244 PMID:41385096 "[{""id"":""uuid:00626550-4f59-4264-9efa-63a0ab0af8fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:808e543f-5a3a-412c-b60e-768d919dd309"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:be15c03d-b098-4c64-b3e7-0c42498fa948"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ultomiris""]},{""id"":""uuid:8737434b-e738-4ac4-af1f-764e0580018a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ULTOMIRIS is a complement inhibitor indicated for: the treatment of adult and pediatric patients one month of age and older with paroxysmal nocturnal hemoglobinuria (PNH). ( 1.1 ) the treatment of adult and pediatric patients one month of age and older with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA). ( 1.2 ) Limitations of Use: ULTOMIRIS is not indicated for the treatment of patients with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS). the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive. ( 1.3 ) the treatment of adult patients with neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin-4 (AQP4) antibody-positive. ( 1.4 )|[EMA] Paroxysmal nocturnal haemoglobinuria (PNH)Ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with PNH:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity.- in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5.1).Atypical haemolytic uremic syndrome (aHUS)Ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with aHUS who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5.1).Generalized myasthenia gravis (gMG)Ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gMG who are anti-acetylcholine receptor (AChR) antibody-positive.Neuromyelitis Optica Spectrum Disorder (NMOSD)Ultomiris is indicated in the treatment of adult patients with NMOSD who are anti-aquaporin 4 (AQP4) antibody-positive (see section 5.1).Ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity.- in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months.Ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (aHUS) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.|[PMDA] A drug with a new indication and a new dosage for the treatment of atypical hemolytic uremic syndrome (aHUS). uuid:7a4ce95e-fc69-4616-aa49-243fd893563b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:C3VX249T6L biolink:treats MONDO:0009688 PMID:41385096 "[{""id"":""uuid:ea926ef7-118d-4181-bd5d-d54feeb4d998"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b5b8932f-a7f6-4672-b2dd-18652117b39a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:3261f40a-c7d2-4e67-910b-b8b6bdb334b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ultomiris""]},{""id"":""uuid:065dd4b3-cf25-4b3c-a9f8-d623fcd6d92f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ULTOMIRIS is a complement inhibitor indicated for: the treatment of adult and pediatric patients one month of age and older with paroxysmal nocturnal hemoglobinuria (PNH). ( 1.1 ) the treatment of adult and pediatric patients one month of age and older with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA). ( 1.2 ) Limitations of Use: ULTOMIRIS is not indicated for the treatment of patients with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS). the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive. ( 1.3 ) the treatment of adult patients with neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin-4 (AQP4) antibody-positive. ( 1.4 )|[EMA] Paroxysmal nocturnal haemoglobinuria (PNH)Ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with PNH:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity.- in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5.1).Atypical haemolytic uremic syndrome (aHUS)Ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with aHUS who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5.1).Generalized myasthenia gravis (gMG)Ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gMG who are anti-acetylcholine receptor (AChR) antibody-positive.Neuromyelitis Optica Spectrum Disorder (NMOSD)Ultomiris is indicated in the treatment of adult patients with NMOSD who are anti-aquaporin 4 (AQP4) antibody-positive (see section 5.1).Ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity.- in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months.Ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (aHUS) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.|[PMDA] Drugs with a new indication for the treatment of generalized myasthenia gravis (for use only in patients whose symptoms cannot be sufficiently controlled with high-dose intravenous immunoglobulin therapy or plasmapheresis). uuid:60c7c575-e51d-48e0-bc40-be09e0bd1178 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:C3VX249T6L biolink:treats MONDO:0035663 PMID:41385096 "[{""id"":""uuid:c2cae207-6bb7-409c-b868-43a6c831ad0e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:737da61d-5dcc-4ccb-9aec-9397b9d69461"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f4ac5ce7-0536-4e79-b8d0-3d16a36f4a2a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ultomiris""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] ULTOMIRIS is a complement inhibitor indicated for: the treatment of adult and pediatric patients one month of age and older with paroxysmal nocturnal hemoglobinuria (PNH). ( 1.1 ) the treatment of adult and pediatric patients one month of age and older with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA). ( 1.2 ) Limitations of Use: ULTOMIRIS is not indicated for the treatment of patients with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS). the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive. ( 1.3 ) the treatment of adult patients with neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin-4 (AQP4) antibody-positive. ( 1.4 )|[EMA] Paroxysmal nocturnal haemoglobinuria (PNH)Ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with PNH:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity.- in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5.1).Atypical haemolytic uremic syndrome (aHUS)Ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with aHUS who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5.1).Generalized myasthenia gravis (gMG)Ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gMG who are anti-acetylcholine receptor (AChR) antibody-positive.Neuromyelitis Optica Spectrum Disorder (NMOSD)Ultomiris is indicated in the treatment of adult patients with NMOSD who are anti-aquaporin 4 (AQP4) antibody-positive (see section 5.1).Ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity.- in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months.Ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (aHUS) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab. uuid:ebe5aeb5-9c47-48bc-a7d1-98a65811d3c7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:70BSQ12069 biolink:treats MONDO:0005090 PMID:41385096 "[{""id"":""uuid:dfe77c52-80cd-47b0-8378-45696c4e68f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8dfafcf8-9608-4a88-92c6-8a4e2f692550"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CAPLYTA is indicated for the treatment of: Schizophrenia in adults [see Clinical Studies (14.1) ] . Depressive episodes associated with bipolar I or II disorder (bipolar depression) in adults, as monotherapy and as adjunctive therapy with lithium or valproate [see Clinical Studies (14.2) ] . uuid:c7e10109-e2d3-46d0-91d5-1d8166ae2b33 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:70BSQ12069 biolink:treats MONDO:0024613 PMID:41385096 "[{""id"":""uuid:04c03401-4267-409a-8d64-8cfe40cb0fce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6d06b156-bc54-422c-9b63-600e7f476f41"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CAPLYTA is indicated for the treatment of: Schizophrenia in adults [see Clinical Studies (14.1) ] . Depressive episodes associated with bipolar I or II disorder (bipolar depression) in adults, as monotherapy and as adjunctive therapy with lithium or valproate [see Clinical Studies (14.2) ] . uuid:d8591b38-45a5-4789-91b5-86c0447c7938 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16469 biolink:treats MONDO:0006491 PMID:41385096 "[{""id"":""uuid:883d7888-1b7a-4295-92ab-ec0d78d0f532"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e92f3864-9ea5-4ac3-9327-2c1e4dfef002"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Estradiol is indicated in the treatment of: 1. Estrogen deficiency in Hysterectomized Women. (There is no evidence that estrogens are effective for nervous symptoms or depression which might occur during menopause, and they should not be used to treat these conditions.) 2. Atrophic vaginitis. 3. Kraurosis vulvae. 4. Female hypogonadism. 5. Female castration. 6. Primary ovarian failure. 7. Breast cancer (for palliation only) in approximately selected women and men with metastatic disease. 8. Postpartum breast engorgement - Although estrogens have been widely used for the prevention of postpatum breast engorgement, controlled studies have demonstrated that the incidence of significant painful engorgement in patients not receiving such hormonal therapy is low and usually responsive to appropriate analgesic or other supportive therapy. Consequently, the benefit to be derived from estrogen therapy for this indication must be carefully weighed against the potential increased risk or puerperal thromboembolism associated with the use of large doses of estrogen. 20,22 ESTRADIOL HAS NOT BEEN SHOWN TO BE EFFECTIVE FOR ANY PURPOSE DURING PREGNANCY AND ITS USE MAY CAUSE SEVERE HARM TO THE FETUS (SEE BOXED WARNING). uuid:83486375-8a25-40b2-a8a1-18e8e37e2aef biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16469 biolink:treats HP:0000134 PMID:41385096 "[{""id"":""uuid:0eb5e5f2-c8bd-4f57-a95f-da87096228af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0f3c325b-a64d-4a99-809c-1103fb07c45b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Estradiol is indicated in the treatment of: 1. Estrogen deficiency in Hysterectomized Women. (There is no evidence that estrogens are effective for nervous symptoms or depression which might occur during menopause, and they should not be used to treat these conditions.) 2. Atrophic vaginitis. 3. Kraurosis vulvae. 4. Female hypogonadism. 5. Female castration. 6. Primary ovarian failure. 7. Breast cancer (for palliation only) in approximately selected women and men with metastatic disease. 8. Postpartum breast engorgement - Although estrogens have been widely used for the prevention of postpatum breast engorgement, controlled studies have demonstrated that the incidence of significant painful engorgement in patients not receiving such hormonal therapy is low and usually responsive to appropriate analgesic or other supportive therapy. Consequently, the benefit to be derived from estrogen therapy for this indication must be carefully weighed against the potential increased risk or puerperal thromboembolism associated with the use of large doses of estrogen. 20,22 ESTRADIOL HAS NOT BEEN SHOWN TO BE EFFECTIVE FOR ANY PURPOSE DURING PREGNANCY AND ITS USE MAY CAUSE SEVERE HARM TO THE FETUS (SEE BOXED WARNING). uuid:3fe35f1c-5356-448b-aa0f-90b4a4413ef8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16469 biolink:treats NCIT:C92746 PMID:41385096 "[{""id"":""uuid:406d3b90-3fa3-4477-b785-4095bf40adbf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1b2b32a9-ee9b-4e00-921c-e46ba5be799e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Estradiol is indicated in the treatment of: 1. Estrogen deficiency in Hysterectomized Women. (There is no evidence that estrogens are effective for nervous symptoms or depression which might occur during menopause, and they should not be used to treat these conditions.) 2. Atrophic vaginitis. 3. Kraurosis vulvae. 4. Female hypogonadism. 5. Female castration. 6. Primary ovarian failure. 7. Breast cancer (for palliation only) in approximately selected women and men with metastatic disease. 8. Postpartum breast engorgement - Although estrogens have been widely used for the prevention of postpatum breast engorgement, controlled studies have demonstrated that the incidence of significant painful engorgement in patients not receiving such hormonal therapy is low and usually responsive to appropriate analgesic or other supportive therapy. Consequently, the benefit to be derived from estrogen therapy for this indication must be carefully weighed against the potential increased risk or puerperal thromboembolism associated with the use of large doses of estrogen. 20,22 ESTRADIOL HAS NOT BEEN SHOWN TO BE EFFECTIVE FOR ANY PURPOSE DURING PREGNANCY AND ITS USE MAY CAUSE SEVERE HARM TO THE FETUS (SEE BOXED WARNING). uuid:068952f8-f977-4926-b727-0618878f9077 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68478 biolink:treats MONDO:0700079 PMID:41385096 "[{""id"":""uuid:705c5f76-e267-4212-8606-591f453f6d50"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0bd86bae-7bb5-4b88-befb-78b13d6d2351"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Everolimus tablets are kinase inhibitor indicated for the treatment of: Postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole. ( 1.1 ) Adults with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery. ( 1.4 ) Everolimus tablets are kinase inhibitors indicated for the treatment of adult and pediatric patients aged 1 year and older with TSC who have subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected. ( 1.5 ) uuid:2aeac315-bb23-4b2a-b015-d5b870d7a664 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:72305 biolink:treats MONDO:0015183 PMID:41385096 "[{""id"":""uuid:551b299d-5dda-4ea4-80a7-0bf79bbef96a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5b6ce795-5883-45df-889f-93f0e4445c06"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:fdb1432f-581d-4dae-a502-9f194355bf96"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/revestive""]},{""id"":""uuid:f6b5a6c6-59eb-4fbf-b51b-6973c14dddd5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] GATTEX ® is indicated for the treatment of adults and pediatric patients 1 year of age and older with Short Bowel Syndrome (SBS) who are dependent on parenteral support .|[EMA] Revestive is indicated for the treatment of patients aged 1 year and above with Short Bowel Syndrome (SBS). Patients should be stable following a period of intestinal adaptation after surgery.Revestive is indicated for the treatment of patients aged 1 year and above with Short Bowel Syndrome. Patients should be stable following a period of intestinal adaptation after surgery.|[PMDA] A drug with a new active ingredient indicated for the treatment of short bowel syndrome. [Orphan drug] uuid:ffc3ca8a-9328-4a47-a189-3b34419f0c87 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:1864 biolink:treats MONDO:0005059 PMID:41385096 "[{""id"":""uuid:fa93cdd7-9d9c-4a19-ad5d-c2bf308b2188"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:90fee35d-a045-422e-93b1-968f134b54ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cyclophosphamide is an alkylating drug indicated for treatment of adults and pediatric patients with: Malignant Diseases: malignant lymphomas: Hodgkin's disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt's lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma. ( 1.1 ) uuid:8f785d25-db1f-45b5-bb1b-971b90a2c905 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:61390 biolink:treats UMLS:C0278987 PMID:41385096 "[{""id"":""uuid:011a298c-2caa-4f5b-96f9-bab2fe028af8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c9c1196d-6417-40e1-ad54-c965438f15ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] GILOTRIF is a kinase inhibitor indicated for: First-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test ( 1.1 ) Limitations of Use : Safety and efficacy of GILOTRIF were not established in patients whose tumors have resistant EGFR mutations ( 1.1 ) Treatment of patients with metastatic, squamous NSCLC progressing after platinum-based chemotherapy ( 1.2 ) uuid:54eeef1b-e215-4deb-9de0-4240b62a6710 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:61390 biolink:treats MONDO:0056806 PMID:41385096 "[{""id"":""uuid:25c2308d-a771-4996-9890-58a9ad740a7c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:59f8d724-de79-4cb7-b006-46305a615751"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] GILOTRIF is a kinase inhibitor indicated for: First-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test ( 1.1 ) Limitations of Use : Safety and efficacy of GILOTRIF were not established in patients whose tumors have resistant EGFR mutations ( 1.1 ) Treatment of patients with metastatic, squamous NSCLC progressing after platinum-based chemotherapy ( 1.2 ) uuid:c123f643-8c52-4fc3-be47-9de9af3c6069 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:56842108 biolink:treats MONDO:0011122 PMID:41385096 "[{""id"":""uuid:5885da27-1946-41db-acf3-6eb1440601a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e4f19951-4030-4607-b57f-a0d6292d8231"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] QSYMIA is indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in: Adults and pediatric patients aged 12 years and older with obesity Adults with overweight in the presence of at least one weight-related comorbid condition uuid:d3a05d5d-d2af-49d2-b0e8-cf9591497c80 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:56842108 biolink:treats EFO:0005935 PMID:41385096 "[{""id"":""uuid:9d625597-b7bc-4c56-9d3c-6656bac117d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cb5e83e1-5ea4-429a-9b8d-4a12fd44dfc0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] QSYMIA is indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in: Adults and pediatric patients aged 12 years and older with obesity Adults with overweight in the presence of at least one weight-related comorbid condition uuid:e77a7a7b-c69d-4398-a42f-532b93dd3065 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50841 biolink:treats MONDO:0001866 PMID:41385096 "[{""id"":""uuid:de1a9921-4cb5-4bd2-9b9e-6677789d54f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:90d4599d-6202-4d91-9022-665af3a756a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ADASUVE is indicated for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults [see Clinical Studies (14) ] . uuid:31f02f26-2805-4ec8-9ffc-7de302aeb8a9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:Q85FFY6179 biolink:treats MONDO:0018982 PMID:41385096 "[{""id"":""uuid:04fb0baf-6a55-4541-bee5-5184fe839381"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ac9630eb-3005-4d06-b1fd-1b9feffc37b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MIPLYFFA is indicated for use in combination with miglustat for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in adult and pediatric patients 2 years of age and older. uuid:ddf90712-5aeb-43c7-92c4-5bed31f6f2e4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63623 biolink:treats MONDO:0005240 PMID:41385096 "[{""id"":""uuid:882782cb-8f4f-42a4-9874-69fd06c61764"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bcaba865-b4ac-4edc-b53e-2694be529cc2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NEPHROSCAN, after radiolabeling with technetium Tc 99m, is indicated for use as an aid in the scintigraphic evaluation of renal parenchymal disorders in adult and pediatric patients including term neonates. uuid:35d6b8de-da0d-4b8a-912d-ebb5d2035341 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats UMLS:C3824874 PMID:41385096 "[{""id"":""uuid:1ffe7bb9-c8e1-4474-b2fa-da20d6b2c9e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:07e4dd47-4436-4246-a022-33c6780368e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Minocycline hydrochloride capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (Ornithosis) due to Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence . Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis. Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection). When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal infections. Infections in women caused by Neisseria gonorrhoeae. Syphilis caused by Treponema pallidum subspecies pallidum. Yaws caused by Treponema pallidum subspecies pertenue. Listeriosis due to Listeria monocytogenes. Anthrax due to Bacillus anthracis. Vincent’s infection caused by Fusobacterium fusiforme. Actinomycosis caused by Actinomyces israelii. Infections caused by Clostridium species . In acute intestinal amebiasis, minocycline may be a useful adjunct to amebicides. In severe acne , minocycline may be useful adjunctive therapy. Oral minocycline is indicated in the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:1f62d17f-1a65-4ebd-9170-07efdbeeded4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0005340 PMID:41385096 "[{""id"":""uuid:df7386b1-2244-440b-a105-9b0a1b4df53e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:41959ea9-3639-4011-b30c-785ec08ac886"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] A. For Intramuscular Administration When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of methylprednisolone acetate injectable suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic ophthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. B. For Intra-articular Or Soft Tissue Administration ( See WARNINGS ) Methylprednisolone acetate injectable suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. C. For Intralesional Administration Methylprednisolone acetate injectable suspension is indicated for intralesional use in alopecia areata, discoid lupus erythematosus; keloids, localized hypertrophic, infiltrated inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis) and psoriatic plaques; necrobiosis lipoidica diabeticorum. Methylprednisolone acetate injectable suspension also may be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:8aa0970a-cf9e-4b71-9316-7e962e7ab0f8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0019558 PMID:41385096 "[{""id"":""uuid:ae45975a-aa10-4435-8d68-e8f3e2e32e91"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8b9cff35-1241-44a8-b966-6c72c36c210e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] A. For Intramuscular Administration When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of methylprednisolone acetate injectable suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic ophthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. B. For Intra-articular Or Soft Tissue Administration ( See WARNINGS ) Methylprednisolone acetate injectable suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. C. For Intralesional Administration Methylprednisolone acetate injectable suspension is indicated for intralesional use in alopecia areata, discoid lupus erythematosus; keloids, localized hypertrophic, infiltrated inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis) and psoriatic plaques; necrobiosis lipoidica diabeticorum. Methylprednisolone acetate injectable suspension also may be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:e8007a94-8e9b-4708-9941-13ff875edf29 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0005348 PMID:41385096 "[{""id"":""uuid:27213a0c-b956-429a-95e5-e90f0df88572"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:12f774b0-a31c-4d5a-a590-b892f45e6a47"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] A. For Intramuscular Administration When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of methylprednisolone acetate injectable suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic ophthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. B. For Intra-articular Or Soft Tissue Administration ( See WARNINGS ) Methylprednisolone acetate injectable suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. C. For Intralesional Administration Methylprednisolone acetate injectable suspension is indicated for intralesional use in alopecia areata, discoid lupus erythematosus; keloids, localized hypertrophic, infiltrated inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis) and psoriatic plaques; necrobiosis lipoidica diabeticorum. Methylprednisolone acetate injectable suspension also may be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:59d6bccb-ff8d-4aa3-881f-7e4c1291bb1f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0006554 PMID:41385096 "[{""id"":""uuid:783ca7a9-7b84-41b7-b07b-f35768026249"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:69e54957-d9d1-4c1f-b5f1-672f3fdecb4a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] A. For Intramuscular Administration When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of methylprednisolone acetate injectable suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic ophthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. B. For Intra-articular Or Soft Tissue Administration ( See WARNINGS ) Methylprednisolone acetate injectable suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. C. For Intralesional Administration Methylprednisolone acetate injectable suspension is indicated for intralesional use in alopecia areata, discoid lupus erythematosus; keloids, localized hypertrophic, infiltrated inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis) and psoriatic plaques; necrobiosis lipoidica diabeticorum. Methylprednisolone acetate injectable suspension also may be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:28b26c2a-3a96-4aa9-9cc3-a7f46e205373 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0006572 PMID:41385096 "[{""id"":""uuid:4d762ba4-584b-4e31-839d-85a2dc1e2c3e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:014a7b91-3c07-4807-8cfe-7e2578222867"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] A. For Intramuscular Administration When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of methylprednisolone acetate injectable suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic ophthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. B. For Intra-articular Or Soft Tissue Administration ( See WARNINGS ) Methylprednisolone acetate injectable suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. C. For Intralesional Administration Methylprednisolone acetate injectable suspension is indicated for intralesional use in alopecia areata, discoid lupus erythematosus; keloids, localized hypertrophic, infiltrated inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis) and psoriatic plaques; necrobiosis lipoidica diabeticorum. Methylprednisolone acetate injectable suspension also may be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:10221f6c-b6e2-408b-a807-7bf1b1b85131 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0006585 PMID:41385096 "[{""id"":""uuid:b8a1781b-69f7-4bd1-8da5-cc1de27e62ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:24b104de-ce9f-4990-9181-30a83c4b93df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] A. For Intramuscular Administration When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of methylprednisolone acetate injectable suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic ophthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. B. For Intra-articular Or Soft Tissue Administration ( See WARNINGS ) Methylprednisolone acetate injectable suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. C. For Intralesional Administration Methylprednisolone acetate injectable suspension is indicated for intralesional use in alopecia areata, discoid lupus erythematosus; keloids, localized hypertrophic, infiltrated inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis) and psoriatic plaques; necrobiosis lipoidica diabeticorum. Methylprednisolone acetate injectable suspension also may be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:b5ab0358-46aa-45e0-a9be-3047008bf0ef biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats UMLS:C0392445 PMID:41385096 "[{""id"":""uuid:480a4072-0575-456d-9046-ecd1e53aa9db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:907b3a7d-47d0-4a84-b442-4ef3a9044ab8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] A. For Intramuscular Administration When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of methylprednisolone acetate injectable suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic ophthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. B. For Intra-articular Or Soft Tissue Administration ( See WARNINGS ) Methylprednisolone acetate injectable suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. C. For Intralesional Administration Methylprednisolone acetate injectable suspension is indicated for intralesional use in alopecia areata, discoid lupus erythematosus; keloids, localized hypertrophic, infiltrated inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis) and psoriatic plaques; necrobiosis lipoidica diabeticorum. Methylprednisolone acetate injectable suspension also may be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:0e21f102-f53c-4780-8d00-445ab0089745 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0019801 PMID:41385096 "[{""id"":""uuid:0ceee1a3-13d9-4048-8783-11ba8fb66de9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1338f139-727c-4d84-aa83-54b8e52fab64"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:f925d92a-722d-4ccf-baa0-bd30d87d7cb2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats UMLS:C1290158 PMID:41385096 "[{""id"":""uuid:e86302d7-cec3-486f-a7b4-164cef699426"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e26f718f-85ee-44fd-847a-f5ddafef2444"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:75f17a6e-3d6f-42c0-aca1-8b3c05008b04 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0006545 PMID:41385096 "[{""id"":""uuid:25e2ecbe-e00f-4891-a9a2-8db595850b3e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:588a1f55-27cd-46b6-820d-abb3c6c41bf7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:b05143a2-dab5-4610-b076-a33d18eacb75 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0006608 PMID:41385096 "[{""id"":""uuid:ec031023-fb0e-40f3-836a-76793e9b0937"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0eeef72a-c8b7-49e1-91dc-797133296392"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:efc5eb77-462e-409a-8d88-3856879bdb2e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0005083 PMID:41385096 "[{""id"":""uuid:9852d81c-1c94-4a4a-bc16-d08f832afe39"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2585c0c8-a5dd-4632-b13b-160a589db081"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:7294f352-b7ba-4643-a758-8b00eb845a65 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats UMLS:C0274440 PMID:41385096 "[{""id"":""uuid:dad5745e-e917-47a5-a984-2238a464863e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:df9098ca-d45d-4f79-ab9b-d71d13515c67"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:db21478d-d531-4db1-a02d-400ee2d5bf12 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0005883 PMID:41385096 "[{""id"":""uuid:021970e1-6656-4ba5-993f-9eb9db7cc825"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:21786289-6d09-464c-88ff-ed177158cde5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:15d7724d-5382-4f4e-bda1-aeb9f7cbc70f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0006814 PMID:41385096 "[{""id"":""uuid:2f189fd7-c82e-4504-ae03-39d4ad0a0e0b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b999dc35-0ff4-42c5-844a-be963df1e71f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:9bb96ea7-cf53-45ec-9087-16ab07c7fe79 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0004773 PMID:41385096 "[{""id"":""uuid:104a351d-c880-4d15-bc7b-86012a403722"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8e4ac72f-f670-48f3-99a5-ef51f9c19c06"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:406940a6-e248-4778-9545-8ddb2a106c25 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0004674 PMID:41385096 "[{""id"":""uuid:ad460b38-c1f1-4378-a15e-d2a75a39a1c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:92aad7a0-6a1c-4a50-b76e-07e2a4b14baf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:f8aaa154-e3ee-4d83-9db9-03985865fe6d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0006918 PMID:41385096 "[{""id"":""uuid:bb71976a-1097-4d74-bf02-f1c5ec44a0a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8f52ac10-9ea3-4233-ab9b-1aee17a066fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:e970700e-7ef4-42f7-b163-82398b92cea3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0001280 PMID:41385096 "[{""id"":""uuid:186ec79a-559e-45bb-803e-e7902ec57176"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a1c19351-17ce-4bcc-b3a1-4daded12477c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:ea761d8e-6d69-4a62-87c0-6e96890f1d9e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0005885 PMID:41385096 "[{""id"":""uuid:12015ee9-55e3-4d56-800b-ec2a27c5308c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dd308fbe-7aaf-497e-8e2a-2265d9b19174"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:3f65539e-9f46-4dd0-b568-ed0b7405f1f7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0006651 PMID:41385096 "[{""id"":""uuid:0e8b8751-e341-4c04-8698-b118cde6e688"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5b47d001-210e-4d3a-a392-d13c0292e42f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:e322b493-9158-4e3b-a5da-7da48eed92a3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0003085 PMID:41385096 "[{""id"":""uuid:cc284d94-0b7a-432c-b866-cc0b173cabba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:56a436c9-5855-4eda-bcb6-447e0da749ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:efb2f4ff-2888-4c35-8722-e2b396f679cb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0001034 PMID:41385096 "[{""id"":""uuid:3e6e858f-f060-48a1-9dd4-86a317574da8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ea53fca0-2967-4e68-8739-16461a8970e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:f63372c3-afe1-4c3d-93d2-27dc3b7de094 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0002572 PMID:41385096 "[{""id"":""uuid:8450c9e4-4180-4cc1-90fa-638bb1765fc6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b09d4c0a-ef68-41a6-8160-20988fab0dc3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:cca54b21-583c-4d14-a241-887af6d04ed5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats UMLS:C0002879 PMID:41385096 "[{""id"":""uuid:d9eb3d08-90bb-4ab4-9e4a-df048c7a79c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6f400af7-61b7-40a7-8683-23aa38e860f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:f0430c02-75f4-488e-a41c-996b0f6a5b82 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0019098 PMID:41385096 "[{""id"":""uuid:b166a2eb-efb3-49e3-b77f-f874a184d5ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:627b4339-5185-4d61-96fa-4592eb41c072"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:b21e259d-0b1b-430a-9827-a8208c035661 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0002280 PMID:41385096 "[{""id"":""uuid:489d0398-b717-43c0-9fea-500e4ed146a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3b87dce0-54db-4c7c-b518-bfeebde28055"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:ca105ff7-b25c-45c8-a055-7e239eb62a28 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats HP:0001908 PMID:41385096 "[{""id"":""uuid:06909ecc-b665-4760-815c-e85ddd2f8b8d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:621a6597-b11b-40a1-b281-d7df3a71d5d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:5a3e2d4e-64dc-4099-b5c5-3ad872469714 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0004355 PMID:41385096 "[{""id"":""uuid:cf454b15-6359-49d1-8f35-e441ed14271b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:687fabc0-f6ee-4ed5-8a05-a0be2c298282"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:880cbd9b-433c-47f1-9239-e1aab1768624 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0005377 PMID:41385096 "[{""id"":""uuid:d46ea56e-4da3-4630-89ea-31150df7ac14"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2b47c75f-a7c0-43bc-b124-6b0c34eeaf77"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:81e51196-b52b-4af4-af4d-40d5b4883139 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0006640 PMID:41385096 "[{""id"":""uuid:ba17983e-3f21-457e-84e2-5e548d32a194"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:194e23ca-f99b-4c62-84cf-b1f4bab259c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:2003a8c8-c3db-4c5e-86f8-5aa614f761d6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0000004 PMID:41385096 "[{""id"":""uuid:ebb7d79f-3cb9-455f-b4f0-853a34534014"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2ff26d36-15d2-470a-b55e-3e46de621c37"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:f64b90d3-1e23-4b72-837b-4d1c276ec99f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0005301 PMID:41385096 "[{""id"":""uuid:380a9b54-fe79-4c71-9e40-5762d1f6226d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4e25f5b9-3eba-4f7b-ac1a-58f26f96625f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:a2c1c644-1798-4327-a19f-01b741a1fcdd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0021632 PMID:41385096 "[{""id"":""uuid:d7eda2f2-2cd3-45c1-8ffe-f03e7575d079"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3a1acc6b-42be-46f6-8be4-c4cca5902258"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:e77af5ca-246a-4361-b000-26f77072c48b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:1040026 PMID:41385096 "[{""id"":""uuid:35281d6e-8c86-4a0d-8200-cfe4465c4b64"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:93320148-bc20-4a23-8be1-b3f2e6c31a08"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:ff32427f-cdcb-4fc8-8eab-12ad18215da9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0004670 PMID:41385096 "[{""id"":""uuid:92509eaf-b6ae-466a-b534-3912da968b62"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1a4afc14-e716-4f8a-85d3-188219fb0b26"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:686dd623-e3e1-4f94-b395-7aea519fd36c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0004874 PMID:41385096 "[{""id"":""uuid:ff94dbc9-f5a9-47b9-81f5-415a3f9c3984"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6fb9c8df-0128-4913-8266-f2dde79e624c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:0a1a369e-2b1d-4e89-b923-ed1d0b25d3c4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats NCIT:C27003 PMID:41385096 "[{""id"":""uuid:88d21c0b-00cb-4e6c-af05-5f0800a88e4f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:681ff28e-c2d0-443f-9b64-ca0054b11164"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of ketorolac tromethamine and other treatment options before deciding to use ketorolac. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Acute Pain in Adult Patients Ketorolac tromethamine is indicated for the short-term (≤5 days) management of moderately severe acute pain that requires analgesia at the opioid level, usually in a postoperative setting. Therapy should always be initiated with intravenous or intramuscular dosing of ketorolac tromethamine, and oral ketorolac tromethamine is to be used only as continuation treatment, if necessary. The total combined duration of use of ketorolac tromethamine injection and oral ketorolac tromethamine is not to exceed 5 days of use because of the potential of increasing the frequency and severity of adverse reactions associated with the recommended doses (see WARNINGS , PRECAUTIONS , DOSAGE AND ADMINISTRATION , and ADVERSE REACTIONS ). Patients should be switched to alternative analgesics as soon as possible, but ketorolac tromethamine therapy is not to exceed 5 days. uuid:5b4d43bf-2990-480d-b8ed-0547714e453d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats NCIT:C34887 PMID:41385096 "[{""id"":""uuid:16c3ce28-7082-47e3-958f-7f9471fd7ef8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:361b8fa4-edc1-4d97-9d26-312e0e892cba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of ketorolac tromethamine and other treatment options before deciding to use ketorolac. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Acute Pain in Adult Patients Ketorolac tromethamine is indicated for the short-term (≤5 days) management of moderately severe acute pain that requires analgesia at the opioid level, usually in a postoperative setting. Therapy should always be initiated with intravenous or intramuscular dosing of ketorolac tromethamine, and oral ketorolac tromethamine is to be used only as continuation treatment, if necessary. The total combined duration of use of ketorolac tromethamine injection and oral ketorolac tromethamine is not to exceed 5 days of use because of the potential of increasing the frequency and severity of adverse reactions associated with the recommended doses (see WARNINGS , PRECAUTIONS , DOSAGE AND ADMINISTRATION , and ADVERSE REACTIONS ). Patients should be switched to alternative analgesics as soon as possible, but ketorolac tromethamine therapy is not to exceed 5 days. uuid:361f0673-1261-4a4d-aeb2-b6e43010d433 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:37804 biolink:treats MONDO:0005010 PMID:41385096 "[{""id"":""uuid:ad0677b5-49a3-49ca-a7f3-32621b53eee5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:95ddd31b-b655-4a0f-a084-93fde3aa212d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Thallous Chloride Tl 201 Injection is a diagnostic radiopharmaceutical indicated for Myocardial perfusion imaging with planar scintigraphy or single-photon emission computed tomography (SPECT) for the diagnosis of coronary artery disease by localization of: Non-reversible defects (myocardial infarction) which may have prognostic value regarding survival. Reversible defects (myocardial ischemia) when used in conjunction with exercise or pharmacologic stress. Localization of sites of parathyroid hyperactivity pre- and post-operatively in patients with elevated serum calcium and parathyroid hormone levels. uuid:a46710d2-623b-4e6c-bee1-d863fa789c65 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:37804 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:7722de24-e205-4ebc-bcdf-26114f25d95c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f8faa392-c11c-4f16-bd51-f67950fd1e45"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Thallous Chloride Tl 201 Injection is a diagnostic radiopharmaceutical indicated for Myocardial perfusion imaging with planar scintigraphy or single-photon emission computed tomography (SPECT) for the diagnosis of coronary artery disease by localization of: Non-reversible defects (myocardial infarction) which may have prognostic value regarding survival. Reversible defects (myocardial ischemia) when used in conjunction with exercise or pharmacologic stress. Localization of sites of parathyroid hyperactivity pre- and post-operatively in patients with elevated serum calcium and parathyroid hormone levels. uuid:cad8abaf-179d-402f-9dc1-705a6721e3a3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:37804 biolink:treats MONDO:0024644 PMID:41385096 "[{""id"":""uuid:88cbc187-92dd-4706-aea9-d98549c8213e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f07609f3-d733-4e02-b0b8-accb5713dd55"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Thallous Chloride Tl 201 Injection is a diagnostic radiopharmaceutical indicated for Myocardial perfusion imaging with planar scintigraphy or single-photon emission computed tomography (SPECT) for the diagnosis of coronary artery disease by localization of: Non-reversible defects (myocardial infarction) which may have prognostic value regarding survival. Reversible defects (myocardial ischemia) when used in conjunction with exercise or pharmacologic stress. Localization of sites of parathyroid hyperactivity pre- and post-operatively in patients with elevated serum calcium and parathyroid hormone levels. uuid:969e38f0-7400-43d2-92d2-6badf7041454 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:37804 biolink:treats MONDO:0001741 PMID:41385096 "[{""id"":""uuid:7d78c04e-fb1c-41b1-b9eb-350ad4103bb7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8c551f97-843a-44d6-a4ee-8f95a242c518"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Thallous Chloride Tl 201 Injection is a diagnostic radiopharmaceutical indicated for Myocardial perfusion imaging with planar scintigraphy or single-photon emission computed tomography (SPECT) for the diagnosis of coronary artery disease by localization of: Non-reversible defects (myocardial infarction) which may have prognostic value regarding survival. Reversible defects (myocardial ischemia) when used in conjunction with exercise or pharmacologic stress. Localization of sites of parathyroid hyperactivity pre- and post-operatively in patients with elevated serum calcium and parathyroid hormone levels. uuid:a0d50144-912f-43c3-bb0e-cc0591aec33c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1942744 biolink:treats MONDO:0019457 PMID:41385096 "[{""id"":""uuid:c52a4bb1-a66c-4796-85c5-70a77f0c6c77"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:cc70df25-7b0e-4d15-8fbf-b8a416128993"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:70e6fb32-9739-4f35-a8c8-bc3262258386"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/vyxeos-liposomal""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] VYXEOS is indicated for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.|[EMA] Vyxeos liposomal is indicated for the treatment of adults with newly diagnosed, therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC). uuid:b0d3bc01-8b5c-4632-ba10-b217a9fce5b4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1942744 biolink:treats MONDO:0019456 PMID:41385096 "[{""id"":""uuid:bb6be285-54a1-42ec-8e49-58e73bf7aa18"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:5e6dd38b-5dae-45d9-9919-26c6f283233b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:71ae6690-af1b-4947-a7c0-5ac81cfca511"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/vyxeos-liposomal""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] VYXEOS is indicated for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.|[EMA] Vyxeos liposomal is indicated for the treatment of adults with newly diagnosed, therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC). uuid:4e84c1d8-2b1a-4490-a6c2-f45c8a70a941 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:30830 biolink:treats HP:0001262 PMID:41385096 "[{""id"":""uuid:b251964b-daf6-41fb-beb8-6061afa3416a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8dde29af-ffb9-4705-911e-60c84b743a25"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XYWAV is a central nervous system depressant indicated for the treatment of: • Cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy ( 1.1 ). • Idiopathic Hypersomnia (IH) in adults ( 1.2 ). uuid:8e9f0c07-84f1-4745-b0fd-28b303b58d03 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:30830 biolink:treats MONDO:0021107 PMID:41385096 "[{""id"":""uuid:3dd0404d-c586-450c-aae6-c9d7d7438074"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ad7c6f94-8464-4ed9-a7af-9fe9e4f88791"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XYWAV is a central nervous system depressant indicated for the treatment of: • Cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy ( 1.1 ). • Idiopathic Hypersomnia (IH) in adults ( 1.2 ). uuid:1614d6fa-ba61-439d-8000-da00bc635633 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:30830 biolink:treats MONDO:0018044 PMID:41385096 "[{""id"":""uuid:521b0688-0ada-4a80-aae3-4bd112ad93bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:94449f7b-4de8-48f6-8d1e-11576a6cbee8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XYWAV is a central nervous system depressant indicated for the treatment of: • Cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy ( 1.1 ). • Idiopathic Hypersomnia (IH) in adults ( 1.2 ). uuid:90c73953-f381-4f31-b7fa-cf792f9ec9b6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32660 biolink:treats MONDO:0004967 PMID:41385096 "[{""id"":""uuid:d7671479-d9e7-4f51-92e1-6cffcb0a14ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:1c5c21c3-2bc9-4773-b501-2d6110910354"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:81583b47-7559-4a1d-a199-394c3a10dc9b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/spectrila""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] RYLAZE is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients 1 month or older who have developed hypersensitivity to E. coli -derived asparaginase.|[EMA] Spectrila is indicated as a component of antineoplastic combination therapy for the treatment of acute lymphoblastic leukaemia (ALL) in paediatric patients from birth to 18 years and adults. uuid:bce94bac-d0e8-46a5-a346-c460ea0a7918 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32660 biolink:treats MONDO:0000873 PMID:41385096 "[{""id"":""uuid:b9bcfa54-000a-455a-8785-b0618eb85fca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:93de32ca-9c02-410c-abe6-95b7fa3d3280"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:bdb84535-a90e-4f71-9835-70725f8479a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/enrylaze""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] RYLAZE is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients 1 month or older who have developed hypersensitivity to E. coli -derived asparaginase.|[EMA] Enrylaze is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma (LBL) in adult and paediatric patients (1 month and older) who developed hypersensitivity or silent inactivation to E. coli-derived asparaginase. uuid:e445cae7-e2b0-4eed-a291-0de7e58b2313 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:WP58SVM6R4 biolink:treats MONDO:0011758 PMID:41385096 "[{""id"":""uuid:01fd4005-31c0-42cb-bfde-046ee2e6b00c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9946e464-66d1-4218-a53c-4f8a5086d2e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ALDURAZYME ® is indicated for the treatment of: adult and pediatric patients with Hurler and Hurler-Scheie forms of Mucopolysaccharidosis I (MPS I) and patients with the Scheie form of MPS I who have moderate to severe symptoms. uuid:41339f0e-3a41-4da8-8ad8-9a9fb2a35bf8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:WP58SVM6R4 biolink:treats MONDO:0011759 PMID:41385096 "[{""id"":""uuid:4cf4ec54-1b85-43a5-8a72-71fbb56f9c04"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2181bde6-8753-48fa-8917-c35f9cc395d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ALDURAZYME ® is indicated for the treatment of: adult and pediatric patients with Hurler and Hurler-Scheie forms of Mucopolysaccharidosis I (MPS I) and patients with the Scheie form of MPS I who have moderate to severe symptoms. uuid:71f3727c-5d68-4435-bc71-9fce729610ca biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:WP58SVM6R4 biolink:treats MONDO:0011760 PMID:41385096 "[{""id"":""uuid:080fd24d-dc36-4a2c-ad38-2fe4d177e5fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:949a356e-5738-4bfe-ad7c-207db2591248"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ALDURAZYME ® is indicated for the treatment of: adult and pediatric patients with Hurler and Hurler-Scheie forms of Mucopolysaccharidosis I (MPS I) and patients with the Scheie form of MPS I who have moderate to severe symptoms. uuid:79ec050b-d165-4dc6-83dc-af69d047b484 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:100241 biolink:treats MONDO:0001051 PMID:41385096 "[{""id"":""uuid:22b95464-f74e-4c56-8712-7b741d0fab52"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e0ad8c51-7a5c-4d0b-984c-557b83b1be6b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CETRAXAL is a quinolone antimicrobial indicated for the treatment of acute otitis externa due to susceptible isolates of Pseudomonas aeruginosa or Staphylococcus aureus. uuid:ef407526-160c-4315-8e1d-c8ecbc095cea biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:T9FVH03HMZ biolink:treats MONDO:0004967 PMID:41385096 "[{""id"":""uuid:1968e0d4-9088-4d24-8520-c81a7ba1f998"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8b82b128-fbfd-4b2e-850f-1338d96ca563"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ASPARLAS is an asparagine specific enzyme indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia in pediatric and young adult patients age 1 month to 21 years. ( 1.1 ) uuid:fefc4ae5-c53a-431b-8cb8-535ccea9e235 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1291856 biolink:treats MONDO:0005324 PMID:41385096 "[{""id"":""uuid:47992e33-f4e0-4f43-bae7-3dd2cf6a0500"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d2abfd8d-ae3e-42cf-9d2f-21c2c6b54fbf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azelastine hydrochloride and fluticasone propionate nasal spray is indicated for the relief of symptoms of seasonal allergic rhinitis in adult and pediatric patients 6 years of age and older. uuid:2444d1ed-92a7-43bb-944d-36b31ccc83a8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3S252O2Z4X biolink:treats MONDO:0015541 PMID:41385096 "[{""id"":""uuid:891a5e6f-53a8-4add-9ef7-8d3857b2e0a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3e0d1773-c445-4b14-8a84-109c87cf30b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] GAMIFANT is indicated for the treatment of adult and pediatric (newborn and older) patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance with conventional HLH therapy. uuid:15dae003-dbd8-40e7-b702-27e0662b1ba8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3S252O2Z4X biolink:treats MONDO:0015540 PMID:41385096 "[{""id"":""uuid:fa0a3b17-e4bc-4f33-b0a3-4fcf222703d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f4d891ee-0bd8-492f-b8ad-702f9da9df3f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] GAMIFANT is indicated for the treatment of adult and pediatric (newborn and older) patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance with conventional HLH therapy. uuid:560a8088-3fe4-4822-af11-ee19c46cad60 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:100241 biolink:treats UMLS:C0854135 PMID:41385096 "[{""id"":""uuid:4a36e0bb-64ac-4256-9165-7c47198604f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:de95071a-2970-4a05-80ec-ca6fec7f9e17"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ciprofloxacin Otic Solution is a quinolone antimicrobial indicated for the treatment of acute otitis externa due to susceptible isolates of Pseudomonas aeruginosa or Staphylococcus aureus . uuid:8505e421-7e4a-4f4a-a065-75c98991e0e8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:145536 biolink:treats MONDO:0009693 PMID:41385096 "[{""id"":""uuid:8fe1e6a9-462c-4c29-8249-9b14b28624fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c0c3c245-30bf-4a95-88db-426aab778465"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] APHEXDA is indicated in combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma. uuid:c8a4e0ca-b98b-40f3-a802-2fc4c4bb2a06 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3638 biolink:treats MONDO:0005136 PMID:41385096 "[{""id"":""uuid:71a49331-6b78-4dd2-8fa9-404c9e3d2ced"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fb21c15f-dd14-473e-bba5-f68cedd1e5ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Chloroquine phosphate tablets are indicated for the: Treatment of uncomplicated malaria due to susceptible strains of P. falciparum, P. malariae, P. ovale, and P. vivax . Prophylaxis of malaria in geographic areas where resistance to chloroquine is not present. Treatment of extraintestinal amebiasis. Chloroquine phosphate tablets do not prevent relapses in patients with vivax or ovale malaria because it is not effective against exoerythrocytic forms of the parasites. Limitations of Use in Malaria: Do not use Chloroquine phosphate tablets for the treatment of complicated malaria (high-grade parasitemia and/or complications e.g., cerebral malaria or acute renal failure). Do not use Chloroquine phosphate tablets for malaria prophylaxis in areas where chloroquine resistance occurs, Resistance to Chloroquine phosphate tablets is widespread in P. falciparum , and is reported in P. vivax (see WARNINGS ). Concomitant therapy with an 8-aminoquinoline drug is necessary for treatment of the hypnozoite liver stage forms of P. vivax and P. ovale (see DOSAGE AND ADMINISTRATION ). uuid:cd731da1-f150-4f8f-b8a9-6c647b3c199f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32130 biolink:treats UMLS:C0043255 PMID:41385096 "[{""id"":""uuid:01287ef7-05de-4f23-87d0-c568f5b7d353"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4a098805-0c3c-4f9c-99f2-afb840f3181b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] On the skin, applications of silver nitrate are recommended for cauterization of wounds and sluggish ulcers, also for removal of granulation tissue and warts. On mucous membranes, silver nitrate may be applied to small ulcers and aphthae in the mouth resulting from injury or stomatitis, to infected tonsils, to rectal fissures and fistulae, and to vaginal or cervical ulcerations or erosions. Epistaxis may be controlled by direct application to the site of hemorrhage within the nostrils. uuid:16ebacc2-8d9c-4c85-99b9-7ef771d2be88 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32130 biolink:treats MONDO:0005318 PMID:41385096 "[{""id"":""uuid:5ac1eba0-742b-49b6-8df9-249ab2474126"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:066a6522-2e8e-4ac5-98f0-6e634cbb39a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] On the skin, applications of silver nitrate are recommended for cauterization of wounds and sluggish ulcers, also for removal of granulation tissue and warts. On mucous membranes, silver nitrate may be applied to small ulcers and aphthae in the mouth resulting from injury or stomatitis, to infected tonsils, to rectal fissures and fistulae, and to vaginal or cervical ulcerations or erosions. Epistaxis may be controlled by direct application to the site of hemorrhage within the nostrils. uuid:2ec5b47c-a4f4-4414-8227-7bf0a8285828 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32130 biolink:treats MONDO:0004842 PMID:41385096 "[{""id"":""uuid:b7d76cc6-49c3-41ed-aafa-05ab84d0fabb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b088fe98-5f38-409f-8b97-16cfd4b9f4dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] On the skin, applications of silver nitrate are recommended for cauterization of wounds and sluggish ulcers, also for removal of granulation tissue and warts. On mucous membranes, silver nitrate may be applied to small ulcers and aphthae in the mouth resulting from injury or stomatitis, to infected tonsils, to rectal fissures and fistulae, and to vaginal or cervical ulcerations or erosions. Epistaxis may be controlled by direct application to the site of hemorrhage within the nostrils. uuid:6e22dce3-460c-4a31-b80c-829d68e3eb9a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32130 biolink:treats MONDO:0001039 PMID:41385096 "[{""id"":""uuid:e2dce8c4-f223-4b76-8767-9211681287d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:63b6f7f3-7cd7-40c5-9bad-798e71cf2037"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] On the skin, applications of silver nitrate are recommended for cauterization of wounds and sluggish ulcers, also for removal of granulation tissue and warts. On mucous membranes, silver nitrate may be applied to small ulcers and aphthae in the mouth resulting from injury or stomatitis, to infected tonsils, to rectal fissures and fistulae, and to vaginal or cervical ulcerations or erosions. Epistaxis may be controlled by direct application to the site of hemorrhage within the nostrils. uuid:56290b47-964e-4fb2-b34d-a7a8f3811959 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32130 biolink:treats HP:0100590 PMID:41385096 "[{""id"":""uuid:5e44907c-0de6-4f9e-84a6-3348f87457c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6699ce2e-109b-4d77-bb42-b94630fd69f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] On the skin, applications of silver nitrate are recommended for cauterization of wounds and sluggish ulcers, also for removal of granulation tissue and warts. On mucous membranes, silver nitrate may be applied to small ulcers and aphthae in the mouth resulting from injury or stomatitis, to infected tonsils, to rectal fissures and fistulae, and to vaginal or cervical ulcerations or erosions. Epistaxis may be controlled by direct application to the site of hemorrhage within the nostrils. uuid:9fed60c4-6a84-490c-aa36-627bf68a3996 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32130 biolink:treats UMLS:C0566951 PMID:41385096 "[{""id"":""uuid:f867bcd5-cbe5-4be4-94f1-2e587c011fbf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6bc6480b-5ae7-4828-9f27-a68c2d5935aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] On the skin, applications of silver nitrate are recommended for cauterization of wounds and sluggish ulcers, also for removal of granulation tissue and warts. On mucous membranes, silver nitrate may be applied to small ulcers and aphthae in the mouth resulting from injury or stomatitis, to infected tonsils, to rectal fissures and fistulae, and to vaginal or cervical ulcerations or erosions. Epistaxis may be controlled by direct application to the site of hemorrhage within the nostrils. uuid:0d4124ee-9874-421f-b3ea-0adc136e4b63 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32130 biolink:treats MONDO:0006696 PMID:41385096 "[{""id"":""uuid:778db716-ad7f-4078-913a-c792d35cf361"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:98419eca-7d75-410b-94ac-184e928c804f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] On the skin, applications of silver nitrate are recommended for cauterization of wounds and sluggish ulcers, also for removal of granulation tissue and warts. On mucous membranes, silver nitrate may be applied to small ulcers and aphthae in the mouth resulting from injury or stomatitis, to infected tonsils, to rectal fissures and fistulae, and to vaginal or cervical ulcerations or erosions. Epistaxis may be controlled by direct application to the site of hemorrhage within the nostrils. uuid:3132a31a-3ec9-4a28-a7df-3f89f578723f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32130 biolink:treats MONDO:0001433 PMID:41385096 "[{""id"":""uuid:6fda9957-e435-4805-accb-2ac93127dcaf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3e6160b8-6d7d-4f1f-a923-e451b84d7723"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] On the skin, applications of silver nitrate are recommended for cauterization of wounds and sluggish ulcers, also for removal of granulation tissue and warts. On mucous membranes, silver nitrate may be applied to small ulcers and aphthae in the mouth resulting from injury or stomatitis, to infected tonsils, to rectal fissures and fistulae, and to vaginal or cervical ulcerations or erosions. Epistaxis may be controlled by direct application to the site of hemorrhage within the nostrils. uuid:aca9117d-fef7-4725-a827-b914f72faf34 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32130 biolink:treats HP:0000421 PMID:41385096 "[{""id"":""uuid:f318a6dc-04b1-4dd7-967e-70c9c8b2ae80"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8d6d991e-8820-465e-b3b3-d103c96e5d0b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] On the skin, applications of silver nitrate are recommended for cauterization of wounds and sluggish ulcers, also for removal of granulation tissue and warts. On mucous membranes, silver nitrate may be applied to small ulcers and aphthae in the mouth resulting from injury or stomatitis, to infected tonsils, to rectal fissures and fistulae, and to vaginal or cervical ulcerations or erosions. Epistaxis may be controlled by direct application to the site of hemorrhage within the nostrils. uuid:a0f6cb48-aeae-47d7-aae5-4cf091e9fbb4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:D7RD81HE4W biolink:treats NCIT:C97128 PMID:41385096 "[{""id"":""uuid:824d0f7b-cfcb-4034-ae85-db82f67d9869"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0aabee6f-4641-459f-b62e-a50c4bfa6318"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] THYMOGLOBULIN is indicated for the prophylaxis and treatment of acute rejection in patients receiving a kidney transplant. THYMOGLOBULIN is to be used in conjunction with concomitant immunosuppression. uuid:1cf973d1-a52a-4eb6-873d-63917e70367d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134718 biolink:treats MONDO:0005180 PMID:41385096 "[{""id"":""uuid:3dc0f952-aa40-4ff6-8752-5ae968a249a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:662938e3-bcac-44c1-9307-30ee1dbebbcb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:76a53fea-10df-4128-92f9-85b2ceb97da4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:02137152-1d15-4db0-b51b-f546d253ae46"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] XADAGO is indicated as adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease (PD) experiencing ""off"" episodes.|[EMA] Xadago is indicated for the treatment of adult patients with idiopathic Parkinson’s disease (PD) as add-on therapy to a stable dose of Levodopa (L-dopa) alone or in combination with other PD medicinal products in mid-to late-stage fluctuating patients.|[PMDA] A drug with a new active ingredient indicated for the improvement of wearing-off phenomenon in patients with Parkinson’s disease under the treatment with levodopa-containing preparations." uuid:6d15cb87-d41f-42a8-8819-20f380be8cd8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46859 biolink:treats MONDO:0008638 PMID:41385096 "[{""id"":""uuid:201488f9-9e6f-4f4b-a2d4-6e0dbdc92209"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d3dba8e2-1ed2-43f9-80bc-ffd94ff93cbf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e3453aca-b09c-4265-abfc-919d7d2b8104"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VARITHENA (polidocanol injectable foam) is indicated for the treatment of incompetent great saphenous veins, accessory saphenous veins, and visible varicosities of the great saphenous vein (GSV) system above and below the knee. VARITHENA improves the symptoms of superficial venous incompetence and the appearance of visible varicosities.|[PMDA] Drugs with a new route of administration, used as a sclerosant to treat primary varicose veins of the lower extremity (excluding the varicosity of the main stem of the saphenous vein). uuid:d4574fb3-8335-46ee-99aa-5b32ae374440 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46859 biolink:treats MONDO:0000945 PMID:41385096 "[{""id"":""uuid:397513b0-2627-48a6-9674-b70d463c829d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2b923766-c70c-43e4-ae8c-ec9d40c5a238"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VARITHENA (polidocanol injectable foam) is indicated for the treatment of incompetent great saphenous veins, accessory saphenous veins, and visible varicosities of the great saphenous vein (GSV) system above and below the knee. VARITHENA improves the symptoms of superficial venous incompetence and the appearance of visible varicosities. uuid:457df6f7-7fe7-4420-aba8-fded37156d54 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8694 biolink:treats MONDO:0013600 PMID:41385096 "[{""id"":""uuid:0e2bd68c-3ce9-4d3d-aef2-8a9d59fb4258"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c66d5229-d304-43ae-b67b-d2293d27c4c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Quazepam Tablets are indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. The effectiveness of Quazepam Tablets has been established in placebo-controlled clinical studies of 5 nights duration in acute and chronic insomnia. The sustained effectiveness of Quazepam Tablets has been established in chronic insomnia in a sleep lab (polysomnographic) study of 28 nights duration. Because insomnia is often transient and intermittent, the prolonged administration of Quazepam Tablets is generally not necessary or recommended. Since insomnia may be a symptom of several other disorders, the possibility that the complaint may be related to a condition for which there is a more specific treatment should be considered. uuid:1fc7d601-8359-4ab4-8033-bf4d583b8afb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8694 biolink:treats UMLS:C4546137 PMID:41385096 "[{""id"":""uuid:4fbe8199-2fab-48de-a102-8b4f0fb4656d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:07964cbc-d504-4390-8e38-afff9dfa010e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Quazepam Tablets are indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. The effectiveness of Quazepam Tablets has been established in placebo-controlled clinical studies of 5 nights duration in acute and chronic insomnia. The sustained effectiveness of Quazepam Tablets has been established in chronic insomnia in a sleep lab (polysomnographic) study of 28 nights duration. Because insomnia is often transient and intermittent, the prolonged administration of Quazepam Tablets is generally not necessary or recommended. Since insomnia may be a symptom of several other disorders, the possibility that the complaint may be related to a condition for which there is a more specific treatment should be considered. uuid:e546e98c-56f1-4f74-a4e5-3de7e201ac8c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8694 biolink:treats UMLS:C0751249 PMID:41385096 "[{""id"":""uuid:676bd25b-a6bd-4a7d-84f6-b6b1f2a724f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:da63b132-7c79-430f-90a8-b8fc6e122f76"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Quazepam Tablets are indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. The effectiveness of Quazepam Tablets has been established in placebo-controlled clinical studies of 5 nights duration in acute and chronic insomnia. The sustained effectiveness of Quazepam Tablets has been established in chronic insomnia in a sleep lab (polysomnographic) study of 28 nights duration. Because insomnia is often transient and intermittent, the prolonged administration of Quazepam Tablets is generally not necessary or recommended. Since insomnia may be a symptom of several other disorders, the possibility that the complaint may be related to a condition for which there is a more specific treatment should be considered. uuid:b730e194-df70-4ffd-b558-9628c26a3846 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:21904A5386 biolink:treats MONDO:0004652 PMID:41385096 "[{""id"":""uuid:8b924635-30f9-404e-ab24-d40827260e60"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1f0177ea-1367-42aa-ab78-059e4da3cfdf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XENLETA is a pleuromutilin antibacterial indicated for the treatment of adults with community-acquired bacterial pneumonia (CABP) caused by susceptible microorganisms. ( 1.1 ) To reduce the development of drug resistant bacteria and maintain the effectiveness of XENLETA and other antibacterial drugs, XENLETA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.2 ) uuid:67329725-23dd-4943-b6c9-fb40d492750d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22652 biolink:treats HP:0000978 PMID:41385096 "[{""id"":""uuid:bbe202e9-fbe6-4d00-ac60-9b8d02c2c0e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2569985f-8b85-493b-8ee2-edb1cabbc0b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bruselix™ Bruising Tablets are formulated to provide nutritional support during the body’s natural recovery process. They may be helpful for individuals experiencing bruising due to minor injuries, surgical procedures, or sensitive skin. The formula contains antioxidants, enzymes, and natural extracts that are traditionally used to support overall skin health and recovery. uuid:c4cc2c7d-1c0b-4dd8-b29f-7687215014a5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:LMQ24G57E9 biolink:treats MONDO:0013600 PMID:41385096 "[{""id"":""uuid:0b3d8369-6bb6-4bc2-85db-a3e460885c30"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f379a7d4-dbb0-43b4-8d2c-1c1e1fecdcdc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:9c4cfd2f-b699-4d01-847b-ab8253b4b0a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] QUVIVIQ is indicated for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance [see Clinical Studies (14.1) ] .|[EMA] Quviviq is indicated for the treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning. uuid:b087d331-3d39-44c0-a1bb-b6aa4c219b10 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2386036 biolink:treats MONDO:0005002 PMID:41385096 "[{""id"":""uuid:b71a6e81-b44e-4177-b566-7b488b59e579"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:5e3a098e-c2a2-4782-aafa-0aa48ee5e81e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e3e3fcb0-d370-42c0-a4a8-d107b07183a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/trixeo-aerosphere""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] BREZTRI AEROSPHERE is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Limitations of Use: BREZTRI AEROSPHERE is not indicated for the relief of acute bronchospasm or for the treatment of asthma [see Warnings and Precautions (5.1 , 5.2) ] .|[EMA] Trixeo Aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long acting beta2 agonist or combination of a long-acting beta2 agonist and a long acting muscarinic antagonist. uuid:cb5ad106-3be5-4fb6-a263-3e26978a1431 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2386036 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:fc7e2a85-7cd9-4b57-9293-1c51c3b7c76c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e5ad1c40-88bd-484c-9352-a8c75eedd0d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BREZTRI AEROSPHERE is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Limitations of Use: BREZTRI AEROSPHERE is not indicated for the relief of acute bronchospasm or for the treatment of asthma [see Warnings and Precautions (5.1 , 5.2) ] . uuid:21bcf98e-fc38-45da-b682-0727867d93fb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:177453 biolink:treats MONDO:0005133 PMID:41385096 "[{""id"":""uuid:6b0a05bd-1a1c-434e-8743-49c53532d962"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:22dc560f-a274-4c2d-ab71-f8ff0f6a21f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ORILISSA is indicated for the management of moderate to severe pain associated with endometriosis. Limitation s of Use: Limit the duration of use based on the dose and coexisting condition (see Table 1 ) [see D osage and Administration ( 2.1 ) and Warnings and Precautions ( 5.1 ) ] . uuid:726ca1c0-4c4f-4231-a10b-f99dcea0993f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:ZJ0EKR6M10 biolink:treats MONDO:0008315 PMID:41385096 "[{""id"":""uuid:a640e90b-fe9d-4c20-807a-b90b9ca09432"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:81cc6263-1379-4f2c-9969-00d04f5b16a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:6144c54e-c9d5-4b2e-a68a-d34d27107d39"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/locametz""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gallium Ga 68 Gozeotide Injection is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer: with suspected metastasis who are candidates for initial definitive therapy. with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level.|[EMA] This medicinal product is for diagnostic use only. Locametz, after radiolabelling with gallium 68, is indicated for the detection of prostate specific membrane antigen (PSMA) positive lesions with positron emission tomography (PET) in adults with prostate cancer (PCa) in the following clinical settings:Primary staging of patients with high risk PCa prior to primary curative therapy,Suspected PCa recurrence in patients with increasing levels of serum prostate specific antigen (PSA) after primary curative therapy,Identification of patients with PSMA positive progressive metastatic castration resistant prostate cancer (mCRPC) for whom PSMA targeted therapy is indicated (see section 4.4). uuid:dbc23906-38b4-45ef-a00a-9cf97df1d815 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47426 biolink:treats MONDO:0006932 PMID:41385096 "[{""id"":""uuid:be03510f-94d1-48d6-9046-b6ef25294b5c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:293266ff-a44b-404e-8aff-9c7f451fccdd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FUROSEMIDE INJECTION is a loop diuretic indicated for: • The treatment of edema associated with heart failure, cirrhosis of the liver, and renal disease ( 1.1 ) • Acute pulmonary edema as adjunctive therapy ( 1.2 ) uuid:f0b4893d-e186-48cd-9a3b-34b7b73bc085 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10125 biolink:treats UMLS:C0393759 PMID:41385096 "[{""id"":""uuid:e59caec9-df6b-446f-a9ce-3efc0c4013be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8f858dd9-3211-4341-b40a-ab21cbf24e09"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Zolpidem Tartrate Capsules are indicated for the short-term treatment of transient insomnia characterized by difficulties with sleep initiation in adults younger than 65 years of age [see Dosage and Administration ( 2.1 ) and Clinical Studies ( 14 )] . uuid:5ad5778a-77bc-47bd-b6f8-4f6fe4f66aca biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:F7BD3Z4X8L biolink:treats MONDO:0008170 PMID:41385096 "[{""id"":""uuid:577c16be-d347-4377-9143-6c46c09f708d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ba3ea079-4805-47d0-b104-fe8f96aa9797"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CYTALUX is indicated as an adjunct for intraoperative identification of: Malignant lesions in adult patients with ovarian cancer. Malignant and non-malignant pulmonary lesions in adult patients with known or suspected cancer in the lung. uuid:4bcafb06-2fb1-4055-b3e4-e9479c0d01df biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:QQA9MLH692 biolink:treats MONDO:0000901 PMID:41385096 "[{""id"":""uuid:ef83952c-b542-475e-8a4a-e6c39faa5b71"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:1af8b966-10f9-4cdb-b44b-c83823aff3e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:0b7b36ff-a913-4474-be33-ef720edccdb3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/minjuvi""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] MONJUVI, in combination with lenalidomide, is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT). This indication is approved under accelerated approval based on overall response rate [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).|[EMA] Minjuvi is indicated in combination with lenalidomide followed by Minjuvi monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT). uuid:d492d2f3-033e-41e1-9102-0b9d752ec53f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:QQA9MLH692 biolink:treats MONDO:0018905 PMID:41385096 "[{""id"":""uuid:ff38db2d-44f6-4ad7-b525-5fd46f8c13f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a797d0ae-704c-4a49-9150-f22303a34d00"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MONJUVI, in combination with lenalidomide, is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT). This indication is approved under accelerated approval based on overall response rate [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). uuid:b112d88d-4bca-4881-ad24-ac5cf1519635 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6801 biolink:treats MONDO:0012819 PMID:41385096 "[{""id"":""uuid:c23b6877-b60f-40b0-9745-8bc3ec859aca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cb039ece-5d29-4834-bfd0-ecdf18a58ed7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Metformin hydrochloride extended-release tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Important Limitations of Use Metformin hydrochloride extended-release tablets should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings. uuid:8143cb5a-abdd-4ada-a70a-1b54fc0dab61 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats MONDO:0024619 PMID:41385096 "[{""id"":""uuid:3da7d1da-ac2d-4c1b-8105-a75422e0355f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:92e3712b-8f4f-4d1a-bbff-a2ffb62b88ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Gentamicin Injection, USP and other antibacterial drugs, Gentamicin Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Gentamicin Injection is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: Pseudomonas aeruginosa, Proteus species (indole-positive and indole-negative), Escherichia coli, Klebsiella-Enterobacter-Serratia species, Citrobacter species, and Staphylococcus species (coagulase-positive and coagulase-negative). Clinical studies have shown Gentamicin Injection to be effective in bacterial neonatal sepsis; bacterial septicemia; and serious bacterial infections of the central nervous system (meningitis), urinary tract, respiratory tract, gastrointestinal tract (including peritonitis), skin, bone and soft tissue (including burns). Aminoglycosides, including gentamicin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are susceptible to these antibiotics and are not susceptible to antibiotics having less potential for toxicity. Specimens for bacterial culture should be obtained to isolate and identify causative organisms and to determine their susceptibility to gentamicin. Gentamicin may be considered as initial therapy in suspected or confirmed gram-negative infections, and therapy may be instituted before obtaining results of susceptibility testing. The decision to continue therapy with this drug should be based on the results of susceptibility tests, the severity of the infection, and the important additional concepts contained in the WARNINGS box above. If the causative organisms are resistant to gentamicin, other appropriate therapy should be instituted. In serious infections when the causative organisms are unknown, gentamicin may be administered as initial therapy in conjunction with a penicillin-type or cephalosporin type drug before obtaining results of susceptibility testing. If anaerobic organisms are suspected as etiologic agents, consideration should be given to using other suitable antimicrobial therapy in conjunction with gentamicin. Following identification of the organism and its susceptibility, appropriate antibiotic therapy should then be continued. Gentamicin has been used effectively in combination with carbenicillin for the treatment of life-threatening infections caused by Pseudomonas aeruginosa. It has also been found effective when used in conjunction with a penicillin-type drug for the treatment of endocarditis caused by group D streptococci. Gentamicin Injection has also been shown to be effective in the treatment of serious staphylococcal infections. While not the antibiotic of first choice, gentamicin may be considered when penicillins or other less potentially toxic drugs are contraindicated and bacterial susceptibility tests and clinical judgment indicate its use. It may also be considered in mixed infections caused by susceptible strains of staphylococci and gram-negative organisms. In the neonate with suspected bacterial sepsis or staphylococcal pneumonia, a penicillin-type drug is also usually indicated as concomitant therapy with gentamicin. uuid:ae96289c-7ea7-47dd-9fde-72842652c8eb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1158563 biolink:treats MONDO:0005709 PMID:41385096 "[{""id"":""uuid:efe3de45-1b7c-4048-9bef-a4732f8a069c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1d8a56a9-fafe-42e1-adc1-aaa95252bbd0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OBREDON is indicated for the symptomatic relief of cough and to loosen mucus associated with the common cold in patients 18 years of age and older. Important Limitations of Use Not indicated for pediatric patients under 18 years of age [ see Use in Specific Populations ( 8.4 ) ]. Contraindicated in pediatric patients less than 6 years of age [ see Contraindications ( 4 ) ] Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, reserve OBREDON for use in adult patients for whom the benefits of cough suppression are expected to outweigh the risks, and in whom an adequate assessment of the etiology of the cough has been made. uuid:52c28781-6d43-4123-b3a5-23dea64a9b97 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:205919 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:e447c626-d155-419d-a814-e5e0014cfe7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e585f302-f116-40c0-81fc-6bb116dce602"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clobetasol Propionate Ophthalmic Suspension 0.05% is indicated for the treatment of post-operative inflammation and pain following ocular surgery. uuid:486897b3-315a-44c0-ab56-ebe9817d5928 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:474180 biolink:treats UMLS:C0746883 PMID:41385096 "[{""id"":""uuid:4e313abe-9880-42f1-80d6-8e1819d998f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5d094dea-d395-40c0-a5bb-eaad415a7cf7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:416812a0-d32d-4fd5-a438-9aecb49065d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CANCIDAS is an echinocandin antifungal indicated in adults and pediatric patients (3 months of age and older) for: Empirical therapy for presumed fungal infections in febrile, neutropenic patients. ( 1 ) Treatment of candidemia and the following Candida infections: intra-abdominal abscesses, peritonitis and pleural space infections. ( 1 ) Treatment of esophageal candidiasis. ( 1 ) Treatment of invasive aspergillosis in patients who are refractory to or intolerant of other therapies. ( 1 )|[PMDA] Drugs with a new active ingredient indicated for the treatment of febrile neutropenia suspected of a fungal infection and fungal infections due to Candida or Aspergillus (esophageal candidiasis, invasive candidiasis, aspergillosis). uuid:65c4f706-4069-439f-9b3a-f948985eee26 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27504 biolink:treats MONDO:0020654 PMID:41385096 "[{""id"":""uuid:7d8529ec-34a3-412f-9ae5-ea1abf84ea88"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a7d2745a-29dd-4570-9a2a-63fcaa54a3c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] JELMYTO ® is indicated for the treatment of adult patients with low-grade Upper Tract Urothelial Cancer (LG-UTUC). uuid:34876734-dd48-4556-9b02-c2f68b0dac69 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2955 biolink:treats MONDO:0000922 PMID:41385096 "[{""id"":""uuid:955b5a6b-ec4f-4843-9809-96a0d8976aba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f8a5db7a-2693-4ac6-a373-3d6122f33b3e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:a7507a89-2031-4a2a-bc8b-4f93f15f2075"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azithromycin for Injection, USP is indicated for the treatment of patients with infections caused by susceptible strains of the designated microorganisms in the conditions listed below. As recommended dosages, durations of therapy, and applicable patient populations vary among these infections, please see DOSAGE AND ADMINISTRATION for dosing recommendations. Community-acquired pneumonia due to Chlamydia pneumoniae, Haemophilus influenzae, Legionella pneumophila, Moraxella catarrhalis, Mycoplasma pneumoniae, Staphylococcus aureus, or Streptococcus pneumoniae in patients who require initial intravenous therapy. Pelvic inflammatory disease due to Chlamydia trachomatis, Neisseria gonorrhoeae, or Mycoplasma hominis in patients who require initial intravenous therapy. If anaerobic microorganisms are suspected of contributing to the infection, an antimicrobial agent with anaerobic activity should be administered in combination with Azithromycin for Injection, USP. Azithromycin for Injection, USP should be followed by azithromycin by the oral route as required (see DOSAGE AND ADMINISTRATION ). Appropriate culture and susceptibility tests should be performed before treatment to determine the causative microorganism and its susceptibility to azithromycin. Therapy with azithromycin may be initiated before results of these tests are known; once the results become available, antimicrobial therapy should be adjusted accordingly. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Azithromycin for Injection, USP and other antibacterial drugs, Azithromycin for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.|[PMDA] Drugs with a new additional indication and a new dosage for the treatment of pelvic inflammatory diseases. uuid:5e5fd3fa-4a65-4700-8dff-423db033607d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29101 biolink:treats MONDO:0000440 PMID:41385096 "[{""id"":""uuid:8bc6f035-555c-446a-9d17-73149232ecac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eedd40cc-f355-4306-83d7-41e35f459166"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of hemoglobin and its breakdown products. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis – e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO 2 content is crucial – e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis. uuid:62707f2f-7238-4196-816e-9fc1ee96ead2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29101 biolink:treats MONDO:0001106 PMID:41385096 "[{""id"":""uuid:09740cd2-af42-47d1-832f-3a98d70d8391"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:80183267-9fcf-4186-bdb4-ad4ad3524a38"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of hemoglobin and its breakdown products. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis – e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO 2 content is crucial – e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis. uuid:cddbe597-66fc-4b83-8b3d-0f1487643d77 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29101 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:9ef92021-5c4f-41fe-ad90-294f64aa4209"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:038b8075-8bee-433b-90c4-2f08b7f5e6d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of hemoglobin and its breakdown products. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis – e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO 2 content is crucial – e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis. uuid:e9ac5abf-aee2-4d91-9de3-aa71a6e1b0bc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29101 biolink:treats HP:0031273 PMID:41385096 "[{""id"":""uuid:d4cac0a7-9c1a-4ff3-82ef-80f22de6b486"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e75c3e2d-141a-4317-aea6-26fa66ad0e72"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of hemoglobin and its breakdown products. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis – e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO 2 content is crucial – e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis. uuid:bc9526db-ea3a-49e4-8bad-61df8cca0bf7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29101 biolink:treats UMLS:C3472181 PMID:41385096 "[{""id"":""uuid:16ba3d7d-b673-48e9-8944-96da07ecf9f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1c6d5633-d902-410e-8cc0-f610ab60ecc4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of hemoglobin and its breakdown products. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis – e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO 2 content is crucial – e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis. uuid:31bc6956-cddd-4ace-8d02-b9cfcd2aa755 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29101 biolink:treats MONDO:0000745 PMID:41385096 "[{""id"":""uuid:9bdcf8a7-d883-4b36-9916-adab71aa8fcf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1300a986-9816-4ac4-82ae-df8dce109bac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of hemoglobin and its breakdown products. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis – e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO 2 content is crucial – e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis. uuid:a2553989-5441-43b8-8603-a6bd78d02249 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29101 biolink:treats MONDO:0006040 PMID:41385096 "[{""id"":""uuid:d7ef6bce-53dd-4f74-b54e-c5b4bc5da7bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b0e254bc-91c4-49c4-ba1c-cce8fe37fa2a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of hemoglobin and its breakdown products. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis – e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO 2 content is crucial – e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis. uuid:cbee023d-8896-4575-82de-db9691aec962 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29101 biolink:treats EFO:0009574 PMID:41385096 "[{""id"":""uuid:dca34123-ddd3-4f81-ba9a-ee2c880bd917"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7f1da8dd-8310-4e8b-bb90-47561d92fcbc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of hemoglobin and its breakdown products. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis – e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO 2 content is crucial – e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis. uuid:3d01ccc4-f7a2-4ed6-ac74-e5b1cacae146 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29101 biolink:treats UMLS:C0161558 PMID:41385096 "[{""id"":""uuid:9221d6fc-6ca8-432a-bc7e-22e9077d7473"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:888fb8f8-3224-4ed7-a2e6-ac98a8caf86d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of hemoglobin and its breakdown products. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis – e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO 2 content is crucial – e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis. uuid:406bf10d-8bdc-47b6-95c2-6cc2f920bd37 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29101 biolink:treats UMLS:C0161544 PMID:41385096 "[{""id"":""uuid:a5742baa-2098-4a47-9448-e7b269e9939f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b599b964-79fe-493f-ba68-696debc7b8b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of hemoglobin and its breakdown products. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis – e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO 2 content is crucial – e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis. uuid:01f6f88e-548d-4252-b6bc-97cecb99ade6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29101 biolink:treats UMLS:C0161680 PMID:41385096 "[{""id"":""uuid:adc1c46c-1f7f-4bbc-806b-ff5b02989550"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:15791b8d-9814-474e-86a0-e4efac5735db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of hemoglobin and its breakdown products. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis – e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO 2 content is crucial – e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis. uuid:525efbbc-97ad-4733-852b-6e8000f2b112 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29101 biolink:treats UMLS:C0235575 PMID:41385096 "[{""id"":""uuid:349b3d0f-de3b-449e-a91f-b4f2e05fc656"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c86cdc29-62ff-4687-b19f-b746894215a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of hemoglobin and its breakdown products. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis – e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO 2 content is crucial – e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis. uuid:d2a12879-96bc-4bd3-b0da-4136c770735e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29101 biolink:treats UMLS:C1443924 PMID:41385096 "[{""id"":""uuid:d198ac8a-951e-4278-9fbb-98809b6ab0e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:41611a8c-5d40-4116-b0c9-3c0002b87492"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of hemoglobin and its breakdown products. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis – e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO 2 content is crucial – e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis. uuid:3fe90553-981d-4afb-8edf-075cf153a7e4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29101 biolink:treats MONDO:0012819 PMID:41385096 "[{""id"":""uuid:ce52741e-1c9a-4463-a904-6cd0c6034495"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b1018d98-70c3-48f3-a813-5a2a1c5b6ea2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of hemoglobin and its breakdown products. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis – e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO 2 content is crucial – e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis. uuid:4406a4ef-1d09-4a34-b4d0-a4cddbc06d2e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:71492GE1FX biolink:treats UMLS:C0581126 PMID:41385096 "[{""id"":""uuid:99a328d5-df96-48b0-9620-4471a29a7fbb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b970c4ab-d92b-41a6-adfe-ff36aba584b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FASENRA is an interleukin-5 receptor alpha-directed cytolytic monoclonal antibody (IgG1, kappa) indicated for: • add-on maintenance treatment of adult and pediatric patients aged 6 years and older with severe asthma, and with an eosinophilic phenotype. (1.1) • treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). (1.2) Limitations of Use: Not for relief of acute bronchospasm or status asthmaticus. (1.1) uuid:5a210835-0b58-4518-a253-01fd12e8c74a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:71492GE1FX biolink:treats MONDO:0015943 PMID:41385096 "[{""id"":""uuid:4f72a413-7e82-485c-8715-035e2659d06c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:14b87a79-3cce-4cd5-8565-db6b4472a6d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FASENRA is an interleukin-5 receptor alpha-directed cytolytic monoclonal antibody (IgG1, kappa) indicated for: • add-on maintenance treatment of adult and pediatric patients aged 6 years and older with severe asthma, and with an eosinophilic phenotype. (1.1) • treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). (1.2) Limitations of Use: Not for relief of acute bronchospasm or status asthmaticus. (1.1) uuid:ecb901b5-879f-4ac6-a7bb-8a6fefd699ec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0030602 PMID:41385096 "[{""id"":""uuid:0214cd3f-4486-4a68-b879-814b2a5ca7ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fcc0d5a9-def2-4693-b205-2395d7f68622"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline for injection and other antibacterial drugs, doxycycline for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever, and the typhus group, Q fever, rickettsialpox and tick fevers). Mycoplasma pneumoniae (PPLO, Eaton Agent). Agents of psittacosis and ornithosis. Agents of lymphogranuloma venereum and granuloma inguinale. The spirochetal agent of relapsing fever (Borrelia recurrentis). The following gram-negative microorganisms: Haemophilus ducreyi (chancroid), Yersinia pestis Francisella tularensis, Bartonella bacilliformis, Bacteroides species, Vibrio cholerae and Campylobacte fetus, Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli, Enterobacter aerogenes, Shigella species, Acinetobacter species, Haemophilus influenzae (respiratory infections), Klebsiella species (respiratory and urinary infections). Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Streptococcus pneumoniae, Staphylococcus aureus, respiratory skin and soft tissue infections. Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections. Anthrax due to Bacillus anthracis, including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of infections due to: Neisseria gonorrhoeae and N. meningitidis, Treponema pallidum and Treponema pallidum subspecies pertenue (syphilis and yaws), Listeria monocytogenes, Clostridium species, Fusobacterium fusiforme (Vincent’s infection), Actinomyces species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. Doxycycline is indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. uuid:bc86bb87-89d6-47a2-ac71-5ec380a218e6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28748 biolink:treats MONDO:0004989 PMID:41385096 "[{""id"":""uuid:8fab2457-bf3d-45cf-90f7-95f80c8743c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a5f0d9c8-de73-4976-9112-cb917cb72d6e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Doxorubicin Hydrochloride Injection, USP has been used successfully to produce regression in disseminated neoplastic conditions such as acute lymphoblastic leukemia, acute myeloblastic leukemia, Wilms' tumor, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, ovarian carcinoma, transitional cell bladder carcinoma, thyroid carcinoma, gastric carcinoma, Hodgkin's disease, malignant lymphoma and bronchogenic carcinoma in which the small cell histologic type is the most responsive compared to other cell types. Doxorubicin is also indicated for use as a component of adjuvant therapy in women with evidence of axillary lymph node involvement following resection of primary breast cancer. uuid:917fcd4b-b601-4ad3-bfc6-50cc7efbb699 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28748 biolink:treats MONDO:0005062 PMID:41385096 "[{""id"":""uuid:4ff93613-d2dc-4160-83c2-06602bcc5957"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ef369b69-d88b-4945-9c6b-55f9a092a141"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:da70ac77-ee7e-4104-bc5d-618e577f4371"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Doxorubicin Hydrochloride Injection, USP has been used successfully to produce regression in disseminated neoplastic conditions such as acute lymphoblastic leukemia, acute myeloblastic leukemia, Wilms' tumor, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, ovarian carcinoma, transitional cell bladder carcinoma, thyroid carcinoma, gastric carcinoma, Hodgkin's disease, malignant lymphoma and bronchogenic carcinoma in which the small cell histologic type is the most responsive compared to other cell types. Doxorubicin is also indicated for use as a component of adjuvant therapy in women with evidence of axillary lymph node involvement following resection of primary breast cancer.|[PMDA] Drugs with a revised indication and a new dosage for the relief of symptoms of malignant lymphoma. [Expedited review] uuid:3bbba926-37ab-45c9-b30b-efaab282772f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:119915 biolink:treats HP:0030858 PMID:41385096 "[{""id"":""uuid:7fa6b527-437c-406a-84d6-66259fc2c851"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b6955559-a4c0-498a-b71b-3e0776321479"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fentanyl transdermal system is indicated for the management of severe and persistent pain in opioid tolerant patients, that requires an extended treatment period with a daily opioid analgesic and for which alternative treatment options are inadequate. Patients considered opioid-tolerant are those who are taking, for one week or longer, at least 60 mg morphine per day, 25 mcg transdermal fentanyl per hour, 30 mg oral oxycodone per day, 8 mg oral hydromorphone per day, 25 mg oral oxymorphone per day, 60 mg oral hydrocodone per day, or an equianalgesic dose of another opioid. Limitations of Use: • Because of the risks of addiction, abuse, and misuse with opioids, which can occur at any dosage or duration, and because of the greater risks of overdose and death with extended-release/long-acting opioid formulations [see Warnings and Precautions (5.1) ] , reserve fentanyl transdermal system for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated or would be otherwise inadequate to provide sufficient management of pain. • Fentanyl transdermal system is not indicated as an as-needed (prn) analgesic. uuid:6fa7a708-c9eb-4261-aa26-e80211af3b3d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:119915 biolink:treats MONDO:0002491 PMID:41385096 "[{""id"":""uuid:425f269b-3118-4932-97a6-378b9a0fdd8d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b67ce0c9-4914-4fa2-ac48-8dd810887f28"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fentanyl transdermal system is indicated for the management of severe and persistent pain in opioid tolerant patients, that requires an extended treatment period with a daily opioid analgesic and for which alternative treatment options are inadequate. Patients considered opioid-tolerant are those who are taking, for one week or longer, at least 60 mg morphine per day, 25 mcg transdermal fentanyl per hour, 30 mg oral oxycodone per day, 8 mg oral hydromorphone per day, 25 mg oral oxymorphone per day, 60 mg oral hydrocodone per day, or an equianalgesic dose of another opioid. Limitations of Use: • Because of the risks of addiction, abuse, and misuse with opioids, which can occur at any dosage or duration, and because of the greater risks of overdose and death with extended-release/long-acting opioid formulations [see Warnings and Precautions (5.1) ] , reserve fentanyl transdermal system for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated or would be otherwise inadequate to provide sufficient management of pain. • Fentanyl transdermal system is not indicated as an as-needed (prn) analgesic. uuid:2c65dc94-6175-433e-839b-d0158139a7f1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:119915 biolink:treats EFO:0011049 PMID:41385096 "[{""id"":""uuid:2053a065-e648-4467-85d5-547cf52e384e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5e6590be-19e0-4576-92fc-cf05e4ed392b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fentanyl transdermal system is indicated for the management of severe and persistent pain in opioid tolerant patients, that requires an extended treatment period with a daily opioid analgesic and for which alternative treatment options are inadequate. Patients considered opioid-tolerant are those who are taking, for one week or longer, at least 60 mg morphine per day, 25 mcg transdermal fentanyl per hour, 30 mg oral oxycodone per day, 8 mg oral hydromorphone per day, 25 mg oral oxymorphone per day, 60 mg oral hydrocodone per day, or an equianalgesic dose of another opioid. Limitations of Use: • Because of the risks of addiction, abuse, and misuse with opioids, which can occur at any dosage or duration, and because of the greater risks of overdose and death with extended-release/long-acting opioid formulations [see Warnings and Precautions (5.1) ] , reserve fentanyl transdermal system for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated or would be otherwise inadequate to provide sufficient management of pain. • Fentanyl transdermal system is not indicated as an as-needed (prn) analgesic. uuid:cfe66dfb-9547-42db-955b-3223e176747b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:119915 biolink:treats EFO:0020911 PMID:41385096 "[{""id"":""uuid:b4096225-3871-420e-958d-555d2e82c2b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8c2daa2d-5e7a-440c-ad19-200ad95a871a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fentanyl transdermal system is indicated for the management of severe and persistent pain in opioid tolerant patients, that requires an extended treatment period with a daily opioid analgesic and for which alternative treatment options are inadequate. Patients considered opioid-tolerant are those who are taking, for one week or longer, at least 60 mg morphine per day, 25 mcg transdermal fentanyl per hour, 30 mg oral oxycodone per day, 8 mg oral hydromorphone per day, 25 mg oral oxymorphone per day, 60 mg oral hydrocodone per day, or an equianalgesic dose of another opioid. Limitations of Use: • Because of the risks of addiction, abuse, and misuse with opioids, which can occur at any dosage or duration, and because of the greater risks of overdose and death with extended-release/long-acting opioid formulations [see Warnings and Precautions (5.1) ] , reserve fentanyl transdermal system for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated or would be otherwise inadequate to provide sufficient management of pain. • Fentanyl transdermal system is not indicated as an as-needed (prn) analgesic. uuid:18db120f-74f0-4134-ad0a-bc3c5fa7c847 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:5284632 biolink:treats MONDO:0005090 PMID:41385096 "[{""id"":""uuid:a37a9dbe-c83c-4075-bc19-97313ac8d6a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2ed6c437-0a1c-42e5-be4c-34d35c5f1d75"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] COBENFY is indicated for the treatment of schizophrenia in adults. uuid:729be05c-06dd-41df-9665-367b4c7f993c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135983 biolink:treats MONDO:0001220 PMID:41385096 "[{""id"":""uuid:c8492f8d-c2aa-4600-a586-fa09c054fe77"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f18d1db7-9893-4e9c-8e17-81dc1774ef66"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] YORVIPATH is indicated for the treatment of hypoparathyroidism in adults. uuid:95b20320-9a08-48b4-b132-825430574426 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50729 biolink:treats MONDO:0005301 PMID:41385096 "[{""id"":""uuid:bbebcb98-12a0-47f6-911f-bc6f5c6d3834"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:88e2075a-6557-45f1-8cdc-c8b27e9dc328"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mitoxantrone Injection, USP is indicated for reducing neurologic disability and/or the frequency of clinical relapses in patients with secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis (i.e., patients whose neurologic status is significantly abnormal between relapses). Mitoxantrone Injection, USP is not indicated in the treatment of patients with primary progressive multiple sclerosis. The clinical patterns of multiple sclerosis in the studies were characterized as follows: secondary progressive and progressive relapsing disease were characterized by gradual increasing disability with or without superimposed clinical relapses, and worsening relapsing-remitting disease was characterized by clinical relapses resulting in a step-wise worsening of disability. Mitoxantrone Injection, USP in combination with corticosteroids is indicated as initial chemotherapy for the treatment of patients with pain related to advanced hormone-refractory prostate cancer. Mitoxantrone Injection, USP in combination with other approved drug(s) is indicated in the initial therapy of acute nonlymphocytic leukemia (ANLL) in adults. This category includes myelogenous, promyelocytic, monocytic, and erythroid acute leukemias. uuid:140dd08c-6c83-4f4c-b6ad-ca09e226d74c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50729 biolink:treats MONDO:0000450 PMID:41385096 "[{""id"":""uuid:dde0a25d-5cc9-4992-b8dc-76c8d26204d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d7dfc3c4-4408-4f73-b124-4b27560806bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mitoxantrone Injection, USP is indicated for reducing neurologic disability and/or the frequency of clinical relapses in patients with secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis (i.e., patients whose neurologic status is significantly abnormal between relapses). Mitoxantrone Injection, USP is not indicated in the treatment of patients with primary progressive multiple sclerosis. The clinical patterns of multiple sclerosis in the studies were characterized as follows: secondary progressive and progressive relapsing disease were characterized by gradual increasing disability with or without superimposed clinical relapses, and worsening relapsing-remitting disease was characterized by clinical relapses resulting in a step-wise worsening of disability. Mitoxantrone Injection, USP in combination with corticosteroids is indicated as initial chemotherapy for the treatment of patients with pain related to advanced hormone-refractory prostate cancer. Mitoxantrone Injection, USP in combination with other approved drug(s) is indicated in the initial therapy of acute nonlymphocytic leukemia (ANLL) in adults. This category includes myelogenous, promyelocytic, monocytic, and erythroid acute leukemias. uuid:ef52dec8-3778-4c8a-9399-2753fabc6571 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50729 biolink:treats MONDO:0000452 PMID:41385096 "[{""id"":""uuid:2fbe396a-14a5-487a-b790-9458144bede3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bb626678-a0b6-40c2-9bef-c6ec1caf70e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mitoxantrone Injection, USP is indicated for reducing neurologic disability and/or the frequency of clinical relapses in patients with secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis (i.e., patients whose neurologic status is significantly abnormal between relapses). Mitoxantrone Injection, USP is not indicated in the treatment of patients with primary progressive multiple sclerosis. The clinical patterns of multiple sclerosis in the studies were characterized as follows: secondary progressive and progressive relapsing disease were characterized by gradual increasing disability with or without superimposed clinical relapses, and worsening relapsing-remitting disease was characterized by clinical relapses resulting in a step-wise worsening of disability. Mitoxantrone Injection, USP in combination with corticosteroids is indicated as initial chemotherapy for the treatment of patients with pain related to advanced hormone-refractory prostate cancer. Mitoxantrone Injection, USP in combination with other approved drug(s) is indicated in the initial therapy of acute nonlymphocytic leukemia (ANLL) in adults. This category includes myelogenous, promyelocytic, monocytic, and erythroid acute leukemias. uuid:2b571c4b-8a18-48cd-87f8-da2db9d5a078 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50729 biolink:treats MONDO:0005314 PMID:41385096 "[{""id"":""uuid:9340afbf-04a3-4e07-800e-5e49f688b270"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:48a2da82-d49a-4853-85c6-8a036c6ab97f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mitoxantrone Injection, USP is indicated for reducing neurologic disability and/or the frequency of clinical relapses in patients with secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis (i.e., patients whose neurologic status is significantly abnormal between relapses). Mitoxantrone Injection, USP is not indicated in the treatment of patients with primary progressive multiple sclerosis. The clinical patterns of multiple sclerosis in the studies were characterized as follows: secondary progressive and progressive relapsing disease were characterized by gradual increasing disability with or without superimposed clinical relapses, and worsening relapsing-remitting disease was characterized by clinical relapses resulting in a step-wise worsening of disability. Mitoxantrone Injection, USP in combination with corticosteroids is indicated as initial chemotherapy for the treatment of patients with pain related to advanced hormone-refractory prostate cancer. Mitoxantrone Injection, USP in combination with other approved drug(s) is indicated in the initial therapy of acute nonlymphocytic leukemia (ANLL) in adults. This category includes myelogenous, promyelocytic, monocytic, and erythroid acute leukemias. uuid:e393ccd8-17c2-4bae-98c3-05cd27ad099e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50729 biolink:treats MONDO:0004956 PMID:41385096 "[{""id"":""uuid:2863742b-532a-47df-a0ba-d01722dbcb14"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:04caea1c-0b9a-4657-8cd8-8fad4f732f40"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mitoxantrone Injection, USP is indicated for reducing neurologic disability and/or the frequency of clinical relapses in patients with secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis (i.e., patients whose neurologic status is significantly abnormal between relapses). Mitoxantrone Injection, USP is not indicated in the treatment of patients with primary progressive multiple sclerosis. The clinical patterns of multiple sclerosis in the studies were characterized as follows: secondary progressive and progressive relapsing disease were characterized by gradual increasing disability with or without superimposed clinical relapses, and worsening relapsing-remitting disease was characterized by clinical relapses resulting in a step-wise worsening of disability. Mitoxantrone Injection, USP in combination with corticosteroids is indicated as initial chemotherapy for the treatment of patients with pain related to advanced hormone-refractory prostate cancer. Mitoxantrone Injection, USP in combination with other approved drug(s) is indicated in the initial therapy of acute nonlymphocytic leukemia (ANLL) in adults. This category includes myelogenous, promyelocytic, monocytic, and erythroid acute leukemias. uuid:95edb0c7-14c1-4e05-8387-1220b11ac9f2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50729 biolink:treats MONDO:0018874 PMID:41385096 "[{""id"":""uuid:a1b32411-352c-4575-ae86-084a4d0de462"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8fcdb109-4bad-4eee-97e8-d2350c2097cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mitoxantrone Injection, USP is indicated for reducing neurologic disability and/or the frequency of clinical relapses in patients with secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis (i.e., patients whose neurologic status is significantly abnormal between relapses). Mitoxantrone Injection, USP is not indicated in the treatment of patients with primary progressive multiple sclerosis. The clinical patterns of multiple sclerosis in the studies were characterized as follows: secondary progressive and progressive relapsing disease were characterized by gradual increasing disability with or without superimposed clinical relapses, and worsening relapsing-remitting disease was characterized by clinical relapses resulting in a step-wise worsening of disability. Mitoxantrone Injection, USP in combination with corticosteroids is indicated as initial chemotherapy for the treatment of patients with pain related to advanced hormone-refractory prostate cancer. Mitoxantrone Injection, USP in combination with other approved drug(s) is indicated in the initial therapy of acute nonlymphocytic leukemia (ANLL) in adults. This category includes myelogenous, promyelocytic, monocytic, and erythroid acute leukemias. uuid:f9412ba2-b224-4529-81a4-a4f0b8b6c6ff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50729 biolink:treats MONDO:0012883 PMID:41385096 "[{""id"":""uuid:2f1d0144-6237-46dc-ba6a-fd963a0dc570"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e10cbac5-cfd4-4edb-b4e8-1abf79920c3e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mitoxantrone Injection, USP is indicated for reducing neurologic disability and/or the frequency of clinical relapses in patients with secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis (i.e., patients whose neurologic status is significantly abnormal between relapses). Mitoxantrone Injection, USP is not indicated in the treatment of patients with primary progressive multiple sclerosis. The clinical patterns of multiple sclerosis in the studies were characterized as follows: secondary progressive and progressive relapsing disease were characterized by gradual increasing disability with or without superimposed clinical relapses, and worsening relapsing-remitting disease was characterized by clinical relapses resulting in a step-wise worsening of disability. Mitoxantrone Injection, USP in combination with corticosteroids is indicated as initial chemotherapy for the treatment of patients with pain related to advanced hormone-refractory prostate cancer. Mitoxantrone Injection, USP in combination with other approved drug(s) is indicated in the initial therapy of acute nonlymphocytic leukemia (ANLL) in adults. This category includes myelogenous, promyelocytic, monocytic, and erythroid acute leukemias. uuid:a5447e35-c743-47bd-96ea-6191d8a4f17f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50729 biolink:treats MONDO:0007896 PMID:41385096 "[{""id"":""uuid:6d00fdb4-91c8-4039-b49c-4f1be3711c4b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:08a2cfb7-e93c-42a8-9982-97350f7a571f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mitoxantrone Injection, USP is indicated for reducing neurologic disability and/or the frequency of clinical relapses in patients with secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis (i.e., patients whose neurologic status is significantly abnormal between relapses). Mitoxantrone Injection, USP is not indicated in the treatment of patients with primary progressive multiple sclerosis. The clinical patterns of multiple sclerosis in the studies were characterized as follows: secondary progressive and progressive relapsing disease were characterized by gradual increasing disability with or without superimposed clinical relapses, and worsening relapsing-remitting disease was characterized by clinical relapses resulting in a step-wise worsening of disability. Mitoxantrone Injection, USP in combination with corticosteroids is indicated as initial chemotherapy for the treatment of patients with pain related to advanced hormone-refractory prostate cancer. Mitoxantrone Injection, USP in combination with other approved drug(s) is indicated in the initial therapy of acute nonlymphocytic leukemia (ANLL) in adults. This category includes myelogenous, promyelocytic, monocytic, and erythroid acute leukemias. uuid:bbbd1fa6-3844-4ce2-bf21-d390b24151ae biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50729 biolink:treats MONDO:0017858 PMID:41385096 "[{""id"":""uuid:9b3474c2-8fe7-4627-b889-6dfadb2564e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3e6fd348-6f0f-4944-83f7-0d2d2ab47b6a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mitoxantrone Injection, USP is indicated for reducing neurologic disability and/or the frequency of clinical relapses in patients with secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis (i.e., patients whose neurologic status is significantly abnormal between relapses). Mitoxantrone Injection, USP is not indicated in the treatment of patients with primary progressive multiple sclerosis. The clinical patterns of multiple sclerosis in the studies were characterized as follows: secondary progressive and progressive relapsing disease were characterized by gradual increasing disability with or without superimposed clinical relapses, and worsening relapsing-remitting disease was characterized by clinical relapses resulting in a step-wise worsening of disability. Mitoxantrone Injection, USP in combination with corticosteroids is indicated as initial chemotherapy for the treatment of patients with pain related to advanced hormone-refractory prostate cancer. Mitoxantrone Injection, USP in combination with other approved drug(s) is indicated in the initial therapy of acute nonlymphocytic leukemia (ANLL) in adults. This category includes myelogenous, promyelocytic, monocytic, and erythroid acute leukemias. uuid:f8ee4343-faf6-44ae-843f-46ec59447ecd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45081 biolink:treats MONDO:0012268 PMID:41385096 "[{""id"":""uuid:112a860c-56b1-4a8f-89c6-cb68bbd7c9ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:170eb01c-42e9-4729-94d0-f3eb28b38261"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NebuPent is indicated for the prevention of Pneumocystis jiroveci pneumonia (PJP) in high-risk, HIV-infected patients defined by one or both of the following criteria: i. a history of one or more episodes of PJP ii. a peripheral CD4+ (T4 helper/inducer) lymphocyte count less than or equal to 200/mm 3 . These indications are based on the results of an 18-month randomized, dose-response trial in high risk HIV-infected patients and on existing epidemiological data from natural history studies. The patient population of the controlled trial consisted of 408 patients, 237 of whom had a history of one or more episodes of PJP. The remaining patients without a history of PJP included 55 patients with Kaposi’s sarcoma and 116 patients with other AIDS diagnoses, ARC or asymptomatic HIV infection. Patients were randomly assigned to receive NebuPent via the Respirgard ® II nebulizer at one of the following three doses: 30 mg every two weeks (n=135), 150 mg every two weeks (n=134) or 300 mg every four weeks (n=139). The results of the trial demonstrated a significant protective effect (p<0.01) against PJP with the 300 mg every four week dosage regimen compared to the 30 mg every two week dosage regimen. The 300 mg dose regimen reduced the risk of developing PJP by 50 to 70% compared to the 30 mg regimen. A total of 293 patients (72% of all patients) also received zidovudine at sometime during the trial. The analysis of the data demonstrated the efficacy of the 300 mg dose even after adjusting for the effect of zidovudine. The results of the trial further demonstrate that the dose and frequency of dosing are important to the efficacy of NebuPent prophylaxis in that multiple analyses consistently demonstrated a trend toward greater efficacy with 300 mg every four weeks as compared to 150 mg every two weeks. No dose-response was observed for reduction in overall mortality; however, mortality from PJP was low in all three dosage groups. uuid:f40ae824-79e5-45e2-9140-be54e13580a0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1043561 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:4c18066c-243f-4303-8f01-932c27bc6207"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:fa2f3e16-8651-44a9-9ef4-602b7149eeb2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:8b1e5373-18a6-4d41-8871-915913a25e82"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/komboglyze""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] KOMBIGLYZE XR is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus [ see Clinical Studies (14) ].|[EMA] Komboglyze is indicated as an adjunct to diet and exercise to improve glycaemic control in adult patients aged 18 years and older with type-2 diabetes mellitus inadequately controlled on their maximally tolerated dose of metformin alone or those already being treated with the combination of saxagliptin and metformin as separate tablets.Komboglyze is also indicated in combination with insulin (i.e. triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in adult patients aged 18 years and older with type-2 diabetes mellitus when insulin and metformin alone do not provide adequate glycaemic control. uuid:536aed14-24a5-4cc7-b1c3-e40956732218 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:1864 biolink:treats MONDO:0006835 PMID:41385096 "[{""id"":""uuid:28aeaf27-6e7c-444b-a6c2-1334633654e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1ea83b76-5af9-4058-98fc-60039635152f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cyclophosphamide is an alkylating drug indicated for treatment of: Malignant Diseases: malignant lymphomas: Hodgkin's disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt's lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma ( 1.1 ) Minimal Change Nephrotic Syndrome in Pediatric Patients: biopsy proven minimal change nephrotic syndrome patients who failed to adequately respond to or are unable to tolerate adrenocorticosteroid therapy ( 1.2 ) Limitations of Use: The safety and effectiveness for the treatment of nephrotic syndrome in adults or other renal disease has not been established. uuid:d561a0cc-dbfe-4005-ba2b-2b5a04d54daa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75179 biolink:treats MONDO:0004768 PMID:41385096 "[{""id"":""uuid:0ba514d8-5b4a-4039-8642-1b1fd479b4f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8e9df253-9a65-4bd3-a951-8ae1edc3a24d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE: Trifluridine Ophthalmic Solution is indicated for the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to herpes simplex virus, types 1 and 2. uuid:4a7e9054-0137-45f3-9ddb-126043ff5d0d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75179 biolink:treats MONDO:0015289 PMID:41385096 "[{""id"":""uuid:f7fc0d1f-4940-4d19-a877-6f8c658db104"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8283d3e9-71d4-43cc-bd86-2d29a0de026c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE: Trifluridine Ophthalmic Solution is indicated for the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to herpes simplex virus, types 1 and 2. uuid:a5def7c6-76c6-4c27-882d-113748f2a876 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:166177295 biolink:treats MONDO:0005180 PMID:41385096 "[{""id"":""uuid:0ed84113-50fa-43c8-95e1-e412fe6d3167"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:df9bc760-658f-47d5-b0a3-1bb518a143a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VYALEV is indicated for the treatment of motor fluctuations in adults with advanced Parkinson’s disease (PD). uuid:6fc7d552-9ac2-40e2-a6f6-bb2019512194 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1999667 biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:1a2fb4c8-b58e-4982-a0c9-921eac699c96"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3ffafc1d-49de-4704-9f9e-2349b0fb0f93"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BIKTARVY is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in: adults and pediatric patients weighing at least 14 kg: who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no known or suspected substitutions associated with resistance to bictegravir or tenofovir [see Dosage and Administration (2.4) , and Use in Specific Populations (8.1) ]. uuid:f52d0d93-5c09-4dcb-ad69-a932de08b392 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:229680 biolink:treats MONDO:0044070 PMID:41385096 "[{""id"":""uuid:ec88ce7b-5725-4da1-bed4-df7a3a4f1468"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0b100897-22c0-437f-912f-3788860c4181"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] REZZAYO is an echinocandin antifungal indicated in patients 18 years of age or older who have limited or no alternative options for the treatment of candidemia and invasive candidiasis. Approval of this indication is based on limited clinical safety and efficacy data for REZZAYO. ( 1 , 12.4 , 14 ) Limitations of Use REZZAYO has not been studied in patients with endocarditis, osteomyelitis, and meningitis due to Candida. ( 1 ) uuid:ea29d595-1e5a-4bf8-8163-e5f068c85e31 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:229680 biolink:treats MONDO:0044067 PMID:41385096 "[{""id"":""uuid:15fa7ddc-275f-407f-bcbc-ab5a602b12b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f2793a61-b4c7-4c2a-a304-ee726a0fe52e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] REZZAYO is an echinocandin antifungal indicated in patients 18 years of age or older who have limited or no alternative options for the treatment of candidemia and invasive candidiasis. Approval of this indication is based on limited clinical safety and efficacy data for REZZAYO. ( 1 , 12.4 , 14 ) Limitations of Use REZZAYO has not been studied in patients with endocarditis, osteomyelitis, and meningitis due to Candida. ( 1 ) uuid:6c447c61-0370-4764-b922-e68c530b4fb0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:229680 biolink:treats MONDO:0000565 PMID:41385096 "[{""id"":""uuid:3948bd5f-c6f5-45a0-b0b6-eddd5142bf7b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:83dfca68-8b6b-4c66-a532-3964602a8820"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] REZZAYO is an echinocandin antifungal indicated in patients 18 years of age or older who have limited or no alternative options for the treatment of candidemia and invasive candidiasis. Approval of this indication is based on limited clinical safety and efficacy data for REZZAYO. ( 1 , 12.4 , 14 ) Limitations of Use REZZAYO has not been studied in patients with endocarditis, osteomyelitis, and meningitis due to Candida. ( 1 ) uuid:2076e2b7-7378-4e5b-bb9c-d15400e1285d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:229680 biolink:treats MONDO:0006764 PMID:41385096 "[{""id"":""uuid:cd71a1b0-0556-4862-90c8-188bbc7eff96"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d6f04e8d-15be-44cd-aa92-85f0e020016f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] REZZAYO is an echinocandin antifungal indicated in patients 18 years of age or older who have limited or no alternative options for the treatment of candidemia and invasive candidiasis. Approval of this indication is based on limited clinical safety and efficacy data for REZZAYO. ( 1 , 12.4 , 14 ) Limitations of Use REZZAYO has not been studied in patients with endocarditis, osteomyelitis, and meningitis due to Candida. ( 1 ) uuid:32b53ead-640b-41da-b112-782395e84cf9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7565 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:eef74678-f7e2-48ab-881b-22ca2c79e1d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:64ab1f0d-0385-471b-9331-50be734456a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] I. Vasospastic Angina Nifedipine Extended-release Tablet is indicated for the management of vasospastic angina confirmed by any of the following criteria: 1) classical pattern of angina at rest accompanied by ST segment elevation, 2) angina or coronary artery spasm provoked by ergonovine, or 3) angiographically demonstrated coronary artery spasm. In those patients who have had angiography, the presence of significant fixed obstructive disease is not incompatible with the diagnosis of vasospastic angina, provided that the above criteria are satisfied. Nifedipine Extended-release Tablet may also be used where the clinical presentation suggests a possible vasospastic component but where vasospasm has not been confirmed, e.g., where pain has a variable threshold on exertion or in unstable angina where electrocardiographic findings are compatible with intermittent vasospasm, or when angina is refractory to nitrates and/or adequate doses of beta-blockers. II. Chronic Stable Angina (Classical Effort-Associated Angina) Nifedipine Extended-release Tablet is indicated for the management of chronic stable angina (effort-associated angina) without evidence of vasospasm in patients who remain symptomatic despite adequate doses of beta-blockers and/or organic nitrates or who cannot tolerate those agents. In chronic stable angina (effort-associated angina) nifedipine has been effective in controlled trials of up to eight weeks duration in reducing angina frequency and increasing exercise tolerance, but confirmation of sustained effectiveness and evaluation of long-term safety in these patients is incomplete. Controlled studies in small numbers of patients suggest concomitant use of nifedipine and beta-blocking agents may be beneficial in patients with chronic stable angina, but available information is not sufficient to predict with confidence the effects of concurrent treatment, especially in patients with compromised left ventricular function or cardiac conduction abnormalities. When introducing such concomitant therapy, care must be taken to monitor blood pressure closely since severe hypotension can occur from the combined effects of the drugs (see WARNINGS .) III. Hypertension Nifedipine Extended-release Tablet is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents. Nifedipine Extended-release Tablet is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including Nifedipine Extended-release Tablet. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Nifedipine Extended-release Tablet may be used alone or in combination with other antihypertensive agents. uuid:b4c4e52a-9579-4022-9cd4-3c3fa12cdc44 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18332 biolink:treats UMLS:C0271795 PMID:41385096 "[{""id"":""uuid:f8e87387-0d8a-4312-b154-8b349d681d03"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8697504d-04cd-4e00-80eb-4d15816d3ab7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TIROSINT-SOL is L-thyroxine (T4) indicated in adult and pediatric patients, including neonates, for: Hypothyroidism - As replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism ( 1 ) Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression - As an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer ( 1 ) Limitations of Use Not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients ( 1 ) Not indicated for treatment of transient hypothyroidism during the recovery phase of subacute thyroiditis ( 1 ) uuid:68600a11-d3c4-4f51-805d-432a068c2de8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:36572 biolink:treats MONDO:0017639 PMID:41385096 "[{""id"":""uuid:f9dd0dd8-018d-4f7f-acdc-5c30a56c7c3a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:748fd329-200d-4151-9746-fd6b735e26d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RYTARY is indicated for the treatment of Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication. uuid:474ea94a-16b6-46a5-b0fe-e69a7baffc7f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:36572 biolink:treats MONDO:0017638 PMID:41385096 "[{""id"":""uuid:df290c9d-c2cb-4fe3-9085-9f60f4afd36c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4cc330b4-bd45-4281-8753-479691ef4d40"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RYTARY is indicated for the treatment of Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication. uuid:a501d7bd-4d05-42a1-aac6-a9b3177f4a10 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3638 biolink:treats MONDO:0005920 PMID:41385096 "[{""id"":""uuid:48f37284-13e1-4f1c-96a5-40223f6bc19f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ccd6404f-7197-4b57-8a83-2d96d902eb57"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Chloroquine phosphate tablets are indicated for the: Treatment of uncomplicated malaria due to susceptible strains of P. falciparum, P.malariae, P. ovale, and P.vivax . Prophylaxis of malaria in geographic areas where resistance to chloroquine is not present. Treatment of extraintestinal amebiasis. Chloroquine phosphate tablets do not prevent relapses in patients with vivax or ovale malaria because it is not effective against exoerythrocytic forms of the parasites. Limitations of Use in Malaria: Do not use chloroquine phosphate tablets for the treatment of complicated malaria (high-grade parasitemia and/or complications e.g., cerebral malaria or acute renal failure). Do not use chloroquine phosphate tablets for malaria prophylaxis in areas where chloroquine resistance occurs, Resistance to chloroquine phosphate tablets is widespread in P. falciparum, and is reported in P.vivax (see WARNINGS ). Concomitant therapy with an 8-aminoquinoline drug is necessary for treatment of the hypnozoite liver stage forms of P.vivax and P.ovale (see DOSAGE AND ADMINISTRATION ). uuid:eb26ab2e-153c-4d8a-9f9d-a17f5f88adb3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3181 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:46cbc389-2978-4040-a289-a4311a0206dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8e77d4eb-4703-4534-9efa-17ad28adca08"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CYCLOSET is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. uuid:606cc850-d111-415f-9233-0491ccdf8cc7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16094 biolink:treats MONDO:0001874 PMID:41385096 "[{""id"":""uuid:820778dd-ed0c-4d15-a5db-d5240ca994be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f2bef120-af00-4ca8-bc30-e52c96e7e94b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PEDMARK is indicated to reduce the risk of ototoxicity associated with cisplatin in pediatric patients 1 month of age and older with localized, non-metastatic solid tumors. uuid:6f1ec313-c61e-4b0f-abbb-bc45d2279c40 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9168 biolink:treats MONDO:0006359 PMID:41385096 "[{""id"":""uuid:2fdb5032-f84c-46bd-aaa8-df81c537b8a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:809405a4-df70-47e4-be24-f92731cbadea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FYARRO ™ is indicated for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa). uuid:9147f6b8-e7f8-4e63-807b-87830532955a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:232810 biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:b14d3103-e790-450a-bb9b-0ff312426719"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:0beac66e-55a0-48d5-929e-be37714356f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:29713bb7-abfe-4f6d-a831-3efc3d6a059b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/alunbrig""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] ALUNBRIG is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test [see Dosage and Administration (2.1) ] .|[EMA] Alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)‑positive advanced non‑small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor.Alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase ALKpositive advanced NSCLC previously treated with crizotinib. UNII:HYW8DB273J uuid:447f3688-449f-43da-901c-88ba0fb93a41 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5959 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:0a709436-68f3-4f96-8cc1-e6ddc3e904b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:8e593b53-ccc2-4478-9411-5b4c6c88d441"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:52b02239-fe92-4d3a-9d22-0fc84050d845"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/irbesartan-teva""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Irbesartan tablets are an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. (1.1) Treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes, an elevated serum creatinine, and proteinuria. (1.2)|[EMA] Treatment of essential hypertension.Treatment of renal disease in patients with hypertension and type 2 diabetes mellitus as part of an antihypertensive medicinal product regimen. uuid:8e8f1300-1433-4f56-a7a8-6bcbe3d5be08 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:P76B05O5V6 biolink:treats MONDO:0008315 PMID:41385096 "[{""id"":""uuid:e7643c6d-b8a4-4822-b00d-a1125b9f7fa8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d7eacabd-96ed-4036-89f7-62384ae8e58d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ORGOVYX is indicated for the treatment of adult patients with advanced prostate cancer. uuid:cc658d1f-e81f-4865-946c-12b77e78280a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2637040 biolink:treats HP:0001662 PMID:41385096 "[{""id"":""uuid:b8b788bd-f0c7-445f-8520-4c568c3be8ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3cc0cb34-83e2-466c-a641-ac36276f6b1d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PREVDUO ® , a fixed dose combination of cholinesterase inhibitor and antimuscarinic agent, is indicated in patients age two years and above for the reversal of the effects of nondepolarizing neuromuscular blocking agents (NMBA) after surgery, while decreasing the peripheral muscarinic effects (e.g., bradycardia and excessive secretions) associated with cholinesterase inhibition following NMBA reversal administration. uuid:197d99b5-3ed9-4197-94bf-052e1143cf65 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:98DE7VN88D biolink:treats MONDO:0005140 PMID:41385096 "[{""id"":""uuid:309ec4eb-c0fa-44d2-b37e-55b831c94579"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1fa854b7-3b8a-4629-9d88-2899dd72c6a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ELAHERE ® is indicated for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. Select patients for therapy based on an FDA-approved test [see Dosage and Administration ( 2.1 )] . uuid:182c98f2-b816-485e-aef4-cbf74b095f06 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:98DE7VN88D biolink:treats MONDO:0002158 PMID:41385096 "[{""id"":""uuid:862920c4-9bba-4985-8bcc-18dae65bbd4c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8cd2733c-710c-45e7-b6ee-df179891a490"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ELAHERE ® is indicated for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. Select patients for therapy based on an FDA-approved test [see Dosage and Administration ( 2.1 )] . uuid:916eb4e0-56e6-4367-a74c-20c02e627364 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:98DE7VN88D biolink:treats MONDO:0015686 PMID:41385096 "[{""id"":""uuid:fe6ed1d6-75e5-4b5b-a8da-ef3f713e45b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:969f1ecd-f22e-4b11-a6ed-467ebabae73c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ELAHERE ® is indicated for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. Select patients for therapy based on an FDA-approved test [see Dosage and Administration ( 2.1 )] . uuid:14752f08-dc2b-4b7c-a0d5-f1cfa7074bfd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0006050 biolink:treats EFO:0006865 PMID:41385096 "[{""id"":""uuid:6390a85e-adb4-4ed3-a0fb-bb323cdbef62"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0c9c3669-5b9f-4f02-9ae5-ff2be5edef43"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BOTOX is an acetylcholine release inhibitor and a neuromuscular blocking agent indicated for: Treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and frequency, in adults who have an inadequate response to or are intolerant of an anticholinergic medication ( 1.1 ) Treatment of urinary incontinence due to detrusor overactivity associated with a neurologic condition [e.g., spinal cord injury (SCI), multiple sclerosis (MS)] in adults who have an inadequate response to or are intolerant of an anticholinergic medication ( 1.1 ) Treatment of neurogenic detrusor overactivity (NDO) in pediatric patients 5 years of age and older who have an inadequate response to or are intolerant of anticholinergic medication. ( 1.2 ) Prophylaxis of headaches in adult patients with chronic migraine (≥15 days per month with headache lasting 4 hours a day or longer) ( 1.3 ) Treatment of spasticity in patients 2 years of age and older ( 1.4 ) Treatment of cervical dystonia in adult patients, to reduce the severity of abnormal head position and neck pain ( 1.5 ) Treatment of severe axillary hyperhidrosis that is inadequately managed by topical agents in adult patients ( 1.6 ) Treatment of blepharospasm associated with dystonia in patients 12 years of age and older ( 1.7 ) Treatment of strabismus in patients 12 years of age and older ( 1.7 ) Limitations of Use Safety and effectiveness of BOTOX have not been established for: Prophylaxis of episodic migraine (14 headache days or fewer per month) ( 1.3 ) Treatment of hyperhidrosis in body areas other than axillary ( 1.6 ) DRUGBANK:DB00083 uuid:2f0db27d-9d0b-449f-a7ea-223cf7c34f02 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0006050 biolink:treats MONDO:0043797 PMID:41385096 "[{""id"":""uuid:7e4d68c3-8e11-4829-952e-6db4e259c313"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b43b0234-fd7d-4357-bb30-6a1a64ac92da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BOTOX is an acetylcholine release inhibitor and a neuromuscular blocking agent indicated for: Treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and frequency, in adults who have an inadequate response to or are intolerant of an anticholinergic medication ( 1.1 ) Treatment of urinary incontinence due to detrusor overactivity associated with a neurologic condition [e.g., spinal cord injury (SCI), multiple sclerosis (MS)] in adults who have an inadequate response to or are intolerant of an anticholinergic medication ( 1.1 ) Treatment of neurogenic detrusor overactivity (NDO) in pediatric patients 5 years of age and older who have an inadequate response to or are intolerant of anticholinergic medication. ( 1.2 ) Prophylaxis of headaches in adult patients with chronic migraine (≥15 days per month with headache lasting 4 hours a day or longer) ( 1.3 ) Treatment of spasticity in patients 2 years of age and older ( 1.4 ) Treatment of cervical dystonia in adult patients, to reduce the severity of abnormal head position and neck pain ( 1.5 ) Treatment of severe axillary hyperhidrosis that is inadequately managed by topical agents in adult patients ( 1.6 ) Treatment of blepharospasm associated with dystonia in patients 12 years of age and older ( 1.7 ) Treatment of strabismus in patients 12 years of age and older ( 1.7 ) Limitations of Use Safety and effectiveness of BOTOX have not been established for: Prophylaxis of episodic migraine (14 headache days or fewer per month) ( 1.3 ) Treatment of hyperhidrosis in body areas other than axillary ( 1.6 ) DRUGBANK:DB00083 uuid:4a829ea1-f73f-425c-883e-0405cb2d6f6e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0006050 biolink:treats MONDO:0005301 PMID:41385096 "[{""id"":""uuid:39619e0f-7239-4407-8560-9f384535d912"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5178e747-c315-47db-a809-e3907f94aa59"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BOTOX is an acetylcholine release inhibitor and a neuromuscular blocking agent indicated for: Treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and frequency, in adults who have an inadequate response to or are intolerant of an anticholinergic medication ( 1.1 ) Treatment of urinary incontinence due to detrusor overactivity associated with a neurologic condition [e.g., spinal cord injury (SCI), multiple sclerosis (MS)] in adults who have an inadequate response to or are intolerant of an anticholinergic medication ( 1.1 ) Treatment of neurogenic detrusor overactivity (NDO) in pediatric patients 5 years of age and older who have an inadequate response to or are intolerant of anticholinergic medication. ( 1.2 ) Prophylaxis of headaches in adult patients with chronic migraine (≥15 days per month with headache lasting 4 hours a day or longer) ( 1.3 ) Treatment of spasticity in patients 2 years of age and older ( 1.4 ) Treatment of cervical dystonia in adult patients, to reduce the severity of abnormal head position and neck pain ( 1.5 ) Treatment of severe axillary hyperhidrosis that is inadequately managed by topical agents in adult patients ( 1.6 ) Treatment of blepharospasm associated with dystonia in patients 12 years of age and older ( 1.7 ) Treatment of strabismus in patients 12 years of age and older ( 1.7 ) Limitations of Use Safety and effectiveness of BOTOX have not been established for: Prophylaxis of episodic migraine (14 headache days or fewer per month) ( 1.3 ) Treatment of hyperhidrosis in body areas other than axillary ( 1.6 ) DRUGBANK:DB00083 uuid:b552967e-2982-41d5-af42-b2a64f64214a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0006050 biolink:treats UMLS:C0341736 PMID:41385096 "[{""id"":""uuid:dd560b06-5229-4b64-b764-ad30baef2730"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8702f9fe-f396-4026-a6d5-38bf4beadff3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BOTOX is an acetylcholine release inhibitor and a neuromuscular blocking agent indicated for: Treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and frequency, in adults who have an inadequate response to or are intolerant of an anticholinergic medication ( 1.1 ) Treatment of urinary incontinence due to detrusor overactivity associated with a neurologic condition [e.g., spinal cord injury (SCI), multiple sclerosis (MS)] in adults who have an inadequate response to or are intolerant of an anticholinergic medication ( 1.1 ) Treatment of neurogenic detrusor overactivity (NDO) in pediatric patients 5 years of age and older who have an inadequate response to or are intolerant of anticholinergic medication. ( 1.2 ) Prophylaxis of headaches in adult patients with chronic migraine (≥15 days per month with headache lasting 4 hours a day or longer) ( 1.3 ) Treatment of spasticity in patients 2 years of age and older ( 1.4 ) Treatment of cervical dystonia in adult patients, to reduce the severity of abnormal head position and neck pain ( 1.5 ) Treatment of severe axillary hyperhidrosis that is inadequately managed by topical agents in adult patients ( 1.6 ) Treatment of blepharospasm associated with dystonia in patients 12 years of age and older ( 1.7 ) Treatment of strabismus in patients 12 years of age and older ( 1.7 ) Limitations of Use Safety and effectiveness of BOTOX have not been established for: Prophylaxis of episodic migraine (14 headache days or fewer per month) ( 1.3 ) Treatment of hyperhidrosis in body areas other than axillary ( 1.6 ) DRUGBANK:DB00083 uuid:a4bdd0dc-9999-404c-b589-6834a5aa4f11 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0006050 biolink:treats HP:0000975 PMID:41385096 "[{""id"":""uuid:6059cd12-cffe-4170-88bd-d2c868165e09"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f21842b2-6cd7-4563-9a26-0a8cac0f88da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:fac5fddb-fcc6-4181-b34e-a77226b9fa54"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BOTOX is an acetylcholine release inhibitor and a neuromuscular blocking agent indicated for: Treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and frequency, in adults who have an inadequate response to or are intolerant of an anticholinergic medication ( 1.1 ) Treatment of urinary incontinence due to detrusor overactivity associated with a neurologic condition [e.g., spinal cord injury (SCI), multiple sclerosis (MS)] in adults who have an inadequate response to or are intolerant of an anticholinergic medication ( 1.1 ) Treatment of neurogenic detrusor overactivity (NDO) in pediatric patients 5 years of age and older who have an inadequate response to or are intolerant of anticholinergic medication. ( 1.2 ) Prophylaxis of headaches in adult patients with chronic migraine (≥15 days per month with headache lasting 4 hours a day or longer) ( 1.3 ) Treatment of spasticity in patients 2 years of age and older ( 1.4 ) Treatment of cervical dystonia in adult patients, to reduce the severity of abnormal head position and neck pain ( 1.5 ) Treatment of severe axillary hyperhidrosis that is inadequately managed by topical agents in adult patients ( 1.6 ) Treatment of blepharospasm associated with dystonia in patients 12 years of age and older ( 1.7 ) Treatment of strabismus in patients 12 years of age and older ( 1.7 ) Limitations of Use Safety and effectiveness of BOTOX have not been established for: Prophylaxis of episodic migraine (14 headache days or fewer per month) ( 1.3 ) Treatment of hyperhidrosis in body areas other than axillary ( 1.6 )|[PMDA] Drugs with a new route of administration and an additional indication for the treatment of severe primary axillary hyperhidrosis. DRUGBANK:DB00083 uuid:3405a805-b41b-4dc7-a3a3-353b367c9b3c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0006050 biolink:treats MONDO:0019772 PMID:41385096 "[{""id"":""uuid:47130f06-93eb-4fe5-84ba-26c37af86c5d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:27168878-47ce-4299-9fa1-d58d8ebe2094"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BOTOX is an acetylcholine release inhibitor and a neuromuscular blocking agent indicated for: Treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and frequency, in adults who have an inadequate response to or are intolerant of an anticholinergic medication ( 1.1 ) Treatment of urinary incontinence due to detrusor overactivity associated with a neurologic condition [e.g., spinal cord injury (SCI), multiple sclerosis (MS)] in adults who have an inadequate response to or are intolerant of an anticholinergic medication ( 1.1 ) Treatment of neurogenic detrusor overactivity (NDO) in pediatric patients 5 years of age and older who have an inadequate response to or are intolerant of anticholinergic medication. ( 1.2 ) Prophylaxis of headaches in adult patients with chronic migraine (≥15 days per month with headache lasting 4 hours a day or longer) ( 1.3 ) Treatment of spasticity in patients 2 years of age and older ( 1.4 ) Treatment of cervical dystonia in adult patients, to reduce the severity of abnormal head position and neck pain ( 1.5 ) Treatment of severe axillary hyperhidrosis that is inadequately managed by topical agents in adult patients ( 1.6 ) Treatment of blepharospasm associated with dystonia in patients 12 years of age and older ( 1.7 ) Treatment of strabismus in patients 12 years of age and older ( 1.7 ) Limitations of Use Safety and effectiveness of BOTOX have not been established for: Prophylaxis of episodic migraine (14 headache days or fewer per month) ( 1.3 ) Treatment of hyperhidrosis in body areas other than axillary ( 1.6 ) DRUGBANK:DB00083 uuid:33df5fc0-a203-4252-a988-29dd7bff92a7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0006050 biolink:treats MONDO:0003432 PMID:41385096 "[{""id"":""uuid:3c251221-c11d-4d62-9515-ba620c78ad69"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8727b1b0-2569-4c0b-b647-2f307c3f14b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:42feea99-dad5-4e16-801c-be02804a604e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BOTOX is an acetylcholine release inhibitor and a neuromuscular blocking agent indicated for: Treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and frequency, in adults who have an inadequate response to or are intolerant of an anticholinergic medication ( 1.1 ) Treatment of urinary incontinence due to detrusor overactivity associated with a neurologic condition [e.g., spinal cord injury (SCI), multiple sclerosis (MS)] in adults who have an inadequate response to or are intolerant of an anticholinergic medication ( 1.1 ) Treatment of neurogenic detrusor overactivity (NDO) in pediatric patients 5 years of age and older who have an inadequate response to or are intolerant of anticholinergic medication. ( 1.2 ) Prophylaxis of headaches in adult patients with chronic migraine (≥15 days per month with headache lasting 4 hours a day or longer) ( 1.3 ) Treatment of spasticity in patients 2 years of age and older ( 1.4 ) Treatment of cervical dystonia in adult patients, to reduce the severity of abnormal head position and neck pain ( 1.5 ) Treatment of severe axillary hyperhidrosis that is inadequately managed by topical agents in adult patients ( 1.6 ) Treatment of blepharospasm associated with dystonia in patients 12 years of age and older ( 1.7 ) Treatment of strabismus in patients 12 years of age and older ( 1.7 ) Limitations of Use Safety and effectiveness of BOTOX have not been established for: Prophylaxis of episodic migraine (14 headache days or fewer per month) ( 1.3 ) Treatment of hyperhidrosis in body areas other than axillary ( 1.6 )|[PMDA] Drugs with a new additional indication and a new dosage for the treatment of strabismus. DRUGBANK:DB00083 uuid:cc495112-c269-44f2-89ee-6f7b9c7caa72 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB17381 biolink:treats MONDO:0004200 PMID:41385096 "[{""id"":""uuid:7adb9b2e-c1f3-43fd-8624-01798585f15c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e541b3c8-c6c4-4a32-ae41-b70a3f647f47"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ADSTILADRIN ® is indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-Muscle Invasive Bladder Cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. uuid:9af3f086-6848-447b-97e0-c44dd53ae6ca biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB17381 biolink:treats MONDO:0004641 PMID:41385096 "[{""id"":""uuid:752f916e-af01-4886-91c2-bf4c8f11a836"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d3b8dd4e-5255-4225-8ee1-f34faa58191c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ADSTILADRIN ® is indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-Muscle Invasive Bladder Cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. uuid:97e9d277-733a-4398-ae66-8aa384627ab3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C2826078 biolink:treats MONDO:0009212 PMID:41385096 "[{""id"":""uuid:12b116a1-81e2-4783-ac74-4c66c090875b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:21545164-aeaa-4b45-a6e6-24cb4a7eb183"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:8f1fbca2-8d8c-4e8a-8677-8becadc37b00"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/coagadex""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] COAGADEX, Coagulation Factor X (Human), is a plasma-derived human blood coagulation Factor indicated in adults and children with hereditary Factor X deficiency for: Routine prophylaxis to reduce the frequency of bleeding episodes On-demand treatment and control of bleeding episodes Perioperative management of bleeding in patients with mild, moderate, and severe hereditary Factor X deficiency|[EMA] Coagadex is indicated for the treatment and prophylaxis of bleeding episodes and for perioperative management in patients with hereditary factor X deficiency. Coagadex is indicated in all age groups. DRUGBANK:DB13148 uuid:1368dfe0-fd4c-41c9-8ad5-0ef5e80fa4f8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C2826078 biolink:treats MONDO:0002243 PMID:41385096 "[{""id"":""uuid:2af15a9b-6dae-4053-acd6-3ee78232ca22"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e6d5f0e4-e0ca-416b-9efd-4801f7358e79"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] COAGADEX, Coagulation Factor X (Human), is a plasma-derived human blood coagulation Factor indicated in adults and children with hereditary Factor X deficiency for: Routine prophylaxis to reduce the frequency of bleeding episodes On-demand treatment and control of bleeding episodes Perioperative management of bleeding in patients with mild, moderate, and severe hereditary Factor X deficiency DRUGBANK:DB13148 uuid:13e0df72-3743-467d-9a04-18a1d0aa22b0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50924 biolink:treats UMLS:C1112459 PMID:41385096 "[{""id"":""uuid:c5f52d80-b637-4d22-9193-0422766f74ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:76652b14-b250-40f4-8576-fbca59db42c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sorafenib tablets are a kinase inhibitor indicated for the treatment of • Unresectable hepatocellular carcinoma ( 1.1 ) • Advanced renal cell carcinoma ( 1.2 ) • Locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) refractory to radioactive iodine treatment ( 1.3 ) uuid:f6e4dd9a-53cd-4c1f-908c-7db60a2349a7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50924 biolink:treats UMLS:C4727069 PMID:41385096 "[{""id"":""uuid:1170146e-6cfa-4af3-966a-119cde96c935"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bb5eff42-882d-4be7-810e-0fead3a4925c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sorafenib tablets are a kinase inhibitor indicated for the treatment of • Unresectable hepatocellular carcinoma ( 1.1 ) • Advanced renal cell carcinoma ( 1.2 ) • Locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) refractory to radioactive iodine treatment ( 1.3 ) uuid:e3d71b93-5192-4b53-afb1-018ed538541c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50924 biolink:treats MONDO:0015447 PMID:41385096 "[{""id"":""uuid:f03f85d7-1175-4e9b-bd4d-4008a9ffd9cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0dbfd392-b097-4a87-8958-7df0a7c8c70b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:649be639-18de-4e20-b4e2-98ac353ebbf8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/nexavar""]},{""id"":""uuid:7977b908-9a80-4d34-86fb-fa7f45e222e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sorafenib tablets are a kinase inhibitor indicated for the treatment of • Unresectable hepatocellular carcinoma ( 1.1 ) • Advanced renal cell carcinoma ( 1.2 ) • Locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) refractory to radioactive iodine treatment ( 1.3 )|[EMA] Hepatocellular carcinomaNexavar is indicated for the treatment of hepatocellular carcinoma.Renal cell carcinomaNexavar is indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy.Differentiated thyroid carcinomaNexavar is indicated for the treatment of patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma, refractory to radioactive iodine.|[PMDA] A drug with a new additional indication for the treatment of unresectable differentiated thyroid carcinoma. [Orphan drug] uuid:477be258-a890-4916-979a-c495f26e9bbb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7488 biolink:treats MONDO:0020944 PMID:41385096 "[{""id"":""uuid:f63b566d-9c88-4511-ad17-b8c8a74d1b49"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:527eb9f0-4b65-4651-a905-cc300e13c42d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NATACYN™ (natamycin ophthalmic suspension) 5% is indicated for the treatment of fungal blepharitis, conjunctivitis, and keratitis caused by susceptible organisms including Fusarium solani keratitis. As in other forms of suppurative keratitis, initial and sustained therapy of fungal keratitis should be determined by the clinical diagnosis, laboratory diagnosis by smear and culture of corneal scrapings and drug response. Whenever possible the in vitro activity of natamycin against the responsible fungus should be determined. The effectiveness of natamycin as a single agent in fungal endophthalmitis has not been established. uuid:89acac8a-cfaa-4d0d-aac1-e4779aee7f9e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7488 biolink:treats MONDO:0003799 PMID:41385096 "[{""id"":""uuid:6f4073d7-5109-4d20-b18a-04fd2b8a82fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:41087ee3-f91d-4bee-aff9-2570e473ec00"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NATACYN™ (natamycin ophthalmic suspension) 5% is indicated for the treatment of fungal blepharitis, conjunctivitis, and keratitis caused by susceptible organisms including Fusarium solani keratitis. As in other forms of suppurative keratitis, initial and sustained therapy of fungal keratitis should be determined by the clinical diagnosis, laboratory diagnosis by smear and culture of corneal scrapings and drug response. Whenever possible the in vitro activity of natamycin against the responsible fungus should be determined. The effectiveness of natamycin as a single agent in fungal endophthalmitis has not been established. uuid:54760b06-06b3-434c-9e3e-a21743e1edad biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7488 biolink:treats MONDO:0003085 PMID:41385096 "[{""id"":""uuid:38db8752-c89a-47eb-990a-834beb63abbb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d36a3aa4-77e1-430d-990f-0104b8ace9ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NATACYN™ (natamycin ophthalmic suspension) 5% is indicated for the treatment of fungal blepharitis, conjunctivitis, and keratitis caused by susceptible organisms including Fusarium solani keratitis. As in other forms of suppurative keratitis, initial and sustained therapy of fungal keratitis should be determined by the clinical diagnosis, laboratory diagnosis by smear and culture of corneal scrapings and drug response. Whenever possible the in vitro activity of natamycin against the responsible fungus should be determined. The effectiveness of natamycin as a single agent in fungal endophthalmitis has not been established. uuid:040ed6b2-5e11-4c4e-9df9-c61733dfefa3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7488 biolink:treats MONDO:0033821 PMID:41385096 "[{""id"":""uuid:04c19d8b-79e7-4034-a034-2599b4ab37b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a49926fe-f097-46aa-b179-7b9c9ac86e55"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NATACYN™ (natamycin ophthalmic suspension) 5% is indicated for the treatment of fungal blepharitis, conjunctivitis, and keratitis caused by susceptible organisms including Fusarium solani keratitis. As in other forms of suppurative keratitis, initial and sustained therapy of fungal keratitis should be determined by the clinical diagnosis, laboratory diagnosis by smear and culture of corneal scrapings and drug response. Whenever possible the in vitro activity of natamycin against the responsible fungus should be determined. The effectiveness of natamycin as a single agent in fungal endophthalmitis has not been established. uuid:8a3d6ec3-b11f-46d2-abe0-1a7f877e4906 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7488 biolink:treats UMLS:C1532533 PMID:41385096 "[{""id"":""uuid:5bed4f5f-64d6-4a02-9278-76a1cff9fa41"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:55173e8c-1b15-44c3-acda-f63d9bfd0bb3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NATACYN™ (natamycin ophthalmic suspension) 5% is indicated for the treatment of fungal blepharitis, conjunctivitis, and keratitis caused by susceptible organisms including Fusarium solani keratitis. As in other forms of suppurative keratitis, initial and sustained therapy of fungal keratitis should be determined by the clinical diagnosis, laboratory diagnosis by smear and culture of corneal scrapings and drug response. Whenever possible the in vitro activity of natamycin against the responsible fungus should be determined. The effectiveness of natamycin as a single agent in fungal endophthalmitis has not been established. uuid:f63a859d-329e-4231-9be8-5f62a207102f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:88SH1NBL2B biolink:treats MONDO:0019623 PMID:41385096 "[{""id"":""uuid:85d188af-7d9c-449b-a301-5a072005cc90"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:887c04be-5700-481e-a2f2-6de72c59db1c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:df8a6184-1f82-4b54-857e-de638e191e87"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ORLADEYO ® is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years of age and older.|[PMDA] A drug with a new active ingredient indicated for the prophylaxis of acute attacks of hereditary angioedema. [SAKIGAKE review, orphan drug] uuid:38bb4b8f-6519-4a7a-8ba7-bfd6a187cfd7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:88SH1NBL2B biolink:treats MONDO:0012526 PMID:41385096 "[{""id"":""uuid:fbe95161-8f94-4207-816c-c8f85e233cce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d3b85891-d3b8-45b7-97c0-575e1fb71f15"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ORLADEYO ® is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years of age and older. uuid:e9b2fa77-4d0c-4a66-abed-cf68eb549882 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63584 biolink:treats MONDO:0004956 PMID:41385096 "[{""id"":""uuid:1d8daf27-a99f-4911-a6bd-fe39a31ad2aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:86803359-1160-4825-afa5-bd4b078d630a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:1d38f72a-f576-49ed-b350-b860aeb87424"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/cabazitaxel-accord""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cabazitaxel Injection is indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing treatment regimen.|[EMA] Jevtana in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen. uuid:3e394250-9521-4907-82dd-f961ef3f6ee8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63916 biolink:treats UMLS:C0016736 PMID:41385096 "[{""id"":""uuid:804541a7-56e5-46e0-8a1e-a8724e3ae78b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:59e9bd60-6b8f-4a35-ae76-fc706e50b462"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AURLUMYN is a prostacyclin mimetic indicated for the treatment of severe frostbite in adults to reduce the risk of digit amputations. Effectiveness was established in young, healthy adults who suffered frostbite at high altitudes ( 1.1 ). uuid:8059b91d-30f6-4370-b174-118f4dd9c56b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:233412 biolink:treats MONDO:0005301 PMID:41385096 "[{""id"":""uuid:3943b5c8-2c67-4ca7-b0a4-b204777824a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f10ec5cb-d3b6-42e8-aee4-e4419b901611"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:3f0703cf-bed2-41a8-86e1-265753cf8524"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ponvory""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] PONVORY is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.|[EMA] Ponvory is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features. PUBCHEM.COMPOUND:11363176 uuid:10b8af65-fe59-43eb-9d19-a9b9958815cc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:233412 biolink:treats UMLS:C2921627 PMID:41385096 "[{""id"":""uuid:f3b9520f-c10a-4f82-945a-d649c8abc8bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c8a4e8ed-6e88-496f-854f-85a78a3196ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PONVORY is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. PUBCHEM.COMPOUND:11363176 uuid:ae115ac8-7a26-4424-bab4-e622a00d97b9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:233412 biolink:treats MONDO:0000450 PMID:41385096 "[{""id"":""uuid:0cde5215-055d-4720-bc9d-04fb46ff70f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:56b837ea-d98d-4d81-8af7-9ea32e8874a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PONVORY is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. PUBCHEM.COMPOUND:11363176 uuid:ac155af3-9082-46a7-9038-d76e5f4dad0f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PVI5M0M1GW biolink:treats MONDO:0033938 PMID:41385096 "[{""id"":""uuid:7b59b10d-9a72-475b-8c3c-b3629ff07c74"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:664fdec8-aa66-400e-8cd7-27d0aa30c095"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZARXIO is a leukocyte growth factor indicated to • Decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti‑cancer drugs associated with a significant incidence of severe neutropenia with fever ( 1.1 ) • Reduce the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML) ( 1.2 ) • Reduce the duration of neutropenia and neutropenia-related clinical sequelae‚ e.g.‚ febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation (BMT) ( 1.3 ) • Mobilize autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis ( 1.4 ) • Reduce the incidence and duration of sequelae of severe neutropenia (e.g.‚ fever‚ infections‚ oropharyngeal ulcers) in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia ( 1.5 ) • Increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome) ( 1.6 ) uuid:9cea7afe-41ec-460f-8aff-01c3d0102629 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5134 biolink:treats EFO:1002029 PMID:41385096 "[{""id"":""uuid:03136bf2-8427-45c6-8377-ae875ff14529"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:52f06364-2678-4b81-9808-fe584c65289c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XHANCE is a corticosteroid indicated for the treatment of: • Chronic rhinosinusitis with nasal polyps (CRSwNP) in adults. ( 1.1 ) • Chronic rhinosinusitis without nasal polyps (CRSsNP) in adults. ( 1.2 ) uuid:de97fe5c-1371-4871-8f6d-b128f45909bc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5134 biolink:treats EFO:1002030 PMID:41385096 "[{""id"":""uuid:3846f06f-382a-4806-932f-bad435348919"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b754008b-0fdc-4de0-99e1-b51473dcd068"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XHANCE is a corticosteroid indicated for the treatment of: • Chronic rhinosinusitis with nasal polyps (CRSwNP) in adults. ( 1.1 ) • Chronic rhinosinusitis without nasal polyps (CRSsNP) in adults. ( 1.2 ) uuid:0659f9b3-1762-49cd-99a6-5d938d255f9c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:24755620 biolink:treats MONDO:0006993 PMID:41385096 "[{""id"":""uuid:b374e39c-b6b3-433b-8f51-8f525925487d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ac56eed6-98d0-49d0-b81f-f05b575d3d0a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sacubitril and valsartan tablet is a combination of sacubitril, a neprilisin inhibitor, and valsartan, an angiotensin II receptor blocker, and is indicated: • to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal. ( 1.1 ) • for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. Sacubitril and valsartan tablet reduce NT-proBNP and is expected to improve cardiovascular outcomes. ( 1.2 ) uuid:1cbcb17b-413b-4b2d-9e59-f7d23592b208 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134892 biolink:treats MONDO:0004986 PMID:41385096 "[{""id"":""uuid:38254ef2-82e2-4802-980f-86e08dd7d94d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:de3cb209-d9a7-40f1-a54f-cbd3179a9052"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cysview is indicated for use in the cystoscopic detection of carcinoma of the bladder, including carcinoma in situ (CIS), among patients suspected or known to have lesion(s) on the basis of a prior cystoscopy, or in patients undergoing surveillance cystoscopy for carcinoma of the bladder. Cysview is used with the Karl Storz D-Light C Photodynamic Diagnostic (PDD) system to perform Blue Light Cystoscopy (BLC ® ) as an adjunct to the white light cystoscopy. uuid:04f5b252-8310-45bb-9b54-2f13a6beedd5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134892 biolink:treats MONDO:0004641 PMID:41385096 "[{""id"":""uuid:f4555e4f-58ba-46ce-b491-aabae5d4666a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b02daa29-30ee-44f2-ad6e-fb8f63ad4ad5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cysview is indicated for use in the cystoscopic detection of carcinoma of the bladder, including carcinoma in situ (CIS), among patients suspected or known to have lesion(s) on the basis of a prior cystoscopy, or in patients undergoing surveillance cystoscopy for carcinoma of the bladder. Cysview is used with the Karl Storz D-Light C Photodynamic Diagnostic (PDD) system to perform Blue Light Cystoscopy (BLC ® ) as an adjunct to the white light cystoscopy. uuid:e69c9400-e2bb-4bdf-83ac-0969f7a9683d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:310870 biolink:treats HP:0032004 PMID:41385096 "[{""id"":""uuid:357c37f3-c5a7-4a21-aadc-5d60ffff1c29"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fbe8e4bc-b325-448f-80f1-db023127674b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: “Possibly” Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); moniliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation. uuid:f4ecb7a3-7e87-4372-a4d6-cd156f85a172 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:310870 biolink:treats UMLS:C0451941 PMID:41385096 "[{""id"":""uuid:c7e60e9d-c934-4222-8dca-4209d12a567c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9d106914-d62a-4d48-805b-0821ca1b0551"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: “Possibly” Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); moniliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation. uuid:213bc6de-85bc-4bda-806d-018fc344f999 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:310870 biolink:treats UMLS:C0033775 PMID:41385096 "[{""id"":""uuid:a9ecdd1c-143f-467f-9cda-c993f855304b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:da76ac6c-b424-40af-a976-581c83363b83"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: “Possibly” Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); moniliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation. uuid:e3b79724-dca1-4c2e-8297-6c935890e752 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats UMLS:C0343886 PMID:41385096 "[{""id"":""uuid:3dccb67c-6ab6-428f-b0b3-911c8e8590a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:48cdf512-3fbf-4155-8731-2db260cdc586"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: “Possibly” Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); monliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation. uuid:def83a86-15bd-4c4a-9e1b-e4ffdceff757 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:A92JFM5XNU biolink:treats MONDO:0006014 PMID:41385096 "[{""id"":""uuid:5465f5ac-7d8c-449b-853e-05df095202a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:76f09364-e22a-4803-a141-6ab45da9d308"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BREXAFEMME is a triterpenoid antifungal indicated in adult and post-menarchal pediatric females for: Treatment of vulvovaginal candidiasis (VVC). ( 1.1 ) Reduction in the incidence of recurrent vulvovaginal candidiasis (RVVC) ( 1.1 ) uuid:f2750c96-f226-4a92-9646-28b77d777470 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:A92JFM5XNU biolink:treats HP:0012204 PMID:41385096 "[{""id"":""uuid:2f426a23-a648-429d-8c17-007ddbeb23a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6dcf4cd0-985a-4345-bd19-a59a063167b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BREXAFEMME is a triterpenoid antifungal indicated in adult and post-menarchal pediatric females for: Treatment of vulvovaginal candidiasis (VVC). ( 1.1 ) Reduction in the incidence of recurrent vulvovaginal candidiasis (RVVC) ( 1.1 ) uuid:2e9a41b0-b9f1-48d6-a909-5f8ecb058f44 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:T41737F88A biolink:treats MONDO:0002974 PMID:41385096 "[{""id"":""uuid:c23474eb-7c19-4896-9c73-320c90e139e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e942a8a1-c207-4628-ac43-6c87b107ce3a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TIVDAK ® is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. uuid:48740d1b-7aaf-4e24-a027-c7a48f83ddb8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:G9WJT6RD29 biolink:treats MONDO:0020720 PMID:41385096 "[{""id"":""uuid:3b38cc63-39cd-49e7-a45c-20d1bd768f06"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:158417da-adfa-4510-b0d3-468a732191fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CRYSVITA is a fibroblast growth factor 23 (FGF23) blocking antibody indicated for: The treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 6 months of age and older. ( 1.1 ) The treatment of FGF23-related hypophosphatemia in tumor-induced osteomalacia (TIO) associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized in adult and pediatric patients 2 years of age and older. ( 1.2 ) uuid:55cdad01-fd56-49f5-bbbf-28126d261961 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:G9WJT6RD29 biolink:treats MONDO:0018124 PMID:41385096 "[{""id"":""uuid:894b6987-d63f-453e-ae40-52e4eae1c385"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:70b2f88f-c141-4f89-bcb6-ef84aa33fc87"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:66117be0-6514-44f3-8a63-c7e9bff7a7ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/crysvita""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] CRYSVITA is a fibroblast growth factor 23 (FGF23) blocking antibody indicated for: The treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 6 months of age and older. ( 1.1 ) The treatment of FGF23-related hypophosphatemia in tumor-induced osteomalacia (TIO) associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized in adult and pediatric patients 2 years of age and older. ( 1.2 )|[EMA] Crysvita is indicated for the treatment of X-linked hypophosphataemia, in children and adolescents aged 1 to 17 years with radiographic evidence of bone disease, and in adults.Crysvita is indicated for the treatment of FGF23-related hypophosphataemia in tumour-induced osteomalacia associated with phosphaturic mesenchymal tumours that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults. uuid:39a8b3f9-988c-4189-87ca-f1d977d448a1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:76018 biolink:treats MONDO:0013024 PMID:41385096 "[{""id"":""uuid:41de7fa9-d4a3-403c-8d5a-5ed260375aa6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ba66bbec-6dd9-401d-9933-98afb588d8ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:8d95e6aa-8407-4a2e-864b-e82a55006ab6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/adempas""]},{""id"":""uuid:ce5227a6-eed8-41be-bad9-9f19693a08e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Adempas is a soluble guanylate cyclase (sGC) stimulator indicated for the treatment of adults with: • Persistent/recurrent Chronic Thromboembolic Pulmonary Hypertension (CTEPH) (WHO Group 4) after surgical treatment or inoperable CTEPH to improve exercise capacity and WHO functional class. ( 1.1 ) • Pulmonary Arterial Hypertension (PAH) (WHO Group 1) to improve exercise capacity, improve WHO functional class and to delay clinical worsening. ( 1.2 )|[EMA] Chronic thromboembolic pulmonary hypertension (CTEPH)Adempas is indicated for the treatment of adult patients with WHO Functional Class (FC) II to III withinoperable CTEPH,persistent or recurrent CTEPH after surgical treatment,to improve exercise capacity.Pulmonary arterial hypertension (PAH)AdultsAdempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (PAH) with WHO Functional Class (FC) II to III to improve exercise capacity.Efficacy has been shown in a PAH population including aetiologies of idiopathic or heritable PAH or PAH associated with connective tissue disease.PaediatricsAdempas is indicated for the treatment of PAH in paediatric patients aged less than 18 years of age and body weight ≥ 50 kg with WHO Functional Class (FC) II to III in combination with endothelin receptor antagonists.|[PMDA] Drugs with a new active ingredient indicated for the treatment of persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) after surgical treatment or inoperable CTEPH. [Orphan drug] uuid:37a5c412-07c5-483d-bd43-17c8e40771ef biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:76018 biolink:treats MONDO:0015924 PMID:41385096 "[{""id"":""uuid:2cd6ce8f-30d2-44c2-a0c1-129b10777b72"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:268f5241-9df6-4680-8445-a584fa4e35bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:af0a31e9-aa32-4b48-be28-39a117e761f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/adempas""]},{""id"":""uuid:1933dfbe-f04f-41ef-8877-18eaa9de0cf8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Adempas is a soluble guanylate cyclase (sGC) stimulator indicated for the treatment of adults with: • Persistent/recurrent Chronic Thromboembolic Pulmonary Hypertension (CTEPH) (WHO Group 4) after surgical treatment or inoperable CTEPH to improve exercise capacity and WHO functional class. ( 1.1 ) • Pulmonary Arterial Hypertension (PAH) (WHO Group 1) to improve exercise capacity, improve WHO functional class and to delay clinical worsening. ( 1.2 )|[EMA] Chronic thromboembolic pulmonary hypertension (CTEPH)Adempas is indicated for the treatment of adult patients with WHO Functional Class (FC) II to III withinoperable CTEPH,persistent or recurrent CTEPH after surgical treatment,to improve exercise capacity.Pulmonary arterial hypertension (PAH)AdultsAdempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (PAH) with WHO Functional Class (FC) II to III to improve exercise capacity.Efficacy has been shown in a PAH population including aetiologies of idiopathic or heritable PAH or PAH associated with connective tissue disease.PaediatricsAdempas is indicated for the treatment of PAH in paediatric patients aged less than 18 years of age and body weight ≥ 50 kg with WHO Functional Class (FC) II to III in combination with endothelin receptor antagonists.|[PMDA] Drugs with a new additional indication for the treatment of pulmonary arterial hypertension. uuid:699a6f72-c97c-4144-9ea3-dc14feadbb3a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2184139 biolink:treats MONDO:0004652 PMID:41385096 "[{""id"":""uuid:5d126717-b769-46e8-bcce-7d260d380d3e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e4feaa37-d62b-4651-bd6d-137d22d21bc6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RECARBRIO is a combination of imipenem, a penem antibacterial, cilastatin, a renal dehydropeptidase inhibitor, and relebactam, a beta-lactamase inhibitor, indicated in patients 18 years of age and older for the treatment of the following infections caused by susceptible gram-negative microorganisms: Hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP). ( 1.1 ) Complicated urinary tract infections, including pyelonephritis (cUTI) in patients who have limited or no alternative treatment options. ( 1.2 ) Complicated intra-abdominal infections (cIAI) in patients who have limited or no alternative treatment options. ( 1.3 ) Approval of the cUTI and cIAI indications is based on limited clinical safety and efficacy data for RECARBRIO. ( 1.2 , 1.3 , 14 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of RECARBRIO and other antibacterial drugs, RECARBRIO should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.3 ) uuid:7d8c6c93-d306-4ce8-9da8-00c372b53c79 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2184139 biolink:treats MONDO:0006939 PMID:41385096 "[{""id"":""uuid:b6b7e4ea-b2b5-438d-90fe-63f18db9418b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:801b3216-879a-499f-9789-01fd27c6b0a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RECARBRIO is a combination of imipenem, a penem antibacterial, cilastatin, a renal dehydropeptidase inhibitor, and relebactam, a beta-lactamase inhibitor, indicated in patients 18 years of age and older for the treatment of the following infections caused by susceptible gram-negative microorganisms: Hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP). ( 1.1 ) Complicated urinary tract infections, including pyelonephritis (cUTI) in patients who have limited or no alternative treatment options. ( 1.2 ) Complicated intra-abdominal infections (cIAI) in patients who have limited or no alternative treatment options. ( 1.3 ) Approval of the cUTI and cIAI indications is based on limited clinical safety and efficacy data for RECARBRIO. ( 1.2 , 1.3 , 14 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of RECARBRIO and other antibacterial drugs, RECARBRIO should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.3 ) uuid:d78c2c21-1459-4c6d-b8c0-00f5af5eabbb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2184139 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:3a10bcdf-0883-4180-af0e-91bc2bc0afeb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4d9479b8-da4c-49b8-8bcf-a3d0533d4f34"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RECARBRIO is a combination of imipenem, a penem antibacterial, cilastatin, a renal dehydropeptidase inhibitor, and relebactam, a beta-lactamase inhibitor, indicated in patients 18 years of age and older for the treatment of the following infections caused by susceptible gram-negative microorganisms: Hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP). ( 1.1 ) Complicated urinary tract infections, including pyelonephritis (cUTI) in patients who have limited or no alternative treatment options. ( 1.2 ) Complicated intra-abdominal infections (cIAI) in patients who have limited or no alternative treatment options. ( 1.3 ) Approval of the cUTI and cIAI indications is based on limited clinical safety and efficacy data for RECARBRIO. ( 1.2 , 1.3 , 14 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of RECARBRIO and other antibacterial drugs, RECARBRIO should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.3 ) uuid:4ed36aa4-d273-4a1e-953a-3ea6911f89fa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2R27AB6766 biolink:treats MONDO:0019740 PMID:41385096 "[{""id"":""uuid:ce72e89d-fceb-40bc-9ed3-9e40d664df1d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5ab3f60e-2e15-4bd5-ba3d-b2db428b4951"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:48b5de9c-3352-46dc-b0c3-eb16f4af4064"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/cablivi""]},{""id"":""uuid:a35997d5-4cc6-4c54-9416-bc86f3b2b724"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CABLIVI is indicated for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.|[EMA] Cablivi is indicated for the treatment of adults experiencing an episode of acquired thrombotic thrombocytopenic purpura (aTTP), in conjunction with plasma exchange and immunosuppression.|[PMDA] A drug with a new active ingredient indicated for the treatment of acquired thrombotic thrombocytopenic purpura. [Orphan drug] uuid:c86fc301-e8b9-4945-b1df-34eadfcf5696 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8499 biolink:treats MONDO:0011191 PMID:41385096 "[{""id"":""uuid:52ffa261-7650-441e-a1e4-fed0e9bc51bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ff5911ca-718d-49c5-9fed-f420e4419b3e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f5bb1db5-b7fb-41bb-baa2-7ecf60018a44"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] HEMANGEOL oral solution contains the beta-adrenergic blocker propranolol hydrochloride and is indicated for the treatment of proliferating infantile hemangioma requiring systemic therapy.|[PMDA] A drug with a new indication in a new dosage form indicated for the treatment of infantile hemangioma. [Orphan drug] uuid:c42e7b28-782b-4761-bef9-842f2471721f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6ZA31Y954Z biolink:treats UMLS:C0406317 PMID:41385096 "[{""id"":""uuid:80d1f6aa-0bec-414c-92be-65ff2ce1685f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1e707f6e-eb7b-41c7-8a19-c4a65e9fb690"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:070c3eeb-ce7b-4fa8-814d-9fd55979de8a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SILIQ ® (brodalumab) is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies.|[PMDA] A drug with a new active ingredient indicated for the treatment of plaque psoriasis, psoriatic arthritis, pustular psoriasis, and erythrodermic psoriasis in patients who have not responded sufficiently to conventional therapies. uuid:04decf47-ccee-48f5-bb3e-2e005e7cc3a3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29101 biolink:treats MONDO:0006022 PMID:41385096 "[{""id"":""uuid:9602986e-fea1-4e5d-b2a7-9511cd928bf8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2442b987-0b27-4d78-afc5-1341f5327f14"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ionosol MB and 5% Dextrose Injection is indicated for intravenous administration to infants for treatment of dehydration, acidosis, diarrhea, and burns, but only after administration of an initial priming solution: 15 mL of 5% dextrose and 0.45% Sodium Chloride Injection/kg of body weight. In adults, Ionosol MB and 5% Dextrose Injection is indicated postoperatively for intravenous fluid and electrolyte maintenance therapy, with a small amount of carbohydrate calories for reducing catabolism of endogenous protein reserves. uuid:8070e04a-07a8-4325-9772-f428dbc18ffb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29101 biolink:treats MONDO:0001673 PMID:41385096 "[{""id"":""uuid:d642fd87-122d-47ba-9fe5-067195bac3f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a53bdf7b-5d1a-4e21-97dd-05ec4a0f40cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ionosol MB and 5% Dextrose Injection is indicated for intravenous administration to infants for treatment of dehydration, acidosis, diarrhea, and burns, but only after administration of an initial priming solution: 15 mL of 5% dextrose and 0.45% Sodium Chloride Injection/kg of body weight. In adults, Ionosol MB and 5% Dextrose Injection is indicated postoperatively for intravenous fluid and electrolyte maintenance therapy, with a small amount of carbohydrate calories for reducing catabolism of endogenous protein reserves. uuid:56be335c-5f98-49ba-916f-cf8b87efb123 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:231702 biolink:treats MONDO:0005173 PMID:41385096 "[{""id"":""uuid:651b6ca4-876f-4e33-bbb4-ad005f4a1393"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f26cc5ae-465c-4f26-aaf5-70c4bb0da68c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:0f44d615-d915-45ad-b924-973a2f72ef5b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/klisyri""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] KLISYRI is indicated for the topical field treatment of actinic keratosis on the face or scalp.|[EMA] Klisyri is indicated for the field treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis (Olsen grade 1) of the face or scalp in adults. uuid:feaf32e2-7078-4175-b115-84eacc4e904d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:76037163 biolink:treats MONDO:0004975 PMID:41385096 "[{""id"":""uuid:a03115d0-f3ee-4b3c-aa83-749e05291a31"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2e6b8fc1-0477-4485-92e6-c9ad86a6074c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NAMZARIC is indicated for the treatment of moderate to severe dementia of the Alzheimer’s type in patients stabilized on 10 mg of donepezil hydrochloride once daily. uuid:d80b3635-a723-4880-a75b-157ed4c78fdb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29101 biolink:treats MONDO:0006844 PMID:41385096 "[{""id"":""uuid:81319271-0cd7-4184-ad26-0361809e15d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3d6bc14e-7003-4dd4-a8ae-6d5dd04c71ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Normosol-M and 5% Dextrose Injection (Multiple Electrolytes and 5% Dextrose Injection Type 1, USP) is indicated for parenteral maintenance of routine daily fluid and electrolyte requirements with minimal carbohydrate calories from dextrose. Magnesium in the formula may help to prevent iatrogenic magnesium deficiency in patients receiving prolonged parenteral therapy. uuid:34a61d00-61dc-4127-908a-7d2181541402 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64355 biolink:treats MONDO:0005886 PMID:41385096 "[{""id"":""uuid:f195fa75-cb4a-49ee-99af-f66f294d99e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:3790b947-bac4-41a6-98a2-c9ef43551343"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:48a45519-af98-4bc9-8aa5-fadb819ad79c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/posaconazole-ahcl""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Noxafil is an azole antifungal indicated as follows: Noxafil injection and Noxafil delayed-release tablets are indicated for the treatment of invasive aspergillosis in adults and pediatric patients 13 years of age and older. ( 1.1 ) Noxafil is indicated for the prophylaxis of invasive Aspergillus and Candida infections in patients who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD) or those with hematologic malignancies with prolonged neutropenia from chemotherapy as follows: ( 1.2 ) Noxafil injection: adults and pediatric patients 2 years of age and older Noxafil delayed-release tablets: adults and pediatric patients 2 years of age and older who weigh greater than 40 kg Noxafil oral suspension: adults and pediatric patients 13 years of age and older Noxafil PowderMix for delayed-release oral suspension: pediatric patients 2 years of age and older who weigh 40 kg or less Noxafil oral suspension is indicated for the treatment of oropharyngeal candidiasis (OPC), including OPC refractory (rOPC) to itraconazole and/or fluconazole in adult and pediatric patients aged 13 years and older. ( 1.3 )|[EMA] Posaconazole AHCL oral suspension is indicated for use in the treatment of the following fungal infections in adults:Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products;Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B;Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products.Oropharyngeal candidiasis: as first-line therapy in patients who have severe disease or are immunocompromised, in whom response to topical therapy is expected to be poor.Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.Posaconazole AHCL oral suspension is also indicated for prophylaxis of invasive fungal infections in the following patients:Patients receiving remission-induction chemotherapy for acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections. uuid:f2c0e2aa-ee80-4e53-8a53-4694a5ae6520 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27953 biolink:treats UMLS:C0001969 PMID:41385096 "[{""id"":""uuid:7041f831-b05c-4bea-b060-6d32cc542b3f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1c4ca12a-12cb-4334-811b-bbe62653a3ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ANTICHOLIUM ® is indicated for: 1. the use as an antidote and/or antagonist in case of intoxication with and/or overdose of: alcohol tropane alkaloids (hyoscyamine, atropine, scopolamine, as e.g. in brugmansia, datura, atropa belladonna) amanita pantherina and amanita muscaria tricyclic antidepressants (amitriptyline, imipramine, trimipramine, clomipramine, doxepine) antiemetics/antihistamines (phenothiazine, thioridazine, chlorpromazine, promethazine, diphenhydramine, dimenhydrinate) neuroleptic drugs (especially butyrophenones) benzodiazepines tolterodine, oxybutynine amantadine, diphenhydramine baclofen 4-hydroxybutyric acid (GHB) inhalation anesthetics ketamine 3-quinuclidinyl benzilate 2. the treatment of postoperative disorders: Central anticholinergic syndrome (CAS) Delayed postoperative awakening Shivering uuid:e3bf8795-d796-4c2e-8dd8-ccc6e22e5f71 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27953 biolink:treats UMLS:C0275249 PMID:41385096 "[{""id"":""uuid:235c8c0c-1c06-40e6-8bc6-fe54dedba484"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b78a997c-8cf6-41c6-9ee7-09c39b4bac8f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ANTICHOLIUM ® is indicated for: 1. the use as an antidote and/or antagonist in case of intoxication with and/or overdose of: alcohol tropane alkaloids (hyoscyamine, atropine, scopolamine, as e.g. in brugmansia, datura, atropa belladonna) amanita pantherina and amanita muscaria tricyclic antidepressants (amitriptyline, imipramine, trimipramine, clomipramine, doxepine) antiemetics/antihistamines (phenothiazine, thioridazine, chlorpromazine, promethazine, diphenhydramine, dimenhydrinate) neuroleptic drugs (especially butyrophenones) benzodiazepines tolterodine, oxybutynine amantadine, diphenhydramine baclofen 4-hydroxybutyric acid (GHB) inhalation anesthetics ketamine 3-quinuclidinyl benzilate 2. the treatment of postoperative disorders: Central anticholinergic syndrome (CAS) Delayed postoperative awakening Shivering uuid:ce90de45-c4f0-4e55-869a-d4e637611123 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27953 biolink:treats UMLS:C0275193 PMID:41385096 "[{""id"":""uuid:ee7af984-fb72-4b89-bd1b-14e51debda01"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:59390f64-b689-4c8e-bf22-7e1f66dbc87a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ANTICHOLIUM ® is indicated for: 1. the use as an antidote and/or antagonist in case of intoxication with and/or overdose of: alcohol tropane alkaloids (hyoscyamine, atropine, scopolamine, as e.g. in brugmansia, datura, atropa belladonna) amanita pantherina and amanita muscaria tricyclic antidepressants (amitriptyline, imipramine, trimipramine, clomipramine, doxepine) antiemetics/antihistamines (phenothiazine, thioridazine, chlorpromazine, promethazine, diphenhydramine, dimenhydrinate) neuroleptic drugs (especially butyrophenones) benzodiazepines tolterodine, oxybutynine amantadine, diphenhydramine baclofen 4-hydroxybutyric acid (GHB) inhalation anesthetics ketamine 3-quinuclidinyl benzilate 2. the treatment of postoperative disorders: Central anticholinergic syndrome (CAS) Delayed postoperative awakening Shivering uuid:93926312-c458-4098-a7c4-61f2b47462d8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27953 biolink:treats UMLS:C0413031 PMID:41385096 "[{""id"":""uuid:7513a940-d70e-483c-aa80-87daf1c15ffc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e2e6692c-3f9a-401b-94f4-1055a2ba27d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ANTICHOLIUM ® is indicated for: 1. the use as an antidote and/or antagonist in case of intoxication with and/or overdose of: alcohol tropane alkaloids (hyoscyamine, atropine, scopolamine, as e.g. in brugmansia, datura, atropa belladonna) amanita pantherina and amanita muscaria tricyclic antidepressants (amitriptyline, imipramine, trimipramine, clomipramine, doxepine) antiemetics/antihistamines (phenothiazine, thioridazine, chlorpromazine, promethazine, diphenhydramine, dimenhydrinate) neuroleptic drugs (especially butyrophenones) benzodiazepines tolterodine, oxybutynine amantadine, diphenhydramine baclofen 4-hydroxybutyric acid (GHB) inhalation anesthetics ketamine 3-quinuclidinyl benzilate 2. the treatment of postoperative disorders: Central anticholinergic syndrome (CAS) Delayed postoperative awakening Shivering uuid:eceb2c44-eb71-4c29-abc5-f82648ae118d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27953 biolink:treats UMLS:C0413030 PMID:41385096 "[{""id"":""uuid:b8f30683-2fcc-4448-972b-a2e4f9e89923"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d7bf6672-c7eb-45d9-9c11-bc4cff8d96b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ANTICHOLIUM ® is indicated for: 1. the use as an antidote and/or antagonist in case of intoxication with and/or overdose of: alcohol tropane alkaloids (hyoscyamine, atropine, scopolamine, as e.g. in brugmansia, datura, atropa belladonna) amanita pantherina and amanita muscaria tricyclic antidepressants (amitriptyline, imipramine, trimipramine, clomipramine, doxepine) antiemetics/antihistamines (phenothiazine, thioridazine, chlorpromazine, promethazine, diphenhydramine, dimenhydrinate) neuroleptic drugs (especially butyrophenones) benzodiazepines tolterodine, oxybutynine amantadine, diphenhydramine baclofen 4-hydroxybutyric acid (GHB) inhalation anesthetics ketamine 3-quinuclidinyl benzilate 2. the treatment of postoperative disorders: Central anticholinergic syndrome (CAS) Delayed postoperative awakening Shivering uuid:20bcd20e-f088-4155-94b7-1884e454ea93 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27953 biolink:treats MONDO:0018547 PMID:41385096 "[{""id"":""uuid:78edc9c5-19a0-466e-b0ae-89d56909cbe1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:adf546b8-bb16-4cc6-9226-cd58f02ba2fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ANTICHOLIUM ® is indicated for: 1. the use as an antidote and/or antagonist in case of intoxication with and/or overdose of: alcohol tropane alkaloids (hyoscyamine, atropine, scopolamine, as e.g. in brugmansia, datura, atropa belladonna) amanita pantherina and amanita muscaria tricyclic antidepressants (amitriptyline, imipramine, trimipramine, clomipramine, doxepine) antiemetics/antihistamines (phenothiazine, thioridazine, chlorpromazine, promethazine, diphenhydramine, dimenhydrinate) neuroleptic drugs (especially butyrophenones) benzodiazepines tolterodine, oxybutynine amantadine, diphenhydramine baclofen 4-hydroxybutyric acid (GHB) inhalation anesthetics ketamine 3-quinuclidinyl benzilate 2. the treatment of postoperative disorders: Central anticholinergic syndrome (CAS) Delayed postoperative awakening Shivering uuid:349c4b63-8d5c-449a-91ba-9966d8e003c8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27953 biolink:treats UMLS:C0572718 PMID:41385096 "[{""id"":""uuid:b061ed08-37da-46f0-80c7-75dbd96cedb5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f449e0d6-e241-4111-88d3-34abe28cbeba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ANTICHOLIUM ® is indicated for: 1. the use as an antidote and/or antagonist in case of intoxication with and/or overdose of: alcohol tropane alkaloids (hyoscyamine, atropine, scopolamine, as e.g. in brugmansia, datura, atropa belladonna) amanita pantherina and amanita muscaria tricyclic antidepressants (amitriptyline, imipramine, trimipramine, clomipramine, doxepine) antiemetics/antihistamines (phenothiazine, thioridazine, chlorpromazine, promethazine, diphenhydramine, dimenhydrinate) neuroleptic drugs (especially butyrophenones) benzodiazepines tolterodine, oxybutynine amantadine, diphenhydramine baclofen 4-hydroxybutyric acid (GHB) inhalation anesthetics ketamine 3-quinuclidinyl benzilate 2. the treatment of postoperative disorders: Central anticholinergic syndrome (CAS) Delayed postoperative awakening Shivering uuid:ad14f03e-5d58-4f8b-b88b-1bc3c9ee6c7e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27953 biolink:treats UMLS:C0568195 PMID:41385096 "[{""id"":""uuid:3f8b6075-db20-4015-b3c4-f42720f0da0d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f36993b3-5626-4a67-9196-c3a870a86085"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ANTICHOLIUM ® is indicated for: 1. the use as an antidote and/or antagonist in case of intoxication with and/or overdose of: alcohol tropane alkaloids (hyoscyamine, atropine, scopolamine, as e.g. in brugmansia, datura, atropa belladonna) amanita pantherina and amanita muscaria tricyclic antidepressants (amitriptyline, imipramine, trimipramine, clomipramine, doxepine) antiemetics/antihistamines (phenothiazine, thioridazine, chlorpromazine, promethazine, diphenhydramine, dimenhydrinate) neuroleptic drugs (especially butyrophenones) benzodiazepines tolterodine, oxybutynine amantadine, diphenhydramine baclofen 4-hydroxybutyric acid (GHB) inhalation anesthetics ketamine 3-quinuclidinyl benzilate 2. the treatment of postoperative disorders: Central anticholinergic syndrome (CAS) Delayed postoperative awakening Shivering uuid:5f02debb-c7c2-4c9b-b8ac-4823c338e4aa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27953 biolink:treats UMLS:C0572305 PMID:41385096 "[{""id"":""uuid:a91e5da9-c031-4c4c-9f9f-41380780244e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e0c73cda-fa55-4224-9600-848f6b227a56"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ANTICHOLIUM ® is indicated for: 1. the use as an antidote and/or antagonist in case of intoxication with and/or overdose of: alcohol tropane alkaloids (hyoscyamine, atropine, scopolamine, as e.g. in brugmansia, datura, atropa belladonna) amanita pantherina and amanita muscaria tricyclic antidepressants (amitriptyline, imipramine, trimipramine, clomipramine, doxepine) antiemetics/antihistamines (phenothiazine, thioridazine, chlorpromazine, promethazine, diphenhydramine, dimenhydrinate) neuroleptic drugs (especially butyrophenones) benzodiazepines tolterodine, oxybutynine amantadine, diphenhydramine baclofen 4-hydroxybutyric acid (GHB) inhalation anesthetics ketamine 3-quinuclidinyl benzilate 2. the treatment of postoperative disorders: Central anticholinergic syndrome (CAS) Delayed postoperative awakening Shivering uuid:23405c42-2420-458c-bab8-e532fdc5ee1d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27953 biolink:treats UMLS:C0274565 PMID:41385096 "[{""id"":""uuid:29ca1d26-69af-4431-b67f-65ab6100ae6f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a66b22fa-76df-4d0e-a156-93c8eaf48f89"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ANTICHOLIUM ® is indicated for: 1. the use as an antidote and/or antagonist in case of intoxication with and/or overdose of: alcohol tropane alkaloids (hyoscyamine, atropine, scopolamine, as e.g. in brugmansia, datura, atropa belladonna) amanita pantherina and amanita muscaria tricyclic antidepressants (amitriptyline, imipramine, trimipramine, clomipramine, doxepine) antiemetics/antihistamines (phenothiazine, thioridazine, chlorpromazine, promethazine, diphenhydramine, dimenhydrinate) neuroleptic drugs (especially butyrophenones) benzodiazepines tolterodine, oxybutynine amantadine, diphenhydramine baclofen 4-hydroxybutyric acid (GHB) inhalation anesthetics ketamine 3-quinuclidinyl benzilate 2. the treatment of postoperative disorders: Central anticholinergic syndrome (CAS) Delayed postoperative awakening Shivering uuid:0ca730c8-8fea-4f43-b261-2cdfded06040 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27953 biolink:treats UMLS:C0274967 PMID:41385096 "[{""id"":""uuid:db328a15-7b41-4a68-8683-4aeb13a11d59"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:606a4fc5-fa34-4648-aa27-015ea55e7515"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ANTICHOLIUM ® is indicated for: 1. the use as an antidote and/or antagonist in case of intoxication with and/or overdose of: alcohol tropane alkaloids (hyoscyamine, atropine, scopolamine, as e.g. in brugmansia, datura, atropa belladonna) amanita pantherina and amanita muscaria tricyclic antidepressants (amitriptyline, imipramine, trimipramine, clomipramine, doxepine) antiemetics/antihistamines (phenothiazine, thioridazine, chlorpromazine, promethazine, diphenhydramine, dimenhydrinate) neuroleptic drugs (especially butyrophenones) benzodiazepines tolterodine, oxybutynine amantadine, diphenhydramine baclofen 4-hydroxybutyric acid (GHB) inhalation anesthetics ketamine 3-quinuclidinyl benzilate 2. the treatment of postoperative disorders: Central anticholinergic syndrome (CAS) Delayed postoperative awakening Shivering uuid:81ea23e6-62ca-42df-8ef6-9911ce74c1d2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27953 biolink:treats UMLS:C0568550 PMID:41385096 "[{""id"":""uuid:4fa479ee-a54e-4393-b46e-cf93238b9816"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3d309600-aa4f-4101-9521-9a50bbaad6c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ANTICHOLIUM ® is indicated for: 1. the use as an antidote and/or antagonist in case of intoxication with and/or overdose of: alcohol tropane alkaloids (hyoscyamine, atropine, scopolamine, as e.g. in brugmansia, datura, atropa belladonna) amanita pantherina and amanita muscaria tricyclic antidepressants (amitriptyline, imipramine, trimipramine, clomipramine, doxepine) antiemetics/antihistamines (phenothiazine, thioridazine, chlorpromazine, promethazine, diphenhydramine, dimenhydrinate) neuroleptic drugs (especially butyrophenones) benzodiazepines tolterodine, oxybutynine amantadine, diphenhydramine baclofen 4-hydroxybutyric acid (GHB) inhalation anesthetics ketamine 3-quinuclidinyl benzilate 2. the treatment of postoperative disorders: Central anticholinergic syndrome (CAS) Delayed postoperative awakening Shivering uuid:69f2a871-5a71-49e1-9e10-5d4960631bd1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27953 biolink:treats UMLS:C0344133 PMID:41385096 "[{""id"":""uuid:e960251f-9cf3-451f-ab83-e2abb32af748"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cd285e8e-3da8-4176-a751-a24291f44b6e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ANTICHOLIUM ® is indicated for: 1. the use as an antidote and/or antagonist in case of intoxication with and/or overdose of: alcohol tropane alkaloids (hyoscyamine, atropine, scopolamine, as e.g. in brugmansia, datura, atropa belladonna) amanita pantherina and amanita muscaria tricyclic antidepressants (amitriptyline, imipramine, trimipramine, clomipramine, doxepine) antiemetics/antihistamines (phenothiazine, thioridazine, chlorpromazine, promethazine, diphenhydramine, dimenhydrinate) neuroleptic drugs (especially butyrophenones) benzodiazepines tolterodine, oxybutynine amantadine, diphenhydramine baclofen 4-hydroxybutyric acid (GHB) inhalation anesthetics ketamine 3-quinuclidinyl benzilate 2. the treatment of postoperative disorders: Central anticholinergic syndrome (CAS) Delayed postoperative awakening Shivering uuid:8f7329e7-48c0-49ad-8093-b5502f4e3eb1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27953 biolink:treats UMLS:C4076763 PMID:41385096 "[{""id"":""uuid:bbd04ae4-ca3f-4def-a2c3-5e8add440069"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:db33b937-09e0-483a-9bc2-a41c6eb212aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ANTICHOLIUM ® is indicated for: 1. the use as an antidote and/or antagonist in case of intoxication with and/or overdose of: alcohol tropane alkaloids (hyoscyamine, atropine, scopolamine, as e.g. in brugmansia, datura, atropa belladonna) amanita pantherina and amanita muscaria tricyclic antidepressants (amitriptyline, imipramine, trimipramine, clomipramine, doxepine) antiemetics/antihistamines (phenothiazine, thioridazine, chlorpromazine, promethazine, diphenhydramine, dimenhydrinate) neuroleptic drugs (especially butyrophenones) benzodiazepines tolterodine, oxybutynine amantadine, diphenhydramine baclofen 4-hydroxybutyric acid (GHB) inhalation anesthetics ketamine 3-quinuclidinyl benzilate 2. the treatment of postoperative disorders: Central anticholinergic syndrome (CAS) Delayed postoperative awakening Shivering uuid:a0a21cac-27a4-49aa-a64f-026159c88ad2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27953 biolink:treats UMLS:C4511354 PMID:41385096 "[{""id"":""uuid:45a8d313-03a9-47e5-960c-108e6d65bba3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2cef3f9c-33cd-47de-ad17-9e2e3be22535"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ANTICHOLIUM ® is indicated for: 1. the use as an antidote and/or antagonist in case of intoxication with and/or overdose of: alcohol tropane alkaloids (hyoscyamine, atropine, scopolamine, as e.g. in brugmansia, datura, atropa belladonna) amanita pantherina and amanita muscaria tricyclic antidepressants (amitriptyline, imipramine, trimipramine, clomipramine, doxepine) antiemetics/antihistamines (phenothiazine, thioridazine, chlorpromazine, promethazine, diphenhydramine, dimenhydrinate) neuroleptic drugs (especially butyrophenones) benzodiazepines tolterodine, oxybutynine amantadine, diphenhydramine baclofen 4-hydroxybutyric acid (GHB) inhalation anesthetics ketamine 3-quinuclidinyl benzilate 2. the treatment of postoperative disorders: Central anticholinergic syndrome (CAS) Delayed postoperative awakening Shivering uuid:47e56857-ea57-4312-b31b-3e644bd989f3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27953 biolink:treats UMLS:C0520757 PMID:41385096 "[{""id"":""uuid:dc8bfd10-8b31-4c30-bf22-612e9ed3858a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3a11cbc7-a6cd-4e7a-8e3f-53a3962447e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ANTICHOLIUM ® is indicated for: 1. the use as an antidote and/or antagonist in case of intoxication with and/or overdose of: alcohol tropane alkaloids (hyoscyamine, atropine, scopolamine, as e.g. in brugmansia, datura, atropa belladonna) amanita pantherina and amanita muscaria tricyclic antidepressants (amitriptyline, imipramine, trimipramine, clomipramine, doxepine) antiemetics/antihistamines (phenothiazine, thioridazine, chlorpromazine, promethazine, diphenhydramine, dimenhydrinate) neuroleptic drugs (especially butyrophenones) benzodiazepines tolterodine, oxybutynine amantadine, diphenhydramine baclofen 4-hydroxybutyric acid (GHB) inhalation anesthetics ketamine 3-quinuclidinyl benzilate 2. the treatment of postoperative disorders: Central anticholinergic syndrome (CAS) Delayed postoperative awakening Shivering uuid:e3e25f0a-e28f-4c33-803f-74180729af2e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27953 biolink:treats HP:0025144 PMID:41385096 "[{""id"":""uuid:b9496725-1c5a-41ab-a142-6affeb2d2b86"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:986c4b85-0907-483d-b182-b70849df9945"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ANTICHOLIUM ® is indicated for: 1. the use as an antidote and/or antagonist in case of intoxication with and/or overdose of: alcohol tropane alkaloids (hyoscyamine, atropine, scopolamine, as e.g. in brugmansia, datura, atropa belladonna) amanita pantherina and amanita muscaria tricyclic antidepressants (amitriptyline, imipramine, trimipramine, clomipramine, doxepine) antiemetics/antihistamines (phenothiazine, thioridazine, chlorpromazine, promethazine, diphenhydramine, dimenhydrinate) neuroleptic drugs (especially butyrophenones) benzodiazepines tolterodine, oxybutynine amantadine, diphenhydramine baclofen 4-hydroxybutyric acid (GHB) inhalation anesthetics ketamine 3-quinuclidinyl benzilate 2. the treatment of postoperative disorders: Central anticholinergic syndrome (CAS) Delayed postoperative awakening Shivering uuid:32889f4f-1196-48bc-b078-18c2e81a97ca biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:43602 biolink:treats MONDO:0005388 PMID:41385096 "[{""id"":""uuid:57a15e3f-f666-4b95-816a-73a9bc75c3c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:b3363fad-2fcf-4217-99ab-6152e82692fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:a71097af-66e4-47f1-9786-59921368b2d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ocaliva""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] OCALIVA ® is indicated for the treatment of adult patients with primary biliary cholangitis (PBC) without cirrhosis or with compensated cirrhosis who do not have evidence of portal hypertension, either in combination with ursodeoxycholic acid (UDCA) with an inadequate response to UDCA or as monotherapy in patients unable to tolerate UDCA. This indication is approved under accelerated approval based on a reduction in alkaline phosphatase (ALP) [see Clinical Studies (14) ] . An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.|[EMA] Ocaliva is indicated for the treatment of primary biliary cholangitis (also known as primary biliary cirrhosis) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA. uuid:06a72f91-d661-42c7-b1ab-c497e8328195 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:43602 biolink:treats MONDO:0007193 PMID:41385096 "[{""id"":""uuid:41291ff7-2741-4837-a10a-0c682e4aaea4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2ba532fa-1592-4722-9928-e4f26477e1d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OCALIVA ® is indicated for the treatment of adult patients with primary biliary cholangitis (PBC) without cirrhosis or with compensated cirrhosis who do not have evidence of portal hypertension, either in combination with ursodeoxycholic acid (UDCA) with an inadequate response to UDCA or as monotherapy in patients unable to tolerate UDCA. This indication is approved under accelerated approval based on a reduction in alkaline phosphatase (ALP) [see Clinical Studies (14) ] . An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. uuid:6c0be68b-ba5b-4be3-bc0f-ecaf2f5189c5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1861726 biolink:treats MONDO:1010182 PMID:41385096 "[{""id"":""uuid:f7d1a8a8-3671-4a80-8a89-dc267c0a3756"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:94685d92-0b0a-4b7d-a6fb-2d6ac847d458"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Beyaz is a combination of drospirenone, a progestin and ethinyl estradiol, an estrogen containing a folate, indicated for use by females of reproductive potential to: • Prevent pregnancy. ( 1.1 ) • Treat symptoms of premenstrual dysphoric disorder (PMDD) for females of reproductive potential who choose to use an oral contraceptive for contraception. ( 1.2 ) • Treat moderate acne for females of reproductive potential at least 14 years old only if the patient desires an oral contraceptive for birth control. ( 1.3 ) • Raise folate levels in females of reproductive potential who choose to use an oral contraceptive for contraception. ( 1.4 ) UMLS:C0520676 uuid:4f84613e-52bd-4b4a-81d3-4b78c3be8ab5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1861726 biolink:treats MONDO:0011438 PMID:41385096 "[{""id"":""uuid:09eb3570-5c4c-493a-b3b4-0a7db870dc36"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dd15fc2a-8344-4997-b04f-f343fa345653"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Beyaz is a combination of drospirenone, a progestin and ethinyl estradiol, an estrogen containing a folate, indicated for use by females of reproductive potential to: • Prevent pregnancy. ( 1.1 ) • Treat symptoms of premenstrual dysphoric disorder (PMDD) for females of reproductive potential who choose to use an oral contraceptive for contraception. ( 1.2 ) • Treat moderate acne for females of reproductive potential at least 14 years old only if the patient desires an oral contraceptive for birth control. ( 1.3 ) • Raise folate levels in females of reproductive potential who choose to use an oral contraceptive for contraception. ( 1.4 ) uuid:08d17deb-4d74-48db-bdc6-e5f4d73e631d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2S9ZZM9Q9V biolink:treats EFO:1001480 PMID:41385096 "[{""id"":""uuid:e9e8d9ff-d693-437c-a9d7-40871ef03892"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e3f75cb3-44f1-4876-beb1-d51edc52a39e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MVASI is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment. ( 1.1 ) Metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen. ( 1.1 ) Limitations of Use : MVASI is not indicated for adjuvant treatment of colon cancer. ( 1.1 ) Unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel for first-line treatment. ( 1.2 ) Recurrent glioblastoma in adults. ( 1.3 ) Metastatic renal cell carcinoma in combination with interferon-alfa. ( 1.4 ) Persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin, or paclitaxel and topotecan. ( 1.5 ) Epithelial ovarian, fallopian tube, or primary peritoneal cancer: in combination with carboplatin and paclitaxel, followed by MVASI as a single agent, for stage III or IV disease following initial surgical resection ( 1.6 ) in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease who received no more than 2 prior chemotherapy regimens ( 1.6 ) in combination with carboplatin and paclitaxel or carboplatin and gemcitabine, followed by MVASI as a single agent, for platinum-sensitive recurrent disease ( 1.6 ) uuid:aa427c9e-d435-4693-b3cb-b2bc0a26510f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2S9ZZM9Q9V biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:1641d5f4-6904-4b36-81bc-277503b669fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:73cce375-72b4-4536-b5cb-7338919e9c8f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:6fa55140-d06e-4b6a-8d00-0b898bbcb9a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/abevmy""]},{""id"":""uuid:0c28f298-5af2-4b71-9aab-cd7f750e8503"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MVASI is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment. ( 1.1 ) Metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen. ( 1.1 ) Limitations of Use : MVASI is not indicated for adjuvant treatment of colon cancer. ( 1.1 ) Unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel for first-line treatment. ( 1.2 ) Recurrent glioblastoma in adults. ( 1.3 ) Metastatic renal cell carcinoma in combination with interferon-alfa. ( 1.4 ) Persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin, or paclitaxel and topotecan. ( 1.5 ) Epithelial ovarian, fallopian tube, or primary peritoneal cancer: in combination with carboplatin and paclitaxel, followed by MVASI as a single agent, for stage III or IV disease following initial surgical resection ( 1.6 ) in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease who received no more than 2 prior chemotherapy regimens ( 1.6 ) in combination with carboplatin and paclitaxel or carboplatin and gemcitabine, followed by MVASI as a single agent, for platinum-sensitive recurrent disease ( 1.6 )|[EMA] Abevmy in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum.Abevmy in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. For further information as to human epidermal growth factor receptor 2 (HER2) status, please refer to section 5.1.Abevmy in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. Patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with Abevmy in combination with capecitabine. For further information as to HER2 status, please refer to section 5.1.Abevmy, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology.Abevmy, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating mutations (see section 5.1).Abevmy in combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer.Abevmy, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (International Federation of Gynecology and Obstetrics [FIGO] stages III B, III C and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5.1).Abevmy, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor–targeted agents.Abevmy in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor–targeted agents (see section 5.1).Abevmy, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.1).|[PMDA] Follow-on biologics indicated for the treatment of unresectable advanced or recurrent colon or rectal cancer and unresectable advanced or recurrent non-squamous non-small cell lung cancer. uuid:5a108353-d9c2-4f3e-80e0-692608d7bc26 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2S9ZZM9Q9V biolink:treats UMLS:C4288305 PMID:41385096 "[{""id"":""uuid:e9ce079f-0446-4ad3-968e-952b449d1fec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d7777c98-079e-4b9d-afbd-a759a0945c01"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MVASI is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment. ( 1.1 ) Metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen. ( 1.1 ) Limitations of Use : MVASI is not indicated for adjuvant treatment of colon cancer. ( 1.1 ) Unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel for first-line treatment. ( 1.2 ) Recurrent glioblastoma in adults. ( 1.3 ) Metastatic renal cell carcinoma in combination with interferon-alfa. ( 1.4 ) Persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin, or paclitaxel and topotecan. ( 1.5 ) Epithelial ovarian, fallopian tube, or primary peritoneal cancer: in combination with carboplatin and paclitaxel, followed by MVASI as a single agent, for stage III or IV disease following initial surgical resection ( 1.6 ) in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease who received no more than 2 prior chemotherapy regimens ( 1.6 ) in combination with carboplatin and paclitaxel or carboplatin and gemcitabine, followed by MVASI as a single agent, for platinum-sensitive recurrent disease ( 1.6 ) uuid:afabe18c-ccd7-48a8-b8c5-c44278453b3b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2S9ZZM9Q9V biolink:treats UMLS:C4721698 PMID:41385096 "[{""id"":""uuid:87027dd4-8f66-4871-98c3-aa5d3ab46393"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dbaca5f8-0146-48a9-a859-dc5dc637a3b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MVASI is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment. ( 1.1 ) Metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen. ( 1.1 ) Limitations of Use : MVASI is not indicated for adjuvant treatment of colon cancer. ( 1.1 ) Unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel for first-line treatment. ( 1.2 ) Recurrent glioblastoma in adults. ( 1.3 ) Metastatic renal cell carcinoma in combination with interferon-alfa. ( 1.4 ) Persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin, or paclitaxel and topotecan. ( 1.5 ) Epithelial ovarian, fallopian tube, or primary peritoneal cancer: in combination with carboplatin and paclitaxel, followed by MVASI as a single agent, for stage III or IV disease following initial surgical resection ( 1.6 ) in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease who received no more than 2 prior chemotherapy regimens ( 1.6 ) in combination with carboplatin and paclitaxel or carboplatin and gemcitabine, followed by MVASI as a single agent, for platinum-sensitive recurrent disease ( 1.6 ) uuid:1e9cf812-c5c5-4cd1-9ce0-1997415fcf7f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2S9ZZM9Q9V biolink:treats MONDO:0002974 PMID:41385096 "[{""id"":""uuid:7268c725-0a17-434b-90a3-376b3b693498"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:bf2a38bf-48ed-4ef9-a8cb-a49cd716a21a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:2faada1c-6110-4002-a7aa-a9e9b7f79cab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MVASI is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment. ( 1.1 ) Metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen. ( 1.1 ) Limitations of Use : MVASI is not indicated for adjuvant treatment of colon cancer. ( 1.1 ) Unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel for first-line treatment. ( 1.2 ) Recurrent glioblastoma in adults. ( 1.3 ) Metastatic renal cell carcinoma in combination with interferon-alfa. ( 1.4 ) Persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin, or paclitaxel and topotecan. ( 1.5 ) Epithelial ovarian, fallopian tube, or primary peritoneal cancer: in combination with carboplatin and paclitaxel, followed by MVASI as a single agent, for stage III or IV disease following initial surgical resection ( 1.6 ) in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease who received no more than 2 prior chemotherapy regimens ( 1.6 ) in combination with carboplatin and paclitaxel or carboplatin and gemcitabine, followed by MVASI as a single agent, for platinum-sensitive recurrent disease ( 1.6 )|[PMDA] Drugs with a new additional indication for the treatment of advanced or recurrent cervical cancer. [Orphan drug] uuid:755e958c-7375-4e8b-9b06-bdcbaca7265c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2S9ZZM9Q9V biolink:treats MONDO:0005140 PMID:41385096 "[{""id"":""uuid:960cba8c-fe34-4567-a251-e96240b85cce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:efcf03a1-63e5-41c5-bf06-f4eaf95d7126"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:41faf87c-1f07-43f9-a4c4-2edbde7fe83f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/abevmy""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] MVASI is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment. ( 1.1 ) Metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen. ( 1.1 ) Limitations of Use : MVASI is not indicated for adjuvant treatment of colon cancer. ( 1.1 ) Unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel for first-line treatment. ( 1.2 ) Recurrent glioblastoma in adults. ( 1.3 ) Metastatic renal cell carcinoma in combination with interferon-alfa. ( 1.4 ) Persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin, or paclitaxel and topotecan. ( 1.5 ) Epithelial ovarian, fallopian tube, or primary peritoneal cancer: in combination with carboplatin and paclitaxel, followed by MVASI as a single agent, for stage III or IV disease following initial surgical resection ( 1.6 ) in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease who received no more than 2 prior chemotherapy regimens ( 1.6 ) in combination with carboplatin and paclitaxel or carboplatin and gemcitabine, followed by MVASI as a single agent, for platinum-sensitive recurrent disease ( 1.6 )|[EMA] Mvasi in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum.Mvasi in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. For further information as to human epidermal growth factor receptor 2 (HER2) status, please refer to section 5.1.Mvasi, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology.Mvasi in combination with interferon alfa-2a is indicated for first-line treatment of adult patients with advanced and/or metastatic renal cell cancer.Mvasi, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (International Federation of Gynecology and Obstetrics (FIGO) stages IIIB, IIIC and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer.Mvasi, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor-targeted agents.Mvasi in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor-targeted agents.Mvasi, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix. uuid:ce347be5-4e6a-41f1-b575-e1b19a058afa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2S9ZZM9Q9V biolink:treats MONDO:0002158 PMID:41385096 "[{""id"":""uuid:647bbae2-5b40-4c57-849a-7bbc7c41d3ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:382d4049-7d77-49d3-b677-aae3527539ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:4631e0ff-2934-43eb-9294-5dfe60f3133d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/abevmy""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] MVASI is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment. ( 1.1 ) Metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen. ( 1.1 ) Limitations of Use : MVASI is not indicated for adjuvant treatment of colon cancer. ( 1.1 ) Unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel for first-line treatment. ( 1.2 ) Recurrent glioblastoma in adults. ( 1.3 ) Metastatic renal cell carcinoma in combination with interferon-alfa. ( 1.4 ) Persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin, or paclitaxel and topotecan. ( 1.5 ) Epithelial ovarian, fallopian tube, or primary peritoneal cancer: in combination with carboplatin and paclitaxel, followed by MVASI as a single agent, for stage III or IV disease following initial surgical resection ( 1.6 ) in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease who received no more than 2 prior chemotherapy regimens ( 1.6 ) in combination with carboplatin and paclitaxel or carboplatin and gemcitabine, followed by MVASI as a single agent, for platinum-sensitive recurrent disease ( 1.6 )|[EMA] Mvasi in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum.Mvasi in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. For further information as to human epidermal growth factor receptor 2 (HER2) status, please refer to section 5.1.Mvasi, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology.Mvasi in combination with interferon alfa-2a is indicated for first-line treatment of adult patients with advanced and/or metastatic renal cell cancer.Mvasi, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (International Federation of Gynecology and Obstetrics (FIGO) stages IIIB, IIIC and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer.Mvasi, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor-targeted agents.Mvasi in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor-targeted agents.Mvasi, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix. uuid:d763de24-8c30-4f55-9e3c-62ada17fce08 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2S9ZZM9Q9V biolink:treats MONDO:0015686 PMID:41385096 "[{""id"":""uuid:562ad4cf-e5b6-4d6e-8cef-21a7a8a82195"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:ca0c41d1-fdfe-43ae-ac9c-d2b0c4ff8585"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:1195d4cd-46c5-49d6-acaa-208758b569f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/abevmy""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] MVASI is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment. ( 1.1 ) Metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen. ( 1.1 ) Limitations of Use : MVASI is not indicated for adjuvant treatment of colon cancer. ( 1.1 ) Unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel for first-line treatment. ( 1.2 ) Recurrent glioblastoma in adults. ( 1.3 ) Metastatic renal cell carcinoma in combination with interferon-alfa. ( 1.4 ) Persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin, or paclitaxel and topotecan. ( 1.5 ) Epithelial ovarian, fallopian tube, or primary peritoneal cancer: in combination with carboplatin and paclitaxel, followed by MVASI as a single agent, for stage III or IV disease following initial surgical resection ( 1.6 ) in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease who received no more than 2 prior chemotherapy regimens ( 1.6 ) in combination with carboplatin and paclitaxel or carboplatin and gemcitabine, followed by MVASI as a single agent, for platinum-sensitive recurrent disease ( 1.6 )|[EMA] Mvasi in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum.Mvasi in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. For further information as to human epidermal growth factor receptor 2 (HER2) status, please refer to section 5.1.Mvasi, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology.Mvasi in combination with interferon alfa-2a is indicated for first-line treatment of adult patients with advanced and/or metastatic renal cell cancer.Mvasi, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (International Federation of Gynecology and Obstetrics (FIGO) stages IIIB, IIIC and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer.Mvasi, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor-targeted agents.Mvasi in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor-targeted agents.Mvasi, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix. uuid:3a8a7ae1-6c29-40b4-a1cf-d00719eac1fc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PUE0TO3XDR biolink:treats MONDO:0006805 PMID:41385096 "[{""id"":""uuid:73a9e737-7c4e-4cf4-a0ee-4a5fc3493189"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:45e31b55-5bdf-43b5-abef-7fcc2ea67375"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FRAGMIN is a low molecular weight heparin (LMWH) indicated for • Prophylaxis of ischemic complications of unstable angina and non-Q-wave myocardial infarction ( 1.1 ) • Prophylaxis of deep vein thrombosis (DVT) in abdominal surgery, hip replacement surgery or medical patients with severely restricted mobility during acute illness ( 1.2 ) • Extended treatment of symptomatic venous thromboembolism (VTE) to reduce the recurrence in adult patients with cancer. In these patients, the FRAGMIN therapy begins with the initial VTE treatment and continues for six months ( 1.3 ) • Treatment of symptomatic venous thromboembolism (VTE) to reduce the recurrence in pediatric patients from birth (gestational age at least 35 weeks) ( 1.4 ) • Limitations of Use FRAGMIN is not indicated for the acute treatment of VTE ( 1.5 ) uuid:b8774d6a-d75a-475a-8895-92be29ed18b5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PUE0TO3XDR biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:f0e0a4b4-13ca-488e-b459-d075225e2387"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:938cbf62-01da-40a5-874f-1fb5bb5aec45"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FRAGMIN is a low molecular weight heparin (LMWH) indicated for • Prophylaxis of ischemic complications of unstable angina and non-Q-wave myocardial infarction ( 1.1 ) • Prophylaxis of deep vein thrombosis (DVT) in abdominal surgery, hip replacement surgery or medical patients with severely restricted mobility during acute illness ( 1.2 ) • Extended treatment of symptomatic venous thromboembolism (VTE) to reduce the recurrence in adult patients with cancer. In these patients, the FRAGMIN therapy begins with the initial VTE treatment and continues for six months ( 1.3 ) • Treatment of symptomatic venous thromboembolism (VTE) to reduce the recurrence in pediatric patients from birth (gestational age at least 35 weeks) ( 1.4 ) • Limitations of Use FRAGMIN is not indicated for the acute treatment of VTE ( 1.5 ) uuid:b8fc03da-2bbb-461c-85a0-6f3d8ff5b579 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PUE0TO3XDR biolink:treats HP:0002625 PMID:41385096 "[{""id"":""uuid:18aa7134-90c3-487a-a617-49d0fd7379e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6951d12c-86aa-4352-99a2-e98eb80743bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FRAGMIN is a low molecular weight heparin (LMWH) indicated for • Prophylaxis of ischemic complications of unstable angina and non-Q-wave myocardial infarction ( 1.1 ) • Prophylaxis of deep vein thrombosis (DVT) in abdominal surgery, hip replacement surgery or medical patients with severely restricted mobility during acute illness ( 1.2 ) • Extended treatment of symptomatic venous thromboembolism (VTE) to reduce the recurrence in adult patients with cancer. In these patients, the FRAGMIN therapy begins with the initial VTE treatment and continues for six months ( 1.3 ) • Treatment of symptomatic venous thromboembolism (VTE) to reduce the recurrence in pediatric patients from birth (gestational age at least 35 weeks) ( 1.4 ) • Limitations of Use FRAGMIN is not indicated for the acute treatment of VTE ( 1.5 ) uuid:d8a0cace-71db-4124-96bd-5223312e2795 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PUE0TO3XDR biolink:treats MONDO:0005399 PMID:41385096 "[{""id"":""uuid:52f3dc62-f620-4052-840e-7ea891d0d324"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:00debf62-80e7-4bd2-bcd1-7e065f698108"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FRAGMIN is a low molecular weight heparin (LMWH) indicated for • Prophylaxis of ischemic complications of unstable angina and non-Q-wave myocardial infarction ( 1.1 ) • Prophylaxis of deep vein thrombosis (DVT) in abdominal surgery, hip replacement surgery or medical patients with severely restricted mobility during acute illness ( 1.2 ) • Extended treatment of symptomatic venous thromboembolism (VTE) to reduce the recurrence in adult patients with cancer. In these patients, the FRAGMIN therapy begins with the initial VTE treatment and continues for six months ( 1.3 ) • Treatment of symptomatic venous thromboembolism (VTE) to reduce the recurrence in pediatric patients from birth (gestational age at least 35 weeks) ( 1.4 ) • Limitations of Use FRAGMIN is not indicated for the acute treatment of VTE ( 1.5 ) uuid:6371dd99-cd0d-4e81-beda-e157a03cb35a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2565805 biolink:treats MONDO:0011438 PMID:41385096 "[{""id"":""uuid:bdc2a696-f989-43a4-8a93-9c761f50426d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dfe398a3-c811-4011-864b-40c957d353c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TWYNEO is indicated for the topical treatment of acne vulgaris in adults and pediatric patients 9 years of age and older. uuid:53ceb762-bc2d-429e-a021-aea4ef35245b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:232556 biolink:treats MONDO:0040679 PMID:41385096 "[{""id"":""uuid:8afd81c3-dbcb-48f2-8b05-3b0be1419950"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:47f0fa19-e3c1-408c-84ca-e4405c67f9e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BALVERSA is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Select patients for therapy based on an FDA-approved companion diagnostic for BALVERSA [see Dosage and Administration (2.1) and Clinical Studies (14.1) ] . uuid:13932ae5-b28c-4162-a706-78f6c4df6564 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:232556 biolink:treats UMLS:C4288754 PMID:41385096 "[{""id"":""uuid:5980720f-7317-4f4e-89b3-99b34408418c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9b3476c0-2e02-4a58-9eea-26746f34ad7c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BALVERSA is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Select patients for therapy based on an FDA-approved companion diagnostic for BALVERSA [see Dosage and Administration (2.1) and Clinical Studies (14.1) ] . uuid:dc4c1cdc-ed60-48c0-b9e7-681f68c83d5d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:82405 biolink:treats MONDO:0006604 PMID:41385096 "[{""id"":""uuid:1efb6af2-33f9-499e-85f9-391c903fee5a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f2c32d9d-dc48-48fb-aa26-90b72c4452f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EPSOLAY is indicated for the treatment of inflammatory lesions of rosacea in adults. uuid:f31990a6-8d41-4347-9779-90e41c1f8894 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1597612 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:549b0465-c53d-4975-adf1-0f1ad6be297e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5bf7eb52-5336-4cba-acaf-9518ebaecfc6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZERBAXA (ceftolozane and tazobactam) is a combination of ceftolozane, a cephalosporin antibacterial, and tazobactam, a beta-lactamase inhibitor, indicated for the treatment of the following infections caused by designated susceptible microorganisms: Complicated Intra-abdominal Infections (cIAI), used in combination with metronidazole, in adult and pediatric patients (birth to less than 18 years old). ( 1.1 ) Complicated Urinary Tract Infections (cUTI), Including Pyelonephritis, in adult and pediatric patients (birth to less than 18 years old). ( 1.2 ) Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia (HABP/VABP), in adult patients 18 years and older. ( 1.3 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZERBAXA and other antibacterial drugs, ZERBAXA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.4 ) uuid:1d7213ed-9bdf-4ea1-8bfe-4ca5d43a8b19 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1597612 biolink:treats MONDO:0006939 PMID:41385096 "[{""id"":""uuid:ea46dead-9531-4ce6-9e42-a5e1ff656dc1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ed0ed96b-d165-43aa-a431-c2c2f0d66e9b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:146a941d-6c76-4546-8472-5a4945813849"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZERBAXA (ceftolozane and tazobactam) is a combination of ceftolozane, a cephalosporin antibacterial, and tazobactam, a beta-lactamase inhibitor, indicated for the treatment of the following infections caused by designated susceptible microorganisms: Complicated Intra-abdominal Infections (cIAI), used in combination with metronidazole, in adult and pediatric patients (birth to less than 18 years old). ( 1.1 ) Complicated Urinary Tract Infections (cUTI), Including Pyelonephritis, in adult and pediatric patients (birth to less than 18 years old). ( 1.2 ) Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia (HABP/VABP), in adult patients 18 years and older. ( 1.3 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZERBAXA and other antibacterial drugs, ZERBAXA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.4 )|[PMDA] A new combination drug with new active ingredients indicated for the treatment of cystitis, pyelonephritis, peritonitis, intra-abdominal abscess, cholecystitis, and liver abscess caused by Zerbaxa- sensitive Streptococcus spp., Escherichia coli , Citrobacter spp., Klebsiella spp., Enterobacter spp., Proteus spp., or Pseudomonas aeruginosa . uuid:92ca620b-8ee5-47b7-bf50-654158619eab biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1597612 biolink:treats MONDO:0004652 PMID:41385096 "[{""id"":""uuid:a56b4d23-4603-4bee-9464-f0e8cf88a4bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4089bf41-15f7-4c2e-9ed6-b9c3e535392e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZERBAXA (ceftolozane and tazobactam) is a combination of ceftolozane, a cephalosporin antibacterial, and tazobactam, a beta-lactamase inhibitor, indicated for the treatment of the following infections caused by designated susceptible microorganisms: Complicated Intra-abdominal Infections (cIAI), used in combination with metronidazole, in adult and pediatric patients (birth to less than 18 years old). ( 1.1 ) Complicated Urinary Tract Infections (cUTI), Including Pyelonephritis, in adult and pediatric patients (birth to less than 18 years old). ( 1.2 ) Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia (HABP/VABP), in adult patients 18 years and older. ( 1.3 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZERBAXA and other antibacterial drugs, ZERBAXA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.4 ) uuid:af1763c5-f1f5-449b-baea-384ca0e342c1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:8JXN261VVA biolink:treats MONDO:0015459 PMID:41385096 "[{""id"":""uuid:6e4ec648-2f98-41a0-a3f8-a0c77affa64e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:80852715-8109-4f8c-a203-52d98da563df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LOQTORZI is a programmed death receptor-1 (PD-1)- blocking antibody indicated: in combination with cisplatin and gemcitabine, for first-line treatment of adults with metastatic or with recurrent locally advanced nasopharyngeal carcinoma (NPC) ( 1.1 ) as a single agent for the treatment of adults with recurrent unresectable or metastatic NPC with disease progression on or after a platinum-containing chemotherapy ( 1.2 ) uuid:bdcd3fbb-3742-409e-8bec-f5f257e481b2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:8JXN261VVA biolink:treats MONDO:0024879 PMID:41385096 "[{""id"":""uuid:7921a453-bfe3-486e-90f5-6bc5a0eafd46"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0581e03b-501a-402f-a00d-3974f966f8f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LOQTORZI is a programmed death receptor-1 (PD-1)- blocking antibody indicated: in combination with cisplatin and gemcitabine, for first-line treatment of adults with metastatic or with recurrent locally advanced nasopharyngeal carcinoma (NPC) ( 1.1 ) as a single agent for the treatment of adults with recurrent unresectable or metastatic NPC with disease progression on or after a platinum-containing chemotherapy ( 1.2 ) uuid:26995cc6-1339-44ac-bd5c-0e3f7f368818 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7457 biolink:treats UMLS:C0151559 PMID:41385096 "[{""id"":""uuid:eb9b28b9-b1ec-48c5-bd5d-fa9665bf312c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:99ae0e73-cc76-4250-91f7-d0972265257b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OPVEE nasal spray is indicated for the emergency treatment of known or suspected overdose induced by natural or synthetic opioids in adults and pediatric patients aged 12 years and older, as manifested by respiratory and/or central nervous system depression. OPVEE nasal spray is intended for immediate administration as emergency therapy in settings where opioids may be present. OPVEE nasal spray is not a substitute for emergency medical care. uuid:07a0b234-b8ed-4736-ad68-eb25a12780f0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1163417 biolink:treats MONDO:0005093 PMID:41385096 "[{""id"":""uuid:bf9e2e98-88ad-4230-9bd1-f90416f945d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b6391a31-6c0c-435a-b35e-6f48b06fbf51"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the temporary relief of pain and itching associated with minor burns, sunburns, minor skin irritations or hemmorhoids and itching associated with inflammation, and rashes due to eczema. uuid:88fe7bb2-3d58-4637-b270-49b620f88ac9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:66880 biolink:treats MONDO:0004975 PMID:41385096 "[{""id"":""uuid:e61cde64-49c9-4d7f-b78e-402acdf93a88"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6b0ca8c2-5601-4cce-a313-89db651e4818"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:fd503722-5356-4f4a-8294-892d4346f0e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:0241e1e6-13dc-4541-a516-e2eccc18520a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amyvid is indicated for Positron Emission Tomography (PET) imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's Disease (AD) and other causes of cognitive decline. A negative Amyvid scan indicates sparse to no neuritic plaques and is inconsistent with a neuropathological diagnosis of AD at the time of image acquisition; a negative scan result reduces the likelihood that a patient's cognitive impairment is due to AD. A positive Amyvid scan indicates moderate to frequent amyloid neuritic plaques; neuropathological examination has shown this amount of amyloid neuritic plaque is present in patients with AD, but may also be present in patients with other types of neurologic conditions as well as older people with normal cognition. Amyvid is an adjunct to other diagnostic evaluations.|[EMA] This medicinal product is for diagnostic use only.Amyvid is a radiopharmaceutical indicated for Positron Emission Tomography (PET) imaging of β-amyloid neuritic plaque density in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD) and other causes of cognitive impairment. Amyvid should be used in conjunction with a clinical evaluation.A negative scan indicates sparse or no plaques, which is not consistent with a diagnosis of AD.|[PMDA] A drug with a new active ingredient indicated for visualization of beta‑amyloid plaques in the brain of patients with cognitive impairment suspected to be Alzheimer's disease. uuid:819912ca-49c9-4210-8322-90e2da678b36 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:66880 biolink:treats MONDO:0850292 PMID:41385096 "[{""id"":""uuid:801fafb9-a165-42b4-ac58-99667f7cda06"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8df339bf-9ec1-4509-9590-6d1f6cc30ef4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amyvid is indicated for Positron Emission Tomography (PET) imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's Disease (AD) and other causes of cognitive decline. A negative Amyvid scan indicates sparse to no neuritic plaques and is inconsistent with a neuropathological diagnosis of AD at the time of image acquisition; a negative scan result reduces the likelihood that a patient's cognitive impairment is due to AD. A positive Amyvid scan indicates moderate to frequent amyloid neuritic plaques; neuropathological examination has shown this amount of amyloid neuritic plaque is present in patients with AD, but may also be present in patients with other types of neurologic conditions as well as older people with normal cognition. Amyvid is an adjunct to other diagnostic evaluations. uuid:0bb5f05a-754e-4f46-8a6b-cbb8b3c18117 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17824 biolink:treats MONDO:0005301 PMID:41385096 "[{""id"":""uuid:10877601-f4da-4c17-822e-781325432796"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:88722d24-8ff0-4c29-a4c5-e6959ac18e12"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AVONEX is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. uuid:fd9671d7-1153-4258-b67f-d95bdb4fe9fb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17824 biolink:treats UMLS:C2921627 PMID:41385096 "[{""id"":""uuid:41086071-54b5-4efa-bd88-14333fe752eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ab8b2864-db8a-4e62-8abf-9145f97cbf67"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AVONEX is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. uuid:393897d4-6020-42ee-9d27-9cb27927e7d4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17824 biolink:treats MONDO:0000450 PMID:41385096 "[{""id"":""uuid:78910cb1-ccf0-497e-9a06-b143ca454eeb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1abfe2ed-5e50-4992-9617-e53e2b3ee7c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AVONEX is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. uuid:efe710ac-2541-41af-be15-b81368dee899 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:9013DUQ28K biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:c65700ed-89df-430d-b3d6-04e1399852ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:0b886eda-a68d-42b3-9585-8ae2edc9d68f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:feb304e7-cb20-458b-9856-486697f0e37d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/kineret""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] KINERET is an interleukin-1 receptor antagonist indicated for: Rheumatoid Arthritis (RA) Reduction in signs and symptoms and slowing the progression of structural damage in moderately to severely active rheumatoid arthritis, in patients 18 years of age or older who have failed 1 or more disease modifying antirheumatic drugs (DMARDs) ( 1.1 ) Cryopyrin-Associated Periodic Syndromes (CAPS) Treatment of Neonatal-Onset Multisystem Inflammatory Disease (NOMID) ( 1.2 ) Deficiency of Interleukin-1 Receptor Antagonist (DIRA) Treatment of Deficiency of Interleukin-1 Receptor Antagonist (DIRA) ( 1.3 )|[EMA] Rheumatoid Arthritis (RA)Kineret is indicated in adults for the treatment of the signs and symptoms of RA in combination with methotrexate, with an inadequate response to methotrexate alone.COVID-19Kineret is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adult patients with pneumonia requiring supplemental oxygen (low- or high-flow oxygen) who are at risk of progressing to severe respiratory failure determined by plasma concentration of soluble urokinase plasminogen activator receptor (suPAR) ≥ 6 ng/ml.Periodic fever syndromesKineret is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above:Cryopyrin-Associated Periodic Syndromes (CAPS)Kineret is indicated for the treatment of CAPS, including:Neonatal-Onset Multisystem Inflammatory Disease (NOMID) / Chronic Infantile Neurological, Cutaneous, Articular Syndrome (CINCA)Muckle-Wells Syndrome (MWS)Familial Cold Autoinflammatory Syndrome (FCAS)Familial Mediterranean Fever (FMF)Kineret is indicated for the treatment of Familial Mediterranean Fever (FMF). Kineret should be given in combination with colchicine, if appropriate.Still’s DiseaseKineret is indicated in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above for the treatment of Still’s disease, including Systemic Juvenile Idiopathic Arthritis (SJIA) and Adult-Onset Still’s Disease (AOSD), with active systemic features of moderate to high disease activity, or in patients with continued disease activity after treatment with non-steroidal anti-inflammatory drugs (NSAIDs) or glucocorticoids.Kineret can be given as monotherapy or in combination with other anti-inflammatory drugs and disease-modifying antirheumatic drugs (DMARDs). uuid:a3f0e40a-a981-4aa9-b46d-6a694635f238 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:9013DUQ28K biolink:treats MONDO:0011776 PMID:41385096 "[{""id"":""uuid:2757543d-15a1-407e-948d-cd23f7c455f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:989c202c-f087-4272-98c7-9cbbfdddcab4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:98703ad7-4d06-4aad-b3da-63333f29eca2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/kineret""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] KINERET is an interleukin-1 receptor antagonist indicated for: Rheumatoid Arthritis (RA) Reduction in signs and symptoms and slowing the progression of structural damage in moderately to severely active rheumatoid arthritis, in patients 18 years of age or older who have failed 1 or more disease modifying antirheumatic drugs (DMARDs) ( 1.1 ) Cryopyrin-Associated Periodic Syndromes (CAPS) Treatment of Neonatal-Onset Multisystem Inflammatory Disease (NOMID) ( 1.2 ) Deficiency of Interleukin-1 Receptor Antagonist (DIRA) Treatment of Deficiency of Interleukin-1 Receptor Antagonist (DIRA) ( 1.3 )|[EMA] Rheumatoid Arthritis (RA)Kineret is indicated in adults for the treatment of the signs and symptoms of RA in combination with methotrexate, with an inadequate response to methotrexate alone.COVID-19Kineret is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adult patients with pneumonia requiring supplemental oxygen (low- or high-flow oxygen) who are at risk of progressing to severe respiratory failure determined by plasma concentration of soluble urokinase plasminogen activator receptor (suPAR) ≥ 6 ng/ml.Periodic fever syndromesKineret is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above:Cryopyrin-Associated Periodic Syndromes (CAPS)Kineret is indicated for the treatment of CAPS, including:Neonatal-Onset Multisystem Inflammatory Disease (NOMID) / Chronic Infantile Neurological, Cutaneous, Articular Syndrome (CINCA)Muckle-Wells Syndrome (MWS)Familial Cold Autoinflammatory Syndrome (FCAS)Familial Mediterranean Fever (FMF)Kineret is indicated for the treatment of Familial Mediterranean Fever (FMF). Kineret should be given in combination with colchicine, if appropriate.Still’s DiseaseKineret is indicated in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above for the treatment of Still’s disease, including Systemic Juvenile Idiopathic Arthritis (SJIA) and Adult-Onset Still’s Disease (AOSD), with active systemic features of moderate to high disease activity, or in patients with continued disease activity after treatment with non-steroidal anti-inflammatory drugs (NSAIDs) or glucocorticoids.Kineret can be given as monotherapy or in combination with other anti-inflammatory drugs and disease-modifying antirheumatic drugs (DMARDs). uuid:7c6fcd05-171d-407f-86d6-ce09a4d1b961 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:I8309403R0 biolink:treats MONDO:0005301 PMID:41385096 "[{""id"":""uuid:839a0825-17d4-40f2-a994-ade5f51bee52"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3df96fc5-00b4-48f1-91e6-0bf44aec7106"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PLEGRIDY is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. uuid:a10ac078-d517-41d8-af68-e6ca6a527a2a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:I8309403R0 biolink:treats UMLS:C2921627 PMID:41385096 "[{""id"":""uuid:2b4cc292-bc4c-4dff-977a-600b0869ee53"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e6b930ad-2437-46eb-ab48-76822e88c13f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PLEGRIDY is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. uuid:3b34273a-d11d-419f-8105-036a00dcc354 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:I8309403R0 biolink:treats MONDO:0000450 PMID:41385096 "[{""id"":""uuid:088ca03f-2e04-438d-9cb0-e053d19e1747"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:244491e6-7258-4dc2-9bf1-efc0ce0f4de1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PLEGRIDY is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. uuid:3c7a7d81-9476-4509-b542-32c1757af1d4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:142432 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:64acbd4d-1f44-4809-b14a-1fa08fcc25f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:48e77081-3055-46d2-8cda-e8e20a482cd0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f9214f22-7a67-465d-b1df-a3e2337b08d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/verquvo""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] VERQUVO ® is indicated to reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for heart failure or need for outpatient IV diuretics, in adults with symptomatic chronic HF and ejection fraction less than 45% [see Clinical Studies (14) ] .|[EMA] Treatment of symptomatic chronic heart failure uuid:f53fb594-5c02-4804-a211-2c0f8103fbd4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1925495 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:a533c210-2ccf-477d-a03d-841c1d1fc802"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:8688c0aa-6816-4715-add6-9e31f313c4fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:04d02efc-a366-4228-9499-679d57312c0e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/qtern""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] QTERN is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use QTERN is not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus [ see WARNINGS AND PRECAUTIONS (5.1) ].|[EMA] Qtern, fixed dose combination of saxagliptin and dapagliflozin, is indicated in adults aged 18 years and older with type 2 diabetes mellitus:to improve glycaemic control when metformin and/or sulphonylurea (SU) and one of the monocomponents of Qtern do not provide adequate glycaemic control,when already being treated with the free combination of dapagliflozin and saxagliptin.(See sections 4.2, 4.4, 4.5 and 5.1 for available data on combinations studied.) uuid:1318521c-6721-478a-8b55-2a32d68aa60f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1925495 biolink:treats MONDO:0005147 PMID:41385096 "[{""id"":""uuid:61fd594f-175e-425f-8b86-a43a43501aa2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c9d634fd-c034-45b8-b6c4-193062b552d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] QTERN is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use QTERN is not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus [ see WARNINGS AND PRECAUTIONS (5.1) ]. uuid:93d0a438-aa26-4ce5-ac25-337a9a6e51cf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:138865 biolink:treats MONDO:8000006 PMID:41385096 "[{""id"":""uuid:27cd3f86-c130-4a6f-bfbb-10cdecca63a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:21750da6-e8ff-4341-8cd0-b1379863647d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XOLREMDI is indicated in patients 12 years of age and older with WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis) to increase the number of circulating mature neutrophils and lympocytes. uuid:4b540e68-ca19-4f5b-b8f3-dd95064104c8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2NU6F9601K biolink:treats MONDO:0004976 PMID:41385096 "[{""id"":""uuid:f5339bc5-a6ce-4417-9f7a-6e2d7f2152e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c87801bc-51d1-4b44-9ca2-2787e3b3c1cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] QALSODY is indicated for the treatment of amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 ( SOD1 ) gene. This indication is approved under accelerated approval based on reduction in plasma neurofilament light chain (NfL) observed in patients treated with QALSODY [see Clinical Studies ( 14 )] . Continued approval for this indication may be contingent upon verification of clinical benefit in confirmatory trial(s). uuid:8cb946e0-832b-4fc9-9372-64b82f17b184 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2NU6F9601K biolink:treats MONDO:0008781 PMID:41385096 "[{""id"":""uuid:07f1c2d4-66a0-40a9-b6c5-5c6ba9f1274e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:27a42e1b-9e86-4541-8133-d9a927562c5e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] QALSODY is indicated for the treatment of amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 ( SOD1 ) gene. This indication is approved under accelerated approval based on reduction in plasma neurofilament light chain (NfL) observed in patients treated with QALSODY [see Clinical Studies ( 14 )] . Continued approval for this indication may be contingent upon verification of clinical benefit in confirmatory trial(s). uuid:360a519a-26f7-4043-83d3-c8ff8cb4b5d1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4A2Y23XK11 biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:66f43dd4-71e3-44f6-b10b-4896ef8362cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:519e24c2-e05a-49e1-83bf-e4dac80ae979"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LAZCLUZE, in combination with amivantamab, is indicated for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test [see Dosage and Administration (2.1) ] . uuid:abeafb8a-b0e8-4e26-94e9-2042f0934795 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4A2Y23XK11 biolink:treats UMLS:C0278987 PMID:41385096 "[{""id"":""uuid:fc668be2-49f4-4a77-9bde-fccc13663b03"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eb7785b1-ad65-44fe-84fe-75324b4798ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LAZCLUZE, in combination with amivantamab, is indicated for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test [see Dosage and Administration (2.1) ] . uuid:926b61e0-3164-4ff8-b77e-8b1aa6fb8022 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1790637 biolink:treats MONDO:0005002 PMID:41385096 "[{""id"":""uuid:aa2e7bea-6341-489d-be5c-533e05e1ef4d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:7f8f5c5c-1d12-431a-a5bc-283c679632ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:53c35ca2-1dbd-4376-aeb3-eba7d7a20c10"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/bevespi-aerosphere""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] BEVESPI AEROSPHERE is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Limitations of Use: BEVESPI AEROSPHERE is not indicated for the relief of acute bronchospasm or for the treatment of asthma [see Warnings and Precautions ( 5.1 , 5.2 )] .|[EMA] Bevespi Aerosphere is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). uuid:0bde29c1-90d0-4fe1-b87c-8e8d6ee323c6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1790637 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:65af0297-8c8e-4e01-bdca-0f4509e29547"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f92cca15-75ac-4d24-b400-cb4f7f8a343f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BEVESPI AEROSPHERE is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Limitations of Use: BEVESPI AEROSPHERE is not indicated for the relief of acute bronchospasm or for the treatment of asthma [see Warnings and Precautions ( 5.1 , 5.2 )] . uuid:fcd2720e-ce67-4d24-b63d-ba7f8dbef623 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133326 biolink:treats HP:0002043 PMID:41385096 "[{""id"":""uuid:3ca1d4c7-f84b-4739-a780-f3da1da24888"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:081ac4d0-57ef-4526-b5e1-ecb7c70cf740"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] E-Z-DISK is indicated for use in radiography of the esophagus, for detection of esophageal strictures. uuid:b0fea42b-5d8d-4a27-953b-cde1b732e738 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:228302 biolink:treats MONDO:0000594 PMID:41385096 "[{""id"":""uuid:f36f14f4-ddae-4dc9-ad8e-710a41319c38"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:48fa0f29-0e89-4fb8-8d61-e4d2488f32d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZURZUVAE is indicated for the treatment of postpartum depression (PPD) in adults. uuid:c72a3744-5bc9-4a5c-8084-a6f70c3a5537 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7NL2E3F6K3 biolink:treats MONDO:0010602 PMID:41385096 "[{""id"":""uuid:772506f5-a7f8-4b7d-8632-36176456ec55"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:69165e2a-41af-4fbe-89c8-9ef143ae1b83"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:59df3c7f-7f0a-438a-b1ed-a7a04af51e61"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/hemlibra""]},{""id"":""uuid:4d1c9bf9-6720-44e3-b9ef-f85ab1cef700"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] HEMLIBRA is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients ages newborn and older with hemophilia A (congenital factor VIII deficiency) with or without factor VIII inhibitors.|[EMA] Hemlibra is indicated for routine prophylaxis of bleeding episodes in patients with haemophilia A (congenital factor VIII deficiency):with factor VIII inhibitorswithout factor VIII inhibitors who have:severe disease (FVIII < 1%)moderate disease (FVIII ≥ 1% and ≤ 5%) with severe bleeding phenotype.Hemlibra can be used in all age groups.|[PMDA] Drugs with a new active ingredient indicated for the control of bleeding tendency in patients with congenital blood coagulation factor VIII deficiency with blood coagulation factor VIII inhibitors. [Orphan drug] uuid:de7235cb-8871-42c1-baa6-d8f4b1ed1cba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:513P80B4YJ biolink:treats MONDO:0020333 PMID:41385096 "[{""id"":""uuid:ca7b51bb-4af1-49bf-a89f-0037d8fcd211"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aa3d2d49-019a-4b67-86b4-331f273831e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AYVAKIT is a kinase inhibitor indicated for: Gastrointestinal Stromal Tumor (GIST) the treatment of adults with unresectable or metastatic GIST harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations. ( 1.1 , 2.2 ) Advanced Systemic Mastocytosis (AdvSM) the treatment of adult patients with AdvSM. AdvSM includes patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL). ( 1.2 ) Limitations of Use: AYVAKIT is not recommended for the treatment of patients with AdvSM with platelet counts of less than 50 × 10 9 /L ( 1.2 ) Indolent Systemic Mastocytosis (ISM) the treatment of adult patients with ISM. ( 1.3 ) Limitations of Use: AYVAKIT is not recommended for the treatment of patients with ISM with platelet counts of less than 50 × 10 9 /L ( 1.2 ) uuid:afaaa175-6deb-4b7c-a64a-00f3930ffeb2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:513P80B4YJ biolink:treats MONDO:0020332 PMID:41385096 "[{""id"":""uuid:43c079aa-0f8a-461d-b57f-c34360f392fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a6566834-54de-47bc-baac-46d4205b8fb5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AYVAKIT is a kinase inhibitor indicated for: Gastrointestinal Stromal Tumor (GIST) the treatment of adults with unresectable or metastatic GIST harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations. ( 1.1 , 2.2 ) Advanced Systemic Mastocytosis (AdvSM) the treatment of adult patients with AdvSM. AdvSM includes patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL). ( 1.2 ) Limitations of Use: AYVAKIT is not recommended for the treatment of patients with AdvSM with platelet counts of less than 50 × 10 9 /L ( 1.2 ) Indolent Systemic Mastocytosis (ISM) the treatment of adult patients with ISM. ( 1.3 ) Limitations of Use: AYVAKIT is not recommended for the treatment of patients with ISM with platelet counts of less than 50 × 10 9 /L ( 1.2 ) uuid:6dcc2639-1986-4c30-893d-c3abeed3fa3f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:513P80B4YJ biolink:treats MONDO:0020334 PMID:41385096 "[{""id"":""uuid:7b3702ad-9067-4e4d-80f1-2f61485550ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c30aee89-45d6-4928-8443-5cb21bdbeeef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AYVAKIT is a kinase inhibitor indicated for: Gastrointestinal Stromal Tumor (GIST) the treatment of adults with unresectable or metastatic GIST harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations. ( 1.1 , 2.2 ) Advanced Systemic Mastocytosis (AdvSM) the treatment of adult patients with AdvSM. AdvSM includes patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL). ( 1.2 ) Limitations of Use: AYVAKIT is not recommended for the treatment of patients with AdvSM with platelet counts of less than 50 × 10 9 /L ( 1.2 ) Indolent Systemic Mastocytosis (ISM) the treatment of adult patients with ISM. ( 1.3 ) Limitations of Use: AYVAKIT is not recommended for the treatment of patients with ISM with platelet counts of less than 50 × 10 9 /L ( 1.2 ) uuid:0f38a024-a477-4098-8ece-37b96b6a1124 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:513P80B4YJ biolink:treats MONDO:0020331 PMID:41385096 "[{""id"":""uuid:7ed25d92-d015-433b-a46e-02c30e30fea9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bf97988b-c081-4528-a68c-9c4bd4095c6b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AYVAKIT is a kinase inhibitor indicated for: Gastrointestinal Stromal Tumor (GIST) the treatment of adults with unresectable or metastatic GIST harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations. ( 1.1 , 2.2 ) Advanced Systemic Mastocytosis (AdvSM) the treatment of adult patients with AdvSM. AdvSM includes patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL). ( 1.2 ) Limitations of Use: AYVAKIT is not recommended for the treatment of patients with AdvSM with platelet counts of less than 50 × 10 9 /L ( 1.2 ) Indolent Systemic Mastocytosis (ISM) the treatment of adult patients with ISM. ( 1.3 ) Limitations of Use: AYVAKIT is not recommended for the treatment of patients with ISM with platelet counts of less than 50 × 10 9 /L ( 1.2 ) uuid:b48ef894-a061-46ba-8616-d3ebaf9f75ba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB10343 biolink:treats MONDO:0004703 PMID:41385096 "[{""id"":""uuid:0d475584-4037-49cb-b71e-9f3f88c556ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5cf0684a-f271-4543-8c43-9273e78e91f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ed699265-2893-4b0c-9676-08e87c40cb4e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TICE ® BCG is indicated for: the treatment and prophylaxis of carcinoma in situ (CIS) of the urinary bladder the prophylaxis of primary or recurrent stage Ta and/or T1 papillary tumors following transurethral resection (TUR) Limitations of Use: TICE BCG is not recommended for stage TaG1 papillary tumors, unless they are judged to be at high risk of tumor recurrence. TICE BCG is not indicated for papillary tumors of stages higher than T1.|[PMDA] A drug with a new additional dosage indicated for the treatment of superficial bladder cancer and carcinoma in situ of bladder. uuid:741fa02e-d55f-459c-97bf-dbdba4896e03 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB10343 biolink:treats MONDO:0006509 PMID:41385096 "[{""id"":""uuid:ee2f93b9-2d3b-4993-afbf-5e4688c76657"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:94057b35-446f-4384-b640-6f309a331ab5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TICE ® BCG is indicated for: the treatment and prophylaxis of carcinoma in situ (CIS) of the urinary bladder the prophylaxis of primary or recurrent stage Ta and/or T1 papillary tumors following transurethral resection (TUR) Limitations of Use: TICE BCG is not recommended for stage TaG1 papillary tumors, unless they are judged to be at high risk of tumor recurrence. TICE BCG is not indicated for papillary tumors of stages higher than T1. uuid:cafb0132-5456-4de2-be12-e91c15beb722 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5280 biolink:treats UMLS:C1096572 PMID:41385096 "[{""id"":""uuid:1bf39408-943e-4c9f-b712-3febf7445b52"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d29af02a-2a90-417a-8e38-e1a5b9026831"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZYMAXID ® is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Aerobic gram-positive bacteria: Staphylococcus aureus Staphylococcus epidermidis Streptococcus mitis group * Streptococcus oralis * Streptococcus pneumoniae Aerobic gram-negative bacteria: Haemophilus influenzae *Efficacy for these organisms were studied in fewer than 10 infections . uuid:991a4c6a-6ece-49e3-bf8b-dc45c19c017e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5280 biolink:treats MONDO:0021680 PMID:41385096 "[{""id"":""uuid:22e5408e-363e-4264-9d76-370ecae82d46"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3ee324dd-8b44-4d7b-b16a-5ceb78e4e32c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZYMAXID ® is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Aerobic gram-positive bacteria: Staphylococcus aureus Staphylococcus epidermidis Streptococcus mitis group * Streptococcus oralis * Streptococcus pneumoniae Aerobic gram-negative bacteria: Haemophilus influenzae *Efficacy for these organisms were studied in fewer than 10 infections . uuid:42f4ff3f-c2a8-4a46-b1e9-22e2efb37154 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5280 biolink:treats UMLS:C0348321 PMID:41385096 "[{""id"":""uuid:4012765f-7828-4299-a821-665eb5971365"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f7444e1c-d203-41d4-8d77-024af49a69fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZYMAXID ® is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Aerobic gram-positive bacteria: Staphylococcus aureus Staphylococcus epidermidis Streptococcus mitis group * Streptococcus oralis * Streptococcus pneumoniae Aerobic gram-negative bacteria: Haemophilus influenzae *Efficacy for these organisms were studied in fewer than 10 infections . uuid:f81f683a-98cb-45a8-b378-c6e6cff22157 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:82717 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:69e0c895-58c0-4996-9606-329eb2fcfba0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:fbac3b65-04d0-4bd1-ae51-ca00f27913f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:87f95ac0-8bff-4869-bb25-57a84c5bbb2b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/sivextro""]},{""id"":""uuid:ff52e7da-5000-4952-958a-e731e41f03fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SIVEXTRO is an oxazolidinone antibacterial indicated in adult and pediatric patients 12 years of age and older for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible bacteria. ( 1.1 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of SIVEXTRO and other antibacterial drugs, SIVEXTRO should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.|[EMA] Sivextro is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults and adolescents 12 years of age and older.|[PMDA] Drugs with a new active ingredient indicated for the treatment of bacterial skin infections mainly involving the dermis and/or subcutaneous tissues, secondary bacterial infections of pre-existing skin ulcers and/or erosion, and secondary bacterial infections of trauma, burn, and surgical wounds. uuid:086a38b9-8622-4f01-a1b0-6577cc2da497 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:82717 biolink:treats UMLS:C4552483 PMID:41385096 "[{""id"":""uuid:bae25046-ca3a-4efe-876f-dbd18313f8bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:05112556-37bb-4ced-b47a-137099f9336a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SIVEXTRO is an oxazolidinone antibacterial indicated in adult and pediatric patients 12 years of age and older for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible bacteria. ( 1.1 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of SIVEXTRO and other antibacterial drugs, SIVEXTRO should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. uuid:f323859d-a756-4cdb-922a-491ed23c873f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:NQX9KB6PCL biolink:treats MONDO:0005300 PMID:41385096 "[{""id"":""uuid:7c23490e-8300-474e-b261-7789a7c7e230"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7629f8cd-cf8b-4fc9-855c-234efac047ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ad485a56-3f8b-4f53-8134-dfa8d1baefae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/omnitrope""]},{""id"":""uuid:ef2f1c1c-2f3f-4a94-bf1f-8b43387e606a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nutropin AQ is a recombinant human growth hormone indicated for: Pediatric Patients : Treatment of children with growth failure due to growth hormone deficiency (GHD), idiopathic short stature (ISS), Turner syndrome (TS), and chronic kidney disease (CKD) up to the time of renal transplantation ( 1.1 ). Adult Patients: Treatment of adults with either childhood-onset or adult-onset GHD ( 1.2 ).|[EMA] Infants, children and adolescentsGrowth disturbance due to insufficient secretion of growth hormone (GH).Growth disturbance associated with Turner syndrome.Growth disturbance associated with chronic renal insufficiency.Growth disturbance (current height standard-deviation score (SDS) < -2.5 and parental adjusted SDS < -1) in short children / adolescents born small for gestational age (SGA), with a birth weight and / or length below -2 standard deviations (SDs), who failed to show catch-up growth (height velocity (HV) SDS < 0 during the last year) by four years of age or later.Prader-Willi syndrome (PWS), for improvement of growth and body composition. The diagnosis of PWS should be confirmed by appropriate genetic testing.AdultsReplacement therapy in adults with pronounced growth hormone deficiency. Patients with severe growth hormone deficiency in adulthood are defined as patients with known hypothalamic pituitary pathology and at least one known deficiency of a pituitary hormone not being prolactin. These patients should undergo a single dynamic test in order to diagnose or exclude a growth hormone deficiency. In patients with childhood-onset isolated GH deficiency (no evidence of hypothalamic-pituitary disease or cranial irradiation), two dynamic tests should be recommended, except for those having low insulin-like-growth-factor-I (IGF-I) concentrations (SDS < -2) who may be considered for one test. The cut-off point of the dynamic test should be strict.|[PMDA] Follow-on biologics indicated for the treatment of growth disturbance due to growth hormone deficiency before epiphyseal closure and growth disturbance associated with Turner syndrome or chronic renal insufficiency before epiphyseal closure. uuid:f32cf208-b084-4c14-ad0c-d4ded6d3b09b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:52CMI0WC3Y biolink:treats UMLS:C0278987 PMID:41385096 "[{""id"":""uuid:baf8ca63-7839-4f69-bda6-0c0a8f593494"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9555c5b4-21b1-4726-ae31-936a2d3e953d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TECENTRIQ is a programmed death-ligand 1 (PD-L1) blocking antibody indicated: Non-Small Cell Lung Cancer (NSCLC) as adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage II to IIIA NSCLC whose tumors have PD-L1 expression on ≥ 1% of tumor cells, as determined by an FDA-approved test. ( 1.1 , 14.1 ) for the first-line treatment of adult patients with metastatic NSCLC whose tumors have high PD-L1 expression (PD-L1 stained ≥ 50% of tumor cells [TC ≥ 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering ≥ 10% of the tumor area [IC ≥ 10%] ), as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations. ( 1.1 ) in combination with bevacizumab, paclitaxel, and carboplatin, for the first-line treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations. ( 1.1 ) in combination with paclitaxel protein-bound and carboplatin for the first-line treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations ( 1.1 ) for the treatment of adult patients with metastatic NSCLC who have disease progression during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for NSCLC harboring these aberrations prior to receiving TECENTRIQ. ( 1.1 ) Small Cell Lung Cancer (SCLC) in combination with carboplatin and etoposide, for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC). ( 1.2 ) Hepatocellular Carcinoma (HCC) in combination with bevacizumab for the treatment of adult patients with unresectable or metastatic HCC who have not received prior systemic therapy. ( 1.3 ) Melanoma in combination with cobimetinib and vemurafenib for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma. ( 1.4 ) Alveolar Soft Part Sarcoma (ASPS) for the treatment of adult and pediatric patients 2 years of age and older with unresectable or metastatic ASPS. ( 1.5 ) uuid:3a9d29b6-663a-4c51-906a-79cba5c04fdd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:52CMI0WC3Y biolink:treats UMLS:C0744869 PMID:41385096 "[{""id"":""uuid:2311d8bf-f2ec-4c11-955c-f48a016b56aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2a3b6248-1b91-489b-9091-0e4193ca6e54"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TECENTRIQ is a programmed death-ligand 1 (PD-L1) blocking antibody indicated: Non-Small Cell Lung Cancer (NSCLC) as adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage II to IIIA NSCLC whose tumors have PD-L1 expression on ≥ 1% of tumor cells, as determined by an FDA-approved test. ( 1.1 , 14.1 ) for the first-line treatment of adult patients with metastatic NSCLC whose tumors have high PD-L1 expression (PD-L1 stained ≥ 50% of tumor cells [TC ≥ 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering ≥ 10% of the tumor area [IC ≥ 10%] ), as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations. ( 1.1 ) in combination with bevacizumab, paclitaxel, and carboplatin, for the first-line treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations. ( 1.1 ) in combination with paclitaxel protein-bound and carboplatin for the first-line treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations ( 1.1 ) for the treatment of adult patients with metastatic NSCLC who have disease progression during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for NSCLC harboring these aberrations prior to receiving TECENTRIQ. ( 1.1 ) Small Cell Lung Cancer (SCLC) in combination with carboplatin and etoposide, for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC). ( 1.2 ) Hepatocellular Carcinoma (HCC) in combination with bevacizumab for the treatment of adult patients with unresectable or metastatic HCC who have not received prior systemic therapy. ( 1.3 ) Melanoma in combination with cobimetinib and vemurafenib for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma. ( 1.4 ) Alveolar Soft Part Sarcoma (ASPS) for the treatment of adult and pediatric patients 2 years of age and older with unresectable or metastatic ASPS. ( 1.5 ) uuid:a6e19b2d-d01c-4597-861b-c29c838fe09c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:81570 biolink:treats MONDO:0011122 PMID:41385096 "[{""id"":""uuid:eda2d240-b450-42ee-9297-8992d3c37a72"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ef33f062-e0c5-44a6-8d4b-eb7a676797e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] HCG HAS NOT BEEN DEMONSTRATED TO BE EFFECTIVE ADJUNCTIVE THERAPY IN THE TREATMENT OF OBESITY. THERE IS NO SUBSTANTIAL EVIDENCE THAT IT INCREASES WEIGHT LOSS BEYOND THAT RESULTING FROM CALORIC RESTRICTION, THAT IT CAUSES A MORE ATTRACTIVE OR ""NORMAL"" DISTRIBUTION OF FAT, OR THAT IT DECREASES THE HUNGER AND DISCOMFORT ASSOCIATED WITH CALORIE-RESTRICTED DIETS. Prepubertal cryptorchidism not due to anatomic obstruction. In general, HCG is thought to induce testicular descent in situations when descent would have occurred at puberty. HCG thus may help to predict whether or not orchiopexy will be needed in the future. Although, in some cases, descent following HCG administration is permanent, in most cases the response is temporary. Therapy is usually instituted between the ages of 4 and 9. Selected cases of hypogonadotropic hypogonadism (hypogonadism secondary to a pituitary deficiency) in males. Induction of ovulation and pregnancy in the anovulatory, infertile woman in whom the cause of anovulation is secondary and not due to primary ovarian failure, and who has been appropriately pretreated with human menotropins." uuid:c0530acd-4c5b-45c2-8f17-e587f1871872 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:81570 biolink:treats MONDO:0009047 PMID:41385096 "[{""id"":""uuid:60eeeec7-aa09-4375-8890-aaf3dcd809d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a03018f1-5391-4961-9e68-ec7767047567"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] HCG HAS NOT BEEN DEMONSTRATED TO BE EFFECTIVE ADJUNCTIVE THERAPY IN THE TREATMENT OF OBESITY. THERE IS NO SUBSTANTIAL EVIDENCE THAT IT INCREASES WEIGHT LOSS BEYOND THAT RESULTING FROM CALORIC RESTRICTION, THAT IT CAUSES A MORE ATTRACTIVE OR ""NORMAL"" DISTRIBUTION OF FAT, OR THAT IT DECREASES THE HUNGER AND DISCOMFORT ASSOCIATED WITH CALORIE-RESTRICTED DIETS. Prepubertal cryptorchidism not due to anatomic obstruction. In general, HCG is thought to induce testicular descent in situations when descent would have occurred at puberty. HCG thus may help to predict whether or not orchiopexy will be needed in the future. Although, in some cases, descent following HCG administration is permanent, in most cases the response is temporary. Therapy is usually instituted between the ages of 4 and 9. Selected cases of hypogonadotropic hypogonadism (hypogonadism secondary to a pituitary deficiency) in males. Induction of ovulation and pregnancy in the anovulatory, infertile woman in whom the cause of anovulation is secondary and not due to primary ovarian failure, and who has been appropriately pretreated with human menotropins." uuid:a2a8a9ad-1a92-4dce-955e-e501435d47d6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:81570 biolink:treats MONDO:0018555 PMID:41385096 "[{""id"":""uuid:1cfc4fb6-d1af-4eb4-9404-395d2deb0168"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0ccc3ad2-e7b0-4bcf-92b7-066bdc3fa92d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] HCG HAS NOT BEEN DEMONSTRATED TO BE EFFECTIVE ADJUNCTIVE THERAPY IN THE TREATMENT OF OBESITY. THERE IS NO SUBSTANTIAL EVIDENCE THAT IT INCREASES WEIGHT LOSS BEYOND THAT RESULTING FROM CALORIC RESTRICTION, THAT IT CAUSES A MORE ATTRACTIVE OR ""NORMAL"" DISTRIBUTION OF FAT, OR THAT IT DECREASES THE HUNGER AND DISCOMFORT ASSOCIATED WITH CALORIE-RESTRICTED DIETS. Prepubertal cryptorchidism not due to anatomic obstruction. In general, HCG is thought to induce testicular descent in situations when descent would have occurred at puberty. HCG thus may help to predict whether or not orchiopexy will be needed in the future. Although, in some cases, descent following HCG administration is permanent, in most cases the response is temporary. Therapy is usually instituted between the ages of 4 and 9. Selected cases of hypogonadotropic hypogonadism (hypogonadism secondary to a pituitary deficiency) in males. Induction of ovulation and pregnancy in the anovulatory, infertile woman in whom the cause of anovulation is secondary and not due to primary ovarian failure, and who has been appropriately pretreated with human menotropins." uuid:af5d6823-b29a-4daa-9732-545309e9961f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:81570 biolink:treats MONDO:0002775 PMID:41385096 "[{""id"":""uuid:2fc1c625-e85f-4d14-9a08-1bc039f01a66"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9290f1da-c311-4c76-a0bf-1b0eda131cb3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] HCG HAS NOT BEEN DEMONSTRATED TO BE EFFECTIVE ADJUNCTIVE THERAPY IN THE TREATMENT OF OBESITY. THERE IS NO SUBSTANTIAL EVIDENCE THAT IT INCREASES WEIGHT LOSS BEYOND THAT RESULTING FROM CALORIC RESTRICTION, THAT IT CAUSES A MORE ATTRACTIVE OR ""NORMAL"" DISTRIBUTION OF FAT, OR THAT IT DECREASES THE HUNGER AND DISCOMFORT ASSOCIATED WITH CALORIE-RESTRICTED DIETS. Prepubertal cryptorchidism not due to anatomic obstruction. In general, HCG is thought to induce testicular descent in situations when descent would have occurred at puberty. HCG thus may help to predict whether or not orchiopexy will be needed in the future. Although, in some cases, descent following HCG administration is permanent, in most cases the response is temporary. Therapy is usually instituted between the ages of 4 and 9. Selected cases of hypogonadotropic hypogonadism (hypogonadism secondary to a pituitary deficiency) in males. Induction of ovulation and pregnancy in the anovulatory, infertile woman in whom the cause of anovulation is secondary and not due to primary ovarian failure, and who has been appropriately pretreated with human menotropins." uuid:c4bafdfc-1ae3-4d7e-bbb9-796aacce00e3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:81570 biolink:treats MONDO:0005047 PMID:41385096 "[{""id"":""uuid:c57ed8a2-62fb-4c88-b7ae-63f2f8b8668b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cac74a7f-c46b-4631-8a1a-461fc631fa2d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] HCG HAS NOT BEEN DEMONSTRATED TO BE EFFECTIVE ADJUNCTIVE THERAPY IN THE TREATMENT OF OBESITY. THERE IS NO SUBSTANTIAL EVIDENCE THAT IT INCREASES WEIGHT LOSS BEYOND THAT RESULTING FROM CALORIC RESTRICTION, THAT IT CAUSES A MORE ATTRACTIVE OR ""NORMAL"" DISTRIBUTION OF FAT, OR THAT IT DECREASES THE HUNGER AND DISCOMFORT ASSOCIATED WITH CALORIE-RESTRICTED DIETS. Prepubertal cryptorchidism not due to anatomic obstruction. In general, HCG is thought to induce testicular descent in situations when descent would have occurred at puberty. HCG thus may help to predict whether or not orchiopexy will be needed in the future. Although, in some cases, descent following HCG administration is permanent, in most cases the response is temporary. Therapy is usually instituted between the ages of 4 and 9. Selected cases of hypogonadotropic hypogonadism (hypogonadism secondary to a pituitary deficiency) in males. Induction of ovulation and pregnancy in the anovulatory, infertile woman in whom the cause of anovulation is secondary and not due to primary ovarian failure, and who has been appropriately pretreated with human menotropins." uuid:2367f125-e2c5-4b8e-a88a-2614bc888ff1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63637 biolink:treats MONDO:0005105 PMID:41385096 "[{""id"":""uuid:346215a0-b4f2-49cf-a064-1184d1452efb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:9362da7b-b2bd-4d90-9dbd-ba3c7c7eb7ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:11c84407-23fc-442d-9315-e91d8c99cba0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/zelboraf""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZELBORAF ® is a kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test. ( 1.1 , 2.1 ) ZELBORAF ® is indicated for the treatment of patients with Erdheim- Chester Disease with BRAF V600 mutation. ( 1.2 , 2.1 ) Limitation of Use: ZELBORAF is not indicated for treatment of patients with wild-type BRAF melanoma ( 2.1 , 5.2 )|[EMA] Vemurafenib is indicated in monotherapy for the treatment of adult patients with BRAF-V600-mutation-positive unresectable or metastatic melanoma., uuid:7c08d6c7-2817-4599-a9c8-193c4e76c8b6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28925 biolink:treats MONDO:0009691 PMID:41385096 "[{""id"":""uuid:5de63f2e-cba7-4239-9b0d-fb4d91c543b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:8aa9830d-2055-47a7-bb63-052b1d5f66fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:07b0da47-8b09-4b76-b4ab-fc1285005663"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ledaga""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] VALCHLOR is indicated for the topical treatment of Stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma in patients who have received prior skin-directed therapy.|[EMA] Ledaga is indicated for the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma (MF-type CTCL) in adult patients. uuid:ca7efaf8-118f-469f-a286-bfdac0f03481 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:ZJ0EKR6M10 biolink:treats UMLS:C0027627 PMID:41385096 "[{""id"":""uuid:96af8848-6a37-4f74-a519-807d15c06559"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9a2350d9-09aa-4a3f-bd1e-ac05fb0356d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gallium Ga 68 Gozetotide Injection is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer: with suspected metastasis who are candidates for initial definitive therapy. with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level. uuid:de6f573a-1b3e-4b3b-a268-95ab0ce9809a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2P471X1Z11 biolink:treats MONDO:0850282 PMID:41385096 "[{""id"":""uuid:125925a4-227c-45db-98ba-71f732f897c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:038df42a-e6d1-46ad-8221-19fd07ca423a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XOLAIR is an anti-IgE antibody indicated for: Moderate to severe persistent asthma in adults and pediatric patients 6 years of age and older with a positive skin test or in vitro reactivity to a perennial aeroallergen and symptoms that are inadequately controlled with inhaled corticosteroids ( 1.1 ) Chronic rhinosinusitis with nasal polyps (CRSwNP) in adult patients 18 years of age and older with inadequate response to nasal corticosteroids, as add-on maintenance treatment ( 1.2 ) IgE-mediated food allergy in adult and pediatric patients aged 1 year and older for the reduction of allergic reactions (Type I), including anaphylaxis, that may occur with accidental exposure to one or more foods. To be used in conjunction with food allergen avoidance ( 1.3 ) Chronic spontaneous urticaria (CSU) in adults and adolescents 12 years of age and older who remain symptomatic despite H1 antihistamine treatment ( 1.4 ) Limitations of Use : Not indicated for acute bronchospasm or status asthmaticus. ( 1.1 , 5.3 ) Not indicated for the emergency treatment of allergic reactions, including anaphylaxis ( 1.3 ) Not indicated for other forms of urticaria. ( 1.4 ) uuid:bb34cb3c-110f-4df9-8fa0-20e344076cf8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2P471X1Z11 biolink:treats EFO:1002029 PMID:41385096 "[{""id"":""uuid:717b6abd-db1a-404c-b130-f6f5dfa4f153"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:158a12e7-1d11-42d2-935a-a9a282b9d638"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XOLAIR is an anti-IgE antibody indicated for: Moderate to severe persistent asthma in adults and pediatric patients 6 years of age and older with a positive skin test or in vitro reactivity to a perennial aeroallergen and symptoms that are inadequately controlled with inhaled corticosteroids ( 1.1 ) Chronic rhinosinusitis with nasal polyps (CRSwNP) in adult patients 18 years of age and older with inadequate response to nasal corticosteroids, as add-on maintenance treatment ( 1.2 ) IgE-mediated food allergy in adult and pediatric patients aged 1 year and older for the reduction of allergic reactions (Type I), including anaphylaxis, that may occur with accidental exposure to one or more foods. To be used in conjunction with food allergen avoidance ( 1.3 ) Chronic spontaneous urticaria (CSU) in adults and adolescents 12 years of age and older who remain symptomatic despite H1 antihistamine treatment ( 1.4 ) Limitations of Use : Not indicated for acute bronchospasm or status asthmaticus. ( 1.1 , 5.3 ) Not indicated for the emergency treatment of allergic reactions, including anaphylaxis ( 1.3 ) Not indicated for other forms of urticaria. ( 1.4 ) uuid:60f00864-5338-41c3-8f92-68f921f44466 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2P471X1Z11 biolink:treats MONDO:0700226 PMID:41385096 "[{""id"":""uuid:74c0037f-38ba-434f-a712-90855922bf93"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bd1b04ee-1040-498b-bf73-5022ba413ce1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XOLAIR is an anti-IgE antibody indicated for: Moderate to severe persistent asthma in adults and pediatric patients 6 years of age and older with a positive skin test or in vitro reactivity to a perennial aeroallergen and symptoms that are inadequately controlled with inhaled corticosteroids ( 1.1 ) Chronic rhinosinusitis with nasal polyps (CRSwNP) in adult patients 18 years of age and older with inadequate response to nasal corticosteroids, as add-on maintenance treatment ( 1.2 ) IgE-mediated food allergy in adult and pediatric patients aged 1 year and older for the reduction of allergic reactions (Type I), including anaphylaxis, that may occur with accidental exposure to one or more foods. To be used in conjunction with food allergen avoidance ( 1.3 ) Chronic spontaneous urticaria (CSU) in adults and adolescents 12 years of age and older who remain symptomatic despite H1 antihistamine treatment ( 1.4 ) Limitations of Use : Not indicated for acute bronchospasm or status asthmaticus. ( 1.1 , 5.3 ) Not indicated for the emergency treatment of allergic reactions, including anaphylaxis ( 1.3 ) Not indicated for other forms of urticaria. ( 1.4 ) uuid:6a3dfe4a-dd85-4d54-8ca1-0f69207a6280 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2P471X1Z11 biolink:treats MONDO:0044212 PMID:41385096 "[{""id"":""uuid:7b406746-c52e-42dd-80bd-ade4d298522b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:23737c10-baf2-4fe8-b23b-54bc20bb1845"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:49825d4d-7854-40b0-af62-5b81e5220dbb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XOLAIR is an anti-IgE antibody indicated for: Moderate to severe persistent asthma in adults and pediatric patients 6 years of age and older with a positive skin test or in vitro reactivity to a perennial aeroallergen and symptoms that are inadequately controlled with inhaled corticosteroids ( 1.1 ) Chronic rhinosinusitis with nasal polyps (CRSwNP) in adult patients 18 years of age and older with inadequate response to nasal corticosteroids, as add-on maintenance treatment ( 1.2 ) IgE-mediated food allergy in adult and pediatric patients aged 1 year and older for the reduction of allergic reactions (Type I), including anaphylaxis, that may occur with accidental exposure to one or more foods. To be used in conjunction with food allergen avoidance ( 1.3 ) Chronic spontaneous urticaria (CSU) in adults and adolescents 12 years of age and older who remain symptomatic despite H1 antihistamine treatment ( 1.4 ) Limitations of Use : Not indicated for acute bronchospasm or status asthmaticus. ( 1.1 , 5.3 ) Not indicated for the emergency treatment of allergic reactions, including anaphylaxis ( 1.3 ) Not indicated for other forms of urticaria. ( 1.4 )|[PMDA] Drugs with a new additional indication and a new dosage for the treatment of chronic idiopathic urticaria (for use only in patients who have not responded sufficiently to conventional therapies). uuid:4299305f-20d9-4a08-b102-500347ec0a76 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C4331966 biolink:treats MONDO:0003060 PMID:41385096 "[{""id"":""uuid:39c11347-794a-450b-89fb-30085c9cdcd1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:62e5e4be-50ee-4ec2-8449-bf54837facc1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZIIHERA is indicated for the treatment of adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC), as detected by an FDA-approved test [see Dosage and Administration ( 2.1 )]. This indication is approved under accelerated approval based on overall response rate and duration of response [see Clinical Studies ( 14 )] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). DRUGBANK:DB15471 uuid:358aad11-cf17-4713-aa2f-24da5026ab3d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90851 biolink:treats MONDO:0005105 PMID:41385096 "[{""id"":""uuid:ebd11454-b8e3-477e-86e2-c761616f22ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:296af9f2-b651-4307-99eb-68cbc0a96c4c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:0ae81248-1046-42ea-b04a-15fd7f5ba390"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] COTELLIC ® is a kinase inhibitor indicated: For the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib. ( 1.1 , 14.1 ) As a single agent for the treatment of adult patients with histiocytic neoplasms. ( 1.2 , 14.2 )|[EMA] Cotellic is indicated for use in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation. uuid:ce1685c6-207e-4a29-a4eb-a83a410d2161 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90851 biolink:treats MONDO:0006247 PMID:41385096 "[{""id"":""uuid:4d64489a-b4aa-4b67-a7a9-416efb2b10df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fac722ec-8841-40e1-b548-a4da6bca3e37"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] COTELLIC ® is a kinase inhibitor indicated: For the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib. ( 1.1 , 14.1 ) As a single agent for the treatment of adult patients with histiocytic neoplasms. ( 1.2 , 14.2 ) uuid:2f3f55ac-60ef-40a4-8774-ef21d4b2ce3a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:42355 biolink:treats MONDO:0008647 PMID:41385096 "[{""id"":""uuid:e89b1455-5e9c-4811-ad99-c57452b81058"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8eabc20e-81b2-4446-9a69-9da978b8e143"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Erythromycin lactobionate for injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below when oral administration is not possible or when the severity of the infection requires immediate high serum levels of erythromycin. Intravenous therapy should be replaced by oral administration at the appropriate time. Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes (Group A beta-hemolytic streptococci); Streptococcus pneumoniae (Diplococcus pneumoniae); Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H . influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information). Lower respiratory tract infections of mild to moderate severity caused by Streptococcus pyogenes (Group A beta-hemolytic streptococci); Streptococcus pneumoniae (Diplococcus pneumoniae). Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes and Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: As an adjunct to antitoxin infections due to Corynebacterium diphtheriae to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma: In the treatment of infections due to Corynebacterium minutissimum . Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae : Erythromycin lactobionate for injection, USP followed by erythromycin stearate or erythromycin base orally, as an alternative drug in treatment of acute pelvic inflammatory disease caused by N . gonorrhoeae in female patients with a history of sensitivity to penicillin. Before treatment of gonorrhea, patients who are suspected of also having syphilis should have a microscopic examination for T . pallidum (by immunofluorescence or darkfield) before receiving erythromycin and monthly serologic tests for a minimum of 4 months thereafter. Legionnaires’ Disease caused by Legionella pneumophila . Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires’ Disease. Prevention of Initial Attacks of Rheumatic Fever Penicillin is considered by the American Heart Association to be the drug of choice in the prevention of initial attacks of rheumatic fever (treatment of Group A beta-hemolytic streptococcal infections of the upper respiratory tract e.g., tonsillitis, or pharyngitis).1 Erythromycin is indicated for the treatment of penicillin-allergic patients. The therapeutic dose should be administered for ten days. Prevention of Recurrent Attacks of Rheumatic Fever Penicillin or sulfonamides are considered by the American Heart Association to be the drugs of choice in the prevention of recurrent attacks of rheumatic fever. In patients who are allergic to penicillin and sulfonamides, oral erythromycin is recommended by the American Heart Association in the long-term prophylaxis of streptococcal pharyngitis (for the prevention of recurrent attacks of rheumatic fever). 1 Prevention of Bacterial Endocarditis Although no controlled clinical efficacy trials have been conducted, oral erythromycin has been recommended by the American Heart Association for prevention of bacterial endocarditis in penicillin- allergic patients with prosthetic cardiac valves, most congenital cardiac malformations, surgically constructed systemic pulmonary shunts, rheumatic or other acquired valvular dysfunction, idiopathic hypertrophic subaortic stenosis (IHSS), previous history of bacterial endocarditis and mitral valve prolapse with insufficiency when they undergo dental procedures and surgical procedures of the upper respiratory tract. 2 To reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin and other antibacterial drugs, erythromycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:7abb9da5-935c-4905-b74d-30e0b0c8cee3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:195558 biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:9fbfd7d5-4665-41f5-a8dc-d90bb7737494"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7de96471-fad1-4e4e-b781-808d1e53a87c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:6ba6742d-526c-44e9-8079-47c56c12de1d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/rozlytrek""]},{""id"":""uuid:7d811a15-68fe-46e4-9184-c024e23c24b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ROZLYTREK is a kinase inhibitor indicated for the treatment of: Adult patients with ROS1- positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. ( 1.1 ) Adult and pediatric patients older than 1 month of age with solid tumors that: have a neurotrophic tyrosine receptor kinase ( NTRK) gene fusion, as detected by an FDA-approved test without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory alternative therapy. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. ( 1.2 )|[EMA] Rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion,who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, andwho have not received a prior NTRK inhibitorwho have no satisfactory treatment options.Rozlytrek as monotherapy is indicated for the treatment of adult patients with ROS1 positive, advanced non small cell lung cancer (NSCLC) not previously treated with ROS1 inhibitors.|[PMDA] Drugs with a new indication and a new dosage for the treatment of ROS1 fusion gene-positive unresectable advanced or recurrent non-small-cell lung cancer. uuid:8e9d6f9b-8ca8-4c84-a6c0-40402a0e6f95 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:195558 biolink:treats UMLS:C4728198 PMID:41385096 "[{""id"":""uuid:cebf02d3-cbd9-4c07-acf4-4c364849f221"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4baf4b64-2303-4497-a1b6-0a8d13c5abed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ROZLYTREK is a kinase inhibitor indicated for the treatment of: Adult patients with ROS1- positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. ( 1.1 ) Adult and pediatric patients older than 1 month of age with solid tumors that: have a neurotrophic tyrosine receptor kinase ( NTRK) gene fusion, as detected by an FDA-approved test without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory alternative therapy. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. ( 1.2 ) uuid:de2533d3-8326-48e3-ba33-b8f3e9a9de7d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:229217 biolink:treats MONDO:0005031 PMID:41385096 "[{""id"":""uuid:ab59944e-260e-42dc-8862-8fafd977833f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cf10c9aa-de9b-4c1d-88b6-435d4465f5d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OGSIVEO is indicated for adult patients with progressing desmoid tumors who require systemic treatment. uuid:8850cac3-7912-4988-bf6f-c1dc6eebdeb7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:70718 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:da706319-a16e-4883-ad5b-783c41dd72da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ad92b705-5994-4719-819f-59fba95de359"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Teflaro is a cephalosporin antibacterial indicated in adult and pediatric patients for the treatment of the following infection caused by designated susceptible bacteria: Acute bacterial skin and skin structure infections (ABSSSI) in adult and pediatric patients (at least 34 weeks gestational age and 12 days postnatal age) ( 1.1 ) Community-acquired bacterial pneumonia (CABP) in adult and pediatric patients 2 months of age and older ( 1.2 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Teflaro and other antibacterial drugs, Teflaro should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.3 ) uuid:96b19dae-7d4f-4a60-b233-d825808223ed biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:70718 biolink:treats MONDO:0004652 PMID:41385096 "[{""id"":""uuid:71172425-2270-4a5a-b35f-88933d5b2d56"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9b3c1a1e-21c9-4225-b050-d60d2149138f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Teflaro is a cephalosporin antibacterial indicated in adult and pediatric patients for the treatment of the following infection caused by designated susceptible bacteria: Acute bacterial skin and skin structure infections (ABSSSI) in adult and pediatric patients (at least 34 weeks gestational age and 12 days postnatal age) ( 1.1 ) Community-acquired bacterial pneumonia (CABP) in adult and pediatric patients 2 months of age and older ( 1.2 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Teflaro and other antibacterial drugs, Teflaro should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.3 ) uuid:bfbbb893-866e-4cfd-bd36-a6aaf0411461 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:A10SJL62JY biolink:treats MONDO:0005314 PMID:41385096 "[{""id"":""uuid:e7726ed6-a23f-4707-963f-772bd5c012d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:77240efc-e49f-406d-b133-ef89eeddf5b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:20353381-c539-494f-abee-cf4051a80a8c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ocrevus""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] OCREVUS is indicated for the treatment of: Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults Primary progressive MS, in adults|[EMA] Treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.Treatment of adult patients with early primary progressive multiple sclerosis (PPMS) in terms of disease duration and level of disability, and with imaging features characteristic of inflammatory activity. uuid:7de79dd4-0580-4f92-a4ef-cc558fcd3320 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:A10SJL62JY biolink:treats UMLS:C2921627 PMID:41385096 "[{""id"":""uuid:3c119e07-edc7-44d6-a196-0355c27fe124"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5f4f5bb4-0b74-495c-81e2-ac42c54c3249"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OCREVUS is indicated for the treatment of: Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults Primary progressive MS, in adults uuid:27554ef3-9d63-4c0e-9073-946093b2c504 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:A10SJL62JY biolink:treats MONDO:0000450 PMID:41385096 "[{""id"":""uuid:9030e552-445e-4fe4-acc6-6d5c39d2ef02"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2db5bc1d-590b-45e4-be06-1a4288e44330"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OCREVUS is indicated for the treatment of: Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults Primary progressive MS, in adults uuid:fd3478e1-6a26-445f-9404-96a549859f38 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:A10SJL62JY biolink:treats MONDO:0000451 PMID:41385096 "[{""id"":""uuid:e2897999-9dd7-4191-b7af-e0f1e6a3c422"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:ffde8927-9447-441a-a700-5067c9af1d89"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:541ec4e0-aab2-4f16-8650-0aa63281a8b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ocrevus""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] OCREVUS is indicated for the treatment of: Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults Primary progressive MS, in adults|[EMA] Treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.Treatment of adult patients with early primary progressive multiple sclerosis (PPMS) in terms of disease duration and level of disability, and with imaging features characteristic of inflammatory activity. uuid:6613f18b-1f6d-4bf9-bb0f-68a4191d7a2b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16000 biolink:treats MONDO:0021645 PMID:41385096 "[{""id"":""uuid:e8ed23d4-eb07-47d8-90cc-79b15775d874"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3b1a330f-659b-4d2d-a5df-189df46ac3b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ETHAMOLIN Injection is indicated for the treatment of patients with esophageal varices that have recently bled, to prevent rebleeding. ETHAMOLIN is not indicated for the treatment of patients with esophageal varices that have not bled. There is no evidence that treatment of this population decreases the likelihood of bleeding. Sclerotherapy with ETHAMOLIN has no beneficial effect upon portal hypertension, the cause of esophageal varices, so that recanalization and collateralization may occur, necessitating reinjection. uuid:aef8f7db-cf31-4fd7-8bd5-9da2bf8ab970 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16000 biolink:treats MONDO:0001221 PMID:41385096 "[{""id"":""uuid:fdcf578d-557f-4c90-a9fe-a348fb0483e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:54ee7d2b-3526-4c4d-886e-6fbe8891ac3d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ETHAMOLIN Injection is indicated for the treatment of patients with esophageal varices that have recently bled, to prevent rebleeding. ETHAMOLIN is not indicated for the treatment of patients with esophageal varices that have not bled. There is no evidence that treatment of this population decreases the likelihood of bleeding. Sclerotherapy with ETHAMOLIN has no beneficial effect upon portal hypertension, the cause of esophageal varices, so that recanalization and collateralization may occur, necessitating reinjection. uuid:4bfb869a-f3ad-49cc-886e-a8b12035bd3a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2719 biolink:treats MONDO:0001881 PMID:41385096 "[{""id"":""uuid:31d68f13-0faf-4baa-be6f-e71b01078dcd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aae31fd5-9dc2-48db-a30b-31f1b13d67db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] GIAPREZA increases blood pressure in adults with septic or other distributive shock [see Clinical Studies (14)] . uuid:a20dda07-fb41-416b-a021-edb2bdbb8b6e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2719 biolink:treats HP:0031275 PMID:41385096 "[{""id"":""uuid:70b15139-1025-400a-989d-e5e7bb6acdc4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:949655e0-56c7-43d9-bce6-d8c3134ca553"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:1b8ec233-d9c5-48c8-9074-ba34311105f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] GIAPREZA increases blood pressure in adults with septic or other distributive shock [see Clinical Studies (14)] .|[EMA] Giapreza is indicated for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies. uuid:a905b93d-c1c0-410c-956e-5380aee99f38 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:I031V2H011 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:e20fb4f5-9d0b-460c-82d0-79834259f1ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3ac41f10-9f11-4c94-b1e4-f7048ac61606"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:2ed18cbc-843b-4e30-adb9-f5e59b96fce6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/roactemra""]},{""id"":""uuid:2615f3ee-271b-44b2-a5a4-c78e406ddbc6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ACTEMRA ® (tocilizumab) is an interleukin-6 (IL-6) receptor antagonist indicated for treatment of: Rheumatoid Arthritis (RA) ( 1.1 ) Adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). Giant Cell Arteritis (GCA) ( 1.2 ) Adult patients with giant cell arteritis. Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) ( 1.3 ) Slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) Polyarticular Juvenile Idiopathic Arthritis (PJIA) ( 1.4 ) Patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis. Systemic Juvenile Idiopathic Arthritis (SJIA) ( 1.5 ) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis. Cytokine Release Syndrome (CRS) ( 1.6 ) Adults and pediatric patients 2 years of age and older with chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome. Coronavirus Disease 2019 (COVID-19) ( 1.7 ) Hospitalized adult patients with coronavirus disease 2019 (COVID-19) who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).|[EMA] RoActemra, in combination with methotrexate (MTX), is indicated forthe treatment of severe, active and progressive rheumatoid arthritis (RA) in adults not previously treated with MTX.the treatment of moderate to severe active RA in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) or tumour necrosis factor (TNF) antagonists.In these patients, RoActemra can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.RoActemra has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function when given in combination with methotrexate.RoActemra is indicated for the treatment of active systemic juvenile idiopathic arthritis (sJIA) in patients 1 year of age and older, who have responded inadequately to previous therapy with NSAIDs and systemic corticosteroids. RoActemra can be given as monotherapy (in case of intolerance to MTX or where treatment with MTX is inappropriate) or in combination with MTX.RoActemra in combination with methotrexate (MTX) is indicated for the treatment of juvenile idiopathic polyarthritis (pJIA; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with MTX. RoActemra can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.RoActemra is indicated for the treatment of Giant Cell Arteritis (GCA) in adult patients.RoActemra, in combination with methotrexate (MTX), is indicated for:the treatment of severe, active and progressive rheumatoid arthritis (RA) in adults not previously treated with MTX.the treatment of moderate to severe active RA in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) or tumour necrosis factor (TNF) antagonists.In these patients, RoActemra can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate. RoActemra has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function when given in combination with methotrexate.RoActemra is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation.RoActemra is indicated for the treatment of active systemic juvenile idiopathic arthritis (sJIA) in patients 2 years of age and older, who have responded inadequately to previous therapy with NSAIDs and systemic corticosteroids. RoActemra can be given as monotherapy (in case of intolerance to MTX or where treatment with MTX is inappropriate) or in combination with MTX.RoActemra in combination with methotrexate (MTX) is indicated for the treatment of juvenile idiopathic polyarthritis (pJIA; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with MTX. RoActemra can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.RoActemra is indicated for the treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in adults and paediatric patients 2 years of age and older.RoActemra, in combination with methotrexate (MTX), is indicated for:the treatment of severe, active and progressive rheumatoid arthritis (RA) in adults not previously treated with MTX.the treatment of moderate to severe active RA in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) or tumour necrosis factor (TNF) antagonists.In these patients, RoActemra can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate. RoActemra has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function when given in combination with methotrexate.RoActemra is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation.RoActemra is indicated for the treatment of active systemic juvenile idiopathic arthritis (sJIA) in patients 2 years of age and older, who have responded inadequately to previous therapy with NSAIDs and systemic corticosteroids. RoActemra can be given as monotherapy (in case of intolerance to MTX or where treatment with MTX is inappropriate) or in combination with MTX.RoActemra in combination with methotrexate (MTX) is indicated for the treatment of juvenile idiopathic polyarthritis (pJIA; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with MTX. RoActemra can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.RoActemra is indicated for the treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in adults and paediatric patients 2 years of age and older.|[PMDA] Drugs with a new route of administration indicated for the treatment of rheumatoid arthritis (including prevention of structural joint damage) in patients who have not sufficiently responded to conventional treatments. uuid:7b7ca02a-b3f0-4036-9ae1-5e8dd6e19402 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:I031V2H011 biolink:treats MONDO:0008538 PMID:41385096 "[{""id"":""uuid:f442b877-13de-476e-b46c-49332b700fc3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:edb6aded-009d-442c-bfc8-309a2e506d77"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c1900350-b54e-4900-950c-ccb2a106ff70"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/roactemra""]},{""id"":""uuid:894d9109-6c4c-4d35-8667-e20a9ab66629"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ACTEMRA ® (tocilizumab) is an interleukin-6 (IL-6) receptor antagonist indicated for treatment of: Rheumatoid Arthritis (RA) ( 1.1 ) Adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). Giant Cell Arteritis (GCA) ( 1.2 ) Adult patients with giant cell arteritis. Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) ( 1.3 ) Slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) Polyarticular Juvenile Idiopathic Arthritis (PJIA) ( 1.4 ) Patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis. Systemic Juvenile Idiopathic Arthritis (SJIA) ( 1.5 ) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis. Cytokine Release Syndrome (CRS) ( 1.6 ) Adults and pediatric patients 2 years of age and older with chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome. Coronavirus Disease 2019 (COVID-19) ( 1.7 ) Hospitalized adult patients with coronavirus disease 2019 (COVID-19) who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).|[EMA] RoActemra, in combination with methotrexate (MTX), is indicated forthe treatment of severe, active and progressive rheumatoid arthritis (RA) in adults not previously treated with MTX.the treatment of moderate to severe active RA in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) or tumour necrosis factor (TNF) antagonists.In these patients, RoActemra can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.RoActemra has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function when given in combination with methotrexate.RoActemra is indicated for the treatment of active systemic juvenile idiopathic arthritis (sJIA) in patients 1 year of age and older, who have responded inadequately to previous therapy with NSAIDs and systemic corticosteroids. RoActemra can be given as monotherapy (in case of intolerance to MTX or where treatment with MTX is inappropriate) or in combination with MTX.RoActemra in combination with methotrexate (MTX) is indicated for the treatment of juvenile idiopathic polyarthritis (pJIA; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with MTX. RoActemra can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.RoActemra is indicated for the treatment of Giant Cell Arteritis (GCA) in adult patients.RoActemra, in combination with methotrexate (MTX), is indicated for:the treatment of severe, active and progressive rheumatoid arthritis (RA) in adults not previously treated with MTX.the treatment of moderate to severe active RA in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) or tumour necrosis factor (TNF) antagonists.In these patients, RoActemra can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate. RoActemra has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function when given in combination with methotrexate.RoActemra is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation.RoActemra is indicated for the treatment of active systemic juvenile idiopathic arthritis (sJIA) in patients 2 years of age and older, who have responded inadequately to previous therapy with NSAIDs and systemic corticosteroids. RoActemra can be given as monotherapy (in case of intolerance to MTX or where treatment with MTX is inappropriate) or in combination with MTX.RoActemra in combination with methotrexate (MTX) is indicated for the treatment of juvenile idiopathic polyarthritis (pJIA; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with MTX. RoActemra can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.RoActemra is indicated for the treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in adults and paediatric patients 2 years of age and older.RoActemra, in combination with methotrexate (MTX), is indicated for:the treatment of severe, active and progressive rheumatoid arthritis (RA) in adults not previously treated with MTX.the treatment of moderate to severe active RA in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) or tumour necrosis factor (TNF) antagonists.In these patients, RoActemra can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate. RoActemra has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function when given in combination with methotrexate.RoActemra is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation.RoActemra is indicated for the treatment of active systemic juvenile idiopathic arthritis (sJIA) in patients 2 years of age and older, who have responded inadequately to previous therapy with NSAIDs and systemic corticosteroids. RoActemra can be given as monotherapy (in case of intolerance to MTX or where treatment with MTX is inappropriate) or in combination with MTX.RoActemra in combination with methotrexate (MTX) is indicated for the treatment of juvenile idiopathic polyarthritis (pJIA; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with MTX. RoActemra can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.RoActemra is indicated for the treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in adults and paediatric patients 2 years of age and older.|[PMDA] Drugs with new additional indications and a new dosage for the treatment of Takayasu arteritis and giant cell arteritis in patients who have not responded sufficiently to conventional treatments. [Orphan drug] uuid:f3bde16e-596b-4314-97e6-d066f432a795 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:I031V2H011 biolink:treats MONDO:0002047 PMID:41385096 "[{""id"":""uuid:f454faed-784e-4da3-849c-2db2952020e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3a29b99d-37b3-4221-8e8a-074b1378224f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ACTEMRA ® (tocilizumab) is an interleukin-6 (IL-6) receptor antagonist indicated for treatment of: Rheumatoid Arthritis (RA) ( 1.1 ) Adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). Giant Cell Arteritis (GCA) ( 1.2 ) Adult patients with giant cell arteritis. Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) ( 1.3 ) Slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) Polyarticular Juvenile Idiopathic Arthritis (PJIA) ( 1.4 ) Patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis. Systemic Juvenile Idiopathic Arthritis (SJIA) ( 1.5 ) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis. Cytokine Release Syndrome (CRS) ( 1.6 ) Adults and pediatric patients 2 years of age and older with chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome. Coronavirus Disease 2019 (COVID-19) ( 1.7 ) Hospitalized adult patients with coronavirus disease 2019 (COVID-19) who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). uuid:a8185177-57b2-4ebe-b972-eab5ac0c5fb0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:I031V2H011 biolink:treats MONDO:0018456 PMID:41385096 "[{""id"":""uuid:ca46e2d0-1494-4d0d-81f4-fd242c853d3d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:5e1b3348-ff74-46e9-9d9d-8c48cf129e42"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:9382ec74-fa18-4f63-ae18-c731f4f3ef0c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/roactemra""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] ACTEMRA ® (tocilizumab) is an interleukin-6 (IL-6) receptor antagonist indicated for treatment of: Rheumatoid Arthritis (RA) ( 1.1 ) Adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). Giant Cell Arteritis (GCA) ( 1.2 ) Adult patients with giant cell arteritis. Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) ( 1.3 ) Slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) Polyarticular Juvenile Idiopathic Arthritis (PJIA) ( 1.4 ) Patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis. Systemic Juvenile Idiopathic Arthritis (SJIA) ( 1.5 ) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis. Cytokine Release Syndrome (CRS) ( 1.6 ) Adults and pediatric patients 2 years of age and older with chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome. Coronavirus Disease 2019 (COVID-19) ( 1.7 ) Hospitalized adult patients with coronavirus disease 2019 (COVID-19) who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).|[EMA] RoActemra, in combination with methotrexate (MTX), is indicated forthe treatment of severe, active and progressive rheumatoid arthritis (RA) in adults not previously treated with MTX.the treatment of moderate to severe active RA in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) or tumour necrosis factor (TNF) antagonists.In these patients, RoActemra can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.RoActemra has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function when given in combination with methotrexate.RoActemra is indicated for the treatment of active systemic juvenile idiopathic arthritis (sJIA) in patients 1 year of age and older, who have responded inadequately to previous therapy with NSAIDs and systemic corticosteroids. RoActemra can be given as monotherapy (in case of intolerance to MTX or where treatment with MTX is inappropriate) or in combination with MTX.RoActemra in combination with methotrexate (MTX) is indicated for the treatment of juvenile idiopathic polyarthritis (pJIA; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with MTX. RoActemra can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.RoActemra is indicated for the treatment of Giant Cell Arteritis (GCA) in adult patients.RoActemra, in combination with methotrexate (MTX), is indicated for:the treatment of severe, active and progressive rheumatoid arthritis (RA) in adults not previously treated with MTX.the treatment of moderate to severe active RA in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) or tumour necrosis factor (TNF) antagonists.In these patients, RoActemra can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate. RoActemra has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function when given in combination with methotrexate.RoActemra is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation.RoActemra is indicated for the treatment of active systemic juvenile idiopathic arthritis (sJIA) in patients 2 years of age and older, who have responded inadequately to previous therapy with NSAIDs and systemic corticosteroids. RoActemra can be given as monotherapy (in case of intolerance to MTX or where treatment with MTX is inappropriate) or in combination with MTX.RoActemra in combination with methotrexate (MTX) is indicated for the treatment of juvenile idiopathic polyarthritis (pJIA; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with MTX. RoActemra can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.RoActemra is indicated for the treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in adults and paediatric patients 2 years of age and older.RoActemra, in combination with methotrexate (MTX), is indicated for:the treatment of severe, active and progressive rheumatoid arthritis (RA) in adults not previously treated with MTX.the treatment of moderate to severe active RA in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) or tumour necrosis factor (TNF) antagonists.In these patients, RoActemra can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate. RoActemra has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function when given in combination with methotrexate.RoActemra is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation.RoActemra is indicated for the treatment of active systemic juvenile idiopathic arthritis (sJIA) in patients 2 years of age and older, who have responded inadequately to previous therapy with NSAIDs and systemic corticosteroids. RoActemra can be given as monotherapy (in case of intolerance to MTX or where treatment with MTX is inappropriate) or in combination with MTX.RoActemra in combination with methotrexate (MTX) is indicated for the treatment of juvenile idiopathic polyarthritis (pJIA; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with MTX. RoActemra can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.RoActemra is indicated for the treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in adults and paediatric patients 2 years of age and older. uuid:f5de6ca2-65fd-4889-87fd-198ee72c889d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:I031V2H011 biolink:treats MONDO:0019434 PMID:41385096 "[{""id"":""uuid:ec5e0d73-3800-4ea1-8a7a-0f449de4257f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:777aa8d9-5746-4420-b321-bc6805b85fb5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e9426eb2-2063-4b3c-a431-7323439bcb01"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/roactemra""]},{""id"":""uuid:43b47378-5f37-4c2e-961b-c1abe1b0b536"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ACTEMRA ® (tocilizumab) is an interleukin-6 (IL-6) receptor antagonist indicated for treatment of: Rheumatoid Arthritis (RA) ( 1.1 ) Adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). Giant Cell Arteritis (GCA) ( 1.2 ) Adult patients with giant cell arteritis. Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) ( 1.3 ) Slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) Polyarticular Juvenile Idiopathic Arthritis (PJIA) ( 1.4 ) Patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis. Systemic Juvenile Idiopathic Arthritis (SJIA) ( 1.5 ) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis. Cytokine Release Syndrome (CRS) ( 1.6 ) Adults and pediatric patients 2 years of age and older with chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome. Coronavirus Disease 2019 (COVID-19) ( 1.7 ) Hospitalized adult patients with coronavirus disease 2019 (COVID-19) who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).|[EMA] RoActemra, in combination with methotrexate (MTX), is indicated forthe treatment of severe, active and progressive rheumatoid arthritis (RA) in adults not previously treated with MTX.the treatment of moderate to severe active RA in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) or tumour necrosis factor (TNF) antagonists.In these patients, RoActemra can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.RoActemra has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function when given in combination with methotrexate.RoActemra is indicated for the treatment of active systemic juvenile idiopathic arthritis (sJIA) in patients 1 year of age and older, who have responded inadequately to previous therapy with NSAIDs and systemic corticosteroids. RoActemra can be given as monotherapy (in case of intolerance to MTX or where treatment with MTX is inappropriate) or in combination with MTX.RoActemra in combination with methotrexate (MTX) is indicated for the treatment of juvenile idiopathic polyarthritis (pJIA; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with MTX. RoActemra can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.RoActemra is indicated for the treatment of Giant Cell Arteritis (GCA) in adult patients.RoActemra, in combination with methotrexate (MTX), is indicated for:the treatment of severe, active and progressive rheumatoid arthritis (RA) in adults not previously treated with MTX.the treatment of moderate to severe active RA in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) or tumour necrosis factor (TNF) antagonists.In these patients, RoActemra can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate. RoActemra has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function when given in combination with methotrexate.RoActemra is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation.RoActemra is indicated for the treatment of active systemic juvenile idiopathic arthritis (sJIA) in patients 2 years of age and older, who have responded inadequately to previous therapy with NSAIDs and systemic corticosteroids. RoActemra can be given as monotherapy (in case of intolerance to MTX or where treatment with MTX is inappropriate) or in combination with MTX.RoActemra in combination with methotrexate (MTX) is indicated for the treatment of juvenile idiopathic polyarthritis (pJIA; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with MTX. RoActemra can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.RoActemra is indicated for the treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in adults and paediatric patients 2 years of age and older.RoActemra, in combination with methotrexate (MTX), is indicated for:the treatment of severe, active and progressive rheumatoid arthritis (RA) in adults not previously treated with MTX.the treatment of moderate to severe active RA in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) or tumour necrosis factor (TNF) antagonists.In these patients, RoActemra can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate. RoActemra has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function when given in combination with methotrexate.RoActemra is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation.RoActemra is indicated for the treatment of active systemic juvenile idiopathic arthritis (sJIA) in patients 2 years of age and older, who have responded inadequately to previous therapy with NSAIDs and systemic corticosteroids. RoActemra can be given as monotherapy (in case of intolerance to MTX or where treatment with MTX is inappropriate) or in combination with MTX.RoActemra in combination with methotrexate (MTX) is indicated for the treatment of juvenile idiopathic polyarthritis (pJIA; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with MTX. RoActemra can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.RoActemra is indicated for the treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in adults and paediatric patients 2 years of age and older.|[PMDA] Drugs with a new indication and a new dosage in a new dosage form for the treatment of rheumatoid arthritis (including prevention of structural damage of joint) that cannot be treated sufficiently with conventional therapies, active juvenile idiopathic arthritis in multiple joints, and systemic juvenile idiopathic arthritis. [Priority review] [Expedited review] uuid:22ad33f4-cdef-4cdc-8e82-abb683759070 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:I031V2H011 biolink:treats MONDO:0600008 PMID:41385096 "[{""id"":""uuid:4d33ee96-af04-4f19-87c4-2cc2eb73816d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d0ed08ac-fae1-4d8c-a15e-c81fc3ba0905"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f47dddb0-de2c-49c2-a2d5-dccf1cee6269"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/roactemra""]},{""id"":""uuid:4b484419-e44c-4c96-807a-e01aa35538dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ACTEMRA ® (tocilizumab) is an interleukin-6 (IL-6) receptor antagonist indicated for treatment of: Rheumatoid Arthritis (RA) ( 1.1 ) Adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). Giant Cell Arteritis (GCA) ( 1.2 ) Adult patients with giant cell arteritis. Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) ( 1.3 ) Slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) Polyarticular Juvenile Idiopathic Arthritis (PJIA) ( 1.4 ) Patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis. Systemic Juvenile Idiopathic Arthritis (SJIA) ( 1.5 ) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis. Cytokine Release Syndrome (CRS) ( 1.6 ) Adults and pediatric patients 2 years of age and older with chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome. Coronavirus Disease 2019 (COVID-19) ( 1.7 ) Hospitalized adult patients with coronavirus disease 2019 (COVID-19) who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).|[EMA] RoActemra, in combination with methotrexate (MTX), is indicated forthe treatment of severe, active and progressive rheumatoid arthritis (RA) in adults not previously treated with MTX.the treatment of moderate to severe active RA in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) or tumour necrosis factor (TNF) antagonists.In these patients, RoActemra can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.RoActemra has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function when given in combination with methotrexate.RoActemra is indicated for the treatment of active systemic juvenile idiopathic arthritis (sJIA) in patients 1 year of age and older, who have responded inadequately to previous therapy with NSAIDs and systemic corticosteroids. RoActemra can be given as monotherapy (in case of intolerance to MTX or where treatment with MTX is inappropriate) or in combination with MTX.RoActemra in combination with methotrexate (MTX) is indicated for the treatment of juvenile idiopathic polyarthritis (pJIA; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with MTX. RoActemra can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.RoActemra is indicated for the treatment of Giant Cell Arteritis (GCA) in adult patients.RoActemra, in combination with methotrexate (MTX), is indicated for:the treatment of severe, active and progressive rheumatoid arthritis (RA) in adults not previously treated with MTX.the treatment of moderate to severe active RA in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) or tumour necrosis factor (TNF) antagonists.In these patients, RoActemra can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate. RoActemra has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function when given in combination with methotrexate.RoActemra is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation.RoActemra is indicated for the treatment of active systemic juvenile idiopathic arthritis (sJIA) in patients 2 years of age and older, who have responded inadequately to previous therapy with NSAIDs and systemic corticosteroids. RoActemra can be given as monotherapy (in case of intolerance to MTX or where treatment with MTX is inappropriate) or in combination with MTX.RoActemra in combination with methotrexate (MTX) is indicated for the treatment of juvenile idiopathic polyarthritis (pJIA; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with MTX. RoActemra can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.RoActemra is indicated for the treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in adults and paediatric patients 2 years of age and older.RoActemra, in combination with methotrexate (MTX), is indicated for:the treatment of severe, active and progressive rheumatoid arthritis (RA) in adults not previously treated with MTX.the treatment of moderate to severe active RA in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) or tumour necrosis factor (TNF) antagonists.In these patients, RoActemra can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate. RoActemra has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function when given in combination with methotrexate.RoActemra is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation.RoActemra is indicated for the treatment of active systemic juvenile idiopathic arthritis (sJIA) in patients 2 years of age and older, who have responded inadequately to previous therapy with NSAIDs and systemic corticosteroids. RoActemra can be given as monotherapy (in case of intolerance to MTX or where treatment with MTX is inappropriate) or in combination with MTX.RoActemra in combination with methotrexate (MTX) is indicated for the treatment of juvenile idiopathic polyarthritis (pJIA; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with MTX. RoActemra can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.RoActemra is indicated for the treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in adults and paediatric patients 2 years of age and older.|[PMDA] Drugs with a new indication for the treatment of cytokine release syndrome induced by the treatment for malignant tumor. uuid:e21f2b45-c8e1-4a45-a146-674b9649a9de biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:I031V2H011 biolink:treats MONDO:0100096 PMID:41385096 "[{""id"":""uuid:bab3c60a-22cc-4118-81ae-d7677d0d3204"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:6be9aaa8-237f-4332-89dc-8f9e69831ba4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:9e5807fe-7dc0-4d94-bf9a-997a4ce4724a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/roactemra""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] ACTEMRA ® (tocilizumab) is an interleukin-6 (IL-6) receptor antagonist indicated for treatment of: Rheumatoid Arthritis (RA) ( 1.1 ) Adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). Giant Cell Arteritis (GCA) ( 1.2 ) Adult patients with giant cell arteritis. Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) ( 1.3 ) Slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) Polyarticular Juvenile Idiopathic Arthritis (PJIA) ( 1.4 ) Patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis. Systemic Juvenile Idiopathic Arthritis (SJIA) ( 1.5 ) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis. Cytokine Release Syndrome (CRS) ( 1.6 ) Adults and pediatric patients 2 years of age and older with chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome. Coronavirus Disease 2019 (COVID-19) ( 1.7 ) Hospitalized adult patients with coronavirus disease 2019 (COVID-19) who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).|[EMA] RoActemra, in combination with methotrexate (MTX), is indicated forthe treatment of severe, active and progressive rheumatoid arthritis (RA) in adults not previously treated with MTX.the treatment of moderate to severe active RA in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) or tumour necrosis factor (TNF) antagonists.In these patients, RoActemra can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.RoActemra has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function when given in combination with methotrexate.RoActemra is indicated for the treatment of active systemic juvenile idiopathic arthritis (sJIA) in patients 1 year of age and older, who have responded inadequately to previous therapy with NSAIDs and systemic corticosteroids. RoActemra can be given as monotherapy (in case of intolerance to MTX or where treatment with MTX is inappropriate) or in combination with MTX.RoActemra in combination with methotrexate (MTX) is indicated for the treatment of juvenile idiopathic polyarthritis (pJIA; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with MTX. RoActemra can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.RoActemra is indicated for the treatment of Giant Cell Arteritis (GCA) in adult patients.RoActemra, in combination with methotrexate (MTX), is indicated for:the treatment of severe, active and progressive rheumatoid arthritis (RA) in adults not previously treated with MTX.the treatment of moderate to severe active RA in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) or tumour necrosis factor (TNF) antagonists.In these patients, RoActemra can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate. RoActemra has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function when given in combination with methotrexate.RoActemra is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation.RoActemra is indicated for the treatment of active systemic juvenile idiopathic arthritis (sJIA) in patients 2 years of age and older, who have responded inadequately to previous therapy with NSAIDs and systemic corticosteroids. RoActemra can be given as monotherapy (in case of intolerance to MTX or where treatment with MTX is inappropriate) or in combination with MTX.RoActemra in combination with methotrexate (MTX) is indicated for the treatment of juvenile idiopathic polyarthritis (pJIA; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with MTX. RoActemra can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.RoActemra is indicated for the treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in adults and paediatric patients 2 years of age and older.RoActemra, in combination with methotrexate (MTX), is indicated for:the treatment of severe, active and progressive rheumatoid arthritis (RA) in adults not previously treated with MTX.the treatment of moderate to severe active RA in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) or tumour necrosis factor (TNF) antagonists.In these patients, RoActemra can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate. RoActemra has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function when given in combination with methotrexate.RoActemra is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation.RoActemra is indicated for the treatment of active systemic juvenile idiopathic arthritis (sJIA) in patients 2 years of age and older, who have responded inadequately to previous therapy with NSAIDs and systemic corticosteroids. RoActemra can be given as monotherapy (in case of intolerance to MTX or where treatment with MTX is inappropriate) or in combination with MTX.RoActemra in combination with methotrexate (MTX) is indicated for the treatment of juvenile idiopathic polyarthritis (pJIA; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with MTX. RoActemra can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.RoActemra is indicated for the treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in adults and paediatric patients 2 years of age and older. uuid:8eea7113-ed5a-4c55-b8cd-df63ec59fe28 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:231350 biolink:treats MONDO:0009692 PMID:41385096 "[{""id"":""uuid:a6559b4e-47c4-42eb-a59d-e0dca6be263b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:52823656-9756-498e-8a0e-16a3ae2554eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VONJO is indicated for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF) with a platelet count below 50 × 10 9 /L. This indication is approved under accelerated approval based on spleen volume reduction [see Clinical Studies (14.2)] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). uuid:08475be6-922f-4ab8-b28b-0780c913d52d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64213 biolink:treats MONDO:0005855 PMID:41385096 "[{""id"":""uuid:54ead486-cdf8-413d-b0c2-91471572132a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:deee946c-f293-4cd9-a102-0d3350b48f18"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] YCANTH is indicated for the topical treatment of molluscum contagiosum in adult and pediatric patients 2 years of age and older. uuid:5a3c1163-2c14-4fd4-bc9c-208b3c6352a9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1090966 biolink:treats MONDO:0001356 PMID:41385096 "[{""id"":""uuid:7427957e-cc96-45da-b92b-8af7d5422651"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cdb81f2d-88f4-468c-98a8-64f060bbab81"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Davimet™ with Iron Multivitamin Chewable Tablets are indicated for the treatment of iron deficiency anemia and folate deficiency, commonly seen in conditionssuch as extended convalescence, menorrhagia, pregnancy, puberty, excessive blood loss, and advanced age. They are also indicated for condition in which irondeficiency and vitamin C deficiency occur together, along with a deficient intake or increased need for B-Complex vitamins in chronic and acute illness, as well as casesof metabolic stress, and in convalescence. uuid:df19540f-edec-49d3-81d7-42c76a99f5d6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:82975 biolink:treats MONDO:0100187 PMID:41385096 "[{""id"":""uuid:8cf7eb31-28c5-4a8b-ab94-e6de2a33b436"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:5077168b-3ced-412f-b395-f7fc845325be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:10497cec-a23c-4afb-9eba-cb3b931d860c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MOVANTIK ® is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation.|[EMA] Treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxative(s). uuid:4d65394c-479a-447e-8cca-7030b1f0dc23 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:82975 biolink:treats HP:0012532 PMID:41385096 "[{""id"":""uuid:f89a5bc1-b94b-4cbb-9137-a7637482c53b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:44859930-9ac4-4d28-ba38-c51c3b4e97a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MOVANTIK ® is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation. uuid:f8903b6b-5c20-4631-b5cc-3399675dd817 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:82975 biolink:treats EFO:0801084 PMID:41385096 "[{""id"":""uuid:f48ea364-2834-4b13-9a43-49dc26f73bf7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:58111978-80c8-4543-a38e-4c2136e99191"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MOVANTIK ® is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation. uuid:270fcbf8-0dfd-45c9-b101-f50158d32f13 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:54534MX6Z9 biolink:treats UMLS:C5577628 PMID:41385096 "[{""id"":""uuid:228bc22b-071e-43ec-afe3-724b94abe3da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:840e8a96-80ff-407e-a98c-8dfb2fa12fcc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TECVAYLI is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody. This indication is approved under accelerated approval based on response rate [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). uuid:8742ca48-431c-4a56-b635-c4aef98eca3b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:54534MX6Z9 biolink:treats UMLS:C4551538 PMID:41385096 "[{""id"":""uuid:402dfdc3-819e-4e41-a4e4-4c6137fedb27"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c316215f-3224-4f6a-890d-6a5789bb1838"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TECVAYLI is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody. This indication is approved under accelerated approval based on response rate [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). uuid:3f3b8f4d-6615-4e5f-9f52-d1f7e93c92a2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4H5YMK1H2E biolink:treats EFO:0009130 PMID:41385096 "[{""id"":""uuid:57080410-6dae-4ab5-983d-2b7e9142c944"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b3668a54-319e-44fd-8f3b-68e4e31e5690"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e16c5981-f12f-41e1-8007-47a004512a21"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZINPLAVA™ is indicated to reduce recurrence of Clostridioides difficile infection (CDI) in adults and pediatric patients 1 year of age and older who are receiving antibacterial drug treatment for CDI and are at a high risk for CDI recurrence.|[PMDA] A drug with a new active ingredient indicated for the prevention of recurrent Clostridium difficile infection. uuid:1b42f635-9de0-4284-bfc6-222af923a32c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4H5YMK1H2E biolink:treats MONDO:0019846 PMID:41385096 "[{""id"":""uuid:0cbe248e-f485-4526-9566-7b503107c8f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9549cc31-4a57-4c5e-921e-b45e41c86e53"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZINPLAVA™ is indicated to reduce recurrence of Clostridioides difficile infection (CDI) in adults and pediatric patients 1 year of age and older who are receiving antibacterial drug treatment for CDI and are at a high risk for CDI recurrence. uuid:51fca782-850e-4634-b097-bfbe50e5d36a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45716 biolink:treats MONDO:0015758 PMID:41385096 "[{""id"":""uuid:77e2c7fb-929f-4479-ab13-51e8ce5cc2c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f127eb04-f8ef-470b-831f-af9e54af1ac1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:4d78d6cb-8b55-4d4d-aa38-7ea8734f84fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZOLINZA ® is indicated for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma who have progressive, persistent or recurrent disease on or following two systemic therapies.|[PMDA] A drug with a new active ingredient indicated for the treatment of cutaneous T-cell lymphoma. uuid:ae2bed1d-7b3e-40ef-b91e-44a0085a3539 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4724 biolink:treats HP:0000155 PMID:41385096 "[{""id"":""uuid:f2aa6752-c20b-407a-9b44-c2f5eef05883"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0ee87de8-ce5d-4e6f-9940-9004e347b2a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dyclonine HCl Topical Solution, USP is indicated for anesthetizing accessible mucous membranes (e.g., the mouth, pharynx, larynx, trachea, esophagus, and urethra) prior to various endoscopic procedures. Dyclonine HCl Topical Solution, USP, 0.5% topical anesthetic may also be used to block the gag reflex, to relieve the pain of oral ulcers or stomatitis and to relieve pain associated with ano-genital lesions. uuid:dd9f6599-e940-4184-8918-66b3c6fabdee biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4724 biolink:treats MONDO:0004842 PMID:41385096 "[{""id"":""uuid:fef69d6c-e9ac-4178-99de-1bdbf6338c55"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4f7242f1-e729-4476-a1bd-559ab56221b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dyclonine HCl Topical Solution, USP is indicated for anesthetizing accessible mucous membranes (e.g., the mouth, pharynx, larynx, trachea, esophagus, and urethra) prior to various endoscopic procedures. Dyclonine HCl Topical Solution, USP, 0.5% topical anesthetic may also be used to block the gag reflex, to relieve the pain of oral ulcers or stomatitis and to relieve pain associated with ano-genital lesions. uuid:fe21c069-6b2f-44f6-8068-996ed315d1c9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4724 biolink:treats MONDO:0005647 PMID:41385096 "[{""id"":""uuid:56b77098-73f7-4aa2-992a-188e404894e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:63d2371d-e3dc-4810-82b2-045b940f90e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dyclonine HCl Topical Solution, USP is indicated for anesthetizing accessible mucous membranes (e.g., the mouth, pharynx, larynx, trachea, esophagus, and urethra) prior to various endoscopic procedures. Dyclonine HCl Topical Solution, USP, 0.5% topical anesthetic may also be used to block the gag reflex, to relieve the pain of oral ulcers or stomatitis and to relieve pain associated with ano-genital lesions. uuid:c64f023e-8bbc-4eb4-ba89-413f9f1047d8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:52172 biolink:treats MONDO:0011996 PMID:41385096 "[{""id"":""uuid:73ba2c66-4463-4523-917b-55bfa509e838"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:b68f09cb-49df-4e6d-a40f-a50076dfb600"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:b749a218-2443-4baa-a697-2a10b22f65da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/tasigna""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] DANZITEN is a kinase inhibitor indicated for the treatment of: • Adult patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. ( 1.1 ) • Adult patients with chronic phase (CP) and accelerated phase (AP) Ph+ CML resistant to or intolerant to prior therapy that included imatinib. ( 1.2 )|[EMA] Tasigna is indicated for the treatment of:adult and paediatric patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukaemia (CML) in the chronic phase,paediatric patients with Philadelphia chromosome positive CML in chronic phase with resistance or intolerance to prior therapy including imatinib.Tasigna is indicated for the treatment of:adult and paediatric patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukaemia (CML) in the chronic phase,adult patients with chronic phase and accelerated phase Philadelphia chromosome positive CML with resistance or intolerance to prior therapy including imatinib. Efficacy data in patients with CML in blast crisis are not available,paediatric patients with chronic phase Philadelphia chromosome positive CML with resistance or intolerance to prior therapy including imatinib. uuid:f5ace000-cc7e-4d2e-badb-91c4cd0ba997 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:52172 biolink:treats MONDO:0021367 PMID:41385096 "[{""id"":""uuid:0da21c86-b205-481a-888c-2f34a84b86c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8d4f8c7c-832a-4db9-a742-152b481c805e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DANZITEN is a kinase inhibitor indicated for the treatment of: • Adult patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. ( 1.1 ) • Adult patients with chronic phase (CP) and accelerated phase (AP) Ph+ CML resistant to or intolerant to prior therapy that included imatinib. ( 1.2 ) uuid:45e661d0-3db1-4565-a8bb-2398028095da biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:375139 biolink:treats NCIT:C50743 PMID:41385096 "[{""id"":""uuid:99749a00-6ae7-4f48-90dc-e0f18f785169"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b0b72fcc-9cab-44ba-a667-b62b6eea9184"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the temporary relief of pain and itching associated with minor burns, sunburn, minor cuts, scrapes, insect bites, and minor skin irritation. This formulation can be used to assist patients in the treatment of mild to moderate acute or chronic aches or pain. Muscle or joint pain can be due to musculoligamentous strains, simple backache, tendonitis, osteoarthritis, rheumatoid arthritis, peripheral neuropathies such as diabetic neuropathy or post herpetic neuralgia, and other complex regional pains. If consulted by your physician, it may be used for other conditions as well. If consulted by your physician, it may be used for other conditions as well. uuid:f3c1ffbb-1840-40ad-b2f7-5eac7187ff96 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:375139 biolink:treats UMLS:C0080194 PMID:41385096 "[{""id"":""uuid:de5aeab3-ed74-469e-b74f-c4c971d802c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:072e6fc7-beea-4a85-9bf7-b80936b085bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the temporary relief of pain and itching associated with minor burns, sunburn, minor cuts, scrapes, insect bites, and minor skin irritation. This formulation can be used to assist patients in the treatment of mild to moderate acute or chronic aches or pain. Muscle or joint pain can be due to musculoligamentous strains, simple backache, tendonitis, osteoarthritis, rheumatoid arthritis, peripheral neuropathies such as diabetic neuropathy or post herpetic neuralgia, and other complex regional pains. If consulted by your physician, it may be used for other conditions as well. If consulted by your physician, it may be used for other conditions as well. uuid:16bd9739-59ab-455b-b40e-5330533a9c55 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:375139 biolink:treats MONDO:0002321 PMID:41385096 "[{""id"":""uuid:edb04ab9-a818-489f-9cd4-cc77cd9f438e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:37282b8d-bbb1-49d3-a8bc-189b2231d257"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the temporary relief of pain and itching associated with minor burns, sunburn, minor cuts, scrapes, insect bites, and minor skin irritation. This formulation can be used to assist patients in the treatment of mild to moderate acute or chronic aches or pain. Muscle or joint pain can be due to musculoligamentous strains, simple backache, tendonitis, osteoarthritis, rheumatoid arthritis, peripheral neuropathies such as diabetic neuropathy or post herpetic neuralgia, and other complex regional pains. If consulted by your physician, it may be used for other conditions as well. If consulted by your physician, it may be used for other conditions as well. uuid:260eee4a-dd12-429e-8fec-c63eb124626a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:S51J6N56M7 biolink:treats MONDO:0012084 PMID:41385096 "[{""id"":""uuid:ada08685-926e-4ddb-867b-6390df3c4858"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a17949f4-609a-4f35-adf7-2901a7377736"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e5cbcf91-7c33-4542-8bc6-de1c19051b01"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/upstaza""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] KEBILIDI (eladocagene exuparvovec-tneq) is an adeno-associated virus (AAV) vector-based gene therapy indicated for the treatment of adult and pediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency. This indication is approved under accelerated approval based on the change from baseline in gross motor milestone achievement at 48 weeks post treatment [see Clinical Studies ( 14 )] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory clinical trial.|[EMA] Upstaza is indicated for the treatment of patients aged 18 months and older with a clinical, molecular, and genetically confirmed diagnosis of aromatic L amino acid decarboxylase (AADC) deficiency with a severe phenotype (see section 5.1). uuid:32f7c9b9-4411-4446-8ca3-62eef9f44d6c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3756 biolink:treats MONDO:0010826 PMID:41385096 "[{""id"":""uuid:bf5dc5db-5cf2-415f-a1d7-0c19b35ac6bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c0e972ae-389d-4977-866f-a977a0a98dff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Klonopin is useful alone or as an adjunct in the treatment of the Lennox-Gastaut syndrome (petit mal variant), akinetic, and myoclonic seizures. In patients with absence seizures (petit mal) who have failed to respond to succinimides, Klonopin may be useful. Some loss of effect may occur during the course of clonazepam treatment (see PRECAUTIONS: Loss of Effect ). uuid:f2f96c3c-0b50-4e83-b52b-8fe34ef77022 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2DJ8R0NT7K biolink:treats MONDO:0018912 PMID:41385096 "[{""id"":""uuid:ce9ef7e9-b599-46d9-9229-c0dd697cbc5a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3b7d71b8-8466-4b9a-b4e7-b9207fcfc251"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RECORLEV is indicated for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome for whom surgery is not an option or has not been curative. Limitations of Use RECORLEV is not approved for the treatment of fungal infections. The safety and effectiveness of RECORLEV for the treatment of fungal infections have not been established. uuid:8d761cc0-84d3-440d-8ffb-f88148bf7d7b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2DJ8R0NT7K biolink:treats MONDO:0002041 PMID:41385096 "[{""id"":""uuid:3a7211d1-9adc-4420-9034-edf317d9bd8b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:811da850-c2bc-4401-b12b-1b3e6a812853"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RECORLEV is indicated for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome for whom surgery is not an option or has not been curative. Limitations of Use RECORLEV is not approved for the treatment of fungal infections. The safety and effectiveness of RECORLEV for the treatment of fungal infections have not been established. uuid:bdda96dc-13e0-4530-874f-5422aea2da9d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5108 biolink:treats MONDO:0020283 PMID:41385096 "[{""id"":""uuid:5785433d-d83e-4aa8-9b42-f785954fbed2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:552fce6d-37e8-4281-84f0-7a22debf24dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] YUTIQ ® (fluocinolone acetonide intravitreal implant) 0.18 mg is indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. uuid:6fd6f804-c983-4063-8acf-fd888f12c6d6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:KG6VO684Z6 biolink:treats MONDO:0018905 PMID:41385096 "[{""id"":""uuid:685bb84e-bb64-476e-8e54-5f9054bacc0b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:295ee227-6d81-4809-a31c-ac81df41580a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:278c52b1-0694-42dc-b9ce-827d75dbd0f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/polivy""]},{""id"":""uuid:5da9ebda-2b4d-4150-9246-f35e33f3fdd4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] POLIVY is a CD79b-directed antibody and microtubule inhibitor conjugate indicated: in combination with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for the treatment of adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index score of 2 or greater. ( 1.1 ) in combination with bendamustine and a rituximab product for the treatment of adult patients with relapsed or refractory DLBCL, NOS, after at least two prior therapies. ( 1.2 )|[EMA] Polivy in combination with bendamustine and rituximab is indicated for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for haematopoietic stem cell transplant.Polivy in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) is indicated for the treatment of adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL).|[PMDA] Drugs with a new indication and a new dosage for the treatment of diffuse large B-cell lymphoma. [Orphan drug] uuid:2da071ee-fac0-4eee-b6d1-f3f84abbed7d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:KG6VO684Z6 biolink:treats MONDO:0044889 PMID:41385096 "[{""id"":""uuid:720910bc-9b8b-4baa-ba1a-593203234a53"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a0e63610-8ef5-4605-bf99-d99bc6b75e98"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] POLIVY is a CD79b-directed antibody and microtubule inhibitor conjugate indicated: in combination with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for the treatment of adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index score of 2 or greater. ( 1.1 ) in combination with bendamustine and a rituximab product for the treatment of adult patients with relapsed or refractory DLBCL, NOS, after at least two prior therapies. ( 1.2 ) uuid:a3f1c461-7171-4280-81b5-0592f9f63b4d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:KG6VO684Z6 biolink:treats MONDO:0000901 PMID:41385096 "[{""id"":""uuid:373fb8af-2dac-4f65-ad12-94b5192826e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8bfe5af9-644a-419f-a373-a054d7f957e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c8d2eae0-18c3-4a1f-90e8-11b886a660c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/polivy""]},{""id"":""uuid:ab436485-5844-4737-bb55-ef71d2acd658"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] POLIVY is a CD79b-directed antibody and microtubule inhibitor conjugate indicated: in combination with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for the treatment of adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index score of 2 or greater. ( 1.1 ) in combination with bendamustine and a rituximab product for the treatment of adult patients with relapsed or refractory DLBCL, NOS, after at least two prior therapies. ( 1.2 )|[EMA] Polivy in combination with bendamustine and rituximab is indicated for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for haematopoietic stem cell transplant.Polivy in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) is indicated for the treatment of adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL).|[PMDA] Drugs with a new active ingredient indicated for the treatment of relapsed or refractory diffuse large B-cell lymphoma. [Orphan drug] uuid:4fe14292-d2f5-41a2-9f74-16f5f60ce4e0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2382602 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:66b78d1b-6a0c-49e3-ba6e-22b05dbe6661"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7ae0d9fc-803c-40fc-80b4-2b10b8eee717"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:28dea900-2577-4fef-baf8-9363d07474b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PHESGO is a combination of pertuzumab and trastuzumab, HER2/neu receptor antagonists, and hyaluronidase, an endoglycosidase, indicated for: Use in combination with chemotherapy as: neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. ( 1.1 ) adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence ( 1.1 ) Use in combination with docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. ( 1.2 )|[PMDA] New combination drugs with a new active ingredient indicated for the treatment of HER2- positive breast cancer and unresectable advanced or recurrent HER2-positive colon or rectal cancer that has progressed after cancer chemotherapy. uuid:ad5f0709-510e-4714-b8f7-647e9c5acdf3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2382602 biolink:treats UMLS:C0278488 PMID:41385096 "[{""id"":""uuid:d7cadee4-d27b-4674-be07-62eeeda09656"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4d460a3f-4ab2-4157-b94a-1cb5fdffc285"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PHESGO is a combination of pertuzumab and trastuzumab, HER2/neu receptor antagonists, and hyaluronidase, an endoglycosidase, indicated for: Use in combination with chemotherapy as: neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. ( 1.1 ) adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence ( 1.1 ) Use in combination with docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. ( 1.2 ) uuid:65430e0e-36ee-4f89-9cd9-d59c9834d94f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90933 biolink:treats MONDO:0005090 PMID:41385096 "[{""id"":""uuid:104ab7b6-d996-4619-879a-1b7c581bdba3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:b2722d7f-9ec5-4570-bea7-8b81eb0989a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:b114f2c5-397e-4d2a-8308-54b7e3f95e64"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VRAYLAR ® is indicated for: Treatment of schizophrenia in adults [see Clinical Studies ( 14.1 )] Acute treatment of manic or mixed episodes associated with bipolar I disorder in adults [see Clinical Studies ( 14.2 )] Treatment of depressive episodes associated with bipolar I disorder (bipolar depression) in adults [see Clinical Studies ( 14.3 )] Adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults [see Clinical Studies ( 14.4 )]|[EMA] Reagila is indicated for the treatment of schizophrenia in adult patients. uuid:0b3fd507-5846-4037-9e96-5bc226613195 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90933 biolink:treats MONDO:0001866 PMID:41385096 "[{""id"":""uuid:11e32724-0e88-4941-852f-630d22f66614"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f7a02ede-c381-4d67-8545-f8832c622c08"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VRAYLAR ® is indicated for: Treatment of schizophrenia in adults [see Clinical Studies ( 14.1 )] Acute treatment of manic or mixed episodes associated with bipolar I disorder in adults [see Clinical Studies ( 14.2 )] Treatment of depressive episodes associated with bipolar I disorder (bipolar depression) in adults [see Clinical Studies ( 14.3 )] Adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults [see Clinical Studies ( 14.4 )] uuid:9edbca44-e0ae-4cf7-befc-ad871c113e5b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90933 biolink:treats MONDO:0024613 PMID:41385096 "[{""id"":""uuid:71ea1bd1-f689-45eb-9462-ee7859dd93fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d77407fe-aafa-457c-8841-51ef1beaa7f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VRAYLAR ® is indicated for: Treatment of schizophrenia in adults [see Clinical Studies ( 14.1 )] Acute treatment of manic or mixed episodes associated with bipolar I disorder in adults [see Clinical Studies ( 14.2 )] Treatment of depressive episodes associated with bipolar I disorder (bipolar depression) in adults [see Clinical Studies ( 14.3 )] Adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults [see Clinical Studies ( 14.4 )] uuid:c0240537-f83a-4b5e-a7b2-9ca821b34ca5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90933 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:3a2fa97a-996d-4822-9de9-b855a931bd79"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a6031ced-e0bf-4117-bad7-b242f485d4fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VRAYLAR ® is indicated for: Treatment of schizophrenia in adults [see Clinical Studies ( 14.1 )] Acute treatment of manic or mixed episodes associated with bipolar I disorder in adults [see Clinical Studies ( 14.2 )] Treatment of depressive episodes associated with bipolar I disorder (bipolar depression) in adults [see Clinical Studies ( 14.3 )] Adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults [see Clinical Studies ( 14.4 )] uuid:b55900df-02e1-47cf-ac47-1769c11215a8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:95341 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:c55b1315-40a0-4a90-bd7e-fbb31bca8c57"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0a229d53-ccf7-4da0-a24e-1de8d1aa3c2d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:b0426cb4-9f8f-4604-b91d-1c19a7852cf4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/olumiant""]},{""id"":""uuid:4c54f281-f979-42d9-b96b-351b1c4c634c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OLUMIANT ® is a Janus kinase (JAK) inhibitor indicated for: the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more TNF blockers. ( 1.1 ) Limitations of Use : Not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.1 ) the treatment of COVID-19 in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or ECMO. ( 1.2 ) the treatment of adult patients with severe alopecia areata. ( 1.3 ) Limitations of Use : Not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, cyclosporine or other potent immunosuppressants. ( 1.3 )|[EMA] Rheumatoid arthritisBaricitinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (DMARDs). Olumiant may be used as monotherapy or in combination with methotrexate.Atopic DermatitisOlumiant is indicated for the treatment of moderate to severe atopic dermatitis in adult and paediatric patients 2 years of age and older who are candidates for systemic therapy.Alopecia areataBaricitinib is indicated for the treatment of severe alopecia areata in adult patients (see section 5.1).Juvenile idiopathic arthritisBaricitinib is indicated for the treatment of active juvenile idiopathic arthritis in patients 2 years of age and older who have had an inadequate response or intolerance to one or more prior conventional synthetic or biologic DMARDs:- Polyarticular juvenile idiopathic arthritis (polyarticular rheumatoid factor positive [RF+] or negative [RF-], extended oligoarticular),- Enthesitis related arthritis, and- Juvenile psoriatic arthritis.Baricitinib may be used as monotherapy or in combination with methotrexate.|[PMDA] Drugs with a new active ingredient indicated for the treatment of rheumatoid arthritis (including prevention of structural joint damage) in patients who have not responded sufficiently to conventional treatments. uuid:8883dcdc-8cfc-41d5-87c8-8f7fecd87a44 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:95341 biolink:treats MONDO:0100096 PMID:41385096 "[{""id"":""uuid:134d3cdb-121e-47d2-91ab-dbe6bbb13380"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:341525e5-cb35-47a2-9746-7bd919f44831"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OLUMIANT ® is a Janus kinase (JAK) inhibitor indicated for: the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more TNF blockers. ( 1.1 ) Limitations of Use : Not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.1 ) the treatment of COVID-19 in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or ECMO. ( 1.2 ) the treatment of adult patients with severe alopecia areata. ( 1.3 ) Limitations of Use : Not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, cyclosporine or other potent immunosuppressants. ( 1.3 ) uuid:5dfe2758-a6a9-46e1-9047-b4724dce3188 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:95341 biolink:treats MONDO:0005340 PMID:41385096 "[{""id"":""uuid:54931764-4ace-4447-8691-63e9d87ce260"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ca460ddb-5ccf-470d-8d5a-a57558358e51"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:754a490d-f5e0-40aa-9bbe-a703e0a13b93"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/olumiant""]},{""id"":""uuid:7d3448da-18b4-4c6d-914d-dbbf0e2ba269"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OLUMIANT ® is a Janus kinase (JAK) inhibitor indicated for: the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more TNF blockers. ( 1.1 ) Limitations of Use : Not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.1 ) the treatment of COVID-19 in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or ECMO. ( 1.2 ) the treatment of adult patients with severe alopecia areata. ( 1.3 ) Limitations of Use : Not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, cyclosporine or other potent immunosuppressants. ( 1.3 )|[EMA] Rheumatoid arthritisBaricitinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (DMARDs). Olumiant may be used as monotherapy or in combination with methotrexate.Atopic DermatitisOlumiant is indicated for the treatment of moderate to severe atopic dermatitis in adult and paediatric patients 2 years of age and older who are candidates for systemic therapy.Alopecia areataBaricitinib is indicated for the treatment of severe alopecia areata in adult patients (see section 5.1).Juvenile idiopathic arthritisBaricitinib is indicated for the treatment of active juvenile idiopathic arthritis in patients 2 years of age and older who have had an inadequate response or intolerance to one or more prior conventional synthetic or biologic DMARDs:- Polyarticular juvenile idiopathic arthritis (polyarticular rheumatoid factor positive [RF+] or negative [RF-], extended oligoarticular),- Enthesitis related arthritis, and- Juvenile psoriatic arthritis.Baricitinib may be used as monotherapy or in combination with methotrexate.|[PMDA] Drugs with a new indication and a new dosage for the treatment of alopecia areata (for use only in patients with intractable and extensive alopecia areata). uuid:fdcfa3aa-33a9-49df-901d-270605f06b6e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50861 biolink:treats UMLS:C3697982 PMID:41385096 "[{""id"":""uuid:a77fec8b-12d7-4a0f-adc7-a6a56bd1584b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2dcd573e-91b5-4dbe-aeaf-c94b9ff40ca7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Orenitram is a prostacyclin mimetic indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1): To delay disease progression and to improve exercise capacity. The studies that established effectiveness included predominately patients with WHO functional class II-III symptoms and etiologies of idiopathic or heritable PAH (66%) or PAH associated with connective tissue disease (26%). ( 1.1 ) uuid:b2cdbecb-5c34-4fdd-a98e-bfcfe7e04c10 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:953A26OA1Y biolink:treats MONDO:0009061 PMID:41385096 "[{""id"":""uuid:4b40fe7c-986f-4086-979a-9bab2ea36020"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1bca411c-594e-4c77-ac27-d90bfad35bdb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:3a6258aa-f644-43d2-acf9-a993a5eb2525"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PULMOZYME ® is indicated, in conjunction with standard therapies, for the management of pediatric and adult patients with cystic fibrosis (CF) to improve pulmonary function. In CF patients with an FVC ≥ 40% of predicted, daily administration of PULMOZYME has also been shown to reduce the risk of respiratory tract infections requiring parenteral antibiotics.|[PMDA] A drug with a new active ingredient indicated for the improvement of lung function in patients with cystic fibrosis. [Orphan drug] uuid:094a4f91-cc36-4766-8589-8cc24bdefdac biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:953A26OA1Y biolink:treats MONDO:0024355 PMID:41385096 "[{""id"":""uuid:d70ae063-faeb-49f1-a5af-efca789e1d4d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8fe1aa65-f6b4-4ae5-b0c0-8126df9a66a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PULMOZYME ® is indicated, in conjunction with standard therapies, for the management of pediatric and adult patients with cystic fibrosis (CF) to improve pulmonary function. In CF patients with an FVC ≥ 40% of predicted, daily administration of PULMOZYME has also been shown to reduce the risk of respiratory tract infections requiring parenteral antibiotics. uuid:4857cea7-2833-4574-9604-cbd561eeec63 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:229220 biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:ba781246-68b3-4f29-8a19-07b13a53aedc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:387173cb-32cc-49e0-88f3-a64d564e206c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AUGTYRO is a kinase inhibitor indicated for the treatment of • adult patients with locally advanced or metastatic ROS1- positive non-small cell lung cancer (NSCLC). ( 1.1 ) • adult and pediatric patients 12 years of age and older with solid tumors that: • have a neurotrophic tyrosine receptor kinase ( NTRK ) gene fusion and • are locally advanced or metastatic or where surgical resection is likely to result in severe morbidity. • have progressed following treatment or have no satisfactory alternative therapy. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. ( 1.2 ) uuid:1df842f7-86f0-4914-86fa-f5233fbbc969 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:229220 biolink:treats UMLS:C0280100 PMID:41385096 "[{""id"":""uuid:68a751bc-71c2-4ace-a7e3-be5b0a3ed903"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2921b23d-e0c4-4919-91eb-3eae80b8141f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AUGTYRO is a kinase inhibitor indicated for the treatment of • adult patients with locally advanced or metastatic ROS1- positive non-small cell lung cancer (NSCLC). ( 1.1 ) • adult and pediatric patients 12 years of age and older with solid tumors that: • have a neurotrophic tyrosine receptor kinase ( NTRK ) gene fusion and • are locally advanced or metastatic or where surgical resection is likely to result in severe morbidity. • have progressed following treatment or have no satisfactory alternative therapy. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. ( 1.2 ) uuid:4088bd7e-525f-4240-ab29-5df4ed5f2f6e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6427 biolink:treats MONDO:0005133 PMID:41385096 "[{""id"":""uuid:1ce907a5-cafd-4b5b-a5a8-4a6a33aea516"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:059150a7-701a-4af5-b1d8-723722bf26c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LUPRON DEPOT 3.75 mg is a gonadotropin-releasing hormone (GnRH) agonist indicated for: Endometriosis Management of endometriosis, including pain relief and reduction of endometriotic lesions. ( 1.1 ) In combination with a norethindrone acetate for initial management of the painful symptoms of endometriosis and for management of recurrence of symptoms. ( 1.1 ) Limitations of Use: The total duration of therapy with LUPRON DEPOT 3.75 mg plus add-back therapy should not exceed 12 months due to concerns about adverse impact on bone mineral density. ( 1.1 , 2.1 , 5.1 ) Uterine Leiomyomata (Fibroids) Concomitant use with iron therapy for preoperative hematologic improvement of women with anemia caused by fibroids for whom three months of hormonal suppression is deemed necessary. ( 1.2 ) Limitations of Use: LUPRON DEPOT 3.75 mg is not indicated for combination use with norethindrone acetate add-back therapy for the preoperative hematologic improvement of women with anemia caused by heavy menstrual bleeding due to fibroids. ( 1.2 ) uuid:8ae65c07-8815-4875-b03d-73da144a244d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:LDJ89SS0YG biolink:treats UMLS:C1335723 PMID:41385096 "[{""id"":""uuid:267d1b10-a76c-4d3d-a4bd-4a3ed84799c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ca10d289-24ea-43ff-83a9-2f4432a7c112"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LUNSUMIO is a bispecific CD20-directed CD3 T-cell engager indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy. This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1.1 ) uuid:ab8d6339-e7a4-4699-a025-fc8e24d4357a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2283226 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:8ca5dd49-250f-46cc-a106-ecbc0dcfcfc1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eea6a64a-f8e0-4489-bea7-709fdfb12e93"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NEXLIZET, a combination of bempedoic acid and ezetimibe, is indicated: As an adjunct to diet, alone or in combination with other low-density lipoprotein cholesterol (LDL-C) lowering therapies, to reduce LDL-C in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH). The bempedoic acid component of NEXLIZET is indicated: To reduce the risk of myocardial infarction and coronary revascularization in adults who are unable to take recommended statin therapy (including those not taking a statin) with: established cardiovascular disease (CVD), or a high risk for a CVD event but without established CVD. uuid:1a666f58-69c6-46e5-af05-71869d3cea9a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2283226 biolink:treats UMLS:C0342882 PMID:41385096 "[{""id"":""uuid:c708f786-7c67-4346-b22a-61358349fcf0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:031454f6-dc3d-4955-b994-23c0494b8c08"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NEXLIZET, a combination of bempedoic acid and ezetimibe, is indicated: As an adjunct to diet, alone or in combination with other low-density lipoprotein cholesterol (LDL-C) lowering therapies, to reduce LDL-C in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH). The bempedoic acid component of NEXLIZET is indicated: To reduce the risk of myocardial infarction and coronary revascularization in adults who are unable to take recommended statin therapy (including those not taking a statin) with: established cardiovascular disease (CVD), or a high risk for a CVD event but without established CVD. uuid:d66bf08a-04ed-4bbb-8904-2f8bd9cba0ed biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2283226 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:90c7b6d4-b096-44c9-b535-d74958eca7ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a449a2ae-9a65-4a6d-adab-7b631ae37286"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NEXLIZET, a combination of bempedoic acid and ezetimibe, is indicated: As an adjunct to diet, alone or in combination with other low-density lipoprotein cholesterol (LDL-C) lowering therapies, to reduce LDL-C in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH). The bempedoic acid component of NEXLIZET is indicated: To reduce the risk of myocardial infarction and coronary revascularization in adults who are unable to take recommended statin therapy (including those not taking a statin) with: established cardiovascular disease (CVD), or a high risk for a CVD event but without established CVD. uuid:04735853-81fc-4ecc-b66d-27d13cd2ffeb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2283226 biolink:treats MONDO:0004995 PMID:41385096 "[{""id"":""uuid:6d1cfc06-e9db-4123-b453-7464b123126f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b8f90188-9fb2-4726-b623-0dcbb3a3d154"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NEXLIZET, a combination of bempedoic acid and ezetimibe, is indicated: As an adjunct to diet, alone or in combination with other low-density lipoprotein cholesterol (LDL-C) lowering therapies, to reduce LDL-C in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH). The bempedoic acid component of NEXLIZET is indicated: To reduce the risk of myocardial infarction and coronary revascularization in adults who are unable to take recommended statin therapy (including those not taking a statin) with: established cardiovascular disease (CVD), or a high risk for a CVD event but without established CVD. uuid:1bccbcba-d1c5-465c-8707-9ce2ff142ff4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:149601 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:5c96af4b-fe8d-4512-831a-aa13a7cb2e27"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b101ce2d-fb91-41c8-95ef-3f1ef7fe7d74"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NEXLETOL is indicated: To reduce the risk of myocardial infarction and coronary revascularization in adults who are unable to take recommended statin therapy (including those not taking a statin) with: established cardiovascular disease (CVD), or a high risk for a CVD event but without established CVD. As an adjunct to diet, in combination with other low-density lipoprotein cholesterol (LDL-C) lowering therapies, or alone when concomitant LDL-C lowering therapy is not possible, to reduce LDL-C in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH). uuid:845ea464-ec68-4a25-a923-d098cf51fee3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:149601 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:ad034d93-1994-4201-9c39-f895fadf5ab3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4dfe8d1c-c7ed-42e5-9d2b-0a1811af9492"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NEXLETOL is indicated: To reduce the risk of myocardial infarction and coronary revascularization in adults who are unable to take recommended statin therapy (including those not taking a statin) with: established cardiovascular disease (CVD), or a high risk for a CVD event but without established CVD. As an adjunct to diet, in combination with other low-density lipoprotein cholesterol (LDL-C) lowering therapies, or alone when concomitant LDL-C lowering therapy is not possible, to reduce LDL-C in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH). uuid:e7087203-ec9e-49ba-8d4b-c2aed7092ffc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:149601 biolink:treats UMLS:C0342882 PMID:41385096 "[{""id"":""uuid:6b4039ad-241d-4c1b-b99c-04d294667bbd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:24e76105-ccf3-4816-b2cf-dfcd2786d82a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NEXLETOL is indicated: To reduce the risk of myocardial infarction and coronary revascularization in adults who are unable to take recommended statin therapy (including those not taking a statin) with: established cardiovascular disease (CVD), or a high risk for a CVD event but without established CVD. As an adjunct to diet, in combination with other low-density lipoprotein cholesterol (LDL-C) lowering therapies, or alone when concomitant LDL-C lowering therapy is not possible, to reduce LDL-C in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH). uuid:6a52af45-d1c2-4fc1-9720-82f149f7d465 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0005972 PMID:41385096 "[{""id"":""uuid:58ba3639-1a4d-4996-829d-9df1b3d3f1e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b0e6bb8d-2bda-4a7f-a783-7ed7e6759d76"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline for injection and other antibacterial drugs, doxycycline for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers). Mycoplasma pneumoniae (PPLO, Eaton Agent). Agents of psittacosis and ornithosis. Agents of lymphogranuloma venereum and granuloma inguinale. The spirochetal agent of relapsing fever ( Borrelia recurrentis ). The following gram-negative microorganisms: Haemophilus ducreyi (chancroid) Yersinia pestis Francisella tularensis Bartonella bacilliformis Bacteroides species Vibrio cholerae and Campylobacte fetus Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Haemophilus influenzae (respiratory infections) Klebsiella species (respiratory and urinary infections) Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Streptococcus pneumoniae Staphylococcus aureus , respiratory, skin and soft tissue infections. Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections. Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of infections due to: Neisseria gonorrhoeae and N. meningitidis Treponema pallidum and Treponema pallidum subspecies pertenue (syphilis and yaws) Listeria monocytogenes Clostridium species Fusobacterium fusiforme (Vincent’s infection) Actinomyces species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. Doxycycline is indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. uuid:ae425112-50d8-4b36-975e-41c4e5d2a90f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16480 biolink:treats UMLS:C3805211 PMID:41385096 "[{""id"":""uuid:cadb4f0b-d693-4223-997b-e1cb891fcfa4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:70c3053d-b550-4785-ae54-da48a50e36ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:34353068-dba1-452b-8fd5-bd8de6c9222a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] GENOSYL ® is indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents.|[PMDA] A drug containing a new active ingredient indicated for the treatment of hypoxic respiratory failure (HRF) with concurrent pulmonary hypertension in neonates. [Orphan drug] uuid:44ef9959-a314-44b9-8370-9b3996e4a12e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16480 biolink:treats MONDO:0005149 PMID:41385096 "[{""id"":""uuid:7f982e93-1afa-4359-a8f7-e777320af8d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b8e11d38-a2c6-4c3b-8b9d-f2d5b4c5713e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:91c27ec6-6965-4929-b433-093b7286229d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:cfa99f5f-5da6-4435-be55-94a17b926bbe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] GENOSYL ® is indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents.|[EMA] INOmax, in conjunction with ventilatory support and other appropriate active substances, is indicated:for the treatment of newborn infants ≥34 weeks gestation with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension, in order to improve oxygenation and to reduce the need for extracorporeal membrane oxygenation;as part of the treatment of peri- and post-operative pulmonary hypertension in adults and newborn infants, infants and toddlers, children and adolescents, ages 0-17 years in conjunction to heart surgery, in order to selectively decrease pulmonary arterial pressure and improve right ventricular function and oxygenation.|[PMDA] A drug containing a new active ingredient indicated for the treatment of hypoxic respiratory failure (HRF) with concurrent pulmonary hypertension in neonates. [Orphan drug] uuid:9051f402-c50f-4275-b76f-246df1300249 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4SED7F4BSG biolink:treats MONDO:0009290 PMID:41385096 "[{""id"":""uuid:14f6223e-d66c-47b4-a0a0-22ece5d28321"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f6b557d4-ee53-420b-81d6-540cd49bc249"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e9d6e647-b741-43a5-a96f-c8cddd0601d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/pombiliti""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] POMBILITI is indicated, in combination with Opfolda, for the treatment of adult patients with late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency) weighing ≥40 kg and who are not improving on their current enzyme replacement therapy (ERT).|[EMA] Pombiliti (cipaglucosidase alfa) is a long-term enzyme replacement therapy used in combination with the enzyme stabiliser miglustat for the treatment of adults with late-onset Pompe disease (acid α-glucosidase [GAA] deficiency). uuid:1d7fdb91-cbec-4df1-a127-afd3fbcadacf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50381 biolink:treats MONDO:0009290 PMID:41385096 "[{""id"":""uuid:22afb494-e13e-45af-9c10-be9aa6ef07af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:4260eff0-d576-4d38-997d-b12452d45fc5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:0588bf8e-ab75-4dc1-ad86-90744d9928a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/opfolda""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] OPFOLDA is indicated, in combination with Pombiliti, for the treatment of adult patients with late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency) weighing ≥40 kg and who are not improving on their current enzyme replacement therapy (ERT).|[EMA] Opfolda (miglustat) is an enzyme stabiliser of cipaglucosidase alfa long-term enzyme replacement therapy in adults with late-onset Pompe disease (acid α- glucosidase [GAA] deficiency). uuid:57b0e0fb-c507-4b6f-872e-91a68b51f561 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71219 biolink:treats UMLS:C4727069 PMID:41385096 "[{""id"":""uuid:54449ada-c8fb-4f54-a0e0-532e4068a64a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bb6d7cb0-7c97-4ac5-8e21-f87f6ba02b03"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pazopanib tablets are a kinase inhibitor indicated for the treatment of adults with: Advanced renal cell carcinoma (RCC). ( 1.1 ) Advanced soft tissue sarcoma (STS) who have received prior chemotherapy. ( 1.2 ) Limitations of Use : The efficacy of pazopanib tablets for the treatment of patients with adipocytic soft tissue sarcoma or gastrointestinal stromal tumors has not been demonstrated. uuid:50fc6899-3c08-4170-969c-7a0f30723db6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71219 biolink:treats UMLS:C5206410 PMID:41385096 "[{""id"":""uuid:a307559c-a9db-411c-b1eb-26d7a3244c76"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fe3bc723-a0e3-4ae0-bf10-fca3ed93ce44"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pazopanib tablets are a kinase inhibitor indicated for the treatment of adults with: Advanced renal cell carcinoma (RCC). ( 1.1 ) Advanced soft tissue sarcoma (STS) who have received prior chemotherapy. ( 1.2 ) Limitations of Use : The efficacy of pazopanib tablets for the treatment of patients with adipocytic soft tissue sarcoma or gastrointestinal stromal tumors has not been demonstrated. uuid:e0e9de68-7b93-4ef1-96c4-8581775f85d2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3423 biolink:treats MONDO:0100342 PMID:41385096 "[{""id"":""uuid:6a0c05d7-ec8b-4df5-8e82-d5012d8fa39f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8f8f7d9c-5ae5-44a7-91c6-b95a6b3382bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:4de4a0c1-a050-46a0-93ca-57009652e0c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] GLIADEL Wafer is indicated for the treatment of patients with: newly-diagnosed high-grade glioma as an adjunct to surgery and radiation, and recurrent glioblastoma as an adjunct to surgery.|[PMDA] A drug with a new active ingredient indicated for the treatment of malignant glioma. [Orphan drug] uuid:0af5702c-d43a-4c17-8a1e-62cedb5faa5f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C1589331 biolink:treats MONDO:0015804 PMID:41385096 "[{""id"":""uuid:abbe6cc9-cf0e-4a78-94a8-6b5d3ea3af8f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0d208010-4e0c-4ff3-9f48-136fe738c009"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BabyBIG ® , Botulism Immune Globulin Intravenous (Human), is indicated for the treatment of infant botulism caused by toxin type A or B in patients below one year of age. DRUGBANK:DB14115 uuid:bc8103fd-a4d1-431b-9418-fc609874a201 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C1589331 biolink:treats MONDO:0005498 PMID:41385096 "[{""id"":""uuid:94ef52c2-0818-4d22-986b-8c908edf1084"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:35f86f0d-0bf6-47e6-96a4-35d5a66207ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BabyBIG ® , Botulism Immune Globulin Intravenous (Human), is indicated for the treatment of infant botulism caused by toxin type A or B in patients below one year of age. DRUGBANK:DB14115 uuid:4f587539-a647-430d-9cb6-a25685dea811 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7573 biolink:treats MONDO:0008315 PMID:41385096 "[{""id"":""uuid:045dce7a-b797-4b02-aa17-d8a7a51809c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a66f4376-aeb1-433f-9497-07ff367e53d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NILANDRON tablets are indicated for use in combination with surgical castration for the treatment of metastatic prostate cancer (Stage D 2 ). For maximum benefit, NILANDRON treatment must begin on the same day as or on the day after surgical castration. uuid:e4084e54-4625-418e-99c0-27c300e8b9df biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:231416 biolink:treats UMLS:C0312854 PMID:41385096 "[{""id"":""uuid:1801461a-c91a-43f5-967c-c047a3b3504a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:90387697-a5bc-445c-b3f3-a1a2f4542713"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VOYDEYA is indicated as add-on therapy to ravulizumab or eculizumab for the treatment of extravascular hemolysis (EVH) in adults with paroxysmal nocturnal hemoglobinuria (PNH). uuid:f40714a1-d0be-4da0-a694-af8ee9a70f12 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:231416 biolink:treats MONDO:0100244 PMID:41385096 "[{""id"":""uuid:81e473c3-79d8-4cdc-92af-b1f6b814a28c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:807fd7a7-5dcd-45e1-8d5b-40f5c2568deb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:5fb360c9-7920-47d6-a865-9367fd0273f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VOYDEYA is indicated as add-on therapy to ravulizumab or eculizumab for the treatment of extravascular hemolysis (EVH) in adults with paroxysmal nocturnal hemoglobinuria (PNH).|[PMDA] A drug with a new active ingredient indicated for the treatment of paroxysmal nocturnal haemoglobinuria. [Orphan drug] uuid:17fd0ef2-4fd0-4a47-9318-947fa3a3b3dd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:66903 biolink:treats UMLS:C1304306 PMID:41385096 "[{""id"":""uuid:c611c476-f357-499c-8b23-42f230d674b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f2f7cdf9-f7f8-4096-b171-26c632d9a159"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ERIVEDGE is indicated for the treatment of adults with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery and who are not candidates for radiation. uuid:e48b5e6d-4e34-4cc8-a09a-6c0e015bc57d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:66903 biolink:treats UMLS:C4745056 PMID:41385096 "[{""id"":""uuid:f196dd35-959a-46a8-bc36-31a59011515c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d87017fe-c28b-4097-865e-22874f5ff689"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ERIVEDGE is indicated for the treatment of adults with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery and who are not candidates for radiation. uuid:8c5f588e-cb22-4ba5-bda4-f5bd84d6fdaf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7566 biolink:treats MONDO:0001444 PMID:41385096 "[{""id"":""uuid:50cde76e-44b1-4e33-99a4-c6a87ff5ab3c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:40309a6b-28bd-4b09-a155-fab15dd1009d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LAMPIT is indicated in pediatric patients (birth to less than 18 years of age and weighing at least 2.5 kg) for the treatment of Chagas disease (American Trypanosomiasis) caused by Trypanosoma cruzi [see Clinical Studies ( 14 )]. uuid:2d2a07dc-d6cd-469b-9d6d-a8cceb435962 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:23HYE36B0I biolink:treats MONDO:0009265 PMID:41385096 "[{""id"":""uuid:1c532d6f-8a96-4706-9906-ea884ed2a59a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:2d4e42b5-02a5-4aa6-b710-7e50a04e53fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:11814c93-b489-4b0a-8c1e-23af3964b7d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/vpriv""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] VPRIV is indicated for long-term enzyme replacement therapy (ERT) for patients with type 1 Gaucher disease.|[EMA] Vpriv is indicated for long-term enzyme-replacement therapy (ERT) in patients with type-1 Gaucher disease. uuid:f6c735da-9534-4d73-aa09-dc5f91926849 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:59UA429E5G biolink:treats MONDO:0009661 PMID:41385096 "[{""id"":""uuid:7c4ec45b-de5c-4628-8c07-cab068ddf865"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:313a89da-0d4e-46a6-99cc-cbf1dc0f64a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:914f6e30-8cec-49f9-8d26-b508594d4d93"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/naglazyme""]},{""id"":""uuid:7ba3015c-cfc8-4ead-8c42-669752a89b12"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NAGLAZYME is indicated for patients with Mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy syndrome). NAGLAZYME has been shown to improve walking and stair-climbing capacity.|[EMA] Naglazyme is indicated for long-term enzyme-replacement therapy in patients with a confirmed diagnosis of mucopolysaccharidosis VI (MPS VI; N-acetylgalactosamine-4-sulfatase deficiency; Maroteaux-Lamy syndrome) (see section 5.1)., , As for all lysosomal genetic disorders, it is of primary importance, especially in severe forms, to initiate treatment as early as possible, before appearance of non-reversible clinical manifestations of the disease., , A key issue is to treat young patients aged|[PMDA] A drug containing a new active ingredient indicated for the treatment of mucopolysaccharidosis VI. [Orphan drug] uuid:26455454-182a-4bdf-9353-36d76630e69b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:8ZHS5657EH biolink:treats MONDO:0019467 PMID:41385096 "[{""id"":""uuid:2de35a6d-5234-4dd7-afcf-b77fb879b1e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:aeac76fe-90e5-4311-b917-c368267811f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:0bbe7cdc-64cb-4f44-bbf3-bb30f641f8ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/elzonris""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] ELZONRIS is indicated for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients 2 years and older.|[EMA] Elzonris is indicated as monotherapy for the first-line treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). uuid:0a41445a-4e67-4310-92e2-f7e0c6b2ec28 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:NQX9KB6PCL biolink:treats MONDO:0000050 PMID:41385096 "[{""id"":""uuid:8e5ff451-1f66-4f6c-abb8-025818ffb646"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9dc6c6f4-89d9-4006-82e5-b93e08d3528c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:64fac49b-9a53-4782-9ce5-7cfe8affc6ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/omnitrope""]},{""id"":""uuid:fc673dd2-742f-4c76-b660-dc04bd0bcfeb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] HUMATROPE is a recombinant human growth hormone indicated for: Pediatric Patients: growth failure due to inadequate secretion of endogenous growth hormone (GH); short stature associated with Turner syndrome; Idiopathic Short Stature (ISS), height standard deviation score (SDS) <-2.25, and associated with growth rates unlikely to permit attainment of adult height in the normal range; short stature or growth failure in short stature homeobox-containing gene (SHOX) deficiency; short stature born small for gestational age (SGA) with no catch-up growth by 2 years to 4 years of age. ( 1.1 ) Adult Patients: replacement of endogenous GH in adults with GH deficiency. ( 1.2 )|[EMA] Long-term treatment of children with growth failure due to inadequate endogenous growth hormone secretion.Long-term treatment of growth failure associated with Turner syndrome.Treatment of prepubertal children with growth failure associated with chronic renal insufficiency up to the time of renal transplantation.Replacement of endogenous growth hormone in adults with growth hormone deficiency of either childhood or adult-onset etiology. Growth hormone deficiency should be confirmed appropriately prior to treatment.|[PMDA] Follow-on biologics indicated for the treatment of growth disturbance due to growth hormone deficiency before epiphyseal closure and growth disturbance associated with Turner syndrome or chronic renal insufficiency before epiphyseal closure. uuid:35dcf521-c927-4c4a-839b-a6f786aa01e4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:5TAA004E22 biolink:treats MONDO:0018874 PMID:41385096 "[{""id"":""uuid:56eb419a-2dbe-4a38-a4e6-895354ee2d3c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ff939ac9-b201-4e15-b1ba-0b15272e2013"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LEUKINE is a leukocyte growth factor indicated: To shorten time to neutrophil recovery and to reduce the incidence of severe and life-threatening infections and infections resulting in death following induction chemotherapy in adult patients 55 years and older with acute myeloid leukemia (AML). ( 1.1 ) For the mobilization of hematopoietic progenitor cells into peripheral blood for collection by leukapheresis and autologous transplantation in adult patients. ( 1.2 ) For the acceleration of myeloid reconstitution following autologous bone marrow or peripheral blood progenitor cell transplantation in adult and pediatric patients 2 years of age and older. ( 1.3 ) For the acceleration of myeloid reconstitution following allogeneic bone marrow transplantation in adult and pediatric patients 2 years of age and older. ( 1.4 ) For treatment of delayed neutrophil recovery or graft failure after autologous or allogeneic bone marrow transplantation in adult and pediatric patients 2 years of age and older. ( 1.5 ) To increase survival in adult and pediatric patients from birth to 17 years of age acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome [H-ARS]). ( 1.6 ) uuid:61dde66f-b3f0-4db2-9cc8-96edf62caadc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:5TAA004E22 biolink:treats MONDO:0033938 PMID:41385096 "[{""id"":""uuid:ea8d9abe-6ef2-44d7-9469-65ff844580e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:055fc8ef-e9a8-49d1-b0d6-4323318d65ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LEUKINE is a leukocyte growth factor indicated: To shorten time to neutrophil recovery and to reduce the incidence of severe and life-threatening infections and infections resulting in death following induction chemotherapy in adult patients 55 years and older with acute myeloid leukemia (AML). ( 1.1 ) For the mobilization of hematopoietic progenitor cells into peripheral blood for collection by leukapheresis and autologous transplantation in adult patients. ( 1.2 ) For the acceleration of myeloid reconstitution following autologous bone marrow or peripheral blood progenitor cell transplantation in adult and pediatric patients 2 years of age and older. ( 1.3 ) For the acceleration of myeloid reconstitution following allogeneic bone marrow transplantation in adult and pediatric patients 2 years of age and older. ( 1.4 ) For treatment of delayed neutrophil recovery or graft failure after autologous or allogeneic bone marrow transplantation in adult and pediatric patients 2 years of age and older. ( 1.5 ) To increase survival in adult and pediatric patients from birth to 17 years of age acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome [H-ARS]). ( 1.6 ) uuid:9daa3516-3cbb-4c4f-ac5a-b3e37707e603 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:5TAA004E22 biolink:treats UMLS:C1262018 PMID:41385096 "[{""id"":""uuid:a72eaf86-8f7c-4353-a4a8-68a3e1fbb9a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0f4e6983-472d-47c3-a721-6c2658615611"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LEUKINE is a leukocyte growth factor indicated: To shorten time to neutrophil recovery and to reduce the incidence of severe and life-threatening infections and infections resulting in death following induction chemotherapy in adult patients 55 years and older with acute myeloid leukemia (AML). ( 1.1 ) For the mobilization of hematopoietic progenitor cells into peripheral blood for collection by leukapheresis and autologous transplantation in adult patients. ( 1.2 ) For the acceleration of myeloid reconstitution following autologous bone marrow or peripheral blood progenitor cell transplantation in adult and pediatric patients 2 years of age and older. ( 1.3 ) For the acceleration of myeloid reconstitution following allogeneic bone marrow transplantation in adult and pediatric patients 2 years of age and older. ( 1.4 ) For treatment of delayed neutrophil recovery or graft failure after autologous or allogeneic bone marrow transplantation in adult and pediatric patients 2 years of age and older. ( 1.5 ) To increase survival in adult and pediatric patients from birth to 17 years of age acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome [H-ARS]). ( 1.6 ) uuid:52824957-c506-472c-9753-44e4ac7fcdd7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:ODJ69JZG85 biolink:treats MONDO:0009659 PMID:41385096 "[{""id"":""uuid:1ff3b1c3-c23d-46f7-a8ea-4cf1ffa4e876"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:cb5a419c-7ed0-4fe9-8605-47a476b4112c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:bfa59bb6-eb94-44f2-9f04-18efff147db7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f5397c2a-0230-4144-a3b5-16b3ab5c992b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vimizim (elosulfase alfa) is indicated for patients with Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome).|[EMA] Vimizim is indicated for the treatment of mucopolysaccharidosis, type IVA (Morquio A Syndrome, MPS IVA) in patients of all ages.|[PMDA] A drug with a new active ingredient indicated for the treatment of mucopolysaccharidosis type IVA. [Orphan drug] uuid:b6329a3b-206c-47cb-9ccd-103032342f6c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:ODJ69JZG85 biolink:treats MONDO:0018938 PMID:41385096 "[{""id"":""uuid:2e18c57e-f455-4e2d-ab49-3afbab4db86b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2baca208-e153-4cde-ac6b-9573553ee78c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vimizim (elosulfase alfa) is indicated for patients with Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome). uuid:e7529f93-ea4b-4c00-b78e-0d2531d8892a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3A189DH42V biolink:treats MONDO:0004948 PMID:41385096 "[{""id"":""uuid:5eaf95b2-d7bf-427a-a8c1-d64814038e22"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:70c1878e-e5ac-45d1-b00b-32a87aad4a71"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CAMPATH is indicated as a single agent for the treatment of B-cell chronic lymphocytic leukemia (B-CLL). uuid:dd375c86-35a1-44fa-866d-a8470960838d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB17278 biolink:treats MONDO:0024503 PMID:41385096 "[{""id"":""uuid:1cc2bf21-924b-450e-8976-1021a607c1f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:06ed3e22-8885-4285-b817-74e1fc1ea435"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LUTATHERA is indicated for the treatment of adult and pediatric patients 12 years and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors. uuid:7ed63347-31fa-40e5-be12-70cf1bef2081 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB17278 biolink:treats MONDO:0018510 PMID:41385096 "[{""id"":""uuid:bb8501d2-0929-4dbd-b1ec-5e55820aca44"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b56cfc9b-cac9-44ad-b62a-f1bd9ac9e948"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LUTATHERA is indicated for the treatment of adult and pediatric patients 12 years and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors. uuid:b520090b-f033-4e07-8823-9829e2df8a78 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB17278 biolink:treats MONDO:0003646 PMID:41385096 "[{""id"":""uuid:601c778a-1e5e-4187-9666-21e39689922c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:abcd5aff-8481-4860-9714-cbbc6d0bdc20"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LUTATHERA is indicated for the treatment of adult and pediatric patients 12 years and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors. uuid:25410580-407c-4ccd-a7f7-d45fbb8a8e17 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:44476258 biolink:treats MONDO:0006652 PMID:41385096 "[{""id"":""uuid:9d0070b5-64c0-4878-a4c0-1335eb3eebd2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c0d2eb37-f606-4518-baaa-8e641e9341b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets are a combination of olmesartan medoximil, an angiotensin II receptor blocker, amlodipine, a dihydropyridine calcium channel blocker, and hydrochlorothiazide, a thiazide diuretic indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1 ). Limitations of Use Olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets is not indicated for initial therapy ( 1 ). uuid:97ea7e74-18e5-433e-ba75-e678e21cac64 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17234 biolink:treats UMLS:C0854100 PMID:41385096 "[{""id"":""uuid:c56c13cb-4c1c-424f-9acd-39743f5c37de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ad3879d3-a2f0-4fad-ac4e-a5298c069f29"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 70% Dextrose Injection USP is indicated as a caloric component in a parenteral nutrition regimen. 70% Dextrose Injection USP is used with an appropriate protein (nitrogen) source in the prevention of nitrogen loss or in the treatment of negative nitrogen balance in patients where: (1) the alimentary tract cannot or should not be used, (2) gastrointestinal absorption of protein is impaired, or (3) metabolic requirements for protein are substantially increased, as with extensive burns. uuid:2c42f222-5814-4136-9964-ab56988eb66b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135983 biolink:treats MONDO:0005298 PMID:41385096 "[{""id"":""uuid:3e930ad0-5767-4112-b2bf-d9ea5fda11c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ffe12cc6-a6c7-42d2-80fa-2ce9948411ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:d0e5d785-597b-40a2-b665-08dcbbc27279"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/kauliv""]},{""id"":""uuid:34ab3706-5a85-4181-922b-5bcbf84e11cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FORTEO is indicated: For the treatment of postmenopausal women with osteoporosis at high risk for fracture (defined herein as having a history of osteoporotic fracture or multiple risk factors for fracture) or who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, FORTEO reduces the risk of vertebral and nonvertebral fractures. To increase bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy. For the treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy (daily dosage equivalent to 5 mg or greater of prednisone) at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy.|[EMA] Kauliv is indicated in adults., , Treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5.1). In postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated., , Treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.1).,|[PMDA] A drug with a new dosage in an additional dosage form indicated for the treatment of osteoporosis with a high risk of fracture. uuid:ae518c81-3a8d-4664-a49b-01cb3f79fcae biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135983 biolink:treats UMLS:C0521170 PMID:41385096 "[{""id"":""uuid:24e40670-2565-494f-932d-0d940f50722a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2dbd49a6-e8cb-4203-96dd-4bf41fcc21df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FORTEO is indicated: For the treatment of postmenopausal women with osteoporosis at high risk for fracture (defined herein as having a history of osteoporotic fracture or multiple risk factors for fracture) or who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, FORTEO reduces the risk of vertebral and nonvertebral fractures. To increase bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy. For the treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy (daily dosage equivalent to 5 mg or greater of prednisone) at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy. uuid:84bd6a4a-1dd5-424e-8d39-863b2823bfd0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135983 biolink:treats UMLS:C0410438 PMID:41385096 "[{""id"":""uuid:a788ca9e-bd19-4009-8ffc-d05086ab5304"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e17f3264-1d3c-4cbe-a4ab-d9cab4245e88"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FORTEO is indicated: For the treatment of postmenopausal women with osteoporosis at high risk for fracture (defined herein as having a history of osteoporotic fracture or multiple risk factors for fracture) or who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, FORTEO reduces the risk of vertebral and nonvertebral fractures. To increase bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy. For the treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy (daily dosage equivalent to 5 mg or greater of prednisone) at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy. uuid:399f7d86-4df3-4263-96dd-5b8f7a512a20 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5118 biolink:treats MONDO:1010182 PMID:41385096 "[{""id"":""uuid:325cf86d-43bf-472a-8940-622b38c70c69"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eb60282d-7f33-4be2-a1f9-153a76f7caab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fluoxetine tablets, USP are selective serotonin reuptake inhibitor (SSRI) indicated for the treatment of Premenstrual Dysphoric Disorder (PMDD) ( 1.1 ) UMLS:C0520676 uuid:757f259c-d785-4b27-9ee7-1d80541a64b3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1157512 biolink:treats MONDO:0005277 PMID:41385096 "[{""id"":""uuid:d556bf2e-1db9-4bac-8632-0792ae20a372"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4e7659f4-b824-452f-a133-874d16af2c3c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sumatriptan and naproxen sodium tablets are indicated for the acute treatment of migraine with or without aura in adults and pediatric patients 12 years of age and older. Limitations of Use: Use only if a clear diagnosis of migraine headache has been established. If a patient has no response to the first migraine attack treated with sumatriptan and naproxen sodium tablets, reconsider the diagnosis of migraine before sumatriptan and naproxen sodium tablets are administered to treat any subsequent attacks. Sumatriptan and naproxen sodium tablets are not indicated for the prevention of migraine attacks. Safety and effectiveness of sumatriptan and naproxen sodium tablets have not been established for cluster headache. uuid:d3eaa0d5-476d-4d48-8aa9-b57e9a6a43d9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:9829639 biolink:treats EFO:1001480 PMID:41385096 "[{""id"":""uuid:3496c736-f083-4fa9-bdf3-563b49ece237"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:16e24bea-a1a7-485d-bd7c-b35a4f0279d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LONSURF is a combination of trifluridine, a nucleoside metabolic inhibitor, and tipiracil, a thymidine phosphorylase inhibitor, indicated for the treatment of adult patients with: metastatic colorectal cancer as a single agent or in combination with bevacizumab who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy. ( 1.1 ) metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy. ( 1.2 ) uuid:7a0203e3-c04e-4e7f-ae7f-9899ef8540d9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:9829639 biolink:treats UMLS:C3160888 PMID:41385096 "[{""id"":""uuid:63096434-3891-4b01-88f1-7a99831a2e85"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:65ef0bed-70b0-4457-84db-4e7bf763bc96"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LONSURF is a combination of trifluridine, a nucleoside metabolic inhibitor, and tipiracil, a thymidine phosphorylase inhibitor, indicated for the treatment of adult patients with: metastatic colorectal cancer as a single agent or in combination with bevacizumab who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy. ( 1.1 ) metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy. ( 1.2 ) uuid:d01c16d2-9219-458f-885d-4f5c67bf9f32 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:9829639 biolink:treats UMLS:C4725845 PMID:41385096 "[{""id"":""uuid:750c134d-5274-4810-9878-26dfcfd7b1b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c4b9ed95-ac5b-4ab6-a29f-c26525f50f2b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LONSURF is a combination of trifluridine, a nucleoside metabolic inhibitor, and tipiracil, a thymidine phosphorylase inhibitor, indicated for the treatment of adult patients with: metastatic colorectal cancer as a single agent or in combination with bevacizumab who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy. ( 1.1 ) metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy. ( 1.2 ) uuid:d57e846b-5498-4099-a8a7-968072136726 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9754 biolink:treats MONDO:0000440 PMID:41385096 "[{""id"":""uuid:005faf2e-8e1c-4e96-8fc0-dac3f33a086e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2583fa0e-0155-4b57-b845-b8b0ef90428d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tham Solution (tromethamine injection) is indicated for the prevention and correction of metabolic acidosis. In the following conditions it may help to sustain vital functions and thus provide time for treatment of the primary disease: Metabolic Acidosis Associated with Cardiac Bypass Surgery. Tham Solution has been found to be primarily beneficial in correcting metabolic acidosis which may occur during or immediately following cardiac bypass surgical procedures. Correction of Acidity of ACD Blood in Cardiac Bypass Surgery. It is well known that ACD blood is acidic and becomes more acidic on storage. Tromethamine effectively corrects this acidity. Tham Solution may be added directly to the blood used to prime the pump-oxygenator. When ACD blood is brought to a normal pH range the patient is spared an initial acid load. Additional tromethamine may be indicated during cardiac bypass surgery should metabolic acidosis appear. Metabolic Acidosis Associated with Cardiac Arrest. Acidosis is nearly always one of the consequences of cardiac arrest and, in some instances, may even be a causative factor in arrest. It is important therefore, that the correction of acidosis should be started promptly with other resuscitative efforts. By correcting acidosis, Tham Solution (tromethamine injection) has caused the arrested heart to respond to resuscitative efforts after standard methods alone had failed. In these cases, tromethamine was given intraventricularly. It is to be noted, however, that such precariously ill patients often have died subsequently of causes unrelated to the administration of tromethamine. With administration by the peripheral venous route, metabolic acidosis has been corrected in a majority of patients. The success in reinstitution of cardiac rhythm by this means probably has not been of the same order of magnitude as with the intraventricular route. uuid:dd890119-4841-4a47-96f4-113344ab786c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9754 biolink:treats MONDO:0006022 PMID:41385096 "[{""id"":""uuid:e80d13f3-5548-4262-add4-9b94691d82b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:95d0e45c-26c2-4eb1-9f4f-fd0607b64ee8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tham Solution (tromethamine injection) is indicated for the prevention and correction of metabolic acidosis. In the following conditions it may help to sustain vital functions and thus provide time for treatment of the primary disease: Metabolic Acidosis Associated with Cardiac Bypass Surgery. Tham Solution has been found to be primarily beneficial in correcting metabolic acidosis which may occur during or immediately following cardiac bypass surgical procedures. Correction of Acidity of ACD Blood in Cardiac Bypass Surgery. It is well known that ACD blood is acidic and becomes more acidic on storage. Tromethamine effectively corrects this acidity. Tham Solution may be added directly to the blood used to prime the pump-oxygenator. When ACD blood is brought to a normal pH range the patient is spared an initial acid load. Additional tromethamine may be indicated during cardiac bypass surgery should metabolic acidosis appear. Metabolic Acidosis Associated with Cardiac Arrest. Acidosis is nearly always one of the consequences of cardiac arrest and, in some instances, may even be a causative factor in arrest. It is important therefore, that the correction of acidosis should be started promptly with other resuscitative efforts. By correcting acidosis, Tham Solution (tromethamine injection) has caused the arrested heart to respond to resuscitative efforts after standard methods alone had failed. In these cases, tromethamine was given intraventricularly. It is to be noted, however, that such precariously ill patients often have died subsequently of causes unrelated to the administration of tromethamine. With administration by the peripheral venous route, metabolic acidosis has been corrected in a majority of patients. The success in reinstitution of cardiac rhythm by this means probably has not been of the same order of magnitude as with the intraventricular route. uuid:497e13ea-80aa-47c6-9f24-3664d9982101 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9754 biolink:treats MONDO:0000745 PMID:41385096 "[{""id"":""uuid:5443136f-d0a4-477a-be57-6209676db805"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8e69868b-cd41-45d6-8bce-fef9a1e4bd53"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tham Solution (tromethamine injection) is indicated for the prevention and correction of metabolic acidosis. In the following conditions it may help to sustain vital functions and thus provide time for treatment of the primary disease: Metabolic Acidosis Associated with Cardiac Bypass Surgery. Tham Solution has been found to be primarily beneficial in correcting metabolic acidosis which may occur during or immediately following cardiac bypass surgical procedures. Correction of Acidity of ACD Blood in Cardiac Bypass Surgery. It is well known that ACD blood is acidic and becomes more acidic on storage. Tromethamine effectively corrects this acidity. Tham Solution may be added directly to the blood used to prime the pump-oxygenator. When ACD blood is brought to a normal pH range the patient is spared an initial acid load. Additional tromethamine may be indicated during cardiac bypass surgery should metabolic acidosis appear. Metabolic Acidosis Associated with Cardiac Arrest. Acidosis is nearly always one of the consequences of cardiac arrest and, in some instances, may even be a causative factor in arrest. It is important therefore, that the correction of acidosis should be started promptly with other resuscitative efforts. By correcting acidosis, Tham Solution (tromethamine injection) has caused the arrested heart to respond to resuscitative efforts after standard methods alone had failed. In these cases, tromethamine was given intraventricularly. It is to be noted, however, that such precariously ill patients often have died subsequently of causes unrelated to the administration of tromethamine. With administration by the peripheral venous route, metabolic acidosis has been corrected in a majority of patients. The success in reinstitution of cardiac rhythm by this means probably has not been of the same order of magnitude as with the intraventricular route. uuid:cea836e6-2d7f-4ee1-b66d-c0b5639fdd21 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:205919 biolink:treats MONDO:0005093 PMID:41385096 "[{""id"":""uuid:5d5c1ec5-d87b-4198-a273-ecce6de50378"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6f02aa5c-dc6d-4126-a20d-17e84a472e5d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tovet Foam is indicated for the treatment of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 12 years and older. uuid:d2f23e2c-6daf-4451-85da-4df32dcda872 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135920 biolink:treats UMLS:C0341736 PMID:41385096 "[{""id"":""uuid:f6a00e1a-9858-456f-acd0-cf56386d1ede"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4fc80731-1bd0-42c1-b6c7-a7164c080d6c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Toviaz is indicated for the treatment of: • Overactive bladder (OAB) in adults with symptoms of urge urinary incontinence, urgency, and frequency. ( 1.1 ) • Neurogenic detrusor overactivity (NDO) in pediatric patients 6 years of age and older and weighing greater than 25 kg. ( 1.2 ) uuid:981c8b8d-8f03-4c41-b7d7-826e03ac4dda biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29108 biolink:treats MONDO:0005300 PMID:41385096 "[{""id"":""uuid:98035875-6a66-4755-b9f9-37be29bc60da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c4a12f5a-fea4-4129-a4d3-955620a9e54e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELFLEX® is indicated in the treatment of chronic kidney failure in patients being maintained on peritoneal dialysis. uuid:8b248d17-fe18-4166-be04-2fb7afbd11da biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2562180 biolink:treats MONDO:0005302 PMID:41385096 "[{""id"":""uuid:30d37e04-f5aa-4bd6-ada1-b885ea8f7bed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:25023c77-e069-4a35-817f-61ab59a3de85"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dexmethylphenidate hydrochloride tablets are indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) [see Clinical Studies (14)] . uuid:f5d65e9a-6b15-4bc0-9e19-fa50572c22b9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135957 biolink:treats MONDO:0005556 PMID:41385096 "[{""id"":""uuid:f0dc89f7-7a33-4590-8459-d03baf5383d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:c36213b9-fce6-4faf-8f93-33fa542c6570"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e702f6d2-d4e2-4f39-a50e-04b08742a7a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/lupkynis""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] LUPKYNIS is indicated in combination with a background immunosuppressive therapy regimen [see Clinical Studies ( 14 )] for the treatment of adult patients with active lupus nephritis (LN). Limitations of Use: Safety and efficacy of LUPKYNIS have not been established in combination with cyclophosphamide. Use of LUPKYNIS is not recommended in this situation.|[EMA] Lupkynis is indicated in combination with mycophenolate mofetil for the treatment of adult patients with active class III, IV or V (including mixed class III/V and IV/V) lupus nephritis (LN). uuid:544f00e9-9ea4-4bfb-9fec-5560449778a3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135957 biolink:treats MONDO:0002486 PMID:41385096 "[{""id"":""uuid:16adc015-a70f-4af6-b228-c66028ec9dd2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:96153e09-23f3-40b8-bb2f-22f98a44b7e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LUPKYNIS is indicated in combination with a background immunosuppressive therapy regimen [see Clinical Studies ( 14 )] for the treatment of adult patients with active lupus nephritis (LN). Limitations of Use: Safety and efficacy of LUPKYNIS have not been established in combination with cyclophosphamide. Use of LUPKYNIS is not recommended in this situation. uuid:fbaabca2-8700-4898-b9c1-08526c9ed741 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:39112 biolink:treats MONDO:0011996 PMID:41385096 "[{""id"":""uuid:d140fa36-5804-4e7c-ac8f-f1964bd33097"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b8e20428-9532-4f10-a631-932490f186ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:a102bda4-3f28-4869-b313-3812a397ac29"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c998ebb8-8a38-4d9d-8875-76fb400cd528"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BOSULIF is indicated for the treatment of: • Adult and pediatric patients 1 year of age and older with chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML), newly-diagnosed or resistant or intolerant to prior therapy [see Clinical Studies ( 14.1 , 14.2 , 14.3 )] . • Adult patients with accelerated phase (AP), or blast phase (BP) Ph+ CML with resistance or intolerance to prior therapy [see Clinical Studies (14.2) ] .|[EMA] Bosulif is indicated for the treatment of adult patients with:newly‑diagnosed chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukaemia (Ph+ CML).CP, accelerated phase (AP), and blast phase (BP) Ph+ CML previously treated with one or more tyrosine kinase inhibitor(s) [TKI(s)] and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.|[PMDA] A drug with a new active ingredient indicated for the treatment of chronic myelogenous leukemia with resistance or intolerance to prior drug therapies. [Orphan drug] uuid:8d1829dd-0d58-4638-8ddd-a53640d00344 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:39112 biolink:treats MONDO:0021367 PMID:41385096 "[{""id"":""uuid:c26b35e8-f9bf-48a5-9295-935cab409992"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:3f80ccb1-0c20-4b90-b77e-160cdf6466cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:3b704190-ed0a-46c7-819a-123d329daad9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BOSULIF is indicated for the treatment of: • Adult and pediatric patients 1 year of age and older with chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML), newly-diagnosed or resistant or intolerant to prior therapy [see Clinical Studies ( 14.1 , 14.2 , 14.3 )] . • Adult patients with accelerated phase (AP), or blast phase (BP) Ph+ CML with resistance or intolerance to prior therapy [see Clinical Studies (14.2) ] .|[EMA] Bosulif is indicated for the treatment of adult patients with:newly‑diagnosed chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukaemia (Ph+ CML).CP, accelerated phase (AP), and blast phase (BP) Ph+ CML previously treated with one or more tyrosine kinase inhibitor(s) [TKI(s)] and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options. uuid:fa8bf4b4-847f-48e3-a263-845207a66015 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:39112 biolink:treats MONDO:0006115 PMID:41385096 "[{""id"":""uuid:4151390c-d8f4-4b75-bd89-3b216b45b36b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:76104348-1760-4dcf-9bd4-819caa36eee4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:a043eeaf-a737-4fba-9059-7443bf1029ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BOSULIF is indicated for the treatment of: • Adult and pediatric patients 1 year of age and older with chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML), newly-diagnosed or resistant or intolerant to prior therapy [see Clinical Studies ( 14.1 , 14.2 , 14.3 )] . • Adult patients with accelerated phase (AP), or blast phase (BP) Ph+ CML with resistance or intolerance to prior therapy [see Clinical Studies (14.2) ] .|[EMA] Bosulif is indicated for the treatment of adult patients with:newly‑diagnosed chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukaemia (Ph+ CML).CP, accelerated phase (AP), and blast phase (BP) Ph+ CML previously treated with one or more tyrosine kinase inhibitor(s) [TKI(s)] and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options. uuid:83202b75-33c2-4470-97ea-965c309e57c5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:760I9WM792 biolink:treats MONDO:0005475 PMID:41385096 "[{""id"":""uuid:244fa456-9d36-4f4f-9e5d-57d3ee01c332"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:453e47bf-0406-4d35-a979-9fbfc9350853"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] REYVOW ® is indicated for the acute treatment of migraine with or without aura in adults. uuid:56efd7e7-2220-4c14-a894-1352ddd5e76c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:760I9WM792 biolink:treats MONDO:0100431 PMID:41385096 "[{""id"":""uuid:b47ffb51-efed-4909-9d28-490e42c2446c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bf498608-b00d-4ac5-a993-e424a6676261"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] REYVOW ® is indicated for the acute treatment of migraine with or without aura in adults. uuid:46a662bc-f67e-4fc0-ba34-9506741b05da biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:174856 biolink:treats MONDO:0005984 PMID:41385096 "[{""id"":""uuid:efbe28d1-149f-4458-b53d-1f922ddd062a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:956344d4-a18e-4a0a-b28d-037e0b6cd81f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clotrimazole and betamethasone dipropionate cream is a combination of an azole antifungal and corticosteroid and is indicated for the topical treatment of symptomatic inflammatory tinea pedis, tinea cruris, and tinea corporis due to Epidermophyton floccosum, Trichophyton mentagrophytes, and Trichophyton rubrum in patients 17 years and older. uuid:3895a42c-8609-4f9c-a665-458bf2cfe18d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:174856 biolink:treats MONDO:0001405 PMID:41385096 "[{""id"":""uuid:0c837b64-22be-4f40-929b-7d46fae1366b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d408fb80-960b-4bb4-b1d6-4edf0c7792cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clotrimazole and betamethasone dipropionate cream is a combination of an azole antifungal and corticosteroid and is indicated for the topical treatment of symptomatic inflammatory tinea pedis, tinea cruris, and tinea corporis due to Epidermophyton floccosum, Trichophyton mentagrophytes, and Trichophyton rubrum in patients 17 years and older. uuid:809398e6-720a-42a9-9c58-1e780ffe86bc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:174856 biolink:treats MONDO:0001461 PMID:41385096 "[{""id"":""uuid:64613c53-3ccb-4c5c-9f7a-d09f8483af67"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:074386e0-0547-4194-95e9-20edac1a4bf9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clotrimazole and betamethasone dipropionate cream is a combination of an azole antifungal and corticosteroid and is indicated for the topical treatment of symptomatic inflammatory tinea pedis, tinea cruris, and tinea corporis due to Epidermophyton floccosum, Trichophyton mentagrophytes, and Trichophyton rubrum in patients 17 years and older. uuid:9eb5c3e9-a2cb-4976-a28d-94e5ec3fd4ec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:O880NM097T biolink:treats MONDO:0012105 PMID:41385096 "[{""id"":""uuid:ebbcffa3-6ff0-40ba-8979-c084391b676d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e12b550f-4fed-409d-88cf-41acfb06d125"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:b06fe3e4-43f4-454d-8964-094281350711"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/tavneos""]},{""id"":""uuid:6696a740-6463-4f75-bf58-9e8d73a72fcd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TAVNEOS is indicated as an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis [GPA] and microscopic polyangiitis [MPA]) in combination with standard therapy including glucocorticoids. TAVNEOS does not eliminate glucocorticoid use.|[EMA] Tavneos, in combination with a rituximab or cyclophosphamide regimen, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA).|[PMDA] A drug with a new active ingredient indicated for the treatment of microscopic polyangiitis and granulomatosis with polyangiitis. [Orphan drug] uuid:632c24d3-7651-40f4-b94f-0a2a99d7b574 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:O880NM097T biolink:treats MONDO:0019124 PMID:41385096 "[{""id"":""uuid:7e5f0473-20d6-4aa6-9942-88dcb76d8d13"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:44fca786-6879-41d0-9e4c-5cc8e1b3b34a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:68f17450-6fda-42e3-9d67-9fcee92ce81e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/tavneos""]},{""id"":""uuid:12900328-f5bc-49ef-81fa-e1c963b7afb9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TAVNEOS is indicated as an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis [GPA] and microscopic polyangiitis [MPA]) in combination with standard therapy including glucocorticoids. TAVNEOS does not eliminate glucocorticoid use.|[EMA] Tavneos, in combination with a rituximab or cyclophosphamide regimen, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA).|[PMDA] A drug with a new active ingredient indicated for the treatment of microscopic polyangiitis and granulomatosis with polyangiitis. [Orphan drug] uuid:a0d5fc5a-6c6b-4e62-992d-fb06cc381121 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47381 biolink:treats MONDO:0005277 PMID:41385096 "[{""id"":""uuid:2df7b4ec-5287-459b-be1f-ef79cb696391"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8425bc4b-5b7c-464b-ae9c-7e117fc883d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CAMBIA is indicated for the acute treatment of migraine attacks with or without aura in adults (18 years of age or older). Limitations of Use: CAMBIA is not indicated for the prophylactic therapy of migraine. The safety and effectiveness of CAMBIA have not been established for cluster headache, which is present in an older, predominantly male population. uuid:044c303b-08a9-49c4-a399-3ff808e5b4c8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:216989 biolink:treats NCIT:C3837 PMID:41385096 "[{""id"":""uuid:8994ec35-205c-4784-b3dd-f0737733ed43"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6890b1b3-aa37-494d-8509-4c91d6e65231"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Esterified Estrogens and Methyltestosterone Full and Half-Strength Tablets are indicated in the: • Treatment of moderate to severe vasomotor symptoms associated with the menopause in those patients not improved by estrogens alone. (There is no evidence that estrogens are effective for nervous symptoms or depression without associated vasomotor symptoms, and they should not be used to treat such conditions.) • Esterified Estrogens and Methyltestosterone Full and Half-Strength Tablets have not been shown to be effective for any purpose during pregnancy and its use may cause severe harm to the fetus. uuid:9af2b192-68c2-424b-b2a3-131bbec0a1fd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:216989 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:fc6f94e6-ded8-4302-ab2e-f205a2ba24bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2f1e9a69-f6a8-461b-9fae-6ce10e9c49e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Esterified Estrogens and Methyltestosterone Full and Half-Strength Tablets are indicated in the: • Treatment of moderate to severe vasomotor symptoms associated with the menopause in those patients not improved by estrogens alone. (There is no evidence that estrogens are effective for nervous symptoms or depression without associated vasomotor symptoms, and they should not be used to treat such conditions.) • Esterified Estrogens and Methyltestosterone Full and Half-Strength Tablets have not been shown to be effective for any purpose during pregnancy and its use may cause severe harm to the fetus. uuid:bdb00ff4-8f48-4c01-a92a-1383fcf72914 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17141 biolink:treats MONDO:0100151 PMID:41385096 "[{""id"":""uuid:31e3a1fd-32b8-4053-ad56-a8767ca60083"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c671f5c4-e697-43ce-ba02-99facd5c449e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:9a87fa29-dbe0-4581-a59b-200e36670f66"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:3827a261-53bd-4422-9370-492cc5a5ebd8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CYSTAGON ® is indicated for the management of nephropathic cystinosis in children and adults.|[EMA] Procysbi is indicated for the treatment of proven nephropathic cystinosis. Cysteamine reduces cystine accumulation in some cells (e.g. leukocytes, muscle and liver cells) of nephropathic cystinosis patients and, when treatment is started early, it delays the development of renal failure.|[PMDA] Drugs with a new active ingredient indicated for the treatment of nephropathic cystinosis. [Orphan drug] uuid:1e6ec112-840f-4c2f-99ab-b6d7d1cb60d2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15765 biolink:treats MONDO:0005180 PMID:41385096 "[{""id"":""uuid:a0e59308-9301-4bed-ba16-c05d93ccc6e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:4773d893-67af-4482-951e-2b7a64b277c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:0bb6c89b-cc91-4ba0-b553-277f79b2dc25"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/inbrija""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] INBRIJA is indicated for the intermittent treatment of OFF episodes in patients with Parkinson's disease treated with carbidopa/levodopa.|[EMA] Inbrija is indicated for the intermittent treatment of episodic motor fluctuations (OFF episodes) in adult patients with Parkinson’s disease (PD) treated with a levodopa/dopa-decarboxylase inhibitor. uuid:c613c096-2b7f-47d1-a718-0a0fb5e27aa5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15765 biolink:treats UMLS:C5681154 PMID:41385096 "[{""id"":""uuid:2df87303-3964-4ff6-9e89-5ed1c62a0daa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:797cc096-91b9-4567-8042-881b1ccda505"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:fd5ff238-2f6c-4910-85a3-008d55e3c350"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/inbrija""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] INBRIJA is indicated for the intermittent treatment of OFF episodes in patients with Parkinson's disease treated with carbidopa/levodopa.|[EMA] Inbrija is indicated for the intermittent treatment of episodic motor fluctuations (OFF episodes) in adult patients with Parkinson’s disease (PD) treated with a levodopa/dopa-decarboxylase inhibitor. uuid:07e64717-dd64-4410-89ec-dc62383d73de biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7D0YB67S97 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:1d5f926f-8f12-4c63-8a99-3daeb66aeacf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c3116564-0a4f-4951-9860-588c1224ab57"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:a5ade6df-9b80-40cb-a8f5-51127e6b02b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/orencia""]},{""id"":""uuid:1aae7abc-5263-4003-898e-b32dd8e34a9b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ORENCIA is a selective T cell costimulation modulator indicated for: • the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA). (1.1) • the treatment of patients 2 years of age and older with moderately to severely active polyarticular juvenile idiopathic arthritis (pJIA). (1.2) • the treatment of patients 2 years of age and older with active psoriatic arthritis (PsA). (1.3) • the prophylaxis of acute graft versus host disease (aGVHD), in combination with a calcineurin inhibitor and methotrexate, in adults and pediatric patients 2 years of age and older undergoing hematopoietic stem cell transplantation (HSCT) from a matched or 1 allele-mismatched unrelated donor. (1.4) Limitations of Use: Concomitant use of ORENCIA with other immunosuppressives [e.g., biologic disease-modifying antirheumatic drugs (bDMARDS), Janus kinase (JAK) inhibitors] is not recommended ( 1.5 , 5.1) .|[EMA] Rheumatoid arthritisOrencia, in combination with methotrexate, is indicated for:the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who responded inadequately to previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) including methotrexate (MTX) or a tumour necrosis factor (TNF)-alpha inhibitor.the treatment of highly active and progressive disease in adult patients with rheumatoid arthritis not previously treated with methotrexate.A reduction in the progression of joint damage and improvement of physical function have been demonstrated during combination treatment with abatacept and methotrexate.Psoriatic arthritisOrencia, alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis (PsA) in adult patients when the response to previous DMARD therapy including MTX has been inadequate, and for whom additional systemic therapy for psoriatic skin lesions is not required. Polyarticular juvenile idiopathic arthritisOrencia in combination with methotrexate is indicated for the treatment of moderate to severe active polyarticular juvenile idiopathic arthritis (pJIA) in paediatric patients 2 years of age and older who have had an inadequate response to previous DMARD therapy.Orencia can be given as monotherapy in case of intolerance to methotrexate or when treatment with methotrexate is inappropriate.|[PMDA] A drug with a new route of administration and a new dosage in a new dosage form indicated for the treatment of rheumatoid arthritis in patients who have not responded sufficiently to conventional treatments. uuid:e9bf67c6-1632-423a-91a7-da1bfeaf1f9e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7D0YB67S97 biolink:treats MONDO:0018456 PMID:41385096 "[{""id"":""uuid:60fae4a1-1788-4d9b-b182-cf3860943ffe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:0d7df398-7713-4e71-9082-8d04cdd1a5d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:2454435e-595e-4fc0-8e31-69a91ba459c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/orencia""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] ORENCIA is a selective T cell costimulation modulator indicated for: • the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA). (1.1) • the treatment of patients 2 years of age and older with moderately to severely active polyarticular juvenile idiopathic arthritis (pJIA). (1.2) • the treatment of patients 2 years of age and older with active psoriatic arthritis (PsA). (1.3) • the prophylaxis of acute graft versus host disease (aGVHD), in combination with a calcineurin inhibitor and methotrexate, in adults and pediatric patients 2 years of age and older undergoing hematopoietic stem cell transplantation (HSCT) from a matched or 1 allele-mismatched unrelated donor. (1.4) Limitations of Use: Concomitant use of ORENCIA with other immunosuppressives [e.g., biologic disease-modifying antirheumatic drugs (bDMARDS), Janus kinase (JAK) inhibitors] is not recommended ( 1.5 , 5.1) .|[EMA] Rheumatoid arthritisOrencia, in combination with methotrexate, is indicated for:the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who responded inadequately to previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) including methotrexate (MTX) or a tumour necrosis factor (TNF)-alpha inhibitor.the treatment of highly active and progressive disease in adult patients with rheumatoid arthritis not previously treated with methotrexate.A reduction in the progression of joint damage and improvement of physical function have been demonstrated during combination treatment with abatacept and methotrexate.Psoriatic arthritisOrencia, alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis (PsA) in adult patients when the response to previous DMARD therapy including MTX has been inadequate, and for whom additional systemic therapy for psoriatic skin lesions is not required. Polyarticular juvenile idiopathic arthritisOrencia in combination with methotrexate is indicated for the treatment of moderate to severe active polyarticular juvenile idiopathic arthritis (pJIA) in paediatric patients 2 years of age and older who have had an inadequate response to previous DMARD therapy.Orencia can be given as monotherapy in case of intolerance to methotrexate or when treatment with methotrexate is inappropriate. uuid:c791c970-b923-4394-b617-95450c7fe133 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7D0YB67S97 biolink:treats MONDO:0011849 PMID:41385096 "[{""id"":""uuid:80175cf7-dd75-4feb-9e73-4b10288dc1f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:55ad2036-3917-4051-8766-7fa818582261"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:642e8156-cf59-4802-939c-1979464cc763"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/orencia""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] ORENCIA is a selective T cell costimulation modulator indicated for: • the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA). (1.1) • the treatment of patients 2 years of age and older with moderately to severely active polyarticular juvenile idiopathic arthritis (pJIA). (1.2) • the treatment of patients 2 years of age and older with active psoriatic arthritis (PsA). (1.3) • the prophylaxis of acute graft versus host disease (aGVHD), in combination with a calcineurin inhibitor and methotrexate, in adults and pediatric patients 2 years of age and older undergoing hematopoietic stem cell transplantation (HSCT) from a matched or 1 allele-mismatched unrelated donor. (1.4) Limitations of Use: Concomitant use of ORENCIA with other immunosuppressives [e.g., biologic disease-modifying antirheumatic drugs (bDMARDS), Janus kinase (JAK) inhibitors] is not recommended ( 1.5 , 5.1) .|[EMA] Rheumatoid arthritisOrencia, in combination with methotrexate, is indicated for:the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who responded inadequately to previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) including methotrexate (MTX) or a tumour necrosis factor (TNF)-alpha inhibitor.the treatment of highly active and progressive disease in adult patients with rheumatoid arthritis not previously treated with methotrexate.A reduction in the progression of joint damage and improvement of physical function have been demonstrated during combination treatment with abatacept and methotrexate.Psoriatic arthritisOrencia, alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis (PsA) in adult patients when the response to previous DMARD therapy including MTX has been inadequate, and for whom additional systemic therapy for psoriatic skin lesions is not required. Polyarticular juvenile idiopathic arthritisOrencia in combination with methotrexate is indicated for the treatment of moderate to severe active polyarticular juvenile idiopathic arthritis (pJIA) in paediatric patients 2 years of age and older who have had an inadequate response to previous DMARD therapy.Orencia can be given as monotherapy in case of intolerance to methotrexate or when treatment with methotrexate is inappropriate. uuid:87b0315d-8049-4726-966e-7f5db7357870 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7D0YB67S97 biolink:treats MONDO:0020546 PMID:41385096 "[{""id"":""uuid:ffddcd7f-d4c6-44a5-a913-355e9ac27126"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:339b09f0-e436-4792-af19-fa2ee5c50c14"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ORENCIA is a selective T cell costimulation modulator indicated for: • the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA). (1.1) • the treatment of patients 2 years of age and older with moderately to severely active polyarticular juvenile idiopathic arthritis (pJIA). (1.2) • the treatment of patients 2 years of age and older with active psoriatic arthritis (PsA). (1.3) • the prophylaxis of acute graft versus host disease (aGVHD), in combination with a calcineurin inhibitor and methotrexate, in adults and pediatric patients 2 years of age and older undergoing hematopoietic stem cell transplantation (HSCT) from a matched or 1 allele-mismatched unrelated donor. (1.4) Limitations of Use: Concomitant use of ORENCIA with other immunosuppressives [e.g., biologic disease-modifying antirheumatic drugs (bDMARDS), Janus kinase (JAK) inhibitors] is not recommended ( 1.5 , 5.1) . uuid:f2b74ef1-82aa-4ff6-b404-7cebb5b477e8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7SE5582Q2P biolink:treats MONDO:0007037 PMID:41385096 "[{""id"":""uuid:b650494d-e4b1-4b9f-9349-603187c487c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6c9dd8ab-1d41-4f94-a5d1-efa4190b099b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:1d0b0223-2efb-456e-9c83-7ce09db8339a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/voxzogo""]},{""id"":""uuid:3b1e8e05-62c0-4a4e-a09c-887ec469273d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VOXZOGO is indicated to increase linear growth in pediatric patients with achondroplasia with open epiphyses. This indication is approved under accelerated approval based on an improvement in annualized growth velocity [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).|[EMA] Voxzogo is indicated for the treatment of achondroplasia in patients 4 months of age and older whose epiphyses are not closed. The diagnosis of achondroplasia should be confirmed by appropriate genetic testing.|[PMDA] Drugs with a new active ingredient indicated for the treatment of achondroplasia prior to epiphyseal closure. [Orphan drug] uuid:6a98744b-3a48-43fd-8bf6-27ca815d2d88 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:87PZU03K0K biolink:treats MONDO:0005300 PMID:41385096 "[{""id"":""uuid:1cc82790-9a18-46e3-9053-265346386c6f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:131d676e-1a10-43af-85c0-27d787f7c73a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Velphoro is indicated for the control of serum phosphorus levels in adults and pediatric patients 9 years of age and older with chronic kidney disease (CKD) on dialysis. uuid:754c1f3f-d2d2-4017-9ea5-c84ff3305136 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:73B0K5S26A biolink:treats MONDO:0005556 PMID:41385096 "[{""id"":""uuid:018f9e1f-7d79-40c7-9eb4-d83359af0e42"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:37c340c7-9458-4d2d-92d0-ceef2a66b474"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ad794f79-3d0e-49e0-985b-5e5491a47bb3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/benlysta""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] BENLYSTA (belimumab) is indicated for the treatment of: • patients 5 years of age and older with active systemic lupus erythematosus (SLE) who are receiving standard therapy, and • patients 5 years of age and older with active lupus nephritis who are receiving standard therapy. Limitations of Use The efficacy of BENLYSTA has not been evaluated in patients with severe active central nervous system (CNS) lupus. Use of BENLYSTA is not recommended in this situation.|[EMA] Benlysta is indicated as add-on therapy in patients aged 5 years and older with active, autoantibody positive systemic lupus erythematosus (SLE) with a high degree of disease activity (e.g., positive anti dsDNA and low complement) despite standard therapy.Benlysta is indicated in combination with background immunosuppressive therapies for the treatment of adult patients with active lupus nephritis. uuid:134b1dc6-3475-442f-8502-a400136d8c5c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:84050 biolink:treats MONDO:0005060 PMID:41385096 "[{""id"":""uuid:69e2b112-5d9b-4aa1-8529-8f44b714f296"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:778078d7-de0c-4642-847a-aebc1c3901ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:2a6962bd-0435-4df0-b623-7c4fafe9dcd2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/yondelis""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] YONDELIS ® is indicated for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen [see Clinical Studies (14) ] .|[EMA] Yondelis is indicated for the treatment of patients with advanced soft-tissue sarcoma, after failure of anthracyclines and ifosfamide, or who are unsuited to receive these agents. Efficacy data are based mainly on liposarcoma and leiomyosarcoma patients.Yondelis in combination with pegylated liposomal doxorubicin (PLD) is indicated for the treatment of patients with relapsed platinum-sensitive ovarian cancer. uuid:1054e02b-4ea6-4428-8cd7-60c8c8335c31 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:84050 biolink:treats MONDO:0005058 PMID:41385096 "[{""id"":""uuid:1f654f73-8574-4271-b042-ba7efe59b6f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:80f160a5-eb48-4009-bc25-b762ffed6072"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:8ed846b8-0ede-4493-b599-7b2c076c097c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/yondelis""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] YONDELIS ® is indicated for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen [see Clinical Studies (14) ] .|[EMA] Yondelis is indicated for the treatment of patients with advanced soft-tissue sarcoma, after failure of anthracyclines and ifosfamide, or who are unsuited to receive these agents. Efficacy data are based mainly on liposarcoma and leiomyosarcoma patients.Yondelis in combination with pegylated liposomal doxorubicin (PLD) is indicated for the treatment of patients with relapsed platinum-sensitive ovarian cancer. uuid:33f558b5-0617-470f-8a56-ce0812d38c3a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18358 biolink:treats MONDO:0015758 PMID:41385096 "[{""id"":""uuid:7b311c54-5f3c-4be2-aee8-83f036317c45"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:650dc3fb-b1e5-4c01-8e76-27e4c0fb3bb9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] UVADEX ® (methoxsalen) Sterile Solution is indicated for extracorporeal administration with the THERAKOS ® CELLEX ® Photopheresis System in the palliative treatment of the skin manifestations of Cutaneous T-Cell Lymphoma (CTCL) that is unresponsive to other forms of treatment. uuid:ab2ae1ea-aa1a-41d5-b8f8-c978580c9307 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:8680B21W73 biolink:treats UMLS:C1720505 PMID:41385096 "[{""id"":""uuid:4b34fd5c-b609-4a02-ac10-bf78a486b5c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e0ca9895-ce7a-4c60-8b62-2547c95767f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MACRILEN is indicated for the diagnosis of adult growth hormone deficiency (AGHD). uuid:f8b728de-6031-49e2-8fb3-fd2e17bae6ce biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63577 biolink:treats MONDO:0100192 PMID:41385096 "[{""id"":""uuid:d4be3f46-17cc-4b96-87ed-4cdf324a93be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aab3db07-0efa-46e2-8790-9cccf31194d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lamivudine tablets (HBV) are indicated for the treatment of chronic hepatitis B virus (HBV) infection associated with evidence of hepatitis B viral replication and active liver inflammation [see Clinical Studies ( 14.1 , 14.2 )]. The following points should be considered when initiating therapy with Lamivudine tablets (HBV): • Due to high rates of resistance development in treated patients, initiation of treatment with Lamivudine tablets (HBV) should only be considered when the use of an alternative antiviral agent with a higher genetic barrier to resistance is not available or appropriate. • Lamivudine tablets (HBV) have not been evaluated in patients co-infected with human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis delta virus. • Lamivudine tablets (HBV) have not been evaluated in liver transplant recipients or in patients with chronic hepatitis B virus infection with decompensated liver disease. uuid:7e6af724-534b-419b-b0f0-8fd34d53223f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:BTY153760O biolink:treats UMLS:C0406317 PMID:41385096 "[{""id"":""uuid:832e4786-72cd-45bc-97eb-0959b9bc4ba0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a7f5c612-35ce-45f0-bb39-08cf668f2813"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:82d05cf4-8642-4aac-93f7-e1d53ea16bdc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TALTZ ® is a humanized interleukin-17A antagonist indicated for the treatment of: patients aged 6 years or older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. ( 1.1 ) adults with active psoriatic arthritis. ( 1.2 ) adults with active ankylosing spondylitis. ( 1.3 ) adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation. ( 1.4 )|[PMDA] Drugs with a new active ingredient indicated for the treatment of plaque psoriasis, psoriatic arthritis, pustular psoriasis, and erythrodermic psoriasis in patients who have not responded sufficiently to conventional therapies. uuid:9c6bcd2c-b092-44a0-91a6-997b539d1d07 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:BTY153760O biolink:treats MONDO:0011849 PMID:41385096 "[{""id"":""uuid:863712ce-3269-4892-997a-edd13599bbb3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2a2c9798-a960-4a13-aadb-db193ec3ec85"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:2d2a84b1-7c2a-4141-aefe-fc23334ca5bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/taltz""]},{""id"":""uuid:84e54b9c-ce8c-4107-aaeb-0616129f4eb6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TALTZ ® is a humanized interleukin-17A antagonist indicated for the treatment of: patients aged 6 years or older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. ( 1.1 ) adults with active psoriatic arthritis. ( 1.2 ) adults with active ankylosing spondylitis. ( 1.3 ) adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation. ( 1.4 )|[EMA] Plaque psoriasisTaltz is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.Psoriatic arthritisTaltz, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drug (DMARD) therapies.|[PMDA] Drugs with a new active ingredient indicated for the treatment of plaque psoriasis, psoriatic arthritis, pustular psoriasis, and erythrodermic psoriasis in patients who have not responded sufficiently to conventional therapies. uuid:5263e033-a5e5-4449-859f-71785409aac3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:BTY153760O biolink:treats MONDO:0005306 PMID:41385096 "[{""id"":""uuid:e5f4de24-8c34-4656-bda7-3f539a53d2b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a9b1dad2-5ebc-444e-b112-ef224a91f678"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:1665e3a1-fdef-4a48-912c-018c6534b6a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TALTZ ® is a humanized interleukin-17A antagonist indicated for the treatment of: patients aged 6 years or older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. ( 1.1 ) adults with active psoriatic arthritis. ( 1.2 ) adults with active ankylosing spondylitis. ( 1.3 ) adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation. ( 1.4 )|[PMDA] Drugs with a new additional indication and a new dosage for the treatment of ankylosing spondylitis in patients who have not responded sufficiently to conventional treatments. uuid:398b6085-d966-4313-be2d-92f5561ac9db biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:BTY153760O biolink:treats UMLS:C3203547 PMID:41385096 "[{""id"":""uuid:b70cffbd-8448-48f6-abd4-688468316194"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:39fe115f-eab3-44e7-b043-1d03b6c80f0c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:628ef5ca-4093-409c-b71c-92fe12d2c607"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TALTZ ® is a humanized interleukin-17A antagonist indicated for the treatment of: patients aged 6 years or older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. ( 1.1 ) adults with active psoriatic arthritis. ( 1.2 ) adults with active ankylosing spondylitis. ( 1.3 ) adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation. ( 1.4 )|[PMDA] Drugs with a new indication and a new dosage for the treatment of non-radiographic axial spondyloarthritis in patients who have not responded sufficiently to conventional treatments. uuid:0f58fa3e-e8e7-46c9-97ea-cd3c17b134ca biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:78543 biolink:treats MONDO:0011996 PMID:41385096 "[{""id"":""uuid:483b3931-ea8d-46ee-b0bb-6ed2148ab1bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d3f2ff46-af44-4f7c-8b3f-c7b39f5821d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:80306630-baeb-4200-a5d0-be9c2f2abe04"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/iclusig""]},{""id"":""uuid:399090d6-51ed-4655-b4b7-7ab09e50c9db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ICLUSIG is indicated for the treatment of adult patients with: Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Newly diagnosed Ph+ ALL in combination with chemotherapy. This indication is approved under accelerated approval based on minimal residual disease (MRD)-negative complete remission (CR) at the end of induction [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s). As monotherapy in Ph+ ALL for whom no other kinase inhibitors are indicated or T315I-positive Ph+ ALL. Chronic Myeloid Leukemia (CML) Chronic phase (CP) CML with resistance or intolerance to at least two prior kinase inhibitors. Accelerated phase (AP) or blast phase (BP) CML for whom no other kinase inhibitors are indicated. T315I-positive CML (chronic phase, accelerated phase, or blast phase).|[EMA] Iclusig is indicated in adult patients withchronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (CML) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutationPhiladelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation.See sections 4.2 Assessment of cardiovascular status prior to start of therapy and 4.4 situations where an alternative treatment may be considered.|[PMDA] A drug with a new active ingredient indicated for the treatment of chronic myelogenous leukemia with resistance or intolerance to prior drug therapies, and recurrent or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia. [Orphan drug] uuid:99b00ee0-e551-4e17-84eb-cfab8f2e5c14 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63626 biolink:treats MONDO:0006573 PMID:41385096 "[{""id"":""uuid:0b09f3c4-9887-4a83-83bd-8733ccbba2f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8df9f6fd-3c3b-478b-a17b-62e50a5fa4eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EGRIFTA SV is indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy. Limitations of Use: Long-term cardiovascular safety of EGRIFTA SV has not been established. Consider risk/benefit of continuation of treatment in patients who have not had a reduction in visceral adipose tissue. EGRIFTA SV is not indicated for weight loss management as it has a weight neutral effect. There are no data to support improved compliance with anti-retroviral therapies in HIV-positive patients taking EGRIFTA SV. uuid:6ded1ddf-fb25-4616-83f3-e513ddc9fe46 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0006050 biolink:treats HP:0006986 PMID:41385096 "[{""id"":""uuid:85056799-6af3-4a90-a157-ff38433655f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8ed68e40-798c-4d10-9ba6-af1120bbdb51"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XEOMIN is an acetylcholine release inhibitor and neuromuscular blocking agent indicated for the treatment or improvement of: Chronic sialorrhea in patients 2 years of age and older ( 1.1 ) Upper limb spasticity in adults ( 1.2 ) Upper limb spasticity in pediatric patients 2 to 17 years of age, excluding spasticity caused by cerebral palsy ( 1.2 ) Cervical dystonia in adults ( 1.3 ) Blepharospasm in adults ( 1.4 ) the appearance of upper facial lines in adults: moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity ( 1.5 ) moderate to severe horizontal forehead lines associated with frontalis muscle activity ( 1.5 ) moderate to severe lateral canthal lines associated with orbicularis oculi muscle activity ( 1.5 ) DRUGBANK:DB00083 uuid:ccdcb007-2230-40e2-8df9-fff12dcc2e71 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0006050 biolink:treats MONDO:0011728 PMID:41385096 "[{""id"":""uuid:cb2d52c5-a5c3-4d6c-95ae-cc3e85abf897"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2f0dcade-23f1-496a-aa4c-28b10e9490de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XEOMIN is an acetylcholine release inhibitor and neuromuscular blocking agent indicated for the treatment or improvement of: Chronic sialorrhea in patients 2 years of age and older ( 1.1 ) Upper limb spasticity in adults ( 1.2 ) Upper limb spasticity in pediatric patients 2 to 17 years of age, excluding spasticity caused by cerebral palsy ( 1.2 ) Cervical dystonia in adults ( 1.3 ) Blepharospasm in adults ( 1.4 ) the appearance of upper facial lines in adults: moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity ( 1.5 ) moderate to severe horizontal forehead lines associated with frontalis muscle activity ( 1.5 ) moderate to severe lateral canthal lines associated with orbicularis oculi muscle activity ( 1.5 ) DRUGBANK:DB00083 uuid:185514af-fc68-44fd-922f-1e80caea5fda biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1655924 biolink:treats MONDO:0009061 PMID:41385096 "[{""id"":""uuid:0c7bc6c6-441e-4c2b-94ca-5aeca0f28a0c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:14d22e59-914c-4562-8c96-b17a99b2d1c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ORKAMBI is indicated for the treatment of cystic fibrosis (CF) in patients aged 1 year and older who are homozygous for the F508del mutation in the CFTR gene. If the patient's genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of the F508del mutation on both alleles of the CFTR gene. uuid:2c50fa2d-0d93-4aea-8f20-e3f57df02235 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:QMS40680K6 biolink:treats MONDO:0005588 PMID:41385096 "[{""id"":""uuid:e1ebecde-4077-4661-ac9c-e3ac9a7f39e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:202d9f64-9b7e-4a0e-988c-41419524b1cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Kepivance is a mucocutaneous epithelial human growth factor indicated to decrease the incidence and duration of severe oral mucositis in patients with hematologic malignancies receiving myelotoxic therapy in the setting of autologous hematopoietic stem cell support. Kepivance is indicated as supportive care for preparative regimens predicted to result in ≥ WHO Grade 3 mucositis in the majority of patients. ( 1.1 ) Limitations of Use The safety and efficacy of Kepivance have not been established in patients with non-hematologic malignancies ( 1.2 , 5.1 ) Kepivance was not effective in decreasing the incidence of severe mucositis in patients with hematologic malignancies receiving myelotoxic therapy in the setting of allogeneic hematopoietic stem cell support. ( 1.2 , 14.3 ) Kepivance is not recommended for use with melphalan 200 mg/m 2 as a conditioning regimen ( 14.2 ). uuid:01d8e550-30b7-4ba4-86fe-2c4afe94b0fe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:QMS40680K6 biolink:treats NCIT:C157387 PMID:41385096 "[{""id"":""uuid:1f70087c-3cbb-4f3e-bfd2-d46327f8a9e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a17dfc74-babf-461c-a660-8357e1b98102"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Kepivance is a mucocutaneous epithelial human growth factor indicated to decrease the incidence and duration of severe oral mucositis in patients with hematologic malignancies receiving myelotoxic therapy in the setting of autologous hematopoietic stem cell support. Kepivance is indicated as supportive care for preparative regimens predicted to result in ≥ WHO Grade 3 mucositis in the majority of patients. ( 1.1 ) Limitations of Use The safety and efficacy of Kepivance have not been established in patients with non-hematologic malignancies ( 1.2 , 5.1 ) Kepivance was not effective in decreasing the incidence of severe mucositis in patients with hematologic malignancies receiving myelotoxic therapy in the setting of allogeneic hematopoietic stem cell support. ( 1.2 , 14.3 ) Kepivance is not recommended for use with melphalan 200 mg/m 2 as a conditioning regimen ( 14.2 ). uuid:cb6ac97f-7410-40ac-9f47-b941e300ed6b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:I60W9520VV biolink:treats UMLS:C5438213 PMID:41385096 "[{""id"":""uuid:28b6895a-2e5b-482a-aa0e-8ee625b30aa1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e887cc9e-c5dd-44d7-a268-868a66415d28"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VAFSEO is indicated for the treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least three months. Limitations of Use VAFSEO has not been shown to improve quality of life, fatigue, or patient well-being. VAFSEO is not indicated for use: As a substitute for red blood cell transfusions in patients who require immediate correction of anemia In patients with anemia due to CKD not on dialysis [see Warnings and Precautions ( 5.6 )] . uuid:aabe390c-eafe-4e11-a3e4-eb2d1e694434 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:I60W9520VV biolink:treats MONDO:0002280 PMID:41385096 "[{""id"":""uuid:8ce5ca5a-3cbe-473d-aa4d-1ba7074c13fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a356a623-221d-4aa9-992b-4db711b39996"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:72f062e8-29fd-49bb-b838-8cb66371dbd8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/vafseo""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] VAFSEO is indicated for the treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least three months. Limitations of Use VAFSEO has not been shown to improve quality of life, fatigue, or patient well-being. VAFSEO is not indicated for use: As a substitute for red blood cell transfusions in patients who require immediate correction of anemia In patients with anemia due to CKD not on dialysis [see Warnings and Precautions ( 5.6 )] .|[EMA] Vafseo is indicated for the treatment of symptomatic anaemia associated with chronic kidney disease (CKD) in adults on chronic maintenance dialysis. uuid:08b25a73-056d-484c-b145-a2c24ab95c7d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:T1JP1KYU9O biolink:treats MONDO:0004975 PMID:41385096 "[{""id"":""uuid:582c80ce-c239-4c1a-9ce1-a7cf51054539"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cea95f7c-82ae-4c6b-a867-f14d69aec7c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TAUVID is indicated for use with positron emission tomography (PET) imaging of the brain to estimate the density and distribution of aggregated tau neurofibrillary tangles (NFTs) in adult patients with cognitive impairment who are being evaluated for Alzheimer's disease (AD). uuid:2bda1592-b6bc-4b4d-a6fe-f14a10513b12 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:T1JP1KYU9O biolink:treats HP:0100543 PMID:41385096 "[{""id"":""uuid:6e79f290-fd8f-4c26-ad9f-be3514734a3d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1768e44d-a882-4f4a-bb1b-0def592b9b0b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TAUVID is indicated for use with positron emission tomography (PET) imaging of the brain to estimate the density and distribution of aggregated tau neurofibrillary tangles (NFTs) in adult patients with cognitive impairment who are being evaluated for Alzheimer's disease (AD). uuid:b648545c-5c63-4047-a76d-c5bb056e97d7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50861 biolink:treats MONDO:0002429 PMID:41385096 "[{""id"":""uuid:b928c122-2354-4ff6-8568-6238bab41d1f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5f8a5f59-4a79-4257-baa7-8f9de438c509"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tyvaso is a prostacyclin mimetic indicated for the treatment of: Pulmonary arterial hypertension (PAH; WHO Group 1) to improve exercise ability. Studies establishing effectiveness predominately included patients with NYHA Functional Class III symptoms and etiologies of idiopathic or heritable PAH (56%) or PAH associated with connective tissue diseases (33%). ( 1.1 ) Pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability. The study establishing effectiveness predominately included patients with etiologies of idiopathic interstitial pneumonia (IIP) (45%) inclusive of idiopathic pulmonary fibrosis (IPF), combined pulmonary fibrosis and emphysema (CPFE) (25%), and WHO Group 3 connective tissue disease (22%). ( 1.2 ) uuid:d97f2329-198d-4671-958e-05f82c7f4d0f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50861 biolink:treats MONDO:0002771 PMID:41385096 "[{""id"":""uuid:4374d888-c340-4598-8c6c-8987467a275d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e3d1fa63-dc87-4408-9f10-2d0eaf881706"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tyvaso is a prostacyclin mimetic indicated for the treatment of: Pulmonary arterial hypertension (PAH; WHO Group 1) to improve exercise ability. Studies establishing effectiveness predominately included patients with NYHA Functional Class III symptoms and etiologies of idiopathic or heritable PAH (56%) or PAH associated with connective tissue diseases (33%). ( 1.1 ) Pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability. The study establishing effectiveness predominately included patients with etiologies of idiopathic interstitial pneumonia (IIP) (45%) inclusive of idiopathic pulmonary fibrosis (IPF), combined pulmonary fibrosis and emphysema (CPFE) (25%), and WHO Group 3 connective tissue disease (22%). ( 1.2 ) uuid:0cf534da-e19e-4935-bd1a-924597582939 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50861 biolink:treats MONDO:0017591 PMID:41385096 "[{""id"":""uuid:485b3207-ea9b-41c6-95ba-315a69e736b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9500f5f8-fcdf-4349-b9bb-aa3374811e80"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tyvaso is a prostacyclin mimetic indicated for the treatment of: Pulmonary arterial hypertension (PAH; WHO Group 1) to improve exercise ability. Studies establishing effectiveness predominately included patients with NYHA Functional Class III symptoms and etiologies of idiopathic or heritable PAH (56%) or PAH associated with connective tissue diseases (33%). ( 1.1 ) Pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability. The study establishing effectiveness predominately included patients with etiologies of idiopathic interstitial pneumonia (IIP) (45%) inclusive of idiopathic pulmonary fibrosis (IPF), combined pulmonary fibrosis and emphysema (CPFE) (25%), and WHO Group 3 connective tissue disease (22%). ( 1.2 ) uuid:38f7e204-3f69-44f1-8438-939125a9a560 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50861 biolink:treats MONDO:0003900 PMID:41385096 "[{""id"":""uuid:f59f9e9d-8c17-424b-bc54-07906c922afa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8cc8b0ff-47ca-454c-b172-18518a0e70f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tyvaso is a prostacyclin mimetic indicated for the treatment of: Pulmonary arterial hypertension (PAH; WHO Group 1) to improve exercise ability. Studies establishing effectiveness predominately included patients with NYHA Functional Class III symptoms and etiologies of idiopathic or heritable PAH (56%) or PAH associated with connective tissue diseases (33%). ( 1.1 ) Pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability. The study establishing effectiveness predominately included patients with etiologies of idiopathic interstitial pneumonia (IIP) (45%) inclusive of idiopathic pulmonary fibrosis (IPF), combined pulmonary fibrosis and emphysema (CPFE) (25%), and WHO Group 3 connective tissue disease (22%). ( 1.2 ) uuid:e7c5ddc7-d754-4afe-8c1f-c68fd4eaac2a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7SQY4ZUD30 biolink:treats MONDO:0005072 PMID:41385096 "[{""id"":""uuid:a5e6a613-0eac-4592-b1a6-3801be6c72ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ab7aab88-1c90-4f4c-b122-eca252bc3eeb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:564b86f6-9fd5-4143-bc37-20e8b5830c2a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Unituxin (dinutuximab) is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy [see Clinical Studies (14) ].|[PMDA] A drug with a new active ingredient indicated for the treatment of neuroblastoma following high- dose chemotherapy. [Orphan drug] uuid:b373da73-e304-49cc-bf82-d266e2cc5885 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22652 biolink:treats MONDO:0020696 PMID:41385096 "[{""id"":""uuid:0bd4764a-0e69-41f9-8e7f-28e526a0e418"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5ac74a06-3366-4c06-9b0b-c87720adafb9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PaxLyte is indicated in the TREATMENT of vitamin deficiency – specifically vitamin B 12 deficiency, and the PREVENTION of vitamin B 12 -cofactor deficiency, l-methylfolate. uuid:8ac18b77-2d01-4e3f-9c68-b5f8ad2e9ba8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:82699 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:e47017eb-8303-433b-a444-7f4a54d4b2a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f56f3f4b-56ea-49fe-b3fb-8aedf5fda432"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:9ca2ec80-5287-4ac2-9261-8bc7a5bf8693"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ORBACTIV is a lipoglycopeptide antibacterial drug indicated for the treatment of adult patients with acute bacterial skin and skin structure infections caused or suspected to be caused by susceptible isolates of designated Gram-positive microorganisms. ( 1.1 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of ORBACTIV and other antibacterial drugs, ORBACTIV should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.2 )|[EMA] Tenkasi is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults and paediatric patients aged 3 months and older (see sections 4.2, 4.4 and 5.1).Consideration should be given to official guidance on the appropriate use of antibacterial agents. uuid:f6fe04e8-4764-42c2-99d3-7f9415eed979 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB17743 biolink:treats EFO:0009130 PMID:41385096 "[{""id"":""uuid:0f728d67-97de-456c-b58a-35f692cc0117"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f4984cf6-40b7-4fa4-a0aa-cea78afde912"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] REBYOTA is indicated for the prevention of recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older following antibiotic treatment for recurrent CDI. uuid:a2050643-e284-4508-b636-0ad9c539c679 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB17743 biolink:treats UMLS:C5230640 PMID:41385096 "[{""id"":""uuid:988ea35c-60b7-4e39-9d3b-8efb92841290"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2f4485ee-0e82-4d07-9fda-376345821da2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] REBYOTA is indicated for the prevention of recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older following antibiotic treatment for recurrent CDI. uuid:ded406aa-fc09-42a9-8849-499171086d8a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31485 biolink:treats NCIT:C3137 PMID:41385096 "[{""id"":""uuid:800da85b-349c-49de-885a-a320eb495fd0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9e3a9c75-c52f-45c1-9379-ac0906cf04fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Difluprednate ophthalmic emulsion is a topical corticosteroid that is indicated for: The treatment of inflammation and pain associated with ocular surgery. ( 1.1 ) The treatment of endogenous anterior uveitis. ( 1.2 ) uuid:8aa78deb-4108-43c2-afa0-3eccf5fcdf52 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31485 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:ab65dead-7b5b-49a7-a1ed-91de970b6fa3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7d471d66-dd18-463e-8f01-3d1ba192f4ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Difluprednate ophthalmic emulsion is a topical corticosteroid that is indicated for: The treatment of inflammation and pain associated with ocular surgery. ( 1.1 ) The treatment of endogenous anterior uveitis. ( 1.2 ) uuid:7d4977e8-167c-42a1-9683-e1628cd78d19 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2670458 biolink:treats MONDO:0043544 PMID:41385096 "[{""id"":""uuid:b276e71e-5c70-48a3-bb84-06eb9389012b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9074ff7d-6583-47ff-b8d0-f6eed4b4a389"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LIMITED POPULATION: DEFENCATH ® is indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis (HD) through a central venous catheter (CVC). This drug is indicated for use in a limited and specific population of patients [see Clinical Studies (14) ]. Limitations of Use The safety and effectiveness of DEFENCATH have not been established for use in populations other than adult patients with kidney failure receiving chronic HD through a CVC. uuid:990737c7-707e-4ffe-a97b-6fdaa7317df2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2670458 biolink:treats MONDO:0001106 PMID:41385096 "[{""id"":""uuid:c17fc45a-c448-4710-99b1-8b83a2bc51e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3b59e111-1b09-437e-ba78-cc91036b173e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LIMITED POPULATION: DEFENCATH ® is indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis (HD) through a central venous catheter (CVC). This drug is indicated for use in a limited and specific population of patients [see Clinical Studies (14) ]. Limitations of Use The safety and effectiveness of DEFENCATH have not been established for use in populations other than adult patients with kidney failure receiving chronic HD through a CVC. uuid:ea90d93b-c4be-4999-9dcc-e70214f9a635 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16301 biolink:treats MONDO:0018754 PMID:41385096 "[{""id"":""uuid:009a3e0f-7d02-4842-b550-2bb3d57d4b8a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f350f71f-bc13-4377-b2fb-c2e7f5b7a0bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Nitrite Injection, an antidote, is indicated for sequential use with sodium thiosulfate for the treatment of acute cyanide poisoning that is judged to be serious or life-threatening. When the diagnosis of cyanide poisoning is uncertain, the potentially life-threatening risks associated with Sodium Nitrite Injection should be carefully weighed against the potential benefits, especially if the patient is not in extremis. uuid:3f586471-1a4e-484a-ac52-4ad7a0b45540 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16094 biolink:treats MONDO:0018754 PMID:41385096 "[{""id"":""uuid:b21e7d1b-4f1c-44e5-81b7-6d688490f8db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4b91b61c-7a67-4d0a-a839-0e2830abd5b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Thiosulfate Injection is indicated for sequential use with sodium nitrite for the treatment of acute cyanide poisoning that is judged to be serious or life-threatening. When the diagnosis of cyanide poisoning is uncertain, the potential risks associated with Sodium Thiosulfate Injection should be carefully weighed against the potential benefits, especially if the patient is not in extremis. uuid:ed0c3918-df18-4931-8ea4-d72190b6e806 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135552 biolink:treats UMLS:C0267509 PMID:41385096 "[{""id"":""uuid:ed597014-da44-4070-84fa-86da386b9c72"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b0c54af7-9681-4648-8fb4-e1dceac821bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prucalopride tablet is indicated for the treatment of chronic idiopathic constipation (CIC) in adults. uuid:20b6c6ab-739b-4c73-bf70-b6ee3f00fc08 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135552 biolink:treats MONDO:0956989 PMID:41385096 "[{""id"":""uuid:8b045f05-475b-4bc3-9539-0d32985912aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4430f8de-f378-4141-b898-b5fa66eda8d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prucalopride tablet is indicated for the treatment of chronic idiopathic constipation (CIC) in adults. uuid:e5287c93-ebc6-4ef3-a6b0-ee5cc574ad0c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17439 biolink:treats MONDO:0007705 PMID:41385096 "[{""id"":""uuid:b304e63f-8e22-4903-86dc-f445d7c9cc7e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9335ac04-1165-4ae1-89d4-8fc55ce7a8cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the treatment of all anemias responsive to oral iron therapy, such as hypochromic anemia associated with pregnancy, chronic or acute blood loss, dietary restriction, metabolic disease and post-surgical convalescence. uuid:d48c1877-a8f3-46ab-b0a6-fe7ddf6c5be1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17439 biolink:treats MONDO:0001357 PMID:41385096 "[{""id"":""uuid:b8f2b160-a5cc-4a0c-b2d1-44b14db89ed0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:af74e3ed-143f-4a2c-b837-30932de5f90f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the treatment of all anemias responsive to oral iron therapy, such as hypochromic anemia associated with pregnancy, chronic or acute blood loss, dietary restriction, metabolic disease and post-surgical convalescence. uuid:78cef62c-46f5-4dfc-b87e-43a1808e3661 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6D848RA61B biolink:treats MONDO:0008250 PMID:41385096 "[{""id"":""uuid:0a447552-d2bc-4f96-ac82-9fb8e15f93d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:fad4060c-bdf6-48fc-abd1-1790b0a202df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:1ae58417-4463-484f-9ac8-52aed885eb47"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ngenla""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] NGENLA is indicated for the treatment of pediatric patients aged 3 years and older who have growth failure due to an inadequate secretion of endogenous growth hormone.|[EMA] Indicated for the long-term treatment of paediatric patients with growth disturbance due to insufficient secretion of growth hormone uuid:e6bdddcc-ab4e-476f-baaf-a8a22364e2fd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1487516 biolink:treats MONDO:0005002 PMID:41385096 "[{""id"":""uuid:97ee4897-f47b-4028-80a9-4f511809578a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f9f6588d-b511-470c-b0e9-59fa183b2ee7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:3aaeed9a-c926-4650-a0b5-92d448965349"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/anoro-ellipta""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] ANORO ELLIPTA is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Limitations of Use ANORO ELLIPTA is NOT indicated for the relief of acute bronchospasm or for the treatment of asthma. The safety and effectiveness of ANORO ELLIPTA in asthma have not been established.|[EMA] Anoro Ellipta is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). uuid:1e87ee5d-b4da-4dc7-8002-f8834ecee604 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1487516 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:9919ad28-3e17-40f3-a01c-64cca50b0e9b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a9d7433c-3ed9-43eb-90a3-2a1a7bcd9a07"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ANORO ELLIPTA is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Limitations of Use ANORO ELLIPTA is NOT indicated for the relief of acute bronchospasm or for the treatment of asthma. The safety and effectiveness of ANORO ELLIPTA in asthma have not been established. uuid:169a7f61-5223-4f87-8f41-013ac4bbfbc0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0007256 PMID:41385096 "[{""id"":""uuid:345d217c-9ad7-49e0-801d-1e8667abd9a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1a5dbf14-4d3a-46e4-a527-0569e209402e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lipiodol is an oil-based radio-opaque contrast agent indicated for: hysterosalpingography in adults lymphography in adult and pediatric patients selective hepatic intra-arterial use for imaging tumors in adults with known hepatocellular carcinoma (HCC) uuid:39ed392c-056b-444b-90f3-32eccd2839d8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1545147 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:6b48502e-3c3d-4adf-b58d-91934db48fa7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:4a40eb81-7285-4b10-b112-0d940204310c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:85871829-39f7-4813-bab7-8d3b483af9f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/vokanamet""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] INVOKAMET and INVOKAMET XR are a combination of canagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, and metformin hydrochloride (HCl), a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus ( 1 ). Canagliflozin Canagliflozin, when used as a component of INVOKAMET or INVOKAMET XR is indicated in adults with type 2 diabetes mellitus to reduce the risk of: Major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease ( 1 ). End-stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in adults with type 2 diabetes mellitus and diabetic nephropathy with albuminuria ( 1 ). Limitations of Use: Not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus ( 1 ).|[EMA] Vokanamet is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:in patients not adequately controlled on their maximally tolerated doses of metformin alonein patients on their maximally tolerated doses of metformin along with other glucose lowering medicinal products including insulin, when these do not provide adequate glycaemic control.in patients already being treated with the combination of canagliflozin and metformin as separate tabletsFor study results with respect to combination of therapies, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1. uuid:b167e6ac-5d5b-42ed-87c5-ed93d673bdb9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1545147 biolink:treats MONDO:0004995 PMID:41385096 "[{""id"":""uuid:90514411-e4f2-403e-ad9a-d6009e08234e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:88eb526f-d7ba-46aa-ac39-c2a4e5ae22b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INVOKAMET and INVOKAMET XR are a combination of canagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, and metformin hydrochloride (HCl), a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus ( 1 ). Canagliflozin Canagliflozin, when used as a component of INVOKAMET or INVOKAMET XR is indicated in adults with type 2 diabetes mellitus to reduce the risk of: Major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease ( 1 ). End-stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in adults with type 2 diabetes mellitus and diabetic nephropathy with albuminuria ( 1 ). Limitations of Use: Not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus ( 1 ). uuid:1387f292-0a2d-4625-a030-1726becb908b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1545147 biolink:treats MONDO:0005016 PMID:41385096 "[{""id"":""uuid:2db03466-4410-477a-8148-f55bd4e152f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:09639c79-6e28-4c99-90cf-ef1f80dc81ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INVOKAMET and INVOKAMET XR are a combination of canagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, and metformin hydrochloride (HCl), a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus ( 1 ). Canagliflozin Canagliflozin, when used as a component of INVOKAMET or INVOKAMET XR is indicated in adults with type 2 diabetes mellitus to reduce the risk of: Major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease ( 1 ). End-stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in adults with type 2 diabetes mellitus and diabetic nephropathy with albuminuria ( 1 ). Limitations of Use: Not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus ( 1 ). uuid:20e2a2fb-6567-4871-9001-f48098e53c03 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1545147 biolink:treats MONDO:0004375 PMID:41385096 "[{""id"":""uuid:27207fc7-b62a-4202-8635-cfbdb378addf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b2553aef-f79b-47a9-aeff-a146d0bf6f79"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INVOKAMET and INVOKAMET XR are a combination of canagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, and metformin hydrochloride (HCl), a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus ( 1 ). Canagliflozin Canagliflozin, when used as a component of INVOKAMET or INVOKAMET XR is indicated in adults with type 2 diabetes mellitus to reduce the risk of: Major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease ( 1 ). End-stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in adults with type 2 diabetes mellitus and diabetic nephropathy with albuminuria ( 1 ). Limitations of Use: Not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus ( 1 ). uuid:4e5e0605-56bd-4c85-8112-a80e579df9e7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1545147 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:3ead5afd-7e7e-463a-8809-8669b31dc8c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:87fe4186-1a07-472a-b072-42abe2288c21"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INVOKAMET and INVOKAMET XR are a combination of canagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, and metformin hydrochloride (HCl), a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus ( 1 ). Canagliflozin Canagliflozin, when used as a component of INVOKAMET or INVOKAMET XR is indicated in adults with type 2 diabetes mellitus to reduce the risk of: Major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease ( 1 ). End-stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in adults with type 2 diabetes mellitus and diabetic nephropathy with albuminuria ( 1 ). Limitations of Use: Not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus ( 1 ). uuid:c214b1d5-19cc-4c8a-a7e2-1620161f55e0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1545147 biolink:treats MONDO:0005147 PMID:41385096 "[{""id"":""uuid:8a934a4c-8daf-4e97-849a-dea4fc01dc77"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ac76c76e-a55b-4c31-8195-cabc653dbd40"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INVOKAMET and INVOKAMET XR are a combination of canagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, and metformin hydrochloride (HCl), a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus ( 1 ). Canagliflozin Canagliflozin, when used as a component of INVOKAMET or INVOKAMET XR is indicated in adults with type 2 diabetes mellitus to reduce the risk of: Major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease ( 1 ). End-stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in adults with type 2 diabetes mellitus and diabetic nephropathy with albuminuria ( 1 ). Limitations of Use: Not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus ( 1 ). uuid:576a2d91-53f2-49e2-880f-7a3599d6f3c6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:66910 biolink:treats MONDO:0005086 PMID:41385096 "[{""id"":""uuid:fca91987-864f-4398-9cc2-d1d5e462f53b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b70b4a79-91e3-440f-8367-1af2df2a7ba3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:78b99ba5-6262-4b25-aa5f-84a56220351f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/inlyta""]},{""id"":""uuid:b0bc90d3-404b-41c2-a382-e7b6248984c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INLYTA is a kinase inhibitor indicated: • in combination with avelumab, for the first-line treatment of patients with advanced renal cell carcinoma (RCC). ( 1.1 ) • in combination with pembrolizumab, for the first-line treatment of patients with advanced RCC. ( 1.1 ) • as a single agent, for the treatment of advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy. ( 1.2 )|[EMA] Inlyta is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of prior treatment with sunitinib or a cytokine.|[PMDA] Drugs with a new active ingredient indicated for the treatment of unresectable or metastatic renal cell carcinoma. uuid:35c0bc54-6175-4f94-8794-0a08a1074949 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:66910 biolink:treats UMLS:C4727069 PMID:41385096 "[{""id"":""uuid:d84f69a1-b17d-4c6f-8a1d-8adee8a933e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ba0feb7d-1f1b-44ac-aedb-ec5ad5cd0f16"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INLYTA is a kinase inhibitor indicated: • in combination with avelumab, for the first-line treatment of patients with advanced renal cell carcinoma (RCC). ( 1.1 ) • in combination with pembrolizumab, for the first-line treatment of patients with advanced RCC. ( 1.1 ) • as a single agent, for the treatment of advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy. ( 1.2 ) uuid:534a264b-5015-4a6c-be3f-7c506834582c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C5881776 biolink:treats EFO:1001480 PMID:41385096 "[{""id"":""uuid:6775b1ee-acda-4bb6-98bd-79a32c238403"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7779f963-2fbf-450b-8ee5-8a93032e5ed7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Avzivi is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil­based chemotherapy for first- or second-line treatment. ( 1.1 ) Metastatic colorectal cancer, in combination with fluoropyrimidine­ irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen. ( 1.1 ) Limitations of Use : Avzivi is not indicated for adjuvant treatment of colon cancer. ( 1.1 ) Unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel for first-line treatment. ( 1.2 ) Recurrent glioblastoma in adults. ( 1.3 ) Metastatic renal cell carcinoma in combination with interferon alfa. ( 1.4 ) Persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin, or paclitaxel and topotecan. ( 1.5 ) Epithelial ovarian, fallopian tube, or primary peritoneal cancer in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease who received no more than 2 prior chemotherapy regimens. ( 1.6 ) uuid:147ec399-8080-4950-a3e8-ee481cd5c866 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C5881776 biolink:treats MONDO:0021063 PMID:41385096 "[{""id"":""uuid:0e57eda2-26d3-4881-8ec4-ec9cacc84bdc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1b52a73f-7051-43d8-abc6-4d040d5b0ca0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Avzivi is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil­based chemotherapy for first- or second-line treatment. ( 1.1 ) Metastatic colorectal cancer, in combination with fluoropyrimidine­ irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen. ( 1.1 ) Limitations of Use : Avzivi is not indicated for adjuvant treatment of colon cancer. ( 1.1 ) Unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel for first-line treatment. ( 1.2 ) Recurrent glioblastoma in adults. ( 1.3 ) Metastatic renal cell carcinoma in combination with interferon alfa. ( 1.4 ) Persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin, or paclitaxel and topotecan. ( 1.5 ) Epithelial ovarian, fallopian tube, or primary peritoneal cancer in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease who received no more than 2 prior chemotherapy regimens. ( 1.6 ) uuid:2e2a8215-00da-41d6-b629-2cd210ba2429 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C5881776 biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:fa07e068-7290-4541-9c43-8749612505f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d9abcdd3-d109-4762-8058-be10754bd417"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Avzivi is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil­based chemotherapy for first- or second-line treatment. ( 1.1 ) Metastatic colorectal cancer, in combination with fluoropyrimidine­ irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen. ( 1.1 ) Limitations of Use : Avzivi is not indicated for adjuvant treatment of colon cancer. ( 1.1 ) Unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel for first-line treatment. ( 1.2 ) Recurrent glioblastoma in adults. ( 1.3 ) Metastatic renal cell carcinoma in combination with interferon alfa. ( 1.4 ) Persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin, or paclitaxel and topotecan. ( 1.5 ) Epithelial ovarian, fallopian tube, or primary peritoneal cancer in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease who received no more than 2 prior chemotherapy regimens. ( 1.6 ) uuid:d6baceb4-8879-446a-a217-c4e03c6452a2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C5881776 biolink:treats UMLS:C4288305 PMID:41385096 "[{""id"":""uuid:741f4eb1-22bf-4543-b0b4-ced8deda47bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a0041939-619a-462d-904f-c0ea960bc6d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Avzivi is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil­based chemotherapy for first- or second-line treatment. ( 1.1 ) Metastatic colorectal cancer, in combination with fluoropyrimidine­ irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen. ( 1.1 ) Limitations of Use : Avzivi is not indicated for adjuvant treatment of colon cancer. ( 1.1 ) Unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel for first-line treatment. ( 1.2 ) Recurrent glioblastoma in adults. ( 1.3 ) Metastatic renal cell carcinoma in combination with interferon alfa. ( 1.4 ) Persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin, or paclitaxel and topotecan. ( 1.5 ) Epithelial ovarian, fallopian tube, or primary peritoneal cancer in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease who received no more than 2 prior chemotherapy regimens. ( 1.6 ) uuid:362a0184-a91b-4387-89b1-208e1c58cc8e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C5881776 biolink:treats UMLS:C4721698 PMID:41385096 "[{""id"":""uuid:dba58986-8535-45a9-ab9a-d80b12408273"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0b8f6475-aff3-46ef-ba2e-200d67a38f85"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Avzivi is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil­based chemotherapy for first- or second-line treatment. ( 1.1 ) Metastatic colorectal cancer, in combination with fluoropyrimidine­ irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen. ( 1.1 ) Limitations of Use : Avzivi is not indicated for adjuvant treatment of colon cancer. ( 1.1 ) Unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel for first-line treatment. ( 1.2 ) Recurrent glioblastoma in adults. ( 1.3 ) Metastatic renal cell carcinoma in combination with interferon alfa. ( 1.4 ) Persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin, or paclitaxel and topotecan. ( 1.5 ) Epithelial ovarian, fallopian tube, or primary peritoneal cancer in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease who received no more than 2 prior chemotherapy regimens. ( 1.6 ) uuid:6f424419-f67b-45af-8a2a-60fac9982a49 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C5881776 biolink:treats MONDO:0002974 PMID:41385096 "[{""id"":""uuid:68241639-9fef-4ce4-b38f-f9324314391e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:03addcf6-9258-4a78-81c6-bbabf5051ca3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Avzivi is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil­based chemotherapy for first- or second-line treatment. ( 1.1 ) Metastatic colorectal cancer, in combination with fluoropyrimidine­ irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen. ( 1.1 ) Limitations of Use : Avzivi is not indicated for adjuvant treatment of colon cancer. ( 1.1 ) Unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel for first-line treatment. ( 1.2 ) Recurrent glioblastoma in adults. ( 1.3 ) Metastatic renal cell carcinoma in combination with interferon alfa. ( 1.4 ) Persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin, or paclitaxel and topotecan. ( 1.5 ) Epithelial ovarian, fallopian tube, or primary peritoneal cancer in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease who received no more than 2 prior chemotherapy regimens. ( 1.6 ) uuid:a5625d4f-69df-438e-9c8b-7e612ce506d7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C5881776 biolink:treats UMLS:C0278579 PMID:41385096 "[{""id"":""uuid:760813f8-5d16-4368-857e-edb06368e7a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8370506b-a38b-45c8-bd3d-dc906335fe0f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Avzivi is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil­based chemotherapy for first- or second-line treatment. ( 1.1 ) Metastatic colorectal cancer, in combination with fluoropyrimidine­ irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen. ( 1.1 ) Limitations of Use : Avzivi is not indicated for adjuvant treatment of colon cancer. ( 1.1 ) Unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel for first-line treatment. ( 1.2 ) Recurrent glioblastoma in adults. ( 1.3 ) Metastatic renal cell carcinoma in combination with interferon alfa. ( 1.4 ) Persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin, or paclitaxel and topotecan. ( 1.5 ) Epithelial ovarian, fallopian tube, or primary peritoneal cancer in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease who received no more than 2 prior chemotherapy regimens. ( 1.6 ) uuid:f5a64221-f22f-4562-9e03-6f17ab61e28b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C5881776 biolink:treats MONDO:0005140 PMID:41385096 "[{""id"":""uuid:3ddbbbdc-1194-410f-b5e2-74d9a13d5264"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3d8b7969-9a0e-42d5-9305-00928ae5c2d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Avzivi is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil­based chemotherapy for first- or second-line treatment. ( 1.1 ) Metastatic colorectal cancer, in combination with fluoropyrimidine­ irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen. ( 1.1 ) Limitations of Use : Avzivi is not indicated for adjuvant treatment of colon cancer. ( 1.1 ) Unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel for first-line treatment. ( 1.2 ) Recurrent glioblastoma in adults. ( 1.3 ) Metastatic renal cell carcinoma in combination with interferon alfa. ( 1.4 ) Persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin, or paclitaxel and topotecan. ( 1.5 ) Epithelial ovarian, fallopian tube, or primary peritoneal cancer in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease who received no more than 2 prior chemotherapy regimens. ( 1.6 ) uuid:ab7ee427-9020-4931-81f9-e53ba3ede116 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C5881776 biolink:treats MONDO:0002158 PMID:41385096 "[{""id"":""uuid:c4e032ce-a472-48ab-8087-acea9d0dfa56"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:503ee98b-ef21-49e8-86ec-c2dd613327aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Avzivi is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil­based chemotherapy for first- or second-line treatment. ( 1.1 ) Metastatic colorectal cancer, in combination with fluoropyrimidine­ irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen. ( 1.1 ) Limitations of Use : Avzivi is not indicated for adjuvant treatment of colon cancer. ( 1.1 ) Unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel for first-line treatment. ( 1.2 ) Recurrent glioblastoma in adults. ( 1.3 ) Metastatic renal cell carcinoma in combination with interferon alfa. ( 1.4 ) Persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin, or paclitaxel and topotecan. ( 1.5 ) Epithelial ovarian, fallopian tube, or primary peritoneal cancer in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease who received no more than 2 prior chemotherapy regimens. ( 1.6 ) uuid:226551c5-d56e-420c-8f01-cd72d18bdace biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C5881776 biolink:treats MONDO:0015686 PMID:41385096 "[{""id"":""uuid:6801cfb0-2ce9-4cdf-a5b8-cb3c82d0c3e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:45442379-b217-430b-8bf7-7876126084c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Avzivi is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil­based chemotherapy for first- or second-line treatment. ( 1.1 ) Metastatic colorectal cancer, in combination with fluoropyrimidine­ irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen. ( 1.1 ) Limitations of Use : Avzivi is not indicated for adjuvant treatment of colon cancer. ( 1.1 ) Unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel for first-line treatment. ( 1.2 ) Recurrent glioblastoma in adults. ( 1.3 ) Metastatic renal cell carcinoma in combination with interferon alfa. ( 1.4 ) Persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin, or paclitaxel and topotecan. ( 1.5 ) Epithelial ovarian, fallopian tube, or primary peritoneal cancer in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease who received no more than 2 prior chemotherapy regimens. ( 1.6 ) uuid:ec8ee886-ad12-4d7f-beaf-d4d034bf6237 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49603 biolink:treats UMLS:C3495917 PMID:41385096 "[{""id"":""uuid:c0b20706-5b1c-49e5-a8a8-ab9c7057af06"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8bbda7fb-0f26-461b-badb-f039ee54bb28"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lapatinib tablets are indicated in combination with: capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (HER2) and who have received prior therapy, including an anthracycline, a taxane, and trastuzumab. Limitations of Use : Patients should have disease progression on trastuzumab prior to initiation of treatment with lapatinib tablets in combination with capecitabine. letrozole for the treatment of postmenopausal women with hormone receptor-positive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated. Lapatinib tablets in combination with an aromatase inhibitor has not been compared to a trastuzumab-containing chemotherapy regimen for the treatment of metastatic breast cancer. uuid:d6a557a4-e57e-4f0b-a83b-4bb63fed2624 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49603 biolink:treats UMLS:C0278488 PMID:41385096 "[{""id"":""uuid:4104c6b8-1b5a-4a9e-b903-422a4aad9421"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e6dd63e2-945c-4b90-b63b-3be9da0d6c7e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lapatinib tablets are indicated in combination with: capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (HER2) and who have received prior therapy, including an anthracycline, a taxane, and trastuzumab. Limitations of Use : Patients should have disease progression on trastuzumab prior to initiation of treatment with lapatinib tablets in combination with capecitabine. letrozole for the treatment of postmenopausal women with hormone receptor-positive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated. Lapatinib tablets in combination with an aromatase inhibitor has not been compared to a trastuzumab-containing chemotherapy regimen for the treatment of metastatic breast cancer. uuid:5c54537a-66bf-4e87-9e4d-2e3ab1e53a55 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:LT369U66CE biolink:treats MONDO:0004951 PMID:41385096 "[{""id"":""uuid:75e48054-946a-40a9-be3e-fd814313e39f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a75e498b-1b99-4a35-aee0-25e1c7681ca8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TROGARZO, in combination with other antiretroviral(s), is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection failing their current antiretroviral regimen. uuid:bbd4f97a-9c93-4b58-87b5-f74f359c12e4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:Q6U6J48BWY biolink:treats MONDO:0009265 PMID:41385096 "[{""id"":""uuid:4de87dc0-2341-4056-bbb4-2896510befe4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f749fa08-8027-40b3-84b3-f30c8f0e0461"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cerezyme is indicated for treatment of adults and pediatric patients 2 years of age and older with Type 1 Gaucher disease that results in one or more of the following conditions: anemia thrombocytopenia bone disease hepatomegaly or splenomegaly uuid:0ffb0cc2-b4ba-4406-a7fb-8ddfb8f56417 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:Q6U6J48BWY biolink:treats MONDO:0002280 PMID:41385096 "[{""id"":""uuid:53cddbba-978b-47db-abf2-b22252b9a262"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:0eb1d461-1c8d-4bb0-89fa-f49ebcdf767d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:15740626-1d66-4319-bedd-aabe73839bb4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/cerezyme""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cerezyme is indicated for treatment of adults and pediatric patients 2 years of age and older with Type 1 Gaucher disease that results in one or more of the following conditions: anemia thrombocytopenia bone disease hepatomegaly or splenomegaly|[EMA] Cerezyme (imiglucerase) is indicated for use as longterm enzyme replacement therapy in patients with a confirmed diagnosis of non-neuronopathic (Type 1) or chronic neuronopathic (Type 3) Gaucher disease who exhibit clinically significant nonneurological manifestations of the disease. The non-neurological manifestations of Gaucher disease include one or more of the following conditions:anaemia after exclusion of other causes, such as iron deficiencyThrombocytopeniaBone disease after exclusion of other causes such as Vitamin D deficiencyhepatomegaly or splenomegaly uuid:1ae42620-8ac7-4bf6-9834-00820ccdaf35 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:Q6U6J48BWY biolink:treats MONDO:0002049 PMID:41385096 "[{""id"":""uuid:7903364a-9960-446f-9290-c73280ace77e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:7beac2db-3314-4e05-a7f8-e39c402c8936"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:0ae35a34-b408-417e-b467-62c1104add8a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/cerezyme""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cerezyme is indicated for treatment of adults and pediatric patients 2 years of age and older with Type 1 Gaucher disease that results in one or more of the following conditions: anemia thrombocytopenia bone disease hepatomegaly or splenomegaly|[EMA] Cerezyme (imiglucerase) is indicated for use as longterm enzyme replacement therapy in patients with a confirmed diagnosis of non-neuronopathic (Type 1) or chronic neuronopathic (Type 3) Gaucher disease who exhibit clinically significant nonneurological manifestations of the disease. The non-neurological manifestations of Gaucher disease include one or more of the following conditions:anaemia after exclusion of other causes, such as iron deficiencyThrombocytopeniaBone disease after exclusion of other causes such as Vitamin D deficiencyhepatomegaly or splenomegaly uuid:f3033ff4-a299-4981-9c2a-5963d05d87cc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:Q6U6J48BWY biolink:treats MONDO:0005381 PMID:41385096 "[{""id"":""uuid:31d1f842-3d2f-4b3f-8ff9-bee2048a4392"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:c4b8d130-7b88-4214-8c0b-3e0d115f181c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f6e0e52a-fb30-4290-b5b0-23b62954f19e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/cerezyme""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cerezyme is indicated for treatment of adults and pediatric patients 2 years of age and older with Type 1 Gaucher disease that results in one or more of the following conditions: anemia thrombocytopenia bone disease hepatomegaly or splenomegaly|[EMA] Cerezyme (imiglucerase) is indicated for use as longterm enzyme replacement therapy in patients with a confirmed diagnosis of non-neuronopathic (Type 1) or chronic neuronopathic (Type 3) Gaucher disease who exhibit clinically significant nonneurological manifestations of the disease. The non-neurological manifestations of Gaucher disease include one or more of the following conditions:anaemia after exclusion of other causes, such as iron deficiencyThrombocytopeniaBone disease after exclusion of other causes such as Vitamin D deficiencyhepatomegaly or splenomegaly uuid:7c01c420-3b49-4540-8133-fdb358401a38 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:Q6U6J48BWY biolink:treats HP:0002240 PMID:41385096 "[{""id"":""uuid:5f9ea41f-c517-441a-a2cd-8b4322004a8a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:b55121ff-1ef6-40d6-ad15-747b292d9e1f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c371e2af-6962-4e2c-bdb8-c706a397a6f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/cerezyme""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cerezyme is indicated for treatment of adults and pediatric patients 2 years of age and older with Type 1 Gaucher disease that results in one or more of the following conditions: anemia thrombocytopenia bone disease hepatomegaly or splenomegaly|[EMA] Cerezyme (imiglucerase) is indicated for use as longterm enzyme replacement therapy in patients with a confirmed diagnosis of non-neuronopathic (Type 1) or chronic neuronopathic (Type 3) Gaucher disease who exhibit clinically significant nonneurological manifestations of the disease. The non-neurological manifestations of Gaucher disease include one or more of the following conditions:anaemia after exclusion of other causes, such as iron deficiencyThrombocytopeniaBone disease after exclusion of other causes such as Vitamin D deficiencyhepatomegaly or splenomegaly uuid:fc80a4d0-902d-42eb-93cb-336f2eeae5a9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:Q6U6J48BWY biolink:treats HP:0001744 PMID:41385096 "[{""id"":""uuid:22b3fb25-7b5b-40f0-9498-00ce85eb800c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:50745125-9bfb-4d11-b00d-8f6e7af1ccef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cerezyme is indicated for treatment of adults and pediatric patients 2 years of age and older with Type 1 Gaucher disease that results in one or more of the following conditions: anemia thrombocytopenia bone disease hepatomegaly or splenomegaly uuid:061cff34-3c18-45ab-9328-4b8af1a60848 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats UMLS:C3824874 PMID:41385096 "[{""id"":""uuid:e3189d41-6e3e-4b29-a0c1-56d05b76f99e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:34844ff9-35e0-46af-b8be-1f5a2e575df2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline for injection and other antibacterial drugs, doxycycline for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever, and the typhus group, Q fever, rickettsialpox and tick fevers). Mycoplasma pneumoniae (PPLO, Eaton Agent). Agents of psittacosis and ornithosis. Agents of lymphogranuloma venereum and granuloma inguinale. The spirochetal agent of relapsing fever ( Borrelia recurrentis ). The following gram-negative microorganisms: Haemophilus ducreyi ( chancroid ), Yersinia pestis Francisella tularensis, Bartonella bacilliformis, Bacteroides species, Vibrio cholerae and Campylobacte fetus, Brucella species ( in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli, Enterobacter aerogenes, Shigella species, Acinetobacter species, Haemophilus influenzae (respiratory infections), Klebsiella species (respiratory and urinary infections). Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Streptococcus pneumoniae, Staphylococcus aureus , respiratory skin and soft tissue infections. Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections. Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of infections due to: Neisseria gonorrhoeae and N. meningitidis, Treponema pallidum and Treponema pallidum subspecie s pertenue (syphilis and yaws), Listeria monocytogenes, Clostridium species, Fusobacterium fusiforme (Vincent's infection), Actinomyces species . In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. Doxycycline is indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. uuid:4f993bfc-62de-4c7f-a666-375d70fa6e7e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats UMLS:C0948205 PMID:41385096 "[{""id"":""uuid:66387ef8-9ab2-41ad-82cc-270dc08abb63"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:39da0457-d392-428c-ad4c-3c6b55fec70f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline for injection and other antibacterial drugs, doxycycline for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever, and the typhus group, Q fever, rickettsialpox and tick fevers). Mycoplasma pneumoniae (PPLO, Eaton Agent). Agents of psittacosis and ornithosis. Agents of lymphogranuloma venereum and granuloma inguinale. The spirochetal agent of relapsing fever ( Borrelia recurrentis ). The following gram-negative microorganisms: Haemophilus ducreyi ( chancroid ), Yersinia pestis Francisella tularensis, Bartonella bacilliformis, Bacteroides species, Vibrio cholerae and Campylobacte fetus, Brucella species ( in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli, Enterobacter aerogenes, Shigella species, Acinetobacter species, Haemophilus influenzae (respiratory infections), Klebsiella species (respiratory and urinary infections). Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Streptococcus pneumoniae, Staphylococcus aureus , respiratory skin and soft tissue infections. Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections. Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of infections due to: Neisseria gonorrhoeae and N. meningitidis, Treponema pallidum and Treponema pallidum subspecie s pertenue (syphilis and yaws), Listeria monocytogenes, Clostridium species, Fusobacterium fusiforme (Vincent's infection), Actinomyces species . In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. Doxycycline is indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. uuid:0c0a4616-ff50-4993-91d7-e1298b1207cd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0005247 PMID:41385096 "[{""id"":""uuid:64bd277b-faed-4be4-a068-623cc3eae098"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:66f66361-999c-4873-aed0-5dbb3011fab0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline for injection and other antibacterial drugs, doxycycline for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever, and the typhus group, Q fever, rickettsialpox and tick fevers). Mycoplasma pneumoniae (PPLO, Eaton Agent). Agents of psittacosis and ornithosis. Agents of lymphogranuloma venereum and granuloma inguinale. The spirochetal agent of relapsing fever ( Borrelia recurrentis ). The following gram-negative microorganisms: Haemophilus ducreyi ( chancroid ), Yersinia pestis Francisella tularensis, Bartonella bacilliformis, Bacteroides species, Vibrio cholerae and Campylobacte fetus, Brucella species ( in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli, Enterobacter aerogenes, Shigella species, Acinetobacter species, Haemophilus influenzae (respiratory infections), Klebsiella species (respiratory and urinary infections). Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Streptococcus pneumoniae, Staphylococcus aureus , respiratory skin and soft tissue infections. Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections. Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of infections due to: Neisseria gonorrhoeae and N. meningitidis, Treponema pallidum and Treponema pallidum subspecie s pertenue (syphilis and yaws), Listeria monocytogenes, Clostridium species, Fusobacterium fusiforme (Vincent's infection), Actinomyces species . In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. Doxycycline is indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. uuid:89ef1722-da50-4bfc-8fda-42ef53396cec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats UMLS:C0554628 PMID:41385096 "[{""id"":""uuid:74708cc7-afac-49d1-a9fa-3094de7d9284"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7ff09132-9c8b-4349-a52d-cf25ba5520d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline for injection and other antibacterial drugs, doxycycline for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever, and the typhus group, Q fever, rickettsialpox and tick fevers). Mycoplasma pneumoniae (PPLO, Eaton Agent). Agents of psittacosis and ornithosis. Agents of lymphogranuloma venereum and granuloma inguinale. The spirochetal agent of relapsing fever ( Borrelia recurrentis ). The following gram-negative microorganisms: Haemophilus ducreyi ( chancroid ), Yersinia pestis Francisella tularensis, Bartonella bacilliformis, Bacteroides species, Vibrio cholerae and Campylobacte fetus, Brucella species ( in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli, Enterobacter aerogenes, Shigella species, Acinetobacter species, Haemophilus influenzae (respiratory infections), Klebsiella species (respiratory and urinary infections). Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Streptococcus pneumoniae, Staphylococcus aureus , respiratory skin and soft tissue infections. Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections. Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of infections due to: Neisseria gonorrhoeae and N. meningitidis, Treponema pallidum and Treponema pallidum subspecie s pertenue (syphilis and yaws), Listeria monocytogenes, Clostridium species, Fusobacterium fusiforme (Vincent's infection), Actinomyces species . In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. Doxycycline is indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. uuid:2aad5886-65d7-40f5-aae1-05c9b87e1dce biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats UMLS:C1739131 PMID:41385096 "[{""id"":""uuid:bfbdc3f3-e009-43a5-aeab-5d8abd5d180b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:683523a2-74c3-48f2-b6dd-6521a5648bee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline for injection and other antibacterial drugs, doxycycline for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever, and the typhus group, Q fever, rickettsialpox and tick fevers). Mycoplasma pneumoniae (PPLO, Eaton Agent). Agents of psittacosis and ornithosis. Agents of lymphogranuloma venereum and granuloma inguinale. The spirochetal agent of relapsing fever ( Borrelia recurrentis ). The following gram-negative microorganisms: Haemophilus ducreyi ( chancroid ), Yersinia pestis Francisella tularensis, Bartonella bacilliformis, Bacteroides species, Vibrio cholerae and Campylobacte fetus, Brucella species ( in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli, Enterobacter aerogenes, Shigella species, Acinetobacter species, Haemophilus influenzae (respiratory infections), Klebsiella species (respiratory and urinary infections). Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Streptococcus pneumoniae, Staphylococcus aureus , respiratory skin and soft tissue infections. Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections. Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of infections due to: Neisseria gonorrhoeae and N. meningitidis, Treponema pallidum and Treponema pallidum subspecie s pertenue (syphilis and yaws), Listeria monocytogenes, Clostridium species, Fusobacterium fusiforme (Vincent's infection), Actinomyces species . In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. Doxycycline is indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. uuid:fc1ab280-9c09-475e-8073-ff51f80002e6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0003634 PMID:41385096 "[{""id"":""uuid:d06ad62a-5093-4270-b8aa-90b085f982bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:79e991c7-f9f1-4a3b-a9af-21c4ae45250e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler's syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:30628981-8b43-4466-b352-19e80faca070 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0007008 PMID:41385096 "[{""id"":""uuid:84250024-2632-477d-afa0-9a5fc6e50ca0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ae9ad061-550c-4337-b540-dd4fe598d5ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler's syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:8dbb1f4d-f485-4f57-b4cb-e2b680e2f227 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90863 biolink:treats MONDO:0020804 PMID:41385096 "[{""id"":""uuid:a6053479-0743-432f-8b56-d704d1141420"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5a0a3d55-6ee9-414a-97df-6c7d48ac222d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ODOMZO (sonidegib) is indicated for the treatment of adult patients with locally advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy. uuid:21abf644-1ecc-4924-aaa1-a7b57f1ad22a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90863 biolink:treats UMLS:C4745056 PMID:41385096 "[{""id"":""uuid:80397227-4cc6-4ea8-bbfa-1fdd78503e16"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1aa91d93-74fc-4be2-90e8-b7f61a34290a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ODOMZO (sonidegib) is indicated for the treatment of adult patients with locally advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy. uuid:74cc87c7-2ae6-4c0f-b6dd-dca217ced9f0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:78538 biolink:treats MONDO:0018018 PMID:41385096 "[{""id"":""uuid:89f5251c-b0b5-4015-a2d8-a3bea4491a59"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:30ec21bc-ec86-4e24-92a2-3310f18fd4d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VYNDAQEL and VYNDAMAX are indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization. uuid:6a51a8b0-5631-4a36-9ee4-3bc84f5ad07c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:78538 biolink:treats MONDO:0971008 PMID:41385096 "[{""id"":""uuid:9b8c230f-0530-4946-b827-53c5ce4c4e8d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cdb4fc52-0c55-4e59-8de5-041506ace8fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VYNDAQEL and VYNDAMAX are indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization. uuid:cc8a95c3-c045-4e2f-9ca8-e3faa63b431f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:CEGM9YBNGD biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:2e8d5933-5b48-4aff-a2ec-47ad3bf56964"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c9803cf7-f85e-4a10-b9f4-15b550e2e783"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e3dc5ac6-f45c-4b80-b786-5b3cee456ddc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/retsevmo""]},{""id"":""uuid:44910b4b-9880-43bd-8909-91b9f58e75de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RETEVMO ® is a kinase inhibitor indicated for the treatment of: Adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a rearranged during transfection (RET) gene fusion, as detected by an FDA-approved test ( 1.1 ) Adult and pediatric patients 2 years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation, as detected by an FDA-approved test, who require systemic therapy ( 1.2 ) Adult and pediatric patients 2 years of age and older with advanced or metastatic thyroid cancer with a RET gene fusion, as detected by an FDA-approved test, who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate) ( 1.3 ) Adult and pediatric patients 2 years of age and older with locally advanced or metastatic solid tumors with a RET gene fusion, as detected by an FDA-approved test, that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options 1 ( 1.4 ) 1 This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).|[EMA] Retsevmo as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with advanced RET-mutant medullary thyroid cancer (MTC)advanced RET fusion-positive non-small cell lung cancer (NSCLC) not previously treated with a RET inhibitoradvanced RET fusion-positive thyroid cancer who require systematic therapy following prior treatment|[PMDA] Drugs with a new active ingredient indicated for the treatment of RET fusion gene-positive unresectable advanced or recurrent non-small cell lung cancer. [Orphan drug] uuid:1b1c4b18-4e15-4668-80a9-d28f20da89ef biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:CEGM9YBNGD biolink:treats MONDO:0015277 PMID:41385096 "[{""id"":""uuid:bdecb87a-97e9-4d64-b94e-0a4b886f0d3e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:03a592ff-4251-42fe-89b2-2c8d9a17ab30"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:312f0ff5-2bf7-4581-9494-74011a75db9c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/retsevmo""]},{""id"":""uuid:ca6cc82e-079a-4e72-a697-c867fa3c4a53"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RETEVMO ® is a kinase inhibitor indicated for the treatment of: Adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a rearranged during transfection (RET) gene fusion, as detected by an FDA-approved test ( 1.1 ) Adult and pediatric patients 2 years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation, as detected by an FDA-approved test, who require systemic therapy ( 1.2 ) Adult and pediatric patients 2 years of age and older with advanced or metastatic thyroid cancer with a RET gene fusion, as detected by an FDA-approved test, who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate) ( 1.3 ) Adult and pediatric patients 2 years of age and older with locally advanced or metastatic solid tumors with a RET gene fusion, as detected by an FDA-approved test, that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options 1 ( 1.4 ) 1 This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).|[EMA] Retsevmo as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with advanced RET-mutant medullary thyroid cancer (MTC)advanced RET fusion-positive non-small cell lung cancer (NSCLC) not previously treated with a RET inhibitoradvanced RET fusion-positive thyroid cancer who require systematic therapy following prior treatment|[PMDA] Drugs with a new indication and a new dosage for the treatment of RET fusion gene-positive unresectable thyroid cancer and RET gene mutation-positive unresectable medullary thyroid cancer. [Orphan drug] uuid:831dbd07-6d66-4833-90fd-a081e811f036 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:CEGM9YBNGD biolink:treats MONDO:0002108 PMID:41385096 "[{""id"":""uuid:a2a0b16b-a1cf-4217-a0bb-849ebf367698"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:4281ed30-cb7e-4ee9-a3dd-2c5262906a09"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:901d3f4b-3d43-4b22-8c41-c24ae4b357f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/retsevmo""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] RETEVMO ® is a kinase inhibitor indicated for the treatment of: Adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a rearranged during transfection (RET) gene fusion, as detected by an FDA-approved test ( 1.1 ) Adult and pediatric patients 2 years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation, as detected by an FDA-approved test, who require systemic therapy ( 1.2 ) Adult and pediatric patients 2 years of age and older with advanced or metastatic thyroid cancer with a RET gene fusion, as detected by an FDA-approved test, who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate) ( 1.3 ) Adult and pediatric patients 2 years of age and older with locally advanced or metastatic solid tumors with a RET gene fusion, as detected by an FDA-approved test, that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options 1 ( 1.4 ) 1 This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).|[EMA] Retsevmo as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with advanced RET-mutant medullary thyroid cancer (MTC)advanced RET fusion-positive non-small cell lung cancer (NSCLC) not previously treated with a RET inhibitoradvanced RET fusion-positive thyroid cancer who require systematic therapy following prior treatment uuid:4edffd14-e7b1-47b7-8f52-ca0dcc4b1523 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:CEGM9YBNGD biolink:treats UMLS:C0280100 PMID:41385096 "[{""id"":""uuid:6ddb0610-a143-4b8e-8b77-12faac684c35"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:84874bd0-0cc9-4c16-82d9-0a947cf396d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RETEVMO ® is a kinase inhibitor indicated for the treatment of: Adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a rearranged during transfection (RET) gene fusion, as detected by an FDA-approved test ( 1.1 ) Adult and pediatric patients 2 years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation, as detected by an FDA-approved test, who require systemic therapy ( 1.2 ) Adult and pediatric patients 2 years of age and older with advanced or metastatic thyroid cancer with a RET gene fusion, as detected by an FDA-approved test, who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate) ( 1.3 ) Adult and pediatric patients 2 years of age and older with locally advanced or metastatic solid tumors with a RET gene fusion, as detected by an FDA-approved test, that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options 1 ( 1.4 ) 1 This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). uuid:734fbfae-3010-4264-adcd-b2f158c63908 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:XN7MM8XG2M biolink:treats MONDO:0011438 PMID:41385096 "[{""id"":""uuid:6df5d1c3-21a9-43be-ad91-60c4b4789454"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ec1357bf-bba0-40a8-ba6e-8cc2f8aea7c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] WINLEVI (clascoterone) cream is an androgen receptor inhibitor indicated for the topical treatment of acne vulgaris in patients 12 years of age and older. uuid:72f357ca-2e26-494e-b75c-0092924b308d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60311 biolink:treats MONDO:0005420 PMID:41385096 "[{""id"":""uuid:26f93f28-2c8a-4512-a01c-6496d4685aa7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3ce85c64-0def-4f3d-b46a-d80d44288aa3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Thyroid Tablets, USP are indicated: 1. As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (See WARNINGS ). 2. As pituitary TSH suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto’s), multinodular goiter, and in the management of thyroid cancer. uuid:07d26ec6-6de9-4f45-b48d-70afdf4b1143 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60311 biolink:treats MONDO:0018612 PMID:41385096 "[{""id"":""uuid:2515a309-2db0-4112-906f-86b4cb1bfc15"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:49ce2131-9db6-4150-bda8-ba677990515f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Thyroid Tablets, USP are indicated: 1. As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (See WARNINGS ). 2. As pituitary TSH suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto’s), multinodular goiter, and in the management of thyroid cancer. uuid:4121c0d0-ee47-4d63-aa50-e21077745506 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60311 biolink:treats MONDO:0009718 PMID:41385096 "[{""id"":""uuid:f3c84844-7f15-48e6-a4f2-b920ade4076c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:566cf1db-07eb-41da-a7c3-996056594ddc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Thyroid Tablets, USP are indicated: 1. As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (See WARNINGS ). 2. As pituitary TSH suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto’s), multinodular goiter, and in the management of thyroid cancer. uuid:28a9266a-d2ad-45ed-8114-329e87e95e38 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60311 biolink:treats MONDO:0001658 PMID:41385096 "[{""id"":""uuid:dccf5b39-938c-4122-90ac-7f6f9af0b6d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d1559ee2-a86d-46f4-9394-dd0ace4b6077"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Thyroid Tablets, USP are indicated: 1. As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (See WARNINGS ). 2. As pituitary TSH suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto’s), multinodular goiter, and in the management of thyroid cancer. uuid:ec5a5c96-25ea-4839-9a79-f1876e881a7c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60311 biolink:treats HP:0025388 PMID:41385096 "[{""id"":""uuid:2d8f592b-9003-41d7-bc19-505e3a4b8e0f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2f9ad49d-fab6-440e-a18a-fefc4ac68643"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Thyroid Tablets, USP are indicated: 1. As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (See WARNINGS ). 2. As pituitary TSH suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto’s), multinodular goiter, and in the management of thyroid cancer. uuid:00f243b0-bb48-436c-8feb-79bb9951074b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60311 biolink:treats MONDO:0006982 PMID:41385096 "[{""id"":""uuid:97dd3c0c-1255-46f5-b1b4-0f893fdcf7e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4f109960-f684-41c7-9c98-a87c573a887b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Thyroid Tablets, USP are indicated: 1. As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (See WARNINGS ). 2. As pituitary TSH suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto’s), multinodular goiter, and in the management of thyroid cancer. uuid:4a9ed183-9e3c-4c96-82cc-7344000ebfc5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60311 biolink:treats MONDO:0007699 PMID:41385096 "[{""id"":""uuid:d95a744d-3f23-4fbc-9551-aab3e4d78412"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1445669d-eeda-4513-a490-abf00191de82"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Thyroid Tablets, USP are indicated: 1. As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (See WARNINGS ). 2. As pituitary TSH suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto’s), multinodular goiter, and in the management of thyroid cancer. uuid:d232d9d1-391a-4376-bbd1-e5e502a97d33 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60311 biolink:treats MONDO:0000334 PMID:41385096 "[{""id"":""uuid:167e58d5-cfa3-4562-8770-f870a3ca30ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8b86a68c-1254-428b-b7cc-d222b01831d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Thyroid Tablets, USP are indicated: 1. As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (See WARNINGS ). 2. As pituitary TSH suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto’s), multinodular goiter, and in the management of thyroid cancer. uuid:ae672a1c-902f-41f7-9fd9-469e7c12f2df biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60311 biolink:treats MONDO:0002108 PMID:41385096 "[{""id"":""uuid:fb572ce6-3187-4934-95e7-b15c9631bf00"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1d824d26-82d7-4cff-abc6-9c926dd538b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Thyroid Tablets, USP are indicated: 1. As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (See WARNINGS ). 2. As pituitary TSH suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto’s), multinodular goiter, and in the management of thyroid cancer. uuid:5084db70-5e4f-478c-9bdf-fb04a5bc5739 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2118728 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:f9edfea7-6d97-443c-a8a1-2dd5bba91087"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:712fe97d-c346-47a7-b08e-af9ccb1a52d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] APADAZ is indicated for the short-term (no more than 14 days) management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, and misuse with opioids, which can occur at any dosage or duration [see Warnings and Precautions ( 5.1 ) ] reserve APADAZ for use in patients for whom alternative treatment options [e.g., non-opioid analgesics]: Have not been tolerated or are not expected to be tolerated, Have not provided adequate analgesia or are not expected to provide adequate analgesia. APADAZ should not be used for an extended period of time unless the pain remains severe enough to require an opioid analgesic and for which alternative treatment options continue to be inadequate. uuid:e9a89d62-2ec7-4f21-a3c6-902942de728b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29034 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:6d44e312-7796-4dc8-806c-af74767294b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c97fb807-f0c3-44b6-87f2-440e11a43bac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Injectafer is indicated for the treatment of: • iron deficiency anemia (IDA) in: adult and pediatric patients 1 year of age and older who have either intolerance or an unsatisfactory response to oral iron. adult patients who have non-dialysis dependent chronic kidney disease. • iron deficiency in adult patients with heart failure and New York Heart Association class II/III to improve exercise capacity. uuid:ccbdcf9e-4ead-4676-9233-ec7ebc55d53b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2S9ZZM9Q9V biolink:treats UMLS:C0278579 PMID:41385096 "[{""id"":""uuid:71aa5b72-323c-40d7-a8d4-790c33246795"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a2ffa533-4392-448c-8609-6da8a0313d2c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Avastin is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment. ( 1.1 ) Metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen. ( 1.1 ) Limitations of Use : Avastin is not indicated for adjuvant treatment of colon cancer. ( 1.1 ) Unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel for first-line treatment. ( 1.2 ) Recurrent glioblastoma in adults. ( 1.3 ) Metastatic renal cell carcinoma in combination with interferon alfa. ( 1.4 ) Persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin, or paclitaxel and topotecan. ( 1.5 ) Epithelial ovarian, fallopian tube, or primary peritoneal cancer: in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, for stage III or IV disease following initial surgical resection ( 1.6 ) in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease who received no more than 2 prior chemotherapy regimens ( 1.6 ) in combination with carboplatin and paclitaxel or carboplatin and gemcitabine, followed by Avastin as a single agent, for platinum-sensitive recurrent disease ( 1.6 ) Hepatocellular Carcinoma (HCC) in combination with atezolizumab for the treatment of patients with unresectable or metastatic HCC who have not received prior systemic therapy ( 1.7 ) uuid:ecf2ac26-7ba6-42eb-b808-a83a1eefde6d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2S9ZZM9Q9V biolink:treats MONDO:0007256 PMID:41385096 "[{""id"":""uuid:0a8184cd-a7b7-42c4-8c77-022a3a4f96e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e93039a7-1acf-413b-b5e0-8d19496dbbbd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c0d3bb62-fd9c-4432-91c9-abef48891b61"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Avastin is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment. ( 1.1 ) Metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen. ( 1.1 ) Limitations of Use : Avastin is not indicated for adjuvant treatment of colon cancer. ( 1.1 ) Unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel for first-line treatment. ( 1.2 ) Recurrent glioblastoma in adults. ( 1.3 ) Metastatic renal cell carcinoma in combination with interferon alfa. ( 1.4 ) Persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin, or paclitaxel and topotecan. ( 1.5 ) Epithelial ovarian, fallopian tube, or primary peritoneal cancer: in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, for stage III or IV disease following initial surgical resection ( 1.6 ) in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease who received no more than 2 prior chemotherapy regimens ( 1.6 ) in combination with carboplatin and paclitaxel or carboplatin and gemcitabine, followed by Avastin as a single agent, for platinum-sensitive recurrent disease ( 1.6 ) Hepatocellular Carcinoma (HCC) in combination with atezolizumab for the treatment of patients with unresectable or metastatic HCC who have not received prior systemic therapy ( 1.7 )|[PMDA] Drugs with a new indication and a new dosage for the treatment of unresectable hepatocellular carcinoma. [Priority review] uuid:25f621e2-c573-4a1f-8695-34b06ee61b81 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63616 biolink:treats UMLS:C5770027 PMID:41385096 "[{""id"":""uuid:9996886c-4796-4400-9cbd-191a78527f8d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5366e2fc-5e11-4bd5-b6bc-0de190ba2466"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AXTLE is a folate analog metabolic inhibitor indicated: in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic, non-squamous NSCLC. ( 1.1 ) as a single agent for the maintenance treatment of patients with locally advanced or metastatic, non-squamous NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. ( 1.1 ) as a single agent for the treatment of patients with recurrent, metastatic non-squamous, NSCLC after prior chemotherapy. ( 1.1 ) Limitations of Use: AXTLE is not indicated for the treatment of patients with squamous cell, non-small cell lung cancer. ( 1.1 ) initial treatment, in combination with cisplatin, of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery. ( 1.2 ) uuid:756ceca4-7500-411e-8c96-2253b5bcab33 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4F4X42SYQ6 biolink:treats MONDO:0018908 PMID:41385096 "[{""id"":""uuid:6f023aa4-72cd-4453-b514-467e1a261a3b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:11a8302c-ec7d-40b7-b513-eae4b020156c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:31ad9a96-a35f-4dda-b0ee-14aa7d2fb03a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/riximyo""]},{""id"":""uuid:745e47cb-6d2a-44b8-b787-49f92e52ba79"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RITUXAN is a CD20-directed cytolytic antibody indicated for the treatment of: Adult patients with Non-Hodgkin's Lymphoma (NHL) ( 1.1 ). Relapsed or refractory, low grade or follicular, CD20-positive B-cell NHL as a single agent. Previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy. Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy. Previously untreated diffuse large B-cell, CD20-positive NHL in combination with (cyclophosphamide, doxorubicin, vincristine, and prednisone) (CHOP) or other anthracycline-based chemotherapy regimens. Pediatric patients aged 6 months and older with mature B-cell NHL and mature B-cell acute leukemia (B-AL) ( 1.1 ) Previously untreated, advanced stage, CD20-positive, diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL) or mature B-cell acute leukemia (B-AL) in combination with chemotherapy. Adult patients with Chronic Lymphocytic Leukemia (CLL) ( 1.2 ). Previously untreated and previously treated CD20-positive CLL in combination with fludarabine and cyclophosphamide (FC). Rheumatoid Arthritis (RA) in combination with methotrexate in adult patients with moderately-to severely-active RA who have inadequate response to one or more TNF antagonist therapies ( 1.3 ). Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA) in adult and pediatric patients 2 years of age and older in combination with glucocorticoids ( 1.4 ). Moderate to severe Pemphigus Vulgaris (PV) in adult patients ( 1.5 ).|[EMA] Riximyo is indicated in adults for the following indications:Non-Hodgkin’s lymphoma (NHL)Riximyo is indicated for the treatment of previously untreated adult patients with stage III-IV follicular lymphoma in combination with chemotherapy.Riximyo maintenance therapy is indicated for the treatment of adult follicular lymphoma patients responding to induction therapy.Riximyo monotherapy is indicated for treatment of adult patients with stage III-IV follicular lymphoma who are chemoresistant or are in their second or subsequent relapse after chemotherapy.Riximyo is indicated for the treatment of adult patients with CD20 positive diffuse large B cell non-Hodgkin’s lymphoma in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy.Riximyo in combination with chemotherapy is indicated for the treatment of paediatric patients (aged ≥ 6 months to < 18 years old) with previously untreated advanced stage CD20 positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL)/Burkitt leukaemia (mature B-cell acute leukaemia) (BAL) or Burkitt-like lymphoma (BLL).Chronic lymphocytic leukaemia (CLL)Riximyo in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory chronic lymphocytic leukaemia. Only limited data are available on efficacy and safety for patients previously treated with monoclonal antibodies including rituximab or patients refractory to previous rituximab plus chemotherapy.See section 5.1 for further information.Rheumatoid arthritisRiximyo in combination with methotrexate is indicated for the treatment of adult patients with severe active rheumatoid arthritis who have had an inadequate response or intolerance to other disease-modifying anti-rheumatic drugs (DMARD) including one or more tumour necrosis factor (TNF) inhibitor therapies.Rituximab has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate.Granulomatosis with polyangiitis and microscopic polyangiitisRiximyo, in combination with glucocorticoids, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (Wegener’s) (GPA) and microscopic polyangiitis (MPA).Riximyo, in combination with glucocorticoids, is indicated for the induction of remission in paediatric patients (aged ≥ 2 to < 18 years old) with severe, active GPA (Wegener’s) and MPA.Pemphigus vulgarisRiximyo is indicated for the treatment of patients with moderate to severe pemphigus vulgaris (PV).|[PMDA] Follow-on biologics indicated for the treatment of CD20-positive B-cell non-Hodgkin's lymphoma, CD20-positive B-cell lymphoproliferative disorder associated with immunosuppression, Wegener's granulomatosis, and microscopic polyangiitis. uuid:e2612c8e-c0c0-4067-8762-99115387d954 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4F4X42SYQ6 biolink:treats MONDO:0018906 PMID:41385096 "[{""id"":""uuid:1d2a71a4-dfe6-4ecd-8e0c-fbd1c22b0fca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:e2efc6d2-ee94-45c5-acd3-8e476b7aca7e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:84ab178a-7fad-436d-91ab-69cf2fd5d634"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/riximyo""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] RITUXAN is a CD20-directed cytolytic antibody indicated for the treatment of: Adult patients with Non-Hodgkin's Lymphoma (NHL) ( 1.1 ). Relapsed or refractory, low grade or follicular, CD20-positive B-cell NHL as a single agent. Previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy. Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy. Previously untreated diffuse large B-cell, CD20-positive NHL in combination with (cyclophosphamide, doxorubicin, vincristine, and prednisone) (CHOP) or other anthracycline-based chemotherapy regimens. Pediatric patients aged 6 months and older with mature B-cell NHL and mature B-cell acute leukemia (B-AL) ( 1.1 ) Previously untreated, advanced stage, CD20-positive, diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL) or mature B-cell acute leukemia (B-AL) in combination with chemotherapy. Adult patients with Chronic Lymphocytic Leukemia (CLL) ( 1.2 ). Previously untreated and previously treated CD20-positive CLL in combination with fludarabine and cyclophosphamide (FC). Rheumatoid Arthritis (RA) in combination with methotrexate in adult patients with moderately-to severely-active RA who have inadequate response to one or more TNF antagonist therapies ( 1.3 ). Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA) in adult and pediatric patients 2 years of age and older in combination with glucocorticoids ( 1.4 ). Moderate to severe Pemphigus Vulgaris (PV) in adult patients ( 1.5 ).|[EMA] Riximyo is indicated in adults for the following indications:Non-Hodgkin’s lymphoma (NHL)Riximyo is indicated for the treatment of previously untreated adult patients with stage III-IV follicular lymphoma in combination with chemotherapy.Riximyo maintenance therapy is indicated for the treatment of adult follicular lymphoma patients responding to induction therapy.Riximyo monotherapy is indicated for treatment of adult patients with stage III-IV follicular lymphoma who are chemoresistant or are in their second or subsequent relapse after chemotherapy.Riximyo is indicated for the treatment of adult patients with CD20 positive diffuse large B cell non-Hodgkin’s lymphoma in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy.Riximyo in combination with chemotherapy is indicated for the treatment of paediatric patients (aged ≥ 6 months to < 18 years old) with previously untreated advanced stage CD20 positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL)/Burkitt leukaemia (mature B-cell acute leukaemia) (BAL) or Burkitt-like lymphoma (BLL).Chronic lymphocytic leukaemia (CLL)Riximyo in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory chronic lymphocytic leukaemia. Only limited data are available on efficacy and safety for patients previously treated with monoclonal antibodies including rituximab or patients refractory to previous rituximab plus chemotherapy.See section 5.1 for further information.Rheumatoid arthritisRiximyo in combination with methotrexate is indicated for the treatment of adult patients with severe active rheumatoid arthritis who have had an inadequate response or intolerance to other disease-modifying anti-rheumatic drugs (DMARD) including one or more tumour necrosis factor (TNF) inhibitor therapies.Rituximab has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate.Granulomatosis with polyangiitis and microscopic polyangiitisRiximyo, in combination with glucocorticoids, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (Wegener’s) (GPA) and microscopic polyangiitis (MPA).Riximyo, in combination with glucocorticoids, is indicated for the induction of remission in paediatric patients (aged ≥ 2 to < 18 years old) with severe, active GPA (Wegener’s) and MPA.Pemphigus vulgarisRiximyo is indicated for the treatment of patients with moderate to severe pemphigus vulgaris (PV). uuid:cea46262-6e39-4dbe-8d09-ec2c0c79d2d1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4F4X42SYQ6 biolink:treats MONDO:0018905 PMID:41385096 "[{""id"":""uuid:aa2cae98-837a-4572-ae78-0c6a7b9196ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:b237b69d-4498-4ae3-9893-9f809463eda8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:974062ca-abb4-4a84-99ee-c1d577138424"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/riximyo""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] RITUXAN is a CD20-directed cytolytic antibody indicated for the treatment of: Adult patients with Non-Hodgkin's Lymphoma (NHL) ( 1.1 ). Relapsed or refractory, low grade or follicular, CD20-positive B-cell NHL as a single agent. Previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy. Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy. Previously untreated diffuse large B-cell, CD20-positive NHL in combination with (cyclophosphamide, doxorubicin, vincristine, and prednisone) (CHOP) or other anthracycline-based chemotherapy regimens. Pediatric patients aged 6 months and older with mature B-cell NHL and mature B-cell acute leukemia (B-AL) ( 1.1 ) Previously untreated, advanced stage, CD20-positive, diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL) or mature B-cell acute leukemia (B-AL) in combination with chemotherapy. Adult patients with Chronic Lymphocytic Leukemia (CLL) ( 1.2 ). Previously untreated and previously treated CD20-positive CLL in combination with fludarabine and cyclophosphamide (FC). Rheumatoid Arthritis (RA) in combination with methotrexate in adult patients with moderately-to severely-active RA who have inadequate response to one or more TNF antagonist therapies ( 1.3 ). Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA) in adult and pediatric patients 2 years of age and older in combination with glucocorticoids ( 1.4 ). Moderate to severe Pemphigus Vulgaris (PV) in adult patients ( 1.5 ).|[EMA] Riximyo is indicated in adults for the following indications:Non-Hodgkin’s lymphoma (NHL)Riximyo is indicated for the treatment of previously untreated adult patients with stage III-IV follicular lymphoma in combination with chemotherapy.Riximyo maintenance therapy is indicated for the treatment of adult follicular lymphoma patients responding to induction therapy.Riximyo monotherapy is indicated for treatment of adult patients with stage III-IV follicular lymphoma who are chemoresistant or are in their second or subsequent relapse after chemotherapy.Riximyo is indicated for the treatment of adult patients with CD20 positive diffuse large B cell non-Hodgkin’s lymphoma in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy.Riximyo in combination with chemotherapy is indicated for the treatment of paediatric patients (aged ≥ 6 months to < 18 years old) with previously untreated advanced stage CD20 positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL)/Burkitt leukaemia (mature B-cell acute leukaemia) (BAL) or Burkitt-like lymphoma (BLL).Chronic lymphocytic leukaemia (CLL)Riximyo in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory chronic lymphocytic leukaemia. Only limited data are available on efficacy and safety for patients previously treated with monoclonal antibodies including rituximab or patients refractory to previous rituximab plus chemotherapy.See section 5.1 for further information.Rheumatoid arthritisRiximyo in combination with methotrexate is indicated for the treatment of adult patients with severe active rheumatoid arthritis who have had an inadequate response or intolerance to other disease-modifying anti-rheumatic drugs (DMARD) including one or more tumour necrosis factor (TNF) inhibitor therapies.Rituximab has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate.Granulomatosis with polyangiitis and microscopic polyangiitisRiximyo, in combination with glucocorticoids, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (Wegener’s) (GPA) and microscopic polyangiitis (MPA).Riximyo, in combination with glucocorticoids, is indicated for the induction of remission in paediatric patients (aged ≥ 2 to < 18 years old) with severe, active GPA (Wegener’s) and MPA.Pemphigus vulgarisRiximyo is indicated for the treatment of patients with moderate to severe pemphigus vulgaris (PV). uuid:e6cfbb0e-2049-467f-8c53-646e2994a945 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4F4X42SYQ6 biolink:treats MONDO:0004949 PMID:41385096 "[{""id"":""uuid:212f803c-a349-4066-807b-4bd8ce8a710f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e991542e-387c-469d-9bad-308d5ed6f3d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RITUXAN is a CD20-directed cytolytic antibody indicated for the treatment of: Adult patients with Non-Hodgkin's Lymphoma (NHL) ( 1.1 ). Relapsed or refractory, low grade or follicular, CD20-positive B-cell NHL as a single agent. Previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy. Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy. Previously untreated diffuse large B-cell, CD20-positive NHL in combination with (cyclophosphamide, doxorubicin, vincristine, and prednisone) (CHOP) or other anthracycline-based chemotherapy regimens. Pediatric patients aged 6 months and older with mature B-cell NHL and mature B-cell acute leukemia (B-AL) ( 1.1 ) Previously untreated, advanced stage, CD20-positive, diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL) or mature B-cell acute leukemia (B-AL) in combination with chemotherapy. Adult patients with Chronic Lymphocytic Leukemia (CLL) ( 1.2 ). Previously untreated and previously treated CD20-positive CLL in combination with fludarabine and cyclophosphamide (FC). Rheumatoid Arthritis (RA) in combination with methotrexate in adult patients with moderately-to severely-active RA who have inadequate response to one or more TNF antagonist therapies ( 1.3 ). Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA) in adult and pediatric patients 2 years of age and older in combination with glucocorticoids ( 1.4 ). Moderate to severe Pemphigus Vulgaris (PV) in adult patients ( 1.5 ). uuid:df40395e-91da-496a-bd23-5c729c19eb02 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4F4X42SYQ6 biolink:treats MONDO:0004947 PMID:41385096 "[{""id"":""uuid:d9129359-b046-459b-b556-da5e6bb20e35"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d53605d0-f9ba-484e-bebc-0f48dabbfadf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RITUXAN is a CD20-directed cytolytic antibody indicated for the treatment of: Adult patients with Non-Hodgkin's Lymphoma (NHL) ( 1.1 ). Relapsed or refractory, low grade or follicular, CD20-positive B-cell NHL as a single agent. Previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy. Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy. Previously untreated diffuse large B-cell, CD20-positive NHL in combination with (cyclophosphamide, doxorubicin, vincristine, and prednisone) (CHOP) or other anthracycline-based chemotherapy regimens. Pediatric patients aged 6 months and older with mature B-cell NHL and mature B-cell acute leukemia (B-AL) ( 1.1 ) Previously untreated, advanced stage, CD20-positive, diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL) or mature B-cell acute leukemia (B-AL) in combination with chemotherapy. Adult patients with Chronic Lymphocytic Leukemia (CLL) ( 1.2 ). Previously untreated and previously treated CD20-positive CLL in combination with fludarabine and cyclophosphamide (FC). Rheumatoid Arthritis (RA) in combination with methotrexate in adult patients with moderately-to severely-active RA who have inadequate response to one or more TNF antagonist therapies ( 1.3 ). Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA) in adult and pediatric patients 2 years of age and older in combination with glucocorticoids ( 1.4 ). Moderate to severe Pemphigus Vulgaris (PV) in adult patients ( 1.5 ). uuid:700a6658-6b01-46d1-8cac-dea47c32fae7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4F4X42SYQ6 biolink:treats MONDO:0007243 PMID:41385096 "[{""id"":""uuid:55eb63b1-8da3-4bf5-b853-403b167dbc1b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:cf19b559-2e03-471c-abfd-3028b7e12ea5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:37dabbec-621d-4770-a11e-b3601b6dc3ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/riximyo""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] RITUXAN is a CD20-directed cytolytic antibody indicated for the treatment of: Adult patients with Non-Hodgkin's Lymphoma (NHL) ( 1.1 ). Relapsed or refractory, low grade or follicular, CD20-positive B-cell NHL as a single agent. Previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy. Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy. Previously untreated diffuse large B-cell, CD20-positive NHL in combination with (cyclophosphamide, doxorubicin, vincristine, and prednisone) (CHOP) or other anthracycline-based chemotherapy regimens. Pediatric patients aged 6 months and older with mature B-cell NHL and mature B-cell acute leukemia (B-AL) ( 1.1 ) Previously untreated, advanced stage, CD20-positive, diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL) or mature B-cell acute leukemia (B-AL) in combination with chemotherapy. Adult patients with Chronic Lymphocytic Leukemia (CLL) ( 1.2 ). Previously untreated and previously treated CD20-positive CLL in combination with fludarabine and cyclophosphamide (FC). Rheumatoid Arthritis (RA) in combination with methotrexate in adult patients with moderately-to severely-active RA who have inadequate response to one or more TNF antagonist therapies ( 1.3 ). Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA) in adult and pediatric patients 2 years of age and older in combination with glucocorticoids ( 1.4 ). Moderate to severe Pemphigus Vulgaris (PV) in adult patients ( 1.5 ).|[EMA] Riximyo is indicated in adults for the following indications:Non-Hodgkin’s lymphoma (NHL)Riximyo is indicated for the treatment of previously untreated adult patients with stage III-IV follicular lymphoma in combination with chemotherapy.Riximyo maintenance therapy is indicated for the treatment of adult follicular lymphoma patients responding to induction therapy.Riximyo monotherapy is indicated for treatment of adult patients with stage III-IV follicular lymphoma who are chemoresistant or are in their second or subsequent relapse after chemotherapy.Riximyo is indicated for the treatment of adult patients with CD20 positive diffuse large B cell non-Hodgkin’s lymphoma in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy.Riximyo in combination with chemotherapy is indicated for the treatment of paediatric patients (aged ≥ 6 months to < 18 years old) with previously untreated advanced stage CD20 positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL)/Burkitt leukaemia (mature B-cell acute leukaemia) (BAL) or Burkitt-like lymphoma (BLL).Chronic lymphocytic leukaemia (CLL)Riximyo in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory chronic lymphocytic leukaemia. Only limited data are available on efficacy and safety for patients previously treated with monoclonal antibodies including rituximab or patients refractory to previous rituximab plus chemotherapy.See section 5.1 for further information.Rheumatoid arthritisRiximyo in combination with methotrexate is indicated for the treatment of adult patients with severe active rheumatoid arthritis who have had an inadequate response or intolerance to other disease-modifying anti-rheumatic drugs (DMARD) including one or more tumour necrosis factor (TNF) inhibitor therapies.Rituximab has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate.Granulomatosis with polyangiitis and microscopic polyangiitisRiximyo, in combination with glucocorticoids, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (Wegener’s) (GPA) and microscopic polyangiitis (MPA).Riximyo, in combination with glucocorticoids, is indicated for the induction of remission in paediatric patients (aged ≥ 2 to < 18 years old) with severe, active GPA (Wegener’s) and MPA.Pemphigus vulgarisRiximyo is indicated for the treatment of patients with moderate to severe pemphigus vulgaris (PV). uuid:e822f6cb-e81a-45c2-bf31-a5aae9b7b8d8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4F4X42SYQ6 biolink:treats MONDO:0004948 PMID:41385096 "[{""id"":""uuid:e12621b6-f449-42a1-bbc0-dd09eacf8575"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7b02c8ee-f4a1-41bb-af4a-934998902149"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:724b57ef-1375-4932-b0a0-fd2288345523"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/riximyo""]},{""id"":""uuid:e38574ce-838b-4747-a0e8-792fc27f9ae9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RITUXAN is a CD20-directed cytolytic antibody indicated for the treatment of: Adult patients with Non-Hodgkin's Lymphoma (NHL) ( 1.1 ). Relapsed or refractory, low grade or follicular, CD20-positive B-cell NHL as a single agent. Previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy. Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy. Previously untreated diffuse large B-cell, CD20-positive NHL in combination with (cyclophosphamide, doxorubicin, vincristine, and prednisone) (CHOP) or other anthracycline-based chemotherapy regimens. Pediatric patients aged 6 months and older with mature B-cell NHL and mature B-cell acute leukemia (B-AL) ( 1.1 ) Previously untreated, advanced stage, CD20-positive, diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL) or mature B-cell acute leukemia (B-AL) in combination with chemotherapy. Adult patients with Chronic Lymphocytic Leukemia (CLL) ( 1.2 ). Previously untreated and previously treated CD20-positive CLL in combination with fludarabine and cyclophosphamide (FC). Rheumatoid Arthritis (RA) in combination with methotrexate in adult patients with moderately-to severely-active RA who have inadequate response to one or more TNF antagonist therapies ( 1.3 ). Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA) in adult and pediatric patients 2 years of age and older in combination with glucocorticoids ( 1.4 ). Moderate to severe Pemphigus Vulgaris (PV) in adult patients ( 1.5 ).|[EMA] Riximyo is indicated in adults for the following indications:Non-Hodgkin’s lymphoma (NHL)Riximyo is indicated for the treatment of previously untreated adult patients with stage III-IV follicular lymphoma in combination with chemotherapy.Riximyo maintenance therapy is indicated for the treatment of adult follicular lymphoma patients responding to induction therapy.Riximyo monotherapy is indicated for treatment of adult patients with stage III-IV follicular lymphoma who are chemoresistant or are in their second or subsequent relapse after chemotherapy.Riximyo is indicated for the treatment of adult patients with CD20 positive diffuse large B cell non-Hodgkin’s lymphoma in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy.Riximyo in combination with chemotherapy is indicated for the treatment of paediatric patients (aged ≥ 6 months to < 18 years old) with previously untreated advanced stage CD20 positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL)/Burkitt leukaemia (mature B-cell acute leukaemia) (BAL) or Burkitt-like lymphoma (BLL).Chronic lymphocytic leukaemia (CLL)Riximyo in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory chronic lymphocytic leukaemia. Only limited data are available on efficacy and safety for patients previously treated with monoclonal antibodies including rituximab or patients refractory to previous rituximab plus chemotherapy.See section 5.1 for further information.Rheumatoid arthritisRiximyo in combination with methotrexate is indicated for the treatment of adult patients with severe active rheumatoid arthritis who have had an inadequate response or intolerance to other disease-modifying anti-rheumatic drugs (DMARD) including one or more tumour necrosis factor (TNF) inhibitor therapies.Rituximab has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate.Granulomatosis with polyangiitis and microscopic polyangiitisRiximyo, in combination with glucocorticoids, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (Wegener’s) (GPA) and microscopic polyangiitis (MPA).Riximyo, in combination with glucocorticoids, is indicated for the induction of remission in paediatric patients (aged ≥ 2 to < 18 years old) with severe, active GPA (Wegener’s) and MPA.Pemphigus vulgarisRiximyo is indicated for the treatment of patients with moderate to severe pemphigus vulgaris (PV).|[PMDA] Drugs with a new additional indication and a new dosage for the treatment of CD20-positive chronic lymphocytic leukemia. [Orphan drug] uuid:907e3a71-266f-4e1d-ab63-57bc7e8a87d5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4F4X42SYQ6 biolink:treats UMLS:C0861880 PMID:41385096 "[{""id"":""uuid:2a9f19bc-49da-4f37-b721-f2cfde7069f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:72cf775c-bdf7-42e8-87f0-9709a06032de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RITUXAN is a CD20-directed cytolytic antibody indicated for the treatment of: Adult patients with Non-Hodgkin's Lymphoma (NHL) ( 1.1 ). Relapsed or refractory, low grade or follicular, CD20-positive B-cell NHL as a single agent. Previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy. Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy. Previously untreated diffuse large B-cell, CD20-positive NHL in combination with (cyclophosphamide, doxorubicin, vincristine, and prednisone) (CHOP) or other anthracycline-based chemotherapy regimens. Pediatric patients aged 6 months and older with mature B-cell NHL and mature B-cell acute leukemia (B-AL) ( 1.1 ) Previously untreated, advanced stage, CD20-positive, diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL) or mature B-cell acute leukemia (B-AL) in combination with chemotherapy. Adult patients with Chronic Lymphocytic Leukemia (CLL) ( 1.2 ). Previously untreated and previously treated CD20-positive CLL in combination with fludarabine and cyclophosphamide (FC). Rheumatoid Arthritis (RA) in combination with methotrexate in adult patients with moderately-to severely-active RA who have inadequate response to one or more TNF antagonist therapies ( 1.3 ). Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA) in adult and pediatric patients 2 years of age and older in combination with glucocorticoids ( 1.4 ). Moderate to severe Pemphigus Vulgaris (PV) in adult patients ( 1.5 ). uuid:5b9e9f02-006c-4ac8-99a3-b1c05262780a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4F4X42SYQ6 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:920c1870-300b-49c6-88c8-56907cf2fbed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:8cc9ef6f-411a-468c-b20f-0b47577974fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:dfd6c0c6-d5a2-4219-a293-ee43a7caea96"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/riximyo""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] RITUXAN is a CD20-directed cytolytic antibody indicated for the treatment of: Adult patients with Non-Hodgkin's Lymphoma (NHL) ( 1.1 ). Relapsed or refractory, low grade or follicular, CD20-positive B-cell NHL as a single agent. Previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy. Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy. Previously untreated diffuse large B-cell, CD20-positive NHL in combination with (cyclophosphamide, doxorubicin, vincristine, and prednisone) (CHOP) or other anthracycline-based chemotherapy regimens. Pediatric patients aged 6 months and older with mature B-cell NHL and mature B-cell acute leukemia (B-AL) ( 1.1 ) Previously untreated, advanced stage, CD20-positive, diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL) or mature B-cell acute leukemia (B-AL) in combination with chemotherapy. Adult patients with Chronic Lymphocytic Leukemia (CLL) ( 1.2 ). Previously untreated and previously treated CD20-positive CLL in combination with fludarabine and cyclophosphamide (FC). Rheumatoid Arthritis (RA) in combination with methotrexate in adult patients with moderately-to severely-active RA who have inadequate response to one or more TNF antagonist therapies ( 1.3 ). Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA) in adult and pediatric patients 2 years of age and older in combination with glucocorticoids ( 1.4 ). Moderate to severe Pemphigus Vulgaris (PV) in adult patients ( 1.5 ).|[EMA] Riximyo is indicated in adults for the following indications:Non-Hodgkin’s lymphoma (NHL)Riximyo is indicated for the treatment of previously untreated adult patients with stage III-IV follicular lymphoma in combination with chemotherapy.Riximyo maintenance therapy is indicated for the treatment of adult follicular lymphoma patients responding to induction therapy.Riximyo monotherapy is indicated for treatment of adult patients with stage III-IV follicular lymphoma who are chemoresistant or are in their second or subsequent relapse after chemotherapy.Riximyo is indicated for the treatment of adult patients with CD20 positive diffuse large B cell non-Hodgkin’s lymphoma in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy.Riximyo in combination with chemotherapy is indicated for the treatment of paediatric patients (aged ≥ 6 months to < 18 years old) with previously untreated advanced stage CD20 positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL)/Burkitt leukaemia (mature B-cell acute leukaemia) (BAL) or Burkitt-like lymphoma (BLL).Chronic lymphocytic leukaemia (CLL)Riximyo in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory chronic lymphocytic leukaemia. Only limited data are available on efficacy and safety for patients previously treated with monoclonal antibodies including rituximab or patients refractory to previous rituximab plus chemotherapy.See section 5.1 for further information.Rheumatoid arthritisRiximyo in combination with methotrexate is indicated for the treatment of adult patients with severe active rheumatoid arthritis who have had an inadequate response or intolerance to other disease-modifying anti-rheumatic drugs (DMARD) including one or more tumour necrosis factor (TNF) inhibitor therapies.Rituximab has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate.Granulomatosis with polyangiitis and microscopic polyangiitisRiximyo, in combination with glucocorticoids, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (Wegener’s) (GPA) and microscopic polyangiitis (MPA).Riximyo, in combination with glucocorticoids, is indicated for the induction of remission in paediatric patients (aged ≥ 2 to < 18 years old) with severe, active GPA (Wegener’s) and MPA.Pemphigus vulgarisRiximyo is indicated for the treatment of patients with moderate to severe pemphigus vulgaris (PV). uuid:22bce86b-fe09-42e5-b736-f4bfca6c3516 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4F4X42SYQ6 biolink:treats MONDO:0012105 PMID:41385096 "[{""id"":""uuid:39395888-a9e4-43f7-a75e-d1d03b31711a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:cf64f553-900f-4cab-8cc4-b5186e0c0752"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:32d17095-ae13-4d55-8b5e-cd415c4b21ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/riximyo""]},{""id"":""uuid:21690267-90c6-4f62-8055-936f36f8d7b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RITUXAN is a CD20-directed cytolytic antibody indicated for the treatment of: Adult patients with Non-Hodgkin's Lymphoma (NHL) ( 1.1 ). Relapsed or refractory, low grade or follicular, CD20-positive B-cell NHL as a single agent. Previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy. Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy. Previously untreated diffuse large B-cell, CD20-positive NHL in combination with (cyclophosphamide, doxorubicin, vincristine, and prednisone) (CHOP) or other anthracycline-based chemotherapy regimens. Pediatric patients aged 6 months and older with mature B-cell NHL and mature B-cell acute leukemia (B-AL) ( 1.1 ) Previously untreated, advanced stage, CD20-positive, diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL) or mature B-cell acute leukemia (B-AL) in combination with chemotherapy. Adult patients with Chronic Lymphocytic Leukemia (CLL) ( 1.2 ). Previously untreated and previously treated CD20-positive CLL in combination with fludarabine and cyclophosphamide (FC). Rheumatoid Arthritis (RA) in combination with methotrexate in adult patients with moderately-to severely-active RA who have inadequate response to one or more TNF antagonist therapies ( 1.3 ). Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA) in adult and pediatric patients 2 years of age and older in combination with glucocorticoids ( 1.4 ). Moderate to severe Pemphigus Vulgaris (PV) in adult patients ( 1.5 ).|[EMA] Riximyo is indicated in adults for the following indications:Non-Hodgkin’s lymphoma (NHL)Riximyo is indicated for the treatment of previously untreated adult patients with stage III-IV follicular lymphoma in combination with chemotherapy.Riximyo maintenance therapy is indicated for the treatment of adult follicular lymphoma patients responding to induction therapy.Riximyo monotherapy is indicated for treatment of adult patients with stage III-IV follicular lymphoma who are chemoresistant or are in their second or subsequent relapse after chemotherapy.Riximyo is indicated for the treatment of adult patients with CD20 positive diffuse large B cell non-Hodgkin’s lymphoma in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy.Riximyo in combination with chemotherapy is indicated for the treatment of paediatric patients (aged ≥ 6 months to < 18 years old) with previously untreated advanced stage CD20 positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL)/Burkitt leukaemia (mature B-cell acute leukaemia) (BAL) or Burkitt-like lymphoma (BLL).Chronic lymphocytic leukaemia (CLL)Riximyo in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory chronic lymphocytic leukaemia. Only limited data are available on efficacy and safety for patients previously treated with monoclonal antibodies including rituximab or patients refractory to previous rituximab plus chemotherapy.See section 5.1 for further information.Rheumatoid arthritisRiximyo in combination with methotrexate is indicated for the treatment of adult patients with severe active rheumatoid arthritis who have had an inadequate response or intolerance to other disease-modifying anti-rheumatic drugs (DMARD) including one or more tumour necrosis factor (TNF) inhibitor therapies.Rituximab has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate.Granulomatosis with polyangiitis and microscopic polyangiitisRiximyo, in combination with glucocorticoids, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (Wegener’s) (GPA) and microscopic polyangiitis (MPA).Riximyo, in combination with glucocorticoids, is indicated for the induction of remission in paediatric patients (aged ≥ 2 to < 18 years old) with severe, active GPA (Wegener’s) and MPA.Pemphigus vulgarisRiximyo is indicated for the treatment of patients with moderate to severe pemphigus vulgaris (PV).|[PMDA] Follow-on biologics indicated for the treatment of CD20-positive B-cell non-Hodgkin's lymphoma, CD20-positive B-cell lymphoproliferative disorder associated with immunosuppression, Wegener's granulomatosis, and microscopic polyangiitis. uuid:bc3a3d1f-aedd-4294-b959-edd79daf52c7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4F4X42SYQ6 biolink:treats MONDO:0019124 PMID:41385096 "[{""id"":""uuid:ae6f6798-16d7-4c52-a67e-28558a26f42f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2cae1977-693e-4664-983b-51121a61feb4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:2eb59329-f2d9-48fc-8560-995e2e5c1cbc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/riximyo""]},{""id"":""uuid:14c18c1e-f0ad-41bb-8443-55fcd9d30429"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RITUXAN is a CD20-directed cytolytic antibody indicated for the treatment of: Adult patients with Non-Hodgkin's Lymphoma (NHL) ( 1.1 ). Relapsed or refractory, low grade or follicular, CD20-positive B-cell NHL as a single agent. Previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy. Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy. Previously untreated diffuse large B-cell, CD20-positive NHL in combination with (cyclophosphamide, doxorubicin, vincristine, and prednisone) (CHOP) or other anthracycline-based chemotherapy regimens. Pediatric patients aged 6 months and older with mature B-cell NHL and mature B-cell acute leukemia (B-AL) ( 1.1 ) Previously untreated, advanced stage, CD20-positive, diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL) or mature B-cell acute leukemia (B-AL) in combination with chemotherapy. Adult patients with Chronic Lymphocytic Leukemia (CLL) ( 1.2 ). Previously untreated and previously treated CD20-positive CLL in combination with fludarabine and cyclophosphamide (FC). Rheumatoid Arthritis (RA) in combination with methotrexate in adult patients with moderately-to severely-active RA who have inadequate response to one or more TNF antagonist therapies ( 1.3 ). Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA) in adult and pediatric patients 2 years of age and older in combination with glucocorticoids ( 1.4 ). Moderate to severe Pemphigus Vulgaris (PV) in adult patients ( 1.5 ).|[EMA] Riximyo is indicated in adults for the following indications:Non-Hodgkin’s lymphoma (NHL)Riximyo is indicated for the treatment of previously untreated adult patients with stage III-IV follicular lymphoma in combination with chemotherapy.Riximyo maintenance therapy is indicated for the treatment of adult follicular lymphoma patients responding to induction therapy.Riximyo monotherapy is indicated for treatment of adult patients with stage III-IV follicular lymphoma who are chemoresistant or are in their second or subsequent relapse after chemotherapy.Riximyo is indicated for the treatment of adult patients with CD20 positive diffuse large B cell non-Hodgkin’s lymphoma in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy.Riximyo in combination with chemotherapy is indicated for the treatment of paediatric patients (aged ≥ 6 months to < 18 years old) with previously untreated advanced stage CD20 positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL)/Burkitt leukaemia (mature B-cell acute leukaemia) (BAL) or Burkitt-like lymphoma (BLL).Chronic lymphocytic leukaemia (CLL)Riximyo in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory chronic lymphocytic leukaemia. Only limited data are available on efficacy and safety for patients previously treated with monoclonal antibodies including rituximab or patients refractory to previous rituximab plus chemotherapy.See section 5.1 for further information.Rheumatoid arthritisRiximyo in combination with methotrexate is indicated for the treatment of adult patients with severe active rheumatoid arthritis who have had an inadequate response or intolerance to other disease-modifying anti-rheumatic drugs (DMARD) including one or more tumour necrosis factor (TNF) inhibitor therapies.Rituximab has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate.Granulomatosis with polyangiitis and microscopic polyangiitisRiximyo, in combination with glucocorticoids, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (Wegener’s) (GPA) and microscopic polyangiitis (MPA).Riximyo, in combination with glucocorticoids, is indicated for the induction of remission in paediatric patients (aged ≥ 2 to < 18 years old) with severe, active GPA (Wegener’s) and MPA.Pemphigus vulgarisRiximyo is indicated for the treatment of patients with moderate to severe pemphigus vulgaris (PV).|[PMDA] Follow-on biologics indicated for the treatment of CD20-positive B-cell non-Hodgkin's lymphoma, CD20-positive B-cell lymphoproliferative disorder associated with immunosuppression, Wegener's granulomatosis, and microscopic polyangiitis. uuid:d03ce711-84f7-4678-b688-1d4558a157de biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4F4X42SYQ6 biolink:treats MONDO:0008219 PMID:41385096 "[{""id"":""uuid:fe3b5ea3-9905-4aa6-b2f8-a79680f6711e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a53663fc-2b19-4383-aee9-44fedd8097ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:b8904a0a-f2ba-46f6-99ef-761140ca9345"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/riximyo""]},{""id"":""uuid:2b8e1e9a-1f4b-4ac2-9671-6145fd84c14f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RITUXAN is a CD20-directed cytolytic antibody indicated for the treatment of: Adult patients with Non-Hodgkin's Lymphoma (NHL) ( 1.1 ). Relapsed or refractory, low grade or follicular, CD20-positive B-cell NHL as a single agent. Previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy. Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy. Previously untreated diffuse large B-cell, CD20-positive NHL in combination with (cyclophosphamide, doxorubicin, vincristine, and prednisone) (CHOP) or other anthracycline-based chemotherapy regimens. Pediatric patients aged 6 months and older with mature B-cell NHL and mature B-cell acute leukemia (B-AL) ( 1.1 ) Previously untreated, advanced stage, CD20-positive, diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL) or mature B-cell acute leukemia (B-AL) in combination with chemotherapy. Adult patients with Chronic Lymphocytic Leukemia (CLL) ( 1.2 ). Previously untreated and previously treated CD20-positive CLL in combination with fludarabine and cyclophosphamide (FC). Rheumatoid Arthritis (RA) in combination with methotrexate in adult patients with moderately-to severely-active RA who have inadequate response to one or more TNF antagonist therapies ( 1.3 ). Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA) in adult and pediatric patients 2 years of age and older in combination with glucocorticoids ( 1.4 ). Moderate to severe Pemphigus Vulgaris (PV) in adult patients ( 1.5 ).|[EMA] Riximyo is indicated in adults for the following indications:Non-Hodgkin’s lymphoma (NHL)Riximyo is indicated for the treatment of previously untreated adult patients with stage III-IV follicular lymphoma in combination with chemotherapy.Riximyo maintenance therapy is indicated for the treatment of adult follicular lymphoma patients responding to induction therapy.Riximyo monotherapy is indicated for treatment of adult patients with stage III-IV follicular lymphoma who are chemoresistant or are in their second or subsequent relapse after chemotherapy.Riximyo is indicated for the treatment of adult patients with CD20 positive diffuse large B cell non-Hodgkin’s lymphoma in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy.Riximyo in combination with chemotherapy is indicated for the treatment of paediatric patients (aged ≥ 6 months to < 18 years old) with previously untreated advanced stage CD20 positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL)/Burkitt leukaemia (mature B-cell acute leukaemia) (BAL) or Burkitt-like lymphoma (BLL).Chronic lymphocytic leukaemia (CLL)Riximyo in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory chronic lymphocytic leukaemia. Only limited data are available on efficacy and safety for patients previously treated with monoclonal antibodies including rituximab or patients refractory to previous rituximab plus chemotherapy.See section 5.1 for further information.Rheumatoid arthritisRiximyo in combination with methotrexate is indicated for the treatment of adult patients with severe active rheumatoid arthritis who have had an inadequate response or intolerance to other disease-modifying anti-rheumatic drugs (DMARD) including one or more tumour necrosis factor (TNF) inhibitor therapies.Rituximab has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate.Granulomatosis with polyangiitis and microscopic polyangiitisRiximyo, in combination with glucocorticoids, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (Wegener’s) (GPA) and microscopic polyangiitis (MPA).Riximyo, in combination with glucocorticoids, is indicated for the induction of remission in paediatric patients (aged ≥ 2 to < 18 years old) with severe, active GPA (Wegener’s) and MPA.Pemphigus vulgarisRiximyo is indicated for the treatment of patients with moderate to severe pemphigus vulgaris (PV).|[PMDA] Drugs with a new indication and a new dosage for the treatment of refractory pemphigus vulgaris and pemphigus foliaceus. [Orphan drug] uuid:2505890d-a93b-4b6d-9a2b-8bb767658098 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:143117 biolink:treats UMLS:C0278987 PMID:41385096 "[{""id"":""uuid:25b9a178-f99f-4d22-a00e-bcecff08bb40"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:88856f7f-a4af-4f16-9881-e76416f2ef01"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LORBRENA ® is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. uuid:a4c85909-e26a-479d-83c3-d53f0cbacf2b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64310 biolink:treats UMLS:C0278987 PMID:41385096 "[{""id"":""uuid:a07153a4-2f36-4704-af4d-00e997545717"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:417784bc-3757-4c68-b8db-154e7060ec50"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XALKORI is a kinase inhibitor indicated for the treatment of • adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK) or ROS1-positive as detected by an FDA-approved test. ( 1.1 , 2.1 ) • pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. ( 1.2 , 2.3 ) o Limitations of Use: The safety and efficacy of XALKORI have not been established in older adults with relapsed or refractory, systemic ALK-positive ALCL. • adult and pediatric patients 1 year of age and older with unresectable, recurrent, or refractory inflammatory myofibroblastic tumor (IMT) that is ALK-positive. ( 1.3 , 2.3 ) uuid:c2b4141a-5c38-45e1-85ec-a62047e9116a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64310 biolink:treats UMLS:C1336548 PMID:41385096 "[{""id"":""uuid:ed2a5139-bdf8-428b-9644-765cbe598ffc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f0813245-13a4-4d96-bc0a-59b9a2c3c881"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XALKORI is a kinase inhibitor indicated for the treatment of • adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK) or ROS1-positive as detected by an FDA-approved test. ( 1.1 , 2.1 ) • pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. ( 1.2 , 2.3 ) o Limitations of Use: The safety and efficacy of XALKORI have not been established in older adults with relapsed or refractory, systemic ALK-positive ALCL. • adult and pediatric patients 1 year of age and older with unresectable, recurrent, or refractory inflammatory myofibroblastic tumor (IMT) that is ALK-positive. ( 1.3 , 2.3 ) uuid:4fabef17-2a95-478f-b14f-bce1a9550c0e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64310 biolink:treats MONDO:0015798 PMID:41385096 "[{""id"":""uuid:7d6e9915-45ee-43e2-bbc0-174d2f716b59"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d5445a49-e064-4650-a639-c9dee13d03ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XALKORI is a kinase inhibitor indicated for the treatment of • adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK) or ROS1-positive as detected by an FDA-approved test. ( 1.1 , 2.1 ) • pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. ( 1.2 , 2.3 ) o Limitations of Use: The safety and efficacy of XALKORI have not been established in older adults with relapsed or refractory, systemic ALK-positive ALCL. • adult and pediatric patients 1 year of age and older with unresectable, recurrent, or refractory inflammatory myofibroblastic tumor (IMT) that is ALK-positive. ( 1.3 , 2.3 ) uuid:f013a84b-02fc-42ee-ac0f-6878473b5908 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:Q4K217VGA9 biolink:treats MONDO:0006502 PMID:41385096 "[{""id"":""uuid:9e53528a-a85a-4628-af8e-79fa7022219f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:48654140-2c2a-47df-93a9-3573d516e0c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INFASURF is indicated: to reduce the risk of respiratory distress syndrome (RDS) in preterm neonates <29 weeks of gestational age at risk for RDS. for the rescue treatment of RDS in preterm neonates ≤72 hours of age with RDS who require endotracheal intubation. uuid:79c0947e-0d7b-48f2-8eb9-24bde10c9133 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:Q4K217VGA9 biolink:treats MONDO:0009971 PMID:41385096 "[{""id"":""uuid:3c026ba5-ded4-4be0-8b92-bee4433c40d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:95b3dccc-3d2f-418d-b051-bfc2f10c7f6e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INFASURF is indicated: to reduce the risk of respiratory distress syndrome (RDS) in preterm neonates <29 weeks of gestational age at risk for RDS. for the rescue treatment of RDS in preterm neonates ≤72 hours of age with RDS who require endotracheal intubation. uuid:e94f94d9-8608-4e47-9f8b-73fef18221eb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0982025 biolink:treats MONDO:0010602 PMID:41385096 "[{""id"":""uuid:096d0e7a-966a-4402-bb10-60badaf68df4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:13c00389-13ff-4e86-8ba1-cc30987a9757"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:411dfc05-5ee0-43c2-9030-61fe34fbb878"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FEIBA is an Anti-Inhibitor Coagulant Complex indicated for use in hemophilia A and B patients with inhibitors for: Control and prevention of bleeding episodes Perioperative management Routine prophylaxis to prevent or reduce the frequency of bleeding episodes. FEIBA is not indicated for the treatment of bleeding episodes resulting from coagulation factor deficiencies in the absence of inhibitors to coagulation factor VIII or coagulation factor IX.|[PMDA] Drugs with a revised indication and a new dosage for inhibition of bleeding tendency by promoting the blood coagulation in the plasma in patients with inhibitors to blood coagulation factor VIII or factor IX. DRUGBANK:DB13151 uuid:54e9e571-f887-4db5-9ebf-63643b3ce770 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0982025 biolink:treats MONDO:0010604 PMID:41385096 "[{""id"":""uuid:72ef6bcd-7ce2-4df9-8852-19450ae91cac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2cfbb966-3f93-47be-a9b9-2c6155201a36"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:22d27bf0-4d7b-40fb-bfb0-d1187835bf8a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FEIBA is an Anti-Inhibitor Coagulant Complex indicated for use in hemophilia A and B patients with inhibitors for: Control and prevention of bleeding episodes Perioperative management Routine prophylaxis to prevent or reduce the frequency of bleeding episodes. FEIBA is not indicated for the treatment of bleeding episodes resulting from coagulation factor deficiencies in the absence of inhibitors to coagulation factor VIII or coagulation factor IX.|[PMDA] Drugs with a revised indication and a new dosage for inhibition of bleeding tendency by promoting the blood coagulation in the plasma in patients with inhibitors to blood coagulation factor VIII or factor IX. DRUGBANK:DB13151 uuid:ed2a65a0-c8fc-4d40-ab4f-ce83410cc4f9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0009197 PMID:41385096 "[{""id"":""uuid:d582c489-8e31-4c6f-be65-1d2cb75ba6f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5965cdb4-34c7-4347-b732-725e18cacfc1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone tablets are indicated in the following conditions: Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis EpicondylitisAcute gouty arthritis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler's syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Nervous System Acute exacerbations of multiple sclerosis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:bfb88333-1381-4218-81cb-55ff865753d5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134677 biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:a0325863-60fb-47db-8d20-0ca4d6678355"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:07d49aaa-f4cc-4349-8678-5485df6a5733"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EUCRISA is indicated for topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients 3 months of age and older. uuid:9c97f1d6-f9c5-4edd-b1e2-8c0dae9fab71 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:681848 biolink:treats UMLS:C0865850 PMID:41385096 "[{""id"":""uuid:4a2c95c2-78fe-456e-b249-449ec1182567"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2383dc7b-d2dd-4827-8180-ca681ba054cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Postanesthesia When the possibility of airway obstruction and/or hypoxia have been eliminated, doxapram may be used to stimulate respiration in patients with drug-induced postanesthesia respiratory depression or apnea other than that due to muscle relaxant drugs. To pharmacologically stimulate deep breathing in the postoperative patient. (A quantitative method of assessing oxygenation, such as pulse oximetry, is recommended.) Drug-Induced Central Nervous System Depression Exercising care to prevent vomiting and aspiration, doxapram may be used to stimulate respiration, hasten arousal, and to encourage the return of laryngopharyngeal reflexes in patients with mild to moderate respiratory and CNS depression due to drug overdosage. Chronic Pulmonary Disease Associated with Acute Hypercapnia Doxapram is indicated as a temporary measure in hospitalized patients with acute respiratory insufficiency superimposed on chronic obstructive pulmonary disease. Its use should be for a short period of time (see DOSAGE & ADMINISTRATION ) as an aid in the prevention of elevation of arterial CO2 tension during the administration of oxygen. It should not be used in conjunction with mechanical ventilation. uuid:f53cdb38-35fe-4c6b-8aac-c593faabafe4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:681848 biolink:treats MONDO:0005002 PMID:41385096 "[{""id"":""uuid:c92bfbf0-e9b7-464c-9e62-33dd5c11c276"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f5ac8d0e-0335-462a-8a51-3e48eaa85462"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Postanesthesia When the possibility of airway obstruction and/or hypoxia have been eliminated, doxapram may be used to stimulate respiration in patients with drug-induced postanesthesia respiratory depression or apnea other than that due to muscle relaxant drugs. To pharmacologically stimulate deep breathing in the postoperative patient. (A quantitative method of assessing oxygenation, such as pulse oximetry, is recommended.) Drug-Induced Central Nervous System Depression Exercising care to prevent vomiting and aspiration, doxapram may be used to stimulate respiration, hasten arousal, and to encourage the return of laryngopharyngeal reflexes in patients with mild to moderate respiratory and CNS depression due to drug overdosage. Chronic Pulmonary Disease Associated with Acute Hypercapnia Doxapram is indicated as a temporary measure in hospitalized patients with acute respiratory insufficiency superimposed on chronic obstructive pulmonary disease. Its use should be for a short period of time (see DOSAGE & ADMINISTRATION ) as an aid in the prevention of elevation of arterial CO2 tension during the administration of oxygen. It should not be used in conjunction with mechanical ventilation. uuid:d0095adf-7130-45fe-b3b0-700d03efd80f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:681848 biolink:treats HP:0012416 PMID:41385096 "[{""id"":""uuid:1e872120-13da-4b43-9353-c9a9bc2c8556"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e5a09ba5-438f-4713-809c-f0b1f708746c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Postanesthesia When the possibility of airway obstruction and/or hypoxia have been eliminated, doxapram may be used to stimulate respiration in patients with drug-induced postanesthesia respiratory depression or apnea other than that due to muscle relaxant drugs. To pharmacologically stimulate deep breathing in the postoperative patient. (A quantitative method of assessing oxygenation, such as pulse oximetry, is recommended.) Drug-Induced Central Nervous System Depression Exercising care to prevent vomiting and aspiration, doxapram may be used to stimulate respiration, hasten arousal, and to encourage the return of laryngopharyngeal reflexes in patients with mild to moderate respiratory and CNS depression due to drug overdosage. Chronic Pulmonary Disease Associated with Acute Hypercapnia Doxapram is indicated as a temporary measure in hospitalized patients with acute respiratory insufficiency superimposed on chronic obstructive pulmonary disease. Its use should be for a short period of time (see DOSAGE & ADMINISTRATION ) as an aid in the prevention of elevation of arterial CO2 tension during the administration of oxygen. It should not be used in conjunction with mechanical ventilation. uuid:33a00379-e594-492b-a37f-15a8a3b1b399 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7903 biolink:treats MONDO:0005382 PMID:41385096 "[{""id"":""uuid:2bac877b-93e5-41f1-8a72-a59e80a27122"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3d1d9d29-322f-46e4-9352-8829a6b3d23f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypercalcemia of Malignancy Pamidronate disodium, in conjunction with adequate hydration, is indicated for the treatment of moderate or severe hypercalcemia associated with malignancy, with or without bone metastases. Patients who have either epidermoid or non-epidermoid tumors respond to treatment with pamidronate disodium. Vigorous saline hydration, an integral part of hypercalcemia therapy, should be initiated promptly and an attempt should be made to restore the urine output to about 2 L/day throughout treatment. Mild or asymptomatic hypercalcemia may be treated with conservative measures (i.e., saline hydration, with or without loop diuretics). Patients should be hydrated adequately throughout the treatment, but overhydration, especially in those patients who have cardiac failure, must be avoided. Diuretic therapy should not be employed prior to correction of hypovolemia. The safety and efficacy of pamidronate disodium in the treatment of hypercalcemia associated with hyperparathyroidism or with other non-tumor-related conditions has not been established. Paget’s Disease Pamidronate disodium is indicated for the treatment of patients with moderate to severe Paget’s disease of bone. The effectiveness of pamidronate disodium was demonstrated primarily in patients with serum alkaline phosphatase ≥ 3 times the upper limit of normal. Pamidronate disodium therapy in patients with Paget’s disease has been effective in reducing serum alkaline phosphatase and urinary hydroxyproline levels by ≥ 50% in at least 50% of patients, and by ≥ 30% in at least 80% of patients. Pamidronate disodium therapy has also been effective in reducing these biochemical markers in patients with Paget’s disease who failed to respond, or no longer responded to other treatments. Osteolytic Bone Metastases of Breast Cancer and Osteolytic Lesions of Multiple Myeloma Pamidronate disodium is indicated, in conjunction with standard antineoplastic therapy, for the treatment of osteolytic bone metastases of breast cancer and osteolytic lesions of multiple myeloma. The pamidronate disodium treatment effect appeared to be smaller in the study of breast cancer patients receiving hormonal therapy than in the study of those receiving chemotherapy, however, overall evidence of clinical benefit has been demonstrated (see CLINICAL PHARMACOLOGY , Osteolytic Bone Metastases of Breast Cancer and Osteolytic Lesions of Multiple Myeloma, Clinical Trials section). uuid:fde5239d-8245-4530-a771-4cf2b07657a3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7903 biolink:treats UMLS:C3898069 PMID:41385096 "[{""id"":""uuid:845225d9-fcd6-4ac2-a246-78f5db67045f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:705eceef-4501-41ca-9bd1-686292a3a6c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypercalcemia of Malignancy Pamidronate disodium, in conjunction with adequate hydration, is indicated for the treatment of moderate or severe hypercalcemia associated with malignancy, with or without bone metastases. Patients who have either epidermoid or non-epidermoid tumors respond to treatment with pamidronate disodium. Vigorous saline hydration, an integral part of hypercalcemia therapy, should be initiated promptly and an attempt should be made to restore the urine output to about 2 L/day throughout treatment. Mild or asymptomatic hypercalcemia may be treated with conservative measures (i.e., saline hydration, with or without loop diuretics). Patients should be hydrated adequately throughout the treatment, but overhydration, especially in those patients who have cardiac failure, must be avoided. Diuretic therapy should not be employed prior to correction of hypovolemia. The safety and efficacy of pamidronate disodium in the treatment of hypercalcemia associated with hyperparathyroidism or with other non-tumor-related conditions has not been established. Paget’s Disease Pamidronate disodium is indicated for the treatment of patients with moderate to severe Paget’s disease of bone. The effectiveness of pamidronate disodium was demonstrated primarily in patients with serum alkaline phosphatase ≥ 3 times the upper limit of normal. Pamidronate disodium therapy in patients with Paget’s disease has been effective in reducing serum alkaline phosphatase and urinary hydroxyproline levels by ≥ 50% in at least 50% of patients, and by ≥ 30% in at least 80% of patients. Pamidronate disodium therapy has also been effective in reducing these biochemical markers in patients with Paget’s disease who failed to respond, or no longer responded to other treatments. Osteolytic Bone Metastases of Breast Cancer and Osteolytic Lesions of Multiple Myeloma Pamidronate disodium is indicated, in conjunction with standard antineoplastic therapy, for the treatment of osteolytic bone metastases of breast cancer and osteolytic lesions of multiple myeloma. The pamidronate disodium treatment effect appeared to be smaller in the study of breast cancer patients receiving hormonal therapy than in the study of those receiving chemotherapy, however, overall evidence of clinical benefit has been demonstrated (see CLINICAL PHARMACOLOGY , Osteolytic Bone Metastases of Breast Cancer and Osteolytic Lesions of Multiple Myeloma, Clinical Trials section). uuid:179d6031-a8e2-4ae3-8e3f-e2ff279a615a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0001658 PMID:41385096 "[{""id"":""uuid:9442e213-73f8-4b38-8db6-d9aec986f914"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:abb7793e-848e-45a4-899d-910ae1f1db04"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Strong Iodine Solution, containing 5 percent of iodine and 10 percent of potassium iodide, is employed in the prophylaxis of simple and colloid goiters and in the treatment of exophthalmic goiter. It can be used alone as a preoperative preparation but is now most commonly used concomitantly with propylthiouracil and other antithyroid drugs. When used with these drugs, Strong Iodine Solution produces involution of the hyperplastic gland thus making a less triable and vascular gland for thyroidectomy. In addition, it has an additive antithyroid action that helps make the patient enthyroid faster than if the antithyroid drugs were used alone. uuid:f8953fdc-cd28-4925-a318-58d998e5a32b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0006869 PMID:41385096 "[{""id"":""uuid:3274ab49-3a4a-4da4-acd2-ceaa7be6fff8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5487aeb0-bc9a-4fae-ae48-e997886aed10"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Strong Iodine Solution, containing 5 percent of iodine and 10 percent of potassium iodide, is employed in the prophylaxis of simple and colloid goiters and in the treatment of exophthalmic goiter. It can be used alone as a preoperative preparation but is now most commonly used concomitantly with propylthiouracil and other antithyroid drugs. When used with these drugs, Strong Iodine Solution produces involution of the hyperplastic gland thus making a less triable and vascular gland for thyroidectomy. In addition, it has an additive antithyroid action that helps make the patient enthyroid faster than if the antithyroid drugs were used alone. uuid:54cf22ac-fede-4368-a96a-604486eda4b9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0005364 PMID:41385096 "[{""id"":""uuid:55f109fb-df76-463e-80d2-ff0c443be68b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:11baa706-3655-4e40-9b03-dd41fc37a38e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Strong Iodine Solution, containing 5 percent of iodine and 10 percent of potassium iodide, is employed in the prophylaxis of simple and colloid goiters and in the treatment of exophthalmic goiter. It can be used alone as a preoperative preparation but is now most commonly used concomitantly with propylthiouracil and other antithyroid drugs. When used with these drugs, Strong Iodine Solution produces involution of the hyperplastic gland thus making a less triable and vascular gland for thyroidectomy. In addition, it has an additive antithyroid action that helps make the patient enthyroid faster than if the antithyroid drugs were used alone. uuid:f4dc54a0-d550-4ac5-ad87-d4b94e40537b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:AIW6036FAS biolink:treats MONDO:0010679 PMID:41385096 "[{""id"":""uuid:a4a033d3-9a12-4431-9c00-7d871855fd83"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:af3b1dc1-0973-4faa-a881-05d393186ae4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EXONDYS 51 is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping. This indication is approved under accelerated approval based on an increase in dystrophin in skeletal muscle observed in some patients treated with EXONDYS 51 [see Clinical Studies ( 14 )] . Continued approval for this indication may be contingent upon verification of a clinical benefit in confirmatory trials. uuid:2da3b5d1-98f9-4454-a374-81a5a85807ca biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5959 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:2bb349a1-718c-4b6c-8651-78edc88fd2bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9d879202-cb29-46bc-beb0-61d6f56c8d85"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Hypertension Irbesartan tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Irbesartan tablets may be used alone or in combination with other antihypertensive agents. 1.2 Nephropathy in Type 2 Diabetic Patients Irbesartan tablets are indicated for the treatment of diabetic nephropathy in patients with type 2 diabetes and hypertension, an elevated serum creatinine, and proteinuria (>300 mg/day). In this population, irbesartan reduces the rate of progression of nephropathy as measured by the occurrence of doubling of serum creatinine or end-stage renal disease (need for dialysis or renal transplantation) [see Clinical Studies (14.2)]. uuid:eaa60e1c-ceb7-4992-80ae-a4d99d723c25 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5959 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:f6754910-ae5d-434a-b31a-494e6be106b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5bcfa989-07a3-4c85-808d-1be4a75146ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Hypertension Irbesartan tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Irbesartan tablets may be used alone or in combination with other antihypertensive agents. 1.2 Nephropathy in Type 2 Diabetic Patients Irbesartan tablets are indicated for the treatment of diabetic nephropathy in patients with type 2 diabetes and hypertension, an elevated serum creatinine, and proteinuria (>300 mg/day). In this population, irbesartan reduces the rate of progression of nephropathy as measured by the occurrence of doubling of serum creatinine or end-stage renal disease (need for dialysis or renal transplantation) [see Clinical Studies (14.2)]. uuid:1f6b3e25-e1e7-491c-84b4-4109662b42f1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5959 biolink:treats MONDO:0004375 PMID:41385096 "[{""id"":""uuid:7aceb4f3-2459-4c50-aa61-08398185fb2e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:30bad70f-729b-484d-bf8f-1bb7be2ba29a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Hypertension Irbesartan tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Irbesartan tablets may be used alone or in combination with other antihypertensive agents. 1.2 Nephropathy in Type 2 Diabetic Patients Irbesartan tablets are indicated for the treatment of diabetic nephropathy in patients with type 2 diabetes and hypertension, an elevated serum creatinine, and proteinuria (>300 mg/day). In this population, irbesartan reduces the rate of progression of nephropathy as measured by the occurrence of doubling of serum creatinine or end-stage renal disease (need for dialysis or renal transplantation) [see Clinical Studies (14.2)]. uuid:e6e3a02f-1348-41d2-aa73-4697bb3dc964 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17933 biolink:treats MONDO:0006964 PMID:41385096 "[{""id"":""uuid:79f9a890-e2a3-49ba-b3e2-39c1a4022c55"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:93d4622a-0c4b-47c6-806e-b19af5422b69"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RAYALDEE is a vitamin D 3 analog indicated for the treatment of secondary hyperparathyroidism in adult patients with stage 3 or 4 chronic kidney disease and serum total 25-hydroxyvitamin D levels less than 30 ng/mL. Limitations of Use RAYALDEE is not indicated for the treatment of secondary hyperparathyroidism in patients with stage 5 chronic kidney disease or in patients with end-stage renal disease on dialysis. uuid:211877d7-1cb6-4727-8107-7a4e4106e775 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17933 biolink:treats MONDO:0005300 PMID:41385096 "[{""id"":""uuid:43206ce0-e175-4414-8527-6c0809eb6153"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:88274dd7-7ba0-4c4c-b9df-df081b131106"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RAYALDEE is a vitamin D 3 analog indicated for the treatment of secondary hyperparathyroidism in adult patients with stage 3 or 4 chronic kidney disease and serum total 25-hydroxyvitamin D levels less than 30 ng/mL. Limitations of Use RAYALDEE is not indicated for the treatment of secondary hyperparathyroidism in patients with stage 5 chronic kidney disease or in patients with end-stage renal disease on dialysis. uuid:253e0487-f769-400f-9d9b-bc36115525eb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90959 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:3fbfa454-72ff-49df-9475-bcd2c86535a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5773fde5-0137-4372-9b03-145843a11d98"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:8f525673-b5f6-4908-bbb1-416daadd5c6a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SPIRIVA RESPIMAT is an anticholinergic indicated for: The long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), and for reducing COPD exacerbations ( 1.1 ) The long-term, once-daily, maintenance treatment of asthma in patients 6 years of age and older ( 1.2 ) Limitation of Use: Not indicated for relief of acute bronchospasm ( 1.1 , 1.2 , 5.1 )|[PMDA] Drugs with a new additional indication, dosage, and dosage form for the relief of symptoms secondary to airway obstructive disorders in mild to moderate persistent bronchial asthma. uuid:611d8c74-ac61-46cd-94be-a5a5ed9b2d18 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90959 biolink:treats UMLS:C0853854 PMID:41385096 "[{""id"":""uuid:35a8dc0c-d5f8-43eb-816b-6257b30f9a0d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b6531b12-76f7-437e-be22-8b7799539445"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SPIRIVA RESPIMAT is an anticholinergic indicated for: The long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), and for reducing COPD exacerbations ( 1.1 ) The long-term, once-daily, maintenance treatment of asthma in patients 6 years of age and older ( 1.2 ) Limitation of Use: Not indicated for relief of acute bronchospasm ( 1.1 , 1.2 , 5.1 ) uuid:2c6febaa-1b84-482d-854a-e6da8ba0707b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:132268 biolink:treats UMLS:C0278987 PMID:41385096 "[{""id"":""uuid:7e3237c7-2708-481e-9171-c5a8132e348c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8300e8d6-f54f-40d4-b829-77a2e8c2f7c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VIZIMPRO is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test [see Dosage and Administration (2.1) ] . uuid:637b4482-60fa-4189-83d1-0a938227b4d6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:132268 biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:ac76ea51-0bb8-4703-86ec-51319c0d7359"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ff5f148a-49cf-4604-8ea6-626fef872d56"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:27bcc807-6ce5-415d-951f-80be72dcb2ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f805067d-3cad-475c-84c4-3f431b757106"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VIZIMPRO is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test [see Dosage and Administration (2.1) ] .|[EMA] Vizimpro, as monotherapy, is indicated for the first-line treatment of adult patients with locally advanced or metastatic non small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) activating mutations.|[PMDA] Drugs with a new active ingredient indicated for the treatment of inoperable or recurrent non-small cell lung cancer with EGFR gene mutation. [Priority review] uuid:83e1500d-e312-4922-a128-a55aef0161d5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1992822 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:61d40944-0241-487a-98f8-e13595dcc601"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:7e27eb46-f85e-4cab-a71c-09194460ece0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:642feaf2-4356-457c-950e-c1286d95aa7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/steglujan""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] STEGLUJAN ® is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use Not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus [see Warnings and Precautions (5.1) ]. Has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using STEGLUJAN [see Warnings and Precautions (5.2) ] .|[EMA] Steglujan is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:when metformin and/or a sulphonylurea (SU) and one of the monocomponents of Steglujan do not provide adequate glycaemic control.in patients already being treated with the combination of ertugliflozin and sitagliptin as separate tablets. uuid:5e92152c-8ae5-47a4-b051-8792746f80ce biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1992822 biolink:treats MONDO:0005147 PMID:41385096 "[{""id"":""uuid:be052f12-bc71-471f-b3de-4e952af50af7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e681701f-dad1-403f-9d0e-906002a6e4da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] STEGLUJAN ® is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use Not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus [see Warnings and Precautions (5.1) ]. Has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using STEGLUJAN [see Warnings and Precautions (5.2) ] . uuid:6e97e477-3a61-4d53-8df1-1fbd47847b69 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1992822 biolink:treats MONDO:0004982 PMID:41385096 "[{""id"":""uuid:98e00057-260f-4a37-88cc-784d9ff84572"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:582059bc-d7f9-40c6-8090-d344796025c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] STEGLUJAN ® is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use Not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus [see Warnings and Precautions (5.1) ]. Has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using STEGLUJAN [see Warnings and Precautions (5.2) ] . uuid:76a4c9ef-e7c8-4c9d-a14e-f1097d46d68f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:581255 biolink:treats UMLS:C0854100 PMID:41385096 "[{""id"":""uuid:90c17f98-fe19-4b9f-916b-226b5ac445bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7a6d1761-309c-4fac-9f41-e4c4bc5d4bca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PROSOL is indicated as a source of amino acids for patients requiring parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. PROSOL may be used to treat negative nitrogen balance in patients. uuid:bab51b1d-358b-4856-840c-3e69757ea3a0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:MCN858TCP0 biolink:treats NCIT:C27003 PMID:41385096 "[{""id"":""uuid:35013b45-be2b-4906-b9c4-1d5c2153e44c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3b440301-1118-4add-9046-face2c62b039"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OLINVYK is indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, and misuse with opioids, which can occur at any dosage or duration [see Warnings and Precautions ( 5.1 )] , reserve OLINVYK for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]: Have not been tolerated, or are not expected to be tolerated Have not provided adequate analgesia, or are not expected to provide adequate analgesia. The cumulative total daily dose should not exceed 27 mg, as total daily doses greater than 27 mg may increase the risk for QTc interval prolongation [see Warnings and Precautions ( 5.5 ] . uuid:5ab710a5-571f-4014-9327-ecb65852644c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DTI67O9503 biolink:treats MONDO:0009290 PMID:41385096 "[{""id"":""uuid:74fd1434-bdd8-4a31-b4a6-f1baac5d86aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:91f1ffee-fd4e-43d2-83ff-f88cd49b87c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:05987876-c40f-4a82-93b2-04ef886d16a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/myozyme""]},{""id"":""uuid:c65d0512-efa3-460a-ab03-af5ebeac20c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LUMIZYME ® is a hydrolytic lysosomal glycogen-specific enzyme indicated for patients with Pompe disease (acid α-glucosidase [GAA] deficiency).|[EMA] Myozyme is indicated for long-term enzyme-replacement therapy (ERT) in patients with a confirmed diagnosis of Pompe disease (acid-α-glucosidase deficiency).In patients with late-onset Pompe disease the evidence of efficacy is limited.|[PMDA] A drug containing a new active ingredient indicated for the treatment of type 2 glycogenosis. [Orphan drug] uuid:87d97c44-0734-45c1-a2cd-374e0bb7f8f5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:188719 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:a1054388-ae0a-48ac-bf57-c45bc264f8b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:b68ff7c9-b875-428f-b356-6c9342f2f96c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ef26b365-358c-4d74-9d7d-2101e3391045"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] STEGLATRO ® is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.|[EMA] Steglatro is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:as monotherapy in patients for whom the use of metformin is considered inappropriate due to intolerance or contraindications.in addition to other medicinal products for the treatment of diabetes. uuid:b76fe843-e9c9-4153-915e-54521447f4e6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1591939 biolink:treats MONDO:0005354 PMID:41385096 "[{""id"":""uuid:ddffa7e7-6fa1-4cb3-9436-ac0477b6edb3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:50bdebe6-abbd-48f0-8419-9efb53630285"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:a590f643-e530-4af5-952e-245b45baabd5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] HARVONI is indicated for the treatment of adults and pediatric patients 3 years of age and older with chronic hepatitis C virus (HCV) [see Dosage and Administration (2.2 and 2.3) and Clinical Studies (14) ] : genotype 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis genotype 1 infection with decompensated cirrhosis, for use in combination with ribavirin genotype 1 or 4 infection who are liver transplant recipients without cirrhosis or with compensated cirrhosis, for use in combination with ribavirin|[PMDA] A new combination drug with new active ingredients indicated for the improvement of viremia in patients with chronic hepatitis C or compensated cirrhosis type C in serogroup 1 (genotype 1). [Priority review] uuid:e3800cb4-e9db-4a34-8b2b-85ee1e022ece biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:794PGL549S biolink:treats MONDO:0016595 PMID:41385096 "[{""id"":""uuid:f41ca744-fe0b-4fc4-898d-976b326eac40"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:11efac97-7588-4d14-9290-689f4735bd87"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Raxibacumab is indicated for the treatment of adult and pediatric patients with inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs, and for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate. ( 1.1 ) Limitations of Use: The effectiveness of raxibacumab is based solely on efficacy studies in animal models of inhalational anthrax. ( 1.2 , 14.1 ) There have been no studies of raxibacumab in the pediatric population. Dosing in pediatric patients was derived using an extrapolation approach. ( 1.2 , 8.4 ) Raxibacumab does not cross the blood-brain barrier and does not prevent or treat meningitis. Raxibacumab should be used in combination with appropriate antibacterial drugs. ( 1.2 ) uuid:f0fffd3c-b6b3-4aab-93d3-45bf7a6baa7f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:794PGL549S biolink:treats MONDO:0021108 PMID:41385096 "[{""id"":""uuid:43f6458c-eb13-4de4-a772-45fe3f175c60"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:06166cf6-c9ea-4660-b325-c30eab163c1f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Raxibacumab is indicated for the treatment of adult and pediatric patients with inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs, and for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate. ( 1.1 ) Limitations of Use: The effectiveness of raxibacumab is based solely on efficacy studies in animal models of inhalational anthrax. ( 1.2 , 14.1 ) There have been no studies of raxibacumab in the pediatric population. Dosing in pediatric patients was derived using an extrapolation approach. ( 1.2 , 8.4 ) Raxibacumab does not cross the blood-brain barrier and does not prevent or treat meningitis. Raxibacumab should be used in combination with appropriate antibacterial drugs. ( 1.2 ) uuid:42f86efc-eb98-4523-961c-04bd22768793 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB17831 biolink:treats MONDO:0006543 PMID:41385096 "[{""id"":""uuid:5195a99b-d2c8-4aaf-82e4-227d15125bd9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cbf275d6-15da-4298-af7a-c5ae83cc333f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VYJUVEK is indicated for the treatment of wounds in patients 6 months of age and older with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene. uuid:bd31ec2c-9733-44a8-9b32-0185fd18d0f9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135752 biolink:treats MONDO:0005136 PMID:41385096 "[{""id"":""uuid:fc4655cd-79b5-43e5-8e22-21eb3572858c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:77475bc5-af4c-4883-9bb2-e837654aff40"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ARAKODA is indicated for the prophylaxis of malaria in patients aged 18 years and older. uuid:683a24e2-2acf-4042-a52f-128211ad78ea biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:82700 biolink:treats MONDO:0005002 PMID:41385096 "[{""id"":""uuid:279f1ac5-1382-40ce-870c-cba972f25174"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5d5a5ac0-1afd-459f-839e-59ba38fe835f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] STRIVERDI RESPIMAT Inhalation Spray is a long-acting beta 2 -adrenergic agonist (LABA) indicated for: The long-term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. ( 1.1 ) Important limitations: STRIVERDI RESPIMAT is NOT indicated to treat acute deterioration of COPD. ( 1.2 ) STRIVERDI RESPIMAT is NOT indicated to treat asthma. ( 1.2 ) uuid:d4c378eb-04e8-4e2d-bb55-d43fa0f1f461 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:82700 biolink:treats MONDO:0005607 PMID:41385096 "[{""id"":""uuid:550a5318-dffe-4d54-beae-61a141a334ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:95c7a38f-6a53-4293-b045-e9966c9007ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] STRIVERDI RESPIMAT Inhalation Spray is a long-acting beta 2 -adrenergic agonist (LABA) indicated for: The long-term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. ( 1.1 ) Important limitations: STRIVERDI RESPIMAT is NOT indicated to treat acute deterioration of COPD. ( 1.2 ) STRIVERDI RESPIMAT is NOT indicated to treat asthma. ( 1.2 ) uuid:03f6d151-22c1-434a-aa7c-756c1413bd0a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:82700 biolink:treats MONDO:0004849 PMID:41385096 "[{""id"":""uuid:fcff23ad-f452-44f3-b402-a1302515797a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:35832b69-6828-433d-ad0a-326667ed4cc7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] STRIVERDI RESPIMAT Inhalation Spray is a long-acting beta 2 -adrenergic agonist (LABA) indicated for: The long-term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. ( 1.1 ) Important limitations: STRIVERDI RESPIMAT is NOT indicated to treat acute deterioration of COPD. ( 1.2 ) STRIVERDI RESPIMAT is NOT indicated to treat asthma. ( 1.2 ) uuid:cba9ac1e-883b-430e-bd31-126c0804ab8b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:T8B2ORP1DW biolink:treats MONDO:0018328 PMID:41385096 "[{""id"":""uuid:e622c745-2857-4194-a1f2-3a4a2e179664"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ba4c9408-cc7c-407c-bd08-b1b0112a7563"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f192e910-9bf5-4645-a45b-36fa8a61e502"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/evkeeza""]},{""id"":""uuid:db46308a-490b-4d02-9560-b07f9b4d1676"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EVKEEZA is indicated as an adjunct to other low-density lipoprotein-cholesterol (LDL-C) lowering therapies for the treatment of adult and pediatric patients, aged 5 years and older, with homozygous familial hypercholesterolemia (HoFH).|[EMA] Evkeeza is indicated as an adjunct to diet and other low-density lipoprotein-cholesterol (LDL-C) lowering therapies for the treatment of adult and adolescent patients aged 12 years and older with homozygous familial hypercholesterolaemia (HoFH).|[PMDA] A drug with a new active ingredient indicated for the treatment of homozygous familial hypercholesterolemia. [Orphan drug] uuid:925a6fb6-5173-4de8-99ef-f90f33dbb73b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:40303 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:6a94ff62-b022-4648-b9d4-94f3c3d95e72"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4de5c0dc-38aa-4f7b-b735-f255720cb47a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Altoprev is indicated: • To reduce the risk of myocardial infarction, unstable angina, and coronary revascularization procedures in adults at high risk for coronary heart disease. • As an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) and slow the progression of coronary atherosclerosis in adults with coronary heart disease. • As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH). uuid:6b41c780-b7e3-4a02-ae74-d99552c8dc28 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB11294 biolink:treats MONDO:0005706 PMID:41385096 "[{""id"":""uuid:e37b9be8-cde0-4f2b-942f-2c16b73393e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:107caefc-3acf-427c-b905-faeffa1526a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Spherusol ® is a skin test antigen indicated for the detection of delayed-type hypersensitivity to Coccidioides immitis in individuals with a history of pulmonary coccidioidomycosis. Spherusol ® is approved for use in individuals 18-64 years of age. The use of Spherusol ® to detect delayed-type hypersensitivity responses in a general population with unknown exposure to C. immitis has not been evaluated. Persons with acute or disseminated coccidioidomycosis may not develop a delayed-type hypersensitivity response to Spherusol ® . Persons with immunodeficiency and a history of coccidioidomycosis may not develop a delayed-type hypersensitivity response to Spherusol ® . uuid:5f4b09b4-1cfd-485e-9705-22f2e98cbfbc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB11294 biolink:treats UMLS:C3840167 PMID:41385096 "[{""id"":""uuid:8d3de5d5-3a1c-4f78-9652-275e0fed2364"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e1a1aae6-ed10-45e2-a509-003b02ce4473"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Spherusol ® is a skin test antigen indicated for the detection of delayed-type hypersensitivity to Coccidioides immitis in individuals with a history of pulmonary coccidioidomycosis. Spherusol ® is approved for use in individuals 18-64 years of age. The use of Spherusol ® to detect delayed-type hypersensitivity responses in a general population with unknown exposure to C. immitis has not been evaluated. Persons with acute or disseminated coccidioidomycosis may not develop a delayed-type hypersensitivity response to Spherusol ® . Persons with immunodeficiency and a history of coccidioidomycosis may not develop a delayed-type hypersensitivity response to Spherusol ® . uuid:46413dc4-2f7b-4d1c-9120-2c0bbcf0db63 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB11294 biolink:treats UMLS:C0276667 PMID:41385096 "[{""id"":""uuid:3ce2fb1e-bf0c-4d95-9e43-1e112831bd29"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1624999e-9f44-4b0f-ab3a-7f9a9f797059"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Spherusol ® is a skin test antigen indicated for the detection of delayed-type hypersensitivity to Coccidioides immitis in individuals with a history of pulmonary coccidioidomycosis. Spherusol ® is approved for use in individuals 18-64 years of age. The use of Spherusol ® to detect delayed-type hypersensitivity responses in a general population with unknown exposure to C. immitis has not been evaluated. Persons with acute or disseminated coccidioidomycosis may not develop a delayed-type hypersensitivity response to Spherusol ® . Persons with immunodeficiency and a history of coccidioidomycosis may not develop a delayed-type hypersensitivity response to Spherusol ® . uuid:24631bb6-c047-459b-b46a-3325c10caaf9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85980 biolink:treats UMLS:C0348898 PMID:41385096 "[{""id"":""uuid:3b3a6fac-72ec-4f5b-a1b9-9d84068bbc43"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f088e74c-37c9-4e8e-a6a3-fca0e5f29507"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VIBERZI is indicated in adults for the treatment of irritable bowel syndrome with diarrhea (IBS-D). uuid:90db6c9c-168d-4b25-91d1-91ac808c2ca0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:372452 biolink:treats NCIT:C27003 PMID:41385096 "[{""id"":""uuid:688c8f83-9e37-404e-9dcc-485b0e29202c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:98d7877f-0116-4811-a588-5bc708a81e0e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] COMBOGESIC is indicated in adults for the short-term management of mild to moderate acute pain. uuid:04511622-b98d-45e3-b056-0b49741822bf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:581255 biolink:treats UMLS:C0856633 PMID:41385096 "[{""id"":""uuid:7a23d76d-0584-49b2-b73e-7a870dde9355"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:add9284f-24b3-40f3-a2bd-e8a3d34a36f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 15% CLINISOL - sulfite-free (Amino Acid) Injection Pharmacy Bulk Package is indicated as an adjunct in the offsetting of nitrogen loss or in the treatment of negative nitrogen balance in patients where: (1) the alimentary tract cannot or should not be used, (2) gastrointestinal absorption of protein is impaired, or (3) metabolic requirements for protein are substantially increased, as with extensive burns. uuid:1959a2cc-049d-47fd-9c91-9315ad3511f1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7XZ4062R17 biolink:treats MONDO:0009662 PMID:41385096 "[{""id"":""uuid:3fe6dc21-1dc9-475c-94b3-385262807322"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e2fbac3d-c6bf-40cb-8d96-f8c4f46794e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ecebfefa-3192-4205-8194-562812da9021"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/mepsevii""]},{""id"":""uuid:3c8c17d3-48ed-414a-b59e-921fe3736eab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MEPSEVII is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII (MPS VII, Sly syndrome). Limitations of Use The effect of MEPSEVII on the central nervous system manifestations of MPS VII has not been determined.|[EMA] Mepsevii is indicated for the treatment of non-neurological manifestations of Mucopolysaccharidosis VII (MPS VII; Sly syndrome).|[PMDA] A drug with a new active ingredient indicated for the treatment of mucopolysaccharidosis type VII. [Orphan drug] uuid:f7c6e93d-c43d-4350-a3b8-d18016f8e277 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6710 biolink:treats MONDO:0011429 PMID:41385096 "[{""id"":""uuid:cae860c1-70dd-4a63-8bc2-5eef78f73eff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4c445233-cc90-47ba-9125-19af6d16387a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of meclofenamate sodium capsules and other treatment options before deciding to use meclofenamate sodium capsules. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Meclofenamate sodium capsules are indicated: • For reduction of fever in adults • For relief of mild to moderate pain in adults • For relief of signs and symptoms of juvenile arthritis. • For relief of the signs and symptoms of rheumatoid arthritis • For relief of the signs and symptoms of osteoarthritis. • For treatment of primary dysmenorrhea. • For acute or long-term use in the relief of signs and symptoms of the following: 1. Ankylosing spondylitis 2. Acute painful shoulder (Acute subacromial bursitis/supraspinatus tendinitis) 3. Acute gouty arthritis Meclofenamate sodium capsules are also indicated for the treatment of idiopathic heavy menstrual blood loss (see CLINICAL PHARMACOLOGY and PRECAUTIONS ). As with all nonsteroidal anti-inflammatory drugs, selection of meclofenamate sodium capsules require a careful assessment of the benefit/risk ratio (see WARNINGS , PRECAUTIONS and ADVERSE REACTIONS ). Meclofenamate sodium capsules are not recommended in children because adequate studies to demonstrate safety and efficacy have not been carried out. uuid:6de67154-2cc1-43a2-9c79-76895b91b5dc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6710 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:ba3be66e-9d78-4cbd-a311-c8467bc84b19"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:acdc9373-6e93-47eb-b1d2-968653d35a0c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of meclofenamate sodium capsules and other treatment options before deciding to use meclofenamate sodium capsules. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Meclofenamate sodium capsules are indicated: • For reduction of fever in adults • For relief of mild to moderate pain in adults • For relief of signs and symptoms of juvenile arthritis. • For relief of the signs and symptoms of rheumatoid arthritis • For relief of the signs and symptoms of osteoarthritis. • For treatment of primary dysmenorrhea. • For acute or long-term use in the relief of signs and symptoms of the following: 1. Ankylosing spondylitis 2. Acute painful shoulder (Acute subacromial bursitis/supraspinatus tendinitis) 3. Acute gouty arthritis Meclofenamate sodium capsules are also indicated for the treatment of idiopathic heavy menstrual blood loss (see CLINICAL PHARMACOLOGY and PRECAUTIONS ). As with all nonsteroidal anti-inflammatory drugs, selection of meclofenamate sodium capsules require a careful assessment of the benefit/risk ratio (see WARNINGS , PRECAUTIONS and ADVERSE REACTIONS ). Meclofenamate sodium capsules are not recommended in children because adequate studies to demonstrate safety and efficacy have not been carried out. uuid:a315be7b-cc52-497b-852a-ba52bfe495f6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6710 biolink:treats MONDO:0005178 PMID:41385096 "[{""id"":""uuid:8d2a0f4c-d081-4aaa-9b1c-9cb4f1f997c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:07299188-3ad0-4255-844c-bc39377c0306"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of meclofenamate sodium capsules and other treatment options before deciding to use meclofenamate sodium capsules. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Meclofenamate sodium capsules are indicated: • For reduction of fever in adults • For relief of mild to moderate pain in adults • For relief of signs and symptoms of juvenile arthritis. • For relief of the signs and symptoms of rheumatoid arthritis • For relief of the signs and symptoms of osteoarthritis. • For treatment of primary dysmenorrhea. • For acute or long-term use in the relief of signs and symptoms of the following: 1. Ankylosing spondylitis 2. Acute painful shoulder (Acute subacromial bursitis/supraspinatus tendinitis) 3. Acute gouty arthritis Meclofenamate sodium capsules are also indicated for the treatment of idiopathic heavy menstrual blood loss (see CLINICAL PHARMACOLOGY and PRECAUTIONS ). As with all nonsteroidal anti-inflammatory drugs, selection of meclofenamate sodium capsules require a careful assessment of the benefit/risk ratio (see WARNINGS , PRECAUTIONS and ADVERSE REACTIONS ). Meclofenamate sodium capsules are not recommended in children because adequate studies to demonstrate safety and efficacy have not been carried out. uuid:e2cc394f-99c3-4219-a628-86960085ddb9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6710 biolink:treats MONDO:1060206 PMID:41385096 "[{""id"":""uuid:47bd2846-728c-4871-8681-9054336164e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:36cc0b38-eb7a-4c14-ad63-f05d2a070c6a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of meclofenamate sodium capsules and other treatment options before deciding to use meclofenamate sodium capsules. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Meclofenamate sodium capsules are indicated: • For reduction of fever in adults • For relief of mild to moderate pain in adults • For relief of signs and symptoms of juvenile arthritis. • For relief of the signs and symptoms of rheumatoid arthritis • For relief of the signs and symptoms of osteoarthritis. • For treatment of primary dysmenorrhea. • For acute or long-term use in the relief of signs and symptoms of the following: 1. Ankylosing spondylitis 2. Acute painful shoulder (Acute subacromial bursitis/supraspinatus tendinitis) 3. Acute gouty arthritis Meclofenamate sodium capsules are also indicated for the treatment of idiopathic heavy menstrual blood loss (see CLINICAL PHARMACOLOGY and PRECAUTIONS ). As with all nonsteroidal anti-inflammatory drugs, selection of meclofenamate sodium capsules require a careful assessment of the benefit/risk ratio (see WARNINGS , PRECAUTIONS and ADVERSE REACTIONS ). Meclofenamate sodium capsules are not recommended in children because adequate studies to demonstrate safety and efficacy have not been carried out. UMLS:C0149875 uuid:94205408-aa9f-4daa-917b-ef7ac29fe2a0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6710 biolink:treats MONDO:0005306 PMID:41385096 "[{""id"":""uuid:d55885d5-cc47-4ea8-8457-dbbd4431e2ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f6f95450-f12e-4763-a215-ec20de386a17"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of meclofenamate sodium capsules and other treatment options before deciding to use meclofenamate sodium capsules. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Meclofenamate sodium capsules are indicated: • For reduction of fever in adults • For relief of mild to moderate pain in adults • For relief of signs and symptoms of juvenile arthritis. • For relief of the signs and symptoms of rheumatoid arthritis • For relief of the signs and symptoms of osteoarthritis. • For treatment of primary dysmenorrhea. • For acute or long-term use in the relief of signs and symptoms of the following: 1. Ankylosing spondylitis 2. Acute painful shoulder (Acute subacromial bursitis/supraspinatus tendinitis) 3. Acute gouty arthritis Meclofenamate sodium capsules are also indicated for the treatment of idiopathic heavy menstrual blood loss (see CLINICAL PHARMACOLOGY and PRECAUTIONS ). As with all nonsteroidal anti-inflammatory drugs, selection of meclofenamate sodium capsules require a careful assessment of the benefit/risk ratio (see WARNINGS , PRECAUTIONS and ADVERSE REACTIONS ). Meclofenamate sodium capsules are not recommended in children because adequate studies to demonstrate safety and efficacy have not been carried out. uuid:59424a77-f20e-4a6b-bcef-6e3b1cb90bc0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6710 biolink:treats UMLS:C0149896 PMID:41385096 "[{""id"":""uuid:b0fa3de9-d6fa-4442-a799-39964f257444"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c068df48-c645-4a55-b0b5-436a81683639"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of meclofenamate sodium capsules and other treatment options before deciding to use meclofenamate sodium capsules. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Meclofenamate sodium capsules are indicated: • For reduction of fever in adults • For relief of mild to moderate pain in adults • For relief of signs and symptoms of juvenile arthritis. • For relief of the signs and symptoms of rheumatoid arthritis • For relief of the signs and symptoms of osteoarthritis. • For treatment of primary dysmenorrhea. • For acute or long-term use in the relief of signs and symptoms of the following: 1. Ankylosing spondylitis 2. Acute painful shoulder (Acute subacromial bursitis/supraspinatus tendinitis) 3. Acute gouty arthritis Meclofenamate sodium capsules are also indicated for the treatment of idiopathic heavy menstrual blood loss (see CLINICAL PHARMACOLOGY and PRECAUTIONS ). As with all nonsteroidal anti-inflammatory drugs, selection of meclofenamate sodium capsules require a careful assessment of the benefit/risk ratio (see WARNINGS , PRECAUTIONS and ADVERSE REACTIONS ). Meclofenamate sodium capsules are not recommended in children because adequate studies to demonstrate safety and efficacy have not been carried out. uuid:6eb57652-f2d7-4d9d-867a-e36f206ff01d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6710 biolink:treats HP:0000132 PMID:41385096 "[{""id"":""uuid:8e61e3de-b31f-4db5-87d4-d4f2c24d653c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d24afe8d-dfb8-42cb-9fb8-bf0a2bc51db9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of meclofenamate sodium capsules and other treatment options before deciding to use meclofenamate sodium capsules. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Meclofenamate sodium capsules are indicated: • For reduction of fever in adults • For relief of mild to moderate pain in adults • For relief of signs and symptoms of juvenile arthritis. • For relief of the signs and symptoms of rheumatoid arthritis • For relief of the signs and symptoms of osteoarthritis. • For treatment of primary dysmenorrhea. • For acute or long-term use in the relief of signs and symptoms of the following: 1. Ankylosing spondylitis 2. Acute painful shoulder (Acute subacromial bursitis/supraspinatus tendinitis) 3. Acute gouty arthritis Meclofenamate sodium capsules are also indicated for the treatment of idiopathic heavy menstrual blood loss (see CLINICAL PHARMACOLOGY and PRECAUTIONS ). As with all nonsteroidal anti-inflammatory drugs, selection of meclofenamate sodium capsules require a careful assessment of the benefit/risk ratio (see WARNINGS , PRECAUTIONS and ADVERSE REACTIONS ). Meclofenamate sodium capsules are not recommended in children because adequate studies to demonstrate safety and efficacy have not been carried out. uuid:00a16a13-57a0-4b32-94a1-dbc3b1929dad biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46859 biolink:treats MONDO:0001576 PMID:41385096 "[{""id"":""uuid:df8c68cf-f72f-45ea-8ac4-5fb220f2d0ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:820daf09-488c-4ca1-9087-4cae4e37a285"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Asclera ® (polidocanol) is indicated to sclerose uncomplicated spider veins (varicose veins ≤1 mm in diameter) and uncomplicated reticular veins (varicose veins 1 to 3 mm in diameter) in the lower extremity. Asclera has not been studied in varicose veins more than 3 mm in diameter. uuid:b2a75a8e-47c8-4712-b391-294f6738c670 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46859 biolink:treats UMLS:C5906718 PMID:41385096 "[{""id"":""uuid:c3d1dbb6-0643-4abd-9500-db2d7f9240b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bd7a212f-24e4-4e36-9316-2ada69129267"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Asclera ® (polidocanol) is indicated to sclerose uncomplicated spider veins (varicose veins ≤1 mm in diameter) and uncomplicated reticular veins (varicose veins 1 to 3 mm in diameter) in the lower extremity. Asclera has not been studied in varicose veins more than 3 mm in diameter. uuid:67a7dac2-79d2-4a4f-9e7e-17d3b4d17a2f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49618 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:7ee8fe9e-8cbe-4f9e-8be9-1579c72d653a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b43063d2-0149-4be1-9a88-1b0e6443a80b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gadobutrol injection is a gadolinium-based contrast agent indicated for use with magnetic resonance imaging (MRI): To detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system in adult and pediatric patients, including term neonates ( 1.1 ) To assess the presence and extent of malignant breast disease in adult patients ( 1.2 ) To evaluate known or suspected supra-aortic or renal artery disease in adult and pediatric patients, including term neonates ( 1.3 ) To assess myocardial perfusion (stress, rest) and late gadolinium enhancement in adult patients with known or suspected coronary artery disease (CAD). ( 1.4 ). uuid:a3262f8d-fb87-44d3-a802-f81239300e21 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49618 biolink:treats MONDO:0005010 PMID:41385096 "[{""id"":""uuid:4c7c330a-2885-4750-9706-cf1dc0a804b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c2db1b37-0604-4089-9b18-4912a83be3e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gadobutrol injection is a gadolinium-based contrast agent indicated for use with magnetic resonance imaging (MRI): To detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system in adult and pediatric patients, including term neonates ( 1.1 ) To assess the presence and extent of malignant breast disease in adult patients ( 1.2 ) To evaluate known or suspected supra-aortic or renal artery disease in adult and pediatric patients, including term neonates ( 1.3 ) To assess myocardial perfusion (stress, rest) and late gadolinium enhancement in adult patients with known or suspected coronary artery disease (CAD). ( 1.4 ). uuid:31d1e001-15ac-4d3c-a1ae-21843c1bfa61 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:233309 biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:4d5f3430-b297-436a-a245-4a3dadb90db2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:48a50a8d-7bc9-4d3b-a6dd-bcc26f3f73e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KRAZATI is an inhibitor of the RAS GTPase family indicated for: Non-small cell lung cancer (NSCLC)* • As a single agent, for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC, as determined by an FDA-approved test, who have received at least one prior systemic therapy. ( 1.1 ) Colorectal cancer (CRC)* • In combination with cetuximab, for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic CRC, as determined by an FDA-approved test, who have received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. ( 1.2 ) *These indications are approved under accelerated approval based on objective response rate (ORR) and duration of response (DOR). Continued approval for these indications may be contingent upon verification and description of a clinical benefit in confirmatory trials. ( 1.1 , 1.2 ) UNII:8EOO6HQF8Y uuid:8c8ab38c-99ee-45df-831b-0ac4048fd211 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:233309 biolink:treats MONDO:0005575 PMID:41385096 "[{""id"":""uuid:6f8c5dc3-ed02-40cd-ba85-90124355cfdc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c3ff0486-04c2-4c72-a0da-f0364c73b0ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KRAZATI is an inhibitor of the RAS GTPase family indicated for: Non-small cell lung cancer (NSCLC)* • As a single agent, for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC, as determined by an FDA-approved test, who have received at least one prior systemic therapy. ( 1.1 ) Colorectal cancer (CRC)* • In combination with cetuximab, for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic CRC, as determined by an FDA-approved test, who have received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. ( 1.2 ) *These indications are approved under accelerated approval based on objective response rate (ORR) and duration of response (DOR). Continued approval for these indications may be contingent upon verification and description of a clinical benefit in confirmatory trials. ( 1.1 , 1.2 ) UNII:8EOO6HQF8Y uuid:19dff79c-5024-4a80-ba0e-e5a6eeaa3328 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:72291 biolink:treats MONDO:0004951 PMID:41385096 "[{""id"":""uuid:47838e3a-f26c-481c-b6ee-13a8cb765594"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:65ecd77b-0449-4d33-bdb1-9d8ac38ce94f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TYBOST is a CYP3A inhibitor indicated to increase systemic exposure of atazanavir or darunavir (once daily dosing regimen) in combination with other antiretroviral agents in the treatment of HIV-1 infection in adults and in pediatric patients: weighing at least 35 kg coadministered with atazanavir or weighing at least 40 kg coadministered with darunavir. ( 1.1 ) Limitations of Use : TYBOST is not interchangeable with ritonavir to increase systemic exposure of darunavir 600 mg twice daily, fosamprenavir, saquinavir, or tipranavir due to lack of exposure data. The use of TYBOST is not recommended with darunavir 600 mg twice daily, fosamprenavir, saquinavir, or tipranavir. ( 1.2 , 5.4 ) Complex or unknown mechanisms of drug interactions preclude extrapolation of ritonavir drug interactions to certain TYBOST interactions. TYBOST and ritonavir when administered with either atazanavir or darunavir may result in different drug interactions when used with concomitant medications. ( 1.2 , 5.3 , 7 , 12.3 ) uuid:1449eb5f-d164-428a-8ddd-b374e8bf48e5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:140296 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:1b7a33a5-f54f-46a6-8cf8-4d1a4a86e5c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:54052d04-d933-4d9e-866f-d36c2ac7e6a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ACCUPRIL is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with ACCUPRIL. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. ACCUPRIL may be used alone or in combination with thiazide diuretics . uuid:8c2a7b9f-7d15-4f0f-b165-9277f7735440 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:145373 biolink:treats MONDO:0002522 PMID:41385096 "[{""id"":""uuid:6fea53ce-33f4-4025-9d0d-1fb1e8381786"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7b94c48c-4ae0-4146-ace7-82197113ef4f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TURALIO is indicated for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery. uuid:da4f42d1-7971-421d-8700-521d25a30b38 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:145373 biolink:treats MONDO:0010108 PMID:41385096 "[{""id"":""uuid:7122d838-35b7-4e33-9ef6-355687b9cf2f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:415d8ed0-b1de-4abc-ad01-ed65530a5e66"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TURALIO is indicated for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery. uuid:9eec0633-5146-4c25-8046-f7b4653f7336 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:FU77B4U5Z0 biolink:treats UMLS:C0406317 PMID:41385096 "[{""id"":""uuid:c8e00c4b-6f81-4380-8a78-b05cce4e32b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6548a8ca-2b7c-4ef8-aad9-958ffce7dc73"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:3d672a6d-2df3-4a36-a0c9-c73bff8c3bc1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OTULFI is a human interleukin-12 and -23 antagonist indicated for the treatment of: Adult patients with: moderate to severe plaque psoriasis (PsO) who are candidates for phototherapy or systemic therapy. ( 1.1 ) active psoriatic arthritis (PsA) . ( 1.2 ) moderately to severely active Crohn's disease (CD) . ( 1.3 ) moderately to severely active ulcerative colitis. ( 1.4 ) Pediatric patients 6 years and older with: moderate to severe plaque psoriasis , who are candidates for phototherapy or systemic therapy. ( 1.1 ) active psoriatic arthritis (PsA) . ( 1.2 )|[PMDA] A biosimilar indicated for the treatment of the following disease in patients who have not sufficiently responded to conventional therapies: plaque psoriasis and psoriatic arthritis uuid:9917093b-4d9f-46cb-b657-cd57d07178d0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:FU77B4U5Z0 biolink:treats MONDO:0011849 PMID:41385096 "[{""id"":""uuid:988ad54b-6ce6-4280-b27c-bdf444433a20"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2a35f335-1761-4bf7-b1b9-c7ac0be1a79e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:b3a06a44-c94f-4c32-9c0d-90f281658718"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/stelara""]},{""id"":""uuid:fcc4bdd8-8840-4f67-9268-90d1f1f09a0f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OTULFI is a human interleukin-12 and -23 antagonist indicated for the treatment of: Adult patients with: moderate to severe plaque psoriasis (PsO) who are candidates for phototherapy or systemic therapy. ( 1.1 ) active psoriatic arthritis (PsA) . ( 1.2 ) moderately to severely active Crohn's disease (CD) . ( 1.3 ) moderately to severely active ulcerative colitis. ( 1.4 ) Pediatric patients 6 years and older with: moderate to severe plaque psoriasis , who are candidates for phototherapy or systemic therapy. ( 1.1 ) active psoriatic arthritis (PsA) . ( 1.2 )|[EMA] Crohn’s DiseaseStelara is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a TNFα antagonist or have medical contraindications to such therapies.Ulcerative colitisSTELARA is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies.Plaque psoriasisStelara is indicated for the treatment of moderate to severe plaque psoriasis in adults who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate and psoralen ultraviolet A.Paediatric plaque psoriasisStelara is indicated for the treatment of moderate to severe plaque psoriasis in children and adolescent patients from the age of 6 years and older, who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.Psoriatic arthritisStelara, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous non-biological disease-modifying antirheumatic drug (DMARD) therapy has been inadequate.|[PMDA] A biosimilar indicated for the treatment of the following disease in patients who have not sufficiently responded to conventional therapies: plaque psoriasis and psoriatic arthritis uuid:4ed3532b-c764-442b-a8dc-f2e7fecbde96 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:FU77B4U5Z0 biolink:treats MONDO:0005011 PMID:41385096 "[{""id"":""uuid:ebc84b69-3ea9-466b-a280-f312b55b5b36"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:4d5e521a-d4d1-43c3-ac4c-fc3dc31d8eb2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:291645be-d579-44ad-b092-531645f783e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/stelara""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] OTULFI is a human interleukin-12 and -23 antagonist indicated for the treatment of: Adult patients with: moderate to severe plaque psoriasis (PsO) who are candidates for phototherapy or systemic therapy. ( 1.1 ) active psoriatic arthritis (PsA) . ( 1.2 ) moderately to severely active Crohn's disease (CD) . ( 1.3 ) moderately to severely active ulcerative colitis. ( 1.4 ) Pediatric patients 6 years and older with: moderate to severe plaque psoriasis , who are candidates for phototherapy or systemic therapy. ( 1.1 ) active psoriatic arthritis (PsA) . ( 1.2 )|[EMA] Crohn’s DiseaseStelara is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a TNFα antagonist or have medical contraindications to such therapies.Ulcerative colitisSTELARA is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies.Plaque psoriasisStelara is indicated for the treatment of moderate to severe plaque psoriasis in adults who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate and psoralen ultraviolet A.Paediatric plaque psoriasisStelara is indicated for the treatment of moderate to severe plaque psoriasis in children and adolescent patients from the age of 6 years and older, who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.Psoriatic arthritisStelara, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous non-biological disease-modifying antirheumatic drug (DMARD) therapy has been inadequate. uuid:367fd0e1-962a-46c1-b6e8-21b93ecd7d85 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:FU77B4U5Z0 biolink:treats MONDO:0005101 PMID:41385096 "[{""id"":""uuid:570b6c36-98f6-4e38-8921-173a2f392f83"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c7ae2c0a-45a2-4acc-b9de-d68f654a44e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:140fcb9f-b682-4e41-aaf9-a84842b98e6f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/stelara""]},{""id"":""uuid:553fe076-f520-4776-a1f6-93d94780e46e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OTULFI is a human interleukin-12 and -23 antagonist indicated for the treatment of: Adult patients with: moderate to severe plaque psoriasis (PsO) who are candidates for phototherapy or systemic therapy. ( 1.1 ) active psoriatic arthritis (PsA) . ( 1.2 ) moderately to severely active Crohn's disease (CD) . ( 1.3 ) moderately to severely active ulcerative colitis. ( 1.4 ) Pediatric patients 6 years and older with: moderate to severe plaque psoriasis , who are candidates for phototherapy or systemic therapy. ( 1.1 ) active psoriatic arthritis (PsA) . ( 1.2 )|[EMA] Crohn’s DiseaseStelara is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a TNFα antagonist or have medical contraindications to such therapies.Ulcerative colitisSTELARA is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies.Plaque psoriasisStelara is indicated for the treatment of moderate to severe plaque psoriasis in adults who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate and psoralen ultraviolet A.Paediatric plaque psoriasisStelara is indicated for the treatment of moderate to severe plaque psoriasis in children and adolescent patients from the age of 6 years and older, who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.Psoriatic arthritisStelara, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous non-biological disease-modifying antirheumatic drug (DMARD) therapy has been inadequate.|[PMDA] A drug with a new indication for the remission induction therapy of moderate to severe ulcerative colitis (for use only in patients who have not sufficiently responded to conventional treatments). A drug with a new indication for the maintenance therapy of moderate to severe ulcerative colitis (for use only in patients who have not sufficiently responded to conventional treatments). uuid:232e1da6-60be-4ee1-a1bf-27a60dfdb088 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9637 biolink:treats HP:0000969 PMID:41385096 "[{""id"":""uuid:e9fddb72-e3e8-4c62-8940-a9159e0d6576"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7bd7d016-715c-4d62-bc6b-d222cd035699"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Edema Torsemide tablets are indicated for the treatment of edema associated with heart failure, renal disease or hepatic disease. 1.2 Hypertension Torsemide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with torsemide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. The antihypertensive effects of torsemide tablets are on the average greater in black patients than in nonblack patients [see Clinical Pharmacology (12.2)]. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Torsemide tablets can be used alone or in combination with other antihypertensive agents. uuid:fac567c9-de4c-4965-92d8-0ff74015e266 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9637 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:efcf9233-522f-4a55-851b-2069a1b88067"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5f8b456d-664d-4d6a-a4e6-4e5db98abd54"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Edema Torsemide tablets are indicated for the treatment of edema associated with heart failure, renal disease or hepatic disease. 1.2 Hypertension Torsemide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with torsemide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. The antihypertensive effects of torsemide tablets are on the average greater in black patients than in nonblack patients [see Clinical Pharmacology (12.2)]. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Torsemide tablets can be used alone or in combination with other antihypertensive agents. uuid:471844e0-dc68-49aa-a184-9027a705ace9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9637 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:6f25d3b6-4e3c-4eb8-8c75-a96feaaf9f33"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aea2cdca-6516-4ef1-9558-b31bd9eba3e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Edema Torsemide tablets are indicated for the treatment of edema associated with heart failure, renal disease or hepatic disease. 1.2 Hypertension Torsemide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with torsemide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. The antihypertensive effects of torsemide tablets are on the average greater in black patients than in nonblack patients [see Clinical Pharmacology (12.2)]. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Torsemide tablets can be used alone or in combination with other antihypertensive agents. uuid:883d2180-da71-4d6d-89d2-ad653b76125d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9637 biolink:treats MONDO:0005016 PMID:41385096 "[{""id"":""uuid:0a79a721-8505-4110-8e01-8a434f2a0bde"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c7d35d4c-73ba-4f63-9000-89e96312042e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Edema Torsemide tablets are indicated for the treatment of edema associated with heart failure, renal disease or hepatic disease. 1.2 Hypertension Torsemide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with torsemide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. The antihypertensive effects of torsemide tablets are on the average greater in black patients than in nonblack patients [see Clinical Pharmacology (12.2)]. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Torsemide tablets can be used alone or in combination with other antihypertensive agents. uuid:bae139cb-1540-4744-b020-cf447b8cc7cd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9637 biolink:treats HP:0001681 PMID:41385096 "[{""id"":""uuid:bf35bb4b-7a05-482a-b8d5-37995cc3ec60"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:97cca8c6-d6fc-4873-b1dc-84d2671b8be4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Edema Torsemide tablets are indicated for the treatment of edema associated with heart failure, renal disease or hepatic disease. 1.2 Hypertension Torsemide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with torsemide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. The antihypertensive effects of torsemide tablets are on the average greater in black patients than in nonblack patients [see Clinical Pharmacology (12.2)]. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Torsemide tablets can be used alone or in combination with other antihypertensive agents. uuid:e2e07945-e156-4e4a-b796-634f2841d57c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6722 biolink:treats UMLS:C0278802 PMID:41385096 "[{""id"":""uuid:9bd57da1-c9e4-4314-b04c-9aab30a3b093"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a0972352-1c3e-4c27-974d-fd09518d8f52"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Megestrol Acetate Tablets are indicated for the palliative treatment of advanced carcinoma of the breast or endometrium (i.e., recurrent, inoperable, or metastatic disease). It should not be used in lieu of currently accepted procedures such as surgery, radiation, or chemotherapy. uuid:81afded7-44a9-4f2e-b75c-eaca9c1c0276 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6722 biolink:treats UMLS:C0813148 PMID:41385096 "[{""id"":""uuid:ee2a500a-636c-46a2-a2e6-83a41dfb25c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4ee3e5f9-b129-495d-bee8-27601e2de9e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Megestrol Acetate Tablets are indicated for the palliative treatment of advanced carcinoma of the breast or endometrium (i.e., recurrent, inoperable, or metastatic disease). It should not be used in lieu of currently accepted procedures such as surgery, radiation, or chemotherapy. uuid:b32dac2b-7de7-427c-b24e-59312f93b965 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:36704 biolink:treats MONDO:0002954 PMID:41385096 "[{""id"":""uuid:b999b96e-9cef-41b5-8f67-699fc45ec208"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:edf3b3c5-6027-43cf-a36c-d4f920355d73"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:2588a834-e48a-4035-a619-d33d77fd33f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/zyclara""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Actinic Keratosis Imiquimod Cream is indicated for the topical treatment of clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses on the face or scalp in immunocompetent adults. 1.2 Superficial Basal Cell Carcinoma Imiquimod Cream is indicated for the topical treatment of biopsy-confirmed, primary superficial basal cell carcinoma (sBCC) in immunocompetent adults, with a maximum tumor diameter of 2.0 cm, located on the trunk (excluding anogenital skin), neck, or extremities (excluding hands and feet), only when surgical methods are medically less appropriate and patient follow-up can be reasonably assured. The histological diagnosis of superficial basal cell carcinoma should be established prior to treatment, since safety and efficacy of Imiquimod Cream have not been established for other types of basal cell carcinomas, including nodular and morpheaform (fibrosing or sclerosing) types. 1.3 External Genital Warts Imiquimod Cream is indicated for the treatment of external genital and perianal warts/condyloma acuminata in patients 12 years old and older. 1.4 Limitations of Use Imiquimod cream has been evaluated in children ages 2 to 12 years with molluscum contagiosum and these studies failed to demonstrate efficacy. [see USE IN SPECIFIC POPULATIONS (8.4)]. 1.5 Unevaluated Populations The safety and efficacy of Imiquimod Cream in immunosuppressed patients have not been established. Imiquimod Cream should be used with caution in patients with pre-existing autoimmune conditions. The efficacy and safety of Imiquimod Cream have not been established for patients with Basal Cell Nevus Syndrome or Xeroderma Pigmentosum.|[EMA] Imiquimod cream is indicated for the topical treatment of :External genital and perianal warts (condylomata acuminata) in adults.Small superficial basal cell carcinomas (sBCCs) in adults.Clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses (AKs) on the face or scalp in immunocompetent adult patients when size or number of lesions limit the efficacy and/or acceptability of cryotherapy and other topical treatment options are contraindicated or less appropriate. uuid:3595f29d-04dc-4002-9659-e54a2f520856 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4708 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:b1a3ede8-1bad-4550-95c8-1f18cc1cf64d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b78c4e6f-e364-44ef-9c1d-ce14fb4c95eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Benign Prostatic Hyperplasia (BPH) Doxazosin tablets, USP are indicated for the treatment of the signs and symptoms of BPH. 1.2 Hypertension Doxazosin tablets, USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Doxazosin tablets, USP may be used alone or in combination with other antihypertensives. uuid:0eeb393d-5f1e-4783-bb04-f12e815b5a01 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4708 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:541d3ad1-4755-4786-a590-0ca9faa04b57"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e4e8be6f-e33a-4424-9f04-394270b9ef68"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Benign Prostatic Hyperplasia (BPH) Doxazosin tablets, USP are indicated for the treatment of the signs and symptoms of BPH. 1.2 Hypertension Doxazosin tablets, USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Doxazosin tablets, USP may be used alone or in combination with other antihypertensives. uuid:79b3ffb4-860f-40d5-9fa9-68eebb48cb92 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4708 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:b54c13a6-8e92-4f9d-881c-24686229d0bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f5e82f6c-35f5-4968-b49d-3eed91421bf6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Benign Prostatic Hyperplasia (BPH) Doxazosin tablets, USP are indicated for the treatment of the signs and symptoms of BPH. 1.2 Hypertension Doxazosin tablets, USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Doxazosin tablets, USP may be used alone or in combination with other antihypertensives. uuid:1163011e-74eb-4013-a510-84c91eb5b794 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4708 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:4ed10752-89c0-4ec5-9e3e-709ab0c1910f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bc18bc0d-42a4-4572-8f14-03b4c4f99ea3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Benign Prostatic Hyperplasia (BPH) Doxazosin tablets, USP are indicated for the treatment of the signs and symptoms of BPH. 1.2 Hypertension Doxazosin tablets, USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Doxazosin tablets, USP may be used alone or in combination with other antihypertensives. uuid:8580ea1a-0beb-460b-ab0f-4145ee8d347c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4708 biolink:treats HP:0001681 PMID:41385096 "[{""id"":""uuid:90a12980-d473-4b14-8d2c-df3ed195f00b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:90235624-69ef-48a9-a8d9-a2ced3f86d37"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Benign Prostatic Hyperplasia (BPH) Doxazosin tablets, USP are indicated for the treatment of the signs and symptoms of BPH. 1.2 Hypertension Doxazosin tablets, USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Doxazosin tablets, USP may be used alone or in combination with other antihypertensives. uuid:131533d3-38b6-470c-9bcd-21853f2ff79d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4708 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:08dbf6d4-d9dd-4b6a-abb9-b52c55d62b4f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3be22b1f-60ed-4896-aadf-88e23e009251"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Benign Prostatic Hyperplasia (BPH) Doxazosin tablets, USP are indicated for the treatment of the signs and symptoms of BPH. 1.2 Hypertension Doxazosin tablets, USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Doxazosin tablets, USP may be used alone or in combination with other antihypertensives. uuid:18e5dafe-8de9-4b8e-820f-104d7208b789 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4708 biolink:treats MONDO:0005016 PMID:41385096 "[{""id"":""uuid:c4375fe4-e69e-4cf2-89a7-be17c0defac3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:669157ec-c71b-4a35-b2df-657f8067bf29"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Benign Prostatic Hyperplasia (BPH) Doxazosin tablets, USP are indicated for the treatment of the signs and symptoms of BPH. 1.2 Hypertension Doxazosin tablets, USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Doxazosin tablets, USP may be used alone or in combination with other antihypertensives. uuid:f417d9d6-5d95-4ab0-afdf-6bb4a478e219 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1152283 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:88fe17e9-eee0-4d41-8ec5-bcf7f51bc4ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e00e2798-e909-48e5-b535-4020051475ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Hypertension Amlodipine besylate tablets is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including Amlodipine besylate tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Amlodipine besylate tablets may be used alone or in combination with other antihypertensive agents. 1.2 Coronary Artery Disease (CAD) Chronic Stable Angina Amlodipine besylate tablets is indicated for the symptomatic treatment of chronic stable angina. Amlodipine besylate tablets may be used alone or in combination with other antianginal agents. Vasospastic Angina (Prinzmetal’s or Variant Angina) Amlodipine besylate tablets is indicated for the treatment of confirmed or suspected vasospastic angina. Amlodipine besylate tablets may be used as monotherapy or in combination with other antianginal agents. Angiographically Documented CAD In patients with recently documented CAD by angiography and without heart failure or an ejection fraction <40%, Amlodipine besylate tablets is indicated to reduce the risk of hospitalization for angina and to reduce the risk of a coronary revascularization procedure. uuid:2bf55a7c-f4c9-47c4-980b-7b8fbde5e1a5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1152283 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:2d0b27b7-e53a-4794-80a2-87338cca073e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4608c76b-d722-4ec8-ba04-46385af54736"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Hypertension Amlodipine besylate tablets is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including Amlodipine besylate tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Amlodipine besylate tablets may be used alone or in combination with other antihypertensive agents. 1.2 Coronary Artery Disease (CAD) Chronic Stable Angina Amlodipine besylate tablets is indicated for the symptomatic treatment of chronic stable angina. Amlodipine besylate tablets may be used alone or in combination with other antianginal agents. Vasospastic Angina (Prinzmetal’s or Variant Angina) Amlodipine besylate tablets is indicated for the treatment of confirmed or suspected vasospastic angina. Amlodipine besylate tablets may be used as monotherapy or in combination with other antianginal agents. Angiographically Documented CAD In patients with recently documented CAD by angiography and without heart failure or an ejection fraction <40%, Amlodipine besylate tablets is indicated to reduce the risk of hospitalization for angina and to reduce the risk of a coronary revascularization procedure. uuid:5794c0d8-7e66-43d4-98b7-de0ce5bb2cbe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1152283 biolink:treats MONDO:0006021 PMID:41385096 "[{""id"":""uuid:88f88891-0eb7-4cac-9f6e-9991a9407b68"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:60e9deb1-4bbe-4bfe-b82a-0c3041b95759"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Hypertension Amlodipine besylate tablets is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including Amlodipine besylate tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Amlodipine besylate tablets may be used alone or in combination with other antihypertensive agents. 1.2 Coronary Artery Disease (CAD) Chronic Stable Angina Amlodipine besylate tablets is indicated for the symptomatic treatment of chronic stable angina. Amlodipine besylate tablets may be used alone or in combination with other antianginal agents. Vasospastic Angina (Prinzmetal’s or Variant Angina) Amlodipine besylate tablets is indicated for the treatment of confirmed or suspected vasospastic angina. Amlodipine besylate tablets may be used as monotherapy or in combination with other antianginal agents. Angiographically Documented CAD In patients with recently documented CAD by angiography and without heart failure or an ejection fraction <40%, Amlodipine besylate tablets is indicated to reduce the risk of hospitalization for angina and to reduce the risk of a coronary revascularization procedure. uuid:460224b6-456c-441e-bcfa-9eceffc7bb17 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4031 biolink:treats MONDO:0019085 PMID:41385096 "[{""id"":""uuid:72e5ed72-2666-4f14-9bc8-d4e5e3583ae1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6e50f478-402e-4c47-bd76-904a92fd49a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:8ac32a6c-9c91-4fd5-ac3f-24a42b313eee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/verkazia""]},{""id"":""uuid:34f99f65-fdb1-49ec-b767-31c64d9f9125"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Verkazia ophthalmic emulsion is indicated for the treatment of vernal keratoconjunctivitis (VKC) in children and adults.|[EMA] Treatment of severe vernal keratoconjunctivitis (VKC) in children from 4 years of age and adolescents.|[PMDA] Eye drops indicated for the treatment of spring catarrh (where treatment with anti-allergic agents is inadequate) [Orphan drug] uuid:63fbbd42-f06f-4d4f-97b2-a09f48cfb916 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:145428 biolink:treats MONDO:0018874 PMID:41385096 "[{""id"":""uuid:5be00c91-4e63-4942-a812-95fd278f38b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f04a3586-a487-43e0-9136-48aba72655dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:150f7584-6621-491f-8568-f11d7947e748"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DAURISMO is indicated, in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adult patients who are ≥75 years old or who have comorbidities that preclude use of intensive induction chemotherapy.|[EMA] Daurismo is indicated, in combination with low-dose cytarabine, for the treatment of newly diagnosed de novo or secondary acute myeloid leukaemia (AML) in adult patients who are not candidates for standard induction chemotherapy. uuid:5c54731a-f5ff-4632-b7e6-11f2f1927b85 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50729 biolink:treats MONDO:0000451 PMID:41385096 "[{""id"":""uuid:ddc39967-c07b-4786-bdbb-d030145c1526"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b80c6aff-3567-4a04-a05c-7d326bd34360"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mitoxantrone is indicated for reducing neurologic disability and/or the frequency of clinical relapses in patients with secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis (i.e., patients whose neurologic status is significantly abnormal between relapses). Mitoxantrone is not indicated in the treatment of patients with primary progressive multiple sclerosis. The clinical patterns of multiple sclerosis in the studies were characterized as follows: secondary progressive and progressive relapsing disease were characterized by gradual increasing disability with or without superimposed clinical relapses, and worsening relapsing-remitting disease was characterized by clinical relapses resulting in a step-wise worsening of disability. Mitoxantrone in combination with corticosteroids is indicated as initial chemotherapy for the treatment of patients with pain related to advanced hormone-refractory prostate cancer. Mitoxantrone in combination with other approved drug(s) is indicated in the initial therapy of acute nonlymphocytic leukemia (ANLL) in adults. This category includes myelogenous, promyelocytic, monocytic, and erythroid acute leukemias. uuid:f1195df4-9995-4ce8-bcf3-26b8f04b0695 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64312 biolink:treats UMLS:C3494871 PMID:41385096 "[{""id"":""uuid:22858667-4991-4296-9ca9-43fd374cda42"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8311dd6e-147b-4101-961b-2ae5b5ab1a8c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Memantine hydrochloride tablets, USP are indicated for the treatment of moderate to severe dementia of the Alzheimer's type. uuid:2f1564f4-9ba5-484b-b5c4-b288f5009566 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64312 biolink:treats UMLS:C3494652 PMID:41385096 "[{""id"":""uuid:996694ef-ac34-421f-95ba-3c80c544c0ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1506a8c0-67d5-4a96-bee2-e1a57a0825fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Memantine hydrochloride tablets, USP are indicated for the treatment of moderate to severe dementia of the Alzheimer's type. uuid:49c61c17-8a49-4c29-a8ef-596a5bc9a17f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1162127 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:10fe2144-abad-4213-b2a8-d58e32a0e6dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7e00024a-6e9b-4229-9097-c6687705708a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Hypertension Losartan potassium and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan and hydrochlorothiazide. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in Black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. This fixed dose combination is not indicated for initial therapy of hypertension, except when the hypertension is severe enough that the value of achieving prompt blood pressure control exceeds the risk of initiating combination therapy in these patients [see Clinical Studies (14) and Dosage and Administration (2.1)]. Losartan potassium and hydrochlorothiazide tablets may be administered with other antihypertensive agents. 1.2 Hypertensive Patients with Left Ventricular Hypertrophy Losartan potassium and hydrochlorothiazide tablets are indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to Black patients. [See Use in Specific Populations (8.6), Clinical Pharmacology (12.3), and Dosage and Administration (2.2).] uuid:2e67d673-a670-4d1d-8394-4675845ef553 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1162127 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:27517cdd-5d73-43c1-b8ff-51890feda581"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7d036b92-2534-4d37-bfe8-e35104ed04ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Hypertension Losartan potassium and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan and hydrochlorothiazide. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in Black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. This fixed dose combination is not indicated for initial therapy of hypertension, except when the hypertension is severe enough that the value of achieving prompt blood pressure control exceeds the risk of initiating combination therapy in these patients [see Clinical Studies (14) and Dosage and Administration (2.1)]. Losartan potassium and hydrochlorothiazide tablets may be administered with other antihypertensive agents. 1.2 Hypertensive Patients with Left Ventricular Hypertrophy Losartan potassium and hydrochlorothiazide tablets are indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to Black patients. [See Use in Specific Populations (8.6), Clinical Pharmacology (12.3), and Dosage and Administration (2.2).] uuid:10af1a30-7343-4623-b0a9-e2ff723ecf5f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1162127 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:de3dad2f-074c-4392-ba93-85defe0641bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f03127b3-e9c2-4293-a577-2d380a482bda"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Hypertension Losartan potassium and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan and hydrochlorothiazide. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in Black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. This fixed dose combination is not indicated for initial therapy of hypertension, except when the hypertension is severe enough that the value of achieving prompt blood pressure control exceeds the risk of initiating combination therapy in these patients [see Clinical Studies (14) and Dosage and Administration (2.1)]. Losartan potassium and hydrochlorothiazide tablets may be administered with other antihypertensive agents. 1.2 Hypertensive Patients with Left Ventricular Hypertrophy Losartan potassium and hydrochlorothiazide tablets are indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to Black patients. [See Use in Specific Populations (8.6), Clinical Pharmacology (12.3), and Dosage and Administration (2.2).] uuid:53f2bed3-cad2-4b17-b59f-6e660550d18f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1162127 biolink:treats HP:0001681 PMID:41385096 "[{""id"":""uuid:94eff068-7bc3-410d-8703-f28c4fc5b4fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f21497e6-453e-4c70-81ca-72667ef1fbdc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Hypertension Losartan potassium and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan and hydrochlorothiazide. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in Black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. This fixed dose combination is not indicated for initial therapy of hypertension, except when the hypertension is severe enough that the value of achieving prompt blood pressure control exceeds the risk of initiating combination therapy in these patients [see Clinical Studies (14) and Dosage and Administration (2.1)]. Losartan potassium and hydrochlorothiazide tablets may be administered with other antihypertensive agents. 1.2 Hypertensive Patients with Left Ventricular Hypertrophy Losartan potassium and hydrochlorothiazide tablets are indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to Black patients. [See Use in Specific Populations (8.6), Clinical Pharmacology (12.3), and Dosage and Administration (2.2).] uuid:7d790f32-45e8-43c6-91bc-e35f7aee91c6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1162127 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:852d967d-c37c-4aef-9e2a-6eb76a3c6876"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eafb1f73-6dc5-467e-8dfc-20f995e77616"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Hypertension Losartan potassium and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan and hydrochlorothiazide. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in Black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. This fixed dose combination is not indicated for initial therapy of hypertension, except when the hypertension is severe enough that the value of achieving prompt blood pressure control exceeds the risk of initiating combination therapy in these patients [see Clinical Studies (14) and Dosage and Administration (2.1)]. Losartan potassium and hydrochlorothiazide tablets may be administered with other antihypertensive agents. 1.2 Hypertensive Patients with Left Ventricular Hypertrophy Losartan potassium and hydrochlorothiazide tablets are indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to Black patients. [See Use in Specific Populations (8.6), Clinical Pharmacology (12.3), and Dosage and Administration (2.2).] uuid:d1c072fd-ca6a-4ba6-b6fb-6a1d8d3986bb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1162127 biolink:treats MONDO:0005016 PMID:41385096 "[{""id"":""uuid:ba2a817f-bb66-4efe-a449-b14337231e94"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0f35bd3d-0c7d-4169-bb42-df636c0e4a89"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Hypertension Losartan potassium and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan and hydrochlorothiazide. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in Black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. This fixed dose combination is not indicated for initial therapy of hypertension, except when the hypertension is severe enough that the value of achieving prompt blood pressure control exceeds the risk of initiating combination therapy in these patients [see Clinical Studies (14) and Dosage and Administration (2.1)]. Losartan potassium and hydrochlorothiazide tablets may be administered with other antihypertensive agents. 1.2 Hypertensive Patients with Left Ventricular Hypertrophy Losartan potassium and hydrochlorothiazide tablets are indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to Black patients. [See Use in Specific Populations (8.6), Clinical Pharmacology (12.3), and Dosage and Administration (2.2).] uuid:97ddb7f8-21f5-466c-82c4-34edc7608879 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:379056 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:5934ba81-2693-43cf-a860-719315c4d8dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:86938363-3266-4c9f-9e0a-346f55b26a1d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:a5d33dce-72ef-478e-86a0-ddd3071c934f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NOVOLOG is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.|[PMDA] New combination drugs indicated for the treatment of diabetes mellitus in cases where insulin therapy is indicated. uuid:ae2cd00b-d155-4b99-a6fe-8795f7d8fffe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:RWM8CCW8GP biolink:treats MONDO:0001673 PMID:41385096 "[{""id"":""uuid:9bc03d49-504c-4a29-a874-abda0bc2152f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fb217ec3-e5e1-4299-adc0-432757a0f781"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sandostatin Injection is a somatostatin analogue indicated: Acromegaly : To reduce blood levels of growth hormone (GH) and insulin growth factor-1 (IGF-1; somatomedin C) in acromegaly patients who have had inadequate response to or cannot be treated with surgical resection, pituitary irradiation, and bromocriptine mesylate at maximally tolerated doses. ( 1.1 ) Carcinoid Tumors : For the symptomatic treatment of patients with metastatic carcinoid tumors where it suppresses or inhibits the severe diarrhea and flushing episodes associated with the disease. ( 1.2 ) Vasoactive Intestinal Peptide Tumors (VIPomas) : For the treatment of profuse watery diarrhea associated with VIP-secreting tumors. ( 1.3 ) Limitations of Use Improvement in clinical signs and symptoms, or reduction in tumor size or rate of growth, were not shown in clinical trials performed with Sandostatin Injection; these trials were not optimally designed to detect such effects. ( 1.4 ) uuid:3824059c-566e-4105-8179-3c7406628652 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:AE72RB1W1X biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:8ee572b1-77e1-47eb-9a20-e16e672b8313"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8a1eb3b9-3f6a-46eb-a6b5-1d5e53e5948a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BIZENGRI® is a bispecific HER2- and HER3-directed antibody indicated for the treatment of: Adults with advanced, unresectable or metastatic non-small cell lung cancer (NSCLC) harboring a neuregulin 1 ( NRG1 ) gene fusion with disease progression on or after prior systemic therapy.* ( 1.1 ) Adults with advanced, unresectable or metastatic pancreatic adenocarcinoma harboring a neuregulin 1 ( NRG1 ) gene fusion with disease progression on or after prior systemic therapy.* ( 1.2 ) *This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). uuid:da5e4889-4ad9-4934-99ed-8ea0030a6d0f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:AE72RB1W1X biolink:treats MONDO:0006047 PMID:41385096 "[{""id"":""uuid:883479b5-606d-4021-8f7f-44dca617cb5d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ae7d71b5-8796-440f-bbce-07ed37eb9981"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BIZENGRI® is a bispecific HER2- and HER3-directed antibody indicated for the treatment of: Adults with advanced, unresectable or metastatic non-small cell lung cancer (NSCLC) harboring a neuregulin 1 ( NRG1 ) gene fusion with disease progression on or after prior systemic therapy.* ( 1.1 ) Adults with advanced, unresectable or metastatic pancreatic adenocarcinoma harboring a neuregulin 1 ( NRG1 ) gene fusion with disease progression on or after prior systemic therapy.* ( 1.2 ) *This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). uuid:8e44d105-2fac-490b-965a-9a1fc3371472 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:17276 biolink:treats HP:0000969 PMID:41385096 "[{""id"":""uuid:d747f3af-c24e-4c86-9ca5-09315436b2c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:56754f3a-fb78-4a3f-bbb9-3db954150b5b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Spironolactone, an ingredient of spironolactone and hydrochlorothiazide tablets, has been shown to be a tumorigen in chronic toxicity studies in rats (see Precautions section). Spironolactone and hydrochlorothiazide tablets should be used only in those conditions described below. Unnecessary use of this drug should be avoided. Spironolactone and hydrochlorothiazide tablets are indicated for: Edematous conditions for patients with: Congestive heart failure: • For the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures; • The treatment of diuretic-induced hypokalemia in patients with congestive heart failure when other measures are considered inappropriate; • The treatment of patients with congestive heart failure taking digitalis when other therapies are considered inadequate or inappropriate. Cirrhosis of the liver accompanied by edema and/or ascites: • Aldosterone levels may be exceptionally high in this condition. Spironolactone and hydrochlorothiazide tablets are indicated for maintenance therapy together with bed rest and the restriction of fluid and sodium. The nephrotic syndrome: • For nephrotic patients when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics do not provide an adequate response. Essential hypertension: • For patients with essential hypertension in whom other measures are considered inadequate or inappropriate; • In hypertensive patients for the treatment of a diuretic-induced hypokalemia when other measures are considered inappropriate; • Spironolactone and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the classes to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with spironolactone and hydrochlorothiazide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. uuid:601cf39c-5073-4f1b-8990-40b1607573bf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:17276 biolink:treats UMLS:C4722157 PMID:41385096 "[{""id"":""uuid:881153ac-811c-424f-8984-823eb7c6ae03"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7e851652-81e2-44de-b06a-420a15016752"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Spironolactone, an ingredient of spironolactone and hydrochlorothiazide tablets, has been shown to be a tumorigen in chronic toxicity studies in rats (see Precautions section). Spironolactone and hydrochlorothiazide tablets should be used only in those conditions described below. Unnecessary use of this drug should be avoided. Spironolactone and hydrochlorothiazide tablets are indicated for: Edematous conditions for patients with: Congestive heart failure: • For the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures; • The treatment of diuretic-induced hypokalemia in patients with congestive heart failure when other measures are considered inappropriate; • The treatment of patients with congestive heart failure taking digitalis when other therapies are considered inadequate or inappropriate. Cirrhosis of the liver accompanied by edema and/or ascites: • Aldosterone levels may be exceptionally high in this condition. Spironolactone and hydrochlorothiazide tablets are indicated for maintenance therapy together with bed rest and the restriction of fluid and sodium. The nephrotic syndrome: • For nephrotic patients when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics do not provide an adequate response. Essential hypertension: • For patients with essential hypertension in whom other measures are considered inadequate or inappropriate; • In hypertensive patients for the treatment of a diuretic-induced hypokalemia when other measures are considered inappropriate; • Spironolactone and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the classes to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with spironolactone and hydrochlorothiazide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. uuid:efbe3d17-1fcc-4328-848a-3b7350bf8fe4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1592709 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:9f0e31f4-720b-4fb3-99e3-d0064c2ed39a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3383451d-131c-475c-9bd2-3be3d7b8124e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XIGDUO XR is a combination of dapagliflozin and metformin hydrochloride (HCl) extended-release, indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. Dapagliflozin, when used as a component of XIGDUO XR, is indicated in adults with type 2 diabetes mellitus to reduce the risk of: • Sustained eGFR decline, end‑stage kidney disease, cardiovascular death, and hospitalization for heart failure in patients with chronic kidney disease at risk of progression. • Cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in patients with heart failure. • Hospitalization for heart failure in patients with type 2 diabetes mellitus and either established cardiovascular disease (CVD) or multiple cardiovascular (CV) risk factors. Limitations of Use • XIGDUO XR is not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus [see Warnings and Precautions (5.2) ] . • Because of the metformin HCl component, the use of XIGDUO XR is limited to patients with type 2 diabetes mellitus for all indications. • XIGDUO XR is not recommended for the treatment of chronic kidney disease in patients with polycystic kidney disease or patients requiring or with a recent history of immunosuppressive therapy for kidney disease. XIGDUO XR is not expected to be effective in these populations. uuid:3138a8a3-3282-4ea8-8a4f-1f26a80c27d1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1592709 biolink:treats MONDO:0005300 PMID:41385096 "[{""id"":""uuid:6db7ccd6-2752-4e27-a25a-144bb6ea54f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b00d64cc-57e3-4091-9496-83021f260e91"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XIGDUO XR is a combination of dapagliflozin and metformin hydrochloride (HCl) extended-release, indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. Dapagliflozin, when used as a component of XIGDUO XR, is indicated in adults with type 2 diabetes mellitus to reduce the risk of: • Sustained eGFR decline, end‑stage kidney disease, cardiovascular death, and hospitalization for heart failure in patients with chronic kidney disease at risk of progression. • Cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in patients with heart failure. • Hospitalization for heart failure in patients with type 2 diabetes mellitus and either established cardiovascular disease (CVD) or multiple cardiovascular (CV) risk factors. Limitations of Use • XIGDUO XR is not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus [see Warnings and Precautions (5.2) ] . • Because of the metformin HCl component, the use of XIGDUO XR is limited to patients with type 2 diabetes mellitus for all indications. • XIGDUO XR is not recommended for the treatment of chronic kidney disease in patients with polycystic kidney disease or patients requiring or with a recent history of immunosuppressive therapy for kidney disease. XIGDUO XR is not expected to be effective in these populations. uuid:b5430bdc-eb61-4c6b-8168-1c89d5d65fa6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1592709 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:4bb02610-3249-44c4-aa56-a75057214cf1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8f174d07-5363-4ac7-a57a-b4180143d6c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XIGDUO XR is a combination of dapagliflozin and metformin hydrochloride (HCl) extended-release, indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. Dapagliflozin, when used as a component of XIGDUO XR, is indicated in adults with type 2 diabetes mellitus to reduce the risk of: • Sustained eGFR decline, end‑stage kidney disease, cardiovascular death, and hospitalization for heart failure in patients with chronic kidney disease at risk of progression. • Cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in patients with heart failure. • Hospitalization for heart failure in patients with type 2 diabetes mellitus and either established cardiovascular disease (CVD) or multiple cardiovascular (CV) risk factors. Limitations of Use • XIGDUO XR is not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus [see Warnings and Precautions (5.2) ] . • Because of the metformin HCl component, the use of XIGDUO XR is limited to patients with type 2 diabetes mellitus for all indications. • XIGDUO XR is not recommended for the treatment of chronic kidney disease in patients with polycystic kidney disease or patients requiring or with a recent history of immunosuppressive therapy for kidney disease. XIGDUO XR is not expected to be effective in these populations. uuid:e40a6233-681a-459b-8772-e69ca1f6a59b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1592709 biolink:treats MONDO:0004375 PMID:41385096 "[{""id"":""uuid:daf26b9e-b587-4ee3-894d-34186049c6db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:533cba52-ad71-43b6-89ee-2ae05be6c7b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XIGDUO XR is a combination of dapagliflozin and metformin hydrochloride (HCl) extended-release, indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. Dapagliflozin, when used as a component of XIGDUO XR, is indicated in adults with type 2 diabetes mellitus to reduce the risk of: • Sustained eGFR decline, end‑stage kidney disease, cardiovascular death, and hospitalization for heart failure in patients with chronic kidney disease at risk of progression. • Cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in patients with heart failure. • Hospitalization for heart failure in patients with type 2 diabetes mellitus and either established cardiovascular disease (CVD) or multiple cardiovascular (CV) risk factors. Limitations of Use • XIGDUO XR is not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus [see Warnings and Precautions (5.2) ] . • Because of the metformin HCl component, the use of XIGDUO XR is limited to patients with type 2 diabetes mellitus for all indications. • XIGDUO XR is not recommended for the treatment of chronic kidney disease in patients with polycystic kidney disease or patients requiring or with a recent history of immunosuppressive therapy for kidney disease. XIGDUO XR is not expected to be effective in these populations. uuid:42b761c9-85da-47bd-8145-60cf8250a7a1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1592709 biolink:treats MONDO:0005147 PMID:41385096 "[{""id"":""uuid:2a475cd7-8683-4591-9e44-6e988cbc4ce8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7cb05c49-3622-4f3a-9c17-89f422fe1b99"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XIGDUO XR is a combination of dapagliflozin and metformin hydrochloride (HCl) extended-release, indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. Dapagliflozin, when used as a component of XIGDUO XR, is indicated in adults with type 2 diabetes mellitus to reduce the risk of: • Sustained eGFR decline, end‑stage kidney disease, cardiovascular death, and hospitalization for heart failure in patients with chronic kidney disease at risk of progression. • Cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in patients with heart failure. • Hospitalization for heart failure in patients with type 2 diabetes mellitus and either established cardiovascular disease (CVD) or multiple cardiovascular (CV) risk factors. Limitations of Use • XIGDUO XR is not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus [see Warnings and Precautions (5.2) ] . • Because of the metformin HCl component, the use of XIGDUO XR is limited to patients with type 2 diabetes mellitus for all indications. • XIGDUO XR is not recommended for the treatment of chronic kidney disease in patients with polycystic kidney disease or patients requiring or with a recent history of immunosuppressive therapy for kidney disease. XIGDUO XR is not expected to be effective in these populations. uuid:5cc11abd-d5e8-4a82-a7d1-8b3e088a3b21 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1592709 biolink:treats MONDO:0020642 PMID:41385096 "[{""id"":""uuid:7af48a94-ef87-4109-8022-7dad6d12bb36"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:06c278f9-8e3e-4902-a0fe-ef370c07f7c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XIGDUO XR is a combination of dapagliflozin and metformin hydrochloride (HCl) extended-release, indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. Dapagliflozin, when used as a component of XIGDUO XR, is indicated in adults with type 2 diabetes mellitus to reduce the risk of: • Sustained eGFR decline, end‑stage kidney disease, cardiovascular death, and hospitalization for heart failure in patients with chronic kidney disease at risk of progression. • Cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in patients with heart failure. • Hospitalization for heart failure in patients with type 2 diabetes mellitus and either established cardiovascular disease (CVD) or multiple cardiovascular (CV) risk factors. Limitations of Use • XIGDUO XR is not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus [see Warnings and Precautions (5.2) ] . • Because of the metformin HCl component, the use of XIGDUO XR is limited to patients with type 2 diabetes mellitus for all indications. • XIGDUO XR is not recommended for the treatment of chronic kidney disease in patients with polycystic kidney disease or patients requiring or with a recent history of immunosuppressive therapy for kidney disease. XIGDUO XR is not expected to be effective in these populations. uuid:382ce12a-8951-4fd4-a156-727f1a9045f3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:L4C1UY2NYH biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:3731eb3a-a222-41f7-815e-3d2842e34d3e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8ace793e-94b0-4d17-b9c5-7ea014b23182"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ITOVEBI, in combination with palbociclib and fulvestrant, is indicated for the treatment of adults with endocrine-resistant, PIK3CA -mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant endocrine therapy [see Clinical Studies (14.1) ] . uuid:1487a5d1-8a06-4929-aa18-0388db231289 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2S9ZZM9Q9V biolink:treats MONDO:0018177 PMID:41385096 "[{""id"":""uuid:798c1ca7-07a3-4e20-87e0-ad7f0fdc0cc4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6846322a-2a3e-4e7f-bd00-a4dc29bc5891"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZIRABEV is a vascular endothelial growth factor inhibitor indicated for the treatment of: • Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment. ( 1.1 ) • Metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen. ( 1.1 ) Limitations of Use : ZIRABEV is not indicated for adjuvant treatment of colon cancer. ( 1.1 ) • Unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel for first-line treatment. ( 1.2 ) • Recurrent glioblastoma in adults. ( 1.3 ) • Metastatic renal cell carcinoma in combination with interferon alfa. ( 1.4 ) • Persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin or paclitaxel and topotecan. ( 1.5 ) • Epithelial ovarian, fallopian tube, or primary peritoneal cancer: o in combination with carboplatin and paclitaxel, followed by ZIRABEV as a single agent, for stage III or IV disease following initial surgical resection. ( 1.6 ) o in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease who received no more than 2 prior chemotherapy regimens. ( 1.6 ) o in combination with carboplatin and paclitaxel or carboplatin and gemcitabine, followed by ZIRABEV as a single agent, for platinum-sensitive recurrent disease. ( 1.6 ) uuid:614126c8-cc53-45fb-8703-c31d49e7b414 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17786 biolink:treats MONDO:0018982 PMID:41385096 "[{""id"":""uuid:a45cf91e-4c45-4ac6-9580-58b33f17f09d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:06ac851b-31ed-4806-8b0b-3f28b26b28f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AQNEURSA™ is indicated for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in adults and pediatric patients weighing ≥15 kg. uuid:1a2c0d3a-d43e-4727-aa06-60cae558f040 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:145372 biolink:treats MONDO:0018874 PMID:41385096 "[{""id"":""uuid:f355dc97-ed38-4707-b43f-44ccaf9cbd88"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a222ccc4-fd29-46a4-b250-9e1fc806e585"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:cbbd2703-3d7c-48b8-880a-9c73439cfeb6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XOSPATA is a kinase inhibitor indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test. ( 1.1 )|[EMA] Xospata is indicated as monotherapy for the treatment of adult patients who have relapsed or refractory acute myeloid leukaemia (AML) with a FLT3 mutation., uuid:e8ec9732-1a6a-4a90-aaa5-13e9fd93ee3c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:67101 biolink:treats UMLS:C0278493 PMID:41385096 "[{""id"":""uuid:bb1a74ea-49ad-4f2d-9b3c-08c6d99b3832"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4b72b851-c797-4cd2-96a1-26114b656b7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CERIANNA is indicated for use with positron emission tomography (PET) imaging for the detection of estrogen receptor (ER)-positive lesions as an adjunct to biopsy in patients with recurrent or metastatic breast cancer. uuid:2b01420b-8564-4ac0-ad5e-a09740607e48 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:67101 biolink:treats UMLS:C0278488 PMID:41385096 "[{""id"":""uuid:98b82ce9-4981-4872-b84f-527878872543"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a7dd5538-c596-433f-aa47-2046a788c49b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CERIANNA is indicated for use with positron emission tomography (PET) imaging for the detection of estrogen receptor (ER)-positive lesions as an adjunct to biopsy in patients with recurrent or metastatic breast cancer. uuid:880c6972-bd4c-4ff1-9508-94ae0990a766 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:145994 biolink:treats MONDO:0100096 PMID:41385096 "[{""id"":""uuid:a27151b8-ce86-4ea4-88fb-c0a493b3c84b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:44d4f16f-6075-43a8-9dcc-215faebbea19"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:9a0c1e62-7234-436d-a8f6-f589be6dacde"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/veklury""]},{""id"":""uuid:188fbe46-5c4a-4fa9-ab9d-d7c96dfb9e62"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VEKLURY is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adults and pediatric patients (birth to less than 18 years of age weighing at least 1.5 kg) who are [see Clinical Studies (14) ] : Hospitalized, or Not hospitalized and have mild-to-moderate COVID-19, and are at high risk for progression to severe COVID-19, including hospitalization or death.|[EMA] Veklury is indicated for the treatment of coronavirus disease 2019 (COVID 19) in:adults and paediatric patients (at least 4 weeks of age and weighing at least 3 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment)adults and paediatric patients (weighing at least 40 kg) who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19|[PMDA] Drugs with a new active ingredient indicated for the treatment of disease caused by SARS-CoV-2 infection (COVID-19). [Drug pertaining to Special Approval for Emergency] uuid:f84d7fad-ffd5-47b2-8374-1593079c61df biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:0R4NLX88O4 biolink:treats MONDO:0009265 PMID:41385096 "[{""id"":""uuid:b67e91e6-e914-4d7e-9824-28367b399cc1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e16e0ee7-9cca-44ff-b0e7-74f77dab31c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ELELYSO is indicated for the treatment of patients 4 years of age and older with a confirmed diagnosis of Type 1 Gaucher disease. uuid:e2ed1309-588a-47cb-8739-7448f0fd8441 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68478 biolink:treats MONDO:0005815 PMID:41385096 "[{""id"":""uuid:8ab82a35-a644-4a79-85a7-750e6c2ca4be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dc02d6c8-266e-438a-98e0-6b7f081e85b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Everolimus tablets are a kinase inhibitor indicated for the treatment of: Postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole. ( 1.1 ) Adults with progressive neuroendocrine tumors of pancreatic origin (PNET) and adults with progressive, well-differentiated, non-functional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin that are unresectable, locally advanced or metastatic. Limitations of Use: Everolimus tablets are not indicated for the treatment of patients with functional carcinoid tumors. ( 1.2 ) Adults with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib. ( 1.3 ) Adults with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery. ( 1.4 ) Everolimus tablets and everolimus tablets for oral suspension are kinase inhibitors indicated for the treatment of adult and pediatric patients aged 1 year and older with TSC who have subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected. ( 1.5 ) uuid:4a93981a-830f-46fa-9d8e-b67a14f76343 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68478 biolink:treats MONDO:0024503 PMID:41385096 "[{""id"":""uuid:21fb0688-62ac-48e3-982d-ce4ad8a97878"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2ff88a1c-5d75-4050-8aff-37f612ea6483"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Everolimus tablets are a kinase inhibitor indicated for the treatment of: Postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole. ( 1.1 ) Adults with progressive neuroendocrine tumors of pancreatic origin (PNET) and adults with progressive, well-differentiated, non-functional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin that are unresectable, locally advanced or metastatic. Limitations of Use: Everolimus tablets are not indicated for the treatment of patients with functional carcinoid tumors. ( 1.2 ) Adults with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib. ( 1.3 ) Adults with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery. ( 1.4 ) Everolimus tablets and everolimus tablets for oral suspension are kinase inhibitors indicated for the treatment of adult and pediatric patients aged 1 year and older with TSC who have subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected. ( 1.5 ) uuid:a4abb712-6902-4779-ab3d-92b3b50c8041 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68478 biolink:treats MONDO:0005454 PMID:41385096 "[{""id"":""uuid:777a6376-031e-4dac-b27f-a503d6c93dbf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a4641215-1da0-451e-a0b6-c9e1f92ad6b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:7a629be0-346b-4764-a787-098d091ee8fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/votubia""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Everolimus tablets are a kinase inhibitor indicated for the treatment of: Postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole. ( 1.1 ) Adults with progressive neuroendocrine tumors of pancreatic origin (PNET) and adults with progressive, well-differentiated, non-functional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin that are unresectable, locally advanced or metastatic. Limitations of Use: Everolimus tablets are not indicated for the treatment of patients with functional carcinoid tumors. ( 1.2 ) Adults with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib. ( 1.3 ) Adults with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery. ( 1.4 ) Everolimus tablets and everolimus tablets for oral suspension are kinase inhibitors indicated for the treatment of adult and pediatric patients aged 1 year and older with TSC who have subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected. ( 1.5 )|[EMA] Hormone-receptor-positive advanced breast cancerAfinitor is indicated for the treatment of hormone-receptor-positive, HER2/neu-negative advanced breast cancer, in combination with exemestane, in post-menopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor.Neuroendocrine tumours of pancreatic originAfinitor is indicated for the treatment of unresectable or metastatic, well or moderately differentiated neuroendocrine tumours of pancreatic origin in adults with progressive disease.Neuroendocrine tumours of gastrointestinal or lung originAfinitor is indicated for the treatment of unresectable or metastatic, well-differentiated (Grade 1 or Grade 2) non-functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease.Renal-cell carcinomaAfinitor is indicated for the treatment of patients with advanced renal-cell carcinoma, whose disease has progressed on or after treatment with VEGF-targeted therapy. uuid:aedde121-8360-4ec2-b61d-9d188131ed23 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68478 biolink:treats UMLS:C4727069 PMID:41385096 "[{""id"":""uuid:7fb80002-20c9-4df7-9615-92fa673029f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d2982b12-b312-44df-b9cb-0e2f2f5154ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Everolimus tablets are a kinase inhibitor indicated for the treatment of: Postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole. ( 1.1 ) Adults with progressive neuroendocrine tumors of pancreatic origin (PNET) and adults with progressive, well-differentiated, non-functional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin that are unresectable, locally advanced or metastatic. Limitations of Use: Everolimus tablets are not indicated for the treatment of patients with functional carcinoid tumors. ( 1.2 ) Adults with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib. ( 1.3 ) Adults with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery. ( 1.4 ) Everolimus tablets and everolimus tablets for oral suspension are kinase inhibitors indicated for the treatment of adult and pediatric patients aged 1 year and older with TSC who have subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected. ( 1.5 ) uuid:46323a6e-09fe-4bfc-bd60-2e4b04172604 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:145374 biolink:treats MONDO:0018874 PMID:41385096 "[{""id"":""uuid:295ce6b9-f6b5-4545-9c06-94ff98a28580"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9d17656f-7d1b-48d3-9a74-c7d0d57fe1a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] IDHIFA is an isocitrate dehydrogenase-2 inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test ( 1.1 ). uuid:4a0dea26-52ed-4ca2-81fa-09b8c8cdc056 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:145374 biolink:treats UMLS:C4528668 PMID:41385096 "[{""id"":""uuid:1ce154cb-5123-49b6-9e26-9c799a157c61"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:178fb8cc-cad7-4db3-84c0-5e411d0098e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] IDHIFA is an isocitrate dehydrogenase-2 inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test ( 1.1 ). uuid:a354591f-5e7c-4df1-92c0-1788a0e10f97 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:R96Z451BMC biolink:treats MONDO:0020547 PMID:41385096 "[{""id"":""uuid:2acffcbd-3183-4de9-a220-984702a60163"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e04f75cb-64ea-4732-8ca4-2edc01eb32d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NIKTIMVO is indicated for the treatment of chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg. uuid:0dbc9f66-8457-47d0-9b81-84f2e47439a9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:R96Z451BMC biolink:treats UMLS:C3539781 PMID:41385096 "[{""id"":""uuid:56d65579-41bb-4150-8b2d-b077ab804627"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:80b1c475-fba0-4e9a-9a47-cf8f66b823df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NIKTIMVO is indicated for the treatment of chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg. uuid:f34336a6-8ccd-4229-95c9-1c5d2dedeb9c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:178199 biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:7f595778-7312-4d92-8f33-7f0ced167264"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:723d3115-9ad7-4740-9730-6b533e0c04c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:dd904fd6-2744-4c99-a1e5-b48574af9aea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/lumykras""]},{""id"":""uuid:52563ee8-6bd3-4902-8ab9-5443f71779df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LUMAKRAS is an inhibitor of the RAS GTPase family indicated for: KRAS G12C-mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) As a single agent, for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC, as determined by an FDA-approved test, who have received at least one prior systemic therapy. ( 1.1 ) This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DOR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1.1 ) KRAS G12C-mutated Metastatic Colorectal Cancer (mCRC) In combination with panitumumab, for the treatment of adult patients with KRAS G12C-mutated mCRC as determined by an FDA approved-test, who have received prior fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy. ( 1.2 )|[EMA] Lumykras as monotherapy is indicated for the treatment of adults with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and who have progressed after at least one prior line of systemic therapy.|[PMDA] A drug with a new active ingredient indicated for the treatment of unresectable advanced or recurrent KRAS G12C mutation-positive non-small cell lung cancer that has progressed after cancer chemotherapy. [Orphan drug] uuid:d16b5579-9052-4263-b28e-4b7aa9e98b16 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:178199 biolink:treats EFO:1001480 PMID:41385096 "[{""id"":""uuid:c8ed9d17-4fa3-4afb-8826-89f219336025"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d5ea8751-014d-4761-a4a9-1a11ea34a890"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LUMAKRAS is an inhibitor of the RAS GTPase family indicated for: KRAS G12C-mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) As a single agent, for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC, as determined by an FDA-approved test, who have received at least one prior systemic therapy. ( 1.1 ) This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DOR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1.1 ) KRAS G12C-mutated Metastatic Colorectal Cancer (mCRC) In combination with panitumumab, for the treatment of adult patients with KRAS G12C-mutated mCRC as determined by an FDA approved-test, who have received prior fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy. ( 1.2 ) uuid:cc92ed76-7c6f-40fd-a27c-a7e5f253681e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:167707 biolink:treats MONDO:0018876 PMID:41385096 "[{""id"":""uuid:fd3d1f5f-6a1f-4426-9512-0ca3b13b2f85"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bdede5f9-f7b3-4a96-8db8-e24a17fdad07"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CALQUENCE is a kinase inhibitor indicated: • In combination with bendamustine and rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous hematopoietic stem cell transplantation (HSCT). ( 1.1 ) • For the treatment of adult patients with MCL who have received at least one prior therapy. ( 1.2 ) • For the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). (1.3) uuid:89cbc288-e15e-4535-99bc-eb163b615ea5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:167707 biolink:treats MONDO:0004948 PMID:41385096 "[{""id"":""uuid:2d2bb936-c514-43d8-ac03-e1460b5d4378"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:97c8554b-5376-4c49-9d8e-9c2dd577cf7f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:26945f9f-7fc9-4f18-b7ef-7c29a0325a93"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/calquence""]},{""id"":""uuid:5912ab57-879f-4883-96ca-a0f7a24a6074"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CALQUENCE is a kinase inhibitor indicated: • In combination with bendamustine and rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous hematopoietic stem cell transplantation (HSCT). ( 1.1 ) • For the treatment of adult patients with MCL who have received at least one prior therapy. ( 1.2 ) • For the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). (1.3)|[EMA] Calquence as monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).Calquence as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy.|[PMDA] A drug with a new active ingredient indicated for the treatment of relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. uuid:44c6b165-487d-4663-bb68-fd32c5205a31 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:167707 biolink:treats MONDO:0003864 PMID:41385096 "[{""id"":""uuid:b2ecd4b2-4540-4711-9e07-2ff1043c5a1d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:143fe606-5eea-430b-b862-f7b35389154c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:05f8b364-4637-409a-9d35-96c14dc19e41"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CALQUENCE is a kinase inhibitor indicated: • In combination with bendamustine and rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous hematopoietic stem cell transplantation (HSCT). ( 1.1 ) • For the treatment of adult patients with MCL who have received at least one prior therapy. ( 1.2 ) • For the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). (1.3)|[PMDA] A drug with a new active ingredient indicated for the treatment of relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. uuid:8dce2691-5793-4ea3-8af1-f9232ac76c41 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:43830 biolink:treats UMLS:C0271905 PMID:41385096 "[{""id"":""uuid:c5b02fe0-dcc2-40e1-ac13-b55ec3fdbdca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1bb5fa90-ef7b-4adc-8d66-ee7d6fea8f98"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylene blue injection is indicated for the treatment of pediatric and adult patients with acquired methemoglobinemia. uuid:9eb088c4-98c4-443d-a43e-a2c2cce6bbab biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:44241 biolink:treats MONDO:0000004 PMID:41385096 "[{""id"":""uuid:a710ec19-cd7d-4522-92e3-0ce7d5f82c85"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4e6de544-3192-4b03-a745-893a9692a635"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Metopirone is indicated, in combination with other diagnostic tests, for the diagnosis of adrenal insufficiency in adult and pediatric patients. uuid:808e3731-ba2e-441b-8d17-9f69948fc330 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:40237 biolink:treats MONDO:0005147 PMID:41385096 "[{""id"":""uuid:be6c0376-cc1d-4314-bae7-76eabb56d305"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c7058dfd-7878-479f-a6fb-7319e1e95826"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sitagliptin Tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use Sitagliptin Tablets is not recommended in patients with type 1 diabetes mellitus. Sitagliptin Tablets have not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using Sitagliptin Tablets. [see Warnings and Precautions (5.1) ]. uuid:be784b25-11ee-4560-9a73-fb56ca1c6e56 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:12PYH0FTU9 biolink:treats MONDO:0004975 PMID:41385096 "[{""id"":""uuid:bd9bd3fe-0561-4ec5-a3f0-7e85f10b6e81"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7af344f1-a559-40e5-9077-b6adb2a18f83"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:075bf23e-f35b-4a6f-a4e3-733f1938c016"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LEQEMBI is indicated for the treatment of Alzheimer’s disease. Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials.|[PMDA] Drugs with a new active ingredient indicated for slowing the progression of mild cognitive impairment and mild dementia due to Alzheimer’s disease. [Priority review] uuid:9f93750b-ea03-4aad-ba50-5e842d7eed38 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:12PYH0FTU9 biolink:treats EFO:0007982 PMID:41385096 "[{""id"":""uuid:83785f53-fd1f-440c-b287-d553dd3ee77b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b03e4cb1-0eb1-4e15-a3fd-f2b681cc74ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f5ac96fd-47fe-4d9c-942b-193a4099f2fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LEQEMBI is indicated for the treatment of Alzheimer’s disease. Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials.|[PMDA] Drugs with a new active ingredient indicated for slowing the progression of mild cognitive impairment and mild dementia due to Alzheimer’s disease. [Priority review] uuid:405b3f52-d9bf-4d08-bb78-f233f0527aa3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:12PYH0FTU9 biolink:treats UMLS:C3494623 PMID:41385096 "[{""id"":""uuid:b6120cf3-cf75-4049-b444-eee2f74b8161"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d0f7e18f-782f-417e-84da-016995f5e1cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LEQEMBI is indicated for the treatment of Alzheimer’s disease. Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials. uuid:f8bfda8c-1d47-4be2-a9c4-9115a883b2a7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:61033 biolink:treats MONDO:0005399 PMID:41385096 "[{""id"":""uuid:d0f8e19e-bc45-4807-bfcf-67b466c4f33a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a4abf013-fdbb-4fed-9c8f-eebc380c6ae7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:800c48ef-a531-445a-a975-ee91f4c8a409"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/arixtra""]},{""id"":""uuid:43d12bfe-daf4-47c2-8ef0-099435d23608"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ARIXTRA is a Factor Xa inhibitor (anticoagulant) indicated for: • Prophylaxis of deep vein thrombosis (DVT) in adult patients undergoing hip fracture surgery (including extended prophylaxis), hip replacement surgery, knee replacement surgery, or abdominal surgery. ( 1.1 ) • Treatment of DVT or acute pulmonary embolism (PE) in adult patients when administered in conjunction with warfarin sodium. ( 1.2 , 1.3 ) • Treatment of venous thromboembolism (VTE) in pediatric patients aged 1 year or older weighing at least 10 kg. ( 1.4 )|[EMA] 1.5-mg/0.3-ml and 2.5-mg/0.5-ml solution for injectionPrevention of venous thromboembolic events (VTE) in adults undergoing major orthopaedic surgery of the lower limbs such as hip fracture, major knee surgery or hip-replacement surgery.Prevention of VTE in adults undergoing abdominal surgery who are judged to be at high risk of thromboembolic complications, such as patients undergoing abdominal cancer surgery.Prevention of VTE in adult medical patients who are judged to be at high risk for VTE and who are immobilised due to acute illness such as cardiac insufficiency and / or acute respiratory disorders, and / or acute infectious or inflammatory disease.Treatment of adults with acute symptomatic spontaneous superficial-vein thrombosis of the lower limbs without concomitant deep-vein thrombosis.2.5-mg/0.5-ml solution for injectionTreatment of unstable angina or non-ST-segment-elevation myocardial infarction (UA/NSTEMI) in adult patients for whom urgent (< 120 mins) invasive management (PCI) is not indicated.infarction (STEMI) in adult patients who are managed with thrombolytics or who initially are to receive no other form of reperfusion therapy.5-mg/0.4-ml, 7.5-mg/0.6-ml and 10-mg/0.8-ml solution for injectionTreatment of adults with acute deep-vein thrombosis (DVT) and treatment of acute pulmonary embolism (PE), except in haemodynamically unstable patients or patients who require thrombolysis or pulmonary embolectomy.|[PMDA] Drugs containing a new active ingredient indicated for the prevention of venous thromboembolism in high-risk patients who have undergone lower-extremity orthopedic surgery. [Priority review] uuid:077e94c1-f78a-4969-bae3-bfe7cfe1fae8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:94405 biolink:treats MONDO:0005302 PMID:41385096 "[{""id"":""uuid:a0456ff9-a356-4f7d-b4f1-ec82a00f964d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a9d72500-67e8-4641-8787-9834aee05f20"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Qelbree is indicated for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older. uuid:1afd3b4e-a135-46e8-9c8f-c022166ef666 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:N3858377KC biolink:treats MONDO:0019496 PMID:41385096 "[{""id"":""uuid:801739f4-d824-45d1-aaeb-65249a66bc9b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1f359fe9-0770-4795-9ca3-7fb615836305"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Detectnet is indicated for use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult patients. uuid:ada00cb2-2236-42c4-b2ca-a4b47e323b74 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6076 biolink:treats UMLS:C0348805 PMID:41385096 "[{""id"":""uuid:65b5ffdc-6596-4099-84f7-2ea74cd1f144"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9154413f-00e3-4acd-932b-70913998dca6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Itraconazole capsules are indicated for the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: 1. Blastomycosis, pulmonary and extrapulmonary 2. Histoplasmosis, including chronic cavitary pulmonary disease and disseminated, non-meningeal histoplasmosis, and 3. Aspergillosis, pulmonary and extrapulmonary, in patients who are intolerant of or who are refractory to amphotericin B therapy. Specimens for fungal cultures and other relevant laboratory studies (wet mount, histopathology, serology) should be obtained before therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, antiinfective therapy should be adjusted accordingly. Itraconazole capsules are also indicated for the treatment of the following fungal infections in non-immunocompromised patients: 1. Onychomycosis of the toenail, with or without fingernail involvement, due to dermatophytes (tinea unguium), and 2. Onychomycosis of the fingernail due to dermatophytes (tinea unguium). Prior to initiating treatment, appropriate nail specimens for laboratory testing (KOH preparation, fungal culture, or nail biopsy) should be obtained to confirm the diagnosis of onychomycosis. (See CLINICAL PHARMACOLOGY: Special Populations, CONTRAINDICATIONS, WARNINGS, and ADVERSE REACTIONS: Postmarketing Experience for more information.) Description of Clinical Studies: Blastomycosis: Analyses were conducted on data from two open-label, non-concurrently controlled studies (N=73 combined) in patients with normal or abnormal immune status. The median dose was 200 mg/day. A response for most signs and symptoms was observed within the first 2 weeks, and all signs and symptoms cleared between 3 and 6 months. Results of these two studies demonstrated substantial evidence of the effectiveness of itraconazole for the treatment of blastomycosis compared with the natural history of untreated cases. Histoplasmosis: Analyses were conducted on data from two open-label, non-concurrently controlled studies (N=34 combined) in patients with normal or abnormal immune status (not including HIV-infected patients). The median dose was 200 mg/day. A response for most signs and symptoms was observed within the first 2 weeks, and all signs and symptoms cleared between 3 and 12 months. Results of these two studies demonstrated substantial evidence of the effectiveness of itraconazole for the treatment of histoplasmosis, compared with the natural history of untreated cases. Histoplasmosis in HIV-infected patients: Data from a small number of HIV-infected patients suggested that the response rate of histoplasmosis in HIV-infected patients is similar to that of non-HIV-infected patients. The clinical course of histoplasmosis in HIV-infected patients is more severe and usually requires maintenance therapy to prevent relapse. Aspergillosis: Analyses were conducted on data from an open-label, “single-patient-use” protocol designed to make itraconazole available in the U.S. for patients who either failed or were intolerant of amphotericin B therapy (N=190). The findings were corroborated by two smaller open-label studies (N=31 combined) in the same patient population. Most adult patients were treated with a daily dose of 200 to 400 mg, with a median duration of 3 months. Results of these studies demonstrated substantial evidence of effectiveness of itraconazole as a second-line therapy for the treatment of aspergillosis compared with the natural history of the disease in patients who either failed or were intolerant of amphotericin B therapy. Onychomycosis of the toenail: Analyses were conducted on data from three double-blind, placebo-controlled studies (N=214 total; 110 given itraconazole capsules) in which patients with onychomycosis of the toenails received 200 mg of itraconazole capsules once daily for 12 consecutive weeks. Results of these studies demonstrated mycologic cure, defined as simultaneous occurrence of negative KOH plus negative culture, in 54% of patients. Thirty-five percent (35%) of patients were considered an overall success (mycologic cure plus clear or minimal nail involvement with significantly decreased signs) and 14% of patients demonstrated mycologic cure plus clinical cure (clearance of all signs, with or without residual nail deformity). The mean time to overall success was approximately 10 months. Twenty-one percent (21%) of the overall success group had a relapse (worsening of the global score or conversion of KOH or culture from negative to positive). Onychomycosis of the fingernail: Analyses were conducted on data from a double-blind, placebo-controlled study (N=73 total; 37 given itraconazole capsules) in which patients with onychomycosis of the fingernails received a 1-week course of 200 mg of itraconazole capsules b.i.d., followed by a 3-week period without itraconazole, which was followed by a second 1-week course of 200 mg of itraconazole capsules b.i.d. Results demonstrated mycologic cure in 61% of patients. Fifty-six percent (56%) of patients were considered an overall success and 47% of patients demonstrated mycologic cure plus clinical cure. The mean time to overall success was approximately 5 months. None of the patients who achieved overall success relapsed. uuid:17146549-8154-42b0-8a9f-26f3427794bf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:139399801 biolink:treats MONDO:0009061 PMID:41385096 "[{""id"":""uuid:5f3472a2-0242-4122-8b39-d1b1504880c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f1b7ce63-8cdd-40e9-b96f-b60dc3f5d644"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ALYFTREK is indicated for the treatment of cystic fibrosis (CF) in patients 6 years of age and older who have at least one F508del mutation or another responsive mutation in the cystic fibrosis transmembrane conductance regulator ( CFTR ) gene (see Table 5 ) [see Clinical Pharmacology (12.1) ]. If the patient's genotype is unknown, an FDA-cleared CF mutation test should be used to confirm the presence of at least one indicated mutation. uuid:3a0e3596-c481-4d77-ae02-3e38d42192bb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:72317 biolink:treats MONDO:0015277 PMID:41385096 "[{""id"":""uuid:da8f6c37-f198-4d4c-bc14-7af8795fcc56"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:05418b2a-fedf-4f58-af2a-a22e0f123237"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:9ab98a17-25df-4275-b9aa-42fdd00b91b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/cometriq""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] COMETRIQ is indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer (MTC).|[EMA] Treatment of adult patients with progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma. uuid:d02a588e-f915-4039-b06c-1a39031fb671 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5778 biolink:treats MONDO:0005240 PMID:41385096 "[{""id"":""uuid:50482edb-28f1-4cff-bc99-72c27a70a8c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:85dbf9b1-4bb6-44cb-bace-905c13eb52fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INZIRQO™ (hydrochlorothiazide) is a thiazide diuretic indicated for: The treatment of hypertension in adult and pediatric patients alone or in combination with other antihypertensive agents, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarction (1.1). The treatment of edema associated with congestive heart failure, hepatic cirrhosis and renal disease including the nephrotic syndrome in adult and pediatric patients. (1.2). uuid:538e4ca1-f6ab-40cb-9a12-f260bee59baa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3207 biolink:treats MONDO:0005361 PMID:41385096 "[{""id"":""uuid:5b91a6c3-9703-49e1-9406-35e4725a6b5b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:72436956-017b-4422-9047-54d8efc4273d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:abe728bd-c071-4906-b877-8a77c4736092"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EOHILIA ™ is indicated for 12 weeks of treatment in adult and pediatric patients 11 years of age and older with eosinophilic esophagitis (EoE). Limitations of Use EOHILIA has not been shown to be safe and effective for the treatment of EoE for longer than 12 weeks [see Dosage and Administration (2.1) , Clinical Studies (14) ].|[EMA] Jorveza is indicated for the treatment of eosinophilic esophagitis (EoE) in adults (older than 18 years of age). uuid:463d4b04-ee12-4ff1-b1dc-1e5eddc5aa23 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1799208 biolink:treats MONDO:0005354 PMID:41385096 "[{""id"":""uuid:92f6ef12-e7f5-43de-9fc3-54d07bfc803e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f1c13b64-04b4-46f4-8360-27293b1d2f89"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ca3926b2-e753-45bf-a9f9-e6053042f733"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/epclusa""]},{""id"":""uuid:affa0ae9-0be7-45a9-9eda-aeaa53e1e35d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EPCLUSA is indicated for the treatment of adults and pediatric patients 3 years of age and older with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection [see Dosage and Administration (2.2 , 2.3 , 2.4) and Clinical Studies (14) ] : without cirrhosis or with compensated cirrhosis with decompensated cirrhosis for use in combination with ribavirin.|[EMA] Epclusa is indicated for the treatment of chronic hepatitis C virus (HCV) infection in patients 3 years of age and older (see sections 4.2, 4.4 and 5.1).|[PMDA] A drug with a new indication and a new dosage for the improvement of viremia in patients with chronic hepatitis C or compensated cirrhosis type C who are naïve or have not previously been treated. uuid:8f472985-045d-464b-952b-3f9df350a244 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:1FQ2RY5YHH biolink:treats HP:0002153 PMID:41385096 "[{""id"":""uuid:4a396ecb-f0e1-4545-b5c8-3f39b88e78c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:b1d7eb03-3ec5-464a-9733-d8b991bcfb06"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e8593e78-3663-4258-bb25-032d7b548188"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Veltassa is indicated for the treatment of hyperkalemia in adults and pediatric patients ages 12 years and older. Limitation of Use: Veltassa should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action [see Clinical Pharmacology (12.2) ] .|[EMA] Veltassa is indicated for the treatment of hyperkalaemia in adults. uuid:cafac955-7777-489d-9a19-9dd2c247b15d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68602 biolink:treats MONDO:0004951 PMID:41385096 "[{""id"":""uuid:2b825a72-e1c3-454f-b388-a23b01ce4930"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:44f057d5-56c2-4f0d-a709-384db6349634"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EDURANT and EDURANT PED are a human immunodeficiency virus type 1 (HIV-1) specific, non-nucleoside reverse transcriptase inhibitor (NNRTI) indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in treatment-naïve patients 2 years of age and older and weighing at least 14 kg with HIV-1 RNA less than or equal to 100,000 copies/mL. ( 1.1 ). Limitations of Use: More EDURANT treated subjects with HIV-1 RNA greater than 100,000 copies/mL at the start of therapy experienced virologic failure (HIV-1 RNA ≥50 copies/mL) compared to EDURANT treated subjects with HIV-1 RNA less than or equal to 100,000 copies/mL. ( 1.1 , 14 ) EDURANT is indicated in combination with VOCABRIA (cabotegravir), for short-term treatment of HIV-1 infection in adults and adolescents 12 years and older and weighing at least 35 kg who are virologically suppressed (HIV-1 RNA less than 50 copies/mL) on a stable regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine. ( 1.2 ) uuid:c14c2f58-0132-4840-8ead-4f3f38e6d62d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2003249 biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:589c9868-aa93-4387-b771-196b3fa451b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:771c567c-9943-4571-931c-ce2c8429b2fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CIMDUO ® (lamivudine and tenofovir disoproxil fumarate) is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adult and pediatric patients weighing at least 35 kg. uuid:87041ed3-c2e1-446a-a343-3d074f2cea56 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:167574 biolink:treats MONDO:0005300 PMID:41385096 "[{""id"":""uuid:b04ae56c-c252-4d8c-bb9f-50f96d75c3ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:59607f0b-a969-4c13-80eb-5ddaef131d6b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OZEMPIC is indicated: • as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. • to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease. • to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes mellitus and chronic kidney disease . uuid:f6a16a4e-3f12-4109-a436-595873e8ec1b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9086 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:c7eadf77-35c0-4d18-8201-d1d0f7cd4185"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ef8da48b-c0a1-4de1-9fe5-fa37f27a13f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EMSAM (selegiline transdermal system) is a monoamine oxidase inhibitor (MAOI) indicated for the treatment of adults with major depressive disorder (MDD) [see Clinical Studies (14) ] . uuid:24e93033-3c23-4b2c-894b-2e9504f1810e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:233446 biolink:treats NCIT:C27003 PMID:41385096 "[{""id"":""uuid:cfe6d0ac-beb3-4962-b7ec-56cb76272139"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c2edb166-99ce-448d-8223-4753e3e19a18"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] JOURNAVX is indicated for the treatment of moderate to severe acute pain in adults. PUBCHEM.COMPOUND:156445116 uuid:f0708a27-09b5-4109-9fe5-f6177fd870b3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:78432 biolink:treats UMLS:C0278987 PMID:41385096 "[{""id"":""uuid:1f67cdbb-d808-43a9-b0f6-72a820383385"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ea26dbe3-1db6-4308-94b3-306d7f82c6b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZYKADIA ® is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test [see Dosage and Administration (2.1)] . uuid:c307d513-affa-4c6f-b35f-decbad1cd63a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:JD24M53P9U biolink:treats UMLS:C0701836 PMID:41385096 "[{""id"":""uuid:0c2c0488-c572-4ec1-9268-65ffe6f1dd00"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1059501a-8470-4290-98a4-b1e3727feeca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NEXOBRID is indicated for eschar removal in adults and pediatric patients with deep partial thickness (DPT) and/or full thickness (FT) thermal burns. Limitations of Use The safety and effectiveness of NEXOBRID have not been established for treatment of: Chemical or electrical burns Burns on the face, perineum, or genitalia Burns on the feet of patients with diabetes mellitus or on the feet of patients with occlusive vascular disease Circumferential burns Burns in patients with significant cardiopulmonary disease, including inhalation injury NEXOBRID is not recommended for: Wounds contaminated with radioactive and other hazardous substances to avoid unforeseeable reactions with the product and an increased risk of spreading the noxious substance. Treatment of burn wounds where medical devices (e.g., implants, pacemakers, shunts) or vital structures (e.g., large vessels) could become exposed during eschar removal. uuid:05ea1183-88f9-4615-8c62-574ac89b60b1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:VRN8S9CW5V biolink:treats MONDO:0001577 PMID:41385096 "[{""id"":""uuid:ea49b77e-df4d-4759-93dc-5dc6ebd2194c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7dd9ebda-6952-49e5-8b61-f272fd24055e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:7c359a77-3121-42ba-bbce-1da96e55307d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/beyfortus""]},{""id"":""uuid:bdfa83e3-e535-44f0-931f-e9d8828ce7e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BEYFORTUS is indicated for the prevention of Respiratory Syncytial Virus (RSV) lower respiratory tract disease in: • Neonates and infants born during or entering their first RSV season. • Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.|[EMA] Beyfortus is indicated for the prevention of Respiratory Syncytial Virus (RSV) lower respiratory tract disease in neonates and infants during their first RSV season.Beyfortus should be used in accordance with official recommendations.|[PMDA] Drugs with a new active ingredient indicated for as follows: The prevention of lower respiratory tract disease caused by respiratory syncytial (RS) virus infection in neonates, infants and children at risk of serious RS virus infection entering their first or second RS virus season after birth. The prophylaxis of lower respiratory tract disease caused by RS virus infection in all neonates and infants other than those described in Item 1 entering their first RS virus season after birth. uuid:0cf35e53-5621-4e8d-83a8-e31c1e9bb595 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:91820600 biolink:treats MONDO:0004951 PMID:41385096 "[{""id"":""uuid:a63b7919-56ce-4060-a93b-b54c8bdf0aeb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2fb69898-e716-43e3-b535-64bd59e9604e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SYMFI ® (efavirenz, lamivudine and tenofovir disoproxil fumarate) is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adult and pediatric patients weighing at least 40 kg. uuid:33b78de4-0f45-4133-82c9-cd82cb75a9e8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:B6E7K36KT8 biolink:treats MONDO:0015290 PMID:41385096 "[{""id"":""uuid:952692b6-e600-421e-ace3-2f3314de9d86"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:5bb81f07-bbce-404f-94ae-9ccbe79dd170"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:1470a7be-4ba1-4ad4-9bee-f5a786292b57"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OXERVATE ® (cenegermin-bkbj) ophthalmic solution 0.002% is indicated for the treatment of neurotrophic keratitis.|[EMA] Treatment of moderate (persistent epithelial defect) or severe (corneal ulcer) neurotrophic keratitis in adults uuid:68cb891a-c690-4de7-a4aa-682362ea695b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:229648 biolink:treats MONDO:0004956 PMID:41385096 "[{""id"":""uuid:b8a0c658-5ed7-4d98-9c4b-0bde1460533c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:689fa45a-e814-43fe-a003-f677c955775b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] POSLUMA is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy. with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level. uuid:047e5f4e-dfe2-453a-8d5c-c83571869a25 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:229648 biolink:treats MONDO:0008315 PMID:41385096 "[{""id"":""uuid:275056a3-c9ef-490a-bc71-636c36b830b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:022c46d5-20e3-440a-9ce4-417bc66cac3e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] POSLUMA is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy. with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level. uuid:61b31b7e-b532-4e22-9a15-2b54183818f7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:TG8IQ19NG2 biolink:treats MONDO:0005737 PMID:41385096 "[{""id"":""uuid:9d37c470-984f-447d-b44a-54824dc5656b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3646abdd-fba8-45c4-bd86-882fde0a0a5a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EBANGA is indicated for the treatment of infection caused by Zaire ebolavirus in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Zaire ebolavirus infection [see Dosage and Administration (2.2) and Clinical Studies (14) ] . uuid:32e497cb-3df5-4180-94ad-d8049f8b2e10 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:0UB3OA67O7 biolink:treats MONDO:0010602 PMID:41385096 "[{""id"":""uuid:33386278-aac6-4c61-a991-a921c376f293"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a32f2245-77d2-43ef-86e0-4cf7c1db61e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] HYMPAVZI is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with: • hemophilia A (congenital factor VIII deficiency) without factor VIII inhibitors, or • hemophilia B (congenital factor IX deficiency) without factor IX inhibitors. uuid:6a1c22a8-f9a7-4188-bea9-cc23aa39d786 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:0UB3OA67O7 biolink:treats MONDO:0010604 PMID:41385096 "[{""id"":""uuid:dd3b4720-ff80-4c64-b4bb-60dea0a8aa79"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3959a502-66ca-40f6-ba35-f14543105473"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] HYMPAVZI is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with: • hemophilia A (congenital factor VIII deficiency) without factor VIII inhibitors, or • hemophilia B (congenital factor IX deficiency) without factor IX inhibitors. uuid:074fbef5-a1fd-4fe5-b873-3ce12aa1a0c2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:U59UGK3IPC biolink:treats MONDO:0005301 PMID:41385096 "[{""id"":""uuid:ebc2af28-27d9-4ba6-8a3e-9fa8f93e5bbb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:18330a60-cfad-40a9-b5e5-b1eb564a05bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BRIUMVI is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. uuid:3239371a-221e-486a-9ad1-a72bb7437153 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:U59UGK3IPC biolink:treats UMLS:C2921627 PMID:41385096 "[{""id"":""uuid:f0965718-b19d-41e0-aec0-76cf724e3922"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eb1aa934-f215-4cb1-b093-a08900e03130"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BRIUMVI is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. uuid:9ff36f6c-75b1-40ed-aab5-897333a62264 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:U59UGK3IPC biolink:treats MONDO:0000450 PMID:41385096 "[{""id"":""uuid:4478a101-71f8-4015-bdec-aa1398632eaa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1359a1fd-018a-414e-b8a2-4c9a38071dee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BRIUMVI is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. uuid:29ac6041-33f4-48ce-b44c-267a9229713e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:183811 biolink:treats MONDO:0017137 PMID:41385096 "[{""id"":""uuid:d8e28b0d-857f-4593-b99c-efe3178db011"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:00266a6a-8d8b-4cff-9d19-6b8f8c9b31b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Moxidectin Tablets are indicated for the treatment of onchocerciasis due to Onchocerca volvulus in adult and pediatric patients aged 4 years and older and weighing at least 13 kg [see Clinical Studies ( 14 )] . Limitations of Use: Moxidectin Tablets does not kill adult Onchocerca volvulus (O. volvulus) parasites . Follow-up evaluation is advised. The safety and efficacy of repeat administration of Moxidectin Tablets in patients with O . volvulus has not been studied. uuid:42a845fc-c9ed-4aa7-a883-a48e395c3b71 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:43830 biolink:treats MONDO:0018740 PMID:41385096 "[{""id"":""uuid:2debe292-15c0-4cd6-aac4-41656d629885"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:004a6bf3-7969-4259-9525-e5dc46195400"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Drug-induced methemoglobinemia uuid:c480dacc-ebcf-4c66-b157-893190e6a203 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:34969 biolink:treats MONDO:0060783 PMID:41385096 "[{""id"":""uuid:076b80ad-b44f-463c-a1aa-5d1f75da044d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:17c16451-7b91-4b4b-90af-54177bba733d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CRENESSITY is indicated as adjunctive treatment to glucocorticoid replacement to control androgens in adults and pediatric patients 4 years of age and older with classic congenital adrenal hyperplasia (CAH) . uuid:d140c83e-8f3b-4a0c-8a76-c5849f7fbce2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:34969 biolink:treats MONDO:0018479 PMID:41385096 "[{""id"":""uuid:94619052-b45b-4b06-9161-cbb27dc4dec6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b415f239-b5cc-4666-8c09-1142dd367813"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CRENESSITY is indicated as adjunctive treatment to glucocorticoid replacement to control androgens in adults and pediatric patients 4 years of age and older with classic congenital adrenal hyperplasia (CAH) . uuid:b308dff0-a70f-4fea-be0e-a35c2f60ce7f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:76016 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:962c4f55-9303-476c-a0f2-07379cd6e702"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bb7b0a19-17fa-4fa6-86f6-4f26eb990f65"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TRINTELLIX is indicated for the treatment of major depressive disorder (MDD) in adults. uuid:5542b05c-b7d2-420b-803e-3d3ab080f655 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:65370 biolink:treats MONDO:0005301 PMID:41385096 "[{""id"":""uuid:1eb6a417-be3c-45b5-ad97-badc16ac34d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:287a9c7d-4448-4a6d-bea0-c352a4bbb44b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:2180186b-7b16-4fee-82f5-ac3df9f2c2c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Glatopa is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.|[PMDA] A drug with a new active ingredient indicated for the prevention of relapse in multiple sclerosis. [Orphan drug] uuid:9bd446bf-b0fb-46a2-a280-ab1a65af099d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:65370 biolink:treats UMLS:C2921627 PMID:41385096 "[{""id"":""uuid:c0ebe9b8-4efa-4cfa-85be-0f4c59da14dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d5c7aba5-cbd7-493d-8041-cc4cd0f82422"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Glatopa is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. uuid:a2eefe86-31a3-4887-adc4-4345ef98a0fa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:65370 biolink:treats MONDO:0000450 PMID:41385096 "[{""id"":""uuid:095eb073-96fd-4996-8a82-41b2bab99cb8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:38beda16-560c-4214-9990-544055910fb9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Glatopa is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. uuid:2eba7341-7b42-4ca3-b53c-19e8fb230acd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17824 biolink:treats MONDO:0001516 PMID:41385096 "[{""id"":""uuid:5e51dd05-25aa-4f2b-a2a0-bcf6f0a4d1a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:be5d84ac-9b8d-49fb-beec-23165e99e12c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZOLGENSMA is an adeno-associated virus (AAV) vector-based gene therapy indicated for the treatment of pediatric patients less than 2 years of age with spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene. Limitations of Use The safety and effectiveness of repeat administration of ZOLGENSMA have not been evaluated [see Adverse Reactions ( 6.2 )] . The use of ZOLGENSMA in patients with advanced SMA (e.g., complete paralysis of limbs, permanent ventilator-dependence) has not been evaluated [see Clinical Studies ( 14 )] . uuid:2f6a9bdf-814d-40a9-be27-f5183639e9f2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:G2AE2VE07O biolink:treats MONDO:0005002 PMID:41385096 "[{""id"":""uuid:b570e763-06bf-4fd7-bc4c-6842e17f15b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9823d3fa-bb36-4235-81f4-56aada0515fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] YUPELRI is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). uuid:91e1155a-d2c2-4af5-bad7-5fb12c1b0a88 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:G2AE2VE07O biolink:treats MONDO:0011751 PMID:41385096 "[{""id"":""uuid:929d68be-7afb-44ff-95cd-a87eb0315d97"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9aa6ca2a-745d-4655-9264-05494f2e5cd2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] YUPELRI is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). uuid:a6372d83-efeb-4375-b8a1-f88b8bd0e68d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16899 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:981fa911-5d77-44b5-8a1b-8a7a91510edd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:018054ae-d31a-408f-868e-45f038a63b46"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ARIDOL is indicated for the assessment of bronchial hyperresponsiveness in adult and pediatric patients 6 years of age or older who do not have clinically apparent asthma. Limitations of Use: ARIDOL is not a standalone test or a screening test for asthma. Bronchial challenge testing with ARIDOL should be used only as part of a physician's overall assessment of asthma. uuid:d4026d49-1c1c-4026-9fea-036fdd05289b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:8FOJ430U94 biolink:treats MONDO:0008250 PMID:41385096 "[{""id"":""uuid:46f57e1f-7a7d-48ef-9da0-3be10d46654b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:1bba9a2b-cf3e-43f3-acb5-946c0c374eaa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:4b5091a6-27fb-4b69-b6fc-3c9c3a316635"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/sogroya""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] SOGROYA is indicated for the: • Treatment of pediatric patients aged 2.5 years and older who have growth failure due to inadequate secretion of endogenous growth hormone (GH). • Replacement of endogenous GH in adults with growth hormone deficiency (GHD).|[EMA] Sogroya is indicated for the replacement of endogenous growth hormone (GH) in children aged 3 years and above, and adolescents with growth failure due to growth hormone deficiency (paediatric GHD), and in adults with growth hormone deficiency (adult GHD). uuid:287a8623-1105-4ff6-bd4b-1cb612499027 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:165363555 biolink:treats MONDO:0009061 PMID:41385096 "[{""id"":""uuid:2b825c6f-0b09-477a-95f5-2c93fbdca6b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c71acd89-ddeb-4bf2-9691-b4fb5a514f6b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TRIKAFTA is indicated for the treatment of cystic fibrosis (CF) in patients aged 2 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator ( CFTR ) gene or a mutation in the CFTR gene that is responsive based on clinical and/or in vitro data (see Table 6 ) [see Clinical Pharmacology (12.1) ] . If the patient's genotype is unknown, an FDA-cleared CF mutation test should be used to confirm the presence of at least one indicated mutation [see Clinical Pharmacology (12.1) ] . uuid:20b70f71-98d3-4504-9301-e7af026daa8a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7XL5ISS668 biolink:treats MONDO:0004665 PMID:41385096 "[{""id"":""uuid:d32d34f7-c16f-4b52-8a2f-546dc0215087"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:659abc8c-d8c0-4611-97b2-bf412f2aff9c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ADCETRIS is a CD30-directed antibody and microtubule inhibitor conjugate indicated for treatment of: • Adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vinblastine, and dacarbazine ( 1.1 ). • Pediatric patients 2 years and older with previously untreated high risk classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide ( 1.2 ). • Adult patients with classical Hodgkin lymphoma (cHL) at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation ( 1.3 ). • Adult patients with classical Hodgkin lymphoma (cHL) after failure of auto-HSCT or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates ( 1.4 ). • Adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified (NOS), in combination with cyclophosphamide, doxorubicin, and prednisone ( 1.5 ). • Adult patients with systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen ( 1.6 ). • Adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy ( 1.7 ). • Adult patients with relapsed or refractory large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) NOS, DLBCL arising from indolent lymphoma, or high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy who are not eligible for auto-HSCT or CAR T-cell therapy, in combination with lenalidomide and a rituximab product ( 1.8 ). uuid:13a601e4-a28b-4515-8343-6be3201b4198 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7XL5ISS668 biolink:treats UMLS:C1336548 PMID:41385096 "[{""id"":""uuid:f89b8962-b4b4-4b27-856c-47464466fadb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:43b6524c-6e20-4068-b1c7-8779867fc031"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ADCETRIS is a CD30-directed antibody and microtubule inhibitor conjugate indicated for treatment of: • Adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vinblastine, and dacarbazine ( 1.1 ). • Pediatric patients 2 years and older with previously untreated high risk classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide ( 1.2 ). • Adult patients with classical Hodgkin lymphoma (cHL) at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation ( 1.3 ). • Adult patients with classical Hodgkin lymphoma (cHL) after failure of auto-HSCT or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates ( 1.4 ). • Adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified (NOS), in combination with cyclophosphamide, doxorubicin, and prednisone ( 1.5 ). • Adult patients with systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen ( 1.6 ). • Adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy ( 1.7 ). • Adult patients with relapsed or refractory large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) NOS, DLBCL arising from indolent lymphoma, or high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy who are not eligible for auto-HSCT or CAR T-cell therapy, in combination with lenalidomide and a rituximab product ( 1.8 ). uuid:7bc291ed-dc19-4c45-9020-ca212010d08e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7XL5ISS668 biolink:treats MONDO:0004977 PMID:41385096 "[{""id"":""uuid:2632c6a0-97f7-441d-b24b-b227de8dae53"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ad1187f9-fe3b-4d3e-9922-761793b05a93"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ADCETRIS is a CD30-directed antibody and microtubule inhibitor conjugate indicated for treatment of: • Adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vinblastine, and dacarbazine ( 1.1 ). • Pediatric patients 2 years and older with previously untreated high risk classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide ( 1.2 ). • Adult patients with classical Hodgkin lymphoma (cHL) at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation ( 1.3 ). • Adult patients with classical Hodgkin lymphoma (cHL) after failure of auto-HSCT or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates ( 1.4 ). • Adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified (NOS), in combination with cyclophosphamide, doxorubicin, and prednisone ( 1.5 ). • Adult patients with systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen ( 1.6 ). • Adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy ( 1.7 ). • Adult patients with relapsed or refractory large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) NOS, DLBCL arising from indolent lymphoma, or high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy who are not eligible for auto-HSCT or CAR T-cell therapy, in combination with lenalidomide and a rituximab product ( 1.8 ). uuid:ec021363-f085-421f-889d-be8850ace971 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7XL5ISS668 biolink:treats MONDO:0004964 PMID:41385096 "[{""id"":""uuid:476b8d7f-d565-4410-a1e6-a705e8eb5516"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ffdaecab-d2bb-479a-af2b-1753761c33d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ADCETRIS is a CD30-directed antibody and microtubule inhibitor conjugate indicated for treatment of: • Adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vinblastine, and dacarbazine ( 1.1 ). • Pediatric patients 2 years and older with previously untreated high risk classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide ( 1.2 ). • Adult patients with classical Hodgkin lymphoma (cHL) at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation ( 1.3 ). • Adult patients with classical Hodgkin lymphoma (cHL) after failure of auto-HSCT or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates ( 1.4 ). • Adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified (NOS), in combination with cyclophosphamide, doxorubicin, and prednisone ( 1.5 ). • Adult patients with systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen ( 1.6 ). • Adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy ( 1.7 ). • Adult patients with relapsed or refractory large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) NOS, DLBCL arising from indolent lymphoma, or high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy who are not eligible for auto-HSCT or CAR T-cell therapy, in combination with lenalidomide and a rituximab product ( 1.8 ). uuid:eb6c4068-0e5f-4adf-b2e8-6618788aec41 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7XL5ISS668 biolink:treats MONDO:0017598 PMID:41385096 "[{""id"":""uuid:35957b5f-a990-4884-a3e5-50252dffa1ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:81c39069-511f-4868-91cc-a53c47cf23b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:d6c05134-6987-457e-a6c7-d329c8022963"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ADCETRIS is a CD30-directed antibody and microtubule inhibitor conjugate indicated for treatment of: • Adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vinblastine, and dacarbazine ( 1.1 ). • Pediatric patients 2 years and older with previously untreated high risk classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide ( 1.2 ). • Adult patients with classical Hodgkin lymphoma (cHL) at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation ( 1.3 ). • Adult patients with classical Hodgkin lymphoma (cHL) after failure of auto-HSCT or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates ( 1.4 ). • Adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified (NOS), in combination with cyclophosphamide, doxorubicin, and prednisone ( 1.5 ). • Adult patients with systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen ( 1.6 ). • Adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy ( 1.7 ). • Adult patients with relapsed or refractory large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) NOS, DLBCL arising from indolent lymphoma, or high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy who are not eligible for auto-HSCT or CAR T-cell therapy, in combination with lenalidomide and a rituximab product ( 1.8 ).|[PMDA] A drug with a new indication and a new dosage for the treatment of relapsed or refractory CD30- positive cutaneous T-cell lymphoma. uuid:7825e0c6-dd3a-42b1-8081-5d3987488316 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7XL5ISS668 biolink:treats MONDO:0009691 PMID:41385096 "[{""id"":""uuid:77441da6-13b3-4d15-a968-94fe4b65d20a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:391aa528-0fab-4b50-93f4-a3212ab93ec2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ADCETRIS is a CD30-directed antibody and microtubule inhibitor conjugate indicated for treatment of: • Adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vinblastine, and dacarbazine ( 1.1 ). • Pediatric patients 2 years and older with previously untreated high risk classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide ( 1.2 ). • Adult patients with classical Hodgkin lymphoma (cHL) at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation ( 1.3 ). • Adult patients with classical Hodgkin lymphoma (cHL) after failure of auto-HSCT or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates ( 1.4 ). • Adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified (NOS), in combination with cyclophosphamide, doxorubicin, and prednisone ( 1.5 ). • Adult patients with systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen ( 1.6 ). • Adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy ( 1.7 ). • Adult patients with relapsed or refractory large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) NOS, DLBCL arising from indolent lymphoma, or high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy who are not eligible for auto-HSCT or CAR T-cell therapy, in combination with lenalidomide and a rituximab product ( 1.8 ). uuid:0bd4c634-ddb2-4f21-85a0-c1ae30046e7f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7XL5ISS668 biolink:treats MONDO:0018905 PMID:41385096 "[{""id"":""uuid:5eebb2ce-8114-4ee5-8c77-65076ec25ead"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2445d77d-70a3-4573-af1a-172df6b0f8f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ADCETRIS is a CD30-directed antibody and microtubule inhibitor conjugate indicated for treatment of: • Adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vinblastine, and dacarbazine ( 1.1 ). • Pediatric patients 2 years and older with previously untreated high risk classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide ( 1.2 ). • Adult patients with classical Hodgkin lymphoma (cHL) at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation ( 1.3 ). • Adult patients with classical Hodgkin lymphoma (cHL) after failure of auto-HSCT or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates ( 1.4 ). • Adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified (NOS), in combination with cyclophosphamide, doxorubicin, and prednisone ( 1.5 ). • Adult patients with systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen ( 1.6 ). • Adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy ( 1.7 ). • Adult patients with relapsed or refractory large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) NOS, DLBCL arising from indolent lymphoma, or high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy who are not eligible for auto-HSCT or CAR T-cell therapy, in combination with lenalidomide and a rituximab product ( 1.8 ). uuid:696db65c-dd5d-4dd9-ac14-d93983edb44e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:5SML1T733B biolink:treats MONDO:0010096 PMID:41385096 "[{""id"":""uuid:11337119-49a9-49af-97f7-06be0399aed3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ae468a12-295d-4752-a677-b5b759d0cf73"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INGREZZA and INGREZZA SPRINKLE are indicated for the treatment of adults with: - tardive dyskinesia [see Clinical Studies ( 14.1 )] . - chorea associated with Huntington’s disease [see Clinical Studies ( 14.2 )] . uuid:64129d5c-3b17-4263-8764-a3f4ff1b5b48 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:5SML1T733B biolink:treats MONDO:0007739 PMID:41385096 "[{""id"":""uuid:f7069ecb-f441-495a-9083-8f1fada4c155"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4d9662de-37fe-4379-b7a3-92de89d14a9f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INGREZZA and INGREZZA SPRINKLE are indicated for the treatment of adults with: - tardive dyskinesia [see Clinical Studies ( 14.1 )] . - chorea associated with Huntington’s disease [see Clinical Studies ( 14.2 )] . uuid:0abc6192-8ef4-4ae6-ba47-7ae1e378dfe8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60773 biolink:treats MONDO:0007576 PMID:41385096 "[{""id"":""uuid:35ca41be-0843-4846-9288-a8bfbc464a40"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8159b35f-f65a-4976-82f2-cb0952186286"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PHOTOFRIN is a photoactivated radical generator indicated for: Esophageal Cancer ( 1.1 ) Palliation of patients with completely obstructing esophageal cancer, or of patients with partially obstructing esophageal cancer who, in the opinion of their physician, cannot be satisfactorily treated with Nd:YAG laser therapy Endobronchial Cancer ( 1.2 ) Treatment of microinvasive endobronchial non-small-cell lung cancer (NSCLC) in patients for whom surgery and radiotherapy are not indicated Reduction of obstruction and palliation of symptoms in patients with completely or partially obstructing endobronchial NSCLC High-Grade Dysplasia in Barrett’s Esophagus ( 1.3 ) Ablation of high-grade dysplasia (HGD) in Barrett’s esophagus (BE) patients who do not undergo esophagectomy uuid:2bf8c6b0-c3e8-40d9-bbb3-bba7d02bb23c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60773 biolink:treats MONDO:0008903 PMID:41385096 "[{""id"":""uuid:64d09ac0-e1e6-48f5-b7fc-8cb74a30af56"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:60461772-ec34-4832-944e-ced224f96451"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PHOTOFRIN is a photoactivated radical generator indicated for: Esophageal Cancer ( 1.1 ) Palliation of patients with completely obstructing esophageal cancer, or of patients with partially obstructing esophageal cancer who, in the opinion of their physician, cannot be satisfactorily treated with Nd:YAG laser therapy Endobronchial Cancer ( 1.2 ) Treatment of microinvasive endobronchial non-small-cell lung cancer (NSCLC) in patients for whom surgery and radiotherapy are not indicated Reduction of obstruction and palliation of symptoms in patients with completely or partially obstructing endobronchial NSCLC High-Grade Dysplasia in Barrett’s Esophagus ( 1.3 ) Ablation of high-grade dysplasia (HGD) in Barrett’s esophagus (BE) patients who do not undergo esophagectomy uuid:7594cc72-8735-49e4-af9e-370956945b19 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60773 biolink:treats UMLS:C1334003 PMID:41385096 "[{""id"":""uuid:f3f616e2-fadd-46f7-b315-84a054518d4f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:20df0a46-6aab-443b-a9c4-bbf7804f81a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PHOTOFRIN is a photoactivated radical generator indicated for: Esophageal Cancer ( 1.1 ) Palliation of patients with completely obstructing esophageal cancer, or of patients with partially obstructing esophageal cancer who, in the opinion of their physician, cannot be satisfactorily treated with Nd:YAG laser therapy Endobronchial Cancer ( 1.2 ) Treatment of microinvasive endobronchial non-small-cell lung cancer (NSCLC) in patients for whom surgery and radiotherapy are not indicated Reduction of obstruction and palliation of symptoms in patients with completely or partially obstructing endobronchial NSCLC High-Grade Dysplasia in Barrett’s Esophagus ( 1.3 ) Ablation of high-grade dysplasia (HGD) in Barrett’s esophagus (BE) patients who do not undergo esophagectomy uuid:39c1ca5e-622c-4850-b05c-d9d536ab1707 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16704 biolink:treats MONDO:0009797 PMID:41385096 "[{""id"":""uuid:0a36bd8e-06e7-487b-a59c-07cd556acc46"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:76241e4f-de1a-4473-85c3-73f101eabc83"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XURIDEN ® is indicated in adult and pediatric patients for the treatment of hereditary orotic aciduria. uuid:80a725b1-e414-4797-962e-6d0cb28dbc12 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:XOI2Q0ZF7G biolink:treats MONDO:0004975 PMID:41385096 "[{""id"":""uuid:3cba5705-ed30-4775-a55e-87915785dbe1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1f9ee8eb-ce4f-4e79-81cb-75b8948c3e76"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZUNVEYL is indicated for the treatment of mild to moderate dementia of the Alzheimer's type in adults. uuid:ccc8c062-cf35-4c23-909a-d9112279908e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63622 biolink:treats MONDO:0000190 PMID:41385096 "[{""id"":""uuid:cb07777a-f44a-429e-a7cb-91cbfdf55d72"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7755b855-01a3-4fe0-b898-41539430a4ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sotalol hydrochloride tablets are an antiarrhythmic indicated for: • the treatment of life-threatening ventricular arrhythmias ( Error! Hyperlink reference not valid. ) • the maintenance of normal sinus rhythm in patients with atrial fibrillation or flutter (AFIB/AFL) ( Error! Hyperlink reference not valid. ) Limitations of Use • Sotalol hydrochloride tablets have not been shown to enhance survival in patients with life-threatening ventricular arrhythmias ( Error! Hyperlink reference not valid. ) • Avoid use in patients with minimally symptomatic or easily reversible AFIB/AFL ( Error! Hyperlink reference not valid. ) uuid:14bba522-ee8d-4d00-85f0-e548ee6add55 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59771 biolink:treats MONDO:0008015 PMID:41385096 "[{""id"":""uuid:96c0c307-1768-4298-aaca-b2fd03c5ff63"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ce341893-c54c-4b96-9d79-60949bbea319"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dimenhydrinate Injection, USP is indicated for the prevention and treatment of nausea, vomiting, or vertigo of motion sickness. uuid:de197c66-aaa7-4ac4-8276-e8c906c101c4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59771 biolink:treats HP:0002018 PMID:41385096 "[{""id"":""uuid:f108f40c-58c2-4727-819c-8c10531973a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:514df747-c2b3-4441-b162-61548742584c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dimenhydrinate Injection, USP is indicated for the prevention and treatment of nausea, vomiting, or vertigo of motion sickness. uuid:99da0aa6-151b-4537-910c-f6cae97ff28d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59771 biolink:treats HP:0002013 PMID:41385096 "[{""id"":""uuid:9fec7d78-209c-48e4-87f7-0c03d84f235f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2c255554-febd-4d80-9b49-67cbe715c575"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dimenhydrinate Injection, USP is indicated for the prevention and treatment of nausea, vomiting, or vertigo of motion sickness. uuid:2bd5e2ee-0dcd-480b-b708-7285cc09fdc0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59771 biolink:treats MONDO:0004900 PMID:41385096 "[{""id"":""uuid:1d98f528-6bbb-444f-ab9b-ea0ba2e407f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:af938381-5f30-4efe-8211-99548c0b8dd1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dimenhydrinate Injection, USP is indicated for the prevention and treatment of nausea, vomiting, or vertigo of motion sickness. uuid:06037c53-5dae-470d-9ad2-6503ce1ec24f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PX9FTM69BF biolink:treats MONDO:0002522 PMID:41385096 "[{""id"":""uuid:f2998825-95d5-4f68-a10a-d937f4c83118"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b0c090ab-65f0-4e57-a68c-29f9d3e243b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ROMVIMZA is indicated for treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause worsening functional limitation or severe morbidity. uuid:20392c86-0fd3-4262-9336-d62501bf9ef9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PX9FTM69BF biolink:treats MONDO:0010108 PMID:41385096 "[{""id"":""uuid:e2ac5688-bee2-45dd-a45b-9c618bf2621c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9911e81a-839a-42c2-b3ff-d24f59d511d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ROMVIMZA is indicated for treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause worsening functional limitation or severe morbidity. uuid:86047d04-3a2b-48c7-9440-cb7a98aa339d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:Y64GQ0KC0A biolink:treats MONDO:0001509 PMID:41385096 "[{""id"":""uuid:a8dfe60c-8881-4371-b3f4-37f57fd3d4de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e216718d-b816-4056-911a-0ee90f662813"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TEPEZZA is indicated for the treatment of Thyroid Eye Disease regardless of Thyroid Eye Disease activity or duration. uuid:372d8c23-d00b-4d38-b9f5-0ecd8ba35425 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:83766 biolink:treats MONDO:0008170 PMID:41385096 "[{""id"":""uuid:603e7ae0-79fa-4ad2-a5f8-480fc2098fe1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f4dd7d6c-bf3a-41d4-a118-b1bb0b5f5f29"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:89469776-79f5-49a0-a37d-22a1dd668b2e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/lynparza""]},{""id"":""uuid:b6565894-c7d3-4f6b-9b55-14a6eb03f10b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated: Ovarian cancer • for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA -mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.1 , 2.1 ) • in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either: • a deleterious or suspected deleterious BRCA mutation, and/or • genomic instability. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.2 , 2.1 ) • for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.3 , 2.1 ) Breast cancer • for the adjuvant treatment of adult patients with deleterious or suspected deleterious g BRCA m human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.4 , 2.1 ) • for the treatment of adult patients with deleterious or suspected deleterious gBRCA m, HER2-negative metastatic breast cancer who have been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.5 , 2.1 ) Pancreatic cancer • for the maintenance treatment of adult patients with deleterious or suspected deleterious gBRCA m metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.6 , 2.1 ) Prostate cancer • for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.7 , 2.1 ) • in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA -mutated ( BRCA m) metastatic castration-resistant prostate cancer (mCRPC). Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.8 , 2.1 )|[EMA] Ovarian cancerLynparza is indicated as monotherapy for the:maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.maintenance treatment of adult patients with platinum sensitive relapsed high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy.Lynparza in combination with bevacizumab is indicated for the:maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability (see section 5.1).Breast cancerLynparza is indicated as:monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2-mutations who have HER2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy (see sections 4.2 and 5.1).monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2 negative locally advanced or metastatic breast cancer. Patients should have previously been treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless patients were not suitable for these treatments (see section 5.1). Patients with hormone receptor (HR)-positive breast cancer should also have progressed on or after prior endocrine therapy, or be considered unsuitable for endocrine therapy.Adenocarcinoma of the pancreasLynparza is indicated as:monotherapy for the maintenance treatment of adult patients with germline BRCA1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen.Prostate cancerLynparza is indicated as:monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with mCRPC in whom chemotherapy is not clinically indicated (see section 5.1).|[PMDA] Drugs with new indications and new dosage for the maintenance treatment of homologous recombination deficiency (HRD)-positive ovarian cancer in patients who have received first chemotherapy including treatment with bevacizumab and the treatment of metastatic, BRCA mutation-positive, castration-resistant prostate cancer. uuid:62a54940-557f-4c69-a79a-906ee6a0f64e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:83766 biolink:treats MONDO:0002158 PMID:41385096 "[{""id"":""uuid:f59d7c40-f7a1-4cf1-82ff-15b4eb703f53"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f913c254-1472-451c-8551-f4a05a8b1297"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f95709b1-809f-439c-aa61-b4341de43807"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/lynparza""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated: Ovarian cancer • for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA -mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.1 , 2.1 ) • in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either: • a deleterious or suspected deleterious BRCA mutation, and/or • genomic instability. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.2 , 2.1 ) • for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.3 , 2.1 ) Breast cancer • for the adjuvant treatment of adult patients with deleterious or suspected deleterious g BRCA m human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.4 , 2.1 ) • for the treatment of adult patients with deleterious or suspected deleterious gBRCA m, HER2-negative metastatic breast cancer who have been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.5 , 2.1 ) Pancreatic cancer • for the maintenance treatment of adult patients with deleterious or suspected deleterious gBRCA m metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.6 , 2.1 ) Prostate cancer • for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.7 , 2.1 ) • in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA -mutated ( BRCA m) metastatic castration-resistant prostate cancer (mCRPC). Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.8 , 2.1 )|[EMA] Ovarian cancerLynparza is indicated as monotherapy for the:maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.maintenance treatment of adult patients with platinum sensitive relapsed high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy.Lynparza in combination with bevacizumab is indicated for the:maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability (see section 5.1).Breast cancerLynparza is indicated as:monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2-mutations who have HER2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy (see sections 4.2 and 5.1).monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2 negative locally advanced or metastatic breast cancer. Patients should have previously been treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless patients were not suitable for these treatments (see section 5.1). Patients with hormone receptor (HR)-positive breast cancer should also have progressed on or after prior endocrine therapy, or be considered unsuitable for endocrine therapy.Adenocarcinoma of the pancreasLynparza is indicated as:monotherapy for the maintenance treatment of adult patients with germline BRCA1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen.Prostate cancerLynparza is indicated as:monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with mCRPC in whom chemotherapy is not clinically indicated (see section 5.1). uuid:87608a72-5754-42e3-ae23-c4fd0134fd56 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:83766 biolink:treats MONDO:0015686 PMID:41385096 "[{""id"":""uuid:fd66f39d-7181-4477-81d6-72ca46ca1bcf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:c0e223a2-28db-436e-89da-3ecf3e8e1934"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:298a6489-a163-48a2-a2c8-32d21020d34f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/lynparza""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated: Ovarian cancer • for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA -mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.1 , 2.1 ) • in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either: • a deleterious or suspected deleterious BRCA mutation, and/or • genomic instability. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.2 , 2.1 ) • for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.3 , 2.1 ) Breast cancer • for the adjuvant treatment of adult patients with deleterious or suspected deleterious g BRCA m human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.4 , 2.1 ) • for the treatment of adult patients with deleterious or suspected deleterious gBRCA m, HER2-negative metastatic breast cancer who have been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.5 , 2.1 ) Pancreatic cancer • for the maintenance treatment of adult patients with deleterious or suspected deleterious gBRCA m metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.6 , 2.1 ) Prostate cancer • for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.7 , 2.1 ) • in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA -mutated ( BRCA m) metastatic castration-resistant prostate cancer (mCRPC). Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.8 , 2.1 )|[EMA] Ovarian cancerLynparza is indicated as monotherapy for the:maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.maintenance treatment of adult patients with platinum sensitive relapsed high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy.Lynparza in combination with bevacizumab is indicated for the:maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability (see section 5.1).Breast cancerLynparza is indicated as:monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2-mutations who have HER2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy (see sections 4.2 and 5.1).monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2 negative locally advanced or metastatic breast cancer. Patients should have previously been treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless patients were not suitable for these treatments (see section 5.1). Patients with hormone receptor (HR)-positive breast cancer should also have progressed on or after prior endocrine therapy, or be considered unsuitable for endocrine therapy.Adenocarcinoma of the pancreasLynparza is indicated as:monotherapy for the maintenance treatment of adult patients with germline BRCA1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen.Prostate cancerLynparza is indicated as:monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with mCRPC in whom chemotherapy is not clinically indicated (see section 5.1). uuid:808ccd17-fa9e-48e1-bea6-0a85ae4f31cf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:83766 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:ece2528d-ad9c-4d56-a092-e7d0ac6dbdd7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4049415a-b12e-428d-a015-ec46919509a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:58d63e9e-5d66-475b-8693-4d0bcf6a5306"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/lynparza""]},{""id"":""uuid:584ed0ff-9ed7-40a3-b444-7f7b3512be32"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated: Ovarian cancer • for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA -mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.1 , 2.1 ) • in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either: • a deleterious or suspected deleterious BRCA mutation, and/or • genomic instability. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.2 , 2.1 ) • for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.3 , 2.1 ) Breast cancer • for the adjuvant treatment of adult patients with deleterious or suspected deleterious g BRCA m human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.4 , 2.1 ) • for the treatment of adult patients with deleterious or suspected deleterious gBRCA m, HER2-negative metastatic breast cancer who have been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.5 , 2.1 ) Pancreatic cancer • for the maintenance treatment of adult patients with deleterious or suspected deleterious gBRCA m metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.6 , 2.1 ) Prostate cancer • for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.7 , 2.1 ) • in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA -mutated ( BRCA m) metastatic castration-resistant prostate cancer (mCRPC). Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.8 , 2.1 )|[EMA] Ovarian cancerLynparza is indicated as monotherapy for the:maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.maintenance treatment of adult patients with platinum sensitive relapsed high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy.Lynparza in combination with bevacizumab is indicated for the:maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability (see section 5.1).Breast cancerLynparza is indicated as:monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2-mutations who have HER2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy (see sections 4.2 and 5.1).monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2 negative locally advanced or metastatic breast cancer. Patients should have previously been treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless patients were not suitable for these treatments (see section 5.1). Patients with hormone receptor (HR)-positive breast cancer should also have progressed on or after prior endocrine therapy, or be considered unsuitable for endocrine therapy.Adenocarcinoma of the pancreasLynparza is indicated as:monotherapy for the maintenance treatment of adult patients with germline BRCA1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen.Prostate cancerLynparza is indicated as:monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with mCRPC in whom chemotherapy is not clinically indicated (see section 5.1).|[PMDA] Drugs with a new indication and a new dosage for the postoperative adjuvant treatment of BRCA mutation- positive and HER2-negative breast cancer with a high risk of recurrence. [Orphan drug] uuid:6e6665b2-d4bd-46ff-b677-f4abcae5899b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:83766 biolink:treats MONDO:0021040 PMID:41385096 "[{""id"":""uuid:bba4af44-b54d-4a6a-9875-2e4c14306f9f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ada751bb-f968-46d8-8435-3a950680afd2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated: Ovarian cancer • for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA -mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.1 , 2.1 ) • in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either: • a deleterious or suspected deleterious BRCA mutation, and/or • genomic instability. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.2 , 2.1 ) • for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.3 , 2.1 ) Breast cancer • for the adjuvant treatment of adult patients with deleterious or suspected deleterious g BRCA m human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.4 , 2.1 ) • for the treatment of adult patients with deleterious or suspected deleterious gBRCA m, HER2-negative metastatic breast cancer who have been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.5 , 2.1 ) Pancreatic cancer • for the maintenance treatment of adult patients with deleterious or suspected deleterious gBRCA m metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.6 , 2.1 ) Prostate cancer • for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.7 , 2.1 ) • in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA -mutated ( BRCA m) metastatic castration-resistant prostate cancer (mCRPC). Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.8 , 2.1 ) uuid:24e4917b-ab1b-4a2f-88cf-e55ccbf34e02 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:83766 biolink:treats UMLS:C0861727 PMID:41385096 "[{""id"":""uuid:9775d41b-8aaa-494d-8382-1d014d321dea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:945111d0-a318-4d9d-b762-66e976e60a4d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated: Ovarian cancer • for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA -mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.1 , 2.1 ) • in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either: • a deleterious or suspected deleterious BRCA mutation, and/or • genomic instability. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.2 , 2.1 ) • for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.3 , 2.1 ) Breast cancer • for the adjuvant treatment of adult patients with deleterious or suspected deleterious g BRCA m human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.4 , 2.1 ) • for the treatment of adult patients with deleterious or suspected deleterious gBRCA m, HER2-negative metastatic breast cancer who have been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.5 , 2.1 ) Pancreatic cancer • for the maintenance treatment of adult patients with deleterious or suspected deleterious gBRCA m metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.6 , 2.1 ) Prostate cancer • for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.7 , 2.1 ) • in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA -mutated ( BRCA m) metastatic castration-resistant prostate cancer (mCRPC). Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.8 , 2.1 ) uuid:bee77545-05af-43db-91f6-6ee70bc74815 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:83766 biolink:treats MONDO:0008315 PMID:41385096 "[{""id"":""uuid:39f34d5b-1c90-4c2e-87f7-e11f4eb8b1da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d2be2ba7-592b-4a92-9650-78ff083df1f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:4e42a132-b9f4-4dc6-a96c-6bd603bbb012"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/lynparza""]},{""id"":""uuid:31c9e8c5-f5bb-4923-8625-8d34cbcbccae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated: Ovarian cancer • for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA -mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.1 , 2.1 ) • in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either: • a deleterious or suspected deleterious BRCA mutation, and/or • genomic instability. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.2 , 2.1 ) • for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.3 , 2.1 ) Breast cancer • for the adjuvant treatment of adult patients with deleterious or suspected deleterious g BRCA m human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.4 , 2.1 ) • for the treatment of adult patients with deleterious or suspected deleterious gBRCA m, HER2-negative metastatic breast cancer who have been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.5 , 2.1 ) Pancreatic cancer • for the maintenance treatment of adult patients with deleterious or suspected deleterious gBRCA m metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.6 , 2.1 ) Prostate cancer • for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.7 , 2.1 ) • in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA -mutated ( BRCA m) metastatic castration-resistant prostate cancer (mCRPC). Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.8 , 2.1 )|[EMA] Ovarian cancerLynparza is indicated as monotherapy for the:maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.maintenance treatment of adult patients with platinum sensitive relapsed high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy.Lynparza in combination with bevacizumab is indicated for the:maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability (see section 5.1).Breast cancerLynparza is indicated as:monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2-mutations who have HER2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy (see sections 4.2 and 5.1).monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2 negative locally advanced or metastatic breast cancer. Patients should have previously been treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless patients were not suitable for these treatments (see section 5.1). Patients with hormone receptor (HR)-positive breast cancer should also have progressed on or after prior endocrine therapy, or be considered unsuitable for endocrine therapy.Adenocarcinoma of the pancreasLynparza is indicated as:monotherapy for the maintenance treatment of adult patients with germline BRCA1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen.Prostate cancerLynparza is indicated as:monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with mCRPC in whom chemotherapy is not clinically indicated (see section 5.1).|[PMDA] Drugs with new indications and new dosage for the maintenance treatment of homologous recombination deficiency (HRD)-positive ovarian cancer in patients who have received first chemotherapy including treatment with bevacizumab and the treatment of metastatic, BRCA mutation-positive, castration-resistant prostate cancer. uuid:a60e9ca0-306d-4ae6-84ba-9b5ffe71e52c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:83766 biolink:treats MONDO:0004956 PMID:41385096 "[{""id"":""uuid:b844203a-e98c-41c2-8551-4aa14c992675"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c330be2d-8b10-494a-bbfd-02132cf0d9e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:d3dc551c-4539-4c72-bb6a-62c3e6439d5b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated: Ovarian cancer • for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA -mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.1 , 2.1 ) • in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either: • a deleterious or suspected deleterious BRCA mutation, and/or • genomic instability. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.2 , 2.1 ) • for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.3 , 2.1 ) Breast cancer • for the adjuvant treatment of adult patients with deleterious or suspected deleterious g BRCA m human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.4 , 2.1 ) • for the treatment of adult patients with deleterious or suspected deleterious gBRCA m, HER2-negative metastatic breast cancer who have been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.5 , 2.1 ) Pancreatic cancer • for the maintenance treatment of adult patients with deleterious or suspected deleterious gBRCA m metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.6 , 2.1 ) Prostate cancer • for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.7 , 2.1 ) • in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA -mutated ( BRCA m) metastatic castration-resistant prostate cancer (mCRPC). Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.8 , 2.1 )|[PMDA] Drugs with a new dosage indicated for the treatment of BRCA mutation-positive, metastatic castration-resistant prostate cancer. uuid:52ed85d1-e9fc-4463-ad47-ce42a7d73eaf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:93752 biolink:treats UMLS:C3495917 PMID:41385096 "[{""id"":""uuid:b9f22a0b-6816-4ebb-8854-d40487a6306e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e70d5ee1-183b-481a-b3df-a808a072e07c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PIQRAY is indicated in combination with fulvestrant for the treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen. uuid:7b5cb676-275f-4dea-a42b-4cc6e6f2d891 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:93752 biolink:treats UMLS:C0278488 PMID:41385096 "[{""id"":""uuid:514ea449-207b-4257-add0-07961fab20ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c7053dc8-783f-422a-aa3b-34e729f01f56"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PIQRAY is indicated in combination with fulvestrant for the treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen. uuid:5d4c4af2-53c4-4321-b6ca-5cfd139d9511 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:82701 biolink:treats MONDO:0004948 PMID:41385096 "[{""id"":""uuid:6d643225-8d7e-421c-8115-e989f536e0d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:e24027a9-b86e-4df6-9d4c-a31acd848ab4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:57636677-d425-44c9-8824-1283b06903bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/zydelig""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Zydelig is indicated, in combination with rituximab, for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL) for whom rituximab alone would be considered appropriate therapy due to other co-morbidities.|[EMA] Zydelig is indicated in combination with an anti‑CD20 monoclonal antibody (rituximab or ofatumumab) for the treatment of adult patients with chronic lymphocytic leukaemia (CLL):who have received at least one prior therapy, oras first line treatment in the presence of 17p deletion or TP53 mutation in patients who are not eligible for any other therapies.Zydelig is indicated as monotherapy for the treatment of adult patients with follicular lymphoma (FL) that is refractory to two prior lines of treatment. uuid:ff6c371f-e49c-4d4d-83f2-43eb973d8e72 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:82701 biolink:treats UMLS:C0861880 PMID:41385096 "[{""id"":""uuid:1e9383a8-1ddb-4180-be5d-187f19b7b26f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:29758c5c-e5c6-4ce6-90de-e87ec4c4b63a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Zydelig is indicated, in combination with rituximab, for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL) for whom rituximab alone would be considered appropriate therapy due to other co-morbidities. uuid:30c2c813-df78-43c3-8981-9297be07ae78 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:78323835 biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:6f580314-574d-4dec-80c9-c3c186916a35"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0ea90eea-f17d-4af2-94db-da0f3eff840f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f9706a8d-2f23-46ee-a19a-5720d98ac20e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/cibinqo""]},{""id"":""uuid:0efe574f-887d-4927-9f6d-95b0f7743e6e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CIBINQO is indicated for the treatment of adults and pediatric patients 12 years of age and older with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable.|[EMA] Cibinqo is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy.|[PMDA] Drugs with a new active ingredient indicated for the treatment of atopic dermatitis in patients who have not responded sufficiently to conventional treatments. uuid:15feb6bf-dd61-40c7-8e76-1e192d8c5df3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:229222 biolink:treats UMLS:C3495949 PMID:41385096 "[{""id"":""uuid:4e6d351e-d41b-455b-8452-3b99a32b9532"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:921c291e-6085-4752-8074-ad36a6a63ed9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TRUQAP, in combination with fulvestrant, is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN -alteration as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. uuid:d4732cbe-3274-418a-8874-b381785f0151 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:229222 biolink:treats UMLS:C0278488 PMID:41385096 "[{""id"":""uuid:ba267a2f-f986-4662-9efb-dec8ef3163b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bb527c51-dbe1-4731-9e59-aa2f1802fe3e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TRUQAP, in combination with fulvestrant, is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN -alteration as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. uuid:2ed5cb2d-c7ba-42a5-9452-fc1375793cd7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63605 biolink:treats UMLS:C0278488 PMID:41385096 "[{""id"":""uuid:b382e422-b574-4e09-8790-81975535ab53"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2306a2ef-534b-4b21-a13d-2ff55bbc4d74"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] IXEMPRA is indicated in combination with capecitabine for the treatment of patients with metastatic or locally advanced breast cancer resistant to treatment with an anthracycline and a taxane, or whose cancer is taxane resistant and for whom further anthracycline therapy is contraindicated. Anthracycline resistance is defined as progression while on therapy or within 6 months in the adjuvant setting or 3 months in the metastatic setting. Taxane resistance is defined as progression while on therapy or within 12 months in the adjuvant setting or 4 months in the metastatic setting [see Clinical Studies ( 14 )]. IXEMPRA is indicated as a single agent for the treatment of patients with metastatic or locally advanced breast cancer whose tumors are resistant or refractory to anthracyclines, taxanes, and capecitabine [see Clinical Studies ( 14 )]. uuid:59a70555-d173-4021-9b9a-d37b10c5350d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63605 biolink:treats UMLS:C3495949 PMID:41385096 "[{""id"":""uuid:e784bdc2-29a8-47d6-8c7e-d6355dcc5a6e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5deb9c31-6a5c-46fa-9d80-9ef83ac7dbca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] IXEMPRA is indicated in combination with capecitabine for the treatment of patients with metastatic or locally advanced breast cancer resistant to treatment with an anthracycline and a taxane, or whose cancer is taxane resistant and for whom further anthracycline therapy is contraindicated. Anthracycline resistance is defined as progression while on therapy or within 6 months in the adjuvant setting or 3 months in the metastatic setting. Taxane resistance is defined as progression while on therapy or within 12 months in the adjuvant setting or 4 months in the metastatic setting [see Clinical Studies ( 14 )]. IXEMPRA is indicated as a single agent for the treatment of patients with metastatic or locally advanced breast cancer whose tumors are resistant or refractory to anthracyclines, taxanes, and capecitabine [see Clinical Studies ( 14 )]. uuid:40a7a89c-003d-4cba-9c29-627d0220a3cc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4031 biolink:treats UMLS:C0400968 PMID:41385096 "[{""id"":""uuid:79ac47b0-2918-4e9d-9fc3-152599b7904c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e81e681f-b336-4aaf-ae63-dd2d523aca99"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cyclosporine capsules, USP MODIFIED are indicated for the prophylaxis of organ rejection in kidney, liver, and heart allogeneic transplants. Cyclosporine capsules, USP MODIFIED have been used in combination with azathioprine and corticosteroids. uuid:cbeedb10-8271-43fc-b49b-5a9d5fb0886f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1999385 biolink:treats MONDO:0009061 PMID:41385096 "[{""id"":""uuid:e5f79556-b9c0-41af-9f70-c7ac5d81433c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a5f12327-e6df-47e2-8e30-0a9ae0195edf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:981a93d4-986a-4363-ad43-f37ac0c14146"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/symkevi""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] SYMDEKO is indicated for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who are homozygous for the F508del mutation or who have at least one mutation in the cystic fibrosis transmembrane conductance regulator ( CFTR ) gene that is responsive to tezacaftor/ivacaftor based on in vitro data and/or clinical evidence [see Clinical Pharmacology (12.1) and Clinical Studies (14) ] . If the patient's genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of a CFTR mutation followed by verification with bi-directional sequencing when recommended by the mutation test instructions for use.|[EMA] Symkevi is indicated in a combination regimen with ivacaftor tablets for the treatment of patients with cystic fibrosis (CF) aged 6 years and older who are homozygous for the F508del mutation or who are heterozygous for the F508del mutation and have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: P67L, R117C, L206W, R352Q, A455E, D579G, 711+3A→G, S945L, S977F, R1070W, D1152H, 2789+5G→A, 3272 26A→G, and 3849+10kbC→T. uuid:228aee3c-e0f4-4757-9a4f-54e9643ce0ec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64318 biolink:treats MONDO:0005277 PMID:41385096 "[{""id"":""uuid:2d3ff8c9-3e2a-47c2-9567-92e7cb8e5ef7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0298ad50-22f0-40f5-8142-cb561f08db5d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Ergomar ® is indicated as therapy to abort or prevent vascular headache, e.g., migraine, migraine variants or so-called ""histaminic cephalalgia""." uuid:e9a0850b-4dc5-4434-acf4-c5947e82c14e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64318 biolink:treats MONDO:0043537 PMID:41385096 "[{""id"":""uuid:74131d49-5156-45ba-9b3f-4464dbfefbaa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4c24b8b0-677f-4d77-b705-43cb32efd84d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Ergomar ® is indicated as therapy to abort or prevent vascular headache, e.g., migraine, migraine variants or so-called ""histaminic cephalalgia""." uuid:fbcac614-9717-435b-9ca6-932d4e0d66ac biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DEW6X41BEK biolink:treats UMLS:C0406317 PMID:41385096 "[{""id"":""uuid:7bb5f280-714b-4013-a256-ebde4171b28e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:64fc943a-ffc0-4091-9e6f-6499cab653e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:691e101b-afdd-4ac0-882c-1b59702c510a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ILUMYA ® is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.|[PMDA] A drug with a new active ingredient indicated for the treatment of plaque psoriasis in patients who have not responded sufficiently to conventional therapies. uuid:c6b384c2-5c5c-4327-92c9-72caaeb20df7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:0JSR7Z0NB6 biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:fda745e9-d3bd-4831-a65a-e30482fceb96"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:4f402dc7-76df-4ac9-bb9b-aed7e7fb3c40"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:86e81255-f4c8-4b13-b3fb-e1f9332db530"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/rybrevant""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] RYBREVANT is a bispecific EGF receptor-directed and MET receptor-directed antibody indicated: in combination with lazertinib for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test. ( 1 , 2.2 ) in combination with carboplatin and pemetrexed for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations, whose disease has progressed on or after treatment with an EGFR tyrosine kinase inhibitor. ( 1 , 2.2 ) in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test. ( 1 , 2.2 ) as a single agent for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy. ( 1 , 2.2 )|[EMA] Rybrevant as monotherapy is indicated for treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) Exon 20 insertion mutations, after failure of platinum-based chemotherapy. uuid:45a14a13-6cd3-402b-9534-38e13440f927 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8354 biolink:treats MONDO:0029000 PMID:41385096 "[{""id"":""uuid:50fb4909-25e9-414e-ac7c-cef073bc1ada"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:10ae5b95-da3c-4ce1-9e68-557ab716dfba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PROTOPAM Chloride is indicated as an antidote: 1. In the treatment of poisoning due to those pesticides and chemicals (e.g., nerve agents) of the organophosphate class which have anticholinesterase activity and 2. In the control of overdosage by anticholinesterase drugs used in the treatment of myasthenia gravis. The principal indications for the use of PROTOPAM Chloride are muscle weakness and respiratory depression. In severe poisoning, respiratory depression may be due to muscle weakness. uuid:2af964a0-04d9-4e44-adf3-e084588393cc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8354 biolink:treats MONDO:0009688 PMID:41385096 "[{""id"":""uuid:8b75d19c-f953-42d8-b1a5-bb099a231324"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9e6a5208-ab08-46fd-bf90-dbab51fe8087"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PROTOPAM Chloride is indicated as an antidote: 1. In the treatment of poisoning due to those pesticides and chemicals (e.g., nerve agents) of the organophosphate class which have anticholinesterase activity and 2. In the control of overdosage by anticholinesterase drugs used in the treatment of myasthenia gravis. The principal indications for the use of PROTOPAM Chloride are muscle weakness and respiratory depression. In severe poisoning, respiratory depression may be due to muscle weakness. uuid:c5232e6b-201d-4b14-9369-90bcb2006a48 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8354 biolink:treats HP:0001324 PMID:41385096 "[{""id"":""uuid:3ae4d75f-d8f4-4a47-a479-5f2c37767ae6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6762ad23-55e6-4843-9123-68b8f27a79fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PROTOPAM Chloride is indicated as an antidote: 1. In the treatment of poisoning due to those pesticides and chemicals (e.g., nerve agents) of the organophosphate class which have anticholinesterase activity and 2. In the control of overdosage by anticholinesterase drugs used in the treatment of myasthenia gravis. The principal indications for the use of PROTOPAM Chloride are muscle weakness and respiratory depression. In severe poisoning, respiratory depression may be due to muscle weakness. uuid:28e92a7e-ed8a-4f0b-9150-59c16bf86095 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8354 biolink:treats MONDO:0043775 PMID:41385096 "[{""id"":""uuid:91e6bdb7-6b8c-4db2-aece-6215d49846f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ae7c5017-45b4-4a6e-b250-30d5954dd984"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PROTOPAM Chloride is indicated as an antidote: 1. In the treatment of poisoning due to those pesticides and chemicals (e.g., nerve agents) of the organophosphate class which have anticholinesterase activity and 2. In the control of overdosage by anticholinesterase drugs used in the treatment of myasthenia gravis. The principal indications for the use of PROTOPAM Chloride are muscle weakness and respiratory depression. In severe poisoning, respiratory depression may be due to muscle weakness. uuid:bc2dab41-fea2-486b-88c4-793f1c59161d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:231087 biolink:treats MONDO:0008433 PMID:41385096 "[{""id"":""uuid:8e8942e4-1013-41bb-b44c-4919bdd4e6fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:533922f9-be0a-43a6-b487-1017084737ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] COSELA is indicated to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer (ES-SCLC). uuid:0a9bc3ed-4ff7-4d18-ad83-9b7cbecae4b4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:82721 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:51da967a-9fa7-408e-9c6e-7592207e838b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:35f05975-adb8-4370-b07b-7daf57f72776"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:1ea431dd-02a6-4a97-a6f3-bd49cf975a86"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DALVANCE is a lipoglycopeptide antibacterial indicated for the treatment of adult and pediatric patients with acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible strains of Gram-positive microorganisms. ( 1.1 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of DALVANCE and other antibacterial drugs, DALVANCE should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. ( 1.2 )|[EMA] Treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults. uuid:7122f86f-9d90-4268-95c6-d079641240e8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:82721 biolink:treats UMLS:C4552483 PMID:41385096 "[{""id"":""uuid:14100977-3029-4aaa-88b0-2f052888862c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:1685d39b-7e8d-45ea-b6c7-239bc9b2c896"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c54c6f5b-cd88-41f1-ab44-9f143085163a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DALVANCE is a lipoglycopeptide antibacterial indicated for the treatment of adult and pediatric patients with acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible strains of Gram-positive microorganisms. ( 1.1 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of DALVANCE and other antibacterial drugs, DALVANCE should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. ( 1.2 )|[EMA] Treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults. uuid:3856a28c-72c3-44c2-a597-30b565c5e27b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90943 biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:e7fffb3e-d778-4dad-af1e-4dae848d5db1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f04499b6-8ba3-4e96-ad24-17cf1309c11c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:1c97cc3c-d597-4cf2-8477-7b24b9d25793"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:875c7f33-c482-49e7-b9c2-b62dfc5a2ec0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TAGRISSO is a kinase inhibitor indicated for: • adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. ( 1.1 , 2.2 ) • the treatment of adult patients with locally advanced, unresectable (stage III) NSCLC whose disease has not progressed during or following concurrent or sequential platinum-based chemoradiation therapy and whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. ( 1.2 , 2.2 ) • the first-line treatment of adult patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. ( 1.3 , 2.2 ) • in combination with pemetrexed and platinum-based chemotherapy, the first-line treatment of adult patients with locally advanced or metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. ( 1.4 , 2.2 ) • the treatment of adult patients with metastatic EGFR T790M mutation-positive NSCLC, as detected by an FDA-approved test, whose disease has progressed on or after EGFR TKI therapy. ( 1.5 , 2.2 )|[EMA] TAGRISSO as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations- the first-line treatment of adult patients NSCLC with activating EGFR mutations.- the treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC.TAGRISSO as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.- the first-line treatment of adult patients with locally advanced or metastatic NSCLC with activating EGFR mutations.- the treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC.|[PMDA] Drugs with a new active ingredient indicated for the treatment of inoperable or recurrent epidermal growth factor receptor (EGFR) T790M mutation- positive non-small-cell lung cancer with resistance to EGFR tyrosine kinase inhibitors. uuid:4d5d265c-7e58-4ccd-ba33-f71aa4c7e251 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90943 biolink:treats UMLS:C0278987 PMID:41385096 "[{""id"":""uuid:33f4398a-22f2-4e2f-abca-be82adfe293c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a026f413-cf7f-409c-bd34-48d088c46bb1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TAGRISSO is a kinase inhibitor indicated for: • adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. ( 1.1 , 2.2 ) • the treatment of adult patients with locally advanced, unresectable (stage III) NSCLC whose disease has not progressed during or following concurrent or sequential platinum-based chemoradiation therapy and whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. ( 1.2 , 2.2 ) • the first-line treatment of adult patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. ( 1.3 , 2.2 ) • in combination with pemetrexed and platinum-based chemotherapy, the first-line treatment of adult patients with locally advanced or metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. ( 1.4 , 2.2 ) • the treatment of adult patients with metastatic EGFR T790M mutation-positive NSCLC, as detected by an FDA-approved test, whose disease has progressed on or after EGFR TKI therapy. ( 1.5 , 2.2 ) uuid:0db1cd41-c3b2-4edc-9491-6b0ccede534a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:RE0V0T1ES0 biolink:treats MONDO:0007027 PMID:41385096 "[{""id"":""uuid:90c55223-468b-41bb-91a8-17eaefb7ca21"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5044a152-506a-41a4-b7d8-c1368dfbb6c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] REZDIFFRA is indicated in conjunction with diet and exercise for the treatment of adults with noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis). This indication is approved under accelerated approval based on improvement of NASH and fibrosis [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. Limitations of Use Avoid use of REZDIFFRA in patients with decompensated cirrhosis [see Use in Specific Populations (8.7) , Clinical Pharmacology (12.3) ] . uuid:f074763e-1648-4f9a-9b8f-2f8de51bfaa8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:RE0V0T1ES0 biolink:treats UMLS:C1619727 PMID:41385096 "[{""id"":""uuid:5ad56f84-d72b-44f8-97f5-c9ed8398ad42"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:09e26270-f1dd-4eb9-9cdd-88e0b540c53d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] REZDIFFRA is indicated in conjunction with diet and exercise for the treatment of adults with noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis). This indication is approved under accelerated approval based on improvement of NASH and fibrosis [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. Limitations of Use Avoid use of REZDIFFRA in patients with decompensated cirrhosis [see Use in Specific Populations (8.7) , Clinical Pharmacology (12.3) ] . uuid:67a26f2f-07b9-4d28-b6ae-4e57e59b333f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:A3ULP0F556 biolink:treats MONDO:0100244 PMID:41385096 "[{""id"":""uuid:847c874c-dfb4-4291-8117-b0414f9ef57a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:952699a3-4abb-4c4e-b16d-35b1ceef9c73"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:aeb481c9-51d1-4367-8f2c-4f62c3698477"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/soliris""]},{""id"":""uuid:8a475ec3-4fcb-4ad5-9071-45206e60fde5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BKEMV is a complement inhibitor indicated for: The treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis. ( 1.1 ) The treatment of patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy. ( 1.2 ) Limitation of Use BKEMV is not indicated for the treatment of patients with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS). The treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AchR) antibody positive. ( 1.3 )|[EMA] Soliris is indicated in adults and children for the treatment of:Paroxysmal nocturnal haemoglobinuria (PNH).Evidence of clinical benefit is demonstrated in patients with haemolysis with clinical symptom(s) indicative of high disease activity, regardless of transfusion history (see section 5.1). Atypical haemolytic uremic syndrome (aHUS).Soliris is indicated in adults for the treatment of:Refractory generalized myasthenia gravis (gMG) in patients who are anti-acetylcholine receptor (AChR) antibody-positive (see section 5.1).Neuromyelitis optica spectrum disorder (NMOSD) in patients who are anti-aquaporin-4 (AQP4) antibody-positive with a relapsing course of the disease.|[PMDA] A drug with a new active ingredient indicated to reduce hemolysis in patients with paroxysmal nocturnal hemoglobinuria. [Orphan drug] uuid:ee092644-f73a-4a18-b091-dd92a467b5a2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:A3ULP0F556 biolink:treats MONDO:0016244 PMID:41385096 "[{""id"":""uuid:022678f1-a652-45ae-b342-0fcaa0ae7b5b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b1933c07-e6ad-4d11-a1ab-38d046bfd4e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:2f309127-075e-47e2-9dbc-f6e7972a9184"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/soliris""]},{""id"":""uuid:2930c089-2936-4c93-9205-93c0d36bd7bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BKEMV is a complement inhibitor indicated for: The treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis. ( 1.1 ) The treatment of patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy. ( 1.2 ) Limitation of Use BKEMV is not indicated for the treatment of patients with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS). The treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AchR) antibody positive. ( 1.3 )|[EMA] Soliris is indicated in adults and children for the treatment of:Paroxysmal nocturnal haemoglobinuria (PNH).Evidence of clinical benefit is demonstrated in patients with haemolysis with clinical symptom(s) indicative of high disease activity, regardless of transfusion history (see section 5.1). Atypical haemolytic uremic syndrome (aHUS).Soliris is indicated in adults for the treatment of:Refractory generalized myasthenia gravis (gMG) in patients who are anti-acetylcholine receptor (AChR) antibody-positive (see section 5.1).Neuromyelitis optica spectrum disorder (NMOSD) in patients who are anti-aquaporin-4 (AQP4) antibody-positive with a relapsing course of the disease.|[PMDA] A drug with a new additional indication and a new dosage for the treatment of patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy. uuid:7682f887-5f75-4f0e-98ca-d82c6cf309b9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:A3ULP0F556 biolink:treats MONDO:0009688 PMID:41385096 "[{""id"":""uuid:df69b47e-38b7-477a-8131-d57f3d5acb9a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:61dc3966-bb94-4d2d-b52f-29203d8fc975"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:698b427d-46f3-4c1f-90b0-33db7d56fcc1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/soliris""]},{""id"":""uuid:3ed479dc-deb5-483d-b6d9-48449dc4574e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BKEMV is a complement inhibitor indicated for: The treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis. ( 1.1 ) The treatment of patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy. ( 1.2 ) Limitation of Use BKEMV is not indicated for the treatment of patients with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS). The treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AchR) antibody positive. ( 1.3 )|[EMA] Soliris is indicated in adults and children for the treatment of:Paroxysmal nocturnal haemoglobinuria (PNH).Evidence of clinical benefit is demonstrated in patients with haemolysis with clinical symptom(s) indicative of high disease activity, regardless of transfusion history (see section 5.1). Atypical haemolytic uremic syndrome (aHUS).Soliris is indicated in adults for the treatment of:Refractory generalized myasthenia gravis (gMG) in patients who are anti-acetylcholine receptor (AChR) antibody-positive (see section 5.1).Neuromyelitis optica spectrum disorder (NMOSD) in patients who are anti-aquaporin-4 (AQP4) antibody-positive with a relapsing course of the disease.|[PMDA] A drug with a new additional pediatric dosage indicated for the treatment of generalized myasthenia gravis (for use only in patients whose symptoms cannot be sufficiently controlled with high-dose intravenous immunoglobulin therapy or plasmapheresis). [Orphan drug] uuid:0a88f058-619a-445f-9715-4b77b8971485 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45367 biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:582cb667-ba52-4b24-bc11-ec499bbbbc7e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:575a6d67-bcd4-45a1-a101-e2dc397c3adc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Rifabutin capsules USP are indicated for the prevention of disseminated Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection. uuid:09bfac40-fa80-42a2-a708-b1080f3ef573 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4735 biolink:treats MONDO:0018019 PMID:41385096 "[{""id"":""uuid:a1b6fd82-a36b-4c84-94a4-eac0ae0a549d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7a8c2b07-e3be-4c28-b4f0-41173762ad5c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Edetate calcium disodium is indicated for the reduction of blood levels and depot stores of lead in lead poisoning (acute and chronic) and lead encephalopathy, in both pediatric populations and adults. Chelation therapy should not replace effective measures to eliminate or reduce further exposure to lead. uuid:d197307f-3f5c-492f-9907-c685202a34b3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4735 biolink:treats UMLS:C0338472 PMID:41385096 "[{""id"":""uuid:811f9609-b13d-487e-a502-ca80305110d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:427d9ad3-5671-4f03-9b25-20f59d9392b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Edetate calcium disodium is indicated for the reduction of blood levels and depot stores of lead in lead poisoning (acute and chronic) and lead encephalopathy, in both pediatric populations and adults. Chelation therapy should not replace effective measures to eliminate or reduce further exposure to lead. uuid:d1c1846e-a76d-4ce0-8b6e-211d1114ee5b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:25E79B5CTM biolink:treats MONDO:0015758 PMID:41385096 "[{""id"":""uuid:82c7c3fa-1fbb-4983-a359-5eee41cae172"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d2a6ee0e-0cc4-49c0-9803-fc5a54aa2d81"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LYMPHIR is indicated for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy. uuid:8596187d-15a7-4d91-8367-94a4c15fca65 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:25E79B5CTM biolink:treats MONDO:0009691 PMID:41385096 "[{""id"":""uuid:205f3210-09c0-4286-9186-d69393b2a774"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:31976480-6c6b-4dcc-bace-590e1b96553b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LYMPHIR is indicated for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy. uuid:7055abc2-d261-4cfa-b430-f787647a0848 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C5547273 biolink:treats MONDO:0005011 PMID:41385096 "[{""id"":""uuid:6a0373f9-e3c1-4a19-a05a-f70496280332"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6338f7e9-e2c5-4bf7-83cd-d739e8b397f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CIMZIA is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy ( 1.1 ) Treatment of adults with moderately to severely active rheumatoid arthritis ( 1.2 ) Treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years of age and older ( 1.3 ) Treatment of adult patients with active psoriatic arthritis. ( 1.4 ) Treatment of adults with active ankylosing spondylitis ( 1.5 ) Treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation ( 1.6 ) Treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy ( 1.7 ) uuid:de28299a-bf21-4459-a09c-c84128a653f1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C5547273 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:c4c6afb2-fc08-4f4f-a29f-09a46f5e6645"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:68db6bf9-fe94-4129-b172-389b21582cfd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CIMZIA is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy ( 1.1 ) Treatment of adults with moderately to severely active rheumatoid arthritis ( 1.2 ) Treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years of age and older ( 1.3 ) Treatment of adult patients with active psoriatic arthritis. ( 1.4 ) Treatment of adults with active ankylosing spondylitis ( 1.5 ) Treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation ( 1.6 ) Treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy ( 1.7 ) uuid:cb3918b3-6c2e-4593-8766-7029c3841d29 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C5547273 biolink:treats MONDO:0018456 PMID:41385096 "[{""id"":""uuid:c629a4ae-b91c-4b4a-83e4-e564312d31d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f81a0fcf-f56e-4921-aef0-ee247e82a33b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CIMZIA is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy ( 1.1 ) Treatment of adults with moderately to severely active rheumatoid arthritis ( 1.2 ) Treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years of age and older ( 1.3 ) Treatment of adult patients with active psoriatic arthritis. ( 1.4 ) Treatment of adults with active ankylosing spondylitis ( 1.5 ) Treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation ( 1.6 ) Treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy ( 1.7 ) uuid:7bb59092-9e6b-4f3d-a015-ffbf5ad1ced8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C5547273 biolink:treats MONDO:0011849 PMID:41385096 "[{""id"":""uuid:c5405a4c-743d-47f7-8876-fb1635eca7ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:184fcff8-8d95-49d7-b99e-b36e05a6db70"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CIMZIA is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy ( 1.1 ) Treatment of adults with moderately to severely active rheumatoid arthritis ( 1.2 ) Treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years of age and older ( 1.3 ) Treatment of adult patients with active psoriatic arthritis. ( 1.4 ) Treatment of adults with active ankylosing spondylitis ( 1.5 ) Treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation ( 1.6 ) Treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy ( 1.7 ) uuid:0a253538-05e7-4c93-80b4-65f9f871d5d4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C5547273 biolink:treats MONDO:0005306 PMID:41385096 "[{""id"":""uuid:52a97359-73e9-4810-a584-f2833916aaa2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9d14522e-5186-4d5a-aae2-168d335a85cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CIMZIA is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy ( 1.1 ) Treatment of adults with moderately to severely active rheumatoid arthritis ( 1.2 ) Treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years of age and older ( 1.3 ) Treatment of adult patients with active psoriatic arthritis. ( 1.4 ) Treatment of adults with active ankylosing spondylitis ( 1.5 ) Treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation ( 1.6 ) Treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy ( 1.7 ) uuid:a560befa-6f96-4e1f-a995-2101c5bd1295 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C5547273 biolink:treats UMLS:C3203547 PMID:41385096 "[{""id"":""uuid:032f2c7c-1089-4c7d-9737-dba7932ced11"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3fda63d7-65e1-45b6-ac1c-95acbdbdfb54"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CIMZIA is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy ( 1.1 ) Treatment of adults with moderately to severely active rheumatoid arthritis ( 1.2 ) Treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years of age and older ( 1.3 ) Treatment of adult patients with active psoriatic arthritis. ( 1.4 ) Treatment of adults with active ankylosing spondylitis ( 1.5 ) Treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation ( 1.6 ) Treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy ( 1.7 ) uuid:f1103414-e568-4962-8047-b5384993a193 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C5547273 biolink:treats UMLS:C0406317 PMID:41385096 "[{""id"":""uuid:397c9095-e5dc-4344-a79e-59c0e1c5f158"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dec2d0a8-8f6d-44a9-b4b5-de435eae095d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CIMZIA is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy ( 1.1 ) Treatment of adults with moderately to severely active rheumatoid arthritis ( 1.2 ) Treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years of age and older ( 1.3 ) Treatment of adult patients with active psoriatic arthritis. ( 1.4 ) Treatment of adults with active ankylosing spondylitis ( 1.5 ) Treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation ( 1.6 ) Treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy ( 1.7 ) uuid:8e595819-70fe-4e7c-93c4-e0e1d7044a9a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:0K5743G68X biolink:treats MONDO:0013600 PMID:41385096 "[{""id"":""uuid:9928a7ed-5875-4c03-9f8e-e393dd38e965"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b03e835f-a929-459e-a7ac-11016c751057"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:0904e508-f8aa-4c90-af1e-0adb1162c42b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DAYVIGO is indicated for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance [see Clinical Studies ( 14.1 )] .|[PMDA] Drugs with a new active ingredient indicated for the treatment of insomnia. uuid:ca799014-c6ce-40d8-a659-3bd5be3a4d8a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:230905 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:de93c305-1104-49c0-a750-46d9ee4642a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:030f3dd2-7e35-42d5-bb45-912074c561fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KISQALI is a kinase inhibitor indicated: in combination with an aromatase inhibitor for the adjuvant treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III early breast cancer at high risk of recurrence. ( 1 ) for the treatment of adults with HR-positive, HER2-negative advanced or metastatic breast cancer in combination with: an aromatase inhibitor as initial endocrine-based therapy; or fulvestrant as initial endocrine-based therapy or following disease progression on endocrine therapy. ( 1 ) uuid:9ae46ed2-521e-45d8-91b1-e6bc95c41cc8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:230905 biolink:treats UMLS:C3495917 PMID:41385096 "[{""id"":""uuid:30f16caa-33ad-4071-af43-fbdfd9b1b723"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8aaf2c93-f45b-451b-b655-304a018afd19"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KISQALI is a kinase inhibitor indicated: in combination with an aromatase inhibitor for the adjuvant treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III early breast cancer at high risk of recurrence. ( 1 ) for the treatment of adults with HR-positive, HER2-negative advanced or metastatic breast cancer in combination with: an aromatase inhibitor as initial endocrine-based therapy; or fulvestrant as initial endocrine-based therapy or following disease progression on endocrine therapy. ( 1 ) uuid:dd0dd758-a7bc-4354-aae9-17073886ff8b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:230905 biolink:treats UMLS:C0278488 PMID:41385096 "[{""id"":""uuid:7e226295-2c26-439d-a2e7-e8de40d06e2c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d02b593e-f697-467d-8d5d-d5c30ab65a67"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KISQALI is a kinase inhibitor indicated: in combination with an aromatase inhibitor for the adjuvant treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III early breast cancer at high risk of recurrence. ( 1 ) for the treatment of adults with HR-positive, HER2-negative advanced or metastatic breast cancer in combination with: an aromatase inhibitor as initial endocrine-based therapy; or fulvestrant as initial endocrine-based therapy or following disease progression on endocrine therapy. ( 1 ) uuid:65c63c09-a74c-4a18-bbe9-1e2d8f53186b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27363 biolink:treats MONDO:0010200 PMID:41385096 "[{""id"":""uuid:c812a8af-deee-4e89-bcf0-21fc53efff03"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:fdc31276-0d6d-4e51-9026-7ce03e0174dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:7c3793cd-a974-4b06-973e-9c98b557c24a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/wilzin""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Zinc acetate therapy is indicated for maintenance treatment of patients with Wilson’s disease who have been initially treated with a chelating agent (See PRECAUTIONS: Monitoring Patients ).|[EMA] Treatment of Wilson's disease. uuid:fd26fdd1-e2fc-40d5-a503-b0cba3199991 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1651267 biolink:treats MONDO:0005002 PMID:41385096 "[{""id"":""uuid:6d823b80-5042-4376-bfa1-e5be99e623cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:af8f4129-f267-4868-ac93-61c9a4c9d57c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] STIOLTO RESPIMAT is a combination of tiotropium bromide, an anticholinergic and olodaterol, a long-acting beta 2 -adrenergic agonist (LABA) indicated for the long-term, once-daily maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). ( 1.1 ) Important limitations: STIOLTO RESPIMAT is NOT indicated to treat acute deterioration of COPD. ( 1.1 ) STIOLTO RESPIMAT is NOT indicated to treat asthma. ( 1.1 ) uuid:579a12b1-663d-43f2-bd9e-13fd536f1a6e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1651267 biolink:treats MONDO:0011751 PMID:41385096 "[{""id"":""uuid:a463d4a9-6ad0-418c-ac44-d320431691d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5bebe9a1-b0d7-49d8-abbe-a5e452c587ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] STIOLTO RESPIMAT is a combination of tiotropium bromide, an anticholinergic and olodaterol, a long-acting beta 2 -adrenergic agonist (LABA) indicated for the long-term, once-daily maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). ( 1.1 ) Important limitations: STIOLTO RESPIMAT is NOT indicated to treat acute deterioration of COPD. ( 1.1 ) STIOLTO RESPIMAT is NOT indicated to treat asthma. ( 1.1 ) uuid:c6085951-529d-448c-b524-afe7a0ef7f24 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1651267 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:845233b5-6ebe-4f9f-8d94-5912c07f6286"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7b8537c6-c3e2-4569-8721-15e37c18d84d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] STIOLTO RESPIMAT is a combination of tiotropium bromide, an anticholinergic and olodaterol, a long-acting beta 2 -adrenergic agonist (LABA) indicated for the long-term, once-daily maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). ( 1.1 ) Important limitations: STIOLTO RESPIMAT is NOT indicated to treat acute deterioration of COPD. ( 1.1 ) STIOLTO RESPIMAT is NOT indicated to treat asthma. ( 1.1 ) uuid:625242bd-2ea9-4b1d-9986-767d903203bb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5971 biolink:treats UMLS:C0861727 PMID:41385096 "[{""id"":""uuid:d536811f-634a-4552-a573-629b09d2e36a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1aca73ba-b92e-4fce-a304-620b911ee38d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ONIVYDE is indicated, in combination with oxaliplatin, fluorouracil and leucovorin for the first-line treatment of adult patients with metastatic pancreatic adenocarcinoma. ONIVYDE is indicated, in combination with fluorouracil and leucovorin, for the treatment of adult patients with metastatic pancreatic adenocarcinoma after disease progression following gemcitabine-based therapy. Limitations of Use: ONIVYDE is not indicated as a single agent for the treatment of patients with metastatic pancreatic adenocarcinoma. [see Clinical Studies (14) ] . uuid:64a402d8-59e8-406f-8a3c-3bbbb4b39dc4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6D5766Q4OP biolink:treats MONDO:0100464 PMID:41385096 "[{""id"":""uuid:5a16d607-d99c-4b6c-b847-9e02f7f5216e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d4c174fa-3f79-427b-a315-48a6746d00b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:b56b76f1-bccc-4c80-b4b4-6374a5e49e68"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/xenpozyme""]},{""id"":""uuid:b922f24d-7a62-49d2-a611-2f150fd456a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XENPOZYME is indicated for treatment of non–central nervous system manifestations of acid sphingomyelinase deficiency (ASMD) in adult and pediatric patients.|[EMA] Xenpozyme is indicated as an enzyme replacement therapy for the treatment of non-Central Nervous System (CNS) manifestations of Acid Sphingomyelinase Deficiency (ASMD) in paediatric and adult patients with type A/B or type B.|[PMDA] A drug with a new active ingredient indicated for the treatment of acid sphingomyelinase deficiency. [SAKIGAKE designation, orphan drug] uuid:03f58ae9-e3e7-4b8e-b4e9-baea8bffb1e4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45951 biolink:treats UMLS:C0235136 PMID:41385096 "[{""id"":""uuid:531017b3-0aa9-4291-8857-c01e05bfe258"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fea9beed-1d7c-4c85-96d4-555eda533d81"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the management of schizophrenia. Trifluoperazine hydrochloride tablets, USP are effective for the short-term treatment of generalized non-psychotic anxiety. However, trifluoperazine hydrochloride tablets are not the first drug to be used in therapy for most patients with non-psychotic anxiety because certain risks associated with its use are not shared by common alternative treatments (i.e., benzodiazepines). When used in the treatment of non-psychotic anxiety, trifluoperazine hydrochloride tablets should not be administered at doses of more than 6 mg per day or for longer than 12 weeks because the use of trifluoperazine hydrochloride tablets at higher doses or for longer intervals may cause persistent tardive dyskinesia that may prove irreversible (see WARNINGS ). The effectiveness of trifluoperazine hydrochloride tablets as a treatment for non-psychotic anxiety was established in a 4-week clinical multicenter study of outpatients with generalized anxiety disorder (DSM-III). This evidence does not predict that trifluoperazine hydrochloride tablets will be useful in patients with other non-psychotic conditions in which anxiety, or signs that mimic anxiety, are found (i.e., physical illness, organic mental conditions, agitated depression, character pathologies, etc.). Trifluoperazine hydrochloride tablets have not been shown effective in the management of behavioral complications in patients with mental retardation. uuid:cc2027a3-7d66-48c2-bb4c-be1974e6bd72 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71200 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:3d257355-f352-434e-9a55-763d323e18c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f57adb72-47cc-462a-b585-43719c57d594"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:dc1722ee-0293-44ff-a613-d3b71ae90884"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XELJANZ/XELJANZ XR/XELJANZ Oral Solution is a Janus kinase (JAK) inhibitor indicated for: • Rheumatoid Arthritis : XELJANZ/XELJANZ XR is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more TNF blockers. o Limitations of Use: Use of XELJANZ/XELJANZ XR in combination with biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine is not recommended. ( 1.1 ) • Psoriatic Arthritis : XELJANZ/XELJANZ XR is indicated for the treatment of adult patients with active psoriatic arthritis who have had an inadequate response or intolerance to one or more TNF blockers. o Limitations of Use: Use of XELJANZ/XELJANZ XR in combination with biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine is not recommended. ( 1.2 ) • Ankylosing Spondylitis : XELJANZ/XELJANZ XR is indicated for the treatment of adult patients with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more TNF blockers. o Limitations of Use: Use of XELJANZ/XELJANZ XR in combination with biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine is not recommended. ( 1.3 ) • Ulcerative Colitis : XELJANZ/XELJANZ XR is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC), who have had an inadequate response or intolerance to one or more TNF blockers. o Limitations of Use: Use of XELJANZ/XELJANZ XR in combination with biological therapies for UC or with potent immunosuppressants such as azathioprine and cyclosporine is not recommended. ( 1.4 ) • Polyarticular Course Juvenile Idiopathic Arthritis : XELJANZ/XELJANZ Oral Solution is indicated for the treatment of active polyarticular course juvenile idiopathic arthritis (pcJIA) in patients 2 years of age and older who have had an inadequate response or intolerance to one or more TNF blockers. o Limitations of Use: Use of XELJANZ/XELJANZ Oral Solution in combination with biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine is not recommended. ( 1.5 )|[PMDA] A drug with a new active ingredient for the treatment of rheumatoid arthritis in patients who have not sufficiently responded to conventional treatments. uuid:739708e0-e26c-4183-ba04-9dd10f1499e1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71200 biolink:treats MONDO:0011849 PMID:41385096 "[{""id"":""uuid:ca817729-48b8-4abb-9cf5-bfecaf5fbe9a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:84757878-1a03-40f5-9d1b-6f8a628f1e24"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XELJANZ/XELJANZ XR/XELJANZ Oral Solution is a Janus kinase (JAK) inhibitor indicated for: • Rheumatoid Arthritis : XELJANZ/XELJANZ XR is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more TNF blockers. o Limitations of Use: Use of XELJANZ/XELJANZ XR in combination with biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine is not recommended. ( 1.1 ) • Psoriatic Arthritis : XELJANZ/XELJANZ XR is indicated for the treatment of adult patients with active psoriatic arthritis who have had an inadequate response or intolerance to one or more TNF blockers. o Limitations of Use: Use of XELJANZ/XELJANZ XR in combination with biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine is not recommended. ( 1.2 ) • Ankylosing Spondylitis : XELJANZ/XELJANZ XR is indicated for the treatment of adult patients with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more TNF blockers. o Limitations of Use: Use of XELJANZ/XELJANZ XR in combination with biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine is not recommended. ( 1.3 ) • Ulcerative Colitis : XELJANZ/XELJANZ XR is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC), who have had an inadequate response or intolerance to one or more TNF blockers. o Limitations of Use: Use of XELJANZ/XELJANZ XR in combination with biological therapies for UC or with potent immunosuppressants such as azathioprine and cyclosporine is not recommended. ( 1.4 ) • Polyarticular Course Juvenile Idiopathic Arthritis : XELJANZ/XELJANZ Oral Solution is indicated for the treatment of active polyarticular course juvenile idiopathic arthritis (pcJIA) in patients 2 years of age and older who have had an inadequate response or intolerance to one or more TNF blockers. o Limitations of Use: Use of XELJANZ/XELJANZ Oral Solution in combination with biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine is not recommended. ( 1.5 ) uuid:03756362-ee64-4c05-8dc3-11c7601e4bc1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71200 biolink:treats MONDO:0005306 PMID:41385096 "[{""id"":""uuid:46e8b582-5176-4936-be98-d20fdcf84469"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:604ea01b-be18-4667-ba6b-756ac5c78965"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XELJANZ/XELJANZ XR/XELJANZ Oral Solution is a Janus kinase (JAK) inhibitor indicated for: • Rheumatoid Arthritis : XELJANZ/XELJANZ XR is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more TNF blockers. o Limitations of Use: Use of XELJANZ/XELJANZ XR in combination with biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine is not recommended. ( 1.1 ) • Psoriatic Arthritis : XELJANZ/XELJANZ XR is indicated for the treatment of adult patients with active psoriatic arthritis who have had an inadequate response or intolerance to one or more TNF blockers. o Limitations of Use: Use of XELJANZ/XELJANZ XR in combination with biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine is not recommended. ( 1.2 ) • Ankylosing Spondylitis : XELJANZ/XELJANZ XR is indicated for the treatment of adult patients with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more TNF blockers. o Limitations of Use: Use of XELJANZ/XELJANZ XR in combination with biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine is not recommended. ( 1.3 ) • Ulcerative Colitis : XELJANZ/XELJANZ XR is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC), who have had an inadequate response or intolerance to one or more TNF blockers. o Limitations of Use: Use of XELJANZ/XELJANZ XR in combination with biological therapies for UC or with potent immunosuppressants such as azathioprine and cyclosporine is not recommended. ( 1.4 ) • Polyarticular Course Juvenile Idiopathic Arthritis : XELJANZ/XELJANZ Oral Solution is indicated for the treatment of active polyarticular course juvenile idiopathic arthritis (pcJIA) in patients 2 years of age and older who have had an inadequate response or intolerance to one or more TNF blockers. o Limitations of Use: Use of XELJANZ/XELJANZ Oral Solution in combination with biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine is not recommended. ( 1.5 ) uuid:e7ecfd79-10f9-4d67-b6b4-5e3421653cbd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71200 biolink:treats MONDO:0005101 PMID:41385096 "[{""id"":""uuid:1f80ba8e-2f19-46cb-b7e9-f328a1c52bd3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7a838cd0-c24d-43f1-afb3-16a5ea64e0a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:070fd5ea-3fca-43b7-901e-ebf6f2df7dbf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XELJANZ/XELJANZ XR/XELJANZ Oral Solution is a Janus kinase (JAK) inhibitor indicated for: • Rheumatoid Arthritis : XELJANZ/XELJANZ XR is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more TNF blockers. o Limitations of Use: Use of XELJANZ/XELJANZ XR in combination with biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine is not recommended. ( 1.1 ) • Psoriatic Arthritis : XELJANZ/XELJANZ XR is indicated for the treatment of adult patients with active psoriatic arthritis who have had an inadequate response or intolerance to one or more TNF blockers. o Limitations of Use: Use of XELJANZ/XELJANZ XR in combination with biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine is not recommended. ( 1.2 ) • Ankylosing Spondylitis : XELJANZ/XELJANZ XR is indicated for the treatment of adult patients with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more TNF blockers. o Limitations of Use: Use of XELJANZ/XELJANZ XR in combination with biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine is not recommended. ( 1.3 ) • Ulcerative Colitis : XELJANZ/XELJANZ XR is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC), who have had an inadequate response or intolerance to one or more TNF blockers. o Limitations of Use: Use of XELJANZ/XELJANZ XR in combination with biological therapies for UC or with potent immunosuppressants such as azathioprine and cyclosporine is not recommended. ( 1.4 ) • Polyarticular Course Juvenile Idiopathic Arthritis : XELJANZ/XELJANZ Oral Solution is indicated for the treatment of active polyarticular course juvenile idiopathic arthritis (pcJIA) in patients 2 years of age and older who have had an inadequate response or intolerance to one or more TNF blockers. o Limitations of Use: Use of XELJANZ/XELJANZ Oral Solution in combination with biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine is not recommended. ( 1.5 )|[PMDA] A drug with a new additional indication and a new dosage for the remission induction and maintenance therapy of moderate to severe ulcerative colitis (for use only in patients who have not sufficiently responded to conventional treatments). uuid:c7ed1cfd-4b87-4dfc-af83-34a7aa0ccfb7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71200 biolink:treats MONDO:0018456 PMID:41385096 "[{""id"":""uuid:2364123f-4390-4d79-8ad3-d65deac176b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1e582ed4-4886-4788-8c38-bf61ed3824d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XELJANZ/XELJANZ XR/XELJANZ Oral Solution is a Janus kinase (JAK) inhibitor indicated for: • Rheumatoid Arthritis : XELJANZ/XELJANZ XR is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more TNF blockers. o Limitations of Use: Use of XELJANZ/XELJANZ XR in combination with biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine is not recommended. ( 1.1 ) • Psoriatic Arthritis : XELJANZ/XELJANZ XR is indicated for the treatment of adult patients with active psoriatic arthritis who have had an inadequate response or intolerance to one or more TNF blockers. o Limitations of Use: Use of XELJANZ/XELJANZ XR in combination with biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine is not recommended. ( 1.2 ) • Ankylosing Spondylitis : XELJANZ/XELJANZ XR is indicated for the treatment of adult patients with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more TNF blockers. o Limitations of Use: Use of XELJANZ/XELJANZ XR in combination with biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine is not recommended. ( 1.3 ) • Ulcerative Colitis : XELJANZ/XELJANZ XR is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC), who have had an inadequate response or intolerance to one or more TNF blockers. o Limitations of Use: Use of XELJANZ/XELJANZ XR in combination with biological therapies for UC or with potent immunosuppressants such as azathioprine and cyclosporine is not recommended. ( 1.4 ) • Polyarticular Course Juvenile Idiopathic Arthritis : XELJANZ/XELJANZ Oral Solution is indicated for the treatment of active polyarticular course juvenile idiopathic arthritis (pcJIA) in patients 2 years of age and older who have had an inadequate response or intolerance to one or more TNF blockers. o Limitations of Use: Use of XELJANZ/XELJANZ Oral Solution in combination with biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine is not recommended. ( 1.5 ) uuid:6872e8e2-bf08-4e01-b944-192cb54f299d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:94759 biolink:treats MONDO:0004668 PMID:41385096 "[{""id"":""uuid:52cb63a9-0410-41e1-bcf0-26fc8da717c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:680a2ad3-3870-4535-be52-56441d576d2f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EGATEN ® is indicated for the treatment of fascioliasis in patients 6 years of age and older. uuid:d83fcf14-6d66-495d-a734-a13f89ca7aa4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133833 biolink:treats MONDO:0001444 PMID:41385096 "[{""id"":""uuid:e29cd262-6eae-40c7-9821-ab31fa622d70"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f7e2949d-e93b-4bb2-a666-71ae16a2410f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Benznidazole Tablets are indicated in pediatric patients 2 to 12 years of age for the treatment of Chagas disease (American trypanosomiasis) caused by Trypanosoma cruzi . This indication is approved under accelerated approval based on the number of treated patients who became Immunoglobulin G (IgG) antibody negative against the recombinant antigens of T. cruzi [see Clinical Studies ( 14 )] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. uuid:296d5d4b-a399-401a-afe4-f27f666a2ee9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3934EF02T7 biolink:treats MONDO:0008315 PMID:41385096 "[{""id"":""uuid:b4c95878-a9a1-40cb-8d38-b13322a3c8b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:9341fc2f-f334-441f-90d5-c16e0e0c0646"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:a47b8e06-ebfb-4e10-8f11-859b90bc3fb6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PYLARIFY is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer: with suspected metastasis who are candidates for initial definitive therapy. with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level.|[EMA] This medicinal product is for diagnostic use only.Pylclari is indicated for the detection of prostate-specific membrane antigen (PSMA) positive lesions with positron emission tomography (PET) in adults with prostate cancer (PCa) in the following clinical settings:Primary staging of patients with high-risk PCa prior to initial curative therapy,To localize recurrence of PCa in patients with a suspected recurrence based on increasing serum prostate-specific antigen (PSA) levels after primary treatment with curative intent.Pylclari is indicated for use with positron emission tomography (PET). uuid:1ee03daa-91b5-429b-93ab-153b7b82e6ba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3892 biolink:treats MONDO:0011849 PMID:41385096 "[{""id"":""uuid:bf99214b-35f8-4383-b21d-293519c9ede7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6a987624-fbc6-4ff9-b68a-af25a8fdbe7d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Purified Cortrophin Gel is indicated in the following disorders: 1. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis. Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Ankylosing spondylitis. Acute gouty arthritis. 2. Collagen diseases: During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus. Systemic dermatomyositis (polymyositis). 3. Dermatologic diseases: Severe erythema multiforme (Stevens-Johnson syndrome). Severe psoriasis. 4. Allergic states: Atopic dermatitis Serum sickness. 5. Ophthalmic diseases: Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis. Keratitis. Iritis and iridocyclitis. Diffuse posterior uveitis and choroiditis. Optic neuritis. Chorioretinitis. Anterior segment inflammation. 6. Respiratory diseases: Symptomatic sarcoidosis. 7. Edematous states: To induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus. 8. Nervous system: Acute exacerbations of multiple sclerosis. uuid:27fdacb4-2619-432e-8be0-7d5baaf7800b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3892 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:69a3af82-de79-4396-bba4-5b1cf815f79c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3eec61e7-37a0-4b21-9292-99fda445397f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Purified Cortrophin Gel is indicated in the following disorders: 1. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis. Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Ankylosing spondylitis. Acute gouty arthritis. 2. Collagen diseases: During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus. Systemic dermatomyositis (polymyositis). 3. Dermatologic diseases: Severe erythema multiforme (Stevens-Johnson syndrome). Severe psoriasis. 4. Allergic states: Atopic dermatitis Serum sickness. 5. Ophthalmic diseases: Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis. Keratitis. Iritis and iridocyclitis. Diffuse posterior uveitis and choroiditis. Optic neuritis. Chorioretinitis. Anterior segment inflammation. 6. Respiratory diseases: Symptomatic sarcoidosis. 7. Edematous states: To induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus. 8. Nervous system: Acute exacerbations of multiple sclerosis. uuid:b3991500-0d2b-491c-b53d-29454e80d544 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3892 biolink:treats MONDO:0011429 PMID:41385096 "[{""id"":""uuid:f3b095b7-698c-430b-b469-740a9e25e5a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:28415cab-d972-4306-94d3-20c10db33f08"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Purified Cortrophin Gel is indicated in the following disorders: 1. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis. Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Ankylosing spondylitis. Acute gouty arthritis. 2. Collagen diseases: During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus. Systemic dermatomyositis (polymyositis). 3. Dermatologic diseases: Severe erythema multiforme (Stevens-Johnson syndrome). Severe psoriasis. 4. Allergic states: Atopic dermatitis Serum sickness. 5. Ophthalmic diseases: Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis. Keratitis. Iritis and iridocyclitis. Diffuse posterior uveitis and choroiditis. Optic neuritis. Chorioretinitis. Anterior segment inflammation. 6. Respiratory diseases: Symptomatic sarcoidosis. 7. Edematous states: To induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus. 8. Nervous system: Acute exacerbations of multiple sclerosis. uuid:da8eaa92-8455-4cd4-a3ed-647b0c78bacc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3892 biolink:treats MONDO:0005306 PMID:41385096 "[{""id"":""uuid:a4e4ee90-7c38-4198-a8fe-9c973ce6b90e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eda64a05-83c6-4793-a6a6-992695b41a3c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Purified Cortrophin Gel is indicated in the following disorders: 1. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis. Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Ankylosing spondylitis. Acute gouty arthritis. 2. Collagen diseases: During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus. Systemic dermatomyositis (polymyositis). 3. Dermatologic diseases: Severe erythema multiforme (Stevens-Johnson syndrome). Severe psoriasis. 4. Allergic states: Atopic dermatitis Serum sickness. 5. Ophthalmic diseases: Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis. Keratitis. Iritis and iridocyclitis. Diffuse posterior uveitis and choroiditis. Optic neuritis. Chorioretinitis. Anterior segment inflammation. 6. Respiratory diseases: Symptomatic sarcoidosis. 7. Edematous states: To induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus. 8. Nervous system: Acute exacerbations of multiple sclerosis. uuid:3be23474-8e71-4f02-a9fc-f25ecd3abac3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3892 biolink:treats UMLS:C0149896 PMID:41385096 "[{""id"":""uuid:63933fbb-c2d4-4baa-ad93-bede162b572b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4d90e4c9-2f8d-44cd-a03a-476aa6dd5f1a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Purified Cortrophin Gel is indicated in the following disorders: 1. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis. Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Ankylosing spondylitis. Acute gouty arthritis. 2. Collagen diseases: During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus. Systemic dermatomyositis (polymyositis). 3. Dermatologic diseases: Severe erythema multiforme (Stevens-Johnson syndrome). Severe psoriasis. 4. Allergic states: Atopic dermatitis Serum sickness. 5. Ophthalmic diseases: Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis. Keratitis. Iritis and iridocyclitis. Diffuse posterior uveitis and choroiditis. Optic neuritis. Chorioretinitis. Anterior segment inflammation. 6. Respiratory diseases: Symptomatic sarcoidosis. 7. Edematous states: To induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus. 8. Nervous system: Acute exacerbations of multiple sclerosis. uuid:f7b57d85-9219-4f98-990e-e0f0995e9d83 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3892 biolink:treats MONDO:0016367 PMID:41385096 "[{""id"":""uuid:1c43ba0e-f53c-435c-b0cc-fa27d453a98d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9bb9636c-7180-4023-ba8d-7a1d74691ed2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Purified Cortrophin Gel is indicated in the following disorders: 1. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis. Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Ankylosing spondylitis. Acute gouty arthritis. 2. Collagen diseases: During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus. Systemic dermatomyositis (polymyositis). 3. Dermatologic diseases: Severe erythema multiforme (Stevens-Johnson syndrome). Severe psoriasis. 4. Allergic states: Atopic dermatitis Serum sickness. 5. Ophthalmic diseases: Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis. Keratitis. Iritis and iridocyclitis. Diffuse posterior uveitis and choroiditis. Optic neuritis. Chorioretinitis. Anterior segment inflammation. 6. Respiratory diseases: Symptomatic sarcoidosis. 7. Edematous states: To induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus. 8. Nervous system: Acute exacerbations of multiple sclerosis. uuid:194eb4ec-181a-4d0f-8bd3-ffe2d0af6378 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3892 biolink:treats MONDO:0019127 PMID:41385096 "[{""id"":""uuid:707e24e9-5298-4679-bda8-623d3b704a7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:76bb8d3c-6428-4b0d-a53d-7b73fcae1fd0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Purified Cortrophin Gel is indicated in the following disorders: 1. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis. Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Ankylosing spondylitis. Acute gouty arthritis. 2. Collagen diseases: During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus. Systemic dermatomyositis (polymyositis). 3. Dermatologic diseases: Severe erythema multiforme (Stevens-Johnson syndrome). Severe psoriasis. 4. Allergic states: Atopic dermatitis Serum sickness. 5. Ophthalmic diseases: Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis. Keratitis. Iritis and iridocyclitis. Diffuse posterior uveitis and choroiditis. Optic neuritis. Chorioretinitis. Anterior segment inflammation. 6. Respiratory diseases: Symptomatic sarcoidosis. 7. Edematous states: To induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus. 8. Nervous system: Acute exacerbations of multiple sclerosis. uuid:db91276a-40bc-4411-88ed-cae197012138 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3892 biolink:treats MONDO:0006545 PMID:41385096 "[{""id"":""uuid:5d1ab974-ef64-4328-95aa-ce8e86987e92"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c0c3fc8c-ca08-4f90-a939-1f6a7a92ba7c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Purified Cortrophin Gel is indicated in the following disorders: 1. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis. Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Ankylosing spondylitis. Acute gouty arthritis. 2. Collagen diseases: During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus. Systemic dermatomyositis (polymyositis). 3. Dermatologic diseases: Severe erythema multiforme (Stevens-Johnson syndrome). Severe psoriasis. 4. Allergic states: Atopic dermatitis Serum sickness. 5. Ophthalmic diseases: Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis. Keratitis. Iritis and iridocyclitis. Diffuse posterior uveitis and choroiditis. Optic neuritis. Chorioretinitis. Anterior segment inflammation. 6. Respiratory diseases: Symptomatic sarcoidosis. 7. Edematous states: To induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus. 8. Nervous system: Acute exacerbations of multiple sclerosis. uuid:caa45211-8e30-48bf-89f2-13dcd3cf92c0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3892 biolink:treats MONDO:0018229 PMID:41385096 "[{""id"":""uuid:da715ab6-6a8e-467d-9b27-3f0b2ed6ab02"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:881ff494-95d6-4b6e-903b-259d76d12196"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Purified Cortrophin Gel is indicated in the following disorders: 1. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis. Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Ankylosing spondylitis. Acute gouty arthritis. 2. Collagen diseases: During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus. Systemic dermatomyositis (polymyositis). 3. Dermatologic diseases: Severe erythema multiforme (Stevens-Johnson syndrome). Severe psoriasis. 4. Allergic states: Atopic dermatitis Serum sickness. 5. Ophthalmic diseases: Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis. Keratitis. Iritis and iridocyclitis. Diffuse posterior uveitis and choroiditis. Optic neuritis. Chorioretinitis. Anterior segment inflammation. 6. Respiratory diseases: Symptomatic sarcoidosis. 7. Edematous states: To induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus. 8. Nervous system: Acute exacerbations of multiple sclerosis. uuid:4c46e164-8929-4ddc-befc-25cd7949099d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3892 biolink:treats MONDO:0005083 PMID:41385096 "[{""id"":""uuid:08956794-a73d-43b7-b638-9f9b24b6e587"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:04fee287-33c0-42b6-8efc-ec41cb263676"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Purified Cortrophin Gel is indicated in the following disorders: 1. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis. Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Ankylosing spondylitis. Acute gouty arthritis. 2. Collagen diseases: During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus. Systemic dermatomyositis (polymyositis). 3. Dermatologic diseases: Severe erythema multiforme (Stevens-Johnson syndrome). Severe psoriasis. 4. Allergic states: Atopic dermatitis Serum sickness. 5. Ophthalmic diseases: Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis. Keratitis. Iritis and iridocyclitis. Diffuse posterior uveitis and choroiditis. Optic neuritis. Chorioretinitis. Anterior segment inflammation. 6. Respiratory diseases: Symptomatic sarcoidosis. 7. Edematous states: To induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus. 8. Nervous system: Acute exacerbations of multiple sclerosis. uuid:c100ee79-f740-4b21-9622-0e6a5087b8d6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3892 biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:9a45f48e-e038-4e3f-b21d-df582c1107fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bd9ef6e6-cd7a-4bb9-b86a-6783edd50015"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Purified Cortrophin Gel is indicated in the following disorders: 1. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis. Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Ankylosing spondylitis. Acute gouty arthritis. 2. Collagen diseases: During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus. Systemic dermatomyositis (polymyositis). 3. Dermatologic diseases: Severe erythema multiforme (Stevens-Johnson syndrome). Severe psoriasis. 4. Allergic states: Atopic dermatitis Serum sickness. 5. Ophthalmic diseases: Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis. Keratitis. Iritis and iridocyclitis. Diffuse posterior uveitis and choroiditis. Optic neuritis. Chorioretinitis. Anterior segment inflammation. 6. Respiratory diseases: Symptomatic sarcoidosis. 7. Edematous states: To induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus. 8. Nervous system: Acute exacerbations of multiple sclerosis. uuid:c7211e78-84b4-4ec2-96ac-f4461eb09b5f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3892 biolink:treats MONDO:0043789 PMID:41385096 "[{""id"":""uuid:9e22c691-b9cb-4923-bd58-5bc0dd7f297b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fab6f79b-0e78-4d80-bb75-79d412a9b5eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Purified Cortrophin Gel is indicated in the following disorders: 1. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis. Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Ankylosing spondylitis. Acute gouty arthritis. 2. Collagen diseases: During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus. Systemic dermatomyositis (polymyositis). 3. Dermatologic diseases: Severe erythema multiforme (Stevens-Johnson syndrome). Severe psoriasis. 4. Allergic states: Atopic dermatitis Serum sickness. 5. Ophthalmic diseases: Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis. Keratitis. Iritis and iridocyclitis. Diffuse posterior uveitis and choroiditis. Optic neuritis. Chorioretinitis. Anterior segment inflammation. 6. Respiratory diseases: Symptomatic sarcoidosis. 7. Edematous states: To induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus. 8. Nervous system: Acute exacerbations of multiple sclerosis. uuid:e0baf053-f843-4d16-ba75-88edd67de6a0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3892 biolink:treats MONDO:0003085 PMID:41385096 "[{""id"":""uuid:56abdfe8-6fef-4769-b6be-72cd209c6591"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e46cf6ef-f046-4a4e-b47e-79e30c423702"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Purified Cortrophin Gel is indicated in the following disorders: 1. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis. Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Ankylosing spondylitis. Acute gouty arthritis. 2. Collagen diseases: During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus. Systemic dermatomyositis (polymyositis). 3. Dermatologic diseases: Severe erythema multiforme (Stevens-Johnson syndrome). Severe psoriasis. 4. Allergic states: Atopic dermatitis Serum sickness. 5. Ophthalmic diseases: Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis. Keratitis. Iritis and iridocyclitis. Diffuse posterior uveitis and choroiditis. Optic neuritis. Chorioretinitis. Anterior segment inflammation. 6. Respiratory diseases: Symptomatic sarcoidosis. 7. Edematous states: To induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus. 8. Nervous system: Acute exacerbations of multiple sclerosis. uuid:923a7450-7579-4d4d-98d5-9448c1ac91b4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3892 biolink:treats MONDO:0004773 PMID:41385096 "[{""id"":""uuid:4c2279cf-92da-4ef0-a05b-61a942166f2f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:62280f8f-dfb3-49e9-b56a-1f357e34e37e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Purified Cortrophin Gel is indicated in the following disorders: 1. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis. Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Ankylosing spondylitis. Acute gouty arthritis. 2. Collagen diseases: During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus. Systemic dermatomyositis (polymyositis). 3. Dermatologic diseases: Severe erythema multiforme (Stevens-Johnson syndrome). Severe psoriasis. 4. Allergic states: Atopic dermatitis Serum sickness. 5. Ophthalmic diseases: Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis. Keratitis. Iritis and iridocyclitis. Diffuse posterior uveitis and choroiditis. Optic neuritis. Chorioretinitis. Anterior segment inflammation. 6. Respiratory diseases: Symptomatic sarcoidosis. 7. Edematous states: To induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus. 8. Nervous system: Acute exacerbations of multiple sclerosis. uuid:7547d537-453f-4c65-94c7-a47fc15ff272 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3892 biolink:treats MONDO:0006918 PMID:41385096 "[{""id"":""uuid:57932e1b-0ade-43c8-9e05-4b980dd3aaf8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:29d2a9bb-de33-4fa0-99f5-4312af27d3c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Purified Cortrophin Gel is indicated in the following disorders: 1. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis. Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Ankylosing spondylitis. Acute gouty arthritis. 2. Collagen diseases: During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus. Systemic dermatomyositis (polymyositis). 3. Dermatologic diseases: Severe erythema multiforme (Stevens-Johnson syndrome). Severe psoriasis. 4. Allergic states: Atopic dermatitis Serum sickness. 5. Ophthalmic diseases: Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis. Keratitis. Iritis and iridocyclitis. Diffuse posterior uveitis and choroiditis. Optic neuritis. Chorioretinitis. Anterior segment inflammation. 6. Respiratory diseases: Symptomatic sarcoidosis. 7. Edematous states: To induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus. 8. Nervous system: Acute exacerbations of multiple sclerosis. uuid:1fe63d7e-ea1f-4f25-b57f-f43bc637df44 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3892 biolink:treats MONDO:0001280 PMID:41385096 "[{""id"":""uuid:498bdbf0-1a94-4704-b997-9c76bcacbba0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e049bb87-bd90-49eb-8959-ef409fdaf9e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Purified Cortrophin Gel is indicated in the following disorders: 1. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis. Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Ankylosing spondylitis. Acute gouty arthritis. 2. Collagen diseases: During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus. Systemic dermatomyositis (polymyositis). 3. Dermatologic diseases: Severe erythema multiforme (Stevens-Johnson syndrome). Severe psoriasis. 4. Allergic states: Atopic dermatitis Serum sickness. 5. Ophthalmic diseases: Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis. Keratitis. Iritis and iridocyclitis. Diffuse posterior uveitis and choroiditis. Optic neuritis. Chorioretinitis. Anterior segment inflammation. 6. Respiratory diseases: Symptomatic sarcoidosis. 7. Edematous states: To induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus. 8. Nervous system: Acute exacerbations of multiple sclerosis. uuid:aca68a7c-fe43-43b4-b7bb-50bb7a7ef798 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3892 biolink:treats MONDO:0005885 PMID:41385096 "[{""id"":""uuid:865b4edd-0fa8-41a2-8c6e-0fd48056721c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:50402a00-b1d2-48ff-8e32-d152af755dce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Purified Cortrophin Gel is indicated in the following disorders: 1. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis. Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Ankylosing spondylitis. Acute gouty arthritis. 2. Collagen diseases: During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus. Systemic dermatomyositis (polymyositis). 3. Dermatologic diseases: Severe erythema multiforme (Stevens-Johnson syndrome). Severe psoriasis. 4. Allergic states: Atopic dermatitis Serum sickness. 5. Ophthalmic diseases: Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis. Keratitis. Iritis and iridocyclitis. Diffuse posterior uveitis and choroiditis. Optic neuritis. Chorioretinitis. Anterior segment inflammation. 6. Respiratory diseases: Symptomatic sarcoidosis. 7. Edematous states: To induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus. 8. Nervous system: Acute exacerbations of multiple sclerosis. uuid:b706c349-ba92-455a-b2da-358f7c6a7f28 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3892 biolink:treats MONDO:0004674 PMID:41385096 "[{""id"":""uuid:1b0c986b-beb5-4648-96a7-b75035ac3d40"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:56a11060-9bf9-49ce-9d0e-9f221dda9573"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Purified Cortrophin Gel is indicated in the following disorders: 1. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis. Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Ankylosing spondylitis. Acute gouty arthritis. 2. Collagen diseases: During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus. Systemic dermatomyositis (polymyositis). 3. Dermatologic diseases: Severe erythema multiforme (Stevens-Johnson syndrome). Severe psoriasis. 4. Allergic states: Atopic dermatitis Serum sickness. 5. Ophthalmic diseases: Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis. Keratitis. Iritis and iridocyclitis. Diffuse posterior uveitis and choroiditis. Optic neuritis. Chorioretinitis. Anterior segment inflammation. 6. Respiratory diseases: Symptomatic sarcoidosis. 7. Edematous states: To induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus. 8. Nervous system: Acute exacerbations of multiple sclerosis. uuid:d8fc91a3-f650-4ede-a690-d4e8910e228e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3892 biolink:treats MONDO:0006651 PMID:41385096 "[{""id"":""uuid:5cf5d328-3f50-494a-b077-d1f4037c9282"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8f6cadce-cde9-46fa-ab3a-a6f95318c2b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Purified Cortrophin Gel is indicated in the following disorders: 1. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis. Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Ankylosing spondylitis. Acute gouty arthritis. 2. Collagen diseases: During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus. Systemic dermatomyositis (polymyositis). 3. Dermatologic diseases: Severe erythema multiforme (Stevens-Johnson syndrome). Severe psoriasis. 4. Allergic states: Atopic dermatitis Serum sickness. 5. Ophthalmic diseases: Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis. Keratitis. Iritis and iridocyclitis. Diffuse posterior uveitis and choroiditis. Optic neuritis. Chorioretinitis. Anterior segment inflammation. 6. Respiratory diseases: Symptomatic sarcoidosis. 7. Edematous states: To induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus. 8. Nervous system: Acute exacerbations of multiple sclerosis. uuid:bcf2d7cc-c506-43bb-be67-0ad6082819c1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3892 biolink:treats MONDO:0019338 PMID:41385096 "[{""id"":""uuid:95f71475-b038-4322-aa8e-54fd44ee5f44"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:26a94bc2-762c-4369-b98e-bd4d112c2c9c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Purified Cortrophin Gel is indicated in the following disorders: 1. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis. Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Ankylosing spondylitis. Acute gouty arthritis. 2. Collagen diseases: During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus. Systemic dermatomyositis (polymyositis). 3. Dermatologic diseases: Severe erythema multiforme (Stevens-Johnson syndrome). Severe psoriasis. 4. Allergic states: Atopic dermatitis Serum sickness. 5. Ophthalmic diseases: Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis. Keratitis. Iritis and iridocyclitis. Diffuse posterior uveitis and choroiditis. Optic neuritis. Chorioretinitis. Anterior segment inflammation. 6. Respiratory diseases: Symptomatic sarcoidosis. 7. Edematous states: To induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus. 8. Nervous system: Acute exacerbations of multiple sclerosis. uuid:99f32a88-cde8-46e6-9c46-de5962fa1d1a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3892 biolink:treats MONDO:0005377 PMID:41385096 "[{""id"":""uuid:318daac5-01d6-480d-85b8-60f92c6201cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1c61bced-5d38-4928-9ab0-6063cc0b0856"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Purified Cortrophin Gel is indicated in the following disorders: 1. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis. Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Ankylosing spondylitis. Acute gouty arthritis. 2. Collagen diseases: During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus. Systemic dermatomyositis (polymyositis). 3. Dermatologic diseases: Severe erythema multiforme (Stevens-Johnson syndrome). Severe psoriasis. 4. Allergic states: Atopic dermatitis Serum sickness. 5. Ophthalmic diseases: Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis. Keratitis. Iritis and iridocyclitis. Diffuse posterior uveitis and choroiditis. Optic neuritis. Chorioretinitis. Anterior segment inflammation. 6. Respiratory diseases: Symptomatic sarcoidosis. 7. Edematous states: To induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus. 8. Nervous system: Acute exacerbations of multiple sclerosis. uuid:e34a9c43-4da8-46b3-9124-7c5cd9887e0d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3892 biolink:treats MONDO:0005301 PMID:41385096 "[{""id"":""uuid:d81c6755-4f8a-4c22-a41f-95d6b2858c0e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9aae0d47-0e39-4f9d-80c0-beb7619bd704"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Purified Cortrophin Gel is indicated in the following disorders: 1. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis. Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Ankylosing spondylitis. Acute gouty arthritis. 2. Collagen diseases: During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus. Systemic dermatomyositis (polymyositis). 3. Dermatologic diseases: Severe erythema multiforme (Stevens-Johnson syndrome). Severe psoriasis. 4. Allergic states: Atopic dermatitis Serum sickness. 5. Ophthalmic diseases: Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis. Keratitis. Iritis and iridocyclitis. Diffuse posterior uveitis and choroiditis. Optic neuritis. Chorioretinitis. Anterior segment inflammation. 6. Respiratory diseases: Symptomatic sarcoidosis. 7. Edematous states: To induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus. 8. Nervous system: Acute exacerbations of multiple sclerosis. uuid:fa3b00dc-a15f-49bc-a773-76bc00b28e7a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:76612 biolink:treats MONDO:0004948 PMID:41385096 "[{""id"":""uuid:84081ba3-84e7-4640-8fd3-84ca9eefb760"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:025634cd-1f67-4a82-a26a-0581e998983c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:d20b7c0d-accd-4ecf-997f-3fd9113353c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/imbruvica""]},{""id"":""uuid:b28a7ab8-bf3a-4b43-8229-c64ff4c5bac9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] IMBRUVICA is a kinase inhibitor indicated for the treatment of: Adult patients with chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) ( 1.1 ). Adult patients with chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) with 17p deletion ( 1.2 ). Adult patients with Waldenström’s macroglobulinemia (WM) ( 1.3 ). Adult and pediatric patients age 1 year and older with chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy ( 1.4 ).|[EMA] IMBRUVICA as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).IMBRUVICA as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) (see section 5.1).IMBRUVICA as a single agent or in combination with bendamustine and rituximab (BR) is indicated for the treatment of adult patients with CLL who have received at least one prior therapy.IMBRUVICA as a single agent is indicated for the treatment of adult patients with Waldenström’s macroglobulinaemia (WM) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. IMBRUVICA in combination with rituximab is indicated for the treatment of adult patients with WM.|[PMDA] A drug with a new active ingredient indicated for the treatment of relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. uuid:87339b44-d2c0-43b9-8514-3e0a829b50d4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:76612 biolink:treats MONDO:0003864 PMID:41385096 "[{""id"":""uuid:5512c5d0-05d2-4401-a73e-c4bfde5018bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2513e827-55f3-4670-b299-faf41d3164c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:759a193d-d35a-4d1b-96d9-a8290dc8b9ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] IMBRUVICA is a kinase inhibitor indicated for the treatment of: Adult patients with chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) ( 1.1 ). Adult patients with chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) with 17p deletion ( 1.2 ). Adult patients with Waldenström’s macroglobulinemia (WM) ( 1.3 ). Adult and pediatric patients age 1 year and older with chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy ( 1.4 ).|[PMDA] A drug with a new active ingredient indicated for the treatment of relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. uuid:bd9294ad-d43c-454e-9652-f738847cb34b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:76612 biolink:treats MONDO:0100280 PMID:41385096 "[{""id"":""uuid:1df28bdb-9a69-405a-8ae7-04e6ad93c69f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:24a83e80-8f5c-466a-aaa5-774c2b1a6521"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:d8514317-ab04-4ad7-abff-7e7872ad65a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/imbruvica""]},{""id"":""uuid:78850e1c-22ae-48ba-a59c-81175c7cd232"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] IMBRUVICA is a kinase inhibitor indicated for the treatment of: Adult patients with chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) ( 1.1 ). Adult patients with chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) with 17p deletion ( 1.2 ). Adult patients with Waldenström’s macroglobulinemia (WM) ( 1.3 ). Adult and pediatric patients age 1 year and older with chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy ( 1.4 ).|[EMA] IMBRUVICA as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).IMBRUVICA as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) (see section 5.1).IMBRUVICA as a single agent or in combination with bendamustine and rituximab (BR) is indicated for the treatment of adult patients with CLL who have received at least one prior therapy.IMBRUVICA as a single agent is indicated for the treatment of adult patients with Waldenström’s macroglobulinaemia (WM) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. IMBRUVICA in combination with rituximab is indicated for the treatment of adult patients with WM.|[PMDA] A drug with new indications for the treatment of Waldenström's macroglobulinemia and lymphoplasmacytic lymphoma. [Orphan drug] uuid:cb4634cc-b26f-4a5f-83ea-dbd33a4aa6e0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:76612 biolink:treats MONDO:0020547 PMID:41385096 "[{""id"":""uuid:ab8e9e3d-b50c-4dca-92e6-807b15f73bd5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5225c8e2-db6a-4140-87da-e282fc8a637f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:0f44c644-c113-4b94-8eab-411477fb2a42"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] IMBRUVICA is a kinase inhibitor indicated for the treatment of: Adult patients with chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) ( 1.1 ). Adult patients with chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) with 17p deletion ( 1.2 ). Adult patients with Waldenström’s macroglobulinemia (WM) ( 1.3 ). Adult and pediatric patients age 1 year and older with chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy ( 1.4 ).|[PMDA] A drug with a new indication and a new dosage for the treatment of chronic graft-versus-host disease after hematopoietic stem cell transplantation (for use when steroid drugs are not sufficiently effective). [Orphan drug] uuid:da782469-54db-4df0-b8c5-809269c0f50e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:229221 biolink:treats EFO:1001480 PMID:41385096 "[{""id"":""uuid:35d692b4-3840-46a1-84ad-34f8e9494831"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2322b1f2-3a0d-4b9a-8783-776d06a7dac3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FRUZAQLA is indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine‑, oxaliplatin‑, and irinotecan‑based chemotherapy, an anti‑VEGF therapy, and, if RAS wild‑type and medically appropriate, an anti-EGFR therapy. uuid:9388b412-f991-47e0-898d-30b4bf584ac6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68647 biolink:treats EFO:1001480 PMID:41385096 "[{""id"":""uuid:75dbb134-9977-4dce-a443-0b629e80d4df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d681eed8-93fa-48e9-a941-f0c9b8e94969"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] STIVARGA is a kinase inhibitor indicated for the treatment of patients with: • Metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type, an anti-EGFR therapy. ( 1.1 ) • Locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. ( 1.2 ) • Hepatocellular carcinoma (HCC) who have been previously treated with sorafenib ( 1.3 ) uuid:a2c2af7f-cf8e-414a-bc99-4c4d171166dd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68647 biolink:treats MONDO:0007256 PMID:41385096 "[{""id"":""uuid:8a19b7c9-a6b5-43c6-84da-9210c3848cd2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:baa410ae-42ed-4831-9068-d61770a67acb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:a24d9b78-5f69-40b3-a1d8-059bce04fb0a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/stivarga""]},{""id"":""uuid:25db0b00-0696-4640-a480-0f07f5f3f492"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] STIVARGA is a kinase inhibitor indicated for the treatment of patients with: • Metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type, an anti-EGFR therapy. ( 1.1 ) • Locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. ( 1.2 ) • Hepatocellular carcinoma (HCC) who have been previously treated with sorafenib ( 1.3 )|[EMA] Stivarga is indicated as monotherapy for the treatment of adult patients with:metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies - these include fluoropyrimidine-based chemotherapy, an anti-VEGF therapy and an anti-EGFR therapy;unresectable or metastatic gastrointestinal stromal tumors (GIST) who progressed on or are intolerant to prior treatment with imatinib and sunitinib;hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.|[PMDA] A drug with a new additional indication for the treatment of unresectable hepatocellular carcinoma which has progressed after cancer chemotherapy. [Priority review] uuid:673c24f4-6da6-4bfd-99a9-62b47bdc2d5f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:233362 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:a76ab688-de40-4744-81d5-3c25a11c7036"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:79eac4de-a161-454c-a970-d37406750655"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:dc23c2d5-629b-4398-9b0b-fcab359cf2e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/verzenios""]},{""id"":""uuid:6c81b663-4456-400f-87b0-3bc26e8029a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VERZENIO ® is a kinase inhibitor indicated: in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of recurrence. ( 1.1 , 14.1 ) in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. ( 1.2 ) in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. ( 1.2 ) as monotherapy for the treatment of adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting. ( 1.2 )|[EMA] Early Breast CancerVerzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative, node positive early breast cancer at high risk of recurrence (see section 5.1).In pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist.Advanced or Metastatic Breast CancerVerzenios is indicated for the treatment of women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy.In pre- or perimenopausal women, the endocrine therapy should be combined with a LHRH agonist.|[PMDA] Drugs with a new active ingredient indicated for the treatment of hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)- negative inoperable or recurrent breast cancer. UNII:60UAB198HK uuid:ce1e751e-cf2f-417d-a68b-063ff347767e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:233362 biolink:treats UMLS:C3495917 PMID:41385096 "[{""id"":""uuid:9702d3c1-f334-48e9-a23d-6202e7428391"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d3fe17ef-3879-4954-b2d4-6461bca1b72a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VERZENIO ® is a kinase inhibitor indicated: in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of recurrence. ( 1.1 , 14.1 ) in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. ( 1.2 ) in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. ( 1.2 ) as monotherapy for the treatment of adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting. ( 1.2 ) UNII:60UAB198HK uuid:447cf375-f18f-4e3d-9833-c478754e217d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:233362 biolink:treats UMLS:C0278488 PMID:41385096 "[{""id"":""uuid:30630fda-789d-4ebc-bb5d-43824f4e0e34"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d2686c6b-06f7-477c-b49f-19d10ca5139c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VERZENIO ® is a kinase inhibitor indicated: in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of recurrence. ( 1.1 , 14.1 ) in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. ( 1.2 ) in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. ( 1.2 ) as monotherapy for the treatment of adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting. ( 1.2 ) UNII:60UAB198HK uuid:32053c81-1025-4ad3-9455-3debc880fddf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PTB4X93HE1 biolink:treats MONDO:0005132 PMID:41385096 "[{""id"":""uuid:bb69a828-5ac0-434f-b352-2a5f99e4714a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:20e8e33e-c78d-4852-b699-4798b6b936de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:536ad80b-aea6-43cf-91ad-23968e9ac1b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/livtencity""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] LIVTENCITY is indicated for the treatment of adults and pediatric patients (12 years of age and older and weighing at least 35 kg) with post-transplant cytomegalovirus (CMV) infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir or foscarnet [see Use in Specific Populations (8.4) and Clinical Studies (14) ] .|[EMA] LIVTENCITY is indicated for the treatment of cytomegalovirus (CMV) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a haematopoietic stem cell transplant (HSCT) or solid organ transplant (SOT).Consideration should be given to official guidance on the appropriate use of antiviral agents. uuid:5ae20b94-a86b-4f45-880d-4f20df3a1bfa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49375 biolink:treats MONDO:0024685 PMID:41385096 "[{""id"":""uuid:302b0139-29f3-46fa-8437-ff2f6c2535d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2acd5cfe-bd1b-40ae-8a49-597b3751a2c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dasatinib tablets are indicated for the treatment of adult patients with • newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. • chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. • Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. Dasatinib tablets are indicated for the treatment of pediatric patients 1 year of age and older with • Ph+ CML in chronic phase. • newly diagnosed Ph+ ALL in combination with chemotherapy. uuid:ec83810b-78b1-4656-b583-63523fe1ec8f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:84500 biolink:treats MONDO:0006733 PMID:41385096 "[{""id"":""uuid:f4c2eeff-dc4a-4d0c-ba4c-f19eee22a7d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b527f1d4-a2b7-407a-a07d-7a2bf6be7eeb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TYRVAYA (varenicline solution) nasal spray is indicated for the treatment of the signs and symptoms of dry eye disease. uuid:d8391da7-4479-40f6-96fe-b94350dacc4d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:A3ULP0F556 biolink:treats MONDO:0035663 PMID:41385096 "[{""id"":""uuid:88a76c2f-004a-491c-98f9-bbf2c6df98e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a90b7d1c-1c21-40f0-be67-2c44bc1b0e5c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:7658a87b-4f51-4111-97f7-64f5a0a089cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/soliris""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] SOLIRIS is a complement inhibitor indicated for: the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis. ( 1.1 ) the treatment of patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy. ( 1.2 ) Limitation of Use SOLIRIS is not indicated for the treatment of patients with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS). the treatment of generalized myasthenia gravis (gMG) in adult and pediatric patients six years of age and older who are anti-acetylcholine receptor (AChR) antibody positive. ( 1.3 ) the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive. ( 1.4 )|[EMA] Soliris is indicated in adults and children for the treatment of:Paroxysmal nocturnal haemoglobinuria (PNH).Evidence of clinical benefit is demonstrated in patients with haemolysis with clinical symptom(s) indicative of high disease activity, regardless of transfusion history (see section 5.1). Atypical haemolytic uremic syndrome (aHUS).Soliris is indicated in adults for the treatment of:Refractory generalized myasthenia gravis (gMG) in patients who are anti-acetylcholine receptor (AChR) antibody-positive (see section 5.1).Neuromyelitis optica spectrum disorder (NMOSD) in patients who are anti-aquaporin-4 (AQP4) antibody-positive with a relapsing course of the disease. uuid:357af012-47ce-4bcc-b3e6-efac4402370d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2372V1TKXK biolink:treats MONDO:0019623 PMID:41385096 "[{""id"":""uuid:33b64705-8828-4bad-944b-7c5a6d2c5304"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9a2751ab-c6be-4430-b008-8e9a43170bf7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:2b466ada-a180-428d-a89d-24edeb4838b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/takhzyro""]},{""id"":""uuid:e17c1962-c85a-4725-bab0-7a69648740cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TAKHZYRO ® is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 2 years and older.|[EMA] TAKHZYRO is indicated for routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 2 years and older.|[PMDA] A drug with a new active ingredient indicated for the prophylaxis of acute attacks of hereditary angioedema. [Orphan drug] uuid:505d34b4-6a53-4601-b5d3-8fbe69601bb2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2372V1TKXK biolink:treats MONDO:0012526 PMID:41385096 "[{""id"":""uuid:f0181c1a-d6f5-4a4d-9198-620c5f2d183b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:60750a38-638d-4a15-940f-6d15a026a8e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TAKHZYRO ® is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 2 years and older. uuid:47d35b3d-3248-4a65-b6e4-8754aff5557d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22652 biolink:treats MONDO:0010525 PMID:41385096 "[{""id"":""uuid:d2a16e09-349d-4117-bab0-f5bdf7effae6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0596ca87-a10c-4988-ad32-873c0491cfab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Accentrate® PNV (Folate/Omega-3/Iron) (6 mg-210 mg-10 mg) is a Prescription Prenatal Multivitamin Tablet and combination Omega-3 Softgel/Mineral Capsule indicated for preventing neural tube defects and use in improving the nutritional status of women prior to conception, throughout pregnancy, and in the postnatal period for both lactating and nonlactating mothers. uuid:6a17e4b6-43e0-40b2-9a11-13a436750827 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:229225 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:f07b21d4-1c57-40a1-9d96-e7efd2bec70f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:11cf8ca3-36e2-4d58-aadd-ade1432b4992"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bexagliflozin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use Bexagliflozin is not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus. [see Warnings and Precautions ( 5.1 )] . uuid:164cfcad-7a79-4e78-ae02-d2be4a8f89c9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:229225 biolink:treats MONDO:0005147 PMID:41385096 "[{""id"":""uuid:2d4a1671-8b59-4502-8e0f-87eb10d492b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1cc50ecb-02a2-4930-a624-6b753f094d46"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bexagliflozin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use Bexagliflozin is not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus. [see Warnings and Precautions ( 5.1 )] . uuid:a7ffae61-5b18-4dd9-b825-e07387223f19 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:8K80YB5GMG biolink:treats MONDO:0016168 PMID:41385096 "[{""id"":""uuid:2e21f1f4-460f-4326-8d0f-e07dd3b2e2dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eef99ed0-eb3a-490f-aa28-2238aa3484c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ARCALYST (rilonacept) is an interleukin-1 blocker indicated for: Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS), and Muckle-Wells Syndrome (MWS) in adults and children 12 years and older ( 1.1 , 14.1 ) Maintenance of remission of Deficiency of Interleukin-1 Receptor Antagonist (DIRA) in adults and pediatric patients weighing 10 kg or more ( 1.2 , 14.2 ) Treatment of recurrent pericarditis (RP) and reduction in risk of recurrence in adults and children 12 years and older ( 1.3 , 14.3 ) uuid:901d1100-d450-4fe3-97f7-a9d9108055c3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:8K80YB5GMG biolink:treats MONDO:0018768 PMID:41385096 "[{""id"":""uuid:5cea953e-4b10-4b58-a5cc-1c871786e7ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7098c054-97e4-4628-9bc4-2dca553930cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ARCALYST (rilonacept) is an interleukin-1 blocker indicated for: Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS), and Muckle-Wells Syndrome (MWS) in adults and children 12 years and older ( 1.1 , 14.1 ) Maintenance of remission of Deficiency of Interleukin-1 Receptor Antagonist (DIRA) in adults and pediatric patients weighing 10 kg or more ( 1.2 , 14.2 ) Treatment of recurrent pericarditis (RP) and reduction in risk of recurrence in adults and children 12 years and older ( 1.3 , 14.3 ) uuid:0f0e349e-4412-4007-aaf2-b752429b8ed6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:8K80YB5GMG biolink:treats UMLS:C5577988 PMID:41385096 "[{""id"":""uuid:d20b3e9a-f5fe-443d-bf1d-d7ab180fedc9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f406be5c-c982-4bda-8121-0d6aa3f46a20"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ARCALYST (rilonacept) is an interleukin-1 blocker indicated for: Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS), and Muckle-Wells Syndrome (MWS) in adults and children 12 years and older ( 1.1 , 14.1 ) Maintenance of remission of Deficiency of Interleukin-1 Receptor Antagonist (DIRA) in adults and pediatric patients weighing 10 kg or more ( 1.2 , 14.2 ) Treatment of recurrent pericarditis (RP) and reduction in risk of recurrence in adults and children 12 years and older ( 1.3 , 14.3 ) uuid:df993546-9467-49bc-a576-5ac14c2ed4f9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47426 biolink:treats MONDO:0005300 PMID:41385096 "[{""id"":""uuid:423e579c-6d65-4fa6-a611-020cd6b68578"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4b106add-1e37-439d-9255-e03755805322"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FUROSCIX is indicated for the treatment of edema in adult patients with chronic heart failure or chronic kidney disease (CKD), including the nephrotic syndrome. uuid:001416fa-0d06-47f6-a486-3138f16446ea biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:TT0V5JLG5B biolink:treats HP:0031609 PMID:41385096 "[{""id"":""uuid:33514fb7-2e77-4e97-a951-9606e6010f0c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:91e9536c-c039-4325-bcb6-f43e69a498de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] IZERVAY ™ is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). uuid:cc02d1d5-3f11-4aff-a86c-46e1f8455d88 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:TT0V5JLG5B biolink:treats MONDO:0005150 PMID:41385096 "[{""id"":""uuid:c70485cb-71e9-4031-be41-19a8691da7f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5a9ecc91-bf2d-42ac-815c-df3b9afaa540"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] IZERVAY ™ is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). uuid:ba810b07-95f8-4eb9-9439-822da2ab36a7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2570392 biolink:treats MONDO:0005090 PMID:41385096 "[{""id"":""uuid:d799e33e-0799-4644-97ce-6e3a0486e57b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aeb90e11-ca99-458f-8e62-9688d8dd834f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LYBALVI is indicated for the treatment of: Schizophrenia in adults Bipolar I disorder in adults Acute treatment of manic or mixed episodes as monotherapy and as adjunct to lithium or valproate Maintenance monotherapy treatment uuid:43afecd7-4970-48d5-ab6a-3a8c040b4295 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2570392 biolink:treats MONDO:0001866 PMID:41385096 "[{""id"":""uuid:ac158329-763d-42be-917b-90ee2442322f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:77e8e1e7-182b-4004-abca-c77b4dca989f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LYBALVI is indicated for the treatment of: Schizophrenia in adults Bipolar I disorder in adults Acute treatment of manic or mixed episodes as monotherapy and as adjunct to lithium or valproate Maintenance monotherapy treatment uuid:7b795360-ecab-415f-ad19-a0f070c60d81 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2570392 biolink:treats MONDO:0024612 PMID:41385096 "[{""id"":""uuid:1791c6f3-f2b4-4f29-ade5-c3eb0db66ab6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6d32afb2-8d0e-4c61-9bf1-e0127701cb84"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LYBALVI is indicated for the treatment of: Schizophrenia in adults Bipolar I disorder in adults Acute treatment of manic or mixed episodes as monotherapy and as adjunct to lithium or valproate Maintenance monotherapy treatment uuid:f285f574-c52d-47be-b93a-c72b394b09c2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:229659 biolink:treats MONDO:0009688 PMID:41385096 "[{""id"":""uuid:e78de7d0-86b5-4130-84c0-8b623eb72348"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1e77f5ac-0322-4041-b6a9-098ee56fe96a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f278e5d5-85a1-4b39-9015-c15c88e25d2c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZILBRYSQ is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.|[PMDA] Drugs with a new active ingredient indicated for the treatment of generalized myasthenia gravis (for use only in patients who have not sufficiently responded to steroids or other immunosuppressants). uuid:8f8625c1-435f-41ce-8fef-b13c96c59034 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50848 biolink:treats MONDO:0006733 PMID:41385096 "[{""id"":""uuid:49099378-eb23-4f2d-a86c-ebab5ffafac7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:645e18cd-54d9-4ce9-8e16-60348e6b4836"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EYSUVIS is a corticosteroid indicated for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease. uuid:10be8ede-1689-44c7-813b-821bd32066a1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:9961469 biolink:treats MONDO:0005338 PMID:41385096 "[{""id"":""uuid:81baac0f-f108-4dee-9349-5c150eed415c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5981d14e-9f82-4801-970d-d7f21bfea56a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SIMBRINZA (brinzolamide/brimonidine tartrate ophthalmic suspension) 1%/0.2% is a fixed combination of a carbonic anhydrase inhibitor and an alpha 2 adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. uuid:2fe1f843-44d7-4c9d-988b-a669cad6776e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:9961469 biolink:treats MONDO:0006875 PMID:41385096 "[{""id"":""uuid:5bef95b8-aed2-4ee2-93bb-04bb2a653c79"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:975e94a4-269f-4d72-aa8c-f5911e52f753"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SIMBRINZA (brinzolamide/brimonidine tartrate ophthalmic suspension) 1%/0.2% is a fixed combination of a carbonic anhydrase inhibitor and an alpha 2 adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. uuid:b68f3900-2105-45e9-ba15-9e02bd2a9c9a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18358 biolink:treats MONDO:0005083 PMID:41385096 "[{""id"":""uuid:9bdb07bf-c00e-464e-96a5-ec8908bcf78b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ff867a28-dd88-44cf-a2d4-bb68bf6ba9ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Photochemotherapy (Methoxsalen with long wave UVA radiation) is indicated for the symptomatic control of severe, recalcitrant, disabling psoriasis not adequately responsive to other forms of therapy and when the diagnosis has been supported by biopsy. Methoxsalen is intended to be administered only in conjunction with a schedule of controlled doses of long wave ultraviolet radiation. uuid:6edcde60-f25a-47b9-9b4e-35a65dfa1503 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:231601 biolink:treats MONDO:0003219 PMID:41385096 "[{""id"":""uuid:7c5bd547-937a-4606-b64f-2480ee7c63b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f5b76092-5553-4eb3-92a6-874cbee632ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ontruzant is a HER2/neu receptor antagonist indicated in adults for: The treatment of HER2-overexpressing breast cancer. ( 1.1 , 1.2 ) The treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. ( 1.3 ) Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product ( 1 , 2.2 ). uuid:9a27e25f-e15b-4c0e-b314-3a2d18309ea8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:229223 biolink:treats MONDO:0020725 PMID:41385096 "[{""id"":""uuid:d59dd324-8cf0-4d02-b25a-362b3dbd0125"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:affa01ca-05f5-4c4a-961b-11a2ff80630c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] JESDUVROQ is indicated for the treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least four months. Limitations of Use JESDUVROQ has not been shown to improve quality of life, fatigue, or patient well-being. JESDUVROQ is not indicated for use: • As a substitute for red blood cell transfusions in patients who require immediate correction of anemia. • For treatment of anemia of chronic kidney disease in patients who are not on dialysis. uuid:19d481c4-db89-45d4-a349-bd07aa65dfb1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:229764 biolink:treats MONDO:0009693 PMID:41385096 "[{""id"":""uuid:7a95481c-011f-4053-a139-6cc29b6d2efa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:780a0e48-0542-46fa-a896-da6338564179"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:0d90f0a4-803a-412e-9aeb-7a581b00cde4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/nexpovio""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] XPOVIO is a nuclear export inhibitor indicated: In combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy ( 1.1 ). In combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody ( 1.1 ). For the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy. This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s) ( 1.2 ).|[EMA] NEXPOVIO is indicatedin combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy. uuid:29979cf6-f3c7-4b22-b3c5-5c0bc05d01ff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:229764 biolink:treats MONDO:0000901 PMID:41385096 "[{""id"":""uuid:335ad163-7f2d-41f4-b48a-af89b0a9fda2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:53ddedab-7386-434a-9fce-b49b8689a4a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XPOVIO is a nuclear export inhibitor indicated: In combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy ( 1.1 ). In combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody ( 1.1 ). For the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy. This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s) ( 1.2 ). uuid:9594fdd9-a178-43ab-8f84-d3b3d31b7ec5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:229764 biolink:treats MONDO:0018908 PMID:41385096 "[{""id"":""uuid:cf84fb5e-bb1e-4521-98e7-22dac8ef3e2c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e5eb85cc-ac19-42ec-bcda-d3e5b7117d3d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XPOVIO is a nuclear export inhibitor indicated: In combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy ( 1.1 ). In combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody ( 1.1 ). For the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy. This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s) ( 1.2 ). uuid:b66a5834-ef27-46e1-a876-3c8a916cfd3f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:033072U4MZ biolink:treats MONDO:0010679 PMID:41385096 "[{""id"":""uuid:4fd3d323-3f86-401b-9dbc-c473ccc79369"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bbf17955-049d-406e-8e9c-7c904243c9a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VYONDYS 53 is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with VYONDYS 53 [see Clinical Studies ( 14 )] . Continued approval for this indication may be contingent upon verification of a clinical benefit in confirmatory trials. uuid:9893d863-45da-405d-9746-c02da60da648 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:161680 biolink:treats MONDO:0009061 PMID:41385096 "[{""id"":""uuid:9b72d72e-c63c-491c-9c02-486046286412"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cff37577-14ec-47ac-a735-2bfda33cf587"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CAYSTON ® is indicated to improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa . Safety and effectiveness have not been established in pediatric patients below the age of 7 years, patients with FEV 1 <25% or >75% predicted, or patients colonized with Burkholderia cepacia [see Clinical Studies (14) ]. To reduce the development of drug-resistant bacteria and maintain the effectiveness of CAYSTON and other antibacterial drugs, CAYSTON should be used only to treat patients with CF known to have Pseudomonas aeruginosa in the lungs. uuid:4d96d56b-ed67-4a26-b2ec-5427deda2dfc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:161680 biolink:treats UMLS:C0854135 PMID:41385096 "[{""id"":""uuid:607ba174-b64f-42fc-b9bc-13275b70395d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b3738604-7337-4f9f-9b3d-f89de0235ff9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CAYSTON ® is indicated to improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa . Safety and effectiveness have not been established in pediatric patients below the age of 7 years, patients with FEV 1 <25% or >75% predicted, or patients colonized with Burkholderia cepacia [see Clinical Studies (14) ]. To reduce the development of drug-resistant bacteria and maintain the effectiveness of CAYSTON and other antibacterial drugs, CAYSTON should be used only to treat patients with CF known to have Pseudomonas aeruginosa in the lungs. uuid:1d214fdc-2538-424e-870e-da25547d08c8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29101 biolink:treats HP:0001892 PMID:41385096 "[{""id"":""uuid:56d4e7c7-76cf-4cd8-9537-3af0258c8fef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fed3bd10-ca77-42dc-8941-dc0809a25963"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] REGIOCIT (sodium chloride and sodium citrate) solution is indicated for use as replacement solution for regional citrate anticoagulation (RCA) of the extracorporeal circuit in patients treated with continuous renal replacement therapy (CRRT), particularly when systemic anticoagulation with heparin is contraindicated, e.g., in patients with increased bleeding risks. REGIOCIT should be administered only under the supervision of a physician experienced in the use of CRRT. Pediatrics Pediatrics (<18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. Geriatrics Geriatrics (> 65 years of age): Evidence from clinical studies and experience suggests that use in the geriatric population is not associated with differences in safety or effectiveness. uuid:517752a7-211a-4f38-a775-df07e17642b5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6709 biolink:treats MONDO:0002643 PMID:41385096 "[{""id"":""uuid:d80d55a8-9336-4a10-aeee-46777ac7655b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c97e093f-19ac-4dfa-a3e6-70201b6e3c0e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Meclizine hydrochloride tablet is indicated for the treatment of vertigo associated with diseases affecting the vestibular system in adults. uuid:51ed2661-aefa-4ee9-885c-865240369a5b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:229212 biolink:treats MONDO:0004948 PMID:41385096 "[{""id"":""uuid:6e8e45ae-6cbf-4a9d-9755-22cfe55b3b4e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:096b9993-7d7b-40b1-93de-107f49585754"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] JAYPIRCA ® is a kinase inhibitor indicated for the treatment of Adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor. ( 1.1 ). This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor. ( 1.2 ). This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. uuid:d0f7577f-37ba-4948-9993-07511408f43a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:229212 biolink:treats MONDO:0003864 PMID:41385096 "[{""id"":""uuid:d12caabd-6257-41f2-9b8f-aeb3b9a5dfd8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:710648c3-81aa-4611-bf71-af5a914deca9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] JAYPIRCA ® is a kinase inhibitor indicated for the treatment of Adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor. ( 1.1 ). This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor. ( 1.2 ). This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. uuid:203771ef-7dd3-4f3e-915a-92839522c3b5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:8CQO07490I biolink:treats MONDO:0010679 PMID:41385096 "[{""id"":""uuid:842a7e62-bc2e-4f1f-a115-42ca912de8b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:38239a10-4152-4ead-bd73-779ee30e3f96"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AMONDYS 45 is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 45 skipping. This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with AMONDYS 45 [see Clinical Studies ( 14 )] . Continued approval for this indication may be contingent upon verification of a clinical benefit in confirmatory trials. uuid:47d97d18-0aac-47bb-b344-2a18c76e8b06 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:229233 biolink:treats MONDO:0005340 PMID:41385096 "[{""id"":""uuid:5ea8ae0b-262f-4ab2-a10a-34d4c6235a87"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3502e904-7709-4d94-b0b5-376ca616440d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ceb96147-7573-4293-abea-a4f909acb18c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:88db7b3f-f9ff-4687-aa39-d9946822994e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LITFULO is a kinase inhibitor indicated for the treatment of severe alopecia areata in adults and adolescents 12 years and older. Limitations of Use : Not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, cyclosporine or other potent immunosuppressants.|[EMA] Litfulo is indicated for the treatment of severe alopecia areata in adults and adolescents 12 years of age and older.|[PMDA] A drug with a new active ingredient indicated for the treatment of alopecia areata (for use only in patients with intractable and extensive alopecia areata). uuid:1fd54bcd-087f-4d7d-b184-b3be0746d8a3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:BT2LV86QKA biolink:treats MONDO:0007739 PMID:41385096 "[{""id"":""uuid:16887424-96a4-44c2-ba7f-060d95e981a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4328b241-4fa2-4fed-9976-7d6b610ac5b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AUSTEDO XR ® and AUSTEDO ® are indicated in adults for the treatment of: chorea associated with Huntington’s disease [see Clinical Studies ( 14.1 )] tardive dyskinesia [see Clinical Studies ( 14.2 )] uuid:7b941ef1-8383-4137-a3a4-e2e33e0e9b14 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:BT2LV86QKA biolink:treats MONDO:0010096 PMID:41385096 "[{""id"":""uuid:77f28447-d7e8-4d72-a370-2307b3306fe3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3f3d9508-c180-4649-9f3e-f0d9d5e160c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AUSTEDO XR ® and AUSTEDO ® are indicated in adults for the treatment of: chorea associated with Huntington’s disease [see Clinical Studies ( 14.1 )] tardive dyskinesia [see Clinical Studies ( 14.2 )] uuid:fee569db-8306-4523-9d1f-aaf8a5abb38a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2119698 biolink:treats MONDO:0005338 PMID:41385096 "[{""id"":""uuid:9bcd201c-b5ab-4cc9-b1ae-d7fd8b60ad5f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:134725e0-8255-4c8e-8891-1594142fded9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:6399430c-cdff-4aa9-b664-150083a773e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ROCKLATAN is a fixed dose combination of a Rho kinase inhibitor and a prostaglandin F 2α analogue indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.|[EMA] Roclanda is indicated for the reduction of elevated intraocular pressure (IOP) in adult patients with primary open-angle glaucoma or ocular hypertension for whom monotherapy with a prostaglandin or netarsudil provides insufficient IOP reduction. uuid:591886de-049c-4310-a2f9-d767c6223dfd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2119698 biolink:treats MONDO:0006875 PMID:41385096 "[{""id"":""uuid:9008c99f-e22f-4254-8eb5-d37a2967a9e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:15630978-755a-4092-bb49-717e8c87aec2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:19ae69b8-b8a3-4aa0-907b-98cb396868e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ROCKLATAN is a fixed dose combination of a Rho kinase inhibitor and a prostaglandin F 2α analogue indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.|[EMA] Roclanda is indicated for the reduction of elevated intraocular pressure (IOP) in adult patients with primary open-angle glaucoma or ocular hypertension for whom monotherapy with a prostaglandin or netarsudil provides insufficient IOP reduction. uuid:ab92aac4-3d28-4bfd-adc5-bbe6d46710c3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0001947 PMID:41385096 "[{""id"":""uuid:113ad5dd-d7c3-40ba-a29c-141b49cf7e0e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1805ab68-0b2c-43e4-8616-fa252b153790"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramuscular use of SOLU-MEDROL Sterile Powder is indicated as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliiative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportable thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hemotologic disorders: Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administration is contraindicated), pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous System: Acute exacerbations of multiple sclerosis; cerebral adema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, temporal arteritis, polymyositis, and systemic lupus erythematosus. uuid:218e51b8-daad-4dc3-8296-13d8011211f2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:76RS4S2ET1 biolink:treats MONDO:0001516 PMID:41385096 "[{""id"":""uuid:0cb28e38-53c1-480c-a58c-a3e79ffdfb8b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6cd4d31d-cc86-4df3-8cb2-196e90afc47a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f339b4ba-a772-45f4-a79f-7bce0df7f110"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/evrysdi""]},{""id"":""uuid:8d7d6534-962f-425f-96bb-7dd030cc1a57"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EVRYSDI is indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.|[EMA] Evrysdi is indicated for the treatment of 5q spinal muscular atrophy (SMA) in patients with a clinical diagnosis of SMA Type 1, Type 2 or Type 3 or with one to four SMN2 copies.|[PMDA] A drug with a new active ingredient indicated for the treatment of spinal muscular atrophy. [Orphan drug] uuid:19c83c5a-5876-4de4-8b74-320caed8c81f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:76RS4S2ET1 biolink:treats MONDO:0019079 PMID:41385096 "[{""id"":""uuid:85c5a0f0-91fc-4fc6-8066-6a637ca93c19"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:de78a0ba-c3e5-43dc-ac88-2ab663a4e2cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EVRYSDI is indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients. uuid:aa083814-95c6-4c1a-9aa1-46981afef20c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3746 biolink:treats MONDO:0024389 PMID:41385096 "[{""id"":""uuid:3ef7f256-4aa8-4dc1-b151-f9cfc4c10bea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8a31c990-e20b-4eda-aa6b-f3d24871ae44"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clindamycin Phosphate in Sodium Chloride Injection contains clindamycin, a lincosamide antibacterial indicated for the treatment of the following in adult and pediatric patients for whom appropriate dosing with this formulation can be achieved: • Serious infections caused by susceptible anaerobic bacteria ( 1.1 ) • Infections Due to Susceptible Isolates of Streptococci, Pneumococci and Staphylococci. ( 1.2 ) • Lower Respiratory Tract Infections. ( 1.3 ) • Skin and Skin Structure Infections. ( 1.4 ) • Gynecological Infections. ( 1.5 ) • Intra-abdominal Infections. ( 1.6 ) • Septicemia. ( 1.7 ) • Bone and Joint Infections. ( 1.8 ) Limitation of use Since clindamycin does not diffuse adequately into the cerebrospinal fluid, Clindamycin Phosphate in Sodium Chloride Injection should not be used in the treatment of meningitis ( 1.9 ) Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of Clindamycin Phosphate in Sodium Chloride Injection and other antibacterial drugs, Clindamycin Phosphate in Sodium Chloride Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. ( 1.10 ) uuid:b8592ca8-e0b3-4eb0-8361-dfc0c0bf0819 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:188559 biolink:treats MONDO:0007606 PMID:41385096 "[{""id"":""uuid:27b5bc32-da77-4c9d-a250-649463b5fdfa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ce9d403a-b057-4551-add1-fe2ec043afa0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SOHONOS is indicated for the reduction in volume of new heterotopic ossification in adults and pediatric patients aged 8 years and older for females and 10 years and older for males with fibrodysplasia ossificans progressiva (FOP). uuid:6f9290da-f0e6-4552-9e8c-851cfec31d28 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:188559 biolink:treats HP:0011986 PMID:41385096 "[{""id"":""uuid:238c91d6-aa68-4d15-82c8-3746b5f75128"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:636f0b58-2be6-4c61-93ed-d212dd0e6a8c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SOHONOS is indicated for the reduction in volume of new heterotopic ossification in adults and pediatric patients aged 8 years and older for females and 10 years and older for males with fibrodysplasia ossificans progressiva (FOP). uuid:8aaf2e79-11be-453a-8baf-8c59805b8f37 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:145371 biolink:treats MONDO:0005105 PMID:41385096 "[{""id"":""uuid:f656b1e6-d683-4303-b6f9-41851c063ce0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:94d01dc0-fffb-461e-a8c0-7ebcd2c20570"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:7a962c16-f2fc-469d-ab92-df5a8068628d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/mektovi""]},{""id"":""uuid:fd0b657a-0a77-4f20-a1ac-64da68e66d3b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MEKTOVI is a kinase inhibitor indicated: • in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test. ( 1.1 , 2.1 ) • in combination with encorafenib, for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test. ( 1.2 , 2.1 )|[EMA] Binimetinib in combination with encorafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.|[PMDA] A drug with a new active ingredient indicated for the treatment of unresectable melanoma with BRAF gene mutation. [Orphan drug] uuid:a87cb174-4ca2-423d-9677-abb47f0e2831 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:145371 biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:74eafe39-61bc-4a4e-b2e2-3226c1e6f29f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5731a42f-c95a-43ec-b004-412d208a7f1c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MEKTOVI is a kinase inhibitor indicated: • in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test. ( 1.1 , 2.1 ) • in combination with encorafenib, for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test. ( 1.2 , 2.1 ) uuid:45cb6813-138f-4885-a7ff-6c77cd8b9f41 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1664312 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:7fcee91d-39a9-4775-9484-7f564430a902"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:4db79555-f36e-4ec6-8110-98bbf0711384"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:57bf8086-b0d0-460f-8546-ea927836d082"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/synjardy""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] SYNJARDY SYNJARDY is a combination of empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor and metformin hydrochloride (HCl) immediate-release, a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. SYNJARDY XR SYNJARDY XR is a combination of empagliflozin, a SGLT2 inhibitor and metformin HCl extended-release, a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus . Empagliflozin Empagliflozin, when used as a component of SYNJARDY or SYNJARDY XR, is indicated in adults with type 2 diabetes mellitus to reduce the risk of: Cardiovascular (CV) death in adults with established CV disease. ( 1 ) CV death and hospitalization for heart failure in adults with heart failure. ( 1 ) Sustained decline in eGFR, end-stage kidney disease, CV death, and hospitalization in adults with chronic kidney disease at risk of progression. ( 1 ) Limitations of Use : Not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus. It may increase the risk of diabetic ketoacidosis in these patients. ( 1 ) Because of the metformin HCl component, the use of SYNJARDY or SYNJARDY XR is limited to patients with type 2 diabetes mellitus for all indications. ( 1 ) Empagliflozin, when used as a component of SYNJARDY or SYNJARDY XR, is not recommended for the treatment of chronic kidney disease in patients with polycystic kidney disease or patients requiring or with a recent history of intravenous immunosuppressive therapy or greater than 45 mg of prednisone or equivalent for kidney disease. Empagliflozin is not expected to be effective in these populations. ( 1 )|[EMA] Synjardy is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:in patients inadequately controlled on their maximally tolerated dose of metformin alone;in patients inadequately controlled with metformin in combination with other glucose-lowering medicinal products, including insulin;in patients already being treated with the combination of empagliflozin and metformin as separate tablets. uuid:afea5bb4-e1e4-4a1b-9998-ce981ffad2b5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1664312 biolink:treats MONDO:0004995 PMID:41385096 "[{""id"":""uuid:852a778e-dc00-4e9c-8587-29757dbb2992"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ac986f11-6e01-4f05-8b32-da3ccaf68a47"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SYNJARDY SYNJARDY is a combination of empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor and metformin hydrochloride (HCl) immediate-release, a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. SYNJARDY XR SYNJARDY XR is a combination of empagliflozin, a SGLT2 inhibitor and metformin HCl extended-release, a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus . Empagliflozin Empagliflozin, when used as a component of SYNJARDY or SYNJARDY XR, is indicated in adults with type 2 diabetes mellitus to reduce the risk of: Cardiovascular (CV) death in adults with established CV disease. ( 1 ) CV death and hospitalization for heart failure in adults with heart failure. ( 1 ) Sustained decline in eGFR, end-stage kidney disease, CV death, and hospitalization in adults with chronic kidney disease at risk of progression. ( 1 ) Limitations of Use : Not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus. It may increase the risk of diabetic ketoacidosis in these patients. ( 1 ) Because of the metformin HCl component, the use of SYNJARDY or SYNJARDY XR is limited to patients with type 2 diabetes mellitus for all indications. ( 1 ) Empagliflozin, when used as a component of SYNJARDY or SYNJARDY XR, is not recommended for the treatment of chronic kidney disease in patients with polycystic kidney disease or patients requiring or with a recent history of intravenous immunosuppressive therapy or greater than 45 mg of prednisone or equivalent for kidney disease. Empagliflozin is not expected to be effective in these populations. ( 1 ) uuid:98336eed-cd47-4f26-9b5b-80c47f1d2862 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1664312 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:ed57818a-07fb-4b92-9c42-513903d33be3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2f96205d-7c7a-453d-944b-9b6f372a6eef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SYNJARDY SYNJARDY is a combination of empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor and metformin hydrochloride (HCl) immediate-release, a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. SYNJARDY XR SYNJARDY XR is a combination of empagliflozin, a SGLT2 inhibitor and metformin HCl extended-release, a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus . Empagliflozin Empagliflozin, when used as a component of SYNJARDY or SYNJARDY XR, is indicated in adults with type 2 diabetes mellitus to reduce the risk of: Cardiovascular (CV) death in adults with established CV disease. ( 1 ) CV death and hospitalization for heart failure in adults with heart failure. ( 1 ) Sustained decline in eGFR, end-stage kidney disease, CV death, and hospitalization in adults with chronic kidney disease at risk of progression. ( 1 ) Limitations of Use : Not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus. It may increase the risk of diabetic ketoacidosis in these patients. ( 1 ) Because of the metformin HCl component, the use of SYNJARDY or SYNJARDY XR is limited to patients with type 2 diabetes mellitus for all indications. ( 1 ) Empagliflozin, when used as a component of SYNJARDY or SYNJARDY XR, is not recommended for the treatment of chronic kidney disease in patients with polycystic kidney disease or patients requiring or with a recent history of intravenous immunosuppressive therapy or greater than 45 mg of prednisone or equivalent for kidney disease. Empagliflozin is not expected to be effective in these populations. ( 1 ) uuid:7b82240e-dd51-4487-bc00-debc476e416d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1664312 biolink:treats MONDO:0005300 PMID:41385096 "[{""id"":""uuid:dd503375-6794-4bb4-8c5a-925708e65e5e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bef76f34-be87-4988-add3-b13670b7fb98"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SYNJARDY SYNJARDY is a combination of empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor and metformin hydrochloride (HCl) immediate-release, a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. SYNJARDY XR SYNJARDY XR is a combination of empagliflozin, a SGLT2 inhibitor and metformin HCl extended-release, a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus . Empagliflozin Empagliflozin, when used as a component of SYNJARDY or SYNJARDY XR, is indicated in adults with type 2 diabetes mellitus to reduce the risk of: Cardiovascular (CV) death in adults with established CV disease. ( 1 ) CV death and hospitalization for heart failure in adults with heart failure. ( 1 ) Sustained decline in eGFR, end-stage kidney disease, CV death, and hospitalization in adults with chronic kidney disease at risk of progression. ( 1 ) Limitations of Use : Not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus. It may increase the risk of diabetic ketoacidosis in these patients. ( 1 ) Because of the metformin HCl component, the use of SYNJARDY or SYNJARDY XR is limited to patients with type 2 diabetes mellitus for all indications. ( 1 ) Empagliflozin, when used as a component of SYNJARDY or SYNJARDY XR, is not recommended for the treatment of chronic kidney disease in patients with polycystic kidney disease or patients requiring or with a recent history of intravenous immunosuppressive therapy or greater than 45 mg of prednisone or equivalent for kidney disease. Empagliflozin is not expected to be effective in these populations. ( 1 ) uuid:ca0ab270-4a2b-4144-9d9c-f0460bb8ae31 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1664312 biolink:treats MONDO:0005147 PMID:41385096 "[{""id"":""uuid:0da9eb45-f243-41ef-8122-a33de5aa7e3d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5cd99d9c-1562-4697-b904-eac0a57b6dad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SYNJARDY SYNJARDY is a combination of empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor and metformin hydrochloride (HCl) immediate-release, a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. SYNJARDY XR SYNJARDY XR is a combination of empagliflozin, a SGLT2 inhibitor and metformin HCl extended-release, a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus . Empagliflozin Empagliflozin, when used as a component of SYNJARDY or SYNJARDY XR, is indicated in adults with type 2 diabetes mellitus to reduce the risk of: Cardiovascular (CV) death in adults with established CV disease. ( 1 ) CV death and hospitalization for heart failure in adults with heart failure. ( 1 ) Sustained decline in eGFR, end-stage kidney disease, CV death, and hospitalization in adults with chronic kidney disease at risk of progression. ( 1 ) Limitations of Use : Not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus. It may increase the risk of diabetic ketoacidosis in these patients. ( 1 ) Because of the metformin HCl component, the use of SYNJARDY or SYNJARDY XR is limited to patients with type 2 diabetes mellitus for all indications. ( 1 ) Empagliflozin, when used as a component of SYNJARDY or SYNJARDY XR, is not recommended for the treatment of chronic kidney disease in patients with polycystic kidney disease or patients requiring or with a recent history of intravenous immunosuppressive therapy or greater than 45 mg of prednisone or equivalent for kidney disease. Empagliflozin is not expected to be effective in these populations. ( 1 ) uuid:1fbfeced-ece2-487a-a909-7a7615dc2985 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1664312 biolink:treats MONDO:0012819 PMID:41385096 "[{""id"":""uuid:cb38b9f2-207d-4f7d-b353-d8bd03b98281"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a07ecc52-6329-4e4c-a15a-7da547caa4eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SYNJARDY SYNJARDY is a combination of empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor and metformin hydrochloride (HCl) immediate-release, a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. SYNJARDY XR SYNJARDY XR is a combination of empagliflozin, a SGLT2 inhibitor and metformin HCl extended-release, a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus . Empagliflozin Empagliflozin, when used as a component of SYNJARDY or SYNJARDY XR, is indicated in adults with type 2 diabetes mellitus to reduce the risk of: Cardiovascular (CV) death in adults with established CV disease. ( 1 ) CV death and hospitalization for heart failure in adults with heart failure. ( 1 ) Sustained decline in eGFR, end-stage kidney disease, CV death, and hospitalization in adults with chronic kidney disease at risk of progression. ( 1 ) Limitations of Use : Not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus. It may increase the risk of diabetic ketoacidosis in these patients. ( 1 ) Because of the metformin HCl component, the use of SYNJARDY or SYNJARDY XR is limited to patients with type 2 diabetes mellitus for all indications. ( 1 ) Empagliflozin, when used as a component of SYNJARDY or SYNJARDY XR, is not recommended for the treatment of chronic kidney disease in patients with polycystic kidney disease or patients requiring or with a recent history of intravenous immunosuppressive therapy or greater than 45 mg of prednisone or equivalent for kidney disease. Empagliflozin is not expected to be effective in these populations. ( 1 ) uuid:dcb4a72a-2a19-41ff-8f35-f170d2d58cf8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1664312 biolink:treats MONDO:0020642 PMID:41385096 "[{""id"":""uuid:c8341b67-797a-4918-95b1-ea3f8f873cc4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ddc5d7cb-9841-4e91-8de2-bdc7dff92935"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SYNJARDY SYNJARDY is a combination of empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor and metformin hydrochloride (HCl) immediate-release, a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. SYNJARDY XR SYNJARDY XR is a combination of empagliflozin, a SGLT2 inhibitor and metformin HCl extended-release, a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus . Empagliflozin Empagliflozin, when used as a component of SYNJARDY or SYNJARDY XR, is indicated in adults with type 2 diabetes mellitus to reduce the risk of: Cardiovascular (CV) death in adults with established CV disease. ( 1 ) CV death and hospitalization for heart failure in adults with heart failure. ( 1 ) Sustained decline in eGFR, end-stage kidney disease, CV death, and hospitalization in adults with chronic kidney disease at risk of progression. ( 1 ) Limitations of Use : Not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus. It may increase the risk of diabetic ketoacidosis in these patients. ( 1 ) Because of the metformin HCl component, the use of SYNJARDY or SYNJARDY XR is limited to patients with type 2 diabetes mellitus for all indications. ( 1 ) Empagliflozin, when used as a component of SYNJARDY or SYNJARDY XR, is not recommended for the treatment of chronic kidney disease in patients with polycystic kidney disease or patients requiring or with a recent history of intravenous immunosuppressive therapy or greater than 45 mg of prednisone or equivalent for kidney disease. Empagliflozin is not expected to be effective in these populations. ( 1 ) uuid:a0b649e6-7120-49f5-97e6-c05f23aa4f5a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:229652 biolink:treats MONDO:0100244 PMID:41385096 "[{""id"":""uuid:6f7dfc47-e525-4e64-95a2-5b832735fa36"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d1382fc8-81c1-462e-8787-906cdfe552b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FABHALTA is a complement factor B inhibitor, indicated for: the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH). ( 1.1 ) the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥ 1.5 g/g. ( 1.2 ) This indication is approved under accelerated approval based on reduction of proteinuria. It has not been established whether FABHALTA slows kidney function decline in patients with IgAN. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory clinical trial. the treatment of adults with complement 3 glomerulopathy (C3G), to reduce proteinuria. ( 1.3 ) uuid:5bf112cd-1ed8-4b6b-bb37-908f757bada1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:229652 biolink:treats MONDO:0005342 PMID:41385096 "[{""id"":""uuid:29cf6998-0664-45fc-9684-33e311b3f9dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2773a9f1-e48c-4263-a217-6f821bc0984d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FABHALTA is a complement factor B inhibitor, indicated for: the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH). ( 1.1 ) the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥ 1.5 g/g. ( 1.2 ) This indication is approved under accelerated approval based on reduction of proteinuria. It has not been established whether FABHALTA slows kidney function decline in patients with IgAN. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory clinical trial. the treatment of adults with complement 3 glomerulopathy (C3G), to reduce proteinuria. ( 1.3 ) uuid:935a1794-176c-42fb-a0f7-2fbab6625c79 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3JB47N2Q2P biolink:treats MONDO:0005301 PMID:41385096 "[{""id"":""uuid:3c678a34-b853-4e27-8bd6-013d4fda0319"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4473293d-c366-4f40-a4b7-e6b41de8520b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:4ba75319-a0dc-41f6-b0f4-bb5208d98a4b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TYSABRI is an integrin receptor antagonist indicated for treatment of: Multiple Sclerosis (MS) TYSABRI is indicated as monotherapy for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. TYSABRI increases the risk of PML [See Warnings and Precautions ( 5.1 ) ]. When initiating and continuing treatment with TYSABRI, physicians should consider whether the expected benefit of TYSABRI is sufficient to offset this risk. ( 1.1 ) Crohn's Disease (CD) TYSABRI is indicated for inducing and maintaining clinical response and remission in adult patients with moderately to severely active Crohn's disease with evidence of inflammation who have had an inadequate response to, or are unable to tolerate, conventional CD therapies and inhibitors of TNF-α. ( 1.2 ) Important Limitations: In CD, TYSABRI should not be used in combination with immunosuppressants or inhibitors of TNF-α. ( 1.2 )|[PMDA] A drug with a new active ingredient indicated for the prevention of relapse and for delaying the accumulation of physical disability in multiple sclerosis. [Orphan drug] uuid:fd7be1b9-dd4b-49ea-89eb-7f9e8b09f380 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3JB47N2Q2P biolink:treats UMLS:C2921627 PMID:41385096 "[{""id"":""uuid:d9f4e00b-8f27-4a66-8a1b-62c4af2a2317"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:218c8056-079d-4e18-90c9-a224d2972bd8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TYSABRI is an integrin receptor antagonist indicated for treatment of: Multiple Sclerosis (MS) TYSABRI is indicated as monotherapy for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. TYSABRI increases the risk of PML [See Warnings and Precautions ( 5.1 ) ]. When initiating and continuing treatment with TYSABRI, physicians should consider whether the expected benefit of TYSABRI is sufficient to offset this risk. ( 1.1 ) Crohn's Disease (CD) TYSABRI is indicated for inducing and maintaining clinical response and remission in adult patients with moderately to severely active Crohn's disease with evidence of inflammation who have had an inadequate response to, or are unable to tolerate, conventional CD therapies and inhibitors of TNF-α. ( 1.2 ) Important Limitations: In CD, TYSABRI should not be used in combination with immunosuppressants or inhibitors of TNF-α. ( 1.2 ) uuid:996552bb-bf66-4a74-81a4-8e50c9ebc866 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3JB47N2Q2P biolink:treats MONDO:0000450 PMID:41385096 "[{""id"":""uuid:4ed6175b-e5fb-4121-b560-03dd578f303a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0f8aafd8-51ce-48ef-b971-6b56aefecad8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TYSABRI is an integrin receptor antagonist indicated for treatment of: Multiple Sclerosis (MS) TYSABRI is indicated as monotherapy for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. TYSABRI increases the risk of PML [See Warnings and Precautions ( 5.1 ) ]. When initiating and continuing treatment with TYSABRI, physicians should consider whether the expected benefit of TYSABRI is sufficient to offset this risk. ( 1.1 ) Crohn's Disease (CD) TYSABRI is indicated for inducing and maintaining clinical response and remission in adult patients with moderately to severely active Crohn's disease with evidence of inflammation who have had an inadequate response to, or are unable to tolerate, conventional CD therapies and inhibitors of TNF-α. ( 1.2 ) Important Limitations: In CD, TYSABRI should not be used in combination with immunosuppressants or inhibitors of TNF-α. ( 1.2 ) uuid:93d17c47-a566-4f22-8f37-bfd5dfbc5b35 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3JB47N2Q2P biolink:treats MONDO:0005011 PMID:41385096 "[{""id"":""uuid:7832ac3b-90fa-4c74-b61c-eed91d60ec75"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3b213f18-39c7-454c-bb98-4d90c3529c80"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TYSABRI is an integrin receptor antagonist indicated for treatment of: Multiple Sclerosis (MS) TYSABRI is indicated as monotherapy for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. TYSABRI increases the risk of PML [See Warnings and Precautions ( 5.1 ) ]. When initiating and continuing treatment with TYSABRI, physicians should consider whether the expected benefit of TYSABRI is sufficient to offset this risk. ( 1.1 ) Crohn's Disease (CD) TYSABRI is indicated for inducing and maintaining clinical response and remission in adult patients with moderately to severely active Crohn's disease with evidence of inflammation who have had an inadequate response to, or are unable to tolerate, conventional CD therapies and inhibitors of TNF-α. ( 1.2 ) Important Limitations: In CD, TYSABRI should not be used in combination with immunosuppressants or inhibitors of TNF-α. ( 1.2 ) uuid:8f9d6797-24ac-4df2-8649-840e822b0447 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:82698 biolink:treats MONDO:0013600 PMID:41385096 "[{""id"":""uuid:445ea5cc-dd57-4678-982b-b4f5624e119d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:264166ae-db0e-4270-b74d-01af93604e2f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:71be68dc-9651-40de-be29-ba3036b8715b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BELSOMRA ® (suvorexant) is indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.|[PMDA] Drugs with a new active ingredient indicated for the treatment of insomnia. uuid:5478b921-5202-4e8b-a4a0-0b25b91201f4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEMBL.COMPOUND:CHEMBL2108334 biolink:treats MONDO:0010602 PMID:41385096 "[{""id"":""uuid:477ec578-9fbb-4f7a-ae76-dcea0db1ee2e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:49d4c3e1-6f84-4c92-86ba-ebb84eed0cfc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SEVENFACT [coagulation factor VIIa (recombinant)-jncw] is indicated for the treatment and control of bleeding episodes occurring in adults and adolescents (12 years of age and older) with hemophilia A or B with inhibitors. Limitation of Use: SEVENFACT is not indicated for the treatment of patients with congenital Factor VII deficiency. uuid:2882f6c7-245c-4c7b-b17b-84d4fd81af78 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEMBL.COMPOUND:CHEMBL2108334 biolink:treats MONDO:0010604 PMID:41385096 "[{""id"":""uuid:6fd6a346-ad13-4261-949d-ccad26a8f334"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e9fd4a84-13aa-4fa2-80d3-fce671b924ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SEVENFACT [coagulation factor VIIa (recombinant)-jncw] is indicated for the treatment and control of bleeding episodes occurring in adults and adolescents (12 years of age and older) with hemophilia A or B with inhibitors. Limitation of Use: SEVENFACT is not indicated for the treatment of patients with congenital Factor VII deficiency. uuid:4f6021f0-9cb7-4c27-bc02-1f10b46e01c9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEMBL.COMPOUND:CHEMBL2108334 biolink:treats MONDO:0009211 PMID:41385096 "[{""id"":""uuid:edea7217-f6fd-43a1-836b-bd9cef719734"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e1232b98-fd67-44a3-be98-692852e42e39"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:cfa251a2-4839-4247-98e2-7310f4e3cdcd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SEVENFACT [coagulation factor VIIa (recombinant)-jncw] is indicated for the treatment and control of bleeding episodes occurring in adults and adolescents (12 years of age and older) with hemophilia A or B with inhibitors. Limitation of Use: SEVENFACT is not indicated for the treatment of patients with congenital Factor VII deficiency.|[PMDA] Drugs with a new additional indication and a new dosage for inhibition of bleeding tendency in patients with congenital factor VII deficiency. uuid:c0d8d484-58af-4c9f-86e8-26b6d3ef9425 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:J3LVA7RZT2 biolink:treats UMLS:C5231121 PMID:41385096 "[{""id"":""uuid:1a82753d-96c2-4b3f-88c5-a5c9fa702ab1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0eba56b2-19d5-49ee-a435-389f3402b13f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ENCELTO is indicated for the treatment of adults with idiopathic macular telangiectasia type 2 (MacTel). uuid:bf5bf9a1-ed72-4ae4-88cb-537158025f3b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5108 biolink:treats MONDO:0004728 PMID:41385096 "[{""id"":""uuid:cab8778e-ea9a-4846-9978-144e653824e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:05341a7c-8cf2-4b1a-9130-a14e1e7be021"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ILUVIEN is a corticosteroid indicated for: the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure. (1.1) the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. (1.2) uuid:00178679-5425-457c-974c-67eb48ed32d2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41948 biolink:treats MONDO:0005072 PMID:41385096 "[{""id"":""uuid:4332fc59-3733-44c7-a5f2-d14d0b7a386b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3ccd6ffe-dd8b-4fe7-84f1-4a041c683f00"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] IWILFIN (eflornithine) is indicated to reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma (HRNB) who have demonstrated at least a partial response to prior multiagent, multimodality therapy including anti-GD2 immunotherapy. uuid:f636f494-98bf-4d68-8e7a-160e9f61d19e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2637 biolink:treats MONDO:0005866 PMID:41385096 "[{""id"":""uuid:42ee720b-0a30-41fa-be6d-1eec058ed390"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9931b24a-b5d5-407e-ac49-6e864d23171d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:18770e8f-dcd7-4076-a8fe-1763e0560d2f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:aa3a87f5-0193-4e78-b8d9-fd70b4697f30"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LIMITED POPULATION: ARIKAYCE ® is indicated in adults, who have limited or no alternative treatment options, for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen in patients who do not achieve negative sputum cultures after a minimum of 6 consecutive months of a multidrug background regimen therapy. As only limited clinical safety and effectiveness data for ARIKAYCE are currently available, reserve ARIKAYCE for use in adults who have limited or no alternative treatment options . This drug is indicated for use in a limited and specific population of patients. This indication is approved under accelerated approval based on achieving sputum culture conversion (defined as 3 consecutive negative monthly sputum cultures) by Month 6. Clinical benefit has not yet been established [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials .|[EMA] Arikayce liposomal is indicated for the treatment of non-tuberculous mycobacterial (NTM) lung infections caused by Mycobacterium avium Complex (MAC) in adults with limited treatment options who do not have cystic fibrosis.|[PMDA] A drug with a new route of administration indicated for the treatment of nontuberculous mycobacterial pulmonary disease caused by amikacin-sensitive Mycobacterium avium complex (MAC). uuid:d24f0581-fb82-4422-9409-7982f0709fd1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DVF0PR037D biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:8c2b6fb3-2960-4ccc-be61-00a0b70f9aaa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f3d8d455-6808-4e3b-aaff-5772aa9826e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BLUJEPA is a triazaacenaphthylene bacterial type II topoisomerase inhibitor indicated for the treatment of female adult and pediatric patients 12 years of age and older weighing at least 40 kilograms (kg) with uncomplicated urinary tract infections (uUTI) caused by the following susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii complex , Staphylococcus saprophyticus, and Enterococcus faecalis . ( 1.1 ) Usage to Reduce Development of Drug-Resistant Bacteria To reduce the development of drug-resistant bacteria and maintain the effectiveness of BLUJEPA and other antibacterial drugs, BLUJEPA should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. ( 1.2 ) uuid:02acd63a-d69b-42f7-8c41-fb83c76ad698 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DVF0PR037D biolink:treats MONDO:0020920 PMID:41385096 "[{""id"":""uuid:e9590476-36ef-4068-88ec-7c205d9f4088"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7e94d313-fd0a-4539-89d2-52a9d87d4bcb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BLUJEPA is a triazaacenaphthylene bacterial type II topoisomerase inhibitor indicated for the treatment of female adult and pediatric patients 12 years of age and older weighing at least 40 kilograms (kg) with uncomplicated urinary tract infections (uUTI) caused by the following susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii complex , Staphylococcus saprophyticus, and Enterococcus faecalis . ( 1.1 ) Usage to Reduce Development of Drug-Resistant Bacteria To reduce the development of drug-resistant bacteria and maintain the effectiveness of BLUJEPA and other antibacterial drugs, BLUJEPA should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. ( 1.2 ) uuid:ae970557-9129-482b-8aa5-ed57b9f0b320 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DVF0PR037D biolink:treats UMLS:C0948802 PMID:41385096 "[{""id"":""uuid:6abb603d-a32c-4cff-ba66-a10b12e4ca7e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:463c4b1b-7186-4c0c-8fe8-f03c9addb7f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BLUJEPA is a triazaacenaphthylene bacterial type II topoisomerase inhibitor indicated for the treatment of female adult and pediatric patients 12 years of age and older weighing at least 40 kilograms (kg) with uncomplicated urinary tract infections (uUTI) caused by the following susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii complex , Staphylococcus saprophyticus, and Enterococcus faecalis . ( 1.1 ) Usage to Reduce Development of Drug-Resistant Bacteria To reduce the development of drug-resistant bacteria and maintain the effectiveness of BLUJEPA and other antibacterial drugs, BLUJEPA should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. ( 1.2 ) uuid:0d920476-250a-4109-a285-1c3430acd33e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DVF0PR037D biolink:treats UMLS:C1142267 PMID:41385096 "[{""id"":""uuid:16ab2e29-7326-468a-8791-827527f0ad07"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4c6e3e9e-1196-4eec-81f8-60bb1298a642"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BLUJEPA is a triazaacenaphthylene bacterial type II topoisomerase inhibitor indicated for the treatment of female adult and pediatric patients 12 years of age and older weighing at least 40 kilograms (kg) with uncomplicated urinary tract infections (uUTI) caused by the following susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii complex , Staphylococcus saprophyticus, and Enterococcus faecalis . ( 1.1 ) Usage to Reduce Development of Drug-Resistant Bacteria To reduce the development of drug-resistant bacteria and maintain the effectiveness of BLUJEPA and other antibacterial drugs, BLUJEPA should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. ( 1.2 ) uuid:b5111574-22b2-4a46-81c4-454875863d90 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DVF0PR037D biolink:treats MONDO:0005121 PMID:41385096 "[{""id"":""uuid:0b46d929-0ddc-42b9-bd4b-749d33de4e07"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:18171f6d-f329-4a3a-889c-339a582a479d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BLUJEPA is a triazaacenaphthylene bacterial type II topoisomerase inhibitor indicated for the treatment of female adult and pediatric patients 12 years of age and older weighing at least 40 kilograms (kg) with uncomplicated urinary tract infections (uUTI) caused by the following susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii complex , Staphylococcus saprophyticus, and Enterococcus faecalis . ( 1.1 ) Usage to Reduce Development of Drug-Resistant Bacteria To reduce the development of drug-resistant bacteria and maintain the effectiveness of BLUJEPA and other antibacterial drugs, BLUJEPA should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. ( 1.2 ) uuid:c816d959-3492-4967-95a2-48265a09c30c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2636536 biolink:treats EFO:0009130 PMID:41385096 "[{""id"":""uuid:27c5e8d0-9e5a-4a14-a32c-0b80edfa2788"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3e61a5ae-fdcb-4879-bd08-299f270b260d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VOWST is indicated to prevent the recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older following antibacterial treatment for recurrent CDI (rCDI). uuid:664c7be2-3331-4864-90cc-c07f1361ed5a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2636536 biolink:treats UMLS:C5230640 PMID:41385096 "[{""id"":""uuid:bf27c253-bb4c-4e58-abc0-28059a66d280"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a6cd6788-defd-4976-93d5-4cb2fc37bb0f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VOWST is indicated to prevent the recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older following antibacterial treatment for recurrent CDI (rCDI). uuid:2dc2cee7-b9eb-4db5-b0f7-bfe14398f11a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63633 biolink:treats MONDO:0008315 PMID:41385096 "[{""id"":""uuid:f6421057-a129-4b01-bcd5-d029f41ad823"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cf1e318f-b873-4f0d-97fa-7e27925ee409"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TRELSTAR is indicated for the treatment of advanced prostate cancer [ see Clinical Studies (14) ]. uuid:43e57148-3f7f-4ded-b522-d0487e1f0afe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:176844 biolink:treats MONDO:0018364 PMID:41385096 "[{""id"":""uuid:461cde0f-9e7c-4ea3-be60-e9f8a178fd42"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:92d9b884-7536-417b-b978-a85b44c653f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZEJULA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated: • for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy. ( 1.1 ) • for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA -mutated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for ZEJULA ( 1.2 , 2.1 ) uuid:da65e78b-214d-4a06-b4d5-d43ca63a51d5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:176844 biolink:treats MONDO:0002158 PMID:41385096 "[{""id"":""uuid:9ff455bf-896c-4b55-bfa1-d4c330e90c9c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:48da26d0-a9c2-4961-9204-806869bb1e56"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:cf04a251-b6e6-494a-8965-6e1a2d3e0a35"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZEJULA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated: • for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy. ( 1.1 ) • for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA -mutated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for ZEJULA ( 1.2 , 2.1 )|[EMA] Zejula is indicated:, , , as monotherapy for the maintenance treatment of adult patients with advanced epithelial (FIGO Stages III and IV) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy., as monotherapy for the maintenance treatment of adult patients with platinum sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy., , uuid:9f987ba0-a028-464e-9147-ac9ad99f56e1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:176844 biolink:treats MONDO:0015686 PMID:41385096 "[{""id"":""uuid:fa2e4f32-ca58-4882-ad1b-b74b62865744"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:515b007d-35af-4af5-a41a-4bb5a71b1565"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:367769e9-5ac2-499b-86f5-9a22f70ff101"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZEJULA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated: • for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy. ( 1.1 ) • for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA -mutated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for ZEJULA ( 1.2 , 2.1 )|[EMA] Zejula is indicated:, , , as monotherapy for the maintenance treatment of adult patients with advanced epithelial (FIGO Stages III and IV) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy., as monotherapy for the maintenance treatment of adult patients with platinum sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy., , uuid:fe1c9242-b4d6-4c76-9c9d-96f9c48012ff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:176844 biolink:treats UMLS:C3897738 PMID:41385096 "[{""id"":""uuid:39b14406-2829-4b77-9bdd-1e5baa3d9ee8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f80fcb66-6ab2-442e-a194-fff004909e01"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZEJULA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated: • for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy. ( 1.1 ) • for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA -mutated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for ZEJULA ( 1.2 , 2.1 ) uuid:ca183f9a-4e2e-4faa-b6f8-f8bc1b8a59f2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:176844 biolink:treats UMLS:C3897731 PMID:41385096 "[{""id"":""uuid:05d09df2-fc68-473a-ac6f-b73fbdaef723"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f12860aa-2520-4560-bfb4-5322089b9f1e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZEJULA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated: • for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy. ( 1.1 ) • for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA -mutated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for ZEJULA ( 1.2 , 2.1 ) uuid:189b90e8-2082-4b8f-92ad-f8725d65e988 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2W150K0UUC biolink:treats MONDO:0015762 PMID:41385096 "[{""id"":""uuid:2edc4db7-dc20-4baa-a20a-09a65d256213"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:33ef799d-a9fe-4d65-a40f-38780feab582"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:0faf390a-ec39-433f-83e1-33533c9797e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/bylvay""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] BYLVAY is an ileal bile acid transporter (IBAT) inhibitor indicated for: Progressive Familial Intrahepatic Cholestasis (PFIC) the treatment of pruritus in patients 3 months of age and older with progressive familial intrahepatic cholestasis (PFIC). ( 1.1 ) Limitation of Use : BYLVAY may not be effective in a subgroup of PFIC type 2 patients with specific ABCB11 variants resulting in non-functional or complete absence of the bile salt export pump protein. ( 1.1 , 12.5 , 14 ) Alagille Syndrome (ALGS) the treatment of cholestatic pruritus in patients 12 months of age and older with Alagille syndrome (ALGS). ( 1.2 )|[EMA] Bylvay is indicated for the treatment of progressive familial intrahepatic cholestasis (PFIC) in patients aged 6 months or older (see sections 4.4 and 5.1). uuid:fcaf2001-4b5c-4de5-b1e1-0be8f5211f44 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2W150K0UUC biolink:treats HP:0000989 PMID:41385096 "[{""id"":""uuid:806a43fc-9974-4024-8ce7-eebaa03c3aeb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e29f32a2-e762-46f1-bda4-e4d162bac49b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BYLVAY is an ileal bile acid transporter (IBAT) inhibitor indicated for: Progressive Familial Intrahepatic Cholestasis (PFIC) the treatment of pruritus in patients 3 months of age and older with progressive familial intrahepatic cholestasis (PFIC). ( 1.1 ) Limitation of Use : BYLVAY may not be effective in a subgroup of PFIC type 2 patients with specific ABCB11 variants resulting in non-functional or complete absence of the bile salt export pump protein. ( 1.1 , 12.5 , 14 ) Alagille Syndrome (ALGS) the treatment of cholestatic pruritus in patients 12 months of age and older with Alagille syndrome (ALGS). ( 1.2 ) uuid:f8be0632-c83d-4144-873b-078053e0157d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2W150K0UUC biolink:treats MONDO:0007318 PMID:41385096 "[{""id"":""uuid:2fd0e834-88db-4d56-8497-c0607419369a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:49d966ef-4d76-4ca3-aee9-de82f87b59b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BYLVAY is an ileal bile acid transporter (IBAT) inhibitor indicated for: Progressive Familial Intrahepatic Cholestasis (PFIC) the treatment of pruritus in patients 3 months of age and older with progressive familial intrahepatic cholestasis (PFIC). ( 1.1 ) Limitation of Use : BYLVAY may not be effective in a subgroup of PFIC type 2 patients with specific ABCB11 variants resulting in non-functional or complete absence of the bile salt export pump protein. ( 1.1 , 12.5 , 14 ) Alagille Syndrome (ALGS) the treatment of cholestatic pruritus in patients 12 months of age and older with Alagille syndrome (ALGS). ( 1.2 ) uuid:4873142b-3df4-48df-ad6f-3f139c495413 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2W150K0UUC biolink:treats UMLS:C1535964 PMID:41385096 "[{""id"":""uuid:44847c46-eb0d-4be2-af1d-efd6dceda1e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f4fdeb18-d0f2-4152-b1ec-d0f5091d4bf3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BYLVAY is an ileal bile acid transporter (IBAT) inhibitor indicated for: Progressive Familial Intrahepatic Cholestasis (PFIC) the treatment of pruritus in patients 3 months of age and older with progressive familial intrahepatic cholestasis (PFIC). ( 1.1 ) Limitation of Use : BYLVAY may not be effective in a subgroup of PFIC type 2 patients with specific ABCB11 variants resulting in non-functional or complete absence of the bile salt export pump protein. ( 1.1 , 12.5 , 14 ) Alagille Syndrome (ALGS) the treatment of cholestatic pruritus in patients 12 months of age and older with Alagille syndrome (ALGS). ( 1.2 ) uuid:9637ebbf-8e0e-47f3-b236-bb3b62943b6f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:15C2VL427D biolink:treats MONDO:0005417 PMID:41385096 "[{""id"":""uuid:b4c983cf-8586-45bd-bcf0-ca2a7d812f2c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:3f48ed8f-c327-41c5-aa86-c115d0f7ab94"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:d3d7ce5e-a616-4525-8c5c-e8b019be40d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/yesafili""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1 INDICATIONS AND USAGE AHZANTIVE is indicated for the treatment of: 1.1 Neovascular (Wet) Age-Related Macular Degeneration (AMD) 1.2 Macular Edema Following Retinal Vein Occlusion (RVO) 1.3 Diabetic Macular Edema (DME) 1.4 Diabetic Retinopathy (DR)|[EMA] Yesafili is indicated for adults for the treatment ofneovascular (wet) age-related macular degeneration (AMD) (see section 5.1),visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) (see section 5.1),visual impairment due to diabetic macular oedema (DME) (see section 5.1),visual impairment due to myopic choroidal neovascularisation (myopic CNV) (see section 5.1). uuid:d9ad5fa6-9d77-4ed6-82ad-9f548ff0c193 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:15C2VL427D biolink:treats MONDO:0041093 PMID:41385096 "[{""id"":""uuid:e0a28809-e5f5-406e-ba88-4c3b3963ea64"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b03483de-bcb8-42ff-861b-6ea22f21928a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:051aa68b-bcdb-441f-a4f8-de6ac94c830f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1 INDICATIONS AND USAGE AHZANTIVE is indicated for the treatment of: 1.1 Neovascular (Wet) Age-Related Macular Degeneration (AMD) 1.2 Macular Edema Following Retinal Vein Occlusion (RVO) 1.3 Diabetic Macular Edema (DME) 1.4 Diabetic Retinopathy (DR)|[PMDA] Drugs with a revised indication for the treatment of macular edema following retinal vein occlusion. uuid:c58ae9c1-5a1c-4096-9750-46ea021d708b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:15C2VL427D biolink:treats MONDO:0004728 PMID:41385096 "[{""id"":""uuid:431a9a2f-2d8f-4b5c-bb52-4b85681c651b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:65774eac-f23d-4562-a5e0-8ec973f8dace"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ca8559c4-6068-4d0c-aa9a-bb8ff0278887"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/yesafili""]},{""id"":""uuid:e7748034-22b1-47fc-9ba9-42047ffe3b83"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1 INDICATIONS AND USAGE AHZANTIVE is indicated for the treatment of: 1.1 Neovascular (Wet) Age-Related Macular Degeneration (AMD) 1.2 Macular Edema Following Retinal Vein Occlusion (RVO) 1.3 Diabetic Macular Edema (DME) 1.4 Diabetic Retinopathy (DR)|[EMA] Yesafili is indicated for adults for the treatment ofneovascular (wet) age-related macular degeneration (AMD) (see section 5.1),visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) (see section 5.1),visual impairment due to diabetic macular oedema (DME) (see section 5.1),visual impairment due to myopic choroidal neovascularisation (myopic CNV) (see section 5.1).|[PMDA] A drug in a new dosage form indicated for the treatment of age-related macular degeneration associated with subfoveal choroidal neovascularization and diabetic macular edema. uuid:e1182381-02a0-485b-bb48-543b6da40320 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:15C2VL427D biolink:treats MONDO:0005266 PMID:41385096 "[{""id"":""uuid:1b0cf65c-fee0-4864-9507-e2d8f6b93f36"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9cf7da00-296a-44e4-b092-af78df43de96"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1 INDICATIONS AND USAGE AHZANTIVE is indicated for the treatment of: 1.1 Neovascular (Wet) Age-Related Macular Degeneration (AMD) 1.2 Macular Edema Following Retinal Vein Occlusion (RVO) 1.3 Diabetic Macular Edema (DME) 1.4 Diabetic Retinopathy (DR) uuid:e448344b-76b3-4312-9922-ef8a3ff7b2bc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:88249 biolink:treats MONDO:0003304 PMID:41385096 "[{""id"":""uuid:050748c1-34e5-4754-a1d3-5396b4902873"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:86813658-1a1b-4e24-a051-175b614ecd93"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] GOMEKLI is indicated for the treatment of adult and pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) not amenable to complete resection [see Clinical Studies (14) ]. uuid:1ebffce8-0a31-4bc6-8833-1a96829801fe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134699 biolink:treats MONDO:0005180 PMID:41385096 "[{""id"":""uuid:bd108456-90f2-4d16-95ba-b9d1b404b724"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:38680fc6-13cb-4777-b918-f52ee00fac62"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:39c83517-5cf6-4122-a0a3-bde323d3a155"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ontilyv""]},{""id"":""uuid:f28a3021-5f58-40ed-aab9-510858ffbec6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ONGENTYS is indicated as adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease (PD) experiencing “off” episodes.|[EMA] Ontilyv is indicated as adjunctive therapy to preparations of levodopa/ DOPA decarboxylase inhibitors (DDCI) in adult patients with Parkinson’s disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.|[PMDA] A drug with a new active ingredient indicated for the improvement of wearing-off phenomenon in patients with Parkinson’s disease in combination with levodopa/carbidopa or levodopa/benserazide hydrochloride. uuid:01554159-af87-4e79-b16a-711d872fcc71 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:127780 biolink:treats MONDO:0043905 PMID:41385096 "[{""id"":""uuid:66d95bb0-bfb5-4961-b36b-d6fbcf57e731"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:baa8674d-7170-4efe-96cc-8b0ca6e09019"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Foscarnet sodium injection is indicated for the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS). Combination therapy with foscarnet sodium and ganciclovir is indicated for patients who have relapsed after monotherapy with either drug. SAFETY AND EFFICACY OF FOSCARNET SODIUM INJETION HAVE NOT BEEN ESTABLISHED FOR TREATMENT OF OTHER CMV INFECTIONS (e.g., PNEUMONITIS, GASTROENTERITIS); CONGENITAL OR NEONATAL CMV DISEASE; OR NONIMMUNOCOMPROMISED INDIVIDUALS. uuid:dd2af994-d7db-4874-8bcd-2b1141c1f585 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:127780 biolink:treats MONDO:0002269 PMID:41385096 "[{""id"":""uuid:b2ab22b0-dff5-4f51-a8dd-cd07faa14b9a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cef9976a-3f66-445b-b2df-e94913192ff5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Foscarnet sodium injection is indicated for the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS). Combination therapy with foscarnet sodium and ganciclovir is indicated for patients who have relapsed after monotherapy with either drug. SAFETY AND EFFICACY OF FOSCARNET SODIUM INJETION HAVE NOT BEEN ESTABLISHED FOR TREATMENT OF OTHER CMV INFECTIONS (e.g., PNEUMONITIS, GASTROENTERITIS); CONGENITAL OR NEONATAL CMV DISEASE; OR NONIMMUNOCOMPROMISED INDIVIDUALS. uuid:f6ec71c3-fcb8-4fab-9811-6f17717e5dfe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:127780 biolink:treats MONDO:0017409 PMID:41385096 "[{""id"":""uuid:3021898a-d318-4894-9e75-b5f863e6874f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8cc42b82-973a-482e-a3d4-607857fb243c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Foscarnet sodium injection is indicated for the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS). Combination therapy with foscarnet sodium and ganciclovir is indicated for patients who have relapsed after monotherapy with either drug. SAFETY AND EFFICACY OF FOSCARNET SODIUM INJETION HAVE NOT BEEN ESTABLISHED FOR TREATMENT OF OTHER CMV INFECTIONS (e.g., PNEUMONITIS, GASTROENTERITIS); CONGENITAL OR NEONATAL CMV DISEASE; OR NONIMMUNOCOMPROMISED INDIVIDUALS. uuid:82ae0452-417e-426c-9a88-86daabeaddbe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:127780 biolink:treats MONDO:0005132 PMID:41385096 "[{""id"":""uuid:683fa9c2-7b64-4694-afec-85cce583bcb4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5af75708-6d9e-45aa-9335-213d9d4759e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:9d03683c-40e3-460d-b2b0-0f4104857b3b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Foscarnet sodium injection is indicated for the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS). Combination therapy with foscarnet sodium and ganciclovir is indicated for patients who have relapsed after monotherapy with either drug. SAFETY AND EFFICACY OF FOSCARNET SODIUM INJETION HAVE NOT BEEN ESTABLISHED FOR TREATMENT OF OTHER CMV INFECTIONS (e.g., PNEUMONITIS, GASTROENTERITIS); CONGENITAL OR NEONATAL CMV DISEASE; OR NONIMMUNOCOMPROMISED INDIVIDUALS.|[PMDA] A drug with new additional indications and a new dosage for the treatment of cytomegalovirus viremia and cytomegalovirus infection in patients undergoing hematopoietic stem cell transplantation. uuid:04c8a83e-ab70-425b-8def-d311146e0408 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:119058042 biolink:treats MONDO:0010602 PMID:41385096 "[{""id"":""uuid:666ace49-cfe0-4259-86a8-14795125e940"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:233b76bb-a85a-405a-9723-7fec0e468c6e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] QFITLIA is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients aged 12 years and older with hemophilia A or B with or without factor VIII or IX inhibitors. uuid:66764fc5-f14e-4311-aca2-b6ef1fda0dad biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:119058042 biolink:treats MONDO:0010604 PMID:41385096 "[{""id"":""uuid:b0666628-c9dc-47f7-9fd1-9d2e4c12378d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8c8bec0c-05ba-4c6f-9be9-a3441d7df15a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] QFITLIA is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients aged 12 years and older with hemophilia A or B with or without factor VIII or IX inhibitors. uuid:e5a44886-9ff8-4ab8-8def-e79c36bfff54 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1989496 biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:20b11fba-a589-4b27-ac00-6e0fdd07fc83"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8aabc2a5-089c-4f31-8788-5a0f4ca9a3e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] JULUCA is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies/mL) on a stable antiretroviral regimen for at least 6 months with no history of treatment failure and no known substitutions associated with resistance to the individual components of JULUCA. uuid:cb158d40-392f-4add-be08-ed9de026fe31 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:GB4I2JI8UI biolink:treats MONDO:0007100 PMID:41385096 "[{""id"":""uuid:dbc09c7d-b250-49be-bed5-028ae06872ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8b89e6d3-0663-4a42-9622-8ac1d747b915"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ae1155b8-cc71-4ee1-a703-e8a0eac0bb72"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e457d7ff-0c63-4153-9a26-906d7c96bcfb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AMVUTTRA is a transthyretin-directed small interfering RNA indicated for the treatment of: the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults ( 1.1 ) the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failure visits ( 1.2 )|[EMA] Treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy.|[PMDA] A drug with a new active ingredient indicated for the treatment of transthyretin familial amyloid polyneuropathy. [Orphan drug] uuid:9650b8d1-c142-4d94-82e1-8f8c22300c5f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:GB4I2JI8UI biolink:treats MONDO:0018018 PMID:41385096 "[{""id"":""uuid:66821f0f-2183-421d-9bbe-ec7e6a6224ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:34c7bfc8-398b-41eb-aad1-2534f780dba3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AMVUTTRA is a transthyretin-directed small interfering RNA indicated for the treatment of: the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults ( 1.1 ) the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failure visits ( 1.2 ) uuid:fc04a87e-b87f-4e6c-8c0a-496afbf0e842 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:GB4I2JI8UI biolink:treats MONDO:0971008 PMID:41385096 "[{""id"":""uuid:4333f323-7a54-4c4b-905d-0ec367cfc600"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d58e303c-217b-4517-81ee-9affaf8acc13"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AMVUTTRA is a transthyretin-directed small interfering RNA indicated for the treatment of: the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults ( 1.1 ) the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failure visits ( 1.2 ) uuid:fbaeb679-9a6e-45bc-89df-efdb4894714f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:GB4I2JI8UI biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:801afc22-f16a-41d8-a8ec-4ea56e702b01"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:07cb4ab0-025e-40e8-8513-9a8d71a7f330"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AMVUTTRA is a transthyretin-directed small interfering RNA indicated for the treatment of: the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults ( 1.1 ) the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failure visits ( 1.2 ) uuid:8984f352-0eb4-4f79-a856-c60cd4c403b2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:G6UF363ECX biolink:treats MONDO:0004956 PMID:41385096 "[{""id"":""uuid:5ec7fc98-5f3f-48eb-a921-914131a45c03"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:47bbeb5d-7571-4ebd-9861-043eafba4fce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:6a50ca7a-950c-4256-84f4-d9129571d9e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PLUVICTO is indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor pathway inhibitor (ARPI) therapy, and are considered appropriate to delay taxane-based chemotherapy, or have received prior taxane-based chemotherapy.|[EMA] Pluvicto in combination with androgen deprivation therapy (ADT) with or without androgen receptor (AR) pathway inhibition is indicated for the treatment of adult patients with progressive prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with AR pathway inhibition and taxane based chemotherapy. uuid:f14ee0c2-e68f-4679-bf6b-8838a9d633c9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:231693 biolink:treats UMLS:C0278987 PMID:41385096 "[{""id"":""uuid:049d37b9-d260-4c58-96a1-9eba7f2d57a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:61d9e4e1-e59c-480e-b03d-b2c578563c1a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TABRECTA is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test. uuid:2d168b40-50ca-446d-bfd6-6c1efef238d0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:231693 biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:720269c1-3524-4da9-b8fe-ce96e5bffe73"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7ffd9961-0623-45fd-b351-95306ed24046"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TABRECTA is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test. uuid:5fc01651-9e31-4398-95c2-54787b009446 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:37924 biolink:treats MONDO:0018477 PMID:41385096 "[{""id"":""uuid:79ce2087-8363-4c02-b1bb-4020db452528"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:356d62da-cabe-49ba-b28a-411d66996745"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Atazanavir capsules are indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and in pediatric patients 6 years and older weighing at least 15 kg. Limitations of Use: Atazanavir capsules are not recommended for use in pediatric patients below the age of 3 months due to the risk of kernicterus [see Use in Specific Populations ( 8.4 )] . Use of atazanavir capsules with ritonavir in treatment-experienced patients should be guided by the number of baseline primary protease inhibitor resistance substitutions [see Microbiology ( 12.4 )] . uuid:f9c02f77-cbba-458f-bda1-6bc882027eac biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16755 biolink:treats MONDO:0008948 PMID:41385096 "[{""id"":""uuid:f6739723-029d-4098-9011-032ccf0b6656"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:326a4964-7728-4687-b752-b619db59679c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:b0320029-9cc6-42bc-9516-4e20848b84a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/chenodeoxycholic-acid-leadiant""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] CTEXLI is indicated for the treatment of cerebrotendinous xanthomatosis (CTX) in adults.|[EMA] Chenodeoxycholic acid is indicated for the treatment of inborn errors of primary bile acid synthesis due to sterol 27 hydroxylase deficiency (presenting as cerebrotendinous xanthomatosis (CTX)) in infants, children and adolescents aged 1 month to 18 years and adults. uuid:ed5dabed-9ae9-4119-9a11-0000a0dccc3f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:ZJ0EKR6M10 biolink:treats MONDO:0008315 PMID:41385096 "[{""id"":""uuid:b488fce3-6c3c-4c53-b197-8466832180b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7557331a-6ebc-403b-9019-e302844f9f44"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LOCAMETZ, after radiolabeling with gallium-68, is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA)-positive lesions in men with prostate cancer: with suspected metastasis who are candidates for initial definitive therapy. with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level. for selection of patients who are indicated for PSMA-directed therapy as described in the prescribing information of the therapeutic products. PUBCHEM.COMPOUND:91800164 uuid:1fbdf3fa-d747-4588-aee5-0af57708cbbc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17996 biolink:treats UMLS:C1112600 PMID:41385096 "[{""id"":""uuid:9eaedf9c-abfa-49d1-a3b2-b787b4a27010"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f6b46e40-3852-42fb-859e-2841b2adff15"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapeutic indications TURKFLEKS 0.9% ISOTONIC SODIUM CHLORIDE is indicated for: - Treatment of isotonic extracellular dehydration - Treatment of sodium depletion - As diluent of compatible drugs for parenteral administration. uuid:fd81dd96-9ff6-42fa-bf8e-04d373246a0b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C4753359 biolink:treats MONDO:0018874 PMID:41385096 "[{""id"":""uuid:e3317579-863c-482d-8017-5dc5a64aa3d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:098c0942-bf8f-447b-a74a-9ba2b362f21b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MYLOTARG is a CD33-directed antibody and cytotoxic drug conjugate indicated for: • treatment of newly-diagnosed CD33-positive acute myeloid leukemia (AML) in adults and pediatric patients 1 month and older ( 1.1 ). • treatment of relapsed or refractory CD33-positive AML in adults and pediatric patients 2 years and older ( 1.2 ). uuid:fb5411e1-af8e-43b9-865f-73b17a57d5e3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:Z7HVY03PHP biolink:treats MONDO:0005101 PMID:41385096 "[{""id"":""uuid:996d8904-76d1-49cf-b83d-caf344949733"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ad243bf2-317b-4c14-8d53-7b1637461d6c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:b069052f-2267-4431-8dd0-72628e6e9124"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/omvoh""]},{""id"":""uuid:190f224d-5b3e-4f5f-b433-a1a2319ba102"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OMVOH is indicated for the treatment of: moderately to severely active ulcerative colitis in adults. moderately to severely active Crohn's disease in adults.|[EMA] Omvoh is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic treatment.|[PMDA] A drug with a new active ingredient indicated for the remission induction therapy of moderate to severe ulcerative colitis (for use only in patients who have not sufficiently responded to conventional treatments). (3) Drugs with a new active ingredient indicated for the maintenance therapy of moderate to severe ulcerative colitis (for use only in patients who have not sufficiently responded to conventional treatments). uuid:0a7c378d-695a-4d68-a4a6-73b4de9d3c94 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:Z7HVY03PHP biolink:treats MONDO:0005011 PMID:41385096 "[{""id"":""uuid:d8532352-8fd0-45b1-a715-640e2ec84642"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0bf1c577-c88f-465f-8b3d-5b1702b7b2bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OMVOH is indicated for the treatment of: moderately to severely active ulcerative colitis in adults. moderately to severely active Crohn's disease in adults. uuid:56d5c852-bd26-4025-a5d3-1ac595bd9b31 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:156963654 biolink:treats UMLS:C0278488 PMID:41385096 "[{""id"":""uuid:fc3f2583-91c0-4d33-8e16-5b2e16956662"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7399569b-dbed-414b-85b5-c9261530d7a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TRODELVY is a Trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with: Locally Advanced or Metastatic Breast Cancer Unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease. ( 1.1 , 14.1 ) Unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH–) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting. ( 1.1 , 14.2 ) uuid:9369e2b1-62f6-46f3-9546-d9a8a2a71d90 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:156963654 biolink:treats MONDO:0005494 PMID:41385096 "[{""id"":""uuid:dd06b1ac-f15c-4e97-9cf0-8905d57bb678"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e7c26d50-6f63-442c-ac6d-e95d1c3ca571"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TRODELVY is a Trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with: Locally Advanced or Metastatic Breast Cancer Unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease. ( 1.1 , 14.1 ) Unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH–) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting. ( 1.1 , 14.2 ) uuid:1f38ecd8-67a1-45de-a761-c9d8a589549b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:156963654 biolink:treats MONDO:0700079 PMID:41385096 "[{""id"":""uuid:9b878ba7-07c3-42f5-ad97-3fe12da279e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b4e0ff75-6e40-4f81-8af6-b3ca448220a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TRODELVY is a Trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with: Locally Advanced or Metastatic Breast Cancer Unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease. ( 1.1 , 14.1 ) Unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH–) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting. ( 1.1 , 14.2 ) uuid:7592b934-236c-483f-810d-639c4cc7f5b4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135923 biolink:treats MONDO:0010526 PMID:41385096 "[{""id"":""uuid:8453ce18-9c19-49d2-a1d3-59239f1d5bde"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3b397ecf-ad98-46db-abbb-5d2bfa36dfc3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:020c9b84-a03c-4341-b82b-0d84bb9635ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:325aacd5-ad46-4424-b198-541fa92e9596"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] GALAFOLD is indicated for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene ( GLA ) variant based on in vitro assay data [see Dosage and Administration (2.1) and Clinical Pharmacology (12.1) ] . This indication is approved under accelerated approval based on reduction in kidney interstitial capillary cell globotriaosylceramide (KIC GL-3) substrate [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.|[EMA] Galafold is indicated for long-term treatment of adults and adolescents aged 16 years and older with a confirmed diagnosis of Fabry disease (α-galactosidase A deficiency) and who have an amenable mutation.|[PMDA] A drug with a new active ingredient indicated for the treatment of Fabry disease in patients with GLA mutations categorized as amenable to treatment with migalastat. [Orphan drug] uuid:476d908f-454f-4aae-9d3d-88a3496e86cd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:65173 biolink:treats MONDO:0005478 PMID:41385096 "[{""id"":""uuid:f98a36c7-864f-4aac-892b-022f3d84c9e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:42a17198-9a8e-48f4-b466-268dbe395888"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Iloperidone tablets are indicated for the treatment of schizophrenia in adults. When deciding among the alternative treatments available for this condition, the prescriber should consider the finding that iloperidone tablets are associated with prolongation of the QTc interval [see Warnings and Precautions (5.3) ] . Prolongation of the QTc interval is associated in some other drugs with the ability to cause torsade de pointes-type arrhythmia, a potentially fatal polymorphic ventricular tachycardia which can result in sudden death. In many cases this would lead to the conclusion that other drugs should be tried first. Whether iloperidone tablets will cause torsade de pointes or increase the rate of sudden death is not yet known. Patients must be titrated to an effective dose of iloperidone tablets. Thus, control of symptoms may be delayed during the first 1 to 2 weeks of treatment compared to some other antipsychotic drugs that do not require a similar titration. Prescribers should be mindful of this delay when selecting an antipsychotic drug for the treatment of schizophrenia [see Dosage and Administration (2.1) and Clinical Studies (14) ] . uuid:a5a5cb5a-c42f-434b-8d95-d1b0c840579c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:65173 biolink:treats MONDO:0005477 PMID:41385096 "[{""id"":""uuid:da38ebe3-8937-421a-a7b6-9418f2aead21"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c200f549-167a-456e-9988-f5d728553408"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Iloperidone tablets are indicated for the treatment of schizophrenia in adults. When deciding among the alternative treatments available for this condition, the prescriber should consider the finding that iloperidone tablets are associated with prolongation of the QTc interval [see Warnings and Precautions (5.3) ] . Prolongation of the QTc interval is associated in some other drugs with the ability to cause torsade de pointes-type arrhythmia, a potentially fatal polymorphic ventricular tachycardia which can result in sudden death. In many cases this would lead to the conclusion that other drugs should be tried first. Whether iloperidone tablets will cause torsade de pointes or increase the rate of sudden death is not yet known. Patients must be titrated to an effective dose of iloperidone tablets. Thus, control of symptoms may be delayed during the first 1 to 2 weeks of treatment compared to some other antipsychotic drugs that do not require a similar titration. Prescribers should be mindful of this delay when selecting an antipsychotic drug for the treatment of schizophrenia [see Dosage and Administration (2.1) and Clinical Studies (14) ] . uuid:0284e9a6-3b43-4c22-8626-32b4cf089cfb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:8202AY8I7H biolink:treats MONDO:0005277 PMID:41385096 "[{""id"":""uuid:12c4cfbe-8e00-4609-96eb-988d49611733"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:afb29673-ba65-4f4e-897a-cbd46a991ee6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:5d13d902-d233-47d8-8c15-932f04e2a5d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/vyepti""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] VYEPTI is indicated for the preventive treatment of migraine in adults.|[EMA] Vyepti is indicated for the prophylaxis of migraine in adults who have at least 4 migraine days per month. uuid:3901d7c1-c611-44f8-956d-6716b3ef7517 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17347 biolink:treats MONDO:0006908 PMID:41385096 "[{""id"":""uuid:789db2a9-e6ec-4d3f-b316-dbe570697750"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7c238a91-999e-4380-890f-235a83b55a54"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XYOSTED (testosterone enanthate) injection is an androgen indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone. Primary hypogonadism (congenital or acquired): testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter's syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone concentrations and gonadotropins (follicle-stimulating hormone [FSH], luteinizing hormone [LH]) above the normal range. Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation. These men have low testosterone serum concentrations but have gonadotropins in the normal or low range. Limitations of Use: Safety and efficacy of XYOSTED in men with “age-related hypogonadism” has not been established. Safety and efficacy of XYOSTED in males less than 18 years old have not been established [see Use in Specific Populations ( 8.4 )] . uuid:ba67e240-2671-4475-91eb-7f731801fa7d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17347 biolink:treats MONDO:0002150 PMID:41385096 "[{""id"":""uuid:2d54bae8-8be3-4c29-9519-36ef90448b83"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d7bd97ea-78ed-4136-827a-3a27fb6f5e41"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XYOSTED (testosterone enanthate) injection is an androgen indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone. Primary hypogonadism (congenital or acquired): testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter's syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone concentrations and gonadotropins (follicle-stimulating hormone [FSH], luteinizing hormone [LH]) above the normal range. Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation. These men have low testosterone serum concentrations but have gonadotropins in the normal or low range. Limitations of Use: Safety and efficacy of XYOSTED in men with “age-related hypogonadism” has not been established. Safety and efficacy of XYOSTED in males less than 18 years old have not been established [see Use in Specific Populations ( 8.4 )] . uuid:365b25a0-8a27-469b-839a-65b1d53161c5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:76511460 biolink:treats MONDO:0004951 PMID:41385096 "[{""id"":""uuid:92aa9384-1d34-4c78-9a08-81ab726af86b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a9b93e23-93fe-4955-93ac-5068cbe2d5c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PREZCOBIX is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV-1) in treatment-naïve and treatment-experienced adults and pediatric patients weighing at least 25 kg with no darunavir resistance-associated substitutions (V11I, V32I, L33F, I47V, I50V, I54L, I54M, T74P, L76V, I84V, L89V). uuid:08ddacb2-5c7b-4d17-977b-d3f26b2836ee biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:1383NM3Q0H biolink:treats MONDO:0005475 PMID:41385096 "[{""id"":""uuid:0d8a927a-606f-40a7-a4c8-29e3c22920eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6c828416-1e56-4b79-9d94-2e6edd02281a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NURTEC ODT is a calcitonin gene-related peptide receptor antagonist indicated for the: • acute treatment of migraine with or without aura in adults ( 1.1 ) • preventive treatment of episodic migraine in adults ( 1.2 ) uuid:e511998a-fe08-4394-affc-cc75541055f1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:1383NM3Q0H biolink:treats MONDO:0100431 PMID:41385096 "[{""id"":""uuid:5f2e8c98-5cc9-4721-afc2-3516708064fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f8e15144-e64b-49f6-a61b-1f5e027ab7e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NURTEC ODT is a calcitonin gene-related peptide receptor antagonist indicated for the: • acute treatment of migraine with or without aura in adults ( 1.1 ) • preventive treatment of episodic migraine in adults ( 1.2 ) uuid:c0cabd0e-8a3f-48f1-aaa7-291ae7966cad biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:1383NM3Q0H biolink:treats UMLS:C4760993 PMID:41385096 "[{""id"":""uuid:19dd502b-a14f-413c-9b40-cfb3a6de94bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5a2d6cb5-32bf-4a20-b775-db01eaa209cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NURTEC ODT is a calcitonin gene-related peptide receptor antagonist indicated for the: • acute treatment of migraine with or without aura in adults ( 1.1 ) • preventive treatment of episodic migraine in adults ( 1.2 ) uuid:e57d99b0-6a4f-4a3d-92cb-3b5fc667deaa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68534 biolink:treats MONDO:0004956 PMID:41385096 "[{""id"":""uuid:d811844f-34a7-4239-a5ff-30c6bd84fc57"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:090d2680-28b4-42f1-9fbb-5e64fd6439da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e8dd086a-4a2d-4fbc-940d-c6657b324cd7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/xtandi""]},{""id"":""uuid:da8dc507-ad52-427e-af96-5bfdd9ca8f1f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XTANDI ® is indicated for the treatment of patients with: • castration-resistant prostate cancer (CRPC) • metastatic castration-sensitive prostate cancer (mCSPC) • non‑metastatic castration‑sensitive prostate cancer (nmCSPC) with biochemical recurrence at high risk for metastasis (high-risk BCR)|[EMA] Xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (see section 5.1).the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (CRPC) (see section 5.1).the treatment of adult men with metastatic CRPC who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5.1).the treatment of adult men with metastatic CRPC whose disease has progressed on or after docetaxel therapy.|[PMDA] Drugs with a new indication for the treatment of metastatic prostate cancer. uuid:3103c898-7054-4311-a686-bbb4428a502f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68534 biolink:treats MONDO:0008315 PMID:41385096 "[{""id"":""uuid:72e57f76-ff42-403a-828a-b1d7346e2150"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2e36deee-278a-4e65-aca9-665e4bbded7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XTANDI ® is indicated for the treatment of patients with: • castration-resistant prostate cancer (CRPC) • metastatic castration-sensitive prostate cancer (mCSPC) • non‑metastatic castration‑sensitive prostate cancer (nmCSPC) with biochemical recurrence at high risk for metastasis (high-risk BCR) uuid:98bddff4-a9a1-493b-a3a3-69135d9921ed biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:81569 biolink:treats MONDO:0005047 PMID:41385096 "[{""id"":""uuid:2fbeb931-ee76-49d8-8200-307540eb673f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:499c3b86-d914-41cf-9965-1a6a8cb3b0dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] GONAL-f ® RFF Redi-ject ® is a prefilled gonadotropin-containing auto-injection device indicated for: Induction of ovulation and pregnancy in oligo-anovulatory women in whom the cause of infertility is functional and not due to primary ovarian failure ( 1.1 ) Development of multiple follicles in ovulatory women as part of an Assisted Reproductive Technology (ART) cycle ( 1.2 ) uuid:20205c69-9d73-4c0c-847a-1bca72562bc8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:I5I8VB78VT biolink:treats MONDO:0005277 PMID:41385096 "[{""id"":""uuid:55414085-7ba9-40a6-b714-284044593a4c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f471b564-7624-4509-abf0-0e8b4a36a669"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:d578c87e-2285-41ca-8f23-45e2d7ab36d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/aimovig""]},{""id"":""uuid:c05e672a-1dab-48de-bac5-d60291919b61"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AIMOVIG is indicated for the preventive treatment of migraine in adults.|[EMA] Aimovig is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month when initiating treatment with Aimovig.|[PMDA] A drug with a new active ingredient indicated for the prevention of migraine attacks. uuid:d2dc81c9-363c-4ab3-b19a-427a301a4305 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4T36H88UA7 biolink:treats MONDO:0004956 PMID:41385096 "[{""id"":""uuid:4942bf1c-ad14-4002-a49a-1bac8313d1d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:230a3164-259c-4f2e-b65a-2c354375a10a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e3d00e89-42b7-4334-a2d5-fc324ed53b2b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/erleada""]},{""id"":""uuid:31267e1e-86d0-45fb-8802-ad83dfef3d49"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ERLEADA is indicated for the treatment of patients with Metastatic castration-sensitive prostate cancer (mCSPC) Non-metastatic castration-resistant prostate cancer (nmCRPC)|[EMA] Erleada is indicated:in adult men for the treatment of non metastatic castration resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease.in adult men for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT).|[PMDA] A drug with a new indication for the treatment of metastatic prostate cancer. uuid:189417a3-2a41-49dc-92e7-f6ce5d729a05 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:BDT58WJ9WE biolink:treats MONDO:0004951 PMID:41385096 "[{""id"":""uuid:d4080d33-775e-4a85-9292-ae89dc097047"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f004662a-e33a-4a6a-ab34-0d38f4604927"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SUNLENCA, in combination with other antiretroviral(s), is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug resistant HIV-1 whose current antiretroviral regimen is failing due to resistance, intolerance, or safety considerations. uuid:8bde497d-59f6-4f92-9a5c-e81f24d4d88f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:142418 biolink:treats EFO:0006865 PMID:41385096 "[{""id"":""uuid:fe8de5fa-09ab-4888-8a26-66564e083df7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d5ed1f01-7ab0-4c9b-be25-e92af10d50b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:3f7a13b8-0a39-4515-ab10-525a7db84633"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] GEMTESA is a beta-3 adrenergic agonist indicated for the treatment of: overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults. ( 1.1 ) overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adult males on pharmacological therapy for benign prostatic hyperplasia (BPH). ( 1.2 )|[PMDA] A drug with a new active ingredient indicated for the treatment of urinary urgency, urinary frequency, and urge urinary incontinence associated with overactive bladder. uuid:6f98a9c9-c8b6-4dba-95f1-9a75ff1b26a0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:142418 biolink:treats MONDO:0010811 PMID:41385096 "[{""id"":""uuid:76b38d8a-b5ba-4dbd-9c2d-a3ccea6f6ecb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0d63213d-776d-4e09-bd55-7d2b35942dcb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] GEMTESA is a beta-3 adrenergic agonist indicated for the treatment of: overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults. ( 1.1 ) overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adult males on pharmacological therapy for benign prostatic hyperplasia (BPH). ( 1.2 ) uuid:b52bde9a-9d6e-4fd5-aab7-9c353cae57f8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:69478 biolink:treats MONDO:0100135 PMID:41385096 "[{""id"":""uuid:d935ab2b-f97c-409e-aef5-3d13dd0ee4e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f4b0ce5a-5b0c-442b-bc36-82ac45036334"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:9da73606-ccdd-4001-8299-f80c4db62293"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/epidyolex""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] EPIDIOLEX is indicated for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC) in patients 1 year of age and older.|[EMA] Epidyolex is indicated for use as adjunctive therapy of seizures associated with Lennox Gastaut syndrome (LGS) or Dravet syndrome (DS), in conjunction with clobazam, for patients 2 years of age and older. uuid:d4614c9c-7f0c-49bc-b3c8-dbd90f424d9a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0021108 PMID:41385096 "[{""id"":""uuid:c85434de-109e-4cb1-9591-15e77886c7c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f31fa900-70d8-402a-93ca-741edce3468f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MINOCIN ® Intravenous is indicated in the treatment of the following infections due to susceptible isolates of the designated bacteria: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following Gram-negative bacteria when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli . Enterobacter aerogenes . Shigella species . Acinetobacter species . Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species . MINOCIN ® Intravenous is indicated for the treatment of infections caused by the following Gram-positive bacteria when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Meningitis due to Neisseria meningitidis . Syphilis caused by Treponema pallidum subspecies pallidum . Yaws caused by Treponema pallidum subspecies pertenue . Listeriosis due to Listeria monocytogenes . Anthrax due to Bacillus anthracis . Vincent's infection caused by Fusobacterium fusiforme. Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species . In acute intestinal amebiasis , minocycline may be a useful adjunct to amebicides. In severe acne , minocycline may be useful adjunctive therapy. To reduce the development of drug-resistant bacteria and maintain the effectiveness of MINOCIN ® (minocycline) for Injection and other antibacterial drugs, MINOCIN ® (minocycline) for Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:cc1e83fd-96eb-4415-84a7-d8d90e19e529 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:647208 biolink:treats MONDO:0005147 PMID:41385096 "[{""id"":""uuid:2b81d8b5-f444-4a22-907d-8730f2209c00"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6c297d25-457d-4d11-bbbc-b21cc4e61729"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DUETACT is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who are already treated with a thiazolidinedione and sulfonylurea or who have inadequate glycemic control on a thiazolidinedione alone or a sulfonylurea alone [see Clinical Studies ( 14 )] . Important Limitations of Use Pioglitazone exerts its antihyperglycemic effect only in the presence of endogenous insulin. DUETACT should not be used to treat type 1 diabetes or diabetic ketoacidosis, as it would not be effective in these settings. Use caution in patients with liver disease [see Warnings and Precautions ( 5.5 )] . uuid:50c5bc5c-a014-496e-8135-70adc78401f5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:647208 biolink:treats MONDO:0012819 PMID:41385096 "[{""id"":""uuid:ceb5827f-957e-4161-a84d-89a83addbaf2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:87b890f2-e6d2-494f-b869-af4a3fad2000"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DUETACT is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who are already treated with a thiazolidinedione and sulfonylurea or who have inadequate glycemic control on a thiazolidinedione alone or a sulfonylurea alone [see Clinical Studies ( 14 )] . Important Limitations of Use Pioglitazone exerts its antihyperglycemic effect only in the presence of endogenous insulin. DUETACT should not be used to treat type 1 diabetes or diabetic ketoacidosis, as it would not be effective in these settings. Use caution in patients with liver disease [see Warnings and Precautions ( 5.5 )] . uuid:7fbcc233-c734-4f37-9820-2e7080714f16 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:92043599 biolink:treats UMLS:C5438213 PMID:41385096 "[{""id"":""uuid:f9b99f56-a49b-4a4b-9236-58cc9e69c8a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:19940e61-1257-4774-8dc3-160a1ef15169"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PROCRIT is an erythropoiesis-stimulating agent (ESA) indicated for: Treatment of anemia due to Chronic Kidney Disease (CKD) in patients on dialysis and not on dialysis ( 1.1 ). Zidovudine in patients with Human Immunodeficiency Virus (HIV) infection ( 1.2 ). The effects of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy ( 1.3 ). Reduction of allogeneic red blood cell (RBC) transfusions in patients undergoing elective, noncardiac, nonvascular surgery ( 1.4 ). Limitations of Use PROCRIT has not been shown to improve quality of life, fatigue, or patient well-being ( 1.5 ). PROCRIT is not indicated for use: In patients with cancer receiving hormonal agents, biologic products, or radiotherapy, unless also receiving concomitant myelosuppressive chemotherapy ( 1.5 ). In patients with cancer receiving myelosuppressive chemotherapy when the anticipated outcome is cure ( 1.5 ). In patients with cancer receiving myelosuppressive chemotherapy in whom the anemia can be managed by transfusion ( 1.5 ). In patients scheduled for surgery who are willing to donate autologous blood ( 1.5 ). In patients undergoing cardiac or vascular surgery ( 1.5 ). As a substitute for RBC transfusions in patients who require immediate correction of anemia ( 1.5 ). uuid:2980177a-81d2-4676-9572-5316e7d74a28 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:92043599 biolink:treats UMLS:C0343751 PMID:41385096 "[{""id"":""uuid:bb0309fb-c00b-4645-8218-2b36239ff066"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:19c9ceff-c89f-41d6-8d33-68b8cb2d4f78"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PROCRIT is an erythropoiesis-stimulating agent (ESA) indicated for: Treatment of anemia due to Chronic Kidney Disease (CKD) in patients on dialysis and not on dialysis ( 1.1 ). Zidovudine in patients with Human Immunodeficiency Virus (HIV) infection ( 1.2 ). The effects of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy ( 1.3 ). Reduction of allogeneic red blood cell (RBC) transfusions in patients undergoing elective, noncardiac, nonvascular surgery ( 1.4 ). Limitations of Use PROCRIT has not been shown to improve quality of life, fatigue, or patient well-being ( 1.5 ). PROCRIT is not indicated for use: In patients with cancer receiving hormonal agents, biologic products, or radiotherapy, unless also receiving concomitant myelosuppressive chemotherapy ( 1.5 ). In patients with cancer receiving myelosuppressive chemotherapy when the anticipated outcome is cure ( 1.5 ). In patients with cancer receiving myelosuppressive chemotherapy in whom the anemia can be managed by transfusion ( 1.5 ). In patients scheduled for surgery who are willing to donate autologous blood ( 1.5 ). In patients undergoing cardiac or vascular surgery ( 1.5 ). As a substitute for RBC transfusions in patients who require immediate correction of anemia ( 1.5 ). uuid:c1ee8e91-798e-4fb6-83c3-7b967eba5613 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:92043599 biolink:treats MONDO:0002280 PMID:41385096 "[{""id"":""uuid:40452d41-7fb1-403e-b4ea-7dcb47808cae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d30ed4eb-7b84-4ebf-8e12-b1d34bd7ccb0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:dcabc3a0-f77f-4db8-a9d5-daef0134c97d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/epoetin-alfa-hexal""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] PROCRIT is an erythropoiesis-stimulating agent (ESA) indicated for: Treatment of anemia due to Chronic Kidney Disease (CKD) in patients on dialysis and not on dialysis ( 1.1 ). Zidovudine in patients with Human Immunodeficiency Virus (HIV) infection ( 1.2 ). The effects of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy ( 1.3 ). Reduction of allogeneic red blood cell (RBC) transfusions in patients undergoing elective, noncardiac, nonvascular surgery ( 1.4 ). Limitations of Use PROCRIT has not been shown to improve quality of life, fatigue, or patient well-being ( 1.5 ). PROCRIT is not indicated for use: In patients with cancer receiving hormonal agents, biologic products, or radiotherapy, unless also receiving concomitant myelosuppressive chemotherapy ( 1.5 ). In patients with cancer receiving myelosuppressive chemotherapy when the anticipated outcome is cure ( 1.5 ). In patients with cancer receiving myelosuppressive chemotherapy in whom the anemia can be managed by transfusion ( 1.5 ). In patients scheduled for surgery who are willing to donate autologous blood ( 1.5 ). In patients undergoing cardiac or vascular surgery ( 1.5 ). As a substitute for RBC transfusions in patients who require immediate correction of anemia ( 1.5 ).|[EMA] Treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adult and paediatric patients:, , , treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis;, Treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis., , , Treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre-existing anaemia at the start of chemotherapy)., uuid:25806adf-ceb9-41dc-9c5d-a74ea6516ec4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4495 biolink:treats HP:0002591 PMID:41385096 "[{""id"":""uuid:a4afb87d-066e-4204-af41-fbb4b37d7213"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3b0d9957-1280-422f-a805-cf84aa8270cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VYKAT XR is indicated for the treatment of hyperphagia in adults and pediatric patients 4 years of age and older with Prader-Willi syndrome (PWS). uuid:0883e59c-5d4c-4707-9521-07cb3c57d0bb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:789Q85GA8P biolink:treats MONDO:0016686 PMID:41385096 "[{""id"":""uuid:06d1ea65-29ae-48cc-9006-86acb7655f09"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:538a1389-dc4f-4aca-90af-ad6592ce13db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VORANIGO is indicated for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) or isocitrate dehydrogenase-2 (IDH2) mutation, as detected by an FDA-approved test, following surgery including biopsy, sub-total resection, or gross total resection [see Dosage and Administration (2.1) , Clinical Pharmacology (12.1) and Clinical Studies (14) ] . uuid:1d491709-bfcc-4e30-8498-f40643b15e8d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:789Q85GA8P biolink:treats MONDO:0016695 PMID:41385096 "[{""id"":""uuid:0c213596-b6fb-4712-bf40-ecd6fb85ec45"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9fc9cee6-527d-492c-a1cc-4268f543c56a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VORANIGO is indicated for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) or isocitrate dehydrogenase-2 (IDH2) mutation, as detected by an FDA-approved test, following surgery including biopsy, sub-total resection, or gross total resection [see Dosage and Administration (2.1) , Clinical Pharmacology (12.1) and Clinical Studies (14) ] . uuid:d55e455c-67fc-4dc1-b3bc-39272d0aadec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:090IP5RV8F biolink:treats MONDO:0004652 PMID:41385096 "[{""id"":""uuid:c523c6fc-3a2d-4623-9db0-3eefe467c2b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:16bae7ec-650a-4c8e-962b-d187f51b4b07"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NUZYRA is a tetracycline class antibacterial indicated for the treatment of adult patients with the following infections caused by susceptible microorganisms ( 1 ): Community-acquired bacterial pneumonia (CABP) ( 1.1 ) Acute bacterial skin and skin structure infections (ABSSSI) ( 1.2 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of NUZYRA and other antibacterial drugs, NUZYRA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. ( 1.3 ) uuid:0e2f4001-54d4-46c9-b12b-7b68ee093a35 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:090IP5RV8F biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:0a101001-16dd-4d1e-bb2c-12bd71df8809"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:921c13d5-c1f2-4cb0-979b-09181edc1bd7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NUZYRA is a tetracycline class antibacterial indicated for the treatment of adult patients with the following infections caused by susceptible microorganisms ( 1 ): Community-acquired bacterial pneumonia (CABP) ( 1.1 ) Acute bacterial skin and skin structure infections (ABSSSI) ( 1.2 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of NUZYRA and other antibacterial drugs, NUZYRA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. ( 1.3 ) uuid:5b255715-49b3-44e2-8aff-6ff7ca81b50d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:28X28X9OKV biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:a2fc8228-4b0a-4ce0-a475-bd4937b2c252"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4885c4ac-b6b0-4766-aa5f-6fb694ff5c58"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:bb21552a-5395-43f9-a761-ae2046946d1a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/imfinzi""]},{""id"":""uuid:18cda7f8-15a3-4dc0-a0bc-d166ef57c67d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] IMFINZI is a programmed death-ligand 1 (PD-L1) blocking antibody indicated: • in combination with platinum-containing chemotherapy as neoadjuvant treatment, followed by IMFINZI continued as a single agent as adjuvant treatment after surgery, for the treatment of adult patients with resectable (tumors ≥ 4 cm and/or node positive) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements. ( 1.1 ) • as a single agent, for the treatment of adult patients with unresectable, Stage III NSCLC whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. ( 1.1 ) • in combination with tremelimumab-actl and platinum-based chemotherapy, for the treatment of adult patients with metastatic NSCLC with no sensitizing EGFR mutations or ALK genomic tumor aberrations. ( 1.1 ) • as a single agent, for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. ( 1.2 ) • in combination with etoposide and either carboplatin or cisplatin, as first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC). ( 1.2 ) • in combination with gemcitabine and cisplatin, as treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC). ( 1.3 ) • in combination with tremelimumab-actl, for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC). ( 1.4 ) • in combination with carboplatin and paclitaxel followed by IMFINZI as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR) as determined by an FDA-approved test. ( 1.5 , 2.1 ) • in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent IMFINZI as adjuvant treatment following radical cystectomy, for the treatment of adult patients with muscle invasive bladder cancer (MIBC). ( 1.6 )|[EMA] Non-Small Cell Lung Cancer (NSCLC)IMFINZI as monotherapy is indicated for the treatment of locally advanced, unresectable non small cell lung cancer (NSCLC) in adults whose tumours express PD-L1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum based chemoradiation therapy (see section 5.1).IMFINZI in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic NSCLC with no sensitising EGFR mutations or ALK positive mutations.Small Cell Lung Cancer (SCLC)IMFINZI in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (ES-SCLC).Biliary Tract Cancer (BTC)IMFINZI in combination with gemcitabine and cisplatin is indicated for the first line treatment of adults with unresectable or metastatic biliary tract cancer (BTC).Hepatocellular Carcinoma (HCC)IMFINZI in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC).|[PMDA] Drugs with a new active ingredient indicated for the maintenance treatment of locally-advanced, unresectable non-small cell lung cancer following definitive chemoradiation therapy. uuid:4fd18745-7d9f-4d47-aa50-3e9d623f29de biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:28X28X9OKV biolink:treats MONDO:0008433 PMID:41385096 "[{""id"":""uuid:6ec71750-7d27-412c-9172-1b453b21d939"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e60efa8e-6608-4829-ab76-041b5f34c29f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:fcc1461e-be77-4606-81ac-b3137f98417c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/imfinzi""]},{""id"":""uuid:12bc564f-fd43-4694-8504-4a08ecfd1e85"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] IMFINZI is a programmed death-ligand 1 (PD-L1) blocking antibody indicated: • in combination with platinum-containing chemotherapy as neoadjuvant treatment, followed by IMFINZI continued as a single agent as adjuvant treatment after surgery, for the treatment of adult patients with resectable (tumors ≥ 4 cm and/or node positive) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements. ( 1.1 ) • as a single agent, for the treatment of adult patients with unresectable, Stage III NSCLC whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. ( 1.1 ) • in combination with tremelimumab-actl and platinum-based chemotherapy, for the treatment of adult patients with metastatic NSCLC with no sensitizing EGFR mutations or ALK genomic tumor aberrations. ( 1.1 ) • as a single agent, for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. ( 1.2 ) • in combination with etoposide and either carboplatin or cisplatin, as first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC). ( 1.2 ) • in combination with gemcitabine and cisplatin, as treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC). ( 1.3 ) • in combination with tremelimumab-actl, for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC). ( 1.4 ) • in combination with carboplatin and paclitaxel followed by IMFINZI as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR) as determined by an FDA-approved test. ( 1.5 , 2.1 ) • in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent IMFINZI as adjuvant treatment following radical cystectomy, for the treatment of adult patients with muscle invasive bladder cancer (MIBC). ( 1.6 )|[EMA] Non-Small Cell Lung Cancer (NSCLC)IMFINZI as monotherapy is indicated for the treatment of locally advanced, unresectable non small cell lung cancer (NSCLC) in adults whose tumours express PD-L1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum based chemoradiation therapy (see section 5.1).IMFINZI in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic NSCLC with no sensitising EGFR mutations or ALK positive mutations.Small Cell Lung Cancer (SCLC)IMFINZI in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (ES-SCLC).Biliary Tract Cancer (BTC)IMFINZI in combination with gemcitabine and cisplatin is indicated for the first line treatment of adults with unresectable or metastatic biliary tract cancer (BTC).Hepatocellular Carcinoma (HCC)IMFINZI in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC).|[PMDA] Drugs with a new indication and a new dosage for the treatment of extensive-stage small-cell lung cancer. uuid:7ef3291b-5cc3-469a-b1d9-639c0a8a3743 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:28X28X9OKV biolink:treats MONDO:0003060 PMID:41385096 "[{""id"":""uuid:462ec067-9df3-4e5b-928b-4217db28c5a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8b924ba6-549b-4e33-850f-22e41e3d14ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:3482b059-d3a6-4e73-a1fc-2a7396d3ff75"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/imfinzi""]},{""id"":""uuid:cabd4954-a1d2-4936-8852-4cc5fb8c1498"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] IMFINZI is a programmed death-ligand 1 (PD-L1) blocking antibody indicated: • in combination with platinum-containing chemotherapy as neoadjuvant treatment, followed by IMFINZI continued as a single agent as adjuvant treatment after surgery, for the treatment of adult patients with resectable (tumors ≥ 4 cm and/or node positive) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements. ( 1.1 ) • as a single agent, for the treatment of adult patients with unresectable, Stage III NSCLC whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. ( 1.1 ) • in combination with tremelimumab-actl and platinum-based chemotherapy, for the treatment of adult patients with metastatic NSCLC with no sensitizing EGFR mutations or ALK genomic tumor aberrations. ( 1.1 ) • as a single agent, for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. ( 1.2 ) • in combination with etoposide and either carboplatin or cisplatin, as first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC). ( 1.2 ) • in combination with gemcitabine and cisplatin, as treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC). ( 1.3 ) • in combination with tremelimumab-actl, for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC). ( 1.4 ) • in combination with carboplatin and paclitaxel followed by IMFINZI as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR) as determined by an FDA-approved test. ( 1.5 , 2.1 ) • in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent IMFINZI as adjuvant treatment following radical cystectomy, for the treatment of adult patients with muscle invasive bladder cancer (MIBC). ( 1.6 )|[EMA] Non-Small Cell Lung Cancer (NSCLC)IMFINZI as monotherapy is indicated for the treatment of locally advanced, unresectable non small cell lung cancer (NSCLC) in adults whose tumours express PD-L1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum based chemoradiation therapy (see section 5.1).IMFINZI in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic NSCLC with no sensitising EGFR mutations or ALK positive mutations.Small Cell Lung Cancer (SCLC)IMFINZI in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (ES-SCLC).Biliary Tract Cancer (BTC)IMFINZI in combination with gemcitabine and cisplatin is indicated for the first line treatment of adults with unresectable or metastatic biliary tract cancer (BTC).Hepatocellular Carcinoma (HCC)IMFINZI in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC).|[PMDA] Drugs with a new indication and a new dosage for the treatment of unresectable biliary tract cancer. [Orphan drug] uuid:70312c68-b3a3-4293-81fa-c4889f2448b1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:28X28X9OKV biolink:treats MONDO:0007256 PMID:41385096 "[{""id"":""uuid:118d61d9-6b98-4762-8a59-6091dfd9f9ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e8d9e3d8-065b-431b-9153-696d2c6a65f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:7b2c5f0c-9a7e-44c4-a437-96dade7fb675"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/imfinzi""]},{""id"":""uuid:dd4c3e8e-409e-49ad-bbcb-c456632dc237"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] IMFINZI is a programmed death-ligand 1 (PD-L1) blocking antibody indicated: • in combination with platinum-containing chemotherapy as neoadjuvant treatment, followed by IMFINZI continued as a single agent as adjuvant treatment after surgery, for the treatment of adult patients with resectable (tumors ≥ 4 cm and/or node positive) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements. ( 1.1 ) • as a single agent, for the treatment of adult patients with unresectable, Stage III NSCLC whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. ( 1.1 ) • in combination with tremelimumab-actl and platinum-based chemotherapy, for the treatment of adult patients with metastatic NSCLC with no sensitizing EGFR mutations or ALK genomic tumor aberrations. ( 1.1 ) • as a single agent, for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. ( 1.2 ) • in combination with etoposide and either carboplatin or cisplatin, as first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC). ( 1.2 ) • in combination with gemcitabine and cisplatin, as treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC). ( 1.3 ) • in combination with tremelimumab-actl, for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC). ( 1.4 ) • in combination with carboplatin and paclitaxel followed by IMFINZI as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR) as determined by an FDA-approved test. ( 1.5 , 2.1 ) • in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent IMFINZI as adjuvant treatment following radical cystectomy, for the treatment of adult patients with muscle invasive bladder cancer (MIBC). ( 1.6 )|[EMA] Non-Small Cell Lung Cancer (NSCLC)IMFINZI as monotherapy is indicated for the treatment of locally advanced, unresectable non small cell lung cancer (NSCLC) in adults whose tumours express PD-L1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum based chemoradiation therapy (see section 5.1).IMFINZI in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic NSCLC with no sensitising EGFR mutations or ALK positive mutations.Small Cell Lung Cancer (SCLC)IMFINZI in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (ES-SCLC).Biliary Tract Cancer (BTC)IMFINZI in combination with gemcitabine and cisplatin is indicated for the first line treatment of adults with unresectable or metastatic biliary tract cancer (BTC).Hepatocellular Carcinoma (HCC)IMFINZI in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC).|[PMDA] (1) Drugs with a new indication and a new dosage for the treatment of unresectable advanced or recurrent non-small-cell lung cancer. (2) Drugs with a new indication and a new dosage for the treatment of unresectable hepatocellular carcinoma. uuid:67e34629-ca89-4668-bcd9-085e7f513c28 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:28X28X9OKV biolink:treats MONDO:0011962 PMID:41385096 "[{""id"":""uuid:25666227-d631-410d-9a69-661aaab82e41"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7814ad7f-1d6d-4da7-b9cc-56b919b8ac31"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] IMFINZI is a programmed death-ligand 1 (PD-L1) blocking antibody indicated: • in combination with platinum-containing chemotherapy as neoadjuvant treatment, followed by IMFINZI continued as a single agent as adjuvant treatment after surgery, for the treatment of adult patients with resectable (tumors ≥ 4 cm and/or node positive) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements. ( 1.1 ) • as a single agent, for the treatment of adult patients with unresectable, Stage III NSCLC whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. ( 1.1 ) • in combination with tremelimumab-actl and platinum-based chemotherapy, for the treatment of adult patients with metastatic NSCLC with no sensitizing EGFR mutations or ALK genomic tumor aberrations. ( 1.1 ) • as a single agent, for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. ( 1.2 ) • in combination with etoposide and either carboplatin or cisplatin, as first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC). ( 1.2 ) • in combination with gemcitabine and cisplatin, as treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC). ( 1.3 ) • in combination with tremelimumab-actl, for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC). ( 1.4 ) • in combination with carboplatin and paclitaxel followed by IMFINZI as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR) as determined by an FDA-approved test. ( 1.5 , 2.1 ) • in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent IMFINZI as adjuvant treatment following radical cystectomy, for the treatment of adult patients with muscle invasive bladder cancer (MIBC). ( 1.6 ) uuid:aa840f4a-5141-4e6a-a57e-f61b2787cbf3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:28X28X9OKV biolink:treats MONDO:0003890 PMID:41385096 "[{""id"":""uuid:05b2a4a3-41d2-4f83-bdc5-6e1371f47e88"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0037c7df-78c9-416b-aca2-64abd6e862ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] IMFINZI is a programmed death-ligand 1 (PD-L1) blocking antibody indicated: • in combination with platinum-containing chemotherapy as neoadjuvant treatment, followed by IMFINZI continued as a single agent as adjuvant treatment after surgery, for the treatment of adult patients with resectable (tumors ≥ 4 cm and/or node positive) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements. ( 1.1 ) • as a single agent, for the treatment of adult patients with unresectable, Stage III NSCLC whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. ( 1.1 ) • in combination with tremelimumab-actl and platinum-based chemotherapy, for the treatment of adult patients with metastatic NSCLC with no sensitizing EGFR mutations or ALK genomic tumor aberrations. ( 1.1 ) • as a single agent, for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. ( 1.2 ) • in combination with etoposide and either carboplatin or cisplatin, as first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC). ( 1.2 ) • in combination with gemcitabine and cisplatin, as treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC). ( 1.3 ) • in combination with tremelimumab-actl, for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC). ( 1.4 ) • in combination with carboplatin and paclitaxel followed by IMFINZI as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR) as determined by an FDA-approved test. ( 1.5 , 2.1 ) • in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent IMFINZI as adjuvant treatment following radical cystectomy, for the treatment of adult patients with muscle invasive bladder cancer (MIBC). ( 1.6 ) uuid:24a49d85-3564-4445-964e-433927381a77 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7852 biolink:treats HP:0030858 PMID:41385096 "[{""id"":""uuid:5a1a51ac-b639-4426-a1ea-67c8954ac2ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:89501467-2cc9-4f5a-bd06-26cfda3a1edd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxycodone hydrochloride tablets are an opioid agonist indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. ( 1) Limitations of Use ( 1) Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, reserve oxycodone hydrochloride tablets for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or non-opioid combination products): Have not been tolerated, or are not expected to be tolerated, Have not provided adequate analgesia or are not expected to provide adequate analgesia. Oxycodone hydrochloride tablets are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see Warnings and Precautions (5.1) ] , reserve oxycodone hydrochloride tablets for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or opioid combination products): Have not been tolerated or are not expected to be tolerated, Have not provided adequate analgesia or are not expected to provide adequate analgesia. uuid:42b2f84f-8d97-4d9f-9295-2ee1c18ec5b8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7852 biolink:treats MONDO:0002491 PMID:41385096 "[{""id"":""uuid:b9b628ed-d543-4cb4-8658-ba621d676de7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:121fad9c-27de-498a-b61e-71d020ec8207"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxycodone hydrochloride tablets are an opioid agonist indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. ( 1) Limitations of Use ( 1) Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, reserve oxycodone hydrochloride tablets for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or non-opioid combination products): Have not been tolerated, or are not expected to be tolerated, Have not provided adequate analgesia or are not expected to provide adequate analgesia. Oxycodone hydrochloride tablets are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see Warnings and Precautions (5.1) ] , reserve oxycodone hydrochloride tablets for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or opioid combination products): Have not been tolerated or are not expected to be tolerated, Have not provided adequate analgesia or are not expected to provide adequate analgesia. uuid:1eafd06a-d92f-4f68-b156-26763f313991 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7852 biolink:treats EFO:0011049 PMID:41385096 "[{""id"":""uuid:d666c3c5-518f-49ba-a7ea-e180d12e44d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4a02b0a3-884c-4dfe-a891-2342fa8915d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxycodone hydrochloride tablets are an opioid agonist indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. ( 1) Limitations of Use ( 1) Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, reserve oxycodone hydrochloride tablets for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or non-opioid combination products): Have not been tolerated, or are not expected to be tolerated, Have not provided adequate analgesia or are not expected to provide adequate analgesia. Oxycodone hydrochloride tablets are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see Warnings and Precautions (5.1) ] , reserve oxycodone hydrochloride tablets for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or opioid combination products): Have not been tolerated or are not expected to be tolerated, Have not provided adequate analgesia or are not expected to provide adequate analgesia. uuid:37d94367-2eeb-4614-bd1c-9125494a7afe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB17635 biolink:treats MONDO:0009823 PMID:41385096 "[{""id"":""uuid:5680fe77-30db-4662-82d2-d35db7140084"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cd8cae59-1c35-4e19-8c65-aa7454f43467"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RIVFLOZA is indicated to lower urinary oxalate levels in children 2 years of age and older and adults with primary hyperoxaluria type 1 (PH1) and relatively preserved kidney function, e.g., eGFR ≥30 mL/min/1.73 m 2 [see Clinical Pharmacology (‎ 12.3 )], Clinical Studies (‎ 14.1 )]. uuid:628131f3-a8fb-41d9-9c5d-d160400c8d6c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB17635 biolink:treats MONDO:0024685 PMID:41385096 "[{""id"":""uuid:3d015239-2e42-4e9d-bb09-f5a50bc5f086"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b45c2880-d69b-4ec0-a1ff-7e8285235d7e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RIVFLOZA is indicated to lower urinary oxalate levels in children 2 years of age and older and adults with primary hyperoxaluria type 1 (PH1) and relatively preserved kidney function, e.g., eGFR ≥30 mL/min/1.73 m 2 [see Clinical Pharmacology (‎ 12.3 )], Clinical Studies (‎ 14.1 )]. uuid:884c9919-864b-4ccf-be48-ad1e2f5c257b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9334 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:d9bf531c-4a51-4fc6-9e1d-d7ec0cb15957"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8904ec4f-eebd-4ff2-a20e-9a7208366eac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AZULFIDINE EN-tabs Tablets are indicated: • in the treatment of mild to moderate ulcerative colitis, and as adjunctive therapy in severe ulcerative colitis; • for the prolongation of the remission period between acute attacks of ulcerative colitis; • in the treatment of patients with rheumatoid arthritis who have responded inadequately to salicylates or other nonsteroidal anti-inflammatory drugs (e.g., an insufficient therapeutic response to, or intolerance of, an adequate trial of full doses of one or more nonsteroidal anti-inflammatory drugs); and • in the treatment of pediatric patients with polyarticular-course 1 juvenile rheumatoid arthritis who have responded inadequately to salicylates or other nonsteroidal anti-inflammatory drugs. AZULFIDINE EN-tabs is particularly indicated in patients with ulcerative colitis who cannot take uncoated sulfasalazine tablets because of gastrointestinal intolerance, and in whom there is evidence that this intolerance is not primarily the result of high blood levels of sulfapyridine and its metabolites, e.g., patients experiencing nausea and vomiting with the first few doses of the drug, or patients in whom a reduction in dosage does not alleviate the adverse gastrointestinal effects. In patients with rheumatoid arthritis or juvenile rheumatoid arthritis, rest and physiotherapy as indicated should be continued. Unlike anti-inflammatory drugs, AZULFIDINE EN-tabs does not produce an immediate response. Concurrent treatment with analgesics and/or nonsteroidal anti-inflammatory drugs is recommended at least until the effect of AZULFIDINE EN-tabs is apparent. uuid:7d71b980-f8f1-44a6-b058-70c6fb18f807 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9334 biolink:treats MONDO:0011429 PMID:41385096 "[{""id"":""uuid:b4965924-e924-4d49-85e6-1b7b94a5dbd1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0661e2bf-01f0-4e45-9175-bc563afcf028"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AZULFIDINE EN-tabs Tablets are indicated: • in the treatment of mild to moderate ulcerative colitis, and as adjunctive therapy in severe ulcerative colitis; • for the prolongation of the remission period between acute attacks of ulcerative colitis; • in the treatment of patients with rheumatoid arthritis who have responded inadequately to salicylates or other nonsteroidal anti-inflammatory drugs (e.g., an insufficient therapeutic response to, or intolerance of, an adequate trial of full doses of one or more nonsteroidal anti-inflammatory drugs); and • in the treatment of pediatric patients with polyarticular-course 1 juvenile rheumatoid arthritis who have responded inadequately to salicylates or other nonsteroidal anti-inflammatory drugs. AZULFIDINE EN-tabs is particularly indicated in patients with ulcerative colitis who cannot take uncoated sulfasalazine tablets because of gastrointestinal intolerance, and in whom there is evidence that this intolerance is not primarily the result of high blood levels of sulfapyridine and its metabolites, e.g., patients experiencing nausea and vomiting with the first few doses of the drug, or patients in whom a reduction in dosage does not alleviate the adverse gastrointestinal effects. In patients with rheumatoid arthritis or juvenile rheumatoid arthritis, rest and physiotherapy as indicated should be continued. Unlike anti-inflammatory drugs, AZULFIDINE EN-tabs does not produce an immediate response. Concurrent treatment with analgesics and/or nonsteroidal anti-inflammatory drugs is recommended at least until the effect of AZULFIDINE EN-tabs is apparent. uuid:66ed310c-cf93-4686-b122-32eb9e7a0969 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17303 biolink:treats MONDO:0018362 PMID:41385096 "[{""id"":""uuid:e4cf75bb-0b6c-4413-b209-c2426f2dcee6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4bdd37d6-ad1a-4ab5-82a7-bdc8cdcc2ff2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MS CONTIN is indicated for the management of severe and persistent pain that requires an extended treatment period with a daily opioid analgesic and for which alternative treatment options are inadequate. uuid:15295eaf-4570-4afa-b7dc-adc5e06c01db biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18243 biolink:treats MONDO:0006652 PMID:41385096 "[{""id"":""uuid:afa59e45-6c3d-424e-98e0-9aa25c5dfca1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2310c383-4a04-4875-a0d4-4b60bb49fcc9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dopamine hydrochloride is indicated for the correction of hemodynamic imbalances present in the shock syndrome due to myocardial infarctions, trauma, endotoxic septicemia, open heart surgery, renal failure and chronic cardiac decompensation as in congestive failure. Where appropriate, restoration of blood volume with a suitable plasma expander or whole blood should be instituted or completed prior to administration of dopamine hydrochloride. Patients most likely to respond adequately to dopamine hydrochloride are those in whom physiological parameters, such as urine flow, myocardial function and blood pressure have not undergone profound deterioration. Reports indicate that the shorter the time interval between onset of signs and symptoms and initiation of therapy with volume correction and dopamine hydrochloride, the better the prognosis. uuid:5c48be57-5e16-45fe-9f77-ed06b10c91c2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2XOI31YC4N biolink:treats MONDO:0006052 PMID:41385096 "[{""id"":""uuid:a04c07e9-00d8-4ed4-8e1d-5208292f7f3d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7bbc6dc6-9b12-42a5-aa53-25ca426c07f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Limited Population: Pretomanid Tablet is indicated, as part of a combination regimen with bedaquiline and linezolid for the treatment of adults with pulmonary tuberculosis (TB) resistant to isoniazid, rifamycins, a fluoroquinolone and a second line injectable antibacterial drug OR adults with pulmonary TB resistant to isoniazid and rifampin, who are treatment-intolerant or nonresponsive to standard therapy. Approval of this indication is based on limited clinical safety and efficacy data. This drug is indicated for use in a limited and specific population of patients. Limitations of Use: • Pretomanid Tablets are not indicated in patients with: o Drug-sensitive (DS) TB o Latent infection due to Mycobacterium tuberculosis o Extra-pulmonary infection due to Mycobacterium tuberculosis o TB resistant to isoniazid and rifampin who are responsive to standard therapy and not treatment-intolerant o TB with known resistance to any component of the combination • Safety and effectiveness of Pretomanid Tablets have not been established for its use in combination with drugs other than bedaquiline and linezolid as part of the recommended dosing regimen [see Dosage and Administration (2.2) ] . uuid:4a9c5731-f9af-4a9b-a8dd-fc9ef4453c2a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2XOI31YC4N biolink:treats MONDO:0100479 PMID:41385096 "[{""id"":""uuid:80eb459e-42a3-4cb1-b91f-eeb0189670a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5a52bbec-b5ff-464e-8722-63613b06fe40"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Limited Population: Pretomanid Tablet is indicated, as part of a combination regimen with bedaquiline and linezolid for the treatment of adults with pulmonary tuberculosis (TB) resistant to isoniazid, rifamycins, a fluoroquinolone and a second line injectable antibacterial drug OR adults with pulmonary TB resistant to isoniazid and rifampin, who are treatment-intolerant or nonresponsive to standard therapy. Approval of this indication is based on limited clinical safety and efficacy data. This drug is indicated for use in a limited and specific population of patients. Limitations of Use: • Pretomanid Tablets are not indicated in patients with: o Drug-sensitive (DS) TB o Latent infection due to Mycobacterium tuberculosis o Extra-pulmonary infection due to Mycobacterium tuberculosis o TB resistant to isoniazid and rifampin who are responsive to standard therapy and not treatment-intolerant o TB with known resistance to any component of the combination • Safety and effectiveness of Pretomanid Tablets have not been established for its use in combination with drugs other than bedaquiline and linezolid as part of the recommended dosing regimen [see Dosage and Administration (2.2) ] . uuid:3af221ee-2f80-422e-b46e-f353a0c615a6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2XOI31YC4N biolink:treats MONDO:0100482 PMID:41385096 "[{""id"":""uuid:707dbcd9-7bd8-4e1f-8206-bf99038c61eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:97c47676-ab2a-4765-ae8a-7c0f45a4b3ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:eb4f59ed-9154-42ec-b634-d07b6b1c80b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/dovprela-previously-pretomanid-fgk""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Limited Population: Pretomanid Tablet is indicated, as part of a combination regimen with bedaquiline and linezolid for the treatment of adults with pulmonary tuberculosis (TB) resistant to isoniazid, rifamycins, a fluoroquinolone and a second line injectable antibacterial drug OR adults with pulmonary TB resistant to isoniazid and rifampin, who are treatment-intolerant or nonresponsive to standard therapy. Approval of this indication is based on limited clinical safety and efficacy data. This drug is indicated for use in a limited and specific population of patients. Limitations of Use: • Pretomanid Tablets are not indicated in patients with: o Drug-sensitive (DS) TB o Latent infection due to Mycobacterium tuberculosis o Extra-pulmonary infection due to Mycobacterium tuberculosis o TB resistant to isoniazid and rifampin who are responsive to standard therapy and not treatment-intolerant o TB with known resistance to any component of the combination • Safety and effectiveness of Pretomanid Tablets have not been established for its use in combination with drugs other than bedaquiline and linezolid as part of the recommended dosing regimen [see Dosage and Administration (2.2) ] .|[EMA] Dovprela is indicated in combination with bedaquiline and linezolid, in adults, for the treatment of pulmonary extensively drug resistant (XDR), or treatment-intolerant or nonresponsive multidrug-resistant (MDR) tuberculosis (TB).Consideration should be given to official guidance on the appropriate use of antibacterial agents. uuid:55d744e6-526c-4245-9c77-871d403f435d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2XOI31YC4N biolink:treats MONDO:0005861 PMID:41385096 "[{""id"":""uuid:5112583a-b6ab-4529-9750-80cc4378cf22"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:28e2b1b7-b9dd-4b6f-bb7a-e7bf4d11e208"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:11eba9f5-d87a-483f-817c-2b824e62e567"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/dovprela-previously-pretomanid-fgk""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Limited Population: Pretomanid Tablet is indicated, as part of a combination regimen with bedaquiline and linezolid for the treatment of adults with pulmonary tuberculosis (TB) resistant to isoniazid, rifamycins, a fluoroquinolone and a second line injectable antibacterial drug OR adults with pulmonary TB resistant to isoniazid and rifampin, who are treatment-intolerant or nonresponsive to standard therapy. Approval of this indication is based on limited clinical safety and efficacy data. This drug is indicated for use in a limited and specific population of patients. Limitations of Use: • Pretomanid Tablets are not indicated in patients with: o Drug-sensitive (DS) TB o Latent infection due to Mycobacterium tuberculosis o Extra-pulmonary infection due to Mycobacterium tuberculosis o TB resistant to isoniazid and rifampin who are responsive to standard therapy and not treatment-intolerant o TB with known resistance to any component of the combination • Safety and effectiveness of Pretomanid Tablets have not been established for its use in combination with drugs other than bedaquiline and linezolid as part of the recommended dosing regimen [see Dosage and Administration (2.2) ] .|[EMA] Dovprela is indicated in combination with bedaquiline and linezolid, in adults, for the treatment of pulmonary extensively drug resistant (XDR), or treatment-intolerant or nonresponsive multidrug-resistant (MDR) tuberculosis (TB).Consideration should be given to official guidance on the appropriate use of antibacterial agents. uuid:f0789995-2f3c-417b-8fe8-43098c930085 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2XOI31YC4N biolink:treats MONDO:0040753 PMID:41385096 "[{""id"":""uuid:af9ec3a4-82e4-4282-8a77-fff6d51c7915"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f5913e8b-4436-4adc-baad-36a8725c74ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Limited Population: Pretomanid Tablet is indicated, as part of a combination regimen with bedaquiline and linezolid for the treatment of adults with pulmonary tuberculosis (TB) resistant to isoniazid, rifamycins, a fluoroquinolone and a second line injectable antibacterial drug OR adults with pulmonary TB resistant to isoniazid and rifampin, who are treatment-intolerant or nonresponsive to standard therapy. Approval of this indication is based on limited clinical safety and efficacy data. This drug is indicated for use in a limited and specific population of patients. Limitations of Use: • Pretomanid Tablets are not indicated in patients with: o Drug-sensitive (DS) TB o Latent infection due to Mycobacterium tuberculosis o Extra-pulmonary infection due to Mycobacterium tuberculosis o TB resistant to isoniazid and rifampin who are responsive to standard therapy and not treatment-intolerant o TB with known resistance to any component of the combination • Safety and effectiveness of Pretomanid Tablets have not been established for its use in combination with drugs other than bedaquiline and linezolid as part of the recommended dosing regimen [see Dosage and Administration (2.2) ] . uuid:5d1012bb-c303-43c7-909c-683bd5bb08b0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2XOI31YC4N biolink:treats MONDO:0018076 PMID:41385096 "[{""id"":""uuid:7a1f7419-ba86-4a2f-bbe8-c3156e047ad1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:547db507-c893-4052-87ea-063329f381f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Limited Population: Pretomanid Tablet is indicated, as part of a combination regimen with bedaquiline and linezolid for the treatment of adults with pulmonary tuberculosis (TB) resistant to isoniazid, rifamycins, a fluoroquinolone and a second line injectable antibacterial drug OR adults with pulmonary TB resistant to isoniazid and rifampin, who are treatment-intolerant or nonresponsive to standard therapy. Approval of this indication is based on limited clinical safety and efficacy data. This drug is indicated for use in a limited and specific population of patients. Limitations of Use: • Pretomanid Tablets are not indicated in patients with: o Drug-sensitive (DS) TB o Latent infection due to Mycobacterium tuberculosis o Extra-pulmonary infection due to Mycobacterium tuberculosis o TB resistant to isoniazid and rifampin who are responsive to standard therapy and not treatment-intolerant o TB with known resistance to any component of the combination • Safety and effectiveness of Pretomanid Tablets have not been established for its use in combination with drugs other than bedaquiline and linezolid as part of the recommended dosing regimen [see Dosage and Administration (2.2) ] . uuid:be3ad617-2470-41b0-9f9c-beb48979f27e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:82720 biolink:treats MONDO:0005300 PMID:41385096 "[{""id"":""uuid:67eba74f-6d05-4954-9afb-d8a54e5f5349"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:32f548a5-3e01-437a-b863-3c972610f054"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:95ff138c-4cf2-46df-b98e-827d2179e635"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/jardiance""]},{""id"":""uuid:4461ee0e-f76c-43a2-a32d-8ee67158a3da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] JARDIANCE is indicated: to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure. to reduce the risk of sustained decline in eGFR, end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease at risk of progression. to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease. as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus.|[EMA] Type 2 diabetes mellitusJardiance is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered in addition to other medicinal products for the treatment of diabetesFor study results with respect to combinations of therapies, effects on glycaemic control, and cardiovascular and renal events, and the populations studied, see sections 4.4, 4.5 and 5.1. of the annex.Heart failureJardiance is indicated in adults for the treatment of symptomatic chronic heart failure. Chronic kidney diseaseJardiance is indicated in adults for the treatment of chronic kidney disease.|[PMDA] A drug with a new indication and a new dosage for the treatment of chronic kidney disease. uuid:fef2f5fd-6555-4168-a373-7e11cd10fec2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:580134 biolink:treats UMLS:C0240066 PMID:41385096 "[{""id"":""uuid:4b1c84c0-e85c-4871-842a-db73d02d2bfb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c5a45aaa-29ee-40a5-b6ad-166cbc173f64"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS: Chromagen™ is a multivitamin/multimineral dietary supplement indicated for use in improving the nutritional status of patients with iron deficiency. uuid:a65eaea0-ed2e-41d6-8798-72cc29083d81 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:AG9MHG098Z biolink:treats MONDO:0018876 PMID:41385096 "[{""id"":""uuid:8ea83ac9-5661-4976-a7a6-2a843fa5cb38"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:14265225-ae58-478d-ae88-8d3f2e0c8682"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BRUKINSA is a kinase inhibitor indicated for the treatment of adult patients with: Mantle cell lymphoma (MCL) who have received at least one prior therapy. ( 1.1 ) This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Waldenström's macroglobulinemia (WM). ( 1.2 ) Relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti–CD20-based regimen. ( 1.3 ) This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). ( 1.4 ) Relapsed or refractory follicular lymphoma (FL), in combination with obinutuzumab, after two or more lines of systemic therapy. ( 1.5 ) This indication is approved under accelerated approval based on response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. uuid:5c48997d-5de8-4953-948b-44237ebb26d6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:AG9MHG098Z biolink:treats MONDO:0100280 PMID:41385096 "[{""id"":""uuid:e09a8bae-467b-49b2-aac4-f88783278a1f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:264f2ec2-0505-4f68-b8a0-e600673b4fe7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:cc9b8d5b-bd95-4d3c-9994-aa14d48a5485"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/brukinsa""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] BRUKINSA is a kinase inhibitor indicated for the treatment of adult patients with: Mantle cell lymphoma (MCL) who have received at least one prior therapy. ( 1.1 ) This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Waldenström's macroglobulinemia (WM). ( 1.2 ) Relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti–CD20-based regimen. ( 1.3 ) This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). ( 1.4 ) Relapsed or refractory follicular lymphoma (FL), in combination with obinutuzumab, after two or more lines of systemic therapy. ( 1.5 ) This indication is approved under accelerated approval based on response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.|[EMA] Brukinsa as monotherapy is indicated for the treatment of adult patients with Waldenström’s macroglobulinaemia (WM) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy.Brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based therapy.Brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL). uuid:4a5f6c00-82f1-4746-90ab-023f1afcb3b7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:AG9MHG098Z biolink:treats MONDO:0017604 PMID:41385096 "[{""id"":""uuid:369769af-985f-4884-82f0-8b5161a50ce3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:67ccca6f-6b0e-418a-90e6-73e569e95756"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e390b59b-82be-4fa9-a3cb-37f8f009ff62"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/brukinsa""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] BRUKINSA is a kinase inhibitor indicated for the treatment of adult patients with: Mantle cell lymphoma (MCL) who have received at least one prior therapy. ( 1.1 ) This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Waldenström's macroglobulinemia (WM). ( 1.2 ) Relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti–CD20-based regimen. ( 1.3 ) This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). ( 1.4 ) Relapsed or refractory follicular lymphoma (FL), in combination with obinutuzumab, after two or more lines of systemic therapy. ( 1.5 ) This indication is approved under accelerated approval based on response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.|[EMA] Brukinsa as monotherapy is indicated for the treatment of adult patients with Waldenström’s macroglobulinaemia (WM) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy.Brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based therapy.Brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL). uuid:166eaffc-ba36-4c2a-9edb-1f188af18279 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:AG9MHG098Z biolink:treats MONDO:0004948 PMID:41385096 "[{""id"":""uuid:be2dab6e-a8ce-41aa-98d9-40c350f6f181"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f02904b9-25de-4643-b334-877ef2a80ac6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BRUKINSA is a kinase inhibitor indicated for the treatment of adult patients with: Mantle cell lymphoma (MCL) who have received at least one prior therapy. ( 1.1 ) This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Waldenström's macroglobulinemia (WM). ( 1.2 ) Relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti–CD20-based regimen. ( 1.3 ) This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). ( 1.4 ) Relapsed or refractory follicular lymphoma (FL), in combination with obinutuzumab, after two or more lines of systemic therapy. ( 1.5 ) This indication is approved under accelerated approval based on response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. uuid:5914eb10-2bba-4a79-a8a6-2f2a7865d618 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:AG9MHG098Z biolink:treats MONDO:0003864 PMID:41385096 "[{""id"":""uuid:4e56871a-ebb8-4e39-9fa7-7f954c382e35"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:be98ee0f-94ac-4c07-a60c-8e2c0be6d369"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:fe0cf5ee-8ced-4bdc-aece-671b86cd08d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/brukinsa""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] BRUKINSA is a kinase inhibitor indicated for the treatment of adult patients with: Mantle cell lymphoma (MCL) who have received at least one prior therapy. ( 1.1 ) This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Waldenström's macroglobulinemia (WM). ( 1.2 ) Relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti–CD20-based regimen. ( 1.3 ) This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). ( 1.4 ) Relapsed or refractory follicular lymphoma (FL), in combination with obinutuzumab, after two or more lines of systemic therapy. ( 1.5 ) This indication is approved under accelerated approval based on response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.|[EMA] Brukinsa as monotherapy is indicated for the treatment of adult patients with Waldenström’s macroglobulinaemia (WM) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy.Brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based therapy.Brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL). uuid:25f70c2b-840b-4e37-b961-3f97443ae834 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:AG9MHG098Z biolink:treats MONDO:0018906 PMID:41385096 "[{""id"":""uuid:1dcc2c31-1a26-4b48-9ef4-18f65863f86c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:80b8cf45-862c-42d5-8efa-af9bf99e25dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BRUKINSA is a kinase inhibitor indicated for the treatment of adult patients with: Mantle cell lymphoma (MCL) who have received at least one prior therapy. ( 1.1 ) This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Waldenström's macroglobulinemia (WM). ( 1.2 ) Relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti–CD20-based regimen. ( 1.3 ) This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). ( 1.4 ) Relapsed or refractory follicular lymphoma (FL), in combination with obinutuzumab, after two or more lines of systemic therapy. ( 1.5 ) This indication is approved under accelerated approval based on response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. uuid:bf1bbd9d-df91-4c8c-8836-02ec665e77a5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:AVK0I6HY2U biolink:treats MONDO:0005298 PMID:41385096 "[{""id"":""uuid:850d3d02-4347-4f1d-8989-9d19f2e385b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:bd2a4075-6b2d-4373-a853-90a75a336094"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:2a3aa1d5-6b2d-4143-8548-f1c139d814e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/eladynos""]},{""id"":""uuid:5e6b5aaa-f420-4ca1-bd56-f474100b9b19"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TYMLOS is a human parathyroid hormone related peptide [PTHrP(1-34)] analog indicated for the: Treatment of postmenopausal women with osteoporosis at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy. ( 1.1 ) Treatment to increase bone density in men with osteoporosis at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy. ( 1.2 )|[EMA] Treatment of osteoporosis in postmenopausal women at increased risk of fracture.|[PMDA] A drug with a new active ingredient indicated for the treatment of osteoporosis with a high risk of fracture. uuid:ea6b582b-3521-4a6d-a566-49bcff14e3ae biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:370572 biolink:treats MONDO:0011918 PMID:41385096 "[{""id"":""uuid:988976a4-e6c0-4a5f-ab9c-92cc2d23d3cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7e0b68bc-08bb-48d6-bc9d-f821e0d12f0d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Perphenazine and amitriptyline hydrochloride tablets are recommended for treatment of (1) patients with moderate to severe anxiety and/or agitation and depressed mood, (2) patients with depression in whom anxiety and/or agitation are severe, and (3) patients with depression and anxiety in association with chronic physical disease. In many of these patients, anxiety masks the depressive state so that, although therapy with a tranquilizer appears to be indicated, the administration of a tranquilizer alone will not be adequate. Schizophrenic patients who have associated depressive symptoms should be considered for therapy with perphenazine and amitriptyline hydrochloride tablets. uuid:e6c7c50c-2c10-49a0-9d89-eeeafe03a39c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:370572 biolink:treats HP:0000713 PMID:41385096 "[{""id"":""uuid:d8268251-c953-41f9-82d0-24511744ae04"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:592c6384-6273-442f-9ce8-b6dab50bac98"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Perphenazine and amitriptyline hydrochloride tablets are recommended for treatment of (1) patients with moderate to severe anxiety and/or agitation and depressed mood, (2) patients with depression in whom anxiety and/or agitation are severe, and (3) patients with depression and anxiety in association with chronic physical disease. In many of these patients, anxiety masks the depressive state so that, although therapy with a tranquilizer appears to be indicated, the administration of a tranquilizer alone will not be adequate. Schizophrenic patients who have associated depressive symptoms should be considered for therapy with perphenazine and amitriptyline hydrochloride tablets. uuid:0303c37f-938e-4d14-bd1e-d43239f7f5b4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:370572 biolink:treats MONDO:0002050 PMID:41385096 "[{""id"":""uuid:38719c9e-1b88-4fa6-a57b-6e6f39eb8417"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2accc9f3-9b53-46c3-8962-f379bef18342"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Perphenazine and amitriptyline hydrochloride tablets are recommended for treatment of (1) patients with moderate to severe anxiety and/or agitation and depressed mood, (2) patients with depression in whom anxiety and/or agitation are severe, and (3) patients with depression and anxiety in association with chronic physical disease. In many of these patients, anxiety masks the depressive state so that, although therapy with a tranquilizer appears to be indicated, the administration of a tranquilizer alone will not be adequate. Schizophrenic patients who have associated depressive symptoms should be considered for therapy with perphenazine and amitriptyline hydrochloride tablets. uuid:6641c6c3-f076-4471-9809-fddac3b5e2c8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:370572 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:996899c0-bd7d-496f-a32f-2ca28dacef0f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dd99a280-aecd-4e88-ad97-6fee02d015c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Perphenazine and amitriptyline hydrochloride tablets are recommended for treatment of (1) patients with moderate to severe anxiety and/or agitation and depressed mood, (2) patients with depression in whom anxiety and/or agitation are severe, and (3) patients with depression and anxiety in association with chronic physical disease. In many of these patients, anxiety masks the depressive state so that, although therapy with a tranquilizer appears to be indicated, the administration of a tranquilizer alone will not be adequate. Schizophrenic patients who have associated depressive symptoms should be considered for therapy with perphenazine and amitriptyline hydrochloride tablets. uuid:2608a780-7790-4e5b-b3b5-d558274d7d65 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:370572 biolink:treats MONDO:0005090 PMID:41385096 "[{""id"":""uuid:01ae6dbf-1d06-4d5f-bfb0-480193d3940f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:28955a86-0498-4aa6-bb56-7d4eb852c859"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Perphenazine and amitriptyline hydrochloride tablets are recommended for treatment of (1) patients with moderate to severe anxiety and/or agitation and depressed mood, (2) patients with depression in whom anxiety and/or agitation are severe, and (3) patients with depression and anxiety in association with chronic physical disease. In many of these patients, anxiety masks the depressive state so that, although therapy with a tranquilizer appears to be indicated, the administration of a tranquilizer alone will not be adequate. Schizophrenic patients who have associated depressive symptoms should be considered for therapy with perphenazine and amitriptyline hydrochloride tablets. uuid:35358c1b-d103-4314-af44-a72035c3c11c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75998 biolink:treats MONDO:0005105 PMID:41385096 "[{""id"":""uuid:c7510f85-05c7-456c-b49d-8ef087f4891d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:2014a6a2-d581-49ca-b30c-0e9312e1b3ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:a9e6e03a-030e-44f7-81f6-d8ec2d4740eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/mekinist""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] MEKINIST is a kinase inhibitor indicated as a single agent for the treatment of BRAF-inhibitor treatment-naïve patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. ( 1.1 , 2.1 ) MEKINIST is indicated, in combination with dabrafenib, for: the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. ( 1.1 , 2.1 ) the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection. ( 1.2 , 2.1 ) the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test. ( 1.3 , 2.1 ) the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation, as detected by an FDA-approved test, and with no satisfactory locoregional treatment options. ( 1.4 , 2.1 ) the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1.5 , 2.1 ) the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. ( 1.6 , 2.1 ) Limitations of Use : MEKINIST is not indicated for treatment of patients with colorectal cancer because of known intrinsic resistance to BRAF inhibition. ( 1.7 , 12.1 )|[EMA] MelanomaTrametinib as monotherapy or in combination with dabrafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation (see sections 4.4 and 5.1).Trametinib monotherapy has not demonstrated clinical activity in patients who have progressed on a prior BRAF inhibitor therapy (see section 5.1).Adjuvant treatment of melanomaTrametinib in combination with dabrafenib is indicated for the adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection.Non-small cell lung cancer (NSCLC)Trametinib in combination with dabrafenib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 mutation. uuid:33ebf3cb-5944-484d-8271-0ef24f66de88 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75998 biolink:treats MONDO:0005191 PMID:41385096 "[{""id"":""uuid:525f8978-04db-4724-86d2-a0d7d55d34a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6132d0f9-3c27-485c-a579-a8fd62be452a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MEKINIST is a kinase inhibitor indicated as a single agent for the treatment of BRAF-inhibitor treatment-naïve patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. ( 1.1 , 2.1 ) MEKINIST is indicated, in combination with dabrafenib, for: the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. ( 1.1 , 2.1 ) the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection. ( 1.2 , 2.1 ) the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test. ( 1.3 , 2.1 ) the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation, as detected by an FDA-approved test, and with no satisfactory locoregional treatment options. ( 1.4 , 2.1 ) the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1.5 , 2.1 ) the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. ( 1.6 , 2.1 ) Limitations of Use : MEKINIST is not indicated for treatment of patients with colorectal cancer because of known intrinsic resistance to BRAF inhibition. ( 1.7 , 12.1 ) uuid:140b470c-5aaf-4c28-96e7-26d2f02156d0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75998 biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:c815bbab-e034-4901-9e71-4457a0df268c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0358ed58-f5a4-4f9a-9b70-becb9b38e97b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:d2dd34ef-7e65-4cdc-8dc8-ce2da6da5bed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/mekinist""]},{""id"":""uuid:33f2da63-b5cd-485b-9ca5-8657d2f5f6f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MEKINIST is a kinase inhibitor indicated as a single agent for the treatment of BRAF-inhibitor treatment-naïve patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. ( 1.1 , 2.1 ) MEKINIST is indicated, in combination with dabrafenib, for: the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. ( 1.1 , 2.1 ) the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection. ( 1.2 , 2.1 ) the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test. ( 1.3 , 2.1 ) the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation, as detected by an FDA-approved test, and with no satisfactory locoregional treatment options. ( 1.4 , 2.1 ) the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1.5 , 2.1 ) the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. ( 1.6 , 2.1 ) Limitations of Use : MEKINIST is not indicated for treatment of patients with colorectal cancer because of known intrinsic resistance to BRAF inhibition. ( 1.7 , 12.1 )|[EMA] MelanomaTrametinib as monotherapy or in combination with dabrafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation (see sections 4.4 and 5.1).Trametinib monotherapy has not demonstrated clinical activity in patients who have progressed on a prior BRAF inhibitor therapy (see section 5.1).Adjuvant treatment of melanomaTrametinib in combination with dabrafenib is indicated for the adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection.Non-small cell lung cancer (NSCLC)Trametinib in combination with dabrafenib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 mutation.|[PMDA] Drugs with a new additional indication for the treatment of unresectable advanced or recurrent BRAF mutation-positive non-small-cell lung cancer. [Orphan drug] uuid:e8064195-4a09-40d0-b60c-edf42ced4a29 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75998 biolink:treats MONDO:0006468 PMID:41385096 "[{""id"":""uuid:6ce4dc3f-e285-426c-a98c-66a48a17a511"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7be38f94-8ba0-4121-8170-82ed417f304b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MEKINIST is a kinase inhibitor indicated as a single agent for the treatment of BRAF-inhibitor treatment-naïve patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. ( 1.1 , 2.1 ) MEKINIST is indicated, in combination with dabrafenib, for: the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. ( 1.1 , 2.1 ) the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection. ( 1.2 , 2.1 ) the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test. ( 1.3 , 2.1 ) the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation, as detected by an FDA-approved test, and with no satisfactory locoregional treatment options. ( 1.4 , 2.1 ) the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1.5 , 2.1 ) the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. ( 1.6 , 2.1 ) Limitations of Use : MEKINIST is not indicated for treatment of patients with colorectal cancer because of known intrinsic resistance to BRAF inhibition. ( 1.7 , 12.1 ) uuid:a4af35ed-f6ff-4b25-8af7-a6e983932996 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75998 biolink:treats MONDO:0024879 PMID:41385096 "[{""id"":""uuid:ee37f7dc-678b-4f04-a68b-02f67364d1ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eacfb81c-7ae4-4cab-995f-c06fbe639b7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MEKINIST is a kinase inhibitor indicated as a single agent for the treatment of BRAF-inhibitor treatment-naïve patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. ( 1.1 , 2.1 ) MEKINIST is indicated, in combination with dabrafenib, for: the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. ( 1.1 , 2.1 ) the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection. ( 1.2 , 2.1 ) the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test. ( 1.3 , 2.1 ) the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation, as detected by an FDA-approved test, and with no satisfactory locoregional treatment options. ( 1.4 , 2.1 ) the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1.5 , 2.1 ) the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. ( 1.6 , 2.1 ) Limitations of Use : MEKINIST is not indicated for treatment of patients with colorectal cancer because of known intrinsic resistance to BRAF inhibition. ( 1.7 , 12.1 ) uuid:9f09775e-cf7a-410d-b83e-bf88b4e53653 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75998 biolink:treats MONDO:0021042 PMID:41385096 "[{""id"":""uuid:5dd4e101-0c06-41af-8cc3-2355429e1bac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:26e00d71-fb3f-424d-9c67-c6689c752532"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MEKINIST is a kinase inhibitor indicated as a single agent for the treatment of BRAF-inhibitor treatment-naïve patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. ( 1.1 , 2.1 ) MEKINIST is indicated, in combination with dabrafenib, for: the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. ( 1.1 , 2.1 ) the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection. ( 1.2 , 2.1 ) the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test. ( 1.3 , 2.1 ) the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation, as detected by an FDA-approved test, and with no satisfactory locoregional treatment options. ( 1.4 , 2.1 ) the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1.5 , 2.1 ) the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. ( 1.6 , 2.1 ) Limitations of Use : MEKINIST is not indicated for treatment of patients with colorectal cancer because of known intrinsic resistance to BRAF inhibition. ( 1.7 , 12.1 ) uuid:bd31cea1-feb1-476b-8121-e582f4107c98 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:RZT8C352O1 biolink:treats MONDO:0009823 PMID:41385096 "[{""id"":""uuid:124b564d-e2c6-4a30-b579-331f61407140"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:b79c68a5-8450-4fca-8fbe-f5f84d0a1f81"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:3418cc33-228c-48aa-a18d-40feaaab0017"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OXLUMO is indicated for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary and plasma oxalate levels in pediatric and adult patients [see Clinical Pharmacology (12.1) , Clinical Studies (14.1 , 14.2 , 14.3) ] .|[EMA] Treatment of primary hyperoxaluria type 1 (PH1) in all age groups. uuid:0b4e0442-1b04-4588-859b-5d24d3adff6f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:RZT8C352O1 biolink:treats MONDO:0024685 PMID:41385096 "[{""id"":""uuid:3ab29641-01a8-415f-b59e-47990356f07d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:13f9c6a1-e268-4921-b134-cf3f2e4f8dc9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OXLUMO is indicated for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary and plasma oxalate levels in pediatric and adult patients [see Clinical Pharmacology (12.1) , Clinical Studies (14.1 , 14.2 , 14.3) ] . uuid:e078f363-0413-4eae-a076-04dc3f305ee6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:76607 biolink:treats MONDO:0015924 PMID:41385096 "[{""id"":""uuid:ade3e733-82d5-44b7-8b6a-4b53fc59f251"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c2006950-2ccb-4e9f-a65d-e152c25dbd6e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:854e18c2-72e3-4c36-84aa-6e75e76cd3f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/opsumit""]},{""id"":""uuid:9d808081-0581-40aa-8a7f-a448f12a18cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OPSUMIT is an endothelin receptor antagonist (ERA) indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) in adults to reduce the risks of disease progression and hospitalization for PAH ( 1.1 ).|[EMA] Opsumit, as monotherapy or in combination, is indicated for the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients of WHO Functional Class (FC) II to III.Efficacy has been shown in a PAH population including idiopathic and heritable PAH, PAH associated with connective tissue disorders, and PAH associated with corrected simple congenital heart disease.|[PMDA] A drug with a new active ingredient indicated for the treatment of pulmonary arterial hypertension. uuid:3d5ac17f-840c-438c-be27-2fee1bba5706 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:WGD229O42W biolink:treats MONDO:0041656 PMID:41385096 "[{""id"":""uuid:3710f879-7781-4782-ade4-a37ea67bf2e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2b69ffb1-2075-4404-ac1c-21f4f377641b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TNKase ® is indicated to reduce the risk of death associated with acute ST elevation myocardial infarction (STEMI). uuid:124e5da1-be18-41e9-a398-2e58935fc612 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135913 biolink:treats MONDO:0001684 PMID:41385096 "[{""id"":""uuid:3b8bbde6-413c-4853-a2fb-d351584f40e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:11c4e6c2-58b0-4fb1-8305-b55bf6487173"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ChiRhoStim ® is indicated for the stimulation of: pancreatic secretions, including bicarbonate, to aid in the diagnosis of pancreatic exocrine dysfunction. gastrin secretion to aid in the diagnosis of gastrinoma, and pancreatic secretions to facilitate the identification of the ampulla of Vater and accessory papilla during endoscopic retrograde cholangiopancreatography (ERCP). uuid:26dd9a59-fa9f-4146-98be-7c95ec93ee70 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135913 biolink:treats MONDO:0003523 PMID:41385096 "[{""id"":""uuid:dcc057a1-7d91-4d4a-85e0-b5e5cb057687"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:87c5a1b0-e44b-481e-9e44-6d18a38c9223"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ChiRhoStim ® is indicated for the stimulation of: pancreatic secretions, including bicarbonate, to aid in the diagnosis of pancreatic exocrine dysfunction. gastrin secretion to aid in the diagnosis of gastrinoma, and pancreatic secretions to facilitate the identification of the ampulla of Vater and accessory papilla during endoscopic retrograde cholangiopancreatography (ERCP). uuid:b4120e5f-f6ab-4980-975a-acddda86a84a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:132233 biolink:treats MONDO:0005302 PMID:41385096 "[{""id"":""uuid:9366eb51-b446-4a65-8d38-c69a6892cf63"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:228fb5e8-05b2-41a7-93a9-64d468df4a61"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ADZENYS XR-ODT is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years and older [see Clinical Studies (14) ]. uuid:b1ba2ab6-543c-465a-a2ee-c3c934cc44ff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:WGD229O42W biolink:treats HP:0002140 PMID:41385096 "[{""id"":""uuid:85efb281-eaee-4c83-8323-e0cf185eeb05"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fb5d8d13-d3ad-4094-8ce0-38023996aae4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TNKase is a tissue plasminogen activator (tPA) indicated: for the treatment of acute ischemic stroke (AIS) in adults. ( 1.1 ) to reduce the risk of death associated with acute ST elevation myocardial infarction (STEMI) in adults. ( 1.2 ) uuid:fb7bffa9-f80d-4cb9-b8cc-a4108ced5df9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75045 biolink:treats UMLS:C4725093 PMID:41385096 "[{""id"":""uuid:26c7d807-eef4-4f13-9855-073c11c60c3a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3eade012-a1be-4b94-b054-01f9301366ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TAFINLAR is a kinase inhibitor indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test. ( 1.1 , 2.1 ) TAFINLAR is indicated, in combination with trametinib , for: the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. ( 1.2 , 2.1 ) the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection. ( 1.3 , 2.1 ) the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test. ( 1.4 , 2.1 ) the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation, as detected by an FDA-approved test, and with no satisfactory locoregional treatment options. ( 1.5 , 2.1 ) the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DoR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1.6 , 2.1 ) the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. ( 1.7 , 2.1 ) Limitations of Use : TAFINLAR is not indicated for treatment of patients with colorectal cancer because of known intrinsic resistance to BRAF inhibition. ( 1.8 , 12.1 ) TAFINLAR is not indicated for treatment of patients with wild-type BRAF solid tumors. ( 5.2 ) uuid:330d11c8-cde7-4a4e-b99a-ea8471e2c636 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75045 biolink:treats MONDO:0005191 PMID:41385096 "[{""id"":""uuid:8a346a96-b5f9-430d-b965-fcd4b73c777d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aac2670b-ef1e-45c3-ae9a-d7b4c1a7b312"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TAFINLAR is a kinase inhibitor indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test. ( 1.1 , 2.1 ) TAFINLAR is indicated, in combination with trametinib , for: the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. ( 1.2 , 2.1 ) the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection. ( 1.3 , 2.1 ) the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test. ( 1.4 , 2.1 ) the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation, as detected by an FDA-approved test, and with no satisfactory locoregional treatment options. ( 1.5 , 2.1 ) the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DoR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1.6 , 2.1 ) the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. ( 1.7 , 2.1 ) Limitations of Use : TAFINLAR is not indicated for treatment of patients with colorectal cancer because of known intrinsic resistance to BRAF inhibition. ( 1.8 , 12.1 ) TAFINLAR is not indicated for treatment of patients with wild-type BRAF solid tumors. ( 5.2 ) uuid:f195e0b8-b20f-49d1-83b2-532b39161446 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75045 biolink:treats MONDO:0005438 PMID:41385096 "[{""id"":""uuid:97335686-9a2b-4478-a2c0-89e6e51f4651"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1016291a-f787-4e8c-970f-7274c8e0ae8d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TAFINLAR is a kinase inhibitor indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test. ( 1.1 , 2.1 ) TAFINLAR is indicated, in combination with trametinib , for: the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. ( 1.2 , 2.1 ) the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection. ( 1.3 , 2.1 ) the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test. ( 1.4 , 2.1 ) the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation, as detected by an FDA-approved test, and with no satisfactory locoregional treatment options. ( 1.5 , 2.1 ) the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DoR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1.6 , 2.1 ) the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. ( 1.7 , 2.1 ) Limitations of Use : TAFINLAR is not indicated for treatment of patients with colorectal cancer because of known intrinsic resistance to BRAF inhibition. ( 1.8 , 12.1 ) TAFINLAR is not indicated for treatment of patients with wild-type BRAF solid tumors. ( 5.2 ) uuid:83a591e8-562a-4cd9-9bca-4f408dc5de79 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75045 biolink:treats UMLS:C0278987 PMID:41385096 "[{""id"":""uuid:4241f300-84b7-49b3-af4b-c1668c32e208"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:68591173-0593-4d2c-b33c-583f4d23b7dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TAFINLAR is a kinase inhibitor indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test. ( 1.1 , 2.1 ) TAFINLAR is indicated, in combination with trametinib , for: the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. ( 1.2 , 2.1 ) the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection. ( 1.3 , 2.1 ) the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test. ( 1.4 , 2.1 ) the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation, as detected by an FDA-approved test, and with no satisfactory locoregional treatment options. ( 1.5 , 2.1 ) the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DoR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1.6 , 2.1 ) the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. ( 1.7 , 2.1 ) Limitations of Use : TAFINLAR is not indicated for treatment of patients with colorectal cancer because of known intrinsic resistance to BRAF inhibition. ( 1.8 , 12.1 ) TAFINLAR is not indicated for treatment of patients with wild-type BRAF solid tumors. ( 5.2 ) uuid:54419cc2-f602-428f-956f-534e0bba992e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75045 biolink:treats MONDO:0006468 PMID:41385096 "[{""id"":""uuid:fccb5c5f-c086-45d3-8d30-a9d435dfe5f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fee83e02-ec17-4514-afd1-e1540d80f797"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TAFINLAR is a kinase inhibitor indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test. ( 1.1 , 2.1 ) TAFINLAR is indicated, in combination with trametinib , for: the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. ( 1.2 , 2.1 ) the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection. ( 1.3 , 2.1 ) the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test. ( 1.4 , 2.1 ) the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation, as detected by an FDA-approved test, and with no satisfactory locoregional treatment options. ( 1.5 , 2.1 ) the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DoR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1.6 , 2.1 ) the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. ( 1.7 , 2.1 ) Limitations of Use : TAFINLAR is not indicated for treatment of patients with colorectal cancer because of known intrinsic resistance to BRAF inhibition. ( 1.8 , 12.1 ) TAFINLAR is not indicated for treatment of patients with wild-type BRAF solid tumors. ( 5.2 ) uuid:9e3f022b-64c1-42ea-95d5-1d933c800fba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75045 biolink:treats MONDO:0024879 PMID:41385096 "[{""id"":""uuid:73817dbd-da3b-4e8f-8c95-a2c867091503"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a5b4e059-cb04-4fec-b2d7-8d3a6105b88c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TAFINLAR is a kinase inhibitor indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test. ( 1.1 , 2.1 ) TAFINLAR is indicated, in combination with trametinib , for: the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. ( 1.2 , 2.1 ) the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection. ( 1.3 , 2.1 ) the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test. ( 1.4 , 2.1 ) the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation, as detected by an FDA-approved test, and with no satisfactory locoregional treatment options. ( 1.5 , 2.1 ) the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DoR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1.6 , 2.1 ) the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. ( 1.7 , 2.1 ) Limitations of Use : TAFINLAR is not indicated for treatment of patients with colorectal cancer because of known intrinsic resistance to BRAF inhibition. ( 1.8 , 12.1 ) TAFINLAR is not indicated for treatment of patients with wild-type BRAF solid tumors. ( 5.2 ) uuid:60214637-ea23-4da2-9c19-09b9b049be85 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75045 biolink:treats MONDO:0021042 PMID:41385096 "[{""id"":""uuid:fa6476eb-997f-45c3-9483-13f9824874fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c0250994-cb94-40a8-bc7e-ae23aeb392f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TAFINLAR is a kinase inhibitor indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test. ( 1.1 , 2.1 ) TAFINLAR is indicated, in combination with trametinib , for: the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. ( 1.2 , 2.1 ) the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection. ( 1.3 , 2.1 ) the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test. ( 1.4 , 2.1 ) the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation, as detected by an FDA-approved test, and with no satisfactory locoregional treatment options. ( 1.5 , 2.1 ) the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DoR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1.6 , 2.1 ) the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. ( 1.7 , 2.1 ) Limitations of Use : TAFINLAR is not indicated for treatment of patients with colorectal cancer because of known intrinsic resistance to BRAF inhibition. ( 1.8 , 12.1 ) TAFINLAR is not indicated for treatment of patients with wild-type BRAF solid tumors. ( 5.2 ) uuid:c8185907-0c8d-47e5-8221-7583c53d0939 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2677762 biolink:treats MONDO:0015924 PMID:41385096 "[{""id"":""uuid:39847de3-cf8f-4ebb-97d5-cee2989aabd1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a7e423a1-8102-4aa0-bdd2-895bb32272a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OPSYNVI is a combination of macitentan, an endothelin receptor antagonist (ERA), and tadalafil, a phosphodiesterase 5 (PDE5) inhibitor, indicated for chronic treatment of pulmonary arterial hypertension (PAH, WHO Group I) in adult patients of WHO functional class (FC) II–III. ( 1.1 ) Individually, macitentan reduces the risk of clinical worsening events and hospitalization, and tadalafil improves exercise ability. ( 1.1 , 14 ) uuid:150b806e-30e7-4eb6-9634-1662cbc8a369 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:961YV2O515 biolink:treats MONDO:0009688 PMID:41385096 "[{""id"":""uuid:e5ebcd99-3cd6-4018-a80f-b349a8018bb1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:082241f5-fae3-4823-b310-16bbe2f9183d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c83817a1-f694-4edb-996f-0d2d9c499cdb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/vyvgart""]},{""id"":""uuid:9669ae42-4edb-45c5-8089-ece1186f46e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VYVGART is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.|[EMA] Vyvgart is indicated as an add on to standard therapy for the treatment of adult patients with generalised myasthenia gravis (gMG) who are anti acetylcholine receptor (AChR) antibody positive.|[PMDA] A drug with a new active ingredient indicated for the treatment of generalized myasthenia gravis (for use only in patients who have not sufficiently responded to steroids or other immunosuppressants). [Orphan drug] uuid:6c9cc470-ea18-4310-86f2-245155bc4ff8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:228304 biolink:treats MONDO:0010679 PMID:41385096 "[{""id"":""uuid:b2c0601c-1973-4f46-9fef-ec32b7969311"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2dc01139-db0b-4682-969d-9853fff36ef9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AGAMREE is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older. uuid:4ac2f724-9e1b-456d-85e6-e4bc05726317 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:140407 biolink:treats MONDO:0005545 PMID:41385096 "[{""id"":""uuid:69787a64-965f-4d8c-a3ab-a552f2107f65"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d9fb6533-9161-42fd-9718-55a1f268c5b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZEVTERA is a cephalosporin antibacterial indicated for the treatment of: Adult patients with Staphylococcus aureus bloodstream infections (bacteremia) (SAB), including those with right-sided infective endocarditis ( 1.1 ), Adult patients with acute bacterial skin and skin structure infections (ABSSSI) ( 1.2 ), and Adult and pediatric patients (3 months to less than 18 years old) with community-acquired bacterial pneumonia (CABP) ( 1.3 ). To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZEVTERA and other antibacterial drugs, ZEVTERA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria ( 1.4 ). uuid:73b2aca0-9726-46ea-acba-b374b0750f8d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:140407 biolink:treats MONDO:0005229 PMID:41385096 "[{""id"":""uuid:58002718-faf3-4988-9bf9-121ad9197742"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d888c8e5-dfe0-4046-9fa5-caa58042c1bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZEVTERA is a cephalosporin antibacterial indicated for the treatment of: Adult patients with Staphylococcus aureus bloodstream infections (bacteremia) (SAB), including those with right-sided infective endocarditis ( 1.1 ), Adult patients with acute bacterial skin and skin structure infections (ABSSSI) ( 1.2 ), and Adult and pediatric patients (3 months to less than 18 years old) with community-acquired bacterial pneumonia (CABP) ( 1.3 ). To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZEVTERA and other antibacterial drugs, ZEVTERA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria ( 1.4 ). uuid:b4d225a3-adb8-48d4-9a4d-71642d815d4d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:140407 biolink:treats MONDO:0000565 PMID:41385096 "[{""id"":""uuid:8307c157-0930-468d-a5d2-a83f6b87f424"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8fad5936-a174-4871-bae6-6993e00701a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZEVTERA is a cephalosporin antibacterial indicated for the treatment of: Adult patients with Staphylococcus aureus bloodstream infections (bacteremia) (SAB), including those with right-sided infective endocarditis ( 1.1 ), Adult patients with acute bacterial skin and skin structure infections (ABSSSI) ( 1.2 ), and Adult and pediatric patients (3 months to less than 18 years old) with community-acquired bacterial pneumonia (CABP) ( 1.3 ). To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZEVTERA and other antibacterial drugs, ZEVTERA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria ( 1.4 ). uuid:0b56bc29-c306-44e0-a60b-511ea38141d4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:140407 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:b8999a09-eb76-4e06-862e-fd343de926d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:10526ebd-fed0-4f6c-a4ce-fd98cc9a21f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZEVTERA is a cephalosporin antibacterial indicated for the treatment of: Adult patients with Staphylococcus aureus bloodstream infections (bacteremia) (SAB), including those with right-sided infective endocarditis ( 1.1 ), Adult patients with acute bacterial skin and skin structure infections (ABSSSI) ( 1.2 ), and Adult and pediatric patients (3 months to less than 18 years old) with community-acquired bacterial pneumonia (CABP) ( 1.3 ). To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZEVTERA and other antibacterial drugs, ZEVTERA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria ( 1.4 ). uuid:9916ce48-cfb7-41be-b9b8-81d07f55ee99 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:140407 biolink:treats MONDO:0004652 PMID:41385096 "[{""id"":""uuid:7dbefab0-9c6a-487a-b421-b99967c9f221"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8855d0e1-4022-433a-b446-0e11d3349b47"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZEVTERA is a cephalosporin antibacterial indicated for the treatment of: Adult patients with Staphylococcus aureus bloodstream infections (bacteremia) (SAB), including those with right-sided infective endocarditis ( 1.1 ), Adult patients with acute bacterial skin and skin structure infections (ABSSSI) ( 1.2 ), and Adult and pediatric patients (3 months to less than 18 years old) with community-acquired bacterial pneumonia (CABP) ( 1.3 ). To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZEVTERA and other antibacterial drugs, ZEVTERA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria ( 1.4 ). uuid:1125f20a-a5f0-4794-a4b1-aa12f77bde62 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:XII270YC6M biolink:treats UMLS:C3854623 PMID:41385096 "[{""id"":""uuid:607e843d-a91e-4bea-baa1-c5a3c5f98877"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2180efb9-0d48-4363-8f08-f61e1cd26b7e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nabi-HB, Hepatitis B Immune Globulin (Human), is indicated for treatment of acute exposure to blood containing HBsAg, perinatal exposure of infants born to HBsAg-positive mothers, sexual exposure to HBsAg-positive persons and household exposure to persons with acute HBV infec- tion in the following settings: Acute Exposure to Blood Containing HBsAg: Following either parenteral exposure (needlestick, bite, sharps), direct mucous membrane contact (accidental splash), or oral ingestion (pipetting accident), involving HBsAg-positive materials such as blood, plasma, or serum. Perinatal Exposure of Infants Born to HBsAg-positive Mothers: Infants born to mothers positive for HBsAg with or without HBeAg 12 . Sexual Exposure to HBsAg-positive Persons: Sexual partners of HBsAg-positive persons. Household Exposure to Persons with Acute HBV Infection: Infants less than 12 months old whose mother or primary caregiver is positive for HBsAg. Other household contacts with an identifiable blood exposure to the index patient. Nabi-HB is indicated for intramuscular use only. uuid:08a744f8-5eb4-4cda-bf74-c36ddd8e196c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4Z63YK6E0E biolink:treats MONDO:0009693 PMID:41385096 "[{""id"":""uuid:cf9f40ea-775d-4b1c-8614-5773c74ffe2e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:cfe8eacd-f330-4bb4-bf7f-4de891129f89"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:bac0f7c6-ab67-412d-ae68-1c4bfe0d9ea6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/darzalex""]},{""id"":""uuid:bfa65697-8b7e-4f6d-b0c2-8a32d06d36fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DARZALEX is indicated for the treatment of adult patients with multiple myeloma: in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy. in combination with bortezomib, melphalan and prednisone in newly diagnosed patients who are ineligible for autologous stem cell transplant. in combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for autologous stem cell transplant. in combination with bortezomib and dexamethasone in patients who have received at least one prior therapy. in combination with carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy. in combination with pomalidomide and dexamethasone in patients who have received at least two prior therapies including lenalidomide and a proteasome inhibitor. as monotherapy, in patients who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent.|[EMA] Multiple MyelomaDarzalex is indicated: in combination with lenalidomide and dexamethasone or with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.in combination with bortezomib, thalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one prior therapy containing a proteasome inhibitor and lenalidomide and were lenalidomide refractory, or who have received at least two prior therapies that included lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or after the last therapy (see section 5.1).as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy.AL AmyloidosisDARZALEX is indicated in combination with cyclophosphamide, bortezomib and dexamethasone for the treatment of adult patients with newly diagnosed systemic light chain (AL) amyloidosis.|[PMDA] Drugs with a new active ingredient indicated for the treatment of relapsed or refractory multiple myeloma. [Orphan drug] uuid:7bd6a44e-c575-4e04-9415-8e8c7ad4ffc5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:76609 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:a9d11f0d-54b9-4d85-913f-4e446f048223"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:76ed8052-cc53-45e7-8871-bdadd481f0d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TRYVIO, in combination with other antihypertensive drugs, is indicated for the treatment of hypertension, to lower blood pressure (BP) in adult patients who are not adequately controlled on other drugs. Lowering BP reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. There are no controlled trials demonstrating reduction of risk of these events with TRYVIO. Control of high BP should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve BP goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is BP reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher BPs, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from BP reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower BP goal. uuid:d08a9163-ee26-46f8-92c6-6d006c000953 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:76609 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:4a04eec4-d48a-4928-bd12-e4e0942966e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8dd2a332-38cb-41be-896f-07da0b0ae56b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TRYVIO, in combination with other antihypertensive drugs, is indicated for the treatment of hypertension, to lower blood pressure (BP) in adult patients who are not adequately controlled on other drugs. Lowering BP reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. There are no controlled trials demonstrating reduction of risk of these events with TRYVIO. Control of high BP should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve BP goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is BP reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher BPs, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from BP reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower BP goal. uuid:2e34ef01-503c-451d-8c85-1a529f658ce8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:76609 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:aabc91eb-45c9-439b-8f0e-0097ef3fb559"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eab2cd9b-0091-4e86-bec7-52ff365f843f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TRYVIO, in combination with other antihypertensive drugs, is indicated for the treatment of hypertension, to lower blood pressure (BP) in adult patients who are not adequately controlled on other drugs. Lowering BP reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. There are no controlled trials demonstrating reduction of risk of these events with TRYVIO. Control of high BP should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve BP goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is BP reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher BPs, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from BP reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower BP goal. uuid:3360f243-bb3a-4761-b5f0-85b85125f481 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:76609 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:093fcbf3-4e0b-4a40-bdce-01698a738fa6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2a49a9a9-1b2a-4473-836e-b366863b0434"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TRYVIO, in combination with other antihypertensive drugs, is indicated for the treatment of hypertension, to lower blood pressure (BP) in adult patients who are not adequately controlled on other drugs. Lowering BP reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. There are no controlled trials demonstrating reduction of risk of these events with TRYVIO. Control of high BP should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve BP goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is BP reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher BPs, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from BP reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower BP goal. uuid:3f186017-6d18-4afe-8562-409a237c418c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:76609 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:20a19aba-80d3-47ea-b7f6-4e3c5b5f6cb8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c899b0ac-6b6b-4ac2-9bc6-4b8532f79bbb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TRYVIO, in combination with other antihypertensive drugs, is indicated for the treatment of hypertension, to lower blood pressure (BP) in adult patients who are not adequately controlled on other drugs. Lowering BP reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. There are no controlled trials demonstrating reduction of risk of these events with TRYVIO. Control of high BP should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve BP goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is BP reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher BPs, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from BP reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower BP goal. uuid:c06fc86e-223e-43b1-8e5e-b6e0e824dae6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1945215 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:df51da3f-894e-4ab1-bf08-46b0daf66370"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d47fe8b6-9ed5-4520-9051-faa8ec6e1fce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:83b0f3fa-9bae-45ac-9a4a-2b16977d9480"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/vaborem""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] VABOMERE (meropenem and vaborbactam) is a combination of meropenem, a penem antibacterial, and vaborbactam, a beta-lactamase inhibitor, indicated for the treatment of patients 18 years and older with complicated urinary tract infections (cUTI) including pyelonephritis caused by designated susceptible bacteria. ( 1.1 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of VABOMERE and other antibacterial drugs, VABOMERE should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. ( 1.2 )|[EMA] Vaborem is indicated for the treatment of the following infections in adults:Complicated urinary tract infection (cUTI), including pyelonephritisComplicated intra-abdominal infection (cIAI)Hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP).Treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.Vaborem is also indicated for the treatment of infections due to aerobic Gram-negative organisms in adults with limited treatment options.Consideration should be given to official guidance on the appropriate use of antibacterial agents. uuid:1489b30b-7f26-4f3a-9b3e-faa48d7553a6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1945215 biolink:treats MONDO:0006939 PMID:41385096 "[{""id"":""uuid:c6cd1b62-26e4-41a4-9784-fafd999429db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:1fc27feb-2514-4ae4-9c3c-3ca707a129d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:043c8af3-ff4e-4a62-baf0-2b14136560cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/vaborem""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] VABOMERE (meropenem and vaborbactam) is a combination of meropenem, a penem antibacterial, and vaborbactam, a beta-lactamase inhibitor, indicated for the treatment of patients 18 years and older with complicated urinary tract infections (cUTI) including pyelonephritis caused by designated susceptible bacteria. ( 1.1 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of VABOMERE and other antibacterial drugs, VABOMERE should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. ( 1.2 )|[EMA] Vaborem is indicated for the treatment of the following infections in adults:Complicated urinary tract infection (cUTI), including pyelonephritisComplicated intra-abdominal infection (cIAI)Hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP).Treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.Vaborem is also indicated for the treatment of infections due to aerobic Gram-negative organisms in adults with limited treatment options.Consideration should be given to official guidance on the appropriate use of antibacterial agents. uuid:811c799f-dbe5-4cb2-821c-03c84664b93b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:8L7891MRB6 biolink:treats MONDO:0005105 PMID:41385096 "[{""id"":""uuid:5daffe4f-cd5b-499d-979c-154c15eb38ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a15ac2f5-fcb1-4c3a-8127-0e6752baa0d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:0c536e02-e73b-4efc-8d41-fb66bf71985e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/braftovi""]},{""id"":""uuid:44fae367-7346-4e3d-844e-4ad9c8759cc3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BRAFTOVI is a kinase inhibitor indicated: Melanoma • in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test. ( 1.1 , 2.1 ) Colorectal Cancer (CRC) • in combination with cetuximab and mFOLFOX6, for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by an FDA‑approved test. ( 1.2 , 2.1 ) This indication is approved under accelerated approval based on response rate and durability of response [see Clinical Studies (14.2) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). • in combination with cetuximab, for the treatment of adult patients with metastatic CRC with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy. ( 1.2 , 2.1 ) Non-Small Cell Lung Cancer (NSCLC) • in combination with binimetinib, for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test. ( 1.3 , 2.1 ) Limitations of Use BRAFTOVI is not indicated for treatment of patients with wild-type BRAF melanoma, wild-type BRAF CRC, or wild-type BRAF NSCLC. ( 1.4 , 5.2 )|[EMA] Encorafenib is indicated:in combination with binimetinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutationin combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, who have received prior systemic therapy|[PMDA] A drug with a new active ingredient indicated for the treatment of unresectable melanoma with BRAF gene mutation. [Orphan drug] uuid:9cc7142c-44b7-4c5b-95a4-289874e8ae87 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:8L7891MRB6 biolink:treats MONDO:0005191 PMID:41385096 "[{""id"":""uuid:35d042fc-9f61-40fb-b6a7-64e93605a58e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a6c22e94-c32d-4455-a211-936ccae00818"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BRAFTOVI is a kinase inhibitor indicated: Melanoma • in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test. ( 1.1 , 2.1 ) Colorectal Cancer (CRC) • in combination with cetuximab and mFOLFOX6, for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by an FDA‑approved test. ( 1.2 , 2.1 ) This indication is approved under accelerated approval based on response rate and durability of response [see Clinical Studies (14.2) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). • in combination with cetuximab, for the treatment of adult patients with metastatic CRC with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy. ( 1.2 , 2.1 ) Non-Small Cell Lung Cancer (NSCLC) • in combination with binimetinib, for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test. ( 1.3 , 2.1 ) Limitations of Use BRAFTOVI is not indicated for treatment of patients with wild-type BRAF melanoma, wild-type BRAF CRC, or wild-type BRAF NSCLC. ( 1.4 , 5.2 ) uuid:2c662802-ef64-4a04-8595-7ba2430fa121 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:8L7891MRB6 biolink:treats MONDO:0005575 PMID:41385096 "[{""id"":""uuid:9d4851e6-d51c-4abb-bef3-1038eb6c66d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4951f7f2-8ec2-427d-bc9c-042f9231ad83"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:df7ec1cb-0219-4249-8154-bde4e7745c17"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/braftovi""]},{""id"":""uuid:812d3cbe-91e6-453d-a567-0a296bda5a5a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BRAFTOVI is a kinase inhibitor indicated: Melanoma • in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test. ( 1.1 , 2.1 ) Colorectal Cancer (CRC) • in combination with cetuximab and mFOLFOX6, for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by an FDA‑approved test. ( 1.2 , 2.1 ) This indication is approved under accelerated approval based on response rate and durability of response [see Clinical Studies (14.2) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). • in combination with cetuximab, for the treatment of adult patients with metastatic CRC with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy. ( 1.2 , 2.1 ) Non-Small Cell Lung Cancer (NSCLC) • in combination with binimetinib, for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test. ( 1.3 , 2.1 ) Limitations of Use BRAFTOVI is not indicated for treatment of patients with wild-type BRAF melanoma, wild-type BRAF CRC, or wild-type BRAF NSCLC. ( 1.4 , 5.2 )|[EMA] Encorafenib is indicated:in combination with binimetinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutationin combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, who have received prior systemic therapy|[PMDA] Drugs with a new indication and a new dosage for the treatment of unresectable, advanced or recurrent BRAF mutation-positive colorectal cancer that has progressed after cancer chemotherapy. [Priority review] uuid:779ac910-5bb7-4cfe-8d6d-e8c0a3abe380 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:8L7891MRB6 biolink:treats EFO:1001480 PMID:41385096 "[{""id"":""uuid:d3c55870-8f83-451b-baf4-922d0709d948"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:159b34d0-c0fb-4391-b569-515fee81465a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BRAFTOVI is a kinase inhibitor indicated: Melanoma • in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test. ( 1.1 , 2.1 ) Colorectal Cancer (CRC) • in combination with cetuximab and mFOLFOX6, for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by an FDA‑approved test. ( 1.2 , 2.1 ) This indication is approved under accelerated approval based on response rate and durability of response [see Clinical Studies (14.2) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). • in combination with cetuximab, for the treatment of adult patients with metastatic CRC with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy. ( 1.2 , 2.1 ) Non-Small Cell Lung Cancer (NSCLC) • in combination with binimetinib, for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test. ( 1.3 , 2.1 ) Limitations of Use BRAFTOVI is not indicated for treatment of patients with wild-type BRAF melanoma, wild-type BRAF CRC, or wild-type BRAF NSCLC. ( 1.4 , 5.2 ) uuid:2c1ecf66-f98f-45ae-b45a-61419d19b75f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:8L7891MRB6 biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:0209344d-d9b9-4fe4-872a-b4b1601098e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c84f5b51-8170-46d2-9fca-9e78ebc99405"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BRAFTOVI is a kinase inhibitor indicated: Melanoma • in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test. ( 1.1 , 2.1 ) Colorectal Cancer (CRC) • in combination with cetuximab and mFOLFOX6, for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by an FDA‑approved test. ( 1.2 , 2.1 ) This indication is approved under accelerated approval based on response rate and durability of response [see Clinical Studies (14.2) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). • in combination with cetuximab, for the treatment of adult patients with metastatic CRC with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy. ( 1.2 , 2.1 ) Non-Small Cell Lung Cancer (NSCLC) • in combination with binimetinib, for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test. ( 1.3 , 2.1 ) Limitations of Use BRAFTOVI is not indicated for treatment of patients with wild-type BRAF melanoma, wild-type BRAF CRC, or wild-type BRAF NSCLC. ( 1.4 , 5.2 ) uuid:7f24d320-259d-48c5-b80d-42b953741c8e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:8L7891MRB6 biolink:treats UMLS:C0278987 PMID:41385096 "[{""id"":""uuid:84474bf9-09b6-4daa-bf12-93a4c0df6f65"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d7b4f75d-3be2-4903-8ab1-2e1bb0e70226"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BRAFTOVI is a kinase inhibitor indicated: Melanoma • in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test. ( 1.1 , 2.1 ) Colorectal Cancer (CRC) • in combination with cetuximab and mFOLFOX6, for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by an FDA‑approved test. ( 1.2 , 2.1 ) This indication is approved under accelerated approval based on response rate and durability of response [see Clinical Studies (14.2) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). • in combination with cetuximab, for the treatment of adult patients with metastatic CRC with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy. ( 1.2 , 2.1 ) Non-Small Cell Lung Cancer (NSCLC) • in combination with binimetinib, for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test. ( 1.3 , 2.1 ) Limitations of Use BRAFTOVI is not indicated for treatment of patients with wild-type BRAF melanoma, wild-type BRAF CRC, or wild-type BRAF NSCLC. ( 1.4 , 5.2 ) uuid:c5e79ac9-d845-4f41-b837-ce4fde903e4c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:5W8JGG2651 biolink:treats MONDO:0010674 PMID:41385096 "[{""id"":""uuid:95220ce9-b53a-43e3-813f-d5929cc1838e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d0781dc7-d8cb-42aa-baa6-26558b1ff932"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:4ee0280b-6f3b-466d-891f-27253eebe402"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/elaprase""]},{""id"":""uuid:bb23aa95-3601-47da-b1f3-35fae6340725"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ELAPRASE is indicated for patients with Hunter syndrome (Mucopolysaccharidosis II, MPS II). ELAPRASE has been shown to improve walking capacity in patients 5 years and older. In patients 16 months to 5 years of age, no data are available to demonstrate improvement in disease-related symptoms or long term clinical outcome; however, treatment with ELAPRASE has reduced spleen volume similarly to that of adults and children 5 years of age and older. The safety and efficacy of ELAPRASE have not been established in pediatric patients less than 16 months of age [see Use in Specific Populations (8.4) ].|[EMA] Elaprase is indicated for the long-term treatment of patients with Hunter syndrome (mucopolysaccharidosis II, MPS II). Heterozygous females were not studied in the clinical trials.|[PMDA] A drug with a new active ingredient indicated for the treatment of mucopolysaccharidosis type II. [Orphan drug] uuid:658ced4d-0887-449b-92c1-6dbc098e02c1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:07730V90L6 biolink:treats MONDO:0005105 PMID:41385096 "[{""id"":""uuid:4aecd046-2f08-4f87-a285-d9c3b7ea1632"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:db524e3b-ec7d-4dbb-99ae-460720b495b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:d3cce49e-d32b-4a5e-b50f-27fe62d47c83"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/imlygic""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] IMLYGIC is a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery. Limitations of use : IMLYGIC has not been shown to improve overall survival or have an effect on visceral metastases.|[EMA] Imlygic is indicated for the treatment of adults with unresectable melanoma that is regionally or distantly metastatic (Stage IIIB, IIIC and IVM1a) with no bone, brain, lung or other visceral disease. uuid:f4add332-d94c-4a70-9668-fcfc1df56d8f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:961YV2O515 biolink:treats MONDO:0006702 PMID:41385096 "[{""id"":""uuid:aef1fbda-bc30-4c55-b8be-6109d0fb62ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:49880d04-3a57-4816-8781-1afe51599592"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VYVGART HYTRULO is indicated for the treatment of adult patients with: generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive chronic inflammatory demyelinating polyneuropathy (CIDP) uuid:63bdff22-e322-40ff-b39c-1920fedc12d5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:74T7185BMM biolink:treats MONDO:0017287 PMID:41385096 "[{""id"":""uuid:2bd8fd01-ef8c-40a0-aa0f-db4621d51ab4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:918cc8e0-e066-49fb-bd3e-e73c9608da9e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] UPLIZNA is a CD19-directed cytolytic antibody indicated for: The treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive. ( 1.1 ) The treatment of Immunoglobulin G4-related disease (IgG4-RD) in adult patients. ( 1.2 ) uuid:2190ccff-4dfd-41ff-b11d-efc0410a7f01 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:229643 biolink:treats MONDO:0005475 PMID:41385096 "[{""id"":""uuid:762604c7-ec7a-47d5-ba84-953f63c9bbf9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bbd4b342-b3ee-4508-852d-a2f3448892de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZAVZPRET is indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use ZAVZPRET is not indicated for the preventive treatment of migraine. uuid:8baa1284-d820-4f63-887e-25fec2195443 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:229643 biolink:treats MONDO:0100431 PMID:41385096 "[{""id"":""uuid:34bf6f30-2fb0-4676-856b-2cb82b8a0b95"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fa246645-953e-476c-8219-4f687a9a1c4c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZAVZPRET is indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use ZAVZPRET is not indicated for the preventive treatment of migraine. uuid:0ace9c15-14e7-4ee3-a73b-0ab36788908b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:D99YVK4L0X biolink:treats UMLS:C5237824 PMID:41385096 "[{""id"":""uuid:e1aaec0c-3b99-468c-8c87-5b264553701d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:77f88eed-d1b8-4360-b9fe-efdc07e52a82"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CYRAMZA ® is a human vascular endothelial growth factor receptor 2 (VEGFR2) antagonist indicated: as a single agent or in combination with paclitaxel, for treatment of adults with advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy. ( 1.1 ) in combination with erlotinib, for first-line treatment of adults with metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations. ( 1.2 ) in combination with docetaxel, for treatment of adults with metastatic non-small cell lung cancer with disease progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving CYRAMZA. ( 1.2 ) in combination with FOLFIRI, for the treatment of adults with metastatic colorectal cancer with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine. ( 1.3 ) as a single agent, for the treatment of adults with hepatocellular carcinoma in patients who have an alpha fetoprotein of ≥400 ng/mL and have been treated with sorafenib. ( 1.4 ) uuid:72a460d0-70df-48bf-8157-9a917ffdd8bb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:D99YVK4L0X biolink:treats UMLS:C3160888 PMID:41385096 "[{""id"":""uuid:4021231d-6bf2-4231-9993-8a8a6c435054"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:81364b52-be3f-4ea2-85e0-9c49ee32a58c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CYRAMZA ® is a human vascular endothelial growth factor receptor 2 (VEGFR2) antagonist indicated: as a single agent or in combination with paclitaxel, for treatment of adults with advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy. ( 1.1 ) in combination with erlotinib, for first-line treatment of adults with metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations. ( 1.2 ) in combination with docetaxel, for treatment of adults with metastatic non-small cell lung cancer with disease progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving CYRAMZA. ( 1.2 ) in combination with FOLFIRI, for the treatment of adults with metastatic colorectal cancer with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine. ( 1.3 ) as a single agent, for the treatment of adults with hepatocellular carcinoma in patients who have an alpha fetoprotein of ≥400 ng/mL and have been treated with sorafenib. ( 1.4 ) uuid:b662cb18-86dd-4b8e-8116-3ae655cab3d5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:D99YVK4L0X biolink:treats MONDO:0003219 PMID:41385096 "[{""id"":""uuid:4a49cccb-6a0d-414e-97fe-d42bdfc6e184"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:9ea270d1-b6b7-4b63-a155-fa5490325d0d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:54db9b10-e331-49e6-a41e-f10739b2544d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/cyramza""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] CYRAMZA ® is a human vascular endothelial growth factor receptor 2 (VEGFR2) antagonist indicated: as a single agent or in combination with paclitaxel, for treatment of adults with advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy. ( 1.1 ) in combination with erlotinib, for first-line treatment of adults with metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations. ( 1.2 ) in combination with docetaxel, for treatment of adults with metastatic non-small cell lung cancer with disease progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving CYRAMZA. ( 1.2 ) in combination with FOLFIRI, for the treatment of adults with metastatic colorectal cancer with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine. ( 1.3 ) as a single agent, for the treatment of adults with hepatocellular carcinoma in patients who have an alpha fetoprotein of ≥400 ng/mL and have been treated with sorafenib. ( 1.4 )|[EMA] Gastric cancerCyramza in combination with paclitaxel is indicated for the treatment of adult patients with advanced gastric cancer or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum and fluoropyrimidine chemotherapy.Cyramza monotherapy is indicated for the treatment of adult patients with advanced gastric cancer or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum or fluoropyrimidine chemotherapy, for whom treatment in combination with paclitaxel is not appropriate.Colorectal cancerCyramza, in combination with FOLFIRI (irinotecan, folinic acid, and 5‑fluorouracil), is indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin and a fluoropyrimidine.Non-small cell lung cancerCyramza in combination with docetaxel is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with disease progression after platinum-based chemotherapy.Hepatocellular carcinomaCyramza monotherapy is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have a serum alpha fetoprotein (AFP) of ≥ 400 ng/ml and who have been previously treated with sorafenib. uuid:4aaf2360-154c-4004-b092-4bd76fd04c76 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:D99YVK4L0X biolink:treats UMLS:C0278987 PMID:41385096 "[{""id"":""uuid:c26220dd-d684-4598-9360-d8e0ec386f66"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5091282b-9a1a-4e82-bdd5-17fdc26f1e7f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CYRAMZA ® is a human vascular endothelial growth factor receptor 2 (VEGFR2) antagonist indicated: as a single agent or in combination with paclitaxel, for treatment of adults with advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy. ( 1.1 ) in combination with erlotinib, for first-line treatment of adults with metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations. ( 1.2 ) in combination with docetaxel, for treatment of adults with metastatic non-small cell lung cancer with disease progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving CYRAMZA. ( 1.2 ) in combination with FOLFIRI, for the treatment of adults with metastatic colorectal cancer with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine. ( 1.3 ) as a single agent, for the treatment of adults with hepatocellular carcinoma in patients who have an alpha fetoprotein of ≥400 ng/mL and have been treated with sorafenib. ( 1.4 ) uuid:0fe80ffa-659b-4664-b4f3-f5fd91760ecf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:D99YVK4L0X biolink:treats EFO:1001480 PMID:41385096 "[{""id"":""uuid:06017051-35d5-44bd-a3da-8493b155a8b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:64b6e548-a8d5-4d6d-9cc7-a54b62374332"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CYRAMZA ® is a human vascular endothelial growth factor receptor 2 (VEGFR2) antagonist indicated: as a single agent or in combination with paclitaxel, for treatment of adults with advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy. ( 1.1 ) in combination with erlotinib, for first-line treatment of adults with metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations. ( 1.2 ) in combination with docetaxel, for treatment of adults with metastatic non-small cell lung cancer with disease progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving CYRAMZA. ( 1.2 ) in combination with FOLFIRI, for the treatment of adults with metastatic colorectal cancer with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine. ( 1.3 ) as a single agent, for the treatment of adults with hepatocellular carcinoma in patients who have an alpha fetoprotein of ≥400 ng/mL and have been treated with sorafenib. ( 1.4 ) uuid:910e62fc-1639-4059-83ed-4e50ef29aa56 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:D99YVK4L0X biolink:treats MONDO:0007256 PMID:41385096 "[{""id"":""uuid:baed14ba-3295-4e8e-b0f5-8230d6075a96"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2d9bd5b5-5b9c-4f10-84a9-0dc79e8e90cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:3d755a97-88b5-4b2b-a2ea-2c2260bd6cd3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/cyramza""]},{""id"":""uuid:80d23c41-af70-40ac-9a1d-1a6e7cd104dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CYRAMZA ® is a human vascular endothelial growth factor receptor 2 (VEGFR2) antagonist indicated: as a single agent or in combination with paclitaxel, for treatment of adults with advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy. ( 1.1 ) in combination with erlotinib, for first-line treatment of adults with metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations. ( 1.2 ) in combination with docetaxel, for treatment of adults with metastatic non-small cell lung cancer with disease progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving CYRAMZA. ( 1.2 ) in combination with FOLFIRI, for the treatment of adults with metastatic colorectal cancer with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine. ( 1.3 ) as a single agent, for the treatment of adults with hepatocellular carcinoma in patients who have an alpha fetoprotein of ≥400 ng/mL and have been treated with sorafenib. ( 1.4 )|[EMA] Gastric cancerCyramza in combination with paclitaxel is indicated for the treatment of adult patients with advanced gastric cancer or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum and fluoropyrimidine chemotherapy.Cyramza monotherapy is indicated for the treatment of adult patients with advanced gastric cancer or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum or fluoropyrimidine chemotherapy, for whom treatment in combination with paclitaxel is not appropriate.Colorectal cancerCyramza, in combination with FOLFIRI (irinotecan, folinic acid, and 5‑fluorouracil), is indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin and a fluoropyrimidine.Non-small cell lung cancerCyramza in combination with docetaxel is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with disease progression after platinum-based chemotherapy.Hepatocellular carcinomaCyramza monotherapy is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have a serum alpha fetoprotein (AFP) of ≥ 400 ng/ml and who have been previously treated with sorafenib.|[PMDA] Drugs with a new dosage indicated for the treatment of unresectable advanced or recurrent non-small cell lung cancer. Drugs with a new dosage indicated for the treatment of unresectable advanced or recurrent gastric cancer, unresectable advanced or recurrent colon or rectal cancer, unresectable advanced or recurrent non-small cell lung cancer, and unresectable hepatocellular carcinoma whose serum AFP level is greater than 400 ng/mL and conditions have progressed after cancer chemotherapy. uuid:c44fe694-12db-444b-89d6-9beabb22bb0b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5790 biolink:treats MONDO:0005530 PMID:41385096 "[{""id"":""uuid:80905381-b8ac-48bc-9d3d-b0c49fa0838d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a1b7b4b2-0d97-4718-b8b8-fe9eadec7e5d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydromorphone Hydrochloride Injection is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Hydromorphone Hydrochloride Injection [high potency formulation (HPF)] is indicated for use in opioid-tolerant patients who require higher doses of opioids for the management of pain severe enough to require an opioid analgesic and for which alternate treatments are inadequate. Patients considered opioid tolerant are those who are taking for one week or longer, around-the-clock medicine consisting of at least 60 mg oral morphine per day, or at least 25 mcg transdermal fentanyl per hour, or at least 30 mg oral oxycodone per day, or at least 8 g oral hydromorphone per day, or at least 25 mg oral oxymorphone per day, or at least 60 mg oral hydrocodone per day, or an equianalgesic dose of another opioid for one week or longer. Patients must remain on around-the-clock opioids while administering Hydromorphone Hydrochloride Injection (HPF). Limitations of Use: Because of the risks of addiction, abuse, and misuse with opioids, which can occur at any dosage or duration [see Warnings and Precautions ( 5.2 )] , reserve Hydromorphone Hydrochloride Injection and Hydromorphone Hydrochloride Injection [high potency formulation (HPF)] for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or opioid combination products): • Have not been tolerated or are not expected to be tolerated, • Have not provided adequate analgesia or are not expected to provide adequate analgesia. Hydromorphone Hydrochloride Injection or Hydromorphone Hydrochloride Injection (HPF) should not be used for an extended period of time unless the pain remains severe enough to require an opioid analgesic and for which alternative treatment options continue to be inadequate. uuid:956967d5-64c6-4eb1-a231-53948fc6fa3c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5790 biolink:treats MONDO:0001225 PMID:41385096 "[{""id"":""uuid:8b4c979a-1ad5-4ee5-bc6d-4a5b491f9c9f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b37447bc-2c29-4b34-8283-44b6696dcb22"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydromorphone Hydrochloride Injection is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Hydromorphone Hydrochloride Injection [high potency formulation (HPF)] is indicated for use in opioid-tolerant patients who require higher doses of opioids for the management of pain severe enough to require an opioid analgesic and for which alternate treatments are inadequate. Patients considered opioid tolerant are those who are taking for one week or longer, around-the-clock medicine consisting of at least 60 mg oral morphine per day, or at least 25 mcg transdermal fentanyl per hour, or at least 30 mg oral oxycodone per day, or at least 8 g oral hydromorphone per day, or at least 25 mg oral oxymorphone per day, or at least 60 mg oral hydrocodone per day, or an equianalgesic dose of another opioid for one week or longer. Patients must remain on around-the-clock opioids while administering Hydromorphone Hydrochloride Injection (HPF). Limitations of Use: Because of the risks of addiction, abuse, and misuse with opioids, which can occur at any dosage or duration [see Warnings and Precautions ( 5.2 )] , reserve Hydromorphone Hydrochloride Injection and Hydromorphone Hydrochloride Injection [high potency formulation (HPF)] for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or opioid combination products): • Have not been tolerated or are not expected to be tolerated, • Have not provided adequate analgesia or are not expected to provide adequate analgesia. Hydromorphone Hydrochloride Injection or Hydromorphone Hydrochloride Injection (HPF) should not be used for an extended period of time unless the pain remains severe enough to require an opioid analgesic and for which alternative treatment options continue to be inadequate. uuid:511bf20a-4947-4203-89f8-5068c3d92002 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5000 biolink:treats MONDO:0100135 PMID:41385096 "[{""id"":""uuid:5dab897d-b966-4d65-91c9-0b88fd2d5ed0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:33d7c2f4-6716-437a-9871-2cc3cbbe8f1a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:2c3cbf61-191c-417f-ba59-c4d35d7bc01f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:d721a8db-6c81-431f-92cf-963683e883d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FINTEPLA is indicated for the treatment of seizures associated with Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS) in patients 2 years of age and older.|[EMA] Treatment of seizures associated with Dravet syndrome as an add-on therapy to other antiepileptic medicines for patients 2 years of age and older.Fintepla is indicated for the treatment of seizures associated with Dravet syndrome and Lennox-Gastaut syndrome as an add-on therapy to other anti-epileptic medicines for patients 2 years of age and older.|[PMDA] A drug with a new active ingredient indicated for use as an adjunctive therapy with other antiepileptic drugs to treat epileptic seizures in patients with Dravet syndrome who have not responded sufficiently to other antiepileptic drugs. [Orphan drug] uuid:bc238976-0062-4e52-b264-dcb6ef03c679 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:172944 biolink:treats MONDO:0004951 PMID:41385096 "[{""id"":""uuid:c4a91a44-91fa-40e6-b91c-02a44d4c2d33"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:da0fef6a-a652-4e13-ad54-3bd78170dd06"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] APRETUDE is indicated for pre‑exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in adults and adolescents weighing at least 35 kg who are at risk for HIV-1 acquisition. Individuals must have a negative HIV-1 test prior to initiating APRETUDE (with or without an oral lead-in with oral cabotegravir) for HIV-1 PrEP [see Dosage and Administration ( 2.2 , 2.4 ), Contraindications ( 4 ), Warnings and Precautions ( 5.1 )] . uuid:ad5c9ed9-0602-4f4b-910c-abf09a0fcdaf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3VHF2ZD92J biolink:treats MONDO:0005298 PMID:41385096 "[{""id"":""uuid:89a09ca8-f20e-4391-bf77-045e9f01e8ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ead38d7c-a149-4b4a-8a91-8d589369ef0d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:85147ba5-cc44-4f89-aae6-eb2be8b45443"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/evenity""]},{""id"":""uuid:7d9319cd-0c8e-408b-b81a-2696be24daf2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EVENITY is a sclerostin inhibitor indicated for the treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. ( 1 ) Limitations of Use: Limit duration of use to 12 monthly doses. If osteoporosis therapy remains warranted, continued therapy with an anti-resorptive agent should be considered. ( 1.2 )|[EMA] Evenity is indicated in treatment of severe osteoporosis in postmenopausal women at high risk of fracture.|[PMDA] A drug with a new active ingredient indicated for the treatment of osteoporosis with a high risk of fracture. uuid:9b124bc5-a188-4799-9c29-c74c662fb159 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3VHF2ZD92J biolink:treats UMLS:C0521170 PMID:41385096 "[{""id"":""uuid:c3b02711-f703-46d3-8da3-c054e2b702fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d7be2a99-1556-4ad6-a897-343aea3ef222"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EVENITY is a sclerostin inhibitor indicated for the treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. ( 1 ) Limitations of Use: Limit duration of use to 12 monthly doses. If osteoporosis therapy remains warranted, continued therapy with an anti-resorptive agent should be considered. ( 1.2 ) uuid:d2933d3e-1d46-4f1c-b323-b0da61537289 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9445 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:bee46961-a904-4d19-8b92-6155d2ed8a6a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a453e6a0-ac3a-418a-9a1e-49c4b5575da4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TEZRULY TM (terazosin) is an alpha-1 adrenoceptor antagonist indicated for: The treatment of signs and symptoms of benign prostatic hyperplasia (BPH) (1.1) The treatment of hypertension alone or with other antihypertensive agents, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarction. (1.2) uuid:a4354bed-f3e8-4d44-8a4f-67eaeb8d1034 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9445 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:87a2d1d3-4f6b-4515-9b6a-6446a8d3efd6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a049d6c3-3cab-4115-a4db-5fd5844c6c0f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TEZRULY TM (terazosin) is an alpha-1 adrenoceptor antagonist indicated for: The treatment of signs and symptoms of benign prostatic hyperplasia (BPH) (1.1) The treatment of hypertension alone or with other antihypertensive agents, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarction. (1.2) uuid:1811ba92-79df-4fd2-83dd-880240bdd447 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats HP:0100533 PMID:41385096 "[{""id"":""uuid:0645eeda-4557-4bac-a405-f219fd758aa4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b0e96cca-5f6f-468d-bae0-60ee2dce4bad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DEXTENZA ® is a corticosteroid indicated for: The treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients. ( 1.1 ). The treatment of ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged 2 years and older. The use of DEXTENZA is not recommended for the treatment of ocular itching associated with allergic conjunctivitis in pediatric patients who require sedation for the insertion procedure. ( 1.2 ). uuid:2856d575-894d-44b8-9222-3d668a438401 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:c3651d83-d95c-452e-9911-44158bf05773"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0988a30a-d79f-42c1-92a5-1454267971f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DEXTENZA ® is a corticosteroid indicated for: The treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients. ( 1.1 ). The treatment of ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged 2 years and older. The use of DEXTENZA is not recommended for the treatment of ocular itching associated with allergic conjunctivitis in pediatric patients who require sedation for the insertion procedure. ( 1.2 ). uuid:b9149d20-471e-4435-b9e3-778b9cdae24d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats HP:0033841 PMID:41385096 "[{""id"":""uuid:538be34b-a3bc-465a-b1b5-a2605df75182"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fce2187d-5ff6-4a3a-b645-d8b61fb52110"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DEXTENZA ® is a corticosteroid indicated for: The treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients. ( 1.1 ). The treatment of ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged 2 years and older. The use of DEXTENZA is not recommended for the treatment of ocular itching associated with allergic conjunctivitis in pediatric patients who require sedation for the insertion procedure. ( 1.2 ). uuid:db3bfeb9-330e-43ee-9d37-76782681f120 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:VY5YX2TQ1F biolink:treats UMLS:C0278987 PMID:41385096 "[{""id"":""uuid:4fef7df0-89c4-4677-9cae-717a2c25e3e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ce388f70-167b-4796-b0d1-3c8b49f0f027"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TEPMETKO is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition ( MET ) exon 14 skipping alterations. uuid:f8c1d2d3-2fe4-4938-9c1b-d380b8be0f6b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27504 biolink:treats MONDO:0005041 PMID:41385096 "[{""id"":""uuid:eb17bf85-551e-4892-bfae-83117b8ed8f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c1dd4151-5d94-4b55-915e-41a619dadeb9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:899c6422-e9fe-4094-904c-56b1118970df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mitosol ® is an antimetabolite indicated for use as an adjunct to ab externo glaucoma surgery.|[PMDA] A drug with a new route of administration indicated for an adjunct to incisional glaucoma surgery. uuid:e5f11b15-411d-43fe-b618-a0e63bdbd966 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29101 biolink:treats UMLS:C0342579 PMID:41385096 "[{""id"":""uuid:f637af43-85b5-4687-9464-5043937851de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d87dd692-8cf2-4fbc-81e8-e1aa56b7a5e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PRISMASOL and PHOXILLUM solutions are indicated in pediatric and adult patients for use as a replacement solution in Continuous Renal Replacement Therapy (CRRT) to replace plasma volume removed by ultrafiltration and to correct electrolyte and acid-base imbalances. They may also be used in case of drug poisoning when CRRT is used to remove dialyzable substances. uuid:e5b0c7c5-6af9-4864-84c9-60552dd03aaa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29101 biolink:treats HP:0004360 PMID:41385096 "[{""id"":""uuid:a61ab6ff-24e9-4b56-a102-e5f3ce6dc2f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:34ea52d0-a92a-4dbe-a89d-bace11ed0d5a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PRISMASOL and PHOXILLUM solutions are indicated in pediatric and adult patients for use as a replacement solution in Continuous Renal Replacement Therapy (CRRT) to replace plasma volume removed by ultrafiltration and to correct electrolyte and acid-base imbalances. They may also be used in case of drug poisoning when CRRT is used to remove dialyzable substances. uuid:3cc4bd8c-def9-4194-9a12-fb011fad1c67 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29101 biolink:treats UMLS:C0013221 PMID:41385096 "[{""id"":""uuid:69af24d2-a4f1-4ba4-8a85-a2d8ffa067e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:86823fb0-cc20-4a5c-89ab-2987efe2a2fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PRISMASOL and PHOXILLUM solutions are indicated in pediatric and adult patients for use as a replacement solution in Continuous Renal Replacement Therapy (CRRT) to replace plasma volume removed by ultrafiltration and to correct electrolyte and acid-base imbalances. They may also be used in case of drug poisoning when CRRT is used to remove dialyzable substances. uuid:21a6f5b3-d5f0-48d6-9eac-8b573937835d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3756 biolink:treats HP:0025269 PMID:41385096 "[{""id"":""uuid:408c2b9a-38e5-41b2-8754-a5f293c4199f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cb7ca132-75dc-49fe-b393-1c352986ff8b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Seizure Disorders: ; Clonazepam tablets are useful alone or as an adjunct in the treatment of the Lennox-Gastaut syndrome (petit mal variant), akinetic, and myoclonic seizures. In patients with absence seizures (petit mal) who have failed to respond to succinimides, clonazepam tablets may be useful. Some loss of effect may occur during the course of clonazepam treatment (see; PRECAUTIONS : Loss of Effect ). Panic Disorder:; Clonazepam tablets are indicated for the treatment of panic disorder, with or without agoraphobia, as defined in DSM-V. Panic disorder is characterized by the occurrence of unexpected panic attacks and associated concern about having additional attacks, worry about the implications or consequences of the attacks, and/or a significant change in behavior related to the attacks. The efficacy of clonazepam tablets was established in two 6- to 9-week trials in panic disorder patients whose diagnoses corresponded to the DSM-IIIR category of panic disorder (see; CLINICAL PHARMACOLOGY: ;Clinical Trials ). Panic disorder (DSM-V) is characterized by recurrent unexpected panic attacks, i.e., a discrete period of intense fear or discomfort in which four (or more) of the following symptoms develop abruptly and reach a peak within 10 minutes: (1) palpitations, pounding heart or accelerated heart rate; (2) sweating; (3) trembling or shaking; (4) sensations of shortness of breath or smothering; (5) feeling of choking; (6) chest pain or discomfort; (7) nausea or abdominal distress; (8) feeling dizzy, unsteady, lightheaded or faint; (9) derealization (feelings of unreality) or depersonalization (being detached from oneself); (10) fear of losing control; (11) fear of dying; (12) paresthesias (numbness or tingling sensations); (13) chills or hot flushes. The effectiveness of clonazepam tablets in long-term use, that is, for more than 9 weeks, has not been systematically studied in controlled clinical trials. The physician who elects to use clonazepam tablets for extended periods should periodically reevaluate the long-term usefulness of the drug for the individual patient (see; DOSAGE AND ADMINISTRATION ). uuid:38713e99-1450-4dd9-820f-d90d34554868 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:229526 biolink:treats MONDO:0005342 PMID:41385096 "[{""id"":""uuid:d9886662-a942-4f5e-9b50-a406b8981921"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:392a2250-7806-46f6-8b74-d1df08d667f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FILSPARI is indicated to slow kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression. uuid:75299a64-abad-48f5-8ce4-bcc31a184680 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:229526 biolink:treats MONDO:0008072 PMID:41385096 "[{""id"":""uuid:7623e66b-64a3-4b36-8f8e-11a1e3502cde"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:32ff1e07-60bb-49a8-a849-86f17711f08a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FILSPARI is indicated to slow kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression. uuid:10cdd814-b391-4c07-bf23-d4224c4c887e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:92043599 biolink:treats MONDO:0020725 PMID:41385096 "[{""id"":""uuid:568ba2cb-b1b7-4713-8e35-80aeb566f624"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:e8e94742-fd9e-4172-8ace-e63ae254b936"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:0a48e142-d95b-4a13-94fd-e9b968c1eb10"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/epoetin-alfa-hexal""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Epogen is an erythropoiesis-stimulating agent (ESA) indicated for: Treatment of anemia due to: - Chronic Kidney Disease (CKD) in patients on dialysis and not on dialysis ( 1.1 ). - Zidovudine in patients with Human Immunodeficiency Virus (HIV) infection ( 1.2 ). - The effects of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy ( 1.3 ). Reduction of allogeneic red blood cell (RBC) transfusions in patients undergoing elective, noncardiac, nonvascular surgery ( 1.4 ). Limitations of Use Epogen has not been shown to improve quality of life, fatigue, or patient well-being ( 1.5 ). Epogen is not indicated for use: In patients with cancer receiving hormonal agents, biologic products, or radiotherapy, unless also receiving concomitant myelosuppressive chemotherapy ( 1.5 ). In patients with cancer receiving myelosuppressive chemotherapy when the anticipated outcome is cure ( 1.5 ). In patients with cancer receiving myelosuppressive chemotherapy in whom the anemia can be managed by transfusion ( 1.5 ). In patients scheduled for surgery who are willing to donate autologous blood ( 1.5 ). In patients undergoing cardiac or vascular surgery ( 1.5 ). As a substitute for RBC transfusions in patients who require immediate correction of anemia ( 1.5 ).|[EMA] Treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adult and paediatric patients:, , , treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis;, treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis;, Treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre-existing anaemia at the start of chemotherapy)., , uuid:b57d3966-2c05-4c2c-90ae-507d92bc6fb9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:V78M04F0XC biolink:treats MONDO:0007318 PMID:41385096 "[{""id"":""uuid:73e7b54b-d591-48c6-b0c4-b29a5f77ed3b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:fb2560ee-882f-43f1-9540-d9564def4a24"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:d1f629a0-2bd3-464d-be07-6985322227b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/livmarli""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] LIVMARLI is an ileal bile acid transporter (IBAT) inhibitor indicated for: • the treatment of cholestatic pruritus in patients 3 months of age and older with Alagille syndrome (ALGS). ( 1.1 ) • the treatment of cholestatic pruritus in patients 12 months of age and older with progressive familial intrahepatic cholestasis (PFIC). ( 1.2 ) o Limitations of Use: LIVMARLI is not recommended in a subgroup of PFIC type 2 patients with specific ABCB11 variants resulting in non-functional or complete absence of bile salt export pump (BSEP) protein. ( 14.2 )|[EMA] Livmarli is indicated for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) 2 months of age and older. uuid:cf9514cf-646e-4244-88d0-d14b772af16d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:V78M04F0XC biolink:treats MONDO:0015762 PMID:41385096 "[{""id"":""uuid:335216b6-ee52-440f-93a6-45cdb2e33f34"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5a0472a4-d7cf-4575-9704-f013e154c1ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LIVMARLI is an ileal bile acid transporter (IBAT) inhibitor indicated for: • the treatment of cholestatic pruritus in patients 3 months of age and older with Alagille syndrome (ALGS). ( 1.1 ) • the treatment of cholestatic pruritus in patients 12 months of age and older with progressive familial intrahepatic cholestasis (PFIC). ( 1.2 ) o Limitations of Use: LIVMARLI is not recommended in a subgroup of PFIC type 2 patients with specific ABCB11 variants resulting in non-functional or complete absence of bile salt export pump (BSEP) protein. ( 14.2 ) uuid:bb14eb1d-0eff-4d82-9f8b-411f45b2e7da biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:LZ0M43NNF2 biolink:treats MONDO:0010643 PMID:41385096 "[{""id"":""uuid:c02f76cc-7a62-4f89-a1d1-81643b34baa5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c91c8784-4784-4244-afe1-ff29038ce352"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] REVUFORJ is a menin inhibitor indicated for the treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients 1 year and older. ( 1 ) uuid:02c14785-1b27-4e06-a6e9-b544cbe5a80b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:LZ0M43NNF2 biolink:treats UMLS:C4725027 PMID:41385096 "[{""id"":""uuid:5ff63a5a-f692-4285-b630-f0a45cac206e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9b077ef8-7132-45bf-a427-6e20dea5abad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] REVUFORJ is a menin inhibitor indicated for the treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients 1 year and older. ( 1 ) uuid:f5470a7c-a3bb-469a-b4a6-66bd901f33ba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85993 biolink:treats UMLS:C3495917 PMID:41385096 "[{""id"":""uuid:b8267b5d-af93-4d8a-af08-abeae9522c7b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:987ee6ec-b6bd-4ed6-8ccf-9e1d750830da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] IBRANCE is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with: • an aromatase inhibitor as initial endocrine-based therapy; or • fulvestrant in patients with disease progression following endocrine therapy. uuid:1b3b3b65-1ac0-48fa-a0b5-178f66db887c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85993 biolink:treats UMLS:C0278488 PMID:41385096 "[{""id"":""uuid:2e87186e-c631-4db3-a67c-ac0ca1527826"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d6613373-c183-4bd2-bb1b-a57ac86946bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] IBRANCE is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with: • an aromatase inhibitor as initial endocrine-based therapy; or • fulvestrant in patients with disease progression following endocrine therapy. uuid:1a37ac60-731f-473d-aa59-6481995c2142 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2668195 biolink:treats MONDO:0011438 PMID:41385096 "[{""id"":""uuid:52dc7362-d677-48ab-8edd-36ab2cfa8147"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6e3005be-e822-4d81-9a09-547a81ae7104"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:dee7bbc0-d554-482e-9efb-a92ff1a419bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CABTREO is indicated for the topical treatment of acne vulgaris in adult and pediatric patients 12 years of age and older.|[PMDA] A new combination drug with a new active ingredient indicated for the treatment of acne vulgaris. uuid:09aae8fe-6ff5-453e-95d9-e680d0a5d9c4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68579 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:9f751935-e82e-404b-a1f1-573c0aa3e1ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:dfa49d53-4cbc-4f10-8d20-692900f8f0ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:9ac1a0d5-1530-4a94-b1a7-e4ce69fce9fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/rivaroxaban-accord""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Rivaroxaban tablets are a factor Xa inhibitor indicated: to reduce risk of stroke and systemic embolism in nonvalvular atrial fibrillation ( 1.1 ) for treatment of deep vein thrombosis (DVT) ( 1.2 ) for treatment of pulmonary embolism (PE) ( 1.3 ) for reduction in the risk of recurrence of DVT or PE ( 1.4 ) for the prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery ( 1.5 ) for prophylaxis of venous thromboembolism (VTE) in acutely ill medical patients ( 1.6 ) to reduce the risk of major cardiovascular events in patients with coronary artery disease (CAD) ( 1.7 ) to reduce the risk of major thrombotic vascular events in patients with peripheral artery disease (PAD), including patients after recent lower extremity revascularization due to symptomatic PAD ( 1.8 ) for treatment of VTE and reduction in the risk of recurrent VTE in pediatric patients from birth to less than 18 years ( 1.9 ) for thromboprophylaxis in pediatric patients 2 years and older with congenital heart disease after the Fontan procedure ( 1.10 )|[EMA] Prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for haemodynamically unstable PE patients.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for haemodynamically unstable PE patients).AdultsPrevention of stroke and systemic embolism in adult patients with non valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for haemodynamically unstable PE patients.)Paediatric populationTreatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment.Rivaroxaban Accord, co administered with acetylsalicylic acid (ASA) alone or with ASA plus ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers (see sections 4.3, 4.4 and 5.1).Rivaroxaban Accord, co administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischaemic events.AdultsPrevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for haemodynamically unstable PE patients.)Paediatric populationTreatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment. uuid:09e07c6e-29d8-4ff0-ae73-5ca7fe36ef1b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68579 biolink:treats UMLS:C5400523 PMID:41385096 "[{""id"":""uuid:dc18094c-8c21-4fa4-aaaf-7e9a1d4761f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:092d6e3d-9fc9-4dc8-8ccf-23ed09af3e97"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e6c8c263-ae92-478b-a2f5-5a5afd9a8453"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Rivaroxaban tablets are a factor Xa inhibitor indicated: to reduce risk of stroke and systemic embolism in nonvalvular atrial fibrillation ( 1.1 ) for treatment of deep vein thrombosis (DVT) ( 1.2 ) for treatment of pulmonary embolism (PE) ( 1.3 ) for reduction in the risk of recurrence of DVT or PE ( 1.4 ) for the prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery ( 1.5 ) for prophylaxis of venous thromboembolism (VTE) in acutely ill medical patients ( 1.6 ) to reduce the risk of major cardiovascular events in patients with coronary artery disease (CAD) ( 1.7 ) to reduce the risk of major thrombotic vascular events in patients with peripheral artery disease (PAD), including patients after recent lower extremity revascularization due to symptomatic PAD ( 1.8 ) for treatment of VTE and reduction in the risk of recurrent VTE in pediatric patients from birth to less than 18 years ( 1.9 ) for thromboprophylaxis in pediatric patients 2 years and older with congenital heart disease after the Fontan procedure ( 1.10 )|[PMDA] Drugs with a new active ingredient indicated for the prevention of ischemic stroke and systemic embolism in patients with nonvalvular atrial fibrillation. uuid:fa68c406-db79-410c-8672-e4e1681fd6be biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75283 biolink:treats MONDO:0005445 PMID:41385096 "[{""id"":""uuid:bf20082e-9d43-49e5-9ed9-ea51ee9100c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:24de7861-39fe-4cda-bc27-1263d89b0319"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] IMPAVIDO (miltefosine) capsules are indicated in adults and pediatric patients 12 years of age and older weighing greater than or equal to 30 kg (66 lbs) for the treatment of: • Visceral leishmaniasis caused by Leishmania donovani [see Clinical Trials ( 14.1 )] . • Cutaneous leishmaniasis caused by Leishmania braziliensis , Leishmania guyanensis, and Leishmania panamensis [see Clinical Trials ( 14.2 )] . • Mucosal leishmaniasis caused by Leishmania braziliensis [see Clinical Trials ( 14.3 )] . Limitations of Use: • Leishmania species studied in clinical trials evaluating IMPAVIDO were based on epidemiologic data [see Clinical Trials ( 14.1 , 14.2 )] . • There may be geographic variation in clinical response of the same Leishmania species to IMPAVIDO [see Clinical Trials ( 14.1 , 14.2 )] . • The efficacy of IMPAVIDO in the treatment of other Leishmania species has not been evaluated. uuid:cc2aefcc-b3bb-4b21-b791-497f055ac6fe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75283 biolink:treats MONDO:0005446 PMID:41385096 "[{""id"":""uuid:f9aabc65-967a-474e-8c6b-632e9d14b5aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:52182912-2c45-4d3d-85e4-9867c4c74632"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] IMPAVIDO (miltefosine) capsules are indicated in adults and pediatric patients 12 years of age and older weighing greater than or equal to 30 kg (66 lbs) for the treatment of: • Visceral leishmaniasis caused by Leishmania donovani [see Clinical Trials ( 14.1 )] . • Cutaneous leishmaniasis caused by Leishmania braziliensis , Leishmania guyanensis, and Leishmania panamensis [see Clinical Trials ( 14.2 )] . • Mucosal leishmaniasis caused by Leishmania braziliensis [see Clinical Trials ( 14.3 )] . Limitations of Use: • Leishmania species studied in clinical trials evaluating IMPAVIDO were based on epidemiologic data [see Clinical Trials ( 14.1 , 14.2 )] . • There may be geographic variation in clinical response of the same Leishmania species to IMPAVIDO [see Clinical Trials ( 14.1 , 14.2 )] . • The efficacy of IMPAVIDO in the treatment of other Leishmania species has not been evaluated. uuid:98baa06e-d67f-4b2c-8394-dc78b4041106 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:N7V53U4U4T biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:0c24087d-04d5-4d4d-b5a4-6f158a0a3d09"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:6d1e1e36-1971-412b-a9da-58cead8a15c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:d82c5c7d-7735-4833-952f-4f536c695beb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BAXDELA is a fluoroquinolone antibacterial indicated for the treatment of adults with the following infections caused by designated susceptible bacteria: Acute Bacterial Skin and Skin Structure Infections (ABSSSI) ( 1.1 ) Community-Acquired Bacterial Pneumonia (CABP) ( 1.2 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of BAXDELA and other antibacterial drugs, BAXDELA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.3 )|[EMA] Quofenix is indicated for the treatment of the following infections in adults:acute bacterial skin and skin structure infections (ABSSSI),community-acquired pneumonia (CAP), when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the initial treatment of these infections (see sections 4.4 and 5.1).Consideration should be given to official guidance on the appropriate use of antibacterial agents. uuid:9dbe7c64-5fb5-44cd-8910-552fe8ed2622 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:N7V53U4U4T biolink:treats MONDO:0004652 PMID:41385096 "[{""id"":""uuid:95b4d5d0-5fe3-4258-8f27-f4ed2b84e5a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a77e0c05-7dd6-481d-9390-f19509967163"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BAXDELA is a fluoroquinolone antibacterial indicated for the treatment of adults with the following infections caused by designated susceptible bacteria: Acute Bacterial Skin and Skin Structure Infections (ABSSSI) ( 1.1 ) Community-Acquired Bacterial Pneumonia (CABP) ( 1.2 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of BAXDELA and other antibacterial drugs, BAXDELA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.3 ) uuid:3fc50070-4ff0-4900-beea-9e49489228f5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:82720 biolink:treats MONDO:0012819 PMID:41385096 "[{""id"":""uuid:6347c652-1e80-483e-a1c8-db0509fbddd3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7365229f-5550-4c19-88b6-ff959c062e41"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] JARDIANCE is indicated: as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, to reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and established cardiovascular disease. Limitations of Use JARDIANCE is not recommended for patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. uuid:e338ad8a-580b-4d35-bf36-9ec245b024cd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:91X1KLU43E biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:0d1d1566-b6c0-4ec4-aad1-9f9fa25f6cdd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:18a18e49-723b-451a-9274-776069af08c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ca596a7f-58b1-4cdf-843b-f0c2f77eef3e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/simponi""]},{""id"":""uuid:5e8fb491-dc3a-4dd5-b88a-f48bb5fc2af2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SIMPONI ARIA is a tumor necrosis factor (TNF) blocker indicated for the treatment of: Adult patients with moderately to severely active Rheumatoid Arthritis (RA) in combination with methotrexate ( 1.1 ) Active Psoriatic Arthritis (PsA) in patients 2 years of age and older ( 1.2 ) Adult patients with active Ankylosing Spondylitis (AS) ( 1.3 ) Active polyarticular Juvenile Idiopathic Arthritis (pJIA) in patients 2 years of age and older ( 1.4 )|[EMA] Rheumatoid arthritis (RA)Simponi, in combination with methotrexate (MTX), is indicated for:the treatment of moderate to severe, active rheumatoid arthritis in adults when the response to disease modifying anti rheumatic drug (DMARD) therapy including MTX has been inadequate.the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with MTX.Simponi, in combination with MTX, has been shown to reduce the rate of progression of joint damage as measured by X ray and to improve physical function.For information regarding the polyarticular juvenile idiopathic arthritis indication, please see the Simponi 50 mg SmPC.Psoriatic arthritis (PsA)Simponi, alone or in combination with MTX, is indicated for the treatment of active and progressive psoriatic arthritis in adult patients when the response to previous DMARD therapy has been inadequate. Simponi has been shown to reduce the rate of progression of peripheral joint damage as measured by X ray in patients with polyarticular symmetrical subtypes of the disease (see section 5.1) and to improve physical function.Axial spondyloarthritisAnkylosing spondylitis (AS)Simponi is indicated for the treatment of severe, active ankylosing spondylitis in adults who have responded inadequately to conventional therapy.Non radiographic axial spondyloarthritis (nr Axial SpA)Simponi is indicated for the treatment of adults with severe, active non radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs).Ulcerative colitis (UC)Simponi is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6 mercaptopurine (6 MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.Juvenile idiopathic arthritisPolyarticular juvenile idiopathic arthritis (pJIA)Simponi in combination with methotrexate (MTX) is indicated for the treatment of polyarticular juvenile idiopathic arthritis in children 2 years of age and older, who have responded inadequately to previous therapy with MTX.Rheumatoid arthritis (RA)Simponi, in combination with methotrexate (MTX), is indicated for:the treatment of moderate to severe, active rheumatoid arthritis in adults when the response to disease modifying anti rheumatic drug (DMARD) therapy including MTX has been inadequate.the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with MTX.Simponi, in combination with MTX, has been shown to reduce the rate of progression of joint damage as measured by X ray and to improve physical function.Juvenile idiopathic arthritisPolyarticular juvenile idiopathic arthritis (pJIA)Simponi in combination with MTX is indicated for the treatment of polyarticular juvenile idiopathic arthritis in children 2 years of age and older, who have responded inadequately to previous therapy with MTX.Psoriatic arthritis (PsA)Simponi, alone or in combination with MTX, is indicated for the treatment of active and progressive psoriatic arthritis in adult patients when the response to previous DMARD therapy has been inadequate. Simponi has been shown to reduce the rate of progression of peripheral joint damage as measured by X ray in patients with polyarticular symmetrical subtypes of the disease (see section 5.1) and to improve physical function.Axial spondyloarthritisAnkylosing spondylitis (AS)Simponi is indicated for the treatment of severe, active ankylosing spondylitis in adults who have responded inadequately to conventional therapy.Non radiographic axial spondyloarthritis (nr Axial SpA)Simponi is indicated for the treatment of adults with severe, active non radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs).Ulcerative colitis (UC)Simponi is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6 mercaptopurine (6 MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.|[PMDA] A drug with a new active ingredient indicated for the treatment of rheumatoid arthritis (including prevention of structural joint damage) in patients who have not sufficiently responded to conventional treatments. uuid:7ebf7188-5559-4ab9-b5b8-b0518854f81a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:91X1KLU43E biolink:treats MONDO:0011849 PMID:41385096 "[{""id"":""uuid:beb33a5b-f4e7-44ca-a4ff-6a16f38426ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:64f1ab70-055e-43bc-8381-ffd9b08a03d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ba3f0449-cbf4-450c-8e94-cbc5f4db81a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/simponi""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] SIMPONI ARIA is a tumor necrosis factor (TNF) blocker indicated for the treatment of: Adult patients with moderately to severely active Rheumatoid Arthritis (RA) in combination with methotrexate ( 1.1 ) Active Psoriatic Arthritis (PsA) in patients 2 years of age and older ( 1.2 ) Adult patients with active Ankylosing Spondylitis (AS) ( 1.3 ) Active polyarticular Juvenile Idiopathic Arthritis (pJIA) in patients 2 years of age and older ( 1.4 )|[EMA] Rheumatoid arthritis (RA)Simponi, in combination with methotrexate (MTX), is indicated for:the treatment of moderate to severe, active rheumatoid arthritis in adults when the response to disease modifying anti rheumatic drug (DMARD) therapy including MTX has been inadequate.the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with MTX.Simponi, in combination with MTX, has been shown to reduce the rate of progression of joint damage as measured by X ray and to improve physical function.For information regarding the polyarticular juvenile idiopathic arthritis indication, please see the Simponi 50 mg SmPC.Psoriatic arthritis (PsA)Simponi, alone or in combination with MTX, is indicated for the treatment of active and progressive psoriatic arthritis in adult patients when the response to previous DMARD therapy has been inadequate. Simponi has been shown to reduce the rate of progression of peripheral joint damage as measured by X ray in patients with polyarticular symmetrical subtypes of the disease (see section 5.1) and to improve physical function.Axial spondyloarthritisAnkylosing spondylitis (AS)Simponi is indicated for the treatment of severe, active ankylosing spondylitis in adults who have responded inadequately to conventional therapy.Non radiographic axial spondyloarthritis (nr Axial SpA)Simponi is indicated for the treatment of adults with severe, active non radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs).Ulcerative colitis (UC)Simponi is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6 mercaptopurine (6 MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.Juvenile idiopathic arthritisPolyarticular juvenile idiopathic arthritis (pJIA)Simponi in combination with methotrexate (MTX) is indicated for the treatment of polyarticular juvenile idiopathic arthritis in children 2 years of age and older, who have responded inadequately to previous therapy with MTX.Rheumatoid arthritis (RA)Simponi, in combination with methotrexate (MTX), is indicated for:the treatment of moderate to severe, active rheumatoid arthritis in adults when the response to disease modifying anti rheumatic drug (DMARD) therapy including MTX has been inadequate.the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with MTX.Simponi, in combination with MTX, has been shown to reduce the rate of progression of joint damage as measured by X ray and to improve physical function.Juvenile idiopathic arthritisPolyarticular juvenile idiopathic arthritis (pJIA)Simponi in combination with MTX is indicated for the treatment of polyarticular juvenile idiopathic arthritis in children 2 years of age and older, who have responded inadequately to previous therapy with MTX.Psoriatic arthritis (PsA)Simponi, alone or in combination with MTX, is indicated for the treatment of active and progressive psoriatic arthritis in adult patients when the response to previous DMARD therapy has been inadequate. Simponi has been shown to reduce the rate of progression of peripheral joint damage as measured by X ray in patients with polyarticular symmetrical subtypes of the disease (see section 5.1) and to improve physical function.Axial spondyloarthritisAnkylosing spondylitis (AS)Simponi is indicated for the treatment of severe, active ankylosing spondylitis in adults who have responded inadequately to conventional therapy.Non radiographic axial spondyloarthritis (nr Axial SpA)Simponi is indicated for the treatment of adults with severe, active non radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs).Ulcerative colitis (UC)Simponi is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6 mercaptopurine (6 MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies. uuid:c57e274b-6b1e-4605-ad05-143f761327d4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:91X1KLU43E biolink:treats MONDO:0005306 PMID:41385096 "[{""id"":""uuid:5ba21c4a-0df2-43d1-8c74-d48362072b9d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:e427cf5d-aff7-4a79-8768-6aba688674ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:105821d4-de2d-4a89-bfa1-5659c3e2254a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/simponi""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] SIMPONI ARIA is a tumor necrosis factor (TNF) blocker indicated for the treatment of: Adult patients with moderately to severely active Rheumatoid Arthritis (RA) in combination with methotrexate ( 1.1 ) Active Psoriatic Arthritis (PsA) in patients 2 years of age and older ( 1.2 ) Adult patients with active Ankylosing Spondylitis (AS) ( 1.3 ) Active polyarticular Juvenile Idiopathic Arthritis (pJIA) in patients 2 years of age and older ( 1.4 )|[EMA] Rheumatoid arthritis (RA)Simponi, in combination with methotrexate (MTX), is indicated for:the treatment of moderate to severe, active rheumatoid arthritis in adults when the response to disease modifying anti rheumatic drug (DMARD) therapy including MTX has been inadequate.the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with MTX.Simponi, in combination with MTX, has been shown to reduce the rate of progression of joint damage as measured by X ray and to improve physical function.For information regarding the polyarticular juvenile idiopathic arthritis indication, please see the Simponi 50 mg SmPC.Psoriatic arthritis (PsA)Simponi, alone or in combination with MTX, is indicated for the treatment of active and progressive psoriatic arthritis in adult patients when the response to previous DMARD therapy has been inadequate. Simponi has been shown to reduce the rate of progression of peripheral joint damage as measured by X ray in patients with polyarticular symmetrical subtypes of the disease (see section 5.1) and to improve physical function.Axial spondyloarthritisAnkylosing spondylitis (AS)Simponi is indicated for the treatment of severe, active ankylosing spondylitis in adults who have responded inadequately to conventional therapy.Non radiographic axial spondyloarthritis (nr Axial SpA)Simponi is indicated for the treatment of adults with severe, active non radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs).Ulcerative colitis (UC)Simponi is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6 mercaptopurine (6 MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.Juvenile idiopathic arthritisPolyarticular juvenile idiopathic arthritis (pJIA)Simponi in combination with methotrexate (MTX) is indicated for the treatment of polyarticular juvenile idiopathic arthritis in children 2 years of age and older, who have responded inadequately to previous therapy with MTX.Rheumatoid arthritis (RA)Simponi, in combination with methotrexate (MTX), is indicated for:the treatment of moderate to severe, active rheumatoid arthritis in adults when the response to disease modifying anti rheumatic drug (DMARD) therapy including MTX has been inadequate.the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with MTX.Simponi, in combination with MTX, has been shown to reduce the rate of progression of joint damage as measured by X ray and to improve physical function.Juvenile idiopathic arthritisPolyarticular juvenile idiopathic arthritis (pJIA)Simponi in combination with MTX is indicated for the treatment of polyarticular juvenile idiopathic arthritis in children 2 years of age and older, who have responded inadequately to previous therapy with MTX.Psoriatic arthritis (PsA)Simponi, alone or in combination with MTX, is indicated for the treatment of active and progressive psoriatic arthritis in adult patients when the response to previous DMARD therapy has been inadequate. Simponi has been shown to reduce the rate of progression of peripheral joint damage as measured by X ray in patients with polyarticular symmetrical subtypes of the disease (see section 5.1) and to improve physical function.Axial spondyloarthritisAnkylosing spondylitis (AS)Simponi is indicated for the treatment of severe, active ankylosing spondylitis in adults who have responded inadequately to conventional therapy.Non radiographic axial spondyloarthritis (nr Axial SpA)Simponi is indicated for the treatment of adults with severe, active non radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs).Ulcerative colitis (UC)Simponi is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6 mercaptopurine (6 MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies. uuid:67161e23-a54f-4621-8b60-cf02c1d90f4c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:91X1KLU43E biolink:treats MONDO:0018456 PMID:41385096 "[{""id"":""uuid:0eb26448-1d52-4922-b733-f118fe34d270"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:491a6b23-54bb-440f-8613-ea39523dd596"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:46893510-4a20-4cb2-9b10-d436dc6d5dd0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/simponi""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] SIMPONI ARIA is a tumor necrosis factor (TNF) blocker indicated for the treatment of: Adult patients with moderately to severely active Rheumatoid Arthritis (RA) in combination with methotrexate ( 1.1 ) Active Psoriatic Arthritis (PsA) in patients 2 years of age and older ( 1.2 ) Adult patients with active Ankylosing Spondylitis (AS) ( 1.3 ) Active polyarticular Juvenile Idiopathic Arthritis (pJIA) in patients 2 years of age and older ( 1.4 )|[EMA] Rheumatoid arthritis (RA)Simponi, in combination with methotrexate (MTX), is indicated for:the treatment of moderate to severe, active rheumatoid arthritis in adults when the response to disease modifying anti rheumatic drug (DMARD) therapy including MTX has been inadequate.the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with MTX.Simponi, in combination with MTX, has been shown to reduce the rate of progression of joint damage as measured by X ray and to improve physical function.For information regarding the polyarticular juvenile idiopathic arthritis indication, please see the Simponi 50 mg SmPC.Psoriatic arthritis (PsA)Simponi, alone or in combination with MTX, is indicated for the treatment of active and progressive psoriatic arthritis in adult patients when the response to previous DMARD therapy has been inadequate. Simponi has been shown to reduce the rate of progression of peripheral joint damage as measured by X ray in patients with polyarticular symmetrical subtypes of the disease (see section 5.1) and to improve physical function.Axial spondyloarthritisAnkylosing spondylitis (AS)Simponi is indicated for the treatment of severe, active ankylosing spondylitis in adults who have responded inadequately to conventional therapy.Non radiographic axial spondyloarthritis (nr Axial SpA)Simponi is indicated for the treatment of adults with severe, active non radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs).Ulcerative colitis (UC)Simponi is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6 mercaptopurine (6 MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.Juvenile idiopathic arthritisPolyarticular juvenile idiopathic arthritis (pJIA)Simponi in combination with methotrexate (MTX) is indicated for the treatment of polyarticular juvenile idiopathic arthritis in children 2 years of age and older, who have responded inadequately to previous therapy with MTX.Rheumatoid arthritis (RA)Simponi, in combination with methotrexate (MTX), is indicated for:the treatment of moderate to severe, active rheumatoid arthritis in adults when the response to disease modifying anti rheumatic drug (DMARD) therapy including MTX has been inadequate.the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with MTX.Simponi, in combination with MTX, has been shown to reduce the rate of progression of joint damage as measured by X ray and to improve physical function.Juvenile idiopathic arthritisPolyarticular juvenile idiopathic arthritis (pJIA)Simponi in combination with MTX is indicated for the treatment of polyarticular juvenile idiopathic arthritis in children 2 years of age and older, who have responded inadequately to previous therapy with MTX.Psoriatic arthritis (PsA)Simponi, alone or in combination with MTX, is indicated for the treatment of active and progressive psoriatic arthritis in adult patients when the response to previous DMARD therapy has been inadequate. Simponi has been shown to reduce the rate of progression of peripheral joint damage as measured by X ray in patients with polyarticular symmetrical subtypes of the disease (see section 5.1) and to improve physical function.Axial spondyloarthritisAnkylosing spondylitis (AS)Simponi is indicated for the treatment of severe, active ankylosing spondylitis in adults who have responded inadequately to conventional therapy.Non radiographic axial spondyloarthritis (nr Axial SpA)Simponi is indicated for the treatment of adults with severe, active non radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs).Ulcerative colitis (UC)Simponi is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6 mercaptopurine (6 MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies. uuid:fb318321-906f-4faa-930d-6308401f4bd6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17824 biolink:treats MONDO:0020546 PMID:41385096 "[{""id"":""uuid:e40edb94-b1a9-427a-8e09-95f191bb70c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eff40e24-b061-4610-9e74-b7d108473b60"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RYONCIL is indicated for the treatment of steroid refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months of age and older. uuid:6f2bad7c-14de-4c17-93cb-4696f9b44155 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:79033 biolink:treats MONDO:0004975 PMID:41385096 "[{""id"":""uuid:f3ce9d5d-da96-47ad-9669-cb678a981117"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d8bf02ec-7b68-4d8d-8a12-f83eb852ab64"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:298989a5-3681-4405-87a8-2c2dcc0f435f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Neuraceq is indicated for Positron Emission Tomography (PET) imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer’s Disease (AD) and other causes of cognitive decline. A negative Neuraceq scan indicates sparse to no amyloid neuritic plaques and is inconsistent with a neuropathological diagnosis of AD at the time of image acquisition; a negative scan result reduces the likelihood that a patient’s cognitive impairment is due to AD. A positive Neuraceq scan indicates moderate to frequent amyloid neuritic plaques; neuropathological examination has shown this amount of amyloid neuritic plaque is present in patients with AD, but may also be present in patients with other types of neurologic conditions as well as older people with normal cognition. Neuraceq is an adjunct to other diagnostic evaluations. Limitations of Use • A positive Neuraceq scan does not establish the diagnosis of AD or any other cognitive disorder. • Safety and effectiveness of Neuraceq have not been established for: o Predicting development of dementia or other neurologic conditions; o Monitoring responses to therapies.|[EMA] This medicinal product is for diagnostic use only.Neuraceq is a radiopharmaceutical indicated for Positron Emission Tomography (PET) imaging of β amyloid neuritic plaque density in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD) and other causes of cognitive impairment. Neuraceq should be used in conjunction with a clinical evaluation.A negative scan indicates sparse or no plaques, which is not consistent with a diagnosis of AD. uuid:a6c6c895-57fe-44d1-b1a8-e8cab99cb3aa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:79033 biolink:treats MONDO:0002039 PMID:41385096 "[{""id"":""uuid:f28684f3-2f42-4abe-99da-492078b51eb9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:4b4dd4a4-cc0b-4b10-af4b-e9b6d7d41658"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:a1f5ab03-0bbf-4b72-92d2-ab87f2200f9c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Neuraceq is indicated for Positron Emission Tomography (PET) imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer’s Disease (AD) and other causes of cognitive decline. A negative Neuraceq scan indicates sparse to no amyloid neuritic plaques and is inconsistent with a neuropathological diagnosis of AD at the time of image acquisition; a negative scan result reduces the likelihood that a patient’s cognitive impairment is due to AD. A positive Neuraceq scan indicates moderate to frequent amyloid neuritic plaques; neuropathological examination has shown this amount of amyloid neuritic plaque is present in patients with AD, but may also be present in patients with other types of neurologic conditions as well as older people with normal cognition. Neuraceq is an adjunct to other diagnostic evaluations. Limitations of Use • A positive Neuraceq scan does not establish the diagnosis of AD or any other cognitive disorder. • Safety and effectiveness of Neuraceq have not been established for: o Predicting development of dementia or other neurologic conditions; o Monitoring responses to therapies.|[EMA] This medicinal product is for diagnostic use only.Neuraceq is a radiopharmaceutical indicated for Positron Emission Tomography (PET) imaging of β amyloid neuritic plaque density in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD) and other causes of cognitive impairment. Neuraceq should be used in conjunction with a clinical evaluation.A negative scan indicates sparse or no plaques, which is not consistent with a diagnosis of AD. uuid:9326d89e-eb57-43e0-a17c-0990dcf34489 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27375 biolink:treats MONDO:0009348 PMID:41385096 "[{""id"":""uuid:3745257b-2dbd-412c-918f-2cf640fdd97e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2487126e-4b75-43ec-ad3c-0ef6e92c6ae3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vinblastine Sulfate Injection is indicated in the palliative treatment of the following: I. Frequently Responsive Malignancies • Generalized Hodgkin’s disease (Stages III and IV, Ann Arbor modification of Rye staging system) • Lymphocytic lymphoma (nodular and diffuse, poorly and well differentiated) • Histiocytic lymphoma • Mycosis fungoides (advanced stages) • Advanced carcinoma of the testis • Kaposi’s sarcoma • Letterer-Siwe disease (histiocytosis X) II. Less Frequently Responsive Malignancies • Choriocarcinoma resistant to other chemotherapeutic agents • Carcinoma of the breast, unresponsive to appropriate endocrine surgery and hormonal therapy Current principles of chemotherapy for many types of cancer include the concurrent administration of several antineoplastic agents. For enhanced therapeutic effect without additive toxicity, agents with different dose-limiting clinical toxicities and different mechanisms of action are generally selected. Therefore, although vinblastine sulfate is effective as a single agent in the aforementioned indications, it is usually administered in combination with other antineoplastic drugs. Such combination therapy produces a greater percentage of response than does a single-agent regimen. These principles have been applied, for example, in the chemotherapy of Hodgkin’s disease. uuid:d5957ab7-f409-4cfb-9edd-3ac3c1cfe9b4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27375 biolink:treats MONDO:0003864 PMID:41385096 "[{""id"":""uuid:77565fc1-bc89-4902-a94f-375d61cb4b36"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a726616a-9dc8-4b5b-8537-642c2dd0d429"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vinblastine Sulfate Injection is indicated in the palliative treatment of the following: I. Frequently Responsive Malignancies • Generalized Hodgkin’s disease (Stages III and IV, Ann Arbor modification of Rye staging system) • Lymphocytic lymphoma (nodular and diffuse, poorly and well differentiated) • Histiocytic lymphoma • Mycosis fungoides (advanced stages) • Advanced carcinoma of the testis • Kaposi’s sarcoma • Letterer-Siwe disease (histiocytosis X) II. Less Frequently Responsive Malignancies • Choriocarcinoma resistant to other chemotherapeutic agents • Carcinoma of the breast, unresponsive to appropriate endocrine surgery and hormonal therapy Current principles of chemotherapy for many types of cancer include the concurrent administration of several antineoplastic agents. For enhanced therapeutic effect without additive toxicity, agents with different dose-limiting clinical toxicities and different mechanisms of action are generally selected. Therefore, although vinblastine sulfate is effective as a single agent in the aforementioned indications, it is usually administered in combination with other antineoplastic drugs. Such combination therapy produces a greater percentage of response than does a single-agent regimen. These principles have been applied, for example, in the chemotherapy of Hodgkin’s disease. uuid:53ef5074-35d0-486a-a4e4-80e39479b77a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27375 biolink:treats MONDO:0004604 PMID:41385096 "[{""id"":""uuid:389518e5-bb77-4816-92c6-92798e36cd2d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:639c9923-cdf5-4ef5-818b-19ee15a4a7cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vinblastine Sulfate Injection is indicated in the palliative treatment of the following: I. Frequently Responsive Malignancies • Generalized Hodgkin’s disease (Stages III and IV, Ann Arbor modification of Rye staging system) • Lymphocytic lymphoma (nodular and diffuse, poorly and well differentiated) • Histiocytic lymphoma • Mycosis fungoides (advanced stages) • Advanced carcinoma of the testis • Kaposi’s sarcoma • Letterer-Siwe disease (histiocytosis X) II. Less Frequently Responsive Malignancies • Choriocarcinoma resistant to other chemotherapeutic agents • Carcinoma of the breast, unresponsive to appropriate endocrine surgery and hormonal therapy Current principles of chemotherapy for many types of cancer include the concurrent administration of several antineoplastic agents. For enhanced therapeutic effect without additive toxicity, agents with different dose-limiting clinical toxicities and different mechanisms of action are generally selected. Therefore, although vinblastine sulfate is effective as a single agent in the aforementioned indications, it is usually administered in combination with other antineoplastic drugs. Such combination therapy produces a greater percentage of response than does a single-agent regimen. These principles have been applied, for example, in the chemotherapy of Hodgkin’s disease. uuid:835a1e64-7fb6-436c-bf0a-d379893cc4f6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27375 biolink:treats MONDO:0009691 PMID:41385096 "[{""id"":""uuid:69bb9e24-d790-432d-ae48-9e0caf00d37a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:61e3db0e-00d9-4055-af99-5063dfbd247a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vinblastine Sulfate Injection is indicated in the palliative treatment of the following: I. Frequently Responsive Malignancies • Generalized Hodgkin’s disease (Stages III and IV, Ann Arbor modification of Rye staging system) • Lymphocytic lymphoma (nodular and diffuse, poorly and well differentiated) • Histiocytic lymphoma • Mycosis fungoides (advanced stages) • Advanced carcinoma of the testis • Kaposi’s sarcoma • Letterer-Siwe disease (histiocytosis X) II. Less Frequently Responsive Malignancies • Choriocarcinoma resistant to other chemotherapeutic agents • Carcinoma of the breast, unresponsive to appropriate endocrine surgery and hormonal therapy Current principles of chemotherapy for many types of cancer include the concurrent administration of several antineoplastic agents. For enhanced therapeutic effect without additive toxicity, agents with different dose-limiting clinical toxicities and different mechanisms of action are generally selected. Therefore, although vinblastine sulfate is effective as a single agent in the aforementioned indications, it is usually administered in combination with other antineoplastic drugs. Such combination therapy produces a greater percentage of response than does a single-agent regimen. These principles have been applied, for example, in the chemotherapy of Hodgkin’s disease. uuid:745f6fb4-e97e-434a-a747-b3c65d072352 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27375 biolink:treats MONDO:0006446 PMID:41385096 "[{""id"":""uuid:334921c1-572f-4c5c-ab7c-e98d7164ce85"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e7467baa-1807-4a82-832e-260141198d4d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vinblastine Sulfate Injection is indicated in the palliative treatment of the following: I. Frequently Responsive Malignancies • Generalized Hodgkin’s disease (Stages III and IV, Ann Arbor modification of Rye staging system) • Lymphocytic lymphoma (nodular and diffuse, poorly and well differentiated) • Histiocytic lymphoma • Mycosis fungoides (advanced stages) • Advanced carcinoma of the testis • Kaposi’s sarcoma • Letterer-Siwe disease (histiocytosis X) II. Less Frequently Responsive Malignancies • Choriocarcinoma resistant to other chemotherapeutic agents • Carcinoma of the breast, unresponsive to appropriate endocrine surgery and hormonal therapy Current principles of chemotherapy for many types of cancer include the concurrent administration of several antineoplastic agents. For enhanced therapeutic effect without additive toxicity, agents with different dose-limiting clinical toxicities and different mechanisms of action are generally selected. Therefore, although vinblastine sulfate is effective as a single agent in the aforementioned indications, it is usually administered in combination with other antineoplastic drugs. Such combination therapy produces a greater percentage of response than does a single-agent regimen. These principles have been applied, for example, in the chemotherapy of Hodgkin’s disease. uuid:9d31f96e-c3e6-4129-aa7a-555d19644b01 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27375 biolink:treats MONDO:0005055 PMID:41385096 "[{""id"":""uuid:b7285581-77e3-4b4b-bcb0-e7289e27cd25"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f92136aa-aba2-4a1b-b657-4c35a0dccfa4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vinblastine Sulfate Injection is indicated in the palliative treatment of the following: I. Frequently Responsive Malignancies • Generalized Hodgkin’s disease (Stages III and IV, Ann Arbor modification of Rye staging system) • Lymphocytic lymphoma (nodular and diffuse, poorly and well differentiated) • Histiocytic lymphoma • Mycosis fungoides (advanced stages) • Advanced carcinoma of the testis • Kaposi’s sarcoma • Letterer-Siwe disease (histiocytosis X) II. Less Frequently Responsive Malignancies • Choriocarcinoma resistant to other chemotherapeutic agents • Carcinoma of the breast, unresponsive to appropriate endocrine surgery and hormonal therapy Current principles of chemotherapy for many types of cancer include the concurrent administration of several antineoplastic agents. For enhanced therapeutic effect without additive toxicity, agents with different dose-limiting clinical toxicities and different mechanisms of action are generally selected. Therefore, although vinblastine sulfate is effective as a single agent in the aforementioned indications, it is usually administered in combination with other antineoplastic drugs. Such combination therapy produces a greater percentage of response than does a single-agent regimen. These principles have been applied, for example, in the chemotherapy of Hodgkin’s disease. uuid:c9f11dd9-216a-4065-8409-2a9d70383f47 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27375 biolink:treats MONDO:0005207 PMID:41385096 "[{""id"":""uuid:46f87a25-e46b-4747-9213-4c17a6ecb771"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:91134284-9e8e-4e7b-9e2b-c6b4185dff06"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vinblastine Sulfate Injection is indicated in the palliative treatment of the following: I. Frequently Responsive Malignancies • Generalized Hodgkin’s disease (Stages III and IV, Ann Arbor modification of Rye staging system) • Lymphocytic lymphoma (nodular and diffuse, poorly and well differentiated) • Histiocytic lymphoma • Mycosis fungoides (advanced stages) • Advanced carcinoma of the testis • Kaposi’s sarcoma • Letterer-Siwe disease (histiocytosis X) II. Less Frequently Responsive Malignancies • Choriocarcinoma resistant to other chemotherapeutic agents • Carcinoma of the breast, unresponsive to appropriate endocrine surgery and hormonal therapy Current principles of chemotherapy for many types of cancer include the concurrent administration of several antineoplastic agents. For enhanced therapeutic effect without additive toxicity, agents with different dose-limiting clinical toxicities and different mechanisms of action are generally selected. Therefore, although vinblastine sulfate is effective as a single agent in the aforementioned indications, it is usually administered in combination with other antineoplastic drugs. Such combination therapy produces a greater percentage of response than does a single-agent regimen. These principles have been applied, for example, in the chemotherapy of Hodgkin’s disease. uuid:dbe30fdb-570c-4138-8e1b-4202555fc0f6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27375 biolink:treats MONDO:0004989 PMID:41385096 "[{""id"":""uuid:fa48aa95-c928-4efd-a36b-ef157b64d4b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:74ee293d-90ce-41a7-ad05-065801e61ce2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vinblastine Sulfate Injection is indicated in the palliative treatment of the following: I. Frequently Responsive Malignancies • Generalized Hodgkin’s disease (Stages III and IV, Ann Arbor modification of Rye staging system) • Lymphocytic lymphoma (nodular and diffuse, poorly and well differentiated) • Histiocytic lymphoma • Mycosis fungoides (advanced stages) • Advanced carcinoma of the testis • Kaposi’s sarcoma • Letterer-Siwe disease (histiocytosis X) II. Less Frequently Responsive Malignancies • Choriocarcinoma resistant to other chemotherapeutic agents • Carcinoma of the breast, unresponsive to appropriate endocrine surgery and hormonal therapy Current principles of chemotherapy for many types of cancer include the concurrent administration of several antineoplastic agents. For enhanced therapeutic effect without additive toxicity, agents with different dose-limiting clinical toxicities and different mechanisms of action are generally selected. Therefore, although vinblastine sulfate is effective as a single agent in the aforementioned indications, it is usually administered in combination with other antineoplastic drugs. Such combination therapy produces a greater percentage of response than does a single-agent regimen. These principles have been applied, for example, in the chemotherapy of Hodgkin’s disease. uuid:708466c5-d606-45a2-9e67-20400527dab6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:91X1KLU43E biolink:treats MONDO:0005101 PMID:41385096 "[{""id"":""uuid:b8f2a2be-ca56-4715-9aa7-0b37815575db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:08960b72-21ff-42f1-92aa-6f5192978e18"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:2ffe1a0a-76f1-4034-a6d8-50996f32de42"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/simponi""]},{""id"":""uuid:95e1d92c-5fe5-4e64-a027-596279467c94"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SIMPONI is a tumor necrosis factor (TNF) blocker indicated for the treatment of adult patients with: Moderately to severely active rheumatoid arthritis (RA) in combination with methotrexate ( 1.1 ) Active psoriatic arthritis (PsA) alone, or in combination with methotrexate ( 1.2 ) Active ankylosing spondylitis (AS) ( 1.3 ) Moderate to severe Ulcerative colitis (UC) with an inadequate response or intolerant to prior treatment or requiring continuous steroid therapy ( 1.4 ) inducing and maintaining clinical response improving endoscopic appearance of the mucosa during induction inducing clinical remission achieving and sustaining clinical remission in induction responders|[EMA] Rheumatoid arthritis (RA)Simponi, in combination with methotrexate (MTX), is indicated for:the treatment of moderate to severe, active rheumatoid arthritis in adults when the response to disease modifying anti rheumatic drug (DMARD) therapy including MTX has been inadequate.the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with MTX.Simponi, in combination with MTX, has been shown to reduce the rate of progression of joint damage as measured by X ray and to improve physical function.For information regarding the polyarticular juvenile idiopathic arthritis indication, please see the Simponi 50 mg SmPC.Psoriatic arthritis (PsA)Simponi, alone or in combination with MTX, is indicated for the treatment of active and progressive psoriatic arthritis in adult patients when the response to previous DMARD therapy has been inadequate. Simponi has been shown to reduce the rate of progression of peripheral joint damage as measured by X ray in patients with polyarticular symmetrical subtypes of the disease (see section 5.1) and to improve physical function.Axial spondyloarthritisAnkylosing spondylitis (AS)Simponi is indicated for the treatment of severe, active ankylosing spondylitis in adults who have responded inadequately to conventional therapy.Non radiographic axial spondyloarthritis (nr Axial SpA)Simponi is indicated for the treatment of adults with severe, active non radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs).Ulcerative colitis (UC)Simponi is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6 mercaptopurine (6 MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.Juvenile idiopathic arthritisPolyarticular juvenile idiopathic arthritis (pJIA)Simponi in combination with methotrexate (MTX) is indicated for the treatment of polyarticular juvenile idiopathic arthritis in children 2 years of age and older, who have responded inadequately to previous therapy with MTX.Rheumatoid arthritis (RA)Simponi, in combination with methotrexate (MTX), is indicated for:the treatment of moderate to severe, active rheumatoid arthritis in adults when the response to disease modifying anti rheumatic drug (DMARD) therapy including MTX has been inadequate.the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with MTX.Simponi, in combination with MTX, has been shown to reduce the rate of progression of joint damage as measured by X ray and to improve physical function.Juvenile idiopathic arthritisPolyarticular juvenile idiopathic arthritis (pJIA)Simponi in combination with MTX is indicated for the treatment of polyarticular juvenile idiopathic arthritis in children 2 years of age and older, who have responded inadequately to previous therapy with MTX.Psoriatic arthritis (PsA)Simponi, alone or in combination with MTX, is indicated for the treatment of active and progressive psoriatic arthritis in adult patients when the response to previous DMARD therapy has been inadequate. Simponi has been shown to reduce the rate of progression of peripheral joint damage as measured by X ray in patients with polyarticular symmetrical subtypes of the disease (see section 5.1) and to improve physical function.Axial spondyloarthritisAnkylosing spondylitis (AS)Simponi is indicated for the treatment of severe, active ankylosing spondylitis in adults who have responded inadequately to conventional therapy.Non radiographic axial spondyloarthritis (nr Axial SpA)Simponi is indicated for the treatment of adults with severe, active non radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs).Ulcerative colitis (UC)Simponi is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6 mercaptopurine (6 MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.|[PMDA] Drugs with a new additional indication and a new dosage, in a new additional dosage form for improvement and maintenance of moderate to severe ulcerative colitis (for use only in patients who have not responded sufficiently to conventional treatments). uuid:f857197a-29c6-4f90-be9c-436cd831d3e9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:834YJF89WO biolink:treats MONDO:0020547 PMID:41385096 "[{""id"":""uuid:80d66013-21a2-4030-9e03-9c94c48fed1e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5e093c64-1d4e-490b-8253-6a2eb66bd908"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:4041e1b8-946e-4e0c-ba97-dda1e8f53f3e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] REZUROCK is indicated for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy.|[PMDA] A drug with a new active ingredient indicated for the treatment of chronic graft-versus-host disease after hematopoietic stem cell transplantation (for use when steroid drugs are not sufficiently effective). [Orphan drug] uuid:7c70229e-0469-48d1-b36d-2f8f99ac883a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:SMA5ZS5B22 biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:fa4f743c-15aa-4a89-a236-618ea1d748f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:129b5b5e-ba4e-4bb8-aa7a-9a6079ef7354"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ENSACOVE is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously received an ALK-inhibitor. uuid:626c028d-8670-4836-b10f-950bd130359e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:91407 biolink:treats MONDO:0009692 PMID:41385096 "[{""id"":""uuid:a5361e9e-4d73-46f1-aced-c60eb1a88f6a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0b9e316a-a1d7-45f7-8399-71011b2a9969"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OJJAARA is indicated for the treatment of intermediate or high-risk myelofibrosis (MF), including primary MF or secondary MF [post-polycythemia vera (PV) and post-essential thrombocythemia (ET)], in adults with anemia. uuid:09a986fb-b669-4dcb-bcd8-3f5fe7cfbf44 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:91407 biolink:treats MONDO:0004463 PMID:41385096 "[{""id"":""uuid:afbeda51-dd84-4d7c-9e21-93078926eaa1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3e0575de-6585-41c1-a2dd-90099d050d2e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OJJAARA is indicated for the treatment of intermediate or high-risk myelofibrosis (MF), including primary MF or secondary MF [post-polycythemia vera (PV) and post-essential thrombocythemia (ET)], in adults with anemia. uuid:1a58bf9a-5203-451f-8e54-00b00cebcd56 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:91407 biolink:treats UMLS:C0242006 PMID:41385096 "[{""id"":""uuid:7ea5839e-a72f-4c62-8f0a-0daab87604a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:62fb2454-c668-4547-a064-9839551251f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OJJAARA is indicated for the treatment of intermediate or high-risk myelofibrosis (MF), including primary MF or secondary MF [post-polycythemia vera (PV) and post-essential thrombocythemia (ET)], in adults with anemia. uuid:0fd6cb4a-4faf-4727-983c-5dd6c21e54c9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C4723695 biolink:treats MONDO:0015459 PMID:41385096 "[{""id"":""uuid:e961ca5f-0006-48ae-9b0f-d322aa3215f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b378f007-7542-4d01-a76b-f61b4ab7fbd3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Penpulimab-kcqx is a programmed death receptor-1 (PD-1)-blocking antibody indicated: in combination with either cisplatin or carboplatin and gemcitabine for the first-line treatment of adults with recurrent or metastatic non-keratinizing nasopharyngeal carcinoma (NPC) ( 1.1 ) as a single agent for the treatment of adults with metastatic non-keratinizing NPC with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy. ( 1.2 ) DRUGBANK:DB16747 uuid:4f10a279-8582-4db2-b0e1-ae91845d8507 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C4723695 biolink:treats MONDO:0024879 PMID:41385096 "[{""id"":""uuid:2d270171-e29f-44e2-9364-11053e757a55"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e509233d-ab7d-47d0-b584-715e30afe581"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Penpulimab-kcqx is a programmed death receptor-1 (PD-1)-blocking antibody indicated: in combination with either cisplatin or carboplatin and gemcitabine for the first-line treatment of adults with recurrent or metastatic non-keratinizing nasopharyngeal carcinoma (NPC) ( 1.1 ) as a single agent for the treatment of adults with metastatic non-keratinizing NPC with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy. ( 1.2 ) DRUGBANK:DB16747 uuid:bbf3c2a8-b092-48ce-9984-7719d77f5086 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:5YL4IQ1078 biolink:treats MONDO:0018912 PMID:41385096 "[{""id"":""uuid:b00bbb50-0b8f-4ff2-b0ad-148ca1d3dc9c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:df7f008e-ee14-4515-adc5-a0ade50238aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:13e12385-2e50-43ba-9383-8964c70e541f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c0d8ccb7-9f64-4f21-88e3-a9a981cf33d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ISTURISA is indicated for the treatment of endogenous hypercortisolemia in adults with Cushing's syndrome for whom surgery is not an option or has not been curative.|[EMA] Isturisa is indicated for the treatment of endogenous Cushing’s syndrome in adults.|[PMDA] Drugs with a new active ingredient indicated for the treatment of Cushing's syndrome (when surgical therapies are not sufficiently effective or are difficult to be performed). uuid:bbbe007a-c44e-4b11-ba3b-4a66ff6ead7c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4RA0KN46E0 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:b2af4403-ef03-4674-9cb7-9021233c765d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:df09ab01-d924-4c43-b54f-3bc09ea4183a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:604fc71b-091d-4dad-a9b2-eb8e698f6306"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/rinvoq""]},{""id"":""uuid:19f003a5-5497-467b-a8b4-2ece41863e3b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RINVOQ/RINVOQ LQ is a Janus kinase (JAK) inhibitor. RINVOQ is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.1 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.1 ) RINVOQ/RINVOQ LQ is indicated for the treatment of adults and pediatric patients 2 years of age and older with active psoriatic arthritis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.2 ) Limitation s of Use RINVOQ/RINVOQ LQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.2 ) RINVOQ is indicated for the treatment of adults and pediatric patients 12 years of age and older with refractory, moderate to severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies are inadvisable. ( 1.3 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, or with other immunosuppressants. ( 1.3 ) RINVOQ is indicated for the treatment of adults with moderately to severely active ulcerative colitis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.4 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biological therapies for ulcerative colitis, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.4 ) RINVOQ is indicated for the treatment of adults with moderately to severely active Crohn’s disease who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.5 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biological therapies for Crohn’s disease, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.5 ) RINVOQ is indicated for the treatment of adults with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.6 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.6 ) RINVOQ is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation who have had an inadequate response or intolerance to TNF blocker therapy. ( 1.7 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.7 ) RINVOQ/RINVOQ LQ is indicated for the treatment of patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.8 ) Limitations of Use RINVOQ/RINVOQ LQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.8 ) RINVOQ is indicated for the treatment of adults with giant cell arteritis ( 1.9 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.9 )|[EMA] Rheumatoid arthritisRINVOQ is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). RINVOQ may be used as monotherapy or in combination with methotrexate.Psoriatic arthritisRINVOQ is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more DMARDs. RINVOQ may be used as monotherapy or in combination with methotrexate.Axial spondyloarthritisNon-radiographic axial spondyloarthritis (nr-axSpA)RINVOQ is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).Ankylosing spondylitis (AS, radiographic axial spondyloarthritis)RINVOQ is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy.Atopic dermatitisRINVOQ is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.Ulcerative colitisRINVOQ is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent. Crohn’s diseaseRINVOQ is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.|[PMDA] Drugs with a new active ingredient indicated for the treatment of rheumatoid arthritis (including the prevention of structural joint damage) in patients who have not responded sufficiently to conventional treatments. uuid:1fce7e32-4983-4d8a-a3ac-f3b7cb4a982c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4RA0KN46E0 biolink:treats MONDO:0011849 PMID:41385096 "[{""id"":""uuid:a60ca103-ec18-4341-bb2b-88829c8e75e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:cd48bbe8-e97d-49b0-8b82-cd15930b54cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:b52225fc-a309-4ad3-a51b-64c6754cc6db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/rinvoq""]},{""id"":""uuid:3db25235-17db-4cc7-a643-53e967c6494b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RINVOQ/RINVOQ LQ is a Janus kinase (JAK) inhibitor. RINVOQ is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.1 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.1 ) RINVOQ/RINVOQ LQ is indicated for the treatment of adults and pediatric patients 2 years of age and older with active psoriatic arthritis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.2 ) Limitation s of Use RINVOQ/RINVOQ LQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.2 ) RINVOQ is indicated for the treatment of adults and pediatric patients 12 years of age and older with refractory, moderate to severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies are inadvisable. ( 1.3 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, or with other immunosuppressants. ( 1.3 ) RINVOQ is indicated for the treatment of adults with moderately to severely active ulcerative colitis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.4 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biological therapies for ulcerative colitis, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.4 ) RINVOQ is indicated for the treatment of adults with moderately to severely active Crohn’s disease who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.5 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biological therapies for Crohn’s disease, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.5 ) RINVOQ is indicated for the treatment of adults with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.6 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.6 ) RINVOQ is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation who have had an inadequate response or intolerance to TNF blocker therapy. ( 1.7 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.7 ) RINVOQ/RINVOQ LQ is indicated for the treatment of patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.8 ) Limitations of Use RINVOQ/RINVOQ LQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.8 ) RINVOQ is indicated for the treatment of adults with giant cell arteritis ( 1.9 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.9 )|[EMA] Rheumatoid arthritisRINVOQ is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). RINVOQ may be used as monotherapy or in combination with methotrexate.Psoriatic arthritisRINVOQ is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more DMARDs. RINVOQ may be used as monotherapy or in combination with methotrexate.Axial spondyloarthritisNon-radiographic axial spondyloarthritis (nr-axSpA)RINVOQ is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).Ankylosing spondylitis (AS, radiographic axial spondyloarthritis)RINVOQ is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy.Atopic dermatitisRINVOQ is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.Ulcerative colitisRINVOQ is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent. Crohn’s diseaseRINVOQ is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.|[PMDA] Drugs with a new indication and a new dosage for the treatment of psoriatic arthritis in patients who have not responded sufficiently to conventional therapies. uuid:6e68f13f-6c6f-4799-9ebb-335238ee7114 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4RA0KN46E0 biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:f0f1ed60-d498-4b3f-983a-0f011918a4c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:543b20ea-77c4-45c7-895c-e4711118c4af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:b5bb07c8-50ad-4c74-a018-221c0e5af776"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/rinvoq""]},{""id"":""uuid:7063857a-fcc1-4d1b-8764-1c6b02ae3513"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RINVOQ/RINVOQ LQ is a Janus kinase (JAK) inhibitor. RINVOQ is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.1 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.1 ) RINVOQ/RINVOQ LQ is indicated for the treatment of adults and pediatric patients 2 years of age and older with active psoriatic arthritis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.2 ) Limitation s of Use RINVOQ/RINVOQ LQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.2 ) RINVOQ is indicated for the treatment of adults and pediatric patients 12 years of age and older with refractory, moderate to severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies are inadvisable. ( 1.3 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, or with other immunosuppressants. ( 1.3 ) RINVOQ is indicated for the treatment of adults with moderately to severely active ulcerative colitis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.4 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biological therapies for ulcerative colitis, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.4 ) RINVOQ is indicated for the treatment of adults with moderately to severely active Crohn’s disease who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.5 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biological therapies for Crohn’s disease, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.5 ) RINVOQ is indicated for the treatment of adults with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.6 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.6 ) RINVOQ is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation who have had an inadequate response or intolerance to TNF blocker therapy. ( 1.7 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.7 ) RINVOQ/RINVOQ LQ is indicated for the treatment of patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.8 ) Limitations of Use RINVOQ/RINVOQ LQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.8 ) RINVOQ is indicated for the treatment of adults with giant cell arteritis ( 1.9 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.9 )|[EMA] Rheumatoid arthritisRINVOQ is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). RINVOQ may be used as monotherapy or in combination with methotrexate.Psoriatic arthritisRINVOQ is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more DMARDs. RINVOQ may be used as monotherapy or in combination with methotrexate.Axial spondyloarthritisNon-radiographic axial spondyloarthritis (nr-axSpA)RINVOQ is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).Ankylosing spondylitis (AS, radiographic axial spondyloarthritis)RINVOQ is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy.Atopic dermatitisRINVOQ is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.Ulcerative colitisRINVOQ is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent. Crohn’s diseaseRINVOQ is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.|[PMDA] A drug in an additional dosage form indicated for the treatment of atopic dermatitis in patients who have not responded sufficiently to conventional treatments. uuid:a50d65a4-f38f-4c84-bc67-0a67525d1cdc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4RA0KN46E0 biolink:treats MONDO:0005101 PMID:41385096 "[{""id"":""uuid:3cdfd85f-aed4-45b8-b0b7-453730a21af4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:06e9ddfb-8bf7-4633-83bd-1f0e29b998b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:aa0b944a-5e6a-4f8d-95f4-fb50deefe413"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/rinvoq""]},{""id"":""uuid:29fb3318-55f7-4f41-a88b-a6fd8dc41bbc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RINVOQ/RINVOQ LQ is a Janus kinase (JAK) inhibitor. RINVOQ is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.1 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.1 ) RINVOQ/RINVOQ LQ is indicated for the treatment of adults and pediatric patients 2 years of age and older with active psoriatic arthritis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.2 ) Limitation s of Use RINVOQ/RINVOQ LQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.2 ) RINVOQ is indicated for the treatment of adults and pediatric patients 12 years of age and older with refractory, moderate to severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies are inadvisable. ( 1.3 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, or with other immunosuppressants. ( 1.3 ) RINVOQ is indicated for the treatment of adults with moderately to severely active ulcerative colitis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.4 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biological therapies for ulcerative colitis, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.4 ) RINVOQ is indicated for the treatment of adults with moderately to severely active Crohn’s disease who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.5 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biological therapies for Crohn’s disease, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.5 ) RINVOQ is indicated for the treatment of adults with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.6 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.6 ) RINVOQ is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation who have had an inadequate response or intolerance to TNF blocker therapy. ( 1.7 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.7 ) RINVOQ/RINVOQ LQ is indicated for the treatment of patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.8 ) Limitations of Use RINVOQ/RINVOQ LQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.8 ) RINVOQ is indicated for the treatment of adults with giant cell arteritis ( 1.9 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.9 )|[EMA] Rheumatoid arthritisRINVOQ is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). RINVOQ may be used as monotherapy or in combination with methotrexate.Psoriatic arthritisRINVOQ is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more DMARDs. RINVOQ may be used as monotherapy or in combination with methotrexate.Axial spondyloarthritisNon-radiographic axial spondyloarthritis (nr-axSpA)RINVOQ is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).Ankylosing spondylitis (AS, radiographic axial spondyloarthritis)RINVOQ is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy.Atopic dermatitisRINVOQ is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.Ulcerative colitisRINVOQ is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent. Crohn’s diseaseRINVOQ is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.|[PMDA] (1) (2) (3) Drugs with a new indication and a new dosage for the remission induction and maintenance therapy of moderate to severe ulcerative colitis (for use only in patients who have not sufficiently responded to conventional treatments). (4) A drug with a new indication and a new dosage in an additional dosage form for the remission induction therapy of moderate to severe ulcerative colitis (for use only in patients who have not sufficiently responded to conventional treatments). uuid:19b2624c-3130-48f2-8b7d-7bbb589efbd2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4RA0KN46E0 biolink:treats MONDO:0005011 PMID:41385096 "[{""id"":""uuid:804f91a4-e459-44df-b2d2-0feabdf09f74"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:c0bcb672-f415-4118-a1f4-186b697b0cef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:0c842398-08c2-47de-bc6c-72b7527f119f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/rinvoq""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] RINVOQ/RINVOQ LQ is a Janus kinase (JAK) inhibitor. RINVOQ is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.1 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.1 ) RINVOQ/RINVOQ LQ is indicated for the treatment of adults and pediatric patients 2 years of age and older with active psoriatic arthritis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.2 ) Limitation s of Use RINVOQ/RINVOQ LQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.2 ) RINVOQ is indicated for the treatment of adults and pediatric patients 12 years of age and older with refractory, moderate to severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies are inadvisable. ( 1.3 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, or with other immunosuppressants. ( 1.3 ) RINVOQ is indicated for the treatment of adults with moderately to severely active ulcerative colitis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.4 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biological therapies for ulcerative colitis, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.4 ) RINVOQ is indicated for the treatment of adults with moderately to severely active Crohn’s disease who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.5 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biological therapies for Crohn’s disease, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.5 ) RINVOQ is indicated for the treatment of adults with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.6 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.6 ) RINVOQ is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation who have had an inadequate response or intolerance to TNF blocker therapy. ( 1.7 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.7 ) RINVOQ/RINVOQ LQ is indicated for the treatment of patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.8 ) Limitations of Use RINVOQ/RINVOQ LQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.8 ) RINVOQ is indicated for the treatment of adults with giant cell arteritis ( 1.9 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.9 )|[EMA] Rheumatoid arthritisRINVOQ is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). RINVOQ may be used as monotherapy or in combination with methotrexate.Psoriatic arthritisRINVOQ is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more DMARDs. RINVOQ may be used as monotherapy or in combination with methotrexate.Axial spondyloarthritisNon-radiographic axial spondyloarthritis (nr-axSpA)RINVOQ is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).Ankylosing spondylitis (AS, radiographic axial spondyloarthritis)RINVOQ is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy.Atopic dermatitisRINVOQ is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.Ulcerative colitisRINVOQ is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent. Crohn’s diseaseRINVOQ is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent. uuid:c4b01cb5-fd8d-44a8-a508-1b4b31061091 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4RA0KN46E0 biolink:treats MONDO:0005306 PMID:41385096 "[{""id"":""uuid:bfcb740e-0072-428a-afd1-01bc07ec6e73"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1c830d77-f5bc-4623-82db-f6fc5a7120ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:0059b0bd-b6a3-41d1-a451-826717bcb779"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/rinvoq""]},{""id"":""uuid:91a13329-8b4a-43ce-a154-56d1e97f0d56"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RINVOQ/RINVOQ LQ is a Janus kinase (JAK) inhibitor. RINVOQ is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.1 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.1 ) RINVOQ/RINVOQ LQ is indicated for the treatment of adults and pediatric patients 2 years of age and older with active psoriatic arthritis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.2 ) Limitation s of Use RINVOQ/RINVOQ LQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.2 ) RINVOQ is indicated for the treatment of adults and pediatric patients 12 years of age and older with refractory, moderate to severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies are inadvisable. ( 1.3 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, or with other immunosuppressants. ( 1.3 ) RINVOQ is indicated for the treatment of adults with moderately to severely active ulcerative colitis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.4 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biological therapies for ulcerative colitis, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.4 ) RINVOQ is indicated for the treatment of adults with moderately to severely active Crohn’s disease who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.5 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biological therapies for Crohn’s disease, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.5 ) RINVOQ is indicated for the treatment of adults with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.6 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.6 ) RINVOQ is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation who have had an inadequate response or intolerance to TNF blocker therapy. ( 1.7 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.7 ) RINVOQ/RINVOQ LQ is indicated for the treatment of patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.8 ) Limitations of Use RINVOQ/RINVOQ LQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.8 ) RINVOQ is indicated for the treatment of adults with giant cell arteritis ( 1.9 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.9 )|[EMA] Rheumatoid arthritisRINVOQ is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). RINVOQ may be used as monotherapy or in combination with methotrexate.Psoriatic arthritisRINVOQ is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more DMARDs. RINVOQ may be used as monotherapy or in combination with methotrexate.Axial spondyloarthritisNon-radiographic axial spondyloarthritis (nr-axSpA)RINVOQ is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).Ankylosing spondylitis (AS, radiographic axial spondyloarthritis)RINVOQ is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy.Atopic dermatitisRINVOQ is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.Ulcerative colitisRINVOQ is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent. Crohn’s diseaseRINVOQ is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.|[PMDA] Drugs with a new indication and a new dosage for the treatment of ankylosing spondylitis in patients who have not responded sufficiently to conventional treatments. uuid:092563ad-a8b1-44fc-9f85-dd40d6a902ee biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4RA0KN46E0 biolink:treats UMLS:C3203547 PMID:41385096 "[{""id"":""uuid:9c2b3685-3de5-4f5a-bcc4-ffa38fc3f97e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:917f57d0-a9c5-42b7-aff2-8e2aada20667"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ed6c8b43-69f3-4bf2-b342-c944ae94f315"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RINVOQ/RINVOQ LQ is a Janus kinase (JAK) inhibitor. RINVOQ is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.1 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.1 ) RINVOQ/RINVOQ LQ is indicated for the treatment of adults and pediatric patients 2 years of age and older with active psoriatic arthritis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.2 ) Limitation s of Use RINVOQ/RINVOQ LQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.2 ) RINVOQ is indicated for the treatment of adults and pediatric patients 12 years of age and older with refractory, moderate to severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies are inadvisable. ( 1.3 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, or with other immunosuppressants. ( 1.3 ) RINVOQ is indicated for the treatment of adults with moderately to severely active ulcerative colitis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.4 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biological therapies for ulcerative colitis, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.4 ) RINVOQ is indicated for the treatment of adults with moderately to severely active Crohn’s disease who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.5 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biological therapies for Crohn’s disease, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.5 ) RINVOQ is indicated for the treatment of adults with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.6 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.6 ) RINVOQ is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation who have had an inadequate response or intolerance to TNF blocker therapy. ( 1.7 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.7 ) RINVOQ/RINVOQ LQ is indicated for the treatment of patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.8 ) Limitations of Use RINVOQ/RINVOQ LQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.8 ) RINVOQ is indicated for the treatment of adults with giant cell arteritis ( 1.9 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.9 )|[PMDA] Drugs with a new indication and a new dosage for the treatment of non-radiographic axial spondyloarthritis in patients who have not responded sufficiently to conventional treatments. uuid:3e02b6d7-6b62-47be-89d1-e75642986a1f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4RA0KN46E0 biolink:treats MONDO:0018456 PMID:41385096 "[{""id"":""uuid:df24ba52-c100-4f84-9baa-1b2eb54451a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e311afb3-0af8-4a90-b386-a731974a4103"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RINVOQ/RINVOQ LQ is a Janus kinase (JAK) inhibitor. RINVOQ is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.1 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.1 ) RINVOQ/RINVOQ LQ is indicated for the treatment of adults and pediatric patients 2 years of age and older with active psoriatic arthritis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.2 ) Limitation s of Use RINVOQ/RINVOQ LQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.2 ) RINVOQ is indicated for the treatment of adults and pediatric patients 12 years of age and older with refractory, moderate to severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies are inadvisable. ( 1.3 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, or with other immunosuppressants. ( 1.3 ) RINVOQ is indicated for the treatment of adults with moderately to severely active ulcerative colitis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.4 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biological therapies for ulcerative colitis, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.4 ) RINVOQ is indicated for the treatment of adults with moderately to severely active Crohn’s disease who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.5 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biological therapies for Crohn’s disease, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.5 ) RINVOQ is indicated for the treatment of adults with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.6 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.6 ) RINVOQ is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation who have had an inadequate response or intolerance to TNF blocker therapy. ( 1.7 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.7 ) RINVOQ/RINVOQ LQ is indicated for the treatment of patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.8 ) Limitations of Use RINVOQ/RINVOQ LQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.8 ) RINVOQ is indicated for the treatment of adults with giant cell arteritis ( 1.9 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.9 ) uuid:49cf69db-7e1e-4de6-8c1e-3ff51a7c6006 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4RA0KN46E0 biolink:treats MONDO:0008538 PMID:41385096 "[{""id"":""uuid:af23ad4b-b023-4405-bed4-e9fa46818dac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b6232356-25c8-4328-8962-2e97ecf1fd69"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RINVOQ/RINVOQ LQ is a Janus kinase (JAK) inhibitor. RINVOQ is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.1 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.1 ) RINVOQ/RINVOQ LQ is indicated for the treatment of adults and pediatric patients 2 years of age and older with active psoriatic arthritis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.2 ) Limitation s of Use RINVOQ/RINVOQ LQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.2 ) RINVOQ is indicated for the treatment of adults and pediatric patients 12 years of age and older with refractory, moderate to severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies are inadvisable. ( 1.3 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, or with other immunosuppressants. ( 1.3 ) RINVOQ is indicated for the treatment of adults with moderately to severely active ulcerative colitis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.4 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biological therapies for ulcerative colitis, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.4 ) RINVOQ is indicated for the treatment of adults with moderately to severely active Crohn’s disease who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.5 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biological therapies for Crohn’s disease, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.5 ) RINVOQ is indicated for the treatment of adults with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.6 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.6 ) RINVOQ is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation who have had an inadequate response or intolerance to TNF blocker therapy. ( 1.7 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.7 ) RINVOQ/RINVOQ LQ is indicated for the treatment of patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.8 ) Limitations of Use RINVOQ/RINVOQ LQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.8 ) RINVOQ is indicated for the treatment of adults with giant cell arteritis ( 1.9 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.9 ) uuid:3fd32c5b-32c1-4618-ac10-03b6b2a30d15 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3757 biolink:treats MONDO:0007743 PMID:41385096 "[{""id"":""uuid:30b445c0-882c-4056-8c34-66d2091eb3dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3e0d85f7-98c1-497f-b613-cbc1fab44aa8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ONYDA XR is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) as monotherapy and as adjunctive therapy to central nervous system (CNS) stimulant medications in pediatric patients 6 years of age and older [see Clinical Studies ( 14 )]. uuid:53b5b147-acd5-410a-8a5b-6894097cd15b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:21K6M2I7AG biolink:treats MONDO:0018305 PMID:41385096 "[{""id"":""uuid:bb227e9a-92b0-4d95-a315-2f993e2836d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6a67514c-cf83-43d2-bcc4-45ad0b4dbd78"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ACTIMMUNE is indicated for reducing the frequency and severity of serious infections associated with Chronic Granulomatous Disease (CGD). ACTIMMUNE is indicated for delaying time to disease progression in patients with severe, malignant osteopetrosis (SMO). uuid:6e676f3f-efe5-4006-931f-322794f9f600 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:21K6M2I7AG biolink:treats MONDO:0019026 PMID:41385096 "[{""id"":""uuid:a11d40b2-0764-4622-937e-3949889642b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9dd83226-acb7-4fba-a687-81fd6e11bd1f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ACTIMMUNE is indicated for reducing the frequency and severity of serious infections associated with Chronic Granulomatous Disease (CGD). ACTIMMUNE is indicated for delaying time to disease progression in patients with severe, malignant osteopetrosis (SMO). uuid:f153d576-22f1-43bd-b2d0-437f04fbba28 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:QX45B99R3J biolink:treats MONDO:0005045 PMID:41385096 "[{""id"":""uuid:08a38c86-cd2f-4f32-b88a-5e399f43f770"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:c0c9ca96-9be8-4876-bd37-f94219b697f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:59f0cd1b-fc3d-4ebc-9dfc-3d04c9ceb085"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/camzyos""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] CAMZYOS ® is indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms.|[EMA] Treatment of symptomatic obstructive hypertrophic cardiomyopathy. uuid:0e50f28d-b595-4bd4-81da-4499d32bf01b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47381 biolink:treats HP:0100607 PMID:41385096 "[{""id"":""uuid:334566c0-d2a0-4746-8515-98de0e455178"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:97fc7503-db3e-4a97-b93a-23548ced5cdd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of diclofenac potassium tablets and other treatment options before deciding to use diclofenac potassium tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see ). Diclofenac potassium tablets are indicated: • for treatment of primary dysmenorrhea • for relief of mild to moderate pain • for relief of the signs and symptoms of osteoarthritis • for relief of the signs and symptoms of rheumatoid arthritis uuid:4fb063f6-ca46-457c-9ff1-ad390688f4c7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:50605O2ZNS biolink:treats MONDO:0005300 PMID:41385096 "[{""id"":""uuid:d2530a79-0e4f-481a-89a2-3285c51ebb5e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ad462f79-6d09-4503-8762-86db21246e24"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e618ca09-a51e-4bf2-9a28-323d214fb7a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XPHOZAH is indicated to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.|[PMDA] Drugs with a new active ingredient indicated for the improvement of hyperphosphatemia in patients with chronic kidney disease on dialysis. uuid:ae89ea14-8b83-42fe-afa7-bef4f13d6ee0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3614 biolink:treats HP:0032674 PMID:41385096 "[{""id"":""uuid:1f4d7bee-40e5-4a52-b820-d92b70faa7f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3bae9311-16d0-4859-bc95-ab5dd621e2da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] healthcare personnel handwash: helps reduce bacteria that potentially can cause disease skin wound and general skin cleansing uuid:d8ec0271-b755-45d1-b2f0-c06305c8a760 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85979 biolink:treats MONDO:0000240 PMID:41385096 "[{""id"":""uuid:88e47816-328c-4a14-a421-b67bf0d38cee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:fce1fd11-6bfe-4bf7-aae8-1e2a097e4255"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:48e54753-3d0d-428b-9ec5-4b2a69e673a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/cresemba""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] CRESEMBA ® is an azole antifungal indicated for the treatment of: Invasive aspergillosis ( 1.1 ) and Invasive mucormycosis ( 1.2 ) as follows: • CRESEMBA for injection : adults and pediatric patients 1 year of age and older • CRESEMBA capsules : adults and pediatric patients 6 years of age and older who weigh 16 kilograms (kg) and greater|[EMA] Cresemba is indicated in adults for the treatment of:invasive aspergillosismucormycosis in patients for whom amphotericin B is inappropriateConsideration should be given to official guidance on the appropriate use of antifungal agents. uuid:befd9673-9163-4969-9409-effb0e84ee59 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85979 biolink:treats MONDO:0019136 PMID:41385096 "[{""id"":""uuid:621b37e0-f0e0-46a1-9a6a-93c66efbf056"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:318fc262-263d-46a5-99fe-1a8e0ba9bd31"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CRESEMBA ® is an azole antifungal indicated for the treatment of: Invasive aspergillosis ( 1.1 ) and Invasive mucormycosis ( 1.2 ) as follows: • CRESEMBA for injection : adults and pediatric patients 1 year of age and older • CRESEMBA capsules : adults and pediatric patients 6 years of age and older who weigh 16 kilograms (kg) and greater uuid:8595932b-a2c5-4aac-8d68-cde4b63c5455 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17141 biolink:treats MONDO:0016239 PMID:41385096 "[{""id"":""uuid:c30bec4e-44f0-453a-a831-5dce3da1b484"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3c2acca1-e9f9-4ac1-beae-8688a5b21e36"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:94953b1e-b839-4cb1-b3ac-ccaf8e1e3f94"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:801b937e-b091-47fe-a118-3bcd0940682c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CYSTARAN ® is a cystine-depleting agent indicated for the treatment of corneal cystine crystal accumulation in patients with cystinosis.|[EMA] Cystadrops is indicated for the treatment of corneal cystine crystal deposits in adults and children from 2 years of age with cystinosis.|[PMDA] A drug with a new active ingredient indicated for the reduction of corneal cystine crystals in patients with cystinosis. [Orphan drug] uuid:b017a01a-b138-4da7-90aa-8bc5e37e435d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1603837 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:3f579a50-4f37-4018-be32-a9e219778d68"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:67c7257e-94de-4158-95ff-728076b141f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AVYCAZ is a combination of ceftazidime, a cephalosporin, and avibactam, a beta-lactamase inhibitor, indicated for the treatment of the following infections caused by designated susceptible Gram-negative microorganisms in adult and pediatric patients (at least 31 weeks gestational age): Complicated Intra-abdominal Infections (cIAI), used in combination with metronidazole ( 1.1 ) Complicated Urinary Tract Infections (cUTI), including Pyelonephritis ( 1.2 ) Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia (HABP/VABP) ( 1.3 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of AVYCAZ and other antibacterial drugs, AVYCAZ should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. ( 1.4 ) uuid:b3914f9f-a611-4646-adda-7d976d54b745 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1603837 biolink:treats MONDO:0006939 PMID:41385096 "[{""id"":""uuid:95803d9e-3c6c-416e-aede-5d34f06aa19e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:7d94cdfe-9265-419d-8266-638bffaeaeaf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:d19730d7-9097-434d-8dd6-bc1abc680044"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/zavicefta""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] AVYCAZ is a combination of ceftazidime, a cephalosporin, and avibactam, a beta-lactamase inhibitor, indicated for the treatment of the following infections caused by designated susceptible Gram-negative microorganisms in adult and pediatric patients (at least 31 weeks gestational age): Complicated Intra-abdominal Infections (cIAI), used in combination with metronidazole ( 1.1 ) Complicated Urinary Tract Infections (cUTI), including Pyelonephritis ( 1.2 ) Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia (HABP/VABP) ( 1.3 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of AVYCAZ and other antibacterial drugs, AVYCAZ should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. ( 1.4 )|[EMA] Zavicefta is indicated in adults and paediatric patients aged 3 months and older for the treatment of the following infections:Complicated intra-abdominal infection (cIAI)Complicated urinary tract infection (cUTI), including pyelonephritisHospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP)Treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.Zavicefta is also indicated for the treatment of infections due to aerobic Gram-negative organisms in adults and paediatric patients aged 3 months and older with limited treatment options.Consideration should be given to official guidance on the appropriate use of antibacterial agents. uuid:c3f56e8b-c737-420d-aa56-feb9b530714b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1603837 biolink:treats MONDO:0004652 PMID:41385096 "[{""id"":""uuid:3fd36e0a-f917-4371-b602-312cb0aee623"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:738c6af9-b6cb-42cd-a1e5-05f29aad8492"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AVYCAZ is a combination of ceftazidime, a cephalosporin, and avibactam, a beta-lactamase inhibitor, indicated for the treatment of the following infections caused by designated susceptible Gram-negative microorganisms in adult and pediatric patients (at least 31 weeks gestational age): Complicated Intra-abdominal Infections (cIAI), used in combination with metronidazole ( 1.1 ) Complicated Urinary Tract Infections (cUTI), including Pyelonephritis ( 1.2 ) Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia (HABP/VABP) ( 1.3 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of AVYCAZ and other antibacterial drugs, AVYCAZ should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. ( 1.4 ) uuid:dd346945-2e6b-49e1-8e1f-827fde641aa9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:72296 biolink:treats MONDO:0005399 PMID:41385096 "[{""id"":""uuid:d7ed6e2a-7a72-453c-a784-212352836656"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:3f963952-e982-4419-ac89-011d68fdcbd2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:84a292f9-a3f4-49ed-8020-3eccbadc158d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/eliquis""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] ELIQUIS is a factor Xa inhibitor indicated: • to reduce the risk of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation. (1.1) • for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in adult patients who have undergone hip or knee replacement surgery. (1.2) • for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE in adult patients following initial therapy. (1.3 , 1.4 , 1.5) • Treatment of venous thromboembolism (VTE) and reduction in the risk of recurrent VTE in pediatric patients from birth and older after at least 5 days of initial anticoagulant treatment. (1.6)|[EMA] For Eliquis 2.5 mg film-coated tablets:Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery.Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II).Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults (see section 4.4 for haemodynamically unstable PE patients).For Eliquis 5 mg film-coated tablets:Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II).Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults (see section 4.4 for haemodynamically unstable PE patients). uuid:65f70b1b-c9a1-4cd8-b406-9161222a1ada biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6954 biolink:treats MONDO:0008734 PMID:41385096 "[{""id"":""uuid:0d26798e-69f4-4fe8-bd9b-9fe8bf6680e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:439d8147-1535-4ef2-953d-5e926d3033e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LYSODREN is indicated for the treatment of patients with inoperable, functional or nonfunctional, adrenocortical carcinoma (ACC). uuid:9732f654-e71e-471c-9675-37d10991f7a9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6954 biolink:treats MONDO:0008808 PMID:41385096 "[{""id"":""uuid:f21f0435-e910-409d-a8dc-2af22941fae2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f5a02014-b67a-4347-93bb-35328f09a53b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LYSODREN is indicated for the treatment of patients with inoperable, functional or nonfunctional, adrenocortical carcinoma (ACC). uuid:28653fb0-02fa-4d0b-95d5-6fe3543f2c6c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:2877953 biolink:treats MONDO:0015924 PMID:41385096 "[{""id"":""uuid:f3e9fb83-4ef9-4c0a-9195-2c590c8a6967"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f7d381f5-2837-4250-9253-18702f2eabd9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] WINREVAIR™ is indicated for the treatment of adults with pulmonary arterial hypertension (PAH, World Health Organization [WHO] Group 1) to increase exercise capacity, improve WHO functional class (FC), and reduce the risk of clinical worsening events. uuid:53a608bb-d349-46cf-91d7-316a32f299e7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:42797 biolink:treats MONDO:0005391 PMID:41385096 "[{""id"":""uuid:8f40bb5f-568d-4257-a3a0-700c576c29bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:223aa275-a67d-4cbc-ae5c-975f2efe0c44"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:fbc55926-b719-41a4-9b04-bb96f94f3cfc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] HORIZANT is indicated for: treatment of moderate-to-severe primary Restless Legs Syndrome (RLS) in adults. ( 1.1 ) management of postherpetic neuralgia (PHN) in adults. ( 1.2 )|[PMDA] A drug with a new active ingredient indicated for the treatment of moderate to severe idiopathic restless legs syndrome. uuid:365cabc9-c32d-474a-83ac-362f4ef0934b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:306ERL82IR biolink:treats MONDO:0005459 PMID:41385096 "[{""id"":""uuid:07b34ae8-de80-48a3-a072-2ec7328283b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6430ae96-38ea-4a9e-9e64-e41b85104162"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fexinidazole Tablets are indicated for the treatment of both the first-stage (hemolymphatic) and second-stage (meningoencephalitic) human African trypanosomiasis (HAT) due to Trypanosoma brucei gambiense in patients 6 years of age and older and weighing at least 20 kg. uuid:a1c3eda3-49bc-4a0f-bf75-cb8f78908ecb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB16257 biolink:treats MONDO:0009688 PMID:41385096 "[{""id"":""uuid:ac0582a3-9c10-4b81-9239-831c35e77641"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a9960804-7a8e-48b4-aa27-31a949eab4cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] IMAAVY is indicated for the treatment of generalized myasthenia gravis (gMG) in adult and pediatric patients 12 years of age and older who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive. uuid:53cd93ba-2bd0-4832-b3f2-ddb8d2366416 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB00028 biolink:treats MONDO:0003778 PMID:41385096 "[{""id"":""uuid:626f45ee-01d1-4f49-b4fa-33e07bea4168"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ac8d08a2-9b22-4723-8524-4fbba07cdca9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BIVIGAM is an Immune Globulin Intravenous (Human), 10% Liquid, indicated for the treatment of adults and pediatric patients 2 years of age and older with primary humoral immunodeficiency (PI). [1] uuid:05527eb8-840a-4664-8db1-e59e1fd174f4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB00028 biolink:treats MONDO:0001902 PMID:41385096 "[{""id"":""uuid:2676ffe3-655e-4ca7-a7dd-90d8d2f543b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a0ef1764-64a6-48fd-aeb8-79ccfeeb6f0f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ASCENIV (immune globulin intravenous, human – slra) is a 10% immune globulin liquid for intravenous injection, indicated for the treatment of primary humoral immunodeficiency (PI) in adults and adolescents (12 to 17 years of age). PI includes, but is not limited to, the humoral immune defect in congenital agammaglobulinemia, common variable immunodeficiency (CVID), X-linked agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies (SCID). uuid:8279522a-38a6-480f-bac9-3c564b470d5e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB00028 biolink:treats MONDO:0015517 PMID:41385096 "[{""id"":""uuid:d2463f2f-2e67-4d6c-a415-f1c9470bc7ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b63e4f2c-9433-40ea-bca3-1e09836b8f28"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ASCENIV (immune globulin intravenous, human – slra) is a 10% immune globulin liquid for intravenous injection, indicated for the treatment of primary humoral immunodeficiency (PI) in adults and adolescents (12 to 17 years of age). PI includes, but is not limited to, the humoral immune defect in congenital agammaglobulinemia, common variable immunodeficiency (CVID), X-linked agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies (SCID). uuid:f16af03c-9378-474d-8a09-427183a74f15 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB00028 biolink:treats MONDO:0010421 PMID:41385096 "[{""id"":""uuid:d6d038b6-ecf1-4d51-bbf9-8cfb9fc98190"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9ef4f884-288f-4cdb-88ab-cb19b2ede3f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ASCENIV (immune globulin intravenous, human – slra) is a 10% immune globulin liquid for intravenous injection, indicated for the treatment of primary humoral immunodeficiency (PI) in adults and adolescents (12 to 17 years of age). PI includes, but is not limited to, the humoral immune defect in congenital agammaglobulinemia, common variable immunodeficiency (CVID), X-linked agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies (SCID). uuid:aa6e7af2-6616-4986-92e8-6bb8caca155e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB00028 biolink:treats MONDO:0015974 PMID:41385096 "[{""id"":""uuid:9a560319-7106-48c6-9bc2-bf9d30dba726"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bd571874-d46c-4050-862d-7b61d3875d25"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ASCENIV (immune globulin intravenous, human – slra) is a 10% immune globulin liquid for intravenous injection, indicated for the treatment of primary humoral immunodeficiency (PI) in adults and adolescents (12 to 17 years of age). PI includes, but is not limited to, the humoral immune defect in congenital agammaglobulinemia, common variable immunodeficiency (CVID), X-linked agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies (SCID). uuid:7844d9c9-4792-4ed3-8294-a2a6d52f88f5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85993 biolink:treats MONDO:0000618 PMID:41385096 "[{""id"":""uuid:030b69e0-5b25-4b81-968e-487e7ce8b2f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:895aafe0-97dd-42ab-8ef0-dc784d71fa13"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:a7ca7b9d-5045-46dc-99fb-65e19cffc427"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ibrance""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] IBRANCE is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with: • an aromatase inhibitor as initial endocrine-based therapy; or • fulvestrant in patients with disease progression following endocrine therapy. IBRANCE is indicated in combination with inavolisib and fulvestrant for the treatment of adult patients with endocrine-resistant, PIK3CA -mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant endocrine therapy.|[EMA] Ibrance is indicated for the treatment of hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer:in combination with an aromatase inhibitor;in combination with fulvestrant in women who have received prior endocrine therapy.In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone releasing hormone (LHRH) agonist. uuid:5427042b-b562-462c-8911-d1fa0eb333bf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:GN465U8B72 biolink:treats MONDO:0026045 PMID:41385096 "[{""id"":""uuid:32562200-0f50-4b1c-9c20-45fa3aa25e25"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:79ce18c0-e544-4b48-a7f4-9aedc2dbeb99"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:fed22db8-2480-448a-9ffd-9f4495f912aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NEMLUVIO is indicated for the treatment of adults with prurigo nodularis.|[PMDA] A drug with a new indication and a new dosage for the treatment of prurigo nodularis in patients who have not responded sufficiently to conventional treatments, and a new additional pediatric dosage in an additional dosage form, indicated for the treatment of pruritus associated with atopic dermatitis in patients who have not responded sufficiently to conventional treatments. uuid:5eae0f79-ce33-424b-9223-ec594baafaed biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:N658GY6L3E biolink:treats MONDO:0006486 PMID:41385096 "[{""id"":""uuid:d9afe375-fad6-4817-9e07-7f9a0d26084a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:faeda5dc-dc74-4d51-80f1-2ed69f006df6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:81f01b9a-cec8-4916-9053-3231205365bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/kimmtrak""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] KIMMTRAK is indicated for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.|[EMA] Kimmtrak is indicated as monotherapy for the treatment of human leukocyte antigen (HLA)-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma. uuid:72d036bc-2577-4d47-8f7c-e631e4ff8212 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:N658GY6L3E biolink:treats UMLS:C4725091 PMID:41385096 "[{""id"":""uuid:9635530c-fe82-43d7-9875-5650c126ddf3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d0c6f6fe-6f92-4fab-9387-73dcd4a4adb7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KIMMTRAK is indicated for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma. uuid:aea76522-66cf-4771-b2a5-9c476f35127e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:P7186074QC biolink:treats MONDO:0009688 PMID:41385096 "[{""id"":""uuid:ca7c2121-0f66-41e0-874f-d41350ccdb56"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:014cc62c-b54e-4077-8ebb-c85da4d9707a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:88859348-461e-4a84-afb0-e193f507f6a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RYSTIGGO is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.|[PMDA] A drug with a new active ingredient indicated for the treatment of generalized myasthenia gravis (for use only in patients who have not sufficiently responded to steroids or other immunosuppressants). [Orphan drug] uuid:4f2caf69-8f26-4f3c-a171-605d6b6e6d40 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:231425 biolink:treats MONDO:0004691 PMID:41385096 "[{""id"":""uuid:e48e37f5-526b-4707-9966-ead129a28ae2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:40f42f7a-f913-43d4-9be9-41723299ec20"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f2866353-bee2-4510-935b-3c67092729c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/jinarc""]},{""id"":""uuid:c5940f49-1d20-489d-9db4-c40e00a5e9ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] JYNARQUE is indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD).|[EMA] Jinarc is indicated to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (ADPKD) in adults with CKD stage 1 to 3 at initiation of treatment with evidence of rapidly progressing disease.|[PMDA] Drugs with a new additional indication and a new dosage, and a drug with a newly-added dosage form indicated for inhibiting the progression of autosomal dominant polycystic kidney disease in patients whose kidney volume already have increased and enlarged at a rapid rate. [Orphan drug] uuid:f30baaa6-5d31-4c0b-83bd-aba77a44e40e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85966 biolink:treats MONDO:0006993 PMID:41385096 "[{""id"":""uuid:5e8c8854-f574-4ab9-bf8a-4e0bd6efef3f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:21da337a-174e-4390-bcb3-3a2f93e3e950"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ivabradine tablets are a hyperpolarization-activated cyclic nucleotide-gated channel blocker indicated: To reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with reduced left ventricular ejection fraction. ( 1.1 ) uuid:9291f98b-5eb9-4c5f-9daf-1288c4f06722 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:OP35X9610Y biolink:treats MONDO:0008250 PMID:41385096 "[{""id"":""uuid:f726ad11-f000-4b54-8f67-268afe5a32da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:c3833684-8fea-43c0-8f35-e14931d55f36"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:9cf1956e-70af-4cba-b216-c5d28ac069ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/skytrofa-previously-lonapegsomatropin-ascendis-pharma""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] SKYTROFA (lonapegsomatropin-tcgd) is a human growth hormone indicated for the treatment of pediatric patients 1 year and older who weigh at least 11.5 kg and have growth failure due to inadequate secretion of endogenous growth hormone (GH).|[EMA] Growth failure in children and adolescents aged from 3 years up to 18 years due to insufficient endogenous growth hormone secretion (growth hormone deficiency [GHD]), uuid:d00de1fa-ed76-413f-9db9-873ab3ce4359 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:80343 biolink:treats MONDO:0000050 PMID:41385096 "[{""id"":""uuid:22d35f6a-cc92-4d0a-bdf7-7ff185e8e7fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6d0a6469-551a-46b8-8023-4ea97f4c2625"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Severe Primary IGF-1 Deficiency (Primary IGFD) INCRELEX is indicated for the treatment of growth failure in pediatric patients 2 years of age and older with: severe primary IGF-1 deficiency or growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH. Severe Primary IGF-1 deficiency (IGFD) is defined by: height standard deviation score ≤ –3.0 and basal IGF-1 standard deviation score ≤ –3.0 and normal or elevated growth hormone (GH). uuid:48aab964-bac0-4091-a9a6-4289fad303fa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:YI437801BE biolink:treats MONDO:0009691 PMID:41385096 "[{""id"":""uuid:5cf3c1e1-c6eb-4a79-909e-1817ea449020"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:68485d66-e95e-45fb-8989-ff99811f5089"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:04348345-6799-4ead-86da-fa1ef32219da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/poteligeo""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] POTELIGEO is indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy.|[EMA] Poteligeo is indicated for the treatment of adult patients with mycosis fungoides (MF) or Sézary syndrome (SS) who have received at least one prior systemic therapy. uuid:9326b1b8-e328-452d-8188-a90765722a90 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:YI437801BE biolink:treats MONDO:0017844 PMID:41385096 "[{""id"":""uuid:3b6fa313-8de7-4a65-90be-59b7573b02d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5707e089-5bd7-4f7e-a3f6-c4051778893f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] POTELIGEO is indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy. uuid:1b6376eb-f415-4d53-b767-04a81a242584 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:S4M959U2IJ biolink:treats MONDO:0005147 PMID:41385096 "[{""id"":""uuid:6b4f00f2-9924-4e40-bd61-9137e3a8055c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:98e312a6-a6e8-4e07-8bfc-6bcdc2fc2775"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TZIELD is indicated to delay the onset of Stage 3 type 1 diabetes in adults and pediatric patients 8 years of age and older with Stage 2 type 1 diabetes [see Dosage and Administration ( 2.1 )] . uuid:1a15af80-d5b0-4382-863d-626e2e2bac12 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:K16AIQ8CTM biolink:treats UMLS:C0278488 PMID:41385096 "[{""id"":""uuid:7075d59a-aea4-44c7-a6ff-2bf7bdc511e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ad92a4a8-4952-40c5-b112-be536cbd45b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PERJETA is a HER2/neu receptor antagonist indicated for: Use in combination with trastuzumab and docetaxel for treatment of adults with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. ( 1.1 ) Use in combination with trastuzumab and chemotherapy as neoadjuvant treatment of adults with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. ( 1.2 , 2.2 , 14.2 ) adjuvant treatment of adults with HER2-positive early breast cancer at high risk of recurrence ( 1.2 , 2.2 , 14.3 ) uuid:3da42e90-c17c-4cae-b7a1-d0b42d396668 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:K16AIQ8CTM biolink:treats MONDO:0006804 PMID:41385096 "[{""id"":""uuid:63fd38ca-13e5-4e0b-ba1d-a56e24a99028"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:912b608f-2996-45af-8e18-d2aecc4f2371"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ab9e9e95-9020-4279-b3e6-8beeb8e74d79"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/perjeta""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] PERJETA is a HER2/neu receptor antagonist indicated for: Use in combination with trastuzumab and docetaxel for treatment of adults with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. ( 1.1 ) Use in combination with trastuzumab and chemotherapy as neoadjuvant treatment of adults with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. ( 1.2 , 2.2 , 14.2 ) adjuvant treatment of adults with HER2-positive early breast cancer at high risk of recurrence ( 1.2 , 2.2 , 14.3 )|[EMA] Metastatic Breast Cancer:Perjeta is indicated for use in combination with trastuzumab and docetaxel in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease.Neoadjuvant Treatment of Breast Cancer:Perjeta is indicated for use in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence. uuid:6b8163c8-ea64-442e-88e8-c19d62412e51 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:K16AIQ8CTM biolink:treats UMLS:C2986665 PMID:41385096 "[{""id"":""uuid:3c5f8ca1-8fe7-4ee2-83dd-3871df18930d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8aca4543-94b7-4612-b866-f2213b5c1dab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PERJETA is a HER2/neu receptor antagonist indicated for: Use in combination with trastuzumab and docetaxel for treatment of adults with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. ( 1.1 ) Use in combination with trastuzumab and chemotherapy as neoadjuvant treatment of adults with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. ( 1.2 , 2.2 , 14.2 ) adjuvant treatment of adults with HER2-positive early breast cancer at high risk of recurrence ( 1.2 , 2.2 , 14.3 ) uuid:422244f8-4241-483d-9e83-4208afc426ba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:TO3JYR3BOU biolink:treats HP:0031609 PMID:41385096 "[{""id"":""uuid:879b693d-3f71-440b-a15d-a6475b9f456b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8545c4bd-1d59-46cd-8428-8f1122b47cd3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SYFOVRE is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). uuid:5c1c524b-a06b-4ecb-8b0c-7dd1b16a0e73 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:TO3JYR3BOU biolink:treats MONDO:0005150 PMID:41385096 "[{""id"":""uuid:b633d420-0fe0-4e2b-8035-6a231e6623c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:66f6965e-3587-440d-98c0-1cef69120af0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SYFOVRE is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). uuid:c3c87890-b2eb-477b-a266-487ba2292bda biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:72690 biolink:treats MONDO:0009693 PMID:41385096 "[{""id"":""uuid:85232825-8668-4aae-be26-df4299a9c2c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:083f7128-d575-4218-ae03-40cbadfededf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:44a7c0db-2014-4693-8abc-231c87226230"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/imnovid""]},{""id"":""uuid:7095493b-0230-47ac-8fcc-427605025ccf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] POMALYST is a thalidomide analogue indicated for the treatment of adult patients: • in combination with dexamethasone, for patients with multiple myeloma (MM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy ( 1.1 ). • with AIDS-related Kaposi sarcoma (KS) after failure of highly active antiretroviral therapy (HAART) or in patients with KS who are HIV-negative. This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s) ( 1.2 ).|[EMA] Imnovid in combination with bortezomib and dexamethasone is indicated in the treatment of adult patients with multiple myeloma who have received at least one prior treatment regimen including lenalidomide.Imnovid in combination with dexamethasone is indicated in the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.|[PMDA] Drugs with a new active ingredient indicated for the treatment of relapsed or refractory multiple myeloma. [Orphan drug] uuid:edd116b8-bae8-4e47-be54-0bf7a96c1a41 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:72690 biolink:treats MONDO:0005055 PMID:41385096 "[{""id"":""uuid:8f75159d-5b83-488c-a179-075ea020836f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8f6f3f2a-e71c-4efa-9e94-e49f4053896e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] POMALYST is a thalidomide analogue indicated for the treatment of adult patients: • in combination with dexamethasone, for patients with multiple myeloma (MM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy ( 1.1 ). • with AIDS-related Kaposi sarcoma (KS) after failure of highly active antiretroviral therapy (HAART) or in patients with KS who are HIV-negative. This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s) ( 1.2 ). uuid:629fb417-76fd-4296-925e-2ce40c855990 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:1RXS4UE564 biolink:treats HP:0002140 PMID:41385096 "[{""id"":""uuid:e22392e0-a63f-45ee-afa5-1910aa7b1b77"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:50c6e8fa-4e79-46b1-8cbc-aa078442c350"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Activase is a tissue plasminogen activator (tPA) indicated for the treatment of: Acute Ischemic Stroke (AIS). ( 1.1 ) Acute Myocardial Infarction (AMI) to reduce mortality and incidence of heart failure. ( 1.2 ) Limitation of Use in AMI: the risk of stroke may be greater than the benefit in patients at low risk of death from cardiac causes. ( 1.2 ) Acute Massive Pulmonary Embolism (PE) for lysis. ( 1.3 ) uuid:a7c62688-687a-4b79-b188-de63571a17f8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:1RXS4UE564 biolink:treats MONDO:0004781 PMID:41385096 "[{""id"":""uuid:f7b30e4c-9eef-4886-926a-b50c7743fcc2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:64c79c5d-b7c2-4b65-8287-6debb40c6626"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Activase is a tissue plasminogen activator (tPA) indicated for the treatment of: Acute Ischemic Stroke (AIS). ( 1.1 ) Acute Myocardial Infarction (AMI) to reduce mortality and incidence of heart failure. ( 1.2 ) Limitation of Use in AMI: the risk of stroke may be greater than the benefit in patients at low risk of death from cardiac causes. ( 1.2 ) Acute Massive Pulmonary Embolism (PE) for lysis. ( 1.3 ) uuid:801233e7-9e07-45e1-b4a9-e838c1ac6bef biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:1RXS4UE564 biolink:treats UMLS:C0340535 PMID:41385096 "[{""id"":""uuid:21475a64-cc9b-4fa0-bbf1-34754d5fb1f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6a002d54-1517-4c3b-9a75-ff699b7a79e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Activase is a tissue plasminogen activator (tPA) indicated for the treatment of: Acute Ischemic Stroke (AIS). ( 1.1 ) Acute Myocardial Infarction (AMI) to reduce mortality and incidence of heart failure. ( 1.2 ) Limitation of Use in AMI: the risk of stroke may be greater than the benefit in patients at low risk of death from cardiac causes. ( 1.2 ) Acute Massive Pulmonary Embolism (PE) for lysis. ( 1.3 ) uuid:e61f8de9-94d5-40f9-85cb-e3ef1b6f27e8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4FR53SIF3A biolink:treats MONDO:0004967 PMID:41385096 "[{""id"":""uuid:a3aa646a-eab0-4765-8313-149c0aa68f1c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:701df4a5-7be8-43e7-bff2-350944df8ade"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:b38f9eae-fca7-4552-bc0d-be1cca2eecb1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BLINCYTO is a bispecific CD19-directed CD3 T-cell engager indicated for the treatment of adult and pediatric patients one month and older with: CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%. ( 1.1 ) Relapsed or refractory CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL). ( 1.2 ) CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of multiphase chemotherapy. ( 1.3 )|[PMDA] A drug with a new active ingredient indicated for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia. [Orphan drug] uuid:2e2d0cf9-5318-4972-947c-e7865db34fe4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4FR53SIF3A biolink:treats MONDO:0020511 PMID:41385096 "[{""id"":""uuid:f7e5e1fb-e3f8-45d7-87b2-cf99b5f2509a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:60c2983e-fbb3-453c-b55f-9ca81260cf35"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:4beac034-f533-441d-9c45-6b5927bd5a97"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/blincyto""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] BLINCYTO is a bispecific CD19-directed CD3 T-cell engager indicated for the treatment of adult and pediatric patients one month and older with: CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%. ( 1.1 ) Relapsed or refractory CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL). ( 1.2 ) CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of multiphase chemotherapy. ( 1.3 )|[EMA] Blincyto is indicated as monotherapy for the treatment of adults with CD19 positive relapsed or refractory B precursor acute lymphoblastic leukaemia (ALL). Patients with Philadelphia chromosome positive B-precursor ALL should have failed treatment with at least 2 tyrosine kinase inhibitors (TKIs) and have no alternative treatment options., , Blincyto is indicated as monotherapy for the treatment of adults with Philadelphia chromosome negative CD19 positive B-precursor ALL in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%., , Blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with Philadelphia chromosome negative CD19 positive B precursor ALL which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation., , Blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed Philadelphia chromosome negative CD19 positive B-precursor ALL as part of the consolidation therapy (see section 4.2)., uuid:8aa99a6f-ffdd-4e4e-80b5-95b2ab026348 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:0KVO411B3N biolink:treats MONDO:0005580 PMID:41385096 "[{""id"":""uuid:8ebe4d0e-2926-46b5-bc00-7390096ba1f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:c47d62e5-5ab2-482a-83b7-95ee9cbc3e34"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:cf618f92-5f48-464a-9e86-681e74d5cfb6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/tevimbra""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] TEVIMBRA is a programmed death receptor-1 (PD-1)-blocking antibody indicated for: Esophageal Cancer in combination with platinum-containing chemotherapy for the first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1 (≥1). ( 1.1 ) as a single agent in adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) after prior systemic chemotherapy that did not include a PD-(L)1 inhibitor. ( 1.1 ) Gastric Cancer in combination with platinum and fluoropyrimidine-based chemotherapy in adults for the first line treatment of unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 (≥1). ( 1.2 )|[EMA] Oesophageal squamous cell carcinoma (OSCC) Tevimbra as monotherapy is indicated for the treatment of adult patients with unresectable, locally advanced or metastatic oesophageal squamous cell carcinoma after prior platinum-based chemotherapy. uuid:f55f2f57-5bb2-477c-818a-5d519c37fe08 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:0KVO411B3N biolink:treats MONDO:0001056 PMID:41385096 "[{""id"":""uuid:d8128365-2ae7-4fce-b48b-2d13fd883b99"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0b165c09-d854-4201-9d2e-a96ba3db4da8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TEVIMBRA is a programmed death receptor-1 (PD-1)-blocking antibody indicated for: Esophageal Cancer in combination with platinum-containing chemotherapy for the first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1 (≥1). ( 1.1 ) as a single agent in adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) after prior systemic chemotherapy that did not include a PD-(L)1 inhibitor. ( 1.1 ) Gastric Cancer in combination with platinum and fluoropyrimidine-based chemotherapy in adults for the first line treatment of unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 (≥1). ( 1.2 ) uuid:d29e3ea0-86e9-4eb3-8031-8fe07d769025 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:0KVO411B3N biolink:treats MONDO:0003219 PMID:41385096 "[{""id"":""uuid:81dd081a-5e44-40e3-89a1-3b86ca009864"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:284be1d5-bc84-4a70-b4a4-0e395c92ca27"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TEVIMBRA is a programmed death receptor-1 (PD-1)-blocking antibody indicated for: Esophageal Cancer in combination with platinum-containing chemotherapy for the first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1 (≥1). ( 1.1 ) as a single agent in adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) after prior systemic chemotherapy that did not include a PD-(L)1 inhibitor. ( 1.1 ) Gastric Cancer in combination with platinum and fluoropyrimidine-based chemotherapy in adults for the first line treatment of unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 (≥1). ( 1.2 ) uuid:3030a035-456a-4220-a7e7-d9872c684291 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB18728 biolink:treats MONDO:0018637 PMID:41385096 "[{""id"":""uuid:75f6d21a-6ca7-4939-98b4-4cdf34539bbc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d02a3183-a71a-40c9-a716-06c2e4301ccf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TRYNGOLZA is indicated as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS). uuid:d705ecd9-3424-4a39-87d4-42043faddfe7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:65173 biolink:treats MONDO:0001866 PMID:41385096 "[{""id"":""uuid:14802075-1b40-4b99-91bc-4bfe8242389c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6103149f-5f60-40fd-a1cc-1035c78f17d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FANAPT ® is indicated for: Treatment of schizophrenia in adults [see Clinical Studies (14.1) ]. Acute treatment of manic or mixed episodes associated with bipolar I disorder in adults [see Clinical Studies (14.2) ] . uuid:db117740-fc8f-4bdd-89bc-f8d266df16d9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85010 biolink:treats MONDO:0002048 PMID:41385096 "[{""id"":""uuid:441bf1a3-2b67-434a-a4d9-4685fbd921fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2f2b2e34-f8df-4e3c-82ca-35228ccd47b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Eltrombopag for oral suspension is a thrombopoietin receptor agonist indicated: • for the treatment of thrombocytopenia in adult and pediatric patients 1 year and older with persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. Eltrombopag for oral suspension should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increase the risk for bleeding. ( 1.1 ) • for the treatment of thrombocytopenia in patients with chronic hepatitis C to allow the initiation and maintenance of interferon-based therapy. Eltrombopag for oral suspension should be used only in patients with chronic hepatitis C whose degree of thrombocytopenia prevents the initiation of interferon-based therapy or limits the ability to maintain interferon-based therapy. ( 1.2 ) • for the treatment of patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy. ( 1.3 ) Limitations of Use: • Eltrombopag for oral suspension is not indicated for the treatment of patients with myelodysplastic syndrome (MDS). ( 1.4 ) • Safety and efficacy have not been established in combination with direct-acting antiviral agents used without interferon for treatment of chronic hepatitis C infection. ( 1.4 ) uuid:5c09915a-5bee-4fe4-bb9d-434d5ec5b018 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85010 biolink:treats MONDO:0005354 PMID:41385096 "[{""id"":""uuid:d1f7f8dd-166b-44c2-a852-3a3a9ee197d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:ada4401e-6d27-4b90-98f3-39f462241dd7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:5e6cbc29-9168-45ce-8b2d-0da26b648589"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/revolade""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Eltrombopag for oral suspension is a thrombopoietin receptor agonist indicated: • for the treatment of thrombocytopenia in adult and pediatric patients 1 year and older with persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. Eltrombopag for oral suspension should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increase the risk for bleeding. ( 1.1 ) • for the treatment of thrombocytopenia in patients with chronic hepatitis C to allow the initiation and maintenance of interferon-based therapy. Eltrombopag for oral suspension should be used only in patients with chronic hepatitis C whose degree of thrombocytopenia prevents the initiation of interferon-based therapy or limits the ability to maintain interferon-based therapy. ( 1.2 ) • for the treatment of patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy. ( 1.3 ) Limitations of Use: • Eltrombopag for oral suspension is not indicated for the treatment of patients with myelodysplastic syndrome (MDS). ( 1.4 ) • Safety and efficacy have not been established in combination with direct-acting antiviral agents used without interferon for treatment of chronic hepatitis C infection. ( 1.4 )|[EMA] Revolade is indicated for the treatment of adult patients with primary immune thrombocytopenia (ITP) who are refractory to other treatments (e.g. corticosteroids, immunoglobulins) (see sections 4.2 and 5.1).Revolade is indicated for the treatment of paediatric patients aged 1 year and above with primary immune thrombocytopenia (ITP) lasting 6 months or longer from diagnosis and who are refractory to other treatments (e.g. corticosteroids, immunoglobulins) (see sections 4.2 and 5.1).Revolade is indicated in adult patients with chronic hepatitis C virus (HCV) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy (see sections 4.4 and 5.1).Revolade is indicated in adult patients with acquired severe aplastic anaemia (SAA) who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for haematopoietic stem cell transplantation (see section 5.1). uuid:9d91d269-6ad1-482b-8a14-300167797d69 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85010 biolink:treats UMLS:C1883018 PMID:41385096 "[{""id"":""uuid:32df92ab-dd99-4c27-9ab7-55c3e6d9beb5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f798270e-2110-4f44-b630-49b9eac08978"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Eltrombopag for oral suspension is a thrombopoietin receptor agonist indicated: • for the treatment of thrombocytopenia in adult and pediatric patients 1 year and older with persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. Eltrombopag for oral suspension should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increase the risk for bleeding. ( 1.1 ) • for the treatment of thrombocytopenia in patients with chronic hepatitis C to allow the initiation and maintenance of interferon-based therapy. Eltrombopag for oral suspension should be used only in patients with chronic hepatitis C whose degree of thrombocytopenia prevents the initiation of interferon-based therapy or limits the ability to maintain interferon-based therapy. ( 1.2 ) • for the treatment of patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy. ( 1.3 ) Limitations of Use: • Eltrombopag for oral suspension is not indicated for the treatment of patients with myelodysplastic syndrome (MDS). ( 1.4 ) • Safety and efficacy have not been established in combination with direct-acting antiviral agents used without interferon for treatment of chronic hepatitis C infection. ( 1.4 ) uuid:1818f662-6f9b-4caf-8e61-683b5095906f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85010 biolink:treats MONDO:0002049 PMID:41385096 "[{""id"":""uuid:6e85bc35-fc55-41bd-aadb-88b0d6e0ca68"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cde7b3d5-81ab-4cdd-a02d-398bf45ef980"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Eltrombopag for oral suspension is a thrombopoietin receptor agonist indicated: • for the treatment of thrombocytopenia in adult and pediatric patients 1 year and older with persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. Eltrombopag for oral suspension should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increase the risk for bleeding. ( 1.1 ) • for the treatment of thrombocytopenia in patients with chronic hepatitis C to allow the initiation and maintenance of interferon-based therapy. Eltrombopag for oral suspension should be used only in patients with chronic hepatitis C whose degree of thrombocytopenia prevents the initiation of interferon-based therapy or limits the ability to maintain interferon-based therapy. ( 1.2 ) • for the treatment of patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy. ( 1.3 ) Limitations of Use: • Eltrombopag for oral suspension is not indicated for the treatment of patients with myelodysplastic syndrome (MDS). ( 1.4 ) • Safety and efficacy have not been established in combination with direct-acting antiviral agents used without interferon for treatment of chronic hepatitis C infection. ( 1.4 ) uuid:a6b476e7-6a4f-48c9-8b93-5cd7db15de5e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60799 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:a49e3871-ab9b-46f5-a7bc-36e7d58f9f9c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d7caf953-88d7-4d2e-bd3e-f7e6c78beba9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:2f0f4455-154a-4f01-8cdc-4aa379ef08dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SPRAVATO is indicated for the treatment of: Treatment-resistant depression (TRD) in adults as monotherapy or in conjunction with an oral antidepressant Depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior in conjunction with an oral antidepressant|[EMA] Spravato, in combination with a SSRI or SNRI, is indicated for adults with treatment-resistant Major Depressive Disorder, who have not responded to at least two different treatments with antidepressants in the current moderate to severe depressive episode. uuid:86a1f0be-9b69-4ff4-81fa-11f9c22b3c93 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8310 biolink:treats MONDO:0040732 PMID:41385096 "[{""id"":""uuid:9bded51c-621d-4b83-a395-c16eaa5b019f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:971b399f-3de8-4939-b6f7-69f243fe865a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Acute Infections Caused by Susceptible Strains of Pseudomonas aeruginosa . Polymyxin B sulfate is a drug of choice in the treatment of infections of the urinary tract, meninges, and bloodstream caused by susceptible strains of Ps. aeruginosa. It may also be used topically and subconjunctivally in the treatment of infections of the eye caused by susceptible strains of Ps. aeruginosa . It may be indicated in serious infections caused by susceptible strains of the following organisms, when less potentially toxic drugs are ineffective or contraindicated: H. influenzae , specifically meningeal infections. Escherichia coli , specifically urinary tract infections. Aerobacter aerogenes , specifically bacteremia. Klebsiella pneumoniae , specifically bacteremia. NOTE: IN MENINGEAL INFECTIONS, POLYMYXIN B SULFATE SHOULD BE ADMINISTERED ONLY BY THE INTRATHECAL ROUTE. To reduce the development of drug-resistant bacteria and maintain the effectiveness of polymyxin B and other antibacterial drugs, polymyxin B should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:9fda31bf-189b-42d2-bcae-fdcd6808694b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8310 biolink:treats MONDO:0000889 PMID:41385096 "[{""id"":""uuid:90a9436e-875a-4343-b9b5-fe062b8033bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:190c24ac-8972-4814-8490-972978704a43"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Acute Infections Caused by Susceptible Strains of Pseudomonas aeruginosa . Polymyxin B sulfate is a drug of choice in the treatment of infections of the urinary tract, meninges, and bloodstream caused by susceptible strains of Ps. aeruginosa. It may also be used topically and subconjunctivally in the treatment of infections of the eye caused by susceptible strains of Ps. aeruginosa . It may be indicated in serious infections caused by susceptible strains of the following organisms, when less potentially toxic drugs are ineffective or contraindicated: H. influenzae , specifically meningeal infections. Escherichia coli , specifically urinary tract infections. Aerobacter aerogenes , specifically bacteremia. Klebsiella pneumoniae , specifically bacteremia. NOTE: IN MENINGEAL INFECTIONS, POLYMYXIN B SULFATE SHOULD BE ADMINISTERED ONLY BY THE INTRATHECAL ROUTE. To reduce the development of drug-resistant bacteria and maintain the effectiveness of polymyxin B and other antibacterial drugs, polymyxin B should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:69204248-c73c-48db-a71a-8d88c06760b8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85010 biolink:treats MONDO:0019098 PMID:41385096 "[{""id"":""uuid:0683c53a-3867-49e4-96a4-cc0fd0517283"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:69712469-d904-4412-82a3-fa84a7996825"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:a27f4537-0b49-4f84-b9a2-5e8b502c1186"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Eltrombopag tablet is a thrombopoietin receptor agonist indicated: • for the treatment of thrombocytopenia in adult and pediatric patients 1 year and older with persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. Eltrombopag tablets should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increase the risk for bleeding. (1.1) • for the treatment of thrombocytopenia in patients with chronic hepatitis C to allow the initiation and maintenance of interferon-based therapy. Eltrombopag tablets should be used only in patients with chronic hepatitis C whose degree of thrombocytopenia prevents the initiation of interferon-based therapy or limits the ability to maintain interferon-based therapy. (1.2) • for the treatment of patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy. (1.3) Limitations of Use: • Eltrombopag tablets are not indicated for the treatment of patients with myelodysplastic syndrome (MDS). (1.4) • Safety and efficacy have not been established in combination with direct-acting antiviral agents used without interferon for treatment of chronic hepatitis C infection. (1.4)|[PMDA] Drugs with a new active ingredient indicated for the treatment of chronic idiopathic thrombocytopenic purpura. [Orphan drug] uuid:666f6b39-ec1e-4fb0-9c3a-8d3c90fd363f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22652 biolink:treats MONDO:0001357 PMID:41385096 "[{""id"":""uuid:e6c9dbe2-c07f-43ac-a1ab-46debfcdbc17"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:194a2484-2955-4e97-99c3-ab7c7c0f8044"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATION AND USAGE: IROSPAN 24/6 is indicated for the treatment of all anemias that are responsive to oral iron therapy. These include: hypochromic anemia associated with pregnancy, chronic and/or acute blood loss, metabolic disease, post-surgical convalescence, and dietary needs. uuid:1c2b59be-e13a-44ec-a4b2-f04ebc92ba86 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:08GY9K1EUO biolink:treats MONDO:0005059 PMID:41385096 "[{""id"":""uuid:dc5e7ee2-7d15-4043-ac23-d99b3c4ed29b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9ce18126-d79c-4617-bc17-035a4261f627"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Elitek is indicated for the initial management of plasma uric acid levels in pediatric and adult patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anticancer therapy expected to result in tumor lysis and subsequent elevation of plasma uric acid. uuid:7f96f3df-c063-425c-aa47-6ba30213717e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:08GY9K1EUO biolink:treats MONDO:0005062 PMID:41385096 "[{""id"":""uuid:96ba62ab-79a1-42ae-a4a6-4fa4347f1015"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5343f116-09ee-4e88-b534-9efab17c9c2c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Elitek is indicated for the initial management of plasma uric acid levels in pediatric and adult patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anticancer therapy expected to result in tumor lysis and subsequent elevation of plasma uric acid. uuid:75a29c12-4bf0-413b-8da6-1ed6eb173955 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:08GY9K1EUO biolink:treats MONDO:0004992 PMID:41385096 "[{""id"":""uuid:a0afc5ea-271f-4aa6-9542-426e37d94a7d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f96eb0eb-599b-4e49-bbbc-7a3d47256255"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Elitek is indicated for the initial management of plasma uric acid levels in pediatric and adult patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anticancer therapy expected to result in tumor lysis and subsequent elevation of plasma uric acid. uuid:86893723-d57e-49f9-b525-be19a1434d09 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68478 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:e1e87035-61e5-42a1-acbb-3281eda23f46"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d0d14fd8-1460-4eb1-bc38-4568e05482cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:899b293d-5984-48a9-90e2-4f485d49fd86"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/votubia""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] AFINITOR is a kinase inhibitor indicated for the treatment of: Postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole. ( 1.1 ) Adults with progressive neuroendocrine tumors of pancreatic origin (PNET) and adults with progressive, well-differentiated, non-functional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin that are unresectable, locally advanced or metastatic. Limitations of Use: AFINITOR is not indicated for the treatment of patients with functional carcinoid tumors. ( 1.2 ) Adults with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib. ( 1.3 ) Adults with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery. ( 1.4 ) AFINITOR and AFINITOR DISPERZ are kinase inhibitors indicated for the treatment of adult and pediatric patients aged 1 year and older with TSC who have subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected. ( 1.5 ) AFINITOR DISPERZ is a kinase inhibitor indicated for the adjunctive treatment of adult and pediatric patients aged 2 years and older with TSC-associated partial-onset seizures. ( 1.6 )|[EMA] Hormone-receptor-positive advanced breast cancerAfinitor is indicated for the treatment of hormone-receptor-positive, HER2/neu-negative advanced breast cancer, in combination with exemestane, in post-menopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor.Neuroendocrine tumours of pancreatic originAfinitor is indicated for the treatment of unresectable or metastatic, well or moderately differentiated neuroendocrine tumours of pancreatic origin in adults with progressive disease.Neuroendocrine tumours of gastrointestinal or lung originAfinitor is indicated for the treatment of unresectable or metastatic, well-differentiated (Grade 1 or Grade 2) non-functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease.Renal-cell carcinomaAfinitor is indicated for the treatment of patients with advanced renal-cell carcinoma, whose disease has progressed on or after treatment with VEGF-targeted therapy. uuid:78a533ff-67fe-4be0-824c-816ec7e85733 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2CN60TN6ZS biolink:treats MONDO:0008433 PMID:41385096 "[{""id"":""uuid:471d91b0-f488-43f1-935b-54743442200e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:af6910c3-e376-4e07-8380-ef71a4dc9497"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZEPZELCA is indicated for the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy. This indication is approved under accelerated approval based on overall response rate and duration of response [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). uuid:3ae9c2fb-aaf2-413d-a4bb-57f570439806 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2CN60TN6ZS biolink:treats UMLS:C5706270 PMID:41385096 "[{""id"":""uuid:1024254b-e480-4aa0-8011-4e4557ce9b81"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:58c1078b-da5d-43ab-8b17-f163eddeb8e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZEPZELCA is indicated for the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy. This indication is approved under accelerated approval based on overall response rate and duration of response [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). uuid:cd2eac9f-972f-489c-94e5-50ca3fffe7d2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:YB18NF020M biolink:treats MONDO:0035663 PMID:41385096 "[{""id"":""uuid:c3847d6b-0f7b-4f64-a6b0-7db155314770"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:43612aeb-2308-4931-a73f-848d6bba600b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:675ff606-fee0-4d51-80bc-b0d47ce35432"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/enspryng""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] ENSPRYNG is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.|[EMA] Satralizumab (Enspryng) is indicated as a monotherapy or in combination with immunosuppressive therapy (IST) for the treatment of neuromyelitis optica spectrum disorders (NMOSD) in adult and adolescent patients from 12 years of age who are anti-aquaporin-4 IgG (AQP4-IgG) seropositive. uuid:2f6c785d-2508-4dc2-a370-3c286c2c5fd1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:YB18NF020M biolink:treats MONDO:0019100 PMID:41385096 "[{""id"":""uuid:c510bb06-e001-47b2-82ee-cbfaa98c5db6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e3d48f70-887e-46dd-8454-c5eba4919190"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:d3be18de-79dd-41b8-9aeb-b8f3a126da44"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ENSPRYNG is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.|[PMDA] A drug with a new active ingredient indicated for the prevention of relapse of neuromyelitis optica spectrum disorder (including neuromyelitis optica). [Orphan drug] uuid:713903cb-5c3a-460c-9d0d-4074f297453d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:VY9C88C2NV biolink:treats MONDO:0018018 PMID:41385096 "[{""id"":""uuid:9dd8db19-0cd4-4ddb-ac24-a6d9f3ede2d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dedd724a-76aa-406e-91b0-8b6a1ef4543f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ATTRUBY is indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization. uuid:2df842f2-f39d-489b-b254-956d8591f805 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:VY9C88C2NV biolink:treats MONDO:0019441 PMID:41385096 "[{""id"":""uuid:646f33f6-b9a7-4fc2-9206-1440969874c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3cb04e53-5d12-4df6-8c8a-9c125c1d949b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ATTRUBY is indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization. uuid:2e0b203e-8607-463a-82a7-6e9bbb6109e0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:167672 biolink:treats MONDO:0859591 PMID:41385096 "[{""id"":""uuid:a48a187c-f944-4128-9af3-528224794c10"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:51546a80-ee1c-4632-8009-536dbb701a89"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OJEMDA is indicated for the treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. This indication is approved under accelerated approval based on response rate and duration of response [see Clinical Studies (14) ]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). uuid:f1c11648-6e58-4af2-ac5b-ac9b50a29a5b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:68603V9EAF biolink:treats MONDO:0010602 PMID:41385096 "[{""id"":""uuid:5b297efb-cfce-4ec2-b7ea-6b112b04308d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:406f0434-3503-4da7-b8c3-a99c84a7d548"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Alhemo is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with: • hemophilia A (congenital factor VIII deficiency) with FVIII inhibitors • hemophilia B (congenital factor IX deficiency) with FIX inhibitors uuid:8b12401c-e4bf-4a85-a4d5-207846d1deca biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:68603V9EAF biolink:treats MONDO:0010604 PMID:41385096 "[{""id"":""uuid:a202cde8-3b9a-46d2-8a2e-616a1e5542df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2de8a94f-ae40-452b-afe7-03b6fd5b5388"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Alhemo is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with: • hemophilia A (congenital factor VIII deficiency) with FVIII inhibitors • hemophilia B (congenital factor IX deficiency) with FIX inhibitors uuid:d2412182-d0ea-419e-975e-4ba389f6335a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:0T4IMT8S5Z biolink:treats MONDO:0018874 PMID:41385096 "[{""id"":""uuid:04ae0cfd-cd42-44f6-b1c3-e32484d32ac6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:03e8d60d-56c6-4300-b014-4beac42bf06c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Relapsed or Refractory Acute Myeloid Leukemia REZLIDHIA is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test [see Dosage and Administration ( 2.1 ), Clinical Pharmacology ( 12.1 ), and Clinical Studies ( 14.1 )] . uuid:d8d50a56-7823-4843-b33f-557f8fbf6a83 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:0T4IMT8S5Z biolink:treats UMLS:C4528668 PMID:41385096 "[{""id"":""uuid:12b729f6-1532-4486-aa10-223ced81a970"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5fc593de-4762-47a1-853c-12cf828abff8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Relapsed or Refractory Acute Myeloid Leukemia REZLIDHIA is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test [see Dosage and Administration ( 2.1 ), Clinical Pharmacology ( 12.1 ), and Clinical Studies ( 14.1 )] . uuid:40193a1d-8e28-4a4c-9f62-6d274a7f2ef4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats MONDO:0005114 PMID:41385096 "[{""id"":""uuid:0774a9dc-3069-4667-861f-716cacbf795a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2d392cd6-f954-40e2-9b1e-f36f194211b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli , Klebsiella , etc. Other infections caused by susceptible gram-negative organisms such as E. coli , Enterobacter aerogenes , Shigella sp. , Acinetobacter sp. , Klebsiella sp. , and Bacteroides sp . In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: Syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent’s infection caused by Fusobacterium fusiforme , Infections caused by Neisseria gonorrhoeae , Anthrax caused by Bacillus anthracis , Infections due to Listeria monocytogenes , Actinomycosis caused by Actinomyces species, Infections due to Clostridium species. uuid:7b6a9f49-47d8-428f-8d8d-6d99481cee26 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats MONDO:0006926 PMID:41385096 "[{""id"":""uuid:edcd0046-b095-4da7-ba2f-dee84567a5c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7a16a3f1-e999-414f-9b4e-bc8358a69192"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli , Klebsiella , etc. Other infections caused by susceptible gram-negative organisms such as E. coli , Enterobacter aerogenes , Shigella sp. , Acinetobacter sp. , Klebsiella sp. , and Bacteroides sp . In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: Syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent’s infection caused by Fusobacterium fusiforme , Infections caused by Neisseria gonorrhoeae , Anthrax caused by Bacillus anthracis , Infections due to Listeria monocytogenes , Actinomycosis caused by Actinomyces species, Infections due to Clostridium species. uuid:7ac56ded-aa39-4369-8ea0-9d69fb5cb505 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats UMLS:C3824874 PMID:41385096 "[{""id"":""uuid:d0dfc0b5-053a-4203-a32b-c46d59fb866c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b2d9ef2a-081d-40aa-9283-2ca4fe77d7f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli , Klebsiella , etc. Other infections caused by susceptible gram-negative organisms such as E. coli , Enterobacter aerogenes , Shigella sp. , Acinetobacter sp. , Klebsiella sp. , and Bacteroides sp . In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: Syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent’s infection caused by Fusobacterium fusiforme , Infections caused by Neisseria gonorrhoeae , Anthrax caused by Bacillus anthracis , Infections due to Listeria monocytogenes , Actinomycosis caused by Actinomyces species, Infections due to Clostridium species. uuid:31da8087-9c3d-4024-803f-6ec16b9ec1bc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats MONDO:0030603 PMID:41385096 "[{""id"":""uuid:ab9f2dcd-d938-4106-9429-4a4901b31f1a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c8e1b489-d21a-4c08-93e8-b23c73029863"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli , Klebsiella , etc. Other infections caused by susceptible gram-negative organisms such as E. coli , Enterobacter aerogenes , Shigella sp. , Acinetobacter sp. , Klebsiella sp. , and Bacteroides sp . In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: Syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent’s infection caused by Fusobacterium fusiforme , Infections caused by Neisseria gonorrhoeae , Anthrax caused by Bacillus anthracis , Infections due to Listeria monocytogenes , Actinomycosis caused by Actinomyces species, Infections due to Clostridium species. uuid:8d3c54e0-fb3e-43e5-90dc-a0b9060aee26 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats MONDO:0005545 PMID:41385096 "[{""id"":""uuid:e55bb997-7516-4b02-b6a2-c93b39f6694f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:447fc351-2ce1-459b-a658-b3ba2e435951"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli , Klebsiella , etc. Other infections caused by susceptible gram-negative organisms such as E. coli , Enterobacter aerogenes , Shigella sp. , Acinetobacter sp. , Klebsiella sp. , and Bacteroides sp . In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: Syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent’s infection caused by Fusobacterium fusiforme , Infections caused by Neisseria gonorrhoeae , Anthrax caused by Bacillus anthracis , Infections due to Listeria monocytogenes , Actinomycosis caused by Actinomyces species, Infections due to Clostridium species. uuid:aa85c7b4-357b-4a12-8673-ce6214a689cf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats MONDO:0006956 PMID:41385096 "[{""id"":""uuid:cc30a9d2-fa43-4810-828d-b22d696090e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e2a79c96-2b1f-4875-9b5d-62e60168c2c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli , Klebsiella , etc. Other infections caused by susceptible gram-negative organisms such as E. coli , Enterobacter aerogenes , Shigella sp. , Acinetobacter sp. , Klebsiella sp. , and Bacteroides sp . In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: Syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent’s infection caused by Fusobacterium fusiforme , Infections caused by Neisseria gonorrhoeae , Anthrax caused by Bacillus anthracis , Infections due to Listeria monocytogenes , Actinomycosis caused by Actinomyces species, Infections due to Clostridium species. uuid:bf02266b-bdfc-4f5a-a39d-8b227fefcaff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats MONDO:0021697 PMID:41385096 "[{""id"":""uuid:306d6c4a-95dd-4ddf-b246-97031635a29c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6172fb04-000b-44c6-a7f0-17f91034893e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli , Klebsiella , etc. Other infections caused by susceptible gram-negative organisms such as E. coli , Enterobacter aerogenes , Shigella sp. , Acinetobacter sp. , Klebsiella sp. , and Bacteroides sp . In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: Syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent’s infection caused by Fusobacterium fusiforme , Infections caused by Neisseria gonorrhoeae , Anthrax caused by Bacillus anthracis , Infections due to Listeria monocytogenes , Actinomycosis caused by Actinomyces species, Infections due to Clostridium species. uuid:9564f1ae-6d8d-4a23-b786-78adfe9e65f6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats MONDO:0006681 PMID:41385096 "[{""id"":""uuid:684496ee-782c-430e-b578-46283a22358e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:63a0c0c8-1b43-4d5a-b5be-403197ffe072"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli , Klebsiella , etc. Other infections caused by susceptible gram-negative organisms such as E. coli , Enterobacter aerogenes , Shigella sp. , Acinetobacter sp. , Klebsiella sp. , and Bacteroides sp . In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: Syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent’s infection caused by Fusobacterium fusiforme , Infections caused by Neisseria gonorrhoeae , Anthrax caused by Bacillus anthracis , Infections due to Listeria monocytogenes , Actinomycosis caused by Actinomyces species, Infections due to Clostridium species. uuid:32727e99-e6ec-4ab0-980e-2b2f67874eb2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats MONDO:0018984 PMID:41385096 "[{""id"":""uuid:bb97bfcc-c0c1-4ffa-8b5a-09a809502a58"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8a4d042b-b846-4168-a6e2-185b0ecbdc21"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli , Klebsiella , etc. Other infections caused by susceptible gram-negative organisms such as E. coli , Enterobacter aerogenes , Shigella sp. , Acinetobacter sp. , Klebsiella sp. , and Bacteroides sp . In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: Syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent’s infection caused by Fusobacterium fusiforme , Infections caused by Neisseria gonorrhoeae , Anthrax caused by Bacillus anthracis , Infections due to Listeria monocytogenes , Actinomycosis caused by Actinomyces species, Infections due to Clostridium species. uuid:051e89f4-2590-462a-a064-a9c55c37aa5c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats MONDO:0019095 PMID:41385096 "[{""id"":""uuid:ef1b4836-59f7-466c-a67d-88c948145930"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f002f57b-d1b3-4351-89c7-d57d499ce1bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli , Klebsiella , etc. Other infections caused by susceptible gram-negative organisms such as E. coli , Enterobacter aerogenes , Shigella sp. , Acinetobacter sp. , Klebsiella sp. , and Bacteroides sp . In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: Syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent’s infection caused by Fusobacterium fusiforme , Infections caused by Neisseria gonorrhoeae , Anthrax caused by Bacillus anthracis , Infections due to Listeria monocytogenes , Actinomycosis caused by Actinomyces species, Infections due to Clostridium species. uuid:faafb050-5886-45b4-881e-e8f22e007c7c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats MONDO:0020920 PMID:41385096 "[{""id"":""uuid:c1f60614-8ed2-401e-a15e-67b37f075f04"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:032d73ac-5841-4f48-9df1-25e6a0d1c073"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli , Klebsiella , etc. Other infections caused by susceptible gram-negative organisms such as E. coli , Enterobacter aerogenes , Shigella sp. , Acinetobacter sp. , Klebsiella sp. , and Bacteroides sp . In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: Syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent’s infection caused by Fusobacterium fusiforme , Infections caused by Neisseria gonorrhoeae , Anthrax caused by Bacillus anthracis , Infections due to Listeria monocytogenes , Actinomycosis caused by Actinomyces species, Infections due to Clostridium species. uuid:a83edc7c-a33b-404d-a416-a3b8e72b06b1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats MONDO:0019345 PMID:41385096 "[{""id"":""uuid:3b063f1f-c345-4520-a24d-551855000df5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:699f738a-ab02-4daa-af58-f7622d42b245"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli , Klebsiella , etc. Other infections caused by susceptible gram-negative organisms such as E. coli , Enterobacter aerogenes , Shigella sp. , Acinetobacter sp. , Klebsiella sp. , and Bacteroides sp . In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: Syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent’s infection caused by Fusobacterium fusiforme , Infections caused by Neisseria gonorrhoeae , Anthrax caused by Bacillus anthracis , Infections due to Listeria monocytogenes , Actinomycosis caused by Actinomyces species, Infections due to Clostridium species. uuid:173f9fdb-2723-459a-acb2-062f9768bed9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats MONDO:0006635 PMID:41385096 "[{""id"":""uuid:aad41663-3899-4375-bb28-24f24c95613b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0902ff0b-42b7-4946-9f1b-1f601c332c60"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli , Klebsiella , etc. Other infections caused by susceptible gram-negative organisms such as E. coli , Enterobacter aerogenes , Shigella sp. , Acinetobacter sp. , Klebsiella sp. , and Bacteroides sp . In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: Syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent’s infection caused by Fusobacterium fusiforme , Infections caused by Neisseria gonorrhoeae , Anthrax caused by Bacillus anthracis , Infections due to Listeria monocytogenes , Actinomycosis caused by Actinomyces species, Infections due to Clostridium species. uuid:170dab2b-9f43-4f82-9ab0-fb5ec6ec1252 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats MONDO:0006671 PMID:41385096 "[{""id"":""uuid:79e3329c-d171-4bce-85df-24f1733433e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:28f0ac0e-8c2a-46fe-9b28-ced4c653b8d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli , Klebsiella , etc. Other infections caused by susceptible gram-negative organisms such as E. coli , Enterobacter aerogenes , Shigella sp. , Acinetobacter sp. , Klebsiella sp. , and Bacteroides sp . In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: Syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent’s infection caused by Fusobacterium fusiforme , Infections caused by Neisseria gonorrhoeae , Anthrax caused by Bacillus anthracis , Infections due to Listeria monocytogenes , Actinomycosis caused by Actinomyces species, Infections due to Clostridium species. uuid:bd077706-b0bc-4c16-bb21-e9c6e68d2cb0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats MONDO:0015306 PMID:41385096 "[{""id"":""uuid:a520778d-a82b-4675-ac59-3fd63a814f15"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:23a5d925-50cc-4e9e-be00-69719012f79c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli , Klebsiella , etc. Other infections caused by susceptible gram-negative organisms such as E. coli , Enterobacter aerogenes , Shigella sp. , Acinetobacter sp. , Klebsiella sp. , and Bacteroides sp . In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: Syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent’s infection caused by Fusobacterium fusiforme , Infections caused by Neisseria gonorrhoeae , Anthrax caused by Bacillus anthracis , Infections due to Listeria monocytogenes , Actinomycosis caused by Actinomyces species, Infections due to Clostridium species. uuid:7193e7e5-01f6-4445-adfa-e424e226f29c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats MONDO:0001719 PMID:41385096 "[{""id"":""uuid:981d87af-e4a4-4698-bf7e-1098a586b84d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a1172cd2-3309-4142-8f07-15222a59bc7f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli , Klebsiella , etc. Other infections caused by susceptible gram-negative organisms such as E. coli , Enterobacter aerogenes , Shigella sp. , Acinetobacter sp. , Klebsiella sp. , and Bacteroides sp . In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: Syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent’s infection caused by Fusobacterium fusiforme , Infections caused by Neisseria gonorrhoeae , Anthrax caused by Bacillus anthracis , Infections due to Listeria monocytogenes , Actinomycosis caused by Actinomyces species, Infections due to Clostridium species. uuid:9bdf2d7c-fbad-49cc-a788-5f6993581674 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:976X9VXC3Z biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:b4cc341f-c621-4659-a36f-7bc510112274"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6722708f-9c82-44c4-a505-aeced217e2bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EMRELIS is indicated for the treatment of adult patients with locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression [≥50% of tumor cells with strong (3+) staining], as determined by an FDA-approved test [see Dosage and Administration ( 2.1 )] , who have received a prior systemic therapy . This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DOR) [see Clinical Studies ( 14 )] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). uuid:3bac2bc2-5875-4d27-9e33-3374b197f393 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:089658A12D biolink:treats UMLS:C0406317 PMID:41385096 "[{""id"":""uuid:04a7d34d-f6cc-44ed-9c0c-9262f1c39de1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6c098190-4798-496b-98bc-3a546347ca83"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:3f2f5b38-7af0-4036-b5cb-2fb419cc3532"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TREMFYA is an interleukin-23 antagonist indicated for the treatment of adult patients with: moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy ( 1.1 ) active psoriatic arthritis ( 1.2 ) moderately to severely active ulcerative colitis ( 1.3 ) moderately to severely active Crohn’s disease ( 1.4 )|[PMDA] A drug with a new active ingredient indicated for the treatment of plaque psoriasis, psoriatic arthritis, pustular psoriasis, and erythrodermic psoriasis in patients who have not responded sufficiently to conventional therapies. uuid:a097c0c2-b00b-4b0e-8a4d-db018b28ba1b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:089658A12D biolink:treats MONDO:0011849 PMID:41385096 "[{""id"":""uuid:56251058-ad60-4249-b573-e4fb4967645a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:403269df-8919-414a-a32b-88b3dd0dad2e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:56efafdf-1103-4d5a-bb19-5109c691b33f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/tremfya""]},{""id"":""uuid:60653c4f-2db0-4052-9c55-904a1c891523"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TREMFYA is an interleukin-23 antagonist indicated for the treatment of adult patients with: moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy ( 1.1 ) active psoriatic arthritis ( 1.2 ) moderately to severely active ulcerative colitis ( 1.3 ) moderately to severely active Crohn’s disease ( 1.4 )|[EMA] Plaque psoriasis, , Tremfya is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy., , Psoriatic arthritis, , Tremfya, alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (DMARD) therapy (see section 5.1).,|[PMDA] A drug with a new active ingredient indicated for the treatment of plaque psoriasis, psoriatic arthritis, pustular psoriasis, and erythrodermic psoriasis in patients who have not responded sufficiently to conventional therapies. uuid:050abfaf-be63-439c-bdcc-8e237ea6ff29 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:089658A12D biolink:treats MONDO:0005101 PMID:41385096 "[{""id"":""uuid:3562c02e-a45c-4cd5-aebf-2e8b0e07df7f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:785d9840-3876-402a-9ef7-c0e8baed5942"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TREMFYA is an interleukin-23 antagonist indicated for the treatment of adult patients with: moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy ( 1.1 ) active psoriatic arthritis ( 1.2 ) moderately to severely active ulcerative colitis ( 1.3 ) moderately to severely active Crohn’s disease ( 1.4 ) uuid:802790df-42a2-4fa0-af6a-727175b5aa26 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:089658A12D biolink:treats MONDO:0005011 PMID:41385096 "[{""id"":""uuid:8fe5ee05-4f3d-43d4-b82a-4d0032198592"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f4666523-79d1-41c0-91e5-2649cb743c48"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TREMFYA is an interleukin-23 antagonist indicated for the treatment of adult patients with: moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy ( 1.1 ) active psoriatic arthritis ( 1.2 ) moderately to severely active ulcerative colitis ( 1.3 ) moderately to severely active Crohn’s disease ( 1.4 ) uuid:ac1e6157-c1b9-4603-aa78-6c3c1c0161b0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135809 biolink:treats MONDO:0004981 PMID:41385096 "[{""id"":""uuid:a3492657-d8ff-4311-b8b3-30220648dab6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7169a072-cd09-4ef5-a1b8-d3419dfc0fbb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:7a61d514-be98-42a3-a343-cecdc8d56b22"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RAPIBLYK is indicated for the short-term reduction of ventricular rate in adults with supraventricular tachycardia including atrial fibrillation and atrial flutter.|[PMDA] A drug with a new additional indication and a new dosage for the treatment of tachyarrhythmia including atrial fibrillation/flutter in patients with low cardiac function. uuid:93c145cf-f61b-46c6-b301-2e482ed9f827 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135809 biolink:treats MONDO:0005310 PMID:41385096 "[{""id"":""uuid:bac40930-ff0b-4f06-9a6e-bedfa01efabf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2ecf17ee-45b6-4f10-8f47-40202a144e35"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:9ea85f94-19e5-4ea6-af3d-0e0451315627"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RAPIBLYK is indicated for the short-term reduction of ventricular rate in adults with supraventricular tachycardia including atrial fibrillation and atrial flutter.|[PMDA] A drug with a new additional indication and a new dosage for the treatment of tachyarrhythmia including atrial fibrillation/flutter in patients with low cardiac function. uuid:4e64d83a-761e-487b-a6c5-027b9b4b5402 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135809 biolink:treats HP:0004755 PMID:41385096 "[{""id"":""uuid:7cc5b9cd-4259-453d-9168-06e80408ae30"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9a3d4643-241a-4d34-847f-30b02c737427"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:0eb634ab-34ea-421b-ae08-682fe19c6c51"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RAPIBLYK is indicated for the short-term reduction of ventricular rate in adults with supraventricular tachycardia including atrial fibrillation and atrial flutter.|[PMDA] Drugs with a new indication and a new additional pediatric dosage for the treatment of the following tachyarrhythmia in patients with low cardiac function: supraventricular tachycardia, atrial fibrillation, and atrial flutter. uuid:92b96b29-0171-470c-85fd-64bcb3345ab1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1424887 biolink:treats MONDO:0005002 PMID:41385096 "[{""id"":""uuid:982941ef-36e3-4d7f-a6ef-37582d7dffe8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:2bdc953b-d9a7-49c4-88c4-b75442777d5b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:a1cf2a38-fe59-4b4e-a0b6-28da54d6d0ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/relvar-ellipta""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] BREO ELLIPTA is a combination of fluticasone furoate, a corticosteroid, and vilanterol, a long-acting beta 2 -adrenergic agonist (LABA), indicated for: • the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). ( 1.1 ) • the maintenance treatment of asthma in patients aged 5 years and older. ( 1.2 ) Limitations of Use: Not indicated for relief of acute bronchospasm. ( 1.3 , 5.2 )|[EMA] Asthma indication:Relvar Ellipta is indicated in the regular treatment of asthma in adults and adolescents aged 12 years and older, where use of a combination product (long-acting beta2-agonist and inhaled corticosteroid) is appropriate:patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short acting beta2-agonists.patients already adequately controlled on both inhaled corticosteroid and long-acting beta2-agonist.COPD indication:Relvar Ellipta is indicated for the symptomatic treatment of adults with COPD with a FEV1 uuid:ee3d886f-2879-42b0-aa7a-144016a61e93 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1424887 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:695e852b-eb02-4589-bfff-05137827fa6f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:e6df387a-5934-4f9f-ac41-747ef3ebec49"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:9d2459ca-04ca-4caf-b64c-fe4603ab8372"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/relvar-ellipta""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] BREO ELLIPTA is a combination of fluticasone furoate, a corticosteroid, and vilanterol, a long-acting beta 2 -adrenergic agonist (LABA), indicated for: • the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). ( 1.1 ) • the maintenance treatment of asthma in patients aged 5 years and older. ( 1.2 ) Limitations of Use: Not indicated for relief of acute bronchospasm. ( 1.3 , 5.2 )|[EMA] Asthma indication:Relvar Ellipta is indicated in the regular treatment of asthma in adults and adolescents aged 12 years and older, where use of a combination product (long-acting beta2-agonist and inhaled corticosteroid) is appropriate:patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short acting beta2-agonists.patients already adequately controlled on both inhaled corticosteroid and long-acting beta2-agonist.COPD indication:Relvar Ellipta is indicated for the symptomatic treatment of adults with COPD with a FEV1 uuid:285c3e2f-06ff-400a-83ef-a1b2736e4b26 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:177658 biolink:treats MONDO:0010396 PMID:41385096 "[{""id"":""uuid:af253796-5c07-4e06-a516-cf96cf1c35b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6329226d-967b-4840-a0a8-59eae40216fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZTALMY is indicated for the treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients 2 years of age and older. uuid:47389832-0d3b-4826-b994-9ce2ea1d8f9b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28876 biolink:treats MONDO:0006486 PMID:41385096 "[{""id"":""uuid:555d923d-5d09-46cf-892e-84ba9db75e12"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1bdfe36a-3686-46da-bc6f-9436bbdb4630"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] HEPZATO for injection, as a component of the HEPZATO KIT, is indicated as a liver-directed treatment for adult patients with uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation. uuid:cd3c75a7-c711-47bd-a157-1f9ab6d4e83d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28876 biolink:treats UMLS:C0153690 PMID:41385096 "[{""id"":""uuid:75714ba7-5ec8-4e65-b1f7-55ebc85ae4b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:29ca8d16-ea1a-4ab1-aaf8-ebc2f9d606e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] HEPZATO for injection, as a component of the HEPZATO KIT, is indicated as a liver-directed treatment for adult patients with uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation. uuid:7fdbd29c-c137-4a92-a056-1a1e076cb6cb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28876 biolink:treats MONDO:0005438 PMID:41385096 "[{""id"":""uuid:573c078b-0a84-4a78-bdf9-8fb63193e1a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b2a942c5-3be6-4f24-bdfa-466cef3dd2d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] HEPZATO for injection, as a component of the HEPZATO KIT, is indicated as a liver-directed treatment for adult patients with uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation. uuid:2f4190ff-e872-4b6d-9502-c2474296d090 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:5384HK7574 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:fdf67e69-07a2-4122-b64c-dc79c702264d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:377fb853-844a-4a34-983f-ba1d98f1d333"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:a54e4797-02b8-4b77-a89a-51154ce6168c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ogivri""]},{""id"":""uuid:f91edb9c-112a-482b-b67e-c7984d47b7c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ENHERTU is a HER2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of: adult patients with unresectable or metastatic HER2-positive (IHC 3+ or ISH positive) breast cancer who have received a prior anti-HER2-based regimen either: in the metastatic setting, or in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy. ( 1.1 ) adult patients with unresectable or metastatic Hormone receptor (HR)-positive, HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer, as determined by an FDA-approved test, that has progressed on one or more endocrine therapies in the metastatic setting. (1.2) HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer, as determined by an FDA-approved test, who have received a prior chemotherapy in the metastatic setting; or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy. ( 1.2 ) adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating HER2 (ERBB2) mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy.* ( 1.3 ) adult patients with locally advanced or metastatic HER2-positive (IHC 3+ or IHC 2+/ISH positive) gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen. ( 1.4 ) adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options.* ( 1.5 ) * These indications are approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. ( 14.3 , 14.5 )|[EMA] Breast cancerMetastatic breast cancerOgivri is indicated for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC):as monotherapy for the treatment of those patients who have received at least two chemotherapy regimens for their metastatic disease. Prior chemotherapy must have included at least an anthracycline and a taxane unless patients are unsuitable for these treatments. Hormone receptor positive patients must also have failed hormonal therapy, unless patients are unsuitable for these treatmentsin combination with paclitaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease and for whom an anthracycline is not suitablein combination with docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic diseasein combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive MBC, not previously treated with trastuzumab.Early breast cancer Ogivri is indicated for the treatment of adult patients with HER2 positive early breast cancer (EBC):following surgery, chemotherapy (neoadjuvant or adjuvant) and radiotherapy (if applicable)following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxelin combination with adjuvant chemotherapy consisting of docetaxel and carboplatin.in combination with neoadjuvant chemotherapy followed by adjuvant Ogivri therapy, for locally advanced (including inflammatory) disease or tumours > 2 cm in diameter.Ogivri should only be used in patients with metastatic or EBC whose tumours have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.Metastatic gastric cancerOgivri in combination with capecitabine or 5-fluorouracil and cisplatin is indicated for the treatment of adult patients with HER2 positive metastatic adenocarcinoma of the stomach or gastroesophageal junction who have not received prior anti-cancer treatment for their metastatic disease.Ogivri should only be used in patients with metastatic gastric cancer (MGC) whose tumours have HER2 overexpression as defined by IHC2+ and a confirmatory SISH or FISH result, or by an IHC 3+ result. Accurate and validated assay methods should be used.|[PMDA] A drug with a new indication for the treatment of unresectable or recurrent HER2-low breast cancer in patients who have previously been treated with chemotherapy. [Priority review] uuid:8f5d264d-28e8-4dfe-a852-a9553154ef8f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:5384HK7574 biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:4ef6495d-4728-4d35-aab7-a2e12acb5a98"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:bdd6ab39-0642-46ff-977b-504ed21b766f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:dabde01d-8ca8-45ef-ad45-ad51e96ab948"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/enhertu""]},{""id"":""uuid:f80affe6-586f-452a-93cb-99ffef3ffb85"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ENHERTU is a HER2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of: adult patients with unresectable or metastatic HER2-positive (IHC 3+ or ISH positive) breast cancer who have received a prior anti-HER2-based regimen either: in the metastatic setting, or in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy. ( 1.1 ) adult patients with unresectable or metastatic Hormone receptor (HR)-positive, HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer, as determined by an FDA-approved test, that has progressed on one or more endocrine therapies in the metastatic setting. (1.2) HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer, as determined by an FDA-approved test, who have received a prior chemotherapy in the metastatic setting; or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy. ( 1.2 ) adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating HER2 (ERBB2) mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy.* ( 1.3 ) adult patients with locally advanced or metastatic HER2-positive (IHC 3+ or IHC 2+/ISH positive) gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen. ( 1.4 ) adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options.* ( 1.5 ) * These indications are approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. ( 14.3 , 14.5 )|[EMA] Breast cancerHER2-positive breast cancerEnhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens.HER2-low breast cancerEnhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy (see section 4.2).Non-small cell lung cancer (NSCLC)Enhertu as monotherapy is indicated for the treatment of adult patients with advanced NSCLC whose tumours have an activating HER2 (ERBB2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy.Gastric cancerEnhertu as monotherapy is indicated for the treatment of adult patients with advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.|[PMDA] A drug with a new indication for the treatment of unresectable advanced or recurrent HER2 (ERBB2 ) mutation-positive non-small cell lung cancer that has progressed after cancer chemotherapy. [Orphan drug] uuid:a0595050-7369-4e8c-a08b-ada448d068bb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:5384HK7574 biolink:treats MONDO:0003219 PMID:41385096 "[{""id"":""uuid:fd9d26c0-da3c-48aa-9d39-9efe6d1082ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:968a02c0-b2ad-453d-9ce9-2cf1f9bbb547"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ffdb4737-36d3-4dd0-bf1a-497d88d58759"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/enhertu""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] ENHERTU is a HER2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of: adult patients with unresectable or metastatic HER2-positive (IHC 3+ or ISH positive) breast cancer who have received a prior anti-HER2-based regimen either: in the metastatic setting, or in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy. ( 1.1 ) adult patients with unresectable or metastatic Hormone receptor (HR)-positive, HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer, as determined by an FDA-approved test, that has progressed on one or more endocrine therapies in the metastatic setting. (1.2) HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer, as determined by an FDA-approved test, who have received a prior chemotherapy in the metastatic setting; or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy. ( 1.2 ) adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating HER2 (ERBB2) mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy.* ( 1.3 ) adult patients with locally advanced or metastatic HER2-positive (IHC 3+ or IHC 2+/ISH positive) gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen. ( 1.4 ) adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options.* ( 1.5 ) * These indications are approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. ( 14.3 , 14.5 )|[EMA] Breast cancerHER2-positive breast cancerEnhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens.HER2-low breast cancerEnhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy (see section 4.2).Non-small cell lung cancer (NSCLC)Enhertu as monotherapy is indicated for the treatment of adult patients with advanced NSCLC whose tumours have an activating HER2 (ERBB2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy.Gastric cancerEnhertu as monotherapy is indicated for the treatment of adult patients with advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen. uuid:1cb340ff-532e-4328-b059-902437531079 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7K28NB895L biolink:treats MONDO:0008667 PMID:41385096 "[{""id"":""uuid:e4215fe0-9ae9-4e36-a9e8-67c918ec8340"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:21540ab9-d588-4218-851b-387302e878fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] WELIREG is a hypoxia-inducible factor inhibitor indicated: von Hippel-Lindau (VHL) disease for treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery. ( 1.1 ) Advanced Renal Cell Carcinoma (RCC) for treatment of adult patients with advanced renal cell carcinoma (RCC) with a clear cell component following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI). ( 1.2 ) Pheochromocytoma or Paraganglioma (PPGL) for treatment of adult and pediatric patients 12 years and older with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma (PPGL). ( 1.3 ) uuid:135d27bb-d0ae-45f0-8305-ea9c433a5f0b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7K28NB895L biolink:treats MONDO:0005086 PMID:41385096 "[{""id"":""uuid:e6473f58-6716-4ffc-a527-484bab7bde6e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:56093c7e-5673-4d33-a6f5-5aef4db28d9c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] WELIREG is a hypoxia-inducible factor inhibitor indicated: von Hippel-Lindau (VHL) disease for treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery. ( 1.1 ) Advanced Renal Cell Carcinoma (RCC) for treatment of adult patients with advanced renal cell carcinoma (RCC) with a clear cell component following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI). ( 1.2 ) Pheochromocytoma or Paraganglioma (PPGL) for treatment of adult and pediatric patients 12 years and older with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma (PPGL). ( 1.3 ) uuid:9c9e857c-05c7-4d34-9b42-a0d6cd0821b7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7K28NB895L biolink:treats MONDO:0000628 PMID:41385096 "[{""id"":""uuid:001522c5-28b2-49e8-90e8-3945bfec3502"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8ab907c8-11b6-44b8-babd-fea73bc4d3ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] WELIREG is a hypoxia-inducible factor inhibitor indicated: von Hippel-Lindau (VHL) disease for treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery. ( 1.1 ) Advanced Renal Cell Carcinoma (RCC) for treatment of adult patients with advanced renal cell carcinoma (RCC) with a clear cell component following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI). ( 1.2 ) Pheochromocytoma or Paraganglioma (PPGL) for treatment of adult and pediatric patients 12 years and older with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma (PPGL). ( 1.3 ) uuid:52bc83ca-14f0-4f77-854e-b6ae9182ba26 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7K28NB895L biolink:treats MONDO:0005815 PMID:41385096 "[{""id"":""uuid:345c6a02-66ea-41f0-a018-4ff28bd578e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ad979a40-1e89-44b6-b67b-8a479a8a3fb1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] WELIREG is a hypoxia-inducible factor inhibitor indicated: von Hippel-Lindau (VHL) disease for treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery. ( 1.1 ) Advanced Renal Cell Carcinoma (RCC) for treatment of adult patients with advanced renal cell carcinoma (RCC) with a clear cell component following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI). ( 1.2 ) Pheochromocytoma or Paraganglioma (PPGL) for treatment of adult and pediatric patients 12 years and older with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma (PPGL). ( 1.3 ) uuid:dea90c3a-0c57-44b2-8b24-485c8207c173 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7K28NB895L biolink:treats MONDO:0008233 PMID:41385096 "[{""id"":""uuid:a07333f3-8a87-4328-bbf8-7891b90c861e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9eb7ddb7-aa97-4499-a430-1953e1718847"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] WELIREG is a hypoxia-inducible factor inhibitor indicated: von Hippel-Lindau (VHL) disease for treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery. ( 1.1 ) Advanced Renal Cell Carcinoma (RCC) for treatment of adult patients with advanced renal cell carcinoma (RCC) with a clear cell component following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI). ( 1.2 ) Pheochromocytoma or Paraganglioma (PPGL) for treatment of adult and pediatric patients 12 years and older with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma (PPGL). ( 1.3 ) uuid:6406b790-b503-41ca-9b46-a024316ccd56 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7K28NB895L biolink:treats MONDO:0000448 PMID:41385096 "[{""id"":""uuid:1897ca44-d261-4e4d-82cf-af92cb73f2e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7df012be-6524-4554-9067-8ec9ba9275dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] WELIREG is a hypoxia-inducible factor inhibitor indicated: von Hippel-Lindau (VHL) disease for treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery. ( 1.1 ) Advanced Renal Cell Carcinoma (RCC) for treatment of adult patients with advanced renal cell carcinoma (RCC) with a clear cell component following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI). ( 1.2 ) Pheochromocytoma or Paraganglioma (PPGL) for treatment of adult and pediatric patients 12 years and older with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma (PPGL). ( 1.3 ) uuid:90dae686-8060-44c8-93e5-2095d111e846 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:163341910 biolink:treats UMLS:C0278488 PMID:41385096 "[{""id"":""uuid:b0f325f8-88a0-46c9-92d4-e895418a691e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fa0da681-4dd3-4763-bf4a-7723c6337fba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KADCYLA is a HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for: the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: received prior therapy for metastatic disease, or developed disease recurrence during or within six months of completing adjuvant therapy. ( 1.1 ) the adjuvant treatment of patients with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment. ( 1.2 ) Select patients for therapy based on an FDA-approved companion diagnostic for KADCYLA [see Dosage and Administration (2.1) ] uuid:8bd96f53-51a1-4ad8-9e56-f037bf8ebd80 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:163341910 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:711ac145-8884-4c00-8cac-ca27caa76f65"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:823ac6cf-ac1c-4eda-b732-dc628dc63db3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KADCYLA is a HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for: the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: received prior therapy for metastatic disease, or developed disease recurrence during or within six months of completing adjuvant therapy. ( 1.1 ) the adjuvant treatment of patients with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment. ( 1.2 ) Select patients for therapy based on an FDA-approved companion diagnostic for KADCYLA [see Dosage and Administration (2.1) ] uuid:d2afd107-cb9b-4188-ad5c-10d961eeac90 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:9K8GNJ2874 biolink:treats MONDO:0005072 PMID:41385096 "[{""id"":""uuid:72f501f3-701d-4ccc-8e9a-7b55180b5b57"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:44693705-39c8-4922-ad12-b2fd5c00ec7b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DANYELZA is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), for the treatment of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy. This indication is approved under accelerated approval based on overall response rate and duration of response [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). uuid:f4d7f90f-5663-47c9-96a6-829ee7be8822 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:9K8GNJ2874 biolink:treats UMLS:C0278695 PMID:41385096 "[{""id"":""uuid:4782b591-97ee-4c1f-8f74-897653fecc07"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a831ad48-8e56-4a6c-9c89-3b2bd1d5d1b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DANYELZA is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), for the treatment of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy. This indication is approved under accelerated approval based on overall response rate and duration of response [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). uuid:bde2bb0c-7a83-411b-98f8-6d22e1e94964 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:9K8GNJ2874 biolink:treats UMLS:C4525059 PMID:41385096 "[{""id"":""uuid:03d33f01-9824-4589-ab32-b1548aa94ac0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:93e4bc6a-5778-421d-bcf0-95160884c692"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DANYELZA is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), for the treatment of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy. This indication is approved under accelerated approval based on overall response rate and duration of response [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). uuid:cb993566-f710-4097-a217-07c6180474b5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47381 biolink:treats HP:0003326 PMID:41385096 "[{""id"":""uuid:043fcca6-3229-43d3-996f-d7b1e8e16fad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f9a920fb-ddac-418e-82cf-66b037141345"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Xiclofen TM Ointment is indicated in adults over the age of 12 years old for the treatment of signs and symptoms of osteoarthritis of the joints, and of acute and chronic pain in muscles and joints associated with muscle soreness, strains, sprains, arthritis, simple backache, muscle stiffness, and more. uuid:515204c0-dbb5-46d1-9789-51d16b36f0e2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47381 biolink:treats MONDO:0005578 PMID:41385096 "[{""id"":""uuid:a8f6fc19-eea9-4984-ac53-92ec082d66d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0f72c80d-4a88-4c83-875e-c57cc71c65a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Xiclofen TM Ointment is indicated in adults over the age of 12 years old for the treatment of signs and symptoms of osteoarthritis of the joints, and of acute and chronic pain in muscles and joints associated with muscle soreness, strains, sprains, arthritis, simple backache, muscle stiffness, and more. uuid:e69da954-fe15-45a9-8226-7b06966752bd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47381 biolink:treats HP:0003552 PMID:41385096 "[{""id"":""uuid:1f39d4cf-e13b-497e-8bab-9acac5f626a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:68e2c772-dda2-48e1-a925-e3699f143bc4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Xiclofen TM Ointment is indicated in adults over the age of 12 years old for the treatment of signs and symptoms of osteoarthritis of the joints, and of acute and chronic pain in muscles and joints associated with muscle soreness, strains, sprains, arthritis, simple backache, muscle stiffness, and more. uuid:c29fa33d-c0e6-4a96-a3f0-b57a7eea804e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats HP:0020165 PMID:41385096 "[{""id"":""uuid:90f7bfdb-beb5-42a6-8f69-4a32a450ed92"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7fb8b64d-b085-45e3-af16-1401e988756d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OZURDEX ® is a corticosteroid indicated for: The treatment of macular edema following branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO) ( 1.1 ) The treatment of non-infectious uveitis affecting the posterior segment of the eye ( 1.2 ) The treatment of diabetic macular edema ( 1.3 ) uuid:c341d24b-2b1d-48e7-8830-b856feb12684 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0002303 PMID:41385096 "[{""id"":""uuid:51c66d7d-6a75-4092-ab2c-fe6142e50e83"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6babf550-1e1c-4265-8e48-f9daeaffbde3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OZURDEX ® is a corticosteroid indicated for: The treatment of macular edema following branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO) ( 1.1 ) The treatment of non-infectious uveitis affecting the posterior segment of the eye ( 1.2 ) The treatment of diabetic macular edema ( 1.3 ) uuid:98c3b592-48b3-4131-83f9-f0f574c87b29 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0041093 PMID:41385096 "[{""id"":""uuid:b678a6c5-331c-4a24-aea9-90818d7af43e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2d82906f-890c-4dff-a97d-08a3574b7080"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OZURDEX ® is a corticosteroid indicated for: The treatment of macular edema following branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO) ( 1.1 ) The treatment of non-infectious uveitis affecting the posterior segment of the eye ( 1.2 ) The treatment of diabetic macular edema ( 1.3 ) uuid:184d1b36-75b4-4a6c-ba47-bc022773fc4c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0004728 PMID:41385096 "[{""id"":""uuid:52ff4eb4-80b0-4bdd-8fbb-58b71663373d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0f1f4e3f-0093-4f2d-a871-895b72640f2e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OZURDEX ® is a corticosteroid indicated for: The treatment of macular edema following branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO) ( 1.1 ) The treatment of non-infectious uveitis affecting the posterior segment of the eye ( 1.2 ) The treatment of diabetic macular edema ( 1.3 ) uuid:d2bce925-7529-4766-a12c-2aabc074a605 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:N7T15V1FUY biolink:treats MONDO:0012335 PMID:41385096 "[{""id"":""uuid:9f54193d-cbe4-4d7e-a9c7-57d0e7f9b288"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f08cb0e9-f98d-4665-873b-e8c72c44f064"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:cca77bdf-1f6c-4db2-8e6b-fbe7f300ad56"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/imcivree""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] IMCIVREE is indicated to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 2 years and older with syndromic or monogenic obesity due to: Bardet-Biedl syndrome (BBS) [see Dosage and Administration ( 2.1 )] Pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency as determined by an FDA-approved test demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS) [see Dosage and Administration ( 2.1 )]. Limitations of Use: IMCIVREE is not indicated for the treatment of patients with the following conditions as IMCIVREE would not be expected to be effective: Obesity due to suspected POMC, PCSK1, or LEPR deficiency with POMC , PCSK1 , or LEPR variants classified as benign or likely benign Other types of obesity not related to BBS or POMC, PCSK1, or LEPR deficiency, including obesity associated with other genetic syndromes and general (polygenic) obesity|[EMA] Imcivree is indicated for the treatment of obesity and the control of hunger associated with genetically confirmed Bardet Biedl syndrome (BBS), loss-of-function biallelic pro-opiomelanocortin (POMC), including PCSK1, deficiency or biallelic leptin receptor (LEPR) deficiency in adults and children 6 years of age and above. uuid:1529f982-7429-4b6b-885b-4fef438f1958 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:N7T15V1FUY biolink:treats MONDO:0010961 PMID:41385096 "[{""id"":""uuid:196f24bc-1b28-4970-82c1-118d99d56841"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:3d8956fc-0f58-4cea-a163-18e736fdb818"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:1ce2bb1a-3b9c-44c8-af85-c40b679bae08"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/imcivree""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] IMCIVREE is indicated to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 2 years and older with syndromic or monogenic obesity due to: Bardet-Biedl syndrome (BBS) [see Dosage and Administration ( 2.1 )] Pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency as determined by an FDA-approved test demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS) [see Dosage and Administration ( 2.1 )]. Limitations of Use: IMCIVREE is not indicated for the treatment of patients with the following conditions as IMCIVREE would not be expected to be effective: Obesity due to suspected POMC, PCSK1, or LEPR deficiency with POMC , PCSK1 , or LEPR variants classified as benign or likely benign Other types of obesity not related to BBS or POMC, PCSK1, or LEPR deficiency, including obesity associated with other genetic syndromes and general (polygenic) obesity|[EMA] Imcivree is indicated for the treatment of obesity and the control of hunger associated with genetically confirmed Bardet Biedl syndrome (BBS), loss-of-function biallelic pro-opiomelanocortin (POMC), including PCSK1, deficiency or biallelic leptin receptor (LEPR) deficiency in adults and children 6 years of age and above. uuid:5e5bf9f4-d54e-4aa3-ae77-a25f98de77a1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:N7T15V1FUY biolink:treats MONDO:0013992 PMID:41385096 "[{""id"":""uuid:b489c0d3-a420-4ca2-8c6c-b5edeebdfc00"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:e7271f42-1c8d-482f-b67a-15acfdb16118"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:d0bbde9e-5661-4d4b-b473-8ba7611760e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/imcivree""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] IMCIVREE is indicated to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 2 years and older with syndromic or monogenic obesity due to: Bardet-Biedl syndrome (BBS) [see Dosage and Administration ( 2.1 )] Pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency as determined by an FDA-approved test demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS) [see Dosage and Administration ( 2.1 )]. Limitations of Use: IMCIVREE is not indicated for the treatment of patients with the following conditions as IMCIVREE would not be expected to be effective: Obesity due to suspected POMC, PCSK1, or LEPR deficiency with POMC , PCSK1 , or LEPR variants classified as benign or likely benign Other types of obesity not related to BBS or POMC, PCSK1, or LEPR deficiency, including obesity associated with other genetic syndromes and general (polygenic) obesity|[EMA] Imcivree is indicated for the treatment of obesity and the control of hunger associated with genetically confirmed Bardet Biedl syndrome (BBS), loss-of-function biallelic pro-opiomelanocortin (POMC), including PCSK1, deficiency or biallelic leptin receptor (LEPR) deficiency in adults and children 6 years of age and above. uuid:5bd32b49-a94a-4d2c-9c1a-e025e40563b8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:N7T15V1FUY biolink:treats MONDO:0011122 PMID:41385096 "[{""id"":""uuid:cf919727-781f-4921-9d89-75259542d9cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:35e50fc5-6bae-49f8-b032-783befae8d8b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:42a7b680-2056-4793-93f6-bc230712c3c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/imcivree""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] IMCIVREE is indicated to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 2 years and older with syndromic or monogenic obesity due to: Bardet-Biedl syndrome (BBS) [see Dosage and Administration ( 2.1 )] Pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency as determined by an FDA-approved test demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS) [see Dosage and Administration ( 2.1 )]. Limitations of Use: IMCIVREE is not indicated for the treatment of patients with the following conditions as IMCIVREE would not be expected to be effective: Obesity due to suspected POMC, PCSK1, or LEPR deficiency with POMC , PCSK1 , or LEPR variants classified as benign or likely benign Other types of obesity not related to BBS or POMC, PCSK1, or LEPR deficiency, including obesity associated with other genetic syndromes and general (polygenic) obesity|[EMA] Imcivree is indicated for the treatment of obesity and the control of hunger associated with genetically confirmed Bardet Biedl syndrome (BBS), loss-of-function biallelic pro-opiomelanocortin (POMC), including PCSK1, deficiency or biallelic leptin receptor (LEPR) deficiency in adults and children 6 years of age and above. uuid:546f81f7-35d5-468b-b5ea-92eb1a0db030 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:NU90V55F8I biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:758b384f-879e-4ffe-8363-05d7e55e9984"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:99d546e8-2a8c-443f-adef-b9ffdc548f73"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:62d81db5-8f2d-444b-a2b3-ff09dadafe54"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/kevzara""]},{""id"":""uuid:c2481cef-a556-410f-be97-cccf20724806"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KEVZARA ® is an interleukin-6 (IL-6) receptor antagonist indicated for treatment of: adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs). ( 1.1 ) adult patients with polymyalgia rheumatica (PMR) who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper. ( 1.2 ) patients who weigh 63 kg or greater with active polyarticular juvenile idiopathic arthritis (pJIA). ( 1.3 )|[EMA] Kevzara in combination with methotrexate (MTX) is indicated for the treatment of moderately to severely active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (DMARDs). Kevzara can be given as monotherapy in case of intolerance to MTX or when treatment with MTX is inappropriate.|[PMDA] Drugs with a new active ingredient indicated for the treatment of rheumatoid arthritis in patients who have not responded sufficiently to conventional treatments. uuid:172e9d7f-0785-4431-81e9-596832cdcd3e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:NU90V55F8I biolink:treats MONDO:0019735 PMID:41385096 "[{""id"":""uuid:14522007-708a-4f09-a557-570f3e8cc917"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c23ef13e-dc47-4f5f-ac3a-2c7df0a44c73"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KEVZARA ® is an interleukin-6 (IL-6) receptor antagonist indicated for treatment of: adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs). ( 1.1 ) adult patients with polymyalgia rheumatica (PMR) who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper. ( 1.2 ) patients who weigh 63 kg or greater with active polyarticular juvenile idiopathic arthritis (pJIA). ( 1.3 ) uuid:4eee1555-a6d1-42c5-9c32-7be2e40bd992 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:NU90V55F8I biolink:treats MONDO:0018456 PMID:41385096 "[{""id"":""uuid:03310d3f-3d91-4c17-889f-bf80e7b0a8c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:04625851-9805-49fe-8bad-e190f59ad818"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KEVZARA ® is an interleukin-6 (IL-6) receptor antagonist indicated for treatment of: adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs). ( 1.1 ) adult patients with polymyalgia rheumatica (PMR) who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper. ( 1.2 ) patients who weigh 63 kg or greater with active polyarticular juvenile idiopathic arthritis (pJIA). ( 1.3 ) uuid:3f3aa930-6d8f-4ca4-b6e1-ef3d93b520e7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6344 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:2aa89402-6b77-4422-b967-968e1a8536ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:88ccf3ba-ffb5-4d8b-9559-868e48983be5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Labetalol Hydrochloride is indicated in the management of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including beta adrenergic blockers. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Labetalol Hydrochloride Tablets, USP may be used alone or in combination with other antihypertensive agents, especially thiazide and loop diuretics. uuid:99570383-154c-4773-8767-ed2b1f7aa403 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6344 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:ea679f21-7ca7-43f8-8f04-2914323c6009"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4c7b340d-6a43-42de-b4e5-38977db1883f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Labetalol Hydrochloride is indicated in the management of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including beta adrenergic blockers. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Labetalol Hydrochloride Tablets, USP may be used alone or in combination with other antihypertensive agents, especially thiazide and loop diuretics. uuid:8f07294c-f96b-4da3-87c9-a37000875221 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6344 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:44f53d22-87f1-49ca-bcac-4b8001584505"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ddd84666-9bad-476f-bf7b-502190749226"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Labetalol Hydrochloride is indicated in the management of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including beta adrenergic blockers. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Labetalol Hydrochloride Tablets, USP may be used alone or in combination with other antihypertensive agents, especially thiazide and loop diuretics. uuid:0b0d0fd7-a5be-4fe4-b3f8-7dc5daeee6e1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6344 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:699dfca6-c945-4515-b5f7-180f54b84457"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a0521ddd-f94f-4573-b2d5-64be18d4c51d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Labetalol Hydrochloride is indicated in the management of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including beta adrenergic blockers. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Labetalol Hydrochloride Tablets, USP may be used alone or in combination with other antihypertensive agents, especially thiazide and loop diuretics. uuid:393e11bb-0fe7-4d9b-9720-fd7962296742 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6344 biolink:treats HP:0001681 PMID:41385096 "[{""id"":""uuid:ab40a488-446c-4194-ba0a-d1355969d725"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a509b644-5f71-4ed7-9e0e-7537d409cbf8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Labetalol Hydrochloride is indicated in the management of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including beta adrenergic blockers. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Labetalol Hydrochloride Tablets, USP may be used alone or in combination with other antihypertensive agents, especially thiazide and loop diuretics. uuid:6d6ddce4-4f44-41e7-adfe-248fee63d70d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6344 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:c5307537-ab60-4b53-83f8-148a5433a3cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a37bb9eb-aa8d-4ef6-ac06-98331743d00b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Labetalol Hydrochloride is indicated in the management of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including beta adrenergic blockers. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Labetalol Hydrochloride Tablets, USP may be used alone or in combination with other antihypertensive agents, especially thiazide and loop diuretics. uuid:c8ecbfe5-0bce-4ab8-aa43-fc321e794bd2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6344 biolink:treats MONDO:0005016 PMID:41385096 "[{""id"":""uuid:88349020-a0ba-4cd8-b989-2d018949a814"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:baa99b9e-116f-4d64-934e-640bbd23b128"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Labetalol Hydrochloride is indicated in the management of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including beta adrenergic blockers. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Labetalol Hydrochloride Tablets, USP may be used alone or in combination with other antihypertensive agents, especially thiazide and loop diuretics. uuid:36188c0a-424e-4d7a-b319-b012dcd32500 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6809 biolink:treats MONDO:0007743 PMID:41385096 "[{""id"":""uuid:3ba55f96-1dac-468d-aa0a-3ff11d87b889"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4ae60f0f-bf2a-4589-94d9-95d1d835f672"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methamphetamine hydrochloride tablets are indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 years of age and older. uuid:1e78e87a-62d9-4e38-87a3-4392da161a73 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134726 biolink:treats MONDO:0005180 PMID:41385096 "[{""id"":""uuid:f85e5811-27d8-46e2-9acb-72cfd70b3327"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2d3cb06c-883a-4ddd-9a0f-7cec14017e6a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c5a5afd6-6d55-486c-823d-c56f1c1de63e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] NOURIANZ is indicated as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinson's disease (PD) experiencing ""off"" episodes.|[PMDA] A drug with a new active ingredient indicated for the improvement of wearing-off phenomenon in patients with Parkinson's disease on treatment with levodopa-containing products." uuid:b67f99d6-363b-46e8-b629-b0e30bdefae5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:343262 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:3d1180b1-3f45-4dab-b784-79ee30ca80a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:64732fd9-3651-4414-ba9c-db6c6736749f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] HUMALOG is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. uuid:939e0ad7-2e34-4f3d-91a4-a8fb6c809641 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85164 biolink:treats MONDO:0002771 PMID:41385096 "[{""id"":""uuid:dfbaecc8-86a6-4d44-bc75-cb7c1a56b808"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5fdd0706-1d72-4aff-8eb0-62143ecd828e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:97761d60-724d-4c54-b125-0a8dc51979ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OFEV is a kinase inhibitor indicated in adults for: Treatment of idiopathic pulmonary fibrosis (IPF) ( 1.1 ) Treatment of chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype ( 1.2 ) Slowing the rate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) ( 1.3 )|[PMDA] Drugs with a new active ingredient indicated for the treatment of idiopathic pulmonary fibrosis. [Orphan drug] uuid:01bd3ef5-a860-4267-b9e7-8110a6a325fd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85164 biolink:treats MONDO:0002047 PMID:41385096 "[{""id"":""uuid:b1493f16-f067-4ce3-9121-489f0cdc3125"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b0254550-691d-4e67-9c71-581fd6ec5633"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:df4e630c-dec7-4535-aa02-048647830f52"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OFEV is a kinase inhibitor indicated in adults for: Treatment of idiopathic pulmonary fibrosis (IPF) ( 1.1 ) Treatment of chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype ( 1.2 ) Slowing the rate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) ( 1.3 )|[PMDA] Drugs with a new additional indication for the treatment of systemic sclerosis associated interstitial lung disease. [Orphan drug] uuid:50b5ddcc-f5bc-4365-8279-d3efaa2f9d9b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49960 biolink:treats MONDO:0015277 PMID:41385096 "[{""id"":""uuid:98471aaf-a36f-4a35-9e4b-2613bc3466de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7d646dbb-3371-4d39-8172-85b62a9d1acc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:65ff2af5-7695-4b7a-af6b-b0e7c327d292"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/caprelsa""]},{""id"":""uuid:6d995769-730d-43f7-8ea2-b70fdb1179f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CAPRELSA is indicated for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease. Use CAPRELSA in patients with indolent, asymptomatic or slowly progressing disease only after careful consideration of the treatment related risks of CAPRELSA.|[EMA] Caprelsa is indicated for the treatment of aggressive and symptomatic medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease.Caprelsa is indicated in adults, children and adolescents aged 5 years and older.For patients in whom re-arranged-during-transfection(RET) mutation is not known or is negative, a possible lower benefit should be taken into account before individual treatment decision.|[PMDA] A drug with a new active ingredient indicated for the treatment of unresectable medullary thyroid cancer. [Orphan drug] uuid:5f3e510e-beff-4d33-8d20-4b4a25b11fc6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:15C2VL427D biolink:treats EFO:1001480 PMID:41385096 "[{""id"":""uuid:57bdd602-ee79-4652-9d1d-5dd0dd0f5a95"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ee589ba3-093a-44f7-8974-40b7de93666c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZALTRAP, in combination with fluorouracil, leucovorin, irinotecan-(FOLFIRI), is indicated for the treatment of patients with metastatic colorectal cancer (mCRC) that is resistant to or has progressed following an oxaliplatin-containing regimen. uuid:e3744061-9532-4217-aa60-94ea7cc7a1e7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1601650 biolink:treats MONDO:0004951 PMID:41385096 "[{""id"":""uuid:e9407272-f4bc-44bd-80d0-2410e447c186"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:06dfc24c-ac8e-4c72-b5a2-417e6a5d1f88"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EVOTAZ is a two-drug combination of atazanavir, a human immunodeficiency virus (HIV-1) protease inhibitor, and cobicistat, a CYP3A inhibitor indicated for use in combination with other antiretroviral agents for the treatment of HIV‑1 infection in adults and pediatric patients weighing at least 35 kg. (1) Limitations of Use Use of EVOTAZ in treatment-experienced patients should be guided by the number of baseline primary protease inhibitor resistance substitutions. (1) uuid:33958783-ec94-4f39-99d6-7bc447d8a9ba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:LKC0U3A8NJ biolink:treats MONDO:0004995 PMID:41385096 "[{""id"":""uuid:ea3e58ba-fa8b-4929-9491-037ba7a58ea4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:528246e9-096f-4b86-9ceb-480a29f7d480"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] REPATHA is indicated: To reduce the risk of major adverse cardiovascular (CV) events (CV death, myocardial infarction, stroke, unstable angina requiring hospitalization, or coronary revascularization) in adults with established cardiovascular disease As an adjunct to diet, alone or in combination with other low-density lipoprotein cholesterol (LDL-C)-lowering therapies, in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), to reduce LDL-C As an adjunct to diet and other LDL-C-lowering therapies in pediatric patients aged 10 years and older with HeFH, to reduce LDL-C As an adjunct to other LDL-C-lowering therapies in adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia (HoFH), to reduce LDL-C uuid:6f0437e2-f63d-473b-9dbe-4bbdd3657409 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:LKC0U3A8NJ biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:44a0ea38-15bf-40d3-bc8d-bd562c39e02c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a24e0133-c6ea-4297-a354-4e27239fd2b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] REPATHA is indicated: To reduce the risk of major adverse cardiovascular (CV) events (CV death, myocardial infarction, stroke, unstable angina requiring hospitalization, or coronary revascularization) in adults with established cardiovascular disease As an adjunct to diet, alone or in combination with other low-density lipoprotein cholesterol (LDL-C)-lowering therapies, in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), to reduce LDL-C As an adjunct to diet and other LDL-C-lowering therapies in pediatric patients aged 10 years and older with HeFH, to reduce LDL-C As an adjunct to other LDL-C-lowering therapies in adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia (HoFH), to reduce LDL-C uuid:5e8d72fc-69c5-43a6-b4f3-e1c4ed0c935d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:LKC0U3A8NJ biolink:treats UMLS:C0342882 PMID:41385096 "[{""id"":""uuid:2cc5d4c6-9ae2-4ea4-b020-4c802aa05267"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8db3f8db-8b3c-45ec-bf45-3ce88bcc301a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] REPATHA is indicated: To reduce the risk of major adverse cardiovascular (CV) events (CV death, myocardial infarction, stroke, unstable angina requiring hospitalization, or coronary revascularization) in adults with established cardiovascular disease As an adjunct to diet, alone or in combination with other low-density lipoprotein cholesterol (LDL-C)-lowering therapies, in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), to reduce LDL-C As an adjunct to diet and other LDL-C-lowering therapies in pediatric patients aged 10 years and older with HeFH, to reduce LDL-C As an adjunct to other LDL-C-lowering therapies in adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia (HoFH), to reduce LDL-C uuid:e3a28d4f-84f0-43be-b2d9-70eeac35b3a9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:LKC0U3A8NJ biolink:treats MONDO:0018328 PMID:41385096 "[{""id"":""uuid:4ec61604-1c56-41ff-82de-f6af3f199bc5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:56a9ba03-3eb2-4a18-9d22-9c5a0352ae1a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:fc0adcc8-df3c-45c4-9120-d93b53682b06"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/repatha""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] REPATHA is indicated: To reduce the risk of major adverse cardiovascular (CV) events (CV death, myocardial infarction, stroke, unstable angina requiring hospitalization, or coronary revascularization) in adults with established cardiovascular disease As an adjunct to diet, alone or in combination with other low-density lipoprotein cholesterol (LDL-C)-lowering therapies, in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), to reduce LDL-C As an adjunct to diet and other LDL-C-lowering therapies in pediatric patients aged 10 years and older with HeFH, to reduce LDL-C As an adjunct to other LDL-C-lowering therapies in adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia (HoFH), to reduce LDL-C|[EMA] Hypercholesterolaemia and mixed dyslipidaemiaRepatha is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:in combination with a statin or statin with other lipid lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin or,alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.Homozygous familial hypercholesterolaemiaRepatha is indicated in adults and adolescents aged 12 years and over with homozygous familial hypercholesterolaemia in combination with other lipid-lowering therapies.Established atherosclerotic cardiovascular diseaseRepatha is indicated in adults with established atherosclerotic cardiovascular disease (myocardial infarction, stroke or peripheral arterial disease) to reduce cardiovascular risk by lowering LDL-C levels, as an adjunct to correction of other risk factors:in combination with the maximum tolerated dose of a statin with or without other lipid-lowering therapies or,alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.For study results with respect to effects on LDL-C, cardiovascular events and populations studied see section 5.1. uuid:30a42865-ee51-4017-ab4e-930687d038c8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:91327 biolink:treats MONDO:0005086 PMID:41385096 "[{""id"":""uuid:a38b8239-4c59-4bc4-a42a-e47aa31557c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:15c51cca-0ae8-45ac-a98a-014ee0a5b8d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FOTIVDA is indicated for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies. uuid:704690be-f7ad-48b2-98d6-c456136df803 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:91408 biolink:treats MONDO:0009692 PMID:41385096 "[{""id"":""uuid:835cda43-2088-464c-93ba-52bc9abdf552"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:2c0520f1-3170-4026-a4da-ca88630e3402"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:20c8eb72-2ec5-47a8-a318-00d847c2d39b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INREBIC ® is indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF).|[EMA] Inrebic is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are Janus Associated Kinase (JAK) inhibitor naïve or have been treated with ruxolitinib. uuid:a73927eb-1239-45c6-8e93-2eb45d81a7cd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:GE2T1418SV biolink:treats MONDO:0005002 PMID:41385096 "[{""id"":""uuid:1cc7a5b9-ad7f-4341-b151-114d867b177a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:9820b530-3697-41a3-a9ce-8bb130d55458"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:947ba247-7757-4053-9504-5944d623db62"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INCRUSE ELLIPTA is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).|[EMA] Rolufta is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD)., uuid:5efaf428-7558-45da-a429-58f56bad8c92 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:GE2T1418SV biolink:treats MONDO:0011751 PMID:41385096 "[{""id"":""uuid:ea05ab68-bad0-427a-9610-3760bfd6fd84"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:734760ff-2a2b-4556-bf42-07718ffb9ef2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INCRUSE ELLIPTA is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). uuid:a64936d2-8285-4e52-ab66-b39130ffde4c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68554 biolink:treats MONDO:0000984 PMID:41385096 "[{""id"":""uuid:5af0a7f1-0f19-48ed-aab7-daa76d6e471e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:75ddb2cd-e6bf-4e78-a9c7-8af26e58b609"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FERRIPROX Oral Solution is indicated for the treatment of transfusional iron overload in adult and pediatric patients 3 years of age and older with thalassemia syndromes, sickle cell disease or other anemias. uuid:717452d7-02f8-431f-8dca-cd80fc8d7445 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68554 biolink:treats MONDO:0011382 PMID:41385096 "[{""id"":""uuid:79db4b52-c897-4f89-841f-da8e8eb3598b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c19f4205-19be-4686-a436-d6f326d88129"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FERRIPROX Oral Solution is indicated for the treatment of transfusional iron overload in adult and pediatric patients 3 years of age and older with thalassemia syndromes, sickle cell disease or other anemias. uuid:cae7d5c4-4f87-4726-a570-96b1de96ebcd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:194186 biolink:treats MONDO:0011122 PMID:41385096 "[{""id"":""uuid:819d74aa-bb0f-4315-9dfb-29498631b52a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0d7978dd-cb42-4865-89c3-58e13a5d2776"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZEPBOUND ® is indicated in combination with a reduced-calorie diet and increased physical activity: to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity. uuid:f12ce1fc-706f-4d39-9a8e-f1adb47accfc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:194186 biolink:treats MONDO:0007147 PMID:41385096 "[{""id"":""uuid:b937fe39-111c-4975-a171-6dbd3a71dbe1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c3ca61b7-9ed5-46cc-8792-bc1df89fa110"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZEPBOUND ® is indicated in combination with a reduced-calorie diet and increased physical activity: to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity. uuid:4a5dd932-6320-414c-bd96-17489b3f589b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:26271 biolink:treats UMLS:C0854100 PMID:41385096 "[{""id"":""uuid:0c87cadd-cdf1-4147-900e-4a98d3a65d1b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f7705b45-03a9-484f-9cfb-7013f70c1ff4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CLINIMIX is indicated as a source of calories and protein for patients requiring parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. CLINIMIX may be used to treat negative nitrogen balance in patients. uuid:c34e7f01-379e-4674-94aa-c3c587239eca biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47657 biolink:treats MONDO:0006608 PMID:41385096 "[{""id"":""uuid:6211a735-769a-49af-9f4c-4e1fe83de744"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:822c4cea-6625-4cb0-ab30-a5dfa2978621"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZORYVE topical foam, 0.3%, is a phosphodiesterase 4 inhibitor indicated for the treatment of seborrheic dermatitis in adult and pediatric patients 9 years of age and older. ( 1.1 ) plaque psoriasis of the scalp and body in adult and pediatric patients 12 years of age and older. ( 1.2 ) uuid:9a87ee29-f7b0-4367-934b-2a491f4ed872 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15854 biolink:treats MONDO:0005136 PMID:41385096 "[{""id"":""uuid:b757a9ad-a6a5-4778-93e3-348bc6ab160f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c3198b51-5818-44c9-b996-10ba35c35138"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Quinine sulfate capsule USP is a cinchona alkaloid indicated for treatment of uncomplicated Plasmodium falciparum malaria ( 1 ). uuid:855254bf-a631-4ed1-bb49-cdb8a9ba9fe5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:QI30938BMS biolink:treats MONDO:0004781 PMID:41385096 "[{""id"":""uuid:8357d5bf-0606-4c4c-8178-51ae75668867"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a88ecf21-4376-40ee-8016-c6c031cdee03"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Technetium Tc 99m Pyrophosphate Injection is a skeletal imaging agent used to demonstrate areas of altered osteogenesis, and a cardiac imaging agent used as an adjunct in the diagnosis of acute myocardial infarction. As an adjunct in the diagnosis of confirmed myocardial infarction (ECG and serum enzymes positive), the incidence of false negative images has been found to be 6%. False negative images can also occur if made too early in the evolutionary phase of the infarct or too late in the resolution phase. In a limited study involving 22 patients in whom the ECG was positive and serum enzymes questionable or negative, but in whom the final diagnosis of acute myocardial infarction was made, the incidence of false negative images was 23%. The incidence of false positive images has been found to be 7 to 9%. False positive images have been reported following coronary by-pass graft surgery, in unstable angina pectoris, old myocardial infarcts and in cardiac contusions. Technescan PYP is a blood pool imaging agent which may be used for gated blood pool imaging and for the detection of sites of gastrointestinal bleeding. When administered intravenously 15 to 30 minutes prior to intravenous administration of sodium pertechnetate Tc 99m for in vivo red blood cell labeling, approximately 75% of the injected activity remains in the blood pool. The modified in vivo/in vitro red blood cell labeling method may also be used for blood pool imaging. uuid:6f6bb29b-47a7-4547-b5dd-a4104810ae3b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:QI30938BMS biolink:treats MONDO:0006805 PMID:41385096 "[{""id"":""uuid:44cc9496-a4f8-4e73-90ba-15c8d9b1ea62"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:44c2d614-ae3c-4a75-9163-badbf70fa03a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Technetium Tc 99m Pyrophosphate Injection is a skeletal imaging agent used to demonstrate areas of altered osteogenesis, and a cardiac imaging agent used as an adjunct in the diagnosis of acute myocardial infarction. As an adjunct in the diagnosis of confirmed myocardial infarction (ECG and serum enzymes positive), the incidence of false negative images has been found to be 6%. False negative images can also occur if made too early in the evolutionary phase of the infarct or too late in the resolution phase. In a limited study involving 22 patients in whom the ECG was positive and serum enzymes questionable or negative, but in whom the final diagnosis of acute myocardial infarction was made, the incidence of false negative images was 23%. The incidence of false positive images has been found to be 7 to 9%. False positive images have been reported following coronary by-pass graft surgery, in unstable angina pectoris, old myocardial infarcts and in cardiac contusions. Technescan PYP is a blood pool imaging agent which may be used for gated blood pool imaging and for the detection of sites of gastrointestinal bleeding. When administered intravenously 15 to 30 minutes prior to intravenous administration of sodium pertechnetate Tc 99m for in vivo red blood cell labeling, approximately 75% of the injected activity remains in the blood pool. The modified in vivo/in vitro red blood cell labeling method may also be used for blood pool imaging. uuid:156ac2b2-39a2-4dc0-af75-555ce1d10d11 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:QI30938BMS biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:a5a10731-75a8-4b9c-b538-4df1cf334138"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a3657322-278c-4cf2-97c7-37f119931595"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Technetium Tc 99m Pyrophosphate Injection is a skeletal imaging agent used to demonstrate areas of altered osteogenesis, and a cardiac imaging agent used as an adjunct in the diagnosis of acute myocardial infarction. As an adjunct in the diagnosis of confirmed myocardial infarction (ECG and serum enzymes positive), the incidence of false negative images has been found to be 6%. False negative images can also occur if made too early in the evolutionary phase of the infarct or too late in the resolution phase. In a limited study involving 22 patients in whom the ECG was positive and serum enzymes questionable or negative, but in whom the final diagnosis of acute myocardial infarction was made, the incidence of false negative images was 23%. The incidence of false positive images has been found to be 7 to 9%. False positive images have been reported following coronary by-pass graft surgery, in unstable angina pectoris, old myocardial infarcts and in cardiac contusions. Technescan PYP is a blood pool imaging agent which may be used for gated blood pool imaging and for the detection of sites of gastrointestinal bleeding. When administered intravenously 15 to 30 minutes prior to intravenous administration of sodium pertechnetate Tc 99m for in vivo red blood cell labeling, approximately 75% of the injected activity remains in the blood pool. The modified in vivo/in vitro red blood cell labeling method may also be used for blood pool imaging. uuid:a1039d5b-641c-4d41-a9cc-2274fb7f7553 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:QI30938BMS biolink:treats UMLS:C0273112 PMID:41385096 "[{""id"":""uuid:5b3bff0a-bc77-447a-bb45-a72d7aff007e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:595f7a20-f495-4340-8c5c-d858d452c5d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Technetium Tc 99m Pyrophosphate Injection is a skeletal imaging agent used to demonstrate areas of altered osteogenesis, and a cardiac imaging agent used as an adjunct in the diagnosis of acute myocardial infarction. As an adjunct in the diagnosis of confirmed myocardial infarction (ECG and serum enzymes positive), the incidence of false negative images has been found to be 6%. False negative images can also occur if made too early in the evolutionary phase of the infarct or too late in the resolution phase. In a limited study involving 22 patients in whom the ECG was positive and serum enzymes questionable or negative, but in whom the final diagnosis of acute myocardial infarction was made, the incidence of false negative images was 23%. The incidence of false positive images has been found to be 7 to 9%. False positive images have been reported following coronary by-pass graft surgery, in unstable angina pectoris, old myocardial infarcts and in cardiac contusions. Technescan PYP is a blood pool imaging agent which may be used for gated blood pool imaging and for the detection of sites of gastrointestinal bleeding. When administered intravenously 15 to 30 minutes prior to intravenous administration of sodium pertechnetate Tc 99m for in vivo red blood cell labeling, approximately 75% of the injected activity remains in the blood pool. The modified in vivo/in vitro red blood cell labeling method may also be used for blood pool imaging. uuid:6183329a-6956-4806-96a2-a2ca30ae73e1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2WTV10SIKH biolink:treats MONDO:0003664 PMID:41385096 "[{""id"":""uuid:b9f95ac2-21e2-40c0-8096-0974aa7d688b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:29ecca72-de4e-4adb-b6ad-0a98c9ba67f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PYRUKYND is indicated for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency. uuid:1425d5d9-9dfb-400e-858f-b5482e2ffae1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2WTV10SIKH biolink:treats MONDO:0009950 PMID:41385096 "[{""id"":""uuid:579156fe-8b20-4260-845c-6398805923e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:1051d151-695a-4a6c-a49e-e8311b072f34"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:80f8b609-38d2-4bcb-834f-26e550bccd70"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PYRUKYND is indicated for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency.|[EMA] Pyrukynd is indicated for the treatment of pyruvate kinase deficiency (PK deficiency) in adult patients (see section 4.4). uuid:0f7c5402-e1e4-421f-8004-0ab365d66f76 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90841 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:fb982e1f-a374-43a0-a8a2-950f641a8648"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:964c2810-94bb-4d09-ac3f-36ea2ad804c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KENGREAL is indicated as an adjunct to percutaneous coronary intervention (PCI) to reduce the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients who have not been treated with a P2Y 12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor [see Clinical Studies ( 14.1 )]. uuid:212f2ee4-e9d0-4536-89d5-3e43649b69b3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90841 biolink:treats UMLS:C3897493 PMID:41385096 "[{""id"":""uuid:48f8653c-d9ef-466e-be98-b7de8a5dbfa8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1c969153-3de3-4827-b164-7273411902f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KENGREAL is indicated as an adjunct to percutaneous coronary intervention (PCI) to reduce the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients who have not been treated with a P2Y 12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor [see Clinical Studies ( 14.1 )]. uuid:358e855c-e9a8-4de5-859e-05211680f55e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90942 biolink:treats MONDO:0009693 PMID:41385096 "[{""id"":""uuid:59780ef4-cbda-4a8a-bc74-3a253eb77823"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1b00be76-7f14-4ef6-ad88-ae4fd854e287"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f6f2f52e-72a1-4b50-8d80-3461d1d896f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NINLARO is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.|[PMDA] Drugs with a new active ingredient indicated for the treatment of relapsed or refractory multiple myeloma. [Orphan drug] uuid:56d571e1-b8d2-425f-86e4-bd1f9b0e58de biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:140376 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:791d0ce0-e6cd-4d2f-8748-9e753d336b9a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e3631c82-afc4-4d20-9691-a44cd85618e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FETROJA is a cephalosporin antibacterial indicated in patients 18 years of age or older for the treatment of the following infections caused by susceptible Gram-negative microorganisms: Complicated Urinary Tract Infections (cUTI), including Pyelonephritis ( 1.1 ) Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia (HABP/VABP) ( 1.2 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of FETROJA and other antibacterial drugs, FETROJA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.3 ) uuid:f7ce9229-107e-4355-ba48-824e716241d6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:140376 biolink:treats MONDO:0006939 PMID:41385096 "[{""id"":""uuid:fd67efc0-3f2b-48e0-89d5-b2f830b1ed22"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:27b82427-4d5e-4be1-98a9-e279202aacbd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FETROJA is a cephalosporin antibacterial indicated in patients 18 years of age or older for the treatment of the following infections caused by susceptible Gram-negative microorganisms: Complicated Urinary Tract Infections (cUTI), including Pyelonephritis ( 1.1 ) Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia (HABP/VABP) ( 1.2 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of FETROJA and other antibacterial drugs, FETROJA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.3 ) uuid:85abdad6-f381-4e47-bbeb-0e33c5a6b826 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:140376 biolink:treats MONDO:0004652 PMID:41385096 "[{""id"":""uuid:9eb38cf6-5618-4327-97b6-91d5e825aa80"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:90a5ba8b-7519-411b-9a18-9ca26e34ceee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FETROJA is a cephalosporin antibacterial indicated in patients 18 years of age or older for the treatment of the following infections caused by susceptible Gram-negative microorganisms: Complicated Urinary Tract Infections (cUTI), including Pyelonephritis ( 1.1 ) Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia (HABP/VABP) ( 1.2 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of FETROJA and other antibacterial drugs, FETROJA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.3 ) uuid:3e6533df-1b9c-42d4-8e28-b634282d7bb4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8389 biolink:treats UMLS:C3650625 PMID:41385096 "[{""id"":""uuid:56c7a595-6393-46ba-a970-2ad83c5727c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c1d7cdff-9090-433e-9241-2c529e08030a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Premarin Intravenous (conjugated estrogens, USP) for injection is indicated in the treatment of abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology. Premarin Intravenous is indicated for short-term use only, to provide a rapid and temporary increase in estrogen levels. uuid:549817ca-0ca8-41fd-b51b-f2bf066d4ee9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:51208 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:858a8028-72c1-4ac5-890d-d041f50f318e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:373766b8-68ad-4769-a8cc-4a1f8f9b6586"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PIVYA is a penicillin class antibacterial indicated for the treatment of female patients 18 years of age and older with uncomplicated urinary tract infections (uUTI) caused by susceptible isolates of Escherichia coli, Proteus mirabilis and Staphylococcus saprophyticus . ( 1.1 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of PIVYA and other antibacterial drugs, PIVYA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.2 ) uuid:16390667-a3d3-497c-b2eb-082bc831d105 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:51208 biolink:treats MONDO:0020920 PMID:41385096 "[{""id"":""uuid:5b4ac403-e0f2-4e57-a79d-da66fe230eda"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b6b056fd-5a97-44bc-8382-f4efc90f65d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PIVYA is a penicillin class antibacterial indicated for the treatment of female patients 18 years of age and older with uncomplicated urinary tract infections (uUTI) caused by susceptible isolates of Escherichia coli, Proteus mirabilis and Staphylococcus saprophyticus . ( 1.1 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of PIVYA and other antibacterial drugs, PIVYA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.2 ) uuid:b26f8539-7a86-43af-b6a0-a2b8cf21d0ce biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:51208 biolink:treats MONDO:0006929 PMID:41385096 "[{""id"":""uuid:6a7f7281-6ef9-4414-b1c2-7d37ae88e1da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:13a33735-8631-44b3-ba00-f796b491ee27"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PIVYA is a penicillin class antibacterial indicated for the treatment of female patients 18 years of age and older with uncomplicated urinary tract infections (uUTI) caused by susceptible isolates of Escherichia coli, Proteus mirabilis and Staphylococcus saprophyticus . ( 1.1 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of PIVYA and other antibacterial drugs, PIVYA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.2 ) uuid:11137ad0-efe5-456b-a95c-9bc5c6f73d20 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5931 biolink:treats MONDO:0012819 PMID:41385096 "[{""id"":""uuid:bd115454-4e65-4aef-abab-4b1c32f3a3b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fbf09c3b-968e-4d2b-bf09-1aa202ee2cb3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AFREZZA ® is a rapid acting inhaled human insulin indicated to improve glycemic control in adult patients with diabetes mellitus. Limitations of Use: AFREZZA is not recommended for the treatment of diabetic ketoacidosis [see Warning and Precautions ( 5.6 )] . The safety and effectiveness of AFREZZA in patients who smoke have not been established. The use of AFREZZA is not recommended in patients who smoke or who have recently stopped smoking. uuid:4885e9e9-dbcc-4d48-976b-842580b464fe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3892 biolink:treats MONDO:0018097 PMID:41385096 "[{""id"":""uuid:830b27c5-e56d-47b2-a5b8-c5a3478f9be2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:82f040a6-9e9b-445c-949b-5356681f7521"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Acthar Gel is indicated as monotherapy for the treatment of infantile spasms in infants and children under 2 years of age. ( 1.1 ) Acthar Gel is indicated for the treatment of exacerbations of multiple sclerosis in adults. ( 1.2 ) Acthar Gel may be used for the following disorders and diseases: rheumatic ( 1.3 ); collagen ( 1.4 ); dermatologic ( 1.5 ); allergic states ( 1.6 ); ophthalmic ( 1.7 ); respiratory ( 1.8 ); and edematous state. ( 1.9 ) uuid:10308e18-5643-49aa-bc34-0942255968c6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3892 biolink:treats MONDO:0005554 PMID:41385096 "[{""id"":""uuid:1ad2dbb8-7fee-4a04-a91d-6dfb6c7cc9f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ccde1e56-3a20-4275-a716-2abea5f30e96"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Acthar Gel is indicated as monotherapy for the treatment of infantile spasms in infants and children under 2 years of age. ( 1.1 ) Acthar Gel is indicated for the treatment of exacerbations of multiple sclerosis in adults. ( 1.2 ) Acthar Gel may be used for the following disorders and diseases: rheumatic ( 1.3 ); collagen ( 1.4 ); dermatologic ( 1.5 ); allergic states ( 1.6 ); ophthalmic ( 1.7 ); respiratory ( 1.8 ); and edematous state. ( 1.9 ) uuid:90ed4da6-8a41-44a4-9ec7-be175fb99c67 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3892 biolink:treats MONDO:0005093 PMID:41385096 "[{""id"":""uuid:3c6216a6-94e2-4e53-8e0e-9d39c3d53b09"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2c4dade2-e34a-42ad-8846-04b15bdb1249"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Acthar Gel is indicated as monotherapy for the treatment of infantile spasms in infants and children under 2 years of age. ( 1.1 ) Acthar Gel is indicated for the treatment of exacerbations of multiple sclerosis in adults. ( 1.2 ) Acthar Gel may be used for the following disorders and diseases: rheumatic ( 1.3 ); collagen ( 1.4 ); dermatologic ( 1.5 ); allergic states ( 1.6 ); ophthalmic ( 1.7 ); respiratory ( 1.8 ); and edematous state. ( 1.9 ) uuid:cee3083b-ab3d-440a-8f7d-ba3bf95aed6a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3892 biolink:treats MONDO:0005271 PMID:41385096 "[{""id"":""uuid:b8f0352a-c864-415d-828c-5f385e99eb0e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:53e1cbef-850b-40eb-a7de-5a6782983a9e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Acthar Gel is indicated as monotherapy for the treatment of infantile spasms in infants and children under 2 years of age. ( 1.1 ) Acthar Gel is indicated for the treatment of exacerbations of multiple sclerosis in adults. ( 1.2 ) Acthar Gel may be used for the following disorders and diseases: rheumatic ( 1.3 ); collagen ( 1.4 ); dermatologic ( 1.5 ); allergic states ( 1.6 ); ophthalmic ( 1.7 ); respiratory ( 1.8 ); and edematous state. ( 1.9 ) uuid:fe20c81d-dbce-42ca-9af6-18d57650842d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3892 biolink:treats MONDO:0005328 PMID:41385096 "[{""id"":""uuid:23591dac-988c-4d76-9683-fccb62edd660"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:87eacd9b-0dac-4c6f-af56-f964263a8cfb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Acthar Gel is indicated as monotherapy for the treatment of infantile spasms in infants and children under 2 years of age. ( 1.1 ) Acthar Gel is indicated for the treatment of exacerbations of multiple sclerosis in adults. ( 1.2 ) Acthar Gel may be used for the following disorders and diseases: rheumatic ( 1.3 ); collagen ( 1.4 ); dermatologic ( 1.5 ); allergic states ( 1.6 ); ophthalmic ( 1.7 ); respiratory ( 1.8 ); and edematous state. ( 1.9 ) uuid:7f1d726e-5797-43fd-8396-849761dec491 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3892 biolink:treats MONDO:0005087 PMID:41385096 "[{""id"":""uuid:5cfb5414-1799-4a67-849a-d9b67b922097"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c31396ae-d772-472b-9dde-aba2cf99d59f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Acthar Gel is indicated as monotherapy for the treatment of infantile spasms in infants and children under 2 years of age. ( 1.1 ) Acthar Gel is indicated for the treatment of exacerbations of multiple sclerosis in adults. ( 1.2 ) Acthar Gel may be used for the following disorders and diseases: rheumatic ( 1.3 ); collagen ( 1.4 ); dermatologic ( 1.5 ); allergic states ( 1.6 ); ophthalmic ( 1.7 ); respiratory ( 1.8 ); and edematous state. ( 1.9 ) uuid:bb881be5-bb37-400c-87d5-8f664c2f5b14 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:ZL1R02VT79 biolink:treats MONDO:0005417 PMID:41385096 "[{""id"":""uuid:18486e36-5102-4628-8d1c-daae7e158b73"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:e7da8fbb-ac24-45c1-ac84-53eb4c7ec49d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e9fe409b-4636-4676-8553-7de8be2c9d52"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ranivisio""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] SUSVIMO (ranibizumab injection) is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with: Neovascular (wet) Age-related Macular Degeneration (AMD) who have previously responded to at least two intravitreal injections of a VEGF inhibitor ( 1.1 ). Diabetic Macular Edema (DME) who have previously responded to at least two intravitreal injections of a VEGF inhibitor ( 1.2 ). Diabetic Retinopathy (DR) who have previously responded to at least two intravitreal injections of a VEGF inhibitor ( 1.3 ).|[EMA] Ranivisio is indicated in adults for:• The treatment of neovascular (wet) age-related macular degeneration (AMD)• The treatment of visual impairment due to diabetic macular oedema (DME)• The treatment of proliferative diabetic retinopathy (PDR)• The treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO)• The treatment of visual impairment due to choroidal neovascularisation (CNV) uuid:63641732-855a-4843-97d5-8a113787c86e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:ZL1R02VT79 biolink:treats MONDO:0004728 PMID:41385096 "[{""id"":""uuid:86019bfe-70b2-4179-a1ef-ee0848c3702f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2efc00bc-4df5-4c35-b441-bdb217ab729e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:1528f2f4-3cbe-4b45-b39e-2cdfb6296fa8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ranivisio""]},{""id"":""uuid:5e03dff6-7f3f-4385-a80c-6a601e928da0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SUSVIMO (ranibizumab injection) is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with: Neovascular (wet) Age-related Macular Degeneration (AMD) who have previously responded to at least two intravitreal injections of a VEGF inhibitor ( 1.1 ). Diabetic Macular Edema (DME) who have previously responded to at least two intravitreal injections of a VEGF inhibitor ( 1.2 ). Diabetic Retinopathy (DR) who have previously responded to at least two intravitreal injections of a VEGF inhibitor ( 1.3 ).|[EMA] Ranivisio is indicated in adults for:• The treatment of neovascular (wet) age-related macular degeneration (AMD)• The treatment of visual impairment due to diabetic macular oedema (DME)• The treatment of proliferative diabetic retinopathy (PDR)• The treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO)• The treatment of visual impairment due to choroidal neovascularisation (CNV)|[PMDA] A drug with a new additional indication for the treatment of diabetic macular edema. uuid:a39581e9-3f38-49f5-87ee-cece18b1894d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:ZL1R02VT79 biolink:treats MONDO:0005266 PMID:41385096 "[{""id"":""uuid:557876cb-afb0-44e9-8567-f84b6ecc181a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c6770722-ebdc-4af0-a63b-6fa1905d955e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SUSVIMO (ranibizumab injection) is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with: Neovascular (wet) Age-related Macular Degeneration (AMD) who have previously responded to at least two intravitreal injections of a VEGF inhibitor ( 1.1 ). Diabetic Macular Edema (DME) who have previously responded to at least two intravitreal injections of a VEGF inhibitor ( 1.2 ). Diabetic Retinopathy (DR) who have previously responded to at least two intravitreal injections of a VEGF inhibitor ( 1.3 ). uuid:614775f8-9a62-4121-b564-85928513f8bf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4EQZ6YO2HI biolink:treats MONDO:0005298 PMID:41385096 "[{""id"":""uuid:7dc29de1-e142-4b02-88f6-8c125f41ac5d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c4ad3e3d-d006-4a5e-b70d-78572ef3bf5c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:a81c0937-2d9a-433e-86cb-87a6fa36c69a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/prolia""]},{""id"":""uuid:b45af4fb-bef1-42de-bc55-95d7a7d33f9c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Jubbonti is a RANK ligand (RANKL) inhibitor indicated for treatment: • of postmenopausal women with osteoporosis at high risk for fracture. ( 1.1 ) • to increase bone mass in men with osteoporosis at high risk for fracture. ( 1.2 ) • of glucocorticoid-induced osteoporosis in men and women at high risk for fracture. ( 1.3 ) • to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer. ( 1.4 ) • to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer. ( 1.5 )|[EMA] Treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures. In postmenopausal women Prolia significantly reduces the risk of vertebral, non vertebral and hip fractures.Treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures. In men with prostate cancer receiving hormone ablation, Prolia significantly reduces the risk of vertebral fractures.|[PMDA] A drug with a new indication and a new dosage for the treatment of osteoporosis. uuid:8213441e-a3c5-4a3f-ac97-4d0947abf783 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4EQZ6YO2HI biolink:treats MONDO:0024651 PMID:41385096 "[{""id"":""uuid:d1ee5f6a-07b3-4995-80e3-3cfbe35c264e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e3397fc5-6c45-4136-bac6-5d02df534e70"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Jubbonti is a RANK ligand (RANKL) inhibitor indicated for treatment: • of postmenopausal women with osteoporosis at high risk for fracture. ( 1.1 ) • to increase bone mass in men with osteoporosis at high risk for fracture. ( 1.2 ) • of glucocorticoid-induced osteoporosis in men and women at high risk for fracture. ( 1.3 ) • to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer. ( 1.4 ) • to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer. ( 1.5 ) uuid:7aa3dbdb-10e4-4df7-a947-d5a92acb50cd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4EQZ6YO2HI biolink:treats MONDO:0008315 PMID:41385096 "[{""id"":""uuid:e9190063-a21b-4f81-89aa-225f5755f5b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ad671f9a-b77d-4017-8bbb-01b95fedc148"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Jubbonti is a RANK ligand (RANKL) inhibitor indicated for treatment: • of postmenopausal women with osteoporosis at high risk for fracture. ( 1.1 ) • to increase bone mass in men with osteoporosis at high risk for fracture. ( 1.2 ) • of glucocorticoid-induced osteoporosis in men and women at high risk for fracture. ( 1.3 ) • to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer. ( 1.4 ) • to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer. ( 1.5 ) uuid:ba8dfca4-ede5-4ae6-a188-098f4b649ec8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4EQZ6YO2HI biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:b5341f25-069d-4429-9499-205f3ab06613"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:997980aa-cfa4-4af8-8ef8-cbeb99286090"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Jubbonti is a RANK ligand (RANKL) inhibitor indicated for treatment: • of postmenopausal women with osteoporosis at high risk for fracture. ( 1.1 ) • to increase bone mass in men with osteoporosis at high risk for fracture. ( 1.2 ) • of glucocorticoid-induced osteoporosis in men and women at high risk for fracture. ( 1.3 ) • to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer. ( 1.4 ) • to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer. ( 1.5 ) uuid:c1f5cb5d-2e68-46c1-85cf-90c022e7d86c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4EQZ6YO2HI biolink:treats MONDO:0009693 PMID:41385096 "[{""id"":""uuid:a320e69f-6824-4b9a-b6fb-ac7d7c7b8e3d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ddbef9c4-5676-4174-8651-120661a387d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:0df47269-8f75-4801-98ce-b75bacf1e5f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Wyost is a RANK ligand (RANKL) inhibitor indicated for: • Prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors. ( 1.1 ) • Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity. ( 1.2 , 14.3 ) • Treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy. ( 1.3 )|[PMDA] A drug with a new active ingredient indicated for the treatment of bone lesions due to multiple myeloma and bone lesions due to bone metastasis of solid tumor. uuid:a5d3eeba-5c38-4c3a-8582-6b12e8b09787 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4EQZ6YO2HI biolink:treats UMLS:C0153690 PMID:41385096 "[{""id"":""uuid:9174edb4-9175-411e-b37a-c4dfd7296882"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e41ceffa-9880-4d3b-a25f-91ab76c07a8d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:9d23296d-d1b3-4c48-bc54-48b5bc1ae230"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Wyost is a RANK ligand (RANKL) inhibitor indicated for: • Prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors. ( 1.1 ) • Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity. ( 1.2 , 14.3 ) • Treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy. ( 1.3 )|[PMDA] A drug with a new active ingredient indicated for the treatment of bone lesions due to multiple myeloma and bone lesions due to bone metastasis of solid tumor. uuid:66aea6bf-c57c-4276-8585-98e7e9cb9d53 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4EQZ6YO2HI biolink:treats MONDO:0005674 PMID:41385096 "[{""id"":""uuid:bee9ddec-356c-48f2-b403-fb7e0fe9ded1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ff1b8aef-dd31-4dbb-bf40-f37696fd3b64"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:09542a6a-7f2c-431f-8736-bfa6526204ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/prolia""]},{""id"":""uuid:f4b7e41f-27b8-4e40-87cb-842299d404cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Wyost is a RANK ligand (RANKL) inhibitor indicated for: • Prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors. ( 1.1 ) • Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity. ( 1.2 , 14.3 ) • Treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy. ( 1.3 )|[EMA] Prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with advanced malignancies involving bone (see section 5.1).Treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity.|[PMDA] A drug with a new additional indication and a new dosage for the treatment of giant cell tumor of bone. [Orphan drug] uuid:e944f1ca-b249-4232-a619-04700fd567af biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4EQZ6YO2HI biolink:treats MONDO:0043455 PMID:41385096 "[{""id"":""uuid:ae38e1e7-6ce0-4a82-afea-cb380719df9a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b2eb5c57-6b55-4af7-bb22-90a1247a0453"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Wyost is a RANK ligand (RANKL) inhibitor indicated for: • Prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors. ( 1.1 ) • Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity. ( 1.2 , 14.3 ) • Treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy. ( 1.3 ) uuid:e0a69dd1-b66c-4020-a53e-26e87aca11e4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17234 biolink:treats HP:0002013 PMID:41385096 "[{""id"":""uuid:8816419e-bbdf-41cd-94eb-dacbe576b1a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7e09ca05-6609-435b-937a-620fa5f863b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] (1) Energy and fluid supplementation;It is used for underfeeding or massive fluid loss caused by various reasons (such as vomiting, diarrhea, etc.), total intravenous nutrition, and starvation ketosis. (2) Drug diluents. uuid:eedca145-3db1-4226-9a1e-e14a9ae10c7b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17234 biolink:treats MONDO:0001673 PMID:41385096 "[{""id"":""uuid:53f49e66-8cf8-4ec9-9658-fac524d3f9c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1ca99e63-7d28-4d26-888b-87a6efcb48ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] (1) Energy and fluid supplementation;It is used for underfeeding or massive fluid loss caused by various reasons (such as vomiting, diarrhea, etc.), total intravenous nutrition, and starvation ketosis. (2) Drug diluents. uuid:68d01a1b-d2b7-422b-b328-b169a2afe69c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:L7451S9126 biolink:treats MONDO:0011382 PMID:41385096 "[{""id"":""uuid:aa7b9ea2-ec88-488e-8bc2-6428fca5e8d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c904e728-fd19-4b3b-b62b-f5adbd91f0e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ADAKVEO ® is indicated to reduce the frequency of vaso-occlusive crises (VOCs) in adults and pediatric patients aged 16 years and older with sickle cell disease. uuid:cf008a44-f20e-420a-b4a3-d23ba1bddc74 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:L7451S9126 biolink:treats UMLS:C0750151 PMID:41385096 "[{""id"":""uuid:ae5b7f23-36e5-4172-8375-baee30f89253"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b70b8277-6dcb-419f-ae45-7f86c2be19c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ADAKVEO ® is indicated to reduce the frequency of vaso-occlusive crises (VOCs) in adults and pediatric patients aged 16 years and older with sickle cell disease. uuid:3602616c-8944-4240-a0c4-9450631f796f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB10385 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:a6fb6082-1b8c-4600-acdc-c5fa41094b18"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6fcc1690-a94a-424f-ab09-62909c90c48e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Studies have shown that properly performed an interpreted skin tests with ragweed pollen extract are useful in the diagnosis of allergy to ragweed pollen 7, 8, 20, 21 . Immunotherapy with the appropriate dosage of short ragweed pollen extract is effective in reducing symptoms of hay fever and asthma resulting from exposure to short ragweed pollen (9, 10, 11), and it is believed to be effective with extract of giant ragweed, although carefully controlled studies are unavailable. However, clinical observations and known cross reactivity between short and giant ragweed pollens have led to the practice of using a mixture of the two species for skin testing and treatment 22, 23, 24, 25, 26, 27 . This form of treatment is recommended for patients who cannot avoid exposure to pollen and who do not obtain satisfactory relief of symptoms from other medications, such as antihistamines. Immunologic changes resulting from treatment with short ragweed pollen extract are believed to include: The induction of specific anti-ragweed IgG antibodies commonly referred to as ""blocking antibodies"" 12, 13 . A decrease in the elevation of ragweed specific IgE during and immediately following the ragweed pollen season 14 . A reduction of circulating anti-ragweed IgE after long-term immunotherapy 15 . A decrease in skin reactivity to the extract 16 and a decrease in leukocyte sensitivity to histamine release 17 after long-term immunotherapy." uuid:a56bd95c-2636-4e10-9612-9065cc2152e7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:50605O2ZNS biolink:treats MONDO:0005052 PMID:41385096 "[{""id"":""uuid:0fc252cc-b0b4-43dc-8101-774b101efeaa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2a003877-c464-4298-a553-d92f91dad94e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] IBSRELA is indicated for treatment of irritable bowel syndrome with constipation (IBS-C) in adults. uuid:2d357245-4b59-4391-99d8-cc7a59b211f6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:55KHL3P693 biolink:treats MONDO:0005277 PMID:41385096 "[{""id"":""uuid:952a2f14-fcad-42a7-9f80-026a31c76281"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e2dbb260-e186-42f1-90f7-99af4172c5be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:b68400ea-bcae-4ca2-9a07-0697043d0747"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/emgality""]},{""id"":""uuid:1971683a-4f48-4842-b53b-090f407d04bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EMGALITY ® is a calcitonin-gene related peptide antagonist indicated in adults for the: preventive treatment of migraine. ( 1.1 ) treatment of episodic cluster headache. ( 1.2 )|[EMA] Emgality is indicated for the prophylaxis of migraine in adults who have at least 4 migraine days per month.|[PMDA] Drugs with a new active ingredient indicated for the prevention of migraine attacks. uuid:2a250106-0565-48a0-9ba6-bf20b6c2cc9e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:55KHL3P693 biolink:treats UMLS:C0393739 PMID:41385096 "[{""id"":""uuid:0531c323-dc1d-4dd6-b173-55dc7ac08ec9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c21d47bf-f904-40b5-857d-919994c416c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EMGALITY ® is a calcitonin-gene related peptide antagonist indicated in adults for the: preventive treatment of migraine. ( 1.1 ) treatment of episodic cluster headache. ( 1.2 ) uuid:547089a8-78f0-4b1a-817b-3a8d24c25b8f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:229599 biolink:treats MONDO:0010726 PMID:41385096 "[{""id"":""uuid:189bbf01-fc14-4498-96b2-e7abf79777f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dea21876-4c1c-430a-a22a-9953d97c6e5e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DAYBUE is indicated for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older. uuid:3d6f30f2-501e-44c4-9301-8e363e576127 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27436 biolink:treats MONDO:0008573 PMID:41385096 "[{""id"":""uuid:273d16fc-b3ff-4eca-9a11-c524695474db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:02b4e4df-94dc-4e79-9a61-14920ae82e61"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Males Androgens are indicated for replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenita or acquired) — Testicular failure due to cryptohidism, bilateral torsion, orchitis, vanishing testis syndrome, or orchidectomy. Hypogonadotropic hypogonadism (congenital or acquired) — Gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation. (Appropriate adrenal cortical and thyroid hormone replacement therapy are still necessary, however, and are actually of primary importance.) If the above conditions occur prior to puberty, androgen replacement therapy will be needed during the adolescent years for development of secondary sexual characteristics. Prolonged androgen treatment will be required to maintain sexual characteristics in these and other males who develop testosterone deficiency after puberty. Safety and efficacy of methyltestosterone in men with “age-related hypogonadism” (also referred to as “late-onset hypogonadism”) have not been established. Androgens may be used to stimulate puberty in carefully selected males with clearly delayed puberty. These patients usually have a familial pattern of delayed puberty that is not secondary to a pathological disorder; puberty is expected to occur spontaneously at a relatively late date. Brief treatment with conservative doses may occasionally be justified in these patients if they do not respond to psychological support. The potential adverse effect on bone maturation should be discussed with the patient and parents prior to androgen administration. An X-ray of the hand and wrist to determine bone age should be obtained every 6 months to assess the effect of treatment on the epiphyseal centers (see WARNINGS ). 2. Females Androgens may be used secondarily in women with advancing inoperable metastatic (skeletal) mammary cancer who are 1 to 5 years postmenopausal. Primary goals of therapy in these women include ablation of the ovaries. Other methods of counteracting estrogen activity are adrenalectomy, hypophysectomy, and/or antiestrogen therapy. This treatment has also been used in premenopausal women with breast cancer who have benefitted from oophorectomy and are considered to have a hormone-responsive tumor. Judgment concerning androgen therapy should be made by an oncologist with expertise in this field. uuid:ba676ed6-ef85-48df-880e-b2b8e2208f57 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:U9JLP7V031 biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:9ca3c2a6-b25a-4038-b793-e3fd3fd8ac75"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d4891da1-23c4-445b-95b4-ab3c2dec2c75"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:8bdec697-10b1-4b04-82c5-ea4a27bf5633"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ebglyss""]},{""id"":""uuid:0ca1cae3-1360-41cb-8c5c-fb71b8f535d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EBGLYSS is indicated for the treatment of adults and pediatric patients 12 years of age and older who weigh at least 40 kg with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. EBGLYSS can be used with or without topical corticosteroids.|[EMA] Ebglyss is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older with a body weight of at least 40 kg who are candidates for systemic therapy.|[PMDA] Drugs with a new active ingredient indicated for the treatment of atopic dermatitis in patients who have not responded sufficiently to conventional treatments. uuid:9ab44328-c81f-40e4-bf64-c7943df31262 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27436 biolink:treats MONDO:0002146 PMID:41385096 "[{""id"":""uuid:27cb8847-04c9-44d7-9e30-de400e21ddb6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bc61c5df-4626-4089-943f-94acb18a9857"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Androgens are indicated for replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired) — testicular failure due to cryptorchidism, bilateral torsions, orchitis, vanishing testis syndrome; or orchidectomy. Hypogonadotropic hypogonadism (congenital or acquired) — gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency, or pituitary hypothalamic injury from tumors, trauma, or radiation. (Appropriate adrenal cortical and thyroid hormone replacement therapy are still necessary, however, and are actually of primary importance.) If the above conditions occur prior to puberty, androgen replacement therapy will be needed during the adolescent years for development of secondary sexual characteristics. Prolonged androgen treatment will be required to maintain sexual characteristics in these and other males who develop testosterone deficiency after puberty. Safety and efficacy of methyltestosterone in men with “age-related hypogonadism” (also referred to as “late-onset hypogonadism”) have not been established. Androgens may be used to stimulate puberty in carefully selected males with clearly delayed puberty. These patients usually have a familial pattern of delayed puberty that is not secondary to a pathological disorder; puberty is expected to occur spontaneously at a relatively late date. Brief treatment with conservative doses may occasionally be justified in these patients if they do not respond to psychological support. The potential adverse effect on bone maturation should be discussed with the patient and parents prior to androgen administration. An X-ray of the hand and wrist to determine bone age should be obtained every 6 months to assess the effect of treatment on the epiphyseal centers (see WARNINGS ). uuid:97871bc0-ef8d-4846-992c-6d47b0ec4088 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27436 biolink:treats UMLS:C1963961 PMID:41385096 "[{""id"":""uuid:6c72a41b-5c81-4264-9a93-42640c32ec6d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:56598cf2-ba0b-4677-b545-bd1ad529aa8f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Androgens are indicated for replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired) — testicular failure due to cryptorchidism, bilateral torsions, orchitis, vanishing testis syndrome; or orchidectomy. Hypogonadotropic hypogonadism (congenital or acquired) — gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency, or pituitary hypothalamic injury from tumors, trauma, or radiation. (Appropriate adrenal cortical and thyroid hormone replacement therapy are still necessary, however, and are actually of primary importance.) If the above conditions occur prior to puberty, androgen replacement therapy will be needed during the adolescent years for development of secondary sexual characteristics. Prolonged androgen treatment will be required to maintain sexual characteristics in these and other males who develop testosterone deficiency after puberty. Safety and efficacy of methyltestosterone in men with “age-related hypogonadism” (also referred to as “late-onset hypogonadism”) have not been established. Androgens may be used to stimulate puberty in carefully selected males with clearly delayed puberty. These patients usually have a familial pattern of delayed puberty that is not secondary to a pathological disorder; puberty is expected to occur spontaneously at a relatively late date. Brief treatment with conservative doses may occasionally be justified in these patients if they do not respond to psychological support. The potential adverse effect on bone maturation should be discussed with the patient and parents prior to androgen administration. An X-ray of the hand and wrist to determine bone age should be obtained every 6 months to assess the effect of treatment on the epiphyseal centers (see WARNINGS ). uuid:452625b5-ee07-4860-bdbe-799b1ffa4200 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB10499 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:797574f1-e2d2-4a48-8a26-023c61b498ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4bc25424-7f83-4dfd-b8fc-580685cc8cff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Studies have shown that skin tests with cat extract are useful in the diagnosis of cat allergy. As a rule, persons with cat allergy have positive skin reactions when tested with cat extract, and non-allergic individuals rarely react (7, 8, 9). However, the relationship between a positive skin test and the appearance of clinical symptoms after exposure to a cat is not absolute, i.e., some skin-test positive persons do not experience allergic symptoms after exposure (10). Failure to experience symptoms may be dose related, since it is known that cats vary significantly in the amount of Fel d1 they produce (11). The efficacy of cat extract immunotherapy in the treatment of bronchial asthma has been shown in two studies (12, 13) A reduction in bronchial sensitivity was observed in five patients with cat allergy, whereas no reduction was observed in placebo treated, cat-allergic patients. uuid:0c6e56cb-d4fb-4d3c-9c6d-53703c3ec5ec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:66901 biolink:treats MONDO:0009061 PMID:41385096 "[{""id"":""uuid:80fce587-96da-4291-a81b-586653d2497b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:31b1476e-c70b-443b-8582-45559258b679"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f154d88b-534a-4614-a8ab-76487d7e4db9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/kalydeco""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] KALYDECO is indicated for the treatment of cystic fibrosis (CF) in patients aged 1 month and older who have at least one mutation in the CFTR gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data [see Clinical Pharmacology (12.1) and Clinical Studies (14) ] . If the patient's genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of a CFTR mutation followed by verification with bi-directional sequencing when recommended by the mutation test instructions for use.|[EMA] Kalydeco tablets are indicated:As monotherapy for the treatment of adults, adolescents, and children aged 6 years and older and weighing 25 kg or more with cystic fibrosis (CF) who have an R117H CFTR mutation or one of the following gating (class III) mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R (see sections 4.4 and 5.1).In a combination regimen with tezacaftor/ivacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (CF) who are homozygous for the F508del mutation or who are heterozygous for the F508del mutation and have one of the following mutations in the CFTR gene: P67L, R117C, L206W, R352Q, A455E, D579G, 711+3A→G, S945L, S977F, R1070W, D1152H, 2789+5G→A, 3272 26A→G, and 3849+10kbC→T.In a combination regimen with ivacaftor/tezacaftor/elexacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (CF) who have at least one F508del mutation in the CFTR gene (see section 5.1).Kalydeco granules are indicated for the treatment of infants aged at least 4 months, toddlers and children weighing 5 kg to less than 25 kg with cystic fibrosis (CF) who have an R117H CFTR mutation or one of the following gating (class III) mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R (see sections 4.4 and 5.1).In a combination regimen with ivacaftor/tezacaftor/elexacaftor for the treatment of cystic fibrosis (CF) in paediatric patients aged 2 to less than 6 years who have at least one F508del mutation in the CFTR gene. uuid:1f973031-85d1-43b7-a558-99cdcac95806 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB10400 biolink:treats UMLS:C4087338 PMID:41385096 "[{""id"":""uuid:d72843b1-f11e-4973-a4eb-e445b3f7e041"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6fb92440-20ea-4050-89a0-af5aa3688779"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Standardized mite extract is indicated for use in the diagnosis of patients with a history of allergy to mites or house dust and for the treatment of patients with a history of mite allergy who have established sensitivity to mites by diagnostic skin testing. The use of mite extract for the above purposes should be made only by physicians with special familiarity and knowledge of allergy as described in a standard allergy textbook (10). uuid:094d0465-879a-4cba-84be-481fd7c845a2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85994 biolink:treats MONDO:0015447 PMID:41385096 "[{""id"":""uuid:55e8d453-fd33-4ee7-8ee2-0a742a3f861f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:8596dcd7-8d6a-41a2-8bf2-e2ded0f844ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:9a622b3f-0e26-4b97-a996-ca28fe5c782e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LENVIMA is a kinase inhibitor that is indicated: Differentiated Thyroid Cancer (DTC) For the treatment of adult patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC). ( 1.1 ) Renal Cell Carcinoma (RCC) In combination with pembrolizumab, for the first line treatment of adult patients with advanced renal cell carcinoma (RCC). ( 1.2 ) In combination with everolimus, for the treatment of adult patients with advanced renal cell carcinoma (RCC) following one prior anti-angiogenic therapy. ( 1.2 ) Hepatocellular Carcinoma (HCC) For the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC). ( 1.3 ) Endometrial Carcinoma (EC) In combination with pembrolizumab, for the treatment of patients with advanced endometrial carcinoma (EC) that is mismatch repair proficient (pMMR) or not microsatellite instability-high (MSI-H), as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.4 , 2.1 )|[EMA] Lenvima is indicated as monotherapy for the treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine (RAI).Lenvima is indicated as monotherapy for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have received no prior systemic therapy. uuid:8b184fa3-c5cf-4ae4-ac36-506770668321 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85994 biolink:treats MONDO:0005086 PMID:41385096 "[{""id"":""uuid:f0fffeea-8a6f-40ba-b9bc-f79dca4080be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9680643a-b19b-4c20-a2ea-a2b84a28c658"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:bb3ceafd-80c7-4658-8a77-30727a420846"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e65e834f-2251-419f-b9b8-e941babc3cfb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LENVIMA is a kinase inhibitor that is indicated: Differentiated Thyroid Cancer (DTC) For the treatment of adult patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC). ( 1.1 ) Renal Cell Carcinoma (RCC) In combination with pembrolizumab, for the first line treatment of adult patients with advanced renal cell carcinoma (RCC). ( 1.2 ) In combination with everolimus, for the treatment of adult patients with advanced renal cell carcinoma (RCC) following one prior anti-angiogenic therapy. ( 1.2 ) Hepatocellular Carcinoma (HCC) For the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC). ( 1.3 ) Endometrial Carcinoma (EC) In combination with pembrolizumab, for the treatment of patients with advanced endometrial carcinoma (EC) that is mismatch repair proficient (pMMR) or not microsatellite instability-high (MSI-H), as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.4 , 2.1 )|[EMA] Kisplyx is indicated for the treatment of adults with advanced renal cell carcinoma (RCC):in combination with pembrolizumab, as first-line treatment (see section 5.1).in combination with everolimus, following one prior vascular endothelial growth factor (VEGF)-targeted therapy.|[PMDA] Drugs with a new indication and a new dosage for the treatment of unresectable or metastatic renal cell carcinoma. uuid:8364ccc2-2aad-4d13-ae7b-f28177dcde55 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85994 biolink:treats MONDO:0007256 PMID:41385096 "[{""id"":""uuid:30e0f869-7af0-4dfb-987c-d35372c31d35"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ebf1f364-d734-4c50-9e4d-8eb0bca50522"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f012af37-502b-46bf-bedf-73189cb05bfb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:30626b22-45bb-42db-90ac-f9502eb5c8a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LENVIMA is a kinase inhibitor that is indicated: Differentiated Thyroid Cancer (DTC) For the treatment of adult patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC). ( 1.1 ) Renal Cell Carcinoma (RCC) In combination with pembrolizumab, for the first line treatment of adult patients with advanced renal cell carcinoma (RCC). ( 1.2 ) In combination with everolimus, for the treatment of adult patients with advanced renal cell carcinoma (RCC) following one prior anti-angiogenic therapy. ( 1.2 ) Hepatocellular Carcinoma (HCC) For the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC). ( 1.3 ) Endometrial Carcinoma (EC) In combination with pembrolizumab, for the treatment of patients with advanced endometrial carcinoma (EC) that is mismatch repair proficient (pMMR) or not microsatellite instability-high (MSI-H), as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.4 , 2.1 )|[EMA] Lenvima is indicated as monotherapy for the treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine (RAI).Lenvima is indicated as monotherapy for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have received no prior systemic therapy.|[PMDA] A drug with a new additional indication and a new dosage indicated for the treatment of unresectable hepatic cell carcinoma. uuid:dd2d6edd-499f-42df-b7be-61269c1949c8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85994 biolink:treats MONDO:0002447 PMID:41385096 "[{""id"":""uuid:7ed05f85-8ec8-4c0b-aca3-cc987923facc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:21b172ad-1163-4a62-852b-d0a53602ef8c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:41ceca6f-b33e-4322-b372-56519d1cf246"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LENVIMA is a kinase inhibitor that is indicated: Differentiated Thyroid Cancer (DTC) For the treatment of adult patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC). ( 1.1 ) Renal Cell Carcinoma (RCC) In combination with pembrolizumab, for the first line treatment of adult patients with advanced renal cell carcinoma (RCC). ( 1.2 ) In combination with everolimus, for the treatment of adult patients with advanced renal cell carcinoma (RCC) following one prior anti-angiogenic therapy. ( 1.2 ) Hepatocellular Carcinoma (HCC) For the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC). ( 1.3 ) Endometrial Carcinoma (EC) In combination with pembrolizumab, for the treatment of patients with advanced endometrial carcinoma (EC) that is mismatch repair proficient (pMMR) or not microsatellite instability-high (MSI-H), as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.4 , 2.1 )|[PMDA] Drugs with a new indication and a new dosage for the treatment of unresectable advanced or recurrent endometrial carcinoma that has progressed after cancer chemotherapy. [Orphan drug] uuid:b594e663-0e8a-4ced-83bd-de3249bc43ca biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8060 biolink:treats MONDO:0001485 PMID:41385096 "[{""id"":""uuid:e9a30296-d5e2-4415-8747-d3e677582d62"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:62c124ee-0e08-4cf6-86c9-a37e4abb2d7d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Phenelzine sulfate has been found to be effective in depressed patients clinically characterized as ""atypical,"" ""nonendogenous,"" or ""neurotic."" These patients often have mixed anxiety and depression and phobic or hypochondriacal features. There is less conclusive evidence of its usefulness with severely depressed patients with endogenous features. Phenelzine sulfate should rarely be the first antidepressant drug used. Rather, it is more suitable for use with patients who have failed to respond to the drugs more commonly used for these conditions." uuid:e940ee15-a6c8-4a79-aead-c1eb25423bb8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8060 biolink:treats MONDO:0024614 PMID:41385096 "[{""id"":""uuid:e3667c93-fe28-444d-b986-c9638efa0497"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e5dfe74a-3369-40f1-ab63-ccacf330fca8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Phenelzine sulfate has been found to be effective in depressed patients clinically characterized as ""atypical,"" ""nonendogenous,"" or ""neurotic."" These patients often have mixed anxiety and depression and phobic or hypochondriacal features. There is less conclusive evidence of its usefulness with severely depressed patients with endogenous features. Phenelzine sulfate should rarely be the first antidepressant drug used. Rather, it is more suitable for use with patients who have failed to respond to the drugs more commonly used for these conditions." uuid:74866be8-8ced-41b4-ac11-340c7d240b90 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6T8C155666 biolink:treats MONDO:0005105 PMID:41385096 "[{""id"":""uuid:5854ca60-f431-48de-af1f-cbc2554523fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1ebdd1ad-56df-44c4-8614-c0d95115d234"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:a7547c8a-4366-40a3-bd4e-2bf10515c5f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/yervoy""]},{""id"":""uuid:f3f21929-6e10-475b-8656-f00bd75314d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] YERVOY is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for: Melanoma • Treatment of unresectable or metastatic melanoma in adults and pediatric patients 12 years and older as a single agent or in combination with nivolumab. (1.1) • Adjuvant treatment of adult patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection, including total lymphadenectomy. (1.2) Renal Cell Carcinoma (RCC) • Treatment of adult patients with intermediate or poor risk advanced renal cell carcinoma, as first-line treatment in combination with nivolumab. (1.3) Colorectal Cancer • Treatment of adults and pediatric patients 12 years and older with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) in combination with nivolumab. (1.4) Hepatocellular Carcinoma • adult patients with unresectable or metastatic hepatocellular carcinoma (HCC) as first-line treatment in combination with nivolumab. ( 1.5 ) • in combination with nivolumab in adult patients with unresectable or metastatic HCC who have been previously treated with sorafenib. (1.5) Non-Small Cell Lung Cancer (NSCLC) • Treatment of adult patients with metastatic non-small cell lung cancer expressing PD-L1 (≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, as first-line treatment in combination with nivolumab. (1.6) • Treatment of adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy. (1.6) Malignant Pleural Mesothelioma • Treatment of adult patients with unresectable malignant pleural mesothelioma, as first-line treatment in combination with nivolumab. (1.7) Esophageal Cancer • Treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, as first line treatment in combination with nivolumab whose tumors express PD-L1 (≥1). (1.8)|[EMA] MelanomaYERVOY as monotherapy or combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older (see section 4.4). YERVOY in combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults.Relative to nivolumab monotherapy, an increase in progression-free survival (PFS) and overall survival (OS) for the combination of nivolumab with ipilimumab is established only in patients with low tumour PD-L1 expression (see sections 4.4 and 5.1).Renal cell carcinoma (RCC)YERVOY in combination with nivolumab is indicated for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma (see section 5.1).Non-small cell lung cancer (NSCLC)YERVOY in combination with nivolumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising EGFR mutation or ALK translocation.Malignant pleural mesothelioma (MPM)YERVOY in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma.Mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal cancer (CRC)YERVOY in combination with nivolumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine based combination chemotherapy (see section 5.1).Oesophageal squamous cell carcinoma (OSCC)YERVOY in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell PD-L1 expression ≥ 1%.|[PMDA] A drug with a new active ingredient indicated for the treatment of unresectable melanoma. [Orphan drug] uuid:ceb30b6a-172b-4d9f-b0de-6a00d8499563 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6T8C155666 biolink:treats MONDO:0005191 PMID:41385096 "[{""id"":""uuid:bb13ac55-f9c8-4c3d-b655-ea6a4cd9f78f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f15fced6-185f-405c-b82d-5b4a07c51e46"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] YERVOY is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for: Melanoma • Treatment of unresectable or metastatic melanoma in adults and pediatric patients 12 years and older as a single agent or in combination with nivolumab. (1.1) • Adjuvant treatment of adult patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection, including total lymphadenectomy. (1.2) Renal Cell Carcinoma (RCC) • Treatment of adult patients with intermediate or poor risk advanced renal cell carcinoma, as first-line treatment in combination with nivolumab. (1.3) Colorectal Cancer • Treatment of adults and pediatric patients 12 years and older with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) in combination with nivolumab. (1.4) Hepatocellular Carcinoma • adult patients with unresectable or metastatic hepatocellular carcinoma (HCC) as first-line treatment in combination with nivolumab. ( 1.5 ) • in combination with nivolumab in adult patients with unresectable or metastatic HCC who have been previously treated with sorafenib. (1.5) Non-Small Cell Lung Cancer (NSCLC) • Treatment of adult patients with metastatic non-small cell lung cancer expressing PD-L1 (≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, as first-line treatment in combination with nivolumab. (1.6) • Treatment of adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy. (1.6) Malignant Pleural Mesothelioma • Treatment of adult patients with unresectable malignant pleural mesothelioma, as first-line treatment in combination with nivolumab. (1.7) Esophageal Cancer • Treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, as first line treatment in combination with nivolumab whose tumors express PD-L1 (≥1). (1.8) uuid:9b4df88f-a66f-451f-9e6b-cd41d423dead biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6T8C155666 biolink:treats MONDO:0005012 PMID:41385096 "[{""id"":""uuid:75bbb773-ec85-4bca-beca-257fb3429329"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f9104ed0-a655-40c7-b601-fe6ec048fae2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] YERVOY is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for: Melanoma • Treatment of unresectable or metastatic melanoma in adults and pediatric patients 12 years and older as a single agent or in combination with nivolumab. (1.1) • Adjuvant treatment of adult patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection, including total lymphadenectomy. (1.2) Renal Cell Carcinoma (RCC) • Treatment of adult patients with intermediate or poor risk advanced renal cell carcinoma, as first-line treatment in combination with nivolumab. (1.3) Colorectal Cancer • Treatment of adults and pediatric patients 12 years and older with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) in combination with nivolumab. (1.4) Hepatocellular Carcinoma • adult patients with unresectable or metastatic hepatocellular carcinoma (HCC) as first-line treatment in combination with nivolumab. ( 1.5 ) • in combination with nivolumab in adult patients with unresectable or metastatic HCC who have been previously treated with sorafenib. (1.5) Non-Small Cell Lung Cancer (NSCLC) • Treatment of adult patients with metastatic non-small cell lung cancer expressing PD-L1 (≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, as first-line treatment in combination with nivolumab. (1.6) • Treatment of adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy. (1.6) Malignant Pleural Mesothelioma • Treatment of adult patients with unresectable malignant pleural mesothelioma, as first-line treatment in combination with nivolumab. (1.7) Esophageal Cancer • Treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, as first line treatment in combination with nivolumab whose tumors express PD-L1 (≥1). (1.8) uuid:d9562ace-28b6-4935-b3b8-1ae16d4c7b3c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6T8C155666 biolink:treats MONDO:0005086 PMID:41385096 "[{""id"":""uuid:32287035-d407-48b5-98be-a81c04f9636b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5f165598-a309-4640-8d14-b11cbfdac37e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f111fdeb-2e8e-46d2-a06e-b345884e6fe4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/yervoy""]},{""id"":""uuid:fad6e774-c67a-452e-a6ed-038ed576867e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] YERVOY is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for: Melanoma • Treatment of unresectable or metastatic melanoma in adults and pediatric patients 12 years and older as a single agent or in combination with nivolumab. (1.1) • Adjuvant treatment of adult patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection, including total lymphadenectomy. (1.2) Renal Cell Carcinoma (RCC) • Treatment of adult patients with intermediate or poor risk advanced renal cell carcinoma, as first-line treatment in combination with nivolumab. (1.3) Colorectal Cancer • Treatment of adults and pediatric patients 12 years and older with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) in combination with nivolumab. (1.4) Hepatocellular Carcinoma • adult patients with unresectable or metastatic hepatocellular carcinoma (HCC) as first-line treatment in combination with nivolumab. ( 1.5 ) • in combination with nivolumab in adult patients with unresectable or metastatic HCC who have been previously treated with sorafenib. (1.5) Non-Small Cell Lung Cancer (NSCLC) • Treatment of adult patients with metastatic non-small cell lung cancer expressing PD-L1 (≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, as first-line treatment in combination with nivolumab. (1.6) • Treatment of adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy. (1.6) Malignant Pleural Mesothelioma • Treatment of adult patients with unresectable malignant pleural mesothelioma, as first-line treatment in combination with nivolumab. (1.7) Esophageal Cancer • Treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, as first line treatment in combination with nivolumab whose tumors express PD-L1 (≥1). (1.8)|[EMA] MelanomaYERVOY as monotherapy or combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older (see section 4.4). YERVOY in combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults.Relative to nivolumab monotherapy, an increase in progression-free survival (PFS) and overall survival (OS) for the combination of nivolumab with ipilimumab is established only in patients with low tumour PD-L1 expression (see sections 4.4 and 5.1).Renal cell carcinoma (RCC)YERVOY in combination with nivolumab is indicated for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma (see section 5.1).Non-small cell lung cancer (NSCLC)YERVOY in combination with nivolumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising EGFR mutation or ALK translocation.Malignant pleural mesothelioma (MPM)YERVOY in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma.Mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal cancer (CRC)YERVOY in combination with nivolumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine based combination chemotherapy (see section 5.1).Oesophageal squamous cell carcinoma (OSCC)YERVOY in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell PD-L1 expression ≥ 1%.|[PMDA] A drug with a new indication and a new dosage for the treatment of unresectable or metastatic renal cell carcinoma. [Priority review] uuid:0f3982eb-baad-43b2-a3a9-0c217fc865a2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6T8C155666 biolink:treats UMLS:C4727069 PMID:41385096 "[{""id"":""uuid:ec7b22d1-a15d-4c27-bf9e-f43a7ace3ecf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3cc80cd0-22a3-440a-8819-9a5d704a7b4c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] YERVOY is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for: Melanoma • Treatment of unresectable or metastatic melanoma in adults and pediatric patients 12 years and older as a single agent or in combination with nivolumab. (1.1) • Adjuvant treatment of adult patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection, including total lymphadenectomy. (1.2) Renal Cell Carcinoma (RCC) • Treatment of adult patients with intermediate or poor risk advanced renal cell carcinoma, as first-line treatment in combination with nivolumab. (1.3) Colorectal Cancer • Treatment of adults and pediatric patients 12 years and older with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) in combination with nivolumab. (1.4) Hepatocellular Carcinoma • adult patients with unresectable or metastatic hepatocellular carcinoma (HCC) as first-line treatment in combination with nivolumab. ( 1.5 ) • in combination with nivolumab in adult patients with unresectable or metastatic HCC who have been previously treated with sorafenib. (1.5) Non-Small Cell Lung Cancer (NSCLC) • Treatment of adult patients with metastatic non-small cell lung cancer expressing PD-L1 (≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, as first-line treatment in combination with nivolumab. (1.6) • Treatment of adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy. (1.6) Malignant Pleural Mesothelioma • Treatment of adult patients with unresectable malignant pleural mesothelioma, as first-line treatment in combination with nivolumab. (1.7) Esophageal Cancer • Treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, as first line treatment in combination with nivolumab whose tumors express PD-L1 (≥1). (1.8) uuid:7312accd-d841-4e89-b78e-d7de83aa24e9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6T8C155666 biolink:treats MONDO:0005575 PMID:41385096 "[{""id"":""uuid:c78f764d-1816-4a87-b32a-f3f84d8ff05a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f6dba82c-2fbd-4705-a6c5-7e1396ed4eb1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:16168c24-eb36-41c0-aae3-dfa79fc702e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/yervoy""]},{""id"":""uuid:57105b75-6b71-4794-a8cc-761a2a87169c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] YERVOY is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for: Melanoma • Treatment of unresectable or metastatic melanoma in adults and pediatric patients 12 years and older as a single agent or in combination with nivolumab. (1.1) • Adjuvant treatment of adult patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection, including total lymphadenectomy. (1.2) Renal Cell Carcinoma (RCC) • Treatment of adult patients with intermediate or poor risk advanced renal cell carcinoma, as first-line treatment in combination with nivolumab. (1.3) Colorectal Cancer • Treatment of adults and pediatric patients 12 years and older with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) in combination with nivolumab. (1.4) Hepatocellular Carcinoma • adult patients with unresectable or metastatic hepatocellular carcinoma (HCC) as first-line treatment in combination with nivolumab. ( 1.5 ) • in combination with nivolumab in adult patients with unresectable or metastatic HCC who have been previously treated with sorafenib. (1.5) Non-Small Cell Lung Cancer (NSCLC) • Treatment of adult patients with metastatic non-small cell lung cancer expressing PD-L1 (≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, as first-line treatment in combination with nivolumab. (1.6) • Treatment of adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy. (1.6) Malignant Pleural Mesothelioma • Treatment of adult patients with unresectable malignant pleural mesothelioma, as first-line treatment in combination with nivolumab. (1.7) Esophageal Cancer • Treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, as first line treatment in combination with nivolumab whose tumors express PD-L1 (≥1). (1.8)|[EMA] MelanomaYERVOY as monotherapy or combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older (see section 4.4). YERVOY in combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults.Relative to nivolumab monotherapy, an increase in progression-free survival (PFS) and overall survival (OS) for the combination of nivolumab with ipilimumab is established only in patients with low tumour PD-L1 expression (see sections 4.4 and 5.1).Renal cell carcinoma (RCC)YERVOY in combination with nivolumab is indicated for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma (see section 5.1).Non-small cell lung cancer (NSCLC)YERVOY in combination with nivolumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising EGFR mutation or ALK translocation.Malignant pleural mesothelioma (MPM)YERVOY in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma.Mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal cancer (CRC)YERVOY in combination with nivolumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine based combination chemotherapy (see section 5.1).Oesophageal squamous cell carcinoma (OSCC)YERVOY in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell PD-L1 expression ≥ 1%.|[PMDA] A drug with a new indication for the treatment of unresectable advanced or recurrent microsatellite instability-high (MSI-High) colorectal cancer that has progressed after cancer chemotherapy. uuid:799561ef-b6d2-41c1-8b6d-6d878f0c7109 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6T8C155666 biolink:treats UMLS:C4544822 PMID:41385096 "[{""id"":""uuid:b74d0b58-d300-45d8-98a2-5d4380170172"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b4e68655-60f8-4c75-8d43-8c844cbe112e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] YERVOY is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for: Melanoma • Treatment of unresectable or metastatic melanoma in adults and pediatric patients 12 years and older as a single agent or in combination with nivolumab. (1.1) • Adjuvant treatment of adult patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection, including total lymphadenectomy. (1.2) Renal Cell Carcinoma (RCC) • Treatment of adult patients with intermediate or poor risk advanced renal cell carcinoma, as first-line treatment in combination with nivolumab. (1.3) Colorectal Cancer • Treatment of adults and pediatric patients 12 years and older with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) in combination with nivolumab. (1.4) Hepatocellular Carcinoma • adult patients with unresectable or metastatic hepatocellular carcinoma (HCC) as first-line treatment in combination with nivolumab. ( 1.5 ) • in combination with nivolumab in adult patients with unresectable or metastatic HCC who have been previously treated with sorafenib. (1.5) Non-Small Cell Lung Cancer (NSCLC) • Treatment of adult patients with metastatic non-small cell lung cancer expressing PD-L1 (≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, as first-line treatment in combination with nivolumab. (1.6) • Treatment of adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy. (1.6) Malignant Pleural Mesothelioma • Treatment of adult patients with unresectable malignant pleural mesothelioma, as first-line treatment in combination with nivolumab. (1.7) Esophageal Cancer • Treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, as first line treatment in combination with nivolumab whose tumors express PD-L1 (≥1). (1.8) uuid:d36b2d0b-7554-4a6c-a026-bd2828806430 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6T8C155666 biolink:treats MONDO:0007256 PMID:41385096 "[{""id"":""uuid:0e68c0ca-2727-404c-b075-352342891fd0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6f5baef3-4883-4c72-b6d3-34d9bcdfe542"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] YERVOY is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for: Melanoma • Treatment of unresectable or metastatic melanoma in adults and pediatric patients 12 years and older as a single agent or in combination with nivolumab. (1.1) • Adjuvant treatment of adult patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection, including total lymphadenectomy. (1.2) Renal Cell Carcinoma (RCC) • Treatment of adult patients with intermediate or poor risk advanced renal cell carcinoma, as first-line treatment in combination with nivolumab. (1.3) Colorectal Cancer • Treatment of adults and pediatric patients 12 years and older with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) in combination with nivolumab. (1.4) Hepatocellular Carcinoma • adult patients with unresectable or metastatic hepatocellular carcinoma (HCC) as first-line treatment in combination with nivolumab. ( 1.5 ) • in combination with nivolumab in adult patients with unresectable or metastatic HCC who have been previously treated with sorafenib. (1.5) Non-Small Cell Lung Cancer (NSCLC) • Treatment of adult patients with metastatic non-small cell lung cancer expressing PD-L1 (≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, as first-line treatment in combination with nivolumab. (1.6) • Treatment of adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy. (1.6) Malignant Pleural Mesothelioma • Treatment of adult patients with unresectable malignant pleural mesothelioma, as first-line treatment in combination with nivolumab. (1.7) Esophageal Cancer • Treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, as first line treatment in combination with nivolumab whose tumors express PD-L1 (≥1). (1.8) uuid:79a02485-68b5-4f53-bef1-9a4cc67dbfa9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6T8C155666 biolink:treats UMLS:C0744869 PMID:41385096 "[{""id"":""uuid:15d772e8-3bb2-4936-876b-c8eb0a25ea57"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:289c7a2d-9ecc-401a-ae5c-8ac43466e27b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] YERVOY is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for: Melanoma • Treatment of unresectable or metastatic melanoma in adults and pediatric patients 12 years and older as a single agent or in combination with nivolumab. (1.1) • Adjuvant treatment of adult patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection, including total lymphadenectomy. (1.2) Renal Cell Carcinoma (RCC) • Treatment of adult patients with intermediate or poor risk advanced renal cell carcinoma, as first-line treatment in combination with nivolumab. (1.3) Colorectal Cancer • Treatment of adults and pediatric patients 12 years and older with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) in combination with nivolumab. (1.4) Hepatocellular Carcinoma • adult patients with unresectable or metastatic hepatocellular carcinoma (HCC) as first-line treatment in combination with nivolumab. ( 1.5 ) • in combination with nivolumab in adult patients with unresectable or metastatic HCC who have been previously treated with sorafenib. (1.5) Non-Small Cell Lung Cancer (NSCLC) • Treatment of adult patients with metastatic non-small cell lung cancer expressing PD-L1 (≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, as first-line treatment in combination with nivolumab. (1.6) • Treatment of adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy. (1.6) Malignant Pleural Mesothelioma • Treatment of adult patients with unresectable malignant pleural mesothelioma, as first-line treatment in combination with nivolumab. (1.7) Esophageal Cancer • Treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, as first line treatment in combination with nivolumab whose tumors express PD-L1 (≥1). (1.8) uuid:0bf366ab-9b7a-4bec-a2d6-6e8ec5594719 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6T8C155666 biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:9fa8d2fa-e65c-4194-8d21-07bede4ddd0a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a22d199c-43c1-48d4-8af2-b9b9dcfa8d22"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:0e8cc221-5b34-4ef5-8d04-b77ec621b005"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/yervoy""]},{""id"":""uuid:98422791-500e-4fdc-8f0c-3b44b10be88f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] YERVOY is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for: Melanoma • Treatment of unresectable or metastatic melanoma in adults and pediatric patients 12 years and older as a single agent or in combination with nivolumab. (1.1) • Adjuvant treatment of adult patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection, including total lymphadenectomy. (1.2) Renal Cell Carcinoma (RCC) • Treatment of adult patients with intermediate or poor risk advanced renal cell carcinoma, as first-line treatment in combination with nivolumab. (1.3) Colorectal Cancer • Treatment of adults and pediatric patients 12 years and older with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) in combination with nivolumab. (1.4) Hepatocellular Carcinoma • adult patients with unresectable or metastatic hepatocellular carcinoma (HCC) as first-line treatment in combination with nivolumab. ( 1.5 ) • in combination with nivolumab in adult patients with unresectable or metastatic HCC who have been previously treated with sorafenib. (1.5) Non-Small Cell Lung Cancer (NSCLC) • Treatment of adult patients with metastatic non-small cell lung cancer expressing PD-L1 (≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, as first-line treatment in combination with nivolumab. (1.6) • Treatment of adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy. (1.6) Malignant Pleural Mesothelioma • Treatment of adult patients with unresectable malignant pleural mesothelioma, as first-line treatment in combination with nivolumab. (1.7) Esophageal Cancer • Treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, as first line treatment in combination with nivolumab whose tumors express PD-L1 (≥1). (1.8)|[EMA] MelanomaYERVOY as monotherapy or combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older (see section 4.4). YERVOY in combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults.Relative to nivolumab monotherapy, an increase in progression-free survival (PFS) and overall survival (OS) for the combination of nivolumab with ipilimumab is established only in patients with low tumour PD-L1 expression (see sections 4.4 and 5.1).Renal cell carcinoma (RCC)YERVOY in combination with nivolumab is indicated for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma (see section 5.1).Non-small cell lung cancer (NSCLC)YERVOY in combination with nivolumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising EGFR mutation or ALK translocation.Malignant pleural mesothelioma (MPM)YERVOY in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma.Mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal cancer (CRC)YERVOY in combination with nivolumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine based combination chemotherapy (see section 5.1).Oesophageal squamous cell carcinoma (OSCC)YERVOY in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell PD-L1 expression ≥ 1%.|[PMDA] A drug with a new indication and a new dosage for the treatment of unresectable advanced or recurrent non- small cell lung cancer. uuid:64bd5b24-e6f8-4d33-8ace-32bbcb6a44cd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6T8C155666 biolink:treats UMLS:C0278987 PMID:41385096 "[{""id"":""uuid:272bbf61-f09d-491d-9c10-4febac881f46"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f61dffb1-4a67-4955-bb48-2dc3b7e4e355"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] YERVOY is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for: Melanoma • Treatment of unresectable or metastatic melanoma in adults and pediatric patients 12 years and older as a single agent or in combination with nivolumab. (1.1) • Adjuvant treatment of adult patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection, including total lymphadenectomy. (1.2) Renal Cell Carcinoma (RCC) • Treatment of adult patients with intermediate or poor risk advanced renal cell carcinoma, as first-line treatment in combination with nivolumab. (1.3) Colorectal Cancer • Treatment of adults and pediatric patients 12 years and older with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) in combination with nivolumab. (1.4) Hepatocellular Carcinoma • adult patients with unresectable or metastatic hepatocellular carcinoma (HCC) as first-line treatment in combination with nivolumab. ( 1.5 ) • in combination with nivolumab in adult patients with unresectable or metastatic HCC who have been previously treated with sorafenib. (1.5) Non-Small Cell Lung Cancer (NSCLC) • Treatment of adult patients with metastatic non-small cell lung cancer expressing PD-L1 (≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, as first-line treatment in combination with nivolumab. (1.6) • Treatment of adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy. (1.6) Malignant Pleural Mesothelioma • Treatment of adult patients with unresectable malignant pleural mesothelioma, as first-line treatment in combination with nivolumab. (1.7) Esophageal Cancer • Treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, as first line treatment in combination with nivolumab whose tumors express PD-L1 (≥1). (1.8) uuid:e9acd04d-77e9-40f6-b585-ad76f6c47df0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6T8C155666 biolink:treats UMLS:C0278517 PMID:41385096 "[{""id"":""uuid:93d98ca2-b67b-48fc-a399-825a642e6c49"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5f5e8992-be05-42eb-b69a-0fff7eb0ace6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] YERVOY is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for: Melanoma • Treatment of unresectable or metastatic melanoma in adults and pediatric patients 12 years and older as a single agent or in combination with nivolumab. (1.1) • Adjuvant treatment of adult patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection, including total lymphadenectomy. (1.2) Renal Cell Carcinoma (RCC) • Treatment of adult patients with intermediate or poor risk advanced renal cell carcinoma, as first-line treatment in combination with nivolumab. (1.3) Colorectal Cancer • Treatment of adults and pediatric patients 12 years and older with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) in combination with nivolumab. (1.4) Hepatocellular Carcinoma • adult patients with unresectable or metastatic hepatocellular carcinoma (HCC) as first-line treatment in combination with nivolumab. ( 1.5 ) • in combination with nivolumab in adult patients with unresectable or metastatic HCC who have been previously treated with sorafenib. (1.5) Non-Small Cell Lung Cancer (NSCLC) • Treatment of adult patients with metastatic non-small cell lung cancer expressing PD-L1 (≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, as first-line treatment in combination with nivolumab. (1.6) • Treatment of adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy. (1.6) Malignant Pleural Mesothelioma • Treatment of adult patients with unresectable malignant pleural mesothelioma, as first-line treatment in combination with nivolumab. (1.7) Esophageal Cancer • Treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, as first line treatment in combination with nivolumab whose tumors express PD-L1 (≥1). (1.8) uuid:271469e4-561e-4a5e-aa44-3b2343b7153c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6T8C155666 biolink:treats MONDO:0005112 PMID:41385096 "[{""id"":""uuid:67c543d6-b8f0-46f5-8aa1-50d02ca7f3bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4a7e1e29-d658-46a1-b101-335a208c46b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:8ab71804-93ba-443e-999f-337525a33b4a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/yervoy""]},{""id"":""uuid:2ee52faa-ff3a-4845-a0b1-6eb7e49991ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] YERVOY is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for: Melanoma • Treatment of unresectable or metastatic melanoma in adults and pediatric patients 12 years and older as a single agent or in combination with nivolumab. (1.1) • Adjuvant treatment of adult patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection, including total lymphadenectomy. (1.2) Renal Cell Carcinoma (RCC) • Treatment of adult patients with intermediate or poor risk advanced renal cell carcinoma, as first-line treatment in combination with nivolumab. (1.3) Colorectal Cancer • Treatment of adults and pediatric patients 12 years and older with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) in combination with nivolumab. (1.4) Hepatocellular Carcinoma • adult patients with unresectable or metastatic hepatocellular carcinoma (HCC) as first-line treatment in combination with nivolumab. ( 1.5 ) • in combination with nivolumab in adult patients with unresectable or metastatic HCC who have been previously treated with sorafenib. (1.5) Non-Small Cell Lung Cancer (NSCLC) • Treatment of adult patients with metastatic non-small cell lung cancer expressing PD-L1 (≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, as first-line treatment in combination with nivolumab. (1.6) • Treatment of adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy. (1.6) Malignant Pleural Mesothelioma • Treatment of adult patients with unresectable malignant pleural mesothelioma, as first-line treatment in combination with nivolumab. (1.7) Esophageal Cancer • Treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, as first line treatment in combination with nivolumab whose tumors express PD-L1 (≥1). (1.8)|[EMA] MelanomaYERVOY as monotherapy or combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older (see section 4.4). YERVOY in combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults.Relative to nivolumab monotherapy, an increase in progression-free survival (PFS) and overall survival (OS) for the combination of nivolumab with ipilimumab is established only in patients with low tumour PD-L1 expression (see sections 4.4 and 5.1).Renal cell carcinoma (RCC)YERVOY in combination with nivolumab is indicated for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma (see section 5.1).Non-small cell lung cancer (NSCLC)YERVOY in combination with nivolumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising EGFR mutation or ALK translocation.Malignant pleural mesothelioma (MPM)YERVOY in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma.Mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal cancer (CRC)YERVOY in combination with nivolumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine based combination chemotherapy (see section 5.1).Oesophageal squamous cell carcinoma (OSCC)YERVOY in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell PD-L1 expression ≥ 1%.|[PMDA] A drug with a new indication and a new dosage for the treatment of unresectable advanced or recurrent malignant pleural mesothelioma. [Orphan drug] uuid:c865debf-42fb-47b2-9064-6be33e015ba3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6T8C155666 biolink:treats MONDO:0005580 PMID:41385096 "[{""id"":""uuid:94906a21-3dee-4afb-ab69-f121b5b7ab85"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:97a13b2a-4dd8-401a-97d4-0451daae54b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:a908bb16-da7a-4a64-81a6-af2257247ace"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/yervoy""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] YERVOY is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for: Melanoma • Treatment of unresectable or metastatic melanoma in adults and pediatric patients 12 years and older as a single agent or in combination with nivolumab. (1.1) • Adjuvant treatment of adult patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection, including total lymphadenectomy. (1.2) Renal Cell Carcinoma (RCC) • Treatment of adult patients with intermediate or poor risk advanced renal cell carcinoma, as first-line treatment in combination with nivolumab. (1.3) Colorectal Cancer • Treatment of adults and pediatric patients 12 years and older with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) in combination with nivolumab. (1.4) Hepatocellular Carcinoma • adult patients with unresectable or metastatic hepatocellular carcinoma (HCC) as first-line treatment in combination with nivolumab. ( 1.5 ) • in combination with nivolumab in adult patients with unresectable or metastatic HCC who have been previously treated with sorafenib. (1.5) Non-Small Cell Lung Cancer (NSCLC) • Treatment of adult patients with metastatic non-small cell lung cancer expressing PD-L1 (≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, as first-line treatment in combination with nivolumab. (1.6) • Treatment of adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy. (1.6) Malignant Pleural Mesothelioma • Treatment of adult patients with unresectable malignant pleural mesothelioma, as first-line treatment in combination with nivolumab. (1.7) Esophageal Cancer • Treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, as first line treatment in combination with nivolumab whose tumors express PD-L1 (≥1). (1.8)|[EMA] MelanomaYERVOY as monotherapy or combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older (see section 4.4). YERVOY in combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults.Relative to nivolumab monotherapy, an increase in progression-free survival (PFS) and overall survival (OS) for the combination of nivolumab with ipilimumab is established only in patients with low tumour PD-L1 expression (see sections 4.4 and 5.1).Renal cell carcinoma (RCC)YERVOY in combination with nivolumab is indicated for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma (see section 5.1).Non-small cell lung cancer (NSCLC)YERVOY in combination with nivolumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising EGFR mutation or ALK translocation.Malignant pleural mesothelioma (MPM)YERVOY in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma.Mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal cancer (CRC)YERVOY in combination with nivolumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine based combination chemotherapy (see section 5.1).Oesophageal squamous cell carcinoma (OSCC)YERVOY in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell PD-L1 expression ≥ 1%. uuid:d7772322-731c-4ef0-b4db-087da4292760 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6T8C155666 biolink:treats UMLS:C1142025 PMID:41385096 "[{""id"":""uuid:45e18a68-619b-475e-94d1-1d6a8a24dd5e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:08f886c1-92f0-4861-87f3-a4e86e2f606b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] YERVOY is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for: Melanoma • Treatment of unresectable or metastatic melanoma in adults and pediatric patients 12 years and older as a single agent or in combination with nivolumab. (1.1) • Adjuvant treatment of adult patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection, including total lymphadenectomy. (1.2) Renal Cell Carcinoma (RCC) • Treatment of adult patients with intermediate or poor risk advanced renal cell carcinoma, as first-line treatment in combination with nivolumab. (1.3) Colorectal Cancer • Treatment of adults and pediatric patients 12 years and older with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) in combination with nivolumab. (1.4) Hepatocellular Carcinoma • adult patients with unresectable or metastatic hepatocellular carcinoma (HCC) as first-line treatment in combination with nivolumab. ( 1.5 ) • in combination with nivolumab in adult patients with unresectable or metastatic HCC who have been previously treated with sorafenib. (1.5) Non-Small Cell Lung Cancer (NSCLC) • Treatment of adult patients with metastatic non-small cell lung cancer expressing PD-L1 (≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, as first-line treatment in combination with nivolumab. (1.6) • Treatment of adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy. (1.6) Malignant Pleural Mesothelioma • Treatment of adult patients with unresectable malignant pleural mesothelioma, as first-line treatment in combination with nivolumab. (1.7) Esophageal Cancer • Treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, as first line treatment in combination with nivolumab whose tumors express PD-L1 (≥1). (1.8) uuid:dd3fccae-9884-49e3-8bb0-34ca2089d12a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:P85X70RZWS biolink:treats MONDO:0006710 PMID:41385096 "[{""id"":""uuid:80a94d28-c893-4a44-a5de-fa6210a6711f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8c4a86fb-33fd-4507-a630-382a66af21e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XCOPRI is indicated for the treatment of partial-onset seizures in adult patients. uuid:6c465600-1b45-43e8-ae3f-5c974ef7760a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PF8K38CG54 biolink:treats MONDO:0005277 PMID:41385096 "[{""id"":""uuid:12d1e899-bf3e-4a0f-b272-67720d3ef0f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0b0a93fe-b184-412e-ab34-cb9e8427ff65"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:353c03d9-5a43-44b1-99a2-587784ed68d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ajovy""]},{""id"":""uuid:0de82bf5-af52-44c9-acf0-65cdef9dda2f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AJOVY is indicated for the preventive treatment of migraine in adults.|[EMA] Ajovy is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month.|[PMDA] A drug with a new active ingredient indicated for the prevention of migraine attacks. uuid:69c9ea42-5bfc-4f2c-8e94-03deeef79058 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68554 biolink:treats MONDO:0018881 PMID:41385096 "[{""id"":""uuid:212c4280-b7c9-4e9f-a4ea-2fcce9ad4b2a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1b6946d5-91d7-4c19-857c-4ea850cb1109"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Deferiprone tablets are indicated for the treatment of transfusional iron overload in adult patients with thalassemia syndromes when current chelation therapy is inadequate. Limitations of Use: • Safety and effectiveness have not been established for the treatment of transfusional iron overload in patients with myelodysplastic syndrome or in patients with Diamond Blackfan anemia. Pediatric use information is approved for Chiesi USA, Inc.’s FERRIPROX ® (deferiprone) tablets. However, due to Chiesi USA, Inc.’s marketing exclusivity rights, this drug product is not labeled with that information. uuid:29197c10-82cc-4e9c-9fe3-4f7b19762ccf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68554 biolink:treats MONDO:0015253 PMID:41385096 "[{""id"":""uuid:ee884d9e-74c3-4ecf-b6af-67e2b76ea293"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:066b0eab-be92-4778-814b-27153a255014"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Deferiprone tablets are indicated for the treatment of transfusional iron overload in adult patients with thalassemia syndromes when current chelation therapy is inadequate. Limitations of Use: • Safety and effectiveness have not been established for the treatment of transfusional iron overload in patients with myelodysplastic syndrome or in patients with Diamond Blackfan anemia. Pediatric use information is approved for Chiesi USA, Inc.’s FERRIPROX ® (deferiprone) tablets. However, due to Chiesi USA, Inc.’s marketing exclusivity rights, this drug product is not labeled with that information. uuid:b296441b-75cc-4fce-aedd-7f9d775b2b55 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:31YO63LBSN biolink:treats MONDO:0005105 PMID:41385096 "[{""id"":""uuid:7d15dfde-57ad-41b6-ba3f-c51e4c7a8796"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ec432bc8-d419-4d42-b95e-d9d10e71065f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:6a1c0d8d-5a82-45ae-a1bf-3dbae854ff13"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OPDIVO is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of: Melanoma • adult and pediatric (12 years and older) patients with unresectable or metastatic melanoma, as a single agent or in combination with ipilimumab. (1.1) • for the adjuvant treatment of adult and pediatric patients 12 years and older with completely resected Stage IIB, Stage IIC, Stage III, or Stage IV melanoma. (1.2) Non-Small Cell Lung Cancer (NSCLC) • adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer in the neoadjuvant setting, in combination with platinum-doublet chemotherapy. (1.3) • adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer and no known EGFR mutations or ALK rearrangements, for neoadjuvant treatment, in combination with platinum-doublet chemotherapy, followed by single-agent OPDIVO as adjuvant treatment after surgery. (1.4) • adult patients with metastatic non-small cell lung cancer expressing PD‑L1 (≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, as first-line treatment in combination with ipilimumab. (1.5) • adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy. (1.5) • adult patients with metastatic non-small cell lung cancer and progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO. (1.5) Malignant Pleural Mesothelioma • adult patients with unresectable malignant pleural mesothelioma, as first-line treatment in combination with ipilimumab. (1.6) Renal Cell Carcinoma (RCC) • adult patients with intermediate or poor risk advanced renal cell carcinoma, as a first-line treatment in combination with ipilimumab. (1.7) • adult patients with advanced renal cell carcinoma, as a first-line treatment in combination with cabozantinib. (1.7) • adult patients with advanced renal cell carcinoma who have received prior anti-angiogenic therapy. (1.7) Classical Hodgkin Lymphoma (cHL) • adult patients with classical Hodgkin lymphoma that has relapsed or progressed after a : (1.8) • autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin, or • 3 or more lines of systemic therapy that includes autologous HSCT. Squamous Cell Carcinoma of the Head and Neck (SCCHN) • adult patients with recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after a platinum-based therapy. (1.9) Urothelial Carcinoma • adjuvant treatment of adult patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection of UC. (1.10) • adult patients with unresectable or metastatic urothelial carcinoma, as first-line treatment in combination with cisplatin and gemcitabine. (1.10) • adult patients with locally advanced or metastatic urothelial carcinoma who: • have disease progression during or following platinum-containing chemotherapy. • have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. (1.10) Colorectal Cancer • adult and pediatric (12 years and older) patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) in combination with ipilimumab. (1.11) • adult and pediatric (12 years and older) patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. ( 1.11 ) Hepatocellular Carcinoma (HCC) • adult patients with unresectable or metastatic hepatocellular carcinoma (HCC), as a first-line treatment in combination with ipilimumab. (1.12) • in combination with ipilimumab in adult patients with unresectable or metastatic HCC who have been previously treated with sorafenib. ( 1.12 ) Esophageal Cancer • adult patients with completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease, who have received neoadjuvant chemoradiotherapy (CRT). (1.13) • adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma as first-line treatment in combination with fluoropyrimidine- and platinum‑containing chemotherapy whose tumors express PD-L1 (≥1). (1.13) • adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma as first-line treatment in combination with ipilimumab whose tumors express PD-L1 (≥1). (1.13) • adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy. (1.13) Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma • adult patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma whose tumors express PD-L1 (≥1) in combination with fluoropyrimidine- and platinum-containing chemotherapy. (1.14) a This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.|[PMDA] A drug with new indications and a new dosage in an additional dosage form for the treatment of unresectable or recurrent malignant pleural mesothelioma and melanoma that have progressed after chemotherapy. [Orphan drug] A drug with a new dosage in an additional dosage form indicated for the treatment of melanoma, unresectable or recurrent non-small cell lung cancer, unresectable or metastatic renal cell carcinoma, relapsed or refractory classical Hodgkin lymphoma, recurrent or metastatic head and neck cancer, unresectable or recurrent gastric cancer that has progressed after chemotherapy, and (3) unresectable or metastatic renal cell carcinoma. [(3) Priority review] uuid:6fb0757a-05a0-4eee-baa3-0472d366d429 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:31YO63LBSN biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:29dee588-0630-452e-a75c-0fd3836ce8e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0b04ed6e-9fcf-48e1-aa1a-de442c8b00fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:71e79c2e-6e6d-43a7-a780-b05d5f0a5577"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OPDIVO is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of: Melanoma • adult and pediatric (12 years and older) patients with unresectable or metastatic melanoma, as a single agent or in combination with ipilimumab. (1.1) • for the adjuvant treatment of adult and pediatric patients 12 years and older with completely resected Stage IIB, Stage IIC, Stage III, or Stage IV melanoma. (1.2) Non-Small Cell Lung Cancer (NSCLC) • adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer in the neoadjuvant setting, in combination with platinum-doublet chemotherapy. (1.3) • adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer and no known EGFR mutations or ALK rearrangements, for neoadjuvant treatment, in combination with platinum-doublet chemotherapy, followed by single-agent OPDIVO as adjuvant treatment after surgery. (1.4) • adult patients with metastatic non-small cell lung cancer expressing PD‑L1 (≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, as first-line treatment in combination with ipilimumab. (1.5) • adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy. (1.5) • adult patients with metastatic non-small cell lung cancer and progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO. (1.5) Malignant Pleural Mesothelioma • adult patients with unresectable malignant pleural mesothelioma, as first-line treatment in combination with ipilimumab. (1.6) Renal Cell Carcinoma (RCC) • adult patients with intermediate or poor risk advanced renal cell carcinoma, as a first-line treatment in combination with ipilimumab. (1.7) • adult patients with advanced renal cell carcinoma, as a first-line treatment in combination with cabozantinib. (1.7) • adult patients with advanced renal cell carcinoma who have received prior anti-angiogenic therapy. (1.7) Classical Hodgkin Lymphoma (cHL) • adult patients with classical Hodgkin lymphoma that has relapsed or progressed after a : (1.8) • autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin, or • 3 or more lines of systemic therapy that includes autologous HSCT. Squamous Cell Carcinoma of the Head and Neck (SCCHN) • adult patients with recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after a platinum-based therapy. (1.9) Urothelial Carcinoma • adjuvant treatment of adult patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection of UC. (1.10) • adult patients with unresectable or metastatic urothelial carcinoma, as first-line treatment in combination with cisplatin and gemcitabine. (1.10) • adult patients with locally advanced or metastatic urothelial carcinoma who: • have disease progression during or following platinum-containing chemotherapy. • have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. (1.10) Colorectal Cancer • adult and pediatric (12 years and older) patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) in combination with ipilimumab. (1.11) • adult and pediatric (12 years and older) patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. ( 1.11 ) Hepatocellular Carcinoma (HCC) • adult patients with unresectable or metastatic hepatocellular carcinoma (HCC), as a first-line treatment in combination with ipilimumab. (1.12) • in combination with ipilimumab in adult patients with unresectable or metastatic HCC who have been previously treated with sorafenib. ( 1.12 ) Esophageal Cancer • adult patients with completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease, who have received neoadjuvant chemoradiotherapy (CRT). (1.13) • adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma as first-line treatment in combination with fluoropyrimidine- and platinum‑containing chemotherapy whose tumors express PD-L1 (≥1). (1.13) • adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma as first-line treatment in combination with ipilimumab whose tumors express PD-L1 (≥1). (1.13) • adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy. (1.13) Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma • adult patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma whose tumors express PD-L1 (≥1) in combination with fluoropyrimidine- and platinum-containing chemotherapy. (1.14) a This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.|[PMDA] A drug with new indications and a new dosage in an additional dosage form for the treatment of unresectable or recurrent malignant pleural mesothelioma and melanoma that have progressed after chemotherapy. [Orphan drug] A drug with a new dosage in an additional dosage form indicated for the treatment of melanoma, unresectable or recurrent non-small cell lung cancer, unresectable or metastatic renal cell carcinoma, relapsed or refractory classical Hodgkin lymphoma, recurrent or metastatic head and neck cancer, unresectable or recurrent gastric cancer that has progressed after chemotherapy, and (3) unresectable or metastatic renal cell carcinoma. [(3) Priority review] uuid:97204c47-f1be-49fa-a2c5-85c5ae4eeb15 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:31YO63LBSN biolink:treats MONDO:0005112 PMID:41385096 "[{""id"":""uuid:5e870119-963d-43b4-a672-baafc869b6f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a131d818-51ae-4e6a-a6f8-7ce2a001f4ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:35472027-ee2a-455f-a57d-263feabd6a33"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OPDIVO is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of: Melanoma • adult and pediatric (12 years and older) patients with unresectable or metastatic melanoma, as a single agent or in combination with ipilimumab. (1.1) • for the adjuvant treatment of adult and pediatric patients 12 years and older with completely resected Stage IIB, Stage IIC, Stage III, or Stage IV melanoma. (1.2) Non-Small Cell Lung Cancer (NSCLC) • adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer in the neoadjuvant setting, in combination with platinum-doublet chemotherapy. (1.3) • adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer and no known EGFR mutations or ALK rearrangements, for neoadjuvant treatment, in combination with platinum-doublet chemotherapy, followed by single-agent OPDIVO as adjuvant treatment after surgery. (1.4) • adult patients with metastatic non-small cell lung cancer expressing PD‑L1 (≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, as first-line treatment in combination with ipilimumab. (1.5) • adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy. (1.5) • adult patients with metastatic non-small cell lung cancer and progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO. (1.5) Malignant Pleural Mesothelioma • adult patients with unresectable malignant pleural mesothelioma, as first-line treatment in combination with ipilimumab. (1.6) Renal Cell Carcinoma (RCC) • adult patients with intermediate or poor risk advanced renal cell carcinoma, as a first-line treatment in combination with ipilimumab. (1.7) • adult patients with advanced renal cell carcinoma, as a first-line treatment in combination with cabozantinib. (1.7) • adult patients with advanced renal cell carcinoma who have received prior anti-angiogenic therapy. (1.7) Classical Hodgkin Lymphoma (cHL) • adult patients with classical Hodgkin lymphoma that has relapsed or progressed after a : (1.8) • autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin, or • 3 or more lines of systemic therapy that includes autologous HSCT. Squamous Cell Carcinoma of the Head and Neck (SCCHN) • adult patients with recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after a platinum-based therapy. (1.9) Urothelial Carcinoma • adjuvant treatment of adult patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection of UC. (1.10) • adult patients with unresectable or metastatic urothelial carcinoma, as first-line treatment in combination with cisplatin and gemcitabine. (1.10) • adult patients with locally advanced or metastatic urothelial carcinoma who: • have disease progression during or following platinum-containing chemotherapy. • have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. (1.10) Colorectal Cancer • adult and pediatric (12 years and older) patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) in combination with ipilimumab. (1.11) • adult and pediatric (12 years and older) patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. ( 1.11 ) Hepatocellular Carcinoma (HCC) • adult patients with unresectable or metastatic hepatocellular carcinoma (HCC), as a first-line treatment in combination with ipilimumab. (1.12) • in combination with ipilimumab in adult patients with unresectable or metastatic HCC who have been previously treated with sorafenib. ( 1.12 ) Esophageal Cancer • adult patients with completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease, who have received neoadjuvant chemoradiotherapy (CRT). (1.13) • adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma as first-line treatment in combination with fluoropyrimidine- and platinum‑containing chemotherapy whose tumors express PD-L1 (≥1). (1.13) • adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma as first-line treatment in combination with ipilimumab whose tumors express PD-L1 (≥1). (1.13) • adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy. (1.13) Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma • adult patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma whose tumors express PD-L1 (≥1) in combination with fluoropyrimidine- and platinum-containing chemotherapy. (1.14) a This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.|[PMDA] A drug with new indications and a new dosage in an additional dosage form for the treatment of unresectable or recurrent malignant pleural mesothelioma and melanoma that have progressed after chemotherapy. [Orphan drug] A drug with a new dosage in an additional dosage form indicated for the treatment of melanoma, unresectable or recurrent non-small cell lung cancer, unresectable or metastatic renal cell carcinoma, relapsed or refractory classical Hodgkin lymphoma, recurrent or metastatic head and neck cancer, unresectable or recurrent gastric cancer that has progressed after chemotherapy, and (3) unresectable or metastatic renal cell carcinoma. [(3) Priority review] uuid:5feac1d0-9895-4579-8efb-b05b66f00fca biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:31YO63LBSN biolink:treats MONDO:0005086 PMID:41385096 "[{""id"":""uuid:5f1822bd-9ac6-4657-aa0e-e5c2fd7a0362"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:026aa016-3ece-4542-b686-eac3d37760a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:7d00528d-5372-49de-8d55-3161ab98690b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OPDIVO is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of: Melanoma • adult and pediatric (12 years and older) patients with unresectable or metastatic melanoma, as a single agent or in combination with ipilimumab. (1.1) • for the adjuvant treatment of adult and pediatric patients 12 years and older with completely resected Stage IIB, Stage IIC, Stage III, or Stage IV melanoma. (1.2) Non-Small Cell Lung Cancer (NSCLC) • adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer in the neoadjuvant setting, in combination with platinum-doublet chemotherapy. (1.3) • adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer and no known EGFR mutations or ALK rearrangements, for neoadjuvant treatment, in combination with platinum-doublet chemotherapy, followed by single-agent OPDIVO as adjuvant treatment after surgery. (1.4) • adult patients with metastatic non-small cell lung cancer expressing PD‑L1 (≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, as first-line treatment in combination with ipilimumab. (1.5) • adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy. (1.5) • adult patients with metastatic non-small cell lung cancer and progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO. (1.5) Malignant Pleural Mesothelioma • adult patients with unresectable malignant pleural mesothelioma, as first-line treatment in combination with ipilimumab. (1.6) Renal Cell Carcinoma (RCC) • adult patients with intermediate or poor risk advanced renal cell carcinoma, as a first-line treatment in combination with ipilimumab. (1.7) • adult patients with advanced renal cell carcinoma, as a first-line treatment in combination with cabozantinib. (1.7) • adult patients with advanced renal cell carcinoma who have received prior anti-angiogenic therapy. (1.7) Classical Hodgkin Lymphoma (cHL) • adult patients with classical Hodgkin lymphoma that has relapsed or progressed after a : (1.8) • autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin, or • 3 or more lines of systemic therapy that includes autologous HSCT. Squamous Cell Carcinoma of the Head and Neck (SCCHN) • adult patients with recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after a platinum-based therapy. (1.9) Urothelial Carcinoma • adjuvant treatment of adult patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection of UC. (1.10) • adult patients with unresectable or metastatic urothelial carcinoma, as first-line treatment in combination with cisplatin and gemcitabine. (1.10) • adult patients with locally advanced or metastatic urothelial carcinoma who: • have disease progression during or following platinum-containing chemotherapy. • have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. (1.10) Colorectal Cancer • adult and pediatric (12 years and older) patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) in combination with ipilimumab. (1.11) • adult and pediatric (12 years and older) patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. ( 1.11 ) Hepatocellular Carcinoma (HCC) • adult patients with unresectable or metastatic hepatocellular carcinoma (HCC), as a first-line treatment in combination with ipilimumab. (1.12) • in combination with ipilimumab in adult patients with unresectable or metastatic HCC who have been previously treated with sorafenib. ( 1.12 ) Esophageal Cancer • adult patients with completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease, who have received neoadjuvant chemoradiotherapy (CRT). (1.13) • adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma as first-line treatment in combination with fluoropyrimidine- and platinum‑containing chemotherapy whose tumors express PD-L1 (≥1). (1.13) • adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma as first-line treatment in combination with ipilimumab whose tumors express PD-L1 (≥1). (1.13) • adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy. (1.13) Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma • adult patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma whose tumors express PD-L1 (≥1) in combination with fluoropyrimidine- and platinum-containing chemotherapy. (1.14) a This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.|[PMDA] A drug with new indications and a new dosage in an additional dosage form for the treatment of unresectable or recurrent malignant pleural mesothelioma and melanoma that have progressed after chemotherapy. [Orphan drug] A drug with a new dosage in an additional dosage form indicated for the treatment of melanoma, unresectable or recurrent non-small cell lung cancer, unresectable or metastatic renal cell carcinoma, relapsed or refractory classical Hodgkin lymphoma, recurrent or metastatic head and neck cancer, unresectable or recurrent gastric cancer that has progressed after chemotherapy, and (3) unresectable or metastatic renal cell carcinoma. [(3) Priority review] uuid:c751dfa1-cc76-41bd-9e36-42be4a066278 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:31YO63LBSN biolink:treats MONDO:0004665 PMID:41385096 "[{""id"":""uuid:4c206848-428f-4044-903a-125509f3065c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:57c9e2d7-2453-482b-a59f-f864c83bdc78"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:4b3a37b5-1246-48be-8869-a64068cd4811"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OPDIVO is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of: Melanoma • adult and pediatric (12 years and older) patients with unresectable or metastatic melanoma, as a single agent or in combination with ipilimumab. (1.1) • for the adjuvant treatment of adult and pediatric patients 12 years and older with completely resected Stage IIB, Stage IIC, Stage III, or Stage IV melanoma. (1.2) Non-Small Cell Lung Cancer (NSCLC) • adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer in the neoadjuvant setting, in combination with platinum-doublet chemotherapy. (1.3) • adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer and no known EGFR mutations or ALK rearrangements, for neoadjuvant treatment, in combination with platinum-doublet chemotherapy, followed by single-agent OPDIVO as adjuvant treatment after surgery. (1.4) • adult patients with metastatic non-small cell lung cancer expressing PD‑L1 (≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, as first-line treatment in combination with ipilimumab. (1.5) • adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy. (1.5) • adult patients with metastatic non-small cell lung cancer and progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO. (1.5) Malignant Pleural Mesothelioma • adult patients with unresectable malignant pleural mesothelioma, as first-line treatment in combination with ipilimumab. (1.6) Renal Cell Carcinoma (RCC) • adult patients with intermediate or poor risk advanced renal cell carcinoma, as a first-line treatment in combination with ipilimumab. (1.7) • adult patients with advanced renal cell carcinoma, as a first-line treatment in combination with cabozantinib. (1.7) • adult patients with advanced renal cell carcinoma who have received prior anti-angiogenic therapy. (1.7) Classical Hodgkin Lymphoma (cHL) • adult patients with classical Hodgkin lymphoma that has relapsed or progressed after a : (1.8) • autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin, or • 3 or more lines of systemic therapy that includes autologous HSCT. Squamous Cell Carcinoma of the Head and Neck (SCCHN) • adult patients with recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after a platinum-based therapy. (1.9) Urothelial Carcinoma • adjuvant treatment of adult patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection of UC. (1.10) • adult patients with unresectable or metastatic urothelial carcinoma, as first-line treatment in combination with cisplatin and gemcitabine. (1.10) • adult patients with locally advanced or metastatic urothelial carcinoma who: • have disease progression during or following platinum-containing chemotherapy. • have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. (1.10) Colorectal Cancer • adult and pediatric (12 years and older) patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) in combination with ipilimumab. (1.11) • adult and pediatric (12 years and older) patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. ( 1.11 ) Hepatocellular Carcinoma (HCC) • adult patients with unresectable or metastatic hepatocellular carcinoma (HCC), as a first-line treatment in combination with ipilimumab. (1.12) • in combination with ipilimumab in adult patients with unresectable or metastatic HCC who have been previously treated with sorafenib. ( 1.12 ) Esophageal Cancer • adult patients with completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease, who have received neoadjuvant chemoradiotherapy (CRT). (1.13) • adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma as first-line treatment in combination with fluoropyrimidine- and platinum‑containing chemotherapy whose tumors express PD-L1 (≥1). (1.13) • adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma as first-line treatment in combination with ipilimumab whose tumors express PD-L1 (≥1). (1.13) • adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy. (1.13) Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma • adult patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma whose tumors express PD-L1 (≥1) in combination with fluoropyrimidine- and platinum-containing chemotherapy. (1.14) a This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.|[PMDA] A drug with new indications and a new dosage in an additional dosage form for the treatment of unresectable or recurrent malignant pleural mesothelioma and melanoma that have progressed after chemotherapy. [Orphan drug] A drug with a new dosage in an additional dosage form indicated for the treatment of melanoma, unresectable or recurrent non-small cell lung cancer, unresectable or metastatic renal cell carcinoma, relapsed or refractory classical Hodgkin lymphoma, recurrent or metastatic head and neck cancer, unresectable or recurrent gastric cancer that has progressed after chemotherapy, and (3) unresectable or metastatic renal cell carcinoma. [(3) Priority review] uuid:e0b7b43f-db0e-45be-aa18-9f362c317549 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:31YO63LBSN biolink:treats MONDO:0010150 PMID:41385096 "[{""id"":""uuid:162ebfd9-56ff-4b67-bcd3-c741ca54df5d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0b2fe969-da5f-4c91-bd49-f2ec1c89c578"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OPDIVO is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of: Melanoma • adult and pediatric (12 years and older) patients with unresectable or metastatic melanoma, as a single agent or in combination with ipilimumab. (1.1) • for the adjuvant treatment of adult and pediatric patients 12 years and older with completely resected Stage IIB, Stage IIC, Stage III, or Stage IV melanoma. (1.2) Non-Small Cell Lung Cancer (NSCLC) • adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer in the neoadjuvant setting, in combination with platinum-doublet chemotherapy. (1.3) • adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer and no known EGFR mutations or ALK rearrangements, for neoadjuvant treatment, in combination with platinum-doublet chemotherapy, followed by single-agent OPDIVO as adjuvant treatment after surgery. (1.4) • adult patients with metastatic non-small cell lung cancer expressing PD‑L1 (≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, as first-line treatment in combination with ipilimumab. (1.5) • adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy. (1.5) • adult patients with metastatic non-small cell lung cancer and progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO. (1.5) Malignant Pleural Mesothelioma • adult patients with unresectable malignant pleural mesothelioma, as first-line treatment in combination with ipilimumab. (1.6) Renal Cell Carcinoma (RCC) • adult patients with intermediate or poor risk advanced renal cell carcinoma, as a first-line treatment in combination with ipilimumab. (1.7) • adult patients with advanced renal cell carcinoma, as a first-line treatment in combination with cabozantinib. (1.7) • adult patients with advanced renal cell carcinoma who have received prior anti-angiogenic therapy. (1.7) Classical Hodgkin Lymphoma (cHL) • adult patients with classical Hodgkin lymphoma that has relapsed or progressed after a : (1.8) • autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin, or • 3 or more lines of systemic therapy that includes autologous HSCT. Squamous Cell Carcinoma of the Head and Neck (SCCHN) • adult patients with recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after a platinum-based therapy. (1.9) Urothelial Carcinoma • adjuvant treatment of adult patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection of UC. (1.10) • adult patients with unresectable or metastatic urothelial carcinoma, as first-line treatment in combination with cisplatin and gemcitabine. (1.10) • adult patients with locally advanced or metastatic urothelial carcinoma who: • have disease progression during or following platinum-containing chemotherapy. • have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. (1.10) Colorectal Cancer • adult and pediatric (12 years and older) patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) in combination with ipilimumab. (1.11) • adult and pediatric (12 years and older) patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. ( 1.11 ) Hepatocellular Carcinoma (HCC) • adult patients with unresectable or metastatic hepatocellular carcinoma (HCC), as a first-line treatment in combination with ipilimumab. (1.12) • in combination with ipilimumab in adult patients with unresectable or metastatic HCC who have been previously treated with sorafenib. ( 1.12 ) Esophageal Cancer • adult patients with completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease, who have received neoadjuvant chemoradiotherapy (CRT). (1.13) • adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma as first-line treatment in combination with fluoropyrimidine- and platinum‑containing chemotherapy whose tumors express PD-L1 (≥1). (1.13) • adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma as first-line treatment in combination with ipilimumab whose tumors express PD-L1 (≥1). (1.13) • adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy. (1.13) Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma • adult patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma whose tumors express PD-L1 (≥1) in combination with fluoropyrimidine- and platinum-containing chemotherapy. (1.14) a This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. uuid:fa3ad8a9-bf53-47ed-bee1-2fa1064ca7ae biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:31YO63LBSN biolink:treats MONDO:0040679 PMID:41385096 "[{""id"":""uuid:7c5f315b-8002-401e-a5da-ed9ed9e2ec5c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:13955ee3-dbd1-4cbe-af65-1b40937b8bc3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:020056b6-6755-4a60-bc44-21f74aaed67a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OPDIVO is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of: Melanoma • adult and pediatric (12 years and older) patients with unresectable or metastatic melanoma, as a single agent or in combination with ipilimumab. (1.1) • for the adjuvant treatment of adult and pediatric patients 12 years and older with completely resected Stage IIB, Stage IIC, Stage III, or Stage IV melanoma. (1.2) Non-Small Cell Lung Cancer (NSCLC) • adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer in the neoadjuvant setting, in combination with platinum-doublet chemotherapy. (1.3) • adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer and no known EGFR mutations or ALK rearrangements, for neoadjuvant treatment, in combination with platinum-doublet chemotherapy, followed by single-agent OPDIVO as adjuvant treatment after surgery. (1.4) • adult patients with metastatic non-small cell lung cancer expressing PD‑L1 (≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, as first-line treatment in combination with ipilimumab. (1.5) • adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy. (1.5) • adult patients with metastatic non-small cell lung cancer and progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO. (1.5) Malignant Pleural Mesothelioma • adult patients with unresectable malignant pleural mesothelioma, as first-line treatment in combination with ipilimumab. (1.6) Renal Cell Carcinoma (RCC) • adult patients with intermediate or poor risk advanced renal cell carcinoma, as a first-line treatment in combination with ipilimumab. (1.7) • adult patients with advanced renal cell carcinoma, as a first-line treatment in combination with cabozantinib. (1.7) • adult patients with advanced renal cell carcinoma who have received prior anti-angiogenic therapy. (1.7) Classical Hodgkin Lymphoma (cHL) • adult patients with classical Hodgkin lymphoma that has relapsed or progressed after a : (1.8) • autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin, or • 3 or more lines of systemic therapy that includes autologous HSCT. Squamous Cell Carcinoma of the Head and Neck (SCCHN) • adult patients with recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after a platinum-based therapy. (1.9) Urothelial Carcinoma • adjuvant treatment of adult patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection of UC. (1.10) • adult patients with unresectable or metastatic urothelial carcinoma, as first-line treatment in combination with cisplatin and gemcitabine. (1.10) • adult patients with locally advanced or metastatic urothelial carcinoma who: • have disease progression during or following platinum-containing chemotherapy. • have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. (1.10) Colorectal Cancer • adult and pediatric (12 years and older) patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) in combination with ipilimumab. (1.11) • adult and pediatric (12 years and older) patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. ( 1.11 ) Hepatocellular Carcinoma (HCC) • adult patients with unresectable or metastatic hepatocellular carcinoma (HCC), as a first-line treatment in combination with ipilimumab. (1.12) • in combination with ipilimumab in adult patients with unresectable or metastatic HCC who have been previously treated with sorafenib. ( 1.12 ) Esophageal Cancer • adult patients with completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease, who have received neoadjuvant chemoradiotherapy (CRT). (1.13) • adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma as first-line treatment in combination with fluoropyrimidine- and platinum‑containing chemotherapy whose tumors express PD-L1 (≥1). (1.13) • adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma as first-line treatment in combination with ipilimumab whose tumors express PD-L1 (≥1). (1.13) • adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy. (1.13) Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma • adult patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma whose tumors express PD-L1 (≥1) in combination with fluoropyrimidine- and platinum-containing chemotherapy. (1.14) a This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.|[PMDA] Drugs with a new indication and a new dosage for the postoperative adjuvant therapy for urothelial carcinoma. uuid:190ee8cc-84a6-43e3-86ee-7c9f5384864d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:31YO63LBSN biolink:treats MONDO:0005575 PMID:41385096 "[{""id"":""uuid:3aaef778-4b68-4b40-92e2-1af04f41f3f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:716874b0-c287-4bcd-9331-6507354c41c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:48b1ad56-4e29-4500-9cee-bf6219670930"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OPDIVO is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of: Melanoma • adult and pediatric (12 years and older) patients with unresectable or metastatic melanoma, as a single agent or in combination with ipilimumab. (1.1) • for the adjuvant treatment of adult and pediatric patients 12 years and older with completely resected Stage IIB, Stage IIC, Stage III, or Stage IV melanoma. (1.2) Non-Small Cell Lung Cancer (NSCLC) • adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer in the neoadjuvant setting, in combination with platinum-doublet chemotherapy. (1.3) • adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer and no known EGFR mutations or ALK rearrangements, for neoadjuvant treatment, in combination with platinum-doublet chemotherapy, followed by single-agent OPDIVO as adjuvant treatment after surgery. (1.4) • adult patients with metastatic non-small cell lung cancer expressing PD‑L1 (≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, as first-line treatment in combination with ipilimumab. (1.5) • adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy. (1.5) • adult patients with metastatic non-small cell lung cancer and progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO. (1.5) Malignant Pleural Mesothelioma • adult patients with unresectable malignant pleural mesothelioma, as first-line treatment in combination with ipilimumab. (1.6) Renal Cell Carcinoma (RCC) • adult patients with intermediate or poor risk advanced renal cell carcinoma, as a first-line treatment in combination with ipilimumab. (1.7) • adult patients with advanced renal cell carcinoma, as a first-line treatment in combination with cabozantinib. (1.7) • adult patients with advanced renal cell carcinoma who have received prior anti-angiogenic therapy. (1.7) Classical Hodgkin Lymphoma (cHL) • adult patients with classical Hodgkin lymphoma that has relapsed or progressed after a : (1.8) • autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin, or • 3 or more lines of systemic therapy that includes autologous HSCT. Squamous Cell Carcinoma of the Head and Neck (SCCHN) • adult patients with recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after a platinum-based therapy. (1.9) Urothelial Carcinoma • adjuvant treatment of adult patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection of UC. (1.10) • adult patients with unresectable or metastatic urothelial carcinoma, as first-line treatment in combination with cisplatin and gemcitabine. (1.10) • adult patients with locally advanced or metastatic urothelial carcinoma who: • have disease progression during or following platinum-containing chemotherapy. • have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. (1.10) Colorectal Cancer • adult and pediatric (12 years and older) patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) in combination with ipilimumab. (1.11) • adult and pediatric (12 years and older) patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. ( 1.11 ) Hepatocellular Carcinoma (HCC) • adult patients with unresectable or metastatic hepatocellular carcinoma (HCC), as a first-line treatment in combination with ipilimumab. (1.12) • in combination with ipilimumab in adult patients with unresectable or metastatic HCC who have been previously treated with sorafenib. ( 1.12 ) Esophageal Cancer • adult patients with completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease, who have received neoadjuvant chemoradiotherapy (CRT). (1.13) • adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma as first-line treatment in combination with fluoropyrimidine- and platinum‑containing chemotherapy whose tumors express PD-L1 (≥1). (1.13) • adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma as first-line treatment in combination with ipilimumab whose tumors express PD-L1 (≥1). (1.13) • adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy. (1.13) Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma • adult patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma whose tumors express PD-L1 (≥1) in combination with fluoropyrimidine- and platinum-containing chemotherapy. (1.14) a This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.|[PMDA] Drugs with a new dosage for the treatment of unresectable advanced or recurrent microsatellite instability-high (MSI-High) colorectal cancer that has progressed after cancer chemotherapy. Drugs with a new dosage for the treatment of melanoma, unresectable advanced or recurrent non- small cell lung cancer, unresectable or metastatic renal cell carcinoma, relapsed or refractory classical Hodgkin lymphoma, recurrent or metastatic head and neck cancer, unresectable advanced or recurrent gastric cancer that has progressed after cancer chemotherapy, unresectable advanced or recurrent malignant pleural mesothelioma that have progressed after cancer chemotherapy, unresectable advanced or recurrent microsatellite instability-high (MSI-High) colorectal cancer that has progressed after cancer chemotherapy, and unresectable advanced or recurrent esophageal cancer that has progressed after cancer chemotherapy. uuid:7169e6e0-95cc-4067-bd6b-c4a862926edb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:31YO63LBSN biolink:treats MONDO:0007256 PMID:41385096 "[{""id"":""uuid:12f4c458-135f-4716-affb-a102d47c656d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ceb52c21-f459-4396-9765-e5dd2d478779"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OPDIVO is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of: Melanoma • adult and pediatric (12 years and older) patients with unresectable or metastatic melanoma, as a single agent or in combination with ipilimumab. (1.1) • for the adjuvant treatment of adult and pediatric patients 12 years and older with completely resected Stage IIB, Stage IIC, Stage III, or Stage IV melanoma. (1.2) Non-Small Cell Lung Cancer (NSCLC) • adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer in the neoadjuvant setting, in combination with platinum-doublet chemotherapy. (1.3) • adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer and no known EGFR mutations or ALK rearrangements, for neoadjuvant treatment, in combination with platinum-doublet chemotherapy, followed by single-agent OPDIVO as adjuvant treatment after surgery. (1.4) • adult patients with metastatic non-small cell lung cancer expressing PD‑L1 (≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, as first-line treatment in combination with ipilimumab. (1.5) • adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy. (1.5) • adult patients with metastatic non-small cell lung cancer and progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO. (1.5) Malignant Pleural Mesothelioma • adult patients with unresectable malignant pleural mesothelioma, as first-line treatment in combination with ipilimumab. (1.6) Renal Cell Carcinoma (RCC) • adult patients with intermediate or poor risk advanced renal cell carcinoma, as a first-line treatment in combination with ipilimumab. (1.7) • adult patients with advanced renal cell carcinoma, as a first-line treatment in combination with cabozantinib. (1.7) • adult patients with advanced renal cell carcinoma who have received prior anti-angiogenic therapy. (1.7) Classical Hodgkin Lymphoma (cHL) • adult patients with classical Hodgkin lymphoma that has relapsed or progressed after a : (1.8) • autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin, or • 3 or more lines of systemic therapy that includes autologous HSCT. Squamous Cell Carcinoma of the Head and Neck (SCCHN) • adult patients with recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after a platinum-based therapy. (1.9) Urothelial Carcinoma • adjuvant treatment of adult patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection of UC. (1.10) • adult patients with unresectable or metastatic urothelial carcinoma, as first-line treatment in combination with cisplatin and gemcitabine. (1.10) • adult patients with locally advanced or metastatic urothelial carcinoma who: • have disease progression during or following platinum-containing chemotherapy. • have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. (1.10) Colorectal Cancer • adult and pediatric (12 years and older) patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) in combination with ipilimumab. (1.11) • adult and pediatric (12 years and older) patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. ( 1.11 ) Hepatocellular Carcinoma (HCC) • adult patients with unresectable or metastatic hepatocellular carcinoma (HCC), as a first-line treatment in combination with ipilimumab. (1.12) • in combination with ipilimumab in adult patients with unresectable or metastatic HCC who have been previously treated with sorafenib. ( 1.12 ) Esophageal Cancer • adult patients with completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease, who have received neoadjuvant chemoradiotherapy (CRT). (1.13) • adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma as first-line treatment in combination with fluoropyrimidine- and platinum‑containing chemotherapy whose tumors express PD-L1 (≥1). (1.13) • adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma as first-line treatment in combination with ipilimumab whose tumors express PD-L1 (≥1). (1.13) • adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy. (1.13) Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma • adult patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma whose tumors express PD-L1 (≥1) in combination with fluoropyrimidine- and platinum-containing chemotherapy. (1.14) a This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. uuid:32be2158-dc6a-465e-8aba-2475981f67ee biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:31YO63LBSN biolink:treats MONDO:0007576 PMID:41385096 "[{""id"":""uuid:d4f44a4a-2aca-46ee-b021-710c0b5ce060"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:fb372be2-6e29-4dd5-8df6-b7212d198d56"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:85e60472-9bb4-42b8-b191-b4ba415b521a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OPDIVO is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of: Melanoma • adult and pediatric (12 years and older) patients with unresectable or metastatic melanoma, as a single agent or in combination with ipilimumab. (1.1) • for the adjuvant treatment of adult and pediatric patients 12 years and older with completely resected Stage IIB, Stage IIC, Stage III, or Stage IV melanoma. (1.2) Non-Small Cell Lung Cancer (NSCLC) • adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer in the neoadjuvant setting, in combination with platinum-doublet chemotherapy. (1.3) • adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer and no known EGFR mutations or ALK rearrangements, for neoadjuvant treatment, in combination with platinum-doublet chemotherapy, followed by single-agent OPDIVO as adjuvant treatment after surgery. (1.4) • adult patients with metastatic non-small cell lung cancer expressing PD‑L1 (≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, as first-line treatment in combination with ipilimumab. (1.5) • adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy. (1.5) • adult patients with metastatic non-small cell lung cancer and progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO. (1.5) Malignant Pleural Mesothelioma • adult patients with unresectable malignant pleural mesothelioma, as first-line treatment in combination with ipilimumab. (1.6) Renal Cell Carcinoma (RCC) • adult patients with intermediate or poor risk advanced renal cell carcinoma, as a first-line treatment in combination with ipilimumab. (1.7) • adult patients with advanced renal cell carcinoma, as a first-line treatment in combination with cabozantinib. (1.7) • adult patients with advanced renal cell carcinoma who have received prior anti-angiogenic therapy. (1.7) Classical Hodgkin Lymphoma (cHL) • adult patients with classical Hodgkin lymphoma that has relapsed or progressed after a : (1.8) • autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin, or • 3 or more lines of systemic therapy that includes autologous HSCT. Squamous Cell Carcinoma of the Head and Neck (SCCHN) • adult patients with recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after a platinum-based therapy. (1.9) Urothelial Carcinoma • adjuvant treatment of adult patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection of UC. (1.10) • adult patients with unresectable or metastatic urothelial carcinoma, as first-line treatment in combination with cisplatin and gemcitabine. (1.10) • adult patients with locally advanced or metastatic urothelial carcinoma who: • have disease progression during or following platinum-containing chemotherapy. • have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. (1.10) Colorectal Cancer • adult and pediatric (12 years and older) patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) in combination with ipilimumab. (1.11) • adult and pediatric (12 years and older) patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. ( 1.11 ) Hepatocellular Carcinoma (HCC) • adult patients with unresectable or metastatic hepatocellular carcinoma (HCC), as a first-line treatment in combination with ipilimumab. (1.12) • in combination with ipilimumab in adult patients with unresectable or metastatic HCC who have been previously treated with sorafenib. ( 1.12 ) Esophageal Cancer • adult patients with completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease, who have received neoadjuvant chemoradiotherapy (CRT). (1.13) • adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma as first-line treatment in combination with fluoropyrimidine- and platinum‑containing chemotherapy whose tumors express PD-L1 (≥1). (1.13) • adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma as first-line treatment in combination with ipilimumab whose tumors express PD-L1 (≥1). (1.13) • adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy. (1.13) Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma • adult patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma whose tumors express PD-L1 (≥1) in combination with fluoropyrimidine- and platinum-containing chemotherapy. (1.14) a This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.|[PMDA] Drugs with a new dosage for the treatment of unresectable advanced or recurrent microsatellite instability-high (MSI-High) colorectal cancer that has progressed after cancer chemotherapy. Drugs with a new dosage for the treatment of melanoma, unresectable advanced or recurrent non- small cell lung cancer, unresectable or metastatic renal cell carcinoma, relapsed or refractory classical Hodgkin lymphoma, recurrent or metastatic head and neck cancer, unresectable advanced or recurrent gastric cancer that has progressed after cancer chemotherapy, unresectable advanced or recurrent malignant pleural mesothelioma that have progressed after cancer chemotherapy, unresectable advanced or recurrent microsatellite instability-high (MSI-High) colorectal cancer that has progressed after cancer chemotherapy, and unresectable advanced or recurrent esophageal cancer that has progressed after cancer chemotherapy. uuid:ece7ee9e-d623-4e6d-bf32-1833b7eb0cc0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:31YO63LBSN biolink:treats UMLS:C5400195 PMID:41385096 "[{""id"":""uuid:fe975540-95c0-4c73-a1e6-cb21dc7406b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d5bd1d52-1297-445e-9afd-ed3447d41900"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OPDIVO is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of: Melanoma • adult and pediatric (12 years and older) patients with unresectable or metastatic melanoma, as a single agent or in combination with ipilimumab. (1.1) • for the adjuvant treatment of adult and pediatric patients 12 years and older with completely resected Stage IIB, Stage IIC, Stage III, or Stage IV melanoma. (1.2) Non-Small Cell Lung Cancer (NSCLC) • adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer in the neoadjuvant setting, in combination with platinum-doublet chemotherapy. (1.3) • adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer and no known EGFR mutations or ALK rearrangements, for neoadjuvant treatment, in combination with platinum-doublet chemotherapy, followed by single-agent OPDIVO as adjuvant treatment after surgery. (1.4) • adult patients with metastatic non-small cell lung cancer expressing PD‑L1 (≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, as first-line treatment in combination with ipilimumab. (1.5) • adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy. (1.5) • adult patients with metastatic non-small cell lung cancer and progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO. (1.5) Malignant Pleural Mesothelioma • adult patients with unresectable malignant pleural mesothelioma, as first-line treatment in combination with ipilimumab. (1.6) Renal Cell Carcinoma (RCC) • adult patients with intermediate or poor risk advanced renal cell carcinoma, as a first-line treatment in combination with ipilimumab. (1.7) • adult patients with advanced renal cell carcinoma, as a first-line treatment in combination with cabozantinib. (1.7) • adult patients with advanced renal cell carcinoma who have received prior anti-angiogenic therapy. (1.7) Classical Hodgkin Lymphoma (cHL) • adult patients with classical Hodgkin lymphoma that has relapsed or progressed after a : (1.8) • autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin, or • 3 or more lines of systemic therapy that includes autologous HSCT. Squamous Cell Carcinoma of the Head and Neck (SCCHN) • adult patients with recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after a platinum-based therapy. (1.9) Urothelial Carcinoma • adjuvant treatment of adult patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection of UC. (1.10) • adult patients with unresectable or metastatic urothelial carcinoma, as first-line treatment in combination with cisplatin and gemcitabine. (1.10) • adult patients with locally advanced or metastatic urothelial carcinoma who: • have disease progression during or following platinum-containing chemotherapy. • have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. (1.10) Colorectal Cancer • adult and pediatric (12 years and older) patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) in combination with ipilimumab. (1.11) • adult and pediatric (12 years and older) patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. ( 1.11 ) Hepatocellular Carcinoma (HCC) • adult patients with unresectable or metastatic hepatocellular carcinoma (HCC), as a first-line treatment in combination with ipilimumab. (1.12) • in combination with ipilimumab in adult patients with unresectable or metastatic HCC who have been previously treated with sorafenib. ( 1.12 ) Esophageal Cancer • adult patients with completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease, who have received neoadjuvant chemoradiotherapy (CRT). (1.13) • adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma as first-line treatment in combination with fluoropyrimidine- and platinum‑containing chemotherapy whose tumors express PD-L1 (≥1). (1.13) • adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma as first-line treatment in combination with ipilimumab whose tumors express PD-L1 (≥1). (1.13) • adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy. (1.13) Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma • adult patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma whose tumors express PD-L1 (≥1) in combination with fluoropyrimidine- and platinum-containing chemotherapy. (1.14) a This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. uuid:be14274e-c6dc-4825-ac88-86a977995298 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:31YO63LBSN biolink:treats MONDO:0005028 PMID:41385096 "[{""id"":""uuid:8a44f35f-b877-4cc5-85ba-bc1298f83624"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ce7e51a9-0493-4ec5-867e-dc64f715d485"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OPDIVO is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of: Melanoma • adult and pediatric (12 years and older) patients with unresectable or metastatic melanoma, as a single agent or in combination with ipilimumab. (1.1) • for the adjuvant treatment of adult and pediatric patients 12 years and older with completely resected Stage IIB, Stage IIC, Stage III, or Stage IV melanoma. (1.2) Non-Small Cell Lung Cancer (NSCLC) • adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer in the neoadjuvant setting, in combination with platinum-doublet chemotherapy. (1.3) • adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer and no known EGFR mutations or ALK rearrangements, for neoadjuvant treatment, in combination with platinum-doublet chemotherapy, followed by single-agent OPDIVO as adjuvant treatment after surgery. (1.4) • adult patients with metastatic non-small cell lung cancer expressing PD‑L1 (≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, as first-line treatment in combination with ipilimumab. (1.5) • adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy. (1.5) • adult patients with metastatic non-small cell lung cancer and progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO. (1.5) Malignant Pleural Mesothelioma • adult patients with unresectable malignant pleural mesothelioma, as first-line treatment in combination with ipilimumab. (1.6) Renal Cell Carcinoma (RCC) • adult patients with intermediate or poor risk advanced renal cell carcinoma, as a first-line treatment in combination with ipilimumab. (1.7) • adult patients with advanced renal cell carcinoma, as a first-line treatment in combination with cabozantinib. (1.7) • adult patients with advanced renal cell carcinoma who have received prior anti-angiogenic therapy. (1.7) Classical Hodgkin Lymphoma (cHL) • adult patients with classical Hodgkin lymphoma that has relapsed or progressed after a : (1.8) • autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin, or • 3 or more lines of systemic therapy that includes autologous HSCT. Squamous Cell Carcinoma of the Head and Neck (SCCHN) • adult patients with recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after a platinum-based therapy. (1.9) Urothelial Carcinoma • adjuvant treatment of adult patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection of UC. (1.10) • adult patients with unresectable or metastatic urothelial carcinoma, as first-line treatment in combination with cisplatin and gemcitabine. (1.10) • adult patients with locally advanced or metastatic urothelial carcinoma who: • have disease progression during or following platinum-containing chemotherapy. • have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. (1.10) Colorectal Cancer • adult and pediatric (12 years and older) patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) in combination with ipilimumab. (1.11) • adult and pediatric (12 years and older) patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. ( 1.11 ) Hepatocellular Carcinoma (HCC) • adult patients with unresectable or metastatic hepatocellular carcinoma (HCC), as a first-line treatment in combination with ipilimumab. (1.12) • in combination with ipilimumab in adult patients with unresectable or metastatic HCC who have been previously treated with sorafenib. ( 1.12 ) Esophageal Cancer • adult patients with completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease, who have received neoadjuvant chemoradiotherapy (CRT). (1.13) • adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma as first-line treatment in combination with fluoropyrimidine- and platinum‑containing chemotherapy whose tumors express PD-L1 (≥1). (1.13) • adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma as first-line treatment in combination with ipilimumab whose tumors express PD-L1 (≥1). (1.13) • adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy. (1.13) Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma • adult patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma whose tumors express PD-L1 (≥1) in combination with fluoropyrimidine- and platinum-containing chemotherapy. (1.14) a This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. uuid:b1ac8c4d-7c9a-4096-b41e-ea20cc2b57ca biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:31YO63LBSN biolink:treats MONDO:0001056 PMID:41385096 "[{""id"":""uuid:c463675e-6b91-4ed8-b6e3-fe89a330b8fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:bf28a1b0-257c-4b4d-bb20-829c89ce8c1a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:5ecaadd3-6866-4710-859e-b91c767c6b9c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OPDIVO is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of: Melanoma • adult and pediatric (12 years and older) patients with unresectable or metastatic melanoma, as a single agent or in combination with ipilimumab. (1.1) • for the adjuvant treatment of adult and pediatric patients 12 years and older with completely resected Stage IIB, Stage IIC, Stage III, or Stage IV melanoma. (1.2) Non-Small Cell Lung Cancer (NSCLC) • adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer in the neoadjuvant setting, in combination with platinum-doublet chemotherapy. (1.3) • adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer and no known EGFR mutations or ALK rearrangements, for neoadjuvant treatment, in combination with platinum-doublet chemotherapy, followed by single-agent OPDIVO as adjuvant treatment after surgery. (1.4) • adult patients with metastatic non-small cell lung cancer expressing PD‑L1 (≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, as first-line treatment in combination with ipilimumab. (1.5) • adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy. (1.5) • adult patients with metastatic non-small cell lung cancer and progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO. (1.5) Malignant Pleural Mesothelioma • adult patients with unresectable malignant pleural mesothelioma, as first-line treatment in combination with ipilimumab. (1.6) Renal Cell Carcinoma (RCC) • adult patients with intermediate or poor risk advanced renal cell carcinoma, as a first-line treatment in combination with ipilimumab. (1.7) • adult patients with advanced renal cell carcinoma, as a first-line treatment in combination with cabozantinib. (1.7) • adult patients with advanced renal cell carcinoma who have received prior anti-angiogenic therapy. (1.7) Classical Hodgkin Lymphoma (cHL) • adult patients with classical Hodgkin lymphoma that has relapsed or progressed after a : (1.8) • autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin, or • 3 or more lines of systemic therapy that includes autologous HSCT. Squamous Cell Carcinoma of the Head and Neck (SCCHN) • adult patients with recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after a platinum-based therapy. (1.9) Urothelial Carcinoma • adjuvant treatment of adult patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection of UC. (1.10) • adult patients with unresectable or metastatic urothelial carcinoma, as first-line treatment in combination with cisplatin and gemcitabine. (1.10) • adult patients with locally advanced or metastatic urothelial carcinoma who: • have disease progression during or following platinum-containing chemotherapy. • have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. (1.10) Colorectal Cancer • adult and pediatric (12 years and older) patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) in combination with ipilimumab. (1.11) • adult and pediatric (12 years and older) patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. ( 1.11 ) Hepatocellular Carcinoma (HCC) • adult patients with unresectable or metastatic hepatocellular carcinoma (HCC), as a first-line treatment in combination with ipilimumab. (1.12) • in combination with ipilimumab in adult patients with unresectable or metastatic HCC who have been previously treated with sorafenib. ( 1.12 ) Esophageal Cancer • adult patients with completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease, who have received neoadjuvant chemoradiotherapy (CRT). (1.13) • adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma as first-line treatment in combination with fluoropyrimidine- and platinum‑containing chemotherapy whose tumors express PD-L1 (≥1). (1.13) • adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma as first-line treatment in combination with ipilimumab whose tumors express PD-L1 (≥1). (1.13) • adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy. (1.13) Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma • adult patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma whose tumors express PD-L1 (≥1) in combination with fluoropyrimidine- and platinum-containing chemotherapy. (1.14) a This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.|[PMDA] A drug with new indications and a new dosage in an additional dosage form for the treatment of unresectable or recurrent malignant pleural mesothelioma and melanoma that have progressed after chemotherapy. [Orphan drug] A drug with a new dosage in an additional dosage form indicated for the treatment of melanoma, unresectable or recurrent non-small cell lung cancer, unresectable or metastatic renal cell carcinoma, relapsed or refractory classical Hodgkin lymphoma, recurrent or metastatic head and neck cancer, unresectable or recurrent gastric cancer that has progressed after chemotherapy, and (3) unresectable or metastatic renal cell carcinoma. [(3) Priority review] uuid:77cd2978-8f42-4f01-84a6-1684ca55022a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:TY3V24C029 biolink:treats MONDO:0005010 PMID:41385096 "[{""id"":""uuid:51922634-b92c-4676-860b-da4f2f997adb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:09a54388-d789-4e40-82db-c1692bc99d9a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FLYRCADO is indicated for positron emission tomography (PET) myocardial perfusion imaging (MPI) under rest or stress (pharmacologic or exercise) in adult patients with known or suspected coronary artery disease (CAD) to evaluate for myocardial ischemia and infarction. ( 1 ) uuid:35c233c9-1e5f-4739-8f34-e6e0213cb94f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:TY3V24C029 biolink:treats MONDO:0024644 PMID:41385096 "[{""id"":""uuid:e0b6cc4c-ddbb-4e8c-94fe-ebf84af5ebf1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b702409e-cca5-4d42-87c2-72c314bf0b9d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FLYRCADO is indicated for positron emission tomography (PET) myocardial perfusion imaging (MPI) under rest or stress (pharmacologic or exercise) in adult patients with known or suspected coronary artery disease (CAD) to evaluate for myocardial ischemia and infarction. ( 1 ) uuid:e1024dca-9b66-49bc-bf0b-e2dcd8d221be biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:TY3V24C029 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:ee6f2f0f-b9ad-41fa-8bc3-6f02ef31bad1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a93800c9-342a-4376-a273-5f3b0281d976"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FLYRCADO is indicated for positron emission tomography (PET) myocardial perfusion imaging (MPI) under rest or stress (pharmacologic or exercise) in adult patients with known or suspected coronary artery disease (CAD) to evaluate for myocardial ischemia and infarction. ( 1 ) uuid:a95fde8f-6196-473c-aacc-017e669f00a7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:EO144CP0X9 biolink:treats MONDO:0009290 PMID:41385096 "[{""id"":""uuid:882e7325-a00e-4167-8ff7-f25a92e6e52c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:03e0f2d9-5185-4d7b-8211-fd8b2a1d8b93"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:819c6fe3-3a50-45f9-b714-22298817c9bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/nexviadyme""]},{""id"":""uuid:597ee2e8-98b6-45f8-b0a8-b950eb73ec7e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NEXVIAZYME is indicated for the treatment of patients 1 year of age and older with late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency).|[EMA] Nexviadyme (avalglucosidase alfa) is indicated for long-term enzyme replacement therapy for the treatment of patients with Pompe disease (acid α-glucosidase deficiency).|[PMDA] A drug with a new active ingredient indicated for the treatment of Pompe disease. [Orphan drug] uuid:b8d7c553-163c-4cf7-8a8a-479554907075 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17347 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:0b09755c-cf1a-4854-93b7-3525c5c38487"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cbd156a0-9277-4090-9cc4-5f3dea57e29a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Males Testosterone enanthate injection is indicated for replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone. Primary hypogonadism (congenital or acquired) – Testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, or orchidectomy. Hypogonadotropic hypogonadism (congenital or acquired) – Gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation. (Appropriate adrenal cortical and thyroid hormone replacement therapy are still necessary, however, and are actually of primary importance.) If the above conditions occur prior to puberty, androgen replacement therapy will be needed during the adolescent years for development of secondary sexual characteristics. Prolonged androgen treatment will be required to maintain sexual characteristics in these and other males who develop testosterone deficiency after puberty. Safety and efficacy of testosterone enanthate injection in men with age-related hypogonadism have not been established. Delayed puberty – Testosterone enanthate injection may be used to stimulate puberty in carefully selected males with clearly delayed puberty. These patients usually have a familial pattern of delayed puberty that is not secondary to a pathological disorder; puberty is expected to occur spontaneously at a relatively late date. Brief treatment with conservative doses may occasionally be justified in these patients if they do not respond to psychological support. The potential adverse effect on bone maturation should be discussed with the patient and parents prior to androgen administration. An X-ray of the hand and wrist to determine bone age should be obtained every six months to assess the effect of treatment on the epiphyseal centers (see WARNINGS ). Females Metastatic mammary cancer – Testosterone enanthate injection may be used secondarily in women with advancing inoperable metastatic (skeletal) mammary cancer who are one to five years postmenopausal. Primary goals of therapy in these women include ablation of the ovaries. Other methods of counteracting estrogen activity are adrenalectomy, hypophysectomy, and/or antiestrogen therapy. This treatment has also been used in premenopausal women with breast cancer who have benefited from oophorectomy and are considered to have a hormone-responsive tumor. Judgment concerning androgen therapy should be made by an oncologist with expertise in this field. uuid:1fb4811c-f1d4-495e-973b-3bf04439bf35 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135810 biolink:treats MONDO:0005342 PMID:41385096 "[{""id"":""uuid:89570c2d-46e3-461b-aa4b-f7f25d87e6ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ad0e8a6a-8732-47a7-9b2a-453d3960ac9a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VANRAFIA is indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥ 1.5 g/g. This indication is approved under accelerated approval based on a reduction of proteinuria [see Clinical Studies (14.1)] . It has not been established whether VANRAFIA slows kidney function decline in patients with IgAN. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory clinical trial. uuid:8fef3a9c-e583-4e25-8690-249d8859b1f9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135810 biolink:treats MONDO:0008072 PMID:41385096 "[{""id"":""uuid:254afaa9-c78e-4838-bc43-e07938ae7e43"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:80bb385d-2ea1-4c82-af4a-2f30beede00d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VANRAFIA is indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥ 1.5 g/g. This indication is approved under accelerated approval based on a reduction of proteinuria [see Clinical Studies (14.1)] . It has not been established whether VANRAFIA slows kidney function decline in patients with IgAN. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory clinical trial. uuid:ec8a4ea3-95d0-41a0-aa83-c5c39281f9bb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29108 biolink:treats MONDO:0002492 PMID:41385096 "[{""id"":""uuid:9b7136aa-431c-430e-b4b7-f8dcc5afa88f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bc955048-eb60-4fe4-943a-f95699a3b09e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DIANEAL peritoneal dialysis solutions are indicated for patients in acute or chronic renal failure. uuid:895542c0-3fff-4d27-90dc-6b0fceb2e298 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0000004 PMID:41385096 "[{""id"":""uuid:94b113b5-3471-4b30-8d2e-4ce04de5d16b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:96e995ed-ae99-45af-aede-cbc6796e5553"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:68cc3624-944a-48f7-a10f-b51ffd37e8b2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0018479 PMID:41385096 "[{""id"":""uuid:421bb081-cce8-453d-b62c-d8817819a078"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cb8244bd-8d7a-4604-8275-53cd3cacdf18"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:30df1511-b9ff-43cc-95a0-0b33116a28d0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0006982 PMID:41385096 "[{""id"":""uuid:662992a2-756f-4616-a503-d45feff1ed47"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:58b3c653-42b4-4bdd-b20e-c42697423068"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:cafd3321-ad57-48af-880d-c2059bcdd295 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0043455 PMID:41385096 "[{""id"":""uuid:cf279352-b35d-431d-99da-5dbf98f7e611"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b6cdc7d8-7150-4bd6-a3cc-71f321175a67"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:aec24dcf-c6d6-42d7-90bd-474f63908542 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0011849 PMID:41385096 "[{""id"":""uuid:3a4ff216-8718-4d6c-b9a0-9906aed0f0bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:568b1611-f792-4147-8e1a-df62a8d22bfc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:42927a83-ceae-4ec9-af1c-0b53c5219501 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:f1ab937e-5983-450f-9c28-9bd247d4cf3c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:db29abdb-e31e-4b3b-8018-d192e08791cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:df02a8e8-e58a-4d14-a222-a08e1059c158 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0011429 PMID:41385096 "[{""id"":""uuid:6e4ae701-b943-46d9-ad91-3b741e552627"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:775be941-b910-4dff-b38e-15cbd1c783e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:06408174-c559-4b1a-b865-11117768e93f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0005306 PMID:41385096 "[{""id"":""uuid:4df63e57-48cf-422a-a2ca-df7e46857c97"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fbe55ed4-91b3-4807-b0f5-dd4b06fac642"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:23c4252d-07b9-47d2-9f3a-b53548b85dd7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats UMLS:C1290158 PMID:41385096 "[{""id"":""uuid:a9f45823-3b9e-4fc3-8f09-91d9a4622ec1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:78fb4096-0ae0-4513-ac12-93fd0cb79bbb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:ec869015-ac03-45ab-b554-6a9de61fe83f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0040698 PMID:41385096 "[{""id"":""uuid:6cff2e6f-1b35-4390-9ba9-4e1f0eabb3e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4c7cb004-6a64-412d-a966-94ddb4550e66"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:31f85b9b-6101-44b7-b77e-24e2b71c868f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0004855 PMID:41385096 "[{""id"":""uuid:d3b4921d-7863-4b98-8b94-d395f67ebc0f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:24aa0221-9f1b-49c6-84bf-7c78c6588723"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:2304db10-f174-46d0-b28c-aae9aa10cd27 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats UMLS:C0149896 PMID:41385096 "[{""id"":""uuid:b7ff658d-b7b8-4319-a6e4-a1423bc9a02d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:47aad066-28be-4c22-b964-57f4b8324140"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:e3c6e183-fbeb-495e-94b9-237949a00286 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0005178 PMID:41385096 "[{""id"":""uuid:9d369945-36d0-4159-bc55-623e84563e9c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:98e29c53-04a5-451f-9d3b-7209296793ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:77eafbd2-cb12-4107-af7b-c7c355fcb944 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0001875 PMID:41385096 "[{""id"":""uuid:b2ff441c-90da-4d4c-9f02-6aa070eed177"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:76d76754-07ce-4bad-8fd3-cbb6b0cce545"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:cf0ab006-da78-4bd3-9536-c2ef8de51030 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats UMLS:C5441648 PMID:41385096 "[{""id"":""uuid:bb80405f-3fa9-439f-b8dc-36caa02dbe28"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:042212a5-8075-4b2c-8779-3fa59d90f7b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:a04f49e3-7f85-4717-a881-c6c2334aede4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0016367 PMID:41385096 "[{""id"":""uuid:5d6d405d-94c3-435e-a2b9-fffec847aac7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:126a94d6-810d-494e-8b6f-fc237b2a53b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:0c70842e-deeb-4e62-b0a2-1cb403b01750 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0019127 PMID:41385096 "[{""id"":""uuid:5ab2561c-f535-4a54-babe-b26a80c7dddb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:344d3fb3-3a5b-4ac0-bff0-485274fce615"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:5bb2467b-c701-48c4-8a89-c25ea88346cd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0006594 PMID:41385096 "[{""id"":""uuid:99d9f5f6-8f6e-43de-a42e-ecafc7587ab1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:60e2bd4f-5fa8-4ca2-9e35-0fc730d0ec26"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:6171377b-aefd-4961-b02f-6f3576c807bf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0015614 PMID:41385096 "[{""id"":""uuid:11f43cfc-5dc6-4d7f-8a95-3433df4b711f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1fe9ec0f-987b-4e16-bbf5-53fa2f902ec3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:26efc7f9-1061-4797-b416-583638abdd19 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0006545 PMID:41385096 "[{""id"":""uuid:b14afb8b-f43f-4639-9819-7c6ca10712b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8e34dc4a-448c-42e1-966c-5b09f5186cb1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:420b9b9d-afa7-4c79-8137-45f2db098f4e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0018229 PMID:41385096 "[{""id"":""uuid:d685c621-d7af-4717-9773-2e7ef014045f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5933257a-fa7a-4f25-aa58-54b07f0906f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:b0c5773a-a366-4fc8-9edb-75dfdf024b2c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0043233 PMID:41385096 "[{""id"":""uuid:b0298283-2a43-41f7-9d01-8f1324fba3fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:47e0d5dd-df52-41ae-8312-db2d4fbf901f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:849e1eb6-fbb9-4dca-96a9-7c062bf25240 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0009691 PMID:41385096 "[{""id"":""uuid:4ebedd1b-6d25-43fe-83f7-32adec5f00c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a9c1767b-da90-4eac-9ead-b26519cefe49"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:2b527bbd-460d-4a17-bf25-f4d8014cb90c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0005083 PMID:41385096 "[{""id"":""uuid:16f954e3-1eb9-42ab-8c7c-986014969872"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d1e3e243-8dd2-4207-8d69-cbc1552fced6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:47142279-8ec5-4e02-86b6-a72b717377f5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0006608 PMID:41385096 "[{""id"":""uuid:3065c363-3bd8-40fb-880c-8dc05e239ae7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e30e49fe-9325-49a0-ad22-ef8b2b65a04d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:e36b1dfb-73c2-4b80-8c16-b482d1fbdd45 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0005324 PMID:41385096 "[{""id"":""uuid:565405f9-a785-4127-a312-7e3615537bfe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:de2807df-d11a-44fd-aa49-efa646a46e4d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:028b4850-3231-4a8f-b82f-da4f0e5edcf7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0024332 PMID:41385096 "[{""id"":""uuid:0867a330-3d23-47aa-86e0-f322e43d0a3d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1a56c7a7-8e13-480e-98b2-5c4d1cda7914"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:c6e0a823-5297-47a5-ab61-e29f15827f1c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:b3feb0e1-2fe5-4497-82a7-91f980bed99b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:04957095-143a-4f4a-9262-d571127e1c5f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:1dd7de56-8f3e-4ba8-ae6d-fb4cf36f2e39 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0005480 PMID:41385096 "[{""id"":""uuid:edfc0513-0f11-4c3b-b2b6-3a7a39c269bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6bef477a-4519-4484-93df-85788f352464"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:49c22c9c-95d8-4853-a48b-fadbb8f35d2d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:47a69844-75b5-4987-bfb6-0efba0358e86"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7ec277bf-9e0a-4670-b12f-5642dc68df58"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:2026571c-5b7b-45d2-acc0-7e1438f2e9c3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0043789 PMID:41385096 "[{""id"":""uuid:d3562b15-de38-4d4c-827b-9d26512ec3f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2398d7e7-93c3-4765-bd23-9e2f934c98b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:9b94f893-27f5-46d5-a746-b8593669d1e7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0000775 PMID:41385096 "[{""id"":""uuid:44aa9de9-784b-48d0-bf2c-f62490912654"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:de4a84e5-3bc7-4d2f-bdc7-f450e45103a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:ccf60fd7-fbb3-444a-a42d-b1a12a4ccfc0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0003085 PMID:41385096 "[{""id"":""uuid:291ac739-1f99-46dd-9d47-db146a373a8b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c9c92db6-2f48-47ec-b28c-618d6da44098"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:32680dcc-b833-47f0-8695-8655e97d49b4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0001034 PMID:41385096 "[{""id"":""uuid:8e1ff0f7-a830-47f1-9bda-5ec4bc4ef085"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a7f22bdb-12fa-43e7-99b6-e1f0cd184202"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:df705a33-22ca-46ee-a866-644b81b507e8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0005883 PMID:41385096 "[{""id"":""uuid:fcd2c883-5113-442b-888b-6c890803e590"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:51f0e197-fa2f-4927-b695-26f570c90f8a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:153a4a1f-45ea-4613-8e4e-f5e6f2a81f7b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0006814 PMID:41385096 "[{""id"":""uuid:a1d0e90c-2d49-447f-8462-1a232df57514"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b9a729e8-7226-4f5e-93f3-57d023057f7e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:257c93bf-da63-4f49-98f9-6660717e06b4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0004773 PMID:41385096 "[{""id"":""uuid:7f08352b-e22d-40c4-9c92-16d4bc8d3777"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2f8a60ad-566e-4a08-b4df-0e38ecf9433c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:43e1a975-0eb5-4498-8ae3-ee99ae8fedec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0004674 PMID:41385096 "[{""id"":""uuid:cd677765-6601-4ce4-8feb-205ba619a8c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a38d5c20-4baa-4dd9-a95a-092dd43fd603"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:bc5f9524-3a80-4fab-8e4f-0d7efc267107 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0006651 PMID:41385096 "[{""id"":""uuid:8d8dc8fc-3ea6-478b-ba18-bf813f7d0eb2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dab664fa-048d-42a8-b332-c250116ad845"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:114bc4fc-c64f-47b6-aaef-6e1c1e4527d3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0006918 PMID:41385096 "[{""id"":""uuid:94ac4b40-bc7b-41e7-829c-1c3d97ac4d25"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bc175846-561a-4b15-9c18-5c1f5fd359a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:33c73437-5b40-48a6-99ed-613067ad7115 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0001280 PMID:41385096 "[{""id"":""uuid:e39fcb7f-fe7e-43e0-bce5-bc2da2fc83d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:46cc3668-1dab-4a21-a78d-2beba9b6279d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:499c2742-f237-4e86-8246-b78747c500f5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0005885 PMID:41385096 "[{""id"":""uuid:e82e0f61-8e97-4752-b9de-4b2101f00d9d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4e509b57-a5a5-4f92-852f-290d507319fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:ea86c004-7661-4639-994a-58efac493a41 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0019198 PMID:41385096 "[{""id"":""uuid:39c0dc93-cf74-49d4-9198-5ddea7e7e4bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:95658986-c55e-44a2-a96f-32fbead6ea6c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:d4fa44cb-1696-4ea9-ad3a-f566979710c5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0019338 PMID:41385096 "[{""id"":""uuid:4227a435-c04e-4c5f-9061-33d1e99f5e1e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7e2dcf51-5702-4766-9db9-5a763a549ced"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:020cd248-f466-43fe-879b-2f8d57411c88 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0015274 PMID:41385096 "[{""id"":""uuid:fd7b5567-34b0-4284-b035-a4052d92ab6b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3f39f2ef-ca90-4ef5-b260-dd3b6b8755b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:2d7807ab-682f-44b3-b92b-d3832cbac40c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0006052 PMID:41385096 "[{""id"":""uuid:aba27448-e838-4f38-b4e7-b1ec8cb29a96"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:74e38bb4-259c-4a49-b9d0-81b5f980010b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:26f531c9-970a-48ce-9518-c1dc7c27e5d7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0005848 PMID:41385096 "[{""id"":""uuid:890f8d79-66e8-4859-b78c-01ce5f78b1b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:25f23d9e-9046-4431-896f-cbc9313747ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:faf28171-4980-4243-84ba-1c921887527a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0002572 PMID:41385096 "[{""id"":""uuid:4138e511-0844-49b8-a592-a1b716d96654"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:64bc93be-e3a8-45de-a652-f2070ab7f601"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:e4f5e439-0ef6-48f5-86e3-3cca3ada5838 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0019098 PMID:41385096 "[{""id"":""uuid:bbaf19a4-13b0-4a27-a288-20a5edda2780"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b71c9683-6f46-4cc2-b021-6f5fe8e337b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:44ea8e2e-3b8d-4862-a358-f834fc57dc37 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0001198 PMID:41385096 "[{""id"":""uuid:51f70459-757f-4bc1-93cf-368e5968c697"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4ef608e1-9bb2-4c56-9ff9-653e3d1fa784"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:35972368-85a4-4306-8b83-16e023769b1b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats UMLS:C0002879 PMID:41385096 "[{""id"":""uuid:5e2e4832-0831-413a-9b95-c5a58b47abe0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9ff9d331-f4a3-4076-a217-bd7a57e3b2a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:266dda0d-12fa-4f6e-b3d1-639b3112817c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0020108 PMID:41385096 "[{""id"":""uuid:c09b8980-7f5f-4d00-beee-9fcec3de74ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c062e501-42d7-4ccd-b027-98d927131cb4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:a0137fcb-4e90-47a3-95a3-fc5ee19f34c3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0002280 PMID:41385096 "[{""id"":""uuid:2b08a734-7453-4ae7-8581-67936ce5730d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:443178c7-4608-44f7-8acd-524997fd4840"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:863da50f-e75f-43a3-b744-3541ea5ccbe2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0015253 PMID:41385096 "[{""id"":""uuid:1bd40518-c18e-4583-85eb-11dd5107e277"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:240d28d0-a34f-4825-88b7-cc024bd62ac4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:0e9607fe-0b31-4ed2-8161-34e37ebbbd99 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0005059 PMID:41385096 "[{""id"":""uuid:afaea510-0acc-4b56-994e-a5cab0075a71"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:891b9f63-11e3-48d4-a417-e5878d4448f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:1fb3e0cd-0858-45be-be54-00c5f1c73562 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0004095 PMID:41385096 "[{""id"":""uuid:b422a407-e715-47f9-aef3-aa2c1e7f8ad0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fabe80fb-8d83-46fe-ae50-d6d993d4c80a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:8268d204-4123-46cf-9d61-81c0c8c91294 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0004355 PMID:41385096 "[{""id"":""uuid:cebc7568-2a6f-47af-b3d3-314b9b1d6a92"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9b0b98e7-0091-4c46-ba39-614b5d65f645"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:f40a3b4c-9c1c-477f-84ad-b4546a43b6ee biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0005377 PMID:41385096 "[{""id"":""uuid:af85a389-3ffd-4e08-815c-c12135c0dad8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:37352df7-f38b-42f5-9afb-196771f1baad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:451a32b0-35d7-41ad-8b40-e2505d2d2376 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0005101 PMID:41385096 "[{""id"":""uuid:8cfe8c33-4215-4b99-9d62-32bc9a8f1f88"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5803eff7-53c9-4de8-9c67-d0bc623e4252"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:ce26525d-a1b0-4229-a1fb-dd87ed46d191 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats UMLS:C0678202 PMID:41385096 "[{""id"":""uuid:bb7852f8-2052-43f5-be16-ac4e4082c535"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:83584cb5-8ce9-49a4-93ae-0da24e5c0567"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:2b535747-32f7-4ed7-a195-c239d91e7770 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0006042 PMID:41385096 "[{""id"":""uuid:4d816c58-beb5-4b4d-b68a-5cc1972e96e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2f2a95ea-5a6b-460c-9704-7a9ad6fa11c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:4338967d-feff-4c74-b71d-c3652c6e4c84 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0019444 PMID:41385096 "[{""id"":""uuid:2933a9b6-763f-485f-a0ba-6ca1f820528b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a8571cf9-a54e-4a0b-bd99-b6a0552799ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:f754be35-6971-453f-8a65-9399cdb94364 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0001719 PMID:41385096 "[{""id"":""uuid:b78e2548-4f34-47e3-88dd-eaeab12776db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aa6de2ec-0fa9-4d74-af23-c28a95c74bef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Doxycycline for Injection, USP and other antibacterial drugs, Doxycycline for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline for Injection, USP is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever, and the typhus group, Q fever, rickettsial pox and tick fevers). Mycoplasma pneumoniae (PPLO, Eaton Agent). Agents of psittacosis and ornithosis. Agents of lymphogranuloma venereum and granuloma inguinale. The spirochetal agent of relapsing fever (Borrelia recurrentis) . The following gram-negative microorganisms: Haemophilus ducreyi (chancroid). Yersinia pestis and Francisella tularensis . Bartonella bacilliformis . Bacteroides species. Vibrio cholerae and Campylobacter fetus . Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Enterobacter aerogenes . Shigella species. Acinetobacter species. Haemophilus influenzae (respiratory infections). Klebsiella species (respiratory and urinary infections). Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Enterococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Streptococcus pneumoniae . Staphylococcus aureus , respiratory, skin and soft tissue infections. Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections. Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of infections due to: Neisseria gonorrhoeae and N. meningitidis . Treponema pallidum and Treponema pallidum subspecies pertenue (syphilis and yaws). Listeria monocytogenes . Clostridium species. Fusobacterium fusiforme (Vincent's infection). Actinomyces species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. Doxycycline is indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. uuid:33d347f3-03d6-4ede-a578-28ac897f4351 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0005373 PMID:41385096 "[{""id"":""uuid:515fad0b-e9e6-4000-a3a2-93e718b87370"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d890fa35-1fd1-4874-95bf-924f9887979c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Doxycycline for Injection, USP and other antibacterial drugs, Doxycycline for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline for Injection, USP is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever, and the typhus group, Q fever, rickettsial pox and tick fevers). Mycoplasma pneumoniae (PPLO, Eaton Agent). Agents of psittacosis and ornithosis. Agents of lymphogranuloma venereum and granuloma inguinale. The spirochetal agent of relapsing fever (Borrelia recurrentis) . The following gram-negative microorganisms: Haemophilus ducreyi (chancroid). Yersinia pestis and Francisella tularensis . Bartonella bacilliformis . Bacteroides species. Vibrio cholerae and Campylobacter fetus . Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Enterobacter aerogenes . Shigella species. Acinetobacter species. Haemophilus influenzae (respiratory infections). Klebsiella species (respiratory and urinary infections). Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Enterococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Streptococcus pneumoniae . Staphylococcus aureus , respiratory, skin and soft tissue infections. Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections. Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of infections due to: Neisseria gonorrhoeae and N. meningitidis . Treponema pallidum and Treponema pallidum subspecies pertenue (syphilis and yaws). Listeria monocytogenes . Clostridium species. Fusobacterium fusiforme (Vincent's infection). Actinomyces species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. Doxycycline is indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. uuid:30f041c0-9d2f-4bd1-af98-4c3965df00ad biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64045 biolink:treats EFO:0004888 PMID:41385096 "[{""id"":""uuid:514cc845-8866-48e6-acc8-d2291a3de750"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:466b2ad0-e532-44fc-a29e-dbe72f22b802"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BARHEMSYS ® is indicated in adults for: prevention of postoperative nausea and vomiting (PONV), either alone or in combination with an antiemetic of a different class. treatment of PONV in patients who have received antiemetic prophylaxis with an agent of a different class or have not received prophylaxis. uuid:41e032f8-aff7-4128-9c6f-3c6bb8ebe7ad biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:P0GVQ9A4S5 biolink:treats MONDO:0011962 PMID:41385096 "[{""id"":""uuid:4802c6a4-9deb-491a-8672-0efe49bf5888"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:dd4b930e-a267-42c8-b1b1-45222cd87c60"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:2ad66eeb-3db0-4cbd-be2c-4da901ccb52c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/jemperli""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] JEMPERLI is a programmed death receptor-1 (PD-1)–blocking antibody indicated: Endometrial Cancer • in combination with carboplatin and paclitaxel, followed by JEMPERLI as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial cancer (EC). ( 1.1 ) • as a single agent for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced EC, as determined by an FDA-approved test, that has progressed on or following prior treatment with a platinum-containing regimen in any setting and are not candidates for curative surgery or radiation. ( 1.1 , 2.1 ) Mismatch Repair Deficient Recurrent or Advanced Solid Tumors • as a single agent for the treatment of adult patients with dMMR recurrent or advanced solid tumors, as determined by an FDA-approved test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options. 1 ( 1.2 , 2.1 ) 1 This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1.2 )|[EMA] Jemparli is indicated as monotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI H) recurrent or advanced endometrial cancer (EC) that has progressed on or following prior treatment with a platinum-containing regimen. uuid:b1b5bca4-2a2e-4e40-9a29-43967efdaa5d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:43830 biolink:treats MONDO:0001117 PMID:41385096 "[{""id"":""uuid:b40ad173-1218-4a88-b09f-fa72d30c3207"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:98b5b0b9-66bd-4454-9d3c-b836ad1c1ab3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e8fca00f-1df7-43bd-b345-6b309d32f8af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/lumeblue""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] PROVAYBLUE is indicated for the treatment of pediatric and adult patients with acquired methemoglobinemia.|[EMA] Acute symptomatic treatment of medicinal and chemical products- induced methaemoglobinaemia.Methylthioninium chloride Proveblue is indicated in adults, children and adolescents (aged 0 to 17 years old). uuid:ccc92723-cbf8-4e80-bce5-34b1ecdae23d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4B6J53W8N3 biolink:treats MONDO:0004951 PMID:41385096 "[{""id"":""uuid:11271a84-7ebe-4541-badc-dd3e0387077b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2945cf7a-7cd0-409f-b2f7-fe85dbda9ffd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RUKOBIA, in combination with other antiretroviral(s), is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen due to resistance, intolerance, or safety considerations [see Clinical Studies ( 14 )]. uuid:1c0689f0-3a83-4b29-b3a8-6cc9e8887087 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:139589551 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:fa72730f-7f26-4a7c-8191-2d1fd1fd1ea2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:af8668f3-a0dd-4be2-b614-dc409ad6a30f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:584ee05a-e64f-44a9-94ab-32479543840e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] APIDRA is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus.|[EMA] Treatment of adults, adolescents and children, six years or older with diabetes mellitus, where treatment with insulin is required. uuid:7f52fb3a-9562-413d-8c25-49bd7fe688dc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:229649 biolink:treats MONDO:0014222 PMID:41385096 "[{""id"":""uuid:8bc0e759-a203-4e98-9fb8-eecf0e22cebd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c4084045-affc-4d0b-9cf6-a7ad3adcb6a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] JOENJA is indicated for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and pediatric patients 12 years of age and older. uuid:7b750167-ddfc-4378-9c13-146085874b92 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:229649 biolink:treats MONDO:0018338 PMID:41385096 "[{""id"":""uuid:4a55d0ea-57a1-466e-92eb-58bc701674c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ab98bd3b-6b07-4b00-a13a-82a0986aff3f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] JOENJA is indicated for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and pediatric patients 12 years of age and older. uuid:e844920b-e298-4a1c-b003-4829bf58c1e4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C4294565 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:ed819868-6147-4e41-b6fd-ed6e2c28c057"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:112e2d8f-0f6a-4adf-97d2-5efdf5543b74"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:38d4cf57-e542-47df-bbcd-57f102141980"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XULTOPHY 100/3.6 is a combination of insulin degludec and liraglutide and is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use: • XULTOPHY 100/3.6 contains liraglutide. Coadministration with any other product containing liraglutide or another glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended [ see Warnings and Precautions ( 5.5 ) ]. • XULTOPHY 100/3.6 is not recommended for the treatment of diabetic ketoacidosis. • XULTOPHY 100/3.6 has not been studied in combination with prandial insulin.|[PMDA] A new combination drug indicated for the treatment of type 2 diabetes mellitus in cases where insulin therapy is indicated. MESH:C000629636 uuid:5e16732e-a3f0-49fb-847d-0be23cc2cff9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C4294565 biolink:treats MONDO:0012819 PMID:41385096 "[{""id"":""uuid:ca32515b-f771-46f7-8d69-bdb9422f1d7f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c11dad4c-645d-4f06-9540-60c9ced50ecb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XULTOPHY 100/3.6 is a combination of insulin degludec and liraglutide and is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use: • XULTOPHY 100/3.6 contains liraglutide. Coadministration with any other product containing liraglutide or another glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended [ see Warnings and Precautions ( 5.5 ) ]. • XULTOPHY 100/3.6 is not recommended for the treatment of diabetic ketoacidosis. • XULTOPHY 100/3.6 has not been studied in combination with prandial insulin. MESH:C000629636 uuid:e2479665-e3d8-4a05-a8eb-3609abede000 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:379014 biolink:treats MONDO:0004872 PMID:41385096 "[{""id"":""uuid:da16393d-d6bb-46e8-92a4-276b53149243"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:88e9f28a-ccee-46f6-9c8e-dccb2383721c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Product is used for the anti-inflammatory and anesthetic relief of itching, pain, soreness and discomfort due to hemorrhoids, anal fissures, pruritus ani and similar conditions of the anal area. uuid:ea4cce20-5b34-458a-ae55-5338b4b241fe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:379014 biolink:treats HP:0012390 PMID:41385096 "[{""id"":""uuid:883713ee-95b7-43b8-b014-9ebf2009cff3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0d40efd8-8508-4cd4-b89e-0127eef2edcb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Product is used for the anti-inflammatory and anesthetic relief of itching, pain, soreness and discomfort due to hemorrhoids, anal fissures, pruritus ani and similar conditions of the anal area. uuid:1b24d26a-423f-42aa-a24d-404788bfb863 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:379014 biolink:treats UMLS:C0033775 PMID:41385096 "[{""id"":""uuid:30795f4e-adcb-4902-a551-d036a8909c53"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:70743d99-c407-4f8e-be88-b34073673305"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Product is used for the anti-inflammatory and anesthetic relief of itching, pain, soreness and discomfort due to hemorrhoids, anal fissures, pruritus ani and similar conditions of the anal area. uuid:d60476d8-b6b9-4e5b-9df8-70f41663c596 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:5IB2J79MCX biolink:treats MONDO:0100491 PMID:41385096 "[{""id"":""uuid:27079960-d2c5-4553-9d6d-3fffbe1ae286"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d4a68d28-2970-4903-a98a-17e3c059d5d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:36669801-0022-436e-86e6-c1425d53f2fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/spevigo""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] SPEVIGO is indicated for the treatment of generalized pustular psoriasis (GPP) in adults and pediatric patients 12 years of age and older and weighing at least 40 kg.|[EMA] Spevigo is indicated for the treatment of flares in adult patients with generalised pustular psoriasis (GPP) as monotherapy. uuid:5947eaf8-595f-4f16-abac-699c6d1b00a6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1858992 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:dc83cc8d-003f-408f-8c82-209b3bd3dd1b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3271c0a1-148c-4293-aab7-e25fc8d88dcf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:2a6da94d-1bd3-4fc2-92ee-91b51e07b398"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/suliqua""]},{""id"":""uuid:744824f4-3957-4acf-9fc5-f5c1783329c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SOLIQUA 100/33 is a combination of insulin glargine and lixisenatide and is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.|[EMA] Suliqua is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise in addition to metformin with or without SGLT-2 inhibitors.,|[PMDA] A new combination drug indicated for the treatment of type 2 diabetes mellitus in cases where insulin therapy is indicated. uuid:eb6a80d1-d1d8-43b4-aee7-d2882f47d79e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2P6O7CFW5K biolink:treats MONDO:0017713 PMID:41385096 "[{""id"":""uuid:ff58bb8d-69e2-4386-87bf-346cceb84aea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5dba547c-d1f5-4ee3-a46b-9d0c7b42062f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DOJOLVI is indicated as a source of calories and fatty acids for the treatment of adult and pediatric patients with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD). uuid:a02b5dd8-8636-4f9c-bf50-f1d6665eba8b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17141 biolink:treats MONDO:0009064 PMID:41385096 "[{""id"":""uuid:4068a1f1-0444-4203-8d82-7d9e9acbf77f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:410f6b8a-ff6d-4fb8-9128-be8c0c9f9435"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CYSTADROPS is a cystine-depleting agent indicated for the treatment of corneal cystine crystal deposits in adults and children with cystinosis. uuid:fa188067-7669-4b0c-813e-6d00f02164c7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:370571 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:40878f24-9399-40b7-8f33-383fb03ee514"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6bd642fd-7cba-43ea-9305-3612157e2e3d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Chlordiazepoxide and amitriptyline hydrochloride tablets are indicated for the treatment of patients with moderate to severe depression associated with moderate to severe anxiety. The therapeutic response to chlordiazepoxide and amitriptyline hydrochloride tablet occurs earlier and with fewer treatment failures than when either amitriptyline or chlordiazepoxide is used alone. Symptoms likely to respond in the first week of treatment include: insomnia, feelings of guilt or worthlessness, agitation, psychic and somatic anxiety, suicidal ideation and anorexia. uuid:6b66e343-55e2-4000-bd6f-0c68e3c6264c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:370571 biolink:treats MONDO:0011918 PMID:41385096 "[{""id"":""uuid:00703ce2-dc27-4545-8199-766b243c9636"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4d660306-14e4-440c-9ac3-d56bcebd9d14"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Chlordiazepoxide and amitriptyline hydrochloride tablets are indicated for the treatment of patients with moderate to severe depression associated with moderate to severe anxiety. The therapeutic response to chlordiazepoxide and amitriptyline hydrochloride tablet occurs earlier and with fewer treatment failures than when either amitriptyline or chlordiazepoxide is used alone. Symptoms likely to respond in the first week of treatment include: insomnia, feelings of guilt or worthlessness, agitation, psychic and somatic anxiety, suicidal ideation and anorexia. uuid:808f3f5b-aba8-48b5-8ec6-a1bc72050a46 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:370571 biolink:treats MONDO:0013600 PMID:41385096 "[{""id"":""uuid:8ad3e535-472d-46b9-96ed-d3d6220c302b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:563d3aa9-56b0-4196-aa6a-ff91b8db53b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Chlordiazepoxide and amitriptyline hydrochloride tablets are indicated for the treatment of patients with moderate to severe depression associated with moderate to severe anxiety. The therapeutic response to chlordiazepoxide and amitriptyline hydrochloride tablet occurs earlier and with fewer treatment failures than when either amitriptyline or chlordiazepoxide is used alone. Symptoms likely to respond in the first week of treatment include: insomnia, feelings of guilt or worthlessness, agitation, psychic and somatic anxiety, suicidal ideation and anorexia. uuid:a641d849-80e5-4e6d-9046-46577c8cdfd3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:370571 biolink:treats MONDO:0005351 PMID:41385096 "[{""id"":""uuid:fb82c77f-3c8d-4326-987b-d0eb02fb3d60"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bd0c6f77-1672-4f18-ac61-42e4786f216f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Chlordiazepoxide and amitriptyline hydrochloride tablets are indicated for the treatment of patients with moderate to severe depression associated with moderate to severe anxiety. The therapeutic response to chlordiazepoxide and amitriptyline hydrochloride tablet occurs earlier and with fewer treatment failures than when either amitriptyline or chlordiazepoxide is used alone. Symptoms likely to respond in the first week of treatment include: insomnia, feelings of guilt or worthlessness, agitation, psychic and somatic anxiety, suicidal ideation and anorexia. uuid:9e947586-b3d5-46d3-bbc0-347b29276697 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:136007 biolink:treats MONDO:0100187 PMID:41385096 "[{""id"":""uuid:449f7071-232e-45ee-afd4-93f063a3343c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:6a00a8be-92c6-4361-86cc-291b33b5c408"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c11dd18a-d675-4445-aaa7-79f5d7c0390f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/relistor""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] RELISTOR is an opioid antagonist. RELISTOR tablets and RELISTOR injection are indicated for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation. ( 1.1 ) RELISTOR injection is indicated for the treatment of OIC in adults with advanced illness or pain caused by active cancer who require opioid dosage escalation for palliative care. ( 1.2 )|[EMA] Treatment of opioid-induced constipation in advanced-illness patients who are receiving palliative care when response to usual laxative therapy has not been sufficient. uuid:47b9b536-a9b7-4ced-9024-de547f0bea6b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:194186 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:40ed9270-98af-4e53-b09a-41477650109a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3d1a64d7-14f7-4720-97f2-f660463a56f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ab7f5718-ae71-46f3-a277-70a4d5858fbd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/mounjaro""]},{""id"":""uuid:89469cb7-830c-4d68-beea-ad7e928df51b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MOUNJARO ® is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.|[EMA] Mounjaro is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance or contraindications- in addition to other medicinal products for the treatment of diabetes.For study results with respect to combinations, effects on glycaemic control and the populations studied, see sections 4.4, 4.5 and 5.1.|[PMDA] Drugs with a new active ingredient indicated for the treatment of type 2 diabetes mellitus. uuid:72dd8581-152b-4430-b6b4-169588d8b965 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB18704 biolink:treats UMLS:C0746883 PMID:41385096 "[{""id"":""uuid:e10c2604-8eb1-4a47-b8e5-41d075d49282"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eb839b3d-40e5-43f7-a9df-b9c0d0a465f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RYZNEUTA is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. Limitations of Use RYZNEUTA is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation. uuid:02c424d3-cd66-4d86-ba60-271b4af51c22 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:1L7BVT4Z4Z biolink:treats MONDO:0006733 PMID:41385096 "[{""id"":""uuid:e7e865be-cc8e-4f55-bad2-a5cff6e284e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:af6a1903-17b0-4677-858e-210a6f7a40e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TRYPTYR is indicated for the treatment of the signs and symptoms of dry eye disease. uuid:359701b7-283d-4062-9e3e-6442168a5212 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1940699 biolink:treats MONDO:0005231 PMID:41385096 "[{""id"":""uuid:e217f495-b982-4dce-83e3-7bab9011a68d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:70cd1e61-ebf9-404f-b863-82504950b6ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MAVYRET is indicated for the treatment of adult and pediatric patients 3 years and older with acute or chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A). MAVYRET is indicated for the treatment of adult and pediatric patients 3 years and older with HCV genotype 1 infection, who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor (PI), but not both [see Dosage and Administration ( 2.2 ) and Clinical Studies ( 14 )]. uuid:dc31245f-e3bb-43bf-91f0-dcc2eea5a547 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:ZJ0EKR6M10 biolink:treats UMLS:C0027627 PMID:41385096 "[{""id"":""uuid:72975a3b-fc25-4492-99e5-1b6e26a54274"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ae1f04fc-823f-49be-b617-744ef3b0a770"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ILLUCCIX, after radiolabeling with Ga 68, is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer: With suspected metastasis who are candidates for initial definitive therapy. With suspected recurrence based on elevated serum prostate-specific antigen (PSA) level. For selection of patients who are indicated for PSMA-directed therapy as described in the prescribing information of the therapeutic products. PUBCHEM.COMPOUND:91800164 uuid:2c712c3a-d76f-40da-9ac5-d879fff61c0d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:ZJ0EKR6M10 biolink:treats UMLS:C2825055 PMID:41385096 "[{""id"":""uuid:d9e4e061-c2f6-4832-98c9-63194c1f39c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ac18423f-d438-4659-ac59-400a44b235cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ILLUCCIX, after radiolabeling with Ga 68, is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer: With suspected metastasis who are candidates for initial definitive therapy. With suspected recurrence based on elevated serum prostate-specific antigen (PSA) level. For selection of patients who are indicated for PSMA-directed therapy as described in the prescribing information of the therapeutic products. PUBCHEM.COMPOUND:91800164 uuid:1cc00d63-b49f-4775-bd67-5241c646d8e4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3766 biolink:treats MONDO:0001475 PMID:41385096 "[{""id"":""uuid:080c65e2-49cf-492b-8fa6-170bb625440d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:884e5f81-f6cc-40a3-a07d-ab4db7656c51"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clozapine orally disintegrating tablets (Clozapine ODT) is an atypical antipsychotic indicated for: Treatment of severely ill patients with schizophrenia who fail to respond adequately to standard antipsychotic treatment. Because of the risks of severe neutropenia and of seizure associated with its use, Clozapine ODT should be used only in patients who have failed to respond adequately to standard antipsychotic treatment ( 1.1 ) Reducing the risk of recurrent suicidal behavior in patients with schizophrenia or schizoaffective disorder who are judged to be at chronic risk for re-experiencing suicidal behavior ( 1.2 ) uuid:ad2140c0-6600-4ebe-8dbb-386182a2e150 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C5908975 biolink:treats MONDO:0100096 PMID:41385096 "[{""id"":""uuid:ddab5f69-e56b-4205-bf0e-59a9576d2707"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5131e054-14f9-43cc-bd6a-6a5d5f02753d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the emergency use of the unapproved product PEMGARDA (pemivibart) for the pre-exposure prophylaxis of coronavirus disease 2019 (COVID-19) in adults and adolescents (12 years of age and older weighing at least 40 kg): Who are not currently infected with SARS-CoV-2 and who have not had a known recent exposure to an individual infected with SARS-CoV-2 and Who have moderate-to-severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments and are unlikely to mount an adequate response to COVID-19 vaccination. Medical conditions or treatments that may result in moderate to severe immune compromise and an inadequate immune response to COVID-19 vaccination include: Active treatment for solid tumor and hematologic malignancies Hematologic malignancies associated with poor responses to COVID-19 vaccines regardless of current treatment status (e.g., chronic lymphocytic leukemia, non-Hodgkin lymphoma, multiple myeloma, acute leukemia) Receipt of solid-organ transplant or an islet transplant and taking immunosuppressive therapy Receipt of chimeric antigen receptor (CAR)-T-cell or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppressive therapy) Moderate or severe primary immunodeficiency (e.g., common variable immunodeficiency disease, severe combined immunodeficiency, DiGeorge syndrome, Wiskott-Aldrich syndrome) Advanced or untreated HIV infection (people with HIV and CD4 cell counts <200/mm 3 , history of an AIDS-defining illness without immune reconstitution, or clinical manifestations of symptomatic HIV) Active treatment with high-dose corticosteroids (i.e., ≥20 mg prednisone or equivalent per day when administered for ≥2 weeks), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, and biologic agents that are immunosuppressive or immunomodulatory (e.g., B-cell depleting agents) Limitations of Authorized Use PEMGARDA is not authorized for use: For treatment of COVID-19, or For post-exposure prophylaxis of COVID-19 in individuals who have been exposed to someone infected with SARS-CoV-2. Pre-exposure prophylaxis with PEMGARDA is not a substitute for vaccination in individuals for whom COVID-19 vaccination is recommended. Individuals for whom COVID-19 vaccination is recommended, including individuals with moderate-to-severe immune compromise who may derive benefit from COVID-19 vaccination, should receive COVID‑19 vaccination. In individuals who have recently received a COVID-19 vaccine, PEMGARDA should be administered at least 2 weeks after vaccination. PEMGARDA may only be prescribed for an individual patient by physicians, advanced practice registered nurses, and physician assistants that are licensed or authorized under State law to prescribe drugs. PEMGARDA has been authorized by FDA for the emergency use described above. PEMGARDA is not FDA-approved for any use, including use for pre-exposure prophylaxis of COVID-19. PEMGARDA is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of PEMGARDA under section 564(b)(1) of the FD&C Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. Justification for Emergency Use of Drugs During the COVID‑19 Pandemic: There is currently an outbreak of coronavirus disease 2019 (COVID‑19) caused by SARS‑CoV‑2, a novel coronavirus. The Secretary of the U.S. Department of Health and Human Services (HHS) has: Determined that there is a public health emergency, or significant potential for a public health emergency [1] . Declared that circumstances exist justifying the authorization of emergency use of drugs and biological products for the prevention or treatment of COVID-19 [2] . An EUA is an FDA authorization for the emergency use of an unapproved product or unapproved use of an approved product (i.e., drug, biological product, or device) in the United States under certain circumstances including, but not limited to, when the Secretary of HHS declares that there is a public health emergency that affects the national security or the health and security of United States citizens living abroad, and that involves biological agent(s) or a disease or condition that may be attributable to such agent(s). Criteria for issuing an EUA include: The biological agent(s) can cause a serious or life-threatening disease or condition. Based on the totality of the available scientific evidence (including data from adequate and well controlled clinical trials, if available), it is reasonable to believe that: the product may be effective in diagnosing, treating, or preventing the serious or life-threatening disease or condition; and the known and potential benefits of the product - when used to diagnose, prevent, or treat such disease or condition - outweigh the known and potential risks of the product, taking into consideration the material threat posed by the biological agent(s). There is no adequate, approved, and available alternative to the product for diagnosing, preventing, or treating the serious or life-threatening disease or condition. Information Regarding Available Alternatives for the EUA Authorized Use There are no adequate, approved, and available alternatives to PEMGARDA for the pre-exposure prophylaxis of COVID-19 in individuals who are unlikely to mount an adequate immune response to COVID-19 vaccination. For information on clinical studies of PEMGARDA and other therapies for the pre-exposure prophylaxis of COVID-19, see www.clinicaltrials.gov . DRUGBANK:DB18720 uuid:6d4db94a-8945-4969-a7a4-43782015f4eb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C5908975 biolink:treats UMLS:C0280100 PMID:41385096 "[{""id"":""uuid:7e292390-33dc-4708-818e-5d8d2978d0a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fb67685f-ea8b-4b97-8b75-6309c6f73ff4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the emergency use of the unapproved product PEMGARDA (pemivibart) for the pre-exposure prophylaxis of coronavirus disease 2019 (COVID-19) in adults and adolescents (12 years of age and older weighing at least 40 kg): Who are not currently infected with SARS-CoV-2 and who have not had a known recent exposure to an individual infected with SARS-CoV-2 and Who have moderate-to-severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments and are unlikely to mount an adequate response to COVID-19 vaccination. Medical conditions or treatments that may result in moderate to severe immune compromise and an inadequate immune response to COVID-19 vaccination include: Active treatment for solid tumor and hematologic malignancies Hematologic malignancies associated with poor responses to COVID-19 vaccines regardless of current treatment status (e.g., chronic lymphocytic leukemia, non-Hodgkin lymphoma, multiple myeloma, acute leukemia) Receipt of solid-organ transplant or an islet transplant and taking immunosuppressive therapy Receipt of chimeric antigen receptor (CAR)-T-cell or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppressive therapy) Moderate or severe primary immunodeficiency (e.g., common variable immunodeficiency disease, severe combined immunodeficiency, DiGeorge syndrome, Wiskott-Aldrich syndrome) Advanced or untreated HIV infection (people with HIV and CD4 cell counts <200/mm 3 , history of an AIDS-defining illness without immune reconstitution, or clinical manifestations of symptomatic HIV) Active treatment with high-dose corticosteroids (i.e., ≥20 mg prednisone or equivalent per day when administered for ≥2 weeks), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, and biologic agents that are immunosuppressive or immunomodulatory (e.g., B-cell depleting agents) Limitations of Authorized Use PEMGARDA is not authorized for use: For treatment of COVID-19, or For post-exposure prophylaxis of COVID-19 in individuals who have been exposed to someone infected with SARS-CoV-2. Pre-exposure prophylaxis with PEMGARDA is not a substitute for vaccination in individuals for whom COVID-19 vaccination is recommended. Individuals for whom COVID-19 vaccination is recommended, including individuals with moderate-to-severe immune compromise who may derive benefit from COVID-19 vaccination, should receive COVID‑19 vaccination. In individuals who have recently received a COVID-19 vaccine, PEMGARDA should be administered at least 2 weeks after vaccination. PEMGARDA may only be prescribed for an individual patient by physicians, advanced practice registered nurses, and physician assistants that are licensed or authorized under State law to prescribe drugs. PEMGARDA has been authorized by FDA for the emergency use described above. PEMGARDA is not FDA-approved for any use, including use for pre-exposure prophylaxis of COVID-19. PEMGARDA is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of PEMGARDA under section 564(b)(1) of the FD&C Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. Justification for Emergency Use of Drugs During the COVID‑19 Pandemic: There is currently an outbreak of coronavirus disease 2019 (COVID‑19) caused by SARS‑CoV‑2, a novel coronavirus. The Secretary of the U.S. Department of Health and Human Services (HHS) has: Determined that there is a public health emergency, or significant potential for a public health emergency [1] . Declared that circumstances exist justifying the authorization of emergency use of drugs and biological products for the prevention or treatment of COVID-19 [2] . An EUA is an FDA authorization for the emergency use of an unapproved product or unapproved use of an approved product (i.e., drug, biological product, or device) in the United States under certain circumstances including, but not limited to, when the Secretary of HHS declares that there is a public health emergency that affects the national security or the health and security of United States citizens living abroad, and that involves biological agent(s) or a disease or condition that may be attributable to such agent(s). Criteria for issuing an EUA include: The biological agent(s) can cause a serious or life-threatening disease or condition. Based on the totality of the available scientific evidence (including data from adequate and well controlled clinical trials, if available), it is reasonable to believe that: the product may be effective in diagnosing, treating, or preventing the serious or life-threatening disease or condition; and the known and potential benefits of the product - when used to diagnose, prevent, or treat such disease or condition - outweigh the known and potential risks of the product, taking into consideration the material threat posed by the biological agent(s). There is no adequate, approved, and available alternative to the product for diagnosing, preventing, or treating the serious or life-threatening disease or condition. Information Regarding Available Alternatives for the EUA Authorized Use There are no adequate, approved, and available alternatives to PEMGARDA for the pre-exposure prophylaxis of COVID-19 in individuals who are unlikely to mount an adequate immune response to COVID-19 vaccination. For information on clinical studies of PEMGARDA and other therapies for the pre-exposure prophylaxis of COVID-19, see www.clinicaltrials.gov . DRUGBANK:DB18720 uuid:afa3a8f2-5913-4dce-a523-d1d7ef106872 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C5908975 biolink:treats NCIT:C157387 PMID:41385096 "[{""id"":""uuid:b8336b68-2e51-4304-a99e-8443d894171d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c10acd79-8c22-4411-b04b-51590cf6d47c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the emergency use of the unapproved product PEMGARDA (pemivibart) for the pre-exposure prophylaxis of coronavirus disease 2019 (COVID-19) in adults and adolescents (12 years of age and older weighing at least 40 kg): Who are not currently infected with SARS-CoV-2 and who have not had a known recent exposure to an individual infected with SARS-CoV-2 and Who have moderate-to-severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments and are unlikely to mount an adequate response to COVID-19 vaccination. Medical conditions or treatments that may result in moderate to severe immune compromise and an inadequate immune response to COVID-19 vaccination include: Active treatment for solid tumor and hematologic malignancies Hematologic malignancies associated with poor responses to COVID-19 vaccines regardless of current treatment status (e.g., chronic lymphocytic leukemia, non-Hodgkin lymphoma, multiple myeloma, acute leukemia) Receipt of solid-organ transplant or an islet transplant and taking immunosuppressive therapy Receipt of chimeric antigen receptor (CAR)-T-cell or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppressive therapy) Moderate or severe primary immunodeficiency (e.g., common variable immunodeficiency disease, severe combined immunodeficiency, DiGeorge syndrome, Wiskott-Aldrich syndrome) Advanced or untreated HIV infection (people with HIV and CD4 cell counts <200/mm 3 , history of an AIDS-defining illness without immune reconstitution, or clinical manifestations of symptomatic HIV) Active treatment with high-dose corticosteroids (i.e., ≥20 mg prednisone or equivalent per day when administered for ≥2 weeks), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, and biologic agents that are immunosuppressive or immunomodulatory (e.g., B-cell depleting agents) Limitations of Authorized Use PEMGARDA is not authorized for use: For treatment of COVID-19, or For post-exposure prophylaxis of COVID-19 in individuals who have been exposed to someone infected with SARS-CoV-2. Pre-exposure prophylaxis with PEMGARDA is not a substitute for vaccination in individuals for whom COVID-19 vaccination is recommended. Individuals for whom COVID-19 vaccination is recommended, including individuals with moderate-to-severe immune compromise who may derive benefit from COVID-19 vaccination, should receive COVID‑19 vaccination. In individuals who have recently received a COVID-19 vaccine, PEMGARDA should be administered at least 2 weeks after vaccination. PEMGARDA may only be prescribed for an individual patient by physicians, advanced practice registered nurses, and physician assistants that are licensed or authorized under State law to prescribe drugs. PEMGARDA has been authorized by FDA for the emergency use described above. PEMGARDA is not FDA-approved for any use, including use for pre-exposure prophylaxis of COVID-19. PEMGARDA is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of PEMGARDA under section 564(b)(1) of the FD&C Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. Justification for Emergency Use of Drugs During the COVID‑19 Pandemic: There is currently an outbreak of coronavirus disease 2019 (COVID‑19) caused by SARS‑CoV‑2, a novel coronavirus. The Secretary of the U.S. Department of Health and Human Services (HHS) has: Determined that there is a public health emergency, or significant potential for a public health emergency [1] . Declared that circumstances exist justifying the authorization of emergency use of drugs and biological products for the prevention or treatment of COVID-19 [2] . An EUA is an FDA authorization for the emergency use of an unapproved product or unapproved use of an approved product (i.e., drug, biological product, or device) in the United States under certain circumstances including, but not limited to, when the Secretary of HHS declares that there is a public health emergency that affects the national security or the health and security of United States citizens living abroad, and that involves biological agent(s) or a disease or condition that may be attributable to such agent(s). Criteria for issuing an EUA include: The biological agent(s) can cause a serious or life-threatening disease or condition. Based on the totality of the available scientific evidence (including data from adequate and well controlled clinical trials, if available), it is reasonable to believe that: the product may be effective in diagnosing, treating, or preventing the serious or life-threatening disease or condition; and the known and potential benefits of the product - when used to diagnose, prevent, or treat such disease or condition - outweigh the known and potential risks of the product, taking into consideration the material threat posed by the biological agent(s). There is no adequate, approved, and available alternative to the product for diagnosing, preventing, or treating the serious or life-threatening disease or condition. Information Regarding Available Alternatives for the EUA Authorized Use There are no adequate, approved, and available alternatives to PEMGARDA for the pre-exposure prophylaxis of COVID-19 in individuals who are unlikely to mount an adequate immune response to COVID-19 vaccination. For information on clinical studies of PEMGARDA and other therapies for the pre-exposure prophylaxis of COVID-19, see www.clinicaltrials.gov . DRUGBANK:DB18720 uuid:1f40b20a-8b41-42b6-a199-8dc078abae1e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C5908975 biolink:treats MONDO:0004948 PMID:41385096 "[{""id"":""uuid:8dca6e6b-610d-455f-a532-18b7c5007e1f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a3871ef8-78ae-445e-900c-7ebdef2df006"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the emergency use of the unapproved product PEMGARDA (pemivibart) for the pre-exposure prophylaxis of coronavirus disease 2019 (COVID-19) in adults and adolescents (12 years of age and older weighing at least 40 kg): Who are not currently infected with SARS-CoV-2 and who have not had a known recent exposure to an individual infected with SARS-CoV-2 and Who have moderate-to-severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments and are unlikely to mount an adequate response to COVID-19 vaccination. Medical conditions or treatments that may result in moderate to severe immune compromise and an inadequate immune response to COVID-19 vaccination include: Active treatment for solid tumor and hematologic malignancies Hematologic malignancies associated with poor responses to COVID-19 vaccines regardless of current treatment status (e.g., chronic lymphocytic leukemia, non-Hodgkin lymphoma, multiple myeloma, acute leukemia) Receipt of solid-organ transplant or an islet transplant and taking immunosuppressive therapy Receipt of chimeric antigen receptor (CAR)-T-cell or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppressive therapy) Moderate or severe primary immunodeficiency (e.g., common variable immunodeficiency disease, severe combined immunodeficiency, DiGeorge syndrome, Wiskott-Aldrich syndrome) Advanced or untreated HIV infection (people with HIV and CD4 cell counts <200/mm 3 , history of an AIDS-defining illness without immune reconstitution, or clinical manifestations of symptomatic HIV) Active treatment with high-dose corticosteroids (i.e., ≥20 mg prednisone or equivalent per day when administered for ≥2 weeks), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, and biologic agents that are immunosuppressive or immunomodulatory (e.g., B-cell depleting agents) Limitations of Authorized Use PEMGARDA is not authorized for use: For treatment of COVID-19, or For post-exposure prophylaxis of COVID-19 in individuals who have been exposed to someone infected with SARS-CoV-2. Pre-exposure prophylaxis with PEMGARDA is not a substitute for vaccination in individuals for whom COVID-19 vaccination is recommended. Individuals for whom COVID-19 vaccination is recommended, including individuals with moderate-to-severe immune compromise who may derive benefit from COVID-19 vaccination, should receive COVID‑19 vaccination. In individuals who have recently received a COVID-19 vaccine, PEMGARDA should be administered at least 2 weeks after vaccination. PEMGARDA may only be prescribed for an individual patient by physicians, advanced practice registered nurses, and physician assistants that are licensed or authorized under State law to prescribe drugs. PEMGARDA has been authorized by FDA for the emergency use described above. PEMGARDA is not FDA-approved for any use, including use for pre-exposure prophylaxis of COVID-19. PEMGARDA is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of PEMGARDA under section 564(b)(1) of the FD&C Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. Justification for Emergency Use of Drugs During the COVID‑19 Pandemic: There is currently an outbreak of coronavirus disease 2019 (COVID‑19) caused by SARS‑CoV‑2, a novel coronavirus. The Secretary of the U.S. Department of Health and Human Services (HHS) has: Determined that there is a public health emergency, or significant potential for a public health emergency [1] . Declared that circumstances exist justifying the authorization of emergency use of drugs and biological products for the prevention or treatment of COVID-19 [2] . An EUA is an FDA authorization for the emergency use of an unapproved product or unapproved use of an approved product (i.e., drug, biological product, or device) in the United States under certain circumstances including, but not limited to, when the Secretary of HHS declares that there is a public health emergency that affects the national security or the health and security of United States citizens living abroad, and that involves biological agent(s) or a disease or condition that may be attributable to such agent(s). Criteria for issuing an EUA include: The biological agent(s) can cause a serious or life-threatening disease or condition. Based on the totality of the available scientific evidence (including data from adequate and well controlled clinical trials, if available), it is reasonable to believe that: the product may be effective in diagnosing, treating, or preventing the serious or life-threatening disease or condition; and the known and potential benefits of the product - when used to diagnose, prevent, or treat such disease or condition - outweigh the known and potential risks of the product, taking into consideration the material threat posed by the biological agent(s). There is no adequate, approved, and available alternative to the product for diagnosing, preventing, or treating the serious or life-threatening disease or condition. Information Regarding Available Alternatives for the EUA Authorized Use There are no adequate, approved, and available alternatives to PEMGARDA for the pre-exposure prophylaxis of COVID-19 in individuals who are unlikely to mount an adequate immune response to COVID-19 vaccination. For information on clinical studies of PEMGARDA and other therapies for the pre-exposure prophylaxis of COVID-19, see www.clinicaltrials.gov . DRUGBANK:DB18720 uuid:18c64b83-d7d2-4229-be72-5804d961a0c4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C5908975 biolink:treats MONDO:0018908 PMID:41385096 "[{""id"":""uuid:3e9c885b-22b9-4aa0-b19f-0f1b447f73fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:49a8d42a-7925-4a03-9ba3-e1d42f8ac5c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the emergency use of the unapproved product PEMGARDA (pemivibart) for the pre-exposure prophylaxis of coronavirus disease 2019 (COVID-19) in adults and adolescents (12 years of age and older weighing at least 40 kg): Who are not currently infected with SARS-CoV-2 and who have not had a known recent exposure to an individual infected with SARS-CoV-2 and Who have moderate-to-severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments and are unlikely to mount an adequate response to COVID-19 vaccination. Medical conditions or treatments that may result in moderate to severe immune compromise and an inadequate immune response to COVID-19 vaccination include: Active treatment for solid tumor and hematologic malignancies Hematologic malignancies associated with poor responses to COVID-19 vaccines regardless of current treatment status (e.g., chronic lymphocytic leukemia, non-Hodgkin lymphoma, multiple myeloma, acute leukemia) Receipt of solid-organ transplant or an islet transplant and taking immunosuppressive therapy Receipt of chimeric antigen receptor (CAR)-T-cell or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppressive therapy) Moderate or severe primary immunodeficiency (e.g., common variable immunodeficiency disease, severe combined immunodeficiency, DiGeorge syndrome, Wiskott-Aldrich syndrome) Advanced or untreated HIV infection (people with HIV and CD4 cell counts <200/mm 3 , history of an AIDS-defining illness without immune reconstitution, or clinical manifestations of symptomatic HIV) Active treatment with high-dose corticosteroids (i.e., ≥20 mg prednisone or equivalent per day when administered for ≥2 weeks), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, and biologic agents that are immunosuppressive or immunomodulatory (e.g., B-cell depleting agents) Limitations of Authorized Use PEMGARDA is not authorized for use: For treatment of COVID-19, or For post-exposure prophylaxis of COVID-19 in individuals who have been exposed to someone infected with SARS-CoV-2. Pre-exposure prophylaxis with PEMGARDA is not a substitute for vaccination in individuals for whom COVID-19 vaccination is recommended. Individuals for whom COVID-19 vaccination is recommended, including individuals with moderate-to-severe immune compromise who may derive benefit from COVID-19 vaccination, should receive COVID‑19 vaccination. In individuals who have recently received a COVID-19 vaccine, PEMGARDA should be administered at least 2 weeks after vaccination. PEMGARDA may only be prescribed for an individual patient by physicians, advanced practice registered nurses, and physician assistants that are licensed or authorized under State law to prescribe drugs. PEMGARDA has been authorized by FDA for the emergency use described above. PEMGARDA is not FDA-approved for any use, including use for pre-exposure prophylaxis of COVID-19. PEMGARDA is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of PEMGARDA under section 564(b)(1) of the FD&C Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. Justification for Emergency Use of Drugs During the COVID‑19 Pandemic: There is currently an outbreak of coronavirus disease 2019 (COVID‑19) caused by SARS‑CoV‑2, a novel coronavirus. The Secretary of the U.S. Department of Health and Human Services (HHS) has: Determined that there is a public health emergency, or significant potential for a public health emergency [1] . Declared that circumstances exist justifying the authorization of emergency use of drugs and biological products for the prevention or treatment of COVID-19 [2] . An EUA is an FDA authorization for the emergency use of an unapproved product or unapproved use of an approved product (i.e., drug, biological product, or device) in the United States under certain circumstances including, but not limited to, when the Secretary of HHS declares that there is a public health emergency that affects the national security or the health and security of United States citizens living abroad, and that involves biological agent(s) or a disease or condition that may be attributable to such agent(s). Criteria for issuing an EUA include: The biological agent(s) can cause a serious or life-threatening disease or condition. Based on the totality of the available scientific evidence (including data from adequate and well controlled clinical trials, if available), it is reasonable to believe that: the product may be effective in diagnosing, treating, or preventing the serious or life-threatening disease or condition; and the known and potential benefits of the product - when used to diagnose, prevent, or treat such disease or condition - outweigh the known and potential risks of the product, taking into consideration the material threat posed by the biological agent(s). There is no adequate, approved, and available alternative to the product for diagnosing, preventing, or treating the serious or life-threatening disease or condition. Information Regarding Available Alternatives for the EUA Authorized Use There are no adequate, approved, and available alternatives to PEMGARDA for the pre-exposure prophylaxis of COVID-19 in individuals who are unlikely to mount an adequate immune response to COVID-19 vaccination. For information on clinical studies of PEMGARDA and other therapies for the pre-exposure prophylaxis of COVID-19, see www.clinicaltrials.gov . DRUGBANK:DB18720 uuid:bd0e8cb1-5ae7-4e1c-9dbf-3829c5e85045 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C5908975 biolink:treats MONDO:0009693 PMID:41385096 "[{""id"":""uuid:1ae9cb3e-9279-4b13-9a81-1ffd174d8e9b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dea82b40-2268-4349-a9d2-e48f75bd2c35"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the emergency use of the unapproved product PEMGARDA (pemivibart) for the pre-exposure prophylaxis of coronavirus disease 2019 (COVID-19) in adults and adolescents (12 years of age and older weighing at least 40 kg): Who are not currently infected with SARS-CoV-2 and who have not had a known recent exposure to an individual infected with SARS-CoV-2 and Who have moderate-to-severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments and are unlikely to mount an adequate response to COVID-19 vaccination. Medical conditions or treatments that may result in moderate to severe immune compromise and an inadequate immune response to COVID-19 vaccination include: Active treatment for solid tumor and hematologic malignancies Hematologic malignancies associated with poor responses to COVID-19 vaccines regardless of current treatment status (e.g., chronic lymphocytic leukemia, non-Hodgkin lymphoma, multiple myeloma, acute leukemia) Receipt of solid-organ transplant or an islet transplant and taking immunosuppressive therapy Receipt of chimeric antigen receptor (CAR)-T-cell or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppressive therapy) Moderate or severe primary immunodeficiency (e.g., common variable immunodeficiency disease, severe combined immunodeficiency, DiGeorge syndrome, Wiskott-Aldrich syndrome) Advanced or untreated HIV infection (people with HIV and CD4 cell counts <200/mm 3 , history of an AIDS-defining illness without immune reconstitution, or clinical manifestations of symptomatic HIV) Active treatment with high-dose corticosteroids (i.e., ≥20 mg prednisone or equivalent per day when administered for ≥2 weeks), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, and biologic agents that are immunosuppressive or immunomodulatory (e.g., B-cell depleting agents) Limitations of Authorized Use PEMGARDA is not authorized for use: For treatment of COVID-19, or For post-exposure prophylaxis of COVID-19 in individuals who have been exposed to someone infected with SARS-CoV-2. Pre-exposure prophylaxis with PEMGARDA is not a substitute for vaccination in individuals for whom COVID-19 vaccination is recommended. Individuals for whom COVID-19 vaccination is recommended, including individuals with moderate-to-severe immune compromise who may derive benefit from COVID-19 vaccination, should receive COVID‑19 vaccination. In individuals who have recently received a COVID-19 vaccine, PEMGARDA should be administered at least 2 weeks after vaccination. PEMGARDA may only be prescribed for an individual patient by physicians, advanced practice registered nurses, and physician assistants that are licensed or authorized under State law to prescribe drugs. PEMGARDA has been authorized by FDA for the emergency use described above. PEMGARDA is not FDA-approved for any use, including use for pre-exposure prophylaxis of COVID-19. PEMGARDA is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of PEMGARDA under section 564(b)(1) of the FD&C Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. Justification for Emergency Use of Drugs During the COVID‑19 Pandemic: There is currently an outbreak of coronavirus disease 2019 (COVID‑19) caused by SARS‑CoV‑2, a novel coronavirus. The Secretary of the U.S. Department of Health and Human Services (HHS) has: Determined that there is a public health emergency, or significant potential for a public health emergency [1] . Declared that circumstances exist justifying the authorization of emergency use of drugs and biological products for the prevention or treatment of COVID-19 [2] . An EUA is an FDA authorization for the emergency use of an unapproved product or unapproved use of an approved product (i.e., drug, biological product, or device) in the United States under certain circumstances including, but not limited to, when the Secretary of HHS declares that there is a public health emergency that affects the national security or the health and security of United States citizens living abroad, and that involves biological agent(s) or a disease or condition that may be attributable to such agent(s). Criteria for issuing an EUA include: The biological agent(s) can cause a serious or life-threatening disease or condition. Based on the totality of the available scientific evidence (including data from adequate and well controlled clinical trials, if available), it is reasonable to believe that: the product may be effective in diagnosing, treating, or preventing the serious or life-threatening disease or condition; and the known and potential benefits of the product - when used to diagnose, prevent, or treat such disease or condition - outweigh the known and potential risks of the product, taking into consideration the material threat posed by the biological agent(s). There is no adequate, approved, and available alternative to the product for diagnosing, preventing, or treating the serious or life-threatening disease or condition. Information Regarding Available Alternatives for the EUA Authorized Use There are no adequate, approved, and available alternatives to PEMGARDA for the pre-exposure prophylaxis of COVID-19 in individuals who are unlikely to mount an adequate immune response to COVID-19 vaccination. For information on clinical studies of PEMGARDA and other therapies for the pre-exposure prophylaxis of COVID-19, see www.clinicaltrials.gov . DRUGBANK:DB18720 uuid:36117145-0eff-4acd-b504-633b50c1eed0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C5908975 biolink:treats MONDO:0010643 PMID:41385096 "[{""id"":""uuid:2690b54e-9e93-4b1a-bc3f-9e4410b1fe66"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ce60ca84-dfc1-449f-8182-04eb2cbed88c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the emergency use of the unapproved product PEMGARDA (pemivibart) for the pre-exposure prophylaxis of coronavirus disease 2019 (COVID-19) in adults and adolescents (12 years of age and older weighing at least 40 kg): Who are not currently infected with SARS-CoV-2 and who have not had a known recent exposure to an individual infected with SARS-CoV-2 and Who have moderate-to-severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments and are unlikely to mount an adequate response to COVID-19 vaccination. Medical conditions or treatments that may result in moderate to severe immune compromise and an inadequate immune response to COVID-19 vaccination include: Active treatment for solid tumor and hematologic malignancies Hematologic malignancies associated with poor responses to COVID-19 vaccines regardless of current treatment status (e.g., chronic lymphocytic leukemia, non-Hodgkin lymphoma, multiple myeloma, acute leukemia) Receipt of solid-organ transplant or an islet transplant and taking immunosuppressive therapy Receipt of chimeric antigen receptor (CAR)-T-cell or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppressive therapy) Moderate or severe primary immunodeficiency (e.g., common variable immunodeficiency disease, severe combined immunodeficiency, DiGeorge syndrome, Wiskott-Aldrich syndrome) Advanced or untreated HIV infection (people with HIV and CD4 cell counts <200/mm 3 , history of an AIDS-defining illness without immune reconstitution, or clinical manifestations of symptomatic HIV) Active treatment with high-dose corticosteroids (i.e., ≥20 mg prednisone or equivalent per day when administered for ≥2 weeks), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, and biologic agents that are immunosuppressive or immunomodulatory (e.g., B-cell depleting agents) Limitations of Authorized Use PEMGARDA is not authorized for use: For treatment of COVID-19, or For post-exposure prophylaxis of COVID-19 in individuals who have been exposed to someone infected with SARS-CoV-2. Pre-exposure prophylaxis with PEMGARDA is not a substitute for vaccination in individuals for whom COVID-19 vaccination is recommended. Individuals for whom COVID-19 vaccination is recommended, including individuals with moderate-to-severe immune compromise who may derive benefit from COVID-19 vaccination, should receive COVID‑19 vaccination. In individuals who have recently received a COVID-19 vaccine, PEMGARDA should be administered at least 2 weeks after vaccination. PEMGARDA may only be prescribed for an individual patient by physicians, advanced practice registered nurses, and physician assistants that are licensed or authorized under State law to prescribe drugs. PEMGARDA has been authorized by FDA for the emergency use described above. PEMGARDA is not FDA-approved for any use, including use for pre-exposure prophylaxis of COVID-19. PEMGARDA is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of PEMGARDA under section 564(b)(1) of the FD&C Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. Justification for Emergency Use of Drugs During the COVID‑19 Pandemic: There is currently an outbreak of coronavirus disease 2019 (COVID‑19) caused by SARS‑CoV‑2, a novel coronavirus. The Secretary of the U.S. Department of Health and Human Services (HHS) has: Determined that there is a public health emergency, or significant potential for a public health emergency [1] . Declared that circumstances exist justifying the authorization of emergency use of drugs and biological products for the prevention or treatment of COVID-19 [2] . An EUA is an FDA authorization for the emergency use of an unapproved product or unapproved use of an approved product (i.e., drug, biological product, or device) in the United States under certain circumstances including, but not limited to, when the Secretary of HHS declares that there is a public health emergency that affects the national security or the health and security of United States citizens living abroad, and that involves biological agent(s) or a disease or condition that may be attributable to such agent(s). Criteria for issuing an EUA include: The biological agent(s) can cause a serious or life-threatening disease or condition. Based on the totality of the available scientific evidence (including data from adequate and well controlled clinical trials, if available), it is reasonable to believe that: the product may be effective in diagnosing, treating, or preventing the serious or life-threatening disease or condition; and the known and potential benefits of the product - when used to diagnose, prevent, or treat such disease or condition - outweigh the known and potential risks of the product, taking into consideration the material threat posed by the biological agent(s). There is no adequate, approved, and available alternative to the product for diagnosing, preventing, or treating the serious or life-threatening disease or condition. Information Regarding Available Alternatives for the EUA Authorized Use There are no adequate, approved, and available alternatives to PEMGARDA for the pre-exposure prophylaxis of COVID-19 in individuals who are unlikely to mount an adequate immune response to COVID-19 vaccination. For information on clinical studies of PEMGARDA and other therapies for the pre-exposure prophylaxis of COVID-19, see www.clinicaltrials.gov . DRUGBANK:DB18720 uuid:c4f5a12c-1e46-4224-9a87-84b520169bec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C5908975 biolink:treats MONDO:0003778 PMID:41385096 "[{""id"":""uuid:4fbeab3a-c490-4a19-908b-d2b68936a673"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9da8a768-33da-4060-8bb3-104375a0f781"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the emergency use of the unapproved product PEMGARDA (pemivibart) for the pre-exposure prophylaxis of coronavirus disease 2019 (COVID-19) in adults and adolescents (12 years of age and older weighing at least 40 kg): Who are not currently infected with SARS-CoV-2 and who have not had a known recent exposure to an individual infected with SARS-CoV-2 and Who have moderate-to-severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments and are unlikely to mount an adequate response to COVID-19 vaccination. Medical conditions or treatments that may result in moderate to severe immune compromise and an inadequate immune response to COVID-19 vaccination include: Active treatment for solid tumor and hematologic malignancies Hematologic malignancies associated with poor responses to COVID-19 vaccines regardless of current treatment status (e.g., chronic lymphocytic leukemia, non-Hodgkin lymphoma, multiple myeloma, acute leukemia) Receipt of solid-organ transplant or an islet transplant and taking immunosuppressive therapy Receipt of chimeric antigen receptor (CAR)-T-cell or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppressive therapy) Moderate or severe primary immunodeficiency (e.g., common variable immunodeficiency disease, severe combined immunodeficiency, DiGeorge syndrome, Wiskott-Aldrich syndrome) Advanced or untreated HIV infection (people with HIV and CD4 cell counts <200/mm 3 , history of an AIDS-defining illness without immune reconstitution, or clinical manifestations of symptomatic HIV) Active treatment with high-dose corticosteroids (i.e., ≥20 mg prednisone or equivalent per day when administered for ≥2 weeks), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, and biologic agents that are immunosuppressive or immunomodulatory (e.g., B-cell depleting agents) Limitations of Authorized Use PEMGARDA is not authorized for use: For treatment of COVID-19, or For post-exposure prophylaxis of COVID-19 in individuals who have been exposed to someone infected with SARS-CoV-2. Pre-exposure prophylaxis with PEMGARDA is not a substitute for vaccination in individuals for whom COVID-19 vaccination is recommended. Individuals for whom COVID-19 vaccination is recommended, including individuals with moderate-to-severe immune compromise who may derive benefit from COVID-19 vaccination, should receive COVID‑19 vaccination. In individuals who have recently received a COVID-19 vaccine, PEMGARDA should be administered at least 2 weeks after vaccination. PEMGARDA may only be prescribed for an individual patient by physicians, advanced practice registered nurses, and physician assistants that are licensed or authorized under State law to prescribe drugs. PEMGARDA has been authorized by FDA for the emergency use described above. PEMGARDA is not FDA-approved for any use, including use for pre-exposure prophylaxis of COVID-19. PEMGARDA is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of PEMGARDA under section 564(b)(1) of the FD&C Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. Justification for Emergency Use of Drugs During the COVID‑19 Pandemic: There is currently an outbreak of coronavirus disease 2019 (COVID‑19) caused by SARS‑CoV‑2, a novel coronavirus. The Secretary of the U.S. Department of Health and Human Services (HHS) has: Determined that there is a public health emergency, or significant potential for a public health emergency [1] . Declared that circumstances exist justifying the authorization of emergency use of drugs and biological products for the prevention or treatment of COVID-19 [2] . An EUA is an FDA authorization for the emergency use of an unapproved product or unapproved use of an approved product (i.e., drug, biological product, or device) in the United States under certain circumstances including, but not limited to, when the Secretary of HHS declares that there is a public health emergency that affects the national security or the health and security of United States citizens living abroad, and that involves biological agent(s) or a disease or condition that may be attributable to such agent(s). Criteria for issuing an EUA include: The biological agent(s) can cause a serious or life-threatening disease or condition. Based on the totality of the available scientific evidence (including data from adequate and well controlled clinical trials, if available), it is reasonable to believe that: the product may be effective in diagnosing, treating, or preventing the serious or life-threatening disease or condition; and the known and potential benefits of the product - when used to diagnose, prevent, or treat such disease or condition - outweigh the known and potential risks of the product, taking into consideration the material threat posed by the biological agent(s). There is no adequate, approved, and available alternative to the product for diagnosing, preventing, or treating the serious or life-threatening disease or condition. Information Regarding Available Alternatives for the EUA Authorized Use There are no adequate, approved, and available alternatives to PEMGARDA for the pre-exposure prophylaxis of COVID-19 in individuals who are unlikely to mount an adequate immune response to COVID-19 vaccination. For information on clinical studies of PEMGARDA and other therapies for the pre-exposure prophylaxis of COVID-19, see www.clinicaltrials.gov . DRUGBANK:DB18720 uuid:f88f386d-c2ce-427c-ae09-552274feae20 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C5908975 biolink:treats MONDO:0015517 PMID:41385096 "[{""id"":""uuid:daabd404-2c57-4e7a-a48c-435aa4ef599c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5b2b9af9-5e2e-4837-939e-fa14f5a84460"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the emergency use of the unapproved product PEMGARDA (pemivibart) for the pre-exposure prophylaxis of coronavirus disease 2019 (COVID-19) in adults and adolescents (12 years of age and older weighing at least 40 kg): Who are not currently infected with SARS-CoV-2 and who have not had a known recent exposure to an individual infected with SARS-CoV-2 and Who have moderate-to-severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments and are unlikely to mount an adequate response to COVID-19 vaccination. Medical conditions or treatments that may result in moderate to severe immune compromise and an inadequate immune response to COVID-19 vaccination include: Active treatment for solid tumor and hematologic malignancies Hematologic malignancies associated with poor responses to COVID-19 vaccines regardless of current treatment status (e.g., chronic lymphocytic leukemia, non-Hodgkin lymphoma, multiple myeloma, acute leukemia) Receipt of solid-organ transplant or an islet transplant and taking immunosuppressive therapy Receipt of chimeric antigen receptor (CAR)-T-cell or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppressive therapy) Moderate or severe primary immunodeficiency (e.g., common variable immunodeficiency disease, severe combined immunodeficiency, DiGeorge syndrome, Wiskott-Aldrich syndrome) Advanced or untreated HIV infection (people with HIV and CD4 cell counts <200/mm 3 , history of an AIDS-defining illness without immune reconstitution, or clinical manifestations of symptomatic HIV) Active treatment with high-dose corticosteroids (i.e., ≥20 mg prednisone or equivalent per day when administered for ≥2 weeks), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, and biologic agents that are immunosuppressive or immunomodulatory (e.g., B-cell depleting agents) Limitations of Authorized Use PEMGARDA is not authorized for use: For treatment of COVID-19, or For post-exposure prophylaxis of COVID-19 in individuals who have been exposed to someone infected with SARS-CoV-2. Pre-exposure prophylaxis with PEMGARDA is not a substitute for vaccination in individuals for whom COVID-19 vaccination is recommended. Individuals for whom COVID-19 vaccination is recommended, including individuals with moderate-to-severe immune compromise who may derive benefit from COVID-19 vaccination, should receive COVID‑19 vaccination. In individuals who have recently received a COVID-19 vaccine, PEMGARDA should be administered at least 2 weeks after vaccination. PEMGARDA may only be prescribed for an individual patient by physicians, advanced practice registered nurses, and physician assistants that are licensed or authorized under State law to prescribe drugs. PEMGARDA has been authorized by FDA for the emergency use described above. PEMGARDA is not FDA-approved for any use, including use for pre-exposure prophylaxis of COVID-19. PEMGARDA is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of PEMGARDA under section 564(b)(1) of the FD&C Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. Justification for Emergency Use of Drugs During the COVID‑19 Pandemic: There is currently an outbreak of coronavirus disease 2019 (COVID‑19) caused by SARS‑CoV‑2, a novel coronavirus. The Secretary of the U.S. Department of Health and Human Services (HHS) has: Determined that there is a public health emergency, or significant potential for a public health emergency [1] . Declared that circumstances exist justifying the authorization of emergency use of drugs and biological products for the prevention or treatment of COVID-19 [2] . An EUA is an FDA authorization for the emergency use of an unapproved product or unapproved use of an approved product (i.e., drug, biological product, or device) in the United States under certain circumstances including, but not limited to, when the Secretary of HHS declares that there is a public health emergency that affects the national security or the health and security of United States citizens living abroad, and that involves biological agent(s) or a disease or condition that may be attributable to such agent(s). Criteria for issuing an EUA include: The biological agent(s) can cause a serious or life-threatening disease or condition. Based on the totality of the available scientific evidence (including data from adequate and well controlled clinical trials, if available), it is reasonable to believe that: the product may be effective in diagnosing, treating, or preventing the serious or life-threatening disease or condition; and the known and potential benefits of the product - when used to diagnose, prevent, or treat such disease or condition - outweigh the known and potential risks of the product, taking into consideration the material threat posed by the biological agent(s). There is no adequate, approved, and available alternative to the product for diagnosing, preventing, or treating the serious or life-threatening disease or condition. Information Regarding Available Alternatives for the EUA Authorized Use There are no adequate, approved, and available alternatives to PEMGARDA for the pre-exposure prophylaxis of COVID-19 in individuals who are unlikely to mount an adequate immune response to COVID-19 vaccination. For information on clinical studies of PEMGARDA and other therapies for the pre-exposure prophylaxis of COVID-19, see www.clinicaltrials.gov . DRUGBANK:DB18720 uuid:cee8b97f-f731-46b3-8b1b-8b0444644ff1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C5908975 biolink:treats MONDO:0015974 PMID:41385096 "[{""id"":""uuid:31b25614-211c-45a5-ae08-406aa416e95f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4b059db0-a5b0-43ac-b1c9-ca6f4e802cc1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the emergency use of the unapproved product PEMGARDA (pemivibart) for the pre-exposure prophylaxis of coronavirus disease 2019 (COVID-19) in adults and adolescents (12 years of age and older weighing at least 40 kg): Who are not currently infected with SARS-CoV-2 and who have not had a known recent exposure to an individual infected with SARS-CoV-2 and Who have moderate-to-severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments and are unlikely to mount an adequate response to COVID-19 vaccination. Medical conditions or treatments that may result in moderate to severe immune compromise and an inadequate immune response to COVID-19 vaccination include: Active treatment for solid tumor and hematologic malignancies Hematologic malignancies associated with poor responses to COVID-19 vaccines regardless of current treatment status (e.g., chronic lymphocytic leukemia, non-Hodgkin lymphoma, multiple myeloma, acute leukemia) Receipt of solid-organ transplant or an islet transplant and taking immunosuppressive therapy Receipt of chimeric antigen receptor (CAR)-T-cell or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppressive therapy) Moderate or severe primary immunodeficiency (e.g., common variable immunodeficiency disease, severe combined immunodeficiency, DiGeorge syndrome, Wiskott-Aldrich syndrome) Advanced or untreated HIV infection (people with HIV and CD4 cell counts <200/mm 3 , history of an AIDS-defining illness without immune reconstitution, or clinical manifestations of symptomatic HIV) Active treatment with high-dose corticosteroids (i.e., ≥20 mg prednisone or equivalent per day when administered for ≥2 weeks), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, and biologic agents that are immunosuppressive or immunomodulatory (e.g., B-cell depleting agents) Limitations of Authorized Use PEMGARDA is not authorized for use: For treatment of COVID-19, or For post-exposure prophylaxis of COVID-19 in individuals who have been exposed to someone infected with SARS-CoV-2. Pre-exposure prophylaxis with PEMGARDA is not a substitute for vaccination in individuals for whom COVID-19 vaccination is recommended. Individuals for whom COVID-19 vaccination is recommended, including individuals with moderate-to-severe immune compromise who may derive benefit from COVID-19 vaccination, should receive COVID‑19 vaccination. In individuals who have recently received a COVID-19 vaccine, PEMGARDA should be administered at least 2 weeks after vaccination. PEMGARDA may only be prescribed for an individual patient by physicians, advanced practice registered nurses, and physician assistants that are licensed or authorized under State law to prescribe drugs. PEMGARDA has been authorized by FDA for the emergency use described above. PEMGARDA is not FDA-approved for any use, including use for pre-exposure prophylaxis of COVID-19. PEMGARDA is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of PEMGARDA under section 564(b)(1) of the FD&C Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. Justification for Emergency Use of Drugs During the COVID‑19 Pandemic: There is currently an outbreak of coronavirus disease 2019 (COVID‑19) caused by SARS‑CoV‑2, a novel coronavirus. The Secretary of the U.S. Department of Health and Human Services (HHS) has: Determined that there is a public health emergency, or significant potential for a public health emergency [1] . Declared that circumstances exist justifying the authorization of emergency use of drugs and biological products for the prevention or treatment of COVID-19 [2] . An EUA is an FDA authorization for the emergency use of an unapproved product or unapproved use of an approved product (i.e., drug, biological product, or device) in the United States under certain circumstances including, but not limited to, when the Secretary of HHS declares that there is a public health emergency that affects the national security or the health and security of United States citizens living abroad, and that involves biological agent(s) or a disease or condition that may be attributable to such agent(s). Criteria for issuing an EUA include: The biological agent(s) can cause a serious or life-threatening disease or condition. Based on the totality of the available scientific evidence (including data from adequate and well controlled clinical trials, if available), it is reasonable to believe that: the product may be effective in diagnosing, treating, or preventing the serious or life-threatening disease or condition; and the known and potential benefits of the product - when used to diagnose, prevent, or treat such disease or condition - outweigh the known and potential risks of the product, taking into consideration the material threat posed by the biological agent(s). There is no adequate, approved, and available alternative to the product for diagnosing, preventing, or treating the serious or life-threatening disease or condition. Information Regarding Available Alternatives for the EUA Authorized Use There are no adequate, approved, and available alternatives to PEMGARDA for the pre-exposure prophylaxis of COVID-19 in individuals who are unlikely to mount an adequate immune response to COVID-19 vaccination. For information on clinical studies of PEMGARDA and other therapies for the pre-exposure prophylaxis of COVID-19, see www.clinicaltrials.gov . DRUGBANK:DB18720 uuid:bd123ba1-9bd7-446f-9b3a-313dca0b09fc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C5908975 biolink:treats MONDO:0008564 PMID:41385096 "[{""id"":""uuid:67c12ab1-8df0-4f35-83b6-696e279d12c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7afa561b-2aaf-45b0-8acd-9d4fe30f5723"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the emergency use of the unapproved product PEMGARDA (pemivibart) for the pre-exposure prophylaxis of coronavirus disease 2019 (COVID-19) in adults and adolescents (12 years of age and older weighing at least 40 kg): Who are not currently infected with SARS-CoV-2 and who have not had a known recent exposure to an individual infected with SARS-CoV-2 and Who have moderate-to-severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments and are unlikely to mount an adequate response to COVID-19 vaccination. Medical conditions or treatments that may result in moderate to severe immune compromise and an inadequate immune response to COVID-19 vaccination include: Active treatment for solid tumor and hematologic malignancies Hematologic malignancies associated with poor responses to COVID-19 vaccines regardless of current treatment status (e.g., chronic lymphocytic leukemia, non-Hodgkin lymphoma, multiple myeloma, acute leukemia) Receipt of solid-organ transplant or an islet transplant and taking immunosuppressive therapy Receipt of chimeric antigen receptor (CAR)-T-cell or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppressive therapy) Moderate or severe primary immunodeficiency (e.g., common variable immunodeficiency disease, severe combined immunodeficiency, DiGeorge syndrome, Wiskott-Aldrich syndrome) Advanced or untreated HIV infection (people with HIV and CD4 cell counts <200/mm 3 , history of an AIDS-defining illness without immune reconstitution, or clinical manifestations of symptomatic HIV) Active treatment with high-dose corticosteroids (i.e., ≥20 mg prednisone or equivalent per day when administered for ≥2 weeks), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, and biologic agents that are immunosuppressive or immunomodulatory (e.g., B-cell depleting agents) Limitations of Authorized Use PEMGARDA is not authorized for use: For treatment of COVID-19, or For post-exposure prophylaxis of COVID-19 in individuals who have been exposed to someone infected with SARS-CoV-2. Pre-exposure prophylaxis with PEMGARDA is not a substitute for vaccination in individuals for whom COVID-19 vaccination is recommended. Individuals for whom COVID-19 vaccination is recommended, including individuals with moderate-to-severe immune compromise who may derive benefit from COVID-19 vaccination, should receive COVID‑19 vaccination. In individuals who have recently received a COVID-19 vaccine, PEMGARDA should be administered at least 2 weeks after vaccination. PEMGARDA may only be prescribed for an individual patient by physicians, advanced practice registered nurses, and physician assistants that are licensed or authorized under State law to prescribe drugs. PEMGARDA has been authorized by FDA for the emergency use described above. PEMGARDA is not FDA-approved for any use, including use for pre-exposure prophylaxis of COVID-19. PEMGARDA is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of PEMGARDA under section 564(b)(1) of the FD&C Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. Justification for Emergency Use of Drugs During the COVID‑19 Pandemic: There is currently an outbreak of coronavirus disease 2019 (COVID‑19) caused by SARS‑CoV‑2, a novel coronavirus. The Secretary of the U.S. Department of Health and Human Services (HHS) has: Determined that there is a public health emergency, or significant potential for a public health emergency [1] . Declared that circumstances exist justifying the authorization of emergency use of drugs and biological products for the prevention or treatment of COVID-19 [2] . An EUA is an FDA authorization for the emergency use of an unapproved product or unapproved use of an approved product (i.e., drug, biological product, or device) in the United States under certain circumstances including, but not limited to, when the Secretary of HHS declares that there is a public health emergency that affects the national security or the health and security of United States citizens living abroad, and that involves biological agent(s) or a disease or condition that may be attributable to such agent(s). Criteria for issuing an EUA include: The biological agent(s) can cause a serious or life-threatening disease or condition. Based on the totality of the available scientific evidence (including data from adequate and well controlled clinical trials, if available), it is reasonable to believe that: the product may be effective in diagnosing, treating, or preventing the serious or life-threatening disease or condition; and the known and potential benefits of the product - when used to diagnose, prevent, or treat such disease or condition - outweigh the known and potential risks of the product, taking into consideration the material threat posed by the biological agent(s). There is no adequate, approved, and available alternative to the product for diagnosing, preventing, or treating the serious or life-threatening disease or condition. Information Regarding Available Alternatives for the EUA Authorized Use There are no adequate, approved, and available alternatives to PEMGARDA for the pre-exposure prophylaxis of COVID-19 in individuals who are unlikely to mount an adequate immune response to COVID-19 vaccination. For information on clinical studies of PEMGARDA and other therapies for the pre-exposure prophylaxis of COVID-19, see www.clinicaltrials.gov . DRUGBANK:DB18720 uuid:dcd4267b-dabd-4c3f-8f63-6073b75fd95f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C5908975 biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:02f7e36b-3b2a-4fe1-bd56-298247861e60"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:481a4e93-7c3d-4f10-9d28-4859e1232d71"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the emergency use of the unapproved product PEMGARDA (pemivibart) for the pre-exposure prophylaxis of coronavirus disease 2019 (COVID-19) in adults and adolescents (12 years of age and older weighing at least 40 kg): Who are not currently infected with SARS-CoV-2 and who have not had a known recent exposure to an individual infected with SARS-CoV-2 and Who have moderate-to-severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments and are unlikely to mount an adequate response to COVID-19 vaccination. Medical conditions or treatments that may result in moderate to severe immune compromise and an inadequate immune response to COVID-19 vaccination include: Active treatment for solid tumor and hematologic malignancies Hematologic malignancies associated with poor responses to COVID-19 vaccines regardless of current treatment status (e.g., chronic lymphocytic leukemia, non-Hodgkin lymphoma, multiple myeloma, acute leukemia) Receipt of solid-organ transplant or an islet transplant and taking immunosuppressive therapy Receipt of chimeric antigen receptor (CAR)-T-cell or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppressive therapy) Moderate or severe primary immunodeficiency (e.g., common variable immunodeficiency disease, severe combined immunodeficiency, DiGeorge syndrome, Wiskott-Aldrich syndrome) Advanced or untreated HIV infection (people with HIV and CD4 cell counts <200/mm 3 , history of an AIDS-defining illness without immune reconstitution, or clinical manifestations of symptomatic HIV) Active treatment with high-dose corticosteroids (i.e., ≥20 mg prednisone or equivalent per day when administered for ≥2 weeks), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, and biologic agents that are immunosuppressive or immunomodulatory (e.g., B-cell depleting agents) Limitations of Authorized Use PEMGARDA is not authorized for use: For treatment of COVID-19, or For post-exposure prophylaxis of COVID-19 in individuals who have been exposed to someone infected with SARS-CoV-2. Pre-exposure prophylaxis with PEMGARDA is not a substitute for vaccination in individuals for whom COVID-19 vaccination is recommended. Individuals for whom COVID-19 vaccination is recommended, including individuals with moderate-to-severe immune compromise who may derive benefit from COVID-19 vaccination, should receive COVID‑19 vaccination. In individuals who have recently received a COVID-19 vaccine, PEMGARDA should be administered at least 2 weeks after vaccination. PEMGARDA may only be prescribed for an individual patient by physicians, advanced practice registered nurses, and physician assistants that are licensed or authorized under State law to prescribe drugs. PEMGARDA has been authorized by FDA for the emergency use described above. PEMGARDA is not FDA-approved for any use, including use for pre-exposure prophylaxis of COVID-19. PEMGARDA is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of PEMGARDA under section 564(b)(1) of the FD&C Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. Justification for Emergency Use of Drugs During the COVID‑19 Pandemic: There is currently an outbreak of coronavirus disease 2019 (COVID‑19) caused by SARS‑CoV‑2, a novel coronavirus. The Secretary of the U.S. Department of Health and Human Services (HHS) has: Determined that there is a public health emergency, or significant potential for a public health emergency [1] . Declared that circumstances exist justifying the authorization of emergency use of drugs and biological products for the prevention or treatment of COVID-19 [2] . An EUA is an FDA authorization for the emergency use of an unapproved product or unapproved use of an approved product (i.e., drug, biological product, or device) in the United States under certain circumstances including, but not limited to, when the Secretary of HHS declares that there is a public health emergency that affects the national security or the health and security of United States citizens living abroad, and that involves biological agent(s) or a disease or condition that may be attributable to such agent(s). Criteria for issuing an EUA include: The biological agent(s) can cause a serious or life-threatening disease or condition. Based on the totality of the available scientific evidence (including data from adequate and well controlled clinical trials, if available), it is reasonable to believe that: the product may be effective in diagnosing, treating, or preventing the serious or life-threatening disease or condition; and the known and potential benefits of the product - when used to diagnose, prevent, or treat such disease or condition - outweigh the known and potential risks of the product, taking into consideration the material threat posed by the biological agent(s). There is no adequate, approved, and available alternative to the product for diagnosing, preventing, or treating the serious or life-threatening disease or condition. Information Regarding Available Alternatives for the EUA Authorized Use There are no adequate, approved, and available alternatives to PEMGARDA for the pre-exposure prophylaxis of COVID-19 in individuals who are unlikely to mount an adequate immune response to COVID-19 vaccination. For information on clinical studies of PEMGARDA and other therapies for the pre-exposure prophylaxis of COVID-19, see www.clinicaltrials.gov . DRUGBANK:DB18720 uuid:d11cd298-1009-4b59-9bc8-c5e83df2af1e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C5908975 biolink:treats UMLS:C0740830 PMID:41385096 "[{""id"":""uuid:8dae7cea-ef4e-4b05-b58d-2609e22f1a02"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2fa7bd4a-d0dc-4a80-a3c0-065e871d1cb1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the emergency use of the unapproved product PEMGARDA (pemivibart) for the pre-exposure prophylaxis of coronavirus disease 2019 (COVID-19) in adults and adolescents (12 years of age and older weighing at least 40 kg): Who are not currently infected with SARS-CoV-2 and who have not had a known recent exposure to an individual infected with SARS-CoV-2 and Who have moderate-to-severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments and are unlikely to mount an adequate response to COVID-19 vaccination. Medical conditions or treatments that may result in moderate to severe immune compromise and an inadequate immune response to COVID-19 vaccination include: Active treatment for solid tumor and hematologic malignancies Hematologic malignancies associated with poor responses to COVID-19 vaccines regardless of current treatment status (e.g., chronic lymphocytic leukemia, non-Hodgkin lymphoma, multiple myeloma, acute leukemia) Receipt of solid-organ transplant or an islet transplant and taking immunosuppressive therapy Receipt of chimeric antigen receptor (CAR)-T-cell or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppressive therapy) Moderate or severe primary immunodeficiency (e.g., common variable immunodeficiency disease, severe combined immunodeficiency, DiGeorge syndrome, Wiskott-Aldrich syndrome) Advanced or untreated HIV infection (people with HIV and CD4 cell counts <200/mm 3 , history of an AIDS-defining illness without immune reconstitution, or clinical manifestations of symptomatic HIV) Active treatment with high-dose corticosteroids (i.e., ≥20 mg prednisone or equivalent per day when administered for ≥2 weeks), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, and biologic agents that are immunosuppressive or immunomodulatory (e.g., B-cell depleting agents) Limitations of Authorized Use PEMGARDA is not authorized for use: For treatment of COVID-19, or For post-exposure prophylaxis of COVID-19 in individuals who have been exposed to someone infected with SARS-CoV-2. Pre-exposure prophylaxis with PEMGARDA is not a substitute for vaccination in individuals for whom COVID-19 vaccination is recommended. Individuals for whom COVID-19 vaccination is recommended, including individuals with moderate-to-severe immune compromise who may derive benefit from COVID-19 vaccination, should receive COVID‑19 vaccination. In individuals who have recently received a COVID-19 vaccine, PEMGARDA should be administered at least 2 weeks after vaccination. PEMGARDA may only be prescribed for an individual patient by physicians, advanced practice registered nurses, and physician assistants that are licensed or authorized under State law to prescribe drugs. PEMGARDA has been authorized by FDA for the emergency use described above. PEMGARDA is not FDA-approved for any use, including use for pre-exposure prophylaxis of COVID-19. PEMGARDA is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of PEMGARDA under section 564(b)(1) of the FD&C Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. Justification for Emergency Use of Drugs During the COVID‑19 Pandemic: There is currently an outbreak of coronavirus disease 2019 (COVID‑19) caused by SARS‑CoV‑2, a novel coronavirus. The Secretary of the U.S. Department of Health and Human Services (HHS) has: Determined that there is a public health emergency, or significant potential for a public health emergency [1] . Declared that circumstances exist justifying the authorization of emergency use of drugs and biological products for the prevention or treatment of COVID-19 [2] . An EUA is an FDA authorization for the emergency use of an unapproved product or unapproved use of an approved product (i.e., drug, biological product, or device) in the United States under certain circumstances including, but not limited to, when the Secretary of HHS declares that there is a public health emergency that affects the national security or the health and security of United States citizens living abroad, and that involves biological agent(s) or a disease or condition that may be attributable to such agent(s). Criteria for issuing an EUA include: The biological agent(s) can cause a serious or life-threatening disease or condition. Based on the totality of the available scientific evidence (including data from adequate and well controlled clinical trials, if available), it is reasonable to believe that: the product may be effective in diagnosing, treating, or preventing the serious or life-threatening disease or condition; and the known and potential benefits of the product - when used to diagnose, prevent, or treat such disease or condition - outweigh the known and potential risks of the product, taking into consideration the material threat posed by the biological agent(s). There is no adequate, approved, and available alternative to the product for diagnosing, preventing, or treating the serious or life-threatening disease or condition. Information Regarding Available Alternatives for the EUA Authorized Use There are no adequate, approved, and available alternatives to PEMGARDA for the pre-exposure prophylaxis of COVID-19 in individuals who are unlikely to mount an adequate immune response to COVID-19 vaccination. For information on clinical studies of PEMGARDA and other therapies for the pre-exposure prophylaxis of COVID-19, see www.clinicaltrials.gov . DRUGBANK:DB18720 uuid:dc3ffbf4-e260-4c8f-a422-33f1b6c9fa58 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:X05U0N2RCO biolink:treats MONDO:0004956 PMID:41385096 "[{""id"":""uuid:5b7693f7-10dd-4ff7-b43a-fbff55f4fee7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1a27dde0-743e-48dd-8282-9245be1f9dc2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ca8433ce-9d36-4243-b44d-304933a4103b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/nubeqa""]},{""id"":""uuid:797bfe33-cecf-474c-b364-e5a76566cb4d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NUBEQA is an androgen receptor inhibitor indicated for the treatment of adult patients with: non-metastatic castration-resistant prostate cancer (nmCRPC). ( 1 ) metastatic castration-sensitive prostate cancer (mCSPC). ( 1 ) metastatic castration-sensitive prostate cancer (mCSPC) in combination with docetaxel. ( 1 )|[EMA] NUBEQA is indicated for the treatment of adult men with- non metastatic castration resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease (see section 5.1).- metastatic hormone sensitive prostate cancer (mHSPC) in combination with docetaxel and androgen deprivation therapy (see section 5.1).|[PMDA] A drug with a new indication and a new dosage for the treatment of metastatic prostate cancer. uuid:824de656-d580-4d89-827d-19951ae105e3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:09495UIM6V biolink:treats UMLS:C0406317 PMID:41385096 "[{""id"":""uuid:fed205b4-a7e9-491c-902b-3bfa3eb913be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b306a6df-aa15-4a8f-aec2-cb7ed0c31559"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:78cfddb1-c204-40bb-b056-8c7776553f2f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BIMZELX is a humanized interleukin-17A and F antagonist indicated for the treatment of: Moderate to severe plaque psoriasis (PSO) in adults who are candidates for systemic therapy or phototherapy. ( 1.1 ) Adults with active psoriatic arthritis (PsA) . ( 1.2 ) Adults with active non-radiographic axial spondyloarthritis ( nr-axSpA ) with objective signs of inflammation. ( 1.3 ) Adults with active ankylosing spondylitis ( AS ). ( 1.4 ) Adults with moderate to severe hidradenitis suppurativa (HS) . ( 1.5 )|[PMDA] Drugs with a new active ingredient indicated for the treatment of plaque psoriasis, pustular psoriasis, and erythrodermic psoriasis in patients who have not responded sufficiently to conventional therapies. uuid:6110cad9-08ed-409e-9768-6a2987179314 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:09495UIM6V biolink:treats MONDO:0011849 PMID:41385096 "[{""id"":""uuid:747a20b7-e203-491c-86ae-28ab9393e669"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:66f15efd-89c4-4a7b-a0cc-51bb14907cf9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:82c15c03-adba-40d9-858d-38e52ff88132"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/bimzelx""]},{""id"":""uuid:8c820337-e220-41a3-8090-ff2a7c0bfc6e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BIMZELX is a humanized interleukin-17A and F antagonist indicated for the treatment of: Moderate to severe plaque psoriasis (PSO) in adults who are candidates for systemic therapy or phototherapy. ( 1.1 ) Adults with active psoriatic arthritis (PsA) . ( 1.2 ) Adults with active non-radiographic axial spondyloarthritis ( nr-axSpA ) with objective signs of inflammation. ( 1.3 ) Adults with active ankylosing spondylitis ( AS ). ( 1.4 ) Adults with moderate to severe hidradenitis suppurativa (HS) . ( 1.5 )|[EMA] Plaque psoriasisBimzelx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.Psoriatic arthritisBimzelx, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (DMARDs).Axial spondyloarthritisNon-radiographic axial spondyloarthritis (nr-axSpA)Bimzelx is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs (NSAIDs).Ankylosing spondylitis (AS, radiographic axial spondyloarthritis)Bimzelx is indicated for the treatment of adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.|[PMDA] Drugs with a new indication and a new dosage for the treatment of psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis in patients who have not sufficiently responded to conventional treatments. uuid:16d7f02a-81f1-4302-8e6d-5ea283b75207 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:09495UIM6V biolink:treats UMLS:C3203547 PMID:41385096 "[{""id"":""uuid:0295d2d2-c7da-4b85-9a9c-92f0bd99b31b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ae498d20-d4d8-4213-8bc8-f4bae1fcafc3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:249e2434-2297-4674-8b86-d5a702d100ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BIMZELX is a humanized interleukin-17A and F antagonist indicated for the treatment of: Moderate to severe plaque psoriasis (PSO) in adults who are candidates for systemic therapy or phototherapy. ( 1.1 ) Adults with active psoriatic arthritis (PsA) . ( 1.2 ) Adults with active non-radiographic axial spondyloarthritis ( nr-axSpA ) with objective signs of inflammation. ( 1.3 ) Adults with active ankylosing spondylitis ( AS ). ( 1.4 ) Adults with moderate to severe hidradenitis suppurativa (HS) . ( 1.5 )|[PMDA] Drugs with a new indication and a new dosage for the treatment of psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis in patients who have not sufficiently responded to conventional treatments. uuid:9b4dc97f-7093-41ae-af34-168d9232eda8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:09495UIM6V biolink:treats MONDO:0005306 PMID:41385096 "[{""id"":""uuid:eaf6a5b8-0aba-4cfa-8011-b48e0561a407"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1fed8f2d-fbc4-4d78-994d-a3168066a21f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:85f8f8f8-2315-4625-ba1e-2c0f99115b19"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/bimzelx""]},{""id"":""uuid:0291201f-f94c-4e47-b3e3-ecdcb6ed89b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BIMZELX is a humanized interleukin-17A and F antagonist indicated for the treatment of: Moderate to severe plaque psoriasis (PSO) in adults who are candidates for systemic therapy or phototherapy. ( 1.1 ) Adults with active psoriatic arthritis (PsA) . ( 1.2 ) Adults with active non-radiographic axial spondyloarthritis ( nr-axSpA ) with objective signs of inflammation. ( 1.3 ) Adults with active ankylosing spondylitis ( AS ). ( 1.4 ) Adults with moderate to severe hidradenitis suppurativa (HS) . ( 1.5 )|[EMA] Plaque psoriasisBimzelx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.Psoriatic arthritisBimzelx, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (DMARDs).Axial spondyloarthritisNon-radiographic axial spondyloarthritis (nr-axSpA)Bimzelx is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs (NSAIDs).Ankylosing spondylitis (AS, radiographic axial spondyloarthritis)Bimzelx is indicated for the treatment of adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.|[PMDA] Drugs with a new indication and a new dosage for the treatment of psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis in patients who have not sufficiently responded to conventional treatments. uuid:64d47c34-e7af-47b1-8cb6-bb2816afc769 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:09495UIM6V biolink:treats MONDO:0006559 PMID:41385096 "[{""id"":""uuid:3387c5c2-2f37-49dc-8921-31f738fb91f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a33abedb-3263-4eee-9a31-40b26d5c3a7e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BIMZELX is a humanized interleukin-17A and F antagonist indicated for the treatment of: Moderate to severe plaque psoriasis (PSO) in adults who are candidates for systemic therapy or phototherapy. ( 1.1 ) Adults with active psoriatic arthritis (PsA) . ( 1.2 ) Adults with active non-radiographic axial spondyloarthritis ( nr-axSpA ) with objective signs of inflammation. ( 1.3 ) Adults with active ankylosing spondylitis ( AS ). ( 1.4 ) Adults with moderate to severe hidradenitis suppurativa (HS) . ( 1.5 ) uuid:d0400e6c-73d4-44b9-a387-326def57d160 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133013 biolink:treats MONDO:0006710 PMID:41385096 "[{""id"":""uuid:cb2020af-0119-4bb1-b987-c47ab813f821"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4eacafcf-8118-4421-940c-ba4d42aa4684"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BRIVIACT is indicated for the treatment of partial-onset seizures in patients 1 month of age and older. uuid:5c10374d-0492-4ce0-8719-ad250a1209a9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28887 biolink:treats MONDO:0004948 PMID:41385096 "[{""id"":""uuid:929872ee-40ca-4615-969a-f3c1d637ab32"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:15c2e5ca-5cd0-4780-bb32-6470892511cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:2e83a45d-faae-4218-94b4-f91f037680f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Chronic Lymphocytic Leukemia (CLL) ARZERRA (ofatumumab) is indicated: in combination with chlorambucil, for the treatment of previously untreated patients with CLL for whom fludarabine-based therapy is considered inappropriate [see Clinical Studies (14.1)] in combination with fludarabine and cyclophosphamide for the treatment of patients with relapsed CLL [see Clinical Studies (14.2)] for extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive CLL [see Clinical Studies (14.3)] for the treatment of patients with CLL refractory to fludarabine and alemtuzumab [see Clinical Studies (14.4)]|[PMDA] Drugs with a new active ingredient indicated for the treatment of relapsed or refractory CD20- positive chronic lymphocytic leukemia. [Orphan drug] uuid:164c4184-d5aa-4797-aff8-f0c44e85c6e1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28887 biolink:treats UMLS:C0854802 PMID:41385096 "[{""id"":""uuid:17e27256-e1cd-45fe-8460-84b7605d4872"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aab06684-cac4-4268-bbe2-2f311e5328b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Chronic Lymphocytic Leukemia (CLL) ARZERRA (ofatumumab) is indicated: in combination with chlorambucil, for the treatment of previously untreated patients with CLL for whom fludarabine-based therapy is considered inappropriate [see Clinical Studies (14.1)] in combination with fludarabine and cyclophosphamide for the treatment of patients with relapsed CLL [see Clinical Studies (14.2)] for extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive CLL [see Clinical Studies (14.3)] for the treatment of patients with CLL refractory to fludarabine and alemtuzumab [see Clinical Studies (14.4)] uuid:e92a7753-b42f-4042-a966-f54cad324def biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63577 biolink:treats MONDO:0005231 PMID:41385096 "[{""id"":""uuid:c48c17e5-d941-4ed3-8f1e-2be657d199fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2b32f72d-28a6-462c-b305-c58e4a90da6c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lamivudine tablets (HBV) are indicated for the treatment of chronic hepatitis B virus (HBV) infection associated with evidence of hepatitis B viral replication and active liver inflammation [ see Clinical Studies ( 14.1 , 14.2 ) ]. The following points should be considered when initiating therapy with lamivudine tablets (HBV): Due to high rates of resistance development in treated patients, initiation of treatment with lamivudine tablets (HBV) should only be considered when the use of an alternative antiviral agent with a higher genetic barrier to resistance is not available or appropriate. Lamivudine tablets (HBV) have not been evaluated in patients co-infected with human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis delta virus. Lamivudine tablets (HBV) have not been evaluated in liver transplant recipients or in patients with chronic hepatitis B virus infection with decompensated liver disease. uuid:57e10019-996b-4468-ad88-dd7babb1f3c3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:196955 biolink:treats MONDO:0005277 PMID:41385096 "[{""id"":""uuid:38c3855d-d583-4183-8a83-730661e1e628"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:53033d0e-a9b2-42c2-86da-fa5a3883a5df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:67a9a9aa-451a-416a-bde5-f6bf79906d73"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/aquipta""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] QULIPTA is indicated for the preventive treatment of migraine in adults.|[EMA] Aquipta is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month uuid:d3cc949a-a5bb-4b7a-ae84-3d535e0682d8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:TO3JYR3BOU biolink:treats MONDO:0100244 PMID:41385096 "[{""id"":""uuid:a15fa048-b01d-4242-a904-e538d12f2e94"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:04bac20a-34a6-4bee-9867-8f18b9298090"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:27379271-d6d8-4e30-9b88-a29d73dd0bd1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/aspaveli""]},{""id"":""uuid:695d722d-a9a1-488b-8a7b-070da847d5a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EMPAVELI ® is indicated for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH).|[EMA] Aspaveli is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who are anaemic after treatment with a C5 inhibitor for at least 3 months.|[PMDA] A drug with a new active ingredient indicated for the treatment of paroxysmal nocturnal haemoglobinuria. uuid:cdffc0e5-e409-4cac-957b-27bf168d15ce biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:91083 biolink:treats MONDO:0002048 PMID:41385096 "[{""id"":""uuid:09b90b8d-3204-4ef7-b3c4-53f8abcc85e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:410bf77c-92b7-427c-9afa-dbfaea888141"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nplate is a thrombopoietin receptor agonist indicated for the treatment of thrombocytopenia in: Adult patients with immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. ( 1.1 ) Pediatric patients 1 year of age and older with ITP for at least 6 months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. ( 1.1 ) Nplate is indicated to increase survival in adults and in pediatric patients (including term neonates) acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome [HS-ARS]). ( 1.2 ) Limitations of Use: Nplate is not indicated for the treatment of thrombocytopenia due to myelodysplastic syndrome (MDS) or any cause of thrombocytopenia other than ITP. Nplate should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increases the risk for bleeding. Nplate should not be used in an attempt to normalize platelet counts. ( 1 ) uuid:22a0ee88-6929-49eb-9652-25c49b672e1c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:91083 biolink:treats MONDO:0033938 PMID:41385096 "[{""id"":""uuid:4572af22-a245-4554-ada5-b9a918ce66ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:efa33560-9311-4c4b-827d-039e3c8bace4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nplate is a thrombopoietin receptor agonist indicated for the treatment of thrombocytopenia in: Adult patients with immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. ( 1.1 ) Pediatric patients 1 year of age and older with ITP for at least 6 months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. ( 1.1 ) Nplate is indicated to increase survival in adults and in pediatric patients (including term neonates) acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome [HS-ARS]). ( 1.2 ) Limitations of Use: Nplate is not indicated for the treatment of thrombocytopenia due to myelodysplastic syndrome (MDS) or any cause of thrombocytopenia other than ITP. Nplate should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increases the risk for bleeding. Nplate should not be used in an attempt to normalize platelet counts. ( 1 ) uuid:52843f22-2491-4036-a33a-e4a19b443cad biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:91083 biolink:treats MONDO:0002049 PMID:41385096 "[{""id"":""uuid:86cef86d-c7b4-4488-985a-fb1c62e5a6ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cc2e71f0-cc6a-4f8e-be23-d6057e0ebedf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nplate is a thrombopoietin receptor agonist indicated for the treatment of thrombocytopenia in: Adult patients with immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. ( 1.1 ) Pediatric patients 1 year of age and older with ITP for at least 6 months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. ( 1.1 ) Nplate is indicated to increase survival in adults and in pediatric patients (including term neonates) acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome [HS-ARS]). ( 1.2 ) Limitations of Use: Nplate is not indicated for the treatment of thrombocytopenia due to myelodysplastic syndrome (MDS) or any cause of thrombocytopenia other than ITP. Nplate should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increases the risk for bleeding. Nplate should not be used in an attempt to normalize platelet counts. ( 1 ) uuid:00b83345-dbd2-4b04-ab57-5a2839c5c5f2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB16199 biolink:treats MONDO:0007100 PMID:41385096 "[{""id"":""uuid:0d561fbd-4be9-4081-ba81-e81fce1cfd59"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:57489067-9983-44c3-af5a-d6f9c91c7473"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] WAINUA is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. uuid:e7433449-cc6e-42e2-a199-0e6730cded50 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:AD0O8X2QJR biolink:treats MONDO:0005475 PMID:41385096 "[{""id"":""uuid:d2a18f1d-2d80-40ce-a978-0186e2e09f0b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6262e0a9-d512-4a93-bb8d-dfe118183fae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] UBRELVY is indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use UBRELVY is not indicated for the preventive treatment of migraine. uuid:514ee7e7-b0a2-4bba-8edb-a3add2bfa0d6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:AD0O8X2QJR biolink:treats MONDO:0100431 PMID:41385096 "[{""id"":""uuid:70558c1d-8618-456e-8fa0-3a9b166ae77b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c93953bb-c51f-475d-ae22-a291aec02ac5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] UBRELVY is indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use UBRELVY is not indicated for the preventive treatment of migraine. uuid:366fccc3-f7b6-4e2d-ae7e-ff260c16d9b7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6KLL51GNBG biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:9e13bdeb-184a-45d9-9d46-44e19ccba000"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d841e650-4bdc-405f-8421-b38b3663ace6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] IBTROZI ™ (taletrectinib) is indicated for the treatment of adult patients with locally advanced or metastatic ROS1 -positive non-small cell lung cancer (NSCLC) [see Dosage and Administration ( 2.1 )] . uuid:fe89f8f7-0403-4280-a07f-ff12d7a0286e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:KXG2PJ551I biolink:treats MONDO:0019210 PMID:41385096 "[{""id"":""uuid:37f0534e-d96f-4b3a-a0af-49965f9ec65c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:15b7bbf0-5b3d-4184-aba1-fd53b0f802f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:001e8d0b-6fa8-4e79-a489-e49a530de470"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/bavencio""]},{""id"":""uuid:cb1db117-af7c-4573-ad50-975a06f8b373"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BAVENCIO is a programmed death ligand-1 (PD-L1) blocking antibody indicated for: Merkel Cell Carcinoma (MCC) Adults and pediatric patients 12 years and older with metastatic MCC. ( 1.1 , 14.1 ) Urothelial Carcinoma (UC) Maintenance treatment of patients with locally advanced or metastatic UC that has not progressed with first-line platinum-containing chemotherapy. ( 1.2 , 14.2 ) Patients with locally advanced or metastatic UC who: Have disease progression during or following platinum-containing chemotherapy. ( 1.2 , 14.2 ) Have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. ( 1.2 , 14.2 ) Renal Cell Carcinoma (RCC) First-line treatment, in combination with axitinib, of patients with advanced RCC. ( 1.3 , 14.3 )|[EMA] Bavencio is indicated as monotherapy for the treatment of adult patients with metastatic Merkel cell carcinoma (MCC).Bavencio in combination with axitinib is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC).Bavencio is indicated as monotherapy for the first‑line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) who are progression-free following platinum‑based chemotherapy.|[PMDA] A drug with a new active ingredient indicated for the treatment of unresectable Merkel cell carcinoma. [Orphan drug] uuid:68b8e559-19f3-4ed3-abbb-f523b2f5994d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:KXG2PJ551I biolink:treats MONDO:0040679 PMID:41385096 "[{""id"":""uuid:d8b0bbcc-5af5-4b14-b779-4743079aa328"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:66888069-f7c3-4a59-b156-578216350395"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:a4920cde-1a2c-4924-a8de-a98c9d32e5a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/bavencio""]},{""id"":""uuid:997fd1cf-b318-459a-aead-4256f81f785a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BAVENCIO is a programmed death ligand-1 (PD-L1) blocking antibody indicated for: Merkel Cell Carcinoma (MCC) Adults and pediatric patients 12 years and older with metastatic MCC. ( 1.1 , 14.1 ) Urothelial Carcinoma (UC) Maintenance treatment of patients with locally advanced or metastatic UC that has not progressed with first-line platinum-containing chemotherapy. ( 1.2 , 14.2 ) Patients with locally advanced or metastatic UC who: Have disease progression during or following platinum-containing chemotherapy. ( 1.2 , 14.2 ) Have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. ( 1.2 , 14.2 ) Renal Cell Carcinoma (RCC) First-line treatment, in combination with axitinib, of patients with advanced RCC. ( 1.3 , 14.3 )|[EMA] Bavencio is indicated as monotherapy for the treatment of adult patients with metastatic Merkel cell carcinoma (MCC).Bavencio in combination with axitinib is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC).Bavencio is indicated as monotherapy for the first‑line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) who are progression-free following platinum‑based chemotherapy.|[PMDA] A drug with a new indication for the maintenance therapy of unresectable urothelial carcinoma in patients who have received chemotherapy. [Priority review] uuid:f78afc6b-fa24-464b-8137-4389aafa45aa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:KXG2PJ551I biolink:treats MONDO:0005086 PMID:41385096 "[{""id"":""uuid:20bb74cb-b8dc-4a4e-8c76-6c270f5c438e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:efcbf7a3-41a2-4acb-b1f5-3bdc4b86dd0e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:aaf4d425-515e-4b0a-9151-9106b66241d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/bavencio""]},{""id"":""uuid:8d4a56d1-6ef3-452e-ab7f-051a3c8bfee0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BAVENCIO is a programmed death ligand-1 (PD-L1) blocking antibody indicated for: Merkel Cell Carcinoma (MCC) Adults and pediatric patients 12 years and older with metastatic MCC. ( 1.1 , 14.1 ) Urothelial Carcinoma (UC) Maintenance treatment of patients with locally advanced or metastatic UC that has not progressed with first-line platinum-containing chemotherapy. ( 1.2 , 14.2 ) Patients with locally advanced or metastatic UC who: Have disease progression during or following platinum-containing chemotherapy. ( 1.2 , 14.2 ) Have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. ( 1.2 , 14.2 ) Renal Cell Carcinoma (RCC) First-line treatment, in combination with axitinib, of patients with advanced RCC. ( 1.3 , 14.3 )|[EMA] Bavencio is indicated as monotherapy for the treatment of adult patients with metastatic Merkel cell carcinoma (MCC).Bavencio in combination with axitinib is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC).Bavencio is indicated as monotherapy for the first‑line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) who are progression-free following platinum‑based chemotherapy.|[PMDA] A drug with a new indication and a new dosage for the treatment of unresectable or metastatic renal cell carcinoma. uuid:be1cc977-df93-425e-be9d-4cc0ef51d933 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85010 biolink:treats MONDO:0018881 PMID:41385096 "[{""id"":""uuid:2760a55b-d3bf-4f13-84f7-7ee25f809ead"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c767d31b-7f2d-4847-a01a-d47e35b2789e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PROMACTA is a thrombopoietin receptor agonist indicated: for the treatment of thrombocytopenia in adult and pediatric patients 1 year and older with persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. PROMACTA should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increase the risk for bleeding. ( 1.1 ) for the treatment of thrombocytopenia in patients with chronic hepatitis C to allow the initiation and maintenance of interferon-based therapy. PROMACTA should be used only in patients with chronic hepatitis C whose degree of thrombocytopenia prevents the initiation of interferon-based therapy or limits the ability to maintain interferon-based therapy. ( 1.2 ) in combination with standard immunosuppressive therapy for the first-line treatment of adult and pediatric patients 2 years and older with severe aplastic anemia. ( 1.3 ) for the treatment of patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy. ( 1.3 ) Limitations of Use: PROMACTA is not indicated for the treatment of patients with myelodysplastic syndrome (MDS). ( 1.4 ) Safety and efficacy have not been established in combination with direct-acting antiviral agents used without interferon for treatment of chronic hepatitis C infection. ( 1.4 ) uuid:c5c78451-a134-49bb-a0b9-0e3a3ab15a69 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:31YO63LBSN biolink:treats MONDO:0005580 PMID:41385096 "[{""id"":""uuid:ec089f8f-0e10-46a8-8ec5-edf80095b967"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:71f3cfae-ea3a-46db-9c4b-80eb1dbb9552"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OPDIVO QVANTIG is a combination of nivolumab, a programmed death receptor-1 (PD-1)-blocking antibody, and hyaluronidase, an endoglycosidase, indicated for the treatment of: Renal Cell Carcinoma (RCC) • adult patients with intermediate or poor risk advanced RCC, as a first-line treatment following combination treatment with intravenous nivolumab and ipilimumab. (1.1) • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of renal cell carcinoma. • adult patients with advanced RCC, as a first-line treatment in combination with cabozantinib. (1.1) • adult patients with advanced RCC who have received prior anti-angiogenic therapy. ( 1.1 ) Melanoma • adult patients with unresectable or metastatic melanoma. (1.2) • adult patients with unresectable or metastatic melanoma following combination treatment with intravenous nivolumab and ipilimumab. (1.2) • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of unresectable or metastatic melanoma. • for the adjuvant treatment of adult patients with completely resected Stage IIB, Stage IIC, Stage III, or Stage IV melanoma. (1.3) Non-Small Cell Lung Cancer (NSCLC) • adult patients with resectable (tumors ≥4 cm or node positive) NSCLC in the neoadjuvant setting, in combination with platinum-doublet chemotherapy. (1.4) • adult patients with resectable (tumors ≥4 cm or node positive) NSCLC and no known EGFR mutations or ALK rearrangements, for neoadjuvant treatment, in combination with platinum-doublet chemotherapy, followed by OPDIVO QVANTIG monotherapy as adjuvant treatment after surgery. (1.5) • adult patients with metastatic NSCLC and progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO QVANTIG. (1.6) • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of metastatic NSCLC. Squamous Cell Carcinoma of the Head and Neck (SCCHN) • adult patients with recurrent or metastatic SCCHN with disease progression on or after a platinum-based therapy. (1.7) Urothelial Carcinoma (UC) • adjuvant treatment of adult patients with UC who are at high risk of recurrence after undergoing radical resection of UC. (1.8) • adult patients with unresectable or metastatic urothelial carcinoma, as first-line treatment in combination with cisplatin and gemcitabine. (1.8) • adult patients with locally advanced or metastatic UC who: • have disease progression during or following platinum-containing chemotherapy. • have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. (1.8) Colorectal Cancer • adult patients with MSI-H or dMMR metastatic CRC that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan, as monotherapy or as monotherapy following combination treatment with intravenous nivolumab and ipilimumab. a (1.9) • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of MSI-H or dMMR metastatic CRC. Hepatocellular Carcinoma (HCC) • adult patients with HCC previously treated with sorafenib and following combination treatment with intravenous nivolumab and ipilimumab. a (1.10) • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of HCC. Esophageal Cancer • adult patients with completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease, who have received neoadjuvant chemoradiotherapy (CRT). (1.11) • adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) as first-line treatment in combination with fluoropyrimidine- and platinum-containing chemotherapy whose tumors express PD-L1 (≥1). (1.11) • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of patients with unresectable advanced or metastatic ESCC. • adult patients with unresectable advanced, recurrent or metastatic ESCC after prior fluoropyrimidine- and platinum-based chemotherapy. (1.11) Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma • adult patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma whose tumors express PD-L1 (≥1) in combination with fluoropyrimidine- and platinum-containing chemotherapy. (1.12) a This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. uuid:40d323e8-4119-4765-bb08-76c86a6964af biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4F4X42SYQ6 biolink:treats MONDO:0017594 PMID:41385096 "[{""id"":""uuid:6798ec5d-5615-4f3a-9430-6596adc63239"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4afe2119-6a7c-41d4-a0aa-761855b77c88"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TRUXIMA (rituximab-abbs) is a CD20-directed cytolytic antibody indicated for the treatment of adult patients with: Non-Hodgkin's Lymphoma (NHL) ( 1.1 ). Relapsed or refractory, low grade or follicular, CD20-positive B-cell NHL as a single agent. Previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy. Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy. Previously untreated diffuse large B-cell, CD20-positive NHL in combination with (cyclophosphamide, doxorubicin, vincristine, and prednisone) (CHOP) or other anthracycline-based chemotherapy regimens. Chronic Lymphocytic Leukemia (CLL) ( 1.2 ). Previously untreated and previously treated CD20-positive CLL in combination with fludarabine and cyclophosphamide (FC). Rheumatoid Arthritis (RA) in combination with methotrexate in adult patients with moderately-to severely-active RA who have inadequate response to one or more TNF antagonist therapies ( 1.3 ). Granulomatosis with Polyangiitis (GPA) (Wegener’s Granulomatosis) and Microscopic Polyangiitis (MPA) in adult patients in combination with glucocorticoids ( 1.4 ). Moderate to severe Pemphigus Vulgaris (PV) in adult patients ( 1.5 ) uuid:652e9d6d-6950-4214-9ce7-7e0504f63752 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63628 biolink:treats MONDO:0004951 PMID:41385096 "[{""id"":""uuid:de5eb6a3-0e90-4d0c-afde-77bce4000446"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4d3a0b09-7327-4ff6-a661-2f95e5d11902"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] APTIVUS, co-administered with ritonavir, is indicated for combination antiretroviral treatment of HIV-1 infected adults and pediatric patients weighing 36 kg or higher who are treatment-experienced and infected with HIV-1 strains resistant to more than one protease inhibitor (PI) [see Use in Specific Populations (8.4) ] . This indication is based on analyses of plasma HIV-1 RNA levels in two controlled studies of APTIVUS/ritonavir of 48 weeks duration in treatment-experienced adults and one open-label 48-week study in pediatric patients. The adult studies were conducted in clinically advanced, 3-class antiretroviral (NRTI, NNRTI, PI) treatment-experienced adults with evidence of HIV-1 replication despite ongoing antiretroviral therapy. The following points should be considered when initiating therapy with APTIVUS/ritonavir: The use of APTIVUS/ritonavir in treatment-naïve patients is not recommended [ see Warnings and Precautions (5.2) ]. The use of other active agents with APTIVUS/ritonavir is associated with a greater likelihood of treatment response [ see Microbiology (12.4) and Clinical Studies (14) ]. Genotypic or phenotypic testing and/or treatment history should guide the use of APTIVUS/ritonavir [ see Microbiology (12.4) ]. The number of baseline primary protease inhibitor mutations affects the virologic response to APTIVUS/ritonavir [ see Microbiology (12.4) ]. Use caution when prescribing APTIVUS/ritonavir to patients with elevated transaminases, hepatitis B or C co-infection or patients with mild hepatic impairment [ see Warnings and Precautions (5.2) ]. Liver function tests should be performed at initiation of therapy with APTIVUS/ritonavir and monitored frequently throughout the duration of treatment [ see Warnings and Precautions (5.2) ]. The drug-drug interaction potential of APTIVUS/ritonavir when co-administered with other drugs must be considered prior to and during APTIVUS/ritonavir use [ see Contraindications (4) and Drug Interactions (7) ]. Use caution when prescribing APTIVUS/ritonavir in patients who may be at risk for increased bleeding or who are receiving medications known to increase the risk of bleeding [ see Warnings and Precautions (5.5) ]. There are no study results demonstrating the effect of APTIVUS/ritonavir on clinical progression of HIV-1. uuid:2bf5395d-22d7-497f-97c9-6bb74bdb3ae2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63628 biolink:treats MONDO:0005344 PMID:41385096 "[{""id"":""uuid:3f76e62e-7e90-40b5-9f53-c5ebf57f2419"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ae7451ca-88f3-4698-a41e-5c09b8620a44"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] APTIVUS, co-administered with ritonavir, is indicated for combination antiretroviral treatment of HIV-1 infected adults and pediatric patients weighing 36 kg or higher who are treatment-experienced and infected with HIV-1 strains resistant to more than one protease inhibitor (PI) [see Use in Specific Populations (8.4) ] . This indication is based on analyses of plasma HIV-1 RNA levels in two controlled studies of APTIVUS/ritonavir of 48 weeks duration in treatment-experienced adults and one open-label 48-week study in pediatric patients. The adult studies were conducted in clinically advanced, 3-class antiretroviral (NRTI, NNRTI, PI) treatment-experienced adults with evidence of HIV-1 replication despite ongoing antiretroviral therapy. The following points should be considered when initiating therapy with APTIVUS/ritonavir: The use of APTIVUS/ritonavir in treatment-naïve patients is not recommended [ see Warnings and Precautions (5.2) ]. The use of other active agents with APTIVUS/ritonavir is associated with a greater likelihood of treatment response [ see Microbiology (12.4) and Clinical Studies (14) ]. Genotypic or phenotypic testing and/or treatment history should guide the use of APTIVUS/ritonavir [ see Microbiology (12.4) ]. The number of baseline primary protease inhibitor mutations affects the virologic response to APTIVUS/ritonavir [ see Microbiology (12.4) ]. Use caution when prescribing APTIVUS/ritonavir to patients with elevated transaminases, hepatitis B or C co-infection or patients with mild hepatic impairment [ see Warnings and Precautions (5.2) ]. Liver function tests should be performed at initiation of therapy with APTIVUS/ritonavir and monitored frequently throughout the duration of treatment [ see Warnings and Precautions (5.2) ]. The drug-drug interaction potential of APTIVUS/ritonavir when co-administered with other drugs must be considered prior to and during APTIVUS/ritonavir use [ see Contraindications (4) and Drug Interactions (7) ]. Use caution when prescribing APTIVUS/ritonavir in patients who may be at risk for increased bleeding or who are receiving medications known to increase the risk of bleeding [ see Warnings and Precautions (5.5) ]. There are no study results demonstrating the effect of APTIVUS/ritonavir on clinical progression of HIV-1. uuid:b33e14cb-d8df-4386-8363-451a215d6323 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63628 biolink:treats MONDO:0005231 PMID:41385096 "[{""id"":""uuid:0922f197-05da-4ebe-a584-027b9ffe5112"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b3f95e79-a784-447f-b2f2-a843a0c21f91"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] APTIVUS, co-administered with ritonavir, is indicated for combination antiretroviral treatment of HIV-1 infected adults and pediatric patients weighing 36 kg or higher who are treatment-experienced and infected with HIV-1 strains resistant to more than one protease inhibitor (PI) [see Use in Specific Populations (8.4) ] . This indication is based on analyses of plasma HIV-1 RNA levels in two controlled studies of APTIVUS/ritonavir of 48 weeks duration in treatment-experienced adults and one open-label 48-week study in pediatric patients. The adult studies were conducted in clinically advanced, 3-class antiretroviral (NRTI, NNRTI, PI) treatment-experienced adults with evidence of HIV-1 replication despite ongoing antiretroviral therapy. The following points should be considered when initiating therapy with APTIVUS/ritonavir: The use of APTIVUS/ritonavir in treatment-naïve patients is not recommended [ see Warnings and Precautions (5.2) ]. The use of other active agents with APTIVUS/ritonavir is associated with a greater likelihood of treatment response [ see Microbiology (12.4) and Clinical Studies (14) ]. Genotypic or phenotypic testing and/or treatment history should guide the use of APTIVUS/ritonavir [ see Microbiology (12.4) ]. The number of baseline primary protease inhibitor mutations affects the virologic response to APTIVUS/ritonavir [ see Microbiology (12.4) ]. Use caution when prescribing APTIVUS/ritonavir to patients with elevated transaminases, hepatitis B or C co-infection or patients with mild hepatic impairment [ see Warnings and Precautions (5.2) ]. Liver function tests should be performed at initiation of therapy with APTIVUS/ritonavir and monitored frequently throughout the duration of treatment [ see Warnings and Precautions (5.2) ]. The drug-drug interaction potential of APTIVUS/ritonavir when co-administered with other drugs must be considered prior to and during APTIVUS/ritonavir use [ see Contraindications (4) and Drug Interactions (7) ]. Use caution when prescribing APTIVUS/ritonavir in patients who may be at risk for increased bleeding or who are receiving medications known to increase the risk of bleeding [ see Warnings and Precautions (5.5) ]. There are no study results demonstrating the effect of APTIVUS/ritonavir on clinical progression of HIV-1. uuid:ef6846c3-341c-409a-9fc8-474534d9eb6f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6970 biolink:treats MONDO:0001358 PMID:41385096 "[{""id"":""uuid:f3fe8fd3-c853-4bb5-9c4e-2574c6657fdc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2ca47d90-f6c6-4409-921e-47619202eb41"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ASMANEX HFA is a corticosteroid indicated for: Maintenance treatment of asthma as prophylactic therapy in patients 5 years of age and older. ( 1.1 ) Important limitations: Not indicated for the relief of acute bronchospasm. ( 1.1 ) uuid:2d446c41-de05-4292-970c-62609a292f53 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63452 biolink:treats MONDO:0018874 PMID:41385096 "[{""id"":""uuid:42790ba4-6929-48c1-baca-7fbe7e531bb7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:950b78f2-2ccc-49c5-ab9f-f5448f00688a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:7ebc8f71-5951-4de2-b14b-504d772cadf5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/rydapt""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] RYDAPT is a kinase inhibitor indicated for the treatment of adult patients with: Newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive as detected by an FDA-approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation. ( 1.1 ) Limitations of Use: RYDAPT is not indicated as a single-agent induction therapy for the treatment of patients with AML. Aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL). ( 1.2 )|[EMA] Rydapt is indicated:in combination with standard daunorubicin and cytarabine induction and high dose cytarabine consolidation chemotherapy, and for patients in complete response followed by Rydapt single agent maintenance therapy, for adult patients with newly diagnosed acute myeloid leukaemia (AML) who are FLT3 mutation positive (see section 4.2);as monotherapy for the treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated haematological neoplasm (SM AHN), or mast cell leukaemia (MCL). uuid:60c7f267-4447-42f7-b97e-424929887d45 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63452 biolink:treats MONDO:0020333 PMID:41385096 "[{""id"":""uuid:74c6f025-7f92-4fd2-90c0-8afcb87ce025"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:33c64a7d-b346-4797-9e23-b4f17f99b7f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:6189f178-f28f-4676-accf-5c25bfd9360d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/rydapt""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] RYDAPT is a kinase inhibitor indicated for the treatment of adult patients with: Newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive as detected by an FDA-approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation. ( 1.1 ) Limitations of Use: RYDAPT is not indicated as a single-agent induction therapy for the treatment of patients with AML. Aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL). ( 1.2 )|[EMA] Rydapt is indicated:in combination with standard daunorubicin and cytarabine induction and high dose cytarabine consolidation chemotherapy, and for patients in complete response followed by Rydapt single agent maintenance therapy, for adult patients with newly diagnosed acute myeloid leukaemia (AML) who are FLT3 mutation positive (see section 4.2);as monotherapy for the treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated haematological neoplasm (SM AHN), or mast cell leukaemia (MCL). uuid:08adb1f6-f43f-4720-8e3d-03c9914a4398 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63452 biolink:treats MONDO:0020332 PMID:41385096 "[{""id"":""uuid:29d9fab3-795b-4cba-8f41-06c5f1d14ebb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f15a851c-e762-4d5c-9ed8-e69ac9e68e56"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:39576142-fcb2-4233-a089-f7882a9b7197"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/rydapt""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] RYDAPT is a kinase inhibitor indicated for the treatment of adult patients with: Newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive as detected by an FDA-approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation. ( 1.1 ) Limitations of Use: RYDAPT is not indicated as a single-agent induction therapy for the treatment of patients with AML. Aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL). ( 1.2 )|[EMA] Rydapt is indicated:in combination with standard daunorubicin and cytarabine induction and high dose cytarabine consolidation chemotherapy, and for patients in complete response followed by Rydapt single agent maintenance therapy, for adult patients with newly diagnosed acute myeloid leukaemia (AML) who are FLT3 mutation positive (see section 4.2);as monotherapy for the treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated haematological neoplasm (SM AHN), or mast cell leukaemia (MCL). uuid:fc4445fc-afca-4072-ac41-a588353ee327 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63452 biolink:treats MONDO:0020334 PMID:41385096 "[{""id"":""uuid:e1b07d57-d66e-4e11-86e9-8657819603d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:39c516aa-0b11-4047-9303-0680bd081cd3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:b03852e8-c185-4d77-8704-34a320f03293"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/rydapt""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] RYDAPT is a kinase inhibitor indicated for the treatment of adult patients with: Newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive as detected by an FDA-approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation. ( 1.1 ) Limitations of Use: RYDAPT is not indicated as a single-agent induction therapy for the treatment of patients with AML. Aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL). ( 1.2 )|[EMA] Rydapt is indicated:in combination with standard daunorubicin and cytarabine induction and high dose cytarabine consolidation chemotherapy, and for patients in complete response followed by Rydapt single agent maintenance therapy, for adult patients with newly diagnosed acute myeloid leukaemia (AML) who are FLT3 mutation positive (see section 4.2);as monotherapy for the treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated haematological neoplasm (SM AHN), or mast cell leukaemia (MCL). uuid:de6d5527-93d3-4ae4-bf98-71cb3af09880 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:06P3KLK2J8 biolink:treats MONDO:0000901 PMID:41385096 "[{""id"":""uuid:59cc911b-0687-4952-bc8f-df73223297fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1c329953-24fe-46e8-91e1-9cb1a3616233"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] COLUMVI is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) or large B-cell lymphoma (LBCL) arising from follicular lymphoma, after two or more lines of systemic therapy. This indication is approved under accelerated approval based on response rate and durability of response [see Clinical Studies (14.1) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). uuid:16b94e0b-d190-4e8e-8516-773a4a87f28f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:06P3KLK2J8 biolink:treats MONDO:0018905 PMID:41385096 "[{""id"":""uuid:e33d1e2b-2198-47a9-a9f5-6996d264f2e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:e982843d-4fc8-4ae3-a137-04cdce4ecac4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:26dd7fa3-58c6-41ae-9dd4-fece367a1862"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/columvi""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] COLUMVI is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) or large B-cell lymphoma (LBCL) arising from follicular lymphoma, after two or more lines of systemic therapy. This indication is approved under accelerated approval based on response rate and durability of response [see Clinical Studies (14.1) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).|[EMA] Columvi as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL), after two or more lines of systemic therapy. uuid:7fe3c56e-4672-4aee-9b58-69ea2015127d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:RR6P8L282I biolink:treats UMLS:C2921627 PMID:41385096 "[{""id"":""uuid:38b65082-3ec3-498c-b606-2e60b1bbe403"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c33c5678-c366-4038-8705-d64060317890"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MAYZENT is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. uuid:6edd7b8d-8c1d-4a89-868c-c2a68d0bbd28 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:RR6P8L282I biolink:treats MONDO:0000450 PMID:41385096 "[{""id"":""uuid:6aeb8479-80c6-4b35-9f23-9d001147fc98"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:fbb8b519-41a7-4870-b3ca-0e9f02e9645c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:66581d12-0d19-4f9c-8f07-64b2bd6b9869"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MAYZENT is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.|[EMA] Mayzent is indicated for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features of inflammatory activity. uuid:269b3641-58ae-4be3-b1a1-7cbabd01f719 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:RR6P8L282I biolink:treats MONDO:0005301 PMID:41385096 "[{""id"":""uuid:258ff735-99d3-483f-9d4b-b1c0c63ef853"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:909f74e7-70b2-4f2d-ab1c-f6683de1cf86"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:25b13905-ea49-454d-bffc-fede459dd130"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MAYZENT is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.|[EMA] Mayzent is indicated for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features of inflammatory activity. uuid:f49ce856-22e8-43be-b859-7005467f764c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:RJ1IW3B4QX biolink:treats UMLS:C0581126 PMID:41385096 "[{""id"":""uuid:c394584e-3277-41c1-b501-ec5cf938d3af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:726c33a8-9858-4306-96e8-92b9f4fc3133"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TEZSPIRE is indicated for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma. Limitations of Use: TEZSPIRE is not indicated for the relief of acute bronchospasm or status asthmaticus. uuid:dfdbf93a-0f63-4736-b8a9-e30dda1da985 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:RJ1IW3B4QX biolink:treats UMLS:C0741804 PMID:41385096 "[{""id"":""uuid:7134f0be-f884-4b47-bc9c-b63ed17d6686"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e8cea9ec-e83a-4dc0-be7a-442d16d3fe8c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TEZSPIRE is indicated for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma. Limitations of Use: TEZSPIRE is not indicated for the relief of acute bronchospasm or status asthmaticus. uuid:2d5e35a1-13c4-4890-a05d-f231ed04d89a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:RJ1IW3B4QX biolink:treats MONDO:0004766 PMID:41385096 "[{""id"":""uuid:d2560a9c-c21d-49b0-88ea-0f035087dde7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:ab8d4886-4d5c-4414-bf15-0fd9cb82872d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e9a5871b-ba40-4f4d-ad57-d1d05f962f1f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/tezspire""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] TEZSPIRE is indicated for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma. Limitations of Use: TEZSPIRE is not indicated for the relief of acute bronchospasm or status asthmaticus.|[EMA] Tezspire is indicated as an add-on maintenance treatment in adults and adolescents 12 years and older with severe asthma who are inadequately controlled despite high dose inhaled corticosteroids plus another medicinal product for maintenance treatment. uuid:4b1c29d4-d348-4df8-bd6c-91e9c52ead7a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:93752 biolink:treats MONDO:1040002 PMID:41385096 "[{""id"":""uuid:e09cf15c-5ee0-4eb1-9f5b-86ace23acfb7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:48e5fc4c-141c-4e8f-905e-055ebf922d43"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:d1c33418-92ca-4e3b-b9d9-c4c19c37e297"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/piqray""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] VIJOICE is indicated for the treatment of adult and pediatric patients 2 years of age and older with severe manifestations of PIK3CA-Related Overgrowth Spectrum (PROS) who require systemic therapy. This indication is approved under accelerated approval based on response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).|[EMA] Piqray is indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with a PIK3CA mutation after disease progression following endocrine therapy as monotherapy (see section 5.1). uuid:94b2016a-5a00-4117-8012-43c1b761dae2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28887 biolink:treats MONDO:0005301 PMID:41385096 "[{""id"":""uuid:b17ff58a-318d-4b33-a249-9f570cb92b25"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:eea02be9-dd12-4de8-afff-43172841ff1e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:af6a52da-88b9-43c5-be6a-2016404a07ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KESIMPTA is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.|[PMDA] A drug with a new route of administration and new indications for the prevention of relapse and for delaying the accumulation of physical disability in relapsing- remitting multiple sclerosis (RRMS) and active secondary progressive multiple sclerosis (active SPMS). [Orphan drug] uuid:05c9deda-6146-4413-9dc5-bd0f26be3309 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28887 biolink:treats UMLS:C2921627 PMID:41385096 "[{""id"":""uuid:420f762e-81bd-4aeb-8a92-bdb2f03088c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d282c2a1-1383-4b11-844c-f9fd6dae690b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KESIMPTA is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. uuid:9136962f-a598-4f4b-8cb0-9a3f02d2ae44 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28887 biolink:treats MONDO:0000450 PMID:41385096 "[{""id"":""uuid:0ed29bca-1509-415a-8807-b17408b1143f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c039310e-704d-422d-8dcc-611cb3b49a8a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:9aedd7c1-a831-4a75-850d-d24cc046ba17"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KESIMPTA is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.|[PMDA] A drug with a new route of administration and new indications for the prevention of relapse and for delaying the accumulation of physical disability in relapsing- remitting multiple sclerosis (RRMS) and active secondary progressive multiple sclerosis (active SPMS). [Orphan drug] uuid:ce72e896-0585-427c-a7b6-dd4f4a3692fa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:176399 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:bb006610-a820-4405-8e92-78577a673cc5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:935a8881-223d-430e-bf8e-3c6290017df3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LEQVIO ® is indicated as an adjunct to diet and statin therapy for the treatment of adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), to reduce low-density lipoprotein cholesterol (LDL-C). uuid:82b8299f-5ee6-473f-9a47-2b7c3dfb532e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:176399 biolink:treats UMLS:C0342882 PMID:41385096 "[{""id"":""uuid:dadd8eb9-2181-45d0-9309-6a1c04b804be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6b2822f4-9ae7-4f69-b1cd-d86b341287c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LEQVIO ® is indicated as an adjunct to diet and statin therapy for the treatment of adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), to reduce low-density lipoprotein cholesterol (LDL-C). uuid:0f527fa2-8746-44ed-a2c7-3aa61b1159d5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:37CQ2C7X93 biolink:treats MONDO:0016168 PMID:41385096 "[{""id"":""uuid:24d4c509-d154-4c9e-a8cc-e2eff85c6f9d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:c878adc4-e505-4b73-8c5e-eac5d441037c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:80b2b28f-fe65-473f-a42d-9d1068fb6d9e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ilaris""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] ILARIS is an interleukin-1β blocker indicated for the treatment of: • Periodic Fever Syndromes ( 1.1 ): - Cryopyrin-Associated Periodic Syndromes (CAPS), in adults and children 4 years of age and older, including: ◾ Familial Cold Auto-inflammatory Syndrome (FCAS) ◾ Muckle-Wells Syndrome (MWS) - Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS) in adult and pediatric patients - Hyperimmunoglobulin D Syndrome (HIDS)/ Mevalonate Kinase Deficiency (MKD) in adult and pediatric patients - Familial Mediterranean Fever (FMF) in adult and pediatric patients • Active Still’s Disease, including Adult-Onset Still’s Disease (AOSD) and Systemic Juvenile Idiopathic Arthritis (SJIA) in patients 2 years of age and older ( 1.2 ) • Gout flares in adults in whom non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate ( 1.3 )|[EMA] Periodic fever syndromesIlaris is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents and children aged 2 years and older:Cryopyrin-associated periodic syndromesIlaris is indicated for the treatment of cryopyrin-associated periodic syndromes (CAPS) including:Muckle-Wells syndrome (MWS),Neonatal-onset multisystem inflammatory disease (NOMID) / chronic infantile neurological, cutaneous, articular syndrome (CINCA),Severe forms of familial cold autoinflammatory syndrome (FCAS) / familial cold urticaria (FCU) presenting with signs and symptoms beyond cold-induced urticarial skin rash.Tumour necrosis factor receptor associated periodic syndrome (TRAPS)Ilaris is indicated for the treatment of tumour necrosis factor (TNF) receptor associated periodic syndrome (TRAPS).Hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD)Ilaris is indicated for the treatment of hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD).Familial Mediterranean fever (FMF)Ilaris is indicated for the treatment of Familial Mediterranean Fever (FMF). Ilaris should be given in combination with colchicine, if appropriate.Ilaris is also indicated for the treatment of:Still’s diseaseIlaris is indicated for the treatment of active Still’s disease including adult-onset Still’s disease (AOSD) and systemic juvenile idiopathic arthritis (SJIA) in patients aged 2 years and older who have responded inadequately to previous therapy with non-steroidal anti-inflammatory drugs (NSAIDs) and systemic corticosteroids. Ilaris can be given as monotherapy or in combination with methotrexate.Gouty arthritisIlaris is indicated for the symptomatic treatment of adult patients with frequent gouty arthritis attacks (at least 3 attacks in the previous 12 months) in whom non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate. uuid:e5bc3a7b-4464-4ecf-b280-9f8bb42a3ec8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:37CQ2C7X93 biolink:treats MONDO:0018768 PMID:41385096 "[{""id"":""uuid:e3d8da92-c2ad-42be-ad6a-6b08a407a63f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:db8c85fb-8c73-41d6-8abf-afa665b05958"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:36363cc4-d962-4a1e-8676-3f912842a3cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ilaris""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] ILARIS is an interleukin-1β blocker indicated for the treatment of: • Periodic Fever Syndromes ( 1.1 ): - Cryopyrin-Associated Periodic Syndromes (CAPS), in adults and children 4 years of age and older, including: ◾ Familial Cold Auto-inflammatory Syndrome (FCAS) ◾ Muckle-Wells Syndrome (MWS) - Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS) in adult and pediatric patients - Hyperimmunoglobulin D Syndrome (HIDS)/ Mevalonate Kinase Deficiency (MKD) in adult and pediatric patients - Familial Mediterranean Fever (FMF) in adult and pediatric patients • Active Still’s Disease, including Adult-Onset Still’s Disease (AOSD) and Systemic Juvenile Idiopathic Arthritis (SJIA) in patients 2 years of age and older ( 1.2 ) • Gout flares in adults in whom non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate ( 1.3 )|[EMA] Periodic fever syndromesIlaris is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents and children aged 2 years and older:Cryopyrin-associated periodic syndromesIlaris is indicated for the treatment of cryopyrin-associated periodic syndromes (CAPS) including:Muckle-Wells syndrome (MWS),Neonatal-onset multisystem inflammatory disease (NOMID) / chronic infantile neurological, cutaneous, articular syndrome (CINCA),Severe forms of familial cold autoinflammatory syndrome (FCAS) / familial cold urticaria (FCU) presenting with signs and symptoms beyond cold-induced urticarial skin rash.Tumour necrosis factor receptor associated periodic syndrome (TRAPS)Ilaris is indicated for the treatment of tumour necrosis factor (TNF) receptor associated periodic syndrome (TRAPS).Hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD)Ilaris is indicated for the treatment of hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD).Familial Mediterranean fever (FMF)Ilaris is indicated for the treatment of Familial Mediterranean Fever (FMF). Ilaris should be given in combination with colchicine, if appropriate.Ilaris is also indicated for the treatment of:Still’s diseaseIlaris is indicated for the treatment of active Still’s disease including adult-onset Still’s disease (AOSD) and systemic juvenile idiopathic arthritis (SJIA) in patients aged 2 years and older who have responded inadequately to previous therapy with non-steroidal anti-inflammatory drugs (NSAIDs) and systemic corticosteroids. Ilaris can be given as monotherapy or in combination with methotrexate.Gouty arthritisIlaris is indicated for the symptomatic treatment of adult patients with frequent gouty arthritis attacks (at least 3 attacks in the previous 12 months) in whom non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate. uuid:6e927610-88d6-4d0c-98c4-6eb286e16f57 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:37CQ2C7X93 biolink:treats MONDO:0007727 PMID:41385096 "[{""id"":""uuid:f2de36cb-1b40-4c7b-949b-65621fdfaec5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e54b2173-e182-4608-a121-ec589b68529e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c8f29439-8e13-4a69-bc41-eee576539c22"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ILARIS is an interleukin-1β blocker indicated for the treatment of: • Periodic Fever Syndromes ( 1.1 ): - Cryopyrin-Associated Periodic Syndromes (CAPS), in adults and children 4 years of age and older, including: ◾ Familial Cold Auto-inflammatory Syndrome (FCAS) ◾ Muckle-Wells Syndrome (MWS) - Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS) in adult and pediatric patients - Hyperimmunoglobulin D Syndrome (HIDS)/ Mevalonate Kinase Deficiency (MKD) in adult and pediatric patients - Familial Mediterranean Fever (FMF) in adult and pediatric patients • Active Still’s Disease, including Adult-Onset Still’s Disease (AOSD) and Systemic Juvenile Idiopathic Arthritis (SJIA) in patients 2 years of age and older ( 1.2 ) • Gout flares in adults in whom non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate ( 1.3 )|[PMDA] A drug with a new active ingredient indicated for the treatment of cryopyrin-associated periodic syndrome. [Orphan drug] uuid:b29a958f-c40a-4589-9a42-b89000176e03 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:37CQ2C7X93 biolink:treats MONDO:0009849 PMID:41385096 "[{""id"":""uuid:0dafb92b-8655-49b0-8635-2cd222265b65"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:522d0bc1-3629-44fb-9682-d99fe324158e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:06ad2bc4-72fc-4e88-a554-8652cd3d1c6f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ilaris""]},{""id"":""uuid:dd0cd80c-bce2-4916-b023-175d716d1cc7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ILARIS is an interleukin-1β blocker indicated for the treatment of: • Periodic Fever Syndromes ( 1.1 ): - Cryopyrin-Associated Periodic Syndromes (CAPS), in adults and children 4 years of age and older, including: ◾ Familial Cold Auto-inflammatory Syndrome (FCAS) ◾ Muckle-Wells Syndrome (MWS) - Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS) in adult and pediatric patients - Hyperimmunoglobulin D Syndrome (HIDS)/ Mevalonate Kinase Deficiency (MKD) in adult and pediatric patients - Familial Mediterranean Fever (FMF) in adult and pediatric patients • Active Still’s Disease, including Adult-Onset Still’s Disease (AOSD) and Systemic Juvenile Idiopathic Arthritis (SJIA) in patients 2 years of age and older ( 1.2 ) • Gout flares in adults in whom non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate ( 1.3 )|[EMA] Periodic fever syndromesIlaris is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents and children aged 2 years and older:Cryopyrin-associated periodic syndromesIlaris is indicated for the treatment of cryopyrin-associated periodic syndromes (CAPS) including:Muckle-Wells syndrome (MWS),Neonatal-onset multisystem inflammatory disease (NOMID) / chronic infantile neurological, cutaneous, articular syndrome (CINCA),Severe forms of familial cold autoinflammatory syndrome (FCAS) / familial cold urticaria (FCU) presenting with signs and symptoms beyond cold-induced urticarial skin rash.Tumour necrosis factor receptor associated periodic syndrome (TRAPS)Ilaris is indicated for the treatment of tumour necrosis factor (TNF) receptor associated periodic syndrome (TRAPS).Hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD)Ilaris is indicated for the treatment of hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD).Familial Mediterranean fever (FMF)Ilaris is indicated for the treatment of Familial Mediterranean Fever (FMF). Ilaris should be given in combination with colchicine, if appropriate.Ilaris is also indicated for the treatment of:Still’s diseaseIlaris is indicated for the treatment of active Still’s disease including adult-onset Still’s disease (AOSD) and systemic juvenile idiopathic arthritis (SJIA) in patients aged 2 years and older who have responded inadequately to previous therapy with non-steroidal anti-inflammatory drugs (NSAIDs) and systemic corticosteroids. Ilaris can be given as monotherapy or in combination with methotrexate.Gouty arthritisIlaris is indicated for the symptomatic treatment of adult patients with frequent gouty arthritis attacks (at least 3 attacks in the previous 12 months) in whom non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate.|[PMDA] A drug with new additional indications and a new dosage for the treatment of patients with familial Mediterranean fever who have not responded sufficiently to conventional therapies, TNF receptor-associated periodic syndrome, or hyper IgD syndrome (mevalonate kinase deficiency). [Orphan drug] uuid:eb0ec985-b6a9-40f4-9f3c-f126f98264ba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:37CQ2C7X93 biolink:treats MONDO:0017708 PMID:41385096 "[{""id"":""uuid:33ca1158-e66f-4719-8faa-c73ceada0c98"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:7945fb67-8df8-4358-a75b-e034fd90efb0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:4a8697ed-d15d-406f-840f-3788e7ef5261"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ilaris""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] ILARIS is an interleukin-1β blocker indicated for the treatment of: • Periodic Fever Syndromes ( 1.1 ): - Cryopyrin-Associated Periodic Syndromes (CAPS), in adults and children 4 years of age and older, including: ◾ Familial Cold Auto-inflammatory Syndrome (FCAS) ◾ Muckle-Wells Syndrome (MWS) - Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS) in adult and pediatric patients - Hyperimmunoglobulin D Syndrome (HIDS)/ Mevalonate Kinase Deficiency (MKD) in adult and pediatric patients - Familial Mediterranean Fever (FMF) in adult and pediatric patients • Active Still’s Disease, including Adult-Onset Still’s Disease (AOSD) and Systemic Juvenile Idiopathic Arthritis (SJIA) in patients 2 years of age and older ( 1.2 ) • Gout flares in adults in whom non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate ( 1.3 )|[EMA] Periodic fever syndromesIlaris is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents and children aged 2 years and older:Cryopyrin-associated periodic syndromesIlaris is indicated for the treatment of cryopyrin-associated periodic syndromes (CAPS) including:Muckle-Wells syndrome (MWS),Neonatal-onset multisystem inflammatory disease (NOMID) / chronic infantile neurological, cutaneous, articular syndrome (CINCA),Severe forms of familial cold autoinflammatory syndrome (FCAS) / familial cold urticaria (FCU) presenting with signs and symptoms beyond cold-induced urticarial skin rash.Tumour necrosis factor receptor associated periodic syndrome (TRAPS)Ilaris is indicated for the treatment of tumour necrosis factor (TNF) receptor associated periodic syndrome (TRAPS).Hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD)Ilaris is indicated for the treatment of hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD).Familial Mediterranean fever (FMF)Ilaris is indicated for the treatment of Familial Mediterranean Fever (FMF). Ilaris should be given in combination with colchicine, if appropriate.Ilaris is also indicated for the treatment of:Still’s diseaseIlaris is indicated for the treatment of active Still’s disease including adult-onset Still’s disease (AOSD) and systemic juvenile idiopathic arthritis (SJIA) in patients aged 2 years and older who have responded inadequately to previous therapy with non-steroidal anti-inflammatory drugs (NSAIDs) and systemic corticosteroids. Ilaris can be given as monotherapy or in combination with methotrexate.Gouty arthritisIlaris is indicated for the symptomatic treatment of adult patients with frequent gouty arthritis attacks (at least 3 attacks in the previous 12 months) in whom non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate. uuid:3690347a-e7c8-4701-acb7-e500b9f016e7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:37CQ2C7X93 biolink:treats MONDO:0018088 PMID:41385096 "[{""id"":""uuid:4c783885-8bfd-42cf-a917-db58a8f7786c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f1180250-12ea-4346-b89b-be76bcb0a633"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:91001810-1b23-4bd7-8576-cb0cbb5a3943"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ilaris""]},{""id"":""uuid:5ccdc6d6-5b43-46ef-bfec-7d0b8e42c15c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ILARIS is an interleukin-1β blocker indicated for the treatment of: • Periodic Fever Syndromes ( 1.1 ): - Cryopyrin-Associated Periodic Syndromes (CAPS), in adults and children 4 years of age and older, including: ◾ Familial Cold Auto-inflammatory Syndrome (FCAS) ◾ Muckle-Wells Syndrome (MWS) - Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS) in adult and pediatric patients - Hyperimmunoglobulin D Syndrome (HIDS)/ Mevalonate Kinase Deficiency (MKD) in adult and pediatric patients - Familial Mediterranean Fever (FMF) in adult and pediatric patients • Active Still’s Disease, including Adult-Onset Still’s Disease (AOSD) and Systemic Juvenile Idiopathic Arthritis (SJIA) in patients 2 years of age and older ( 1.2 ) • Gout flares in adults in whom non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate ( 1.3 )|[EMA] Periodic fever syndromesIlaris is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents and children aged 2 years and older:Cryopyrin-associated periodic syndromesIlaris is indicated for the treatment of cryopyrin-associated periodic syndromes (CAPS) including:Muckle-Wells syndrome (MWS),Neonatal-onset multisystem inflammatory disease (NOMID) / chronic infantile neurological, cutaneous, articular syndrome (CINCA),Severe forms of familial cold autoinflammatory syndrome (FCAS) / familial cold urticaria (FCU) presenting with signs and symptoms beyond cold-induced urticarial skin rash.Tumour necrosis factor receptor associated periodic syndrome (TRAPS)Ilaris is indicated for the treatment of tumour necrosis factor (TNF) receptor associated periodic syndrome (TRAPS).Hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD)Ilaris is indicated for the treatment of hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD).Familial Mediterranean fever (FMF)Ilaris is indicated for the treatment of Familial Mediterranean Fever (FMF). Ilaris should be given in combination with colchicine, if appropriate.Ilaris is also indicated for the treatment of:Still’s diseaseIlaris is indicated for the treatment of active Still’s disease including adult-onset Still’s disease (AOSD) and systemic juvenile idiopathic arthritis (SJIA) in patients aged 2 years and older who have responded inadequately to previous therapy with non-steroidal anti-inflammatory drugs (NSAIDs) and systemic corticosteroids. Ilaris can be given as monotherapy or in combination with methotrexate.Gouty arthritisIlaris is indicated for the symptomatic treatment of adult patients with frequent gouty arthritis attacks (at least 3 attacks in the previous 12 months) in whom non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate.|[PMDA] A drug with new additional indications and a new dosage for the treatment of patients with familial Mediterranean fever who have not responded sufficiently to conventional therapies, TNF receptor-associated periodic syndrome, or hyper IgD syndrome (mevalonate kinase deficiency). [Orphan drug] uuid:e4380cf8-9c86-4949-806a-8a345ce0d19a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:37CQ2C7X93 biolink:treats MONDO:0019355 PMID:41385096 "[{""id"":""uuid:7c821ea9-4c32-48c0-82fe-3421101c8828"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:2b7ffb21-2a81-454f-a083-2d4e0351ede1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:402c7528-c48b-44a4-b6c2-08ea23d88339"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ilaris""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] ILARIS is an interleukin-1β blocker indicated for the treatment of: • Periodic Fever Syndromes ( 1.1 ): - Cryopyrin-Associated Periodic Syndromes (CAPS), in adults and children 4 years of age and older, including: ◾ Familial Cold Auto-inflammatory Syndrome (FCAS) ◾ Muckle-Wells Syndrome (MWS) - Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS) in adult and pediatric patients - Hyperimmunoglobulin D Syndrome (HIDS)/ Mevalonate Kinase Deficiency (MKD) in adult and pediatric patients - Familial Mediterranean Fever (FMF) in adult and pediatric patients • Active Still’s Disease, including Adult-Onset Still’s Disease (AOSD) and Systemic Juvenile Idiopathic Arthritis (SJIA) in patients 2 years of age and older ( 1.2 ) • Gout flares in adults in whom non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate ( 1.3 )|[EMA] Periodic fever syndromesIlaris is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents and children aged 2 years and older:Cryopyrin-associated periodic syndromesIlaris is indicated for the treatment of cryopyrin-associated periodic syndromes (CAPS) including:Muckle-Wells syndrome (MWS),Neonatal-onset multisystem inflammatory disease (NOMID) / chronic infantile neurological, cutaneous, articular syndrome (CINCA),Severe forms of familial cold autoinflammatory syndrome (FCAS) / familial cold urticaria (FCU) presenting with signs and symptoms beyond cold-induced urticarial skin rash.Tumour necrosis factor receptor associated periodic syndrome (TRAPS)Ilaris is indicated for the treatment of tumour necrosis factor (TNF) receptor associated periodic syndrome (TRAPS).Hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD)Ilaris is indicated for the treatment of hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD).Familial Mediterranean fever (FMF)Ilaris is indicated for the treatment of Familial Mediterranean Fever (FMF). Ilaris should be given in combination with colchicine, if appropriate.Ilaris is also indicated for the treatment of:Still’s diseaseIlaris is indicated for the treatment of active Still’s disease including adult-onset Still’s disease (AOSD) and systemic juvenile idiopathic arthritis (SJIA) in patients aged 2 years and older who have responded inadequately to previous therapy with non-steroidal anti-inflammatory drugs (NSAIDs) and systemic corticosteroids. Ilaris can be given as monotherapy or in combination with methotrexate.Gouty arthritisIlaris is indicated for the symptomatic treatment of adult patients with frequent gouty arthritis attacks (at least 3 attacks in the previous 12 months) in whom non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate. uuid:0d2f0170-c8cc-49dd-967a-a5e761fb3f3c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:37CQ2C7X93 biolink:treats MONDO:0019434 PMID:41385096 "[{""id"":""uuid:68840a40-a695-4270-af04-ffeb3983c69a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:27fabea2-9e5c-4e51-9ac8-f6582e3bdaa8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:dbbf76b1-a9d0-4429-bba6-2f8356655170"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ilaris""]},{""id"":""uuid:0468dc56-800c-4080-8b34-7a8fb0ec6c89"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ILARIS is an interleukin-1β blocker indicated for the treatment of: • Periodic Fever Syndromes ( 1.1 ): - Cryopyrin-Associated Periodic Syndromes (CAPS), in adults and children 4 years of age and older, including: ◾ Familial Cold Auto-inflammatory Syndrome (FCAS) ◾ Muckle-Wells Syndrome (MWS) - Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS) in adult and pediatric patients - Hyperimmunoglobulin D Syndrome (HIDS)/ Mevalonate Kinase Deficiency (MKD) in adult and pediatric patients - Familial Mediterranean Fever (FMF) in adult and pediatric patients • Active Still’s Disease, including Adult-Onset Still’s Disease (AOSD) and Systemic Juvenile Idiopathic Arthritis (SJIA) in patients 2 years of age and older ( 1.2 ) • Gout flares in adults in whom non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate ( 1.3 )|[EMA] Periodic fever syndromesIlaris is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents and children aged 2 years and older:Cryopyrin-associated periodic syndromesIlaris is indicated for the treatment of cryopyrin-associated periodic syndromes (CAPS) including:Muckle-Wells syndrome (MWS),Neonatal-onset multisystem inflammatory disease (NOMID) / chronic infantile neurological, cutaneous, articular syndrome (CINCA),Severe forms of familial cold autoinflammatory syndrome (FCAS) / familial cold urticaria (FCU) presenting with signs and symptoms beyond cold-induced urticarial skin rash.Tumour necrosis factor receptor associated periodic syndrome (TRAPS)Ilaris is indicated for the treatment of tumour necrosis factor (TNF) receptor associated periodic syndrome (TRAPS).Hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD)Ilaris is indicated for the treatment of hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD).Familial Mediterranean fever (FMF)Ilaris is indicated for the treatment of Familial Mediterranean Fever (FMF). Ilaris should be given in combination with colchicine, if appropriate.Ilaris is also indicated for the treatment of:Still’s diseaseIlaris is indicated for the treatment of active Still’s disease including adult-onset Still’s disease (AOSD) and systemic juvenile idiopathic arthritis (SJIA) in patients aged 2 years and older who have responded inadequately to previous therapy with non-steroidal anti-inflammatory drugs (NSAIDs) and systemic corticosteroids. Ilaris can be given as monotherapy or in combination with methotrexate.Gouty arthritisIlaris is indicated for the symptomatic treatment of adult patients with frequent gouty arthritis attacks (at least 3 attacks in the previous 12 months) in whom non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate.|[PMDA] Drugs with a new additional indication and a new dosage for the treatment of systemic juvenile idiopathic arthritis in patients who have not responded sufficiently to conventional treatments. [Orphan drug] uuid:812f0fe0-d931-435a-8e7a-b720a3e6bcd7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:37CQ2C7X93 biolink:treats MONDO:0005393 PMID:41385096 "[{""id"":""uuid:344b3450-d054-4130-8d57-a0405fb59890"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:af9a8c7b-513a-4fda-bbc7-3662615c7136"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:cb5fc737-5890-45a1-901b-1bdc2eca6ca2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ilaris""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] ILARIS is an interleukin-1β blocker indicated for the treatment of: • Periodic Fever Syndromes ( 1.1 ): - Cryopyrin-Associated Periodic Syndromes (CAPS), in adults and children 4 years of age and older, including: ◾ Familial Cold Auto-inflammatory Syndrome (FCAS) ◾ Muckle-Wells Syndrome (MWS) - Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS) in adult and pediatric patients - Hyperimmunoglobulin D Syndrome (HIDS)/ Mevalonate Kinase Deficiency (MKD) in adult and pediatric patients - Familial Mediterranean Fever (FMF) in adult and pediatric patients • Active Still’s Disease, including Adult-Onset Still’s Disease (AOSD) and Systemic Juvenile Idiopathic Arthritis (SJIA) in patients 2 years of age and older ( 1.2 ) • Gout flares in adults in whom non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate ( 1.3 )|[EMA] Periodic fever syndromesIlaris is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents and children aged 2 years and older:Cryopyrin-associated periodic syndromesIlaris is indicated for the treatment of cryopyrin-associated periodic syndromes (CAPS) including:Muckle-Wells syndrome (MWS),Neonatal-onset multisystem inflammatory disease (NOMID) / chronic infantile neurological, cutaneous, articular syndrome (CINCA),Severe forms of familial cold autoinflammatory syndrome (FCAS) / familial cold urticaria (FCU) presenting with signs and symptoms beyond cold-induced urticarial skin rash.Tumour necrosis factor receptor associated periodic syndrome (TRAPS)Ilaris is indicated for the treatment of tumour necrosis factor (TNF) receptor associated periodic syndrome (TRAPS).Hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD)Ilaris is indicated for the treatment of hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD).Familial Mediterranean fever (FMF)Ilaris is indicated for the treatment of Familial Mediterranean Fever (FMF). Ilaris should be given in combination with colchicine, if appropriate.Ilaris is also indicated for the treatment of:Still’s diseaseIlaris is indicated for the treatment of active Still’s disease including adult-onset Still’s disease (AOSD) and systemic juvenile idiopathic arthritis (SJIA) in patients aged 2 years and older who have responded inadequately to previous therapy with non-steroidal anti-inflammatory drugs (NSAIDs) and systemic corticosteroids. Ilaris can be given as monotherapy or in combination with methotrexate.Gouty arthritisIlaris is indicated for the symptomatic treatment of adult patients with frequent gouty arthritis attacks (at least 3 attacks in the previous 12 months) in whom non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate. uuid:1d4d7bf6-ca18-4371-ba0d-6d764151d6a4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134709 biolink:treats MONDO:0021107 PMID:41385096 "[{""id"":""uuid:ebeadb2b-7553-4103-b16b-ba26b401c5ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:e8d2f93e-7b66-4ca6-b7eb-871c85b9ef14"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:4557f76e-b277-4ca0-8018-342aad430baf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ozawade""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] WAKIX is indicated for the: treatment of excessive daytime sleepiness (EDS) or cataplexy in adult patients with narcolepsy. treatment of excessive daytime sleepiness (EDS) in pediatric patients 6 years of age and older with narcolepsy.|[EMA] Wakix is indicated in adults, adolescents and children from the age of 6 years for the treatment of narcolepsy with or without cataplexy (see also section 5.1). uuid:8a4273eb-ffd5-48a6-a0e3-731ccba57124 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:998040 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:019a84e8-9590-4160-ac93-91c5a9765917"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3bda30aa-f2fc-4c40-a8bf-acbf3fd894d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DULERA is a combination product containing a corticosteroid and a long-acting beta 2 -adrenergic agonist (LABA) indicated for: Treatment of asthma in patients 5 years of age and older. ( 1.1 ) Important Limitation of Use: Not indicated for the relief of acute bronchospasm. ( 1.1 ) uuid:1f5e2bf0-2c57-483a-ab5f-ea04842e2f62 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:998040 biolink:treats UMLS:C0741804 PMID:41385096 "[{""id"":""uuid:3c5d1556-7658-4769-9314-c1f9714f1140"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:af74312b-cbcf-4cf9-b8a4-9f3953319279"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DULERA is a combination product containing a corticosteroid and a long-acting beta 2 -adrenergic agonist (LABA) indicated for: Treatment of asthma in patients 5 years of age and older. ( 1.1 ) Important Limitation of Use: Not indicated for the relief of acute bronchospasm. ( 1.1 ) uuid:922242a0-29ab-4ca3-a775-6667d2ea5347 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:76611 biolink:treats MONDO:0004975 PMID:41385096 "[{""id"":""uuid:83487254-99d6-4bfe-9ab5-17d0e1e4eb0e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:60dfedf2-896d-4409-8085-d1956d4eb56a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:965008c7-afa9-4ab5-bec5-2e4aefbfd9b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:7ecde251-5565-4017-9813-7cf8c7e80b74"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vizamyl is indicated for Positron Emission Tomography (PET) imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's Disease (AD) and other causes of cognitive decline. A negative Vizamyl scan indicates sparse to no neuritic plaques and is inconsistent with a neuropathological diagnosis of AD at the time of image acquisition; a negative scan result reduces the likelihood that a patient's cognitive impairment is due to AD. A positive Vizamyl scan indicates moderate to frequent amyloid neuritic plaques; neuropathological examination has shown this amount of amyloid neuritic plaque is present in patients with AD, but may also be present in patients with other types of neurologic conditions as well as in older people with normal cognition. Vizamyl is an adjunct to other diagnostic evaluations. Limitations of Use: A positive Vizamyl scan does not establish a diagnosis of AD or other cognitive disorder. Safety and effectiveness of Vizamyl have not been established for: Predicting development of dementia or other neurologic condition. Monitoring responses to therapies.|[EMA] This medicinal product is for diagnostic use only.Vizamyl is a radiopharmaceutical medicinal product indicated for Positron Emission Tomography (PET) imaging of β amyloid neuritic plaque density in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD) and other causes of cognitive impairment. Vizamyl should be used in conjunction with a clinical evaluation.A negative scan indicates sparse or no plaques, which is not consistent with a diagnosis of AD.|[PMDA] A drug with a new active ingredient indicated for visualization of beta‑amyloid plaques in the brains of patients with cognitive impairment suspected to be Alzheimer's disease. uuid:10a4f173-a1a2-4a75-a652-d47fb3a8ae5a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:76611 biolink:treats MONDO:0850292 PMID:41385096 "[{""id"":""uuid:e0aa839b-2f16-46e6-981d-6eb229ccc2ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c0f2c1aa-3ffd-4500-86bb-c8e5ae2845b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vizamyl is indicated for Positron Emission Tomography (PET) imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's Disease (AD) and other causes of cognitive decline. A negative Vizamyl scan indicates sparse to no neuritic plaques and is inconsistent with a neuropathological diagnosis of AD at the time of image acquisition; a negative scan result reduces the likelihood that a patient's cognitive impairment is due to AD. A positive Vizamyl scan indicates moderate to frequent amyloid neuritic plaques; neuropathological examination has shown this amount of amyloid neuritic plaque is present in patients with AD, but may also be present in patients with other types of neurologic conditions as well as in older people with normal cognition. Vizamyl is an adjunct to other diagnostic evaluations. Limitations of Use: A positive Vizamyl scan does not establish a diagnosis of AD or other cognitive disorder. Safety and effectiveness of Vizamyl have not been established for: Predicting development of dementia or other neurologic condition. Monitoring responses to therapies. uuid:281dc113-f81f-4bab-9599-901cc3e43485 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:76611 biolink:treats MONDO:0001627 PMID:41385096 "[{""id"":""uuid:e11804b2-401a-4758-90e9-b225e0f87f89"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2230d21b-a7e7-43af-9b1f-daf216749937"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vizamyl is indicated for Positron Emission Tomography (PET) imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's Disease (AD) and other causes of cognitive decline. A negative Vizamyl scan indicates sparse to no neuritic plaques and is inconsistent with a neuropathological diagnosis of AD at the time of image acquisition; a negative scan result reduces the likelihood that a patient's cognitive impairment is due to AD. A positive Vizamyl scan indicates moderate to frequent amyloid neuritic plaques; neuropathological examination has shown this amount of amyloid neuritic plaque is present in patients with AD, but may also be present in patients with other types of neurologic conditions as well as in older people with normal cognition. Vizamyl is an adjunct to other diagnostic evaluations. Limitations of Use: A positive Vizamyl scan does not establish a diagnosis of AD or other cognitive disorder. Safety and effectiveness of Vizamyl have not been established for: Predicting development of dementia or other neurologic condition. Monitoring responses to therapies. uuid:bd718f0f-f94a-46b5-a78c-816797ad5487 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:C5U34S9XFV biolink:treats MONDO:0011996 PMID:41385096 "[{""id"":""uuid:84120c4c-9cfc-49c0-a002-c0a1a99c400c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:871424b5-2b32-46bb-b7ff-389ed1e53d2f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:b9709f03-cff4-4217-aacb-9d8bfc0ab16a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:275168dd-7556-41f5-9c8f-f6e06ea97821"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SCEMBLIX is indicated for the treatment of adult patients with: Newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP). This indication is approved under accelerated approval based on major molecular response rate [see Clinical Studies (14.1)] . Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s). Previously treated Ph+ CML in CP. Ph+ CML in CP with the T315I mutation.|[EMA] Scemblix is indicated for the treatment of adult patients with Philadelphia chromosome positive chronic myeloid leukaemia in chronic phase (Ph+ CML CP) previously treated with two or more tyrosine kinase inhibitors (see section 5.1).|[PMDA] Drugs with a new active ingredient indicated for the treatment of chronic myelogenous leukemia with resistance or intolerance to prior drug therapies. [Orphan drug] uuid:69d4d28c-0121-43d3-95e3-0d947d9eee16 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49005 biolink:treats MONDO:0016487 PMID:41385096 "[{""id"":""uuid:4d8dfcf0-b526-4d46-a7ed-9ba1756956a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2804a910-9fec-48f9-99ee-c935e823e2e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] JADENU is an iron chelator indicated for the treatment of chronic iron overload due to blood transfusions in patients 2 years of age and older. ( 1.1 ) JADENU is indicated for the treatment of chronic iron overload in patients 10 years of age and older with non-transfusion-dependent thalassemia (NTDT) syndromes, and with a liver iron (Fe) concentration (LIC) of at least 5 mg Fe per gram of dry weight (Fe/g dw) and a serum ferritin greater than 300 mcg/L. ( 1.2 ) Limitations of Use: The safety and efficacy of JADENU when administered with other iron chelation therapy have not been established. ( 1.3 ) uuid:0fc385b7-1859-4d05-9057-6f1d5ba47130 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2682 biolink:treats MONDO:0000256 PMID:41385096 "[{""id"":""uuid:2b02dd76-ba9d-42de-9fc4-cc96f00729c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6ce7558b-e3a3-4a9a-ac53-802871364196"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amphotericin B liposome for injection is indicated for the following: Empirical therapy for presumed fungal infection in febrile, neutropenic patients. Treatment of Cryptococcal Meningitis in HIV-infected patients (see DESCRIPTION OF CLINICAL STUDIES ). Treatment of patients with Aspergillus species, Candida species and/or Cryptococcus species infections (see above for the treatment of Cryptococcal Meningitis) refractory to amphotericin B deoxycholate, or in patients where renal impairment or unacceptable toxicity precludes the use of amphotericin B deoxycholate. Treatment of visceral leishmaniasis. In immunocompromised patients with visceral leishmaniasis treated with amphotericin B liposome for injection, relapse rates were high following initial clearance of parasites (see DESCRIPTION OF CLINICAL STUDIES ). See DOSAGE AND ADMINISTRATION for recommended doses by indication. DESCRIPTION OF CLINICAL STUDIES Eleven clinical studies supporting the efficacy and safety of amphotericin B liposome for injection were conducted. This clinical program included both controlled and uncontrolled studies. These studies, which involved 2,171 patients, included patients with confirmed systemic mycoses, empirical therapy, and visceral leishmaniasis. Nineteen hundred and forty-six (1946) episodes were evaluable for efficacy, of which 1,280 (302 pediatric and 978 adults) were treated with amphotericin B liposome for injection. Three controlled empirical therapy trials compared the efficacy and safety of amphotericin B liposome for injection to amphotericin B. One of these studies was conducted in a pediatric population, one in adults, and a third in patients aged 2 years or more. In addition, a controlled empirical therapy trial comparing the safety of amphotericin B liposome for injection to Abelcet ® (amphotericin B lipid complex) was conducted in patients aged 2 years or more. One controlled trial compared the efficacy and safety of amphotericin B liposome for injection to amphotericin B in HIV patients with cryptococcal meningitis. One compassionate use study enrolled patients who had failed amphotericin B deoxycholate therapy or who were unable to receive amphotericin B deoxycholate because of renal insufficiency. uuid:c9b8268d-461a-44d0-8eec-0b3f38300159 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4735 biolink:treats MONDO:0001358 PMID:41385096 "[{""id"":""uuid:88c34d02-d20f-4a0b-a130-5b9558873e92"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:73ae54b0-afb0-4d46-aef3-2168418e7e55"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levalbuterol Inhalation Solution, USP is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease. uuid:a81ef397-577f-4eb9-aa33-50c2276d2c74 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4735 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:a0a32400-7681-47af-93c6-45ca8653d03c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d74e0778-704a-45e5-ad93-374f99305116"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levalbuterol Inhalation Solution, USP is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease. uuid:41915e82-e42b-414a-a932-384ee4fe8bd6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:TF5MPQ8WGY biolink:treats MONDO:0005036 PMID:41385096 "[{""id"":""uuid:318cbb10-2f7b-47ad-9c7d-bd0a29b37709"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2cb1b4f9-5b99-452c-b2e5-4562f33a2126"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VYLOY, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adults with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)‑negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are claudin (CLDN) 18.2 positive as determined by an FDA-approved test [see Dosage and Administration ( 2.1 ) and Clinical Studies ( 14 )]. uuid:815196d9-e163-4605-a0ea-4b968fb393b0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:TF5MPQ8WGY biolink:treats MONDO:0003219 PMID:41385096 "[{""id"":""uuid:5e228ae7-cea4-433e-82cc-b28afc7f4d87"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3d53e568-32e2-42c8-bc24-f73d072a3688"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VYLOY, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adults with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)‑negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are claudin (CLDN) 18.2 positive as determined by an FDA-approved test [see Dosage and Administration ( 2.1 ) and Clinical Studies ( 14 )]. uuid:38ee2bcb-0bf5-4bb6-9130-a5f5da5c009c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C5238067 biolink:treats MONDO:0019623 PMID:41385096 "[{""id"":""uuid:361ab4d0-6b4f-419a-9d30-3d446aed2e24"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c75da1d3-0236-481f-9f9a-7b9f628ee545"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ANDEMBRY is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older. DRUGBANK:DB15629 uuid:e245419d-e57c-496c-a805-8b4534e1617a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C5238067 biolink:treats MONDO:0012526 PMID:41385096 "[{""id"":""uuid:d1723e0b-c582-4198-8472-31bd187fdda7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4eebc658-55c0-4e43-b07a-81492d498086"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ANDEMBRY is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older. DRUGBANK:DB15629 uuid:0e8750d1-9b1d-498e-9b2e-576b5968417e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1591939 biolink:treats MONDO:0005231 PMID:41385096 "[{""id"":""uuid:7c76c298-18a2-46fd-8a03-a5f01d8a08b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:93a3a970-046c-42f1-8bfd-517bb8213c03"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] HARVONI is a fixed-dose combination of ledipasvir, a hepatitis C virus (HCV) NS5A inhibitor, and sofosbuvir, an HCV nucleotide analog NS5B polymerase inhibitor, and is indicated for the treatment of chronic hepatitis C virus (HCV) in: Adults with genotype 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis Adults with genotype 1 infection with decompensated cirrhosis, in combination with ribavirin Adults with genotype 1 or 4 infection who are liver transplant recipients without cirrhosis or with compensated cirrhosis, in combination with ribavirin Pediatric patients 12 years of age and older or weighing at least 35 kg with genotype 1, 4, 5, or 6 without cirrhosis or with compensated cirrhosis. ( 1 ) uuid:87d9a195-9951-43c4-9d29-a8be8860e4b5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134716 biolink:treats MONDO:0004975 PMID:41385096 "[{""id"":""uuid:9b80be18-14df-485c-a38b-5acec2dcd93e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cede8a39-a1ba-4a9c-8af9-a5a8e2ce1a56"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] REXULTI is indicated for: Adjunctive treatment to antidepressants for major depressive disorder (MDD) in adults Treatment of schizophrenia in adults and pediatric patients ages 13 years and older Treatment of agitation associated with dementia due to Alzheimer's disease Limitations of Use: REXULTI is not indicated as an as needed (""prn"") treatment for agitation associated with dementia due to Alzheimer's disease [see Clinical Studies (14.3) ] ." uuid:f25445e6-c130-4ac1-90bb-cc0ae5870c38 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DPT0O3T46P biolink:treats MONDO:0005105 PMID:41385096 "[{""id"":""uuid:03a5ed0a-3abc-43a6-b805-77ec6520f5d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:645dd696-a0b2-4b82-9998-2341d6aaf261"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:a2d9da3b-dad2-49bc-a9c4-294b49171c6e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated: Melanoma for the treatment of patients with unresectable or metastatic melanoma. ( 1.1 ) for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC, or III melanoma following complete resection. ( 1.1 ) Non-Small Cell Lung Cancer (NSCLC) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations. ( 1.2 ) in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, as first-line treatment of patients with metastatic squamous NSCLC. ( 1.2 ) as a single agent for the first-line treatment of patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) ≥1%] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and is: Stage III where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic. ( 1.2 , 2.1 ) as a single agent for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA. ( 1.2 , 2.1 ) for the treatment of patients with resectable (tumors ≥4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.2 ) as a single agent, for adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage IB (T2a ≥4 cm), II, or IIIA NSCLC. ( 1.2 ) Malignant Pleural Mesothelioma (MPM) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of adult patients with unresectable advanced or metastatic MPM. ( 1.3 ) Head and Neck Squamous Cell Cancer (HNSCC) for the treatment of adult patients with resectable locally advanced HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test, as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as a single agent. ( 1.4 ) in combination with platinum and FU for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC. ( 1.4 ) as a single agent for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test. ( 1.4 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy. ( 1.4 ) Classical Hodgkin Lymphoma (cHL) for the treatment of adult patients with relapsed or refractory cHL. ( 1.5 ) for the treatment of pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapy. ( 1.5 ) Primary Mediastinal Large B-Cell Lymphoma (PMBCL) for the treatment of adult and pediatric patients with refractory PMBCL, or who have relapsed after 2 or more prior lines of therapy. ( 1.6 ) Limitations of Use : KEYTRUDA is not recommended for treatment of patients with PMBCL who require urgent cytoreductive therapy. Urothelial Cancer in combination with enfortumab vedotin, for the treatment of adult patients with locally advanced or metastatic urothelial cancer. ( 1.7 ) as a single agent for the treatment of patients with locally advanced or metastatic urothelial carcinoma who: are not eligible for any platinum-containing chemotherapy, or who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. ( 1.7 ) as a single agent for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy. ( 1.7 ) Microsatellite Instability-High or Mismatch Repair Deficient Cancer for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. ( 1.8 , 2.1 ) Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer (CRC) for the treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by an FDA-approved test. ( 1.9 , 2.1 ) Gastric Cancer in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.10 ) in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.10 ) Esophageal Cancer for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation either: in combination with platinum- and fluoropyrimidine-based chemotherapy for patients whose tumors express PD-L1 (CPS ≥1), or as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS ≥10) as determined by an FDA-approved test. ( 1.11 , 2.1 ) Cervical Cancer in combination with chemoradiotherapy, for the treatment of patients with locally advanced cervical cancer involving the lower third of the vagina, with or without extension to pelvic sidewall, or hydronephrosis/non-functioning kidney, or spread to adjacent pelvic organs (FIGO 2014 Stage III-IVA). ( 1.12 ) in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.12 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.12 , 2.1 ) Hepatocellular Carcinoma (HCC) for the treatment of patients with HCC secondary to hepatitis B who have received prior systemic therapy other than a PD-1/PD-L1-containing regimen. ( 1.13 ) Biliary Tract Cancer (BTC) in combination with gemcitabine and cisplatin, for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer. ( 1.14 ) Merkel Cell Carcinoma (MCC) for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma. ( 1.15 ) Renal Cell Carcinoma (RCC) in combination with axitinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) in combination with lenvatinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. ( 1.16 ) Endometrial Carcinoma in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma. ( 1.17 ) in combination with lenvatinib, for the treatment of adult patients with advanced endometrial carcinoma that is mismatch repair proficient (pMMR) or not MSI-H as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) as a single agent, for the treatment of adult patients with advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) Tumor Mutational Burden-High (TMB-H) Cancer for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. 1 ( 1.18 , 2.1 ) Limitations of Use : The safety and effectiveness of KEYTRUDA in pediatric patients with TMB-H central nervous system cancers have not been established. Cutaneous Squamous Cell Carcinoma (cSCC) for the treatment of patients with recurrent or metastatic cSCC or locally advanced cSCC that is not curable by surgery or radiation. ( 1.19 ) Triple-Negative Breast Cancer (TNBC) for the treatment of patients with high-risk early-stage TNBC in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.20 ) in combination with chemotherapy, for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA approved test. ( 1.20 , 2.1 ) Adult Classical Hodgkin Lymphoma and Adult Primary Mediastinal Large B-Cell Lymphoma: Additional Dosing Regimen of 400 mg Every 6 Weeks for use at an additional recommended dosage of 400 mg every 6 weeks for Classical Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma in adults. 2 ( 1.21 , 2.2 ) 1 This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. 2 This indication is approved under accelerated approval based on pharmacokinetic data, the relationship of exposure to efficacy, and the relationship of exposure to safety. Continued approval for this dosing may be contingent upon verification and description of clinical benefit in the confirmatory trials.|[PMDA] Drugs with new indications and a new dosage for the treatment of: advanced or recurrent microsatellite instability- high (MSI-High) solid tumors that have progressed after cancer chemotherapy (for use only if refractory or intolerant to standard therapies), melanoma, and unresectable advanced or recurrent non-small cell lung cancer. [(1) Conditional early approval, (2) Orphan drug, (3) Priority review] uuid:5fa962e3-91ab-4de2-beb9-a6522013d73f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DPT0O3T46P biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:eee5f46f-375b-4e2f-bc63-15cb7e3e0ba6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9641e72b-969a-4442-aec2-8c7c023894eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ee4d1ca3-63da-4a53-85bf-ed49582b83d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated: Melanoma for the treatment of patients with unresectable or metastatic melanoma. ( 1.1 ) for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC, or III melanoma following complete resection. ( 1.1 ) Non-Small Cell Lung Cancer (NSCLC) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations. ( 1.2 ) in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, as first-line treatment of patients with metastatic squamous NSCLC. ( 1.2 ) as a single agent for the first-line treatment of patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) ≥1%] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and is: Stage III where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic. ( 1.2 , 2.1 ) as a single agent for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA. ( 1.2 , 2.1 ) for the treatment of patients with resectable (tumors ≥4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.2 ) as a single agent, for adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage IB (T2a ≥4 cm), II, or IIIA NSCLC. ( 1.2 ) Malignant Pleural Mesothelioma (MPM) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of adult patients with unresectable advanced or metastatic MPM. ( 1.3 ) Head and Neck Squamous Cell Cancer (HNSCC) for the treatment of adult patients with resectable locally advanced HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test, as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as a single agent. ( 1.4 ) in combination with platinum and FU for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC. ( 1.4 ) as a single agent for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test. ( 1.4 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy. ( 1.4 ) Classical Hodgkin Lymphoma (cHL) for the treatment of adult patients with relapsed or refractory cHL. ( 1.5 ) for the treatment of pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapy. ( 1.5 ) Primary Mediastinal Large B-Cell Lymphoma (PMBCL) for the treatment of adult and pediatric patients with refractory PMBCL, or who have relapsed after 2 or more prior lines of therapy. ( 1.6 ) Limitations of Use : KEYTRUDA is not recommended for treatment of patients with PMBCL who require urgent cytoreductive therapy. Urothelial Cancer in combination with enfortumab vedotin, for the treatment of adult patients with locally advanced or metastatic urothelial cancer. ( 1.7 ) as a single agent for the treatment of patients with locally advanced or metastatic urothelial carcinoma who: are not eligible for any platinum-containing chemotherapy, or who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. ( 1.7 ) as a single agent for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy. ( 1.7 ) Microsatellite Instability-High or Mismatch Repair Deficient Cancer for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. ( 1.8 , 2.1 ) Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer (CRC) for the treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by an FDA-approved test. ( 1.9 , 2.1 ) Gastric Cancer in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.10 ) in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.10 ) Esophageal Cancer for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation either: in combination with platinum- and fluoropyrimidine-based chemotherapy for patients whose tumors express PD-L1 (CPS ≥1), or as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS ≥10) as determined by an FDA-approved test. ( 1.11 , 2.1 ) Cervical Cancer in combination with chemoradiotherapy, for the treatment of patients with locally advanced cervical cancer involving the lower third of the vagina, with or without extension to pelvic sidewall, or hydronephrosis/non-functioning kidney, or spread to adjacent pelvic organs (FIGO 2014 Stage III-IVA). ( 1.12 ) in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.12 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.12 , 2.1 ) Hepatocellular Carcinoma (HCC) for the treatment of patients with HCC secondary to hepatitis B who have received prior systemic therapy other than a PD-1/PD-L1-containing regimen. ( 1.13 ) Biliary Tract Cancer (BTC) in combination with gemcitabine and cisplatin, for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer. ( 1.14 ) Merkel Cell Carcinoma (MCC) for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma. ( 1.15 ) Renal Cell Carcinoma (RCC) in combination with axitinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) in combination with lenvatinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. ( 1.16 ) Endometrial Carcinoma in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma. ( 1.17 ) in combination with lenvatinib, for the treatment of adult patients with advanced endometrial carcinoma that is mismatch repair proficient (pMMR) or not MSI-H as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) as a single agent, for the treatment of adult patients with advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) Tumor Mutational Burden-High (TMB-H) Cancer for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. 1 ( 1.18 , 2.1 ) Limitations of Use : The safety and effectiveness of KEYTRUDA in pediatric patients with TMB-H central nervous system cancers have not been established. Cutaneous Squamous Cell Carcinoma (cSCC) for the treatment of patients with recurrent or metastatic cSCC or locally advanced cSCC that is not curable by surgery or radiation. ( 1.19 ) Triple-Negative Breast Cancer (TNBC) for the treatment of patients with high-risk early-stage TNBC in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.20 ) in combination with chemotherapy, for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA approved test. ( 1.20 , 2.1 ) Adult Classical Hodgkin Lymphoma and Adult Primary Mediastinal Large B-Cell Lymphoma: Additional Dosing Regimen of 400 mg Every 6 Weeks for use at an additional recommended dosage of 400 mg every 6 weeks for Classical Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma in adults. 2 ( 1.21 , 2.2 ) 1 This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. 2 This indication is approved under accelerated approval based on pharmacokinetic data, the relationship of exposure to efficacy, and the relationship of exposure to safety. Continued approval for this dosing may be contingent upon verification and description of clinical benefit in the confirmatory trials.|[PMDA] Drugs with a new additional indication and a new dosage for the treatment of patients with PD-L1- positive, unresectable, recurrent or advanced non- small cell lung cancer. uuid:7d639ef6-ca2d-4d1d-b3e4-6bd1fd8ac193 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DPT0O3T46P biolink:treats MONDO:0005112 PMID:41385096 "[{""id"":""uuid:661b1ce8-f270-433e-839e-0371367e904f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8ab2690e-b1b5-44ea-9430-a3af6e51b8d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated: Melanoma for the treatment of patients with unresectable or metastatic melanoma. ( 1.1 ) for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC, or III melanoma following complete resection. ( 1.1 ) Non-Small Cell Lung Cancer (NSCLC) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations. ( 1.2 ) in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, as first-line treatment of patients with metastatic squamous NSCLC. ( 1.2 ) as a single agent for the first-line treatment of patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) ≥1%] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and is: Stage III where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic. ( 1.2 , 2.1 ) as a single agent for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA. ( 1.2 , 2.1 ) for the treatment of patients with resectable (tumors ≥4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.2 ) as a single agent, for adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage IB (T2a ≥4 cm), II, or IIIA NSCLC. ( 1.2 ) Malignant Pleural Mesothelioma (MPM) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of adult patients with unresectable advanced or metastatic MPM. ( 1.3 ) Head and Neck Squamous Cell Cancer (HNSCC) for the treatment of adult patients with resectable locally advanced HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test, as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as a single agent. ( 1.4 ) in combination with platinum and FU for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC. ( 1.4 ) as a single agent for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test. ( 1.4 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy. ( 1.4 ) Classical Hodgkin Lymphoma (cHL) for the treatment of adult patients with relapsed or refractory cHL. ( 1.5 ) for the treatment of pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapy. ( 1.5 ) Primary Mediastinal Large B-Cell Lymphoma (PMBCL) for the treatment of adult and pediatric patients with refractory PMBCL, or who have relapsed after 2 or more prior lines of therapy. ( 1.6 ) Limitations of Use : KEYTRUDA is not recommended for treatment of patients with PMBCL who require urgent cytoreductive therapy. Urothelial Cancer in combination with enfortumab vedotin, for the treatment of adult patients with locally advanced or metastatic urothelial cancer. ( 1.7 ) as a single agent for the treatment of patients with locally advanced or metastatic urothelial carcinoma who: are not eligible for any platinum-containing chemotherapy, or who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. ( 1.7 ) as a single agent for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy. ( 1.7 ) Microsatellite Instability-High or Mismatch Repair Deficient Cancer for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. ( 1.8 , 2.1 ) Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer (CRC) for the treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by an FDA-approved test. ( 1.9 , 2.1 ) Gastric Cancer in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.10 ) in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.10 ) Esophageal Cancer for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation either: in combination with platinum- and fluoropyrimidine-based chemotherapy for patients whose tumors express PD-L1 (CPS ≥1), or as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS ≥10) as determined by an FDA-approved test. ( 1.11 , 2.1 ) Cervical Cancer in combination with chemoradiotherapy, for the treatment of patients with locally advanced cervical cancer involving the lower third of the vagina, with or without extension to pelvic sidewall, or hydronephrosis/non-functioning kidney, or spread to adjacent pelvic organs (FIGO 2014 Stage III-IVA). ( 1.12 ) in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.12 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.12 , 2.1 ) Hepatocellular Carcinoma (HCC) for the treatment of patients with HCC secondary to hepatitis B who have received prior systemic therapy other than a PD-1/PD-L1-containing regimen. ( 1.13 ) Biliary Tract Cancer (BTC) in combination with gemcitabine and cisplatin, for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer. ( 1.14 ) Merkel Cell Carcinoma (MCC) for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma. ( 1.15 ) Renal Cell Carcinoma (RCC) in combination with axitinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) in combination with lenvatinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. ( 1.16 ) Endometrial Carcinoma in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma. ( 1.17 ) in combination with lenvatinib, for the treatment of adult patients with advanced endometrial carcinoma that is mismatch repair proficient (pMMR) or not MSI-H as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) as a single agent, for the treatment of adult patients with advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) Tumor Mutational Burden-High (TMB-H) Cancer for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. 1 ( 1.18 , 2.1 ) Limitations of Use : The safety and effectiveness of KEYTRUDA in pediatric patients with TMB-H central nervous system cancers have not been established. Cutaneous Squamous Cell Carcinoma (cSCC) for the treatment of patients with recurrent or metastatic cSCC or locally advanced cSCC that is not curable by surgery or radiation. ( 1.19 ) Triple-Negative Breast Cancer (TNBC) for the treatment of patients with high-risk early-stage TNBC in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.20 ) in combination with chemotherapy, for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA approved test. ( 1.20 , 2.1 ) Adult Classical Hodgkin Lymphoma and Adult Primary Mediastinal Large B-Cell Lymphoma: Additional Dosing Regimen of 400 mg Every 6 Weeks for use at an additional recommended dosage of 400 mg every 6 weeks for Classical Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma in adults. 2 ( 1.21 , 2.2 ) 1 This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. 2 This indication is approved under accelerated approval based on pharmacokinetic data, the relationship of exposure to efficacy, and the relationship of exposure to safety. Continued approval for this dosing may be contingent upon verification and description of clinical benefit in the confirmatory trials. uuid:cc554c20-41f9-4a77-a7af-447ff70dda02 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DPT0O3T46P biolink:treats MONDO:0010150 PMID:41385096 "[{""id"":""uuid:a7c530e5-6b0d-4107-a175-8733912dd4ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:49491b1a-82e6-4d67-b6e6-5bf78efda481"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated: Melanoma for the treatment of patients with unresectable or metastatic melanoma. ( 1.1 ) for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC, or III melanoma following complete resection. ( 1.1 ) Non-Small Cell Lung Cancer (NSCLC) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations. ( 1.2 ) in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, as first-line treatment of patients with metastatic squamous NSCLC. ( 1.2 ) as a single agent for the first-line treatment of patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) ≥1%] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and is: Stage III where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic. ( 1.2 , 2.1 ) as a single agent for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA. ( 1.2 , 2.1 ) for the treatment of patients with resectable (tumors ≥4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.2 ) as a single agent, for adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage IB (T2a ≥4 cm), II, or IIIA NSCLC. ( 1.2 ) Malignant Pleural Mesothelioma (MPM) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of adult patients with unresectable advanced or metastatic MPM. ( 1.3 ) Head and Neck Squamous Cell Cancer (HNSCC) for the treatment of adult patients with resectable locally advanced HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test, as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as a single agent. ( 1.4 ) in combination with platinum and FU for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC. ( 1.4 ) as a single agent for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test. ( 1.4 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy. ( 1.4 ) Classical Hodgkin Lymphoma (cHL) for the treatment of adult patients with relapsed or refractory cHL. ( 1.5 ) for the treatment of pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapy. ( 1.5 ) Primary Mediastinal Large B-Cell Lymphoma (PMBCL) for the treatment of adult and pediatric patients with refractory PMBCL, or who have relapsed after 2 or more prior lines of therapy. ( 1.6 ) Limitations of Use : KEYTRUDA is not recommended for treatment of patients with PMBCL who require urgent cytoreductive therapy. Urothelial Cancer in combination with enfortumab vedotin, for the treatment of adult patients with locally advanced or metastatic urothelial cancer. ( 1.7 ) as a single agent for the treatment of patients with locally advanced or metastatic urothelial carcinoma who: are not eligible for any platinum-containing chemotherapy, or who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. ( 1.7 ) as a single agent for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy. ( 1.7 ) Microsatellite Instability-High or Mismatch Repair Deficient Cancer for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. ( 1.8 , 2.1 ) Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer (CRC) for the treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by an FDA-approved test. ( 1.9 , 2.1 ) Gastric Cancer in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.10 ) in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.10 ) Esophageal Cancer for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation either: in combination with platinum- and fluoropyrimidine-based chemotherapy for patients whose tumors express PD-L1 (CPS ≥1), or as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS ≥10) as determined by an FDA-approved test. ( 1.11 , 2.1 ) Cervical Cancer in combination with chemoradiotherapy, for the treatment of patients with locally advanced cervical cancer involving the lower third of the vagina, with or without extension to pelvic sidewall, or hydronephrosis/non-functioning kidney, or spread to adjacent pelvic organs (FIGO 2014 Stage III-IVA). ( 1.12 ) in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.12 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.12 , 2.1 ) Hepatocellular Carcinoma (HCC) for the treatment of patients with HCC secondary to hepatitis B who have received prior systemic therapy other than a PD-1/PD-L1-containing regimen. ( 1.13 ) Biliary Tract Cancer (BTC) in combination with gemcitabine and cisplatin, for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer. ( 1.14 ) Merkel Cell Carcinoma (MCC) for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma. ( 1.15 ) Renal Cell Carcinoma (RCC) in combination with axitinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) in combination with lenvatinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. ( 1.16 ) Endometrial Carcinoma in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma. ( 1.17 ) in combination with lenvatinib, for the treatment of adult patients with advanced endometrial carcinoma that is mismatch repair proficient (pMMR) or not MSI-H as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) as a single agent, for the treatment of adult patients with advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) Tumor Mutational Burden-High (TMB-H) Cancer for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. 1 ( 1.18 , 2.1 ) Limitations of Use : The safety and effectiveness of KEYTRUDA in pediatric patients with TMB-H central nervous system cancers have not been established. Cutaneous Squamous Cell Carcinoma (cSCC) for the treatment of patients with recurrent or metastatic cSCC or locally advanced cSCC that is not curable by surgery or radiation. ( 1.19 ) Triple-Negative Breast Cancer (TNBC) for the treatment of patients with high-risk early-stage TNBC in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.20 ) in combination with chemotherapy, for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA approved test. ( 1.20 , 2.1 ) Adult Classical Hodgkin Lymphoma and Adult Primary Mediastinal Large B-Cell Lymphoma: Additional Dosing Regimen of 400 mg Every 6 Weeks for use at an additional recommended dosage of 400 mg every 6 weeks for Classical Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma in adults. 2 ( 1.21 , 2.2 ) 1 This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. 2 This indication is approved under accelerated approval based on pharmacokinetic data, the relationship of exposure to efficacy, and the relationship of exposure to safety. Continued approval for this dosing may be contingent upon verification and description of clinical benefit in the confirmatory trials. uuid:278e1fff-68e3-4b34-9d82-7137dfe6eadf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DPT0O3T46P biolink:treats MONDO:0004665 PMID:41385096 "[{""id"":""uuid:63efe850-239b-4dfa-a51e-85592a75056e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2b4c0f62-209d-443b-a8b9-9c2d6cdc770f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated: Melanoma for the treatment of patients with unresectable or metastatic melanoma. ( 1.1 ) for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC, or III melanoma following complete resection. ( 1.1 ) Non-Small Cell Lung Cancer (NSCLC) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations. ( 1.2 ) in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, as first-line treatment of patients with metastatic squamous NSCLC. ( 1.2 ) as a single agent for the first-line treatment of patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) ≥1%] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and is: Stage III where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic. ( 1.2 , 2.1 ) as a single agent for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA. ( 1.2 , 2.1 ) for the treatment of patients with resectable (tumors ≥4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.2 ) as a single agent, for adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage IB (T2a ≥4 cm), II, or IIIA NSCLC. ( 1.2 ) Malignant Pleural Mesothelioma (MPM) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of adult patients with unresectable advanced or metastatic MPM. ( 1.3 ) Head and Neck Squamous Cell Cancer (HNSCC) for the treatment of adult patients with resectable locally advanced HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test, as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as a single agent. ( 1.4 ) in combination with platinum and FU for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC. ( 1.4 ) as a single agent for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test. ( 1.4 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy. ( 1.4 ) Classical Hodgkin Lymphoma (cHL) for the treatment of adult patients with relapsed or refractory cHL. ( 1.5 ) for the treatment of pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapy. ( 1.5 ) Primary Mediastinal Large B-Cell Lymphoma (PMBCL) for the treatment of adult and pediatric patients with refractory PMBCL, or who have relapsed after 2 or more prior lines of therapy. ( 1.6 ) Limitations of Use : KEYTRUDA is not recommended for treatment of patients with PMBCL who require urgent cytoreductive therapy. Urothelial Cancer in combination with enfortumab vedotin, for the treatment of adult patients with locally advanced or metastatic urothelial cancer. ( 1.7 ) as a single agent for the treatment of patients with locally advanced or metastatic urothelial carcinoma who: are not eligible for any platinum-containing chemotherapy, or who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. ( 1.7 ) as a single agent for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy. ( 1.7 ) Microsatellite Instability-High or Mismatch Repair Deficient Cancer for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. ( 1.8 , 2.1 ) Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer (CRC) for the treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by an FDA-approved test. ( 1.9 , 2.1 ) Gastric Cancer in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.10 ) in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.10 ) Esophageal Cancer for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation either: in combination with platinum- and fluoropyrimidine-based chemotherapy for patients whose tumors express PD-L1 (CPS ≥1), or as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS ≥10) as determined by an FDA-approved test. ( 1.11 , 2.1 ) Cervical Cancer in combination with chemoradiotherapy, for the treatment of patients with locally advanced cervical cancer involving the lower third of the vagina, with or without extension to pelvic sidewall, or hydronephrosis/non-functioning kidney, or spread to adjacent pelvic organs (FIGO 2014 Stage III-IVA). ( 1.12 ) in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.12 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.12 , 2.1 ) Hepatocellular Carcinoma (HCC) for the treatment of patients with HCC secondary to hepatitis B who have received prior systemic therapy other than a PD-1/PD-L1-containing regimen. ( 1.13 ) Biliary Tract Cancer (BTC) in combination with gemcitabine and cisplatin, for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer. ( 1.14 ) Merkel Cell Carcinoma (MCC) for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma. ( 1.15 ) Renal Cell Carcinoma (RCC) in combination with axitinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) in combination with lenvatinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. ( 1.16 ) Endometrial Carcinoma in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma. ( 1.17 ) in combination with lenvatinib, for the treatment of adult patients with advanced endometrial carcinoma that is mismatch repair proficient (pMMR) or not MSI-H as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) as a single agent, for the treatment of adult patients with advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) Tumor Mutational Burden-High (TMB-H) Cancer for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. 1 ( 1.18 , 2.1 ) Limitations of Use : The safety and effectiveness of KEYTRUDA in pediatric patients with TMB-H central nervous system cancers have not been established. Cutaneous Squamous Cell Carcinoma (cSCC) for the treatment of patients with recurrent or metastatic cSCC or locally advanced cSCC that is not curable by surgery or radiation. ( 1.19 ) Triple-Negative Breast Cancer (TNBC) for the treatment of patients with high-risk early-stage TNBC in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.20 ) in combination with chemotherapy, for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA approved test. ( 1.20 , 2.1 ) Adult Classical Hodgkin Lymphoma and Adult Primary Mediastinal Large B-Cell Lymphoma: Additional Dosing Regimen of 400 mg Every 6 Weeks for use at an additional recommended dosage of 400 mg every 6 weeks for Classical Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma in adults. 2 ( 1.21 , 2.2 ) 1 This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. 2 This indication is approved under accelerated approval based on pharmacokinetic data, the relationship of exposure to efficacy, and the relationship of exposure to safety. Continued approval for this dosing may be contingent upon verification and description of clinical benefit in the confirmatory trials. uuid:00d78d7c-e63c-4734-9305-8e3a26e9ca40 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DPT0O3T46P biolink:treats MONDO:0020323 PMID:41385096 "[{""id"":""uuid:ac0226a3-3c3c-423e-8f64-2bd2f06234c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:03af7238-a759-4fee-9443-c14b6c5aa465"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated: Melanoma for the treatment of patients with unresectable or metastatic melanoma. ( 1.1 ) for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC, or III melanoma following complete resection. ( 1.1 ) Non-Small Cell Lung Cancer (NSCLC) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations. ( 1.2 ) in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, as first-line treatment of patients with metastatic squamous NSCLC. ( 1.2 ) as a single agent for the first-line treatment of patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) ≥1%] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and is: Stage III where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic. ( 1.2 , 2.1 ) as a single agent for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA. ( 1.2 , 2.1 ) for the treatment of patients with resectable (tumors ≥4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.2 ) as a single agent, for adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage IB (T2a ≥4 cm), II, or IIIA NSCLC. ( 1.2 ) Malignant Pleural Mesothelioma (MPM) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of adult patients with unresectable advanced or metastatic MPM. ( 1.3 ) Head and Neck Squamous Cell Cancer (HNSCC) for the treatment of adult patients with resectable locally advanced HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test, as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as a single agent. ( 1.4 ) in combination with platinum and FU for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC. ( 1.4 ) as a single agent for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test. ( 1.4 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy. ( 1.4 ) Classical Hodgkin Lymphoma (cHL) for the treatment of adult patients with relapsed or refractory cHL. ( 1.5 ) for the treatment of pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapy. ( 1.5 ) Primary Mediastinal Large B-Cell Lymphoma (PMBCL) for the treatment of adult and pediatric patients with refractory PMBCL, or who have relapsed after 2 or more prior lines of therapy. ( 1.6 ) Limitations of Use : KEYTRUDA is not recommended for treatment of patients with PMBCL who require urgent cytoreductive therapy. Urothelial Cancer in combination with enfortumab vedotin, for the treatment of adult patients with locally advanced or metastatic urothelial cancer. ( 1.7 ) as a single agent for the treatment of patients with locally advanced or metastatic urothelial carcinoma who: are not eligible for any platinum-containing chemotherapy, or who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. ( 1.7 ) as a single agent for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy. ( 1.7 ) Microsatellite Instability-High or Mismatch Repair Deficient Cancer for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. ( 1.8 , 2.1 ) Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer (CRC) for the treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by an FDA-approved test. ( 1.9 , 2.1 ) Gastric Cancer in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.10 ) in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.10 ) Esophageal Cancer for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation either: in combination with platinum- and fluoropyrimidine-based chemotherapy for patients whose tumors express PD-L1 (CPS ≥1), or as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS ≥10) as determined by an FDA-approved test. ( 1.11 , 2.1 ) Cervical Cancer in combination with chemoradiotherapy, for the treatment of patients with locally advanced cervical cancer involving the lower third of the vagina, with or without extension to pelvic sidewall, or hydronephrosis/non-functioning kidney, or spread to adjacent pelvic organs (FIGO 2014 Stage III-IVA). ( 1.12 ) in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.12 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.12 , 2.1 ) Hepatocellular Carcinoma (HCC) for the treatment of patients with HCC secondary to hepatitis B who have received prior systemic therapy other than a PD-1/PD-L1-containing regimen. ( 1.13 ) Biliary Tract Cancer (BTC) in combination with gemcitabine and cisplatin, for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer. ( 1.14 ) Merkel Cell Carcinoma (MCC) for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma. ( 1.15 ) Renal Cell Carcinoma (RCC) in combination with axitinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) in combination with lenvatinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. ( 1.16 ) Endometrial Carcinoma in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma. ( 1.17 ) in combination with lenvatinib, for the treatment of adult patients with advanced endometrial carcinoma that is mismatch repair proficient (pMMR) or not MSI-H as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) as a single agent, for the treatment of adult patients with advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) Tumor Mutational Burden-High (TMB-H) Cancer for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. 1 ( 1.18 , 2.1 ) Limitations of Use : The safety and effectiveness of KEYTRUDA in pediatric patients with TMB-H central nervous system cancers have not been established. Cutaneous Squamous Cell Carcinoma (cSCC) for the treatment of patients with recurrent or metastatic cSCC or locally advanced cSCC that is not curable by surgery or radiation. ( 1.19 ) Triple-Negative Breast Cancer (TNBC) for the treatment of patients with high-risk early-stage TNBC in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.20 ) in combination with chemotherapy, for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA approved test. ( 1.20 , 2.1 ) Adult Classical Hodgkin Lymphoma and Adult Primary Mediastinal Large B-Cell Lymphoma: Additional Dosing Regimen of 400 mg Every 6 Weeks for use at an additional recommended dosage of 400 mg every 6 weeks for Classical Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma in adults. 2 ( 1.21 , 2.2 ) 1 This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. 2 This indication is approved under accelerated approval based on pharmacokinetic data, the relationship of exposure to efficacy, and the relationship of exposure to safety. Continued approval for this dosing may be contingent upon verification and description of clinical benefit in the confirmatory trials. uuid:39334df7-ad2e-4395-b893-87f90dc2cba7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DPT0O3T46P biolink:treats UMLS:C4049507 PMID:41385096 "[{""id"":""uuid:cc9f466b-d745-4c3d-998c-4499c2fbb379"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bdcb2755-95a0-483a-99c6-888a442b269a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated: Melanoma for the treatment of patients with unresectable or metastatic melanoma. ( 1.1 ) for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC, or III melanoma following complete resection. ( 1.1 ) Non-Small Cell Lung Cancer (NSCLC) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations. ( 1.2 ) in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, as first-line treatment of patients with metastatic squamous NSCLC. ( 1.2 ) as a single agent for the first-line treatment of patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) ≥1%] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and is: Stage III where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic. ( 1.2 , 2.1 ) as a single agent for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA. ( 1.2 , 2.1 ) for the treatment of patients with resectable (tumors ≥4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.2 ) as a single agent, for adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage IB (T2a ≥4 cm), II, or IIIA NSCLC. ( 1.2 ) Malignant Pleural Mesothelioma (MPM) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of adult patients with unresectable advanced or metastatic MPM. ( 1.3 ) Head and Neck Squamous Cell Cancer (HNSCC) for the treatment of adult patients with resectable locally advanced HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test, as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as a single agent. ( 1.4 ) in combination with platinum and FU for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC. ( 1.4 ) as a single agent for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test. ( 1.4 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy. ( 1.4 ) Classical Hodgkin Lymphoma (cHL) for the treatment of adult patients with relapsed or refractory cHL. ( 1.5 ) for the treatment of pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapy. ( 1.5 ) Primary Mediastinal Large B-Cell Lymphoma (PMBCL) for the treatment of adult and pediatric patients with refractory PMBCL, or who have relapsed after 2 or more prior lines of therapy. ( 1.6 ) Limitations of Use : KEYTRUDA is not recommended for treatment of patients with PMBCL who require urgent cytoreductive therapy. Urothelial Cancer in combination with enfortumab vedotin, for the treatment of adult patients with locally advanced or metastatic urothelial cancer. ( 1.7 ) as a single agent for the treatment of patients with locally advanced or metastatic urothelial carcinoma who: are not eligible for any platinum-containing chemotherapy, or who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. ( 1.7 ) as a single agent for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy. ( 1.7 ) Microsatellite Instability-High or Mismatch Repair Deficient Cancer for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. ( 1.8 , 2.1 ) Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer (CRC) for the treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by an FDA-approved test. ( 1.9 , 2.1 ) Gastric Cancer in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.10 ) in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.10 ) Esophageal Cancer for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation either: in combination with platinum- and fluoropyrimidine-based chemotherapy for patients whose tumors express PD-L1 (CPS ≥1), or as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS ≥10) as determined by an FDA-approved test. ( 1.11 , 2.1 ) Cervical Cancer in combination with chemoradiotherapy, for the treatment of patients with locally advanced cervical cancer involving the lower third of the vagina, with or without extension to pelvic sidewall, or hydronephrosis/non-functioning kidney, or spread to adjacent pelvic organs (FIGO 2014 Stage III-IVA). ( 1.12 ) in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.12 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.12 , 2.1 ) Hepatocellular Carcinoma (HCC) for the treatment of patients with HCC secondary to hepatitis B who have received prior systemic therapy other than a PD-1/PD-L1-containing regimen. ( 1.13 ) Biliary Tract Cancer (BTC) in combination with gemcitabine and cisplatin, for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer. ( 1.14 ) Merkel Cell Carcinoma (MCC) for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma. ( 1.15 ) Renal Cell Carcinoma (RCC) in combination with axitinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) in combination with lenvatinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. ( 1.16 ) Endometrial Carcinoma in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma. ( 1.17 ) in combination with lenvatinib, for the treatment of adult patients with advanced endometrial carcinoma that is mismatch repair proficient (pMMR) or not MSI-H as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) as a single agent, for the treatment of adult patients with advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) Tumor Mutational Burden-High (TMB-H) Cancer for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. 1 ( 1.18 , 2.1 ) Limitations of Use : The safety and effectiveness of KEYTRUDA in pediatric patients with TMB-H central nervous system cancers have not been established. Cutaneous Squamous Cell Carcinoma (cSCC) for the treatment of patients with recurrent or metastatic cSCC or locally advanced cSCC that is not curable by surgery or radiation. ( 1.19 ) Triple-Negative Breast Cancer (TNBC) for the treatment of patients with high-risk early-stage TNBC in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.20 ) in combination with chemotherapy, for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA approved test. ( 1.20 , 2.1 ) Adult Classical Hodgkin Lymphoma and Adult Primary Mediastinal Large B-Cell Lymphoma: Additional Dosing Regimen of 400 mg Every 6 Weeks for use at an additional recommended dosage of 400 mg every 6 weeks for Classical Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma in adults. 2 ( 1.21 , 2.2 ) 1 This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. 2 This indication is approved under accelerated approval based on pharmacokinetic data, the relationship of exposure to efficacy, and the relationship of exposure to safety. Continued approval for this dosing may be contingent upon verification and description of clinical benefit in the confirmatory trials. uuid:5a33bb42-6a69-41a1-b419-52ed25040419 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DPT0O3T46P biolink:treats MONDO:0004703 PMID:41385096 "[{""id"":""uuid:5bfaec47-f5c8-4172-88eb-a3f62f166b4d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:605cc236-dbf8-41a0-a31e-fc9f72223017"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated: Melanoma for the treatment of patients with unresectable or metastatic melanoma. ( 1.1 ) for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC, or III melanoma following complete resection. ( 1.1 ) Non-Small Cell Lung Cancer (NSCLC) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations. ( 1.2 ) in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, as first-line treatment of patients with metastatic squamous NSCLC. ( 1.2 ) as a single agent for the first-line treatment of patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) ≥1%] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and is: Stage III where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic. ( 1.2 , 2.1 ) as a single agent for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA. ( 1.2 , 2.1 ) for the treatment of patients with resectable (tumors ≥4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.2 ) as a single agent, for adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage IB (T2a ≥4 cm), II, or IIIA NSCLC. ( 1.2 ) Malignant Pleural Mesothelioma (MPM) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of adult patients with unresectable advanced or metastatic MPM. ( 1.3 ) Head and Neck Squamous Cell Cancer (HNSCC) for the treatment of adult patients with resectable locally advanced HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test, as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as a single agent. ( 1.4 ) in combination with platinum and FU for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC. ( 1.4 ) as a single agent for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test. ( 1.4 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy. ( 1.4 ) Classical Hodgkin Lymphoma (cHL) for the treatment of adult patients with relapsed or refractory cHL. ( 1.5 ) for the treatment of pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapy. ( 1.5 ) Primary Mediastinal Large B-Cell Lymphoma (PMBCL) for the treatment of adult and pediatric patients with refractory PMBCL, or who have relapsed after 2 or more prior lines of therapy. ( 1.6 ) Limitations of Use : KEYTRUDA is not recommended for treatment of patients with PMBCL who require urgent cytoreductive therapy. Urothelial Cancer in combination with enfortumab vedotin, for the treatment of adult patients with locally advanced or metastatic urothelial cancer. ( 1.7 ) as a single agent for the treatment of patients with locally advanced or metastatic urothelial carcinoma who: are not eligible for any platinum-containing chemotherapy, or who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. ( 1.7 ) as a single agent for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy. ( 1.7 ) Microsatellite Instability-High or Mismatch Repair Deficient Cancer for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. ( 1.8 , 2.1 ) Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer (CRC) for the treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by an FDA-approved test. ( 1.9 , 2.1 ) Gastric Cancer in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.10 ) in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.10 ) Esophageal Cancer for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation either: in combination with platinum- and fluoropyrimidine-based chemotherapy for patients whose tumors express PD-L1 (CPS ≥1), or as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS ≥10) as determined by an FDA-approved test. ( 1.11 , 2.1 ) Cervical Cancer in combination with chemoradiotherapy, for the treatment of patients with locally advanced cervical cancer involving the lower third of the vagina, with or without extension to pelvic sidewall, or hydronephrosis/non-functioning kidney, or spread to adjacent pelvic organs (FIGO 2014 Stage III-IVA). ( 1.12 ) in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.12 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.12 , 2.1 ) Hepatocellular Carcinoma (HCC) for the treatment of patients with HCC secondary to hepatitis B who have received prior systemic therapy other than a PD-1/PD-L1-containing regimen. ( 1.13 ) Biliary Tract Cancer (BTC) in combination with gemcitabine and cisplatin, for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer. ( 1.14 ) Merkel Cell Carcinoma (MCC) for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma. ( 1.15 ) Renal Cell Carcinoma (RCC) in combination with axitinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) in combination with lenvatinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. ( 1.16 ) Endometrial Carcinoma in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma. ( 1.17 ) in combination with lenvatinib, for the treatment of adult patients with advanced endometrial carcinoma that is mismatch repair proficient (pMMR) or not MSI-H as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) as a single agent, for the treatment of adult patients with advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) Tumor Mutational Burden-High (TMB-H) Cancer for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. 1 ( 1.18 , 2.1 ) Limitations of Use : The safety and effectiveness of KEYTRUDA in pediatric patients with TMB-H central nervous system cancers have not been established. Cutaneous Squamous Cell Carcinoma (cSCC) for the treatment of patients with recurrent or metastatic cSCC or locally advanced cSCC that is not curable by surgery or radiation. ( 1.19 ) Triple-Negative Breast Cancer (TNBC) for the treatment of patients with high-risk early-stage TNBC in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.20 ) in combination with chemotherapy, for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA approved test. ( 1.20 , 2.1 ) Adult Classical Hodgkin Lymphoma and Adult Primary Mediastinal Large B-Cell Lymphoma: Additional Dosing Regimen of 400 mg Every 6 Weeks for use at an additional recommended dosage of 400 mg every 6 weeks for Classical Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma in adults. 2 ( 1.21 , 2.2 ) 1 This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. 2 This indication is approved under accelerated approval based on pharmacokinetic data, the relationship of exposure to efficacy, and the relationship of exposure to safety. Continued approval for this dosing may be contingent upon verification and description of clinical benefit in the confirmatory trials. uuid:1d0022eb-b85b-4d75-8dff-041810370a26 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DPT0O3T46P biolink:treats MONDO:0030840 PMID:41385096 "[{""id"":""uuid:6e77dbff-7a36-4553-95f2-abca7149ed85"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7a9f8970-ecad-4ecc-aff0-7c5fecba51a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated: Melanoma for the treatment of patients with unresectable or metastatic melanoma. ( 1.1 ) for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC, or III melanoma following complete resection. ( 1.1 ) Non-Small Cell Lung Cancer (NSCLC) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations. ( 1.2 ) in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, as first-line treatment of patients with metastatic squamous NSCLC. ( 1.2 ) as a single agent for the first-line treatment of patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) ≥1%] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and is: Stage III where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic. ( 1.2 , 2.1 ) as a single agent for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA. ( 1.2 , 2.1 ) for the treatment of patients with resectable (tumors ≥4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.2 ) as a single agent, for adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage IB (T2a ≥4 cm), II, or IIIA NSCLC. ( 1.2 ) Malignant Pleural Mesothelioma (MPM) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of adult patients with unresectable advanced or metastatic MPM. ( 1.3 ) Head and Neck Squamous Cell Cancer (HNSCC) for the treatment of adult patients with resectable locally advanced HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test, as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as a single agent. ( 1.4 ) in combination with platinum and FU for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC. ( 1.4 ) as a single agent for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test. ( 1.4 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy. ( 1.4 ) Classical Hodgkin Lymphoma (cHL) for the treatment of adult patients with relapsed or refractory cHL. ( 1.5 ) for the treatment of pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapy. ( 1.5 ) Primary Mediastinal Large B-Cell Lymphoma (PMBCL) for the treatment of adult and pediatric patients with refractory PMBCL, or who have relapsed after 2 or more prior lines of therapy. ( 1.6 ) Limitations of Use : KEYTRUDA is not recommended for treatment of patients with PMBCL who require urgent cytoreductive therapy. Urothelial Cancer in combination with enfortumab vedotin, for the treatment of adult patients with locally advanced or metastatic urothelial cancer. ( 1.7 ) as a single agent for the treatment of patients with locally advanced or metastatic urothelial carcinoma who: are not eligible for any platinum-containing chemotherapy, or who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. ( 1.7 ) as a single agent for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy. ( 1.7 ) Microsatellite Instability-High or Mismatch Repair Deficient Cancer for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. ( 1.8 , 2.1 ) Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer (CRC) for the treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by an FDA-approved test. ( 1.9 , 2.1 ) Gastric Cancer in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.10 ) in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.10 ) Esophageal Cancer for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation either: in combination with platinum- and fluoropyrimidine-based chemotherapy for patients whose tumors express PD-L1 (CPS ≥1), or as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS ≥10) as determined by an FDA-approved test. ( 1.11 , 2.1 ) Cervical Cancer in combination with chemoradiotherapy, for the treatment of patients with locally advanced cervical cancer involving the lower third of the vagina, with or without extension to pelvic sidewall, or hydronephrosis/non-functioning kidney, or spread to adjacent pelvic organs (FIGO 2014 Stage III-IVA). ( 1.12 ) in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.12 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.12 , 2.1 ) Hepatocellular Carcinoma (HCC) for the treatment of patients with HCC secondary to hepatitis B who have received prior systemic therapy other than a PD-1/PD-L1-containing regimen. ( 1.13 ) Biliary Tract Cancer (BTC) in combination with gemcitabine and cisplatin, for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer. ( 1.14 ) Merkel Cell Carcinoma (MCC) for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma. ( 1.15 ) Renal Cell Carcinoma (RCC) in combination with axitinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) in combination with lenvatinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. ( 1.16 ) Endometrial Carcinoma in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma. ( 1.17 ) in combination with lenvatinib, for the treatment of adult patients with advanced endometrial carcinoma that is mismatch repair proficient (pMMR) or not MSI-H as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) as a single agent, for the treatment of adult patients with advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) Tumor Mutational Burden-High (TMB-H) Cancer for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. 1 ( 1.18 , 2.1 ) Limitations of Use : The safety and effectiveness of KEYTRUDA in pediatric patients with TMB-H central nervous system cancers have not been established. Cutaneous Squamous Cell Carcinoma (cSCC) for the treatment of patients with recurrent or metastatic cSCC or locally advanced cSCC that is not curable by surgery or radiation. ( 1.19 ) Triple-Negative Breast Cancer (TNBC) for the treatment of patients with high-risk early-stage TNBC in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.20 ) in combination with chemotherapy, for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA approved test. ( 1.20 , 2.1 ) Adult Classical Hodgkin Lymphoma and Adult Primary Mediastinal Large B-Cell Lymphoma: Additional Dosing Regimen of 400 mg Every 6 Weeks for use at an additional recommended dosage of 400 mg every 6 weeks for Classical Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma in adults. 2 ( 1.21 , 2.2 ) 1 This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. 2 This indication is approved under accelerated approval based on pharmacokinetic data, the relationship of exposure to efficacy, and the relationship of exposure to safety. Continued approval for this dosing may be contingent upon verification and description of clinical benefit in the confirmatory trials. uuid:5606d81c-763c-4daf-a762-5cdfbe99d860 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DPT0O3T46P biolink:treats UMLS:C4544822 PMID:41385096 "[{""id"":""uuid:4fad55a2-38e6-411d-bf46-2d0973efd807"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:71b2f8ac-183f-4cdb-b4ca-ca0688be2957"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated: Melanoma for the treatment of patients with unresectable or metastatic melanoma. ( 1.1 ) for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC, or III melanoma following complete resection. ( 1.1 ) Non-Small Cell Lung Cancer (NSCLC) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations. ( 1.2 ) in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, as first-line treatment of patients with metastatic squamous NSCLC. ( 1.2 ) as a single agent for the first-line treatment of patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) ≥1%] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and is: Stage III where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic. ( 1.2 , 2.1 ) as a single agent for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA. ( 1.2 , 2.1 ) for the treatment of patients with resectable (tumors ≥4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.2 ) as a single agent, for adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage IB (T2a ≥4 cm), II, or IIIA NSCLC. ( 1.2 ) Malignant Pleural Mesothelioma (MPM) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of adult patients with unresectable advanced or metastatic MPM. ( 1.3 ) Head and Neck Squamous Cell Cancer (HNSCC) for the treatment of adult patients with resectable locally advanced HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test, as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as a single agent. ( 1.4 ) in combination with platinum and FU for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC. ( 1.4 ) as a single agent for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test. ( 1.4 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy. ( 1.4 ) Classical Hodgkin Lymphoma (cHL) for the treatment of adult patients with relapsed or refractory cHL. ( 1.5 ) for the treatment of pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapy. ( 1.5 ) Primary Mediastinal Large B-Cell Lymphoma (PMBCL) for the treatment of adult and pediatric patients with refractory PMBCL, or who have relapsed after 2 or more prior lines of therapy. ( 1.6 ) Limitations of Use : KEYTRUDA is not recommended for treatment of patients with PMBCL who require urgent cytoreductive therapy. Urothelial Cancer in combination with enfortumab vedotin, for the treatment of adult patients with locally advanced or metastatic urothelial cancer. ( 1.7 ) as a single agent for the treatment of patients with locally advanced or metastatic urothelial carcinoma who: are not eligible for any platinum-containing chemotherapy, or who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. ( 1.7 ) as a single agent for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy. ( 1.7 ) Microsatellite Instability-High or Mismatch Repair Deficient Cancer for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. ( 1.8 , 2.1 ) Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer (CRC) for the treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by an FDA-approved test. ( 1.9 , 2.1 ) Gastric Cancer in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.10 ) in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.10 ) Esophageal Cancer for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation either: in combination with platinum- and fluoropyrimidine-based chemotherapy for patients whose tumors express PD-L1 (CPS ≥1), or as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS ≥10) as determined by an FDA-approved test. ( 1.11 , 2.1 ) Cervical Cancer in combination with chemoradiotherapy, for the treatment of patients with locally advanced cervical cancer involving the lower third of the vagina, with or without extension to pelvic sidewall, or hydronephrosis/non-functioning kidney, or spread to adjacent pelvic organs (FIGO 2014 Stage III-IVA). ( 1.12 ) in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.12 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.12 , 2.1 ) Hepatocellular Carcinoma (HCC) for the treatment of patients with HCC secondary to hepatitis B who have received prior systemic therapy other than a PD-1/PD-L1-containing regimen. ( 1.13 ) Biliary Tract Cancer (BTC) in combination with gemcitabine and cisplatin, for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer. ( 1.14 ) Merkel Cell Carcinoma (MCC) for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma. ( 1.15 ) Renal Cell Carcinoma (RCC) in combination with axitinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) in combination with lenvatinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. ( 1.16 ) Endometrial Carcinoma in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma. ( 1.17 ) in combination with lenvatinib, for the treatment of adult patients with advanced endometrial carcinoma that is mismatch repair proficient (pMMR) or not MSI-H as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) as a single agent, for the treatment of adult patients with advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) Tumor Mutational Burden-High (TMB-H) Cancer for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. 1 ( 1.18 , 2.1 ) Limitations of Use : The safety and effectiveness of KEYTRUDA in pediatric patients with TMB-H central nervous system cancers have not been established. Cutaneous Squamous Cell Carcinoma (cSCC) for the treatment of patients with recurrent or metastatic cSCC or locally advanced cSCC that is not curable by surgery or radiation. ( 1.19 ) Triple-Negative Breast Cancer (TNBC) for the treatment of patients with high-risk early-stage TNBC in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.20 ) in combination with chemotherapy, for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA approved test. ( 1.20 , 2.1 ) Adult Classical Hodgkin Lymphoma and Adult Primary Mediastinal Large B-Cell Lymphoma: Additional Dosing Regimen of 400 mg Every 6 Weeks for use at an additional recommended dosage of 400 mg every 6 weeks for Classical Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma in adults. 2 ( 1.21 , 2.2 ) 1 This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. 2 This indication is approved under accelerated approval based on pharmacokinetic data, the relationship of exposure to efficacy, and the relationship of exposure to safety. Continued approval for this dosing may be contingent upon verification and description of clinical benefit in the confirmatory trials. uuid:10727598-c687-4b46-8462-32699ef6d51c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DPT0O3T46P biolink:treats MONDO:0001056 PMID:41385096 "[{""id"":""uuid:c43b29d1-449a-4d3a-8dd8-7ed193f83cc3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f98005db-abcf-4ee2-85e5-5381ac7fff9a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated: Melanoma for the treatment of patients with unresectable or metastatic melanoma. ( 1.1 ) for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC, or III melanoma following complete resection. ( 1.1 ) Non-Small Cell Lung Cancer (NSCLC) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations. ( 1.2 ) in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, as first-line treatment of patients with metastatic squamous NSCLC. ( 1.2 ) as a single agent for the first-line treatment of patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) ≥1%] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and is: Stage III where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic. ( 1.2 , 2.1 ) as a single agent for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA. ( 1.2 , 2.1 ) for the treatment of patients with resectable (tumors ≥4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.2 ) as a single agent, for adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage IB (T2a ≥4 cm), II, or IIIA NSCLC. ( 1.2 ) Malignant Pleural Mesothelioma (MPM) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of adult patients with unresectable advanced or metastatic MPM. ( 1.3 ) Head and Neck Squamous Cell Cancer (HNSCC) for the treatment of adult patients with resectable locally advanced HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test, as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as a single agent. ( 1.4 ) in combination with platinum and FU for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC. ( 1.4 ) as a single agent for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test. ( 1.4 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy. ( 1.4 ) Classical Hodgkin Lymphoma (cHL) for the treatment of adult patients with relapsed or refractory cHL. ( 1.5 ) for the treatment of pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapy. ( 1.5 ) Primary Mediastinal Large B-Cell Lymphoma (PMBCL) for the treatment of adult and pediatric patients with refractory PMBCL, or who have relapsed after 2 or more prior lines of therapy. ( 1.6 ) Limitations of Use : KEYTRUDA is not recommended for treatment of patients with PMBCL who require urgent cytoreductive therapy. Urothelial Cancer in combination with enfortumab vedotin, for the treatment of adult patients with locally advanced or metastatic urothelial cancer. ( 1.7 ) as a single agent for the treatment of patients with locally advanced or metastatic urothelial carcinoma who: are not eligible for any platinum-containing chemotherapy, or who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. ( 1.7 ) as a single agent for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy. ( 1.7 ) Microsatellite Instability-High or Mismatch Repair Deficient Cancer for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. ( 1.8 , 2.1 ) Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer (CRC) for the treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by an FDA-approved test. ( 1.9 , 2.1 ) Gastric Cancer in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.10 ) in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.10 ) Esophageal Cancer for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation either: in combination with platinum- and fluoropyrimidine-based chemotherapy for patients whose tumors express PD-L1 (CPS ≥1), or as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS ≥10) as determined by an FDA-approved test. ( 1.11 , 2.1 ) Cervical Cancer in combination with chemoradiotherapy, for the treatment of patients with locally advanced cervical cancer involving the lower third of the vagina, with or without extension to pelvic sidewall, or hydronephrosis/non-functioning kidney, or spread to adjacent pelvic organs (FIGO 2014 Stage III-IVA). ( 1.12 ) in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.12 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.12 , 2.1 ) Hepatocellular Carcinoma (HCC) for the treatment of patients with HCC secondary to hepatitis B who have received prior systemic therapy other than a PD-1/PD-L1-containing regimen. ( 1.13 ) Biliary Tract Cancer (BTC) in combination with gemcitabine and cisplatin, for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer. ( 1.14 ) Merkel Cell Carcinoma (MCC) for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma. ( 1.15 ) Renal Cell Carcinoma (RCC) in combination with axitinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) in combination with lenvatinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. ( 1.16 ) Endometrial Carcinoma in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma. ( 1.17 ) in combination with lenvatinib, for the treatment of adult patients with advanced endometrial carcinoma that is mismatch repair proficient (pMMR) or not MSI-H as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) as a single agent, for the treatment of adult patients with advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) Tumor Mutational Burden-High (TMB-H) Cancer for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. 1 ( 1.18 , 2.1 ) Limitations of Use : The safety and effectiveness of KEYTRUDA in pediatric patients with TMB-H central nervous system cancers have not been established. Cutaneous Squamous Cell Carcinoma (cSCC) for the treatment of patients with recurrent or metastatic cSCC or locally advanced cSCC that is not curable by surgery or radiation. ( 1.19 ) Triple-Negative Breast Cancer (TNBC) for the treatment of patients with high-risk early-stage TNBC in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.20 ) in combination with chemotherapy, for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA approved test. ( 1.20 , 2.1 ) Adult Classical Hodgkin Lymphoma and Adult Primary Mediastinal Large B-Cell Lymphoma: Additional Dosing Regimen of 400 mg Every 6 Weeks for use at an additional recommended dosage of 400 mg every 6 weeks for Classical Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma in adults. 2 ( 1.21 , 2.2 ) 1 This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. 2 This indication is approved under accelerated approval based on pharmacokinetic data, the relationship of exposure to efficacy, and the relationship of exposure to safety. Continued approval for this dosing may be contingent upon verification and description of clinical benefit in the confirmatory trials. uuid:b9f544ce-8a11-4927-8125-163c9376904d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DPT0O3T46P biolink:treats MONDO:0007576 PMID:41385096 "[{""id"":""uuid:8de40678-29c3-4aa8-80b2-bf9fbc45615f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:71a4902b-22ff-48c9-83a1-d92d7bcead0e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:0a09dc19-8386-4a37-ab6d-c0dc1271eb92"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated: Melanoma for the treatment of patients with unresectable or metastatic melanoma. ( 1.1 ) for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC, or III melanoma following complete resection. ( 1.1 ) Non-Small Cell Lung Cancer (NSCLC) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations. ( 1.2 ) in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, as first-line treatment of patients with metastatic squamous NSCLC. ( 1.2 ) as a single agent for the first-line treatment of patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) ≥1%] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and is: Stage III where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic. ( 1.2 , 2.1 ) as a single agent for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA. ( 1.2 , 2.1 ) for the treatment of patients with resectable (tumors ≥4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.2 ) as a single agent, for adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage IB (T2a ≥4 cm), II, or IIIA NSCLC. ( 1.2 ) Malignant Pleural Mesothelioma (MPM) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of adult patients with unresectable advanced or metastatic MPM. ( 1.3 ) Head and Neck Squamous Cell Cancer (HNSCC) for the treatment of adult patients with resectable locally advanced HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test, as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as a single agent. ( 1.4 ) in combination with platinum and FU for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC. ( 1.4 ) as a single agent for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test. ( 1.4 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy. ( 1.4 ) Classical Hodgkin Lymphoma (cHL) for the treatment of adult patients with relapsed or refractory cHL. ( 1.5 ) for the treatment of pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapy. ( 1.5 ) Primary Mediastinal Large B-Cell Lymphoma (PMBCL) for the treatment of adult and pediatric patients with refractory PMBCL, or who have relapsed after 2 or more prior lines of therapy. ( 1.6 ) Limitations of Use : KEYTRUDA is not recommended for treatment of patients with PMBCL who require urgent cytoreductive therapy. Urothelial Cancer in combination with enfortumab vedotin, for the treatment of adult patients with locally advanced or metastatic urothelial cancer. ( 1.7 ) as a single agent for the treatment of patients with locally advanced or metastatic urothelial carcinoma who: are not eligible for any platinum-containing chemotherapy, or who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. ( 1.7 ) as a single agent for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy. ( 1.7 ) Microsatellite Instability-High or Mismatch Repair Deficient Cancer for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. ( 1.8 , 2.1 ) Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer (CRC) for the treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by an FDA-approved test. ( 1.9 , 2.1 ) Gastric Cancer in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.10 ) in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.10 ) Esophageal Cancer for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation either: in combination with platinum- and fluoropyrimidine-based chemotherapy for patients whose tumors express PD-L1 (CPS ≥1), or as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS ≥10) as determined by an FDA-approved test. ( 1.11 , 2.1 ) Cervical Cancer in combination with chemoradiotherapy, for the treatment of patients with locally advanced cervical cancer involving the lower third of the vagina, with or without extension to pelvic sidewall, or hydronephrosis/non-functioning kidney, or spread to adjacent pelvic organs (FIGO 2014 Stage III-IVA). ( 1.12 ) in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.12 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.12 , 2.1 ) Hepatocellular Carcinoma (HCC) for the treatment of patients with HCC secondary to hepatitis B who have received prior systemic therapy other than a PD-1/PD-L1-containing regimen. ( 1.13 ) Biliary Tract Cancer (BTC) in combination with gemcitabine and cisplatin, for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer. ( 1.14 ) Merkel Cell Carcinoma (MCC) for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma. ( 1.15 ) Renal Cell Carcinoma (RCC) in combination with axitinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) in combination with lenvatinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. ( 1.16 ) Endometrial Carcinoma in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma. ( 1.17 ) in combination with lenvatinib, for the treatment of adult patients with advanced endometrial carcinoma that is mismatch repair proficient (pMMR) or not MSI-H as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) as a single agent, for the treatment of adult patients with advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) Tumor Mutational Burden-High (TMB-H) Cancer for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. 1 ( 1.18 , 2.1 ) Limitations of Use : The safety and effectiveness of KEYTRUDA in pediatric patients with TMB-H central nervous system cancers have not been established. Cutaneous Squamous Cell Carcinoma (cSCC) for the treatment of patients with recurrent or metastatic cSCC or locally advanced cSCC that is not curable by surgery or radiation. ( 1.19 ) Triple-Negative Breast Cancer (TNBC) for the treatment of patients with high-risk early-stage TNBC in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.20 ) in combination with chemotherapy, for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA approved test. ( 1.20 , 2.1 ) Adult Classical Hodgkin Lymphoma and Adult Primary Mediastinal Large B-Cell Lymphoma: Additional Dosing Regimen of 400 mg Every 6 Weeks for use at an additional recommended dosage of 400 mg every 6 weeks for Classical Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma in adults. 2 ( 1.21 , 2.2 ) 1 This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. 2 This indication is approved under accelerated approval based on pharmacokinetic data, the relationship of exposure to efficacy, and the relationship of exposure to safety. Continued approval for this dosing may be contingent upon verification and description of clinical benefit in the confirmatory trials.|[PMDA] A drug with a new indication and a new dosage for the treatment of unresectable advanced or recurrent esophageal cancer. uuid:c63377e8-8eda-4b9f-bd25-3e10be6fd19c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DPT0O3T46P biolink:treats MONDO:0002974 PMID:41385096 "[{""id"":""uuid:af356ea1-68c8-4d01-b040-c6ccb1d69dae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d5de3194-d901-4965-993b-37ade1535b11"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:8daff058-640f-4525-bc65-eb82ac6c44fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated: Melanoma for the treatment of patients with unresectable or metastatic melanoma. ( 1.1 ) for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC, or III melanoma following complete resection. ( 1.1 ) Non-Small Cell Lung Cancer (NSCLC) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations. ( 1.2 ) in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, as first-line treatment of patients with metastatic squamous NSCLC. ( 1.2 ) as a single agent for the first-line treatment of patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) ≥1%] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and is: Stage III where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic. ( 1.2 , 2.1 ) as a single agent for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA. ( 1.2 , 2.1 ) for the treatment of patients with resectable (tumors ≥4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.2 ) as a single agent, for adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage IB (T2a ≥4 cm), II, or IIIA NSCLC. ( 1.2 ) Malignant Pleural Mesothelioma (MPM) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of adult patients with unresectable advanced or metastatic MPM. ( 1.3 ) Head and Neck Squamous Cell Cancer (HNSCC) for the treatment of adult patients with resectable locally advanced HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test, as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as a single agent. ( 1.4 ) in combination with platinum and FU for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC. ( 1.4 ) as a single agent for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test. ( 1.4 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy. ( 1.4 ) Classical Hodgkin Lymphoma (cHL) for the treatment of adult patients with relapsed or refractory cHL. ( 1.5 ) for the treatment of pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapy. ( 1.5 ) Primary Mediastinal Large B-Cell Lymphoma (PMBCL) for the treatment of adult and pediatric patients with refractory PMBCL, or who have relapsed after 2 or more prior lines of therapy. ( 1.6 ) Limitations of Use : KEYTRUDA is not recommended for treatment of patients with PMBCL who require urgent cytoreductive therapy. Urothelial Cancer in combination with enfortumab vedotin, for the treatment of adult patients with locally advanced or metastatic urothelial cancer. ( 1.7 ) as a single agent for the treatment of patients with locally advanced or metastatic urothelial carcinoma who: are not eligible for any platinum-containing chemotherapy, or who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. ( 1.7 ) as a single agent for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy. ( 1.7 ) Microsatellite Instability-High or Mismatch Repair Deficient Cancer for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. ( 1.8 , 2.1 ) Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer (CRC) for the treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by an FDA-approved test. ( 1.9 , 2.1 ) Gastric Cancer in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.10 ) in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.10 ) Esophageal Cancer for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation either: in combination with platinum- and fluoropyrimidine-based chemotherapy for patients whose tumors express PD-L1 (CPS ≥1), or as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS ≥10) as determined by an FDA-approved test. ( 1.11 , 2.1 ) Cervical Cancer in combination with chemoradiotherapy, for the treatment of patients with locally advanced cervical cancer involving the lower third of the vagina, with or without extension to pelvic sidewall, or hydronephrosis/non-functioning kidney, or spread to adjacent pelvic organs (FIGO 2014 Stage III-IVA). ( 1.12 ) in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.12 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.12 , 2.1 ) Hepatocellular Carcinoma (HCC) for the treatment of patients with HCC secondary to hepatitis B who have received prior systemic therapy other than a PD-1/PD-L1-containing regimen. ( 1.13 ) Biliary Tract Cancer (BTC) in combination with gemcitabine and cisplatin, for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer. ( 1.14 ) Merkel Cell Carcinoma (MCC) for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma. ( 1.15 ) Renal Cell Carcinoma (RCC) in combination with axitinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) in combination with lenvatinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. ( 1.16 ) Endometrial Carcinoma in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma. ( 1.17 ) in combination with lenvatinib, for the treatment of adult patients with advanced endometrial carcinoma that is mismatch repair proficient (pMMR) or not MSI-H as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) as a single agent, for the treatment of adult patients with advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) Tumor Mutational Burden-High (TMB-H) Cancer for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. 1 ( 1.18 , 2.1 ) Limitations of Use : The safety and effectiveness of KEYTRUDA in pediatric patients with TMB-H central nervous system cancers have not been established. Cutaneous Squamous Cell Carcinoma (cSCC) for the treatment of patients with recurrent or metastatic cSCC or locally advanced cSCC that is not curable by surgery or radiation. ( 1.19 ) Triple-Negative Breast Cancer (TNBC) for the treatment of patients with high-risk early-stage TNBC in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.20 ) in combination with chemotherapy, for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA approved test. ( 1.20 , 2.1 ) Adult Classical Hodgkin Lymphoma and Adult Primary Mediastinal Large B-Cell Lymphoma: Additional Dosing Regimen of 400 mg Every 6 Weeks for use at an additional recommended dosage of 400 mg every 6 weeks for Classical Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma in adults. 2 ( 1.21 , 2.2 ) 1 This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. 2 This indication is approved under accelerated approval based on pharmacokinetic data, the relationship of exposure to efficacy, and the relationship of exposure to safety. Continued approval for this dosing may be contingent upon verification and description of clinical benefit in the confirmatory trials.|[PMDA] A drug with a new indication for the treatment of advanced or recurrent cervical cancer. A drug with a new indication and a new dosage for the preoperative and postoperative adjuvant treatment of hormone receptor (HR)-negative and human epidermal growth factor receptor 2 (HER2)-negative breast cancer with a high risk of recurrence. uuid:e28fdcec-fc42-4a85-92f9-059435c0e3d8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DPT0O3T46P biolink:treats MONDO:0007256 PMID:41385096 "[{""id"":""uuid:d6abba27-6294-43af-b26a-2e7981c74ad0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1348995d-56ea-4a3f-a01f-2ffbcf6373b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated: Melanoma for the treatment of patients with unresectable or metastatic melanoma. ( 1.1 ) for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC, or III melanoma following complete resection. ( 1.1 ) Non-Small Cell Lung Cancer (NSCLC) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations. ( 1.2 ) in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, as first-line treatment of patients with metastatic squamous NSCLC. ( 1.2 ) as a single agent for the first-line treatment of patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) ≥1%] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and is: Stage III where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic. ( 1.2 , 2.1 ) as a single agent for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA. ( 1.2 , 2.1 ) for the treatment of patients with resectable (tumors ≥4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.2 ) as a single agent, for adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage IB (T2a ≥4 cm), II, or IIIA NSCLC. ( 1.2 ) Malignant Pleural Mesothelioma (MPM) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of adult patients with unresectable advanced or metastatic MPM. ( 1.3 ) Head and Neck Squamous Cell Cancer (HNSCC) for the treatment of adult patients with resectable locally advanced HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test, as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as a single agent. ( 1.4 ) in combination with platinum and FU for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC. ( 1.4 ) as a single agent for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test. ( 1.4 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy. ( 1.4 ) Classical Hodgkin Lymphoma (cHL) for the treatment of adult patients with relapsed or refractory cHL. ( 1.5 ) for the treatment of pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapy. ( 1.5 ) Primary Mediastinal Large B-Cell Lymphoma (PMBCL) for the treatment of adult and pediatric patients with refractory PMBCL, or who have relapsed after 2 or more prior lines of therapy. ( 1.6 ) Limitations of Use : KEYTRUDA is not recommended for treatment of patients with PMBCL who require urgent cytoreductive therapy. Urothelial Cancer in combination with enfortumab vedotin, for the treatment of adult patients with locally advanced or metastatic urothelial cancer. ( 1.7 ) as a single agent for the treatment of patients with locally advanced or metastatic urothelial carcinoma who: are not eligible for any platinum-containing chemotherapy, or who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. ( 1.7 ) as a single agent for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy. ( 1.7 ) Microsatellite Instability-High or Mismatch Repair Deficient Cancer for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. ( 1.8 , 2.1 ) Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer (CRC) for the treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by an FDA-approved test. ( 1.9 , 2.1 ) Gastric Cancer in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.10 ) in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.10 ) Esophageal Cancer for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation either: in combination with platinum- and fluoropyrimidine-based chemotherapy for patients whose tumors express PD-L1 (CPS ≥1), or as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS ≥10) as determined by an FDA-approved test. ( 1.11 , 2.1 ) Cervical Cancer in combination with chemoradiotherapy, for the treatment of patients with locally advanced cervical cancer involving the lower third of the vagina, with or without extension to pelvic sidewall, or hydronephrosis/non-functioning kidney, or spread to adjacent pelvic organs (FIGO 2014 Stage III-IVA). ( 1.12 ) in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.12 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.12 , 2.1 ) Hepatocellular Carcinoma (HCC) for the treatment of patients with HCC secondary to hepatitis B who have received prior systemic therapy other than a PD-1/PD-L1-containing regimen. ( 1.13 ) Biliary Tract Cancer (BTC) in combination with gemcitabine and cisplatin, for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer. ( 1.14 ) Merkel Cell Carcinoma (MCC) for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma. ( 1.15 ) Renal Cell Carcinoma (RCC) in combination with axitinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) in combination with lenvatinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. ( 1.16 ) Endometrial Carcinoma in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma. ( 1.17 ) in combination with lenvatinib, for the treatment of adult patients with advanced endometrial carcinoma that is mismatch repair proficient (pMMR) or not MSI-H as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) as a single agent, for the treatment of adult patients with advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) Tumor Mutational Burden-High (TMB-H) Cancer for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. 1 ( 1.18 , 2.1 ) Limitations of Use : The safety and effectiveness of KEYTRUDA in pediatric patients with TMB-H central nervous system cancers have not been established. Cutaneous Squamous Cell Carcinoma (cSCC) for the treatment of patients with recurrent or metastatic cSCC or locally advanced cSCC that is not curable by surgery or radiation. ( 1.19 ) Triple-Negative Breast Cancer (TNBC) for the treatment of patients with high-risk early-stage TNBC in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.20 ) in combination with chemotherapy, for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA approved test. ( 1.20 , 2.1 ) Adult Classical Hodgkin Lymphoma and Adult Primary Mediastinal Large B-Cell Lymphoma: Additional Dosing Regimen of 400 mg Every 6 Weeks for use at an additional recommended dosage of 400 mg every 6 weeks for Classical Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma in adults. 2 ( 1.21 , 2.2 ) 1 This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. 2 This indication is approved under accelerated approval based on pharmacokinetic data, the relationship of exposure to efficacy, and the relationship of exposure to safety. Continued approval for this dosing may be contingent upon verification and description of clinical benefit in the confirmatory trials. uuid:290524f5-2a55-4abe-b4be-4faf5436f006 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DPT0O3T46P biolink:treats MONDO:0003060 PMID:41385096 "[{""id"":""uuid:4cce4405-3085-4063-b5ba-7a00d5d24c1b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:69d31cd3-f466-4b40-bba0-ffe332593dcf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated: Melanoma for the treatment of patients with unresectable or metastatic melanoma. ( 1.1 ) for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC, or III melanoma following complete resection. ( 1.1 ) Non-Small Cell Lung Cancer (NSCLC) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations. ( 1.2 ) in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, as first-line treatment of patients with metastatic squamous NSCLC. ( 1.2 ) as a single agent for the first-line treatment of patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) ≥1%] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and is: Stage III where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic. ( 1.2 , 2.1 ) as a single agent for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA. ( 1.2 , 2.1 ) for the treatment of patients with resectable (tumors ≥4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.2 ) as a single agent, for adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage IB (T2a ≥4 cm), II, or IIIA NSCLC. ( 1.2 ) Malignant Pleural Mesothelioma (MPM) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of adult patients with unresectable advanced or metastatic MPM. ( 1.3 ) Head and Neck Squamous Cell Cancer (HNSCC) for the treatment of adult patients with resectable locally advanced HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test, as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as a single agent. ( 1.4 ) in combination with platinum and FU for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC. ( 1.4 ) as a single agent for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test. ( 1.4 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy. ( 1.4 ) Classical Hodgkin Lymphoma (cHL) for the treatment of adult patients with relapsed or refractory cHL. ( 1.5 ) for the treatment of pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapy. ( 1.5 ) Primary Mediastinal Large B-Cell Lymphoma (PMBCL) for the treatment of adult and pediatric patients with refractory PMBCL, or who have relapsed after 2 or more prior lines of therapy. ( 1.6 ) Limitations of Use : KEYTRUDA is not recommended for treatment of patients with PMBCL who require urgent cytoreductive therapy. Urothelial Cancer in combination with enfortumab vedotin, for the treatment of adult patients with locally advanced or metastatic urothelial cancer. ( 1.7 ) as a single agent for the treatment of patients with locally advanced or metastatic urothelial carcinoma who: are not eligible for any platinum-containing chemotherapy, or who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. ( 1.7 ) as a single agent for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy. ( 1.7 ) Microsatellite Instability-High or Mismatch Repair Deficient Cancer for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. ( 1.8 , 2.1 ) Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer (CRC) for the treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by an FDA-approved test. ( 1.9 , 2.1 ) Gastric Cancer in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.10 ) in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.10 ) Esophageal Cancer for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation either: in combination with platinum- and fluoropyrimidine-based chemotherapy for patients whose tumors express PD-L1 (CPS ≥1), or as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS ≥10) as determined by an FDA-approved test. ( 1.11 , 2.1 ) Cervical Cancer in combination with chemoradiotherapy, for the treatment of patients with locally advanced cervical cancer involving the lower third of the vagina, with or without extension to pelvic sidewall, or hydronephrosis/non-functioning kidney, or spread to adjacent pelvic organs (FIGO 2014 Stage III-IVA). ( 1.12 ) in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.12 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.12 , 2.1 ) Hepatocellular Carcinoma (HCC) for the treatment of patients with HCC secondary to hepatitis B who have received prior systemic therapy other than a PD-1/PD-L1-containing regimen. ( 1.13 ) Biliary Tract Cancer (BTC) in combination with gemcitabine and cisplatin, for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer. ( 1.14 ) Merkel Cell Carcinoma (MCC) for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma. ( 1.15 ) Renal Cell Carcinoma (RCC) in combination with axitinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) in combination with lenvatinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. ( 1.16 ) Endometrial Carcinoma in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma. ( 1.17 ) in combination with lenvatinib, for the treatment of adult patients with advanced endometrial carcinoma that is mismatch repair proficient (pMMR) or not MSI-H as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) as a single agent, for the treatment of adult patients with advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) Tumor Mutational Burden-High (TMB-H) Cancer for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. 1 ( 1.18 , 2.1 ) Limitations of Use : The safety and effectiveness of KEYTRUDA in pediatric patients with TMB-H central nervous system cancers have not been established. Cutaneous Squamous Cell Carcinoma (cSCC) for the treatment of patients with recurrent or metastatic cSCC or locally advanced cSCC that is not curable by surgery or radiation. ( 1.19 ) Triple-Negative Breast Cancer (TNBC) for the treatment of patients with high-risk early-stage TNBC in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.20 ) in combination with chemotherapy, for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA approved test. ( 1.20 , 2.1 ) Adult Classical Hodgkin Lymphoma and Adult Primary Mediastinal Large B-Cell Lymphoma: Additional Dosing Regimen of 400 mg Every 6 Weeks for use at an additional recommended dosage of 400 mg every 6 weeks for Classical Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma in adults. 2 ( 1.21 , 2.2 ) 1 This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. 2 This indication is approved under accelerated approval based on pharmacokinetic data, the relationship of exposure to efficacy, and the relationship of exposure to safety. Continued approval for this dosing may be contingent upon verification and description of clinical benefit in the confirmatory trials. uuid:a15d13d0-abff-4be6-b36d-5b6d2ef393fb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DPT0O3T46P biolink:treats MONDO:0019210 PMID:41385096 "[{""id"":""uuid:31272a69-656c-4c58-8429-e0bc54795ac3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:36afc26c-6948-4240-ae1a-6e2e900af7b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated: Melanoma for the treatment of patients with unresectable or metastatic melanoma. ( 1.1 ) for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC, or III melanoma following complete resection. ( 1.1 ) Non-Small Cell Lung Cancer (NSCLC) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations. ( 1.2 ) in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, as first-line treatment of patients with metastatic squamous NSCLC. ( 1.2 ) as a single agent for the first-line treatment of patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) ≥1%] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and is: Stage III where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic. ( 1.2 , 2.1 ) as a single agent for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA. ( 1.2 , 2.1 ) for the treatment of patients with resectable (tumors ≥4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.2 ) as a single agent, for adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage IB (T2a ≥4 cm), II, or IIIA NSCLC. ( 1.2 ) Malignant Pleural Mesothelioma (MPM) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of adult patients with unresectable advanced or metastatic MPM. ( 1.3 ) Head and Neck Squamous Cell Cancer (HNSCC) for the treatment of adult patients with resectable locally advanced HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test, as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as a single agent. ( 1.4 ) in combination with platinum and FU for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC. ( 1.4 ) as a single agent for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test. ( 1.4 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy. ( 1.4 ) Classical Hodgkin Lymphoma (cHL) for the treatment of adult patients with relapsed or refractory cHL. ( 1.5 ) for the treatment of pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapy. ( 1.5 ) Primary Mediastinal Large B-Cell Lymphoma (PMBCL) for the treatment of adult and pediatric patients with refractory PMBCL, or who have relapsed after 2 or more prior lines of therapy. ( 1.6 ) Limitations of Use : KEYTRUDA is not recommended for treatment of patients with PMBCL who require urgent cytoreductive therapy. Urothelial Cancer in combination with enfortumab vedotin, for the treatment of adult patients with locally advanced or metastatic urothelial cancer. ( 1.7 ) as a single agent for the treatment of patients with locally advanced or metastatic urothelial carcinoma who: are not eligible for any platinum-containing chemotherapy, or who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. ( 1.7 ) as a single agent for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy. ( 1.7 ) Microsatellite Instability-High or Mismatch Repair Deficient Cancer for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. ( 1.8 , 2.1 ) Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer (CRC) for the treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by an FDA-approved test. ( 1.9 , 2.1 ) Gastric Cancer in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.10 ) in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.10 ) Esophageal Cancer for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation either: in combination with platinum- and fluoropyrimidine-based chemotherapy for patients whose tumors express PD-L1 (CPS ≥1), or as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS ≥10) as determined by an FDA-approved test. ( 1.11 , 2.1 ) Cervical Cancer in combination with chemoradiotherapy, for the treatment of patients with locally advanced cervical cancer involving the lower third of the vagina, with or without extension to pelvic sidewall, or hydronephrosis/non-functioning kidney, or spread to adjacent pelvic organs (FIGO 2014 Stage III-IVA). ( 1.12 ) in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.12 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.12 , 2.1 ) Hepatocellular Carcinoma (HCC) for the treatment of patients with HCC secondary to hepatitis B who have received prior systemic therapy other than a PD-1/PD-L1-containing regimen. ( 1.13 ) Biliary Tract Cancer (BTC) in combination with gemcitabine and cisplatin, for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer. ( 1.14 ) Merkel Cell Carcinoma (MCC) for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma. ( 1.15 ) Renal Cell Carcinoma (RCC) in combination with axitinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) in combination with lenvatinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. ( 1.16 ) Endometrial Carcinoma in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma. ( 1.17 ) in combination with lenvatinib, for the treatment of adult patients with advanced endometrial carcinoma that is mismatch repair proficient (pMMR) or not MSI-H as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) as a single agent, for the treatment of adult patients with advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) Tumor Mutational Burden-High (TMB-H) Cancer for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. 1 ( 1.18 , 2.1 ) Limitations of Use : The safety and effectiveness of KEYTRUDA in pediatric patients with TMB-H central nervous system cancers have not been established. Cutaneous Squamous Cell Carcinoma (cSCC) for the treatment of patients with recurrent or metastatic cSCC or locally advanced cSCC that is not curable by surgery or radiation. ( 1.19 ) Triple-Negative Breast Cancer (TNBC) for the treatment of patients with high-risk early-stage TNBC in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.20 ) in combination with chemotherapy, for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA approved test. ( 1.20 , 2.1 ) Adult Classical Hodgkin Lymphoma and Adult Primary Mediastinal Large B-Cell Lymphoma: Additional Dosing Regimen of 400 mg Every 6 Weeks for use at an additional recommended dosage of 400 mg every 6 weeks for Classical Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma in adults. 2 ( 1.21 , 2.2 ) 1 This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. 2 This indication is approved under accelerated approval based on pharmacokinetic data, the relationship of exposure to efficacy, and the relationship of exposure to safety. Continued approval for this dosing may be contingent upon verification and description of clinical benefit in the confirmatory trials. uuid:bf176b24-06c1-4a5e-9814-0fd9ac64369b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DPT0O3T46P biolink:treats MONDO:0005086 PMID:41385096 "[{""id"":""uuid:9024fca1-8c1a-4a78-a499-be1fa5f94ae4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9d66368b-5513-4aa6-ba88-3e93b0e9d233"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:6750a0f8-a21a-4b13-b073-324c8ab836d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated: Melanoma for the treatment of patients with unresectable or metastatic melanoma. ( 1.1 ) for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC, or III melanoma following complete resection. ( 1.1 ) Non-Small Cell Lung Cancer (NSCLC) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations. ( 1.2 ) in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, as first-line treatment of patients with metastatic squamous NSCLC. ( 1.2 ) as a single agent for the first-line treatment of patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) ≥1%] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and is: Stage III where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic. ( 1.2 , 2.1 ) as a single agent for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA. ( 1.2 , 2.1 ) for the treatment of patients with resectable (tumors ≥4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.2 ) as a single agent, for adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage IB (T2a ≥4 cm), II, or IIIA NSCLC. ( 1.2 ) Malignant Pleural Mesothelioma (MPM) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of adult patients with unresectable advanced or metastatic MPM. ( 1.3 ) Head and Neck Squamous Cell Cancer (HNSCC) for the treatment of adult patients with resectable locally advanced HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test, as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as a single agent. ( 1.4 ) in combination with platinum and FU for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC. ( 1.4 ) as a single agent for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test. ( 1.4 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy. ( 1.4 ) Classical Hodgkin Lymphoma (cHL) for the treatment of adult patients with relapsed or refractory cHL. ( 1.5 ) for the treatment of pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapy. ( 1.5 ) Primary Mediastinal Large B-Cell Lymphoma (PMBCL) for the treatment of adult and pediatric patients with refractory PMBCL, or who have relapsed after 2 or more prior lines of therapy. ( 1.6 ) Limitations of Use : KEYTRUDA is not recommended for treatment of patients with PMBCL who require urgent cytoreductive therapy. Urothelial Cancer in combination with enfortumab vedotin, for the treatment of adult patients with locally advanced or metastatic urothelial cancer. ( 1.7 ) as a single agent for the treatment of patients with locally advanced or metastatic urothelial carcinoma who: are not eligible for any platinum-containing chemotherapy, or who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. ( 1.7 ) as a single agent for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy. ( 1.7 ) Microsatellite Instability-High or Mismatch Repair Deficient Cancer for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. ( 1.8 , 2.1 ) Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer (CRC) for the treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by an FDA-approved test. ( 1.9 , 2.1 ) Gastric Cancer in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.10 ) in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.10 ) Esophageal Cancer for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation either: in combination with platinum- and fluoropyrimidine-based chemotherapy for patients whose tumors express PD-L1 (CPS ≥1), or as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS ≥10) as determined by an FDA-approved test. ( 1.11 , 2.1 ) Cervical Cancer in combination with chemoradiotherapy, for the treatment of patients with locally advanced cervical cancer involving the lower third of the vagina, with or without extension to pelvic sidewall, or hydronephrosis/non-functioning kidney, or spread to adjacent pelvic organs (FIGO 2014 Stage III-IVA). ( 1.12 ) in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.12 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.12 , 2.1 ) Hepatocellular Carcinoma (HCC) for the treatment of patients with HCC secondary to hepatitis B who have received prior systemic therapy other than a PD-1/PD-L1-containing regimen. ( 1.13 ) Biliary Tract Cancer (BTC) in combination with gemcitabine and cisplatin, for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer. ( 1.14 ) Merkel Cell Carcinoma (MCC) for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma. ( 1.15 ) Renal Cell Carcinoma (RCC) in combination with axitinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) in combination with lenvatinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. ( 1.16 ) Endometrial Carcinoma in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma. ( 1.17 ) in combination with lenvatinib, for the treatment of adult patients with advanced endometrial carcinoma that is mismatch repair proficient (pMMR) or not MSI-H as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) as a single agent, for the treatment of adult patients with advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) Tumor Mutational Burden-High (TMB-H) Cancer for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. 1 ( 1.18 , 2.1 ) Limitations of Use : The safety and effectiveness of KEYTRUDA in pediatric patients with TMB-H central nervous system cancers have not been established. Cutaneous Squamous Cell Carcinoma (cSCC) for the treatment of patients with recurrent or metastatic cSCC or locally advanced cSCC that is not curable by surgery or radiation. ( 1.19 ) Triple-Negative Breast Cancer (TNBC) for the treatment of patients with high-risk early-stage TNBC in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.20 ) in combination with chemotherapy, for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA approved test. ( 1.20 , 2.1 ) Adult Classical Hodgkin Lymphoma and Adult Primary Mediastinal Large B-Cell Lymphoma: Additional Dosing Regimen of 400 mg Every 6 Weeks for use at an additional recommended dosage of 400 mg every 6 weeks for Classical Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma in adults. 2 ( 1.21 , 2.2 ) 1 This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. 2 This indication is approved under accelerated approval based on pharmacokinetic data, the relationship of exposure to efficacy, and the relationship of exposure to safety. Continued approval for this dosing may be contingent upon verification and description of clinical benefit in the confirmatory trials.|[PMDA] A drug with a new indication and a new dosage for postoperative adjuvant treatment for renal cell carcinoma. uuid:2677ecc8-6ddc-49f5-840e-c0cd9d9789a5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DPT0O3T46P biolink:treats MONDO:0002447 PMID:41385096 "[{""id"":""uuid:3ddbe33f-c32c-43d7-a4ae-a6e7565ba3ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5a14bad8-9598-4216-8ff5-dadf31b6057b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated: Melanoma for the treatment of patients with unresectable or metastatic melanoma. ( 1.1 ) for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC, or III melanoma following complete resection. ( 1.1 ) Non-Small Cell Lung Cancer (NSCLC) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations. ( 1.2 ) in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, as first-line treatment of patients with metastatic squamous NSCLC. ( 1.2 ) as a single agent for the first-line treatment of patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) ≥1%] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and is: Stage III where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic. ( 1.2 , 2.1 ) as a single agent for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA. ( 1.2 , 2.1 ) for the treatment of patients with resectable (tumors ≥4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.2 ) as a single agent, for adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage IB (T2a ≥4 cm), II, or IIIA NSCLC. ( 1.2 ) Malignant Pleural Mesothelioma (MPM) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of adult patients with unresectable advanced or metastatic MPM. ( 1.3 ) Head and Neck Squamous Cell Cancer (HNSCC) for the treatment of adult patients with resectable locally advanced HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test, as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as a single agent. ( 1.4 ) in combination with platinum and FU for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC. ( 1.4 ) as a single agent for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test. ( 1.4 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy. ( 1.4 ) Classical Hodgkin Lymphoma (cHL) for the treatment of adult patients with relapsed or refractory cHL. ( 1.5 ) for the treatment of pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapy. ( 1.5 ) Primary Mediastinal Large B-Cell Lymphoma (PMBCL) for the treatment of adult and pediatric patients with refractory PMBCL, or who have relapsed after 2 or more prior lines of therapy. ( 1.6 ) Limitations of Use : KEYTRUDA is not recommended for treatment of patients with PMBCL who require urgent cytoreductive therapy. Urothelial Cancer in combination with enfortumab vedotin, for the treatment of adult patients with locally advanced or metastatic urothelial cancer. ( 1.7 ) as a single agent for the treatment of patients with locally advanced or metastatic urothelial carcinoma who: are not eligible for any platinum-containing chemotherapy, or who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. ( 1.7 ) as a single agent for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy. ( 1.7 ) Microsatellite Instability-High or Mismatch Repair Deficient Cancer for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. ( 1.8 , 2.1 ) Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer (CRC) for the treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by an FDA-approved test. ( 1.9 , 2.1 ) Gastric Cancer in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.10 ) in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.10 ) Esophageal Cancer for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation either: in combination with platinum- and fluoropyrimidine-based chemotherapy for patients whose tumors express PD-L1 (CPS ≥1), or as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS ≥10) as determined by an FDA-approved test. ( 1.11 , 2.1 ) Cervical Cancer in combination with chemoradiotherapy, for the treatment of patients with locally advanced cervical cancer involving the lower third of the vagina, with or without extension to pelvic sidewall, or hydronephrosis/non-functioning kidney, or spread to adjacent pelvic organs (FIGO 2014 Stage III-IVA). ( 1.12 ) in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.12 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.12 , 2.1 ) Hepatocellular Carcinoma (HCC) for the treatment of patients with HCC secondary to hepatitis B who have received prior systemic therapy other than a PD-1/PD-L1-containing regimen. ( 1.13 ) Biliary Tract Cancer (BTC) in combination with gemcitabine and cisplatin, for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer. ( 1.14 ) Merkel Cell Carcinoma (MCC) for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma. ( 1.15 ) Renal Cell Carcinoma (RCC) in combination with axitinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) in combination with lenvatinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. ( 1.16 ) Endometrial Carcinoma in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma. ( 1.17 ) in combination with lenvatinib, for the treatment of adult patients with advanced endometrial carcinoma that is mismatch repair proficient (pMMR) or not MSI-H as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) as a single agent, for the treatment of adult patients with advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) Tumor Mutational Burden-High (TMB-H) Cancer for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. 1 ( 1.18 , 2.1 ) Limitations of Use : The safety and effectiveness of KEYTRUDA in pediatric patients with TMB-H central nervous system cancers have not been established. Cutaneous Squamous Cell Carcinoma (cSCC) for the treatment of patients with recurrent or metastatic cSCC or locally advanced cSCC that is not curable by surgery or radiation. ( 1.19 ) Triple-Negative Breast Cancer (TNBC) for the treatment of patients with high-risk early-stage TNBC in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.20 ) in combination with chemotherapy, for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA approved test. ( 1.20 , 2.1 ) Adult Classical Hodgkin Lymphoma and Adult Primary Mediastinal Large B-Cell Lymphoma: Additional Dosing Regimen of 400 mg Every 6 Weeks for use at an additional recommended dosage of 400 mg every 6 weeks for Classical Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma in adults. 2 ( 1.21 , 2.2 ) 1 This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. 2 This indication is approved under accelerated approval based on pharmacokinetic data, the relationship of exposure to efficacy, and the relationship of exposure to safety. Continued approval for this dosing may be contingent upon verification and description of clinical benefit in the confirmatory trials. uuid:7148d9d5-6a17-4f27-bf94-e4f94686b54f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DPT0O3T46P biolink:treats UMLS:C5442339 PMID:41385096 "[{""id"":""uuid:8ba8dc98-b8aa-459e-8433-5115c8f13459"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cfbf01ef-b0e7-493e-974d-a0e8b7dc6bf9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated: Melanoma for the treatment of patients with unresectable or metastatic melanoma. ( 1.1 ) for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC, or III melanoma following complete resection. ( 1.1 ) Non-Small Cell Lung Cancer (NSCLC) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations. ( 1.2 ) in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, as first-line treatment of patients with metastatic squamous NSCLC. ( 1.2 ) as a single agent for the first-line treatment of patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) ≥1%] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and is: Stage III where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic. ( 1.2 , 2.1 ) as a single agent for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA. ( 1.2 , 2.1 ) for the treatment of patients with resectable (tumors ≥4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.2 ) as a single agent, for adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage IB (T2a ≥4 cm), II, or IIIA NSCLC. ( 1.2 ) Malignant Pleural Mesothelioma (MPM) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of adult patients with unresectable advanced or metastatic MPM. ( 1.3 ) Head and Neck Squamous Cell Cancer (HNSCC) for the treatment of adult patients with resectable locally advanced HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test, as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as a single agent. ( 1.4 ) in combination with platinum and FU for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC. ( 1.4 ) as a single agent for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test. ( 1.4 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy. ( 1.4 ) Classical Hodgkin Lymphoma (cHL) for the treatment of adult patients with relapsed or refractory cHL. ( 1.5 ) for the treatment of pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapy. ( 1.5 ) Primary Mediastinal Large B-Cell Lymphoma (PMBCL) for the treatment of adult and pediatric patients with refractory PMBCL, or who have relapsed after 2 or more prior lines of therapy. ( 1.6 ) Limitations of Use : KEYTRUDA is not recommended for treatment of patients with PMBCL who require urgent cytoreductive therapy. Urothelial Cancer in combination with enfortumab vedotin, for the treatment of adult patients with locally advanced or metastatic urothelial cancer. ( 1.7 ) as a single agent for the treatment of patients with locally advanced or metastatic urothelial carcinoma who: are not eligible for any platinum-containing chemotherapy, or who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. ( 1.7 ) as a single agent for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy. ( 1.7 ) Microsatellite Instability-High or Mismatch Repair Deficient Cancer for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. ( 1.8 , 2.1 ) Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer (CRC) for the treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by an FDA-approved test. ( 1.9 , 2.1 ) Gastric Cancer in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.10 ) in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.10 ) Esophageal Cancer for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation either: in combination with platinum- and fluoropyrimidine-based chemotherapy for patients whose tumors express PD-L1 (CPS ≥1), or as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS ≥10) as determined by an FDA-approved test. ( 1.11 , 2.1 ) Cervical Cancer in combination with chemoradiotherapy, for the treatment of patients with locally advanced cervical cancer involving the lower third of the vagina, with or without extension to pelvic sidewall, or hydronephrosis/non-functioning kidney, or spread to adjacent pelvic organs (FIGO 2014 Stage III-IVA). ( 1.12 ) in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.12 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.12 , 2.1 ) Hepatocellular Carcinoma (HCC) for the treatment of patients with HCC secondary to hepatitis B who have received prior systemic therapy other than a PD-1/PD-L1-containing regimen. ( 1.13 ) Biliary Tract Cancer (BTC) in combination with gemcitabine and cisplatin, for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer. ( 1.14 ) Merkel Cell Carcinoma (MCC) for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma. ( 1.15 ) Renal Cell Carcinoma (RCC) in combination with axitinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) in combination with lenvatinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. ( 1.16 ) Endometrial Carcinoma in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma. ( 1.17 ) in combination with lenvatinib, for the treatment of adult patients with advanced endometrial carcinoma that is mismatch repair proficient (pMMR) or not MSI-H as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) as a single agent, for the treatment of adult patients with advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) Tumor Mutational Burden-High (TMB-H) Cancer for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. 1 ( 1.18 , 2.1 ) Limitations of Use : The safety and effectiveness of KEYTRUDA in pediatric patients with TMB-H central nervous system cancers have not been established. Cutaneous Squamous Cell Carcinoma (cSCC) for the treatment of patients with recurrent or metastatic cSCC or locally advanced cSCC that is not curable by surgery or radiation. ( 1.19 ) Triple-Negative Breast Cancer (TNBC) for the treatment of patients with high-risk early-stage TNBC in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.20 ) in combination with chemotherapy, for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA approved test. ( 1.20 , 2.1 ) Adult Classical Hodgkin Lymphoma and Adult Primary Mediastinal Large B-Cell Lymphoma: Additional Dosing Regimen of 400 mg Every 6 Weeks for use at an additional recommended dosage of 400 mg every 6 weeks for Classical Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma in adults. 2 ( 1.21 , 2.2 ) 1 This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. 2 This indication is approved under accelerated approval based on pharmacokinetic data, the relationship of exposure to efficacy, and the relationship of exposure to safety. Continued approval for this dosing may be contingent upon verification and description of clinical benefit in the confirmatory trials. uuid:085712c0-3a03-4b8b-906c-86e39d23a928 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DPT0O3T46P biolink:treats MONDO:0002529 PMID:41385096 "[{""id"":""uuid:5f9991ec-5416-4889-a3bb-99a9612a5b11"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8e683371-3c79-40af-9868-344775836f2a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated: Melanoma for the treatment of patients with unresectable or metastatic melanoma. ( 1.1 ) for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC, or III melanoma following complete resection. ( 1.1 ) Non-Small Cell Lung Cancer (NSCLC) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations. ( 1.2 ) in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, as first-line treatment of patients with metastatic squamous NSCLC. ( 1.2 ) as a single agent for the first-line treatment of patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) ≥1%] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and is: Stage III where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic. ( 1.2 , 2.1 ) as a single agent for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA. ( 1.2 , 2.1 ) for the treatment of patients with resectable (tumors ≥4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.2 ) as a single agent, for adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage IB (T2a ≥4 cm), II, or IIIA NSCLC. ( 1.2 ) Malignant Pleural Mesothelioma (MPM) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of adult patients with unresectable advanced or metastatic MPM. ( 1.3 ) Head and Neck Squamous Cell Cancer (HNSCC) for the treatment of adult patients with resectable locally advanced HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test, as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as a single agent. ( 1.4 ) in combination with platinum and FU for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC. ( 1.4 ) as a single agent for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test. ( 1.4 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy. ( 1.4 ) Classical Hodgkin Lymphoma (cHL) for the treatment of adult patients with relapsed or refractory cHL. ( 1.5 ) for the treatment of pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapy. ( 1.5 ) Primary Mediastinal Large B-Cell Lymphoma (PMBCL) for the treatment of adult and pediatric patients with refractory PMBCL, or who have relapsed after 2 or more prior lines of therapy. ( 1.6 ) Limitations of Use : KEYTRUDA is not recommended for treatment of patients with PMBCL who require urgent cytoreductive therapy. Urothelial Cancer in combination with enfortumab vedotin, for the treatment of adult patients with locally advanced or metastatic urothelial cancer. ( 1.7 ) as a single agent for the treatment of patients with locally advanced or metastatic urothelial carcinoma who: are not eligible for any platinum-containing chemotherapy, or who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. ( 1.7 ) as a single agent for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy. ( 1.7 ) Microsatellite Instability-High or Mismatch Repair Deficient Cancer for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. ( 1.8 , 2.1 ) Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer (CRC) for the treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by an FDA-approved test. ( 1.9 , 2.1 ) Gastric Cancer in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.10 ) in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.10 ) Esophageal Cancer for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation either: in combination with platinum- and fluoropyrimidine-based chemotherapy for patients whose tumors express PD-L1 (CPS ≥1), or as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS ≥10) as determined by an FDA-approved test. ( 1.11 , 2.1 ) Cervical Cancer in combination with chemoradiotherapy, for the treatment of patients with locally advanced cervical cancer involving the lower third of the vagina, with or without extension to pelvic sidewall, or hydronephrosis/non-functioning kidney, or spread to adjacent pelvic organs (FIGO 2014 Stage III-IVA). ( 1.12 ) in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.12 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.12 , 2.1 ) Hepatocellular Carcinoma (HCC) for the treatment of patients with HCC secondary to hepatitis B who have received prior systemic therapy other than a PD-1/PD-L1-containing regimen. ( 1.13 ) Biliary Tract Cancer (BTC) in combination with gemcitabine and cisplatin, for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer. ( 1.14 ) Merkel Cell Carcinoma (MCC) for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma. ( 1.15 ) Renal Cell Carcinoma (RCC) in combination with axitinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) in combination with lenvatinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. ( 1.16 ) Endometrial Carcinoma in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma. ( 1.17 ) in combination with lenvatinib, for the treatment of adult patients with advanced endometrial carcinoma that is mismatch repair proficient (pMMR) or not MSI-H as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) as a single agent, for the treatment of adult patients with advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) Tumor Mutational Burden-High (TMB-H) Cancer for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. 1 ( 1.18 , 2.1 ) Limitations of Use : The safety and effectiveness of KEYTRUDA in pediatric patients with TMB-H central nervous system cancers have not been established. Cutaneous Squamous Cell Carcinoma (cSCC) for the treatment of patients with recurrent or metastatic cSCC or locally advanced cSCC that is not curable by surgery or radiation. ( 1.19 ) Triple-Negative Breast Cancer (TNBC) for the treatment of patients with high-risk early-stage TNBC in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.20 ) in combination with chemotherapy, for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA approved test. ( 1.20 , 2.1 ) Adult Classical Hodgkin Lymphoma and Adult Primary Mediastinal Large B-Cell Lymphoma: Additional Dosing Regimen of 400 mg Every 6 Weeks for use at an additional recommended dosage of 400 mg every 6 weeks for Classical Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma in adults. 2 ( 1.21 , 2.2 ) 1 This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. 2 This indication is approved under accelerated approval based on pharmacokinetic data, the relationship of exposure to efficacy, and the relationship of exposure to safety. Continued approval for this dosing may be contingent upon verification and description of clinical benefit in the confirmatory trials. uuid:a709d263-9ed4-44a2-b7bf-b0fdd26e1e82 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DPT0O3T46P biolink:treats MONDO:0005494 PMID:41385096 "[{""id"":""uuid:75677a3b-0e0c-4e13-b6b7-21270ebd7d64"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:666b92c7-ce34-43ef-a16f-85d0a1663471"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:1f18b045-6794-4bde-8beb-07e197721b13"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated: Melanoma for the treatment of patients with unresectable or metastatic melanoma. ( 1.1 ) for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC, or III melanoma following complete resection. ( 1.1 ) Non-Small Cell Lung Cancer (NSCLC) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations. ( 1.2 ) in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, as first-line treatment of patients with metastatic squamous NSCLC. ( 1.2 ) as a single agent for the first-line treatment of patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) ≥1%] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and is: Stage III where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic. ( 1.2 , 2.1 ) as a single agent for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA. ( 1.2 , 2.1 ) for the treatment of patients with resectable (tumors ≥4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.2 ) as a single agent, for adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage IB (T2a ≥4 cm), II, or IIIA NSCLC. ( 1.2 ) Malignant Pleural Mesothelioma (MPM) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of adult patients with unresectable advanced or metastatic MPM. ( 1.3 ) Head and Neck Squamous Cell Cancer (HNSCC) for the treatment of adult patients with resectable locally advanced HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test, as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as a single agent. ( 1.4 ) in combination with platinum and FU for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC. ( 1.4 ) as a single agent for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test. ( 1.4 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy. ( 1.4 ) Classical Hodgkin Lymphoma (cHL) for the treatment of adult patients with relapsed or refractory cHL. ( 1.5 ) for the treatment of pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapy. ( 1.5 ) Primary Mediastinal Large B-Cell Lymphoma (PMBCL) for the treatment of adult and pediatric patients with refractory PMBCL, or who have relapsed after 2 or more prior lines of therapy. ( 1.6 ) Limitations of Use : KEYTRUDA is not recommended for treatment of patients with PMBCL who require urgent cytoreductive therapy. Urothelial Cancer in combination with enfortumab vedotin, for the treatment of adult patients with locally advanced or metastatic urothelial cancer. ( 1.7 ) as a single agent for the treatment of patients with locally advanced or metastatic urothelial carcinoma who: are not eligible for any platinum-containing chemotherapy, or who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. ( 1.7 ) as a single agent for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy. ( 1.7 ) Microsatellite Instability-High or Mismatch Repair Deficient Cancer for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. ( 1.8 , 2.1 ) Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer (CRC) for the treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by an FDA-approved test. ( 1.9 , 2.1 ) Gastric Cancer in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.10 ) in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.10 ) Esophageal Cancer for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation either: in combination with platinum- and fluoropyrimidine-based chemotherapy for patients whose tumors express PD-L1 (CPS ≥1), or as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS ≥10) as determined by an FDA-approved test. ( 1.11 , 2.1 ) Cervical Cancer in combination with chemoradiotherapy, for the treatment of patients with locally advanced cervical cancer involving the lower third of the vagina, with or without extension to pelvic sidewall, or hydronephrosis/non-functioning kidney, or spread to adjacent pelvic organs (FIGO 2014 Stage III-IVA). ( 1.12 ) in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.12 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.12 , 2.1 ) Hepatocellular Carcinoma (HCC) for the treatment of patients with HCC secondary to hepatitis B who have received prior systemic therapy other than a PD-1/PD-L1-containing regimen. ( 1.13 ) Biliary Tract Cancer (BTC) in combination with gemcitabine and cisplatin, for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer. ( 1.14 ) Merkel Cell Carcinoma (MCC) for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma. ( 1.15 ) Renal Cell Carcinoma (RCC) in combination with axitinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) in combination with lenvatinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. ( 1.16 ) Endometrial Carcinoma in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma. ( 1.17 ) in combination with lenvatinib, for the treatment of adult patients with advanced endometrial carcinoma that is mismatch repair proficient (pMMR) or not MSI-H as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) as a single agent, for the treatment of adult patients with advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) Tumor Mutational Burden-High (TMB-H) Cancer for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. 1 ( 1.18 , 2.1 ) Limitations of Use : The safety and effectiveness of KEYTRUDA in pediatric patients with TMB-H central nervous system cancers have not been established. Cutaneous Squamous Cell Carcinoma (cSCC) for the treatment of patients with recurrent or metastatic cSCC or locally advanced cSCC that is not curable by surgery or radiation. ( 1.19 ) Triple-Negative Breast Cancer (TNBC) for the treatment of patients with high-risk early-stage TNBC in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.20 ) in combination with chemotherapy, for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA approved test. ( 1.20 , 2.1 ) Adult Classical Hodgkin Lymphoma and Adult Primary Mediastinal Large B-Cell Lymphoma: Additional Dosing Regimen of 400 mg Every 6 Weeks for use at an additional recommended dosage of 400 mg every 6 weeks for Classical Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma in adults. 2 ( 1.21 , 2.2 ) 1 This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. 2 This indication is approved under accelerated approval based on pharmacokinetic data, the relationship of exposure to efficacy, and the relationship of exposure to safety. Continued approval for this dosing may be contingent upon verification and description of clinical benefit in the confirmatory trials.|[PMDA] A drug with a new indication for the treatment of unresectable advanced or recurrent microsatellite instability-high (MSI-High) colorectal cancer. A drug with a new indication and a new dosage for the treatment of PD-L1-positive, hormone receptor-negative and HER2-negative inoperable or recurrent breast cancer. uuid:0c24afe0-6a66-4df2-9086-a4eddcca6f52 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134700 biolink:treats MONDO:0006964 PMID:41385096 "[{""id"":""uuid:4530f492-dccd-44b6-a03d-53bf06246ae0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:99940a7a-72a9-4c22-a3a3-e49d79354108"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:60c5c11f-a0e1-4789-940e-49b163bd2adc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:1774d2f5-2add-4ac0-b48e-8257bc40eff8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PARSABIV is indicated for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis.|[EMA] Parsabiv is indicated for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with chronic kidney disease (CKD) on haemodialysis therapy.|[PMDA] Drugs with a new active ingredient indicated for the treatment of secondary hyperparathyroidism in patients on hemodialysis. uuid:4ab1fd6b-5082-4b01-b09d-42838446bc06 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134700 biolink:treats MONDO:0005300 PMID:41385096 "[{""id"":""uuid:3e5a6cf7-3b0e-46dd-908c-5d53b48984db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a4e56bf8-fe29-4309-a25c-43b2bca8cc63"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:cf469063-c1df-4b70-9cb3-19b4c13cc50a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PARSABIV is indicated for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis.|[EMA] Parsabiv is indicated for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with chronic kidney disease (CKD) on haemodialysis therapy. uuid:cdcfc4f7-b062-4745-90d1-73918a09d6f9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6A901E312A biolink:treats EFO:1001480 PMID:41385096 "[{""id"":""uuid:08db1cf5-712b-4534-a8e7-924e801da398"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f85e60d3-41f1-4b0b-9ab9-ec76e22bb935"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vectibix is an epidermal growth factor receptor (EGFR) antagonist indicated for the treatment of: Adult patients with wild-type RAS (defined as wild-type in both KRAS and NRAS as determined by an FDA-approved test) Metastatic Colorectal Cancer (mCRC)*: In combination with FOLFOX for first-line treatment. ( 1 , 14.2 ) As monotherapy following disease progression after prior treatment with fluoropyrimidine, oxaliplatin, and irinotecan-containing chemotherapy. ( 1 , 14.1 ) KRAS G12C-mutated Metastatic Colorectal Cancer (mCRC)* In combination with sotorasib, for the treatment of adult patients with KRAS G12C- mutated mCRC, as determined by an FDA-approved test, who have received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. ( 1 ) *Limitations of Use: Vectibix is not indicated for the treatment of patients with RAS -mutant mCRC unless used in combination with sotorasib in KRAS G12C-mutated mCRC. Vectibix is not indicated for the treatment of patients with mCRC for whom RAS mutation status is unknown ( 1 , 2.1 , 5.2 , 12.1 , 14.3 ). uuid:25b5f91f-133a-4f70-8c95-d07b35aeb187 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85973 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:3c72a527-4632-4754-9759-44af14acaeb0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:dc806002-2c40-41d8-bd0f-3ed63edb2314"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e7cff190-9233-4202-87ca-72454bac355e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SAVAYSA is a factor Xa inhibitor indicated: To reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF) ( 1.1 ) Limitation of Use for NVAF SAVAYSA should not be used in patients with creatinine clearance (CrCL) > 95 mL/min because of increased risk of ischemic stroke compared to warfarin at the highest dose studied (60 mg) ( 1.1 ) SAVAYSA is indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5 to 10 days of initial therapy with a parenteral anticoagulant ( 1.2 )|[EMA] Prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF) with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack (TIA).Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. uuid:865886ab-257a-4f43-b06d-3d873c57f118 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85973 biolink:treats UMLS:C5400523 PMID:41385096 "[{""id"":""uuid:c3a8551a-b919-4456-ab78-83e2d6f2094f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:618730fb-ca91-46b4-b6fe-2d1eece9912f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c3832a1f-6ca8-488b-aa49-505b00e26e8b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SAVAYSA is a factor Xa inhibitor indicated: To reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF) ( 1.1 ) Limitation of Use for NVAF SAVAYSA should not be used in patients with creatinine clearance (CrCL) > 95 mL/min because of increased risk of ischemic stroke compared to warfarin at the highest dose studied (60 mg) ( 1.1 ) SAVAYSA is indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5 to 10 days of initial therapy with a parenteral anticoagulant ( 1.2 )|[PMDA] Drugs with a new dosage indicated for the prevention of ischemic stroke and systemic embolism in patients with non-valvular atrial fibrillation. uuid:caf47e3c-93c9-4092-8214-e95d50aa5829 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85973 biolink:treats MONDO:0004981 PMID:41385096 "[{""id"":""uuid:1a340c03-7614-4c39-9556-9ce4178cea9e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6a19a15f-886b-4cac-a711-020307fb86a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SAVAYSA is a factor Xa inhibitor indicated: To reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF) ( 1.1 ) Limitation of Use for NVAF SAVAYSA should not be used in patients with creatinine clearance (CrCL) > 95 mL/min because of increased risk of ischemic stroke compared to warfarin at the highest dose studied (60 mg) ( 1.1 ) SAVAYSA is indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5 to 10 days of initial therapy with a parenteral anticoagulant ( 1.2 ) uuid:78fda205-cc09-496d-b2e0-c148536c4c53 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85973 biolink:treats HP:0002625 PMID:41385096 "[{""id"":""uuid:96b8efa1-35b1-4926-ae59-92e2e609eca5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:49380bdb-b4fa-4604-8824-c1c1ac9b175f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:dbe12f67-89f4-43e5-9dfd-ebbd081296dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:9e4421ea-f8f2-4b25-845b-bc824243a595"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SAVAYSA is a factor Xa inhibitor indicated: To reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF) ( 1.1 ) Limitation of Use for NVAF SAVAYSA should not be used in patients with creatinine clearance (CrCL) > 95 mL/min because of increased risk of ischemic stroke compared to warfarin at the highest dose studied (60 mg) ( 1.1 ) SAVAYSA is indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5 to 10 days of initial therapy with a parenteral anticoagulant ( 1.2 )|[EMA] Prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF) with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack (TIA).Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.|[PMDA] Drugs with new additional indications and new dosages, and a drug with a newly-added dosage form indicated for prevention of ischemic stroke and systemic embolism in patients with non- valvular atrial fibrillation, or for the treatment and prevention of the recurrence of venous thromboembolism (deep vein thrombosis and pulmonary thromboembolism). uuid:bfedfab5-0c2d-4795-8bcc-f721b21a8cf3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85973 biolink:treats MONDO:0005279 PMID:41385096 "[{""id"":""uuid:0051fb51-8fbd-48b4-8547-58712bcf4875"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:2fcee03e-20cd-4562-9307-f7bba5473029"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:b83a3f29-3fd2-4e9a-ba04-c5976985fa01"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SAVAYSA is a factor Xa inhibitor indicated: To reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF) ( 1.1 ) Limitation of Use for NVAF SAVAYSA should not be used in patients with creatinine clearance (CrCL) > 95 mL/min because of increased risk of ischemic stroke compared to warfarin at the highest dose studied (60 mg) ( 1.1 ) SAVAYSA is indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5 to 10 days of initial therapy with a parenteral anticoagulant ( 1.2 )|[EMA] Prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF) with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack (TIA).Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. uuid:c93fc9c2-27dd-4ccf-9c71-4f092c582a7a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:420K487FSG biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:69a19b98-b97b-479e-af95-442f26f24f71"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:aee3c01a-9575-4e1a-a381-8d91a6f7684a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:60902657-6b1f-49ca-bc33-3cb6fbd86d8d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/dupixent""]},{""id"":""uuid:9c6aba92-052c-44ea-a42c-ca6cde7a4b61"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DUPIXENT is an interleukin-4 receptor alpha antagonist indicated: Atopic Dermatitis for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe AD whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids. ( 1.1 ) Asthma as an add-on maintenance treatment of adult and pediatric patients aged 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma. ( 1.2 ) Limitations of Use: Not for the relief of acute bronchospasm or status asthmaticus. ( 1.2 ) Chronic Rhinosinusitis with Nasal Polyps as an add-on maintenance treatment in adult and pediatric patients aged 12 years and older with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP). ( 1.3 ) Eosinophilic Esophagitis for the treatment of adult and pediatric patients aged 1 year and older, weighing at least 15 kg, with eosinophilic esophagitis (EoE). ( 1.4 ) Prurigo Nodularis for the treatment of adult patients with prurigo nodularis (PN). ( 1.5 ) Chronic Obstructive Pulmonary Disease as an add-on maintenance treatment of adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. ( 1.6 ) Limitations of Use: Not for the relief of acute bronchospasm. ( 1.6 ) Chronic Spontaneous Urticaria for the treatment of adult and pediatric patients aged 12 years and older with chronic spontaneous urticaria (CSU) who remain symptomatic despite H1 antihistamine treatment. ( 1.7 ) Limitations of Use: Not indicated for other forms of urticaria. ( 1.7 ) Bullous Pemphigoid for the treatment of adult patients with bullous pemphigoid (BP). ( 1.8 )|[EMA] Atopic dermatitisAdults and adolescentsDupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.Children 6 months to 11 years of ageDupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy.AsthmaAdults and adolescentsDupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (FeNO), see section 5.1, who are inadequately controlled with high dose inhaled corticosteroids (ICS) plus another medicinal product for maintenance treatment.Children 6 to 11 years of ageDupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (FeNO), who are inadequately controlled with medium to high dose inhaled corticosteroids (ICS) plus another medicinal product for maintenance treatment.Chronic rhinosinusitis with nasal polyposis (CRSwNP)Dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe CRSwNP for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control.Prurigo Nodularis (PN)Dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (PN) who are candidates for systemic therapy.Eosinophilic esophagitis (EoE)Dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.|[PMDA] A drug with a new active ingredient indicated for the treatment of atopic dermatitis in patients who have not responded sufficiently to conventional treatments. uuid:3083d4cc-13a2-42db-95c8-16b50f00cbc7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:420K487FSG biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:a01cdc15-6a21-4c66-9d49-15646e846322"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:527e9e59-041e-4288-9a09-20690ad34987"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:b3b91521-842a-487c-9256-8daa55b5fb6f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/dupixent""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] DUPIXENT is an interleukin-4 receptor alpha antagonist indicated: Atopic Dermatitis for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe AD whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids. ( 1.1 ) Asthma as an add-on maintenance treatment of adult and pediatric patients aged 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma. ( 1.2 ) Limitations of Use: Not for the relief of acute bronchospasm or status asthmaticus. ( 1.2 ) Chronic Rhinosinusitis with Nasal Polyps as an add-on maintenance treatment in adult and pediatric patients aged 12 years and older with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP). ( 1.3 ) Eosinophilic Esophagitis for the treatment of adult and pediatric patients aged 1 year and older, weighing at least 15 kg, with eosinophilic esophagitis (EoE). ( 1.4 ) Prurigo Nodularis for the treatment of adult patients with prurigo nodularis (PN). ( 1.5 ) Chronic Obstructive Pulmonary Disease as an add-on maintenance treatment of adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. ( 1.6 ) Limitations of Use: Not for the relief of acute bronchospasm. ( 1.6 ) Chronic Spontaneous Urticaria for the treatment of adult and pediatric patients aged 12 years and older with chronic spontaneous urticaria (CSU) who remain symptomatic despite H1 antihistamine treatment. ( 1.7 ) Limitations of Use: Not indicated for other forms of urticaria. ( 1.7 ) Bullous Pemphigoid for the treatment of adult patients with bullous pemphigoid (BP). ( 1.8 )|[EMA] Atopic dermatitisAdults and adolescentsDupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.Children 6 months to 11 years of ageDupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy.AsthmaAdults and adolescentsDupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (FeNO), see section 5.1, who are inadequately controlled with high dose inhaled corticosteroids (ICS) plus another medicinal product for maintenance treatment.Children 6 to 11 years of ageDupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (FeNO), who are inadequately controlled with medium to high dose inhaled corticosteroids (ICS) plus another medicinal product for maintenance treatment.Chronic rhinosinusitis with nasal polyposis (CRSwNP)Dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe CRSwNP for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control.Prurigo Nodularis (PN)Dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (PN) who are candidates for systemic therapy.Eosinophilic esophagitis (EoE)Dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy. uuid:bfbe9aaa-a8d5-415b-b71b-b4afbb14fee3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:420K487FSG biolink:treats EFO:1002029 PMID:41385096 "[{""id"":""uuid:dde3217d-ba1c-4d65-bc14-7d3d4f760042"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c056c1f0-9581-433c-b8cd-9b0efef0705a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:9b6992d0-88a2-4a30-86a8-9e4b080911b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DUPIXENT is an interleukin-4 receptor alpha antagonist indicated: Atopic Dermatitis for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe AD whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids. ( 1.1 ) Asthma as an add-on maintenance treatment of adult and pediatric patients aged 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma. ( 1.2 ) Limitations of Use: Not for the relief of acute bronchospasm or status asthmaticus. ( 1.2 ) Chronic Rhinosinusitis with Nasal Polyps as an add-on maintenance treatment in adult and pediatric patients aged 12 years and older with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP). ( 1.3 ) Eosinophilic Esophagitis for the treatment of adult and pediatric patients aged 1 year and older, weighing at least 15 kg, with eosinophilic esophagitis (EoE). ( 1.4 ) Prurigo Nodularis for the treatment of adult patients with prurigo nodularis (PN). ( 1.5 ) Chronic Obstructive Pulmonary Disease as an add-on maintenance treatment of adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. ( 1.6 ) Limitations of Use: Not for the relief of acute bronchospasm. ( 1.6 ) Chronic Spontaneous Urticaria for the treatment of adult and pediatric patients aged 12 years and older with chronic spontaneous urticaria (CSU) who remain symptomatic despite H1 antihistamine treatment. ( 1.7 ) Limitations of Use: Not indicated for other forms of urticaria. ( 1.7 ) Bullous Pemphigoid for the treatment of adult patients with bullous pemphigoid (BP). ( 1.8 )|[PMDA] A drug with a new additional indication and a new dosage for the treatment of chronic rhinosinusitis with nasal polyps (for use only in patients who have not responded sufficiently to conventional treatments). uuid:17884efc-20b0-41af-955f-b22ae6d09295 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:420K487FSG biolink:treats MONDO:0005361 PMID:41385096 "[{""id"":""uuid:a0df8c92-a0ed-4423-ab00-776918fd4ae6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:beb9efd2-8f4f-47d0-915d-7421760fc3df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:7b88aefa-cc54-44cf-b7ec-b7d817ed08a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/dupixent""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] DUPIXENT is an interleukin-4 receptor alpha antagonist indicated: Atopic Dermatitis for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe AD whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids. ( 1.1 ) Asthma as an add-on maintenance treatment of adult and pediatric patients aged 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma. ( 1.2 ) Limitations of Use: Not for the relief of acute bronchospasm or status asthmaticus. ( 1.2 ) Chronic Rhinosinusitis with Nasal Polyps as an add-on maintenance treatment in adult and pediatric patients aged 12 years and older with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP). ( 1.3 ) Eosinophilic Esophagitis for the treatment of adult and pediatric patients aged 1 year and older, weighing at least 15 kg, with eosinophilic esophagitis (EoE). ( 1.4 ) Prurigo Nodularis for the treatment of adult patients with prurigo nodularis (PN). ( 1.5 ) Chronic Obstructive Pulmonary Disease as an add-on maintenance treatment of adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. ( 1.6 ) Limitations of Use: Not for the relief of acute bronchospasm. ( 1.6 ) Chronic Spontaneous Urticaria for the treatment of adult and pediatric patients aged 12 years and older with chronic spontaneous urticaria (CSU) who remain symptomatic despite H1 antihistamine treatment. ( 1.7 ) Limitations of Use: Not indicated for other forms of urticaria. ( 1.7 ) Bullous Pemphigoid for the treatment of adult patients with bullous pemphigoid (BP). ( 1.8 )|[EMA] Atopic dermatitisAdults and adolescentsDupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.Children 6 months to 11 years of ageDupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy.AsthmaAdults and adolescentsDupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (FeNO), see section 5.1, who are inadequately controlled with high dose inhaled corticosteroids (ICS) plus another medicinal product for maintenance treatment.Children 6 to 11 years of ageDupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (FeNO), who are inadequately controlled with medium to high dose inhaled corticosteroids (ICS) plus another medicinal product for maintenance treatment.Chronic rhinosinusitis with nasal polyposis (CRSwNP)Dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe CRSwNP for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control.Prurigo Nodularis (PN)Dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (PN) who are candidates for systemic therapy.Eosinophilic esophagitis (EoE)Dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy. uuid:432e9e7a-3c23-401b-aa17-f21dc7bb84e9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:420K487FSG biolink:treats MONDO:0026045 PMID:41385096 "[{""id"":""uuid:b3f9d288-fb05-4888-95b3-9a88d3b24098"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:98eea637-0adb-4c60-9f9e-c42bf8216767"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f13b8c3f-7540-47f9-a6d9-68292b85a6fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/dupixent""]},{""id"":""uuid:99afddcf-cd86-42eb-adbd-d92797b643af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DUPIXENT is an interleukin-4 receptor alpha antagonist indicated: Atopic Dermatitis for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe AD whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids. ( 1.1 ) Asthma as an add-on maintenance treatment of adult and pediatric patients aged 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma. ( 1.2 ) Limitations of Use: Not for the relief of acute bronchospasm or status asthmaticus. ( 1.2 ) Chronic Rhinosinusitis with Nasal Polyps as an add-on maintenance treatment in adult and pediatric patients aged 12 years and older with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP). ( 1.3 ) Eosinophilic Esophagitis for the treatment of adult and pediatric patients aged 1 year and older, weighing at least 15 kg, with eosinophilic esophagitis (EoE). ( 1.4 ) Prurigo Nodularis for the treatment of adult patients with prurigo nodularis (PN). ( 1.5 ) Chronic Obstructive Pulmonary Disease as an add-on maintenance treatment of adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. ( 1.6 ) Limitations of Use: Not for the relief of acute bronchospasm. ( 1.6 ) Chronic Spontaneous Urticaria for the treatment of adult and pediatric patients aged 12 years and older with chronic spontaneous urticaria (CSU) who remain symptomatic despite H1 antihistamine treatment. ( 1.7 ) Limitations of Use: Not indicated for other forms of urticaria. ( 1.7 ) Bullous Pemphigoid for the treatment of adult patients with bullous pemphigoid (BP). ( 1.8 )|[EMA] Atopic dermatitisAdults and adolescentsDupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.Children 6 months to 11 years of ageDupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy.AsthmaAdults and adolescentsDupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (FeNO), see section 5.1, who are inadequately controlled with high dose inhaled corticosteroids (ICS) plus another medicinal product for maintenance treatment.Children 6 to 11 years of ageDupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (FeNO), who are inadequately controlled with medium to high dose inhaled corticosteroids (ICS) plus another medicinal product for maintenance treatment.Chronic rhinosinusitis with nasal polyposis (CRSwNP)Dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe CRSwNP for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control.Prurigo Nodularis (PN)Dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (PN) who are candidates for systemic therapy.Eosinophilic esophagitis (EoE)Dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.|[PMDA] Drugs with a new indication and a new dosage for the treatment of prurigo nodularis in patients who have not responded sufficiently to conventional treatments. uuid:55777cfc-11ef-4abc-abed-8a0545d7d02b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:420K487FSG biolink:treats MONDO:0005002 PMID:41385096 "[{""id"":""uuid:ce2d839b-86ed-4830-a288-04b0c8c99c59"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:77d281c8-d73c-43d3-a979-e9db41f1b7b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DUPIXENT is an interleukin-4 receptor alpha antagonist indicated: Atopic Dermatitis for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe AD whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids. ( 1.1 ) Asthma as an add-on maintenance treatment of adult and pediatric patients aged 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma. ( 1.2 ) Limitations of Use: Not for the relief of acute bronchospasm or status asthmaticus. ( 1.2 ) Chronic Rhinosinusitis with Nasal Polyps as an add-on maintenance treatment in adult and pediatric patients aged 12 years and older with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP). ( 1.3 ) Eosinophilic Esophagitis for the treatment of adult and pediatric patients aged 1 year and older, weighing at least 15 kg, with eosinophilic esophagitis (EoE). ( 1.4 ) Prurigo Nodularis for the treatment of adult patients with prurigo nodularis (PN). ( 1.5 ) Chronic Obstructive Pulmonary Disease as an add-on maintenance treatment of adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. ( 1.6 ) Limitations of Use: Not for the relief of acute bronchospasm. ( 1.6 ) Chronic Spontaneous Urticaria for the treatment of adult and pediatric patients aged 12 years and older with chronic spontaneous urticaria (CSU) who remain symptomatic despite H1 antihistamine treatment. ( 1.7 ) Limitations of Use: Not indicated for other forms of urticaria. ( 1.7 ) Bullous Pemphigoid for the treatment of adult patients with bullous pemphigoid (BP). ( 1.8 ) uuid:d6123b55-c79a-4245-8462-d4299f06f6ae biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:420K487FSG biolink:treats MONDO:0044212 PMID:41385096 "[{""id"":""uuid:dec62c87-17f8-42fc-99af-297f0b9213ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ef7aa2fa-0773-4c47-a1d6-83b10b7db231"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:4e8d2203-a789-4799-ad8f-323b2b910bf2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DUPIXENT is an interleukin-4 receptor alpha antagonist indicated: Atopic Dermatitis for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe AD whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids. ( 1.1 ) Asthma as an add-on maintenance treatment of adult and pediatric patients aged 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma. ( 1.2 ) Limitations of Use: Not for the relief of acute bronchospasm or status asthmaticus. ( 1.2 ) Chronic Rhinosinusitis with Nasal Polyps as an add-on maintenance treatment in adult and pediatric patients aged 12 years and older with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP). ( 1.3 ) Eosinophilic Esophagitis for the treatment of adult and pediatric patients aged 1 year and older, weighing at least 15 kg, with eosinophilic esophagitis (EoE). ( 1.4 ) Prurigo Nodularis for the treatment of adult patients with prurigo nodularis (PN). ( 1.5 ) Chronic Obstructive Pulmonary Disease as an add-on maintenance treatment of adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. ( 1.6 ) Limitations of Use: Not for the relief of acute bronchospasm. ( 1.6 ) Chronic Spontaneous Urticaria for the treatment of adult and pediatric patients aged 12 years and older with chronic spontaneous urticaria (CSU) who remain symptomatic despite H1 antihistamine treatment. ( 1.7 ) Limitations of Use: Not indicated for other forms of urticaria. ( 1.7 ) Bullous Pemphigoid for the treatment of adult patients with bullous pemphigoid (BP). ( 1.8 )|[PMDA] Drugs with a new indication and a new dosage for the treatment of chronic spontaneous urticaria in patients who have not responded sufficiently to conventional treatments. uuid:5269bbfc-de98-450b-a873-7cf1ac0a6d0a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:420K487FSG biolink:treats MONDO:0019082 PMID:41385096 "[{""id"":""uuid:2d90b494-6d62-4d27-8f98-2293d2792d4a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b66aa89b-b6c9-4196-a66b-ccba1783f427"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DUPIXENT is an interleukin-4 receptor alpha antagonist indicated: Atopic Dermatitis for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe AD whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids. ( 1.1 ) Asthma as an add-on maintenance treatment of adult and pediatric patients aged 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma. ( 1.2 ) Limitations of Use: Not for the relief of acute bronchospasm or status asthmaticus. ( 1.2 ) Chronic Rhinosinusitis with Nasal Polyps as an add-on maintenance treatment in adult and pediatric patients aged 12 years and older with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP). ( 1.3 ) Eosinophilic Esophagitis for the treatment of adult and pediatric patients aged 1 year and older, weighing at least 15 kg, with eosinophilic esophagitis (EoE). ( 1.4 ) Prurigo Nodularis for the treatment of adult patients with prurigo nodularis (PN). ( 1.5 ) Chronic Obstructive Pulmonary Disease as an add-on maintenance treatment of adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. ( 1.6 ) Limitations of Use: Not for the relief of acute bronchospasm. ( 1.6 ) Chronic Spontaneous Urticaria for the treatment of adult and pediatric patients aged 12 years and older with chronic spontaneous urticaria (CSU) who remain symptomatic despite H1 antihistamine treatment. ( 1.7 ) Limitations of Use: Not indicated for other forms of urticaria. ( 1.7 ) Bullous Pemphigoid for the treatment of adult patients with bullous pemphigoid (BP). ( 1.8 ) uuid:1476fc0a-e5b0-4e0d-8a2d-8a1c38a482c2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:R30772KCU0 biolink:treats MONDO:0009693 PMID:41385096 "[{""id"":""uuid:853d18b7-2f3c-4b0a-86b7-43b4ed948f42"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f00476c3-a483-44bd-af24-0fddfaa8530e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:fdbd1b87-a201-4a95-a94b-18006bbf1382"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/sarclisa""]},{""id"":""uuid:56923dcd-ef83-4511-86bd-9742d1396988"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SARCLISA is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least 2 prior therapies including lenalidomide and a proteasome inhibitor. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of therapy. in combination with bortezomib, lenalidomide, and dexamethasone, for the treatment of adult patients with newly diagnosed multiple myeloma who are not eligible for autologous stem cell transplant (ASCT).|[EMA] Sarclisa is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (MM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (PI) and have demonstrated disease progression on the last therapy.in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.1).|[PMDA] Drugs with a new active ingredient indicated for the treatment of relapsed or refractory multiple myeloma. uuid:7408cc69-4e4f-4ae7-8ffc-d806102758e0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2637 biolink:treats MONDO:0005230 PMID:41385096 "[{""id"":""uuid:9a24770d-03ff-472f-afef-d818d39b2175"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bb3020e6-3559-464a-a83e-a6fc8a38d3b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amikacin Sulfate Injection USP is indicated in the short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria, including Pseudomonas species, Escherichia coli , species of indole-positive and indole-negative Proteus , Providencia species, Klebsiella-Enterobacter-Serratia species, and Acinetobacter ( Mima-Herellea ) species. Clinical studies have shown Amikacin Sulfate Injection USP to be effective in bacterial septicemia (including neonatal sepsis); in serious infections of the respiratory tract, bones and joints, central nervous system (including meningitis) and skin and soft tissue; intra-abdominal infections (including peritonitis); and in burns and post-operative infections (including post-vascular surgery). Clinical studies have shown amikacin also to be effective in serious complicated and recurrent urinary tract infections due to these organisms. Aminoglycosides, including Amikacin Sulfate Injection USP are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics having less potential toxicity. Bacteriologic studies should be performed to identify causative organisms and their susceptibilities to amikacin. Amikacin may be considered as initial therapy in suspected Gram-negative infections and therapy may be instituted before obtaining the results of susceptibility testing. Clinical trials demonstrated that amikacin was effective in infections caused by gentamicin and/or tobramycin-resistant strains of Gram-negative organisms, particularly Proteus rettgeri , Providencia stuartii , Serratia marcescens , and Pseudomonas aeruginosa . The decision to continue therapy with the drug should be based on results of the susceptibility tests, the severity of the infection, the response of the patient and the important additional considerations contained in the WARNINGS box above. Amikacin has also been shown to be effective in staphylococcal infections and may be considered as initial therapy under certain conditions in the treatment of known or suspected staphylococcal disease such as, severe infections where the causative organism may be either a Gram-negative bacterium or a staphylococcus, infections due to susceptible strains of staphylococci in patients allergic to other antibiotics, and in mixed staphylococci/Gram-negative infections. In certain severe infections such as neonatal sepsis, concomitant therapy with a penicillin-type drug may be indicated because of the possibility of infections due to Gram-positive organisms such as streptococci or pneumococci. To reduce the development of drug-resistant bacteria and maintain the effectiveness of amikacin and other antibacterial drugs, amikacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:2627e0e2-77f3-4ff1-a29a-9eeb36694dbb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2055806 biolink:treats MONDO:0004951 PMID:41385096 "[{""id"":""uuid:216648f1-b887-48a3-9f89-f072a984c8ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2c47f772-8f5b-47b9-a15b-27f2f735069c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELSTRIGO ® is indicated as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg: with no prior antiretroviral treatment history, OR to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no history of treatment failure and no known substitutions associated with resistance to the individual components of DELSTRIGO [see Clinical Studies (14) ] . uuid:04623982-3a17-4c0f-8159-736ac07f444c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:81579 biolink:treats MONDO:0020725 PMID:41385096 "[{""id"":""uuid:95a8a337-7e9c-4837-a827-51d943b51c08"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:869b004d-b8dd-4877-8f49-648520da5ce2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RETACRIT is an erythropoiesis-stimulating agent (ESA) indicated for: • Treatment of anemia due to o Chronic Kidney Disease (CKD) in patients on dialysis and not on dialysis ( 1.1 ). o Zidovudine in patients with Human Immunodeficiency Virus (HIV) infection ( 1.2 ). o The effects of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy ( 1.3 ). • Reduction of allogeneic red blood cell (RBC) transfusions in patients undergoing elective, noncardiac, nonvascular surgery ( 1.4 ). Limitations of Use RETACRIT has not been shown to improve quality of life, fatigue, or patient well-being ( 1.5 ). RETACRIT is not indicated for use: • In patients with cancer receiving hormonal agents, biologic products, or radiotherapy, unless also receiving concomitant myelosuppressive chemotherapy ( 1.5 ). • In patients with cancer receiving myelosuppressive chemotherapy when the anticipated outcome is cure ( 1.5 ). • In patients with cancer receiving myelosuppressive chemotherapy in whom the anemia can be managed by transfusion ( 1.5 ). • In patients scheduled for surgery who are willing to donate autologous blood ( 1.5 ). • In patients undergoing cardiac or vascular surgery ( 1.5 ). • As a substitute for RBC transfusions in patients who require immediate correction of anemia ( 1.5 ). uuid:f15bd97e-4bc4-45cc-b25c-e9ffe1d14e77 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:90ZX3Q3FR7 biolink:treats UMLS:C0406317 PMID:41385096 "[{""id"":""uuid:f6ef1304-8f9f-444c-9dd2-08bbefe70847"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:73215d57-0589-47e1-80a9-ee576870d172"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:4e756adc-3927-4c7a-bda3-df0e07cdc536"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SKYRIZI is an interleukin-23 antagonist indicated for the treatment of: moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. ( 1.1 ) active psoriatic arthritis in adults. ( 1.2 ) moderately to severely active Crohn's disease in adults. ( 1.3 ) moderately to severely active ulcerative colitis in adults. ( 1.4 )|[PMDA] A drug with a new active ingredient indicated for the treatment of plaque psoriasis, psoriatic arthritis, pustular psoriasis and erythrodermic psoriasis in patients who have not responded sufficiently to conventional therapies. uuid:b343d4dc-a36e-4e05-a7c1-f1e652cbd0ad biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:90ZX3Q3FR7 biolink:treats MONDO:0011849 PMID:41385096 "[{""id"":""uuid:c9599d51-0fde-4521-80b2-6f98a39f4ed6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:20c90bf7-3adc-48fd-b74b-d61b51427c1e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:8393b46f-5993-4919-aaa0-223300e707e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/skyrizi""]},{""id"":""uuid:8615169a-02a8-410d-91f9-f75925e09ee7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SKYRIZI is an interleukin-23 antagonist indicated for the treatment of: moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. ( 1.1 ) active psoriatic arthritis in adults. ( 1.2 ) moderately to severely active Crohn's disease in adults. ( 1.3 ) moderately to severely active ulcerative colitis in adults. ( 1.4 )|[EMA] Plaque PsoriasisSkyrizi is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.Psoriatic ArthritisSkyrizi, alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (DMARDs).Crohn's diseaseSkyrizi is indicated for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.|[PMDA] A drug with a new active ingredient indicated for the treatment of plaque psoriasis, psoriatic arthritis, pustular psoriasis and erythrodermic psoriasis in patients who have not responded sufficiently to conventional therapies. uuid:4cecd6d4-36c4-4bf1-b017-7df2871ea251 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:90ZX3Q3FR7 biolink:treats MONDO:0005011 PMID:41385096 "[{""id"":""uuid:2dcb15a8-2d0d-408f-8474-de176005e110"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f6e10b8d-ecf7-4736-82b2-6f4a3042d3a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:309cb61f-7309-41a9-bfb2-c26ab3081eb4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/skyrizi""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] SKYRIZI is an interleukin-23 antagonist indicated for the treatment of: moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. ( 1.1 ) active psoriatic arthritis in adults. ( 1.2 ) moderately to severely active Crohn's disease in adults. ( 1.3 ) moderately to severely active ulcerative colitis in adults. ( 1.4 )|[EMA] Plaque PsoriasisSkyrizi is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.Psoriatic ArthritisSkyrizi, alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (DMARDs).Crohn's diseaseSkyrizi is indicated for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy. uuid:e374b11c-e9ec-4df7-a2c8-74e4fcb25a5d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:90ZX3Q3FR7 biolink:treats MONDO:0005101 PMID:41385096 "[{""id"":""uuid:418c2f2e-1617-411b-9859-5345b3820b48"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:56250c9b-cbb8-4063-b8b9-c3e8a2d171a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SKYRIZI is an interleukin-23 antagonist indicated for the treatment of: moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. ( 1.1 ) active psoriatic arthritis in adults. ( 1.2 ) moderately to severely active Crohn's disease in adults. ( 1.3 ) moderately to severely active ulcerative colitis in adults. ( 1.4 ) uuid:e8201755-f43b-4d2b-99db-53cefedbe39e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135351 biolink:treats MONDO:0005180 PMID:41385096 "[{""id"":""uuid:c79bf42f-94ca-4e71-82fb-2e2710c515af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c1424a0b-f4ac-4105-b1a2-633c2fd7b6d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:2780cafb-f8ca-4c31-8b74-c983ffdb22f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/leganto""]},{""id"":""uuid:db39a747-4b1f-40f1-a873-d566da1d1954"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NEUPRO is a dopamine agonist indicated for the treatment of: Parkinson's disease ( 1.1 ) Moderate-to-severe primary Restless Legs Syndrome ( 1.2 )|[EMA] Parkinson's disease: Neupro is indicated for the treatment of the signs and symptoms of early-stage idiopathic Parkinson's disease as monotherapy (i.e. without levodopa) or in combination with levodopa, i.e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end of dose or 'on-off' fluctuations).Restless-legs syndrome: Neupro is indicated for the symptomatic treatment of moderate to severe idiopathic restless-legs syndrome in adults.|[PMDA] [2] Drugs with a new active ingredient indicated for the treatment of Parkinson's disease and moderate to severe idiopathic restless legs syndrome. [3] [4] Drugs with a new active ingredient indicated for the treatment of Parkinson's disease. uuid:67974f12-be5e-46d3-8dc3-ba41ed4e48d8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135351 biolink:treats MONDO:0005391 PMID:41385096 "[{""id"":""uuid:623c5e45-9929-4e75-9cbf-af986e2562ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2106c1e1-95f4-40bd-98fd-8379d9380e8c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:49d9bfb9-a55c-400e-91f8-0e7c04c16142"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/leganto""]},{""id"":""uuid:614e6f1a-f13b-4294-b94e-d0d08025657b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NEUPRO is a dopamine agonist indicated for the treatment of: Parkinson's disease ( 1.1 ) Moderate-to-severe primary Restless Legs Syndrome ( 1.2 )|[EMA] Parkinson's disease: Neupro is indicated for the treatment of the signs and symptoms of early-stage idiopathic Parkinson's disease as monotherapy (i.e. without levodopa) or in combination with levodopa, i.e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end of dose or 'on-off' fluctuations).Restless-legs syndrome: Neupro is indicated for the symptomatic treatment of moderate to severe idiopathic restless-legs syndrome in adults.|[PMDA] [2] Drugs with a new active ingredient indicated for the treatment of Parkinson's disease and moderate to severe idiopathic restless legs syndrome. [3] [4] Drugs with a new active ingredient indicated for the treatment of Parkinson's disease. uuid:b736b5f0-fc5a-4366-90d9-8f2f99b777c4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:25187 biolink:treats MONDO:0005984 PMID:41385096 "[{""id"":""uuid:bd161e8b-2439-4bc0-adf2-efab88527b11"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b9a20602-faee-4e2f-92d8-60f35241ef83"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clotrimazole and Betamethasone Dipropionate Cream is a combination of an azole antifungal and corticosteroid and is indicated for the topical treatment of symptomatic inflammatory tinea pedis, tinea cruris, and tinea corporis due to Epidermophyton floccosum , Trichophyton mentagrophytes , and Trichophyton rubrum in patients 17 years and older. uuid:a7433e82-7448-4192-ae9c-c68d54dc8ac8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:25187 biolink:treats MONDO:0001405 PMID:41385096 "[{""id"":""uuid:99b56da3-4360-4403-9e0b-f29182a15f31"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:841d3a81-44cf-4373-91f6-dd63d671ef15"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clotrimazole and Betamethasone Dipropionate Cream is a combination of an azole antifungal and corticosteroid and is indicated for the topical treatment of symptomatic inflammatory tinea pedis, tinea cruris, and tinea corporis due to Epidermophyton floccosum , Trichophyton mentagrophytes , and Trichophyton rubrum in patients 17 years and older. uuid:02960c08-67a8-4bde-8f56-5222d477c093 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:25187 biolink:treats MONDO:0001461 PMID:41385096 "[{""id"":""uuid:4a468a2d-6b0b-40c5-bb9b-1fddc346d121"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e8aecec0-6af3-4ffe-ace2-9555fad5d087"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clotrimazole and Betamethasone Dipropionate Cream is a combination of an azole antifungal and corticosteroid and is indicated for the topical treatment of symptomatic inflammatory tinea pedis, tinea cruris, and tinea corporis due to Epidermophyton floccosum , Trichophyton mentagrophytes , and Trichophyton rubrum in patients 17 years and older. uuid:51930864-e681-47da-92f5-c98ef09fd88e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:0CA0VSF91Y biolink:treats MONDO:0005340 PMID:41385096 "[{""id"":""uuid:a457c144-4982-4597-9ee8-ea9fbd49e735"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9009ab93-9166-4798-8e29-eb4fd7549ec4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LEQSELVI™ is indicated for the treatment of adult patients with severe alopecia areata. Limitations of Use LEQSELVI is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, cyclosporine, or other potent immunosuppressants. uuid:2d888cea-c130-4900-b25c-050bcb3b6c0a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6741 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:edb2a7fb-cb94-4fab-93b9-c96edff13cdb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ec906fb4-7595-4323-8ba4-b37038ce78dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XIFYRM is indicated for use in adults for the management of moderate-to-severe pain, alone or in combination with non-NSAID analgesics. Limitation of Use Because of delayed onset of analgesia, XIFYRM alone is not recommended for use when rapid onset of analgesia is required. uuid:03004d6e-7283-4fa1-b264-4a168dd6f83a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C5670521 biolink:treats MONDO:0001577 PMID:41385096 "[{""id"":""uuid:a76cbf70-7b35-4faa-8b73-ddaa1f694159"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c0c0f9d4-0abb-43ee-8f60-e235c8633c7b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ENFLONSIA is indicated for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants who are born during or entering their first RSV season. DRUGBANK:DB18877 uuid:62901629-2ba3-4e69-8af4-b3e14bc8a49a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:65347 biolink:treats UMLS:C5577628 PMID:41385096 "[{""id"":""uuid:ceda5e5c-3b4c-4171-bbbf-bcc036b56e90"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:46393d33-f55c-4737-b1c8-cef686a8273d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Kyprolis is a proteasome inhibitor that is indicated: for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with Lenalidomide and dexamethasone; or Dexamethasone; or Daratumumab and dexamethasone; or Daratumumab and hyaluronidase-fihj and dexamethasone; or Isatuximab and dexamethasone. ( 1 , 14 ) as a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy. ( 1 , 14 ) uuid:c722919c-c043-48ac-8b99-2138e1912678 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:65347 biolink:treats UMLS:C4551538 PMID:41385096 "[{""id"":""uuid:1df2cc30-dec1-429c-9a54-a81c40837ca2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b83a3ba2-a629-4fbc-af5d-4e890070a371"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Kyprolis is a proteasome inhibitor that is indicated: for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with Lenalidomide and dexamethasone; or Dexamethasone; or Daratumumab and dexamethasone; or Daratumumab and hyaluronidase-fihj and dexamethasone; or Isatuximab and dexamethasone. ( 1 , 14 ) as a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy. ( 1 , 14 ) uuid:84aa2c91-85b1-4f63-9617-11c1b36792a5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2682677 biolink:treats MONDO:0004200 PMID:41385096 "[{""id"":""uuid:457bf212-a456-4c08-8b48-c79647407263"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2e546467-dd00-4352-bcbd-bcc4a392e1bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ANKTIVA in combination with Bacillus Calmette-Guérin (BCG) is indicated for the treatment of adult patients with BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. uuid:0c4a9f59-daed-46d0-9c5a-ad90cb9ccd97 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2682677 biolink:treats MONDO:0004641 PMID:41385096 "[{""id"":""uuid:c63a2119-7c5f-4950-912c-610f64be3d6e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2f1b26ae-49a8-40f1-a07d-28686693392a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ANKTIVA in combination with Bacillus Calmette-Guérin (BCG) is indicated for the treatment of adult patients with BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. uuid:c1cc44bf-b8d6-47b5-ab3c-d5f4ad8f3609 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:90Z2UF0E52 biolink:treats UMLS:C0581126 PMID:41385096 "[{""id"":""uuid:0a015279-8b84-4bb2-8b52-d1aac3ddd5d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:50fa7651-197e-4084-8662-e8389bec9a19"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NUCALA is an interleukin-5 (IL-5) antagonist monoclonal antibody (IgG1 kappa) indicated for: • Add-on maintenance treatment of adult and pediatric patients aged 6 years and older with severe asthma and with an eosinophilic phenotype. ( 1.1 ) • Add-on maintenance treatment of adult patients aged 18 years and older with chronic rhinosinusitis with nasal polyps (CRSwNP). ( 1.2 ) • Add-on maintenance treatment of adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. ( 1.3 ) • The treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). ( 1.4 ) • The treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) for greater than or equal to 6 months without an identifiable non-hematologic secondary cause. ( 1.5 ) Limitations of use: Not for relief of acute bronchospasm or status asthmaticus. ( 1.1 , 1.3 ) uuid:259a4518-b9f3-4196-9a27-4e5c0a074202 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:90Z2UF0E52 biolink:treats EFO:1002029 PMID:41385096 "[{""id"":""uuid:2fd3f772-4255-472f-8b2b-2b9aeb299f0d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c10a169b-9ce4-448c-96fa-73ecbe4abed6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NUCALA is an interleukin-5 (IL-5) antagonist monoclonal antibody (IgG1 kappa) indicated for: • Add-on maintenance treatment of adult and pediatric patients aged 6 years and older with severe asthma and with an eosinophilic phenotype. ( 1.1 ) • Add-on maintenance treatment of adult patients aged 18 years and older with chronic rhinosinusitis with nasal polyps (CRSwNP). ( 1.2 ) • Add-on maintenance treatment of adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. ( 1.3 ) • The treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). ( 1.4 ) • The treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) for greater than or equal to 6 months without an identifiable non-hematologic secondary cause. ( 1.5 ) Limitations of use: Not for relief of acute bronchospasm or status asthmaticus. ( 1.1 , 1.3 ) uuid:244ec78d-7113-4951-bcb7-d00ff61a8507 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:90Z2UF0E52 biolink:treats MONDO:0005002 PMID:41385096 "[{""id"":""uuid:6897bb56-bb36-4cee-b06f-4e797d158f32"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c432f153-6230-487e-9ad8-44e1547ec6b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NUCALA is an interleukin-5 (IL-5) antagonist monoclonal antibody (IgG1 kappa) indicated for: • Add-on maintenance treatment of adult and pediatric patients aged 6 years and older with severe asthma and with an eosinophilic phenotype. ( 1.1 ) • Add-on maintenance treatment of adult patients aged 18 years and older with chronic rhinosinusitis with nasal polyps (CRSwNP). ( 1.2 ) • Add-on maintenance treatment of adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. ( 1.3 ) • The treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). ( 1.4 ) • The treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) for greater than or equal to 6 months without an identifiable non-hematologic secondary cause. ( 1.5 ) Limitations of use: Not for relief of acute bronchospasm or status asthmaticus. ( 1.1 , 1.3 ) uuid:4911dd9c-b471-4388-9083-60cbcb6c9360 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:90Z2UF0E52 biolink:treats MONDO:0015943 PMID:41385096 "[{""id"":""uuid:c1fe1d73-cc1e-430e-a86e-f95c76e7f24c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:36bef6b7-16ba-4258-89eb-3568990b99fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:dd3dfaf3-4c2f-4a6b-8008-88f26351c354"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/nucala""]},{""id"":""uuid:fe4825fb-af64-45d8-9f6a-fa89040062cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NUCALA is an interleukin-5 (IL-5) antagonist monoclonal antibody (IgG1 kappa) indicated for: • Add-on maintenance treatment of adult and pediatric patients aged 6 years and older with severe asthma and with an eosinophilic phenotype. ( 1.1 ) • Add-on maintenance treatment of adult patients aged 18 years and older with chronic rhinosinusitis with nasal polyps (CRSwNP). ( 1.2 ) • Add-on maintenance treatment of adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. ( 1.3 ) • The treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). ( 1.4 ) • The treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) for greater than or equal to 6 months without an identifiable non-hematologic secondary cause. ( 1.5 ) Limitations of use: Not for relief of acute bronchospasm or status asthmaticus. ( 1.1 , 1.3 )|[EMA] Severe eosinophilic asthmaNucala is indicated as an add-on treatment for severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older .Chronic rhinosinusitis with nasal polyps (CRSwNP)Nucala is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe CRSwNP for whom therapy with systemic corticosteroids and/or surgery do not provide adequate control.Eosinophilic granulomatosis with polyangiitis (EGPA)Nucala is indicated as an add-on treatment for patients aged 6 years and older with relapsing-remitting or refractory eosinophilic granulomatosis with polyangiitis (EGPA).Hypereosinophilic syndrome (HES)Nucala is indicated as an add-on treatment for adult patients with inadequately controlled hypereosinophilic syndrome without an identifiable non-haematologic secondary cause.|[PMDA] A drug with a new additional indication and a new dosage for the treatment of eosinophilic granulomatosis with polyangiitis in patients who have not responded sufficiently to conventional treatments. [Orphan drug] uuid:0edfd735-508a-4e21-b432-d41ef01545bf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:90Z2UF0E52 biolink:treats MONDO:0011895 PMID:41385096 "[{""id"":""uuid:6de94741-fd32-47dd-a85c-8acaf327a3d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:516307b6-11be-4cde-9365-351f7a5df483"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NUCALA is an interleukin-5 (IL-5) antagonist monoclonal antibody (IgG1 kappa) indicated for: • Add-on maintenance treatment of adult and pediatric patients aged 6 years and older with severe asthma and with an eosinophilic phenotype. ( 1.1 ) • Add-on maintenance treatment of adult patients aged 18 years and older with chronic rhinosinusitis with nasal polyps (CRSwNP). ( 1.2 ) • Add-on maintenance treatment of adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. ( 1.3 ) • The treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). ( 1.4 ) • The treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) for greater than or equal to 6 months without an identifiable non-hematologic secondary cause. ( 1.5 ) Limitations of use: Not for relief of acute bronchospasm or status asthmaticus. ( 1.1 , 1.3 ) uuid:d51cf8d7-1390-4e01-91ff-8fc407bd43b2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB16410 biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:6daa3db3-ae2f-4a5c-986e-5688ade8188c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7ce9a6a1-18ef-4c38-96d4-81884749f5ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DATROWAY is a Trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of: adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) who have received prior EGFR-directed therapy and platinum-based chemotherapy. ( 1.1 ) This indication is approved under accelerated approval based on objective response rate and duration of response [see Clinical Studies (14.1) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial. adult patients with unresectable or metastatic, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease. ( 1.2 ) uuid:f0ecf4f1-6024-4ecf-b909-1fc529524c89 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB16410 biolink:treats MONDO:0700079 PMID:41385096 "[{""id"":""uuid:ecada641-3db6-48d2-be34-1f47187ea972"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3a1cf210-e13c-4694-bc86-381c738a1ea7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DATROWAY is a Trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of: adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) who have received prior EGFR-directed therapy and platinum-based chemotherapy. ( 1.1 ) This indication is approved under accelerated approval based on objective response rate and duration of response [see Clinical Studies (14.1) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial. adult patients with unresectable or metastatic, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease. ( 1.2 ) uuid:0f1979ec-b79c-4588-8a98-bb77476b63d0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4875 biolink:treats MONDO:0019436 PMID:41385096 "[{""id"":""uuid:2357d734-5d3e-4b2e-9ee5-f871ce61b7dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2ddfe5cb-5be6-4a9f-a29d-0affc9dcae2e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Enbrel is a tumor necrosis factor (TNF) blocker indicated for the treatment of: Adult patients with: Rheumatoid Arthritis (RA) ( 1.1 ) Psoriatic Arthritis (PsA) ( 1.3 ) Ankylosing Spondylitis (AS) ( 1.4 ) Plaque Psoriasis (PsO) ( 1.5 ) Pediatric patients with: Polyarticular Juvenile Idiopathic Arthritis (pJIA), 2 years of age or older ( 1.2 ) Juvenile Psoriatic Arthritis, 2 years of age or older (JPsA) ( 1.6 ) Plaque Psoriasis, 4 years of age or older ( 1.5 ) uuid:69916573-8294-4568-9249-8911a940e404 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:122173976 biolink:treats MONDO:0002076 PMID:41385096 "[{""id"":""uuid:c873ea6b-fb79-45e6-9867-074744cfe838"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:14060682-bf78-4b73-b5f5-e246d470270c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.INDICATIONS AND USAGE 1.1 Malignant Pleural Effusion STERITALC is indicated to decrease the recurrence of malignant pleural effusions in symptomatic patients following maximal drainage of the pleural effusion. 1.2 Pneumothorax STERITALC is indicated in adults to decrease the recurrence of pneumothorax. uuid:1238dc05-403a-4709-9c01-384a051e2d3f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18050 biolink:treats MONDO:0005632 PMID:41385096 "[{""id"":""uuid:c6c3f7e7-3809-466f-9215-b325d0ce4629"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bd3840e4-e79a-413f-b76f-10d73307c9c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endari is indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years of age and older. uuid:9a3c2b0a-b9aa-4e46-a582-e5dac5cf45cf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2556801 biolink:treats MONDO:0007886 PMID:41385096 "[{""id"":""uuid:e455eb65-884d-46a4-b3cc-d723c96eeb56"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:dc8144eb-4cdf-443d-83fa-30a1bb90598c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ryeqo""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Ryeqo is indicated in adult women of reproductive age for:- treatment of moderate to severe symptoms of uterine fibroids,- symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis. uuid:236d78df-6706-42f7-8f24-152934820679 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2556801 biolink:treats MONDO:0005133 PMID:41385096 "[{""id"":""uuid:e8a97be6-a411-47d0-a060-492356b7906f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:01b9a2c3-cb3e-4b98-96f5-6d37261946ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ryeqo""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Ryeqo is indicated in adult women of reproductive age for:- treatment of moderate to severe symptoms of uterine fibroids,- symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis. uuid:33763fab-3542-44db-a5a3-d6fb0547961c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:15C2VL427D biolink:treats MONDO:0006951 PMID:41385096 "[{""id"":""uuid:6a2dc554-8976-4c4a-a9de-145574f2156a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:dc112959-57dc-4751-b9f9-3245f4db3351"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/yesafili""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Yesafili is indicated for adults for the treatment ofneovascular (wet) age-related macular degeneration (AMD) (see section 5.1),visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) (see section 5.1),visual impairment due to diabetic macular oedema (DME) (see section 5.1),visual impairment due to myopic choroidal neovascularisation (myopic CNV) (see section 5.1). uuid:324a4bd3-01e6-4845-ba53-76b72763ad11 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:15C2VL427D biolink:treats MONDO:0810000 PMID:41385096 "[{""id"":""uuid:e6d74680-c06e-4f9f-90b5-d6f5fc0526b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b874de0c-9e8a-4a28-9303-ce7ff887477f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/yesafili""]},{""id"":""uuid:cee4a15c-a350-4343-8248-d1dac61e1f86"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Yesafili is indicated for adults for the treatment ofneovascular (wet) age-related macular degeneration (AMD) (see section 5.1),visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) (see section 5.1),visual impairment due to diabetic macular oedema (DME) (see section 5.1),visual impairment due to myopic choroidal neovascularisation (myopic CNV) (see section 5.1).|[PMDA] Drugs with a new additional indication for the treatment of choroidal neovascularization in patients with pathologic myopia. uuid:9c38b56a-9085-45ab-91c9-ea517addb971 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PVI5M0M1GW biolink:treats MONDO:0011996 PMID:41385096 "[{""id"":""uuid:bc3d8d6b-d912-4e6c-8549-82d284e37812"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:dc3f2e95-e54c-43bb-a951-7ba31ec67366"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/filgrastim-hexal""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone-marrow transplantation considered to be at increased risk of prolonged severe neutropenia.The safety and efficacy of filgrastim are similar in adults and children receiving cytotoxic chemotherapy.Mobilisation of peripheral blood progenitor cells (PBPCs).In children and adults with severe congenital, cyclic, or idiopathic neutropenia with an absolute neutrophil count (ANC) of of ≤ 0.5 x 109/l, and a history of severe or recurrent infections, long-term administration of filgrastim is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.Treatment of persistent neutropenia (ANC ≤ 0.5 x 109/l), and a history of severe or recurrent infections, long-term administration of filgrastim is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.in patients with advanced HIV infection, in order to reduce the risk of bacterial infections when other therapeutic options are inappropriate. uuid:1f9fb5ce-f6c3-4e7e-b797-c4430403f68b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PVI5M0M1GW biolink:treats MONDO:0018881 PMID:41385096 "[{""id"":""uuid:e967e844-a25f-4651-a7ac-832aa96a7b11"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:cb32bae2-a090-4223-88e4-cec22eeb1417"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/filgrastim-hexal""]},{""id"":""uuid:1b0b3e11-2f1d-41e8-9808-20e572be55cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone-marrow transplantation considered to be at increased risk of prolonged severe neutropenia.The safety and efficacy of filgrastim are similar in adults and children receiving cytotoxic chemotherapy.Mobilisation of peripheral blood progenitor cells (PBPCs).In children and adults with severe congenital, cyclic, or idiopathic neutropenia with an absolute neutrophil count (ANC) of of ≤ 0.5 x 109/l, and a history of severe or recurrent infections, long-term administration of filgrastim is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.Treatment of persistent neutropenia (ANC ≤ 0.5 x 109/l), and a history of severe or recurrent infections, long-term administration of filgrastim is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.in patients with advanced HIV infection, in order to reduce the risk of bacterial infections when other therapeutic options are inappropriate.|[PMDA] Follow-on biologics indicated for mobilization of hematopoietic stem cell to peripheral blood, promotion of increase in neutrophil count at the time of hematopoietic stem cell transplantation, and the treatment of neutropenia caused by cancer chemotherapy, neutropenia which affects the treatment of human immunodeficiency virus (HIV) infection, neutropenia associated with myelodysplastic syndrome, neutropenia associated with aplastic anemia and congenital/idiopathic neutropenia. uuid:d58dcfe9-bbf8-4fb3-877e-08cfa268ae4d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PVI5M0M1GW biolink:treats MONDO:0011922 PMID:41385096 "[{""id"":""uuid:b7222de2-4e2f-410e-988d-76c136ea6d6d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:267b0bb8-f738-4b00-9254-dd26b0424f12"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/filgrastim-hexal""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone-marrow transplantation considered to be at increased risk of prolonged severe neutropenia.The safety and efficacy of filgrastim are similar in adults and children receiving cytotoxic chemotherapy.Mobilisation of peripheral blood progenitor cells (PBPCs).In children and adults with severe congenital, cyclic, or idiopathic neutropenia with an absolute neutrophil count (ANC) of of ≤ 0.5 x 109/l, and a history of severe or recurrent infections, long-term administration of filgrastim is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.Treatment of persistent neutropenia (ANC ≤ 0.5 x 109/l), and a history of severe or recurrent infections, long-term administration of filgrastim is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.in patients with advanced HIV infection, in order to reduce the risk of bacterial infections when other therapeutic options are inappropriate. uuid:85d7e66c-eb60-42f0-a0f9-6afe03018dc7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PVI5M0M1GW biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:4986dd85-82dc-4227-802b-0e59119a38e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:82f832c1-046f-4ff3-baa4-0d2240649907"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/filgrastim-hexal""]},{""id"":""uuid:67c01ded-cb98-4431-bd8a-0835b6a7dbbf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone-marrow transplantation considered to be at increased risk of prolonged severe neutropenia.The safety and efficacy of filgrastim are similar in adults and children receiving cytotoxic chemotherapy.Mobilisation of peripheral blood progenitor cells (PBPCs).In children and adults with severe congenital, cyclic, or idiopathic neutropenia with an absolute neutrophil count (ANC) of of ≤ 0.5 x 109/l, and a history of severe or recurrent infections, long-term administration of filgrastim is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.Treatment of persistent neutropenia (ANC ≤ 0.5 x 109/l), and a history of severe or recurrent infections, long-term administration of filgrastim is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.in patients with advanced HIV infection, in order to reduce the risk of bacterial infections when other therapeutic options are inappropriate.|[PMDA] Follow-on biologics indicated for mobilization of hematopoietic stem cell to peripheral blood, promotion of increase in neutrophil count at the time of hematopoietic stem cell transplantation, and the treatment of neutropenia caused by cancer chemotherapy, neutropenia which affects the treatment of human immunodeficiency virus (HIV) infection, neutropenia associated with myelodysplastic syndrome, neutropenia associated with aplastic anemia and congenital/idiopathic neutropenia. uuid:c8b2fafd-f636-44a3-8474-24d4a5785fcd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:66917 biolink:treats MONDO:0008661 PMID:41385096 "[{""id"":""uuid:641588b7-6523-4640-96e9-01f6c8b62148"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:3c43a2d0-4f61-4034-8557-708ff306eb67"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Opzelura is indicated for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age. uuid:966d589f-ce12-4e0b-8527-e6514383a740 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3A58010674 biolink:treats MONDO:0001475 PMID:41385096 "[{""id"":""uuid:b6693c9d-2b3d-4aa3-a61d-0a63ddd08be9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:205af5c4-31aa-4099-bebb-3240f9099650"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ziextenzo""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes). uuid:91322a84-654a-484e-a6ec-a8357e3c3f4d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3374 biolink:treats MONDO:0021667 PMID:41385096 "[{""id"":""uuid:ecc24894-82c0-4b0b-9d57-99bcb5d51374"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:4253d15d-770c-4f6b-ac89-56e7984047e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/qutenza""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Qutenza is indicated for the treatment of peripheral neuropathic pain in adults either alone or in combination with other medicinal products for pain. uuid:840214e0-e609-423e-9df3-c72e181def8b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3759 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:aa3d964d-9311-4b4c-95f7-793ff7393a66"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:02d70358-4215-499b-a55b-efbf3f97a7ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Clopidogrel is indicated in adults for the prevention of atherothrombotic events in:Patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. uuid:325e1951-4fa4-46d9-b8f1-7fefbb6c5b80 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3759 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:353ea5f2-0a07-40eb-b751-348e2ddbb7cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:9642a1b9-2d90-4ad4-9128-8acdfb55e9be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Clopidogrel is indicated in adults for the prevention of atherothrombotic events in:Patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. uuid:e239fea4-3f5a-4e41-9462-737224e45d29 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3759 biolink:treats MONDO:0005386 PMID:41385096 "[{""id"":""uuid:892b02db-8e07-4ad3-a7b8-2a4e885dba19"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:771a7f81-5405-4a41-9313-0389f2d3afac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Clopidogrel is indicated in adults for the prevention of atherothrombotic events in:Patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. uuid:c1d0f01a-4672-4f23-a130-ed2db85c094a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:16213489 biolink:treats MONDO:0006781 PMID:41385096 "[{""id"":""uuid:177e17c0-4ad3-4b26-af26-ad9ddcb87f8b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a53c0793-d53d-4fd6-99a0-e71e437df1c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] This medicinal product is for diagnostic use only.For in vivo diagnosis of gastroduodenal Helicobacter pylori (H. pylori) infection. uuid:99115191-5a3c-4bc9-8a5a-6f4e6dece3b9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:XZA0KB1BDQ biolink:treats MONDO:0019623 PMID:41385096 "[{""id"":""uuid:3dd226a3-19e8-47f1-843d-653ce0c22072"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:c426441c-0142-4d57-8c94-45b658c47ddb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Orladeyo is indicated for routine prevention of recurrent attacks of hereditary angioedema (HAE) in adult and adolescent patients aged 12 years and older. uuid:612b386b-153c-4151-b0e6-e5b227d30e26 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:5384HK7574 biolink:treats MONDO:0001056 PMID:41385096 "[{""id"":""uuid:03ac3252-71f8-4694-949d-ccb01ee666df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c48c871c-a1e2-414c-9506-1cb21eaafef0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ogivri""]},{""id"":""uuid:5e7c6895-1df6-4645-9443-104f8e861913"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Breast cancerMetastatic breast cancerOgivri is indicated for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC):as monotherapy for the treatment of those patients who have received at least two chemotherapy regimens for their metastatic disease. Prior chemotherapy must have included at least an anthracycline and a taxane unless patients are unsuitable for these treatments. Hormone receptor positive patients must also have failed hormonal therapy, unless patients are unsuitable for these treatmentsin combination with paclitaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease and for whom an anthracycline is not suitablein combination with docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic diseasein combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive MBC, not previously treated with trastuzumab.Early breast cancer Ogivri is indicated for the treatment of adult patients with HER2 positive early breast cancer (EBC):following surgery, chemotherapy (neoadjuvant or adjuvant) and radiotherapy (if applicable)following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxelin combination with adjuvant chemotherapy consisting of docetaxel and carboplatin.in combination with neoadjuvant chemotherapy followed by adjuvant Ogivri therapy, for locally advanced (including inflammatory) disease or tumours > 2 cm in diameter.Ogivri should only be used in patients with metastatic or EBC whose tumours have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.Metastatic gastric cancerOgivri in combination with capecitabine or 5-fluorouracil and cisplatin is indicated for the treatment of adult patients with HER2 positive metastatic adenocarcinoma of the stomach or gastroesophageal junction who have not received prior anti-cancer treatment for their metastatic disease.Ogivri should only be used in patients with metastatic gastric cancer (MGC) whose tumours have HER2 overexpression as defined by IHC2+ and a confirmatory SISH or FISH result, or by an IHC 3+ result. Accurate and validated assay methods should be used.|[PMDA] A drug with a new indication and a new dosage for the treatment of unresectable advanced or recurrent HER2- positive gastric cancer that has progressed after cancer chemotherapy. [SAKIGAKE designation] uuid:6c5e5470-85db-45f9-8862-7daa17167513 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7XL5ISS668 biolink:treats MONDO:0004952 PMID:41385096 "[{""id"":""uuid:08a763e0-7c5e-4078-ad29-b3b98b90f210"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:88797e61-93ed-4bd0-890d-0405d3d55c6e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/adcetris""]},{""id"":""uuid:b474d4cc-66c0-4a35-9572-7e0197ba5458"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Hodgkin lymphomaAdcetris is indicated for adult patients with previously untreated CD30+ Stage IV Hodgkin lymphoma (HL) in combination with doxorubicin, vinblastine and dacarbazine (AVD).Adcetris is indicated for the treatment of adult patients with CD30+ HL at increased risk of relapse or progression following autologous stem cell transplant (ASCT).Adcetris is indicated for the treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL):following ASCT, orfollowing at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option.Systemic anaplastic large cell lymphomaAdcetris in combination with cyclophosphamide, doxorubicin and prednisone (CHP) is indicated for adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL).Adcetris is indicated for the treatment of adult patients with relapsed or refractory sALCL.Cutaneous T cell lymphomaAdcetris is indicated for the treatment of adult patients with CD30+ cutaneous T cell lymphoma (CTCL) after at least 1 prior systemic therapy.|[PMDA] A drug with a new additional pediatric dosage indicated for the treatment of CD30-positive Hodgkin's lymphoma. [Orphan drug] uuid:b35b2662-17a0-4292-b208-b65cbd443892 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7XL5ISS668 biolink:treats MONDO:0020325 PMID:41385096 "[{""id"":""uuid:6ad945b0-9cd7-46f9-a73d-2d26097fe13e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:13b0f1a4-3c7d-442c-8aea-7a4e0fb95fa8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/adcetris""]},{""id"":""uuid:87c30aaf-8910-4a92-a567-785a9654be1c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Hodgkin lymphomaAdcetris is indicated for adult patients with previously untreated CD30+ Stage IV Hodgkin lymphoma (HL) in combination with doxorubicin, vinblastine and dacarbazine (AVD).Adcetris is indicated for the treatment of adult patients with CD30+ HL at increased risk of relapse or progression following autologous stem cell transplant (ASCT).Adcetris is indicated for the treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL):following ASCT, orfollowing at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option.Systemic anaplastic large cell lymphomaAdcetris in combination with cyclophosphamide, doxorubicin and prednisone (CHP) is indicated for adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL).Adcetris is indicated for the treatment of adult patients with relapsed or refractory sALCL.Cutaneous T cell lymphomaAdcetris is indicated for the treatment of adult patients with CD30+ cutaneous T cell lymphoma (CTCL) after at least 1 prior systemic therapy.|[PMDA] A drug with a new active ingredient indicated for the treatment of relapsed or refractory CD30- positive Hodgkin’s lymphoma and anaplastic large- cell lymphoma. [Orphan drug] uuid:f843c705-d6c0-4adc-8250-3d96c1ccceda biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7XL5ISS668 biolink:treats MONDO:0015758 PMID:41385096 "[{""id"":""uuid:ba299c5a-2191-49e2-9ffb-40d2c554ba78"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a5c7d989-117c-4b64-adef-353d5faea1be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/adcetris""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Hodgkin lymphomaAdcetris is indicated for adult patients with previously untreated CD30+ Stage IV Hodgkin lymphoma (HL) in combination with doxorubicin, vinblastine and dacarbazine (AVD).Adcetris is indicated for the treatment of adult patients with CD30+ HL at increased risk of relapse or progression following autologous stem cell transplant (ASCT).Adcetris is indicated for the treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL):following ASCT, orfollowing at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option.Systemic anaplastic large cell lymphomaAdcetris in combination with cyclophosphamide, doxorubicin and prednisone (CHP) is indicated for adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL).Adcetris is indicated for the treatment of adult patients with relapsed or refractory sALCL.Cutaneous T cell lymphomaAdcetris is indicated for the treatment of adult patients with CD30+ cutaneous T cell lymphoma (CTCL) after at least 1 prior systemic therapy. uuid:961913ab-8511-448c-bae2-cea8e91f5f6f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:78540 biolink:treats MONDO:0005083 PMID:41385096 "[{""id"":""uuid:212ac654-4312-46e1-9e84-be52f8d2f7cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:cd4cbdb9-6899-4bd4-a2f4-86802398832a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/otezla""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Psoriatic arthritisOtezla, alone or in combination with Disease Modifying Antirheumatic Drugs (DMARDs), is indicated for the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or who have been intolerant to a prior DMARD therapy.PsoriasisOtezla is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who failed to respond to or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or psoralen and ultraviolet-A light (PUVA). uuid:2f11f8f7-fff9-43f1-87b3-2725a1af4a30 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3759 biolink:treats MONDO:0006805 PMID:41385096 "[{""id"":""uuid:6286c7c7-78b5-4c03-b5af-436b6f687f64"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f5200ea0-f8ba-49fc-9460-15a5de246d58"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Secondary prevention of atherothrombotic eventsClopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from seven days until less than six months) or established peripheral arterial disease;adult patients suffering from acute coronary syndrome:non-ST-segment-elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA);ST-segment-elevation acute myocardial infarction, in combination with ASA in patients undergoing percutaneous coronary intervention (including patients undergoing a stent replacement) or medically treated patients eligible for thrombolytic/fibrinolytic therapy.In patients with moderate to high-risk Transient Ischemic Attack (TIA) or minor Ischemic Stroke (IS)Clopidogrel in combination with ASA is indicated in:Adult patients with moderate to high-risk TIA (ABCD2 score ≥4) or minor IS (NIHSS ≤3) within 24 hours of either the TIA or IS event.Prevention of atherothrombotic and thromboembolic events in atrial fibrillationIn adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin-K antagonists and who have a low bleeding risk, clopidogrel is indicated in combination with ASA for the prevention of atherothrombotic and thromboembolic events, including stroke. uuid:67de4b09-d430-4449-8607-22e2a0957bcf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3759 biolink:treats MONDO:0003674 PMID:41385096 "[{""id"":""uuid:56573fcc-c321-4e0e-bd67-a9ce1ac9801a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:42e83c39-d3f8-45c4-94a6-194f2b808b28"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Secondary prevention of atherothrombotic eventsClopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from seven days until less than six months) or established peripheral arterial disease;adult patients suffering from acute coronary syndrome:non-ST-segment-elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA);ST-segment-elevation acute myocardial infarction, in combination with ASA in patients undergoing percutaneous coronary intervention (including patients undergoing a stent replacement) or medically treated patients eligible for thrombolytic/fibrinolytic therapy.In patients with moderate to high-risk Transient Ischemic Attack (TIA) or minor Ischemic Stroke (IS)Clopidogrel in combination with ASA is indicated in:Adult patients with moderate to high-risk TIA (ABCD2 score ≥4) or minor IS (NIHSS ≤3) within 24 hours of either the TIA or IS event.Prevention of atherothrombotic and thromboembolic events in atrial fibrillationIn adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin-K antagonists and who have a low bleeding risk, clopidogrel is indicated in combination with ASA for the prevention of atherothrombotic and thromboembolic events, including stroke. uuid:e9cb823e-861d-4b3f-a7b4-7b07e174d91a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3759 biolink:treats MONDO:0041656 PMID:41385096 "[{""id"":""uuid:e3c2c9d9-9a6a-485a-8a50-7be134a8a124"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:e8a44cba-c56f-4f49-b59f-da101a49334e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Secondary prevention of atherothrombotic eventsClopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from seven days until less than six months) or established peripheral arterial disease;adult patients suffering from acute coronary syndrome:non-ST-segment-elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA);ST-segment-elevation acute myocardial infarction, in combination with ASA in patients undergoing percutaneous coronary intervention (including patients undergoing a stent replacement) or medically treated patients eligible for thrombolytic/fibrinolytic therapy.In patients with moderate to high-risk Transient Ischemic Attack (TIA) or minor Ischemic Stroke (IS)Clopidogrel in combination with ASA is indicated in:Adult patients with moderate to high-risk TIA (ABCD2 score ≥4) or minor IS (NIHSS ≤3) within 24 hours of either the TIA or IS event.Prevention of atherothrombotic and thromboembolic events in atrial fibrillationIn adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin-K antagonists and who have a low bleeding risk, clopidogrel is indicated in combination with ASA for the prevention of atherothrombotic and thromboembolic events, including stroke. uuid:1bd34456-5982-44aa-b855-50c0108acdcd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3759 biolink:treats MONDO:0005264 PMID:41385096 "[{""id"":""uuid:84634d9c-1608-4c13-b66e-92516a75187a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:316ca63c-758f-4af8-9f83-96b08a9401df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Secondary prevention of atherothrombotic eventsClopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from seven days until less than six months) or established peripheral arterial disease;adult patients suffering from acute coronary syndrome:non-ST-segment-elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA);ST-segment-elevation acute myocardial infarction, in combination with ASA in patients undergoing percutaneous coronary intervention (including patients undergoing a stent replacement) or medically treated patients eligible for thrombolytic/fibrinolytic therapy.In patients with moderate to high-risk Transient Ischemic Attack (TIA) or minor Ischemic Stroke (IS)Clopidogrel in combination with ASA is indicated in:Adult patients with moderate to high-risk TIA (ABCD2 score ≥4) or minor IS (NIHSS ≤3) within 24 hours of either the TIA or IS event.Prevention of atherothrombotic and thromboembolic events in atrial fibrillationIn adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin-K antagonists and who have a low bleeding risk, clopidogrel is indicated in combination with ASA for the prevention of atherothrombotic and thromboembolic events, including stroke. uuid:51aed2b2-183a-4ae2-94c9-ad957c093d7f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3759 biolink:treats HP:0002140 PMID:41385096 "[{""id"":""uuid:b85e5ef4-dbb6-48bb-8288-9deba6bd3109"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:1792fc3b-0b3a-40df-92b7-55b05353b0f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Secondary prevention of atherothrombotic eventsClopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from seven days until less than six months) or established peripheral arterial disease;adult patients suffering from acute coronary syndrome:non-ST-segment-elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA);ST-segment-elevation acute myocardial infarction, in combination with ASA in patients undergoing percutaneous coronary intervention (including patients undergoing a stent replacement) or medically treated patients eligible for thrombolytic/fibrinolytic therapy.In patients with moderate to high-risk Transient Ischemic Attack (TIA) or minor Ischemic Stroke (IS)Clopidogrel in combination with ASA is indicated in:Adult patients with moderate to high-risk TIA (ABCD2 score ≥4) or minor IS (NIHSS ≤3) within 24 hours of either the TIA or IS event.Prevention of atherothrombotic and thromboembolic events in atrial fibrillationIn adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin-K antagonists and who have a low bleeding risk, clopidogrel is indicated in combination with ASA for the prevention of atherothrombotic and thromboembolic events, including stroke. uuid:1985899d-6ee3-4250-b98e-382bb96dace1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3759 biolink:treats MONDO:0004981 PMID:41385096 "[{""id"":""uuid:6fa91dca-11d2-4e8c-bd85-c028893fd23b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:efea06cb-04a9-49cb-8262-1f3df3654c22"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Secondary prevention of atherothrombotic eventsClopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from seven days until less than six months) or established peripheral arterial disease;adult patients suffering from acute coronary syndrome:non-ST-segment-elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA);ST-segment-elevation acute myocardial infarction, in combination with ASA in patients undergoing percutaneous coronary intervention (including patients undergoing a stent replacement) or medically treated patients eligible for thrombolytic/fibrinolytic therapy.In patients with moderate to high-risk Transient Ischemic Attack (TIA) or minor Ischemic Stroke (IS)Clopidogrel in combination with ASA is indicated in:Adult patients with moderate to high-risk TIA (ABCD2 score ≥4) or minor IS (NIHSS ≤3) within 24 hours of either the TIA or IS event.Prevention of atherothrombotic and thromboembolic events in atrial fibrillationIn adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin-K antagonists and who have a low bleeding risk, clopidogrel is indicated in combination with ASA for the prevention of atherothrombotic and thromboembolic events, including stroke. uuid:ef8ca61c-0d48-49b2-918f-7c73c0f7134b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134709 biolink:treats MONDO:0007147 PMID:41385096 "[{""id"":""uuid:3ec690db-6c5f-4d46-9e5c-7c6533f797cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a1d23ef9-f84b-47ce-a5f7-c526f66f59b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ozawade""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Ozawade is indicated to improve wakefulness and reduce excessive daytime sleepiness (EDS) in adult patients with obstructive sleep apnoea (OSA) uuid:da119194-2d7e-49a2-b4e9-d0c468a21404 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134709 biolink:treats MONDO:0005466 PMID:41385096 "[{""id"":""uuid:9deb3a7d-1794-4b85-a94a-4ba802100df4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:4a9e7a5a-01d7-40d9-801f-1eec266bca0e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ozawade""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Ozawade is indicated to improve wakefulness and reduce excessive daytime sleepiness (EDS) in adult patients with obstructive sleep apnoea (OSA) uuid:36acfb0f-d625-45a2-9282-dabfb5191752 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PP0SHH6V16 biolink:treats MONDO:0021661 PMID:41385096 "[{""id"":""uuid:11962f32-5031-454a-8cc1-e1e59e8a73f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f8d38d9f-ceb7-476a-aba8-83cc48037489"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/praluent""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Primary hypercholesterolaemia and mixed dyslipidaemiaPraluent is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:in combination with a statin or statin with other lipid lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin or,alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.Established atherosclerotic cardiovascular disease Praluent is indicated in adults with established atherosclerotic cardiovascular disease to reduce cardiovascular risk by lowering LDL-C levels, as an adjunct to correction of other risk factors:in combination with the maximum tolerated dose of a statin with or without other lipid-lowering therapies or,alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.For study results with respect to effects on LDL-C, cardiovascular events and populations studied see section 5.1. uuid:5807b141-86d1-4967-a7b8-4aa90e7f2d3c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation MESH:C000723076 biolink:treats MONDO:0018874 PMID:41385096 "[{""id"":""uuid:26d51140-90e3-4f11-998a-f59734e80414"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a94f2f5c-0e81-453e-8eee-425b5c7cc7fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Inaqovi is indicated as monotherapy for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for standard induction chemotherapy. uuid:239d6f00-853f-4885-92f8-5780cc017f29 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:FYS6T7F842 biolink:treats MONDO:0019437 PMID:41385096 "[{""id"":""uuid:f3ceb12e-96c6-4223-a281-623c4af5856c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:fb169538-8228-4749-8724-a4bb72b6f7fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/hulio""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Rheumatoid arthritisYuflyma in combination with methotrexate, is indicated for:- the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate.- the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.Yuflyma can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.Adalimumab has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate.Juvenile idiopathic arthritisPolyarticular juvenile idiopathic arthritisYuflyma in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). Yuflyma can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate (for the efficacy in monotherapy see section 5.1). Adalimumab has not been studied in patients aged less than 2 years.Enthesitis-related arthritisYuflyma is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy (see section 5.1).Axial spondyloarthritisAnkylosing spondylitis (AS)Yuflyma is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy.Axial spondyloarthritis without radiographic evidence of ASYuflyma is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of AS but with objective signs of inflammation by elevated CRP and/or MRI, who have had an inadequate response to, or are intolerant to non-steroidal anti-inflammatory drugs (NSAIDs).Psoriatic arthritisYuflyma is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate.Adalimumab has been shown to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease (see section 5.1) and to improve physical function.PsoriasisYuflyma is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy.Paediatric plaque psoriasisYuflyma is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies.Hidradenitis suppurativa (HS)Yuflyma is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults and adolescents from 12 years of age with an inadequate response to conventional systemic HS therapy (see sections 5.1 and 5.2).Crohn’s diseaseYuflyma is indicated for treatment of moderately to severely active Crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies.Paediatric Crohn's diseaseYuflyma is indicated for the treatment of moderately to severely active Crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or have contraindications for such therapies.Ulcerative colitisYuflyma is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.Paediatric ulcerative colitisYuflyma is indicated for the treatment of moderately to severely active ulcerative colitis in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including corticosteroids and/or 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.UveitisYuflyma is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid- sparing, or in whom corticosteroid treatment is inappropriate.Paediatric uveitisYuflyma is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate. uuid:f33a8753-ea45-4c75-8652-f0efb26a8ac0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:FYS6T7F842 biolink:treats MONDO:0005083 PMID:41385096 "[{""id"":""uuid:22400609-fe0d-49c2-a370-edc1f6d0ed87"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:0872e244-aa9d-4ab8-add8-9fb41289587d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/hulio""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Rheumatoid arthritisYuflyma in combination with methotrexate, is indicated for:- the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate.- the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.Yuflyma can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.Adalimumab has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate.Juvenile idiopathic arthritisPolyarticular juvenile idiopathic arthritisYuflyma in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). Yuflyma can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate (for the efficacy in monotherapy see section 5.1). Adalimumab has not been studied in patients aged less than 2 years.Enthesitis-related arthritisYuflyma is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy (see section 5.1).Axial spondyloarthritisAnkylosing spondylitis (AS)Yuflyma is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy.Axial spondyloarthritis without radiographic evidence of ASYuflyma is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of AS but with objective signs of inflammation by elevated CRP and/or MRI, who have had an inadequate response to, or are intolerant to non-steroidal anti-inflammatory drugs (NSAIDs).Psoriatic arthritisYuflyma is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate.Adalimumab has been shown to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease (see section 5.1) and to improve physical function.PsoriasisYuflyma is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy.Paediatric plaque psoriasisYuflyma is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies.Hidradenitis suppurativa (HS)Yuflyma is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults and adolescents from 12 years of age with an inadequate response to conventional systemic HS therapy (see sections 5.1 and 5.2).Crohn’s diseaseYuflyma is indicated for treatment of moderately to severely active Crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies.Paediatric Crohn's diseaseYuflyma is indicated for the treatment of moderately to severely active Crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or have contraindications for such therapies.Ulcerative colitisYuflyma is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.Paediatric ulcerative colitisYuflyma is indicated for the treatment of moderately to severely active ulcerative colitis in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including corticosteroids and/or 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.UveitisYuflyma is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid- sparing, or in whom corticosteroid treatment is inappropriate.Paediatric uveitisYuflyma is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate. uuid:849686bd-f63f-4237-8595-bbb8fe6f7ea6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63916 biolink:treats MONDO:0001999 PMID:41385096 "[{""id"":""uuid:cfaa1e29-e966-42fb-a0e7-9d80526c6ec4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d58ee4a4-af29-44d7-a215-dc50532a17bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ventavis""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of patients with primary pulmonary hypertension, classified as New York Heart Association functional class III, to improve exercise capacity and symptoms. uuid:d3e1bb7d-3294-47ad-892d-bbf2b4d87969 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2S9ZZM9Q9V biolink:treats MONDO:0041447 PMID:41385096 "[{""id"":""uuid:6906bc81-7311-41d3-afdf-87f167250704"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:3dca5767-8b99-455d-b2fd-d38b09236150"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/abevmy""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Abevmy in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum.Abevmy in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. For further information as to human epidermal growth factor receptor 2 (HER2) status, please refer to section 5.1.Abevmy in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. Patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with Abevmy in combination with capecitabine. For further information as to HER2 status, please refer to section 5.1.Abevmy, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology.Abevmy, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating mutations (see section 5.1).Abevmy in combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer.Abevmy, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (International Federation of Gynecology and Obstetrics [FIGO] stages III B, III C and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5.1).Abevmy, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor–targeted agents.Abevmy in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor–targeted agents (see section 5.1).Abevmy, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.1). uuid:1eda9de7-3a0d-4d06-a4b6-570b1a890b64 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2S9ZZM9Q9V biolink:treats MONDO:0005086 PMID:41385096 "[{""id"":""uuid:ca5e5321-4989-43a1-a74c-2c1d26f01bd5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f3f2f6c4-ed7c-4c38-aea8-72439300c3c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/abevmy""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Abevmy in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum.Abevmy in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. For further information as to human epidermal growth factor receptor 2 (HER2) status, please refer to section 5.1.Abevmy in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. Patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with Abevmy in combination with capecitabine. For further information as to HER2 status, please refer to section 5.1.Abevmy, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology.Abevmy, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating mutations (see section 5.1).Abevmy in combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer.Abevmy, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (International Federation of Gynecology and Obstetrics [FIGO] stages III B, III C and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5.1).Abevmy, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor–targeted agents.Abevmy in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor–targeted agents (see section 5.1).Abevmy, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.1). uuid:b968af55-29fd-40e8-8084-5b30ff568b66 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2S9ZZM9Q9V biolink:treats MONDO:0005131 PMID:41385096 "[{""id"":""uuid:d1cb0d73-e9e9-474b-bece-1aced79a9e82"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d6e65120-9172-4d82-be3e-df2ce379f0fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/abevmy""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Abevmy in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum.Abevmy in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. For further information as to human epidermal growth factor receptor 2 (HER2) status, please refer to section 5.1.Abevmy in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. Patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with Abevmy in combination with capecitabine. For further information as to HER2 status, please refer to section 5.1.Abevmy, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology.Abevmy, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating mutations (see section 5.1).Abevmy in combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer.Abevmy, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (International Federation of Gynecology and Obstetrics [FIGO] stages III B, III C and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5.1).Abevmy, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor–targeted agents.Abevmy in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor–targeted agents (see section 5.1).Abevmy, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.1). uuid:06c15f43-eca1-4430-8e00-cdff0361a62b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:1KUR4BN70F biolink:treats MONDO:0100096 PMID:41385096 "[{""id"":""uuid:541ff8db-47ee-43f8-b092-4faef7b24878"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a699a388-09c9-43a3-97e5-c2645d6e624b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/evusheld""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Prevention of COVID-19. uuid:7ba06af8-a19f-4a7f-bdfd-1e7978d48022 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2P471X1Z11 biolink:treats MONDO:0004784 PMID:41385096 "[{""id"":""uuid:a1b0308c-5cf1-43be-93af-448f47729248"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:58dfdeba-14c1-4fc3-9261-72c376f4303b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/xolair""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Allergic asthmaXolair is indicated in adults, adolescents and children (6 to uuid:9a3da3e7-10fa-499e-8e4e-a14d7454f17e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:F70C5K4786 biolink:treats MONDO:0009693 PMID:41385096 "[{""id"":""uuid:442146a9-5f54-46e7-ae4d-f2512a32a7d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:ce75c651-1818-4f1c-9e41-f30732bc80ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Pepaxti is indicated, in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-CD38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. For patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation (see section 4.4). uuid:55b700e6-bc6b-4012-b997-17da92420a45 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:284904 biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:9ef6db1d-715b-4ddc-98fe-a1c286ace250"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:69686422-6986-4ad4-be8b-f451f53fc95d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Trizivir is indicated for the treatment of human-immunodeficiency-virus (HIV) infection in adults.This fixed combination replaces the three components (abacavir, lamivudine and zidovudine) used separately in similar dosages. It is recommended that treatment is started with abacavir, lamivudine,and zidovudine separately for the first six to eight weeks. The choice of this fixed combination should be based not only on potential adherence criteria, but mainly on expected efficacy and risk related to the three nucleoside analogues.The demonstration of the benefit of Trizivir is mainly based on results of studies performed in treatment naive patients or moderately antiretroviral experienced patients with non-advanced disease.In patients with high viral load (>100,000 copies/ml) choice of therapy needs special consideration.Overall, the virologic suppression with this triple nucleoside regimen could be inferior to that obtained with other multitherapies notably including boosted protease inhibitors or non-nucleoside reverse-transcriptase inhibitors, therefore the use of Trizivir should only be considered under special circumstances (e.g. co-infection with tuberculosis).Before initiating treatment with abacavir, screening for carriage of the HLA-B*5701 allele should be performed in any HIV-infected patient, irrespective of racial origin. Screening is also recommended prior to re-initiation of abacavir in patients of unknown HLA-B*5701 status who have previously tolerated abacavir (see 'management after an interruption of Trizivir therapy'). Abacavir should not be used in patients known to carry the HLA-B*5701 allele, unless no other therapeutic option is available in these patients, based on the treatment history and resistance testing. uuid:6a00dac8-1866-4702-85af-bb0c07956626 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:284904 biolink:treats MONDO:0018076 PMID:41385096 "[{""id"":""uuid:76d36a30-f2a5-43e6-ad1d-2125d4d81212"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:259cfb6a-b06c-45e2-a63f-da76d2f21634"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Trizivir is indicated for the treatment of human-immunodeficiency-virus (HIV) infection in adults.This fixed combination replaces the three components (abacavir, lamivudine and zidovudine) used separately in similar dosages. It is recommended that treatment is started with abacavir, lamivudine,and zidovudine separately for the first six to eight weeks. The choice of this fixed combination should be based not only on potential adherence criteria, but mainly on expected efficacy and risk related to the three nucleoside analogues.The demonstration of the benefit of Trizivir is mainly based on results of studies performed in treatment naive patients or moderately antiretroviral experienced patients with non-advanced disease.In patients with high viral load (>100,000 copies/ml) choice of therapy needs special consideration.Overall, the virologic suppression with this triple nucleoside regimen could be inferior to that obtained with other multitherapies notably including boosted protease inhibitors or non-nucleoside reverse-transcriptase inhibitors, therefore the use of Trizivir should only be considered under special circumstances (e.g. co-infection with tuberculosis).Before initiating treatment with abacavir, screening for carriage of the HLA-B*5701 allele should be performed in any HIV-infected patient, irrespective of racial origin. Screening is also recommended prior to re-initiation of abacavir in patients of unknown HLA-B*5701 status who have previously tolerated abacavir (see 'management after an interruption of Trizivir therapy'). Abacavir should not be used in patients known to carry the HLA-B*5701 allele, unless no other therapeutic option is available in these patients, based on the treatment history and resistance testing. uuid:975e90c6-d482-4b95-bb47-48b5ae7f3de1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16796 biolink:treats MONDO:0013600 PMID:41385096 "[{""id"":""uuid:f1d91211-ff3e-400c-bd66-c31f50b0f312"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:966ae460-cf4e-46e5-8492-6d7cef4b6cb8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/slenyto""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Slenyto is indicated for the treatment of insomnia in children and adolescents aged 2-18 with Autism Spectrum Disorder (ASD) and / or Smith-Magenis syndrome, where sleep hygiene measures have been insufficient. uuid:f41ced93-d67a-4ff4-bb29-7ad6789b5303 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16796 biolink:treats MONDO:0005258 PMID:41385096 "[{""id"":""uuid:402e54d0-8fb1-40f3-a8ba-84698cb760d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:60ee7062-88b1-4199-8cef-0bd65329101f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/slenyto""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Slenyto is indicated for the treatment of insomnia in children and adolescents aged 2-18 with Autism Spectrum Disorder (ASD) and / or Smith-Magenis syndrome, where sleep hygiene measures have been insufficient. uuid:a46d73cd-ca06-41b3-87c4-e753c3460e63 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:B72HH48FLU biolink:treats MONDO:0005083 PMID:41385096 "[{""id"":""uuid:61f3899d-b6c8-470c-80f0-36690d538560"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:57df886c-e11d-4a33-82bc-6dc817903b86"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/zessly""]},{""id"":""uuid:be1a2c4d-cb09-4ae1-88ae-8761edb98367"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and psoriasis.|[PMDA] Follow-on biologics indicated for the treatment of rheumatoid arthritis, psoriasis, Crohn’s disease, and ulcerative colitis. uuid:91903bce-2f86-454e-b9b6-031088dc7868 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:D99YVK4L0X biolink:treats MONDO:0001056 PMID:41385096 "[{""id"":""uuid:52d09902-ada7-4613-a0f0-fd8d7dd4fbbf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:330f2e10-0907-472a-bf1a-970c055f0f04"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/cyramza""]},{""id"":""uuid:e84ef787-3eb9-45a6-b037-071a054f89af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Gastric cancerCyramza in combination with paclitaxel is indicated for the treatment of adult patients with advanced gastric cancer or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum and fluoropyrimidine chemotherapy.Cyramza monotherapy is indicated for the treatment of adult patients with advanced gastric cancer or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum or fluoropyrimidine chemotherapy, for whom treatment in combination with paclitaxel is not appropriate.Colorectal cancerCyramza, in combination with FOLFIRI (irinotecan, folinic acid, and 5‑fluorouracil), is indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin and a fluoropyrimidine.Non-small cell lung cancerCyramza in combination with docetaxel is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with disease progression after platinum-based chemotherapy.Hepatocellular carcinomaCyramza monotherapy is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have a serum alpha fetoprotein (AFP) of ≥ 400 ng/ml and who have been previously treated with sorafenib.|[PMDA] Drugs with a new active ingredient indicated for the treatment of unresectable advanced or recurrent gastric cancer. [Priority review] uuid:4bce36da-90b3-4968-8367-bca32a83111b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:D99YVK4L0X biolink:treats MONDO:0005575 PMID:41385096 "[{""id"":""uuid:d4bba389-8a59-4e9a-a85c-937c2a2d0272"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3b66dbf5-398d-42fb-b328-af382a02bb2c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/cyramza""]},{""id"":""uuid:86a28eba-080e-4ff1-bac1-ff77c5bc74f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Gastric cancerCyramza in combination with paclitaxel is indicated for the treatment of adult patients with advanced gastric cancer or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum and fluoropyrimidine chemotherapy.Cyramza monotherapy is indicated for the treatment of adult patients with advanced gastric cancer or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum or fluoropyrimidine chemotherapy, for whom treatment in combination with paclitaxel is not appropriate.Colorectal cancerCyramza, in combination with FOLFIRI (irinotecan, folinic acid, and 5‑fluorouracil), is indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin and a fluoropyrimidine.Non-small cell lung cancerCyramza in combination with docetaxel is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with disease progression after platinum-based chemotherapy.Hepatocellular carcinomaCyramza monotherapy is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have a serum alpha fetoprotein (AFP) of ≥ 400 ng/ml and who have been previously treated with sorafenib.|[PMDA] Drugs with a new additional indication and a new dosage for the treatment of unresectable advanced or recurrent colorectal cancer. uuid:a39a067c-b0de-45d1-8e5d-dddf42bbf885 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:D99YVK4L0X biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:62d7e6b9-b57c-4295-8f55-0e16008ffd1a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8da76c52-6fa3-4c20-894f-d4e434c7db2c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/cyramza""]},{""id"":""uuid:ba62f868-3c46-464b-bd80-0612f518f495"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Gastric cancerCyramza in combination with paclitaxel is indicated for the treatment of adult patients with advanced gastric cancer or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum and fluoropyrimidine chemotherapy.Cyramza monotherapy is indicated for the treatment of adult patients with advanced gastric cancer or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum or fluoropyrimidine chemotherapy, for whom treatment in combination with paclitaxel is not appropriate.Colorectal cancerCyramza, in combination with FOLFIRI (irinotecan, folinic acid, and 5‑fluorouracil), is indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin and a fluoropyrimidine.Non-small cell lung cancerCyramza in combination with docetaxel is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with disease progression after platinum-based chemotherapy.Hepatocellular carcinomaCyramza monotherapy is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have a serum alpha fetoprotein (AFP) of ≥ 400 ng/ml and who have been previously treated with sorafenib.|[PMDA] Drugs with a new dosage indicated for the treatment of unresectable advanced or recurrent non-small cell lung cancer. Drugs with a new dosage indicated for the treatment of unresectable advanced or recurrent gastric cancer, unresectable advanced or recurrent colon or rectal cancer, unresectable advanced or recurrent non-small cell lung cancer, and unresectable hepatocellular carcinoma whose serum AFP level is greater than 400 ng/mL and conditions have progressed after cancer chemotherapy. uuid:2812beb0-29b2-4d5c-83e3-7142f4401b07 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB15699 biolink:treats MONDO:0018876 PMID:41385096 "[{""id"":""uuid:1b846dce-21bc-48f3-8390-26c47851b660"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:2cf94a2f-2832-4478-9a2b-5d4e2321a5d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Mantle cell lymphomaTecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after two or more lines of systemic therapy including a Bruton’s tyrosine kinase (BTK) inhibitor.Acute lymphoblastic leukaemiaTecartus is indicated for the treatment of adult patients 26 years of age and above with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL). uuid:0155f122-3782-455d-be6e-81790906ea4f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB15699 biolink:treats MONDO:0004967 PMID:41385096 "[{""id"":""uuid:1bf95be9-6249-4a14-b151-065f45df7d14"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d4241760-9193-455e-82c2-b009f79cb7a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Mantle cell lymphomaTecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after two or more lines of systemic therapy including a Bruton’s tyrosine kinase (BTK) inhibitor.Acute lymphoblastic leukaemiaTecartus is indicated for the treatment of adult patients 26 years of age and above with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL). uuid:1818e217-5af8-4a26-a50f-3bfd3b3cae20 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:229213 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:57020936-9c45-48e9-8509-d99087071d5c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:14a1811d-7621-40ce-b52d-c0b6b0d0a5a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/orserdu""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (ER) positive, HER2-negative, locally advanced or metastatic breast cancer with an activating ESR1 mutation who have disease progression following at least one line of endocrine therapy including a CDK 4/6 inhibitor. uuid:f13ef693-339b-4a69-aa1a-c02b21992294 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1546884 biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:31837a74-ca1b-4184-89ae-8a8cf62b32e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:cdd6b1da-14bd-406b-ae27-eb63dccbc2c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:2b3bd383-b82d-4de4-9f68-68389bc30f4a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Triumeq is indicated for the treatment of Human Immunodeficiency Virus (HIV) infected adults, adolescents and children weighing at least 25 kg who are antiretroviral treatment-naïve or are infected with HIV without documented or clinically suspected resistance to any of the three antiretroviral agents in Triumeq.|[PMDA] A new combination drug indicated for the treatment of HIV infection. [Orphan drug] uuid:7613335b-0905-4d87-a05f-3ff89269c3c1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:G6UF363ECX biolink:treats MONDO:0008315 PMID:41385096 "[{""id"":""uuid:bdc6da5f-deb8-4b84-a6a3-550884520355"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:245cc09b-40a5-4fe8-9088-ceae2f5fe19e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Pluvicto in combination with androgen deprivation therapy (ADT) with or without androgen receptor (AR) pathway inhibition is indicated for the treatment of adult patients with progressive prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with AR pathway inhibition and taxane based chemotherapy. uuid:ae6840d3-fd05-4020-aadb-f34e07245be4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:901639 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:0647fc13-44ed-44f1-9640-a7126a66bcc5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:5693dbe9-635e-4e30-81d8-48f511b902dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Active immunisation for the prevention of invasive disease, pneumonia and acute otitis media caused by Streptococcus pneumoniae in infants, children and adolescents from 6 weeks to 17 years of age.Active immunisation for the prevention of invasive disease caused by Streptococcus pneumoniae in adults ≥18 years of age and the elderly.See sections 4.4 and 5.1 for information on protection against specific pneumococcal serotypes.The use of Prevenar 13 should be determined on the basis of official recommendations taking into consideration the risk of invasive disease in different age groups, underlying comorbidities as well as the variability of serotype epidemiology in different geographical areas. uuid:85aaaf67-825f-4bca-8fbf-4db9c0ac2998 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:901639 biolink:treats MONDO:0001031 PMID:41385096 "[{""id"":""uuid:69597366-7ea3-457a-8c37-661b93ccab07"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f7317554-7933-424e-800e-e7b008ba83b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Active immunisation for the prevention of invasive disease, pneumonia and acute otitis media caused by Streptococcus pneumoniae in infants, children and adolescents from 6 weeks to 17 years of age.Active immunisation for the prevention of invasive disease caused by Streptococcus pneumoniae in adults ≥18 years of age and the elderly.See sections 4.4 and 5.1 for information on protection against specific pneumococcal serotypes.The use of Prevenar 13 should be determined on the basis of official recommendations taking into consideration the risk of invasive disease in different age groups, underlying comorbidities as well as the variability of serotype epidemiology in different geographical areas. uuid:75b29e09-4fb7-4097-bd7d-5de5f9b95205 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5938 biolink:treats MONDO:0005314 PMID:41385096 "[{""id"":""uuid:f6700630-d6b2-435b-9e79-d9cc3c106726"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:8e27a470-a7ee-413a-b809-6036ee371f9b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/betaferon""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Betaferon is indicated for the treatment ofpatients with a single demyelinating event with an active inflammatory process, if it is severe enough to warrant treatment with intravenous corticosteroids, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite multiple sclerosis;patients with relapsing-remitting multiple sclerosis and two or more relapses within the last two years;patients with secondary progressive multiple sclerosis with active disease, evidenced by relapses. uuid:4ca54ac7-830c-4df8-b588-038d3618d7c8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:70746 biolink:treats MONDO:0005399 PMID:41385096 "[{""id"":""uuid:3854f627-3a4d-498d-b8c1-f6cf406cac34"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d37c77aa-b200-4cbc-8018-19e2847c0948"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Pradaxa 75 mgPrimary prevention of venous thromboembolic events in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery.Pradaxa 110 mgPrimary prevention of venous thromboembolic events in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery.Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischemic attack (TIA); age ≥ 75 years; heart failure (NYHA Class ≥ II); diabetes mellitus; hypertension.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.Pradaxa 150 mgPrevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischemic attack (TIA); age ≥ 75 years; heart failure (NYHA Class ≥ II); diabetes mellitus; hypertension.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. uuid:5fdf07a9-741d-49cb-b299-1b3fad59e2fd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4FR53SIF3A biolink:treats HP:0004848 PMID:41385096 "[{""id"":""uuid:243cc699-9d82-4416-9d82-9c1e15a74918"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:2f6d440d-9225-43a5-8208-e16aa2c87907"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/blincyto""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Blincyto is indicated as monotherapy for the treatment of adults with CD19 positive relapsed or refractory B precursor acute lymphoblastic leukaemia (ALL). Patients with Philadelphia chromosome positive B-precursor ALL should have failed treatment with at least 2 tyrosine kinase inhibitors (TKIs) and have no alternative treatment options., , Blincyto is indicated as monotherapy for the treatment of adults with Philadelphia chromosome negative CD19 positive B-precursor ALL in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%., , Blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with Philadelphia chromosome negative CD19 positive B precursor ALL which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation., , Blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed Philadelphia chromosome negative CD19 positive B-precursor ALL as part of the consolidation therapy (see section 4.2)., uuid:46fbb0e8-2338-408d-a88f-fed87ad0678e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4FR53SIF3A biolink:treats UMLS:C4075283 PMID:41385096 "[{""id"":""uuid:fd4f23cf-eaaf-4f72-a539-719fa901f043"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d6be01c3-b1fd-4fa3-bc6b-945c5378ce22"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/blincyto""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Blincyto is indicated as monotherapy for the treatment of adults with CD19 positive relapsed or refractory B precursor acute lymphoblastic leukaemia (ALL). Patients with Philadelphia chromosome positive B-precursor ALL should have failed treatment with at least 2 tyrosine kinase inhibitors (TKIs) and have no alternative treatment options., , Blincyto is indicated as monotherapy for the treatment of adults with Philadelphia chromosome negative CD19 positive B-precursor ALL in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%., , Blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with Philadelphia chromosome negative CD19 positive B precursor ALL which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation., , Blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed Philadelphia chromosome negative CD19 positive B-precursor ALL as part of the consolidation therapy (see section 4.2)., uuid:fb76377a-39fe-4b51-9bbb-69e9a5719e33 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3423 biolink:treats MONDO:0002911 PMID:41385096 "[{""id"":""uuid:3d2e09c5-6b3e-4c45-8b20-b2f8e622a3af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:fb5f2e1a-6c16-4fe4-b9a5-0b38398ab377"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/carmustine-medac-previously-carmustine-obvius""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Carmustine is indicated n adults in the following malignant neoplasms as a single agent or in combination with other antineoplastic agents and/or other therapeutic measures (radiotherapy, surgery):, , , Brain tumours (glioblastoma, brain-stem gliomas, medulloblastoma, astrocytoma and ependymoma), brain metastases, Secondary therapy in non-Hodgkin’s lymphoma and Hodgkin’s disease, as conditioning treatment prior to autologous haematopoietic progenitor cell transplantation (HPCT) in malignant haematological diseases (Hodgkin’s disease / Non-hodgkin’s lymphoma)., , uuid:3b924378-da11-42e3-94c9-98111dc981aa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3423 biolink:treats MONDO:0018908 PMID:41385096 "[{""id"":""uuid:3341a000-f341-4191-8b41-5957b02ecf9c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:df558e95-d963-43fe-bb57-6f2a9d89c644"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/carmustine-medac-previously-carmustine-obvius""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Carmustine is indicated n adults in the following malignant neoplasms as a single agent or in combination with other antineoplastic agents and/or other therapeutic measures (radiotherapy, surgery):, , , Brain tumours (glioblastoma, brain-stem gliomas, medulloblastoma, astrocytoma and ependymoma), brain metastases, Secondary therapy in non-Hodgkin’s lymphoma and Hodgkin’s disease, as conditioning treatment prior to autologous haematopoietic progenitor cell transplantation (HPCT) in malignant haematological diseases (Hodgkin’s disease / Non-hodgkin’s lymphoma)., , uuid:97e4f7f3-69fa-45d9-b79f-b5b34efedd9c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3423 biolink:treats MONDO:0004952 PMID:41385096 "[{""id"":""uuid:fa27963b-2357-42bb-b23a-aae4a1759432"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f94d0e96-7816-401a-b14b-c66d62893847"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/carmustine-medac-previously-carmustine-obvius""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Carmustine is indicated n adults in the following malignant neoplasms as a single agent or in combination with other antineoplastic agents and/or other therapeutic measures (radiotherapy, surgery):, , , Brain tumours (glioblastoma, brain-stem gliomas, medulloblastoma, astrocytoma and ependymoma), brain metastases, Secondary therapy in non-Hodgkin’s lymphoma and Hodgkin’s disease, as conditioning treatment prior to autologous haematopoietic progenitor cell transplantation (HPCT) in malignant haematological diseases (Hodgkin’s disease / Non-hodgkin’s lymphoma)., , uuid:88731849-effe-417c-965b-1d6a497b7c2a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64356 biolink:treats MONDO:0021667 PMID:41385096 "[{""id"":""uuid:0e2e7e47-aa35-430e-a4c2-2d0c20771dd1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:1dfff2e7-4a87-4b79-ae00-fa04f4849525"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/pregabalin-sandoz""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Neuropathic painPregabalin Sandoz is indicated for the treatment of peripheral and central neuropathic pain in adults.EpilepsyPregabalin Sandoz is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.Generalised Anxiety DisorderPregabalin Sandoz is indicated for the treatment of Generalised Anxiety Disorder (GAD) in adults. uuid:79d25de0-f9af-44a4-be62-cafe7feef18e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64356 biolink:treats MONDO:0005027 PMID:41385096 "[{""id"":""uuid:c15ced65-89c5-45c9-bb71-4e5992ff992d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:5481dd82-4a5c-4f6d-b16f-c7ad9580688c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/pregabalin-sandoz""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Neuropathic painPregabalin Sandoz is indicated for the treatment of peripheral and central neuropathic pain in adults.EpilepsyPregabalin Sandoz is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.Generalised Anxiety DisorderPregabalin Sandoz is indicated for the treatment of Generalised Anxiety Disorder (GAD) in adults. uuid:4fa451ad-04dc-4df2-b03d-d904755f0044 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64356 biolink:treats MONDO:0001942 PMID:41385096 "[{""id"":""uuid:01428e8f-101f-4919-bae1-a4339c5c71e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:741484d3-c802-494b-bd15-c6d10e24fb35"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/pregabalin-sandoz""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Neuropathic painPregabalin Sandoz is indicated for the treatment of peripheral and central neuropathic pain in adults.EpilepsyPregabalin Sandoz is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.Generalised Anxiety DisorderPregabalin Sandoz is indicated for the treatment of Generalised Anxiety Disorder (GAD) in adults. uuid:1ccfbf26-0b1a-44f6-97ea-4dbe4e6aa8a0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:EPK39PL4R4 biolink:treats MONDO:0100096 PMID:41385096 "[{""id"":""uuid:c4511249-71f5-4ae0-a7cd-431c647cc092"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:58901686-6549-4d10-a147-9e021875e89e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:9dcb2c4d-efd2-44ad-92de-cef16291b08c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Spikevax is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older.Spikevax bivalent Original/Omicron BA.1 is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against COVID-19.Spikevax bivalent Original/Omicron BA.4-5 is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older. Spikevax XBB.1.5 is indicated for active immunisation to prevent COVID 19 caused by SARS-CoV-2 in individuals 6 months of age and older.The use of this vaccine should be in accordance with official recommendations.|[PMDA] A drug with a new additional pediatric dosage indicated for the prevention of disease caused by SARS-CoV-2 infection (COVID-19). [Drug pertaining to Special Approval for Emergency] uuid:5658f3e7-b83a-40a7-8f4c-75b5ba2f744f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:92043599 biolink:treats MONDO:0005300 PMID:41385096 "[{""id"":""uuid:114e41be-f5ca-4ab2-979a-e2c355fe61ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:de78282d-014f-4a76-a537-31c3a6fb1b32"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/epoetin-alfa-hexal""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adult and paediatric patients:, , , treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis;, Treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis., , , Treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre-existing anaemia at the start of chemotherapy)., uuid:7bf82919-0dd1-4e1a-aed9-6c76dec64c62 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:92043599 biolink:treats MONDO:0009693 PMID:41385096 "[{""id"":""uuid:831aba5a-db06-4b29-91b6-002814a49a0a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:27da65af-ebd1-4e9d-8578-110c0daacfeb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/epoetin-alfa-hexal""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adult and paediatric patients:, , , treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis;, Treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis., , , Treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre-existing anaemia at the start of chemotherapy)., uuid:6399b29c-9c8f-46b7-9933-927bcab300f2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:92043599 biolink:treats MONDO:0005062 PMID:41385096 "[{""id"":""uuid:288c5668-b396-437b-8a29-f4b1eacf29b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f8018c27-5139-467c-bb3c-197d06379e2b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/epoetin-alfa-hexal""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adult and paediatric patients:, , , treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis;, Treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis., , , Treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre-existing anaemia at the start of chemotherapy)., uuid:40f6c44a-72cb-48cf-a7ad-2aa0e15bb7a7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB00058 biolink:treats MONDO:0004849 PMID:41385096 "[{""id"":""uuid:11853846-2a70-4c60-8c35-ade7e178bf24"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:57de8125-23bc-4359-beb2-3e2acd0913d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Respreeza is indicated for maintenance treatment, to slow the progression of emphysema in adults with documented severe alpha1-proteinase inhibitor deficiency (e.g. genotypes PiZZ, PiZ(null), Pi(null,null), PiSZ). Patients are to be under optimal pharmacologic and non-pharmacologic treatment and show evidence of progressive lung disease (e.g. lower forced expiratory volume per second (FEV1) predicted, impaired walking capacity or increased number of exacerbations) as evaluated by a healthcare professional experienced in the treatment of alpha1-proteinase inhibitor deficiency. uuid:9ba93916-619c-4866-ac22-4d0f05b2c54a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB00058 biolink:treats MONDO:0013282 PMID:41385096 "[{""id"":""uuid:1369dccb-8257-4af9-94ce-8058734dd534"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4af5e505-1ffe-4111-b1f5-5336947b14ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:5fcff5cb-55e3-4a0c-ab51-ea2c2147742d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Respreeza is indicated for maintenance treatment, to slow the progression of emphysema in adults with documented severe alpha1-proteinase inhibitor deficiency (e.g. genotypes PiZZ, PiZ(null), Pi(null,null), PiSZ). Patients are to be under optimal pharmacologic and non-pharmacologic treatment and show evidence of progressive lung disease (e.g. lower forced expiratory volume per second (FEV1) predicted, impaired walking capacity or increased number of exacerbations) as evaluated by a healthcare professional experienced in the treatment of alpha1-proteinase inhibitor deficiency.|[PMDA] A drug with a new active ingredient indicated for the augmentation and maintenance therapy of severe alpha 1-antitrypsin deficiency. [Orphan drug] uuid:a0b41cfe-0db5-4386-b231-686e027172ee biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:95341 biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:db46c98f-1bd0-4120-b337-b2a67ebcc6a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f320d47c-8169-45e1-80b7-3b7c361736c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/olumiant""]},{""id"":""uuid:c52972cd-83ba-418d-93d2-bce7d20df007"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Rheumatoid arthritisBaricitinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (DMARDs). Olumiant may be used as monotherapy or in combination with methotrexate.Atopic DermatitisOlumiant is indicated for the treatment of moderate to severe atopic dermatitis in adult and paediatric patients 2 years of age and older who are candidates for systemic therapy.Alopecia areataBaricitinib is indicated for the treatment of severe alopecia areata in adult patients (see section 5.1).Juvenile idiopathic arthritisBaricitinib is indicated for the treatment of active juvenile idiopathic arthritis in patients 2 years of age and older who have had an inadequate response or intolerance to one or more prior conventional synthetic or biologic DMARDs:- Polyarticular juvenile idiopathic arthritis (polyarticular rheumatoid factor positive [RF+] or negative [RF-], extended oligoarticular),- Enthesitis related arthritis, and- Juvenile psoriatic arthritis.Baricitinib may be used as monotherapy or in combination with methotrexate.|[PMDA] Drugs with a new indication for the treatment of atopic dermatitis in patients who have not responded sufficiently to conventional treatments. uuid:d3b75a65-6b30-4b02-8db2-657d89bd7759 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:95341 biolink:treats MONDO:0011429 PMID:41385096 "[{""id"":""uuid:0b92116a-11e9-4c6d-ac52-aa6ad34cfee7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:29821f31-f32f-4a04-ba3f-54640529f416"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/olumiant""]},{""id"":""uuid:f32de989-71df-4670-9d7f-90c017ccb1b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Rheumatoid arthritisBaricitinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (DMARDs). Olumiant may be used as monotherapy or in combination with methotrexate.Atopic DermatitisOlumiant is indicated for the treatment of moderate to severe atopic dermatitis in adult and paediatric patients 2 years of age and older who are candidates for systemic therapy.Alopecia areataBaricitinib is indicated for the treatment of severe alopecia areata in adult patients (see section 5.1).Juvenile idiopathic arthritisBaricitinib is indicated for the treatment of active juvenile idiopathic arthritis in patients 2 years of age and older who have had an inadequate response or intolerance to one or more prior conventional synthetic or biologic DMARDs:- Polyarticular juvenile idiopathic arthritis (polyarticular rheumatoid factor positive [RF+] or negative [RF-], extended oligoarticular),- Enthesitis related arthritis, and- Juvenile psoriatic arthritis.Baricitinib may be used as monotherapy or in combination with methotrexate.|[PMDA] (1), (2) Drugs with a new indication and a new dosage and (3) a drug with a new indication and a new dosage in an additional dosage form, for the treatment of polyarticular-course juvenile idiopathic arthritis in patients who have not responded sufficiently to conventional treatments. uuid:b25f8417-31e7-4e6c-9429-0b63f688e048 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1600704 biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:1fabc1df-2a1e-4005-a7c4-9d7a5141769d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9c299a7a-cb2d-4c68-aac4-d075e3e6e146"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/rezolsta""]},{""id"":""uuid:775bdd17-6472-4da4-86fe-ae8f5bcf2a94"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Rezolsta, is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus 1 (HIV 1) infection in adults aged 18 years or older.Genotypic testing should guide the use of Rezolsta.|[PMDA] A new combination drug with a new active ingredient indicated for the treatment of HIV infection. [Orphan drug] uuid:d1352d41-e116-4e6f-9379-ae11f818971d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90939 biolink:treats MONDO:0009693 PMID:41385096 "[{""id"":""uuid:c1d243e2-b2c6-414c-b09a-2829c8311eed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:cd6d1b48-1692-41ee-ac78-7a3788c75050"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Ninlaro in combination with lenalidomide and dexamethasone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. uuid:80fd6f8b-4d7d-4669-bc2e-1b20c889a1ca biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49005 biolink:treats MONDO:0016486 PMID:41385096 "[{""id"":""uuid:b50301f6-3a15-4357-8b07-698e76fdf000"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:761253ac-abac-49e7-9221-02ae1d9439d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/exjade""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Exjade is indicated for the treatment of chronic iron overload due to frequent blood transfusions (≥ 7 ml/kg/month of packed red blood cells) in patients with beta thalassaemia major aged six years and older.Exjade is also indicated for the treatment of chronic iron overload due to blood transfusions when deferoxamine therapy is contraindicated or inadequate in the following patient groups:in patients with beta thalassaemia major with iron overload due to frequent blood transfusions (≥ 7 ml/kg/month of packed red blood cells) aged two to five years;in patients with beta thalassaemia major with iron overload due to infrequent blood transfusions (< 7 ml/kg/month of packed red blood cells) aged two years and older;in patients with other anaemias aged two years and older.Exjade is also indicated for the treatment of chronic iron overload requiring chelation therapy when deferoxamine therapy is contraindicated or inadequate in patients with non-transfusion-dependent thalassaemia syndromes aged 10 years and older. uuid:6f9b2fc2-d8a3-477d-92a9-0e136001e88b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49005 biolink:treats MONDO:0000984 PMID:41385096 "[{""id"":""uuid:bf12e754-d6a3-4c48-b5c3-ec8b3b3cee53"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:bc76a4c8-d116-4e82-af73-fe7221a9759e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/exjade""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Exjade is indicated for the treatment of chronic iron overload due to frequent blood transfusions (≥ 7 ml/kg/month of packed red blood cells) in patients with beta thalassaemia major aged six years and older.Exjade is also indicated for the treatment of chronic iron overload due to blood transfusions when deferoxamine therapy is contraindicated or inadequate in the following patient groups:in patients with beta thalassaemia major with iron overload due to frequent blood transfusions (≥ 7 ml/kg/month of packed red blood cells) aged two to five years;in patients with beta thalassaemia major with iron overload due to infrequent blood transfusions (< 7 ml/kg/month of packed red blood cells) aged two years and older;in patients with other anaemias aged two years and older.Exjade is also indicated for the treatment of chronic iron overload requiring chelation therapy when deferoxamine therapy is contraindicated or inadequate in patients with non-transfusion-dependent thalassaemia syndromes aged 10 years and older. uuid:478cc91c-919d-4243-8ea0-35ab6b1781a9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:9Y9727LS4D biolink:treats MONDO:0010602 PMID:41385096 "[{""id"":""uuid:865cd568-cbaa-4e0c-a9f1-206b42577926"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:daf5b2c4-c8a3-46a8-a377-5d8cdc9c0f5e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/esperoct""]},{""id"":""uuid:4e1fcd82-e9bd-4010-aff0-dc8dbaf69b02"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment and prophylaxis of bleeding in patients 12 years and above with haemophilia A (congenital factor VIII deficiency).|[PMDA] Drugs with a new active ingredient indicated for the control of bleeding tendency in patients with blood coagulation factor VIII deficiency. uuid:9582b6f1-092a-4d90-9eb7-8babf8122090 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:VY5YX2TQ1F biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:0dc5f6cb-3e99-47ee-80cb-bf6a36f7d09a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:8e0a5ea4-4e8a-4b22-af43-f7d097498b44"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Tepmetko as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy. uuid:d6e800a9-3b3d-41e8-99a4-26e3bf0d617c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:VY5YX2TQ1F biolink:treats UMLS:C4330599 PMID:41385096 "[{""id"":""uuid:49475ef1-3bb8-47b8-a133-b61e79e9bb5e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:dcfc4f4b-9b3a-4978-a011-29f8c7a612b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Tepmetko as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy. uuid:5268817b-7f54-4738-9d52-f40a5a57ceaa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:230905 biolink:treats MONDO:0000618 PMID:41385096 "[{""id"":""uuid:a60ba0aa-dbe2-485f-9e52-d0f91373bedd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:67e47de2-ad90-473c-a3a7-3dca3600788a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Kisqali is indicated for the treatment of women with hormone receptor (HR)‑positive, human epidermal growth factor receptor 2 (HER2)‑negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy.In pre‑ or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone‑releasing hormone (LHRH) agonist. uuid:b3b41444-b0d4-4060-aa57-46726dbada01 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32660 biolink:treats MONDO:0004969 PMID:41385096 "[{""id"":""uuid:0046afab-8aa2-4098-a40e-2acedf2a7a48"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:95a155fc-b0b5-484d-b02a-f3d1589336ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/spectrila""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Spectrila is indicated as a component of antineoplastic combination therapy for the treatment of acute lymphoblastic leukaemia (ALL) in paediatric patients from birth to 18 years and adults. uuid:ee9401cf-7021-4655-873b-e1912ba2d60e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3JB47N2Q2P biolink:treats MONDO:0005314 PMID:41385096 "[{""id"":""uuid:b68e25d3-7d46-4189-ac42-50824678427e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:b04c0ddc-cab1-4b97-a117-79ff669ed078"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/tysabri""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups:, , , Patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (DMT) (for exceptions and information about washout periods see sections 4.4 and 5.1), , or, Patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more Gadolinium enhancing lesions on brain MRI or a significant increase in T2 lesion load as compared to a previous recent MRI., , uuid:d89b0f14-ab53-405f-ad27-4005263ab1a4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:44185 biolink:treats MONDO:0011429 PMID:41385096 "[{""id"":""uuid:4821da04-8ac4-4a24-b848-f70a625f7203"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:05bec437-255a-480e-8482-0874c92826b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/nordimet""]},{""id"":""uuid:a2abd888-9b8b-4cf2-8ead-1bb78c665ee9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Nordimet is indicated for the treatment of:active rheumatoid arthritis in adult patients,polyarthritic forms of severe, active juvenile idiopathic arthritis (JIA), when the response to nonsteroidal anti-inflammatory drugs (NSAIDs) has been inadequate,moderate to severe plaque psoriasis in adults who are candidates for systemic therapy, and severe psoriatic arthritis in adult patients, induction of remission in moderate steroid-dependent Crohn's disease in adult patients, in combination with corticosteroids and for maintenance of remission, as monotherapy, in patients who have responded to methotrexate.|[PMDA] Drugs with a new indication and a new dosage for the treatment of juvenile idiopathic arthritis accompanied by articular symptoms. [Expedited review] uuid:9f555397-1524-41eb-8ecc-7e5f4bac065d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:44185 biolink:treats MONDO:0011849 PMID:41385096 "[{""id"":""uuid:fdb4768d-4a6c-4ee1-8588-4c54f22107fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e2e4ac3b-dd9e-4e52-b323-aa53e521eb1d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/nordimet""]},{""id"":""uuid:8fc6ae0b-f203-4b08-b87e-cbda87670f01"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Nordimet is indicated for the treatment of:active rheumatoid arthritis in adult patients,polyarthritic forms of severe, active juvenile idiopathic arthritis (JIA), when the response to nonsteroidal anti-inflammatory drugs (NSAIDs) has been inadequate,moderate to severe plaque psoriasis in adults who are candidates for systemic therapy, and severe psoriatic arthritis in adult patients, induction of remission in moderate steroid-dependent Crohn's disease in adult patients, in combination with corticosteroids and for maintenance of remission, as monotherapy, in patients who have responded to methotrexate.|[PMDA] A drug with new additional indications and a new dosage for the treatment of plaque psoriasis in patients who have not responded sufficiently to topical therapy, or psoriatic arthritis, pustular psoriasis and erythrodermic psoriasis . [Public knowledge-based application after PAFSC's preliminary assessment] uuid:fa6f8638-c504-420f-a4bf-0fbfa997d5a2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:44185 biolink:treats MONDO:0005011 PMID:41385096 "[{""id"":""uuid:13eb21e7-a195-447a-9f16-3d8a4ca728da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:5a92d39c-47cb-4e0a-8c47-ccb495dccb31"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/nordimet""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Nordimet is indicated for the treatment of:active rheumatoid arthritis in adult patients,polyarthritic forms of severe, active juvenile idiopathic arthritis (JIA), when the response to nonsteroidal anti-inflammatory drugs (NSAIDs) has been inadequate,moderate to severe plaque psoriasis in adults who are candidates for systemic therapy, and severe psoriatic arthritis in adult patients, induction of remission in moderate steroid-dependent Crohn's disease in adult patients, in combination with corticosteroids and for maintenance of remission, as monotherapy, in patients who have responded to methotrexate. uuid:8c339963-ed81-4786-9633-6e374bc55db9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1161287 biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:50554e5d-f4e8-495b-ae94-abccaaa4179e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:b1f6b431-de1b-4b5d-ae48-8a51a297ede0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/efavirenz-emtricitabine-tenofovir-disoproxil-mylan""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan is a fixed-dose combination of efavirenz, emtricitabine and tenofovir disoproxil. It is indicated for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults aged 18 years and over with virologic suppression to HIV-1 RNA levels of < 50 copies/ml on their current combination antiretroviral therapy for more than three months. Patients must not have experienced virological failure on any prior antiretroviral therapy and must be known not to have harboured virus strains with mutations conferring significant resistance to any of the three components contained in Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan prior to initiation of their first antiretroviral treatment regimen.The demonstration of the benefit of efavirenz/emtricitabine/tenofovir disoproxil is primarily based on 48-week data from a clinical study in which patients with stable virologic suppression on a combination antiretroviral therapy changed to efavirenz/emtricitabine/tenofovir disoproxil (see section 5.1). No data are currently available from clinical studies with efavirenz/emtricitabine/tenofovir disoproxil in treatment-naïve or in heavily pretreated patients.No data are available to support the combination of efavirenz/emtricitabine/tenofovir disoproxil and other antiretroviral agents. uuid:2efb1ef9-fbb9-4e68-b669-fbc0fe222f13 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90943 biolink:treats NCIT:C150124 PMID:41385096 "[{""id"":""uuid:d241c72c-94f5-486b-b233-f5f878cee127"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:51730831-966a-4994-8383-a6ca72af0a27"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] TAGRISSO as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations- the first-line treatment of adult patients NSCLC with activating EGFR mutations.- the treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC.TAGRISSO as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.- the first-line treatment of adult patients with locally advanced or metastatic NSCLC with activating EGFR mutations.- the treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC. uuid:0428aacd-b0f9-42bc-8765-908f06df7a8c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4Z63YK6E0E biolink:treats MONDO:0019438 PMID:41385096 "[{""id"":""uuid:df945030-de1a-4e0e-8a06-10e8c16d7b6d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:99c13461-7945-46ae-93a9-d8d0ddc66d51"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/darzalex""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Multiple MyelomaDarzalex is indicated: in combination with lenalidomide and dexamethasone or with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.in combination with bortezomib, thalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one prior therapy containing a proteasome inhibitor and lenalidomide and were lenalidomide refractory, or who have received at least two prior therapies that included lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or after the last therapy (see section 5.1).as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy.AL AmyloidosisDARZALEX is indicated in combination with cyclophosphamide, bortezomib and dexamethasone for the treatment of adult patients with newly diagnosed systemic light chain (AL) amyloidosis. uuid:8475e5fa-8ebe-41f9-8eaa-203ddc2b1437 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63112 biolink:treats MONDO:0005301 PMID:41385096 "[{""id"":""uuid:05269664-2a26-429c-8e39-e72c48d3a525"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:5029e9b6-c84b-4ec0-9e27-9733de8cd703"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older:, , Patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4.4 and 5.1), , or, , Patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more Gadolinium enhancing lesions on brain MRI or a significant increase in T2 lesion load as compared to a previous recent MRI., uuid:8723b008-e3da-4c82-a7e4-e6689f118670 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9139 biolink:treats MONDO:0001999 PMID:41385096 "[{""id"":""uuid:aa47b4d3-3104-4b66-a6bc-68789ddc0726"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:4fe38563-3f89-4937-a325-6efe4a288ef4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/revatio""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of adult patients with pulmonary arterial hypertension classified as World Health Organization (WHO) functional class II and III, to improve exercise capacity. Efficacy has been shown in primary pulmonary hypertension and pulmonary hypertension associated with connective tissue disease.Paediatric populationTreatment of paediatric patients aged one year to 17 years old with pulmonary arterial hypertension. Efficacy in terms of improvement of exercise capacity or pulmonary haemodynamics has been shown in primary pulmonary hypertension and pulmonary hypertension associated with congenital heart disease.Revatio solution for injection is for the treatment of adult patients with pulmonary arterial hypertension who are currently prescribed oral Revatio and who are temporarily unable to take oral therapy, but are otherwise clinically and haemodynamically stable.Revatio (oral) is indicated for treatment of adult patients with pulmonary arterial hypertension classified as WHO functional class II and III, to improve exercise capacity. Efficacy has been shown in primary pulmonary hypertension and pulmonary hypertension associated with connective tissue disease. uuid:b1aa27eb-dec2-4331-89e3-78cf3b956a6b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:229212 biolink:treats MONDO:0018876 PMID:41385096 "[{""id"":""uuid:0170c240-5805-4a1f-8821-07f8fcd8d01d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d0e276f0-df15-4a66-855f-a82acdb9b9f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/jaypirca""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of mantle cell lymphoma (MCL) uuid:4b3314a5-095a-44b9-97f1-ef84f21172ea biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64355 biolink:treats MONDO:0016426 PMID:41385096 "[{""id"":""uuid:2420f405-6292-42cf-b28f-2e7a8a88b235"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:98d57395-a077-4300-8dfe-6219536579a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/posaconazole-ahcl""]},{""id"":""uuid:db9ffa8f-2418-4ef2-bf62-fd757ad042c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Posaconazole AHCL oral suspension is indicated for use in the treatment of the following fungal infections in adults:Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products;Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B;Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products.Oropharyngeal candidiasis: as first-line therapy in patients who have severe disease or are immunocompromised, in whom response to topical therapy is expected to be poor.Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.Posaconazole AHCL oral suspension is also indicated for prophylaxis of invasive fungal infections in the following patients:Patients receiving remission-induction chemotherapy for acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections.|[PMDA] Drugs with a new active ingredient indicated for the prophylaxis of deep mycosis in hematopoietic stem cell transplantation recipients or patients with hematologic malignancy who are predicated to decrease neutrophil. treatment of the following mycoses: Fusariosis, mucormycosis, coccidioidomycosis, chromoblastomycosis, and mycetoma. uuid:3f02faca-411e-403b-99e1-69a19f6864d6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64355 biolink:treats MONDO:0015908 PMID:41385096 "[{""id"":""uuid:483b02ad-60f0-4d1c-9d52-c3b7d15df172"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:23b4c886-f20b-4f4e-96a6-7377cde35513"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/posaconazole-ahcl""]},{""id"":""uuid:4d91a5da-3518-46fb-8ce7-f72e8b17b690"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Posaconazole AHCL oral suspension is indicated for use in the treatment of the following fungal infections in adults:Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products;Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B;Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products.Oropharyngeal candidiasis: as first-line therapy in patients who have severe disease or are immunocompromised, in whom response to topical therapy is expected to be poor.Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.Posaconazole AHCL oral suspension is also indicated for prophylaxis of invasive fungal infections in the following patients:Patients receiving remission-induction chemotherapy for acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections.|[PMDA] Drugs with a new active ingredient indicated for the prophylaxis of deep mycosis in hematopoietic stem cell transplantation recipients or patients with hematologic malignancy who are predicated to decrease neutrophil. treatment of the following mycoses: Fusariosis, mucormycosis, coccidioidomycosis, chromoblastomycosis, and mycetoma. uuid:c836f913-bb1d-4f2e-9b68-3c4ec8773392 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64355 biolink:treats MONDO:0016823 PMID:41385096 "[{""id"":""uuid:ceb8ba02-b38f-4086-bf88-a61d5756fd80"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:311b4cf1-dd4d-4736-8a30-885033838974"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/posaconazole-ahcl""]},{""id"":""uuid:fe9217d9-122b-4c95-adc4-3268e9684372"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Posaconazole AHCL oral suspension is indicated for use in the treatment of the following fungal infections in adults:Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products;Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B;Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products.Oropharyngeal candidiasis: as first-line therapy in patients who have severe disease or are immunocompromised, in whom response to topical therapy is expected to be poor.Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.Posaconazole AHCL oral suspension is also indicated for prophylaxis of invasive fungal infections in the following patients:Patients receiving remission-induction chemotherapy for acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections.|[PMDA] Drugs with a new active ingredient indicated for the prophylaxis of deep mycosis in hematopoietic stem cell transplantation recipients or patients with hematologic malignancy who are predicated to decrease neutrophil. treatment of the following mycoses: Fusariosis, mucormycosis, coccidioidomycosis, chromoblastomycosis, and mycetoma. uuid:6055aa10-4f53-4b1c-82b6-62f24114789a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64355 biolink:treats MONDO:0005706 PMID:41385096 "[{""id"":""uuid:99df8e28-de7c-4981-9e12-47ee8a8a9a9a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:04c0be51-2458-4413-abfd-73727d623123"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/posaconazole-ahcl""]},{""id"":""uuid:c5383340-28dd-405a-9405-7ac495803d8a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Posaconazole AHCL oral suspension is indicated for use in the treatment of the following fungal infections in adults:Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products;Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B;Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products.Oropharyngeal candidiasis: as first-line therapy in patients who have severe disease or are immunocompromised, in whom response to topical therapy is expected to be poor.Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.Posaconazole AHCL oral suspension is also indicated for prophylaxis of invasive fungal infections in the following patients:Patients receiving remission-induction chemotherapy for acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections.|[PMDA] Drugs with a new active ingredient indicated for the prophylaxis of deep mycosis in hematopoietic stem cell transplantation recipients or patients with hematologic malignancy who are predicated to decrease neutrophil. treatment of the following mycoses: Fusariosis, mucormycosis, coccidioidomycosis, chromoblastomycosis, and mycetoma. uuid:bb0a96a9-2c42-4602-b0b5-bbff912c4bbe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:8GZG754X6M biolink:treats MONDO:0018874 PMID:41385096 "[{""id"":""uuid:36e70dad-8be2-49ca-8884-ec6a11aeb9f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:41505f59-24a5-40ee-ae87-f635f944e00f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/mylotarg-0""]},{""id"":""uuid:96ad850b-4e63-4e09-801e-8211aa58b400"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Mylotarg is indicated for combination therapy with daunorubicin (DNR) and cytarabine (AraC) for the treatment of patients age 15 years and above with previously untreated, de novo CD33-positive acute myeloid leukaemia (AML), except acute promyelocytic leukaemia (APL).|[PMDA] A drug containing a new active ingredient indicated for the treatment of relapsing or intractable CD33 positive acute myeloid [Orphan drug] uuid:1cbd4907-0e3e-4cff-9a48-54a499849e40 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:8GZG754X6M biolink:treats MONDO:0012883 PMID:41385096 "[{""id"":""uuid:ce8338b8-a0e3-4c4a-a0fe-d4f3cad9a2d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:cfe1f95d-5dff-4eae-bb87-c78a3168eca2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/mylotarg-0""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Mylotarg is indicated for combination therapy with daunorubicin (DNR) and cytarabine (AraC) for the treatment of patients age 15 years and above with previously untreated, de novo CD33-positive acute myeloid leukaemia (AML), except acute promyelocytic leukaemia (APL). uuid:bdc675fc-1d5f-44c9-9377-39b5984f7237 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4875 biolink:treats MONDO:0011429 PMID:41385096 "[{""id"":""uuid:6ac9fc60-2ffe-4421-b55a-f81a8fc3db84"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:82a80589-6e1c-4cc0-bb06-ca217825acc2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/enbrel""]},{""id"":""uuid:1c24d307-9455-4b06-aeb8-a88c5f232879"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Rheumatoid arthritis, , Enbrel in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adults when the response to disease-modifying antirheumatic drugs, including methotrexate (unless contraindicated), has been inadequate., , Enbrel can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate., , Enbrel is also indicated in the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate., , Enbrel, alone or in combination with methotrexate, has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function., , Juvenile idiopathic arthritis, , Treatment of polyarthritis (rheumatoid-factor-positive or -negative) and extended oligoarthritis in children and adolescents from the age of two years who have had an inadequate response to, or who have proved intolerant of, methotrexate., , Treatment of psoriatic arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, methotrexate., , Treatment of enthesitis-related arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, conventional therapy., , Enbrel has not been studied in children aged less than two years., , Psoriatic arthritis, , Treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying antirheumatic drug therapy has been inadequate. Enbrel has been shown to improve physical function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease., , Axial spondyloarthritis, , Ankylosing spondylitis (AS), , Treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy., , Non-radiographic axial spondyloarthritis, , Treatment of adults with severe non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to nonsteroidal anti-inflammatory drugs (NSAIDs). , , Plaque psoriasis , , Treatment of adults with moderate to severe plaque psoriasis who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapy, including ciclosporin, methotrexate or psoralen and ultraviolet-A light (PUVA)., , Paediatric plaque psoriasis , , Treatment of chronic severe plaque psoriasis in children and adolescents from the age of six years who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.,|[PMDA] Follow-on biologics indicated for the treatment of rheumatoid arthritis (including the prevention of structural joint damage) and polyarticular-course juvenile idiopathic arthritis in patients who have not responded sufficiently to conventional therapies. uuid:784bd15c-2997-4246-8156-5c33a488603a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4875 biolink:treats MONDO:0005083 PMID:41385096 "[{""id"":""uuid:3d6401e9-111d-4b05-aa2d-df0494dfe792"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:1b6de7ac-fb4e-4a3b-bd53-76fe7ad1e2fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/enbrel""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Rheumatoid arthritis, , Enbrel in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adults when the response to disease-modifying antirheumatic drugs, including methotrexate (unless contraindicated), has been inadequate., , Enbrel can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate., , Enbrel is also indicated in the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate., , Enbrel, alone or in combination with methotrexate, has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function., , Juvenile idiopathic arthritis, , Treatment of polyarthritis (rheumatoid-factor-positive or -negative) and extended oligoarthritis in children and adolescents from the age of two years who have had an inadequate response to, or who have proved intolerant of, methotrexate., , Treatment of psoriatic arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, methotrexate., , Treatment of enthesitis-related arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, conventional therapy., , Enbrel has not been studied in children aged less than two years., , Psoriatic arthritis, , Treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying antirheumatic drug therapy has been inadequate. Enbrel has been shown to improve physical function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease., , Axial spondyloarthritis, , Ankylosing spondylitis (AS), , Treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy., , Non-radiographic axial spondyloarthritis, , Treatment of adults with severe non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to nonsteroidal anti-inflammatory drugs (NSAIDs). , , Plaque psoriasis , , Treatment of adults with moderate to severe plaque psoriasis who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapy, including ciclosporin, methotrexate or psoralen and ultraviolet-A light (PUVA)., , Paediatric plaque psoriasis , , Treatment of chronic severe plaque psoriasis in children and adolescents from the age of six years who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies., uuid:31497a64-113c-4f77-97d5-5906cf06ce10 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:178199 biolink:treats UMLS:C2747837 PMID:41385096 "[{""id"":""uuid:c8eb2d43-9ec0-4b84-9e60-1b8635b313c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:8f3b291c-2652-42cc-b7ec-e26b5ea7c2b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/lumykras""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Lumykras as monotherapy is indicated for the treatment of adults with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and who have progressed after at least one prior line of systemic therapy. uuid:869701a1-d24a-48e3-81e4-e6701c7d9768 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45783 biolink:treats MONDO:0004967 PMID:41385096 "[{""id"":""uuid:07914fee-e65b-426a-9e58-89b50a134aec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8d722db8-a564-45a0-9683-96a37ef1ec1f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/glivec""]},{""id"":""uuid:a8973c4a-c616-4579-a320-fdaaee2546dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Glivec is indicated for the treatment of, , , adult and paediatric patients with newly diagnosed Philadelphia-chromosome (bcr-abl)-positive (Ph+) chronic myeloid leukaemia (CML) for whom bone-marrow transplantation is not considered as the first line of treatment;, adult and paediatric patients with Ph+ CML in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis;, adult and paediatric patients with newly diagnosed Philadelphia-chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy;, adult patients with relapsed or refractory Ph+ ALL as monotherapy;, adult patients with myelodysplastic / myeloproliferative diseases (MDS / MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements;, adult patients with advanced hypereosinophilic syndrome (HES) and / or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFRa rearrangement., , , The effect of Glivec on the outcome of bone-marrow transplantation has not been determined., , Glivec is indicated for:, , , the treatment of adult patients with Kit (CD 117)-positive unresectable and / or metastatic malignant gastrointestinal stromal tumours (GIST);, the adjuvant treatment of adult patients who are at significant risk of relapse following resection of Kit (CD117)-positive GIST. Patients who have a low or very low risk of recurrence should not receive adjuvant treatment;, the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and / or metastatic DFSP who are not eligible for surgery., , , In adult and paediatric patients, the effectiveness of Glivec is based on overall haematological and cytogenetic response rates and progression-free survival in CML, on haematological and cytogenetic response rates in Ph+ ALL, MDS / MPD, on haematological response rates in HES / CEL and on objective response rates in adult patients with unresectable and / or metastatic GIST and DFSP and on recurrence-free survival in adjuvant GIST. The experience with Glivec in patients with MDS / MPD associated with PDGFR gene re-arrangements is very limited (see section 5.1). Except in newly diagnosed chronic phase CML, there are no controlled trials demonstrating a clinical benefit or increased survival for these diseases.,|[PMDA] Drug with a new indication and dosage for treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. [Orphan Drug] uuid:9df97d29-2bf2-46a1-9258-3eb7094e1df3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45783 biolink:treats MONDO:0015691 PMID:41385096 "[{""id"":""uuid:b1be1f0c-9598-4e77-b74a-c97e22196790"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:15beb76d-ddba-4d29-a575-2fe2d58c9ebe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/glivec""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Glivec is indicated for the treatment of, , , adult and paediatric patients with newly diagnosed Philadelphia-chromosome (bcr-abl)-positive (Ph+) chronic myeloid leukaemia (CML) for whom bone-marrow transplantation is not considered as the first line of treatment;, adult and paediatric patients with Ph+ CML in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis;, adult and paediatric patients with newly diagnosed Philadelphia-chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy;, adult patients with relapsed or refractory Ph+ ALL as monotherapy;, adult patients with myelodysplastic / myeloproliferative diseases (MDS / MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements;, adult patients with advanced hypereosinophilic syndrome (HES) and / or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFRa rearrangement., , , The effect of Glivec on the outcome of bone-marrow transplantation has not been determined., , Glivec is indicated for:, , , the treatment of adult patients with Kit (CD 117)-positive unresectable and / or metastatic malignant gastrointestinal stromal tumours (GIST);, the adjuvant treatment of adult patients who are at significant risk of relapse following resection of Kit (CD117)-positive GIST. Patients who have a low or very low risk of recurrence should not receive adjuvant treatment;, the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and / or metastatic DFSP who are not eligible for surgery., , , In adult and paediatric patients, the effectiveness of Glivec is based on overall haematological and cytogenetic response rates and progression-free survival in CML, on haematological and cytogenetic response rates in Ph+ ALL, MDS / MPD, on haematological response rates in HES / CEL and on objective response rates in adult patients with unresectable and / or metastatic GIST and DFSP and on recurrence-free survival in adjuvant GIST. The experience with Glivec in patients with MDS / MPD associated with PDGFR gene re-arrangements is very limited (see section 5.1). Except in newly diagnosed chronic phase CML, there are no controlled trials demonstrating a clinical benefit or increased survival for these diseases., uuid:df78d2b4-4d7e-400c-aabf-394715b77cb4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45783 biolink:treats MONDO:0011719 PMID:41385096 "[{""id"":""uuid:ce9ab96a-bde2-40a7-9746-221f1dd0dbb0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:fa08a288-016a-4392-9f24-0f81ed8fe216"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/glivec""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Glivec is indicated for the treatment of, , , adult and paediatric patients with newly diagnosed Philadelphia-chromosome (bcr-abl)-positive (Ph+) chronic myeloid leukaemia (CML) for whom bone-marrow transplantation is not considered as the first line of treatment;, adult and paediatric patients with Ph+ CML in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis;, adult and paediatric patients with newly diagnosed Philadelphia-chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy;, adult patients with relapsed or refractory Ph+ ALL as monotherapy;, adult patients with myelodysplastic / myeloproliferative diseases (MDS / MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements;, adult patients with advanced hypereosinophilic syndrome (HES) and / or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFRa rearrangement., , , The effect of Glivec on the outcome of bone-marrow transplantation has not been determined., , Glivec is indicated for:, , , the treatment of adult patients with Kit (CD 117)-positive unresectable and / or metastatic malignant gastrointestinal stromal tumours (GIST);, the adjuvant treatment of adult patients who are at significant risk of relapse following resection of Kit (CD117)-positive GIST. Patients who have a low or very low risk of recurrence should not receive adjuvant treatment;, the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and / or metastatic DFSP who are not eligible for surgery., , , In adult and paediatric patients, the effectiveness of Glivec is based on overall haematological and cytogenetic response rates and progression-free survival in CML, on haematological and cytogenetic response rates in Ph+ ALL, MDS / MPD, on haematological response rates in HES / CEL and on objective response rates in adult patients with unresectable and / or metastatic GIST and DFSP and on recurrence-free survival in adjuvant GIST. The experience with Glivec in patients with MDS / MPD associated with PDGFR gene re-arrangements is very limited (see section 5.1). Except in newly diagnosed chronic phase CML, there are no controlled trials demonstrating a clinical benefit or increased survival for these diseases., uuid:22d6c243-9c6a-48ef-8100-0c96fa80c716 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133013 biolink:treats HP:0007359 PMID:41385096 "[{""id"":""uuid:be54f75d-6aeb-4987-9ac2-a0d757fe9ac5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:482ab2ce-5dce-4ecb-ad77-17df31c52b51"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/briviact-italy-nubriveo""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Briviact is indicated as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adult and adolescent patients from 16 years of age with epilepsy. uuid:c2b49983-d5f1-4936-8c35-6e7c4c4088ee biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133013 biolink:treats HP:0011188 PMID:41385096 "[{""id"":""uuid:249a78f4-8cf7-4937-88ea-db28a9a42d03"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:edd346d7-30b0-47e4-8965-0c9865641a64"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/briviact-italy-nubriveo""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Briviact is indicated as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adult and adolescent patients from 16 years of age with epilepsy. uuid:71bad825-eb4f-493e-9fe6-907d8a242b22 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133013 biolink:treats MONDO:0005027 PMID:41385096 "[{""id"":""uuid:3876020c-4d98-44bc-8b33-1538e8e1c0d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:50a38580-06a5-4355-997d-ba04d68a22aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/briviact-italy-nubriveo""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Briviact is indicated as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adult and adolescent patients from 16 years of age with epilepsy. uuid:2cec8995-3ac2-47b4-9995-ced44d63da69 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:52CMI0WC3Y biolink:treats MONDO:0040679 PMID:41385096 "[{""id"":""uuid:310caaf8-7a0a-4a9a-a93f-47efa12d9ae9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:0289739b-d25d-4275-8fa3-5a17f29dc970"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/tecentriq""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Urothelial carcinomaTecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC):- after prior platinum containing chemotherapy, or - who are considered cisplatin ineligible, and whose tumours have a PD-L1 expression ≥ 5% (see section 5.1).Non-small cell lung cancer Tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non small cell lung cancer (NSCLC). In patients with EGFR mutant or ALK-positive NSCLC, Tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies (see section 5.1).Tecentriq, in combination with nab paclitaxel and carboplatin, is indicated for the first line treatment of adult patients with metastatic non-squamous NSCLC who do not have EGFR mutant or ALK positive NSCLC (see section 5.1).Tecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have a PD-L1 expression ≥ 50% tumour cells (TC) or ≥ 10% tumour-infiltrating immune cells (IC) and who do not have EGFR mutant or ALK-positive NSCLC (see section 5.1).Tecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC after prior chemotherapy. Patients with EGFR mutant or ALK positive NSCLC should also have received targeted therapies before receiving Tecentriq (see section 5.1).Small cell lung cancerTecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) (see section 5.1).Hepatocellular carcinomaTecentriq, in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy (see section 5.1).Urothelial carcinomaTecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC):- after prior platinum containing chemotherapy, or- who are considered cisplatin ineligible, and whose tumours have a PD-L1 expression ≥ 5% (see section 5.1).Non-small cell lung cancerTecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have a PD-L1 expression ≥ 50% tumour cells (TC) or ≥ 10% tumour-infiltrating immune cells (IC) and who do not have EGFR mutant or ALK-positive NSCLC (see section 5.1).Tecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC after prior chemotherapy. Patients with EGFR mutant or ALK positive NSCLC should also have received targeted therapies before receiving Tecentriq (see section 5.1).Triple-negative breast cancerTecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumours have PD-L1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease. uuid:72afb5cb-b3c4-4d1b-baa1-902d2166796c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:52CMI0WC3Y biolink:treats MONDO:0005494 PMID:41385096 "[{""id"":""uuid:06ba1974-358b-47bc-a1d0-8903d19c7d1b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:57a2e326-5288-4743-8d07-13941c693ff6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/tecentriq""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Urothelial carcinomaTecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC):- after prior platinum containing chemotherapy, or - who are considered cisplatin ineligible, and whose tumours have a PD-L1 expression ≥ 5% (see section 5.1).Non-small cell lung cancer Tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non small cell lung cancer (NSCLC). In patients with EGFR mutant or ALK-positive NSCLC, Tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies (see section 5.1).Tecentriq, in combination with nab paclitaxel and carboplatin, is indicated for the first line treatment of adult patients with metastatic non-squamous NSCLC who do not have EGFR mutant or ALK positive NSCLC (see section 5.1).Tecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have a PD-L1 expression ≥ 50% tumour cells (TC) or ≥ 10% tumour-infiltrating immune cells (IC) and who do not have EGFR mutant or ALK-positive NSCLC (see section 5.1).Tecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC after prior chemotherapy. Patients with EGFR mutant or ALK positive NSCLC should also have received targeted therapies before receiving Tecentriq (see section 5.1).Small cell lung cancerTecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) (see section 5.1).Hepatocellular carcinomaTecentriq, in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy (see section 5.1).Urothelial carcinomaTecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC):- after prior platinum containing chemotherapy, or- who are considered cisplatin ineligible, and whose tumours have a PD-L1 expression ≥ 5% (see section 5.1).Non-small cell lung cancerTecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have a PD-L1 expression ≥ 50% tumour cells (TC) or ≥ 10% tumour-infiltrating immune cells (IC) and who do not have EGFR mutant or ALK-positive NSCLC (see section 5.1).Tecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC after prior chemotherapy. Patients with EGFR mutant or ALK positive NSCLC should also have received targeted therapies before receiving Tecentriq (see section 5.1).Triple-negative breast cancerTecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumours have PD-L1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease. uuid:b4ceebfc-61bb-4caa-b7f9-5768a8711392 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63918 biolink:treats MONDO:0005625 PMID:41385096 "[{""id"":""uuid:04fa7394-79f0-4ad9-8892-239f4beaa4f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:1d315e80-b6ff-4973-a465-4c1c3c30328e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/artesunate-amivas""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Artesunate Amivas is indicated for the initial treatment of severe malaria in adults and children.Consideration should be given to official guidance on the appropriate use of antimalarial agents. uuid:880aff47-9147-4b68-8bef-7b245e25bc84 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85164 biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:bff12308-7510-4c03-a504-05d552639014"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:00581e7d-f078-4f99-a1f6-374cc8180204"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/vargatef""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Vargatef is indicated in combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first line chemotherapy. uuid:797374f1-12c3-4ddd-a057-d59f34b1e5d9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85164 biolink:treats MONDO:0004970 PMID:41385096 "[{""id"":""uuid:c2178e99-c545-4f77-8270-2f1152f18fbd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:cb443c8b-4ebd-4dc1-9aad-2d2de2be908f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/vargatef""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Vargatef is indicated in combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first line chemotherapy. uuid:af4dcc5f-c9ba-4fce-a58d-b4e97c002e78 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:09495UIM6V biolink:treats MONDO:0005083 PMID:41385096 "[{""id"":""uuid:c3546133-563c-490b-9f9e-8089da318efe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:651f363e-842a-4d78-93a5-8806d4356082"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/bimzelx""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Plaque psoriasisBimzelx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.Psoriatic arthritisBimzelx, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (DMARDs).Axial spondyloarthritisNon-radiographic axial spondyloarthritis (nr-axSpA)Bimzelx is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs (NSAIDs).Ankylosing spondylitis (AS, radiographic axial spondyloarthritis)Bimzelx is indicated for the treatment of adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy. uuid:d3bb4201-bde3-489c-af68-98f469c4cc5e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71197 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:5152fcb7-8ddb-4bc4-b0e0-83a52c95816a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:9dc4970a-1e90-48da-b8cc-08462b73f774"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/xeljanz""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Rheumatoid arthritisTofacitinib in combination with methotrexate (MTX) is indicated for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (DMARDs) (see section 5.1). Tofacitinib can be given as monotherapy in case of intolerance to MTX or when treatment with MTX is inappropriate (see sections 4.4 and 4.5).Psoriatic arthritisTofacitinib in combination with MTX is indicated for the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (DMARD) therapy (see section 5.1).Ulcerative colitisTofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent (see section 5.1).Tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [RF+] or negative [RF-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (PsA) in patients 2 years of age and older, who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (DMARDs).Tofacitinib can be given in combination with methotrexate (MTX) or as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.Ankylosing spondylitisTofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (AS) who have responded inadequately to conventional therapy. uuid:bc3365f4-4342-4029-a641-8ed074318dff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71197 biolink:treats MONDO:0011849 PMID:41385096 "[{""id"":""uuid:c3a970f3-d990-40d7-8dae-d938f05ac14c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f28bb0e1-4f50-40d4-9177-f5d0cd928d16"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/xeljanz""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Rheumatoid arthritisTofacitinib in combination with methotrexate (MTX) is indicated for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (DMARDs) (see section 5.1). Tofacitinib can be given as monotherapy in case of intolerance to MTX or when treatment with MTX is inappropriate (see sections 4.4 and 4.5).Psoriatic arthritisTofacitinib in combination with MTX is indicated for the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (DMARD) therapy (see section 5.1).Ulcerative colitisTofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent (see section 5.1).Tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [RF+] or negative [RF-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (PsA) in patients 2 years of age and older, who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (DMARDs).Tofacitinib can be given in combination with methotrexate (MTX) or as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.Ankylosing spondylitisTofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (AS) who have responded inadequately to conventional therapy. uuid:30c727c4-8166-46f4-9de0-d48c2bde7aa1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71197 biolink:treats MONDO:0005101 PMID:41385096 "[{""id"":""uuid:beefbb2b-8df5-4f23-9512-8459e0f95b3e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:8b1aa800-da69-490d-b933-ba50566f47e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/xeljanz""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Rheumatoid arthritisTofacitinib in combination with methotrexate (MTX) is indicated for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (DMARDs) (see section 5.1). Tofacitinib can be given as monotherapy in case of intolerance to MTX or when treatment with MTX is inappropriate (see sections 4.4 and 4.5).Psoriatic arthritisTofacitinib in combination with MTX is indicated for the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (DMARD) therapy (see section 5.1).Ulcerative colitisTofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent (see section 5.1).Tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [RF+] or negative [RF-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (PsA) in patients 2 years of age and older, who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (DMARDs).Tofacitinib can be given in combination with methotrexate (MTX) or as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.Ankylosing spondylitisTofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (AS) who have responded inadequately to conventional therapy. uuid:5a00df97-f5e6-4a1c-a83b-a5c2f50364f3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71197 biolink:treats MONDO:0018456 PMID:41385096 "[{""id"":""uuid:2d931393-8e70-4f48-8fb2-d653984eda62"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:56cc573b-66b8-4459-80bd-4834d799e934"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/xeljanz""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Rheumatoid arthritisTofacitinib in combination with methotrexate (MTX) is indicated for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (DMARDs) (see section 5.1). Tofacitinib can be given as monotherapy in case of intolerance to MTX or when treatment with MTX is inappropriate (see sections 4.4 and 4.5).Psoriatic arthritisTofacitinib in combination with MTX is indicated for the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (DMARD) therapy (see section 5.1).Ulcerative colitisTofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent (see section 5.1).Tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [RF+] or negative [RF-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (PsA) in patients 2 years of age and older, who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (DMARDs).Tofacitinib can be given in combination with methotrexate (MTX) or as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.Ankylosing spondylitisTofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (AS) who have responded inadequately to conventional therapy. uuid:2fed4314-955e-4955-bfc2-1b7d20ce808b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71197 biolink:treats MONDO:0019436 PMID:41385096 "[{""id"":""uuid:4215ae1d-0328-42e1-af4e-0ba8071fd44b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:5bc9a676-d6b5-4bbe-8726-6acffb2977ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/xeljanz""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Rheumatoid arthritisTofacitinib in combination with methotrexate (MTX) is indicated for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (DMARDs) (see section 5.1). Tofacitinib can be given as monotherapy in case of intolerance to MTX or when treatment with MTX is inappropriate (see sections 4.4 and 4.5).Psoriatic arthritisTofacitinib in combination with MTX is indicated for the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (DMARD) therapy (see section 5.1).Ulcerative colitisTofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent (see section 5.1).Tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [RF+] or negative [RF-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (PsA) in patients 2 years of age and older, who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (DMARDs).Tofacitinib can be given in combination with methotrexate (MTX) or as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.Ankylosing spondylitisTofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (AS) who have responded inadequately to conventional therapy. uuid:c686d13c-e809-497f-9b61-c1c20ddd6604 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71197 biolink:treats MONDO:0005306 PMID:41385096 "[{""id"":""uuid:47bd21df-6b32-464a-9634-25f8364f6082"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:5b4f0167-c95a-4c18-aaa9-14be13d409b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/xeljanz""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Rheumatoid arthritisTofacitinib in combination with methotrexate (MTX) is indicated for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (DMARDs) (see section 5.1). Tofacitinib can be given as monotherapy in case of intolerance to MTX or when treatment with MTX is inappropriate (see sections 4.4 and 4.5).Psoriatic arthritisTofacitinib in combination with MTX is indicated for the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (DMARD) therapy (see section 5.1).Ulcerative colitisTofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent (see section 5.1).Tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [RF+] or negative [RF-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (PsA) in patients 2 years of age and older, who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (DMARDs).Tofacitinib can be given in combination with methotrexate (MTX) or as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.Ankylosing spondylitisTofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (AS) who have responded inadequately to conventional therapy. uuid:3644654b-28a3-44e0-8d24-44cd5ca453a4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:A10SJL62JY biolink:treats MONDO:0005301 PMID:41385096 "[{""id"":""uuid:0487b6df-b8b8-4e7d-81db-9633e94692db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:309c0c8f-4714-4120-88f8-1e67f98029ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ocrevus""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.Treatment of adult patients with early primary progressive multiple sclerosis (PPMS) in terms of disease duration and level of disability, and with imaging features characteristic of inflammatory activity. uuid:8ccd0ba0-2a72-4815-b0f3-552b11ba0063 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:9RV78Q2002 biolink:treats MONDO:0005312 PMID:41385096 "[{""id"":""uuid:4db409f8-cc2e-478c-9846-133f08f3d323"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:9f7e26dc-ec97-4c30-ae77-9263772cc987"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/entyvio""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Ulcerative colitisEntyvio is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor alpha (TNFα) antagonist.Crohn’s diseaseEntyvio is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor alpha (TNFα) antagonist.PouchitisEntyvio is indicated for the treatment of adult patients with moderately to severely active chronic pouchitis, who have undergone proctocolectomy and ileal pouch anal anastomosis for ulcerative colitis, and have had an inadequate response with or lost response to antibiotic therapy. uuid:96b69794-a8a1-4ebf-8777-3417711e97da biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:LDJ89SS0YG biolink:treats MONDO:0018906 PMID:41385096 "[{""id"":""uuid:c3ab2a59-17d8-4a5b-a0e2-7a9b00706b90"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:24afcc3a-7a15-4977-a705-62eabb99fac1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/lunsumio""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Lunsumio as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least two prior systemic therapies. uuid:07b250cb-a1a4-4a93-a77e-9c69178653d1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:90ZX3Q3FR7 biolink:treats MONDO:0005083 PMID:41385096 "[{""id"":""uuid:ae079058-405e-4246-a616-3bac192aab4c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a6e49992-0bbb-4b1a-96f1-1db7ca180701"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/skyrizi""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Plaque PsoriasisSkyrizi is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.Psoriatic ArthritisSkyrizi, alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (DMARDs).Crohn's diseaseSkyrizi is indicated for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy. uuid:e7f3be70-73bb-4365-ae76-72f71ce393d7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4AWF0N6QV3 biolink:treats MONDO:0001475 PMID:41385096 "[{""id"":""uuid:8d8e5741-a3f8-4d1e-91a0-e9f91871e1df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:24f86ee3-348c-4f93-b625-2a3d5aab5434"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/lonquex""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Lonquex is indicated in adults and in children 2 years of age and older for reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes). uuid:7d4e1048-52c4-46f5-b077-93643673dbba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4AWF0N6QV3 biolink:treats MONDO:0004992 PMID:41385096 "[{""id"":""uuid:30f4f5d7-6bd6-49fe-acbb-9293b6308875"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:5277671b-f965-4dbc-b503-ac41bcf4c65d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/lonquex""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Lonquex is indicated in adults and in children 2 years of age and older for reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes). uuid:14d2c35c-6e66-48d6-9fb2-705e9a3d49a3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:757603 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:147d6a2e-bc1c-49d3-9223-53abf80bfbbe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:071b733c-10f1-4997-8da9-aa79096bda07"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/velmetia""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] For patients with type-2 diabetes mellitus:Velmetia is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin.Velmetia is indicated in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea.Velmetia is indicated as triple combination therapy with a PPAR agonist (i.e. a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a PPAR agonist.Velmetia is also indicated as add on to insulin (i.e. triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dosage of insulin and metformin alone do not provide adequate glycaemic control. uuid:e43c7edc-6868-4532-94db-0c24a93665bd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10023 biolink:treats MONDO:0044067 PMID:41385096 "[{""id"":""uuid:270a82fb-76d9-4933-b332-e2fa508730e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:54e154b0-9967-49ca-a78f-1d55d72d3391"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/vfend""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Voriconazole, is a broad spectrum, triazole antifungal agent and is indicated in adults and children aged 2 years and above as follows:treatment of invasive aspergillosis;treatment of in candidaemianon-neutropenic patients;treatment of fluconazole-resistant serious invasive Candida infections (including C. krusei);Treatment of serious fungal infections caused by Scedosporium spp. and Fusarium spp.Vfend should be administered primarily to patients with progressive, possibly life-threatening infections.Prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (HSCT) recipients. uuid:606377bc-45a7-4f11-82dc-da122e3ff000 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10023 biolink:treats MONDO:0002041 PMID:41385096 "[{""id"":""uuid:efcd25f8-9c69-4439-b82e-47d0476ceb2b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a9ca387f-fdef-4e1e-8099-f03824a0b30e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/vfend""]},{""id"":""uuid:499c4d4b-1920-4369-a1dd-0d518b41b8ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Voriconazole, is a broad spectrum, triazole antifungal agent and is indicated in adults and children aged 2 years and above as follows:treatment of invasive aspergillosis;treatment of in candidaemianon-neutropenic patients;treatment of fluconazole-resistant serious invasive Candida infections (including C. krusei);Treatment of serious fungal infections caused by Scedosporium spp. and Fusarium spp.Vfend should be administered primarily to patients with progressive, possibly life-threatening infections.Prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (HSCT) recipients.|[PMDA] Drugs with new additional pediatric dosages, and a drug with a new additional pediatric dosage in an additional dosage form of dry syrup indicated for the treatment of severe or refractory fungus infection. uuid:b55cb931-4c77-4bd0-bbab-9647d0aed50a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:71308244 biolink:treats MONDO:0100187 PMID:41385096 "[{""id"":""uuid:4d5a1749-e2c5-4b26-812d-e682e6210047"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2ef55dc3-fa6e-479f-8843-5aaa80cb21b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:5b034e2b-d3c8-486c-b72c-dbde4a26e05c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Rizmoic is indicated for the treatment of opioid-induced constipation (OIC) in adult patients who have previously been treated with a laxative.|[PMDA] A drug with a new active ingredient indicated for the treatment of opioid-induced constipation. uuid:600d2bc6-94b4-4410-a43c-dda5b616c16c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135939 biolink:treats HP:0007359 PMID:41385096 "[{""id"":""uuid:ab9cdcc8-a5a4-408c-b32e-475fd3c825ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d08bd22c-449d-41e1-8abd-55f12eea7959"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/vimpat""]},{""id"":""uuid:87c09412-992c-4e30-9601-ef43872b5acc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Vimpat is indicated as monotherapy and adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.|[PMDA] Drugs with a new active ingredient indicated for the use as an adjunctive therapy with other antiepileptic drugs to treat partial seizures (including secondary generalized seizures) in patients with epilepsy who have not responded sufficiently to other antiepileptic drugs. uuid:4f28af02-27c6-47ad-b647-47456bf881fe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135939 biolink:treats MONDO:0005027 PMID:41385096 "[{""id"":""uuid:b9447fc5-114a-43aa-9131-e890a67ad29c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d4d88a22-2d15-46eb-a0f4-f91e67b407ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/vimpat""]},{""id"":""uuid:c8740a88-a932-47c7-adb5-a43fcc682aa6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Vimpat is indicated as monotherapy and adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.|[PMDA] Drugs with a new active ingredient indicated for the use as an adjunctive therapy with other antiepileptic drugs to treat partial seizures (including secondary generalized seizures) in patients with epilepsy who have not responded sufficiently to other antiepileptic drugs. uuid:2bf70484-3e91-4f06-9048-b0f1611b3abe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:176844 biolink:treats MONDO:0008170 PMID:41385096 "[{""id"":""uuid:8f967704-6896-4c84-836c-8e55a588d7f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:afbb20db-e624-4191-bb9e-4f3371a6c433"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e2917f35-78f9-4797-8371-e16b41c6bdcc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Zejula is indicated:, , , as monotherapy for the maintenance treatment of adult patients with advanced epithelial (FIGO Stages III and IV) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy., as monotherapy for the maintenance treatment of adult patients with platinum sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy., ,|[PMDA] A drug with a new active ingredient indicated for the maintenance treatment of ovarian cancer in patients who have received first chemotherapy, the maintenance treatment of recurrent ovarian cancer in patients who are in a complete or partial response to platinum-based chemotherapy, and the treatment of homologous recombination deficiency (HRD)-positive recurrent ovarian cancer in patients who are in a complete or partial response to platinum-based chemotherapy. uuid:2f28c4d0-9999-460c-abeb-1343ab442db1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:76607 biolink:treats MONDO:0017147 PMID:41385096 "[{""id"":""uuid:2066a2ba-ff07-468c-9008-611bb8306957"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:87adbdc4-06ae-488e-a66d-5d1cb8e965a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/opsumit""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Opsumit, as monotherapy or in combination, is indicated for the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients of WHO Functional Class (FC) II to III.Efficacy has been shown in a PAH population including idiopathic and heritable PAH, PAH associated with connective tissue disorders, and PAH associated with corrected simple congenital heart disease. uuid:cccf91f6-7b6c-4145-91eb-1764a8bce628 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:76607 biolink:treats MONDO:0017148 PMID:41385096 "[{""id"":""uuid:21527dfb-eaff-4b62-a6de-e0e2ce3a9fe0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:864e2c7e-4c51-451e-b0ee-1770c1705696"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/opsumit""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Opsumit, as monotherapy or in combination, is indicated for the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients of WHO Functional Class (FC) II to III.Efficacy has been shown in a PAH population including idiopathic and heritable PAH, PAH associated with connective tissue disorders, and PAH associated with corrected simple congenital heart disease. uuid:c24acf25-5331-4dd4-befb-66dfc52e6cd9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:27Y83O992Q biolink:treats MONDO:0010604 PMID:41385096 "[{""id"":""uuid:6bde4ca4-b01e-4b7d-8822-221874f2c55e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4de95764-f8a8-4bb8-b61c-6731304062e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/refixia""]},{""id"":""uuid:02caf7d3-f798-4101-a5a9-ad3815d2ee3c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency)., Refixia can be used for all age groups.,|[PMDA] Drugs with a new active ingredient indicated for the control of bleeding tendency in patients with coagulation factor IX deficiency. uuid:9eda04b7-7cd3-4ceb-9ab9-3c9d3f6bc7c6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:72297 biolink:treats MONDO:0018328 PMID:41385096 "[{""id"":""uuid:e59b58fb-ca33-4e8b-a934-a0df87143fc0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6d30bc1d-a5f4-4997-9f81-2b6b800d2f7f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/lojuxta""]},{""id"":""uuid:cf2ffa21-518f-4ea7-80e9-2a0a8a0b71dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Lojuxta is indicated as an adjunct to a low‑fat diet and other lipid‑lowering medicinal products with or without low-density-lipoprotein (LDL) apheresis in adult patients with homozygous familial hypercholesterolaemia (HoFH)., , Genetic confirmation of HoFH should be obtained whenever possible. Other forms of primary hyperlipoproteinaemia and secondary causes of hypercholesterolaemia (e.g. nephrotic syndrome, hypothyroidism) must be excluded.,|[PMDA] Drugs with a new active ingredient indicated for the treatment of homozygous familial hypercholesterolemia. [Orphan drug] uuid:072c3cb5-5137-4807-bc14-f4898b038858 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:72297 biolink:treats MONDO:0005377 PMID:41385096 "[{""id"":""uuid:346567fc-785d-4436-8628-bb0b49666dbc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:2e4831e7-a911-4061-b45d-5aaa7906ca55"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/lojuxta""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Lojuxta is indicated as an adjunct to a low‑fat diet and other lipid‑lowering medicinal products with or without low-density-lipoprotein (LDL) apheresis in adult patients with homozygous familial hypercholesterolaemia (HoFH)., , Genetic confirmation of HoFH should be obtained whenever possible. Other forms of primary hyperlipoproteinaemia and secondary causes of hypercholesterolaemia (e.g. nephrotic syndrome, hypothyroidism) must be excluded., uuid:b7ea92cf-ed13-4eae-8b10-40416725a0a2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:72297 biolink:treats MONDO:0005420 PMID:41385096 "[{""id"":""uuid:9aeca91b-0c4c-4c96-96e6-e13843b30f66"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:9887cbf0-5578-48ec-b9f7-96ffef49a50a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/lojuxta""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Lojuxta is indicated as an adjunct to a low‑fat diet and other lipid‑lowering medicinal products with or without low-density-lipoprotein (LDL) apheresis in adult patients with homozygous familial hypercholesterolaemia (HoFH)., , Genetic confirmation of HoFH should be obtained whenever possible. Other forms of primary hyperlipoproteinaemia and secondary causes of hypercholesterolaemia (e.g. nephrotic syndrome, hypothyroidism) must be excluded., uuid:7223c1fc-78d3-4f99-b7d2-433cfafa53a7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB00028 biolink:treats MONDO:0021094 PMID:41385096 "[{""id"":""uuid:50feb504-59ee-439a-875b-2d86501c46ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:631a53e5-7f26-498c-85ac-15b1074616f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/flebogamma-dif""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Replacement therapy in adults, children and adolescents (0-18 years) in:, , , primary immunodeficiency syndromes with impaired antibody production;, hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic luekaemia, in whom prophylactic antibiotics have failed;, hypogammaglobulinaemia and recurrent bacterial infections in plateau-phase-multiple-myeloma patients who failed to respond to pneumococcal immunisation;, hypogammaglobulinaemia in patients after allogenic haematopoietic-stem-cell transplantation (HSCT);, congenital AIDS with recurrent bacterial infections., , , Immunomodulation in adults, children and adolescents (0-18 years) in:, , , primary immune thrombocytopenia (ITP), in patients at high risk of bleeding or prior to surgery to correct the platelet count;, Guillain Barré syndrome;, Kawasaki disease., , uuid:df8813d8-31f2-4cc3-af7e-a2de68648fbf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB00028 biolink:treats MONDO:0003864 PMID:41385096 "[{""id"":""uuid:35e8381e-2bb8-4fe7-9d40-65d9c54ed6df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:ba0d2e57-0528-466d-8ca8-ec1fcc70ed67"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/flebogamma-dif""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Replacement therapy in adults, children and adolescents (0-18 years) in:, , , primary immunodeficiency syndromes with impaired antibody production;, hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic luekaemia, in whom prophylactic antibiotics have failed;, hypogammaglobulinaemia and recurrent bacterial infections in plateau-phase-multiple-myeloma patients who failed to respond to pneumococcal immunisation;, hypogammaglobulinaemia in patients after allogenic haematopoietic-stem-cell transplantation (HSCT);, congenital AIDS with recurrent bacterial infections., , , Immunomodulation in adults, children and adolescents (0-18 years) in:, , , primary immune thrombocytopenia (ITP), in patients at high risk of bleeding or prior to surgery to correct the platelet count;, Guillain Barré syndrome;, Kawasaki disease., , uuid:adb5c8c2-38b6-4583-83b5-6046af2d8588 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB00028 biolink:treats MONDO:0012268 PMID:41385096 "[{""id"":""uuid:f2438a73-2dc1-4b6d-92b2-0e468e1ae0db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:21cddb3b-c524-4bf1-bb7d-8de4e7ce8448"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/flebogamma-dif""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Replacement therapy in adults, children and adolescents (0-18 years) in:, , , primary immunodeficiency syndromes with impaired antibody production;, hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic luekaemia, in whom prophylactic antibiotics have failed;, hypogammaglobulinaemia and recurrent bacterial infections in plateau-phase-multiple-myeloma patients who failed to respond to pneumococcal immunisation;, hypogammaglobulinaemia in patients after allogenic haematopoietic-stem-cell transplantation (HSCT);, congenital AIDS with recurrent bacterial infections., , , Immunomodulation in adults, children and adolescents (0-18 years) in:, , , primary immune thrombocytopenia (ITP), in patients at high risk of bleeding or prior to surgery to correct the platelet count;, Guillain Barré syndrome;, Kawasaki disease., , uuid:fc8bfd91-124d-4656-ad30-82d1d855fd8c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB00028 biolink:treats MONDO:0008558 PMID:41385096 "[{""id"":""uuid:ab6871ec-0187-407d-a2dd-f1028d230a7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:7496116b-72b0-4afc-9191-f3fbea3a2fbd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/flebogamma-dif""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Replacement therapy in adults, children and adolescents (0-18 years) in:, , , primary immunodeficiency syndromes with impaired antibody production;, hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic luekaemia, in whom prophylactic antibiotics have failed;, hypogammaglobulinaemia and recurrent bacterial infections in plateau-phase-multiple-myeloma patients who failed to respond to pneumococcal immunisation;, hypogammaglobulinaemia in patients after allogenic haematopoietic-stem-cell transplantation (HSCT);, congenital AIDS with recurrent bacterial infections., , , Immunomodulation in adults, children and adolescents (0-18 years) in:, , , primary immune thrombocytopenia (ITP), in patients at high risk of bleeding or prior to surgery to correct the platelet count;, Guillain Barré syndrome;, Kawasaki disease., , uuid:3b610adb-c32e-45fc-b2ad-163103ee4ce1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB00028 biolink:treats MONDO:0016218 PMID:41385096 "[{""id"":""uuid:7e2204fc-f4af-4ac2-b88f-c03c8af67690"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:5582deed-d1c0-4377-a4eb-fbfd6db04e88"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/flebogamma-dif""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Replacement therapy in adults, children and adolescents (0-18 years) in:, , , primary immunodeficiency syndromes with impaired antibody production;, hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic luekaemia, in whom prophylactic antibiotics have failed;, hypogammaglobulinaemia and recurrent bacterial infections in plateau-phase-multiple-myeloma patients who failed to respond to pneumococcal immunisation;, hypogammaglobulinaemia in patients after allogenic haematopoietic-stem-cell transplantation (HSCT);, congenital AIDS with recurrent bacterial infections., , , Immunomodulation in adults, children and adolescents (0-18 years) in:, , , primary immune thrombocytopenia (ITP), in patients at high risk of bleeding or prior to surgery to correct the platelet count;, Guillain Barré syndrome;, Kawasaki disease., , uuid:2ff9992b-e639-48b8-be85-81a39631aa9e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB00028 biolink:treats MONDO:0012727 PMID:41385096 "[{""id"":""uuid:39ad558d-7851-4f90-a541-3f7d5946968f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:5df1040a-00aa-4b4c-aa2c-6223ac178281"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/flebogamma-dif""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Replacement therapy in adults, children and adolescents (0-18 years) in:, , , primary immunodeficiency syndromes with impaired antibody production;, hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic luekaemia, in whom prophylactic antibiotics have failed;, hypogammaglobulinaemia and recurrent bacterial infections in plateau-phase-multiple-myeloma patients who failed to respond to pneumococcal immunisation;, hypogammaglobulinaemia in patients after allogenic haematopoietic-stem-cell transplantation (HSCT);, congenital AIDS with recurrent bacterial infections., , , Immunomodulation in adults, children and adolescents (0-18 years) in:, , , primary immune thrombocytopenia (ITP), in patients at high risk of bleeding or prior to surgery to correct the platelet count;, Guillain Barré syndrome;, Kawasaki disease., , uuid:fc12de29-d4c6-4b56-a66f-817b400573a7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:OP35X9610Y biolink:treats NCIT:C118469 PMID:41385096 "[{""id"":""uuid:be822ebe-3af6-49dd-9605-24defe6f6b5a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:1cb6a24c-c078-4cf3-a520-c1d75a36e1eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/skytrofa-previously-lonapegsomatropin-ascendis-pharma""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Growth failure in children and adolescents aged from 3 years up to 18 years due to insufficient endogenous growth hormone secretion (growth hormone deficiency [GHD]), uuid:711b09d9-db7f-44dd-adbd-cdb84a4da0f2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:125354 biolink:treats MONDO:0005062 PMID:41385096 "[{""id"":""uuid:009372af-b9c5-4db5-9008-ba30769b8d5d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:c68942a3-3101-4f7d-863f-1892814ae01f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/mozobil""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Mozobil is indicated in combination with granulocyte-colony-stimulating factor to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with lymphoma and multiple myeloma whose cells mobilise poorly., uuid:256115c0-cdb0-4663-9fea-ed869f1c6dd6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:261454 biolink:treats MONDO:0001134 PMID:41385096 "[{""id"":""uuid:0aa134f2-7caa-4fca-92e5-85b0ec23bb37"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:658a0ed1-4c8d-4f0a-b220-0b1c53260fb9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/coaprovel""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of essential hypertension. This fixed dose combination is indicated in adult patients whose blood pressure is not adequately controlled on irbesartan or hydrochlorothiazide alone. uuid:2a41fd42-9caa-4192-941a-c30b0f20b027 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:84500 biolink:treats UMLS:C2586081 PMID:41385096 "[{""id"":""uuid:10288008-c66b-4009-b222-d895943e9d04"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:41a4bdd1-8ee1-41e2-99da-59111cedd138"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/champix""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Champix is indicated for smoking cessation in adults. uuid:cfe0fd34-9fb8-4004-a281-9172add07c26 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:JSV288Q5CV biolink:treats MONDO:0100096 PMID:41385096 "[{""id"":""uuid:8e3ca0cd-4d6f-4e34-bbb5-fec615715b25"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:33e3bb80-77d8-423a-be36-d7219213780e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:738642c8-2cd6-473c-9f7c-fd976bb70a48"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in individuals 12 years of age and older. Comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in individuals 12 years of age and older. Comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in children aged 5 to 11 years. Comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in infants and children aged 6 months to 4 years. Comirnaty Original/Omicron BA.1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against COVID-19.Comirnaty Original/Omicron BA.4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in individuals 12 years of age and older.Comirnaty Original/Omicron BA.4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in children aged 5 to 11 years.Comirnaty Original/Omicron BA.4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in children aged 5 to 11 years. Comirnaty Original/Omicron BA.4-5 (1.5/1.5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in infants and children aged 6 months to 4 years. Comirnaty Omicron XBB.1.5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in individuals 12 years of age and older.Comirnaty Omicron XBB.1.5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in children aged 5 to 11 years.Comirnaty Omicron XBB.1.5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in children aged 5 to 11 years.Comirnaty Omicron XBB.1.5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in infants and children aged 6 months to 4 years.The use of this vaccine should be in accordance with official recommendations.|[PMDA] A drug with a new additional pediatric dosage in an additional dosage form indicated for the prevention of disease caused by SARS-CoV-2 infection (COVID-19). [Drug pertaining to Special Approval for Emergency] uuid:3d7fb640-597a-4df8-b323-8e1ea7f72087 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71013 biolink:treats HP:0007359 PMID:41385096 "[{""id"":""uuid:10a185d4-a967-4ba0-b2f5-af4848c4f750"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c2d08266-243c-4a13-b76c-4c55044014d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/fycompa""]},{""id"":""uuid:1d647f52-6d79-45a5-9aee-287db2a1e870"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Fycompa is indicated for the adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in adult and adolescent patients from 12 years of age with epilepsy.Fycompa is indicated for the adjunctive treatment of primary generalised tonic-clonic seizures in adult and adolescent patients from 12 years of age with idiopathic generalised epilepsy.|[PMDA] A drug with a new route of administration indicated for the following treatment: partial seizures (including secondary generalized seizures) in patients with epilepsy and an adjunctive therapy with other antiepileptic drugs to treat tonic-clonic seizure in patients with epilepsy who have not responded sufficiently to other antiepileptic drugs. It is used as an alternative therapy for perampanel oral formulation in patients who are temporarily unable to be administered orally. uuid:449fc96a-7772-404c-983d-d1a557eccff7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71013 biolink:treats UMLS:C0270838 PMID:41385096 "[{""id"":""uuid:3c08155b-d000-4f08-a4e0-498b1df713b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:0f6eebd3-7325-40cc-9cb4-da70e1172586"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/fycompa""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Fycompa is indicated for the adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in adult and adolescent patients from 12 years of age with epilepsy.Fycompa is indicated for the adjunctive treatment of primary generalised tonic-clonic seizures in adult and adolescent patients from 12 years of age with idiopathic generalised epilepsy. uuid:5a358788-4789-4d78-80f6-55943a542c09 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:73B0K5S26A biolink:treats MONDO:0007915 PMID:41385096 "[{""id"":""uuid:6564e802-0105-4a63-a91d-43901d853503"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:349a217c-ba84-4b50-8bda-7c31958526f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/benlysta""]},{""id"":""uuid:a2a87d7a-3db2-4e10-9d19-f15b5e261c9a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Benlysta is indicated as add-on therapy in patients aged 5 years and older with active, autoantibody positive systemic lupus erythematosus (SLE) with a high degree of disease activity (e.g., positive anti dsDNA and low complement) despite standard therapy.Benlysta is indicated in combination with background immunosuppressive therapies for the treatment of adult patients with active lupus nephritis.|[PMDA] Drugs with a new active ingredient indicated for the treatment of systemic lupus erythematosus in patients who have not responded sufficiently to conventional treatments. uuid:70cd63f6-3a29-4718-8fd0-6fb56a5a362c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB13915 biolink:treats MONDO:0018905 PMID:41385096 "[{""id"":""uuid:7be9902f-ae6c-4af0-9f9c-2f73d6955a1b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a1887456-9d86-4944-b21c-9d1e50cb014b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/yescarta""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Yescarta is indicated for the treatment of adult patients with diffuse large B cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy.Yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) DLBCL and primary mediastinal large B cell lymphoma (PMBCL), after two or more lines of systemic therapy.Yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (FL) after three or more lines of systemic therapy. uuid:27859085-78fa-4f46-80c6-11e1b7ec7943 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB13915 biolink:treats MONDO:0020323 PMID:41385096 "[{""id"":""uuid:4f2a3108-561a-4b04-9f80-113f97e013d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:7beb0197-1e93-46bd-b774-03908b865f1f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/yescarta""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Yescarta is indicated for the treatment of adult patients with diffuse large B cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy.Yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) DLBCL and primary mediastinal large B cell lymphoma (PMBCL), after two or more lines of systemic therapy.Yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (FL) after three or more lines of systemic therapy. uuid:11ffc468-449a-471c-8c01-287c4250ae7f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB13915 biolink:treats MONDO:0018906 PMID:41385096 "[{""id"":""uuid:e046b01f-0f0b-4009-8cda-b76d961cf9dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d7dda574-89e2-484b-96fb-c62d0282f6a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/yescarta""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Yescarta is indicated for the treatment of adult patients with diffuse large B cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy.Yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) DLBCL and primary mediastinal large B cell lymphoma (PMBCL), after two or more lines of systemic therapy.Yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (FL) after three or more lines of systemic therapy. uuid:ebd1bb63-325b-4e26-a732-b53a297cd14e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49375 biolink:treats MONDO:0006115 PMID:41385096 "[{""id"":""uuid:ad365071-69c3-4810-8cf1-9a4f53d252cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:ce2427e0-d8d7-4bbb-8a15-3fbf87429219"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Sprycel is indicated for the treatment of paediatric patients with:newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukaemia in chronic phase (Ph+ CML CP) or Ph+ CML CP resistant or intolerant to prior therapy including imatinib.newly diagnosed Ph+ acute lymphoblastic leukaemia (ALL) in combination with chemotherapy.Sprycel is indicated for the treatment of adult patients with:newly diagnosed Philadelphia-chromosome-positive (Ph+) chronic myelogenous leukaemia (CML) in the chronic phase;chronic, accelerated or blast phase CML with resistance or intolerance to prior therapy including imatinib mesilate;Ph+ acute lymphoblastic leukaemia (ALL) and lymphoid blast CML with resistance or intolerance to prior therapy.Sprycel is indicated for the treatment of paediatric patients with:newly diagnosed Ph+ CML in chronic phase (Ph+ CML-CP) or Ph+ CML-CP resistant or intolerant to prior therapy including imatinib. uuid:c064597d-1228-42d8-bc3e-48e5cd21fdb9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:9H414A99MD biolink:treats MONDO:0043731 PMID:41385096 "[{""id"":""uuid:739cae85-277d-4157-8afe-d7ae5f4cdd91"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:728ecfbf-1495-48c6-8366-662d76cd4f86"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Xofigo is indicated for the treatment of adults with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases. uuid:73f88f6a-15c5-49da-a91b-47a681c34118 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:54534MX6Z9 biolink:treats MONDO:0009693 PMID:41385096 "[{""id"":""uuid:bd7c0ffe-ecdc-4df0-9a1a-04b576bb5173"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:865ece4a-c23f-4b73-ab3a-30142f4d9949"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/tecvayli""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] TECVAYLI is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy. uuid:4dfefcab-1a99-4e78-b93d-5b3300ee504e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31687 biolink:treats MONDO:0010788 PMID:41385096 "[{""id"":""uuid:3d850134-bf0b-4648-9c34-2f75c73914c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:9404acb7-0e31-47f1-8d7e-d3045afa77bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/raxone""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Raxone is indicated for the treatment of visual impairment in adolescent and adult patients with Leber’s Hereditary Optic Neuropathy (LHON). uuid:9fc2dd52-c2a8-4a19-8da7-066e2eeba75e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3A189DH42V biolink:treats MONDO:0005314 PMID:41385096 "[{""id"":""uuid:e64d78ff-bf09-4292-aa9e-3bc219d99329"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:3602aaf9-2cf4-488d-bd56-30d87f05ab0c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/lemtrada""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Lemtrada is indicated for adult patients with relapsing-remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features. uuid:2d42397f-9046-44df-80aa-326f05164198 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:391960 biolink:treats UMLS:C0150045 PMID:41385096 "[{""id"":""uuid:4445a871-67d3-4db7-ba68-7fb83442694e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:560103ae-5923-43d6-a308-5bea4365a16f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/emselex""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in adult patients with overactive bladder syndrome. uuid:d5af98a5-dd7b-4416-94e9-4a6539ed16a7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:391960 biolink:treats MONDO:0006624 PMID:41385096 "[{""id"":""uuid:5faeacdf-68e6-46e7-9fed-da053e055b7d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:712d96fc-f6f1-4b6d-8a5a-92d5b31eb22f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/emselex""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in adult patients with overactive bladder syndrome. uuid:0c5a92ba-a53d-4f69-99c0-f4fd5d49f2dc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:93752 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:16c65a94-5225-4af6-8c20-08b5ad20e7ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:bea2b5e6-12ad-44e2-8efc-aaee118d3256"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/piqray""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Piqray is indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with a PIK3CA mutation after disease progression following endocrine therapy as monotherapy (see section 5.1). uuid:9613c59c-eec5-4980-b85f-6a8150dc4233 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:93752 biolink:treats MONDO:0700079 PMID:41385096 "[{""id"":""uuid:a3490888-92eb-4a13-8d8c-057b2fa5c47c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:03bcf7d4-16f5-47bc-84c7-fa5831fe670f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/piqray""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Piqray is indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with a PIK3CA mutation after disease progression following endocrine therapy as monotherapy (see section 5.1). uuid:43594e97-2e57-4e90-83a1-5c8efa3c90b9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:93752 biolink:treats MONDO:0000618 PMID:41385096 "[{""id"":""uuid:6f8581be-366f-42f1-b507-d46196f143dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:37dd813a-34fb-44c0-bb5b-1ec040385c79"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/piqray""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Piqray is indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with a PIK3CA mutation after disease progression following endocrine therapy as monotherapy (see section 5.1). uuid:2ef3e745-564e-4885-839b-fd64a9c6294d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:93752 biolink:treats MONDO:0004379 PMID:41385096 "[{""id"":""uuid:736af890-708b-4ef2-931d-8a4100eb9169"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:870600e4-3197-4cdd-97b7-fdc8adf798d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/piqray""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Piqray is indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with a PIK3CA mutation after disease progression following endocrine therapy as monotherapy (see section 5.1). uuid:1a8110e5-9aa1-44d8-be22-0dd7e3075af6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:129762253 biolink:treats EFO:0006951 PMID:41385096 "[{""id"":""uuid:89eb583d-86a1-4c85-bacd-e31a5fe86030"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:2e13af1b-c377-4761-8b64-0aaa8d431be6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/pedmarqsi""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Pedmarqsi is indicated for the prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to < 18 years of age with localised, non-metastatic, solid tumours. uuid:3da6886f-ecf0-4317-9039-c75dc15d4b78 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:129762253 biolink:treats MONDO:0004992 PMID:41385096 "[{""id"":""uuid:0893f196-2f7f-48ff-86fb-ee210f12f53a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:6335e935-8ca9-4ec9-a6e8-3f0986a527b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/pedmarqsi""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Pedmarqsi is indicated for the prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to < 18 years of age with localised, non-metastatic, solid tumours. uuid:91f8e3cc-d4da-4cf9-96fa-65c8a15b002f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DB1041CXDG biolink:treats MONDO:0009693 PMID:41385096 "[{""id"":""uuid:9253efac-6eba-41d5-a97d-3e6f1677010b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d3bd398c-b594-4bf4-b2ed-762a15e649f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/blenrep""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Blenrep is indicated as monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy. uuid:1ba758a9-d055-4d9b-9da0-3360cc107993 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:216293 biolink:treats MONDO:0001134 PMID:41385096 "[{""id"":""uuid:ca16a85c-adc1-4aa6-b7a0-ab41a0b41bee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:8a76fb3b-e9b3-4994-9ed9-027c156e1a25"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/actelsar-hct""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of essential hypertension.Actelsar HCT fixed-dose combination (40 mg telmisartan / 12.5 mg hydrochlorothiazide) is indicated in adults whose blood pressure is not adequately controlled on telmisartan alone.Actelsar HCT fixed-dose combination (80 mg telmisartan / 12.5 mg hydrochlorothiazide) is indicated in adults whose blood pressure is not adequately controlled on telmisartan alone.Actelsar HCT fixed-dose combination (80 mg telmisartan / 25 mg hydrochlorothiazide) is indicated in adults whose blood pressure is not adequately controlled on Actelsar HCT 80 mg / 12.5 mg (80 mg telmisartan / 12.5 mg hydrochlorothiazide) or adults who have been previously stabilised on telmisartan and hydrochlorothiazide given separately. uuid:0c6808ce-6b15-490d-8f34-cf7ad791198f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9434 biolink:treats MONDO:0005010 PMID:41385096 "[{""id"":""uuid:913337b7-289e-4cba-82ac-88f59cf0c46a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a699ef20-c345-4273-9d22-f09491ccdac8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/telmisartan-actavis""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] HypertensionTreatment of essential hypertension in adults.Cardiovascular preventionReduction of cardiovascular morbidity in patients with:manifest atherothrombotic cardiovascular disease (history of coronary heart disease, stroke, or peripheral arterial disease) or;type 2 diabetes mellitus with documented target organ damage. uuid:cb109efa-b39f-4cad-bf02-290408ac7a50 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9434 biolink:treats MONDO:0005386 PMID:41385096 "[{""id"":""uuid:297d6ec7-5a5b-4dda-8e49-1b4b652225d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:c0855ed3-8677-4962-9ce3-6760a618d4b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/telmisartan-actavis""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] HypertensionTreatment of essential hypertension in adults.Cardiovascular preventionReduction of cardiovascular morbidity in patients with:manifest atherothrombotic cardiovascular disease (history of coronary heart disease, stroke, or peripheral arterial disease) or;type 2 diabetes mellitus with documented target organ damage. uuid:57827de3-df84-4cbf-bdec-da637d89b00b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9434 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:e730913b-647c-4949-940f-679dc898660d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:c44b0805-9006-484f-baca-ff8ebf07427a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/telmisartan-actavis""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] HypertensionTreatment of essential hypertension in adults.Cardiovascular preventionReduction of cardiovascular morbidity in patients with:manifest atherothrombotic cardiovascular disease (history of coronary heart disease, stroke, or peripheral arterial disease) or;type 2 diabetes mellitus with documented target organ damage. uuid:5a601eed-63b1-4b6d-8233-16ac43c7cc75 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4EQZ6YO2HI biolink:treats HP:0020110 PMID:41385096 "[{""id"":""uuid:adcfb98f-96ee-4a4f-a21c-81a570b9d18c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:6b366eb8-a890-42c7-86b7-6bb66ca45bc2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/prolia""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures. In postmenopausal women Prolia significantly reduces the risk of vertebral, non vertebral and hip fractures.Treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures. In men with prostate cancer receiving hormone ablation, Prolia significantly reduces the risk of vertebral fractures. uuid:7d70b222-a5cc-496c-a5bd-40b3e83a90d7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4EQZ6YO2HI biolink:treats MONDO:0000837 PMID:41385096 "[{""id"":""uuid:cdcb48a2-04b3-4bac-a4d0-660de72e8bc9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:0f018812-4b3f-4416-9312-77882850ef56"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/prolia""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures. In postmenopausal women Prolia significantly reduces the risk of vertebral, non vertebral and hip fractures.Treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures. In men with prostate cancer receiving hormone ablation, Prolia significantly reduces the risk of vertebral fractures. uuid:b35e1af6-cf4e-4a4d-8447-95106604fba2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:76015 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:47326016-c029-4a87-8059-13d69d982b8c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:5848a4f1-de46-451a-b423-b65a26bef7c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/brintellix""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of major depressive episodes in adults. uuid:51235cda-6d6f-427e-82d0-910553b9ece3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63587 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:75631b97-c11b-43f3-8007-15e454126f56"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f1c71e84-ac76-423d-88c8-b3eacca0213c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/halaven""]},{""id"":""uuid:99b562a4-0416-434d-828e-ecde0ac0d0eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Halaven monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimens for advanced disease (see section 5.1). Prior therapy should have included an anthracycline and a taxane unless patients were not suitable for these treatments.Halaven is indicated for the treatment of adult patients with unresectable liposarcoma who have received prior anthracycline containing therapy (unless unsuitable) for advanced or metastatic disease (see section 5.1).|[PMDA] A drug with a new active ingredient indicated for the treatment of inoperable or recurrent breast cancer. [Priority review] uuid:39970b1b-9609-40f2-b54d-58b04571d247 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63587 biolink:treats MONDO:0005060 PMID:41385096 "[{""id"":""uuid:078b5e2f-cb26-4ee7-a1d3-eff841b19dd0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:cc6bd12e-ac29-44f7-957f-088080cc6b2b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/halaven""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Halaven monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimens for advanced disease (see section 5.1). Prior therapy should have included an anthracycline and a taxane unless patients were not suitable for these treatments.Halaven is indicated for the treatment of adult patients with unresectable liposarcoma who have received prior anthracycline containing therapy (unless unsuitable) for advanced or metastatic disease (see section 5.1). uuid:42024fb4-ad87-4ea4-b6e4-bbbd251d042f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9570 biolink:treats MONDO:0005570 PMID:41385096 "[{""id"":""uuid:62e079b4-9b9f-47bb-9420-6245346eed95"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:c51d67b4-62af-4690-b452-9035ff80f3fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/thiotepa-riemser""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Thiotepa Riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (TBI), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with HPCT support is appropriate for the treatment of solid tumours in adult and paediatric patients.Thiotepa Riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (TBI), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with HPCT support is appropriate for the treatment of solid tumours in adult and paediatric patients uuid:6a39db16-a540-42d6-a9c6-48350e1d01f7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:142406 biolink:treats MONDO:0024317 PMID:41385096 "[{""id"":""uuid:9015f783-d505-4650-95cb-b65499201790"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:0df950e7-7aa2-49c2-b948-63102c1a1136"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/prialt""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Ziconotide is indicated for the treatment of severe, chronic pain in patients who require intrathecal (IT) analgesia. uuid:683b8b99-0101-4cd1-82e5-f2fa1b071122 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:94686 biolink:treats EFO:0005935 PMID:41385096 "[{""id"":""uuid:ed3ec0ac-389a-4fcd-aa65-6df4003cc2ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:4c35d901-1da0-4efd-a012-b8f77e4e746f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/alli""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Alli is indicated for weight loss in adults who are overweight (body mass index, BMI, ≥ 28 kg/m2) and should be taken in conjunction with a mildly hypocaloric, lower-fat diet. uuid:a18261ea-d6e6-461c-acf8-08cfcbfc33e1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63791 biolink:treats MONDO:0018881 PMID:41385096 "[{""id"":""uuid:b288398c-e1c3-4d2c-96c2-db65bee2b63f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4e09bdb2-25dd-49c5-a45e-b86a974c8040"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/revlimid""]},{""id"":""uuid:648ab28d-09c8-4f20-b065-5a1798298664"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Multiple myelomaRevlimid as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation.Revlimid as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4.2) is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant.Revlimid in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy.Myelodysplastic syndromesRevlimid as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.Mantle cell lymphomaRevlimid as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma.Follicular lymphomaRevlimid in combination with rituximab (anti-CD20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (Grade 1 – 3a).|[PMDA] A drug with a new additional indication and a new dosage for the treatment of myelodysplastic syndrome associated with a deletion 5q cytogenetic abnormality. [Orphan drug] uuid:6c09ecaf-ce5e-4210-ad37-578703001710 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:567361 biolink:treats MONDO:0005301 PMID:41385096 "[{""id"":""uuid:6a732be3-c8a0-47d2-a9f3-b446da101cbb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:2748c16f-ceca-43d3-ab20-2de784cfdfdd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/mavenclad""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of adult patients with highly active relapsing multiple sclerosis (MS) as defined by clinical or imaging features. uuid:e4295a45-0b5d-443e-892e-a0b1821f4893 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:939U7C91AI biolink:treats MONDO:0020066 PMID:41385096 "[{""id"":""uuid:7c2465ca-46d1-4278-a23b-b06ef5c4247f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d3af512b-0d47-4c64-8c45-62436523c6a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Sunosi is indicated to improve wakefulness and reduce excessive daytime sleepiness in adult patients with narcolepsy (with or without cataplexy).Sunosi is indicated to improve wakefulness and reduce excessive daytime sleepiness (EDS) in adult patients with obstructive sleep apnoea (OSA) whose EDS has not been satisfactorily treated by primary OSA therapy, such as continuous positive airway pressure (CPAP). uuid:3c4ebb92-45e6-4dc9-a54b-63bb1cb5c144 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31602 biolink:treats HP:0032149 PMID:41385096 "[{""id"":""uuid:e2e1b82f-207d-4443-8222-778166775e48"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:b85854f7-ab74-4a7c-a779-e31194c3f26d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Instanyl is indicated for the management of breakthrough pain in adults already receiving maintenance opioid therapy for chronic cancer pain. Breakthrough pain is a transitory exacerbation of pain that occurs on a background of otherwise controlled persistent pain. Patients receiving maintenance opioid therapy are those who are taking at least 60 mg of oral morphine daily, at least 25 micrograms of transdermal fentanyl per hour, at least 30 mg oxycodone daily, at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid for a week or longer. uuid:8162e775-445a-419d-adee-cf3040371561 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31602 biolink:treats NCIT:C9467 PMID:41385096 "[{""id"":""uuid:3b5572c4-0035-45b4-80ca-4d65c4f9c50e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:440c2e35-b598-46ad-b5ee-d8967c7e6a33"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Instanyl is indicated for the management of breakthrough pain in adults already receiving maintenance opioid therapy for chronic cancer pain. Breakthrough pain is a transitory exacerbation of pain that occurs on a background of otherwise controlled persistent pain. Patients receiving maintenance opioid therapy are those who are taking at least 60 mg of oral morphine daily, at least 25 micrograms of transdermal fentanyl per hour, at least 30 mg oxycodone daily, at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid for a week or longer. uuid:f7cd7ccd-bd6c-4081-9660-7b573626e6fd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:284756 biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:3d7d6b07-687d-4600-8698-58a81739c569"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f5f00110-0b3e-48f4-9d7c-98f03f666c07"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/kaletra""]},{""id"":""uuid:d207c833-edba-47c7-9e08-54e065502dd0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Kaletra is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infected adults, adolescents and children aged from 14 days and older.The choice of Kaletra to treat protease inhibitor experienced HIV-1 infected patients should be based on individual viral resistance testing and treatment history of patients.|[PMDA] Drug with a new dosage indicated for treatment of HIV infection. [Orphan Drug] uuid:87b84414-368e-4be3-9c4e-d70366acdc5c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59900 biolink:treats MONDO:0044067 PMID:41385096 "[{""id"":""uuid:b4aab1a2-b9d3-42e9-af12-e97adac6b012"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:0dac648b-e4b3-4929-80f5-8d4e7f3d78bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of invasive candidiasis in adult or paediatric patients;treatment of invasive aspergillosis in adult or paediatric patients who are refractory to or intolerant of amphotericin B, lipid formulations of amphotericin B and / or itraconazole. Refractoriness is defined as progression of infection or failure to improve after a minimum of seven days of prior therapeutic doses of effective antifungal therapy;empirical therapy for presumed fungal infections (such as Candida or Aspergillus) in febrile, neutropaenic adult or paediatric patients. uuid:cdc22274-41e0-4060-bec9-c7dc375326e1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59900 biolink:treats MONDO:0000240 PMID:41385096 "[{""id"":""uuid:e8859409-6af1-4efa-9234-d4eddbd678b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:b40a188f-4b6c-4d7f-9c51-64e85bb64805"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of invasive candidiasis in adult or paediatric patients;treatment of invasive aspergillosis in adult or paediatric patients who are refractory to or intolerant of amphotericin B, lipid formulations of amphotericin B and / or itraconazole. Refractoriness is defined as progression of infection or failure to improve after a minimum of seven days of prior therapeutic doses of effective antifungal therapy;empirical therapy for presumed fungal infections (such as Candida or Aspergillus) in febrile, neutropaenic adult or paediatric patients. uuid:0321a42e-995e-4167-9a6d-9ade6a2bd8a3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59900 biolink:treats MONDO:0002041 PMID:41385096 "[{""id"":""uuid:0bf3aff4-7eb3-4181-b917-f3082c67609d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:bc6dac19-a16f-485b-ae54-10cd46086970"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of invasive candidiasis in adult or paediatric patients;treatment of invasive aspergillosis in adult or paediatric patients who are refractory to or intolerant of amphotericin B, lipid formulations of amphotericin B and / or itraconazole. Refractoriness is defined as progression of infection or failure to improve after a minimum of seven days of prior therapeutic doses of effective antifungal therapy;empirical therapy for presumed fungal infections (such as Candida or Aspergillus) in febrile, neutropaenic adult or paediatric patients. uuid:359c8934-573e-42a4-b85c-01bc6ff535f8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59900 biolink:treats MONDO:0002026 PMID:41385096 "[{""id"":""uuid:b8ffa363-389e-49ad-b11e-63929a2f4288"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:5f421b41-312b-4a97-9b52-725512a18acd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of invasive candidiasis in adult or paediatric patients;treatment of invasive aspergillosis in adult or paediatric patients who are refractory to or intolerant of amphotericin B, lipid formulations of amphotericin B and / or itraconazole. Refractoriness is defined as progression of infection or failure to improve after a minimum of seven days of prior therapeutic doses of effective antifungal therapy;empirical therapy for presumed fungal infections (such as Candida or Aspergillus) in febrile, neutropaenic adult or paediatric patients. uuid:7716593c-7a64-4ffc-8e40-f32b2dd3952a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59900 biolink:treats MONDO:0005657 PMID:41385096 "[{""id"":""uuid:3e72d3fd-f85a-473a-8dc8-8bdf2717ea23"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:ac156dfd-5832-4929-8b70-5ac67a918bff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of invasive candidiasis in adult or paediatric patients;treatment of invasive aspergillosis in adult or paediatric patients who are refractory to or intolerant of amphotericin B, lipid formulations of amphotericin B and / or itraconazole. Refractoriness is defined as progression of infection or failure to improve after a minimum of seven days of prior therapeutic doses of effective antifungal therapy;empirical therapy for presumed fungal infections (such as Candida or Aspergillus) in febrile, neutropaenic adult or paediatric patients. uuid:785f13f2-e404-4722-a08d-99763c86b328 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4B93MGE4AL biolink:treats MONDO:0019087 PMID:41385096 "[{""id"":""uuid:ee5efe2d-d279-4ad5-9d4e-58cb445f94e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:5bbec5e3-a9ad-403e-922f-24e343872aa4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/lytgobi""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Lytgobi monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy. uuid:abaab3a8-c515-4d8f-8475-c91e9ffe9411 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:8680B21W73 biolink:treats MONDO:0000050 PMID:41385096 "[{""id"":""uuid:a6d67b18-de73-42ab-9adb-4850ee5125a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:fe592542-d2e8-4aaf-8929-0d2612e80689"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] This medicinal product is for diagnostic use only. GHRYVELIN is indicated for the diagnosis of growth hormone deficiency (GHD) in adults. uuid:bf8120ac-9773-48d5-a066-f884e631477c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:U59UGK3IPC biolink:treats MONDO:0005314 PMID:41385096 "[{""id"":""uuid:9b14813e-58db-4977-9f57-a6708edca663"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:47fb3e09-45b6-41f8-ad37-bb2d7a20bf16"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/briumvi""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Briumvi is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features. uuid:f2c9d1f1-c23b-4019-8d86-115a2e6c32e8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:MLU3LU3EVV biolink:treats MONDO:0001516 PMID:41385096 "[{""id"":""uuid:e104dfd5-5a22-49a1-b0ad-f7f3429683b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:6884982c-8e98-4b6f-8ec8-6b643207514d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/zolgensma""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Zolgensma is indicated for the treatment of:patients with 5q spinal muscular atrophy (SMA) with a bi-allelic mutation in the SMN1 gene and a clinical diagnosis of SMA Type 1, orpatients with 5q SMA with a bi-allelic mutation in the SMN1 gene and up to 3 copies of the SMN2 gene. uuid:0e833d3b-c0b0-4694-a385-7d15e7c5918b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:MLU3LU3EVV biolink:treats MONDO:0009669 PMID:41385096 "[{""id"":""uuid:02dafb54-9d13-4906-973b-6533ade146dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:386a26c0-6d35-4a7c-a452-42eef4fdae91"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/zolgensma""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Zolgensma is indicated for the treatment of:patients with 5q spinal muscular atrophy (SMA) with a bi-allelic mutation in the SMN1 gene and a clinical diagnosis of SMA Type 1, orpatients with 5q SMA with a bi-allelic mutation in the SMN1 gene and up to 3 copies of the SMN2 gene. uuid:b29dcc7c-77da-4ac4-97b4-dce71ce24e18 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:TL60C27RLH biolink:treats MONDO:0006573 PMID:41385096 "[{""id"":""uuid:85e69e9f-9c24-4ce7-934a-c4ade7a32626"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:05c3256d-975e-42bd-a792-31b24366d469"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/myalepta""]},{""id"":""uuid:2b89a499-c90a-4b8c-91b9-eae9e70ae4ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Myalepta is indicated as an adjunct to diet as a replacement therapy to treat the complications of leptin deficiency in lipodystrophy (LD) patients:with confirmed congenital generalised LD (Berardinelli-Seip syndrome) or acquired generalised LD (Lawrence syndrome) in adults and children 2 years of age and abovewith confirmed familial partial LD or acquired partial LD (Barraquer-Simons syndrome), in adults and children 12 years of age and above for whom standard treatments have failed to achieve adequate metabolic control.|[PMDA] A drug with a new active ingredient for the treatment of lipodystrophy. [Orphan drug] uuid:023c4f91-034c-4b72-ae8c-de110dae63fa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:TL60C27RLH biolink:treats MONDO:0006536 PMID:41385096 "[{""id"":""uuid:b6da0a3d-7170-490d-924a-40e6168d3660"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:90ace2b7-6866-4b26-9f8b-ef473b2b7e3d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/myalepta""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Myalepta is indicated as an adjunct to diet as a replacement therapy to treat the complications of leptin deficiency in lipodystrophy (LD) patients:with confirmed congenital generalised LD (Berardinelli-Seip syndrome) or acquired generalised LD (Lawrence syndrome) in adults and children 2 years of age and abovewith confirmed familial partial LD or acquired partial LD (Barraquer-Simons syndrome), in adults and children 12 years of age and above for whom standard treatments have failed to achieve adequate metabolic control. uuid:cdedf7e4-e66c-4833-8d98-d8cf351a890d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:TL60C27RLH biolink:treats MONDO:0020088 PMID:41385096 "[{""id"":""uuid:fdd6fddc-734d-48b3-b9dd-94a064d42d91"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:0adbeeba-e21d-46f6-86d0-758d8c2342f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/myalepta""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Myalepta is indicated as an adjunct to diet as a replacement therapy to treat the complications of leptin deficiency in lipodystrophy (LD) patients:with confirmed congenital generalised LD (Berardinelli-Seip syndrome) or acquired generalised LD (Lawrence syndrome) in adults and children 2 years of age and abovewith confirmed familial partial LD or acquired partial LD (Barraquer-Simons syndrome), in adults and children 12 years of age and above for whom standard treatments have failed to achieve adequate metabolic control. uuid:1418e7e0-b478-4ebb-8cf9-70251f2994d1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB16536 biolink:treats MONDO:0006543 PMID:41385096 "[{""id"":""uuid:e53f4906-c5e5-48e1-bfe2-62d2fd05a930"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:ab6cfbc5-f40a-4e19-84a7-ec654e0cd8cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of partial thickness wounds associated with dystrophic and junctional epidermolysis bullosa (EB) in patients 6 months and older. uuid:78dd6249-dc51-45a8-b087-bc807de15138 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB16536 biolink:treats MONDO:0017612 PMID:41385096 "[{""id"":""uuid:dfb3e858-89cf-41d0-9fd9-d26e6f65c943"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:99b4de52-0f12-417a-984d-10c84845eb66"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of partial thickness wounds associated with dystrophic and junctional epidermolysis bullosa (EB) in patients 6 months and older. uuid:eda29b49-0b3c-4502-bc66-5ac8bfbfae41 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:11564052 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:0c9e658c-b079-4b0a-826a-1fea8377f152"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:4f5bc5f9-b228-457f-af68-9b474c5e8226"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Maintenance treatment of asthma in adults whose disease is not adequately controlled. uuid:d8fd116e-4ee5-410b-b48c-671030f348f0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:25099114 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:1384ba86-a0da-4e4d-aa84-0309570322fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:7684e667-4212-425f-8419-0687553e3c50"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/atectura-breezhaler""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Atectura Breezhaler is indicated as a maintenance treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists. uuid:b6b8be93-22e1-49bd-83a1-e8e8943a97c3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:ZL1R02VT79 biolink:treats MONDO:0001660 PMID:41385096 "[{""id"":""uuid:9ceef006-acd8-470e-9312-8a6f7b3afc99"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:2fd2ea16-1917-4701-a1f8-b5c2bb71641f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ranivisio""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Ranivisio is indicated in adults for:• The treatment of neovascular (wet) age-related macular degeneration (AMD)• The treatment of visual impairment due to diabetic macular oedema (DME)• The treatment of proliferative diabetic retinopathy (PDR)• The treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO)• The treatment of visual impairment due to choroidal neovascularisation (CNV) uuid:4083c0f4-8319-4c5b-88ff-e2bf2c253a85 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:ZL1R02VT79 biolink:treats MONDO:0041093 PMID:41385096 "[{""id"":""uuid:c5d086ac-757b-41c5-8e89-798d131b3f0d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:519e75c5-c91d-4832-aa88-8ee84a386229"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ranivisio""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Ranivisio is indicated in adults for:• The treatment of neovascular (wet) age-related macular degeneration (AMD)• The treatment of visual impairment due to diabetic macular oedema (DME)• The treatment of proliferative diabetic retinopathy (PDR)• The treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO)• The treatment of visual impairment due to choroidal neovascularisation (CNV) uuid:729ebbf4-ea39-4703-aaef-416a8fd6af61 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:ZL1R02VT79 biolink:treats MONDO:0810000 PMID:41385096 "[{""id"":""uuid:abd15b87-9a01-43c8-be1d-62c781e5378a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:aaa9bddc-55d5-4ba7-9e09-988b8855763a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ranivisio""]},{""id"":""uuid:36a27a3f-4846-4087-a7d3-87ce95680fad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Ranivisio is indicated in adults for:• The treatment of neovascular (wet) age-related macular degeneration (AMD)• The treatment of visual impairment due to diabetic macular oedema (DME)• The treatment of proliferative diabetic retinopathy (PDR)• The treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO)• The treatment of visual impairment due to choroidal neovascularisation (CNV)|[PMDA] A drug containing a new active ingredient indicated for treatment of age-related macular degeneration with concurrent choroidal neovascularization. [Orphan drug] uuid:1629227d-b8f7-4683-b371-65475e731904 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:1MTK0BPN8V biolink:treats MONDO:0100096 PMID:41385096 "[{""id"":""uuid:760ef312-ede8-4735-b2b0-c96a483451c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ec827b2d-3b72-4c97-9303-c525d2f534dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/xevudy""]},{""id"":""uuid:b3a5f102-a8b5-486f-8af4-292c30a4393e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Xevudy is indicated for the treatment of adults and adolescents (aged 12 years and over and weighing at least 40 kg) with coronavirus disease 2019 (COVID-19) who do not require oxygen supplementation and who are at increased risk of progressing to severe COVID-19.|[PMDA] A drug with a new active ingredient indicated for the treatment of disease caused by SARS-CoV-2 infection (COVID-19). [Drug pertaining to Special Approval for Emergency] uuid:58054e70-51fe-4e02-9156-fa56a36deeac biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68602 biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:b22da3e0-df93-41b4-a63d-d8d5eee2a9d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:aa6c2e13-1f7e-4f47-b880-afe540e95f16"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/rekambys""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Rekambys is indicated, in combination with cabotegravir injection, for the treatment of human immunodeficiency virus type 1 (HIV 1) infection in adults who are virologically suppressed (HIV-1 RNA < 50 copies/mL) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with, agents of the NNRTI and INI class. uuid:901f0748-737f-485b-8a07-5e6972e4db5f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68579 biolink:treats MONDO:0004634 PMID:41385096 "[{""id"":""uuid:c53c2ed9-20b5-4f54-90ad-de141e2f026c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:4b53395f-fd87-40d4-ba48-bd442fd13cfa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/rivaroxaban-accord""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for haemodynamically unstable PE patients.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for haemodynamically unstable PE patients).AdultsPrevention of stroke and systemic embolism in adult patients with non valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for haemodynamically unstable PE patients.)Paediatric populationTreatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment.Rivaroxaban Accord, co administered with acetylsalicylic acid (ASA) alone or with ASA plus ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers (see sections 4.3, 4.4 and 5.1).Rivaroxaban Accord, co administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischaemic events.AdultsPrevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for haemodynamically unstable PE patients.)Paediatric populationTreatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment. uuid:0dd22fc8-405f-43af-b29e-6dd7446b63e5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB16582 biolink:treats MONDO:0018905 PMID:41385096 "[{""id"":""uuid:fcd80840-38a8-49e3-a51e-65c93e789f60"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:c0422d6e-2550-4633-b80e-9f9e84fe70c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Breyanzi is indicated for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma (HGBCL), primary mediastinal large B-cell lymphoma (PMBCL) and follicular lymphoma grade 3B (FL3B), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy. uuid:a16f1621-22a3-412c-abee-982f52f59c06 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB16582 biolink:treats MONDO:0044889 PMID:41385096 "[{""id"":""uuid:781a4aea-13df-419f-9f4c-db223dd9d029"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:cd31072f-19de-46fa-9c3f-5d859230636b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Breyanzi is indicated for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma (HGBCL), primary mediastinal large B-cell lymphoma (PMBCL) and follicular lymphoma grade 3B (FL3B), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy. uuid:d35aa79c-9758-4543-bae3-0a9d30edfa3d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB16582 biolink:treats MONDO:0020323 PMID:41385096 "[{""id"":""uuid:c97dd31e-ec34-4452-8016-ca10ad1f152c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:8ead9552-292d-4d7d-879e-292a8cf138b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Breyanzi is indicated for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma (HGBCL), primary mediastinal large B-cell lymphoma (PMBCL) and follicular lymphoma grade 3B (FL3B), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy. uuid:f1e85d6f-26b3-48b9-91a9-1f381482b40a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEMBL.COMPOUND:CHEMBL4298180 biolink:treats MONDO:0005011 PMID:41385096 "[{""id"":""uuid:49807b9b-08d5-4bc8-817c-4e972c05a23f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:c2e5823c-3e1f-42c7-a306-e412bcd24d37"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/alofisel""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Alofisel is indicated for the treatment of complex perianal fistulas in adult patients with non-active/mildly active luminal Crohn’s disease, when fistulas have shown an inadequate response to at least one conventional or biologic therapy. Alofisel should be used after conditioning of fistula. uuid:409a0efc-7e7f-48b0-8961-d2d8329b55df biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEMBL.COMPOUND:CHEMBL4298180 biolink:treats HP:0005218 PMID:41385096 "[{""id"":""uuid:14853876-7f58-4437-a903-3314aef979fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:339ee154-4959-4f89-adde-4e8d26251ad7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/alofisel""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Alofisel is indicated for the treatment of complex perianal fistulas in adult patients with non-active/mildly active luminal Crohn’s disease, when fistulas have shown an inadequate response to at least one conventional or biologic therapy. Alofisel should be used after conditioning of fistula. uuid:6b98fed1-58d4-472c-8839-efd0d63bbf60 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DQ448MW7KS biolink:treats MONDO:0001577 PMID:41385096 "[{""id"":""uuid:786fe25b-2ce5-4a1a-9d76-346e7c0fb013"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4ae4e018-e0af-4898-811e-a2633d91fdc2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/synagis""]},{""id"":""uuid:a82572ca-bd5d-4405-a2c9-e25e086d382e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Synagis is indicated for the prevention of serious lower-respiratory-tract disease requiring hospitalisation caused by respiratory syncytial virus (RSV) in children at high risk for RSV disease:children born at 35 weeks of gestation or less and less than six months of age at the onset of the RSV season;children less than two years of age and requiring treatment for bronchopulmonary dysplasia within the last six months;children less than two years of age and with haemodynamically significant congenital heart disease.|[PMDA] Drugs with a new indication for the prevention of serious lower respiratory tract disease caused by respiratory syncytial (RS) virus infection in neonates, infants, and children aged 24 months and younger with pulmonary hypoplasia, airway stenosis, congenital esophageal atresia, congenital metabolic disorder, or neuromuscular disease at the early stage of the RS virus season. [Priority review] uuid:c77d60cb-81c4-414d-9b6b-4b95a8daa994 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation MESH:D000090984 biolink:treats MONDO:0100096 PMID:41385096 "[{""id"":""uuid:21006dc4-92e4-48b3-ac06-bb2968b705c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:b3bef675-17c1-4c78-9b7b-cba83e89313e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Jcovden is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older.The use of this vaccine should be in accordance with official recommendations. uuid:7047ff92-6a06-4bdc-bb39-1ae3c456e8e2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:72317 biolink:treats MONDO:0005086 PMID:41385096 "[{""id"":""uuid:411e1da9-e191-4227-9430-e138c10b05d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:37e572c6-ab1e-4949-9395-e396fd961285"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/cometriq""]},{""id"":""uuid:3d710889-75e0-41c9-ae2f-fce9c982a4b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Renal Cell Carcinoma (RCC)Cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (RCC):in treatment-naïve adults with intermediate or poor risk,in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy.Cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults.Hepatocellular Carcinoma (HCC)Cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenib.|[PMDA] Drugs with a new active ingredient indicated for the treatment of unresectable or metastatic renal cell carcinoma. uuid:eb7c9c4d-2488-475b-b01f-78d7cd582860 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:72317 biolink:treats MONDO:0007256 PMID:41385096 "[{""id"":""uuid:209a2934-9da7-40a6-b394-15316f9ed75d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:974d5cad-4dd1-4b66-b388-e5c3f57ae89d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/cometriq""]},{""id"":""uuid:abcd86b6-1e38-458d-af61-f8c5954ef91f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Renal Cell Carcinoma (RCC)Cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (RCC):in treatment-naïve adults with intermediate or poor risk,in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy.Cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults.Hepatocellular Carcinoma (HCC)Cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenib.|[PMDA] Drugs with a new indication for the treatment of unresectable hepatocellular carcinoma that has progressed after cancer chemotherapy. uuid:f24dad39-21b9-4fc2-8728-a98225b918e6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:38RL9AE51Q biolink:treats MONDO:0007915 PMID:41385096 "[{""id"":""uuid:76b5537b-92a3-4939-9f2a-4d4b6a880958"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6a6dc07d-dde8-470c-b567-210c14bdb8d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/saphnelo""]},{""id"":""uuid:1a66953f-c3e6-4953-94a7-506aea22de97"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Saphnelo is indicated as an add-on therapy for the treatment of adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus (SLE), despite standard therapy.,|[PMDA] A drug with a new active ingredient indicated for the treatment of systemic lupus erythematosus in patients who have not responded sufficiently to conventional treatments. uuid:eec6a840-325c-42e7-b61a-050a4623d717 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:420K487FSG biolink:treats MONDO:0006031 PMID:41385096 "[{""id"":""uuid:a4661409-acf7-46be-9987-fce0e2a3670d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:6e2fa41c-17f2-428b-ade2-c36307a201cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/dupixent""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Atopic dermatitisAdults and adolescentsDupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.Children 6 months to 11 years of ageDupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy.AsthmaAdults and adolescentsDupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (FeNO), see section 5.1, who are inadequately controlled with high dose inhaled corticosteroids (ICS) plus another medicinal product for maintenance treatment.Children 6 to 11 years of ageDupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (FeNO), who are inadequately controlled with medium to high dose inhaled corticosteroids (ICS) plus another medicinal product for maintenance treatment.Chronic rhinosinusitis with nasal polyposis (CRSwNP)Dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe CRSwNP for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control.Prurigo Nodularis (PN)Dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (PN) who are candidates for systemic therapy.Eosinophilic esophagitis (EoE)Dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy. uuid:0f7dbe7b-f4ba-460f-a37c-3ae92502b239 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:AQK7UBA1LS biolink:treats MONDO:0019402 PMID:41385096 "[{""id"":""uuid:e2c4d963-6446-4fde-be2a-e11e49a5d0f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:4a6883fe-5125-44e7-b757-b8743b001857"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/reblozyl""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Reblozyl is indicated for the treatment of adult patients with transfusion-dependent anaemia due to very low, low and intermediate-risk myelodysplastic syndromes (MDS) with ring sideroblasts, who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy (see section 5.1).Reblozyl is indicated in adults for the treatment of anaemia associated with transfusion dependent and non transfusion dependent beta thalassaemia (see section 5.1). uuid:45fd4eca-12f4-4d76-8c60-2e38f1331f36 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:81569 biolink:treats MONDO:0002775 PMID:41385096 "[{""id"":""uuid:4718d888-0b49-4426-aeec-02b9b3844188"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:05b109fa-5109-43d1-9faa-40594dc5587b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/gonal-f""]},{""id"":""uuid:18c735f4-296f-40e0-aee2-b77d4354b6aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Anovulation (including polycystic ovarian disease, PCOD) in women who have been unresponsive to treatment with clomiphene citrate.Stimulation of multifollicular development in patients undergoing superovulation for assisted reproductive technologies (ART) such as in-vitro fertilisation (IVF), gamete intra-fallopian transfer (GIFT) and zygote intra-fallopian transfer (ZIFT).GONAL-f in association with a luteinising hormone (LH) preparation is recommended for the stimulation of follicular development in women with severe LH and FSH deficiency. In clinical trials these patients were defined by an endogenous serum LH level|[PMDA] A drug with a new additional indication and a new dosage for induction of ovulation in patients with anovulation and infrequent ovulation associated with hypothalamic-pituitary dysfunction or polycystic ovarian syndrome. uuid:12afd1f6-016f-4389-bf3e-7308e68a7a75 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:81569 biolink:treats MONDO:0008487 PMID:41385096 "[{""id"":""uuid:00a9ed62-d204-4ccf-b3a9-bd6115c95765"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8e8229b0-1d81-4b9c-98b3-b69625498189"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/gonal-f""]},{""id"":""uuid:4bc990b2-60f2-49c9-8918-10325e6a465d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Anovulation (including polycystic ovarian disease, PCOD) in women who have been unresponsive to treatment with clomiphene citrate.Stimulation of multifollicular development in patients undergoing superovulation for assisted reproductive technologies (ART) such as in-vitro fertilisation (IVF), gamete intra-fallopian transfer (GIFT) and zygote intra-fallopian transfer (ZIFT).GONAL-f in association with a luteinising hormone (LH) preparation is recommended for the stimulation of follicular development in women with severe LH and FSH deficiency. In clinical trials these patients were defined by an endogenous serum LH level|[PMDA] A drug with a new additional indication and a new dosage for induction of ovulation in patients with anovulation and infrequent ovulation associated with hypothalamic-pituitary dysfunction or polycystic ovarian syndrome. uuid:a65b0fa2-e7f8-42a2-9e06-6f8873a536b9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:81569 biolink:treats MONDO:0009239 PMID:41385096 "[{""id"":""uuid:98a17957-ac33-45eb-894b-0fc098abca92"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:54bb001f-5b6d-47de-a3ad-712f02ee86ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/gonal-f""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Anovulation (including polycystic ovarian disease, PCOD) in women who have been unresponsive to treatment with clomiphene citrate.Stimulation of multifollicular development in patients undergoing superovulation for assisted reproductive technologies (ART) such as in-vitro fertilisation (IVF), gamete intra-fallopian transfer (GIFT) and zygote intra-fallopian transfer (ZIFT).GONAL-f in association with a luteinising hormone (LH) preparation is recommended for the stimulation of follicular development in women with severe LH and FSH deficiency. In clinical trials these patients were defined by an endogenous serum LH level uuid:ddadccba-6710-46dc-8911-a6778420feb5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB14443 biolink:treats MONDO:0015766 PMID:41385096 "[{""id"":""uuid:3d46eb70-c501-4799-8390-bed1d3f6c7ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a19be6f7-1acb-4a8a-b90e-29a4fefa20ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Vaxchora is indicated for active immunisation against disease caused by Vibrio cholerae serogroup O1 in adults and children aged 2 years and older.This vaccine should be used in accordance with official recommendations. uuid:929aa67c-3bad-4e28-9ee9-ace85f3a1c8f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:WP58SVM6R4 biolink:treats MONDO:0001586 PMID:41385096 "[{""id"":""uuid:6e9f6207-999d-4442-bc2a-4a42784f3ff4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:46bcb1c6-4533-4e7d-b0d4-a287288f2539"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/aldurazyme""]},{""id"":""uuid:16f604a1-e72b-432e-b86e-dfe38d5d8578"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Aldurazyme is indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of mucopolysaccharidosis I (MPS I; alpha-L-iduronidase deficiency) to treat the nonneurological manifestations of the disease.|[PMDA] Drug containing a new active ingredient indicated for treatment of mucopolysaccharidosis I. [Orphan Drug] uuid:5f96adeb-c2f2-497f-92c4-c25371b1cbaa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2038 biolink:treats MONDO:0015041 PMID:41385096 "[{""id"":""uuid:bcec9816-f75d-4cbc-9e14-502054a9333c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:018288e3-802f-44e3-ac3c-2d9c276aaf3a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/azacitidine-mylan""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Azacitidine Mylan is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (HSCT) with:intermediate 2 and high risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System (IPSS),chronic myelomonocytic leukaemia (CMML) with 10 29% marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (AML) with 20 30% blasts and multi lineage dysplasia, according to World Health Organisation (WHO) classification,AML with > 30% marrow blasts according to the WHO classification. uuid:708c3ac4-7de5-4f8a-8fb7-532cefb35c27 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71193 biolink:treats MONDO:0007147 PMID:41385096 "[{""id"":""uuid:4dbfd0ab-880d-4140-9872-98b14bbe3691"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:743e6614-836f-4cce-bdb7-ad85e2adc813"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/saxenda""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Saxenda is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial Body Mass Index (BMI) of• ≥ 30 kg/m² (obese), or• ≥ 27 kg/m² to < 30 kg/m² (overweight) in the presence of at least one weight-related comorbidity such as dysglycaemia (pre-diabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia or obstructive sleep apnoea.Treatment with Saxenda should be discontinued after 12 weeks on the 3.0 mg/day dose if patients have not lost at least 5% of their initial body weight. uuid:c3ed1d12-9ac7-40bf-9384-c3d2c014548c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:34650 biolink:treats MONDO:0009061 PMID:41385096 "[{""id"":""uuid:e40c6971-dff8-4a53-aec4-c620e56d5cfd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:49a0f1f5-ec8f-4082-b6bb-bca508727bd6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/colobreathe""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Colobreathe is indicated for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis (CF) aged six years and older.Consideration should be given to official guidance on the appropriate use of antibacterial agents. uuid:8d306476-d760-418d-b434-aa6a5f019a8b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:34650 biolink:treats MONDO:0040732 PMID:41385096 "[{""id"":""uuid:f5d9e8d6-69fd-4b02-a21d-35e376f820cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f4f74e29-1ef7-455e-911e-5fb747526575"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/colobreathe""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Colobreathe is indicated for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis (CF) aged six years and older.Consideration should be given to official guidance on the appropriate use of antibacterial agents. uuid:5841b561-36a2-4497-b59e-402d49e6d20f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1367006 biolink:treats MONDO:0008159 PMID:41385096 "[{""id"":""uuid:a20522bc-5585-48d0-9553-663741023b10"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:2a3d13ac-5194-4cd0-967b-af96de62ee58"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/vantavo""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of postmenopausal osteoporosis in patients at risk of vitamin-D insufficiency.Vantavo reduces the risk of vertebral and hip fractures.Treatment of postmenopausal osteoporosis in patients who are not receiving vitamin-D supplementation and are at risk of vitamin-D insufficiency.Vantavo reduces the risk of vertebral and hip fractures. uuid:3315e2b2-014e-443a-a955-1ab3e9afb63c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1367006 biolink:treats MONDO:0005298 PMID:41385096 "[{""id"":""uuid:2f6f5aa8-397c-4b6b-bc99-90b73ed83f79"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:c0944e6d-22d2-4180-8758-0aae7ebf6b1e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/vantavo""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of postmenopausal osteoporosis in patients at risk of vitamin-D insufficiency.Fosavance reduces the risk of vertebral and hip fractures. uuid:c43421e1-67f8-4cd0-91a0-cc3260b56c14 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8764 biolink:treats UMLS:C0400968 PMID:41385096 "[{""id"":""uuid:d04b80b8-1169-4cc9-ae48-88ffd4da7642"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:50614bd6-30d2-4b01-bcff-05a1e98a7ee1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/cellcept""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] CellCept is indicated in combination with ciclosporin and corticosteroids for the prophylaxis of acute transplant rejection in patients receiving allogeneic renal, cardiac or hepatic transplants. uuid:fe97b048-bce5-4bb7-b9d6-074ddd4b6b27 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85973 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:a0c1b7a2-24f8-41b4-b3ed-2f7aee5a87bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:01180fe4-802d-4da8-b396-32caa28c5276"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF) with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack (TIA).Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. uuid:83119197-9286-493c-9bcc-63ede3ad6d47 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85973 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:9caad7ee-c989-4d88-937c-171a44494b70"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:4b7efaeb-39c0-4c99-bdbb-ef0683adcc3c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF) with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack (TIA).Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. uuid:f436f7da-0961-4285-8e18-fee16be5dfd2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85973 biolink:treats MONDO:0005264 PMID:41385096 "[{""id"":""uuid:d57beeac-5485-4dbb-ab33-c8e21e1d5c3a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:49226f74-d07e-4ecc-995c-aa73962598ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF) with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack (TIA).Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. uuid:a76610c0-5678-4a44-bc89-f23e82c260c1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:5X3GF74R79 biolink:treats MONDO:0010602 PMID:41385096 "[{""id"":""uuid:e554022b-ef8b-4536-9d2c-b988b389b4d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2a37806a-abaf-489d-9a98-a683b0332db1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/adynovi""]},{""id"":""uuid:5b789199-8ade-4407-ba90-4cdcb95938bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment and prophylaxis of bleeding in patients 12 years and above with haemophilia A (congenital factor VIII deficiency).|[PMDA] Drugs with a new active ingredient indicated for the control of bleeding tendency in patients with blood coagulation factor VIII deficiency. uuid:cc7c529d-41a9-4e18-8eab-d0070bcb6bd9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:ZJ0EKR6M10 biolink:treats MONDO:0850353 PMID:41385096 "[{""id"":""uuid:2b726a4e-c904-46da-a891-7cc2832a8171"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d8ea92e6-948b-48d3-9057-766776041dfd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/locametz""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] This medicinal product is for diagnostic use only. Locametz, after radiolabelling with gallium 68, is indicated for the detection of prostate specific membrane antigen (PSMA) positive lesions with positron emission tomography (PET) in adults with prostate cancer (PCa) in the following clinical settings:Primary staging of patients with high risk PCa prior to primary curative therapy,Suspected PCa recurrence in patients with increasing levels of serum prostate specific antigen (PSA) after primary curative therapy,Identification of patients with PSMA positive progressive metastatic castration resistant prostate cancer (mCRPC) for whom PSMA targeted therapy is indicated (see section 4.4). uuid:24b33200-5fa9-4ef7-ac8c-7614e73ec36c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4672 biolink:treats MONDO:0008315 PMID:41385096 "[{""id"":""uuid:6d7ce088-195c-4e0c-9d1d-6469d26526b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d85c4500-c2a6-4bc4-b5e9-5da04645079e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/docetaxel-kabi""]},{""id"":""uuid:01ebca8a-73c9-4c83-aaf1-fb0c6ee6e056"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Breast cancerDocetaxel Kabi in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:operable node-positive breast cancer;operable node-negative breast cancer.For patients with operable node-negative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer.Docetaxel Kabi in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.Docetaxel Kabi monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent.Docetaxel Kabi in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress HER2 and who previously have not received chemotherapy for metastatic disease.Docetaxel Kabi in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline.Non-small-cell lung cancerDocetaxel Kabi is indicated for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer after failure of prior chemotherapy.Docetaxel Kabi in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small-cell lung cancer, in patients who have not previously received chemotherapy for this condition.Prostate cancerDocetaxel Kabi in combination with prednisone or prednisolone is indicated for the treatment of patients with castration-resistant metastatic prostate cancer.Docetaxel Kabi in combination with androgen-deprivation therapy (ADT), with or without prednisone or prednisolone, is indicated for the treatment of patients with metastatic hormone-sensitive prostate cancer.Gastric adenocarcinomaDocetaxel Kabi in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease.Head and neck cancerDocetaxel Kabi in combination with cisplatin and 5-fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.|[PMDA] A drug with a new indication and a new dosage for the treatment of prostate cancer. [Priority review] uuid:83c2da15-97de-415d-a9bd-6b9c227d5723 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4672 biolink:treats MONDO:0005627 PMID:41385096 "[{""id"":""uuid:ba21e5ca-1d87-4855-aa82-389d1142b6d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f0d27ed2-e4bc-470e-ae87-de4db829ec78"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/docetaxel-kabi""]},{""id"":""uuid:7c8192d2-0f5d-4d4a-8523-e7aec6c2e907"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Breast cancerDocetaxel Kabi in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:operable node-positive breast cancer;operable node-negative breast cancer.For patients with operable node-negative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer.Docetaxel Kabi in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.Docetaxel Kabi monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent.Docetaxel Kabi in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress HER2 and who previously have not received chemotherapy for metastatic disease.Docetaxel Kabi in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline.Non-small-cell lung cancerDocetaxel Kabi is indicated for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer after failure of prior chemotherapy.Docetaxel Kabi in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small-cell lung cancer, in patients who have not previously received chemotherapy for this condition.Prostate cancerDocetaxel Kabi in combination with prednisone or prednisolone is indicated for the treatment of patients with castration-resistant metastatic prostate cancer.Docetaxel Kabi in combination with androgen-deprivation therapy (ADT), with or without prednisone or prednisolone, is indicated for the treatment of patients with metastatic hormone-sensitive prostate cancer.Gastric adenocarcinomaDocetaxel Kabi in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease.Head and neck cancerDocetaxel Kabi in combination with cisplatin and 5-fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.|[PMDA] Drugs with new dosages for the treatment of breast cancer, non-small cell lung cancer, gastric cancer, head and neck cancer and ovarian cancer. uuid:2d4ba5c7-13e3-4b7b-97b9-7309deb4bbd2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:848145 biolink:treats MONDO:0001134 PMID:41385096 "[{""id"":""uuid:101160fb-28c1-4281-9b10-4829ccf87cbc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:0f3f9b4d-093f-40a7-a65b-4aaeaa709ed5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/exforge-hct""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of essential hypertension as substitution therapy in adult patients whose blood pressure is adequately controlled on the combination of amlodipine, valsartan and hydrochlorothiazide (HCT), taken either as three single-component formulations or as a dual-component and a single-component formulation. uuid:39e192e1-4a02-4e64-a68a-ab7bdd6ef914 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:U194AS08HZ biolink:treats MONDO:0024503 PMID:41385096 "[{""id"":""uuid:c44ea971-c88b-4ec1-a8fe-c04bc9e240f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:76a5b34e-1a55-4f6f-9787-da434a652a88"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/somakit-toc""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] This medicinal product is for diagnostic use only.After radiolabelling with gallium (68Ga) chloride solution, the solution of gallium (68Ga) edotreotide obtained is indicated for Positron Emission Tomography (PET) imaging of somatostatin receptor overexpression in adult patients with confirmed or suspected well-differentiated gastro-enteropancreatic neuroendocrine tumours (GEP-NET) for localizing primary tumours and their metastases. uuid:8b93bbb8-c130-4278-8430-89cba5c2d176 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:U194AS08HZ biolink:treats MONDO:0000386 PMID:41385096 "[{""id"":""uuid:e7b252f9-5c18-403d-90e3-9ea42a5da1af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a9720b1e-b662-4370-a1b4-75dd3e47fd3c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/somakit-toc""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] This medicinal product is for diagnostic use only.After radiolabelling with gallium (68Ga) chloride solution, the solution of gallium (68Ga) edotreotide obtained is indicated for Positron Emission Tomography (PET) imaging of somatostatin receptor overexpression in adult patients with confirmed or suspected well-differentiated gastro-enteropancreatic neuroendocrine tumours (GEP-NET) for localizing primary tumours and their metastases. uuid:c6c23823-e65b-4f6f-b946-f86eb3d31ea9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:WKM56H3TLB biolink:treats MONDO:0005789 PMID:41385096 "[{""id"":""uuid:b6933ffa-784b-40d0-aa6a-1dfaad059557"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:768d6af5-dbd6-4246-9097-5b83c6cad459"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Hepcludex is indicated for the treatment of chronic hepatitis delta virus (HDV) infection in plasma (or serum) HDV-RNA positive adult patients with compensated liver disease. uuid:48e62481-4c87-4f71-a66e-9134c00c1c66 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1603837 biolink:treats UMLS:C0949083 PMID:41385096 "[{""id"":""uuid:c0da70f7-1f18-4725-8018-12d393d5773d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:acb5a644-c02a-4492-a1c3-01bb2abcf344"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/zavicefta""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Zavicefta is indicated in adults and paediatric patients aged 3 months and older for the treatment of the following infections:Complicated intra-abdominal infection (cIAI)Complicated urinary tract infection (cUTI), including pyelonephritisHospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP)Treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.Zavicefta is also indicated for the treatment of infections due to aerobic Gram-negative organisms in adults and paediatric patients aged 3 months and older with limited treatment options.Consideration should be given to official guidance on the appropriate use of antibacterial agents. uuid:d5c66afe-c5ab-4a62-9538-453ef2461e92 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4T36H88UA7 biolink:treats MONDO:0850353 PMID:41385096 "[{""id"":""uuid:8c596de0-e6b6-498f-8297-0bd57fb65017"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:17e25cc3-8b52-466d-9ad6-6d50d8d09ee6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/erleada""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Erleada is indicated:in adult men for the treatment of non metastatic castration resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease.in adult men for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT). uuid:c73040df-4a56-49c6-9a29-6228ed7f1e86 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEMBL.COMPOUND:CHEMBL2108290 biolink:treats MONDO:0020725 PMID:41385096 "[{""id"":""uuid:14a1685b-d84c-4ad9-90e1-10d80966e72e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:015bf749-41a4-4118-8a38-a06174b7d86e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/eporatio""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of symptomatic anaemia associated with chronic renal failure in adult patients.Treatment of symptomatic anaemia in adult cancer patients with non-myeloid malignancies receiving chemotherapy. uuid:df193cca-8ee3-4637-9bb5-91e36d31aa22 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEMBL.COMPOUND:CHEMBL2108290 biolink:treats MONDO:0002280 PMID:41385096 "[{""id"":""uuid:7b3bddd8-0e93-4161-9884-517937b6d152"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:eb6a51e1-c7e8-427e-85cc-e6c4a8882f06"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/eporatio""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of symptomatic anaemia associated with chronic renal failure in adult patients.Treatment of symptomatic anaemia in adult cancer patients with non-myeloid malignancies receiving chemotherapy. uuid:8efe5cb7-33bc-473f-9fa2-5e0c1bf48a29 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:216653 biolink:treats MONDO:0001134 PMID:41385096 "[{""id"":""uuid:6c685a0e-cad8-49a4-b2eb-6b165c2f8a09"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:60bc0d98-40fb-4945-80d6-be7b5ce39411"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/copalia-hct""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of essential hypertension as substitution therapy in adult patients whose blood pressure is adequately controlled on the combination of amlodipine, valsartan and hydrochlorothiazide (HCT), taken either as three single-component formulations or as a dual-component and a single-component formulation. uuid:38479778-1ce8-411b-adfb-abdcbcc60b8a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50861 biolink:treats MONDO:0013024 PMID:41385096 "[{""id"":""uuid:b68e1997-8fd7-4555-8f8d-d8a2db215c78"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f31d984a-7b42-43b7-8631-5b6929ece351"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of adult patients with WHO Functional Class (FC) III or IV and:inoperable chronic thromboembolic pulmonary hypertension (CTEPH), orpersistent or recurrent CTEPH after surgical treatmentto improve exercise capacity. uuid:c8c2221e-857e-4d32-89a1-5250e6377480 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85083 biolink:treats MONDO:0005231 PMID:41385096 "[{""id"":""uuid:d6260f6e-b738-4a12-8931-72f96cc6fc6f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:70378a83-5ad0-4f7e-a1c6-667efe8e5f9e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/sovaldi""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Sovaldi is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adult and paediatric patients aged 3 years and above (see sections 4.2, 4.4 and 5.1).For hepatitis C virus (HCV) genotype specific activity, see sections 4.4 and 5.1.Sovaldi is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adults and paediatric patients aged 3 years and above (see sections 4.2, 4.4 and 5.1).For hepatitis C virus (HCV) genotype specific activity, see sections 4.4 and 5.1. uuid:02f6e70f-bf15-420a-bd62-f30d794191af biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:129011857 biolink:treats MONDO:0005354 PMID:41385096 "[{""id"":""uuid:ad9cfcb0-df5f-4c98-a73d-d86009f8a689"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:161af03d-54bc-445f-85e1-7db11b935f1c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/vosevi""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Vosevi is indicated for the treatment of chronic hepatitis C virus (HCV) infection in patients aged 12 years and older and weighing at least 30 kg. (see sections 4.2, 4.4 and 5.1). uuid:dd5f08a4-18ac-4518-a360-7bbf37206e2f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:72734365 biolink:treats MONDO:0005354 PMID:41385096 "[{""id"":""uuid:7e04b99d-ccb1-439b-9c68-61b6ee3f7056"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:fd62aa50-90e2-4846-936b-faff7dc31530"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/harvoni""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Harvoni is indicated for the treatment of chronic hepatitis C (CHC) in adult and paediatric patients aged 3 years and above (see sections 4.2, 4.4 and 5.1).For hepatitis C virus (HCV) genotype-specific activity see sections 4.4 and 5.1. uuid:d11a1175-de4b-4916-b30f-490dfc3d5cd6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:72734365 biolink:treats MONDO:0005231 PMID:41385096 "[{""id"":""uuid:faab9746-7408-4189-b7e3-f8051ae90777"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:1151e2e2-aa97-491c-b9c4-d3979b951cb9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/harvoni""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Harvoni is indicated for the treatment of chronic hepatitis C (CHC) in adult and paediatric patients aged 3 years and above (see sections 4.2, 4.4 and 5.1).For hepatitis C virus (HCV) genotype-specific activity see sections 4.4 and 5.1. uuid:e966a10e-f321-4a14-9150-28bf20a679cd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2642142 biolink:treats MONDO:0001577 PMID:41385096 "[{""id"":""uuid:ecd290d7-c481-42d9-8a9a-f52451c4689a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:28a7c013-1e4d-410d-b708-c6580416cec3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:51edb35b-d344-40d2-9cd1-cf7a65adf17b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Abrysvo is indicated for:Passive protection against lower respiratory tract disease caused by respiratory syncytial virus (RSV) in infants from birth through 6 months of age following maternal immunisation during pregnancy. See sections 4.2 and 5.1.Active immunisation of individuals 60 years of age and older for the prevention of lower respiratory tract disease caused by RSV.The use of this vaccine should be in accordance with official recommendations.|[PMDA] A drug with a new active ingredient indicated for active immunization of pregnant individuals for the prevention of lower respiratory tract disease caused by respiratory syncytial virus in neonates and infants. uuid:7622f12e-5008-4f7c-a78f-40c27d25569f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68639 biolink:treats MONDO:0008315 PMID:41385096 "[{""id"":""uuid:762b4b7b-7c22-41d9-aa56-3a9a7dfa44d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:7a746ab3-21d7-468f-a783-7d03d1548941"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Abiraterone Accord is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT)the treatment of metastatic castration resistant prostate cancer (mCRPC) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicatedthe treatment of mCRPC in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen. uuid:fa8c0330-0124-4517-9716-468511030518 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68639 biolink:treats MONDO:0004956 PMID:41385096 "[{""id"":""uuid:d3ad8c30-7996-4a82-8075-a1e9db817324"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:cc11097a-863e-4a1c-b53e-0685d55ca610"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Abiraterone Accord is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT)the treatment of metastatic castration resistant prostate cancer (mCRPC) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicatedthe treatment of mCRPC in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen. uuid:a5267f93-e013-4232-bd84-d7854e1cb218 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68639 biolink:treats MONDO:0850353 PMID:41385096 "[{""id"":""uuid:702602c2-014b-4fd4-83b3-9db624e3c0c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a14919ca-9343-438e-ab0b-fe5a85479288"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Abiraterone Accord is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT)the treatment of metastatic castration resistant prostate cancer (mCRPC) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicatedthe treatment of mCRPC in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen. uuid:6e132b7b-812d-4c55-90ed-b2ce97f444be biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9168 biolink:treats HP:0010615 PMID:41385096 "[{""id"":""uuid:4341fbf9-4063-4d2d-9d8e-935751d4ea3c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:5234a878-b33e-475d-a634-c296e2b793e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/hyftor""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Hyftor is indicated for the treatment of facial angiofibroma associated with tuberous sclerosis complex in adults and paediatric patients aged 6 years and older. uuid:d8f67d2f-c99f-408a-8134-e266e9a9175f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7735 biolink:treats MONDO:0004985 PMID:41385096 "[{""id"":""uuid:4982ec6a-c31a-4e6b-a064-57fd679b6175"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d295a3b3-3fd7-46fe-a43c-602aeee6ef48"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/olanzapine-teva""]},{""id"":""uuid:81b141a0-f65e-42cd-9da5-536bc3098b62"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] AdultsOlanzapine is indicated for the treatment of schizophrenia.Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.Olanzapine is indicated for the treatment of moderate to severe manic episode.In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder.|[PMDA] Drugs with a new additional indication and a new dosage for the improvement of depressive symptoms in patients with bipolar disorder. uuid:96350878-ab42-4eb1-a0d7-3f8966b94d68 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5441 biolink:treats MONDO:0016391 PMID:41385096 "[{""id"":""uuid:fd654ec5-80ac-4046-ba57-fcd3ec5c5337"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:255eb6af-f499-4432-97aa-26364726772c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/amglidia""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Amglidia is indicated for the treatment of neonatal diabetes mellitus, for use in newborns, infants and children.Sulphonylureas like Amglidia have been shown to be effective in patients with mutations in the genes coding for the β-cell ATP-sensitive potassium channel and chromosome 6q24-related transient neonatal diabetes mellitus. uuid:f283913d-223b-4471-8a19-39b36e5d76ec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5441 biolink:treats MONDO:0020525 PMID:41385096 "[{""id"":""uuid:727bb3e7-358c-4973-a6e9-517c1967ec9f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:be08a6f7-98c2-4b49-852f-13263ef57469"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/amglidia""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Amglidia is indicated for the treatment of neonatal diabetes mellitus, for use in newborns, infants and children.Sulphonylureas like Amglidia have been shown to be effective in patients with mutations in the genes coding for the β-cell ATP-sensitive potassium channel and chromosome 6q24-related transient neonatal diabetes mellitus. uuid:ce56ac46-2ae0-45f2-9c4e-ee7e84381639 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:76612 biolink:treats MONDO:0018876 PMID:41385096 "[{""id"":""uuid:daad06f6-09ed-4f76-9654-84f1362966a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6292b625-0545-494b-976a-a2e6f070a1b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/imbruvica""]},{""id"":""uuid:a5cecacc-2697-47a7-95cf-0123fdd1cec8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] IMBRUVICA as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).IMBRUVICA as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) (see section 5.1).IMBRUVICA as a single agent or in combination with bendamustine and rituximab (BR) is indicated for the treatment of adult patients with CLL who have received at least one prior therapy.IMBRUVICA as a single agent is indicated for the treatment of adult patients with Waldenström’s macroglobulinaemia (WM) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. IMBRUVICA in combination with rituximab is indicated for the treatment of adult patients with WM.|[PMDA] A drug with a new indication and a new dosage for the treatment of mantle cell lymphoma. [Orphan drug] uuid:517510e5-b955-4af1-9abd-06f66d39a823 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:76RS4S2ET1 biolink:treats MONDO:0009669 PMID:41385096 "[{""id"":""uuid:dcb8ccea-2dad-47d4-85ef-cfb90f04c992"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:86b3ec07-4a2c-418f-9b55-a59c7a9d7bac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/evrysdi""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Evrysdi is indicated for the treatment of 5q spinal muscular atrophy (SMA) in patients with a clinical diagnosis of SMA Type 1, Type 2 or Type 3 or with one to four SMN2 copies. uuid:2a61e3a6-6bfc-49d2-8238-01e2b5377071 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:76RS4S2ET1 biolink:treats MONDO:0009673 PMID:41385096 "[{""id"":""uuid:942b4a97-4be6-44b9-a00b-ebc2f2636c9f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:9668dee9-a5cf-4b0c-9a02-5498f860766f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/evrysdi""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Evrysdi is indicated for the treatment of 5q spinal muscular atrophy (SMA) in patients with a clinical diagnosis of SMA Type 1, Type 2 or Type 3 or with one to four SMN2 copies. uuid:de8e82a1-239a-4bf7-a085-768e43e39102 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:76RS4S2ET1 biolink:treats MONDO:0009672 PMID:41385096 "[{""id"":""uuid:a49e1fde-25ab-4d73-96ca-4332836e537a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:3a512f4c-5b61-46ba-b976-47bd09743dfc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/evrysdi""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Evrysdi is indicated for the treatment of 5q spinal muscular atrophy (SMA) in patients with a clinical diagnosis of SMA Type 1, Type 2 or Type 3 or with one to four SMN2 copies. uuid:e9a9ad18-8407-46cd-972a-71a31309f6a2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:78538 biolink:treats MONDO:0018634 PMID:41385096 "[{""id"":""uuid:a41f2c2a-fbc6-4f9e-82c7-90b28a289ec9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:27182099-e42c-4578-b818-49419a10562d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/vyndaqel""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Vyndaqel is indicated for the treatment of transthyretin amyloidosis in adult patients with stage-1 symptomatic polyneuropathy to delay peripheral neurologic impairment. uuid:3847567c-cca8-4bab-ad48-b7186b7a75be biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:78538 biolink:treats MONDO:0001824 PMID:41385096 "[{""id"":""uuid:889f7944-a1fd-4a00-80e2-624fb4bc5ce2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a5188b81-d65b-4bd2-907a-adcb68fe6e89"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/vyndaqel""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Vyndaqel is indicated for the treatment of transthyretin amyloidosis in adult patients with stage-1 symptomatic polyneuropathy to delay peripheral neurologic impairment. uuid:fbb6b25a-078f-4bd7-ac43-b3e032be97de biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:QEN1X95CIX biolink:treats MONDO:0007256 PMID:41385096 "[{""id"":""uuid:b463f08c-4c56-46cf-83a4-8cdd6c05977d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e6df9a08-5c29-4811-bcc2-98ad50828596"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/imjudo""]},{""id"":""uuid:732122c7-7c3b-4d9e-b488-874eac0519ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC).Imjudo in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (NSCLC) with no sensitising EGFR mutations or ALK positive mutations.|[PMDA] Drugs with a new active ingredient indicated for the treatment of unresectable advanced or recurrent non- small-cell lung cancer and unresectable hepatocellular carcinoma. uuid:cdf6b8ae-e2cc-45f4-9917-84bcb1edc040 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:QEN1X95CIX biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:cd586205-a6ec-4815-b21f-3e090d9767a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e2e9deac-147e-4e9c-9728-d34a0f48725a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/imjudo""]},{""id"":""uuid:c6703d71-bc35-4374-a2ee-4dc56af2b59a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC).Imjudo in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (NSCLC) with no sensitising EGFR mutations or ALK positive mutations.|[PMDA] Drugs with a new active ingredient indicated for the treatment of unresectable advanced or recurrent non- small-cell lung cancer and unresectable hepatocellular carcinoma. uuid:11db0160-5192-4ab6-9dd3-510c311ab884 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:131952892 biolink:treats MONDO:0000386 PMID:41385096 "[{""id"":""uuid:a6aaa179-4c7e-44d0-b5a1-d9e07a605c7f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:36c83ee9-6b69-435d-9bfc-73215492eec4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Lutathera is indicated for the treatment of unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours (GEP‑NETs) in adults. uuid:14c56f1d-15e1-49d7-a24b-04f2884e6306 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PF9462I9HX biolink:treats MONDO:0024883 PMID:41385096 "[{""id"":""uuid:117aed18-7431-404d-a2ff-30a41cd7deff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:ce52d4ee-d04e-4de5-a2af-bb7a0edb4477"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Vitrakvi as monotherapy is indicated for the treatment of adult and paediatric patients with solid tumours that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion,who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, andwho have no satisfactory treatment options. uuid:72fd7314-3f72-4632-ade3-01c0f553ac5a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:82699 biolink:treats UMLS:C4552483 PMID:41385096 "[{""id"":""uuid:0fdc1097-a194-4cac-8f81-7f59e29e6246"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:2d1cea3e-8e7d-41fd-b41c-73e5adede8b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Tenkasi is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults and paediatric patients aged 3 months and older (see sections 4.2, 4.4 and 5.1).Consideration should be given to official guidance on the appropriate use of antibacterial agents. uuid:0554bed2-ba1e-47f7-b7b4-2dc0bd4d2146 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:83766 biolink:treats MONDO:0006047 PMID:41385096 "[{""id"":""uuid:db62f818-04b8-4661-a655-01c73fe0654b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:026c5a45-3942-4519-b16c-6410f36b3929"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/lynparza""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Ovarian cancerLynparza is indicated as monotherapy for the:maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.maintenance treatment of adult patients with platinum sensitive relapsed high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy.Lynparza in combination with bevacizumab is indicated for the:maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability (see section 5.1).Breast cancerLynparza is indicated as:monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2-mutations who have HER2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy (see sections 4.2 and 5.1).monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2 negative locally advanced or metastatic breast cancer. Patients should have previously been treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless patients were not suitable for these treatments (see section 5.1). Patients with hormone receptor (HR)-positive breast cancer should also have progressed on or after prior endocrine therapy, or be considered unsuitable for endocrine therapy.Adenocarcinoma of the pancreasLynparza is indicated as:monotherapy for the maintenance treatment of adult patients with germline BRCA1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen.Prostate cancerLynparza is indicated as:monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with mCRPC in whom chemotherapy is not clinically indicated (see section 5.1). uuid:911edece-a5cd-4b60-aaa4-05d0d47c6d1a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation MESH:C541234 biolink:treats MONDO:0005504 PMID:41385096 "[{""id"":""uuid:fd952b12-31a2-4ce1-b32a-0ef251585684"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:6b8b921c-8625-44af-8e51-84ea8a891277"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Infanrix Hexa is indicated for primary and booster vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and disease caused by Haemophilus influenzae type-b. uuid:b1bc22f2-0a67-4164-959d-09d92fdb9c40 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation MESH:C541234 biolink:treats MONDO:0005526 PMID:41385096 "[{""id"":""uuid:f746f81c-f4c9-415d-928f-4e54aa2632cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:725c1bea-0f5a-4b80-a297-c0c7461e05a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Infanrix Hexa is indicated for primary and booster vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and disease caused by Haemophilus influenzae type-b. uuid:d5d67d85-a347-497e-9ad1-befdbaf7a805 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation MESH:C541234 biolink:treats MONDO:0005077 PMID:41385096 "[{""id"":""uuid:54ebcd7e-0611-4e29-85b9-ff362e66e390"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:0228a2e3-7f32-4c30-8d81-8c46572336fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Infanrix Hexa is indicated for primary and booster vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and disease caused by Haemophilus influenzae type-b. uuid:cf507487-4afa-4f2f-b53a-1adffb8ea155 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation MESH:C541234 biolink:treats MONDO:0005344 PMID:41385096 "[{""id"":""uuid:707ece22-2b02-457f-b070-12cdff4822cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:788ea2e2-9269-4c65-ac31-72f79b9fd8f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Infanrix Hexa is indicated for primary and booster vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and disease caused by Haemophilus influenzae type-b. uuid:64996e74-96d9-4965-9370-49bf5ff69b76 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation MESH:C541234 biolink:treats MONDO:0017373 PMID:41385096 "[{""id"":""uuid:70092696-cfbd-4195-a7d9-dd4bd7d79f02"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:57f2f7c4-85bd-44b2-8fc8-f00d734783ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Infanrix Hexa is indicated for primary and booster vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and disease caused by Haemophilus influenzae type-b. uuid:eee73a89-2f68-4b20-80d5-b46c2e6664ce biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation MESH:C541234 biolink:treats MONDO:0006926 PMID:41385096 "[{""id"":""uuid:9108897a-9b62-4076-9a5e-6246ddbd86e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d8adf3e4-7d69-412d-9ce4-e3519486b7b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Infanrix Hexa is indicated for primary and booster vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and disease caused by Haemophilus influenzae type-b. uuid:5aa9e619-924c-417e-bed1-9c42c50477bd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB15656 biolink:treats MONDO:0100096 PMID:41385096 "[{""id"":""uuid:e8de6248-36c0-4aab-a501-01394480e2fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9d5d8e90-d20c-4569-a8b8-57207ef568c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ec101bdd-5a3f-4a91-a97f-16e2151c5b20"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Vaxzevria is indicated for active immunisation to prevent COVID 19 caused by SARS CoV 2, in individuals 18 years of age and older.The use of this vaccine should be in accordance with official recommendations.|[PMDA] A drug with a new active ingredient indicated for the prevention of disease caused by SARS-CoV-2 infection (COVID-19). [Priority review] uuid:47ccc5ed-60a2-4fb3-b731-afcacba5603c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:76611 biolink:treats MONDO:0002039 PMID:41385096 "[{""id"":""uuid:48dd53dd-226c-4d4e-8614-1066f88145e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:50856fd2-486f-436f-a296-7efebb7737ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] This medicinal product is for diagnostic use only.Vizamyl is a radiopharmaceutical medicinal product indicated for Positron Emission Tomography (PET) imaging of β amyloid neuritic plaque density in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD) and other causes of cognitive impairment. Vizamyl should be used in conjunction with a clinical evaluation.A negative scan indicates sparse or no plaques, which is not consistent with a diagnosis of AD. uuid:291b4844-75ce-4e1b-8044-b3053cec1f11 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:76004 biolink:treats MONDO:0005314 PMID:41385096 "[{""id"":""uuid:a21a0ba4-1a2e-41db-b2c4-d7880ed3fe34"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:fd6c50bd-147b-45d6-b2fb-2c5458e45f49"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/tecfidera""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Tecfidera is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (RRMS). uuid:0369d772-61be-468e-aa31-b511cb4e697b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB17593 biolink:treats MONDO:0007064 PMID:41385096 "[{""id"":""uuid:e96541df-e792-491a-8983-16ce9c29132b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:ec156f33-778b-48ae-a60a-d8514089dd4c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Strimvelis is indicated for the treatment of patients with severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID), for whom no suitable human leukocyte antigen (HLA)-matched related stem cell donor is available (see section 4.2 and section 4.4). uuid:bfb27e43-2a81-43ac-ad5b-b51053683357 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:5PKM8P0G5I biolink:treats MONDO:0024574 PMID:41385096 "[{""id"":""uuid:0cd58f0e-d2fb-44ee-b35e-4d5fdc4683b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:abda7504-39ea-491c-89ee-14f3102d01f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/veyvondi""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Veyvondi is indicated in adults (age 18 and older) with von Willebrand Disease (VWD), when desmopressin (DDAVP) treatment alone is ineffective or not indicated for the- Treatment of haemorrhage and surgical bleeding- Prevention of surgical bleeding.Veyvondi should not be used in the treatment of Haemophilia A. uuid:52081a83-3431-4be2-b571-1ef3b8f35fe4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:5PKM8P0G5I biolink:treats NCIT:C26791 PMID:41385096 "[{""id"":""uuid:48d431e4-6198-4fbd-bda7-ad2ded67fbce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:ecce4e95-3f5b-4349-a886-4b5140c0c49c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/veyvondi""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Veyvondi is indicated in adults (age 18 and older) with von Willebrand Disease (VWD), when desmopressin (DDAVP) treatment alone is ineffective or not indicated for the- Treatment of haemorrhage and surgical bleeding- Prevention of surgical bleeding.Veyvondi should not be used in the treatment of Haemophilia A. uuid:5b9d6fc7-e96f-47d7-9d8e-fa252622cfaf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:5PKM8P0G5I biolink:treats NCIT:C35135 PMID:41385096 "[{""id"":""uuid:f3908ee9-b782-4335-8212-2697adaed591"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:5811a968-f3f3-44ef-8ce5-dcf4479be94f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/veyvondi""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Veyvondi is indicated in adults (age 18 and older) with von Willebrand Disease (VWD), when desmopressin (DDAVP) treatment alone is ineffective or not indicated for the- Treatment of haemorrhage and surgical bleeding- Prevention of surgical bleeding.Veyvondi should not be used in the treatment of Haemophilia A. uuid:c3e9bb1f-3404-47dc-9508-eb46a65c60e0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45863 biolink:treats MONDO:0018364 PMID:41385096 "[{""id"":""uuid:c866c97e-64ee-48b7-8c70-db110bea1e91"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:1d903601-6ac4-4ff4-bfbf-0f424742e44f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/apealea""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Apealea in combination with carboplatin is indicated for the treatment of adult patients with first relapse of platinum‑sensitive epithelial ovarian cancer, primary peritoneal cancer and fallopian tube cancer. uuid:3c90b3a6-dfac-4ea5-8a80-d09b7b6d7a47 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45863 biolink:treats MONDO:0015686 PMID:41385096 "[{""id"":""uuid:fed801ca-d7ae-42b2-afbc-db9122db7371"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:5506b163-93bb-468b-9c11-a460908da6f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/apealea""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Apealea in combination with carboplatin is indicated for the treatment of adult patients with first relapse of platinum‑sensitive epithelial ovarian cancer, primary peritoneal cancer and fallopian tube cancer. uuid:6175a6ae-aeee-4020-8cd3-9141b023d70e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45863 biolink:treats MONDO:0002158 PMID:41385096 "[{""id"":""uuid:a1737970-7f14-46f5-baa0-c3858d313178"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:3b4fec60-c048-421c-848c-b28a37955374"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/apealea""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Apealea in combination with carboplatin is indicated for the treatment of adult patients with first relapse of platinum‑sensitive epithelial ovarian cancer, primary peritoneal cancer and fallopian tube cancer. uuid:a387a808-683b-4be6-bc79-be5ad2286fed biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:231425 biolink:treats HP:0012623 PMID:41385096 "[{""id"":""uuid:f40d43dc-883b-414b-a251-01e3b2ccbf0d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:10a1f16f-5531-4422-a289-eebc159ff91f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/jinarc""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Jinarc is indicated to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (ADPKD) in adults with CKD stage 1 to 3 at initiation of treatment with evidence of rapidly progressing disease. uuid:868a0aef-d8be-4686-b7ea-fe44d05b681f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:231425 biolink:treats HP:0012624 PMID:41385096 "[{""id"":""uuid:3b339237-5459-4b16-a43f-acf5dfadc917"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:7c0a3971-46b7-46ab-9b20-6861d8554962"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/jinarc""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Jinarc is indicated to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (ADPKD) in adults with CKD stage 1 to 3 at initiation of treatment with evidence of rapidly progressing disease. uuid:389d4b23-e0c4-421f-9d2c-ffecddfbc207 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:231425 biolink:treats HP:0012625 PMID:41385096 "[{""id"":""uuid:114510b8-4380-4278-b4ec-bc61aaa92b4d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:50ccf38c-abe4-4ab5-8483-8742e71659ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/jinarc""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Jinarc is indicated to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (ADPKD) in adults with CKD stage 1 to 3 at initiation of treatment with evidence of rapidly progressing disease. uuid:e6307382-35c8-4b7c-a1e0-451f333b1a09 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:A57KX1VL5P biolink:treats MONDO:0010604 PMID:41385096 "[{""id"":""uuid:fe0d2a86-8a99-4b01-aed2-c6f042c82afe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9db52526-160c-41c1-af84-24e41c769b70"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/idelvion""]},{""id"":""uuid:2a808a26-606f-4aa3-862c-86bba72fcdc3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency).|[PMDA] Drugs with a new active ingredient indicated for the control of bleeding tendency in patients with coagulation factor IX deficiency. uuid:b3616a06-6606-423c-9129-14e5c14a90d3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:15C2VL427D biolink:treats MONDO:0003005 PMID:41385096 "[{""id"":""uuid:dff6bb06-eebe-407d-a4d8-ae6da2fb820b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:7f4cfd15-78bd-4fe1-ba43-04615266ca30"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/yesafili""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Eylea is indicated for adults for the treatment of:neovascular (wet) age-related macular degeneration (AMD);visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO);visual impairment due to diabetic macular oedema (DME);visual impairment due to myopic choroidal neovascularisation (myopic CNV). uuid:e9061cb7-b6ca-4f5c-86d1-0997118085a6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1656336 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:e46e3dd0-0dfb-40f4-b859-cb331a8ab9ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:ecc86d0d-1c10-4707-a25f-200148777847"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/neparvis""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Paediatric heart failureNeparvis is indicated in children and adolescents aged one year or older for treatment of symptomatic chronic heart failure with left ventricular systolic dysfunction (see section 5.1).Adult heart failureNeparvis is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction (see section 5.1). uuid:e366e389-20d2-4290-9306-d6089e85555a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1656336 biolink:treats HP:0025169 PMID:41385096 "[{""id"":""uuid:770d48a6-0d25-4a91-9e06-7904a5aabea1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:adb4edd8-4255-4bb2-9401-7519d15d322b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/neparvis""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Paediatric heart failureNeparvis is indicated in children and adolescents aged one year or older for treatment of symptomatic chronic heart failure with left ventricular systolic dysfunction (see section 5.1).Adult heart failureNeparvis is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction (see section 5.1). uuid:77348243-deb5-4771-a19a-7bc2d6c76be5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1656336 biolink:treats HP:0012664 PMID:41385096 "[{""id"":""uuid:7266face-a768-477b-baac-c60519e7ec6c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f8c3b592-243d-434c-9e85-485c8c8f4b53"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/neparvis""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Paediatric heart failureNeparvis is indicated in children and adolescents aged one year or older for treatment of symptomatic chronic heart failure with left ventricular systolic dysfunction (see section 5.1).Adult heart failureNeparvis is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction (see section 5.1). uuid:daa1788a-1ad8-4567-a009-23cbee5ab0a2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:XSZ53G39H5 biolink:treats MONDO:0005417 PMID:41385096 "[{""id"":""uuid:f2d0a768-3509-4a52-b0d6-071198f269f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:716f7987-639f-412c-a137-34bf18e79703"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/beovu""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Beovu is indicated in adults for the treatment of neovascular (wet) age-related macular degeneration (AMD). uuid:0e11c41c-427f-43a1-9cec-c152e39d2e86 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:Y6BX7BL23K biolink:treats MONDO:0019087 PMID:41385096 "[{""id"":""uuid:06a0ca76-f286-41b2-8450-77a3a04a4b34"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d29e18f2-98ac-4b37-9c4d-bfe5088befba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/pemazyre""]},{""id"":""uuid:da656ff8-1f06-4516-aa40-cd39d8a47f4f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Pemazyre monotherapy is indicated for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.|[PMDA] A drug with a new active ingredient indicated for the treatment of unresectable FGFR2 fusion gene-positive biliary tract cancer that has progressed after cancer chemotherapy. [Orphan drug] uuid:5a6a1a7d-1c9d-43ec-bd10-18184a9dd58e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:9829639 biolink:treats MONDO:0005575 PMID:41385096 "[{""id"":""uuid:36af0737-f1f1-42a5-b96c-a0ff0d48f654"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:6cc64469-ab55-4f68-a92e-204f9eb46db1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/lonsurf""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Colorectal cancerLonsurf is indicated in combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer (CRC) who have received two prior anticancer treatment regimens including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and/or anti-EGFR agents.Lonsurf is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and anti EGFR agentsGastric cancerLonsurf is indicated as monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease. uuid:e7ad1ae7-2d0f-4339-8fd4-b0b6879f301b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:9829639 biolink:treats MONDO:0001056 PMID:41385096 "[{""id"":""uuid:b9d70f5c-4dd0-47c8-a4ba-8b577023a8f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:59d51942-115b-445a-9a9e-81a9fb1676ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/lonsurf""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Colorectal cancerLonsurf is indicated in combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer (CRC) who have received two prior anticancer treatment regimens including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and/or anti-EGFR agents.Lonsurf is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and anti EGFR agentsGastric cancerLonsurf is indicated as monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease. uuid:c2160437-b9cf-489b-bf38-3924fe5eb7f2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:78759283 biolink:treats HP:0002018 PMID:41385096 "[{""id"":""uuid:7421261e-ea43-471f-bdb6-7d71d7e25a4a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:2f208543-53a9-4b0d-96ff-3289de844e5b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/akynzeo""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Akynzeo is indicated in adults for the:Prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin based cancer chemotherapy.Prevention of acute and delayed nausea and vomiting associated with moderately emetogenic cancer chemotherapy. uuid:6fafee06-0011-4d83-8a87-7828c34d5a34 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:78759283 biolink:treats HP:0002013 PMID:41385096 "[{""id"":""uuid:4236ede3-5bad-490c-b17f-16a27b6d5a39"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:26508077-024b-409a-bff7-17acf444aa9f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/akynzeo""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Akynzeo is indicated in adults for the:Prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin based cancer chemotherapy.Prevention of acute and delayed nausea and vomiting associated with moderately emetogenic cancer chemotherapy. uuid:d8c5bb61-9a0d-40f8-bc84-d277e88644cb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5959 biolink:treats MONDO:0001134 PMID:41385096 "[{""id"":""uuid:84a799a3-7111-4487-b029-859fbf7010e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:51ebc0eb-debd-4dd9-9271-89da5a5ceec4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/irbesartan-teva""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of essential hypertension.Treatment of renal disease in patients with hypertension and type 2 diabetes mellitus as part of an antihypertensive medicinal product regimen. uuid:ae64de74-79eb-4038-b7cb-bb98e4c14327 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5959 biolink:treats MONDO:0005240 PMID:41385096 "[{""id"":""uuid:2ee746f5-c285-4b52-ba5e-ad4c1f4c84c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:56255c32-9c05-422e-b7e0-d152e333a8d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/irbesartan-teva""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of essential hypertension.Treatment of renal disease in patients with hypertension and type 2 diabetes mellitus as part of an antihypertensive medicinal product regimen. uuid:6842497a-e6b5-45f7-98d2-fe69058c0535 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:K0N0Z40J3W biolink:treats MONDO:0005314 PMID:41385096 "[{""id"":""uuid:d1cd2182-4e21-43cc-afe2-e7986036ee4e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:dd20c258-d08a-4f89-b78f-192a190c5d1a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Vumerity is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (see Section 5.1 for important information on the populations for which efficacy has been established). uuid:b142f1a7-5bd5-423e-85ac-45bf95e552fc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85010 biolink:treats MONDO:0008558 PMID:41385096 "[{""id"":""uuid:c3334f42-9078-4af7-b584-595048fbbc2f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:92d70726-656c-4b04-9c7e-9834fc774be7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/revolade""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Revolade is indicated for the treatment of adult patients with primary immune thrombocytopenia (ITP) who are refractory to other treatments (e.g. corticosteroids, immunoglobulins) (see sections 4.2 and 5.1).Revolade is indicated for the treatment of paediatric patients aged 1 year and above with primary immune thrombocytopenia (ITP) lasting 6 months or longer from diagnosis and who are refractory to other treatments (e.g. corticosteroids, immunoglobulins) (see sections 4.2 and 5.1).Revolade is indicated in adult patients with chronic hepatitis C virus (HCV) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy (see sections 4.4 and 5.1).Revolade is indicated in adult patients with acquired severe aplastic anaemia (SAA) who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for haematopoietic stem cell transplantation (see section 5.1). uuid:2317ea5c-be32-409e-8409-9b09a21751d4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85010 biolink:treats MONDO:0015610 PMID:41385096 "[{""id"":""uuid:af6cc6eb-972f-414f-aab6-0193c02aa64b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:7993ebdc-7789-4071-bd53-e39815ca5749"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/revolade""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Revolade is indicated for the treatment of adult patients with primary immune thrombocytopenia (ITP) who are refractory to other treatments (e.g. corticosteroids, immunoglobulins) (see sections 4.2 and 5.1).Revolade is indicated for the treatment of paediatric patients aged 1 year and above with primary immune thrombocytopenia (ITP) lasting 6 months or longer from diagnosis and who are refractory to other treatments (e.g. corticosteroids, immunoglobulins) (see sections 4.2 and 5.1).Revolade is indicated in adult patients with chronic hepatitis C virus (HCV) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy (see sections 4.4 and 5.1).Revolade is indicated in adult patients with acquired severe aplastic anaemia (SAA) who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for haematopoietic stem cell transplantation (see section 5.1). uuid:057ed57e-0276-4710-9e92-147f31e6de82 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75045 biolink:treats MONDO:0005105 PMID:41385096 "[{""id"":""uuid:e8ff977e-2e79-4220-9523-eb77c14c3191"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:89e2d48c-1251-413d-9cdb-dccbc5e5f560"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] MelanomaDabrafenib as monotherapy or in combination with trametinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation (see sections 4.4 and 5.1).Adjuvant treatment of melanomaDabrafenib in combination with trametinib is indicated for the adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection.Non-small cell lung cancer (NSCLC)Dabrafenib in combination with trametinib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 mutation. uuid:34ca3148-aa00-48d2-8464-3f54abb55579 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75045 biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:36c075e8-8541-49f9-b459-294ccffb82d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8baeb3f7-424e-4140-9096-39b245f00592"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:31c88459-2f16-4288-b828-ed34eea39d07"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] MelanomaDabrafenib as monotherapy or in combination with trametinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation (see sections 4.4 and 5.1).Adjuvant treatment of melanomaDabrafenib in combination with trametinib is indicated for the adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection.Non-small cell lung cancer (NSCLC)Dabrafenib in combination with trametinib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 mutation.|[PMDA] Drugs with a new additional indication and a new dosage indicated for the treatment of unresectable advanced or recurrent BRAF mutation-positive non-small-cell lung cancer. [Orphan drug] uuid:5fcfc9dd-0cff-4320-8967-a1da0906584d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:9XW757O13D biolink:treats MONDO:0011719 PMID:41385096 "[{""id"":""uuid:91771445-7a1b-47eb-b250-49c231b6c1d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:54843e26-dc45-433e-965a-e382425eec63"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/qinlock""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Qinlock is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumour (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib. uuid:5dfb386e-0d72-4aa4-a218-071a2275c0dc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DLG4EML025 biolink:treats MONDO:0005083 PMID:41385096 "[{""id"":""uuid:d42098c7-caca-480b-9419-1fe0f5e2a1b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:1efcbe16-f7f9-464e-89ea-20b0206f02b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/cosentyx""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Plaque psoriasisCosentyx is indicated for the treatment of moderate to severe plaque psoriasis in adults and children from the age of 6 years old who are candidates for systemic therapy.Hidradenitis suppurativa (HS)Cosentyx is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic HS therapy.Psoriatic arthritisCosentyx, alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous disease modifying anti rheumatic drug (DMARD) therapy has been inadequate.Axial spondyloarthritis (axSpA)Ankylosing spondylitis (AS, radiographic axial spondyloarthritis)Cosentyx is indicated for the treatment of active ankylosing spondylitis in adults who have responded inadequately to conventional therapy.Non-radiographic axial spondyloarthritis (nr-axSpA)Cosentyx is indicated for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence in adults who have responded inadequately to non steroidal anti inflammatory drugs (NSAIDs).Juvenile idiopathic arthritis (JIA)Enthesitis-related arthritis (ERA)Cosentyx, alone or in combination with methotrexate (MTX), is indicated for the treatment of active enthesitis-related arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.Juvenile psoriatic arthritis (JPsA)Cosentyx, alone or in combination with methotrexate (MTX), is indicated for the treatment of active juvenile psoriatic arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy. uuid:ecb8b9e6-f203-46ea-908b-42fcbc35716e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DLG4EML025 biolink:treats MONDO:0006559 PMID:41385096 "[{""id"":""uuid:f59a1be5-2705-4c65-85a8-370989ede52c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:9835e68f-7b4e-43c0-a53b-3d902b95b1fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/cosentyx""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Plaque psoriasisCosentyx is indicated for the treatment of moderate to severe plaque psoriasis in adults and children from the age of 6 years old who are candidates for systemic therapy.Hidradenitis suppurativa (HS)Cosentyx is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic HS therapy.Psoriatic arthritisCosentyx, alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous disease modifying anti rheumatic drug (DMARD) therapy has been inadequate.Axial spondyloarthritis (axSpA)Ankylosing spondylitis (AS, radiographic axial spondyloarthritis)Cosentyx is indicated for the treatment of active ankylosing spondylitis in adults who have responded inadequately to conventional therapy.Non-radiographic axial spondyloarthritis (nr-axSpA)Cosentyx is indicated for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence in adults who have responded inadequately to non steroidal anti inflammatory drugs (NSAIDs).Juvenile idiopathic arthritis (JIA)Enthesitis-related arthritis (ERA)Cosentyx, alone or in combination with methotrexate (MTX), is indicated for the treatment of active enthesitis-related arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.Juvenile psoriatic arthritis (JPsA)Cosentyx, alone or in combination with methotrexate (MTX), is indicated for the treatment of active juvenile psoriatic arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy. uuid:a6b03664-fcd9-44b5-bc1b-f4702d751637 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DLG4EML025 biolink:treats MONDO:0011849 PMID:41385096 "[{""id"":""uuid:ec93ed90-aa94-4fdc-8af0-69d2e17b096c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0d3d5294-7597-4e48-b269-b9c37648e10b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/cosentyx""]},{""id"":""uuid:4177816e-69f1-4bbc-b8aa-38ad091434ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Plaque psoriasisCosentyx is indicated for the treatment of moderate to severe plaque psoriasis in adults and children from the age of 6 years old who are candidates for systemic therapy.Hidradenitis suppurativa (HS)Cosentyx is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic HS therapy.Psoriatic arthritisCosentyx, alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous disease modifying anti rheumatic drug (DMARD) therapy has been inadequate.Axial spondyloarthritis (axSpA)Ankylosing spondylitis (AS, radiographic axial spondyloarthritis)Cosentyx is indicated for the treatment of active ankylosing spondylitis in adults who have responded inadequately to conventional therapy.Non-radiographic axial spondyloarthritis (nr-axSpA)Cosentyx is indicated for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence in adults who have responded inadequately to non steroidal anti inflammatory drugs (NSAIDs).Juvenile idiopathic arthritis (JIA)Enthesitis-related arthritis (ERA)Cosentyx, alone or in combination with methotrexate (MTX), is indicated for the treatment of active enthesitis-related arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.Juvenile psoriatic arthritis (JPsA)Cosentyx, alone or in combination with methotrexate (MTX), is indicated for the treatment of active juvenile psoriatic arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.|[PMDA] Drugs with a new active ingredient indicated for the treatment of plaque psoriasis and psoriatic arthritis in patients who have not responded sufficiently to conventional therapies. uuid:6a03bcf9-5cce-471b-b124-2b5d80590439 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DLG4EML025 biolink:treats MONDO:0005306 PMID:41385096 "[{""id"":""uuid:e71c5f32-95bf-4944-a029-a006e7cb043c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:af02a023-c959-43b1-8546-4e6ca6161911"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/cosentyx""]},{""id"":""uuid:67a736cb-09ef-4a80-a579-ada525af1547"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Plaque psoriasisCosentyx is indicated for the treatment of moderate to severe plaque psoriasis in adults and children from the age of 6 years old who are candidates for systemic therapy.Hidradenitis suppurativa (HS)Cosentyx is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic HS therapy.Psoriatic arthritisCosentyx, alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous disease modifying anti rheumatic drug (DMARD) therapy has been inadequate.Axial spondyloarthritis (axSpA)Ankylosing spondylitis (AS, radiographic axial spondyloarthritis)Cosentyx is indicated for the treatment of active ankylosing spondylitis in adults who have responded inadequately to conventional therapy.Non-radiographic axial spondyloarthritis (nr-axSpA)Cosentyx is indicated for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence in adults who have responded inadequately to non steroidal anti inflammatory drugs (NSAIDs).Juvenile idiopathic arthritis (JIA)Enthesitis-related arthritis (ERA)Cosentyx, alone or in combination with methotrexate (MTX), is indicated for the treatment of active enthesitis-related arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.Juvenile psoriatic arthritis (JPsA)Cosentyx, alone or in combination with methotrexate (MTX), is indicated for the treatment of active juvenile psoriatic arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.|[PMDA] Drugs with a new additional indication and a new dosage for the treatment of ankylosing spondylitis in patients who have not responded sufficiently to conventional treatments. uuid:317cce12-763a-4bfa-9cce-10bc462b4bfe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DLG4EML025 biolink:treats MONDO:0019437 PMID:41385096 "[{""id"":""uuid:cf24dc11-28fb-4df3-b398-391440cb636c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:4af7d11a-2d50-4d21-9fc6-5bb5a07313ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/cosentyx""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Plaque psoriasisCosentyx is indicated for the treatment of moderate to severe plaque psoriasis in adults and children from the age of 6 years old who are candidates for systemic therapy.Hidradenitis suppurativa (HS)Cosentyx is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic HS therapy.Psoriatic arthritisCosentyx, alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous disease modifying anti rheumatic drug (DMARD) therapy has been inadequate.Axial spondyloarthritis (axSpA)Ankylosing spondylitis (AS, radiographic axial spondyloarthritis)Cosentyx is indicated for the treatment of active ankylosing spondylitis in adults who have responded inadequately to conventional therapy.Non-radiographic axial spondyloarthritis (nr-axSpA)Cosentyx is indicated for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence in adults who have responded inadequately to non steroidal anti inflammatory drugs (NSAIDs).Juvenile idiopathic arthritis (JIA)Enthesitis-related arthritis (ERA)Cosentyx, alone or in combination with methotrexate (MTX), is indicated for the treatment of active enthesitis-related arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.Juvenile psoriatic arthritis (JPsA)Cosentyx, alone or in combination with methotrexate (MTX), is indicated for the treatment of active juvenile psoriatic arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy. uuid:e7fa3033-8e78-4e04-906a-96a0ba338378 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DLG4EML025 biolink:treats MONDO:0019436 PMID:41385096 "[{""id"":""uuid:d093210f-6422-4c31-b18c-257a7641780c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:ccf136a3-4448-45af-bca3-6c7209094137"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/cosentyx""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Plaque psoriasisCosentyx is indicated for the treatment of moderate to severe plaque psoriasis in adults and children from the age of 6 years old who are candidates for systemic therapy.Hidradenitis suppurativa (HS)Cosentyx is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic HS therapy.Psoriatic arthritisCosentyx, alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous disease modifying anti rheumatic drug (DMARD) therapy has been inadequate.Axial spondyloarthritis (axSpA)Ankylosing spondylitis (AS, radiographic axial spondyloarthritis)Cosentyx is indicated for the treatment of active ankylosing spondylitis in adults who have responded inadequately to conventional therapy.Non-radiographic axial spondyloarthritis (nr-axSpA)Cosentyx is indicated for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence in adults who have responded inadequately to non steroidal anti inflammatory drugs (NSAIDs).Juvenile idiopathic arthritis (JIA)Enthesitis-related arthritis (ERA)Cosentyx, alone or in combination with methotrexate (MTX), is indicated for the treatment of active enthesitis-related arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.Juvenile psoriatic arthritis (JPsA)Cosentyx, alone or in combination with methotrexate (MTX), is indicated for the treatment of active juvenile psoriatic arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy. uuid:f9cefbca-d6ec-40d3-89cb-65c59fc84595 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:K16AIQ8CTM biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:a1719a70-a3d3-4929-bcee-4b595ed1ffcf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:770a8ddf-2af2-4d87-a21f-637178721659"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/perjeta""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Metastatic Breast Cancer:Perjeta is indicated for use in combination with trastuzumab and docetaxel in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease.Neoadjuvant Treatment of Breast Cancer:Perjeta is indicated for use in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence. uuid:15d075b1-dc3e-45ed-af73-02e032fc49b2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:K16AIQ8CTM biolink:treats MONDO:0004989 PMID:41385096 "[{""id"":""uuid:4d45e3db-48ee-4faa-ab8a-671af37d361b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:be0e5b87-568b-44a7-a86f-b18697ca5fea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/perjeta""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Metastatic Breast Cancer:Perjeta is indicated for use in combination with trastuzumab and docetaxel in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease.Neoadjuvant Treatment of Breast Cancer:Perjeta is indicated for use in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence. uuid:ea26f843-a59f-4769-b389-b221d855a78d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135957 biolink:treats HP:0033730 PMID:41385096 "[{""id"":""uuid:7b4da043-df48-4f67-96a9-951c13127e7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a2b1119b-3336-47d5-971d-2e986004f4b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/lupkynis""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Lupkynis is indicated in combination with mycophenolate mofetil for the treatment of adult patients with active class III, IV or V (including mixed class III/V and IV/V) lupus nephritis (LN). uuid:8efd32a4-2722-4803-ac3c-cb9a2599adc6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:GNWE7KJ995 biolink:treats MONDO:0003664 PMID:41385096 "[{""id"":""uuid:13344464-d935-4dd0-935a-e7c417565826"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:c48b5bee-0091-4f8d-a0ea-de706145f1ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/enjaymo""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Enjaymo is indicated for the treatment of haemolytic anaemia in adult patients with cold agglutinin disease (CAD). uuid:4acfbcdd-ddec-41a2-995f-44afad8aca4c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:37CQ2C7X93 biolink:treats MONDO:0011776 PMID:41385096 "[{""id"":""uuid:547c325e-e1d9-42bc-83aa-226a191f57e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:ee186fd4-763f-4781-a3ab-b5dbebc4e9c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ilaris""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Periodic fever syndromesIlaris is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents and children aged 2 years and older:Cryopyrin-associated periodic syndromesIlaris is indicated for the treatment of cryopyrin-associated periodic syndromes (CAPS) including:Muckle-Wells syndrome (MWS),Neonatal-onset multisystem inflammatory disease (NOMID) / chronic infantile neurological, cutaneous, articular syndrome (CINCA),Severe forms of familial cold autoinflammatory syndrome (FCAS) / familial cold urticaria (FCU) presenting with signs and symptoms beyond cold-induced urticarial skin rash.Tumour necrosis factor receptor associated periodic syndrome (TRAPS)Ilaris is indicated for the treatment of tumour necrosis factor (TNF) receptor associated periodic syndrome (TRAPS).Hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD)Ilaris is indicated for the treatment of hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD).Familial Mediterranean fever (FMF)Ilaris is indicated for the treatment of Familial Mediterranean Fever (FMF). Ilaris should be given in combination with colchicine, if appropriate.Ilaris is also indicated for the treatment of:Still’s diseaseIlaris is indicated for the treatment of active Still’s disease including adult-onset Still’s disease (AOSD) and systemic juvenile idiopathic arthritis (SJIA) in patients aged 2 years and older who have responded inadequately to previous therapy with non-steroidal anti-inflammatory drugs (NSAIDs) and systemic corticosteroids. Ilaris can be given as monotherapy or in combination with methotrexate.Gouty arthritisIlaris is indicated for the symptomatic treatment of adult patients with frequent gouty arthritis attacks (at least 3 attacks in the previous 12 months) in whom non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate. uuid:caf17a0e-94c5-4a5f-9b79-2e763a148361 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1860167 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:5b3e55ac-67cb-4c02-b206-00e0d2d5ddea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:c2c639dc-5c34-498f-8afd-fe178054f4f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/xultophy""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Xultophy is indicated for the treatment of adults with type-2 diabetes mellitus to improve glycaemic control in combination with oral glucose-lowering medicinal products when these alone or combined with a GLP-1 receptor agonist or basal insulin do not provide adequate glycaemic control. uuid:c2754648-34f2-4dff-a2d6-4dc791f46460 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6402 biolink:treats MONDO:0011849 PMID:41385096 "[{""id"":""uuid:c3dc50b4-2538-4781-90e4-c6f538673482"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:b340cc47-6435-4f3d-8b60-f6b325a5506c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/leflunomide-medac""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Leflunomide is indicated for the treatment of adult patients with:active rheumatoid arthritis as a 'disease-modifying antirheumatic drug' (DMARD);active psoriatic arthritis.Recent or concurrent treatment with hepatotoxic or haematotoxic DMARDs (e.g. methotrexate) may result in an increased risk of serious adverse reactions; therefore, the initiation of leflunomide treatment has to be carefully considered regarding these benefit / risk aspects.Moreover, switching from leflunomide to another DMARD without following the washout procedure may also increase the risk of serious adverse reactions even for a long time after the switching. uuid:02188be2-4f76-485f-bf97-3d96374a1612 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:36795 biolink:treats MONDO:0006626 PMID:41385096 "[{""id"":""uuid:fcf265fb-ce8b-46cc-b2f3-954fbcefdf2d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:998decf1-4931-418f-b863-a7c2a503e1da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/duloxetine-mylan""]},{""id"":""uuid:c424e7d4-7579-410f-b19a-d3bddd3b203a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of major depressive disorder;Treatment of diabetic peripheral neuropathic pain;Treatment of generalised anxiety disorder;Duloxetine Mylan is indicated in adults.|[PMDA] Drugs with a new additional indication for the treatment of pain associated with diabetic neuropathy. uuid:27b9b1a4-592f-4da0-b3b1-adfc52a6895c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31348 biolink:treats MONDO:0002032 PMID:41385096 "[{""id"":""uuid:03648276-b187-46ed-8bea-05fdb9ca28bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ae70b96e-0853-4e47-bd96-3ece63b6c75e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ecansya""]},{""id"":""uuid:aec1480a-0ed0-4473-b6bc-855904f6c5e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Ecansya is indicated for the adjuvant treatment of patients following surgery of stage-III (Dukes’ stage-C) colon cancer.Ecansya is indicated for the treatment of metastatic colorectal cancer.Ecansya is indicated for first-line treatment of advanced gastric cancer in combination with a platinum-based regimen.Ecansya in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline. Ecansya is also indicated as monotherapy for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline containing chemotherapy regimen or for whom further anthracycline therapy is not indicated.|[PMDA] A drug with a new indication and dosage for use as a postoperative adjuvant chemotherapy of colon cancer. A drug with a new dosage for the treatment of inoperable or relapsed breast cancer. uuid:ae49b597-08b6-4768-8b16-494662f97cb2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31348 biolink:treats MONDO:0004379 PMID:41385096 "[{""id"":""uuid:03fd3df8-8445-4a26-be99-de6473699479"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:966a1de1-d806-4e97-b3dc-e602f5cb4984"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ecansya""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Ecansya is indicated for the adjuvant treatment of patients following surgery of stage-III (Dukes’ stage-C) colon cancer.Ecansya is indicated for the treatment of metastatic colorectal cancer.Ecansya is indicated for first-line treatment of advanced gastric cancer in combination with a platinum-based regimen.Ecansya in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline. Ecansya is also indicated as monotherapy for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline containing chemotherapy regimen or for whom further anthracycline therapy is not indicated. uuid:4d337d6b-77b4-43fb-8794-873464472391 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:I0BGE6P6I6 biolink:treats MONDO:0100096 PMID:41385096 "[{""id"":""uuid:6acf7899-445f-4901-aea6-2533dcb19dc0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:be89ee4a-bac3-49d0-a65d-ef935cc21b06"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/regkirona""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Regdanvimab is indicated for the treatment of adults with coronavirus disease 2019 (COVID-19) who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19. uuid:e903eacf-9ab4-45d1-a65e-546bf696afec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:216293 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:3924a9d5-5905-4f69-b12f-c84feaec07d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:143f4b6d-a9ca-4be1-b513-9b7de749ae32"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/actelsar-hct""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Tolucombi fixed-dose combination (80 mg telmisartan/25 mg hydrochlorothiazide) is indicated in adults whose blood pressure is not adequately controlled on Tolucombi 80 mg/12.5 mg (80 mg telmisartan/12.5 mg hydrochlorothiazide) or adults who have been previously stabilised on telmisartan and hydrochlorothiazide given separately. uuid:4689119b-449f-4739-b0e3-cbb9e7a7d708 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB14764 biolink:treats MONDO:0005502 PMID:41385096 "[{""id"":""uuid:052e2f1a-443e-4cf4-b010-ed316f241089"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:3df2ce37-13e5-48db-aa25-3fcfe393e00b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Dengvaxia is indicated for the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3 and 4 in individuals 6 to 45 years of age with test-confirmed previous dengue infection (see sections 4.2, 4.4 and 4.8).The use of Dengvaxia should be in accordance with official recommendations. uuid:a1349154-544a-419c-8225-b7f2fc5eb0e5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB15595 biolink:treats MONDO:0005737 PMID:41385096 "[{""id"":""uuid:56ca7912-f01c-4e50-86e7-5d844caa105b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:25c93dac-7cdb-45f1-82ff-773f45e182dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Ervebo is indicated for active immunization of individuals 1 year of age or older to protect against Ebola Virus Disease (EVD) caused by Zaire Ebola virus.The use of Ervebo should be in accordance with official recommendations. uuid:2e3a4629-1227-45ce-b278-739a8411cff0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:SB96YO2BR8 biolink:treats MONDO:0004651 PMID:41385096 "[{""id"":""uuid:2c315260-1580-4a96-b507-a0614d985d18"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:6a063c5e-57fa-489d-ace0-4c034ea5e31a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Tecovirimat SIGA is indicated for the treatment of the following viral infections in adults and children with body weight at least 13 kg:- Smallpox- Monkeypox- CowpoxTecovirimat SIGA is also indicated to treat complications due to replication of vaccinia virus following vaccination against smallpox in adults and children with body weight at least 13 kg (see sections 4.4 and 5.1).Tecovirimat SIGA should be used in accordance with official recommendations. uuid:f752a56b-5598-48e2-bdae-c73d58c726f8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:SB96YO2BR8 biolink:treats MONDO:0002594 PMID:41385096 "[{""id"":""uuid:3d083aae-1885-4e6c-aee2-114ac3c62298"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a92564a6-2e1b-48e1-8b8d-66247ce03b0f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Tecovirimat SIGA is indicated for the treatment of the following viral infections in adults and children with body weight at least 13 kg:- Smallpox- Monkeypox- CowpoxTecovirimat SIGA is also indicated to treat complications due to replication of vaccinia virus following vaccination against smallpox in adults and children with body weight at least 13 kg (see sections 4.4 and 5.1).Tecovirimat SIGA should be used in accordance with official recommendations. uuid:474923ff-9555-4c9f-be4f-e868ed88e6b9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:SB96YO2BR8 biolink:treats MONDO:0005720 PMID:41385096 "[{""id"":""uuid:9d672b4b-fc63-4625-ad0a-ca4c8199148e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:02c642e4-f9bd-4115-9cc9-b3cfe5f6e020"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Tecovirimat SIGA is indicated for the treatment of the following viral infections in adults and children with body weight at least 13 kg:- Smallpox- Monkeypox- CowpoxTecovirimat SIGA is also indicated to treat complications due to replication of vaccinia virus following vaccination against smallpox in adults and children with body weight at least 13 kg (see sections 4.4 and 5.1).Tecovirimat SIGA should be used in accordance with official recommendations. uuid:169a6233-4b36-4f01-bca7-ae31f0d45b07 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:234248D0HH biolink:treats MONDO:0004989 PMID:41385096 "[{""id"":""uuid:20a5a8c6-62c9-4024-a7ff-193b5474da39"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:c2efd134-b69a-49c0-957e-8429ecdd0603"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/tukysa""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Tukysa is indicated in combination with trastuzumab and capecitabine for the treatment of adult patients with HER2‑positive locally advanced or metastatic breast cancer who have received at least 2 prior anti‑HER2 treatment regimens. uuid:acfd9375-6a52-4496-a3cd-10a6d44d50eb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:81569 biolink:treats MONDO:0015770 PMID:41385096 "[{""id"":""uuid:574969a8-1027-4387-aa2f-bf06621e1541"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:93581c86-a848-490b-b892-5546c1c329a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/gonal-f""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] In adult womenAnovulation (including polycystic ovarian syndrome) in women who have been unresponsive to treatment with clomifene citrate;Stimulation of multifollicular development in women undergoing superovulation for assisted reproductive technologies (ART) such as in vitro fertilisation (IVF), gamete intra-fallopian transfer and zygote intra-fallopian transfer;Ovaleap in association with a luteinising hormone (LH) preparation is recommended for the stimulation of follicular development in women with severe LH and FSH deficiency. In clinical trials these patients were defined by an endogenous serum LH level < 1.2 IU/L.In adult menOvaleap is indicated for the stimulation of spermatogenesis in men who have congenital or acquired hypogonadotropic hypogonadism with concomitant human chorionic gonadotropin (hCG) therapy. uuid:71495180-5cc6-43af-95ba-4466edaf303f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:81569 biolink:treats MONDO:0018555 PMID:41385096 "[{""id"":""uuid:9e38a43a-bac9-4305-8e40-7fc8f6ac618b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:2f2bd5a5-9095-4b0f-b5ba-16c6abb8901a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/gonal-f""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] In adult womenAnovulation (including polycystic ovarian syndrome) in women who have been unresponsive to treatment with clomifene citrate;Stimulation of multifollicular development in women undergoing superovulation for assisted reproductive technologies (ART) such as in vitro fertilisation (IVF), gamete intra-fallopian transfer and zygote intra-fallopian transfer;Ovaleap in association with a luteinising hormone (LH) preparation is recommended for the stimulation of follicular development in women with severe LH and FSH deficiency. In clinical trials these patients were defined by an endogenous serum LH level < 1.2 IU/L.In adult menOvaleap is indicated for the stimulation of spermatogenesis in men who have congenital or acquired hypogonadotropic hypogonadism with concomitant human chorionic gonadotropin (hCG) therapy. uuid:6b65724a-fedb-4a6f-81ce-ddebe83e96a2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135285 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:08144e72-7fc3-47db-aef1-2dc47ce5ad61"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b3484c7c-a8d1-4e73-b765-859031646628"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/jalra""]},{""id"":""uuid:22ac5fee-ec66-4a5f-b1e9-bb8accb5941f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance.in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4.4, 4.5 and 5.1 for available data on different combinations).|[PMDA] A drug with a new active ingredient indicated for the treatment of type 2 diabetes mellitus (for use only in patients who have not responded sufficiently to either [1] diet and exercise therapies alone or [2] sulfonylurea along with diet and exercise therapies). uuid:815e2ebe-36c7-487b-bbb4-c7746bb9d134 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:722125 biolink:treats MONDO:0001134 PMID:41385096 "[{""id"":""uuid:7808b4ac-5571-4618-ad76-4dc42fa24cdd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:e0d5cde4-fa73-4b9a-8e2d-f9c3fe734995"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/amlodipine-valsartan-mylan""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of essential hypertension.Amlodipine/Valsartan Mylan is indicated in adults whose blood pressure is not adequately controlled on amlodipine or valsartan monotherapy. uuid:f343d9ed-f2a8-4e51-9468-cbec42f7eebe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134742 biolink:treats MONDO:0005861 PMID:41385096 "[{""id"":""uuid:e2241b0e-c9e3-4f0d-ba77-731d1cc5cecf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:0bfbb0fe-b313-48e0-883a-49edf135f474"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/deltyba""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Deltyba is indicated for use as part of an appropriate combination regimen for pulmonary multi-drug resistant tuberculosis (MDR-TB) in adults, adolescents, children and infants with a body weight of at least 10 kg when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability (see sections 4.2, 4.4 and 5.1).Consideration should be given to official guidance on the appropriate use of antibacterial agents. uuid:707bf5fe-9bd4-4c1b-940a-8a79cfeba6d5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:UMD7G2653W biolink:treats MONDO:0005298 PMID:41385096 "[{""id"":""uuid:34fa6096-1432-4940-9bde-daec27635a9a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b7d03f27-d7c6-44e6-86c8-1e7a5f7155f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/bonviva""]},{""id"":""uuid:213c9c43-be50-4de8-aefa-f67a16554bcf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of osteoporosis in postmenopausal women at increased risk of fracture (see section 5.1). A reduction in the risk of vertebral fractures has been demonstrated, efficacy on femoral neck fractures has not been established.|[PMDA] A drug with a new route of administration indicated for the treatment of osteoporosis. uuid:10d978ea-b793-47b1-aa88-4e2978885e43 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:156963654 biolink:treats MONDO:0005494 PMID:41385096 "[{""id"":""uuid:18da8b9a-7a44-4ee2-9229-820123dc586a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:ea617f00-692c-49bf-ad03-3b99bbc7cd71"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/trodelvy""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Trodelvy as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, including at least one of them for advanced disease. HMDB:HMDB0257437 uuid:cb2d9f93-f7a9-446b-bd6d-2b61fe09f902 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DEW6X41BEK biolink:treats MONDO:0005083 PMID:41385096 "[{""id"":""uuid:2d769977-540c-4f3b-aef8-4f9a705c0823"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f894bf78-0975-42cb-a2f7-05ba2861a4b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ilumetri""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Ilumetri is indicated for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy. uuid:81dd22f2-6e73-4c46-947d-6682857f2b5a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:82557 biolink:treats MONDO:0004992 PMID:41385096 "[{""id"":""uuid:ccc94712-b484-49a5-8d58-3b44b1d941bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:26370b8d-5f02-4cb4-abca-c6c1b0c287c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/trecondi""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treosulfan in combination with fludarabine is indicated as part of conditioning treatment prior to allogeneic haematopoietic stem cell transplantation (alloHSCT) in adult patients and in paediatric patients older than one month with malignant and non-malignant diseases. uuid:8586a450-375d-4d47-90a1-645405651ab7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:23HYE36B0I biolink:treats MONDO:0018150 PMID:41385096 "[{""id"":""uuid:4c408b52-8bd6-4aa0-8907-0092413dcd9e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:16e045ff-4156-45d4-b2e6-de3fb2e9458b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/vpriv""]},{""id"":""uuid:0712f3e5-5c29-459f-a90d-ddf15a124bf5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Vpriv is indicated for long-term enzyme-replacement therapy (ERT) in patients with type-1 Gaucher disease.|[PMDA] A drug with a new active ingredient indicated for the improvement of various symptoms of Gaucher disease (anemia, thrombocytopenia, hepatosplenomegaly, and bone disease). [Orphan drug] uuid:c316513f-3d59-434d-874a-6b514884e256 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:125354 biolink:treats MONDO:0004992 PMID:41385096 "[{""id"":""uuid:2292bfbc-d9b7-4281-a629-890caef4be8b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:e1610597-11b3-447d-86a1-d1ee2e5c358b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/mozobil""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Adult patientsPlerixafor Accord is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in adult patients with lymphoma or multiple myeloma whose cells mobilise poorly (see section 4.2).Paediatric patients (1 to less than 18 years)Plerixafor Accord is indicated in combination with G-CSF to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in children with lymphoma or solid malignant tumours, either:- pre-emptively, when circulating stem cell count on the predicted day of collection after adequate mobilization with G-CSF (with or without chemotherapy) is expected to be insufficient with regards to desired hematopoietic stem cells yield, or- who previously failed to collect sufficient haematopoietic stem cells (see section 4.2). uuid:9edf138a-2fe3-4ed5-a59a-236e5e5e31f0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1664472 biolink:treats MONDO:0005812 PMID:41385096 "[{""id"":""uuid:96635a9d-2970-4aad-94e5-78855b3cb5d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:48f3f2a9-d781-4b2e-85d3-76f86b73c88b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Prophylaxis of influenza in children and adolescents from 24 months to less than 18 years of age. The use of Fluenz Tetra should be based on official recommendations. uuid:3cbf6bfe-f20b-46df-afe7-973c266c4f6f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C4723522 biolink:treats MONDO:0005812 PMID:41385096 "[{""id"":""uuid:a4b3dbcd-df21-45df-90fe-1f322e5e5bbd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:68aaba5b-5c9b-4b18-8c8f-d15f1cbba905"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Prophylaxis of influenza in adults and children from 2 years of age.Flucelvax Tetra should be used in accordance with official recommendations. DRUGBANK:DB15507 uuid:afcbd453-86db-4a8e-be11-e40412bf2f77 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32127 biolink:treats MONDO:0000328 PMID:41385096 "[{""id"":""uuid:fde6608f-3226-4047-8b13-3bf6ea00acf4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a95aeee4-2fbe-44c2-8315-618bdcd42cec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/renagel""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Renagel is indicated for the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis.Renagel should be used within the context of a multiple therapeutic approach, which could include calcium supplements, 1,25 - dihydroxy Vitamin D3 or one of its analogues to control the development of renal bone disease. uuid:c036041f-6002-4ee8-93c4-8123f4d5decf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32127 biolink:treats MONDO:0006946 PMID:41385096 "[{""id"":""uuid:6c965784-566e-4055-bcc9-3f71dd10d30f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:70cc6131-114c-4237-bf8c-23fdb5695cd6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/renagel""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Renagel is indicated for the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis.Renagel should be used within the context of a multiple therapeutic approach, which could include calcium supplements, 1,25 - dihydroxy Vitamin D3 or one of its analogues to control the development of renal bone disease. uuid:e3eb8fc5-0fb2-4b1a-aaea-a5d68f6cf851 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:5QS67N4551 biolink:treats MONDO:0010481 PMID:41385096 "[{""id"":""uuid:20279c7d-9105-438e-aa8b-1c1e23334556"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:3b2b74aa-5f39-4c31-9168-77353585badf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Ruconest is indicated for treatment of acute angioedema attacks in adults with hereditary angioedema (HAE) due to C1-esterase-inhibitor deficiency. uuid:a49ce3aa-b366-4720-ae4f-6876fa09777f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2637 biolink:treats MONDO:0018469 PMID:41385096 "[{""id"":""uuid:0d54bc82-64ae-47cc-9f21-d54143727b3d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9cae0717-dc01-464f-90a3-62aabf01e7cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:26a2c1de-671c-46e6-8fdd-f8f6d21b1fd5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Arikayce liposomal is indicated for the treatment of non-tuberculous mycobacterial (NTM) lung infections caused by Mycobacterium avium Complex (MAC) in adults with limited treatment options who do not have cystic fibrosis.|[PMDA] A drug with a new route of administration indicated for the treatment of nontuberculous mycobacterial pulmonary disease caused by amikacin-sensitive Mycobacterium avium complex (MAC). uuid:57ad044d-f645-4bb4-a670-16aed9719950 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:913P6LK81M biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:3f3cacdf-94b5-4908-85bb-379efc2ec635"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:b4311e48-556c-4301-9b47-55db05401741"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/pifeltro""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Pifeltro is indicated, in combination with other antiretroviral medicinal products, for the treatment of adults, and adolescents aged 12 years and older weighing at least 35 kg infected with HIV 1 without past or present evidence of resistance to the NNRTI class. uuid:904eb274-862d-4b3f-91e8-64e0a4247eff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1592713 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:e4e26a1e-74c9-4e56-845b-b838db19ad6e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:ea51dd7f-d131-4e25-ae6e-2366b54a42bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ebymect""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Type 2 diabetes mellitusFor the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise.as monotherapy when metformin is considered inappropriate due to intolerance.in addition to other medicinal products for the treatment of type 2 diabetes.For study results with respect to combination of therapies, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1.Type 1 diabetes mellitusEdistride is indicated in adults for the treatment of insufficiently controlled type 1 diabetes mellitus as an adjunct to insulin in patients with BMI ≥ 27 kg/m2, when insulin alone does not provide adequate glycaemic control despite optimal insulin therapy. uuid:abd0a803-ded7-4a01-9c6d-4d23e74ac1cc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1592713 biolink:treats MONDO:0005147 PMID:41385096 "[{""id"":""uuid:6efe6f9b-ec90-4a88-a8d6-cbfa664c0f51"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:94902d2f-6c56-4063-ad46-d2a211a425f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ebymect""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Type 2 diabetes mellitusFor the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise.as monotherapy when metformin is considered inappropriate due to intolerance.in addition to other medicinal products for the treatment of type 2 diabetes.For study results with respect to combination of therapies, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1.Type 1 diabetes mellitusEdistride is indicated in adults for the treatment of insufficiently controlled type 1 diabetes mellitus as an adjunct to insulin in patients with BMI ≥ 27 kg/m2, when insulin alone does not provide adequate glycaemic control despite optimal insulin therapy. uuid:6c9a7458-7f60-444e-82d4-4b830b5ce2ff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:291342 biolink:treats MONDO:0011786 PMID:41385096 "[{""id"":""uuid:7801e4ba-1457-4da3-825e-10ed0499946a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:87e5db78-c2e5-4aa0-9bb4-ad4fff8bee5d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/neoclarityn""]},{""id"":""uuid:332bd919-3756-40c7-a231-b1208a7d208c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Neoclarityn is indicated for the relief of symptoms associated with:allergic rhinitisurticaria|[PMDA] A drug with a new active ingredient indicated for the treatment of allergic rhinitis, urticaria, and itching associated with skin diseases (eczema/dermatitis, cutaneous pruritus). uuid:a3964b80-3198-4602-9939-eb2837d87f79 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:291342 biolink:treats MONDO:0005492 PMID:41385096 "[{""id"":""uuid:14ca0564-6911-4fb1-b362-fef180d3d24d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ae906cb3-f492-43eb-aa44-6160004368e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/neoclarityn""]},{""id"":""uuid:dbb56e7a-1048-4abf-97ea-cb06c8392cd0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Neoclarityn is indicated for the relief of symptoms associated with:allergic rhinitisurticaria|[PMDA] A drug with a new active ingredient indicated for the treatment of allergic rhinitis, urticaria, and itching associated with skin diseases (eczema/dermatitis, cutaneous pruritus). uuid:d78405b3-1da9-4028-bca3-d7494f92da0d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68579 biolink:treats MONDO:0005542 PMID:41385096 "[{""id"":""uuid:5642917b-a6fc-4027-86dc-8bddd76b43c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:14808cbc-e9e8-4dd6-9367-39fb07158806"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/rivaroxaban-accord""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Xarelto, co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers.Xarelto, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischaemic events.Prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.AdultsPrevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack.Paediatric population Treatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment.Paediatric population Treatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment. uuid:a5bf9a35-cb47-4026-b3d8-ac2a57aff4b9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:44423 biolink:treats MONDO:0005632 PMID:41385096 "[{""id"":""uuid:4d65af4a-ed9d-497b-9be1-be72d33e17da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f2219207-79a2-47ae-b39d-5a892a0402d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/siklos""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Siklos is indicated for the prevention of recurrent painful vaso-occlusive crises including acute chest syndrome in paediatric and adult patients suffering from symptomatic sickle-cell syndrome. uuid:fc54c470-69fe-44e0-a43f-914f5d0b06ab biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:177658 biolink:treats MONDO:0013056 PMID:41385096 "[{""id"":""uuid:c7a99145-1907-4d75-9efd-2dc8afa8ed7b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:19c3959d-b107-4166-ac66-9d06315045e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ztalmy""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Ztalmy is indicated for the adjunctive treatment of epileptic seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients 2 to 17 years of age. Ztalmy may be continued in patients 18 years of age and older. uuid:105099e9-2bf3-4efc-99cc-718d16e1a8a4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:66917 biolink:treats MONDO:0044903 PMID:41385096 "[{""id"":""uuid:4dc1b77d-f910-43f8-9757-6f04a18562ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:bcf9018d-aa79-4df2-b1ad-efd6af025ec1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Myelofibrosis (MF)Jakavi is indicated for the treatment of disease related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis.Polycythaemia vera (PV)Jakavi is indicated for the treatment of adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea.Graft versus host disease (GvHD)Jakavi is indicated for the treatment of patients aged 12 years and older with acute graft versus host disease or chronic graft versus host disease who have inadequate response to corticosteroids or other systemic therapies (see section 5.1). uuid:f0b7eb19-1835-402f-9df5-4bf892e51b3a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:66917 biolink:treats MONDO:0009891 PMID:41385096 "[{""id"":""uuid:38c6e7e6-6486-4f24-880c-b1c225cfa831"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:e8e1a08b-6dda-4ebe-b5d1-40e0f1f0aeb2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Myelofibrosis (MF)Jakavi is indicated for the treatment of disease related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis.Polycythaemia vera (PV)Jakavi is indicated for the treatment of adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea.Graft versus host disease (GvHD)Jakavi is indicated for the treatment of patients aged 12 years and older with acute graft versus host disease or chronic graft versus host disease who have inadequate response to corticosteroids or other systemic therapies (see section 5.1). uuid:aeea6150-a99c-413b-9a61-cfddf3aba93d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:66917 biolink:treats MONDO:0013730 PMID:41385096 "[{""id"":""uuid:c10f0509-524e-4cac-aa85-ca6aea9d63fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:4366f169-da8a-411d-ba08-0d925831b140"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Myelofibrosis (MF)Jakavi is indicated for the treatment of disease related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis.Polycythaemia vera (PV)Jakavi is indicated for the treatment of adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea.Graft versus host disease (GvHD)Jakavi is indicated for the treatment of patients aged 12 years and older with acute graft versus host disease or chronic graft versus host disease who have inadequate response to corticosteroids or other systemic therapies (see section 5.1). uuid:efc2a443-c95d-4e4e-9dcd-bc683c14c044 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:493191 biolink:treats MONDO:0005194 PMID:41385096 "[{""id"":""uuid:00cd8a11-b912-4940-9c19-a54acd9084ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f5fcd2bf-d689-4dbc-b266-a85ad62c5c86"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Rotarix is indicated for the active immunisation of infants aged 6 to 24 weeks for prevention of gastroenteritis due to rotavirus infection.The use of Rotarix should be based on official recommendation. uuid:c6437f06-b036-4b0a-8d82-7bbf4e2dd729 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135983 biolink:treats HP:0020110 PMID:41385096 "[{""id"":""uuid:c29364ba-967c-4e51-8c29-68fa9a547e89"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:fa111bec-a4fa-42fc-8e95-9e000ca0bd6c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/kauliv""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Terrosa is indicated in adults.Treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture. In postmenopausal women, a significant reduction in the incidence of vertebral and non vertebral fractures but not hip fractures has been demonstrated.Treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture. uuid:8dc54155-0104-4104-bbd7-8a46d20d0398 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135983 biolink:treats HP:0041166 PMID:41385096 "[{""id"":""uuid:f41dd9ec-7bd2-433d-ae35-309276ac6c02"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:4ad4a164-3445-400f-a538-c4e7c1334917"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/kauliv""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Terrosa is indicated in adults.Treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture. In postmenopausal women, a significant reduction in the incidence of vertebral and non vertebral fractures but not hip fractures has been demonstrated.Treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture. uuid:6308e7b0-15d5-473e-bf7a-32bcec8e691c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135983 biolink:treats UMLS:C0162385 PMID:41385096 "[{""id"":""uuid:7870285e-e32d-4cb8-9680-90e916158a18"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:3531d77f-e5d9-433b-ab1d-5402e61fe173"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/kauliv""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Terrosa is indicated in adults.Treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture. In postmenopausal women, a significant reduction in the incidence of vertebral and non vertebral fractures but not hip fractures has been demonstrated.Treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture. uuid:8630a571-c7b2-49bd-a729-dd4bd2fb3a86 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB13932 biolink:treats MONDO:0019118 PMID:41385096 "[{""id"":""uuid:b56761d3-a447-410f-87a8-79918c826e38"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d7d809c9-8e58-4564-ba9e-cb2194e9b908"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/luxturna""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Luxturna is indicated for the treatment of adult and paediatric patients with vision loss due to inherited retinal dystrophy caused by confirmed biallelic RPE65 mutations and who have sufficient viable retinal cells. uuid:49d5c36a-c9d8-40a6-94df-24c245aead31 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB13932 biolink:treats MONDO:0001941 PMID:41385096 "[{""id"":""uuid:7f265b0c-2c1e-4144-ab36-42b7716ce460"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:92c738f9-674c-4e46-a6b0-8620a0973496"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/luxturna""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Luxturna is indicated for the treatment of adult and paediatric patients with vision loss due to inherited retinal dystrophy caused by confirmed biallelic RPE65 mutations and who have sufficient viable retinal cells. uuid:262704fd-68f2-46b8-ab0d-9a3f375d0fa8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:71494926 biolink:treats MONDO:0009061 PMID:41385096 "[{""id"":""uuid:ebb284c0-895b-4517-8f5e-d9d2d505deec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:8ede0355-9749-437e-ae54-3cd3cf9268cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/orkambi""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Orkambi tablets are indicated for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who are homozygous for the F508del mutation in the CFTR gene.Orkambi granules are indicated for the treatment of cystic fibrosis (CF) in children aged 1 year and older who are homozygous for the F508del mutation in the CFTR gene. uuid:76406f57-a062-47e4-acaa-28565f96da36 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63584 biolink:treats MONDO:0008315 PMID:41385096 "[{""id"":""uuid:2c78eac4-dcbe-4636-a701-e4f9ab3901bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:3adb6dfa-e43f-44bb-b99b-70031801749c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/cabazitaxel-accord""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of patients with hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen. uuid:82a17b6f-2684-4bd8-b53b-56fb7d69d7b3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB16665 biolink:treats MONDO:0009693 PMID:41385096 "[{""id"":""uuid:2ffd2d7d-14a0-486c-a65c-adc0b8119a9a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:e1cd8ad3-b886-40ee-b4f5-2e5c54df87e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/abecma""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti CD38 antibody and have demonstrated disease progression on the last therapy. uuid:7da4ded7-6619-4fa0-ab93-a915d3379342 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:8NZ41MIK1O biolink:treats MONDO:0005399 PMID:41385096 "[{""id"":""uuid:7dc16c74-b223-42d9-9632-eb0eda620841"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b0a65d33-021f-40eb-8b00-9d82b297d07a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/inhixa""]},{""id"":""uuid:e13ac030-804f-4871-bda2-9063812aa7dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Inhixa is indicated for adults for:Prophylaxis of venous thromboembolism, particularly in patients undergoing orthopaedic, general or oncological surgery.Prophylaxis of venous thromboembolism in patients bedridden due to acute illnesses including acute heart failure, acute respiratory failure, severe infections, as well as exacerbation of rheumatic diseases causing immobilisation of the patient (applies to strengths of 40 mg/0.4 mL).Treatment of deep vein thrombosis (DVT), complicated or uncomplicated by pulmonary embolism.Treatment of unstable angina and non Q wave myocardial infarction, in combination with acetylsalicylic acid (ASA).Treatment of acute ST segment elevation myocardial infarction (STEMI) including patients who will be treated conservatively or who will later undergo percutaneous coronary angioplasty (applies to strengths of 60 mg/0.6 mL, 80 mg/0.8 mL, and 100 mg/1 mL).Blood clot prevention in the extracorporeal circulation during haemodialysis.|[PMDA] A drug containing a new active ingredient indicated for the prevention of venous thromboembolism in patients who have undergone total hip replacement, total knee replacement and hip fracture surgery. [Priority review] uuid:b1f4c5df-77e9-4a8c-a333-eb618f594f0a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:8NZ41MIK1O biolink:treats MONDO:0003674 PMID:41385096 "[{""id"":""uuid:04cfa4c4-731a-4e23-8602-48ffac99786c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:7dff6b92-c7ca-4e16-b970-b6041dbdcabd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/inhixa""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Inhixa is indicated for adults for:Prophylaxis of venous thromboembolism, particularly in patients undergoing orthopaedic, general or oncological surgery.Prophylaxis of venous thromboembolism in patients bedridden due to acute illnesses including acute heart failure, acute respiratory failure, severe infections, as well as exacerbation of rheumatic diseases causing immobilisation of the patient (applies to strengths of 40 mg/0.4 mL).Treatment of deep vein thrombosis (DVT), complicated or uncomplicated by pulmonary embolism.Treatment of unstable angina and non Q wave myocardial infarction, in combination with acetylsalicylic acid (ASA).Treatment of acute ST segment elevation myocardial infarction (STEMI) including patients who will be treated conservatively or who will later undergo percutaneous coronary angioplasty (applies to strengths of 60 mg/0.6 mL, 80 mg/0.8 mL, and 100 mg/1 mL).Blood clot prevention in the extracorporeal circulation during haemodialysis. uuid:d2b66602-fff3-41ac-b89f-230364c76f2a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3XVL385Q0M biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:faeb3f0f-c9ae-4124-ac0d-f78f315b4426"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2f547dd3-8118-4818-87c1-b02ecf06cbca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:68a8b366-3937-4910-87f7-6faadb20dbc6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Rheumatoid arthritisJyseleca is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (DMARDs). Jyseleca may be used as monotherapy or in combination with methotrexate (MTX).Ulcerative colitisJyseleca is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent.|[PMDA] Drugs with a new active ingredient indicated for the treatment of rheumatoid arthritis (including the prevention of structural joint damage) in patients who have not responded sufficiently to conventional treatments. uuid:52e6c1aa-9557-4420-bd31-e6ca970be102 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3XVL385Q0M biolink:treats MONDO:0005101 PMID:41385096 "[{""id"":""uuid:109a63bb-4e77-4b3a-bbb1-dfdf89d75ca5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:730d4f35-032d-4aa7-a969-e25c60b5281f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:dac1bab0-d89d-4c40-ad36-562478340615"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Rheumatoid arthritisJyseleca is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (DMARDs). Jyseleca may be used as monotherapy or in combination with methotrexate (MTX).Ulcerative colitisJyseleca is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent.|[PMDA] Drugs with a new indication and a new dosage for the treatment and the maintenance therapy of moderate to severe ulcerative colitis (for use only in patients who have not sufficiently responded to conventional treatments). uuid:ac04bc9b-4c33-4898-aad5-f6ec5f2b6bf2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2382436 biolink:treats MONDO:0005812 PMID:41385096 "[{""id"":""uuid:4b8ad93e-ff0c-4157-ab3f-7d12810d828d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:ad6ba6a3-77c5-4140-999c-eb93ac129b15"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Supemtek is indicated for active immunization for the prevention of influenza disease in adults.Supemtek should be used in accordance with official recommendations. uuid:d41706e4-5a5d-4bbc-a207-66ae9c8fc957 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2257008 biolink:treats MONDO:0009061 PMID:41385096 "[{""id"":""uuid:40bf42a1-8a3c-4f05-ada1-b1d2f34841fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:65ed5737-53c9-4aba-bf7f-ab4301d7297a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/kaftrio""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Kaftrio is indicated in a combination regimen with ivacaftor for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. uuid:a3f77425-eec9-4b44-a682-5bd50cb3a803 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C1997870 biolink:treats MONDO:0020725 PMID:41385096 "[{""id"":""uuid:f85cc002-9751-4a5e-bcc3-57d62893e7fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:8d627ed7-b041-4f85-8096-963e083aab91"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/retacrit""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adult and paediatric patients:treatment of anaemia associated with chronic renal failure in adult and paediatric patients on haemodialysis and adult patients on peritoneal dialysis;treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis.Treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre-existing anaemia at the start of chemotherapy).Retacrit can be used to increase the yield of autologous blood from patients in a predonation programme. Its use in this indication must be balanced against the reported risk of thromboembolic events. Treatment should only be given to patients with moderate anaemia (no iron deficiency), if blood-saving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (four or more units of blood for females or five or more units for males).Retacrit can be used to reduce exposure to allogeneic blood transfusions in adult non-iron-deficient patients prior to major elective orthopaedic surgery, having a high perceived risk for transfusion complications. Use should be restricted to patients with moderate anaemia (e.g. Hb 10-13 g/dl) who do not have an autologous predonation programme available and with expected moderate blood loss (900 to 1800 ml). MESH:C530192 uuid:778b265c-89f6-43ca-9fb3-53eaf83634e6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C1997870 biolink:treats MONDO:0002280 PMID:41385096 "[{""id"":""uuid:d0ad1702-4774-4c26-a043-28314f371859"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:9dea4f6a-dbc3-4bd1-9e4e-b94ebf62f540"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/retacrit""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adult and paediatric patients:treatment of anaemia associated with chronic renal failure in adult and paediatric patients on haemodialysis and adult patients on peritoneal dialysis;treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis.Treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre-existing anaemia at the start of chemotherapy).Retacrit can be used to increase the yield of autologous blood from patients in a predonation programme. Its use in this indication must be balanced against the reported risk of thromboembolic events. Treatment should only be given to patients with moderate anaemia (no iron deficiency), if blood-saving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (four or more units of blood for females or five or more units for males).Retacrit can be used to reduce exposure to allogeneic blood transfusions in adult non-iron-deficient patients prior to major elective orthopaedic surgery, having a high perceived risk for transfusion complications. Use should be restricted to patients with moderate anaemia (e.g. Hb 10-13 g/dl) who do not have an autologous predonation programme available and with expected moderate blood loss (900 to 1800 ml). MESH:C530192 uuid:67fee888-27ec-4ac2-a30b-2758ae6c22c9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C1997870 biolink:treats MONDO:0009693 PMID:41385096 "[{""id"":""uuid:0ec05334-2e37-47a4-843b-23d92e9298cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:df4e6871-2750-4f18-bcfb-9422ef3ee991"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/retacrit""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adult and paediatric patients:treatment of anaemia associated with chronic renal failure in adult and paediatric patients on haemodialysis and adult patients on peritoneal dialysis;treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis.Treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre-existing anaemia at the start of chemotherapy).Retacrit can be used to increase the yield of autologous blood from patients in a predonation programme. Its use in this indication must be balanced against the reported risk of thromboembolic events. Treatment should only be given to patients with moderate anaemia (no iron deficiency), if blood-saving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (four or more units of blood for females or five or more units for males).Retacrit can be used to reduce exposure to allogeneic blood transfusions in adult non-iron-deficient patients prior to major elective orthopaedic surgery, having a high perceived risk for transfusion complications. Use should be restricted to patients with moderate anaemia (e.g. Hb 10-13 g/dl) who do not have an autologous predonation programme available and with expected moderate blood loss (900 to 1800 ml). MESH:C530192 uuid:9d0452a7-9567-42cb-a1ac-959bdb1c59d8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C1997870 biolink:treats MONDO:0005062 PMID:41385096 "[{""id"":""uuid:1f4c22b6-17f5-41d8-ad98-bef3fe48bce0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:7b08a148-2fbb-479b-9b4d-9b30e8e0aaa0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/retacrit""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adult and paediatric patients:treatment of anaemia associated with chronic renal failure in adult and paediatric patients on haemodialysis and adult patients on peritoneal dialysis;treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis.Treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre-existing anaemia at the start of chemotherapy).Retacrit can be used to increase the yield of autologous blood from patients in a predonation programme. Its use in this indication must be balanced against the reported risk of thromboembolic events. Treatment should only be given to patients with moderate anaemia (no iron deficiency), if blood-saving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (four or more units of blood for females or five or more units for males).Retacrit can be used to reduce exposure to allogeneic blood transfusions in adult non-iron-deficient patients prior to major elective orthopaedic surgery, having a high perceived risk for transfusion complications. Use should be restricted to patients with moderate anaemia (e.g. Hb 10-13 g/dl) who do not have an autologous predonation programme available and with expected moderate blood loss (900 to 1800 ml). MESH:C530192 uuid:3afc4161-a907-44c2-a82a-4663840334e8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB16738 biolink:treats MONDO:0009693 PMID:41385096 "[{""id"":""uuid:48de3e74-50db-4a88-a503-1b24b4c8c883"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:05e04e8a-b909-4370-bc2b-3817c90dc421"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/carvykti""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody and have demonstrated disease progression on the last therapy. uuid:3a406b2a-422c-425b-be09-0a063a940760 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50381 biolink:treats MONDO:0018982 PMID:41385096 "[{""id"":""uuid:bc407c17-4287-464a-a044-a47df2777a73"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:67ad4ce1-571f-471f-aba1-c256eb49b48d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/opfolda""]},{""id"":""uuid:08e312e5-f391-4a7a-aa35-cee24873940f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Miglustat Dipharma is indicated for the oral treatment of adult patients with mild to moderate type 1 Gaucher disease.Miglustat Dipharma may be used only in the treatment of patients for whom enzyme replacement therapy is unsuitable.Miglustat Dipharma is indicated for the treatment of progressive neurological manifestations in adult patients and paediatric patients with Niemann-Pick type C disease.|[PMDA] A drug with a new active ingredient indicated for the treatment of Niemann-Pick disease Type C. [Orphan drug] uuid:cdf7ee2d-d73e-42e6-b7f1-86547f8ab957 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1597091 biolink:treats MONDO:0002974 PMID:41385096 "[{""id"":""uuid:563ef60e-6b3c-47ff-9cbc-1b6ee899cfe2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:bab749be-e025-47e6-9034-e220c8373257"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:aa829699-47a2-4e64-8abc-077763bbc8ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Gardasil 9 is indicated for active immunisation of individuals from the age of 9 years against the following HPV diseases:Premalignant lesions and cancers affecting the cervix, vulva, vagina and anus caused by vaccine HPV typesGenital warts (Condyloma acuminata) caused by specific HPV types.See sections 4.4 and 5.1 for important information on the data that support these indications.The use of Gardasil 9 should be in accordance with official recommendations.|[PMDA] A drug with a new active ingredient indicated for the prevention of the following diseases caused by infection with human papillomavirus types 6, 11, 16, 18, 31, 33, 45, 52, and 58: Cervical cancer (squamous cell carcinoma and adenosquamous carcinoma) and its precursor lesions (cervical intraepithelial neoplasia [CIN] 1, 2, and 3, and adenocarcinoma in situ [AIS]) Vulvar intraepithelial neoplasia (VIN) 1, 2, and 3, and vaginal intraepithelial noeplasia (VaIN) 1, 2, and 3 Condyloma acuminatum uuid:4b91707c-f8b0-49b2-9343-690b3c4cf9ce biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1597091 biolink:treats MONDO:0001528 PMID:41385096 "[{""id"":""uuid:dcb52848-dfd1-41e2-8c26-22199094b12b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:40d84c21-de6c-4c61-9056-4f3e34880da3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Gardasil 9 is indicated for active immunisation of individuals from the age of 9 years against the following HPV diseases:Premalignant lesions and cancers affecting the cervix, vulva, vagina and anus caused by vaccine HPV typesGenital warts (Condyloma acuminata) caused by specific HPV types.See sections 4.4 and 5.1 for important information on the data that support these indications.The use of Gardasil 9 should be in accordance with official recommendations. uuid:ba0e3e17-c232-4035-8089-f03acb1a0a03 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1597091 biolink:treats MONDO:0001402 PMID:41385096 "[{""id"":""uuid:a96cfe5b-7abe-4428-a4bd-18a238e04a04"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:6756f322-a6a4-4d9e-8828-adb04b20e199"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Gardasil 9 is indicated for active immunisation of individuals from the age of 9 years against the following HPV diseases:Premalignant lesions and cancers affecting the cervix, vulva, vagina and anus caused by vaccine HPV typesGenital warts (Condyloma acuminata) caused by specific HPV types.See sections 4.4 and 5.1 for important information on the data that support these indications.The use of Gardasil 9 should be in accordance with official recommendations. uuid:2f1b1acb-ace4-4ff5-9e5e-bd12505c9642 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1597091 biolink:treats MONDO:0003199 PMID:41385096 "[{""id"":""uuid:de2051ab-70ee-4bfe-abe9-89930d464bd4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:e6b9e91e-2c27-44b6-bdec-07b7c88c4b41"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Gardasil 9 is indicated for active immunisation of individuals from the age of 9 years against the following HPV diseases:Premalignant lesions and cancers affecting the cervix, vulva, vagina and anus caused by vaccine HPV typesGenital warts (Condyloma acuminata) caused by specific HPV types.See sections 4.4 and 5.1 for important information on the data that support these indications.The use of Gardasil 9 should be in accordance with official recommendations. uuid:8f784509-7ed7-4dab-89a1-63f74b90e588 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1597091 biolink:treats MONDO:0005647 PMID:41385096 "[{""id"":""uuid:782f8d4b-4c7e-45eb-b03c-1730522cfc4b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:57c78a5f-6444-41ea-86fa-7871aee1a131"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Gardasil 9 is indicated for active immunisation of individuals from the age of 9 years against the following HPV diseases:Premalignant lesions and cancers affecting the cervix, vulva, vagina and anus caused by vaccine HPV typesGenital warts (Condyloma acuminata) caused by specific HPV types.See sections 4.4 and 5.1 for important information on the data that support these indications.The use of Gardasil 9 should be in accordance with official recommendations. uuid:2500211b-4d6a-4ba0-93c8-43f75046ec4e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9241 biolink:treats MONDO:0008829 PMID:41385096 "[{""id"":""uuid:c3b30733-5b9a-4e28-931f-641bd19d7022"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a725fbd5-2be3-40bc-8d06-3f36c8d1580c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/qaialdo""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] In the management of refractory oedema associated with congestive cardiac failure; hepatic cirrhosis with ascites and oedema, malignant ascites, nephrotic syndrome, diagnosis and treatment of primary aldosteronism, essential hypertension.Neonates, children and adolescents should only be treated under guidance of a paediatric specialist (see sections 5.1 and 5.2). uuid:052b8a9c-d155-4943-b2ce-a5af60895033 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PVI5M0M1GW biolink:treats MONDO:0001475 PMID:41385096 "[{""id"":""uuid:d748da71-1e8b-4d0d-843c-8488a1206910"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:81c1bc24-93d8-43e7-af37-aed6ce91fbc1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/filgrastim-hexal""]},{""id"":""uuid:1a4a5372-9bcf-41b9-97f7-a21f57eaaf5e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Accofil is indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and for the reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone marrow transplantation considered to be at increased risk of prolonged severe neutropenia. The safety and efficacy of Accofil are similar in adults and children receiving cytotoxic chemotherapy.Accofil is indicated for the mobilisation of peripheral blood progenitor cells (PBPCs).In patients, children or adults with severe congenital, cyclic, or idiopathic neutropenia with an absolute neutrophil count (ANC) of ≤ 0.5 x 109/L, and a history of severe or recurrent infections, long term administration of Accofil is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.Accofil is indicated for the treatment of persistent neutropenia (ANC less than or equal to 1.0 x 109/L) in patients with advanced HIV infection, in order to reduce the risk of bacterial infections when other options to manage neutropenia are inappropriate.|[PMDA] Follow-on biologics indicated for mobilization of hematopoietic stem cell to peripheral blood, promotion of increase in neutrophil count at the time of hematopoietic stem cell transplantation, and the treatment of neutropenia caused by cancer chemotherapy, neutropenia which affects the treatment of human immunodeficiency virus (HIV) infection, neutropenia associated with myelodysplastic syndrome, neutropenia associated with aplastic anemia and congenital/idiopathic neutropenia. uuid:f92d9e99-f94e-473f-b69c-4a06b57d007d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PVI5M0M1GW biolink:treats MONDO:0008089 PMID:41385096 "[{""id"":""uuid:5bbb5fdb-491d-4036-af25-e30a658caef5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:6c063e93-c4f2-418e-82df-73f6cd3ab6c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/filgrastim-hexal""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Accofil is indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and for the reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone marrow transplantation considered to be at increased risk of prolonged severe neutropenia. The safety and efficacy of Accofil are similar in adults and children receiving cytotoxic chemotherapy.Accofil is indicated for the mobilisation of peripheral blood progenitor cells (PBPCs).In patients, children or adults with severe congenital, cyclic, or idiopathic neutropenia with an absolute neutrophil count (ANC) of ≤ 0.5 x 109/L, and a history of severe or recurrent infections, long term administration of Accofil is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.Accofil is indicated for the treatment of persistent neutropenia (ANC less than or equal to 1.0 x 109/L) in patients with advanced HIV infection, in order to reduce the risk of bacterial infections when other options to manage neutropenia are inappropriate. uuid:e7d9104d-8f22-41d3-a66e-baef3cfa9371 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PVI5M0M1GW biolink:treats MONDO:0005113 PMID:41385096 "[{""id"":""uuid:754c7904-f0a8-4d44-b278-49075d030d39"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:544ac170-2416-4e03-a0e7-2d10730c90ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/filgrastim-hexal""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Accofil is indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and for the reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone marrow transplantation considered to be at increased risk of prolonged severe neutropenia. The safety and efficacy of Accofil are similar in adults and children receiving cytotoxic chemotherapy.Accofil is indicated for the mobilisation of peripheral blood progenitor cells (PBPCs).In patients, children or adults with severe congenital, cyclic, or idiopathic neutropenia with an absolute neutrophil count (ANC) of ≤ 0.5 x 109/L, and a history of severe or recurrent infections, long term administration of Accofil is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.Accofil is indicated for the treatment of persistent neutropenia (ANC less than or equal to 1.0 x 109/L) in patients with advanced HIV infection, in order to reduce the risk of bacterial infections when other options to manage neutropenia are inappropriate. uuid:93d41b53-8da9-4eac-b1d6-366728cec401 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1551466 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:dd4e4a9b-6fc9-476e-b85c-c8080d9b5d7b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:e112c8f6-3d99-432c-9cf7-39e60f2892dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/mysimba""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Mysimba is indicated, as an adjunct to a reduced-calorie diet and increased physical activity, for the management of weight in adult patients (≥18 years) with an initial Body Mass Index (BMI) of≥ 30 kg/m2 (obese), or≥ 27 kg/m2 to < 30 kg/m2 (overweight) in the presence of one or more weight-related co morbidities (e.g., type 2 diabetes, dyslipidaemia, or controlled hypertension)Treatment with Mysimba should be discontinued after 16 weeks if patients have not lost at least 5% of their initial body weight. uuid:43f96b03-8444-4e61-a05a-8aa38883393f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1551466 biolink:treats HP:0003119 PMID:41385096 "[{""id"":""uuid:25d7b3ec-becb-4fff-b6d5-4aad2debb4a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:8beb0be3-0bea-40eb-9b91-90c10ce6df29"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/mysimba""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Mysimba is indicated, as an adjunct to a reduced-calorie diet and increased physical activity, for the management of weight in adult patients (≥18 years) with an initial Body Mass Index (BMI) of≥ 30 kg/m2 (obese), or≥ 27 kg/m2 to < 30 kg/m2 (overweight) in the presence of one or more weight-related co morbidities (e.g., type 2 diabetes, dyslipidaemia, or controlled hypertension)Treatment with Mysimba should be discontinued after 16 weeks if patients have not lost at least 5% of their initial body weight. uuid:a4a5a8a7-04f6-40fa-b3de-70822a5825b0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:NQX9KB6PCL biolink:treats NCIT:C118469 PMID:41385096 "[{""id"":""uuid:bb488842-d751-4b0b-930e-dd2887b3ddc9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:69b3d915-d366-4bc0-a979-05e676770160"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/omnitrope""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Long-term treatment of children with growth failure due to inadequate endogenous growth hormone secretion.Long-term treatment of growth failure associated with Turner syndrome.Treatment of prepubertal children with growth failure associated with chronic renal insufficiency up to the time of renal transplantation.Replacement of endogenous growth hormone in adults with growth hormone deficiency of either childhood or adult-onset etiology. Growth hormone deficiency should be confirmed appropriately prior to treatment. uuid:f7bf48e1-1dd5-4d3a-9aaa-58f2fd6a0eba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71028 biolink:treats MONDO:0009475 PMID:41385096 "[{""id"":""uuid:94b040fc-daef-4910-9361-cb6fb6af975b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0c77be8a-996a-4ea7-8c67-00f1e3dbf8cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/carbaglu""]},{""id"":""uuid:8773cbc2-3608-48a0-8ff0-f149a71ac391"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Carbaglu is indicated in treatment of:hyperammonaemia due to N-acetylglutamate-synthase primary deficiency;hyperammonaemia due to isovaleric acidaemia;hyperammonaemia due to methymalonic acidaemia;hyperammonaemia due to propionic acidaemia.|[PMDA] A drug with a new active ingredient indicated for the treatment of hyperammonemia due to N- acetylglutamate synthetase deficiency, isovaleric acidemia, methylmalonic acidemia, and propionic acidemia. [Orphan drug] uuid:6f15a33e-bb18-4d4a-b5ba-8badbe076dc9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71028 biolink:treats MONDO:0009615 PMID:41385096 "[{""id"":""uuid:95b09fd8-8fce-45a8-b2d0-7f1fbd742856"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:88e11e77-bc91-4461-b487-1094f723b708"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/carbaglu""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Carbaglu is indicated in treatment of:hyperammonaemia due to N-acetylglutamate-synthase primary deficiency;hyperammonaemia due to isovaleric acidaemia;hyperammonaemia due to methymalonic acidaemia;hyperammonaemia due to propionic acidaemia. uuid:bd02746b-8740-4305-9b8b-5c7717c0d49b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB10284 biolink:treats MONDO:0005373 PMID:41385096 "[{""id"":""uuid:005d60cb-a1ba-49c5-af11-9aa5f943a4c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:cbb1d2ff-54a7-4807-81f7-00bc3fca6e2f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Active immunisation against invasive disease caused by Neisseria meningitidis serogroup-B strains., uuid:e0291521-51e2-4f63-8a55-9262c180f90a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:QC4F7FKK7I biolink:treats MONDO:0005417 PMID:41385096 "[{""id"":""uuid:51a5415b-8498-4fe5-b9ca-50dfdb747c6c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:faf934c3-87a7-4db8-b7cd-4190de6b5fc2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/vabysmo""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Vabysmo is indicated for the treatment of adult patients with:neovascular (wet) age-related macular degeneration (nAMD),visual impairment due to diabetic macular oedema (DME). uuid:7f6f35e7-a575-4f11-bd75-ec307f1b37d0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:QC4F7FKK7I biolink:treats MONDO:0004728 PMID:41385096 "[{""id"":""uuid:3b36a16d-8926-473f-872e-0d9fad94305d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e6c7cdbe-3c16-4c14-aad9-ca8f49267864"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/vabysmo""]},{""id"":""uuid:b563fd6d-390e-41db-8102-01cd0337bdb4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Vabysmo is indicated for the treatment of adult patients with:neovascular (wet) age-related macular degeneration (nAMD),visual impairment due to diabetic macular oedema (DME).|[PMDA] A drug with a new active ingredient indicated for the treatment of age-related macular degeneration associated with subfoveal choroidal neovascularization and diabetic macular edema. uuid:024ee99d-046b-4972-89de-b416bb467007 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3614 biolink:treats MONDO:0000809 PMID:41385096 "[{""id"":""uuid:f9ea1294-1782-40f4-a5d7-215020edc069"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2ccd61ac-93d1-456f-ab07-180c7a41a900"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ceprotin""]},{""id"":""uuid:a2d922ec-b08b-4f2f-b1c7-b0d44e21ef73"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] CEPROTIN is indicated for prophylaxis and treatment of purpura fulminans coumarin-induced skin necrosis and venous thrombotic events in patients with severe congenital protein C deficiency.|[PMDA] A drug with a new active ingredient indicated for the treatment of venous thromboembolism and purpura fulminans and for the control of thrombophilia, in patients with congenital protein C deficiency. uuid:300cb04e-c30c-408f-a688-8f219b3c62a0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3614 biolink:treats MONDO:0005380 PMID:41385096 "[{""id"":""uuid:089b923b-d290-4bef-bf53-7f959a851927"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a0711525-f85f-4dea-85bf-20071c9853a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ceprotin""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] CEPROTIN is indicated for prophylaxis and treatment of purpura fulminans coumarin-induced skin necrosis and venous thrombotic events in patients with severe congenital protein C deficiency. uuid:9fd76ab8-75e2-4132-8764-6d00c6194b15 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3614 biolink:treats MONDO:0005399 PMID:41385096 "[{""id"":""uuid:e13b0670-5446-438e-be3e-b0184f0ceeb1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f2c49d67-902e-470d-951b-d5d95498e800"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ceprotin""]},{""id"":""uuid:86f53357-0571-44e2-9cfa-c94f73606597"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] CEPROTIN is indicated for prophylaxis and treatment of purpura fulminans coumarin-induced skin necrosis and venous thrombotic events in patients with severe congenital protein C deficiency.|[PMDA] A drug with a new active ingredient indicated for the treatment of venous thromboembolism and purpura fulminans and for the control of thrombophilia, in patients with congenital protein C deficiency. uuid:fc4301c5-4527-44de-826b-c9f5beb7002f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6QVL057INT biolink:treats MONDO:0002529 PMID:41385096 "[{""id"":""uuid:31588332-1493-4f58-8858-30c5bde5439e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:41e103a3-7a1e-4d36-8876-c1916d2ae172"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/libtayo""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Cutaneous Squamous Cell CarcinomaLibtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mCSCC or laCSCC) who are not candidates for curative surgery or curative radiation.Basal Cell CarcinomaLibtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (laBCC or mBCC) who have progressed on or are intolerant to a hedgehog pathway inhibitor (HHI).Non-Small Cell Lung CancerLibtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) expressing PD-L1 (in ≥ 50% tumour cells), with no EGFR, ALK or ROS1 aberrations, who have:locally advanced NSCLC who are not candidates for definitive chemoradiation, ormetastatic NSCLC.Libtayo in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with NSCLC expressing PD-L1 (in ≥ 1% of tumour cells), with no EGFR, ALK or ROS1 aberrations, who have:locally advanced NSCLC who are not candidates for definitive chemoradiation, ormetastatic NSCLC.Cervical CancerLibtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy. uuid:18762dea-ab9d-44fd-8024-f224fac76a22 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6QVL057INT biolink:treats MONDO:0002974 PMID:41385096 "[{""id"":""uuid:f1d4b613-2990-4b72-a5eb-b17935f0fbc9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:bbd5bf89-198e-47dc-b338-9585e9ba02cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/libtayo""]},{""id"":""uuid:080afe24-5e60-4d0e-95e6-4863f94e86d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Cutaneous Squamous Cell CarcinomaLibtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mCSCC or laCSCC) who are not candidates for curative surgery or curative radiation.Basal Cell CarcinomaLibtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (laBCC or mBCC) who have progressed on or are intolerant to a hedgehog pathway inhibitor (HHI).Non-Small Cell Lung CancerLibtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) expressing PD-L1 (in ≥ 50% tumour cells), with no EGFR, ALK or ROS1 aberrations, who have:locally advanced NSCLC who are not candidates for definitive chemoradiation, ormetastatic NSCLC.Libtayo in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with NSCLC expressing PD-L1 (in ≥ 1% of tumour cells), with no EGFR, ALK or ROS1 aberrations, who have:locally advanced NSCLC who are not candidates for definitive chemoradiation, ormetastatic NSCLC.Cervical CancerLibtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.|[PMDA] A drug with a new active ingredient indicated for the treatment of advanced or recurrent cervical cancer that has progressed after cancer chemotherapy. uuid:51f00b5f-3949-4861-8ec9-5247b7e73a0d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:195558 biolink:treats MONDO:0958299 PMID:41385096 "[{""id"":""uuid:22216a1a-2331-4010-9807-31a8fedeed49"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:89c068e9-91bf-4df1-9244-be5f90ee0aa0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/rozlytrek""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion,who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, andwho have not received a prior NTRK inhibitorwho have no satisfactory treatment options.Rozlytrek as monotherapy is indicated for the treatment of adult patients with ROS1 positive, advanced non small cell lung cancer (NSCLC) not previously treated with ROS1 inhibitors. uuid:fb376d88-1bf8-47c1-9c39-8a3d40640d9a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4H5YMK1H2E biolink:treats MONDO:0000705 PMID:41385096 "[{""id"":""uuid:784c938e-004f-4e43-8d94-ecf94aa22fb0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:22df9953-e206-48a9-8ce3-4e17a9ac73df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/zinplava""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Zinplava is indicated for the prevention of recurrence of Clostridium difficile infection (CDI) in adults at high risk for recurrence of CDI. uuid:205a2583-b90f-46ac-8fed-30ca5a8bdc10 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4H5YMK1H2E biolink:treats MONDO:0015790 PMID:41385096 "[{""id"":""uuid:3d1fb2fc-e264-410e-9eb2-5fb66feaba65"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:52a19946-fdb3-4f2d-a88d-357839d467e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/zinplava""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Zinplava is indicated for the prevention of recurrence of Clostridium difficile infection (CDI) in adults at high risk for recurrence of CDI. uuid:9be9a6e7-ea2e-485e-81c5-6de12eba7c58 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85662 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:66cbe8e4-fe68-4af3-8868-a68d97def238"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e37f1218-331b-4f10-ae84-7b069aa4d14a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/lyxumia""]},{""id"":""uuid:b26b6fcf-2257-4504-b013-e4b8ffeeb9df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Lyxumia is indicated for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with oral glucose lowering medicinal products and/or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control.,|[PMDA] A drug with a new active ingredient indicated for the treatment of type 2 diabetes mellitus (for use only in patients who have not responded sufficiently to either treatment (1) or (2): (1) Use of sulfonylureas (including combination with biguanides) in addition to diet and exercise therapies; (2) Use of long-acting soluble insulin or intermediate-acting insulin preparations (including combination with sulfonylureas) in addition to diet and exercise therapies. uuid:b3ec0975-9849-4e50-b889-ec9a52a02e71 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:FU77B4U5Z0 biolink:treats MONDO:0005083 PMID:41385096 "[{""id"":""uuid:99673be6-42a7-417d-91fe-83652ca5620d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:2d398a4d-4bb0-41f2-8084-571167b85e90"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/stelara""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Crohn’s DiseaseStelara is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a TNFα antagonist or have medical contraindications to such therapies.Ulcerative colitisSTELARA is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies.Plaque psoriasisStelara is indicated for the treatment of moderate to severe plaque psoriasis in adults who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate and psoralen ultraviolet A.Paediatric plaque psoriasisStelara is indicated for the treatment of moderate to severe plaque psoriasis in children and adolescent patients from the age of 6 years and older, who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.Psoriatic arthritisStelara, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous non-biological disease-modifying antirheumatic drug (DMARD) therapy has been inadequate. uuid:bbabf0e0-2689-4f98-a8f2-a394d3ab39bf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB00028 biolink:treats MONDO:0004948 PMID:41385096 "[{""id"":""uuid:6aa40471-b9b0-4ce2-8f8d-62297370548d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:c6d2b870-0484-456a-84a8-f5629c59eb8c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/flebogamma-dif""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Replacement therapy in adults, children and adolescents (0-18 years) in:Primary immunodeficiency syndromes with impaired antibody production.Hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic leukaemia (CLL), in whom prophylactic antibiotics have failed or are contra‑indicated.Hypogammaglobulinaemia and recurrent bacterial infections in multiple myeloma (MM) patients.Hypogammaglobulinaemia in patients pre‑ and post‑allogeneic hematopoietic stem cell transplantation (HSCT). uuid:89a6aa2c-131d-41a7-9938-8298a55b11e8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB00028 biolink:treats MONDO:0009693 PMID:41385096 "[{""id"":""uuid:d56a0ef2-f04a-4a5f-afd2-578980600f2e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:0fda41ef-21f2-4957-b103-932939f9f00c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/flebogamma-dif""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Replacement therapy in adults, children and adolescents (0-18 years) in:Primary immunodeficiency syndromes with impaired antibody production.Hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic leukaemia (CLL), in whom prophylactic antibiotics have failed or are contra‑indicated.Hypogammaglobulinaemia and recurrent bacterial infections in multiple myeloma (MM) patients.Hypogammaglobulinaemia in patients pre‑ and post‑allogeneic hematopoietic stem cell transplantation (HSCT). uuid:81d29a02-93d1-43f0-9bac-0643415cc86d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB10061 biolink:treats MONDO:0005373 PMID:41385096 "[{""id"":""uuid:30301c31-cd00-4ee6-b6aa-d17be0d5231b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:0efad190-84f2-4aea-a5e8-88868b3385a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Nimenrix is indicated for active immunisation of individuals from the age of 6 weeks against invasive meningococcal diseases caused by Neisseria meningitidis group A, C, W-135, and Y. uuid:0f2f6fbf-0ce9-4a1e-80e8-12071a5c7908 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:I8309403R0 biolink:treats MONDO:0005314 PMID:41385096 "[{""id"":""uuid:b79777fa-bfbd-4d50-90b0-42be7ceda24b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:217aeb0b-f14f-4355-98a6-c0f7d8b622b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/plegridy""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of relapsing remitting multiple sclerosis in adult patients. uuid:97aca444-2dd2-485e-9f42-7702783c469e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:9013DUQ28K biolink:treats MONDO:0100096 PMID:41385096 "[{""id"":""uuid:12a3ead3-c304-44de-b68f-40946f1e7d9e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:380b6591-e4a0-425e-8eee-0612a672ab59"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/kineret""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Rheumatoid Arthritis (RA)Kineret is indicated in adults for the treatment of the signs and symptoms of RA in combination with methotrexate, with an inadequate response to methotrexate alone.COVID-19Kineret is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adult patients with pneumonia requiring supplemental oxygen (low- or high-flow oxygen) who are at risk of progressing to severe respiratory failure determined by plasma concentration of soluble urokinase plasminogen activator receptor (suPAR) ≥ 6 ng/ml.Periodic fever syndromesKineret is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above:Cryopyrin-Associated Periodic Syndromes (CAPS)Kineret is indicated for the treatment of CAPS, including:Neonatal-Onset Multisystem Inflammatory Disease (NOMID) / Chronic Infantile Neurological, Cutaneous, Articular Syndrome (CINCA)Muckle-Wells Syndrome (MWS)Familial Cold Autoinflammatory Syndrome (FCAS)Familial Mediterranean Fever (FMF)Kineret is indicated for the treatment of Familial Mediterranean Fever (FMF). Kineret should be given in combination with colchicine, if appropriate.Still’s DiseaseKineret is indicated in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above for the treatment of Still’s disease, including Systemic Juvenile Idiopathic Arthritis (SJIA) and Adult-Onset Still’s Disease (AOSD), with active systemic features of moderate to high disease activity, or in patients with continued disease activity after treatment with non-steroidal anti-inflammatory drugs (NSAIDs) or glucocorticoids.Kineret can be given as monotherapy or in combination with other anti-inflammatory drugs and disease-modifying antirheumatic drugs (DMARDs). uuid:dda2c097-d2cb-4b5b-8647-a8f4565fef1f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:9013DUQ28K biolink:treats MONDO:0016168 PMID:41385096 "[{""id"":""uuid:13df36d8-7af8-41a7-bc1c-b3fdd59cecc0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d4a5d70b-c3ce-4397-9d29-01760e308bd7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/kineret""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Rheumatoid Arthritis (RA)Kineret is indicated in adults for the treatment of the signs and symptoms of RA in combination with methotrexate, with an inadequate response to methotrexate alone.COVID-19Kineret is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adult patients with pneumonia requiring supplemental oxygen (low- or high-flow oxygen) who are at risk of progressing to severe respiratory failure determined by plasma concentration of soluble urokinase plasminogen activator receptor (suPAR) ≥ 6 ng/ml.Periodic fever syndromesKineret is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above:Cryopyrin-Associated Periodic Syndromes (CAPS)Kineret is indicated for the treatment of CAPS, including:Neonatal-Onset Multisystem Inflammatory Disease (NOMID) / Chronic Infantile Neurological, Cutaneous, Articular Syndrome (CINCA)Muckle-Wells Syndrome (MWS)Familial Cold Autoinflammatory Syndrome (FCAS)Familial Mediterranean Fever (FMF)Kineret is indicated for the treatment of Familial Mediterranean Fever (FMF). Kineret should be given in combination with colchicine, if appropriate.Still’s DiseaseKineret is indicated in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above for the treatment of Still’s disease, including Systemic Juvenile Idiopathic Arthritis (SJIA) and Adult-Onset Still’s Disease (AOSD), with active systemic features of moderate to high disease activity, or in patients with continued disease activity after treatment with non-steroidal anti-inflammatory drugs (NSAIDs) or glucocorticoids.Kineret can be given as monotherapy or in combination with other anti-inflammatory drugs and disease-modifying antirheumatic drugs (DMARDs). uuid:b1172452-7127-471d-ad31-ce08fe58ae83 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:9013DUQ28K biolink:treats MONDO:0018768 PMID:41385096 "[{""id"":""uuid:1685dad8-d3d4-459a-8a5b-9cac6e18f12b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:20abeea5-c747-4ace-8c32-4614528d7b38"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/kineret""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Rheumatoid Arthritis (RA)Kineret is indicated in adults for the treatment of the signs and symptoms of RA in combination with methotrexate, with an inadequate response to methotrexate alone.COVID-19Kineret is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adult patients with pneumonia requiring supplemental oxygen (low- or high-flow oxygen) who are at risk of progressing to severe respiratory failure determined by plasma concentration of soluble urokinase plasminogen activator receptor (suPAR) ≥ 6 ng/ml.Periodic fever syndromesKineret is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above:Cryopyrin-Associated Periodic Syndromes (CAPS)Kineret is indicated for the treatment of CAPS, including:Neonatal-Onset Multisystem Inflammatory Disease (NOMID) / Chronic Infantile Neurological, Cutaneous, Articular Syndrome (CINCA)Muckle-Wells Syndrome (MWS)Familial Cold Autoinflammatory Syndrome (FCAS)Familial Mediterranean Fever (FMF)Kineret is indicated for the treatment of Familial Mediterranean Fever (FMF). Kineret should be given in combination with colchicine, if appropriate.Still’s DiseaseKineret is indicated in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above for the treatment of Still’s disease, including Systemic Juvenile Idiopathic Arthritis (SJIA) and Adult-Onset Still’s Disease (AOSD), with active systemic features of moderate to high disease activity, or in patients with continued disease activity after treatment with non-steroidal anti-inflammatory drugs (NSAIDs) or glucocorticoids.Kineret can be given as monotherapy or in combination with other anti-inflammatory drugs and disease-modifying antirheumatic drugs (DMARDs). uuid:1f0950bb-1ebf-4dd6-a1d5-c6465af8ac41 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:9013DUQ28K biolink:treats MONDO:0018088 PMID:41385096 "[{""id"":""uuid:8e08d682-7a81-4c89-ac6c-d54df4948fc3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:8bef977c-7f22-43dc-93ba-affe9404765d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/kineret""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Rheumatoid Arthritis (RA)Kineret is indicated in adults for the treatment of the signs and symptoms of RA in combination with methotrexate, with an inadequate response to methotrexate alone.COVID-19Kineret is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adult patients with pneumonia requiring supplemental oxygen (low- or high-flow oxygen) who are at risk of progressing to severe respiratory failure determined by plasma concentration of soluble urokinase plasminogen activator receptor (suPAR) ≥ 6 ng/ml.Periodic fever syndromesKineret is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above:Cryopyrin-Associated Periodic Syndromes (CAPS)Kineret is indicated for the treatment of CAPS, including:Neonatal-Onset Multisystem Inflammatory Disease (NOMID) / Chronic Infantile Neurological, Cutaneous, Articular Syndrome (CINCA)Muckle-Wells Syndrome (MWS)Familial Cold Autoinflammatory Syndrome (FCAS)Familial Mediterranean Fever (FMF)Kineret is indicated for the treatment of Familial Mediterranean Fever (FMF). Kineret should be given in combination with colchicine, if appropriate.Still’s DiseaseKineret is indicated in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above for the treatment of Still’s disease, including Systemic Juvenile Idiopathic Arthritis (SJIA) and Adult-Onset Still’s Disease (AOSD), with active systemic features of moderate to high disease activity, or in patients with continued disease activity after treatment with non-steroidal anti-inflammatory drugs (NSAIDs) or glucocorticoids.Kineret can be given as monotherapy or in combination with other anti-inflammatory drugs and disease-modifying antirheumatic drugs (DMARDs). uuid:ea12ae4f-2595-4ec1-b40f-c5a3ebfd2954 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:9013DUQ28K biolink:treats MONDO:0019355 PMID:41385096 "[{""id"":""uuid:1ed3cd0e-90ab-42ee-8c67-ad3498a56158"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:5b6195dc-fb87-4097-8b37-383dee041394"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/kineret""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Rheumatoid Arthritis (RA)Kineret is indicated in adults for the treatment of the signs and symptoms of RA in combination with methotrexate, with an inadequate response to methotrexate alone.COVID-19Kineret is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adult patients with pneumonia requiring supplemental oxygen (low- or high-flow oxygen) who are at risk of progressing to severe respiratory failure determined by plasma concentration of soluble urokinase plasminogen activator receptor (suPAR) ≥ 6 ng/ml.Periodic fever syndromesKineret is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above:Cryopyrin-Associated Periodic Syndromes (CAPS)Kineret is indicated for the treatment of CAPS, including:Neonatal-Onset Multisystem Inflammatory Disease (NOMID) / Chronic Infantile Neurological, Cutaneous, Articular Syndrome (CINCA)Muckle-Wells Syndrome (MWS)Familial Cold Autoinflammatory Syndrome (FCAS)Familial Mediterranean Fever (FMF)Kineret is indicated for the treatment of Familial Mediterranean Fever (FMF). Kineret should be given in combination with colchicine, if appropriate.Still’s DiseaseKineret is indicated in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above for the treatment of Still’s disease, including Systemic Juvenile Idiopathic Arthritis (SJIA) and Adult-Onset Still’s Disease (AOSD), with active systemic features of moderate to high disease activity, or in patients with continued disease activity after treatment with non-steroidal anti-inflammatory drugs (NSAIDs) or glucocorticoids.Kineret can be given as monotherapy or in combination with other anti-inflammatory drugs and disease-modifying antirheumatic drugs (DMARDs). uuid:41186d10-92a6-46c5-8ab8-39b58665ad37 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:9013DUQ28K biolink:treats MONDO:0019434 PMID:41385096 "[{""id"":""uuid:0d0cd650-d2e8-4ae5-9702-e8aae67ddfc3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:678b8f6f-87d5-43c8-b3a0-51c959c54379"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/kineret""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Rheumatoid Arthritis (RA)Kineret is indicated in adults for the treatment of the signs and symptoms of RA in combination with methotrexate, with an inadequate response to methotrexate alone.COVID-19Kineret is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adult patients with pneumonia requiring supplemental oxygen (low- or high-flow oxygen) who are at risk of progressing to severe respiratory failure determined by plasma concentration of soluble urokinase plasminogen activator receptor (suPAR) ≥ 6 ng/ml.Periodic fever syndromesKineret is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above:Cryopyrin-Associated Periodic Syndromes (CAPS)Kineret is indicated for the treatment of CAPS, including:Neonatal-Onset Multisystem Inflammatory Disease (NOMID) / Chronic Infantile Neurological, Cutaneous, Articular Syndrome (CINCA)Muckle-Wells Syndrome (MWS)Familial Cold Autoinflammatory Syndrome (FCAS)Familial Mediterranean Fever (FMF)Kineret is indicated for the treatment of Familial Mediterranean Fever (FMF). Kineret should be given in combination with colchicine, if appropriate.Still’s DiseaseKineret is indicated in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above for the treatment of Still’s disease, including Systemic Juvenile Idiopathic Arthritis (SJIA) and Adult-Onset Still’s Disease (AOSD), with active systemic features of moderate to high disease activity, or in patients with continued disease activity after treatment with non-steroidal anti-inflammatory drugs (NSAIDs) or glucocorticoids.Kineret can be given as monotherapy or in combination with other anti-inflammatory drugs and disease-modifying antirheumatic drugs (DMARDs). uuid:a21961a2-06bb-484f-9d03-a1f0a73e5cd2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4EQZ6YO2HI biolink:treats HP:0002756 PMID:41385096 "[{""id"":""uuid:4ad84b6c-a708-4e34-9822-24a7e6762fcb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:fbc2343d-e0ea-4595-a4e1-7c08b58b1fc8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/prolia""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with advanced malignancies involving bone (see section 5.1).Treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity. uuid:75e2ee4e-2ebc-4117-83d0-48393b29efe3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4EQZ6YO2HI biolink:treats MONDO:0043735 PMID:41385096 "[{""id"":""uuid:1664370e-8fee-4cb5-9a65-d57d45c4a40b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:e8783cbd-c94e-4cc0-a12f-363d995768bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/prolia""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with advanced malignancies involving bone (see section 5.1).Treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity. uuid:de2dbf81-0be0-4679-99df-ad0c5ec9791b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4EQZ6YO2HI biolink:treats MONDO:0002545 PMID:41385096 "[{""id"":""uuid:70d430a1-7398-4325-8cac-c70e585c2863"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:69a3163f-1053-40f8-b8d0-21741827d7be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/prolia""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with advanced malignancies involving bone (see section 5.1).Treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity. uuid:7baf3f2e-aac0-49cd-adde-cfdcce1eef8e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9635 biolink:treats MONDO:0005628 PMID:41385096 "[{""id"":""uuid:75359623-7eaa-490e-a3f9-17fb7e4d28a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:55e93fc5-8e83-4327-91bb-28c126ef6025"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/fareston""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] First line hormone treatment of hormone-dependent metastatic breast cancer in postmenopausal patients.Fareston is not recommended for patients with estrogen receptor negative tumours. uuid:abfefb8d-9f9c-4c4b-8c13-0796484d6402 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:UMD7G2653W biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:03df2515-4f8b-4464-b8c0-57e667b495ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:7ebb8ecb-19a6-4e1c-b9d4-703cbf7571b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/bonviva""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Bondronat is indicated for:prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases;treatment of tumour-induced hypercalcaemia with or without metastases. uuid:752d0d16-2c30-49e7-957d-023a2cdb2eac biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:UMD7G2653W biolink:treats MONDO:0043731 PMID:41385096 "[{""id"":""uuid:f28edb01-8ba8-44b8-accb-f90fb1dff399"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:48d906ff-1f09-46fe-a996-89e220d93eea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/bonviva""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Bondronat is indicated for:prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases;treatment of tumour-induced hypercalcaemia with or without metastases. uuid:eb3ffed0-e4a8-448e-9833-c8ad36d04219 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:UMD7G2653W biolink:treats MONDO:0043455 PMID:41385096 "[{""id"":""uuid:0388fd62-349c-4240-a243-700d67300f19"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:2a75568f-69f5-4999-beef-40c23561065f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/bonviva""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Bondronat is indicated for:prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases;treatment of tumour-induced hypercalcaemia with or without metastases. uuid:9b9c9866-5b76-4677-9d1b-6bb534ce1730 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135906 biolink:treats MONDO:0009807 PMID:41385096 "[{""id"":""uuid:2bf39c13-5ac0-4cfc-82a7-55dcb9aff778"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a3a81713-327d-44f5-9b1b-c2d3d032c277"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/mepact""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Mepact is indicated in children, adolescents and young adults for the treatment of high-grade resectable non-metastatic osteosarcoma after macroscopically complete surgical resection. It is used in combination with postoperative multi-agent chemotherapy. Safety and efficacy have been assessed in studies of patients two to 30 years of age at initial diagnosis. uuid:e4decec4-65d2-4f2f-91e1-3a73e93e6c82 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:61033 biolink:treats MONDO:0006805 PMID:41385096 "[{""id"":""uuid:cb5067a0-0203-4f67-9966-0c1a38eb4370"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:08ae92d6-b56c-4543-b50c-a7a60fa88b49"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/arixtra""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] 1.5-mg/0.3-ml and 2.5-mg/0.5-ml solution for injectionPrevention of venous thromboembolic events (VTE) in adults undergoing major orthopaedic surgery of the lower limbs such as hip fracture, major knee surgery or hip-replacement surgery.Prevention of VTE in adults undergoing abdominal surgery who are judged to be at high risk of thromboembolic complications, such as patients undergoing abdominal cancer surgery.Prevention of VTE in adult medical patients who are judged to be at high risk for VTE and who are immobilised due to acute illness such as cardiac insufficiency and / or acute respiratory disorders, and / or acute infectious or inflammatory disease.Treatment of adults with acute symptomatic spontaneous superficial-vein thrombosis of the lower limbs without concomitant deep-vein thrombosis.2.5-mg/0.5-ml solution for injectionTreatment of unstable angina or non-ST-segment-elevation myocardial infarction (UA/NSTEMI) in adult patients for whom urgent (< 120 mins) invasive management (PCI) is not indicated.infarction (STEMI) in adult patients who are managed with thrombolytics or who initially are to receive no other form of reperfusion therapy.5-mg/0.4-ml, 7.5-mg/0.6-ml and 10-mg/0.8-ml solution for injectionTreatment of adults with acute deep-vein thrombosis (DVT) and treatment of acute pulmonary embolism (PE), except in haemodynamically unstable patients or patients who require thrombolysis or pulmonary embolectomy. uuid:4a100c4e-78ab-4f03-866b-93cd94194913 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:61033 biolink:treats MONDO:0000990 PMID:41385096 "[{""id"":""uuid:5df889bb-e744-4497-a1b2-d73162b8949f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:443241a7-de4b-45ec-bd23-e8a76963ecd5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/arixtra""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] 1.5-mg/0.3-ml and 2.5-mg/0.5-ml solution for injectionPrevention of venous thromboembolic events (VTE) in adults undergoing major orthopaedic surgery of the lower limbs such as hip fracture, major knee surgery or hip-replacement surgery.Prevention of VTE in adults undergoing abdominal surgery who are judged to be at high risk of thromboembolic complications, such as patients undergoing abdominal cancer surgery.Prevention of VTE in adult medical patients who are judged to be at high risk for VTE and who are immobilised due to acute illness such as cardiac insufficiency and / or acute respiratory disorders, and / or acute infectious or inflammatory disease.Treatment of adults with acute symptomatic spontaneous superficial-vein thrombosis of the lower limbs without concomitant deep-vein thrombosis.2.5-mg/0.5-ml solution for injectionTreatment of unstable angina or non-ST-segment-elevation myocardial infarction (UA/NSTEMI) in adult patients for whom urgent (< 120 mins) invasive management (PCI) is not indicated.infarction (STEMI) in adult patients who are managed with thrombolytics or who initially are to receive no other form of reperfusion therapy.5-mg/0.4-ml, 7.5-mg/0.6-ml and 10-mg/0.8-ml solution for injectionTreatment of adults with acute deep-vein thrombosis (DVT) and treatment of acute pulmonary embolism (PE), except in haemodynamically unstable patients or patients who require thrombolysis or pulmonary embolectomy. uuid:e31c3792-d791-49ca-9d6e-bc29967e0094 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:61033 biolink:treats MONDO:0041656 PMID:41385096 "[{""id"":""uuid:edd57b40-f03b-48a0-8b8d-82054027f157"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:c7d55442-bc34-45e7-90ab-1a03d1c557b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/arixtra""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] 1.5-mg/0.3-ml and 2.5-mg/0.5-ml solution for injectionPrevention of venous thromboembolic events (VTE) in adults undergoing major orthopaedic surgery of the lower limbs such as hip fracture, major knee surgery or hip-replacement surgery.Prevention of VTE in adults undergoing abdominal surgery who are judged to be at high risk of thromboembolic complications, such as patients undergoing abdominal cancer surgery.Prevention of VTE in adult medical patients who are judged to be at high risk for VTE and who are immobilised due to acute illness such as cardiac insufficiency and / or acute respiratory disorders, and / or acute infectious or inflammatory disease.Treatment of adults with acute symptomatic spontaneous superficial-vein thrombosis of the lower limbs without concomitant deep-vein thrombosis.2.5-mg/0.5-ml solution for injectionTreatment of unstable angina or non-ST-segment-elevation myocardial infarction (UA/NSTEMI) in adult patients for whom urgent (< 120 mins) invasive management (PCI) is not indicated.infarction (STEMI) in adult patients who are managed with thrombolytics or who initially are to receive no other form of reperfusion therapy.5-mg/0.4-ml, 7.5-mg/0.6-ml and 10-mg/0.8-ml solution for injectionTreatment of adults with acute deep-vein thrombosis (DVT) and treatment of acute pulmonary embolism (PE), except in haemodynamically unstable patients or patients who require thrombolysis or pulmonary embolectomy. uuid:4b84ee4d-7a56-478c-ac3c-4fce35e766eb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:61033 biolink:treats MONDO:0005279 PMID:41385096 "[{""id"":""uuid:287d46d5-8a5a-49a5-a6f5-ee5383c85518"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:8e758444-5118-407d-9583-6e85e8b23e29"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/arixtra""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] 1.5-mg/0.3-ml and 2.5-mg/0.5-ml solution for injectionPrevention of venous thromboembolic events (VTE) in adults undergoing major orthopaedic surgery of the lower limbs such as hip fracture, major knee surgery or hip-replacement surgery.Prevention of VTE in adults undergoing abdominal surgery who are judged to be at high risk of thromboembolic complications, such as patients undergoing abdominal cancer surgery.Prevention of VTE in adult medical patients who are judged to be at high risk for VTE and who are immobilised due to acute illness such as cardiac insufficiency and / or acute respiratory disorders, and / or acute infectious or inflammatory disease.Treatment of adults with acute symptomatic spontaneous superficial-vein thrombosis of the lower limbs without concomitant deep-vein thrombosis.2.5-mg/0.5-ml solution for injectionTreatment of unstable angina or non-ST-segment-elevation myocardial infarction (UA/NSTEMI) in adult patients for whom urgent (< 120 mins) invasive management (PCI) is not indicated.infarction (STEMI) in adult patients who are managed with thrombolytics or who initially are to receive no other form of reperfusion therapy.5-mg/0.4-ml, 7.5-mg/0.6-ml and 10-mg/0.8-ml solution for injectionTreatment of adults with acute deep-vein thrombosis (DVT) and treatment of acute pulmonary embolism (PE), except in haemodynamically unstable patients or patients who require thrombolysis or pulmonary embolectomy. uuid:01199626-d151-43e5-bd7f-962307cc3fee biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:233412 biolink:treats MONDO:0005314 PMID:41385096 "[{""id"":""uuid:1ad93b6f-faaa-41a9-a7f9-d00cf203ec13"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:6c3ec792-efa3-4976-920f-67368d9cdfd4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ponvory""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Ponvory is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features. PUBCHEM.COMPOUND:11363176 uuid:89bdbcee-46d4-43b7-a403-c63f6873ca8d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:233412 biolink:treats NCIT:C202263 PMID:41385096 "[{""id"":""uuid:b1b847b4-eff0-45a0-b5d9-910c774cbdde"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:60353189-61df-4f22-a14d-c030e43050ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ponvory""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Ponvory is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features. PUBCHEM.COMPOUND:11363176 uuid:2a453ba2-6a99-4c0e-a830-5632802ce369 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:233362 biolink:treats MONDO:0004956 PMID:41385096 "[{""id"":""uuid:e7442050-6bb6-409d-a1e7-ff4aad42f856"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d11be67e-c0f2-4381-8d1e-d1ecc3adb22d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/verzenios""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Early Breast CancerVerzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative, node positive early breast cancer at high risk of recurrence (see section 5.1).In pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist.Advanced or Metastatic Breast CancerVerzenios is indicated for the treatment of women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy.In pre- or perimenopausal women, the endocrine therapy should be combined with a LHRH agonist. UNII:60UAB198HK uuid:698043dc-4a6f-449b-bc4f-74b06d7db709 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5931 biolink:treats HP:0001993 PMID:41385096 "[{""id"":""uuid:fab191f0-18c0-4cdd-b5d7-5818b8ae6b8a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:e33acdee-288f-408b-90bc-72c2a791115f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/insuman""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Diabetes mellitus where treatment with insulin is required. Insuman Rapid is also suitable for the treatment of hyperglycaemic coma and ketoacidosis, as well as for achieving pre-, intra- and postoperative stabilisation in patients with diabetes mellitus. uuid:7ec254e5-3fbf-4c39-ba92-c7400de307ac biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:72734364 biolink:treats MONDO:0001134 PMID:41385096 "[{""id"":""uuid:fc225d2d-f588-404f-85f9-3ef6a8dcf000"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:0cfee209-1f90-4e15-a936-86f9c3efcff4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/twynsta""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of essential hypertension in adults:Add-on therapyTwynsta is indicated in adults whose blood pressure is not adequately controlled on amlodipine.Replacement therapyAdult patients receiving telmisartan and amlodipine from separate tablets can instead receive tablets of Twynsta containing the same component doses. uuid:73814a7c-b941-495b-b5bd-9fc85f344538 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:66563540 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:646c94b6-d6a7-49a5-afb0-4caa89ed8b03"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d4474643-02c9-4141-b207-e63f5b3157e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/vipdomet""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Vipdomet is indicated in the treatment of adult patients aged 18 years and older with type-2 diabetes mellitus:as an adjunct to diet and exercise to improve glycaemic control in adult patients, inadequately controlled on their maximal tolerated dose of metformin alone, or those already being treated with the combination of alogliptin and metformin;in combination with pioglitazone (i.e. triple combination therapy) as an adjunct to diet and exercise in adult patients inadequately controlled on their maximal tolerated dose of metformin and pioglitazone;in combination with insulin (i.e. triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when insulin at a stable dose and metformin alone do not provide adequate glycaemic control. uuid:bc05848f-a890-4bf6-8903-4917879e80dd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2556915 biolink:treats MONDO:0100096 PMID:41385096 "[{""id"":""uuid:76ef8c02-fc4f-44a1-adf9-6778bef329c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:fd8bbc1f-284a-4a38-94d3-cf120065b807"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ronapreve""]},{""id"":""uuid:6428b55e-33dc-4759-892f-55f63971cc9e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Ronapreve is indicated for:Treatment of COVID-19 in adults and adolescents aged 12 years and older weighing at least 40 kg who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19 (see section 4.2).Prevention of COVID-19 in adults and adolescents aged 12 years and older weighing at least 40 kg (see section 4.2).The use of Ronapreve should take into account information on the activity of Ronapreve against viral variants of concern. See sections 4.4 and 5.1.|[PMDA] Drugs with new active ingredients indicated for the treatment of disease caused by SARS-CoV-2 infection (COVID-19). [Drug pertaining to Special Approval for Emergency] uuid:abbbc62e-6b87-4053-a12b-fbd1e339c1de biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:261542 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:44787b16-1ffc-4474-9669-fb0fc31617e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f1bb520e-2b90-402b-9a77-a60a4d90811c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] For the treatment of adults and children with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis. Insulin lispro Sanofi is also indicated for the initial stabilisation of diabetes mellitus. uuid:1a43e26e-de15-45b9-a88a-d324aa6bc2fd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6437 biolink:treats HP:0011188 PMID:41385096 "[{""id"":""uuid:90562f78-1294-4bbe-9e3c-9ff9759b1625"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:69750e23-01ae-4c76-879d-c42798cd24b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/levetiracetam-sun""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Levetiracetam Hospira is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in adults and adolescents from 16 years of age with newly diagnosed epilepsy.Levetiracetam Hospira is indicated as adjunctive therapyin the treatment of partial onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with Idiopathic Generalised Epilepsy.Levetiracetam Hospira concentrate is an alternative for patients when oral administration is temporarily not feasible. uuid:468c4ea8-290d-4ec4-a015-0e0ab43fab89 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:149836 biolink:treats MONDO:0018602 PMID:41385096 "[{""id"":""uuid:346e857d-d719-480d-a424-1a6b1d5d5eea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:874ec7e7-2cad-4e54-bed8-3dcb4ea61209"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/tigecycline-accord""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Tygecycline Accord is indicated in adults and in children from the age of eight years for the treatment of the following infections (see sections 4.4 and 5.1):Complicated skin and soft tissue infections (cSSTI), excluding diabetic foot infections (see section 4.4)Complicated intra-abdominal infections (cIAI)Tygecycline Accord should be used only in situations where other alternative antibiotics are not suitable (see sections 4.4, 4.8 and 5.1).Consideration should be given to official guidance on the appropriate use of antibacterial agents. uuid:3ec5b9ca-726a-4e52-b3bf-409cc159df09 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:149836 biolink:treats MONDO:0043424 PMID:41385096 "[{""id"":""uuid:d2aa0949-8319-4d15-a247-3bac78e37d14"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:0ec705cc-b087-434b-9db4-479c24430972"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/tigecycline-accord""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Tygecycline Accord is indicated in adults and in children from the age of eight years for the treatment of the following infections (see sections 4.4 and 5.1):Complicated skin and soft tissue infections (cSSTI), excluding diabetic foot infections (see section 4.4)Complicated intra-abdominal infections (cIAI)Tygecycline Accord should be used only in situations where other alternative antibiotics are not suitable (see sections 4.4, 4.8 and 5.1).Consideration should be given to official guidance on the appropriate use of antibacterial agents. uuid:0acee88b-a3a5-4175-b2dd-ad0716b38b66 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50924 biolink:treats MONDO:0007256 PMID:41385096 "[{""id"":""uuid:7c4ecd0c-6e00-40f5-8d47-5e900ef902d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:5a4772e8-7f45-4b4a-80c6-8c480fb875f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/nexavar""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Hepatocellular carcinomaNexavar is indicated for the treatment of hepatocellular carcinoma.Renal cell carcinomaNexavar is indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy.Differentiated thyroid carcinomaNexavar is indicated for the treatment of patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma, refractory to radioactive iodine. uuid:32a3fdc4-6995-4d86-a243-afbe5c536a45 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50924 biolink:treats MONDO:0005086 PMID:41385096 "[{""id"":""uuid:4697cc32-4910-43fc-a86e-7748babd15f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:832be995-633f-424c-88d3-caa7a66dbbe2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/nexavar""]},{""id"":""uuid:04a489ee-4eee-48c9-8f81-d1feb5125b3d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Hepatocellular carcinomaNexavar is indicated for the treatment of hepatocellular carcinoma.Renal cell carcinomaNexavar is indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy.Differentiated thyroid carcinomaNexavar is indicated for the treatment of patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma, refractory to radioactive iodine.|[PMDA] A drug containing a new active ingredient indicated for the treatment of unresectable or metastatic renal cell carcinoma. [Priority review] uuid:5150f90d-a94a-41c4-bcaf-8696ea32f2d4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:G9WJT6RD29 biolink:treats MONDO:0010619 PMID:41385096 "[{""id"":""uuid:681984eb-ed7c-4887-ba8a-22f97026255d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:6beb3c80-d36e-4178-8eff-8318f3de209b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/crysvita""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Crysvita is indicated for the treatment of X-linked hypophosphataemia, in children and adolescents aged 1 to 17 years with radiographic evidence of bone disease, and in adults.Crysvita is indicated for the treatment of FGF23-related hypophosphataemia in tumour-induced osteomalacia associated with phosphaturic mesenchymal tumours that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults. uuid:79e65090-c6a6-4c3c-a956-65cdb4ffbad5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2670556 biolink:treats MONDO:0021108 PMID:41385096 "[{""id"":""uuid:ab8b33f9-85bb-431b-82b0-2bf2855a8106"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:e24cb3dd-f3cb-416a-ac57-2490edbe2989"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/menveo""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] VialsMenveo is indicated for active immunisation of children (from two years of age), adolescents and adults at risk of exposure to Neisseria meningitidis groups A, C, W135 and Y, to prevent invasive disease.The use of this vaccine should be in accordance with official recommendations. uuid:9dee5173-249f-4542-877c-4fabca9d917b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:30830 biolink:treats MONDO:0016158 PMID:41385096 "[{""id"":""uuid:a5252282-a0a7-49dc-9eaa-f47cc9192e16"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:5ce689e4-4f7e-4633-9f4e-939acd68a8dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/xyrem""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of narcolepsy with cataplexy in adult patients. uuid:ba667a43-b7d8-4927-ad22-9e23f6a52aa7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:BI009E452R biolink:treats MONDO:0002243 PMID:41385096 "[{""id"":""uuid:29fd4e99-0551-4f18-9ba0-0ff2593d4f4f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:47bd244e-e01b-45a3-b6fd-d04cae9b5d3e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ondexxya""]},{""id"":""uuid:5151416a-57f1-414e-ad34-e3ace4e07d1c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] For adult patients treated with a direct factor Xa (FXa) inhibitor (apixaban or rivaroxaban) when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.|[PMDA] A drug with a new active ingredient indicated for the reversal of anticoagulant effect in life- threatening or uncontrolled bleeding in patients treated with a direct-acting factor Xa inhibitor (apixaban, rivaroxaban, or edoxaban tosilate hydrate). [Orphan drug] uuid:9e2a897b-cab7-41a7-8e2c-6db3568af2c4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63717 biolink:treats MONDO:0005344 PMID:41385096 "[{""id"":""uuid:fd7f97da-5c9e-4a47-a474-ea40c0c4eaa7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:7ab8888e-db59-416e-8a1e-3bb91b4ac629"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] HIV‑1 infectionTenofovir disoproxil Zentiva is indicated in combination with other antiretroviral medicinal products for the treatment of HIV‑1 infected adults.In adults, the demonstration of the benefit of tenofovir disoproxil in HIV‑1 infection is based on results of one study in treatment‑naïve patients, including patients with a high viral load (> 100,000 copies/ml) and studies in which tenofovir disoproxil was added to stable background therapy (mainly tritherapy) in antiretroviral pre‑treated patients experiencing early virological failure (< 10,000 copies/ml, with the majority of patients having < 5,000 copies/ml).Tenofovir disoproxil Zentiva is also indicated for the treatment of HIV‑1 infected adolescents, with NRTI (nucleotide reverse transcriptase inhibitor) resistance or toxicities precluding the use of first line agents, aged 12 to < 18 years.The choice of Tenofovir disoproxil Zentiva to treat antiretroviral‑experienced patients with HIV‑1 infection should be based on individual viral resistance testing and/or treatment history of patients.Hepatitis B infectionTenofovir disoproxil Zentiva is indicated for the treatment of chronic hepatitis B in adults with:compensated liver disease, with evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active inflammation and/or fibrosis (see section 5.1);evidence of lamivudine-resistant hepatitis B virus (see sections 4.8 and 5.1);decompensated liver disease (see sections 4.4, 4.8 and 5.1).Tenofovir disoproxil Zentiva is indicated for the treatment of chronic hepatitis B in adolescents 12 to < 18 years of age with:compensated liver disease and evidence of immune active disease, i.e. active viral replication, persistently elevated serum ALT levels and histological evidence of active inflammation and/or fibrosis (see sections 4.4, 4.8 and 5.1). uuid:30439281-d31d-4493-8af1-f7de6acd85e8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:69478 biolink:treats MONDO:0016532 PMID:41385096 "[{""id"":""uuid:960a01d3-6ba2-4500-93ba-69e94418a9a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:16b8d8ce-e743-4f32-913b-48e1af0d2fc5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/epidyolex""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Epidyolex is indicated for use as adjunctive therapy of seizures associated with Lennox Gastaut syndrome (LGS) or Dravet syndrome (DS), in conjunction with clobazam, for patients 2 years of age and older. uuid:06c94751-a677-4886-9ed7-3628fdccaa2d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90227 biolink:treats MONDO:0018975 PMID:41385096 "[{""id"":""uuid:33125679-e14d-4e54-b7a1-bbbf64295321"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ae5231cf-b708-4748-864b-a0a0dfd4b0c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:33c8d37d-c088-42e4-a59a-891127b098bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Koselugo as monotherapy is indicated for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in paediatric patients with neurofibromatosis type 1 (NF1) aged 3 years and above|[PMDA] Drugs with a new active ingredient indicated for the treatment of plexiform neurofibroma in patients with neurofibromatosis type 1. [Orphan drug] DOID:0111253 uuid:19cced00-45a9-462a-ac5d-cb7b4dc0bdf7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64733 biolink:treats MONDO:0015827 PMID:41385096 "[{""id"":""uuid:afe7aba7-bf99-4f63-89e1-44bbfc4c4c9a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:62db3d59-b390-4ec3-ba24-4e01bcec8fb1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/sibnayal""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Sibnayal is indicated for the treatment of distal renal tubular acidosis (dRTA) in adults, adolescents and children aged one year and older. uuid:65c176e5-386a-4ffa-8a32-90cd427054a5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:513P80B4YJ biolink:treats MONDO:0011719 PMID:41385096 "[{""id"":""uuid:7854fd86-581d-4e14-b1e9-8933bc5172cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:33a4adaf-e4f7-43b7-ba1c-6f1bbe65403c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ayvakyt""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Ayvakyt is indicated as monotherapy for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumours (GIST) harbouring the platelet-derived growth factor receptor alpha (PDGFRA) D842V mutation. uuid:2fb95fac-8df1-497c-8a16-c87d10468b1c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:P85X70RZWS biolink:treats HP:0007359 PMID:41385096 "[{""id"":""uuid:e2851d1d-0072-49cf-b2a3-a719278256f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:3a89b82f-489c-4cfc-a90e-171ba59a9775"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ontozry""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Adjunctive treatment of focal-onset seizures with or without secondary generalisation in adult patients with epilepsy who have not been adequately controlled despite a history of treatment with at least 2 anti-epileptic medicinal products. uuid:26e39952-4833-4d24-bc14-2d6828f2a75b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:P85X70RZWS biolink:treats MONDO:0005027 PMID:41385096 "[{""id"":""uuid:0ae147e7-cf9d-46d1-b1f3-d4a8ccda4504"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:819b14f5-c225-4fa5-a6b6-fa14958345f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ontozry""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Adjunctive treatment of focal-onset seizures with or without secondary generalisation in adult patients with epilepsy who have not been adequately controlled despite a history of treatment with at least 2 anti-epileptic medicinal products. uuid:d4bdec0d-e8e8-4e36-bf6d-7c2017bb8517 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50659 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:594d3f0a-48e5-46ae-a2db-d3a244a5797b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:2faa0a9c-9a0c-4f26-99fb-7ba0e5ec0f91"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/multaq-0""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Multaq is indicated for the maintenance of sinus rhythm after successful cardioversion in adult clinically stable patients with paroxysmal or persistent atrial fibrillation (AF). Due to its safety profile, Multaq should only be prescribed after alternative treatment options have been considered.Multaq should not be given to patients with left ventricular systolic dysfunction or to patients with current or previous episodes of heart failure. uuid:324339b5-d769-42d1-805a-9775e2ecaa7b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:08GY9K1EUO biolink:treats MONDO:0002492 PMID:41385096 "[{""id"":""uuid:4a698fbb-ba3f-4c85-8e6e-23d54e32282f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:cfc36d80-a943-43d9-a6ce-77a358217b80"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/fasturtec""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment and prophylaxis of acute hyperuricaemia, in order to prevent acute renal failure, in adults, children and adolescents (aged 0 to 17 years) with haematological malignancy with a high tumour burden and at risk of a rapid tumour lysis or shrinkage at initiation of chemotherapy. uuid:a54c569a-ebe9-4042-9214-8a4e0648368f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:55346 biolink:treats MONDO:0044067 PMID:41385096 "[{""id"":""uuid:651e1419-6b0d-4742-b72c-fe87622695b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:4a696e78-44e2-4ced-b8c0-082023463680"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ecalta""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of invasive candidiasis in adults and paediatric patients aged 1 month to < 18 years. uuid:328b649c-57eb-4599-bc53-fa33f931076c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:BDT58WJ9WE biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:7befff53-345a-4d70-832c-f05770e957e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:e2c1d50a-8a38-4aa3-9ec1-892c6168f9bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Sunlenca injection, in combination with other antiretroviral(s), is indicated for the treatment of adults with multidrug resistant HIV 1 infection for whom it is otherwise not possible to construct a suppressive anti viral regimen (see sections 4.2 and 5.1).Sunlenca tablet, in combination with other antiretroviral(s), is indicated for the treatment of adults with multidrug resistant HIV 1 infection for whom it is otherwise not possible to construct a suppressive anti viral regimen, for oral loading prior to administration of long-acting lenacapavir injection (see sections 4.2 and 5.1). uuid:de0cb53a-5c15-4e76-8d13-93951bbe2004 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2109612 biolink:treats MONDO:0005504 PMID:41385096 "[{""id"":""uuid:f821a998-e2af-4fef-8da9-4d6dfab58274"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a999e35b-ba67-4899-bf2b-9979331018aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Hexyon (DTaP-IPV-HB-Hib) is indicated for primary and booster vaccination of infants and toddlers from six weeks of age against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and invasive diseases caused by Haemophilus influenzae type b (Hib).The use of this vaccine should be in accordance with official recommendations. uuid:563ac1bb-8c26-4f07-8e9b-5846fb2706ee biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2109612 biolink:treats MONDO:0005526 PMID:41385096 "[{""id"":""uuid:124b76bc-33f5-4ab3-a998-ce58511ee02b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:060dbff9-5ec6-456b-93d6-96f8e293b90c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Hexyon (DTaP-IPV-HB-Hib) is indicated for primary and booster vaccination of infants and toddlers from six weeks of age against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and invasive diseases caused by Haemophilus influenzae type b (Hib).The use of this vaccine should be in accordance with official recommendations. uuid:da460ce9-1c7c-44e6-bd46-1a7afcfff710 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2109612 biolink:treats MONDO:0005077 PMID:41385096 "[{""id"":""uuid:7f7939d3-a17f-482a-a51c-0c10fa6ffda2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:01238df0-4162-47b0-9ef7-b29e76c548ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Hexyon (DTaP-IPV-HB-Hib) is indicated for primary and booster vaccination of infants and toddlers from six weeks of age against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and invasive diseases caused by Haemophilus influenzae type b (Hib).The use of this vaccine should be in accordance with official recommendations. uuid:d37c3c88-0c06-4213-828d-c763a8d43bc3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2109612 biolink:treats MONDO:0005344 PMID:41385096 "[{""id"":""uuid:74d9b225-d02d-4f85-b633-917ce1e65113"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:43b6679b-025c-492b-a88e-b6a62e939ee8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Hexyon (DTaP-IPV-HB-Hib) is indicated for primary and booster vaccination of infants and toddlers from six weeks of age against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and invasive diseases caused by Haemophilus influenzae type b (Hib).The use of this vaccine should be in accordance with official recommendations. uuid:6d3e9f76-d9b4-4b31-90e8-e07076a2102f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2109612 biolink:treats MONDO:0017373 PMID:41385096 "[{""id"":""uuid:3ca38317-1d8d-4634-baee-42503d9ac033"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:88069e6b-c635-4d90-9c1c-e960f463f100"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Hexyon (DTaP-IPV-HB-Hib) is indicated for primary and booster vaccination of infants and toddlers from six weeks of age against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and invasive diseases caused by Haemophilus influenzae type b (Hib).The use of this vaccine should be in accordance with official recommendations. uuid:b45d97b3-0e51-42c3-9851-44d19ce8d489 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2109612 biolink:treats MONDO:0006926 PMID:41385096 "[{""id"":""uuid:bfae9b03-8957-4009-b1fb-7c150931d0a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:e3f5add4-2b5a-4734-bb5d-742f1df0dd2c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Hexyon (DTaP-IPV-HB-Hib) is indicated for primary and booster vaccination of infants and toddlers from six weeks of age against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and invasive diseases caused by Haemophilus influenzae type b (Hib).The use of this vaccine should be in accordance with official recommendations. uuid:aa7087cd-d0de-4f72-a436-47e9a9bddef2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:82701 biolink:treats MONDO:0018906 PMID:41385096 "[{""id"":""uuid:cbed1b38-29ff-4235-9191-be49e97d2d76"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:6d3bd1d6-9daf-4e6f-b573-d2feb0b5ac8e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/zydelig""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Zydelig is indicated in combination with an anti‑CD20 monoclonal antibody (rituximab or ofatumumab) for the treatment of adult patients with chronic lymphocytic leukaemia (CLL):who have received at least one prior therapy, oras first line treatment in the presence of 17p deletion or TP53 mutation in patients who are not eligible for any other therapies.Zydelig is indicated as monotherapy for the treatment of adult patients with follicular lymphoma (FL) that is refractory to two prior lines of treatment. uuid:d0829652-02c7-4a83-b10a-ed0bdc9630f0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:72296 biolink:treats MONDO:0004634 PMID:41385096 "[{""id"":""uuid:85406f59-f01d-4411-a31b-ea39cf624c52"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:0cfa2913-907c-4566-8274-8657ec0fd0c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/eliquis""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] For Eliquis 2.5 mg film-coated tablets:Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery.Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II).Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults (see section 4.4 for haemodynamically unstable PE patients).For Eliquis 5 mg film-coated tablets:Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II).Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults (see section 4.4 for haemodynamically unstable PE patients). uuid:a77c9c0e-7472-40de-939b-011b39a8b4b9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:07896928ZC biolink:treats MONDO:0043424 PMID:41385096 "[{""id"":""uuid:e35bfde2-8f27-4225-ac02-80c367a979dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:182bc350-893c-4ba3-92d5-23ee959dc1d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/xerava""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Xerava is indicated for the treatment of complicated intra-abdominal infections (cIAI) in adults.Consideration should be given to official guidance on the appropriate use of antibacterial agents. uuid:99b0d484-23df-49a8-94f7-f59c0ae933c6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:61390 biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:22a5d68c-49fd-445a-a4f7-8f7c6a6cce1d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:536a856a-80f7-4e95-974c-71a783b11fc5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/giotrif""]},{""id"":""uuid:687072e8-a911-4bb0-87e2-3ca7d883dfe0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Giotrif as monotherapy is indicated for the treatment ofEpidermal Growth Factor Receptor (EGFR) TKI-naïve adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s);locally advanced or metastatic NSCLC of squamous histology progressing on or after platinum-based chemotherapy.|[PMDA] Drugs with a new active ingredient indicated for the treatment of unresectable advanced or recurrent non-small cell lung cancer with EGFR gene mutation. uuid:f9421723-2d2d-4687-8e16-ac21deccf1d5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:61390 biolink:treats MONDO:0005097 PMID:41385096 "[{""id"":""uuid:5eae9c7e-8970-4455-829d-d12cbe1e6bd3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:0b1a7929-aa84-4358-b974-63178be65ef8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/giotrif""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Giotrif as monotherapy is indicated for the treatment ofEpidermal Growth Factor Receptor (EGFR) TKI-naïve adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s);locally advanced or metastatic NSCLC of squamous histology progressing on or after platinum-based chemotherapy. uuid:2b8b9192-ff5b-403f-ac2b-26b97f68aa3e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64355 biolink:treats MONDO:0018874 PMID:41385096 "[{""id"":""uuid:b1b308a4-8c28-4f51-8957-828a16ac3817"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:32e92900-39a3-4511-8176-4425b851bbcd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/posaconazole-ahcl""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Noxafil gastro-resistant tablets are indicated for use in the treatment of the following fungal infections in adults (see sections 4.2 and 5.1):- Invasive aspergillosisNoxafil gastro-resistant tablets are indicated for use in the treatment of the following fungal infections in paediatric patients from 2 years of age weighing more than 40 kg and adults (see sections 4.2 and 5.1):- Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products;- Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B;- Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products.Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.Noxafil gastro-resistant tablets are also indicated for prophylaxis of invasive fungal infections in the following paediatric patients from 2 years of age weighing more than 40 kg and adults (see sections 4.2 and 5.1):- Patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections.Please refer to the Summary of Product Characteristics of Noxafil oral suspension for use in oropharyngeal candidiasis. Noxafil concentrate for solution for infusion is indicated for use in the treatment of the following fungal infections in adults (see sections 4.2 and 5.1):- Invasive aspergillosisNoxafil concentrate for solution for infusion is indicated for use in the treatment of the following fungal infections in adult and paediatric patients from 2 years of age (see sections 4.2 and 5.1):- Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products;- Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B;- Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products.Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.Noxafil concentrate for solution for infusion is also indicated for prophylaxis of invasive fungal infections in the following adult and paediatric patients from 2 years of age (see sections 4.2 and 5.1):- Patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease (GVHD) and who are at high risk of developing invasive fungal infections.Please refer to the Summary of Product Characteristics of Noxafil oral suspension for use in oropharyngeal candidiasis. Noxafil gastro resistant powder and solvent for oral suspension is indicated for use in the treatment of the following fungal infections in paediatric patients from 2 years of age (see sections 4.2 and 5.1):- Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products;- Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B;- Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products.Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.Noxafil gastro-resistant powder and solvent for oral suspension is indicated for prophylaxis of invasive fungal infections in the following paediatric patients from 2 years of age:- Patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- Haematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections.Please refer to the Summary of Product Characteristics of Noxafil concentrate for solution for infusion and the gastro-resistant tablets for use in primary treatment of invasive aspergillosis.Please refer to the Summary of Product Characteristics of Noxafil oral suspension for use in oropharyngeal candidiasis. Noxafil oral suspension is indicated for use in the treatment of the following fungal infections in adults (see section 5.1):- Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products;- Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B;- Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products;- Oropharyngeal candidiasis: as first-line therapy in patients who have severe disease or are immunocompromised, in whom response to topical therapy is expected to be poor.Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.Noxafil oral suspension is also indicated for prophylaxis of invasive fungal infections in the following patients:- Patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections.Please refer to the Summary of Product Characteristics of Noxafil concentrate for solution for infusion and the gastro-resistant tablets for use in primary treatment of invasive aspergillosis. uuid:a64b1fe4-8bf7-4577-93c8-3de0fed84d6c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64355 biolink:treats MONDO:0018881 PMID:41385096 "[{""id"":""uuid:ec1517bd-097a-4039-84e6-ac507ec9c19a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f8f75eb8-6501-4d91-8870-ee84a171d1a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/posaconazole-ahcl""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Noxafil gastro-resistant tablets are indicated for use in the treatment of the following fungal infections in adults (see sections 4.2 and 5.1):- Invasive aspergillosisNoxafil gastro-resistant tablets are indicated for use in the treatment of the following fungal infections in paediatric patients from 2 years of age weighing more than 40 kg and adults (see sections 4.2 and 5.1):- Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products;- Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B;- Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products.Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.Noxafil gastro-resistant tablets are also indicated for prophylaxis of invasive fungal infections in the following paediatric patients from 2 years of age weighing more than 40 kg and adults (see sections 4.2 and 5.1):- Patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections.Please refer to the Summary of Product Characteristics of Noxafil oral suspension for use in oropharyngeal candidiasis. Noxafil concentrate for solution for infusion is indicated for use in the treatment of the following fungal infections in adults (see sections 4.2 and 5.1):- Invasive aspergillosisNoxafil concentrate for solution for infusion is indicated for use in the treatment of the following fungal infections in adult and paediatric patients from 2 years of age (see sections 4.2 and 5.1):- Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products;- Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B;- Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products.Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.Noxafil concentrate for solution for infusion is also indicated for prophylaxis of invasive fungal infections in the following adult and paediatric patients from 2 years of age (see sections 4.2 and 5.1):- Patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease (GVHD) and who are at high risk of developing invasive fungal infections.Please refer to the Summary of Product Characteristics of Noxafil oral suspension for use in oropharyngeal candidiasis. Noxafil gastro resistant powder and solvent for oral suspension is indicated for use in the treatment of the following fungal infections in paediatric patients from 2 years of age (see sections 4.2 and 5.1):- Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products;- Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B;- Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products.Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.Noxafil gastro-resistant powder and solvent for oral suspension is indicated for prophylaxis of invasive fungal infections in the following paediatric patients from 2 years of age:- Patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- Haematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections.Please refer to the Summary of Product Characteristics of Noxafil concentrate for solution for infusion and the gastro-resistant tablets for use in primary treatment of invasive aspergillosis.Please refer to the Summary of Product Characteristics of Noxafil oral suspension for use in oropharyngeal candidiasis. Noxafil oral suspension is indicated for use in the treatment of the following fungal infections in adults (see section 5.1):- Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products;- Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B;- Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products;- Oropharyngeal candidiasis: as first-line therapy in patients who have severe disease or are immunocompromised, in whom response to topical therapy is expected to be poor.Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.Noxafil oral suspension is also indicated for prophylaxis of invasive fungal infections in the following patients:- Patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections.Please refer to the Summary of Product Characteristics of Noxafil concentrate for solution for infusion and the gastro-resistant tablets for use in primary treatment of invasive aspergillosis. uuid:8a7ad899-8481-4266-a34d-94bf21259d27 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:72564 biolink:treats MONDO:0100342 PMID:41385096 "[{""id"":""uuid:98474832-7696-43f3-9ef5-001177365bc2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f5b15690-c8e0-4754-b932-07a4617a4872"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/temozolomide-accord""]},{""id"":""uuid:f7e0ecc4-a79e-471b-8238-960bbb0d2498"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Temodal hard capsules is indicated for the treatment of:adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and subsequently as monotherapy treatment;children from the age of three years, adolescents and adult patients with malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy.|[PMDA] A drug with a new route of administration indicated for the treatment of malignant glioma. uuid:0f5aef72-04df-494f-965f-1b8f850fafde biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:1H09Y5WO1F biolink:treats MONDO:0005132 PMID:41385096 "[{""id"":""uuid:78be956d-9c96-406d-a161-0602ec34a92a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:56051f20-18fe-4b8e-8874-ecc775c9b6aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/prevymis""]},{""id"":""uuid:f4663a95-79a8-46a8-a161-7c81ebe97c67"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Prevymis is indicated for prophylaxis of cytomegalovirus (CMV) reactivation and disease in adult CMV-seropositive recipients [R+] of an allogeneic haematopoietic stem cell transplant (HSCT).Consideration should be given to official guidance on the appropriate use of antiviral agents.|[PMDA] Drugs with a new active ingredient indicated for the prophylaxis of cytomegalovirus disease in allogeneic hematopoietic stem cell transplant recipients. [Orphan drug] uuid:d228800c-579a-4fa4-b089-5941d96f1379 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:ZL1R02VT79 biolink:treats MONDO:0005150 PMID:41385096 "[{""id"":""uuid:56386932-55d3-4316-b4b8-d3d76a37dbf9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2268c632-d678-44d4-b88f-3931668e1cf4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ranivisio""]},{""id"":""uuid:80401b52-a666-4b7e-9fd6-6787cb4eae25"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Ximluci is indicated in adults for:The treatment of neovascular (wet) age-related macular degeneration (AMD)The treatment of visual impairment due to diabetic macular oedema (DME)The treatment of proliferative diabetic retinopathy (PDR)The treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO)The treatment of visual impairment due to choroidal neovascularisation (CNV)|[PMDA] Follow-on biologics indicated for the treatment of age-related macular degeneration associated with subfoveal choroidal neovascularization or choroidal neovascularization in patients with pathologic myopia. uuid:623b6cde-ba48-42b3-b425-6f51dbb387f5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:ZL1R02VT79 biolink:treats MONDO:0006951 PMID:41385096 "[{""id"":""uuid:12586101-1a5f-44ea-88b0-71a1aac0ac88"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4862f31b-7520-4909-9afc-94a4e045693c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ranivisio""]},{""id"":""uuid:1364f801-19bd-4c5a-bdb5-ff7c2022d5a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Ximluci is indicated in adults for:The treatment of neovascular (wet) age-related macular degeneration (AMD)The treatment of visual impairment due to diabetic macular oedema (DME)The treatment of proliferative diabetic retinopathy (PDR)The treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO)The treatment of visual impairment due to choroidal neovascularisation (CNV)|[PMDA] A drug with new additional indications and a new dosage for the treatment of macular edema following retinal vein occlusion and choroidal neovascularisasion in pathologic myopia. uuid:f5118a74-1232-4b1e-8278-af465638a788 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90972 biolink:treats HP:0002307 PMID:41385096 "[{""id"":""uuid:6941aeb8-cfc3-4a6c-80a3-004981b8adc4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:ac1b378f-a247-4949-a35c-3a77f63e48b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Symptomatic treatment of severe sialorrhoea (chronic pathological drooling) in children and adolescents aged 3 years and older with chronic neurological disorders. uuid:260164e1-92de-44ea-86e5-61047f96df82 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90972 biolink:treats MONDO:0005071 PMID:41385096 "[{""id"":""uuid:28c5acd2-dc1f-4084-8023-6fadb9b0211e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:16dc0da9-6d63-419d-8d97-cc4a7782a643"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Symptomatic treatment of severe sialorrhoea (chronic pathological drooling) in children and adolescents aged 3 years and older with chronic neurological disorders. uuid:e7a6fa41-82a2-40b5-b918-d20942152bba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:61397 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:b6ed9fbe-92fd-4d28-85ff-d01bce2c7628"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:82c25211-9b33-4dfa-8d00-52832e62890e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/nerlynx""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Nerlynx is indicated for the extended adjuvant treatment of adult patients with early stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who are less than one year from the completion of prior adjuvant trastuzumab based therapy. uuid:c4021936-0e80-4213-8335-9e46b8256611 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB00028 biolink:treats MONDO:0006702 PMID:41385096 "[{""id"":""uuid:9b54cb88-5f7f-4e27-ac5e-e1cf41379031"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:cb40d92b-af6f-403e-99ab-50cb70515ce4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/privigen""]},{""id"":""uuid:9aa3df3c-1ba2-41f8-a2af-a3fee009d436"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Replacement therapy in adults, and children and adolescents (0-18 years) in:primary immunodeficiency (PID) syndromes with impaired antibody production;hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic leukaemia, in whom prophylactic antibiotics have failed;hypogammaglobulinaemia and recurrent bacterial infections in plateau-phase-multiple-myeloma patients who have failed to respond to pneumococcal immunisation;hypogammaglobulinaemia in patients after allogeneic haematopoietic-stem-cell transplantation (HSCT);congenital AIDS with recurrent bacterial infections.Immunomodulation in adults, and children and adolescents (0-18 years) in:primary immune thrombocytopenia (ITP), in patients at high risk of bleeding or prior to surgery to correct the platelet count;Guillain-Barré syndrome;Kawasaki disease;chronic inflammatory demyelinating polyneuropathy (CIDP). Only limited experience is available of use of intravenous immunoglobulins in children with CIDP.|[PMDA] Drugs with a new active ingredient indicated for the improvement of muscle weakness in chronic inflammatory demyelinating polyneuropathy and for inhibiting progression of motor disability due to chronic inflammatory demyelinating polyneuropathy (in the cases where patients show an improvement in their acute phase treatment). uuid:44037729-c603-4d79-843d-45b29f114737 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3759 biolink:treats MONDO:0005542 PMID:41385096 "[{""id"":""uuid:00f19570-8756-4f34-9cdf-5f62c1596226"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:328b9082-eb0c-41d3-9a80-e9da1b434be0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Prevention of atherothrombotic eventsClopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from seven days until less than six months) or established peripheral arterial disease;adult patients suffering from acute coronary syndrome:non-ST-segment-elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA);ST-segment-elevation acute myocardial infarction, in combination with ASA in medically treated patients eligible for thrombolytic therapy.Prevention of atherothrombotic and thromboembolic events in atrial fibrillationIn adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin-K antagonists and who have a low bleeding risk, clopidogrel is indicated in combination with ASA for the prevention of atherothrombotic and thromboembolic events, including stroke. uuid:c8ed71fd-55ef-460d-9b29-839f41bd9935 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1940699 biolink:treats MONDO:0005354 PMID:41385096 "[{""id"":""uuid:cd112c22-80fa-459b-b0ba-d2669e90b195"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d156cd63-fc19-44d7-a4bc-dce810a82504"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/maviret""]},{""id"":""uuid:3b274882-c0a4-4a45-8ade-a227a729ead8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Maviret is indicated for the treatment of chronic hepatitis C virus (HCV) infection in adults and children aged 3 years and older.Maviret coated granules is indicated for the treatment of chronic hepatitis C virus (HCV) infection in children 3 years and older.|[PMDA] A new combination drug with a new active ingredient indicated for the improvement of viremia in patients with chronic hepatitis C or compensated cirrhosis type C. [Priority review] uuid:192e69f7-a71e-4bc1-8dd1-f3cdb9229ed4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:132774 biolink:treats MONDO:0002280 PMID:41385096 "[{""id"":""uuid:3db974cd-c62a-4224-a6b1-dca4b88266f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:1eb3044e-654f-47e1-bf46-fa3e05141f74"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/evrenzo""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Evrenzo is indicated for treatment of adult patients with symptomatic anaemia associated with chronic kidney disease (CKD). uuid:be1ef420-76aa-41be-a23a-d5802e4a4a67 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:132774 biolink:treats MONDO:0005300 PMID:41385096 "[{""id"":""uuid:ad6e733b-a162-4d3a-b01a-55218f5534ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:90f4c890-342e-4079-9ee2-e41837686c6e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/evrenzo""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Evrenzo is indicated for treatment of adult patients with symptomatic anaemia associated with chronic kidney disease (CKD). uuid:598c51a8-122e-44a8-8bd0-3f1419a38593 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10127 biolink:treats HP:0011188 PMID:41385096 "[{""id"":""uuid:6f66818e-02ef-466c-baab-8865fcc342ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:4a6fcc9b-e1f4-44eb-8e34-77fed2b1501a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/zonisamide-mylan""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Monotherapy in the treatment of partial seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy;adjunctive therapy in the treatment of partial seizures, with or without secondary generalisation, in adults, adolescents, and children aged 6 years and above. uuid:da2b6fdf-b4d4-41f5-980d-6c024ef83df6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1243017 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:788ea79e-8c3b-457a-8cdd-f12ed4f8b0bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:33119b3c-8624-48cf-ad70-bf2798a2a5c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/jentadueto""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of adult patients with type-2 diabetes mellitus:Jentadueto is indicated as an adjunct to diet and exercise to improve glycaemic control in adult patients inadequately controlled on their maximal tolerated dose of metformin alone, or those already being treated with the combination of linagliptin and metformin.Jentadueto is indicated in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in adult patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea. uuid:28afdb5d-31a2-44ce-a7fa-a0dc7996c154 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:30496 biolink:treats MONDO:0004995 PMID:41385096 "[{""id"":""uuid:d86e77c3-45b9-4130-b9f8-f123b938840e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f117a4bb-8a0a-4b2e-9040-feff0cbdcd2b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/sonovue""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] This medicinal product is for diagnostic use only.SonoVue is for use with ultrasound imaging to enhance the echogenicity of the blood, or of fluids in the urinary tract which results in an improved signal to noise ratio.SonoVue should only be used in patients where study without contrast enhancement is inconclusive.EchocardiographySonoVue is a transpulmonary echocardiographic contrast agent for use in adult patients with suspected or established cardiovascular disease to provide opacification of cardiac chambers and enhance left ventricular endocardial border delineation.Doppler of macrovasculatureSonoVue increases the accuracy in detection or exclusion of abnormalities in cerebral arteries and extracranial carotid or peripheral arteries in adult patients by improving the Doppler signal to noise ratio.SonoVue increases the quality of the Doppler flow image and the duration of clinically useful signal enhancement in portal vein assessment in adult patients.Doppler of microvasculatureSonoVue improves display of the vascularity of liver and breast lesions during Doppler sonography in adult patients leading to more specific lesion characterisation.Ultrasonography of excretory urinary tractSonoVue is indicated for use in ultrasonography of the excretory tract in paediatric patients from newborn to 18 years to detect vesicoureteral reflux. For the limitation in the interpretation of a negative urosonography. uuid:d7256c91-1acf-472c-8541-637484a66db7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:30496 biolink:treats MONDO:0005269 PMID:41385096 "[{""id"":""uuid:6e801ef8-0f6a-4331-a6a8-4b0eb7b548c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:1013efc6-104e-4c66-b7d6-299cd84def20"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/sonovue""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] This medicinal product is for diagnostic use only.SonoVue is for use with ultrasound imaging to enhance the echogenicity of the blood, or of fluids in the urinary tract which results in an improved signal to noise ratio.SonoVue should only be used in patients where study without contrast enhancement is inconclusive.EchocardiographySonoVue is a transpulmonary echocardiographic contrast agent for use in adult patients with suspected or established cardiovascular disease to provide opacification of cardiac chambers and enhance left ventricular endocardial border delineation.Doppler of macrovasculatureSonoVue increases the accuracy in detection or exclusion of abnormalities in cerebral arteries and extracranial carotid or peripheral arteries in adult patients by improving the Doppler signal to noise ratio.SonoVue increases the quality of the Doppler flow image and the duration of clinically useful signal enhancement in portal vein assessment in adult patients.Doppler of microvasculatureSonoVue improves display of the vascularity of liver and breast lesions during Doppler sonography in adult patients leading to more specific lesion characterisation.Ultrasonography of excretory urinary tractSonoVue is indicated for use in ultrasonography of the excretory tract in paediatric patients from newborn to 18 years to detect vesicoureteral reflux. For the limitation in the interpretation of a negative urosonography. uuid:a5465340-8148-465e-8168-c5eecec58cf9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:30496 biolink:treats MONDO:0005386 PMID:41385096 "[{""id"":""uuid:47419600-06dd-4e4f-8f67-c51b8dd7527b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:c047c332-aefa-40b8-9d17-db06383d38f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/sonovue""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] This medicinal product is for diagnostic use only.SonoVue is for use with ultrasound imaging to enhance the echogenicity of the blood, or of fluids in the urinary tract which results in an improved signal to noise ratio.SonoVue should only be used in patients where study without contrast enhancement is inconclusive.EchocardiographySonoVue is a transpulmonary echocardiographic contrast agent for use in adult patients with suspected or established cardiovascular disease to provide opacification of cardiac chambers and enhance left ventricular endocardial border delineation.Doppler of macrovasculatureSonoVue increases the accuracy in detection or exclusion of abnormalities in cerebral arteries and extracranial carotid or peripheral arteries in adult patients by improving the Doppler signal to noise ratio.SonoVue increases the quality of the Doppler flow image and the duration of clinically useful signal enhancement in portal vein assessment in adult patients.Doppler of microvasculatureSonoVue improves display of the vascularity of liver and breast lesions during Doppler sonography in adult patients leading to more specific lesion characterisation.Ultrasonography of excretory urinary tractSonoVue is indicated for use in ultrasonography of the excretory tract in paediatric patients from newborn to 18 years to detect vesicoureteral reflux. For the limitation in the interpretation of a negative urosonography. uuid:444f6da4-8eee-462b-a01b-3eef0f8d0c3d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:30496 biolink:treats MONDO:0043693 PMID:41385096 "[{""id"":""uuid:44f1ee6f-80e0-4677-9fd1-96ba83948d6f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:41339bec-2983-4873-b06b-3c6663529b00"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/sonovue""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] This medicinal product is for diagnostic use only.SonoVue is for use with ultrasound imaging to enhance the echogenicity of the blood, or of fluids in the urinary tract which results in an improved signal to noise ratio.SonoVue should only be used in patients where study without contrast enhancement is inconclusive.EchocardiographySonoVue is a transpulmonary echocardiographic contrast agent for use in adult patients with suspected or established cardiovascular disease to provide opacification of cardiac chambers and enhance left ventricular endocardial border delineation.Doppler of macrovasculatureSonoVue increases the accuracy in detection or exclusion of abnormalities in cerebral arteries and extracranial carotid or peripheral arteries in adult patients by improving the Doppler signal to noise ratio.SonoVue increases the quality of the Doppler flow image and the duration of clinically useful signal enhancement in portal vein assessment in adult patients.Doppler of microvasculatureSonoVue improves display of the vascularity of liver and breast lesions during Doppler sonography in adult patients leading to more specific lesion characterisation.Ultrasonography of excretory urinary tractSonoVue is indicated for use in ultrasonography of the excretory tract in paediatric patients from newborn to 18 years to detect vesicoureteral reflux. For the limitation in the interpretation of a negative urosonography. uuid:6f3badc7-ae26-48cf-a40a-d557eb93c173 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:30496 biolink:treats NCIT:C159594 PMID:41385096 "[{""id"":""uuid:a6255880-f2bc-4e62-982a-8ad2d60d8f97"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:03546d29-13e5-4807-a2f1-e3ea9671356f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/sonovue""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] This medicinal product is for diagnostic use only.SonoVue is for use with ultrasound imaging to enhance the echogenicity of the blood, or of fluids in the urinary tract which results in an improved signal to noise ratio.SonoVue should only be used in patients where study without contrast enhancement is inconclusive.EchocardiographySonoVue is a transpulmonary echocardiographic contrast agent for use in adult patients with suspected or established cardiovascular disease to provide opacification of cardiac chambers and enhance left ventricular endocardial border delineation.Doppler of macrovasculatureSonoVue increases the accuracy in detection or exclusion of abnormalities in cerebral arteries and extracranial carotid or peripheral arteries in adult patients by improving the Doppler signal to noise ratio.SonoVue increases the quality of the Doppler flow image and the duration of clinically useful signal enhancement in portal vein assessment in adult patients.Doppler of microvasculatureSonoVue improves display of the vascularity of liver and breast lesions during Doppler sonography in adult patients leading to more specific lesion characterisation.Ultrasonography of excretory urinary tractSonoVue is indicated for use in ultrasonography of the excretory tract in paediatric patients from newborn to 18 years to detect vesicoureteral reflux. For the limitation in the interpretation of a negative urosonography. uuid:8f4acc38-5991-4dd9-9134-e77d96a928ba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:30496 biolink:treats MONDO:0006007 PMID:41385096 "[{""id"":""uuid:65f8c3b9-08c4-4a33-a0ee-59e65f9363c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:96511755-2260-4e74-b696-20f539269ec1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/sonovue""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] This medicinal product is for diagnostic use only.SonoVue is for use with ultrasound imaging to enhance the echogenicity of the blood, or of fluids in the urinary tract which results in an improved signal to noise ratio.SonoVue should only be used in patients where study without contrast enhancement is inconclusive.EchocardiographySonoVue is a transpulmonary echocardiographic contrast agent for use in adult patients with suspected or established cardiovascular disease to provide opacification of cardiac chambers and enhance left ventricular endocardial border delineation.Doppler of macrovasculatureSonoVue increases the accuracy in detection or exclusion of abnormalities in cerebral arteries and extracranial carotid or peripheral arteries in adult patients by improving the Doppler signal to noise ratio.SonoVue increases the quality of the Doppler flow image and the duration of clinically useful signal enhancement in portal vein assessment in adult patients.Doppler of microvasculatureSonoVue improves display of the vascularity of liver and breast lesions during Doppler sonography in adult patients leading to more specific lesion characterisation.Ultrasonography of excretory urinary tractSonoVue is indicated for use in ultrasonography of the excretory tract in paediatric patients from newborn to 18 years to detect vesicoureteral reflux. For the limitation in the interpretation of a negative urosonography. uuid:bb5ee212-da62-469e-b431-17c941ad61cd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:997WVV895X biolink:treats MONDO:0005277 PMID:41385096 "[{""id"":""uuid:cac99d85-1f26-4856-a973-059a554223e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:08fbdc36-39bd-4cec-884e-b90adb60b45d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/vydura""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Vydura is indicated for theAcute treatment of migraine with or without aura in adults;Preventative treatment of episodic migraine in adults who have at least 4 migraine attacks per month. uuid:f92e7ba9-d0d6-4515-b3b6-59adf669f3b8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:997WVV895X biolink:treats MONDO:0005475 PMID:41385096 "[{""id"":""uuid:8ea5cb5c-6ae7-42e4-af87-518727a310dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:de2b009e-51cd-4c0f-9145-10647f6c193b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/vydura""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Vydura is indicated for theAcute treatment of migraine with or without aura in adults;Preventative treatment of episodic migraine in adults who have at least 4 migraine attacks per month. uuid:0269bb70-e0da-43f2-aa4b-ecb6649ec82c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50378 biolink:treats MONDO:0010161 PMID:41385096 "[{""id"":""uuid:ae5d3113-0e6e-48c0-baec-9bc06ede13e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d6909556-18fd-4fcd-8bf6-30436f85c266"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/nitisinone-mdk""]},{""id"":""uuid:18f7b5ff-a23b-48e1-b231-99d10efdbea4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of adult and paediatric patients with confirmed diagnosis of hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine.|[PMDA] Drugs with a new active ingredient indicated for the treatment of type I hypertyrosinemia. uuid:a3b09835-ea23-40cb-9265-d1b4b72775cf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:50FKX8CB2Y biolink:treats MONDO:0001824 PMID:41385096 "[{""id"":""uuid:5ad62cb3-f1c2-4c53-86f7-78309f588334"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:448bf5a7-dac4-4712-a0b3-9b96952804c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Onpattro is indicated for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy. uuid:f7c9fb6b-5797-4be4-b636-28076fa07bf4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46557 biolink:treats HP:0002756 PMID:41385096 "[{""id"":""uuid:59b38f2e-8130-4edb-baf3-2e8a43440ab4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:dec46410-b7d1-43a3-9c72-a3621aeaab93"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Prevention of skeletal-related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone.Treatment of adult patients with tumour-induced hypercalcaemia. uuid:d2df6465-80cb-4080-940a-44aa3ad764b8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46557 biolink:treats HP:0002176 PMID:41385096 "[{""id"":""uuid:215af61c-dcb9-489c-b8cb-704b9a712462"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a9fef907-ad3b-4603-a120-7fd6f1ec9eb0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Prevention of skeletal-related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone.Treatment of adult patients with tumour-induced hypercalcaemia. uuid:58450f5f-acdc-4fb4-8e77-2a1c56b0e15f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:144551 biolink:treats UMLS:C0150045 PMID:41385096 "[{""id"":""uuid:98886eac-2644-4ff8-aa29-b4da230139b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a1d2bf71-7c5b-4ad7-926c-cbe0ebc11da3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/kentera-previously-oxybutynin-nicobrand""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in adult patients with unstable bladder. uuid:1f5bf512-c929-47dc-a619-21c17e6462fd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:144551 biolink:treats MONDO:0006624 PMID:41385096 "[{""id"":""uuid:f2907b98-79f5-4db1-803a-623c458abcfc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1b47a301-042a-43ff-978d-b749910594c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/kentera-previously-oxybutynin-nicobrand""]},{""id"":""uuid:6dc04c00-5146-4c6f-9f3b-d5522b3dfe4c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in adult patients with unstable bladder.|[PMDA] A drug with a new route of administration and new indications for the treatment of urinary urgency, urinary frequency, and urge urinary incontinence associated with overactive bladder. uuid:e43371f1-40b5-479f-a167-7bbbd3a0bce3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:144551 biolink:treats NCIT:C143907 PMID:41385096 "[{""id"":""uuid:ab2d4dd7-a2e4-4e6d-9083-dc8f96e20366"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:054486f0-9d80-4d94-b4c7-bacf2dc7e5e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/kentera-previously-oxybutynin-nicobrand""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in adult patients with unstable bladder. uuid:83c368dd-6961-44e9-8378-e96ed21c8f2a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DQA630RIE9 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:5ea1cee5-d663-4517-81bf-1a168cee82bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:9ae75a4e-510b-4b1c-bc02-06b69eba01d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/rapilysin""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Rapilysin is indicated for the thrombolytic treatment of suspected myocardial infarction with persistent ST elevation or recent left bundle branch block within 12 hours after the onset of acute-myocardial-infarction (AMI) symptoms. uuid:021b8e79-b99a-4049-af87-9767944b2d8c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63632 biolink:treats MONDO:0005131 PMID:41385096 "[{""id"":""uuid:37a179a2-4df1-458a-b7f6-c55b7e40206b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:de5004ce-698a-47ad-a866-194b724d87dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/hycamtin""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Topotecan monotherapy is indicated for the treatment of:- patients with metastatic carcinoma of the ovary after failure of first-line or subsequent therapy- patients with relapsed small cell lung cancer (SCLC) for whom re-treatment with the first-line regimen is not considered appropriate (see section 5.1).Topotecan in combination with cisplatin is indicated for patients with carcinoma of the cervix recurrent after radiotherapy and for patients with Stage IVB disease. Patients with prior exposure to cisplatin require a sustained treatment free interval to justify treatment with the combination (see section 5.1). uuid:e1208b2f-1a4d-42b3-99bb-cc6bb357dad7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90923 biolink:treats MONDO:0005366 PMID:41385096 "[{""id"":""uuid:983a6799-911a-465a-9a29-c738ea5993f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a34e56fe-e81e-4c4e-b7ac-d9a8d3175316"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Vemlidy is indicated for the treatment of chronic hepatitis B (CHB) in adults and paediatric patients 6 years of age and older weighing at least 25 kg (see section 5.1). uuid:b07737ed-1b19-432d-aa5f-8f8945dac4b0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:I60W9520VV biolink:treats MONDO:0005300 PMID:41385096 "[{""id"":""uuid:2b42d90f-0e91-4fcb-877e-3ec1c6aeef5e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:390959a5-e588-4f40-88d8-8729813b1317"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/vafseo""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Vafseo is indicated for the treatment of symptomatic anaemia associated with chronic kidney disease (CKD) in adults on chronic maintenance dialysis. uuid:0c3c2f07-424b-46dc-a350-463a7854c25f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation MESH:C075654 biolink:treats MONDO:0100244 PMID:41385096 "[{""id"":""uuid:c4d87c7e-0eb1-4db5-9ad8-f1ad49554166"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:47400b97-5508-4bac-851a-5f81250d6e7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Epysqli is indicated in adults and children for the treatment of Paroxysmal nocturnal haemoglobinuria (PNH).Evidence of clinical benefit is demonstrated in patients with haemolysis with clinical symptom(s) indicative of high disease activity, regardless of transfusion history. uuid:e522ae4e-7c75-495c-a655-bc20757ee613 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C5815513 biolink:treats MONDO:0019209 PMID:41385096 "[{""id"":""uuid:09093f2c-dadb-4741-bf62-e2e94d6368c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f7488864-e8af-48df-af45-9b815e874804"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Ixiaro is indicated for active immunisation against Japanese encephalitis in adults, adolescents, children and infants aged two months and older.Ixiaro should be considered for use in individuals at risk of exposure through travel or in the course of their occupation. DRUGBANK:DB17795 uuid:4c44cb9b-cd6d-44ab-ba1a-828b7ac2655a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7915 biolink:treats MONDO:0007186 PMID:41385096 "[{""id"":""uuid:4de12db0-51e0-41c3-8804-c8bb9c111bbc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:9bc0ecab-e8c7-494a-a185-5ef0a12454a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/pantozol-control""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Short-term treatment of reflux symptoms (e.g. heartburn, acid regurgitation) in adults. uuid:92dd536e-01ed-4f0e-89ff-d1a578bd3b54 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:S7V92P67HO biolink:treats MONDO:0012883 PMID:41385096 "[{""id"":""uuid:5ce2d038-b16d-478d-87af-d0167a6ab887"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9c37c32d-0573-47d1-a2ba-2b448cd3c8ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/trisenox""]},{""id"":""uuid:0e023925-0025-458b-91fb-e0b770ea40e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Trisenox is indicated for induction of remission, and consolidation in adult patients with:Newly diagnosed low-to-intermediate risk acute promyelocytic leukaemia (APL) (white blood cell count, ≤ 10 x 103/µl) in combination with all‑trans‑retinoic acid (ATRA)Relapsed/refractory acute promyelocytic leukaemia (APL) (previous treatment should have included a retinoid and chemotherapy)characterised by the presence of the t(15;17) translocation and/or the presence of the Pro-Myelocytic Leukaemia/Retinoic-Acid-Receptor-alpha (PML/RAR-alpha) gene.The response rate of other acute myelogenous leukaemia subtypes to arsenic trioxide has not been examined.|[PMDA] A drug with a new administration route with indications for relapsed or refractory acute promyelocytic leukemia. uuid:f38c7626-770f-46a6-9ec2-8ed1fc17f159 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:681569 biolink:treats MONDO:0004969 PMID:41385096 "[{""id"":""uuid:a2c9c111-3db2-4643-8402-77ed0b5c9c3c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:08adf20e-cdbc-4452-8736-872521ba1ef4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/evoltra""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of acute lymphoblastic leukaemia (ALL) in paediatric patients who have relapsed or are refractory after receiving at least two prior regimens and where there is no other treatment option anticipated to result in a durable response. Safety and efficacy have been assessed in studies of patients ≤ 21 years old at initial diagnosis. uuid:8a8527ab-9e21-4fa1-b569-e320a0432c10 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:803369 biolink:treats MONDO:0005790 PMID:41385096 "[{""id"":""uuid:b30f7ffd-71b6-4d6a-a292-ca9633a99e73"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:1f01ac18-698f-49e2-9317-db880e45b7eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Twinrix Adult is indicated for use in non immune adults and adolescents 16 years of age and above who are at risk of both hepatitis A and hepatitis B infection. uuid:940e8b85-b4ec-43a8-945f-fa45c034f363 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:803369 biolink:treats MONDO:0005344 PMID:41385096 "[{""id"":""uuid:c32c8377-80a8-4740-8922-fe2b4eff6ec3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:205cf88a-e67d-42e2-b517-70a96db57d4f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Twinrix Adult is indicated for use in non immune adults and adolescents 16 years of age and above who are at risk of both hepatitis A and hepatitis B infection. uuid:3bf85659-dbec-4038-8d81-3d77a15b884d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C4541385 biolink:treats MONDO:0005344 PMID:41385096 "[{""id"":""uuid:d34ca6d4-efbd-444e-b210-69869e6e4080"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:50dd202a-d151-4c0a-9cec-6d2b342a7abb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Fendrix is indicated in adolescents and adults from the age of 15 years onwards for active immunisation against hepatitis B virus infection (HBV) caused by all known subtypes for patients with renal insufficiency (including pre-haemodialysis and haemodialysis patients). MESH:C000726347 uuid:2a054628-b97d-43bc-a30b-1d05d350471d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C4541385 biolink:treats MONDO:0001106 PMID:41385096 "[{""id"":""uuid:f932d3fc-2f1b-47e7-843f-60b08ec76e6c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:bf93a774-59e8-4254-a474-4b4f0bbbda76"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Fendrix is indicated in adolescents and adults from the age of 15 years onwards for active immunisation against hepatitis B virus infection (HBV) caused by all known subtypes for patients with renal insufficiency (including pre-haemodialysis and haemodialysis patients). MESH:C000726347 uuid:84cda8a7-43a0-4b6f-a8e3-6a9d0ee06efa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:867485 biolink:treats MONDO:0002974 PMID:41385096 "[{""id"":""uuid:41e2e513-5239-44d3-b043-7c0f701c682b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d00b8d26-8bc7-485e-8ffa-efdaab2dbb88"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Cervarix is a vaccine for use from the age of 9 years for the prevention of premalignant ano-genital lesions (cervical, vulvar, vaginal and anal) and cervical and anal cancers causally related to certain oncogenic Human Papillomavirus (HPV) types. See sections 4.4 and 5.1 for important information on the data that support this indication.The use of Cervarix should be in accordance with official recommendations. uuid:a261b271-4bc5-4e60-8e9b-9ffb2575a9b7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:867485 biolink:treats MONDO:0003199 PMID:41385096 "[{""id"":""uuid:30e90747-b2c1-4567-9d9b-42d23b772be2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:fb82999e-c295-44a6-a8b5-89889096a1c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Cervarix is a vaccine for use from the age of 9 years for the prevention of premalignant ano-genital lesions (cervical, vulvar, vaginal and anal) and cervical and anal cancers causally related to certain oncogenic Human Papillomavirus (HPV) types. See sections 4.4 and 5.1 for important information on the data that support this indication.The use of Cervarix should be in accordance with official recommendations. uuid:20fed4c9-b5ab-43ec-954a-c9269337c043 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:867485 biolink:treats MONDO:0021074 PMID:41385096 "[{""id"":""uuid:895db2bf-283e-4588-8cc1-93d9f57f072f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:1c1bec75-9eae-4bf6-bd5a-d88fb82f2944"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Cervarix is a vaccine for use from the age of 9 years for the prevention of premalignant ano-genital lesions (cervical, vulvar, vaginal and anal) and cervical and anal cancers causally related to certain oncogenic Human Papillomavirus (HPV) types. See sections 4.4 and 5.1 for important information on the data that support this indication.The use of Cervarix should be in accordance with official recommendations. uuid:341c1e03-2c1e-489b-abe6-579e751c418e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:867485 biolink:treats MONDO:0001528 PMID:41385096 "[{""id"":""uuid:0940dbb4-0c37-4639-8e57-bc35a94af48e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:6838a6be-0a43-4434-9651-9d5ee3f75091"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Cervarix is a vaccine for use from the age of 9 years for the prevention of premalignant ano-genital lesions (cervical, vulvar, vaginal and anal) and cervical and anal cancers causally related to certain oncogenic Human Papillomavirus (HPV) types. See sections 4.4 and 5.1 for important information on the data that support this indication.The use of Cervarix should be in accordance with official recommendations. uuid:ba7c2204-7c26-4b32-963e-8175179e37f0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:867485 biolink:treats MONDO:0001402 PMID:41385096 "[{""id"":""uuid:8240645c-99c5-4381-9043-ec104e8ad95a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:bf779e8b-e3c5-4451-9dda-304380957591"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Cervarix is a vaccine for use from the age of 9 years for the prevention of premalignant ano-genital lesions (cervical, vulvar, vaginal and anal) and cervical and anal cancers causally related to certain oncogenic Human Papillomavirus (HPV) types. See sections 4.4 and 5.1 for important information on the data that support this indication.The use of Cervarix should be in accordance with official recommendations. uuid:c9ee1a4a-c4ed-449a-a04f-4aa76f74342e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7NL2E3F6K3 biolink:treats MONDO:0015793 PMID:41385096 "[{""id"":""uuid:f2cdc4ea-9a3f-47a8-a161-6b139ec4b006"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:9439d4cf-aace-4b8c-a877-71393dfd5b24"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/hemlibra""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Hemlibra is indicated for routine prophylaxis of bleeding episodes in patients with haemophilia A (congenital factor VIII deficiency):with factor VIII inhibitorswithout factor VIII inhibitors who have:severe disease (FVIII < 1%)moderate disease (FVIII ≥ 1% and ≤ 5%) with severe bleeding phenotype.Hemlibra can be used in all age groups. uuid:27baed0f-c971-457a-bcbb-25d246f63f9c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45409 biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:7802a476-5394-4430-b6cc-e87a70d8903b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:01f6036f-c9f0-49da-837a-657730a31353"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/norvir""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Ritonavir is indicated in combination with other antiretroviral agents for the treatment of HIV 1 infected patients (adults and children of 2 years of age and older). uuid:15a78e40-d244-4f4a-853a-22761cf8daae biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31596 biolink:treats MONDO:0043875 PMID:41385096 "[{""id"":""uuid:13d409d9-a774-4476-9ddb-8ae66441a423"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:ddd0eee4-92ea-4312-8d7f-e036d55ddc4a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/febuxostat-mylan""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Febuxostat Mylan is indicated for the prevention and treatment of hyperuricaemia in adult patients undergoing chemotherapy for haematologic malignancies at intermediate to high risk of Tumor Lysis Syndrome (TLS).Febuxostat Mylan is indicated for the treatment of chronic hyperuricaemia in conditions where urate deposition has already occurred (including a history, or presence of, tophus and/or gouty arthritis).Febuxostat Mylan is indicated in adults. uuid:f3bebc28-ab61-4a95-95b1-0cd88c64ebc2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:114785 biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:a1b9bfa7-34fd-4526-b531-461d2ad88a7e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2cbbfb9b-6e38-46f6-98c6-7dad8eb74f42"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/tarceva""]},{""id"":""uuid:236758eb-bce7-4288-bd46-07c1d576752a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Non-small cell lung cancer (NSCLC)Tarceva is also indicated for switch maintenance treatment in patients with locally advanced or metastatic non-small cell lung cancer with EGFR activating mutations and stable disease after first-line chemotherapy.Tarceva is also indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.In patients with tumours without EGFR activating mutations, Tarceva is indicated when other treatment options are not considered suitable.When prescribing Tarceva, factors associated with prolonged survival should be taken into account.No survival benefit or other clinically relevant effects of the treatment have been demonstrated in patients with Epidermal Growth Factor Receptor (EGFR)-IHC - negative tumours.Pancreatic cancerTarceva in combination with gemcitabine is indicated for the treatment of patients with metastatic pancreatic cancer.When prescribing Tarceva, factors associated with prolonged survival should be taken into account.|[PMDA] Drugs containing a new active ingredient indicated for the treatment of unresectable, relapsed/advanced non-small cell lung cancer exacerbated after cancer chemotherapy. [Priority review] uuid:bf574fd4-6781-4465-9cb8-72b5b0938139 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:72292 biolink:treats MONDO:0005861 PMID:41385096 "[{""id"":""uuid:f3471e9a-a98f-42f6-8d42-426ab209501c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:2581117f-4417-4b81-8180-6afd06a6e4fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Sirturo is indicated for use as part of an appropriate combination regimen for pulmonary multidrug resistant tuberculosis (MDR TB) in adults and adolescent patients (12 years to less than 18 years of age and weighing at least 30 kg) when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability. Consideration should be given to official guidance on the appropriate use of antibacterial agents. uuid:b6760bcd-9028-4596-a0ac-13490eb4bb14 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:56841116 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:e3a4a157-ddb6-4295-a120-dfcb6eae94da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:e274f504-05f2-4b30-8a0c-0db42b3c6e4d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/biresp-spiromax""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Asthma BiResp Spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists.orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists.COPDBiResp Spiromax is indicated in adults, aged 18 years and older, for the symptomatic treatment of patients with COPD with forced expiratory volume in 1 second (FEV₁) uuid:014c6d86-94eb-4147-b6c7-3ce8bb64237c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:56841116 biolink:treats MONDO:0005002 PMID:41385096 "[{""id"":""uuid:b884cae2-c58f-40ce-8ef2-07115a19a889"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6e4348c1-7ccc-4c7e-abf6-62f90f001e15"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/biresp-spiromax""]},{""id"":""uuid:0b660c41-c487-42cc-85fc-47dc96f190cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Asthma BiResp Spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists.orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists.COPDBiResp Spiromax is indicated in adults, aged 18 years and older, for the symptomatic treatment of patients with COPD with forced expiratory volume in 1 second (FEV₁)|[PMDA] New combination drugs with a new active ingredient indicated for the relief of symptoms in patients with chronic obstructive pulmonary disease (chronic bronchitis, emphysema) (who require a combination therapy with an inhaled corticosteroid, a long-acting inhaled anticholinergic agent and a long-acting beta-2 agonist). uuid:9737358c-edcb-4c14-b189-a144f59dc80a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1001585 biolink:treats MONDO:0043327 PMID:41385096 "[{""id"":""uuid:75063413-0e98-44d1-98a8-3f7cd92710f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:6d6a4d00-cc4c-4b73-bdb3-3544a71758d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/tachosil""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] TachoSil is indicated in adults and children from 1 month of age for supportive treatment in surgery for improvement of haemostasis, to promote tissue sealing and for suture support in vascular surgery where standard techniques are insufficient. TachoSil is indicated in adults for supportive sealing of the dura mater to prevent postoperative cerebrospinal leakage following neurological surgery (see section 5.1). uuid:1ad1acfb-5ccf-4349-8183-9efe39aa6e1d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1001585 biolink:treats MONDO:0001531 PMID:41385096 "[{""id"":""uuid:4b7168c6-11eb-427a-80d5-4185f063a7c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:e1f3c507-f0be-40a3-8859-025de66429e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/tachosil""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] TachoSil is indicated in adults and children from 1 month of age for supportive treatment in surgery for improvement of haemostasis, to promote tissue sealing and for suture support in vascular surgery where standard techniques are insufficient. TachoSil is indicated in adults for supportive sealing of the dura mater to prevent postoperative cerebrospinal leakage following neurological surgery (see section 5.1). uuid:f6515543-ac3b-4672-b37e-60e3514be45e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:441410 biolink:treats MONDO:0008315 PMID:41385096 "[{""id"":""uuid:38d5c8ab-714c-413f-9293-f51d2ff59d25"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9ed8e2f0-d263-459c-aced-698fb9f6a3b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:004408ab-48b3-499b-a075-11fcd3f87ad1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Camcevi is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy.|[PMDA] A drug in a new dosage form indicated for the treatment of prostate cancer and premenopausal breast cancer. uuid:24198f26-9bc2-413a-a095-99b93ba9ec68 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:55345 biolink:treats MONDO:0005029 PMID:41385096 "[{""id"":""uuid:6520a8d2-17c3-43df-bb3e-500bd90d2331"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:37d6e8f5-585e-45a5-a8ed-fe936676db9b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Anagrelide is indicated for the reduction of elevated platelet counts in at risk essential thrombocythaemia (ET) patients who are intolerant to their current therapy or whose elevated platelet counts are not reduced to an acceptable level by their current therapy.An at-risk patientAn at-risk essential thrombocythaemia patient is defined by one or more of the following features:>60 years of age ora platelet count >1,000 x 10⁹/l ora history of thrombo-haemorrhagic events. uuid:2bc44a3a-8d4a-4662-b243-f5443732a324 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:55345 biolink:treats UMLS:C1868936 PMID:41385096 "[{""id"":""uuid:e1d9915f-47f3-479c-9435-e01d74b21074"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:5a354a87-1ab6-4849-be25-e674263486c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Anagrelide is indicated for the reduction of elevated platelet counts in at risk essential thrombocythaemia (ET) patients who are intolerant to their current therapy or whose elevated platelet counts are not reduced to an acceptable level by their current therapy.An at-risk patientAn at-risk essential thrombocythaemia patient is defined by one or more of the following features:>60 years of age ora platelet count >1,000 x 10⁹/l ora history of thrombo-haemorrhagic events. uuid:df997e7f-9e42-448b-8473-788df2165426 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49603 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:60feb8fe-b4f3-4fca-82e8-10da5f3f0657"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8d312f4b-7b3e-4cf0-a84f-f1bae6777fca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/tyverb""]},{""id"":""uuid:70fab99d-7b77-4098-80e8-bf30b4e371c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Tyverb is indicated for the treatment of patients with breast cancer, whose tumours overexpress HER2 (ErbB2):in combination with capecitabine for patients with advanced or metastatic disease with progression following prior therapy, which must have included anthracyclines and taxanes and therapy with trastuzumab in the metastatic setting;in combination with trastuzumab for patients with hormone-receptor-negative metastatic disease that has progressed on prior trastuzumab therapy or therapies in combination with chemotherapy;in combination with an aromatase inhibitor for post-menopausal women with hormone-receptor-positive metastatic disease, not currently intended for chemotherapy. The patients in the registration study had not previously been treated with trastuzumab or an aromatase inhibitor. No data are available on the efficacy of this combination relative to trastuzumab in combination with an aromatase inhibitor in this patient population.|[PMDA] A drug with a new active ingredient indicated for the treatment of inoperable or recurrent breast cancer with HER2 overexpression. [Priority review] uuid:793204cf-b033-4e97-a723-f6ba325cb5fc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49603 biolink:treats MONDO:0005494 PMID:41385096 "[{""id"":""uuid:3d8a9c7c-d3b7-44b6-baa3-4b2aecfe4253"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:9ef6eab6-3976-4b43-83ba-94035421ea93"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/tyverb""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Tyverb is indicated for the treatment of patients with breast cancer, whose tumours overexpress HER2 (ErbB2):in combination with capecitabine for patients with advanced or metastatic disease with progression following prior therapy, which must have included anthracyclines and taxanes and therapy with trastuzumab in the metastatic setting;in combination with trastuzumab for patients with hormone-receptor-negative metastatic disease that has progressed on prior trastuzumab therapy or therapies in combination with chemotherapy;in combination with an aromatase inhibitor for post-menopausal women with hormone-receptor-positive metastatic disease, not currently intended for chemotherapy. The patients in the registration study had not previously been treated with trastuzumab or an aromatase inhibitor. No data are available on the efficacy of this combination relative to trastuzumab in combination with an aromatase inhibitor in this patient population. uuid:fccbd2b9-28be-421c-aaa5-dca838ccbf7d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB13881 biolink:treats MONDO:0004947 PMID:41385096 "[{""id"":""uuid:08c0a6f0-4432-4aa3-be48-f8b76fb02b15"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:aa07bfbb-b9a4-4625-8237-8c681b5827f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/kymriah""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Kymriah is indicated for the treatment of:• Paediatric and young adult patients up to and including 25 years of age with B cell acute lymphoblastic leukaemia (ALL) that is refractory, in relapse post transplant or in second or later relapse.• Adult patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) after two or more lines of systemic therapy.• Adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. uuid:581e87ee-3e95-46ec-821b-22a3a7205978 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB13881 biolink:treats MONDO:0018905 PMID:41385096 "[{""id"":""uuid:b9c440c7-064d-4e0f-94b0-93f49b945451"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:85d078e8-b112-4654-a612-4cf7151c98a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/kymriah""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Kymriah is indicated for the treatment of:• Paediatric and young adult patients up to and including 25 years of age with B cell acute lymphoblastic leukaemia (ALL) that is refractory, in relapse post transplant or in second or later relapse.• Adult patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) after two or more lines of systemic therapy.• Adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. uuid:5a282672-80c8-481f-9520-bc9a09501c57 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB13881 biolink:treats MONDO:0018906 PMID:41385096 "[{""id"":""uuid:493bc89a-4274-4080-9ee5-e3e74a5a1aea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:40594a8a-1f92-44e1-86e1-105e831fd342"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/kymriah""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Kymriah is indicated for the treatment of:• Paediatric and young adult patients up to and including 25 years of age with B cell acute lymphoblastic leukaemia (ALL) that is refractory, in relapse post transplant or in second or later relapse.• Adult patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) after two or more lines of systemic therapy.• Adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. uuid:a553bbe2-557b-45d6-b282-6b33298671e1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6D5766Q4OP biolink:treats MONDO:0011871 PMID:41385096 "[{""id"":""uuid:f85e09f0-938b-422d-a07d-1741006330a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:0c0cac20-1ac6-4d30-a8b8-15b146edbc2b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/xenpozyme""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Xenpozyme is indicated as an enzyme replacement therapy for the treatment of non-Central Nervous System (CNS) manifestations of Acid Sphingomyelinase Deficiency (ASMD) in paediatric and adult patients with type A/B or type B. uuid:0215499c-1265-4113-981c-3d13a687e45d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:0IEO0F56LV biolink:treats MONDO:0001824 PMID:41385096 "[{""id"":""uuid:b73cbbd8-e22e-4239-ae49-207a0ff6d393"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:9e139ca5-c9f9-4e9d-bfdd-2e3ca7d3e8ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of stage 1 or Stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis (hATTR). uuid:6eb1d4ba-ebf6-4ff2-8d75-01ab5b661058 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7K5O7P6QIU biolink:treats MONDO:0018905 PMID:41385096 "[{""id"":""uuid:c7850c27-b505-43dc-93ff-6681553e56ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:e9174381-c973-42b8-a694-a61c152447ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/zynlonta""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Zynlonta as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy. uuid:423b6859-78a3-4939-88bd-68412b8eeabc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7K5O7P6QIU biolink:treats MONDO:0044889 PMID:41385096 "[{""id"":""uuid:f4083965-28fb-4b58-989a-f494eaa97835"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:7dddd062-cb8e-4a37-9f6f-dd3c9df2f19a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/zynlonta""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Zynlonta as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy. uuid:b70de396-c8c2-428c-8df6-4a834bd3c805 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:VHS6SC660Q biolink:treats MONDO:0007886 PMID:41385096 "[{""id"":""uuid:10f0005a-e9b6-4234-8524-12d7385364e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:4d33a4fc-0db5-4246-a85c-09b89364c345"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/yselty""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Yselty is indicated for the treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age. uuid:72ddcc49-ebfe-44d1-92e5-f848fd433f79 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17549 biolink:treats MONDO:0100342 PMID:41385096 "[{""id"":""uuid:879bcf38-4b7d-4712-b5c6-3a63f8e7496b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d8becb46-cd25-4d16-8278-f06bf099319a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/gliolan""]},{""id"":""uuid:32dcfb0a-b309-4d35-9797-02e189da4499"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Gliolan is indicated in adult patients for visualisation of malignant tissue during surgery for malignant glioma (World Health Organization grade III and IV).|[PMDA] Drugs with a new active ingredient indicated for the visualization of tumor tissues during tumorectomy for malignant glioma. [Orphan drug] uuid:70d691e2-50a3-4f69-a698-bea93f3a19de biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1999664 biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:043f8239-17b9-4048-a438-80f77aea0c09"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:b9ac0750-517d-465c-84d7-8d629c7a69b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/biktarvy""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Biktarvy is indicated for the treatment of human immunodeficiency virus 1 (HIV 1) infection in adults and paediatric patients at least 2 years of age and weighing at least 14 kg i without present or past evidence of viral resistance to the integrase inhibitor class, emtricitabine or tenofovir.(see section 5.1) uuid:8b8b3987-636b-43b1-bfb4-54ca51643c55 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:499361 biolink:treats UMLS:C0520909 PMID:41385096 "[{""id"":""uuid:cd234dce-9e48-4686-95c4-1e82f0dcb180"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:699f408f-589f-4586-9c4d-c065693da1dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/emend""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Emend 40 mg hard capsules is indicated for the prevention of postoperative nausea and vomiting (PONV) in adults.Emend is also available as 80 mg and 125 mg hard capsules for the prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults and adolescents from the age of 12 (see separate Summary of Product Characteristics).Emend is also available as 165 mg hard capsules for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin based cancer chemotherapy in adults and the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy in adults.Emend is also available as powder for oral suspension for the prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in children, toddlers and infants from the age of 6 months to less than 12 years.Emend 80 mg, 125 mg, 165 mg hard capsules and Emend powder for oral suspension are given as part of combination therapy. uuid:fb60b60e-d7e0-4eb2-a6f9-7269df7678e4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:UMD07X179E biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:f6a82a16-e277-4b24-97da-b8b75febd1ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e407e54e-0a10-41e9-8097-ee07d504a3c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/cimzia""]},{""id"":""uuid:daa9e48f-235e-48eb-9067-35073ef3f2b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Rheumatoid arthritisCimzia, in combination with methotrexate (MTX), is indicated for:the treatment of moderate to severe, active rheumatoid arthritis (RA) in adult patients when the response to disease-modifying antirheumatic drugs (DMARDs) including MTX, has been inadequate. Cimzia can be given as monotherapy in case of intolerance to MTX or when continued treatment with MTX is inappropriatethe treatment of severe, active and progressive RA in adults not previously treated with MTX or other DMARDs.Cimzia has been shown to reduce the rate of progression of joint damage as measured by X ray and to improve physical function, when given in combination with MTX.Axial spondyloarthritis Cimzia is indicated for the treatment of adult patients with severe active axial spondyloarthritis, comprising:Ankylosing spondylitis (AS)Adults with severe active ankylosing spondylitis who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs).Axial spondyloarthritis without radiographic evidence of ASAdults with severe active axial spondyloarthritis without radiographic evidence of AS but with objective signs of inflammation by elevated C reactive protein (CRP) and /or magnetic resonance imaging (MRI), who have had an inadequate response to, or are intolerant to NSAIDs.Psoriatic arthritis Cimzia, in combination with MTX, is indicated for the treatment of active psoriatic arthritis in adults when the response to previous DMARD therapy has been inadequate.Cimzia can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.|[PMDA] A drug with a new active ingredient indicated for the treatment of rheumatoid arthritis (including prevention of structural joint damage) in patients who have not sufficiently responded to conventional treatments. uuid:dc3f76f5-9da7-4096-979c-aeb0d4a4c231 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:UMD07X179E biolink:treats MONDO:0005306 PMID:41385096 "[{""id"":""uuid:5e44b6fb-ff2e-4ce3-b72f-c10b520a2a87"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:e3ebf5fd-b2f3-446f-a9b8-8651b8ae81d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/cimzia""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Rheumatoid arthritisCimzia, in combination with methotrexate (MTX), is indicated for:the treatment of moderate to severe, active rheumatoid arthritis (RA) in adult patients when the response to disease-modifying antirheumatic drugs (DMARDs) including MTX, has been inadequate. Cimzia can be given as monotherapy in case of intolerance to MTX or when continued treatment with MTX is inappropriatethe treatment of severe, active and progressive RA in adults not previously treated with MTX or other DMARDs.Cimzia has been shown to reduce the rate of progression of joint damage as measured by X ray and to improve physical function, when given in combination with MTX.Axial spondyloarthritis Cimzia is indicated for the treatment of adult patients with severe active axial spondyloarthritis, comprising:Ankylosing spondylitis (AS)Adults with severe active ankylosing spondylitis who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs).Axial spondyloarthritis without radiographic evidence of ASAdults with severe active axial spondyloarthritis without radiographic evidence of AS but with objective signs of inflammation by elevated C reactive protein (CRP) and /or magnetic resonance imaging (MRI), who have had an inadequate response to, or are intolerant to NSAIDs.Psoriatic arthritis Cimzia, in combination with MTX, is indicated for the treatment of active psoriatic arthritis in adults when the response to previous DMARD therapy has been inadequate.Cimzia can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. uuid:3e786607-d5f2-4de3-aa4c-93162e5c2e8a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:UMD07X179E biolink:treats MONDO:0011849 PMID:41385096 "[{""id"":""uuid:74891491-e474-488e-9486-2cf75ccdd0a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:dab826d2-27bb-4535-910c-0d9e3a0b4fe9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/cimzia""]},{""id"":""uuid:a321a8fa-0cab-4f48-a4b7-d80b5a98e294"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Rheumatoid arthritisCimzia, in combination with methotrexate (MTX), is indicated for:the treatment of moderate to severe, active rheumatoid arthritis (RA) in adult patients when the response to disease-modifying antirheumatic drugs (DMARDs) including MTX, has been inadequate. Cimzia can be given as monotherapy in case of intolerance to MTX or when continued treatment with MTX is inappropriatethe treatment of severe, active and progressive RA in adults not previously treated with MTX or other DMARDs.Cimzia has been shown to reduce the rate of progression of joint damage as measured by X ray and to improve physical function, when given in combination with MTX.Axial spondyloarthritis Cimzia is indicated for the treatment of adult patients with severe active axial spondyloarthritis, comprising:Ankylosing spondylitis (AS)Adults with severe active ankylosing spondylitis who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs).Axial spondyloarthritis without radiographic evidence of ASAdults with severe active axial spondyloarthritis without radiographic evidence of AS but with objective signs of inflammation by elevated C reactive protein (CRP) and /or magnetic resonance imaging (MRI), who have had an inadequate response to, or are intolerant to NSAIDs.Psoriatic arthritis Cimzia, in combination with MTX, is indicated for the treatment of active psoriatic arthritis in adults when the response to previous DMARD therapy has been inadequate.Cimzia can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.|[PMDA] Drugs with new additional indications and a new dosage for the treatment of plaque psoriasis, psoriatic arthritis, pustular psoriasis, and erythrodermic psoriasis in patients who have not responded sufficiently to conventional therapies. uuid:41b2a894-6844-4841-b1da-288368f56f27 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:LKC0U3A8NJ biolink:treats HP:0003124 PMID:41385096 "[{""id"":""uuid:78e68824-9438-4132-bf4e-abc0c0463bcc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:bbcdbbbf-d44f-494e-b5e7-46535f75814c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/repatha""]},{""id"":""uuid:e4d29823-0071-4946-a61d-5a64b2e81f31"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Hypercholesterolaemia and mixed dyslipidaemiaRepatha is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:in combination with a statin or statin with other lipid lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin or,alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.Homozygous familial hypercholesterolaemiaRepatha is indicated in adults and adolescents aged 12 years and over with homozygous familial hypercholesterolaemia in combination with other lipid-lowering therapies.Established atherosclerotic cardiovascular diseaseRepatha is indicated in adults with established atherosclerotic cardiovascular disease (myocardial infarction, stroke or peripheral arterial disease) to reduce cardiovascular risk by lowering LDL-C levels, as an adjunct to correction of other risk factors:in combination with the maximum tolerated dose of a statin with or without other lipid-lowering therapies or,alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.For study results with respect to effects on LDL-C, cardiovascular events and populations studied see section 5.1.|[PMDA] Drugs with a new active ingredient indicated for the treatment of familial hypercholesterolemia and hypercholesterolemia (for use only in patients who are at higher risk of developing cardiovascular event and have not responded sufficiently to HMG- CoA reductase inhibitors). uuid:c56f7c0d-b640-46d8-b8d7-294534dc0351 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:LKC0U3A8NJ biolink:treats MONDO:0021661 PMID:41385096 "[{""id"":""uuid:dd421fa8-bc61-4773-ba40-db5d679fc89d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:8e5b7988-ff96-471f-9d25-80ed059ae2d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/repatha""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Hypercholesterolaemia and mixed dyslipidaemiaRepatha is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:in combination with a statin or statin with other lipid lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin or,alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.Homozygous familial hypercholesterolaemiaRepatha is indicated in adults and adolescents aged 12 years and over with homozygous familial hypercholesterolaemia in combination with other lipid-lowering therapies.Established atherosclerotic cardiovascular diseaseRepatha is indicated in adults with established atherosclerotic cardiovascular disease (myocardial infarction, stroke or peripheral arterial disease) to reduce cardiovascular risk by lowering LDL-C levels, as an adjunct to correction of other risk factors:in combination with the maximum tolerated dose of a statin with or without other lipid-lowering therapies or,alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.For study results with respect to effects on LDL-C, cardiovascular events and populations studied see section 5.1. uuid:64c8dfb1-756a-4326-9e04-9acf416ce894 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:LKC0U3A8NJ biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:b026a90a-aed0-40df-9f88-8f29e0320232"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:10d6cba7-9f37-411b-973f-322cc0d030d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/repatha""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Hypercholesterolaemia and mixed dyslipidaemiaRepatha is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:in combination with a statin or statin with other lipid lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin or,alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.Homozygous familial hypercholesterolaemiaRepatha is indicated in adults and adolescents aged 12 years and over with homozygous familial hypercholesterolaemia in combination with other lipid-lowering therapies.Established atherosclerotic cardiovascular diseaseRepatha is indicated in adults with established atherosclerotic cardiovascular disease (myocardial infarction, stroke or peripheral arterial disease) to reduce cardiovascular risk by lowering LDL-C levels, as an adjunct to correction of other risk factors:in combination with the maximum tolerated dose of a statin with or without other lipid-lowering therapies or,alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.For study results with respect to effects on LDL-C, cardiovascular events and populations studied see section 5.1. uuid:efef5502-cceb-498f-ab80-c5461684be68 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:LKC0U3A8NJ biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:b7697530-027b-4804-8c12-cc91b2308203"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:ea8be91b-7fd1-461b-8b62-428ed0a8c1fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/repatha""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Hypercholesterolaemia and mixed dyslipidaemiaRepatha is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:in combination with a statin or statin with other lipid lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin or,alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.Homozygous familial hypercholesterolaemiaRepatha is indicated in adults and adolescents aged 12 years and over with homozygous familial hypercholesterolaemia in combination with other lipid-lowering therapies.Established atherosclerotic cardiovascular diseaseRepatha is indicated in adults with established atherosclerotic cardiovascular disease (myocardial infarction, stroke or peripheral arterial disease) to reduce cardiovascular risk by lowering LDL-C levels, as an adjunct to correction of other risk factors:in combination with the maximum tolerated dose of a statin with or without other lipid-lowering therapies or,alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.For study results with respect to effects on LDL-C, cardiovascular events and populations studied see section 5.1. uuid:a4e1349a-3a4e-41e3-b671-7ceffce51e58 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:LKC0U3A8NJ biolink:treats MONDO:0005386 PMID:41385096 "[{""id"":""uuid:643528a7-67e1-4fd9-b746-fef9c24ff7ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d4f137b1-95b2-4391-b308-bb34941e779f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/repatha""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Hypercholesterolaemia and mixed dyslipidaemiaRepatha is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:in combination with a statin or statin with other lipid lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin or,alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.Homozygous familial hypercholesterolaemiaRepatha is indicated in adults and adolescents aged 12 years and over with homozygous familial hypercholesterolaemia in combination with other lipid-lowering therapies.Established atherosclerotic cardiovascular diseaseRepatha is indicated in adults with established atherosclerotic cardiovascular disease (myocardial infarction, stroke or peripheral arterial disease) to reduce cardiovascular risk by lowering LDL-C levels, as an adjunct to correction of other risk factors:in combination with the maximum tolerated dose of a statin with or without other lipid-lowering therapies or,alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.For study results with respect to effects on LDL-C, cardiovascular events and populations studied see section 5.1. uuid:d6ad2982-6cb3-4b77-ab69-2496b637c2e1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27565 biolink:treats MONDO:0005861 PMID:41385096 "[{""id"":""uuid:49ebeac4-3703-4028-93e0-8d527f8c71e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d3dd7d34-9c9b-4435-bdc4-37c483b274fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/granupas-previously-para-aminosalicylic-acid-lucane""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Granupas is indicated for use as part of an appropriate combination regimen for multi-drug resistant tuberculosis in adults and paediatric patients from 28 days of age and older when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability (see section 4.4).Consideration should be given to official guidance on the appropriate use of antibacterial agents. uuid:51ae4898-e8be-4cfc-9d2c-35df2e241a24 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:D652ZWF066 biolink:treats HP:0002153 PMID:41385096 "[{""id"":""uuid:f31624e7-4af3-4dd2-97c0-e16226d39cc1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9dc60467-388e-421b-b16a-83d053762168"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/lokelma""]},{""id"":""uuid:25293fc3-0ed6-4cbd-b7b1-79fd0ed2abd8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Lokelma is indicated for the treatment of hyperkalaemia in adult patients.|[PMDA] Drugs with a new active ingredient indicated for the treatment of hyperkalaemia. uuid:5cf1fb41-dcc6-48fd-bbd6-82784edf2d46 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134745 biolink:treats MONDO:0004739 PMID:41385096 "[{""id"":""uuid:f5f24502-c532-46b0-9264-42a2018565f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:9985b561-10f8-408a-9dc6-f782779af02c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ravicti""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Ravicti is indicated for use as adjunctive therapy for chronic management of patients with urea cycle disorders (UCDs) including deficiencies of carbamoyl phosphate-synthase-I (CPS), ornithine carbamoyltransferase (OTC), argininosuccinate synthetase (ASS), argininosuccinate lyase (ASL), arginase I (ARG) and ornithine translocase deficiency hyperornithinaemia-hyperammonaemia homocitrullinuria syndrome (HHH) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone.Ravicti must be used with dietary protein restriction and, in some cases, dietary supplements (e.g., essential amino acids, arginine, citrulline, protein-free calorie supplements). uuid:bbe1a537-e148-4a17-b58e-e06638f03eab biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134745 biolink:treats MONDO:0009376 PMID:41385096 "[{""id"":""uuid:0c9c3d99-c468-4cac-807a-b8cead1b7598"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:53f62efe-a27e-4c2c-b667-86a99e100ac1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ravicti""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Ravicti is indicated for use as adjunctive therapy for chronic management of patients with urea cycle disorders (UCDs) including deficiencies of carbamoyl phosphate-synthase-I (CPS), ornithine carbamoyltransferase (OTC), argininosuccinate synthetase (ASS), argininosuccinate lyase (ASL), arginase I (ARG) and ornithine translocase deficiency hyperornithinaemia-hyperammonaemia homocitrullinuria syndrome (HHH) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone.Ravicti must be used with dietary protein restriction and, in some cases, dietary supplements (e.g., essential amino acids, arginine, citrulline, protein-free calorie supplements). uuid:78d68c6e-ecd3-4b2c-bc85-cd20f926ef5b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134745 biolink:treats MONDO:0010703 PMID:41385096 "[{""id"":""uuid:d63690be-5bf7-4450-97ec-a337ec4f7803"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:368675bb-6493-4b3c-a433-74111c6706cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ravicti""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Ravicti is indicated for use as adjunctive therapy for chronic management of patients with urea cycle disorders (UCDs) including deficiencies of carbamoyl phosphate-synthase-I (CPS), ornithine carbamoyltransferase (OTC), argininosuccinate synthetase (ASS), argininosuccinate lyase (ASL), arginase I (ARG) and ornithine translocase deficiency hyperornithinaemia-hyperammonaemia homocitrullinuria syndrome (HHH) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone.Ravicti must be used with dietary protein restriction and, in some cases, dietary supplements (e.g., essential amino acids, arginine, citrulline, protein-free calorie supplements). uuid:46fc7297-d6c8-48c0-9895-3a0f81a01f31 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134745 biolink:treats MONDO:0008815 PMID:41385096 "[{""id"":""uuid:beea4f5d-ac24-4597-a0dd-b78585764b68"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:ac6bac1e-264c-42d7-86ea-891f1431e5eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ravicti""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Ravicti is indicated for use as adjunctive therapy for chronic management of patients with urea cycle disorders (UCDs) including deficiencies of carbamoyl phosphate-synthase-I (CPS), ornithine carbamoyltransferase (OTC), argininosuccinate synthetase (ASS), argininosuccinate lyase (ASL), arginase I (ARG) and ornithine translocase deficiency hyperornithinaemia-hyperammonaemia homocitrullinuria syndrome (HHH) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone.Ravicti must be used with dietary protein restriction and, in some cases, dietary supplements (e.g., essential amino acids, arginine, citrulline, protein-free calorie supplements). uuid:a8e734c5-6fe7-4d83-aa6c-c94e8e8edd99 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134745 biolink:treats MONDO:0008814 PMID:41385096 "[{""id"":""uuid:c1fae464-f09b-4562-a506-5c5bd43825b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:11ef3843-3575-49c9-b5ac-7df21f0b770e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ravicti""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Ravicti is indicated for use as adjunctive therapy for chronic management of patients with urea cycle disorders (UCDs) including deficiencies of carbamoyl phosphate-synthase-I (CPS), ornithine carbamoyltransferase (OTC), argininosuccinate synthetase (ASS), argininosuccinate lyase (ASL), arginase I (ARG) and ornithine translocase deficiency hyperornithinaemia-hyperammonaemia homocitrullinuria syndrome (HHH) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone.Ravicti must be used with dietary protein restriction and, in some cases, dietary supplements (e.g., essential amino acids, arginine, citrulline, protein-free calorie supplements). uuid:25c1e6f5-58e5-4b36-be00-72271a89cfc4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134745 biolink:treats MONDO:0009393 PMID:41385096 "[{""id"":""uuid:2bbe2a18-1a20-4eea-bd0f-83b149a7c676"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:be03d26c-f623-40fa-a472-748bf7c46c92"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ravicti""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Ravicti is indicated for use as adjunctive therapy for chronic management of patients with urea cycle disorders (UCDs) including deficiencies of carbamoyl phosphate-synthase-I (CPS), ornithine carbamoyltransferase (OTC), argininosuccinate synthetase (ASS), argininosuccinate lyase (ASL), arginase I (ARG) and ornithine translocase deficiency hyperornithinaemia-hyperammonaemia homocitrullinuria syndrome (HHH) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone.Ravicti must be used with dietary protein restriction and, in some cases, dietary supplements (e.g., essential amino acids, arginine, citrulline, protein-free calorie supplements). uuid:cfa81b6d-e797-4d16-a10d-0c740ade66aa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0006217 biolink:treats UMLS:C0701836 PMID:41385096 "[{""id"":""uuid:731dbabf-a13e-4a1a-96bb-cfcf821645f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:6925f0df-cddb-4485-9bd7-fe47a0900ad2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] NexoBrid is indicated for removal of eschar in adults with deep partial- and full-thickness thermal burns. DRUGBANK:DB13281 uuid:4e559363-4a8f-4f8f-86b1-92f4250fdde4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:94805 biolink:treats MONDO:0010679 PMID:41385096 "[{""id"":""uuid:f18815f4-b3d8-489b-b3aa-2104371b73e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:318d7414-47c0-4cbc-ace8-b2290c06d609"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/translarna""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Translarna is indicated for the treatment of Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene, in ambulatory patients aged 2 years and older. Efficacy has not been demonstrated in non-ambulatory patients.The presence of a nonsense mutation in the dystrophin gene should be determined by genetic testing. uuid:d874acc3-b411-44f0-a32d-75e6eacab5a5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71271 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:1426fbb7-a71e-405f-96fd-5a7cc1e9263c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:cc0d9f08-6fba-4190-8862-2bb4ac8c98a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/onglyza""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Add-on combination therapyOnglyza is indicated in adult patients aged 18 years and older with type-2 diabetes mellitus to improve glycaemic control:as monotherapy:in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance;as dual oral therapy:in combination with metformin, when metformin alone, with diet and exercise, does not provide adequate glycaemic control;in combination with a sulphonylurea, when the sulphonylurea alone, with diet and exercise, does not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate;in combination with a thiazolidinedione, when the thiazolidinedione alone with diet and exercise, does not provide adequate glycaemic control in patients for whom use of a thiazolidinedione is considered appropriate;as triple oral therapy:in combination with metformin plus a sulphonylurea when this regimen alone, with diet and exercise, does not provide adequate glycaemic control;as combination therapy with insulin (with or without metformin), when this regimen alone, with diet and exercise, does not provide adequate glycaemic control. uuid:67437374-cebb-4298-91a6-71d7fe17a3fc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:291902 biolink:treats MONDO:0006805 PMID:41385096 "[{""id"":""uuid:0e5a8e03-9cee-42e5-a4cb-2586eaed8df9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:db8d5174-d362-4de1-a33e-a37e905db99c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/eptifibatide-accord""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Eptifibatide Accord is intended for use with acetylsalicylic acid and unfractionated heparin.Eptifibatide Accord is indicated for the prevention of early myocardial infarction in adults presenting with unstable angina or non-Q-wave myocardial infarction, with the last episode of chest pain occurring within 24 hours and with electrocardiogram (ECG) changes and/or elevated cardiac enzymes.Patients most likely to benefit from Eptifibatide Accord treatment are those at high risk of developing myocardial infarction within the first 3-4 days after onset of acute angina symptoms including for instance those that are likely to undergo an early PTCA (Percutaneous Transluminal Coronary Angioplasty). uuid:f5a8f578-19cc-40df-9b09-50e891401220 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:291902 biolink:treats MONDO:0003674 PMID:41385096 "[{""id"":""uuid:d06666aa-b98e-4144-9f20-2d0db862f8e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:74e61ac3-db39-4548-8a05-a2d55f42255d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/eptifibatide-accord""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Eptifibatide Accord is intended for use with acetylsalicylic acid and unfractionated heparin.Eptifibatide Accord is indicated for the prevention of early myocardial infarction in adults presenting with unstable angina or non-Q-wave myocardial infarction, with the last episode of chest pain occurring within 24 hours and with electrocardiogram (ECG) changes and/or elevated cardiac enzymes.Patients most likely to benefit from Eptifibatide Accord treatment are those at high risk of developing myocardial infarction within the first 3-4 days after onset of acute angina symptoms including for instance those that are likely to undergo an early PTCA (Percutaneous Transluminal Coronary Angioplasty). uuid:f0580845-dc4d-4e9d-9241-13b8041b2512 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:291902 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:23ad7262-0d73-4976-a28d-31b535014da3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d644152a-2134-4ada-b8aa-c7ed80dc0295"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/eptifibatide-accord""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Eptifibatide Accord is intended for use with acetylsalicylic acid and unfractionated heparin.Eptifibatide Accord is indicated for the prevention of early myocardial infarction in adults presenting with unstable angina or non-Q-wave myocardial infarction, with the last episode of chest pain occurring within 24 hours and with electrocardiogram (ECG) changes and/or elevated cardiac enzymes.Patients most likely to benefit from Eptifibatide Accord treatment are those at high risk of developing myocardial infarction within the first 3-4 days after onset of acute angina symptoms including for instance those that are likely to undergo an early PTCA (Percutaneous Transluminal Coronary Angioplasty). uuid:19a438a4-3bd9-46c4-950f-1021fcb5e4e3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3POA0Q644U biolink:treats MONDO:0018874 PMID:41385096 "[{""id"":""uuid:e6d56123-e06e-4e41-aacf-2536a852d627"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:fd10e31a-2490-43f6-b3c1-54580b14bdfa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ceplene""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Ceplene maintenance therapy is indicated for adult patients with acute myeloid leukaemia in first remission concomitantly treated with interleukin-2 (IL-2). The efficacy of Ceplene has not been fully demonstrated in patients older than age 60. uuid:9e449fbe-82f4-464f-8d52-ce52e196fc17 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:143117 biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:6cc6ff83-b9e6-4cdb-9f52-e015e520d085"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d4ffad3a-96d8-4677-bb7d-52f9dd7948cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/lorviqua""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)‑positive advanced non‑small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor.Lorviqua as monotherapy is indicated for the treatment of adult patients with ALK‑positive advanced NSCLC whose disease has progressed after:alectinib or ceritinib as the first ALK tyrosine kinase inhibitor (TKI) therapy; orcrizotinib and at least one other ALK TKI. uuid:e4c02af8-ebaf-4f9a-9aff-97e603ad873d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:131701323 biolink:treats MONDO:0003529 PMID:41385096 "[{""id"":""uuid:fe03765c-2591-433c-a495-203a8aaf7feb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:fb0c5c0b-8b85-45da-909d-58c81d6bc919"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/zerbaxa""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Zerbaxa is indicated for the treatment of the following infections in adults:Complicated intra abdominal infections;Acute pyelonephritis;Complicated urinary tract infections;Hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP).Consideration should be given to official guidance on the appropriate use of antibacterial agents. uuid:de54aa0c-edd0-4d56-aaf0-997d0f91f8f6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:131701323 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:bd5a20b3-4ea5-485c-b542-62784f024be2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:3e0b7343-a1d3-431e-b32f-1211161739c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/zerbaxa""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Zerbaxa is indicated for the treatment of the following infections in adults:Complicated intra abdominal infections;Acute pyelonephritis;Complicated urinary tract infections;Hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP).Consideration should be given to official guidance on the appropriate use of antibacterial agents. uuid:80be382a-71d8-43e3-b470-8640ed516e3f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50378 biolink:treats MONDO:0008753 PMID:41385096 "[{""id"":""uuid:3d7d1ada-8334-4ed5-b24a-6df2cded566b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:44b99841-739d-4cae-96f5-4f0943953d99"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/nitisinone-mdk""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Hereditary tyrosinemia type 1 (HT 1)Orfadin is indicated for the treatment of adult and paediatric (in any age range) patients with confirmed diagnosis of hereditary tyrosinemia type 1 (HT 1) in combination with dietary restriction of tyrosine and phenylalanine.Alkaptonuria (AKU)Orfadin is indicated for the treatment of adult patients with alkaptonuria (AKU). uuid:fa74dffb-13a5-479b-91b7-c730a50a499f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:25110515 biolink:treats MONDO:0005301 PMID:41385096 "[{""id"":""uuid:ff7b33b3-de22-40cf-8604-e81299507f1b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:92f4eb9f-da76-4c09-9ba8-0330c32683f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Multiple sclerosisZeposia is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease as defined by clinical or imaging features.Ulcerative colitisZeposia is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent. uuid:bc8e398d-9134-4214-b7dd-ef049ee48b7b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:25110515 biolink:treats MONDO:0005101 PMID:41385096 "[{""id"":""uuid:00808df8-1001-4475-b9e5-c0ed7d598488"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:ca9c3d83-ac20-41ad-b8e6-726650e975a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Multiple sclerosisZeposia is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease as defined by clinical or imaging features.Ulcerative colitisZeposia is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent. uuid:ccaa3c14-6289-4e6c-b6fd-d91f1f8c7f4e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85182 biolink:treats MONDO:0005354 PMID:41385096 "[{""id"":""uuid:885a8410-2d66-46a1-888a-c6d9ac9ce41e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:c784fccd-ebda-41f9-914b-50b3a66fb5c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Exviera is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adults.For hepatitis C virus (HCV) genotype specific activity. uuid:661df1b7-f8de-4aec-afc2-35479d59fcaf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85182 biolink:treats MONDO:0005231 PMID:41385096 "[{""id"":""uuid:11defc49-ee5e-42a4-816f-bb629c72e789"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:66e73589-067d-4cba-83c0-dc011a7ea296"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Exviera is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adults.For hepatitis C virus (HCV) genotype specific activity. uuid:44cef86a-46fb-4f47-8f64-ea0b7a647bad biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1597376 biolink:treats MONDO:0005354 PMID:41385096 "[{""id"":""uuid:bba36ce7-9b85-4ed0-947a-56cb787230ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:be7c9635-5a8b-4f52-bfb1-af25b66135e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/viekirax""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Viekirax is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adults.For hepatitis C virus (HCV) genotype specific activity. uuid:b583fa01-2247-41c0-89eb-27a73eeca795 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1597376 biolink:treats MONDO:0005231 PMID:41385096 "[{""id"":""uuid:55a14501-c897-4c3d-a940-68137db1d138"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:18f4b2a0-3597-4e92-afad-da2257d46636"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/viekirax""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Viekirax is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adults.For hepatitis C virus (HCV) genotype specific activity. uuid:a8e0894a-34a5-4eb5-8407-80cbbb4d2f0d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:T7K20Y2GWY biolink:treats MONDO:0018555 PMID:41385096 "[{""id"":""uuid:e9a3f0f5-aee9-4c9e-9c43-569d2cbf6525"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:e81bb7f6-4f0d-4768-8f7b-2efefe01ad37"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/elonva""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Controlled Ovarian Stimulation (COS) in combination with a GnRH antagonist for the development of multiple follicles in women participating in an Assisted Reproductive Technology (ART) program.Elonva is indicated for the treatment of adolescent males (14 to less than 18 years and older) with hypogonadotropic hypogonadism, in combination with human Chorionic Gonadotropin (hCG). uuid:8cf4c751-42ec-45aa-ae60-b911c3576967 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:81567 biolink:treats MONDO:0002108 PMID:41385096 "[{""id"":""uuid:0c012ab5-9695-441a-a5a0-bf5fbd8e0aa6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:74bd21c7-bc3d-4d5c-b1d4-3f53bc3dc9ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Thyrogen is indicated for use with serum thyroglobulin (Tg) testing with or without radioiodine imaging for the detection of thyroid remnants and well-differentiated thyroid cancer in post thyroidectomy patients maintained on hormone suppression therapy (THST).Low risk patients with well-differentiated thyroid carcinoma who have undetectable serum Tg levels on THST and no rh (recombinant human) TSH-stimulated increase of Tg levels may be followed-up by assaying rh TSH-stimulated Tg levels.Thyrogen is indicated for pre-therapeutic stimulation in combination with a range of 30 mCi (1.1 GBq) to 100 mCi (3.7 GBq) radioiodine for ablation of thyroid tissue remnants in patients who have undergone a near-total or total thyroidectomy for well-differentiated thyroid cancer and who do not have evidence of distant metastatic thyroid cancer (see section 4.4). uuid:d234ae82-30d8-4918-a7ee-9a0cbd7d6ee0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:Q6U6J48BWY biolink:treats MONDO:0018150 PMID:41385096 "[{""id"":""uuid:2f98c587-caac-4345-b91b-bf54cbc3855c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:6c185788-ecd1-46f3-b144-396082876ccd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/cerezyme""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Cerezyme (imiglucerase) is indicated for use as longterm enzyme replacement therapy in patients with a confirmed diagnosis of non-neuronopathic (Type 1) or chronic neuronopathic (Type 3) Gaucher disease who exhibit clinically significant nonneurological manifestations of the disease. The non-neurological manifestations of Gaucher disease include one or more of the following conditions:anaemia after exclusion of other causes, such as iron deficiencyThrombocytopeniaBone disease after exclusion of other causes such as Vitamin D deficiencyhepatomegaly or splenomegaly uuid:a508b495-f204-473a-96d4-279f36b75fb4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:Q6U6J48BWY biolink:treats MONDO:0037251 PMID:41385096 "[{""id"":""uuid:7561f920-68d5-49d5-bc86-fc930e983bee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a872246f-80bb-4514-b1b2-727838955484"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/cerezyme""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Cerezyme (imiglucerase) is indicated for use as longterm enzyme replacement therapy in patients with a confirmed diagnosis of non-neuronopathic (Type 1) or chronic neuronopathic (Type 3) Gaucher disease who exhibit clinically significant nonneurological manifestations of the disease. The non-neurological manifestations of Gaucher disease include one or more of the following conditions:anaemia after exclusion of other causes, such as iron deficiencyThrombocytopeniaBone disease after exclusion of other causes such as Vitamin D deficiencyhepatomegaly or splenomegaly uuid:c3d5b74a-322a-4a71-9efa-c57f1c8bf0a9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:N0A21N6RAU biolink:treats MONDO:0005083 PMID:41385096 "[{""id"":""uuid:c9728731-76d2-4895-ab95-30c7512ec0bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:6a2847b8-e212-4d2c-9dc2-8fb639e9894e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/sotyktu""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of moderate-to-severe plaque psoriasis in adults. uuid:cf64b189-e582-45d1-b9a6-1516bcb3188a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2539033 biolink:treats MONDO:0005399 PMID:41385096 "[{""id"":""uuid:f24b9757-b0a4-4e7c-befd-a285e287d603"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:deb4c886-c998-41d5-b6ca-21c22406aaa9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/lydisilka""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Oral contraception.The decision to prescribe Lydisilka should take into consideration the individual woman’s current risk factors, particularly those for venous thromboembolism (VTE), and how the risk of VTE with Lydisilka compares with other combined hormonal contraceptives (CHCs) (see sections 4.3 and 4.4). uuid:570099c9-b803-49d6-a2fe-aae49cb41cdd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:600520 biolink:treats MONDO:0044067 PMID:41385096 "[{""id"":""uuid:e869d7c5-00c7-4250-bd52-82ceb937fc54"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d6e24e58-518b-4875-bb32-43775350cb33"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/mycamine""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Mycamine is indicated for:Adults, adolescents ≥ 16 years of age and elderlytreatment of invasive candidiasis;treatment of oesophageal candidiasis in patients for whom intravenous therapy is appropriate;prophylaxis of Candida infection in patients undergoing allogeneic haematopoietic stem-cell transplantation or patients who are expected to have neutropenia (absolute neutrophil count < 500 cells/µl) for 10 or more days.Children (including neonates) and adolescents < 16 years of agetreatment of invasive candidiasis.prophylaxis of Candida infection in patients undergoing allogeneic haematopoietic stem-cell transplantation or patients who are expected to have neutropenia (absolute neutrophil count < 500 cells/µl) for 10 or more days.The decision to use Mycamine should take into account a potential risk for the development of liver tumours. Mycamine should therefore only be used if other antifungals are not appropriate. uuid:d7b556ac-04e2-4df8-813f-8a96ffa8e7aa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28887 biolink:treats MONDO:0005314 PMID:41385096 "[{""id"":""uuid:c0803f0c-cc93-407d-9271-3c2f4f3bae36"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:11d71a13-b0b8-48d4-a6a3-48d9d6f6af22"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/kesimpta""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Kesimpta is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features (see section 5.1). uuid:b20938c5-5638-4ab5-a23c-328e0e2092e5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB15483 biolink:treats MONDO:0004651 PMID:41385096 "[{""id"":""uuid:ce51e401-d8d7-4237-ba4e-d689299eebac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d09fdc71-7507-44f5-ab31-c56715062ddf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Active immunisation against smallpox, monkeypox and disease caused by vaccinia virus in adults (see sections 4.4 and 5.1).The use of this vaccine should be in accordance with official recommendations. uuid:ba9e63d4-b1ba-431e-8315-ec6d7cc951cf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB15483 biolink:treats MONDO:0002594 PMID:41385096 "[{""id"":""uuid:b626c6c2-cf80-45e2-be42-58f48698fb83"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a1c7d243-c21f-40e9-8e92-f1092052b9de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Active immunisation against smallpox, monkeypox and disease caused by vaccinia virus in adults (see sections 4.4 and 5.1).The use of this vaccine should be in accordance with official recommendations. uuid:c780aec1-c4b3-428b-9e73-bbc3d2226336 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB15483 biolink:treats MONDO:0005108 PMID:41385096 "[{""id"":""uuid:76614f7c-64e6-4a07-bf6d-40bb2163ce0f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d0552003-3214-417b-ab6c-c927956811c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Active immunisation against smallpox, monkeypox and disease caused by vaccinia virus in adults (see sections 4.4 and 5.1).The use of this vaccine should be in accordance with official recommendations. uuid:d9c04ef1-33cb-4400-9809-954cada1554e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:81569 biolink:treats MONDO:0021124 PMID:41385096 "[{""id"":""uuid:d724ae23-1657-455f-94bd-d3a5dba4f900"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:be872c53-e358-4364-a046-301d8ad54760"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/puregon""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] In the female:Puregon is indicated for the treatment of female infertility in the following clinical situations:anovulation (including polycystic ovarian syndrome, PCOS) in women who have been unresponsive to treatment with clomifene citrate;controlled ovarian hyperstimulation to induce the development of multiple follicles in medically assisted reproduction programs (e.g. in-vitro fertilisation / embryo transfer (IVF/ET), gamete intrafallopian transfer (GIFT) and intracytoplasmic sperm injection (ICSI)).In the male:Deficient spermatogenesis due to hypogonadotrophic hypogonadism. uuid:df5050db-5a10-428a-98f5-0d2086a723b1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:N7T15V1FUY biolink:treats MONDO:0015229 PMID:41385096 "[{""id"":""uuid:3ba1e15f-de09-4789-a397-2a022383aacd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:3f7d9a1b-ab8d-45b9-9729-f730b3c6691b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/imcivree""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Imcivree is indicated for the treatment of obesity and the control of hunger associated with genetically confirmed Bardet Biedl syndrome (BBS), loss-of-function biallelic pro-opiomelanocortin (POMC), including PCSK1, deficiency or biallelic leptin receptor (LEPR) deficiency in adults and children 6 years of age and above. uuid:ce0b0cf9-1723-45fb-bafc-eab3a8de5d5e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation MESH:C075654 biolink:treats MONDO:0001134 PMID:41385096 "[{""id"":""uuid:13edbe77-a6eb-4c92-a327-e78c8aa8b39d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:397e2821-f544-4acc-a1c2-99c7b22c387f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of essential hypertension.MicardisPlus fixed-dose combination (40 mg telmisartan / 12.5 mg hydrochlorothiazide, 80 mg telmisartan / 12.5 mg hydrochlorothiazide) is indicated in patients whose blood pressure is not adequately controlled on telmisartan alone.MicardisPlus fixed-dose combination (80 mg telmisartan / 25 mg hydrochlorothiazide) is indicated in patients whose blood pressure is not adequately controlled on MicardisPlus (80 mg telmisartan / 12.5 mg hydrochlorothiazide) or patients who have been previously stabilised on telmisartan and hydrochlorothiazide given separately. uuid:0eb8819c-60e5-4922-95ae-58fd7b994504 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7PCM518YLR biolink:treats MONDO:0010602 PMID:41385096 "[{""id"":""uuid:53d79892-3bab-486b-b979-f44a8a4178ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:96496eaf-7000-4f00-a392-69bb3799caf0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/elocta""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency).Elocta can be used for all age groups. uuid:62835630-8cb7-4e99-80b7-23f57444a1a3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:91408 biolink:treats MONDO:0044903 PMID:41385096 "[{""id"":""uuid:3b25682b-fa9b-4d4d-8eb7-776d5589267d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:26a6daeb-f9cd-4597-9db9-11f82c46e1cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Inrebic is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are Janus Associated Kinase (JAK) inhibitor naïve or have been treated with ruxolitinib. uuid:23ec05c8-07ef-48a1-b118-da888194b9c7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:66903 biolink:treats MONDO:0020804 PMID:41385096 "[{""id"":""uuid:133ed4d9-ae5f-4a02-b781-ac57cc0a81e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d5cab56f-841f-4bc5-94d5-095f0ab0bd2d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/erivedge""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Erivedge is indicated for the treatment of adult patients with:- symptomatic metastatic basal cell carcinoma- locally advanced basal cell carcinoma inappropriate for surgery or radiotherapy uuid:9af43077-a9f2-4cc8-9b24-a7f58ad80866 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:X05U0N2RCO biolink:treats MONDO:0850353 PMID:41385096 "[{""id"":""uuid:05152fba-4397-4037-890d-6e4542008a7b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:e36f6070-ea55-4acb-a9ce-8f1f264b90bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/nubeqa""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] NUBEQA is indicated for the treatment of adult men with- non metastatic castration resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease (see section 5.1).- metastatic hormone sensitive prostate cancer (mHSPC) in combination with docetaxel and androgen deprivation therapy (see section 5.1). uuid:4677e3c6-4d99-4107-96d5-bdf00ec578d9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0357131 biolink:treats MONDO:0005300 PMID:41385096 "[{""id"":""uuid:26d47816-f7af-49c5-9fff-23908543b2c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:01ea6f50-aebf-4aa3-9c84-e14f80c0e3a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/neorecormon""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adult and paediatric patients;treatment of symptomatic anaemia in adult patients with non-myeloid malignancies receiving chemotherapy;increasing the yield of autologous blood from patients in a pre-donation programme. Its use in this indication must be balanced against the reported increased risk of thromboembolic events. Treatment should only be given to patients with moderate anaemia (Hb 10 - 13 g/dl [6.21 - 8.07 mmol/l], no iron deficiency) if blood conserving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males). DRUGBANK:DB19434 uuid:8a79ab2c-972b-4162-8e84-d45f8912dc4d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0357131 biolink:treats MONDO:0004992 PMID:41385096 "[{""id"":""uuid:3cefd1b2-2038-457b-8df3-a030b4da2c93"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:9d76a02e-d274-46ca-91f9-2f14d627e788"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/neorecormon""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adult and paediatric patients;treatment of symptomatic anaemia in adult patients with non-myeloid malignancies receiving chemotherapy;increasing the yield of autologous blood from patients in a pre-donation programme. Its use in this indication must be balanced against the reported increased risk of thromboembolic events. Treatment should only be given to patients with moderate anaemia (Hb 10 - 13 g/dl [6.21 - 8.07 mmol/l], no iron deficiency) if blood conserving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males). DRUGBANK:DB19434 uuid:dd8fc0f5-c5f7-48dc-94ce-c4ed71c9f85d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0357131 biolink:treats MONDO:0002280 PMID:41385096 "[{""id"":""uuid:83a69a51-3afd-4e00-a9a4-2050405b3c0d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:16bfd967-2846-4d9a-8bac-ff54fec73f9f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/neorecormon""]},{""id"":""uuid:c00c3386-60ab-4d8e-8d66-6bcc8a651653"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adult and paediatric patients;treatment of symptomatic anaemia in adult patients with non-myeloid malignancies receiving chemotherapy;increasing the yield of autologous blood from patients in a pre-donation programme. Its use in this indication must be balanced against the reported increased risk of thromboembolic events. Treatment should only be given to patients with moderate anaemia (Hb 10 - 13 g/dl [6.21 - 8.07 mmol/l], no iron deficiency) if blood conserving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males).|[PMDA] Addition of a new indication for anemia in premature infants. DRUGBANK:DB19434 uuid:7084f9e2-6fe8-4fb5-b819-972e9689084f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEMBL.COMPOUND:CHEMBL3990008 biolink:treats MONDO:0019088 PMID:41385096 "[{""id"":""uuid:7d3d27fa-c6ba-4dca-8f76-dc5cf1ce5e41"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:664f3bd5-5389-4e84-995e-3bbe950c7898"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ebvallo""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Ebvallo is indicated as monotherapy for treatment of adult and paediatric patients 2 years of age and older with relapsed or refractory Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) who have received at least one prior therapy. For solid organ transplant patients, prior therapy includes chemotherapy unless chemotherapy is inappropriate. uuid:686d25f7-c518-4363-b894-7d086dc8d5ad biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68647 biolink:treats MONDO:0024883 PMID:41385096 "[{""id"":""uuid:9ccd1098-3c3b-4bfa-afc7-f1703a68b6ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:535c803d-96f4-4517-a3ca-e20d9d8980fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/stivarga""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Stivarga is indicated as monotherapy for the treatment of adult patients with:metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies - these include fluoropyrimidine-based chemotherapy, an anti-VEGF therapy and an anti-EGFR therapy;unresectable or metastatic gastrointestinal stromal tumors (GIST) who progressed on or are intolerant to prior treatment with imatinib and sunitinib;hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. uuid:89f61647-7695-427d-9e9d-22f4f5e94801 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:73275 biolink:treats NCIT:C154264 PMID:41385096 "[{""id"":""uuid:d2ea3fc4-08ac-4a68-98a2-518bf5f9381e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:e14d78c1-e3fc-4f13-96f6-d3d4171c318d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/senshio""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Senshio is indicated for the treatment of moderate to severe symptomatic vulvar and vaginal atrophy (VVA) in post-menopausal women. uuid:49160373-87fa-4d19-a53d-b8d821f2ae43 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:94511 biolink:treats MONDO:0009061 PMID:41385096 "[{""id"":""uuid:560dd266-55bf-4c79-ab46-0a409668fc4b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:125b2712-93b6-4a70-9ad9-4dbc4abe212e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Cayston is indicated for the suppressive therapy of chronic pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis (CF) aged 6 years and older.Consideration should be given to official guidance on the appropriate use of antibacterial agents. uuid:f7a41dd8-4a07-434a-83a8-3a0324e5bc55 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:94511 biolink:treats MONDO:0040732 PMID:41385096 "[{""id"":""uuid:96fee362-17ea-4f05-8d27-fcf036333a90"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:38d85bb6-2865-4f1c-8fc0-ace9ea2f639d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Cayston is indicated for the suppressive therapy of chronic pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis (CF) aged 6 years and older.Consideration should be given to official guidance on the appropriate use of antibacterial agents. uuid:62ad2431-ea3b-4cb6-b240-a70c668e4af8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2670556 biolink:treats MONDO:0005373 PMID:41385096 "[{""id"":""uuid:22ead5d1-3c1b-47d3-8758-ac28bae7d310"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d35af061-a64f-490d-91ce-1977f2acbb33"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/menveo""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] MenQuadfi is indicated for active immunisation of individuals from the age of 12 months and older against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y.The use of this vaccine should be in accordance with available official recommendations. uuid:4213e0cd-04b5-44db-b3c7-d0274313ff3b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68554 biolink:treats MONDO:0016486 PMID:41385096 "[{""id"":""uuid:650f7e0d-85e0-4dbe-98ef-85150d238f21"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:3799540d-15ef-4a43-b6f6-d3413053adf1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ferriprox""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Ferriprox monotherapy is indicated for the treatment of iron overload in patients with thalassaemia major when current chelation therapy is contraindicated or inadequate.Ferriprox in combination with another chelator is indicated in patients with thalassaemia major when monotherapy with any iron chelator is ineffective, or when prevention or treatment of life-threatening consequences of iron overload (mainly cardiac overload) justifies rapid or intensive correction. uuid:6aa375b0-c060-4b6d-a0c7-9ad8c3cd5df9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68554 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:abcfc9b5-ffaa-42be-81bd-58fcf4b95574"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:7f3e1384-206f-4b83-abf6-28645de6285d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ferriprox""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Ferriprox monotherapy is indicated for the treatment of iron overload in patients with thalassaemia major when current chelation therapy is contraindicated or inadequate.Ferriprox in combination with another chelator is indicated in patients with thalassaemia major when monotherapy with any iron chelator is ineffective, or when prevention or treatment of life-threatening consequences of iron overload (mainly cardiac overload) justifies rapid or intensive correction. uuid:74e6622e-fde9-4fcb-a400-a9a59715e3c4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4031 biolink:treats MONDO:0003085 PMID:41385096 "[{""id"":""uuid:c08e774d-687c-45be-ad25-8fb994b3a4d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:659d1faa-28dd-410c-b268-807253125ad6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/verkazia""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of severe keratitis in adult patients with dry eye disease, which has not improved despite treatment with tear substitutes. uuid:c42a8cd9-c2dd-4fa5-a3de-b1fc49640762 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEMBL.COMPOUND:CHEMBL2108334 biolink:treats MONDO:0018660 PMID:41385096 "[{""id"":""uuid:0baf238a-13fc-4227-85f1-8817d06df619"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:02e4f2ed-98e2-4a3f-bb11-f7424026f2b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/novoseven""]},{""id"":""uuid:5c92fc55-7651-48a5-86fb-196626bf0569"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] NovoSeven is indicated for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in the following patient groups:in patients with congenital haemophilia with inhibitors to coagulation factors VIII or IX > 5 Bethesda units (BU);in patients with congenital haemophilia who are expected to have a high anamnestic response to factor-VIII or factor-IX administration;in patients with acquired haemophilia;in patients with congenital factor-VII deficiency;in patients with Glanzmann's thrombasthenia with antibodies to platelet glycoprotein (GP) IIb-IIIa and / or human leucocyte antigens (HLA), and with past or present refractoriness to platelet transfusions.in patients with Glanzmann’s thrombasthenia with past or present refractoriness to platelet transfusions, or where platelets are not readily available.|[PMDA] Drugs with a new dosage to add single-dose administration for the prevention of bleeding in patients with congenital hemophilia who have inhibitors against blood coagulation factor VIII or IX. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:af8c0984-15fd-4945-91c0-7f36b85c17a9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEMBL.COMPOUND:CHEMBL2108334 biolink:treats MONDO:0019139 PMID:41385096 "[{""id"":""uuid:8f3c6cc1-e2d9-4849-916b-14b964812717"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:c71f834d-1f5e-4752-8ad3-ea06535e4fd0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/novoseven""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] NovoSeven is indicated for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in the following patient groups:in patients with congenital haemophilia with inhibitors to coagulation factors VIII or IX > 5 Bethesda units (BU);in patients with congenital haemophilia who are expected to have a high anamnestic response to factor-VIII or factor-IX administration;in patients with acquired haemophilia;in patients with congenital factor-VII deficiency;in patients with Glanzmann's thrombasthenia with antibodies to platelet glycoprotein (GP) IIb-IIIa and / or human leucocyte antigens (HLA), and with past or present refractoriness to platelet transfusions.in patients with Glanzmann’s thrombasthenia with past or present refractoriness to platelet transfusions, or where platelets are not readily available. uuid:cf4bddc9-a3af-4627-ae61-6324ae31dd95 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEMBL.COMPOUND:CHEMBL2108334 biolink:treats MONDO:0100326 PMID:41385096 "[{""id"":""uuid:966fa0ac-d130-4414-b8ac-4e82caff6bc7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0c1ad538-96b3-4d3f-a722-dd2762623ad8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/novoseven""]},{""id"":""uuid:7bdd78d2-4aa4-42f6-a8cd-f8f785c0e0c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] NovoSeven is indicated for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in the following patient groups:in patients with congenital haemophilia with inhibitors to coagulation factors VIII or IX > 5 Bethesda units (BU);in patients with congenital haemophilia who are expected to have a high anamnestic response to factor-VIII or factor-IX administration;in patients with acquired haemophilia;in patients with congenital factor-VII deficiency;in patients with Glanzmann's thrombasthenia with antibodies to platelet glycoprotein (GP) IIb-IIIa and / or human leucocyte antigens (HLA), and with past or present refractoriness to platelet transfusions.in patients with Glanzmann’s thrombasthenia with past or present refractoriness to platelet transfusions, or where platelets are not readily available.|[PMDA] Drugs with a new additional indication and a new dosage for inhibition of bleeding tendency in patients with Glanzmann thrombasthenia with alloantibodies against platelet, and with past or present refractoriness to platelet transfusions. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:0ae7a67d-f348-4cec-bdaa-1d2c8f9ee1fa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7459 biolink:treats HP:0002791 PMID:41385096 "[{""id"":""uuid:ecb34f6f-8780-4db6-b3a8-832ad401e7d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:2cfa2b16-e647-44de-820c-4ab280951fec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Nyxoid is intended for immediate administration as emergency therapy for known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression in both non-medical and healthcare settings.Nyxoid is indicated in adults and adolescents aged 14 years and over.Nyxoid is not a substitute for emergency medical care. uuid:91a8fdc2-cb4f-4d1a-ac5f-9e76ee84b082 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85157 biolink:treats MONDO:0004992 PMID:41385096 "[{""id"":""uuid:7dab1cd2-4e61-4485-9d6d-d1b43fcaa3d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:ece012ad-92c3-4c76-95a8-68bf7c3333aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Aloxi is indicated in adults for:the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy,the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.Aloxi is indicated in paediatric patients 1 month of age and older for:the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy and prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy. uuid:c510599c-02f1-4eb6-bcac-e47d3b7887cc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1720952 biolink:treats MONDO:0005002 PMID:41385096 "[{""id"":""uuid:563c2476-dee5-4083-8d3e-075e0a8407b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:0c16d2b9-2ab0-418e-a9e7-955ca99b21c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ulunar-breezhaler""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Ulunar Breezhaler is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). uuid:2d208c7b-19f0-415a-b20e-35232cc42efe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31638 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:a073caf8-852a-4169-8cab-c98c59704d91"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5b901ecd-e23d-4dfe-a701-0ef95393018a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/fulvestrant-mylan""]},{""id"":""uuid:3274051a-5d66-43d5-b487-f7b330f850f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Fulvestrant is indicated for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women:not previously treated with endocrine therapy, orwith disease relapse on or after adjuvant anti-estrogen therapy, or disease progression on antiestrogen therapy.|[PMDA] A drug with a new active ingredient indicated for the treatment of postmenopausal breast cancer. uuid:17735cd7-d2de-4c97-a8c6-406359554aa4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:601027 biolink:treats MONDO:0001134 PMID:41385096 "[{""id"":""uuid:b108b2ed-da4e-450b-8025-891e194ea74f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:ea1959c5-1c82-462f-af0e-9e1003757a35"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/rasilez""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of essential hypertension. uuid:3f70a3fc-fb96-46d2-bcf4-50070fc8b12d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134966 biolink:treats MONDO:0016532 PMID:41385096 "[{""id"":""uuid:5a9c43ed-1279-4d58-be94-d4f1768baa35"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f3e0df8f-0f83-4493-ab95-d623fd7baf27"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/inovelon""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Inovelon is indicated as adjunctive therapy in the treatment of seizures associated with Lennox Gastaut syndrome in patients 4 years of age and older. uuid:4dee0451-340c-47e7-9851-e4d6aa24a7bd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:BTY153760O biolink:treats MONDO:0005083 PMID:41385096 "[{""id"":""uuid:99ada221-ab81-4265-a83c-0027d33452ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a75750a4-90d0-4d03-ba1c-5a2d658c08a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/taltz""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Plaque psoriasisTaltz is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.Psoriatic arthritisTaltz, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drug (DMARD) therapies. uuid:4c31db6b-b0d5-437f-94fc-a1b31f4dbe0c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6916 biolink:treats MONDO:0054869 PMID:41385096 "[{""id"":""uuid:5a2ef5d0-1153-46d3-b375-348008a0d942"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:b8854959-8d67-420c-8eed-caa2fb622b1a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Namuscla is indicated for the symptomatic treatment of myotonia in adult patients with non-dystrophic myotonic disorders. uuid:94c41e76-8312-4fcc-aa54-665d2a94afac biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32120 biolink:treats MONDO:0016543 PMID:41385096 "[{""id"":""uuid:99afd405-6ae8-485f-80f6-a2bef27bef4f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:90f9344d-b224-4c9b-a7b8-5394a7d86a63"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Sapropterin Dipharma is indicated for the treatment of hyperphenylalaninaemia (HPA) in adults and paediatric patients of all ages with phenylketonuria (PKU) who have been shown to be responsive to such treatment.Sapropterin Dipharma is also indicated for the treatment of hyperphenylalaninaemia (HPA) in adults and paediatric patients of all ages with tetrahydrobiopterin (BH4) deficiency who have been shown to be responsive to such treatment. uuid:5f5b20cc-674a-4305-8722-56936a5a9d90 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32120 biolink:treats MONDO:0009861 PMID:41385096 "[{""id"":""uuid:f0651d21-44d5-4d78-bbc7-2913ec81c4ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:81f4ca50-84e8-42fe-8b4b-38f8c5c204f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Sapropterin Dipharma is indicated for the treatment of hyperphenylalaninaemia (HPA) in adults and paediatric patients of all ages with phenylketonuria (PKU) who have been shown to be responsive to such treatment.Sapropterin Dipharma is also indicated for the treatment of hyperphenylalaninaemia (HPA) in adults and paediatric patients of all ages with tetrahydrobiopterin (BH4) deficiency who have been shown to be responsive to such treatment. uuid:d99105dd-e3d2-4a3e-80c6-ebb1633765a8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1741730 biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:f6f1cec5-a30b-4bd1-b0dd-296b6eeb5d80"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:7c5262f8-a9b4-472f-9436-bbe7769d3b00"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/odefsey""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus 1 (HIV 1) without known mutations associated with resistance to the non nucleoside reverse transcriptase inhibitor (NNRTI) class, tenofovir or emtricitabine and with a viral load ≤ 100,000 HIV 1 RNA copies/mL., uuid:1556f7e9-8312-485a-b773-03cd8f55294f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:51450 biolink:treats MONDO:0019340 PMID:41385096 "[{""id"":""uuid:e1cfa027-918b-4d2a-b15f-7b4837e8c136"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:4cd0c9ab-0c07-432b-9ebd-fdb4b00e5abf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of pulmonary arterial hypertension (PAH) to improve exercise capacity and symptoms in patients with WHO functional class III.Efficacy has been shown in:, , , Primary (idiopathic and familial) PAH;, PAH secondary to scleroderma without significant interstitial pulmonary disease;, PAH associated with congenital systemic-to-pulmonary shunts and Eisenmenger's physiology., , , Some improvements have also been shown in patients with PAH WHO functional class II., , Tracleer is also indicated to reduce the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcer disease., uuid:f7dc03b5-4d51-42ff-aecd-0e65cc45654f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:51450 biolink:treats MONDO:0005100 PMID:41385096 "[{""id"":""uuid:c3d7596a-33ae-4c7b-b11f-220ac443a52c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6e2fc0a9-53f5-49a2-8d5e-3dfd0e352428"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:2420bcb4-549f-4ecb-a3f1-a7a533ed91a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of pulmonary arterial hypertension (PAH) to improve exercise capacity and symptoms in patients with WHO functional class III.Efficacy has been shown in:, , , Primary (idiopathic and familial) PAH;, PAH secondary to scleroderma without significant interstitial pulmonary disease;, PAH associated with congenital systemic-to-pulmonary shunts and Eisenmenger's physiology., , , Some improvements have also been shown in patients with PAH WHO functional class II., , Tracleer is also indicated to reduce the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcer disease.,|[PMDA] A drug with a new additional indication for inhibiting development of digital ulcer in patients with systemic scleroderma (only for patients who currently have digital ulcers or have a history of digital ulcer.) [Orphan drug] uuid:af64dbc2-820b-49a6-b3f0-21e615a1c8a5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:51450 biolink:treats MONDO:0019944 PMID:41385096 "[{""id"":""uuid:da3f6f91-6ad9-4a37-8741-d69fbbc53c01"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:247763cc-fe64-4f62-a881-cadd3d90fee9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of pulmonary arterial hypertension (PAH) to improve exercise capacity and symptoms in patients with WHO functional class III.Efficacy has been shown in:, , , Primary (idiopathic and familial) PAH;, PAH secondary to scleroderma without significant interstitial pulmonary disease;, PAH associated with congenital systemic-to-pulmonary shunts and Eisenmenger's physiology., , , Some improvements have also been shown in patients with PAH WHO functional class II., , Tracleer is also indicated to reduce the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcer disease., uuid:1e758624-6430-4789-9dcb-f24cfe8219bf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C1529800 biolink:treats MONDO:0015924 PMID:41385096 "[{""id"":""uuid:1a4bf080-02ce-4898-8125-af16f0fd2fa1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:5513c70e-8fdc-47b6-a07d-bde63bc7517d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of pulmonary arterial hypertension (PAH) to improve exercise capacity and symptoms in patients with World Health Organization (WHO) functional class III. Efficacy has been shown in:primary (idiopathic and familial) PAH;PAH secondary to scleroderma without significant interstitial pulmonary disease;PAH associated with congenital systemic-to-pulmonary shunts and Eisenmenger’s physiology.Some improvements have also been shown in patients with PAH WHO functional class II.Stayveer is also indicated to reduce the number of new digital ulcers in patients with systemic sclerosis and ongoing digital-ulcer disease. uuid:87555535-fee7-449e-96cf-8bfaf7bf4e63 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C1529800 biolink:treats MONDO:0019340 PMID:41385096 "[{""id"":""uuid:71539375-e34b-44bc-96ae-a16d619cb70d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:90958bbc-ed52-4168-a937-a9b5cb51f1d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of pulmonary arterial hypertension (PAH) to improve exercise capacity and symptoms in patients with World Health Organization (WHO) functional class III. Efficacy has been shown in:primary (idiopathic and familial) PAH;PAH secondary to scleroderma without significant interstitial pulmonary disease;PAH associated with congenital systemic-to-pulmonary shunts and Eisenmenger’s physiology.Some improvements have also been shown in patients with PAH WHO functional class II.Stayveer is also indicated to reduce the number of new digital ulcers in patients with systemic sclerosis and ongoing digital-ulcer disease. uuid:f3360b64-5892-4a47-a0c0-3fc53b105614 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C1529800 biolink:treats MONDO:0005100 PMID:41385096 "[{""id"":""uuid:fc54e83f-f60f-49a6-b1ca-909a6657fcaf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:e1ae4238-bcab-4dad-bbd0-9883241d5c90"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of pulmonary arterial hypertension (PAH) to improve exercise capacity and symptoms in patients with World Health Organization (WHO) functional class III. Efficacy has been shown in:primary (idiopathic and familial) PAH;PAH secondary to scleroderma without significant interstitial pulmonary disease;PAH associated with congenital systemic-to-pulmonary shunts and Eisenmenger’s physiology.Some improvements have also been shown in patients with PAH WHO functional class II.Stayveer is also indicated to reduce the number of new digital ulcers in patients with systemic sclerosis and ongoing digital-ulcer disease. uuid:6d665c79-314c-4542-b88d-3ec17ead4f37 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8499 biolink:treats MONDO:0016223 PMID:41385096 "[{""id"":""uuid:12c6c7b4-e9fc-457d-9a4a-a57c180bedd4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:ecaa579f-3bd4-439f-b129-b30de1dd95c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Hemangiol is indicated in the treatment of proliferating infantile haemangioma requiring systemic therapy:, , , Life- or function-threatening haemangioma,, Ulcerated haemangioma with pain and/or lack of response to simple wound care measures,, Haemangioma with a risk of permanent scars or disfigurement., , , It is to be initiated in infants aged 5 weeks to 5 months., uuid:91922ac6-2ebc-42bf-ad44-81746449e7a4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8499 biolink:treats MONDO:0006500 PMID:41385096 "[{""id"":""uuid:bbe7b427-44ce-4fe2-9e28-b87db0d2c207"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:297a46af-a936-49fb-a02b-266989605a31"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Hemangiol is indicated in the treatment of proliferating infantile haemangioma requiring systemic therapy:, , , Life- or function-threatening haemangioma,, Ulcerated haemangioma with pain and/or lack of response to simple wound care measures,, Haemangioma with a risk of permanent scars or disfigurement., , , It is to be initiated in infants aged 5 weeks to 5 months., uuid:6da6dbb0-f93d-4ac7-b7fb-f2ecdf67fc58 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:44232548 biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:1534893e-f47a-4150-b666-f25ddb8df50c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:2e9a725d-d62f-459b-9561-45005e0a93b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/stribild""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of human immunodeficiency virus 1 (HIV 1) infection in adults aged 18 years and over who are antiretroviral treatment-naïve or are infected with HIV 1 without known mutations associated with resistance to any of the three antiretroviral agents in Stribild. uuid:2aa00a0f-4f5d-4e00-81d7-c6aef32261dc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:16213489 biolink:treats MONDO:0004247 PMID:41385096 "[{""id"":""uuid:f46891d2-ca7c-4163-9683-aaab803d9fdf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:99a80d8e-7d7a-4337-b289-9e2a8b746f05"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Helicobacter Test INFAI may be used for in vivo diagnosis of gastroduodenal Helicobacter pylori infection in:adults;adolescents, who are likely to have peptic ulcer disease.Helicobacter Test INFAI for children aged three to 11 years may be used for in vivo diagnosis of gastrduodenal Helicobacter pylori infection:for the evaluation of the success of eradication treatment, or;when invasive tests cannot be performed, or;when there are discordant results arising from invasive tests.This medicinal product is for diagnostic use only. uuid:264a2a57-18b4-4b68-b0a0-c19efb520e54 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:231693 biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:48dc1927-8efd-4d61-9e3d-611f332cb980"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f4deb310-c5be-496d-9352-9c863ad691d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (NSCLC) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy. UNII:TY34L4F9OZ uuid:29275ef6-53f6-4078-b48b-96a37216d2d0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:981TME683S biolink:treats MONDO:0009891 PMID:41385096 "[{""id"":""uuid:7da66695-53a0-4ee3-9f90-4508d2e43a0a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e90a3fa4-f0c0-4256-b47f-b1fb99fd6473"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/besremi""]},{""id"":""uuid:685dc89b-b470-4cca-9756-91f60aead9a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Besremi is indicated as monotherapy in adults for the treatment of polycythaemia vera without symptomatic splenomegaly.|[PMDA] Drugs with a new active ingredient indicated for the treatment of polycythaemia vera (use only when conventional therapies are not sufficiently effective or inappropriate). uuid:23911766-7a22-4088-b2da-2003b95b62e2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7D96IR0PPM biolink:treats MONDO:0004969 PMID:41385096 "[{""id"":""uuid:92586a1d-01a3-4779-9638-012cf2070c72"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:3345d9d7-7021-4757-9f8a-65f9ef0e4f15"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/oncaspar""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Oncaspar is indicated as a component of antineoplastic combination therapy in acute lymphoblastic leukaemia (ALL) in paediatric patients from birth to 18 years, and adult patients. uuid:98562165-1a65-469b-be80-8e2d00fe0f6f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:WGD229O42W biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:54de5a85-8d1e-40e2-bdca-57b19ca6addb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:3ef888e2-4e15-42f8-8da1-9b5ccd9d6b95"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/metalyse""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Metalyse is indicated for the thrombolytic treatment of suspected myocardial infarction with persistent ST elevation or recent left-bundle-branch block within six hours after the onset of acute-myocardial-infarction symptoms., uuid:71b07e7f-936c-4816-8749-35fd62a36da2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:FYS6T7F842 biolink:treats MONDO:0018456 PMID:41385096 "[{""id"":""uuid:66192d3e-d770-44da-a170-92e742fcbacb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d4ff0376-bc4b-4f00-8cae-91a85a15757a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/hulio""]},{""id"":""uuid:e0eb240f-ff70-445d-bb59-1156ee9f1adf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Rheumatoid arthritis , , Amgevita in combination with methotrexate, is indicated for:, , , the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate., the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate., , , Amgevita can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate., , Amgevita reduces the rate of progression of joint damage as measured by x-ray and improves physical function, when given in combination with methotrexate., , Juvenile idiopathic arthritis, , Polyarticular juvenile idiopathic arthritis, , Amgevita in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). Amgevita can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate (for the efficacy in monotherapy see section 5.1). Adalimumab has not been studied in patients aged less than 2 years., , Enthesitis-related arthritis, , Amgevita is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy (see section 5.1)., , Axial spondyloarthritis, , Ankylosing spondylitis (AS), , Amgevita is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy., , Axial spondyloarthritis without radiographic evidence of AS, , Amgevita is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of AS but with objective signs of inflammation by elevated CRP and/or MRI, who have had an inadequate response to, or are intolerant to non-steroidal anti-inflammatory drugs., , Psoriatic arthritis, , Amgevita is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate. Amgevita reduces the rate of progression of peripheral joint damage as measured by x-ray in patients with polyarticular symmetrical subtypes of the disease (see section 5.1) and improves physical function., , Psoriasis, , Amgevita is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy., , Paediatric plaque psoriasis, , Amgevita is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies., , Hidradenitis suppurativa (HS), , Amgevita is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults and adolescents from 12 years of age with an inadequate response to conventional systemic HS therapy (see sections 5.1 and 5.2)., , Crohn’s disease, , Amgevita is indicated for treatment of moderately to severely active Crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies., , Paediatric Crohn's disease, , Amgevita is indicated for the treatment of moderately to severely active Crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or have contraindications for such therapies., , Ulcerative colitis, , Amgevita is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies., , Uveitis, , Amgevita is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate., , Paediatric uveitis, , Amgevita is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.,|[PMDA] Follow-on biologics indicated for the treatment of rheumatoid arthritis (including the prevention of structural joint damage), and the treatment of the following diseases in patients who have not responded sufficiently to conventional treatments; polyarticular- course juvenile idiopathic arthritis, plaque psoriasis, psoriatic arthritis, pustular psoriasis, ankylosing spondylitis and intestinal Behcet’s disease; and the remission induction therapy and maintenance therapy for moderate to severe active Crohn's disease (for use only in patients who have not sufficiently responded to conventional therapies). uuid:6f96786c-a244-4cad-85d2-a3429f4c510f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6954 biolink:treats MONDO:0006639 PMID:41385096 "[{""id"":""uuid:3ceffa09-6a7c-4193-8d8b-919db9cc4138"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:aa48a3fc-0d72-4c11-9de3-6aec87296c76"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/lysodren""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Symptomatic treatment of advanced (unresectable, metastatic or relapsed) adrenal cortical carcinoma. The effect of Lysodren on non-functional adrenal cortical carcinoma is not established. uuid:6993a5e0-d50c-47d9-9da8-59ef836ccf80 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90841 biolink:treats MONDO:0005010 PMID:41385096 "[{""id"":""uuid:690a35d5-7226-4092-b702-8be0f7d8e37f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:2f99a860-3797-4c29-8225-67b5124deb09"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/kengrexal""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Kengrexal, co-administered with acetylsalicylic acid (ASA), is indicated for the reduction of thrombotic cardiovascular events in adult patients with coronary artery disease undergoing percutaneous coronary intervention (PCI) who have not received an oral P2Y12 inhibitor prior to the PCI procedure and in whom oral therapy with P2Y12 inhibitors is not feasible or desirable. uuid:af72c982-475c-43e0-83de-c6706cd3caea biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63612 biolink:treats MONDO:0004963 PMID:41385096 "[{""id"":""uuid:1d72ccb2-d893-45fb-9db0-f90e0f223746"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:55a9d399-a15a-4f41-b0fc-d65d43bc7c9b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/atriance""]},{""id"":""uuid:46482db3-d935-4771-86d5-bfd58b0eaf44"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Nelarabine is indicated for the treatment of patients with T-cell acute lymphoblastic leukaemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens., , Due to the small patient populations in these disease settings, the information to support these indications is based on limited data.,|[PMDA] A drug containing a new active ingredient indicated for the treatment of relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. [Orphan drug] uuid:bb79fc87-3772-439e-8477-ea81ed677cca biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5938 biolink:treats MONDO:0002562 PMID:41385096 "[{""id"":""uuid:48a96210-83fa-4b10-8c61-d39fabc5ba24"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f0d38b3d-abbc-43a9-981f-d4889a52e369"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/betaferon""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Extavia is indicated for the treatment of:patients with a single demyelinating event with an active inflammatory process, if it is severe enough to warrant treatment with intravenous corticosteroids, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite multiple sclerosis;patients with relapsing-remitting multiple sclerosis and two or more relapses within the last two years;patients with secondary progressive multiple sclerosis with active disease, evidenced by relapses. uuid:c03f3369-e5c6-446f-9ee2-e0b3df7fa38e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:172944 biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:b8f2d3ac-893e-4f78-879f-94ce026689ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:78353cbc-66d2-4f7a-9c80-1343abd793d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/apretude""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Vocabria tablets are indicated in combination with rilpivirine tablets for the short-term treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA uuid:ab3732bc-df73-450f-9050-c58ba1a336f8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135920 biolink:treats UMLS:C0150045 PMID:41385096 "[{""id"":""uuid:d7327e9e-57ce-40cd-a727-469fdbf1f839"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a1bbedb1-99d6-4176-a709-9387597008bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of the symptoms (increased urinary frequency and / or urgency and / or urgency incontinence) that may occur in patients with overactive-bladder syndrome. uuid:b947c9ce-04c6-4054-b082-932ad672b0dc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6ZA31Y954Z biolink:treats MONDO:0005083 PMID:41385096 "[{""id"":""uuid:c1f114bf-5e60-4a9c-b7cf-d638e4b2173b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a914c7ce-afd8-4376-8283-46704e2ffec6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/kyntheum""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Kyntheum is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy. uuid:29f93496-0880-4abc-9cd3-a4e03d86cae9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:GB4I2JI8UI biolink:treats MONDO:0001824 PMID:41385096 "[{""id"":""uuid:c76dee3b-5d17-423b-9270-2b240fb6941b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:abe33340-5bd6-43ce-93bc-b95d69ef80b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy. uuid:2de2a9a1-cd19-4198-8f54-f9a5c7ad160d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2S9ZZM9Q9V biolink:treats MONDO:0018364 PMID:41385096 "[{""id"":""uuid:fddc25da-9295-49f9-837c-14bf454ec324"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:1876c4e6-175b-48c1-ad47-ea6ee444dc9b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/abevmy""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Mvasi in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum.Mvasi in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. For further information as to human epidermal growth factor receptor 2 (HER2) status, please refer to section 5.1.Mvasi, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology.Mvasi in combination with interferon alfa-2a is indicated for first-line treatment of adult patients with advanced and/or metastatic renal cell cancer.Mvasi, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (International Federation of Gynecology and Obstetrics (FIGO) stages IIIB, IIIC and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer.Mvasi, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor-targeted agents.Mvasi in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor-targeted agents.Mvasi, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix. uuid:d3ac141d-c10f-48a6-8427-6b51a1b5324e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2S9ZZM9Q9V biolink:treats MONDO:0006206 PMID:41385096 "[{""id"":""uuid:cbd9f6c0-ee6c-4b91-aba0-0135cd3b126f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:cf650acc-172e-49a5-b279-b5c01289b182"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/abevmy""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Mvasi in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum.Mvasi in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. For further information as to human epidermal growth factor receptor 2 (HER2) status, please refer to section 5.1.Mvasi, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology.Mvasi in combination with interferon alfa-2a is indicated for first-line treatment of adult patients with advanced and/or metastatic renal cell cancer.Mvasi, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (International Federation of Gynecology and Obstetrics (FIGO) stages IIIB, IIIC and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer.Mvasi, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor-targeted agents.Mvasi in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor-targeted agents.Mvasi, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix. uuid:b7edf37f-7a81-43ca-8e2e-310e4d72d581 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63717 biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:55d71291-6edb-45c2-aeba-87d42e8b302b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:ca97aa4d-c1be-432b-a727-247cf078dcee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] HIV 1 infectionViread 123 mg film coated tablets are indicated in combination with other antiretroviral medicinal products for the treatment of HIV 1 infected paediatric patients, with NRTI resistance or toxicities precluding the use of first line agents, aged 6 to < 12 years who weigh from 17 kg to less than 22 kg.The choice of Viread to treat antiretroviral experienced patients with HIV 1 infection should be based on individual viral resistance testing and/or treatment history of patients.Hepatitis B infectionViread 123 mg film coated tablets are indicated for the treatment of chronic hepatitis B in paediatric patients aged 6 to < 12 years who weigh from 17 kg to less than 22 kg, withcompensated liver disease and evidence of immune active disease, i.e. active viral replication and persistently elevated serum ALT levels, or histological evidence of moderate to severe inflammation and/or fibrosis. With respect to the decision to initiate treatment in paediatric patients, see sections 4.2, 4.4, 4.8 and 5.1.HIV 1 infectionViread 163 mg film coated tablets are indicated in combination with other antiretroviral medicinal products for the treatment of HIV 1 infected paediatric patients, with NRTI resistance or toxicities precluding the use of first line agents, aged 6 to < 12 years who weigh from 22 kg to less than 28 kg.The choice of Viread to treat antiretroviral experienced patients with HIV 1 infection should be based on individual viral resistance testing and/or treatment history of patients.Hepatitis B infectionViread 163 mg film coated tablets are indicated for the treatment of chronic hepatitis B in paediatric patients aged 6 to < 12 years who weigh from 22 kg to less than 28 kg, with:compensated liver disease and evidence of immune active disease, i.e. active viral replication and persistently elevated serum ALT levels, or histological evidence of moderate to severe inflammation and/or fibrosis. With respect to the decision to initiate treatment in paediatric patients, see sections 4.2, 4.4, 4.8 and 5.1.HIV 1 infectionViread 204 mg film coated tablets are indicated in combination with other antiretroviral medicinal products for the treatment of HIV 1 infected paediatric patients, with NRTI resistance or toxicities precluding the use of first line agents, aged 6 to < 12 years who weigh from 28 kg to less than 35 kg.The choice of Viread to treat antiretroviral experienced patients with HIV 1 infection should be based on individual viral resistance testing and/or treatment history of patients.Hepatitis B infectionViread 204 mg film coated tablets are indicated for the treatment of chronic hepatitis B in paediatric patients aged 6 to < 12 years who weigh from 28 kg to less than 35 kg, with:compensated liver disease and evidence of immune active disease, i.e. active viral replication and persistently elevated serum ALT levels or histological evidence of moderate to severe inflammation and/or fibrosis. With respect to the decision to initiate treatment in paediatric patients, see sections 4.2, 4.4, 4.8 and 5.1.HIV 1 infectionViread 245 mg film coated tablets are indicated in combination with other antiretroviral medicinal products for the treatment of HIV 1 infected adults.In adults, the demonstration of the benefit of Viread in HIV 1 infection is based on results of one study in treatment naïve patients, including patients with a high viral load (> 100,000 copies/ml) and studies in which Viread was added to stable background therapy (mainly tritherapy) in antiretroviral pre-treated patients experiencing early virological failure (< 10,000 copies/ml, with the majority of patients having < 5,000 copies/ml).Viread 245 mg film coated tablets are also indicated for the treatment of HIV 1 infected adolescents, with NRTI resistance or toxicities precluding the use of first line agents, aged 12 to < 18 years.The choice of Viread to treat antiretroviral experienced patients with HIV 1 infection should be based on individual viral resistance testing and/or treatment history of patients.Hepatitis B infectionViread 245 mg film coated tablets are indicated for the treatment of chronic hepatitis B in adults with:compensated liver disease, with evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active inflammation and/or fibrosis (see section 5.1).evidence of lamivudine resistant hepatitis B virus (see sections 4.8 and 5.1).decompensated liver disease (see sections 4.4, 4.8 and 5.1).Viread 245 mg film coated tablets are indicated for the treatment of chronic hepatitis B in adolescents 12 to < 18 years of age with:compensated liver disease and evidence of immune active disease, i.e. active viral replication and persistently elevated serum ALT levels, or histological evidence of moderate to severe inflammation and/or fibrosis. With respect to the decision to initiate treatment in paediatric patients, see sections 4.2, 4.4, 4.8 and 5.1.HIV 1 infectionViread 33 mg/g granules are indicated in combination with other antiretroviral medicinal products for the treatment of HIV 1 infected paediatric patients, with NRTI resistance or toxicities precluding the use of first line agents, from 2 to < 6 years of age, and above 6 years of age for whom a solid dosage form is not appropriate.Viread 33 mg/g granules are also indicated in combination with other antiretroviral medicinal products for the treatment of HIV 1 infected adults for whom a solid dosage form is not appropriate.In adults, the demonstration of the benefit of Viread in HIV 1 infection is based on results of one study in treatment naïve patients, including patients with a high viral load (> 100,000 copies/ml) and studies in which Viread was added to stable background therapy (mainly tritherapy) in antiretroviral pre-treated patients experiencing early virological failure (< 10,000 copies/ml, with the majority of patients having < 5,000 copies/ml).The choice of Viread to treat antiretroviral experienced patients with HIV 1 infection should be based on individual viral resistance testing and/or treatment history of patients.Hepatitis B infectionViread 33 mg/g granules are indicated for the treatment of chronic hepatitis B in adults for whom a solid dosage form is not appropriate with:compensated liver disease, with evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active inflammation and/or fibrosis (see section 5.1).evidence of lamivudine resistant hepatitis B virus (see sections 4.8 and 5.1).decompensated liver disease (see sections 4.4, 4.8 and 5.1).Viread 33 mg/g granules are also indicated for the treatment of chronic hepatitis B in paediatric patients2 to < 18 years of age for whom a solid dosage form is not appropriate with:compensated liver disease and evidence of immune active disease, i.e. active viral replication, and persistently elevated serum ALT levels, or histological evidence of moderate to severe inflammation and/or fibrosis. With respect to the decision to initiate treatment in paediatric patients, see sections 4.2, 4.4, 4.8 and 5.1. uuid:5db824d7-f920-4398-a268-24311356311f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats MONDO:0009061 PMID:41385096 "[{""id"":""uuid:9a31dfbe-fb18-4bc3-b671-669f0cde48f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:57096158-1adc-4a22-9da3-2805843b844e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/quinsair""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Quinsair is indicated for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.Consideration should be given to official guidance on the appropriate use of antibacterial agents. uuid:118279b3-5064-4f51-a78c-98d247aa1e08 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68590 biolink:treats MONDO:0000705 PMID:41385096 "[{""id"":""uuid:66d0cc3f-1f71-4f8d-bfe4-514642399062"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:831dbead-1ee1-4b1b-95bd-e2e68b38d76a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/dificlir""]},{""id"":""uuid:e0d9d248-5e16-4d2c-8aa9-88b0f2b4c8c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Dificlir film-coated tablets is indicated for the treatment of Clostridioides difficile infections (CDI) also known as C. difficile-associated diarrhoea (CDAD) in adult and paediatric patients with a body weight of at least 12.5 kg.Consideration should be given to official guidelines on the appropriate use of antibacterial agents.Dificlir granules for oral suspension is indicated for the treatment of Clostridioides difficile infections (CDI) also known as C. difficile-associated diarrhoea (CDAD) in adults and paediatric patients from birth to < 18 years of age.Consideration should be given to official guidelines on the appropriate use of antibacterial agents.|[PMDA] A drug with a new active ingredient indicated for the treatment of infectious enteritis (including pseudomembranous colitis) caused by C. difficile . uuid:43c7e184-b9e9-417c-955e-f1a53a63c1af biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68590 biolink:treats UMLS:C0235952 PMID:41385096 "[{""id"":""uuid:5605c04c-03c4-464f-80e6-a84c643315f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:03f1e855-2085-4cc5-903b-75614cc66d2d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/dificlir""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Dificlir film-coated tablets is indicated for the treatment of Clostridioides difficile infections (CDI) also known as C. difficile-associated diarrhoea (CDAD) in adult and paediatric patients with a body weight of at least 12.5 kg.Consideration should be given to official guidelines on the appropriate use of antibacterial agents.Dificlir granules for oral suspension is indicated for the treatment of Clostridioides difficile infections (CDI) also known as C. difficile-associated diarrhoea (CDAD) in adults and paediatric patients from birth to < 18 years of age.Consideration should be given to official guidelines on the appropriate use of antibacterial agents. uuid:03b708d0-bc6b-48bd-b32d-ba1a744dd983 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:15C2VL427D biolink:treats MONDO:0005575 PMID:41385096 "[{""id"":""uuid:55854459-4733-4122-9822-a51cad41266e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4f656cc5-033a-411d-96d8-e2ee5e7229d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/yesafili""]},{""id"":""uuid:81b79acf-bbc3-470f-b43d-8496a5181bb0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of metastatic colorectal cancer (MCRC).|[PMDA] Drugs with a new active ingredient indicated for the treatment of unresectable advanced or recurrent colorectal cancer. uuid:f42fba0e-a6e7-454d-a9a4-65a14876e255 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1421448 biolink:treats MONDO:0005338 PMID:41385096 "[{""id"":""uuid:2a593b72-60e5-414d-94f6-f4cfcdd87455"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:c650c5df-b01f-48a5-8e15-cc6561150f62"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/simbrinza""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Decrease of elevated intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension for whom monotherapy provides insufficient IOP reduction. uuid:bb0d6a5c-89de-48d2-a08f-909be7f16439 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1421448 biolink:treats MONDO:0006875 PMID:41385096 "[{""id"":""uuid:1688eca1-30fc-425f-a9a1-341357f53b09"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:5fc1e030-53b9-43cb-a050-24fccbd2648a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/simbrinza""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Decrease of elevated intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension for whom monotherapy provides insufficient IOP reduction. uuid:315c2ff0-0180-4e31-9925-10c11ee5d66d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134703 biolink:treats MONDO:0008315 PMID:41385096 "[{""id"":""uuid:63e0c95a-fc30-4002-a6e6-7ffd9ce86366"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:98dacfb7-1ab6-4896-828e-ed87e9e3c925"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] This medicinal product is for diagnostic use only.Axumin is indicated for Positron Emission Tomography (PET) imaging to detect recurrence of prostate cancer in adult men with a suspected recurrence based on elevated blood prostate specific antigen (PSA) levels after primary curative treatment. uuid:c68c5c1a-9941-4028-bfd7-2d2b45f5117b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB13924 biolink:treats MONDO:0005609 PMID:41385096 "[{""id"":""uuid:9b2c3184-833a-421f-af08-aba9f8adbbe7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:6e4c1d42-4af5-41c6-b18a-a83b9aca3323"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Shingrix is indicated for prevention of herpes zoster (HZ) and post-herpetic neuralgia (PHN), in:adults 50 years of age or older;adults 18 years of age or older at increased risk of HZ.The use of Shingrix should be in accordance with official recommendations. uuid:5efd0231-b248-4b5d-acf0-5c1163f76a26 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB13924 biolink:treats MONDO:0041052 PMID:41385096 "[{""id"":""uuid:d679b3e4-4cf6-4844-aad0-351f3bf88c51"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:8d932c34-08f6-4499-8095-3fc17b3dc520"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Shingrix is indicated for prevention of herpes zoster (HZ) and post-herpetic neuralgia (PHN), in:adults 50 years of age or older;adults 18 years of age or older at increased risk of HZ.The use of Shingrix should be in accordance with official recommendations. uuid:d2efe989-ee7e-428a-8afb-aca56379789c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41500 biolink:treats MONDO:0004739 PMID:41385096 "[{""id"":""uuid:2a38b5b8-90d3-4f37-951b-37a8c1e12095"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f5b93e46-4028-47b7-afed-f651eb8e4e35"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ammonaps""]},{""id"":""uuid:13ee7078-cfc1-4dd4-9d4d-fe3f7cf68fbc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Ammonaps is indicated as adjunctive therapy in the chronic management of urea cycle disorders, involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase orargininosuccinate synthetase.It is indicated in all patients with neonatal-onset presentation (complete enzyme deficiencies, presenting within the first 28 days of life). It is also indicated in patients with late-onset disease(partial enzyme deficiencies, presenting after the first month of life) who have a history of hyperammonaemic encephalopathy.|[PMDA] Drugs with a new active ingredient indicated for the treatment of urea cycle disorder. [Orphan drug] uuid:e018071a-a0a8-436f-b4bb-5eb027a48a87 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41500 biolink:treats MONDO:0009376 PMID:41385096 "[{""id"":""uuid:085f630a-6a3e-46ce-b0e8-9bf7aa508c6f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:7d7b3c69-e711-4e9e-aa4f-22ee77ad68a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ammonaps""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Ammonaps is indicated as adjunctive therapy in the chronic management of urea cycle disorders, involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase orargininosuccinate synthetase.It is indicated in all patients with neonatal-onset presentation (complete enzyme deficiencies, presenting within the first 28 days of life). It is also indicated in patients with late-onset disease(partial enzyme deficiencies, presenting after the first month of life) who have a history of hyperammonaemic encephalopathy. uuid:2e0b050f-de26-483f-8b68-28c008d7f42e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41500 biolink:treats MONDO:0010703 PMID:41385096 "[{""id"":""uuid:23167791-2ba0-40b5-909f-42c1811eb233"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f983f367-50a8-4833-9cd7-5cc055231f3f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ammonaps""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Ammonaps is indicated as adjunctive therapy in the chronic management of urea cycle disorders, involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase orargininosuccinate synthetase.It is indicated in all patients with neonatal-onset presentation (complete enzyme deficiencies, presenting within the first 28 days of life). It is also indicated in patients with late-onset disease(partial enzyme deficiencies, presenting after the first month of life) who have a history of hyperammonaemic encephalopathy. uuid:cfe857f3-5dda-4455-b875-b74a9739a19f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135552 biolink:treats MONDO:0002203 PMID:41385096 "[{""id"":""uuid:5aa693ea-e16a-449c-a82d-7c44e338ec63"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:399a8d84-5b0e-4e1d-809c-f649a6195bcd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Resolor is indicated for symptomatic treatment of chronic constipation in adults in whom laxatives fail to provide adequate relief. uuid:1b1ab79e-22aa-47e0-9384-5049143699e7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:29Z5DNL48C biolink:treats MONDO:0016595 PMID:41385096 "[{""id"":""uuid:dd25f350-0868-49e9-9dd6-cfe2ad52393e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:ebbd245a-3745-42e5-9051-cde65baf6b11"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Obiltoxaximab SFL is indicated in combination with appropriate antibacterial drugs in all age groups for treatment of inhalational anthrax due to Bacillus anthracis (see section 5.1).Obiltoxaximab SFL is indicated in all age groups for post-exposure prophylaxis of inhalational anthrax when alternative therapies are not appropriate or are not available (see section 5.1). uuid:e374237c-db3a-442d-82e8-7faf61c92cb1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:07730V90L6 biolink:treats MONDO:0005191 PMID:41385096 "[{""id"":""uuid:43331f56-bd32-4202-a1e5-5c77cb851404"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:bfa150cd-3f25-4c53-b9a6-95c1a23805a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/imlygic""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Imlygic is indicated for the treatment of adults with unresectable melanoma that is regionally or distantly metastatic (Stage IIIB, IIIC and IVM1a) with no bone, brain, lung or other visceral disease. uuid:14f7c32a-be22-4f46-8fa1-e4542e166400 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:07730V90L6 biolink:treats MONDO:0005012 PMID:41385096 "[{""id"":""uuid:f7dffa66-398a-4735-bfe2-865aeef19006"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:64224793-003f-460b-bd9f-03de9f04ffe1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/imlygic""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Imlygic is indicated for the treatment of adults with unresectable melanoma that is regionally or distantly metastatic (Stage IIIB, IIIC and IVM1a) with no bone, brain, lung or other visceral disease. uuid:7b8d4636-3ed4-451c-bbe1-ec6ed1a5f6c8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:538316W9ZU biolink:treats MONDO:0005246 PMID:41385096 "[{""id"":""uuid:a87e6e73-18b4-4b8b-b132-42196aa1e6ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:8d160334-76fe-4504-8d6b-d3ab45a2957e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/scintimun""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] This medicinal product is for diagnostic use only and the approved indication is scintigraphic imaging, in conjunction with other appropriate imaging modalities, for determining the location of inflammation/infection in peripheral bone in adults with suspected osteomyelitis. Scintimun should not be used for the diagnosis of diabetic foot infection. uuid:dcb0a0de-abd9-4b87-bad8-30e53f63cc2c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:86278373 biolink:treats MONDO:0006047 PMID:41385096 "[{""id"":""uuid:113a4fca-bddf-45d6-9196-8cfe23b9f43b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:be83f540-4810-44bf-87d5-6f8f719cec75"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of metastatic adenocarcinoma of the pancreas, in combination with 5 fluorouracil (5 FU) and leucovorin (LV), in adult patients who have progressed following gemcitabine based therapy. uuid:8b1c746c-b287-4a77-9cef-cf6aaacb51b1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:177736 biolink:treats MONDO:0100347 PMID:41385096 "[{""id"":""uuid:b92746ee-c965-40ad-886c-884349f59a75"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:147bd355-7714-4d96-858f-780ec298811e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Xermelo is indicated for the treatment of carcinoid syndrome diarrhoea in combination with somatostatin analogue (SSA) therapy in adults inadequately controlled by SSA therapy. uuid:b22c4d1b-bcb7-4c5c-b278-27bc2aa4c56b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C5818382 biolink:treats MONDO:0005300 PMID:41385096 "[{""id"":""uuid:2f1c5962-5093-448e-9e3e-dea4ce46b247"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:59d667da-708a-489a-8722-160801e3ed70"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/velphoro""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Velphoro is indicated for the control of serum phosphorus levels in adult chronic kidney disease (CKD) patients on haemodialysis (HD) or peritoneal dialysis (PD).Velphoro is indicated for the control of serum phosphorus levels in paediatric patients 2 years of age and older with CKD stages 4-5 (defined by a glomerular filtration rate uuid:c6c926cd-9ad8-40cc-beee-2d9d1eb768a2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1157755 biolink:treats MONDO:0005324 PMID:41385096 "[{""id"":""uuid:b4f9b365-28b1-41df-9c7a-11a0312660a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:22ab2cdb-6e58-4321-9a0d-795aaf52a110"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/aerinaze""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Symptomatic treatment of seasonal allergic rhinitis when accompanied by nasal congestion. uuid:24e1cc8c-8a5d-4d50-85c6-e1b9bcb840a8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71255 biolink:treats MONDO:0001866 PMID:41385096 "[{""id"":""uuid:e78dd776-bb61-431d-9bf0-99347dac8355"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:93e98421-bfb7-4e08-ae84-f6b0f407cd03"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Sycrest is indicated for the treatment of moderate to severe manic episodes associated with bipolar I disorder in adults. uuid:b488e41f-3b89-4b77-a55c-38abbe0d2ffa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71255 biolink:treats MONDO:0024612 PMID:41385096 "[{""id"":""uuid:00770f66-b0ae-4620-8e96-61f0ad6977d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:b7c1934e-c4a5-4177-97f3-f9ba78d857cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Sycrest is indicated for the treatment of moderate to severe manic episodes associated with bipolar I disorder in adults. uuid:36c9d4a6-7562-46aa-82bb-44ac032b8500 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:EEO29FZT86 biolink:treats MONDO:0005082 PMID:41385096 "[{""id"":""uuid:cb97236e-e68c-4241-b3db-b544b487f3d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:ab7f5961-7987-4c68-aac6-fc4f520669f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Tookad is indicated as monotherapy for adult patients with previously untreated, unilateral, low risk, adenocarcinoma of the prostate with a life expectancy ≥ 10 years and:Clinical stage T1c or T2a;Gleason Score ≤ 6, based on high-resolution biopsy strategies;PSA ≤ 10 ng/mL;3 positive cancer cores with a maximum cancer core length of 5 mm in any one core or 1-2 positive cancer cores with ≥ 50 % cancer involvement in any one core or a PSA density ≥ 0.15 ng/mL/cm³. uuid:9b2af4b9-83f0-4c30-938a-a0bf35f8adde biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6D848RA61B biolink:treats MONDO:0015514 PMID:41385096 "[{""id"":""uuid:de12eba9-425f-4f69-9f4d-1c6670ac688d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:0c82f077-0caa-421f-8859-96a452b130d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ngenla""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Indicated for the long-term treatment of paediatric patients with growth disturbance due to insufficient secretion of growth hormone uuid:37e6b209-3226-4cef-83bc-9af601cfeca3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68855 biolink:treats MONDO:0003233 PMID:41385096 "[{""id"":""uuid:37c9d95a-a292-4821-959c-5c555ce3ef8a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:498454a8-9748-4836-a3ad-9ac4b0985071"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] This medicinal product is for diagnostic use only.Striascan is indicated for detecting loss of functional dopaminergic neuron terminals in the striatum:In adult patients with clinically uncertain parkinsonian syndromes, for example those with early symptoms, in order to help differentiate essential tremor from parkinsonian syndromes related to idiopathic Parkinson’s disease, multiple system atrophy and progressive supranuclear palsy. Striascan is unable to discriminate between Parkinson's disease, multiple system atrophy and progressive supranuclear palsy.In adult patients, to help differentiate probable dementia with Lewy bodies from Alzheimer’s disease. Striascan is unable to discriminate between dementia with Lewy bodies and Parkinson’s disease dementia. uuid:07a01e03-18d0-4a37-b204-72829b51177d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68855 biolink:treats MONDO:0005180 PMID:41385096 "[{""id"":""uuid:378da0a9-6180-42cf-a546-48ab6c3780b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:ec8776a1-ac4e-4154-a414-a28f88852762"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] This medicinal product is for diagnostic use only.Striascan is indicated for detecting loss of functional dopaminergic neuron terminals in the striatum:In adult patients with clinically uncertain parkinsonian syndromes, for example those with early symptoms, in order to help differentiate essential tremor from parkinsonian syndromes related to idiopathic Parkinson’s disease, multiple system atrophy and progressive supranuclear palsy. Striascan is unable to discriminate between Parkinson's disease, multiple system atrophy and progressive supranuclear palsy.In adult patients, to help differentiate probable dementia with Lewy bodies from Alzheimer’s disease. Striascan is unable to discriminate between dementia with Lewy bodies and Parkinson’s disease dementia. uuid:dc39a170-ea5c-4cf1-92b0-a000a455e184 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68855 biolink:treats MONDO:0007803 PMID:41385096 "[{""id"":""uuid:5e5d00cf-4642-4e80-ac57-e56f680a58ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:2ee30603-39be-4f25-a7fc-35002d24f8e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] This medicinal product is for diagnostic use only.Striascan is indicated for detecting loss of functional dopaminergic neuron terminals in the striatum:In adult patients with clinically uncertain parkinsonian syndromes, for example those with early symptoms, in order to help differentiate essential tremor from parkinsonian syndromes related to idiopathic Parkinson’s disease, multiple system atrophy and progressive supranuclear palsy. Striascan is unable to discriminate between Parkinson's disease, multiple system atrophy and progressive supranuclear palsy.In adult patients, to help differentiate probable dementia with Lewy bodies from Alzheimer’s disease. Striascan is unable to discriminate between dementia with Lewy bodies and Parkinson’s disease dementia. uuid:a160916f-fa6b-4bc3-83dc-d2b83f312342 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68855 biolink:treats MONDO:0019037 PMID:41385096 "[{""id"":""uuid:7b0ec494-ae8d-4a9f-b48a-dd826178e048"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:463c8e20-0ca3-476f-8dc3-d570c527d23f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] This medicinal product is for diagnostic use only.Striascan is indicated for detecting loss of functional dopaminergic neuron terminals in the striatum:In adult patients with clinically uncertain parkinsonian syndromes, for example those with early symptoms, in order to help differentiate essential tremor from parkinsonian syndromes related to idiopathic Parkinson’s disease, multiple system atrophy and progressive supranuclear palsy. Striascan is unable to discriminate between Parkinson's disease, multiple system atrophy and progressive supranuclear palsy.In adult patients, to help differentiate probable dementia with Lewy bodies from Alzheimer’s disease. Striascan is unable to discriminate between dementia with Lewy bodies and Parkinson’s disease dementia. uuid:e716cc4d-1f07-41c2-b481-fc459fcd35bd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68855 biolink:treats MONDO:0007488 PMID:41385096 "[{""id"":""uuid:4629edc4-86b2-4cc5-a6cd-1d03698685fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:c9e23c16-064c-4e13-9312-e9d31718a2d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] This medicinal product is for diagnostic use only.Striascan is indicated for detecting loss of functional dopaminergic neuron terminals in the striatum:In adult patients with clinically uncertain parkinsonian syndromes, for example those with early symptoms, in order to help differentiate essential tremor from parkinsonian syndromes related to idiopathic Parkinson’s disease, multiple system atrophy and progressive supranuclear palsy. Striascan is unable to discriminate between Parkinson's disease, multiple system atrophy and progressive supranuclear palsy.In adult patients, to help differentiate probable dementia with Lewy bodies from Alzheimer’s disease. Striascan is unable to discriminate between dementia with Lewy bodies and Parkinson’s disease dementia. uuid:7a947a05-6f9c-4f50-a15e-5aa473d5781b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68855 biolink:treats MONDO:0004975 PMID:41385096 "[{""id"":""uuid:39f4279e-1083-474f-8f1c-fca00d54dd24"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:5936f5c7-f88d-4417-9e87-242a412e59fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] This medicinal product is for diagnostic use only.Striascan is indicated for detecting loss of functional dopaminergic neuron terminals in the striatum:In adult patients with clinically uncertain parkinsonian syndromes, for example those with early symptoms, in order to help differentiate essential tremor from parkinsonian syndromes related to idiopathic Parkinson’s disease, multiple system atrophy and progressive supranuclear palsy. Striascan is unable to discriminate between Parkinson's disease, multiple system atrophy and progressive supranuclear palsy.In adult patients, to help differentiate probable dementia with Lewy bodies from Alzheimer’s disease. Striascan is unable to discriminate between dementia with Lewy bodies and Parkinson’s disease dementia. uuid:4b766b24-462d-4454-857d-7051f449be0e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64310 biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:96e29b0d-71f6-4b31-99d4-d170dc332e67"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:39f71985-3334-4cfa-870d-e1294fbef16f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/xalkori""]},{""id"":""uuid:165873b4-9b95-4a31-ac8f-f82fc9cc189a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] XALKORI as monotherapy is indicated for:The first‑line treatment of adults with anaplastic lymphoma kinase (ALK)‑positive advanced non‑small cell lung cancer (NSCLC)The treatment of adults with previously treated anaplastic lymphoma kinase (ALK)‑positive advanced non‑small cell lung cancer (NSCLC)The treatment of adults with ROS1‑positive advanced non‑small cell lung cancer (NSCLC)The treatment of paediatric patients (age ≥6 to|[PMDA] Drugs with a new active ingredient indicated for the treatment of unresectable advanced/relapsed ALK fusion gene-positive non-small-cell lung cancer. [Orphan drug] uuid:80f90187-8129-4206-ab7c-e48d6a5dc07f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEMBL.COMPOUND:CHEMBL2108334 biolink:treats MONDO:0002243 PMID:41385096 "[{""id"":""uuid:dc1fadd0-2c6b-4586-8d6d-879f4490ec8f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:c55429c9-c654-4170-8649-059299972424"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] CEVENFACTA is indicated in adults and adolescents (12 years of age and older) for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in the following patient groups:in patients with congenital haemophilia with high-responding inhibitors to coagulation factors VIII or IX (i.e. ≥5 Bethesda Units (BU)); in patients with congenital haemophilia with low titre inhibitors (BU uuid:07dac6d7-0943-4d91-a6ab-f6a18f1b3460 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1306289 biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:9cefe899-7489-4437-8970-ec9fef960cef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:10f4d27d-a81a-4222-8513-34b0a1175184"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/genvoya""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Genvoya is indicated for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus 1 (HIV 1) without any known mutations associated with resistance to the integrase inhibitor class, emtricitabine or tenofovir. uuid:7002f583-7c4b-464e-8856-35196e90c535 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90241 biolink:treats MONDO:0006474 PMID:41385096 "[{""id"":""uuid:8160e0fb-9291-46ce-8af4-319d37b4952b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:28bd9176-0db2-4120-94de-39d49c0ea367"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/javlor""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Javlor is indicated in monotherapy for the treatment of adult patients with advanced or metastatic transitional-cell carcinoma of the urothelial tract after failure of a prior platinum-containing regimen.Efficacy and safety of vinflunine have not been studied in patients with performance status ≥ 2. uuid:aa9eff7e-ae38-4a7d-adcd-da52f085c412 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90241 biolink:treats MONDO:0040679 PMID:41385096 "[{""id"":""uuid:ba82a2c4-c47a-4c1b-8431-3f5e60e004e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:ddacbf50-cb93-40d2-b4a2-f88cc16e1fda"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/javlor""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Javlor is indicated in monotherapy for the treatment of adult patients with advanced or metastatic transitional-cell carcinoma of the urothelial tract after failure of a prior platinum-containing regimen.Efficacy and safety of vinflunine have not been studied in patients with performance status ≥ 2. uuid:891d43e9-23a2-440b-af4f-c9bf58bf8f86 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60070 biolink:treats MONDO:0043424 PMID:41385096 "[{""id"":""uuid:d5760214-092b-423c-9961-e8ea3a586923"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:fd7a85da-f1a0-4809-b058-773138ecfb41"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] TreatmentErtapenem SUN is indicated in paediatric patients (3 months to 17 years of age) and in adults for the treatment of the following infections when caused by bacteria known or very likely to be susceptible to ertapenem and when parenteral therapy is required (see sections 4.4 and 5.1):- Intra-abdominal infections- Community acquired pneumonia- Acute gynaecological infections- Diabetic foot infections of the skin and soft tissue (see section 4.4)PreventionErtapenem SUN is indicated in adults for the prophylaxis of surgical site infection following elective colorectal surgery (see section 4.4).Consideration should be given to official guidance on the appropriate use of antibacterial agents. uuid:c5779714-8979-4880-977e-2e6735c57a80 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60070 biolink:treats MONDO:0005230 PMID:41385096 "[{""id"":""uuid:003c71d2-8a60-4038-b5a3-75b482181bc7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:68ce5111-2bbc-404b-871e-a5e9e6806d6d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] TreatmentErtapenem SUN is indicated in paediatric patients (3 months to 17 years of age) and in adults for the treatment of the following infections when caused by bacteria known or very likely to be susceptible to ertapenem and when parenteral therapy is required (see sections 4.4 and 5.1):- Intra-abdominal infections- Community acquired pneumonia- Acute gynaecological infections- Diabetic foot infections of the skin and soft tissue (see section 4.4)PreventionErtapenem SUN is indicated in adults for the prophylaxis of surgical site infection following elective colorectal surgery (see section 4.4).Consideration should be given to official guidance on the appropriate use of antibacterial agents. uuid:38f366c3-0706-4309-8881-25f7322fee9d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1734632 biolink:treats MONDO:0005231 PMID:41385096 "[{""id"":""uuid:5b798d67-eb20-4487-bddd-eb3e51e44f08"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:33d9f3a9-e5d5-4567-ab24-372831851228"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/zepatier""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] ZEPATIER is indicated for the treatment of chronic hepatitis C (CHC) in adult and paediatric patients 12 years of age and older who weigh at least 30 kg (see sections 4.2, 4.4 and 5.1).For hepatitis C virus (HCV) genotype-specific activity see sections 4.4 and 5.1. uuid:0e2e6937-fff1-4b66-810b-5f2bb45b3313 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50841 biolink:treats MONDO:0004985 PMID:41385096 "[{""id"":""uuid:bc3c1e2f-678b-43d3-b7c5-ac3372036bc9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:968ad41a-0074-407b-8351-a32af8de119a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/adasuve""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Adasuve is indicated for the rapid control of mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder. Patients should receive regular treatment immediately after control of acute agitation symptoms. uuid:739b9064-1b5e-445d-89ba-cbd8aa0873e6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats NCIT:C34887 PMID:41385096 "[{""id"":""uuid:afb5aa36-be57-452b-8c97-41ee0be909dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a4af36c3-2c7f-40e4-8582-cbc7ec220444"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/exparel-liposomal""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Exparel liposomal is indicated:in adults as a brachial plexus block or femoral nerve block for treatment of post-operative pain.in adults and children aged 6 years or older as a field block for treatment of somatic post-operative pain from small- to medium-sized surgical wounds. uuid:a3e4f427-a638-41a6-b778-7511433a68a5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31602 biolink:treats NCIT:C178565 PMID:41385096 "[{""id"":""uuid:cf958a5c-5350-40fb-98d6-1a67fbd5b9dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:6748653b-2af1-46ed-92cb-eb1845e70d63"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Effentora is indicated for the treatment of breakthrough pain (BTP) in adults with cancer who are already receiving maintenance opioid therapy for chronic cancer pain., , BTP is a transitory exacerbation of pain that occurs on a background of otherwise controlled persistent pain., , Patients receiving maintenance opioid therapy are those who are taking at least 60 mg of oral morphine daily, at least 25 micrograms of transdermal fentanyl per hour, at least 30 mg of oxycodone daily, at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid for a week or longer. , uuid:5fa70fa1-92c3-4847-9fcd-bc85ddb75870 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2O4BE0K238 biolink:treats MONDO:0018637 PMID:41385096 "[{""id"":""uuid:77393e7b-91b2-40bd-917d-8a345097cfbd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:4c582e63-e4ff-4bba-8003-04066a608146"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Waylivra is indicated as an adjunct to diet in adult patients with genetically confirmed familial chylomicronemia syndrome (FCS) and at high risk for pancreatitis, in whom response to diet and triglyceride lowering therapy has been inadequate., uuid:2979ee76-d44c-4447-8e03-54ac490f0ef6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2O4BE0K238 biolink:treats MONDO:0004982 PMID:41385096 "[{""id"":""uuid:146bf4c0-a470-442e-af89-5cd7f7360448"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:3d118927-6fe0-45ec-81a6-abe93c092ff8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Waylivra is indicated as an adjunct to diet in adult patients with genetically confirmed familial chylomicronemia syndrome (FCS) and at high risk for pancreatitis, in whom response to diet and triglyceride lowering therapy has been inadequate., uuid:11de4a66-cca7-4c39-8bc0-c0ca6b86c233 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:659877 biolink:treats MONDO:0002974 PMID:41385096 "[{""id"":""uuid:4780647a-191c-4557-8251-8b1537137344"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:435feeb0-47b3-4e04-8bb2-e79bcee88f8d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:4aa9db06-3813-41f3-a6d6-dd175cb23a9c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Gardasil is a vaccine for use from the age of 9 years for the prevention of:premalignant genital lesions (cervical, vulvar and vaginal), premalignant anal lesions, cervical cancers and anal cancers causally related to certain oncogenic Human Papillomavirus (HPV) types;genital warts (condyloma acuminata) causally related to specific HPV types.See sections 4.4 and 5.1 for important information on the data that support this indication.The use of Gardasil should be in accordance with official recommendations.|[PMDA] Drugs with a new active ingredient indicated for the prevention of cervical cancer and its precursor lesions, vulvar intraepithelial neoplasia, vaginal intraepithelial neoplasia, and condyloma acuminatum caused by infection with human papillomavirus types 6, 11, 16 and 18. uuid:7249a028-4cbc-4fb3-9568-fff430856c38 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:659877 biolink:treats MONDO:0003199 PMID:41385096 "[{""id"":""uuid:d75976ad-d1a9-4cd4-ae83-b811b3f6b11b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:658b063a-091a-4823-9db9-1e6850169349"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:2fd119eb-caa7-4c35-8cd2-4fc98d398d83"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Gardasil is a vaccine for use from the age of 9 years for the prevention of:premalignant genital lesions (cervical, vulvar and vaginal), premalignant anal lesions, cervical cancers and anal cancers causally related to certain oncogenic Human Papillomavirus (HPV) types;genital warts (condyloma acuminata) causally related to specific HPV types.See sections 4.4 and 5.1 for important information on the data that support this indication.The use of Gardasil should be in accordance with official recommendations.|[PMDA] A drug with a new indication for the prevention of the following diseases caused by infection with human papillomavirus types 6, 11, 16, and 18: Cervical cancer (squamous cell carcinoma and adenosquamous carcinoma) and its precursor lesions (cervical intraepithelial neoplasia [CIN] 1, 2, and 3, and adenocarcinoma in situ [AIS]) Vulvar intraepithelial neoplasia (VIN) 1, 2, and 3, and vaginal intraepithelial noeplasia (VaIN) 1, 2, and 3 Anal cancer (squamous cell carcinoma) and its precursor lesions (anal intraepithelial neoplasia [AIN] 1, 2, and 3) Condyloma acuminatum uuid:e7289f57-655c-474a-9363-2aec1da29291 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:659877 biolink:treats MONDO:0005647 PMID:41385096 "[{""id"":""uuid:cfe3aa37-465c-418b-a66c-1b42200493e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:df06f839-3ecb-47c9-92c2-56997f794b0a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Gardasil is a vaccine for use from the age of 9 years for the prevention of:premalignant genital lesions (cervical, vulvar and vaginal), premalignant anal lesions, cervical cancers and anal cancers causally related to certain oncogenic Human Papillomavirus (HPV) types;genital warts (condyloma acuminata) causally related to specific HPV types.See sections 4.4 and 5.1 for important information on the data that support this indication.The use of Gardasil should be in accordance with official recommendations. uuid:f762d2ea-8a97-4c98-8090-50b85a6c127b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:659877 biolink:treats MONDO:0021074 PMID:41385096 "[{""id"":""uuid:f5229f38-0a93-47bf-9c53-6de8fcdf5bf9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:19112d9f-5e75-4624-bd5e-4133c80165e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Gardasil is a vaccine for use from the age of 9 years for the prevention of:premalignant genital lesions (cervical, vulvar and vaginal), premalignant anal lesions, cervical cancers and anal cancers causally related to certain oncogenic Human Papillomavirus (HPV) types;genital warts (condyloma acuminata) causally related to specific HPV types.See sections 4.4 and 5.1 for important information on the data that support this indication.The use of Gardasil should be in accordance with official recommendations. uuid:561dfdcf-341d-41fa-bef6-bf7742ac7072 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:5458180 biolink:treats MONDO:0010200 PMID:41385096 "[{""id"":""uuid:43c32bb5-6f34-448e-8517-d7adf2ce7b6d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:8fda0f49-7023-43d5-9592-8c42fb6139cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Cufence is indicated for the treatment of Wilson’s disease in patients intolerant to D-Penicillamine therapy, in adults and children aged 5 years or older. uuid:6ae04910-81af-4164-ae03-090deae18048 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60070 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:51b3ff01-cb6e-482f-8e00-5a005a921011"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d81808ea-0448-45ad-a505-5046f9dc72a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] TreatmentTreatment of the following infections when caused by bacteria known or very likely to be susceptible to ertapenem and when parenteral therapy is required:intra-abdominal infections;community-acquired pneumonia;acute gynaecological infections;diabetic foot infections of the skin and soft tissue.PreventionInvanz is indicated in adults for the prophylaxis of surgical site infection following elective colorectal surgery.Consideration should be given to official guidance on the appropriate use of antibacterial agents. uuid:99370da6-88c9-4c7b-b993-7dc67927ca81 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1437811 biolink:treats MONDO:0010604 PMID:41385096 "[{""id"":""uuid:ec460c03-a7d6-42db-90a2-734957c81f0a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:5f2297db-712b-43a3-9dc9-6eda3890395e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor-IX deficiency)., uuid:621f2047-4726-4adf-9e10-a26b570264b1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:91083 biolink:treats MONDO:0008558 PMID:41385096 "[{""id"":""uuid:6726041e-e65e-4570-bf5e-d2c6bdfa42ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:15027a56-6462-4532-83ac-1bfe439eb11a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/nplate""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Adults:Nplate is indicated for the treatment of primary immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).Paediatrics:Nplate is indicated for the treatment of chronic primary immune thrombocytopenia (ITP) in paediatric patients one year of age and older who are refractory to other treatments (e.g. corticosteroids, immunoglobulins). uuid:eaae57cb-8891-4d1d-b31e-da75a7d4f5e8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:N7V53U4U4T biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:4b1c170d-81a1-4102-ae2f-b0aee0bc25bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d5735613-38c4-448b-bcf0-7a7fca26d470"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Quofenix is indicated for the treatment of the following infections in adults:acute bacterial skin and skin structure infections (ABSSSI),community-acquired pneumonia (CAP), when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the initial treatment of these infections (see sections 4.4 and 5.1).Consideration should be given to official guidance on the appropriate use of antibacterial agents. uuid:8d508bf3-1ec2-46c5-959f-70fde0ca1f5a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:90Z2UF0E52 biolink:treats MONDO:0015691 PMID:41385096 "[{""id"":""uuid:445a22b1-820e-4260-b95d-e48b6ee06d23"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:1a25e747-e9dd-4083-9983-2220c452e36e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/nucala""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Severe eosinophilic asthmaNucala is indicated as an add-on treatment for severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older .Chronic rhinosinusitis with nasal polyps (CRSwNP)Nucala is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe CRSwNP for whom therapy with systemic corticosteroids and/or surgery do not provide adequate control.Eosinophilic granulomatosis with polyangiitis (EGPA)Nucala is indicated as an add-on treatment for patients aged 6 years and older with relapsing-remitting or refractory eosinophilic granulomatosis with polyangiitis (EGPA).Hypereosinophilic syndrome (HES)Nucala is indicated as an add-on treatment for adult patients with inadequately controlled hypereosinophilic syndrome without an identifiable non-haematologic secondary cause. uuid:beafb1e6-c9a3-4bee-b6ee-eb1ea769884a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:760I9WM792 biolink:treats MONDO:0005277 PMID:41385096 "[{""id"":""uuid:1759b663-0876-4839-9880-e76f2f3080c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:90fd2025-007c-4f28-b971-e6892d31d19a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:fe54baf3-4e88-4f4b-a936-2ed9792c5488"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] RAYVOW is indicated for the acute treatment of the headache phase of migraine attacks, with or without aura in adults.|[PMDA] Drugs with a new active ingredient indicated for the treatment of migraine. uuid:1b786008-0543-43a7-8c68-97ea5cd063a8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:760I9WM792 biolink:treats MONDO:0021146 PMID:41385096 "[{""id"":""uuid:a4f6d43a-555b-4f72-b8dd-ac146259690b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:352192c5-4540-42ee-ac5a-c0b8a5998d47"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] RAYVOW is indicated for the acute treatment of the headache phase of migraine attacks, with or without aura in adults. uuid:642008ea-f16e-4742-af6b-86955f3c3bcd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:76004 biolink:treats MONDO:0005083 PMID:41385096 "[{""id"":""uuid:324d0e5a-3b16-4cc8-87c2-134cc3714c0d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:3c91c940-4da4-48b7-8e86-2a5f8d159d87"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/tecfidera""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Skilarence is indicated for the treatment of moderate to severe plaque psoriasis in adults in need of systemic medicinal therapy. uuid:f3b37942-d20e-4bcd-9331-b16a81b1f716 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4762 biolink:treats HP:0009937 PMID:41385096 "[{""id"":""uuid:dc7db180-83a5-4159-b1c1-fb94e1b4e0ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:ac7b044c-1fc5-4908-b0e6-45b49984c945"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/vaniqa""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of facial hirsutism in women. uuid:ff252649-7f23-4401-898f-6639c17ef9b1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2HLC17MX9G biolink:treats MONDO:0010526 PMID:41385096 "[{""id"":""uuid:dfe1357d-5691-4d4e-b550-e15daf3e0548"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8b6ef643-e3c0-4655-bf6d-111615a63310"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/replagal""]},{""id"":""uuid:cfd759e5-c996-45fe-875e-d2eb93f85a36"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Replagal is indicated for long-term enzyme-replacement therapy in patients with a confirmed diagnosis of Fabry disease (α-galactosidase-A deficiency).|[PMDA] Drug with a new active ingredient indicated for treatment of Fabry disease. [Orphan Drug] uuid:0a359a26-77fc-4fb2-bf96-3d4a8e3affab biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3JGY52XJNA biolink:treats MONDO:0009239 PMID:41385096 "[{""id"":""uuid:fb41149c-9385-4050-a15d-f7e6ff15a154"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:2aecf117-f6bb-42a4-aee9-bebc10524399"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/luveris""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Luveris in association with a follicle-stimulating-hormone (FSH) preparation is recommended for the stimulation of follicular development in women with severe luteinising-hormone (LH) and FSH deficiency. In clinical trials, these patients were defined by an endogenous serum LH level uuid:5f43d87c-4159-47f7-9702-9949092cc867 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64321 biolink:treats HP:0002018 PMID:41385096 "[{""id"":""uuid:899a58a6-038c-4192-94ab-941b66ee34d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1108a970-79dd-49c7-a521-4fe5150cc902"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ivemend""]},{""id"":""uuid:5d39f7fb-e89d-451b-92a6-7e859fc61172"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults and paediatric patients aged 6 months and older.Ivemend 150 mg is given as part of a combination therapy.|[PMDA] A drug with a new active ingredient indicated for the treatment of gastrointestinal symptoms (nausea and vomiting) associated with administration of antineoplastic drugs (cisplatin, etc.) (including delayed phase). uuid:0db8df3c-2d0e-4c6e-a1a5-c94ff759a583 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64321 biolink:treats HP:0002013 PMID:41385096 "[{""id"":""uuid:7f814afc-81f3-4056-bf72-f6ce732848d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:dde818f2-96ca-4f3c-8c11-99f0a67e400b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ivemend""]},{""id"":""uuid:23bd72a1-c42e-4bc9-9913-337f62d1155b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults and paediatric patients aged 6 months and older.Ivemend 150 mg is given as part of a combination therapy.|[PMDA] A drug with a new active ingredient indicated for the treatment of gastrointestinal symptoms (nausea and vomiting) associated with administration of antineoplastic drugs (cisplatin, etc.) (including delayed phase). uuid:3afa0c5e-12ff-439f-9e82-bca51c6d56cf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47657 biolink:treats MONDO:0005002 PMID:41385096 "[{""id"":""uuid:71381deb-0659-4fa0-bfdd-4f4cdab4435b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:b697c11f-cf7a-4652-aa92-457be68e9d84"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/daxas""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Daxas is indicated for maintenance treatment of severe chronic obstructive pulmonary disease (COPD) (FEV1 post-bronchodilator less than 50% predicted) associated with chronic bronchitis in adult patients with a history of frequent exacerbations as add-on to bronchodilator treatment., uuid:f9ae2ad9-06fd-457c-aa66-048faee33fe9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:73038 biolink:treats NCIT:C34887 PMID:41385096 "[{""id"":""uuid:7f2b7b2b-a83e-4b69-82eb-16962198c653"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d6c590e8-eb9d-4004-bb69-17a36b88a8ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] For the short-term treatment of postoperative pain in adults., uuid:5e9bfabb-4d6c-4af2-bfff-0bdc7d7ce293 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:36795 biolink:treats MONDO:0002050 PMID:41385096 "[{""id"":""uuid:cae0f89a-8267-479a-8b37-e229bd56c7c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ea691e64-9fc7-4633-97e2-83c72fa7deb9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/duloxetine-mylan""]},{""id"":""uuid:365cac72-0af4-4d5c-a934-7a55f9749438"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment depressive disorder, diabetic neuropathic pain, anxiety disorder., , Duloxetine Zentiva is indicated in adults.,|[PMDA] Drugs with a new active ingredient indicated for the treatment of depression. uuid:d9742eed-97c9-4b56-bb2f-a3ac1881f40c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:36795 biolink:treats MONDO:0005618 PMID:41385096 "[{""id"":""uuid:65350f15-9fd3-478d-9f4a-e17a0eaf9763"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:c34b5f71-0646-4b9d-b90c-8fe0e33b51cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/duloxetine-mylan""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment depressive disorder, diabetic neuropathic pain, anxiety disorder., , Duloxetine Zentiva is indicated in adults., uuid:886b5e53-62b4-4b59-83b9-c895c683d089 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C4541385 biolink:treats MONDO:0005789 PMID:41385096 "[{""id"":""uuid:96e0cef8-ebf1-4a90-927b-729577906ef6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d6ede70f-337b-482b-9681-5d283ca3f651"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] 5 micrograms, , HBVaxPro is indicated for active immunisation against hepatitis-B-virus infection caused by all known subtypes in individuals from birth through 15 years of age considered at risk of exposure to hepatitis-B virus., , The specific at-risk categories to be immunised are to be determined on the basis of the official recommendations., , It can be expected that hepatitis D will also be prevented by immunisation with HBVaxPro as hepatitis D (caused by the delta agent) does not occur in the absence of hepatitis-B infection., , 10 micrograms, , HBVaxPro is indicated for active immunisation against hepatitis-B-virus infection caused by all known subtypes in individuals 16 years of age or more considered at risk of exposure to hepatitis-B virus., , The specific at-risk categories to be immunised are to be determined on the basis of the official recommendations., , It can be expected that hepatitis D will also be prevented by immunisation with HBVaxPro as hepatitis D (caused by the delta agent) does not occur in the absence of hepatitis-B infection., , 40 micrograms, , HBVaxPro is indicated for the active immunisation against hepatitis-B-virus infection caused by all known subtypes in predialysis and dialysis adult patients., , It can be expected that hepatitis D will also be prevented by immunisation with HBVaxPro as hepatitis D (caused by the delta agent) does not occur in the absence of hepatitis B infection., MESH:C000726347 uuid:079431d8-cbe8-4ee5-9105-3b43e670d0f2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134990 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:13d056ef-d3c3-46bb-a987-b1078f4325d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:016b27de-5aa1-4394-bb68-93027193059b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/thymanax""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of major depressive episodes in adults., uuid:ce4cd2dc-c117-45de-bb95-55b467d0198b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:118753636 biolink:treats MONDO:0005338 PMID:41385096 "[{""id"":""uuid:23b84cd0-3bc0-4413-9f69-f49a43b7c028"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:51b6a54d-10ca-44ca-9095-2d417aa7dd13"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/rhokiinsa""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Reduction of elevated intraocular pressure (IOP) in adult patients with primary open-angle glaucoma or ocular hypertension. uuid:81d1e1d7-3ec8-4751-8996-07574fa71362 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:118753636 biolink:treats MONDO:0006875 PMID:41385096 "[{""id"":""uuid:fd6d0963-763c-4a23-8685-4ea71f784654"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:6c53e1f4-5898-4f41-8e27-c82b06c2127c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/rhokiinsa""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Reduction of elevated intraocular pressure (IOP) in adult patients with primary open-angle glaucoma or ocular hypertension. uuid:a155c033-c8c5-4c9a-9260-fa42920201cd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:VQ723R7O8R biolink:treats MONDO:0010602 PMID:41385096 "[{""id"":""uuid:7828c6e1-80d2-4f03-863c-629375f0e196"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:9d79ca47-93c8-4f37-9244-88f75c5fe956"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency).Afstyla can be used for all age groups. uuid:5eca5bf0-ebe4-4d3b-b0f7-5724041e0310 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:089658A12D biolink:treats MONDO:0005083 PMID:41385096 "[{""id"":""uuid:e87dddeb-1209-4a66-afb7-3d89866e1bf0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:7abc4b8b-e34f-458c-b98f-6a3b23ae5123"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/tremfya""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Plaque psoriasis, , Tremfya is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy., , Psoriatic arthritis, , Tremfya, alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (DMARD) therapy (see section 5.1)., uuid:648971d9-7c2c-48cb-a734-cfe22dcf0adc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation MESH:C050102 biolink:treats MONDO:0004619 PMID:41385096 "[{""id"":""uuid:e0a3e181-5e66-4210-aa7a-882e111a3492"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:583bfd94-ad9b-4a5c-a8c9-c7f0e64de7b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] ProQuad is indicated for simultaneous vaccination against measles, mumps, rubella and varicella in individuals from 12 months of age., , ProQuad can be administered to individuals from 9 months of age under special circumstances (e.g., to conform with national vaccination schedules, outbreak situations, or travel to a region with high prevalence of measles., uuid:fc07d8bb-43d7-429c-aacd-62ac7ae94cb4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation MESH:C050102 biolink:treats MONDO:0000989 PMID:41385096 "[{""id"":""uuid:76364856-5ef7-4f15-8966-591759508574"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f14476cc-1194-4514-8ceb-15d420804652"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] ProQuad is indicated for simultaneous vaccination against measles, mumps, rubella and varicella in individuals from 12 months of age., , ProQuad can be administered to individuals from 9 months of age under special circumstances (e.g., to conform with national vaccination schedules, outbreak situations, or travel to a region with high prevalence of measles., uuid:c304daa9-9c37-4298-bf3c-d6361a1061be biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation MESH:C050102 biolink:treats MONDO:0004656 PMID:41385096 "[{""id"":""uuid:8708d1b4-d205-4325-84d0-4f7cbc61c56c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:81f5e785-0baa-44af-9277-dacc363ca7b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] ProQuad is indicated for simultaneous vaccination against measles, mumps, rubella and varicella in individuals from 12 months of age., , ProQuad can be administered to individuals from 9 months of age under special circumstances (e.g., to conform with national vaccination schedules, outbreak situations, or travel to a region with high prevalence of measles., uuid:86e3d0c3-9f2b-4145-8228-44761be1067a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation MESH:C050102 biolink:treats MONDO:0005700 PMID:41385096 "[{""id"":""uuid:15e85c10-f040-4858-a47e-92686fdd4bc9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:3a8338df-411a-4bcc-bfa1-dba2c723052b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] ProQuad is indicated for simultaneous vaccination against measles, mumps, rubella and varicella in individuals from 12 months of age., , ProQuad can be administered to individuals from 9 months of age under special circumstances (e.g., to conform with national vaccination schedules, outbreak situations, or travel to a region with high prevalence of measles., uuid:9b2a25df-3891-4d1d-be6d-7108d874e30a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:72562361 biolink:treats MONDO:0018602 PMID:41385096 "[{""id"":""uuid:686add13-1534-4b6a-8daf-5fadb9c54174"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:2e21b2b6-9989-41f1-ad36-9bd8dbbff5eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/zinforo""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Zinforo is indicated for the treatment of the following infections in neonates, infants, children, adolescents and adults:, , , Complicated skin and soft tissue infections (cSSTI), Community-acquired pneumonia (CAP), , , Consideration should be given to official guidance on the appropriate use of antibacterial agents., uuid:d3a5eddd-cf87-4abe-b9c4-f28d3c6ce1d7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:72562361 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:bd0dba78-6d08-415c-889d-3de3382961f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f39838df-8631-41c2-8c87-bececa7eca2b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/zinforo""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Zinforo is indicated for the treatment of the following infections in neonates, infants, children, adolescents and adults:, , , Complicated skin and soft tissue infections (cSSTI), Community-acquired pneumonia (CAP), , , Consideration should be given to official guidance on the appropriate use of antibacterial agents., uuid:ffb70676-e79e-4ad1-afda-cc9077081217 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:0P70AR5BYB biolink:treats HP:0000989 PMID:41385096 "[{""id"":""uuid:07053d2b-f316-4334-9840-8f0a8caef610"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c9ae5f01-49e0-4bc1-b353-5bd2bc6ebf20"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/kapruvia""]},{""id"":""uuid:88bbc1d4-6d4c-4829-acb3-c5949f0948af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Kapruvia is indicated for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult patients on haemodialysis (see section 5.1).|[PMDA] Drugs with a new active ingredient indicated for the improvement of pruritus in patients on hemodialysis (for use only in patients who have not sufficiently responded to conventional treatments). uuid:a6f9f1c2-1262-4182-8464-4df571d9d768 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:184555 biolink:treats NCIT:C60390 PMID:41385096 "[{""id"":""uuid:714e134a-e099-4ade-a4f2-b9d330e43414"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:bd2c74a9-ddf3-462f-86c3-14fdfd5fa90b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/elmiron""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Elmiron is indicated for the treatment of bladder pain syndrome characterized by either glomerulations or Hunner’s lesions in adults with moderate to severe pain, urgency and frequency of micturition., uuid:0e106517-227f-477b-9c7b-fd648c791238 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0065828 biolink:treats MONDO:0004619 PMID:41385096 "[{""id"":""uuid:daa1ebfc-a5e4-45b1-9d03-aecb4665abbb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:0753a99d-f4a7-4668-9d40-be28cd82123a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] M-M-RVaxPro is indicated for simultaneous vaccination against measles, mumps, and rubella in individuals 12 months or older., , For use in measles outbreaks, or for post-exposure vaccination, or for use in previously unvaccinated children older than 12 months who are in contact with susceptible pregnant women, and persons likely to be susceptible to mumps and rubella., MESH:D022542 uuid:c530e68e-9fba-4c37-904d-d8f358c28a90 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0065828 biolink:treats MONDO:0000989 PMID:41385096 "[{""id"":""uuid:acc09060-ee6e-4d67-9e50-0cae5cdbcccc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:cd35434c-fdfe-40c6-89a9-2a6ac82a2f69"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] M-M-RVaxPro is indicated for simultaneous vaccination against measles, mumps, and rubella in individuals 12 months or older., , For use in measles outbreaks, or for post-exposure vaccination, or for use in previously unvaccinated children older than 12 months who are in contact with susceptible pregnant women, and persons likely to be susceptible to mumps and rubella., MESH:D022542 uuid:bdd395d7-30c6-4305-8afc-d1c800400d83 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0065828 biolink:treats MONDO:0004656 PMID:41385096 "[{""id"":""uuid:b61152dc-cb21-48ab-a5c3-e39ce64c22bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:57407573-04c6-407d-958e-650dcd31fddf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] M-M-RVaxPro is indicated for simultaneous vaccination against measles, mumps, and rubella in individuals 12 months or older., , For use in measles outbreaks, or for post-exposure vaccination, or for use in previously unvaccinated children older than 12 months who are in contact with susceptible pregnant women, and persons likely to be susceptible to mumps and rubella., MESH:D022542 uuid:9f9ebc64-1a96-415f-8a59-04c50ddb8ada biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6A901E312A biolink:treats MONDO:0024883 PMID:41385096 "[{""id"":""uuid:da128f10-24ad-4ab5-bb13-7eb5475f5522"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:bd858f05-6e6b-4ea4-be97-1de17e3edaf1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/vectibix""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Vectibix is indicated for the treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRC):, , , in first-line in combination with Folfox or Folfiri., in second-line in combination with Folfiri for patients who have received first-line fluoropyrimidine-based chemotherapy (excluding irinotecan)., as monotherapy after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens., , uuid:710d5e49-42b9-4d84-8e6a-5fa5d34a0010 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90844 biolink:treats MONDO:0017147 PMID:41385096 "[{""id"":""uuid:7322a847-eebe-4970-ae23-6f3bf94597a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:30fbcacf-4bc4-4425-90ac-4dc48e7c348a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/uptravi""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Uptravi is indicated for the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients with WHO functional class (FC) II–III, either as combination therapy in patients insufficiently controlled with an endothelin receptor antagonist (ERA) and/or a phosphodiesterase type 5 (PDE-5) inhibitor, or as monotherapy in patients who are not candidates for these therapies., , Efficacy has been shown in a PAH population including idiopathic and heritable PAH, PAH associated with connective tissue disorders, and PAH associated with corrected simple congenital heart disease., uuid:ef8e865c-392a-4034-914a-184633d58639 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90844 biolink:treats MONDO:0017148 PMID:41385096 "[{""id"":""uuid:b04a943d-f5d7-43d3-831a-a5756eb0f128"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f14cfb32-77cf-4ccd-b591-28fd7ede171b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/uptravi""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Uptravi is indicated for the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients with WHO functional class (FC) II–III, either as combination therapy in patients insufficiently controlled with an endothelin receptor antagonist (ERA) and/or a phosphodiesterase type 5 (PDE-5) inhibitor, or as monotherapy in patients who are not candidates for these therapies., , Efficacy has been shown in a PAH population including idiopathic and heritable PAH, PAH associated with connective tissue disorders, and PAH associated with corrected simple congenital heart disease., uuid:1ad73a80-63b2-467e-b65e-f8b039223d6a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB10318 biolink:treats MONDO:0005609 PMID:41385096 "[{""id"":""uuid:9f29a1f6-c8a4-46d0-a6c2-efb914343cec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:88ce3ab0-1523-4699-aa34-1fdfd54d6e8f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:cfb1ee96-abc9-4a38-ad89-6ba1961b712f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Zostavax is indicated for prevention of herpes zoster ('zoster' or shingles) and herpes-zoster-related post-herpetic neuralgia., , Zostavax is indicated for immunisation of individuals 50 years of age or older.,|[PMDA] A drug with a new additional indication for the prevention of herpes zoster in individuals 50 years of age and older. uuid:01044490-89e3-45f8-af60-920456bb7e34 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB10318 biolink:treats MONDO:0041052 PMID:41385096 "[{""id"":""uuid:9b989d6c-4d8e-499d-967a-c1228981b553"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:b50f8d87-b216-45ae-af29-7c857314583f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Zostavax is indicated for prevention of herpes zoster ('zoster' or shingles) and herpes-zoster-related post-herpetic neuralgia., , Zostavax is indicated for immunisation of individuals 50 years of age or older., uuid:4e683518-a5d1-430a-a44b-739f337ad532 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB00028 biolink:treats MONDO:0018979 PMID:41385096 "[{""id"":""uuid:f9ee68b1-d45f-4c35-9d53-1961db6a7625"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:0d4a7a8a-ccf0-48b0-855d-6846cdb7dc5e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/flebogamma-dif""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Replacement therapy in adults, and children and adolescents (0-18 years) in:primary immunodeficiency syndromes with impaired antibody production;hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic leukaemia, in whom prophylactic antibiotics have failed;hypogammaglobulinaemia and recurrent bacterial infections in plateau-phase-multiple-myeloma patients who have failed to respond to pneumococcal immunisation;hypogammaglobulinaemia in patients after allogeneic haematopoietic-stem-cell transplantation (HSCT);congenital AIDS and recurrent bacterial infections.Immunomodulation in adults, and children and adolescents (0-18 years) in:primary immune thrombocytopenia (ITP), in patients at high risk of bleeding or prior to surgery to correct the platelet count;Guillain Barré syndrome;Kawasaki disease;multifocal motor neuropathy (MMN). uuid:97887df5-52ab-4915-940d-17d59957efae biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68478 biolink:treats MONDO:0004555 PMID:41385096 "[{""id"":""uuid:ded047ba-ee6b-4075-96d3-5fceb9bf6d51"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:791e057b-3145-4d32-a4ab-75efb0dfe23f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/votubia""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Renal angiomyolipoma associated with tuberous sclerosis complex (TSC)Votubia is indicated for the treatment of adult patients with renal angiomyolipoma associated with tuberous sclerosis complex (TSC) who are at risk of complications (based on factors such as tumour size or presence of aneurysm, or presence of multiple or bilateral tumours) but who do not require immediate surgery.The evidence is based on analysis of change in sum of angiomyolipoma volume.Subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC)Votubia is indicated for the treatment of patients with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC) who require therapeutic intervention but are not amenable to surgery.The evidence is based on analysis of change in SEGA volume. Further clinical benefit, such as improvement in disease‑related symptoms, has not been demonstrated. uuid:f27ea97c-e562-4150-8e89-0074f4281e54 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68478 biolink:treats MONDO:0019954 PMID:41385096 "[{""id"":""uuid:8004e1fd-6899-415f-8c9d-27a7003e4bf5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:45e4e0dd-ec13-4c61-a2a0-53155a81805f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/votubia""]},{""id"":""uuid:be6b5de1-5620-4401-a522-5faba831330c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Hormone-receptor-positive advanced breast cancerAfinitor is indicated for the treatment of hormone-receptor-positive, HER2/neu-negative advanced breast cancer, in combination with exemestane, in post-menopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor.Neuroendocrine tumours of pancreatic originAfinitor is indicated for the treatment of unresectable or metastatic, well or moderately differentiated neuroendocrine tumours of pancreatic origin in adults with progressive disease.Neuroendocrine tumours of gastrointestinal or lung originAfinitor is indicated for the treatment of unresectable or metastatic, well-differentiated (Grade 1 or Grade 2) non-functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease.Renal-cell carcinomaAfinitor is indicated for the treatment of patients with advanced renal-cell carcinoma, whose disease has progressed on or after treatment with VEGF-targeted therapy.|[PMDA] A drug with a new additional indication and a new dosage for the treatment of pancreatic neuroendocrine tumor. uuid:788e0a64-53f0-45ca-b4ee-b863d78f89f9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:79699 biolink:treats MONDO:0018876 PMID:41385096 "[{""id"":""uuid:ff596c87-4fcc-457e-9d0d-8984040e0f7c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a2dc32a7-5218-443a-801a-eac77a66c963"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/torisel""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Renal-cell carcinomaTorisel is indicated for the first-line treatment of adult patients with advanced renal-cell carcinoma (RCC) who have at least three of six prognostic risk factors.Mantle-cell lymphomaTorisel is indicated for the treatment of adult patients with relapsed and / or refractory mantle-cell lymphoma (MCL). uuid:9a023159-6470-4b21-a54a-a2457653aa6a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:65347 biolink:treats MONDO:0009693 PMID:41385096 "[{""id"":""uuid:874e29f6-06dc-4dbd-b32e-fb0ed5633528"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d6eb7606-1be7-45ed-ae28-82808e7295d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/kyprolis""]},{""id"":""uuid:d2832194-47af-4196-8d14-a0c79f9819d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Kyprolis in combination with daratumumab and dexamethasone, with lenalidomide and dexamethasone, or with dexamethasone alone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.|[PMDA] Drugs with a new active ingredient indicated for the treatment of relapsed or refractory multiple myeloma. [Orphan drug] uuid:b6dca423-21a8-4ef4-9967-bd3333277e53 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C4306815 biolink:treats MONDO:0005812 PMID:41385096 "[{""id"":""uuid:92110334-f9db-4a49-b9ed-e424d6e2db7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:74ec509e-56ab-4c6d-abb0-3da432112b08"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Prophylaxis of influenza in an officially declared pandemic situation. Pandemic influenza vaccine should be used in accordance with official guidance. uuid:25bc78f9-4f70-45d7-8c11-a1b38fd9fa9f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7457 biolink:treats MONDO:0007079 PMID:41385096 "[{""id"":""uuid:24da3b73-9b2a-40a1-baaf-bbc452114ae7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:144b92bf-9af9-49bc-977c-9fb49c116e17"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:9d086a1e-6c5a-4891-bc79-45077c3d85e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Selincro is indicated for the reduction of alcohol consumption in adult patients with alcohol dependence who have a high drinking-risk level (see section 5.1), without physical withdrawal symptoms and who do not require immediate detoxification.Selincro should only be prescribed in conjunction with continuous psychosocial support focused on treatment adherence and reducing alcohol consumption.Selincro should be initiated only in patients who continue to have a high drinking-risk level two weeks after initial assessment.|[PMDA] A drug with a new active ingredient indicated to reduce alcohol consumption in patients with alcohol dependence. uuid:fd5fb707-dd3c-4cd5-8f52-118cb7213725 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1660426 biolink:treats MONDO:0024574 PMID:41385096 "[{""id"":""uuid:5d8873b5-26a3-4983-a345-bb6b8e9f7481"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f6152aea-b9a3-4796-ad52-271780276627"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/voncento""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Von Willebrand disease (VWD)Prophylaxis and treatment of haemorrhage or surgical bleeding in patients with VWD, when desmopressin (DDAVP) treatment alone is ineffective or contraindicated.Haemophilia A (congenital factor-VIII deficiency)Prophylaxis and treatment of bleeding in patients with haemophilia A. uuid:85ada15f-2e1b-4235-ad04-270e1d778366 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1660426 biolink:treats MONDO:0010602 PMID:41385096 "[{""id"":""uuid:e1516089-b0c2-4b28-854e-fd5871989e57"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:4d320990-c2e3-4746-8377-d9b264f6067a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/voncento""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Von Willebrand disease (VWD)Prophylaxis and treatment of haemorrhage or surgical bleeding in patients with VWD, when desmopressin (DDAVP) treatment alone is ineffective or contraindicated.Haemophilia A (congenital factor-VIII deficiency)Prophylaxis and treatment of bleeding in patients with haemophilia A. uuid:deb1eda8-6c3f-4adb-a1d1-b0639757f758 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C4294565 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:fd540c19-3a73-44d6-9c79-3ba2f0f6e796"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:6ea28470-4ecf-46d4-8519-78dd8d2f9fe3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of diabetes mellitus in adults. MESH:C000629636 uuid:dd32043c-c730-4eba-a867-ac7f9b6536d3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31652 biolink:treats MONDO:0001056 PMID:41385096 "[{""id"":""uuid:338b8792-94dd-44db-b5dc-873f711e2808"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:249dd9cc-aebc-4828-9a6c-311a5f4a89bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/teysuno""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Teysuno is indicated in adults:- for the treatment of advanced gastric cancer when given in combination with cisplatin (see section 5.1).- as monotherapy or in combination with oxaliplatin or irinotecan, with or without bevacizumab, for the treatment of patients with metastatic colorectal cancer for whom it is not possible to continue treatment with another fluoropyrimidine due to hand-foot syndrome or cardiovascular toxicity that developed in the adjuvant or metastatic setting. uuid:a7d86bf9-3002-4321-b91d-4484731b76ae biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5134 biolink:treats MONDO:0011786 PMID:41385096 "[{""id"":""uuid:d5fc4402-44e6-4f77-a98b-1f1f8c7650ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a4db38a5-702d-49bf-8f46-e15e9af5c938"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/avamys""]},{""id"":""uuid:9de09dfb-9f72-4322-b9a2-6d510dd1e060"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Adults, adolescents (12 years and over) and children (6-11 years). Avamys is indicated for the treatment of the symptoms of allergic rhinitis.|[PMDA] A drug with a new active ingredient indicated for the treatment of allergic rhinitis. uuid:3aa41661-b086-4353-bd09-d4028c470cac biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:84050 biolink:treats MONDO:0018078 PMID:41385096 "[{""id"":""uuid:7551ac0e-e64d-4283-8261-26cc7dd06aa5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:353305bb-13c0-48dd-b576-136cf29384d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/yondelis""]},{""id"":""uuid:5ecf714f-0440-4c99-bf0c-58c4768f4e25"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Yondelis is indicated for the treatment of patients with advanced soft-tissue sarcoma, after failure of anthracyclines and ifosfamide, or who are unsuited to receive these agents. Efficacy data are based mainly on liposarcoma and leiomyosarcoma patients.Yondelis in combination with pegylated liposomal doxorubicin (PLD) is indicated for the treatment of patients with relapsed platinum-sensitive ovarian cancer.|[PMDA] Drugs with a new active ingredient indicated for the treatment of patients with soft tissue sarcoma. [Orphan drug] uuid:034e14bc-9a91-46d4-99a2-6f5d0fa1fe42 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:84050 biolink:treats MONDO:0008170 PMID:41385096 "[{""id"":""uuid:d147ac2b-432c-4c57-8c0f-e79887c9d65e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:6bb660f1-2e48-417f-91d6-807968535d25"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/yondelis""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Yondelis is indicated for the treatment of patients with advanced soft-tissue sarcoma, after failure of anthracyclines and ifosfamide, or who are unsuited to receive these agents. Efficacy data are based mainly on liposarcoma and leiomyosarcoma patients.Yondelis in combination with pegylated liposomal doxorubicin (PLD) is indicated for the treatment of patients with relapsed platinum-sensitive ovarian cancer. uuid:8f1c42bd-7ec6-4a6b-9abe-04b79ad42738 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17549 biolink:treats MONDO:0020804 PMID:41385096 "[{""id"":""uuid:6f321943-7d89-4902-94ca-f764996ef573"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:e4c8b50c-273d-4267-b052-03605156316d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/gliolan""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of actinic keratosis of mild to moderate severity on the face and scalp (Olsen grade 1 to 2; see section 5.1) and of field cancerization in adults.Treatment of superficial and/or nodular basal cell carcinoma unsuitable for surgical treatment due to possible treatment-related morbidity and/or poor cosmetic outcome in adults. uuid:23e3320b-eca2-4924-8c93-93f37f13d00f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:NU23Q531G1 biolink:treats MONDO:0018029 PMID:41385096 "[{""id"":""uuid:e53bd692-ea4c-49a8-92b6-85871a5eca2e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4c80eccb-651a-42f4-afbe-a4a641a2509b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/novothirteen""]},{""id"":""uuid:8ac7e03a-e43e-40d1-95c0-f2b2eba8d809"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Long-term prophylactic treatment of bleeding in adult and paediatric patients 6 years and above with congenital factor-XIII-A-subunit deficiency.|[PMDA] A drug with a new active ingredient indicated for the control of bleeding tendency in patients with congenital blood coagulation factor XIII A-subunit deficiency. [Orphan drug] uuid:60c059b0-70de-4228-bb29-000497dc9a7b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68845 biolink:treats MONDO:0001134 PMID:41385096 "[{""id"":""uuid:53d276c2-cce7-49bc-b991-12224c1eed6d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:22c4ee66-d827-424a-a7a2-2e73a015231f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/edarbi""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Edarbi is indicated for the treatment of essential hypertension in adults. uuid:5caa5550-c355-474d-a667-ed8544959090 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C4753601 biolink:treats MONDO:0004947 PMID:41385096 "[{""id"":""uuid:74865032-2bad-4b3c-8dfb-8e85bdd610c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d010691c-9fe6-4d7d-ae77-a7b82dc460f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/besponsa""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Besponsa is indicated as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B cell precursor acute lymphoblastic leukaemia (ALL). Adult patients with Philadelphia chromosome positive (Ph+) relapsed or refractory B cell precursor ALL should have failed treatment with at least 1 tyrosine kinase inhibitor (TKI). uuid:89c7bd39-3814-4121-ad07-f8364ff7e901 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:87016 biolink:treats HP:0007359 PMID:41385096 "[{""id"":""uuid:37f75fed-6f6e-4479-a465-6c8919ab2a09"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:6052f015-8b99-41ba-a852-e4d929b4d507"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/zebinix""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Zebinix is indicated as adjunctive therapy in adults, adolescents and children aged above 6 years, with partial-onset seizures with or without secondary generalisation. uuid:082a63cf-4053-4f7b-80c1-1d22d0933b59 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:87016 biolink:treats HP:0011188 PMID:41385096 "[{""id"":""uuid:2887772f-8077-422f-a4c9-3b2f4a13f5f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:ff18e7da-47b7-4564-8365-79ca45d37af7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/zebinix""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Zebinix is indicated as adjunctive therapy in adults, adolescents and children aged above 6 years, with partial-onset seizures with or without secondary generalisation. uuid:b1c7f200-4207-44f1-b0a6-46d3f55712b9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2948 biolink:treats MONDO:0016264 PMID:41385096 "[{""id"":""uuid:5cb52b72-969f-48a7-8eb3-fce2b7be9386"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:83b64e1f-ac6c-4d32-b9b4-3af27ac0e1dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/jayempi""]},{""id"":""uuid:bd2c3b35-2fb9-4532-825d-70a41bef329a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. Azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression).Jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response.Jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – DMARDs)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidBehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm IgG antibodieschronic refractory idiopathic thrombocytopenic purpuraJayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (IBD) (Crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice.It is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3Jayempi is indicated for the treatment of generalised myasthenia gravis. Depending on the severity of the disease, Jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.|[PMDA] Drugs with a new additional indication for the treatment of autoimmune hepatitis. [Public knowledge-based application after preliminary assessment by the Pharmaceutical Affairs and Food Sanitation Council (PAFSC)] uuid:fe1371f0-a27d-4d75-ac0b-a1988fd2385a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2948 biolink:treats MONDO:0007915 PMID:41385096 "[{""id"":""uuid:6493a225-4171-40de-9033-cc7abf329d55"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a692d0fb-39b2-4ad0-837c-cfdae014d715"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/jayempi""]},{""id"":""uuid:6e56e4cd-11dd-4435-a164-cd52678d51ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. Azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression).Jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response.Jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – DMARDs)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidBehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm IgG antibodieschronic refractory idiopathic thrombocytopenic purpuraJayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (IBD) (Crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice.It is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3Jayempi is indicated for the treatment of generalised myasthenia gravis. Depending on the severity of the disease, Jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.|[PMDA] Drugs with new additional indications and a new dosage for the treatment of the following treatment- resistant rheumatic diseases: systemic vasculitis (e.g., microscopic polyangiitis, Wegener granulomatosis, polyarteritis nodosa, Churg-Strauss syndrome, aortitis syndrome), systemic lupus erythematosus (SLE), polymyositis, dermatomyositis, pachyderma, mixed connective tissue disease and refractory rheumatic disease. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:cdb01ef9-2867-41f9-8dee-fe8c430e6ea0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2948 biolink:treats MONDO:0016367 PMID:41385096 "[{""id"":""uuid:1a04d8e8-20c1-434a-9f44-5dfc0c5f440c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:bf883f69-cbea-49be-99c6-808013c52ec8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/jayempi""]},{""id"":""uuid:0104afe4-ee2d-434f-b92d-40be64f6fd8f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. Azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression).Jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response.Jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – DMARDs)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidBehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm IgG antibodieschronic refractory idiopathic thrombocytopenic purpuraJayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (IBD) (Crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice.It is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3Jayempi is indicated for the treatment of generalised myasthenia gravis. Depending on the severity of the disease, Jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.|[PMDA] Drugs with new additional indications and a new dosage for the treatment of the following treatment- resistant rheumatic diseases: systemic vasculitis (e.g., microscopic polyangiitis, Wegener granulomatosis, polyarteritis nodosa, Churg-Strauss syndrome, aortitis syndrome), systemic lupus erythematosus (SLE), polymyositis, dermatomyositis, pachyderma, mixed connective tissue disease and refractory rheumatic disease. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:f6fd7a23-42fe-4420-8249-ade27fc45854 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2948 biolink:treats MONDO:0019170 PMID:41385096 "[{""id"":""uuid:db530527-0d92-4b96-b84c-8dd8e1a739b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:812e3729-96ee-433e-8bde-fb506098ae99"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/jayempi""]},{""id"":""uuid:c251057b-b73a-4fe9-8d93-658c67447562"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. Azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression).Jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response.Jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – DMARDs)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidBehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm IgG antibodieschronic refractory idiopathic thrombocytopenic purpuraJayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (IBD) (Crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice.It is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3Jayempi is indicated for the treatment of generalised myasthenia gravis. Depending on the severity of the disease, Jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.|[PMDA] Drugs with new additional indications and a new dosage for the treatment of the following treatment- resistant rheumatic diseases: systemic vasculitis (e.g., microscopic polyangiitis, Wegener granulomatosis, polyarteritis nodosa, Churg-Strauss syndrome, aortitis syndrome), systemic lupus erythematosus (SLE), polymyositis, dermatomyositis, pachyderma, mixed connective tissue disease and refractory rheumatic disease. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:3e3bc790-1b4c-4ec0-a5fe-8a7dd32e7350 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2948 biolink:treats MONDO:0008219 PMID:41385096 "[{""id"":""uuid:e216c856-9d12-4dbb-9f07-7ce401e64dc8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:3e4a9f75-f4e6-4d6f-99e2-c5bf4088a1dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/jayempi""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. Azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression).Jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response.Jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – DMARDs)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidBehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm IgG antibodieschronic refractory idiopathic thrombocytopenic purpuraJayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (IBD) (Crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice.It is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3Jayempi is indicated for the treatment of generalised myasthenia gravis. Depending on the severity of the disease, Jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment. uuid:263e1b64-3e43-45ea-9ae3-27214ce81c43 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2948 biolink:treats MONDO:0019082 PMID:41385096 "[{""id"":""uuid:6dc533a7-0484-4efe-9b1c-827d99c119a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:63685359-dec2-4d3f-9160-9bf25cf5987f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/jayempi""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. Azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression).Jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response.Jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – DMARDs)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidBehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm IgG antibodieschronic refractory idiopathic thrombocytopenic purpuraJayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (IBD) (Crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice.It is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3Jayempi is indicated for the treatment of generalised myasthenia gravis. Depending on the severity of the disease, Jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment. uuid:822ed677-7f68-45fc-bf3b-04493897d695 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2948 biolink:treats MONDO:0020108 PMID:41385096 "[{""id"":""uuid:d93c50c4-9aed-4c31-99be-bf60f2ca2500"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:c48bdb59-0f67-4c70-a0e3-50ea7cb44000"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/jayempi""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. Azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression).Jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response.Jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – DMARDs)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidBehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm IgG antibodieschronic refractory idiopathic thrombocytopenic purpuraJayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (IBD) (Crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice.It is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3Jayempi is indicated for the treatment of generalised myasthenia gravis. Depending on the severity of the disease, Jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment. uuid:d9fd5738-e17b-40a7-960f-62874a10c72b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2948 biolink:treats MONDO:0008558 PMID:41385096 "[{""id"":""uuid:7daab2cc-e5a7-4382-96c8-616e49743cf6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:64bc4d80-8914-458c-b970-60e4bf7bf720"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/jayempi""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. Azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression).Jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response.Jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – DMARDs)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidBehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm IgG antibodieschronic refractory idiopathic thrombocytopenic purpuraJayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (IBD) (Crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice.It is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3Jayempi is indicated for the treatment of generalised myasthenia gravis. Depending on the severity of the disease, Jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment. uuid:d188c917-b102-4037-bab5-37005fa5f58d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2948 biolink:treats MONDO:0005011 PMID:41385096 "[{""id"":""uuid:2aa65843-c4a7-4103-8278-e41155484fcc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:6ee481aa-3a47-484a-9f85-7bf223b8b72b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/jayempi""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. Azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression).Jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response.Jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – DMARDs)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidBehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm IgG antibodieschronic refractory idiopathic thrombocytopenic purpuraJayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (IBD) (Crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice.It is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3Jayempi is indicated for the treatment of generalised myasthenia gravis. Depending on the severity of the disease, Jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment. uuid:19a42131-efdf-437e-9b74-9a3784f9b6b7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2948 biolink:treats MONDO:0005101 PMID:41385096 "[{""id"":""uuid:f36691f9-6913-487b-973e-7a813e61174d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e559cfa2-d8f0-40ab-89e9-8337c737f6af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/jayempi""]},{""id"":""uuid:22208cb0-0206-40a6-9d6e-48e4c8a79a24"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. Azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression).Jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response.Jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – DMARDs)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidBehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm IgG antibodieschronic refractory idiopathic thrombocytopenic purpuraJayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (IBD) (Crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice.It is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3Jayempi is indicated for the treatment of generalised myasthenia gravis. Depending on the severity of the disease, Jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.|[PMDA] Drug with a new indication and dosage indicated for induction and maintenance of remission in steroid- dependent Crohn's disease and maintenance of remission in steroid-dependent ulcerative colitis. [Notification of off-label use] uuid:bb22ade9-09a5-4447-ba89-c9baaab37e94 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2948 biolink:treats MONDO:0005301 PMID:41385096 "[{""id"":""uuid:f7a0b4ce-1c1c-4e51-b097-cd6f208a1c7d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:9a326dba-a575-43c6-8487-3b8a2ec4d9c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/jayempi""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. Azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression).Jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response.Jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – DMARDs)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidBehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm IgG antibodieschronic refractory idiopathic thrombocytopenic purpuraJayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (IBD) (Crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice.It is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3Jayempi is indicated for the treatment of generalised myasthenia gravis. Depending on the severity of the disease, Jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment. uuid:a2430adb-b364-4086-940a-002137122b98 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2948 biolink:treats MONDO:0009688 PMID:41385096 "[{""id"":""uuid:b1caba1e-65ce-4585-88e5-949d1f6c44d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:5fd13ee5-4687-479d-b128-2476843840e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/jayempi""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. Azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression).Jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response.Jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – DMARDs)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidBehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm IgG antibodieschronic refractory idiopathic thrombocytopenic purpuraJayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (IBD) (Crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice.It is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3Jayempi is indicated for the treatment of generalised myasthenia gravis. Depending on the severity of the disease, Jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment. uuid:57c9f86b-05ff-4228-b6bc-2644579c7fdb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7G4J1ZD9UQ biolink:treats MONDO:0004981 PMID:41385096 "[{""id"":""uuid:8f909a47-65fb-4bc5-b90f-6474e4d3e3bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:3ce3095a-ed46-444d-aca9-82b950ef52c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/brinavess""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults:for non-surgery patients: atrial fibrillation uuid:0e8dd29f-5691-406c-ac33-5f162f691ae4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2GFP9BJD79 biolink:treats MONDO:0034212 PMID:41385096 "[{""id"":""uuid:9484915b-c170-424a-b014-52703120b790"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:68b13e77-36ab-46f1-a88d-f074b85a6a8e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/voraxaze-0""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Voraxaze is indicated to reduce toxic plasma methotrexate concentration in adults and children (aged 28 days and older) with delayed methotrexate elimination or at risk of methotrexate toxicity. uuid:9c954c5c-4d3c-44c6-9d12-793ec3c666e0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB00028 biolink:treats MONDO:0017769 PMID:41385096 "[{""id"":""uuid:3a37a87d-1c14-4d81-a2b4-e0042711ddbf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:8a1f36cc-6b5d-4c56-93a3-6148e69ce8a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/hizentra""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Replacement therapy in adults, children and adolescents (0-18 years) in:- Primary immunodeficiency syndromes with impaired antibody production (see section 4.4).- Secondary immunodeficiencies (SID) in patients who suffer from severe or recurrent infections, ineffective antimicrobial treatment and either proven specific antibody failure (PSAF)* or serum IgG level of uuid:14d2aeae-e402-42a3-a7af-68f6774f7d1a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:80343 biolink:treats MONDO:0009877 PMID:41385096 "[{""id"":""uuid:143664b7-65b3-4971-bf30-8c4c9925e5c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:8801d097-8305-48b7-a622-1a3eaf940c25"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/increlex""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] For the long-term treatment of growth failure in children and adolescents with severe primary insulin-like-growth-factor-1 deficiency (primary IGFD).Severe primary IGFD is defined by:height standard deviation score ≤ -3.0 and;basal insulin-like growth factor-1 (IGF-1) levels below the 2.5th percentile for age and gender and;growth hormone (GH) sufficiency;exclusion of secondary forms of IGF-1 deficiency, such as malnutrition, hypothyroidism, or chronic treatment with pharmacologic doses of anti-inflammatory steroids.Severe primary IGFD includes patients with mutations in the GH receptor (GHR), post-GHR signalling pathway, and IGF-1 gene defects; they are not GH deficient, and therefore, they cannot be expected to respond adequately to exogenous GH treatment. It is recommended to confirm the diagnosis by conducting an IGF-1 generation test. uuid:36da8056-5483-4133-a79d-26d566811b78 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:23CA79S88F biolink:treats MONDO:0018078 PMID:41385096 "[{""id"":""uuid:c55b3f04-0426-487b-bc80-8f401f2d4c3f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:9bfba03d-09be-4158-a816-21e86d348189"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/beromun""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Beromun is indicated in adults as an adjunct to surgery for subsequent removal of the tumour so as to prevent or delay amputation, or in the palliative situation, for irresectable soft-tissue sarcoma of the limbs, used in combination with melphalan via mild hyperthermic isolated-limb perfusion (ILP). uuid:408e0a9a-0b24-487d-8444-ed6d2606c4ed biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:36795 biolink:treats MONDO:0004160 PMID:41385096 "[{""id"":""uuid:b64b0c89-c79b-4086-b26d-aa9f8d04242d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:1765470e-87c5-447c-8b58-b7d125613274"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/duloxetine-mylan""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Yentreve is indicated for women for the treatment of moderate to severe stress urinary incontinence (SUI). uuid:ee787ada-14de-4ef3-b227-f12d649707db biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90973 biolink:treats MONDO:0005002 PMID:41385096 "[{""id"":""uuid:699ef686-cf5e-4b58-9064-5a844fdb48e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:0319d5d4-4bc5-4650-b098-cbe9a7c86993"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/seebri-breezhaler""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Seebri Breezhaler is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). uuid:df630633-7ee9-4ffd-8994-8e7c8dfdb144 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:38940 biolink:treats MONDO:0011719 PMID:41385096 "[{""id"":""uuid:eb46e842-dfd1-44fb-9d52-2257bd46bad8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f26bdd01-4d07-4c80-b8ac-71727acd0adb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/sunitinib-accord""]},{""id"":""uuid:62034b3b-2209-472d-9a9d-4ceb85687a0d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Gastrointestinal stromal tumour (GIST)Sunitinib Accord is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST) in adults after failure of imatinib treatment due to resistance or intolerance.Metastatic renal cell carcinoma (MRCC)Sunitinib Accord is indicated for the treatment of advanced/metastatic renal cell carcinoma (MRCC) in adults.Pancreatic neuroendocrine tumours (pNET)Sunitinib Accord is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pNET) with disease progression in adults.|[PMDA] A drug containing a new active ingredient indicated for the treatment of imatinib-resistant gastrointestinal stromal tumors, and unresectable or metastatic renal cell carcinomas. [Priority review] uuid:24471ebf-ea39-4f55-81f8-5ae9405395d0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:231344 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:e19fe647-a53a-4892-934c-1cc29b7a9ae0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:2b51dcda-6951-4d49-9f6d-e096af8fa4a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/talzenna""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Talzenna is indicated as monotherapy for the treatment of adult patients with germline BRCA1/2 mutations, who have HER2-negative locally advanced or metastatic breast cancer. Patients should have been previously treated with an anthracycline and/or a taxane in the (neo)adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine-based therapy, or be considered unsuitable for endocrine-based therapy. uuid:f1dc628b-5c4b-4b54-b7bf-353570bb6ad5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:231344 biolink:treats MONDO:0000618 PMID:41385096 "[{""id"":""uuid:1f4f85d1-439a-49ad-a7d7-74f0826aaad5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1a9a2a63-19f3-4913-bee3-adfc22e868b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/talzenna""]},{""id"":""uuid:1d5f8ec4-e0ce-4f96-b06c-8ab6c59b0c12"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Talzenna is indicated as monotherapy for the treatment of adult patients with germline BRCA1/2 mutations, who have HER2-negative locally advanced or metastatic breast cancer. Patients should have been previously treated with an anthracycline and/or a taxane in the (neo)adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine-based therapy, or be considered unsuitable for endocrine-based therapy.|[PMDA] A drug with a new active ingredient indicated for the treatment of BRCA mutation-positive, metastatic castration-resistant prostate cancer. A drug with a new active ingredient indicated for the treatment of BRCA mutation-positive, metastatic castration-resistant prostate cancer and unresectable or recurrent BRCA mutation-positive and HER2-negative breast cancer in patients who have previously been treated with chemotherapy. A drug with a new active ingredient indicated for the treatment of unresectable or recurrent BRCA mutation-positive and HER2-negative breast cancer in patients who have previously been treated with chemotherapy. uuid:c080516b-f388-4222-9151-b3106e0cf544 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:231344 biolink:treats MONDO:0006512 PMID:41385096 "[{""id"":""uuid:17ba2bfd-2491-4b6c-824e-12e8b4005c04"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:c3232047-15bd-4154-be1e-b26494468c3b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/talzenna""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Talzenna is indicated as monotherapy for the treatment of adult patients with germline BRCA1/2 mutations, who have HER2-negative locally advanced or metastatic breast cancer. Patients should have been previously treated with an anthracycline and/or a taxane in the (neo)adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine-based therapy, or be considered unsuitable for endocrine-based therapy. uuid:3328cc40-d6fb-4069-9178-dfe0cb5146a0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135945 biolink:treats MONDO:0017595 PMID:41385096 "[{""id"":""uuid:5be612ad-6abc-400b-a89b-2f2d86b1ca33"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:4e21b8a0-d255-43d4-8830-b9d98ad89df1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/pixuvri""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Pixuvri is indicated as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphomas (NHL). The benefit of pixantrone treatment has not been established in patients when used as fifth-line or greater chemotherapy in patients who are refractory to last therapy. uuid:6ef593fa-d727-4047-a2f4-b7ea8aa9a03d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28876 biolink:treats MONDO:0005062 PMID:41385096 "[{""id"":""uuid:56a13263-b832-48fd-8ff8-07047abb100a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:442c9dab-6785-40ec-b37d-f4d2b31ebec0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] High-dose of Phelinun used alone or in combination with other cytotoxic medicinal products and/or total body irradiation is indicated in the treatment of:multiple myeloma,malignant lymphoma (Hodgkin, non-Hodgkin lymphoma),acute lymphoblastic and myeloblastic leukemia,childhood neuroblastoma,ovarian cancer,mammary adenocarcinoma.Phelinun in combination with other cytotoxic medicinal products is indicated as reduced intensity conditioning (RIC) treatment prior to allogeneic haematopoietic stem cell transplantation (allo-HSCT) in malignant haematological diseases in adults.Phelinun in combination with other cytotoxic medicinal products is indicated as conditioning regimen prior to allogeneic haematopoietic stem cell transplantation in haematological diseases in the paediatric population as:Myeloablative conditioning (MAC) treatment in case of malignant haematological diseasesRIC treatment in case of non-malignant haematological diseases. uuid:8c604d92-45aa-4c81-8b0a-f6b9d5275eac biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28876 biolink:treats MONDO:0004952 PMID:41385096 "[{""id"":""uuid:e1107758-efc8-4b97-a482-cfe970fea103"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d9b6c521-86bf-45ad-8cd2-d9a594a2026e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] High-dose of Phelinun used alone or in combination with other cytotoxic medicinal products and/or total body irradiation is indicated in the treatment of:multiple myeloma,malignant lymphoma (Hodgkin, non-Hodgkin lymphoma),acute lymphoblastic and myeloblastic leukemia,childhood neuroblastoma,ovarian cancer,mammary adenocarcinoma.Phelinun in combination with other cytotoxic medicinal products is indicated as reduced intensity conditioning (RIC) treatment prior to allogeneic haematopoietic stem cell transplantation (allo-HSCT) in malignant haematological diseases in adults.Phelinun in combination with other cytotoxic medicinal products is indicated as conditioning regimen prior to allogeneic haematopoietic stem cell transplantation in haematological diseases in the paediatric population as:Myeloablative conditioning (MAC) treatment in case of malignant haematological diseasesRIC treatment in case of non-malignant haematological diseases. uuid:46df7902-2bc1-4daf-96db-4e00a1d58e9d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28876 biolink:treats MONDO:0018908 PMID:41385096 "[{""id"":""uuid:5ec2d2eb-d00c-401b-a8c7-63a725928035"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:765c5df4-dafa-4e11-925f-5b96daf16154"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] High-dose of Phelinun used alone or in combination with other cytotoxic medicinal products and/or total body irradiation is indicated in the treatment of:multiple myeloma,malignant lymphoma (Hodgkin, non-Hodgkin lymphoma),acute lymphoblastic and myeloblastic leukemia,childhood neuroblastoma,ovarian cancer,mammary adenocarcinoma.Phelinun in combination with other cytotoxic medicinal products is indicated as reduced intensity conditioning (RIC) treatment prior to allogeneic haematopoietic stem cell transplantation (allo-HSCT) in malignant haematological diseases in adults.Phelinun in combination with other cytotoxic medicinal products is indicated as conditioning regimen prior to allogeneic haematopoietic stem cell transplantation in haematological diseases in the paediatric population as:Myeloablative conditioning (MAC) treatment in case of malignant haematological diseasesRIC treatment in case of non-malignant haematological diseases. uuid:b1879270-5771-4a1f-b498-9321b9fa0108 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28876 biolink:treats MONDO:0004967 PMID:41385096 "[{""id"":""uuid:2183dfdc-b181-4d6b-9546-3c88ada133d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f1ef3f8c-a3cd-4441-bfb1-b164ef2b9b2d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] High-dose of Phelinun used alone or in combination with other cytotoxic medicinal products and/or total body irradiation is indicated in the treatment of:multiple myeloma,malignant lymphoma (Hodgkin, non-Hodgkin lymphoma),acute lymphoblastic and myeloblastic leukemia,childhood neuroblastoma,ovarian cancer,mammary adenocarcinoma.Phelinun in combination with other cytotoxic medicinal products is indicated as reduced intensity conditioning (RIC) treatment prior to allogeneic haematopoietic stem cell transplantation (allo-HSCT) in malignant haematological diseases in adults.Phelinun in combination with other cytotoxic medicinal products is indicated as conditioning regimen prior to allogeneic haematopoietic stem cell transplantation in haematological diseases in the paediatric population as:Myeloablative conditioning (MAC) treatment in case of malignant haematological diseasesRIC treatment in case of non-malignant haematological diseases. uuid:a92f2ec1-ceb0-4f1e-bed5-407a6ededb20 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28876 biolink:treats MONDO:0005072 PMID:41385096 "[{""id"":""uuid:e7dbcc35-cd11-4395-a7b1-e3f9baceef43"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f4542abc-8489-4377-ad4f-70ce4e0a149f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] High-dose of Phelinun used alone or in combination with other cytotoxic medicinal products and/or total body irradiation is indicated in the treatment of:multiple myeloma,malignant lymphoma (Hodgkin, non-Hodgkin lymphoma),acute lymphoblastic and myeloblastic leukemia,childhood neuroblastoma,ovarian cancer,mammary adenocarcinoma.Phelinun in combination with other cytotoxic medicinal products is indicated as reduced intensity conditioning (RIC) treatment prior to allogeneic haematopoietic stem cell transplantation (allo-HSCT) in malignant haematological diseases in adults.Phelinun in combination with other cytotoxic medicinal products is indicated as conditioning regimen prior to allogeneic haematopoietic stem cell transplantation in haematological diseases in the paediatric population as:Myeloablative conditioning (MAC) treatment in case of malignant haematological diseasesRIC treatment in case of non-malignant haematological diseases. uuid:0a9ea1cc-89fb-4769-b983-51dfc15f134a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28876 biolink:treats MONDO:0008170 PMID:41385096 "[{""id"":""uuid:6a494c04-7310-4f7c-b734-51aa20452876"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:6acaf04e-2b39-49db-a01e-a47d310450ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] High-dose of Phelinun used alone or in combination with other cytotoxic medicinal products and/or total body irradiation is indicated in the treatment of:multiple myeloma,malignant lymphoma (Hodgkin, non-Hodgkin lymphoma),acute lymphoblastic and myeloblastic leukemia,childhood neuroblastoma,ovarian cancer,mammary adenocarcinoma.Phelinun in combination with other cytotoxic medicinal products is indicated as reduced intensity conditioning (RIC) treatment prior to allogeneic haematopoietic stem cell transplantation (allo-HSCT) in malignant haematological diseases in adults.Phelinun in combination with other cytotoxic medicinal products is indicated as conditioning regimen prior to allogeneic haematopoietic stem cell transplantation in haematological diseases in the paediatric population as:Myeloablative conditioning (MAC) treatment in case of malignant haematological diseasesRIC treatment in case of non-malignant haematological diseases. uuid:6973cc10-f1b4-4c3b-b3f5-69ba6129a476 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28876 biolink:treats MONDO:0004988 PMID:41385096 "[{""id"":""uuid:80b05dd5-35dc-408d-b419-355686595c3a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:9b7d28c1-7adc-4713-9522-42f6fd906660"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] High-dose of Phelinun used alone or in combination with other cytotoxic medicinal products and/or total body irradiation is indicated in the treatment of:multiple myeloma,malignant lymphoma (Hodgkin, non-Hodgkin lymphoma),acute lymphoblastic and myeloblastic leukemia,childhood neuroblastoma,ovarian cancer,mammary adenocarcinoma.Phelinun in combination with other cytotoxic medicinal products is indicated as reduced intensity conditioning (RIC) treatment prior to allogeneic haematopoietic stem cell transplantation (allo-HSCT) in malignant haematological diseases in adults.Phelinun in combination with other cytotoxic medicinal products is indicated as conditioning regimen prior to allogeneic haematopoietic stem cell transplantation in haematological diseases in the paediatric population as:Myeloablative conditioning (MAC) treatment in case of malignant haematological diseasesRIC treatment in case of non-malignant haematological diseases. uuid:4264502c-61f8-4b91-ab36-cff2ba9aa74b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63638 biolink:treats MONDO:0005384 PMID:41385096 "[{""id"":""uuid:1a74b198-e962-4584-9c28-7318db5c60a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:2f218119-c6e4-4154-8fe3-d6a8aa64f1e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/kigabeq""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Kigabeq is indicated in infants and children from 1 month to less than 7 years of age for:Treatment in monotherapy of infantile spasms (West's syndrome).Treatment in combination with other antiepileptic medicinal products for patients with resistant partial epilepsy (focal onset seizures) with or without secondary generalisation, that is where all other appropriate medicinal product combinations have proved inadequate or have not been tolerated. uuid:493fd5a7-cb09-4ce6-b78b-fea47b216f31 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63638 biolink:treats HP:0011188 PMID:41385096 "[{""id"":""uuid:a84fe728-0c73-4a2e-ba0c-70eff8c76368"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d99c683f-16fc-453c-b670-e207382e4150"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/kigabeq""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Kigabeq is indicated in infants and children from 1 month to less than 7 years of age for:Treatment in monotherapy of infantile spasms (West's syndrome).Treatment in combination with other antiepileptic medicinal products for patients with resistant partial epilepsy (focal onset seizures) with or without secondary generalisation, that is where all other appropriate medicinal product combinations have proved inadequate or have not been tolerated. uuid:26e1bffd-aa7a-4e6c-a845-492cb3914b49 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75922 biolink:treats NCIT:C34887 PMID:41385096 "[{""id"":""uuid:d87b6e76-a86e-4ed5-9523-f3fd021f4a46"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:14c73f00-e1eb-4b87-9570-3c1e42ca43a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/nevanac""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Nevanac is indicated for:, , , prevention and treatment of postoperative pain and inflammation associated with cataract surgery;, reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients., , uuid:3bbc1c26-dc20-490f-be20-af2c51dc8c77 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75922 biolink:treats MONDO:0003005 PMID:41385096 "[{""id"":""uuid:9b4609ca-69f0-4470-be1a-7f4e669ce708"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:3706aa41-e7cc-4f94-b9a3-c98931a645ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/nevanac""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Nevanac is indicated for:, , , prevention and treatment of postoperative pain and inflammation associated with cataract surgery;, reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients., , uuid:d2f88b54-bde5-43a7-98ce-698e66d89fbe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:65349 biolink:treats UMLS:C0150045 PMID:41385096 "[{""id"":""uuid:f12174c0-50f0-4f43-bd28-c848fde03499"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:ba0cbf9c-549d-4dff-a763-20ff79f8fd1b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/betmiga""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Symptomatic treatment of urgency.Increased micturition frequency and / or urgency incontinence as may occur in adult patients with overactive-bladder syndrome. uuid:38325fb8-987e-4cba-bc6f-a875e23c4ce6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17141 biolink:treats MONDO:0001106 PMID:41385096 "[{""id"":""uuid:9c5f73d4-7229-455f-83ed-403cc487727b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:47e9fe42-8c9c-4b08-9766-23bc92296b0a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/cystagon""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Cystagon is indicated for the treatment of proven nephropathic cystinosis. Cysteamine reduces cystine accumulation in some cells (e.g. leukocytes, muscle and liver cells) of nephropathic cystinosis patients and, when treatment is started early, it delays the development of renal failure. uuid:452e4a12-bbd3-436a-af74-8e63d1210115 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:02E00T2QDE biolink:treats MONDO:0010604 PMID:41385096 "[{""id"":""uuid:921531c6-cd0c-4a03-916b-0345c038798f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:16ba31f1-a3e7-4f75-b3c7-ecbdf0651bd7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/alprolix""]},{""id"":""uuid:43c071f5-4dee-4609-81b3-c7e7614ea59c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency).|[PMDA] Drugs with a new active ingredient indicated for inhibition of bleeding tendency in patients with blood coagulation factor IX deficiency. uuid:7f54abd0-bc73-4ca6-9359-b9825e1ecd85 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9434 biolink:treats MONDO:0001134 PMID:41385096 "[{""id"":""uuid:4bda7669-8177-48a8-a520-7b93d44a16e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:e1f1401f-0072-4270-9563-2c61242a23a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/telmisartan-actavis""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of essential hypertension in adults. uuid:f22d7822-ceab-4931-b9e1-4e5e9f59e558 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:T472P45MG6 biolink:treats MONDO:0011385 PMID:41385096 "[{""id"":""uuid:72013112-3542-4d10-ad4a-6f2451e9dcb8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f6bcb38f-dba4-4f60-8554-536d781f3952"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/inductos""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Inductos is indicated for single level lumbar interbody spine fusion as a substitute for autogenous bone graft in adults with degenerative disc disease who have had at least 6 months of non operative treatment for this condition.Inductos is indicated for the treatment of acute tibia fractures in adults, as an adjunct to standard care using open fracture reduction and intramedullary unreamed nail fixation. uuid:aa6b1efe-6d3e-43d3-adfb-816156e316ee biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:T472P45MG6 biolink:treats HP:0041143 PMID:41385096 "[{""id"":""uuid:3f6ff722-483b-419f-ac45-80e335e77736"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:84392175-2cf9-45cf-ac55-6ce048297cc6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/inductos""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Inductos is indicated for single level lumbar interbody spine fusion as a substitute for autogenous bone graft in adults with degenerative disc disease who have had at least 6 months of non operative treatment for this condition.Inductos is indicated for the treatment of acute tibia fractures in adults, as an adjunct to standard care using open fracture reduction and intramedullary unreamed nail fixation. uuid:e98cf7bb-a627-4dd1-a000-007f7ad50969 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50663 biolink:treats UMLS:C0858004 PMID:41385096 "[{""id"":""uuid:de2207af-78c4-44e1-963f-cf1f490883b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:2f33f5cc-6f7b-4722-adfc-346e124c07bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/dectova""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Dectova is indicated for the treatment of complicated and potentially life-threatening influenza A or B virus infection in adult and paediatric patients (aged ≥6 months) when:The patient’s influenza virus is known or suspected to be resistant to anti-influenza medicinal products other than zanamivir, and/orOther anti-viral medicinal products for treatment of influenza, including inhaled zanamivir, are not suitable for the individual patient.Dectova should be used in accordance with official guidance. uuid:95a4fe32-b4da-4479-bc35-b9c345d675aa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68575 biolink:treats MONDO:0005002 PMID:41385096 "[{""id"":""uuid:a61b94c7-f21c-48d7-acb6-47aa12a1d806"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:1809efd1-819a-4bd2-a9b8-0031d56ee9a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Onbrez Breezhaler is indicated for maintenance bronchodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease. uuid:22f8929f-7790-4ff8-a7bd-116967dc8c03 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1994308 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:1a0770d9-a75f-42ac-8f9b-78d4282aa725"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:eaf7a694-2d36-444b-aa58-5770558b83ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ryzodeg""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of diabetes mellitus in adults, adolescents and children from the age of 2 years. uuid:3e690600-be6a-4477-8a64-e4ff5ba405c0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68556 biolink:treats MONDO:0007361 PMID:41385096 "[{""id"":""uuid:bdddc611-021b-45ff-b641-450fcc2422a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:bb6c97a9-79e9-4af1-8d09-98dc2bfc0bc7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/firazyr""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Icatibant Accord is indicated for symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults, adolescents and children aged 2 years and older, with C1 esterase inhibitor deficiency. uuid:e4009638-0ff2-4c35-9e0d-ff837c7eb12d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:132268 biolink:treats UMLS:C3266992 PMID:41385096 "[{""id"":""uuid:04576143-b98c-4b13-9dd4-d8c2da7b7563"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:49698f4a-d9fe-4894-b7ae-c2fa0608a324"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:434ba1e5-cda0-41b7-bf95-86b6c04fab42"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Vizimpro, as monotherapy, is indicated for the first-line treatment of adult patients with locally advanced or metastatic non small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) activating mutations.|[PMDA] Drugs with a new active ingredient indicated for the treatment of inoperable or recurrent non-small cell lung cancer with EGFR gene mutation. [Priority review] uuid:8df54240-8ca4-470b-a80f-722f6c38a44e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50131 biolink:treats MONDO:0018874 PMID:41385096 "[{""id"":""uuid:ea4eaefe-d390-49a5-a554-396e6afc3d79"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:157a63cb-7c92-4073-b844-96aad654e3ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/dacogen""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of adult patients with newly diagnosed de novo or secondary acute myeloid leukaemia (AML), according to the World Health Organization (WHO) classification, who are not candidates for standard induction chemotherapy. uuid:51cd80f6-0b18-4f92-8edb-e781f54f3f79 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:21904A5386 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:99e534c3-18a9-440d-9049-c018db9f801f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:3cb8b7a3-99ae-4224-a04d-6f629ef9e053"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Xenleta is indicated for the treatment of community-acquired pneumonia (CAP) in adults when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of CAP or when these have failed.Consideration should be given to official guidance on the appropriate use of antibacterial agents. uuid:811b9616-c14a-43ac-b78f-f385d96612c1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:21904A5386 biolink:treats MONDO:0015753 PMID:41385096 "[{""id"":""uuid:902342a4-fff9-4877-a19b-e68e9c472944"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:94790e43-6b33-478f-b909-251fa2dd1f1d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Xenleta is indicated for the treatment of community-acquired pneumonia (CAP) in adults when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of CAP or when these have failed.Consideration should be given to official guidance on the appropriate use of antibacterial agents. uuid:e872878c-d2ad-4b62-ab38-cf147f330a7e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3H8GSZ4SQL biolink:treats MONDO:0002049 PMID:41385096 "[{""id"":""uuid:be8b5f0a-ed3e-413c-8e39-348d7f846561"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:aae5b21a-60e1-43bd-8eae-197559eb93dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Doptelet is indicated for the treatment of severe thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo an invasive procedure.Doptelet is indicated for the treatment of primary chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins). uuid:77da3b7b-5b03-46e7-83da-3700e1f7a557 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3H8GSZ4SQL biolink:treats MONDO:0008558 PMID:41385096 "[{""id"":""uuid:605df77a-e834-4b31-86b0-8e445737aa4b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d8ac07a2-e67c-4c1e-940d-43a9f43de8f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Doptelet is indicated for the treatment of severe thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo an invasive procedure.Doptelet is indicated for the treatment of primary chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins). uuid:10af59e0-9972-4059-8d2f-0b87d6b41e59 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47518 biolink:treats MONDO:0018912 PMID:41385096 "[{""id"":""uuid:16ca4fe2-470f-4f5f-90f1-77fc3025bb38"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:7f02faa8-3137-42ce-831c-47ad52b7ac4a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ketoconazole-hra""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Ketoconazole HRA is indicated for the treatment of endogenous Cushing’s syndrome in adults and adolescents above the age of 12 years. uuid:9092d3b5-696c-4cf3-9508-4dd3d77c8d94 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59594 biolink:treats MONDO:0005439 PMID:41385096 "[{""id"":""uuid:7113c5ef-9cde-497f-a0e0-d899becb1f7c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:5faa7ff1-873e-43ad-b1a9-03b4ad50fc81"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Cholestagel co-administered with a 3-hydroxy-3-methyl-glutaryl-coenzyme-A (HMG-CoA)-reductase inhibitor (statin) is indicated as adjunctive therapy to diet to provide an additive reduction in low-density-lipoprotein-cholesterol (LDL-C) levels in adult patients with primary hypercholesterolaemia who are not adequately controlled with a statin alone.Cholestagel as monotherapy is indicated as adjunctive therapy to diet for reduction of elevated total cholesterol and LDL-C in adult patients with primary hypercholesterolaemia, in whom a statin is considered inappropriate or is not well tolerated.Cholestagel can also be used in combination with ezetimibe, with or without a statin, in adult patients with primary hypercholesterolaemia, including patients with familial hypercholesterolaemia (see section 5.1). uuid:809af137-32a5-4c58-a9ff-b0a3b3b4a227 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90863 biolink:treats MONDO:0005341 PMID:41385096 "[{""id"":""uuid:90dc60d9-0807-4f9b-b58b-a881088c1416"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f836d0c3-9a13-4d70-8ba5-6476020b6fe8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Odomzo is indicated for the treatment of adult patients with locally advanced basal cell carcinoma (BCC) who are not amenable to curative surgery or radiation therapy. uuid:97c9681c-3c33-44ab-8030-c9cf9aed0d29 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:66880 biolink:treats MONDO:0002039 PMID:41385096 "[{""id"":""uuid:93a3fec3-2f08-413b-9d63-102aee40de6c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:9e2d6197-c420-45a0-a8cd-a89146781b37"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] This medicinal product is for diagnostic use only.Amyvid is a radiopharmaceutical indicated for Positron Emission Tomography (PET) imaging of β-amyloid neuritic plaque density in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD) and other causes of cognitive impairment. Amyvid should be used in conjunction with a clinical evaluation.A negative scan indicates sparse or no plaques, which is not consistent with a diagnosis of AD. uuid:704dbd68-bd8e-4994-b6e3-43befffa8216 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135947 biolink:treats MONDO:0008159 PMID:41385096 "[{""id"":""uuid:1e7ccff8-b8ee-4465-a9c2-2f071f35a6fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:19443056-850f-45cf-ae25-1634aded1646"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/conbriza""]},{""id"":""uuid:6d91e644-18e3-4c9f-b3dc-d76e0a2af1e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Conbriza is indicated for the treatment of postmenopausal osteoporosis in women at increased risk of fracture. A significant reduction in the incidence of vertebral fractures has been demonstrated; efficacy on hip fractures has not been established.When determining the choice of Conbriza or other therapies, including oestrogens, for an individual postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefits.|[PMDA] A drug with a new active ingredient indicated for the treatment of postmenopausal osteoporosis. uuid:25392136-384f-48a9-9743-b5aa1025744e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135947 biolink:treats HP:0041166 PMID:41385096 "[{""id"":""uuid:71ec7eb6-a0bc-4e2a-8bea-5f5111f5e2bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d926a9c0-8aa8-413f-aadc-14effcf9e24d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/conbriza""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Conbriza is indicated for the treatment of postmenopausal osteoporosis in women at increased risk of fracture. A significant reduction in the incidence of vertebral fractures has been demonstrated; efficacy on hip fractures has not been established.When determining the choice of Conbriza or other therapies, including oestrogens, for an individual postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefits. uuid:f5b53bae-2f34-4ecf-9e72-ac79403aa558 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71025 biolink:treats MONDO:0007886 PMID:41385096 "[{""id"":""uuid:3bd6a69e-e13f-478b-9e79-dbca7d920aa5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:65d480be-0d6e-4735-bc57-51beb2e34017"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ellaone""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Ulipristal acetate is indicated for pre-operative treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.Ulipristal acetate is indicated for intermittent treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age. uuid:74d218c3-93e5-46d8-8bdf-a1871d548548 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7V6HE3DM5A biolink:treats HP:0031151 PMID:41385096 "[{""id"":""uuid:5126fd3e-0b2d-416c-91a9-10391feec731"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:88ba8638-c64c-48a2-8e7c-891d35a38958"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/jetrea""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Jetrea is indicated in adults for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns. uuid:80ad8cf6-a47f-47e2-9eed-8de3736029db biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7V6HE3DM5A biolink:treats MONDO:0006843 PMID:41385096 "[{""id"":""uuid:29c6ab51-afb9-45d4-b716-3bb1aa07ee8a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:c8d79b68-3606-497f-9ca7-41f5321fb5d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/jetrea""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Jetrea is indicated in adults for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns. uuid:1784acb2-2e5f-4237-9f5b-502bb75db8a1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C1997870 biolink:treats MONDO:0018881 PMID:41385096 "[{""id"":""uuid:dfd6984b-0ea5-4e4b-a291-0af54628bfb1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:301e97bf-eebd-4a9b-a750-fbb4e8a7ae60"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/retacrit""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adult and paediatric patientsTreatment of anaemia associated with chronic renal failure in adult and paediatric patients on haemodialysis and adult patients on peritoneal dialysis.Treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis.Treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre‑existing anaemia at the start of chemotherapy).Silapo can be used to increase the yield of autologous blood from patients in a predonation programme. Its use in this indication must be balanced against the reported risk of thromboembolic events. Treatment should only be given to patients with moderate anaemia (no iron deficiency), if blood saving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males).Silapo is indicated for non-iron deficient adults prior to major elective orthopaedic surgery having a high perceived risk for transfusion complications to reduce exposure to allogeneic blood transfusions. Use should be restricted to patients with moderate anaemia (e.g. haemoglobin concentration range between 10 to 13 g/dl) who do not have an autologous predonation programme available and with expected moderate blood loss (900 to 1 800 ml).Silapo can be used to increase haemoglobin concentration in symptomatic anaemia (haemoglobin concentration of ≤10 g/dl) in adults with low- or intermediate-1-risk primary myelodysplastic syndromes (MDS) who have low serum erythropoietin ( MESH:C530192 uuid:ee66c4dd-5e53-41c6-909b-c71b4ea1c654 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB15373 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:b4a6c301-41e8-4c86-89cd-2191f3c31222"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:2b007f65-b1db-46a3-a637-bc2b92835e28"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/lymphoseek""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] This medicinal product is for diagnostic use only.Radiolabelled Lymphoseek is indicated for imaging and intraoperative detection of sentinel lymph nodes draining a primary tumour in adult patients with breast cancer, melanoma, or localised squamous cell carcinoma of the oral cavity.External imaging and intraoperative evaluation may be performed using a gamma detection device. uuid:31ed1876-a72d-4eff-a5f0-316ce860c19c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB15373 biolink:treats MONDO:0005105 PMID:41385096 "[{""id"":""uuid:70835ef3-bb4b-4485-b474-bcc6011d9270"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:c047b37d-c41a-4b4a-8344-885ce7ee999d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/lymphoseek""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] This medicinal product is for diagnostic use only.Radiolabelled Lymphoseek is indicated for imaging and intraoperative detection of sentinel lymph nodes draining a primary tumour in adult patients with breast cancer, melanoma, or localised squamous cell carcinoma of the oral cavity.External imaging and intraoperative evaluation may be performed using a gamma detection device. uuid:87d31f1b-d6ff-4bc1-aa07-cf13a4fb6798 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB15373 biolink:treats MONDO:0004958 PMID:41385096 "[{""id"":""uuid:1e825ddb-eb1e-440a-9926-90f80d26bae1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:072f365f-bbfa-4696-b0c6-00b821dc66fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/lymphoseek""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] This medicinal product is for diagnostic use only.Radiolabelled Lymphoseek is indicated for imaging and intraoperative detection of sentinel lymph nodes draining a primary tumour in adult patients with breast cancer, melanoma, or localised squamous cell carcinoma of the oral cavity.External imaging and intraoperative evaluation may be performed using a gamma detection device. uuid:4c1a5283-9768-4536-9a02-140feca810d0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32293 biolink:treats MONDO:0001383 PMID:41385096 "[{""id"":""uuid:8ee63db2-4af8-4533-8bef-875a69818f43"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:eb0abfec-14ee-4f58-a3b2-5e3ed44a84ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/visudyne""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Visudyne is indicated for the treatment of:adults with exudative (wet) age-related macular degeneration (AMD) with predominantly classic subfoveal choroidal neovascularisation (CNV) or;adults with subfoveal choroidal neovascularisation secondary to pathological myopia. uuid:95708814-f823-4d5f-90a9-813722429f53 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:9938056 biolink:treats MONDO:0024298 PMID:41385096 "[{""id"":""uuid:a8112c18-330f-433d-836c-96926a140be4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:64b3ba75-8d71-4bee-b559-dd88ecd12e1c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/vedrop""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Vedrop is indicated in vitamin-E deficiency due to digestive malabsorption in paediatric patients suffering from congenital chronic cholestasis or hereditary chronic cholestasis, from birth (in term newborns) to 16 or 18 years of age, depending on the region. uuid:c5e35a2c-9996-414b-a3bd-3a11b04ddafd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:9938056 biolink:treats MONDO:0001751 PMID:41385096 "[{""id"":""uuid:956a14c2-1eb1-4d3c-b292-f24cc9e984fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:95c82a23-bbe8-471e-81fb-c8002d7c9f54"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/vedrop""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Vedrop is indicated in vitamin-E deficiency due to digestive malabsorption in paediatric patients suffering from congenital chronic cholestasis or hereditary chronic cholestasis, from birth (in term newborns) to 16 or 18 years of age, depending on the region. uuid:a9c770b3-6f58-4922-99cb-83898e49169c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:9938056 biolink:treats MONDO:0015762 PMID:41385096 "[{""id"":""uuid:e65c15d6-c950-4f14-892d-c63683fdd547"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d8924b55-82b6-447c-828c-a6811c573a53"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/vedrop""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Vedrop is indicated in vitamin-E deficiency due to digestive malabsorption in paediatric patients suffering from congenital chronic cholestasis or hereditary chronic cholestasis, from birth (in term newborns) to 16 or 18 years of age, depending on the region. uuid:7c39fd46-756b-4301-81ed-db87feba1a12 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9437 biolink:treats MONDO:0010150 PMID:41385096 "[{""id"":""uuid:3432cc86-a76a-46e2-9c48-6436fa5e216e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d2570e1f-a2cf-46ca-81db-7f6ddfa00556"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/foscan""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Foscan is indicated for the palliative treatment of patients with advanced head and neck squamous cell carcinoma failing prior therapies and unsuitable for radiotherapy, surgery or systemic chemotherapy. uuid:0038d574-170c-488b-9ca7-39bc2df09d8d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:745X144DZY biolink:treats HP:0002653 PMID:41385096 "[{""id"":""uuid:d4c1678f-d6e6-4a09-a638-12851aebd216"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:ae9fee62-35e5-4105-af6e-23e566a91958"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Quadramet is indicated for the relief of bone pain in patients with multiple painful osteoblastic skeletal metastases which take up technetium [99mTc]-labelled biphosphonates on bone scan.The presence of osteoblastic metastases which take up technetium [99mTc]-labelled biphosphonates should be confirmed prior to therapy. uuid:afcf3720-fbba-4816-a2cf-b5c6fc17b0cd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:176399 biolink:treats MONDO:0005439 PMID:41385096 "[{""id"":""uuid:9f731892-52c2-4ffd-bb6b-58c3e9e80e68"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:181542e5-866e-4252-9fb3-9d3c1aa174b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of familial hypercholesterolemia and hypercholesterolemia (for use only in patients who met all of the followings:) High risk of developing cardiovascular events Patients who have not sufficiently responded to an HMG-CoA reductase inhibitor or in whom treatment with HMG-CoA reductase inhibitors is not suitable. uuid:e38e9d01-eda7-44aa-a7f7-0aba959b7784 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:176399 biolink:treats HP:0003124 PMID:41385096 "[{""id"":""uuid:43e8b9d6-b817-443d-8361-b2b2fb8fc70c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:58dd302c-20b8-4630-9584-160abc4ba459"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of familial hypercholesterolemia and hypercholesterolemia (for use only in patients who met all of the followings:) High risk of developing cardiovascular events Patients who have not sufficiently responded to an HMG-CoA reductase inhibitor or in whom treatment with HMG-CoA reductase inhibitors is not suitable. uuid:b380f352-7b43-475d-be3b-45c8907535b7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71013 biolink:treats HP:0007334 PMID:41385096 "[{""id"":""uuid:3a8275fa-0c1a-46b1-be3b-be446909ebf6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4cd13ae6-a91d-48fd-bde2-51d292681f8c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new route of administration indicated for the following treatment: partial seizures (including secondary generalized seizures) in patients with epilepsy and an adjunctive therapy with other antiepileptic drugs to treat tonic-clonic seizure in patients with epilepsy who have not responded sufficiently to other antiepileptic drugs. It is used as an alternative therapy for perampanel oral formulation in patients who are temporarily unable to be administered orally. uuid:35ae506e-c328-41ee-93d5-95341a0ffe55 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71013 biolink:treats HP:0002069 PMID:41385096 "[{""id"":""uuid:d2d45630-b098-40ef-b6cf-0f4c40d05b12"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6c5352c7-a512-49e2-b9dc-21117f7bffec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new route of administration indicated for the following treatment: partial seizures (including secondary generalized seizures) in patients with epilepsy and an adjunctive therapy with other antiepileptic drugs to treat tonic-clonic seizure in patients with epilepsy who have not responded sufficiently to other antiepileptic drugs. It is used as an alternative therapy for perampanel oral formulation in patients who are temporarily unable to be administered orally. uuid:c47014a9-85f5-4749-9a67-b84d285d3229 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2639950 biolink:treats MONDO:0009688 PMID:41385096 "[{""id"":""uuid:96f9f08c-e9fd-419e-abc2-b055893fa609"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:aa499e93-da83-4794-a8b9-d9da9add2c09"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug with a new active ingredient indicated for the treatment of generalized myasthenia gravis (for use only in patients who have not sufficiently responded to steroids or other immunosuppressants). uuid:a3e46943-e197-4342-81b4-8284be9cf814 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:349962 biolink:treats MONDO:0014945 PMID:41385096 "[{""id"":""uuid:0837c968-4147-472f-9ae6-60a39459998b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:38bf1a6e-8cce-4735-ac9e-12528b68439e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for delaying the progression of muscle weakness in patients with distal myopathy with rimmed vacuoles. [Orphan drug] uuid:ae44265a-1e0c-4a1b-a0fa-4c2cd7f787b6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:15C2VL427D biolink:treats MONDO:0005150 PMID:41385096 "[{""id"":""uuid:36d263d9-1f91-4eeb-9b4f-83582bc367cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:06787e58-8e7c-4ceb-b5e2-b58db4089283"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug in a new dosage form indicated for the treatment of age-related macular degeneration associated with subfoveal choroidal neovascularization and diabetic macular edema. uuid:fb50c257-1c93-4842-bf3d-c5f8b2e3f8b7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:140376 biolink:treats MONDO:0020920 PMID:41385096 "[{""id"":""uuid:3f7e7c81-a5b2-4301-9a83-915bacdd5fc0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b48236dd-9ca9-4183-8527-b2fb5ded2c2a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of infections caused by Cefiderocol- sensitive Escherichia coli , Citrobacter spp, Klebsiella pneumoniae , Klebsiella spp, Enterobacter spp, Serratia marcescens , Proteus spp, Morganella morganii , Pseudomonas aeruginosa , Burkholderia spp, Stenotrophomonas maltophilia , and Acinetobacter spp (limited to bacterial strains resistant to carbapenem antimicrobial drugs). [Orphan drug] uuid:2e3db31a-8ccd-43b0-8434-90d57a03e6ce biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:140376 biolink:treats MONDO:0030602 PMID:41385096 "[{""id"":""uuid:6977e856-dbea-4be8-91d1-cdde7321eb49"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ded82612-a962-437b-9bb5-6967145b86e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of infections caused by Cefiderocol- sensitive Escherichia coli , Citrobacter spp, Klebsiella pneumoniae , Klebsiella spp, Enterobacter spp, Serratia marcescens , Proteus spp, Morganella morganii , Pseudomonas aeruginosa , Burkholderia spp, Stenotrophomonas maltophilia , and Acinetobacter spp (limited to bacterial strains resistant to carbapenem antimicrobial drugs). [Orphan drug] uuid:e377703a-e5de-4fda-839e-1940d46c2ba1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:140376 biolink:treats MONDO:0030603 PMID:41385096 "[{""id"":""uuid:2c9863e6-82ac-4126-8cf0-0648e2be6eb2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:27c33a48-545f-404b-a6e0-fce5e81e09d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of infections caused by Cefiderocol- sensitive Escherichia coli , Citrobacter spp, Klebsiella pneumoniae , Klebsiella spp, Enterobacter spp, Serratia marcescens , Proteus spp, Morganella morganii , Pseudomonas aeruginosa , Burkholderia spp, Stenotrophomonas maltophilia , and Acinetobacter spp (limited to bacterial strains resistant to carbapenem antimicrobial drugs). [Orphan drug] uuid:6ac0b298-8fc0-4366-9d50-c23910522506 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:140376 biolink:treats EFO:1001421 PMID:41385096 "[{""id"":""uuid:74722371-0de2-440a-b2f9-2cde0334570a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7042ec01-dde9-42ed-933c-e54f34066594"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of infections caused by Cefiderocol- sensitive Escherichia coli , Citrobacter spp, Klebsiella pneumoniae , Klebsiella spp, Enterobacter spp, Serratia marcescens , Proteus spp, Morganella morganii , Pseudomonas aeruginosa , Burkholderia spp, Stenotrophomonas maltophilia , and Acinetobacter spp (limited to bacterial strains resistant to carbapenem antimicrobial drugs). [Orphan drug] uuid:f1c7b089-9460-472c-bbac-5ee1a5dd1a34 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:140376 biolink:treats MONDO:0006929 PMID:41385096 "[{""id"":""uuid:593ae9a3-2272-4a2f-84a1-1f1f462caffe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:348a2674-d2d2-4759-8432-46f8078cca45"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of infections caused by Cefiderocol- sensitive Escherichia coli , Citrobacter spp, Klebsiella pneumoniae , Klebsiella spp, Enterobacter spp, Serratia marcescens , Proteus spp, Morganella morganii , Pseudomonas aeruginosa , Burkholderia spp, Stenotrophomonas maltophilia , and Acinetobacter spp (limited to bacterial strains resistant to carbapenem antimicrobial drugs). [Orphan drug] uuid:2a6b1b09-69b6-48d8-85ee-1448f5f8fcb8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:140376 biolink:treats UMLS:C0343404 PMID:41385096 "[{""id"":""uuid:6cf52586-4bd1-4451-9f31-a348febbec52"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b4b91109-7162-4205-9592-b89e19133b02"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of infections caused by Cefiderocol- sensitive Escherichia coli , Citrobacter spp, Klebsiella pneumoniae , Klebsiella spp, Enterobacter spp, Serratia marcescens , Proteus spp, Morganella morganii , Pseudomonas aeruginosa , Burkholderia spp, Stenotrophomonas maltophilia , and Acinetobacter spp (limited to bacterial strains resistant to carbapenem antimicrobial drugs). [Orphan drug] uuid:0ca30ef1-5157-40ef-973a-1c37790f9085 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:140376 biolink:treats MONDO:0005141 PMID:41385096 "[{""id"":""uuid:0702654f-593c-43c4-b484-0cc6af9315fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:907e47e3-f75b-4eb3-a3ee-30511c08c0aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of infections caused by Cefiderocol- sensitive Escherichia coli , Citrobacter spp, Klebsiella pneumoniae , Klebsiella spp, Enterobacter spp, Serratia marcescens , Proteus spp, Morganella morganii , Pseudomonas aeruginosa , Burkholderia spp, Stenotrophomonas maltophilia , and Acinetobacter spp (limited to bacterial strains resistant to carbapenem antimicrobial drugs). [Orphan drug] uuid:bfeb141e-f11f-4844-b6fd-ee80a65183c2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:140376 biolink:treats MONDO:0043953 PMID:41385096 "[{""id"":""uuid:5a003b4f-62c2-47eb-8e4c-2a768d2b2f51"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:92309216-667f-4544-a280-cba3039fb3dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of infections caused by Cefiderocol- sensitive Escherichia coli , Citrobacter spp, Klebsiella pneumoniae , Klebsiella spp, Enterobacter spp, Serratia marcescens , Proteus spp, Morganella morganii , Pseudomonas aeruginosa , Burkholderia spp, Stenotrophomonas maltophilia , and Acinetobacter spp (limited to bacterial strains resistant to carbapenem antimicrobial drugs). [Orphan drug] uuid:b14335c1-0136-4125-9b96-67990f6eea88 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:140376 biolink:treats MONDO:0006635 PMID:41385096 "[{""id"":""uuid:7189c382-d9ee-4229-8c15-73276be6a858"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:123c386d-7c5e-4d20-867f-f3f9aa5f6cda"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of infections caused by Cefiderocol- sensitive Escherichia coli , Citrobacter spp, Klebsiella pneumoniae , Klebsiella spp, Enterobacter spp, Serratia marcescens , Proteus spp, Morganella morganii , Pseudomonas aeruginosa , Burkholderia spp, Stenotrophomonas maltophilia , and Acinetobacter spp (limited to bacterial strains resistant to carbapenem antimicrobial drugs). [Orphan drug] uuid:712ec865-8083-4584-9ce4-e8a9ea3dcac2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PX665RAA3H biolink:treats MONDO:0100096 PMID:41385096 "[{""id"":""uuid:4dbe1a31-8d6f-46c8-a05c-8f3fe0b5c7d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6f68508b-b194-4ed3-a6ef-fc7a297f02ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of disease caused by SARS-CoV-2 infection (COVID-19). uuid:a1278e2a-3c4e-4b11-b518-bcd3187a048c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:GN465U8B72 biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:7dd38f8b-f1fb-418c-9833-ea5b7bd26b91"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d5e35fac-d3f8-4b1a-a845-36302630101e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage for the treatment of prurigo nodularis in patients who have not responded sufficiently to conventional treatments, and a new additional pediatric dosage in an additional dosage form, indicated for the treatment of pruritus associated with atopic dermatitis in patients who have not responded sufficiently to conventional treatments. uuid:fc05ee80-b0e6-44ed-b699-f579e5646121 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:5TAA004E22 biolink:treats MONDO:0012579 PMID:41385096 "[{""id"":""uuid:86087425-3bf3-4ed1-bcce-91c82a0ebca0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c7d2bed9-6d06-438c-b621-7dff16edd6b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of autoimmune pulmonary alveolar proteinosis. [Orphan drug] uuid:17b67b08-8b96-4a7c-8081-5d95ebcc0a78 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7D96IR0PPM biolink:treats MONDO:0005062 PMID:41385096 "[{""id"":""uuid:b4206b2a-d3f9-4492-9ac8-eccd3dc11969"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ec967563-5c7a-4b3e-b094-1db2b1900e5e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of acute lymphocytic leukemia and malignant lymphoma. uuid:d2188eed-2286-4fc6-a59f-fdb3e73d4910 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4B93MGE4AL biolink:treats MONDO:0003060 PMID:41385096 "[{""id"":""uuid:a754f0c4-47bc-4a2b-85ec-4b673c68fa73"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:83198a64-779c-4b88-a85e-42070c6174ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of unresectable FGFR2 fusion gene-positive biliary tract cancer that has progressed after cancer chemotherapy. uuid:eb5b0d98-ac29-4702-9aa1-e9da6f66c6b3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1942744 biolink:treats MONDO:0018874 PMID:41385096 "[{""id"":""uuid:fa8d56da-2d9e-4267-b9a2-fdc2ff4adbc0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f598882b-2b5a-41b8-9f00-746c428e2026"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug indicated for the treatment of high-risk acute myeloid leukemia. [Orphan drug] uuid:42bd00e1-3e2c-4b7d-b2a9-98650e62149a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:TF5MPQ8WGY biolink:treats MONDO:0001056 PMID:41385096 "[{""id"":""uuid:684bd4ce-1492-4ab6-955f-6beb615e4843"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8893f401-550a-486f-8850-4590110b668b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of CLDN18.2 (Claudin-18 splice variant 2)-positive unresectable advanced or recurrent gastric cancer. uuid:18603517-cbcf-4482-9b61-4e03fb996a6d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:AP7FFK83RM biolink:treats MONDO:0100096 PMID:41385096 "[{""id"":""uuid:0f8f82bc-772e-448f-9ed3-e0fba0b3f8a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f74dd73a-5758-4f7d-a208-8b4bae467d2a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the prevention of disease caused by SARS-CoV-2 infection (COVID-19). [Priority review] uuid:24f13a38-ea5c-4a88-a3d0-dc5c6758562d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1153960 biolink:treats MONDO:0005077 PMID:41385096 "[{""id"":""uuid:600a236d-7aa9-4547-bcc1-87797e7e4423"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:97c4c679-8da5-4d2b-aac7-f93087fae59e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug with a new active ingredient indicated for the prevention of pertussis, diphtheria, tetanus, acute poliomyelitis, and infections caused by Haemophilus influenzae type b . uuid:4d978897-89c2-4d10-b68a-a6aa08145478 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1153960 biolink:treats MONDO:0005504 PMID:41385096 "[{""id"":""uuid:1b65adf8-42b8-4c7b-b1c2-e48682b6f7e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4874b28e-8679-4f21-9b7f-28e4bb342aba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug with a new active ingredient indicated for the prevention of pertussis, diphtheria, tetanus, acute poliomyelitis, and infections caused by Haemophilus influenzae type b . uuid:4f6e3182-de78-43f9-b81b-e722bbfa3fe6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1153960 biolink:treats MONDO:0005526 PMID:41385096 "[{""id"":""uuid:1877e094-84da-4b82-93b8-e791e084615f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8278835c-42d7-4062-8ddd-7f84a5bc3890"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug with a new active ingredient indicated for the prevention of pertussis, diphtheria, tetanus, acute poliomyelitis, and infections caused by Haemophilus influenzae type b . uuid:71bbb1fb-c915-401c-8fba-430cfcefb959 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1153960 biolink:treats MONDO:0017373 PMID:41385096 "[{""id"":""uuid:9234c8c3-5f61-4f9c-86c1-3ff935257090"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e03bc660-c074-48fe-aa9e-3f65e61e2ce5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug with a new active ingredient indicated for the prevention of pertussis, diphtheria, tetanus, acute poliomyelitis, and infections caused by Haemophilus influenzae type b . uuid:617f488a-b6d1-4f1f-9a3f-e6a20fca148c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1153960 biolink:treats MONDO:0000889 PMID:41385096 "[{""id"":""uuid:51a5db57-b906-4495-b260-d5a39bf96d4a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0e2913b6-ce55-46b1-abda-b924c56693a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug with a new active ingredient indicated for the prevention of pertussis, diphtheria, tetanus, acute poliomyelitis, and infections caused by Haemophilus influenzae type b . uuid:20d323a2-4d21-4e9d-955a-1f2271060b83 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB18713 biolink:treats MONDO:0001577 PMID:41385096 "[{""id"":""uuid:2ebb82f8-da15-45f3-96e4-0b4728f11c33"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6925e100-358d-4032-87fb-80f28a062eee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the prevention of disease caused by RS virus infection. uuid:4c331287-0122-4fd4-87b8-49a9cbcc397e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C5787321 biolink:treats MONDO:0100096 PMID:41385096 "[{""id"":""uuid:4fec9fdf-579f-4b32-9d68-67abfb7377b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:fc29385b-eeeb-40f0-9ec9-4df2963e8463"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the prevention of disease caused by SARS-CoV-2 infection (COVID-19). [Priority review] uuid:19953a22-5249-457e-82ea-1620bbef3840 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2642142 biolink:treats MONDO:0000270 PMID:41385096 "[{""id"":""uuid:c0b48ebd-ac82-4044-9d11-29027ca40912"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0aebe5cb-28b3-4c8e-8074-834a4213db0f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for active immunization of pregnant individuals for the prevention of lower respiratory tract disease caused by respiratory syncytial virus in neonates and infants. uuid:0c83eb0b-f23d-456c-b9a1-ff5a918afa5d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB10298 biolink:treats MONDO:0005114 PMID:41385096 "[{""id"":""uuid:466ec5bf-4a9f-4246-93d5-51b6db998b42"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c9a65ff3-0251-493f-9bfb-35c5ede00a88"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the prophylaxis of invasive pneumococcal disease (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F) in children. uuid:5274c93f-7687-45e6-b43c-8d02b4e87767 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3614 biolink:treats MONDO:0002305 PMID:41385096 "[{""id"":""uuid:b293a091-8847-490c-a190-68b4cf5ea78e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c7e5af71-16d5-4293-9fb4-a08fdd6399ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of venous thromboembolism and purpura fulminans and for the control of thrombophilia, in patients with congenital protein C deficiency. uuid:47810c69-d68d-49e8-8ede-c48004184e2f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0293742 biolink:treats UMLS:C0433405 PMID:41385096 "[{""id"":""uuid:a8d40a27-f0b1-4d42-9f61-665dc404600f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7dca3fdb-a3f1-48ba-83e0-ab089cf06d8f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the removal of necrotic tissue of deep dermal burn or deep burn. [Orphan drug] DRUGBANK:DB12249 uuid:f5a2d46d-308b-4720-9f00-cd9501571a35 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0293742 biolink:treats UMLS:C1283106 PMID:41385096 "[{""id"":""uuid:da03be8d-6c2d-4a0e-9fc1-97354afbf0e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0faad7f9-81ec-4996-995a-d6dc49f247ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the removal of necrotic tissue of deep dermal burn or deep burn. [Orphan drug] DRUGBANK:DB12249 uuid:502e0cef-810d-477b-835c-d3810a327990 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:144551 biolink:treats HP:0000975 PMID:41385096 "[{""id"":""uuid:71d75a92-b266-453f-b1fb-b956a793127e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:71f859ac-af84-4e41-ada1-9cd03cd578cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication in a new dosage form for the treatment of primary palmar hyperhidrosis. uuid:47fc3dc6-0d90-4814-969c-d8ce871391df biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:62801 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:72310bb9-97ec-4b3a-a1f4-b6d7607d205a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:bb3896e8-c03f-4413-95d8-1c3050c6525a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug in a new dosage form indicated for the treatment of hyperlipidemia. uuid:8433ad37-2b46-4cf9-9fb6-57fc91b45214 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5000 biolink:treats MONDO:0005027 PMID:41385096 "[{""id"":""uuid:9f712223-ad6c-481c-a4c4-1050188549d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7e095873-6fb0-420d-a4b6-9534da8098f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for use as an adjunctive therapy with other antiepileptic drugs to treat epileptic seizures in patients with Dravet syndrome who have not responded sufficiently to other antiepileptic drugs. [Orphan drug] uuid:0ebec401-1cd3-4fa7-8a57-e0dd4a006722 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:F0LZ415Z3B biolink:treats MONDO:0100096 PMID:41385096 "[{""id"":""uuid:1018e80a-95ff-4607-886b-30463eabeb5a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5e2af36e-2bd7-40a4-a8cc-6a50d12b895f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with new active ingredients indicated for the treatment and suppression of development of disease caused by SARS-CoV-2 infection (COVID-19). [Drug pertaining to Special Approval for Emergency] uuid:21712817-a9a5-4340-8b2e-ceeb99663eb0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats MONDO:0004795 PMID:41385096 "[{""id"":""uuid:cef43d94-cee5-4e24-8826-105bd432d588"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5d6bf6d8-2d2b-468e-ab82-c2f10241fd44"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new route of administration indicated for the treatment of otitis externa and otitis media caused by Comlex-senstive Staphylococcus spp., Streptococcus spp., Streptococcus pneumoniae , Moraxella (Branhamella) catarrhalis , Klebsiella pneumoniae , Enterobacter spp., Serratia spp., Haemophilus influenzae , Pseudomonas aeruginosa , and Acinetobacter spp. uuid:19336f0e-1a09-459b-9776-71f40625951e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats MONDO:0005441 PMID:41385096 "[{""id"":""uuid:7c436f78-05d2-4659-a57d-f9b06752e1fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2d32564d-a5ae-4d27-ad56-cff8cd508540"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new route of administration indicated for the treatment of otitis externa and otitis media caused by Comlex-senstive Staphylococcus spp., Streptococcus spp., Streptococcus pneumoniae , Moraxella (Branhamella) catarrhalis , Klebsiella pneumoniae , Enterobacter spp., Serratia spp., Haemophilus influenzae , Pseudomonas aeruginosa , and Acinetobacter spp. uuid:6460d189-617f-4eac-a8f4-e4dc4973f08f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:05ZCK72TXZ biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:b79aeb75-f30f-4e42-9f30-b971efdfaa85"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a7f576c0-66e7-4726-a71a-48a9bcb87284"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of rheumatoid arthritis in patients who have not responded sufficiently to conventional treatments. uuid:c2da7526-ea5f-4f6d-b6e8-354e0fd1c5f2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:5IB2J79MCX biolink:treats MONDO:0022205 PMID:41385096 "[{""id"":""uuid:c031511f-672d-4167-aec1-4b31e81ea3ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:62303740-ecd5-43d1-b984-ca3087726f31"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the improvement of acute symptoms in patients with pustular psoriasis. uuid:bc6b9121-162c-4e38-85b1-bdfe1152836e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:RJ1IW3B4QX biolink:treats MONDO:0100470 PMID:41385096 "[{""id"":""uuid:a6f43fb7-8473-4ec7-84a2-f7dbb7e13c8f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c3b2f0ea-2c0e-49a3-9ebb-40e06186b4d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of bronchial asthma (for use only in patients with severe or intractable bronchial asthma whose asthmatic responses are uncontrollable with conventional therapies). uuid:020f0da4-a25a-4443-87b1-e2b88cce748d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:N0A21N6RAU biolink:treats MONDO:0022205 PMID:41385096 "[{""id"":""uuid:495b6fc0-43af-4816-abd7-8a8e13d90fec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:46e694e7-283e-4006-aa98-ccbf4e091f61"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of plaque psoriasis, pustular psoriasis, and erythrodermic psoriasis in patients who have not responded sufficiently to conventional therapies. uuid:264e30c6-273f-49f3-80d1-378b104de8c6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:N0A21N6RAU biolink:treats UMLS:C0748052 PMID:41385096 "[{""id"":""uuid:9a803dc0-fbce-4042-a47e-206e29fc3f83"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:57f0a864-2b08-415e-b8de-1816bdcd8d14"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of plaque psoriasis, pustular psoriasis, and erythrodermic psoriasis in patients who have not responded sufficiently to conventional therapies. uuid:5e3f643c-8402-40af-a43c-a7dfd66e4b0f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:233475 biolink:treats MONDO:0011719 PMID:41385096 "[{""id"":""uuid:0c6fcf24-0bc4-483c-8fbd-e752c5928d6a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3150131f-e839-496d-a3e9-84b68b3ca611"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of gastrointestinal stromal tumor that has progressed after cancer chemotherapy. UNII:PLO044MUDZ uuid:9bb009e6-1221-4d9d-a545-553c139fad06 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:233475 biolink:treats MONDO:0004992 PMID:41385096 "[{""id"":""uuid:c5a45f53-129d-477a-9095-a48cedfe9e08"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a0798beb-5fd3-429a-a050-1ad2ee74d09c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of gastrointestinal stromal tumor that has progressed after cancer chemotherapy. UNII:PLO044MUDZ uuid:eb8c56f5-1c78-4116-b281-09eb9dc70fdb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2360580 biolink:treats UMLS:C3873491 PMID:41385096 "[{""id"":""uuid:1fc151cb-9244-493d-a246-371424792a2d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:70a5b807-0662-468e-a72f-6861749acf2d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the prophylaxis of invasive meningococcal disease caused by Neisseria meningitidis (serogroups A, C, W and Y). uuid:b794f196-8f9a-43f0-9e75-b0312c2b08d6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:801721 biolink:treats MONDO:0005077 PMID:41385096 "[{""id"":""uuid:a4d7c9dc-791a-4c13-aedc-413eb9e3a843"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:03761a03-ae9a-4f7a-99ca-372a6680d872"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug with a new active ingredient indicated for the prevention of pertussis, diphtheria, tetanus, acute poliomyelitis, and infections caused by Haemophilus influenzae type b . uuid:f15d5cfb-f91a-4d5a-8898-afa9150db12b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:801721 biolink:treats MONDO:0005504 PMID:41385096 "[{""id"":""uuid:45b55650-7ec4-4936-8785-c66c447f8499"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e38f9a5d-5f04-4e1f-9a7f-3898a141da43"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug with a new active ingredient indicated for the prevention of pertussis, diphtheria, tetanus, acute poliomyelitis, and infections caused by Haemophilus influenzae type b . uuid:433502e8-93f2-4099-a28a-e4587b721e32 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:801721 biolink:treats MONDO:0005526 PMID:41385096 "[{""id"":""uuid:cb2e8de3-efd8-4d31-a8a8-f25a421416c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:18b404c5-6969-4748-98a5-ef3750bab4b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug with a new active ingredient indicated for the prevention of pertussis, diphtheria, tetanus, acute poliomyelitis, and infections caused by Haemophilus influenzae type b . uuid:6b2f132f-221e-4d86-978a-8fb4d3b6d76c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:801721 biolink:treats MONDO:0017373 PMID:41385096 "[{""id"":""uuid:fed9c41d-5acb-4eaa-a43e-36fc6ce5bfd6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f914fe2f-2894-4778-a1fc-266b7d6ed28d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug with a new active ingredient indicated for the prevention of pertussis, diphtheria, tetanus, acute poliomyelitis, and infections caused by Haemophilus influenzae type b . uuid:4bfcb335-aac4-4db5-9afb-9c3c35f3d61d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:801721 biolink:treats MONDO:0000889 PMID:41385096 "[{""id"":""uuid:9dcdf02c-8865-43fd-aa30-849e5f42d507"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5a12ad41-77f2-46fe-85f9-d8072b481766"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug with a new active ingredient indicated for the prevention of pertussis, diphtheria, tetanus, acute poliomyelitis, and infections caused by Haemophilus influenzae type b . uuid:3e70157c-eb88-4348-8f84-ce5801588076 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5931 biolink:treats MONDO:0019623 PMID:41385096 "[{""id"":""uuid:1e6eccc6-459f-4060-b24f-a1e85fc8abb5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:43d8e6e0-9011-4dcf-b594-2dc5e741f72f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new route of administration indicated for the prophylaxis of acute attacks of hereditary angioedema. [Orphan drug] uuid:8d85dd5f-a239-46c7-aabc-abab9e89c6e9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:ZR36MFA9P8 biolink:treats HP:0002018 PMID:41385096 "[{""id"":""uuid:14f4d55b-fe6e-4d33-8bd2-7468412fa7b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:410bdaac-432c-4fcf-a33a-bf6e4014004f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of digestive symptoms (nausea and vomiting, including delayed phase) resulting from the administration of antineoplastic agents (cisplatin, etc.). uuid:77c63612-53b6-4e38-9cbd-6f24953bc4d5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:ZR36MFA9P8 biolink:treats HP:0002013 PMID:41385096 "[{""id"":""uuid:2f1593fd-7da7-40b2-90e1-4c111c5bd383"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:29aabc6e-620d-4383-818a-98ee8bd8d196"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of digestive symptoms (nausea and vomiting, including delayed phase) resulting from the administration of antineoplastic agents (cisplatin, etc.). uuid:b45f7c75-cf50-4d5d-bfab-2bd6a613952a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:Y1HYC6SO3F biolink:treats MONDO:0005101 PMID:41385096 "[{""id"":""uuid:f4cd8abf-3153-4209-98d3-6e99b3854573"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0ab79c56-567e-4b83-82b1-5a3dfb443ebf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of moderate ulcerative colitis (for use only in patients who have not sufficiently responded to 5-aminosalicylic acid preparation). uuid:476b0f42-e18e-403b-b87e-d7d937e6463b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:UU226QGU97 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:715a5a11-342c-431c-bef2-828dec1cac73"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1e41ceaf-b404-414e-b4d2-b50a7bf5fe66"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of type 2 diabetes mellitus. uuid:9158484a-04ce-40a0-8dac-61e278ebbe59 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:78538 biolink:treats HP:0031327 PMID:41385096 "[{""id"":""uuid:2f303405-7f89-4608-ba58-c49f79b919d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:26b71b53-845e-4a45-bde5-bdf3a090fc01"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of transthyretin cardiac amyloidosis (wild-type and hereditary). uuid:bf411897-136f-4a85-8e93-aa64d8f4e6f3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:78538 biolink:treats MONDO:0971004 PMID:41385096 "[{""id"":""uuid:7025437f-a002-4754-8b37-81ec8cf90c26"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2d022ea8-16fe-4e67-a7ac-8417fc5c737b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of transthyretin cardiac amyloidosis (wild-type and hereditary). uuid:bf2d53d4-806c-415b-a915-586a817f161d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3DRR0X4728 biolink:treats UMLS:C0265110 PMID:41385096 "[{""id"":""uuid:66897761-8d09-4a0a-a691-33be78e9074b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:99a452c5-d6b4-4f5a-a6a8-5425a7341006"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the prevention of cerebrovascular spasm after surgery for subarachnoid hemorrhage caused by cerebral aneurysm, and cerebral infarctions and cerebral ischemic symptoms accompanying the cerebrovascular spasm. uuid:09349398-8013-4519-b224-bfb79821c5e2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3DRR0X4728 biolink:treats MONDO:0002679 PMID:41385096 "[{""id"":""uuid:0e7c836a-fe31-41df-8d1a-0c02dc24ffe0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:625fefca-c8e9-40bc-b129-26f44ff01ac6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the prevention of cerebrovascular spasm after surgery for subarachnoid hemorrhage caused by cerebral aneurysm, and cerebral infarctions and cerebral ischemic symptoms accompanying the cerebrovascular spasm. uuid:79625598-1c39-485b-9521-071777d2a7b5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3DRR0X4728 biolink:treats MONDO:0005299 PMID:41385096 "[{""id"":""uuid:e45bd37e-93a5-497a-bde6-00b0481a4aee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:40836d8d-80b7-4d7c-bb29-1719a780a692"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the prevention of cerebrovascular spasm after surgery for subarachnoid hemorrhage caused by cerebral aneurysm, and cerebral infarctions and cerebral ischemic symptoms accompanying the cerebrovascular spasm. uuid:5fceae7c-9163-42e0-a5d7-6147adb8875d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17026 biolink:treats MONDO:0000931 PMID:41385096 "[{""id"":""uuid:5b2b9ffb-5ac1-46f2-9021-b1aadc944f72"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9e19cfbd-c3bd-4a29-8e90-922b3603a89b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new route of administration indicated for the prevention of endometrial hyperplasia when estrogen preparations were administered for climacteric disturbance or ovarian deficiency symptoms. uuid:747feb6b-ee12-40f1-8f5c-7813ce945f1b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:170190 biolink:treats MONDO:0024327 PMID:41385096 "[{""id"":""uuid:00fd6174-a8d1-4b86-97eb-918474ceee9e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e23fc1ed-0f57-449b-9046-25792de57f84"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A combination prescription drug with similar formulations to be used as perfusion fluids for hemodialysis in patients with chronic renal failure (use in any of the following cases: ○ when bicarbonate dialysate with high bicarbonate concentration may cause excessive alkalosis; ○ when the patient’s blood sugar level is difficult to control with sugarless dialysate; ○ when other bicarbonate dialysate is not sufficiently effective to improve hyperkalemia and hypermagnesemia or may cause hypercalcemia). uuid:d6b3e1f0-69ab-4d83-80e4-742ca81f549f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:170190 biolink:treats HP:0002153 PMID:41385096 "[{""id"":""uuid:317d332d-d6dc-4030-acaf-8afca3f1ea1a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a7fe9fb0-526a-4bfe-869d-9fe380300cab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A combination prescription drug with similar formulations to be used as perfusion fluids for hemodialysis in patients with chronic renal failure (use in any of the following cases: ○ when bicarbonate dialysate with high bicarbonate concentration may cause excessive alkalosis; ○ when the patient’s blood sugar level is difficult to control with sugarless dialysate; ○ when other bicarbonate dialysate is not sufficiently effective to improve hyperkalemia and hypermagnesemia or may cause hypercalcemia). uuid:241c7480-5af0-487f-b68b-97978ea13248 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:170190 biolink:treats HP:0002918 PMID:41385096 "[{""id"":""uuid:ad701780-6a42-4908-ba7f-939c4868a5f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1af1e183-a779-4ccb-9acd-c9e55ca4d7a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A combination prescription drug with similar formulations to be used as perfusion fluids for hemodialysis in patients with chronic renal failure (use in any of the following cases: ○ when bicarbonate dialysate with high bicarbonate concentration may cause excessive alkalosis; ○ when the patient’s blood sugar level is difficult to control with sugarless dialysate; ○ when other bicarbonate dialysate is not sufficiently effective to improve hyperkalemia and hypermagnesemia or may cause hypercalcemia). uuid:9f194978-85ef-4449-8fa3-a3a5dc4382df biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:170190 biolink:treats MONDO:0001566 PMID:41385096 "[{""id"":""uuid:01491caa-6b45-4437-b01e-847452eb6434"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c9de820a-d503-4eb5-8900-6c4bbda2b00d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A combination prescription drug with similar formulations to be used as perfusion fluids for hemodialysis in patients with chronic renal failure (use in any of the following cases: ○ when bicarbonate dialysate with high bicarbonate concentration may cause excessive alkalosis; ○ when the patient’s blood sugar level is difficult to control with sugarless dialysate; ○ when other bicarbonate dialysate is not sufficiently effective to improve hyperkalemia and hypermagnesemia or may cause hypercalcemia). uuid:a0bd216b-926c-46c8-ad1b-3d2b7079b0ff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:24984318 biolink:treats MONDO:0010096 PMID:41385096 "[{""id"":""uuid:c821f3dd-21f6-4160-9f9d-2b9b614601cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:22546346-6eae-4eae-b55c-16d078b6152d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of tardive dyskinesia. uuid:6e4ad862-6c46-44b6-abe9-dcdd8ab314e0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:QC4F7FKK7I biolink:treats MONDO:0005150 PMID:41385096 "[{""id"":""uuid:d1a5840e-42ec-4368-b011-1e1da9745940"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f229ffe9-0ec8-49f4-9a31-24acc9e114cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of age-related macular degeneration associated with subfoveal choroidal neovascularization and diabetic macular edema. uuid:28ae972f-588e-4826-92a5-52cab22315b8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2184139 biolink:treats MONDO:0020920 PMID:41385096 "[{""id"":""uuid:3f8287a1-ed60-4f1e-a4c1-b4d10f1f27c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:136d0606-b775-41d0-91e6-240bbf01fb90"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug with a new active ingredient indicated for the treatment of infections caused by Recarbrio-sensitive Escherichia coli , Citrobacter spp. , Klebsiella spp. , Enterococcus spp., Serratia spp., Pseudomonas aeruginosa , and Acinetobacter spp. (limited to the bacterial strains resistant to carbapenem antimicrobial drugs) [Orphan drug] uuid:71507979-edfe-437b-aaf5-589830dbcb8b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2184139 biolink:treats MONDO:0030603 PMID:41385096 "[{""id"":""uuid:1cd05cc5-47ea-42e1-a84c-6f683d4def8e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:bc9817ee-856e-4fa8-8749-ed1ca7447bac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug with a new active ingredient indicated for the treatment of infections caused by Recarbrio-sensitive Escherichia coli , Citrobacter spp. , Klebsiella spp. , Enterococcus spp., Serratia spp., Pseudomonas aeruginosa , and Acinetobacter spp. (limited to the bacterial strains resistant to carbapenem antimicrobial drugs) [Orphan drug] uuid:da13bd06-154d-4954-9828-f6e0abe2e861 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2184139 biolink:treats EFO:1001421 PMID:41385096 "[{""id"":""uuid:f8d13adf-00fa-4668-9a15-5423c5b6904e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5d5e7112-8050-46c9-a627-a501f850e3cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug with a new active ingredient indicated for the treatment of infections caused by Recarbrio-sensitive Escherichia coli , Citrobacter spp. , Klebsiella spp. , Enterococcus spp., Serratia spp., Pseudomonas aeruginosa , and Acinetobacter spp. (limited to the bacterial strains resistant to carbapenem antimicrobial drugs) [Orphan drug] uuid:bd9b216c-9522-4c57-8d90-37f848074db1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2184139 biolink:treats MONDO:0005141 PMID:41385096 "[{""id"":""uuid:0bcd3756-ae1a-4e31-802a-fa7c20ef2b3d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:48ace70e-57a5-4c7f-a722-2d6fd130c059"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug with a new active ingredient indicated for the treatment of infections caused by Recarbrio-sensitive Escherichia coli , Citrobacter spp. , Klebsiella spp. , Enterococcus spp., Serratia spp., Pseudomonas aeruginosa , and Acinetobacter spp. (limited to the bacterial strains resistant to carbapenem antimicrobial drugs) [Orphan drug] uuid:cbf4c5e9-3009-48ce-bc21-2531e44793b6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2184139 biolink:treats MONDO:0006635 PMID:41385096 "[{""id"":""uuid:520bedb4-b51f-4332-87b9-ff0a9d757202"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9082cf8f-bf06-4468-ba4d-754f0176cb0a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug with a new active ingredient indicated for the treatment of infections caused by Recarbrio-sensitive Escherichia coli , Citrobacter spp. , Klebsiella spp. , Enterococcus spp., Serratia spp., Pseudomonas aeruginosa , and Acinetobacter spp. (limited to the bacterial strains resistant to carbapenem antimicrobial drugs) [Orphan drug] uuid:a4ff4ba2-56b6-4960-a6e6-dc096509480a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:180653 biolink:treats MONDO:0100096 PMID:41385096 "[{""id"":""uuid:7f119b96-e00a-48fd-b048-bba4bc52eaf4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d5f66c55-2e0c-472d-9048-1e31e6f7ae40"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of disease caused by SARS-CoV-2 infection (COVID-19). [Drug pertaining to Special Approval for Emergency] uuid:0ea5d2c7-3c05-4dcd-ad2f-019c763258a5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6K6L7E3F1L biolink:treats UMLS:C4552486 PMID:41385096 "[{""id"":""uuid:190d5b0f-0c66-453f-95d1-9776ad1fb13b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:15c33590-be1f-495a-ba65-1014c4b7a90a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of refractory chronic cough. uuid:7066b80b-6eea-4e29-aa0c-40afd4826e80 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:131952892 biolink:treats MONDO:0019496 PMID:41385096 "[{""id"":""uuid:9c37e410-efc3-48e2-b679-c5c29da761cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:297b4397-14bb-4a2f-9023-ffbe7fdf6b7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of somatostatin receptor-positive neuroendocrine tumor. uuid:7bc66f9e-3b08-40eb-80f9-20c583ac7d75 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:92769 biolink:treats MONDO:0008233 PMID:41385096 "[{""id"":""uuid:bd4c62be-7014-4d0e-8b74-ba3f6c6162e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4d188aa2-afa6-4efb-8871-4678f5b133e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of unresectable MIBG-positive pheochromocytoma/paraganglioma. [Orphan drug] uuid:1cbf3e14-39e7-4bde-822d-90a9bd4646a5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:92769 biolink:treats MONDO:0000448 PMID:41385096 "[{""id"":""uuid:66d0257f-4ffa-4a19-9223-9d7a2302c484"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3fc28f0a-4270-4804-a5ac-0ce10f00801a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of unresectable MIBG-positive pheochromocytoma/paraganglioma. [Orphan drug] uuid:0fd26ffa-e62b-4889-a203-76a6f66dc660 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:ZL1R02VT79 biolink:treats UMLS:C3537442 PMID:41385096 "[{""id"":""uuid:2b353885-5cb7-4a87-a54c-ae9ad5ba7e85"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:12b81b0e-8a21-4aef-b215-e6ae541344ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Follow-on biologics indicated for the treatment of age-related macular degeneration associated with subfoveal choroidal neovascularization or choroidal neovascularization in patients with pathologic myopia. uuid:2efdfbff-b4e6-4e53-b353-95fb92c8338e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:55F75LJQ0V biolink:treats UMLS:C1391732 PMID:41385096 "[{""id"":""uuid:716b0e3b-5034-497b-b824-13d30a9f381f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2160bbc0-b4c3-448d-8328-39616ecf504a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of cancer cachexia in the following malignancies: non-small cell lung cancer, gastric cancer, pancreatic cancer, and colorectal cancer. uuid:4d4ad27b-8a80-4768-b506-7a2eb52a0831 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:55F75LJQ0V biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:4e2a99c3-ad2b-4374-a2c7-dac853657c9a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:779bc6ee-bc0b-4616-8b31-cdb8da84dc7d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of cancer cachexia in the following malignancies: non-small cell lung cancer, gastric cancer, pancreatic cancer, and colorectal cancer. uuid:65fcd475-c3a3-43e9-888f-4cadd9cb87de biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:55F75LJQ0V biolink:treats MONDO:0001056 PMID:41385096 "[{""id"":""uuid:95315afa-1e62-48b1-a104-ae4f4e4c9bb9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7ca2c914-8498-4f38-a14b-b993dc82d417"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of cancer cachexia in the following malignancies: non-small cell lung cancer, gastric cancer, pancreatic cancer, and colorectal cancer. uuid:d920fb44-83db-4525-88e1-b09202e3a0b4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:55F75LJQ0V biolink:treats MONDO:0009831 PMID:41385096 "[{""id"":""uuid:ff0cea1d-f80c-4c87-aa76-0c3dfd3b5963"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:32c09339-db10-44ef-9624-a0002afe0645"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of cancer cachexia in the following malignancies: non-small cell lung cancer, gastric cancer, pancreatic cancer, and colorectal cancer. uuid:416d17ae-9ab0-4be9-8639-7d0e7f10abf0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:55F75LJQ0V biolink:treats MONDO:0005575 PMID:41385096 "[{""id"":""uuid:91b12a61-276c-4de3-9de6-42ba6b0a80bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3cc34141-db70-46e5-94bd-568125ffdec7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of cancer cachexia in the following malignancies: non-small cell lung cancer, gastric cancer, pancreatic cancer, and colorectal cancer. uuid:b8f80b94-6c9d-4b0e-a82c-6b28ff353e28 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:TRF8S0U6ON biolink:treats MONDO:0010674 PMID:41385096 "[{""id"":""uuid:e7b4bb70-300e-4c9a-a31a-3ebf3f76fd35"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9a253902-bf21-4a54-b0d4-d7e6582fad86"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of mucopolysaccharidosis type II. [SAKIGAKE review, orphan drug] uuid:fe35bcdb-015f-4c4d-a105-eaa5fef948bf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:170190 biolink:treats HP:0003075 PMID:41385096 "[{""id"":""uuid:783aaefc-967c-4095-9274-2d4f8b03d407"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5e718af9-aa81-4a84-949c-3299a1d0f94a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A combination prescription drug with similar formulations indicated for the supplementation of amino acids, electrolytes, calories, fatty acids, water-soluble vitamin, and water in the following conditions. •When patients with insufficient oral intake and mild hypoproteinemia or mild undernutrition. •When patients in the perioperative period uuid:60cfab72-c611-4110-9ccf-ed4539ca61cb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28262 biolink:treats HP:0100515 PMID:41385096 "[{""id"":""uuid:2e5926d4-d39f-45c1-8903-a35d7d9a0dd3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d16773f7-a6f4-4811-901e-77b7203caa63"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the improvement of symptoms (chronic pelvic pain, pressure and discomfort perceived to be related to the urinary bladder; lower urinary tract symptoms such as persistent urge to void and urinary frequency) in patients with interstitial cystitis (Hunner type). [Orphan drug] uuid:6971f699-f52b-487e-9fb5-d090aa9a50e2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134703 biolink:treats MONDO:0100342 PMID:41385096 "[{""id"":""uuid:2cbbf5e8-6ca6-474a-b688-dfe3a7a4003c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ff3153dc-6fe7-411d-9ba4-647ef531ad2a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the visualization of tumors in patients with suspected to be newly identified malignant glioma, (for use only in supporting determination of the extent of tumor resection during tumor resection planning using magnetic resonance imaging). uuid:f80c86c8-19c4-46d3-936a-d2f3447e28b2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:55MOB566V7 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:a1407c87-98ea-4463-9a43-f5dd92c44228"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0a84d5e2-cde0-4f6a-a29d-43ca6d3e6f38"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new route of administration indicated for the treatment of pneumonia, lung abscess, and secondary infection of chronic respiratory disease caused by Lasvic-sensitive Staphylococcus spp, Streptococcus spp, Streptococcus pneumoniae , Enterococcus spp, Moraxella (Branhamella ) catarrhalis , Escherichia coli, Klebsiella spp, Enterobacter spp, Haemophilus influenzae , Legionella pneumophila , Peptostreptococcus spp, Veillonella spp, Bacteroides spp, Prevotella spp, Porphyromonas spp, Fusobacterium spp, and Mycoplasma pneumoniae . uuid:9b7e8ffe-0196-4b52-822d-a94446d7eaf9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:55MOB566V7 biolink:treats MONDO:0000744 PMID:41385096 "[{""id"":""uuid:62009443-cd2c-47ff-b769-545b7e0166ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:589da59e-2bf9-40b5-9a45-dd4513aae469"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new route of administration indicated for the treatment of pneumonia, lung abscess, and secondary infection of chronic respiratory disease caused by Lasvic-sensitive Staphylococcus spp, Streptococcus spp, Streptococcus pneumoniae , Enterococcus spp, Moraxella (Branhamella ) catarrhalis , Escherichia coli, Klebsiella spp, Enterobacter spp, Haemophilus influenzae , Legionella pneumophila , Peptostreptococcus spp, Veillonella spp, Bacteroides spp, Prevotella spp, Porphyromonas spp, Fusobacterium spp, and Mycoplasma pneumoniae . uuid:bc15019c-a9f1-4954-811a-cac034c2ad0f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:55MOB566V7 biolink:treats MONDO:0024355 PMID:41385096 "[{""id"":""uuid:4e3d1d5f-211e-494b-b784-862ca8eeeb51"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2fe413bb-b2a9-4c63-9e1f-0468528c43cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new route of administration indicated for the treatment of pneumonia, lung abscess, and secondary infection of chronic respiratory disease caused by Lasvic-sensitive Staphylococcus spp, Streptococcus spp, Streptococcus pneumoniae , Enterococcus spp, Moraxella (Branhamella ) catarrhalis , Escherichia coli, Klebsiella spp, Enterobacter spp, Haemophilus influenzae , Legionella pneumophila , Peptostreptococcus spp, Veillonella spp, Bacteroides spp, Prevotella spp, Porphyromonas spp, Fusobacterium spp, and Mycoplasma pneumoniae . uuid:7bbf5433-c280-4fb5-a3f9-ca135932b472 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:LG1II3835L biolink:treats MONDO:0005416 PMID:41385096 "[{""id"":""uuid:b8b9064a-d9db-4a52-a6f3-9291259f6b1e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e800759e-0e7f-4f09-a4d9-cc7f4e261530"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of knee and hip osteoarthritis. uuid:4430d6bb-8f54-4fe8-bdab-e183266d306b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:LG1II3835L biolink:treats MONDO:0006629 PMID:41385096 "[{""id"":""uuid:3569c94e-3087-41ed-ab75-d579a563a884"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f257bcf9-5a8b-4440-b521-ea7be011edcc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of knee and hip osteoarthritis. uuid:6a79a206-d1f4-4440-a12b-1446b37f5123 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47381 biolink:treats EFO:0801084 PMID:41385096 "[{""id"":""uuid:44ae69e9-35b3-4abb-bf5a-01493e5044ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:038377f2-a131-44b4-a536-c533acb11312"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication in a new dosage form for analgesia in various types of cancer. uuid:376f305c-6c28-484f-9203-ca8cd18eed79 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:Y6BX7BL23K biolink:treats MONDO:0004992 PMID:41385096 "[{""id"":""uuid:9fb57bba-fedb-4c98-860a-f69b4871fefd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:905ed830-0716-44ed-92a7-e64a962f1031"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of unresectable FGFR2 fusion gene-positive biliary tract cancer that has progressed after cancer chemotherapy. [Orphan drug] uuid:a71062dd-f5f5-4d21-bdc0-140bb9ead11c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1597091 biolink:treats UMLS:C1527424 PMID:41385096 "[{""id"":""uuid:09f4b99a-fda6-401f-8ba3-0ad3596c0479"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:cf9673b5-3495-428c-93c8-b7729fb17789"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the prevention of the following diseases caused by infection with human papillomavirus types 6, 11, 16, 18, 31, 33, 45, 52, and 58: Cervical cancer (squamous cell carcinoma and adenosquamous carcinoma) and its precursor lesions (cervical intraepithelial neoplasia [CIN] 1, 2, and 3, and adenocarcinoma in situ [AIS]) Vulvar intraepithelial neoplasia (VIN) 1, 2, and 3, and vaginal intraepithelial noeplasia (VaIN) 1, 2, and 3 Condyloma acuminatum uuid:e2d1a8ac-2cb4-4e51-aa08-7a5c4b84d663 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1597091 biolink:treats MONDO:0006137 PMID:41385096 "[{""id"":""uuid:9b1acff4-388a-4868-b47f-586b91ac3007"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:70539a80-fcb7-4373-8298-88137c5b59ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the prevention of the following diseases caused by infection with human papillomavirus types 6, 11, 16, 18, 31, 33, 45, 52, and 58: Cervical cancer (squamous cell carcinoma and adenosquamous carcinoma) and its precursor lesions (cervical intraepithelial neoplasia [CIN] 1, 2, and 3, and adenocarcinoma in situ [AIS]) Vulvar intraepithelial neoplasia (VIN) 1, 2, and 3, and vaginal intraepithelial noeplasia (VaIN) 1, 2, and 3 Condyloma acuminatum uuid:6cc24f41-2ff8-4bab-af65-2bcb46b85bf5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1597091 biolink:treats MONDO:0042487 PMID:41385096 "[{""id"":""uuid:b308f93d-fd42-4473-aed0-e4c28c7bc423"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8b3661a6-6995-4797-a626-71094a3ba3b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the prevention of the following diseases caused by infection with human papillomavirus types 6, 11, 16, 18, 31, 33, 45, 52, and 58: Cervical cancer (squamous cell carcinoma and adenosquamous carcinoma) and its precursor lesions (cervical intraepithelial neoplasia [CIN] 1, 2, and 3, and adenocarcinoma in situ [AIS]) Vulvar intraepithelial neoplasia (VIN) 1, 2, and 3, and vaginal intraepithelial noeplasia (VaIN) 1, 2, and 3 Condyloma acuminatum uuid:546b79ba-2420-4b4b-8fd7-13b67d21d11c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1597091 biolink:treats MONDO:0018585 PMID:41385096 "[{""id"":""uuid:8af53f82-6aeb-40fb-a685-246412daa8f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c99df961-7f6e-48b0-9bbc-9f545cbcf8d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the prevention of the following diseases caused by infection with human papillomavirus types 6, 11, 16, 18, 31, 33, 45, 52, and 58: Cervical cancer (squamous cell carcinoma and adenosquamous carcinoma) and its precursor lesions (cervical intraepithelial neoplasia [CIN] 1, 2, and 3, and adenocarcinoma in situ [AIS]) Vulvar intraepithelial neoplasia (VIN) 1, 2, and 3, and vaginal intraepithelial noeplasia (VaIN) 1, 2, and 3 Condyloma acuminatum uuid:7a6653ff-75b2-488c-9c67-fa0ef743139f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1597091 biolink:treats MONDO:0006274 PMID:41385096 "[{""id"":""uuid:b12817ce-0330-4806-a025-52a3049c7676"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2158d9d7-329b-46d1-b29b-128a7e1c96e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the prevention of the following diseases caused by infection with human papillomavirus types 6, 11, 16, 18, 31, 33, 45, 52, and 58: Cervical cancer (squamous cell carcinoma and adenosquamous carcinoma) and its precursor lesions (cervical intraepithelial neoplasia [CIN] 1, 2, and 3, and adenocarcinoma in situ [AIS]) Vulvar intraepithelial neoplasia (VIN) 1, 2, and 3, and vaginal intraepithelial noeplasia (VaIN) 1, 2, and 3 Condyloma acuminatum uuid:7c70bdd5-3371-48c7-a487-c33886f5694d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1597091 biolink:treats UMLS:C0495107 PMID:41385096 "[{""id"":""uuid:1372b299-f83c-4808-b9e1-b94b09d55741"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:37e57814-7b71-45c9-9b92-9b049cdfd6d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the prevention of the following diseases caused by infection with human papillomavirus types 6, 11, 16, 18, 31, 33, 45, 52, and 58: Cervical cancer (squamous cell carcinoma and adenosquamous carcinoma) and its precursor lesions (cervical intraepithelial neoplasia [CIN] 1, 2, and 3, and adenocarcinoma in situ [AIS]) Vulvar intraepithelial neoplasia (VIN) 1, 2, and 3, and vaginal intraepithelial noeplasia (VaIN) 1, 2, and 3 Condyloma acuminatum uuid:e19536e4-f393-4942-8791-7b037948ca67 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1597091 biolink:treats MONDO:0005198 PMID:41385096 "[{""id"":""uuid:cb018fdb-0da4-4de6-8ebb-d59dd4b033ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:134db960-d6af-4f4e-b035-e7da314f5ed7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the prevention of the following diseases caused by infection with human papillomavirus types 6, 11, 16, 18, 31, 33, 45, 52, and 58: Cervical cancer (squamous cell carcinoma and adenosquamous carcinoma) and its precursor lesions (cervical intraepithelial neoplasia [CIN] 1, 2, and 3, and adenocarcinoma in situ [AIS]) Vulvar intraepithelial neoplasia (VIN) 1, 2, and 3, and vaginal intraepithelial noeplasia (VaIN) 1, 2, and 3 Condyloma acuminatum uuid:6a830a51-4b93-4aa2-bca1-06059551d1fc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1597091 biolink:treats UMLS:C0349554 PMID:41385096 "[{""id"":""uuid:0cc39c22-69aa-446f-837f-338e07b8f0bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:da45b7d7-7531-441e-8dbe-b3d77e66da28"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the prevention of the following diseases caused by infection with human papillomavirus types 6, 11, 16, 18, 31, 33, 45, 52, and 58: Cervical cancer (squamous cell carcinoma and adenosquamous carcinoma) and its precursor lesions (cervical intraepithelial neoplasia [CIN] 1, 2, and 3, and adenocarcinoma in situ [AIS]) Vulvar intraepithelial neoplasia (VIN) 1, 2, and 3, and vaginal intraepithelial noeplasia (VaIN) 1, 2, and 3 Condyloma acuminatum uuid:6f878c6a-09df-42b3-a7e9-56953ba238a7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:167600 biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:c3bf42eb-e499-420e-9770-31c7f3f76c94"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f4ea0357-78ed-42cf-8f12-15ff09520131"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of atopic dermatitis. uuid:3a0f8cdc-d55d-4fbf-9bd7-2450cf53a0e0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:70708 biolink:treats HP:0100607 PMID:41385096 "[{""id"":""uuid:175f665a-20fe-4e2c-9371-3bf8f2130d57"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8300c66b-22f7-406a-887e-1ce7b843dc54"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage in an additional dosage form for the treatment of dysmenorrhea. uuid:3ea8ea4b-6ca2-465b-818c-2346d8bfe8c2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:333OX80X87 biolink:treats EFO:0009472 PMID:41385096 "[{""id"":""uuid:773349ac-497a-4070-a8ac-27ed5d6f27e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:26293036-5aee-4864-b3f2-5cb16d69dc5a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new route of administration indicated for the treatment of tympanic membrane perforation. uuid:0682e773-dee5-4be6-bfb1-6e299942ca68 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:861635 biolink:treats MONDO:0005041 PMID:41385096 "[{""id"":""uuid:b67e9350-3e0d-43f7-b770-bf5b385d3954"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6211d45b-6df1-48ab-830c-9f3e31a18764"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug indicated for the treatment of glaucoma and ocular hypertension in patients who have not responded sufficiently to other anti- glaucoma drugs. uuid:761f8d3b-5982-4fd7-ac76-051f51843f62 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:861635 biolink:treats HP:0007906 PMID:41385096 "[{""id"":""uuid:c446c368-5f84-46e9-a348-7a9477f98ab2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:be80d178-f73b-423f-8d9e-620e85acd6fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug indicated for the treatment of glaucoma and ocular hypertension in patients who have not responded sufficiently to other anti- glaucoma drugs. uuid:0463b3f1-dfd0-46a7-9cf2-52394a3faa13 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:XSZ53G39H5 biolink:treats MONDO:0005150 PMID:41385096 "[{""id"":""uuid:0bdde1c9-6e4d-4a5f-9b11-abdf9b5787be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d780584d-c6a7-4e3f-a9f5-50a63ffbc59a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of age-related macular degeneration associated with subfoveal choroidal neovascularization. uuid:794f0f07-383b-44b0-87f5-147610873bc7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:XSZ53G39H5 biolink:treats HP:0031241 PMID:41385096 "[{""id"":""uuid:894340db-939d-46d7-9acf-b148bfa17344"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c6319278-1283-4e7d-984f-15f60e9f009d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of age-related macular degeneration associated with subfoveal choroidal neovascularization. uuid:12fa28fc-544d-4466-ae20-d4b10ee1be08 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1421448 biolink:treats MONDO:0005041 PMID:41385096 "[{""id"":""uuid:e25cc00b-a258-44e6-89f1-83c0556de4b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e1ae10a5-5f93-49cd-b2e7-e6eaa6d11817"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug indicated for the treatment of glaucoma and ocular hypertension in patients who have not responded sufficiently to other anti- glaucoma drugs. uuid:f4891dc1-a5f6-46f1-a103-d89f221242ef biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1421448 biolink:treats HP:0007906 PMID:41385096 "[{""id"":""uuid:d4c9fe17-23f5-4011-9556-f812e2fff124"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8a0e5f5e-f411-4d0b-b11a-834347bb3294"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug indicated for the treatment of glaucoma and ocular hypertension in patients who have not responded sufficiently to other anti- glaucoma drugs. uuid:cb9bc827-9a3a-4797-b2e3-fdf0f2f21082 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134741 biolink:treats UMLS:C0858004 PMID:41385096 "[{""id"":""uuid:98b62211-fdd1-46b6-b12e-2258c264b76e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ec526b0f-937b-4fda-b7cc-03db11648dcb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug in a new dosage form indicated for the treatment of influenza A or B virus infection. uuid:afaaaede-dacd-4fea-9f48-a9aa5e30ca03 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134741 biolink:treats UMLS:C0858005 PMID:41385096 "[{""id"":""uuid:5f4649a1-aa26-4708-a445-cd719e03c6b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1b41e8a5-0adf-4595-8ed5-368afec23ad6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug in a new dosage form indicated for the treatment of influenza A or B virus infection. uuid:387e524b-6c99-48c6-8af3-84dca9ceb9bc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2955 biolink:treats MONDO:0003799 PMID:41385096 "[{""id"":""uuid:21a954de-8197-421c-80fd-d8df1eb2f438"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0903fbb2-3f4a-465d-8719-fbde4623806b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new route of administration indicated for the treatment of conjunctivitis, blepharitis, hordeolum and dacryocystitis caused by azithromycin-sensitive Staphylococcus spp., Streptococcus spp., Streptococcus pneumoniae, Corynebacterium spp., Haemophilus influenzae or Propionibacterium acnes. uuid:341d0083-96b9-4130-908c-978e33ddbac9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2955 biolink:treats MONDO:0004785 PMID:41385096 "[{""id"":""uuid:f6a2860b-f627-4d4d-86b0-39efa015d4a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2e497c71-e5e1-4661-b705-1b4267d53a46"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new route of administration indicated for the treatment of conjunctivitis, blepharitis, hordeolum and dacryocystitis caused by azithromycin-sensitive Staphylococcus spp., Streptococcus spp., Streptococcus pneumoniae, Corynebacterium spp., Haemophilus influenzae or Propionibacterium acnes. uuid:e71fb710-b1f9-4af4-9041-533528bb29e0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2955 biolink:treats MONDO:0005800 PMID:41385096 "[{""id"":""uuid:d04b4b06-26b1-4b87-b562-73b751834f4f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:297801e0-4722-4fb7-958d-25975af973fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new route of administration indicated for the treatment of conjunctivitis, blepharitis, hordeolum and dacryocystitis caused by azithromycin-sensitive Staphylococcus spp., Streptococcus spp., Streptococcus pneumoniae, Corynebacterium spp., Haemophilus influenzae or Propionibacterium acnes. uuid:409759a4-3598-4e10-b072-de47c190455f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2955 biolink:treats MONDO:0004926 PMID:41385096 "[{""id"":""uuid:afa93673-3314-4e38-ac07-31c926450c99"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:39b9b942-a9cd-47a6-beea-6c4c10ab2085"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new route of administration indicated for the treatment of conjunctivitis, blepharitis, hordeolum and dacryocystitis caused by azithromycin-sensitive Staphylococcus spp., Streptococcus spp., Streptococcus pneumoniae, Corynebacterium spp., Haemophilus influenzae or Propionibacterium acnes. uuid:ad309aa5-adc0-44ec-8fcd-5f2cb8dc3f7b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:55MOB566V7 biolink:treats MONDO:0001218 PMID:41385096 "[{""id"":""uuid:fa95e31f-f795-4e31-b1ae-55b27e7a7ef7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:bbd3b042-9260-461f-94b0-977727807b73"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of laryngopharyngitis, tonsillitis (including peritonsillitis and peritonsillar abscess), acute bronchitis, pneumonia, secondary infection of chronic respiratory disease, otitis media, and sinusitis caused by Lasvic-sensitive Staphylococcus spp., Streptococcus spp., Streptococcus pneumoniae , Moraxella (Branhamella) catarrhalis , Klebsiella spp., Enterobacter spp., Haemophilus influenzae , Legionella pneumophila , Prevotella spp., and Mycoplasma pneumoniae . uuid:071ace7b-70eb-4bc8-8e6b-0255f5b05763 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:55MOB566V7 biolink:treats MONDO:0001039 PMID:41385096 "[{""id"":""uuid:f398bf9b-b291-4f4d-9e29-b4165ecb03dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:38a34a87-8baf-4585-8f29-0e486f5cd991"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of laryngopharyngitis, tonsillitis (including peritonsillitis and peritonsillar abscess), acute bronchitis, pneumonia, secondary infection of chronic respiratory disease, otitis media, and sinusitis caused by Lasvic-sensitive Staphylococcus spp., Streptococcus spp., Streptococcus pneumoniae , Moraxella (Branhamella) catarrhalis , Klebsiella spp., Enterobacter spp., Haemophilus influenzae , Legionella pneumophila , Prevotella spp., and Mycoplasma pneumoniae . uuid:30701939-514e-4ea6-bd72-cebad3767fd9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:55MOB566V7 biolink:treats UMLS:C0877267 PMID:41385096 "[{""id"":""uuid:43d49a7d-916e-4333-963e-4a00d61b352a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:89932f88-736a-4b26-a826-25dff141080b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of laryngopharyngitis, tonsillitis (including peritonsillitis and peritonsillar abscess), acute bronchitis, pneumonia, secondary infection of chronic respiratory disease, otitis media, and sinusitis caused by Lasvic-sensitive Staphylococcus spp., Streptococcus spp., Streptococcus pneumoniae , Moraxella (Branhamella) catarrhalis , Klebsiella spp., Enterobacter spp., Haemophilus influenzae , Legionella pneumophila , Prevotella spp., and Mycoplasma pneumoniae . uuid:bd616f6c-9f65-4892-b8f7-7978a82abfd8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:55MOB566V7 biolink:treats MONDO:0005906 PMID:41385096 "[{""id"":""uuid:6025722a-002e-469e-9a82-2041648b0b5a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9d56f5cf-8953-46f2-9896-5d87d656737c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of laryngopharyngitis, tonsillitis (including peritonsillitis and peritonsillar abscess), acute bronchitis, pneumonia, secondary infection of chronic respiratory disease, otitis media, and sinusitis caused by Lasvic-sensitive Staphylococcus spp., Streptococcus spp., Streptococcus pneumoniae , Moraxella (Branhamella) catarrhalis , Klebsiella spp., Enterobacter spp., Haemophilus influenzae , Legionella pneumophila , Prevotella spp., and Mycoplasma pneumoniae . uuid:32fba709-cc04-47c6-8293-332fcc4fdd98 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:55MOB566V7 biolink:treats HP:0012388 PMID:41385096 "[{""id"":""uuid:e2c89e0f-3119-404c-9327-72c5bae5056c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c81b4f90-53fa-44da-bf14-afd5c1e52953"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of laryngopharyngitis, tonsillitis (including peritonsillitis and peritonsillar abscess), acute bronchitis, pneumonia, secondary infection of chronic respiratory disease, otitis media, and sinusitis caused by Lasvic-sensitive Staphylococcus spp., Streptococcus spp., Streptococcus pneumoniae , Moraxella (Branhamella) catarrhalis , Klebsiella spp., Enterobacter spp., Haemophilus influenzae , Legionella pneumophila , Prevotella spp., and Mycoplasma pneumoniae . uuid:07d376c0-349c-41e5-8468-ef2a7902c413 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:55MOB566V7 biolink:treats MONDO:0005441 PMID:41385096 "[{""id"":""uuid:f8e8e567-4eab-4822-87d2-a503ccec1e06"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c2992721-8c3c-4b4a-be6a-6ac096ae49c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of laryngopharyngitis, tonsillitis (including peritonsillitis and peritonsillar abscess), acute bronchitis, pneumonia, secondary infection of chronic respiratory disease, otitis media, and sinusitis caused by Lasvic-sensitive Staphylococcus spp., Streptococcus spp., Streptococcus pneumoniae , Moraxella (Branhamella) catarrhalis , Klebsiella spp., Enterobacter spp., Haemophilus influenzae , Legionella pneumophila , Prevotella spp., and Mycoplasma pneumoniae . uuid:1b0ce289-c99f-43c6-8d1f-a799ad903cae biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:55MOB566V7 biolink:treats MONDO:0005961 PMID:41385096 "[{""id"":""uuid:d64fcdb2-3c7b-407c-9cc1-911326d39e40"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:86921198-36c5-4f9c-8fdf-478c97392565"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of laryngopharyngitis, tonsillitis (including peritonsillitis and peritonsillar abscess), acute bronchitis, pneumonia, secondary infection of chronic respiratory disease, otitis media, and sinusitis caused by Lasvic-sensitive Staphylococcus spp., Streptococcus spp., Streptococcus pneumoniae , Moraxella (Branhamella) catarrhalis , Klebsiella spp., Enterobacter spp., Haemophilus influenzae , Legionella pneumophila , Prevotella spp., and Mycoplasma pneumoniae . uuid:d07a036d-1c34-406f-8dfb-aa2afbca4ad2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2122519 biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:98758530-dc05-4321-a7d4-55b87386e0b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:071a2e86-bef9-4eef-bf98-8d348488eb5a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug indicated for the treatment of HIV infection. [Orphan drug] uuid:93655e0a-4781-42b5-a2ea-a926ce15db31 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2BT4C47RUI biolink:treats MONDO:0005097 PMID:41385096 "[{""id"":""uuid:79fb42c1-e95a-42f8-ac7b-eeaea9ab1d80"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e36fb3cb-1aa3-4803-8075-3bfec7b89702"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of unresectable advanced or recurrent squamous non-small cell lung cancer. uuid:b799a210-08a2-424c-9f0d-49c998140ecc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:52CMI0WC3Y biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:27f604c4-13d0-4cf7-bee9-e1f0c9942dcd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:276442ae-1711-4b65-b06d-6aa1377ab649"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage in an additional dosage form indicated for the treatment of PD-L1-positive, hormone receptor- negative and HER2-negative inoperable or recurrent breast cancer. uuid:47a50053-3110-43e6-9b93-b6ddbbccffae biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:23581792 biolink:treats UMLS:C0854776 PMID:41385096 "[{""id"":""uuid:b56ca03a-4869-4961-af9e-7edaeb2348ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f7c606f6-e99f-4cd3-ae15-b6e9f36dd962"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication in a new dosage form for the treatment of unresectable pancreatic cancer that has progressed after cancer chemotherapy. uuid:e5e07c14-82a2-4741-b553-ed45240fbbf7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:23581792 biolink:treats MONDO:0004992 PMID:41385096 "[{""id"":""uuid:7cb2f850-5c8e-4d26-9b74-f97e11c3acab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b4aa2ca0-4aee-409c-928e-681ac29b86b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication in a new dosage form for the treatment of unresectable pancreatic cancer that has progressed after cancer chemotherapy. uuid:399be00a-52f6-471a-a2a1-66ac20c9b218 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:232544 biolink:treats MONDO:0002571 PMID:41385096 "[{""id"":""uuid:e1c2871d-8cd1-4f62-95a3-3be283926d83"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6bebc1d3-91c7-4acd-a8f6-99d30a6c8369"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of relapsed or refractory primary central nervous system (CNS) lymphoma. [Orphan drug] uuid:d4e9f226-d18d-477b-ba75-dfb2002d0423 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:UID84303EL biolink:treats MONDO:0005627 PMID:41385096 "[{""id"":""uuid:d8c53687-628d-45f7-9074-4c6c60c58b25"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:dbd8c3c1-d580-45c6-9b8b-4792e2c8297f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of locally unresectable recurrent or unresectable advanced head and neck cancer. [SAKIGAKE designation] uuid:d5e8b4b1-b476-48b2-880f-8ca123cd8f39 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:5PKM8P0G5I biolink:treats MONDO:0010191 PMID:41385096 "[{""id"":""uuid:5e21c1ac-faee-4910-9fd4-0c5f5dbc22b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:17f1602d-0bca-4362-9756-526cf16c5f81"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the control of bleeding tendency in patients with von Willebrand disease (VWD). [Orphan drug] uuid:f62f5fc5-5342-4b4a-91d0-2c0293214eef biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation MESH:C033608 biolink:treats HP:0012450 PMID:41385096 "[{""id"":""uuid:72d022b7-a614-4a09-b532-d4ad3aafab80"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b2434b55-cf8d-4c4a-ab8c-7f2d64a78ae5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug indicated for the treatment of chronic constipation (excluding constipation due to organic diseases). uuid:87fbec40-c161-4be5-ac71-577788156b20 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6897GXD6OE biolink:treats MONDO:0002280 PMID:41385096 "[{""id"":""uuid:ed702a31-a074-4adb-9ab4-5b60d7f746ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0325fe44-5f92-4221-ba88-b0994eca721b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of iron-deficiency anemia. uuid:fd134586-c6de-4ef3-aa89-33fc8559b666 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7510J153OT biolink:treats MONDO:0008233 PMID:41385096 "[{""id"":""uuid:b1bcacd9-3a63-49c5-934a-8150a817da9a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1a8a54af-3ef2-4b0e-807f-0dfd4dad5b22"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the improvement of the status of excessive catecholamine secretion in patients with pheochromocytoma. [Orphan drug] PUBCHEM.COMPOUND:12650 uuid:70a51189-fca1-49dc-b257-185fd91af1f9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:G0G0H52U6K biolink:treats MONDO:0005041 PMID:41385096 "[{""id"":""uuid:85d732aa-900c-460e-a9d0-2a2830e1e913"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3aaaab46-3bca-4152-aa8e-35a5ec73b14b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of glaucoma and ocular hypertension. uuid:78936b04-4833-45cc-8d72-ff57eb6ff5ed biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:G0G0H52U6K biolink:treats HP:0007906 PMID:41385096 "[{""id"":""uuid:ca69d921-bff1-4b62-a7c7-cfb25b3579bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e63ad6ea-05b9-4517-8d23-e1bc7318893a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of glaucoma and ocular hypertension. uuid:e3860efe-9aeb-4f85-b2b8-9b010de47039 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68590 biolink:treats UMLS:C0021342 PMID:41385096 "[{""id"":""uuid:c505cfc9-fc7b-4c2f-8819-4ac98964935b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:bdd78b79-ed5f-440f-9b72-b9876476c393"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of infectious enteritis (including pseudomembranous colitis) caused by C. difficile . uuid:bb2dce88-668a-4be3-b3ff-cae909b02b6d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:033ECH6IFG biolink:treats MONDO:0005715 PMID:41385096 "[{""id"":""uuid:8564c31a-c712-4794-9bf4-b16e26a4df6f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5f01fbcb-e862-493f-a885-c03a7ff3dd03"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the prophylaxis of congenital toxoplasmosis. [Orphan drug] uuid:a66d9522-2a55-46c8-acf1-391ef62fe74d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1597612 biolink:treats MONDO:0006032 PMID:41385096 "[{""id"":""uuid:8855ae05-6646-489b-8980-edb7d13152a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5cf3fab1-01ae-4126-9356-1fec4cbec5da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug with new active ingredients indicated for the treatment of cystitis, pyelonephritis, peritonitis, intra-abdominal abscess, cholecystitis, and liver abscess caused by Zerbaxa- sensitive Streptococcus spp., Escherichia coli , Citrobacter spp., Klebsiella spp., Enterobacter spp., Proteus spp., or Pseudomonas aeruginosa . uuid:5eb8c4a3-f69e-4ae6-9051-e59f420e9129 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1597612 biolink:treats MONDO:0004522 PMID:41385096 "[{""id"":""uuid:ebfcf8b2-b2df-4ba6-b114-d261251d03e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5dff8249-8974-4520-a765-5f2f146b8431"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug with new active ingredients indicated for the treatment of cystitis, pyelonephritis, peritonitis, intra-abdominal abscess, cholecystitis, and liver abscess caused by Zerbaxa- sensitive Streptococcus spp., Escherichia coli , Citrobacter spp., Klebsiella spp., Enterobacter spp., Proteus spp., or Pseudomonas aeruginosa . uuid:5abdd097-b160-4bf4-8e87-f666336df5f7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1597612 biolink:treats MONDO:0002155 PMID:41385096 "[{""id"":""uuid:d4a9c789-db0c-40ee-aa40-a579e06b6182"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ce931fd4-1c07-4a63-9089-c3ef68f624c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug with new active ingredients indicated for the treatment of cystitis, pyelonephritis, peritonitis, intra-abdominal abscess, cholecystitis, and liver abscess caused by Zerbaxa- sensitive Streptococcus spp., Escherichia coli , Citrobacter spp., Klebsiella spp., Enterobacter spp., Proteus spp., or Pseudomonas aeruginosa . uuid:96fea4cd-005f-47cd-aca2-5d9bc40124d4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1597612 biolink:treats UMLS:C0023886 PMID:41385096 "[{""id"":""uuid:0f8a1538-1730-4503-89d9-793244762cd1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:384a0d60-267a-47ce-9e4a-e3725e5e1c14"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug with new active ingredients indicated for the treatment of cystitis, pyelonephritis, peritonitis, intra-abdominal abscess, cholecystitis, and liver abscess caused by Zerbaxa- sensitive Streptococcus spp., Escherichia coli , Citrobacter spp., Klebsiella spp., Enterobacter spp., Proteus spp., or Pseudomonas aeruginosa . uuid:fe40c361-4da0-4680-9b86-be2a1416c690 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1799208 biolink:treats MONDO:0005231 PMID:41385096 "[{""id"":""uuid:bd8a9335-65bf-42f9-8ec8-77b718642a11"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4a5e65ed-c87f-4a02-b158-bc4faeffa0ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug with a new active ingredient indicated for: Improvement of viremia in patients with chronic hepatitis C or compensated cirrhosis type C who have previously been treated. Improvement of viremia in patients with decompensated cirrhosis type C. [Priority review] uuid:4eab81c1-2191-45d5-84a5-624517fc036d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1799208 biolink:treats MONDO:0005448 PMID:41385096 "[{""id"":""uuid:5b257146-b487-49ab-8429-fdfff656a395"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b22b65dc-f5a2-434e-adb5-3f9aa6cd00f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug with a new active ingredient indicated for: Improvement of viremia in patients with chronic hepatitis C or compensated cirrhosis type C who have previously been treated. Improvement of viremia in patients with decompensated cirrhosis type C. [Priority review] uuid:fd63a75a-4381-46f3-90b7-fe0c01243a03 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:142418 biolink:treats MONDO:0006624 PMID:41385096 "[{""id"":""uuid:031f5ea1-02bf-4f81-be82-3f06d7660301"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9069d34c-75ac-4d87-ba0d-2ce6b114bfef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of urinary urgency, urinary frequency, and urge urinary incontinence associated with overactive bladder. uuid:75839980-ee2b-485c-b5ed-e4e016af0404 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:142418 biolink:treats HP:0100515 PMID:41385096 "[{""id"":""uuid:ca556278-c544-4f63-b5a6-e6002e369256"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0bd52173-13e5-484d-9878-18dcb1682195"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of urinary urgency, urinary frequency, and urge urinary incontinence associated with overactive bladder. uuid:1c2e5937-f98c-440c-b0d6-1b95f0373b3f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:P76B05O5V6 biolink:treats HP:0000132 PMID:41385096 "[{""id"":""uuid:55ffa0a2-1d9c-46c2-bed5-d32a9c226d5c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6f6ba805-0806-4135-8208-ff874be0ae1b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the alleviation of menorrhagia, lower abdominal pain, backache, and anemia that are associated with uterine fibroids. uuid:b8cfda40-f141-469e-8b87-d1abaeca498e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:P76B05O5V6 biolink:treats NCIT:C35272 PMID:41385096 "[{""id"":""uuid:b7611417-045b-4965-8ecb-a21f810dcdb0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f423a931-84ae-4d5b-ba29-03a150983950"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the alleviation of menorrhagia, lower abdominal pain, backache, and anemia that are associated with uterine fibroids. uuid:ee4dae3f-85e7-41b6-bdf7-9f4b1ac1b4dd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:P76B05O5V6 biolink:treats HP:0003418 PMID:41385096 "[{""id"":""uuid:4b6abf5a-0a0d-42dd-8949-a60a019e82e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b37921bb-1079-4052-9873-57d093494368"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the alleviation of menorrhagia, lower abdominal pain, backache, and anemia that are associated with uterine fibroids. uuid:1f535887-ed8b-4538-ae1c-19d91fa767de biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:P76B05O5V6 biolink:treats MONDO:0002280 PMID:41385096 "[{""id"":""uuid:c0ea04f0-756f-4c63-8374-fb583336c4d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5aa2adde-8306-410f-a5de-f44af9a6cf8a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the alleviation of menorrhagia, lower abdominal pain, backache, and anemia that are associated with uterine fibroids. uuid:b8f40c6d-b88a-4d57-abeb-eb638fb62008 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:90ZX3Q3FR7 biolink:treats MONDO:0022205 PMID:41385096 "[{""id"":""uuid:17707cc0-aac4-40ea-8c71-8722ccc8657d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5b02fc43-ee51-4a3d-ac78-23c33821a88e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of plaque psoriasis, psoriatic arthritis, pustular psoriasis and erythrodermic psoriasis in patients who have not responded sufficiently to conventional therapies. uuid:fbf62a8d-f81d-471f-8baa-60e64051e054 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:90ZX3Q3FR7 biolink:treats UMLS:C0748052 PMID:41385096 "[{""id"":""uuid:9a2ce41e-788e-4a99-ade6-f0960994602f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d6ad9294-02e8-459c-a01e-93da2fcc3e4a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of plaque psoriasis, psoriatic arthritis, pustular psoriasis and erythrodermic psoriasis in patients who have not responded sufficiently to conventional therapies. uuid:6d1b12c3-8559-4a67-a899-223bdb4e2615 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:31YO63LBSN biolink:treats MONDO:0005627 PMID:41385096 "[{""id"":""uuid:341882b3-346f-448c-b0b4-a15b4c8ce9dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:868abd07-1bf1-4f2d-8b3f-71115b133c7e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with new indications and a new dosage in an additional dosage form for the treatment of unresectable or recurrent malignant pleural mesothelioma and melanoma that have progressed after chemotherapy. [Orphan drug] A drug with a new dosage in an additional dosage form indicated for the treatment of melanoma, unresectable or recurrent non-small cell lung cancer, unresectable or metastatic renal cell carcinoma, relapsed or refractory classical Hodgkin lymphoma, recurrent or metastatic head and neck cancer, unresectable or recurrent gastric cancer that has progressed after chemotherapy, and (3) unresectable or metastatic renal cell carcinoma. [(3) Priority review] uuid:7d285b1a-ed6e-408f-b585-8b5f6baf6511 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9570 biolink:treats UMLS:C0280100 PMID:41385096 "[{""id"":""uuid:b5b67272-10f5-4386-b8d8-53afb0604caf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:94c2c174-8cd0-4774-8ae8-ed775d3d66a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the conditioning treatment of solid tumors in pediatric patients prior to autologous hematopoietic stem-cell transplantation. [Expedited review] uuid:d72c7f75-d760-4b26-80af-887375d095fe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB10283 biolink:treats MONDO:0019173 PMID:41385096 "[{""id"":""uuid:437a91c9-b156-4420-aaea-ae432371e26f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4778e5a6-7529-4667-b484-77b48c42a791"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the pre-exposure and post-exposure prophylaxis against rabies. uuid:6f902cb3-7edf-4eaa-82d0-f2eac8e90643 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:B72HH48FLU biolink:treats UMLS:C0852922 PMID:41385096 "[{""id"":""uuid:713df3de-dfea-422e-b79c-3db273f663df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e772e718-7787-47b8-b6ab-bef75010fa32"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Follow-on biologics indicated for the treatment of rheumatoid arthritis, psoriasis, Crohn’s disease, and ulcerative colitis. uuid:2734d538-f097-4055-a54d-39b381c578d2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:865UEK4EJC biolink:treats HP:0012450 PMID:41385096 "[{""id"":""uuid:2227275a-d89c-49fd-be6c-67337b06c5a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6c640799-ecec-4c8d-bb7f-16af9cedd526"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of chronic constipation (excluding constipation due to organic diseases). uuid:6882c42e-c4f1-41cf-b904-50f1d750ccbb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:228365 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:c74a7910-6971-4cb2-9042-160e6d9aa9f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c81f5241-406b-4f2e-8afa-dca5e30eff0e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of hyperlipidaemia (including familial hyperlipidaemia). uuid:60cae35c-00db-4b9c-a288-4252ca002473 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:228365 biolink:treats UMLS:C0694546 PMID:41385096 "[{""id"":""uuid:b76a7144-d2f2-4824-9bc9-becdf414d500"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:74ea0a79-44a6-45ae-81ae-44c6efe3af36"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of hyperlipidaemia (including familial hyperlipidaemia). uuid:dfffd747-4e4c-4257-803c-30085aca2c54 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:5Z9SP3X666 biolink:treats MONDO:0009669 PMID:41385096 "[{""id"":""uuid:ddc11d94-fc00-46e4-9af6-4e78a849a866"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6c52594b-9046-4382-adf7-3c4453a40060"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of infantile spinal muscular atrophy. [Orphan drug] uuid:0182cc48-420d-4068-a55b-d10b9578e344 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7SI2UZG934 biolink:treats HP:0008441 PMID:41385096 "[{""id"":""uuid:e31b8e2a-e505-4d6b-969d-db705cfd5eb3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:fc36c9e3-6eef-4cf4-943b-7db14625aa21"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of lumbar disc herniation with subligamentous extrusion that has not adequately responded to conservative treatment. uuid:cc622404-5b0f-4a19-b74b-5d38a98531b0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:94X46KW4AE biolink:treats MONDO:0005609 PMID:41385096 "[{""id"":""uuid:177ed890-54c6-4ecb-9973-203dc027f5a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5140ce0b-889b-43e9-beb4-0b685dc0ceee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of herpes zoster. uuid:8662bfe6-5ad6-41ba-9033-65180757a4f8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1940699 biolink:treats MONDO:0005155 PMID:41385096 "[{""id"":""uuid:cfb95889-34bc-4282-95b2-9266e0ca9f90"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9261a5a8-fa3c-46a5-803a-c8f51d4045cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug with a new active ingredient indicated for the improvement of viremia in patients with chronic hepatitis C or compensated cirrhosis type C. [Priority review] uuid:9aaa030b-352b-4141-96e6-85a629cc017e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:34549 biolink:treats MONDO:0001628 PMID:41385096 "[{""id"":""uuid:49c15a8b-45d1-4f96-9579-e0337c8bc4c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2da3107e-3980-4744-b8c6-32380588f203"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of onychomycosis due to Trichophyton species. uuid:1a02e46e-dd75-43dc-9d97-5acfa5a75071 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135673 biolink:treats MONDO:0011786 PMID:41385096 "[{""id"":""uuid:9f2f34a7-66b3-4bf3-81e1-fd5af7def2ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1e33046c-19cd-43de-a55a-c1490a6abf0b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of allergic rhinitis, urticaria, and itching associated with skin diseases (eczema/dermatitis, cutaneous pruritus). uuid:87a0cdf0-391f-4672-9e40-c69c9f0e695d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135673 biolink:treats MONDO:0005492 PMID:41385096 "[{""id"":""uuid:fb7e62b9-cb63-42a8-9f5d-4d0e85c8668a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e0d6627f-fabe-4946-920b-ce8998251997"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of allergic rhinitis, urticaria, and itching associated with skin diseases (eczema/dermatitis, cutaneous pruritus). uuid:36d1243b-88db-4605-a75a-5e9ea89a3d55 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135673 biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:36bfb06e-0968-41d4-980b-934a2c8cf57d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:736074ca-478a-4285-8044-bff36cf63e3b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of allergic rhinitis, urticaria, and itching associated with skin diseases (eczema/dermatitis, cutaneous pruritus). uuid:13ffc294-3515-479f-9a66-b48ac487f11a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135673 biolink:treats MONDO:0002406 PMID:41385096 "[{""id"":""uuid:ac0cf6f0-2397-4695-b38f-e0dff5a659d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:efaa6d2a-bce6-41db-a3fc-aa3bd59d69cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of allergic rhinitis, urticaria, and itching associated with skin diseases (eczema/dermatitis, cutaneous pruritus). uuid:e7596730-31c0-4618-8881-b6f369b9f6e0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:71492GE1FX biolink:treats MONDO:0100470 PMID:41385096 "[{""id"":""uuid:6ee0f0ac-ff46-4cbb-8259-02f47baaecaa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3f53c559-52da-461c-a10f-21fb367a38d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of bronchial asthma (for use only in patients with intractable bronchial asthma whose asthmatic responses are uncontrollable with conventional therapies). uuid:faf4dc51-1ad3-456d-8c44-0d855200b5c6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:089658A12D biolink:treats MONDO:0022205 PMID:41385096 "[{""id"":""uuid:b880cc3e-d4dc-4ac0-bcc8-eb10d02c627a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6261ead9-9283-4677-9626-51fd27f5dbd8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of plaque psoriasis, psoriatic arthritis, pustular psoriasis, and erythrodermic psoriasis in patients who have not responded sufficiently to conventional therapies. uuid:6428c47c-760c-462c-9174-6374f9c6cbf5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:089658A12D biolink:treats UMLS:C0748052 PMID:41385096 "[{""id"":""uuid:648b1c15-c6b2-4c31-9176-12ddf971de35"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:328ff889-b27f-4700-9614-add0f168d79d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of plaque psoriasis, psoriatic arthritis, pustular psoriasis, and erythrodermic psoriasis in patients who have not responded sufficiently to conventional therapies. uuid:3d8cbe35-5d76-4111-a248-ff8464bb81e6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17549 biolink:treats MONDO:0004200 PMID:41385096 "[{""id"":""uuid:539143a9-3ecf-4a10-98d5-534e1f05979e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b38efd01-a196-4a4b-b45c-2e4bb450a491"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and a new dosage in an additional dosage form for the visualization of tumor tissues of the non-muscle invasive bladder cancer in transurethral resection of bladder tumor. [Orphan drug] uuid:fc5af5f0-1150-4f32-8de1-6d154005fb4a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:P93RUU11P7 biolink:treats MONDO:0020511 PMID:41385096 "[{""id"":""uuid:2ce19ac3-ba62-4534-8339-2600133a1695"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:88a72c65-7273-4b49-834d-6d4a1fddb10d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of relapsed or refractory CD22- positive acute lymphoblastic leukemia. [Orphan drug] uuid:9c26e152-33c6-43d0-9c96-53fd14a494e8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3207 biolink:treats UMLS:C0852922 PMID:41385096 "[{""id"":""uuid:bd80baa1-76a4-4bd8-a3f2-f63982e779cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:55b98685-a9d0-442b-8200-a0b0a4ed71fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new route of administration indicated for the treatment of mild to moderately active Crohn's disease. uuid:7458c973-2b2a-458c-8e01-20ec705bd6d3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:205919 biolink:treats EFO:1001494 PMID:41385096 "[{""id"":""uuid:96ab605e-aa20-4f90-868b-7f96e5a03fbb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0c4dab3a-ca0a-4be8-958a-f6cdb507375e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug in a new dosage form indicated for the treatment of psoriasis vulgaris of the scalp. uuid:09af7a3e-1b15-4a50-97cd-45f79487d46e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0353697 biolink:treats MONDO:0005180 PMID:41385096 "[{""id"":""uuid:c170deb1-d76e-4843-90d4-9eef46c03d38"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e3f74fe2-e7b2-4c06-8d4f-9bc5977ab515"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug indicated for the improvement of wearing-off phenomenon in the symptoms of Parkinson's disease in patients who have not responded sufficiently to conventional levodopa-containing drug therapies. [Orphan drug] uuid:5be0f02c-e54c-48f1-8292-9829aa9258db biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75246 biolink:treats MONDO:0001711 PMID:41385096 "[{""id"":""uuid:e9c152f1-4114-456b-ae3f-c4aa2c70ca46"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ba178586-dc1a-4119-81b6-c3591ac15691"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the improvement of hyperammonemia in patients with hepatic encephalopathy. [Orphan drug] uuid:9b33ebf2-aa0d-4d78-b8d0-5fafb2c9958c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:132975 biolink:treats MONDO:0005354 PMID:41385096 "[{""id"":""uuid:3b638ba8-0c06-4e3c-848e-ca14c550977c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:83f7889e-fd6a-40ad-8d85-8c07373001e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the improvement of viremia in patients with chronic hepatitis C or compensated cirrhosis type C in serogroup 1 (genotype 1). [Priority review] uuid:1867275c-d116-4ffc-b8de-4e526856b8b0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:132975 biolink:treats MONDO:0005155 PMID:41385096 "[{""id"":""uuid:0baefa77-8e0f-4967-b26f-30471bdc905d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a2001a75-0123-47c4-ac6d-2f90441781e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the improvement of viremia in patients with chronic hepatitis C or compensated cirrhosis type C in serogroup 1 (genotype 1). [Priority review] uuid:119f8cab-fa22-40cd-8446-aaab26ff925c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:132967 biolink:treats MONDO:0005354 PMID:41385096 "[{""id"":""uuid:b09b1fd6-15bf-49d9-bc1f-eb0ca2fe789d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:83d549a5-9ca8-4671-a8a6-6ef15d9193d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the improvement of viremia in patients with chronic hepatitis C or compensated cirrhosis type C in serogroup 1 (genotype 1). [Priority review] uuid:ce53ccdd-771b-46ac-bb55-7037b5ff2048 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:132967 biolink:treats MONDO:0005155 PMID:41385096 "[{""id"":""uuid:0adb029d-3079-4b80-bf58-8932b8934358"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c827ef63-003e-4558-a857-b4fdcdb86a83"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the improvement of viremia in patients with chronic hepatitis C or compensated cirrhosis type C in serogroup 1 (genotype 1). [Priority review] uuid:b6c410e3-0400-4e2c-80c1-9c86815b90a8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:718834 biolink:treats MONDO:0005136 PMID:41385096 "[{""id"":""uuid:124a3b38-3d22-4046-9a27-2c4cecc9ee5e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ffd47f5e-334f-48a2-b364-0bdb6e6be5a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug with new active ingredients indicated for the treatment of malaria. uuid:e2c75799-80a5-4518-a99a-c60097a039e0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90923 biolink:treats MONDO:0005344 PMID:41385096 "[{""id"":""uuid:812eaf5c-93c4-4f66-9832-84b8a81d9cb6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:08ded9a8-1fe0-4133-82df-e9bd3812e1f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the suppression of proliferation of hepatitis B virus in patients with chronic liver disease with hepatitis B virus infection in whom abnormal liver function is confirmed along with hepatitis B virus proliferation. [Priority review] uuid:ed511ab2-ed08-46d2-ac76-3cf8df664756 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90923 biolink:treats UMLS:C0341439 PMID:41385096 "[{""id"":""uuid:6c819941-ad10-4a4b-bfab-aa521f44827d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f8369619-dfad-44c3-8d77-1a9eaff2d04f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the suppression of proliferation of hepatitis B virus in patients with chronic liver disease with hepatitis B virus infection in whom abnormal liver function is confirmed along with hepatitis B virus proliferation. [Priority review] uuid:5dba22c7-1f38-460b-9607-9378c1d6b5ae biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:9874151 biolink:treats MONDO:0005133 PMID:41385096 "[{""id"":""uuid:ae573e0d-53d4-486c-8f6a-c5dd93cf9bc8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:09415398-e8a8-4cf4-842b-cbadbe34d0f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with new indications and a new dosage in an additional dosage form indicated for the alleviation of pain associated with endometriosis, and dysmenorrhea. uuid:61977b1a-3b23-45ab-8c99-e584f405cae4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:9874151 biolink:treats HP:0100607 PMID:41385096 "[{""id"":""uuid:0cedd2a8-c228-4071-81e4-3a032c1f0cf0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:491d37be-7668-4d02-b14d-4d032abfd6b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with new indications and a new dosage in an additional dosage form indicated for the alleviation of pain associated with endometriosis, and dysmenorrhea. uuid:847d4903-02be-48a7-8f04-ce673615a623 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6ZA31Y954Z biolink:treats MONDO:0011849 PMID:41385096 "[{""id"":""uuid:8bc2dc49-9d8e-4fea-afd1-ce9ec3dee0dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:84757394-6bd7-4354-8371-9cbf8e80dde0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of plaque psoriasis, psoriatic arthritis, pustular psoriasis, and erythrodermic psoriasis in patients who have not responded sufficiently to conventional therapies. uuid:cf78c7e5-df61-4010-8d81-368e936b1a37 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6ZA31Y954Z biolink:treats MONDO:0022205 PMID:41385096 "[{""id"":""uuid:b0de9230-856c-441a-8dad-e8e029ac754c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5c7a68a9-1e3b-4abd-9f39-b36ccc0f1214"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of plaque psoriasis, psoriatic arthritis, pustular psoriasis, and erythrodermic psoriasis in patients who have not responded sufficiently to conventional therapies. uuid:d2db1a36-24f9-4314-8584-d4c4b5ef846e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6ZA31Y954Z biolink:treats UMLS:C0748052 PMID:41385096 "[{""id"":""uuid:8d8f365c-31e9-4784-b32a-c767bd8b0500"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9a54c72a-d863-4d20-8193-02f057d0c959"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of plaque psoriasis, psoriatic arthritis, pustular psoriasis, and erythrodermic psoriasis in patients who have not responded sufficiently to conventional therapies. uuid:f6e611b5-c6a5-44df-8988-38d4fef37cc6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:291342 biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:ac37b082-a2cc-4294-be60-ed6ceceabde0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:41845a53-adc9-47cb-9f79-ad6d86b1067e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of allergic rhinitis, urticaria, and itching associated with skin diseases (eczema/dermatitis, cutaneous pruritus). uuid:ed7e76a3-1cec-4a90-9690-75b5a192cbb3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:291342 biolink:treats MONDO:0002406 PMID:41385096 "[{""id"":""uuid:373cf2ac-903a-47a5-8912-54cd6d862d7f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a84ddb15-db35-4ab3-9819-310a206a9e31"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of allergic rhinitis, urticaria, and itching associated with skin diseases (eczema/dermatitis, cutaneous pruritus). uuid:dcec0710-5f5f-4483-b3be-5404dd33d7f1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135954 biolink:treats MONDO:0011786 PMID:41385096 "[{""id"":""uuid:b449d689-f032-4397-b8d5-a6398f3413db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:dc83f742-9279-4558-aba9-54c4b96e0c6f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of allergic rhinitis, urticaria, and itching associated with skin diseases (eczema/dermatitis, cutaneous pruritus). uuid:30b46543-d0e1-4c06-afa3-d8010b36d477 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135954 biolink:treats MONDO:0005492 PMID:41385096 "[{""id"":""uuid:5072d75b-46c8-4fd1-a58a-6d9cea9d5926"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e8fb764c-d312-4ffc-839c-220c8aa87eac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of allergic rhinitis, urticaria, and itching associated with skin diseases (eczema/dermatitis, cutaneous pruritus). uuid:d75f1f98-3bee-4fac-8185-a42fc1b36f84 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135954 biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:3064467d-b645-478e-877c-3ec49faec0aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7bc5dfa1-c611-4b29-bed7-3a748fbf8018"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of allergic rhinitis, urticaria, and itching associated with skin diseases (eczema/dermatitis, cutaneous pruritus). uuid:9c928bd8-0930-465d-bb25-7595e6a31f9b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135954 biolink:treats MONDO:0002406 PMID:41385096 "[{""id"":""uuid:5f757321-d0f3-4c8c-95d9-281b04f50ab2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:51547120-8514-4f60-bd63-589899ade615"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of allergic rhinitis, urticaria, and itching associated with skin diseases (eczema/dermatitis, cutaneous pruritus). uuid:77f07798-cf3a-4f40-92b1-beb7c11cb072 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:78543 biolink:treats MONDO:0004967 PMID:41385096 "[{""id"":""uuid:ab986756-6276-417e-8311-989683f5dca5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5844c37d-5cd8-4ec3-b60c-03083f9a091d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of chronic myelogenous leukemia with resistance or intolerance to prior drug therapies, and recurrent or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia. [Orphan drug] uuid:a9282ce3-025b-45f4-be9c-4accd56df03e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32660 biolink:treats MONDO:0010643 PMID:41385096 "[{""id"":""uuid:7bad4602-2119-4270-bcf1-621f0e65c3ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1bdfef40-6e25-4609-95f4-7db3ff32e843"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of acute leukemia (including blast crisis of chronic leukemia) and malignant lymphoma (only for patients who experienced hypersensitivity to L-asparaginase preparations). uuid:efecb2c2-8908-46c9-b34d-c88ce4ee5ae5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32660 biolink:treats MONDO:0006115 PMID:41385096 "[{""id"":""uuid:793840c6-f227-4847-a234-122a2c53b172"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:75aea837-d0cd-4ede-96d7-75b370f650b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of acute leukemia (including blast crisis of chronic leukemia) and malignant lymphoma (only for patients who experienced hypersensitivity to L-asparaginase preparations). uuid:5da9da39-28b0-41b6-a667-057e1c7dccd9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32660 biolink:treats MONDO:0005062 PMID:41385096 "[{""id"":""uuid:9328df53-4015-4ceb-a728-9768d538623a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:beeaa57c-6811-4164-afbf-5d2034068861"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of acute leukemia (including blast crisis of chronic leukemia) and malignant lymphoma (only for patients who experienced hypersensitivity to L-asparaginase preparations). uuid:aad42e57-8801-4695-8866-a2271542278f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:9X7O8V25IT biolink:treats MONDO:0007476 PMID:41385096 "[{""id"":""uuid:c4d57316-5f58-4c43-9823-42e6e400bf35"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:74c5ecaf-3b63-4769-9a71-bf0b42afb7d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of Dupuytren's contracture. uuid:45dea50f-7b6b-4290-9303-9143cfd46d7d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:882520 biolink:treats EFO:1001494 PMID:41385096 "[{""id"":""uuid:70b5c2da-ca1b-4c40-a4ef-3bb78feecb95"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:078d087d-0118-47f8-981d-bce23a72edd7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug indicated for the treatment of psoriasis vulgaris. uuid:094d20dd-426e-4eaa-87bf-b3ff59f7b73a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63638 biolink:treats HP:0012469 PMID:41385096 "[{""id"":""uuid:09ef0b0c-46d2-4382-817f-b042baf64719"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ecfde7af-3ba4-46d3-bd26-14889612c3ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of infantile spasms. [Orphan drug] uuid:a59707a2-984a-4cd1-8cfc-5467d830abd5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1591939 biolink:treats MONDO:0005155 PMID:41385096 "[{""id"":""uuid:a0bd4837-45e1-4de1-9c80-ae2039fc25f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b30f93b2-1c37-4a10-accd-b2370393d701"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug with new active ingredients indicated for the improvement of viremia in patients with chronic hepatitis C or compensated cirrhosis type C in serogroup 1 (genotype 1). [Priority review] uuid:bbbdf474-a287-4003-8d5f-e19f14fc4a5a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:136050 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:872a3337-7a9d-4262-a62d-6f99f2a9e62e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:aa51cafa-4a91-4671-8da6-581c2284b9bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of superficial skin infections and acne (accompanied by purulent inflammation). uuid:f0e90faa-8c35-4931-a036-9ce4e0ef0d21 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:136050 biolink:treats MONDO:0011438 PMID:41385096 "[{""id"":""uuid:749006f1-5951-4257-8ccd-e7657e754ab6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8cef1ba3-53e0-49cc-a156-10e6ec1a9da7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of superficial skin infections and acne (accompanied by purulent inflammation). uuid:4777ce70-0488-40e0-b28e-86ac09552d08 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1597377 biolink:treats MONDO:0005354 PMID:41385096 "[{""id"":""uuid:f16a3b64-23d2-4941-b0f0-fc0ec1b3e22d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:160b4328-9360-41c1-a3e6-275a33502a8f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug with new active ingredients indicated for the improvement of viremia in patients with chronic hepatitis C or compensated cirrhosis type C in serogroup 1 (genotype 1). [Priority review] uuid:77c3ba5d-2909-4102-ab6a-414972717e8c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1597377 biolink:treats MONDO:0005155 PMID:41385096 "[{""id"":""uuid:68b3922c-3160-466d-9742-fbe0106cfb47"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6b98bef3-3182-4655-b3ad-be285ca7c25e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug with new active ingredients indicated for the improvement of viremia in patients with chronic hepatitis C or compensated cirrhosis type C in serogroup 1 (genotype 1). [Priority review] uuid:770fa55b-afc5-48ba-8776-917418d8d080 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:34825 biolink:treats MONDO:0001628 PMID:41385096 "[{""id"":""uuid:1e8db98e-2c26-4feb-b0ba-a5da757cdf8e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8627b6c1-831d-4dbc-96f0-85b1e76c4155"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication in a new dosage form indicated for the treatment of tinea unguium. uuid:28f268cd-f0b1-44a8-bbd2-135645ebb90b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8405 biolink:treats MONDO:0005136 PMID:41385096 "[{""id"":""uuid:02166492-e124-4795-a576-3b963ed0cfce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0a9675d6-af27-44dc-9c6d-a4a944ca492b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of malaria caused by Plasmodium vivax and Plasmodium oval . uuid:7184a8c7-3865-42dd-b667-8a607475b4e3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8405 biolink:treats MONDO:0001601 PMID:41385096 "[{""id"":""uuid:f08c95a6-f571-4432-9482-1d718b815ffc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d6dede83-2858-48de-9608-8448c09934e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of malaria caused by Plasmodium vivax and Plasmodium oval . uuid:9d7713dd-f62a-4fa3-a2d6-e667009500b9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5801 biolink:treats MONDO:0005282 PMID:41385096 "[{""id"":""uuid:20a7db7c-1455-47e4-9191-63a25f560a87"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4889436e-39b2-49ee-b350-7eec5bb78790"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of cutaneous lupus erythematosus and systemic lupus erythematosus. uuid:ba085c7b-bd9f-4ae3-a5a6-ebde138a2a7d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5801 biolink:treats MONDO:0007915 PMID:41385096 "[{""id"":""uuid:fe6793be-2fe3-49bc-bc3f-dcfd7039b40d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7156fae6-5f2e-40b8-bf5c-57b8f363d1f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of cutaneous lupus erythematosus and systemic lupus erythematosus. uuid:31787cef-5058-4c29-9243-e6ecef480da6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:42446 biolink:treats MONDO:0005178 PMID:41385096 "[{""id"":""uuid:b39590b2-ece8-43fe-a9e2-72e9c90d5cd9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ad6cd231-71e7-4441-a2de-a9f1eb5c5f3d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug with a new active ingredient indicated for the relief of inflammation and pain associated with osteoarthritis. uuid:8aded523-d9b2-4d76-94c9-03eb919fea09 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:90Z2UF0E52 biolink:treats MONDO:0100470 PMID:41385096 "[{""id"":""uuid:775c4f36-ba5b-4fb7-b1c2-0c700674c21a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1c9376eb-4f01-4a7b-a6ad-db0eec2222e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of bronchial asthma (for use only in patients with intractable bronchial asthma whose asthmatic responses are uncontrollable with conventional therapies). uuid:f535d235-575b-41d6-aa7b-10a9c8010a31 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:441410 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:87fb6276-2934-481b-9194-3f34adfb9fc1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:36eafacd-da23-4a56-8216-977f4312f68f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug in a new dosage form indicated for the treatment of prostate cancer and premenopausal breast cancer. uuid:de589e95-d19d-4b44-861a-b895a09420eb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:33325 biolink:treats UMLS:C0153690 PMID:41385096 "[{""id"":""uuid:8d92f2f4-00ea-4182-86c7-4e5a86dfb3ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:317d19d0-4002-46b2-b563-b99cb6376232"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of castration-resistant prostate cancer with bone metastases. uuid:639de067-7974-4945-ac14-2cb7e93ccefe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:78432 biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:b4c6084a-18ef-49b5-86b5-a93ad44993ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:75cb0025-6893-43f6-a0b4-ad2b72af6cdc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of unresectable advanced/relapsed anaplastic lymphoma kinase (ALK)-positive non- small-cell lung cancer with resistance or intolerance to crizotinib. uuid:5bfd877b-eb2b-4541-a611-5630edab2ba7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:C9R35M8XV6 biolink:treats MONDO:0006926 PMID:41385096 "[{""id"":""uuid:5ada1798-781d-4f69-8bd4-8f551b5c6b83"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d7fdb08a-02c3-4291-aa6a-9337a2973605"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the prophylaxis of Haemophilus influenzae type b infections. uuid:a6ead489-3dae-41b3-9b97-21b0652739b3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:9832804 biolink:treats EFO:1001494 PMID:41385096 "[{""id"":""uuid:98353e14-817c-4efa-a1f2-0ee51d3ffb05"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:33ff3e9c-c9a3-4baa-b70b-85112a7c7a4f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug indicated for the treatment of psoriasis vulgaris. uuid:bb1cf37e-0a11-445c-a0ea-670e55025d62 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:43830 biolink:treats UMLS:C1263992 PMID:41385096 "[{""id"":""uuid:30ddaf80-1cac-4413-901f-1bac2b9e168b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:43721108-85d9-41e6-a293-d938ea0668d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of toxic methemoglobinemia. uuid:32d3a68d-7245-4e97-b910-bfe81286439b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6437 biolink:treats MONDO:0006891 PMID:41385096 "[{""id"":""uuid:c60a41c3-5ce1-42d3-af2c-66d2a0b5b682"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c7a6df80-fe56-483a-aaf7-32f483736b89"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new route of administration indicated for use as an adjunctive therapy with other antiepileptic drugs to treat partial seizure (including secondary generalized seizure) in patients with epilepsy who have not responded sufficiently to other antiepileptic drugs. It is used as an alternative therapy for levetiracetam oral formulation in patients who are temporarily unable to be administered orally. uuid:7df17683-b808-40b0-9ad5-3441e71a0f7a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6437 biolink:treats HP:0007334 PMID:41385096 "[{""id"":""uuid:bfc8c836-bec8-4ad9-82b1-e07c316fd591"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:22d6a29b-4f0f-4b6b-8110-8ed4383346ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new route of administration indicated for use as an adjunctive therapy with other antiepileptic drugs to treat partial seizure (including secondary generalized seizure) in patients with epilepsy who have not responded sufficiently to other antiepileptic drugs. It is used as an alternative therapy for levetiracetam oral formulation in patients who are temporarily unable to be administered orally. uuid:e4869209-73e5-41fa-84c2-d021da41a32d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:136046 biolink:treats MONDO:0005041 PMID:41385096 "[{""id"":""uuid:490b39d2-df97-4a83-a43f-e8a507ff2330"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4b9f0e53-3a22-4753-b2b1-982a04033321"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of glaucoma or ocular hypertension in patients who have not sufficiently responded to other therapeutic drugs for glaucoma or who are unable to use them. uuid:d99418bd-9a0b-4437-ad24-6dc911b78b45 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:136046 biolink:treats HP:0007906 PMID:41385096 "[{""id"":""uuid:f90c83db-217f-441b-8978-02eec3f562ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8f769817-8897-4310-84a1-152ae02c085e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of glaucoma or ocular hypertension in patients who have not sufficiently responded to other therapeutic drugs for glaucoma or who are unable to use them. uuid:172472cf-9a88-419e-832a-bd5db9616460 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:136019 biolink:treats HP:0000989 PMID:41385096 "[{""id"":""uuid:c2999959-5ee4-4dc8-8baa-5edece090a82"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f1b5944d-4e5d-462a-aa6e-4a5f3beaa715"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the improvement of pruritus in patients with chronic liver diseases (for use only when conventional therapies are not sufficiently effective). uuid:2e690d41-fd41-45c8-a078-765738bf22ce biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:136019 biolink:treats MONDO:0100193 PMID:41385096 "[{""id"":""uuid:05bf4fa2-9cb2-431e-a3f6-c74d2b5eae18"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:65c6293b-fa1f-4ad1-afce-0c39b6bf657e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the improvement of pruritus in patients with chronic liver diseases (for use only when conventional therapies are not sufficiently effective). uuid:de82bf40-7847-4ff0-b45b-519125348c66 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6909 biolink:treats UMLS:C0021342 PMID:41385096 "[{""id"":""uuid:662cbf8b-7bc8-485b-b0bb-8a49d4774b75"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b562db1d-d41f-485c-9387-da3d8e312051"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new route of administration indicated for the treatment of different kinds of anaerobic bacterial infections, infectious enteritis, and amebic dysentery. uuid:2e15cfdd-a9f4-479a-b2af-f5bee8805ecf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:136047 biolink:treats MONDO:0005354 PMID:41385096 "[{""id"":""uuid:5b0bdc4b-15a9-4b20-a114-aac227bfc619"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8d193c8f-6620-4b60-a0ca-58330ed41ecc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the improvement of viremia in the following patients with serogroup 1 (genotype I [1a] or II [1b]) chronic hepatitis C: Patients with high levels of blood HCV RNA who are treatment-naive, or Patients who are non-responders or relapsed to therapy including interferon. [Priority review] uuid:ce6d7379-ca5f-4d9d-8360-620c5328eee5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85083 biolink:treats MONDO:0005155 PMID:41385096 "[{""id"":""uuid:d302acb3-bec1-4d26-aff2-12e2229b1638"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:18d99332-fc2a-42ba-a80d-dd79bed28ba5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the improvement of viremia in patients with chronic hepatitis C or compensated cirrhosis type C in serogroup 2 (genotype 2) . [Priority review] uuid:2cb7eb01-77b5-4e28-aef5-a29e657f0aa4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:37943 biolink:treats MONDO:0030603 PMID:41385096 "[{""id"":""uuid:a5d4181e-c0ca-4f10-986f-34c564e9edc5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d0d447b5-daa9-42b8-ba6f-91d9eedfc0ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new route of administration indicated for the treatment of infections caused by colistin- sensitive Escherichia coli, Citrobacter, Klebsiella, Enterobacter, Pseudomonas aeruginosa, and Acinetobacter (limited to the strains resistant to other antimicrobial drugs). [Orphan drug] uuid:e2a0b235-1ff8-4a2c-896b-a8bf58b891ac biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:37943 biolink:treats MONDO:0006635 PMID:41385096 "[{""id"":""uuid:87e68097-6dd7-4e9f-a994-a1a586d8d43b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d59dd371-de14-45b0-a487-b367df273069"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new route of administration indicated for the treatment of infections caused by colistin- sensitive Escherichia coli, Citrobacter, Klebsiella, Enterobacter, Pseudomonas aeruginosa, and Acinetobacter (limited to the strains resistant to other antimicrobial drugs). [Orphan drug] uuid:ab6456fd-07fe-461a-aaf3-8c6091804892 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:170190 biolink:treats MONDO:0005137 PMID:41385096 "[{""id"":""uuid:dadafabc-705f-4353-9597-8908bd743e9d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:de210bc9-41a6-40ca-986e-7037deba570e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A combination prescription drug with similar formulations indicated for the supplementation of amino acids, electrolyte, hydrosoluble vitamins, and water. It is used in patients with mild hypoproteinemia or in a mild malnutrition state due to insufficient oral intake or used in perioperative patients. uuid:216e42d2-e303-4b4c-b82b-86a80dadc2f6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46195 biolink:treats UMLS:C0409952 PMID:41385096 "[{""id"":""uuid:ef7f6bc1-6d29-4967-98e1-7927d4f3de81"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4eaa9454-eee1-4851-b2e1-f913588c7ff7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug in an additional dosage form. Note: the product was submitted for an approval application as a drug with a new additional indication for the treatment of osteoarthrosis and with an expanded dosage of acetaminophen in an additional dosage form. The new additional indication and the expanded dosage were approved on January 21, 2011, whereas approval of the additional dosage form had been under review. uuid:ef9d31d3-99ed-44d7-b0be-4316f19c4719 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:82752 biolink:treats MONDO:0018150 PMID:41385096 "[{""id"":""uuid:84eb60dc-6522-4d4a-906d-1f570da5c5c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:468c2b39-cc44-4d7f-90ee-40b2f598c41d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the improvement of various symptoms of Gaucher disease (anemia, thrombocytopenia, hepatosplenomegaly, and bone disease). [Orphan drug] uuid:a31bd92a-5af8-43d0-9186-c3bfccbe7222 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:66919 biolink:treats MONDO:0044903 PMID:41385096 "[{""id"":""uuid:f381e6f4-5e79-455b-a931-2a92f9681341"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c757e263-05ba-4de4-a3f4-44127b4b3cb9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of myelofibrosis. [Orphan drug] uuid:f99e670b-feeb-4891-a76b-5296f82cc62f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:142290 biolink:treats MONDO:0005029 PMID:41385096 "[{""id"":""uuid:2fbb76a2-7a82-45c3-a6a1-3584ca1712bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4bd4c9cb-f039-49cb-b4c3-3ce1eaffcf55"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of essential thrombocythemia. [Orphan drug] uuid:23f33aab-455b-415e-8b92-93ad60c878f8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3A189DH42V biolink:treats MONDO:0003864 PMID:41385096 "[{""id"":""uuid:5c2d8915-7709-4a95-9e48-d966df8308c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:99b7e81f-6315-430d-8ee1-6c1a0955792e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of relapsed or refractory chronic lymphocytic leukemia. [Orphan drug] uuid:ea5f5503-cb41-40a7-bffa-ade606b1040e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9288 biolink:treats MONDO:0019954 PMID:41385096 "[{""id"":""uuid:f9580194-c6ae-458c-ac1d-d5752bb17597"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c3e4fe33-4727-4328-9d2f-cc354632c0bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of neuroendocrine tumors of the pancreas and gastrointestinal tract. [Orphan drug] uuid:c59b61b2-3439-4cfc-968f-3940e4d5b062 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9288 biolink:treats MONDO:0024503 PMID:41385096 "[{""id"":""uuid:73fc23c0-9813-488f-982f-52af48cd294c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:486aaed7-cacc-43ed-8a61-3547f48c4079"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of neuroendocrine tumors of the pancreas and gastrointestinal tract. [Orphan drug] uuid:748353a5-6245-4e41-8fb4-d283e6ba1c1c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB09877 biolink:treats UMLS:C3873491 PMID:41385096 "[{""id"":""uuid:b26a6091-0e33-47d4-a70b-1301fddcfad3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6fdd8422-f4d8-4ecc-a7d3-800f2165c569"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the prophylaxis of invasive meningococcal disease. (serotypes A, C, Y, and W-135). uuid:2ec72f4d-1e3d-4d92-9ba6-f0c11348e014 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1484959 biolink:treats MONDO:0010602 PMID:41385096 "[{""id"":""uuid:dc5f1256-28c1-486a-9a88-531384c5631c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1338c9e9-a48e-41df-b09b-bc5cc8febe15"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug with a new active ingredient indicated for prevention of bleeding in patients who have inhibitors against blood coagulation factor VIII or IX. [Orphan drug] uuid:dd41629b-8fa0-44e3-9f98-1e74d946715a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1484959 biolink:treats MONDO:0010604 PMID:41385096 "[{""id"":""uuid:67cb0648-5b94-4786-9f9c-9b7afef3d097"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6b566551-c113-44c1-bd32-567e790d8408"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug with a new active ingredient indicated for prevention of bleeding in patients who have inhibitors against blood coagulation factor VIII or IX. [Orphan drug] uuid:5cdd120b-18ce-4990-ae8f-7c6cf8b9d221 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134721 biolink:treats MONDO:0011122 PMID:41385096 "[{""id"":""uuid:f869f9fc-487d-4539-a832-81db61ac6030"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:14776f26-7041-43db-8db4-c2d8feee4d39"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of obesity (for use only in patients who have both type 2 diabetes mellitus and dyslipidaemia and whose BMI level is 25kg/m2 or more even with diet and exercise therapies). uuid:4182511d-686f-46e9-8007-e2f403f79698 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134721 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:67572d19-f183-45e7-ae3c-eb85a35b612d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:86b84ebc-1d31-4efe-a441-1bd6efe3a890"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of obesity (for use only in patients who have both type 2 diabetes mellitus and dyslipidaemia and whose BMI level is 25kg/m2 or more even with diet and exercise therapies). uuid:221bf1af-3182-45d7-b463-e89b9c4f0a4a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134721 biolink:treats MONDO:0015905 PMID:41385096 "[{""id"":""uuid:205222e1-b199-40a4-8eb6-7c856f5b96cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b4d3421e-f27b-4a8a-8854-8c80f702183b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of obesity (for use only in patients who have both type 2 diabetes mellitus and dyslipidaemia and whose BMI level is 25kg/m2 or more even with diet and exercise therapies). uuid:bb3cf5fc-fa85-4cc6-8ffb-41b2dacae0ec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:144421 biolink:treats MONDO:0000328 PMID:41385096 "[{""id"":""uuid:ac1de4db-26b1-4b02-8fb0-4139cacc7c62"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3b413a6f-ed85-4029-8e56-1e8cc99fa40f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the improvement of hyperphosphatemia in patients with chronic kidney disease. uuid:286b7bcd-d0c7-489c-b76b-8c8b672475aa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:144421 biolink:treats MONDO:0005300 PMID:41385096 "[{""id"":""uuid:f3c2c182-bfea-4961-adc0-c44ad1abe7af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:268d59ac-4f3f-48a8-ab45-de82497bbe57"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the improvement of hyperphosphatemia in patients with chronic kidney disease. uuid:d127164d-aec7-42e6-a423-e5dfdc59959d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50223 biolink:treats UMLS:C4324343 PMID:41385096 "[{""id"":""uuid:f3fcfa63-c5a0-450c-aa7b-3e540e3cdaaa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ad385b61-4150-4741-9fc7-d4b96d71a4f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of anthracycline extravasation. uuid:3df9fc55-2535-4ef3-a48f-79936d97c396 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:37941 biolink:treats HP:0001681 PMID:41385096 "[{""id"":""uuid:bf3ad5bb-19a5-4038-982e-702fb8b145b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5e47ec41-112a-4a60-9fa9-80927686066e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug indicated for the treatment of ischemic heart diseases (acute coronary syndrome [unstable angina, non-ST-segment elevation myocardial infarction, ST-segment elevation myocardial infarction], stable angina, old myocardial infarction) to which percutaneous coronary intervention (PCI) is applicable. uuid:4029410c-7332-422a-8d53-40252219ba8f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:37941 biolink:treats UMLS:C0155668 PMID:41385096 "[{""id"":""uuid:0af87ba9-77b3-41a6-b596-b16db0f00629"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:86c98e6a-5c9b-4bfd-80c6-e9728a5f7a2b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug indicated for the treatment of ischemic heart diseases (acute coronary syndrome [unstable angina, non-ST-segment elevation myocardial infarction, ST-segment elevation myocardial infarction], stable angina, old myocardial infarction) to which percutaneous coronary intervention (PCI) is applicable. uuid:a73c6476-a9b6-42da-98d5-442cec6669cd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:78538 biolink:treats MONDO:0007100 PMID:41385096 "[{""id"":""uuid:5416e0ab-a1f0-4257-a474-91603ce75ce6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:134d329a-6b24-4d81-a48e-e63f407ae52f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for delaying the peripheral neurologic impairment in transthyretin familial amyloid polyneuropathy. [Orphan drug] uuid:b3ce221a-514c-4d33-8c49-ca9db2d0ef49 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63631 biolink:treats HP:0007334 PMID:41385096 "[{""id"":""uuid:3676b766-ede1-4b7f-b29d-61533f5f7258"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:dc76bb66-cc6f-4966-b91e-b280fc473337"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional pediatric dosage in an additional dosage form. The drug is indicated for use as an adjunctive therapy with other antiepileptic drugs to treat partial seizures (including secondary generalized seizures) in patients with epilepsy who have not responded sufficiently to other antiepileptic drugs. uuid:61de06a3-1e95-4ff4-a69e-f7cbdef9eb48 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:66899 biolink:treats MONDO:0005041 PMID:41385096 "[{""id"":""uuid:83e6e9ea-e70e-4bd3-99a1-93dbf64f1e9d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:dd432065-5055-44df-8aef-eead1d868212"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug indicated for the treatment of glaucoma and ocular hypertension. uuid:c5f832d7-2683-4e2d-a607-655742bfc2f9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:66899 biolink:treats HP:0007906 PMID:41385096 "[{""id"":""uuid:7ed64807-152a-46fd-81b0-00f5493db2f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8057502c-84ba-4050-b61c-d57b4aca9a25"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug indicated for the treatment of glaucoma and ocular hypertension. uuid:9e1ec893-5f97-4c95-b760-61a312d48a09 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3176 biolink:treats MONDO:0005041 PMID:41385096 "[{""id"":""uuid:88b9f028-8c48-421a-95b8-323c78c7dd1e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8d0e1b2a-516a-485d-bc70-41446032a74d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug indicated for the treatment of glaucoma and ocular hypertension in patients who have not responded sufficiently to other glaucoma drugs. uuid:5a70fe97-daa7-4b11-855b-cf31d990752c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3176 biolink:treats HP:0007906 PMID:41385096 "[{""id"":""uuid:f65c4ed7-e493-4299-8c8e-dae81185d1e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a287d894-e9c0-469f-8f85-0b2f12bf5361"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug indicated for the treatment of glaucoma and ocular hypertension in patients who have not responded sufficiently to other glaucoma drugs. uuid:30fa4218-9a09-4fee-8964-58d62a281758 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134743 biolink:treats MONDO:0005354 PMID:41385096 "[{""id"":""uuid:e4898f0f-03c0-44e9-ba84-ff9afa6aca79"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:33513312-0b8c-4fab-949b-3aae48f79de7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the improvement of viraemia in following (1) or (2) patient with chronic hepatitis C serogroup 1 (genotype I [1a] or II [1b]): (1) Patient with high level of blood HCV RNA who have untreated or (2) Patients who have not respond to or relapsed with the treatment including interferon. [Priority review] uuid:9f34b35c-b198-4b1d-96c5-164b405e05c1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134743 biolink:treats MONDO:0011101 PMID:41385096 "[{""id"":""uuid:4aa40b04-317b-45be-b57d-60ca26dc8366"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:86c9f798-fac2-4149-a8c4-c007bbf6512a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the improvement of viraemia in following (1) or (2) patient with chronic hepatitis C serogroup 1 (genotype I [1a] or II [1b]): (1) Patient with high level of blood HCV RNA who have untreated or (2) Patients who have not respond to or relapsed with the treatment including interferon. [Priority review] uuid:ad9827ba-b789-48b8-b792-e009ae3cc2e8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134722 biolink:treats MONDO:0005812 PMID:41385096 "[{""id"":""uuid:a6c76d60-5292-4891-999c-0fb229babda4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:29f6ba5b-d037-4189-b6f8-55f4fad5192d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for novel or re-emerging influenza virus infections (for use only in patients who have not responded or not responded sufficiently to other anti-influenza virus drugs). [Priority review] uuid:e1770fec-3ec7-429a-b0b8-dce519c6cedb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:34916 biolink:treats MONDO:0004525 PMID:41385096 "[{""id"":""uuid:85fa0e76-a5fc-4ac3-baf9-b10a1c953ad7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:98aa44bc-5d08-4b75-b42c-6c7489ba22ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage for the treatment of scabies. [Priority review] uuid:c486037e-86b3-4e09-aeb3-9fb431b1025d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63717 biolink:treats MONDO:0005366 PMID:41385096 "[{""id"":""uuid:344adf91-763e-415b-8476-3651caa37266"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c1525178-694a-4230-8f48-10f353894aff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the growth inhibition of hepatitis B virus in patients with chronic hepatitis B who show liver dysfunction accompanied by proliferation of the virus. [Priority review] uuid:faccc59c-13b7-4a20-ba0f-e3b0d7387e07 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63717 biolink:treats HP:0001410 PMID:41385096 "[{""id"":""uuid:cc6e5dbc-4dbe-4884-8759-894ed2ced780"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:55f4205d-3b1d-49b8-a6e7-71f11c548be8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the growth inhibition of hepatitis B virus in patients with chronic hepatitis B who show liver dysfunction accompanied by proliferation of the virus. [Priority review] uuid:4795a993-dd00-4067-8562-55b22ec86075 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:11564052 biolink:treats MONDO:0005607 PMID:41385096 "[{""id"":""uuid:9ec40162-47ac-40cd-a448-d745d75d35e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:80448852-b926-4000-9fd7-b0a881cd3366"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug indicated for the relief of symptoms secondary to airway obstructive disorder in chronic obstructive pulmonary disease (chronic bronchitis, emphysema) (when a combination treatment of an inhaled long-acting anticholinergic and a long-acting beta-2 agonist is needed). uuid:946f12dd-914e-4756-bfc7-177bac1f6304 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:11564052 biolink:treats MONDO:0004849 PMID:41385096 "[{""id"":""uuid:de6e19e6-39ac-4376-b8d3-42ef8f6ba442"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2a57f1ea-b8f8-41e0-b1f1-0c6b8a56f726"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug indicated for the relief of symptoms secondary to airway obstructive disorder in chronic obstructive pulmonary disease (chronic bronchitis, emphysema) (when a combination treatment of an inhaled long-acting anticholinergic and a long-acting beta-2 agonist is needed). uuid:96e39bae-3c1d-469c-a6e5-69c2b0e7e63a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5050 biolink:treats MONDO:0011786 PMID:41385096 "[{""id"":""uuid:79015e1f-63a6-4b1b-bc27-5415d2a91334"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6e614044-a779-427c-991a-611f40bee27e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional pediatric (6 months of age and older and less than 7 years of age) dosage in an additional dosage form of dry syrup. This drug is indicated for the treatment of allergic rhinitis, urticaria, and itching associated with skin diseases (eczema/dermatitis, pruritus cutaneous, atopic dermatitis). uuid:7631042c-c2e2-405a-82bf-da33be91cc5b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5050 biolink:treats MONDO:0005492 PMID:41385096 "[{""id"":""uuid:7673ea18-a52a-428f-90d3-195243994084"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:71524b8c-2187-40c8-a15a-a13dc8b06738"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional pediatric (6 months of age and older and less than 7 years of age) dosage in an additional dosage form of dry syrup. This drug is indicated for the treatment of allergic rhinitis, urticaria, and itching associated with skin diseases (eczema/dermatitis, pruritus cutaneous, atopic dermatitis). uuid:37fee216-42f0-440e-95e3-21dc42a3bd5a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5050 biolink:treats HP:0000989 PMID:41385096 "[{""id"":""uuid:3cca923a-1c96-4242-8e4c-10a0cb84a625"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:322c2a30-1fde-48f4-a0c6-92b268a05edb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional pediatric (6 months of age and older and less than 7 years of age) dosage in an additional dosage form of dry syrup. This drug is indicated for the treatment of allergic rhinitis, urticaria, and itching associated with skin diseases (eczema/dermatitis, pruritus cutaneous, atopic dermatitis). uuid:c6aba735-e76a-4a62-9486-a82e8f2f4ff5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5050 biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:d93016d5-2ae8-4f38-890b-32f7de448730"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ef79f13c-0144-41c1-9a54-56556164ff27"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional pediatric (6 months of age and older and less than 7 years of age) dosage in an additional dosage form of dry syrup. This drug is indicated for the treatment of allergic rhinitis, urticaria, and itching associated with skin diseases (eczema/dermatitis, pruritus cutaneous, atopic dermatitis). uuid:f36d09d6-8d77-4fc7-9513-5dcf505a9d84 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:94559 biolink:treats MONDO:0011786 PMID:41385096 "[{""id"":""uuid:289ecd30-15bb-4004-aeab-5b9596719a2a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7c565c12-c60e-4f08-b4d0-35b3a19c4097"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional pediatric (6 months of age and older and less than 7 years of age) dosage in an additional dosage form of dry syrup. This drug is indicated for the treatment of allergic rhinitis, urticaria and itching associated with skin disease. (eczema/dermatitis and pruritus cutaneous) uuid:f79d1d2d-4739-45c2-ab41-74fe4b96cd3b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:94559 biolink:treats MONDO:0005492 PMID:41385096 "[{""id"":""uuid:26df516d-90a4-46ee-ae35-d80d6a17ac34"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:feb6f69e-00e8-4c39-9837-2e6ed69b6f68"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional pediatric (6 months of age and older and less than 7 years of age) dosage in an additional dosage form of dry syrup. This drug is indicated for the treatment of allergic rhinitis, urticaria and itching associated with skin disease. (eczema/dermatitis and pruritus cutaneous) uuid:d9469e5d-543d-4549-9a73-9b4f0629cf68 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:94559 biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:7a776f56-670c-4e23-b8c2-6ecc60791d71"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d6110450-7618-457c-8034-1ab3f0ff6adf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional pediatric (6 months of age and older and less than 7 years of age) dosage in an additional dosage form of dry syrup. This drug is indicated for the treatment of allergic rhinitis, urticaria and itching associated with skin disease. (eczema/dermatitis and pruritus cutaneous) uuid:4dbaa594-eafa-4cfb-ae63-3e6f4de86719 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:94559 biolink:treats MONDO:0002406 PMID:41385096 "[{""id"":""uuid:1db9fd6e-3286-4716-9d26-4adc3eff0702"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ec1ba1b0-0a34-4ab9-b7ad-265948dd3d8f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional pediatric (6 months of age and older and less than 7 years of age) dosage in an additional dosage form of dry syrup. This drug is indicated for the treatment of allergic rhinitis, urticaria and itching associated with skin disease. (eczema/dermatitis and pruritus cutaneous) uuid:48290943-f42f-4560-8515-0643895b0528 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:94559 biolink:treats HP:0000989 PMID:41385096 "[{""id"":""uuid:3811428b-d8d0-4e75-8243-661a999330a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a543bec4-dc62-4d28-9f44-8bc6baf92fdb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional pediatric (6 months of age and older and less than 7 years of age) dosage in an additional dosage form of dry syrup. This drug is indicated for the treatment of allergic rhinitis, urticaria and itching associated with skin disease. (eczema/dermatitis and pruritus cutaneous) uuid:56bb18d7-cdb8-4219-a94f-23198751ac63 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:VF232WE742 biolink:treats MONDO:0007488 PMID:41385096 "[{""id"":""uuid:f6ebfcc1-bf97-44f4-b836-cd6ee231ec40"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:022d0056-b46c-4f8f-98c1-8a1cd3708582"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for dopamine transporter scintigraphy in the diagnoses of Parkinson's syndrome and dementia with Lewy bodies. uuid:5ed633ad-01b2-45d6-9a46-84d903937bbf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7662KG2R6K biolink:treats HP:0012450 PMID:41385096 "[{""id"":""uuid:faa76e25-e3b6-4830-bf53-e2bae179ba58"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f53f855a-5850-46a4-b861-5ce4ea651b6d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of chronic constipation (excluding constipation due to organic diseases). uuid:f4b7feaa-8f1d-469c-b245-5fcb69be55e1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:200251 biolink:treats MONDO:0000313 PMID:41385096 "[{""id"":""uuid:388b3238-7b89-4f7e-86db-f1924ebf87f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6e383539-0857-4f8a-b4d1-d725fb8cb633"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage in an additional dosage form for the treatment of hypophosphatemia. [Orphan drug] uuid:393c5d91-ff91-43e0-aa71-a283bbc475ee biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:34523 biolink:treats UMLS:C0267167 PMID:41385096 "[{""id"":""uuid:7afe8da2-4a39-4b48-a138-2e7bbe609f50"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e187899d-e87a-4414-a06c-bd727cd09277"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of postprandial fullness, upper abdominal bloating, and early satiation in functional dyspepsia. uuid:c2c99dea-b7c3-4ed1-8a6f-964e67a4d58a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:D87YGH4Z0Q biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:67aa5265-8029-4ca9-aa60-9192b3a5da23"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:93c17966-1a0c-4f52-b33b-26975bbb3fc5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of hyperlipidaemia. uuid:a26696f3-60cd-4ac4-a8f7-9892f47626f8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64028 biolink:treats MONDO:0001595 PMID:41385096 "[{""id"":""uuid:dbeb7ea2-b8eb-4cb1-af33-fcf022741955"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4e988fbb-877b-4739-ab71-a70163c8e215"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of chorea associated with Huntington's disease. [Orphan drug] uuid:bf840e47-6809-4053-9e33-82f32fc9e88d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:149836 biolink:treats MONDO:0002922 PMID:41385096 "[{""id"":""uuid:c5d3b28b-71e1-4855-a995-436ea8969f24"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:36e4b967-97db-4f0f-a754-fbd2eb032f6d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of deep skin infection, chronic pyoderma, secondary infection of trauma, burn, and surgical wounds, secondary infection of erosion and ulcer, peritonitis, intraperitoneal abscess, and cholecystitis. [Priority review] uuid:72e53bce-48a1-4d9e-85f5-2f1760423878 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:149836 biolink:treats UMLS:C0332803 PMID:41385096 "[{""id"":""uuid:6cd87ec0-08fc-4fcb-b975-9cf4eb1890d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3c178262-d4f1-400f-a306-98356ef0824c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of deep skin infection, chronic pyoderma, secondary infection of trauma, burn, and surgical wounds, secondary infection of erosion and ulcer, peritonitis, intraperitoneal abscess, and cholecystitis. [Priority review] uuid:384f2821-8a3b-44a5-b2d9-585b994d6f70 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:149836 biolink:treats MONDO:0004247 PMID:41385096 "[{""id"":""uuid:feeb25c4-f4dd-425a-b3a9-352ba022c5b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3edab68e-2634-47cd-ad85-94daa60d2ed8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of deep skin infection, chronic pyoderma, secondary infection of trauma, burn, and surgical wounds, secondary infection of erosion and ulcer, peritonitis, intraperitoneal abscess, and cholecystitis. [Priority review] uuid:2d700508-983c-449c-812e-bb2206ca6c78 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:149836 biolink:treats MONDO:0004522 PMID:41385096 "[{""id"":""uuid:1a9c910c-cd60-4958-b821-c941563e0498"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ae9f7190-04f8-4b69-9274-f189f9b9db4f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of deep skin infection, chronic pyoderma, secondary infection of trauma, burn, and surgical wounds, secondary infection of erosion and ulcer, peritonitis, intraperitoneal abscess, and cholecystitis. [Priority review] uuid:c7dc13a6-9623-483d-acf0-bdbdb4d73f92 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:149836 biolink:treats HP:0100592 PMID:41385096 "[{""id"":""uuid:a17d64ec-ebfc-4097-a682-6d0d1e442dd5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:941ddcc2-8f9b-43be-8e88-0f431159934f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of deep skin infection, chronic pyoderma, secondary infection of trauma, burn, and surgical wounds, secondary infection of erosion and ulcer, peritonitis, intraperitoneal abscess, and cholecystitis. [Priority review] uuid:b6e4e344-a3d9-4f5d-bf57-5d6ad863e3f8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:149836 biolink:treats MONDO:0002155 PMID:41385096 "[{""id"":""uuid:979bf9ad-6641-4d1d-9bd2-0b0cafc05c38"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2caa724b-3852-4861-b6e4-6996d85cece2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of deep skin infection, chronic pyoderma, secondary infection of trauma, burn, and surgical wounds, secondary infection of erosion and ulcer, peritonitis, intraperitoneal abscess, and cholecystitis. [Priority review] uuid:65c18601-c662-46d7-9a0a-b349280c7cda biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7934 biolink:treats MONDO:0024275 PMID:41385096 "[{""id"":""uuid:c9e6a1fa-81a1-4e9c-8bd4-93f4319a5cbb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6f929611-c76f-4fd1-94c3-c55e2040adbe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of intestinal amoebiasis. uuid:08c4fd12-dfba-4572-a53a-1f654eae907c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:64759 biolink:treats MONDO:0015790 PMID:41385096 "[{""id"":""uuid:5029358b-f52e-446b-af04-58f04480a294"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:490fd258-e970-4002-bbb5-75a9cf07ed15"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage in an additional dosage form for the treatment of central diabetes insipidus. uuid:3d371d22-190f-4937-80c5-c04a06a0baa0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:144551 biolink:treats HP:0100515 PMID:41385096 "[{""id"":""uuid:dd52ce7d-e833-4e1e-ba89-7bf1bb142023"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:98f8444f-d3ed-4af6-9091-c7adca1bb35f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new route of administration and new indications for the treatment of urinary urgency, urinary frequency, and urge urinary incontinence associated with overactive bladder. uuid:bea29a33-fd8b-4fe9-8df7-b3bf3e96afa7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90973 biolink:treats MONDO:0005607 PMID:41385096 "[{""id"":""uuid:31104352-5a1d-4627-ac0b-00de5fe8bea8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:81447528-ac4a-43a6-9a16-fb1adff452ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the relief of symptoms secondary to airway obstructive disorder in chronic obstructive pulmonary disease (chronic bronchitis, emphysema). uuid:e11ca370-e7d2-4f05-981a-a3aa5e5ac2f3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90973 biolink:treats MONDO:0004849 PMID:41385096 "[{""id"":""uuid:4fa96579-ac07-41ee-9f89-f67dbbd8e914"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0e46035e-64df-4fd6-8229-1e6facf33ce9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the relief of symptoms secondary to airway obstructive disorder in chronic obstructive pulmonary disease (chronic bronchitis, emphysema). uuid:79af32e7-d8ca-442b-9b0b-f18ebf9cc580 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:215122 biolink:treats MONDO:0011786 PMID:41385096 "[{""id"":""uuid:bfdbcd60-44cb-4487-9294-d13c945eb89a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:45af1efa-78ca-4f72-a521-96f6a157e4bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug indicated for the treatment of allergic rhinitis. uuid:3def0761-cd57-4d4a-8eee-0c768ebe2e62 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:136042 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:011350ba-de8b-46c5-a543-3ec5c309b3bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:52d2a9ff-277e-44f7-a351-c5bbf169e2e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of type 2 diabetes mellitus. uuid:92ed4d3a-aee1-437e-b8c3-57444cc35995 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:152770 biolink:treats HP:0002901 PMID:41385096 "[{""id"":""uuid:4edb3b28-b437-413a-bd74-19d16f9d45d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2524c18d-1ae6-4761-920e-c12d62783017"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A combination prescription drug with a similar formulation indicated for the treatment and prevention of hypocalcemia in association with administration of RANKL inhibitors (e.g. denosumab [genetical recombination]) [Expedited review] uuid:480d64cf-48da-43e7-a814-681258f5ef15 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68647 biolink:treats MONDO:0005575 PMID:41385096 "[{""id"":""uuid:0d27573c-6e31-4571-8021-431de582b777"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:05e25258-2b3a-411f-906b-6eaffdc2413f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of unresectable advanced or recurrent colorectal cancer. [Priority review] uuid:57de0c51-543c-4101-9e82-94a9955f8baf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB10796 biolink:treats MONDO:0017373 PMID:41385096 "[{""id"":""uuid:2acc9134-28be-4476-b359-6ccbaa3eb252"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:10a6bd92-cfd8-40a3-8ac0-f5e0fd60f72a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the prevention of acute poliomyelitis. [Expedited review] uuid:dc249d71-dffb-4424-892c-8eb91fa57ab6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB09877 biolink:treats UMLS:C2748361 PMID:41385096 "[{""id"":""uuid:29081c14-9f1b-4b4b-a8b7-23c7b539372c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:610eee9b-5b65-433b-ad3f-b277fbca6fd2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the prevention of pandemic influenza (H5N1). [Orphan drug] uuid:bfd9ef51-2936-4427-b40e-32d766d8eb4a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50275 biolink:treats UMLS:C1442968 PMID:41385096 "[{""id"":""uuid:deeb4023-78d3-4465-a3c7-b468a71082a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:314e4125-f305-4bdc-996a-43971126934e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of gastric ulcer, duodenal ulcer, anastomotic ulcer, reflux esophagitis, non-erosive reflux disease and Zollinger-Ellison syndrome, prevention of recurrence of gastric ulcer or duodenal ulcer in patients treated with nonsteroidal antiinflammatory drugs, and aid to eradication of Helicobacter pylori in patients with gastric ulcer, duodenal ulcer, gastric MALT lymphoma, idiopathic thrombocytopenic purpura, and stomach after endoscopic treatment for early gastric cancer. uuid:6fda73de-7643-401c-8819-7d0e45eb3ebc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50275 biolink:treats MONDO:0006896 PMID:41385096 "[{""id"":""uuid:35a7c416-1c7c-4a63-a140-feda07a08954"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:dde61c69-9c6d-438a-9c7d-4269693702e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of gastric ulcer, duodenal ulcer, anastomotic ulcer, reflux esophagitis, non-erosive reflux disease and Zollinger-Ellison syndrome, prevention of recurrence of gastric ulcer or duodenal ulcer in patients treated with nonsteroidal antiinflammatory drugs, and aid to eradication of Helicobacter pylori in patients with gastric ulcer, duodenal ulcer, gastric MALT lymphoma, idiopathic thrombocytopenic purpura, and stomach after endoscopic treatment for early gastric cancer. uuid:8482edc0-6185-4be8-89d2-c3b0d6b6a506 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50275 biolink:treats MONDO:0006226 PMID:41385096 "[{""id"":""uuid:e0c09c79-17f9-4c2f-abf4-54613b22daac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:722be260-c31d-474b-8c1d-83f404f305a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of gastric ulcer, duodenal ulcer, anastomotic ulcer, reflux esophagitis, non-erosive reflux disease and Zollinger-Ellison syndrome, prevention of recurrence of gastric ulcer or duodenal ulcer in patients treated with nonsteroidal antiinflammatory drugs, and aid to eradication of Helicobacter pylori in patients with gastric ulcer, duodenal ulcer, gastric MALT lymphoma, idiopathic thrombocytopenic purpura, and stomach after endoscopic treatment for early gastric cancer. uuid:9a3aae7c-30d8-45b8-8e46-395954850550 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50275 biolink:treats MONDO:0019098 PMID:41385096 "[{""id"":""uuid:ec60a017-1c31-4006-a27d-ce775481ca64"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6f7df920-3036-471e-b082-1a7c138d1c82"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of gastric ulcer, duodenal ulcer, anastomotic ulcer, reflux esophagitis, non-erosive reflux disease and Zollinger-Ellison syndrome, prevention of recurrence of gastric ulcer or duodenal ulcer in patients treated with nonsteroidal antiinflammatory drugs, and aid to eradication of Helicobacter pylori in patients with gastric ulcer, duodenal ulcer, gastric MALT lymphoma, idiopathic thrombocytopenic purpura, and stomach after endoscopic treatment for early gastric cancer. uuid:7312d669-83a1-4d26-b3ab-acd431ae14c1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50275 biolink:treats MONDO:0004716 PMID:41385096 "[{""id"":""uuid:9c1b284c-022e-4a33-814f-b9dcacbac7de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3793d4ce-89a2-4f93-96d2-2be1ae4d503a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of gastric ulcer, duodenal ulcer, anastomotic ulcer, reflux esophagitis, non-erosive reflux disease and Zollinger-Ellison syndrome, prevention of recurrence of gastric ulcer or duodenal ulcer in patients treated with nonsteroidal antiinflammatory drugs, and aid to eradication of Helicobacter pylori in patients with gastric ulcer, duodenal ulcer, gastric MALT lymphoma, idiopathic thrombocytopenic purpura, and stomach after endoscopic treatment for early gastric cancer. uuid:f20387dd-d241-4bfe-9afa-e435ff21cc82 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50275 biolink:treats MONDO:0019610 PMID:41385096 "[{""id"":""uuid:592a8c9d-5504-4c7e-8fe4-7dc390563400"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d7afe151-d087-45c1-845b-01f16bd11a31"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of gastric ulcer, duodenal ulcer, anastomotic ulcer, reflux esophagitis and Zollinger- Ellison syndrome, prevention of recurrence of gastric ulcer or duodenal ulcer in patients treated with nonsteroidal antiinflammatory drugs, and aid to eradication of Helicobacter pylori in patients with gastric ulcer, duodenal ulcer, gastric MALT lymphoma, idiopathic thrombocytopenic purpura, and stomach after endoscopic treatment for early gastric cancer. uuid:6e2dfd84-4761-4352-8b9b-223eca07af34 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3160WY51LV biolink:treats MONDO:0000328 PMID:41385096 "[{""id"":""uuid:80f22b55-38be-4b9e-a0e5-d2372912655c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:518b0bf2-4cc0-431c-b8f7-c06ff81936e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the improvement of hyperphosphatemia in patients with chronic renal failure under dialysis. uuid:407355f1-0ad7-4134-8ac9-b18505827271 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3160WY51LV biolink:treats MONDO:0024327 PMID:41385096 "[{""id"":""uuid:efded284-a16f-4d17-9172-3a0b7448ba0a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:efd7ac53-deee-4d28-a6c4-9c3070c0831f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the improvement of hyperphosphatemia in patients with chronic renal failure under dialysis. uuid:2d132a90-22fd-4fb0-a56d-2d1246308a9b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:121437280 biolink:treats MONDO:0005180 PMID:41385096 "[{""id"":""uuid:4b624370-1271-45bc-8b8a-760181f0064a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:06aa1d38-fdb5-43e1-aa0b-0615af90f3e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[PMDA] A drug with a new active ingredient indicated for the treatment of ""off"" episodes associated with Parkinson's disease (when levodopa-containing products that are frequently administered and other anti-Parkinson drugs at increased doses are not sufficiently effective). [Orphan drug]" uuid:162d36ee-3d40-4b93-8331-71dd76288b31 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5165 biolink:treats MONDO:0002125 PMID:41385096 "[{""id"":""uuid:72310fd1-cbfd-4b2d-882e-44e1d78160ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:329cad88-3c79-41f3-bdb0-489764bf1e94"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for: treatment of status epilepticus prevention of seizures occurring in connection with neurosurgery, and/or consciousness disorder (head trauma, etc.) temporary substitution of oral phenytoin therapy in epilepsy patients. uuid:2abc07e2-bbba-4f4c-bebc-440cfa9ee16a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5165 biolink:treats MONDO:0005027 PMID:41385096 "[{""id"":""uuid:de8e45ef-c43b-4d18-849f-2d43d14e0acc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:799f1cb2-8db5-4b3a-92fc-e8f3a58ecb86"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for: treatment of status epilepticus prevention of seizures occurring in connection with neurosurgery, and/or consciousness disorder (head trauma, etc.) temporary substitution of oral phenytoin therapy in epilepsy patients. uuid:c29670f1-261c-4b19-8d1c-234fa3a7df2a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3175 biolink:treats MONDO:0005041 PMID:41385096 "[{""id"":""uuid:4d01c46a-23d8-4860-b4bb-ca23a1643b0e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:133adabb-0523-4d17-9fcf-88c3fecca24e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of glaucoma and ocular hypertension when other glaucoma drugs are not sufficiently effective or cannot be used. uuid:c8f7cdf5-e4aa-44f1-afe4-1f75c0676f87 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3175 biolink:treats HP:0007906 PMID:41385096 "[{""id"":""uuid:d95c5586-ae9c-49a7-a907-9c9c6d2ea3ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d7e47980-8368-437f-ac2e-43df20283ee5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of glaucoma and ocular hypertension when other glaucoma drugs are not sufficiently effective or cannot be used. uuid:9eb6f7b6-27eb-4006-bc4b-da674ed0f270 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:209468 biolink:treats MONDO:0024317 PMID:41385096 "[{""id"":""uuid:d0d22f21-e81c-41ac-b60c-6f8673979f7e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:aeff7812-5a7f-4e14-a2ff-abbd2f98d6d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug indicated for analgesia of chronic non-cancer pain and pain after tooth extraction which are not managed by treatments with non-opioid analgesics. uuid:067ac72b-87ae-485f-aa99-0cbb1e0c1114 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:600103 biolink:treats HP:0100806 PMID:41385096 "[{""id"":""uuid:fb4993b4-5373-4455-8384-9b5eaf8e486d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ecf1697b-49e4-4295-af84-da326494b6d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of sepsis, infective endocarditis, deep skin infection, secondary infection of trauma, burn, and surgical wounds, and secondary infection of erosion and ulcer caused by daptomycin-sensitive methicillin-resistant Staphylococcus aureus (MRSA). uuid:5e1dedb5-8fa1-4d31-a880-e08334df2b10 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:600103 biolink:treats UMLS:C0332803 PMID:41385096 "[{""id"":""uuid:389fac6e-b312-42d8-8a84-1192017d879f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:256b1a78-29db-486c-8e68-95d708ff0a86"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of sepsis, infective endocarditis, deep skin infection, secondary infection of trauma, burn, and surgical wounds, and secondary infection of erosion and ulcer caused by daptomycin-sensitive methicillin-resistant Staphylococcus aureus (MRSA). uuid:ffa0fd60-3b05-4d16-8258-5a9117f92514 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:600103 biolink:treats MONDO:0100073 PMID:41385096 "[{""id"":""uuid:b7be8b4a-7b82-4edb-b0c0-39b46b78db6f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0483b2b2-add4-436b-ae83-fbcb3ae3f55a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of sepsis, infective endocarditis, deep skin infection, secondary infection of trauma, burn, and surgical wounds, and secondary infection of erosion and ulcer caused by daptomycin-sensitive methicillin-resistant Staphylococcus aureus (MRSA). uuid:22ab54a7-2285-4ca8-8751-f48096576bb6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68595 biolink:treats MONDO:0005354 PMID:41385096 "[{""id"":""uuid:b8fff453-8cc0-4183-874e-b53916d3ee60"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d5ed3b56-dde6-4326-bf2b-cf9854774e1f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the improvement of viremia in serogroup 1 (genotype I [1a] or II [1b]) chronic hepatitis C in: untreated patients with high blood HCV RNA; or patients who did not respond to, or in whom the symptom relapsed with, interferon monotherapy or interferon-ribavirin combination therapy. [Priority review] uuid:46270b75-c5bb-4a54-b96c-60724a739ba9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31933 biolink:treats MONDO:0011786 PMID:41385096 "[{""id"":""uuid:87be0014-b050-42b9-88a2-34f478651277"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e55b3b50-65d2-453a-a887-ead6eddb40c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with an additional dosage form of granules and with a new additional pediatric dosage indicated for the treatment of allergic rhinitis, urticaria, and itching associated with skin disease (eczema/dermatitis and pruritus cutaneous). uuid:f206a026-af5d-4413-895c-19a15783df6e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31933 biolink:treats MONDO:0005492 PMID:41385096 "[{""id"":""uuid:3380c7e7-c54d-422c-b97f-02c169ed98e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c39ce251-9237-48cd-846f-995198f17952"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with an additional dosage form of granules and with a new additional pediatric dosage indicated for the treatment of allergic rhinitis, urticaria, and itching associated with skin disease (eczema/dermatitis and pruritus cutaneous). uuid:bbae6de8-0c5e-428b-ad1d-631207ecad5b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31933 biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:727b8539-44b2-4e51-8a1a-af709f153a95"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d1e6220a-3e9c-4760-bc09-0c640d58b303"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with an additional dosage form of granules and with a new additional pediatric dosage indicated for the treatment of allergic rhinitis, urticaria, and itching associated with skin disease (eczema/dermatitis and pruritus cutaneous). uuid:81429a3e-0bbc-4bd7-bc06-ba24c9c4abca biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31933 biolink:treats MONDO:0002406 PMID:41385096 "[{""id"":""uuid:ebf064bb-17cc-41d2-860f-12b14b868bfa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a1c9660f-13f8-4237-b9e7-9b5835786742"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with an additional dosage form of granules and with a new additional pediatric dosage indicated for the treatment of allergic rhinitis, urticaria, and itching associated with skin disease (eczema/dermatitis and pruritus cutaneous). uuid:f87c0c4a-9ba1-4143-887c-76487a9d5da9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31933 biolink:treats HP:0000989 PMID:41385096 "[{""id"":""uuid:f9c91604-d29a-45b7-ac38-6de4f58e2f7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:cf5cc089-4458-4bc2-be20-41b57fe73d05"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with an additional dosage form of granules and with a new additional pediatric dosage indicated for the treatment of allergic rhinitis, urticaria, and itching associated with skin disease (eczema/dermatitis and pruritus cutaneous). uuid:45f62526-236d-40ce-8fd3-55cff5a0e29f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68575 biolink:treats MONDO:0005607 PMID:41385096 "[{""id"":""uuid:3bde6195-bc05-4d9f-8415-ba6a155a090d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d71a8d7a-dc52-43bb-98fd-c21bad39f48b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the alleviation of various symptoms due to airway obstructive impairment in chronic obstructive pulmonary diseases (chronic bronchitis and emphysema). uuid:772c5198-7c48-441d-93f0-39243cbac409 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68575 biolink:treats MONDO:0004849 PMID:41385096 "[{""id"":""uuid:0fdd8adf-da91-44b8-8b8d-d73fba10dcfe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:84d877d4-914d-471a-8136-26ff550b5e1c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the alleviation of various symptoms due to airway obstructive impairment in chronic obstructive pulmonary diseases (chronic bronchitis and emphysema). uuid:3e9b3046-2ffa-48d9-b9e5-a608fd97eca3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32090 biolink:treats MONDO:0006733 PMID:41385096 "[{""id"":""uuid:d69d9ffe-39cb-4f5d-a632-af41591a8aa7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:49e1a387-25e1-4905-8964-27a76ca1e263"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new route of administration indicated for the treatment of dry eye. uuid:0d14ab33-cebc-4498-a5b9-556b982b644b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135349 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:4952ad28-c3d0-4f6f-8781-53ee330d5141"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:22bf66a0-2d73-4a74-99e6-fc67713e0b98"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug indicated for the treatment of type 2 diabetes mellitus (only when a concomitant use of mitiglinide calcium hydrate with voglibose is deemed appropriate). uuid:8198de82-bc1a-4f7a-b7cc-3d959f24a728 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:YI437801BE biolink:treats UMLS:C0280427 PMID:41385096 "[{""id"":""uuid:c34345be-2f2b-4fe3-a2a9-cc3d69507fec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b3cdf98b-5e58-4f2c-aaa9-bb105c7e6a63"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of recurrent or relapsed CCR4- positive adult T-cell leukemia/lymphoma. [Orphan drug] uuid:54df58dd-b31f-4490-9947-7407c5f03898 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:493191 biolink:treats MONDO:0002269 PMID:41385096 "[{""id"":""uuid:3bf0a9bc-1d93-4b2d-aae9-18afc0836c43"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:36dc9f7e-5749-4d7e-b635-eb52966bf39f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the prevention of gastroenteritis due to rotavirus. uuid:48ba5f1d-b438-4ecf-a7aa-c10d699b1a47 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:231425 biolink:treats HP:0000969 PMID:41385096 "[{""id"":""uuid:531ba0a0-6e0c-4f90-88c8-4afc71faebb9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:54293a1c-449c-4da6-bb5b-3c39636a4aec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of fluid retention in heart failure patients who have not responded sufficiently to other diuretics to such as loop diuretics. uuid:fee2a95d-5950-4a3c-81a7-58eaf51d3299 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:91083 biolink:treats MONDO:0019098 PMID:41385096 "[{""id"":""uuid:660ac0b1-1598-432b-901e-5aadb4de065e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a7883ccf-e9a0-4a16-a7e6-b945df828462"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of chronic idiopathic thrombocytopenic purpura. [Orphan drug] uuid:35d07b3f-41a3-486d-a7cf-83e000a40cf9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:0Y70779M1F biolink:treats MONDO:0000481 PMID:41385096 "[{""id"":""uuid:30f08614-79cd-407a-8946-58c9dd076e90"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:be9fb13c-9b1b-40f8-ada3-619a36775a5a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of spasmodic torticollis (cervical dystonia). uuid:75cb847f-e273-401a-adc9-39155ec9eb12 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1923432 biolink:treats MONDO:0005041 PMID:41385096 "[{""id"":""uuid:3579982c-0b54-4cfd-8077-3d2b3a453e6a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9ebe8040-cebf-45f9-b9c9-30c6c2cf99da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug indicated for the treatment of glaucoma and ocular hypertension in patients who have not responded sufficiently to other glaucoma drugs. uuid:4183ffc3-bcab-4389-9ea6-7e61447f3b38 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1923432 biolink:treats HP:0007906 PMID:41385096 "[{""id"":""uuid:21b7d3d5-d607-4d39-be55-11508008b100"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b26b070a-d4e9-488d-98f3-ccaf183c8d0e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug indicated for the treatment of glaucoma and ocular hypertension in patients who have not responded sufficiently to other glaucoma drugs. uuid:a63a97c9-e4ab-4c7b-aad7-1bd557022089 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134741 biolink:treats MONDO:0005812 PMID:41385096 "[{""id"":""uuid:601c6889-9d39-40c3-b615-746eca8cc001"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4a08e457-e0f9-4070-a525-f9753f833eff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of influenza A or B virus infections. uuid:d3de7b8e-98c5-40de-92fd-8987fa5ca255 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134741 biolink:treats UMLS:C0276353 PMID:41385096 "[{""id"":""uuid:f682f83e-1a7a-4d7b-8d70-d89f229376bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d6dfbc2b-cb1a-47c1-a2dc-dfc345a493f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of influenza A or B virus infections. uuid:6a500d0f-f1fb-4a08-ac87-1949b5322636 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats MONDO:0004785 PMID:41385096 "[{""id"":""uuid:e779617f-fcf2-4179-a4ca-3a7f7e7825aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ba4e1856-b5cc-45b7-8d6b-ecc0a52dedc7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new dosage of the 1.5% formulation for the treatment of blepharitis, dacryocystitis, hordeolum, conjunctivitis, meibomianitis, and keratitis (including corneal ulcer) and sterilization during the ophthalmic perioperative period. uuid:2b2e6437-aabf-4971-a55b-35b666f7a539 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats MONDO:0004926 PMID:41385096 "[{""id"":""uuid:67f7683b-966f-4631-81bc-2c6e52b4b4a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:dd75a3a9-06d1-4f31-ba31-d1af579d8b94"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new dosage of the 1.5% formulation for the treatment of blepharitis, dacryocystitis, hordeolum, conjunctivitis, meibomianitis, and keratitis (including corneal ulcer) and sterilization during the ophthalmic perioperative period. uuid:22b6a589-3be9-42d5-b480-3ba3d7a07198 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats MONDO:0005800 PMID:41385096 "[{""id"":""uuid:156bc07d-5811-4726-b834-660fba757593"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1e9f0596-46c0-4732-a7a2-e0a577b20544"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new dosage of the 1.5% formulation for the treatment of blepharitis, dacryocystitis, hordeolum, conjunctivitis, meibomianitis, and keratitis (including corneal ulcer) and sterilization during the ophthalmic perioperative period. uuid:5402f5a1-3a39-4694-b998-5ce7f62b3418 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats MONDO:0003799 PMID:41385096 "[{""id"":""uuid:f0694b64-203b-4437-bab4-af1ffefaa468"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:bab1d8ea-24c9-4407-8699-f4deb02d0bba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new dosage of the 1.5% formulation for the treatment of blepharitis, dacryocystitis, hordeolum, conjunctivitis, meibomianitis, and keratitis (including corneal ulcer) and sterilization during the ophthalmic perioperative period. uuid:f000c9b1-ae68-422a-a4ee-cdbb1a304cc6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats UMLS:C0549398 PMID:41385096 "[{""id"":""uuid:17df55a8-a7ab-4e69-9f73-20db8be0dc24"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:27521ca1-ebd1-439c-83c4-23874d13cf11"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new dosage of the 1.5% formulation for the treatment of blepharitis, dacryocystitis, hordeolum, conjunctivitis, meibomianitis, and keratitis (including corneal ulcer) and sterilization during the ophthalmic perioperative period. uuid:84f39425-9ef3-445b-a375-d7590036db66 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats MONDO:0003085 PMID:41385096 "[{""id"":""uuid:38399ab3-f5cf-4ad6-8104-85252ed634e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:496b4216-64ad-43f4-ab73-9f567c5fd3b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new dosage of the 1.5% formulation for the treatment of blepharitis, dacryocystitis, hordeolum, conjunctivitis, meibomianitis, and keratitis (including corneal ulcer) and sterilization during the ophthalmic perioperative period. uuid:1a8e3760-d33b-43d3-b794-a4180698b518 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16336 biolink:treats MONDO:0005416 PMID:41385096 "[{""id"":""uuid:c7270e20-6976-4c97-9eae-87cf54ef3595"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:eb4dde2a-1681-41c1-b5c2-1114ba2f95fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for pain relief in patients with knee osteoarthritis who have not responded sufficiently to conservative non-drug treatment and oral drug treatment. uuid:ed7358d4-fd62-45ca-86c0-3d729ff9aa30 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135515 biolink:treats MONDO:0018876 PMID:41385096 "[{""id"":""uuid:c08b8785-0139-4ea3-afeb-c30e43f2ee1f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:88481c56-8b4a-4c7e-80ab-ab865ccdb007"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of relapsed or refractory indolent B- cell non-Hodgkin’s lymphoma and mantle cell lymphoma. [Orphan drug] uuid:0bac8789-459b-4b6e-addd-a8df808d02e1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2038 biolink:treats MONDO:0018881 PMID:41385096 "[{""id"":""uuid:b9cad887-f6a1-4a21-b816-ef284fbb96cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c4f6f91d-149a-4e20-b0a8-1ea979837fdc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of myelodysplastic syndrome. [Orphan drug] uuid:71005772-9aa9-4dae-9b9d-3bebebca1f7c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:493191 biolink:treats MONDO:0004619 PMID:41385096 "[{""id"":""uuid:41c00479-579c-4249-8f21-c567f8dcbe2d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:63be652b-204b-4e7e-8a55-8cf117e7884c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the prevention of measles and rubella. uuid:1d7c45ae-6dbe-4916-9cb4-6789f4c16bf7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:493191 biolink:treats MONDO:0004656 PMID:41385096 "[{""id"":""uuid:a28425e9-7973-4c7e-a9f5-6f05bcd185f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e63ef409-f60d-4a68-b081-87a0d9857627"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the prevention of measles and rubella. uuid:7f60f7b0-92e1-423f-8b5c-be92e65176a1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB10769 biolink:treats MONDO:0019209 PMID:41385096 "[{""id"":""uuid:ea417758-f95a-4216-9475-7849054c9843"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e91314d7-6139-4b20-a854-87a316cc1d78"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the prevention of Japanese encephalitis. [Expedited review] uuid:7197fc15-73af-48f8-9884-7307427261bc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:283316 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:54990833-43d6-496b-a6f8-200a758732d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6e9177ad-aefd-4757-a451-c0e4ce325de7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] New combination drugs indicated for the treatment of hypertension. uuid:995bfbc1-21da-4cc4-8933-5f78268e74c2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:51230 biolink:treats MONDO:0005041 PMID:41385096 "[{""id"":""uuid:8255168f-f0b9-458e-a8e0-a5e0e070cd77"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:55156710-945b-4a25-8d42-5dd529e511ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of glaucoma and ocular hypertension. uuid:a8b8314a-1355-4203-a21a-7415c48b18c3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:51230 biolink:treats HP:0007906 PMID:41385096 "[{""id"":""uuid:1806d0ba-a8c3-4795-8e99-5582882f5cdc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f48337ce-21b1-402b-b9e2-154e73878231"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of glaucoma and ocular hypertension. uuid:1fba3f60-7ed3-47e6-92ce-f06d166dcf7a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135799 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:3bf22ca0-2f91-4a40-a677-5ee34da469b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7e40af02-cd6f-47b7-ad98-e04b3db65fbc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of pneumonia, otitis media, and sinusitis. uuid:2a0dc5e8-1975-4917-846e-bd40245dd4ce biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135799 biolink:treats MONDO:0005441 PMID:41385096 "[{""id"":""uuid:2ab49c81-a05d-40c5-8856-a76e2fd2e06f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ebd02059-957d-413f-8400-683726a2fdbb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of pneumonia, otitis media, and sinusitis. uuid:e8c59560-8b89-4cef-8df2-12dabd428b2d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135799 biolink:treats MONDO:0005961 PMID:41385096 "[{""id"":""uuid:afcc44c3-334d-484b-a090-bb3570d6bc51"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7a8cc68c-56c5-4825-b8dc-9b2c2437594a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of pneumonia, otitis media, and sinusitis. uuid:c544f175-91be-47ad-a8a9-6b77d6c52bca biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28001 biolink:treats MONDO:0003799 PMID:41385096 "[{""id"":""uuid:d86468c3-73d1-4a75-8352-5e563bc54c6f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7c1a3531-b60e-45f4-81ad-ba60ac5fd72f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new route of administration indicated for the treatment of conjunctivitis, blepharitis, meibomianitis, and dacryocystitis caused by vancomycin-sensitive methicillin- resistant Staphylococcus aureus (MRSA) and methicillin-resistant Staphylococcus epidermidis (MRSE). [Orphan drug] uuid:1e11a830-38a0-4767-81c7-1bac62da37d0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28001 biolink:treats MONDO:0004785 PMID:41385096 "[{""id"":""uuid:87ba4fda-0558-4f27-b956-42f1455b18e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:dab5a6b7-90db-4d55-9614-08fdd2c133c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new route of administration indicated for the treatment of conjunctivitis, blepharitis, meibomianitis, and dacryocystitis caused by vancomycin-sensitive methicillin- resistant Staphylococcus aureus (MRSA) and methicillin-resistant Staphylococcus epidermidis (MRSE). [Orphan drug] uuid:44d4251b-b5da-41c4-af89-86256e380a82 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28001 biolink:treats UMLS:C0549398 PMID:41385096 "[{""id"":""uuid:29fd7c39-1cff-46ae-910a-691efcd694ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:eddfa8bd-d0d9-47d3-afa6-46464b1cbd3c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new route of administration indicated for the treatment of conjunctivitis, blepharitis, meibomianitis, and dacryocystitis caused by vancomycin-sensitive methicillin- resistant Staphylococcus aureus (MRSA) and methicillin-resistant Staphylococcus epidermidis (MRSE). [Orphan drug] uuid:366aab3a-2a58-4a10-b2d2-cbba11ef0377 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28001 biolink:treats MONDO:0004926 PMID:41385096 "[{""id"":""uuid:87b44a2e-4aa5-42f7-913a-3f9985fb4022"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4908c14e-d7ef-415b-8f95-38c48d79ea4a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new route of administration indicated for the treatment of conjunctivitis, blepharitis, meibomianitis, and dacryocystitis caused by vancomycin-sensitive methicillin- resistant Staphylococcus aureus (MRSA) and methicillin-resistant Staphylococcus epidermidis (MRSE). [Orphan drug] uuid:e40883ca-cdfb-43fb-8273-30331e962ac3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77573 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:7295bf27-f78d-40ae-bbd8-82b074631df4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c08b1778-e649-4282-8815-e9158f748c30"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with new additional indications and a new dosage and in a new dosage form for the treatment of pneumonia, cholera, otitis media, and anthrax in children. uuid:89835b3f-ff86-436d-980a-87e59ed1d82b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77573 biolink:treats MONDO:0015766 PMID:41385096 "[{""id"":""uuid:174c05f9-9572-4f54-88d1-b1b9eeaf2ebd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c0213bd3-3905-4945-a4e3-157b077f69a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with new additional indications and a new dosage and in a new dosage form for the treatment of pneumonia, cholera, otitis media, and anthrax in children. uuid:b50f500b-d7cc-4077-82e8-607954a4c96f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77573 biolink:treats MONDO:0005441 PMID:41385096 "[{""id"":""uuid:ca62f582-10ce-4afe-865a-d15ffbd38627"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:850a4641-1750-47c0-91e0-f9e5a66967e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with new additional indications and a new dosage and in a new dosage form for the treatment of pneumonia, cholera, otitis media, and anthrax in children. uuid:a6ca46ba-bf43-42d1-aa90-f76ae9d7fa70 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77573 biolink:treats MONDO:0005119 PMID:41385096 "[{""id"":""uuid:e2b55629-1193-4090-81ee-dda0e93dd585"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7397fb85-f573-43ce-a419-8d2743b4afa0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with new additional indications and a new dosage and in a new dosage form for the treatment of pneumonia, cholera, otitis media, and anthrax in children. uuid:36746aac-bd50-4521-ac12-1b0ab4577f03 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:180554 biolink:treats MONDO:0011786 PMID:41385096 "[{""id"":""uuid:f409c363-2d51-4d00-9704-11ae499b106a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e8e5093d-309c-44ac-8f0b-df2d19e2e66c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of allergic rhinitis. uuid:7e86f571-ad53-42fd-9fdf-bee2ccad7ed5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49603 biolink:treats NCIT:C150634 PMID:41385096 "[{""id"":""uuid:c93905ed-cbe7-4b01-ad39-996abbd3c68e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:cbc2dd9c-5ee8-411f-8bf7-7286240355b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of inoperable or recurrent breast cancer with HER2 overexpression. [Priority review] uuid:af9aa853-b2e4-47fe-a208-6efa59982e52 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:780F0P8N4I biolink:treats MONDO:0007256 PMID:41385096 "[{""id"":""uuid:659e5e85-b771-49af-910b-80de111f2614"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f87fec60-df59-49e7-a5fd-c041add273e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for lipiodolization in hepatocellular carcinoma. uuid:35ae55a1-cd56-4309-900e-0aa894f5edae biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1597091 biolink:treats MONDO:0005096 PMID:41385096 "[{""id"":""uuid:826c9236-4617-4d4d-a46c-b3ff06334f65"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e3b07470-4814-4cd7-8dac-39f4f2b47c07"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for prevention of cervical cancer (squamous-cell carcinoma and adenocarcinoma) and its precursor lesions (cervical intraepithelial neoplasia [CIN] 2 and 3) associated with human papillomavirus (HPV) types 16 and 18 infection. [Priority review] uuid:cdd890dd-ad4b-4a49-b4d8-c4561ee0dacd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1597091 biolink:treats MONDO:0004970 PMID:41385096 "[{""id"":""uuid:8e8d8516-66ca-42a4-a9af-0d40020d5b44"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3d1e5d1d-bef3-4072-b3e4-3818bd7cad4e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for prevention of cervical cancer (squamous-cell carcinoma and adenocarcinoma) and its precursor lesions (cervical intraepithelial neoplasia [CIN] 2 and 3) associated with human papillomavirus (HPV) types 16 and 18 infection. [Priority review] uuid:f4e9c614-1e34-420c-b399-c4c051503464 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1597091 biolink:treats MONDO:0022394 PMID:41385096 "[{""id"":""uuid:9c368bbe-1558-477f-8956-59c4844058f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a13f2091-18fd-40a7-ba8f-b67542aa4855"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for prevention of cervical cancer (squamous-cell carcinoma and adenocarcinoma) and its precursor lesions (cervical intraepithelial neoplasia [CIN] 2 and 3) associated with human papillomavirus (HPV) types 16 and 18 infection. [Priority review] uuid:530dc544-8f88-49df-a4a2-45d0ac763056 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10127 biolink:treats MONDO:0005180 PMID:41385096 "[{""id"":""uuid:576d5a03-2918-4bbb-bb7c-0511bcd763a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c5ffeb40-72c5-423c-9a20-62b78ecf492d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage for the treatment of Parkinson's disease (in patients who have been treated with other anti- Parkinson drugs in combination with a levodopa- containing agent, but sufficient therapeutic effect was not obtained). uuid:ca01e7be-ef3f-4a79-aae0-98a8c2b3824a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2H1PA8H1EN biolink:treats MONDO:0005150 PMID:41385096 "[{""id"":""uuid:20fe4a8c-2014-4194-9f9c-e7afe785049d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ce4552b5-9f6e-4163-bcbd-6504033afc36"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient indicated for treatment of age-related macular degeneration with concurrent choroidal neovascularization. [Orphan drug] uuid:d5856a9f-1f60-4edd-9e56-080053899bb1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2H1PA8H1EN biolink:treats MONDO:0810000 PMID:41385096 "[{""id"":""uuid:f663192f-6272-49b2-8486-8a7899c531b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:25862ef8-4dcc-4468-a44d-0d523ab60b50"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient indicated for treatment of age-related macular degeneration with concurrent choroidal neovascularization. [Orphan drug] uuid:0cbcc03c-f5fa-45f5-9561-49e0e449300e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:25CC4N0P8J biolink:treats HP:0000989 PMID:41385096 "[{""id"":""uuid:23bb8274-3466-4de2-80ec-6b823acba86b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e703f8a7-83bd-4410-9034-3bc5e83beba9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient indicated for the treatment of pruritus in hemodialysis patients (for use only when conventional therapies are not sufficiently effective). PUBCHEM.COMPOUND:6918287 uuid:c0803af3-7424-4772-b82d-bbefd2bf798c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45367 biolink:treats MONDO:0018076 PMID:41385096 "[{""id"":""uuid:c13d8381-ffc6-4f10-9a26-eaf49d0dc9a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:96ab43e6-6d78-45d2-9487-979d63e261a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient indicated for the treatment of 1) tuberculosis, 2) non-tuberculous mycobacteriosis including mycobacterium avium complex (MAC) infections, and 3) prophylaxis of disseminated MAC infections in patients with HIV disease. uuid:e13350c2-74d1-4134-b928-ab39390d8145 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45367 biolink:treats UMLS:C0026919 PMID:41385096 "[{""id"":""uuid:66b7c3cc-fe17-460c-bee4-0a262665e757"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b294b56f-c916-4e42-86a6-4414e00879fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient indicated for the treatment of 1) tuberculosis, 2) non-tuberculous mycobacteriosis including mycobacterium avium complex (MAC) infections, and 3) prophylaxis of disseminated MAC infections in patients with HIV disease. uuid:d756c377-d9b2-4239-be3c-dae7d994a1c7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2955 biolink:treats MONDO:0004277 PMID:41385096 "[{""id"":""uuid:8daecf90-2769-4c1e-a28a-74c9f448d76b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b218c235-06a7-403f-98a3-922f0c27ad49"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication for Neisseria gonorrhoeae infections, with a new dosage in a new dosage form. Conversion from an immediate release formulation of azithromycin to a sustained release formulation. uuid:d92a0fbd-f2e8-42b8-9433-4577f5965b08 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16469 biolink:treats UMLS:C1306878 PMID:41385096 "[{""id"":""uuid:3c6cb293-aef2-4930-a7cf-ba65e7f89a3f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a68cb12e-61cc-4f05-b947-7f746cb8347b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new route of administration indicated for the treatment of vasomotor symptoms (hot flushes and sweating) and vaginal atrophy symptoms associated with climacteric disturbance and ovarian deficiency symptoms. uuid:06df5e2e-077b-4a4b-a310-5ab1a7876e00 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1295555 biolink:treats HP:0031217 PMID:41385096 "[{""id"":""uuid:a3f6c33b-7e88-48e9-80fd-44fe2f0c7bed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c96a1c88-73d6-4697-bf6e-6afe4a6f4707"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug indicated for the treatment of vasomotor symptoms (hot flushes and sweating) associated with climacteric disturbance and ovarian deficiency symptoms. uuid:b295ecbe-5a59-425b-9b56-9f314f78ae87 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1295555 biolink:treats UMLS:C1306878 PMID:41385096 "[{""id"":""uuid:e5db2a54-bb96-41ce-a7d6-68f0db832c10"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e1e3f301-9e96-46a2-9ff0-896a47dcdc2e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug indicated for the treatment of vasomotor symptoms (hot flushes and sweating) associated with climacteric disturbance and ovarian deficiency symptoms. uuid:fea64476-caf7-4d29-a5f8-79c095f011aa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1295555 biolink:treats MONDO:0005387 PMID:41385096 "[{""id"":""uuid:ad610158-6994-4244-bd35-adf7c803a56c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:72a75ad0-0aca-41cb-be95-90db0f6865c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug indicated for the treatment of vasomotor symptoms (hot flushes and sweating) associated with climacteric disturbance and ovarian deficiency symptoms. uuid:b40f49d0-ec62-4b93-9d26-f4f4aff5d7d3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2P471X1Z11 biolink:treats MONDO:0100470 PMID:41385096 "[{""id"":""uuid:ab2c69ae-c23c-498d-bf42-e1568b1e6776"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:783651c3-bae9-48dd-bd62-e1dd3fdaf90e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient indicated for the treatment of bronchial asthma (for use only in patients with intractable bronchial asthma whose asthmatic responses are uncontrollable with conventional therapies). uuid:9208d25a-22b2-45cc-8154-2898bbafad4f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4495 biolink:treats MONDO:0005803 PMID:41385096 "[{""id"":""uuid:bfd6dc23-26a5-487b-aa26-e6064ac2b60a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:575839de-5c70-48df-9174-70345421ed20"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient indicated for the treatment of hyperinsulinemic hypoglycemia. [Priority review] uuid:3dd81602-c0af-438f-ac01-665f784aafb6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PQX0D8J21J biolink:treats MONDO:0024331 PMID:41385096 "[{""id"":""uuid:3316ff8d-2a25-415e-b8e0-f310868980cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2873951d-9984-4a2c-a00e-316f614bbff8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient indicated for the treatment of EGFR-expressing, unresectable and advanced/recurrent colorectal carcinomas. [Priority review] uuid:7b7de0e3-f176-4c02-b011-a3cf8713b2f6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:K37N7BYX3X biolink:treats MONDO:0011996 PMID:41385096 "[{""id"":""uuid:5526d732-9de4-4739-a5d3-87f06969d2c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f4ac1d1c-47f0-4f85-8100-b458273213ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient indicated for the treatment of imatinib-resistant, chronic phase and accelerated phase chronic myelogenous leukemia. [Orphan drug] uuid:276fc787-6174-4fea-904e-7db1fffa0c2b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:K37N7BYX3X biolink:treats MONDO:0021367 PMID:41385096 "[{""id"":""uuid:2c774359-79a8-4244-8ed8-f42b7c7d88c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e6e1e831-436d-41b7-91b6-d25bcdee15cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient indicated for the treatment of imatinib-resistant, chronic phase and accelerated phase chronic myelogenous leukemia. [Orphan drug] uuid:e4057035-a71d-4d03-8564-b89a8a34eb25 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:D7RD81HE4W biolink:treats MONDO:0015909 PMID:41385096 "[{""id"":""uuid:ebd496ab-e81e-4051-b301-1a0e62678356"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:77e3df43-a95a-447f-bce4-00fe298097fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient indicated for the treatment of moderate to very severe aplastic anemia, for use as pretreatment prior to hematopoietic stem cell transplantation, and for the treatment of acute graft-versus-host disease after hematopoietic stem cell transplantation. [Orphan drug] uuid:e2233dc3-5467-4942-8ad7-0ce17e5a68eb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:D7RD81HE4W biolink:treats MONDO:0020546 PMID:41385096 "[{""id"":""uuid:d0033d86-7c5f-4538-99b8-26456af7221a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b1e4368d-b5d3-4da2-9cf9-7e357c811570"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient indicated for the treatment of moderate to very severe aplastic anemia, for use as pretreatment prior to hematopoietic stem cell transplantation, and for the treatment of acute graft-versus-host disease after hematopoietic stem cell transplantation. [Orphan drug] uuid:4ad2bc63-be27-4cae-a6ca-b04c6be6a247 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB05777 biolink:treats MONDO:0001243 PMID:41385096 "[{""id"":""uuid:93759d46-b73d-40c6-972b-336a5311b067"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b3b80fe9-dfe8-42cc-adf6-9e545d12ab06"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient indicated for the treatment of disseminated intravascular coagulation (DIC). uuid:e3b15014-e14a-4ef1-b101-8c29a13960d2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:131716 biolink:treats MONDO:0001218 PMID:41385096 "[{""id"":""uuid:9a4b6333-527e-4cce-8694-ffde97f1889f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:38b1fa7c-b006-455f-913c-fbf401c99dda"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient indicated for the treatment of laryngopharyngitis, tonsillitis (including peritonsillitis and peritonsillar abscess), acute bronchitis, pneumonia, infections secondary to chronic respiratory disease, otitis media, and sinusitis. uuid:1cc11b6e-011b-44bd-b754-2535fca21f1b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:131716 biolink:treats MONDO:0001039 PMID:41385096 "[{""id"":""uuid:87785274-b902-4b7a-8561-9bd30c6d41d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:bbc248b7-22e9-4eb2-8846-9666b5c524fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient indicated for the treatment of laryngopharyngitis, tonsillitis (including peritonsillitis and peritonsillar abscess), acute bronchitis, pneumonia, infections secondary to chronic respiratory disease, otitis media, and sinusitis. uuid:fb5bb1c9-2f45-470e-bbfd-c2b01ee4d69d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:131716 biolink:treats UMLS:C0877267 PMID:41385096 "[{""id"":""uuid:b11f198e-beea-4abf-b7cf-5bbff966c3ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8a796758-3f48-4542-800d-e48ddb04341a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient indicated for the treatment of laryngopharyngitis, tonsillitis (including peritonsillitis and peritonsillar abscess), acute bronchitis, pneumonia, infections secondary to chronic respiratory disease, otitis media, and sinusitis. uuid:0601f6c1-858e-47a2-8bbc-0b2e9913e2bf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:131716 biolink:treats MONDO:0005906 PMID:41385096 "[{""id"":""uuid:1b9c731d-1591-40ca-bfd2-ed1a4e0aebde"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:10d493fa-ab0b-4fcf-bcd2-75e42d7e5511"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient indicated for the treatment of laryngopharyngitis, tonsillitis (including peritonsillitis and peritonsillar abscess), acute bronchitis, pneumonia, infections secondary to chronic respiratory disease, otitis media, and sinusitis. uuid:3ae7aa44-12ef-482b-b159-a0faccbc7a00 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:131716 biolink:treats HP:0012388 PMID:41385096 "[{""id"":""uuid:0040cf83-372f-4ee1-b666-cdb2be796e24"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:53c38c4d-e00b-4a55-b07c-56e99840497e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient indicated for the treatment of laryngopharyngitis, tonsillitis (including peritonsillitis and peritonsillar abscess), acute bronchitis, pneumonia, infections secondary to chronic respiratory disease, otitis media, and sinusitis. uuid:22f27b34-3502-4105-a026-a7bc4458cf60 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:131716 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:f4e1bb4a-63af-4f1c-b4b5-7eeef41f5547"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:da117582-ea5b-4726-874b-e688bb89dee0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient indicated for the treatment of laryngopharyngitis, tonsillitis (including peritonsillitis and peritonsillar abscess), acute bronchitis, pneumonia, infections secondary to chronic respiratory disease, otitis media, and sinusitis. uuid:b1b8b62b-fb49-47a3-97ae-d926b4dfe31a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:131716 biolink:treats MONDO:0024355 PMID:41385096 "[{""id"":""uuid:2ff19818-7947-4bb9-bdb1-227bb3cb35ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:493b9ba2-9aea-4ced-b2b7-c3008ffa51c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient indicated for the treatment of laryngopharyngitis, tonsillitis (including peritonsillitis and peritonsillar abscess), acute bronchitis, pneumonia, infections secondary to chronic respiratory disease, otitis media, and sinusitis. uuid:822ddd25-4d8f-4e76-8f97-c1eb659cd1ca biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:131716 biolink:treats MONDO:0005441 PMID:41385096 "[{""id"":""uuid:762601bc-1bff-4b13-b1c9-c57181ca555b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:59804607-58dd-4fc0-80d7-09ad1ab83afc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient indicated for the treatment of laryngopharyngitis, tonsillitis (including peritonsillitis and peritonsillar abscess), acute bronchitis, pneumonia, infections secondary to chronic respiratory disease, otitis media, and sinusitis. uuid:1c8672cf-7c41-48c8-af3a-c8be64e213ec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:131716 biolink:treats MONDO:0005961 PMID:41385096 "[{""id"":""uuid:425e8b17-d78c-4133-aa68-2cd79543a1eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:28affb1d-2fbd-4857-a628-362780119765"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient indicated for the treatment of laryngopharyngitis, tonsillitis (including peritonsillitis and peritonsillar abscess), acute bronchitis, pneumonia, infections secondary to chronic respiratory disease, otitis media, and sinusitis. uuid:41c4b777-142f-49dd-ac12-dfd230774291 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16469 biolink:treats HP:0031217 PMID:41385096 "[{""id"":""uuid:dc5bcb97-024c-43f7-9a23-5e1b01a38feb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9ef62910-a8f3-43d0-ba13-d904027f4778"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug in a new dosage form, or gel, indicated for the treatment of vasomotor symptoms (hot flushes and sweating) associated with menopausal disorders and ovarian deficiency symptoms. uuid:f87fc779-7ac1-4623-968c-c29e9a337467 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16469 biolink:treats UMLS:C0025319 PMID:41385096 "[{""id"":""uuid:0f66c8ab-5b69-4ca1-9ef1-df345bf4275c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d9a7067c-6d4b-4be5-bba6-9d3ded2b34f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug in a new dosage form, or gel, indicated for the treatment of vasomotor symptoms (hot flushes and sweating) associated with menopausal disorders and ovarian deficiency symptoms. uuid:002c9859-80ee-487c-aff8-22a7679f42e4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:70708 biolink:treats MONDO:0005133 PMID:41385096 "[{""id"":""uuid:dab48ef9-724f-4a3a-8731-1d05a02a02a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f9b0f6c1-2eb9-4315-9952-a246949b1980"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient indicated for the treatment of endometriosis. uuid:f7a2c61e-4880-4e1d-9704-5e7ab10f20c4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:61049 biolink:treats MONDO:0002313 PMID:41385096 "[{""id"":""uuid:6f1353d0-f86b-4c12-b7a9-9ebe9f030f8a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0a8ef3fa-ef3a-4d93-a5e8-1c01e50223bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new route of administration indicated for the treatment of vernal conjunctivitis (in the case where anti-allergic drugs are not sufficiently effective). [Orphan drug] uuid:6fdf9689-b6a5-42ec-8f58-439a72eb8762 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:33324 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:39076cb5-332c-441f-a2bd-da38e44b1eb0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:45b03b07-5617-47c4-bb24-042160819411"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient indicated for pain relief in bone scintigraphy- positive metastatic lesions in patients with solid cancers. uuid:a41c94ff-649a-4fb3-83b8-af5e4c390141 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:33324 biolink:treats MONDO:0004992 PMID:41385096 "[{""id"":""uuid:98f2195c-f577-460d-aade-2c0dfacde0a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:86a7d17d-e9b1-437f-b54d-e64f499d70ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient indicated for pain relief in bone scintigraphy- positive metastatic lesions in patients with solid cancers. uuid:213c9fb5-ed11-4087-a883-542e8db66dc1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:33324 biolink:treats MONDO:0024883 PMID:41385096 "[{""id"":""uuid:9ffc17f2-3153-4049-a657-20f5922464eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0ced021d-f594-44ac-bfdf-e1dfc2ac8961"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient indicated for pain relief in bone scintigraphy- positive metastatic lesions in patients with solid cancers. uuid:c0b72cfd-5d41-4dab-b5d8-d5b31c355510 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7852 biolink:treats EFO:0801084 PMID:41385096 "[{""id"":""uuid:030a07d7-dca9-48c8-8e6a-3caa5eef788a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:56b495bc-c30a-4a73-98e2-32c9b5dac20b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drug with a new dosage form used as an analgesic agent for moderate to severe pain associated with various types of cancer. uuid:ad12709c-be88-4aef-9c99-83f22827bd82 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63611 biolink:treats MONDO:0004785 PMID:41385096 "[{""id"":""uuid:0876e9db-a60b-4445-93d9-e6bad52ec197"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:368514c3-aa3d-4383-8d31-e7eac2d76831"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drug with a new route of administration, indicated for blepharitis, dacryocystitis, hordeolum, conjunctivitis, meibomianitis, keratitis (including corneal ulcer), and perioperative sterilization in ophthalmological surgery. uuid:706b4acc-2379-4751-b1bc-01893b343a2a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63611 biolink:treats MONDO:0004926 PMID:41385096 "[{""id"":""uuid:97a50fb0-0821-4c64-9f87-5b52503fb2f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c9ddea9d-d727-475c-8a32-febb68cec27d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drug with a new route of administration, indicated for blepharitis, dacryocystitis, hordeolum, conjunctivitis, meibomianitis, keratitis (including corneal ulcer), and perioperative sterilization in ophthalmological surgery. uuid:67895a63-7d1f-4bee-a2c3-8062fca35143 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63611 biolink:treats MONDO:0005800 PMID:41385096 "[{""id"":""uuid:a8451059-49bb-43ef-93fe-fac86937a0a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:50b0cee0-d4e8-49b0-bd78-5ba64b5ffbe8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drug with a new route of administration, indicated for blepharitis, dacryocystitis, hordeolum, conjunctivitis, meibomianitis, keratitis (including corneal ulcer), and perioperative sterilization in ophthalmological surgery. uuid:e73d0fd2-f61b-4313-9e84-d41b781f83b9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63611 biolink:treats MONDO:0003799 PMID:41385096 "[{""id"":""uuid:f5977695-daf7-472a-bab7-8c515d63e23a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:226bddbf-195b-4f52-af5a-4d099b38e641"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drug with a new route of administration, indicated for blepharitis, dacryocystitis, hordeolum, conjunctivitis, meibomianitis, keratitis (including corneal ulcer), and perioperative sterilization in ophthalmological surgery. uuid:a80fee75-ae4f-4f33-8098-0414ed076ee6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63611 biolink:treats UMLS:C0549398 PMID:41385096 "[{""id"":""uuid:3e39ecb5-dcb7-4dd4-a204-11cb40bda277"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c230e539-b14c-4d3a-a8f2-68a688ca392d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drug with a new route of administration, indicated for blepharitis, dacryocystitis, hordeolum, conjunctivitis, meibomianitis, keratitis (including corneal ulcer), and perioperative sterilization in ophthalmological surgery. uuid:831622cc-be9c-44c3-bae3-a8ddbd7cecbc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63611 biolink:treats MONDO:0003085 PMID:41385096 "[{""id"":""uuid:e627bbe6-d37c-44b9-85d6-fea4d4a04fab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b9666c77-d4f7-42e0-8dc8-dfdad7693127"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drug with a new route of administration, indicated for blepharitis, dacryocystitis, hordeolum, conjunctivitis, meibomianitis, keratitis (including corneal ulcer), and perioperative sterilization in ophthalmological surgery. uuid:855bac04-ac68-448e-b394-9cdc163a4be0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63611 biolink:treats MONDO:0004577 PMID:41385096 "[{""id"":""uuid:75845e5f-920a-4b5d-ae96-45e483bb259a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:01ba89d6-f730-420a-836d-66135709c29c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drug with a new route of administration, indicated for blepharitis, dacryocystitis, hordeolum, conjunctivitis, meibomianitis, keratitis (including corneal ulcer), and perioperative sterilization in ophthalmological surgery. uuid:eab61476-e273-4f8a-8956-1ab5f32078c6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6076 biolink:treats UMLS:C0085082 PMID:41385096 "[{""id"":""uuid:da930c6f-8ef8-48bd-9c37-4678eedf66ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:218977de-266f-45a2-a37b-5814aa2a33eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drug with a new route of administration indicated for treatment of fungemia, respiratory mycosis, gastrointestinal mycosis, urinary tract mycosis, fungal meningitis, esophageal candidiasis, blastomycosis, and histoplasmosis, caused by Aspergillus species, Candida species, Cryptococcus species, Blastomyces species or Histoplasma species and febrile neutropenia suspected of having fungal infections. uuid:13109f69-9316-4c0f-94d4-5e2579b587ff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6076 biolink:treats MONDO:0024355 PMID:41385096 "[{""id"":""uuid:bc0d7708-522d-43a5-bbb0-be25c815eb96"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9156f80d-ae3a-44c0-9f52-8935e3b65881"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drug with a new route of administration indicated for treatment of fungemia, respiratory mycosis, gastrointestinal mycosis, urinary tract mycosis, fungal meningitis, esophageal candidiasis, blastomycosis, and histoplasmosis, caused by Aspergillus species, Candida species, Cryptococcus species, Blastomyces species or Histoplasma species and febrile neutropenia suspected of having fungal infections. uuid:19f7f270-3177-40c2-969d-e7fbd5503c23 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6076 biolink:treats MONDO:0000256 PMID:41385096 "[{""id"":""uuid:a73bdd2a-8cb8-4ef3-9fa6-59011e79003a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:aac01eef-88a7-4c3c-80b8-af585705de30"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drug with a new route of administration indicated for treatment of fungemia, respiratory mycosis, gastrointestinal mycosis, urinary tract mycosis, fungal meningitis, esophageal candidiasis, blastomycosis, and histoplasmosis, caused by Aspergillus species, Candida species, Cryptococcus species, Blastomyces species or Histoplasma species and febrile neutropenia suspected of having fungal infections. uuid:bed9877f-408d-4cec-8dc0-c0e11327deaa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6076 biolink:treats MONDO:0006764 PMID:41385096 "[{""id"":""uuid:967c1d13-dd6e-47dd-82f5-5e6a1a2e509c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:bd7af348-d8dc-46d8-a93a-1f7a11d0de51"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drug with a new route of administration indicated for treatment of fungemia, respiratory mycosis, gastrointestinal mycosis, urinary tract mycosis, fungal meningitis, esophageal candidiasis, blastomycosis, and histoplasmosis, caused by Aspergillus species, Candida species, Cryptococcus species, Blastomyces species or Histoplasma species and febrile neutropenia suspected of having fungal infections. uuid:5a11f3d1-7132-40b9-b2b2-89a29865d80c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6076 biolink:treats UMLS:C0746883 PMID:41385096 "[{""id"":""uuid:9ecf99a7-a0c7-4bad-af48-07174f9778e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:747467cf-7ea9-42f9-9945-5136bd11a23c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drug with a new route of administration indicated for treatment of fungemia, respiratory mycosis, gastrointestinal mycosis, urinary tract mycosis, fungal meningitis, esophageal candidiasis, blastomycosis, and histoplasmosis, caused by Aspergillus species, Candida species, Cryptococcus species, Blastomyces species or Histoplasma species and febrile neutropenia suspected of having fungal infections. uuid:4f2ff6ea-d172-4756-8c17-2af532722c55 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63599 biolink:treats MONDO:0018908 PMID:41385096 "[{""id"":""uuid:6808fd5c-39b5-41f3-aaa5-f2d0ed6974b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b9c19935-0f22-4c3d-8af9-93df3863adbe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drug with a new route of administration and indications for treatment of low-grade B cell non- Hodgkin lymphoma and mantle-cell lymphoma uuid:db2a1603-c5ed-4b96-bd99-43706b45ca66 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63599 biolink:treats MONDO:0005062 PMID:41385096 "[{""id"":""uuid:1ff40e3f-7eb6-498d-815b-4c511fec44a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:227bfbee-8138-4900-8d2c-652bbe105bce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drug with a new route of administration and indications for treatment of low-grade B cell non- Hodgkin lymphoma and mantle-cell lymphoma uuid:dbc70dac-7b7d-43c3-8701-bb1dc7f7ac3a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32599 biolink:treats UMLS:C0022876 PMID:41385096 "[{""id"":""uuid:9b87cc03-d4e5-44c5-b431-b160848010c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:47983008-9b2f-492b-8adf-86f56f956f28"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new indication and new dosage for relaxing the uterus muscles and suppressing preterm labour [Notification of off label] uuid:6b0de71c-7859-453a-a407-6e0f6fdb8b04 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:76172 biolink:treats MONDO:0005178 PMID:41385096 "[{""id"":""uuid:35368760-054e-477f-abe9-813d4559ba2a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0cf7ebb2-8de0-4c83-a538-2c2f6d794131"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new route of administration indicated for the treatment of osteoarthritis, myalgia, post-traumatic swelling/pain and anti-inflammatory/analgesic effects on these symptoms uuid:e10b5692-8f28-44f9-9e3a-0df354e8ea11 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:76172 biolink:treats HP:0003326 PMID:41385096 "[{""id"":""uuid:f9fd8462-9f05-4235-ace6-938ff43e86b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c93fe742-50a6-4d76-9b85-0bc24587ad33"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new route of administration indicated for the treatment of osteoarthritis, myalgia, post-traumatic swelling/pain and anti-inflammatory/analgesic effects on these symptoms uuid:26a93de4-67db-4555-b836-65ff709d5339 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:76172 biolink:treats NCIT:C3399 PMID:41385096 "[{""id"":""uuid:7a6d0feb-94c9-4c90-b519-7cc3d28c9fbc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:58c25c03-2823-46a4-8dac-66f862018185"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new route of administration indicated for the treatment of osteoarthritis, myalgia, post-traumatic swelling/pain and anti-inflammatory/analgesic effects on these symptoms uuid:850b51e2-63c8-4bc7-bb3c-bc1a50b5e5de biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:76172 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:2bbface6-514d-4127-acb8-3aef6e13967b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:98834e6a-b584-4b5e-8e5f-73d8a0d07af8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new route of administration indicated for the treatment of osteoarthritis, myalgia, post-traumatic swelling/pain and anti-inflammatory/analgesic effects on these symptoms uuid:4e269555-75e6-4f4b-b156-511d5d343dd2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:8GZG754X6M biolink:treats UMLS:C2349276 PMID:41385096 "[{""id"":""uuid:a0b63201-f6ca-4c1c-b80d-420269b60cc0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b48896dc-c4ce-4b86-b5e4-7fa3613e79cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient indicated for the treatment of relapsing or intractable CD33 positive acute myeloid [Orphan drug] uuid:e4e9f269-ef46-456c-b81d-1257ebd03b89 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:RWM8CCW8GP biolink:treats MONDO:0021223 PMID:41385096 "[{""id"":""uuid:b6d7a54d-6ee0-4f59-880b-745fcbd9ce3f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:bea78582-0262-4469-8d7e-5a0e6adac57b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] New form drug with a new administration route administered once every four weeks and which has the following indications: alleviation of various symptoms associated with gastrointestinal hormone-producing tumors and alleviation of excessive secretions of growth hormone and somatomedin-C and other various symptoms in acromegaly and pituitary gigantism uuid:c7b1c603-9a35-46fa-a5fc-99a60291361e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:RWM8CCW8GP biolink:treats MONDO:0020479 PMID:41385096 "[{""id"":""uuid:09e6c149-5f83-4c3b-af66-950ef09b40c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:fb329e1e-6439-4bdb-b794-13d65f59c78a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] New form drug with a new administration route administered once every four weeks and which has the following indications: alleviation of various symptoms associated with gastrointestinal hormone-producing tumors and alleviation of excessive secretions of growth hormone and somatomedin-C and other various symptoms in acromegaly and pituitary gigantism uuid:cfbc5878-32ce-4a60-8be8-b5d7587d61d4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:353007 biolink:treats MONDO:0004873 PMID:41385096 "[{""id"":""uuid:6ed84543-21f7-4db4-8336-d97291ae5be6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:69084ee4-93f8-409d-acf8-c105f1b12a83"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new compound agent for local injection with indications for internal hemorrhoids associated with prolapse and is used for internal hemorrhoid sclerotherapy. uuid:70c579cd-641a-4d9a-9c16-011c3c6d59ea biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:G8RGG88B68 biolink:treats MONDO:0005354 PMID:41385096 "[{""id"":""uuid:8ff70306-f3fd-4db5-838e-1c4dae6b1648"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:fac8c015-770e-48fa-8ce3-06e3ca255fdf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient which enables weekly administration through chemical modification of interferon alfa-2b by polyethylene glycol (PEG) to prolong the drug elimination time in blood and has indications combined with ribavirin to alleviate viremia in patients with chronic hepatitis C with high blood HCV RNA levels for serogroup 1. uuid:57eeaae6-bded-44a1-81e3-3abf0a71ae92 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5001 biolink:treats MONDO:0001336 PMID:41385096 "[{""id"":""uuid:17eab3bb-e96c-4eda-8cbe-2948f569255d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:789ee621-fb9c-40af-9aec-b77108ef5a16"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Pulverization enables a reduction in the dosage to two thirds of the current dosage for hyperlipidemia (including familial hyperlipidemia). uuid:52b2ff2d-e6e1-44dd-8f46-380782f8e857 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:38545 biolink:treats MONDO:0005439 PMID:41385096 "[{""id"":""uuid:a1d9325d-2ff5-47b0-b5ea-3d518c5e146d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:465e7fba-694b-46c7-90fa-66227c714d4a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient with indications for HMG-CoA reductase inhibition for hypercholestelemia and familial hypercholestelemia. uuid:96a2e732-a2bf-41d4-90be-7684243a215a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32230 biolink:treats MONDO:0005607 PMID:41385096 "[{""id"":""uuid:8858d4c4-b0bb-44bc-925d-fce88833b27a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0fb53367-d4cb-48ed-bf53-d9fd5d4a6c98"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient with indications for anticholinergic bronchodilation to alleviate various symptoms due to airway obstructive impairment in chronic obstructive pulmonary diseases (chronic bronchitis and emphysema). uuid:8891014c-e587-4bcf-abd2-21fc326b9c82 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32230 biolink:treats MONDO:0004849 PMID:41385096 "[{""id"":""uuid:515681b9-689e-4291-84bb-c66b3c9a4261"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:522dca9a-d0d8-416b-9baf-0fdb50673e8e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient with indications for anticholinergic bronchodilation to alleviate various symptoms due to airway obstructive impairment in chronic obstructive pulmonary diseases (chronic bronchitis and emphysema). uuid:a5f85aa4-4754-4e01-9a4f-0637e5673c4e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:51032 biolink:treats MONDO:0011786 PMID:41385096 "[{""id"":""uuid:5ece6054-d1b7-455b-a985-cd8dd2a5c0f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:787770af-df26-41af-a7b1-e319b65de3e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A pediatric preparation with indications for allergic rhinitis, urticaria, skin diseases (eczema, dermatitis, skin pruritus) uuid:96e419ae-cd34-4ce9-9ab6-ebbc13bba517 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:51032 biolink:treats MONDO:0005492 PMID:41385096 "[{""id"":""uuid:36cef6c3-ad64-4913-9b43-549316034e63"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5dfe3867-fd11-4df7-9a98-5a5f5c870c8b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A pediatric preparation with indications for allergic rhinitis, urticaria, skin diseases (eczema, dermatitis, skin pruritus) uuid:c0c9f3ff-7070-4b3a-9f08-c6c76a5a9a1f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:51032 biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:dffd3267-64af-47a0-90a5-6cd378347b1e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e73fa7ac-ae84-4309-bc6c-48245adfd099"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A pediatric preparation with indications for allergic rhinitis, urticaria, skin diseases (eczema, dermatitis, skin pruritus) uuid:44c3adec-a865-425f-952c-a54396c94909 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:51032 biolink:treats MONDO:0002406 PMID:41385096 "[{""id"":""uuid:0c230ab8-f87b-44db-b3b6-58949a8a9d5c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:abd94f1b-a738-4dd7-97ec-25adc28d29ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A pediatric preparation with indications for allergic rhinitis, urticaria, skin diseases (eczema, dermatitis, skin pruritus) uuid:da7acd58-6ea3-43d5-8e5c-85ce8bc5eb66 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:51032 biolink:treats HP:0000989 PMID:41385096 "[{""id"":""uuid:8bcd5b5b-6af0-4dc2-88c4-8745b6b9ca4e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:463c0b1c-446a-483c-a3ae-c02801e29763"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A pediatric preparation with indications for allergic rhinitis, urticaria, skin diseases (eczema, dermatitis, skin pruritus) uuid:b67901ad-0ec6-424c-9fbe-1a00878e0602 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5280 biolink:treats MONDO:0004785 PMID:41385096 "[{""id"":""uuid:cfa01a98-b7e7-4ecf-a972-78e850971612"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:61fa6f1e-b37d-4dcd-99df-1e76760f6a6b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] New quinolone antibacterial agent. An ophthalomic solution with indications for blepharitis, hordeolum, dacryocystitis, conjunctivitis, tarsadenitis, keratitis, aseptic therapy for ophthalmologic perioperative period. uuid:894f9739-5390-4b02-808d-0c3d8851c3bf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5280 biolink:treats MONDO:0005800 PMID:41385096 "[{""id"":""uuid:2f7efb51-65e2-4f6e-abdf-0704291233f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:59b657c7-af9b-47a9-a7d0-4568f25470f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] New quinolone antibacterial agent. An ophthalomic solution with indications for blepharitis, hordeolum, dacryocystitis, conjunctivitis, tarsadenitis, keratitis, aseptic therapy for ophthalmologic perioperative period. uuid:78d11576-d91e-4d1f-94d5-625c0d104a45 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5280 biolink:treats MONDO:0004926 PMID:41385096 "[{""id"":""uuid:c33a9f13-902d-4fc2-83e4-f3298c32db80"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7540e6af-5e80-4f8a-80fd-40ef7c5950ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] New quinolone antibacterial agent. An ophthalomic solution with indications for blepharitis, hordeolum, dacryocystitis, conjunctivitis, tarsadenitis, keratitis, aseptic therapy for ophthalmologic perioperative period. uuid:5d7e87ca-e3c4-40ba-93f4-b775f968145b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5280 biolink:treats MONDO:0003799 PMID:41385096 "[{""id"":""uuid:89913d64-596f-4839-bac5-321ad5785822"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1cee67e8-7bb4-4e6f-94c7-a1b543a63a10"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] New quinolone antibacterial agent. An ophthalomic solution with indications for blepharitis, hordeolum, dacryocystitis, conjunctivitis, tarsadenitis, keratitis, aseptic therapy for ophthalmologic perioperative period. uuid:b4b3a3a6-1aab-4e34-bd1c-143922ccc41f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5280 biolink:treats MONDO:0003085 PMID:41385096 "[{""id"":""uuid:d1dc3b70-d3bf-4e27-a17d-b8cbd3eebd3b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6ca473b4-698d-4725-bc56-297cc06265d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] New quinolone antibacterial agent. An ophthalomic solution with indications for blepharitis, hordeolum, dacryocystitis, conjunctivitis, tarsadenitis, keratitis, aseptic therapy for ophthalmologic perioperative period. uuid:e165b834-32e9-4d05-b3dc-dbaf45e02ec4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7DVX185FLQ biolink:treats MONDO:0005027 PMID:41385096 "[{""id"":""uuid:8b350fb1-3274-4049-80a5-51a0d4dba2c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:85fa238b-c7eb-44ce-8adc-9f537730507a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient with indications for detection of epileptic focus in epilepsy by the central benzodiazepine-receptor scintigraphy. uuid:aaeb49ee-2c7f-41ae-bc4f-d6e8ed7e57bf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46557 biolink:treats MONDO:0001566 PMID:41385096 "[{""id"":""uuid:9844e319-8e8f-4d16-a706-b11cb80b1488"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9c84d4c1-0aab-40c1-83e5-17a5ae3b0ed6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient which has a bone-absorption-inhibitory action and has indications for hypercalcemia caused by malignant tumors. uuid:bd8e5924-331d-4ad5-9b19-160975027627 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46557 biolink:treats MONDO:0004992 PMID:41385096 "[{""id"":""uuid:1fb44dcc-ed96-42b2-a211-7854ee993942"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d3c818bc-77b8-4ea1-a69a-850dc299f74f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient which has a bone-absorption-inhibitory action and has indications for hypercalcemia caused by malignant tumors. uuid:1991b5fe-0960-43e0-ad53-6a22ff855165 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16236 biolink:treats MONDO:0007256 PMID:41385096 "[{""id"":""uuid:ba872d27-d3d6-410d-ae7e-02f49c8a02dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:406b92b2-b43b-4aed-9e01-c9f8d9b97a69"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new administration route with indications for percutaneous ethanol injection therapy in hepatocellular carcinoma. uuid:3254d3ec-dace-4b49-bb21-e5c5bd559756 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31941 biolink:treats MONDO:0006519 PMID:41385096 "[{""id"":""uuid:948060bf-5fbc-4974-ba9e-fc2aa9200515"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9ff1cc9e-360b-414b-9e91-4527cc9941ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient with indications for colonic and rectal cancers. uuid:fd6002ca-4fb5-4ad3-b926-9ae925f9f9b4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63635 biolink:treats MONDO:0002708 PMID:41385096 "[{""id"":""uuid:85563bb6-1895-400e-aa65-e66fc7ee7583"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:cddfd0a1-24eb-4c75-89e0-a2579d538c91"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient, L- valine ester of ganciclovir, with indications for treatment of retinitis caused by cytomegalovirus in patients with acquired immune deficiency syndrome (AIDS) and dosage regimen. uuid:0318ab37-57c7-4b8c-ab13-04fd0348867f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:82941 biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:ae62cc5b-1c02-4c35-808f-920abbcc8385"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:05eed070-9ae2-4145-82ad-d8f6024cb3a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient with indications for HIV infection. uuid:c87276ff-0fd5-4bc1-a7a3-620ffe984438 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:57453565 biolink:treats UMLS:C0854521 PMID:41385096 "[{""id"":""uuid:3dbf487f-1996-44dc-b631-651f0dc05bbc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4036128f-8daa-4308-81f2-99becdf08d06"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of hypozincemia. uuid:1d3a737d-a867-42bb-ab37-7ff84525def4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:WB8FT61183 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:0459df35-0176-448b-8568-4a5ad83ebb12"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2b48857f-e2a9-4114-99a6-1bfb1294ab9e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new additional pediatric dosage in an additional dosage form for the treatment of chronic heart failure. uuid:49ab84a5-b8cb-403b-9d69-37693beff6ba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2382602 biolink:treats MONDO:0002032 PMID:41385096 "[{""id"":""uuid:9064db08-7944-442b-a99f-c3a9b53ddd18"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3c00a8ea-1dc4-4e9c-b6c5-1af50856c5a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] New combination drugs with a new active ingredient indicated for the treatment of HER2- positive breast cancer and unresectable advanced or recurrent HER2-positive colon or rectal cancer that has progressed after cancer chemotherapy. uuid:78f78c90-429c-4f31-9f14-376b87f2af1d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2382602 biolink:treats MONDO:0006519 PMID:41385096 "[{""id"":""uuid:ba4e211e-f059-491f-b97e-aef0466e55d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2542389d-0d70-46f6-b1d6-d94c4e144be4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] New combination drugs with a new active ingredient indicated for the treatment of HER2- positive breast cancer and unresectable advanced or recurrent HER2-positive colon or rectal cancer that has progressed after cancer chemotherapy. uuid:ab2266ab-b6fd-41d9-8264-54d814aa9e7f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:D6OMY2L0WA biolink:treats MONDO:0020323 PMID:41385096 "[{""id"":""uuid:c4788951-ffad-4616-b4c5-fe6183ba7df2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:113a98e4-4093-448d-88e0-7121f8ed5ee4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of relapsed or refractory large B-cell lymphoma (diffuse large B-cell lymphoma, high- grade B-cell lymphoma, and primary mediastinal large B-cell lymphoma) or relapsed or refractory follicular lymphoma. uuid:d9ac931b-aeee-49d1-b542-f7431d86915e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:AQK7UBA1LS biolink:treats MONDO:0018881 PMID:41385096 "[{""id"":""uuid:412e8334-28ed-41a1-bf8c-6b675088aac9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a25ac276-b7d3-45d5-a6e9-bf8e0ff6a5f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of anemia associated with myelodysplastic syndrome. [Orphan drug] uuid:135c8e58-cdc3-4972-ad49-5659611c5652 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:229222 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:79377992-1e80-431e-9026-4da167ffda9c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f60ca3a7-47dc-4468-9780-42ca36500a7d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative inoperable or recurrent breast cancer with PIK3CA, AKT1, or PTEN mutation that has progressed after endocrine therapy. uuid:5785f701-2c4f-48dd-b54a-ea07ab727f37 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:L0HR9A577V biolink:treats MONDO:0009693 PMID:41385096 "[{""id"":""uuid:4e33f7d1-1e7b-489c-a810-08283090f827"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a3a89933-07af-42ea-a6f9-8ee3d8c0fba4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of relapsed or refractory multiple myeloma (for use only if refractory or intolerant to standard therapies). [Orphan drug] uuid:5f2c0bb6-4333-482b-91cd-8db21c2808bf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2583638 biolink:treats MONDO:0017572 PMID:41385096 "[{""id"":""uuid:e4d51ac4-da37-4761-b17b-39330a279500"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:fc58dc9f-db10-4de0-aee1-5f7104edea7f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the prevention of tick-borne encephalitis. uuid:aa21b374-78db-4995-ab23-4bc4dcd3ac9f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:90ZX3Q3FR7 biolink:treats UMLS:C0852922 PMID:41385096 "[{""id"":""uuid:cf33f1b6-1adc-4571-80fa-d411086b4f94"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:04120154-88c2-4edc-b57e-b032aa6d1e95"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new route of administration indicated for the remission induction therapy of moderate to severe active Crohn’s disease (for use only in patients who have not sufficiently responded to conventional treatments). A drug with a new indication and a new dosage in an additional dosage form for the maintenance therapy of moderate to severe active Crohn’s disease (for use only in patients who have not sufficiently responded to conventional treatments). uuid:7b531cf6-3e9b-4747-ae16-974aaf4a4834 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:T3U32GLJ0F biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:c5c7676c-d644-47fc-9414-1dcf7f3f29ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:16fca6f3-8f43-4b28-acf3-4305f194c555"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of atopic dermatitis. uuid:ce80f5bb-7911-486c-a5bd-ecc2c62a67b0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:AHU547PI9H biolink:treats MONDO:0002280 PMID:41385096 "[{""id"":""uuid:15997400-fc40-4440-9eb1-2a2bb28fdfb8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f3b20ed5-451a-4303-8380-996f17693b4c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of iron-deficiency anemia. uuid:f567ce16-f1d6-4e2d-86dd-4a6d89139ead biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6D848RA61B biolink:treats MONDO:0000050 PMID:41385096 "[{""id"":""uuid:4c534623-962c-40ff-b7e3-5287e90b6026"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a4e40cf7-09d6-4d04-a5b6-03cff6d845ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of short stature due to growth hormone deficiency prior to epiphyseal closure. uuid:d7e4d309-1c62-4c9d-9062-ac089d365a7c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DE2O63YV8R biolink:treats MONDO:0005016 PMID:41385096 "[{""id"":""uuid:3fa34e08-c3f0-45ed-a6e2-2fffd8e8e118"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b42eed96-6b1e-4328-a431-081c958ebca2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of chronic kidney disease associated with type 2 diabetes mellitus (excluding patients who have end-stage renal failure or are undergoing dialysis). uuid:555e6fba-5fca-432a-a381-3ae4f08900fb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:09495UIM6V biolink:treats MONDO:0022205 PMID:41385096 "[{""id"":""uuid:ca8cbb57-bc5e-4ebd-92ee-1f47f74c9222"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5007128b-42bc-4b0a-aeb7-1992513b0436"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of plaque psoriasis, pustular psoriasis, and erythrodermic psoriasis in patients who have not responded sufficiently to conventional therapies. uuid:902acecc-3b7c-4e79-967a-4811d276a0ac biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:09495UIM6V biolink:treats UMLS:C0748052 PMID:41385096 "[{""id"":""uuid:86e5df62-5e52-4132-841e-b6a159329665"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:97340768-69c0-491a-a6b9-b92fcf3eea11"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of plaque psoriasis, pustular psoriasis, and erythrodermic psoriasis in patients who have not responded sufficiently to conventional therapies. uuid:b1aa9358-b120-4dbd-beec-9b2f593ac116 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2S9ZZM9Q9V biolink:treats MONDO:0002032 PMID:41385096 "[{""id"":""uuid:5da799f4-02e4-4fff-a31f-5abfda5bc055"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4ebdff76-4a58-42ce-9eec-1e2b28f5de84"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Follow-on biologics indicated for the treatment of unresectable advanced or recurrent colon or rectal cancer and unresectable advanced or recurrent non-squamous non-small cell lung cancer. uuid:7960a507-ff66-4fec-8544-6f03aab932c5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2S9ZZM9Q9V biolink:treats MONDO:0006519 PMID:41385096 "[{""id"":""uuid:ca0694a2-c331-492e-8469-986a81d4d021"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:274b9361-b572-4621-8fed-ce1e464ca1c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Follow-on biologics indicated for the treatment of unresectable advanced or recurrent colon or rectal cancer and unresectable advanced or recurrent non-squamous non-small cell lung cancer. uuid:3fe32644-15f0-4545-af95-f38d1e4d9953 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:50899324 biolink:treats UMLS:C1142276 PMID:41385096 "[{""id"":""uuid:a319a113-dee5-47fd-a573-61f7a1c173c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:593fa496-140c-4039-a66e-b9d629e18192"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of renal anemia. uuid:1c731876-d601-4918-8d10-6ecc500dd301 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:8FOJ430U94 biolink:treats UMLS:C1720505 PMID:41385096 "[{""id"":""uuid:19ee5715-eea0-4195-91bc-b7496aaf10b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ebea394c-8f86-4932-9059-091dc77aa35c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of adult growth hormone deficiency (used only for severe cases). uuid:7b143f1a-462d-46c2-98f9-38833d4174a8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:64759 biolink:treats HP:0000017 PMID:41385096 "[{""id"":""uuid:0f30b58d-626c-4c8f-85b8-c629912e3899"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e6f47a6c-2047-4922-93e8-511def770179"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage in an additional dosage form indicated for the treatment of nocturia due to nocturnal polyuria in males. uuid:58332651-6694-43bf-808b-70d14f735719 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:64759 biolink:treats UMLS:C0848232 PMID:41385096 "[{""id"":""uuid:0fa627d0-bfaf-4dcf-a5fe-9e6c6534a4db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9c0b2799-64b1-42af-95a2-4f52a64cffff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage in an additional dosage form indicated for the treatment of nocturia due to nocturnal polyuria in males. uuid:e5f6014b-39f3-4c58-b1eb-3e4d65dfbfee biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:76016 biolink:treats MONDO:0002050 PMID:41385096 "[{""id"":""uuid:99a06a67-bd79-4593-b0bc-5da8f46c6925"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1f4ce22d-92f5-45be-9df6-c756abe56b96"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of depression. uuid:e4ffa51f-8861-4d84-a907-0888fb2a5427 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64355 biolink:treats MONDO:0019136 PMID:41385096 "[{""id"":""uuid:081918d3-ea5c-42f3-9304-030ffd7c349e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4a064943-6302-4ac1-8933-fe1ca638cfff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the prophylaxis of deep mycosis in hematopoietic stem cell transplantation recipients or patients with hematologic malignancy who are predicated to decrease neutrophil. treatment of the following mycoses: Fusariosis, mucormycosis, coccidioidomycosis, chromoblastomycosis, and mycetoma. uuid:8dae1819-f6fd-487d-aca2-774454e2aebe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:56841116 biolink:treats MONDO:0005607 PMID:41385096 "[{""id"":""uuid:5e93e3c4-996e-436e-ac8a-4c369bff2447"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8b1eaa64-6397-46a0-ac35-65209430c24e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] New combination drugs with a new active ingredient indicated for the relief of symptoms in patients with chronic obstructive pulmonary disease (chronic bronchitis, emphysema) (who require a combination therapy with an inhaled corticosteroid, a long-acting inhaled anticholinergic agent and a long-acting beta-2 agonist). uuid:ecc44d5e-c9aa-455e-b7e1-ab620cd00d36 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:56841116 biolink:treats MONDO:0004849 PMID:41385096 "[{""id"":""uuid:01290cc6-e421-411d-bda0-8c4e5127e52d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ba5c1a79-9714-418a-874f-558e26d31637"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] New combination drugs with a new active ingredient indicated for the relief of symptoms in patients with chronic obstructive pulmonary disease (chronic bronchitis, emphysema) (who require a combination therapy with an inhaled corticosteroid, a long-acting inhaled anticholinergic agent and a long-acting beta-2 agonist). uuid:c83f7a79-8b53-4899-a7e4-e3097bf236b0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1790637 biolink:treats MONDO:0005607 PMID:41385096 "[{""id"":""uuid:881d9525-06f9-4f89-b94e-bdd515b6d7a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a5a07dff-91da-46ee-bfe7-6bd412abfa7e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] New combination drugs with a new active ingredient indicated for the relief of symptoms secondary to airway obstructive disorder in patients with chronic obstructive pulmonary disease (chronic bronchitis, emphysema) (who require a combination therapy with a long-acting inhaled anticholinergic agent and a long-acting beta-2 agonist). uuid:ed1f2329-d4e6-4a48-88b3-120a56ed8900 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1790637 biolink:treats MONDO:0004849 PMID:41385096 "[{""id"":""uuid:a0be225e-9c6a-4d4e-88cd-7dbb5e48dcfe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:60049858-2ccb-44cc-99ea-49dcf4d7e6f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] New combination drugs with a new active ingredient indicated for the relief of symptoms secondary to airway obstructive disorder in patients with chronic obstructive pulmonary disease (chronic bronchitis, emphysema) (who require a combination therapy with a long-acting inhaled anticholinergic agent and a long-acting beta-2 agonist). uuid:7319eaf2-b770-4cbf-b463-f11a86aecf58 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:195558 biolink:treats NCIT:C183255 PMID:41385096 "[{""id"":""uuid:d188f11e-1f2b-4b0b-b814-52a65928a062"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b2e05fb7-30b7-4d08-b7d1-86ea6662a837"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of NTRK fusion gene positive advanced or recurrent solid tumors. [SAKIGAKE designation, Orphan drug] uuid:422e523b-3e26-49b9-b700-e5ff7017b4ca biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85993 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:f2b5d94f-fc84-4d86-add6-19630d6abf48"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:25ba0835-a07f-4c2c-a160-05f8a7efcb98"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication in a new dosage form for the treatment of hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative inoperable or recurrent breast cancer. uuid:6525174d-2a3c-40a6-b017-11a69e7adaad biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2S9ZZM9Q9V biolink:treats MONDO:0005575 PMID:41385096 "[{""id"":""uuid:24cf7959-31de-4c92-b1e4-1e80baad9aa2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a56a8bf9-86d1-40fd-a4e0-dbbf4791a779"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Follow-on biologics indicated for the treatment of unresectable advanced or recurrent colorectal cancer. uuid:8f723794-e761-4132-b0cb-cb40e07a249b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2535744 biolink:treats HP:0003124 PMID:41385096 "[{""id"":""uuid:9bfba9de-fe99-4ba0-bbe4-2290bbb866b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:183a3a6a-cf84-48a9-b9d9-da60e66267ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] New combination drugs indicated for the treatment of hypercholesterolemia and familial hypercholesterolemia. uuid:beb53bd0-018a-4d6f-b676-da7bc02403cb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2535744 biolink:treats MONDO:0005439 PMID:41385096 "[{""id"":""uuid:9dc09391-73a3-449f-8272-e0ebf3444dc3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d9754472-3b71-4bf4-9902-e5b3e0c026ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] New combination drugs indicated for the treatment of hypercholesterolemia and familial hypercholesterolemia. uuid:ebb6f6ed-4d50-427e-ad22-6ef55cf2f244 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1945037 biolink:treats MONDO:0005607 PMID:41385096 "[{""id"":""uuid:0283f160-25d6-4e44-b4c1-4cce923260fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d416373e-8f1d-4ed4-86d4-d138306b937e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] New combination drugs indicated for the relief of symptoms in patients with chronic obstructive pulmonary disease (chronic bronchitis, emphysema) (who require a combination therapy with an inhaled corticosteroid, a long-acting inhaled anticholinergic agent and a long-acting beta-2 agonist). uuid:e75ef186-b135-479a-866f-770bd19b4469 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1945037 biolink:treats MONDO:0004849 PMID:41385096 "[{""id"":""uuid:78479044-067f-4da0-a7aa-a2d8acf41e14"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ab24f3e0-870a-402c-9bb2-2435959c21ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] New combination drugs indicated for the relief of symptoms in patients with chronic obstructive pulmonary disease (chronic bronchitis, emphysema) (who require a combination therapy with an inhaled corticosteroid, a long-acting inhaled anticholinergic agent and a long-acting beta-2 agonist). uuid:8d2ada30-8185-4f69-99b9-0da6f1f805f7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:57928403 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:8e206113-9a42-4b7e-801d-43e48a4c3257"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e7a12970-0187-46d9-b26e-db2dca1c8e44"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of rheumatoid arthritis (including prevention of structural joint damage) in patients who have not responded sufficiently to conventional treatments. uuid:7a26fab7-aa95-4c54-a406-6a05679e1782 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:E58MLH082P biolink:treats MONDO:0006964 PMID:41385096 "[{""id"":""uuid:0a68db22-3211-4d90-a9ef-47278f62c7fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9851fc56-b230-48a5-bcdf-e36d8f35f2fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of secondary hyperparathyroidism in patients on maintenance dialysis. uuid:19a2f094-dfd6-436a-bfdc-2d38dbb15eea biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1422082 biolink:treats MONDO:0005439 PMID:41385096 "[{""id"":""uuid:daf7a9ad-f6f8-4342-9659-6d9107acf308"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:58b3d97c-57ee-40e8-8cc0-10a5bd0744ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] New combination drugs indicated for the treatment of hypercholesterolemia and familial hypercholesterolemia. uuid:ffb084fe-3022-497b-9177-1477bdd49d9b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5790 biolink:treats EFO:0801084 PMID:41385096 "[{""id"":""uuid:ccc24818-e944-4b4a-a84e-fa6e19fafd15"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:70417734-fd23-426c-b5ff-f9d927581d65"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new route of administration indicated for management of moderate to severe pain in various types of cancer. uuid:a5567def-cb5c-4dde-9ca0-3f107533d4c6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:82717 biolink:treats MONDO:0005113 PMID:41385096 "[{""id"":""uuid:d13cfdb7-62d3-47d3-8ca1-b281ca468ff9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8bed3b60-2f18-4153-a517-f96ebdd350d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of bacterial skin infections mainly involving the dermis and/or subcutaneous tissues, secondary bacterial infections of pre-existing skin ulcers and/or erosion, and secondary bacterial infections of trauma, burn, and surgical wounds. uuid:60453b22-89f1-4a48-9477-93eac15f394e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:82717 biolink:treats UMLS:C0038941 PMID:41385096 "[{""id"":""uuid:4476ca64-cb1f-4b2e-a0ee-dcdf72fdda4d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:15f91b09-37e8-4200-bdb3-26714ae17b96"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of bacterial skin infections mainly involving the dermis and/or subcutaneous tissues, secondary bacterial infections of pre-existing skin ulcers and/or erosion, and secondary bacterial infections of trauma, burn, and surgical wounds. uuid:e6849fe5-2ad3-4a1a-870f-556ddea1fd13 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4779 biolink:treats MONDO:0011786 PMID:41385096 "[{""id"":""uuid:5590240b-0846-4c8e-a391-8d3912317548"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2e64d76d-c38e-4559-a354-0c5e62d044dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new route of administration indicated for the treatment of allergic rhinitis. uuid:4c4171d2-acba-4e79-b450-a92c81333afb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:83766 biolink:treats UMLS:C0278689 PMID:41385096 "[{""id"":""uuid:b5ca1f5a-e38d-4753-ae02-c0edb36d2c3b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f714bf18-6948-4494-ac23-34208f6b64cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the maintenance treament of recurrent ovarian cancer in patients who are in a complete or partial response to platinum-based chemotherapy. uuid:de19c949-d281-4243-9757-8dc561330912 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4F4X42SYQ6 biolink:treats MONDO:0016537 PMID:41385096 "[{""id"":""uuid:34295079-b2bf-4734-9d2a-0aef39dd45fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f6241eb6-04f4-4088-81a2-9989e0bc6bf8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Follow-on biologics indicated for the treatment of CD20-positive B-cell non-Hodgkin's lymphoma, CD20-positive B-cell lymphoproliferative disorder associated with immunosuppression, Wegener's granulomatosis, and microscopic polyangiitis. uuid:72c1d50a-fb5c-4060-9edc-47d546d8ec2e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:333OX80X87 biolink:treats MONDO:0005076 PMID:41385096 "[{""id"":""uuid:6ddb96b4-6ecd-4f11-9c73-5fa8cbff3274"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6a36c262-da2f-4884-a1cf-6ae36199b42c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new route of administration indicated for the treatment of alveolar bone loss due to periodontitis. uuid:013be07d-d306-482d-9a25-f8790df2e3ba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68558 biolink:treats UMLS:C0155668 PMID:41385096 "[{""id"":""uuid:e5b1d776-9019-446a-89a7-f4ace8cec583"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2fa9b717-f501-459a-bf17-3fa02ed2b6a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of: Old myocardial infarction at especially high risk of developing atherothrombosis with at least one of the following risk factors: age of 65 years or older, with diabetes mellitus requiring drug therapy, history of two or more episodes of myocardial infarction, angiography- confirmed multivessel coronary artery disease, or non-end-stage chronic renal dysfunction. Acute coronary syndrome (unstable angina, non-ST-segment elevation myocardial infarction, and ST-segment elevation myocardial infarction) for which percutaneous coronary intervention (PCI) is indicated. (provided that dual antiplatelet therapy including aspirin is appropriate but the administration of other antiplatelet drugs in combination with aspirin is not suitable for the patient.) uuid:f7152c9b-5308-438f-ab23-500935c79fb0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68558 biolink:treats MONDO:0006805 PMID:41385096 "[{""id"":""uuid:6f3991a4-b3b1-4e54-ab34-60581cef9df2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6520b710-a07a-4fd8-b8b6-ff7ccb96df22"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of: Old myocardial infarction at especially high risk of developing atherothrombosis with at least one of the following risk factors: age of 65 years or older, with diabetes mellitus requiring drug therapy, history of two or more episodes of myocardial infarction, angiography- confirmed multivessel coronary artery disease, or non-end-stage chronic renal dysfunction. Acute coronary syndrome (unstable angina, non-ST-segment elevation myocardial infarction, and ST-segment elevation myocardial infarction) for which percutaneous coronary intervention (PCI) is indicated. (provided that dual antiplatelet therapy including aspirin is appropriate but the administration of other antiplatelet drugs in combination with aspirin is not suitable for the patient.) uuid:9f74453c-f4d7-4dc6-8b73-7c1ea67743e7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68558 biolink:treats MONDO:0000990 PMID:41385096 "[{""id"":""uuid:0ad82361-69db-4360-9bd9-50c06cd33593"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4e5e956c-0bbb-462f-87dd-ef3f7e677e61"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of: Old myocardial infarction at especially high risk of developing atherothrombosis with at least one of the following risk factors: age of 65 years or older, with diabetes mellitus requiring drug therapy, history of two or more episodes of myocardial infarction, angiography- confirmed multivessel coronary artery disease, or non-end-stage chronic renal dysfunction. Acute coronary syndrome (unstable angina, non-ST-segment elevation myocardial infarction, and ST-segment elevation myocardial infarction) for which percutaneous coronary intervention (PCI) is indicated. (provided that dual antiplatelet therapy including aspirin is appropriate but the administration of other antiplatelet drugs in combination with aspirin is not suitable for the patient.) uuid:0158009c-5726-4564-90d0-5c0faecde8ac biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68558 biolink:treats MONDO:0041656 PMID:41385096 "[{""id"":""uuid:54f52eb9-045f-445f-90f7-53c593567a01"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:83af2280-9636-47cb-a785-e18e2d5e0d31"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of: Old myocardial infarction at especially high risk of developing atherothrombosis with at least one of the following risk factors: age of 65 years or older, with diabetes mellitus requiring drug therapy, history of two or more episodes of myocardial infarction, angiography- confirmed multivessel coronary artery disease, or non-end-stage chronic renal dysfunction. Acute coronary syndrome (unstable angina, non-ST-segment elevation myocardial infarction, and ST-segment elevation myocardial infarction) for which percutaneous coronary intervention (PCI) is indicated. (provided that dual antiplatelet therapy including aspirin is appropriate but the administration of other antiplatelet drugs in combination with aspirin is not suitable for the patient.) uuid:62d7b33e-9831-45da-9b5d-4b3f8ca8159c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135939 biolink:treats HP:0007334 PMID:41385096 "[{""id"":""uuid:04ba4482-624c-41f5-a3d2-7e5c8b67c49d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:bec0ef2c-ab49-4e24-9eee-4042f51cfa80"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the use as an adjunctive therapy with other antiepileptic drugs to treat partial seizures (including secondary generalized seizures) in patients with epilepsy who have not responded sufficiently to other antiepileptic drugs. uuid:772bb2a2-2bee-42c6-8e36-6d0b31b129f0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:76004 biolink:treats MONDO:0005301 PMID:41385096 "[{""id"":""uuid:0a6d52f4-5a56-4e04-b55c-d56266d47e5f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b2b50687-2936-413f-b057-c3f8c14ffe2c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the prevention of relapse and for delaying the accumulation of physical disability in multiple sclerosis. [Orphan drug] uuid:d846e98f-bf42-43a6-a74e-77d71369799c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:BTY153760O biolink:treats MONDO:0022205 PMID:41385096 "[{""id"":""uuid:5ce4b5fe-c135-4e6a-a88c-ae5d7e8471c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f8a9b7bf-fa32-42f3-988e-d55f754a244d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of plaque psoriasis, psoriatic arthritis, pustular psoriasis, and erythrodermic psoriasis in patients who have not responded sufficiently to conventional therapies. uuid:aac8e512-955c-4fcd-943f-7ff5602ff48d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:BTY153760O biolink:treats UMLS:C0748052 PMID:41385096 "[{""id"":""uuid:0c705258-81f5-4e7d-873a-d74465df43af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8412aa18-9cb1-44da-9169-74394d2d80b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of plaque psoriasis, psoriatic arthritis, pustular psoriasis, and erythrodermic psoriasis in patients who have not responded sufficiently to conventional therapies. uuid:f7fb06d7-9bfe-4eaa-baa8-34fc0c4daaca biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DPT0O3T46P biolink:treats UMLS:C4725093 PMID:41385096 "[{""id"":""uuid:60b317f7-00d5-4f09-89d4-413f2a50b945"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:62ad168b-568d-4ae5-9531-300aa59a960d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of unresectable melanoma. [Orphan drug] uuid:94cd2410-b184-48dd-b3be-9243a2520b78 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:192761 biolink:treats MONDO:0000328 PMID:41385096 "[{""id"":""uuid:11fdac38-c155-404f-bbf6-8a8a355a90ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:16daeea7-e544-4f9f-9716-1c0444ed872a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the improvement of hyperphosphatemia in patients with chronic kidney disease who are receiving dialysis. uuid:d4031536-4f81-4f99-a994-ae8d9ef26d24 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:192761 biolink:treats MONDO:0005300 PMID:41385096 "[{""id"":""uuid:88585e18-d554-4a0d-88ec-a8f2abab8127"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ef221e7b-bf0f-4736-bf87-f3b658d615a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the improvement of hyperphosphatemia in patients with chronic kidney disease who are receiving dialysis. uuid:628251e6-c0e9-44fe-8844-e6f992d8d78e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:521033 biolink:treats MONDO:0005339 PMID:41385096 "[{""id"":""uuid:f689fb68-3c7e-4fd1-8bc2-ad7eac605b30"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b039372b-1e2f-4065-82a3-fd2e3d504db1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage in an additional dosage form, and a drug with a new indication and a new dosage, indicated for the treatment of the male pattern hair loss (androgenetic alopecia) in men. uuid:f35e9f9f-d8ae-46a5-a044-0f545ad6f6cb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:LKC0U3A8NJ biolink:treats MONDO:0005439 PMID:41385096 "[{""id"":""uuid:ebcc6a72-b2a6-472c-a116-4ea1d20bc0d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5cfd8295-75af-4854-94c9-034711d1d5d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of familial hypercholesterolemia and hypercholesterolemia (for use only in patients who are at higher risk of developing cardiovascular event and have not responded sufficiently to HMG- CoA reductase inhibitors). uuid:d61f5e22-344d-43ce-a057-2797be29032f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9943 biolink:treats MONDO:0002050 PMID:41385096 "[{""id"":""uuid:5c183909-b4be-403a-adfe-1cc8947de72b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:aff9def9-1f2e-4e44-b63d-33b9e9198385"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of depression. uuid:e13d59dc-05ff-4230-8094-3ab88c283f5c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1651267 biolink:treats MONDO:0005607 PMID:41385096 "[{""id"":""uuid:318a1d68-8204-42ba-ad75-b1c689a75529"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:eb74c65e-ff72-43c9-aef2-054ab5c4f222"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] New combination drugs with a new active ingredient indicated for the relief of symptoms secondary to airway obstructive disorder in chronic obstructive pulmonary disease (chronic bronchitis, emphysema) (when a combination treatment of an inhaled long-acting anticholinergic and a long- acting beta-2 agonist is needed). uuid:22959cc1-9ae3-472c-8b9e-55d622795db4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1651267 biolink:treats MONDO:0004849 PMID:41385096 "[{""id"":""uuid:2cdc95c8-7f1b-4abb-b180-3a0394a07b77"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d626ee04-5b47-4404-82de-9491935aea6b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] New combination drugs with a new active ingredient indicated for the relief of symptoms secondary to airway obstructive disorder in chronic obstructive pulmonary disease (chronic bronchitis, emphysema) (when a combination treatment of an inhaled long-acting anticholinergic and a long- acting beta-2 agonist is needed). uuid:a7aa60d3-cd08-4952-96da-52773bba3cab biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134735 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:60626638-85dc-48c2-87ae-3ca715e55b0d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:df93e951-c728-41f3-9f5c-d42fb57b89a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of type 2 diabetes mellitus. uuid:9ec57885-a150-48ed-8776-81d852719095 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:136048 biolink:treats MONDO:0001126 PMID:41385096 "[{""id"":""uuid:cbd87d62-92e6-4ece-a70b-cd1b46b5dfdd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:15debc2f-8628-422a-beed-1b9ac178f4cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of gastric ulcer, duodenal ulcer, reflux esophagitis, prevention of recurrence of gastric or duodenal ulcer in patients treated with low-dose aspirin, prevention of recurrence of gastric or duodenal ulcer in patients treated with non- steroidal anti-inflammatory drugs (NSAIDs), and aid to eradication of Helicobacter pylori in patients with gastric ulcer, duodenal ulcer, gastric MALT lymphoma, idiopathic thrombocytopenic purpura, Helicobacter pylori gastritis, and stomach after endoscopic treatment for early gastric cancer. uuid:088eba29-fc7b-49f0-86fd-d9efd77f9058 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:136048 biolink:treats MONDO:0005412 PMID:41385096 "[{""id"":""uuid:3ffa9a22-d052-4e9a-9c2c-b52c75a5a264"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d50dd63e-0714-4089-b127-f21659f35ca7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of gastric ulcer, duodenal ulcer, reflux esophagitis, prevention of recurrence of gastric or duodenal ulcer in patients treated with low-dose aspirin, prevention of recurrence of gastric or duodenal ulcer in patients treated with non- steroidal anti-inflammatory drugs (NSAIDs), and aid to eradication of Helicobacter pylori in patients with gastric ulcer, duodenal ulcer, gastric MALT lymphoma, idiopathic thrombocytopenic purpura, Helicobacter pylori gastritis, and stomach after endoscopic treatment for early gastric cancer. uuid:e241eabe-b46f-4dc5-82ca-50434d917d65 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:136048 biolink:treats MONDO:0006896 PMID:41385096 "[{""id"":""uuid:c497b961-05a5-4562-a135-a5df55edd430"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4e41522d-b048-42a9-837e-88495268d468"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of gastric ulcer, duodenal ulcer, reflux esophagitis, prevention of recurrence of gastric or duodenal ulcer in patients treated with low-dose aspirin, prevention of recurrence of gastric or duodenal ulcer in patients treated with non- steroidal anti-inflammatory drugs (NSAIDs), and aid to eradication of Helicobacter pylori in patients with gastric ulcer, duodenal ulcer, gastric MALT lymphoma, idiopathic thrombocytopenic purpura, Helicobacter pylori gastritis, and stomach after endoscopic treatment for early gastric cancer. uuid:78a4058f-1d4c-43a4-b74f-ece7706cff59 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:136048 biolink:treats UMLS:C0343378 PMID:41385096 "[{""id"":""uuid:b1efc6ad-2b9c-40f2-bb2b-e5de88b42943"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:bb84c732-2d31-4c1c-97f9-bf85bfd04933"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of gastric ulcer, duodenal ulcer, reflux esophagitis, prevention of recurrence of gastric or duodenal ulcer in patients treated with low-dose aspirin, prevention of recurrence of gastric or duodenal ulcer in patients treated with non- steroidal anti-inflammatory drugs (NSAIDs), and aid to eradication of Helicobacter pylori in patients with gastric ulcer, duodenal ulcer, gastric MALT lymphoma, idiopathic thrombocytopenic purpura, Helicobacter pylori gastritis, and stomach after endoscopic treatment for early gastric cancer. uuid:9f8872af-3d8c-4837-a1e9-2f27b8740fd3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:136048 biolink:treats MONDO:0006226 PMID:41385096 "[{""id"":""uuid:345b0903-db33-4b5e-a833-1399fde7f059"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e3e7c157-4990-4b4b-bcc2-96500b4d04db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of gastric ulcer, duodenal ulcer, reflux esophagitis, prevention of recurrence of gastric or duodenal ulcer in patients treated with low-dose aspirin, prevention of recurrence of gastric or duodenal ulcer in patients treated with non- steroidal anti-inflammatory drugs (NSAIDs), and aid to eradication of Helicobacter pylori in patients with gastric ulcer, duodenal ulcer, gastric MALT lymphoma, idiopathic thrombocytopenic purpura, Helicobacter pylori gastritis, and stomach after endoscopic treatment for early gastric cancer. uuid:7e651787-11b6-451e-a47a-695ce2b1c8ec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:136048 biolink:treats MONDO:0019098 PMID:41385096 "[{""id"":""uuid:8d3af2cd-7cf7-410f-abea-8f2b95087a40"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:27949424-661a-47b9-96ff-f0dfe955d312"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of gastric ulcer, duodenal ulcer, reflux esophagitis, prevention of recurrence of gastric or duodenal ulcer in patients treated with low-dose aspirin, prevention of recurrence of gastric or duodenal ulcer in patients treated with non- steroidal anti-inflammatory drugs (NSAIDs), and aid to eradication of Helicobacter pylori in patients with gastric ulcer, duodenal ulcer, gastric MALT lymphoma, idiopathic thrombocytopenic purpura, Helicobacter pylori gastritis, and stomach after endoscopic treatment for early gastric cancer. uuid:3e0716b4-1a08-47ff-91c1-d06e70299897 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:136048 biolink:treats MONDO:0004716 PMID:41385096 "[{""id"":""uuid:e0e6696b-0d7e-45da-a0a2-81113f9a9d5f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:84d0fb5d-7525-4f27-9235-8fbebe6f4c79"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of gastric ulcer, duodenal ulcer, reflux esophagitis, prevention of recurrence of gastric or duodenal ulcer in patients treated with low-dose aspirin, prevention of recurrence of gastric or duodenal ulcer in patients treated with non- steroidal anti-inflammatory drugs (NSAIDs), and aid to eradication of Helicobacter pylori in patients with gastric ulcer, duodenal ulcer, gastric MALT lymphoma, idiopathic thrombocytopenic purpura, Helicobacter pylori gastritis, and stomach after endoscopic treatment for early gastric cancer. uuid:e46a4070-9671-4b9e-8ae3-0e2b2c65654b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:83800 biolink:treats MONDO:0005354 PMID:41385096 "[{""id"":""uuid:aeded26f-42cb-493c-b4d8-96e92bc6924c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b2ed936a-98a5-4a67-aab8-2e54bdefe152"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new active ingredients indicated for the improvement of viremia in patients with chronic hepatitis C or compensated cirrhosis type C in serogroup 1 (genotype 1) who are untreated and ineligible for, or are intolerant to therapy including interferon; or who did not respond to therapy including interferon. [Priority review] uuid:adc5cc00-27c2-4703-9a39-a0ae7a783b11 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:83800 biolink:treats MONDO:0005155 PMID:41385096 "[{""id"":""uuid:b6af0c84-4472-451d-8829-a52187ed949b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e2f12663-5e6f-4313-bc47-8ef14b18286b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new active ingredients indicated for the improvement of viremia in patients with chronic hepatitis C or compensated cirrhosis type C in serogroup 1 (genotype 1) who are untreated and ineligible for, or are intolerant to therapy including interferon; or who did not respond to therapy including interferon. [Priority review] uuid:9dee1e13-8935-47b0-a1a0-356f37e976b8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1487516 biolink:treats MONDO:0005607 PMID:41385096 "[{""id"":""uuid:b92370e6-e5af-4e78-8379-0ac3f71a213c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a05e288a-6c77-49a7-bd61-24a191805400"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] New combination drugs with a new active ingredient indicated for the relief of symptoms secondary to airway obstructive disorder in chronic obstructive pulmonary disease (chronic bronchitis, emphysema) (when a combination treatment of an inhaled long-acting anticholinergic and a long- acting beta-2 agonist is needed). uuid:4bdccd4c-f928-4c78-9252-adbc73dc8303 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1487516 biolink:treats MONDO:0004849 PMID:41385096 "[{""id"":""uuid:3e89255e-a87f-4d47-927b-20fbfcc4e058"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a5d0e655-ece9-4803-9ea6-e49e067107ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] New combination drugs with a new active ingredient indicated for the relief of symptoms secondary to airway obstructive disorder in chronic obstructive pulmonary disease (chronic bronchitis, emphysema) (when a combination treatment of an inhaled long-acting anticholinergic and a long- acting beta-2 agonist is needed). uuid:acc68be0-7fdc-4001-99d1-ba2c537c398f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DLG4EML025 biolink:treats UMLS:C0406317 PMID:41385096 "[{""id"":""uuid:2c90b942-a419-4159-85aa-db07125286ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3130cb9a-25e2-4db3-8a49-947fdfc2d8b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of plaque psoriasis and psoriatic arthritis in patients who have not responded sufficiently to conventional therapies. uuid:2d1f872e-ff3f-4b36-9d65-45a58d02df4f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:65346 biolink:treats MONDO:0005607 PMID:41385096 "[{""id"":""uuid:286c035d-5ee7-4bb7-8415-60a0edcb7fa0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:335c5017-cade-4097-b6f7-3ce3be15c834"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the relief of symptoms secondary to airway obstructive disorder in chronic obstructive pulmonary disease (chronic bronchitis, emphysema). uuid:e4b8818f-407d-490b-89a8-cf1c765adaab biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:65346 biolink:treats MONDO:0004849 PMID:41385096 "[{""id"":""uuid:fb45ecd1-eefe-45e3-aad4-a7f62de4f7c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:eeebd4d8-3e64-4db1-8549-0aaf7bfd9201"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the relief of symptoms secondary to airway obstructive disorder in chronic obstructive pulmonary disease (chronic bronchitis, emphysema). uuid:1d32f5a9-9fda-4ead-8287-2bdb602d22f4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:GE2T1418SV biolink:treats MONDO:0005607 PMID:41385096 "[{""id"":""uuid:b689d869-2d69-4b85-9e11-6978f8c309cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ae920019-54c0-465b-a17a-23eb5fa09be8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Other drugs with a new dosage indicated for the relief of symptoms secondary to airway obstructive disorder in chronic obstructive pulmonary disease (chronic bronchitis, emphysema). uuid:e7b2c5b5-6dd1-494a-a3b9-e47adad14f6f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:GE2T1418SV biolink:treats MONDO:0004849 PMID:41385096 "[{""id"":""uuid:0fcb01ad-657f-4600-823c-f1971f05b3a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:642cbad3-1752-4e9f-917e-d4f4611d3554"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Other drugs with a new dosage indicated for the relief of symptoms secondary to airway obstructive disorder in chronic obstructive pulmonary disease (chronic bronchitis, emphysema). uuid:c22fd3c5-87b2-41fc-a991-94597afce7c3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4118932Z90 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:4ff3e06c-8d41-471e-9a61-d6cfd536feee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d12ecd87-52f8-40ee-b91e-c3bce5629098"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of type 2 diabetes mellitus. uuid:fb21b742-b8df-4753-842b-383a6f03db2d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90936 biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:6a835b5a-f424-4d81-9dcb-ec0c9e0caa82"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:edf87c45-323b-422f-a85e-fb36a135c54b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of unresectable advanced/relapsed ALK fusion gene-positive non-small-cell lung cancer. [Orphan drug] uuid:039ff6a3-48a5-47dc-9dce-27fadae7c541 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85994 biolink:treats MONDO:0002108 PMID:41385096 "[{""id"":""uuid:8d1b4505-aa06-4da8-b825-6d6b073ea583"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5aff7912-afd5-472d-8f9a-01eaf14bc7e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of unresectable thyroid cancer. [Orphan drug] uuid:4c06d9ad-4450-41af-80bc-72e8b49e869c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3127 biolink:treats MONDO:0001134 PMID:41385096 "[{""id"":""uuid:564ca699-7e10-40ee-8323-f31f4c37c428"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7b66ce4a-ef31-49ec-88d1-a2a663794a15"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of essential hypertension (mild to moderate). uuid:4ae526f0-cf6e-4b31-95c7-1e89a86dc6d7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:87715 biolink:treats MONDO:0005542 PMID:41385096 "[{""id"":""uuid:58b80481-e57a-468b-bc2c-9141474c25a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:91d9362f-2007-45ae-8958-54e05cbb9e45"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of the following ischemic heart diseases managed with percutaneous coronary intervention (PCI): acute coronary syndrome (unstable angina, non ST-segment elevation myocardial infarction, ST- segment elevation myocardial infarction), stable angina, old myocardial infarction. uuid:3f09b2a7-b1ea-4a23-9b4b-a83fa1dd668c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:87715 biolink:treats HP:0001681 PMID:41385096 "[{""id"":""uuid:7b8fef24-85b1-4bfc-85ea-d4a0fcfe6a9a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6647068d-ecb1-4b37-a34f-e7d64a34f415"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of the following ischemic heart diseases managed with percutaneous coronary intervention (PCI): acute coronary syndrome (unstable angina, non ST-segment elevation myocardial infarction, ST- segment elevation myocardial infarction), stable angina, old myocardial infarction. uuid:c2f67036-27fb-40b2-be8c-5176c27ad45d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:87715 biolink:treats UMLS:C0155668 PMID:41385096 "[{""id"":""uuid:b15dab19-8eac-4918-b26a-fdceb1ddf43b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b75f95e4-aa06-4b42-8ed0-5f55f01719dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of the following ischemic heart diseases managed with percutaneous coronary intervention (PCI): acute coronary syndrome (unstable angina, non ST-segment elevation myocardial infarction, ST- segment elevation myocardial infarction), stable angina, old myocardial infarction. uuid:d05cad2c-1c55-4347-82cd-3a8a3716a190 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71940 biolink:treats HP:0100518 PMID:41385096 "[{""id"":""uuid:9730e4e3-8a21-4b11-b49f-ec8e84576f8f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:857b46b8-3c4c-4957-9784-7009c1171ba0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage in a new additional dosage form indicated for the treatment of dysuria associated with benign prostatic hypertrophy. uuid:53f0c825-8bf1-4db9-85b1-91ecd9096579 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134724 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:e991b9d7-f6ae-4165-ab46-68f3b24a0fb7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f654587a-92e1-446a-878f-1ff1ce33c065"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of type 2 diabetes mellitus. uuid:1d6ee2c2-e70c-4626-8614-588099d06180 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134725 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:b1a135c1-4c36-46f4-9aad-bc1042c1be95"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3b640936-6892-4233-8556-4c47851a2101"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of type 2 diabetes mellitus. uuid:828003c3-ad5c-4410-8953-7bce4ee9c658 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:136041 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:e3916855-b655-492a-8c23-f1b02eb5bf14"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c9c7a153-ec5c-49f6-9013-f7856eee8955"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of type 2 diabetes mellitus. uuid:fc72a5cf-a8e5-4753-a820-4c7c32979366 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1670307 biolink:treats MONDO:0005575 PMID:41385096 "[{""id"":""uuid:402a5439-0d55-4982-b687-42030941b92d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:58082462-36b6-432d-aea5-ad433c7c1b39"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] New combination drugs with a new active ingredient indicated for the treatment of unresectable advanced or recurrent colorectal cancer (for use only if refractory or intolerant to standard therapies). uuid:d1684d21-25ae-4b2d-8d7d-7f6fbf072b10 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:72296 biolink:treats HP:0002140 PMID:41385096 "[{""id"":""uuid:d58f12e2-f5dd-404e-98a4-854e2756be13"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:81a4457c-e09d-4a7b-be45-e1d23d8d7d9f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for prevention of ischemic stroke and systemic embolism in patients with nonvalvular atrial fibrillation. uuid:0031358c-1147-41c3-8575-11218f896189 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134966 biolink:treats HP:0032792 PMID:41385096 "[{""id"":""uuid:feda2cce-9a8a-42cc-b582-ae5ed500f647"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:02e936e6-0147-4e8c-b7c6-33fb83ef2721"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for use as a concomitant therapy with other antiepileptic drugs to treat tonic and atonic seizures in patients with Lennox-Gastaut syndrome who have not responded sufficiently to other antiepileptic drugs. [Orphan drug] uuid:1e652a5b-9cc9-4a56-9906-0b052f3776b7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134966 biolink:treats HP:0010819 PMID:41385096 "[{""id"":""uuid:7a35f40a-6f1c-4350-82a4-105d2ea6c8bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5cdc98ee-3fbe-4a8a-95b1-83cb7e6b5f20"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for use as a concomitant therapy with other antiepileptic drugs to treat tonic and atonic seizures in patients with Lennox-Gastaut syndrome who have not responded sufficiently to other antiepileptic drugs. [Orphan drug] uuid:a949ae99-24c9-4d0d-8aac-e5dc963b16e7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:15C2VL427D biolink:treats HP:0031241 PMID:41385096 "[{""id"":""uuid:11df1396-c062-4d3c-81eb-82f234d03542"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:64cf5edf-b8d9-4ac6-93c6-8ac747b45abb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of age-related macular degeneration associated with subfoveal choroidal neovascularization. uuid:df03ced1-0783-4549-897e-3534838b52c2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:167309 biolink:treats EFO:0801084 PMID:41385096 "[{""id"":""uuid:123f1b09-3d3c-4a5a-8fe5-58ca0d800f1d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8875a6e7-4c50-45ab-8a65-6a254d54afcf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for achieving analgesia of moderate to severe pain associated with various types of cancer which can not be managed by treatment with other strong opioid analgesics. uuid:9bb9a951-ed7a-4ce9-8ab1-90ae2461e742 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135920 biolink:treats MONDO:0006624 PMID:41385096 "[{""id"":""uuid:0c42d309-0ac1-4788-bcd2-761d09d24d05"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:bb716389-adac-4c86-99a5-71ebf280e028"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of urinary urgency, urinary frequency, and urge urinary incontinence associated with overactive bladder. uuid:52998f0c-dd7a-4923-af80-d98d5944d6e0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135920 biolink:treats HP:0100515 PMID:41385096 "[{""id"":""uuid:a0f73fdf-0162-44c8-9efa-a70f75486ac0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f5ace67e-d866-461a-b6db-655f7c93df89"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of urinary urgency, urinary frequency, and urge urinary incontinence associated with overactive bladder. uuid:ed7bcd95-258c-4825-9635-ece6947ff8b6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31689 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:a52e50f8-f08b-4a20-883a-5f551bb95387"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:025b7685-1bfc-4bdd-acea-3a398f48e376"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of rheumatoid arthritis. uuid:1c70d8b5-d0a9-418b-b2be-00bbd850617d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:136043 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:a39bd029-dab7-4bc2-be36-43c2a163c763"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:45eb260c-3c7d-4637-9237-d7743e4c050c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of type 2 diabetes mellitus. uuid:fbaff2e0-1638-4fe5-965a-0b030c39fab5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8868 biolink:treats MONDO:0005298 PMID:41385096 "[{""id"":""uuid:b1c4c673-8b43-4816-a30a-3aa484d79337"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e1e130df-1da3-4b0b-810e-f29ac2af66ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage in a new additional dosage form. These drugs are indicated for the treatment of osteoporosis. uuid:41d9bca3-4b5e-4972-9c90-8ed062dae243 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85973 biolink:treats MONDO:0005399 PMID:41385096 "[{""id"":""uuid:b7a2f3fd-19be-4dfe-8c80-1c408616ddb5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0540a072-00c7-46f0-8b94-fc95f73dd81f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for prevention of venous thromboembolism in patients undergoing orthopedic surgery of lower limbs including total knee arthroplasty, total hip arthroplasty and hip fracture surgery. uuid:30da1703-0698-4bdc-a2b3-0037d993d961 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68579 biolink:treats HP:0002140 PMID:41385096 "[{""id"":""uuid:67ab353a-f028-4b4f-8118-91754725edeb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7c1275ed-708d-441b-86a0-2d5cad8d2c8d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the prevention of ischemic stroke and systemic embolism in patients with nonvalvular atrial fibrillation. uuid:55d9e004-111e-43f5-b61f-0d5140480868 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:474180 biolink:treats MONDO:0044067 PMID:41385096 "[{""id"":""uuid:608f62da-d219-43f2-ba06-3cdce783b443"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8631cbbb-d0c4-4bf4-bd05-49ff4154d75d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of febrile neutropenia suspected of a fungal infection and fungal infections due to Candida or Aspergillus (esophageal candidiasis, invasive candidiasis, aspergillosis). uuid:c1729d6d-099e-4732-819c-7535bd819b58 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:474180 biolink:treats MONDO:0005657 PMID:41385096 "[{""id"":""uuid:0a15a2e6-fadd-43f8-b981-37300eb25a4c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:cfdbb1c5-4d65-40a3-97b2-19efda752bcd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of febrile neutropenia suspected of a fungal infection and fungal infections due to Candida or Aspergillus (esophageal candidiasis, invasive candidiasis, aspergillosis). uuid:dca78036-0045-42b9-94d6-4c4b809dc675 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:65349 biolink:treats MONDO:0006624 PMID:41385096 "[{""id"":""uuid:b5b53d4e-b35a-428f-a020-60b148d1884d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9449a822-9dfe-43bc-8bd4-439b25076720"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of urinary urgency, urinary frequency, and urge urinary incontinence associated with overactive bladder. uuid:814d4214-24fa-4bec-bfab-f5689c28bb9c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:64759 biolink:treats MONDO:0000022 PMID:41385096 "[{""id"":""uuid:15f0999f-4bb4-4a14-b772-55872f858fe8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e2fa2ec5-b951-47d7-9b95-6035272767a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new route of administration indicated for the treatment of nocturnal enuresis associated with decreased urine osmolality or urinary specific gravity. uuid:06ee97c4-845f-4d5d-9815-f17974848033 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:40SGR63TGL biolink:treats MONDO:0005298 PMID:41385096 "[{""id"":""uuid:85ae12cc-5886-401b-9af8-4dce0cc6d133"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:cb386515-45f4-4a3f-862b-2ae37a22ef09"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage and an additional dosage form indicated for the treatment of osteoporosis. uuid:427aa3d6-9af5-4aa4-9173-80a8c9c57cb2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:659877 biolink:treats MONDO:0005198 PMID:41385096 "[{""id"":""uuid:7203735e-6be4-4d86-abda-962a0c0f2505"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7c46262d-0a22-47d1-a3da-a4a4a9d67584"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the prevention of cervical cancer and its precursor lesions, vulvar intraepithelial neoplasia, vaginal intraepithelial neoplasia, and condyloma acuminatum caused by infection with human papillomavirus types 6, 11, 16 and 18. uuid:e36ce563-54e5-4e1c-92fd-d5c487fe0dcc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:659877 biolink:treats UMLS:C0346208 PMID:41385096 "[{""id"":""uuid:9f28ee03-5cf4-45e7-a889-b50fc526d7f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ac56a7c5-af8a-43e4-97c0-2c03e7d2bc89"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the prevention of cervical cancer and its precursor lesions, vulvar intraepithelial neoplasia, vaginal intraepithelial neoplasia, and condyloma acuminatum caused by infection with human papillomavirus types 6, 11, 16 and 18. uuid:1e9dd6a5-f5a1-4d7a-97b9-5fb495b4abb9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:70746 biolink:treats HP:0002140 PMID:41385096 "[{""id"":""uuid:e26a1c56-3ca4-4b6d-a005-18986d97c6d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5da3f174-51a5-4a1a-a9c0-daa1a598c569"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for prevention of ischemic stroke and systemic embolism in patients with nonvalvular atrial fibrillation. uuid:71c27598-58a3-4d83-9859-409def3d8c43 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:61033 biolink:treats UMLS:C3873363 PMID:41385096 "[{""id"":""uuid:e938ad9d-302e-4a6d-89d2-7fdc88d8a28d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d48effdf-782f-44f0-b147-bde6d47c1d9b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications and new dosages for the treatment of acute pulmonary thromboembolism and acute deep vein thrombosis. uuid:c6446d16-f549-458c-8daa-ea0871424834 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75722 biolink:treats EFO:0801084 PMID:41385096 "[{""id"":""uuid:28463cc7-7ec9-4d1a-b559-e2f7f4e31bf8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0b4949f4-1d61-488a-952a-073b56e5e071"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new route of administration indicated for analgesia in various types of cancer with mild to moderate pain. uuid:e8467798-03f6-497e-a20f-4d18119e7f11 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats MONDO:0024355 PMID:41385096 "[{""id"":""uuid:6846541d-03a4-40c7-aa63-a13d80d72d85"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1d4323cc-17c6-40bf-b111-9a5ce4e51bf5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new route of administration indicated for the treatment of pneumonia, secondary infection of chronic respiratory disease, typhoid, paratyphoid, anthrax, brucellosis, plague, tularemia and Q fever. uuid:b24eed58-e3ee-4b82-819b-d202dcf3081f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats MONDO:0005619 PMID:41385096 "[{""id"":""uuid:b8a21b9e-717a-4dc7-a9cb-ae678f8f1559"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:571bfd7c-2168-4368-a216-373eacf0cde2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new route of administration indicated for the treatment of pneumonia, secondary infection of chronic respiratory disease, typhoid, paratyphoid, anthrax, brucellosis, plague, tularemia and Q fever. uuid:825459d2-d86d-4b46-8f89-d7b6073c157a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats MONDO:0018626 PMID:41385096 "[{""id"":""uuid:2e8527cb-5037-48da-8ba2-b45ecfbd2c7f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ecc2930a-f029-47ca-a25e-e8294f920bae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new route of administration indicated for the treatment of pneumonia, secondary infection of chronic respiratory disease, typhoid, paratyphoid, anthrax, brucellosis, plague, tularemia and Q fever. uuid:cff5bed5-97db-4431-843a-01f9c20a93da biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats MONDO:0005119 PMID:41385096 "[{""id"":""uuid:37be5af7-a1d2-4b06-bca3-26d5de088987"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f815287f-e692-4e21-930b-66b631c6ae10"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new route of administration indicated for the treatment of pneumonia, secondary infection of chronic respiratory disease, typhoid, paratyphoid, anthrax, brucellosis, plague, tularemia and Q fever. uuid:3ca38156-41ec-4e6c-af89-8a12f156728a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats MONDO:0005683 PMID:41385096 "[{""id"":""uuid:7070898e-04f0-4ecf-8a6e-96dcee68864e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:43d91e63-9bea-4a78-bfd8-29e5497119c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new route of administration indicated for the treatment of pneumonia, secondary infection of chronic respiratory disease, typhoid, paratyphoid, anthrax, brucellosis, plague, tularemia and Q fever. uuid:d172968b-4931-4003-81db-3a93b6edcd2b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats MONDO:0018077 PMID:41385096 "[{""id"":""uuid:8e8ce306-2728-4064-94d2-8936c82cdfe8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6c8349be-caae-4888-8931-e1bbe8b48cef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new route of administration indicated for the treatment of pneumonia, secondary infection of chronic respiratory disease, typhoid, paratyphoid, anthrax, brucellosis, plague, tularemia and Q fever. uuid:855b284f-411a-4cc5-9818-4cd7cbdad841 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats MONDO:0019186 PMID:41385096 "[{""id"":""uuid:23b09222-8be0-499e-a506-dd0f08bd5f4b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9eac1e2c-7f65-4292-bc9a-09ee23de3c97"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new route of administration indicated for the treatment of pneumonia, secondary infection of chronic respiratory disease, typhoid, paratyphoid, anthrax, brucellosis, plague, tularemia and Q fever. uuid:bd61ff64-c710-4be8-bc51-41b56ad508b4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:73927 biolink:treats MONDO:0005298 PMID:41385096 "[{""id"":""uuid:9d3d5a76-6fb2-4e70-83a8-16f82fe8a1da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c7127444-3917-45c1-b718-8319dca6d0d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of osteoporosis. uuid:894352fe-d28e-4a31-b070-8ef150ff2fe0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6A901E312A biolink:treats MONDO:0005575 PMID:41385096 "[{""id"":""uuid:862bad27-62ec-49f1-bfaa-ecc4d1fd820e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:73435e52-61bb-43c6-9922-a649699e7c1c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of unresectable, advanced or recurrent colorectal cancer with wild-type KRAS. uuid:f53dc898-060a-4753-969b-3e298bede884 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6950 biolink:treats MONDO:0002050 PMID:41385096 "[{""id"":""uuid:1c26ce67-9ff6-4b86-b11d-d62e8d0ce93a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e952a338-6b89-4d1a-b827-1aa30a556ab3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of depression. uuid:12c73d23-1580-4402-b14c-bc732ea97681 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85202 biolink:treats MONDO:0005812 PMID:41385096 "[{""id"":""uuid:081e3b1d-634a-4aaf-b0e6-6b68af693630"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d3659ade-0d8e-40d1-9ebf-686c737db919"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of influenza A or B virus infections. uuid:2cc8f95a-5259-4402-aaa5-11b3a918ac4f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:327148 biolink:treats MONDO:0100470 PMID:41385096 "[{""id"":""uuid:fbf01aa0-6947-4b84-9ffe-7fc77a2c2688"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d2a82025-779a-4e79-8b09-45fdf4ef23f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] New combination drugs indicated for the treatment of bronchial asthma (when a combination treatment of an inhaled steroid and a long-acting beta-2 agonist is needed). uuid:85c9c85f-121f-476a-b923-a168ff4dd96b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:08GY9K1EUO biolink:treats HP:0002149 PMID:41385096 "[{""id"":""uuid:f2e23829-5c65-4359-86db-ce5fd07d13e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c540271f-6938-4864-9951-5544302e7f73"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of hyperuricemia in patients receiving cancer chemotherapy. uuid:75764f63-358d-49aa-92ed-be94e8cbc6d5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135156 biolink:treats MONDO:0005052 PMID:41385096 "[{""id"":""uuid:6c634cb4-01dd-48cc-affe-f06ab68ce12b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:54a94a2b-d8a1-4c4b-a728-269357015866"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and new dosages for the treatment of diarrhea-predominant irritable bowel syndrome in men. uuid:44cd6f3a-4eda-4691-98a7-d6989ab0cceb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:0M78EU4V9H biolink:treats MONDO:0000328 PMID:41385096 "[{""id"":""uuid:a3613263-df0f-461a-ac09-7344d37481c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c023a3a8-963e-4bcb-a64b-a43d47b4c266"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs containing a new active ingredient indicated for the treatment of hyperphosphatemia in dialysis patients with chronic renal failure. uuid:8dc14a40-9fd3-4665-a503-892314493047 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:0M78EU4V9H biolink:treats MONDO:0024327 PMID:41385096 "[{""id"":""uuid:ca578dfc-1434-43c0-b1f0-20e6bb6b431b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f5c2577d-8958-4cef-b389-fe1fcee31957"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs containing a new active ingredient indicated for the treatment of hyperphosphatemia in dialysis patients with chronic renal failure. uuid:e34bb9a5-2cd0-4e1a-add9-89de20c1daa2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0250480 biolink:treats MONDO:0700217 PMID:41385096 "[{""id"":""uuid:9366ed44-9d86-4f8a-b7ef-20b8cf44c5ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8e5396cd-8915-435f-8410-4b99d58219f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] New combination drugs indicated for the treatment of septicemia, pneumonia, pyelonephritis, and complicated cystitis. uuid:01a0f3df-80a7-4e0b-b40a-93e51c4a6741 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0250480 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:36a16304-25af-435e-9fcd-065782ea0f8b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2425372b-b235-435d-be88-c88f96ad5574"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] New combination drugs indicated for the treatment of septicemia, pneumonia, pyelonephritis, and complicated cystitis. uuid:cf33cadb-3fbf-4067-9bb6-99e9fc77795f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0250480 biolink:treats MONDO:0006939 PMID:41385096 "[{""id"":""uuid:2742b08f-ee5e-40d7-b264-aa8a9143c151"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5fa40ed8-3694-4d3f-887b-a64c60adcbcf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] New combination drugs indicated for the treatment of septicemia, pneumonia, pyelonephritis, and complicated cystitis. uuid:dc222082-b833-4866-86fb-d84f219aa165 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49375 biolink:treats HP:0004848 PMID:41385096 "[{""id"":""uuid:58c29238-d780-441f-9e14-023cdf989292"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8fa502ad-c10d-49e2-81a6-1ee5fcfc43e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs containing a new active ingredient indicated for the treatment of 1) imatinib-resistant chronic myelogenous leukemia and 2) recurrent or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia. [Orphan drug] uuid:d053f90e-1da8-4e84-81e9-7daf19f2b004 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31270 biolink:treats MONDO:0015924 PMID:41385096 "[{""id"":""uuid:d0eb2a1e-827d-497a-b83b-36963a997d04"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:543fbc9b-d38c-4541-b4b8-accfcc516034"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and dosage and in a new dosage form for the treatment of pulmonary arterial hypertension. [Priority review] uuid:5777e312-e9ab-4d4b-acb5-b12d78da40e2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3437 biolink:treats MONDO:0005041 PMID:41385096 "[{""id"":""uuid:1de3a7a2-8d31-4109-8a9a-e8d79a1ee429"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5b7eda93-2b84-496c-b10c-edae8db46435"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs in a new dosage form indicated for the treatment of glaucoma and ocular hypertension. uuid:4a05b817-3f03-4383-890d-330841e1dabc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3437 biolink:treats HP:0007906 PMID:41385096 "[{""id"":""uuid:c2f6571d-85a0-4c12-8a0a-4da16414f761"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:bfa5d336-a108-4a3e-a069-64f2e99a1a9b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs in a new dosage form indicated for the treatment of glaucoma and ocular hypertension. uuid:257acda0-4084-4f9d-8555-49983aaa5c73 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4304 biolink:treats MONDO:0001218 PMID:41385096 "[{""id"":""uuid:55cbeac6-bf4a-41a7-a559-bd92ac19b9d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c45a1967-b0a6-4a02-8b45-b77ef7464df3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient indicated for the treatment of laryngopharyngitis, tonsillitis (including peritonsillitis and peritonsillar abscess), acute bronchitis, pneumonia, infections secondary to chronic respiratory disease, cystitis, pyelonephritis, urethritis, cervicitis, otitis media, sinusitis, periodontal inflammation, pericoronitis and jaw inflammation. uuid:0ac78f42-ad5f-4a09-8b23-76311259483f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4304 biolink:treats MONDO:0001039 PMID:41385096 "[{""id"":""uuid:1efad1b6-eb9c-4883-b78d-4cc1b76c6fe4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:bccabe18-0832-4eb2-93c3-a3f71d2565d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient indicated for the treatment of laryngopharyngitis, tonsillitis (including peritonsillitis and peritonsillar abscess), acute bronchitis, pneumonia, infections secondary to chronic respiratory disease, cystitis, pyelonephritis, urethritis, cervicitis, otitis media, sinusitis, periodontal inflammation, pericoronitis and jaw inflammation. uuid:18e26bf6-8e80-4478-a3e2-a3ac20e84d2a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4304 biolink:treats UMLS:C0877267 PMID:41385096 "[{""id"":""uuid:b9a07a3f-2ee6-4947-b181-09214316f0e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:53dcccc8-f6a9-4203-b9d4-71975a7a28e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient indicated for the treatment of laryngopharyngitis, tonsillitis (including peritonsillitis and peritonsillar abscess), acute bronchitis, pneumonia, infections secondary to chronic respiratory disease, cystitis, pyelonephritis, urethritis, cervicitis, otitis media, sinusitis, periodontal inflammation, pericoronitis and jaw inflammation. uuid:966eb7ba-4cf3-42db-abd7-02206600157c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4304 biolink:treats MONDO:0005906 PMID:41385096 "[{""id"":""uuid:a8d943ee-08bc-4850-8fba-5eba2f3ba081"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3878499c-acca-4035-b4e2-f87bda8821af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient indicated for the treatment of laryngopharyngitis, tonsillitis (including peritonsillitis and peritonsillar abscess), acute bronchitis, pneumonia, infections secondary to chronic respiratory disease, cystitis, pyelonephritis, urethritis, cervicitis, otitis media, sinusitis, periodontal inflammation, pericoronitis and jaw inflammation. uuid:51e0abdf-394d-4e71-9a8a-d039e21259be biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4304 biolink:treats HP:0012388 PMID:41385096 "[{""id"":""uuid:29e11698-a2cf-49b0-b881-cfc2a57540ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7d86f6db-e1a8-4308-8034-03601e04dd95"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient indicated for the treatment of laryngopharyngitis, tonsillitis (including peritonsillitis and peritonsillar abscess), acute bronchitis, pneumonia, infections secondary to chronic respiratory disease, cystitis, pyelonephritis, urethritis, cervicitis, otitis media, sinusitis, periodontal inflammation, pericoronitis and jaw inflammation. uuid:2e3817cc-0560-4918-8c3e-7ab329b61a6f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4304 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:15584d4a-1501-40db-9d0b-568dc7ff32cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:54561269-a77a-43f1-a014-cc64f8c143ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient indicated for the treatment of laryngopharyngitis, tonsillitis (including peritonsillitis and peritonsillar abscess), acute bronchitis, pneumonia, infections secondary to chronic respiratory disease, cystitis, pyelonephritis, urethritis, cervicitis, otitis media, sinusitis, periodontal inflammation, pericoronitis and jaw inflammation. uuid:144cc771-7ebf-436b-9868-84e586d1baf7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4304 biolink:treats MONDO:0006032 PMID:41385096 "[{""id"":""uuid:90e74e53-9f08-44f2-ac11-babaf607b014"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a8d545f3-5e5e-4ee2-bd09-5919279418c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient indicated for the treatment of laryngopharyngitis, tonsillitis (including peritonsillitis and peritonsillar abscess), acute bronchitis, pneumonia, infections secondary to chronic respiratory disease, cystitis, pyelonephritis, urethritis, cervicitis, otitis media, sinusitis, periodontal inflammation, pericoronitis and jaw inflammation. uuid:d7fa627a-996d-41f3-9dc0-572399ef6856 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4304 biolink:treats MONDO:0006939 PMID:41385096 "[{""id"":""uuid:38a1a38d-3b6a-487d-9ea9-a8382872a62f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:feb808bb-bbc0-45ee-88a1-9eb2b1fdb3c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient indicated for the treatment of laryngopharyngitis, tonsillitis (including peritonsillitis and peritonsillar abscess), acute bronchitis, pneumonia, infections secondary to chronic respiratory disease, cystitis, pyelonephritis, urethritis, cervicitis, otitis media, sinusitis, periodontal inflammation, pericoronitis and jaw inflammation. uuid:92af93b8-dc8d-4e9c-8ca8-4c36b3a6a9b9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4304 biolink:treats MONDO:0005297 PMID:41385096 "[{""id"":""uuid:8ec1a497-4756-41e3-b7d0-5e1865105143"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0e73dcdb-5838-4e45-9185-95b352e03b63"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient indicated for the treatment of laryngopharyngitis, tonsillitis (including peritonsillitis and peritonsillar abscess), acute bronchitis, pneumonia, infections secondary to chronic respiratory disease, cystitis, pyelonephritis, urethritis, cervicitis, otitis media, sinusitis, periodontal inflammation, pericoronitis and jaw inflammation. uuid:baeeb167-9997-4dc2-9b7f-9b3ec85fa6aa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4304 biolink:treats MONDO:0002345 PMID:41385096 "[{""id"":""uuid:80b8b0f9-474e-4084-8deb-07f5ae0ee060"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5c6b78c7-064b-4d90-8edd-9a94203586f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient indicated for the treatment of laryngopharyngitis, tonsillitis (including peritonsillitis and peritonsillar abscess), acute bronchitis, pneumonia, infections secondary to chronic respiratory disease, cystitis, pyelonephritis, urethritis, cervicitis, otitis media, sinusitis, periodontal inflammation, pericoronitis and jaw inflammation. uuid:e4b7427b-1727-4865-9715-1e9f67d63d96 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4304 biolink:treats MONDO:0005441 PMID:41385096 "[{""id"":""uuid:6e90656f-afe6-498e-b6a5-8e17c5126f65"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ca3c1e99-7684-471b-9be7-89190489a95f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient indicated for the treatment of laryngopharyngitis, tonsillitis (including peritonsillitis and peritonsillar abscess), acute bronchitis, pneumonia, infections secondary to chronic respiratory disease, cystitis, pyelonephritis, urethritis, cervicitis, otitis media, sinusitis, periodontal inflammation, pericoronitis and jaw inflammation. uuid:431e7c41-ea67-4e2c-a1fb-890b80d79f1e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4304 biolink:treats MONDO:0005961 PMID:41385096 "[{""id"":""uuid:b0ebeee2-f495-455a-89be-c5d770300340"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:bc77af98-1700-4bb5-98c8-036705f5b75b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient indicated for the treatment of laryngopharyngitis, tonsillitis (including peritonsillitis and peritonsillar abscess), acute bronchitis, pneumonia, infections secondary to chronic respiratory disease, cystitis, pyelonephritis, urethritis, cervicitis, otitis media, sinusitis, periodontal inflammation, pericoronitis and jaw inflammation. uuid:6caf11d6-519f-404b-acf1-9914e4988d44 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4304 biolink:treats UMLS:C3495798 PMID:41385096 "[{""id"":""uuid:9b91390d-eecd-4944-bd0d-392a26196549"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0d2bd709-a897-4325-8cdd-d3fecee0538f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient indicated for the treatment of laryngopharyngitis, tonsillitis (including peritonsillitis and peritonsillar abscess), acute bronchitis, pneumonia, infections secondary to chronic respiratory disease, cystitis, pyelonephritis, urethritis, cervicitis, otitis media, sinusitis, periodontal inflammation, pericoronitis and jaw inflammation. uuid:ec43a9a1-2d72-4e0e-9860-6af9fe88776d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4304 biolink:treats MONDO:0006899 PMID:41385096 "[{""id"":""uuid:91a56d6e-d877-4f0b-89cd-13e3b43be83e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:121a7a1b-addd-4a89-80b4-1276cc72ce41"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient indicated for the treatment of laryngopharyngitis, tonsillitis (including peritonsillitis and peritonsillar abscess), acute bronchitis, pneumonia, infections secondary to chronic respiratory disease, cystitis, pyelonephritis, urethritis, cervicitis, otitis media, sinusitis, periodontal inflammation, pericoronitis and jaw inflammation. uuid:d0a465ac-8f5d-4585-aa72-ac0716c4f8d6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4304 biolink:treats UMLS:C0854217 PMID:41385096 "[{""id"":""uuid:c7c9b8f6-c2e2-44f1-ab58-9391452c7910"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:07fd442f-193c-4e29-a815-feea4746710b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient indicated for the treatment of laryngopharyngitis, tonsillitis (including peritonsillitis and peritonsillar abscess), acute bronchitis, pneumonia, infections secondary to chronic respiratory disease, cystitis, pyelonephritis, urethritis, cervicitis, otitis media, sinusitis, periodontal inflammation, pericoronitis and jaw inflammation. uuid:dfc9d8b1-57b7-4324-a76e-d39c74fc372e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:62984 biolink:treats MONDO:0010200 PMID:41385096 "[{""id"":""uuid:1594911a-1331-408b-9af1-acac7d0626fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:198da12e-f62f-4b3e-a2b8-e27d45723bd9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs containing a new active ingredient indicated for the treatment of Wilson’s disease (hepatolenticular degeneration). [Orphan drug] uuid:e1138b53-54e9-4a1f-9dcb-bd23fca26125 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:92002593 biolink:treats MONDO:0018908 PMID:41385096 "[{""id"":""uuid:7fdb6baa-f1d8-4e17-a8b2-66359f99e700"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ff85895f-c30d-48b5-abf9-877ac8035faa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] 1: A drug containing a new active ingredient indicated for the treatment of relapsed or refractory, CD20-positive lyphomas of the following: low-grade B-cell non-Hodgkin’s lymphoma and mantle cell lymphoma. 2: A drug containing a new active ingredient indicated for determining the site of ibritumomab tiuxetan accumulation. [Orphan drug] uuid:ba15fff3-3357-4872-895e-cd178b7de189 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:92002593 biolink:treats MONDO:0018876 PMID:41385096 "[{""id"":""uuid:161d06aa-20cf-4a1a-b71e-a1bbab7d7f65"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f5338d0b-9566-464a-b5d0-5d4fa089e08b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] 1: A drug containing a new active ingredient indicated for the treatment of relapsed or refractory, CD20-positive lyphomas of the following: low-grade B-cell non-Hodgkin’s lymphoma and mantle cell lymphoma. 2: A drug containing a new active ingredient indicated for determining the site of ibritumomab tiuxetan accumulation. [Orphan drug] uuid:bbb197d5-ca5f-4bae-8798-3684ce3d13c2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135694 biolink:treats HP:0002902 PMID:41385096 "[{""id"":""uuid:e19d4a5f-d0d6-4d75-8796-51b8cace3ed8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4a39f6f4-4131-45e8-bfed-2c32c73d7945"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for improvement of hyponatremia in syndrome of inappropriate secretion of antidiuretic hormone due to paraneoplastic syndrome of inappropriate antidiuretic hormone secretion (used only when conventional therapies are not sufficiently effective). [Orphan Drug] uuid:c2b050bd-b2fa-4285-9cbe-091f5534d0e6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135694 biolink:treats MONDO:0006802 PMID:41385096 "[{""id"":""uuid:2b2fdcca-736b-4388-a1f2-9c7a1cec208b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8b9a1995-deb2-4673-b6d0-b67634e9f013"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for improvement of hyponatremia in syndrome of inappropriate secretion of antidiuretic hormone due to paraneoplastic syndrome of inappropriate antidiuretic hormone secretion (used only when conventional therapies are not sufficiently effective). [Orphan Drug] uuid:2c997149-001d-43c5-aa32-27ae241c2137 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9622 biolink:treats MONDO:0006624 PMID:41385096 "[{""id"":""uuid:42d4a27e-c703-4b2e-b432-a37531b635c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:81cbb176-c478-42b3-802f-c945da20490f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for treatment of urinary urgency, urinary frequency, and urge urinary incontinence associated with overactive bladder. uuid:ba14f477-3a21-4ff3-a43e-4f254109042c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9622 biolink:treats HP:0100515 PMID:41385096 "[{""id"":""uuid:5362d192-4144-4f56-9bec-f8a276afa5c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:793e2078-f586-4a54-bf77-2b9fdd765ec3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for treatment of urinary urgency, urinary frequency, and urge urinary incontinence associated with overactive bladder. uuid:544bb512-13aa-4404-abcd-95f060211f15 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77573 biolink:treats MONDO:0004785 PMID:41385096 "[{""id"":""uuid:9783171a-8aac-4010-9e84-d84109f2a4b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e9ca478b-08fc-4510-a37d-0eef76f3d0f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new route of administration (eye drops) indicated for the treatment of blepharitis, dacryoadenitis, hordeolum, conjunctivitis, inflammation of the tarsal glands, inflammation of the cornea (including corneal ulcer), and aseptic treatment during ophthalmic surgery. uuid:e84791b8-f4cf-4f42-9aa3-62f7485e6ad3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77573 biolink:treats MONDO:0004804 PMID:41385096 "[{""id"":""uuid:22d8af6d-f371-48e9-bb5e-48453a80862c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e4ce27f9-81ec-4495-9630-23c22af8ddcb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new route of administration (eye drops) indicated for the treatment of blepharitis, dacryoadenitis, hordeolum, conjunctivitis, inflammation of the tarsal glands, inflammation of the cornea (including corneal ulcer), and aseptic treatment during ophthalmic surgery. uuid:a306f19a-86c8-4244-8c29-3ca77f81c5ae biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77573 biolink:treats MONDO:0005800 PMID:41385096 "[{""id"":""uuid:5e7a748f-6fd9-4bd7-9456-a7bd1655b557"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:fc4f2186-cb7b-4de6-abea-960e5d0117e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new route of administration (eye drops) indicated for the treatment of blepharitis, dacryoadenitis, hordeolum, conjunctivitis, inflammation of the tarsal glands, inflammation of the cornea (including corneal ulcer), and aseptic treatment during ophthalmic surgery. uuid:44be6252-f01d-45f2-907b-83cb232e5e18 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77573 biolink:treats MONDO:0003799 PMID:41385096 "[{""id"":""uuid:ef251293-43c6-4c73-b22d-db0f8f18fa27"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:00715f30-ebc0-43cd-b970-6e646003d8a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new route of administration (eye drops) indicated for the treatment of blepharitis, dacryoadenitis, hordeolum, conjunctivitis, inflammation of the tarsal glands, inflammation of the cornea (including corneal ulcer), and aseptic treatment during ophthalmic surgery. uuid:ced47a62-0f79-4925-8a94-2af1d417873e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77573 biolink:treats MONDO:0003085 PMID:41385096 "[{""id"":""uuid:ee9ee591-fce5-4362-961f-373fc1645d75"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b345740c-9fb4-4868-9f17-f64b4f2ca167"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new route of administration (eye drops) indicated for the treatment of blepharitis, dacryoadenitis, hordeolum, conjunctivitis, inflammation of the tarsal glands, inflammation of the cornea (including corneal ulcer), and aseptic treatment during ophthalmic surgery. uuid:2f5e531e-7957-4be0-a225-35159342d0f4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77573 biolink:treats MONDO:0004577 PMID:41385096 "[{""id"":""uuid:e59c91a2-afbb-4bb8-afc9-67e397ac336c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9cf216c3-c78e-4ad3-930a-07ed10f6cab6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new route of administration (eye drops) indicated for the treatment of blepharitis, dacryoadenitis, hordeolum, conjunctivitis, inflammation of the tarsal glands, inflammation of the cornea (including corneal ulcer), and aseptic treatment during ophthalmic surgery. uuid:0074f19c-9004-4dae-adb3-8765212766b3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49135 biolink:treats MONDO:0004992 PMID:41385096 "[{""id"":""uuid:bb5ca547-6583-45e3-8f70-0f3df63457ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3c2419bc-74b1-4d85-85fb-63a7a40e302f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs containing a new active ingredient used for making a diagnosis of malignant tumors accompanied by accelerated glucose metabolism, ischemic heart diseases or epilepsy uuid:80e93e9c-f0e9-445c-92c0-8616d81d02eb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49135 biolink:treats MONDO:0024644 PMID:41385096 "[{""id"":""uuid:079bfa03-ae28-41d9-8a18-2627c68c345e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:104d72c6-ca16-46fa-9b01-0d44852f646b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs containing a new active ingredient used for making a diagnosis of malignant tumors accompanied by accelerated glucose metabolism, ischemic heart diseases or epilepsy uuid:d2887892-1bbf-4910-9536-5932110d1781 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49135 biolink:treats MONDO:0005027 PMID:41385096 "[{""id"":""uuid:872ec989-ad75-438a-acf4-f8cc05d76205"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9519bdcd-9b8e-456c-aa71-5ab1e1557e00"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs containing a new active ingredient used for making a diagnosis of malignant tumors accompanied by accelerated glucose metabolism, ischemic heart diseases or epilepsy uuid:727d2a75-14a5-40dc-8bb7-9cbb01e4b08f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16335 biolink:treats MONDO:0005267 PMID:41385096 "[{""id"":""uuid:adec5883-a09a-45a4-b353-0baa4b946cca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3c6709e9-3f5c-4e54-8f71-1fdd9440a1c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs containing a new active ingredient used for load induction to make a diagnosis of heart disease based on myocardial perfusion scintigraphy in patients unable to tolerate sufficient exercise load uuid:5fc7b3e8-2dd6-41ff-a0dd-937fcc7942d6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32181 biolink:treats MONDO:0012883 PMID:41385096 "[{""id"":""uuid:ed193ea8-1fd6-46af-9893-2a9939d4e1d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6971337c-c482-4e7a-80f7-2018c7919737"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs containing a new active ingredient indicated for the treatment of acute promyelocytic leukemia [Orphan drug] uuid:e7d76a40-78e0-4a84-a806-4cc1880138e3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:142432 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:1ac24b3c-dfc4-4a9d-9bd8-50f377c6d99d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4ae5d2f2-a492-4e11-9c2a-d94b11abc594"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of chronic heart failure (for use only in patients receiving standard treatment of chronic heart failure). uuid:f73b11a8-0dbf-490b-8425-9dffa5d529e7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16684 biolink:treats HP:0006986 PMID:41385096 "[{""id"":""uuid:d335e342-4a9e-4854-bdac-c992b9f5a803"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b23c5b5e-61e6-4654-9cc0-7901511ea960"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of upper limb spasticity. uuid:c9fb5690-ddac-40cc-8132-77d642de42a1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1721551 biolink:treats MONDO:0100470 PMID:41385096 "[{""id"":""uuid:205bd236-9571-4903-bf46-1f4af6a6d225"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:16dea5b9-8171-49a6-aec5-18f452c3403d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] New combination drugs with a new active ingredient indicated for the treatment of bronchial asthma (when a combination treatment of an inhaled steroid and a long- acting beta-2 agonist is needed). uuid:652d9c32-c0e7-4b9f-b33e-9e8791bdb478 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:FYS6T7F842 biolink:treats MONDO:0022205 PMID:41385096 "[{""id"":""uuid:05ec1216-1f7f-415a-b99d-ec4b9770b643"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:fb78176d-efe8-42fc-9792-092a659a6b3b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Follow-on biologics indicated for the treatment of rheumatoid arthritis (including the prevention of structural joint damage), and the treatment of the following diseases in patients who have not responded sufficiently to conventional treatments; polyarticular- course juvenile idiopathic arthritis, plaque psoriasis, psoriatic arthritis, pustular psoriasis, ankylosing spondylitis and intestinal Behcet’s disease; and the remission induction therapy and maintenance therapy for moderate to severe active Crohn's disease (for use only in patients who have not sufficiently responded to conventional therapies). uuid:51ea861a-6d1b-4fd3-bf85-67fdd02fb25a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:FYS6T7F842 biolink:treats MONDO:0007191 PMID:41385096 "[{""id"":""uuid:1f7a2655-6f85-483b-bbbd-4aa9edb330ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:42c0d252-f4e0-4c2b-a0ce-34313d38df02"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Follow-on biologics indicated for the treatment of rheumatoid arthritis (including the prevention of structural joint damage), and the treatment of the following diseases in patients who have not responded sufficiently to conventional treatments; polyarticular- course juvenile idiopathic arthritis, plaque psoriasis, psoriatic arthritis, pustular psoriasis, ankylosing spondylitis and intestinal Behcet’s disease; and the remission induction therapy and maintenance therapy for moderate to severe active Crohn's disease (for use only in patients who have not sufficiently responded to conventional therapies). uuid:7240a787-9995-4b30-9756-c6f02d2591d4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:FYS6T7F842 biolink:treats UMLS:C0852922 PMID:41385096 "[{""id"":""uuid:69649fa8-a338-449e-8213-00de0421e6b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3d352202-9364-4c6a-92df-87c5154fae93"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Follow-on biologics indicated for the treatment of rheumatoid arthritis (including the prevention of structural joint damage), and the treatment of the following diseases in patients who have not responded sufficiently to conventional treatments; polyarticular- course juvenile idiopathic arthritis, plaque psoriasis, psoriatic arthritis, pustular psoriasis, ankylosing spondylitis and intestinal Behcet’s disease; and the remission induction therapy and maintenance therapy for moderate to severe active Crohn's disease (for use only in patients who have not sufficiently responded to conventional therapies). uuid:4c7c8622-d7fb-4068-82e5-65a000e90f4b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:132774 biolink:treats UMLS:C1142276 PMID:41385096 "[{""id"":""uuid:e4bbdb64-6184-4e7a-8378-3d949321db2e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:61e1d0ef-dd6f-437f-83fa-946071c08291"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of renal anaemia in patients who are undergoing dialysis. uuid:ce1f7331-f829-4174-bcee-acd4e6219ba5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:305EB53128 biolink:treats MONDO:0005393 PMID:41385096 "[{""id"":""uuid:793337e2-ae5d-41d0-ba5a-911756f4f9cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:bf30acd2-601c-46f4-b6b3-2f729135da4f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of gout and hyperuricemia. uuid:bea5ff16-0fb3-4a07-9584-059e9e4026fa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:305EB53128 biolink:treats HP:0002149 PMID:41385096 "[{""id"":""uuid:c044f9f7-8889-4927-9b72-4324581b7b80"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:bb811a3e-1b10-4fc2-af97-d74d19895e4b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of gout and hyperuricemia. uuid:b1926f1a-900b-4031-8cd9-728996da5452 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31296 biolink:treats MONDO:0005090 PMID:41385096 "[{""id"":""uuid:bd2bffb8-8469-4bbf-98f8-0983c1fba4fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9df68654-1e68-4aab-9b97-1188df6ea6e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new route of administration indicated for the treatment of schizophrenia. uuid:dc0d53a0-ff3e-4f80-a1b3-fd3fec17b438 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:N62TGJ04A1 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:4f847f63-4985-4bb7-be82-c42e46b56631"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8259fade-32e2-4c13-9c3e-d9e503397924"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of hypertension. uuid:6077b497-dc00-4623-9bbd-3b582930778d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:72312 biolink:treats MONDO:0020479 PMID:41385096 "[{""id"":""uuid:f4533df8-1345-40a4-8219-77910ae80e2f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c5bbbefe-83a5-4ef8-8e55-9981c698ee19"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the improvement of hypersecretion of growth hormone and IGF-I (somatomedin-C) and related symptoms in acromegaly and pituitary gigantism (when surgical therapies are not sufficiently effective or are difficult to perform). uuid:417a1347-0900-41d3-8e38-ab153b593db0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135935 biolink:treats EFO:0801084 PMID:41385096 "[{""id"":""uuid:24d4ba17-23cd-4e11-9b2f-f7ca4dbbc8f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:17543afb-8cf3-4061-98d9-ab44f2a4768f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for management of moderate to severe pain in various types of cancer. uuid:02b49471-8202-4cb1-85e1-b4f853829a62 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB00028 biolink:treats MONDO:0015977 PMID:41385096 "[{""id"":""uuid:e3c996ba-821a-4414-975d-60368b1302c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c5090d74-0ea4-4d4a-9cc8-4d9f8354eb89"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of agammaglobulinemia or hypogammaglobulinemia. uuid:ad7f031f-e3d0-457c-9653-c37472ddf9dc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB00028 biolink:treats MONDO:0003827 PMID:41385096 "[{""id"":""uuid:42898b62-e77f-41ec-ab2d-e7de53b1c570"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d74cd7aa-face-4b6c-b7ad-dba4f554a0b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of agammaglobulinemia or hypogammaglobulinemia. uuid:8f03bb61-3fc7-44af-b423-ecf33cd8499a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PVI5M0M1GW biolink:treats MONDO:0015909 PMID:41385096 "[{""id"":""uuid:c59ed006-1d72-47ce-a5d8-f4e7fa755c39"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f8c1b4f0-648b-4d2c-8346-4e17ff47979d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Follow-on biologics indicated for mobilization of hematopoietic stem cell to peripheral blood, promotion of increase in neutrophil count at the time of hematopoietic stem cell transplantation, and the treatment of neutropenia caused by cancer chemotherapy, neutropenia which affects the treatment of human immunodeficiency virus (HIV) infection, neutropenia associated with myelodysplastic syndrome, neutropenia associated with aplastic anemia and congenital/idiopathic neutropenia. uuid:2b005334-96fe-4330-b796-d1c6364b301d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PVI5M0M1GW biolink:treats MONDO:0015134 PMID:41385096 "[{""id"":""uuid:b206cb4f-db77-4ee7-8741-c3e073ef7fc3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b3ee8f42-8489-4287-948c-bf613166d8ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Follow-on biologics indicated for mobilization of hematopoietic stem cell to peripheral blood, promotion of increase in neutrophil count at the time of hematopoietic stem cell transplantation, and the treatment of neutropenia caused by cancer chemotherapy, neutropenia which affects the treatment of human immunodeficiency virus (HIV) infection, neutropenia associated with myelodysplastic syndrome, neutropenia associated with aplastic anemia and congenital/idiopathic neutropenia. uuid:bfd8d6ec-f811-4376-93f7-45ac5f2a75dd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:94435 biolink:treats MONDO:0005754 PMID:41385096 "[{""id"":""uuid:ea2b0b8d-e6e4-4618-a450-c5aff947156f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e1e4bc72-e080-42f2-bda2-9d66d902156e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for use in conjunction with clobazam and sodium valproate as adjunctive therapy of refractory generalized tonic-clonic and clonic seizures in patients with Dravet’s syndrome whose seizures are not adequately controlled with clobazam and sodium valproate. [Orphan drug] uuid:93ed286a-89d6-4ae8-b230-9b2af75699f6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:94435 biolink:treats HP:0020221 PMID:41385096 "[{""id"":""uuid:d228e6d9-8fae-426a-87f6-d36deed01909"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ae97deb6-c4b1-41a3-ab34-3a0dbd159cfc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for use in conjunction with clobazam and sodium valproate as adjunctive therapy of refractory generalized tonic-clonic and clonic seizures in patients with Dravet’s syndrome whose seizures are not adequately controlled with clobazam and sodium valproate. [Orphan drug] uuid:138c211b-7df5-4b12-95c7-8c7c820e245d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135901 biolink:treats MONDO:0020479 PMID:41385096 "[{""id"":""uuid:3a2fa646-bbab-4f9d-ac45-1c0dd08f84be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4c96bbde-1a15-402a-8436-5d86a5a6988a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient for the improvement of hypersecretion of growth hormone and IGF-I (somatomedin-C) and related symptoms in acromegaly and pituitary gigantism (when surgical therapies are not sufficiently effective or are difficult to perform). uuid:dc35c091-227b-4503-b0ca-a3568363211b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3216 biolink:treats MONDO:0005178 PMID:41385096 "[{""id"":""uuid:f95fde10-8b6e-4fb9-a42e-0471aafef13b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b6cca8a7-42dd-41bb-a599-07b1496ea04f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for analgesia of chronic pain associated with osteoarthritis and lumbago which cannot be managed by treatments with non-opioid analgesics. uuid:1b4cd436-e1fc-443d-addf-38079a88b48e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3216 biolink:treats HP:0003419 PMID:41385096 "[{""id"":""uuid:fb216bf3-0ce6-48eb-bbad-345859b4eab9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b5d336d2-3af4-46fd-a058-ac8f49e87d88"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for analgesia of chronic pain associated with osteoarthritis and lumbago which cannot be managed by treatments with non-opioid analgesics. uuid:00a81378-56e3-4878-8c88-56fd75d67394 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:61049 biolink:treats MONDO:0013730 PMID:41385096 "[{""id"":""uuid:c73e04d2-0525-45a2-83de-ab0419e6eade"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c385ecbd-34d2-4cd9-a47d-ace32d454ecc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs in a new dosage form indicated for suppression of organ rejection in renal, liver, heart, lung, and pancreatic transplantation, as well as for suppression of graft rejection and graft versus host disease (GVHD) in bone marrow transplantation. uuid:f7ee0adb-6aea-42eb-9d48-d6483b1aeccc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134720 biolink:treats NCIT:C143907 PMID:41385096 "[{""id"":""uuid:554a6fd9-67a0-42a4-a44a-7da892215b4a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:cc113dbe-e8c5-4b00-a7c7-e4af807fd848"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs containing a new active ingredient indicated for the treatment of micturition urgency, pollakiuria, and urge incontinence associated with overactive bladder. uuid:6152eb9b-6294-4acb-9f43-f7e943a10e3c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134720 biolink:treats HP:0100515 PMID:41385096 "[{""id"":""uuid:eff2299a-9284-43be-9a73-2c95839e3971"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6320d5d5-46b7-441a-8fdc-73ecb08cf384"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs containing a new active ingredient indicated for the treatment of micturition urgency, pollakiuria, and urge incontinence associated with overactive bladder. uuid:7d3f2d13-3b6b-4575-b45b-10f248329d3e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134720 biolink:treats EFO:0006865 PMID:41385096 "[{""id"":""uuid:b8a1359c-4f80-4388-9a97-c0ebafbb67e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9be8c878-1dca-4752-beab-9b799c06c6da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs containing a new active ingredient indicated for the treatment of micturition urgency, pollakiuria, and urge incontinence associated with overactive bladder. uuid:1a2d192a-e67d-484e-a622-2d39554f57db biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:896228 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:2a5ec795-1ee9-42a5-b6df-6441d42f52b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e42ab130-b71f-4f77-9d65-b709ed08736d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug indicated for the treatment of asthma (in the case where a combination of inhaled corticosteroids and inhaled long-acting β2 agonists is necessary). uuid:f53ad802-9851-4f22-8152-c78013a9fc41 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9123 biolink:treats MONDO:0002050 PMID:41385096 "[{""id"":""uuid:291d3a67-3145-411c-add3-e87b117c0d3c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:505dfd33-552a-4ba4-a5af-06e7a273fcca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs containing a new active ingredient, indicated for depression and panic disorder. uuid:0510f6b9-15c0-4d98-83e3-50ac971ae717 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32151 biolink:treats MONDO:0006624 PMID:41385096 "[{""id"":""uuid:6ab40de3-d043-403a-a9eb-7b0b18d4077b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e12be52f-0c74-4099-ae26-85f9869ba7a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for treatment of urinary urgency, urinary frequency, and urge urinary incontinence associated with overactive bladder. uuid:73bf6e1d-c1cc-442a-8766-063608f5e1e6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:5X3GF74R79 biolink:treats MONDO:0002242 PMID:41385096 "[{""id"":""uuid:f928057a-4552-4f89-9444-bf42d422e210"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3d7d26e3-da69-4016-9af3-c3a3718afd80"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs containing a new active ingredient, indicated for the control of bleeding tendency by supplementing blood coagulation factor VIII in patients with blood coagulation factor VIII deficiency (new product that eliminates the addition of human- and animal-derived components). uuid:e8998025-cd3f-4d20-8f6d-045432364ba8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:37941 biolink:treats MONDO:0005299 PMID:41385096 "[{""id"":""uuid:73b5c906-c0a6-415b-8988-382042a96788"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f66f66fa-176d-4b59-a542-7d1754577edc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs containing a new active ingredient indicated for preventing recurrences of ischemic cerebrovascular diseases (except cardiogenic cerebral infarction) [Prompt review] uuid:d4fd57e2-5825-4395-9850-c526912ecce2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:34825 biolink:treats MONDO:0002041 PMID:41385096 "[{""id"":""uuid:539d40e4-436c-4030-ad01-fb3e700e9c6f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:aa03461a-78de-4cbd-b279-7c810785a47f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs containing a new active ingredient, an imidazole anti-fungal agent uuid:294e7f93-0c18-4d08-bf10-e7dfcedc7a6e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:50605O2ZNS biolink:treats MONDO:0000328 PMID:41385096 "[{""id"":""uuid:7ed0771e-dc41-43d4-82a9-5dc6e99c3474"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:37e1c34f-3a18-41ce-b829-f6a522a70640"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the improvement of hyperphosphatemia in patients with chronic kidney disease on dialysis. uuid:3d862f23-170f-4a02-a9e5-7caeea781171 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:68603V9EAF biolink:treats MONDO:0018660 PMID:41385096 "[{""id"":""uuid:98866ac1-237a-4ffd-9a40-f332f6073e06"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ac8c60b6-600c-4a61-8fbc-ec66fcdcf146"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the control of bleeding tendency in patients with congenital haemophilia who have inhibitors against blood coagulation factor VIII or IX. [Orphan drug] uuid:757409fb-9814-42ef-86f1-5c607bf5a58b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:229223 biolink:treats UMLS:C1142276 PMID:41385096 "[{""id"":""uuid:ac13cdef-8715-437e-82fb-d8612f9d6577"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:963baafa-ce72-4a1a-9285-a80e4a0d2bbf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of renal anemia. uuid:26317387-3e17-4f02-b2d3-b776ecbce0f3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:70735 biolink:treats MONDO:0004985 PMID:41385096 "[{""id"":""uuid:2815aa6b-e343-4663-bfdd-0b4bcac39f00"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6959f787-adc0-4c20-b089-dddcd80307b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of schizophrenia and the improvement of depressive symptoms in patients with bipolar disorder. uuid:213dab37-48b5-4c6b-90eb-c11e2a20835e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:S7LK2KDM5U biolink:treats UMLS:C0458960 PMID:41385096 "[{""id"":""uuid:81a43e7d-ed78-4b7e-8524-2b994f99eacc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2ba92f76-6d6a-4ff3-93cc-11c63c89c9c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of peripheral neuropathic pain. uuid:7e3851e5-7a79-456f-9706-d084861e1eb7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0338204 biolink:treats MONDO:0001056 PMID:41385096 "[{""id"":""uuid:7fe1f3b8-e360-4199-b6da-ad8bf602b49d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b36e0ba4-8d86-4a84-8854-42df1b47c16e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Follow-on biologics indicated for the treatment of unresectable advanced or recurrent gastric cancer with HER2 overexpression. MESH:C000721628 uuid:ee650804-edf3-4e1d-b482-0122a30169de biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0338204 biolink:treats NCIT:C150634 PMID:41385096 "[{""id"":""uuid:b4cff1f1-01a6-4eb6-8336-dbc67f800351"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9c7d0634-6a0f-49b2-b58b-499b72ffeff0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Follow-on biologics indicated for the treatment of unresectable advanced or recurrent gastric cancer with HER2 overexpression. MESH:C000721628 uuid:8ff755ba-dc41-48cb-abcf-adc7f6dba1e8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5134 biolink:treats MONDO:0100470 PMID:41385096 "[{""id"":""uuid:3b3e7d14-e957-4a10-b2b5-b16cd77d57b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4c5514ed-6ecf-4284-afe4-b2379f7419f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage and other characteristics indicated for the treatment of bronchial asthma. uuid:1a9e82c0-5dab-4ccf-a7e5-3690d869d67b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8232 biolink:treats HP:0100806 PMID:41385096 "[{""id"":""uuid:ba82f937-4501-434b-8bec-d5e55bf0d1dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5ca72b1c-4f80-44b9-8291-7d8036933558"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage indicated for the treatment of sepsis, acute bronchitis, pneumonia, lung abscess, thoracic empyema, secondary infection of chronic respiratory disease, cystitis, pyelonephritis, cholecystitis, choledochitis, bartholinitis, intrauterine infection, uterine adnexitis, parametritis, and purulent meningitis. uuid:bd6af33d-4978-471d-88fd-244e737911fe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8232 biolink:treats HP:0012388 PMID:41385096 "[{""id"":""uuid:a5419e51-50d6-4075-a6b9-6ea2d97ab7c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:32d6246a-99d0-4a1e-a223-efe3aba4be70"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage indicated for the treatment of sepsis, acute bronchitis, pneumonia, lung abscess, thoracic empyema, secondary infection of chronic respiratory disease, cystitis, pyelonephritis, cholecystitis, choledochitis, bartholinitis, intrauterine infection, uterine adnexitis, parametritis, and purulent meningitis. uuid:f8549cfc-b30a-4f42-90c7-a5bcb38815d7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8232 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:d7f16bdc-81bb-4c88-a2b5-b31a812fe866"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:60b76041-bcd6-4782-a128-d5e7527226bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage indicated for the treatment of sepsis, acute bronchitis, pneumonia, lung abscess, thoracic empyema, secondary infection of chronic respiratory disease, cystitis, pyelonephritis, cholecystitis, choledochitis, bartholinitis, intrauterine infection, uterine adnexitis, parametritis, and purulent meningitis. uuid:01b5a28d-5b98-4160-ac59-1f184340c339 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8232 biolink:treats MONDO:0000744 PMID:41385096 "[{""id"":""uuid:fca08ecd-4456-4a46-a009-0dfda482b70b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1552edbc-ec3e-4464-ac7a-37c6a0b78b7c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage indicated for the treatment of sepsis, acute bronchitis, pneumonia, lung abscess, thoracic empyema, secondary infection of chronic respiratory disease, cystitis, pyelonephritis, cholecystitis, choledochitis, bartholinitis, intrauterine infection, uterine adnexitis, parametritis, and purulent meningitis. uuid:b945ad23-64cf-45f7-9251-36e3f761f0b1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8232 biolink:treats MONDO:0018667 PMID:41385096 "[{""id"":""uuid:41d6d0de-8094-430e-bab3-c0b50739fa6d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:dc523961-fa69-4978-a645-601df1fab64e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage indicated for the treatment of sepsis, acute bronchitis, pneumonia, lung abscess, thoracic empyema, secondary infection of chronic respiratory disease, cystitis, pyelonephritis, cholecystitis, choledochitis, bartholinitis, intrauterine infection, uterine adnexitis, parametritis, and purulent meningitis. uuid:11bfa551-bbcb-4e0c-b784-d8ae7f39bb23 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8232 biolink:treats MONDO:0006032 PMID:41385096 "[{""id"":""uuid:96e9f4ce-53ca-4509-85d8-5d281abae4f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:521908fc-e706-4e91-8e91-9bc50ebf7c3e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage indicated for the treatment of sepsis, acute bronchitis, pneumonia, lung abscess, thoracic empyema, secondary infection of chronic respiratory disease, cystitis, pyelonephritis, cholecystitis, choledochitis, bartholinitis, intrauterine infection, uterine adnexitis, parametritis, and purulent meningitis. uuid:eeab6350-51f1-4af0-8120-eb339a149ccb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8232 biolink:treats MONDO:0006939 PMID:41385096 "[{""id"":""uuid:95de19fd-cd71-4348-beb7-12da41a4689a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d37627cd-a05f-43a9-92e8-82cba7a488bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage indicated for the treatment of sepsis, acute bronchitis, pneumonia, lung abscess, thoracic empyema, secondary infection of chronic respiratory disease, cystitis, pyelonephritis, cholecystitis, choledochitis, bartholinitis, intrauterine infection, uterine adnexitis, parametritis, and purulent meningitis. uuid:00521440-d95e-431c-a027-2b7cd87d6796 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8232 biolink:treats MONDO:0002155 PMID:41385096 "[{""id"":""uuid:561a5dc1-3c22-4fc0-8c3c-181e79611070"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:547260bc-418f-4379-ad52-f8e0510e1cef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage indicated for the treatment of sepsis, acute bronchitis, pneumonia, lung abscess, thoracic empyema, secondary infection of chronic respiratory disease, cystitis, pyelonephritis, cholecystitis, choledochitis, bartholinitis, intrauterine infection, uterine adnexitis, parametritis, and purulent meningitis. uuid:6eddfb2d-0970-426e-8474-1c465715abe8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8232 biolink:treats UMLS:C0004769 PMID:41385096 "[{""id"":""uuid:e97e0bff-3368-4980-88c9-64e62e4e91e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d00444b0-8557-497a-a701-426e1f102ba0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage indicated for the treatment of sepsis, acute bronchitis, pneumonia, lung abscess, thoracic empyema, secondary infection of chronic respiratory disease, cystitis, pyelonephritis, cholecystitis, choledochitis, bartholinitis, intrauterine infection, uterine adnexitis, parametritis, and purulent meningitis. uuid:abb6792b-5d3e-4b38-8f71-c21826a6ba12 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8232 biolink:treats UMLS:C1112157 PMID:41385096 "[{""id"":""uuid:255face7-8528-4dd9-8e7d-0f84b6556ae4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:36519de2-6806-4246-9f4c-460a1280bb2d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage indicated for the treatment of sepsis, acute bronchitis, pneumonia, lung abscess, thoracic empyema, secondary infection of chronic respiratory disease, cystitis, pyelonephritis, cholecystitis, choledochitis, bartholinitis, intrauterine infection, uterine adnexitis, parametritis, and purulent meningitis. uuid:e1103c05-beb7-41d1-a36e-f416de130fa7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8232 biolink:treats UMLS:C0001577 PMID:41385096 "[{""id"":""uuid:6cdcef19-5125-4114-8d48-70b379c5f4a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:916460dd-9925-4445-afad-ec89b18118af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage indicated for the treatment of sepsis, acute bronchitis, pneumonia, lung abscess, thoracic empyema, secondary infection of chronic respiratory disease, cystitis, pyelonephritis, cholecystitis, choledochitis, bartholinitis, intrauterine infection, uterine adnexitis, parametritis, and purulent meningitis. uuid:046aad2a-26a4-4934-8715-f5ea7cc58898 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8232 biolink:treats UMLS:C0865440 PMID:41385096 "[{""id"":""uuid:777740c8-df22-42ba-a5ec-b899452594ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:168189bd-4a4b-4bff-bbae-e0c2c7b4fc24"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage indicated for the treatment of sepsis, acute bronchitis, pneumonia, lung abscess, thoracic empyema, secondary infection of chronic respiratory disease, cystitis, pyelonephritis, cholecystitis, choledochitis, bartholinitis, intrauterine infection, uterine adnexitis, parametritis, and purulent meningitis. uuid:769b5c26-017f-4ac4-bb1b-37256fb8e2fa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:73357808 biolink:treats MONDO:0100470 PMID:41385096 "[{""id"":""uuid:81703983-e0b2-400b-b4d5-4fae9317d046"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c28ea6f6-f98e-4e06-890c-ed7846e38442"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] New combination drugs indicated for the treatment of bronchial asthma (when a combination treatment of an inhaled steroid and a long-acting beta-2 agonist is needed). uuid:e4903aef-5fe2-4273-9c88-ce6afcdc0ad0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1648788 biolink:treats MONDO:0100470 PMID:41385096 "[{""id"":""uuid:79be5604-9c15-4797-9f97-42cfdbf15e68"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:94e6c3c9-2771-46cb-8199-041f07c39b7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] New combination drugs with a new active ingredient indicated for the treatment of bronchial asthma (when a combination treatment of an inhaled steroid and a long-acting beta-2 agonist is needed). uuid:34853cb0-1c72-4078-813f-d7784e7244ee biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:61390 biolink:treats UMLS:C3266992 PMID:41385096 "[{""id"":""uuid:843f13e6-dbf0-49e1-9818-5c84a11b2a76"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:41ab9e6d-2209-41d5-bf09-81e2cf9fc0b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of unresectable advanced or recurrent non-small cell lung cancer with EGFR gene mutation. uuid:ae5ca4e2-4757-4df2-b59e-d984f50ab3e7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:404914 biolink:treats HP:0001681 PMID:41385096 "[{""id"":""uuid:c074401e-cb4d-4168-9c27-d9525c83ec16"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b916395f-04f0-4917-822a-1132c66d4ae0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] New combination drugs indicated for the treatment of comorbidity of hypertension or angina pectoris and hypercholesterolemia or familial hypercholesterolemia. uuid:c1e56baf-fb15-4551-8b9d-8688c87ab16c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:404914 biolink:treats MONDO:0005439 PMID:41385096 "[{""id"":""uuid:5a9f59b6-9fce-49b1-9fd4-c56b6e664bc2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:bde6f0c4-dc4b-48a4-8ddd-dff4128dd84c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] New combination drugs indicated for the treatment of comorbidity of hypertension or angina pectoris and hypercholesterolemia or familial hypercholesterolemia. uuid:ff1f9df8-c9e7-459e-be4f-55a0fa92e7db biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6367 biolink:treats HP:0002197 PMID:41385096 "[{""id"":""uuid:57669e7a-0362-430f-bb02-362f10f4c3b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:bbd8f3fc-a754-4c3c-83a2-8aefb1f00113"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs containing a new active ingredient indicated for use as adjunctive treatment with other antiepileptic drugs for partial seizures (including secondary generalized seizures), tonic-clonic seizures, and generalized seizures associated with Lennox-Gastaut syndrome in patients with epilepsy for whom other antiepileptic drugs are not sufficiently effective. uuid:75e616da-8a0e-40f9-85a9-3cc27b82b9e6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:42797 biolink:treats HP:0007334 PMID:41385096 "[{""id"":""uuid:71ecfba3-aee1-4925-a3dd-a2251d18a9dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ac7e4dc0-7d11-4161-8c1b-8eaae67c02d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs containing a new active ingredient indicated for use as adjunctive therapy with other antiepileptic drugs to treat partial seizures (including secondarily generalized seizure) in patients with epilepsy, to whom other antiepileptic therapies are not sufficiently effective. uuid:faac43d4-f9ce-4d88-907b-e4be90335a26 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:167574 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:4010220b-8811-4117-8e1a-081fcb0c943e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5d87960d-67a7-4eba-99e9-afd08650ea0e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication, a new dosage and other characteristics for the treatment of obesity. Drugs with a new indication and a new dosage in an additional dosage form for the treatment of obesity. For use only in patients with any of hypertension, hyperlipidemia or type 2 diabetes mellitus who have not responded sufficiently to diet therapy and exercise therapy, and meet the following conditions: BMI of 27 kg/m2 or greater in the presence of at least two obesity-related comorbidities or BMI of 35 kg/m2 or greater uuid:df1c066d-cdf3-42de-ac82-bd1807be8e55 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:9JH486CZ13 biolink:treats UMLS:C1142276 PMID:41385096 "[{""id"":""uuid:610db325-d6ba-4e9f-a16d-74a194cb23de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:95e41532-9e5c-43eb-95e1-aa6422ba195f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of renal anemia. uuid:a8bcb4b5-7112-4fc8-aa3f-5d952678b8d5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:0J877412JV biolink:treats MONDO:0005393 PMID:41385096 "[{""id"":""uuid:1ea0c941-2373-4561-8ee0-cdfe5fae9289"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0c47abc7-9b55-4596-bd46-f9bcc4aefbc2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of gout and hyperuricemia. uuid:2d2ccd52-aa40-45cc-850d-a4c4e1def6cf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:0J877412JV biolink:treats HP:0002149 PMID:41385096 "[{""id"":""uuid:d32d3430-31ba-4829-b096-c71fe3b8fd46"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:802e3ed6-25c9-4b32-a4e2-46a5b73c9879"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of gout and hyperuricemia. uuid:ee3bb0b8-76d4-4f9f-8c23-3cc42a736b2d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6149 biolink:treats NCIT:C34887 PMID:41385096 "[{""id"":""uuid:6ca9cbd4-b1f9-4553-a63f-0f856b7256d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f505b9aa-d47a-42d0-b1ab-173c5b8d7bd4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs containing a new active ingredient. The 0.25% formulation is indicated for postoperative analgesia, and the 0.75% formulation is indicated for epidural anaesthesia. uuid:ef43bf55-c3a2-434a-96de-b90183bdcddc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:53444 biolink:treats MONDO:0006525 PMID:41385096 "[{""id"":""uuid:87dc6a2b-0c2a-49aa-9b0f-44e77f8ff4b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:eafaf536-138d-4674-ba16-985435a2feaf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs indicated for use in patch tests to identify allergens in patients with allergic dermatitis. uuid:5f927f29-93a5-421c-a640-02accd2cc96c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:138404169 biolink:treats MONDO:0006964 PMID:41385096 "[{""id"":""uuid:43898e61-7ec5-47e9-a5e6-145fbb985a8c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:df5ca570-4344-4a02-923f-051d7f9e6d59"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of secondary hyperparathyroidism in patients on hemodialysis. uuid:c883a6be-4ea0-4485-b3c5-6b3c00052f3d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:U50VWW6XH6 biolink:treats MONDO:0010602 PMID:41385096 "[{""id"":""uuid:1f88fbfa-9f42-4fff-a0c6-c8ef71b66fc0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:eae5bb45-0a4e-42c9-8a21-0ea26574da41"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the control of bleeding tendency in patients with blood coagulation factor VIII deficiency. uuid:94375bec-17d9-440c-b6e0-bbcdd23c0296 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0357131 biolink:treats UMLS:C1142276 PMID:41385096 "[{""id"":""uuid:82a2259b-fb1b-492c-86e4-08d28d9b13db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3f0a4ad0-5abb-4635-a1af-664ce369c62b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of renal anemia. DRUGBANK:DB19434 uuid:4c77a730-0e1c-42ae-b982-b8b890ad7d9d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1945037 biolink:treats MONDO:0100470 PMID:41385096 "[{""id"":""uuid:57652be6-7601-41e8-a225-e2b2f26d9e61"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:68c38ca8-b056-4fe3-bad2-8d638a684fc8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] , (2) New combination drugs indicated for the treatment of bronchial asthma (when a combination treatment of an inhaled steroid, a long-acting inhaled anticholinergic agent and a long-acting beta-2 agonist is needed). (3), (4) Drugs with a new indication and a new dosage for the treatment of bronchial asthma (when a combination treatment of an inhaled steroid, a long- acting inhaled anticholinergic agent and a long-acting beta-2 agonist is needed). uuid:953385e8-1f39-4a9b-bbb5-816b1e9fd144 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31941 biolink:treats MONDO:0001462 PMID:41385096 "[{""id"":""uuid:c95c93de-4c98-4194-8e5d-e832425ffd44"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:07146d66-30a3-4282-a3dd-5bb407405df4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage in an additional dosage form (Elplat I.V. Infusion Solution 50 mg and Elplat I.V. Infusion Solution 100 mg) for post-operative adjuvant chemotherapy for colon cancer. [Priority review] uuid:dd189f52-e1dd-424e-a64e-8ca8c5f21d4e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68579 biolink:treats HP:0004831 PMID:41385096 "[{""id"":""uuid:f6af7a01-777f-4082-94c3-ca6af0fbca0d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b5f99c02-1243-4ee6-b0fa-d3bae54e7c4c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs ([1-8]) with a new indication and a new additional pediatric dosage for the treatment and prevention of recurrent venous thromboembolism. In addition, drugs ([1, 2]) are in an additional dosage form. uuid:49c63c04-fbf1-4e20-94ab-5ee97cf11cea biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:G9WJT6RD29 biolink:treats MONDO:0024300 PMID:41385096 "[{""id"":""uuid:1eb6ba2e-a472-407e-8240-1f24f83eca84"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f1ad3667-8866-4ab7-8b75-2421ac978251"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of FGF23-related hypophosphatemic rickets/osteomalacia. [Orphan drug] uuid:fb3c54b4-a955-4ab0-8011-0e6ccbf38545 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:FU77B4U5Z0 biolink:treats UMLS:C0852922 PMID:41385096 "[{""id"":""uuid:9c7671a8-6f4b-4a2e-b024-40d2a5ef40b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9c2160b4-699f-4e4c-b144-27854c25c121"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new route of administration indicated for the induction therapy for moderate to severe active Crohn's disease (for use only in patients who have not sufficiently responded to conventional treatments). A drug with a new indication and a new dosage for the maintenance therapy for moderate to severe active Crohn's disease (for use only in patients who have not sufficiently responded to conventional treatments). uuid:6fe54bae-deb2-48c0-a542-fea7ffe3ba6e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8768 biolink:treats MONDO:0001126 PMID:41385096 "[{""id"":""uuid:965fc439-ab6d-4745-ad21-5997e5f0be3c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:275376a9-be9b-46ee-828d-66bb8a0fe358"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and a new dosage in a newly-added dosage form, and a drug with a new additional indication and a new dosage for the prevention of recurrence of gastric ulcer or duodenal ulcer in patients treated with low-dose aspirin. uuid:3b4232f9-3dd7-4c1c-a73a-206d8fa576da biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:I031V2H011 biolink:treats MONDO:0011429 PMID:41385096 "[{""id"":""uuid:5930495f-8a73-406a-a463-3d9a45517d38"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:bc375c22-34f9-4a50-8c32-7194535799e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage in a new dosage form for the treatment of rheumatoid arthritis (including prevention of structural damage of joint) that cannot be treated sufficiently with conventional therapies, active juvenile idiopathic arthritis in multiple joints, and systemic juvenile idiopathic arthritis. [Priority review] [Expedited review] uuid:272512d3-49e4-4330-8d82-24deea463edd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:22145087 biolink:treats UMLS:C0854521 PMID:41385096 "[{""id"":""uuid:0f0417a3-922b-48b6-acf8-1d507c9c6b27"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f2c8a98f-26c5-4759-96d8-323673018fe5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage and a drug in an additional dosage form for the treatment of hypozincemia. uuid:fd102960-852e-4c51-9fe3-a44363d2c6cf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3127 biolink:treats MONDO:0004981 PMID:41385096 "[{""id"":""uuid:5c6e0210-0943-41b5-9acf-a1b3f3b00a50"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:cbaea818-125c-4a4e-a527-44dcbf8a966b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage in an additional dosage form indicated for the treatment of tachycardiac atrial fibrillation. (2)(3) Drugs with a new additional indication, a new dosage, and other characteristics indicated for the treatment of tachycardiac atrial fibrillation. uuid:19be8ab2-3469-4444-88ed-7aa34c3dce0f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:95021 biolink:treats MONDO:0005112 PMID:41385096 "[{""id"":""uuid:c0281028-7b83-40d5-a047-d5c602f61e69"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b799c728-e233-4108-b15c-1821578781c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Combination therapy with a drug containing a new active ingredient and a drug with a new indication and dosage, for use to treat malignant pleural mesothelioma. [Priority Review] [Expedited Review] uuid:729fa29f-cdfa-4aef-bbb6-4d5079591ee8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85978 biolink:treats MONDO:0005657 PMID:41385096 "[{""id"":""uuid:b441e0e3-d050-4eee-b476-ea5426e1aad8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3ac7ef39-ca0f-4119-a313-09ceb568b914"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of the following mycoses: Aspergillosis (invasive aspergillosis, chronic progressive pulmonary aspergillosis, simple pulmonary aspergilloma) Mucormycosis Cryptococcosis (pulmonary cryptococcosis, disseminated cryptococcosis [including cryptococcal meningitis]) uuid:093b4cf9-bbc9-4fef-98d1-6b4b7ce5e92d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85978 biolink:treats MONDO:0019136 PMID:41385096 "[{""id"":""uuid:e3783728-9015-4882-928f-0cd3719e7e15"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:26414d94-45a9-460a-9797-4eba07335f69"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of the following mycoses: Aspergillosis (invasive aspergillosis, chronic progressive pulmonary aspergillosis, simple pulmonary aspergilloma) Mucormycosis Cryptococcosis (pulmonary cryptococcosis, disseminated cryptococcosis [including cryptococcal meningitis]) uuid:e7c09bd2-8af2-4ea9-ac65-defa5b120767 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85978 biolink:treats MONDO:0005724 PMID:41385096 "[{""id"":""uuid:2afa77fb-a9ca-4b88-8607-735e735e97a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:67af64b9-8ba3-4dad-8d68-65823de2795a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of the following mycoses: Aspergillosis (invasive aspergillosis, chronic progressive pulmonary aspergillosis, simple pulmonary aspergilloma) Mucormycosis Cryptococcosis (pulmonary cryptococcosis, disseminated cryptococcosis [including cryptococcal meningitis]) uuid:53cada52-9e54-4705-abee-5a53980a422b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85978 biolink:treats MONDO:0005723 PMID:41385096 "[{""id"":""uuid:da7d0bba-5f69-472e-8b48-b7f9b615af21"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:72e5d304-0c01-461b-8e30-6f4d16fc7160"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of the following mycoses: Aspergillosis (invasive aspergillosis, chronic progressive pulmonary aspergillosis, simple pulmonary aspergilloma) Mucormycosis Cryptococcosis (pulmonary cryptococcosis, disseminated cryptococcosis [including cryptococcal meningitis]) uuid:3deabbbd-4274-44b4-aa19-f536358a2017 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:I60W9520VV biolink:treats UMLS:C1142276 PMID:41385096 "[{""id"":""uuid:7364acb6-eea4-4d72-9ede-a7c82ed7db29"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5684d92b-9c3a-4c6f-857d-4cc02c843897"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of renal anemia. uuid:b3c78c4f-1b6d-4127-b157-50389a9092b2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:Z7G02XZ0M6 biolink:treats MONDO:0000450 PMID:41385096 "[{""id"":""uuid:f3c304e1-cd2d-41cf-9174-2ed266728db9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8ada3d8b-dff3-48dc-b3ce-11f82f32d3c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the prevention of relapse and for delaying the accumulation of physical disability in secondary progressive multiple sclerosis (SPMS). [Orphan drug] uuid:2d7d38c2-ea7c-46dd-9a4d-2d996951f613 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:Z7G02XZ0M6 biolink:treats MONDO:0005301 PMID:41385096 "[{""id"":""uuid:023e44fe-2767-4789-b0a1-fc46de0516b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6fcca2f0-4984-4fb7-8eed-865e34b0fd5f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the prevention of relapse and for delaying the accumulation of physical disability in secondary progressive multiple sclerosis (SPMS). [Orphan drug] uuid:2107f1c0-d730-426d-8f3c-07eb5552a25e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6970 biolink:treats MONDO:0100470 PMID:41385096 "[{""id"":""uuid:18bb8b49-fa0f-4604-8279-f76a34e75eb4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:efacee91-eae5-4929-9f5f-4bb491d89220"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new route of administration indicated for the treatment of bronchial asthma. uuid:b3c78b1e-37a6-4831-afba-28a075e5268f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:200284 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:b3509ebd-1bc0-45e2-80ab-953632b43690"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c942eb0d-254c-4bbe-9df1-0835c101953b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] New combination drugs indicated for the treatment of hypertension. uuid:1000bda7-3875-4d48-934d-8d0eb55f888f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:I031V2H011 biolink:treats MONDO:0015564 PMID:41385096 "[{""id"":""uuid:565df0e7-6f6b-4810-85dc-e8e702e21683"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3ca244ce-d489-43cd-be0a-727c3e03aaea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs containing a new active ingredient indicated for improving various symptoms and laboratory findings associated with Castleman’s disease for which lymphadenectomy is not indicated. [Orphan drug] uuid:13c99a6c-5d2d-4da8-9e5b-796cb7da8628 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:231344 biolink:treats MONDO:0004956 PMID:41385096 "[{""id"":""uuid:9dcd3a0e-1eec-4e9b-8213-4d589f034dfa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2cc27f34-75c2-475c-91db-8d1cc76d52f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of BRCA mutation-positive, metastatic castration-resistant prostate cancer. A drug with a new active ingredient indicated for the treatment of BRCA mutation-positive, metastatic castration-resistant prostate cancer and unresectable or recurrent BRCA mutation-positive and HER2-negative breast cancer in patients who have previously been treated with chemotherapy. A drug with a new active ingredient indicated for the treatment of unresectable or recurrent BRCA mutation-positive and HER2-negative breast cancer in patients who have previously been treated with chemotherapy. uuid:b5c68105-cbfb-423b-91ed-b9656f5c41c6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7824 biolink:treats HP:0007334 PMID:41385096 "[{""id"":""uuid:93252c93-b900-4a3f-b523-7c7529d8ea02"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:07a72e83-5911-4316-a0d6-63d4352faa99"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the use as an adjunctive therapy with other antiepileptic drugs to treat partial seizures (including secondary generalized seizures) in patients with epilepsy who have not responded sufficiently to other antiepileptic drugs. uuid:5ffb2ee6-9e86-42b5-98ba-b11492067e7a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PP0SHH6V16 biolink:treats MONDO:0005439 PMID:41385096 "[{""id"":""uuid:df3a82ce-c313-47d0-8010-4241b5321f77"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f61247a9-d705-406a-a10e-0cfad87b7bac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of familial hypercholesteremia and hypercholesterolemia (for use only in patients who are at higher risk of developing cardiovascular event and have not responded sufficiently to HMG- CoA reductase inhibitors). uuid:bd749606-1144-40ba-b845-a805463218f1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PP0SHH6V16 biolink:treats HP:0003124 PMID:41385096 "[{""id"":""uuid:678fcce8-6c70-46b6-9ba7-53460921c765"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:72a96918-f106-4c5d-8b13-6e503f169c77"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of familial hypercholesteremia and hypercholesterolemia (for use only in patients who are at higher risk of developing cardiovascular event and have not responded sufficiently to HMG- CoA reductase inhibitors). uuid:3099c2ac-7662-4ef0-9528-9bf2c1fe57a8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:FYS6T7F842 biolink:treats MONDO:0006806 PMID:41385096 "[{""id"":""uuid:d90de3d2-5408-4f15-a8e0-dfac837bac9d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a178d9ad-269e-4131-9444-0440482e3bb3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Biosimilars indicated for the treatment of rheumatoid arthritis (including the prevention of structural joint damage), and the treatment of the following diseases in patients who have not sufficiently responded to conventional treatments: polyarticular-course juvenile idiopathic arthritis, plaque psoriasis, psoriatic arthritis, pustular psoriasis, ankylosing spondylitis, intestinal Behcet’ s disease, non-infectious intermediate uveitis, posterior uveitis, and panuveitis; the remission induction therapy and maintenance therapy for moderate to severe active Crohn's disease (for use only in patients who have not sufficiently responded to conventional therapies), and the treatment of moderate or severe ulcerative colitis (for use only in patients who have not sufficiently responded to conventional treatments). uuid:e643d85f-f94e-4cc5-9e6f-e9d950a02369 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:FYS6T7F842 biolink:treats MONDO:0006918 PMID:41385096 "[{""id"":""uuid:1b112638-9b4c-4e2f-9c4b-02771d016ccb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:62d413ab-9801-4fd8-917a-d9e974a9a3da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Biosimilars indicated for the treatment of rheumatoid arthritis (including the prevention of structural joint damage), and the treatment of the following diseases in patients who have not sufficiently responded to conventional treatments: polyarticular-course juvenile idiopathic arthritis, plaque psoriasis, psoriatic arthritis, pustular psoriasis, ankylosing spondylitis, intestinal Behcet’ s disease, non-infectious intermediate uveitis, posterior uveitis, and panuveitis; the remission induction therapy and maintenance therapy for moderate to severe active Crohn's disease (for use only in patients who have not sufficiently responded to conventional therapies), and the treatment of moderate or severe ulcerative colitis (for use only in patients who have not sufficiently responded to conventional treatments). uuid:ba687118-f7b2-47b6-b6e1-5dfe418dbc9c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:FYS6T7F842 biolink:treats MONDO:0017255 PMID:41385096 "[{""id"":""uuid:ed4968e0-6a92-4b0e-b1ec-a3294501a19e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d7d47a0f-1aba-448a-a185-93375fab8203"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Biosimilars indicated for the treatment of rheumatoid arthritis (including the prevention of structural joint damage), and the treatment of the following diseases in patients who have not sufficiently responded to conventional treatments: polyarticular-course juvenile idiopathic arthritis, plaque psoriasis, psoriatic arthritis, pustular psoriasis, ankylosing spondylitis, intestinal Behcet’ s disease, non-infectious intermediate uveitis, posterior uveitis, and panuveitis; the remission induction therapy and maintenance therapy for moderate to severe active Crohn's disease (for use only in patients who have not sufficiently responded to conventional therapies), and the treatment of moderate or severe ulcerative colitis (for use only in patients who have not sufficiently responded to conventional treatments). uuid:ac68545b-8ccc-492f-8431-e5d96852c758 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9168 biolink:treats MONDO:0002013 PMID:41385096 "[{""id"":""uuid:63a4b286-227f-435d-845c-1ff987ecebf9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5f5316a4-9cfc-457b-b989-7107cb44dccf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] (1) A drug with a new indication and a new dosage in an additional dosage form and (2) a drug with a new indication and a new dosage, for the treatment of the following refractory vascular tumors and refractory vascular malformations: lymphangioma (lymphatic malformation), lymphangiomatosis, Gorham disease, lymphangiectasia, hemangioendothelioma, tufted angioma, venous malformation, blue rubber bleb nevus syndrome, mixed vascular malformation and Klippel-Trenaunay-Weber syndrome. [Orphan drug] uuid:b88dcd5c-0f09-4c4e-863e-c7e78d982645 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9168 biolink:treats UMLS:C0334102 PMID:41385096 "[{""id"":""uuid:d7ebed84-d3be-4a4f-9805-4a554c11eb17"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:574e91e2-8ed3-485f-9115-5bcb74f7eaab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] (1) A drug with a new indication and a new dosage in an additional dosage form and (2) a drug with a new indication and a new dosage, for the treatment of the following refractory vascular tumors and refractory vascular malformations: lymphangioma (lymphatic malformation), lymphangiomatosis, Gorham disease, lymphangiectasia, hemangioendothelioma, tufted angioma, venous malformation, blue rubber bleb nevus syndrome, mixed vascular malformation and Klippel-Trenaunay-Weber syndrome. [Orphan drug] uuid:10874f7d-5aa4-4f54-8034-56597756cb34 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9168 biolink:treats MONDO:0007414 PMID:41385096 "[{""id"":""uuid:5f0eeff7-2737-4aff-ae55-40d03d2ee5ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9ea97a90-b2bf-48aa-b518-0c2e885e30be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] (1) A drug with a new indication and a new dosage in an additional dosage form and (2) a drug with a new indication and a new dosage, for the treatment of the following refractory vascular tumors and refractory vascular malformations: lymphangioma (lymphatic malformation), lymphangiomatosis, Gorham disease, lymphangiectasia, hemangioendothelioma, tufted angioma, venous malformation, blue rubber bleb nevus syndrome, mixed vascular malformation and Klippel-Trenaunay-Weber syndrome. [Orphan drug] uuid:9f4510a2-99de-49cf-8ebd-f1020bdc72c4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9168 biolink:treats MONDO:0006840 PMID:41385096 "[{""id"":""uuid:cc59acfb-ea38-4be8-b9e7-7e271e0903e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3b72acef-f7db-4837-96bc-9e6f25470c20"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] (1) A drug with a new indication and a new dosage in an additional dosage form and (2) a drug with a new indication and a new dosage, for the treatment of the following refractory vascular tumors and refractory vascular malformations: lymphangioma (lymphatic malformation), lymphangiomatosis, Gorham disease, lymphangiectasia, hemangioendothelioma, tufted angioma, venous malformation, blue rubber bleb nevus syndrome, mixed vascular malformation and Klippel-Trenaunay-Weber syndrome. [Orphan drug] uuid:7ebd5dfa-1c88-410b-9c97-490fd837b320 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9168 biolink:treats MONDO:0021121 PMID:41385096 "[{""id"":""uuid:88c40fb6-bfc4-4a18-af70-033b19b3ad97"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:246a4658-9d5e-4eff-bee0-cd470b7ec1aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] (1) A drug with a new indication and a new dosage in an additional dosage form and (2) a drug with a new indication and a new dosage, for the treatment of the following refractory vascular tumors and refractory vascular malformations: lymphangioma (lymphatic malformation), lymphangiomatosis, Gorham disease, lymphangiectasia, hemangioendothelioma, tufted angioma, venous malformation, blue rubber bleb nevus syndrome, mixed vascular malformation and Klippel-Trenaunay-Weber syndrome. [Orphan drug] uuid:3d3b7718-bff6-445b-a27b-10ce160764c0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9168 biolink:treats MONDO:0011927 PMID:41385096 "[{""id"":""uuid:72170ef5-c6cd-4af8-93c5-fd51dbb64e50"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c5e84881-0e7f-48d6-ac50-3c7fbf224c53"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] (1) A drug with a new indication and a new dosage in an additional dosage form and (2) a drug with a new indication and a new dosage, for the treatment of the following refractory vascular tumors and refractory vascular malformations: lymphangioma (lymphatic malformation), lymphangiomatosis, Gorham disease, lymphangiectasia, hemangioendothelioma, tufted angioma, venous malformation, blue rubber bleb nevus syndrome, mixed vascular malformation and Klippel-Trenaunay-Weber syndrome. [Orphan drug] uuid:779a19d8-ffb0-456e-b40f-65baddfd4738 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9168 biolink:treats HP:0012721 PMID:41385096 "[{""id"":""uuid:38ded2cf-c8e9-4a8f-b645-51343a00714d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6530155b-f059-484f-9edb-091f0855f7c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] (1) A drug with a new indication and a new dosage in an additional dosage form and (2) a drug with a new indication and a new dosage, for the treatment of the following refractory vascular tumors and refractory vascular malformations: lymphangioma (lymphatic malformation), lymphangiomatosis, Gorham disease, lymphangiectasia, hemangioendothelioma, tufted angioma, venous malformation, blue rubber bleb nevus syndrome, mixed vascular malformation and Klippel-Trenaunay-Weber syndrome. [Orphan drug] uuid:01f61a3b-4d18-4985-884d-0f9663f402fe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9168 biolink:treats MONDO:0007203 PMID:41385096 "[{""id"":""uuid:1296c89d-dcfa-41b2-8176-eb2648b55151"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7558bdbf-7c32-4692-b9fc-570f0dff0ef1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] (1) A drug with a new indication and a new dosage in an additional dosage form and (2) a drug with a new indication and a new dosage, for the treatment of the following refractory vascular tumors and refractory vascular malformations: lymphangioma (lymphatic malformation), lymphangiomatosis, Gorham disease, lymphangiectasia, hemangioendothelioma, tufted angioma, venous malformation, blue rubber bleb nevus syndrome, mixed vascular malformation and Klippel-Trenaunay-Weber syndrome. [Orphan drug] OMIM:112200 uuid:b2b5b423-906a-4c27-8208-5a6804bc8bc5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9168 biolink:treats UMLS:C0340845 PMID:41385096 "[{""id"":""uuid:d90fa3fa-1765-4972-8b1b-0749130684e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e0a81c37-742f-4ca1-b521-95a00de3d103"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] (1) A drug with a new indication and a new dosage in an additional dosage form and (2) a drug with a new indication and a new dosage, for the treatment of the following refractory vascular tumors and refractory vascular malformations: lymphangioma (lymphatic malformation), lymphangiomatosis, Gorham disease, lymphangiectasia, hemangioendothelioma, tufted angioma, venous malformation, blue rubber bleb nevus syndrome, mixed vascular malformation and Klippel-Trenaunay-Weber syndrome. [Orphan drug] uuid:92a64e55-82db-4bee-b854-4b09d59928f5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:91083 biolink:treats MONDO:0015909 PMID:41385096 "[{""id"":""uuid:8fd8ded2-bec5-4532-bcd4-b5bce253ba20"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f2f7da81-d617-4bf9-972c-0ac8aa2cde2b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage for the treatment of aplastic anemia. uuid:d3750c34-014b-4475-8a6e-6e2c751d1ec6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:961YV2O515 biolink:treats MONDO:0019098 PMID:41385096 "[{""id"":""uuid:fc6a6535-3381-46dc-a0bd-a6d42df2dfe2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6c9f4520-88cd-4083-b04a-616f96444e25"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage for the treatment of chronic idiopathic thrombocytopenic purpura. [Orphan drug] uuid:3b929f94-aa8b-4b93-a838-3c661386319c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31617 biolink:treats MONDO:0003308 PMID:41385096 "[{""id"":""uuid:44161f38-fa60-4dee-9731-56eef4acf25a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b694b0b2-65b8-4a38-bffa-4329fc31859f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the diagnosis of malignant tumors (pleural mesothelioma, esophageal cancer, gastric cancer, gastrointestinal stromal tumor, hepatic cancer, biliary tract cancer, pancreatic cancer, bladder cancer, renal pelvis/ureter cancer, uterine cancer, ovarian cancer, bone soft tissue tumor, skin cancer [when the diagnosis of disease stage and metastasis/recurrence cannot be confirmed by other tests/imaging diagnosis]; thymic tumor, renal cancer, testicular tumor, thyroid cancer [when the diagnosis of metastasis/recurrence cannot be confirmed by other tests/imaging diagnosis]; visualization of bone lesion or extramedullary lesion in patients suspected of multiple myeloma or with multiple myeloma [when the presence of bone lesion or extramedullary lesion is suspected by other tests/imaging diagnosis]); and the visualization of inflammatory sites in patients suspected of cardiac sarcoidosis or with cardiac sarcoidosis. [Public knowledge-based application] uuid:f5403845-fe8e-4b6a-9c12-f8842c8993f8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31617 biolink:treats MONDO:0007576 PMID:41385096 "[{""id"":""uuid:1a900f23-4cca-4e2a-9ce2-dfed6c05cbdd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:da15cb25-5f81-4530-8443-c17e59b4b51d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the diagnosis of malignant tumors (pleural mesothelioma, esophageal cancer, gastric cancer, gastrointestinal stromal tumor, hepatic cancer, biliary tract cancer, pancreatic cancer, bladder cancer, renal pelvis/ureter cancer, uterine cancer, ovarian cancer, bone soft tissue tumor, skin cancer [when the diagnosis of disease stage and metastasis/recurrence cannot be confirmed by other tests/imaging diagnosis]; thymic tumor, renal cancer, testicular tumor, thyroid cancer [when the diagnosis of metastasis/recurrence cannot be confirmed by other tests/imaging diagnosis]; visualization of bone lesion or extramedullary lesion in patients suspected of multiple myeloma or with multiple myeloma [when the presence of bone lesion or extramedullary lesion is suspected by other tests/imaging diagnosis]); and the visualization of inflammatory sites in patients suspected of cardiac sarcoidosis or with cardiac sarcoidosis. [Public knowledge-based application] uuid:92e387da-4aef-42f9-97f5-c9d257852cb9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31617 biolink:treats MONDO:0001056 PMID:41385096 "[{""id"":""uuid:13540728-25ba-4193-baa7-baa1725bdc18"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9d3ddad1-b171-4d55-898c-8ea5ea7d6ad7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the diagnosis of malignant tumors (pleural mesothelioma, esophageal cancer, gastric cancer, gastrointestinal stromal tumor, hepatic cancer, biliary tract cancer, pancreatic cancer, bladder cancer, renal pelvis/ureter cancer, uterine cancer, ovarian cancer, bone soft tissue tumor, skin cancer [when the diagnosis of disease stage and metastasis/recurrence cannot be confirmed by other tests/imaging diagnosis]; thymic tumor, renal cancer, testicular tumor, thyroid cancer [when the diagnosis of metastasis/recurrence cannot be confirmed by other tests/imaging diagnosis]; visualization of bone lesion or extramedullary lesion in patients suspected of multiple myeloma or with multiple myeloma [when the presence of bone lesion or extramedullary lesion is suspected by other tests/imaging diagnosis]); and the visualization of inflammatory sites in patients suspected of cardiac sarcoidosis or with cardiac sarcoidosis. [Public knowledge-based application] uuid:61adae89-0c2d-432e-9f75-d926474b92f8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31617 biolink:treats MONDO:0011719 PMID:41385096 "[{""id"":""uuid:a2e865e0-69d6-42e3-a137-2f45929bc0d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b1c809b0-de8f-4d79-8f03-26031ea128b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the diagnosis of malignant tumors (pleural mesothelioma, esophageal cancer, gastric cancer, gastrointestinal stromal tumor, hepatic cancer, biliary tract cancer, pancreatic cancer, bladder cancer, renal pelvis/ureter cancer, uterine cancer, ovarian cancer, bone soft tissue tumor, skin cancer [when the diagnosis of disease stage and metastasis/recurrence cannot be confirmed by other tests/imaging diagnosis]; thymic tumor, renal cancer, testicular tumor, thyroid cancer [when the diagnosis of metastasis/recurrence cannot be confirmed by other tests/imaging diagnosis]; visualization of bone lesion or extramedullary lesion in patients suspected of multiple myeloma or with multiple myeloma [when the presence of bone lesion or extramedullary lesion is suspected by other tests/imaging diagnosis]); and the visualization of inflammatory sites in patients suspected of cardiac sarcoidosis or with cardiac sarcoidosis. [Public knowledge-based application] uuid:65988612-a11b-44b1-89bf-b1ea89930784 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31617 biolink:treats MONDO:0002691 PMID:41385096 "[{""id"":""uuid:97306f07-c83e-4699-806e-b49390baa06e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4ab07780-a1ee-408c-858d-b9c7b52ca79a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the diagnosis of malignant tumors (pleural mesothelioma, esophageal cancer, gastric cancer, gastrointestinal stromal tumor, hepatic cancer, biliary tract cancer, pancreatic cancer, bladder cancer, renal pelvis/ureter cancer, uterine cancer, ovarian cancer, bone soft tissue tumor, skin cancer [when the diagnosis of disease stage and metastasis/recurrence cannot be confirmed by other tests/imaging diagnosis]; thymic tumor, renal cancer, testicular tumor, thyroid cancer [when the diagnosis of metastasis/recurrence cannot be confirmed by other tests/imaging diagnosis]; visualization of bone lesion or extramedullary lesion in patients suspected of multiple myeloma or with multiple myeloma [when the presence of bone lesion or extramedullary lesion is suspected by other tests/imaging diagnosis]); and the visualization of inflammatory sites in patients suspected of cardiac sarcoidosis or with cardiac sarcoidosis. [Public knowledge-based application] uuid:5198e390-d8ce-4890-bc8d-06abdffc7a7c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31617 biolink:treats MONDO:0003060 PMID:41385096 "[{""id"":""uuid:01817fac-4198-429a-a999-440f02526b20"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d7288379-a7f1-4734-9074-f96efb6d0182"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the diagnosis of malignant tumors (pleural mesothelioma, esophageal cancer, gastric cancer, gastrointestinal stromal tumor, hepatic cancer, biliary tract cancer, pancreatic cancer, bladder cancer, renal pelvis/ureter cancer, uterine cancer, ovarian cancer, bone soft tissue tumor, skin cancer [when the diagnosis of disease stage and metastasis/recurrence cannot be confirmed by other tests/imaging diagnosis]; thymic tumor, renal cancer, testicular tumor, thyroid cancer [when the diagnosis of metastasis/recurrence cannot be confirmed by other tests/imaging diagnosis]; visualization of bone lesion or extramedullary lesion in patients suspected of multiple myeloma or with multiple myeloma [when the presence of bone lesion or extramedullary lesion is suspected by other tests/imaging diagnosis]); and the visualization of inflammatory sites in patients suspected of cardiac sarcoidosis or with cardiac sarcoidosis. [Public knowledge-based application] uuid:dd2ff531-30d3-4ee8-b9fd-efcf84aafa57 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31617 biolink:treats MONDO:0009831 PMID:41385096 "[{""id"":""uuid:b5286e34-f032-4456-ada4-6c6de303d97a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7f4727a0-7e4c-4b9e-9a88-9d521839c88a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the diagnosis of malignant tumors (pleural mesothelioma, esophageal cancer, gastric cancer, gastrointestinal stromal tumor, hepatic cancer, biliary tract cancer, pancreatic cancer, bladder cancer, renal pelvis/ureter cancer, uterine cancer, ovarian cancer, bone soft tissue tumor, skin cancer [when the diagnosis of disease stage and metastasis/recurrence cannot be confirmed by other tests/imaging diagnosis]; thymic tumor, renal cancer, testicular tumor, thyroid cancer [when the diagnosis of metastasis/recurrence cannot be confirmed by other tests/imaging diagnosis]; visualization of bone lesion or extramedullary lesion in patients suspected of multiple myeloma or with multiple myeloma [when the presence of bone lesion or extramedullary lesion is suspected by other tests/imaging diagnosis]); and the visualization of inflammatory sites in patients suspected of cardiac sarcoidosis or with cardiac sarcoidosis. [Public knowledge-based application] uuid:c4f03ec6-d76d-42a7-8f5b-73c8e81dfcaf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31617 biolink:treats MONDO:0001187 PMID:41385096 "[{""id"":""uuid:0b543e8a-28f0-4b53-bf15-ac22f3040f8c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ccd8b453-9a69-4b0f-9ba7-e4c319e97f15"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the diagnosis of malignant tumors (pleural mesothelioma, esophageal cancer, gastric cancer, gastrointestinal stromal tumor, hepatic cancer, biliary tract cancer, pancreatic cancer, bladder cancer, renal pelvis/ureter cancer, uterine cancer, ovarian cancer, bone soft tissue tumor, skin cancer [when the diagnosis of disease stage and metastasis/recurrence cannot be confirmed by other tests/imaging diagnosis]; thymic tumor, renal cancer, testicular tumor, thyroid cancer [when the diagnosis of metastasis/recurrence cannot be confirmed by other tests/imaging diagnosis]; visualization of bone lesion or extramedullary lesion in patients suspected of multiple myeloma or with multiple myeloma [when the presence of bone lesion or extramedullary lesion is suspected by other tests/imaging diagnosis]); and the visualization of inflammatory sites in patients suspected of cardiac sarcoidosis or with cardiac sarcoidosis. [Public knowledge-based application] uuid:fdffb508-498b-452a-b45d-2924e477ca88 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31617 biolink:treats MONDO:0005221 PMID:41385096 "[{""id"":""uuid:c5a74628-5a73-4b70-9f1a-a89dd240c5a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8ea9bcbb-4940-4606-a406-db4261cdf9d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the diagnosis of malignant tumors (pleural mesothelioma, esophageal cancer, gastric cancer, gastrointestinal stromal tumor, hepatic cancer, biliary tract cancer, pancreatic cancer, bladder cancer, renal pelvis/ureter cancer, uterine cancer, ovarian cancer, bone soft tissue tumor, skin cancer [when the diagnosis of disease stage and metastasis/recurrence cannot be confirmed by other tests/imaging diagnosis]; thymic tumor, renal cancer, testicular tumor, thyroid cancer [when the diagnosis of metastasis/recurrence cannot be confirmed by other tests/imaging diagnosis]; visualization of bone lesion or extramedullary lesion in patients suspected of multiple myeloma or with multiple myeloma [when the presence of bone lesion or extramedullary lesion is suspected by other tests/imaging diagnosis]); and the visualization of inflammatory sites in patients suspected of cardiac sarcoidosis or with cardiac sarcoidosis. [Public knowledge-based application] uuid:0b780671-d8d8-4253-be3b-ba117e9ae170 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31617 biolink:treats MONDO:0002715 PMID:41385096 "[{""id"":""uuid:7cad5a9d-2b45-44e2-bcce-92bb9b6822ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9f2e31fc-c5ef-4961-bf0c-4d23221ca5b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the diagnosis of malignant tumors (pleural mesothelioma, esophageal cancer, gastric cancer, gastrointestinal stromal tumor, hepatic cancer, biliary tract cancer, pancreatic cancer, bladder cancer, renal pelvis/ureter cancer, uterine cancer, ovarian cancer, bone soft tissue tumor, skin cancer [when the diagnosis of disease stage and metastasis/recurrence cannot be confirmed by other tests/imaging diagnosis]; thymic tumor, renal cancer, testicular tumor, thyroid cancer [when the diagnosis of metastasis/recurrence cannot be confirmed by other tests/imaging diagnosis]; visualization of bone lesion or extramedullary lesion in patients suspected of multiple myeloma or with multiple myeloma [when the presence of bone lesion or extramedullary lesion is suspected by other tests/imaging diagnosis]); and the visualization of inflammatory sites in patients suspected of cardiac sarcoidosis or with cardiac sarcoidosis. [Public knowledge-based application] uuid:6087e61b-65ee-4f4f-a047-7286c7e66507 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31617 biolink:treats MONDO:0008170 PMID:41385096 "[{""id"":""uuid:ef197766-ba51-4c59-93b2-beefec8b23a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a1a5cb92-003b-4d6b-922f-a4a7b913cea7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the diagnosis of malignant tumors (pleural mesothelioma, esophageal cancer, gastric cancer, gastrointestinal stromal tumor, hepatic cancer, biliary tract cancer, pancreatic cancer, bladder cancer, renal pelvis/ureter cancer, uterine cancer, ovarian cancer, bone soft tissue tumor, skin cancer [when the diagnosis of disease stage and metastasis/recurrence cannot be confirmed by other tests/imaging diagnosis]; thymic tumor, renal cancer, testicular tumor, thyroid cancer [when the diagnosis of metastasis/recurrence cannot be confirmed by other tests/imaging diagnosis]; visualization of bone lesion or extramedullary lesion in patients suspected of multiple myeloma or with multiple myeloma [when the presence of bone lesion or extramedullary lesion is suspected by other tests/imaging diagnosis]); and the visualization of inflammatory sites in patients suspected of cardiac sarcoidosis or with cardiac sarcoidosis. [Public knowledge-based application] uuid:585e5dea-c201-421a-8a02-2fce8b5ce222 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31617 biolink:treats MONDO:0002898 PMID:41385096 "[{""id"":""uuid:29754c32-96bd-419e-b358-37dab6a9ac68"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2f88390f-9e38-4513-a317-2181c88afe6b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the diagnosis of malignant tumors (pleural mesothelioma, esophageal cancer, gastric cancer, gastrointestinal stromal tumor, hepatic cancer, biliary tract cancer, pancreatic cancer, bladder cancer, renal pelvis/ureter cancer, uterine cancer, ovarian cancer, bone soft tissue tumor, skin cancer [when the diagnosis of disease stage and metastasis/recurrence cannot be confirmed by other tests/imaging diagnosis]; thymic tumor, renal cancer, testicular tumor, thyroid cancer [when the diagnosis of metastasis/recurrence cannot be confirmed by other tests/imaging diagnosis]; visualization of bone lesion or extramedullary lesion in patients suspected of multiple myeloma or with multiple myeloma [when the presence of bone lesion or extramedullary lesion is suspected by other tests/imaging diagnosis]); and the visualization of inflammatory sites in patients suspected of cardiac sarcoidosis or with cardiac sarcoidosis. [Public knowledge-based application] uuid:3b80cd8e-6984-44e3-b29d-962a73281039 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31617 biolink:treats MONDO:0005197 PMID:41385096 "[{""id"":""uuid:ed8e1838-27af-44ac-9983-117018c2c740"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5ba890b6-98d5-40b8-9303-c3174d8813dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the diagnosis of malignant tumors (pleural mesothelioma, esophageal cancer, gastric cancer, gastrointestinal stromal tumor, hepatic cancer, biliary tract cancer, pancreatic cancer, bladder cancer, renal pelvis/ureter cancer, uterine cancer, ovarian cancer, bone soft tissue tumor, skin cancer [when the diagnosis of disease stage and metastasis/recurrence cannot be confirmed by other tests/imaging diagnosis]; thymic tumor, renal cancer, testicular tumor, thyroid cancer [when the diagnosis of metastasis/recurrence cannot be confirmed by other tests/imaging diagnosis]; visualization of bone lesion or extramedullary lesion in patients suspected of multiple myeloma or with multiple myeloma [when the presence of bone lesion or extramedullary lesion is suspected by other tests/imaging diagnosis]); and the visualization of inflammatory sites in patients suspected of cardiac sarcoidosis or with cardiac sarcoidosis. [Public knowledge-based application] uuid:88767991-7e47-4eff-ad24-45b674f141b3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31617 biolink:treats MONDO:0005206 PMID:41385096 "[{""id"":""uuid:559b8154-73f6-490d-bbdf-71a93e279422"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:074b7683-c36a-40c0-94ef-2a46decbde67"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the diagnosis of malignant tumors (pleural mesothelioma, esophageal cancer, gastric cancer, gastrointestinal stromal tumor, hepatic cancer, biliary tract cancer, pancreatic cancer, bladder cancer, renal pelvis/ureter cancer, uterine cancer, ovarian cancer, bone soft tissue tumor, skin cancer [when the diagnosis of disease stage and metastasis/recurrence cannot be confirmed by other tests/imaging diagnosis]; thymic tumor, renal cancer, testicular tumor, thyroid cancer [when the diagnosis of metastasis/recurrence cannot be confirmed by other tests/imaging diagnosis]; visualization of bone lesion or extramedullary lesion in patients suspected of multiple myeloma or with multiple myeloma [when the presence of bone lesion or extramedullary lesion is suspected by other tests/imaging diagnosis]); and the visualization of inflammatory sites in patients suspected of cardiac sarcoidosis or with cardiac sarcoidosis. [Public knowledge-based application] uuid:78c436cc-66e0-4ec6-b42c-9d937fd877e4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31617 biolink:treats MONDO:0021348 PMID:41385096 "[{""id"":""uuid:63648d35-6ee8-4d02-92cd-15d5e0719048"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:48e5f5d4-c826-480d-9f6c-3f6a41b5b772"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the diagnosis of malignant tumors (pleural mesothelioma, esophageal cancer, gastric cancer, gastrointestinal stromal tumor, hepatic cancer, biliary tract cancer, pancreatic cancer, bladder cancer, renal pelvis/ureter cancer, uterine cancer, ovarian cancer, bone soft tissue tumor, skin cancer [when the diagnosis of disease stage and metastasis/recurrence cannot be confirmed by other tests/imaging diagnosis]; thymic tumor, renal cancer, testicular tumor, thyroid cancer [when the diagnosis of metastasis/recurrence cannot be confirmed by other tests/imaging diagnosis]; visualization of bone lesion or extramedullary lesion in patients suspected of multiple myeloma or with multiple myeloma [when the presence of bone lesion or extramedullary lesion is suspected by other tests/imaging diagnosis]); and the visualization of inflammatory sites in patients suspected of cardiac sarcoidosis or with cardiac sarcoidosis. [Public knowledge-based application] uuid:b3fb04b4-8eb9-45ac-9968-ecac97db96f1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31617 biolink:treats MONDO:0002108 PMID:41385096 "[{""id"":""uuid:e0ac81b3-c957-4cce-92fb-5e001a3b3738"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:10ae86d7-1c59-4662-acb2-9e6d2b931654"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the diagnosis of malignant tumors (pleural mesothelioma, esophageal cancer, gastric cancer, gastrointestinal stromal tumor, hepatic cancer, biliary tract cancer, pancreatic cancer, bladder cancer, renal pelvis/ureter cancer, uterine cancer, ovarian cancer, bone soft tissue tumor, skin cancer [when the diagnosis of disease stage and metastasis/recurrence cannot be confirmed by other tests/imaging diagnosis]; thymic tumor, renal cancer, testicular tumor, thyroid cancer [when the diagnosis of metastasis/recurrence cannot be confirmed by other tests/imaging diagnosis]; visualization of bone lesion or extramedullary lesion in patients suspected of multiple myeloma or with multiple myeloma [when the presence of bone lesion or extramedullary lesion is suspected by other tests/imaging diagnosis]); and the visualization of inflammatory sites in patients suspected of cardiac sarcoidosis or with cardiac sarcoidosis. [Public knowledge-based application] uuid:7c5752d1-50ad-4a02-98bb-969062ff0f97 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31617 biolink:treats MONDO:0009693 PMID:41385096 "[{""id"":""uuid:534edc25-a848-4b08-95c1-b0ff0f437180"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5a6fad78-f100-4cca-b799-2c01777307ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the diagnosis of malignant tumors (pleural mesothelioma, esophageal cancer, gastric cancer, gastrointestinal stromal tumor, hepatic cancer, biliary tract cancer, pancreatic cancer, bladder cancer, renal pelvis/ureter cancer, uterine cancer, ovarian cancer, bone soft tissue tumor, skin cancer [when the diagnosis of disease stage and metastasis/recurrence cannot be confirmed by other tests/imaging diagnosis]; thymic tumor, renal cancer, testicular tumor, thyroid cancer [when the diagnosis of metastasis/recurrence cannot be confirmed by other tests/imaging diagnosis]; visualization of bone lesion or extramedullary lesion in patients suspected of multiple myeloma or with multiple myeloma [when the presence of bone lesion or extramedullary lesion is suspected by other tests/imaging diagnosis]); and the visualization of inflammatory sites in patients suspected of cardiac sarcoidosis or with cardiac sarcoidosis. [Public knowledge-based application] uuid:1203ade2-23ee-48c2-a7ee-ecf4d764e613 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31617 biolink:treats MONDO:0001707 PMID:41385096 "[{""id"":""uuid:045d25af-be7b-44b3-9529-73e4b49ced01"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c8c38f93-25be-492b-901b-a3a35fdae5d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the diagnosis of malignant tumors (pleural mesothelioma, esophageal cancer, gastric cancer, gastrointestinal stromal tumor, hepatic cancer, biliary tract cancer, pancreatic cancer, bladder cancer, renal pelvis/ureter cancer, uterine cancer, ovarian cancer, bone soft tissue tumor, skin cancer [when the diagnosis of disease stage and metastasis/recurrence cannot be confirmed by other tests/imaging diagnosis]; thymic tumor, renal cancer, testicular tumor, thyroid cancer [when the diagnosis of metastasis/recurrence cannot be confirmed by other tests/imaging diagnosis]; visualization of bone lesion or extramedullary lesion in patients suspected of multiple myeloma or with multiple myeloma [when the presence of bone lesion or extramedullary lesion is suspected by other tests/imaging diagnosis]); and the visualization of inflammatory sites in patients suspected of cardiac sarcoidosis or with cardiac sarcoidosis. [Public knowledge-based application] uuid:08a23b49-e265-4a4d-8dcd-e3dc43d02eb3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:76611 biolink:treats EFO:0007982 PMID:41385096 "[{""id"":""uuid:22d96e1f-ac4c-4a1f-9d53-3abbadea17bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7d1c561f-dfbb-4c6c-bc3e-09b289e67803"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the visualization of beta‑amyloid plaques in the brain of patients suspected of mild cognitive impairment or dementia due to Alzheimer's disease. [Expedited review] uuid:018262a5-f661-4fa2-bed2-a89d16237f55 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:66880 biolink:treats EFO:0007982 PMID:41385096 "[{""id"":""uuid:9b1a5e81-f847-47c0-aa4e-4117e5e649b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d555a592-cc93-4680-afe8-3dd3ae7070c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the visualization of beta‑amyloid plaques in the brain of patients suspected of mild cognitive impairment or dementia due to Alzheimer's disease. [Expedited review] uuid:74ebe3c9-4ad4-47e6-be5e-cd4e090fb103 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:92769 biolink:treats MONDO:0005180 PMID:41385096 "[{""id"":""uuid:f6513297-6fb1-4a80-b2ef-e58cac8d17d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5aacfdaa-57a1-4c90-89ec-6364f37e0ba8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage for cardiac scintigraphy in the diagnoses of Parkinson's disease and dementia with Lewy bodies. uuid:0ec4b9ae-c208-4bc6-822a-4045e4aa2bd8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:92769 biolink:treats MONDO:0007488 PMID:41385096 "[{""id"":""uuid:8a1d081f-fb63-4f03-8c93-7dcf76a3f451"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0f24a86e-ca66-49f2-aaa9-fd3dc339908d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage for cardiac scintigraphy in the diagnoses of Parkinson's disease and dementia with Lewy bodies. uuid:222cf803-88de-477d-aeb5-0db1d29fc829 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:QC4F7FKK7I biolink:treats MONDO:0003005 PMID:41385096 "[{""id"":""uuid:ad984154-2e94-42e7-a073-510abf21ba83"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:60072e84-6aa9-4613-b2e8-c91a943f7572"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage for the treatment of macular edema following retinal vein occlusion. uuid:f5a97bf3-a5cf-412f-a60c-d1247d56a055 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:QC4F7FKK7I biolink:treats MONDO:0006951 PMID:41385096 "[{""id"":""uuid:10a71621-fac0-472c-bd8f-6d8f5dd8dac3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1f82505b-6358-4cc0-bc3c-9e08129e8d45"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage for the treatment of macular edema following retinal vein occlusion. uuid:847f86e3-cb36-466e-8ed3-4bf08962f2b2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6ZA31Y954Z biolink:treats MONDO:0015597 PMID:41385096 "[{""id"":""uuid:6a04e143-8ebe-477e-b5df-3d4fbd3a8b7f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:96b71990-51a7-45ce-804f-9095150af8b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the treatment of palmoplantar pustulosis in patients who have not responded sufficiently to conventional therapies. uuid:14220b81-1d8f-47f4-8281-f2cb20d570fb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DPT0O3T46P biolink:treats MONDO:0000901 PMID:41385096 "[{""id"":""uuid:c1ca8b4a-aeeb-4aea-81d6-f4a0fef02fe0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8a236df3-6255-42e3-8c0e-fa2319f8f95b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the treatment of relapsed or refractory primary mediastinal large B- cell lymphoma. [Orphan drug] uuid:1525d492-171d-4566-8ef3-6c0f2056cb31 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:73274 biolink:treats MONDO:0005300 PMID:41385096 "[{""id"":""uuid:8b2479e7-8478-47de-b30e-8fcd8379c561"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:01c41ed5-7340-49b2-ae5e-41d8968f83e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the treatment of chronic kidney disease associated with type 2 diabetes mellitus (excluding patients who have end-stage renal failure or are undergoing dialysis). uuid:73a9ce48-2248-4517-be46-4192595b3d81 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31527 biolink:treats MONDO:0005047 PMID:41385096 "[{""id"":""uuid:5fedb801-a4ad-4723-a4c6-d23349c17be9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7780d491-05ad-4217-b1d0-a2765c75f59e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage indicated for luteal support as part of assisted reproductive technology for infertile women. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:c9076da4-7f4a-4319-934e-39c0082a8a02 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3286 biolink:treats MONDO:0011972 PMID:41385096 "[{""id"":""uuid:9a0a13a8-0f5d-4a3d-8659-22385d43221e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ee322330-0d98-4a00-8a8b-587248324303"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage for the prevention of ovarian hyperstimulation syndrome associated with assisted reproductive technology. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:52f6159d-6e51-4273-b3ec-64cce709fa70 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6437 biolink:treats MONDO:0002125 PMID:41385096 "[{""id"":""uuid:e8c546e4-2e90-4cfd-b23a-f610784cc5a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:930b03fc-cc44-4b72-9761-c717f9d30c12"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage for the treatment of status epilepticus. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:205df458-51c8-4cff-be9c-fa4b4cde5139 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:XSZ53G39H5 biolink:treats MONDO:0004728 PMID:41385096 "[{""id"":""uuid:a56b7cbd-c828-430c-8ee5-a04cea16f250"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:14f13ad9-c376-4ede-bc35-bba71f96f2c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage for the treatment of diabetic macular edema. uuid:b48ab705-7074-4d29-8ff2-47ebcfa6a1e4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:15C2VL427D biolink:treats MONDO:0006952 PMID:41385096 "[{""id"":""uuid:3c6b2479-39f6-4588-b213-97b979962933"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:36272988-ad17-4a03-8582-eb326d2e2ff1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage for the treatment of retinopathy of prematurity. uuid:5714bd05-9b1c-4060-b73a-8b06c8cf5d78 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1799208 biolink:treats MONDO:0005155 PMID:41385096 "[{""id"":""uuid:8652e9c7-cb0e-4334-839d-397fa44b325e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:386c175d-f7e4-401a-bfe8-a4a9fca73500"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage for the improvement of viremia in patients with chronic hepatitis C or compensated cirrhosis type C who are naïve or have not previously been treated. uuid:197a31bd-ec35-4425-8ba9-6556c4b07e13 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:94X46KW4AE biolink:treats UMLS:C0276223 PMID:41385096 "[{""id"":""uuid:8dca0886-bc6b-4cc4-8be5-f726ffdb698a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6bbceb1c-3f2f-47b1-934b-8dbfb4beec43"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage for the treatment of recurrent herpes simplex. uuid:db6e23be-fdc9-4a14-b8f1-6f4694b1b73f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63635 biolink:treats MONDO:0017409 PMID:41385096 "[{""id"":""uuid:ffe26f79-074c-4412-a523-68ece9e46024"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:488823b5-bfe7-4023-9ca1-69a5f7014b46"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage for the treatment of symptomatic congenital cytomegalovirus infection. [Orphan drug] uuid:042defd5-c5e1-4248-bf39-5140c58955d8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47381 biolink:treats HP:0003419 PMID:41385096 "[{""id"":""uuid:d92c5853-5f7d-4819-9ff8-c697dc876ba1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:387cb554-49e4-435c-9ddc-74bb55124689"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage for the analgesia and anti-inflammation in patients with lumbago, periarthritis scapulohumeralis, neck‐shoulder‐ arm syndrome, and tenosynovitis. uuid:2cf569e5-4c2c-4f83-923f-431fa0e5bbc1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47381 biolink:treats UMLS:C0877557 PMID:41385096 "[{""id"":""uuid:ac067149-7b7f-489a-82ff-01c712b7171c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f69610b1-2b27-4ea1-b713-85911494d5f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage for the analgesia and anti-inflammation in patients with lumbago, periarthritis scapulohumeralis, neck‐shoulder‐ arm syndrome, and tenosynovitis. uuid:c8549359-2237-4acd-888d-906f7d6d257c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47381 biolink:treats MONDO:0004855 PMID:41385096 "[{""id"":""uuid:ecbdc871-0ed2-4071-b127-9b30647b9840"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:47666dc1-dc2d-42a9-8d37-f8b3bed4392b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage for the analgesia and anti-inflammation in patients with lumbago, periarthritis scapulohumeralis, neck‐shoulder‐ arm syndrome, and tenosynovitis. uuid:3e02c456-9ace-4b01-a64e-c8050550466b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63599 biolink:treats MONDO:0018874 PMID:41385096 "[{""id"":""uuid:f021109e-8cd5-41c5-a816-4c2b21325979"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8b60d21a-25e2-47ab-8178-57105a809e8d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage for the treatment of relapsed or refractory acute myeloid leukemia. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:d2f48db0-b92f-43ec-8f9e-df813bb2274c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DPT0O3T46P biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:259beb53-c29d-4de9-9bb8-be679e116edb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b12af133-087e-4d1a-bb32-83ee909c3706"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the treatment of advanced or recurrent cervical cancer. A drug with a new indication and a new dosage for the preoperative and postoperative adjuvant treatment of hormone receptor (HR)-negative and human epidermal growth factor receptor 2 (HER2)-negative breast cancer with a high risk of recurrence. uuid:e6536c48-7b99-48fd-b056-503f8ac52389 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PQX0D8J21J biolink:treats MONDO:0002032 PMID:41385096 "[{""id"":""uuid:a055b4d7-1c89-4615-8f40-427f99c8327f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5d0098f4-d15c-4ec6-93d1-31a2efa54475"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional dosage indicated for the treatment of unresectable, advanced or recurrent colon or rectal cancer with wild-type RAS and head and neck cancer. [Public knowledge-based application] uuid:1f713a44-74ac-4d26-bcd9-92efd2af7c84 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PQX0D8J21J biolink:treats MONDO:0006519 PMID:41385096 "[{""id"":""uuid:8d94ce10-227e-4909-b460-0546ddf99ad9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d6edd0c2-e8b9-49e7-9f24-1c1645623bbd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional dosage indicated for the treatment of unresectable, advanced or recurrent colon or rectal cancer with wild-type RAS and head and neck cancer. [Public knowledge-based application] uuid:3588fdee-bf6a-4adb-ab9b-b501a00b3ebc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:76612 biolink:treats MONDO:0000432 PMID:41385096 "[{""id"":""uuid:250f90a0-5498-4c45-b537-80225074d6be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:73a47926-c225-4f85-a4c1-47436d49c2bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with new indications for the treatment of Waldenström's macroglobulinemia and lymphoplasmacytic lymphoma. [Orphan drug] uuid:b3af8926-9839-44e3-a068-19f643aa2a38 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:O43472U9X8 biolink:treats MONDO:0003864 PMID:41385096 "[{""id"":""uuid:fe5067c4-552f-4243-96b0-932f774b7ac1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d5d78042-ae83-493d-a026-67611901a105"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage for the treatment of CD20-positive chronic lymphocytic leukemia (including small lymphocytic lymphoma). uuid:eb7986f5-953b-4d42-8b27-aaece41de35c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:Y6BX7BL23K biolink:treats MONDO:0015688 PMID:41385096 "[{""id"":""uuid:50bb06b8-4d16-45fd-ada9-e70f9a39a9f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5cb32842-18b6-42ba-86d1-89452224114a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage for the treatment of FGFR1 fusion gene-positive myeloid/lymphoid neoplasms. [Orphan drug] uuid:dbf7f1b5-1720-41cf-81b6-9cce77240c11 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:52717 biolink:treats MONDO:0017816 PMID:41385096 "[{""id"":""uuid:1ebe05bb-ff4e-4806-aad4-e35cf1764342"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f2e6272d-aa2a-4556-b79a-01be61ae7b64"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage for the treatment of systemic AL amyloidosis. [Orphan drug] uuid:a0e809ed-b6bd-499b-b8f4-8565f1887190 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:82720 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:75d09658-ddd3-4001-96ab-8e6320569b36"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:baafef3e-5ddf-4809-8495-29d9446db9ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage for the treatment of chronic heart failure (for use only in patients receiving standard treatment of chronic heart failure). uuid:8e9425c5-8f95-45b9-9903-6d5485e2d8da biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:P76B05O5V6 biolink:treats MONDO:0005133 PMID:41385096 "[{""id"":""uuid:be27f689-62ce-4c57-bcd4-32ee9cf9d84a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:10020914-8d80-4f7f-af8e-bc2d0970066f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the alleviation of pain associated with endometriosis. uuid:3fca96b3-267a-40df-bc4b-47b7072552af biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3752 biolink:treats MONDO:0001913 PMID:41385096 "[{""id"":""uuid:517ac07e-8ded-4713-9b42-6946bae07613"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c90ac57b-9f51-477e-b2b7-ba31a510609f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage for the induction of spermatogenesis in oligozoospermia. [Public knowledge-based application] uuid:15cbf7bf-ce44-4c35-b36c-69324f477ec2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75055 biolink:treats MONDO:0005072 PMID:41385096 "[{""id"":""uuid:8152bfb9-3d8b-42f6-9d45-3d5afee3a472"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:615a37c5-d2ac-4098-a844-164011c2e727"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage for the enhancement of an antitumor effect of dinutuximab for neuroblastoma. [Expedited review] uuid:eec86b45-ad18-4b49-8560-1d6387abcce3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DPT0O3T46P biolink:treats MONDO:0005575 PMID:41385096 "[{""id"":""uuid:e4ff6ed0-68cc-4183-90a7-2d30286c6c38"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:cfd0425b-513b-485c-815d-725b3eedab45"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the treatment of unresectable advanced or recurrent microsatellite instability-high (MSI-High) colorectal cancer. A drug with a new indication and a new dosage for the treatment of PD-L1-positive, hormone receptor-negative and HER2-negative inoperable or recurrent breast cancer. uuid:c38420ed-a1e1-4ee5-8d2b-b1a9dc419e3b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28901 biolink:treats MONDO:0012817 PMID:41385096 "[{""id"":""uuid:9eaee480-aaaa-45c6-b2ef-76b6aa15341b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f8b09a21-01db-4e80-a17c-71cb558dced2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new dosage indicated for the conditioning treatments prior to allogeneic hematopoietic stem cell transplantation, and autologous hematopoietic stem-cell transplantation for Ewing's sarcoma family of tumors and neuroblastoma. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:0b61c154-7703-49c3-8222-302a2d122f1e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28901 biolink:treats MONDO:0005072 PMID:41385096 "[{""id"":""uuid:9ec89928-da6f-4ebf-b208-7935c589b386"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2051d0df-87bc-458c-9584-540d5e885cc3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new dosage indicated for the conditioning treatments prior to allogeneic hematopoietic stem cell transplantation, and autologous hematopoietic stem-cell transplantation for Ewing's sarcoma family of tumors and neuroblastoma. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:58563ab9-4b9e-4402-a79c-8ac24211383f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135515 biolink:treats MONDO:0000901 PMID:41385096 "[{""id"":""uuid:c0d857a8-88ff-410a-ab67-e1c09764ef74"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c8e20dc7-0b9c-451c-ae06-6d4682df18fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new dosage indicated for the treatment of low-grade B-cell non-Hodgkin’s lymphoma, mantle cell lymphoma, chronic lymphocytic leukemia, and relapsed or refractory diffuse large B-cell lymphoma. uuid:43285be3-3b43-4bc1-a554-6401448cf8e1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:K16AIQ8CTM biolink:treats MONDO:0002032 PMID:41385096 "[{""id"":""uuid:f5fe6ccd-c7b6-4168-8067-9fdcf8b12391"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ae03cb3a-b762-4a84-8b57-db2b00f3255c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage for the treatment of unresectable advanced or recurrent HER2-positive colon or rectal cancer that has progressed after cancer chemotherapy. uuid:5e8726f2-6a33-4126-b88b-98884fc543d0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:K16AIQ8CTM biolink:treats MONDO:0006519 PMID:41385096 "[{""id"":""uuid:6a45e32f-ce99-4795-bcdc-208e0fee42a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:20fba82e-f941-405a-ba5d-ee5bd5b4db70"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage for the treatment of unresectable advanced or recurrent HER2-positive colon or rectal cancer that has progressed after cancer chemotherapy. uuid:4e5d8330-8250-4f3d-a43a-710afc54c4d9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:144421 biolink:treats MONDO:0001356 PMID:41385096 "[{""id"":""uuid:a8f70038-acb6-452b-affc-80b565c3ae36"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:58a6fe9b-bd03-4c03-adf3-d5f95098d93c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage for the treatment of iron deficiency anemia. uuid:eaa23931-877f-4088-a908-7373bc22917f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6ZA31Y954Z biolink:treats MONDO:0005306 PMID:41385096 "[{""id"":""uuid:d3145d7f-1023-4c68-aa0e-846efa7493be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:bd34e021-6492-45a4-8299-21e109d960f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with new indications for the treatment of ankylosing spondylitis and non-radiographic axial spondyloarthritis in patients who have not responded sufficiently to conventional treatments. uuid:ac4ed1d3-7e4b-499f-a6be-7da931e1afed biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6ZA31Y954Z biolink:treats UMLS:C3203547 PMID:41385096 "[{""id"":""uuid:e4586152-7705-4d18-babb-16fecc97c2c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d30c6b44-e517-447b-a6b4-2585657f9603"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with new indications for the treatment of ankylosing spondylitis and non-radiographic axial spondyloarthritis in patients who have not responded sufficiently to conventional treatments. uuid:5941bd41-59e1-455e-9856-753cee063c9a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DPT0O3T46P biolink:treats MONDO:0005580 PMID:41385096 "[{""id"":""uuid:cc9eda32-d6e8-4b5c-a29e-d02cdf81c2dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:253554d8-c9b2-4df0-8864-99804e024b60"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage for the treatment of unresectable advanced or recurrent PD-L1- positive esophageal squamous cell carcinoma that has progressed after cancer chemotherapy. uuid:c848aea6-24e9-4319-8280-3023cf8f162e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:232544 biolink:treats MONDO:0100280 PMID:41385096 "[{""id"":""uuid:083db781-e9c0-4b7e-8720-fa2681ed9803"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b5bd6e7b-4470-4a4c-9a4c-5c2cf7d38031"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with new indications for the treatment of Waldenström's macroglobulinemia and lymphoplasmacytic lymphoma. [Orphan drug] uuid:2f9f6d7c-e55f-4d57-90e9-5ae671dde511 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:232544 biolink:treats MONDO:0000432 PMID:41385096 "[{""id"":""uuid:3e7ad323-1e33-4833-ad34-978fbf671191"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2d14fff2-c5e4-4473-b281-cf72de1cf41a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with new indications for the treatment of Waldenström's macroglobulinemia and lymphoplasmacytic lymphoma. [Orphan drug] uuid:bde043e8-e69e-4fe9-a989-14a61db47be2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:52CMI0WC3Y biolink:treats UMLS:C1112459 PMID:41385096 "[{""id"":""uuid:c6b69b07-0427-4cbc-a7b3-8b83e5bcd203"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c904416a-0a83-4d7c-8d6a-aa1b66584be6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage for the treatment of unresectable hepatocellular carcinoma. [Priority review] uuid:4bc1198d-bc61-4c81-b5b9-08b059a7d257 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:5384HK7574 biolink:treats MONDO:0005036 PMID:41385096 "[{""id"":""uuid:c63b5cee-42ba-46cf-82c0-0370e59dfbbe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5480907d-4a76-40ca-a758-cee73fbe71f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage for the treatment of unresectable advanced or recurrent HER2- positive gastric cancer that has progressed after cancer chemotherapy. [SAKIGAKE designation] uuid:6932863c-3579-49c8-8bb7-cc200d5700cd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:145371 biolink:treats MONDO:0005575 PMID:41385096 "[{""id"":""uuid:42d00fcd-9951-4869-84bc-b6b779abf41f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b9f73de9-9841-46af-a21a-5454da8d059a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage for the treatment of unresectable, advanced or recurrent BRAF mutation-positive colorectal cancer that has progressed after cancer chemotherapy. [Priority review] uuid:5f6a8b56-b523-44d9-9ba0-7da87d093449 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41977 biolink:treats MONDO:0010643 PMID:41385096 "[{""id"":""uuid:5d9cc817-558c-40ca-ac2b-037943fe5807"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:068d4122-742a-463f-9496-457ed58a50c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new dosage indicated for the treatment of acute leukemia (including blast crisis of chronic myeloid leukemia). [Public knowledge-based application] uuid:a9ba84f1-8c16-4dfb-80df-218605a3ab07 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41977 biolink:treats MONDO:0006115 PMID:41385096 "[{""id"":""uuid:adf54d49-c3f9-49db-9008-68c2465fa221"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8f9f8173-8cc3-4b2a-9220-676c2c87a43c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new dosage indicated for the treatment of acute leukemia (including blast crisis of chronic myeloid leukemia). [Public knowledge-based application] uuid:627ac908-6ffd-4829-abd4-84f91800b743 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:659877 biolink:treats UMLS:C1527424 PMID:41385096 "[{""id"":""uuid:e6cf6ca0-2322-4bc5-b90e-0306275ac915"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:845e67c2-6f57-4ef9-8aee-2bc94feedb23"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the prevention of the following diseases caused by infection with human papillomavirus types 6, 11, 16, and 18: Cervical cancer (squamous cell carcinoma and adenosquamous carcinoma) and its precursor lesions (cervical intraepithelial neoplasia [CIN] 1, 2, and 3, and adenocarcinoma in situ [AIS]) Vulvar intraepithelial neoplasia (VIN) 1, 2, and 3, and vaginal intraepithelial noeplasia (VaIN) 1, 2, and 3 Anal cancer (squamous cell carcinoma) and its precursor lesions (anal intraepithelial neoplasia [AIN] 1, 2, and 3) Condyloma acuminatum uuid:78b0746c-00c5-48dd-9c66-751fc7039cf4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:659877 biolink:treats MONDO:0006137 PMID:41385096 "[{""id"":""uuid:dca21066-2d0f-4894-a630-2062214ce24e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6660076e-e432-4287-9c60-adc8bbada306"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the prevention of the following diseases caused by infection with human papillomavirus types 6, 11, 16, and 18: Cervical cancer (squamous cell carcinoma and adenosquamous carcinoma) and its precursor lesions (cervical intraepithelial neoplasia [CIN] 1, 2, and 3, and adenocarcinoma in situ [AIS]) Vulvar intraepithelial neoplasia (VIN) 1, 2, and 3, and vaginal intraepithelial noeplasia (VaIN) 1, 2, and 3 Anal cancer (squamous cell carcinoma) and its precursor lesions (anal intraepithelial neoplasia [AIN] 1, 2, and 3) Condyloma acuminatum uuid:4c91ffe9-2868-43d7-8e4b-3d80dd513ea2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:659877 biolink:treats MONDO:0042487 PMID:41385096 "[{""id"":""uuid:362d9f2b-69e2-4247-9b05-2e16216aed59"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5766f721-23b3-4ea7-9ba9-7470b7ea6645"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the prevention of the following diseases caused by infection with human papillomavirus types 6, 11, 16, and 18: Cervical cancer (squamous cell carcinoma and adenosquamous carcinoma) and its precursor lesions (cervical intraepithelial neoplasia [CIN] 1, 2, and 3, and adenocarcinoma in situ [AIS]) Vulvar intraepithelial neoplasia (VIN) 1, 2, and 3, and vaginal intraepithelial noeplasia (VaIN) 1, 2, and 3 Anal cancer (squamous cell carcinoma) and its precursor lesions (anal intraepithelial neoplasia [AIN] 1, 2, and 3) Condyloma acuminatum uuid:63fafda2-2af6-4dad-ac4b-d07b94347a6c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:659877 biolink:treats MONDO:0018585 PMID:41385096 "[{""id"":""uuid:151bd482-17a2-4740-967b-8a7335508f75"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:08150a74-a3f8-4629-b830-b3dda9cd9340"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the prevention of the following diseases caused by infection with human papillomavirus types 6, 11, 16, and 18: Cervical cancer (squamous cell carcinoma and adenosquamous carcinoma) and its precursor lesions (cervical intraepithelial neoplasia [CIN] 1, 2, and 3, and adenocarcinoma in situ [AIS]) Vulvar intraepithelial neoplasia (VIN) 1, 2, and 3, and vaginal intraepithelial noeplasia (VaIN) 1, 2, and 3 Anal cancer (squamous cell carcinoma) and its precursor lesions (anal intraepithelial neoplasia [AIN] 1, 2, and 3) Condyloma acuminatum uuid:f58d1037-3046-496f-bbd7-1ad66e086454 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:659877 biolink:treats MONDO:0006274 PMID:41385096 "[{""id"":""uuid:2b4f1ec2-8952-496e-82ea-cdd57cad5446"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b0524bfe-496d-4822-857d-257b20849ff0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the prevention of the following diseases caused by infection with human papillomavirus types 6, 11, 16, and 18: Cervical cancer (squamous cell carcinoma and adenosquamous carcinoma) and its precursor lesions (cervical intraepithelial neoplasia [CIN] 1, 2, and 3, and adenocarcinoma in situ [AIS]) Vulvar intraepithelial neoplasia (VIN) 1, 2, and 3, and vaginal intraepithelial noeplasia (VaIN) 1, 2, and 3 Anal cancer (squamous cell carcinoma) and its precursor lesions (anal intraepithelial neoplasia [AIN] 1, 2, and 3) Condyloma acuminatum uuid:b5e01e81-5139-48b6-8aa7-0199293c1ce9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:659877 biolink:treats UMLS:C0495107 PMID:41385096 "[{""id"":""uuid:5bcdc0ab-5ba6-4369-8a86-525c4375edf4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c4d58811-c3fd-4892-a2d5-38df1fa5c4e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the prevention of the following diseases caused by infection with human papillomavirus types 6, 11, 16, and 18: Cervical cancer (squamous cell carcinoma and adenosquamous carcinoma) and its precursor lesions (cervical intraepithelial neoplasia [CIN] 1, 2, and 3, and adenocarcinoma in situ [AIS]) Vulvar intraepithelial neoplasia (VIN) 1, 2, and 3, and vaginal intraepithelial noeplasia (VaIN) 1, 2, and 3 Anal cancer (squamous cell carcinoma) and its precursor lesions (anal intraepithelial neoplasia [AIN] 1, 2, and 3) Condyloma acuminatum uuid:8d8811b5-0298-4e44-a462-e9256d5ef0a8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:659877 biolink:treats UMLS:C0349554 PMID:41385096 "[{""id"":""uuid:542b6c01-6e55-42bf-a6c8-35ff244aa741"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ce0f4e68-b7fe-4d67-ae00-ecf3ce9c3db1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the prevention of the following diseases caused by infection with human papillomavirus types 6, 11, 16, and 18: Cervical cancer (squamous cell carcinoma and adenosquamous carcinoma) and its precursor lesions (cervical intraepithelial neoplasia [CIN] 1, 2, and 3, and adenocarcinoma in situ [AIS]) Vulvar intraepithelial neoplasia (VIN) 1, 2, and 3, and vaginal intraepithelial noeplasia (VaIN) 1, 2, and 3 Anal cancer (squamous cell carcinoma) and its precursor lesions (anal intraepithelial neoplasia [AIN] 1, 2, and 3) Condyloma acuminatum uuid:468273b3-edd6-4d03-869a-c0d16828d9d7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:659877 biolink:treats MONDO:0859203 PMID:41385096 "[{""id"":""uuid:83e4869a-38d9-4d66-89e0-6035e1cdfd04"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e77a50fc-69e6-4fa5-b858-361bd2228d1a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the prevention of the following diseases caused by infection with human papillomavirus types 6, 11, 16, and 18: Cervical cancer (squamous cell carcinoma and adenosquamous carcinoma) and its precursor lesions (cervical intraepithelial neoplasia [CIN] 1, 2, and 3, and adenocarcinoma in situ [AIS]) Vulvar intraepithelial neoplasia (VIN) 1, 2, and 3, and vaginal intraepithelial noeplasia (VaIN) 1, 2, and 3 Anal cancer (squamous cell carcinoma) and its precursor lesions (anal intraepithelial neoplasia [AIN] 1, 2, and 3) Condyloma acuminatum uuid:b59c8701-4933-4c4b-bfee-81211a0d9cfb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:659877 biolink:treats UMLS:C1274831 PMID:41385096 "[{""id"":""uuid:59e3af10-d594-4692-b216-b22549a78e78"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7423f59a-10e6-44a8-b594-2f9eb5ec4f78"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the prevention of the following diseases caused by infection with human papillomavirus types 6, 11, 16, and 18: Cervical cancer (squamous cell carcinoma and adenosquamous carcinoma) and its precursor lesions (cervical intraepithelial neoplasia [CIN] 1, 2, and 3, and adenocarcinoma in situ [AIS]) Vulvar intraepithelial neoplasia (VIN) 1, 2, and 3, and vaginal intraepithelial noeplasia (VaIN) 1, 2, and 3 Anal cancer (squamous cell carcinoma) and its precursor lesions (anal intraepithelial neoplasia [AIN] 1, 2, and 3) Condyloma acuminatum uuid:82b02424-ea6e-4eb5-bdf6-990dfbead2bd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:9RV78Q2002 biolink:treats UMLS:C0852922 PMID:41385096 "[{""id"":""uuid:72450585-69e9-4e9c-a57d-4ba5f0984ef9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ddcb9aed-02e8-4214-a22e-0b0c65e4f67f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication for the treatment and maintenance therapy of moderate to severe active Crohn's disease (for use only in patients who have not sufficiently responded to conventional treatments). uuid:0ec35093-77b7-439c-a97c-b1d61ab2cade biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:A3ULP0F556 biolink:treats MONDO:0019100 PMID:41385096 "[{""id"":""uuid:f594f51e-bac9-4d62-aa62-6c877d25df5f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e3195b68-a342-44d4-997d-d1070736e6ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication for the prevention of relapse of neuromyelitis optica spectrum disorder (including neuromyelitis optica). [Orphan drug] uuid:5916be07-4810-4a62-b7d1-b4570d127421 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31859 biolink:treats MONDO:0018044 PMID:41385096 "[{""id"":""uuid:ecebb682-bce2-42d3-ab8f-ef71fd63636b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:76279719-c84d-430d-986f-888b79fcaeb9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the treatment of excessive daytime sleepiness associated with idiopathic hypersomnia. [Orphan drug] uuid:5b662f0d-5942-4d40-8dda-74c1c915c406 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:ZL1R02VT79 biolink:treats MONDO:0006952 PMID:41385096 "[{""id"":""uuid:3e1ed361-c25b-4569-93e6-5b08e6780bc1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ce018540-4997-4909-b928-e8ffe785713a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and a new dosage for the treatment of retinopathy of prematurity. [Orphan drug] uuid:68079a1b-7de2-4cc7-899a-ca3c79e98c81 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1597612 biolink:treats HP:0100806 PMID:41385096 "[{""id"":""uuid:d1ae4aa7-4322-4cd3-9f0f-8b384fc3453b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2bcadaf8-1dca-4393-83d0-dc5044e31da8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with new additional indications and a new dosage for the treatment of sepsis and pneumonia caused by Serratia and Haemophilus influenzae . uuid:51881abd-762c-44fd-84e6-fbb273628e17 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1597612 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:54ebf7b1-e5de-4f15-99e9-24147742967a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:54bdf974-b0a8-487b-b8cb-46f41be6361d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with new additional indications and a new dosage for the treatment of sepsis and pneumonia caused by Serratia and Haemophilus influenzae . uuid:1ab5f25b-a2d1-41f2-a68d-1b0d995ece80 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90936 biolink:treats MONDO:0020325 PMID:41385096 "[{""id"":""uuid:2377e8a0-678f-455e-9727-5313084394ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ce29dd92-7a73-4c7d-9ba8-c9a7989db2fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage for the treatment of relapsed or refractory ALK fusion gene-positive anaplastic large cell lymphoma. [Orphan drug] uuid:79c803c2-e7a9-4ed1-a370-f22a2963834f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9570 biolink:treats MONDO:0005062 PMID:41385096 "[{""id"":""uuid:c7c9ec3f-8cfb-40c9-b160-7b262719d9ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:330b6e00-6c32-4698-9d1a-0d035a4eb958"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage for the conditioning treatment of malignant lymphoma in patients prior to autologous hematopoietic stem- cell transplantation. uuid:fb77c670-6132-463c-b6ae-0ad9b5c6d8e7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28901 biolink:treats MONDO:0005062 PMID:41385096 "[{""id"":""uuid:387611c9-7cee-4c35-82ef-9b5dae0bcdc3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e6c57b76-528b-45d1-be33-ed2dd60c07d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage for the conditioning treatment of malignant lymphoma in patients prior to autologous hematopoietic stem- cell transplantation. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:3067c0ce-f09e-408c-bf29-9935de214fba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68551 biolink:treats HP:0012450 PMID:41385096 "[{""id"":""uuid:b2352a76-ed45-4f70-ad5e-4134e01b9f57"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:bfd30730-c315-4f0f-98e1-a89214af4d9d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication for the treatment of chronic constipation (excluding constipation due to organic diseases). uuid:78810c4e-cb23-4e9a-931a-a01568d6e1da biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15891 biolink:treats MONDO:0010789 PMID:41385096 "[{""id"":""uuid:645a239e-b59b-439f-9caf-e90528e2e0af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:18c49767-8f58-4ee6-915a-a7e68b6ce7d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and a new dosage for the inhibition of stroke-like episodes in patients with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS). [Orphan drug] uuid:0dce0c55-f638-48ff-a16f-0aba81c42d15 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15891 biolink:treats HP:0002401 PMID:41385096 "[{""id"":""uuid:b958fc1d-c09e-42f4-af1d-c955c610a2ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:278632da-a019-44e8-b792-93a767997188"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and a new dosage for the inhibition of stroke-like episodes in patients with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS). [Orphan drug] uuid:a9e85f5a-54f5-4493-b82c-34c28100796d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63580 biolink:treats MONDO:0005155 PMID:41385096 "[{""id"":""uuid:666f1525-0b27-4441-9060-e1447a02f3ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c4e5db94-2c31-454a-af67-778eb2d270f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and a new dosage, used in combination with sofosbuvir and velpatasvir, for the improvement of viremia in patients with chronic hepatitis C or compensated cirrhosis type C who have previously been treated. [Expedited review] uuid:ff28d5ae-5b3f-4fcc-9e61-13291de90641 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4974 biolink:treats MONDO:0004609 PMID:41385096 "[{""id"":""uuid:095558d4-75f0-4d59-9e33-ea747e805899"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c43e74d8-6068-4726-af2a-1c8a2977cc40"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new dosage indicated for the treatment of herpes simplex. uuid:a8a1eb42-c9fc-4723-a76e-29fd1964e574 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:127780 biolink:treats MONDO:0027029 PMID:41385096 "[{""id"":""uuid:26b3862b-5551-4551-9199-a5094a2025a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:079cd527-fb4c-4cff-8cc2-b7fd64bc6878"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and a new dosage indicated for the treatment of human herpesvirus 6 encephalitis after hematopoietic stem cell transplantation. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:0432b8a4-b3fa-4905-ab01-b87ea03559b3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:089658A12D biolink:treats MONDO:0015597 PMID:41385096 "[{""id"":""uuid:c1eaeda9-8a7f-42e9-9c27-ea7f488f1598"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a12f76d8-8df3-4552-932d-1a7e6de997ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication for the treatment of palmoplantar pustulosis in patients who have not responded sufficiently to conventional therapies. uuid:5cefa6ad-4a9f-4bb9-ba62-e37e7c09346e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:420K487FSG biolink:treats MONDO:0100470 PMID:41385096 "[{""id"":""uuid:b7720977-7297-468c-aec5-fba497e70557"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:80cd4f3e-955c-4154-8f04-d3b49d203112"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication, a new dosage and other characteristics for the treatment of bronchial asthma (for use only in patients with severe or intractable bronchial asthma whose asthmatic responses are uncontrollable with conventional therapies). uuid:86bb28ef-7a28-4264-b10e-927242b9f574 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:44185 biolink:treats UMLS:C0406317 PMID:41385096 "[{""id"":""uuid:8ca4d8ed-5c6f-4696-bb3b-4a6bc731e650"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ba39b855-7b44-4735-a2a6-1ae02204d315"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with new additional indications and a new dosage for the treatment of plaque psoriasis in patients who have not responded sufficiently to topical therapy, or psoriatic arthritis, pustular psoriasis and erythrodermic psoriasis . [Public knowledge-based application after PAFSC's preliminary assessment] uuid:9973f810-a2e8-4454-8f69-aa2d815b4713 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:44185 biolink:treats MONDO:0022205 PMID:41385096 "[{""id"":""uuid:7398b669-6a03-45fd-b331-03c13c976d87"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c000727a-618a-4480-bcf3-31ad51b30f41"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with new additional indications and a new dosage for the treatment of plaque psoriasis in patients who have not responded sufficiently to topical therapy, or psoriatic arthritis, pustular psoriasis and erythrodermic psoriasis . [Public knowledge-based application after PAFSC's preliminary assessment] uuid:ab816e3a-d7c6-40db-9adf-af3c9c0a2e22 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:44185 biolink:treats UMLS:C0748052 PMID:41385096 "[{""id"":""uuid:4f95f7de-3825-4a16-bb4a-871121348bb7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:05c34539-5fb7-4c08-a52f-fff653c5f2a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with new additional indications and a new dosage for the treatment of plaque psoriasis in patients who have not responded sufficiently to topical therapy, or psoriatic arthritis, pustular psoriasis and erythrodermic psoriasis . [Public knowledge-based application after PAFSC's preliminary assessment] uuid:1bd2402a-0684-4d6a-b20a-02d0f021f0fb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6T8C155666 biolink:treats UMLS:C4725093 PMID:41385096 "[{""id"":""uuid:a969af17-4b5c-462d-b25c-a1126602436a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1a21f905-615a-4062-850b-266c6bcfbcbe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new dosage indicated for the treatment of unresectable melanoma. [Orphan drug] uuid:a8400b38-431d-4bdb-a0f7-8bbec85e0554 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:YI437801BE biolink:treats MONDO:0015758 PMID:41385096 "[{""id"":""uuid:adb0a3a5-e60e-495f-932a-82a94d4e6445"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e6b44dee-9601-4594-b312-9d93c4efdbc7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with new indications and a new dosage for the treatment of relapsed or refractory cutaneous T-cell lymphoma. [Orphan drug] uuid:dfaa884d-139f-47c7-ae27-5ac41df87d4b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4F4X42SYQ6 biolink:treats MONDO:0019098 PMID:41385096 "[{""id"":""uuid:1783ea28-4ce0-4d33-ad70-d3b07d889a43"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:62837bdd-7c5d-4b48-b508-d5b8298aed48"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and a new dosage for the treatment of chronic idiopathic thrombocytopenic purpura. [Public knowledge-based application after preliminary assessment by the Pharmaceutical Affairs and Food Sanitation Council (PAFSC)] uuid:40fe1c87-8ce0-400a-bb0b-86c31e86dc90 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:441410 biolink:treats MONDO:0010735 PMID:41385096 "[{""id"":""uuid:a5605ff7-10ea-4ed9-8862-1ca273629d3b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1f65582d-1125-487c-a9cd-c58cd0e750c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication for inhibiting progression of spinal and bulbar muscular atrophy. [Orphan drug] uuid:201ae874-3cba-4be0-95ba-414f0a790a0f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4EQZ6YO2HI biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:5f860e81-8565-438b-b1a1-1aa0bca9175a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a6b6a508-58f1-4ad8-886f-b9f564792693"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and a new dosage indicated for inhibiting progression of bone erosion associated with rheumatoid arthritis. uuid:c23d37cc-13b9-4573-ae7c-89b7834fcb5c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7D0YB67S97 biolink:treats MONDO:0011429 PMID:41385096 "[{""id"":""uuid:cf68134e-fb79-480d-9799-beb37d60fbce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:fc41859b-e2c4-4eee-a0b1-860fc4c7006b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and a new dosage indicated for the treatment of polyarticular- course juvenile idiopathic arthritis in patients who have not responded sufficiently to conventional therapies. uuid:93e43a70-3e8d-4455-86b4-c50f52512a61 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15355 biolink:treats MONDO:0005356 PMID:41385096 "[{""id"":""uuid:78dedf60-bdef-4178-917f-ca2da195d652"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ee32dc1e-2968-4fa0-a8ff-d280987a977e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new route of administration indicated for the induction of coronary spasm in a drug- induced coronary spasm provocation test during coronary angiography. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:83ddf642-51d4-4ccc-881b-38f8131a1865 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135901 biolink:treats MONDO:0019954 PMID:41385096 "[{""id"":""uuid:a76a4b09-d460-4baa-8f8c-d7dab1eb7c4d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:99531429-b140-44a4-8752-b58413a04b06"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and a new dosage indicated for the treatment of neuroendocrine tumors of the pancreas and gastrointestinal tract. uuid:b441045e-d066-40c9-b15a-4b863359c984 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45863 biolink:treats MONDO:0001056 PMID:41385096 "[{""id"":""uuid:0c8ad04e-bdcd-4cf3-95b5-fd1c2adf9929"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:40261419-8d72-4ccb-927a-73c0379c47c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new dosage indicated for the treatment of gastric cancer. uuid:052a5479-0304-4ab6-83d4-677ce984f1e9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68642 biolink:treats MONDO:0008315 PMID:41385096 "[{""id"":""uuid:ecfcbf54-87df-4734-834a-2594de086dad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f92a6153-49e0-4076-bda8-9a3bf76e430e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication for the treatment of prostate cancer in patients with high- risk prognostic factors who have not received previous endocrine therapy. [Priority review] uuid:1ebaf801-0234-4dfe-b1be-6dd9d8b5cd50 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:52717 biolink:treats MONDO:0100280 PMID:41385096 "[{""id"":""uuid:770073f5-2724-4a59-82ce-06f58d313e37"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9155f39f-8e46-4d43-82e1-dc491511128f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and a new dosage indicated for the treatment of Waldenströ m's macroglobulinemia and lymphoplasmacytic lymphoma. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:05fd190b-8cab-466b-a8ce-026c4ccf346e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:52717 biolink:treats MONDO:0000432 PMID:41385096 "[{""id"":""uuid:544b17bf-c691-45cf-a0e3-bd079eb35928"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:def668ff-b10c-4def-af22-be8cad8877cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and a new dosage indicated for the treatment of Waldenströ m's macroglobulinemia and lymphoplasmacytic lymphoma. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:97877baf-e5e8-438f-a276-78b29d22cd4a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0004728 PMID:41385096 "[{""id"":""uuid:73030c03-51c6-458a-8323-dd1bc154866a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:16292ea1-ce78-4485-bd50-6907faca56e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new route of administration indicated for alleviation of diabetic macular edema and macular edema associated with retinal vein occlusion or non-infectious uveitis. uuid:033036ea-a303-469f-9dd4-8086b866f2ca biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0041093 PMID:41385096 "[{""id"":""uuid:8ccb80a7-7b8f-48a2-a2c0-bf0169990f6e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7da5cb36-3296-4df4-93bd-6b5d89f3503c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new route of administration indicated for alleviation of diabetic macular edema and macular edema associated with retinal vein occlusion or non-infectious uveitis. uuid:da6f1066-39bc-4914-aba7-fe9c28eeaeca biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0003005 PMID:41385096 "[{""id"":""uuid:1246055e-69d5-4449-bfbd-06458373b4c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2542bd25-6198-4484-8828-3c2beafe7754"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new route of administration indicated for alleviation of diabetic macular edema and macular edema associated with retinal vein occlusion or non-infectious uveitis. uuid:cda15aee-b545-4bbc-83dd-886c7c3053c7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:48814 biolink:treats UMLS:C4049395 PMID:41385096 "[{""id"":""uuid:233d65e0-c975-4fdc-a767-4b358064630c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:218b8cc3-be52-433f-aae0-a4772dac797f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and a new dosage for the improvement of viremia in patients with chronic hepatitis C in serogroup 2 (genotype 2). uuid:d974790e-7f12-4ca3-9890-f0e65458a6ed biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63580 biolink:treats UMLS:C4049395 PMID:41385096 "[{""id"":""uuid:838511dd-c85c-445e-8aaf-1a5176ef2003"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6674ad45-ccb8-4db8-a873-bee487dee487"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and a new dosage for the improvement of viremia in patients with chronic hepatitis C in serogroup 2 (genotype 2), for a combination use of ombitasvir hydrate, paritaprevir hydrate, and ritonavir. uuid:dcf9fb1e-1804-4f8d-90f2-dff8b3011c1b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77573 biolink:treats MONDO:0005867 PMID:41385096 "[{""id"":""uuid:4ebf1759-2320-4874-9fa7-759519b547a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:48fe1467-50ba-455d-b103-c8d68a9b66a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication for the treatment of mycoplasma pneumonia caused by Mycoplasma pneumoniae . uuid:ac17c1a0-cedf-4288-a977-e667ca28ba76 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7798 biolink:treats UMLS:C0858004 PMID:41385096 "[{""id"":""uuid:5c1fb029-30a5-46b8-a911-a4b9e0494ccd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:31146ccc-89ab-48d4-9798-56e7b3d4f43a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional dosage for newborns and infants for the treatment of influenza A or B virus infection. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:2d8da721-aad9-444a-970e-0e0a4ea09f4e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7798 biolink:treats UMLS:C0858005 PMID:41385096 "[{""id"":""uuid:e95109bd-b459-462c-8098-8792df1d6f44"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7ef29fba-54ca-4447-b983-68e99b049ca0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional dosage for newborns and infants for the treatment of influenza A or B virus infection. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:bdcc91e4-a116-493c-bba3-c9550fdb469a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:B72HH48FLU biolink:treats MONDO:0022205 PMID:41385096 "[{""id"":""uuid:6c1f3a4e-0f3c-41fc-963c-57993bd64aa9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:34d63f8e-2f4f-4179-866d-5ceb608b67fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new dosage indicated for plaque psoriasis, psoriatic arthritis, pustular psoriasis, and erythrodermic psoriasis in patients who have not responded sufficiently to conventional treatments. uuid:7b48d697-42e8-46e0-8583-9ee1439176f9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:B72HH48FLU biolink:treats UMLS:C0748052 PMID:41385096 "[{""id"":""uuid:ce38486c-3d1b-4ec7-b11a-6d1727297908"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:80a566b4-8e02-4abc-8960-fd25298bbd04"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new dosage indicated for plaque psoriasis, psoriatic arthritis, pustular psoriasis, and erythrodermic psoriasis in patients who have not responded sufficiently to conventional treatments. uuid:a45c2526-afa5-45c1-8b5f-535c767c4841 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3160WY51LV biolink:treats MONDO:0005300 PMID:41385096 "[{""id"":""uuid:3baf37f4-cc72-47bb-b246-bda903a75133"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:93814ca9-1b3c-4978-92c9-88c840916463"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new expanded indication for the improvement of hyperphosphatemia in patients with chronic kidney disease. uuid:cc904f4a-b04a-4ef2-8f34-fd250e28b88a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:51450 biolink:treats HP:0031917 PMID:41385096 "[{""id"":""uuid:4f6f2651-167d-4b07-b128-645a0efa66ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:187ccd33-26b1-4a7d-b33a-1a7f416fffb0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication for inhibiting development of digital ulcer in patients with systemic scleroderma (only for patients who currently have digital ulcers or have a history of digital ulcer.) [Orphan drug] uuid:c1b1e02d-e919-47b4-8849-9564e7fc454a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:36791 biolink:treats MONDO:0001247 PMID:41385096 "[{""id"":""uuid:7f0f4f35-7704-40dd-99a0-691165e25030"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:35bd3431-63d3-4e7e-a624-850f78bed55f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication for the treatment of social anxiety disorder. uuid:576ef9f1-f210-4226-91bc-e98504556c1d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1314134 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:d7a81f42-62e6-4c9b-a1f9-45fae66d8c48"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0a7cb9f8-379b-470c-9b32-1330f756f39c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and a new dosage for adults indicated for the relief of pain during pricking with injection needles and intravenous indwelling needles, and with a new pediatric dosage indicated for the relief of pain during skin laser radiation therapy and pricking with injection needles and intravenous indwelling needles. uuid:c6ae57a2-ca3a-4fb0-85c2-8e9bc020e846 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:100241 biolink:treats HP:0100806 PMID:41385096 "[{""id"":""uuid:78cfcd3f-3d01-4f14-a10c-37be1548d9d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a0e8053c-f647-4a4f-9cc6-adedcf0255b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new increased dose for adults indicated for the treatment of sepsis, pneumonia, etc., and also with new indications and new dosages for children for both the treatment of complicated cystitis, pyelonephritis and anthrax, and the improvement of symptoms associated with respiratory infection caused by Pseudomonas aeruginosa in cystic fibrosis. uuid:b1659e27-e1b3-49c2-bd97-9c714538d239 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:100241 biolink:treats MONDO:0005119 PMID:41385096 "[{""id"":""uuid:066133a6-3073-4621-bd77-635097da2d6c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:61a7d7ac-a061-4c96-b515-2f852c1483ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new increased dose for adults indicated for the treatment of sepsis, pneumonia, etc., and also with new indications and new dosages for children for both the treatment of complicated cystitis, pyelonephritis and anthrax, and the improvement of symptoms associated with respiratory infection caused by Pseudomonas aeruginosa in cystic fibrosis. uuid:c43303eb-6a7d-4827-8bc5-6e515c4d39aa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:100241 biolink:treats MONDO:0037398 PMID:41385096 "[{""id"":""uuid:9ae2c8d4-f054-433d-b868-0d544599fa02"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:18e32073-0d45-49c4-911c-c9b7b2120b2a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new increased dose for adults indicated for the treatment of sepsis, pneumonia, etc., and also with new indications and new dosages for children for both the treatment of complicated cystitis, pyelonephritis and anthrax, and the improvement of symptoms associated with respiratory infection caused by Pseudomonas aeruginosa in cystic fibrosis. uuid:cffa010b-eefc-4759-8568-99f5d13d775c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:66919 biolink:treats MONDO:0009891 PMID:41385096 "[{""id"":""uuid:db951c9d-da1a-4507-a241-bee6eff116a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e8c13261-df05-48ca-b7b4-5fb74866c127"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and a new dosage for the treatment of polycythemia vera (use only when conventional therapies are not sufficiently effective or inappropriate). uuid:2cce3989-2bfb-4b20-a9e6-274c69748411 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63587 biolink:treats MONDO:0018078 PMID:41385096 "[{""id"":""uuid:73a175e4-7878-428c-ac3b-36e128687d3b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:644688c8-48d3-41dd-9790-a2792f58fb09"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication for the treatment of soft tissue sarcoma. [Orphan drug] uuid:5cede6ff-96c6-4bec-be99-9b3d67bf5a90 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50924 biolink:treats MONDO:0002108 PMID:41385096 "[{""id"":""uuid:0f0a074a-4866-4143-83ed-6082584c1763"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:924a1bcc-2f77-4dd0-9477-9e838cbb3340"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a revised indication for the treatment of unresectable thyroid cancer. [Orphan drug] uuid:0ae3543a-904f-44d9-8b7f-ad7e35ed95dd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4F4X42SYQ6 biolink:treats MONDO:0044765 PMID:41385096 "[{""id"":""uuid:f529e852-ab4f-4b55-963b-2712c762413d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1696d41c-02e9-4292-bee2-ce2b2f544d67"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and a new dosage for the treatment of refractory nephrotic syndrome (for use in patients with frequent recurrence or steroid-dependent). [Orphan drug] uuid:39bfedca-f6a7-4ea9-9962-faf82c1fb786 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB00028 biolink:treats UMLS:C0877157 PMID:41385096 "[{""id"":""uuid:f80e61bb-2092-49ab-9ab3-fe1572e81f36"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3182a551-118d-4a31-9bd8-ae3fd0d8a9eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and a new dosage for the treatment of acute rejection after the liver, heart, lungs, pancreas, or small intestinal transplantation. uuid:de3f3db4-26f7-4802-919d-90107259be29 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28001 biolink:treats HP:0100806 PMID:41385096 "[{""id"":""uuid:55dcb6d1-0fb0-4608-aa6f-5f024b8f9b53"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0b784eab-5052-46e6-8412-49febfc53ef0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with new additional indications for the treatment of: sepsis, infective endocarditis, secondary infection of trauma, burn or surgical wounds, osteomyelitis, arthritis, peritonitis and purulent meningitis caused by vancomycin-sensitive methicillin-resistant coagulase-negative Staphylococcus (MRCNS); or febrile neutropenia which is suspected of MRSA or MRCNS infection. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:86a39034-bac2-4a01-9bbc-d7b4dce0441d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28001 biolink:treats MONDO:0005578 PMID:41385096 "[{""id"":""uuid:e11aeba0-86fa-4aeb-9c8a-94a2b7fe8f06"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:513b95a5-3ada-4297-9d1f-7457cb0e59c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with new additional indications for the treatment of: sepsis, infective endocarditis, secondary infection of trauma, burn or surgical wounds, osteomyelitis, arthritis, peritonitis and purulent meningitis caused by vancomycin-sensitive methicillin-resistant coagulase-negative Staphylococcus (MRCNS); or febrile neutropenia which is suspected of MRSA or MRCNS infection. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:2055363e-db06-4b3f-9384-ce21aad1b9b0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28001 biolink:treats MONDO:0004522 PMID:41385096 "[{""id"":""uuid:a9f8b41f-fba9-420d-8b1e-e72e84564f73"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6c863f1b-d47e-42c2-9420-67a81741c3e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with new additional indications for the treatment of: sepsis, infective endocarditis, secondary infection of trauma, burn or surgical wounds, osteomyelitis, arthritis, peritonitis and purulent meningitis caused by vancomycin-sensitive methicillin-resistant coagulase-negative Staphylococcus (MRCNS); or febrile neutropenia which is suspected of MRSA or MRCNS infection. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:6f48dc18-7c3b-4932-ada2-3ee31b19d5b3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28001 biolink:treats UMLS:C0865440 PMID:41385096 "[{""id"":""uuid:d287b3bf-90a4-4bb6-a99d-c4428006d4df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4d600494-8f60-4b68-bc6a-31b197a88f78"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with new additional indications for the treatment of: sepsis, infective endocarditis, secondary infection of trauma, burn or surgical wounds, osteomyelitis, arthritis, peritonitis and purulent meningitis caused by vancomycin-sensitive methicillin-resistant coagulase-negative Staphylococcus (MRCNS); or febrile neutropenia which is suspected of MRSA or MRCNS infection. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:a8964e6e-a169-4bc2-ae17-0da69ba1255b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28001 biolink:treats UMLS:C0746883 PMID:41385096 "[{""id"":""uuid:9bbc276c-f38c-4627-98fa-b6d798d55f3d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ca14389c-2126-40dd-91af-b1ee87e02d28"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with new additional indications for the treatment of: sepsis, infective endocarditis, secondary infection of trauma, burn or surgical wounds, osteomyelitis, arthritis, peritonitis and purulent meningitis caused by vancomycin-sensitive methicillin-resistant coagulase-negative Staphylococcus (MRCNS); or febrile neutropenia which is suspected of MRSA or MRCNS infection. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:f1fc3e17-734b-4268-9296-cc8d05ebc18e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63580 biolink:treats MONDO:0005231 PMID:41385096 "[{""id"":""uuid:b79c18b0-e7ae-4fbc-996f-41c835518f49"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6cf4f7c8-778a-4bca-a065-8b9d460f2af5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and a new dosage for the improvement of viremia with the concomitant use of sofosbuvir in patients with chronic hepatitis C or compensated cirrhosis type C in serogroup 2 (genotype 2) . [Expedited review] uuid:e4de0336-1aeb-47af-a4ce-04fcabed6b62 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63580 biolink:treats MONDO:0005448 PMID:41385096 "[{""id"":""uuid:ad44193c-5f64-4a0d-9011-ec3fcfd18463"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:67d9e57d-f80d-4624-84b9-9e788ff885db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and a new dosage for the improvement of viremia with the concomitant use of sofosbuvir in patients with chronic hepatitis C or compensated cirrhosis type C in serogroup 2 (genotype 2) . [Expedited review] uuid:04637ff8-8881-4329-8e08-fa40d30af21e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6443 biolink:treats HP:0100607 PMID:41385096 "[{""id"":""uuid:66d9320f-b905-430c-9472-81a8f0acad06"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:98f261d8-0909-4750-9a9f-32c48123ca31"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication for the treatment of dysmenorrhoea. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:28f685a3-fa6e-4105-b6ef-fddc4fec7806 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90959 biolink:treats MONDO:0100470 PMID:41385096 "[{""id"":""uuid:6f9398d1-9a43-462a-849b-b8798c68b519"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d1ea2929-f04b-4e09-bd73-fe3ea055627b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication for the relief of symptoms secondary to airway obstructive disorders in bronchial asthma (for use only in patients with the severe persistent type). uuid:30fa5c65-41ae-4603-b878-5e1dc10374bc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:681848 biolink:treats MONDO:0020567 PMID:41385096 "[{""id"":""uuid:1b520c9d-7259-4e44-b80f-6ff69692b2b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f1f4a19c-82d9-4368-bf52-a59f81e1f058"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and a new dosage for the treatment of primary apnoea (apnea of prematurity) in immature or low birth weight infants who have not responded sufficiently to conventional therapies. uuid:5818a625-896e-4a7e-a69f-89ab90239ab9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45863 biolink:treats UMLS:C0854776 PMID:41385096 "[{""id"":""uuid:ebd78e31-df81-4bdd-abd1-953a395cecd8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0b9f880f-f72f-4593-a27a-7dd0695ced27"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and a new dosage for the treatment of unresectable pancreatic cancer. [Priority review] uuid:c8781289-4db4-4ea2-8167-b4b343e11cc9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:YI437801BE biolink:treats MONDO:0019471 PMID:41385096 "[{""id"":""uuid:26716f82-6efd-4908-86c7-3afef6172ed9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5477302c-f51a-490b-be56-fced50f31b0e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a revised indication and a new dosage for the treatment of CCR4-positive adult T-cell leukemia/lymphoma. [Expedited review] uuid:eaed6999-be1c-4376-bcc1-493764ee3c88 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2663 biolink:treats MONDO:0000745 PMID:41385096 "[{""id"":""uuid:4ef87234-f364-4777-a076-2f47bcf798d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7c126126-f6c9-4c11-89cc-a28e8de5ab06"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and a new dosage indicated for the treatment of cardiac arrest due to ventricular fibrillation/pulseless ventricular tachycardia, resistant to electrical cardioversion. uuid:753d4d3b-1083-429d-8e22-557c3dfdebf3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:231425 biolink:treats MONDO:0005155 PMID:41385096 "[{""id"":""uuid:72019ac0-cc00-49ad-9641-a4199d1ec879"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7430d3e4-af13-4b81-81f1-a33bff2f3086"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and a new dosage for the treatment of fluid retention in patients with hepatic cirrhosis who have not responded sufficiently to other diuretics such as loop diuretics. uuid:ba92203c-640d-4140-ad18-48f770524aba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135809 biolink:treats UMLS:C0080203 PMID:41385096 "[{""id"":""uuid:5c8094d7-3117-4f40-8a55-f1d196d66f6e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:abeda5e6-6a79-47cc-8910-a237785806c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and a new dosage for the treatment of tachyarrhythmia including atrial fibrillation/flutter in patients with low cardiac function. uuid:3db6f0b3-40e8-480b-b993-963a773a2c98 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:ZL1R02VT79 biolink:treats MONDO:0003005 PMID:41385096 "[{""id"":""uuid:c6c3be1b-676d-4255-8c16-f4f2e2967ec4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:fbeb0b08-ce31-4f3e-a358-dc6268ce2e20"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with new additional indications and a new dosage for the treatment of macular edema following retinal vein occlusion and choroidal neovascularisasion in pathologic myopia. uuid:57ad40c8-c4a3-4a07-93f4-7356f9fe11f6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17076 biolink:treats UMLS:C5543174 PMID:41385096 "[{""id"":""uuid:faa9d5ff-1781-41c3-af2b-2049db219ccd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3b8d3bc2-38b5-4b9b-87aa-aef5ad5bcaca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and new dosage for the treatment of non-tuberculous mycobacterial infection including mycobacterium avium complex (MAC) caused by streptomycin- sensitive mycobacterium as its applicable microorganism. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:11826978-7ef5-4030-9481-85969c2750c5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17076 biolink:treats MONDO:0005866 PMID:41385096 "[{""id"":""uuid:90606614-4bb5-437a-a042-c64001a8d06f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4f79b418-6e03-4d91-8641-fcf453015fe5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and new dosage for the treatment of non-tuberculous mycobacterial infection including mycobacterium avium complex (MAC) caused by streptomycin- sensitive mycobacterium as its applicable microorganism. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:0e3c99d6-c21f-4bed-b03d-b3709026e2cc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16469 biolink:treats MONDO:0010706 PMID:41385096 "[{""id"":""uuid:894dfede-94b0-40df-819c-b5bc22919c7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a2ee7f77-b0e8-4823-9230-9276c089a78a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and new dosages for the treatment of hypoestrogenism caused by hypogonadism, gonadectomy or primary ovarian insufficiency. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:058a8c56-9747-4057-9cee-7a80c396a586 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68647 biolink:treats MONDO:0011719 PMID:41385096 "[{""id"":""uuid:c0882882-35b4-4891-a75f-00d0d3f9ab15"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d65174bf-e5e7-48bf-b5bd-8c3bd0e2ae08"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication for the treatment of gastrointestinal stromal tumor which has progressed after cancer chemotherapy. [Priority review] uuid:4f74b8eb-6832-4602-a694-f6db3d91fb21 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68647 biolink:treats MONDO:0004992 PMID:41385096 "[{""id"":""uuid:9dea5f95-307e-4646-88ba-29724208eb37"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:db0d8bc6-5fd7-46de-9770-57482e797e56"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication for the treatment of gastrointestinal stromal tumor which has progressed after cancer chemotherapy. [Priority review] uuid:3747d4d0-0922-4554-92ac-fdf540687541 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135875 biolink:treats MONDO:0001657 PMID:41385096 "[{""id"":""uuid:a112acce-d17e-4e2b-818c-ffc8f4994891"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1017b764-0551-4dec-b34b-445e90f1afba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and a new dosage for the treatment of primary malignant brain tumor (only for the case where surgical excision of tumor is performed). [Orphan drug] uuid:097bfa85-cb62-49c6-bb3f-0cf48a6cca80 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5523 biolink:treats UMLS:C0741682 PMID:41385096 "[{""id"":""uuid:575c759d-ea34-4528-8a3d-a677bc5108de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ab1710f2-d60b-4bab-8057-6c98650527b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication for the treatment of premenopausal breast cancer. uuid:65f9b25b-296c-4811-8cfb-54068d168ecd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:NU23Q531G1 biolink:treats MONDO:0021133 PMID:41385096 "[{""id"":""uuid:d45ef0a9-2154-493c-9645-ab42154aff39"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:fdca947d-566f-4a28-bbdc-bdaaa0754c7c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication for the treatment of bleeding tendency caused by acquired blood coagulation factor XIII deficiency. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:69e1c2c6-df80-45dd-a05e-9564d72c7d38 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:NU23Q531G1 biolink:treats HP:0001892 PMID:41385096 "[{""id"":""uuid:3aa27af1-e9be-4bcb-bd3b-8d39e6957502"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:dde2b7ed-3c30-49d4-84fe-3f1dd8454893"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication for the treatment of bleeding tendency caused by acquired blood coagulation factor XIII deficiency. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:c829f5ee-6692-4826-9dbf-e10803680b94 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:K2CJI135MU biolink:treats MONDO:0041996 PMID:41385096 "[{""id"":""uuid:b7d07b60-b94b-424e-b3f4-835b6446b5ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2fedd686-050b-4a4b-bdfc-311dc2831526"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication for the treatment of thallium and thallium compound poisoning. uuid:632f3c5d-ccac-4d54-988d-95ba19276f00 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0005855 PMID:41385096 "[{""id"":""uuid:e295ce95-baab-47e6-8631-89bc7907f787"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:cc5073c2-24e4-4df8-bfb5-d1510f7056dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and a new dosage for pain relief at the resection of molluscum contagiosum. uuid:0243ab4a-9f80-4bb4-9300-82d18a523376 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59343 biolink:treats MONDO:0005441 PMID:41385096 "[{""id"":""uuid:9af08591-93b1-4b38-81ca-7b095e1c3353"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f83b60d8-1441-4986-8441-48084292094e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional dosage for the treatment of pneumonia, otitis media, and sinusitis. uuid:0fa75592-7e8c-4f3f-98a1-c545251686ee biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59343 biolink:treats MONDO:0005961 PMID:41385096 "[{""id"":""uuid:fab8b208-663f-4a75-9e38-b691678b8653"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:03a1a147-8af4-4b91-b60f-29b53563d238"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional dosage for the treatment of pneumonia, otitis media, and sinusitis. uuid:92fb53ff-e4af-4bc8-97a3-c53284bc4354 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6909 biolink:treats MONDO:0024389 PMID:41385096 "[{""id"":""uuid:dab0cd66-ba49-4ace-9e6a-2e30e1627aec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6f8cd68c-e9e3-4b9d-87ab-59ab6c2cc115"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with new additional indications and a new dosage for the treatment of anaerobic bacterial infection, infectious enteritis, amoebic dysentery, and Giardia lamblia infection. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:4d63e521-f3c7-4f49-bb70-f9192dbb196c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6909 biolink:treats MONDO:0001103 PMID:41385096 "[{""id"":""uuid:f1e8a8a9-f4f3-4c93-a313-1e3cd8ff2728"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0764c780-ad7d-4424-a37e-d4aefa049b5d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with new additional indications and a new dosage for the treatment of anaerobic bacterial infection, infectious enteritis, amoebic dysentery, and Giardia lamblia infection. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:ed1fb919-4c57-4fc3-b9e2-8a74b1833dce biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:38940 biolink:treats MONDO:0019954 PMID:41385096 "[{""id"":""uuid:b500cb23-e82e-4df4-be24-dbb00cd28b5a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7f104dc4-5d72-4805-9f6f-aaa309331d0c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and a new dosage for pancreatic neuroendocrine tumour. [Orphan drug] uuid:c8a04757-431f-4af7-8a12-71cb2d18fe47 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:177836 biolink:treats MONDO:0008233 PMID:41385096 "[{""id"":""uuid:6d1e1a61-7b90-4e4b-9f8d-1a75c9e637b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f5ac9a9f-cddf-4334-8d9c-d81bd284dfa3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and a new dosage for the treatment of pheochromocytoma. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:0de04e2f-65d5-42be-b8ed-747745e3a789 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28445 biolink:treats MONDO:0008233 PMID:41385096 "[{""id"":""uuid:311aa68a-1a00-43e7-a468-de5a47dd2bf2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:db438c36-c07f-4566-baac-249bf5bd74e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and a new dosage for the treatment of pheochromocytoma. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:946b35a2-1ad9-44af-a7db-73780da4320d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:44423 biolink:treats MONDO:0005029 PMID:41385096 "[{""id"":""uuid:eb7ac82c-cee3-43b1-87de-0a112e167ee2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:fc8bf591-013b-48ad-8acc-5bfc3c9fe5a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with new additional indications for the treatment of essential thrombocythemia and polycythemia vera. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:6654797e-811e-44bd-8742-fe147b853055 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:44423 biolink:treats MONDO:0009891 PMID:41385096 "[{""id"":""uuid:60f3ef3d-a2c3-40f9-ad9e-d02ca1710dc6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c0765f8b-677c-4af4-877e-91ea0c67dbd3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with new additional indications for the treatment of essential thrombocythemia and polycythemia vera. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:ba776509-2e1f-4446-9e48-090345521bba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:203439 biolink:treats MONDO:0005790 PMID:41385096 "[{""id"":""uuid:b5f85707-a1bf-4357-9405-e1aa1ed0af88"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:fd862a58-c51c-4113-8b6a-383e7fba56be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new pediatric dosage. The drug is indicated for the prevention of hepatitis A. uuid:c0aa6171-f14b-4350-a22e-dcbcfa259833 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4027 biolink:treats MONDO:0005377 PMID:41385096 "[{""id"":""uuid:d5295789-bc69-4ab7-9d25-e90b18fdcb0d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1705cac8-9c5d-46e9-962f-2385ce78aa7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and a new dosage for the treatment of nephrotic syndrome (for use only in patients who have not sufficiently responded to adequate treatment with corticosteroids). [Public knowledge-based application after PAFSC's preliminary assessment] uuid:755aa800-df9b-49b0-9d49-e1d50bc5db91 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77733 biolink:treats UMLS:C0080203 PMID:41385096 "[{""id"":""uuid:02f0098f-2783-46e3-a812-b3e84be0d513"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:140dc48f-be41-4c00-941a-34f0d39e9270"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional dosage indicated for the treatment of tachyarrhythmia in pediatric patients (paroxysmal supraventricular tachycardia, paroxysmal atrial fibrillation, paroxysmal atrial flutter). [Public knowledge-based application after PAFSC's preliminary assessment] uuid:244a16bf-67bf-4a12-8019-c948f83f43f9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77733 biolink:treats MONDO:1030011 PMID:41385096 "[{""id"":""uuid:ed12044d-80f6-4110-8bc8-00ab88ae2045"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7d919618-7177-48a8-a9f7-a3a03f14ee97"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional dosage indicated for the treatment of tachyarrhythmia in pediatric patients (paroxysmal supraventricular tachycardia, paroxysmal atrial fibrillation, paroxysmal atrial flutter). [Public knowledge-based application after PAFSC's preliminary assessment] uuid:e6bd8777-3c3d-4e26-be2d-501b380d5316 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77733 biolink:treats UMLS:C0741292 PMID:41385096 "[{""id"":""uuid:d3b25cba-2eb7-4964-bc24-a3c4854c80bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:159a9cf2-4e43-4f40-89c5-bc79b1c14533"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional dosage indicated for the treatment of tachyarrhythmia in pediatric patients (paroxysmal supraventricular tachycardia, paroxysmal atrial fibrillation, paroxysmal atrial flutter). [Public knowledge-based application after PAFSC's preliminary assessment] uuid:65d50aa4-0434-4082-a2c7-777603aab5ad biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31859 biolink:treats HP:0001262 PMID:41385096 "[{""id"":""uuid:4811cf22-2e18-44d5-8ac0-708bd43f7694"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6a7a37da-50e7-4bc5-bbc7-4e0d301a1067"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication for the treatment of excessive daytime sleepiness in patients with obstructive sleep apnea syndrome who receive treatment of airway obstruction with continuous positive airway pressure (CPAP) therapy, etc. uuid:08caf593-fcd0-4186-b74c-3eed57cc6584 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:127780 biolink:treats UMLS:C0877635 PMID:41385096 "[{""id"":""uuid:250c574e-fdc9-49b1-9ce2-6dfc86eaa1f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:035739b8-682d-4f50-b878-f60bad09b745"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with new additional indications and a new dosage for the treatment of cytomegalovirus viremia and cytomegalovirus infection in patients undergoing hematopoietic stem cell transplantation. uuid:9e343969-bdc7-4c1b-ac55-ef9379503b5f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2955 biolink:treats MONDO:0005823 PMID:41385096 "[{""id"":""uuid:959ed5bc-81dd-4ed2-96f5-fac196c3c353"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:739f7da7-8b0e-4d55-b698-12db2245a3e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication for Legionella pneumophila as applicable microorganism. uuid:f5377877-ecc7-4868-aed2-bc00e51ea421 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6076 biolink:treats MONDO:0002041 PMID:41385096 "[{""id"":""uuid:17c056de-c078-41ba-b3f5-954649006789"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a51e46c1-921f-4557-ba41-30d9e3e9f1c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with new indications for (1) the treatment of fungal infection, (2) the treatment of febrile neutropenia with suspected fungal infection, and (3) the prevention of deep mycosis in patients with hematologic malignancy or hematopoietic stem cell transplantation in whom neutropenia is anticipated. uuid:d4e2e1c3-6560-4ce5-9482-98bc55606bbf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6076 biolink:treats UMLS:C0948382 PMID:41385096 "[{""id"":""uuid:d22d7da5-c924-40a4-a7d5-1901448f6c73"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7f59aa6b-1ccc-4d40-b45f-7554e4d1aa3d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with new indications for (1) the treatment of fungal infection, (2) the treatment of febrile neutropenia with suspected fungal infection, and (3) the prevention of deep mycosis in patients with hematologic malignancy or hematopoietic stem cell transplantation in whom neutropenia is anticipated. uuid:2f752645-45b9-480d-9352-38bbc584754b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:81569 biolink:treats UMLS:C1699041 PMID:41385096 "[{""id"":""uuid:bede0f80-a659-48cb-ac11-6688c83d651b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7ba64cf5-fd5a-44b8-ade2-61dad9302d79"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and a new dosage for induction of ovulation in patients with anovulation and infrequent ovulation associated with hypothalamic-pituitary dysfunction or polycystic ovarian syndrome. uuid:c2b164a1-5076-471c-a9b6-59dd2cf3dea8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:81569 biolink:treats MONDO:0043101 PMID:41385096 "[{""id"":""uuid:877d82cd-d955-4e7e-8ac7-e015b9da7499"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e8eb1ae6-4ec8-4aaa-8033-7b40f59dc411"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and a new dosage for induction of ovulation in patients with anovulation and infrequent ovulation associated with hypothalamic-pituitary dysfunction or polycystic ovarian syndrome. uuid:ccfe04ca-26a4-4ac6-8228-27e99bc5e656 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:94810 biolink:treats MONDO:0011786 PMID:41385096 "[{""id"":""uuid:5d55f369-028e-40ba-9ef8-dfa5f8d71d7d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:15c96111-a885-456b-bace-fad2e3942111"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication for the treatment of allergic rhinitis in pediatric patients. uuid:cf20b862-004f-4d24-9033-3df51526a5dd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:44241 biolink:treats MONDO:0018912 PMID:41385096 "[{""id"":""uuid:6ce9a2a5-2fce-41ba-9649-21be3879dc71"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f4aff9d1-7cb0-4244-85ae-70dfc29e5f06"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and a new dosage for the treatment of Cushing's syndrome. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:bc8b140a-38ef-4755-8716-2cd5c9b1d9b7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5864 biolink:treats MONDO:0005062 PMID:41385096 "[{""id"":""uuid:3e231863-5d0c-47fe-97af-7b9aecca9502"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8b7873d2-2853-4e11-b18d-65f03c0c4e1f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and a new dosage for the treatment of malignant lymphoma. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:30ea4714-b2af-468f-9722-207fa7e32abd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8768 biolink:treats MONDO:0007186 PMID:41385096 "[{""id"":""uuid:49a86d28-af20-4d85-ab95-565558171a22"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0886957f-2631-4285-acf3-95dfc856c55c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and a new dosage for the treatment of non-erosive reflux disease. uuid:b21dc1eb-8d70-4c85-b351-1e96d0ee2b5e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27375 biolink:treats MONDO:0018310 PMID:41385096 "[{""id"":""uuid:254be243-ea16-4e0a-b78f-58960fed7dba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:baad5b6d-da73-4519-b13f-9091ec109f00"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and a new dosage for the treatment of Langerhans cell histiocytosis. [Public knowledge-based application after preliminary assessment by the Pharmaceutical Affairs and Food Sanitation Council (PAFSC)] uuid:9dc951f7-5f84-45ec-8136-53e5ea22d48a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2663 biolink:treats MONDO:0004981 PMID:41385096 "[{""id"":""uuid:2a43dcfe-ccc7-405e-8b2b-050e2cbd64d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5203e4b1-3c3b-41bb-9c6b-46ff137b67b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication for the treatment of arterial fibrillation with cardiac failure (impaired cardiac function). uuid:0a9f640d-e665-46d1-8fa1-657bc0e96fac biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2663 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:2a0055f0-419c-4f5d-9cd6-67cda0d25ade"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:add33ad2-a225-4bb7-9ca3-0a47e307306f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication for the treatment of arterial fibrillation with cardiac failure (impaired cardiac function). uuid:94807575-3c3e-4fb6-909d-a0340ff156b3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB10343 biolink:treats MONDO:0004200 PMID:41385096 "[{""id"":""uuid:6197da30-d331-45b7-8d75-261a9d4dbf54"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ee126ca6-5c8f-4b5f-aa00-4efdb8022ac0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional dosage indicated for the treatment of superficial bladder cancer and carcinoma in situ of bladder. uuid:29a21295-bd9c-4055-b00f-716941e85112 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:XRO4566Q4R biolink:treats MONDO:0005354 PMID:41385096 "[{""id"":""uuid:6f8476fb-f28d-4130-be3f-8bbcc5ffaeae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3d065f0b-ebfc-48cb-8b78-48eb0a9296c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the improvement of viraemia in chronic hepatitis C on concomitant administration with ribavirin. uuid:2d042510-7cf5-41d7-98cc-3269ff091983 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2682 biolink:treats UMLS:C5391333 PMID:41385096 "[{""id"":""uuid:d954a742-e458-4639-a0e2-93573af48619"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b20392a7-6d69-4871-a3bd-b21d1c4b9b8c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with new additional indications and a new dosage for the treatment of fungal infections caused by Mucor species, Absidia species, Rhizopus species, Rhizomucor species, Cladosporium species, Cladophialophora species, Fonsecaea species, Phialophora species, Exophiala species, Coccidioides species, Histoplasma species, and Blastomyces species and visceral leishmaniasis. uuid:ce60aef3-397e-4c16-a79c-4b2879ea1aff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2682 biolink:treats UMLS:C0864807 PMID:41385096 "[{""id"":""uuid:094acce1-c0d8-42f1-8920-87630ccbb4e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:db1c1ced-4fc3-4822-9665-9c91f87f8dbe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with new additional indications and a new dosage for the treatment of fungal infections caused by Mucor species, Absidia species, Rhizopus species, Rhizomucor species, Cladosporium species, Cladophialophora species, Fonsecaea species, Phialophora species, Exophiala species, Coccidioides species, Histoplasma species, and Blastomyces species and visceral leishmaniasis. uuid:b6dbdba6-fae4-4324-85f5-ad6a0c1bbe2b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63599 biolink:treats MONDO:0002280 PMID:41385096 "[{""id"":""uuid:57c55fad-03ef-47d0-b47a-68b37b8a02f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b297ade2-4e23-4433-b4c2-218f80dd5be6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication for the treatment of chronic lymphocytic leukemia with anemia or thrombocytopenia. uuid:d92cc3e2-d6e1-426a-89a4-6fb6e15a7be7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63599 biolink:treats MONDO:0002049 PMID:41385096 "[{""id"":""uuid:221a30f0-2993-4568-b3da-1cb34023bef1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2cd59531-c348-4c91-ae7d-93b235e1d1e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication for the treatment of chronic lymphocytic leukemia with anemia or thrombocytopenia. uuid:b5ea06d0-5889-4770-9697-157e0f9f2649 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63599 biolink:treats MONDO:0018876 PMID:41385096 "[{""id"":""uuid:aa970f84-bcd5-49e3-9754-06b59c51827d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:475f8f4d-2fef-4fa2-8fba-1faf75da5907"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with new additional indications and a new dosage for the treatment of recurrent or refractory low-grade B-cell non-Hodgkin’s lymphoma and mantle cell lymphoma. uuid:217acb42-ed3d-4455-95c0-433ca8e69159 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90117 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:8c1f549e-9222-4e7a-9c0e-4cc852f93f8e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f4346f10-d8e5-4d45-96fd-23073b30cf75"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new route of administration, a new indication, and a new dosage for sentinel lymph node mapping in breast cancer and malignant melanoma. [Expedited review] uuid:b43446b2-1ecb-4b60-a6e2-35366bd28784 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90117 biolink:treats MONDO:0005012 PMID:41385096 "[{""id"":""uuid:f200bf0e-f36e-4a8c-9c7c-48c475d9e1de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2e349e70-e297-427b-a934-73d9f9d7730d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new route of administration, a new indication, and a new dosage for sentinel lymph node mapping in breast cancer and malignant melanoma. [Expedited review] uuid:89c7d903-7f54-4527-83d4-1fd4ccea09af biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31696 biolink:treats MONDO:0005012 PMID:41385096 "[{""id"":""uuid:3f13bff8-d646-4174-96dc-97eb80e97aae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a5aada5b-2228-4d9a-8720-e761151888c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new route of administration, a new indication, and a new dosage for sentinel lymph node mapping in breast cancer and malignant melanoma. [Expedited review] uuid:79c76560-095b-4356-9b33-51391eef9520 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:33353 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:ba897c20-2915-4e61-856e-3a6a6e9ded28"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:555ce7f5-db0c-42e9-9382-aaa3d2669692"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new route of administration and a new indication for sentinel lymph node mapping in breast cancer and malignant melanoma. [Expedited review] uuid:b874a33c-e91a-4b26-b018-a029b7f6e95c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:33353 biolink:treats MONDO:0005012 PMID:41385096 "[{""id"":""uuid:0015d786-3503-4aac-b2ce-1325d7525537"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3280aa05-69e8-4edb-9a1b-9669c8a6b57a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new route of administration and a new indication for sentinel lymph node mapping in breast cancer and malignant melanoma. [Expedited review] uuid:fb97dfb1-544b-494d-acaa-174197a40f3a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:92769 biolink:treats MONDO:0005072 PMID:41385096 "[{""id"":""uuid:c8ef3bfb-3217-4e6a-9074-1fe98bbef82e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:80c53993-1d60-4326-b979-a93edc4a444d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and a new dosage for diagnosis of neuroblastoma in tumor scintigraphy. uuid:206a1128-e97f-4d5d-9653-6ac303a08bf9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:33353 biolink:treats MONDO:0001741 PMID:41385096 "[{""id"":""uuid:f4b635ae-f7ef-4842-a3e8-ef7d0fd4ffe4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a3f61e81-cd12-4ef5-a176-a6e3bad7cd46"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication for diagnostic localization of hyperparathyroidism in parathyroid scintigraphy. uuid:584e1e02-86da-4a2a-be46-3d6218fea96d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:N6OU7HJ70P biolink:treats MONDO:0001741 PMID:41385096 "[{""id"":""uuid:60455240-186f-4f74-a928-167d1ae51b5d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8cd63fa3-7220-45c7-a344-3f584025d2ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication for diagnostic localization of hyperparathyroidism in parathyroid scintigraphy. uuid:1bd4c007-b778-4aed-b440-10b2e42b1141 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:LR3UXN0193 biolink:treats MONDO:0006594 PMID:41385096 "[{""id"":""uuid:6a1f523c-8884-4ad3-9186-0ed75ab20ad7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7da6489e-7c6e-4698-bf6e-0a9dda8a79b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage for the treatment of pemphigus (for use when steroid drugs are not sufficiently effective). uuid:a129783e-f981-4433-ad1b-926af99676f7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0006050 biolink:treats UMLS:C0014670 PMID:41385096 "[{""id"":""uuid:aa102e4c-e3b5-42bf-84d3-9c38cdb7949f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:59cd8e7f-3dfa-4c04-b8e2-45cde960d84a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of equinus deformity associated with lower limb spasticities in juvenile cerebral palsy in patients 2 years or older. DRUGBANK:DB00083 uuid:474652bf-edc3-4395-b7d0-67fa0ce6d761 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0006050 biolink:treats MONDO:0006497 PMID:41385096 "[{""id"":""uuid:c93bcddb-f461-4f90-adbe-725d0d200d51"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:45dbca2e-c688-4822-bd84-609397576b55"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of equinus deformity associated with lower limb spasticities in juvenile cerebral palsy in patients 2 years or older. DRUGBANK:DB00083 uuid:6e5f9bc5-3e1c-43ef-a898-5b751695117c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2469 biolink:treats MONDO:0005344 PMID:41385096 "[{""id"":""uuid:afe40f5d-7934-43ed-8f21-dc303e5a398f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f96dd6a6-c49a-4654-96a5-26629a4b85a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for inhibition of hepatitis B virus replication in patients with type B chronic liver disease in whom abnormal hepatic function was observed in association with proliferation of hepatitis B virus. uuid:b49718b3-632a-4bf9-8646-cb5986272aeb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2469 biolink:treats UMLS:C0341439 PMID:41385096 "[{""id"":""uuid:740ff776-f184-4a98-879d-bc9d4956bcd8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:86dec67d-20d2-499e-b040-74c5184ba516"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for inhibition of hepatitis B virus replication in patients with type B chronic liver disease in whom abnormal hepatic function was observed in association with proliferation of hepatitis B virus. uuid:00b1416b-9e77-4add-b633-67b8ae25488c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:71300723 biolink:treats MONDO:0005002 PMID:41385096 "[{""id"":""uuid:2206771a-a2cb-4645-9283-1c715e4db875"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2bd07aec-6eb9-41b9-9a09-ed3f290f60b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and a new dosage for the alleviation of various symptoms associated with chronic obstructive pulmonary disease (chronic bronchitis and emphysema) (for use when concomitant use of inhaled corticosteroid and long-acting β2-agonist is required). uuid:1dd2c91b-f150-475b-90cc-f594ca811fa1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:71300723 biolink:treats MONDO:0005607 PMID:41385096 "[{""id"":""uuid:361c7686-1a30-431a-9d55-992957e17083"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:44562d3d-8519-4b92-a3ea-e12a34048a38"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and a new dosage for the alleviation of various symptoms associated with chronic obstructive pulmonary disease (chronic bronchitis and emphysema) (for use when concomitant use of inhaled corticosteroid and long-acting β2-agonist is required). uuid:62e89f7c-3ce4-4e54-9609-e76d9bc3b137 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:71300723 biolink:treats MONDO:0004849 PMID:41385096 "[{""id"":""uuid:4a484085-0643-4cbf-8b79-db27fa15803e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f0a00fe0-1177-481d-80a7-3480045f521a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and a new dosage for the alleviation of various symptoms associated with chronic obstructive pulmonary disease (chronic bronchitis and emphysema) (for use when concomitant use of inhaled corticosteroid and long-acting β2-agonist is required). uuid:8a24d1c2-6d55-4db0-a848-658527eb5029 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59560 biolink:treats MONDO:0019335 PMID:41385096 "[{""id"":""uuid:ceaa6073-3aef-474a-87ec-786596555f9c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d2323222-e398-4631-95d1-74e3a0059732"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage for reduction of serum phenylalanine levels in patients with hyperphenylalaninemia (tetrahydrobiopterin-responsive hyperphenylalaninemia) caused by tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. [Orphan drug] uuid:f4d0299f-1232-494a-8200-5c716681421a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59560 biolink:treats MONDO:0017389 PMID:41385096 "[{""id"":""uuid:8b24f06b-c420-4c89-9003-076f6129cae2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8e8fc578-b467-4f97-b845-9d5f4b846d35"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage for reduction of serum phenylalanine levels in patients with hyperphenylalaninemia (tetrahydrobiopterin-responsive hyperphenylalaninemia) caused by tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. [Orphan drug] uuid:8e4b43f7-757a-48b3-b8e2-8f3a28401716 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63599 biolink:treats MONDO:0018881 PMID:41385096 "[{""id"":""uuid:95e596c1-7440-4c75-bfc2-d69a1e965d87"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:762b2320-4186-44ae-ac03-46ae0bdb5dee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage for use as a conditioning prior to allogeneic hematopoietic stem cell transplantation in the following diseases: acute myeloid leukemia, myelodysplastic syndrome, chronic myeloid leukemia, chronic lymphocytic leukemia, malignant lymphoma, and multiple myeloma. uuid:b53ae4bd-94db-4fdc-a423-2b2b647f019b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63599 biolink:treats MONDO:0011996 PMID:41385096 "[{""id"":""uuid:fbecea0f-fce6-490f-80ff-6636d2c32588"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4500b6c7-d2fe-4b96-8a63-46989d0540a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage for use as a conditioning prior to allogeneic hematopoietic stem cell transplantation in the following diseases: acute myeloid leukemia, myelodysplastic syndrome, chronic myeloid leukemia, chronic lymphocytic leukemia, malignant lymphoma, and multiple myeloma. uuid:fbdf2a56-53d1-43d6-b7b0-a7026387bf4a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63599 biolink:treats MONDO:0009693 PMID:41385096 "[{""id"":""uuid:4c7806dd-15ee-4a05-b178-c2d2fd097d04"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f6984481-352c-4e62-8458-7a3864cfd3d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage for use as a conditioning prior to allogeneic hematopoietic stem cell transplantation in the following diseases: acute myeloid leukemia, myelodysplastic syndrome, chronic myeloid leukemia, chronic lymphocytic leukemia, malignant lymphoma, and multiple myeloma. uuid:0eddbf5c-fb16-45ac-b091-3541559f7326 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:175901 biolink:treats MONDO:0040679 PMID:41385096 "[{""id"":""uuid:1ee2a970-c1bd-4704-a2c6-09637ef01ec0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9b3a388f-984e-482a-878b-29e48f7ee173"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication for the treatment of urothelial carcinoma. uuid:b501565d-4a7d-4b18-8315-a3fe343b80b9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:567361 biolink:treats MONDO:0018906 PMID:41385096 "[{""id"":""uuid:e5d7c652-4878-4631-83dd-e51d5966d77b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3bc6511a-6c6e-4564-9a62-56059c2ebab1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional dosage indicated for the treatment of recurrent, relapsing, or refractory indolent B-cell non-Hodgkin's lymphoma including follicular lymphoma, and mantle cell lymphoma. uuid:9fd5052d-f1f3-4c31-b8d8-54e538f70408 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:567361 biolink:treats MONDO:0018876 PMID:41385096 "[{""id"":""uuid:11f5a1a9-fc64-4d5e-b518-18087d5ebf60"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:10e75e3f-71b9-4218-b2b4-54ff3c72b3b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional dosage indicated for the treatment of recurrent, relapsing, or refractory indolent B-cell non-Hodgkin's lymphoma including follicular lymphoma, and mantle cell lymphoma. uuid:49c3b414-8784-494a-93e4-9f862a200cdd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6775 biolink:treats UMLS:C0852922 PMID:41385096 "[{""id"":""uuid:5fdb3d79-1d3a-4d4d-a85b-a6a8cfcd107e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6c04b77d-f427-421c-a08c-71677d60b01d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new dosage for use in pediatric patients for the treatment of ulcerative colitis (excluding severe patients) and Crohn’s disease. uuid:6984d17c-8a94-47c2-89fe-a04033bf8b72 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9919 biolink:treats MONDO:0005700 PMID:41385096 "[{""id"":""uuid:6d676437-75ea-4ea8-a7a7-ed71746d03d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:eead83a2-3ff1-42ce-8bad-71f67d41ba4c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and dosage for the treatment of varicella in children. uuid:7a567faa-80a7-45c6-a38b-48fd82ae5835 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:151392 biolink:treats MONDO:0005230 PMID:41385096 "[{""id"":""uuid:784a1add-26ba-4501-b6c2-c810873f7623"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1187957a-6fa9-49cc-b66b-f7a04eb9579d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the treatment of superficial skin infections, deep skin infections, lymphangitis and lymphadenitis, chronic pyoderma, laryngopharyngitis, tonsillitis, acute bronchitis, cystitis, and pyelonephritis. uuid:09f84406-7c0d-406e-8bb3-1dbe113eee2e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:151392 biolink:treats MONDO:0005832 PMID:41385096 "[{""id"":""uuid:89b9c685-97a2-4e8f-922e-f38bee6ce9d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1f001de7-90fc-453b-88aa-028ff5fc00e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the treatment of superficial skin infections, deep skin infections, lymphangitis and lymphadenitis, chronic pyoderma, laryngopharyngitis, tonsillitis, acute bronchitis, cystitis, and pyelonephritis. uuid:d8812a18-0cb5-4794-8a32-7b376b4d82ec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:151392 biolink:treats MONDO:0002052 PMID:41385096 "[{""id"":""uuid:e0382e51-0070-45a2-877f-5ae44d754777"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b8a7b85f-e2de-4b73-9eb6-db5b5ea3acc9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the treatment of superficial skin infections, deep skin infections, lymphangitis and lymphadenitis, chronic pyoderma, laryngopharyngitis, tonsillitis, acute bronchitis, cystitis, and pyelonephritis. uuid:b0da97d7-39a2-4978-9367-b70f6c737adc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:151392 biolink:treats MONDO:0002922 PMID:41385096 "[{""id"":""uuid:c52c4e19-677a-425f-9f25-27479f821ec6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4c669d3c-33df-44ec-be07-0f922cb284fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the treatment of superficial skin infections, deep skin infections, lymphangitis and lymphadenitis, chronic pyoderma, laryngopharyngitis, tonsillitis, acute bronchitis, cystitis, and pyelonephritis. uuid:efa65d39-fa20-47e6-83a3-3c51202b2dd2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:151392 biolink:treats MONDO:0001218 PMID:41385096 "[{""id"":""uuid:d5fd87d0-86c5-4ae8-bc33-3a42c8e81a3b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f2a19f4f-728d-4b4c-88a9-048e3853f376"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the treatment of superficial skin infections, deep skin infections, lymphangitis and lymphadenitis, chronic pyoderma, laryngopharyngitis, tonsillitis, acute bronchitis, cystitis, and pyelonephritis. uuid:54e826e4-3938-418a-996e-26af595ffaa3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:151392 biolink:treats MONDO:0001039 PMID:41385096 "[{""id"":""uuid:e7aa9d62-a0ea-44fe-a8c0-ebb2f2658513"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:88dbfb93-94ad-4fdd-a7cb-acf2d72386f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the treatment of superficial skin infections, deep skin infections, lymphangitis and lymphadenitis, chronic pyoderma, laryngopharyngitis, tonsillitis, acute bronchitis, cystitis, and pyelonephritis. uuid:bfa9f618-c533-4bc3-9f9f-1f5cdf442c23 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:151392 biolink:treats HP:0012388 PMID:41385096 "[{""id"":""uuid:7636bf38-bce0-409e-8a0b-0d56d9bdb55d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c339b03d-413e-44fe-838f-8570188ebb9b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the treatment of superficial skin infections, deep skin infections, lymphangitis and lymphadenitis, chronic pyoderma, laryngopharyngitis, tonsillitis, acute bronchitis, cystitis, and pyelonephritis. uuid:2bafd1e1-b194-4f97-8190-6d70b66e544e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:151392 biolink:treats MONDO:0006032 PMID:41385096 "[{""id"":""uuid:8caa0ad7-dd48-424c-9c07-740f66277b8d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f79b9ad6-d5f3-4b2b-aff4-20af61d96abb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the treatment of superficial skin infections, deep skin infections, lymphangitis and lymphadenitis, chronic pyoderma, laryngopharyngitis, tonsillitis, acute bronchitis, cystitis, and pyelonephritis. uuid:44f2ee57-a28f-421a-a22b-b50f3afeccec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:151392 biolink:treats MONDO:0006939 PMID:41385096 "[{""id"":""uuid:09ab50d8-2e29-456a-af77-be12a4aab086"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6fd4e9e3-bfd8-4cdc-9ab3-876c0f8dc826"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the treatment of superficial skin infections, deep skin infections, lymphangitis and lymphadenitis, chronic pyoderma, laryngopharyngitis, tonsillitis, acute bronchitis, cystitis, and pyelonephritis. uuid:d7d0d1b4-d0d9-45a1-99e3-7c1b94b82b99 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:71300723 biolink:treats MONDO:0100470 PMID:41385096 "[{""id"":""uuid:dfceaf33-052b-449d-a62e-656132b4ae59"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:dda5a901-bf68-403a-a1f9-7b4dbbdc0578"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional pediatric dosage in a new dosage form indicated for the treatment of bronchial asthma (for use when concomitant use of inhaled corticosteroid and long-acting β2- agonist is required). [Expedited review] uuid:b1be4701-90ee-447e-9b13-3627d7de3f7a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4F4X42SYQ6 biolink:treats MONDO:0005556 PMID:41385096 "[{""id"":""uuid:ea05fe1c-980c-4d60-9e8c-7a26595ee122"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:87420091-ef47-4826-b14a-bb0ec4d03b96"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the treatment of lupus nephritis in patients who have not responded sufficiently to conventional treatments. [Public knowledge-based application after preliminary assessment by the Pharmaceutical Affairs and Food Sanitation Council (PAFSC)] uuid:7035fdd9-13ad-47bb-9523-2a781d35a1e6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4F4X42SYQ6 biolink:treats UMLS:C0340530 PMID:41385096 "[{""id"":""uuid:0a6c6d87-e4eb-4a1d-a149-4872220a4efb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ac2e5237-31e8-48c4-8c89-506f37c9f9f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the suppression of antibody-mediated rejection in the following organ transplantations: kidney transplantation, liver transplantation, heart transplantation, lung transplantation, pancreas transplantation, small intestine transplantation, and the treatment of antibody-mediated rejection in the following organ transplantations: kidney transplantation, liver transplantation, heart transplantation, lung transplantation, pancreas transplantation, small intestine transplantation. [Orphan drug] uuid:457c5440-45f5-4913-965e-7568ccc35602 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85010 biolink:treats MONDO:0015909 PMID:41385096 "[{""id"":""uuid:474a5e87-0575-4a6d-ad47-28f8e8302cf7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b410a06d-b56b-4265-aa94-4d8e382fbe7d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional pediatric dosage indicated for the treatment of aplastic anemia. [Orphan drug] uuid:62931e2d-bb7b-4743-8832-c5129e79677c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:NQX9KB6PCL biolink:treats HP:0004322 PMID:41385096 "[{""id"":""uuid:89bb219d-644a-4db1-90bd-6f861f040336"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:02633ec9-45dd-4796-88f3-652764914f36"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication for the treatment of short stature in SHOX deficiency prior to epiphyseal closure. uuid:09adad4d-982c-44b8-9d11-a062ec831e28 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:NQX9KB6PCL biolink:treats UMLS:C3897045 PMID:41385096 "[{""id"":""uuid:1faf71b2-5fc0-4716-ba13-cb1936b87b38"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:17a2f92a-af3a-4ba9-be18-b2bc46d6dd2d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication for the treatment of short stature in SHOX deficiency prior to epiphyseal closure. uuid:7a995cd8-5c90-417b-b01c-7caf6af46193 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DQ448MW7KS biolink:treats MONDO:0800133 PMID:41385096 "[{""id"":""uuid:c477e645-7e74-4206-a8c2-3256eefebd36"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:045206bb-e4e8-409f-a604-a10ac1d28e13"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication for the prevention of serious lower respiratory tract disease caused by respiratory syncytial (RS) virus infection in neonates, infants, and children aged 24 months and younger with pulmonary hypoplasia, airway stenosis, congenital esophageal atresia, congenital metabolic disorder, or neuromuscular disease at the early stage of the RS virus season. [Priority review] uuid:925b73e5-e474-4788-9b53-6e1488f13b29 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DQ448MW7KS biolink:treats MONDO:0001305 PMID:41385096 "[{""id"":""uuid:7789c07e-2c1a-4a46-866e-4a42d84a4004"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:22ba49ad-56ee-4dcd-8b48-565eb7e9bf3f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication for the prevention of serious lower respiratory tract disease caused by respiratory syncytial (RS) virus infection in neonates, infants, and children aged 24 months and younger with pulmonary hypoplasia, airway stenosis, congenital esophageal atresia, congenital metabolic disorder, or neuromuscular disease at the early stage of the RS virus season. [Priority review] uuid:4da2ac01-5cae-4a82-90a1-88d09ea6105e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DQ448MW7KS biolink:treats MONDO:0001044 PMID:41385096 "[{""id"":""uuid:59b5d244-9a36-4079-a6a5-dd6c801e604b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:845b1ccc-181f-4bb2-814f-adea0e5c8437"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication for the prevention of serious lower respiratory tract disease caused by respiratory syncytial (RS) virus infection in neonates, infants, and children aged 24 months and younger with pulmonary hypoplasia, airway stenosis, congenital esophageal atresia, congenital metabolic disorder, or neuromuscular disease at the early stage of the RS virus season. [Priority review] uuid:d1bfe492-929c-453d-b962-d674458ca303 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DQ448MW7KS biolink:treats MONDO:0019052 PMID:41385096 "[{""id"":""uuid:f60065e0-d582-4302-b781-1f76dc5d8bc8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d9be7368-782b-4b6d-9872-e0ceef1ae43a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication for the prevention of serious lower respiratory tract disease caused by respiratory syncytial (RS) virus infection in neonates, infants, and children aged 24 months and younger with pulmonary hypoplasia, airway stenosis, congenital esophageal atresia, congenital metabolic disorder, or neuromuscular disease at the early stage of the RS virus season. [Priority review] uuid:8d5acff8-3cc0-46c4-92ba-695646cf6a1b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DQ448MW7KS biolink:treats MONDO:0019056 PMID:41385096 "[{""id"":""uuid:6cc38760-f07a-44db-8b3c-121c10be1d4a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:bf4b6cc2-364b-4988-8be0-b4edd03016e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication for the prevention of serious lower respiratory tract disease caused by respiratory syncytial (RS) virus infection in neonates, infants, and children aged 24 months and younger with pulmonary hypoplasia, airway stenosis, congenital esophageal atresia, congenital metabolic disorder, or neuromuscular disease at the early stage of the RS virus season. [Priority review] uuid:743fb788-6f78-4609-bb4c-48bb09d57d93 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28680 biolink:treats MONDO:0010643 PMID:41385096 "[{""id"":""uuid:ac66e1fa-20db-4b0d-a351-97f9eff8df80"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:82244204-1743-4a7c-b006-a59f17260c00"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the treatment of acute leukemia. [Public knowledge-based application, Expedited review] uuid:a8fb6c74-9b3d-4d09-bc5d-3e257b41ed0a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75045 biolink:treats MONDO:0018935 PMID:41385096 "[{""id"":""uuid:9ed2678a-f36c-4082-a8de-31d37ee8f82d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e8d6ab73-3d3b-4213-ad22-c34680450498"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the treatment of advanced or recurrent BRAF mutation-positive solid tumor (excluding colon/rectal cancer) that is refractory or intolerant to standard therapies and relapsed or refractory BRAF mutation-positive hairy cell leukemia. [Orphan drug] uuid:2ca9a348-e70e-49a9-90e0-9d83906c304f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75998 biolink:treats MONDO:0018935 PMID:41385096 "[{""id"":""uuid:fea50e66-703d-4eda-ad6c-a2193b062ee2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:57fa36e2-9498-4b55-8470-9f49224fd797"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the treatment of advanced or recurrent BRAF mutation-positive solid tumor (excluding colon/rectal cancer) that is refractory or intolerant to standard therapies and relapsed or refractory BRAF mutation-positive hairy cell leukemia. [Orphan drug] uuid:b0f88e1c-e487-461b-87ef-2e08564c9c2a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46345 biolink:treats MONDO:0001056 PMID:41385096 "[{""id"":""uuid:f62b54dd-0eb0-4b44-9a89-da57578d26e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8e933b4e-0324-4611-8f52-0d24447268b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the treatment of unresectable advanced or recurrent gastric cancer. [Public knowledge-based application] uuid:0dc87040-269d-491e-938e-cee3cc214b75 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135920 biolink:treats HP:0000011 PMID:41385096 "[{""id"":""uuid:f2a5662b-7c92-4a5c-8586-ab25d50a3dc8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a5a072c2-8826-46e1-b3bb-f794383b8255"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new additional pediatric dosage for the control of urination in patients with neurogenic bladder. uuid:99e09f94-e25b-4d65-a44a-c1608a01c9a4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4F4X42SYQ6 biolink:treats MONDO:0019100 PMID:41385096 "[{""id"":""uuid:9ae74b1a-7fd3-4deb-9715-f6f7ef500f05"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:775f78aa-c961-4d7a-b29a-ea2b77ef48d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the prevention of relapse of neuromyelitis optica spectrum disorder (including neuromyelitis optica). [Orphan drug] uuid:e5b92840-4d45-4c14-8b5f-7fced46d41fc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6T8C155666 biolink:treats MONDO:0007576 PMID:41385096 "[{""id"":""uuid:1c392a47-2977-483c-b601-7750f1fe2d96"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:68964465-a7de-4a59-8e06-e06dee4fb418"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the treatment of unresectable advanced or recurrent esophageal cancer. [Priority review] uuid:f034d5ff-56a7-4995-971f-ebe1f8068b2d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2S9ZZM9Q9V biolink:treats MONDO:0008170 PMID:41385096 "[{""id"":""uuid:ae8b7716-e48e-475e-862b-199eb4142320"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8f60ab6e-7d17-418c-981b-4722b556e362"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage indicated for the treatment of ovarian cancer. Public knowledge-based application after PAFSC's preliminary assessment] uuid:a01d8dc4-aedd-4b1b-8012-95cb9d9004fd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45863 biolink:treats MONDO:0002974 PMID:41385096 "[{""id"":""uuid:b5e22ecb-4e35-464b-b756-b5ae19f55d0e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e493efc7-d517-4cec-a27f-94bd72fb37c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage indicated for thetreatment of advanced or recurrent cervical cancer. [Public knowledge-based application] uuid:3473ae96-986d-4f6d-9f2a-eda7e59d0f53 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22984 biolink:treats MONDO:0001056 PMID:41385096 "[{""id"":""uuid:dd89ad9a-b03c-47d0-a1e5-ae41bf557c0a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:81d44bb5-a03c-44b5-8809-85809edc6c4e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the treatment of unresectable advanced or recurrent gastric cancer. [Public knowledge-based application after PAESC's preliminary assessment] uuid:bfd8db66-8bbc-4cd2-a1ca-f26a9a9d9513 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0017816 PMID:41385096 "[{""id"":""uuid:06db7ab2-2817-4d29-a615-118978cc0e73"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c2c0cce3-8b95-4452-93ea-9de8ce817f27"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the treatment of systemic AL amyloidosis. [Expedited review] uuid:56ba96a5-faf0-4b96-aa56-6d4924d2240a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90844 biolink:treats MONDO:0013024 PMID:41385096 "[{""id"":""uuid:cef8e344-5a42-41e7-a34f-93d2a6912bc0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ff5f0f48-e835-4716-b208-22c064749ff6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication for the treatment of persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) after surgical treatment or inoperable CTEPH. [Orphan drug] uuid:0e1bc450-7564-4bef-a61b-faffaaf2498b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85973 biolink:treats HP:0002140 PMID:41385096 "[{""id"":""uuid:c8c86312-7066-456f-8a14-e7d1b168915e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:968e3903-c84a-4351-aa6a-240c71bcee31"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage indicated for the prevention of ischemic stroke and systemic embolism in patients with non-valvular atrial fibrillation. uuid:a3b12f0a-971d-41c9-9d0f-9a81bf6357ff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29321 biolink:treats UMLS:C0264714 PMID:41385096 "[{""id"":""uuid:32df9a68-2c49-4c70-ae38-91f0b78cd07b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:725a73d4-265d-47a4-828d-48e454a75b21"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the treatment of acute heart failure (including chronic heart failure in the exacerbation period) and hypertensive emergencies. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:8c0975d5-4739-4234-9589-bb2d4d766bd6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29321 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:00eadb9c-4d46-4557-876c-f2f89657ff29"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8832a1e0-2f13-4f65-9194-0c6881080452"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the treatment of acute heart failure (including chronic heart failure in the exacerbation period) and hypertensive emergencies. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:d619dbce-a47a-4de1-b2a7-1ed46c0b796a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29321 biolink:treats HP:0100735 PMID:41385096 "[{""id"":""uuid:3bb9e6a8-d2f2-472f-b524-9e5568257e62"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:07649c5d-2d43-4511-b156-3764eacd1a60"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the treatment of acute heart failure (including chronic heart failure in the exacerbation period) and hypertensive emergencies. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:f202c3e9-8a92-40ec-9c17-d498cfd41a56 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:WB8FT61183 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:cde1f9b8-dfe3-4713-9eee-fbf691829be2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:77475b12-9265-46ff-8eff-a664f4d5b008"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the treatment of hypertension. uuid:3618a249-6021-43ec-a314-1306af6ec1cd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:87715 biolink:treats MONDO:0005299 PMID:41385096 "[{""id"":""uuid:613bab23-bfb7-4641-a3f7-8d1fcd16b742"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:060181dd-24e1-4ba9-bb12-46e2bc3a64dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the prevention of recurrence after ischemic cerebrovascular disease (associated with large artery atherosclerosis or small vessel occlusion) (for use only in patients having a high risk of cerebral infarction). uuid:dc237186-08a2-4b90-b645-1348d109b457 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:87715 biolink:treats MONDO:0002679 PMID:41385096 "[{""id"":""uuid:b2a2ad66-cc8d-4d54-b67c-bc60d289c0c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a57220d2-dacc-4a67-a566-8f554ff0ffc7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the prevention of recurrence after ischemic cerebrovascular disease (associated with large artery atherosclerosis or small vessel occlusion) (for use only in patients having a high risk of cerebral infarction). uuid:506e7438-e8cd-49dc-90fc-d79032fa4e71 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4F4X42SYQ6 biolink:treats MONDO:0005100 PMID:41385096 "[{""id"":""uuid:dbbbe041-f8e6-46cd-ae3c-df2767a16278"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0a931096-f1fc-4cee-8044-20757ebc2a49"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the treatment of systemic sclerosis. [Orphan drug] uuid:ec25c813-52ef-441e-8a02-45015e337efb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4F4X42SYQ6 biolink:treats MONDO:0019324 PMID:41385096 "[{""id"":""uuid:7cb8588f-54b3-4a5b-9058-da4303c7fa75"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8cfdf7dc-da2b-4e1b-a9b7-02d5d902100a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the treatment of refractory pemphigus vulgaris and pemphigus foliaceus. [Orphan drug] uuid:9972604b-81a7-403a-9d9c-a98f5dc1a56f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:231601 biolink:treats MONDO:0000521 PMID:41385096 "[{""id"":""uuid:04cc9abe-b12a-48b4-9228-49d972a79d9f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:953b8cae-65f1-44c1-a952-a51df26491fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the treatment of unresectable advanced or recurrent HER2-positive salivary gland tumors. [Orphan drug] uuid:476de1b4-bac0-4b9e-8b38-a7878b89e2f7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46345 biolink:treats MONDO:0007576 PMID:41385096 "[{""id"":""uuid:4485ef31-8da2-4cfc-8505-115cc8792e9d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:41da176f-db97-4ca3-93fa-129a06d770ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the treatment of esophageal cancer. [Public knowledge-based application] uuid:75a1ce91-6cff-4f6a-b758-8bd174d011a0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:231601 biolink:treats MONDO:0002032 PMID:41385096 "[{""id"":""uuid:823ba3c9-48b4-4d3a-b983-bb4f9e744175"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a64e82fa-4eab-425f-86f6-1cb1f1781636"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the treatment of unresectable advanced or recurrent HER2-positive colon or rectal cancer that has progressed after cancer chemotherapy. uuid:6b5c8b69-6e95-44cb-889c-7893ba7f7dcf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:231601 biolink:treats MONDO:0002169 PMID:41385096 "[{""id"":""uuid:1f0b347b-bc31-461f-ad97-2e2c14957f6f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:938f05ed-4e8d-4075-83eb-ef5b96bb1ce4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the treatment of unresectable advanced or recurrent HER2-positive colon or rectal cancer that has progressed after cancer chemotherapy. uuid:89b2ad99-96dd-4ae9-b868-93995b9923c2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135809 biolink:treats HP:0011703 PMID:41385096 "[{""id"":""uuid:4585c503-7773-4924-8d3f-c5427dc515f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b63ef75f-9a5b-48e6-9fe0-2f4144073f46"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the treatment of the following tachyarrhythmia associated with sepsis: atrial fibrillation, atrial flutter, sinus tachycardia. uuid:8bbc1d6e-e8cf-4b13-9589-16e893cd00ca biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:505CXM6OHG biolink:treats UMLS:C0858004 PMID:41385096 "[{""id"":""uuid:94749e56-8cb8-445e-a13f-49d928d6052c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:519aca11-d1c3-4435-9ac2-6717273d65a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the prophylaxis of influenza A or B virus infection. uuid:64942a85-ac43-46d7-8a4f-46a92bc6702c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:505CXM6OHG biolink:treats UMLS:C0858005 PMID:41385096 "[{""id"":""uuid:4cfe1e99-dd16-4307-8aa4-ceb7d5f0450f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b888932c-aaa2-4c70-913b-635f055ca246"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the prophylaxis of influenza A or B virus infection. uuid:fb78dcde-b46a-45d6-8680-815998a20faf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DLG4EML025 biolink:treats UMLS:C3203547 PMID:41385096 "[{""id"":""uuid:70115e41-63e0-4181-a01a-f622ffe20082"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6612b6dc-d14b-44e8-8b0c-de3e87c784da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the treatment of non-radiographic axial spondyloarthritis in patients who have not responded sufficiently to conventional treatments. [Orphan drug] uuid:291ec168-ef26-4cc2-829a-a1697d6a56f9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:D99YVK4L0X biolink:treats MONDO:0002032 PMID:41385096 "[{""id"":""uuid:e17ec5d2-6bde-48f1-95f4-48f289f2e0b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:70173669-9058-4211-9456-f17dd6b8e3c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage indicated for the treatment of unresectable advanced or recurrent non-small cell lung cancer. Drugs with a new dosage indicated for the treatment of unresectable advanced or recurrent gastric cancer, unresectable advanced or recurrent colon or rectal cancer, unresectable advanced or recurrent non-small cell lung cancer, and unresectable hepatocellular carcinoma whose serum AFP level is greater than 400 ng/mL and conditions have progressed after cancer chemotherapy. uuid:3579c694-5ddd-4505-bdd8-947a19c376fb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:D99YVK4L0X biolink:treats MONDO:0006519 PMID:41385096 "[{""id"":""uuid:267be09c-43b9-4dbb-a3dc-0b161f5e7a00"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6ba5ffaa-6558-41b6-8f40-9bd3e0641c78"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage indicated for the treatment of unresectable advanced or recurrent non-small cell lung cancer. Drugs with a new dosage indicated for the treatment of unresectable advanced or recurrent gastric cancer, unresectable advanced or recurrent colon or rectal cancer, unresectable advanced or recurrent non-small cell lung cancer, and unresectable hepatocellular carcinoma whose serum AFP level is greater than 400 ng/mL and conditions have progressed after cancer chemotherapy. uuid:4b2d15ec-9a87-4805-a714-84a79276ff05 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:83766 biolink:treats MONDO:0009831 PMID:41385096 "[{""id"":""uuid:5727066b-bf79-47d3-9239-6d43ec01f72d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:43442570-ce24-4877-b672-9cab77e63522"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for maintenance therapy of unresectable BRCA mutation- positive pancreatic cancer after chemotherapy including treatment with platinum-based antineoplastic drugs. [Orphan drug] uuid:fec772d3-2968-49fb-9d07-a5624e19200a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85994 biolink:treats UMLS:C4724831 PMID:41385096 "[{""id"":""uuid:1fe82e01-4595-40a2-97ac-79db3074150e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0526f895-6d2c-4f18-a004-956e523221ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication for the treatment of unresectable thymic carcinoma. [Orphan drug] uuid:c0a8a656-e381-4298-9ef4-a161ebe8343f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:E58MLH082P biolink:treats MONDO:0001566 PMID:41385096 "[{""id"":""uuid:3f6cf9a4-fe94-4ece-9023-34d4a72a45dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:86443bdd-b9d0-432b-af30-4325f3c1e997"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications and a new dosage for the treatment of hypercalcemia in patients with parathyroid carcinoma or patients with primary hyperparathyroidism who are unable to undergo parathyroidectomy or relapse after parathyroidectomy. [Orphan drug] uuid:388516c7-040b-4261-a28c-0eab7e14708c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:E58MLH082P biolink:treats MONDO:0012004 PMID:41385096 "[{""id"":""uuid:97576c40-3c49-4a49-a9de-2ee69d8cdaa7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:654d0b5c-fd5f-4bc6-bdc0-aea86190daea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications and a new dosage for the treatment of hypercalcemia in patients with parathyroid carcinoma or patients with primary hyperparathyroidism who are unable to undergo parathyroidectomy or relapse after parathyroidectomy. [Orphan drug] uuid:1e3dd0c2-06fb-447f-8812-84d2d8b8bb92 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:E58MLH082P biolink:treats MONDO:0010837 PMID:41385096 "[{""id"":""uuid:1ba1ebdd-ab49-4bf4-a5d8-41832cad9227"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ad2a909b-f537-4820-abbd-56b8f6276b1b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications and a new dosage for the treatment of hypercalcemia in patients with parathyroid carcinoma or patients with primary hyperparathyroidism who are unable to undergo parathyroidectomy or relapse after parathyroidectomy. [Orphan drug] uuid:4ea5f203-3d1e-4e04-b2eb-6ed365991ae6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4F4X42SYQ6 biolink:treats MONDO:0019740 PMID:41385096 "[{""id"":""uuid:6f5c635c-ee82-4e7b-8fc4-14e636d4d524"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6ee77529-b83b-4f91-8657-be319074971e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the treatment of acquired thrombotic thrombocytopenic purpura. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:c8466a6a-a93f-4028-a67e-5fe37a75e225 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0006050 biolink:treats MONDO:0006624 PMID:41385096 "[{""id"":""uuid:429e254f-46b4-4344-bfb5-4658e5b8ae7b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ce48410e-d991-4e06-aa11-04d33b03e133"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new route of administration indicated for the treatment of urinary urgency, urinary frequency, and urge urinary incontinence associated with overactive bladder or urinary incontinence due to neurogenic bladder, in patients who have not responded sufficiently to conventional therapies or in whom conventional therapies are not suitable. DRUGBANK:DB00083 uuid:ec89d527-5db6-4b2d-b6ec-6cca17d9adc9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0006050 biolink:treats HP:0000020 PMID:41385096 "[{""id"":""uuid:3223c013-1318-4b25-8530-5037aca137fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a84b4030-1b81-4c3d-8a86-b26bdee66a68"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new route of administration indicated for the treatment of urinary urgency, urinary frequency, and urge urinary incontinence associated with overactive bladder or urinary incontinence due to neurogenic bladder, in patients who have not responded sufficiently to conventional therapies or in whom conventional therapies are not suitable. DRUGBANK:DB00083 uuid:0d698797-b303-4b14-8ee0-2f2bbe435009 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0006050 biolink:treats HP:0000011 PMID:41385096 "[{""id"":""uuid:2e222fa9-6551-4fa4-84c1-1a7001a55d67"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:05055dc6-30f9-4eeb-a79b-ed345d83e06b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new route of administration indicated for the treatment of urinary urgency, urinary frequency, and urge urinary incontinence associated with overactive bladder or urinary incontinence due to neurogenic bladder, in patients who have not responded sufficiently to conventional therapies or in whom conventional therapies are not suitable. DRUGBANK:DB00083 uuid:888abe6c-e011-4db0-9f77-5b918a20bcdd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:15C2VL427D biolink:treats MONDO:0019783 PMID:41385096 "[{""id"":""uuid:ba81519b-a652-4d40-b38e-2a9601e81abe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:fba1929d-6a82-4acb-804c-6921a9ee5945"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the treatment of neovascular glaucoma. [Orphan drug] uuid:f8a9e66e-59f0-4db3-8198-426b0b69b49d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:UMD07X179E biolink:treats UMLS:C0406317 PMID:41385096 "[{""id"":""uuid:0cc3b35e-e5ee-42b6-af58-f582b5db6cdd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:32bda121-0571-4af4-a55a-3903e27ef96b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications and a new dosage for the treatment of plaque psoriasis, psoriatic arthritis, pustular psoriasis, and erythrodermic psoriasis in patients who have not responded sufficiently to conventional therapies. uuid:389d2369-0bb5-4cae-8a33-a00b859408c1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:UMD07X179E biolink:treats MONDO:0022205 PMID:41385096 "[{""id"":""uuid:d8b50ea0-363a-4f9f-acd6-4eb7509d542c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a1aa997f-c374-49c8-bd3f-fc955eefc796"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications and a new dosage for the treatment of plaque psoriasis, psoriatic arthritis, pustular psoriasis, and erythrodermic psoriasis in patients who have not responded sufficiently to conventional therapies. uuid:23d292ba-f161-4ef3-baee-7ae7f9a5fa08 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:UMD07X179E biolink:treats UMLS:C0748052 PMID:41385096 "[{""id"":""uuid:0d6dd451-42f2-4c6d-a111-998220b2aa10"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f5099e7a-45c4-4205-8efa-e7900f7b3dc1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications and a new dosage for the treatment of plaque psoriasis, psoriatic arthritis, pustular psoriasis, and erythrodermic psoriasis in patients who have not responded sufficiently to conventional therapies. uuid:f9860726-257b-464d-8d16-1850856e0a22 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1670307 biolink:treats MONDO:0001056 PMID:41385096 "[{""id"":""uuid:5edcfa21-5bc4-4b4c-8e9e-705a06e1f558"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9948a89b-d297-44e8-a87a-2f10c8ae77eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication for the treatment of unresectable advanced or recurrent gastric cancer that have progressed after chemotherapy. uuid:bb77ec09-ab67-4682-a223-425af46f93bd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DPT0O3T46P biolink:treats MONDO:0005627 PMID:41385096 "[{""id"":""uuid:6aa050a5-4b37-461a-8496-707f4770c73a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f51e172d-a07d-4a4a-b781-acf9ad9bd736"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the treatment of unresectable or metastatic renal cell carcinoma. Drugs with a new indication for the treatment of recurrent or metastatic head and neck cancer. uuid:ffb58fbf-bff5-4446-8a31-4a73cde84a18 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10127 biolink:treats MONDO:0021095 PMID:41385096 "[{""id"":""uuid:f09bd90f-f3fa-4959-9461-b3f233975f9e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c8ed8a1d-fd0b-42da-b85d-d04e109797e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of parkinsonism in patients with dementia with Lewy bodies (in the cases where parkinsonism persists after using levodopa-containing products). uuid:e77eb17b-78a6-400c-933b-e19323a14132 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10127 biolink:treats MONDO:0007488 PMID:41385096 "[{""id"":""uuid:fbe5005f-e59c-4cab-bd77-50e197c39c1c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:22e48937-52cb-40db-a156-d71ddd21fa2e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of parkinsonism in patients with dementia with Lewy bodies (in the cases where parkinsonism persists after using levodopa-containing products). uuid:49295da4-ffad-4510-bae8-e27f07164bb8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135809 biolink:treats MONDO:0000190 PMID:41385096 "[{""id"":""uuid:8f7723d0-5a26-4a1e-aeaf-0aa759f8dfa9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d0ad874e-65f7-4750-bcdf-cacc0d591d83"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications and a new dosage for the following life-threatening cardiac arrhythmia in refractory and urgent cases: ventricular fibrillation and hemodynamically unstable ventricular tachycardia. [Orphan drug] uuid:9a6875db-0327-4561-9dc5-dcb25be3a061 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135809 biolink:treats MONDO:0005477 PMID:41385096 "[{""id"":""uuid:71231af8-2a78-484d-90d7-431bfe19cfe7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8b1056c7-da7c-4557-8cee-4496724aae95"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications and a new dosage for the following life-threatening cardiac arrhythmia in refractory and urgent cases: ventricular fibrillation and hemodynamically unstable ventricular tachycardia. [Orphan drug] uuid:0c26118f-f6e3-4303-b7e9-c46536982fc9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0006050 biolink:treats MONDO:0000485 PMID:41385096 "[{""id"":""uuid:d6fecdad-50e0-44c1-ab58-589b19ac0d7e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2fb086a9-6008-4eac-aff2-24ac64ec295a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of spasmodic dysphonia. DRUGBANK:DB00083 uuid:8ac314dd-b974-4c9f-913f-f2b401b0879a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134724 biolink:treats MONDO:0005147 PMID:41385096 "[{""id"":""uuid:18ca1666-029f-4440-b091-2e26ddb37b0e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:80244475-4b19-4744-87d3-3ed2916f9a9c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of type 1 diabetes mellitus. uuid:91f3c180-51fe-44da-a32b-50ce41339a64 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:31YO63LBSN biolink:treats UMLS:C4725093 PMID:41385096 "[{""id"":""uuid:70250f8d-6a02-4b94-bee7-f74fc350d29b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:06e85ac1-29dd-4ca5-80f1-6327a19243e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage indicated for the treatment of unresectable melanoma. [Orphan drug] uuid:bb9f4899-b38b-452e-93fa-c65b33bbee85 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:83766 biolink:treats MONDO:0016419 PMID:41385096 "[{""id"":""uuid:c24698c9-0826-46c8-a864-b6ec1ace22f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9cf3fe99-d245-4607-b8a3-01e7daf97bd6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication for the treatment of unresectable or recurrent BRCA mutation-positive and HER2-negative breast cancer in patients who have previously been treated with chemotherapy. [Orphan drug] uuid:041fdd2d-722f-479d-8ebf-b1cf58540cb7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46345 biolink:treats MONDO:0000956 PMID:41385096 "[{""id"":""uuid:0f0f866f-847e-48e4-b6be-5454df07207f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:875f6d6b-3888-4eb9-b179-e23d7c9dfed9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the treatment of small intestine cancer. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:4d941bb5-249d-45c0-8bed-4b58c9f2427f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DPT0O3T46P biolink:treats UMLS:C4543702 PMID:41385096 "[{""id"":""uuid:f18fa5f9-0083-4d72-b008-231b47c8518f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f1995f45-35f3-405c-9668-6c6d158c56ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new indications and a new dosage for the treatment of: advanced or recurrent microsatellite instability- high (MSI-High) solid tumors that have progressed after cancer chemotherapy (for use only if refractory or intolerant to standard therapies), melanoma, and unresectable advanced or recurrent non-small cell lung cancer. [(1) Conditional early approval, (2) Orphan drug, (3) Priority review] uuid:eefbb967-89a8-4c9b-93f5-c783339583ac biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DPT0O3T46P biolink:treats MONDO:0008903 PMID:41385096 "[{""id"":""uuid:f840333d-0bcb-460e-bb7f-827e92c035ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3f9960d9-29c1-4106-acfe-7c5df95c05ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new indications and a new dosage for the treatment of: advanced or recurrent microsatellite instability- high (MSI-High) solid tumors that have progressed after cancer chemotherapy (for use only if refractory or intolerant to standard therapies), melanoma, and unresectable advanced or recurrent non-small cell lung cancer. [(1) Conditional early approval, (2) Orphan drug, (3) Priority review] uuid:97738555-f58d-499a-882e-be487d964ce3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:I031V2H011 biolink:treats MONDO:0017991 PMID:41385096 "[{""id"":""uuid:b84fc2f1-c606-4c5a-8487-407a41d3f155"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:619fbd58-0d6a-40a4-98c6-a60ff3362c2f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications and a new dosage for the treatment of Takayasu arteritis and giant cell arteritis in patients who have not responded sufficiently to conventional treatments. [Orphan drug] uuid:73684d7f-1c01-4db3-90f2-0cfc72b993ff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DPT0O3T46P biolink:treats MONDO:0004992 PMID:41385096 "[{""id"":""uuid:6989795c-5d4d-4c15-9164-a217c62073fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6d76c671-8eb1-43e9-bf87-afc1775db939"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication for the treatment of unresectable urothelial cancer which progressed after cancer chemotherapy. [Priority review] uuid:a2db39b3-c8f4-4dee-bed1-a493bdc7442e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:70708 biolink:treats MONDO:0010888 PMID:41385096 "[{""id"":""uuid:8c3e36fb-4c15-4b6c-a387-e8d9cad79b13"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:78f7ee07-9a14-4177-8c44-c9a34aaa19d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication for the alleviation of pain associated with uterine adenomyosis. uuid:dae5b433-83c7-40f5-a3fd-2021abda76ee biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68478 biolink:treats MONDO:0019496 PMID:41385096 "[{""id"":""uuid:03a538b3-2a15-4ad6-895a-dc8663598940"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8ca932d8-ebe2-4dcf-bfca-b77693b5976c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[PMDA] Drugs with a revised indication from ""pancreatic neuroendocrine tumor"" to ""neuroendocrine tumor.""" uuid:4a611844-3f2c-447f-9d05-fec570d43c56 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63791 biolink:treats MONDO:0019471 PMID:41385096 "[{""id"":""uuid:581e6aa6-b7ba-49a9-9900-ab43da7426ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7d353551-88bd-47af-8e52-186c56ad6447"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of relapsed or refractory adult T-cell leukemia/lymphoma. [Orphan drug] uuid:bc5ce1f6-7acc-4258-ae28-6aa1f2104df4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68579 biolink:treats HP:0034192 PMID:41385096 "[{""id"":""uuid:d9894f9f-b0c6-4963-ba81-be5883c58aa6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:55ca4b95-562c-4857-9d64-7cd132d6e76c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment and prevention of recurrence of deep vein thrombosis and pulmonary thromboembolism. uuid:0ffa56e8-1a5f-48ab-813a-02ef8eff38f2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:72296 biolink:treats HP:0034192 PMID:41385096 "[{""id"":""uuid:d1cb8ff2-a20e-4238-9df9-221d7fb159c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:18dfeda2-4fae-441f-8caf-7a47bd02d82c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment and prevention of the recurrence of venous thromboembolism (deep vein thrombosis and pulmonary thromboembolism). uuid:ab00a60d-2b60-4007-b918-e8e288394e10 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46081 biolink:treats MONDO:0002234 PMID:41385096 "[{""id"":""uuid:6d4c620d-754f-433b-9115-4ac96d446c2c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5c3086f6-0a16-4db3-a9ad-84e2be19b556"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications and a new dosage for the treatment of vaginitis and vulvovaginitis caused by Candida . uuid:38c30fa2-08e0-4952-ad3c-4415ac5e8474 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46081 biolink:treats MONDO:0007019 PMID:41385096 "[{""id"":""uuid:6173ffe6-4f1c-46df-9e79-18c494e50b40"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:50c03fc5-a04e-4297-8b05-9da6cbff9f57"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications and a new dosage for the treatment of vaginitis and vulvovaginitis caused by Candida . uuid:c5a3cb34-0dd4-47b2-a033-8f4007b5d19a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats MONDO:0006032 PMID:41385096 "[{""id"":""uuid:15de8a2f-5cdb-4f2f-9812-f6dc59d24ba9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1eb7aadc-bce3-4a4f-b33d-62994571dd98"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications for the treatment of cystitis, pyelonephritis, secondary infection of trauma, burns or surgical wounds, and others. uuid:992a961f-954f-4083-a7d7-f7e2efa4d8a0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats MONDO:0006939 PMID:41385096 "[{""id"":""uuid:39f70e8c-27fe-4585-9de7-cc9b2bd787c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5bb9f6b5-3c3d-46aa-aac3-df66433d7c73"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications for the treatment of cystitis, pyelonephritis, secondary infection of trauma, burns or surgical wounds, and others. uuid:6002d0ba-e004-4133-bc65-7cc37dd1d4f8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats UMLS:C0332803 PMID:41385096 "[{""id"":""uuid:54334a41-f5cb-4e37-8130-d5547a1efae1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e8d51498-d72b-473f-9bd7-b02e64d0000d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications for the treatment of cystitis, pyelonephritis, secondary infection of trauma, burns or surgical wounds, and others. uuid:4031a00a-45db-4bd6-a1cc-c7347c787473 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DLG4EML025 biolink:treats MONDO:0022205 PMID:41385096 "[{""id"":""uuid:c0c9f186-cc25-4eb3-ae7e-fcd55d25b460"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6c7bb460-8536-443c-a219-8a525d3e03e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication for the treatment of pustular psoriasis in patients who have not responded sufficiently to conventional therapies. uuid:61bf74e6-316b-47f3-9848-b0f203bf8b5d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8499 biolink:treats HP:0001705 PMID:41385096 "[{""id"":""uuid:e0d94e5d-06ce-4215-b7ec-17fe2bf650fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4cef7505-49d4-4ecd-a185-39a14b6a2542"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the prevention of hypoxic attack caused by right ventricular outflow tract obstruction. [Public knowledge-based application after preliminary assessment by the Pharmaceutical Affairs and Food Sanitation Council (PAFSC)] uuid:2a0f80a2-8d0c-414a-bc89-e08c143074aa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:15C2VL427D biolink:treats UMLS:C3537442 PMID:41385096 "[{""id"":""uuid:dcb1dabe-0af1-46e9-b6cd-4678f85263ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8f8e99c1-7e06-411a-931c-4944e0eb2480"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication for the treatment of choroidal neovascularization in patients with pathologic myopia. uuid:07772dd0-e280-49fc-8adc-4cb889f7622c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9919 biolink:treats MONDO:0004609 PMID:41385096 "[{""id"":""uuid:bccf44be-f8b5-4bb7-bdc9-d1d5802dbdd8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:82c446cf-699d-4268-b95b-3e3c39a743c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and revised indications with a new dosage for prevention of herpes simplex virus infection in adult or pediatric haematopoietic stem cell transplant patients, for treatment of herpes simplex /herpes zoster, and for prevention of recurrent genital herpes in pediatric patients. uuid:2ab0e270-4af0-4011-9b74-17a6be1762ae biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9919 biolink:treats HP:0032157 PMID:41385096 "[{""id"":""uuid:5b846a52-7922-4cd4-b4ee-eca18aba8e8b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a9d69589-4ca6-4876-a538-ebc97ef758f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and revised indications with a new dosage for prevention of herpes simplex virus infection in adult or pediatric haematopoietic stem cell transplant patients, for treatment of herpes simplex /herpes zoster, and for prevention of recurrent genital herpes in pediatric patients. uuid:a686df23-a840-4377-9276-c140dae27346 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7903 biolink:treats MONDO:0019019 PMID:41385096 "[{""id"":""uuid:989f6d4f-8b3d-421e-81fa-31e931f78241"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:297810e4-7bc3-4547-842a-9ede6f3ef02f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of osteogenesis imperfecta. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:0a433709-64e5-477c-90e2-afcd962ad385 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C3500339 biolink:treats MONDO:0009691 PMID:41385096 "[{""id"":""uuid:d2c32bc5-dbe9-4098-860b-f62f8e58432c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7347b9f1-ae45-4bec-bf91-cdaef8789621"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications and a new dosage for the treatment of mycosis fungoides and Sézary syndrome. [Orphan drug] uuid:a9da9913-2610-4334-a4a3-09197e00de7f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32089 biolink:treats MONDO:0005062 PMID:41385096 "[{""id"":""uuid:3bbcd686-1182-4acd-a5e7-82da1baf508f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b8be34b1-dd2a-4571-9dc0-6dff5c9f3c64"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage indicated for the treatment of malignant lymphoma. [Expedited review] uuid:000d37bb-0ef4-45b5-b34a-87452d25e776 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:154705018 biolink:treats MONDO:0005575 PMID:41385096 "[{""id"":""uuid:984092cb-f460-4754-a801-c6c20d1d27ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:10c8600a-9c2e-4b32-bc4d-056b7d199f97"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a revised indication for the treatment of unresectable advanced or recurrent colorectal cancer. [Expedited review] uuid:c48713c0-4d23-40f4-b59b-40c5c5cb4714 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28741 biolink:treats MONDO:0005276 PMID:41385096 "[{""id"":""uuid:3086d2ce-3db8-4d20-b5f3-a94c27e4ccde"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:606ab43f-8108-4c65-a0c7-4a0a4c58163f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage indicated for the prevention of dental caries. uuid:9be27f57-8bb8-412d-9591-4417459bb149 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47780 biolink:treats MONDO:0021107 PMID:41385096 "[{""id"":""uuid:021e6b1a-715d-4fdd-87a1-3bc9139ae853"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4b0e2705-4623-4c93-989d-1975c0c8a4bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of cataplexy associated with narcolepsy. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:c9a6ac75-3744-4e86-8eed-0f83c2afb5e2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3745 biolink:treats MONDO:0005230 PMID:41385096 "[{""id"":""uuid:957c5d57-2a90-42ab-ada2-8fc653770105"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1d433b8e-7b96-47c7-b925-a35f05388b43"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication for cellulitis around the jaw bone and jaw inflammation. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:22b43f74-5bba-46fe-b925-39deb281558f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3745 biolink:treats UMLS:C0854217 PMID:41385096 "[{""id"":""uuid:e49f5a10-6d7a-4099-ab2f-aef62d25dc1b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ba63a1a1-eeef-4e43-81a3-cd9eb24eb470"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication for cellulitis around the jaw bone and jaw inflammation. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:7479c268-9393-487a-a0fe-50041153d9d2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:61049 biolink:treats MONDO:0019622 PMID:41385096 "[{""id"":""uuid:79e2444b-5ce3-4b18-aecc-560a0b72aa5a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:403eae89-9171-4ad5-8bf1-4815ac80a62e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and new dosage for the treatment of interstitial pneumonia associated with polymyositis/dermatomyositis. [Orphan drug] uuid:7b0afef4-d48d-4cb5-a6bc-dcd029d2f049 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2S9ZZM9Q9V biolink:treats MONDO:0100342 PMID:41385096 "[{""id"":""uuid:56e520f0-effc-4d23-8f63-fd127fe0badf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:68406a8a-b5a6-4497-b518-9ac691131997"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of malignant glioma. [Orphan drug] uuid:f77b1e76-adde-436f-9ec9-26ac81b037a4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:231601 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:69cf7e78-1151-4143-89e3-4d1b70ddd3e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:588b3a1a-abcb-4c57-9dca-d317256253f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage for the treatment of breast cancer with HER2 overexpression. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:5f3306ae-51dc-406c-99f7-fe2041cbbcc1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:231601 biolink:treats NCIT:C150634 PMID:41385096 "[{""id"":""uuid:cf4cefaf-9f30-4527-bbff-9cbfc97131f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a91dccec-48ed-4e87-870c-632d31dc7bb4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage for the treatment of breast cancer with HER2 overexpression. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:1e602c7d-124b-4f27-96cd-b978947fbaf5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3311 biolink:treats UMLS:C0854776 PMID:41385096 "[{""id"":""uuid:b1028afe-46fd-4f68-b6bb-366bd2b2cfdd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6e53f2f3-27db-4477-a286-5a21a4fd5148"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of unresectable pancreatic cancer. [Priority review], [Expedited review] uuid:e6ee97ed-8c76-4f37-b04c-ea9bf062e2ce biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46345 biolink:treats UMLS:C0854776 PMID:41385096 "[{""id"":""uuid:67ba17cd-21c4-4d3d-b892-dcb065557118"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e298f2b6-b776-4eb8-8f4c-e57fa0176396"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of unresectable pancreatic cancer. [Priority review], [Expedited review] uuid:431113d1-ce94-4677-96e6-865b1d247470 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8499 biolink:treats UMLS:C0428985 PMID:41385096 "[{""id"":""uuid:28194eac-46c1-43a8-bd31-c282682654c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c697f7fe-7492-48ba-92f2-496e14e3ed93"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional pediatric dosages for extrasystole (supraventricular/ventricular), the prevention of paroxysmal tachycardia, atrial fibrillation with rapid ventricular response (bradycardiac effect), sinus tachycardia, atrial fibrillation, and the prevention of paroxysmal atrial fibrillation. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:3d04c417-1b34-4c9d-bfa7-34aece3f318c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8499 biolink:treats HP:0006688 PMID:41385096 "[{""id"":""uuid:8a124558-ace1-4948-86a8-aee26a2fb622"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3be257bd-be2a-4549-a8cc-8205ef4bc88b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional pediatric dosages for extrasystole (supraventricular/ventricular), the prevention of paroxysmal tachycardia, atrial fibrillation with rapid ventricular response (bradycardiac effect), sinus tachycardia, atrial fibrillation, and the prevention of paroxysmal atrial fibrillation. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:099d7976-4fe6-4128-9830-ad93089a1c64 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8499 biolink:treats MONDO:1030011 PMID:41385096 "[{""id"":""uuid:dbdc0a4b-f936-4260-ba75-81a3f2421ee7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:50f270d2-038d-4493-971b-d6a460b9d938"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional pediatric dosages for extrasystole (supraventricular/ventricular), the prevention of paroxysmal tachycardia, atrial fibrillation with rapid ventricular response (bradycardiac effect), sinus tachycardia, atrial fibrillation, and the prevention of paroxysmal atrial fibrillation. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:295a420b-012e-4741-9932-c8b07fa93af3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:37941 biolink:treats MONDO:0005294 PMID:41385096 "[{""id"":""uuid:ad8aaf6f-35b8-4c1d-a464-13d346878230"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ce9542d8-701c-4f86-b90c-e0348508cd3a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the suppression of embolus/thrombus formation in peripheral arterial diseases. uuid:aafdf141-66f3-4da9-a63d-057348adb2c6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0250480 biolink:treats MONDO:0004522 PMID:41385096 "[{""id"":""uuid:3f1624de-8eeb-45ba-9e86-20e467d0d870"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b3098d9b-41b8-41bb-9f93-400b4fcc0d9a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications for the treatment of peritonitis, intraperitoneal abscess, cholecystitis, and cholangitis. uuid:21f10d59-c7b2-4dcb-846f-cf4e96ba0508 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0250480 biolink:treats HP:0100592 PMID:41385096 "[{""id"":""uuid:13abfa7d-06d9-473d-99fb-34ab3c644678"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a137c0dd-6592-4abe-bbe6-0696025fcdec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications for the treatment of peritonitis, intraperitoneal abscess, cholecystitis, and cholangitis. uuid:d507a964-8f89-4fe1-9345-e200ffa26cbd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0250480 biolink:treats MONDO:0002155 PMID:41385096 "[{""id"":""uuid:86c3c89d-0b05-475b-8f28-0dd472287f87"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:62ea7933-54e5-412a-85a8-3119f67ca36c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications for the treatment of peritonitis, intraperitoneal abscess, cholecystitis, and cholangitis. uuid:dcb4445a-644d-447c-bd05-3bc08c24d19d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0250480 biolink:treats MONDO:0004789 PMID:41385096 "[{""id"":""uuid:44184db4-eab6-46da-b8a4-75fe5b1552a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:84ae2318-22a7-4295-b04d-3cd45f6560de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications for the treatment of peritonitis, intraperitoneal abscess, cholecystitis, and cholangitis. uuid:82c61830-6ed5-45f1-b06e-9d55799b0ec8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63607 biolink:treats HP:0100806 PMID:41385096 "[{""id"":""uuid:889c363b-d2de-43ab-8ec9-ed8111594496"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:470abb1e-e466-4c5d-a374-8a8e00d3574e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional pediatric dosage. These drugs are indicated for sepsis, deep skin infection, chronic pyoderma, secondary infection of trauma, burn, and surgical wounds, and pneumonia. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:6460255d-b322-4856-9559-3022663cbd1c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63607 biolink:treats MONDO:0002922 PMID:41385096 "[{""id"":""uuid:f0c4d95c-f3e3-4bf0-b542-22252785fc81"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7f72842d-04b5-4e0a-b43f-3f155deb97d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional pediatric dosage. These drugs are indicated for sepsis, deep skin infection, chronic pyoderma, secondary infection of trauma, burn, and surgical wounds, and pneumonia. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:6b541d28-88ad-479a-b0b3-373463ad8bdd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63607 biolink:treats UMLS:C0332803 PMID:41385096 "[{""id"":""uuid:dbae5760-5177-47fa-b0dc-8c6c27341059"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:410869ce-02c2-44a2-9c83-8912caee5277"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional pediatric dosage. These drugs are indicated for sepsis, deep skin infection, chronic pyoderma, secondary infection of trauma, burn, and surgical wounds, and pneumonia. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:37347de0-c663-4dce-9a26-92393da3cb85 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:327148 biolink:treats MONDO:0005607 PMID:41385096 "[{""id"":""uuid:0a3764cf-0253-45a2-af64-2d962febabda"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2e686643-902f-4c3f-86d5-0eb1cf242aed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the relief of symptoms of chronic obstructive pulmonary diseases (chronic bronchitis, emphysema). uuid:724a8a69-43e0-4535-99a1-1b3efbebc9b8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:327148 biolink:treats MONDO:0004849 PMID:41385096 "[{""id"":""uuid:75038af2-af73-4364-aa7a-0a6fb5774313"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:abf6754e-f6a1-47a1-b37a-82b41ab32a05"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the relief of symptoms of chronic obstructive pulmonary diseases (chronic bronchitis, emphysema). uuid:0b91061d-5f7a-4a99-922e-ea34e2dbbdb4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4027 biolink:treats MONDO:0008233 PMID:41385096 "[{""id"":""uuid:ded2a4a0-ee97-4082-8453-4780a025a6fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e3a96537-f76c-4e23-8aeb-42d6f24c49f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of pheochromocytoma. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:d4426f68-36d8-4b6f-a72c-bdde8fdf334d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:94385 biolink:treats MONDO:0018048 PMID:41385096 "[{""id"":""uuid:0676ab2f-8e19-4640-8283-3548b5c287d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:050edc36-3afe-4f13-b2db-6d293b2d50de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications and new dosages for the prevention of perfusion blood coagulation during blood extracorporeal circulation (hemodialysis) in patients with heparin-induced thrombocytopenia (HIT) type II and in addition for the prevention of blood coagulation during percutaneous coronary intervention in HIT type II patients (including the patients who have the risk for HIT). [Orphan drug] uuid:acde1561-bc97-4007-808f-ed8b11346b48 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28077 biolink:treats UMLS:C0026919 PMID:41385096 "[{""id"":""uuid:5d5d4b20-12f5-4776-a924-b0ee22d159ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b285df35-ee7d-4c8a-8631-d1f6b06979c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of nontuberculous mycobacteriosis including Mycobacterium avium complex (MAC) infection. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:d1f29728-1ec9-4d9e-be0e-5ca93fc1dec4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28077 biolink:treats MONDO:0005866 PMID:41385096 "[{""id"":""uuid:1a273d73-eb12-4bb7-802a-0e6ed4912627"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4f283d5f-9ed1-4a0e-a812-8d1356d63ff0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of nontuberculous mycobacteriosis including Mycobacterium avium complex (MAC) infection. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:2358dc95-7bf0-4a76-9dc8-3b22e337d1b3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4304 biolink:treats MONDO:0002258 PMID:41385096 "[{""id"":""uuid:c2221929-f840-4716-8e9f-2b936bbaa4e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7b7a8259-d532-47bd-b293-28148109143f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage indicated for the treatment of pharyngitis and laryngitis, tonsillitis (including peritonsillitis and peritonsillar abscess), acute bronchitis, pneumonia, secondary infection of chronic respiratory disease, cystitis, pyelonephritis, urethritis, cervicitis, otitis media, sinusitis, periodontal inflammation, pericoronitis, and jaw inflammation. uuid:2a11c600-dfba-415b-bd6a-1feafc217b90 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4304 biolink:treats MONDO:0002647 PMID:41385096 "[{""id"":""uuid:999bc7f4-4a2b-4eac-85b5-c27d266777fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:588aad37-706d-48f1-b6c0-5233f49f75ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage indicated for the treatment of pharyngitis and laryngitis, tonsillitis (including peritonsillitis and peritonsillar abscess), acute bronchitis, pneumonia, secondary infection of chronic respiratory disease, cystitis, pyelonephritis, urethritis, cervicitis, otitis media, sinusitis, periodontal inflammation, pericoronitis, and jaw inflammation. uuid:c3ed3009-df2c-4469-83f9-a016a699c694 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:441410 biolink:treats MONDO:0019165 PMID:41385096 "[{""id"":""uuid:463eeba0-93be-4e33-a8fd-e5a3a46487eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4fb8752d-f577-414a-84da-477b21d27280"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional dosage indicated for the treatment of central precocious puberty. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:7cd39ef2-d431-45ae-98d6-69870c4ab664 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2948 biolink:treats UMLS:C0264939 PMID:41385096 "[{""id"":""uuid:86fd2dd5-05d7-4be1-a137-a7758dbc406f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8c79c417-7de0-42d2-8dd1-4b067573970c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications and a new dosage for the treatment of the following treatment- resistant rheumatic diseases: systemic vasculitis (e.g., microscopic polyangiitis, Wegener granulomatosis, polyarteritis nodosa, Churg-Strauss syndrome, aortitis syndrome), systemic lupus erythematosus (SLE), polymyositis, dermatomyositis, pachyderma, mixed connective tissue disease and refractory rheumatic disease. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:22dafc3c-5a6f-4b1b-8c46-7d8d025f1faa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2948 biolink:treats MONDO:0019124 PMID:41385096 "[{""id"":""uuid:b1caebac-1667-483c-b221-65c2a6b68bcd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:07e8a13e-728e-432d-b098-4cc3dcc3f7b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications and a new dosage for the treatment of the following treatment- resistant rheumatic diseases: systemic vasculitis (e.g., microscopic polyangiitis, Wegener granulomatosis, polyarteritis nodosa, Churg-Strauss syndrome, aortitis syndrome), systemic lupus erythematosus (SLE), polymyositis, dermatomyositis, pachyderma, mixed connective tissue disease and refractory rheumatic disease. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:a17f4ca7-02d7-4417-a504-bf9e23850ade biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2948 biolink:treats MONDO:0012105 PMID:41385096 "[{""id"":""uuid:c95bf676-33dc-48ba-9fed-4d187d24417c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8716658b-33a8-48df-9cce-7074055303f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications and a new dosage for the treatment of the following treatment- resistant rheumatic diseases: systemic vasculitis (e.g., microscopic polyangiitis, Wegener granulomatosis, polyarteritis nodosa, Churg-Strauss syndrome, aortitis syndrome), systemic lupus erythematosus (SLE), polymyositis, dermatomyositis, pachyderma, mixed connective tissue disease and refractory rheumatic disease. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:c8d12691-899c-4b02-9f93-0dddf0414173 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2948 biolink:treats MONDO:0017991 PMID:41385096 "[{""id"":""uuid:5a89bff5-c439-4063-b374-79c45654efe1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a2168422-f3e7-4be7-b62c-f72f2d1d4327"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications and a new dosage for the treatment of the following treatment- resistant rheumatic diseases: systemic vasculitis (e.g., microscopic polyangiitis, Wegener granulomatosis, polyarteritis nodosa, Churg-Strauss syndrome, aortitis syndrome), systemic lupus erythematosus (SLE), polymyositis, dermatomyositis, pachyderma, mixed connective tissue disease and refractory rheumatic disease. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:ab2b1839-b500-4a46-b0a1-62b4de69f77f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2948 biolink:treats MONDO:0019127 PMID:41385096 "[{""id"":""uuid:ca5912b3-e646-4d6a-9e29-fb7d4496e3d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:32482284-8707-4d43-8f49-dc420dc43ddf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications and a new dosage for the treatment of the following treatment- resistant rheumatic diseases: systemic vasculitis (e.g., microscopic polyangiitis, Wegener granulomatosis, polyarteritis nodosa, Churg-Strauss syndrome, aortitis syndrome), systemic lupus erythematosus (SLE), polymyositis, dermatomyositis, pachyderma, mixed connective tissue disease and refractory rheumatic disease. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:dfbd6980-7390-4800-9947-409755e9732e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2948 biolink:treats HP:0001072 PMID:41385096 "[{""id"":""uuid:837dfed2-3645-4002-9781-91a3d7a0abf6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6ed1565a-f269-44f1-86f6-c009009ab7cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications and a new dosage for the treatment of the following treatment- resistant rheumatic diseases: systemic vasculitis (e.g., microscopic polyangiitis, Wegener granulomatosis, polyarteritis nodosa, Churg-Strauss syndrome, aortitis syndrome), systemic lupus erythematosus (SLE), polymyositis, dermatomyositis, pachyderma, mixed connective tissue disease and refractory rheumatic disease. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:298dbb11-e765-43e7-b8a2-1156d0bdba87 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2948 biolink:treats MONDO:0005854 PMID:41385096 "[{""id"":""uuid:a3a2e99d-f9fe-4d51-981f-1d9b96c20c5d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:55b2c383-5944-47c1-9ed2-e3a6ef9b3293"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications and a new dosage for the treatment of the following treatment- resistant rheumatic diseases: systemic vasculitis (e.g., microscopic polyangiitis, Wegener granulomatosis, polyarteritis nodosa, Churg-Strauss syndrome, aortitis syndrome), systemic lupus erythematosus (SLE), polymyositis, dermatomyositis, pachyderma, mixed connective tissue disease and refractory rheumatic disease. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:bce0ca40-ab9c-410b-beb6-d6dc32dcc5d0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2948 biolink:treats MONDO:0005554 PMID:41385096 "[{""id"":""uuid:de5541fd-26e7-4928-a397-39a59cf5f15b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:10cab976-dfee-4475-be95-c336d16d4788"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications and a new dosage for the treatment of the following treatment- resistant rheumatic diseases: systemic vasculitis (e.g., microscopic polyangiitis, Wegener granulomatosis, polyarteritis nodosa, Churg-Strauss syndrome, aortitis syndrome), systemic lupus erythematosus (SLE), polymyositis, dermatomyositis, pachyderma, mixed connective tissue disease and refractory rheumatic disease. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:ff7e5d8f-5e0b-428f-893f-6f2dce4a4b62 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41423 biolink:treats NCIT:C3137 PMID:41385096 "[{""id"":""uuid:69b3b869-2ce6-4ae6-bb52-3de0fd6c9f2c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:cf49e2b9-94ed-4be8-90c9-66897019f422"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the relief of inflammation and pain after operation, trauma, and tooth extraction. uuid:27c16e2e-9824-43f6-b189-b6e25e2f1fbf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41423 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:39dc7a3d-d340-4c30-a397-95653d00ac66"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3f95b528-b945-4218-be5f-63db0155ea26"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the relief of inflammation and pain after operation, trauma, and tooth extraction. uuid:02a5415c-cb5e-4bb6-bf1d-cf510306d9b9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:114785 biolink:treats UMLS:C0854776 PMID:41385096 "[{""id"":""uuid:50cd2c7e-c648-4bef-b042-1b4aa8ae2837"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:301571b4-fb6c-4417-b1b5-8c0e62902ec2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of unresectable pancreatic cancer. uuid:1a9e133a-91a8-4392-828d-dfd4c10dfda8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:231601 biolink:treats MONDO:0006244 PMID:41385096 "[{""id"":""uuid:e203b2a3-3e9c-4067-a96d-95d2cad4d68d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f794ff6d-aa67-4043-81dd-91260f703f45"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of breast cancer with HER2 overexpression. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:307b114d-8da9-4735-b0f9-1a68e92579e5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C5888472 biolink:treats MONDO:0005812 PMID:41385096 "[{""id"":""uuid:62626ecd-63cb-443b-8fc6-9118207c258d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f13e9613-e003-43ca-af08-a2c17731b8fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new pediatric dosage indicated for the prevention of influenza. [Expedited review] DRUGBANK:DB18750 uuid:22bcbfeb-015c-4c08-9b6f-4b5709c65f92 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32107 biolink:treats MONDO:0001126 PMID:41385096 "[{""id"":""uuid:12c6f437-6195-41b5-8ac6-80b593c8c749"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:17c1d62d-bb13-445a-9179-1ac4529e3389"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional pediatric dosages. These drugs are indicated for gastric ulcer, duodenal ulcer, stomal ulcer, Zollinger-Ellison syndrome, reflux esophagitis, preanesthetic medication and improvement of gastric mucosal lesions (erosion, bleeding, redness, edema) during acute gastritis or acute exacerbation phase of chronic gastritis. uuid:014123f1-8460-4ab7-8d18-8966c406ff84 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32107 biolink:treats MONDO:0005412 PMID:41385096 "[{""id"":""uuid:77c981ba-4f4c-4db0-aeef-d2273a823db3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9406c862-4b19-48d2-b35b-c8d759853850"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional pediatric dosages. These drugs are indicated for gastric ulcer, duodenal ulcer, stomal ulcer, Zollinger-Ellison syndrome, reflux esophagitis, preanesthetic medication and improvement of gastric mucosal lesions (erosion, bleeding, redness, edema) during acute gastritis or acute exacerbation phase of chronic gastritis. uuid:faf2b8d5-31f4-4351-b5ef-3fd6f4a03364 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32107 biolink:treats MONDO:0001155 PMID:41385096 "[{""id"":""uuid:4a558067-cfb2-465c-8377-986ce5c93dcc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2132d8b0-1966-41d5-8409-79f26dec88ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional pediatric dosages. These drugs are indicated for gastric ulcer, duodenal ulcer, stomal ulcer, Zollinger-Ellison syndrome, reflux esophagitis, preanesthetic medication and improvement of gastric mucosal lesions (erosion, bleeding, redness, edema) during acute gastritis or acute exacerbation phase of chronic gastritis. uuid:069967f7-91c9-41e1-bebb-89b6dd7f3469 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32107 biolink:treats MONDO:0006896 PMID:41385096 "[{""id"":""uuid:3aa5403a-3e6e-4127-b5c6-e7b52e20cb22"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:108ff104-ffdc-4f18-b008-cc92c08a280f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional pediatric dosages. These drugs are indicated for gastric ulcer, duodenal ulcer, stomal ulcer, Zollinger-Ellison syndrome, reflux esophagitis, preanesthetic medication and improvement of gastric mucosal lesions (erosion, bleeding, redness, edema) during acute gastritis or acute exacerbation phase of chronic gastritis. uuid:79f8f07d-91c0-4a66-b792-1e49f9269670 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32107 biolink:treats UMLS:C0149518 PMID:41385096 "[{""id"":""uuid:e3d645bd-b384-4095-b928-efb35e588195"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:43c87729-d625-4b6b-8064-efcc622a0362"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional pediatric dosages. These drugs are indicated for gastric ulcer, duodenal ulcer, stomal ulcer, Zollinger-Ellison syndrome, reflux esophagitis, preanesthetic medication and improvement of gastric mucosal lesions (erosion, bleeding, redness, edema) during acute gastritis or acute exacerbation phase of chronic gastritis. uuid:920dc6ff-c8cd-493d-98fb-b087f8938b72 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32107 biolink:treats MONDO:0005001 PMID:41385096 "[{""id"":""uuid:afef6b07-9595-43aa-8edf-fe8da115b989"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1508aafd-ec93-4fe8-b273-467bac6aefab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional pediatric dosages. These drugs are indicated for gastric ulcer, duodenal ulcer, stomal ulcer, Zollinger-Ellison syndrome, reflux esophagitis, preanesthetic medication and improvement of gastric mucosal lesions (erosion, bleeding, redness, edema) during acute gastritis or acute exacerbation phase of chronic gastritis. uuid:9692bbab-42ef-49bd-9d11-bc4a0ecfd5d8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75984 biolink:treats UMLS:C0080203 PMID:41385096 "[{""id"":""uuid:3969d6d3-5a0e-461f-98a2-6dc564dcda89"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d9f2bf54-71c0-4184-8874-ce6bf14dedd2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of tachyarrhythmia (paroxysmal atrial fibrillation/flutter, paroxysmal supraventricular tachycardia, ventricular tachycardia) in children. [Expedited review] uuid:62ddb2b6-7124-46b8-9f07-d0038ca1936f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75984 biolink:treats MONDO:0005477 PMID:41385096 "[{""id"":""uuid:71917e52-672e-45ce-9c86-283e89b8aa59"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:89a35381-abab-44af-bde5-17ef0f89d578"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of tachyarrhythmia (paroxysmal atrial fibrillation/flutter, paroxysmal supraventricular tachycardia, ventricular tachycardia) in children. [Expedited review] uuid:58128b1f-2a43-481e-8366-d66068bbb916 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85202 biolink:treats UMLS:C0858004 PMID:41385096 "[{""id"":""uuid:affc95c8-ead9-40ba-b458-408088d48841"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:25f46589-d1ae-46c2-bb3f-4b5d1a888725"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional pediatric dosages for influenza A or B virus infection. uuid:7d607985-0aa5-4ab4-8bee-ddf6d8d57758 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85202 biolink:treats UMLS:C0858005 PMID:41385096 "[{""id"":""uuid:48e3b341-e99f-4186-981c-d505328cc21c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1669406c-74e8-493b-967a-38b4758cda87"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional pediatric dosages for influenza A or B virus infection. uuid:92bd9372-7405-44b0-9dd9-ce9997cdfd19 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3207 biolink:treats MONDO:0100470 PMID:41385096 "[{""id"":""uuid:50f4bd33-ec80-457d-9517-0b0e1a94b3fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:dc96a7d6-f372-401b-bce0-f0abcca4080c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional adult and pediatric (5 years of age and older) dosages for the treatment of bronchial asthma. uuid:452a752d-92bf-4b6c-a5bd-b93d4224af72 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6128 biolink:treats HP:0003326 PMID:41385096 "[{""id"":""uuid:58a6776b-64f2-408a-ba25-7fb315c7563f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b8d062a0-f5b7-4041-acc0-a8928e9df2af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications for the treatment of myalgia and post-traumatic swelling/pain. uuid:5a3f7b91-ce4d-4a4a-8ede-deda5730adeb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6128 biolink:treats NCIT:C3399 PMID:41385096 "[{""id"":""uuid:62343e7d-0b32-452a-8163-c8419678df83"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:93c442d2-bd4d-4153-bde6-a6ed2c2884a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications for the treatment of myalgia and post-traumatic swelling/pain. uuid:76e4ae7e-f9e8-43bd-9877-7ca31a614de5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4672 biolink:treats MONDO:0001056 PMID:41385096 "[{""id"":""uuid:d61f1c8a-a334-4eb6-b19e-be1554c2639d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a8b01eb0-0706-47b0-bef1-99484a2692b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new dosages for the treatment of breast cancer, non-small cell lung cancer, gastric cancer, head and neck cancer and ovarian cancer. uuid:3cf7bf3c-2c19-4801-a424-6ce0f50831ff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4672 biolink:treats MONDO:0008170 PMID:41385096 "[{""id"":""uuid:6ade3143-d079-41a5-9f00-925e2e006f1c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2a7ab474-3210-4679-86ad-ab9c5f517b33"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new dosages for the treatment of breast cancer, non-small cell lung cancer, gastric cancer, head and neck cancer and ovarian cancer. uuid:3480f514-f3c9-41ba-808d-d7e294748731 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:231601 biolink:treats MONDO:0001056 PMID:41385096 "[{""id"":""uuid:61ee4459-cc9d-4aec-9e4a-21a1c4b5cfc4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2c7334ba-8ba7-43f7-9351-4d542e71c4df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of unresectable advanced or recurrent gastric cancer with HER2 overexpression. [Priority review] uuid:4d35ebeb-664f-478e-938b-67171ec8d22e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31759 biolink:treats MONDO:0006896 PMID:41385096 "[{""id"":""uuid:e1ed9d68-b264-4fde-8a62-2f2da0c54da0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:bc20b0b0-65e5-4f2d-91c5-3aaa32dbe047"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication for the treatment of reflux esophagitis. uuid:9e4cfb53-7d14-4672-a748-17e66299526a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7798 biolink:treats UMLS:C0276353 PMID:41385096 "[{""id"":""uuid:5d865015-38d4-407b-955d-48e7cfaf4a30"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:91b62677-0d47-4ba8-bc5b-2cfb2e205f23"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for prophylaxis of influenza A or B virus infections. uuid:f380377e-44c3-492c-b644-5ad6ddc764a4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0700081 PMID:41385096 "[{""id"":""uuid:fca79cb0-1780-45f2-b53f-a132950aeff4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:cac4f700-ba69-4172-9a6e-e6a7c8cb2a22"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for prevention of neonatal respiratory distress syndrome by way of enhancing fetal lung maturation by maternal administration for use in cases where premature birth is expected. uuid:4fe87c95-76c8-41f5-9516-bf256c67fecf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134720 biolink:treats MONDO:0006624 PMID:41385096 "[{""id"":""uuid:2663e2a0-f34a-4fa7-b8cf-07cd52f7ad9e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:86809fa8-3100-4107-bb41-346fe64ad780"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage indicated for the treatment of urgency of urination, pollakiuria, and urge urinary incontinence associated with overactive bladder. uuid:b66804c5-7505-480b-bb02-28b729016b9a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3561 biolink:treats MONDO:0011786 PMID:41385096 "[{""id"":""uuid:03562558-83fd-4df2-b358-e7cdd1eedcc7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e4a94faa-7448-4c28-9fe2-3e76e78eb64f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional pediatric dosage indicated for the treatment of allergic rhinitis, urticaria, and itching associated with skin disease (eczema/dermatitis and pruritus cutaneous). uuid:979ca1ab-ede9-4ee8-9b0e-a7def591c9ee biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3561 biolink:treats MONDO:0005492 PMID:41385096 "[{""id"":""uuid:8cc3831e-418c-4ab9-80e8-e2c49b0c4bd6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f22addbc-a91f-483d-a245-786f8ac510fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional pediatric dosage indicated for the treatment of allergic rhinitis, urticaria, and itching associated with skin disease (eczema/dermatitis and pruritus cutaneous). uuid:c7f21ed8-4348-4f44-862c-5eb8bff6843c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3561 biolink:treats HP:0000989 PMID:41385096 "[{""id"":""uuid:b8d95a8c-5549-40af-b141-7f4dc6bd533f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:80bcb5e6-898e-4b02-a103-58a6d33ed9af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional pediatric dosage indicated for the treatment of allergic rhinitis, urticaria, and itching associated with skin disease (eczema/dermatitis and pruritus cutaneous). uuid:790983c4-3e07-4f00-a939-559d65060426 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41423 biolink:treats HP:0003419 PMID:41385096 "[{""id"":""uuid:ba1fbceb-35f4-4ece-9446-a1a512d8ec98"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:356cde86-4cc2-4739-961a-81127d7d860b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications for the treatment of lumbago, scapulohumeral periarthritis, cervico-omo-brachial syndrome, and tendinitis/tenosynovitis. uuid:a671d304-04b5-4bc2-b878-c2ec25e80700 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41423 biolink:treats MONDO:0006898 PMID:41385096 "[{""id"":""uuid:4e2e2210-3388-4090-b366-9f984d56fadd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:dd50ec76-a00a-494c-be64-d03bbd9d5a3c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications for the treatment of lumbago, scapulohumeral periarthritis, cervico-omo-brachial syndrome, and tendinitis/tenosynovitis. uuid:ff36616f-f829-4df8-9c30-0673a77ed61a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41423 biolink:treats MONDO:0004857 PMID:41385096 "[{""id"":""uuid:0a71fb54-923e-49d2-ba90-d69f30677583"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:22aefcca-2297-4bdc-8ef1-a14d1cfc2908"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications for the treatment of lumbago, scapulohumeral periarthritis, cervico-omo-brachial syndrome, and tendinitis/tenosynovitis. uuid:75139f10-8377-4c37-b198-5a8fb0a8e576 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41423 biolink:treats MONDO:0004855 PMID:41385096 "[{""id"":""uuid:604859c1-2a70-44f3-9531-9691dabd5d2e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a9582b74-66c0-46db-90e8-d25887d224ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications for the treatment of lumbago, scapulohumeral periarthritis, cervico-omo-brachial syndrome, and tendinitis/tenosynovitis. uuid:af6f27c2-0825-47cd-aeb6-20dc97d0eb2f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32300 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:80ac745a-8e5c-44a6-a6f2-462441e09f5a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:478432eb-3888-448c-a82c-99389e0c4f9a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for prevention of type 2 diabetes mellitus in patients with impaired glucose tolerance (only for whom glycemic control is not sufficient by diet and/or exercise). uuid:41772c57-faf2-402c-896d-96f7011f9092 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32300 biolink:treats HP:0040270 PMID:41385096 "[{""id"":""uuid:7f9955eb-0d81-4297-b6f9-be92d6f22e4b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5ea9725e-1700-47a4-8cb0-06f8865b6350"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for prevention of type 2 diabetes mellitus in patients with impaired glucose tolerance (only for whom glycemic control is not sufficient by diet and/or exercise). uuid:082b40a6-3049-46ab-8f61-3a1b8c83ee7e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:175901 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:8d343ce6-d4f8-46ca-a4a8-2fbeffbd9983"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:fa92329f-ef1d-40d1-8e6f-247f7ec79fa0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of inoperable or recurrent breast cancer. uuid:abb26812-1f19-4fdd-9113-ce082f59156c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31801 biolink:treats MONDO:0015597 PMID:41385096 "[{""id"":""uuid:6065d964-2ecc-4d3f-b267-025af61e6a1d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ebc45e75-4367-477f-9e1d-3d411574e486"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication for the treatment of palmoplantar pustulosis. uuid:2a93ebcd-9c49-4fa0-9ea9-add21535e156 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:94385 biolink:treats MONDO:0000831 PMID:41385096 "[{""id"":""uuid:80ac39fe-53cc-4d73-af4e-9aa10e64c008"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:58d8ea51-b5f4-4072-ba85-183f7a00d9d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for prophylaxis of thrombosis in patients with heparin-induced thrombocytopenia (HIT) type II. [Orphan drug] uuid:e0388fdd-f245-4b0e-acc1-dc9f9d9292df biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3061 biolink:treats MONDO:1030009 PMID:41385096 "[{""id"":""uuid:505fcd5e-e574-4c0b-b226-baf4be336bd3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3799894b-9c3d-42f3-89bf-43360cdf2532"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication for the treatment of persistent atrial fibrillation in patients in whom other antiarrhythmic drugs are contraindicated or who have not responded to other antiarrhythmic drugs. [Priority review] uuid:5d0d29d9-4f90-417d-8844-aa7811f02fcc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3732 biolink:treats UMLS:C0026919 PMID:41385096 "[{""id"":""uuid:1e89627c-e376-44bf-a461-3650e60cb409"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:cdef2aa6-d22e-480d-96c9-4d9f1d8a4a60"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for non-tuberculous mycobacteriosis including mycobacterium avium complex (MAC) infections. uuid:f0054336-a748-43ba-b977-e6a60dedaac5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8868 biolink:treats MONDO:0005382 PMID:41385096 "[{""id"":""uuid:71ff8813-2fe3-4dd4-bcec-d4de5d4c8f94"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a55c159b-4c2b-461d-a102-9b1459fda04f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the treatment of Paget's disease of bone. [Orphan drug] uuid:59ed4d70-1195-4738-a306-1f7ee531c9c8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75984 biolink:treats MONDO:0005310 PMID:41385096 "[{""id"":""uuid:a55a4f7e-18c7-4a88-afc3-a08ae798c3ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e5323c84-d253-4162-b9eb-924620661e87"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication for the treatment of tachyarrhythmia (paroxysmal atrial fibrillation and flutter). uuid:91990092-194c-4328-834c-b9c90c5f3bcc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:637364 biolink:treats MONDO:0003060 PMID:41385096 "[{""id"":""uuid:70d947fa-4ab3-4e07-b90e-d19eed9389e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:67670729-a048-47bb-9b01-dce7ec63c6e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication for the treatment of biliary cancer in addition to gastric cancer, colorectal cancer, head and neck cancer, non- small cell lung cancer, inoperable or relapsed breast cancer, and pancreatic cancer. uuid:a1f99384-a879-4194-a4c7-330298a42341 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:637364 biolink:treats MONDO:0001056 PMID:41385096 "[{""id"":""uuid:c996f418-22ce-4b5b-a068-0da4a550a1be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9a0cc115-7fa6-4250-8abc-a4e2e0f9c812"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication for the treatment of biliary cancer in addition to gastric cancer, colorectal cancer, head and neck cancer, non- small cell lung cancer, inoperable or relapsed breast cancer, and pancreatic cancer. uuid:cf3f3e50-ef0a-45ed-a7d4-d7de7ce803d5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:637364 biolink:treats MONDO:0005575 PMID:41385096 "[{""id"":""uuid:07c71444-1e01-4e1c-ac71-4bae2cafa4f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3c891068-4ba7-45e8-bfdd-262f315b3194"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication for the treatment of biliary cancer in addition to gastric cancer, colorectal cancer, head and neck cancer, non- small cell lung cancer, inoperable or relapsed breast cancer, and pancreatic cancer. uuid:b636db43-1bcd-411c-8e7e-0c8ca090a2d6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:637364 biolink:treats MONDO:0005627 PMID:41385096 "[{""id"":""uuid:b7399adf-54d7-4be0-8c71-e2deda2744eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c880e624-d0ce-4fdf-89d4-d562de11f2c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication for the treatment of biliary cancer in addition to gastric cancer, colorectal cancer, head and neck cancer, non- small cell lung cancer, inoperable or relapsed breast cancer, and pancreatic cancer. uuid:634f8f4b-b3ea-4382-ab28-e93d825dc9b1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:637364 biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:1aa18ac7-2cfd-4d44-83ca-059bb9473eda"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1bf38db4-8c73-49e9-b821-343fed99f2e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication for the treatment of biliary cancer in addition to gastric cancer, colorectal cancer, head and neck cancer, non- small cell lung cancer, inoperable or relapsed breast cancer, and pancreatic cancer. uuid:78c37605-236c-48be-82fd-42b5936033c7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:637364 biolink:treats UMLS:C0278493 PMID:41385096 "[{""id"":""uuid:b31fb0c1-8eed-45f7-a9e0-872bb2f9686f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ab9b8779-f29e-42ba-8eae-7d59fa76ece0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication for the treatment of biliary cancer in addition to gastric cancer, colorectal cancer, head and neck cancer, non- small cell lung cancer, inoperable or relapsed breast cancer, and pancreatic cancer. uuid:5ac6495f-930f-41cb-87f3-a95773e912ce biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:637364 biolink:treats MONDO:0009831 PMID:41385096 "[{""id"":""uuid:57bc9f0f-18eb-4d53-acd9-216342b3e073"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:fd6bd02d-585b-4eed-9021-b23c2a74d800"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication for the treatment of biliary cancer in addition to gastric cancer, colorectal cancer, head and neck cancer, non- small cell lung cancer, inoperable or relapsed breast cancer, and pancreatic cancer. uuid:09e9f2a0-3eb3-4170-b17a-f5f133715497 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:8FOJ430U94 biolink:treats MONDO:0000050 PMID:41385096 "[{""id"":""uuid:b26bcf44-8c01-4451-862d-488d2fe31d39"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9d6cf3aa-3bda-4f9c-9d4f-104e8ee1182f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] (1) Drugs with a new indication, a new dosage, and other characteristics for the treatment of short stature due to growth hormone deficiency prior to epiphyseal closure. (2) A drug with a new indication and a new dosage in an additional dosage form for the treatment of short stature due to growth hormone deficiency prior to epiphyseal closure. uuid:3d11f6b5-75e0-431a-9762-1b5bd408cde4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85973 biolink:treats HP:0034192 PMID:41385096 "[{""id"":""uuid:7f1854c9-1650-4813-b70d-0a87dd61e8b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ee7988fb-95dc-4a90-8ff8-56dfcb88cc3e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications and new dosages, and a drug with a newly-added dosage form indicated for prevention of ischemic stroke and systemic embolism in patients with non- valvular atrial fibrillation, or for the treatment and prevention of the recurrence of venous thromboembolism (deep vein thrombosis and pulmonary thromboembolism). uuid:e135bbbd-d8d1-4bca-a354-475d5e5c653f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31397 biolink:treats MONDO:0100470 PMID:41385096 "[{""id"":""uuid:a219aae3-1544-4b86-97e7-958dce12e3be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2ee674e1-b9ab-4329-a1b5-b1e08e60accf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional pediatric dosage indicated for the treatment of bronchial asthma. uuid:f5dc5809-d0cc-4f94-9c91-f6fbe04b69d5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:C3VX249T6L biolink:treats MONDO:0019100 PMID:41385096 "[{""id"":""uuid:d69b3950-375a-49ff-ac08-df109e306d01"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:32151433-a46d-490a-9e8f-b002bfb096cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication for the prevention of relapse of neuromyelitis optica spectrum disorder (including neuromyelitis optica). uuid:5eeb817a-6ea6-49af-b36c-5bbc3ea358e0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:90ZX3Q3FR7 biolink:treats MONDO:0015597 PMID:41385096 "[{""id"":""uuid:eaf4a793-2ef1-490f-b519-e61377afdd65"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:00086120-6133-4980-ad86-e269a2717b10"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the treatment of palmoplantar pustulosis in patients who have not responded sufficiently to conventional therapies. uuid:f6698852-6cfa-4666-aeca-9dae3b5214f4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31355 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:636ba163-a9fe-4a25-9f38-c302d9597846"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:68b44626-547b-4448-930e-1b79817142dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage indicated for the treatment of breast cancer. uuid:ef18788b-156c-4df7-b3e2-7c6da98c3d43 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4027 biolink:treats MONDO:0017816 PMID:41385096 "[{""id"":""uuid:3990a84b-81ea-413b-b69a-6a45f8dfdf16"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:229af5ac-383b-4dc0-a446-f776b9e04791"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the treatment of systemic AL amyloidosis. [Expedited review] uuid:7ea4090c-feb1-4a72-97b9-545a4f8d581c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16684 biolink:treats HP:0002061 PMID:41385096 "[{""id"":""uuid:ccad2acd-812c-4167-9d9b-903ec8552d1b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5ba656a8-c706-4763-898a-50a93c02724c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the treatment of lower limb spasticity. uuid:77149222-15f8-4019-9833-215348bcf2e9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135901 biolink:treats MONDO:0003837 PMID:41385096 "[{""id"":""uuid:2cb00f2d-c6d7-4893-bf80-41e8e87d1c22"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7fce5482-91dc-45f6-ad4d-447a0eaa3d7f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication for the treatment of thyroid- stimulating hormone secreting pituitary tumour. [Orphan drug] uuid:6cd296d0-9f56-4de4-807f-5dbb318a2cd4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:I031V2H011 biolink:treats MONDO:0019355 PMID:41385096 "[{""id"":""uuid:979662eb-0407-44fd-b50d-f06dfc12b4d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7e832b58-07e3-438d-8aae-522cf697e436"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of adult Still's disease in patients who have not responded sufficiently to conventional treatments. uuid:d98dc4d0-9edb-413c-8573-b84415dc26d9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:78540 biolink:treats HP:0000155 PMID:41385096 "[{""id"":""uuid:20d1b921-53b9-4631-9cba-9e36713c511a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:630fe573-d00c-4cd8-a143-f87497b43921"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication for the treatment of oral ulcer associated with Behcet’s disease in patients who have not responded sufficiently to local treatment. uuid:9bb084d3-b6a6-463e-87ee-6283ba28fa27 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68478 biolink:treats UMLS:C0400968 PMID:41385096 "[{""id"":""uuid:bfb1cac2-ee26-4368-8013-80e2d0b45bdc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:504f4a64-9117-471f-ae09-65a70a5e3b81"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the inhibition of rejection in liver transplantation. uuid:37b30060-af68-49b4-9bc3-cf7f86f95bb3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:74170 biolink:treats MONDO:0005113 PMID:41385096 "[{""id"":""uuid:59931856-3c51-4614-9e8c-79cfcfcfb21b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:77eb88eb-70da-45fb-b410-b87e975a06c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[PMDA] Drugs with additional indications and new dosages for the treatment of ""bacterial skin infections mainly involving the dermis and/or subcutaneous tissues"" and ""secondary bacterial infections of pre-existing skin ulcers and/or erosion""." uuid:ac5db071-7ef9-4fe6-a363-54efd66d7ba0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:LR3UXN0193 biolink:treats MONDO:0016218 PMID:41385096 "[{""id"":""uuid:293c6d5a-3826-4149-a175-6e1b49457872"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1dfb56c6-0728-4f16-a510-811e0b8200c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication for the treatment of Guillain-Barré syndrome (severe cases in an acute exacerbation phase with difficulty in walking). uuid:93007b0b-e215-4aa7-a239-887028ec2b55 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:LR3UXN0193 biolink:treats MONDO:0019082 PMID:41385096 "[{""id"":""uuid:6e560acd-9a8d-463b-9c48-b90bf58b164d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2ee7815a-a35b-4666-aba2-2bf6e6146cad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication for the treatment of bullous pemphigoid (for use when steroid drugs are not sufficiently effective). uuid:5cfb5612-6a5e-4be7-81e7-68fd37e26189 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3441 biolink:treats MONDO:0004981 PMID:41385096 "[{""id"":""uuid:1c4bd20b-c1fd-495d-b7b9-863418e2bdc4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:255a921e-4830-4481-9a8c-c715b7e2e6de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of tachycardiac atrial fibrillation. uuid:e776d528-9d4e-4229-bf2c-3c3c9ad77a6b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0100470 PMID:41385096 "[{""id"":""uuid:ecb838c8-b5a7-40bd-9816-a9b0355debb0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:48e49b94-4274-4c00-a899-209683752a2e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of bronchial asthma. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:f653d982-f50b-4af5-9c0f-168c0cbfea96 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:G8RGG88B68 biolink:treats MONDO:0005105 PMID:41385096 "[{""id"":""uuid:70c94220-58cd-41a5-913c-5d9044d66503"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8a00f901-7933-42f0-8e55-0320e86a9b34"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the adjuvant treatment of melanoma. [Orphan drug] uuid:13472101-d62d-425b-a7cd-53e369216aba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0005062 PMID:41385096 "[{""id"":""uuid:34fe4751-085c-4c21-9d6b-b9f3c860fc28"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:89e5fb75-50e6-4513-98b1-480f827af172"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with revised indications and a new dosage for the treatment of malignant lymphoma and similar diseases (closely-related diseases). [Expedited review] uuid:8a7e3cea-1814-449f-8cf8-f58a5c224f70 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31941 biolink:treats MONDO:0001056 PMID:41385096 "[{""id"":""uuid:d6e049f5-a884-4fb2-9889-2d3247a661a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:871e8c50-bd74-4130-8a4a-855105125506"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of unresectable advanced or recurrent gastric cancer. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:8c50a166-9ce0-4f87-bb2d-2e9b41df9ed7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats HP:0100806 PMID:41385096 "[{""id"":""uuid:30d1fc55-e972-4d6f-a50e-a21e2eaee452"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3e41893f-0afd-4f3d-bce3-79d8ee34acb6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage indicated for the treatment of sepsis, secondary infection of trauma, burn, and surgical wound, pneumonia, cystitis, pyelonephritis, peritonitis, otitis media caused by following applicable microorganisms: Gentamicin-sensitive Staphylococcus, Escherichia coli, Klebsiella, Enterobacter, Serratia, Proteus, Morganella morganii, Providencia, Pseudomonas aeruginosa uuid:db5d5f72-0480-4056-b743-ce3c48a7d637 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats UMLS:C0332803 PMID:41385096 "[{""id"":""uuid:265cdf33-81a2-4bec-971d-7e6fc5e4fa0b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:04c656d5-7ed4-4d71-bf3c-cae6206bd977"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage indicated for the treatment of sepsis, secondary infection of trauma, burn, and surgical wound, pneumonia, cystitis, pyelonephritis, peritonitis, otitis media caused by following applicable microorganisms: Gentamicin-sensitive Staphylococcus, Escherichia coli, Klebsiella, Enterobacter, Serratia, Proteus, Morganella morganii, Providencia, Pseudomonas aeruginosa uuid:a7e4d80b-a4c2-40c7-bcf3-f951d44cc05a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:12ee593b-7fda-4356-92db-6ba3eede2fd1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:819e3143-878b-44b6-98b3-97abcf7bc0e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage indicated for the treatment of sepsis, secondary infection of trauma, burn, and surgical wound, pneumonia, cystitis, pyelonephritis, peritonitis, otitis media caused by following applicable microorganisms: Gentamicin-sensitive Staphylococcus, Escherichia coli, Klebsiella, Enterobacter, Serratia, Proteus, Morganella morganii, Providencia, Pseudomonas aeruginosa uuid:e0569a2c-4c15-45e8-a610-1ce0f0978e6a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats MONDO:0006032 PMID:41385096 "[{""id"":""uuid:22b047ee-7970-4ea5-b216-4c3089fa9115"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:46a0fbd1-2635-47f5-b8e2-31ec2ee2a519"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage indicated for the treatment of sepsis, secondary infection of trauma, burn, and surgical wound, pneumonia, cystitis, pyelonephritis, peritonitis, otitis media caused by following applicable microorganisms: Gentamicin-sensitive Staphylococcus, Escherichia coli, Klebsiella, Enterobacter, Serratia, Proteus, Morganella morganii, Providencia, Pseudomonas aeruginosa uuid:22db4060-1ee8-4cd3-90c8-5d9f9177e347 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats MONDO:0006939 PMID:41385096 "[{""id"":""uuid:9040770b-7068-4272-bf12-9e3bc52cb76d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a8c8ba75-488c-44bb-a3e3-db9d7999ef55"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage indicated for the treatment of sepsis, secondary infection of trauma, burn, and surgical wound, pneumonia, cystitis, pyelonephritis, peritonitis, otitis media caused by following applicable microorganisms: Gentamicin-sensitive Staphylococcus, Escherichia coli, Klebsiella, Enterobacter, Serratia, Proteus, Morganella morganii, Providencia, Pseudomonas aeruginosa uuid:773b71c6-a57c-419f-9241-cb60fbca1a75 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats MONDO:0005441 PMID:41385096 "[{""id"":""uuid:733daf23-6382-4af6-807d-c1e4c97dbfbf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f5e22219-b65a-47a5-9079-7ce973e84c78"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage indicated for the treatment of sepsis, secondary infection of trauma, burn, and surgical wound, pneumonia, cystitis, pyelonephritis, peritonitis, otitis media caused by following applicable microorganisms: Gentamicin-sensitive Staphylococcus, Escherichia coli, Klebsiella, Enterobacter, Serratia, Proteus, Morganella morganii, Providencia, Pseudomonas aeruginosa uuid:f3c97f61-6d85-4699-ad03-cae4ef95135a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:43968 biolink:treats UMLS:C0865440 PMID:41385096 "[{""id"":""uuid:54c16c02-89ef-4876-b1c9-6a0c12312480"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1f40463e-41cc-42a9-80ab-e7872fff4a25"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage (the daily dose has been changed) in patients with purulent meningitis. uuid:8c3eca3a-f83d-4a2a-b673-93baecb38087 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:114785 biolink:treats UMLS:C3266992 PMID:41385096 "[{""id"":""uuid:743e8b52-60ec-4698-8726-c83306371fc2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:74673b99-94a7-4aef-acdc-af5193ea548e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of unresectable advanced or recurrent non-small cell lung cancer with EGFR gene mutation in patients who have not been treated with chemotherapy. uuid:a9924d60-921a-4de4-ad1b-aa63c8ee06c2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31941 biolink:treats UMLS:C0854776 PMID:41385096 "[{""id"":""uuid:1b6c29dd-bff1-4364-9381-58086578a278"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:09d09fc3-96ca-430a-a61e-9beaeccd41ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of unresectable pancreatic cancer. [Priority review], [Expedited review] uuid:cedc4a7d-af0a-4736-a329-72c96a9ffc9a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEMBL.COMPOUND:CHEMBL2108334 biolink:treats NCIT:C26791 PMID:41385096 "[{""id"":""uuid:6706f72b-297e-4cf2-b082-46e806398a92"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a0460295-0567-4706-aff5-d943d2586ffb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage to add single-dose administration for the prevention of bleeding in patients with congenital hemophilia who have inhibitors against blood coagulation factor VIII or IX. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:c071f9db-b03a-4a51-b01f-5536c7a5551b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64356 biolink:treats HP:6000040 PMID:41385096 "[{""id"":""uuid:aaf5f982-5913-4454-8b55-333fddad3042"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:54686210-fcf9-4efb-bf93-5eda21daf6b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication for the treatment of neuropathic pain. uuid:e7ab8626-c920-48d4-bb33-106dbb3d56e3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135928 biolink:treats UMLS:C0865440 PMID:41385096 "[{""id"":""uuid:0f3c4cdf-a7a4-4d33-9ab8-31b0324cc476"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3ac65d70-e131-4508-8022-6527447ad8e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional pediatric dosage and with a new additional indication for the treatment of purulent meningitis. uuid:7d0ec85a-1a5f-4f9c-ad2f-e65853b1252c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:NQX9KB6PCL biolink:treats MONDO:0005030 PMID:41385096 "[{""id"":""uuid:c3fce562-138f-4346-9b3c-73428e281b3f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:53596604-80bd-44bd-8dbe-325f70e36a5b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of SGA (small-for- gestational age) dwarfism not associated with epiphyseal closure. uuid:5be9df2a-97b6-483b-9e8f-21fa6fe750d4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68478 biolink:treats UMLS:C0238217 PMID:41385096 "[{""id"":""uuid:b0d16b35-54d4-48a6-8e4c-8257f84dcf03"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:328c3bf8-b859-4188-acc3-0e7bbdbdc96d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the inhibition of rejection in renal transplantation. uuid:b79fe519-d1d8-48f1-9962-aaeaa89a7d3e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3127 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:a3881def-75b0-4fd9-8b00-e479e909f7f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4ab8fc94-5e70-4d1d-becc-1320e1ec16d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and new dosages for the treatment of chronic heart failure secondary to ischemic heart disease or dilated cardiomyopathy in patients receiving basic treatment with angiotensin converting enzyme inhibitors or angiotensin II receptor antagonists, diuretics, digitalis preparations, etc. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:87f0f895-b175-4235-99ea-7abf16566186 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3127 biolink:treats MONDO:0024644 PMID:41385096 "[{""id"":""uuid:bae2d158-d6b1-49ab-977d-516a9f7af037"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ed9fdc9b-f5ae-4a8d-91b5-8df0fcc3241d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and new dosages for the treatment of chronic heart failure secondary to ischemic heart disease or dilated cardiomyopathy in patients receiving basic treatment with angiotensin converting enzyme inhibitors or angiotensin II receptor antagonists, diuretics, digitalis preparations, etc. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:7faa0552-b86a-48ca-97ff-1491af73f24a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3127 biolink:treats MONDO:0005021 PMID:41385096 "[{""id"":""uuid:7fc9e7c6-1bab-42a0-892a-3b93f0f2bba8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:bc2a7ad1-ba52-419f-aa0c-e68f2e96fff1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and new dosages for the treatment of chronic heart failure secondary to ischemic heart disease or dilated cardiomyopathy in patients receiving basic treatment with angiotensin converting enzyme inhibitors or angiotensin II receptor antagonists, diuretics, digitalis preparations, etc. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:20f7b98b-d6d3-47ef-bd13-b71227f5b018 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:129818801 biolink:treats MONDO:0005277 PMID:41385096 "[{""id"":""uuid:b7190f93-6403-4d5b-a677-cc1cecbfbd90"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b490cd22-5618-4a6d-8055-86465b46159b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for prevention of migraine attack. uuid:598b30a9-5dd4-4309-a222-7ecfab71f618 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:RWM8CCW8GP biolink:treats MONDO:0000386 PMID:41385096 "[{""id"":""uuid:1cacf335-8eb5-42ef-86db-75e41cf05130"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:fedbcc63-a203-4679-9a29-074fddefb327"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of gastrointestinal neuroendocrine tumor. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:b160fc89-5c87-485e-8cf3-1d9317ebcb9c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10033 biolink:treats MONDO:0006809 PMID:41385096 "[{""id"":""uuid:f760082a-966f-42b4-b891-411996d69a10"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0792f708-52ed-4fa3-9753-52709744507b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional pediatric dosages. These drugs are indicated for the treatment and prophylaxis of thromboembolism (e.g., phlebothrombosis, myocardial infarction, pulmonary embolism, brain embolism, slowly- progressive cerebral thrombosis). [Public knowledge-based application after PAFSC's preliminary assessment] uuid:7548c21d-5770-4855-9329-5a51953fe22e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10033 biolink:treats MONDO:0002907 PMID:41385096 "[{""id"":""uuid:60b0ea42-ce6b-4d6b-8292-7e2f895f816c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:66317652-5b4f-42d1-bd94-5050123ad207"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional pediatric dosages. These drugs are indicated for the treatment and prophylaxis of thromboembolism (e.g., phlebothrombosis, myocardial infarction, pulmonary embolism, brain embolism, slowly- progressive cerebral thrombosis). [Public knowledge-based application after PAFSC's preliminary assessment] uuid:e386989d-f873-46f4-8e41-dc55f8396eb0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64356 biolink:treats UMLS:C0458960 PMID:41385096 "[{""id"":""uuid:50548b9c-2331-489d-8e04-3a0d930acc15"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:984a3acb-fd9e-48a4-a398-bbe4a29440cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication for the treatment of peripheral neuropathic pain. uuid:87b9930d-278e-4c25-826c-0e21b0dc48f4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:43968 biolink:treats MONDO:0018542 PMID:41385096 "[{""id"":""uuid:23785f55-cea4-4391-923b-7a5b3354a4d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d1cd9661-3861-4daa-9cad-6469327c2c69"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage (the maximum daily dose has been changed) in patients with general infections that are severe and refractory. uuid:9e8b4be1-908a-4684-a9a3-20e6d4a52488 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4027 biolink:treats MONDO:0005554 PMID:41385096 "[{""id"":""uuid:6fc13822-5d15-4678-b8d4-28cd3b9c9fd9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b17be1d3-fef1-49c1-925f-dc537a0348e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and new dosages for treatment-resistant rheumatic disease in adults and children. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:7d5350d9-70ab-4fb0-bfb3-9df760033269 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:61049 biolink:treats MONDO:0005101 PMID:41385096 "[{""id"":""uuid:4aea0cd0-3a1e-497a-a32e-7d2c69ff1829"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b876802e-b382-4612-ab0d-9c4decd7edd6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of refractory (steroid- resistant/steroid-dependent) active ulcerative colitis (limited to moderate-to-severe cases). uuid:57476d93-4e78-4210-9e83-91ddeb9fe207 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:43968 biolink:treats UMLS:C0746883 PMID:41385096 "[{""id"":""uuid:0ac77c32-0954-4673-ba08-2b50bc739653"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:26b4a725-eb50-4d05-ac01-0a8ae263d7f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of febrile neutropenia. uuid:f25bb5f3-3cc8-4898-b1ca-b9311c86c2f5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8493 biolink:treats HP:0100515 PMID:41385096 "[{""id"":""uuid:bc94aec7-a757-448f-94b4-b2b65393db47"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ed3aca17-b958-4c9c-9f0e-d991d69c2741"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication for the treatment of urgency of urination, pollakiuria, and urge urinary incontinence associated with overactive bladder. uuid:833e37bd-215a-4d73-8746-3f0e7703f440 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8493 biolink:treats EFO:0006865 PMID:41385096 "[{""id"":""uuid:a4a374b4-510c-4d2e-9ad9-f0b99490c10b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a921706f-6f0c-4790-a9bf-ad6e8894a780"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication for the treatment of urgency of urination, pollakiuria, and urge urinary incontinence associated with overactive bladder. uuid:d220b8df-91f4-49c2-a23e-d114e5f8d69d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8493 biolink:treats MONDO:0006624 PMID:41385096 "[{""id"":""uuid:468f23f5-7022-4444-ad6c-0d8e60f1f768"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ed44ea79-77e4-497a-a84f-e4b4443ccb88"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication for the treatment of urgency of urination, pollakiuria, and urge urinary incontinence associated with overactive bladder. uuid:8e65772e-8d0c-4390-a913-c93c86d49d36 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:NQX9KB6PCL biolink:treats UMLS:C1720505 PMID:41385096 "[{""id"":""uuid:42dc6485-578d-463d-baca-5f48da7f2d7b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5e6fa5cd-152f-418b-a764-0882b129ad6e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of adult growth hormone deficiency (for use only in severe cases). uuid:2b879278-b24c-4eb0-a7ae-bb4c0d5ebb16 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6935 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:6ef3e386-6a5f-4167-95e4-e5eef022b805"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:39c0ffd0-5c9e-4b29-bf91-5c25a6188963"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication for improvement of postprandial hyperglycemia in patients with diabetes mellitus (for use only in patients who have not responded sufficiently to treatment with biguanides in conjunction with dietary and exercise regimens). uuid:0790fd70-4f37-44d1-8c33-2675036784a3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6935 biolink:treats MONDO:0005147 PMID:41385096 "[{""id"":""uuid:e6de34b0-a491-462f-9a58-2303ef306104"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e8ad57fa-4d29-4def-8a85-e9f7555285d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication for the treatment of postprandial hyperglycemia in Type 2 diabetes mellitus (for use only in patients who have not benefitted sufficiently from taking insulin preparations in conjunction with dietary and exercise regimens) and the treatment of postprandial hyperglycemia in Type 1 diabetes mellitus (for use only in patients who have not benefited sufficiently from dietary and exercise regimens or from taking sulfonylurea or insulin preparations in conjunction with dietary and exercise regimens). uuid:86f93aa7-eee1-4fdb-8888-60c4ab700988 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:37922 biolink:treats MONDO:0700217 PMID:41385096 "[{""id"":""uuid:181d443e-b429-4dbe-8cfb-70341b8b44bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a801e51a-c3dd-403e-93de-d762940f7883"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage and in a new dosage form indicated for the treatment of septicemia and pneumonia caused by arbekacin-sensitive methicillin-resistant staphylococcus aureus (MRSA). uuid:81ba4649-f5db-4bdb-85ca-adedace6e5d1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:37922 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:72b93c20-21e7-4fc5-8bdb-84d37679c2ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ab1162b4-f771-402b-a03e-c577e812329b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage and in a new dosage form indicated for the treatment of septicemia and pneumonia caused by arbekacin-sensitive methicillin-resistant staphylococcus aureus (MRSA). uuid:b1221428-71f8-4073-b91d-0a5105ce10f8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4RA0KN46E0 biolink:treats UMLS:C0852922 PMID:41385096 "[{""id"":""uuid:2a68849c-e364-4aaf-a76e-7c40a4245573"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:afb3e797-8912-4667-9ec4-267b9748421e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] (1) (2) (3) Drugs with a new indication and a new dosage for the remission induction therapy and the maintenance therapy of moderate to severe active Crohn’s disease (for use only in patients who have not sufficiently responded to conventional treatments). (4) A drug with a new indication and a new dosage for the remission induction therapy of moderate to severe active Crohn’s disease (for use only in patients who have not sufficiently responded to conventional treatments). uuid:4665d98c-944a-4b84-8476-7a72adf3b3d7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:31YO63LBSN biolink:treats MONDO:0006292 PMID:41385096 "[{""id"":""uuid:42d67b77-ef12-4e6e-ab5f-0723593ed2a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:edc7760e-4f16-4615-b10a-a5fae02c381c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the treatment of malignant mesothelioma (excluding malignant pleural mesothelioma). [Orphan drug] uuid:c6ac492e-99d2-4867-9cf8-244a95cdd277 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:31YO63LBSN biolink:treats MONDO:0002898 PMID:41385096 "[{""id"":""uuid:ab283c7f-754d-4af2-bba4-366215f0e8ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b162e287-b12f-40e1-82ef-fd52e76d0a00"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the treatment of unresectable advanced or recurrent epithelial skin malignancies. [Orphan drug] uuid:c5b5239c-887b-4f07-9cb1-949ecd688812 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:S7LK2KDM5U biolink:treats HP:6000040 PMID:41385096 "[{""id"":""uuid:745ee650-9b64-46ed-83b3-cfd581079868"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0fabbcd8-3faf-4302-8dc7-0444ebe45c6b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication for the treatment of neuropathic pain. uuid:2f47254a-a9ed-4b55-9196-103c715e2697 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:31YO63LBSN biolink:treats MONDO:0858997 PMID:41385096 "[{""id"":""uuid:bd7d0b77-1074-4374-ac51-4abd62615cc8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:94a93f1a-70f4-46fd-baf1-0940aaa4b100"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the treatment of carcinoma of unknown primary. [Orphan drug] uuid:58da9a7c-5914-4b71-a802-e4cfda4166cd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:RWM8CCW8GP biolink:treats MONDO:0004946 PMID:41385096 "[{""id"":""uuid:18e28d58-fa80-4fec-bb64-bf6f3802a1fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:39851769-c6d1-4a8c-9692-64a5e73a2546"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of hypoglycemia associated with congenital hyperinsulinism (for use only in patients who have not sufficiently responded to other pharmaceutical therapies ). [Public knowledge-based application after preliminary assessment by the Pharmaceutical Affairs and Food Sanitation Council (PAFSC)] uuid:72643652-b082-49f6-93b0-ccb36d728422 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:RWM8CCW8GP biolink:treats MONDO:0019010 PMID:41385096 "[{""id"":""uuid:21c4929a-c5e5-4986-9b00-ec215c4c49a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e4f04ddd-73fb-4319-8b39-24e438ad2f72"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of hypoglycemia associated with congenital hyperinsulinism (for use only in patients who have not sufficiently responded to other pharmaceutical therapies ). [Public knowledge-based application after preliminary assessment by the Pharmaceutical Affairs and Food Sanitation Council (PAFSC)] uuid:0cab6797-8ce9-485b-8639-912c6677ca70 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:FYS6T7F842 biolink:treats MONDO:0018824 PMID:41385096 "[{""id"":""uuid:34672a6e-ee8b-4d8c-8ee4-62ac265f15f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:14a07892-86db-485b-b8a0-b2848a8ff828"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the treatment of pyoderma gangrenosum. [Orphan drug] uuid:7cba5461-f515-4878-b7a7-12a4b162108f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2P471X1Z11 biolink:treats MONDO:0005324 PMID:41385096 "[{""id"":""uuid:a27d5f92-ef4b-48a7-a849-a97a991ae12b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ed1dbf2e-4913-429e-b7c7-ad3116398de1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of seasonal allergic rhinitis (for use only in severe or the most severe patients who have not responded sufficiently to conventional therapies). uuid:6f0dfdd2-daf9-402d-9f89-0f5dd4980a2b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4031 biolink:treats MONDO:0015909 PMID:41385096 "[{""id"":""uuid:01e5e7b9-be18-40bd-959f-74e888c8d8fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d21b61f8-211c-4336-b732-6f4b3c1041ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a revised indication and a new dosage for the treatment of aplastic anemia which is not severe. [Expedited review] uuid:dcf4d43d-d4ff-4a7a-aca0-69cbfbe0cd61 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:62984 biolink:treats UMLS:C0854521 PMID:41385096 "[{""id"":""uuid:e0e28cba-bad6-4f6f-aac2-39c01eb6791f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:518eee0c-3b09-4304-9847-4d1ce347d0ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of hypozincemia. uuid:2bb6f97b-8ad9-4f6f-a9ee-997ee51cc8e5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71260 biolink:treats MONDO:0005439 PMID:41385096 "[{""id"":""uuid:8662d731-f483-4708-b827-f67e522304bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c94fca95-76f6-4bee-9b68-92c07207ad7f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional pediatric dosage indicated for the treatment of familial hypercholesterolemia. uuid:ab393832-9441-44c8-b3b4-06f1df242018 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6367 biolink:treats HP:0011147 PMID:41385096 "[{""id"":""uuid:b8a46ea9-f6c3-489a-9e3f-04b8e474981f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2c50e9b9-91de-43eb-a54e-551253dcc286"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for use in the monotherapy for the treatment of typical absence seizures in patients with epilepsy. uuid:ca0425ce-c825-4ba8-9179-745dce20d0ce biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2666 biolink:treats UMLS:C0458960 PMID:41385096 "[{""id"":""uuid:45167f1f-6e0a-4db0-a300-f79216877bba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:36fb308e-60bb-46fe-a59e-3d4649fe14a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of peripheral neuropathic pain. [Public knowledge-based application after preliminary assessment by the Pharmaceutical Affairs and Food Sanitation Council (PAFSC)] uuid:860b25de-59ba-4b65-ac59-31b9169554ce biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10023 biolink:treats UMLS:C0948382 PMID:41385096 "[{""id"":""uuid:4fc484b8-b8e0-4411-acc1-a377b045fe3b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:bc7465d1-0513-4ee5-b6b3-1dda24799a1a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and new dosages for the prophylaxis of deep mycosis in patients after hematopoietic stem cell transplantation. uuid:f0fe082b-2cad-4eaa-8e4d-50e1bee045e3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats UMLS:C0264939 PMID:41385096 "[{""id"":""uuid:4720e6a8-36e4-480c-a69c-d52d5f59a406"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a1dae876-f202-4ae4-9169-1a7f167708db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications and a new dosage for the treatment of the following treatment- resistant rheumatic diseases: systemic vasculitis (including microscopic polyangiitis, Wegener's granulomatosis, polyarteritis nodosa, Churg- Strauss syndrome, aortitis syndrome), systemic lupus erythematosus, polymyositis, dermatomyositis, scleroderma, mixed connective tissue disease, and refractory rheumatic disease. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:20feb2d2-475b-49cb-81a5-a2d0357eb300 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0019124 PMID:41385096 "[{""id"":""uuid:c833a05c-ecb9-4ba8-b560-187703b85fd8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f6ddf3fa-f550-43fb-a0d5-f31fb456ef4f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications and a new dosage for the treatment of the following treatment- resistant rheumatic diseases: systemic vasculitis (including microscopic polyangiitis, Wegener's granulomatosis, polyarteritis nodosa, Churg- Strauss syndrome, aortitis syndrome), systemic lupus erythematosus, polymyositis, dermatomyositis, scleroderma, mixed connective tissue disease, and refractory rheumatic disease. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:fb5ff3de-15d3-4fe4-bbe6-0d8a1ccaa808 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0012105 PMID:41385096 "[{""id"":""uuid:b2b458e6-3388-4ebc-bbf5-efcecdf68541"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8ed47781-0f3c-4ef3-80e0-7729ab14a971"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications and a new dosage for the treatment of the following treatment- resistant rheumatic diseases: systemic vasculitis (including microscopic polyangiitis, Wegener's granulomatosis, polyarteritis nodosa, Churg- Strauss syndrome, aortitis syndrome), systemic lupus erythematosus, polymyositis, dermatomyositis, scleroderma, mixed connective tissue disease, and refractory rheumatic disease. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:e3a9ceba-2f55-4e26-a4f9-6499428b3595 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0019170 PMID:41385096 "[{""id"":""uuid:6efdc140-1422-4573-a750-d10e94b8acbb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:80471ed4-3c82-406f-9542-fb1d2d24ef0a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications and a new dosage for the treatment of the following treatment- resistant rheumatic diseases: systemic vasculitis (including microscopic polyangiitis, Wegener's granulomatosis, polyarteritis nodosa, Churg- Strauss syndrome, aortitis syndrome), systemic lupus erythematosus, polymyositis, dermatomyositis, scleroderma, mixed connective tissue disease, and refractory rheumatic disease. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:c290a003-7a24-482b-94c1-78e6a11d7961 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0015943 PMID:41385096 "[{""id"":""uuid:60181147-7b5a-447f-b014-2d0afd68e3fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7ad09f83-a988-4c64-a1d0-597847899ebd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications and a new dosage for the treatment of the following treatment- resistant rheumatic diseases: systemic vasculitis (including microscopic polyangiitis, Wegener's granulomatosis, polyarteritis nodosa, Churg- Strauss syndrome, aortitis syndrome), systemic lupus erythematosus, polymyositis, dermatomyositis, scleroderma, mixed connective tissue disease, and refractory rheumatic disease. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:33b1afe1-908a-4e07-af28-cb175c7de00d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0017991 PMID:41385096 "[{""id"":""uuid:864249b9-e143-4e56-ba23-1656a23d0de9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c0756bdd-0672-458f-84a6-de3428d46052"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications and a new dosage for the treatment of the following treatment- resistant rheumatic diseases: systemic vasculitis (including microscopic polyangiitis, Wegener's granulomatosis, polyarteritis nodosa, Churg- Strauss syndrome, aortitis syndrome), systemic lupus erythematosus, polymyositis, dermatomyositis, scleroderma, mixed connective tissue disease, and refractory rheumatic disease. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:bb7a3191-689b-459c-ac04-80132bb0721d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0007915 PMID:41385096 "[{""id"":""uuid:7a22f3d3-dfd5-454c-99a4-41d15606e7e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2116686c-ddd0-4283-8004-5fe3768d5ee3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications and a new dosage for the treatment of the following treatment- resistant rheumatic diseases: systemic vasculitis (including microscopic polyangiitis, Wegener's granulomatosis, polyarteritis nodosa, Churg- Strauss syndrome, aortitis syndrome), systemic lupus erythematosus, polymyositis, dermatomyositis, scleroderma, mixed connective tissue disease, and refractory rheumatic disease. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:8fa8702d-2938-42f9-b9bf-9e8b5a5becfe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0019340 PMID:41385096 "[{""id"":""uuid:6b935822-7942-4d2a-babc-c7be67788d99"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f8846e8d-35a1-473a-851b-773eddd53d34"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications and a new dosage for the treatment of the following treatment- resistant rheumatic diseases: systemic vasculitis (including microscopic polyangiitis, Wegener's granulomatosis, polyarteritis nodosa, Churg- Strauss syndrome, aortitis syndrome), systemic lupus erythematosus, polymyositis, dermatomyositis, scleroderma, mixed connective tissue disease, and refractory rheumatic disease. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:52eaef5c-716a-4886-b6a9-b83906bb144b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0005854 PMID:41385096 "[{""id"":""uuid:20b51af1-53d7-4404-9176-7834ca0c7d27"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c809b386-27c8-4e3d-93ab-29114043c189"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications and a new dosage for the treatment of the following treatment- resistant rheumatic diseases: systemic vasculitis (including microscopic polyangiitis, Wegener's granulomatosis, polyarteritis nodosa, Churg- Strauss syndrome, aortitis syndrome), systemic lupus erythematosus, polymyositis, dermatomyositis, scleroderma, mixed connective tissue disease, and refractory rheumatic disease. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:5362230b-c1c6-4e81-b150-61cf83ba5fbf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0005554 PMID:41385096 "[{""id"":""uuid:54393a65-2db6-41e0-aa05-218de248ead7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:358ccd6c-bacb-43a1-b777-0d0fa3592d6f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications and a new dosage for the treatment of the following treatment- resistant rheumatic diseases: systemic vasculitis (including microscopic polyangiitis, Wegener's granulomatosis, polyarteritis nodosa, Churg- Strauss syndrome, aortitis syndrome), systemic lupus erythematosus, polymyositis, dermatomyositis, scleroderma, mixed connective tissue disease, and refractory rheumatic disease. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:686d2202-9038-474b-975e-122ee764a723 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:176168 biolink:treats MONDO:0005300 PMID:41385096 "[{""id"":""uuid:bc63df63-95de-4fdf-b8d6-14d3fdf4d684"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c6f3cfd6-d9a8-4402-bf48-0ca31171be70"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication to extend the indication for the improvement of hyperphosphatemia in patients with chronic kidney disease. uuid:2e03fda4-8a09-42cc-90af-c35ecce405ec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DQ448MW7KS biolink:treats MONDO:0021094 PMID:41385096 "[{""id"":""uuid:c15fb652-29ab-48e9-862e-2a408ddd621f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:55dfa22f-1727-4c36-97f8-d60dadb2e327"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new indications for the suppression of development of serious lower respiratory tract disease caused by RS viral infection in newborns, infants, and children aged 24 months or less with immunodeficiency and Down syndrome. [Priority review] uuid:67206a9d-98d3-4de5-a9d8-c5421845e023 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28971 biolink:treats MONDO:0005828 PMID:41385096 "[{""id"":""uuid:dcf78511-10bc-41eb-b113-a32f64da5550"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:89eef626-1ccb-4bb7-b713-767ad24d36eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication for Listeria monocytogenes as an applicable microorganism and with new additional pediatric and neonate dosages. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:79bb974b-7d77-4f67-b9c6-ae97387a4363 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28741 biolink:treats MONDO:0005114 PMID:41385096 "[{""id"":""uuid:d105431a-93f3-4075-b434-1b250d6eed07"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a7babd74-1c49-4df6-8751-d0c285768caa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications for Streptococcus Pneumoniae and Moraxella catarrhalis as applicable microorganisms. A new dosage has been added to enable high-dosage use for severe infections. uuid:b5f2ea72-45d5-4243-95e7-e29e023841af biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28741 biolink:treats MONDO:0006878 PMID:41385096 "[{""id"":""uuid:6eef1bce-bc26-4622-b527-77d3c02ee0bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:149f1f9a-1902-4497-b943-d16f68229a02"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications for Streptococcus Pneumoniae and Moraxella catarrhalis as applicable microorganisms. A new dosage has been added to enable high-dosage use for severe infections. uuid:a5947b0d-aa14-4f4a-9430-bd23cf693881 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4031 biolink:treats MONDO:0020283 PMID:41385096 "[{""id"":""uuid:d36ddcad-df0e-4658-8058-24208b483491"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f288df9c-8df1-4f41-a0a8-23030c48025e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the treatment of non-Behcet's, non-infectious uveitis (active non-infectious uveitis in the intermediate or posterior area in patients who have not responded sufficiently to conventional treatments and may involve deterioration of visual acuity). [Public knowledge-based application after PAFSC's preliminary assessment] uuid:4001274f-7518-4320-9329-bdf14875b655 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4877 biolink:treats UMLS:C0026919 PMID:41385096 "[{""id"":""uuid:6452235d-f3de-4acb-a076-488122679ff8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8d8b7698-1f7d-4b1e-b458-ab6bef818ca9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of nontuberculous mycobacteriosis including Mycobacterium avium complex (MAC) infection. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:4f2498ea-afd8-4b16-827f-206993ee829c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4877 biolink:treats MONDO:0005866 PMID:41385096 "[{""id"":""uuid:9e2ed8ff-54d1-49a9-bb5d-c5e9dc25fcb2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f4aaf3d0-29ad-4766-8676-afd687e2c5ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of nontuberculous mycobacteriosis including Mycobacterium avium complex (MAC) infection. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:dfcdd529-da23-4146-9f34-4aa029f18827 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:204928 biolink:treats UMLS:C0865440 PMID:41385096 "[{""id"":""uuid:979522a6-5f1a-4214-af2a-6c0fd13ea9b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e073a05c-d785-40e4-b3fc-3f95faedbc02"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage for the treatment of pediatric purulent meningitis. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:6d515447-1f7b-4b8e-b620-b8ca3782ceea biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4911 biolink:treats MONDO:0008170 PMID:41385096 "[{""id"":""uuid:9771b03e-c7c7-42fb-8369-a920a1562202"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:93d3fd76-2d08-4f3a-91fc-16a5148fb7ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of ovarian cancer which has progressed after cancer chemotherapy. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:2288ca1e-0cdd-4b3a-8da4-ace12b84fcbd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:61049 biolink:treats MONDO:0009688 PMID:41385096 "[{""id"":""uuid:5bc6cabe-4038-49e7-9968-dee2bd24508f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b0311151-2608-489c-aac0-00eaf5630fdc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a revised indication for the treatment of myasthenia gravis (limitation of patients to be treated was abolished.) [Orphan drug] uuid:9f84cf7a-764a-403d-abbf-603dcb869cfb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:43K1W2T1M6 biolink:treats HP:0020071 PMID:41385096 "[{""id"":""uuid:5defb724-3da3-4d61-bbec-78657be16c10"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:dd02d908-0b22-433c-9ff2-40a87288f391"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the treatment of viremia in patients with compensated cirrhosis type C (excluding patients with high blood levels of serogroup 1 HCV-RNA). uuid:a2c29bef-7811-48cb-b0ee-983b17520747 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:43K1W2T1M6 biolink:treats MONDO:0005448 PMID:41385096 "[{""id"":""uuid:cd8bd186-8d44-450a-8486-667bfe0e531e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:35476923-f8a3-4a83-ad5f-369ae37f194b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the treatment of viremia in patients with compensated cirrhosis type C (excluding patients with high blood levels of serogroup 1 HCV-RNA). uuid:ef99b4ce-e360-44c0-8bab-9361e1ad1ef1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4031 biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:0100faf8-38e3-4daa-b779-154280d134cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e6b76b40-268d-4543-964a-df2b7ff2f8a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the treatment of atopic dermatitis (in patients in whom conventional therapies are not sufficiently effective). uuid:82c7b518-b92e-494f-8167-cfdc2b52380b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UniProtKB:P01233 biolink:treats MONDO:0005047 PMID:41385096 "[{""id"":""uuid:e03bd0d7-7b57-4805-9429-08a49a0ec603"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9137035a-9a9a-4f96-863d-a86c824c6773"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] (1) (2) (3) (4) Drugs with a new route of administration indicated for the induction of final follicular maturation and luteinization as part of assisted reproductive technology as well as induction of ovulation and luteinization in general infertility treatment (fertility treatment for in vivo fertilization). [Public knowledge-based application after PAFSC's preliminary assessment] (5) A drug with a new indication and a new dosage for the induction of final follicular maturation and luteinization as part of assisted reproductive technology as well as induction of ovulation and luteinization in general infertility treatment (fertility treatment for in vivo fertilization). [Public knowledge-based application after PAFSC's preliminary assessment] MESH:D018997 uuid:9cd90dc7-70e9-4619-b933-6d4ecb59aaa9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UniProtKB:P01233 biolink:treats MONDO:0002775 PMID:41385096 "[{""id"":""uuid:4ff34ef8-aa41-47ad-89c5-00d3ac94de28"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ed5c51f8-2372-43f8-a760-376af88fa065"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] (1) (2) (3) (4) Drugs with a new route of administration indicated for the induction of final follicular maturation and luteinization as part of assisted reproductive technology as well as induction of ovulation and luteinization in general infertility treatment (fertility treatment for in vivo fertilization). [Public knowledge-based application after PAFSC's preliminary assessment] (5) A drug with a new indication and a new dosage for the induction of final follicular maturation and luteinization as part of assisted reproductive technology as well as induction of ovulation and luteinization in general infertility treatment (fertility treatment for in vivo fertilization). [Public knowledge-based application after PAFSC's preliminary assessment] MESH:D018997 uuid:040092c6-8a46-46ad-aac7-f4cb51764dc3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7NL2E3F6K3 biolink:treats MONDO:0035735 PMID:41385096 "[{""id"":""uuid:c17ee2bb-52a9-4a5a-9727-d7339a7380a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:50d13f4a-bdfd-4dd7-aeb3-1307a552e4d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the control of bleeding tendency in patients with acquired hemophilia A. [Orphan drug] uuid:f80a808e-bf8e-4370-8363-ab92d139c5f8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135939 biolink:treats HP:0002069 PMID:41385096 "[{""id"":""uuid:5d03bee3-a21c-49a8-b571-1049d738b7e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2379fbc2-5689-4e26-aad5-2d340b5fed2b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] (1)-(3) Drugs with a new indication for use as an adjunctive therapy with other antiepileptic drugs to treat tonic-clonic seizure in patients with epilepsy who have not responded sufficiently to other antiepileptic drugs. (4), (5) Drugs with a new indication for use as an adjunctive therapy with other antiepileptic drugs to treat tonic-clonic seizure in patients with epilepsy who have not responded sufficiently to other antiepileptic drugs. It is used as an alternative therapy for lacosamide oral formulation in patients who are temporarily unable to be administered orally. uuid:ea74b5cf-df25-4617-9d19-4fc8591261cb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28680 biolink:treats MONDO:0859598 PMID:41385096 "[{""id"":""uuid:f6a15748-9356-4e08-bbad-319350dea430"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:68b0a6b2-e40d-4bbb-ad2c-c3fec1c4540e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage indicated for the treatment of acute leukemia (including erythroleukemia and blast crisis of chronic myeloid leukemia). [Public knowledge-based application] uuid:669eb7bb-a7f3-4960-9306-6df279c5f003 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:A57KX1VL5P biolink:treats MONDO:0002242 PMID:41385096 "[{""id"":""uuid:c00022b4-09da-4be4-b07e-e2fc0f0d1808"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5102a7e4-3e44-47c9-934b-ed2f85619291"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage indicated for the control of bleeding tendency in patients with blood coagulation factor IX deficiency. uuid:7ae5b135-05a9-4ee4-9131-4eaff94d7133 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:72564 biolink:treats MONDO:0012817 PMID:41385096 "[{""id"":""uuid:d119b554-0d6b-47d3-956c-d37f81909776"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:df5f3406-bcd1-452a-9b83-85ac2ee36a2b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of relapsed or refractory Ewing's sarcoma. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:69421490-7653-4f13-af2b-f0cae428d33d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28680 biolink:treats MONDO:0017858 PMID:41385096 "[{""id"":""uuid:5b655be4-5600-4db9-80e7-2fcb7207d069"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a8cc3208-0c84-45b6-9c4c-20526d15f32d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new route of administration indicated for the treatment of acute leukemia (including acute erythroid leukemia and blast crisis of chronic myelogenous leukemia). [Expedited review] uuid:76439231-431a-4143-bfa6-fbec28def801 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46081 biolink:treats UMLS:C0948382 PMID:41385096 "[{""id"":""uuid:ef4f633d-2c92-4a28-8408-e3e6318dded4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8ea32e1f-5f32-4f58-845c-4efb2a86bf8b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional pediatric dosage and a new additional indication for the prevention of deep mycosis in patients with hematopoietic stem cell transplantation. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:9d8bd63c-2b83-480e-9a8f-75b92c76c203 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0009693 PMID:41385096 "[{""id"":""uuid:e06ae8e3-6821-4fd0-bb8f-d3bd41c1b15d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:71be828c-21b4-4c62-938a-62b31c24426d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication for the treatment of multiple myeloma. [Expedited review] uuid:6c272200-7e08-4ed0-9a96-3eff3f5f9377 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:NQX9KB6PCL biolink:treats MONDO:0007037 PMID:41385096 "[{""id"":""uuid:09c332ea-34cd-4919-84e3-eddf7d06cef3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3ea7cc16-1d33-4102-a1a8-6f8f3ccb54af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of dwarfism with no epiphyseal closure in patients born small for gestational age (SGA). uuid:7a19149e-e7ad-4534-a01c-51fb0c1c9e62 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31236 biolink:treats MONDO:0004985 PMID:41385096 "[{""id"":""uuid:dd1db9a0-2d58-4258-ac59-8cfbeabf01ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d2a21711-ed2f-48f8-b034-dde7b9166808"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage in new dosage forms for the improvement of manic symptoms in patients with bipolar disorder. uuid:d94e07b0-9daa-4c83-b34b-30f8b9b5138f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6801 biolink:treats MONDO:0008487 PMID:41385096 "[{""id"":""uuid:1680c8c1-b831-43e1-9c8a-ef9ed65bc9bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9a8f12e8-7fee-4e28-8d95-31907913b88b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new indications and a new dosage for the induction of ovulation in patients with polycystic ovarian syndrome and for controlled ovarian stimulation in assisted reproductive technology in patients with polycystic ovarian syndrome (only for the patients with any of obesity, impaired glucose tolerance or insulin resistance). [Public knowledge-based application after PAFSC's preliminary assessment] uuid:3df64cb2-81de-4f80-9d9d-0425c1e4af20 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PVI5M0M1GW biolink:treats MONDO:0005072 PMID:41385096 "[{""id"":""uuid:f910c121-ab00-406c-a70b-43a8876ee19a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:10dd22b2-401f-4554-a2f0-46b7bc442cb2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the enhancement of an antitumor effect of dinutuximab for neuroblastoma. [Expedited review] uuid:5f3314e1-f9b4-4280-88f7-e85d7e220de1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats MONDO:0006052 PMID:41385096 "[{""id"":""uuid:891593e3-d3c6-4e19-a19e-c7c434ac492c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ae27000d-231b-479d-9baa-b237a9543c31"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications and a new dosage for the treatment of pulmonary tuberculosis and other tuberculosis. uuid:19369570-aa06-4c5d-89ee-41a9604dba26 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats MONDO:0018076 PMID:41385096 "[{""id"":""uuid:2e958a13-fbff-4711-ae98-8c6f40f9ccbb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a0820137-805f-4ec8-907f-dda4beb74ca3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications and a new dosage for the treatment of pulmonary tuberculosis and other tuberculosis. uuid:997ef83f-5f04-4654-b3b2-142197deaa29 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:1RXS4UE564 biolink:treats MONDO:0005299 PMID:41385096 "[{""id"":""uuid:e52ad8e3-4af9-4bdd-99cf-fd2204871f22"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:73c32565-d01b-4b3a-8ccd-c483fab19c24"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the improvement of functional impairment in association with acute phase of ischemic cerebrovascular disorder (within 4.5 hours after onset). [Public knowledge-based application after PAFSC's preliminary assessment] uuid:0b6a7cf1-eb25-48b6-89bf-0f639e7c5af7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:231425 biolink:treats UMLS:C0856109 PMID:41385096 "[{""id"":""uuid:506ff0ce-9257-4b9d-a508-a035fddb1a03"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f3f89475-280b-4d0b-ae45-37575acf6e8f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the improvement of hyponatraemia in patients with syndrome of inappropriate secretion of antidiuretic hormone (SIADH). [Orphan drug] uuid:2ca36720-2036-4e5e-a3b8-c7d5cb4c2006 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45863 biolink:treats MONDO:0021348 PMID:41385096 "[{""id"":""uuid:b720f21f-558e-4323-a5ea-482de0e8450a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6cb63328-b26c-4521-b9a1-c508fb05dbc2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications and a new dosage for the treatment of relapsed or refractory germ cell tumors (testicular tumors, ovarian tumors, extragonadal tumors). [Public knowledge-based application after PAFSC's preliminary assessment] uuid:1d5a2055-0e31-4ec3-9735-8652dc71cf52 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45863 biolink:treats MONDO:0021068 PMID:41385096 "[{""id"":""uuid:184e7808-6ec2-4de7-a6e9-ac80b8f53cb1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:424aa7be-bbea-47fc-a3de-045d5f2b9a6b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications and a new dosage for the treatment of relapsed or refractory germ cell tumors (testicular tumors, ovarian tumors, extragonadal tumors). [Public knowledge-based application after PAFSC's preliminary assessment] uuid:2c090c17-79bf-4073-b703-ef82237fb086 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45863 biolink:treats MONDO:0018201 PMID:41385096 "[{""id"":""uuid:98eda0f0-1530-461f-9ead-99f10a00f0ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:367878cf-600c-47c7-ac0a-b8422b1f66cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications and a new dosage for the treatment of relapsed or refractory germ cell tumors (testicular tumors, ovarian tumors, extragonadal tumors). [Public knowledge-based application after PAFSC's preliminary assessment] uuid:09d3d3ef-3115-4ddb-a0e7-88bd8f3899ba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation MESH:C586502 biolink:treats MONDO:0002032 PMID:41385096 "[{""id"":""uuid:e92fcdd4-56df-4e60-9a8f-6f11553428f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:27373c8b-e60e-45a3-87af-f7bb7b76387a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage indicated for the treatment of gastric cancer, colon or rectal cancer, non-small cell lung cancer, pancreatic cancer, and biliary tract cancer. [Public knowledge-based application] uuid:418fb1f6-51ad-46f0-b662-995161804874 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation MESH:C586502 biolink:treats MONDO:0006519 PMID:41385096 "[{""id"":""uuid:bf7d0f42-bb26-49d9-93c1-12c4db95f1de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:80f7f368-b93b-4db8-ad01-98632c27edea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage indicated for the treatment of gastric cancer, colon or rectal cancer, non-small cell lung cancer, pancreatic cancer, and biliary tract cancer. [Public knowledge-based application] uuid:6c3ef505-7c4e-488b-ba5e-c59dfab834c4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation MESH:C586502 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:e97b8dd2-1171-499f-93e3-47660397d827"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:efab03d1-1518-4bfc-b730-15b9167d90c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the postoperative adjuvant treatment of hormone receptor(HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer with a high risk of recurrence. uuid:39116782-b951-4a22-a6cd-1263c5e27aee biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31236 biolink:treats MONDO:0002050 PMID:41385096 "[{""id"":""uuid:6942846f-4653-4d84-ad8b-56a14a2bd353"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6f08aec6-e968-4a50-8ef5-14a8ccda94b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of depression (for use only in patients who have an inadequate response to antidepressant therapy). uuid:5c1ecbf2-7525-4cb2-9ed2-de97d80fba9a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45863 biolink:treats MONDO:0005627 PMID:41385096 "[{""id"":""uuid:418a8bf7-4aff-40c7-b915-a7d5c2f79057"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:793c0c87-34b3-496a-9fb4-160a77b2c76d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications and new dosages for the treatment of relapsed or metastatic head and neck cancer, relapsed or metastatic esophagus cancer, angiosarcoma, advanced or relapsed cervical cancer. A new dosage for once- weekly administration for ovarian cancer has also been added. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:81f29bba-7aa7-4952-87da-f190acc22b44 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45863 biolink:treats MONDO:0024883 PMID:41385096 "[{""id"":""uuid:7e0cec80-02df-4602-b6f7-159038970245"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:81ca1a30-2fd0-4c10-b1e0-c4b2451ece16"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications and new dosages for the treatment of relapsed or metastatic head and neck cancer, relapsed or metastatic esophagus cancer, angiosarcoma, advanced or relapsed cervical cancer. A new dosage for once- weekly administration for ovarian cancer has also been added. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:79166bea-c05c-4a75-b0a3-a829c9e06005 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45863 biolink:treats MONDO:0016982 PMID:41385096 "[{""id"":""uuid:08e21f82-f292-4902-abfd-ded4e8557629"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1c89e471-cbeb-489d-8c79-29a57b7f8a25"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications and new dosages for the treatment of relapsed or metastatic head and neck cancer, relapsed or metastatic esophagus cancer, angiosarcoma, advanced or relapsed cervical cancer. A new dosage for once- weekly administration for ovarian cancer has also been added. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:ff58b521-d2b3-4734-9c4b-bae426e8c4f2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:91809656 biolink:treats MONDO:0000956 PMID:41385096 "[{""id"":""uuid:f09c9ce5-c476-4287-8023-965eae307243"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9177902a-cc9e-4504-9c36-df31b48e69bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the treatment of small intestine cancer. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:b97a6558-4cc3-4ea2-90b7-85554db0b211 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:175901 biolink:treats MONDO:0000901 PMID:41385096 "[{""id"":""uuid:ae7f1783-69ae-4ad0-8924-ef1f2847b48b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6837c295-c408-4940-959b-57b8d794042f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of relapsed or refractory malignant lymphoma. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:540e1fc8-fc94-4db6-8f38-c80e8ed0c1ef biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:23581792 biolink:treats MONDO:0006517 PMID:41385096 "[{""id"":""uuid:5d74715a-ae1a-48a6-ae31-152c34664b08"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:723565e4-cd50-4090-ae50-d4179ac99db7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of pediatric malignant solid tumor. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:7d24012c-0c5b-446a-ad87-f84bb805b28f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:145499 biolink:treats MONDO:0007488 PMID:41385096 "[{""id"":""uuid:f548ed6f-6606-4071-bd54-823e21994562"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0f09e183-f6fd-4095-853f-26bdf016468d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for inhibiting progress of dementia symptoms in patients with dementia with Lewy bodies. uuid:ecdddc66-b845-4403-a169-56fba6506928 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:24847953 biolink:treats MONDO:0004966 PMID:41385096 "[{""id"":""uuid:09ea4387-1372-491d-ab96-0c3921132556"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:bb58e00d-1509-4187-8fc3-2fa6ccb1313e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication for the treatment of gastritis induced by Helicbacter pylori infection. uuid:4ecdd857-1256-436a-a278-2ccaba67bf51 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:24847953 biolink:treats MONDO:0006781 PMID:41385096 "[{""id"":""uuid:f0def970-386f-42cb-94a0-3adf4e78dc5a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:05a9de3e-73ad-42fd-8a8c-22eb8c7b67b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication for the treatment of gastritis induced by Helicbacter pylori infection. uuid:3f64c538-a341-4eac-959b-4474eba21744 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46195 biolink:treats MONDO:0005178 PMID:41385096 "[{""id"":""uuid:e80a22c5-b2c8-4334-900a-5001976a25c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:66695605-7d32-4534-ab5d-f730fbc07485"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication for the treatment of osteoarthritis and with an expanded dosage of acetaminophen. uuid:6f4e61a2-8189-4f87-96e6-aa7e2e758386 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27899 biolink:treats MONDO:0003060 PMID:41385096 "[{""id"":""uuid:bc3f8325-6976-4316-b418-a3228afd2fe4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1f9b197d-cd01-4466-ad08-2a8fd36fdb36"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of biliary tract cancer. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:9ba963c7-c38f-48fe-8074-41791fa4a106 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2676 biolink:treats MONDO:0006226 PMID:41385096 "[{""id"":""uuid:3227368c-113a-4067-958f-7dd1757b602a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f600a5c3-8225-4264-be0a-20798909ebf0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication for helicobacter pylori (H. pylori) eradication therapy for gastric MALT lymphoma, for the stomach after endoscopic treatment of early gastric cancer, and for idiopathic thrombocytopenic purpura, in H. pylori infection. uuid:e488f782-aa30-4b4d-9523-d41cfac5813a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2676 biolink:treats MONDO:0019098 PMID:41385096 "[{""id"":""uuid:7c4510c6-5fae-4472-8da7-eeeab1bcfe33"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7724784d-2f46-4770-b685-77af77db7a88"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication for helicobacter pylori (H. pylori) eradication therapy for gastric MALT lymphoma, for the stomach after endoscopic treatment of early gastric cancer, and for idiopathic thrombocytopenic purpura, in H. pylori infection. uuid:55c3034b-1761-4e38-874b-063e2e23a3be biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:74170 biolink:treats UMLS:C0746883 PMID:41385096 "[{""id"":""uuid:09c8320b-cb72-4e84-bf9a-97c1089396bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f1a6eab8-d0d7-4d3d-9b0d-3ef73b26d361"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of febrile neutropenia. uuid:79ef4577-4e23-43d3-bd5b-0f82c91dff36 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB00028 biolink:treats MONDO:0018229 PMID:41385096 "[{""id"":""uuid:9d1da3e8-7504-46b9-b77c-0b57c9670ea4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b7a8e724-902a-4e10-8203-4ad5521cc112"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications for the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis (for use when steroid drugs are not sufficiently effective). [Orphan drug] uuid:26e400a6-7747-4f10-8266-045369eca154 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB00028 biolink:treats MONDO:0019810 PMID:41385096 "[{""id"":""uuid:5df2370f-f34f-4a3d-812d-77767bc7932d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:fde29842-edb7-4303-9526-6f5d7acf86bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications for the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis (for use when steroid drugs are not sufficiently effective). [Orphan drug] uuid:5611ef17-5464-4464-a8aa-3a1c589afb49 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71260 biolink:treats HP:0003124 PMID:41385096 "[{""id"":""uuid:6e28d214-8f32-49ad-b698-58a303200dc4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1bc784a7-4e92-404d-9667-5f6b0d94c517"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage indicated for the treatment of hypercholesterolemia and familial hypercholesterolemia. uuid:e3bacfef-de99-4700-a8d7-fcad5c6d0603 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31941 biolink:treats MONDO:0000956 PMID:41385096 "[{""id"":""uuid:94b6b2ed-8751-403c-8da0-a354c74843c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d6cad66d-26e4-4295-b54a-8aa461aecaf1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the treatment of small intestine cancer. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:f6c56d35-9717-4ac3-b59e-f888ad7d6557 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71204 biolink:treats MONDO:0011786 PMID:41385096 "[{""id"":""uuid:1eba7f56-ae16-45ab-9d2f-927acfd52773"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:12e027a2-fa59-46c9-b733-d21289a93d38"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional pediatric dosage indicated for the treatment of allergic rhinitis, urticaria, and itching associated with skin diseases (eczema/dermatitis, cutaneous pruritus). uuid:e9d876ec-9402-4a8b-b927-a9476db1092d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71204 biolink:treats MONDO:0005492 PMID:41385096 "[{""id"":""uuid:09ad8e26-f3f8-432d-b59b-42f079b29087"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:63d287c4-500e-4cdd-aff4-d7fc099db41f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional pediatric dosage indicated for the treatment of allergic rhinitis, urticaria, and itching associated with skin diseases (eczema/dermatitis, cutaneous pruritus). uuid:1d2ed802-34a5-4cc3-835a-bfacb4847ba9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71204 biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:ffe525ed-a8cb-420e-ba8f-2d51bcd6514a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:fea6e345-f317-42ce-90be-3a783722a608"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional pediatric dosage indicated for the treatment of allergic rhinitis, urticaria, and itching associated with skin diseases (eczema/dermatitis, cutaneous pruritus). uuid:8570f161-3834-4f3f-9265-263e919a3722 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71204 biolink:treats MONDO:0002406 PMID:41385096 "[{""id"":""uuid:35c7d5c5-eb44-440d-a78d-d3b9915cf3fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a61b88bc-682a-4afd-bb7f-1793e4feaffd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional pediatric dosage indicated for the treatment of allergic rhinitis, urticaria, and itching associated with skin diseases (eczema/dermatitis, cutaneous pruritus). uuid:4998472a-e11e-466c-9c5c-478dbc972256 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4027 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:f2242638-ec98-4e9d-94fa-7743625950cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:64421e02-73a8-4679-ac2f-1a3a62cfbf83"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage indicated for the treatment of breast cancer (preoperative or postoperative chemotherapy in patients with operable breast cancer). [Public knowledge-based application] uuid:2b4d3daa-98fb-4a7b-a368-148f322707f2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85078 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:f5f81a9a-904f-40a0-817b-6de8b05c54fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:98143ab1-e824-45f5-a959-62734741dd3f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the treatment of chronic heart failure (for use only in patients receiving standard treatment of chronic heart failure). uuid:40268afa-ff6d-44de-b0d6-aaddfd3aee9f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1424887 biolink:treats MONDO:0005607 PMID:41385096 "[{""id"":""uuid:f6df00b7-5105-4c8a-ad31-d8bc55a829b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:194500ff-cdb9-463e-af31-76d1231b22d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the relief of symptoms in patients with chronic obstructive pulmonary disease (chronic bronchitis, emphysema) (who require a combination therapy with an inhaled corticosteroid and a long-acting beta-2 agonist). uuid:47dede8d-2fdc-4319-b208-a8bfd9391ce0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1424887 biolink:treats MONDO:0004849 PMID:41385096 "[{""id"":""uuid:a94828f5-f727-468d-8f2f-f967cab739b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:51468b0d-89de-4344-a0be-52984d4b5268"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the relief of symptoms in patients with chronic obstructive pulmonary disease (chronic bronchitis, emphysema) (who require a combination therapy with an inhaled corticosteroid and a long-acting beta-2 agonist). uuid:e8e5fc39-5126-4318-88c9-44b684b03ae8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47898 biolink:treats MONDO:0007256 PMID:41385096 "[{""id"":""uuid:c37f16ff-bded-492c-9953-53c55abd8b78"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:75d5b902-0166-482c-ab8b-f4298d8112d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional dosage indicated for transcatheter arterial chemo-embolization (TACE) in hepatocellular carcinoma. [Public knowledge-based application] uuid:54654b24-a228-4bcc-9ad6-1dbfe41ebee7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8764 biolink:treats MONDO:0005556 PMID:41385096 "[{""id"":""uuid:1e8a98b8-c14d-43a1-8b73-4cb7ea82fee7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5efb12a3-a873-462f-a22f-d457985c509d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of lupus nephritis. [Public knowledge-based application after preliminary assessment by the Pharmaceutical Affairs and Food Sanitation Council (PAFSC)] uuid:fe802739-f284-4738-8b2f-b21b82098a5a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31964 biolink:treats MONDO:0005114 PMID:41385096 "[{""id"":""uuid:6d1efdde-ccfe-4c20-9bc4-ef0f629a4102"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a5c88517-8fb3-4e12-8d6d-cbfd7a9c0d30"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications for the treatment of Streptococcus pneumoniae and sepsis and a new dosage in an additional dosage form. uuid:492ffcf1-3c74-4b30-90cd-6259f842d052 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31964 biolink:treats HP:0100806 PMID:41385096 "[{""id"":""uuid:184d13d2-1c3f-4377-9df7-fc0480379fe0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:fb0286bf-1461-4c6e-9e9c-7555303819ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications for the treatment of Streptococcus pneumoniae and sepsis and a new dosage in an additional dosage form. uuid:8433b68c-ae1c-4edd-9070-2add3cc1a99a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6413 biolink:treats MONDO:0008487 PMID:41385096 "[{""id"":""uuid:b2e80069-3747-46c3-8e1b-4b7bdb024ef5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:01a55833-a509-4e54-b97a-a130b2c580cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with new indications for the induction of ovulation in patients with polycystic ovary syndrome and with unexplained infertility. (3) Drugs with new indications and a new dosage for the induction of ovulation in patients with polycystic ovary syndrome and with unexplained infertility. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:ae8b3104-e9b6-4a8a-95a8-5f52b9540c34 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6413 biolink:treats UMLS:C0404585 PMID:41385096 "[{""id"":""uuid:552fb8c3-11c7-4601-bdea-d884fd7baa4d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8512f42d-87d8-4a93-90f2-3c78a1a18972"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with new indications for the induction of ovulation in patients with polycystic ovary syndrome and with unexplained infertility. (3) Drugs with new indications and a new dosage for the induction of ovulation in patients with polycystic ovary syndrome and with unexplained infertility. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:3f1ceb65-0de6-48cc-9a77-29f911c88db2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6WS4C399GB biolink:treats MONDO:0018874 PMID:41385096 "[{""id"":""uuid:d5440b1e-eb3b-458a-8c62-bcf64e62fa82"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a8ab41f9-da94-4c98-8076-c94dd542fb43"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for use as an adjunctive therapy with antineoplastic agents for the treatment of relapsed or refractory acute myeloid leukemia. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:035db8d9-fb92-4051-b96a-5f2460d20c35 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31905 biolink:treats UMLS:C0264714 PMID:41385096 "[{""id"":""uuid:2047f166-9925-45f5-b41e-b99fb2c50c03"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:49213da5-c980-48e4-88eb-58e1bc3cda09"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and dosage for the treatment of acute cardiac failure including the acute exacerbation period of chronic cardiac failure. uuid:651a45bb-d96f-4e2d-8bf6-5eba2f1371b4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31905 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:0b691334-71e6-4680-bf04-c54f9049b014"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:72b64106-44fe-4955-bc5b-9dd0c1975707"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and dosage for the treatment of acute cardiac failure including the acute exacerbation period of chronic cardiac failure. uuid:1170aa25-6629-4e58-830d-fabeb75fb943 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0010679 PMID:41385096 "[{""id"":""uuid:477da82f-8eec-4ac4-81d2-68b6229f895d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ab1c7d29-a1a1-4588-b87c-a2dd5c9d0cea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of acute-phase Kawasaki's disease (cases where the disease is severe and at risk for coronary artery disorder) ([1] - [6]) and Duchenne muscular dystrophy ([4] - [6]). Duchenne muscular dystrophy: [Public knowledge- based application after PAFSC's preliminary assessment] uuid:c0aa2087-51a6-4571-a6d8-53d376dacbfa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134716 biolink:treats MONDO:0002050 PMID:41385096 "[{""id"":""uuid:2364ce4b-196a-4f0e-8363-5c48823833c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:65122884-540a-4d52-8b9a-08a1db50a97f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the treatment of depression (for use only in patients who have not sufficiently responded to conventional treatments). uuid:9fcb9261-d81b-4856-acd9-c352cf52e469 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7735 biolink:treats HP:0002018 PMID:41385096 "[{""id"":""uuid:2ce306fa-fca0-41e0-adab-b968e4dc1493"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:78465d7c-7ad2-475b-9df6-49a54263e7bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage indicated for the treatment of gastrointestinal symptoms (nausea and vomiting) associated with the administration of antineoplastic drugs (cisplatin, etc.). [Public knowledge-based application after preliminary assessment by the Pharmaceutical Affairs and Food Sanitation Council (PAFSC)] uuid:b71c7d63-f131-493e-a647-3638ce9d2f50 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7735 biolink:treats HP:0002013 PMID:41385096 "[{""id"":""uuid:143f2a1f-8224-4804-b2a5-8211ad4fafc5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:244b2acc-76cc-4219-b02c-5ae677a05ae7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage indicated for the treatment of gastrointestinal symptoms (nausea and vomiting) associated with the administration of antineoplastic drugs (cisplatin, etc.). [Public knowledge-based application after preliminary assessment by the Pharmaceutical Affairs and Food Sanitation Council (PAFSC)] uuid:39b0d8e3-eb29-41a6-86a2-af1dc9e36e6d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C2722689 biolink:treats MONDO:0005812 PMID:41385096 "[{""id"":""uuid:a3a45cf6-d5df-4b61-900a-05a6f478a2cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f340c812-ba1d-4e96-80be-b18120d9fbef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for prophylaxis of pandemic (H1N1) influenza. [Emergency approval] DRUGBANK:DB10781 uuid:40fc69cb-4450-444d-ba7e-15b479ec3b50 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C2722689 biolink:treats MONDO:0005460 PMID:41385096 "[{""id"":""uuid:8b1454c7-526c-45ab-84fa-85d44647640f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:eedca1b0-24ca-41c2-b9c5-ce3d6b842dd8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for prophylaxis of pandemic (H1N1) influenza. [Emergency approval] DRUGBANK:DB10781 uuid:19a69b74-f959-407a-af5b-aa0f9f13fb23 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0015980 biolink:treats HP:0020071 PMID:41385096 "[{""id"":""uuid:9790a104-3a74-4f10-bd4a-1f553dea8099"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:49d085d7-e151-492b-a8f4-b5ed98aa3bf3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drug with a new indication and dosage for treatment of viremia in compensated cirrhosis type C (excluding the patients with a high viral load of HCV serogroup 1). [Priority Review] MESH:D016899 uuid:5115f4f7-80ce-4a92-881e-8d81c4bbcd58 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0015980 biolink:treats MONDO:0005448 PMID:41385096 "[{""id"":""uuid:4023756e-3f0e-4c32-899c-226cc28a44b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1f708e9e-b34c-4dd8-8d21-880a403acb5a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drug with a new indication and dosage for treatment of viremia in compensated cirrhosis type C (excluding the patients with a high viral load of HCV serogroup 1). [Priority Review] MESH:D016899 uuid:1a320970-232a-4f7c-a2e1-d0f371569b52 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2948 biolink:treats UMLS:C0852922 PMID:41385096 "[{""id"":""uuid:9c684354-b8b7-45f6-adad-87d0f66b2b3b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5154a227-9982-4caf-afd4-7e502b1c305f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drug with a new indication and dosage indicated for induction and maintenance of remission in steroid- dependent Crohn's disease and maintenance of remission in steroid-dependent ulcerative colitis. [Notification of off-label use] uuid:595848b9-c3f2-475a-99c1-c957c87a9e4b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32176 biolink:treats EFO:1001494 PMID:41385096 "[{""id"":""uuid:7750bbb9-b778-4852-8542-876eb52ab885"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e8813186-88ee-47f3-b51f-e8257f2cbdf6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drug with a revised indication that eliminates a limitation to use in intractable cases, and now indicated for treatment of psoriasis vulgaris regardless of the severity. uuid:666e4a4d-15d8-4ab6-ad91-191acaada2f3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6078 biolink:treats MONDO:0004525 PMID:41385096 "[{""id"":""uuid:0d93587e-6a98-4975-a6cb-c635d7927afd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:06df2a3a-54ba-4f1d-8216-60f52e5bbe4e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Addition of a new indication and dosage for treatment of scabies. [Notification of off-label use] uuid:ca100224-a937-42ad-9e27-11a9fc80823f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:B72HH48FLU biolink:treats MONDO:0007191 PMID:41385096 "[{""id"":""uuid:1a8702e8-135d-47dd-8317-b300951074e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:484e280c-57bf-47db-8290-d2057a48151a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Addition of an indication for refractory uveoretinitis associated with Behcet's disease (used only when conventional therapies are not sufficiently effective). [Orphan Drug] uuid:0125bbd0-9c01-4df5-af2b-35787a544fb6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5931 biolink:treats MONDO:0019145 PMID:41385096 "[{""id"":""uuid:e1b8cae0-8aaf-4cde-9d14-49e3efcda787"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c01bb099-41e3-4622-96f1-efd0b60d5df0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Addition of an indication and dosage for treatment of purpura fulminans caused by congenital protein C deficiency. [Orphan Drug] uuid:7206ca52-5621-400e-8025-c310586e3338 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63577 biolink:treats HP:0001410 PMID:41385096 "[{""id"":""uuid:87ab1186-d63a-485c-8255-9c077ee1e178"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c440af4e-6706-4d91-b2f5-d267f0d3008b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new indication for “improving viral markers in patients with hepatitis B cirrhosis complicated by proliferation of hepatitis B virus and with abnormal hepatic function to be confirmed” in monotherapy [Priority review] uuid:dc2f0faa-2ee1-4a50-ae7a-5cae478c33b1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50663 biolink:treats MONDO:0005460 PMID:41385096 "[{""id"":""uuid:49df27c3-68e8-437c-b449-593f2f837e78"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c4664eee-bf71-4038-8708-67e476ed5934"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new pediatric dosage regimen indicated for the treatment of influenza virus infection uuid:450cf9a2-d5e9-4bb5-b3c9-b65e033255e9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5280 biolink:treats MONDO:0005823 PMID:41385096 "[{""id"":""uuid:0efe4948-ca58-4bee-b05b-950d97ab15fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:837db9a3-37ff-476b-9fb5-2e92362c795c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new indication for the treatment of genus Legionella infection [Notification of off label use] uuid:6be9636b-79b2-4f68-915d-ca87dcb29848 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:81573 biolink:treats MONDO:0018555 PMID:41385096 "[{""id"":""uuid:b7024747-0b35-4ab5-9b88-fc3572891994"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:081c3a79-9184-43cc-9f4a-ebdaa5096c80"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new indication and a new route of subcutaneous administration for induction of spermatogenesis in male hypogonadotrophic hypogonadism in combination with follitropin alpha [Prompt review drug] uuid:866f3134-8107-4fdb-80cd-9c496b82e060 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45863 biolink:treats MONDO:0002715 PMID:41385096 "[{""id"":""uuid:c76d2685-a2ad-4cf0-95f0-e496d86b05e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0891d346-b55e-4c08-81e9-9dd27b2d71b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new indication for the treatment of cancer of the uterus body, in addition to the current indications for ovarian cancer, non-small-cell lung cancer, breast cancer and stomach cancer uuid:260d6092-4af5-4ad2-a530-45d343f8b7b9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45863 biolink:treats MONDO:0004950 PMID:41385096 "[{""id"":""uuid:e27bcd92-71e0-470c-8640-b06a4a1f6594"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:31716443-35a2-475d-8dc5-e484d870211b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new indication for the treatment of cancer of the uterus body, in addition to the current indications for ovarian cancer, non-small-cell lung cancer, breast cancer and stomach cancer uuid:a0b74966-2b71-48be-af1c-ba72206d9fd1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4672 biolink:treats MONDO:0006003 PMID:41385096 "[{""id"":""uuid:f28ac020-6fae-4b9c-89f1-83a87eff283a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8e4b2c03-d874-4627-96ec-8917cd8b4b33"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[PMDA] A new indication for the treatment of ""cancer of the uterus body"", in addition to the current indications for ovarian cancer, non-small-cell lung cancer, breast cancer, stomach cancer, head and neck carcinoma, and esophageal carcinoma" uuid:828c6560-d86c-4118-bfc0-f063e796d1ec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4672 biolink:treats MONDO:0004950 PMID:41385096 "[{""id"":""uuid:b23096a8-4f49-457f-933d-1e1081215b5c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ca22cb9e-21be-4c85-9491-17b64ac3fa8e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[PMDA] A new indication for the treatment of ""cancer of the uterus body"", in addition to the current indications for ovarian cancer, non-small-cell lung cancer, breast cancer, stomach cancer, head and neck carcinoma, and esophageal carcinoma" uuid:b655280c-a0e4-406f-9d31-d7848322fb2b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4672 biolink:treats MONDO:0002038 PMID:41385096 "[{""id"":""uuid:b6daa2cf-895e-4304-b0ad-24ae53f9d7be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c936bcad-de07-4909-b5df-e0ea7a00639f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[PMDA] A new indication for the treatment of ""cancer of the uterus body"", in addition to the current indications for ovarian cancer, non-small-cell lung cancer, breast cancer, stomach cancer, head and neck carcinoma, and esophageal carcinoma" uuid:291373b6-b8bb-4189-9bcb-c88aa1cc0228 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4672 biolink:treats MONDO:0019086 PMID:41385096 "[{""id"":""uuid:489847ba-d29e-41ea-a92c-a25865fd02ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:317ac604-cca7-403b-b70b-034640d23f78"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[PMDA] A new indication for the treatment of ""cancer of the uterus body"", in addition to the current indications for ovarian cancer, non-small-cell lung cancer, breast cancer, stomach cancer, head and neck carcinoma, and esophageal carcinoma" uuid:6a093fd5-985c-4f01-a708-7df88f404885 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:441410 biolink:treats UMLS:C0741682 PMID:41385096 "[{""id"":""uuid:a8b61c43-eb8b-406c-b62b-4ff5e5ef183f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b42f7fdd-90b1-4ecd-8233-145f7929a773"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[PMDA] A new indication for the treatment of ""premenopausal breast cancer"", in addition to the current indication for prostatic cancer" uuid:44ebbaf2-77cf-49c4-918e-0a35c57ace8e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:441410 biolink:treats MONDO:0004956 PMID:41385096 "[{""id"":""uuid:2b16d6c4-0848-4e7a-80b1-79cc9f95c6b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ef8f2e13-85ae-4d80-9a70-d3b2032c2f9f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[PMDA] A new indication for the treatment of ""premenopausal breast cancer"", in addition to the current indication for prostatic cancer" uuid:16889a70-723f-47a7-aefe-5a9a84e640b3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15365 biolink:treats MONDO:0012727 PMID:41385096 "[{""id"":""uuid:041cdd6a-21fb-49c3-9fe7-f95cbebf070d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9edf05b6-99b5-4d3d-8ad6-9e0a4b2491eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[PMDA] A new indication for ""Kawasaki disease"" [Notification of off label use]" uuid:25764931-e14a-46eb-bcb0-f03328f3ac9b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9907 biolink:treats MONDO:0005354 PMID:41385096 "[{""id"":""uuid:776eb64a-0fa7-42f1-b523-2d51d6a73211"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:caa21e74-f783-4aca-a747-155e157f5b92"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and dosage indicated for the improvement of liver enzyme elevations in chronic hepatitis C. uuid:44e35b8e-d5a2-4c55-9162-58c73328b93a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6541 biolink:treats MONDO:0003634 PMID:41385096 "[{""id"":""uuid:8d114a6b-fcd4-4900-af99-d2aeef487edb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:14444281-6f5d-421c-92d4-a983bcda6eb0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Addition of a new indication for diabetic nephropathy in patients with type2 diabetes, hypertension, and proteinuria. uuid:b158b8f3-152a-40ec-8401-b002d926d67a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63607 biolink:treats MONDO:0100073 PMID:41385096 "[{""id"":""uuid:ecb28ea8-a8d2-4d5e-a5da-b95faa7ca854"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:77b82a29-fc86-4f2c-ae4e-ae2b93e703e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Addition of a new indication for methicillin-resistant Staphylococcus aureus (MRSA). uuid:4cc4993e-86fd-4233-a713-c249851e9f06 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:61049 biolink:treats MONDO:0005556 PMID:41385096 "[{""id"":""uuid:19dfad5f-b63d-465d-a80b-05c65e6ec5b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0a048177-4e5c-4a59-b0f8-be5ef1a6164e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication for lupus nephritis (in cases where steroid therapy is not sufficiently effective or well tolerated due to side effects). [Orphan Drug] uuid:f340cebb-62cd-4330-a6fb-59db48ca1621 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7936 biolink:treats MONDO:0008114 PMID:41385096 "[{""id"":""uuid:b9dac4f8-79a5-4caf-9b0b-f70af6dd4dc6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:88abc3d0-e0b3-4bca-9a98-09a598135caa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new indication for the treatment of “obsessive compulsive disorder” uuid:a82e170a-18fa-40be-aa6d-176a60aebabd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats MONDO:0005823 PMID:41385096 "[{""id"":""uuid:e6177c5c-f1dd-4b6c-b32a-77448345a3a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8fd8e0a5-0c03-4aaa-adf8-036132565570"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new indication for the treatment of genus Legionella infection [Notification of off label use] uuid:8ec2a960-4c9a-4bf1-90fd-c63cdb86c40b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:61049 biolink:treats MONDO:0005554 PMID:41385096 "[{""id"":""uuid:ee8243e7-f272-42f3-8213-77e9947b2b3f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3599098d-eb35-4495-9733-433f63cbe52a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new indication for the treatment of articular rheumatism (only where conventional treatments are inadequate) uuid:6d5b2c67-815a-4c1f-a8f4-dcca0e3b0773 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:480999 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:eec774a8-70dd-4f04-9390-9c569e6c575c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:99b7d255-5c03-4008-a4c2-377ab7564571"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new indication for the treatment of inoperable or recurrent breast cancer, in addition to the current indication for lung cancer uuid:891e3bdd-625b-4265-a081-ba1fe23cbe97 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:480999 biolink:treats MONDO:0008903 PMID:41385096 "[{""id"":""uuid:c6d1f474-16df-4c1b-b486-b726138a38be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:bc67980c-dc99-4f43-8aa1-7fc028a107ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new indication for the treatment of inoperable or recurrent breast cancer, in addition to the current indication for lung cancer uuid:a20bc0ec-bf9c-4e0f-a060-0cfe0c561d7e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats HP:0002018 PMID:41385096 "[{""id"":""uuid:3c24d3fb-be20-4e2e-a92b-8785d8ef9f2c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6f4346b0-7ad7-419e-8abe-5efbb6d52157"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new indication and a new dosage regimen for the treatment of gastrointestinal (nausea, vomiting) symptoms associated with administration of antitumor agents [Combination chemotherapy with anti-cancer drgs] uuid:c05c38e7-5a5b-4b8c-8f1c-6bad40115bd5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats HP:0002013 PMID:41385096 "[{""id"":""uuid:711797d5-77e1-4054-af7a-ecabe1f1d92d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:49ad911d-40a0-4d9f-a335-42dc90738686"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new indication and a new dosage regimen for the treatment of gastrointestinal (nausea, vomiting) symptoms associated with administration of antitumor agents [Combination chemotherapy with anti-cancer drgs] uuid:e0d15f5b-636d-43b4-94c4-f7075114c64b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:0J4C69C6FB biolink:treats MONDO:0005279 PMID:41385096 "[{""id"":""uuid:a2b588bf-9f87-4baa-9885-efceb51eddcd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:694fd8ed-6234-4ff8-8c7d-1839d6da15d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[PMDA] A new indication for ""lysis of pulmonary artery thrombosis caused by acute pulmonary embolism in the presence of hemodynamic instability"" [Orphan drug]" uuid:8a0557f3-38d8-4cf4-a8a4-41c1a84d5e54 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:0J4C69C6FB biolink:treats UMLS:C0151947 PMID:41385096 "[{""id"":""uuid:b472e67f-b1a0-4db1-9b0d-ea6e8dd31e53"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ffe93fe0-8a76-402a-8f42-7103505190b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[PMDA] A new indication for ""lysis of pulmonary artery thrombosis caused by acute pulmonary embolism in the presence of hemodynamic instability"" [Orphan drug]" uuid:68e5f89e-ed47-4417-b41a-30d005cb3689 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3347 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:2caef3b7-c738-4445-aaac-a560f9cf2579"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:69809400-0cea-4fd3-ab4f-5786cd79f720"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new indication for chronic heart failure, extended from use as an angiotensin-converting enzyme inhibitor uuid:4b95cd78-6f35-4d12-b01a-5269b7a0dfca biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:23667621 biolink:treats HP:0002018 PMID:41385096 "[{""id"":""uuid:bfe0221f-5d79-47a8-8943-6a95f1b27867"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ebf93da3-d3b8-4c82-975d-0b3426fc79e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new indication and a new dosage regimen for the treatment of gastrointestinal (nausea, vomiting) symptoms associated with administration of antitumor agents [Combination chemotherapy with anti-cancer drgs] uuid:f8cdf87e-f2a5-4936-a7f9-475c511eaa83 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:23667621 biolink:treats HP:0002013 PMID:41385096 "[{""id"":""uuid:48b9bfdb-70cd-4888-be50-a03753e98cd8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8b71ac81-6e98-4a73-afcc-ce548a12bb60"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new indication and a new dosage regimen for the treatment of gastrointestinal (nausea, vomiting) symptoms associated with administration of antitumor agents [Combination chemotherapy with anti-cancer drgs] uuid:e44857c6-9dd7-49c0-bbd4-8c3bbcc95a7b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4031 biolink:treats MONDO:0009688 PMID:41385096 "[{""id"":""uuid:31ee984f-932b-4635-8957-1fe474595a7e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:35fcdaf1-8811-47a2-9a0b-d856dce6dc5d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Addition of a new indication for systemic myasthenia gravis (in cases where post-thymectomy steroid therapy is not sufficiently effective or not well tolerated due to adverse drug reactions). [Notification of off-label use] uuid:5b05c38d-e938-40a0-8e3b-dd6520554c62 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5138 biolink:treats MONDO:0001247 PMID:41385096 "[{""id"":""uuid:756d96e0-4f63-49a3-af72-b2056b30d766"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:39118880-2a4d-409f-9675-64834a2f316b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new indication for the treatment of “social anxiety disorder” uuid:73b400e9-4e17-4b96-add8-3e690a1a1a84 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:100241 biolink:treats MONDO:0005823 PMID:41385096 "[{""id"":""uuid:25f57ba5-54d1-461d-a3d3-7d6a6447e7ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:933e30ed-83aa-40ec-bb70-4377b860092e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new indication for the treatment of genus Legionella infection [Notification of off label use] uuid:2805d14b-b547-4612-a65b-ecdc3ec26918 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47381 biolink:treats EFO:0010072 PMID:41385096 "[{""id"":""uuid:f5d0f027-b778-4e6f-8ec3-0f0b466de02c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7b83e36b-ddd0-4b0a-82ed-7270d137a7b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[PMDA] A new indication for the treatment of “toothache”, the format of the indication for ""rheumatoid arthritis"" was coordinated. [Notification of off label use]" uuid:85cb76c2-9341-4acc-a76e-3c16748feeed biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3732 biolink:treats MONDO:0005823 PMID:41385096 "[{""id"":""uuid:34d1e09a-f42a-491e-bcec-c3b1aa9d4c0d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:fc2ad7bd-3caf-4693-b3b0-8d999b0fcd4d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new indication for the treatment of genus Legionella infection [Notification of off label use] uuid:1ca8c3ee-6f00-4594-83e8-ceb746efbec5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27899 biolink:treats MONDO:0005062 PMID:41385096 "[{""id"":""uuid:88946d45-6cbe-4894-b4f6-5a9fc07efa40"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2494fc01-07df-4ea8-92a7-26d258e09c78"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new indication and a new dosage regimen in combination with other anti-cancer agents for the treatment of malignant lymphoma [Combination chemotherapy with anti-cancer drgs] uuid:6aa06db2-d70a-4e4f-8af6-e9b49ab1315e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:24847953 biolink:treats MONDO:0001126 PMID:41385096 "[{""id"":""uuid:61e0dc56-a68d-4ae1-a3e7-7338128f192b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ccf2f6ad-9eab-4c2e-b49f-a8cb5658e30e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Addition of a new dosage indicated for a combination therapy with sodium rabeprazole, amoxicillin, and clarithromycin to eradicate Helicobacter pylori in patients with gastric or duodenal ulcer. uuid:c10b19f7-063f-4879-ab99-9cd497ec1b5a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0005062 PMID:41385096 "[{""id"":""uuid:87efcac8-1970-4f0d-91d5-bf91f670cf25"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2355d4cc-0d8e-4d54-8ad3-fd90906c179c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new indication and a new dosage regimen in combination with other anti-cancer agents for the treatment of malignant lymphoma [Combination chemotherapy with anti-cancer drgs] uuid:744085a2-2335-44ff-8023-dede62ca8db7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:76172 biolink:treats EFO:0010072 PMID:41385096 "[{""id"":""uuid:25286ca8-b807-4676-86b2-4295fd096c7d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6ea8c60c-e41a-4b03-9f60-901a1df15ca2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[PMDA] A new indication for the treatment of “toothache”, the format of the indication for ""rheumatoid arthritis"" was coordinated. [Notification of off label use]" uuid:67d13095-9a6f-4aa5-a371-dbaaf8cd1d94 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:76172 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:e919bf98-8720-4fdd-8655-dbf1f04ce4c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:af6c0146-22d3-467a-9d54-5bb63f171640"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[PMDA] A new indication for the treatment of “toothache”, the format of the indication for ""rheumatoid arthritis"" was coordinated. [Notification of off label use]" uuid:b7ddf58d-63f7-426a-8496-9fa167c96b29 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:175901 biolink:treats MONDO:0003060 PMID:41385096 "[{""id"":""uuid:2db49749-27d4-4a4d-86c0-e444ae1dafb5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:58c69112-ca08-4d70-8d53-fffee41599da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Addition of an indication for biliary tract cancer. uuid:0a6c52a2-04cf-4314-8b88-7b73b8b490b1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:600520 biolink:treats MONDO:0005657 PMID:41385096 "[{""id"":""uuid:feab44f3-ef47-4939-a9ef-22c62d0173d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e3bbc3bd-d43e-4fee-82d3-7ea49261ad5b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and dosage for prophylaxis of aspergillosis and candidiasis in hematopoietic stem cell transplant patients. uuid:991ca120-6981-4c40-a008-332e294bca63 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15552 biolink:treats MONDO:0005149 PMID:41385096 "[{""id"":""uuid:dafe0971-0a16-462a-b307-3706f32fca2f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:27b5bbff-47fe-4974-98c8-df21fb0321a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[PMDA] Addition to indications of pulmonary hypertension associated with specific diseases and a change of the description from ""primary pulmonary hypertension"" to ""pulmonary arterial hypertension""" uuid:b1741658-1ae1-468e-b865-1b949d017e7c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3001 biolink:treats MONDO:0100470 PMID:41385096 "[{""id"":""uuid:72bbbd2d-e55a-4a66-b059-379fc05a3913"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d359431a-849e-4fa8-ace2-7d1a6192294f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Addition of a pediatric dosage for bronchial asthma uuid:6d194772-1dd4-4cee-b5c0-c911a917138f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2955 biolink:treats MONDO:0005701 PMID:41385096 "[{""id"":""uuid:bda04ad0-921d-4c9c-987f-c0b769090bfb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e3a21f53-53d6-43a4-9685-ad8fcc870964"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Addition of indications for Chlamydia trachomatis, urethritis and uterine cervicitis and to dosage regimen. uuid:3aa710ed-ae9a-4db5-a546-3997cb3f2ad6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29007 biolink:treats UMLS:C0149966 PMID:41385096 "[{""id"":""uuid:5e618935-1ce9-4c67-92ca-2f8fb172011c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:208a6bb6-7492-44cc-86e3-e24c572a5ae3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Addition of indications for gonococcus and gonococcal pharyngitis, gonococcal urethritis, gonococcal uterine cervicitis, gonococcal pelvic inflammatory diseases, gonococcal epididymitis, gonococcal proctitis, and to dosage regimen. uuid:9fdf96ea-61fc-4703-9e6c-ebe59f4dda28 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29007 biolink:treats MONDO:0020971 PMID:41385096 "[{""id"":""uuid:e6278758-86b6-47a4-96c0-2d5f232d199e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3551cb84-9457-4d43-80cf-1e53a98ab98b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Addition of indications for gonococcus and gonococcal pharyngitis, gonococcal urethritis, gonococcal uterine cervicitis, gonococcal pelvic inflammatory diseases, gonococcal epididymitis, gonococcal proctitis, and to dosage regimen. uuid:d9ae909d-47e2-405d-a084-068c0b0d798a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29007 biolink:treats MONDO:0021157 PMID:41385096 "[{""id"":""uuid:54f709a2-4538-4c9a-93c1-b578ce82dfc0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a060a427-38a9-4c58-86c9-36991b110b4c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Addition of indications for gonococcus and gonococcal pharyngitis, gonococcal urethritis, gonococcal uterine cervicitis, gonococcal pelvic inflammatory diseases, gonococcal epididymitis, gonococcal proctitis, and to dosage regimen. uuid:64269754-4286-48f7-9266-f6552b41bbbc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29007 biolink:treats MONDO:0021159 PMID:41385096 "[{""id"":""uuid:b0044e40-e995-4418-acbb-15868fd33df2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ea54329d-be81-4cd2-b261-a2dd15a0d5e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Addition of indications for gonococcus and gonococcal pharyngitis, gonococcal urethritis, gonococcal uterine cervicitis, gonococcal pelvic inflammatory diseases, gonococcal epididymitis, gonococcal proctitis, and to dosage regimen. uuid:e3d39757-4dc5-4460-b83a-5640ea6f1890 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29007 biolink:treats UMLS:C0341778 PMID:41385096 "[{""id"":""uuid:98a93fa6-2c93-4e46-96fb-77b535f3084a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5c8d5eb5-0c94-430f-8c98-7055fde6dde5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Addition of indications for gonococcus and gonococcal pharyngitis, gonococcal urethritis, gonococcal uterine cervicitis, gonococcal pelvic inflammatory diseases, gonococcal epididymitis, gonococcal proctitis, and to dosage regimen. uuid:acae4d67-1117-410e-89ab-0009ebeba997 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28001 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:3a747736-0035-41b4-aaf5-fa668bbfc2ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:24f2a815-6978-4609-8afc-30215abc73d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Additions of indications for sepsis, pneumonia, and purulent meningitis caused by penicillin- resistant-Streptococcus . uuid:ec15983b-9b03-4e8d-ac57-4e1661d3f872 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31964 biolink:treats MONDO:0005823 PMID:41385096 "[{""id"":""uuid:3a49aa80-a142-40dc-9b23-b9d2651ac820"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1529b977-6caf-450f-af30-b403a2eb2da7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Addition of indications for legionella infection. uuid:40316605-85ee-481e-b635-22307f59de94 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0005040 PMID:41385096 "[{""id"":""uuid:3a3a4145-8332-4fd0-a487-2889e75103c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0f871277-a9a6-4284-98e1-3ac71e7b6ced"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Addition of indications for germ cell tumors and dosage regimen uuid:9f13091b-75c5-43a0-9c65-06f0a10b5ba8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4911 biolink:treats MONDO:0005040 PMID:41385096 "[{""id"":""uuid:66249a22-d22f-4e16-868d-01fc68367b92"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b2eb8336-47fb-4a0c-b25a-0b93afd843a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Addition of indications for germ cell tumors and dosage regimen uuid:3379dbcc-ec8a-40b0-97f0-7fe91015b9ee biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27899 biolink:treats MONDO:0005040 PMID:41385096 "[{""id"":""uuid:d37d2986-0d4c-4c0a-a6ac-a496601378b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7b2ca10a-4010-42f5-a286-b51ddb617d8a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Addition of indications for germ cell tumors and dosage regimen uuid:4934ab6e-686f-4333-98bd-a65271eb16c3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:637364 biolink:treats MONDO:0021063 PMID:41385096 "[{""id"":""uuid:93b1be7a-8035-4f22-860a-98b5a78f413e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6b5a276a-8676-4c55-8e4e-2d82f249819f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] An addition to indications of non-small cell lung cancer to current indications of gastric cancer, rectal and colonic cancers and head and neck cancers. uuid:b7aa75bb-baaf-4c71-83ec-308159b05ece biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5864 biolink:treats MONDO:0021348 PMID:41385096 "[{""id"":""uuid:101beb84-a8ca-4b43-8f7d-d3cff571d64c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:88ad4459-a75f-4381-bf56-fde44e7e3d81"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Addition to indications of relapsed or refractory germ cell tumors (testicular tumor, ovarian tumor, extragonadal tumors) and to dosage regimen. uuid:1be135d5-4510-413c-a0d7-73de08c9acd4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5864 biolink:treats MONDO:0021068 PMID:41385096 "[{""id"":""uuid:6f8341ef-c746-4099-889e-4b8dd4b6e026"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:89e76edd-cbcd-4b80-b720-cc35f55cbf77"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Addition to indications of relapsed or refractory germ cell tumors (testicular tumor, ovarian tumor, extragonadal tumors) and to dosage regimen. uuid:6ff8d534-760d-4228-a728-b2b35df313b5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5864 biolink:treats MONDO:0018201 PMID:41385096 "[{""id"":""uuid:67d957a3-04ff-4348-aa8b-ad1de8e5c570"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:728b3742-93fe-4eee-b2f3-fff620c21665"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Addition to indications of relapsed or refractory germ cell tumors (testicular tumor, ovarian tumor, extragonadal tumors) and to dosage regimen. uuid:ba2de00b-4ed9-40a9-8849-6205b65ef808 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27375 biolink:treats MONDO:0021348 PMID:41385096 "[{""id"":""uuid:296116dd-f91d-4db9-ab96-d682e91e6b57"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:93625817-6473-4fe3-95b3-77e7218c1172"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Addition to indications of relapsed or refractory germ cell tumors (testicular tumor, ovarian tumor, extragonadal tumors) and to dosage regimen. uuid:b3e7c9bf-46a6-4614-ae49-628f9f37ed2a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27375 biolink:treats MONDO:0021068 PMID:41385096 "[{""id"":""uuid:c9d589c1-f5db-42f7-ab68-fd52730e950d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b07c20d8-67ff-4ad6-a6bd-22e49a98d2f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Addition to indications of relapsed or refractory germ cell tumors (testicular tumor, ovarian tumor, extragonadal tumors) and to dosage regimen. uuid:714f274f-b42f-4662-b8d5-c80d16cabc4b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27375 biolink:treats MONDO:0018201 PMID:41385096 "[{""id"":""uuid:5feec5d4-6fb6-4733-9eff-c402b4681076"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5601f4e1-c6d1-4259-af3e-d20787134761"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Addition to indications of relapsed or refractory germ cell tumors (testicular tumor, ovarian tumor, extragonadal tumors) and to dosage regimen. uuid:98a12ea3-ad82-4b3c-bcab-d4503a23eb33 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:C7S8VWP5DH biolink:treats MONDO:0004992 PMID:41385096 "[{""id"":""uuid:2a6f569b-d5c6-41c6-b643-0ba7358a35ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:02248afa-493d-48ad-a5ab-e93d71f243b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] uuid:2145fe0e-64a2-40d4-a929-200a1716a2d8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28748 biolink:treats MONDO:0011962 PMID:41385096 "[{""id"":""uuid:99e1f36e-edf2-41c6-9d04-041e2859126b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ba191c26-3c24-46bf-aff0-fb6e20fd96ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Addition to indications of combined therapy with other anticancer agents in postoperative chemotherapy or chemotherapy for metastasis or recurrence of endometrial cancer uuid:68e5a472-495c-4aed-b037-97808658f351 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28748 biolink:treats UMLS:C0027627 PMID:41385096 "[{""id"":""uuid:ba8418d8-8e71-4f7a-a0e2-997ceff57f49"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ec73ff63-e9f2-4948-b7c9-1f9db662b53f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Addition to indications of combined therapy with other anticancer agents in postoperative chemotherapy or chemotherapy for metastasis or recurrence of endometrial cancer uuid:3919b45c-cc53-43e1-bcf6-28eccaf8cd1a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27899 biolink:treats MONDO:0011962 PMID:41385096 "[{""id"":""uuid:31eec017-b86e-43e5-a2aa-0ee4e7b2c08f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:76b47e39-4283-47ac-a91f-2d58cdaf473e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Addition to indications of combined therapy with other anticancer agents in postoperative chemotherapy or chemotherapy for metastasis or recurrence of endometrial cancer uuid:70b213ed-5a40-44ec-8019-9159245132dc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27899 biolink:treats UMLS:C0027627 PMID:41385096 "[{""id"":""uuid:dea33f35-051c-4e06-ab3b-2830445bf374"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ce3cc3e2-1ed6-4835-8d13-3e2f4158378a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Addition to indications of combined therapy with other anticancer agents in postoperative chemotherapy or chemotherapy for metastasis or recurrence of endometrial cancer uuid:2e9e566a-7a60-4178-bf9f-6899ec48891f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28748 biolink:treats MONDO:0002129 PMID:41385096 "[{""id"":""uuid:64996300-b111-4eb1-a6d6-af68f7da4b55"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ec653830-5e11-4a18-bc09-20ed21db1533"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Addition to indications of combined therapy with other anticancer agents for malignant bone tumors and to dosage regimen. uuid:ce90b7de-5bfa-4f63-a3f5-326d5e1e14c6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5864 biolink:treats MONDO:0002129 PMID:41385096 "[{""id"":""uuid:8bf38fa2-82af-4db3-9751-a7be10f8e891"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d89b78cb-8d92-428d-ada8-638157e509a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Addition to indications of combined therapy with other anticancer agents for malignant bone and soft tissue tumors and to dosage regimen. uuid:51771f06-be47-4041-a7cd-cc5d52f84df5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5864 biolink:treats MONDO:0006424 PMID:41385096 "[{""id"":""uuid:b2998654-af38-415e-bec3-7b8eab52a94e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:62475b80-229c-42b9-95a5-c8ef74aea400"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Addition to indications of combined therapy with other anticancer agents for malignant bone and soft tissue tumors and to dosage regimen. uuid:51bc3813-5400-43e7-98c2-dabc9b096961 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28748 biolink:treats MONDO:0006424 PMID:41385096 "[{""id"":""uuid:03f35cea-5819-415e-add7-800727449b7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ae041b51-0535-4eb2-8f99-4ad91b2f0d30"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Addition to indications of combined therapy with other anticancer agents for malignant bone and soft tissue tumors and to dosage regimen. uuid:5760bd28-d401-4971-9b60-8ceb3b503d6f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31824 biolink:treats MONDO:0005089 PMID:41385096 "[{""id"":""uuid:6f9ff3a5-a1fb-4bb5-95fd-4c8e29cd4560"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2738faaa-49e8-487a-985e-8260c80ae146"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] In line with the addition to the indications of ifosfamide for malignant bone and soft tissue tumors, an addition to dosage for inhibiting the development of urological impairment associated with administration of said ifosfamide. uuid:239686fa-5ec7-47eb-9ccc-7f4aff67b8be biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31824 biolink:treats MONDO:0004992 PMID:41385096 "[{""id"":""uuid:de01f4d9-0555-4587-8c8c-800a6ffbf97d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:448a345b-46fd-4bea-9871-326d4b052fdf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] uuid:59bb94c9-f652-417e-af2a-fe0592e63a1e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31824 biolink:treats MONDO:0002118 PMID:41385096 "[{""id"":""uuid:cbb68438-fab9-408e-8e7c-e6b9c7230323"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ace7d11b-4d71-44a7-86ac-fcf5144c70c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] In line with the addition to the indications of ifofamide for pediatric malignant solid tumors, an addition to dosage for inhibiting the development of urological impairment associated with the administration of said ifosfamide. uuid:d5afec66-171d-46d7-83e1-fa5c339bb503 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:125224 biolink:treats MONDO:0004992 PMID:41385096 "[{""id"":""uuid:8bf38a7c-1973-4bb8-a5d8-299349614b0e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:52d15b94-98f5-4dbf-8a65-f769054b2c49"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] uuid:553a750f-6b48-41c4-9fda-8a7421ed923a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28445 biolink:treats MONDO:0009693 PMID:41385096 "[{""id"":""uuid:b64d2787-1aeb-4017-8985-6a94ae834e42"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c7fb541b-5eec-46b1-be67-d2e91684a275"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Addition to indications of combined therapy with anticancer agents for multiple myeloma and to dosage regimen. uuid:6cfdce69-585f-42c1-a5a3-5073f9237433 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:125224 biolink:treats MONDO:0005627 PMID:41385096 "[{""id"":""uuid:7ba6237b-e1ed-41ab-afa4-9b429489a020"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c7401fc0-1771-4491-a761-276faa82fabd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Addition to indications of combined therapy with other anticancer agents for head and neck cancers and to dosage regimen. uuid:d1c0cb88-f332-41f5-bed1-47e24b92bb30 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71417 biolink:treats MONDO:0021042 PMID:41385096 "[{""id"":""uuid:2a59d8a7-9b51-4023-8f67-674b0fb40583"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:24524f52-0884-40c1-9bfd-8078ab0a8fa3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Addition to indications of combined therapy with other anticancer agents for glioma which possesses components of malignant astrocytoma and oligodendroglioma and to dosage regimen. uuid:bcccafe4-7f68-4c40-88f3-22343c655e77 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71417 biolink:treats MONDO:0016684 PMID:41385096 "[{""id"":""uuid:bc3cc59f-f16a-466b-9fd4-5d2347a0c8e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:efcb16c7-6be4-463f-9b76-a99ce97640e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Addition to indications of combined therapy with other anticancer agents for glioma which possesses components of malignant astrocytoma and oligodendroglioma and to dosage regimen. uuid:9f6e3e68-4a92-4111-87c7-8c002932ff18 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71417 biolink:treats MONDO:0016695 PMID:41385096 "[{""id"":""uuid:38c436b5-675c-41e0-8cd5-ae49c5a036a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ecf6d6c0-0937-45b9-a4c9-0ee0eb78d260"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Addition to indications of combined therapy with other anticancer agents for glioma which possesses components of malignant astrocytoma and oligodendroglioma and to dosage regimen. uuid:204a490f-7921-4022-8c69-a75f1d26fcf6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:C7S8VWP5DH biolink:treats MONDO:0043731 PMID:41385096 "[{""id"":""uuid:3ccbeb61-4312-40a8-b393-6b1ddbb9b4eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:de1008fa-71ff-43d4-a8d6-002a09e8c103"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Addition to indications of combined use with chemotherapy, endocrine therapy, or radiotherapy for osteolytic bone metastases of uuid:13ac2863-a1af-4a1b-84a8-0bcc17d98afc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5864 biolink:treats MONDO:0004992 PMID:41385096 "[{""id"":""uuid:33a26095-6ab7-4841-852c-23f6f457e0f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d5aca10f-8629-473d-b6c1-4e2ae04c05c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA]